ISSN: 0090-1423

National Library of Medicine

CUMULATED INDEX MEDICUS

Volume 37, 1996

Subject Index A

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health

NATIONAL LIBRARY OF MEDICINE
8600 Rockville Pike
Bethesda, Maryland 20894

NIH Publication No. 97-259

Book 2

Cumulated Index Medicus

© All or portions of this publication are protected against copying or other reproduction outside of the United States in accordance with the provisions of Article II of the Universal Copyright Convention.

National Library of Medicine Cataloging in Publication

Cumulated Index medicus.
Vol. 1 (Jan.-Dec. 1960)-
--Chicago : American Medical Association ; Washington, D.C. : Supt. of Docs., U.S. G.P.O. [distributor], 1961-
v.

Vols. for 1971-1978 issued as DHEW publication ; no. (NIH) 72-259, etc.; for 1979- as NIH publication ; no. 80-259, etc.
Annual cumulation of the monthly issues of Index medicus.
Continues: Quarterly cumulative Index medicus.
Issues for 1967- include Bibliography of medical reviews.
Vols. for 1965- issued by the National Library of Medicine.

1. Bibliography of Medicine 2. Medicine - indexes I. American Medical Association II. National Library of Medicine (U.S.). III. Bibliography of medical reviews IV. Index medicus V. Series: DHEW publication ; no. (NIH) 72-259, etc. VI. Series: NIH publication ; no. 80-259, etc.

ISSN 0090-1423 = Cumulated Index medicus.

ZW 1 I384

This book is printed on acid-free paper for permanence.

Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through September 30, 1997.

For sale by the U.S. Government Printing Office
Superintendent of Documents, Mail Stop: SSOP, Washington, DC 20402-9328
ISBN 0-16-048940-7

CUMULATED INDEX MEDICUS 1996

CONTENTS

BOOK 1

Preface v
Index Medicus Citation Format vii
Introduction viii
Materials Indexed viii
The Indexing Operation viii
Subject Heading Changes ix
Arrangement ix
Subject Section ix
Author Section xi
Bibliography of Medical Reviews xi
Access to Articles Cited xii
Interlibrary Loan Policy xii
Other Resources xiv
National Network of Libraries of Medicine xiv
International MEDLARS/MEDLINE Centers xv

MEDICAL SUBJECT HEADINGS (Contents) I-3
Medical Subject Headings 1

JOURNALS INDEXED Abbreviation Listing 1393
Full Title Listing 1489

BOOK 2 Subject Index **A** 1565

BOOK 3 Subject Index **B-Chi** 2972

BOOK 4 Subject Index **Chl-Do** 4295

BOOK 5 Subject Index **Dr-Geo** 5591

BOOK 6 Subject Index **Ger-Ino** 6929

BOOK 7 Subject Index **Inp-Mei** 8260

BOOK 8 Subject Index **Mel-Or** 9583

BOOK 9 Subject Index **Os-Psi** 10915

BOOK 10 Subject Index **Pso-Sr** 12241

BOOK 11 Subject Index **St-Z** 13570

BOOK 12 Author Index **A-Dh** 14907

BOOK 13 Author Index **Di-Jd** 16222

BOOK 14 Author Index **Je-Mor** 17550

BOOK 15 Author Index **Mos-She** 18896

BOOK 16 Author Index **Shi-Z** 20223

BOOK 17 Bibliography of Medical Reviews 21539

SUBJECT SECTION

A-23187 see CALCIMYCIN

A FIBERS see NERVE FIBERS, MYELINATED

ABATE see TEMEFOS

ABATTOIRS

Motivation and characterization of finnish meat inspection veterinarians. Rahkio M, et al. **Acta Vet Scand** 1995; 36(4):563–70

Histopathological alterations of turkey skeletal muscle observed at the slaughterhouse. Cherel Y, et al. **Br Poult Sci** 1995 Jul;36(3):443–53

Abattoir observations of the weights of stomachs and their contents in pigs slaughtered at known times after their last feed. Guise HJ, et al. **Br Vet J** 1995 Nov–Dec;151(6):659–70

Prevalence of anti-Rift-Valley-fever IgM antibody in abattoir workers in the Nile delta during the 1993 outbreak in Egypt. Abu-Elyazeed R, et al. **Bull World Health Organ** 1996;74(2):155–8

Prevalence and risk factors for warts among slaughterhouse workers. Aziz MA, et al. **East Afr Med J** 1996 Mar; 73(3):194–7

The prevalence of latent Equid herpesviruses in the tissues of 40 abattoir horses. Edington N, et al. **Equine Vet J** 1994 Mar;26(2):140–2

Application of a computer model to predict optimum slaughter end points for different biological types of feeder cattle. Williams CB, et al. **J Anim Sci** 1995 Oct; 73(10):2903–15

Re: Lung cancer after Hodgkin's disease [letter] Johnson ES. **J Natl Cancer Inst** 1996 Jan 3;88(1):51–2

Streptococcus suis as threat to pig-farmers and abattoir workers [letter; comment] Bartelink AK, et al. **Lancet** 1995 Dec 23–30;346(8991–8992):1707. Comment on: Lancet 1995 Nov 11;346(8985):1305–6.

A comparison of argon, carbon dioxide, and nitrogen in a broiler killing system. Poole GH, et al. **Poult Sci** 1995 Jul; 74(7):1218–23

Electronic identification with injectable transponders in pig production: results of a field trail on commercial farms and slaughterhouses concerning injectability and retrievability. Lambooij E, et al. **Vet Q** 1995 Dec;17(4):118–23

Effect of pre-slaughter washing of lambs on the microbiological and visible contamination of the carcases. Biss ME, et al. **Vet Rec** 1996 Jan 27;138(4):82–6

Factors affecting the mortality of lambs in transit to or in lairage at a slaughterhouse, and reasons for carcase condemnations. Knowles TG, et al. **Vet Rec** 1994 Jul 30; 135(5):109–11

Recent bruising in cattle at abattoirs. McNally PW, et al. **Vet Rec** 1996 Feb 10;138(6):126–8

Accumulation of protoporphyrin isomers I and III, and multiple decarboxylation products of uroporphyrin in a case of porphyria in a slaughtered pig. Roels S, et al. **Zentralbl Veterinarmed A** 1995 Apr;42(2):145–51

[Mobile slaughter facilities] Briese A. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):58–62 (Eng. Abstr.) **(Ger)**

[Carbon dioxide stunning for the slaughter of turkeys] Erhardt W, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):62–4 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Mass slaughter policy 'wholly unreal' says agriculture minister [news] **Vet Rec** 1996 Apr 20;138(16):374

Minister outlines slaughter plans for older cattle [news] **Vet Rec** 1996 Apr 13;138(15):342

[Bovine spongiform encephalopathy (BSE). Examination in abattoirs compulsory as per March 1 1996] Edel W, et al. **Tijdschr Diergeneeskd** 1996 Feb 15;121(4):113–4 **(Dut)**

[Animal welfare slaughter regulation] Knierim U. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):52–4 (Eng. Abstr.) **(Ger)**

STANDARDS

Foodborne illness prevention before slaughter? Yes! [news] Reed CA, et al. **J Am Vet Med Assoc** 1996 May 1; 208(9):1366

Biochemical and haematological values in abattoir pigs with and without subclinical lesions. Makinde MO, et al. **Onderstepoort J Vet Res** 1996 Mar;63(1):11–4

Use of antimicrobial agents in official abattoirs under meat inspection in the United States of America. Patch MA. **Rev Sci Tech** 1995 Jun;14(2):309–12 (4 ref.)

Docking and other practices [letter; comment] [see comments] Cooper JE. **Vet Rec** 1995 Jul 8;137(2):52. Comment on: Vet Rec 1995 Mar 18;136(11):274. Comment in: Vet Rec 1995 Jul 22;137(4):103.

[Hygienic blood collection] **Tijdschr Diergeneeskd** 1996 Jan 15;121(2):43 **(Dut)**

[Applied animal welfare of slaughter houses] von Holleben K. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):55–8 (Eng. Abstr.) **(Ger)**

ABBREVIATED INJURY SCALE

The effects of seat belts on injury severity of front and rear seat occupants in the same frontal crash. Huelke DF, et al. **Accid Anal Prev** 1995 Dec;27(6):835–8

The abbreviated injury scale as a predictor of outcome of severe head injury. Walder AD, et al. **Intensive Care Med** 1995 Jul;21(7):606–9

Abbreviated Injury Scale does not reflect the added morbidity of multiple lower extremity fractures. Poole GV, et al. **J Trauma** 1996 Jun;40(6):951–4; discussion 954–5

[Admission documentation of multiple trauma patients using the Zurich Trauma Protocol—initial experiences] Heinzelmann M, et al. **Swiss Surg** 1996;(2):35–41 (Eng. Abstr.) **(Ger)**

ABBREVIATIONS

Persistent problems in acronyms [letter; comment] Cheng TO. **J Clin Epidemiol** 1996 Aug;49(8):947. Comment on: J Clin Epidemiol 1995 Sep;48(9):1159–66.

AIDS' nomenclature's spelling or style [letter] Rafiquzzman M. **J R Soc Health** 1995 Oct;115(5):331

Reasons to write [news] Karlén W. **Nature** 1996 Feb 29; 379(6568):766

Eschew obfuscation. Friedman EA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):795–6

ABC TRANSPORTERS

ANALYSIS

Tissue distribution of the multidrug resistance protein. Flens MJ, et al. **Am J Pathol** 1996 Apr;148(4):1237–47

Localisation of the multidrug resistance-associated protein, MRP, in resistant large-cell lung tumour cells. Barrand MA, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1725–9

Multidrug resistance-associated protein expression in clinical gastric carcinoma. Endo K, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1681–7

Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Breuninger LM, et al. **Cancer Res** 1995 Nov 15;55(22):5342–7

Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Kaklamanis L, et al. **Cancer Res** 1995 Nov 15;55(22):5191–4

How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Broxterman HJ, et al. **Eur J Cancer** 1996 Jun;32A(6):1024–33 (86 ref.)

Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung. Sugawara I, et al. **Int J Cancer** 1995 Oct 20;64(5):322–5

Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. Evers R, et al. **J Clin Invest** 1996 Mar 1; 97(5):1211–8

Reciprocal expression of P-glycoprotein and TAP1 accompanied by higher expression of MHC class I antigens in T cells of old mice. Witkowski JM, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B76–82

Residues in TAP2 peptide transporters controlling substrate specificity. Momburg F, et al. **J Immunol** 1996 Mar 1; 156(5):1756–63

Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. Izquierdo MA, et al. **J Natl Cancer Inst** 1995 Aug 16;87(16):1230–7

MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias. Beck J, et al. **Leukemia** 1996 Jul;10 Suppl 3:S39–S45

ANTAGONISTS & INHIBITORS

Vanadate and bafilomycin A1 are potent inhibitors of the ATPase activity of the reconstituted bacterial ATP-binding cassette transporter for maltose (MalFGK2). Hunke S, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):589–94

BIOSYNTHESIS

Membrane transport proteins associated with drug resistance expressed in human melanoma. Schadendorf D, et al. **Am J Pathol** 1995 Dec;147(6):1545–52

Xenobiotic transport differences in mouse mesangial cell clones expressing mdr1 and mdr3. Ernest S, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C910–9

Multidrug resistance-associated protein (MRP) gene expression in human lung cancer. Narasaki F, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2079–82

Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Korkolopoulou P, et al. **Br J Cancer** 1996 Jan;73(2):148–53

MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Kavallaris M, et al. **Cancer Lett** 1996 Apr 19;102(1–2):7–16

Genomic organization, promoter analysis, and chromosomal localization of the gene for the mouse glial high-affinity glutamate transporter Slc1a3. Hagiwara T, et al. **Genomics** 1996 May 1;33(3):508–15

High rate of MDR-1 and heterogeneous pattern of MRP expression without gene amplification in endometrial cancer. Esteller M, et al. **Int J Cancer** 1995 Dec 11; 63(6):798–803

MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Giaccone G, et al. **Int J Cancer** 1996 Jun 11;66(6):760–7

Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Izquierdo MA, et al. **Int J Cancer** 1996 Jan 17;65(2):230–7

On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP). Versantvoort CH, et al. **Int J Cancer** 1995 Dec 11;63(6):855–62

Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines. Zhou DC, et al. **Int J Cancer** 1996 Jan 26;65(3):365–71

The multidrug resistance-associated protein (MRP) subfamily (Yrs1/Yor1) of Saccharomyces cerevisiae is important for the tolerance to a broad range of organic anions. Cui Z, et al. **J Biol Chem** 1996 Jun 21; 271(25):14712–6

Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. Ishikawa T, et al. **J Biol Chem** 1996 Jun 21;271(25):14981–8

Functional expression of the multidrug resistance-associated protein in the yeast Saccharomyces cerevisiae. Ruetz S, et al. **J Biol Chem** 1996 Feb 23;271(8):4154–60

Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas. Oda Y, et al. **J Cancer Res Clin Oncol** 1996;122(3):161–65

Human multidrug resistance 3-P-glycoprotein expression in transgenic mice induces lens membrane alterations leading to cataract. Dunia I, et al. **J Cell Biol** 1996 Feb; 132(4):701–16

LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. Rotem-Yehudar R, et al. **J Exp Med** 1996 Feb 1;183(2):499–514

Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by Stat1 alpha. Min W, et al. **J Immunol** 1996 May 1;156(9):3174–83

Expression pattern of MRP in human tissues and adult solid tumor cell lines. Kruh GD, et al. **J Natl Cancer Inst** 1995 Aug 16;87(16):1256–8

Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line. Naito S, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1112–8

Analysis of MDR1 and MDR3 multidrug resistance gene expression and amplification in consecutive samples in patients with acute leukaemias. MacFarland A, et al. **Leuk Lymphoma** 1995 Sep;19(1–2):135–40

Expression of an ATP-binding cassette transporter-encoding gene (YOR1) is required for oligomycin resistance in Saccharomyces cerevisiae. Katzmann DJ, et al. **Mol Cell Biol** 1995 Dec;15(12):6875–83

A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern. Lombard-Platet G, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1265–9

CHEMISTRY

Mutagenesis of transmembrane domain 11 of P-glycoprotein by alanine scanning. Hanna M, et al. **Biochemistry** 1996 Mar 19;35(11):3625–35

Identification of the ATP transporter of rat liver rough endoplasmic reticulum via photoaffinity labeling and partial purification. Kim SH, et al. **Biochemistry** 1996 Apr 30; 35(17):5418–25

Primary structure of a novel ABC transporter with a chromosomal localization on the band encoding the multidrug resistance-associated protein. Klugbauer N, et al. **FEBS Lett** 1996 Aug 5;391(1–2):61–5

The rat cim effect: TAP allele-dependent changes in a class I MHC anchor motif and evidence against C-terminal trimming of peptides in the ER. Powis SJ, et al. **Immunity** 1996 Feb;4(2):159–65

Topology analysis of the colicin V export protein CvaA in Escherichia coli. Skvirsky RC, et al. **J Bacteriol** 1995 Nov; 177(21):6153–9

Comparative topology studies in Saccharomyces cerevisiae and in Escherichia coli. The N-terminal half of the yeast ABC protein Ste6. Geller D, et al. **J Biol Chem** 1996 Jun 7;271(23):13746–53

Characterization and analysis of conserved motifs in a

peroxisomal ATP-binding cassette transporter. Shani N, et al. **J Biol Chem** 1996 Apr 12;271(15):8725–30

CLASSIFICATION

Phylogenetic analyses of the ATP-binding constituents of bacterial extracytoplasmic receptor-dependent ABC-type nutrient uptake permeases. Kuan G, et al. **Res Microbiol** 1995 May;146(4):271–8 (16 ref.)

GENETICS

Mutational and protein analysis of patients and heterozygous women with X-linked adrenoleukodystrophy. Feigenbaum V, et al. **Am J Hum Genet** 1996 Jun;58(6):1135–44

Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Bristol LA, et al. **Ann Neurol** 1996 May;39(5):676–9

The gluEMP operon from Zymomonas mobilis encodes a high-affinity glutamate carrier with similarity to binding-protein-dependent transport systems. Peekhaus N, et al. **Arch Microbiol** 1996 May;165(5):325–32

ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Leier I, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):433–7

Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder. Clifford SC, et al. **Br J Cancer** 1996 Mar;73(5):659–66

MHC-encoded TAP genes in rheumatic diseases [editorial] Coakley G, et al. **Br J Rheumatol** 1996 Jun;35(6):501–3 (20 ref.)

Genetic analysis of TAP2 in systemic lupus erythematosus patients from two ethnic groups. Ocal L, et al. **Br J Rheumatol** 1996 Jun;35(6):529–33

Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. Kuo MT, et al. **Cancer Res** 1996 Aug 15;56(16):3642–4

TAP2D is associated with HLA-B44 and DR4 and may contribute to rheumatoid arthritis and Felty's syndrome susceptibility. Hillarby MC, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):67–70

The gene for a subunit of an ABC-type heme transporter is transcribed together with the gene for subunit 6 of NADH dehydrogenase in rice mitochondria. Nakazono M, et al. **Curr Genet** 1996 Apr;29(5):412–6

Evolution of ATP-binding cassette transporter genes. Dean M, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):779–85 (42 ref.)

Identification of a gene similar to ABC transporters near the capsule synthesis region of the group A streptococcal chromosome. Ashbaugh CD, et al. **Dev Biol Stand** 1995; 85:231–5

HLA DQA1-DQB1-TAP2 haplotypes in IDDM families: no evidence for an additional contribution to disease risk by the TAP2 locus. Esposito L, et al. **Diabetologia** 1995 Aug;38(8):968–74

Sequence analysis of leukotoxin secretion determinants from a Pasteurella haemolytica-like organism. Chang YF, et al. **DNA Seq** 1995;5(5):291–7

Investigation of the association of major histocompatibility complex genes, including HLA class I, class II and TAP genes, with clinical forms of Crohn's disease. Hesresbach D, et al. **Eur J Immunogenet** 1996 Apr;23(2):141–51

A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity. Armandola EA, et al. **Eur J Immunol** 1996 Aug; 26(8):1748–55

TAP1-deficient mice select a CD8+ T cell repertoire that displays both diversity and peptide specificity. Sandberg JK, et al. **Eur J Immunol** 1996 Feb;26(2):288–93

Primary structure of a novel ABC transporter with a chromosomal localization on the band encoding the multidrug resistance-associated protein. Klugbauer N, et al. **FEBS Lett** 1996 Aug 5;391(1–2):61–5

The use of PCR to isolate a putative ABC transporter from Saccharopolyspora erythraea. O'Neill MP, et al. **FEMS Microbiol Lett** 1995 Sep 1;131(2):189–95

Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Van Nieuwkerk CM, et al. **Gastroenterology** 1996 Jul;111(1):165–71

Analysis of Staphylococcus aureus genes encoding penicillin-binding protein 4 and an ABC-type transporter. Domanski TL, et al. **Gene** 1995 Dec 29;167(1–2):111–3

Molecular characterization of a high-affinity mouse glutamate transporter. Sutherland ML, et al. **Gene** 1995 Sep 11;162(2):271–4

Functional expression of yeast artificial chromosome-human multidrug resistance genes in mouse cells. Kusaba H, et al. **Genome Res** 1995 Oct;5(3):245–58

Genomic organization, promoter analysis, and chromosomal localization of the gene for the mouse glial high-affinity glutamate transporter Slc1a3. Hagiwara T, et al. **Genomics** 1996 May 1;33(3):508–15

Locoregional immuno-chemotherapy transplenic and transtumoral in vivo immunostimulation. Lygidakis NJ, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):440–7 (38 ref.)

Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Deleuze JF, et al. **Hepatology** 1996 Apr;23(4):904–8

Tap-1 and Tap-2 gene therapy selectively restores conformationally dependent HLA Class I expression in type I diabetic cells. Wang F, et al. **Hum Gene Ther** 1995 Aug;6(8):1005–17

Localization of the gene encoding the human L-glutamate transporter (GLT-1) to 11p11.2-p13 by fluorescence in situ hybridization. Takai S, et al. **Hum Genet** 1996 Mar; 97(3):387–9

Family study of linkage disequilibrium between TAP2 transporter and HLA class II genes. Absence of TAP2 contribution to association with insulin-dependent diabetes mellitus. Caillat-Zucman S, et al. **Hum Immunol** 1995 Oct; 44(2):80–7

TAP2 association with insulin-dependent diabetes mellitus is secondary to HLA-DQB1. Jackson DG, et al. **Hum Immunol** 1995 May;43(1):57–65

Reevaluation of the relative risk for susceptibility to celiac disease of HLA-DRB1, -DQA1, -DQB1, -DPB1, and -TAP2 alleles in a French population. Meddeb-Garnaoui A, et al. **Hum Immunol** 1995 Jul;43(3):190–9

TAP1 and TAP2 polymorphism in HLA-B27-positive subpopulations: no allelic differences in ankylosing spondylitis and reactive arthritis. Westman P, et al. **Hum Immunol** 1995 Dec;44(4):236–42

Characterization of a partial pseudogene homologous to the adrenoleukodystrophy gene and application to mutation detection. Braun A, et al. **Hum Mutat** 1996;7(2):105–8

Mutational analysis of patients with X-linked adrenoleukodystrophy. Kok F, et al. **Hum Mutat** 1995; 6(2):104–15

The rat cim effect: TAP allele-dependent changes in a class I MHC anchor motif and evidence against C-terminal trimming of peptides in the ER. Powis SJ, et al. **Immunity** 1996 Feb;4(2):159–65

Polymorphic peptide transporters in MHC class I monomorphic Syrian hamster. Lobigs M, et al. **Immunogenetics** 1995;42(5):398–407

Identification of new TAP2 alleles in gorilla: evolution of the locus within hominoids. Loflin PT, et al. **Immunogenetics** 1996;44(3):161–9

MHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice. Ljunggren HG, et al. **Int Immunol** 1995 Jun;7(6):975–84

Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas. Chuman Y, et al. **Int J Cancer** 1996 Apr 10;66(2):274–9

Lack of primary association between transporter associated with antigen processing genes and atopic dermatitis. Kuwata S, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1051–60

Mutations within the first LSGGQ motif of Ste6p cause defects in a-factor transport and mating in Saccharomyces cerevisiae. Browne BL, et al. **J Bacteriol** 1996 Mar; 178(6):1712–9

The Myxococcus xanthus rfbABC operon encodes an ATP-binding cassette transporter homolog required for O-antigen biosynthesis and multicellular development. Guo D, et al. **J Bacteriol** 1996 Mar;178(6):1631–9

Molecular analysis of the amy gene locus of Thermoanaerobacterium thermosulfurigenes EM1 encoding starch-degrading enzymes and a binding protein-dependent maltose transport system. Sahm K, et al. **J Bacteriol** 1996 Feb;178(4):1039–46

Hormonal and environmental regulation of a plant PDR5-like ABC transporter. Smart CC, et al. **J Biol Chem** 1996 Aug 9;271(32):19351–7

The PAL1 gene product is a peroxisomal ATP-binding cassette transporter in the yeast Saccharomyces cerevisiae. Swartzman EE, et al. **J Cell Biol** 1996 Feb;132(4):549–63

Development of CD8 alpha alpha+ intestinal intraepithelial T cells in beta 2-microglobulin- and/or TAP1-deficient mice. Fujiura Y, et al. **J Immunol** 1996 Apr 15; 156(8):2710–5

Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo. Nair SK, et al. **J Immunol** 1996 Mar 1;156(5):1772–80

Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. Neisig A, et al. **J Immunol** 1996 May 1; 156(9):3196–206

Rat MHC-linked peptide transporter alleles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease. Simmons WA, et al. **J Immunol** 1996 Feb 15;156(4):1661–7

How does the MRP/GS-X pump export doxorubicin? [letter] Ishikawa T, et al. **J Natl Cancer Inst** 1995 Nov 1; 87(21):1639–40

Glutamate transporter mRNA expression in proliferative zones of the developing and adult murine CNS. Sutherland ML, et al. **J Neurosci** 1996 Apr 1;16(7):2191–207

Expression of MRP and mdr1 in human gastrointestinal cancer cell lines: a correlation with resistance against doxorubicin. Murase M, et al. **J Surg Oncol** 1996 Mar; 61(3):223–9

Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. Kim WJ, et al. **J Urol** 1996 Aug;156(2 Pt 1):506–11

Overexpression of multidrug resistance protein gene in human cancer cell lines selected for drug resistance to epipodophyllotoxins. Koike K, et al. **Jpn J Cancer Res** 1996 Jul;87(7):765–72

Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Ross DD, et al. **Leukemia** 1996 Jan;10(1):48–55

Molecular cloning of a mammalian ABC transporter homologous to Drosophila white gene. Savary S, et al. **Mamm Genome** 1996 Sep;7(9):673–6

Localization of rat Pgy3 (mdr2) to the same region as Pgy2 (mdr1b) at 4q11–12. Zimonjic DB, et al. **Mamm Genome** 1996 Aug;7(8):630–1

Analysis of putative ABC transporter genes in Mycoplasma hyopneumoniae. Blanchard B, et al. **Microbiology** 1996 Jul; 142 (Pt 7):1855–62

Molecular analysis of an operon in Bacillus subtilis encoding a novel ABC transporter with a role in exoprotein production, sporulation and competence. Leskelä S, et al. **Microbiology** 1996 Jan;142 (Pt 1):71–7

An operon encoding a novel ABC-type transport system in Bacillus subtilis. Rodriguez F, et al. **Microbiology** 1995 Jul; 141 (Pt 7):1781–4

Endocytosis and vacuolar degradation of the plasma membrane-localized Pdr5 ATP-binding cassette multidrug transporter in Saccharomyces cerevisiae. Egner R, et al. **Mol Cell Biol** 1995 Nov;15(11):5879–87

Expression of an ATP-binding cassette transporter-encoding gene (YOR1) is required for oligomycin resistance in Saccharomyces cerevisiae. Katzmann DJ, et al. **Mol Cell Biol** 1995 Dec;15(12):6875–83

Extension of the Rhizobium meliloti succinoglycan biosynthesis gene cluster: identification of the exsA gene encoding an ABC transporter protein, and the exsB gene which probably codes for a regulator of succinoglycan biosynthesis. Becker A, et al. **Mol Gen Genet** 1995 Dec 15;249(5):487–97

An ABC transporter is essential for resistance to the antitumor agent mithramycin in the producer Streptomyces argillaceus. Fernández E, et al. **Mol Gen Genet** 1996 Jul 26;251(6):692–8

Molecular characterization of spontaneous mutations at the scarlet locus of Drosophila melanogaster. ten Have JF, et al. **Mol Gen Genet** 1995 Dec 20;249(6):673–81

The tagGH operon of Bacillus subtilis 168 encodes a two-component ABC transporter involved in the metabolism of two wall teichoic acids. Lazarevic V, et al. **Mol Microbiol** 1995 Apr;16(2):345–55

Differential expression of two siderophore-dependent iron-acquisition pathways in Erwinia chrysanthemi 3937: characterization of a novel ferrisiderophore permease of the ABC transporter family. Mahé B, et al. **Mol Microbiol** 1995 Oct;18(1):33–43

A second ABC transporter is involved in oleandomycin resistance and its secretion by Streptomyces antibioticus. Olano C, et al. **Mol Microbiol** 1995 Apr;16(2):333–43

Analysis of the localization of STE6/CFTR chimeras in a Saccharomyces cerevisiae model for the cystic fibrosis defect CFTR delta F508. Paddon C, et al. **Mol Microbiol** 1996 Mar;19(5):1007–17

Bacillus licheniformis bacitracin-resistance ABC transporter: relationship to mammalian multidrug resistance. Podlesek Z, et al. **Mol Microbiol** 1995 Jun;16(5):969–76

Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter. Stride BD, et al. **Mol Pharmacol** 1996 Jun;49(6):962–71

Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. Norris MD, et al. **N Engl J Med** 1996 Jan 25;334(4):231–8

A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer [see comments] Chen HL, et al. **Nat Genet** 1996 Jun; 13(2):210–3. Comment in: Nat Genet 1996 Jun;13(2):139–40.

Tapping into tumours [news; comment] Elliott T. **Nat Genet** 1996 Jun;13(2):139–40. Comment on: Nat Genet 1996 Jun;13(2):210–3.

Characterization of the rat mdr2 promoter and its regulation by the transcription factor Sp1. Brown PC, et al. **Nucleic Acids Res** 1996 Aug 15;24(16):3235–41

De novo generation of simple sequence during gene amplification. Kirschner LS. **Nucleic Acids Res** 1996 Jul 15;24(14):2829–34

Expression of the transporter for antigen processing-1 (Tap-1) Gene in subpopulations of human trophoblast cells. Roby KF, et al. **Placenta** 1996 Jan;17(1):27–32

A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern. Lombard-Platet G, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1265–9

Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Paulusma CC, et al. **Science** 1996 Feb 23;271(5252):1126–8

Typing for TAP alleles using PCR-RFLP with amplification-created restriction sites. Fraile A, et al. **Tissue Antigens** 1996 Apr;47(4):346–52

A novel TAP 2 gene RFLP observed in a Japanese. Pattanakitsakul S, et al. **Tissue Antigens** 1996 Apr; 47(4):353–5

HLA and TAP associations in Chinese systemic lupus erythematosus patients. Savage DA, et al. **Tissue Antigens** 1995 Sep;46(3 (Pt 1)):213–6

[Expression of the MRP gene coded conjugate transporter

in human liver and its selective defect in canalicular membrane transport deficient rat hepatocytes] Möhler M, et al. **Z Gastroenterol** 1996 May;34(5):296–7 **(Ger)**

IMMUNOLOGY

A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity. Armandola EA, et al. **Eur J Immunol** 1996 Aug; 26(8):1748–55

Translocation of long peptides by transporters associated with antigen processing (TAP). Koopmann JO, et al. **Eur J Immunol** 1996 Aug;26(8):1720–8

TAP1–deficient mice select a CD8+ T cell repertoire that displays both diversity and peptide specificity. Sandberg JK, et al. **Eur J Immunol** 1996 Feb;26(2):288–93

How selective is the transporter associated with antigen processing? Androlewicz MJ, et al. **Immunity** 1996 Jul; 5(1):1–5 (41 ref.)

In vivo cross–priming of MHC class I–restricted antigens requires the TAP transporter. Huang AY, et al. **Immunity** 1996 Apr;4(4):349–55

Identification of a contact region for peptide on the TAP1 chain of the transporter associated with antigen processing. Nijenhuis M, et al. **J Immunol** 1996 Mar 15;156(6):2186–95

Selection and binding of peptides to human transporters associated with antigen processing and rat cim–a and –b. Wang P, et al. **J Immunol** 1996 Jul 1;157(1):213–20

Characteristics of ATP–dependent peptide transport in isolated microsomes. Yang B, et al. **J Immunol** 1995 Oct 15;155(8):3889–96

ISOLATION & PURIFICATION

Purification and reconstitution of the glutamate carrier GltT of the thermophilic bacterium Bacillus stearothermophilus. Gaillard I, et al. **Biochemistry** 1996 May 14;35(19):6150–6

METABOLISM

Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione–S–transferase, topoisomerase II and MRP in multidrug resistant cell lines. Utz I, et al. **Anticancer Res** 1996 Jan–Feb;16(1):289–96

Cellular and in vitro transport of glutathione conjugates by MRP. Shen H, et al. **Biochemistry** 1996 May 7; 35(18):5719–25

Subcellular metabolite transport and carbon isotope kinetics in the intramyocardial glutamate pool. Yu X, et al. **Biochemistry** 1996 May 28;35(21):6963–8

Pore models for transporters? DeFelice LJ, et al. **Biophys J** 1996 Feb;70(2):579–80

Multidrug resistance proteins and other drug transport–related resistance to natural product agents. Broxterman HJ, et al. **Curr Opin Oncol** 1995 Nov; 7(6):532–40 (78 ref.)

The ABC transporter proteins Pat1 and Pat2 are required for import of long–chain fatty acids into peroxisomes of Saccharomyces cerevisiae. Hettema EH, et al. **EMBO J** 1996 Aug 1;15(15):3813–22

The ATP binding cassette transporter ABC1, is required for the engulfment of corpses generated by apoptotic cell death. Luciani MF, et al. **EMBO J** 1996 Jan 15;15(2):226–35

Translocation of long peptides by transporters associated with antigen processing (TAP). Koopmann JO, et al. **Eur J Immunol** 1996 Aug;26(8):1720–8

Transporter (TAP)–independent processing of a multiple membrane–spanning protein, the Epstein–Barr virus latent membrane protein 2. Lee SP, et al. **Eur J Immunol** 1996 Aug;26(8):1875–83

The yeast multidrug transporter Pdr5 of the plasma membrane is ubiquitinated prior to endocytosis and degradation in the vacuole. Egner R, et al. **FEBS Lett** 1996 Jan 8;378(2):177–81

Transport properties of the multidrug resistance–associated protein (MRP) in human tumour cells. Holló Z, et al. **FEBS Lett** 1996 Mar 25;383(1–2):99–104

Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP. Zaman GJ, et al. **FEBS Lett** 1996 Aug 5;391(1–2):126–30

Absence of the canalicular isoform of the MRP gene–encoded conjugate export pump from the hepatocytes in Dubin–Johnson syndrome. Kartenbeck J, et al. **Hepatology** 1996 May;23(5):1061–6

Expression of a rat liver phosphatidylcholine translocator in Xenopus laevis oocytes. Kullak–Ublick GA, et al. **Hepatology** 1996 May;23(5):1254–9

Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Kurokohchi K, et al. **Hepatology** 1996 May; 23(5):1181–8

The membrane–bound and soluble forms of HLA–G bind identical sets of endogenous peptides but differ with respect to TAP association. Lee N, et al. **Immunity** 1995 Nov; 3(5):591–600

A point mutation in HLA–A*0201 results in failure to bind the TAP complex and to present virus–derived peptides to CTL. Peace–Brewer AL, et al. **Immunity** 1996 May; 4(5):505–14

The maltose transport system of Escherichia coli displays positive cooperativity in ATP hydrolysis. Davidson AL, et al. **J Biol Chem** 1996 Mar 1;271(9):4858–63

An FK506–sensitive transporter selectively decreases intracellular levels and potency of steroid hormones. Kralli A, et al. **J Biol Chem** 1996 Jul 19;271(29):17152–6

Enhancement of Mdr2–mediated phosphatidylcholine translocation by the bile salt taurocholate. Implications for hepatic bile formation. Ruetz S, et al. **J Biol Chem** 1995 Oct 27;270(43):25388–95

TAP–independent, beta 2–microglobulin–dependent surface expression of functional mouse CD1.1. Brutkiewicz RR, et al. **J Exp Med** 1995 Dec 1;182(6):1913–9

Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl–2 and Abl. Martin SJ, et al. **J Exp Med** 1995 Nov 1;182(5):1545–56

MHC class I molecules form ternary complexes with calnexin and TAP and undergo peptide–regulated interaction with TAP via their extracellular domains. Suh WK, et al. **J Exp Med** 1996 Aug 1;184(2):337–48

The peptide–binding motif for the human transporter associated with antigen processing. van Endert PM, et al. **J Exp Med** 1995 Dec 1;182(6):1883–95

TAP associates with a unique class I conformation, whereas calnexin associates with multiple class I forms in mouse and man. Carreno BM, et al. **J Immunol** 1995 Nov 15; 155(10):4726–33

Allele–specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. Neisig A, et al. **J Immunol** 1996 May 1; 156(9):3196–206

Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2–microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. Song R, et al. **J Immunol** 1996 Jun 1;156(11):4182–90

TAP–independent selection of CD8+ intestinal intraepithelial lymphocytes. Sydora BC, et al. **J Immunol** 1996 Jun 1;156(11):4209–16

Selection and binding of peptides to human transporters associated with antigen processing and rat cim–a and –b. Wang P, et al. **J Immunol** 1996 Jul 1;157(1):213–20

Rapid stimulation of EAAC1–mediated Na+–dependent L–glutamate transport activity in C6 glioma cells by phorbol ester. Dowd LA, et al. **J Neurochem** 1996 Aug; 67(2):508–16

Regional deafferentation down–regulates subtypes of glutamate transporter proteins. Ginsberg SD, et al. **J Neurochem** 1995 Dec;65(6):2800–3

Fimbria–fornix transections selectively down–regulate subtypes of glutamate transporter and glutamate receptor proteins in septum and hippocampus. Ginsberg SD, et al. **J Neurochem** 1996 Sep;67(3):1208–16

Increase in chloride–dependent L–glutamate transport activity in synaptic membrane after in vitro ischemic treatment. Koyama Y, et al. **J Neurochem** 1995 Oct; 65(4):1798–804

Nerve injury enhances rat neuronal glutamate transporter expression: identification by differential display PCR. Kiryu S, et al. **J Neurosci** 1995 Dec;15(12):7872–8

Microdialysis as a tool for in vivo investigation of glutamate transport capacity in rat brain. Bruhn T, et al. **J Neurosci Methods** 1995 Jul;59(2):169–74

Expression of multidrug resistance–associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Zhou DC, et al. **Leukemia** 1995 Oct;9(10):1661–6

ATP–binding cassette transporter in Saccharomyces cerevisiae mitochondria. Leighton J. **Methods Enzymol** 1995;260:389–96

Endocytosis and vacuolar degradation of the plasma membrane–localized Pdr5 ATP–binding cassette multidrug transporter in Saccharomyces cerevisiae. Egner R, et al. **Mol Cell Biol** 1995 Nov;15(11):5879–87

A family of bacteriocin ABC transporters carry out proteolytic processing of their substrates concomitant with export. Håvarstein LS, et al. **Mol Microbiol** 1995 Apr; 16(2):229–40

Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Rothstein JD, et al. **Neuron** 1996 Mar; 16(3):675–86

Biology of membrane transport proteins. Sadée W, et al. **Pharm Res** 1995 Dec;12(12):1823–37 (105 ref.)

Retinal glial cell glutamate transporter is coupled to an anionic conductance. Eliasof S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4153–8

ATP–dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Paul S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6929–34

Dependence of peptide binding by MHC class I molecules on their interaction with TAP. Grandea AG 3rd, et al. **Science** 1995 Oct 6;270(5233):105–8

PHARMACOLOGY

Cells treated with TAP–2 antisense oligonucleotides are potent antigen–presenting cells in vitro and in vivo. Nair SK, et al. **J Immunol** 1996 Mar 1;156(5):1772–80

PHYSIOLOGY

Experimental modulation of MRP (multidrug resistance–associated protein)–mediated resistance. Twentyman PR, et al. **Eur J Cancer** 1996 Jun; 32A(6):1002–9 (61 ref.)

Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system. Oxenius A, et al. **Eur J Immunol** 1995 Dec;25(12):3402–11

Down–regulation of glial glutamate transporters after glutamatergic denervation in the rat brain. Levy LM, et al. **Eur J Neurosci** 1995 Oct 1;7(10):2036–41

Neurotransmitter transporters: molecular biology, function, and regulation. Borowsky B, et al. **Int Rev Neurobiol** 1995; 38:139–99 (250 ref.)

Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P–glycoprotein in hepatobiliary organic anion transport. Beukeveld GJ, et al. **J Hepatol** 1996 Mar;24(3):343–52

The role of mdr2 P–glycoprotein in biliary lipid secretion. Cross–talk between cancer research and biliary physiology. Oude Elferink RP, et al. **J Hepatol** 1995 Nov;23(5):617–25 (62 ref.)

Residues in TAP2 peptide transporters controlling substrate specificity. Momburg F, et al. **J Immunol** 1996 Mar 1; 156(5):1756–63

Lack of conventional ATPase properties in CFTR chloride channel gating. Schultz BD, et al. **J Membr Biol** 1996 May; 151(1):63–75

Characterization of an Na(+)–dependent glutamate/aspartate transporter from cultured Bergmann glia. Ruiz M, et al. **Neuroreport** 1995 Oct 23;6(15):2041–4

Molecular cloning and expression of a cyclic AMP–activated chloride conductance regulator: a novel ATP–binding cassette transporter. van Kuijck MA, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5401–6

TOXICITY

Peroxynitrite inhibits glutamate transporter subtypes. Trotti D, et al. **J Biol Chem** 1996 Mar 15;271(11):5976–9

ABDOMEN

Theoretically optimal duty cycles for chest and abdominal compression during external cardiopulmonary resuscitation [see comments] Babbs CF, et al. **Acad Emerg Med** 1995 Aug;2(8):698–707. Comment in: Acad Emerg Med 1995 Aug;2(8):669–71.

Fat distribution and cardiovascular risk factors in obese adolescent girls: importance of the intraabdominal fat depot. Caprio S, et al. **Am J Clin Nutr** 1996 Jul;64(1):12–7

Body fat distribution and dyslipidemia [editorial; comment] Brunzell JD, et al. **Am J Med** 1995 Nov;99(5):457–8. Comment on: Am J Med 1995 Nov;99(5):459–64.

Uterine contractility as assessed by abdominal surface recording of electromyographic activity in rats during pregnancy. Buhimschi C, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):744–53

Changes in lung and chest wall properties with abdominal insufflation of carbon dioxide are immediately reversible. Fahy BG, et al. **Anesth Analg** 1996 Mar;82(3):501–5

The retained surgical sponge. Kaiser CW, et al. **Ann Surg** 1996 Jul;224(1):79–84

Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra–abdominal infections. The Intra–Abdominal Infection Study Group. Solomkin JS, et al. **Ann Surg** 1996 Mar;223(3):303–15

Planned relaparotomy vs relaparotomy on demand in the treatment of intra–abdominal infections. The Peritonitis Study Group of the Surgical Infection Society–Europe. Hau T, et al. **Arch Surg** 1995 Nov;130(11):1193–6; discussion 1196–7

Gossypiboma of the abdomen. Moyle H, et al. **Arch Surg** 1996 May;131(5):566–8

Prognosis in intra–abdominal infections. Multivariate analysis on 604 patients. Pacelli F, et al. **Arch Surg** 1996 Jun; 131(6):641–5

Guided fine needle absorption biopsy in the diagnosis of cysts in maritime workers. Bartelik W, et al. **Bull Inst Marit Trop Med Gdynia** 1993–94;44–45(1–4):33–7

A modified method of harvesting split–thickness skin grafts from the abdomen. Jong LR, et al. **Burns** 1995 Dec; 21(8):610–1

Journey through the abdominal underpass: the subperitoneal pathway of disease spread revisited. Obaro RO, et al. **Can Assoc Radiol J** 1995 Oct;46(5):353–62

Cephalosporin–metronidazole combinations in the management of intra–abdominal infections. Nicolau DP, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun; 22(1–2):189–94 (28 ref.)

Relationship between hydration of lean body mass and visceral adipose tissue. A clinical study of women. Armellini F, et al. **Int J Obes Relat Metab Disord** 1996 Jan;20(1):37–40

Major gene for abdominal visceral fat area in the Québec Family Study. Bouchard C, et al. **Int J Obes Relat Metab Disord** 1996 May;20(5):420–7

Effectiveness of an abdominal obesity reduction programme in men: the GutBuster "waist loss' programme. Egger G, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):227–31

Microsurgical excision of an abdominal mass in a gourami. Harms CA, et al. **J Am Vet Med Assoc** 1995 Nov 1; 207(9):1215–7

Meropenem versus imipenem/cilastatin in intra–abdominal infections requiring surgery. Meropenem Study Group. Geroulanos SJ. **J Antimicrob Chemother** 1995 Jul;36 Suppl

A:191–205

Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. Huizinga WK, et al. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:179–89

Neurologic investigations of childhood abdominal migraine: a combined electrophysiologic approach to diagnosis. Good PA. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S44–8

Adverse consequences of increased intra-abdominal pressure on bowel tissue oxygen. Bongard F, et al. **J Trauma** 1995 Sep;39(3):519–24; discussion 524–5

Dexfenfluramine and abdominal visceral fat [editorial; comment] Bouchard C. **Obes Res** 1996 Jan;4(1):77–9. Comment on: Obes Res 1996 Jan;4(1):1–7.

Systolic blood pressure is related to catecholamine sensitivity in subcutaneous abdominal fat cells. Hoffstedt J, et al. **Obes Res** 1996 Jan;4(1):21–6

Septic and other complications resulting from biliary stones placed in the abdominal cavity. Experimental study in rabbits. Tzardis PJ, et al. **Surg Endosc** 1996 May;10(5):533–6

Adhesion formation after laparoscopic anterior resection in a porcine model: a pilot study. Reissman P, et al. **Surg Laparosc Endosc** 1996 Apr;6(2):136–9

A new method of performing continuous intraabdominal drainage after pancreaticoduodenectomy. Kayahara M, et al. **Surg Today** 1995;25(8):679–83

Testicular dysmorphism associated with abdominoscrotal hydroceles during infancy. Chamberlain SA, et al. **Urology** 1995 Dec;46(6):881–2

Bilateral giant abdominoscrotal hydroceles in childhood. Serels S, et al. **Urology** 1996 May;47(5):763–5 (15 ref.)

[Abdominal variant of benign symmetrical Launois–Bensaude lipomatosis] Amon U, et al. **Hautarzt** 1995 Oct;46(10):722–5 (Eng. Abstr.) **(Ger)**

[Castleman's disease with abdominal localization. Report of an unusual case] Russo R, et al. **Minerva Chir** 1995 Oct; 50(10):901–3 (Eng. Abstr.) **(Ita)**

[Differentiated approach to repeated practicable cleansing of the abdominal cavity in patients with acute diffuse peritonitis] Bondarev VI, et al. **Klin Khir** 1995;(4):16–7 **(Rus)**

[Foreign body of the abdominal cavity] Portnov AN, et al. **Klin Khir** 1995;(7–8):49–50 **(Rus)**

[Abdominal pseudotumor and Whipple's disease] Guilera M, et al. **Gastroenterol Hepatol** 1996 May;19(5):247–9 (16 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Klippel Trenaunay Weber syndrome associated with abdominal hamartoma with undescended testis. Biswas K, et al. **Indian Pediatr** 1995 Jan;32(1):95–9

ANATOMY & HISTOLOGY

Laparoscopic anatomy of the abdomen in dorsally recumbent horses. Galuppo LD, et al. **Am J Vet Res** 1996 Jun; 57(6):923–31

Changes in chest wall compartment volumes on induction of anaesthesia with eltanolone, propofol and thiopentone. Spens HJ, et al. **Br J Anaesth** 1996 Mar;76(3):369–73

Laparoscopic surgical approach and anatomy of the abdomen in llamas. Anderson DE, et al. **J Am Vet Med Assoc** 1996 Jan 1;208(1):111–6

A methodology for co-registering abdominal MR images over multiple breath-holds. Feinberg DA, et al. **Magn Reson Med** 1995 Nov;34(5):770–4

[Significance of fat distribution for metabolic risk factors in healthy males of normal weight] Richelsen B, et al. **Ugeskr Laeger** 1996 Mar 4;158(10):1373–7 (Eng. Abstr.) **(Dan)**

[Comparative value of transverse abdominal diameter and fetal abdominal perimeter. 3844 biometric examinations] Grangé G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(8):843–9 (Eng. Abstr.) **(Fre)**

[Magnetic resonance with fat-saturation sequences in studying the upper abdomen: the normal semeiological aspects] Zuiani C, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):405–12 (Eng. Abstr.) **(Ita)**

BLOOD SUPPLY

Existence and co-existence of vasoactive substances in nerve fibres supplying the abdomino-pelvic arterial tree of the female pig and cow. Majewski M, et al. **Acta Histochem** 1995 Jul;97(3):235–56

MR angiography of abdominal and peripheral arteries. Techniques and clinical applications. Ekelund L, et al. **Acta Radiol** 1996 Jan;37(1):3–13 (109 ref.)

Hypoxia does not directly stimulate ischemically sensitive abdominal visceral afferents during ischemia. Fu LW, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H261–6

Arterial vascularization of the abdominal and pelvic regions in the degu, Octodon degus (Rodentia, Octodontidae). Ventura J, et al. **Anat Anz** 1996 Jun;178(3):285–91

Blood supply to the abdominal and pelvic regions in the Mediterranean pine vole, Microtus duodecimcostatus (Rodentia, Arvicolidae). Ventura J, et al. **Anat Histol Embryol** 1995 Jun;24(2):133–7

Visceral ischemia and organ dysfunction after thoracoabdominal aortic aneurysm repair. A clinical and cost analysis. Harward TR, et al. **Ann Surg** 1996 Jun; 223(6):729–34; discussion 734–6

Systemic venous enhancement patterns during dynamic abdominal CT. Mendelson DS, et al. **Clin Imaging** 1996 Apr–Jun;20(2):103–11

Vascular abdominal emergencies. Walker JS, et al. **Emerg Med Clin North Am** 1996 Aug;14(3):571–92 (85 ref.)

Magnetic resonance angiography of systemic thoracic and abdominal veins. Hartnell GG. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):281–94 (49 ref.)

Phase-contrast magnetic resonance angiography in the abdomen and thorax. Yuasa Y. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):327–38 (25 ref.)

Abdominal venous system in the normal fetus. Mari G, et al. **Obstet Gynecol** 1995 Nov;86(5):729–33

CT angiography with volume rendering: advantages and applications in splanchnic vascular imaging. Johnson PT, et al. **Radiology** 1996 Aug;200(2):564–8

Blood flow velocity waveforms of the abdominal arteries in appropriate- and small-for-gestational-age fetuses. Mari G, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):15–8

[Experimental evaluation of contrast medium enhanced high resolution MR angiography in the animal model. Gd-DTPA compared with Gd-DTPA-polylysine] Vogl TJ, et al. **Radiologe** 1996 Mar;36(3):254–62 (Eng. Abstr.) **(Ger)**

[Three-dimensional helical CT angiography of the abdomen] Shimizu T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Nov;55(14):946–51 (Eng. Abstr.) **(Jpn)**

[The role of anatomical factors in predicting the probability of the development of an abdominal ischemic syndrome] Bondarev VI, et al. **Morfologiia** 1995;108(1):7–9 (Eng. Abstr.) **(Rus)**

[Wounds of the abdomen and pelvis with damage to the major vessels] Lokhvitskiĭ SV, et al. **Vestn Khir Im I I Grek** 1995;154(3):65–7 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Cell fates in the adult abdomen of Drosophila are determined by wingless during pupal development. Shirras AD, et al. **Dev Biol** 1996 Apr 10;175(1):24–36

INJURIES see ABDOMINAL INJURIES

INNERVATION

Consequences and mechanisms of spike broadening of R20 cells in Aplysia californica. Ma M, et al. **J Neurosci** 1995 Oct;15(10):6720–34

Reappraisal of the inferior epigastric flap: a new neurovascular flap model in the rat. Hirigoyen MB, et al. **Plast Reconstr Surg** 1996 Sep;98(4):700–5

MICROBIOLOGY

Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. Jhee SS, et al. **Pharmacotherapy** 1995 Jul-Aug;15(4):472–8

PATHOLOGY

Reduction of peristaltic artifacts on magnetic resonance imaging of the abdomen: a comparative evaluation of three drugs. Martí-Bonmatí L, et al. **Abdom Imaging** 1996 Jul-Aug;21(4):309–13

Abdominopelvic MR imaging in the nonobstetric evaluation of pregnant patients. Forstner R, et al. **AJR Am J Roentgenol** 1996 May;166(5):1139–44

The female pelvic mass. Diagnosis and management. Russell DJ. **Med Clin North Am** 1995 Nov;79(6):1481–93 (19 ref.)

Free-hand technique with ordinary antisepsis in abdominal US-guided fine-needle punctures: three-year experience. Caturelli E, et al. **Radiology** 1996 Jun;199(3):721–3

[Technique of MRT-guided core biopsy in the abdomen using an open low-field scanner: feasibility and initial clinical results] Frahm C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jan;164(1):62–7 (Eng. Abstr.) **(Ger)**

[A technic of MRT-guided abdominal drainage with an open low-field magnet. Its feasibility and the initial results] Gehl HB, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):70–3 (Eng. Abstr.) **(Ger)**

[The role and significance of sagittal abdominal diameter in the determination of adipose tissue distribution] Stokić E, et al. **Med Pregl** 1996;49(5–6):217–20 (Eng. Abstr.) **(Scr)**

PHYSIOLOGY

The effects of neuromuscular block on peak airway pressure and abdominal elastance during pneumoperitoneum. Chassard D, et al. **Anesth Analg** 1996 Mar;82(3):525–7

The effects of increased abdominal pressure on lung and chest wall mechanics during laparoscopic surgery. Fahy BG, et al. **Anesth Analg** 1995 Oct;81(4):744–50

Effects of back support on intra-abdominal pressure and lumbar kinetics during heavy lifting. Woodhouse ML, et al. **Hum Factors** 1995 Sep;37(3):582–90

Fetal transverse cerebellar diameter/abdominal circumference ratio in assessing fetal size. Haller H, et al. **Int J Gynaecol Obstet** 1995 Aug;50(2):159–63

Massage-like stroking of the abdomen lowers blood pressure in anesthetized rats: influence of oxytocin. Kurosawa M, et al. **J Auton Nerv Syst** 1995 Dec 5;56(1–2):26–30

Effects of increased intra-abdominal pressure upon intracranial and cerebral perfusion pressure before and after volume expansion. Bloomfield GL, et al. **J Trauma** 1996 Jun;40(6):936–41; discussion 941–3

Cardiopulmonary effects of raised intra-abdominal pressure before and after intravascular volume expansion. Ridings PC, et al. **J Trauma** 1995 Dec;39(6):1071–5

The accumulation of visceral adipose tissue may be influenced by intra-abdominal temperature. Kahn HS. **Obes Res** 1996 May;4(3):297–9

[Does a tracheal bifurcation shift upward due to increased intraabdominal pressure during laparoscopic surgery?] Kurahashi K, et al. **Masui** 1995 Oct;44(10):1339–42 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Intra-abdominal pressure can be measured by measuring the pressure within the stomach [letter] Collee GG. **Intensive Care Med** 1996 Mar;22(3):269

Respiratory inductive plethysmography in the evaluation of lower airway obstruction during methacholine challenge in infants. Rusconi F, et al. **Pediatr Pulmonol** 1995 Dec; 20(6):396–402

The abdominal compartment syndrome. Burch JM, et al. **Surg Clin North Am** 1996 Aug;76(4):833–42 (35 ref.)

RADIATION EFFECTS

Is risk of diabetes mellitus increased after abdominal radiotherapy? [letter; comment] Hawkins MM, et al. **Lancet** 1996 Feb 24;347(9000):539–40. Comment on: Lancet 1995 Sep 2;346(8975):633–4.

Economic considerations in comparing whole abdominal radiotherapy with combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: how much economic data should be collected? Weeks JC. **Monogr Natl Cancer Inst** 1995;(19):17–9

[Whole abdominal irradiation for peritoneal dissemination of alimentary tract cancers] Sugahara S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Sep; 55(11):751–6 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Imaging of tuberculosis. II. Abdominal manifestations in 112 patients. Lundstedt C, et al. **Acta Radiol** 1996 Jul; 37(4):489–95

Helical CT of the abdomen: comparison of image quality between scan times of 0.75 and 1 sec per revolution. Herts BR, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):58–60

Fistulography in a difficult case: using a new, practical, and inexpensive device [letter] Oksüzoğlu G, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):281

With the high cost of nonionic contrast media, it has been suggested that we use a plain abdominal radiograph (KUB) and renal sonography to evaluate patients with hematuria. Zagoria RJ. **AJR Am J Roentgenol** 1995 Nov;165(5):1297

Segmental inertial parameters of the human trunk as determined from computed tomography. Pearsall DJ, et al. **Ann Biomed Eng** 1996 Mar-Apr;24(2):198–210

Abdominal tuberculosis: comparison of sonography and computed tomography. Sheikh M, et al. **J Clin Ultrasound** 1995 Sep;23(7):413–7

The utility of pre-operative abdominal computerized tomography scanning in colorectal surgery. Isbister WH, et al. **J R Coll Surg Edinb** 1996 Aug;41(4):232–4

Lead poisoning diagnosed by abdominal X-rays. Kulshrestha MK. **J Toxicol Clin Toxicol** 1996;34(1):107–8

Reduced need for sedation in patients undergoing helical CT of the chest and abdomen. White KS. **Pediatr Radiol** 1995; 25(5):344–6

Computed tomographic observations on subcutaneous fat: implications for liposuction. Johnson D, et al. **Plast Reconstr Surg** 1996 Feb;97(2):387–96

HIV infection: analysis in 259 consecutive patients with abnormal abdominal CT findings. Radin R. **Radiology** 1995 Dec;197(3):712–22

[Apropos of evaluation. An attempt to modify diagnostic procedures in standard radiography of the abdomen] Nahum H, et al. **J Radiol** 1996 Mar;77(3):212–3 **(Fre)**

[Diagnostic results of abdominal computerized tomography in HIV-infected patients] Knollmann FD, et al. **Aktuelle Radiol** 1995 Nov;5(6):351–5 (Eng. Abstr.) **(Ger)**

[Calculated organ doses and effective dosage for computerized tomography examination of the thorax and abdomen: are these doses realistic?] Hidajat N, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 May;164(5):382–7 (Eng. Abstr.) **(Ger)**

[Distant migration of a broken Nystrom-Szulc nail used for hip arthrodesis] Pizio Z, et al. **Chir Narzadow Ruchu Ortop Pol** 1994;59(2):143–51 (Eng. Abstr.) **(Pol)**

[Increased abdominal perimeter and pain the right hypochondrium and both iliac fossa] Gutiérrez Aliaga P, et al. **Rev Clin Esp** 1996 Apr;196(4):257–8 **(Spa)**

RADIONUCLIDE IMAGING

Abdominal scintigraphy of CSF leak. Rajendran J, et al. **Clin Nucl Med** 1995 Dec;20(12):1111–2

Differentiation of malignant from benign pancreatic mass by Tl-201 abdominal SPECT. Bom HS, et al. **J Korean Med Sci** 1995 Apr;10(2):93–6

SURGERY

A maximal central venous oxygen saturation (SvO2max) for the surgical patient. Jenstrup M, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:29–32

A "bicycle–handlebar" type of incision for primary and secondary abdominoplasty. Baroudi R, et al. **Aesthetic Plast Surg** 1995 Jul–Aug;19(4):307–20 (27 ref.)

Partial subfascial abdominoplasty. Le Louarn C. **Aesthetic Plast Surg** 1996 Mar–Apr;20(2):123–7

Musculoaponeurotic plication in abdominoplasty: how durable are its effects? Netscher DT, et al. **Aesthetic Plast Surg** 1995 Nov–Dec;19(6):531–4

Laparoscopic sonography during abdominal laparoscopic surgery: technique and imaging findings. Bezzi M, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1193–8

The Kustner technique: a neglected transverse lower abdominal incision [letter; comment] Vercellini P, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1394–5. Comment on: Am J Obstet Gynecol 1995 Aug;173(2):399–405; discussion 405–6.

Acid–base homeostasis parallels anabolism in surgically stressed rats treated with GH and IGF–I. Evans SJ, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E968–74

Greater risk of incisional hernia with morbidly obese than steroid–dependent patients and low recurrence with prefascial polypropylene mesh. Sugerman HJ, et al. **Am J Surg** 1996 Jan;171(1):80–4

The efficacy of adding a continuous intravenous morphine infusion to patient–controlled analgesia (PCA) in abdominal surgery. Dawson PJ, et al. **Anaesth Intensive Care** 1995 Aug;23(4):453–8

Effects of midazolam on heart rate variability during surgery under spinal anaesthesia. Kawamoto M, et al. **Anaesth Intensive Care** 1995 Aug;23(4):464–8

Prolonged unilateral lower limb paresis following abdominal surgery with epidural and general anaesthesia. Lyons B, et al. **Anaesth Intensive Care** 1995 Aug;23(4):507–9

Single–dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol. Paech MJ, et al. **Anaesth Intensive Care** 1995 Oct;23(5):548–54

Peri–operative assessment of glomerular permeability. De Gaudio AR, et al. **Anaesthesia** 1995 Sep;50(9):810–2

The effect of posture on late postoperative oxygenation. Mynster T, et al. **Anaesthesia** 1996 Mar;51(3):225–7

Bilateral paravertebral analgesia for major abdominal vascular surgery: a preliminary report. Richardson J, et al. **Anaesthesia** 1995 Nov;50(11):995–8

Addition of low–dose ketamine to general anesthesia does not improve cardiovascular response during conventional abdominal surgery [letter; comment] Hirata S, et al. **Anesth Analg** 1995 Nov;81(5):1111–2. Comment on: Anesth Analg 1993 Dec;77(6):1161–5.

The role of the phrenic nerves in stress response in upper abdominal surgery. Segawa H, et al. **Anesth Analg** 1996 Jun;82(6):1215–24

The French–line abdominoplasty. Gerow FJ, et al. **Ann Plast Surg** 1996 May;36(5):530–5

The use of the transverse rectus abdominis musculocutaneous flap after abdominoplasty. Sozer SO, et al. **Ann Plast Surg** 1995 Oct;35(4):409–11; discussion 411–2

A better gastric lavage tube: a new use for an 'old' drain. Wedderburn A, et al. **Ann R Coll Surg Engl** 1995 Jul; 77(4):314

Umbilical entry as an alternative in laparoscopy [letter] Naude GP, et al. **Ann Surg** 1996 Aug;224(2):238

White blood cell counts in patients undergoing abdominal surgery. Blennerhassett L, et al. **Aust N Z J Surg** 1996 Jun;66(6):369–71

Prevention of respiratory complications after abdominal surgery: a randomised clinical trial [see comments] Hall JC, et al. **BMJ** 1996 Jan 20;312(7024):148–52; discussion 152–3. Comment in: BMJ 1996 May 4;312(7039):1158–9; discussion 1159–60. Comment in: BMJ 1996 May 4;312(7039):1159; discussion 1159–60. Comment in: BMJ 1996 May 4;312(7039):1159–60.

Postoperative analgesia by continuous extradural infusion of ropivacaine after upper abdominal surgery. Schug SA, et al. **Br J Anaesth** 1996 Apr;76(4):487–91

Comparison of i.v. and s.c. diamorphine infusions for the treatment of acute pain in children. Semple D, et al. **Br J Anaesth** 1996 Feb;76(2):310–2

Abdominal anaesthesia [letter] Heriot JA. **Br J Hosp Med** 1995 Jul 12–Aug 15;54(2–3):115

Optimum method for urinary drainage in major abdominal surgery: a prospective randomized trial of suprapubic versus urethral catheterization. O'Kelly TJ, et al. **Br J Surg** 1995 Oct;82(10):1367–8

Acute ventilatory complications during laparoscopic upper abdominal surgery. Wahba RW, et al. **Can J Anaesth** 1996 Jan;43(1):77–83 (35 ref.)

Risk of pulmonary complications after elective abdominal surgery [see comments] Lawrence VA, et al. **Chest** 1996 Sep;110(3):744–50. Comment in: Chest 1996 Sep;110(3):587–9.

Pulmonary function tests before surgery [editorial; comment] Macpherson DS. **Chest** 1996 Sep;110(3):587–9. Comment on: Chest 1996 Sep;110(3):744–50.

The differential regulation of the circulating levels of the insulin–like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery. Cotterill AM, et al. **Clin Endocrinol (Oxf)** 1996 Jan; 44(1):91–101

Endoscopic abdominoplasty with repair of diastasis recti and abdominal wall hernia. Core GB, et al. **Clin Plast Surg** 1995 Oct;22(4):707–22 (14 ref.)

Endoscopic abdominoplasty, mastopexy, and breast reduction. Faria–Correa MA. **Clin Plast Surg** 1995 Oct; 22(4):723–45 (9 ref.)

Perioperative endotoxemia and bacterial translocation during major abdominal surgery: evidence for the protective effect of endogenous prostacyclin? Brinkmann A, et al. **Crit Care Med** 1996 Aug;24(8):1293–301

The trauma celiotomy: the evolving concepts of damage control. Morris JA Jr, et al. **Curr Probl Surg** 1996 Aug; 33(8):611–700 (341 ref.)

Gastric myoelectric activity changes following open abdominal surgery in humans. Hotokezaka M, et al. **Dig Dis Sci** 1996 May;41(5):864–9

Effects of prostaglandin E1 on intra–operative central and peripheral temperatures during upper abdominal surgery. Matsukawa T, et al. **Eur J Anaesthesiol** 1995 Jul; 12(4):417–22

Mechanical factors influencing the incidence of burst abdomen. Niggebrugge AH, et al. **Eur J Surg** 1995 Sep; 161(9):655–61

The operative peritoneal fibrinolytic response to abdominal operation. Scott–Coombes DM, et al. **Eur J Surg** 1995 Jun; 161(6):395–9

Detection of neopterin, interleukin–6 and acute–phase proteins as parameters of potential monocyte activation in preoperative patients. Haupt W, et al. **Infection** 1995 Sep–Oct;23(5):263–6

Comparison of two solutions with different glucose concentrations for infusion therapy during laparotomies in infants. Fösel TH, et al. **Infusionsther Transfusionsmed** 1996 Apr;23(2):80–4

Morbidity of negative coeliotomy in trauma. Ross SE, et al. **Injury** 1995 Jul;26(6):393–4

Abdominal surgery alters the calibration of bioimpedance cardiac output measurement. Critchley LA, et al. **Int J Clin Monit Comput** 1996 Feb;13(1):1–8

Effect of intrathecal sufentanil on isoflurane requirements during lower abdominal surgery. Swenson JD, et al. **J Clin Anesth** 1995 Sep;7(6):477–80

Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. Lawrence VA, et al. **J Gen Intern Med** 1995 Dec;10(12):671–8

Laparoscopy–guided percutaneous button gastrostomy in children after previous abdominal surgery. Stylianos S, et al. **J Laparoendosc Surg** 1995 Jun;5(3):199–201

Abdomino perineal repair of pulsion enterocele. Brieger GM, et al. **J Obstet Gynaecol Res** 1996 Apr;22(2):151–6

Informed consent in Indian patients. Sanwal AK, et al. **J R Soc Med** 1996 Apr;89(4):196–8

Mammography before abdominoplasty [letter] Spear SL, et al. **Plast Reconstr Surg** 1996 May;97(6):1311

0.1% bupivacaine does not reduce the requirement for epidural fentanyl infusion after major abdominal surgery. Salomäki TE, et al. **Reg Anesth** 1995 Sep–Oct;20(5):435–43

The impact of previous abdominal surgery on outcome following laparoscopic cholecystectomy. Schirmer BD, et al. **Surg Endosc** 1995 Oct;9(10):1085–9

Fibrinolysis in human peritoneum during operation. Holmdahl L, et al. **Surgery** 1996 Jun;119(6):701–5

Clinical relevance of the fibrinogen uptake test in patients undergoing elective general abdominal surgery—relation to major thromboembolism and mortality. Fragmin Multicentre Study Group. Flordal PA, et al. **Thromb Res** 1995 Dec 15;80(6):491–7

Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double–blind multicenter trial. Bergqvist D, et al. **Vasa** 1996;25(2):156–60

Complications of celiotomy incisions in horses. Wilson DA, et al. **Vet Surg** 1995 Nov–Dec;24(6):506–14

Bedside placement of polyglycolic acid mesh: a novel treatment of uncomplicated abdominal wound dehiscence. Chendrasekhar A. **W V Med J** 1996 May–Jun;92(3):136–7

Comparison of cefotaxime plus metronidazole versus cefoxitin for prevention of wound infection after abdominal surgery. Kow L, et al. **World J Surg** 1995 Sep–Oct; 19(5):680–6; discussion 686

[Hydatid cysts of the liver ruptured into the thorax: which approach should be first choice? (letter)] Sakhri J, et al. **Ann Chir** 1996;50(3):284 **(Fre)**

[Thoughts on the role of celiosurgery in patients with major obesity] Lallement M, et al. **J Chir (Paris)** 1995 Oct; 132(10):386–9 (Eng. Abstr.) **(Fre)**

[Cardiovascular function during laparoscopic interventions in surgery and gynecology] Berg K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):446–50 (28 ref.) **(Ger)**

[A technic of MRT–guided abdominal drainage with an open low–field magnet. Its feasibility and the initial results] Gehl HB, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):70–3 (Eng. Abstr.) **(Ger)**

[A novel diagnostic method to study the residual pelvic cavity after Miles abdomino–pelvic resection] La Torre F, et al. **Minerva Chir** 1995 Jul–Aug;50(7–8):653–8 (Eng. Abstr.) **(Ita)**

[Analgesic efficacy of E2078 (dynorphin analog) in patients following abdominal surgery] Fujimoto K, et al. **Masui** 1995 Sep;44(9):1233–7 (Eng. Abstr.) **(Jpn)**

[Epidural buprenorphine does not improve diaphragmatic function after upper abdominal surgery] Fujimura N, et al. **Masui** 1996 Apr;45(4):428–32 (Eng. Abstr.) **(Jpn)**

[Evaluation of the effectiveness of cefazolin + + (Kefzol) in preventing infections in patients after abdominal surgery] Chaber A, et al. **Wiad Lek** 1994 Oct;47(19–20):756–62 (Eng. Abstr.) **(Pol)**

[Cefpiramide (Tamicin) in the treatment of purulent complications of abdominal surgery] Iakovlev VP, et al. **Antibiot Khimioter** 1995 Sep;40(9):30–4 (Eng. Abstr.) **(Rus)**

[Abdominal endoscopic surgery: brief history and present–day state] Malinovskii NN, et al. **Khirurgiia (Mosk)** 1995;(5):7–9 **(Rus)**

[Prevention and treatment of acute suppurative infection in emergency abdominal surgery] Ashrafov AA, et al. **Klin Khir** 1995;(4):29–31 **(Rus)**

[The prevention of surgical wound suppuration in abdominal surgery] Veligotskii NN, et al. **Klin Khir** 1995;(9–10):20–1 **(Rus)**

[The experimental morphological bases for using a microsurgical technic and demineralized bone in the restorative surgery of hollow organs and blood vessels] Kagan II, et al. **Morfologiia** 1995;108(2):20–4 (Eng. Abstr.) **(Rus)**

[The lysosomal hydrolase activity in the blood of patients with inflammatory processes in the parotid gland with surgical pathology of the organs of the abdominal cavity] Dolgov SN, et al. **Stomatologiia (Mosk)** 1995;74(4):16–8 (Eng. Abstr.) **(Rus)**

[Anaerobic infection in abdominal surgery] Bogomolova NS, et al. **Vestn Ross Akad Med Nauk** 1996;(2):30–3 (Eng. Abstr.) **(Rus)**

[Use of taurolin in the prevention of septic complications in emergency abdominal surgery] Popović M, et al. **Acta Chir Iugosl** 1991;38(1):23–33 (Eng. Abstr.) **(Scc)**

[The effect of the design and the direction of cutaneous flaps in the phenomenon of delay: an experimental study on rabbits] Arranz López JL, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):9–13 (Eng. Abstr.) **(Spa)**

[Air embolism: an infrequent complication of abdominal surgery? (letter)] Anadón MP, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):399 **(Spa)**

ULTRASONOGRAPHY

Laparoscopic sonography during abdominal laparoscopic surgery: technique and imaging findings. Bezzi M, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1193–8

Diagnosis of abdominal tuberculosis: sonographic findings in patients with early disease. Jain R, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1391–5

Does routine abdominal ultrasound enhance diagnostic accuracy in irritable bowel syndrome? Francis CY, et al. **Am J Gastroenterol** 1996 Jul;91(7):1348–50

Abdominal lymphadenopathy in benign diseases: sonographic detection and clinical significance. Gimondo P, et al. **J Ultrasound Med** 1996 May;15(5):353–9; quiz 361–2

Abdominal sonographic findings at primary diagnosis of acute lymphoblastic leukemia in children: a comparison with different clinical risk factors. Ojala AE, et al. **Pediatr Hematol Oncol** 1995 Jul–Aug;12(4):355–61

Areas of increased echogenicity in the fetal abdomen: diagnosis and significance. Rypens FF, et al. **Radiographics** 1995 Nov;15(6):1329–44; discussion 1344–5 (58 ref.)

Ultrasonography of the acute pediatric abdomen. Hayden CK Jr. **Radiol Clin North Am** 1996 Jul;34(4):791–806 (86 ref.)

Free–hand technique with ordinary antisepsis in abdominal US–guided fine–needle punctures: three–year experience. Caturelli E, et al. **Radiology** 1996 Jun;199(3):721–3

The significance of echogenic areas in the fetal abdomen. Carroll SG, et al. **Ultrasound Obstet Gynecol** 1996 Apr; 7(4):293–8 (58 ref.)

The value of ultrasonic abdominal circumference in the prediction of gestational age. Dare FO, et al. **West Afr J Med** 1996 Jan–Mar;15(1):45–9

[Ultrasound findings in HIV patients] Lüthen R, et al. **Bildgebung** 1995 Dec;62(4):271–80 (45 ref.) (Eng. Abstr.) **(Ger)**

[Abdominal ultrasound as a screening method] Tatò F, et al. **Bildgebung** 1995 Dec;62(4):225–9 (Eng. Abstr.) **(Ger)**

[The effectiveness of reaferone in chronic myeloid leukemia assessed with ultrasonic and histomorphologic examination] Abdulkadyrov KM, et al. **Vopr Onkol** 1996;42(3):51–6 (Eng. Abstr.) **(Rus)**

ABDOMEN, ACUTE

BLOOD

C–reactive protein for the evaluation of acute abdominal pain. Chi CH, et al. **Am J Emerg Med** 1996 May;14(3):254–6

White blood cell counts in patients undergoing abdominal surgery. Blennerhassett L, et al. **Aust N Z J Surg** 1996 Jun;66(6):369–71

DIAGNOSIS

"Acute appendicitis" of neurosurgical origin. Shoshan Y, et

al. **Eur J Surg** 1996 Apr;162(4):343–5

Intussusception presenting to a paediatric accident and emergency department. Macdonald IA, et al. **J Accid Emerg Med** 1995 Sep;12(3):182–6

Pneumatic rupture of the colon: a sinister consequence of criminal violence [letter] Losanoff J, et al. **J Emerg Med** 1995 Nov–Dec;13(6):821–2

Cost–effective evaluation and management of the acute abdomen. Gill BD, et al. **Surg Clin North Am** 1996 Feb; 76(1):71–82 (13 ref.)

[Laparoscopy in acute abdomen (editorial)] Hovendal CP. **Ugeskr Laeger** 1996 Apr 22;158(17):2366 **(Dan)**

[Laparoscopy in suspected acute appendicitis. Experiences with the first 233 laparoscopies at a university hospital department] Pedersen AG, et al. **Ugeskr Laeger** 1996 Apr 22;158(17):2377–80 (Eng. Abstr.) **(Dan)**

[Radiological case of the week (2). Intestinal wall gangrene in mesenterial infarction with intramural and intraportal gas] Krestin GP. **Schweiz Rundsch Med Prax** 1995 Oct 24; 84(43):1239–41 **(Ger)**

[Acute abdomen in pregnancy. Diagnosis of surgical causes] Bøe HA, et al. **Tidsskr Nor Laegeforen** 1996 Feb 20; 116(5):600–3 (Eng. Abstr.) **(Nor)**

[Is medical/surgical false acute abdomen a clinical reality?] Blidaru P, et al. **Chirurgia (Bucur)** 1995;44(2):55–62 (Eng. Abstr.) **(Rum)**

[Laparoscopy with local anesthesia in the diagnosis of acute and traumatic abdomen (letter)] Serrano L, et al. **Rev Esp Enferm Dig** 1996 May;88(5):383–4 **(Spa)**

[Severe abdominal symptoms may be disguised by NSAID preparations] **Lakartidningen** 1996 May 29;93(22):2169 **(Swe)**

[More penalties without reason by the disciplinary board. Criticism against the handling of appendicitis] Andersson R. **Lakartidningen** 1996 Jun 26;93(26–27):2524–5 **(Swe)**

[Even children may be affected by malignant abdominal tumors. Far too long diagnostic delay in many cases] Lundkvist K, et al. **Lakartidningen** 1996 Jun 12; 93(24):2333–6 **(Swe)**

ECONOMICS

Cost–effective evaluation and management of the acute abdomen. Gill BD, et al. **Surg Clin North Am** 1996 Feb; 76(1):71–82 (13 ref.)

ETIOLOGY

Perforated gastric ulcer in children. Case report. Dilek ON, et al. **Acta Chir Belg** 1995;95(4 Suppl):182–3

The laparoscopic approach of a torsion of a benign mature ovarian teratoma: a case report and review of the literature. Van de Walle P, et al. **Acta Chir Belg** 1996 Apr;96(2):95–8

Hemobilia: a rare complication of cholecystitis and cholecystolithiasis. Case report. Willemsen PJ, et al. **Acta Chir Belg** 1996 Apr;96(2):93–4

Heterotopic pregnancy after in vitro fertilization. Sucov A, et al. **Am J Emerg Med** 1995 Nov;13(6):641–3

Jejunal diverticulitis: an unusual cause of acute abdomen. Leon CJ, et al. **Am J Gastroenterol** 1996 Feb;91(2):393–4

Acute abdomen: an atypical presentation of pubic osteomyelitis. Pang KW, et al. **Bull Hosp Jt Dis** 1995; 54(2):106–8

Unusual presentation of abdominal pregnancy. Shava J, et al. **Cent Afr J Med** 1995 Sep;41(9):293–4

Acute abdomen from pedicle torsion ectopic pelvic spleen. A case report and review of the literature. Pizzo A, et al. **Clin Exp Obstet Gynecol** 1996;23(1):37–8 (5 ref.)

CT appearance of acute abdomen as initial presentation in lymphoma of the large and small bowel. Tamm EP, et al. **Clin Imaging** 1996 Jan–Mar;20(1):21–5

Acute abdomen and intestinal necrosis produced by varicella–zoster virus in an immunocompromised host. Sanz Moreno J, et al. **Clin Infect Dis** 1996 May;22(5):857–8

Vascular abdominal emergencies. Walker JS, et al. **Emerg Med Clin North Am** 1996 Aug;14(3):571–92 (85 ref.)

Luteinized thecoma with sclerosing peritonitis presenting as an acute abdomen. Spiegel GW, et al. **Gynecol Oncol** 1996 May;61(2):275–81

Spontaneous hemoperitoneum. Lucha PA Jr. **J Am Osteopath Assoc** 1996 Jun;96(6):364–5 (7 ref.)

Use of laparoscopy in the treatment of acute and chronic right lower quadrant pain [see comments] Morfesis FA, et al. **J Ky Med Assoc** 1996 Jan;94(1):16–21. Comment in: J Ky Med Assoc 1996 Apr;94(4):160.

Primary omental torsion in a 6–year–old girl. Oğuzkurt P, et al. **J Pediatr Surg** 1995 Dec;30(12):1700–1

Murphy's sign, acute cholecystitis and elderly people. Adedeji OA, et al. **J R Coll Surg Edinb** 1996 Apr;41(2):88–9

Streptococcal myositis and the acute abdomen: a case report. Segar A, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):328–9

Abdominal emergency in a dialysis patient: haemolysis from kinking of dialysis tubing. Rambausek M, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2141–3

Giant ovarian leiomyoma as a rare cause of acute abdomen and hydronephrosis. Khaffaf N, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):872–3

Endometriosis of the appendix with decidual polyp formation: a rare cause of acute appendicitis during pregnancy. Silvestrini IE, et al. **P R Health Sci J** 1995 Sep;14(3):223–5

Case records of the Medical College of Virginia: a 10–year–old girl presenting with an acute onset of abdominal pain [clinical conference] Cunnion KM, et al. **Pediatr Emerg Care** 1996 Feb;12(1):52–5

Perforation of the colon in an adolescent girl. Kinnane J, et al. **Pediatr Emerg Care** 1995 Aug;11(4):230–2

Traumatic rupture of an unsuspected mesenteric cyst: an uncommon cause of an acute surgical abdomen following a minor fall. Klein MD. **Pediatr Emerg Care** 1996 Feb; 12(1):40

Acute abdomen due to gastric volvulus: diagnostic value of a single plain radiograph. Andiran F, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S240

Acute abdominal pain in chronic pancreatitis: hemorrhage from a pseudoaneurysm? [published erratum appears in Z Gastroenterol 1995 Oct;33(10):following table of contents] Mahlke R, et al. **Z Gastroenterol** 1995 Jul;33(7):404–7

[Rupture of follicular and corpus luteum ovarian cysts—the cause of acute gynecological abdomen] Goranov M, et al. **Akush Ginekol (Sofiia)** 1995;34(3):66–7 (Eng. Abstr.) **(Bul)**

[Acute abdominal complications after thoracic–pulmonary operations] Kolarov I, et al. **Khirurgiia (Sofiia)** 1995; 48(6):44–6 (Eng. Abstr.) **(Bul)**

[Abdominal emergencies of infectious origin] Porcel A, et al. **Ann Radiol (Paris)** 1996;39(1):15–36 (20 ref.) (Eng. Abstr.) **(Fre)**

[Management of patients with pain in the right iliac fossa and human immunodeficiency virus infection] Barthod F, et al. **J Chir (Paris)** 1996 Jan;133(1):12–5 (Eng. Abstr.) **(Fre)**

[Acute solitary diverticulitis of the cecum, a rare cause of acute abdomen. Apropos of 9 cases and review of the literature] Villalba Caballero R, et al. **J Chir (Paris)** 1995 Jun–Jul;132(6–7):299–304 (25 ref.) (Eng. Abstr.) **(Fre)**

[Surgical emergency disclosing sarcoidosis. Apropos of a case] Leleu O, et al. **Rev Pneumol Clin** 1996;52(3):196–8 (Eng. Abstr.) **(Fre)**

[Acute abdomen in extensive thrombosis in the inferior vena cava collateral circulation] Biesold M, et al. **Aktuelle Radiol** 1996 Mar;6(2):102–4 (Eng. Abstr.) **(Ger)**

[Efficacy of basic surgical diagnosis in acute abdominal pain] Cassina P, et al. **Chirurg** 1996 Mar;67(3):254–60 (Eng. Abstr.) **(Ger)**

[The torsion of an accessory liver lobe as the rare cause of acute abdomen] Betge L. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1318–20 (11 ref.) (Eng. Abstr.) **(Ger)**

[Torsion of the myoma pedicle as a rare cause of ileus in puerperium] Mickel I, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):721–3 (Eng. Abstr.) **(Ger)**

[24–year–old patient with acute abdomen and ascites] Lessing P, et al. **Internist (Berl)** 1995 Oct;36(10):995–8 **(Ger)**

[Clinical standardization in acute abdominal pain (editorial; comment)] Farthmann EH. **Langenbecks Arch Chir** 1996; 381(2):63–4. Comment on: Langenbecks Arch Chir 1996;381(2):65–74. **(Ger)**

[Clinical standardization in acute abdominal pain (see comments)] Franke C, et al. **Langenbecks Arch Chir** 1996; 381(2):65–74 (Eng. Abstr.). Comment in: Langenbecks Arch Chir 1996;381(2):63–4. **(Ger)**

[Acute abdomen in abdominal actinomycosis] Müller R, et al. **Leber Magen Darm** 1996 Mar;26(2):109–12 (Eng. Abstr.) **(Ger)**

[Cyst of the major omentum—laparoscopic diagnosis] Wermelinger S, et al. **Schweiz Rundsch Med Prax** 1995 Sep 12;84(37):1010–2 (Eng. Abstr.) **(Ger)**

[Renal angiomyolipoma causing an acute abdomen] Artese L, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):901–7 (Eng. Abstr.) **(Ita)**

[Peritoneal mesothelioma as a rare case of acute abdomen. Review of the literature] Cipollone G, et al. **Chir Ital** 1994; 46(6):73–9 (86 ref.) (Eng. Abstr.) **(Ita)**

[Intestinal intussusception in children] Baracchini A, et al. **Minerva Pediatr** 1995 Jun;47(6):215–9 (Eng. Abstr.) **(Ita)**

[Clinical study of ten cases with acute abdomen after eating raw firefly squid (Watasenia scintillans, Hotaruika), which are probably due to type X larvae of the suborder spirurina] Aoyama S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May;93(5):312–21 (Eng. Abstr.) **(Jpn)**

[Acute abdomen caused by torsion of the omentum—case report] Jovović M, et al. **Vojnosanit Pregl** 1995 Mar–Apr; 52(2):178–9 **(Scr)**

[Spontaneous bladder perforation secondary to bacterial cystitis. Cause of acute abdomen in diabetic elderly] Rodríguez Rodríguez A, et al. **Actas Urol Esp** 1995 May; 19(5):393–7 (14 ref.) (Eng. Abstr.) **(Spa)**

[Torsion of the great epiploon as cause of acute abdomen] García–Pugés AM, et al. **Rev Esp Enferm Dig** 1996 Jan; 88(1):39–42 (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Pneumonia in unexpected locations: an occult cause of pediatric abdominal pain. Kanegaye JT, et al. **J Emerg Med** 1995 Nov–Dec;13(6):773–9

RADIOGRAPHY

What radiographic views constitute acute abdominal series? Mindelzun RE, et al. **AJR Am J Roentgenol** 1996 Mar; 166(3):716–7

Radiology for the surgeon. Case 7. Primary epiploic appendagitis. Garant M, et al. **Can J Surg** 1996 Feb; 39(1):10, 35

CT appearance of acute abdomen as initial presentation in lymphoma of the large and small bowel. Tamm EP, et al. **Clin Imaging** 1996 Jan–Mar;20(1):21–5

Linear hepatic gas shadows in a woman with acute abdominal pain. Hariharan R, et al. **Hosp Pract (Off Ed)** 1996 Jan 15;31(1):37–8

Atypical presentation in the elderly—case report of an acute abdomen. Yap KB, et al. **Singapore Med J** 1995 Feb; 36(1):96–8

[Digestive perforations and occlusions] Mehdi M, et al. **Ann Radiol (Paris)** 1996;39(1):5–13 (Eng. Abstr.) **(Fre)**

[Interventional radiology and abdominal emergencies] Rotenberg L, et al. **Ann Radiol (Paris)** 1996;39(2):89–103 (35 ref.) (Eng. Abstr.) **(Fre)**

[Enhanced accuracy of the X–ray diagnosis of acute abdomen with patient in the supine (pregnancy standard) position] Szántó D, et al. **Orv Hetil** 1995 Oct 22;136(43):2329–32 (Eng. Abstr.) **(Hun)**

SURGERY

White blood cell counts in patients undergoing abdominal surgery. Blennerhassett L, et al. **Aust N Z J Surg** 1996 Jun;66(6):369–71

[Surgery in childhood at the hospital for basic and routine general management] Willital GH. **Chirurg** 1996 Jun; 67(6):567–75 (28 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic surgery in abdominal emergencies] Saccia A. **Minerva Chir** 1995 Oct;50(10):859–61 (Eng. Abstr.) **(Ita)**

[Correction of surgical stress during different stages of the treatment of children with acute diseases of abdominal organs] Moskalenko VZ, et al. **Klin Khir** 1995;(4):25–7 **(Rus)**

[Methods of prevention of complications and improving results of relaparotomy in the experience of aviation medicine] Zaĭtsev VT, et al. **Klin Khir** 1995;(5):49–51 **(Rus)**

THERAPY

Endoscopic reduction of acute gastric volvulus. Kodali VP, et al. **J Clin Gastroenterol** 1995 Dec;21(4):331–2

[Acute gastroenterology in black Africa (letter)] Baldi WG. **Schweiz Med Wochenschr** 1995 Dec 9;125(49):2405 **(Ger)**

ULTRASONOGRAPHY

Ultrasonography of the acute pediatric abdomen. Hayden CK Jr. **Radiol Clin North Am** 1996 Jul;34(4):791–806 (86 ref.)

[Effect of intestinal ultrasound on choice of surgical procedure in acute abdominal pain] Heistermann HP, et al. **Ultraschall Med** 1995 Dec;16(6):288–92 (Eng. Abstr.) **(Ger)**

[Role of ultrasonography in abdominal surgical emergencies. Our experience] Cardi F, et al. **Ann Ital Chir** 1996 Jan–Feb; 67(1):61–4 (Eng. Abstr.) **(Ita)**

ABDOMINAL ABSCESS

[Recurrent intra–abdominal abscesses] Vokurka J, et al. **Bratisl Lek Listy** 1995 May;96(5):265–7 **(Cze)**

COMPLICATIONS

Endoscopic management of pancreatic duct leak complicated by retrogastric abscess. Sarzen CD. **Am J Gastroenterol** 1995 Nov;90(11):2039–41

[A rare cause of retroperitoneal fibrosis: actinomycosis] Koutani A, et al. **Ann Urol (Paris)** 1996;30(2):89–93 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Constituent analysis may permit improved diagnosis of intra–abdominal abscess. Galandiuk S, et al. **Am J Surg** 1996 Mar;171(3):335–9

Abdominal actinomycosis. Cintron JR, et al. **Dis Colon Rectum** 1996 Jan;39(1):105–8 (10 ref.)

Retroperitoneal abscesses—rare causes and atypical manifestations: report of two cases. La Greca G, et al. **Surg Today** 1995;25(11):965–9

[A subfascial abscess following cesarean section] Pranchev N. **Akush Ginekol (Sofiia)** 1995;34(1):34–5 **(Bul)**

[Acute abdomen in abdominal actinomycosis] Müller R, et al. **Leber Magen Darm** 1996 Mar;26(2):109–12 (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of intra–abdominal abscesses] Rieber A. **Rontgenpraxis** 1995 Dec;48(12):335–9 (18 ref.) **(Ger)**

[Abdominal actinomycosis in tubo–ovarian abscess] Theodoropoulos G, et al. **Zentralbl Gynakol** 1995; 117(9):494–7 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Ciprofloxacin vs. cefotaxime regimens for the treatment of intra–abdominal infections. Hoogkamp–Korstanje JA. **Infection** 1995 Sep–Oct;23(5):278–82

ETIOLOGY

Jejunal diverticulitis manifesting with abdominal wall abscess. Alvarez OA, et al. **Am J Gastroenterol** 1995 Nov; 90(11):2060–2 (10 ref.)

Salmonella inguinal abscess in a patient with systemic lupus erythematosus. Kumari TG, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S23

Abdominal mass in a patient with Crohn's disease. Ravichandran D, et al. **Postgrad Med J** 1995 Aug; 71(838):505–6

Intraabdominal abscesses following laparoscopic and open appendectomies. Tang E, et al. **Surg Endosc** 1996 Mar; 10(3):327–8

Retroperitoneal abscesses—rare causes and atypical manifestations: report of two cases. La Greca G, et al. **Surg Today** 1995;25(11):965–9

[Perforation in Crohn's ileitis and its consequences in the natural history of disease. 2. Consequences of perforation in the peritoneal cavity: diffuse septic peritonitis, abscesses, external and internal fistulas] Tonelli P. **Ann Ital Chir** 1995 Jul–Aug;66(4):457–66 (Eng. Abstr.) **(Ita)**

[Intra-abdominal infections caused by Eikenella corrodens in children] Gonzálvez Piñera J, et al. **Cir Pediatr** 1995 Oct;8(4):145–7 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

CD4+ T cells mediate preexposure-induced increases in murine intraabdominal abscess formation. Sawyer RG, et al. **Clin Immunol Immunopathol** 1995 Oct;77(1):82–8

METABOLISM

A new model of intraabdominal abscess: usefulness for hydrosaline metabolism studies in parenteral nutrition associated with sepsis. Guirao X, et al. **J Surg Res** 1995 Dec;59(6):658–65

MICROBIOLOGY

Structure and function of Bacteroides fragilis capsular polysaccharides: relationship to induction and prevention of abscesses. Tzianabos AO, et al. **Clin Infect Dis** 1995 Jun; 20 Suppl 2:S132–40 (35 ref.)

A case of Fusobacterium necrophorum sepsis. Martin MJ, et al. **J Infect** 1995 Sep;31(2):151–2

Splenic abscess due to brucella in childhood. A case report. Seçmeer G, et al. **Turk J Pediatr** 1995 Oct–Dec;37(4):403–6

[A case of the greater omentum abscess due to Peptostreptococcus ssp] Tsujimoto M, et al. **Kansenshogaku Zasshi** 1996 May;70(5):512–5 (Eng. Abstr.) **(Jpn)**

[Bacterial virulence factors and their role in the pathogenesis of pyogenic infections of the abdominal cavity and mediastinum] Kotulová D, et al. **Bratisl Lek Listy** 1995 May;96(5):241–4 (Eng. Abstr.) **(Slo)**

PATHOLOGY

[Abscess development caused by ingrown nitinol spiral as a fatal complication of a partially deteriorated MEMOSOND-PEG] Gossner L, et al. **Z Gastroenterol** 1996 Jun;34(6):378–81 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Good and laudable pus [editorial; comment] Gorbach SL. **J Clin Invest** 1995 Dec;96(6):2545. Comment on: J Clin Invest 1995 Dec;96(6):2727–31.

Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis [see comments] Tzianabos AO, et al. **J Clin Invest** 1995 Dec; 96(6):2727–31. Comment in: J Clin Invest 1996 Dec;96(6):2545.

RADIOGRAPHY

Appendiceal stump abscess. Filippi de la Palavesa MM, et al. **Abdom Imaging** 1996 Jan–Feb;21(1):65–6

Mucin-hypersecreting papillary cholangiocarcinoma presenting as abdominal wall abscess: CT and spiral CT cholangiography. Ko SF, et al. **Abdom Imaging** 1996 May–Jun;21(3):222–5

Clostridial infection of the abdomen: CT findings in two successfully treated patients. Spencer JA, et al. **AJR Am J Roentgenol** 1996 May;166(5):1094–6 (8 ref.)

[Septic portal vein thrombosis as a rare complication of Crohn disease with retroperitoneal abscess] Diehl SJ, et al. **Aktuelle Radiol** 1996 Mar;6(2):99–101 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Comparison of 99m technetium hexamethylpropylene-amine oxime labelled leucocyte with 111-indium tropolonate labelled granulocyte scanning and ultrasound in the diagnosis of intra-abdominal abscess. Weldon MJ, et al. **Gut** 1995 Oct;37(4):557–64

Indium-111 leucocyte scintigraphy and ultrasound scanning in the detection of intra-abdominal abscesses in patients without localizing signs. Carter CR, et al. **J R Coll Surg Edinb** 1995 Dec;40(6):380–2

Abdominal abscess detection: gallium, 111In-, and 99mTc-labeled leukocytes, and polyclonal and monoclonal antibodies. Datz FL. **Semin Nucl Med** 1996 Jan;26(1):51–64

SURGERY

Management of intra-abdominal abscesses in Crohn's disease. Ayuk P, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):5–10

Eisenmenger's syndrome and problems with anaesthesia. Jones P, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):214

Use of a laparoscopic trocar for percutaneous introduction of drains into intra-abdominal abscesses. Singh K, et al. **Br J Surg** 1996 May;83(5):670–1

Abdominal actinomycosis. Cintron JR, et al. **Dis Colon Rectum** 1996 Jan;39(1):105–8 (10 ref.)

Medical treatment of postappendectomy intraperitoneal abscesses in children. Héloury Y, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):149–51

[Abdominal abscess. Apropos of 530 cases] Ayerza HA. **Chirurgie** 1994–95;120(10):551–4; discussion 554–5 (Eng. Abstr.) **(Fre)**

–Chronic tubo-ovarian abscess with vaginal fistula after vaginal hysterectomy: combined laparoscopic-vaginal therapy– Rempen A. **Gynakol Geburtshilfliche Rundsch** 1995;35(4):226–8 (Eng. Abstr.) **(Ger)**

[Between extremes—plea for differentiated surgical therapy of intra-abdominal infections (editorial; comment)] Schumpelick V. **Leber Magen Darm** 1996 May;26(3):130–1 . Comment on: Leber Magen Darm 1996 May;26(3):144–8. Comment on: Leber Magen Darm 1996 May;26(3):151–4. **(Ger)**

[Surgical treatment of intra-abdominal abscesses (see comments)] Seelig MH, et al. **Leber Magen Darm** 1996 May;26(3):151–4 (Eng. Abstr.). Comment in: Leber Magen Darm 1996 May;26(3):130–1. **(Ger)**

THERAPY

Nonoperative management for intra-abdominal abscesses. Shuler FW, et al. **Am Surg** 1996 Mar;62(3):218–22

ULTRASONOGRAPHY

Indium-111 leucocyte scintigraphy and ultrasound scanning in the detection of intra-abdominal abscesses in patients without localizing signs. Carter CR, et al. **J R Coll Surg Edinb** 1995 Dec;40(6):380–2

[Diagnostic case: infected cyst of the urachus] Faure F, et al. **J Radiol** 1995 Dec;76(12):1120–1 **(Fre)**

ABDOMINAL CRAMPS see **COLIC**

ABDOMINAL DECOMPRESSION see **LOWER BODY NEGATIVE PRESSURE**

ABDOMINAL INJURIES

Transaxial gunshot injuries. Hirshberg A, et al. **J Trauma** 1996 Sep;41(3):460–1

Blunt trauma to the abdomen. Haller JA Jr. **Pediatr Rev** 1996 Jan;17(1):29–31 (8 ref.)

[Rupture of the duodenum caused by closed abdominal trauma] Famà R, et al. **Minerva Chir** 1995 Jun;50(6):583–6 (Eng. Abstr.) **(Ita)**

[The changing trauma pattern and treatment. Laparotomy in major abdominal injuries (letter)] Husum H. **Tidsskr Nor Laegeforen** 1996 Apr 20;116(10):1259 **(Nor)**

[Transverse rupture of the pancreas in blunt abdominal trauma] Sorokolat AI, et al. **Klin Khir** 1995;(4):47–8 **(Rus)**

[Abdominal war injuries] Cuk V, et al. **Vojnosanit Pregl** 1994 Sep–Oct;51(5):376–80 (Eng. Abstr.) **(Scr)**

[Blast injuries of the intestines in abdominal injuries] Ignjatović D. **Vojnosanit Pregl** 1994 Jan–Feb;51(1):3–12 (Eng. Abstr.) **(Scr)**

[Perforation of hollow viscera in abdominal injuries] Civera Muñoz J, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):793–7 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Small bowel perforation following blunt abdominal trauma. Ceelen W, et al. **Acta Chir Belg** 1995;95(4 Suppl):187–9

Laparoscopic splenic salvage in blunt abdominal trauma [letter] Rizk N, et al. **Acta Chir Belg** 1995;95(4 Suppl):202–4

Segmental hepatic necrosis after blunt abdominal trauma: CT findings. Hatten MT, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):769–70

Traumatic occlusion of the renal artery: helical CT diagnosis. Nuñez D Jr, et al. **AJR Am J Roentgenol** 1996 Sep; 167(3):777–80

How should patients be evaluated radiographically who have microscopic hematuria after blunt trauma to the abdomen? Sandler CM. **AJR Am J Roentgenol** 1995 Nov; 165(5):1298–9

An unusual presentation of post-traumatic pseudocyst of the spleen: case report. Smith DR. **Ala Med** 1995 Nov–1996 Jan;65(5–7):26–8

Pneumothoraces secondary to blunt abdominal trauma: aids to plain film radiographic diagnosis and relationship to solid organ injury. Miller JA, et al. **Am Surg** 1996 May; 62(5):416–20

Evaluation of pancreatic injury after blunt abdominal trauma. Emmick RH Jr, et al. **Ann Emerg Med** 1996 May; 27(5):658–61

Intestinal perforation from trauma to an inguinal hernia. Reynolds RD. **Arch Fam Med** 1995 Nov;4(11):972–4

Acute appendicitis following abdominal trauma. Serour F, et al. **Arch Surg** 1996 Jul;131(7):785–6

Subcutaneous fat necrosis following traumatic pancreatitis. Lee MS, et al. **Australas J Dermatol** 1995 Nov;36(4):196–8

Radiology for the surgeon. Case 10. Traumatic abdominal wall disruption with hernia. Garant M. **Can J Surg** 1996 Aug;39(4):267, 286

Traumatic rupture of hydatid cysts. Leviav S, et al. **Can J Surg** 1996 Aug;39(4):293–6

Traumatic and non-traumatic pancreatitis in pediatric surgery. Schmittenbecher PP, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):86–91

Traumatic rupture of mesenteric cyst: a life-threatening complication of a rare lesion. Ulman I, et al. **Eur J Pediatr Surg** 1995 Aug;5(4):238–9

Selective embolization of pseudo-aneurysms of the renal artery after blunt abdominal injury in a patient with a single kidney. Steffens MG, et al. **Injury** 1996 Apr;27(3):219–20

Laparoscopic repair of a traumatic diaphragmatic hernia. Rasiah KK, et al. **J Laparoendosc Surg** 1995 Dec;5(6):405–7

Pseudoaneurysm of the proper hepatic artery with duodenal fistula appearing as a late complication of blunt abdominal trauma. Aboujaoude M, et al. **J Trauma** 1996 Jan; 40(1):123–5

Is computed tomography a useful adjunct to the clinical examination for the diagnosis of pediatric gastrointestinal perforation from blunt abdominal trauma in children? Albanese CT, et al. **J Trauma** 1996 Mar;40(3):417–21

Posttraumatic chylous ascites in a child: recognition and management of an unusual condition. Benhaim P, et al. **J Trauma** 1995 Dec;39(6):1175–7

Small bowel injury in children after blunt abdominal trauma: is diagnostic delay important? Bensard DD, et al. **J Trauma** 1996 Sep;41(3):476–83

Treatment of increasing intracranial pressure secondary to the acute abdominal compartment syndrome in a patient with combined abdominal and head trauma. Bloomfield GL, et al. **J Trauma** 1995 Dec;39(6):1168–70

Biliary tract injury following blunt abdominal trauma: case reports. Gerndt SJ, et al. **J Trauma** 1995 Sep;39(3):612–5

Intrasplenic posttraumatic pseudoaneurysm: echo color doppler diagnosis. Goletti O, et al. **J Trauma** 1996 Sep; 41(3):542–5

Embolization of splenic artery branch pseudoaneurysm after blunt abdominal trauma. James CA, et al. **J Trauma** 1996 May;40(5):835–7

Vasodilator provocation of occult urinary tract hemorrhage. Kerr A, et al. **J Trauma** 1996 Jan;40(1):152–4

Ureteral entrapment in the sacroiliac joint in pelvic trauma. Konety BR, et al. **J Trauma** 1996 Jan;40(1):150–1

Traumatic lumbar hernia: a seat belt injury. McCarthy MC, et al. **J Trauma** 1996 Jan;40(1):121–2 (10 ref.)

Posttraumatic Budd-Chiari syndrome treated with thrombolytic therapy and angioplasty. Patel NH, et al. **J Trauma** 1996 Feb;40(2):294–8

Computed tomography detection of active mesenteric hemorrhage following blunt abdominal trauma. Sher R, et al. **J Trauma** 1996 Mar;40(3):469–71

Significance of intraabdominal extraluminal air detected by CT scan in blunt abdominal trauma [letter; comment] Sherck J, et al. **J Trauma** 1996 Apr;40(4):674–5. Comment on: J Trauma 1995 Aug;39(2):331–3.

Renal artery pseudoaneurysm after blunt abdominal trauma: case report and literature review. Swana HS, et al. **J Trauma** 1996 Mar;40(3):459–61 (15 ref.)

Delayed rupture of the abdominal aorta in a child after a suspected handlebar injury. Tracy TF Jr, et al. **J Trauma** 1996 Jan;40(1):119–20

Gastrointestinal perforations in children: a continuing challenge to nonoperative treatment of blunt abdominal trauma. Ulman I, et al. **J Trauma** 1996 Jul;41(1):110–3

Intra-abdominal injury with handlebar hernia: case report and literature review. Yarbrough DR 3rd. **J Trauma** 1996 Jan;40(1):116–8 (21 ref.)

Intravascular stenting of traumatic abdominal aortic dissection. Marty-Ané CH, et al. **J Vasc Surg** 1996 Jan; 23(1):156–61 (13 ref.)

Traumatic rupture of an unsuspected mesenteric cyst: an uncommon cause of an acute surgical abdomen following a minor fall. Klein MD. **Pediatr Emerg Care** 1996 Feb; 12(1):40

Incidental mucinous cystadenocarcinoma of the appendix. Lee J, et al. **Postgrad Med J** 1996 Jan;72(843):55–6

Splenic Injuries in children after blunt abdominal trauma. Benya EC, et al. **Semin Ultrasound CT MR** 1996 Apr; 17(2):170–6 (31 ref.)

Diagnosis of pancreatic injury after blunt abdominal trauma. Lane MJ, et al. **Semin Ultrasound CT MR** 1996 Apr; 17(2):177–82 (29 ref.)

Gastric bezoar following penetrating abdominal injury. Diagnosis and endoscopic therapy. Kaplan LJ, et al. **Surg Endosc** 1996 Jan;10(1):62–4 (16 ref.)

Laparoscopic surgery in the management of traumatic hemoperitoneum in stable patients [see comments] Lujan-Mompean JA, et al. **Surg Endosc** 1995 Aug; 9(8):879–81. Comment in: Surg Endosc 1996 Jun;10(6):694–5.

An abdominal hernia secondary to blunt trauma. Lewis JV, et al. **Tenn Med** 1996 May;89(5):167–8

Renal pelvis rupture after blunt abdominal trauma. Gschwend JE, et al. **Urol Int** 1995;55(2):108–10

[Rupture of the ileocecal valve following blunt abdominal trauma in a child (letter)] Loup J. **J Chir (Paris)** 1996 Jun; 133(4):191–2 (Eng. Abstr.) **(Fre)**

[Atrio-caval shunt in injury to the suprahepatic vena cava. Apropos of a case and review of the literature] Orsoni P, et al. **J Chir (Paris)** 1995 Nov;132(11):438–41 (24 ref.) (Eng. Abstr.) **(Fre)**

[Post-traumatic thrombosis of the portal vein] Beaufort P, et al. **Presse Med** 1996 Feb 17;25(6):247–8 (Eng. Abstr.) **(Fre)**

[Disorders of immunity in chest and abdominal injuries] Chalenko VV, et al. **Vestn Khir Im I I Grek** 1992 Feb; 148(2):184–90 (Eng. Abstr.) **(Rus)**

[Postoperative progressive peritonitis in patients wounded in the abdomen] Mamuchishvili NK, et al. **Voen Med Zh** 1995 Nov;(11):31–3 . **(Rus)**

DIAGNOSIS

Therapeutic laparoscopy in trauma. Smith RS, et al. **Am J Surg** 1995 Dec;170(6):632–6; discussion 636–7

Limiting computed tomography to patients with peritoneal lavage–positive results reduces cost and unnecessary celiotomies in blunt trauma. Schreiber MA, et al. **Arch Surg** 1996 Sep;131(9):954–8; discussion 958–9

Blunt abdominal injuries. Diagnostic peritoneal lavage, ultrasonography and computed tomography scanning. Chiquito PE. **Injury** 1996 Mar;27(2):117–24 (92 ref.)

It is time we told the Emperor about his clothes [editorial; comment] Nance ML, et al. **J Trauma** 1996 Feb;40(2):185–6 . Comment on: J Trauma 1996 Feb;40(20:187–90.

Delayed diagnosis of pancreatic transection after blunt abdominal trauma. Smith DR, et al. **J Trauma** 1996 Jun; 40(6):1009–13

Laparoscopy in 121 consecutive patients with abdominal gunshot wounds. Sosa JL, et al. **J Trauma** 1995 Sep; 39(3):501–4; discussion 504–6

Missed injuries in abdominal trauma. Sung CK, et al. **J Trauma** 1996 Aug;41(2):276–82

Role of repeat computed tomography after emergency endoscopic retrograde pancreatography in the diagnosis of traumatic injury to pancreatic ducts. Takishima T, et al. **J Trauma** 1996 Feb;40(2):253–7

Laparoscopic evaluation of penetrating thoracoabdominal traumatic injuries. Ortega AE, et al. **Surg Endosc** 1996 Jan; 10(1):19–22

[Value of celioscopy in the diagnosis of abdominal wounds] de Watteville JC, et al. **Ann Chir** 1995;49(7):602–6 (Eng. Abstr.) **(Fre)**

[Abdominal injuries] Monnier-Cholley L, et al. **Ann Radiol (Paris)** 1996;39(1):45–56 (26 ref.) (Eng. Abstr.) **(Fre)**

[Laparoscopy in treatment of abdominal stab injuries] Waldner H, et al. **Chirurg** 1995 Nov;66(11):1105–9 (Eng. Abstr.) **(Ger)**

[Small bowel injuries in blunt abdominal trauma—a diagnostic problem!] Metzger J, et al. **Swiss Surg** 1995; (5):222–5 (Eng. Abstr.) **(Ger)**

[Blunt and penetrating abdominal trauma. Patient assessment algorithm and principles for management] Ertel W, et al. **Unfallchirurg** 1996 Apr;99(4):288–303 (28 ref.) **(Ger)**

[Diagnostic and tactical error in the treatment of closed abdominal trauma] Tomusiak TL, et al. **Klin Khir** 1995; (4):41 **(Rus)**

[Emergency radiation study in thoracoabdominal gunshot wounds] Ishchenko BI, et al. **Vestn Rentgenol Radiol** 1995 Sep–Oct;(5):14–6 (Eng. Abstr.) **(Rus)**

[Laparoscopy with local anesthesia in the diagnosis of acute and traumatic abdomen (letter)] Serrano L, et al. **Rev Esp Enferm Dig** 1996 May;88(5):383–4 **(Spa)**

DRUG THERAPY

Efficacy of an intraperitoneal antibiotic to reduce the incidence of infection in the trauma patient: a prospective, randomized study. Yelon JA, et al. **J Am Coll Surg** 1996 Jun;182(6):509–14

EPIDEMIOLOGY

A review of intestinal injury from blunt abdominal trauma. Munns J, et al. **Aust N Z J Surg** 1995 Dec;65(12):857–60 (15 ref.)

Review of liver trauma management in Tasmania: an analysis of risk factors for mortality and morbidity. Subramaniam P, et al. **Aust N Z J Surg** 1995 Dec;65(12):861–4

ETIOLOGY

Mesenteritis secondary to the use of a pneumatic jackhammer [published erratum appears in Eur J Gastroenterol Hepatol 1995 Aug;7(8):following 815] van der Hulst RW, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):573–5

Lumbar compression fractures secondary to lap-belt use in children. Sturm PF, et al. **J Pediatr Orthop** 1995 Jul–Aug; 15(4):521–3 (27 ref.)

Intraabdominal bleeding following laparoscopic adnexal surgery. A report of three cases. Wong SM, et al. **J Reprod Med** 1996 Apr;41(4):294–6

Shotgun slug injuries: case report and literature review. Gestring ML, et al. **J Trauma** 1996 Apr;40(4):650–3 (23 ref.)

[Urogenital injuries caused by projectiles. Data on recent conflicts and the North-American civilian experience] Houdelette P. **J Chir (Paris)** 1995 Oct;132(10):375–81 (19 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Immunoregulatory effects of indomethacin on rats with trauma. Pan YC, et al. **J Tongji Med Univ** 1995;15(4):234–7

METABOLISM

Ceftizoxime use in trauma celiotomy: pharmacokinetics and patient outcomes. Rosemurgy AS 2nd, et al. **J Clin Pharmacol** 1995 Nov;35(11):1046–51

MORTALITY

The changing pattern of penetrating torso trauma in KwaZulu/Natal—a clinical and pathological review. Muckart DJ, et al. **S Afr Med J** 1995 Nov;85(11):1172–4

NURSING

Management of upper abdominal solid organ injuries. Richardson JD, et al. **AORN J** 1996 May;63(5):907–16 (15 ref.)

PATHOLOGY

Experimental thoracoabdominal airgun wounds in a porcine model. McKenzie HJ, et al. **J Trauma** 1995 Dec; 39(6):1164–7

PHYSIOPATHOLOGY

Blunt abdominal trauma. Boulanger BR, et al. **Emerg Med Clin North Am** 1996 Feb;14(1):151–71 (89 ref.)

RADIOGRAPHY

Unenhanced CT scans in identifying hematomas after blunt abdominal trauma. Amendola MA, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1544–5

Radiologic management of abdominal trauma in pregnancy. Goldman SM, et al. **AJR Am J Roentgenol** 1996 Apr; 166(4):763–7 (33 ref.)

Low attenuation of acute traumatic hemoperitoneum on CT scans. Levine CD, et al. **AJR Am J Roentgenol** 1996 May; 166(5):1089–93

Acute rupture of the diaphragm due to blunt trauma: diagnostic sensitivity and specificity of CT. Murray JG, et al. **AJR Am J Roentgenol** 1996 May;166(5):1035–9

Diagnostic imaging in the evaluation of blunt abdominal trauma. Barloon TJ, et al. **Am Fam Physician** 1996 Jul; 54(1):205–9 (20 ref.)

Computed tomography: an unreliable indicator of pancreatic trauma. Akhrass R, et al. **Am Surg** 1996 Aug;62(8):647–51

The use of computed tomography in blunt abdominal injuries. Udekwu PO, et al. **Am Surg** 1996 Jan;62(1):56–9

Role of the trauma-room chest x-ray film in assessing the patient with severe blunt traumatic injury [see comments] McLellan BA, et al. **Can J Surg** 1996 Feb;39(1):36–41. Comment in: Can J Surg 1996 Feb;39(1):7.

Trauma-room chest x-ray films [editorial; comment] Waddell JP. **Can J Surg** 1996 Feb;39(1):7. Comment on: Can J Surg 1996 Feb;39(1):36–41.

Abdominal wall haematoma mimicking visceral injury: the role of CT scanning. Hill SA, et al. **Injury** 1995 Nov; 26(9):605–7

Computed tomography vs clinical and multidisciplinary procedures for early evaluation of severe abdomen and chest trauma—a cost analysis approach. Navarrete-Navarro P, et al. **Intensive Care Med** 1996 Mar; 22(3):208–12

Posttraumatic peritoneal fluid: is it a reliable indicator of intraabdominal injury in children? Taylor GA, et al. **J Pediatr Surg** 1995 Dec;30(12):1644–8

Arterial bleeding diagnosed by CT in hemodynamically stable victims of blunt trauma. DiGiacomo JC, et al. **J Trauma** 1996 Feb;40(2):249–52

Adrenocortical neoplasm disguised as a post-traumatic perinephric hematoma. Blake DP, et al. **Mil Med** 1996 Mar; 161(3):173–5

Imaging gastrointestinal perforation in pediatric blunt abdominal trauma. Jamieson DH, et al. **Pediatr Radiol** 1996; 26(3):188–94

CT of abdominal and pelvic trauma. Roberts JL. **Semin Ultrasound CT MR** 1996 Apr;17(2):142–69 (71 ref.)

Giant cyst of the liver with complete resolution following blunt trauma to the abdomen. Eber B, et al. **Z Gastroenterol** 1995 Dec;33(12):709–10

SURGERY

Experience with three prosthetic materials in temporary abdominal wall closure. Nagy KK, et al. **Am Surg** 1996 May;62(5):331–5

Incidence and risk factors for early small bowel obstruction after celiotomy for penetrating abdominal trauma. Tortella BJ, et al. **Am Surg** 1995 Nov;61(11):956–8

Penetrating ureteral injuries: the impact of associated injuries on management. Velmahos GC, et al. **Am Surg** 1996 Jun; 62(6):461–8

Management of upper abdominal solid organ injuries. Richardson JD, et al. **AORN J** 1996 May;63(5):907–16 (15 ref.)

Patterns of injury from major trauma in Victoria [letter; comment] Tulloh BR. **Aust N Z J Surg** 1996 Jul;66(7):491 . Comment on: Aust N Z J Surg 1995 Dec;65(12):848–52.

Open diagnostic peritoneal lavage [letter] Hamid Mat Sain A. **Br J Surg** 1996 Jun;83(6):868

Delayed pancreatoduodenectomy followed by delayed reconstruction for trauma. Mistry BM, et al. **Br J Surg** 1996 Apr;83(4):527

Visceral injury. Porter JM, et al. **Curr Opin Gen Surg** 1993; :62–8 (31 ref.)

The trauma celiotomy: the evolving concepts of damage control. Morris JA Jr, et al. **Curr Probl Surg** 1996 Aug; 33(8):611–700 (341 ref.)

Morbidity of negative coeliotomy in trauma. Ross SE, et al. **Injury** 1995 Jul;26(6):393–4

Complete disruption of the main pancreatic duct: a case successfully managed by percutaneous drainage. Ohno Y, et al. **J Pediatr Surg** 1995 Dec;30(12):1741–2

Significant morbidity and increased LOS [letter] Arrillaga A, et al. **J Trauma** 1996 Sep;41(3):572

Temporary intravenous bag silo closure in severe abdominal trauma. Fernandez L, et al. **J Trauma** 1996 Feb; 40(2):258–60

Truncal gunshot wounds in Finland, 1985 to 1989. Leppäniemi A, et al. **J Trauma** 1996 Mar;40(3 Suppl):S217–22

Complications after negative laparotomy for trauma: long-term follow-up in a health maintenance organization. Morrison JE, et al. **J Trauma** 1996 Sep;41(3):509–13

Aortic balloon control of a traumatic aortoenteric fistula after damage control laparotomy: a case report. Schwab CW, et al. **J Trauma** 1996 Jun;40(6):1021–3

Complete transection of the common bile duct following blunt abdominal trauma. A case report. Sofianos C, et al. **S Afr J Surg** 1994 Jun;32(2):44–5

Abdominal wall reconstruction after temporary abdominal wall closure in trauma patients. Yeh KA, et al. **South Med J** 1996 May;89(5):497–502

Abdominal vascular injuries. Mullins RJ, et al. **Surg Clin North Am** 1996 Aug;76(4):813–32 (45 ref.)

Laparoscopy in trauma. Poole GV, et al. **Surg Clin North Am** 1996 Jun;76(3):547–56 (48 ref.)

Laparoscopic surgery and the management of traumatic hemoperitoneum in stable patients [letter; comment] Hauser CJ, et al. **Surg Endosc** 1996 Jun;10(6):694–5. Comment on: Surg Endosc 1995 Aug;9(8):879–81.

Laparoscopic surgery and the management of traumatic hemoperitoneum in stable patients [letter] Shatz DV. **Surg Endosc** 1996 Jun;10(6):696; discussion 695

Isopneumic laparoscopy in general surgery and trauma: an update. Smith RS, et al. **Surg Laparosc Endosc** 1995 Oct; 5(5):387–92

Polypropylene mesh closure after emergency laparotomy: morbidity and outcome. Brandt CP, et al. **Surgery** 1995 Oct;118(4):736–40; discussion 740–1 (17 ref.)

[Rupture of the diaphragm in closed traumas: apropos of 28 cases] Letoquart JP, et al. **J Chir (Paris)** 1995 Dec; 132(12):478–82 (Eng. Abstr.) **(Fre)**

[Surgery in childhood at the hospital for basic and routine general management] Willital GH. **Chirurg** 1996 Jun; 67(6):567–75 (28 ref.) (Eng. Abstr.) **(Ger)**

[Management of abdominal stab wounds] Mönig SP, et al. **Wien Klin Wochenschr** 1996;108(10):293–5 (Eng. Abstr.) **(Ger)**

[Packing and abbreviated laparotomy in the injured—a life-saving procedure] Kluger Y, et al. **Harefuah** 1996 Mar 15;130(6):366–70, 438 (Eng. Abstr.) **(Heb)**

[Multistage surgical treatment of severe closed trauma to the abdominal cavity organs complicated by hemobilia in an 8-year-old child] Krivchenia DIu, et al. **Klin Khir** 1995; (6):43–4 **(Rus)**

[Relaparotomy in gunshot abdominal injuries] Panov FI. **Klin Khir** 1996;(1):27–9 **(Rus)**

[Diagnostic and tactical error in the treatment of closed abdominal trauma] Tomusiak TL, et al. **Klin Khir** 1995; (4):41 **(Rus)**

[Methods of prevention of complications and improving results of relaparotomy in the experience of aviation medicine] Zaltsev VT, et al. **Klin Khir** 1995;(5):49–51 **(Rus)**

[Combined thoracoscopy in thoracoabdominal wounds using ultrasound, the CO2 laser and the plasma jet] Kabanov AN, et al. **Vestn Khir Im I I Grek** 1995;154(2):71–3 (Eng. Abstr.) **(Rus)**

[Wounds of the abdomen and pelvis with damage to the major vessels] Lokhvitskii SV, et al. **Vestn Khir Im I I Grek** 1995;154(3):65–7 (Eng. Abstr.) **(Rus)**

THERAPY

Abdominal trauma in the pregnant patient. Hill DA, et al. **Am Fam Physician** 1996 Mar;53(4):1269–74

ACOG criteria set. Initial maternal—fetal assessment following acute abdominal trauma. Number 12—November 1995. Committee on Quality Assessment. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Apr;53(1):93–4

The continuing need to formalize pre-hospital triage, highlighted by a case of unusual injury. Lavis M, et al. **J Accid Emerg Med** 1995 Sep;12(3):206–7

Nonoperative management of biliary tract fistulas after blunt abdominal trauma in a child. Poli ML, et al. **J Pediatr Surg** 1995 Dec;30(12):1719–21

Non-operative management of stab wounds to the abdomen with omental evisceration. McFarlane ME. **J R Coll Surg Edinb** 1996 Aug;41(4):239–40

Predicting the need to pack early for severe intra-abdominal hemorrhage. Garrison JR, et al. **J Trauma** 1996 Jun; 40(6):923–7; discussion 927–9

Associated head injury should not prevent nonoperative management of spleen or liver injury in children. Keller MS, et al. **J Trauma** 1996 Sep;41(3):471–5

Gastrointestinal perforations in children: a continuing

challenge to nonoperative treatment of blunt abdominal trauma. Ulman I, et al. **J Trauma** 1996 Jul;41(1):110–3

[Total parenteral nutrition support for patients with major abdominal trauma] Shu Z, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):279–81 (Eng. Abstr.) **(Chi)**

[Resuscitation in severe hepatic injuries] Wodey E, et al. **Cah Anesthesiol** 1996;44(1):55–69 (131 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Evaluation of hemoperitoneum using a single- vs multiple-view ultrasonographic examination [see comments] Ma OJ, et al. **Acad Emerg Med** 1995 Jul; 2(7):581–6. Comment in: Acad Emerg Med 1995 Jul;2(7):575–6.

Ultrasonography for the initial evaluation of blunt abdominal trauma: A review of prospective trials. Pearl WS, et al. **Ann Emerg Med** 1996 Mar;27(3):353–61 (36 ref.)

Emergent abdominal sonography as a screening test in a new diagnostic algorithm for blunt trauma. Boulanger BR, et al. **J Trauma** 1996 Jun;40(6):867–74

A prospective evaluation of abdominal ultrasound in blunt trauma: is it useful? Healey MA, et al. **J Trauma** 1996 Jun; 40(6):875–83; discussion 883–5

Quantitative sensitivity of ultrasound in detecting free intraperitoneal fluid [letter; comment] Lentz KA, et al. **J Trauma** 1996 Jun;40(6):1052–4. Comment on: J Trauma 1995 Aug;39(2):375–80.

1,000 consecutive ultrasounds for blunt abdominal trauma. McKenney MG, et al. **J Trauma** 1996 Apr;40(4):607–10; discussion 611–2

Effective treatment of the multiply injured trauma patient [letter; comment] Mulloy RH. **J Trauma** 1996 Aug; 41(2):368–70. Comment on: J Trauma 1993 Apr;34(4):516–26; discussion 526–7. Comment on: J Trauma 1993 Aug;35(2):181–2. Comment on: J Trauma 1996 Jan;40(1):1–4.

Evaluating blunt abdominal trauma:role for ultrasonography. Lentz KA, et al. **J Ultrasound Med** 1996 Jun;15(6):447–51

Commentary: pediatric blunt abdominal trauma--to sound or not to sound? Filiatrault D, et al. **Pediatr Radiol** 1995; 25(5):329–31

Commentary: sonography in the evaluation of children following blunt trauma: is it to be or not to be? Sivit CJ, et al. **Pediatr Radiol** 1995;25(5):326–8

[Ultrasound findings in rupture of the colon after blunt abdominal trauma] Hegenbarth R, et al. **Ultraschall Med** 1995 Dec;16(6):297–8 (Eng. Abstr.) **(Ger)**

[Role of ultrasonography in abdominal surgical emergencies. Our experience] Cardi F, et al. **Ann Ital Chir** 1996 Jan–Feb; 67(1):61–4 (Eng. Abstr.) **(Ita)**

ABDOMINAL MUSCLES

Jejunal diverticulitis manifesting with abdominal wall abscess. Alvarez OA, et al. **Am J Gastroenterol** 1995 Nov; 90(11):2060–2 (10 ref.)

Acceleration of fetal head induced by vibration of maternal abdominal wall in sheep. Peters AJ, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):552–6

Retroperitoneal and abdominal wall emphysema after transanal excision of a rectal carcinoma. Petros JG, et al. **Am Surg** 1996 Sep;62(9):759–61 (8 ref.)

Avoidance of abdominal wall bleeding in laparoscopic surgery. Mittal VK, et al. **Ann R Coll Surg Engl** 1995 Sep; 77(5):391

Abdominal wall haematoma in anti-coagulated patients: the role of imaging in diagnosis. Davies RS, et al. **Australas Radiol** 1996 May;40(2):109–12

Conventional pneumoperitoneum compared with abdominal wall lift for laparoscopic cholecystectomy. Lindgren L, et al. **Br J Anaesth** 1995 Nov;75(5):567–72

Heterotopic ossification in adenocarcinoma of the colon. Hui Y, et al. **Chin Med J (Engl)** 1995 Oct;108(10):798–800 (2 ref.)

Case report: ossifying metastases from carcinoma of the large bowel demonstrated by bone scintigraphy. Stabler J. **Clin Radiol** 1995 Oct;50(10):730–1

Unusual abdominal location of a dermal cylindroma. Guzzo C, et al. **Cutis** 1995 Oct;56(4):239–40

Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Jacquet P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):568–70 (25 ref.)

Retrograde migration of PEG tubes [letter] Etzkorn KP, et al. **Gastrointest Endosc** 1995 Sep;42(3):279–80

Trans-hepatic proximal migration of percutaneous-endoscopic biliary stent presenting as an abdominal wall abscess. Tan CC, et al. **Gastrointest Endosc** 1996 Feb;43(2 Pt 1):152–4

Ventilatory assistance using electrical stimulation of abdominal muscles. Sorli J, et al. **IEEE Trans Rehabil Eng** 1996 Mar;4(1):1–6

Soft tissue sarcoma of the anterior abdominal wall: review of reconstruction techniques. Gray MW, et al. **J Am Osteopath Assoc** 1996 Jan;96(1):48–53

Necrotizing crepitant fasciitis of abdominal wall following caesarean section. Khan S. **JPMA J Pak Med Assoc** 1995 Sep;45(9):248–9

Rectus syndrome. Another cause of upper abdominal pain. Choi YK, et al. **Reg Anesth** 1995 Jul–Aug;20(4):347–51

Chondroid syringoma of the abdominal wall. A case report and review of the literature. Sliwa-Hähnle K, et al. **S Afr J Surg** 1996 Feb;34(1):46–8 (15 ref.)

Carcinoma implant in the abdominal wall after transurethral resection of bladder tumors using suprapubic trocar. A report of 3 cases. Bartholin J, et al. **Scand J Urol Nephrol Suppl** 1995;172:43–4

Rectus sheath haematoma presenting with Cullen's sign and Grey-Turner's sign. Guthrie CM, et al. **Scott Med J** 1996 Apr;41(2):54–5

Abdominal wall metastasis following percutaneous endoscopic gastrostomy. Becker G, et al. **Support Care Cancer** 1995 Sep;3(5):313–6 (18 ref.)

Laparoscopy without pneumoperitoneum. Effects of abdominal wall retraction versus carbon dioxide insufflation on hemodynamics and gas exchange in pigs. Rademaker BM, et al. **Surg Endosc** 1995 Jul;9(7):797–801

Unexpected gallbladder cancer and laparoscopic surgery. Sandor J, et al. **Surg Endosc** 1995 Nov;9(11):1207–10

[Postoperative necrotizing fasciitis of the anterior abdominal wall] Fichev G, et al. **Khirurgiia (Sofiia)** 1995;48(3):46–8 (Eng. Abstr.) **(Bul)**

[Excessive traction of an endoscopic gastrostomy tube causing migration into the abdominal wall (letter)] Druart F, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):956–7 **(Fre)**

[Parietal impaction of an endoscopic percutaneous gastrostomy tube (letter)] Rieder D, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):955 **(Fre)**

[Abdominal wall endometriosis imitating incisional hernia] Kaplan O, et al. **Harefuah** 1995 Sep;129(5–6):182–3, 223 (Eng. Abstr.) **(Heb)**

[Endometriosis of the abdominal wall. A report of a case secondary to cesarean section] Capanna A, et al. **G Chir** 1995 Aug–Sep;16(8–9):352–6 (19 ref.) (Eng. Abstr.) **(Ita)**

ABNORMALITIES

Hypothermia and sepsis: the major causes of mortality in gastroschisis. Tsai MC, et al. **Acta Paediatr Sin** 1995 Sep–Oct;36(5):328–30

Omphalocele and gastroschisis in Europe: a survey of 3 million births 1980–1990. EUROCAT Working Group. Calzolari E, et al. **Am J Med Genet** 1995 Aug 28; 58(2):187–94

Outcomes of newborns with gastroschisis: the effects of mode of delivery, site of delivery, and interval from birth to surgery. Quirk JG Jr, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1134–8; discussion 1138–40

Tntraoperative vesical pressure measurements as a guide in the closure of abdominal wall defects. Rizzo A, et al. **Am Surg** 1996 Mar;62(3):192–6

A decade of gastroschisis in the era of antenatal ultrasound. Nicholls EA, et al. **Aust N Z J Surg** 1996 Jun;66(6):366–8

Gastroesophageal reflux in neonates with congenital abdominal wall defect. Beaudoin S, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):323–6

Gastroschisis in the decade of prenatal diagnosis: 1983–1993. Haddock G, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):18–22

Body stalk anomaly: prenatal diagnosis. Takeuchi K, et al. **Int J Gynaecol Obstet** 1995 Oct;51(1):49–52

A twin gestation complicated by gastroschisis in both twins. Fuentes A, et al. **J Clin Ultrasound** 1996 Jan;24(1):48–50

Collagen-coated Vicryl mesh: a new bioprosthesis in pediatric surgical practice. Carachi R, et al. **J Pediatr Surg** 1995 Sep;30(9):1302–5

Gastroschisis: a simple technique for staged silo closure. Fischer JD, et al. **J Pediatr Surg** 1995 Aug;30(8):1169–71

Impact of antenatal diagnosis on incidence and prognosis in abdominal wall defects. Fisher R, et al. **J Pediatr Surg** 1996 Apr;31(4):538–41

Effect of intraamniotic dexamethasone administration on intestinal absorption in a rabbit gastroschisis model. Guo W, et al. **J Pediatr Surg** 1995 Jul;30(7):983–6; discussion 986–7

Familial gastroschisis: a case of mother-and son occurrence. Nelson TC, et al. **J Pediatr Surg** 1995 Dec;30(12):1706–8

Impairment of nutrient uptake in a rabbit model of gastroschisis [letter] Tanyel FC, et al. **J Pediatr Surg** 1995 Oct;30(10):1534

First trimester transvaginal sonographic diagnosis of body stalk anomaly [correction of anatomy] Shalev E, et al. **J Ultrasound Med** 1995 Aug;14(8):641–2

Tracheal tube occlusion affecting surgical management of gastroschisis [letter] Burden RJ, et al. **Paediatr Anaesth** 1995;5(2):143–4

Tailoring the small-bowel follow-through examination postoperatively in gastroschisis patients. Soboleski D, et al. **Pediatr Radiol** 1995;25(4):267–8

[Defects of the anterior abdominal wall--their prenatal management] Ruseva R, et al. **Akush Ginekol (Sofiia)** 1995; 34(2):23–6 (Eng. Abstr.) **(Bul)**

[Gastroschisis. Management. 50 cases] Becmeur F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):565–9 (Eng. Abstr.) **(Fre)**

[Diagnostic-therapeutic concept in abnormalities of the abdominal wall and diaphragm] Terinde R, et al. **Gynakologe** 1995 Oct;28(5):368–83 (84 ref.) **(Ger)**

[The pathogenesis and surgical treatment of diastasis recti abdominis] Gireev GI, et al. **Vestn Khir Im I I Grek** 1992 Mar;148(3):372–5 **(Rus)**

[The treatment of newborns with gastroschisis] Zakharov NL, et al. **Vestn Khir Im I I Grek** 1992 Nov–Dec; 149(11–12):346–50 (Eng. Abstr.) **(Rus)**

ANATOMY & HISTOLOGY

Correcting trunk muscle geometry obtained from MRI and CT scans of supine postures for use in standing postures. McGill SM, et al. **J Biomech** 1996 May;29(5):643–6

An anatomic study for the rectus abdominis myocutaneous flap combined with a vascularized rib. Yamamoto Y, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1336–40

BLOOD SUPPLY

Spasm of the gastroepiploic artery used for coronary artery bypass grafting. Cate CM, et al. **Am J Cardiol** 1996 May 1;77(11):1022–3

Lipoteichoic acid from Staphylococcus aureus depresses contractile function of human arteries in vitro due to the induction of nitric oxide synthase. Tsuneyoshi I, et al. **Anesth Analg** 1996 May;82(5):948–53

Coronary reoperation via small laparotomy using right gastroepiploic artery without CPB. Grandjean JG, et al. **Ann Thorac Surg** 1996 Jun;61(6):1853–5

Angiographic 5-year follow-up study of right gastroepiploic artery grafts. Voutilainen S, et al. **Ann Thorac Surg** 1996 Aug;62(2):501–5

Effect of endopeptidase-24.11 inhibitors and C-ANP receptor ligand on responses evoked in arterioles of rat cremaster muscle by atrial natriuretic peptide. Peyroux J, et al. **Br J Pharmacol** 1995 Dec;116(8):3117–24

Effects of competitive blood flow on arterial graft patency and diameter. Medium-term postoperative follow-up. Hashimoto H, et al. **J Thorac Cardiovasc Surg** 1996 Feb; 111(2):399–407

Newborn with congenital arteriovenous fistulas of the abdominal wall complicated by a ductus arteriosus aneurysm. Akita H, et al. **Pediatr Cardiol** 1995 Sep–Oct; 16(5):235–8

Colour flow duplex scanning: an accurate, non-invasive technique for preoperative evaluation of the vascular supply of the rectus abdominis myocutaneous flap. Pacifici A, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Dec; 29(4):319–24

[Intra-abdominal hemorrhage from epigastric vessels] Borovil EM, et al. **Klin Khir** 1995;(4):45–6 **(Ukr)**

DRUG EFFECTS

A double-blind comparison of the abdominal wall relaxation produced by epidural 0.75% ropivacaine and 0.75% bupivacaine in gynecologic surgery. Tuttle AA, et al. **Reg Anesth** 1995 Nov–Dec;20(6):515–20

EMBRYOLOGY

The fetus with gastroschisis: impact of route of delivery and prenatal ultrasonography. Adra AM, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):540–6

Sex-specific differentiation of a male-specific abdominal muscle, the Muscle of Lawrence, is abnormal in hydroxyurea-treated and in fruitless male flies. Taylor BJ, et al. **Development** 1995 Sep;121(9):3079–88

Fetal midgut herniation into the umbilical cord: improved definition of ventral abdominal anomaly with the use of transvaginal sonography. Achiron R, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):256–60

Early development of the abdominal wall, stomach and heart from 7 to 12 weeks of gestation: a longitudinal ultrasound study. Blaas HG, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):240–9

INJURIES

Suicide by sharp instruments: a case of harakiri. Moriani S, et al. **Int J Legal Med** 1996;108(4):219–20

Surgical management of abdominal wall disruption after blunt trauma. Brenneman FD, et al. **J Trauma** 1995 Sep; 39(3):539–44

Evaluation of a novel synthetic material for closure of large abdominal wall defects. Aliabadi-Wahle S, et al. **Surgery** 1996 Feb;119(2):141–5

INNERVATION

Electromyographic findings in ilioinguinal-iliohypogastric nerve entrapment syndrome. Knockaert DC, et al. **Acta Clin Belg** 1996;51(3):156–60

A molecular scheme for the reaction between gamma-aminobutyric acid and the most abundant chloride channel on crayfish deep extensor abdominal muscle. Adelsberger H, et al. **Pflugers Arch** 1996 Mar;431(5):680–9

METABOLISM

Effect of dietary restriction on protein synthesis and wound healing after surgery in the rat. Emery PW, et al. **Clin Sci (Colch)** 1995 Oct;89(4):383–8

MICROBIOLOGY

A case of tuberculous peritonitis associated with abdominal-wall pseudocyst in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD). Ha SK, et al. **Nephrol Dial Transplant** 1995;10(5):706–8

ABDOMINAL MUSCLES

PATHOLOGY

Postliposuction histologic alterations of adipose tissue. Carpaneda CA. **Aesthetic Plast Surg** 1996 May–Jun; 20(3):207–11

Abdominal wall endometrioma in a laparoscopic trocar tract: a case report [see comments] Healy JT, et al. **Am Surg** 1995 Nov;61(11):962–3. Comment in: Am Surg 1996 Jul;62(7):617.

Re: abdominal wall endometrioma in a laparoscopic trocar tract: a case report [letter; comment] Thylan S. **Am Surg** 1996 Jul;62(7):617. Comment on: Am Surg 1995 Nov;61(11):962–3.

PHYSIOLOGY

In vitro biomechanical comparison of the strength of the linea alba of the llama, using two suture patterns. Van Hoogmoed L, et al. **Am J Vet Res** 1996 Jun;57(6):938–42

Electromyography analysis of the rectus abdominis and external oblique muscles of children 8 to 10 years old. Moraes AC, et al. **Electromyogr Clin Neurophysiol** 1995 Nov;35(7):425–30

Some effects of vagal blockade on abdominal muscle activation and shortening in awake dogs. Leevers AM, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):471–81

Motor evoked potentials of the abdominal muscles elicited through magnetic transcranial brain stimulation [letter] Lissens MA, et al. **Muscle Nerve** 1995 Nov;18(11):1353–4

Quantification of functional deficits associated with rectus abdominis muscle flaps. Zauner–Dungl A, et al. **Plast Reconstr Surg** 1995 Dec;96(7):1623–8

Form and function of the musculoskeletal system as revealed by mathematical analysis of the lumbar spine. An essay. Farfan HF. **Spine** 1995 Jul 1;20(13):1462–74

The effects of lumbosacral support belts and abdominal muscle strength on functional lifting ability in healthy women. Smith EB, et al. **Spine** 1996 Feb 1;21(3):356–66

Why leg crossing? The influence of common postures on abdominal muscle activity. Snijders CJ, et al. **Spine** 1995 Sep 15;20(18):1989–93

Effect of maximum ventilation on abdominal muscle relaxation rate. Kyroussis D, et al. **Thorax** 1996 May; 51(5):510–5

[Role of expiratory muscles in chronic obstructive respiratory insufficiency] Ninane V, et al. **Rev Mal Respir** 1995; 12(5):435–40 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Asynchronous thoracoabdominal movements in chronic airflow obstruction (CAO). Active expiration during spontaneous breathing in sleep and wakefulness. Goldman MD, et al. **Adv Exp Med Biol** 1995;393:95–100

RADIOGRAPHY

Mucin–hypersecreting papillary cholangiocarcinoma presenting as abdominal wall abscess: CT and spiral CT cholangiography. Ko SF, et al. **Abdom Imaging** 1996 May–Jun;21(3):222–5

Subcutaneous splenosis. Hibbeln JF, et al. **Clin Nucl Med** 1995 Jul;20(7):591–3

Abdominal wall haematoma mimicking visceral injury: the role of CT scanning. Hill SA, et al. **Injury** 1995 Nov; 26(9):605–7

[Imaging of connective tissue formations of the sub–umbilical anterior abdominal wall] Roy C, et al. **Ann Radiol (Paris)** 1995;38(7–8):389–95 (20 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Abdominal wall uptake of Tc–99m MDP secondary to subcutaneous heparin injection. Somerville P, et al. **Clin Nucl Med** 1996 Feb;21(2):152–3

SURGERY

Postliposuction histologic alterations of adipose tissue. Carpaneda CA. **Aesthetic Plast Surg** 1996 May–Jun; 20(3):207–11

Abdominoplasty with two fusiform plications. Marques A, et al. **Aesthetic Plast Surg** 1996 May–Jun;20(3):249–51

Heterotopic ossification of midline abdominal incisions: CT and MR imaging findings. Jacobs JE, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):579–84

Wound strength in abdominal incisions: a comparison of two continuous mass closure techniques in rats. Meeks GR, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1676–82; discussion 1682–3

Outcomes of newborns with gastroschisis: the effects of mode of delivery, site of delivery, and interval from birth to surgery. Quirk JG Jr, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1134–8; discussion 1138–40

In vitro biomechanical comparison of the strength of the linea alba of the llama, using two suture patterns. Van Hoogmoed L, et al. **Am J Vet Res** 1996 Jun;57(6):938–42

Experience with three prosthetic materials in temporary abdominal wall closure. Nagy KK, et al. **Am Surg** 1996 May;62(5):331–5

Tntraoperative vesical pressure measurements as a guide in the closure of abdominal wall defects. Rizzo A, et al. **Am Surg** 1996 Mar;62(3):192–6

Staged reconstruction of abdominal wall defects after intra–abdominal catastrophes. Okunski WJ, et al. **Ann Plast Surg** 1996 May;36(5):475–8

Small intestinal submucosa: utilization for repair of rodent abdominal wall defects. Prevel CD, et al. **Ann Plast Surg** 1995 Oct;35(4):374–80

Use of groin flap and anterolateral thigh adipofascial flap of tensor fascia lata for reconstruction of a wide lower abdominal wall defect. Terashi H, et al. **Ann Plast Surg** 1995 Sep;35(3):320–1

A comparative study of the cosmetic appeal of abdominal incisions used for hysterectomy [see comments] Currie I, et al. **Br J Obstet Gynaecol** 1996 Mar;103(3):252–4. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):722.

Abdominoplasty following vertical banded gastroplasty for morbid obesity. Soundararajan V, et al. **Br J Plast Surg** 1995 Sep;48(6):423–7

Dissection of the anterior abdominal wall and the deep inguinal region from a laparoscopic perspective. Quinn TH, et al. **Clin Anat** 1995;8(4):245–51

The abdominal lift: is there any advantage for the critically ill patient? [see comments] Thoelke MH, et al. **Endosc Surg Allied Technol** 1995 Aug;3(4):180–2. Comment in: Endosc Surg Allied Technol 1995 Aug;3(4):154–5.

Comparison of a new type of polytetrafluoroethylene patch (Mycro Mesh) and polypropylene prosthesis (Marlex) for repair of abdominal wall defects. Bellón JM, et al. **J Am Coll Surg** 1996 Jul;183(1):11–8

Perixiphoid extension of the midline incision [letter; comment] Kitamura H, et al. **J Am Coll Surg** 1996 Mar; 182(3):278–9. Comment on: J Am Coll Surg 1995 Jun;180(6):739–41.

Chopstick retention suture for the closure of abdominal wounds. Matsuoka J, et al. **J Am Coll Surg** 1995 Nov; 181(5):471–4

Thoracoabdominal wall repair with glutaraldehyde–preserved bovine pericardium. Santillan–Doherty P, et al. **J Invest Surg** 1996 Jan–Feb; 9(1):45–55

Laparoscopic transabdominal preperitoneal herniorrhaphy using abdominal wall–lifting method under regional anesthesia: a preliminary report. Tagaya N, et al. **J Laparoendosc Surg** 1995 Aug;5(4):215–20

Collagen–coated Vicryl mesh: a new bioprosthesis in pediatric surgical practice. Carachi R, et al. **J Pediatr Surg** 1995 Sep;30(9):1302–5

Gastroschisis: a simple technique for staged silo closure. Fischer JD, et al. **J Pediatr Surg** 1995 Aug;30(8):1169–71

Intestine submucosa and polypropylene mesh for abdominal wall repair in dogs. Clarke KM, et al. **J Surg Res** 1996 Jan;60(1):107–14

Surgical management of abdominal wall disruption after blunt trauma. Brenneman FD, et al. **J Trauma** 1995 Sep; 39(3):539–44

A combination of Vicryl and Marlex mesh: a technique for abdominal wall closure in difficult cases. Porter JM. **J Trauma** 1995 Dec;39(6):1178–80

Repair of transversely incised abdominal wall fascia in a rabbit model. Maxwell GL, et al. **Obstet Gynecol** 1996 Jan; 87(1):65–8

Tracheal tube occlusion affecting surgical management of gastroschisis [letter] Burden RJ, et al. **Paediatr Anaesth** 1995;5(2):143–4

Tailoring the small–bowel follow–through examination postoperatively in gastroschisis patients. Soboleski D, et al. **Pediatr Radiol** 1995;25(4):267–8

Abdominal hernia after fasciotomy of the external oblique muscle for abdominal wall closure in TRAM surgery [letter; comment] de Elejabeitia González J, et al. **Plast Reconstr Surg** 1996 Jul;98(1):182–3. Comment on: Plast Reconstr Surg 1992 Oct;90(4):608–13.

Sliding myofascial flap of the rectus abdominus muscles for the closure of recurrent ventral hernias. DiBello JN Jr, et al. **Plast Reconstr Surg** 1996 Sep;98(3):464–9

Advantages of autologous fascia versus synthetic patch abdominal reconstruction in experimental animal defects. Disa JJ, et al. **Plast Reconstr Surg** 1996 Apr;97(4):801–6

Two–stage abdominal wall reconstruction of sepsis–induced dehiscence [letter] Hunsaker RH. **Plast Reconstr Surg** 1996 Jul;98(1):186–7

Gore–Tex patch repair of the anterior rectus sheath in free rectus abdominis muscle and myocutaneous flaps. Pennington DG, et al. **Plast Reconstr Surg** 1996 Jun; 97(7):1436–40; discussion 1441–2

High lateral tension abdominoplasty [letter; comment] Stone A. **Plast Reconstr Surg** 1996 Jul;98(1):184–5. Comment on: Plast Reconstr Surg 1995 Sep;96(3):603–15.

Abdominal wall reconstruction after temporary abdominal wall closure in trauma patients. Yeh KA, et al. **South Med J** 1996 May;89(5):497–502

Necrotizing fasciitis following laparoscopic surgery. Case report and review of the literature. Golshani S, et al. **Surg Endosc** 1996 Jul;10(7):751–4 (20 ref.)

The anterior abdominal wall in laparoscopic procedures and limitations of laparoscopic simulators. McIntyre R, et al. **Surg Endosc** 1996 Apr;10(4):411–3

Evaluation of a novel synthetic material for closure of large abdominal wall defects. Aliabadi–Wahle S, et al. **Surgery** 1996 Feb;119(2):141–5

Polypropylene mesh closure after emergency laparotomy: morbidity and outcome. Brandt CP, et al. **Surgery** 1995 Oct;118(4):736–40; discussion 740–1 (17 ref.)

Meshlaparostomy—a comparison between polypropylene mesh and indigenous nylon net. Shah SR, et al. **Trop Gastroenterol** 1996 Apr–Jun;17(2):49–54

The Giuliani muscle splitting and nerve–sparing anterolateral transabdominal approach to the kidney. Giberti C, et al. **Urology** 1996 Jun;47(6):911–4

[The reconstruction of extensive exenterations with the aid of an absorbable prosthesis] Levasseur J, et al. **Khirurgiia (Sofiia)** 1995;48(3):59–61 **(Bul)**

[Replacement continent bladder in dogs by opening an antro–pyloric graft onto the abdominal wall (seven cases between 1980 and 1983)] Bourdelat D, et al. **Ann Urol (Paris)** 1996;30(2):76–84 (Eng. Abstr.) **(Fre)**

[Pathophysiology of the abdominal wall] Klinge U, et al. **Chirurg** 1996 Mar;67(3):229–33 (12 ref.) (Eng. Abstr.) **(Ger)**

[Reconstructive surgery using the flaps pedicled by rectus abdominis muscle or deep inferior epigastric artery] Hyakusoku H. **Nippon Ika Daigaku Zasshi** 1995 Dec; 62(6):567–73 (22 ref.) **(Jpn)**

[The treatment of newborns with gastroschisis] Zakharov NL, et al. **Vestn Khir Im I I Grek** 1992 Nov–Dec; 149(11–12):346–50 (Eng. Abstr.) **(Rus)**

TRANSPLANTATION

Peculiar indications for the pedicled or free rectus abdominis flap in reconstructive surgery. A review of our experience. Sinsel NK, et al. **Acta Chir Belg** 1995 Nov–Dec; 95(6):289–96

Evidence for the efficacy of TRAM flap delay in a rat model. Hallock GG, et al. **Plast Reconstr Surg** 1995 Nov; 96(6):1351–7

One rectus abdominis muscle for two separated soft–tissue reconstructions. Jeng SF, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1454–8

Extended skin island delay of the unipedicle TRAM flap: experience in 35 patients. Jensen JA, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1341–5

An anatomic study for the rectus abdominis myocutaneous flap combined with a vascularized rib. Yamamoto Y, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1336–40

Quantification of functional deficits associated with rectus abdominis muscle flaps. Zauner–Dungl A, et al. **Plast Reconstr Surg** 1995 Dec;96(7):1623–8

Hernia prevention and aesthetic contouring of the abdomen following TRAM flap breast reconstruction by the use of polypropylene mesh. Zienowicz RJ, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1346–50

ULTRASONOGRAPHY

A decade of gastroschisis in the era of antenatal ultrasound. Nicholls EA, et al. **Aust N Z J Surg** 1996 Jun;66(6):366–8

Endoscopic ultrasound in the placement of a percutaneous endoscopic gastrostomy tube in the non–transilluminated abdominal wall. Panzer S, et al. **Gastrointest Endosc** 1995 Jul;42(1):88–90

Body stalk anomaly: prenatal diagnosis. Takeuchi K, et al. **Int J Gynaecol Obstet** 1995 Oct;51(1):49–52

Colour flow duplex scanning: an accurate, non–invasive technique for preoperative evaluation of the vascular supply of the rectus abdominis myocutaneous flap. Pacifici A, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Dec; 29(4):319–24

Fetal midgut herniation into the umbilical cord: improved definition of ventral abdominal anomaly with the use of transvaginal sonography. Achiron R, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):256–60

Early development of the abdominal wall, stomach and heart from 7 to 12 weeks of gestation: a longitudinal ultrasound study. Blaas HG, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):240–9

[Defects of the anterior abdominal wall—their prenatal management] Ruseva R, et al. **Akush Ginekol (Sofiia)** 1995; 34(2):23–6 (Eng. Abstr.) **(Bul)**

ABDOMINAL NEOPLASMS

Multiple inflammatory fibrosarcoma of the abdominal cavity in a child. Conte M, et al. **Med Pediatr Oncol** 1996 Sep; 27(3):198–201

[Abdominal cystic lymphangiomas (letter)] Uriarte C, et al. **Gastroenterol Hepatol** 1996 Feb;19(2):80–1 **(Spa)**

CHEMISTRY

Intra–abdominal desmoplastic small round cell tumor with extensive extra–abdominal involvement. Resnick MB, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct;15(5):797–803

COMPLICATIONS

Cullen's sign secondary to intra–abdominal non–Hodgkin's lymphoma. Silvestre JF, et al. **Am J Gastroenterol** 1996 May;91(5):1040–1

Malignant ascites. Parsons SL, et al. **Br J Surg** 1996 Jan; 83(1):6–14 (92 ref.)

Intestinal obstruction. Baines MJ. **Cancer Surv** 1994;21:147–56 (32 ref.)

Percutaneous endoscopic gastrostomy as a decompressive technique in bowel obstruction due to abdominal carcinomatosis. Cannizzaro R, et al. **Endoscopy** 1995 May; 27(4):317–20

Favorable outcome in children with Beckwith–Wiedemann

syndrome and intraabdominal malignant tumors. Vaughan WG, et al. **J Pediatr Surg** 1995 Jul;30(7):1042–4; discussion 1044–5

Management of disseminated intra-abdominal lymphangiomatosis with protein-losing enteropathy and intestinal bleeding. Takami A, et al. **South Med J** 1995 Nov; 88(11):1156–8

A child with an intra-abdominal testicular teratoma: a case report and review of prepubertal cryptorchid germ cell tumors. Brown IR, et al. **Urology** 1995 Dec;46(6):863–6 (27 ref.)

[Value of abdominal ultrasonography in deep venous thrombosis. Retrospective study of 104 patients] Netzer P, et al. **Schweiz Med Wochenschr Suppl** 1996;79:58S–63S (Eng. Abstr.) **(Ger)**

[A case of abdominal desmoid causing urinary tract obstruction] Uchida A, et al. **Hinyokika Kiyo** 1995 Oct; 41(10):821–3 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Cytopathologic touch preparations (imprints) from core needle biopsies: accuracy compared with that of fine-needle aspirates. Hahn PF, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1277–9

CT and MR imaging of abdominal liposarcoma. Kim T, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):829–33

MR diagnosis of hepatic metastases from neuroendocrine tumors versus hemangiomas: relative merits of dynamic gadolinium chelate-enhanced gradient-recalled echo and unenhanced spin-echo images. Soyer P, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1407–13

Value of diagnostic laparoscopy in abdominal malignancies. Schrenk P, et al. **Int Surg** 1995 Oct-Dec;80(4):353–5

Cat-scratch disease simulating lymphoma. Wong TZ, et al. **J Comput Assist Tomogr** 1996 Jan-Feb;20(1):165–6

Desmoplastic small cell tumor: a report of three cases and a review of the literature. Kretschmar CS, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):293–8 (29 ref.)

Intraabdominal desmoplastic small round cell tumor presenting as a gastric mural mass with hepatic metastases. Murray JC, et al. **J Pediatr Hematol Oncol** 1996 Aug; 18(3):289–92

When imaging fails: pre-operative localization and treatment of a ganglioneuroma. Mukherjee JJ, et al. **J R Soc Med** 1996 Jul;89(7):409–10

Primary amyloidosis co-presenting with cervical and massive intra-abdominal lymphadenopathy. Segalov E, et al. **Leuk Lymphoma** 1995 Nov;19(5–6):519–20

Intra-abdominal localization of acute leukaemia: report of six cases. Kurtz JE, et al. **Nouv Rev Fr Hematol** 1995; 37(5):273–6

Imaging of thoracoabdominal masses: the difficulty of compartmentalization. Horev G, et al. **Pediatr Radiol** 1996; 26(2):162–4

[Desmoplastic small round cell tumors in adults: a new entity] Farhat F, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):665–73 (39 ref.) (Eng. Abstr.) **(Fre)**

[Echo-planar imaging (EPI) of the abdomen] Reimer P, et al. **Radiologe** 1995 Dec;35(12):925–35 (Eng. Abstr.) **(Ger)**

[HIV infection with abdominal non-Hodgkin's lymphoma presenting as necrotizing pancreatitis] Stoll M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jan;164(1):82–4 **(Ger)**

[Cystic lymphangioma: a case report of abdominal location] Linguerri R, et al. **Minerva Chir** 1996 Mar;51(3):159–61 (Eng. Abstr.) **(Ita)**

[Asymptomatic thoracic and abdominal tumors with lymph nodes metastasis as a reason for consultation] Pardal Refoyo JL, et al. **An Otorrinolaringol Ibero Am** 1996;23(2):161–8 (Eng. Abstr.) **(Spa)**

[Even children may be affected by malignant abdominal tumors. Far too long diagnostic delay in many cases] Lundkvist K, et al. **Lakartidningen** 1996 Jun 12; 93(24):2333–6 **(Swe)**

DRUG THERAPY

Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo. Sharad AC, et al. **Acta Oncol** 1996;35(1):95–100

Hyperthermic intraoperative intraperitoneal chemotherapy safety considerations. White SK, et al. **AORN J** 1996 Apr; 63(4):716–24

Treatment of non-resectable pelvic malignancies by isolated pelvic perfusion. A preliminary study. Kocaoglu H, et al. **Eur J Surg Oncol** 1995 Oct;21(5):535–40

Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. Kushner BH, et al. **J Clin Oncol** 1996 May; 14(5):1526–31

Vascular complications of total abdominal perfusion and aortic stop-flow infusion. Klein ES, et al. **J Surg Oncol** 1996 Jan;61(1):17–9

[Highly effective preoperative intraarterial infusion chemotherapy with CDDP for progressive uterine corpus cancer with a Sister Mary Joseph's nodule] Shirai T, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):791–5 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Gender-related differences in the distribution of thoracic versus abdominal malignant mesothelioma. Delfino RJ, et al. **Cancer Detect Prev** 1995;19(4):301–7

ETIOLOGY

Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Jacquet P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):568–70 (25 ref.)

Incidence and effects on survival of abdominal wall metastases at trocar [letter] van Dam PA. **Gynecol Oncol** 1996 Aug;62(2):322–4

Basal cell carcinoma due to radiotherapy for carcinoma of the cervix. Copas P, et al. **South Med J** 1995 Nov; 88(11):1161–2 (12 ref.)

Abdominal wall metastasis following percutaneous endoscopic gastrostomy. Becker G, et al. **Support Care Cancer** 1995 Sep;3(5):313–6 (18 ref.)

GENETICS

Detection of the EWS/WT1 gene fusion by reverse transcriptase-polymerase chain reaction in the diagnosis of intra-abdominal desmoplastic small round cell tumor. Argatoff LH, et al. **Am J Surg Pathol** 1996 Apr; 20(4):406–12

EWS and WT-1 gene fusion in desmoplastic small round cell tumor of the abdomen. Brodie SG, et al. **Hum Pathol** 1995 Dec;26(12):1370–4

[Identification of the breakpoint-flanking markers on chromosomes 1 and 17 of a constitutional translocation T(1;17)(P36;Q12–21) in a patient with neuroblastoma] Laureys GG. **Verh K Acad Geneeskd Belg** 1995; 57(5):389–422 (65 ref.) (Eng. Abstr.) **(Dut)**

HISTORY

Vignettes in medical history. Sister Mary Joseph and her node. Hill M, et al. **Am Surg** 1996 Apr;62(4):328–9

Sister Mary Joseph's nodule. Stokes MA. **Ir Med J** 1993 May;86(3):86

IMMUNOLOGY

High levels of CA-125 in a case of a parasitic leiomyoma presenting as an abdominal mass. Ghamande SA, et al. **Gynecol Oncol** 1996 May;61(2):297–8

Specificities and functions of CD4+ HLA class II-restricted T cell clones against a human sarcoma: evidence for several recognized antigens. Heike M, et al. **J Immunol** 1996 Mar 15;156(6):2205–13

MORTALITY

High mortality after abdominal operation in patients with large-volume malignant ascites. Yazdi GP, et al. **J Surg Oncol** 1996 Jun;62(2):93–6

PARASITOLOGY

High levels of CA-125 in a case of a parasitic leiomyoma presenting as an abdominal mass. Ghamande SA, et al. **Gynecol Oncol** 1996 May;61(2):297–8

PATHOLOGY

Intraabdominal lesions: fine needle sampling without suction vs. fine needle aspiration [letter; comment] Chess Q. **Acta Cytol** 1996 May-Jun;40(3):610. Comment on: Acta Cytol 1994 May-Jun;38(3):495–6.

Detection of the EWS/WT1 gene fusion by reverse transcriptase-polymerase chain reaction in the diagnosis of intra-abdominal desmoplastic small round cell tumor. Argatoff LH, et al. **Am J Surg Pathol** 1996 Apr; 20(4):406–12

Modification of growth of desmoid tumours in tissue culture by anti-oestrogenic substances: a preliminary report. Serpell JW, et al. **Aust N Z J Surg** 1996 Jul;66(7):457–63

Intraoperative fine-needle aspiration cytology of abdominal lesions--a safe alternative to surgical biopsy. Jain BK, et al. **Br J Surg** 1996 Feb;83(2):272–3

Intraabdominal desmoplastic small cell tumor. Report and discussion of five cases. Amato RJ, et al. **Cancer** 1996 Aug 15;78(4):845–51

Biphasic intraabdominal desmoplastic small round cell tumor: fine-needle aspiration cytology findings. Drut R. **Diagn Cytopathol** 1995 Nov;13(4):325–9

Adult extrarenal Wilms' tumor. A case report. Gürsoy R, et al. **Gynecol Obstet Invest** 1995;40(2):141–4 (7 ref.)

Extrarenal Wilms' tumour--a case report and review of literature. Waingankar VS, et al. **Indian J Cancer** 1995 Sep; 32(3):135–40 (33 ref.)

Intra-abdominal desmoplastic small round cell tumor in children: a clinicopathologic study. Basade MM, et al. **Pediatr Hematol Oncol** 1996 Jan-Feb;13(1):95–9

Intra-abdominal desmoplastic small round cell tumor with extensive extra-abdominal involvement. Resnick MB, et al. **Pediatr Pathol Lab Med** 1995 Sep-Oct;15(5):797–803

[Ambulatory ultrasound-guided puncture in abdominal tumoral pathology. Study of 131 cases] Duchmann JC, et al. **Gastroenterol Clin Biol** 1996;20(3):258–62 (Eng. Abstr.) **(Fre)**

[Cutaneous large cell anaplastic Ki-1 (CD 30) positive T-cell lymphoma] Duve S, et al. **Hautarzt** 1996 Apr;47(4):294–8 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Permission to leave. Eaves SL. **Am J Nurs** 1996 Mar;96(3):80

Symptom reporting in cancer patients: the role of negative affect and experienced social stigma. Koller M, et al. **Cancer** 1996 Mar 1;77(5):983–95

RADIOGRAPHY

Case of the month: differential calculus. Roebuck DJ, et al. **Br J Radiol** 1995 Sep;68(813):1037–8

CT findings of regression in intraabdominal desmoplastic small-cell tumor. Dao HN, et al. **Clin Imaging** 1995 Oct-Dec;19(4):244–6

Spiral CT angiography for preoperative planning in patients with epigastric tumors: comparison with arteriography. Freund M, et al. **J Comput Assist Tomogr** 1996 Sep-Oct; 20(5):786–91

[Abdominal involvement in neurofibromatosis type 1] Pereira P, et al. **Aktuelle Radiol** 1995 Jul;5(4):240–2 (Eng. Abstr.) **(Ger)**

[Volumetry of abdominal tumors. Problems--feasibility] Helmberger H, et al. **Radiologe** 1995 Sep;35(9):587–91 (Eng. Abstr.) **(Ger)**

[Malignant schwannoma of the abdomen (clinical conference)] Krämer SC, et al. **Rontgenpraxis** 1996 May; 49(5):121–3 **(Ger)**

RADIONUCLIDE IMAGING

Intra-abdominal patterns of disease dissemination in colorectal cancer identified using radioimmunoguided surgery. Arnold MW, et al. **Dis Colon Rectum** 1996 May; 39(5):509–13

SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. Schillaci O, et al. **J Nucl Med** 1996 Sep;37(9):1452–6

RADIOTHERAPY

Nausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide. Miralbell R, et al. **Eur J Cancer** 1995;31A(9):1461–4

Comparison of simulated annealing algorithms for conformal therapy treatment planning. Rosen II, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1091–9

Radiotherapy for early infradiaphragmatic Hodgkin's disease: the Australasian experience. Barton M, et al. **Radiother Oncol** 1996 Apr;39(1):1–7

[Radiation injury of the small intestine. Radiobiological, radiopathological aspects; risk factors and prevention] Touboul E, et al. **Ann Chir** 1996;50(1):58–71 (95 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

MR diagnosis of hepatic metastases from neuroendocrine tumors versus hemangiomas: relative merits of dynamic gadolinium chelate-enhanced gradient-recalled echo and unenhanced spin-echo images. Soyer P, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1407–13

Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Averbach AM, et al. **Br J Surg** 1996 Jun;83(6):726–33 (103 ref.)

Adenocarcinoma of the colon presenting with a Sister Mary Joseph's nodule and Trousseau's syndrome. Barnes J, et al. **Cutis** 1995 Nov;56(5):270–2

Intra-abdominal patterns of disease dissemination in colorectal cancer identified using radioimmunoguided surgery. Arnold MW, et al. **Dis Colon Rectum** 1996 May; 39(5):509–13

Imaging of abdominal nodal spread in malignant disease. Delorme S, et al. **Eur Radiol** 1996;6(3):262–74 (47 ref.)

Incidence and effect on survival of abdominal wall metastases at trocar or puncture sites following laparoscopy or paracentesis in women with ovarian cancer. Kruitwagen RF, et al. **Gynecol Oncol** 1996 Feb;60(2):233–7

Endometrial stromal sarcoma with focal smooth muscle differentiation: recurrence after 17 years: a follow-up report with discussion of the nomenclature. Khalifa MA, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):171–6

Metastatic umbilical transitional cell carcinoma from a bladder diverticulum. Rajan N, et al. **J Urol** 1996 May; 155(5):1700

Abdominal wall metastasis following percutaneous endoscopic gastrostomy. Becker G, et al. **Support Care Cancer** 1995 Sep;3(5):313–6 (18 ref.)

[Abdominal recurrence after interventions on the intestines] Siewert JR, et al. **Chirurg** 1995 Oct;66(10):941–8 (Eng. Abstr.) **(Ger)**

[Implantation metastases following laparoscopic cholecystectomy in gallbladder carcinoma] Buhr J, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):57–61; discussion 61–2 (36 ref.) (Eng. Abstr.) **(Ger)**

[Highly effective preoperative intraarterial infusion chemotherapy with CDDP for progressive uterine corpus cancer with a Sister Mary Joseph's nodule] Shirai T, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):791–5 (Eng. Abstr.) **(Jpn)**

SURGERY

Abdominal teratomas in children. Ko YS, et al. **Acta Paediatr Sin** 1995 Sep-Oct;36(5):342–5

Risk factors for infectious complications after abdominal surgery for malignant disease. Velasco E, et al. **Am J Infect Control** 1996 Feb;24(1):1–6

Hyperthermic intraoperative intraperitoneal chemotherapy safety considerations. White SK, et al. **AORN J** 1996 Apr; 63(4):716–24

A proposed model for the movement of cells within the abdominal cavity during CO2 insufflation and laparoscopy. Thomas WM, et al. **Aust N Z J Surg** 1996 Feb;66(2):105–6

Recurrent intraabdominal cancer with intestinal obstruction. Averbach AM, et al. **Int Surg** 1995 Apr–Jun;80(2):141–6

Myth and reality in minimal access oncologic surgical management [editorial] Greene FL. **J Surg Oncol** 1996 Mar; 61(3):167–9

High mortality after abdominal operation in patients with large–volume malignant ascites. Yazdi GP, et al. **J Surg Oncol** 1996 Jun;62(2):93–6

[Abdominal lymphomas in children: place of surgery] Héloury Y, et al. **J Chir (Paris)** 1995 Dec;132(12):483–6 (Eng. Abstr.) **(Fre)**

[Surgical therapy of soft tissue sarcoma. I. General principles and resections of the trunk] Karakousis CP. **Chirurg** 1995 Sep;66(9):905–13 (17 ref.) (Eng. Abstr.) **(Ger)**

[Umbilical reconstruction after excision of melanomas in the area of the umbilicus] Breuninger H, et al. **Hautarzt** 1996 Apr;47(4):273–5 (Eng. Abstr.) **(Ger)**

[Retroperitoneal leiomyosarcoma originating from the inferior vena cava. A case report] Paron L, et al. **Minerva Chir** 1995 Jun;50(6):603–5 (Eng. Abstr.) **(Ita)**

THERAPY

Regional chemotherapy plus hemofiltration for the treatment of regionally advanced malignancy [editorial] Muchmore JH. **Cancer** 1996 Sep 1;78(5):941–3

Favorable outcome in children with Beckwith–Wiedemann syndrome and intraabdominal malignant tumors. Vaughan WG, et al. **J Pediatr Surg** 1995 Jul;30(7):1042–4; discussion 1044–5

Simultaneous occurrence of osteosarcoma and osteochondroma following treatment of neuroblastoma with chemotherapy, radiotherapy, and bone marrow transplantation. Poustchi–Amin M, et al. **Pediatr Radiol** 1996;26(2):155–7

ULTRASONOGRAPHY

A rare case of extra lobar abdominal bronchopulmonary malformation. Asseryanis E, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):850–1

Prenatal diagnosis of a grade IV sacrococcygeal teratoma. Shipp TD, et al. **J Ultrasound Med** 1996 Feb;15(2):175–7

[Value of abdominal ultrasonography in deep venous thrombosis. Retrospective study of 104 patients] Netzer P, et al. **Schweiz Med Wochenschr Suppl** 1996;79:58S–63S (Eng. Abstr.) **(Ger)**

VETERINARY

Diffuse abdominal epithelioid mesothelioma in a cow. Girard CA, et al. **Can Vet J** 1995 Jul;36(7):440–1

Hypoglycemia associated with intra–abdominal leiomyoma and leiomyosarcoma in six dogs. Bagley RS, et al. **J Am Vet Med Assoc** 1996 Jan 1;208(1):69–71

Radiation therapy of thoracic and abdominal tumors. LaRue SM, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug; 10(3):190–6 (32 ref.)

ABDOMINAL PAIN

see related
COLIC

Recurrent abdominal pain in childhood [letter; comment] Feldman W. **Acta Paediatr** 1995 Jul;84(7):834. Comment on: Acta Paediatr 1994 Jul;83(7):775–6.

Noncardiac chest pain and abdominal pain. Ho K. **Ann Emerg Med** 1996 Apr;27(4):457–60 (24 ref.)

Acute abdominal pain in children. Davenport M. **BMJ** 1996 Feb 24;312(7029):498–501 (0 ref.)

Abdominal migraine as a cause of vomiting in children: a clinician's view. Bentley D, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S49–51 (15 ref.)

Abdominal pain, pan–gut eosinophilia, and dog hookworm infection [letter] Khoshoo V, et al. **J Pediatr Gastroenterol Nutr** 1995 Nov;21(4):481

Persistent visceral pain in adolescents. Zeltzer L, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):92–8

BLOOD

Influence of white cell count on surgical decision making in patients with abdominal pain in the right lower quadrant. Vermeulen B, et al. **Eur J Surg** 1995 Jul;161(7):483–6

COMPLICATIONS

Abdominal pain and migraine [letter; comment] Lanzi G. **Headache** 1996 Jan;36(1):57. Comment on: Headache 1995 Apr;35(4):207–9.

DIAGNOSIS

Abdominal pain. What happens in primary care? [editorial; comment] Blondell RD. **Arch Fam Med** 1996 May; 5(5):287–8. Comment on: Arch Fam Med 1996 May;5(5):279–85.

Episodes of care for abdominal pain in a primary care practice [see comments] Klinkman MS. **Arch Fam Med** 1996 May;5(5):279–85. Comment in: Arch Fam Med 1996 May;5(5):287–8.

Abdominal pain in the postpartum: role of imaging. Van Hoe L, et al. **J Belge Radiol** 1995 Jun;78(3):186–9 (17 ref.)

Recurrent abdominal pain [clinical conference] **J Dev Behav Pediatr** 1995 Aug;16(4):277–81

Use of laparoscopy in the treatment of acute and chronic right lower quadrant pain [letter; comment] Griffin LP. **J Ky Med Assoc** 1996 Apr;94(4):160. Comment on: J Ky Med Assoc 1996 Jan;94(1):16–21.

A young boy with abdominal pain. Jabbar A, et al. **JPMA J Pak Med Assoc** 1995 Oct;45(10):284–6

Computer–aided diagnosis and medical decision support are not synonymous [editorial; comment] de Dombal FT. **Methods Inf Med** 1995 Sep;34(4):369–70. Comment on: Methods Inf Med 1995 Sep;34(4):361–8.

Evaluating four diagnostic methods with acute abdominal pain cases [see comments] Puppe B, et al. **Methods Inf Med** 1995 Sep;34(4):361–8. Comment in: Methods Inf Med 1995 Sep;34(4):369–70.

Abdominal pain and vomiting in a paint stripper. Hart SP, et al. **Postgrad Med J** 1996 Apr;72(846):253–5

Bilateral adrenal masses. Lopez E, et al. **Postgrad Med J** 1995 Sep;71(839):567–8

Doctor–dependent changes in complaint–related cognitions and anxiety during medical consultations in functional abdominal complaints. Van Dulmen AM, et al. **Psychol Med** 1995 Sep;25(5):1011–8

[Role of CT in the evaluation of patients with painful symptoms located in the lower right abdominal quadrant] Gualdi GF, et al. **Clin Ter** 1995 Aug–Sep;146(8–9):519–28 (Eng. Abstr.) **(Ita)**

[What is your diagnosis? A child with a painful abdominal mass. Xanthogranulomatous pyelonephritis] Rodríguez Soriano J, et al. **An Esp Pediatr** 1996 Jul;45(1):105–6 **(Spa)**

[Even children may be affected by malignant abdominal tumors. Far too long diagnostic delay in many cases] Lundkvist K, et al. **Lakartidningen** 1996 Jun 12; 93(24):2333–6 **(Swe)**

DRUG THERAPY

Using the "GI cocktail": a descriptive study [see comments] Wrenn K, et al. **Ann Emerg Med** 1995 Dec;26(6):687–90. Comment in: Ann Emerg Med 1996 Jul;28(1):104–5.

Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine [letter; comment] Christensen MF. **Arch Dis Child** 1995 Aug;73(2):183. Comment on: Arch Dis Child 1995 Jan;72(1):48–50.

Phentolamine abolishes the pain of chronic pancreatitis. McCleane GJ. **Br J Hosp Med** 1996 Apr 17–30;55(8):521

"Kapping" visceral pain in patients with irritable bowel syndrome: does it work? Pasricha PJ. **Gastroenterology** 1996 Aug;111(2):531–3

Chemical and preliminary analgesic evaluation of geraniin and furosin isolated from Phyllanthus sellowianus. Miguel OG, et al. **Planta Med** 1996 Apr;62(2):146–9

[Unilateral injection with the patient in lateral position. Simpler pain blockade in pancreatic cancer] Rykowski JJ, et al. **Lakartidningen** 1996 May 22;93(21):2075–7 **(Swe)**

EPIDEMIOLOGY

The role of carbon dioxide and atmospheric air in double–contrast barium enema [see comments] Skovgaard N, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):436–9. Comment in: Abdom Imaging 1996 May–Jun;21(3):282–3.

Abdominal pain and irritable bowel syndrome in adolescents: a community–based study. Hyams JS, et al. **J Pediatr** 1996 Aug;129(2):220–6

[Frequency of abdominal pain in young healthy men: results of a survey in the framework of recruit enlistment (letter)] Peterli R, et al. **Schweiz Med Wochenschr** 1996 Aug 6; 126(31–32):1365–6 **(Ger)**

ETIOLOGY

Rectal perforation following manual–anal intercourse [letter] Spears KL, et al. **Acad Emerg Med** 1995 Sep;2(9):852–3

Spontaneous rupture of the spleen [letter] Gallerani M, et al. **Am J Emerg Med** 1996 May;14(3):333–4

Boerhaave's syndrome presenting with abdominal pain and right hydropneumothorax. Jagminas L, et al. **Am J Emerg Med** 1996 Jan;14(1):53–6 (46 ref.)

Abdominal pain and hemoperitoneum in the gravid patient: a case report of placenta percreta. Smith L, et al. **Am J Emerg Med** 1996 Jan;14(1):45–7

Endosonography–guided celiac plexus injection for abdominal pain due to chronic pancreatitis [letter] Faigel DO, et al. **Am J Gastroenterol** 1996 Aug;91(8):1675

Pain relapses in the first 10 years of chronic pancreatitis. Talamini G, et al. **Am J Surg** 1996 Jun;171(6):565–9

Precholecystectomy esophagogastroduodenoscopy: is it of value? Yavorski CC, et al. **Am Surg** 1995 Dec;61(12):1032–4

Unusual cause of abdominal pain: pelvic vein thrombosis in a nonpregnant woman. Ellis JM, et al. **Ann Emerg Med** 1996 Feb;27(2):254–7

Assessment of peritonism in appendicitis. Golledge J, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):11–4

Management of women presenting to the accident and emergency department with lower abdominal pain [letter; comment] Moss TR, et al. **Ann R Coll Surg Engl** 1995 Sep; 77(5):396. Comment on: Ann R Coll Surg Engl 1995 May;77(3):193–7.

Expulsion of ventriculoperitoneal shunt tubing [letter] Swann IL. **Arch Dis Child** 1996 Feb;74(2):184

'Residual' appendicitis following incomplete laparoscopic appendicectomy. Milne AA, et al. **Br J Surg** 1996 Feb; 83(2):217

Abdominal pain as a presenting symptom of supraventricular tachycardia. Grenier MA, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):380–1

Recurrent abdominal pain in children. Hyams JS. **Curr Opin Pediatr** 1995 Oct;7(5):529–32 (19 ref.)

Endoscopic approach to pancreas divisum. Kozarek RA, et al. **Dig Dis Sci** 1995 Sep;40(9):1974–81

The evaluation of acute abdominal pain in children. Mason JD. **Emerg Med Clin North Am** 1996 Aug;14(3):629–43 (73 ref.)

Unusual causes of abdominal pain. Pearigen PD. **Emerg Med Clin North Am** 1996 Aug;14(3):593–613 (75 ref.)

Evaluation of abdominal pain in the elderly. Sanson TG, et al. **Emerg Med Clin North Am** 1996 Aug;14(3):615–27 (68 ref.)

Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Barbera R, et al. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1051–7

Intracolonic injection of glycerol: a model for abdominal pain in irritable bowel syndrome? Louvel D, et al. **Gastroenterology** 1996 Feb;110(2):351–61

Acute hemoperitoneum in an alcoholic man with ascites. Bhutani MS. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):16G

Recurrent gastrointestinal bleeding in a 21–year–old man. Gerdis MS, et al. **Hosp Pract (Off Ed)** 1996 May 15; 31(5):51–2, 55

Abdominal pain after breast cancer surgery. Yale SH, et al. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):18, 21–2

Use of laparoscopy in the treatment of acute and chronic right lower quadrant pain [see comments] Morfesis FA, et al. **J Ky Med Assoc** 1996 Jan;94(1):16–21. Comment in: J Ky Med Assoc 1996 Apr;94(4):160.

A 38–year–old man with nephrotic syndrome, episodic fever and abdominal pain [clinical conference] Gadallah MF, et al. **J La State Med Soc** 1995 Nov;147(11):493–9

Foreign bodies of dental origin in the appendix. Mellor TK, et al. **J R Army Med Corps** 1995 Oct;141(3):174–6 (25 ref.)

Right–sided low inguinal pain in young women. Kumar S. **J R Coll Surg Edinb** 1996 Apr;41(2):93–4

The great imposter. Hanumanthu S. **J Tenn Med Assoc** 1996 Feb;89(2):47–8

15–year–old boy with abdominal pain and hypertension. Khanfar NM, et al. **Mayo Clin Proc** 1996 Jul;71(7):713–6

22–year–old man with abdominal pain and rash. Kudva YC, et al. **Mayo Clin Proc** 1996 May;71(5):489–92

70–year–old man with abdominal pain amd weight loss. Vlahakis NE, et al. **Mayo Clin Proc** 1996 Jun;71(6):601–4

Sequential test selection in the analysis of abdominal pain. Castro F, et al. **Med Decis Making** 1996 Apr–Jun; 16(2):178–83

An unusual case of cyclical abdominal pain. Livingstone M, et al. **Med J Aust** 1995 Dec 4–18;163(11–12):584–5

Integration of a data dictionary and a clinical database in an expert system for acute abdominal pain. Ohmann C, et al. **Medinfo** 1995;8 Pt 2:943–6

Case records of the Massachusetts general hospital. Weekly clinicopathological exercises. Case 28–1996. A 45–year old woman with abdominal pain and a polypoid mass in the colon. **N Engl J Med** 1996 Sep 12;335(11):807–12

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 40–1995. A 71–year–old woman with right–lower quadrant pain and a cecal mass [clinical conference] **N Engl J Med** 1995 Dec 28; 333(26):1764–9

Case records of the Massachusetts General Hospital. Case 3–1996. Severe abdominal pain during early pregnancy in a woman with previous infertility [clinical conference] **N Engl J Med** 1996 Jan 25;334(4):255–60

How would you treat a 4–year–old boy with nephrotic syndrome in relapse with ascites developed peritonitis and abdominal pain? Potter DE. **Pediatr Nephrol** 1995 Aug; 9(4):411

Abdominal pain. Morgan RJ, et al. **Postgrad Med J** 1995 Jul;71(837):423–4

Discomfort during double–contrast barium enema examination: a placebo–controlled double–blind evaluation of the effect of glucagon and diazepam. Lappas JC, et al. **Radiology** 1995 Oct;197(1):95–9

Sting of the puss caterpillar: an unusual cause of acute abdominal pain. Neustater BR, et al. **South Med J** 1996 Aug;89(8):826–7

An evaluation of laparoscopic adhesiolysis in patients with chronic abdominal pain. Mueller MD, et al. **Surg Endosc** 1995 Jul;9(7):802–4

[Foreign body in the bladder as a cause of lower abdominal pain and recurrent urinary tract infections in a female patient] Vierola H. **Duodecim** 1994;110(16):1529–32 **(Fin)**

[What are abdominal painful syndromes of unexplained origin? Prospective study: 99 patients followed for three years] Champault G, et al. **Ann Chir** 1996;50(3):258–62 (Eng. Abstr.) **(Fre)**

[Recurrent abdominal pain revealing dermatomyositis (letter)] Slaoui B, et al. **Arch Pediatr** 1996 Jan;3(1):90–1 **(Fre)**

[78-year-old patient with chronic epigastric pain] Fetscher S, et al. **Internist (Berl)** 1995 Dec;36(12):1182–9 **(Ger)**

[Epigastric symptoms and alcohol drinking in a mechanic] Swarovsky B, et al. **Internist (Berl)** 1995 Aug;36(8):828–32 **(Ger)**

[Pelvic symptoms 6 months after implantation of an automatic cardioverter-defibrillator] Trappe HJ, et al. **Internist (Berl)** 1995 Aug;36(8):833–6 (Eng. Abstr.) **(Ger)**

[Comments on the contribution by U. Spengler, Ch. Scheurlen and T. Sauerbruch. From symptom to diagnosis (letter)] von Fritsch E. **Internist (Berl)** 1996 Jul;37(7):741–2 **(Ger)**

[Diffuse, right-sided pelvic pain and weight loss. Low malignancy lymphoma of the small intestine of the MALT type (mucosa-associated lymphoid tissue)] Wegmann T. **Radiologe** 1995 Dec;35(12):991–2 **(Ger)**

[What is your diagnosis? Bodypacker] Braunschweig M. **Schweiz Rundsch Med Prax** 1996 Apr 16;85(16):505–6 **(Ger)**

[Abdominal pain (clinical conference)] Hartmeier SH, et al. **Schweiz Rundsch Med Prax** 1996 Jan 30;85(5):126–30 (Eng. Abstr.) **(Ger)**

[Septate gallbladder: a rare cause of recurrent abdominal pain (RAP) in infancy. A case report] Fichera A, et al. **Pediatr Med Chir** 1996 Mar-Apr;18(2):221–2 (Eng. Abstr.) **(Ita)**

[Food allergy in pathogenesis of chronic abdominal pain in children] Ignyś I, et al. **Pediatr Pol** 1995 Apr;70(4):307–11 (Eng. Abstr.) **(Pol)**

[Spontaneous splenic rupture during infectious mononucleosis. Resolution with conservative treatment (letter)] Gálvez MC, et al. **Enferm Infecc Microbiol Clin** 1995 Aug-Sep;13(7):440–1 **(Spa)**

[Pain and jaundice secondary to hemobilia resolved by ERCP and endoscopic sphincterectomy] Defarges V, et al. **Rev Esp Enferm Dig** 1996 Jun;88(6):443–5 (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Pneumonia in unexpected locations: an occult cause of pediatric abdominal pain. Kanegaye JT, et al. **J Emerg Med** 1995 Nov-Dec;13(6):773–9

Small-bowel bacterial overgrowth in children with chronic diarrhea, abdominal pain, or both. de Boissieu D, et al. **J Pediatr** 1996 Feb;128(2):203–7

Helicobacter pylori and recurrent abdominal pain in children. Hardikar W, et al. **J Pediatr Gastroenterol Nutr** 1996 Feb; 22(2):148–52

PARASITOLOGY

Dientamoeba fragilis. An unusual intestinal pathogen. Butler WP. **Dig Dis Sci** 1996 Sep;41(9):1811–3

PATHOLOGY

[A 27-year-old woman with abdominal pain, vomiting, dark urine and hyponatremia (clinical conference)] **Rev Clin Esp** 1995 Oct;195(10):726–36 (74 ref.) **(Spa)**

PHYSIOPATHOLOGY

Influence of bradykinin in gastrointestinal disorders and visceral pain induced by acute or chronic inflammation in rats. Julia V, et al. **Dig Dis Sci** 1995 Sep;40(9):1913–21

The evaluation of changes in functional health status in patients with abdominal complaints. Jacobs HM, et al. **J Clin Epidemiol** 1996 Feb;49(2):163–71

[Abdominal pain syndrome recurring after 40 years: critical revision] Zancan L, et al. **Pediatr Med Chir** 1996 Jan-Feb; 18(1):65–6 (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Visceral pain during caesarean section [letter; comment] Fairfield MC. **Br J Anaesth** 1996 Jan;76(1):167. Comment on: Br J Anaesth 1995 Sep;75(3):266–8.

PSYCHOLOGY

Stomach ache and headache among the siblings of children with acute lymphoblastic leukaemia. Möttönen M, et al. **Acta Paediatr** 1995 Sep;84(9):1072–3

A frequent attender. Crossley N, et al. **Practitioner** 1995 Nov; 239(1556):631–2, 635–8 (3 ref.)

SURGERY

Thoracoscopic bilateral splanchnicotomy for pain control in unresectable pancreatic cancer. Rossi M, et al. **Chir Ital** 1995;47(2):55–7

An evaluation of laparoscopic adhesiolysis in patients with chronic abdominal pain. Mueller MD, et al. **Surg Endosc** 1995 Jul;9(7):802–4

Thoracoscopic splanchnicectomy for the relief of intractable abdominal pain. Takahashi T, et al. **Surg Endosc** 1996 Jan; 10(1):65–8

[Video thoracoscopic splanchnicectomy in persistent epigastric pain] Suchý T, et al. **Rozhl Chir** 1995 Sep; 74(6):277–9 (Eng. Abstr.) **(Cze)**

THERAPY

Endosonography-guided celiac plexus injection for abdominal pain due to chronic pancreatitis [letter] Faigel DO, et al. **Am J Gastroenterol** 1996 Aug;91(8):1675

Comparison of ambulance dispatch protocols for nontraumatic abdominal pain. Lammers RL, et al. **Ann Emerg Med** 1995 Nov;26(5):579–89

Endoscopic approach to pancreas divisum. Kozarek RA, et al. **Dig Dis Sci** 1995 Sep;40(9):1974–81

Endoscopic stenting for pain relief in chronic pancreatitis: results of a standardized protocol. Ponchon T, et al. **Gastrointest Endosc** 1995 Nov;42(5):452–6

Retrocrural splanchnic nerve alcohol neurolysis with a CT-guided anterior transaortic approach. Fields S. **J Comput Assist Tomogr** 1996 Jan-Feb;20(1):157–60

Acupuncture treatment of epigastric pain [clinical conference] Hu J. **J Tradit Chin Med** 1995 Sep;15(3):238–40

Treatment of cancerous abdominal pain by acupuncture on zusanli (ST 36)--a report of 92 cases. Xu S, et al. **J Tradit Chin Med** 1995 Sep;15(3):189–91

Emergency versus casual pediatric emergency medicine. Rosenberg NM. **Pediatr Emerg Care** 1995 Aug;11(4):255–8

Discomfort during double-contrast barium enema examination: a placebo-controlled double-blind evaluation of the effect of glucagon and diazepam. Lappas JC, et al. **Radiology** 1995 Oct;197(1):95–9

ULTRASONOGRAPHY

Sonographic differential diagnosis of right lower quadrant pain other than appendicitis. Jain KA, et al. **Clin Imaging** 1996 Jan-Mar;20(1):12–6

Ultrasonography as an adjunct in the diagnosis of acute appendicitis: a 4-year experience. Ramachandran P, et al. **J Pediatr Surg** 1996 Jan;31(1):164–7; discussion 167–9

[UL-scanning of children with recurrent abdominal pain--a diagnostic gain?] Dahl M, et al. **Ugeskr Laeger** 1996 Jan 15;158(3):278–81 (Eng. Abstr.) **(Dan)**

[Effect of intestinal ultrasound on choice of surgical procedure in acute abdominal pain] Heistermann HP, et al. **Ultraschall Med** 1995 Dec;16(6):288–92 (Eng. Abstr.) **(Ger)**

[Diagnostic impact of ultrasonography in abdominal diseases] Cinotti A, et al. **Radiol Med (Torino)** 1996 May; 91(5):596–600 (Eng. Abstr.) **(Ita)**

[Ultrasonography of pediatric right lower abdominal pain: correlation with clinical and pathological results] Nosaka S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(12):855–60 (Eng. Abstr.) **(Jpn)**

ABDOMINAL WALL see **ABDOMINAL MUSCLES**

ABDUCENS NERVE

Wildervanck syndrome. Kumar A, et al. **Australas Radiol** 1996 May;40(2):160–1

Sixth nerve palsy following radiculography [letter; comment] Lloyd MN. **Br J Radiol** 1995 Sep;68(813):1039–40. Comment on: Br J Radiol 1995 Apr;68(808):424.

Recurrence of systemic lupus erythematosus in a hemodialysis patient presenting as a unilateral abducens nerve palsy. Friedman AS, et al. **Clin Nephrol** 1995 Nov; 44(5):338–9

Pseudotumor cerebri (toxic effect of the "magic bullet"). Alemayehu W. **Ethiop Med J** 1995 Oct;33(4):265–70

Goldenhar, Möbius and hypoglossia-hypodactyly anomalies in a patient: syndrome or association? Preis S, et al. **Eur J Pediatr** 1996 May;155(5):385–9

Spontaneous recovery rates for unilateral sixth nerve palsies. King AJ, et al. **Eye** 1995;9 (Pt 4):476–8

Bilateral ptosis, tonic pupils and abducens palsies following Campylobacter jejuni enteritis [letter] Roberts BN, et al. **Eye** 1995;9 (Pt 5):657–8

Acquired palsy of the oculomotor, trochlear and abducens nerves. Tiffin PA, et al. **Eye** 1996;10 (Pt 3):377–84

Acute diplopia and a solitary lung mass: a unique presentation of light-chain myeloma. Foresman BH, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):371–2

Bilateral infarction of the rostral pontine tegmentum as a cause of isolated bilateral supranuclear sixth nerve palsy related to hypertension [letter] Lopez JM, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb;60(2):238–9

Simultaneous, multiple cranial neuropathies in diabetes mellitus. Eshbaugh CG, et al. **J Neuroophthalmol** 1995 Dec; 15(4):219–24 (23 ref.)

[Paralysis of the 6th cranial nerve secondary to spontaneous intracranial hypotension (letter)] Arjona A, et al. **Rev Clin Esp** 1996 Mar;196(3):201–2 **(Spa)**

BLOOD SUPPLY

Progressive ophthalmoplegia with acute ischemic abducens nerve palsies. Jacobson DM. **Am J Ophthalmol** 1996 Aug; 122(2):278–9

CHEMISTRY

Evidence for colocalization of GABA and glycine in afferents to retrogradely labelled rat abducens motoneurones. Lahjouji F, et al. **Neurosci Lett** 1996 Mar 15;206(2-3):161–4

INJURIES

Traumatic abducens nerve paresis in a child. Freeman JW, et al. **J Neuroimaging** 1995 Oct;5(4):246–7

Bilateral abducens nerve palsy secondary to maxillofacial trauma: report of case with proposed mechanism of injury. Lazow SK, et al. **J Oral Maxillofac Surg** 1995 Oct; 53(10):1197–9

PATHOLOGY

Vascular compressive abducens nerve palsy disclosed by magnetic resonance imaging. Ohtsuka K, et al. **Am J Ophthalmol** 1996 Sep;122(3):416–9

PHYSIOLOGY

Inactivation of brainstem motor nuclei blocks expression but not acquisition of the rabbit's classically conditioned eyeblink response. Krupa DJ, et al. **Behav Neurosci** 1996 Apr;110(2):219–27

Direction-specific differences in the magnitude of abducens nerve responses during off-vertical axis rotation are a basic property of the utriculo-ocular reflex in frogs. Pantle C, et al. **Exp Brain Res** 1995;106(1):28–38

Inputs from the ipsilateral and contralateral vestibular apparatus to behaviorally characterized abducens neurons in rhesus monkeys. Broussard DM, et al. **J Neurophysiol** 1995 Dec;74(6):2445–59

PHYSIOPATHOLOGY

Magnetic resonance imaging features of Gradenigo's syndrome. Hardjasudarma M, et al. **Am J Otolaryngol** 1995 Jul-Aug;16(4):247–50

Sixth nerve palsy from a CNS lesion in chronic inflammatory demyelinating polyneuropathy [letter] Wokke JH, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):695–6

Concurrent trigeminal, abducens, and facial nerve palsies presenting as false localizing signs: case report. Ro LS, et al. **Neurosurgery** 1995 Aug;37(2):322–4; discussion 324–5

[Intracranial hypotension and sixth cranial nerve palsy] Pondal M, et al. **Neurologia** 1995 Oct;10(8):339–41 (Eng. Abstr.) **(Spa)**

ABELSON LEUKEMIA VIRUS

ENZYMOLOGY

Enhanced affinities and specificities of consolidated ligands for the Src homology (SH) 3 and SH2 domains of Abelson protein-tyrosine kinase. Cowburn D, et al. **J Biol Chem** 1995 Nov 10;270(45):26738–41

GENETICS

In vivo association of v-Abl with Shc mediated by a non-phosphotyrosine-dependent SH2 interaction. Raffel GD, et al. **J Biol Chem** 1996 Mar 1;271(9):4640–5

METABOLISM

Ras complements the carboxyl terminus of v-Abl protein in lymphoid transformation. Parmar K, et al. **J Virol** 1996 Feb;70(2):1009–15

Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain. Mysliwiec T, et al. **Oncogene** 1996 Feb 1; 12(3):631–40

ABERRANT TISSUE see **CHORISTOMA**

ABETALIPOPROTEINEMIA

CLASSIFICATION

Lipoproteins containing apolipoprotein B isolated from patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia: identification and characterization. Aguie GA, et al. **Atherosclerosis** 1995 Dec;118(2):183–91

DIAGNOSIS

[Abetalipoproteinemia and transient hyperphosphatemia of childhood (letter)] Diego Núñez MA, et al. **An Esp Pediatr** 1996 Jun;44(6):634–5 **(Spa)**

GENETICS

Mutations of the microsomal triglyceride-transfer-protein gene in abetalipoproteinemia. Narcisi TM, et al. **Am J Hum Genet** 1995 Dec;57(6):1298–310

ABH BLOOD GROUP see **ABO BLOOD-GROUP SYSTEM**

ABILITY see **APTITUDE**

ABL GENES see **GENES, ABL**

ABL ONCOGENE PROTEINS see **ONCOGENE PROTEINS V-ABL**

ABL PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-ABL**

ABLATION, TRANSVENOUS ELECTRIC see CATHETER ABLATION

ABNORMAL FIBRINOGENS see FIBRINOGENS, ABNORMAL

ABNORMALITIES

New IOM report links agent orange exposure to risk of birth defect in Vietnam vets' children [news] Stephenson J. **JAMA** 1996 Apr 10;275(14):1066–7

Genetic abnormalities and oncogenesis. Hirata Y. **Med Hypotheses** 1996 Jan;46(1):17–8

Not perfectly formed. **N Z Med J** 1996 May 24;109(1022):194

Development. The science of damage limitation. Berry C. **Pathol Res Pract** 1995 Jul;191(6):541–6

Telling parents their child has severe congenital anomalies. Ryan S. **Postgrad Med J** 1995 Sep;71(839):529–33 (14 ref.)

[Request for late pregnancy interruption in severe congenital anomalies] van 't Hof DB, et al. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):585–7 **(Dut)**

[Hippocrates or Taigetos—ethical dilemmas in neonatal surgery] Pintér A. **Orv Hetil** 1996 Jan 21;137(3):115–9 (Eng. Abstr.) **(Hun)**

[A small-group center. A model trial for activities of a center for rare diseases and syndromes at the National Hospital] Kase BF, et al. **Tidsskr Nor Laegeforen** 1996 Apr 30; 116(11):1340–4 (Eng. Abstr.) **(Nor)**

CHEMICALLY INDUCED see ABNORMALITIES, DRUG-INDUCED

CLASSIFICATION

Limb defects and chorionic villus sampling [letter; comment] Firth H, et al. **Lancet** 1996 May 18;347(9012):1406; discussion 1407–8. Comment on: Lancet 1996 Feb 24;347(9000):489–94.

Flawed epidemiology of birth defects? [letter; comment] Lie RT. **Lancet** 1995 Oct 14;346(8981):1037. Comment on: Lancet 1995 Aug 12;346(8972):393–6.

DIAGNOSIS

Mild errors of morphogenesis. Frias JL, et al. **Adv Pediatr** 1996;43:27–75 (194 ref.)

Computer assisted diagnosis of malformation syndromes: an evaluation of three databases (LDDB, POSSUM, and SYNDROC). Pelz J, et al. **Am J Med Genet** 1996 May 3;63(1):257–67

Epidemiological analysis of the association between two congenital anomalies in the same child: a method for adjusting nonspecific clustering. Prieto L, et al. **Am J Med Genet** 1996 Mar 1;62(1):61–7

Primary causes of fetal deaths in Athens a clinicopathological study. Agapitos E, et al. **Arch Anat Cytol Pathol** 1995; 43(5–6):338–41

Tardive dyskinesia in schizophrenia. Relationship to minor physical anomalies, frontal lobe dysfunction and cerebral structure on magnetic resonance imaging. Waddington JL, et al. **Br J Psychiatry** 1995 Jul;167(1):41–4

Canadian firm's software helps physicians diagnose fetal abnormalities. Spurgeon D. **Can Med Assoc J** 1996 Jun 1;154(11):1733–4

Amniotic fluid prealbumin as a potential marker of fetal abnormalities. Lolis D, et al. **Gynecol Obstet Invest** 1995; 40(4):231–5

Assessing congenital anomalies after preimplantation genetic diagnosis. Simpson JL, et al. **J Assist Reprod Genet** 1996 Feb;13(2):170–6 (30 ref.)

Genetic and congenital defect conditions that mimic child abuse. Wardinsky TD. **J Fam Pract** 1995 Oct;41(4):377–83 (26 ref.)

Patient good versus patient good [editorial] Benjamin DR. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):iii–iv

Selective termination of an abnormal fetus in multiple gestations [letter; comment] Berkowitz RL. **Prenat Diagn** 1995 Nov;15(11):1085–7. Comment on: Prenat Diagn 1995 Apr;15(4):386–7.

Healing fictions': stories of choosing in the aftermath of the detection of fetal anomalies. Sandelowski M, et al. **Soc Sci Med** 1996 Feb;42(3):353–61

[Prenatal screening for abnormalities and chromosomal disorders (editorial)] Brandt NJ, et al. **Ugeskr Laeger** 1996 Feb 26;158(9):1197 **(Dan)**

[Improved prenatal diagnostic possibilities for congenital abnormalities and chromosomal disorders. Advantages and disadvantages of screening and diagnostic methods] Nørgaard-Pedersen B, et al. **Ugeskr Laeger** 1996 Feb 26; 158(9):1201–7 (29 ref.) (Eng. Abstr.) **(Dan)**

[Late pregnancy interruption] Treffers PE. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):590–2 **(Dut)**

[Applications of magnetic resonance tomography (MRT) in obstetrics] Wischnik A, et al. **Gynakologe** 1995 Oct; 28(5):321–8 (18 ref.) **(Ger)**

[Published effects of screening in parental and child health care] Juttmann RE, et al. **Ned Tijdschr Geneeskd** 1996 Jun 22;140(25):1303–7 (Eng. Abstr.) **(Ger)**

[Early amniocentesis—already an alternative? (editorial)] Rauskolb R. **Z Geburtshilfe Neonatol** 1995 Jul–Aug; 199(4):131 **(Ger)**

[The use of the screening of maternal serum factors for the prenatal diagnosis of fetal developmental defects and chromosomal diseases] Arbuzova SB, et al. **Tsitol Genet** 1995 Jul–Aug;29(4):44–7 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

[Uterine malformations. Diagnosis, prognosis and treatment] Brun JL, et al. **Presse Med** 1995 Nov 18;24(35):1658–62 (25 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Omphalocele and gastroschisis in Europe: a survey of 3 million births 1980–1990. EUROCAT Working Group. Calzolari E, et al. **Am J Med Genet** 1995 Aug 28; 58(2):187–94

Unique demographic situation in the United Arab Emirates [editorial] Al Hosani H, et al. **Am J Med Genet** 1996 Jan 2;61(1):1

Does periconceptional multivitamin use reduce the risk of neural tube defects associated with other birth defects? data from two population-based case-control studies. Khoury MJ, et al. **Am J Med Genet** 1996 Jan 2;61(1):30–6

Clinical/epidemiological analysis of congenital anomalies associated with diaphragmatic hernia. Martínez-Frías ML, et al. **Am J Med Genet** 1996 Mar 1;62(1):71–6

Incidence and spectrum of renal abnormalities in Williams–Beuren syndrome. Pankau R, et al. **Am J Med Genet** 1996 May 3;63(1):301–4

Is polyhydramnios in an ultrasonographically normal fetus an indication for genetic evaluation? Barnhard Y, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1523–7

Previous neurobiological study of Holocaust survivors [letter; comment] Stevenson I. **Am J Psychiatry** 1996 Jun; 153(6):846. Comment on: Am J Psychiatry 1995 Jul;152(7):982–6.

The surveillance of birth defects: the usefulness of the revised US standard birth certificate. Watkins ML, et al. **Am J Public Health** 1996 May;86(5):731–4

Cancer and congenital abnormalities in Asian children: a population-based study from the West Midlands. Powell JE, et al. **Br J Cancer** 1995 Dec;72(6):1563–9

Birth defects in offspring of adult survivors of childhood acute lymphoblastic leukemia. A Childrens Cancer Group/National Institutes of Health Report. Kenney LB, et al. **Cancer** 1996 Jul 1;78(1):169–76

Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Kitzmiller JL, et al. **Diabetes Care** 1996 May;19(5):514–41 (324 ref.)

Congenital malformations in pregnancies complicated by NIDDM. Towner D, et al. **Diabetes Care** 1995 Nov; 18(11):1446–51

Congenital malformations in Gondar Hospital, Ethiopia. Tessema T, et al. **East Afr Med J** 1995 Aug;72(8):495–7

Paternal occupation and risk of birth defects in offspring [see comments] Schnitzer PG, et al. **Epidemiology** 1995 Nov; 6(6):577–83. Comment in: Epidemiology 1995 Nov;6(6):573–4.

Male-mediated developmental toxicity [editorial; comment] Sever LE. **Epidemiology** 1995 Nov;6(6):573–4. Comment on: Epidemiology 1995 Nov;6(6):577–83.

Nutritional effects of the siege on new-born babies in Sarajevo. Simic S, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 2:S33–6

The prevalence of genetic disorders, birth defects and syndromes in central and eastern Kentucky. Cadle RG, et al. **J Ky Med Assoc** 1996 Jun;94(6):237–41 (15 ref.)

Impact of prenatal screening and diagnosis on the epidemiology of structural congenital anomalies. Chi LH, et al. **J Med Screen** 1995;2(2):67–70

The risk figure of 1/270 [editorial] Donnenfeld AE. **J Med Screen** 1995;2(1):1–2

Follow-up validation study of the Victorian Congenital Malformations Register. Kilkenny M, et al. **J Paediatr Child Health** 1995 Aug;31(4):323–5

Maternal obesity increases congenital malformations. Prentice A, et al. **Nutr Rev** 1996 May;54(5):146–50 (19 ref.)

Case ascertainment for state-based birth defects registries: characteristics of unreported infants ascertained through birth certificates and their impact on registry statistics in New York state. Olsen CL, et al. **Paediatr Perinat Epidemiol** 1996 Apr;10(2):161–74

Birth defects surveillance and the future of public health. Hanson JW. **Public Health Rep** 1995 Nov–Dec; 110(6):698–9

High reported prevalence of congenital anomalies in a Scottish city. Stone DH, et al. **Scott Med J** 1994 Dec; 39(6):170–2

The burden of genetic disorders in India. Verma IC. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:3–4

Monitoring birth defects: and seeking the causes [letter] Smithells RW. **World Health Forum** 1995;16(4):398–9

[Comparison of the incidence of selected congenital defects in the Czech Republic 1988–1993 with the ICBDMS and EUROCAT international registries] Sípek A. **Ceska Gynekol** 1996 Apr;61(2):112–21 **(Cze)**

[Congenital defects in the Czech Republic in 1993] Sípek A, et al. **Ceska Gynekol** 1995 Oct;60(5):241–9 **(Cze)**

[The role of prenatal diagnosis on the decreasing incidence of congenital defects in the pediatric population in the Czech Republic 1988–1994] Sípek A, et al. **Ceska Gynekol** 1996 Feb;61(1):59–70 **(Cze)**

[Congenital malformations of urinary tract and gastrointestinal canal. Incidence of diagnosed cases at 2 years of age compared with prenatal registration] Joensen F. **Ugeskr Laeger** 1996 Apr 15;158(16):2246–50 (Eng. Abstr.) **(Dan)**

[Pregnancy termination after prenatal diagnosis—data of the Styrian malformation register (1985–1992)] Häusler MC, et al. **Wien Klin Wochenschr** 1996;108(6):169–74 (Eng. Abstr.) **(Ger)**

[Voluntary interruptions of pregnancy (VIP) because of congenital malformations recorded in the territory of the ex Local Health Unit 13—the Livorno area (1992–1994)] Baggiani A, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):110–1 **(Ita)**

[Working mothers and the risk of congenital defects: the results of the EUROCAT registry in the province of Florence. European Registry of Congenital Anomalies and Twins] Bianchi F, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):197–9 **(Ita)**

[Frequency of birth defects in four different regions in Poland] Sitarek K. **Przegl Epidemiol** 1996;50(1–2):61–5 (Eng. Abstr.) **(Pol)**

[Hereditary diseases and congenital malformations at the Unit of Medical Genetics of the University of Zulia. Years: 1983–1992] González-Ferrer S, et al. **Invest Clin** 1995 Jun; 36(2):47–60 (Eng. Abstr.) **(Spa)**

[The epidemiological problems of hereditary diseases and congenital developmental defects in Ukraine] Serdiuk AM, et al. **Lik Sprava** 1995 Jul–Aug;(7–8):3–6 (Eng. Abstr.) **(Ukr)**

ETIOLOGY

Synchronization of the factors critical for diabetic teratogenesis: an in vitro model. Reece EA, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1284–8

Risk factors for birth defects in Singapore: a case control study. Thein MM, et al. **Ann Acad Med Singapore** 1995 May;24(3):421–7

Vitamins in early pregnancy [editorial] Smithells D. **BMJ** 1996 Jul 20;313(7050):128–9

Birth defects in diabetic pregnancies: where do we go from here? Buchanan TA. **Eur J Endocrinol** 1996 Apr; 134(4):395–7

Insulin treatment fails to abolish the teratogenic potential of serum from diabetic rats. Wentzel P, et al. **Eur J Endocrinol** 1996 Apr;134(4):459–66

"Give me children or I shall die!" New reproductive technologies and harm to children. Cohen CB. **Hastings Cent Rep** 1996 Mar–Apr;26(2):19–27

Genetic risk in micromanipulative assisted reproduction. Meschede D, et al. **Hum Reprod** 1995 Nov;10(11):2880–6 (72 ref.)

Assessment of developmental retardation and abnormality of in vivo produced preimplantation embryos in rat. Rupasri A, et al. **Indian J Exp Biol** 1995 Dec;33(12):911–6

Congenital defects, folic-acid, and homoeobox genes. Milunsky A. **Lancet** 1996 Aug 17;348(9025):419–20 (8 ref.)

Maternal obesity increases congenital malformations. Prentice A, et al. **Nutr Rev** 1996 May;54(5):146–50 (19 ref.)

The pathogenesis of diabetes-associated congenital malformations. Reece EA, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):29–45 (144 ref.)

Expression of keratinocyte growth factor in embryonic liver of transgenic mice causes changes in epithelial growth and differentiation resulting in polycystic kidneys and other organ malformations. Nguyen HQ, et al. **Oncogene** 1996 May 16;12(10):2109–19

The new dysmorphology: application of insights from basic developmental biology to the understanding of human birth defects. Epstein CJ. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8566–73 (92 ref.)

Heat shock proteins and teratogenesis. Buckiová D, et al. **Reprod Toxicol** 1995 Nov–Dec;9(6):501–11 (120 ref.)

Hyperthermia and birth defects. Edwards MJ, et al. **Reprod Toxicol** 1995 Sep–Oct;9(5):411–25 (109 ref.)

Automobile accidents during pregnancy [letter] Källén B, et al. **Reprod Toxicol** 1995 Nov–Dec;9(6):591

Effects of tobacco smoke inhalation on the developing mouse embryo and fetus. Seller MJ, et al. **Reprod Toxicol** 1995 Sep–Oct;9(5):449–59

Interactive effects of alcohol and diabetes during pregnancy on the rat fetus. Lin Y, et al. **Teratog Carcinog Mutagen** 1995;15(3):147–53

Detection of genotype-environment interaction in case-control studies of birth defects: how big a sample size? Khoury MJ, et al. **Teratology** 1995 May;51(5):336–43

Exercise at high temperature causes maternal hyperthermia and fetal anomalies in rats. Sasaki J, et al. **Teratology** 1995 Apr;51(4):233–6

Monitoring birth defects: and seeking the causes [letter] Smithells RW. **World Health Forum** 1995;16(4):398–9

[Sauna and congenital malformations—the myth and how it started (editorial)] Saxén L. **Duodecim** 1995;111(5):387–8 **(Fin)**

[Smoking and pregnancy] Wenderlein JM. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):467–71 (15 ref.) (Eng. Abstr.) **(Ger)**

[European study of working mothers and congenital malformations] Candela S, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):183–5 (17 ref.) **(Ita)**

[Folate deficiency, cancer and congenital abnormalities. Is there a connection?] Christensen B.

Tidsskr Nor Laegeforen 1996 Jan 20;116(2):250–4 (45 ref.) (Eng. Abstr.) **(Nor)**

[Folic acid deficiency, cancer and congenital abnormalities (letter)] Fjeldstrup A. **Tidsskr Nor Laegeforen** 1996 Apr 20;116(10):1258 **(Nor)**

[Folic acid deficiency, cancer and congenital abnormalities (letter)] Spigset O. **Tidsskr Nor Laegeforen** 1996 Mar 10; 116(7):892–3 **(Nor)**

GENETICS

Atavisms in homo sapiens: a Bolkian heterodoxy revisited. Verhulst J. **Acta Biotheor** 1996 Mar;44(1):59–73

Deletion mapping of 22q11 in CATCH22 syndrome: identification of a second critical region. Kurahashi H, et al. **Am J Hum Genet** 1996 Jun;58(6):1377–81

High-frequency developmental abnormalities in p53-deficient mice. Armstrong JF, et al. **Curr Biol** 1995 Aug 1;5(8):931–6

Genetics of disease. **Curr Opin Genet Dev** 1995 Jun; 5(3):399–422

Finding genes involved in human developmental disorders. Muenke M. **Curr Opin Genet Dev** 1995 Jun;5(3):354–61 (80 ref.)

Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects. Yang P, et al. **Genet Epidemiol** 1995;12(5):467–74

Congenital bilateral absence of the vas deferens (CBAVD) and cystic fibrosis transmembrane regulator (CFTR): correlation between genotype and phenotype. Dumur V, et al. **Hum Genet** 1996 Jan;97(1):7–10

Recent molecular advances in dysmorphology. Winter RM. **Hum Mol Genet** 1995;4 Spec No:1699–704 (87 ref.)

Genetic risk in micromanipulative assisted reproduction. Meschede D, et al. **Hum Reprod** 1995 Nov;10(11):2880–6 (72 ref.)

Prenatal diagnosis of genetic disorders. Kulkarni ML, et al. **Indian Pediatr** 1995 Nov;32(11):1229–38 (28 ref.)

A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities. Hahn H, et al. **J Biol Chem** 1996 May 24;271(21):12125–8

Congenital anomalies and genetic disorders in families of children with central nervous system tumours. Jones SM, et al. **J Med Genet** 1995 Aug;32(8):627–32

Mutations, malformations and mortality. Suthers G. **J Paediatr Child Health** 1996 Feb;32(1):10–5 (67 ref.)

Mental modelling [news; comment] Korenberg JR. **Nat Genet** 1995 Oct;11(2):109–11. Comment on: Nat Genet 1995 Oct;11(2):177–84.

Localization of the mouse lissencephaly-1 gene to mouse chromosome 11B3, in close proximity to D11Mit65. Péterfy M, et al. **Somat Cell Mol Genet** 1995 Sep;21(5):345–9

[Does the risk of complications after amniocentesis depend on the indications for intervention? An evaluation of 2,066 punctures] Plöckinger B, et al. **Geburtshilfe Frauenheilkd** 1996 Mar;56(3):128–31 (Eng. Abstr.) **(Ger)**

METABOLISM

Prostaglandin D2 synthase: a component of human amniotic fluid and its association with fetal abnormalities. Melegos DN, et al. **Clin Chem** 1996 Jul;42(7):1042–50

MICROBIOLOGY

Maternal Lyme disease and congenital malformations: a cord blood serosurvey in endemic and control areas. Williams CL, et al. **Paediatr Perinat Epidemiol** 1995 Jul;9(3):320–30

MORTALITY

Early childhood surveillance of developmental disorders by a birth defects surveillance system: methods, prevalence comparisons, and mortality patterns. Kirby RS, et al. **J Dev Behav Pediatr** 1995 Oct;16(5):318–26

The impact of major congenital malformations on mortality in a neonatal intensive care unit. Stewart DL, et al. **J Ky Med Assoc** 1995 Aug;93(8):329–32

Mortality among infants with congenital malformations, New York State, 1983 to 1988. Druschel C, et al. **Public Health Rep** 1996 Jul-Aug;111(4):359–65

Methods for maternal age-standardization of the incidence of congenital abnormalities. Carothers AD. **Stat Med** 1995 Aug 30;14(16):1797–806

PHYSIOPATHOLOGY

Diagnosis of fatal infantile defects of the mitochondrial respiratory chain: age dependence and postmortem analysis of enzyme activities. Majander A, et al. **J Neurol Sci** 1995 Dec;134(1-2):95–102

Cell death in normo- and teratogenesis. II. Cell death in teratogenesis. Sandor S, et al. **Rom J Morphol Embryol** 1994 Jul-Dec;40(3-4):83–91 (67 ref.)

Cell death in normo- and teratogenesis. I. Cell death in normogenesis. Sandor S, et al. **Rom J Morphol Embryol** 1994 Jul-Dec;40(3-4):69–81 (79 ref.)

PREVENTION & CONTROL

Prevention of birth defects: a task for a world alliance. Wertelecki W, et al. **Acta Paediatr Sin** 1996 May-Jun; 37(3):168–72 (57 ref.)

Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Shaw GM, et al. **Am J Med Genet** 1995 Dec 4;59(4):536–45

Prevention of diabetes-associated embryopathy by overexpression of the free radical scavenger copper zinc superoxide dismutase in transgenic mouse embryos. Hagay ZJ, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1036–41

Primary prevention of birth defects by periconceptional care, including multivitamin supplementation. Czeizel AE. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):417–30 (26 ref.)

Diabetes. Oats JN. **Baillieres Clin Obstet Gynaecol** 1995 Sep; 9(3):481–95 (67 ref.)

Maternal serum screening for birth defects: results of a Connecticut regional program. Benn PA, et al. **Conn Med** 1996 Jun;60(6):323–7

Patient attitudes to prenatal screening and termination of pregnancy at Groote Schuur Hospital: a two year prospective study. Viljoen D, et al. **East Afr Med J** 1996 May;73(5):327–9

Insulin treatment fails to abolish the teratogenic potential of serum from diabetic rats. Wentzel P, et al. **Eur J Endocrinol** 1996 Apr;134(4):459–66

A multiple-level, comprehensive approach to the prevention of fetal alcohol syndrome (FAS) and other alcohol-related birth defects (ARBD). May PA. **Int J Addict** 1995; 30(12):1549–602 (160 ref.)

Impact of prenatal screening and diagnosis on the epidemiology of structural congenital anomalies. Chi LH, et al. **J Med Screen** 1995;2(2):67–70

Folic acid and prevention of birth defects [letter; comment] Czeizel AE. **JAMA** 1996 Jun 5;275(21):1635–6. Comment on: JAMA 1995 Dec 6;274(21):1698–702.

Folate prophylaxis in pregnancy [letter] De Jong-Van den Berg LT, et al. **Lancet** 1995 Nov 4;346(8984):1227–8

[Prenatal diagnosis--current aspects] Schmidt W. **Arch Gynecol Obstet** 1995;257(1-4):190–4 **(Ger)**

[The use of the screening of maternal serum factors for the prenatal diagnosis of fetal developmental defects and chromosomal diseases] Arbuzova SB, et al. **Tsitol Genet** 1995 Jul-Aug;29(4):44–7 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Radiological abnormalities in children born as a result of assisted conception. Leighton DM. **Australas Radiol** 1995 Aug;39(3):237–42

SURGERY

Prenatal diagnosis and the pediatric surgeon: the impact of prenatal consultation on perinatal management. Crombleholme TM, et al. **J Pediatr Surg** 1996 Jan; 31(1):156–62; discussion 162–3

[Recent advances and problems in the diagnosis and therapy of congenital deformities] Iwabuchi M, et al. **Nippon Geka Gakkai Zasshi** 1995 Sep;96(9):602–3 **(Jpn)**

THERAPY

The treatment of non-HIV-related conditions in newborns at risk for HIV: a survey of neonatologists [see comments] Levin BW, et al. **Am J Public Health** 1995 Nov; 85(11):1507–13. Comment in: Am J Public Health 1995 Nov;85(11):1484–5.

[Induced delivery in fetal malformations] Boog G. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:54–6 (22 ref.) **(Fre)**

ULTRASONOGRAPHY

Second trimester routine ultrasound and abnormal findings. Eurenius K, et al. **Acta Obstet Gynecol Scand** 1996 Mar; 75(3):235–40

Comprehensive ultrasound examination in a private perinatal practice. Ott WJ, et al. **Am J Perinatol** 1995 Nov; 12(6):385–91 (14 ref.)

Fetal malformations diagnosed antenatally. 2: Ultrasound diagnosis of fetal structural anomalies. Sprigg A. **Br J Hosp Med** 1995 Nov 1-14;54(9):447–50

Use of three-dimensional ultrasonography for the study of normal and pathologic morphology of the human embryo and fetus: preliminary report. Bonilla-Musoles F, et al. **J Ultrasound Med** 1995 Oct;14(10):757–65

Ultrasonography in the detection of aneuploidy in the first trimester. Cullen MT, et al. **J Ultrasound Med** 1995 Aug; 14(8):559–63

Pilot screening for fetal malformations: possibilities and limits of transvaginal sonography. D'Ottavio G, et al. **J Ultrasound Med** 1995 Aug;14(8):575–80

Advances in ultrasound technology [editorial] Rottem S. **J Ultrasound Med** 1995 Aug;14(8):557

Ultrasonography in pregnancy and fetal abnormalities: screening or diagnostic test? IPIMC 1986–1990 register data. Indagine Policentrica Italiana sulle Malformazioni Congenite. Baronciani D, et al. **Prenat Diagn** 1995 Dec; 15(12):1101–8

Ultrasound screening for fetal abnormalities [see comments] Chitty LS. **Prenat Diagn** 1995 Dec;15(13):1241–57 (74 ref.) . Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

Evaluation of routine prenatal diagnosis by a registry of congenital anomalies. Stoll C, et al. **Prenat Diagn** 1995 Sep; 15(9):791–800

Predictive value of antepartum ultrasound examination for anomalies in twin gestations. Edwards MS, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):43–9

Fetal structural disorders--the large series are emerging [comment] Eik-Nes SH. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):364–5 (10 ref.). Comment on: Ultrasound Obstet Gynecol 1995 Jun;5(6):366–71. Comment on: Ultrasound Obstet Gynecol 1995 Jun;5(6):372–80.

End-result of routine ultrasound screening for congenital anomalies: the Belgian Multicentric Study 1984–92 [see comments] Levi S, et al. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):366–71. Comment in: Ultrasound Obstet Gynecol 1995 Jun;5(6):364–5.

IRONFAN--a sonographic window into the natural history of fetal anomalies. International Registry of the Onset of Fetal Anomalies [editorial] Rottem S. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):361–3 (6 ref.)

[Standards in perinatal medicine--Doppler ultrasound in pregnancy] **Geburtshilfe Frauenheilkd** 1996 May; 56(5):M69–73 **(Ger)**

[3-D ultrasound in prenatal diagnosis] Merz E, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:118–21 (Eng. Abstr.) **(Ger)**

[Potential 3-dimensional (3D-)ultrasound in the diagnosis of fetal abnormalities] Steiner H. **Gynakologe** 1995 Oct; 28(5):315–20 (31 ref.) **(Ger)**

[Use of 3D ultrasound technique in prenatal diagnosis] Merz E. **Ultraschall Med** 1995 Aug;16(4):154–61 (28 ref.) (Eng. Abstr.) **(Ger)**

[Malignant sacrococcygeal teratoma: report of a case of "explosive" intrauterine growth] Battaglino F, et al. **Pediatr Med Chir** 1996 Jan-Feb;18(1):95–8 (Eng. Abstr.) **(Ita)**

[Neonatal ultrasonic screening and follow up of urinary tract malformations] Padovani EM, et al. **Pediatr Med Chir** 1996 Jan-Feb;18(1):37–41 (Eng. Abstr.) **(Ita)**

[Polyhydramnios and its relationship with congenital malformations: ultrasonographic diagnosis] Gaxiola Castro R, et al. **Ginecol Obstet Mex** 1995 Dec;63:505–8 (12 ref.) (Eng. Abstr.) **(Spa)**

VETERINARY

Per rectal portal scintigraphy in the diagnosis and management of feline congenital portosystemic shunts. Forster-van Hijfte MA, et al. **J Small Anim Pract** 1996 Jan;37(1):7–11

Dorsal cross pinning of the atlantoaxial joint: new surgical technique for atlantoaxial subluxation. Jeffery ND. **J Small Anim Pract** 1996 Jan;37(1):26–9

Sex steroid levels throughout gestation in cows carrying normal and malformed fetuses. Patel OV, et al. **J Vet Med Sci** 1995 Aug;57(4):659–63

Reproductive abnormalities associated with a coronavirus infection in rats. Macy JD Jr, et al. **Lab Anim Sci** 1996 Feb;46(1):129–32

Cellular proofreading [comment] Brash DE. **Nat Med** 1996 May;2(5):525–6. Comment on: Nat Med 1996 May;2(5):577–80.

Surgical correction of a canine preputial deformity. Dominguez JC, et al. **Vet Rec** 1996 May 18;138(20):496–7

ABNORMALITIES, DRUG-INDUCED

see related

TERATOGENS

Vitamin A teratogenicity reassessed women warned to watch intake [news] **Am J Health Syst Pharm** 1996 Feb 1; 53(3):226, 228

Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Howe AM, et al. **Am J Med Genet** 1995 Sep 11;58(3):238–44 (52 ref.)

Hand anomalies in fetal-hydantoin syndrome: from nail/phalangeal hypoplasia to unilateral acheiria [letter] Sabry MA, et al. **Am J Med Genet** 1996 Apr 24;62(4):410–2 (34 ref.)

Estimating variance functions in developmental toxicity studies. Bowman D, et al. **Biometrics** 1995 Dec; 51(4):1523–8

Drugs and the fetus [editorial] Vallance P. **BMJ** 1996 Apr 27;312(7038):1053–4

Transverse limb deficiency, facial clefting and hypoxic renal damage: an association with treatment of maternal hypertension? Hurst JA, et al. **Clin Dysmorphol** 1995 Oct; 4(4):359–63

Comparative teratological studies on TCDD, endrin and lindane in C57BL/6J and DBA/2J mice. Hassoun EA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Mar;113(3):393–8

Xenopus laevis: a model system for the study of embryonic retinoid metabolism. III. Isomerization and metabolism of all-trans-retinoic acid and 9-cis-retinoic acid and their dysmorphogenic effects in embryos during neurulation. Kraft JC, et al. **Drug Metab Dispos** 1995 Oct;23(10):1058–71

Influence of Phoxim on testicular and seminal vesicle organs, testosterone and cholinesterase level and its tissue residues in male rats. Atef M, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Aug;102(8): 01–5

Potential involvement of yolk sac in teratogenesis [letter] Tiboni GM, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):201

Genotoxicity testing of two red dyes in the somatic and germ

line cells of Drosophila. Tripathy NK, et al. **Food Chem Toxicol** 1995 Nov;33(11):923-7

DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2'-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Liu L, et al. **Free Radic Biol Med** 1995 Nov;19(5):639-48

The reproductive and developmental toxicity of indium in the Swiss mouse. Chapin RE, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):140-8

Determination of a no-observed-effect level for developmental toxicity of ethylene glycol administered by gavage to CD rats and CD-1 mice. Neeper-Bradley TL, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):121-30

Evaluation of the developmental toxicity of ethylene glycol aerosol in CD-1 mice by nose-only exposure. Tyl RW, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):49-62

Considerations of prescription medications for the pregnant podiatric patient. Haverstock BD, et al. **J Am Podiatr Med Assoc** 1996 Jul;86(7):334-46 (108 ref.)

Visceral heterotaxy syndrome induced by retinoids in mouse embryo. Kim SH, et al. **J Korean Med Sci** 1995 Aug; 10(4):250-7

Fetal valproate syndrome. Clayton-Smith J, et al. **J Med Genet** 1995 Sep;32(9):724-7

Long-term administration of high dose vitamin A to rats does not cause fetal malformations: macroscopic, skeletal and physicochemical findings. Biesalski HK, et al. **J Nutr** 1996 Apr;126(4):973-83

Intravenous reproductive and developmental toxicity studies of cimadronate (YM175), a novel bisphosphonate, in rats and rabbits. Okazaki A, et al. **J Toxicol Sci** 1995 Oct;20 Suppl 1:1-13

Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Kuller JA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):789-94 (38 ref.)

Developmental toxicity of formate and formic acid in whole embryo culture: a comparative study with mouse and rat embryos. Andrews JE, et al. **Teratology** 1995 Apr; 51(4):243-51

Pattern of retinoid-induced teratogenic effects: possible relationship with relative selectivity for nuclear retinoid receptors RAR alpha, RAR beta, and RAR gamma. Elmazar MM, et al. **Teratology** 1996 Mar;53(3):158-67

Reactive oxygen species in developmental toxicity: review and hypothesis. Fantel AG. **Teratology** 1996 Mar; 53(3):196-217 (123 ref.)

Placental transfer and developmental effects of 9-cis retinoic acid in mice. Kochhar DM, et al. **Teratology** 1995 Apr; 51(4):257-65

Ethanol-induced teratogenesis: free radical damage as a possible mechanism. Kotch LE, et al. **Teratology** 1995 Sep; 52(3):128-36

Physiologically based pharmacokinetics of methoxyacetic acid: dose-effect considerations in C57BL/6 mice. O'Flaherty EJ, et al. **Teratology** 1995 Aug;52(2):78-89

Teratogen update: ergot and ergotamine. Raymond GV. **Teratology** 1995 May;51(5):344-7 (19 ref.)

Effects of chloroquine and its enantiomers on the development of rat embryos in vitro. Tagoe CN, et al. **Teratology** 1995 Sep;52(3):137-42

Developmental toxicity of mangafodipir trisodium and manganese chloride in Sprague-Dawley rats. Treinen KA, et al. **Teratology** 1995 Aug;52(2):109-15

Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Webster WS, et al. **Teratology** 1996 Mar;53(3):168-75

Developmental effects of dioxins and related endocrine disrupting chemicals. Birnbaum LS. **Toxicol Lett** 1995 Dec; 82-83:743-50 (60 ref.)

Developmental toxicity of mono-n-benzyl phthalate, one of the major metabolites of the plasticizer n-butyl benzyl phthalate, in rats. Ema M, et al. **Toxicol Lett** 1996 Jul; 86(1):19-25

Chemical structure--teratogenicity relationships, toxicokinetics and metabolism in risk assessment of retinoids. Nau H. **Toxicol Lett** 1995 Dec;82-83:975-9

[Teratogenicity study of stevioside in rats] Usami M, et al. **Eisei Shikenjo Hokoku** 1995;(113):31-5 (Eng. Abstr.) **(Jpn)**

[Reproductive toxicity of iodixanol, a new non-ionic, iso-tonic contrast medium in rats and rabbits] Fujikawa K, et al. **J Toxicol Sci** 1995 Oct;20 Suppl 1:107-15 (Eng. Abstr.) **(Jpn)**

[Teratogenic effects of exogenous agents] Graça LM, et al. **Acta Med Port** 1995 Jul-Aug;8(7-8):441-9 (70 ref.) (Eng. Abstr.) **(Por)**

[Experimental induction of abnormalities by the instillation of ethanol in embryonated eggs of chickens (Gallus gallus)] Illanes J, et al. **Anat Histol Embryol** 1995 Dec;24(4):217-21 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Finnell RH, et al. **Teratology** 1995 Dec;52(6):324-32

EMBRYOLOGY

Common arterial trunk and pulmonary atresia: close developmental cousins? results from a teratogen induced animal model. Jackson M, et al. **Cardiovasc Res** 1995 Dec; 30(6):992-1000

Morphological and molecular characterization of retinoic acid-induced limb duplications in mice. Niederreither K, et al. **Dev Biol** 1996 Jun 15;176(2):185-98

Pathogenesis of bromodeoxyuridine-induced cleft palate in mice. Antoniades K, et al. **J Craniomaxillofac Surg** 1995 Aug;23(4):252-5

Cocaine during pregnancy: a critical review of the literature. Offidani C, et al. **Minerva Ginecol** 1995 Sep;47(9):381-90 (40 ref.)

[Contribution and limitations of experimental models to the understanding of certain abnormalities of the face and ear] Louryan S. **Bull Mem Acad R Med Belg** 1995; 150(7-9):320-6; discussion 327 (Eng. Abstr.) **(Fre)**

[The dynamics of developmental disorders of the brain in fetuses obtained from mothers consuming alcohol during pregnancy (14- to 15-week-old fetuses)] Kovetskiĭ NS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(3):58-62 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Serial examination of 20,248 newborn fetuses and infants: correlations between drug exposure and major malformations. Queisser-Luft A, et al. **Am J Med Genet** 1996 May 3;63(1):268-76

Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Altshuler LL, et al. **Am J Psychiatry** 1996 May;153(5):592-606

Congenital malformations in pregnancies complicated by NIDDM. Towner D, et al. **Diabetes Care** 1995 Nov; 18(11):1446-51

Pesticides and birth defects [letter; comment] Czeizel AE. **Epidemiology** 1996 Jan;7(1):111. Comment on: Epidemiology 1995 Jan;6(1):6-7.

Intestinal atresia following intraamniotic use of dyes. Glüer S. **Eur J Pediatr Surg** 1995 Aug;5(4):240-2

Cleft palate, mortality and morbidity in infants of substance abusing mothers. Thomas DB. **J Paediatr Child Health** 1995 Oct;31(5):457-60

High maternal vitamin A intake and risk of anomalies of structures with a cranial neural crest cell contribution [letter; comment] Shaw GM, et al. **Lancet** 1996 Mar 30; 347(9005):899-900. Comment on: Lancet 1995 Aug 12;346(8972):393-6.

Birth outcomes in pregnant women taking fluoxetine [see comments] Chambers CD, et al. **N Engl J Med** 1996 Oct 3;335(14):1010-5. Comment in: N Engl J Med 1996 Oct 3;335(14):1056-8.

ETIOLOGY

Congenital anomalies in two infants born after gestational gamma-globulin prophylaxis. Ross L. **Acta Paediatr** 1995 Dec;84(12):1436-7

The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Magee LA, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):823-8

Congenital genitourinary tract abnormalities following cocaine exposure in utero. Battin M, et al. **Am J Perinatol** 1995 Nov;12(6):425-8

Chlorpyrifos (Dursban)-associated birth defects: report of four cases. Sherman JD. **Arch Environ Health** 1996 Jan-Feb;51(1):5-8

Pregnancy, abortion and the dangers of prescribing vitamin A analogs in Australia [letter] Lipson T. **Australas J Dermatol** 1996 May;37(2):114-5

Safety of tetanus toxoid in pregnant women: a hospital-based case-control study of congenital anomalies. Silveira CM, et al. **Bull World Health Organ** 1995;73(5):605-8

Use of the new quinolones during pregnancy. Koren G. **Can Fam Physician** 1996 Jun;42:1097-9

Biochemical toxicology of chemical teratogenesis. Wells PG, et al. **Crit Rev Biochem Mol Biol** 1996 Feb;31(1):1-40 (200 ref.)

Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study. Magee LA, et al. **Dig Dis Sci** 1996 Jun;41(6):1145-9

Pesticide appliers, biocides, and birth defects in rural Minnesota. Garry VF, et al. **Environ Health Perspect** 1996 Apr;104(4):394-9

The road to embryologically based dose-response models. Kavlock RJ, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:107-21 (88 ref.)

Anticoagulation and pregnancy. Oakley CM. **Eur Heart J** 1995 Oct;16(10):1317-9 (22 ref.)

Ethanol inhibition of retinoic acid synthesis as a potential mechanism for fetal alcohol syndrome. Deltour L, et al. **FASEB J** 1996 Jul;10(9):1050-7

Synergistic interaction of glycoalkaloids alpha-chaconine and alpha-solanine on developmental toxicity in Xenopus embryos. Rayburn JR, et al. **Food Chem Toxicol** 1995 Dec; 33(12):1013-9

Modulation of embryonic glutathione peroxidase activity and phenytoin teratogenicity by dietary deprivation of selenium in CD-1 mice. Ozolins TR, et al. **J Pharmacol Exp Ther** 1996 May;277(2):945-53

Reproductive and developmental toxicity studies of toluene. I. Teratogenicity study of inhalation exposure in pregnant rats. Ono A, et al. **J Toxicol Sci** 1995 May;20(2):109-34

Vitamin A and birth defects [letter] Khoury MJ, et al. **Lancet** 1996 Feb 3;347(8997):322 .

Vitamin A and birth defects [letter] Lipson AH, et al. **Lancet** 1996 Feb 3;347(8997):321-2

Mice lacking all isoforms of retinoic acid receptor beta develop normally and are susceptible to the teratogenic effects of retinoic acid. Luo J, et al. **Mech Dev** 1995 Sep; 53(1):61-71

Mutagenicity, carcinogenicity and teratogenicity of lithium compounds. Léonard A, et al. **Mutat Res** 1995 Oct; 339(3):131-7 (69 ref.)

Teratogenicity of high vitamin A intake [letter; comment] Brent RL, et al. **N Engl J Med** 1996 May 2;334(18):1196; discussion 1197. Comment on: N Engl J Med 1995 Nov 23;333(21):1369-73.

Teratogenicity of high vitamin A intake [letter; comment] Challem JJ. **N Engl J Med** 1996 May 2;334(18):1196-7. Comment on: N Engl J Med 1995 Nov 23;333(21):1369-73.

Vitamin A and birth defects. Continuing caution is needed [editorial; comment] [see comments] Oakley GP Jr, et al. **N Engl J Med** 1995 Nov 23;333(21):1414-5. Comment on: N Engl J Med 1995 Nov 23;333(21):1369-73. Comment in: N Engl J Med 1996 May 2;334(18):1197.

Treatment depression in pregnancy [editorial; comment] Robert E. **N Engl J Med** 1996 Oct 3;335(14):1056-8. Comment on: N Engl J Med 1996 Oct 3;335(14):1010-15.

Teratogenicity of high vitamin A intake [see comments] Rothman KJ, et al. **N Engl J Med** 1995 Nov 23; 333(21):1369-73. Comment in: N Engl J Med 1995 Nov 23;333(21):1414-5. Comment in: N Engl J Med 1996 May 2;334(18):1196; discussion 1197. Comment in: N Engl J Med 1996 May 2;334(18):1196-7.

Teratogenicity of high vitamin A intake [letter; comment] Watkins M, et al. **N Engl J Med** 1996 May 2;334(18):1196; discussion 1197. Comment on: N Engl J Med 1995 Nov 23;333(21):1369-73.

Teratogenicity of high vitamin A intake [letter; comment] Werler, MM, et al. **N Engl J Med** 1996 May 2; 334(18):1195-6; discussion 1197. Comment on: N Engl J Med 1995 Nov 23;333(21):1369-73.

Methotrexate and misoprostol to terminate early pregnancy [letter] Yankowitz J, et al. **N Engl J Med** 1996 Feb 8; 334(6):399; discussion 400

In vitro neuroteratogenicity of valproic acid and 4-en-VPA. Gofflot F, et al. **Neurotoxicol Teratol** 1995 Jul-Aug; 17(4):425-35

The application of the principles of toxicology and teratology in evaluating the risks of new drugs for treatment of drug addiction in women of reproductive age. Brent RL. **NIDA Res Monogr** 1995;149:130-84

Ethanol potentiates valproic acid-induced neural tube defects (NTDs) in mice due to toxicokinetic interactions. Elmazar MM, et al. **Reprod Toxicol** 1995 Sep-Oct;9(5):427-33

Clomiphene-induced ovulation and the risk of neural tube defects [letter] Lammer EJ. **Reprod Toxicol** 1995 Sep-Oct; 9(5):491-3

Orofacial clefts and maternal anticonvulsant use [letter] Shaw GM, et al. **Reprod Toxicol** 1995 Jan-Feb;9(1):97-8

Reproductive disorders due to chemical exposure among hairdressers. Kersemaekers WM, et al. **Scand J Work Environ Health** 1995 Oct;21(5):325-34 (85 ref.)

Exposure assessment needs in studies of delayed health effects. Stolwijk JA. **Sci Total Environ** 1995 Jun 16; 168(2):119-22

Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364-70 (84 ref.)

Effects of prenatal alcohol exposure on the postnatal morphology of the rat oculomotor nucleus. Burrows RC, et al. **Teratology** 1995 May;51(5):318-28

Proof of human teratogenicity [letter; comment] Hood RD, et al. **Teratology** 1995 Apr;51(4):225-8. Comment on: Teratology 1994 Aug;50(2):97-8.

Proof of human teratogenicity [letter; comment] Waddell WJ. **Teratology** 1995 Apr;51(4):229. Comment on: Teratology 1994 Aug;50(2):97-8.

Review of the interaction between TCDD and glucocorticoids in embryonic palate. Abbott BD. **Toxicology** 1995 Dec 28;105(2-3):365-73 (86 ref.)

Agents that cause birth defects. Shepard TH. **Yonsei Med J** 1995 Nov;36(5):393-6 (13 ref.)

[Drug addiction: pregnancy and newborn infant] Lambotte R, et al. **Rev Med Liege** 1996 Feb;51(2):154-9 **(Fre)**

[Tumor therapy and family planning] Theile U, et al. **Med Klin** 1996 Jun 15;91(6):402-9 (43 ref.) **(Ger)**

[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(2)--A teratogenicity study in rats by oral administration] Morinaga T, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:187-206 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(3)--A teratogenicity study in rabbits by oral administration] Morinaga T, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:207-17 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity studies of calcipotriol (MC903): (2)--A teratogenicity study in rats by subcutaneous administration] Uchiyama H, et al. **J Toxicol Sci** 1996 Jul;21 Suppl 2:403-24 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity studies of calcipotriol (MC903): (3)--A teratogenicity study in rabbits by subcutaneous administration] Uchiyama H, et al.

J Toxicol Sci 1996 Jul;21 Suppl 2:425–38 (Eng. Abstr.) **(Jpn)**

[Retinoids—drugs with a strong teratogenic side effect] Jendryczko A, et al. **Ginekol Pol** 1995 Jun;66(6):351–3 (17 ref.) (Eng. Abstr.) **(Pol)**

[Evaluation of the toxicity of indorenate on reproduction] Chamorro G, et al. **Arch Inst Cardiol Mex** 1995 Jul–Aug; 65(4):300–6 (Eng. Abstr.) **(Spa)**

[Comment on the article about teratogenesis due to industrial pollution caused by organic solvents (letter; comment)] Borja Aburto VH. **Salud Publica Mex** 1996 Mar–Apr; 38(2):83–4. Comment on: Salud Publica Mex 1996 Jan–Feb;38(1):3–12. **(Spa)**

[Industrial pollution due to organic solvents as a cause of teratogenesis (see comments)] Saavedra–Ontiveros D, et al. **Salud Publica Mex** 1996 Jan–Feb;38(1):3–12 (Eng. Abstr.). Comment in: Salud Publica Mex 1996 Mar–Apr;38(2):83–4. **(Spa)**

GENETICS

Genetic analysis of the retinoid signal. Giguere V, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:12–22

Mouse embryos lacking RXR alpha are resistant to retinoic–acid–induced limb defects. Sucov HM, et al. **Development** 1995 Dec;121(12):3997–4003

Functional involvement of Pax–1 in somite development: somite dysmorphogenesis in chick embryos treated with Pax–1 paired–box antisense oligodeoxynucleotide. Smith CA, et al. **Teratology** 1995 Dec;52(6):333–45

IMMUNOLOGY

Immunoteratology: I. MHC involvement in the embryo response to teratogens in mice. Torchinsky A, et al. **Am J Reprod Immunol** 1995 Nov;34(5):288–98 (27 ref.)

METABOLISM

Estimating intracellular pH in developing rodent embryos using a computer imaging technique: changes in embryonic pH and proliferation rates following maternal treatment with acetazolamide. Schreiner CM, et al. **Teratology** 1995 Sep;52(3):160–8

NURSING

Case study of the home health management of a child with congenital anomalies associated with prenatal cocaine abuse. Johnson MO, et al. **J Pediatr Nurs** 1995 Dec; 10(6):375–82

PATHOLOGY

Neural tube defects: an experimental model in the foetal rat. Diez–Pardo JA, et al. **Eur J Pediatr Surg** 1995 Aug; 5(4):198–202

PHYSIOPATHOLOGY

Introduction to functional teratology. Dencker L. **Arch Toxicol Suppl** 1996;18:51–6 (10 ref.)

Comparative disposition, receptor affinity, and teratogenic activity of sulfon arotinoids. Willhite CC, et al. **Teratology** 1995 Sep;52(3):169–75

PREVENTION & CONTROL

Oral retinoids and pregnancy. Chan A, et al. **Med J Aust** 1996 Aug 5;165(3):164–7 (20 ref.)

Alcohol and Other Drug–Related Birth Defects Awareness Week, May 12–18, 1996. **MMWR Morb Mortal Wkly Rep** 1996 May 10;45(18):378–9

ACE inhibitors in pregnancy—how to avoid the sting in the tail [editorial] Opie LH. **S Afr Med J** 1996 Apr;86(4):326–7

Pantothenic acid decreases valproic acid–induced neural tube defects in mice (I). Sato M, et al. **Teratology** 1995 Sep; 52(3):143–8

Assessment of the protective activity of monisoamyl meso–2,3–dimercaptosuccinate against methylmercury–induced maternal and embryo/fetal toxicity in mice. Bellés M, et al. **Toxicology** 1996 Jan 8; 106(1–3):93–7

ABNORMALITIES, MULTIPLE

Transient gastric outlet obstruction and tetralogy of Fallot: a true association or a coincidental finding? Regev RH, et al. **Acta Paediatr** 1996 Apr;85(4):514–5

Pediatric case of the day. Biliary atresia and polysplenia syndrome. McIlhenny J, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):269, 271–3

Phenotypic manifestations of branchio–oto–renal syndrome. Chen A, et al. **Am J Med Genet** 1995 Sep 25;58(4):365–70

Child with manifestations of Nager acrofacial dysostosis, and the MURCS, VACTERL, and pulmonary agenesis associations: complex defect of blastogenesis? David A, et al. **Am J Med Genet** 1996 Mar 1;62(1):1–5

New syndrome?: MCA/MR syndrome with multiple circumferential skin creases. Elliott AM, et al. **Am J Med Genet** 1996 Mar 1;62(1):23–5

Syndrome of proximal interstitial deletion 4p15 [letter; comment] Fryns JP. **Am J Med Genet** 1995 Sep 11; 58(3):295–6. Comment on: Am J Med Genet 1995 Jan 16;55(2):147–54.

Galloway–Mowat syndrome in Taiwan. Hou JW, et al. **Am J Med Genet** 1995 Sep 11;58(3):245–8

"New" ectodermal dysplasia with mental retardation and syndactyly. Ilyina HG, et al. **Am J Med Genet** 1995 Sep 25;58(4):345–7 (15 ref.)

Skeletal abnormalities in Rett syndrome: increasing evidence for dysmorphogenetic defects. Leonard H, et al. **Am J Med Genet** 1995 Sep 11;58(3):282–5

Epidemiological analysis of the association of congenital diaphragmatic hernia with upper–limb deficiencies: a primary polytopic developmental field defect. Martínez–Frías ML. **Am J Med Genet** 1996 Mar 1; 62(1):68–70

GAPO syndrome: report on the first case in Japan. Moriya N, et al. **Am J Med Genet** 1995 Sep 11;58(3):257–61

Midline field defects and Hirschsprung disease [letter] Say B, et al. **Am J Med Genet** 1996 Jan 22;61(3):293–4

Dubowitz syndrome: review of 141 cases including 36 previously unreported patients. Tsukahara M, et al. **Am J Med Genet** 1996 May 3;63(1):277–89

Neurovascular anomaly in a patient with VATER association: coincident or syndromal? [letter] Wasserstein ML, et al. **Am J Med Genet** 1995 Sep 25;58(4):383

Anaesthetic problems in the Nance Insley syndrome. Denton R. **Anaesthesia** 1996 Jan;51(1):100–1

Russell–Silver syndrome: a study of 3 cases. Kulkarni ML, et al. **Ann Dent** 1995 Summer–Fall;54(1–2):56–60

PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Frieden IJ, et al. **Arch Dermatol** 1996 Mar; 132(3):307–11

Congenital absence of skin and blistering in a neonate. Bart's syndrome and mandibulofacial dysostosis. Martin RW 3rd, et al. **Arch Dermatol** 1995 Oct;131(10):1197, 1200

Pathological case of the month. Spondylothoracic dysplasia with multiple congenital cardiac anomalies. Adegboyega PA, et al. **Arch Pediatr Adolesc Med** 1996 Feb;150(2):221–2

Disappearance of fetal choroid plexus cysts during the second trimester in cases of chromosomal abnormality. Montemagno R, et al. **Br J Obstet Gynaecol** 1995 Sep; 102(9):752–3

A new oculorenal syndrome: retinal dystrophy and tubulointerstitial nephropathy in craniоectodermal dysplasia [letter] Eke T, et al. **Br J Ophthalmol** 1996 May; 80(5):490–1

Bilateral congenital dentiform cataract and extreme microcornea in eyes with uveal colobomas and persistent hyperplastic primary vitreous [letter] Seitz B, et al. **Br J Ophthalmol** 1996 Apr;80(4):378–9

Urodynamic evaluation of an infant with complete bladder and colonic duplication, sacral dysgenesis, and an imperforate anus. Choo KL, et al. **Br J Urol** 1996 May; 77(5):749–50

Cataracts, radiculomegaly, septal heart defects and hearing loss in two unrelated adult females with normal intelligence and similar facial appearance: confirmation of a syndrome? Aalfs CM, et al. **Clin Dysmorphol** 1996 Apr;5(2):93–103

Mayer–Rokitansky–Küster–Hauser syndrome and ovarian cancer. Report of a case. Ghirardini G, et al. **Clin Exp Obstet Gynecol** 1995;22(3):247–8

Kabuki make–up syndrome associated with an acquired hypogammaglobulinemia and anti–IgA antibodies. Hostoffer RW, et al. **Clin Pediatr (Phila)** 1996 May; 35(5):273–6

Case report: dysosteosclerosis: a unique entity. Maheshwari A, et al. **Clin Radiol** 1996 Mar;51(3):224–8

Superior sagittal sinus thrombosis in a patient with Behçet's disease and the Mayer–Rokitansky–Küster–Hauser syndrome [letter] Sfontouris H, et al. **Clin Rheumatol** 1995 Jul;14(4):486–8

LEOPARD syndrome (cardiocutaneous lentiginosis syndrome). Józwiak S, et al. **Cutis** 1996 Apr;57(4):208–14 (129 ref.)

Developmental neural abnormalities and seizures in epidermal nevus syndrome. Gurecki PJ, et al. **Dev Med Child Neurol** 1996 Aug;38(8):716–23

The Hoyeraal–Hreidarsson syndrome: don't forget the associated immunodeficiency [letter] Berthet F, et al. **Eur J Pediatr** 1995 Dec;154(12):998

Goldenhar, Möbius and hypoglossia–hypodactyly anomalies in a patient: syndrome or association? Preis S, et al. **Eur J Pediatr** 1996 May;155(5):385–9

Growth and symptoms in Silver–Russell syndrome: review on the basis of 386 patients. Wollmann HA, et al. **Eur J Pediatr** 1995 Dec;154(12):958–68

Coexistence of anomalous pancreaticobiliary ductal union with adenomyomatosis of the gallbladder. Wu MS, et al. **Gastrointest Endosc** 1995 Sep;42(3):265–9

Congenital myopathy with focal loss of cross striations: a case report with morphologic and immunohistochemical study. Yun Y, et al. **Gen Diagn Pathol** 1995 Oct; 141(2):155–60

Lissencephaly. Gupte GL, et al. **Indian Pediatr** 1995 May; 32(5):593–6

Weill–Marchesani syndrome. Kulkarni ML, et al. **Indian Pediatr** 1995 Aug;32(8):923–6

Megalourethra. Rajendran R, et al. **Indian Pediatr** 1995 Jan; 32(1):119–22

Epidermal nevus syndrome. Umakumaran P, et al. **Indian Pediatr** 1995 Mar;32(3):343–5

Frontonasal dysplasia: analysis of 21 cases and literature review. Guion–Almeida ML, et al. **Int J Oral Maxillofac Surg** 1996 Apr;25(2):91–7 (62 ref.)

Clinical manifestations of CHARGE Association. Edwards BM, et al. **Int J Pediatr Otorhinolaryngol** 1995 Aug; 33(1):23–42

Embryological considerations on a multiple vascular anomaly in a child. Puzzolo D, et al. **Ital J Anat Embryol** 1995 Jul–Sep;100(3):125–33

Case report: hypoglossia–hypodactylia syndrome. Mishima K, et al. **J Craniomaxillofac Surg** 1996 Feb;24(1):36–9

Ethmocephaly, encephalocele and proboscis. Lakshminarayana P, et al. **J Indian Med Assoc** 1995 Dec; 93(12):466–7

Twenty–four cases of the EEC syndrome: clinical presentation and management. Buss PW, et al. **J Med Genet** 1995 Sep;32(9):716–23

Mirror hands and feet: a further case of Laurin–Sandrow syndrome. Hatchwell E, et al. **J Med Genet** 1996 May; 33(5):426–8

Cerebellar atrophy in a patient with velocardiofacial syndrome. Lynch DR, et al. **J Med Genet** 1995 Jul; 32(7):561–3

A new case of fibrochondrogenesis from Spain. Martínez–Frías ML, et al. **J Med Genet** 1996 May; 33(5):429–31

Right upper limb bud triplication and polythelia, left sided hemihypertrophy and congenital hip dislocation, facial dysmorphism, congenital heart disease, and scoliosis: disorganisation–like spectrum or patterning gene defect? Sabry MA, et al. **J Med Genet** 1995 Jul;32(7):555–6

Hydrometrocolpos and segmental colonic dilatation in a girl with megacystis–microcolon–intestinal hypoperistalsis syndrome. Dewan PA, et al. **J Paediatr Child Health** 1995 Oct;31(5):479–82

Agnathia (severe micrognathia), aglossia and choanal atresia in an infant. Walker PJ, et al. **J Paediatr Child Health** 1995 Aug;31(4):358–61

Extracorporeal membrane oxygenation in the neonate with congenital renal disease and pulmonary hypoplasia. Caesar RE, et al. **J Pediatr Surg** 1995 Nov;30(11):1560–3

Epidermolysis bullosa associated with pyloric, esophageal, and anal atresia: a case report. Cetinkurşun S, et al. **J Pediatr Surg** 1995 Oct;30(10):1477–8

Complete duplication of the bladder and urethra: a case report and review of the literature. Ciftci AO, et al. **J Pediatr Surg** 1995 Nov;30(11):1605–6 (10 ref.)

Biliary atresia with ectopic proliferation of the bile ducts: a case report. Koyama T, et al. **J Pediatr Surg** 1995 Nov; 30(11):1611–2

At 18 weeks' gestation, a normal boy was found, through routine ultrasonography, to have an abdominal cystic mass [letter; comment] Shorter NA, et al. **J Pediatr Surg** 1995 Nov;30(11):1632–3. Comment on: J Pediatr Surg 1995 May;30(5):697–9.

Tracheal left mainstem bronchus and obstructive gastric mucosal intussusception associated with esophageal atresia. Tan CJ, et al. **J Pediatr Surg** 1995 Nov;30(11):1594–5

Microphthalmos associated with esophageal atresia. Ulman I, et al. **J Pediatr Surg** 1996 Mar;31(3):433–4

Central–type eight–toed polydactyly associated with ipsilateral complex renogluteal agenesis: a case report with 8 years' follow–up. Wang HJ, et al. **J Pediatr Surg** 1996 Mar;31(3):444–6

Placental pathology casebook. Long umbilical cord with torsion and diffuse chorionic surface vein thrombosis: multiple associated congenital abnormalities including destructive encephalopathy. Boué DR, et al. **J Perinatol** 1995 Sep–Oct;15(5):429–31

Fraser syndrome (cryptophthalmos [hidden eye]–syndactyly syndrome). Sarman G, et al. **J Perinatol** 1995 Nov–Dec; 15(6):503–6 (12 ref.)

Venoarterial connections in visceral heterotaxy [letter] Anderson RH, et al. **J Thorac Cardiovasc Surg** 1996 May; 111(5):1106–9

Systemic and venous connection in asplenia syndrome [letter] Marino B, et al. **J Thorac Cardiovasc Surg** 1996 May; 111(5):1109

Splenogonadal fusion. Balaji KC, et al. **J Urol** 1996 Aug;156(2 Pt 2):854–6 (20 ref.)

Solitary crossed renal ectopia associated with unicornuate uterus, imperforate anus and congenital scoliosis. Eckford SD, et al. **J Urol** 1996 Jul;156(1):221

Desmosterolosis: a new inborn error of cholesterol biosynthesis [letter] Clayton P, et al. **Lancet** 1996 Aug 10; 348(9024):404

Chondrodysplasia and neurological abnormalities in ATF–2–deficient mice. Reimold AM, et al. **Nature** 1996 Jan 18;379(6562):262–5

Laryngotracheal stenosis in thoracolaryngopelvic dysplasia: Barnes syndrome. Wood E, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):807–9

Multicore myopathy associated with multiple pterygium syndrome and hypertrophic cardiomyopathy. Ohkubo M, et al. **Pediatr Cardiol** 1996 Jan–Feb;17(1):53–6

A case of FG syndrome with gingival hyperplasia and keloids [letter] Elia M, et al. **Pediatr Dermatol** 1995 Dec; 12(4):387–9

Epidermolysis bullosa junctionalis associated with urinary bladder exstrophy: a case report. Moretti G, et al. **Pediatr Dermatol** 1995 Sep;12(3):239–41

Bilateral ulnar agenesis: case report and review of the literature. Bozner P, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):895–913 (84 ref.)

Oculoauriculovertebral spectrum: new manifestations. Johnson KA, et al. **Pediatr Radiol** 1995;25(6):446–8

The anomalous origin of bronchus from the esophagus: report of three cases. Lallemand D, et al. **Pediatr Radiol** 1996; 26(3):179–82

Dominant symphalangism and conductive hearing loss. Makowski A, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995; 116(5):339–40

Gouty arthritis in a patient with Ivemark syndrome [letter] Bhattacharjee M, et al. **South Med J** 1996 Aug;89(8):834–5

Progressive scoliosis in Dubowitz syndrome. Soyer AD, et al. **Spine** 1995 Nov 1;20(21):2335–7

Asymmetric crying facies: an index of other malformations. Aslan Y, et al. **Turk J Pediatr** 1996 Apr–Jun;38(2):271–6

Unusual malformations in occult spinal dysraphism. Gök A, et al. **Turk J Pediatr** 1995 Oct–Dec;37(4):391–7

Congenital generalized lipodystrophy: Berardinelli syndrome. Report of two siblings. Gürakan F, et al. **Turk J Pediatr** 1995 Jul–Sep;37(3):241–6

[Pre-eclampsia in the first half of pregnancy: an unknown problem?] van Hoven M, et al. **Ned Tijdschr Geneeskd** 1996 May 4;140(18):961–3 **(Dut)**

[Weary hereditary sclerosing poikiloderma] Fazio M, et al. **Ann Dermatol Venereol** 1995;122(9):618–20 (Eng. Abstr.) **(Fre)**

[Need for multidisciplinary care management in the treatment of type III laryngo–tracheo–esophageal cleft] Pinlong E, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(1):34–9 (Eng. Abstr.) **(Fre)**

[Hypoglossia–hypodactylia syndrome: apropos of a case with maxillo–mandibular synostosis, glossopalatine ankylosis and cleft palate] Casha P, et al. **Arch Pediatr** 1996 Mar; 3(3):241–4 (Eng. Abstr.) **(Fre)**

[Schizencephaly and upper limb malformation] Humbertclaude V, et al. **Arch Pediatr** 1996 Apr;3(4):357–9 (Eng. Abstr.) **(Fre)**

[Bird headed dwarfism in Seckel syndrome. Nosologic difficulties] Parent P, et al. **Arch Pediatr** 1996 Jan;3(1):55–62 (47 ref.) (Eng. Abstr.) **(Fre)**

[Intermittent chyluria in a young man] Stanzial AM, et al. **Presse Med** 1996 Feb 3;25(4):157–8 (Eng. Abstr.) **(Fre)**

[Malformation of the renal venous system and caudal vena cava presenting as recurrent hematuria] Lebret T, et al. **Prog Urol** 1995 Dec;5(6):992–6 (Eng. Abstr.) **(Fre)**

[Munchmeyer's disease in children] Cottalorda J, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(1):74–7 (Eng. Abstr.) **(Fre)**

[Nevoid basal–cell carcinoma syndrome in a patient with cleft lip and palate] Yatzkaier G, et al. **Harefuah** 1996 Apr 1; 130(7):460–2, 503 (Eng. Abstr.) **(Heb)**

[A case report of congenital stapes fixation accompanied by symphalangism and hypermetropia] Ogawa K, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 May;99(5):689–94 (Eng. Abstr.) **(Jpn)**

[Two cases of agnathia–holoprosencephaly complex] Okuno S, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar; 48(3):237–9 **(Jpn)**

[A case of Smith–Magenis syndrome] Yoshimuru K, et al. **No To Hattatsu** 1996 Jul;28(4):341–5 (Eng. Abstr.) **(Jpn)**

[Floating–Harbor syndrome in a girl with somatic asymmetry] Midro AT, et al. **Pediatr Pol** 1995 Sep; 70(9):775–8 (Eng. Abstr.) **(Pol)**

[Anesthesia in a case of Freeman–Sheldon syndrome (letter)] Ortega JP, et al. **Rev Esp Anestesiol Reanim** 1996 Apr; 43(4):152–3 **(Spa)**

CHEMICALLY INDUCED

An acardiac acephalic monster following in–utero anti–epileptic drug exposure. Kutlay B, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):245–8

Fetal valproate syndrome. Clayton–Smith J, et al. **J Med Genet** 1995 Sep;32(9):724–7

Acardius acephalus after ovulation induction by clomiphene [letter] Martínez–Román S, et al. **Teratology** 1995 Apr; 51(4):231–2

[Isotretinoin (RoAccutane) embryopathy. A case report] Pilorget H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):511–5 (14 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Short rib–dysplasia group (with/without polydactyly): report of a patient suggesting the existence of a continuous spectrum. Franceschini P, et al. **Am J Med Genet** 1995 Nov 20;59(3):359–64

Oral–facial–skeletal syndromes [editorial; comment] Neri G, et al. **Am J Med Genet** 1995 Nov 20;59(3):365–8 (29 ref.) . Comment on: Am J Med Genet 1995 Nov 20;59(3):359–64.

DiGeorge syndrome and related syndromes associated with 22q11.2 deletions. A review. Demczuk S, et al. **Ann Genet** 1995;38(2):59–76 (183 ref.)

OMENS–Plus: analysis of craniofacial and extracraniofacial anomalies in hemifacial microsomia. Horgan JE, et al. **Cleft Palate Craniofac J** 1995 Sep;32(5):405–12

PEHO or PEHO–like syndrome? Chitty LS, et al. **Clin Dysmorphol** 1996 Apr;5(2):143–52

Schinzel–Giedion syndrome: further delineation of the phenotype. Elliott AM, et al. **Clin Dysmorphol** 1996 Apr; 5(2):135–42 (18 ref.)

The EEC syndrome: a literature study. Roelfsema NM, et al. **Clin Dysmorphol** 1996 Apr;5(2):115–27 (124 ref.)

Congenital posterior urethral perineal fistulae: a unique form of urethral duplication. Wagner JR, et al. **Urology** 1996 Aug;48(2):277–80 (12 ref.)

DIAGNOSIS

The first report of a patient with interrupted inferior vena cava, multiple post–renal veins and azygos–hemiazygos continuation. Matsuoka S, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):514–7

Isolated innominate artery in asplenia syndrome with aortic atresia: newly recognized cardiovascular complex. Papagiannis J, et al. **Am Heart J** 1996 May;131(5):1042–4

Lujan–Fryns syndrome in the differential diagnosis of schizophrenia. De Hert M, et al. **Am J Med Genet** 1996 Apr 9;67(2):212–4

Ichthyosis–characteristic appearance–mental retardation syndrome with distinct histological skin abnormalities. Devriendt K, et al. **Am J Med Genet** 1996 Jan 11; 61(2):127–30

Anomalies of the nipple: an additional finding in CHARGE syndrome. Glustein JZ, et al. **Am J Med Genet** 1996 Jan 22;61(3):201

Cerebrofaciothoracic syndrome. Guion–Almeida ML, et al. **Am J Med Genet** 1996 Jan 11;61(2):152–3

Townes–Brocks syndrome associated with mental retardation [letter] Ishikiriyama S, et al. **Am J Med Genet** 1996 Jan 11;61(2):191–2

Three–generation family with resemblance to Townes–Brocks syndrome and Goldenhar/oculoauriculovertebral spectrum. Johnson JP, et al. **Am J Med Genet** 1996 Jan 11;61(2):134–9

Additional case of craniofacial and digital anomalies as reported by Harrod et al. Jurenka SB, et al. **Am J Med Genet** 1996 Jan 11;61(2):168–70

Renal insufficiency is a component of COACH syndrome. Kumar S, et al. **Am J Med Genet** 1996 Jan 11;61(2):122–6

Occipital encephalocele and MURCS association: case report and review of central nervous system anomalies in MURCS patients. Lin HJ, et al. **Am J Med Genet** 1996 Jan 2; 61(1):59–62 (23 ref.)

Computer assisted diagnosis of malformation syndromes: an evaluation of three databases (LDDB, POSSUM, and SYNDROC). Pelz J, et al. **Am J Med Genet** 1996 May 3;63(1):257–67

Frontonasal malformation and cloacal exstrophy: a previously unreported association. Robin NH, et al. **Am J Med Genet** 1996 Jan 2;61(1):75–8

Craniosynostosis, microcephaly, hydrancephaly, humero–radial synostosis, and thumb aplasia: a new syndrome? Samson G, et al. **Am J Med Genet** 1996 Jan 11;61(2):174–7

SHORT syndrome: a new case with probable autosomal dominant inheritance. Sorge G, et al. **Am J Med Genet** 1996 Jan 11;61(2):178–81

Abnormal anatomy of the lumbosacral region imaged by magnetic resonance in children with anorectal malformations. Heij HA, et al. **Arch Dis Child** 1996 May; 74(5):441–4

Rieger anomaly and congenital glaucoma in the SHORT syndrome [letter] Brodsky MC, et al. **Arch Ophthalmol** 1996 Sep;114(9):1146–7

The relationship of minor physical anomalies and other putative indices of developmental disturbance in schizophrenia to abnormalities of cerebral structure on magnetic resonance imaging. O'Callaghan E, et al. **Biol Psychiatry** 1995 Oct 15;38(8):516–24

Congenital absence of pericardium: report of 3 cases. Zheng G, et al. **Chin Med J (Engl)** 1996 Mar;109(3):252–4

Fryns syndrome: two further cases without lateral diaphragmatic defects. Bartsch O, et al. **Clin Dysmorphol** 1995 Oct;4(4):352–8

Multiple lateral meningoceles, distinctive facies and skeletal anomalies: a new case of Lehman syndrome. Philip N, et al. **Clin Dysmorphol** 1995 Oct;4(4):347–51

Oculoauriculofrontonasal syndrome: report of another case and review of differential diagnosis. Toriello HV, et al. **Clin Dysmorphol** 1995 Oct;4(4):338–46 (25 ref.)

Gorlin–Chaudhry–Moss or Saethre–Chotzen syndrome? Preis S, et al. **Clin Genet** 1995 May;47(5):267–9

Clinical overlap of Beckwith–Wiedemann, Perlman and Simpson–Golabi–Behmel syndromes: a diagnostic pitfall. Verloes A, et al. **Clin Genet** 1995 May;47(5):257–62

Absent meibomian glands: a marker for EEC syndrome. Bonnar E, et al. **Eye** 1996;10 (Pt 3):355–61 (34 ref.)

Anomalous systemic venous connections in the absence of isomerism and major intracardiac anomaly. Prasad N, et al. **Indian Heart J** 1996 May–Jun;48(3):276–8

Ebstein's anomaly with coarctation of the aorta—an unusual association. Salkar HR, et al. **Indian Heart J** 1996 May–Jun; 48(3):283–4 (7 ref.)

Complicated anophthalmos. Bajwa GS, et al. **Indian Pediatr** 1995 Apr;32(4):480–2 (5 ref.)

Agenesis of bladder associated with multiple organ anomalies. Sarica K, et al. **Int Urol Nephrol** 1995; 27(6):697–703 (10 ref.)

Long–term follow–up of cutaneous changes in siblings with mandibuloacral dysplasia who were originally considered to have hereditary sclerosing poikiloderma. Fryburg JS, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):900–2

Cerebral gigantism (Sotos' syndrome). A rare cause of delayed walking and awkward gait. Sobel E. **J Am Podiatr Med Assoc** 1995 Sep;85(9):497–9

Stringent delineation of Pallister–Hall syndrome in two long surviving patients: importance of radiological anomalies of the hands. Verloes A, et al. **J Med Genet** 1995 Aug; 32(8):605–11

Urologic problems in anorectal malformations. Part 1: Urodynamic findings and significance of sacral anomalies. Boemers TM, et al. **J Pediatr Surg** 1996 Mar;31(3):407–10

A case–based assistant for diagnosis and analysis of dysmorphic syndromes. Evans CD. **Med Inf (Lond)** 1995 Apr–Jun;20(2):121–31

Double anastomosis of median–ulnar and ulnar–median nerves: report of an electrophysiologically proven case. Oh SJ, et al. **Muscle Nerve** 1995 Nov;18(11):1332–4

Mid–portion agenesis of corpus callosum in a presumed Baller–Gerold syndrome. Dunac A, et al. **Neuropediatrics** 1995 Oct;26(5):273–5

Megacystis–microcolon–intestinal hypoperistalsis syndrome. Kupferman JC, et al. **Pediatr Nephrol** 1995 Oct;9(5):626–7

Spine evaluation in children with anorectal malformations. Beek FJ, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S28–32

Perlman syndrome: report of a case with additional radiographic findings. Herman TE, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S70–2

Unilateral occlusion of duplicated uterus with ipsilateral renal anomaly in young girls: a study with MRI. Li YW, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S54–9

Intracranial calcification in Raine syndrome. Al Mane KA, et al. **Pediatr Radiol** 1996;26(1):55–8

Complex colon duplication mimicking an obstructed, non–functioning kidney in a newborn with imperforate anus and spinal dysraphism. Stylianos S, et al. **Pediatr Radiol** 1995;25(4):269–71

The use of magnetic resonance angiography prior to pharyngeal flap surgery in patients with velocardiofacial syndrome. Mitnick RJ, et al. **Plast Reconstr Surg** 1996 Apr; 97(5):908–19

Prenatal diagnosis of partial monosomy 3p and partial trisomy 2p in a fetus associated with shortening of the long bones and a single umbilical artery. Chen CP, et al. **Prenat Diagn** 1996 Mar;16(3):270–5

Tethered cord and associated vertebral anomalies in children and infants with imperforate anus: evaluation with MR imaging and plain radiography. Long FR, et al. **Radiology** 1996 Aug;200(2):377–82

Tethered cord and associated anomalies in children and infants with imperforate anus: evaluation with MR imaging and plain radiography [editorial] Melhem ER. **Radiology** 1996 Aug;200(2):318–9

Atypical aortic coarctation and innominate artery stenosis associated with clubfoot and lower leg ischemia in an infant. Smith JC, et al. **Teratology** 1995 Dec;52(6):357–60

Isolated pericardial effusion: an indication for fetal karyotyping? Sharland G, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):29–32

[The Wunderlych syndrome] Ivanov IT, et al. **Akush Ginekol (Sofiia)** 1995;34(3):63–6 **(Bul)**

[3 children with velocardiofacial (Shprintzen) syndrome] Lie DA, et al. **Ned Tijdschr Geneeskd** 1996 Feb 17;140(7):372–5 (Eng. Abstr.) **(Dut)**

[3 children with velocardiofacial (Shprintzen) syndrome (letter)] Mulder JW, et al. **Ned Tijdschr Geneeskd** 1996 Apr 27;140(17):952–3 **(Dut)**

[Late pregnancy interruption in Noord–Holland. I. Incidence and abnormalities] van der Wal G, et al. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):600–4 (Eng. Abstr.) **(Dut)**

[Meckel–Gruber syndrome] Szafranko K, et al. **Ginekol Pol** 1996 Jan;67(1):40–1 (Eng. Abstr.) **(Pol)**

[The Tel Hashomer camptodactyly syndrome] Rogovina EG, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(4):83–6 (6 ref.) (Eng. Abstr.) **(Rus)**

[The Townes–Brocks syndrome] Arroyo Carrera I, et al. **An Esp Pediatr** 1996 Apr;44(4):364–6 (18 ref.) **(Spa)**

[The cerebrocostomandibular syndrome] Casas Gómez J, et al. **An Esp Pediatr** 1996 Apr;44(4):369–72 (25 ref.) **(Spa)**

[The Camak syndrome] Maldonado Lozano J, et al. **An Esp Pediatr** 1996 Apr;44(4):377–80 (10 ref.) **(Spa)**

[The MMT syndrome (microcephaly, mesobrachyphalangy and tracheoesophageal fistula). The first case described in Spain and a review of the literature] Martínez–Frías ML, et al. **An Esp Pediatr** 1996 Jul;45(1):87–9 (7 ref.) **(Spa)**

[Epilepsy and psychomotor retardation in a child with aplasia cutis and brachydactyly (Adams–Oliver syndrome)] Verdú Pérez A, et al. **An Esp Pediatr** 1996 Mar;44(3):289–91 (15 ref.) **(Spa)**

DIET THERAPY

Catch–up growth in Fanconi–Bickel syndrome with uncooked cornstarch. Lee PJ, et al. **J Inherit Metab Dis** 1995;18(2):153–6

DRUG THERAPY

Growth hormone and dysmorphic syndromes. Galasso C, et al. **Horm Res** 1995;44 Suppl 3:42–8 (73 ref.)

EMBRYOLOGY

Cleft lip and amniotic bands [letter] Kumar P. **Br J Plast Surg** 1996 Jan;49(1):74–5

MURCS in a male [letter; comment] Zlotogora J. **J Med Genet** 1995 Nov;32(11):919. Comment on: J Med Genet 1995 Apr;32(4):314–5.

Neonatal mesenchyme temporal bone study: typical receding

pattern versus increase in Potter's sequence. Piza JE, et al. **Laryngoscope** 1996 Jul;106(7):856–64

EPIDEMIOLOGY

Urinary tract anomalies associated with unicornuate uterus. Fedele L, et al. **J Urol** 1996 Mar;155(3):847–8

Impact of prenatal mid-trimester screening on the prevalence of fetal structural anomalies: a prospective epidemiological study. Papp Z, et al. **Ultrasound Obstet Gynecol** 1995 Nov; 6(5):320–6

Associated urologic anomalies in low imperforate anus are capable of causing significant morbidity: a 15-year experience. Misra D, et al. **Urology** 1996 Aug;48(2):281–3

[Congenital malformations of the eyeball and its appendices in Zaire] Kaimbo Wa Kaimbo D, et al. **Bull Soc Belge Ophtalmol** 1994;254:165–70 (Eng. Abstr.) **(Fre)**

[Urinary tract abnormalities associated with anorectal malformations] Tohda A, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Aug;86(8):1388–93 (Eng. Abstr.) **(Jpn)**

[The Adams–Oliver syndrome in Spain: the epidemiological aspects] Martínez-Frías ML, et al. **An Esp Pediatr** 1996 Jul;45(1):57–61 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

The Finnish disease heritage: a personal look. Perheentupa J. **Acta Paediatr** 1995 Oct;84(10):1094–9 (26 ref.)

ETIOLOGY

Unique case of growth hormone (GH) deficiency accompanied by clinical anophthalmia, hypoplastic orbits, digital dysplasia, short stature, obesity, and diabetes mellitus. Ishikawa K, et al. **Am J Med Genet** 1996 Apr 9;67(2):191–6

Limb body wall defects the result of trauma? [letter] Moore L, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jul; 75(1):F71

A mirror image of the first and second branchial arch syndrome associated with cleft lip and palate in monozygotic twins. Satoh K, et al. **Br J Plast Surg** 1995 Dec;48(8):601–5

Aarskog syndrome: severe neurological deficit with spastic hemiplegia resulting from perinatal cerebrovascular accidents in two non-related males [letter] Fryns JP, et al. **Clin Genet** 1995 Jul;48(1):54–5

Clinical follow up of a girl with "mental retardation with pterygia, shortness and distinct facial appearance" (Haspeslagh syndrome)[letter] Schrander-Stumpel CT, et al. **Clin Genet** 1995 Jun;47(6):332–4

Thalasselis syndrome and genetic theories on keratoconus. Thalasselis A. **J Am Optom Assoc** 1995 Aug;66(8):495–9 (64 ref.)

Colonic atresia and spinal cord atrophy associated with a case of fetal varicella syndrome. Hitchcock R, et al. **J Pediatr Surg** 1995 Sep;30(9):1344–7

Autism, mental retardation, multiple exostoses and short stature in a female with 46,X,t(X;8)(p22.13;q22.1). Bolton P, et al. **Psychiatr Genet** 1995 Summer;5(2):51–5

Maternal phenylketonuria: a metabolic teratogen. Levy HL, et al. **Teratology** 1996 Mar;53(3):176–84 (54 ref.)

Clinical teratology counseling and consultation case report [letter; comment] Lipson T. **Teratology** 1995 Sep; 52(3):126–7. Comment on: Teratology 1995 Feb;51(2):120–2.

[Diagnosis of Edwards syndrome in newborns] Dunin-Wąsowicz D, et al. **Pediatr Pol** 1995 Oct; 70(10):865–74 (Eng. Abstr.) **(Pol)**

GENETICS

Evidence for possible Mendelian inheritance of septo-optic dysplasia. Wales JK, et al. **Acta Paediatr** 1996 Mar; 85(3):391–2

Comparison of occurrence of genetic syndromes in ventricular septal defect with pulmonic stenosis (classic tetralogy of Fallot) versus ventricular septal defect with pulmonic atresia. Digilio MC, et al. **Am J Cardiol** 1996 Jun 15;77(15):1375–6

Delineation of a contiguous gene syndrome with multiple exostoses, enlarged parietal foramina, craniofacial dysostosis, and mental retardation, caused by deletions in the short arm of chromosome 11. Bartsch O, et al. **Am J Hum Genet** 1996 Apr;58(4):734–42

The 13q- syndrome: the molecular definition of a critical deletion region in band 13q32. Brown S, et al. **Am J Hum Genet** 1995 Oct;57(4):859–66

Haploinsufficiency of cytosolic serine hydroxymethyltransferase in the Smith–Magenis syndrome. Elsea SH, et al. **Am J Hum Genet** 1995 Dec;57(6):1342–50

The same molecular mechanism at the maternal meiosis I produces mono- and dicentric 8p duplications. Floridia G, et al. **Am J Hum Genet** 1996 Apr;58(4):785–96

A novel mutation in the putative DNA helicase XH2 is responsible for male-to-female sex reversal associated with an atypical form of the ATR-X syndrome. Ion A, et al. **Am J Hum Genet** 1996 Jun;58(6):1185–91

Molecular analyses of 17p11.2 deletions in 62 Smith–Magenis syndrome patients. Juyal RC, et al. **Am J Hum Genet** 1996 May;58(5):998–1007

A second locus for Rieger syndrome maps to chromosome 13q14. Phillips JC, et al. **Am J Hum Genet** 1996 Sep; 59(3):613–9

Mutations and phenotype in isolated glycerol kinase deficiency. Walker AP, et al. **Am J Hum Genet** 1996 Jun; 58(6):1205–11

Cytogenetic and molecular analysis in trisomy 12p. Allen TL, et al. **Am J Med Genet** 1996 May 3;63(1):250–6 (33 ref.)

Schinzel–Giedion syndrome: report of two sibs. Antich J, et al. **Am J Med Genet** 1995 Oct 23;59(1):96–9

Monozygotic twins discordant for the Russell–Silver syndrome. Bailey W, et al. **Am J Med Genet** 1995 Aug 28;58(2):101–5 (3 ref.)

Unbalanced translocation in a mother and her son in one of two 5;10 translocation families. Barber JC, et al. **Am J Med Genet** 1996 Mar 1;62(1):84–90

Craniomicromelic syndrome: a newly recognized lethal condition with craniosynostosis, distinct facial anomalies, short limbs, and intrauterine growth retardation. Barr M Jr, et al. **Am J Med Genet** 1995 Sep 25;58(4):348–52

Detection of a subtle rearrangement of chromosome 22 using molecular techniques. Biesecker LG, et al. **Am J Med Genet** 1995 Sep 25;58(4):389–94 (15 ref.)

Kaufman oculocerebrofacial syndrome in a girl of 15 years. Briscioli V, et al. **Am J Med Genet** 1995 Jul 31;58(1):21–3 (6 ref.)

Mosaic vs. nonmosaic trisomy 9: report of a liveborn infant evaluated by fluorescence in situ hybridization and review of the literature. Cantú ES, et al. **Am J Med Genet** 1996 Apr 24;62(4):330–5 (39 ref.)

Terminal deletion of the long arm of chromosome 3 [46,XX,del(3)(q27–>qter)]. Chitayat D, et al. **Am J Med Genet** 1996 Jan 2;61(1):45–8 (8 ref.)

Is there a Baller–Gerold syndrome? [editorial; comment] Cohen MM Jr, et al. **Am J Med Genet** 1996 Jan 2;61(1):63–4 (38 ref.). Comment on: Am J Med Genet 1996 Jan 2;61(1):65–7.

Diffuse polymicrogyria associated with an unusual pattern of multiple congenital anomalies including turribrachycephaly and hypogenitalism. Cohn RD, et al. **Am J Med Genet** 1996 May 3;63(1):314–7

VACTERL with the mitochondrial np 3243 point mutation. Damian MS, et al. **Am J Med Genet** 1996 Apr 24; 62(4):398–403

Inversion duplication of the short arm of chromosome 8: clinical data on seven patients and review of the literature. de Die-Smulders CE, et al. **Am J Med Genet** 1995 Nov 20;59(3):369–74 (16 ref.)

Preliminary phenotypic map of chromosome 4p16 based on 4p deletions [see comments] Estabrooks LL, et al. **Am J Med Genet** 1995 Jul 17;57(4):581–6. Comment in: Am J Med Genet 1995 Jul 17;57(4):587.

The expanding clinical phenotype of the tRNA(Leu(UUR)) A–>G mutation at np 3243 of mitochondrial DNA: diabetic embryopathy associated with mitochondrial cytopathy. Feigenbaum A, et al. **Am J Med Genet** 1996 Apr 24;62(4):404–9

Autosomal dominant Russell–Silver syndrome [letter] Al-Fifi S, et al. **Am J Med Genet** 1996 Jan 2;61(1):96–7

Ullrich–Turner phenotype with unusual manifestation in a patient with mosaicism 45,X/47,XX,+18. Franceschini P, et al. **Am J Med Genet** 1996 Mar 1;62(1):26–8

Diaphragmatic defects, limb deficiencies, and ossification defects of the skull: a distinctive malformation syndrome. Froster UG, et al. **Am J Med Genet** 1996 Mar 1;62(1):48–53

Apparently new "anophthalmia–plus" syndrome in sibs. Fryns JP, et al. **Am J Med Genet** 1995 Aug 28;58(2):113–4

Kabuki make-up (Niikawa–Kuroki) syndrome in five Spanish children. Galán-Gómez E, et al. **Am J Med Genet** 1995 Nov 20;59(3):276–82 (30 ref.)

Interstitial deletion (6)q13q15. Gershoni-Baruch R, et al. **Am J Med Genet** 1996 Apr 24;62(4):345–7 (18 ref.)

Clinical and cytogenetic findings in seven cases of inverted duplication of 8p with evidence of a telomeric deletion using fluorescence in situ hybridization [see comments] Guo WJ, et al. **Am J Med Genet** 1995 Sep 11;58(3):230–6 (20 ref.). Comment in: Am J Med Genet 1995 Sep 11;58(3):237.

A split hand–split foot (SHFM3) gene is located at 10q24–>25. Gurrieri F, et al. **Am J Med Genet** 1996 Apr 24;62(4):427–36

Diastrophic dysplasia: extreme variability within a sibship. Hall BD. **Am J Med Genet** 1996 May 3;63(1):28–33

Mirror image duplication of the hands and feet: report of a sporadic case with multiple congenital anomalies. Hersh JH, et al. **Am J Med Genet** 1995 Nov 20;59(3):341–5 (14 ref.)

Familial partial duplication (1)(p21p31). Hoechstetter L, et al. **Am J Med Genet** 1995 Nov 20;59(3):291–4 (8 ref.)

Four new cases of inverted terminal duplication: a modified hypothesis of mechanism of origin. Hoo JJ, et al. **Am J Med Genet** 1995 Sep 25;58(4):299–304

Hypoglycemia in Coffin–Siris syndrome. Imaizumi K, et al. **Am J Med Genet** 1995 Oct 23;59(1):49–50

Apparent mosaicism for del(17)(p11.2) ruled out by fluorescence in situ hybridization in a Smith–Magenis syndrome patient [letter; comment] Juyal RC, et al. **Am J Med Genet** 1995 Nov 20;59(3):406–7. Comment on: Am J Med Genet 1993 Feb 15;45(4):447–9.

Recurrent anencephaly as a primary manifestation of the acrocallosal syndrome [letter] Kedar I, et al. **Am J Med Genet** 1996 Apr 24;62(4):415–6

Agonadism in two sisters with XY gonosomal constitution, mental retardation, short stature, severely retarded bone age, and multiple extragenital malformations: a new autosomal recessive syndrome. Kennerknecht I, et al. **Am J Med Genet** 1995 Oct 23;59(1):62–7

Neuroblastoma in a boy with MCA/MR syndrome, deletion 11q, and duplication 12q. Koiffmann CP, et al. **Am J Med Genet** 1995 Jul 31;58(1):46–9 (18 ref.)

Osteopathia striata with cranial sclerosis: variable expressivity in a four generation pedigree. König R, et al. **Am J Med Genet** 1996 May 3;63(1):68–73

Distinct craniofacial syndrome of lagophthalmia and bilateral cleft lip and palate. Korula S, et al. **Am J Med Genet** 1995 Nov 6;59(2):229–33

Syndrome of arachnodactyly, disturbance of cranial ossification, protruding eyes, feeding difficulties, and mental retardation. Kosztolányi G, et al. **Am J Med Genet** 1995 Sep 11;58(3):213–6

Uniparental disomy in congenital disorders: a prospective study. Lindor NM, et al. **Am J Med Genet** 1995 Aug 28; 58(2):143–6

Phenotypic mapping and clinical ideology [editorial; comment] Lurie IW, et al. **Am J Med Genet** 1995 Jul 17; 57(4):587. Comment on: Am J Med Genet 1995 Jul 17;57(4):581–6.

Non-cardiac malformations in individuals with outflow tract defects of the heart: the Baltimore–Washington Infant Study (1981–1989). Lurie IW, et al. **Am J Med Genet** 1995 Oct 23;59(1):76–84

Autosomal dominant "Opitz" GBBB syndrome due to a 22q11.2 deletion. McDonald-McGinn DM, et al. **Am J Med Genet** 1995 Oct 23;59(1):103–13

Cleft lip and palate, characteristic facial appearance, malrotation of the intestine, and lethal congenital heart disease in two sibs: a new autosomal recessive condition? McPherson E, et al. **Am J Med Genet** 1996 Mar 1; 62(1):58–60

Jeune syndrome with tongue lobulation and preaxial polydactyly, and Jeune syndrome with situs inversus and asplenia: compound heterozygosity Jeune–Mohr and Jeune–Ivemark? Majewski E, et al. **Am J Med Genet** 1996 May 3;63(1):74–9

Rectal atresia as rare manifestation in EEC syndrome. Majewski F, et al. **Am J Med Genet** 1996 May 3;63(1):190–2

Miller–Dieker syndrome due to maternal cryptic translocation t(10;17) (q26.3;p13.3). Masuno M, et al. **Am J Med Genet** 1995 Dec 4;59(4):441–3

CHARGE association in a child with de novo inverted duplication (14)(q22–>q24.3). North KN, et al. **Am J Med Genet** 1995 Jul 17;57(4):610–4

Uniparental isodisomy of chromosome 14 in two cases: an abnormal child and a normal adult. Papenhausen PR, et al. **Am J Med Genet** 1995 Nov 20;59(3):271–5 (30 ref.)

Hypertrichosis, pigmentary retinopathy, and facial anomalies: a new syndrome? Pivnick EK, et al. **Am J Med Genet** 1996 Apr 24;62(4):386–90

Partial trisomy 13q identified by sequential fluorescence in situ hybridization. Rao VV, et al. **Am J Med Genet** 1995 Jul 31;58(1):50–3

Clinical and molecular cytogenetic observations in three cases of "trisomy 12p syndrome". Rauch A, et al. **Am J Med Genet** 1996 May 3;63(1):243–9 (26 ref.)

Partial monosomy of chromosome 1p36.3: characterization of the critical region and delineation of a syndrome. Reish O, et al. **Am J Med Genet** 1995 Dec 4;59(4):467–75

Duplication of 7p: further delineation of the phenotype and restriction of the critical region to the distal part of the short arm. Reish O, et al. **Am J Med Genet** 1996 Jan 2; 61(1):21–5 (33 ref.)

Distinct 15q genotypes in Russell–Silver and ring 15 syndromes. Rogan PK, et al. **Am J Med Genet** 1996 Mar 1;62(1):10–5

Fanconi anemia in brothers initially diagnosed with VACTERL association with hydrocephalus, and subsequently with Baller–Gerold syndrome [see comments] Rossbach HC, et al. **Am J Med Genet** 1996 Jan 2;61(1):65–7 . Comment in: Am J Med Genet 1996 Jan 2;61(1):63–4.

Autosomal dominant optic nerve colobomas, vesicoureteral reflux, and renal anomalies. Schimmenti LA, et al. **Am J Med Genet** 1995 Nov 6;59(2):204–8

Constellation of congenital abnormalities in an infant: a new syndrome or tissue-specific mosaicism for trisomy 18? Shashi V, et al. **Am J Med Genet** 1996 Mar 1;62(1):38–41

Cataracts, motor system disorder, short stature, learning difficulties, and skeletal abnormalities: a new syndrome? Slavotinek AM, et al. **Am J Med Genet** 1996 Mar 1; 62(1):42–7

Analysis of clinical variation seen in patients with 18q terminal deletions. Strathdee G, et al. **Am J Med Genet** 1995 Dec 4;59(4):476–83

Interstitial duplication 19p. Stratton RF, et al. **Am J Med Genet** 1995 Jul 17;57(4):562–4

Velo-facio-skeletal syndrome in a mother and daughter. Teebi AS, et al. **Am J Med Genet** 1995 Jul 31;58(1):8–12

Another case of the human homologue of the mouse mutant disorganization [letter] Teebi AS, et al. **Am J Med Genet** 1996 Jan 2;61(1):94

Infantile lethal variant of Simpson–Golabi–Behmel syndrome associated with hydrops fetalis. Terespolsky D, et al. **Am J Med Genet** 1995 Nov 20;59(3):329–33

Physical findings in 21q22 deletion suggest critical region for 21q- phenotype in q22. Theodoropoulos DS, et al.

Am J Med Genet 1995 Nov 6;59(2):161–3

Hunter–McAlpine craniosynostosis phenotype associated with skeletal anomalies and interstitial deletion of chromosome 17q. Thomas JA, et al. **Am J Med Genet** 1996 Apr 24;62(4):372–5 (8 ref.)

Teebi hypertelorism syndrome: further observations. Tsukahara M, et al. **Am J Med Genet** 1995 Oct 23; 59(1):59–61

Juberg–Marsidi syndrome: report of an additional case. Tsukahara M, et al. **Am J Med Genet** 1995 Sep 25; 58(4):353–5 (7 ref.)

Distal deletion of chromosome 13 in a child with the "opitz" GBBB syndrome. Urioste M, et al. **Am J Med Genet** 1995 Oct 23;59(1):114–22

Fryns syndrome survivors and neurologic outcome. Van Hove JL, et al. **Am J Med Genet** 1995 Nov 20;59(3):334–40 (39 ref.)

Opitz GBBB syndrome: chromosomal evidence of an X-linked form. Verloes A, et al. **Am J Med Genet** 1995 Oct 23;59(1):123–8

Interstitial deletions of the short arm of chromosome 4 in patients with a similar combination of multiple minor anomalies and mental retardation. White DM, et al. **Am J Med Genet** 1995 Jul 17;57(4):588–97

De novo nonreciprocal translocation 1;8 confirmed by fluorescent in situ hybridization. Wiley JE, et al. **Am J Med Genet** 1995 Jul 17;57(4):579–80

Deletion of the entire NF1 gene detected by the FISH: four deletion patients associated with severe manifestations. Wu BL, et al. **Am J Med Genet** 1995 Dec 4;59(4):528–35

Autosomal recessive omodysplasia. Stoll C, et al. **Ann Genet** 1995;38(2):97–101 (8 ref.)

The genetic basis of paediatric heart disease. Johnson MC, et al. **Ann Med** 1995 Jun;27(3):289–300 (126 ref.)

Genetic analysis of the retinoid signal. Giguere V, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:12–22

Role of parathyroid hormone-related protein in skeletal development. Kronenberg HM, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:119–23

The role of Msx genes in mammalian development. Maas R, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:171–81

Campomelic dysplasia with XY sex reversal: diverse phenotypes resulting from mutations in a single gene. Schafer AJ, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:137–49 (46 ref.)

Stickler syndrome type 2 and linkage to the COL11A1 gene. Snead MP, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:331–2

Prenatal diagnosis by transabdominal chorionic villus sampling in the second and third trimesters. Ko TM, et al. **Arch Gynecol Obstet** 1995;256(4):193–7

Happenstance, circumstance or enemy action: cyclin D1 in breast, eye and brain. Schmidt EV. **Bioessays** 1996 Jan; 18(1):6–8 (29 ref.)

Schizophrenia, CATCH 22 and FISH [editorial] Murphy KC, et al. **Br J Psychiatry** 1996 Apr;168(4):397–8

Confleunce of clinical, theoretical, and laboratory research in syndromology. Sperber GH. **Cleft Palate Craniofac J** 1995 Nov;32(6):527–8

Absent iris stroma, narrow body build and small facial bones: a new association or variant of SHORT syndrome? Bankier A, et al. **Clin Dysmorphol** 1995 Oct;4(4):304–12

Three sibs with microcephaly, congenital heart disease, lung segmentation defects and unilateral absent kidney: a new recessive multiple congenital anomaly (MCA) syndrome? Ellis IH, et al. **Clin Dysmorphol** 1996 Apr;5(2):129–34

Serpentine fibula syndrome: expansion of the phenotype with three affected siblings. Rosser EM, et al. **Clin Dysmorphol** 1996 Apr;5(2):105–13 (12 ref.)

Clinical phenotype associated with terminal 2q37 deletion. Conrad B, et al. **Clin Genet** 1995 Sep;48(3):134–9 (16 ref.)

Joint dislocation and cerebral anomalies are consistently associated with oral–facial–digital syndrome type IV. Digilio MC, et al. **Clin Genet** 1995 Sep;48(3):156–9 (11 ref.)

Phocomelia, ectrodactyly, skull defect and urinary system anomaly: Schinzel–phocomelia syndrome? Evliyaoğlu N, et al. **Clin Genet** 1996 Feb;49(2):70–3

On the nosology of the "primary true microcephaly, chorioretinal dysplasia, lymphoedema" association. Fryns JP, et al. **Clin Genet** 1995 Sep;48(3):131–3

The concurrence of the blepharophimosis, ptosis, epicanthus inversus syndrome (BPES) and Langer type of mesomelic dwarfism in the same patient. Evidence of the location of Langer type of mesomelic dwarfism at 3q22.3–q23? [letter] Fryns JP. **Clin Genet** 1995 Aug;48(2):111–2

The phenotype of a 45,X male with a Y/18 translocation. Gimelli G, et al. **Clin Genet** 1996 Jan;49(1):37–41

Molecular cytogenetic studies of duplication 9q32−−>q34.3 inserted into 9q13. Hou JW, et al. **Clin Genet** 1995 Sep; 48(3):148–50 (9 ref.)

Opitz BBBG syndrome: new family with late-onset, serious complication. Schrander J, et al. **Clin Genet** 1995 Aug; 48(2):76–9

Tracheoesophageal anomalies in oculoauriculovertebral (Goldenhar) spectrum. Sutphen R, et al. **Clin Genet** 1995 Aug;48(2):66–71

Cytogenetic and molecular cytogenetic studies of a case of interstitial deletion of proximal 15q. Tonk V, et al. **Clin Genet** 1995 Sep;48(3):151–5 (15 ref.)

Trisomy 18 mosaicism associated with secondary amenorrhea: ratios of mosaicism in different samples and complications. Uehara S, et al. **Clin Genet** 1996 Feb; 49(2):91–4

Supernumerary ring chromosome 20 characterized by fluorescence in situ hybridization. van Langen IM, et al. **Clin Genet** 1996 Jan;49(1):49–53

Microcephaly, seizures, genital hypoplasia, and abnormalities of the hands and feet in a 4-year-old boy with possible Wiedemann syndrome. Wieczorek D, et al. **Clin Genet** 1996 Feb;49(2):98–102

Mosaic "tetrasomy" 8p: case report and review of the literature. Winters J, et al. **Clin Genet** 1995 Oct;48(4):195–8 (9 ref.)

Use of fluorescence in situ hybridization (FISH) in the diagnosis of DiGeorge sequence and related diseases. Larson RS, et al. **Diagn Mol Pathol** 1995 Dec;4(4):274–8

CRASH syndrome: clinical spectrum of corpus callosum hypoplasia, retardation, adducted thumbs, spastic paraparesis and hydrocephalus due to mutations in one single gene, L1. Fransen E, et al. **Eur J Hum Genet** 1995; 3(5):273–84 (49 ref.)

Full triploidy in a liveborn preterm infant [letter] Smets K, et al. **Eur J Pediatr** 1995 Aug;154(8):688

The Currarino syndrome--hereditary transmitted syndrome of anorectal, sacral and presacral anomalies. Case report and review of the literature. Köchling J, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):114–9 (35 ref.)

Skeletal malformations caused by the Dh (Dominant hemimelia) gene in mice. Suto J, et al. **Exp Anim** 1996 Jan;45(1):95–8

High lethality of F1 (Dh/+) male mice from the cross between DDD female and DH (Dh/+) male. Suto J, et al. **Exp Anim** 1996 Jan;45(1):99–101

Systemic anomalies in 77 patients with congenital anophthalmos or microphthalmos. Tucker S, et al. **Eye** 1996;10 (Pt 3):310–4

"C" trigonocephaly syndrome with diaphragmnatic hernia. Addor MC, et al. **Genet Couns** 1995;6(2):113–20

Follow-up of a patient with partial trisomy 9p and partial monosomy 8p; description of physical and psychosocial development. Ausems MG, et al. **Genet Couns** 1996; 7(1):61–5

Familial bilateral blepharoptosis and subvalvular aortic stenosis. Bazopoulou-Kyrkanidou E, et al. **Genet Couns** 1995;6(3):227–32

Autosomal recessive mode of inheritance of a Coffin–Siris like syndrome. Bonioli E, et al. **Genet Couns** 1995; 6(4):309–12

A Croatian case of the Schinzel–Giedion syndrome. Culić V, et al. **Genet Couns** 1996;7(1):21–5

Craniofrontonasal dysplasia: more severe expression in the mother than in her son. Devriendt K, et al. **Genet Couns** 1995;6(4):361–4

Neuroblastoma in patients with constitutional chromosomal changes [letter] Fryns JP. **Genet Couns** 1996;7(1):73

Oto–palato–digital syndrome with features of type I and II in brothers. Horn D, et al. **Genet Couns** 1995;6(3):233–40

Phenotypic variability in van der Woude syndrome. Lacombe D, et al. **Genet Couns** 1995;6(3):221–6

Inverted nipples in Robinow syndrome. Lorenzetti MH, et al. **Genet Couns** 1996;7(1):67–9

Antley–Bixler syndrome: case report and review of the literature. Poddevin F, et al. **Genet Couns** 1995;6(3):241–6

Costello syndrome: report of an 8-month-old marasmic boy. Popa M, et al. **Genet Couns** 1996;7(1):27–30

Clinical experience with balanced reciprocal translocations. Prieto–Carrasquero M, et al. **Genet Couns** 1995;6(4):349–54

Marden–Walker phenotype: a diagnostic dilemma. Soekarman D, et al. **Genet Couns** 1996;7(1):31–9

A distinct phenotype associated with partial trisomy 10q due to proximal direct duplication 10q11 −−> q223? van Buggenhout G, et al. **Genet Couns** 1996;7(1):53–9 (14 ref.)

Zimmermann–Laband syndrome in a patient with severe mental retardation. Van Buggenhout GJ, et al. **Genet Couns** 1995;6(4):321–7 (15 ref.)

A nine-month-old boy with microcephaly, cataracts, intracerebral calcifications and dysmorphic signs: an additional observation of an autosomal recessive congenital infection–like syndrome? Wieczorek D, et al. **Genet Couns** 1995;6(4):297–302 (18 ref.)

Complementation mapping of skeletal and central nervous system abnormalities in mice of the piebald deletion complex. O'Brien TP, et al. **Genetics** 1996 May; 143(1):447–61

The human B22 subunit of the NADH-ubiquinone oxidoreductase maps to the region of chromosome 8 involved in branchio-oto-renal syndrome. Gu JZ, et al. **Genomics** 1996 Jul 1;35(1):6–10

Characterization of a translocation-associated deletion defines the candidate region for the gene responsible for branchio-oto-renal syndrome. Kalatzis V, et al. **Genomics** 1996 Jun 15;34(3):422–5

Narrowing the genetic interval and yeast artificial chromosome map in the branchio-oto-renal region on chromosome 8q. Kumar S, et al. **Genomics** 1996 Jan 1; 31(1):71–9

Localization of the gene (SYM1) for proximal symphalangism to human chromosome 17q21–q22. Polymeropoulos MH, et al. **Genomics** 1995 May 20;27(2):225–9

Isolation and fine mapping of 16 novel human zinc finger-encoding cDNAs identify putative candidate genes for developmental and malignant disorders. Tommerup N, et al. **Genomics** 1995 May 20;27(2):259–64

Xp-duplications with and without sex reversal. Baumstark A, et al. **Hum Genet** 1996 Jan;97(1):79–86 (32 ref.)

ICF syndrome (immunodeficiency, centromeric instability and facial anomalies): investigation of heterochromatin abnormalities and review of clinical outcome. Brown DC, et al. **Hum Genet** 1995 Oct;96(4):411–6 (15 ref.)

A detailed investigation of two cases exhibiting characteristics of the 6p deletion syndrome. Davies AF, et al. **Hum Genet** 1996 Oct;98(4):454–9

An intragenic TaqI polymorphism in the faciogenital dysplasia (FGD1) locus, the gene responsible for Aarskog syndrome. Pasteris NG, et al. **Hum Genet** 1995 Oct; 96(4):494

Interstitial deletion of chromosome 6q: precise definition of the breakpoints by microdissection, DNA amplification, and reverse painting. Rubtsov N, et al. **Hum Genet** 1996 Jun;97(6):705–9

A clinical and molecular study of mosaicism for trisomy 17. Shaffer LG, et al. **Hum Genet** 1996 Jan;97(1):69–72

The human mitochondrial citrate transporter gene (SLC20A3) maps to chromosome band 22q11 within a region implicated in DiGeorge syndrome, velo–cardio–facial syndrome and schizophrenia. Stoffel M, et al. **Hum Genet** 1996 Jul;98(1):113–5

Characterization of familial partial 10p trisomy by chromosomal microdissection, FISH, and microsatellite dosage analysis. Stone D, et al. **Hum Genet** 1996 Oct; 98(4):396–402

Severe congenital limb deficiencies, vertebral hypersegmentation, absent thymus and mirror polydactyly: a defect expression of a developmental control gene? Urioste M, et al. **Hum Genet** 1996 Feb;97(2):214–7

Possible genetic heterogeneity in the Roberts-SC phocomelia syndrome [letter; comment] Sabry MA. **Hum Hered** 1995 Jul–Aug;45(4):241–2. Comment on: Hum Hered 1994 May–Jun;44(3):121–6.

A gene for ulnar–mammary syndrome maps to 12q23–q24.1. Bamshad M, et al. **Hum Mol Genet** 1995 Oct;4(10):1973–7

Isolation of a testis-specific cDNA on chromosome 17q from a region adjacent to the breakpoint of t(12;17) observed in a patient with acampomelic campomelic dysplasia and sex reversal. Ninomiya S, et al. **Hum Mol Genet** 1996 Jan; 5(1):69–72

A second autosomal split hand/split foot locus maps to chromosome 10q24–q25. Nunes ME, et al. **Hum Mol Genet** 1995 Nov;4(11):2165–70

Tetralogy of Fallot with pulmonary atresia associated with chromosome 22q11 deletion. Momma K, et al. **J Am Coll Cardiol** 1996 Jan;27(1):198–202

Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. Ivy DD, et al. **J Am Soc Nephrol** 1995 Jun;5(12):2032–6

An insulin receptor mutant (Asp707 −−> Ala), involved in leprechaunism, is processed and transported to the cell surface but unable to bind insulin. Hart LM, et al. **J Biol Chem** 1996 Aug 2;271(31):18719–24

A hereditable combination of congenital anomalies. Agarwal RP, et al. **J Bone Joint Surg Br** 1996 May;78(3):492–4

Mesenchymal dysplasia: a recessive mutation on chromosome 13 of the mouse. Sweet HO, et al. **J Hered** 1996 Mar–Apr; 87(2):87–95

Small extra ring chromosome derived from chromosome 10p: clinical report and characterisation by FISH. Blennow E, et al. **J Med Genet** 1996 May;33(5):399–402 (30 ref.)

Molecular analysis of three patients with interstitial deletions of chromosome band 14q31. Byth BC, et al. **J Med Genet** 1995 Jul;32(7):564–7

Otofaciocervical syndrome: a sporadic patient supports splitting from the branchio-oto-renal syndrome. Dallapiccola B, et al. **J Med Genet** 1995 Oct;32(10):816–8

Identification of an unbalanced cryptic translocation t(9;17)(q34.3;p13.3) in a child with dysmorphic features. Estop AM, et al. **J Med Genet** 1995 Oct;32(10):819–22

Monozygotic twins with chromosome 22q11 deletion and discordant phenotype. Goodship J, et al. **J Med Genet** 1995 Sep;32(9):746–8

A new autosomal recessive syndrome of characteristic facies, joint contractures, skeletal abnormalities, and normal development: second report with further clinical delineation. Gupta A, et al. **J Med Genet** 1995 Oct; 32(10):809–12

Filippi syndrome: a new case with skeletal abnormalities. Héron D, et al. **J Med Genet** 1995 Aug;32(8):659–61 (6 ref.)

Absence/hypoplasia of tibia, polydactyly, retrocerebellar arachnoid cyst, and other anomalies: an autosomal recessive disorder. Holmes LB, et al. **J Med Genet** 1995 Nov; 32(11):896–900 (29 ref.)

Chromosome 1p terminal deletion: report of new findings and confirmation of two characteristic phenotypes. Keppler–Noreuil KM, et al. **J Med Genet** 1995 Aug; 32(8):619–22

A new deletion of 18q23 with few typical features of the 18q- syndrome. Kohonen-Corish M, et al. **J Med Genet** 1996 Mar;33(3):240–3

Velocardiofacial syndrome: learning difficulties and intervention. Kok LL, et al. **J Med Genet** 1995 Aug; 32(8):612–8

Pallister–Hall and McKusick–Kaufmann syndromes [letter; comment] Lurie IW. **J Med Genet** 1995 Aug;32(8):668. Comment on: J Med Genet 1995 Feb;32(2):125–8.

Idiopathic hypoparathyroidism in two patients with 22q11 microdeletion [letter; comment] Makita Y, et al. **J Med Genet** 1995 Aug;32(8):669. Comment on: J Med

Genet 1994 Nov;31(11):830–4.
Shwachman syndrome associated with de novo reciprocal translocation t(6;12)(q16.2;q21.2). Masuno M, et al. **J Med Genet** 1995 Nov;32(11):894–5
Holt–Oram syndrome: a clinical genetic study. Newbury–Ecob RA, et al. **J Med Genet** 1996 Apr; 33(4):300–7
Microcephaly, characteristic facies, joint abnormalities, and deficient leucocyte chemotaxis: a further case of the syndrome of Say et al. Perandones C, et al. **J Med Genet** 1996 Mar;33(3):227–9 (7 ref.)
Familial Wolf–Hirschhorn syndrome resulting from a cryptic translocation: a clinical and molecular study. Reid E, et al. **J Med Genet** 1996 Mar;33(3):197–202
A fetus with an X;1 balanced reciprocal translocation and eye disease. Seller MJ, et al. **J Med Genet** 1995 Jul; 32(7):557–60
The Aicardi–Goutières syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). Tolmie JL, et al. **J Med Genet** 1995 Nov;32(11):881–4 (26 ref.)
Renal–hepatic–pancreatic dysplasia: an autosomal recessive malformation. Torra R, et al. **J Med Genet** 1996 May; 33(5):409–12
Large inv dup(15) chromosome in two generations [letter] Van Der Smagt JJ, et al. **J Med Genet** 1996 Mar; 33(3):261–2
A familial Xp+ chromosome, dup (Xq26.3–>qter). Vasquez AI, et al. **J Med Genet** 1995 Nov;32(11):891–3
Pfeiffer type cardiocranial syndrome: a third case report. Williamson–Kruse L, et al. **J Med Genet** 1995 Nov; 32(11):901–3 (5 ref.)
Transient congenital hypoparathyroidism: resolution and recurrence in chromosome 22q11 deletion. Greig F, et al. **J Pediatr** 1996 Apr;128(4):563–7
Genetics casebook. Duplication–deletion syndromes. Day–Salvatore DL, et al. **J Perinatol** 1995 Jul–Aug; 15(4):333–7
Cloning and regional localization of the mouse faciogenital dysplasia (Fgd1) gene. Pasteris NG, et al. **Mamm Genome** 1995 Sep;6(9):658–61
Cloning and comparative mapping of a gene from the commonly deleted region of DiGeorge and Velocardiofacial syndromes conserved in C. elegans. Rizzu P, et al. **Mamm Genome** 1996 Sep;7(9):639–43
DNA fluorescent probes for diagnosis of velocardiofacial and related syndromes. Crifasi PA, et al. **Mayo Clin Proc** 1995 Dec;70(12):1148–53
A common region of 10p deleted in DiGeorge and velocardiofacial syndromes. Daw SC, et al. **Nat Genet** 1996 Aug;13(4):458–60
The locus for Meckel syndrome with multiple congenital anomalies maps to chromosome 17q21–q24. Paavola P, et al. **Nat Genet** 1995 Oct;11(2):213–5
Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis [see comments] Pandolfi PP, et al. **Nat Genet** 1995 Sep;11(1):40–4. Comment in: Nat Genet 1995 Sep;11(1):9–11.
Mutations in GPC3, a glypican gene, cause the Simpson–Golabi–Behmel overgrowth syndrome [see comments] Pilia G, et al. **Nat Genet** 1996 Mar;12(3):241–7 . Comment in: Nat Genet 1996 Mar;12(3):225–7.
Fibroblast growth factor receptor 2 mutations in Beare–Stevenson cutis gyrata syndrome. Przylepa KA, et al. **Nat Genet** 1996 Aug;13(4):492–4
Opitz syndrome is genetically heterogeneous, with one locus on Xp22, and a second locus on 22q11.2. Robin NH, et al. **Nat Genet** 1995 Dec;11(4):459–61
Mutation in fibrillin–1 and the Marfanoid–craniosynostosis (Shprintzen–Goldberg) syndrome. Sood S, et al. **Nat Genet** 1996 Feb;12(2):209–11
What's in a face? [see comments] Winter RM. **Nat Genet** 1996 Feb;12(2):124–9 (40 ref.). Comment in: Nat Genet 1996 Feb;12(2):130–6.
Ophthalmic manifestations of Smith–Magenis syndrome. Chen RM, et al. **Ophthalmology** 1996 Jul;103(7):1084–91 (29 ref.)
Partial deletion of chromosome 6p: autopsy findings in a premature infant and review of the literature. Alashari M, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):941–7 (20 ref.)
Postnatally confirmed trisomy 16 mosaicism: follow–up on a previously reported patient [letter; comment] Hajianpour MJ. **Prenat Diagn** 1995 Sep;15(9):877–9. Comment on: Prenat Diagn 1994 Oct;14(10):933–40.
Prenatal detection of de novo inversion of chromosome (2)(p13q11.2) and postnatal follow–up. Kozma C, et al. **Prenat Diagn** 1996 Apr;16(4):366–70
Identification of chromosome 21 materials using the whole chromosome 21 specific library. Isa MN, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:92–5
[Ring chromosome 9] Kontiokari T, et al. **Duodecim** 1995; 111(5):439–41 **(Fin)**
[Genetics of hereditary cardiopathies] Debrus S, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):619–27 (56 ref.) (Eng. Abstr.) **(Fre)**
[Molecular basis of cystic fibrosis and congenital bilateral agenesis of vas deferens] Bienvenu T, et al. **Contracept Fertil Sex** 1996 Jun;24(6):495–500 (31 ref.) (Eng. Abstr.) **(Fre)**
[Schimmelpenning–Feuerstein–Mims syndrome and its neurologic manifestations. 6 personal cases and review of the literature] Fritzsch C, et al. **Klin Padiatr** 1995 Sep–Oct; 207(5):288–97 (40 ref.) (Eng. Abstr.) (Ger)
[X–chromosomal recessive hydrocephalus internus: a separate disease picture? 2 further case reports and review of the literature] Haverkamp F, et al. **Klin Padiatr** 1996 May–Jun;208(3):93–6 (Eng. Abstr.) (Ger)
[Meckel–Gruber syndrome] Flessa A, et al. **Z Geburtshilfe Neonatol** 1996 Mar–Apr;200(2):66–8 (Eng. Abstr.) (Ger)
[Joubert syndrome] Scheuer E, et al. **Harefuah** 1995 Dec 15;129(12):543–6, 615 (Eng. Abstr.) (Heb)
[A case of type II achondrogenesis] Micheli E, et al. **Pediatr Med Chir** 1996 Jan–Feb;18(1):105–7 (Eng. Abstr.) (Ita)
[Syndrome of congenital malformations and dysmorphic features in a newborn with partial trisomy 16q due to maternal translocation t(9;16)(p24;q13)] Luberda–Zapaśnik J, et al. **Pediatr Pol** 1995 Sep;70(9):769–73 (Eng. Abstr.) (Pol)

IMMUNOLOGY

Dysregulation of temperature and liver cytokine gene expression in immunodeficient wasted mice. Libertin CR, et al. **Cell Immunol** 1996 Apr 10;169(1):62–6

METABOLISM

Sclerosis of the skin in the GEMSS syndrome. An overproduction of normal collagen. Kunz M, et al. **Arch Dermatol** 1995 Oct;131(10):1170–4
An insulin receptor mutant (Asp707 –> Ala), involved in leprechaunism, is processed and transported to the cell surface but unable to bind insulin. Hart LM, et al. **J Biol Chem** 1996 Aug 2;271(31):18719–24
Laminin beta 2 chain and adhalin deficiency in the skeletal muscle of Walker–Warburg syndrome (cerebro–ocular dysplasia–muscular dystrophy). Wewer UM, et al. **Neurology** 1995 Nov;45(11):2099–101
Generalized lysosomal storage in Yunis Varón syndrome. Dworzak F, et al. **Neuromuscul Disord** 1995 Sep;5(5):423–8

MORTALITY

[Congenital defects as a cause of infant mortality in Zielona Góra province in 1987–1992] Krawczyński M, et al. **Pediatr Pol** 1995 Sep;70(9):753–7 (Eng. Abstr.) (Pol)

NURSING

Case study of the home health management of a child with congenital anomalies associated with prenatal cocaine abuse. Johnson MO, et al. **J Pediatr Nurs** 1995 Dec; 10(6):375–82

PATHOLOGY

Analysis of visceral heterotaxy according to splenic status, appendage morphology, or both. Uemura H, et al. **Am J Cardiol** 1995 Oct 15;76(11):846–9
Distinct skeletal abnormalities in four girls with Shprintzen–Goldberg syndrome. Adès LC, et al. **Am J Med Genet** 1995 Jul 17;57(4):565–72 (13 ref.)
Further delineation of brain anomalies in velo–cardio–facial syndrome [letter; comment] Altman DH, et al. **Am J Med Genet** 1995 Apr 24;60(2):174–5. Comment on: Am J Med Genet 1994 Jun 15;54(2):100–6.
Myhre–GOMBO syndrome: possible lumping of two "old" new syndromes [letter] Bottani A, et al. **Am J Med Genet** 1995 Dec 4;59(4):523–4
Penoscrotal transposition and associated anomalies: report of five new cases and review of the literature. Parida SK, et al. **Am J Med Genet** 1995 Oct 23;59(1):68–75 (35 ref.)
Autosomal–recessive microcephaly in two siblings, one with normal IQ and both with protruding mandible, small ears, and curved nose. Rizzo R, et al. **Am J Med Genet** 1995 Dec 4;59(4):421–5
Patient with craniosynostosis and marfanoid phenotype (Shprintzen–Goldberg syndrome) and cloverleaf skull. Saal HM, et al. **Am J Med Genet** 1995 Jul 17;57(4):573–8 (16 ref.)
Coloboma of the optic disk associated with retinal vascular abnormalities. Theodossiadis GP, et al. **Am J Ophthalmol** 1995 Dec;120(6):798–800
Picture of the month. Roberts–SC phocomelia syndrome. Lopez–Allen G, et al. **Arch Pediatr Adolesc Med** 1996 Jun; 150(6):645–6
Aicardi syndrome with multiple tumors: a case report with literature review. Trifiletti RR, et al. **Brain Dev** 1995 Jul–Aug;17(4):283–5
Craniosynostosis with joint contractures, ear deformity, cleft palate, scoliosis, and other features. Iida A, et al. **Cleft Palate Craniofac J** 1995 Nov;32(6):489–93
Marden–Walker syndrome in an adult. Kotzot D, et al. **Clin Dysmorphol** 1995 Jul;4(3):260–5
Ectrodactyly, diaphragmatic hernia, congenital heart defect, and agenesis of the corpus callosum. Saal HM, et al. **Clin Dysmorphol** 1995 Jul;4(3):246–50
A case of lateral facial cleft, cleft lip and palate, anophthalmia, microtia, clavicular agenesis and asternia. Samson G, et al. **Clin Dysmorphol** 1995 Jul;4(3):251–4
Duplication of appendix with segmental dilatation of the colon, myeloschisis and anal atresia. Rizalar R, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):112–3
Vascular malformations associated with other congenital anomalies of the central nervous system: coexistence and possible causal relations. Kuchna I, et al. **Folia Neuropathol** 1995;33(4):255–9
Morphometric analysis of smooth muscle in the exstrophy–epispadias complex. Lais A, et al. **J Urol** 1996 Aug;156(2 Pt 2):819–21
Otocephalus: histopathology and three–dimensional reconstruction. Hinojosa R, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):44–53
Diffuse pulmonary arteriovenous malformation in a child with polysplenia syndrome. Kapur S, et al. **Pediatr Pathol Lab Med** 1995 May–Jun;15(3):463–8
Polysplenia syndrome with common atrioventricular canal and persistent truncus arteriosus. Arai H, et al. **Tohoku J Exp Med** 1995 Oct;177(2):171–7
[Combined neoplasms in the Mayer–Rokŀitansky–Küster syndrome] Savov I, et al. **Akush Ginekol (Sofiia)** 1995; 34(2):60–2 (Eng. Abstr.) **(Bul)**
[Pulmonary malformations associated with congenital cardiopathy] De Rosa N, et al. **Pathologica** 1995 Feb; 87(1):14–9 (Eng. Abstr.) **(Ita)**
[Cerebro–oculofacial dysplasia associated with vertebral changes] Munteanu G, et al. **Oftalmologia** 1995 Oct–Dec; 39(4):316–21 (10 ref.) (Eng. Abstr.) **(Rum)**
[The Hay–Wells syndrome, its incidence in Spain and a review of the literature] Martínez–Frías ML, et al. **An Esp Pediatr** 1996 Jul;45(1):101–4 (24 ref.) **(Spa)**

PHYSIOPATHOLOGY

Apparent Malpuech syndrome: report on three Brazilian patients with additional signs. Guion–Almeida ML. **Am J Med Genet** 1995 Jul 31;58(1):13–7
The spectrum of free neuraminic acid storage disease in childhood: clinical, morphological and biochemical observations in three non–Finnish patients. Sewell AC, et al. **Am J Med Genet** 1996 May 3;63(1):203–8
Haspeslagh syndrome without severe mental retardation and pterygia? van Bever Y, et al. **Clin Genet** 1995 May; 47(5):263–6
Otolaryngologic manifestations of multiple pterygium syndrome. MacArthur CJ, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):135–40
Cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS): a new syndrome. Nicolaides P, et al. **J Med Genet** 1996 May;33(5):419–21

PREVENTION & CONTROL

A sensitive enzyme immunoassay for pregnancy–associated plasma protein A (PAPP–A): a possible first trimester method of screening for Down syndrome and other trisomies. Bersinger NA, et al. **Arch Gynecol Obstet** 1995; 256(4):185–92
Impact of antenatal diagnosis on incidence and prognosis in abdominal wall defects. Fisher R, et al. **J Pediatr Surg** 1996 Apr;31(4):538–41

RADIOGRAPHY

Metaphyseal peg in geroderma osteodysplasticum: a new genetic bone marker and a specific finding? Eich GF, et al. **Am J Med Genet** 1996 May 3;63(1):62–7
Wildervanck syndrome. Kumar A, et al. **Australas Radiol** 1996 May;40(2):160–1
Case report: neonatal platyspondylic dwarfism—a new form. Kozlowski K, et al. **Br J Radiol** 1995 Nov;68(815):1254–6
Radiological changes of frontometaphyseal dysplasia in the neonate. Nishimura G, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S143–6
Mental retardation – megaepiphyses – ulnar pseudoepiphyses – hypoplastic fibulae – brachymesophalangia: a new syndrome. Nishimura G, et al. **Pediatr Radiol** 1996; 26(8):556–8
[Multiple malformation syndrome: situs inversus, multiple spleen and congenital anomaly of the inferior vena cava] Conord S, et al. **J Radiol** 1996 Feb;77(2):145–7 **(Fre)**
[Combination of rare anomalies of the cervical spine and peripheral skeleton] Loreck D, et al. **Aktuelle Radiol** 1995 Jul;5(4):235–7 (Eng. Abstr.) **(Ger)**
[Polysplenia syndrome in adults. Report of an atypical case] Catalano O, et al. **Radiol Med (Torino)** 1995 Dec; 90(6):837–9 (20 ref.) **(Ita)**

REHABILITATION

Helping to solve problems associated with spina bifida: 1. Presentation of the TRS Project: organizing services for low frequency diagnostic groups and 2. Cognitive deficits often seen in young adults with spina bifida: effects in the school and work place. West M, et al. **Eur J Pediatr Surg** 1995 Dec;5 Suppl 1:12–5

SURGERY

Massive intrahepatic shunting seen as severe cyanosis after the Fontan procedure in heterotaxy syndrome. Erickson LC, et al. **Am Heart J** 1996 Mar;131(3):608–11
Anaesthesia and Robinow syndrome [letter] Macdonald I, et al. **Anaesthesia** 1995 Dec;50(12):1097
Anaesthesia in a child with Patau's syndrome. Martlew RA, et al. **Anaesthesia** 1995 Nov;50(11):980–2
Avoiding hypoxemia during unifocalization. Mignosa C, et

al. **Ann Thorac Surg** 1996 Feb;61(2):715–7

Complete repair of PA–VSD with diminutive or discontinuous pulmonary arteries by transverse thoracosternotomy. Moritz A, et al. **Ann Thorac Surg** 1996 Feb;61(2):646–50

Hernia uteri (correction of: uterus) inguinale associated with unilateral renal agenesis. Keating JP, et al. **Aust N Z J Surg** 1995 Sep;65(9):688–90 (10 ref.)

Hanhart's syndrome with facial asymmetry: case report. Rončević R, et al. **Br J Plast Surg** 1995 Oct;48(7):511–4

Duplication of multiple systems and organs. Chen WY, et al. **Br J Urol** 1995 Nov;76(5):663–4

Hemihypertrophy with a liver cyst: a case report. Kyi A, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):363–4

Unilateral duplication of the great toe with anterolateral tibial bowing. Weaver KM, et al. **J Pediatr Orthop** 1996 Jan–Feb; 16(1):73–7

Esophageal duplication cyst associated with pulmonary cystic malformations. Kitano Y, et al. **J Pediatr Surg** 1995 Dec;30(12):1724–7

Congenital megalourethra. Wakhlu AK, et al. **J Pediatr Surg** 1996 Mar;31(3):441–3

Rehabilitation of a child with partial unilateral cryptophthalmos and multiple congenital anomalies. Konrad H, et al. **Trans Am Ophthalmol Soc** 1995;93:219–40; discussion 241–4 (121 ref.)

[Biliary reoperation with the correction of portal hypertension in a female patient with a congenital anomaly] Damianov D, et al. **Khirurgiia (Sofiia)** 1995;48(4):52–4 **(Bul)**

[Correction of the secondary nasal deformity in bilateral cleft lip with a new technique] Zhang L, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Sep;11(5):361–4 (Eng. Abstr.) **(Chi)**

[Surgical treatment of penoscrotal transposition associated hypospadias] Kang C, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):298–300 (Eng. Abstr.) **(Chi)**

[Congenital pyeloureteral junction syndrome in adults treated with laparoscopic surgery] Danjou P, et al. **Prog Urol** 1995 Dec;5(6):946–50 (Eng. Abstr.) **(Fre)**

[A case of pentalogy of Cantrell with tetralogy of Fallot and left ventricular diverticulum] Fukazawa M, et al. **Kyobu Geka** 1995 Aug;48(9):759–62 (Eng. Abstr.) **(Jpn)**

[Surgical management of vascular ring in 5 cases] Sakurai M, et al. **Kyobu Geka** 1995 Sep;48(10):841–4 (Eng. Abstr.) **(Jpn)**

[Genu recurvatum—etiopathogenesis and treatment] Marczyński W, et al. **Chir Narzadow Ruchu Ortop Pol** 1992; 57(4–6):354–8 (Eng. Abstr.) **(Pol)**

[A rare developmental defect of the urogenital system in girls] Moroka TF, et al. **Vestn Khir Im I I Grek** 1992 Mar; 148(3):319–20 **(Rus)**

THERAPY

Tetralogy of Fallot with diminutive pulmonary arteries: preoperative pulmonary valve dilation and transcatheter rehabilitation of pulmonary arteries. Kreutzer J, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1741–7

ULTRASONOGRAPHY

Prenatal diagnosis of omphalocele associated with umbilical cord cyst. Chen CP, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):832–5

Acardius (acardius acephalus). Jønler M, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):412–4

Ultrasonic evaluation of microphthalmos and coloboma. A discussion of 3 cases, with emphasis on microphthalmos with orbital cyst. Fledelius HC. **Acta Ophthalmol Scand Suppl** 1996;(219):23–6

Geleophysic dysplasia: a report of three affected boys—prenatal ultrasound does not detect recurrence. Rosser EM, et al. **Am J Med Genet** 1995 Sep 11; 58(3):217–21

Bilateral brachial amelia, facial clefts, encephalocele, orbital cyst and omphalocele: a recurrent fetal malformation pattern coming into focus. Froster UG, et al. **Clin Dysmorphol** 1996 Apr;5(2):171–4

Sonographic diagnosis of epignathus (oral teratoma), prosencephaly, meromelia and oligohydramnios in a fetus with trisomy 13. Yapar EG, et al. **Clin Dysmorphol** 1995 Jul;4(3):266–71

Meckel–Gruber syndrome associated with Rokitansky–Kuster–Hauser syndrome. Agapitos E, et al. **J Clin Ultrasound** 1995 Sep;23(7):452–5

Prenatal sonographic findings of agenesis of the right and left portal veins and associated intrahepatic portosystemic shunts. Gonçalves LF, et al. **J Ultrasound Med** 1995 Nov; 14(11):849–52

Horseshoe adrenal in Ivemark (asplenia) syndrome. Horgan JG, et al. **J Ultrasound Med** 1995 Oct;14(10):785–6

Early prenatal diagnosis of Larsen's syndrome by transvaginal sonography. Lewit N, et al. **J Ultrasound Med** 1995 Aug;14(8):627–9

Separate origins of the left internal and external carotid arteries directly from the aortic arch: duplex sonographic findings. Woodruff WW 3rd, et al. **J Ultrasound Med** 1995 Nov;14(11):867–9

Omphalocele and pericardial effusion: possible sonographic markers for the pentalogy of Cantrell or its variants. Siles C, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):840–2

Megacystis–microcolon–intestinal–hypoperistalsis syndrome [letter] James C, et al. **Pediatr Nephrol** 1995 Dec;9(6):788–9

The Ivemark syndrome: prenatal diagnosis of an uncommon cystic renal lesion with heterogeneous associations. Larson RS, et al. **Pediatr Nephrol** 1995 Oct;9(5):594–8 (16 ref.)

Abdominal sonography in the evaluation of heterotaxy in children. Oleszczuk–Raschke K, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S150–6

Langer mesomelic dwarfism: ultrasonographic diagnosis of two cases in early mid–trimester. Roth P, et al. **Prenat Diagn** 1996 Mar;16(3):247–51

First–trimester sonographic detection of neurodevelopmental abnormalities in some single–gene disorders. van Zalen–Sprock RM, et al. **Prenat Diagn** 1996 Mar; 16(3):199–202

Prenatal ultrasound diagnosis of Roberts syndrome in a family with negative history. Paladini D, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):208–10

[In utero diagnosis of situs abnormalities. A case of prenatal diagnosis of visceral situs inversus with corrected transposition of great vessels] Abossolo T, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):267–73 (Eng. Abstr.) **(Fre)**

[Value of ultrasonography in utero–vaginal aplasia] Paniel BJ, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):128–30 (Eng. Abstr.) **(Fre)**

[Potential 3–dimensional (3D–)ultrasound in the diagnosis of fetal abnormalities] Steiner H. **Gynakologe** 1995 Oct; 28(5):315–20 (31 ref.) **(Ger)**

[Diagnostic–therapeutic concept in abnormalities of the abdominal wall and diaphragm] Terinde R, et al. **Gynakologe** 1995 Oct;28(5):368–83 (84 ref.) **(Ger)**

[Prenatal diagnosis of left cardiac abnormality] Hajdú J, et al. **Orv Hetil** 1995 Oct 22;136(43):2333–7 (22 ref.) (Eng. Abstr.) **(Hun)**

[Intrauterine ultrasonic diagnosis of ectopia cordis associated with exencephaly] Vajda G, et al. **Orv Hetil** 1996 Jan 28; 137(4):187–8 (Eng. Abstr.) **(Hun)**

VIROLOGY

Congenital anomalies following maternal varicella infection during early pregnancy. Huang YC, et al. **J Formos Med Assoc** 1996 May;95(5):393–5

Chickenpox in pregnancy: how dangerous? Venkatesan P. **Practitioner** 1996 Apr;240(1561):256–9 (5 ref.)

ABNORMALITIES, RADIATION–INDUCED

EMBRYOLOGY

Embryonic death, dwarfism and fetal malformations after irradiation of embryos at the zygote stage: studies on two mouse strains. Jacquet P, et al. **Mutat Res** 1995 Nov; 332(1–2):73–87

EPIDEMIOLOGY

What can we infer from findings in subgroups? [editorial; comment] Hatch M. **Epidemiology** 1995 Sep;6(5):473–5 (4 ref.). Comment on: Epidemiology 1995 Sep;6(5):485–9.

Electric blanket use during pregnancy in relation to the risk of congenital urinary tract anomalies among women with a history of subfertility [see comments] Li DK, et al. **Epidemiology** 1995 Sep;6(5):485–9. Comment in: Epidemiology 1995 Sep;6(5):473–5.

[Study of the relation between dose of ionizing radiation and level of chromosome abnormalities in an adult patient following total body irradiation] Baltus I, et al. **C R Seances Soc Biol Fil** 1995;189(2):289–93 (Eng. Abstr.) **(Fre)**

[The genetic consequences of the Chernobyl accident. The monitoring of congenital developmental defects in newborn infants in Kaluga Province] Guzeev GG, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):640–6 (Eng. Abstr.) **(Rus)**

ETIOLOGY

[Tumor therapy and family planning] Theile U, et al. **Med Klin** 1996 Jun 15;91(6):402–9 (43 ref.) **(Ger)**

PATHOLOGY

Exposure of domestic quail embryos to extremely low frequency magnetic fields. Terol FF, et al. **Int J Radiat Biol** 1995 Sep;68(3):321–30

PREVENTION & CONTROL

Fetal dose estimates and the ICRP abdominal dose limit for occupational exposure of pregnant staff to technetium–99m and iodine–131 patients. Mountford PJ, et al. **Eur J Nucl Med** 1995 Oct;22(10):1173–9

Accidental embryo irradiation during barium enema examinations. An estimation of absorbed dose. Damilakis J, et al. **Invest Radiol** 1996 Apr;31(4):242–5

[Risk of radiologic examinations during pregnancy] Ramos HV. **Acta Med Port** 1996 Jan;9(1):49–53 (Eng. Abstr.) **(Por)**

ABO BLOOD–GROUP SYSTEM

Emergency! Hemolytic transfusion reaction. Huston CJ. **Am J Nurs** 1996 Mar;96(3):47

Characterization of recombinant alpha–galactosidase for use in seroconversion from blood group B to O of human erythrocytes. Zhu A, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):324–9

Affinity of Bandeiraea (Griffonia) simplicifolia lectin–I, isolectin B4 for Gal alpha 1—>4 Gal ligand. Wu AM, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):814–20

The influence of age, gender and ABO blood group on soluble endothelial cell markers and adhesion molecules. Blann AD, et al. **Br J Haematol** 1996 Feb;92(2):498–500

Expression of a recombinant human glycosyltransferase from a synthetic gene and its utilization for synthesis of the human blood group B trisaccharide. Seto NO, et al. **Eur J Biochem** 1995 Nov 15;234(1):323–8

ABO blood group distribution in Kala–Azar in Bihar, India. Lal S, et al. **J Assoc Physicians India** 1995 Apr;43(4):300

Development and evaluation of capture immunoglobulin G and M hemadherence assays by using human type O erythrocytes and recombinant parvovirus B19 antigen. Wang QY, et al. **J Clin Microbiol** 1995 Sep;33(9):2466–7

Oral Candida carriage and blood group antigen secretor status. Ben–Aryeh H, et al. **Mycoses** 1995 Sep–Oct; 38(9–10):355–8

Exchange transfusion the hard way: massive hemolysis following transplantation of bone marrow with minor ABO incompatibility. Greeno EW, et al. **Transfusion** 1996 Jan; 36(1):71–4

Multiple–unit and second transfusions of red cells enzymatically converted from group B to group O: report on the end of phase 1 trials. Lenny LL, et al. **Transfusion** 1995 Nov–Dec;35(11):899–902

Patterns of use of group O, Rh–negative red cells in a large metropolitan area and an action plan to control utilization. Newman BH, et al. **Transfusion** 1996 Mar;36(3):209–12

How much fresh, low–titer, O–negative blood is available? [editorial; comment] Polesky HF. **Transfusion** 1996 May; 36(5):392–3. Comment on: Transfusion 1996 May;36(5):432–7.

A Bombay individual lacking H and Le antigens but expressing normal levels of alpha–2– and alpha–4–fucosyltransferases. Shechter Y, et al. **Transfusion** 1995 Sep;35(9):773–6

ABO mismatched living related donor liver transplantation. Hashimoto T, et al. **Transplant Proc** 1996 Jun;28(3):1217–9

Stratification and successful transplantation of patients awaiting ABO–incompatible (A2 into B and O) transplantation by A–isoagglutinin–titer phenogroup. Nelson PW, et al. **Transplant Proc** 1996 Feb;28(1):221–3

A 16–year experience with 1275 primary living donor kidney transplants: univariate and multivariate analysis of risk factors affecting graft survival. Park K, et al. **Transplant Proc** 1996 Jun;28(3):1578–9

Clinicopathological analysis of rejection episodes in ABO–incompatible kidney transplantation. Tanabe K, et al. **Transplant Proc** 1996 Jun;28(3):1447–8

A reassessment of ABO incompatibility in pediatric liver transplantation. Cacciarelli TV, et al. **Transplantation** 1995 Oct 15;60(7):757–60

[Treatment with bolus methylprednisolone for pure red cell aplasia after ABO incompatible bone marrow transplantation in a patient with chronic myelocytic leukemia] Furuya H, et al. **Rinsho Ketsueki** 1995 Nov; 36(11):1279–83 (Eng. Abstr.) **(Jpn)**

[Maternal blood group 0 as a risk factor of neonatal hyperbilirubinemia requiring treatment] Heier HE, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):34–6 (Eng. Abstr.) **(Nor)**

ANALYSIS

A monoclonal antibody to swine erythrocytes recognizes the B blood group on the major glycophorin. González A, et al. **Anim Genet** 1995 Oct;26(5):351–3

Angiotensin I–converting enzyme (ACE) polymorphism and ABO blood groups as factors codetermining plasma ACE activity. Cidl K, et al. **Exp Hematol** 1996 Jun;24(7):790–4

A new method for the determination of the ABO blood type of semen by immunoblotting using anti–ABH antibodies following immunoprecipitation. Sato I, et al. **J Immunol Methods** 1995 Dec 27;188(2):229–37

Measurement of ABH blood group substances in human saliva by immunoassay using artificial antigens as standard substances. Wang B, et al. **Nippon Hoigaku Zasshi** 1996 Apr;50(2):43–9

Simulated ABO and Rh blood typing. Anderson BV, et al. **Transfusion** 1995 Sep;35(9):754–5

[Blood group antigen expression in papillary carcinoma of the thyroid gland. An immunohistochemical and clinical study of expression of Lewis, ABO and related antigens] Larena A, et al. **Langenbecks Arch Chir** 1996;381(2):102–13 (Eng. Abstr.) **(Ger)**

BLOOD

ABO blood groups among malaria cases from district Mandla, Madhya Pradesh. Singh N, et al. **Indian J Malariol** 1995 Jun;32(2):59–63

Can blood group O red cells of donor origin acquire weak group A reactivity through serum A transferase of the recipient after bone marrow transplantation? Wichmann MG, et al. **Infusionsther Transfusionsmed** 1996 Feb;

23(1):29–31

[Comparative analysis of causes of error in determining blood groups of the ABO system with isohemagglutinating sera and monoclonal antibodies] Zavgorodnil GN, et al. **Gematol Transfuziol** 1995 Jul–Aug;40(4):42–4 **(Rus)**

[The use of proteases for enhancing the sensitivity of reactions to detect group isohemagglutinins in the forensic medical study of blood stains] Sakharov RS, et al. **Sud Med Ekspert** 1996 Jan–Mar;39(1):23–7 (Eng. Abstr.) **(Rus)**

[The frequency of ABO blood groups and the expression of group antigens and isohemagglutinins in Syrian Arabs] Sakharov RS, et al. **Sud Med Ekspert** 1996 Apr–Jun; 39(2):34–6 (Eng. Abstr.) **(Rus)**

[AB–cis phenotype with expression similar to AB–el] González Campos J, et al. **Sangre (Barc)** 1996 Feb; 41(1):55–8 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Conformational analysis of blood group A trisaccharide in solution and in the binding site of Dolichos biflorus lectin using transient and transferred nuclear Overhauser enhancement (NOE) and rotating–frame NOE experiments. Casset F, et al. **Eur J Biochem** 1996 Aug 1;239(3):710–9

Structural and immunochemical identification of Leb glycolipids in the plasma of a group O Le(a–b–) secretor. Henry SM, et al. **Glycoconj J** 1995 Jun;12(3):309–17

Recognition of the blood group H type 2 trisaccharide epitope by 28 monoclonal antibodies and three lectins. Mollicone R, et al. **Glycoconj J** 1996 Apr;13(2):263–71

Blood group phenotype determines lectin–mediated adhesion of Pseudomonas aeruginosa to human outer ear canal epithelium. Steuer MK, et al. **Int J Med Microbiol Virol Parasitol Infect Dis** 1995 Apr; 282(3):287–95

Sandwich capture enzyme immunoassay for water soluble blood group B substance in secretor saliva. Yukawa N, et al. **J Immunoassay** 1995 Aug;16(3):247–61

GENETICS

Molecular basis for secretor type alpha(1,2)–fucosyltransferase gene deficiency in a Japanese population: a fusion gene generated by unequal crossover responsible for the enzyme deficiency. Koda Y, et al. **Am J Hum Genet** 1996 Aug;59(2):343–50

Open–angle glaucoma and blood groups. The Barbados Eye Study. Leske MC, et al. **Arch Ophthalmol** 1996 Feb; 114(2):205–10

An Ael allele–specific nucleotide insertion at the blood group ABO locus and its detection using a sequence–specific polymerase chain reaction. Olsson ML, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):642–7

ABO glycosyltransferase genotyping by polymerase chain reaction using sequence–specific primers. Gassner C, et al. **Blood** 1996 Sep 1;88(5):1852–6

Decreased stability of the O allele mRNA transcript of the ABO gene [letter] O'Keefe DS, et al. **Blood** 1996 Apr 1; 87(7):3061–2

The blood group ABO gene transcript is down–regulated in human bladder tumors and growth–stimulated urothelial cell lines. Orntoft TF, et al. **Cancer Res** 1996 Mar 1; 56(5):1031–36

Heterogeneity in the distribution of ABO blood groups in Hungary. Tauszik T. **Gene Geogr** 1995 Aug;9(2):169–76

Interaction between ABO blood groups and ADA genetic polymorphism during intrauterine life. A comparative analysis of couples with habitual abortion and normal puerperae delivering a live–born infant. Lucarini N, et al. **Hum Genet** 1995 Nov;96(5):527–31

Extensive polymorphism of ABO blood group gene: three major lineages of the alleles for the common ABO phenotypes. Ogasawara K, et al. **Hum Genet** 1996 Jun; 97(6):777–83

Suballeles of the ABO blood group system in a Japanese population. Fukumori Y, et al. **Hum Hered** 1996 Mar–Apr; 46(2):85–91

DNA polymorphism at the ABO locus in the Chinese population of Hong Kong. Yip SP, et al. **Hum Hered** 1995 Sep–Oct;45(5):266–71

Bombay 'O' group blood (Oh phenotype) in two subjects in a family at Calcutta. Chakraborty S, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S26

Loss of ABH antigen expression in bladder cancer is not caused by loss of heterozygosity of the ABO locus. Meldgaard P, et al. **Int J Cancer** 1995 Nov 3;63(3):341–4

The absence of a B allele in acquired B blood group phenotype confirmed by a DNA based genotyping method. Yip SP, et al. **J Clin Pathol** 1996 Feb;49(2):180–1

Efficient and reliable PCR–based detection of the ABO blood group alleles: genotyping on stamps and other biological evidence samples. Liechti–Gallati S, et al. **J Forensic Sci** 1996 Jul;41(4):653–7

A complex alloantigen system in Florida sandhill cranes, Grus canadensis pratensis: evidence for the major histocompatibility (B) system. Jarvi SI, et al. **J Hered** 1995 Sep–Oct;86(5):348–53

Application of ABO genotyping using polymerase chain reaction method to assess engraftment in bone marrow transplantation—a case report. Chang CS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Oct; 11(10):574–7

Polymorphisms at the ABO locus in subgroup A individuals. Olsson ML, et al. **Transfusion** 1996 Apr;36(4):309–13

Relative frequencies of the two O alleles of the histo–blood ABH system in different racial groups. Franco RF, et al. **Vox Sang** 1995;69(1):50–2

A rapid and simple ABO genotype screening method using a novel B/O2 versus A/O2 discriminating nucleotide substitution at the ABO locus. Olsson ML, et al. **Vox Sang** 1995;69(3):242–7

Molecular genetics of the ABO histo–blood group system. Yamamoto F. **Vox Sang** 1995;69(1):1–7 (38 ref.)

[Distribution of ABO allele frequencies in the Cologne registration district (Nordrhein–Westfalen)] Scheil HG, et al. **Anthropol Anz** 1995 Sep;53(3):199–208 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Risk estimation of ABO and Rho(D) incompatibility in persons with mono– and polyphyletic surnames in Monterrey, Mexico. Comparison with other Mexican populations. Garza–Chapa R, et al. **Arch Med Res** 1996 Summer;27(2):243–51

Deantigenation of human type B erythrocytes with Glycine max alpha–D–galactosidase. Hobbs L, et al. **Biomed Pharmacother** 1995;49(5):244–50

Passenger B–lymphocyte–induced severe hemolytic disease after allogeneic peripheral blood stem cell transplantation [letter] Toren A, et al. **Blood** 1996 Jan 15;87(2):843–4

Erythrocyte repopulation after major ABO incompatible transplantation with lymphocyte–depleted bone marrow. Bär BM, et al. **Bone Marrow Transplant** 1995 Dec; 16(6):793–9

Normal levels of allo– but increased levels of potentially autoreactive antibodies against ABO histo–blood group antigens in AIDS patients. Friedli F, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):96–100

Antibody–mediated hemolytic anemia following ABO–mismatched organ transplantation: contributory role of HLA matching and polyclonal antilymphocyte globulin. Fabrega AJ, et al. **Clin Transplant** 1996 Apr;10(2):166–9

Study on the cell expression of human A, B and H blood–group antigens. Sarafyan V, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):27

Computer simulation of histo–blood group oligosaccharides: energy maps of all constituting disaccharides and potential energy surfaces of 14 ABH and Lewis carbohydrate antigens. Imberty A, et al. **Glycoconj J** 1995 Jun; 12(3):331–49

Prognostic value of an assessment of ABH(0) isoantigens and Thomsen–Friedenreich (TF) antigen expression in patients with urinary bladder tumours. Dobrowolski ZF, et al. **Int Urol Nephrol** 1995;27(4):395–404

Characterization of a monoclonal antibody specific for H type 2 structure of ABO blood group, and its use for measuring H type 2 on human red blood cells. Liu Y, et al. **J Clin Lab Anal** 1996;10(3):144–8

Conversion of red blood cells to group O [news] Fricker J. **Lancet** 1996 Mar 9;347(9002):680

Characterization of the 84–kDa protein with ABH activity in human seminal plasma. Sato I. **Nippon Hoigaku Zasshi** 1995 Oct;49(5):281–93

Blood group A antigen expression in platelets is prominently associated with glycoprotein Ib and IIb. Evidence for an A1/A2 difference. Hou M, et al. **Transfus Med** 1996 Mar; 6(1):51–9

Fatal hemolytic transfusion reaction resulting from ABO mistyping of a patient with acquired B antigen detectable only by some monoclonal anti–B reagents. Garratty G, et al. **Transfusion** 1996 Apr;36(4):351–7

Blood group A immunodeterminants on human red cells differ in biologic activity and sensitivity to alpha–N–acetylgalactosaminidase. Hoskins LC, et al. **Transfusion** 1995 Oct;35(10):813–21

Red cell compatibility testing in baboon xenotransplantation. Triulzi DJ, et al. **Transfusion** 1995 Sep;35(9):756–9

Converting alpha–Gal epitope of pig into H antigen. Koike C, et al. **Transplant Proc** 1996 Apr;28(2):553

Combined liver/small bowel transplantation using a blood group compatible but nonidentical donor. Sindhi R, et al. **Transplantation** 1996 Jun 27;61(12):1782–3

Spectrotype analysis of human ABO antibodies: evidence for different clonal heterogeneity of IgM, IgG, and IgA antibody populations. Rieben R, et al. **Vox Sang** 1996; 70(2):104–11

[Hemolysis during immunoglobulin therapy (letter)] Muñoz J, et al. **Sangre (Barc)** 1996 Feb;41(1):72–3 **(Spa)**

METABOLISM

Blood group glycolipids as epithelial cell receptors for Candida albicans. Cameron BJ, et al. **Infect Immun** 1996 Mar;64(3):891–6

Purification and partial characterization of a new anti–A1 lectin of Phaseolus coccineus collected in Oaxaca, Mexico. Feria M, et al. **Prep Biochem Biotechnol** 1996 Feb; 26(1):31–46

PHYSIOLOGY

Characterization of the specificities of human blood group H gene–specified alpha 1,2–L–fucosyltransferase toward sulfated/sialylated/fucosylated acceptors: evidence for an inverse relationship between alpha 1,2–L–fucosylation of Gal and alpha 1,6–L–fucosylation of asparagine–linked GlcNAc. Chandrasekaran EV, et al. **Biochemistry** 1996 Jul 9;35(27):8914–24

ABO FACTORS see **ABO BLOOD–GROUP SYSTEM**

ABOMASUM

Investigating the relationship between abomasal hairballs and perforating abomasal ulcers in unweaned beef calves. Jelinski MD, et al. **Can Vet J** 1996 Jan;37(1):23–6

Relationship between degree of dehydration and serum electrolytes and acid–base status in cows with various abomasal disorders. Taguchi K. **J Vet Med Sci** 1995 Apr; 57(2):257–60

In vitro survival of the BS isolate of Chlamydia psittaci (ovis) in ruminal and abomasal contents. Amin JD, et al. **Res Vet Sci** 1995 Sep;59(2):136–8

Abomasal displacement in the bovine—a review on character, occurrence, aetiology and pathogenesis. Geishauser T. **Zentralbl Veterinarmed A** 1995 Jun; 42(4):229–51 (253 ref.)

[Right displacement of the abomasum in cattle. 1. Pathogenesis, clinical course and prognosis] Kümper H. **Tierarztl Prax** 1995 Aug;23(4):351–9 (30 ref.) (Eng. Abstr.) **(Ger)**

[Estimation of the heritability of abomasal displacement in German black–pied cattle in Hesse] Geishauser T, et al. **Zentralbl Veterinarmed A** 1996 Apr;43(2):87–92 (Eng. Abstr.) **(Ger)**

ABNORMALITIES

[Fat/protein ratio in the milk of cattle herds in which displacement of the abomasum occurs] Geishauser T, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec; 102(12):469–71 (Eng. Abstr.) **(Ger)**

[Indirect and direct determination of selenium levels in the blood of cows with left side displacement of the abomasum] Geishauser T, et al. **Tierarztl Prax** 1995 Oct;23(5):443–5 (Eng. Abstr.) **(Ger)**

[Right displacement of the abomasum in cattle. 2. New aspects of surgical treatment] Kümper H. **Tierarztl Prax** 1995 Oct;23(5):437–42 (Eng. Abstr.) **(Ger)**

ANATOMY & HISTOLOGY

The stomach of the sambar deer (Cervus unicolor unicolor). Stafford KJ. **Anat Histol Embryol** 1995 Dec;24(4):241–9

CHEMISTRY

[pH, sodium, potassium, magnesium, calcium, phosphate and chloride in the rumen and abomasal contents of cows with abomasal displacement] Geishauser T, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jan;103(1):16–20 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Effects of abomasal infusions of sodium caseinate and of casein hydrolysates varying in the relative proportions of peptides and free amino acids on milk production in dairy cows. Choung JJ, et al. **J Dairy Res** 1995 Aug;62(3):423–9

Responses of dairy cows during early lactation to ruminal or abomasal administration of L–carnitine. LaCount DW, et al. **J Dairy Sci** 1995 Aug;78(8):1824–36

Dose response of dairy cows to abomasal administration of four amounts of L–carnitine. LaCount DW, et al. **J Dairy Sci** 1996 Apr;79(4):591–602

EMBRYOLOGY

Maturational effects of cortisol on the exocrine abomasum and pancreas in fetal sheep. Sangild PT, et al. **Reprod Fertil Dev** 1995;7(3):655–8

METABOLISM

Influence of ruminal or abomasal starch hydrolysate infusion on pancreatic exocrine secretion and blood glucose and insulin concentrations in steers. Walker JA, et al. **J Anim Sci** 1995 Dec;73(12):3766–74

PARASITOLOGY

Persistent anthelmintic activity of ivermectin against gastrointestinal nematodes of cattle. Williams JC, et al. **Am J Vet Res** 1995 Sep;56(9):1169–75

The synlophe and other structural characteristics of Sarwaria bubalis (Nematoda: Trichostrongyloidea) from cattle in Guyana. Lichtenfels JR, et al. **J Parasitol** 1996 Feb; 82(1):146–54

Local and plasma antibody responses to the parasitic larval stages of the abomasal nematode Ostertagia circumcincta. Sinski E, et al. **Vet Parasitol** 1995 Sep;59(2):107–18

PATHOLOGY

[Ostertagiasis in bulls used for bullfights] Méndez A, et al. **Zentralbl Veterinarmed [B]** 1995 Nov;42(9):551–6 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Effect of abomasal infusion of saliva on reticular motility and ruminal liquid contents of steers. Froetschel MA.

ABOMASUM

J Dairy Sci 1995 Nov;78(11):2395–401

PHYSIOPATHOLOGY

Electromyography of the reticulum, abomasum and duodenum in dairy cows with left displacement of the abomasum. Nelson DR, et al. **Zentralbl Veterinarmed A** 1995 Jul;42(5):325–37

SURGERY

[Right displacement of the abomasum in cattle. 2. New aspects of surgical treatment] Kümper H. **Tierarztl Prax** 1995 Oct;23(5):437–42 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Sonography as a tool in the diagnosis of displacement of the abomasum] Winter T, et al. **Tierarztl Prax** 1996 Jun; 24(3):243–7 (Eng. Abstr.) **(Ger)**

ABORIGINES

see related

AUSTRALOID RACE

Alcoholism, hepatitis B and C viral infections, and impaired liver function among Taiwanese aboriginal groups. Shen CY, et al. **Am J Epidemiol** 1996 May 1;143(9):936–42

An investigation into the disparity between Australian aboriginal and Caucasian perinatal mortality rates. Coory M. **Ann Epidemiol** 1995 Sep;5(5):393–9

Hypokalaemic paralysis in remote aboriginal communities. Ghose R, et al. **Aust Fam Physician** 1996 Jul;25(7):1172–3

Death in the desert [letter; comment] Johnston F. **Aust Fam Physician** 1995 Nov;24(11):2143; discussion 2144 . Comment on: Aust Fam Physician 1995 Aug;24(8):1475–7.

Death in the desert [letter; comment] Wheeler G, et al. **Aust Fam Physician** 1995 Nov;24(11):2143; discussion 2144 . Comment on: Aust Fam Physician 1995 Aug;24(8):1475–7.

Cultural factors in dialysis and renal transplantation among aborigines and Torres Strait Islanders in north Queensland. Bennett E, et al. **Aust J Public Health** 1995 Dec;19(6):610–5

A community-based cervical screening program in a remote Aboriginal community in the Northern Territory. Gilles MT, et al. **Aust J Public Health** 1995 Oct;19(5):477–81

Evaluating government health and substance abuse programs for indigenous peoples: a comparative review. Gray D, et al. **Aust J Public Health** 1995 Dec;19(6):567–72 (62 ref.)

Diabetes in aborigines and Torres Strait Islanders: effects, causes and strategies. [editorial; comment] Guest C. **Aust J Public Health** 1995 Oct;19(5):442–4. Comment on: Aust J Public Health 1995 Oct;19(5):482–6.

Is there a role for prevention in aboriginal mental health? Hunter E. **Aust J Public Health** 1995 Dec;19(6):573–9 (50 ref.)

Health care policy for aboriginal Australians: the relevance of the American Indian experience. Kunitz SJ, et al. **Aust J Public Health** 1995 Dec;19(6):549–58

Which way kaikai blo umi? Food and nutrition in the Torres Strait. Leonard D, et al. **Aust J Public Health** 1995 Dec; 19(6):589–95

State differences in Aboriginal health [letter] Mathers C. **Aust J Public Health** 1995 Oct;19(5):529

Contact tracing and sexually transmitted disease among aboriginal men on the Anangu Pitjantjatjara lands. Mulvey G, et al. **Aust J Public Health** 1995 Dec;19(6):596–602

Malignant mesothelioma in Pilbara Aborigines. Musk AW, et al. **Aust J Public Health** 1995 Oct;19(5):520–2 (10 ref.)

High mortality from renal disease and infection in Aboriginal central Australians with diabetes [see comments] Phillips CB, et al. **Aust J Public Health** 1995 Oct;19(5):482–6. Comment in: Aust J Public Health 1995 Oct;19(5):442–4.

Aborigines and tuberculosis: why they are at risk. Plant AJ, et al. **Aust J Public Health** 1995 Oct;19(5):487–91

Research from an aboriginal health worker's point of view [see comments] McMasters A. **Aust N Z J Public Health** 1996 Jun;20(3):319–20. Comment in: Aust N Z J Public Health 1996 Jun;20(3):227–9.

Discoid erythematosus in Australian aborigines [letter; comment] Green A. **Australas J Dermatol** 1995 Aug; 36(3):175–7. Comment on: Australas J Dermatol 1995 Feb;36(1):3–10; quiz 11–2.

US awards patent for tribesman's DNA [news] Dyer O. **BMJ** 1995 Dec 2;311(7018):1452

An increased incidence of total anomalous pulmonary venous drainage among aboriginal Canadians. McCrindle BW, et al. **Can J Cardiol** 1996 Jan;12(1):81–5

Benefits and risks of traditional food for Indigenous Peoples: focus on dietary intakes of Arctic men. Kuhnlein HV. **Can J Physiol Pharmacol** 1995 Jun;73(6):765–71

Ethics for working with communities of Indigenous Peoples. Scott K, et al. **Can J Physiol Pharmacol** 1995 Jun; 73(6):751–3

Evaluating food use by Canadian aboriginal peoples. Wein EE. **Can J Physiol Pharmacol** 1995 Jun;73(6):759–64

New World syndrome in Western Australian aborigines. Gracey M. **Clin Exp Pharmacol Physiol** 1995 Mar; 22(3):220–5 (38 ref.)

Invasive pneumococcal disease in central Australia. Trotman J, et al. **Clin Infect Dis** 1995 Jun;20(6):1553–6

Risk factors for diabetes and cardiovascular disease in young Australian aborigines. A 5-year follow-up study. Braun B, et al. **Diabetes Care** 1996 May;19(5):472–9

Carriage of multiple ribotypes of non-encapsulated Haemophilus influenzae in aboriginal infants with otitis media. Smith-Vaughan HC, et al. **Epidemiol Infect** 1996 Apr;116(2):177–83

High mortality rates in Native Hawaiians. Braun KL, et al. **Hawaii Med J** 1995 Sep;54(9):723–9

And now for vertical equity? Some concerns arising from aboriginal health in Australia [editorial] Mooney G. **Health Econ** 1996 Mar–Apr;5(2):99–103

A survey of blood pressure distribution in Pygmy and Bantu populations in Cameroon. Kesteloot H, et al. **Hypertension** 1996 Jan;27(1):108–13

Enhanced cardiac metabolism of plasma glucose in high-altitude natives: adaptation against chronic hypoxia. Holden JE, et al. **J Appl Physiol** 1995 Jul;79(1):222–8

Insulin-like growth factor I resistance in immortalized T cell lines from African Efe Pygmies. Geffner ME, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3732–8

Epidemic of cholera among the aborigines of northern Argentina. Mazzafero VE, et al. **J Diarrhoeal Dis Res** 1995 Jun;13(2):95–8

Hospitalization of Aboriginal adults for digestive disorders in Western Australia, 1989–91. Gracey M, et al. **J Gastroenterol Hepatol** 1995 May–Jun;10(3):313–8

These sorts of people don't do very well': race and allocation of health care resources. Lowe M, et al. **J Med Ethics** 1995 Dec;21(6):356–60

Influence of families on the growth of children in an aboriginal community. Alsop-Shields L, et al. **J Paediatr Child Health** 1995 Oct;31(5):392–4

Immunity to hepatitis B, poliomyelitis and measles in fully vaccinated aboriginal and Torres Strait Island children. Hanna JN, et al. **J Paediatr Child Health** 1995 Aug; 31(4):345–9

Perinatal mortality trends among South Australian aboriginal births 1981–92. Roder D, et al. **J Paediatr Child Health** 1995 Oct;31(5):446–50

Bone mineral density in a native population of Argentina with low calcium intake. Spindler A, et al. **J Rheumatol** 1995 Nov;22(11):2148–51

An evaluation of unleaded petrol as a harm reduction strategy for petrol sniffers in an aboriginal community. Burns CB, et al. **J Toxicol Clin Toxicol** 1996;34(1):27–36

Early-onset group B streptococcal infections in Aboriginal and non-Aboriginal infants. Australasian Study Group for Neonatal Infections. **Med J Aust** 1995 Sep 18;163(6):302–6

Pregnancy outcomes in urban aboriginal women [see comments] de Costa C, et al. **Med J Aust** 1996 May 6; 164(9):523–6. Comment in: Med J Aust 1996 May 6;164(9):516–7.

Does rheumatoid arthritis exist in the indigenous Australian Aboriginal population? [letter] Douglas WA. **Med J Aust** 1996 Feb 5;164(3):191–2

Renal disease in Australian aboriginals [editorial] Hoy WE. **Med J Aust** 1996 Aug 5;165(3):126–7

Going bush—helping medical students learn from aboriginal people. Jamrozik K. **Med J Aust** 1995 Dec 4–18; 163(11–12):591–4

Malnutrition among rural Aboriginal children in the Top End of the Northern Territory [letter; comment] Muller SM, et al. **Med J Aust** 1995 Oct 16;163(8):445. Comment on: Med J Aust 1995 Apr 17;162(8):400–3.

Pregnancy outcomes of Australian aboriginals and Torres Strait Islanders [editorial; comment] O'Connor MC, et al. **Med J Aust** 1996 May 6;164(9):516–7. Comment on: Med J Aust 1996 May 6;164(9):523–6.

Does rheumatoid arthritis exist in the indigenous Australian aboriginal population? [letter] Roberts-Thomson PJ. **Med J Aust** 1995 Oct 16;163(8):444–5

High and low roads to aboriginal health [letter] Scrimgeour DJ, et al. **Med J Aust** 1995 Nov 20;163(10):557–8

Managing HIV. Part 6: People living with HIV. 6.6 HIV and isolated Aboriginal communities. Skov S, et al. **Med J Aust** 1996 Jul 1;165(1):41–2

Evacuation of an Aboriginal community in response to an outbreak of blistering dermatitis induced by a beetle (Paederus australis). Todd RE, et al. **Med J Aust** 1996 Feb 19;164(4):238–40

Asthma and atopy in four rural Australian aboriginal communities. Veale AJ, et al. **Med J Aust** 1996 Aug 19; 165(4):192–6

Te mahi niho hauora ki Ratana Pa: the dental health project at Ratana Pa [see comments] Broughton J. **N Z Dent J** 1995 Sep;91(405):94–6. Comment in: N Z Dent J 1995 Sep;91(405):83.

Oral health of Maori [editorial; comment] Brown RH. **N Z Dent J** 1995 Sep;91(405):83. Comment on: N Z Dent J 1995 Sep;91(405):94–6.

Glomerular disease in whites versus Australian aboriginals: 'last of a race in ruin' (G.K. Chesterton) [editorial] Seymour AE. **Nephrol Dial Transplant** 1995;10(6):769–70

Pathology review of sudden and unexpected death in aboriginal and non-aboriginal infants. Alessandri LM, et al. **Paediatr Perinat Epidemiol** 1995 Oct;9(4):406–19

Suicide rates in Canadian aboriginals and size of population. Lester D. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1282

A breast and cervical cancer project in a native Hawaiian community: Wai'anae cancer research project. Banner RO, et al. **Prev Med** 1995 Sep;24(5):447–53

Development of a new scale for measuring acculturation: the Taiwan Aboriginal Acculturation Scale (TAAS). Cheng AT, et al. **Psychol Med** 1995 Nov;25(6):1281–7

Culture in treatment, culture as treatment. A critical appraisal of developments in addictions programs for indigenous North Americans and Australians. Brady M. **Soc Sci Med** 1995 Dec;41(11):1487–98 (78 ref.)

Effects of culture on back pain in Australian aboriginals. Honeyman PT, et al. **Spine** 1996 Apr 1;21(7):841–3

Hepatitis virus markers in the Baiga tribal population of Madhya Pradesh, India. Reddy PH, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):620

Breastfeeding in Australia. Lund-Adams M, et al. **World Rev Nutr Diet** 1995;78:74–113 (100 ref.)

[Frequency of encountering markers of viral hepatitis A, B, and C in the aboriginal inhabitants of the northwest region of Siberia] Netesova IG, et al. **Vopr Virusol** 1995 Jul–Aug; 40(4):172–4 (Eng. Abstr.) **(Rus)**

EDUCATION

Aboriginal health workers: agents of change? [editorial; comment] Tsey K. **Aust N Z J Public Health** 1996 Jun; 20(3):227–9. Comment on: Aust N Z J Public Health 1996 Jun;20(3):319–20.

GENETICS

Multiple independent origins of the COII/tRNA(Lys) intergenic 9-bp mtDNA deletion in aboriginal Australians [letter] Betty DJ, et al. **Am J Hum Genet** 1996 Feb; 58(2):428–33

An ancient common origin of aboriginal Australians and New Guinea highlanders is supported by alpha-globin haplotype analysis. Roberts-Thomson JM, et al. **Am J Hum Genet** 1996 May;58(5):1017–24

Class I HLA antigens in two long-separated populations: Melanesians and South Amerinds. Bhatia KK, et al. **Am J Phys Anthropol** 1995 Jul;97(3):291–305

HLA-DQ beta 1 typing and non-Asp57 alleles in the aborigine population of Senegal. Chauffert M, et al. **Diabetes Care** 1995 May;18(5):677–80

Marfan syndrome in aboriginals [letter] Adès LC. **Med J Aust** 1996 Jan 1;164(1):54–5

[Genetic-demographic study of mountain populations from Dagestan and their migrants to the lowlands. Comparison of basic parameters of fitness] Bulaeva KB, et al. **Genetika** 1995 Sep;31(9):1300–7 (Eng. Abstr.) **(Rus)**

[Polymorphism of mitochondrial DNA region V in native and migrant inhabitants of Northeast Asia] Maliarchuk BA, et al. **Genetika** 1995 Sep;31(9):1308–13 (Eng. Abstr.) **(Rus)**

[Mitochondrial DNA variation in native inhabitants of Siberia with reconstructions of the evolutional history of the American Indians. Restriction polymorphism] Sukernik RI, et al. **Genetika** 1996 Mar;32(3):432–9 (Eng. Abstr.) **(Rus)**

HISTORY

Iodine nutrition in two Tasmanian cultures. Richards PA. **Med J Aust** 1995 Dec 4–18;163(11–12):628–30

[From Aboriginal psychological medicine to modern psychiatry in Peru] Ochoa-Torres C. **Ann Med Psychol (Paris)** 1995 Oct;153(8):562–5 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

"Freedom's just another word": aboriginal youth and mental health. Hunter E. **Aust N Z J Psychiatry** 1995 Sep; 29(3):374–84 (64 ref.)

Conflicting constructions of aboriginal suicide: a letter in response to Robert Parker [letter; comment] Hunter E. **Aust N Z J Psychiatry** 1995 Jun;29(2):335–7. Comment on: Aust N Z J Psychiatry 1994 Dec;28(4):696–7.

STATISTICS & NUMERICAL DATA

Systemic lupus erythematosus (SLE): different prevalences in different populations of Australian aborigines [letter] Anstey NM, et al. **Aust N Z J Med** 1995 Dec;25(6):736

Risk factors for ill-health in a remote desert-dwelling aboriginal community in Western Australia. Gracey M, et al. **Aust N Z J Med** 1996 Apr;26(2):171–9

Current status of nutritional deficiencies in Canadian aboriginal people. Moffatt ME. **Can J Physiol Pharmacol** 1995 Jun;73(6):754–8

ABORTIFACIENT AGENTS

see related

OXYTOCICS

Abortion in heifers inoculated with a thymidine kinase-negative recombinant of bovine herpesvirus 1. Miller JM, et al. **Am J Vet Res** 1995 Jul;56(7):870–4

Drug combination adds fuel to US abortion debate [news] Rutter TL. **BMJ** 1995 Sep 16;311(7007):705

Medical pregnancy termination in the presence of a massive uterine fibroid. Fenwick DK, et al. **Br J Clin Pract** 1995 Nov-Dec;49(6):332–3

The combined use of prostaglandin and antiprogestin in human fertility control. Baulieu EE. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):115–9 (42 ref.)

Acceptability of medical abortion in early pregnancy. Winikoff B. **Fam Plann Perspect** 1995 Jul–Aug;27(4):142–8, 185 (36 ref.)

Clinical, hormonal and sonographic predictors of successful

RU-486-induced abortions. Menashe Y, et al. **Gynecol Obstet Invest** 1995;40(2):108-12

Methotrexate and misoprostol to terminate early pregnancy [letter] Perrone J, et al. **N Engl J Med** 1996 Feb 8; 334(6):399; discussion 400

[Is abortion murder? (editorial)] Werning C. **Med Monatsschr Pharm** 1995 Sep;18(9):251 **(Ger)**

[Methotrexate as a blastocyst anti-implantation drug (letter)] Márquez Monter H. **Gac Med Mex** 1995 May-Jun; 131(3):373-4 **(Spa)**

ADMINISTRATION & DOSAGE

A prospective randomized evaluation of a hygroscopic cervical dilator, Dilapan, in the preinduction ripening of patients undergoing induction of labor. Gilson GJ, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):145-9

Issues raised by medical abortion [letter; comment] Guilbert E, et al. **Can Med Assoc J** 1996 Jul 1;155(1):19. Comment on: Can Med Assoc J 1996 Jan 15;154(2):165-70.

[Methotrexate and misoprostol for drug-induced abortion in the first trimester] Wolff F. **Dtsch Med Wochenschr** 1995 Dec 22;120(51-52):1804 **(Ger)**

ADVERSE EFFECTS

Issues raised by medical abortion [letter; comment] Reynolds JL. **Can Med Assoc J** 1996 Jul 1;155(1):19-20. Comment on: Can Med Assoc J 1996 Jan 15;154(2):165-70.

PHARMACOLOGY

Termination of early pregnancy (up to and after 63 days of amenorrhea) with mifepristone (RU 486) and increasing doses of misoprostol. Aubény E, et al. **Int J Fertil Menopausal Stud** 1995;40 Suppl 2:85-91

Abortifacient response and plasma vasoconstrictive activity after feeding needles from ponderosa pine trees to cattle and sheep. Short RE, et al. **J Anim Sci** 1995 Jul; 73(7):2102-4

Pregnancy terminating effect of Jatropha curcas in rats. Goonasekera MM, et al. **J Ethnopharmacol** 1995 Jul 28; 47(3):117-23

Methotrexate and misoprostol for abortion. **Med Lett Drugs Ther** 1996 Apr 26;38(973):39-40

THERAPEUTIC USE

Same-day Dilapan insertion before second-trimester dilatation and evacuation for a fetal anomaly or death. Patsner B. **J Reprod Med** 1996 Feb;41(2):71-2

Methotrexate and misoprostol to terminate early pregnancy [letter] Grunberg SM. **N Engl J Med** 1996 Feb 8; 334(6):399-400

ABORTIFACIENT AGENTS, NON-STEROIDAL

A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Jain JK, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):173-7

Termination of pregnancy in rodents by oral administration of praneem, a purified neem seed extract. Mukherjee S, et al. **Am J Reprod Immunol** 1996 Jan;35(1):51-6

Blood loss in termination of early pregnancy with mifepristone and gemeprost. Prasad RN, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):329-31

Medical pregnancy termination in the presence of a massive uterine fibroid. Fenwick DK, et al. **Br J Clin Pract** 1995 Nov-Dec;49(6):332-3

Misoprostol in the management of spontaneous abortion. Chung TK, et al. **Br J Obstet Gynaecol** 1995 Oct; 102(10):832-5

Medical abortion: what does the research tell us? [editorial; comment] [see comments] Ferris LE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):185-7. Comment on: Can Med Assoc J 1996 Jan 15;154(2):165-70. Comment in: Can Med Assoc J 1996 Jul 1;155(1):18-9.

Abortion induced with methotrexate and misoprostol [see comments] Wiebe ER. **Can Med Assoc J** 1996 Jan 15; 154(2):165-70. Comment in: Can Med Assoc J 1996 Jan 15;154(2):185-7. Comment in: Can Med Assoc J 1996 Jul 1;155(1):19. Comment in: Can Med Assoc J 1996 Jul 1;155(1):19-20.

Acceptability of medical abortion with methotrexate and misoprostol. Creinin MD, et al. **Contraception** 1995 Jul; 52(1):41-4

The use of misoprostol for termination of early pregnancy. Koopersmith TB, et al. **Contraception** 1996 Apr; 53(4):238-42

[Mifepristone and misoprostol in therapeutic abortions] Jannet D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(3):277-82 (24 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Is misoprostol the drug of choice for induced cervical ripening in early pregnancy termination? Platz-Christensen JJ, et al. **Acta Obstet Gynecol Scand** 1995 Nov; 74(10):809-12

Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol. Creinin MD. **Am J Obstet Gynecol** 1996 Feb;174(2):776-8

A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. Creinin MD, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1578-84

Combined methotrexate and misoprostol for early induced abortion [letter; comment] Camosy PA. **Arch Fam Med** 1996 May;5(5):263-4. Comment on: Arch Fam Med 1995 Sep;4(9):774-9.

Combined methotrexate and misoprostol for early induced abortion [letter; comment] Lichtenhan JB. **Arch Fam Med** 1996 May;5(5):263; discussion 264. Comment on: Arch Fam Med 1995 Sep;4(9):774-9.

Randomised clinical trial of medical evacuation and surgical curettage for incomplete miscarriage. de Jonge ET, et al. **BMJ** 1995 Sep 9;311(7006):662

Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion. Bugalho A, et al. **Contraception** 1996 Apr;53(4):244-6

[Methotrexate and misoprostol for drug-induced abortion in the first trimester] Wolff F. **Dtsch Med Wochenschr** 1995 Dec 22;120(51-52):1804 **(Ger)**

[Termination of pregnancy in the 2nd trimester by serial administration of gemeprost vaginal suppositories. A retrospective study] Krauss T, et al. **Geburtshilfe Frauenheilkd** 1994 Nov;54(11):623-6 (Eng. Abstr.) **(Ger)**

[Premature termination of pregnancy in the 2nd and 3rd trimester. Serial administration of 1 mg gemeprost vaginal suppositories versus intravenous sulproston] Müller T, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):234-8 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Uterine rupture during therapeutic abortion in the second trimester using mifepristone and prostaglandin [letter; comment] Thong KJ, et al. **Br J Obstet Gynaecol** 1995 Oct;102(10):844-5. Comment on: Br J Obstet Gynaecol 1995 Apr;102(4):332-3.

Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin. Phillips K, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr; 65(2):175-6

Toxic epidermal necrolysis after mifepristone/gemeprost-induced abortion. Lecorvaisier-Pieto C, et al. **J Am Acad Dermatol** 1996 Jul; 35(1):112

Methotrexate and misoprostol to terminate early pregnancy [letter] Yankowitz J, et al. **N Engl J Med** 1996 Feb 8; 334(6):399; discussion 400

[Histopathologic findings of the trophoblast and tubal wall after medicamentous therapy of tubal pregnancies] Klein M, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):671-3 (Eng. Abstr.) **(Ger)**

[Uterine rupture during induced abortion with prostaglandins in the second trimester] Zieger W, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):592-8 (43 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

[Pharmacokinetics of contragestazol (DL-111-IT), a new non-steroid antifertility agent in monkeys] Luo WY, et al. **Yao Hsueh Hsueh Pao** 1995;30(6):408-11 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

The effects of gemeprost on the second trimester fetus. Lazda EJ, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):731-4

Oral misoprostol versus vaginal gemeprost for cervical dilatation prior to vacuum aspiration in women in the sixth to twelfth week of gestation. Ngai SW, et al. **Contraception** 1995 Jun;51(6):347-50

Methotrexate and misoprostol for abortion. **Med Lett Drugs Ther** 1996 Apr 26;38(973):39-40

[Effect of (+), (-) and (+/-) gossypol on early pregnancy in rats] Guan MZ, et al. **Yao Hsueh Hsueh Pao** 1996; 31(1):10-2 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Baird DT, et al. **Hum Reprod** 1995 Jun;10(6):1521-7

Evaluation of the use of intrauterine infusions of oxytetracycline, subcutaneous injections of fenprostalene, or a combination of both, for the treatment of retained fetal membranes in dairy cows. Stevens RD, et al. **J Am Vet Med Assoc** 1995 Dec 15;207(12):1612-5

Use of misoprostol (prostaglandin E1 methyl analogue) to expedite delivery in severe preeclampsia remote from term. Del Valle GO, et al. **J Matern Fetal Med** 1996 Jan-Feb; 5(1):39-40

Methotrexate and misoprostol when surgical abortion fails. Schaff EA, et al. **Obstet Gynecol** 1996 Mar;87(3):450-2

[Randomized study of sulprostone versus misoprostol in the cervical preparation before elective abortion in nulliparous women] Schaub B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):505-10 (Eng. Abstr.) **(Fre)**

[Randomized comparative study of induced labor with oxytocin and misoprostol in prolonged pregnancies] Echeverría E, et al. **Rev Chil Obstet Ginecol** 1995; 60(2):108-11 (Eng. Abstr.) **(Spa)**

ABORTIFACIENT AGENTS, STEROIDAL

Blood loss in termination of early pregnancy with mifepristone and gemeprost. Prasad RN, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):329-31

Mifepristone and first trimester abortion. Murray S, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):474-85 (59 ref.)

[Antiprogesterones--new prospects in induced abortion] Karag ozov I, et al. **Akush Ginekol (Sofiia)** 1994;33(2):47-9 **(Bul)**

[Histological study of uterine cervix during termination of early pregnancy by mifepristone and prostaglandins] Weng L, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Sep; 30(9):522-5 (Eng. Abstr.) **(Chi)**

[Advances in the study of mifepristone] Wong L. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Sep;30(9):565-8 (22 ref.) **(Chi)**

[Mifepristone and misoprostol in therapeutic abortions] Jannet D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(3):277-82 (24 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol. Webster D, et al. **Br J Obstet Gynaecol** 1996 Jul; 103(7):706-9

Listening and learning from women about mifepristone: implications for counseling and health education. Castle MA, et al. **Womens Health Issues** 1995 Fall;5(3):130-8

ADVERSE EFFECTS

Uterine rupture during therapeutic abortion in the second trimester using mifepristone and prostaglandin [letter; comment] Thong KJ, et al. **Br J Obstet Gynaecol** 1995 Oct;102(10):844-5. Comment on: Br J Obstet Gynaecol 1995 Apr;102(4):332-3.

Reproductive function in rats after mifepristone-induced termination of pregnancy. Telleria CM, et al. **Contraception** 1996 Mar;53(3):185-90

Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin. Phillips K, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr; 65(2):175-6

Toxic epidermal necrolysis after mifepristone/gemeprost-induced abortion. Lecorvaisier-Pieto C, et al. **J Am Acad Dermatol** 1996 Jul; 35(1):112

PHARMACOLOGY

The effects of the antihormones RU486 and tamoxifen on fetoplacental development and placental bed vascularisation in the rat: a model for intrauterine fetal growth retardation. Sadek S, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):630-41

Clinical applications of the antiprogestins. Kettel LM. **Clin Obstet Gynecol** 1995 Dec;38(4):921-34 (56 ref.)

THERAPEUTIC USE

New applications of mifepristone (RU 486). Foreword. London S. **Clin Obstet Gynecol** 1996 Jun;39(2):423

Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Baird DT, et al. **Hum Reprod** 1995 Jun;10(6):1521-7

A comparative analysis of fall in haemoglobin following abortions conducted by mifepristone (600 mg) and vacuum aspiration. Thonneau P, et al. **Hum Reprod** 1995 Jun; 10(6):1512-5

ABORTION

see related
ABORTIFACIENT AGENTS

Hospital management commended for first trimester spontaneous abortion [letter; comment] Brown DC. **BMJ** 1995 Sep 23;311(7008):813. Comment on: BMJ 1995 Jun 3;310(6992):1426.

Misoprostol in the management of spontaneous abortion. Chung TK, et al. **Br J Obstet Gynaecol** 1995 Oct; 102(10):832-5

Quo vadis? Fetal tissue transplantation. Michejda M. **J Hematother** 1996 Apr;5(2):185-8 (31 ref.)

BLOOD

CA-125 is elevated in viable pregnancies destined to be miscarried: a prospective longitudinal study. Azogui G, et al. **Fertil Steril** 1996 May;65(5):1059-61

Progesterone profiles in luteal-phase defects associated with recurrent spontaneous abortions. Babalioğlu R, et al. **J Assist Reprod Genet** 1996 Apr;13(4):306-9

The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Sanson BJ, et al. **Thromb Haemost** 1996 Mar;75(3):387-8

[Hemostatic disturbances in women with unexplained fetal loss] Litorowicz A, et al. **Ginekol Pol** 1995 Feb;66(2):89-92 (Eng. Abstr.) **(Pol)**

ABORTION

CHEMICALLY INDUCED

Ethylene glycol ethers and risks of spontaneous abortion and subfertility. Correa A, et al. **Am J Epidemiol** 1996 Apr 1;143(7):707–17

Historical cohort investigation of spontaneous abortion in the Semiconductor Health Study: epidemiologic methods and analyses of risk in fabrication overall and in fabrication work groups. Beaumont JJ, et al. **Am J Ind Med** 1995 Dec; 28(6):735–50

Association of spontaneous abortion and other reproductive effects with work in the semiconductor industry. Schenker MB, et al. **Am J Ind Med** 1995 Dec;28(6):639–59

Historical cohort study of spontaneous abortion among fabrication workers in the Semiconductor Health Study: agent–level analysis. Swan SH, et al. **Am J Ind Med** 1995 Dec;28(6):751–69

Shift work, nitrous oxide exposure, and spontaneous abortion among Swedish midwives. Axelsson G, et al. **Occup Environ Med** 1996 Jun;53(6):374–8

Reproductive disorders due to chemical exposure among hairdressers. Kersemaekers WM, et al. **Scand J Work Environ Health** 1995 Oct;21(5):325–34 (85 ref.)

COMPLICATIONS

Future fertility following conservative management of complete abortion. Kaplan B, et al. **Hum Reprod** 1996 Jan; 11(1):92–4

Abortion and breast cancer risk. Tavani A, et al. **Int J Cancer** 1996 Feb 8;65(4):401–5

[Septic metrothrombophlebitis and acute kidney failure following a spontaneous abortion] Pranchev N. **Akush Ginekol (Sofiia)** 1995;34(2):57–8 (Eng. Abstr.) **(Bul)**

[Is there a relationship between a history of spontaneous abortion and low birthweight in Cotonou (West Africa)?] Fourn L, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):561–4 (Eng. Abstr.) **(Fre)**

[The role of heparin sulfate in the treatment of pregnant women with circulatory deficiency syndrome] Palmeri MA, et al. **Minerva Ginecol** 1996 Mar;48(3):119–23 (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Prediction of first–trimester miscarriage from embryonic bradycardia and embryonic growth delay. Ikegawa A. **J Obst. . Gynaecol** 1995 Dec;21(6):537–44

The empty amnion: a sign of early pregnancy failure. McKenna KM, et al. **J Ultrasound Med** 1995 Feb; 14(2):117–21

[Is sperm analysis of any value in the management of early, spontaneous abortions?] Paillat M, et al. **Contracept Fertil Sex** 1995 Oct;23(10):595–7 **(Fre)**

ENZYMOLOGY

Placental and germ cell alkaline phosphatase RFLPs and haplotypes associated with spontaneous abortion. Wennberg C, et al. **Hum Hered** 1995 Sep–Oct;45(5):272–7

EPIDEMIOLOGY

Celiac disease and pregnancy outcome. Ciacci C, et al. **Am J Gastroenterol** 1996 Apr;91(4):718–22

Hypothyroidism and spontaneous abortions among Hanford, Washington, downwinders. Grossman CM, et al. **Arch Environ Health** 1996 May–Jun;51(3):175–6 (8 ref.)

Selective miscarriage of Down's syndrome fetuses in women aged 35 years and older. Macintosh MC, et al. **Br J Obstet Gynaecol** 1995 Oct;102(10):798–801

Spontaneous abortion and risk of fatal breast cancer in a prospective cohort of United States women. Calle EE, et al. **Cancer Causes Control** 1995 Sep;6(5):460–8

Pre–conception care of diabetes, congenital malformations, and spontaneous abortions. Kitzmiller JL, et al. **Diabetes Care** 1996 May;19(5):514–41 (324 ref.)

Mutation in the mitochondrial tRNA(leu) at position 3243 and spontaneous abortions in Japanese women attending a clinic for diabetic pregnancies. Yanagisawa K, et al. **Diabetologia** 1995 Jul;38(7):809–15

Socio–economic client characteristics and consequences of abortion in Nairobi. Sjöstrand M, et al. **East Afr Med J** 1995 May;72(5):325–32

The profound impact of patient age on pregnancy outcome after early detection of fetal cardiac activity. Smith KE, et al. **Fertil Steril** 1996 Jan;65(1):35–40

Assessing congenital anomalies after preimplantation genetic diagnosis. Simpson JL, et al. **J Assist Reprod Genet** 1996 Feb;13(2):170–6 (30 ref.)

Spontaneous abortion rate. Weerakiet S, et al. **J Med Assoc Thai** 1996 Apr;79(4):249–52

Effects of parental occupational exposure to lead and other metals on spontaneous abortion. Anttila A, et al. **J Occup Environ Med** 1995 Aug;37(8):915–21 (36 ref.)

International, collaborative experience of 1789 patients having multifetal pregnancy reduction: a plateauing of risks and outcomes [see comments] Evans MI, et al. **J Soc Gynecol Investig** 1996 Jan–Feb;3(1):23–6. Comment in: J Soc Gynecol Investig 1996 Jan–Feb;3(1):1–2.

Pregnancy termination in relation to risk of breast cancer [see comments] Newcomb PA, et al. **JAMA** 1996 Jan 24–31;275(4):283–7. Comment in: JAMA 1996 Jan 24–31;275(4):321–2. Comment in: JAMA 1996 Jul 3;276(1):31; discussion 31–2. Comment in: JAMA 1996 Jul 3;276(1):31–2.

Patterns of reproduction among the Fang of Nsork (Equatorial Guinea): pregnancies, abortions and child spacing. Sainz de la Maza Kaufmann M, et al. **Rev Biol Trop** 1994 Apr–Aug;42(1–2):315–8

[Information on previous spontaneous abortions in the Medical Birth Registry] Hjøllund NH. **Ugeskr Laeger** 1996 Aug 19;158(34):4746–8 (Eng. Abstr.) **(Dan)**

[Spontaneous abortions: a little–studied phenomenon] Spinelli A, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):74–5 **(Ita)**

ETIOLOGY

Psychologic stress in the workplace and spontaneous abortion. Fenster L, et al. **Am J Epidemiol** 1995 Dec 1; 142(11):1176–83

Association of stressful life events with chromosomally normal spontaneous abortion. Neugebauer R, et al. **Am J Epidemiol** 1996 Mar 15;143(6):588–96

Prospective assessment of fecundability of female semiconductor workers. Eskenazi B, et al. **Am J Ind Med** 1995 Dec;28(6):817–31

Prospective monitoring of early fetal loss and clinical spontaneous abortion among female semiconductor workers. Eskenazi B, et al. **Am J Ind Med** 1995 Dec; 28(6):833–46

Preimplantation factor (PIF) predicts subsequent pregnancy loss. Coulam CB, et al. **Am J Reprod Immunol** 1995 Aug; 34(2):88–92

The direct embryotoxicity of immunoglobulin G fractions from patients with systemic lupus erythematosus. Nadler DM, et al. **Am J Reprod Immunol** 1995 Dec;34(6):349–55

neu/HER–2 cDNA vaccination and pregnancy loss. Venanzi FM, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:274–7

Stress–induced murine abortion associated with substance P–dependent alteration in cytokines in maternal uterine decidua. Arck PC, et al. **Biol Reprod** 1995 Oct;53(4):814–9

Selenium deficiency and miscarriage: a possible link? Barrington JW, et al. **Br J Obstet Gynaecol** 1996 Feb; 103(2):130–2

Studies on the cytogenetic and endocrinologic background of spontaneous abortion. Hasegawa I, et al. **Fertil Steril** 1996 Jan;65(1):52–4

Results of IVF in patients with endometriosis: the severity of the disease does not affect outcome, or the incidence of miscarriage. Geber S, et al. **Hum Reprod** 1995 Jun; 10(6):1507–11

Infectious processes: an infrequent cause of first trimester spontaneous abortions. Simpson JL, et al. **Hum Reprod** 1996 Mar;11(3):668–72

Risk factors for spontaneous abortion among Saudi women. al–Ansary LA, et al. **J Community Health** 1995 Dec; 20(6):491–500

Male–mediated risk of spontaneous abortion with reference to stainless steel welding. Hjollund NH, et al. **Scand J Work Environ Health** 1995 Aug;21(4):272–6

The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Foster PA. **Thromb Haemost** 1995 Aug;74(2):784–90

[Ectopic pregnancy: factors related to ovum anomalies?] Bouyer J, et al. **Rev Epidemiol Sante Publique** 1996 Apr; 44(2):101–10 (48 ref.) (Eng. Abstr.) **(Fre)**

[Smoking and pregnancy] Wenderlein JM. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):467–71 (15 ref.) (Eng. Abstr.) **(Ger)**

[Genital infections as a cause of abortion in the first trimester of pregnancy. Review of the literature] Capuzzo E, et al. **Minerva Ginecol** 1995 Dec;47(12):557–60 (15 ref.) (Eng. Abstr.) **(Ita)**

[Infection with parvovirus B19 in pregnant women] Oszukowski P, et al. **Ginekol Pol** 1996 Mar;67(3):114–6 (Eng. Abstr.) **(Pol)**

[Bacteremia caused by Campylobacter jejuni associated with spontaneous abortion (letter)] Saavedra JM, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):61–2 **(Spa)**

GENETICS

The natural history of Down syndrome conceptuses diagnosed prenatally that are not electively terminated. Hook EB, et al. **Am J Hum Genet** 1995 Oct;57(4):875–81

Instability at the H–ras minisatellite is associated with the spontaneous abortion of the embryo. Kiaris H, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):788–92

Comparison of ploidy analysis by flow cytometry and image analysis in hydatidiform mole and non–molar abortion. Jeffers MD, et al. **Histopathology** 1995 Nov;27(5):415–21

Molecular studies of the aetiology of trisomy 8 in spontaneous abortions and the liveborn population. James RS, et al. **Hum Genet** 1996 Mar;97(3):283–6

Placental and germ cell alkaline phosphatase RFLPs and haplotypes associated with spontaneous abortion. Wennberg C, et al. **Hum Hered** 1995 Sep–Oct;45(5):272–7

Fetal loss in the first trimester after demonstration of cardiac activity: relation of cytogenetic and ultrasound findings. Bessho T, et al. **Hum Reprod** 1995 Oct;10(10):2696–9

Mutations, malformations and mortality. Suthers G. **J Paediatr Child Health** 1996 Feb;32(1):10–5 (67 ref.)

Pregnancy termination and risk of breast cancer [letter; comment] Lehrer S. **JAMA** 1996 Jul 3;276(1):31–2. Comment on: JAMA 1996 Jan 24–31;275(4):283–7.

IMMUNOLOGY

Immune interferon gamma inhibits translational mobility of a plasma membrane protein in preimplantation stage mouse embryos: a T–heiper 1 mechanism for immunologic reproductive failure. Polgár K, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):282–7

Placental tissue from human miscarriages expresses class II HLA–DR antigens. Athanassakis I, et al. **Am J Reprod Immunol** 1995 Nov;34(5):281–7

Decidual natural killer cytotoxicity decreased in normal pregnancy but not in anembryonic pregnancy and recurrent spontaneous abortion. Chao KH, et al. **Am J Reprod Immunol** 1995 Nov;34(5):274–80

Reciprocal alteration in circulating TJ6+ CD19+ and TJ6+ CD56+ leukocytes in early pregnancy predicts success or miscarriage. Coulam CB, et al. **Am J Reprod Immunol** 1995 Oct;34(4):219–24

Embryo infiltration by maternal macrophages is associated with selective expression of proto–oncogenes in a murine model of spontaneous abortion. Duclos AJ, et al. **Biol Reprod** 1996 May;54(5):1088–95

Antiphospholipid antibodies, low–dose aspirin and pregnancy losses [letter] Balasch J, et al. **Hum Reprod** 1996 May; 11(5):1140–1

Analysis of health insurance cover for reproductive immunology. Engemann KJ, et al. **Hum Reprod** 1996 Jan; 11(1):72–6

Toxoplasma IgG. & IgM. antibodies. A case control study. Attia RA, et al. **J Egypt Soc Parasitol** 1995 Dec; 25(3):877–82

Anti–Mac–1 antibodies and early pregnancy loss in mice. Savion S, et al. **J Reprod Fertil** 1996 May;107(1):7–10

MICROBIOLOGY

Chlamydial antibodies in women who suffer miscarriage. Osser S, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):137–41

[Chlamydia trachomatis during genital tract infection and in imminent abortion] Elias M, et al. **Ginekol Pol** 1995 Sep; 66(9):513–7 (Eng. Abstr.) **(Pol)**

PATHOLOGY

Prevalence and significance of implantation site trophoblastic atypia in hydatidiform moles and spontaneous abortions. Montes M, et al. **Am J Clin Pathol** 1996 Apr;105(4):411–6

Indications for examination of spontaneous abortion specimens: a reassessment. Wolf GC, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1364–8

PHYSIOPATHOLOGY

Effect of 1st–trimester loss on restoration of the hypothalamic–pituitary–ovarian axis. Elkas JC, et al. **Gynecol Obstet Invest** 1995;40(4):257–60

PREVENTION & CONTROL

Low–dose gonadotrophin stimulation for luteal phase defects—does absence of LH help pregnancy rates? Check JH. **Del Med J** 1996 Apr;68(4):223–6

Antiphospholipid antibodies, low–dose aspirin and pregnancy losses [letter] Balasch J, et al. **Hum Reprod** 1996 May; 11(5):1140–1

PSYCHOLOGY

Miscarriage experience and the role of support systems: a pilot study. Conway K. **Br J Med Psychol** 1995 Sep;68 (Pt 3):259–67

The influence of psychological debriefing on emotional adaptation in women following early miscarriage: a preliminary study. Lee C, et al. **Br J Med Psychol** 1996 Mar;69 (Pt 1):47–58

Communication following a stillbirth or neonatal death: room for improvement. Crowther ME. **Br J Obstet Gynaecol** 1995 Dec;102(12):952–6

Life events and miscarriage. O'Hare T, et al. **Br J Psychiatry** 1995 Dec;167(6):799–805

The effects on the family of miscarriage, termination for abnormality, stillbirth and neonatal death. Thomas J. **Child Care Health Dev** 1995 Nov;21(6):413–24

Grief and depression after miscarriage: their separation, antecedents, and course. Beutel M, et al. **Psychosom Med** 1995 Nov–Dec;57(6):517–26

[Medical management after spontaneous abortion] Beutel M, et al. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):M93–5 **(Ger)**

[Assessment of grief exemplified pregnancy loss: development and initial results on the validity of the Munich Grief Scale] Beutel M, et al. **Psychother Psychosom Med Psychol** 1995 Sep–Oct; 45(9–10):295–302 (Eng. Abstr.) **(Ger)**

THERAPY

Analysis of health insurance cover for reproductive immunology. Engemann KJ, et al. **Hum Reprod** 1996 Jan; 11(1):72–6

Future fertility following conservative management of

complete abortion. Kaplan B, et al. **Hum Reprod** 1996 Jan; 11(1):92–4

ULTRASONOGRAPHY

Fetal loss in the first trimester after demonstration of cardiac activity: relation of cytogenetic and ultrasound findings. Bessho T, et al. **Hum Reprod** 1995 Oct;10(10):2696–9

The reliability of transvaginal ultrasonography to detect retained tissue after spontaneous first-trimester abortion, clinically thought to be complete. Alcázar JL, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):126–9

Sonography of pregnancies with first-trimester bleeding and a viable embryo: a study of prognostic indicators by logistic regression analysis. Falco P, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):165–9

[Is the length of gestation a multiple of a fundamental cycle?] Kotoujansky J, et al. **Rev Fr Gynecol Obstet** 1995 Nov; 90(11):486–93 (Eng. Abstr.) **(Fre)**

[Spontaneous abortion of one twin and later spontaneous delivery of the surviving twin] Kouam L, et al. **Zentralbl Gynakol** 1995;117(11):604–7 (Eng. Abstr.) **(Ger)**

URINE

Laboratory methods for evaluating early pregnancy loss in an industry-based population. Lasley BL, et al. **Am J Ind Med** 1995 Dec;28(6):771–81

VETERINARY see ABORTION, VETERINARY

VIROLOGY

Detection of herpes simplex virus DNA in spontaneous abortions from HIV-positive women using non-isotopic in situ hybridization [see comments] Wright CA, et al. **J Pathol** 1995 Aug;176(4):399–402. Comment in: J Pathol 1996 May;179(1):125.

ABORTION APPLICANTS

Ambivalence among women applying for abortion. Husfeldt C, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):813–7

Reasons for pregnancy termination: negligence or failure of contraception? Savonius H, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):818–21

Repeat abortion and use of primary care health services. Westfall JM, et al. **Fam Plann Perspect** 1995 Jul–Aug; 27(4):162–5

[Sex behavior of women seeking hormonal contraception and women seeking induced abortion] Kulovaný E, et al. **Ceska Gynekol** 1996 Feb;61(1):27–31 (Eng. Abstr.) **(Cze)**

[Voluntary interruption of pregnancy: its epidemiology and the prevention possibilities] Spinelli A, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):71–3 **(Ita)**

[Who should conduct abortion counseling? (letter)] Eide A. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):109 **(Nor)**

[Information and counseling of women applying for abortion (letter)] Jordal H, et al. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2215–6 **(Nor)**

[Who should manage abortion counseling? (letter)] Lydersen H, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):109–10 **(Nor)**

PSYCHOLOGY

The abortion decision: reasons and ambivalence. Allanson S, et al. **J Psychosom Obstet Gynaecol** 1995 Sep; 16(3):123–36

[Woman decide themselves whether they want guidelines (letter; comment)] Aavitsland P. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1616–7. Comment on: Tidsskr Nor Laegeforen 1996 Apr 20;116(10):1207–8. **(Nor)**

STATISTICS & NUMERICAL DATA

Prevalence of domestic violence among women seeking abortion services. Evins G, et al. **Womens Health Issues** 1996 Jul–Aug;6(4):204–10

ABORTION, CRIMINAL

Abortion prohibition and acute renal failure: the tragic Romanian experience. Vladutiu DS, et al. **Ren Fail** 1995 Sep;17(5):605–9

[Is illegal abortion a secure procedure? A case report] Iris JM, et al. **Ginecol Obstet Mex** 1996 Jun;64:261–4 (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

Procured abortion in Ilorin, Nigeria. Anate M, et al. **East Afr Med J** 1995 Jun;72(6):386–90

Complications of induced abortions and their preventions in Ghana. Lassey AT. **East Afr Med J** 1995 Dec;72(12):774–7

Induced abortion in Kenya: its determinants and associated factors. Lema VM, et al. **East Afr Med J** 1996 Mar; 73(3):164–8

Socio-economic client characteristics and consequences of abortion in Nairobi. Sjöstrand M, et al. **East Afr Med J** 1995 May;72(5):325–32

TRENDS

Abortion policy and practice in Greece. Georges E. **Soc Sci Med** 1996 Feb;42(4):509–19

Women's perspectives on abortion in Romania. Johnson BR, et al. **Soc Sci Med** 1996 Feb;42(4):521–30

ABORTION, EUGENIC

Population policy and eugenics in China [editorial] [see comments] Pearson V. **Br J Psychiatry** 1995 Jul;167(1):1–4 . Comment in: Br J Psychiatry 1995 Nov;167(5):697–8.

Eugenics [letter; comment] Uzych L. **Br J Psychiatry** 1995 Nov;167(5):697–8. Comment on: Br J Psychiatry 1995 Jul;167(1):1–4.

Abortion and the ethics of genetic sexual orientation research. Murphy TF. **Camb Q Healthc Ethics** 1995 Summer; 4(3):340–50

The road that I see: implications of new reproductive technologies. Steel KO. **Camb Q Healthc Ethics** 1995 Summer;4(3):351–4

Abortion and the maternal-fetal medicine physician [letter] Hilgers TW. **Hastings Cent Rep** 1995 Sep–Oct;25(5):2–3

Abortion and the maternal-fetal medicine physician [letter; comment] Klaus H. **Hastings Cent Rep** 1995 Sep–Oct; 25(5):2; discussion 3. Comment on: Hastings Cent Rep 1995 Jan–Feb;25(1):22–6.

Abortion and the maternal-fetal medicine physician [letter; comment] Wechter DJ. **Hastings Cent Rep** 1995 Sep–Oct; 25(5):2; discussion 3. Comment on: Hastings Cent Rep 1995 Jan–Feb;25(1):22–6.

Ensuring a stillborn: the ethics of fetal lethal injection in late abortion [see comments] Callahan JC. **J Clin Ethics** 1995 Fall;6(3):254–63. Comment in: J Clin Ethics 1995 Fall;6(3):264–70. Comment in: J Clin Ethics 1995 Fall;6(3):270–2.

On learning from mistakes [comment] Fletcher JC. **J Clin Ethics** 1995 Fall;6(3):264–70. Comment on: J Clin Ethics 1995 Fall;6(3):254–63.

Justifying prenatal screening and genetic amniocentesis programs by cost-effectiveness analyses: a re-evaluation. Ganiats TG. **Med Decis Making** 1996 Jan–Mar;16(1):45–50 (61 ref.)

[Late pregnancy interruption in Noord-Holland. II. Carefulness before and review afterwards] Bosma JM, et al. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):605–9 (Eng. Abstr.) **(Dut)**

[Late pregnancy interruption] Treffers PE. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):590–2 **(Dut)**

[Request for late pregnancy interruption in severe congenital anomalies] van 't Hof DB, et al. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):585–7 **(Dut)**

[Termination of pregnancy in the 2nd trimester by serial administration of gemeprost vaginal suppositories. A retrospective study] Krauss T, et al. **Geburtshilfe Frauenheilkd** 1994 Nov;54(11):623–6 (Eng. Abstr.) **(Ger)**

[Premature termination of pregnancy in the 2nd and 3rd trimester. Serial administration of 1 mg gemeprost vaginal suppositories versus intravenous sulproston] Müller T, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):234–8 (Eng. Abstr.) **(Ger)**

[The "hidden" indication (editorial)] Haller U, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):1–2 **(Ger)**

[Observations on ethics in prenatal diagnosis from the viewpoint of the pediatrician] Lenard HG. **Gynakologe** 1995 Oct;28(5):384–8 **(Ger)**

[Pre- and postpartum management of hypoplastic left heart syndrome (letter)] Kattner. **Z Geburtshilfe Neonatol** 1996 Mar–Apr;200(2):75 **(Ger)**

STATISTICS & NUMERICAL DATA

[Late pregnancy interruption in Noord-Holland. I. Incidence and abnormalities] van der Wal G, et al. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):600–4 (Eng. Abstr.) **(Dut)**

[Pregnancy termination after prenatal diagnosis--data of the Styrian malformation register (1985–1992)] Häusler MC, et al. **Wien Klin Wochenschr** 1996;108(6):169–74 (Eng. Abstr.) **(Ger)**

ABORTION, HABITUAL

Habitual abortion: endocrinological aspects. Fedele L, et al. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):351–6 (45 ref.)

Frequency of abnormal karyotypes among abortuses from women with and without a history of recurrent spontaneous abortion. Stern JJ, et al. **Fertil Steril** 1996 Feb; 65(2):250–3

Early pregnancy loss. **Int J Gynaecol Obstet** 1995 Dec; 51(3):278–85 (45 ref.)

BLOOD

Prevalence of embryotoxic factor in sera from women with unexplained recurrent abortion. Thomason EJ, et al. **Am J Reprod Immunol** 1995 Dec;34(6):338–41

The effect of serum follicular phase luteinizing hormone concentrations in habitual abortion: correlation with results of paternal leukocyte immunization. Carp HJ, et al. **Hum Reprod** 1995 Jul;10(7):1702–5

Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Rai RS, et al. **Hum Reprod** 1995 Aug;10(8):2001–5

Correlation of serum cytokine and adhesion molecule determinations with pregnancy outcome. Schust DJ, et al. **J Soc Gynecol Investig** 1996 Sep–Oct;3(5):259–61

CHEMICALLY INDUCED

Exposure to pentachlorophenol as a possible cause of miscarriages. de Maeyer J, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1010–1

DIAGNOSIS

Diagnostic and prognostic significance of anticardiolipin antibodies in patients with recurrent spontaneous abortions. Melk A, et al. **Am J Reprod Immunol** 1995 Mar; 33(3):228–33

Diagnostic relevance of abortion-associated human embryonic antigen expressed on the cell surface of tumour promoter-treated Bloom syndrome cells. Shiraishi Y, et al. **Hum Reprod** 1995 Jul;10(7):1694–701

DRUG THERAPY

Low-dose aspirin and recurrent miscarriage [letter] Christiansen OB. **Hum Reprod** 1995 Nov;10(11):3077–9

Low-dose aspirin and prednisone treatment of pregnancy loss caused by lupus anticoagulants. Harger JH, et al. **J Perinatol** 1995 Nov–Dec;15(6):463–9

ENZYMOLOGY

Phosphotyrosine-protein-phosphatases and human reproduction: an association between low molecular weight acid phosphatase (ACP1) and spontaneous abortion. Gloria-Bottini F, et al. **Dis Markers** 1996 Mar;12(4):261–9

EPIDEMIOLOGY

Incidence of anti-Toxoplasma antibodies in women with high-risk pregnancy and habitual abortions. Galván Ramírez M de la L, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):333–7

ETIOLOGY

Second-trimester pregnancy loss is associated with activated C resistance. Rai R, et al. **Br J Haematol** 1996 Feb; 92(2):489–90

Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Rai RS, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):842–4

Recurrent pregnancy loss. Cook CL, et al. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):357–66 (46 ref.)

Recurrent miscarriage: causes and management. Chung PH, et al. **Hosp Pract (Off Ed)** 1996 May 15;31(5):157–64 (11 ref.)

Massive chronic intervillositis associated with recurrent abortions. Doss BJ, et al. **Hum Pathol** 1995 Nov; 26(11):1245–51

Association between mannan binding protein deficiency and recurrent miscarriage. Kilpatrick DC, et al. **Hum Reprod** 1995 Sep;10(9):2501–5

Semen parameters and sperm morphology in men in unexplained recurrent spontaneous abortion, before and during a 3 year follow-up period. Sbracia S, et al. **Hum Reprod** 1996 Jan;11(1):117–20

Thrombosis of the terminal aorta, deep vein thrombosis, recurrent fetal loss, and antiphospholipid antibodies. Case report. Hohlfeld J, et al. **Vasa** 1996;25(2):194–9

GENETICS

Uniparental isodisomy of chromosome 14 in two cases: an abnormal child and a normal adult. Papenhausen PR, et al. **Am J Med Genet** 1995 Nov 20;59(3):271–5 (30 ref.)

Human leukocyte antigen DQ alpha sharing is not increased in couples with recurrent miscarriage. Dizon-Townson D, et al. **Am J Reprod Immunol** 1995 Oct;34(4):209–12

Phosphotyrosine-protein-phosphatases and human reproduction: an association between low molecular weight acid phosphatase (ACP1) and spontaneous abortion. Gloria-Bottini F, et al. **Dis Markers** 1996 Mar;12(4):261–9

Maternal HLA class II allogenotypes are markers for the predisposition to fetal losses in families of women with unexplained recurrent fetal loss. Christiansen OB, et al. **Eur J Immunogenet** 1995 Aug;22(4):323–34

Interaction between ABO blood groups and ADA genetic polymorphism during intrauterine life. A comparative analysis of couples with habitual abortion and normal puerperae delivering a live-born infant. Lucarini N, et al. **Hum Genet** 1995 Nov;96(5):527–31

HLA-DQA1 and HLA-DQB1 haplotypes in aborted fetuses and couples with recurrent spontaneous abortion. Steck T, et al. **J Reprod Immunol** 1995 Jul;29(2):95–104

IMMUNOLOGY

Decidual natural killer cytotoxicity decreased in normal pregnancy but not in anembryonic pregnancy and recurrent spontaneous abortion. Chao KH, et al. **Am J Reprod Immunol** 1995 Nov;34(5):274–80

Suppression of natural killer cell activity by monocytes following immunotherapy for recurrent spontaneous aborters. Higuchi K, et al. **Am J Reprod Immunol** 1995 Mar;33(3):221–7

Mixed maternal-paternal lymphocyte cultures before and after immunotherapy for recurrent spontaneous abortions.

Komlos L, et al. **Am J Reprod Immunol** 1996 Jan;35(1):30–3

Up-regulated expression of CD56+, CD56+/CD16+, and CD19+ cells in peripheral blood lymphocytes in pregnant women with recurrent pregnancy losses. Kwak JY, et al. **Am J Reprod Immunol** 1995 Aug;34(2):93–9

A subset of patients with recurrent spontaneous abortion is deficient in transforming growth factor beta-2-producing "suppressor cells" in uterine tissue near the placental attachment site. Lea RG, et al. **Am J Reprod Immunol** 1995 Jul;34(1):52–64

Diagnostic and prognostic significance of anticardiolipin antibodies in patients with recurrent spontaneous abortions. Melk A, et al. **Am J Reprod Immunol** 1995 Mar; 33(3):228–33

Anticardiolipin antibodies in patients with pregnancy loss induce factor Xa production in the presence of beta 2-glycoprotein I. Ogasawara M, et al. **Am J Reprod Immunol** 1995 Nov;34(5):269–73

Clinical significance of anti-GM3 antibodies in recurrent pregnancy loss with elevated level of antiphospholipid antibodies. Ozaki Y, et al. **Am J Reprod Immunol** 1995 Mar; 33(3):234–42

Recurrent miscarriage is associated with increased numbers of CD5/20 positive lymphocytes and an increased incidence of thyroid antibodies. Roberts J, et al. **Eur J Endocrinol** 1996 Jan;134(1):84–6

Strong association between the responder status of the FC gamma II receptor and recurrent spontaneous abortion. Lorenz A, et al. **Eur J Immunogenet** 1995 Oct;22(5):397–401

Antibodies to oxidized low-density lipoprotein and to cardiolipin in nonpregnant and pregnant women with habitual abortion. Tulppala M, et al. **Fertil Steril** 1995 Nov; 64(5):947–50

Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Yetman DL, et al. **Fertil Steril** 1996 Oct;66(4):540–6

Thyroid autoantibodies in euthyroid non-pregnant women with recurrent spontaneous abortions. Bussen S, et al. **Hum Reprod** 1995 Nov;10(11):2938–40

T-helper 1-type immunity to trophoblast: evidence for a new immunological mechanism for recurrent abortion in women. Hill JA. **Hum Reprod** 1995 Dec;10 Suppl 2:114–20 (75 ref.)

Materno-fetal immunobiology in normal pregnancy and its possible failure in recurrent spontaneous abortion? Vince GS, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:107–13 (50 ref.)

Endometrial T, B, and NK cells in patients with recurrent spontaneous abortion. Altered profile and pregnancy outcome. Lachapelle MH, et al. **J Immunol** 1996 May 15; 156(10):4027–34

HLA sharing, anti-paternal cytotoxic antibodies and MLR blocking factors in women with recurrent spontaneous abortion. Kishore R, et al. **J Obstet Gynaecol Res** 1996 Apr;22(2):177–83

Intravenous immunoglobulin infusion therapy in women with recurrent spontaneous abortions of immune etiologies. Kwak JY, et al. **J Reprod Immunol** 1995 Mar;28(3):175–88

Are antinuclear antibodies predictive of recurrent miscarriage? [letter] Ogasawara M, et al. **Lancet** 1996 Apr 27;347(9009):1183–4

Specific antiphospholipid antibodies (aPL) eluted from placentae of pregnant women with aPL-positive sera. Katano K, et al. **Lupus** 1995 Aug;4(4):304–8

[An autoantibody to human chorionic gonadotropin in habitual abortion] Ponomareva IV, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):450–2 **(Rus)**

[Antiphospholipid antibodies in women with habitual abortions. Treatment with prednisone and acetylsalicylic acid during pregnancy] Marco P, et al. **Sangre (Barc)** 1995 Oct;40(5):389–92 (Eng. Abstr.) **(Spa)**

METABOLISM

The measurement of CA 125 and placental protein 14 in uterine flushings in women with recurrent miscarriage; relation to endometrial morphology. Dalton CF, et al. **Hum Reprod** 1995 Oct;10(10):2680–4

MUC1 in secretory phase endometrium: expression in precisely dated biopsies and flushings from normal and recurrent miscarriage patients. Hey NA, et al. **Hum Reprod** 1995 Oct;10(10):2655–62

PARASITOLOGY

Toxoplasmosis as a cause of repeated abortion. Sahwi SY, et al. **J Obstet Gynaecol** 1995 Apr;21(2):145–8

PREVENTION & CONTROL

Use of intravenous immunoglobulin to prevent recurrent spontaneous abortion [letter] Grandone E, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1080

A cautionary note [editorial] Hunt JS. **Am J Reprod Immunol** 1995 Mar;33(3):276

Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial. Clifford K, et al. **BMJ** 1996 Jun 15;312(7045):1508–11

Transabdominal cervicoisthmic cerclage in the management of recurrent second trimester miscarriage and preterm delivery [letter; comment] Christiansen OB. **Br J Obstet Gynaecol** 1996 Jun;103(6):595–6. Comment on: Br J Obstet Gynaecol 1995 Oct;102(10):802–6.

The modern preventive treatment of recurrent miscarriage [letter; comment] Farquharson R. **Br J Obstet Gynaecol** 1996 Jul;103(7):723–4. Comment on: Br J Obstet Gynaecol 1996 Feb;103(2):106–10.

The modern preventive treatment of recurrent miscarriage [letter; comment] Manyonda I, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):723. Comment on: Br J Obstet Gynaecol 1996 Feb;103(2):106–10.

The modern preventative treatment of recurrent miscarriage [see comments] Rai R, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):106–10 (41 ref.). Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):723. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):723–4.

Placebo-controlled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with i.v. immunoglobulin. Christiansen OB, et al. **Hum Reprod** 1995 Oct;10(10):2690–5

Is intravenous albumin a placebo? [letter] Rewald E, et al. **Lancet** 1995 Dec 2;346(8988):1497

[Passive immunotherapy in risk of habitual abortion—the course of maternal serum immunoglobulins] Krümmer A, et al. **Zentralbl Gynakol** 1996;118(1):33–6 (Eng. Abstr.) **(Ger)**

[A case of beta 2-glycoprotein I-independent antiphospholipid syndrome] Ozawa N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Oct; 47(10):1079–82 **(Jpn)**

[Characteristics of lymphocytic enzyme status of the newborn after metabolic therapy of pregnant women] Fursova ZK, et al. **Akush Ginekol (Mosk)** 1995;(4):26–8 (Eng. Abstr.) **(Rus)**

[Evaluation of the effectiveness of immunotherapy and prediction of pregnancy outcomes on the basis of parameters of cellular immunity in women with habitual abortion] Mil'ko-Chernomorets IuV, et al. **Gematol Transfuziol** 1995 Jul-Aug;40(4):46 **(Rus)**

[Antiphospholipid antibodies in women with habitual abortions. Treatment with prednisone and acetylsalicylic acid during pregnancy] Marco P, et al. **Sangre (Barc)** 1995 Oct;40(5):389–92 (Eng. Abstr.) **(Spa)**

SURGERY

Transabdominal cervicoisthmic cerclage in the management of recurrent second trimester miscarriage and preterm delivery [see comments] Gibb DM, et al. **Br J Obstet Gynaecol** 1995 Oct;102(10):802–6. Comment in: Br J Obstet Gynaecol 1996 Jun;103(6):595–6.

Reproductive outcome after hysteroscopic metroplasty. Colacurci N, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):147–50

Reproductive outcome following hysteroscopic management of intrauterine septum and adhesions. Goldenberg M, et al. **Hum Reprod** 1995 Oct;10(10):2663–5

THERAPY

Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Coulam CB, et al. **Am J Reprod Immunol** 1995 Dec;34(6):333–7

Mixed maternal-paternal lymphocyte cultures before and after immunotherapy for recurrent spontaneous abortions. Komlos L, et al. **Am J Reprod Immunol** 1996 Jan;35(1):30–3

Recurrent miscarriage: causes and management. Chung PH, et al. **Hosp Pract (Off Ed)** 1996 May 15;31(5):157–64 (11 ref.)

Outcome of pregnancy in women with recurrent spontaneous abortion following immunotherapy with allogeneic lymphocytes. Agrawal S, et al. **Hum Reprod** 1995 Sep; 10(9):2280–4

The Euro-Team Early Pregnancy (ETEP) protocol for recurrent miscarriage. Berry CW, et al. **Hum Reprod** 1995 Jun;10(6):1516–20 (42 ref.)

The effect of serum follicular phase luteinizing hormone concentrations in habitual abortion: correlation with results of paternal leukocyte immunization. Carp HJ, et al. **Hum Reprod** 1995 Jul;10(7):1702–5

Intravenous immunoglobulin infusion therapy in women with recurrent spontaneous abortions of immune etiologies. Kwak JY, et al. **J Reprod Immunol** 1995 Mar;28(3):175–88

[Idiopathic habitual abortion: experiences with active immunotherapy] Sterzik K, et al. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):493–9 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Ultrasonographic characteristics of first-trimester gestations in recurrent spontaneous aborters. Cunningham DS, et al. **J Reprod Med** 1995 Aug;40(8):565–70

ABORTION, ILLEGAL see **ABORTION, CRIMINAL**

ABORTION, INCOMPLETE

Arthrogryposis associated with unsuccessful attempts at termination of pregnancy. Hall JG. **Am J Med Genet** 1996 May 3;63(1):293–300 (40 ref.)

Misoprostol in the management of spontaneous abortion. Chung TK, et al. **Br J Obstet Gynaecol** 1995 Oct; 102(10):832–5

EPIDEMIOLOGY

Socio-economic client characteristics and consequences of abortion in Nairobi. Sjöstrand M, et al. **East Afr Med J** 1995 May;72(5):325–32

ETIOLOGY

Induced abortion in Kenya: its determinants and associated factors. Lema VM, et al. **East Afr Med J** 1996 Mar; 73(3):164–8

PATHOLOGY

[Contemporary biopsy for diagnosis of abortion residues: preliminary experience] Hott H, et al. **Rev Chil Obstet Ginecol** 1995;60(1):38–42 (Eng. Abstr.) **(Spa)**

SURGERY

Suction evacuation of uterine products of conception [letter] de Jong P. **S Afr Med J** 1996 Jun;86(6):700

THERAPY

Randomised clinical trial of medical evacuation and surgical curettage for incomplete miscarriage. de Jonge ET, et al. **BMJ** 1995 Sep 9;311(7006):662

ULTRASONOGRAPHY

Transvaginal sonohysterography: a new aid in the diagnosis of residual trophoblastic tissue. Wolman I, et al. **J Clin Ultrasound** 1996 Jun;24(5):257–61

The reliability of transvaginal ultrasonography to detect retained tissue after spontaneous first-trimester abortion, clinically thought to be complete. Alcázar JL, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):126–9

ABORTION, INDUCED

Ambivalence among women applying for abortion. Husfeldt C, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):813–7

Plasma human chorionic gonadotropin levels after induced abortion. Aral K, et al. **Adv Contracept** 1996 Mar;12(1):11–4

Causative factors in first trimester abortion failure. Gürkan Zorlu C, et al. **Adv Contracept** 1996 Mar;12(1):63–7

Arthrogryposis associated with unsuccessful attempts at termination of pregnancy. Hall JG. **Am J Med Genet** 1996 May 3;63(1):293–300 (40 ref.)

Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol. Creinin MD. **Am J Obstet Gynecol** 1996 Feb;174(2):776–8

A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. Creinin MD, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1578–84

A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Jain JK, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):173–7

Intraoperative embolization for pelvic hemorrhage following termination of pregnancy. Kerr A, et al. **Am J Perinatol** 1996 Apr;13(3):151–3

Termination of pregnancy in rodents by oral administration of praneem, a purified neem seed extract. Mukherjee S, et al. **Am J Reprod Immunol** 1996 Jan;35(1):51–6

The effect of syntocinon on blood loss during first trimester suction curettage. Ali PB, et al. **Anaesthesia** 1996 May; 51(5):483–5

Blood loss in termination of early pregnancy with mifepristone and gemeprost. Prasad RN, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):329–31

Pregnancy, abortion and the dangers of prescribing vitamin A analogs in Australia [letter] Lipson T. **Australas J Dermatol** 1996 May;37(2):114–5

Pill scare linked to rise in abortions [news; comment] Dillner L. **BMJ** 1996 Apr 20;312(7037):996. Comment on: BMJ 1996 Apr 20;312(7037):987–8.

Antiabortionists hijack fetal pain argument [news] Kmietowicz Z. **BMJ** 1996 Jul 27;313(7051):188

Abortion without the woman's consent is unlikely to improve her depression [letter; comment] Menage J. **BMJ** 1996 Apr 6;312(7035):908. Comment on: BMJ 1996 Jan 6;312(7022):11–2.

Patient's consent to abortion is usually necessary even in emergencies [letter; comment] Puxon M. **BMJ** 1996 Feb 17;312(7028):446–7. Comment on: BMJ 1996 Jan 6;312(7022):11–2.

Drug combination adds fuel to US abortion debate [news] Rutter TL. **BMJ** 1995 Sep 16;311(7007):705

Medical pregnancy termination in the presence of a massive uterine fibroid. Fenwick DK, et al. **Br J Clin Pract** 1995 Nov-Dec;49(6):332–3

Is third trimester abortion justified? [letter; comment] Papp Z, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):188. Comment on: Br J Obstet Gynaecol 1995 Jun;102(6):434–5.

Is third trimester abortion justified? [letter; comment] Simms M. **Br J Obstet Gynaecol** 1996 Feb;103(2):187–8. Comment on: Br J Obstet Gynaecol 1995 Jun;102(6):434–5.

Is third trimester abortion justified? [letter; comment] Sirisena J. **Br J Obstet Gynaecol** 1996 Feb;103(2):188–9. Comment on: Br J Obstet Gynaecol 1995 Jun;102(6):434–5.

Ethical dilemma of medical abortion [letter; comment] Gugliotta D. **Can Med Assoc J** 1996 Jul 1;155(1):18–9. Comment on: Can Med Assoc J 1996 Jan 15;154(2):185–7.

Nausea, vomiting and thyroid function before and after

induced abortion in normal pregnancy. Appierto U, et al. **Clin Exp Obstet Gynecol** 1996;23(1):18–20

Mifepristone and first trimester abortion. Murray S, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):474–85 (59 ref.)

Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion. Bugalho A, et al. **Contraception** 1996 Apr;53(4):244–6

The use of misoprostol for termination of early pregnancy. Koopersmith TB, et al. **Contraception** 1996 Apr; 53(4):238–42

Oral misoprostol versus vaginal gemeprost for cervical dilatation prior to vacuum aspiration in women in the sixth to twelfth week of gestation. Ngai SW, et al. **Contraception** 1995 Jun;51(6):347–50

Reproductive function in rats after mifepristone-induced termination of pregnancy. Telleria CM, et al. **Contraception** 1996 Mar;53(3):185–90

Abortion training in family medicine [editorial] Gold M. **Fam Med** 1996 Apr;28(4):287–8

Abortion training in family practice residency programs. Talley PP, et al. **Fam Med** 1996 Apr;28(4):245–8

Clinical, hormonal and sonographic predictors of successful RU-486-induced abortions. Menashe Y, et al. **Gynecol Obstet Invest** 1995;40(2):108–12

Abortion and the maternal–fetal medicine physician [letter] Hilgers TW. **Hastings Cent Rep** 1995 Sep–Oct;25(5):2–3

Abortion and the maternal–fetal medicine physician [letter; comment] Klaus H. **Hastings Cent Rep** 1995 Sep–Oct; 25(5):2; discussion 3. Comment on: Hastings Cent Rep 1995 Jan–Feb;25(1):22–6.

Abortion and the maternal–fetal medicine physician [letter; comment] Meilaender G. **Hastings Cent Rep** 1995 Sep–Oct; 25(5):2; discussion 3. Comment on: Hastings Cent Rep 1995 Jan–Feb;25(1):22–6.

Abortion and the maternal–fetal medicine physician [letter; comment] Wechter DJ. **Hastings Cent Rep** 1995 Sep–Oct; 25(5):2; discussion 3. Comment on: Hastings Cent Rep 1995 Jan–Feb;25(1):22–6.

Changes in the coelomic fluid composition following two different methods of cervical ripening. Gavriil P, et al. **Hum Reprod** 1995 Sep;10(9):2453–5

The quality of abortion services in Turkey. Huntington D, et al. **Int J Gynaecol Obstet** 1996 Apr;53(1):41–9

Toxic epidermal necrolysis after mifepristone/gemeprost-induced abortion. Lecorvaisier-Pieto C, et al. **J Am Acad Dermatol** 1996 Jul; 35(1):112

Certainty and agnosticism about lethal injection in late abortion [comment] Spielman B. **J Clin Ethics** 1995 Fall; 6(3):270–2. Comment on: J Clin Ethics 1995 Fall;6(3):254–63.

Quo vadis? Fetal tissue transplantation. Michejda M. **J Hematother** 1996 Apr;5(2):185–8 (31 ref.)

On life and death: a commentary from Jewish perspective [letter] Steinman GD. **J Med Ethics** 1995 Dec;21(6):368

Adolescents' opinions about genetic risk information, prenatal diagnosis, and pregnancy termination. Decruyenaere M, et al. **J Med Genet** 1995 Oct;32(10):799–804; discussion 805

Reply to the commentary on Decruyenaere et al "adolescents' opinions about genetic risk information, prenatal diagnosis, and pregnancy termination" [letter] Evers-Kiebooms G, et al. **J Med Genet** 1995 Oct;32(10):836

Feticide followed by successful removal of pregnancy products in early abdominal pregnancy. Qureshi RN, et al. **J Obstet Gynaecol** 1995 Feb;21(1):13–6

The use of prostaglandins and oxytocin for transcervical recovery of bovine fetuses at days 33–58 of gestation. Lavoir MC, et al. **J Reprod Fertil** 1996 Jan;106(1):95–100

Elective acquaints medical students with abortion [news] Swartzberg D. **JAMA** 1995 Oct 11;274(14):1107–8

A de-facto end to abortion in USA? [editorial] **Lancet** 1996 Apr 20;347(9008):1055

A survey of women seeking termination of pregnancy in New South Wales. Adelson PL, et al. **Med J Aust** 1995 Oct 16;163(8):419–22

Methotrexate and misoprostol for abortion. **Med Lett Drugs Ther** 1996 Apr 26;38(973):39–40

Methotrexate and misoprostol to terminate early pregnancy [letter] Grunberg SM. **N Engl J Med** 1996 Feb 8; 334(6):399–400

Methotrexate and misoprostol to terminate early pregnancy [letter] Perrone J, et al. **N Engl J Med** 1996 Feb 8; 334(6):399; discussion 400

Methotrexate and misoprostol to terminate early pregnancy [letter] Swanson KT. **N Engl J Med** 1996 Feb 8;334(6):400

Methotrexate and misoprostol to terminate early pregnancy [letter] Yankowitz J, et al. **N Engl J Med** 1996 Feb 8; 334(6):399; discussion 400

New definition of still-birth [letter] Moynihan C. **N Z Med J** 1996 Apr 26;109(1020):151

Abortion education for residents. Castle MA, et al. **Obstet Gynecol** 1996 Apr;87(4):626–9

Cervical dilation from multiple laminaria tents used for abortion. Munsick RA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):726–9

Concentrated oxytocin plus low-dose prostaglandin E2 compared with prostaglandin E2 vaginal suppositories for second-trimester pregnancy termination. Owen J, et al. **Obstet Gynecol** 1996 Jul;88(1):110–3

Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Sawaya GF, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):884–90

Methotrexate and misoprostol when surgical abortion fails. Schaff EA, et al. **Obstet Gynecol** 1996 Mar;87(3):450–2

The adolescent's right to confidential care when considering abortion. American Academy of Pediatrics. Committee on Adolescence. **Pediatrics** 1996 May;97(5):746–51

Anti-life mentality in medical circles [editorial] de Muelenaere CW. **S Afr Med J** 1995 Nov;85(11):1147–50

Abortion—some practical and ethical considerations [letter; comment] Hyams AB. **S Afr Med J** 1994 Nov;84(11):783–4. Comment on: S Afr Med J 1995 Mar;85(3):183–4.

Abortion—some practical and ethical considerations [letter] [see comments] Loubser JS. **S Afr Med J** 1994 Nov; 84(11):783. Comment in: S Afr Med J 1995 Mar;85(3):183–4. **(Eng, Afr)**

Abortion—some practical and ethical considerations [letter] [see comments] Müller FR. **S Afr Med J** 1994 Nov; 84(11):782. Comment in: S Afr Med J 1995 Mar;85(3):183–4.

Abortion traditions in rural Jamaica. Sobo EJ. **Soc Sci Med** 1996 Feb;42(4):495–508

Successful pregnancy after bilateral internal iliac artery ligation monitored by color Doppler imaging. Papp Z, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):211–2

[Histological study of uterine cervix during termination of early pregnancy by mifepristone and prostaglandins] Weng L, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Sep; 30(9):522–5 (Eng. Abstr.) **(Chi)**

[Morning-after pill—abortion (letter)] Kieler F, et al. **Ugeskr Laeger** 1995 Oct 23;157(43):5995–6 **(Dan)**

[Contraception and abortion in the countries of eastern Europe] Hassoun D, et al. **Cah Sociol Demogr Med** 1995 Apr–Sep;35(2):99–123 (Eng. Abstr.) **(Fre)**

[Uterine rupture during induced abortion with prostaglandins in the second trimester] Zieger W, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):592–8 (43 ref.) (Eng. Abstr.) **(Ger)**

[Is abortion murder? (letter)] Schindling U. **Med Monatsschr Pharm** 1995 Nov;18(11):319 **(Ger)**

[Hospital day-surgery: comparative evaluation of 3 general anesthesia techniques] Rossi AE, et al. **Minerva Anestesiol** 1995 Jun;61(6):265–9 (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Post-abortion complications after interruption of pregnancy with misoprostol. Faúndes A, et al. **Adv Contracept** 1996 Mar;12(1):1–9

Risk of breast cancer among white women following induced abortion. Daling JR, et al. **Am J Epidemiol** 1996 Aug 15; 144(4):373–80

Delayed presentation of uterine perforation. Leibner EC. **Ann Emerg Med** 1995 Nov;26(5):643–6

Combined methotrexate and misoprostol for early induced abortion [letter; comment] Danis PG. **Arch Fam Med** 1996 May;5(5):264. Comment on: Arch Fam Med 1995 Sep;4(9):774–9.

Protecting adolescent girls against tetanus. Induced abortion can predispose to tetanus [letter; comment] Akhter S, et al. **BMJ** 1995 Sep 16;311(7007):748–9. Comment on: BMJ 1995 Jul 8;311(6997):73–4.

Factors associated with immediate abortion complications. Ferris LE, et al. **Can Med Assoc J** 1996 Jun 1; 154(11):1677–85

Complications of induced abortions and their preventions in Ghana. Lassey AT. **East Afr Med J** 1995 Dec;72(12):774–7

Gas embolism complicating obstetric or gynecologic procedures. Case reports and review of the literature. Mushkat Y, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):97–103 (54 ref.)

Selections from current literature: abortion, breast cancer and causal inferences. Rahman MI, et al. **Fam Pract** 1996 Apr; 13(2):194–200 (11 ref.)

Induced abortions and risk of ectopic pregnancy. Parazzini F, et al. **Hum Reprod** 1995 Jul;10(7):1841–4

Abortion and the risk of breast cancer: a case-control study in Greece [letter; comment] Gammon MD, et al. **Int J Cancer** 1995 Nov 27;63(5):761. Comment on: Int J Cancer 1995 Apr 10;61(2):181–4.

Abortion and breast cancer risk. Tavani A, et al. **Int J Cancer** 1996 Feb 8;65(4):401–5

Induced midtrimester abortion and future fertility—where are we today? Lurie S, et al. **Int J Fertil Menopausal Stud** 1995 Nov–Dec;40(6):311–5 (39 ref.)

Midtrimester uterine rupture. A case report. Levrant SG, et al. **J Reprod Med** 1996 Mar;41(3):186–90 (28 ref.)

Abortion and the risk of breast cancer. Is there a believable association? [editorial; comment] Gammon MD, et al. **JAMA** 1996 Jan 24–31;275(4):321–2. Comment on: JAMA 1996 Jan 24–31;275(4):283–7.

Uterine perforation during elective first trimester abortions: a 13-year review. Chen LH, et al. **Singapore Med J** 1995 Feb;36(1):63–7

Clinical teratology counseling and consultation case report [letter; comment] Lipson T. **Teratology** 1995 Sep; 52(3):126–7. Comment on: Teratology 1995 Feb;51(2):120–2.

[Is illegal abortion a secure procedure? A case report] Iris JM, et al. **Ginecol Obstet Mex** 1996 Jun;64:261–4 (Eng. Abstr.) **(Spa)**

ECONOMICS

The effect of expansions in Medicaid income eligibility on abortion. Joyce T, et al. **Demography** 1996 May; 33(2):181–92

Abortion—who should decide? [letter] Hart-Davis SJ. **S Afr Med J** 1995 Jul;85(7):682, 684–5

HISTORY

Linking midwives and abortion in the Progressive Era. Reagan LJ. **Bull Hist Med** 1995 Winter;69(4):569–98

METHODS

Uterine evacuation by vaginal misoprostol after second trimester pregnancy interruption. Bugalho A, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):270–3

Effect of vaginal misoprostol application for cervical softening in pregnancy interruption before ten weeks of gestation. Fiçicioğlu C, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):54–6

Combined methotrexate and misoprostol for early induced abortion [letter; comment] Camosy PA. **Arch Fam Med** 1996 May;5(5):263–4. Comment on: Arch Fam Med 1995 Sep;4(9):774–9.

Combined methotrexate and misoprostol for early induced abortion [letter; comment] Lauber JJ. **Arch Fam Med** 1996 May;5(5):263; discussion 264. Comment on: Arch Fam Med 1995 Sep;4(9):774–9.

Combined methotrexate and misoprostol for early induced abortion [letter; comment] Lichtenhan JB. **Arch Fam Med** 1996 May;5(5):263; discussion 264. Comment on: Arch Fam Med 1995 Sep;4(9):774–9.

A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol. Webster D, et al. **Br J Obstet Gynaecol** 1996 Jul; 103(7):706–9

Medical abortion: what does the research tell us? [editorial; comment] [see comments] Ferris LE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):185–7. Comment on: Can Med Assoc J 1996 Jan 15;154(2):165–70. Comment in: Can Med Assoc J 1996 Jul 1;155(1):18–9.

Issues raised by medical abortion [letter; comment] Guilbert E, et al. **Can Med Assoc J** 1996 Jul 1;155(1):19. Comment on: Can Med Assoc J 1996 Jan 15;154(2):165–70.

Issues raised by medical abortion [letter; comment] Reynolds JL. **Can Med Assoc J** 1996 Jul 1;155(1):19–20. Comment on: Can Med Assoc J 1996 Jan 15;154(2):165–70.

Abortion induced with methotrexate and misoprostol [see comments] Wiebe ER. **Can Med Assoc J** 1996 Jan 15; 154(2):165–70. Comment in: Can Med Assoc J 1996 Jan 15;154(2):185–7. Comment in: Can Med Assoc J 1996 Jul 1;155(1):19. Comment in: Can Med Assoc J 1996 Jul 1;155(1):19–20.

Acceptability of medical abortion in early pregnancy. Winikoff B. **Fam Plann Perspect** 1995 Jul–Aug;27(4):142–8, 185 (36 ref.)

Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Baird DT, et al. **Hum Reprod** 1995 Jun;10(6):1521–7

A comparative analysis of fall in haemoglobin following abortions conducted by mifepristone (600 mg) and vacuum aspiration. Thonneau P, et al. **Hum Reprod** 1995 Jun; 10(6):1512–5

Cervical dilation from laminaria tents and synthetic osmotic dilators used for 6 hours before abortion. Kline SB, et al. **Obstet Gynecol** 1995 Dec;86(6):931–5

A double-blind randomized comparison of lidocaine and saline for cervical anesthesia. Miller L, et al. **Obstet Gynecol** 1996 Apr;87(4):600–4

Abortion at 18–22 weeks by laminaria dilation and evacuation. Schneider D, et al. **Obstet Gynecol** 1996 Sep; 88(3):412–4

[Antiprogesterones—new prospects in induced abortion] Karag ozov I, et al. **Akush Ginekol (Sofiia)** 1994;33(2):47–9 **(Bul)**

[Induced delivery in fetal malformations] Boog G. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:54–6 (22 ref.) **(Fre)**

[Randomized study of sulprostone versus misoprostol in the cervical preparation before elective abortion in nulliparous women] Schaub B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):505–10 (Eng. Abstr.) **(Fre)**

[The therapeutic contribution of prostaglandins in obstetrics] Lambotte R. **Rev Med Liege** 1996 Jan;51(1):139–41 **(Fre)**

[Methotrexate and misoprostol for drug-induced abortion in the first trimester] Wolff F. **Dtsch Med Wochenschr** 1995 Dec 22;120(51–52):1804 **(Ger)**

[Termination of pregnancy in the 2nd trimester by serial administration of gemeprost vaginal suppositories. A retrospective study] Krauss T, et al. **Geburtshilfe Frauenheilkd** 1994 Nov;54(11):623–6 (Eng. Abstr.) **(Ger)**

[Premature termination of pregnancy in the 2nd and 3rd trimester. Serial administration of 1 mg gemeprost vaginal suppositories versus intravenous sulproston] Müller T, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):234–8 (Eng. Abstr.) **(Ger)**

ABORTION, INDUCED

PSYCHOLOGY

Termination of pregnancy and psychiatric morbidity. Gilchrist AC, et al. **Br J Psychiatry** 1995 Aug;167(2):243–8

The effects on the family of miscarriage, termination for abnormality, stillbirth and neonatal death. Thomas J. **Child Care Health Dev** 1995 Nov;21(6):413–24

Psychosocial characteristics of psychiatric inpatients with reproductive losses. Thomas T, et al. **J Health Care Poor Underserved** 1996;7(1):15–23

The abortion decision: reasons and ambivalence. Allanson S, et al. **J Psychosom Obstet Gynaecol** 1995 Sep; 16(3):123–36

Teenage pregnancy: a comparative study of teenagers choosing termination of pregnancy or antenatal care [see comments] Pearson VA, et al. **J R Soc Med** 1995 Jul; 88(7):384–8. Comment in: J R Soc Med 1995 Jul;88(7):369–71.

The pregnancy that doesn't stay: the practice and perception of abortion by Ekiti Yoruba women. Renne EP. **Soc Sci Med** 1996 Feb;42(4):483–94

[Induced abortion after the 12th week of pregnancy in the county of Arhus 1993–1994. Psychological consequences] Meyer L, et al. **Ugeskr Laeger** 1996 Jul 29;158(31):4395–8 (Eng. Abstr.) **(Dan)**

[Abortion as experienced by the physician in charge—attitudes in the conflict area of abortion] Poettgen H. **Arch Gynecol Obstet** 1995;257(1–4):499–510 **(Ger)**

[Psychological coping with abortion by the woman] Petersen P. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):M143–5 **(Ger)**

STANDARDS

Acceptability of medical abortion with methotrexate and misoprostol. Creinin MD, et al. **Contraception** 1995 Jul; 52(1):41–4

[Indications for pregnancy termination in cases of pre-eclampsia, hypertension, intrauterine growth retardation, liver and heart disease] Uzan S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:33–40 (54 ref.) **(Fre)**

STATISTICS & NUMERICAL DATA

Towards regional equality in family planning: teenage pregnancies and abortions in Finland from 1976 to 1993. Kosunen EA, et al. **Acta Obstet Gynecol Scand** 1996 Jul; 75(6):540–7

Repeat abortion and use of primary care health services. Westfall JM, et al. **Fam Plann Perspect** 1995 Jul–Aug; 27(4):162–5

Pregnancy termination and risk of breast cancer [letter; comment] Henshaw SK. **JAMA** 1996 Jul 3;276(1):31; discussion 31–2. Comment on: JAMA 1996 Jan 24–31;275(4):283–7.

Pregnancy termination in relation to risk of breast cancer [see comments] Newcomb PA, et al. **JAMA** 1996 Jan 24–31;275(4):283–7. Comment in: JAMA 1996 Jan 24–31;275(4):321–2. Comment in: JAMA 1996 Jul 3;276(1):31; discussion 31–2. Comment in: JAMA 1996 Jul 3;276(1):31–2.

Pregnancy, abortion, and birth rates among US adolescents—1980, 1985, and 1990 [see comments] Spitz AM, et al. **JAMA** 1996 Apr 3;275(13):989–94. Comment in: JAMA 1996 Apr 3;275(13):1030.

Abortion and fertility regulation [see comments] Kulczycki A, et al. **Lancet** 1996 Jun 15;347(9016):1663–8 (41 ref.). Comment in: Lancet 1996 Aug 17;348(9025):478; discussion 478–9.

The health of Australia's mothers and babies [letter] Grover SR, et al. **Med J Aust** 1996 Jul 1;165(1):60

Detecting induced abortions from reports of pregnancy terminations in DHS calendar data. Magnani RJ, et al. **Stud Fam Plann** 1996 Jan–Feb;27(1):36–43

Determinants of induced abortion and their policy implications in four counties in north China. Ping T, et al. **Stud Fam Plann** 1995 Sep–Oct;26(5):278–86

TRENDS

UK "pill scare" led to abortion increase [news] Ramsay S. **Lancet** 1996 Apr 20;347(9008):1109

UTILIZATION

The effect of expansions in Medicaid income eligibility on abortion. Joyce T, et al. **Demography** 1996 May; 33(2):181–92

Pregnancy terminations after oral contraception scare [letter] Child TJ, et al. **Lancet** 1996 May 4;347(9010):1260–1

Infant mortality under scrutiny [letter; comment] Bowes WA Jr. **N C Med J** 1995 Sep;56(9):412–3. Comment on: N C Med J 1995 Jul;56(7):302–6.

[Voluntary interruptions of pregnancy (VIP) because of congenital malformations recorded in the territory of the ex Local Health Unit 13—the Livorno area (1992–1994)] Baggiani A, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):110–1 **(Ita)**

VETERINARY

Effect of flunixin meglumine on endogenous prostaglandin F2 alpha secretion during cloprostenol-induced abortion in mares. Daels PF, et al. **Am J Vet Res** 1995 Dec; 56(12):1603–10

Practical use of a combination of a dopamine agonist and a synthetic prostaglandin analogue to terminate unwanted pregnancy in dogs. Onclin K, et al. **J Small Anim Pract** 1996 May;37(5):211–6

ABORTION, LEGAL

Ambivalence among women applying for abortion. Husfeldt C, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):813–7

Is misoprostol the drug of choice for induced cervical ripening in early pregnancy termination? Platz-Christensen JJ, et al. **Acta Obstet Gynecol Scand** 1995 Nov; 74(10):809–12

Reasons for pregnancy termination: negligence or failure of contraception? Savonius H, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):818–21

Impact of prenatal diagnosis and elective termination on prevalence and risk estimates of neural tube defects in California, 1989–1991. Velie EM, et al. **Am J Epidemiol** 1996 Sep 1;144(5):473–9

Topics for our times: public health on the line—abortion and beyond [editorial] Chavkin W. **Am J Public Health** 1996 Sep;86(9):1204–6

US poised to outlaw late abortion technique [news] Bozalis D. **BMJ** 1995 Nov 18;311(7016):1319–20

Light the blue touchpaper and stand well clear. Duncan N. **BMJ** 1996 Aug 17;313(7054):432

Selective abortions hit the headlines [news] Dyer C. **BMJ** 1996 Aug 17;313(7054):380

Bavaria threatens to reduce abortion access [news] Goldbeck-Wood S. **BMJ** 1996 May 4;312(7039):1118

Dutch investigation launched into abortion clinics [news] Sheldon T. **BMJ** 1996 Mar 23;312(7033):727–8

Prenatal testing leads to row in The Netherlands [news] Sheldon T. **BMJ** 1995 Nov 4;311(7014):1187

Right to choose [letter] White M. **BMJ** 1995 Nov 18; 311(7016):1373

Emergency contraception in the United Kingdom and The Netherlands. Glasier A, et al. **Fam Plann Perspect** 1996 Mar–Apr;28(2):49–51 (17 ref.)

Abortion: the antithesis of womanhood? Timpson J. **J Adv Nurs** 1996 Apr;23(4):776–85 (121 ref.)

Teenage abortion in Germany: with reference to the legal system in the United States. Belling DW, et al. **J Contemp Health Law Policy** 1996 Spring;12(2):475–502 (128 ref.)

An obligation to provide abortion services: what happens when physicians refuse? Meyers C, et al. **J Med Ethics** 1996 Apr;22(2):115–20

Abortion and fertility regulation [letter; comment] Kelly J. **Lancet** 1996 Aug 17;348(9025):478; discussion 478–9. Comment on: Lancet 1996 Jun 15;347(9016):1663–8.

Abortion and fertility regulation [letter; comment] Pillaye J. **Lancet** 1996 Aug 17;348(9025):478; discussion 478–9. Comment on: Lancet 1996 Jun 15;347(9016):1663–8.

Abortion and fertility regulation [letter; comment] Rubiales AS. **Lancet** 1996 Aug 17;348(9025):478; discussion 478–9. Comment on: Lancet 1996 Jun 15;347(9016):1663–8.

Fetal rights versus the female body: contested domains. Heriot MJ. **Med Anthropol Q** 1996 Jun;10(2):176–94

Selective abortion after prenatal diagnosis. Schubert-Lehnhardt V. **Med Law** 1996;15(1):75–81

Referral for abortion [letter] Harison CS. **N Z Med J** 1996 Jul 26;109(1026):284

Referral for abortion [letter] Milne J, et al. **N Z Med J** 1996 Jul 26;109(1026):284

Parental consent for a minor's abortion [letter] Casner PD. **Pharos** 1996 Spring;59(2):44–5; discussion 46

Parental consent for a minor's abortion [letter] Dickstein LJ. **Pharos** 1996 Spring;59(2):44; discussion 46

Parental consent for a minor's abortion [letter] Fleming TN. **Pharos** 1996 Spring;59(2):44; discussion 46

Parental consent for a minor's abortion [letter] Herrington P. **Pharos** 1996 Spring;59(2):45; discussion 46

Parental consent for a minor's abortion [letter] Karlin E. **Pharos** 1996 Spring;59(2):45; discussion 46

Parental consent for a minor's abortion [letter] Nallin EP. **Pharos** 1996 Spring;59(2):46

Parental consent for a minor's abortion [letter] Saberman J. **Pharos** 1996 Spring;59(2):45; discussion 46

Abortion laws and infanticide. Lester D. **Psychol Rep** 1995 Jun;76(3 Pt 2):1370

South African geneticists' attitudes to the present Abortion and Sterilisation Act of 1975. Christianson MA, et al. **S Afr Med J** 1996 May;86(5):534–6

Abortion—some further considerations [letter] Frank AG. **S Afr Med J** 1996 Apr;86(4):384

Abortion—some further considerations [letter] Harle JO. **S Afr Med J** 1996 Apr;86(4):383–4

Abortion—some further considerations [letter] Hyams AB. **S Afr Med J** 1996 Apr;86(4):382–3

[Late pregnancy interruption: how tough is the law?] den Hartogh GA. **Ned Tijdschr Geneeskd** 1996 Mar 16; 140(11):621–4 **(Dut)**

[Decision paths and foundation of the Karlsruhe verdict] Grashoff K. **Arch Gynecol Obstet** 1995;257(1–4):372–6 **(Ger)**

[2 lives—claims and reality: an expanded edition of the opening address at the 23 August 1994 Congress] Hepp H. **Arch Gynecol Obstet** 1995;257(1–4):XVII–XXXVI **(Ger)**

[Reform of section 218 StGB reform—analysis of parliamentary decision] Hiersche HD. **Arch Gynecol Obstet** 1995;257(1–4):377–80 **(Ger)**

[Counseling as procedural model for illegal, but not punishable abortion] Schreiber HL. **Arch Gynecol Obstet** 1995;257(1–4):381–8 **(Ger)**

[The 2nd legal abortion ruling of the German Legislative Court and its consequences] Tröndle H. **Geburtshilfe Frauenheilkd** 1994 Nov;54(11):M147–50 **(Ger)**

[The "hidden" indication (editorial)] Haller U, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):1–2 **(Ger)**

[Is abortion murder? (editorial)] Werning C. **Med Monatsschr Pharm** 1995 Sep;18(9):251 **(Ger)**

[Who should perform abortion counseling? (letter)] Aavitsland P. **Tidsskr Nor Laegeforen** 1995 Nov 30; 115(29):3659 **(Nor)**

[Abortion legislation and physician's role (see comments)] Bergsjø P. **Tidsskr Nor Laegeforen** 1996 Apr 20; 116(10):1207–8. Comment in: Tidsskr Nor Laegeforen 1996 May 20;116(13):1616–7. **(Nor)**

[Abortion proclamation (letter)] Gøthesen O. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):536–7 **(Nor)**

[Who should perform abortion counseling? (letter)] Heskestad S. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3659 **(Nor)**

[Who should perform abortion counseling? (letter)] Vassbø K. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3659–60 **(Nor)**

[Apropos of the project to liberalize the abortion law in Spain (editorial)] Gonzalo Sanz LM. **Rev Med Univ Navarra** 1995 Jul–Sep;39(3):124–5 **(Spa)**

ADVERSE EFFECTS

Preventing pelvic infection after abortion [editorial] Stevenson MM, et al. **Int J STD AIDS** 1995 Sep–Oct; 6(5):305–12 (61 ref.)

The management of the perforated uterus in conjunction with 1st trimester abortions. Weitzner HB. **J Med Assoc State Ala** 1981 Feb;50(8):13–6

[Legal abortion—different methods and complications] Stefanov B. **Akush Ginekol (Sofiia)** 1995;34(1):27–30 (29 ref.) **(Bul)**

METHODS

[Legal abortion—different methods and complications] Stefanov B. **Akush Ginekol (Sofiia)** 1995;34(1):27–30 (29 ref.) **(Bul)**

[The relationship between the methods for performing voluntary pregnancy interruption and the sociodemographic characteristics of the women: the differences between Italian and non-EEC women in Rome, 1987–1993] Papini P, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):115–8 **(Ita)**

PSYCHOLOGY

Continuing with pregnancy after a diagnosis of lethal abnormality: experience of five couples and recommendations for management. Chitty LS, et al. **BMJ** 1996 Aug 24;313(7055):478–80

Seeking influence through characterizing self-categories: an analysis of anti-abortionist rhetoric. Reicher S, et al. **Br J Soc Psychol** 1996 Jun;35 (Pt 2):297–311

[Abortions on demand in adolescents] Porozhanova V, et al. **Akush Ginekol (Sofiia)** 1994;33(2):20–3 (Eng. Abstr.) **(Bul)**

STANDARDS

Reference to abortion [letter] Thomson KJ. **N Z Med J** 1996 Jun 14;109(1023):215

STATISTICS & NUMERICAL DATA

Effect of CSM's warning about safety of third generation oral contraceptives. Abortions increased by nearly 8% in Norway [letter] Iversen OE, et al. **BMJ** 1996 Aug 10; 313(7053):363–4

HIV infection among women undergoing abortion in Montreal [see comments] Remis RS, et al. **Can Med Assoc J** 1995 Nov 1;153(9):1271–9. Comment in: Can Med Assoc J 1996 Feb 15;154(4):444, 446.

Abortion surveillance: preliminary data—United States, 1993. From the Centers for Disease Control and Prevention. **JAMA** 1996 Apr 10;275(14):1073

Abortion surveillance—United States, 1992. Koonin LM, et al. **MMWR CDC Surveill Summ** 1996 May 3;45(3):1–36

Abortion surveillance: preliminary data—United States, 1993. **MMWR Morb Mortal Wkly Rep** 1996 Mar 22;45(11):235–8

Office abortion services for women: private physician providers. Wyatt L Jr, et al. **Women Health** 1995; 23(2):47–65

[Late abortions in the county of Northern Jutland] Fensbo C, et al. **Ugeskr Laeger** 1996 Jun 24;158(26):3776–8 (Eng. Abstr.) **(Dan)**

TRENDS

Abortion in Turkey: a matter of state, family or individual decision. Gürsoy A. **Soc Sci Med** 1996 Feb;42(4):531–42

Women's perspectives on abortion in Romania. Johnson BR, et al. **Soc Sci Med** 1996 Feb;42(4):521–30

Abortion law and practice in China: an overview with comparisons to the United States. Rigdon SM. **Soc Sci Med** 1996 Feb;42(4):543–60 (96 ref.)
Abortion from a crosscultural perspective: an introduction. Rylko-Bauer B. **Soc Sci Med** 1996 Feb;42(4):479–82

UTILIZATION

Abortions in rural Idaho: physicians' attitudes and practices. Rosenblatt RA, et al. **Am J Public Health** 1995 Oct; 85(10):1423–5
[The surveillance of voluntary interruptions of pregnancy in Umbria] Bellini P, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):112–4 **(Ita)**
[Voluntary interruption of pregnancy: its epidemiology and the prevention possibilities] Spinelli A, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):71–3 **(Ita)**

ABORTION, MISSED

GENETICS

Image analysis DNA densitometry measurements on complete and partial hydatidiform mole and nonmolar products of conception. Williams RA, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):300–5

PATHOLOGY

Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Nayar R, et al. **Hum Pathol** 1996 Feb; 27(2):201–6 (36 ref.)
Image analysis DNA densitometry measurements on complete and partial hydatidiform mole and nonmolar products of conception. Williams RA, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):300–5

ULTRASONOGRAPHY

The prevalence of non-viable pregnancy at 10–13 weeks of gestation. Pandya PP, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):170–3

ABORTION ON DEMAND see **ABORTION, LEGAL**

ABORTION SEEKERS see **ABORTION APPLICANTS**

ABORTION, SEPTIC

Toxic shock syndrome [letter; comment] Gill K. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):119. Comment on: J Obstet Gynecol Neonatal Nurs 1995 Jul–Aug;24(6):557–61.

DIAGNOSIS

[Septic abortion in Campylobacter jejuni infection] Abderhalden R, et al. **Geburtshilfe Frauenheilkd** 1995 Oct; 55(10):599–601 (14 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Clostridium perfringens septicemia associated with foodborne toxic infection and abortion] Lantelme P, et al. **Ann Fr Anesth Reanim** 1995;14(4):359–61 (Eng. Abstr.) **(Fre)**

VIROLOGY

Detection of herpes simplex virus DNA in spontaneous abortions from HIV-positive women using non-isotopic in situ hybridization [letter; comment] Fox H. **J Pathol** 1996 May;179(1):125. Comment on: J Pathol 1995 Aug;176(4):399–402.

ABORTION, SPONTANEOUS see **ABORTION**

ABORTION, THERAPEUTIC

Arthrogryposis associated with unsuccessful attempts at termination of pregnancy. Hall JG. **Am J Med Genet** 1996 May 3;63(1):293–300 (40 ref.)
Ballantyne syndrome caused by a large placental chorioangioma. Dorman SL, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1632–3
Obstetric outcome after failed termination of pregnancy—a report of two cases. Ricciotti HA, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1619–20
The role of synthetic prostaglandines in the induction of therapeutical miscarriage. Rolfini G, et al. **Clin Exp Obstet Gynecol** 1995;22(4):345–9
Patient attitudes to prenatal screening and termination of pregnancy at Groote Schuur Hospital: a two year prospective study. Viljoen D, et al. **East Afr Med J** 1996 May;73(5):327–9
Pain control in abortion. Wiebe ER, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):41–6
Epidemiology of Down's syndrome in a Scottish city. Lopez PM, et al. **Paediatr Perinat Epidemiol** 1995 Jul;9(3):331–40
Patient good versus patient good [editorial] Benjamin DR. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):iii–iv
[Apert syndrome. Ultrasonic diagnosis, obstetrical management] Delinière F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):613–7 (Eng. Abstr.) **(Fre)**
[Ethical problems with the current French practice in therapeutic abortions. Part 3: resolving moral dilemmas in fetal medicine] Gold F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):727–32 (Eng. Abstr.) **(Fre)**
[Ethical problems with the current French practice in therapeutic abortions. Part 2: survey by questionnaire in 15 french university hospitals] Gold F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):722–6 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin. Phillips K, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr; 65(2):175–6
Placenta percreta post evacuation: an unusual uterine mass on MRI. Neish AS, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):824–7
Uterine packing in the combined management of obstetrical hemorrhage. Wittich AC, et al. **Mil Med** 1996 Mar; 161(3):180–2

METHODS

Same-day Dilapan insertion before second-trimester dilatation and evacuation for a fetal anomaly or death. Patsner B. **J Reprod Med** 1996 Feb;41(2):71–2
[Mifepristone and misoprostol in therapeutic abortions] Jannet D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(3):277–82 (24 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

[Ethical problems raised by the current French practice of therapeutic abortions. Part I: prospective study for 24 months at the University Hospital of Tours (76 cases)] Gold F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(6):586–94 **(Fre)**

ABORTION, THREATENED

BLOOD

[Changes in the level of serum trophoblastic beta 1-globulin in threatened abortion] Shmagel' KV, et al. **Akush Ginekol (Mosk)** 1995;(6):22–5 (Eng. Abstr.) **(Rus)**
[Adrenal cortex hormones in the mother and fetus in premature labor] Ostró A, et al. **Ceska Gynekol** 1996 Apr; 61(2):86–90 (Eng. Abstr.) **(Slo)**

COMPLICATIONS

Antepartum haemorrhage: the influence of first trimester uterine bleeding. Obed JY, et al. **West Afr J Med** 1996 Jan–Mar;15(1):61–3

DIAGNOSIS

[Value of serum placental protein 14 determination in differential diagnosis of abnormal early pregnancy] Römer T, et al. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):490–2 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Tocolytic substituent treatment with Magnerot in threatened abortions and premature labor from the 16th to the 36th gestational week] Damianov L, et al. **Akush Ginekol (Sofiia)** 1995;34(3):78–81 (Eng. Abstr.) **(Bul)**

ETIOLOGY

The significance of extrachorionic membrane separation in threatened miscarriage. Farrell T, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):926–8

ULTRASONOGRAPHY

Women with bleeding in the first 20 weeks of pregnancy: value of general practice ultrasound in detecting fetal heart movement. Everett CB, et al. **Br J Gen Pract** 1996 Jan; 46(402):7–9

ABORTION, VETERINARY

Abortions, fetal death, and stillbirths in pregnant pygmy goats inoculated with tachyzoites of Neospora caninum. Lindsay DS, et al. **Am J Vet Res** 1995 Sep;56(9):1176–80
Abortion in heifers inoculated with a thymidine kinase-negative recombinant of bovine herpesvirus 1. Miller JM, et al. **Am J Vet Res** 1995 Jul;56(7):870–4
An aborted fetus with a presumptive 60,XX,rob(7;21) karyotype in Japanese black cattle. Hanada H, et al. **Hereditas** 1995;123(1):91–3
The use of prostaglandins and oxytocin for transcervical recovery of bovine fetuses at days 33–58 of gestation. Lavoir MC, et al. **J Reprod Fertil** 1996 Jan;106(1):95–100
Practical use of a combination of a dopamine agonist and a synthetic prostaglandin analogue to terminate unwanted pregnancy in dogs. Onclin K, et al. **J Small Anim Pract** 1996 May;37(5):211–6
Tissue-invasive Tritrichomonas foetus in four aborted bovine fetuses. Rhyan JC, et al. **J Vet Diagn Invest** 1995 Jul; 7(3):409–12
Behaviour of a high-temperature-requirement A (HtrA) deletion mutant of Brucella abortus in goats. Elzer PH, et al. **Res Vet Sci** 1996 Jan;60(1):48–50
[Character of reproductive losses in bank vole populations living in a habitat polluted with toxic substances] Bezel' VS, et al. **Dokl Akad Nauk** 1995 Nov;345(1):135–7 **(Rus)**

CHEMICALLY INDUCED

Oestrogens for mismating in the bitch [letter] Sutton D. **Vet Rec** 1995 Jun 10;136(23):596

EPIDEMIOLOGY

Trends in bovine abortions submitted to the Ontario Ministry of Agriculture, Food and Rural Affairs, 1993–1995. Alves D, et al. **Can Vet J** 1996 May;37(5):287–8
Evaluation of abortions in cattle attributable to neosporosis in selected dairy herds in California. Anderson ML, et al. **J Am Vet Med Assoc** 1995 Nov 1;207(9):1206–10
Patterns of prenatal survival in the common marmoset (Callithrix jacchus). Jaquish CE, et al. **J Med Primatol** 1996 Jan;25(1):57–63
Neospora abortion in cattle in Ireland [letter] Collery PM. **Vet Rec** 1995 Jun 10;136(23):595
Equine viral arteritis with abortions: serological and virological evidence in Germany. Eichhorn W, et al. **Zentralbl Veterinarmed [B]** 1995 Nov;42(9):573–6

ETIOLOGY

Investigation of pregnancy losses in beef cattle herds associated with Neospora sp. infection. Hoar BR, et al. **Can Vet J** 1996 Jun;37(6):364–6
Serological and microbiological findings on 3 farms with equine leptospiral abortions [see comments] Williams DM, et al. **Equine Vet J** 1994 Mar;26(2):105–8. Comment in: Equine Vet J 1994 Mar;26(2):88.
Pregnancy failure following vaginal infection of sheep with Chlamydia psittaci prior to breeding. Papp JR, et al. **Infect Immun** 1996 Apr;64(4):1116–25
Abortifacient response and plasma vasoconstrictive activity after feeding needles from ponderosa pine trees to cattle and sheep. Short RE, et al. **J Anim Sci** 1995 Jul; 73(7):2102–4
Reproductive performance of dairy herds infected with Leptospira interrogans serovar hardjo relative to the year of diagnosis. Dhaliwal GS, et al. **Vet Rec** 1996 Mar 23; 138(12):272–6
[Studies of facilities with increased abortion rates in cattle] Hässig M, et al. **Schweiz Arch Tierheilkd** 1995;137(9):445–53 (Eng. Abstr.) **(Ger)**

METABOLISM

Early embryo loss is associated with local production of nitric oxide by decidual mononuclear cells. Haddad EK, et al. **J Exp Med** 1995 Oct 1;182(4):1143–51

MICROBIOLOGY

Antigenic and restriction enzyme analysis of Campylobacter spp associated with abortion in sheep. Delong WJ, et al. **Am J Vet Res** 1996 Feb;57(2):163–7
Epizootic bovine abortion in a dairy herd: characterization of a Chlamydia psittaci isolate and antibody response. Griffiths PC, et al. **Br Vet J** 1995 Nov–Dec;151(6):683–93
How important are leptospiral infections as a cause of equine disease? [editorial; comment] Wood JL. **Equine Vet J** 1994 Mar;26(2):88. Comment on: Equine Vet J 1994 Mar;26(2):105–8.
Abortion in a mare associated with Corynebacterium pseudotuberculosis infection. Poonacha KB, et al. **J Vet Diagn Invest** 1995 Oct;7(4):563–4
Ovine abortion caused by Yersinia pseudotuberculosis [letter] Otter A. **Vet Rec** 1996 Feb 10;138(6):143–4
A retrospective study of bovine abortions associated with Bacillus licheniformis. Agerholm JS, et al. **Zentralbl Veterinarmed [B]** 1995 Jun;42(4):225–34
Evaluation of immunogenicity of Campylobacter strains isolated from ovine abortions by laboratory test systems. Diker KS, et al. **Zentralbl Veterinarmed [B]** 1995 Mar; 42(1):35–41
[Leptospirosis in animal reproduction: III. Role of the hardjo serovar in bovine leptospirosis in Rio de Janeiro, Brazil] Lilenbaum W, et al. **Rev Latinoam Microbiol** 1995 Apr–Jun; 37(2):87–92 (Eng. Abstr.) **(Por)**

PARASITOLOGY

A case of Neospora associated bovine abortion in Sweden. Holmdahl OJ, et al. **Acta Vet Scand** 1995;36(2):279–81
Neospora abortions in eastern Ontario dairy herds. Duivenvoorden J, et al. **Can Vet J** 1995 Oct;36(10):623
Neosporosis-associated abortion in a dairy goat. Dubey JP, et al. **J Am Vet Med Assoc** 1996 Jan 15;208(2):263–5
The prevalence of neosporosis in aborted bovine foetuses submitted to the Allerton Regional Veterinary Laboratory. Jardine JE, et al. **Onderstepoort J Vet Res** 1995 Sep; 62(3):207–9
Abortion due to Neospora species in a dairy herd. Dannatt L, et al. **Vet Rec** 1995 Nov 25;137(22):566–7
Diagnosis and prevalence of neosporosis in cattle in Northern

Ireland. McNamee PT, et al. **Vet Rec** 1996 Apr 27; 138(17):419–20

A survey of the incidence of Neospora caninum infection in aborted and stillborn bovine fetuses in England and Wales. Otter A, et al. **Vet Rec** 1995 Jun 17;136(24):602–6

PATHOLOGY

Pathology of bovine abortion and newborn calf death caused by dual infection with Chlamydia psittaci and infectious bovine rhinotracheitis virus. Ogino H, et al. **J Vet Med Sci** 1996 Jan;58(1):67–70

Histopathological and immunofluorescent studies on transplacental infection in experimentally induced abortion by equine arteritis virus. Wada R, et al. **Zentralbl Veterinarmed [B]** 1996 Apr;43(2):65–74

PREVENTION & CONTROL

An oligomer of the major outer membrane protein of Chlamydia psittaci is recognized by monoclonal antibodies which protect mice from abortion. de Sa C, et al. **Infect Immun** 1995 Dec;63(12):4912–6

Efficacy of a temperature-sensitive modified-live bovine herpesvirus type-1 vaccine against abortion and stillbirth in pregnant heifers. Cravens RL, et al. **J Am Vet Med Assoc** 1996 Jun 15;208(12):2031–4

Efficacy trials with tissue-culture grown, inactivated vaccines against chlamydial abortion in sheep. Jones GE, et al. **Vaccine** 1995;13(8):715–23

Application of an equine herpesvirus 1 (EHV1) type-specific ELISA to the management of an outbreak of EHV1 abortion. Drummer HE, et al. **Vet Rec** 1995 Jun 10; 136(23):579–81

VIROLOGY

Comparison of detection methods for bovine viral diarrhea virus in bovine abortions and neonatal death. Ellis JA, et al. **J Vet Diagn Invest** 1995 Oct;7(4):433–6

EHV-1-induced abortion in mice and its relationship to stage of gestation. Awan AR, et al. **Res Vet Sci** 1995 Sep; 59(2):139–45

ABRIN

Growth suppression of human colorectal carcinoma in nude mice by monoclonal antibody C27-abrin A chain conjugate. Tsai LC, et al. **Dis Colon Rectum** 1995 Oct; 38(10):1067–74

CHEMISTRY

Sialylated oligosaccharide-specific plant lectin from Japanese elderberry (Sambucus sieboldiana) bark tissue has a homologous structure to type II ribosome-inactivating proteins, ricin and abrin. cDNA cloning and molecular modeling study. Kaku H, et al. **J Biol Chem** 1996 Jan 19; 271(3):1480–5

Crystallization and preliminary crystallographic analysis of recombinant abrin-a A-chain with ribosome inactivating activity. Kohno T, et al. **Proteins** 1995 Sep;23(1):126–7

ABRUPTIO PLACENTAE

The Kleihauer-Betke test. Clinical utility, indication, and correlation in patients with placental abruption and cocaine use. Emery CL, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1032–7

CHEMICALLY INDUCED

Cocaine-associated rhabdomyolysis causing renal failure in pregnancy. Lampley EC, et al. **Obstet Gynecol** 1996 May; 87(5 Pt 2):804–6

COMPLICATIONS

Placental abruption in association with advanced abdominal pregnancy. A case report. Yu S, et al. **J Reprod Med** 1995 Oct;40(10):731–5

Placental abruption and its association with hypertension and prolonged rupture of membranes: a methodologic review and meta-analysis. Ananth CV, et al. **Obstet Gynecol** 1996 Aug;88(2):309–18

[Consumption coagulopathy during pregnancy: a case of afibrinogenemia during the second trimester] Debiéve F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):860–2 (9 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

The occurrence of placental abruption in Norway 1967–1991. Rasmussen S, et al. **Acta Obstet Gynecol Scand** 1996 Mar; 75(3):222–8 (41 ref.)

Perinatal mortality and case fatality after placental abruption in Norway 1967–1991. Rasmussen S, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):229–34

Placental abruption and its association with hypertension and prolonged rupture of membranes: a methodologic review and meta-analysis. Ananth CV, et al. **Obstet Gynecol** 1996 Aug;88(2):309–18

[Paroxystic complications in vasculo-renal syndromes during pregnancy and puerperium at the CHU of Dakar] Traore Ndiaye A, et al. **Dakar Med** 1994;39(2):169–73 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Antepartum haemorrhage: the influence of first trimester uterine bleeding. Obed JY, et al. **West Afr J Med** 1996 Jan-Mar;15(1):61–3

SURGERY

Placental abruption in association with advanced abdominal pregnancy. A case report. Yu S, et al. **J Reprod Med** 1995 Oct;40(10):731–5

ULTRASONOGRAPHY

Doppler ultrasound of the uterine arteries: the importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby. Harrington K, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):182–8

ABSCESS

see related

EMPYEMA

Soft tissue abscesses associated with parenteral drug abuse: presentation, microbiology, and treatment. Bergstein JM, et al. **Am Surg** 1995 Dec;61(12):1105–8

Abscess of the spleen. Peters FP, et al. **Neth J Med** 1996 Jan;48(1):11–4

Renal abscess due to Aspergillus fumigatus in a patient with the acquired immunodeficiency syndrome. Segarra J, et al. **Urol Int** 1995;55(1):60–2

[Pancreatic abscesses] Kothaj P, et al. **Bratisl Lek Listy** 1995 May;96(5):250–3 (Eng. Abstr.) **(Cze)**

[Personal experience with management of abscessing pancreatitis] Sváb J, et al. **Bratisl Lek Listy** 1995 May; 96(5):256–7 **(Cze)**

[Splenic abscess (editorial)] Delaitre B. **Ann Med Interne (Paris)** 1995;146(5):335–8 **(Fre)**

[Pericholecystic abscess] Kogure K. **Ryoikibetsu Shokogun Shirizu** 1996;(9):225–7 (6 ref.) **(Jpn)**

[Prostatic abscess: diagnosis and treatment] Franco A, et al. **Actas Urol Esp** 1996 Feb;20(2):189–92 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Priapism caused by a perineal abscess in a patient with Crohn's disease: CT findings. Alago W Jr, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1199–200

Coronary artery obstruction caused by perivalvular abscess in aortic valve endocarditis. Schlaifer JD, et al. **Am Heart J** 1996 Feb;131(2):413–6 (8 ref.)

Dramatic resolution of chronic urticaria [clinical conference] Ostrov MR. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):227–31

Primary tuberculous muscle abscess in a patient with systemic lupus erythematosus. Belzunegui J, et al. **Br J Rheumatol** 1995 Dec;34(12):1177–8

Adult-onset Langerhans cell histiocytosis associated with severe abscesses. Watson LC, et al. **Clin Exp Dermatol** 1995 Sep;20(5):415–8

Clivus and cervical spinal osteomyelitis with epidural abscess presenting with multiple cranial neuropathies. Azizi SA, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):239–44

Intestinal stricturing as a late presentation of appendiceal abscess. Tasker AD, et al. **Clin Radiol** 1995 Sep;50(9):644–6

Recalcitrant UTI in a patient with multiple sclerosis. Pusztai L, et al. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):63–6

Spinal epidural abscess complicating tuberculous spondylitis. Pareyson D, et al. **Ital J Neurol Sci** 1995 Jun;16(5):321–5

Occult infection as a cause of hip pain in a patient with metastatic breast cancer. Mackey JR, et al. **J Pain Symptom Manage** 1995 Oct;10(7):569–72

Pituitary abscess: an unusual presentation of "aseptic meningitis". Schwartz ID, et al. **J Pediatr Endocrinol Metab** 1995 Apr-Jun;8(2):141–6

Spontaneous drainage of an appendiceal abscess into an orthotopic neobladder. Petrus C, et al. **J Urol** 1996 Jun; 155(6):2028

Infected nasal septal hematoma. Ginsburg CM, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):1012–3

Breast abscess with lethal septicemia due to Pseudomonas aeruginosa in a patient with AIDS. Roca B, et al. **Presse Med** 1996 May 18;25(17):803–4

Acute retention of urine due to prostatic a abscess. Kundu AK, et al. **Trop Doct** 1995 Oct;25(4):186

Staphylococcus periprostatic abscess: an unusual cause of acute urinary retention. Savarirayan S, et al. **Urology** 1995 Oct;46(4):573–4

[Prostatic tuberculous abscess in AIDS. 2 cases (letter)] Greder-Belan A, et al. **Presse Med** 1995 Sep 30;24(28):1315 **(Fre)**

[Fournier's gangrene in a patient with perirectal abscess: a case report] Akita H, et al. **Hinyokika Kiyo** 1995 Aug; 41(8):633–5 (Eng. Abstr.) **(Jpn)**

[A case of multiple myeloma complicated by acute transverse myelopathy due to epidural abscess] Sato S, et al. **No To Shinkei** 1995 Aug;47(8):789–93 (Eng. Abstr.) **(Jpn)**

[Autoimmune hemolytic anemia during the course of pancreatic abscess—case history] Sołowiej D, et al. **Przegl Lek** 1995;52(8):405–6 (Eng. Abstr.) **(Pol)**

[Tuberculous prostatic abscess in a patient with AIDS] Duarte Ojeda JM, et al. **Actas Urol Esp** 1995 Sep; 19(8):655–61 (22 ref.) (Eng. Abstr.) **(Spa)**

[Abscessed brucellar prostatitis. An infrequent location] Guinda Sevillano C, et al. **Actas Urol Esp** 1995 Sep; 19(8):647–50 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Renal abscesses: appearance on gadolinium-enhanced magnetic resonance images. Brown ED, et al. **Abdom Imaging** 1996 Mar-Apr;21(2):172–6

Clostridial splenic abscess: diagnosis, treatment, and outcome. White MT, et al. **Am J Gastroenterol** 1995 Oct; 90(10):1891–2

Tuboovarian abscess caused by Edwardsiella tarda. Pien FD, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):964–5

Atypical mycobacterial adenitis presenting as a parotid abscess. Tunkel DE. **Am J Otolaryngol** 1995 Nov-Dec; 16(6):428–32

Epidural abscess—early magnetic resonance imaging detection and conservative therapy. Wang JS, et al. **Anesth Analg** 1996 May;82(5):1069–71

Cervical spine epidural abscess in a patient with no predisposing risk factors. Vilke GM, et al. **Ann Emerg Med** 1996 Jun;27(6):777–80

Localized transscleral staphylococcal abscess simulating a neoplasm. Kiratli H, et al. **Ger J Ophthalmol** 1995 Sep; 4(5):302–5

Case in point. Aortic root abscess caused by Staphylococcus aureus. Greene GS. **Hosp Pract (Off Ed)** 1995 Sep 15; 30(9):29

Visceral abscess in melioidosis. Dhiensiri T, et al. **J Med Assoc Thai** 1995 May;78(5):225–31

Osteomyelitis or abscess? [letter; comment] Baurmash H. **J Oral Maxillofac Surg** 1996 Jun;54(6):803–4. Comment on: J Oral Maxillofac Surg 1996 Feb;54(2):203–9.

A school-girl with constipation. Stricker T, et al. **Lancet** 1996 Aug 3;348(9023):306

Septic arthritis in a lumbar facet joint: a rare cause of an epidural abscess. Heenan SD, et al. **Neuroradiology** 1995 Aug;37(6):462–4

Tuberculous inguinal lymphadenitis. Challapalli M, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):723–4 (5 ref.)

Treatment of Mycobacterium marinum facial abscess using clarithromycin. Kuhn SM, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):631–2

Endogenous endophthalmitis simulating retinoblastoma. The 1993 David and Mary Seslen Endowment Lecture. Shields JA, et al. **Retina** 1995;15(3):213–9

Actinobacillus actinomycetemcomitans pneumonia with chest wall and subphrenic abscess. Chen AC, et al. **Scand J Infect Dis** 1995;27(3):289–90

Seminal vesicle abscess: a case report and review of literature. Pandey P, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):521–4 (14 ref.)

Prostatic abscess in a child. Shokeir AA, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):525–6

Bruton's agammaglobulinaemia in a child presenting with cryptococcal empyema thoracis and periauricular pyogenic abscess. Wahab JA, et al. **Singapore Med J** 1995 Dec; 36(6):686–9

Gadolinium-DTPA-enhanced magnetic resonance imaging of musculoskeletal infectious processes. Hopkins KL, et al. **Skeletal Radiol** 1995 Jul;24(5):325–30

Wegener's granulomatosis mimicking a sternal abscess. Hennington MH, et al. **South Med J** 1996 Apr;89(4):438–41

Unusual presentation of a pituitary abscess. Har-El G, et al. **Surg Neurol** 1996 Apr;45(4):351–3

Tuberculous subcutaneous abscess: an analysis of seven cases. Chen CH, et al. **Tuber Lung Dis** 1996 Apr;77(2):184–7

[Brodie abscess. Primarily misinterpreted as traumatic lesion] Nicolajsen K, et al. **Ugeskr Laeger** 1996 Jan 8;158(2):171–2 (Eng. Abstr.) **(Dan)**

[Deep neck abscess; a treacherous and life-threatening disorder] Jacobs PP, et al. **Ned Tijdschr Geneeskd** 1995 Sep 9;139(36):1817–20 **(Dut)**

[Suppurative parotitis as a sequela of infection with Salmonella enteritidis] Moser G, et al. **Laryngorhinootologie** 1995 Sep;74(9):581–2 (Eng. Abstr.) **(Ger)**

[The MR tomographic diagnosis of intra- and paraspinal abscesses] Lanfermann H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):36–42 (Eng. Abstr.) **(Ger)**

[Diagnosis of perianal and perirectal fistulas and abscesses] Rieber A, et al. **Rontgenpraxis** 1996 May;49(5):110–4 (20 ref.) **(Ger)**

[A case of epidural lumbar spine abscess] Lebkowski WJ. **Chir Narzadow Ruchu Ortop Pol** 1993;58(6):449–51 **(Pol)**

[Fever and abdominal pain in a 17-year-old patient (clinical conference)] Giménez G, et al. **Med Clin (Barc)** 1996 Mar 23;106(11):430–7 **(Spa)**

DRUG THERAPY

Treatment of Bartholin's cyst and abscess: excision versus silver nitrate insertion. Mungan T, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):61–3

Azithromycin in an experimental Staphylococcus aureus abscess model. Bamberger DM, et al. **J Antimicrob Chemother** 1995 May;35(5):623–9

Aspergillus flavus mycetoma and epidural abscess

successfully treated with itraconazole. Witzig RS, et al. **J Med Vet Mycol** 1996 Mar-Apr;34(2):133-7

Effects of chitosan on experimental abscess with Staphylococcus aureus in dogs. Okamoto Y, et al. **J Vet Med Sci** 1995 Aug;57(4):765-7

Cervical discitis associated with spinal epidural abscess caused by methicillin-resistant staphylococcus aureus. Sawada M, et al. **Neurol Med Chir (Tokyo)** 1996 Jan; 36(1):40-4

[Positive corneal findings of Propioni bacterium acnes and keratitis] Morel C, et al. **J Fr Ophtalmol** 1996;19(1):4-7 (Eng. Abstr.) **(Fre)**

[Splenic abscess following gynecologic infection with complete response to antibiotic treatment] Fombuena Moreno M, et al. **An Med Interna** 1995 Jul;12(7):340-2 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Soft tissue infections of the upper extremities with special consideration of abscesses in parenteral drug abusers. A prospective study. Simmen HP, et al. **J Hand Surg [Br]** 1995 Dec;20(6):797-800

[Tubo-ovarian abscess. An analysis of 20 cases] Varela R, et al. **Acta Med Port** 1995 Oct;8(10):537-42 (Eng. Abstr.) **(Por)**

ETIOLOGY

Pancreatic abscess secondary to central venous catheter infection [letter] Martinez Sempere J, et al. **Am J Gastroenterol** 1996 May;91(5):1059-60

Spinal epidural abscess in hemodialysis patients: report of three cases and review of the literature. Obrador GT, et al. **Am J Kidney Dis** 1996 Jan;27(1):75-83 (34 ref.)

Bilateral tuberculous abscesses on the face (eyelids) of a child. Zorić LD, et al. **Am J Ophthalmol** 1996 Jun;121(6):717-8

Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: a new clinical entity? Franklin DJ, et al. **Am J Otol** 1994 May;15(3):313-20 (21 ref.)

Drug injection in jugular veins: a new risk factor for vascular diseases in HIV-infected patients? A case report. Maggi P, et al. **Angiology** 1995 Nov;46(11):1049-52

Pelvic abscess following laparoscopic appendicectomy [letter] Frizelle FA, et al. **Ann R Coll Surg Engl** 1995 Nov; 77(6):467-8

Pelvic abscess following laparoscopic appendicectomy [letter] Taylor RS. **Ann R Coll Surg Engl** 1995 Nov; 77(6):468

Orbital involvement of cervicofacial necrotizing fasciitis [letter] Sabb PC, et al. **Arch Ophthalmol** 1995 Dec; 113(12):1571

Metastatic choroidal abscess in the acquired immunodeficiency syndrome [letter] Walton RC, et al. **Arch Ophthalmol** 1996 Jul;114(7):880-1

Left scrotal abscess complicating laparoscopic appendicectomy. Kollias J, et al. **Aust N Z J Surg** 1996 Aug;66(8):568-9

The risk of extradural abscess [editorial] Carson D, et al. **Br J Anaesth** 1995 Nov;75(5):520-1 (13 ref.)

Subretinal Pseudomonas abscess after lung transplantation [letter] Webber SK, et al. **Br J Ophthalmol** 1995 Sep; 79(9):861-6

Colonic carcinoma presenting as an appendiceal abscess in a young woman. Ramsay JA, et al. **Can J Surg** 1996 Feb; 39(1):53-6

Isolated apical intracavitary left ventricular abscess in a normal heart: a rare complication of Streptococcus milleri endocarditis. Hurlé A, et al. **Cardiovasc Surg** 1996 Feb; 4(1):61-3

Pelvic abscess caused by Salmonella: a case report. Hung TH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jun; 57(6):457-9

Tuboovarian abscess following transvaginal oocyte retrieval for in vitro fertilization: imaging appearance. Marlowe SD, et al. **Clin Imaging** 1995 Jul-Sep;19(3):180-1

Postpartum retroperitoneal abscess due to Mycoplasma hominis [letter] Barberá J, et al. **Clin Infect Dis** 1995 Sep; 21(3):698-9

Infections complicating tunneled intraspinal catheter systems used to treat chronic pain. Byers K, et al. **Clin Infect Dis** 1995 Aug;21(2):403-8 (30 ref.)

Treatment of perianal infection following bone marrow transplantation. Cohen JS, et al. **Dis Colon Rectum** 1996 Sep;39(9):981-5

Mediastinal abscess following sclerotherapy of oesophageal varices. Althoff M, et al. **Endoscopy** 1995 Oct;27(8):630

Intraperitoneal cholelithiasis after laparoscopic cholecystectomy--behavior of 'lost' concrements and their role in abscess formation. Hornof R, et al. **Eur Surg Res** 1996;28(3):179-89

Ruptured tubo-ovarian abscess complicating transcervical cryopreserved embryo transfer. Friedler S, et al. **Fertil Steril** 1996 May;65(5):1065-6

Trans-hepatic proximal migration of percutaneous-endoscopic biliary stent presenting as an abdominal wall abscess. Tan CC, et al. **Gastrointest Endosc** 1996 Feb;43(2 Pt 1):152-4

Mitral annular abscess in Salmonella endocarditis: resolution with medical therapy. Kothari SS, et al. **Indian Heart J** 1995 May-Jun;47(3):263-4

Unusual complication of temporomandibular joint surgery: cervicomediastinal abscess. Onerci M, et al. **Int J Pediatr Otorhinolaryngol** 1995 Oct;33(2):159-62

Colosplenic fistula and splenic abscess complicating Crohn's colitis. Rowell DL, et al. **J Clin Gastroenterol** 1995 Jul; 21(1):74-5

Incarcerated paraumbilical incisional hernia and abscess--complications of a spilled gallstone. Freedman AN, et al. **J Laparoendosc Surg** 1995 Jun;5(3):189-91

Fourth branchial arch fistula. Johnson IJ, et al. **J Laryngol Otol** 1996 Apr;110(4):391-3

Recurrent cervical abscess due to piriform sinus fistula. Yamashita H, et al. **J Laryngol Otol** 1995 Sep;109(9):886-8

Purulent abscess after bacillus Calmette-Guerin therapy for bladder cancer [letter; comment] Konrad K, et al. **J Rheumatol** 1995 Jul;22(7):1441. Comment on: J Rheumatol 1994 Mar;21(3):564-5.

Infection with Mycobacterium abscessus associated with intramuscular injection of adrenal cortex extract--Colorado and Wyoming, 1995-1996. **MMWR Morb Mortal Wkly Rep** 1996 Aug 23;45(33):713-5

Cervical discitis associated with spinal epidural abscess caused by methicillin-resistant staphylococcus aureus. Sawada M, et al. **Neurol Med Chir (Tokyo)** 1996 Jan; 36(1):40-4

Intrauterine contraceptive device-associated actinomycotic abscess and Actinomyces detection on cervical smear. Fiorino AS. **Obstet Gynecol** 1996 Jan;87(1):142-9 (107 ref.)

Pediatric case of the day. Infected fourth branchial pouch sinus with an extensive complicating cervical and mediastinal abscess and left-sided empyema. Murdoch MJ, et al. **Radiographics** 1995 Jul;15(4):1027-30

Manipulation of the size and clone of an intra-abdominal abscess in rats. Nakatani T, et al. **Res Exp Med (Berl)** 1996; 196(2):117-26

Multiple pancreatic abscesses due to Candida albicans following ERCP. Jalan R, et al. **Scott Med J** 1994 Feb; 39(1):17-8

Intramural abscess of the duodenum resulting from perforated peptic ulcer. Albu E, et al. **South Med J** 1995 Oct; 88(10):1078-80

Cellular mechanisms of abscess formation: macrophage procoagulant activity and major histocompatibility complex recognition. Sawyer RG, et al. **Surgery** 1996 Sep; 120(3):488-95

Perineal abscess after embolization for high-flow priapism. Sandock DS, et al. **Urology** 1996 Aug;48(2):308-11

[Pelvic abscess induced by peritoneal tuberculosis (clinical conference)] **Chung Hua Fu Chan Ko Tsa Chih** 1995 Oct; 30(10):636-8 **(Chi)**

[Abscessing cholangitis after endoscopic manipulation of the biliary tract] Pešková M, et al. **Bratisl Lek Listy** 1995 May; 96(5):264-5 **(Cze)**

[Various unusual complications of intravenous drug use (letter; comment)] Mannaerts GH, et al. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1999. Comment on: Ned Tijdschr Geneeskd 1995 Aug 26;139(34):1721-4. **(Dut)**

[Complications of colostomies. Follow-up study of 500 colostomized patients] Andivot T, et al. **Ann Chir** 1996; 50(3):252-7 (Eng. Abstr.) **(Fre)**

[Mycobacterium avium-intracellulare subcutaneous abscess after injections of interferon alpha in a patient treated for lymphoma] Philippot V, et al. **Ann Dermatol Venereol** 1996; 123(2):103-5 (Eng. Abstr.) **(Fre)**

[Multiple splenic abscesses in a 42-year-old man. Uncommon manifestation of myeloma (letter)] Bernard N, et al. **Ann Med Interne (Paris)** 1995;146(5):337-8 **(Fre)**

[Comparative outcome of aortic valve endocarditis with or without annular abscess] Stchepinsky O, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):993-8 (Eng. Abstr.) **(Fre)**

[Recurrent breast abscess: role of smoking] Salmon RJ. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):242-3 (Eng. Abstr.) **(Fre)**

[Retroperitoneal abscess formation accompanied by intraabdominal free air, a rare complication of transcatheter arterial embolization of renal tumor: a case report] Koga F, et al. **Hinyokika Kiyo** 1996 Jun;42(6):443-6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[A case of pituitary abscess caused by infection of Rathke's cleft cyst] Sato M, et al. **No Shinkei Geka** 1995 Nov; 23(11):991-5 (Eng. Abstr.) **(Jpn)**

[Perinephritic abscess as clinical presentation of pancreatitis] López de Alda González A, et al. **Actas Urol Esp** 1995 May;19(5):398-400 (Eng. Abstr.) **(Spa)**

[Brucella spondylitis with epidural abscess healed by drug treatment. Apropos of a case diagnosed by nuclear magnetic resonance (NMR) (letter)] Geijo Martínez P, et al. **An Med Interna** 1996 Apr;13(4):203-4 **(Spa)**

[Splenic abscess secondary to xanthogranulomatous pyelonephritis] Parra Muntaner LE, et al. **Arch Esp Urol** 1995 Oct;48(8):850-2 (Eng. Abstr.) **(Spa)**

METABOLISM

Functional chemotactic factor CP-10 and MRP-14 are abundant in murine abscesses. Kocher M, et al. **Infect Immun** 1996 Apr;64(4):1342-50

MICROBIOLOGY

Muscular actinomycosis in the back. Coppens L, et al. **Acta Clin Belg** 1996;51(2):94-6

Histoplasma prostatic abscess: rare cause in an immunocompromised patient [letter] Shah RD, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):471

Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: a new clinical entity? Franklin DJ, et al. **Am J Otol** 1994 May;15(3):313-20 (21 ref.)

Tuberculous abscess of the prostate in AIDS [letter] Wolf LE. **Ann Intern Med** 1996 Jul 15;125(2):156

Lemierre's syndrome: a case of postanginal septicemia and bilateral flank abscesses. Karanas YL, et al. **Ann Plast Surg** 1995 Nov;35(5):525-8

Anaerobic and aerobic isolates from a subperiosteal orbital abscess in a 4-year-old [letter] Harris GJ, et al. **Arch Ophthalmol** 1996 Jan;114(1):98

Endogeneous Nocardia subretinal abscess [letter] Jolly SS, et al. **Arch Ophthalmol** 1996 Sep;114(9):1147-8

Coccidioides immitis subperiosteal abscess of the temporal bone in a child. Low WS, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):189-92

Salmonellosis complicated by myocardial abscess and cerebral mycotic aneurysms. Sproule MW, et al. **Br J Clin Pract** 1995 Sep-Oct;49(5):273-4

Primary cerebral abscess due to Nocardia asteroides presenting as stroke. Cheung RT, et al. **Clin Exp Neurol** 1994;31:79-84

Sporotrichoid lymphangitis due to Staphylococcus aureus in a diabetic patient. Lieberman AA, et al. **Clin Infect Dis** 1995 Aug;21(2):433-4

Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Summanen PH, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S279-82

Splenic abscess due to Salmonella heidelberg [letter; comment] Wilmshurst P, et al. **Clin Infect Dis** 1995 Oct; 21(4):1065. Comment on: Clin Infect Dis 1994 Nov;19(5):871-5.

Aspergillus terreus, an uncommon fungus causing aortic root abscess and pseudoaneurysm. Koshi G, et al. **Indian Heart J** 1995 May-Jun;47(3):265-7

Recurrence of Fusarium solani abscess formation in an otherwise healthy patient. Leu HS, et al. **Infection** 1995 Sep-Oct;23(5):303-5

Rapidly progressive pyomyositis. Ceulemans R, et al. **J Belge Radiol** 1995 Aug;78(4):226

Splenic abscess associated with Pasteurella multocida in an immunocompetent patient. Talbodec N, et al. **J Clin Gastroenterol** 1995 Jul;21(1):76

Paravertebral abscess caused by Trichosporon capitatum in a child with acute lymphoblastic leukaemia [letter] Barbor PR, et al. **J Infect** 1995 Nov;31(3):251-2

Mycobacterium kansasii scalp abscesses in an AIDS patient [letter] Nandwani R, et al. **J Infect** 1995 Jul;31(1):79-80

Parapharyngeal abscess from Pseudomonas aeruginosa infection in an HIV positive patient [letter] Sanderson RJ, et al. **J Infect** 1995 Sep;31(2):174

Potential pathogenic properties of members of the "Streptococcus milleri" group in relation to the production of endocarditis and abscesses. Willcox MD. **J Med Microbiol** 1995 Dec;43(6):405-10

Subcutaneous abscess caused by Pleurophomopsis lignicola Petr: first case. Chabasse D, et al. **J Med Vet Mycol** 1995 Nov-Dec;33(6):415-7

Spinal epidural abscess caused by Brucella: case report. Paz JF, et al. **J Neurosurg Sci** 1994 Dec;38(4):245-9 (22 ref.)

Pyomyositis in children, caused by anaerobic bacteria. Brook I. **J Pediatr Surg** 1996 Mar;31(3):394-6

Pasteurella multocida isolation from a tuboovarian abscess. A case report. Lukban JC, et al. **J Reprod Med** 1995 Aug; 40(8):603-5

Primary cutaneous nocardiosis caused by Nocardia otitidiscaviarum: two cases and a review of the literature. Freland C, et al. **J Trop Med Hyg** 1995 Dec;98(6):395-403 (26 ref.)

Microbiology of subperiosteal orbital abscess and associated maxillary sinusitis. Brook I, et al. **Laryngoscope** 1996 Aug; 106(8):1010-3

Spinal epidural abscess due to Aspergillus infection of the vertebrae: report of 3 cases. Dubbeld P, et al. **Neth J Med** 1996 Jan;48(1):18-23

Pasteurella multocida tubo-ovarian abscess in a virgin. Teng FY, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):883

Microbiology and antimicrobial therapy of spinal infections. Sapico FL. **Orthop Clin North Am** 1996 Jan;27(1):9-13 (22 ref.)

Thymic abscess caused by methicillin-resistant Staphylococcus aureus. Immergluck LC, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):96-7

Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Burnett RJ, et al. **Surgery** 1995 Oct;118(4):716-21; discussion 721-3

[Neonatal osteomyelitis: a separate category as far as clinical picture and course are concerned] Joekes EC, et al. **Ned Tijdschr Geneeskd** 1996 May 25;140(21):1105-9 **(Dut)**

[Corneal abscess: therapeutic attitude based on microbiological testing] Briat B, et al. **J Fr Ophtalmol** 1996; 19(5):375-9 (Eng. Abstr.) **(Fre)**

[Positive corneal findings of Propioni bacterium acnes and keratitis] Morel C, et al. **J Fr Ophtalmol** 1996;19(1):4-7 (Eng. Abstr.) **(Fre)**

[Purulent pleurisy due to Salmonella typhi associated with a splenic abscess] Yassine N, et al. **Rev Mal Respir** 1995; 12(6):634–6 (Eng. Abstr.) **(Fre)**

[Clinical manifestations of actinomycosis: literature review apropos of a case] Liaudet L, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):423–8 **(Fre)**

[Retropharyngeal abscess] Crusat Braña S, et al. **An Otorrinolaringol Ibero Am** 1996;23(2):169–78 (Eng. Abstr.) **(Spa)**

[Abscessed skin lesions caused by Mycobacterium marinum (letter)] Cortés E, et al. **Enferm Infecc Microbiol Clin** 1996 Mar;14(3):198 **(Spa)**

PATHOLOGY

Patterns of anterior spinal canal involvement by neoplasms and infections. Schellinger D. **AJNR Am J Neuroradiol** 1996 May;17(5):953–9

Pyoderma fistulans sinifica (fox den disease): a distinctive soft-tissue infection. Wittmann DH, et al. **Clin Infect Dis** 1995 Jul;21(1):162–70

Radiologic–Pathologic Conference of Children's Hospital Boston: chest wall mass in an infant with eczema. Dwek JR, et al. **Pediatr Radiol** 1996;26(2):165–7

PHYSIOPATHOLOGY

US-guided drainage of deep neck space abscess. Ochi K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:120–3

Tragal cartilage in the primary reconstruction of defects resulting from a nasal septal abscess. Schrader M, et al. **Clin Otolaryngol** 1995 Dec;20(6):527–9

[Mathematical model of hydrodynamic flow in irrigation–suction drainage] Turčić J, et al. **Unfallchirurg** 1996 Jun;99(6):435–9 (Eng. Abstr.) **(Ger)**

[Retropharyngeal abscess] Crusat Braña S, et al. **An Otorrinolaringol Ibero Am** 1996;23(2):169–78 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Comparison of cefoxitin, cefotetan, and ampicillin/sulbactam as prophylaxis for polymicrobial infection in mice. Brook I. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S376–7

Efficacy of quinolones in preventing Staphylococcus aureus–induced abscess in mice. Cohen MA, et al. **J Antimicrob Chemother** 1995 Sep;36(3):551–5

RADIOGRAPHY

Primary cerebral abscess due to Nocardia asteroides presenting as stroke. Cheung RT, et al. **Clin Exp Neurol** 1994;31:79–84

Delayed CT findings in acute renal infection [letter; comment] Charig MJ. **Clin Radiol** 1995 Dec;50(12):880–1 . Comment on: Clin Radiol 1995 Jun;50(6):364–70.

Tuberculous abscess in retromammary region: CT findings. Chung SY, et al. **J Comput Assist Tomogr** 1996 Sep–Oct; 20(5):766–9

Pancreatic adenocarcinoma presenting as a splenic abscess: case report and diagnostic approach. Lastrapes RG, et al. **J Okla State Med Assoc** 1995 Aug;88(8):333–6

Subperiosteal abscess of the orbit: computed tomography and the clinical course. Harris GJ. **Ophthal Plast Reconstr Surg** 1996 Mar;12(1):1–8

CT of staphylococcal anterior mediastinal abscess in an infant. Bungay HK, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S205–6

Radiologic–Pathologic Conference of Children's Hospital Boston: chest wall mass in an infant with eczema. Dwek JR, et al. **Pediatr Radiol** 1996;26(2):165–7

CT evaluation of soft tissue and muscle infection and inflammation: a systematic compartmental approach. Beauchamp NJ Jr, et al. **Skeletal Radiol** 1995 Jul; 24(5):317–24 (8 ref.)

[Quiz on an unusual orbital masquerade syndrome] Gloor B, et al. **Klin Monatsbl Augenheilkd** 1995 Dec;207(6):377–80 (Eng. Abstr.) **(Ger)**

[Pyogenic spondylitis in the interarticular portion of the vertebral arch. Case report on primary dorsal spondylitis] Schüle B, et al. **Z Orthop Ihre Grenzgeb** 1996 Mar–Apr; 134(2):185–8 (Eng. Abstr.) **(Ger)**

[Mediastinal abscess. Importance of computerized tomography (a case)] Marchetti M, et al. **Radiol Med (Torino)** 1995 Jul–Aug;90(1–2):143–4 **(Ita)**

RADIONUCLIDE IMAGING

Comparison of Tc-99m HIG and Ga-67 citrate in the evaluation of bacterial abscess in a rat model. Güngör F, et al. **Ann Nucl Med** 1996 Feb;10(1):79–83

Accumulation of Ga-67 citrate in a tuberculous splenic abscess. Report of a rare case. Kao PF, et al. **Clin Nucl Med** 1996 Jan;21(1):49–52

Splenic-perisplenic infected hematoma detected on radiogallium–radiocolloid subtraction study. Lantz MM, et al. **Clin Nucl Med** 1995 Jul;20(7):649–50

Scintigraphic findings in a Brodie's abscess. Silva F, et al. **Clin Nucl Med** 1995 Oct;20(10):913–5

Extraskeletal accumulation of Tc-99m HMDP in a tuberculous cold abscess. Tamgac F, et al. **Clin Nucl Med** 1995 Dec;20(12):1092

Technetium-99m labelled hydrazinonicotinamido human non-specific polyclonal immunoglobulin G for detection of infectious foci: a comparison with two other technetium-labelled immunoglobulin preparations. Claessens RA, et al. **Eur J Nucl Med** 1996 Apr;23(4):414–21

Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model. van der Laken CJ, et al. **Eur J Nucl Med** 1995 Nov;22(11):1249–55

Detecting infection and inflammation with technetium-99m-labeled Stealth liposomes. Oyen WJ, et al. **J Nucl Med** 1996 Aug;37(8):1392–7

SURGERY

US-guided drainage of deep neck space abscess. Ochi K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:120–3

Nosocomial phaeomycotic cyst of the hand. Feldman DL, et al. **Ann Plast Surg** 1995 Jul;35(1):113–5

Long-term results of operation for paravalvular abscess. d'Udekem Y, et al. **Ann Thorac Surg** 1996 Jul;62(1):48–53

Fringed valve prosthesis for aortic root abscess. Hayashi J, et al. **Ann Thorac Surg** 1996 Jul;62(1):262–4

Excision of a pulmonary valve abscess in a 61-year-old woman with single ventricle. Warner KG, et al. **Ann Thorac Surg** 1996 Jan;61(1):213–5

Endoscopic vs external drainage of orbital subperiosteal abscess. Page EL, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):737–40

Spinal epidural abscess: a report of nine cases and the use of intra-operative ultrasonography. Mak KH, et al. **Aust N Z J Surg** 1996 May;66(5):287–90

Extradural anaesthesia for repeated surgical treatment in the presence of infection [see comments] Jakobsen KB, et al. **Br J Anaesth** 1995 Nov;75(5):536–40. Comment in: Br J Anaesth 1996 Jun;76(6):887–8.

Abscess drainage techniques. Grant DS. **Br J Hosp Med** 1995 Nov 1–14;54(9):435–8 (14 ref.)

Splenic abscess [letter; comment] Carr ND, et al. **Br J Surg** 1996 Jan;83(1):134. Comment on: Br J Surg 1995 Mar;82(3):355.

Elective interval laparoscopic management of periappendiceal abscess. Hsia CY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Jul;56(1):52–7

Perianal inflammatory conditions in inflammatory bowel disease. Stein BL, et al. **Curr Opin Gen Surg** 1993;:141–6 (17 ref.)

Treatment of perianal infection following bone marrow transplantation. Cohen JS, et al. **Dis Colon Rectum** 1996 Sep;39(9):981–5

Treatment of Bartholin's cyst and abscess: excision versus silver nitrate insertion. Mungan T, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):61–3

Long-term results of aortic valve translocation for mycotic periannular abscess: comparative study of Danielson's original method and our threadless method. Endo M, et al. **Heart Vessels** 1995;10(6):318–22

Functional endoscopic sinus surgery of orbital subperiosteal abscess in children. Deutsch E, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):181–90

An acute Nocardia brasiliensis infection of the hand: a case report. Shifren JD, et al. **J Hand Surg [Am]** 1996 Mar; 21(2):309–10

Pott's puffy tumor: the forgotten entity. Case report. Babu RP, et al. **J Neurosurg** 1996 Jan;84(1):110–2

Endonasal endoscopic surgery for rhinogen intraorbital abscess: a report of six cases. Wolf SR, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):105–10

Intramedullary spinal cord abscess: case report. Tacconi L, et al. **Neurosurgery** 1995 Oct;37(4):817–9 (25 ref.)

Pathogenesis-based treatment of recurring subareolar breast abscesses. Meguid MM, et al. **Surgery** 1995 Oct; 118(4):775–82

[Laparostomy in abscessing necrotizing pancreatitis] Vraspír V, et al. **Bratisl Lek Listy** 1995 May;96(5):257–8 **(Cze)**

[Peritonsillar abscess. Emergency tonsillectomy?] Marchal F, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):393–8 (26 ref.) (Eng. Abstr.) **(Fre)**

[Recurrent breast abscess: role of smoking] Salmon RJ. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):242–3 (Eng. Abstr.) **(Fre)**

[Fistula, fissure, abscess] Girona J, et al. **Chirurg** 1996 Mar; 67(3):222–8 (28 ref.) (Eng. Abstr.) **(Ger)**

[A case of infective aortic valve endocarditis with splenic abscess] Katayama Y, et al. **Kyobu Geka** 1996 Feb; 49(2):143–5 (Eng. Abstr.) **(Jpn)**

[The establishment of the times for radical operation in acute forms of suppurative inflammation in epithelial coccygeal cysts] Nazarov LU, et al. **Vestn Khir Im I I Grek** 1992 Feb;148(2):161–5 (Eng. Abstr.) **(Rus)**

[Experience in treating postinjection abscesses] Pigin SA, et al. **Vestn Khir Im I I Grek** 1992 Mar;148(3):347–52 **(Rus)**

[Abscess tonsillectomy in acute parapharyngitis] Bobrov VM. **Vestn Otorinolaringol** 1996 Mar–Apr;(2):36–8 **(Rus)**

[Amebic abscess of the brain. First successfully operated case in the world] Quijano-Pitman F. **Gac Med Mex** 1995 Sep–Dec;131(5–6):586 **(Spa)**

THERAPY

CT-guided drainage of multilocular pelvic and gluteal tuberculous abscesses. Dinç H, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):667–8

Clostridial splenic abscess: diagnosis, treatment, and outcome. White MT, et al. **Am J Gastroenterol** 1995 Oct; 90(10):1891–2

Percutaneous cystogastrostomy with a new catheter for drainage of pancreatic pseudocysts and fluid collections. Davies RP, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):128–31

Endoscopic drainage of a pancratic abscess with a transduodenal nasopancreatic catheter. Messmann H, et al. **Endoscopy** 1995 Aug;27(6):466

Percutaneous catheter drainage of breast abscesses. Berna JD, et al. **Eur J Radiol** 1996 Feb;21(3):217–9

Minimal invasive therapy of prostatic abscess by transrectal ultrasound-guided perineal drainage. Bachor R, et al. **Eur Urol** 1995;28(4):320–4

Successful management of breast abscess with ongoing breastfeeding. Banapurmath CR, et al. **Indian Pediatr** 1995 Apr;32(4):488–91 (10 ref.)

Treatment of pyogenic splenic abscess: nonsurgical procedures. Jang TN, et al. **J Formos Med Assoc** 1995 Jun; 94(6):309–12

Pyomyositis during induction chemotherapy for acute lymphocytic leukemia. Corden TE, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):323–6

Is perianal sepsis adequately managed? The results of a five year audit at Royal Naval Hospital Haslar. Parker SJ, et al. **J R Nav Med Serv** 1995 Winter;80(3):148–51

Minimally invasive treatment of renal abscess [see comments] Siegel JF, et al. **J Urol** 1996 Jan;155(1):52–5. Comment in: J Urol 1996 Jan;155(1):56–7.

Endourology—1996 [editorial; comment] Winfield HN. **J Urol** 1996 Jan;155(1):56–7. Comment on: J Urol 1996 Jan;155(1):38–42. Comment on: J Urol 1996 Jan;155(1):43–7. Comment on: J Urol 1996 Jan;155(1):48–51. Comment on: J Urol 1996 Jan;155(1):52–5.

Neurosurgical care of spinal epidural, subdural, and intramedullary abscesses and arachnoiditis. Martin RJ, et al. **Orthop Clin North Am** 1996 Jan;27(1):125–36 (72 ref.)

Pelvic abscesses: transvaginal US-guided drainage with the trocar method. McGahan JP, et al. **Radiology** 1996 Aug; 200(2):579–81

Deep pelvic abscesses in children: transrectal drainage under radiologic guidance. Pereira JK, et al. **Radiology** 1996 Feb; 198(2):393–6

Multifocal metachronous epidural abscesses of the spine. A case report. Chow GH, et al. **Spine** 1996 May 1; 21(9):1094–7 (11 ref.)

[Valve ring abscesses: apropos of 59 cases. A multicenter study] Lesbre JP, et al. **Arch Mal Coeur Vaiss** 1995 Mar; 88(3):321–8 (Eng. Abstr.) **(Fre)**

[Radiologically guided percutaneous drainage: state of the art] Chapuis L, et al. **Schweiz Med Wochenschr** 1996 Jul 20;126(29):1251–7 (Eng. Abstr.) **(Fre)**

[Percutaneous drainage of splenic abscesses under ultrasound] Barzilai M, et al. **Harefuah** 1995 Nov 1;129(9):313–6, 367 (Eng. Abstr.) **(Heb)**

ULTRASONOGRAPHY

Imaging of superficial soft-tissue infections: sonographic findings in cases of cellulitis and abscess. Loyer EM, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):149–52

Mitral ring abscess caused by bacterial endocarditis on a heavily calcified mitral annulus fibrosus: Diagnosis by multiplane transesophageal echocardiography. Eicher JC, et al. **Am Heart J** 1996 Apr;131(4):818–20

Diagnosis of pyogenic abscesses by ultrasound. Strecker W, et al. **Ann Soc Belg Med Trop** 1995 Dec;75(4):305–20

Spinal epidural abscess: a report of nine cases and the use of intra-operative ultrasonography. Mak KH, et al. **Aust N Z J Surg** 1996 May;66(5):287–90

Color Doppler ultrasonographic scanning in prostatitis: clinical correlation. Veneziano S, et al. **Eur Urol** 1995; 28(1):6–9

Glossal abscess presenting as unilateral tongue swelling. Hehar SS, et al. **J Laryngol Otol** 1996 Apr;110(4):389–90

Importance of dynamic assessment of the soft tissues in the sonographic diagnosis of echogenic superficial abscesses. Loyer EM, et al. **J Ultrasound Med** 1995 Sep;14(9):669–71

Pyomyositis: diagnostic value of color Doppler sonography. Gottlieb RH, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S109–11

Microabscesses of the liver and spleen in AIDS: detection with 5-MHz sonography. Murray JG, et al. **Radiology** 1995 Dec;197(3):723–7

[Imaging of peri-anal and perirectal abscesses and fistulae using endoluminal ultrasound diagnosis] Graf D, et al. **Swiss Surg** 1995;(6):294–7; discussion 297 (Eng. Abstr.) **(Ger)**

[Percutaneous drainage of splenic abscesses under ultrasound] Barzilai M, et al. **Harefuah** 1995 Nov 1;129(9):313–6, 367 (Eng. Abstr.) **(Heb)**

VETERINARY

Serum neutralizing antibody response and protection against experimentally induced liver abscesses in steers vaccinated with Fusobacterium necrophorum. Saginala S, et al. **Am J Vet Res** 1996 Apr;57(4):483–8

Role of Pasteurella granulomatis and Dermatobia hominis in the etiology of lechiguana in cattle. Ladeira SL, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:359–68

Epidural abscess and discospondylitis in a dog after administration of a lumbosacral epidural analgesic.

Remedios AM, et al. **Can Vet J** 1996 Feb;37(2):106–7
Diagnostic ophthalmology. Periocular discharge and swelling around the eye in a dog. Wolfer J, et al. **Can Vet J** 1995 Oct;36(10):661–2
Corneal stromal abscesses in the horse: a review of 24 cases. Hendrix DV, et al. **Equine Vet J** 1995 Nov;27(6):440–7
Complications of indwelling, silastic central venous access catheters in dogs and cats. Blaiset MA, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct;31(5):379–84
Traumatic ear canal separations and para-aural abscessation in three dogs. McCarthy PE, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct;31(5):419–24
Clinical Vignette: Urachal abscess and cystitis in a calf. Hassel DM, et al. **J Vet Intern Med** 1995 Jul–Aug; 9(4):286–8
Isolation of obligate and facultative anaerobic bacteria from feline subcutaneous abscesses. Hoshuyama S, et al. **J Vet Med Sci** 1996 Mar;58(3):273–4
Nodules and draining tracts. Beale KM. **Vet Clin North Am Small Anim Pract** 1995 Jul; 25(4):887–900 (50 ref.)
An experimental ovine foot abscess model using a Fusobacterium necrophorum biotype AB. Corner LA, et al. **Vet Microbiol** 1996 Jan;48(1–2):1–7
Intracapsular prostatic omentalization: a new technique for management of prostatic abscesses in dogs. White RA, et al. **Vet Surg** 1995 Sep–Oct;24(5):390–5
[Treatment of orbital abscesses and phlegmon in dogs and cats] Rühli MB, et al. **Tierarztl Prax** 1995 Aug; 23(4):398–401 (Eng. Abstr.) **(Ger)**

ABSCESS, ABDOMINAL see **ABDOMINAL ABSCESS**

ABSCESS, AMEBIC, HEPATIC see **LIVER ABSCESS, AMEBIC**

ABSCESS, CEREBRAL see **BRAIN ABSCESS**

ABSCESS, HEPATIC see **LIVER ABSCESS**

ABSCESS, HEPATIC, AMEBIC see **LIVER ABSCESS, AMEBIC**

ABSCESS, INTRA-ABDOMINAL see **ABDOMINAL ABSCESS**

ABSCESS, LIVER, AMEBIC see **LIVER ABSCESS, AMEBIC**

ABSCESS, PERIAPICAL see **PERIAPICAL ABSCESS**

ABSCESS, PERIODONTAL see **PERIODONTAL ABSCESS**

ABSCESS, PERITONSILLAR see **PERITONSILLAR ABSCESS**

ABSCESS, PSOAS see **PSOAS ABSCESS**

ABSCESS, PULMONARY see **LUNG ABSCESS**

ABSCESS, RETROPHARYNGEAL see **RETROPHARYNGEAL ABSCESS**

ABSCESS, SUBDURAL see **EMPYEMA, SUBDURAL**

ABSCESS, SUBPHRENIC see **SUBPHRENIC ABSCESS**

ABSCISIC ACID

BIOSYNTHESIS

Molecular identification of zeaxanthin epoxidase of Nicotiana plumbaginifolia, a gene involved in abscisic acid biosynthesis and corresponding to the ABA locus of Arabidopsis thaliana. Marin E, et al. **EMBO J** 1996 May 15;15(10):2331–42

GENETICS

Overlap of Viviparous1 (VP1) and abscisic acid response elements in the Em promoter: G-box elements are sufficient but not necessary for VP1 transactivation. Vasil V, et al. **Plant Cell** 1995 Sep;7(9):1511–8

IMMUNOLOGY

Expression of a single-chain Fv antibody against abscisic acid creates a wilty phenotype in transgenic tobacco. Artsaenko O, et al. **Plant J** 1995 Nov;8(5):745–50

METABOLISM

Levels of endogenous cytokinins, indole-3-acetic acid and abscisic acid during the cell cycle of synchronized tobacco BY-2 cells. Redig P, et al. **FEBS Lett** 1996 Aug 5; 391(1–2):175–80

PHARMACOLOGY

Characterization of a ferritin mRNA from Arabidopsis thaliana accumulated in response to iron through an oxidative pathway independent of abscisic acid. Gaymard F, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):67–73
Novel plant Ca(2+)-binding protein expressed in response to abscisic acid and osmotic stress. Frandsen G, et al. **J Biol Chem** 1996 Jan 5;271(1):343–8
Localization and interaction of the cis-acting elements for abscisic acid, VIVIPAROUS1, and light activation of the C1 gene of maize. Kao CY, et al. **Plant Cell** 1996 Jul; 8(7):1171–9
Transcription factor veracity: is GBF3 responsible for ABA-regulated expression of Arabidopsis Adh? Lu G, et al. **Plant Cell** 1996 May;8(5):847–57
Modular nature of abscisic acid (ABA) response complexes: composite promoter units that are necessary and sufficient for ABA induction of gene expression in barley. Shen Q, et al. **Plant Cell** 1996 Jul;8(7):1107–19
Induction of homologous low temperature and ABA-responsive genes in frost resistant (Solanum commersonii) and frost-sensitive (Solanum tuberosum cv. Bintje) potato species. Baudo MM, et al. **Plant Mol Biol** 1996 Jan;30(2):331–6
Differential regulation of two ABA-inducible genes from Craterostigma plantagineum in transgenic Arabidopsis plants. Furini A, et al. **Plant Mol Biol** 1996 Jan;30(2):343–9
Post-transcriptional regulation of bifunctional alpha-amylase/subtilisin inhibitor expression in barley embryos by abscisic acid. Liu JH, et al. **Plant Mol Biol** 1995 Dec;29(5):1087–91
Abscisic acid induces the alcohol dehydrogenase gene in Arabidopsis. de Bruxelles GL, et al. **Plant Physiol** 1996 Jun;111(2):381–91
Sensitivity to abscisic acid of guard-cell K+ channels is suppressed by abi1-1, a mutant Arabidopsis gene encoding a putative protein phosphatase. Armstrong F, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9520–4
A protein farnesyl transferase involved in abscisic acid signal transduction in Arabidopsis. Cutler S, et al. **Science** 1996 Aug 30;273(5279):1239–41

ABSENCE SEIZURES see **EPILEPSY, ABSENCE**

ABSENTEEISM

The economic costs of alcohol-related absenteeism and reduced productivity among the working population of New Zealand. Jones S, et al. **Addiction** 1995 Nov; 90(11):1455–61
Effects of paternal absence on male adolescents' peer relations and self-image. Beaty LA. **Adolescence** 1995 Winter;30(120):873–80
Psychosocial work environment and sickness absence among British civil servants: the Whitehall II study [see comments] North FM, et al. **Am J Public Health** 1996 Mar; 86(3):332–40. Comment in: Am J Public Health 1996 Mar;86(3):301–3.
Effects of smog on absenteeism in forestry workers. Moll Van Charante AW, et al. **Arch Environ Health** 1996 Jan–Feb;51(1):34–41 (39 ref.)
Factors influencing failure to return to work due to traumatic brain injury. Greenspan AI, et al. **Brain Inj** 1996 Mar; 10(3):207–18
Comparison between open and arthroscopic acromioplasties: evaluation of absenteeism [see comments] Kinnard P, et al. **Can J Surg** 1996 Feb;39(1):21–3. Comment in: Can J Surg 1996 Jun;39(3):254.
School absence--a valid morbidity marker for asthma? McCowan C, et al. **Health Bull (Edinb)** 1996 Jul; 54(4):307–13
Controlling for mental health in earnings equations: what do we gain and what do we lose? Savoca E. **Health Econ** 1995 Sep–Oct;4(5):399–410
Is there a relationship between job satisfaction and absenteeism? Matrunola P. **J Adv Nurs** 1996 Apr; 23(4):827–34
Factors relating to return to work after burn injury. Wrigley M, et al. **J Burn Care Rehabil** 1995 Jul–Aug;16(4):445–50; discussion 444 (19 ref.)
The relationship of HIV status, type of coagulation disorder, and school absenteeism to cognition, educational performance, mood, and behavior of boys with hemophilia. Mayes SD, et al. **J Genet Psychol** 1996 Jun;157(2):137–51
Using administrative data to identify elementary schools at increased risk for student absences. Kozinetz CA. **J Sch Health** 1995 Sep;65(7):262–4
Cutting school absenteeism [letter] Vinson CL. **Minn Med** 1996 Jun;79(6):58–9
Reliability of a questionnaire on sickness absence with specific attention to absence due to back pain and respiratory complaints. Burdorf A, et al. **Occup Environ Med** 1996 Jan;53(1):58–62
Do attitudes and beliefs influence work loss due to low back trouble? Symonds TL, et al. **Occup Med (Oxf)** 1996 Feb; 46(1):25–32
Smoking cessation and absence from work. Wooden M, et al. **Prev Med** 1995 Sep;24(5):535–40
Predictors of job satisfaction and job influence--results from a national sample of Swedish nurses. Petterson IL, et al. **Psychother Psychosom** 1995;64(1):9–19
Complex interactions with the work environment [comment] Bush GW. **Public Health Rep** 1996 May–Jun;111(3):242–3 . Comment on: Public Health Rep 1996 May–Jun;111(3):236–41.
Assessment of sickness certification and concepts of musculoskeletal disease and illness in the general population. Brage S, et al. **Scand J Prim Health Care** 1995 Sep;13(3):188–96
Acute low back pain: is the number of patients taking sick leave exponentially related to time? [letter] Schødt T, et al. **Scand J Prim Health Care** 1995 Sep;13(3):238–9
Pregnancy-related sickness absence among employed women in a Swedish county. Alexanderson K, et al. **Scand J Work Environ Health** 1995 Jun;21(3):191–8
Smoking and absence from work: Australian evidence. Bush R, et al. **Soc Sci Med** 1995 Aug;41(3):437–46
The impact on unemployment of an intervention to increase recognition of previously untreated anxiety among primary care physicians. Yelin E, et al. **Soc Sci Med** 1996 Apr; 42(7):1069–75
Absence resulting from low back trouble can be reduced by psychosocial intervention at the work place. Symonds TL, et al. **Spine** 1995 Dec 15;20(24):2738–45
Descriptive study of cough, wheeze and school absence in childhood. Doull IJ, et al. **Thorax** 1996 Jun;51(6):630–1
[Quality of work and absenteeism: lower or higher in elderly workers?] Otten FW, et al. **Tijdschr Gerontol Geriatr** 1995 Dec;26(6):246–52 (Eng. Abstr.) **(Dut)**
[Statistical methodologic comments on epidemiologic work disability trends] Stallmann M. **Gesundheitswesen** 1996 Jun; 58(6):303–10 (Eng. Abstr.) **(Ger)**
[Local school attendance by students with cancer during and after therapy] Häcker W, et al. **Klin Padiatr** 1995 Jul–Aug; 207(4):181–5 (Eng. Abstr.) **(Ger)**
[Comparison of behavioral and emotional problems related to school nonattendance in Japanese elementary and junior high school students] Kuramoto H. **Nippon Koshu Eisei Zasshi** 1995 Nov;42(11):930–41 (Eng. Abstr.) **(Jpn)**
[Analysis of work absenteeism due to illness in the provinces] Szubert Z, et al. **Med Pr** 1996;47(2):117–23 (Eng. Abstr.) **(Pol)**
[Management and monitoring of transient work incapacity. Is the primary care model effective?] Alberquilla Menéndez-Asenjo A, et al. **Aten Primaria** 1996 Jan; 17(1):40–6 (33 ref.) (Eng. Abstr.) **(Spa)**
[Factors conditioning absenteeism among primary care physicians] Nebot Adell C, et al. **Aten Primaria** 1996 Mar 15;17(4):257–60 (Eng. Abstr.) **(Spa)**
[Decrease of labor absenteeism associated with hormone replacement therapy in postmenopausal women] Blümel JE, et al. **Rev Med Chil** 1995 Aug;123(8):948–53 (Eng. Abstr.) **(Spa)**

ABSINTHE

HISTORY

[Verlaine: long sobs on Normandy] Henry R. **Union Med Can** 1995 Mar;124(1):23–5 **(Fre)**

ABSORBABLE CELLULOSE see **CELLULOSE, OXIDIZED**

ABSORPTIOMETRY, DUAL-ENERGY X-RAY see **DENSITOMETRY, X-RAY**

ABSORPTIOMETRY, PHOTON

Comparison of ultrasound transmission velocity with computed metacarpal radiogrammetry and dual-photon absorptiometry. Sili Scavalli A, et al. **Eur Radiol** 1996; 6(2):192–5
Single X-ray absorptiometry: performance characteristics and comparison with single photon absorptiometry. Borg J, et al. **Osteoporos Int** 1995;5(5):377–81
[Dual photon absorptiometry, dual energy X-ray absorptiometry for analysis of body fat mass] Itabashi A. **Nippon Rinsho** 1995 Jun;53 Suppl:174–8 (11 ref.) **(Jpn)**

INSTRUMENTATION

A portable system for measuring bone mineral density in the pre-term neonatal forearm. Truscott JG, et al. **Br J Radiol** 1996 Jun;69(822):532–8

METHODS

Bone absorptiometry: a critical appraisal of various methods. Slosman DO, et al. **Acta Paediatr Suppl** 1995 Sep;411:9–11 (7 ref.)
Replacing DXA scanners: cross-calibration with phantoms may be misleading. Blake GM. **Calcif Tissue Int** 1996 Jul; 59(1):1–5
The state of the art of non-invasive diagnostics for bone densitometry. Methods of photonic absorption. Baruffaldi F, et al. **Chir Organi Mov** 1995 Oct–Dec;80(4):427–48 (71 ref.) **(Eng, Ita)**
The effect of fat on the coherent-to-Compton scattering ratio in the calcaneus: a computational analysis. Guttmann GD, et al. **Med Phys** 1995 Aug;22(8):1229–34
Caffeine does not affect the rate of gain in spine bone in young women. Packard PT, et al. **Osteoporos Int** 1996; 6(2):149–52

STANDARDS

The effects of analytic software and scan analysis technique on the comparison of dual X-ray absorptiometry with dual photon absorptiometry of the hip in the elderly. Kiel DP,

ABSORPTIOMETRY, PHOTON

et al. **J Bone Miner Res** 1995 Jul;10(7):1130–6

ABSORPTION, INTESTINAL see **INTESTINAL ABSORPTION**

ABSORPTION, SKIN see **SKIN ABSORPTION**

ABSTINENCE SYNDROME, NEONATAL see **NEONATAL ABSTINENCE SYNDROME**

ABSTRACTING AND INDEXING

Structured abstracts: still more [letter] Kulkarni H. **Ann Intern Med** 1996 Apr 1;124(7):695–6

Citation analysis of faculty publication: beyond Science Citation Index and Social Science Citation Index. Reed KL. **Bull Med Libr Assoc** 1995 Oct;83(4):503–8

The abstractness of the word 'abstract' [letter] Hurst JW. **Circulation** 1996 Feb 1;93(3):617–8

An analysis of statistical term strength and its use in the indexing and retrieval of molecular biology texts. Wilbur WJ, et al. **Comput Biol Med** 1996 May;26(3):209–22

About those abstract translations [editorial] Laney WR. **Int J Oral Maxillofac Implants** 1996 Mar–Apr;11(2):145

The completeness of MEDLINE for papers published and abstracted in the Journal of Emergency Medicine. Vilke GM, et al. **J Emerg Med** 1995 Jul–Aug;13(4):457–60

Abstract information and structure at scientific meetings [letter] McIntosh N. **Lancet** 1996 Feb 24;347(9000):544–5

Description and advantages of an index-driven medical knowledge base. Bishop CW, et al. **Medinfo** 1995;8 Pt 2:952

Fate of conference abstracts [letter] Liu L, et al. **Nature** 1996 Sep 5;383(6595):20

Comparing clinical vocabularies using coding system fidelity. Klimczak JC, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:883–7

Paving the info superhighway [letter; comment] Sikorski RS, et al. **Science** 1995 Oct 6;270(5233):16–7. Comment on: Science 1995 Sep 8;269(5229):1354–6.

[Indexing in radiology and medical imaging] Morcet N, et al. **J Radiol** 1996 Jul;77(7):515–7 **(Fre)**

[Key words, descriptors, and information retrieval (letter)] Arranz M. **Gac Sanit** 1995 Sep–Oct;9(50):321–2 **(Spa)**

[Lost science in the third world (editorial)] del Brutto OH. **Rev Neurol** 1996 May;24(129):505 **(Spa)**

[Abstracts in medical journals in Spanish] Matias-Guiu J. **Rev Neurol** 1996 Jun;24(130):625–7 **(Spa)**

METHODS

Structured abstracts [editorial] Harrison JE. **Community Dent Health** 1996 Jun;13(2):63–4

Information retrieval in medicine: the SAPHIRE experience. Hersh W, et al. **Medinfo** 1995;8 Pt 2:1433–7

Preliminary assessment of the effect of more informative (structured) abstracts on citation retrieval from MEDLINE. Wilczynski NL, et al. **Medinfo** 1995;8 Pt 2:1457–61

A quantitative ranking of the Biomedical Informatics serials. Sittig DF, et al. **Methods Inf Med** 1995 Sep;34(4):397–40

Automated MeSH indexing of the World-Wide Web. Fowler J, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:893–7

The SAPHIRE server: a new algorithm and implementation. Hersh W, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:858–62

Categorization by reference: a novel approach to MeSH term assignment. Kouramajian V, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:878–82

Contextual models of clinical publications for enhancing retrieval from full-text databases. Purcell GP, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:851–7

STANDARDS

Nonfatal injuries among US children [letter; comment] Kim HJ, et al. **Am J Public Health** 1996 Jun;86(6):892–3. Comment on: Am J Public Health 1995 Jul;85(7):932–8.

Improving participation and interrater agreement in scoring Ambulatory Pediatric Association abstracts. How well have we succeeded? Kemper KJ, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):380–3

Quantitative analyses of scientific literature and their validity for judging Latin American production [comment] Spinak E. **Bull Pan Am Health Organ** 1995 Dec;29(4):352–9; discussion 359–60 (25 ref.). Comment on: Bull Pan Am Health Organ 1995 Mar;29(1):87–95.

The domestic use of pesticides and childhood cancer; thoughts on the importance of the abstracts in environmental publications. von Mühlendahl KE. **Eur J Pediatr** 1995 Dec;154(12):991–2

Reasons for the loss of sensitivity and specificity of methodologic MeSH terms and textwords in MEDLINE. Wilczynski NL, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:436–40

TRENDS

Trends in submitting abstracts to the Italian society of osteoporosis: do they reflect a changing attitude of medical doctors? [letter] Mazzuoli G, et al. **Osteoporos Int** 1995; 5(6):484

ABUSE OF HEALTH SERVICES see **HEALTH SERVICES MISUSE**

ABUSED WOMEN see **BATTERED WOMEN**

ABUTMENTS, DENTAL see **DENTAL ABUTMENTS**

ACACIA

CHEMISTRY

Influence of pH adjustment on microcapsules obtained from complex coacervation of gelatin and acacia. Daniels R, et al. **J Microencapsul** 1995 Nov–Dec;12(6):591–9

ACACIA GUM see **GUM ARABIC**

ACADEMIC MEDICAL CENTERS

Managed care system for central Virginia: its potential impact on academic emergency medicine [letter] Alben MC, et al. **Acad Emerg Med** 1995 Oct;2(10):941–3

New models for emergency and ambulatory care at academic health centers--Part III: Boston and Alberta, Canada. Ling LJ, et al. **Acad Emerg Med** 1995 Nov;2(11):1001–6

Preventing academic medical center from becoming an oxymoron. Berns KI. **Acad Med** 1996 Feb;71(2):117–20

Learning to care, for a healthier tomorrow. Cohen JJ. **Acad Med** 1996 Feb;71(2):121–5

Research collaboration between an HMO and an academic medical center: lessons learned. Donahue DC, et al. **Acad Med** 1996 Feb;71(2):126–32

Managing information in the academic medical center: building an integrated information environment. Fuller S, et al. **Acad Med** 1995 Oct;70(10):887–91

Clinical research 1996: stirrings from the academic health centers. Shulman LE. **Acad Med** 1996 Apr;71(4):362–3, 398

Evaluation of a geriatric consultation unit in an acute university hospital. Friedman G, et al. **Aging (Milano)** 1995 Jun;7(3):234–6

Experience with community academic practice: strategies for the ambulatory education of residents. Hershey CO, et al. **Am J Med** 1995 Nov;99(5):530–6

The impact of managed care on graduate medical education and academic medical centers. Bolognia JL, et al. **Arch Dermatol** 1996 Sep;132(9):1078–84

Albumin and nonprotein colloid solution use in US academic health centers. Yim JM, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2450–5

Postdoctoral training in clinical chemistry: laboratory training aspects. Allen LC, et al. **Clin Biochem** 1995 Oct; 28(5):481–97

Effectiveness and safety of esophagogastroduodenoscopy in family practice: experience at a university medical center. Pope JB, et al. **Fam Med** 1995 Sep;27(8):506–11

Care of patients with upper gastrointestinal hemorrhage in academic medical centers: a community-based comparison. Cooper GS, et al. **Gastroenterology** 1996 Aug;111(2):385–90

Academic medicine: as threatened as most would have us believe? Deckers PJ. **Gynecol Oncol** 1996 Aug;62(2):151–8

Outpatient surgery of varices of the lower limbs: experience of 2,568 cases at four universities. Baccaglini U, et al. **Int Angiol** 1995 Dec;14(4):397–9

Partnership between a Veterans Affairs medical center and a podiatric medical college. Gorecki GA, et al. **J Am Podiatr Med Assoc** 1996 Aug;86(8):376–82

No margin, no mission [editorial] Souba WW. **J Surg Res** 1996 Aug;64(2):109–11

Career development for women in academic medicine: Multiple interventions in a department of medicine. Fried LP, et al. **JAMA** 1996 Sep 18;276(11):898–905

Research design for the project information for analysis of clinical care in the Academic Medical Center, Amsterdam. Prins H, et al. **Medinfo** 1995;8 Pt 1:401

Inpatient costs of specific cerebrovascular events at five academic medical centers [see comments] Holloway RG, et al. **Neurology** 1996 Mar;46(3):854–60. Comment in: Neurology 1996 Mar;46(3):602.

Networking may be key to academic cancer center survival under managed care [news] **Oncology (Huntingt)** 1995 Nov; 9(11):1127, 1133

Drug discovery and development in academic institutions. Burks TF. **Proc West Pharmacol Soc** 1995;38:137–9

Academic research and HIV/AIDS in South Africa. Campbell CM, et al. **S Afr Med J** 1996 Jan;86(1):55–60 (63 ref.)

Limited private practice at academic hospitals -- an 'in-house' group practice. Colborn RP, et al. **S Afr Med J** 1996 Mar;86(3):257–60

The role of tertiary institutions in society undergoing transition to democracy [editorial] Nethononda MR. **S Afr Med J** 1995 Dec;85(12):1267–8

HMOs and AHCs--in defense of town and gown [editorial] Rubin RT. **Science** 1996 Aug 30;273(5279):1153

A tale of two cities--one surgeon's perspective. Roslyn JJ. **Surgery** 1996 Aug;120(2):121–9

Reform in academic health centers [editorial; comment] Trunkey DD. **Surgery** 1996 Jan;119(1):115. Comment on: Surgery 1996 Jan;119(1):1–8.

Town versus gown. Besaw L. **Tex Med** 1995 Oct; 91(10):28–35

The Jeremiah Metzger Lecture. Academic medicine: building on the strengths of the past as we approach a cloudy future. Bennett JC. **Trans Am Clin Climatol Assoc** 1994;106:173–87

ECONOMICS

Financing academic medical centers: a shared responsibility. Hash M. **Acad Med** 1996 Jan;71(1):58–9

Impact of recent economic changes in psychiatry on academic psychiatry programs [editorial] Kane JM. **Am J Psychiatry** 1996 Mar;153(3):307–8

Academic health centers. Vulnerabilities in 1995 and beyond. Martin JB. **Arch Intern Med** 1995 Oct 23;155(19):2045–8

Survey results from academic health center intensive care units: considerations for departments of pharmacy. Matuszewski KA, et al. **Clin Ther** 1995 May–Jun; 17(3):517–24; discussion 516

Academic medicine. Contributing more than care [news] **Hosp Health Netw** 1996 Mar 20;70(6):14

Efficiencies. Fast track to cost-cutting. Nordhaus-Bike AM. **Hosp Health Netw** 1996 Jan 20;70(2):46–8

Managing pharmaceutical sales activities in an academic anesthesiology department. Johnstone RE, et al. **J Clin Anesth** 1995 Sep;7(6):544–8

Limitations of the profit-volume model in analyzing dental teaching clinics [see comments] DuBois LM. **J Dent Educ** 1996 Mar;60(3):274–79. Comment in: J Dent Educ 1996 May;60(5):409.

Academic medical centers and the fight for survival in the new era of managed care. Nauert RC. **J Health Care Finance** 1995 Summer;21(4):47–59 (15 ref.)

TennCare and academic medical centers: the lessons from Tennessee [see comments] Meyer GS, et al. **JAMA** 1996 Sep 4;276(9):672–6. Comment in: JAMA 1996 Sep 4;276(9):725–7.

British medical academic work faces "triple whammy" [news] Dean M. **Lancet** 1996 Jun 15;347(9016):1685

Investing in the future. Miller JP. **Minn Med** 1995 Sep; 78(9):10–8

Compensation for teaching medical students and house staff [letter; comment] Henrikson C. **N Engl J Med** 1996 Jul 4;335(1):58; discussion 58–9. Comment on: N Engl J Med 1996 Jan 18;334(3):162–7.

Tribulations and rewards of academic medicine--where does teaching fit? [editorial; comment] Kassirer JP. **N Engl J Med** 1996 Jan 18;334(3):184–5. Comment on: N Engl J Med 1996 Jan 18;334(3):162–7.

Foundations funding biomedical bodies should shift focus [news] Lehrman S. **Nature** 1996 Sep 12;383(6596):112

HISTORY

The evolution of a contemporary academic health care system. Crichlow RW. **Arch Surg** 1996 Mar;131(3):237–41

Scientific achievements of the Higher Medical Institute, Plovdiv [editorial] Iluchev D. **Folia Med (Plovdiv)** 1995; 37(4A Suppl):11–3

Early Mayo connections with Johns Hopkins. Nelson CW. **Mayo Clin Proc** 1996 Jun;71(6):532

A history of the Neurological Institute of New York and its Department of Neurological Surgery. Quest DO, et al. **Neurosurgery** 1996 Jun;38(6):1232–6

A history of neurological surgery at the University of California, San Francisco. Rosegay H. **Neurosurgery** 1996 Apr;38(4):794–805

The saga of an academic clinician: from micropuncturist to macroadministrator. Stein JH. **Trans Am Clin Climatol Assoc** 1994;106:213–20; discussion 220–1

[30 years of operation at the Cathedral and Orthopedic Clinic of the Medical Academy in Lodz] Zwierzchowski H. **Chir Narzadow Ruchu Ortop Pol** 1994;59(2):105–9 (Eng. Abstr.) **(Pol)**

LEGISLATION & JURISPRUDENCE

Policy. A lean, mean academic medicine machine. MacPherson P. **Hosp Health Netw** 1996 Jun 20;70(12):56, 60

ORGANIZATION & ADMINISTRATION

New models for emergency and ambulatory care at academic health centers--Part I: New York city. Ling LJ, et al. **Acad Emerg Med** 1995 Sep;2(9):836–43

New models for emergency and ambulatory care at academic health centers--Part II: Texas. Ling LJ, et al. **Acad Emerg Med** 1995 Oct;2(10):920–5

Realigning the values of academic health centers: the role of innovative faculty management. Arana GW, et al. **Acad Med** 1995 Dec;70(12):1073–8

A way to approach the strategic decisions facing academic health centers. Capper SA, et al. **Acad Med** 1996 Apr; 71(4):337–42

Business strategies for the survival of the academic medical center. Chessare JB, et al. **Acad Med** 1996 Mar;71(3):215–7

A perspective on academic medicine from the nation's largest managed care purchaser. Fried BM, et al. **Acad Med** 1996 Mar;71(3):260–1

Heavy weather ahead for clinical education in restructured academic health care systems. Kassebaum DG. **Acad Med** 1995 Oct;70(10):859–60

Can academic medical centers compete in a managed care system? Kralewski JE, et al. **Acad Med** 1995 Oct; 70(10):867–72

Leading academic internal medicine through education,

discussion, and advocacy. Ibrahim T, et al. **Am J Med** 1995 Oct;99(4):337–40

How departments of internal medicine can prepare for new relationships in a capitated environment. Stobo JD. **Am J Med** 1995 Oct;99(4):335–7

Improving the quality of health services organization structure by reengineering: circular design and clinical case impact in an academic medical center. Lartin–Drake JM, et al. **Am J Med Qual** 1996 Fall;11(3):151–8

Chief residency in PM&R. A balance of education and administration. Young MA, et al. **Am J Phys Med Rehabil** 1996 Jul–Aug;75(4):257–62

University surgical group. Karp RB. **Ann Thorac Surg** 1995 Nov;60(5):1481–5; discussion 1490–3

Are cost considerations contradictory to quality? Skinner DB. **Ann Thorac Surg** 1995 Nov;60(5):1498–9

The effect of health care reform on academic medicine in Canada. Editorial Committee of the Canadian Institute for Academic Medicine. Hollenberg CH. **Can Med Assoc J** 1996 May 15;154(10):1483–9 (0 ref.)

Academics and the nursing home. Katz PR, et al. **Clin Geriatr Med** 1995 Aug;11(3):503–16 (36 ref.)

Academic health centers in a changing environment. Blumenthal D, et al. **Health Aff (Millwood)** 1996 Summer; 15(2):200–15

Academic medicine. One hospital's managed care makeover. Foti SK. **Hosp Health Netw** 1995 Dec 20;69(24):79

Anything but academic. Hagland M. **Hosp Health Netw** 1996 Jan 5;70(1):20–5

Partnerships. Synergy in Seattle. Hagland M. **Hosp Health Netw** 1996 Jun 20;70(12):55–6

Quick study [interview by Kevin Lumsdon] Metts P. **Hosp Health Netw** 1996 Jul 20;70(14):44–5

Croatia's Academy of Medical Science [letter; comment] Stulhofer M. **Lancet** 1996 Aug 17;348(9025):479. Comment on: Lancet 1996 May 25;347(9013):1419.

Yale's Boyer Center for molecular medicine. Marchesi VT. **Mol Med** 1995 Jul;1(5):477–8

New violence institute extends UMDNJ tradition of service to New Jerseyans. Bergen SS Jr. **N J Med** 1996 Apr; 93(4):53–5

STANDARDS

The appropriateness of coronary artery bypass graft surgery in academic medical centers. Working Group of the Appropriateness Project of the Academic Medical Center Consortium. Leape LL, et al. **Ann Intern Med** 1996 Jul 1;125(1):8–18

Impact of interhospital transfers on outcomes in an academic medical center. Implications for profiling hospital quality. Gordon HS, et al. **Med Care** 1996 Apr;34(4):295–309

Documentation patterns before cataract surgery at ten academic centers. Lee PP, et al. **Ophthalmology** 1996 Aug; 103(8):1179–83

Professionalism, responsibility, and service in academic medicine [see comments] Souba WW. **Surgery** 1996 Jan; 119(1):1–8. Comment in: Surgery 1996 Jan;119(1):115.

STATISTICS & NUMERICAL DATA

High autopsy rates at a university medical center. What has gone right? Haque AK, et al. **Arch Pathol Lab Med** 1996 Aug;120(8):727–32 (19 ref.)

Academia's chilly climate for primary care. Block SD, et al. **JAMA** 1996 Sep 4;276(9):677–82

TRENDS

How one academic health center is successfully facing the future. Abdelhak SS. **Acad Med** 1996 Apr;71(4):329–36

Wagons ho: forward on the managed care trail. Summergrad P, et al. **Gen Hosp Psychiatry** 1995 Jul;17(4):251–9

Our fast-forward future. Davidson D. **Hosp Health Netw** 1995 Dec 20;69(24):90

So what? [editorial] Hadley J. **Inquiry** 1995 Fall;32(3):232–4

Gerald S. Levey, MD [interview] Levey GS. **J Investig Med** 1996 Apr;44(4):106–12

Future challenges to the academic medical center [editorial] Kim E. **JAMA** 1996 Apr 3;275(13):1052

Balancing community and academic health center needs while preserving educational quality. Krause C. **Laryngoscope** 1995 Oct;105(10):1021–3

As time goes by: reflections on 40 years of academic medicine and biomedical research. Firkin BG. **Med J Aust** 1995 Dec 4–18;163(11–12):604–6

UMDNJ and managed care. Bielory L, et al. **N J Med** 1995 Oct;92(10):651–4

How close to closing of academic complexes? [news] van der Linde I. **S Afr Med J** 1994 Nov;84(11):11

UTILIZATION

Comparing the hospitalizations of transfer and non-transfer patients in an academic medical center. Bernard AM, et al. **Acad Med** 1996 Mar;71(3):262–6

A profile of patients in six dental school clinics and implications for the future. Damiano PC, et al. **J Dent Educ** 1995 Dec;59(12):1084–90

A profile of patients in six dental schools [letter] Schneider DA, et al. **J Dent Educ** 1996 Jan;60(1):79–80

Assessment of appropriateness of cataract surgery at ten academic medical centers in 1990. Tobacman JK, et al. **Ophthalmology** 1996 Feb;103(2):207–15

ACADEMIES AND INSTITUTES

The Academy of Radiology Research. Putnam CE, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):313–4

What's in a name? A lot [editorial] Johns ME, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):595

Research note: the Lions Cancer Institute and the Western Australian Society of Plastic Surgeons skin cancer screening programme. Katris P, et al. **Aust N Z J Surg** 1996 Feb;66(2):101–4

Proposed academy of medicine. Academy of Medical Royal Colleges has its own, independent secretariat [letter] Caldicott F. **BMJ** 1996 Jul 27;313(7051):233–4

Proposed medical academy. Junior Doctors Committee proposed an academy in 1994 [letter] Carney A, et al. **BMJ** 1996 Jul 27;313(7051):234

Proposed medical academy. Profession should resist further fragmentation [letter] Cash J. **BMJ** 1996 Jul 27; 313(7051):234

Proposed academy of medicine. An academy would be inappropriate [letter; comment] Grabham AH. **BMJ** 1996 Jun 22;312(7046):1604. Comment on: BMJ 1996 Jun 1;312(7043):1374–5.

Proposed academy of medicine. Proposal is a fudge between academy of medicine and of health [letter] Lilford RJ. **BMJ** 1996 Jul 27;313(7051):233

Proposed academy of medicine. Profession is already more united than ever before [letter; comment] Macara AW. **BMJ** 1996 Jun 22;312(7046):1604. Comment on: BMJ 1996 Jun 1;312(7043):1374–5.

Proposed academy of medicine. Editorial did not acknowledge BMA's work [letter] Ross WM. **BMJ** 1996 Jul 27;313(7051):234

Does Britain need an academy of medicine? [editorial] [see comments] Smith R. **BMJ** 1996 Jun 1;312(7043):1374–5. Comment in: BMJ 1996 Jun 22;312(7046):1604.

The NCIC-Manitoba Breast Tumor Bank: a resource for applied cancer research. Watson PH, et al. **Can Med Assoc J** 1996 Aug 1;155(3):281–3

Environmental science in the city that never sleeps [news] **Environ Health Perspect** 1995 Jul–Aug;103(7–8):654–9

Ethics. The moralsmobile rolls in. Hudson T. **Hosp Health Netw** 1996 Jun 20;70(12):56

Academy for eating disorders. Powers PS. **Int J Eat Disord** 1996 Jan;19(1):1–4

Review of the first interactive workshop on professional flexible labeling. An Animal Health Institute perspective. Farho CJ. **J Am Vet Med Assoc** 1995 Oct 1;207(7):869–71

American Academy of Veterinary Pharmacology and Therapeutics: perspectives on the utility of flexible drug labeling. An AAVPT perspective: Part I. Koritz GD. **J Am Vet Med Assoc** 1995 Oct 1;207(7):875–6

American Academy of Veterinary Pharmacology and Therapeutics: perspectives on the utility of flexible drug labeling. An AAVPT perspective: Part II. Riviere JE. **J Am Vet Med Assoc** 1995 Oct 1;207(7):876–8

Colleges versus academies [editorial] Cohen A. **J R Soc Med** 1996 Jan;89(1):2

A UK Academy of Medicine: hot idea or hot air? [editorial] [see comments] **Lancet** 1996 May 25;347(9013):1419. Comment in: Lancet 1996 Aug 17;348(9025):479.

The Academy stumbles, then advances under fire. Horton R. **Lancet** 1996 Sep 14;348(9029):700

Cold Spring Harbor Laboratory. Stillman B. **Mol Med** 1995 Nov;1(7):715–7

The Institute of Molecular Medicine, University of Oxford. Weatherall D. **Mol Med** 1995 May;1(4):366–8

Rockefeller link for AIDS centre [news] **Nature** 1996 Jun 20;381(6584):641

Political uncertainty delays EMBL decision [news] Abbott A. **Nature** 1996 Jan 4;379(6560):4

EMBO seeks stronger voice on policy [news] Abbott A. **Nature** 1995 Oct 26;377(6551):666

German institute renews east–west unease [news] Abbott A. **Nature** 1996 Aug 8;382(6591):486

Genome laboratory makes its mark [news] Barker S. **Nature** 1996 Feb 29;379(6568):761

MITI turns up heat on research into thermophile genes [news] Barker S. **Nature** 1996 Jun 6;381(6582):455

Japanese genomics combines state and industry backing [news] Barker S. **Nature** 1996 Apr 4;380(6573):375

Japan needs centre of excellence for brain research, council says [news] Barker S. **Nature** 1996 May 23;381(6580):266

Restoring good manners [letter; comment] Morgan MJ. **Nature** 1995 Dec 7;378(6557):533. Comment on: Nature 1995 Sep 21;377(6546):192.

No takers so far for NASA science institutes [news] Reichhardt T. **Nature** 1996 Mar 7;380(6569):7

Resource in addiction psychiatry [letter] Trumble JG. **Postgrad Med** 1996 Mar;99(3):71

Center for the mind pleases the senses [news] Cohen J. **Science** 1995 Oct 27;270(5236):572

Koch keeps new watch on infections [news] Koenig R. **Science** 1996 Jun 7;272(5267):1412–4

Gallo's institute at the last hurdle [news] Marshall E. **Science** 1996 Mar 8;271(5254):1359

Moscow cardiology institute battles for its life [news] Stone R. **Science** 1996 May 3;272(5262):667

EMBnet: an institute without walls. Harper RA. **Trends Biochem Sci** 1996 Apr;21(4):150–2

[Towards greater involvement by the Academy in health policy] De Schouwer P. **Verh K Acad Geneeskd Belg** 1996; 58(1):5–9 (Eng. Abstr.) **(Dut)**

[Elite or cheat research units? (letter)] Andersson LC. **Duodecim** 1995;111(9):891–2 **(Fin)**

[Top groups in science in Finland (editorial)] Vihko R, et al. **Duodecim** 1994;110(19):1759–61 **(Fin)**

[Information on the Federation of National Academies of Medicine and similar institutions of the European Union] Auquier L. **Bull Acad Natl Med** 1995 Oct;179(7):1409–14 **(Fre)**

[Topical transfusion seminars of the National Institute of Blood Transfusion, October 26–27, 1995 (editorial)] Poyart C. **Transfus Clin Biol** 1995;2(6):419–21 **(Fre)**

[Quo vadis radiology? We need an academy (editorial)] Fischer J. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 May;164(5):357–8 **(Ger)**

[South-Hyougo earthquake and Institute for Protein Research] Nakamura M. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1871–5 **(Jpn)**

[The international cooperation of the Institute of Biomedical Problems in 1994 (news)] Kuzin RA, et al. **Aviakosm Ekolog Med** 1995;29(3):61–3 **(Rus)**

[Production of medical technology at the Research-Production Center at the Izhevsk State Medical Institute] Sobolevskiĭ SA. **Med Tekh** 1996 Mar–Apr; (2):18–9 (Eng. Abstr.) **(Rus)**

[Results and prospects of laser irradiation studies at the St. Petersburg Institute of Industrial Hygiene and Occupational Diseases] Ushkova IN, et al. **Med Tr Prom Ekol** 1996;(4):29–31 **(Rus)**

[Publications of investigators of the St. Petersburg Research Institute of Phthisis Pulmonology concerning results of scientific studies on tuberculosis in children and adolescents] Fenster GS. **Probl Tuberk** 1995;(5):60–2 **(Rus)**

[Angioneurosurgery at the Institute of Neurology of the Russian Academy of Medical Sciences] Peresedov VV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):19–23 (Eng. Abstr.) **(Rus)**

[Scientific and technical publications of the Institute of Medical Research and Occupational Health 1988–1993] Simeon-Rudolf V, et al. **Arh Hig Rada Toksikol** 1995 Sep; 46(3):359–67 (Eng. Abstr.) **(Scr)**

[A year of redefinitions at the National Institute of Public Health (editorial)] Sepúlveda J. **Salud Publica Mex** 1996 Mar–Apr;38(2):85–6 **(Spa)**

ECONOMICS

International biotech centre opens in Delhi with plea for cash [news] Jayaraman KS. **Nature** 1996 Mar 7;380(6569):4

HHMI awards [letter] Buxton IL. **Science** 1996 Feb 16; 271(5251):895

Med schools receive Hughes windfall [news] Kaiser J. **Science** 1996 Jan 12;271(5246):138

HISTORY

Instituto Nacional de Cardiologia Ignacio Chávez. Chávez Rivera I. **Acta Cardiol** 1996;51(1):1–8

First W.D.M. Paton Memorial Lecture. An F4-vescent episode: Sir Henry Dale's laboratory 1919–1942. Tansey EM. **Br J Pharmacol** 1995 Aug;115(8):1339–45

Radiotherapy in Macedonia. Smickoska S, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):1073–4

Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry. Takeuchi T. **J Cancer Res Clin Oncol** 1995;121(9–10):505–10 (52 ref.)

The Walter and Eliza Hall Institute of Medical Research 1965–1995: from basic research to clinical triumphs. Nossal GJ. **Med J Aust** 1995 Dec 4–18;163(11–12):599–603

A history of the Neurological Institute of New York and its Department of Neurological Surgery. Quest DO, et al. **Neurosurgery** 1996 Jun;38(6):1232–6

Research, prevention and impact [editorial] Hernberg S. **Scand J Work Environ Health** 1995 Jun;21(3):161–3

[70 years' of the National Health Institute in Prague] Ticháček B. **Epidemiol Mikrobiol Imunol** 1995 Sep; 44(3):99–103 **(Cze)**

[Health organization in Tunisia at the point of the creation of the Pasteur Institute in Tunisia] Annabi-Ben Nefissa K. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):345–9 **(Fre)**

[The Pasteur Institute in independent Tunisia from 1956 to 1988] Chadli A. **Arch Inst Pasteur Tunis** 1994 Jul–Oct; 71(3–4):379–84 **(Fre)**

[The creation of the Pasteur Institutes outside of France] Debre P. **Arch Inst Pasteur Tunis** 1994 Jul–Oct; 71(3–4):339–44 **(Fre)**

[The beginnings of the Pasteur Institute in Tunisia] Huet M. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):351–3 **(Fre)**

[Charles Nicolle, Tunisian savant] Moulin AM. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):355–70 **(Fre)**

[The Pasteur Institute in Tunisia from 1943 to 1956] Vermeil PC. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):375–8 **(Fre)**

[60 years of the Radiotherapy Department of the Hungarian National Institute of Oncology] Németh G. **Orv Hetil** 1996 May 19;137(20):1094–5 **(Hun)**

[The birth of experimental hygiene and the founding of the Istituto di Igiene of the University of Rome] Fantini B,

et al. **Ann Ig** 1994 Jul-Dec;6(4-6):339-55 (Eng. Abstr.) **(Ita)**

[Address given by the rector of the Pomeranian Medical Academy at inauguration of the academic year 1994/1995] Wiechowski S. **Ann Acad Med Stetin** 1995;41:21-7 **(Pol)**

[20 Years at the Central Clinical Hospital of the Medical Academy in Warsaw (editorial)] Nielubowicz J. **Pol Tyg Lek** 1995 Oct;50(40-44):5-6 **(Pol)**

[The 60th anniversary of the Institute of Aviation and Space Medicine] Stupakov GP, et al. **Aviakosm Ekolog Med** 1995; 29(2):4-6 **(Rus)**

[Aerospace radiobiology: the problems and the colleagues (on the 60th anniversary of the Institute of Aviation and Space Medicine)] Ushakov IB, et al. **Aviakosm Ekolog Med** 1995;29(2):59-63 **(Rus)**

[The formation and development of pharmacological research in Russian aviation and space medicine (on the 60th anniversary of the Institute of Aviation and Space Medicine of the Ministry of Defense of the Russian Federation)] Vasil'ev PV, et al. **Eksp Klin Farmakol** 1995 Sep-Oct;58(5):72-3 **(Rus)**

[The pedagogical activities of an academic and scientific complex (on the 20th anniversary of the creation of the P. K. Anokhin Research Institute of Normal Physiology of the Russian Academy of Medical Sciences)] Makarov VA. **Fiziol Zh Im I M Sechenova** 1995 Feb;81(2):109-12 **(Rus)**

[The 70th anniversary of the Saint Petersburg Research Institute of Industrial Hygiene and Occupational Diseases] Dudarev AIa, et al. **Med Tr Prom Ekol** 1995;(11):1-3 (Eng. Abstr.) **(Rus)**

[40th anniversary of the Ufa Research Institute of Occupational Medicine and Human Ecology. Results of activities] Karamova AM, et al. **Med Tr Prom Ekol** 1995; (12):1-6 **(Rus)**

[N. A. Vigdorchik, founder of the Leningrad Research Institute for the Study of Occupational Diseases] Retnev VM. **Med Tr Prom Ekol** 1995;(11):4-5 **(Rus)**

[D. N. Nasonov--founder of the Institute of Cytology] Nikol'skii NN, et al. **Tsitologiia** 1995;37(12):1251-8 **(Rus)**

[The A. L. Polenov Russian Neurosurgical Research Institute] Bersnev VP, et al. **Vestn Khir Im I I Grek** 1995; 154(3):112-4 **(Rus)**

[Role of the Moscow Research Institute of Diagnosis and Surgery in the development of materials and equipment for Russian roentgenology and radiology] Chikirdin EG. **Vestn Rentgenol Radiol** 1996 Jan-Feb;(1):54-6 **(Rus)**

[The Central Institute of Health Resort Medicine on the eve of and during World War II] Semenov BN. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May-Jun; (3):38-40 **(Rus)**

[The anniversary of the Moscow G. N. Gabrichevskiĭ Research Institute of Epidemiology and Microbiology] Aleshkin VA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):111-4 **(Rus)**

[The achievements of the Institute of Neurology of the Russian Academy of Medical Sciences over 50 years] Piradov MA. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):5-10 (Eng. Abstr.) **(Rus)**

[Periodic publications of the National Academy of Medicine in the 19th century] Rodríguez ME. **Gac Med Mex** 1995 Sep-Dec;131(5-6):577-83 **(Spa)**

ORGANIZATION & ADMINISTRATION

Developing a cooperative provider-based statewide peer review service: early experience. Helms CM, et al. **Am J Med Qual** 1996 Spring;11(1):46-50

The Armed Forces Institute of Pathology: an underutilized repository of case material [letter] Peterson MR. **Am J Public Health** 1996 Apr;86(4):592

The Leiden/Amsterdam center for drug research. **Eur J Drug Metab Pharmacokinet** 1995 Jul-Sep;20(3):243-4

Working from upstream to improve health care: the IHI interdisciplinary professional education collaborative. Headrick LA, et al. **Jt Comm J Qual Improv** 1996 Mar; 22(3):149-64

Australian institute gets new director [news] **Nature** 1995 Dec 14;378(6558):650

French genome pioneer goes private [news] Butler D. **Nature** 1996 Feb 8;379(6565):478

Rockefeller biologist tipped for the top at Salk [news] Macilwain C. **Nature** 1996 Feb 8;379(6565):475

Chambon builds institute with U.S. funds and eye for detail [news] Balter M. **Science** 1995 Sep 29;269(5232):1814-5

Salk: under new management [news] Cohen J. **Science** 1996 Aug 23;273(5278):1036-7

Salk Institute picks a new president [news] Cohen J. **Science** 1996 Jun 21;272(5269):1734

Max Planck Institutes brace for change [news] Kahn P. **Science** 1995 Oct 27;270(5236):568-70

Hubert Markl: animal behaviorist puts his learning to work [news] Koenig R. **Science** 1995 Oct 27;270(5236):569

State key labs in China [letter] Tsou CL. **Science** 1996 Jan 26;271(5248):434-5

Rajewsky to head EMBL's Italian lab [news] Williams N. **Science** 1995 Oct 27;270(5236):574

An update on the Jacobs Institute of Women's Health [editorial] Gibbs CE. **Womens Health Issues** 1995 Winter; 5(4):241

[Evolution of the Mycobacteria Laboratory of the Pasteur Institute of Madagascar from 1991 to 1994] Menard D, et al. **Arch Inst Pasteur Madagascar** 1995;62(1):52-8 (Eng. Abstr.) **(Fre)**

[National Laboratory for Mycobacterias. Evolution, missions and activities from 1991 to 1994] Ramarokoto H, et al. **Arch Inst Pasteur Madagascar** 1995;62(1):45-51 (Eng. Abstr.) **(Fre)**

[Research using communication networks: ageing as an example (editorial)] Henrard JC. **Rev Epidemiol Sante Publique** 1996 Apr;44(2):99-100 **(Fre)**

TRENDS

'Mini-Med schools' offer lay public lessons in the science of medicine [news] Stephenson J. **JAMA** 1996 Mar 27; 275(12):897-9

The John Curtin School of Medical Research: past achievements and future directions. Lafferty KJ. **Med J Aust** 1995 Dec 4-18;163(11-12):609-11

Practical applications of IAH research [news] **Vet Rec** 1995 Aug 12;137(7):154-5

[The basic research results and outlook of the Institute on the Problems of Child and Adolescent Hygiene] Makarova LP, et al. **Med Tr Prom Ekol** 1995;(11):6-8 (Eng. Abstr.) **(Rus)**

[The past, present and future of the National Academy of Medicine of Mexico] Campillo Serrano C. **An R Acad Nac Med (Madr)** 1996;Spec No:9-17 **(Spa)**

ACANTHAMOEBA

Disseminated acanthamebiasis in patients with AIDS. A report of five cases and a review of the literature. Murakawa GJ, et al. **Arch Dermatol** 1995 Nov; 131(11):1291-6

Cutaneous Acanthamoeba infection in the acquired immunodeficiency syndrome: response to multidrug therapy. Hunt SJ, et al. **Cutis** 1995 Nov;56(5):285-7

CHEMISTRY

Temperature-dependent changes in plasma-membrane lipid order and the phagocytotic activity of the amoeba Acanthamoeba castellanii are closely correlated. Avery SV, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):811-6

Thermal unfolding of Acanthamoeba myosin II and skeletal muscle myosin. Zolkiewski M, et al. **Biophys Chem** 1996 Apr 16;59(3):365-71 (45 ref.)

Identification of Acan125 as a myosin-I-binding protein present with myosin-I on cellular organelles of Acanthamoeba. Xu P, et al. **J Biol Chem** 1995 Oct 27; 270(43):25316-9

CYTOLOGY

Microtubule-associated movement of mitochondria and small particles in Acanthamoeba castellanii. Baumann O, et al. **Cell Motil Cytoskeleton** 1995;32(4):305-17

DRUG EFFECTS

Susceptibility of Acanthamoeba castellanii to contact lens disinfecting solutions. Zanetti S, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1596-8

A quantitative method to evaluate neutralizer toxicity against Acanthamoeba castellanii. Buck SL, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3521-6

The lethal effects of biguanides on cysts and trophozoites of Acanthamoeba castellanii. Khunkitti W, et al. **J Appl Bacteriol** 1996 Jul;81(1):73-7

ENZYMOLOGY

Characterisation of the fatty acid delta 12-desaturase of Acanthamoeba castellanii. Rutter AJ, et al. **Biochem Soc Trans** 1995 Aug;23(3):407S

Properties of Acanthamoeba myosin I heavy chain kinase bound to phospholipid vesicles. Wang ZY, et al. **J Biol Chem** 1995 Nov 17;270(46):27969-76

Biochemical kinetic characterization of the Acanthamoeba myosin-I ATPase. Ostap EM, et al. **J Cell Biol** 1996 Mar; 132(6):1053-60

Isolation of N-acetyl-beta-hexosaminidase from Acanthamoeba castellanii. Baldwin KM, et al. **J Eukaryot Microbiol** 1995 May-Jun;42(3):237-42

Interstrain polymorphisms of isoenzyme profiles and mitochondrial DNA fingerprints among seven strains assigned to Acanthamoeba polyphaga. Kong HH, et al. **Korean J Parasitol** 1995 Dec;33(4):331-40

Characterization of a plasminogen activator produced by Acanthamoeba castellanii. Mitra MM, et al. **Mol Biochem Parasitol** 1995 Jul;73(1-2):157-64

GENETICS

Cloning, expression, and characterization of the TATA-binding protein (TBP) promoter binding factor, a transcription activator of the Acanthamoeba TBP gene. Huang W, et al. **J Biol Chem** 1995 Dec 1;270(48):28839-47

Expression of a continuous open reading frame encoding subunits 1 and 2 of cytochrome c oxidase in the mitochondrial DNA of Acanthamoeba castellanii. Lonergan KM, et al. **J Mol Biol** 1996 Apr 19; 257(5):1019-30

Interstrain polymorphisms of isoenzyme profiles and mitochondrial DNA fingerprints among seven strains assigned to Acanthamoeba polyphaga. Kong HH, et al. **Korean J Parasitol** 1995 Dec;33(4):331-40

Genus- and subgenus-specific oligonucleotide probes for Acanthamoeba. Gast RJ, et al. **Mol Biochem Parasitol** 1995 May;71(2):255-60

Acanthamoeba castellanii contains a ribosomal RNA enhancer binding protein which stimulates TIF-IB binding and transcription under stringent conditions. Yang Q, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4345-52

[Genetic status of Acanthamoeba spp. Korean isolates on the basis of RAPD markers] Hong YP, et al. **Korean J Parasitol** 1995 Dec;33(4):341-8 (Eng. Abstr.) **(Kor)**

GROWTH & DEVELOPMENT

Viability of pathogenic Acanthamoeba and Naegleria and virulence of N. fowleri during long-term cryopreservation. John DT, et al. **Folia Parasitol (Praha)** 1996;43(1):43-6

IMMUNOLOGY

Identification of antigens of pathogenic free-living amoebae by protein immunoblotting with rabbit immune and human sera. Powell EL, et al. **Clin Diagn Lab Immunol** 1994 Sep; 1(5):493-9

ISOLATION & PURIFICATION

Confocal microscopy findings of Acanthamoeba keratitis [see comments] Pfister DR, et al. **Am J Ophthalmol** 1996 Feb; 121(2):119-28. Comment in: Am J Ophthalmol 1996 Feb;121(2):207-8.

Acanthamoeba griffini. Molecular characterization of a new corneal pathogen. Ledee DR, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):544-50

Acanthamoeba pearcei n. sp. (Protozoa: Amoebida) from sewage contaminated sediments. Nerad TA, et al. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):702-5

METABOLISM

Effect of adhered bacteria on the binding of Acanthamoeba to hydrogel lenses. Gorlin AI, et al. **Arch Ophthalmol** 1996 May;114(5):576-80

The effect of concurrent Pseudomonas or Xanthomonas exposure on adherence of Acanthamoeba castellanii to soft contact lenses. Kelly LD, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 May;234(5):311-4

Nucleotides increase the internal flexibility of filaments of dephosphorylated Acanthamoeba myosin II. Redowicz MJ, et al. **J Biol Chem** 1996 May 24;271(21):12401-7

Sequences, structural models, and cellular localization of the actin-related proteins Arp2 and Arp3 from Acanthamoeba. Kelleher JF, et al. **J Cell Biol** 1995 Oct;131(2):385-97

Characterization of actin and poly-L-proline binding sites of Acanthamoeba profilin with monoclonal antibodies and by mutagenesis. Kaiser DA, et al. **J Mol Biol** 1996 Feb 16;256(1):89-107

Identification of the polyamine N8-acetyltransferase involved in the pathway of 1,3-diaminopropane production in Acanthamoeba culbertsoni. Shukla OP, et al. **Parasitol Res** 1996;82(3):270-2

MICROBIOLOGY

Interaction of Legionella pneumophila with Acanthamoeba castellanii: uptake by coiling phagocytosis and inhibition of phagosome-lysosome fusion. Bozue JA, et al. **Infect Immun** 1996 Feb;64(2):668-73

Transmissibility of bacterial endosymbionts between isolates of Acanthamoeba spp. Gautom RK, et al. **J Eukaryot Microbiol** 1995 Sep-Oct;42(5):452-6

PATHOGENICITY

Acanthamoeba: ecology, pathogenicity and laboratory detection. Walker CW. **Br J Biomed Sci** 1996 Jun; 53(2):146-51 (30 ref.)

The duration of the cyst stage and the viability and virulence of Acanthamoeba isolates. Mazur T, et al. **Trop Med Parasitol** 1995 Jun;46(2):106-8

PHYSIOLOGY

Bacteriolytic activities of the free-living soil amoebae, Acanthamoeba castellanii, Acanthamoeba polyphaga and Hartmannella vermiformis. Weekers PH, et al. **Antonie Van Leeuwenhoek** 1995 Oct;68(3):237-43

Temperature-dependent changes in plasma-membrane lipid order and the phagocytotic activity of the amoeba Acanthamoeba castellanii are closely correlated. Avery SV, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):811-6

Influence of plasma membrane fluidity on phagocytotic activity in Acanthamoeba castellanii. Avery SV, et al. **Biochem Soc Trans** 1995 Aug;23(3):409S

Adherence of cysts and trophozoites of Acanthamoeba to unworn rigid gas permeable and soft contact lenses. Sharma S, et al. **CLAO J** 1995 Oct;21(4):247-51

Chemosensory responses of Acanthamoeba castellanii: visual analysis of random movement and responses to chemical signals. Schuster FL, et al. **J Eukaryot Microbiol** 1996 Mar-Apr;43(2):150-8

The duration of the cyst stage and the viability and virulence of Acanthamoeba isolates. Mazur T, et al.

Trop Med Parasitol 1995 Jun;46(2):106–8

ACANTHAMOEBA KERATITIS

DIAGNOSIS

In vivo confocal microscopy and Acanthamoeba keratitis [editorial; comment] Cavanagh HD, et al. **Am J Ophthalmol** 1996 Feb;121(2):207–8. Comment on: Am J Ophthalmol 1996 Feb;121(2):119–28. Comment on: Am J Ophthalmol 1996 Feb;121(2):129–42.

First case of Acanthamoeba keratitis in Malaysia. Kamel AG, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):652

[Acanthamoeba keratitis] Eggink CA, et al. **Ned Tijdschr Geneeskd** 1996 May 25;140(21):1130–33 (Eng. Abstr.) **(Dut)**

[Early clinical diagnosis of acanthamoeba keratitis. A study of 70 eyes] Bernauer W, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):282–4 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Abuse of Brolene eye drops with putative corneal infection [letter] Kinnear FB, et al. **J Infect** 1996 Mar;32(2):172–4

Treatment of Acanthamoeba keratitis [letter] Niszl IA, et al. **S Afr Med J** 1996 May;86(5):566

EPIDEMIOLOGY

Outbreak of keratitis presumed to be caused by Acanthamoeba [see comments] Mathers WD, et al. **Am J Ophthalmol** 1996 Feb;121(2):129–42. Comment in: Am J Ophthalmol 1996 Feb;121(2):207–8.

ETIOLOGY

Risk factors for acanthamoeba keratitis. Single use disposable contact lenses should cut risk [letter; commeut] [see comments] Edwards M, et al. **BMJ** 1995 Sep 23; 311(7008):808. Comment on: BMJ 1995 Jun 17;310(6994):1567–70. Comment in: BMJ 1996 Jan 20;312(7024):183.

Risk factors for acanthamoeba keratitis [letter; comment] Radford CF, et al. **BMJ** 1996 Jan 20;312(7024):183. Comment on: BMJ 1995 Sep 23;311(7008):808.

Risk factors for acanthamoeba keratitis. Population study is required to confirm results [letter; comment] [see comments] Seal DV, et al. **BMJ** 1995 Sep 23;311(7008):808 . Comment on: BMJ 1995 Jun 17;310(6994):1567–70. Comment in: BMJ 1996 Jan 20;312(7024):183.

[Free living amebas in whirlpools and swimming pools—a risk for contact lens users] Kalso S, et al. **Duodecim** 1994; 110(13):1256–61 **(Fin)**

[A case of Acanthamoeba keratitis after operation for cataract] Takatsu M, et al. **Kansenshogaku Zasshi** 1995 Oct; 69(10):1159–61 (Eng. Abstr.) **(Jpn)**

PARASITOLOGY

Confocal microscopy findings of Acanthamoeba keratitis [see comments] Pfister DR, et al. **Am J Ophthalmol** 1996 Feb; 121(2):119–28. Comment in: Am J Ophthalmol 1996 Feb;121(2):207–8.

Acanthamoeba griffini. Molecular characterization of a new corneal pathogen. Ledee DR, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):544–50

PHYSIOPATHOLOGY

The role of macrophages in Acanthamoeba keratitis. van Klink F, et al. **Invest Ophthalmol Vis Sci** 1996 Jun; 37(7):1271–81

THERAPY

Acanthamoeba keratitis: risk factors and outcome. Illingworth CD, et al. **Br J Ophthalmol** 1995 Dec; 79(12):1078–82

ACANTHOCEPHALA

CHEMISTRY

Cadmium concentrations in two adult acanthocephalans, Pomphorhynchus laevis and Acanthocephalus lucii, as compared with their fish hosts and cadmium and lead levels in larvae of A. lucii as compared with their crustacean host. Sures B, et al. **Parasitol Res** 1995;81(6):494–7

Lipids of fish parasites and their hosts: fatty acid fingerprints of four species of acanthocephalans and of their hosts' intestinal tissues. Taraschewski H, et al. **Parasitol Res** 1995; 81(6):522–6

CLASSIFICATION

The genus Centrorhynchus (Acanthocephala) in North America with description of Centrorhynchus robustus n. sp., redescription of Centrorhynchus conspectus, and a key to species. Richardson DJ, et al. **J Parasitol** 1995 Oct; 81(5):767–72

PHYSIOLOGY

Gammarus pulex (L.) feeding bioassay—effects of parasitism. Pascoe D, et al. **Bull Environ Contam Toxicol** 1995 Oct; 55(4):629–32

Population biology of Pomphorhynchus laevis in brown trout from two lakes in the west of Ireland. Molloy S, et al. **J Helminthol** 1995 Sep;69(3):229–35

Cypria reptans (Crustacea: Ostracoda) as an intermediate host of Neoechinorhynchus rutili (Acanthocephala: Eoacanthocephala) in Italy. Dezfuli BS. **J Parasitol** 1996 Jun;82(3):503–5

Correlation between the level of infection with Bunodera inconstans and Neoechinorhynchus rutili and behavioral intensity in female brook sticklebacks. McLennan DA, et al. **J Parasitol** 1995 Oct;81(5):675–82

Gammarus lacustris harboring Polymorphus paradoxus show altered patterns of serotonin-like immunoreactivity. Maynard BJ, et al. **J Parasitol** 1996 Aug;82(4):663–6

ACANTHOCHEILONEMA see **DIPETALONEMA**

ACANTHOCHEILONEMA PERSTANS see **MANSONELLA**

ACANTHOCHEILONEMIASIS see **DIPETALONEMA INFECTIONS**

ACANTHOCYTES

[Choreoacanthocytosis. A neurologic–hematologic syndrome] Hiersemenzel LP, et al. **Nervenarzt** 1996 Jun; 67(6):490–5 (39 ref.) (Eng. Abstr.) **(Ger)**

[Cardiac involvement in familial amytrophic chorea with acantocytosis: description of two new clinical cases] Cavalli G, et al. **Ann Ital Med Int** 1995 Oct–Dec;10(4):249–52 (Eng. Abstr.) **(Ita)**

PATHOLOGY

The pattern of cognitive impairments in neuroacanthocytosis. A frontosubcortical dementia. Kartsounis LD, et al. **Arch Neurol** 1996 Jan;53(1):77–80

Neuroacanthocytosis presenting with epilepsy [letter] Kazis A, et al. **J Neurol** 1995 Jun;242(6):415–7

PHYSIOLOGY

A novel point mutation in the McLeod syndrome gene in neuroacanthocytosis. Ho MF, et al. **Ann Neurol** 1996 May; 39(5):672–5

ULTRASTRUCTURE

Images in clinical medicine. Spur cells. Doll DC. **N Engl J Med** 1995 Nov 2;333(18):1183

ACANTHOLYSIS

DIAGNOSIS

Relapsing linear acantholytic dermatosis. Duschet P, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):920–2

ETIOLOGY

Transient acantholytic dermatosis associated with superior vena caval syndrome in a patient with carcinoid tumour of the thymus [letter] Miralles ES, et al. **Acta Derm Venereol** 1995 Sep;75(5):410

PATHOLOGY

Focal acantholytic dyskeratosis on the lip. Ahn SK, et al. **Am J Dermatopathol** 1995 Apr;17(2):189–91

A rare presentation of acantholytic dyskeratosis. Hayakawa K, et al. **Br J Dermatol** 1995 Sep;133(3):487–9

Fordyce spots on the glans penis [letter] Massmanian A, et al. **Br J Dermatol** 1995 Sep;133(3):498–500

ACANTHOLYSIS BULLOSA see **EPIDERMOLYSIS BULLOSA**

ACANTHOSIS NIGRICANS

BLOOD

Acanthosis nigricans: a marker for hyperinsulinemia. Brockow K, et al. **Pediatr Dermatol** 1995 Dec;12(4):323–6

COMPLICATIONS

Malignant acanthosis nigricans in adrenal carcinoma. Hiranandani M, et al. **Indian Pediatr** 1995 Aug;32(8):920–3

Follicular mucinosis plus mycosis fungoides and acanthosis nigricans plus alveolar bronchiolar carcinoma. Cottoni F, et al. **Int J Dermatol** 1995 Dec;34(12):867–9

Pre-B acute lymphoblastic leukemia in a patient with partial lipodystrophy and acanthosis nigricans. Franceschini P, et al. **Panminerva Med** 1995 Dec;37(4):248–51

DIAGNOSIS

HAIR-AN syndrome and mental disorders [letter; comment] Morales-Roselló J. **J Neuropsychiatry Clin Neurosci** 1995 Fall;7(4):538–9. Comment on: J Neuropsychiatry Clin Neurosci 1992 Winter;4(1):51–4.

ENZYMOLOGY

Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. D'Armiento J, et al. **Mol Cell Biol** 1995 Oct;15(10):5732–9

GENETICS

Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Meyers GA, et al. **Nat Genet** 1995 Dec;11(4):462–4

PATHOLOGY

Malignant acanthosis nigricans with florid papillary oral lesions. Tyler MT, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):445–9

PHYSIOPATHOLOGY

Hyperandrogenism, insulin resistance, and acanthosis nigricans (HAIR-AN) syndrome: spontaneous remission in a 15-year-old girl. Esperanza LE, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):892–7

ACARI

[A case for diagnosis: Argas reflexus] Le Coz C, et al. **Ann Dermatol Venereol** 1996;123(4):273–4 **(Fre)**

[Relative humidity and acari. An intervention study] Pascual Izaola A, et al. **Allergol Immunopathol (Madr)** 1995 Sep–Oct;23(5):231–4 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Cuticular hydrocarbon variation and progeny phenotypic similarity between laboratory breeds of allopatric populations of Argas (persicargas) persicus (oken) (acari: argasidae). Estrada-Peña A, et al. **Acta Trop** 1995 Aug; 59(4):309–22

GENETICS

Cuticular hydrocarbon variation and progeny phenotypic similarity between laboratory breeds of allopatric populations of Argas (persicargas) persicus (oken) (acari: argasidae). Estrada-Peña A, et al. **Acta Trop** 1995 Aug; 59(4):309–22

IMMUNOLOGY

[Effectiveness of a test for verification of the presence of acari in house dust for the prevention of respiratory allergies in children] Cantani A, et al. **Riv Eur Sci Med Farmacol** 1995 Jan–Feb;17(1):3–9 (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

Borrelia burgdorferi sensu lato in female cement plug of Ixodes persulcatus ticks (Acari, Ixodidae). Alekseev AN, et al. **Exp Appl Acarol** 1995 Sep;19(9):519–22

ACARIASIS see **MITE INFESTATIONS**

ACARUS see **MITES**

ACCELERATED IDIOVENTRICULAR RHYTHM

CHEMICALLY INDUCED

[Transient arrhythmia disclosing major glycine poisoning during hysteroscopy] Gbossou JM, et al. **Ann Fr Anesth Reanim** 1995;14(4):370–3 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Regular atrial fibrillation spells trouble. Drew BJ, et al. **Prog Cardiovasc Nurs** 1995 Summer;10(3):44–5

ACCELERATION

Crash pulse recorder—validation in full scale crash tests. Kullgren A, et al. **Accid Anal Prev** 1995 Oct;27(5):717–27

Linear acceleration perception: frequency dependence of the hilltop illusion. Glasauer S. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:37–40

Influence of centrifugal force on angular velocity estimation. Mittelstaedt ML. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:307–9

Yaw angular acceleration changes in human ocular torsional position. Smith ST, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:301–3

Effect of alcohol on the threshold for detecting angular acceleration. Ross LE, et al. **Aviat Space Environ Med** 1995 Jul;66(7):635–40

Determination of wheelchair dynamic load data for use with finite element analysis. VanSickle DP, et al. **IEEE Trans Rehabil Eng** 1996 Sep;4(3):161–70

The study of kinematic transients in locomotion using the integrated kinematic sensor. Wu G, et al. **IEEE Trans Rehabil Eng** 1996 Sep;4(3):193–200 (18 ref.)

Finite element model study of head impact based on Hybrid III head acceleration: the effects of rotational and translational acceleration. Ueno K, et al. **J Biomech Eng** 1995 Aug;117(3):319–28

Gravitational artefact in frequency spectra of movement

ACCELERATION

acceleration: implications for actigraphy in young and elderly subjects. Van Someren EJ, et al. **J Neurosci Methods** 1996 Mar;65(1):55–62

[Tolerance of chest–to–back [+Gx] and head–to–feet [+Gx] acceleration in drug–induced hypohydration] Noskov VB, et al. **Kosm Biol Aviakosm Med** 1991 Sep–Oct;25(5):4–6 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Greyout, blackout, and G–loss of consciousness in the Brazilian Air Force: a 1991–92 survey. Alvim KM. **Aviat Space Environ Med** 1995 Jul;66(7):675–7

The role of anaerobic power in human tolerance to simulated aerial combat maneuvers. Wiegman JF, et al. **Aviat Space Environ Med** 1995 Oct;66(10):938–42

ACCELOGRAPHY see **KINETOCARDIOGRAPHY**

ACCEPTABILITY OF HEALTH CARE see **PATIENT ACCEPTANCE OF HEALTH CARE**

ACCESS TO HEALTH CARE see **HEALTH SERVICES ACCESSIBILITY**

ACCESSIBILITY OF HEALTH SERVICES see **HEALTH SERVICES ACCESSIBILITY**

ACCESSORY CELLS, IMMUNOLOGIC see **ANTIGEN–PRESENTING CELLS**

ACCESSORY NERVE

Multiple myeloma presenting as the Collet–Sicard syndrome. Tappin JA, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):14

Preservation of spinal accessory nerve in modified neck dissections. Deschler DG, et al. **Laryngoscope** 1996 May; 106(5 Pt 1):664–6

Polyneuritis cranialis due to varicella–zoster virus in the absence of rash. Osaki Y, et al. **Neurology** 1995 Dec; 45(12):2293

Hypoplasia of the internal carotid artery associated with spasmodic torticollis: the possible role of altered vertebrobasilar haemodynamics. Kikuchi K, et al. **Neuroradiology** 1995 Jul;37(5):362–4

EMBRYOLOGY

Fasciculus intramedullaris accessorius in the development of the human embryonic spinal accessory nerve. Skórzewska A, et al. **Folia Morphol (Warsz)** 1995;54(1):15–23

INJURIES

Diagnosis and treatment of iatrogenic spinal accessory nerve injury. Matz PG, et al. **Am Surg** 1996 Aug;62(8):682–5

Spinal accessory nerve injury as a complication of internal jugular vein cannulation [letter] Burns S, et al. **Ann Intern Med** 1996 Oct 15;125(8):700

Iatrogenic accessory nerve injury. London J, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2):146–50

Iatrogenic accessory nerve injury [letter] O'Leary S, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):400

Iatrogenic accessory nerve injury [letter] Starr DG, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):399

[Accessory nerve injury as a complication of therapeutic stretching of the shoulder] Halonen E, et al. **Duodecim** 1994;110(9):889–90 **(Fin)**

[An unusual complication of cervicofacial lift: paralysis of the external branch of the accessory spinal nerve] Costagliola M, et al. **Ann Chir Plast Esthet** 1995 Aug; 40(4):340–8 (Eng. Abstr.) **(Fre)**

[Evaluation of iatrogenic accessory nerve injury in forensic medical practice] Somogyi E, et al. **Orv Hetil** 1996 Apr 14;137(15):803–6 (Eng. Abstr.) **(Hun)**

PHYSIOLOGY

Magnetic stimulation of the spinal accessory nerve: normative data and clinical utility in an isolated stretch–induced palsy. Pelliccioni G, et al. **J Neurol Sci** 1995 Sep;132(1):84–8

PHYSIOPATHOLOGY

Levator scapulae transfer and fascia lata fasciodesis for chronic spinal accessory nerve palsy. Coessens BC, et al. **J Reconstr Microsurg** 1995 Jul;11(4):277–80

SURGERY

Reconstruction of the spinal accessory nerve with an anastomosis to the dorsal C3 branch: technical note. Braun V, et al. **Neurosurgery** 1996 Jan;38(1):208–10

ACCIDENT INSURANCE see **INSURANCE, ACCIDENT**

ACCIDENT PREVENTION

see related
PROTECTIVE DEVICES

Analysis of Hispanic motor vehicle trauma victims in Illinois, 1991–1992 [see comments] Lee P, et al. **Acad Emerg Med** 1996 Mar;3(3):221–7. Comment in: Acad Emerg Med 1996 Mar;3(3):194–7.

On the prevention of accidents and injuries. A comparative analysis of conceptual frameworks. Andersson R, et al. **Accid Anal Prev** 1995 Dec;27(6):757–68 (30 ref.)

Treated injuries in northern Vermont. Waller JA, et al. **Accid Anal Prev** 1995 Dec;27(6):819–28

Protective gloves for high–risk autopsies [letter] Zugibe FT, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):182

Accuracy of ICD–9 coding with regard to childhood accidents. Beattie TF. **Health Bull (Edinb)** 1995 Nov; 53(6):395–7

Methodological considerations in participant event monitoring of low–base–rate events in health psychology: children's injuries as a model. Peterson L, et al. **Health Psychol** 1996 Mar;15(2):124–30

Developing a research strategy for child accident prevention via a cross–cultural picture card game. Hugo J. **J Audiov Media Med** 1995 Mar;18(1):11–5

Health visitors' knowledge, attitudes and practices in childhood accident prevention. Marsh P, et al. **J Public Health Med** 1995 Jun;17(2):193–9

[Accident prevention in 0–to–5–year–old children in Vaud: implications of a population study for medical practice] Addor V, et al. **Rev Med Suisse Romande** 1995 Nov; 115(11):849–57 **(Fre)**

[Accidents in children and adolescents: from analysis to prevention] Reinberg O. **Rev Med Suisse Romande** 1995 Nov;115(11):863–7 **(Fre)**

[Trauma epidemiology––a tool in trauma prevention] Ytterstad B. **Tidsskr Nor Laegeforen** 1996 Apr 20; 116(10):1205–6 **(Nor)**

[Incident reporting leads to safer health care] Bergentz SE. **Lakartidningen** 1996 Aug 28;93(35):2925–6 **(Swe)**

[Great interest in registration of incidents. Worry about reporting to HSAN may put a brake on it] Westerling R, et al. **Lakartidningen** 1996 Aug 28;93(35):2928–30 **(Swe)**

ACCIDENT PRONENESS

Behavioral precursors to accidents and resulting physical impairment. Pulkkinen L. **Child Dev** 1995 Dec; 66(6):1660–79

ACCIDENTAL FALLS

EMG–responses to sudden onset free fall. Bisdorff AR, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:347–9

Predictors of fall–related injuries among community–dwelling elderly people with dementia. Asada T, et al. **Age Ageing** 1996 Jan;25(1):22–8

Physiological factors and medications as predictors of injurious falls by elderly people: a prospective population–based study. Koski K, et al. **Age Ageing** 1996 Jan;25(1):29–38

Fall–related occupational injuries on farms. Nordstrom DL, et al. **Am J Ind Med** 1996 May;29(5):509–15

Exercise effect on dynamic stability in older women: a randomized controlled trial. Lord SR, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3):232–6

Rightward orienting bias, wheelchair maneuvering, and fall risk. Webster JS, et al. **Arch Phys Med Rehabil** 1995 Oct; 76(10):924–8

Community–dwelling older adults' attributions about falls. Weinberg LE, et al. **Arch Phys Med Rehabil** 1995 Oct; 76(10):955–60

Falls due to stroke. Drug treatment and mental status of study patients is unclear [letter; comment] Bhatnagar KS. **BMJ** 1995 Oct 14;311(7011):1022. Comment on: BMJ 1995 Jul 8;311(6997):83–6.

Etiology and prevention of age–related hip fractures. Hayes WC, et al. **Bone** 1996 Jan;18(1 Suppl):77S–86S (110 ref.)

Hot spring burns. Baruchin AM. **Burns** 1996 Mar;22(2):156–7

Late onset muscular dystrophy proximal myopathy and recurrent falls in the elderly. Boonen S. **Clin Rheumatol** 1995 Sep;14(5):586–90

Traumatic separation of the upper femoral epiphysis in a 15–month–old girl: an unusual mechanism of injury. Ashwood N, et al. **Injury** 1995 Dec;26(10):695–6

Fracture of the thumb sesamoid: a new physical sign. Dodenhoff RM. **Injury** 1996 Apr;27(3):213–4

An atypical fracture of a triquetral–lunate synostosis. Höcker K, et al. **Injury** 1996 Apr;27(3):227–8

The epidemiology of pelvic fractures in the Mersey Region. Muir L, et al. **Injury** 1996 Apr;27(3):199–204

Falls in community–dwelling older persons [letter] Kruse WH. **J Am Geriatr Soc** 1996 Aug;44(8):1010

Psychoactive medication, alcohol use, and falls among older adults. Sheahan SL, et al. **J Behav Med** 1995 Apr; 18(2):127–40

Energy–shunting hip padding system attenuates femoral impact force in a simulated fall. Robinovitch SN, et al. **J Biomech Eng** 1995 Nov;117(4):409–13

Dynamic models for sideways falls from standing height. van den Kroonenberg AJ, et al. **J Biomech Eng** 1995 Aug; 117(3):309–18

Drop attacks and instability of the degenerate cervical spine. van Norel GJ, et al. **J Bone Joint Surg Br** 1996 May; 78(3):495–6

Energy–shunting external hip protector attenuates the peak femoral impact force below the theoretical fracture threshold: an in vitro biomechanical study under falling conditions of the elderly. Parkkari J, et al. **J Bone Miner Res** 1995 Oct;10(10):1437–42

The perils of bungee jumping. Shapiro MJ, et al. **J Emerg Med** 1995 Sep–Oct;13(5):629–31

Risk factors for falls in the Chinese elderly population. Ho SC, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep; 51(5):M195–8

Psychological indicators of balance confidence: relationship to actual and perceived abilities. Myers AM, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):M37–43

Clinical and biomechanical measures of balance as fall predictors in ambulatory nursing home residents. Thapa PB, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep; 51(5):M239–46

Strength is a major factor in balance, gait, and the occurrence of falls. Wolfson L, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:64–7

Post–traumatic irreducible nondissociative carpal instability: a case report. Arms DM, et al. **J Hand Surg [Am]** 1995 Sep;20(5):778–80

Night nurse. Moritz SJ. **J Neurosci Nurs** 1995 Dec; 27(6):370–3

Fetal complications related to minor maternal trauma. Huzel PS, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb; 25(2):121–4 (9 ref.)

Force attenuation in trochanteric soft tissues during impact from a fall. Robinovitch SN, et al. **J Orthop Res** 1995 Nov; 13(6):956–62

Fetal heart rate monitoring casebook. Persistent bradycardia. Bayer–Zwirello LA, et al. **J Perinatol** 1995 Nov–Dec; 15(6):514–6

Hip pain in a patient with an earlier fall. Falen SW, et al. **J South Orthop Assoc** 1995 Summer;4(2):124–7

Traumatic spinal subdural hematoma: rapid resolution after repeated lumbar spinal puncture and drainage. Lee JI, et al. **J Trauma** 1996 Apr;40(4):654–5

An 85–year–old woman with a history of falls [clinical conference] Lipsitz LA. **JAMA** 1996 Jul 3;276(1):59–66

Fall–related factors and risk of hip fracture: the EPIDOS prospective study. Epidémiologie de l'ostéoporose. Dargent–Molina P, et al. **Lancet** 1996 Jul 20; 348(9021):145–9

Falls and urinary incontinence in a 66–year–old woman. Yusuf SW, et al. **Lancet** 1996 Jun 22;347(9017):1738

Bilateral proximal sciatic neuropathy caused by a fall [letter] Ku A, et al. **Muscle Nerve** 1996 Jan;19(1):113

Stress distributions within the proximal femur during gait and falls: implications for osteoporotic fracture. Lotz JC, et al. **Osteoporos Int** 1995;5(4):252–61

Age–related hip fractures in men: clinical spectrum and short–term outcomes. Poór G, et al. **Osteoporos Int** 1995; 5(6):419–26

Traumatic rupture of an unsuspected mesenteric cyst: an uncommon cause of an acute surgical abdomen following a minor fall. Klein MD. **Pediatr Emerg Care** 1996 Feb; 12(1):40

Peripheral neuropathy: an often–overlooked cause of falls in the elderly. Richardson JK, et al. **Postgrad Med** 1996 Jun;99(6):161–72 (20 ref.)

[Head injuries from falls in children of 2 ethnic groups] Levi L, et al. **Harefuah** 1995 Jul;129(1–2):9–12, 80, 79 (Eng. Abstr.) **(Heb)**

[Fall in the elderly and periventricular hyperintensity] Adachi T, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):617–20 (Eng. Abstr.) **(Jpn)**

[Patterns of use, popular beliefs and proneness to accidents of a baby walker (go–cart). Bases for a health information campaign] Santos Serrano L, et al. **An Esp Pediatr** 1996 Apr;44(4):337–40 (Eng. Abstr.) **(Spa)**

ECONOMICS

Economic dimensions of slip and fall injuries. Englander F, et al. **J Forensic Sci** 1996 Sep;41(5):733–46 (42 ref.)

MORTALITY

Risk of dying after a free fall from height. Risser D, et al. **Forensic Sci Int** 1996 Apr 23;78(3):187–91

PREVENTION & CONTROL

A standardized instrument to assess hazards for falls in the home of older persons. Rodriguez JG, et al. **Accid Anal Prev** 1995 Oct;27(5):625–31

Case–control study of hazards in the home and risk of falls and hip fractures. Clemson L, et al. **Age Ageing** 1996 Mar; 25(2):97–101

Does multiple risk factor reduction explain the reduction in fall rate in the Yale FICSIT Trial? Frailty and Injuries Cooperative Studies of Intervention Techniques. Tinetti ME, et al. **Am J Epidemiol** 1996 Aug 15;144(4):389–99

Prevention of falls in the elderly. Myers AH, et al. **Bone** 1996 Jan;18(1 Suppl):87S–101S

Elderly people who fall: identifying and managing the causes. Campbell AJ, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):520–3 (21 ref.)

Gait and activity in the elderly: implications for community falls–prevention and treatment programmes. Cwikel J, et al. **Disabil Rehabil** 1995 Aug–Sep;17(6):277–80

Preventing falls: how to identify risk factors, reduce complications. Tideiksaar R. **Geriatrics** 1996 Feb; 51(2):43–6, 49–50, 53, quiz 54–5 (5 ref.)

The effect of a 12–month exercise trial on balance, strength, and falls in older women: a randomized controlled trial. Lord SR, et al. **J Am Geriatr Soc** 1995 Nov;43(11):1198–206

Reducing frailty and falls in older persons: an investigation

of Tai Chi and computerized balance training. Atlanta FICSIT Group. Frailty and Injuries: Cooperative Studies of Intervention Techniques [see comments] Wolf SL, et al. **J Am Geriatr Soc** 1996 May;44(5):489–97. Comment in: J Am Geriatr Soc 1996 May;44(5):599–600.

Airbag safety: deployment in an automobile crash with a fall from height. Barton ED. **J Emerg Med** 1995 Jul–Aug; 13(4):481–4

The cost-effectiveness of a multifactorial targeted prevention program for falls among community elderly persons. Rizzo JA, et al. **Med Care** 1996 Sep;34(9):954–69

Preventing falls in the elderly at home: a community-based program [letter] Frank OR. **Med J Aust** 1996 Aug 19; 165(4):238

Preventing falls in the elderly at home: a community-based program. Thompson PG. **Med J Aust** 1996 May 6; 164(9):530–2

Evaluation and implementation of a research-based falls assessment innovation. McCollam ME.
Nurs Clin North Am 1995 Sep;30(3):507–14

Slip–and–fall accidents. Bell J. **Occup Health Saf** 1995 Dec; 64(12):40–1, 57

Wipe out slips and falls. Brock M. **Occup Health Saf** 1996 Jun;65(6):57

Proper fall protection training. David DA JR.
Occup Health Saf 1996 Jun;65(6):54–6, 58–9

The modified Gait Abnormality Rating Scale for recognizing the risk of recurrent falls in community-dwelling elderly adults. VanSwearingen JM, et al. **Phys Ther** 1996 Sep; 76(9):994–1002

STATISTICS & NUMERICAL DATA

Falls in the elderly: a prospective study of risk factors and risk profiles. Graafmans WC, et al. **Am J Epidemiol** 1996 Jun 1;143(11):1129–36

Exercise effect on dynamic stability in older women: a randomized controlled trial. Lord SR, et al.
Arch Phys Med Rehabil 1996 Mar;77(3):232–6

Prevalence of low vision in elderly patients admitted to an acute geriatric unit in Liverpool: elderly people who fall are more likely to have low vision [see comments] Jack CI, et al. **Gerontology** 1995;41(5):280–5. Comment in: Gerontology 1996;42(1):59.

An epidemiologic study of fall–related fractures among institutionalized older people. Cali CM, et al.
J Am Geriatr Soc 1995 Dec;43(12):1336–40

Physical restraint use and falls in nursing home residents [see comments] Capezuti E, et al. **J Am Geriatr Soc** 1996 Jun; 44(6):627–33. Comment in: J Am Geriatr Soc 1996 Jun;44(6):727–8.

Increased fall rates in nursing home residents after relocation to a new facility. Friedman SM, et al.
J Am Geriatr Soc 1995 Nov;43(11):1237–42

Falls in community-dwelling older persons. King MB, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1146–54 (97 ref.)

Falls among older people: relationship to medication use and orthostatic hypotension [see comments] Liu BA, et al.
J Am Geriatr Soc 1995 Oct;43(10):1141–5. Comment in: J Am Geriatr Soc 1995 Oct;43(10):1169.

Falls leading to femoral neck fractures in lucid older people. Nyberg L, et al. **J Am Geriatr Soc** 1996 Feb;44(2):156–60

To use physical restraints or not? [editorial; comment] Schnelle JF, et al. **J Am Geriatr Soc** 1996 Jun;44(6):727–8 . Comment on: J Am Geriatr Soc 1996 Jun;44(6):627–33.

Injurious falls in nonambulatory nursing home residents: a comparative study of circumstances, incidence, and risk factors. Thapa PB, et al. **J Am Geriatr Soc** 1996 Mar; 44(3):273–8

The contribution of predisposing and situational risk factors to serious fall injuries. Tinetti ME, et al.
J Am Geriatr Soc 1995 Nov;43(11):1207–13

Risk factors for serious injury during falls by older persons in the community. Tinetti ME, et al. **J Am Geriatr Soc** 1995 Nov;43(11):1214–21

Falls, fallacies, and hypertension [editorial; comment; comment] Vogt TM. **J Am Geriatr Soc** 1995 Oct; 43(10):1169. Comment on: J Am Geriatr Soc 1995 Oct;43(10):1141–5.

The relationship between outdoor temperature and the frequency of falls among the elderly in Finland. Luukinen H, et al. **J Epidemiol Community Health** 1996 Feb;50(1):107

Fall frequency and incidence of distal forearm fracture in the UK. O'Neill TW, et al.
J Epidemiol Community Health 1995 Dec;49(6):597–8

Neurologic antecedents to patient falls. Benson C, et al.
J Neurosci Nurs 1995 Dec;27(6):331–7 (25 ref.)

Work-related injuries associated with falls during ice storms—National Institutes of Health, January 1994. From the Centers for Disease Control and Prevention. **JAMA** 1996 Jan 10;275(2):98

Work-related injuries associated with falls during ice storms—National Institutes of Health, January 1994.
MMWR Morb Mortal Wkly Rep 1995 Dec 15;44(49):920–2

Use of the Berg Balance Test to predict falls in elderly persons. Thorbahn LD, et al. **Phys Ther** 1996 Jun; 76(6):576–83; discussion 584–5

Predictors for recurrent falls among the home-dwelling elderly. Luukinen H, et al. **Scand J Prim Health Care** 1995 Dec;13(4):294–9

[Iatrogenic falls] Stäubli M. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):576–83 (33 ref.) (Eng. Abstr.) **(Ger)**

[Injury pattern after fall from great height. An analysis of 101 cases] Hahn MP, et al. **Unfallchirurg** 1995 Dec; 98(12):609–13 (Eng. Abstr.) **(Ger)**

[Falls in the geriatric department: responsibility of the care-giver and the hospital] Shats V, et al. **Harefuah** 1995 Jun 1;128(11):690–3, 743 (Eng. Abstr.) **(Heb)**

[Falls among the elderly living in a rural community—prevalence and circumstances of falls by season] Niino N, et al. **Nippon Koshu Eisei Zasshi** 1995 Nov;42(11):975–81 (Eng. Abstr.) **(Jpn)**

ACCIDENTS

Accidents and acts of God: a history of the terms. Loimer H, et al. **Am J Public Health** 1996 Jan;86(1):101–7

Accidental intra-arterial adrenaline administration. Young RJ, et al. **Anaesth Intensive Care** 1995 Aug;23(4):488–9

Pharyngeal trauma in children—accidental and otherwise. Tostevin PM, et al. **J Laryngol Otol** 1995 Dec; 109(12):1168–75

Amyotrophic lateral sclerosis after accidental injection of mercury [letter] Schwarz S, et al.
J Neurol Neurosurg Psychiatry 1996 Jun;60(6):698

Lawn mower injuries of the pediatric foot and ankle: observations on prevention and management. Vosburgh CL, et al. **J Pediatr Orthop** 1995 Jul–Aug;15(4):504–9

Strangulation injuries in children. Part 1. Clinical analysis [see comments] Sabo RA, et al. **J Trauma** 1996 Jan; 40(1):68–72. Comment in: J Trauma 1996 Jul;41(1):171.

Non-fatal strangulation: an uncommon parachute-related accident. Lwin M, et al. **Med J Malaysia** 1995 Dec; 50(4):419–20

The use of anti-depressants and benzodiazepines in the perpetrators and victims of accidents. Currie D, et al.
Occup Med (Oxf) 1995 Dec;45(6):323–5

Injuries to children related to shopping carts. Smith GA, et al. **Pediatrics** 1996 Feb;97(2):161–5

Factors influencing involvement in farm accidents. Harrell WA. **Percept Mot Skills** 1995 Oct;81(2):592–4

Special features of chemical accidents [editorial] Kulling P. **Przegl Lek** 1996;53(4):216–9

The "EMER.CHEM" project: computerised management of hazardous materials incident [editorial] Magalini SI, et al. **Przegl Lek** 1996;53(4):225–6

Emergency procedures in the event of chemical exposure/accidents [editorial] Meulenbelt J. **Przegl Lek** 1996;53(4):220–4

[Supervision after an electrical accident] Gonska BD.
Dtsch Med Wochenschr 1996 Aug 16;121(33):1032 **(Ger)**

[Fatal accident to a horse from a narrow transverse beam in the box door] Appel G, et al.
DTW Dtsch Tierarztl Wochenschr 1995 Jun;102(6):233–4 (Eng. Abstr.) **(Ger)**

[Activity of a veterinarian within the French fire departments (animal welfare, accidents, disasters)] Buecher M.
DTW Dtsch Tierarztl Wochenschr 1996 Feb;103(2):44–6 (Eng. Abstr.) **(Ger)**

[All-terrain vehicle accidents] Baruchin AM, et al.
Harefuah 1995 Oct;129(7–8):246–9, 295 (Eng. Abstr.) **(Heb)**

[Accidents in childhood. Experiences at the Emergency Department of the Bambino Gesù Hospital of Rome] Spagnoli A, et al. **Pediatr Med Chir** 1996 Mar–Apr; 18(2):187–9 (Eng. Abstr.) **(Ita)**

[Accidental injuries among elementary school children and some of their environmental factors] Ishigure K.
Nippon Eiseigaku Zasshi 1996 Feb;50(6):1067–76 (Eng. Abstr.) **(Jpn)**

[Selected chemical compounds as potential sources of massive poisoning.Physicochemical properties, poisoning symptoms, treatment] Groszek B, et al. **Przegl Lek** 1996; 53(4):227–312 (Eng. Abstr.) **(Pol)**

[State Fire Services in rescuing people injured in chemical accidents and disasters] Kociołek KT. **Przegl Lek** 1996; 53(4):387–9 **(Pol)**

[The characteristics of the work of epidemiological health institutions (subdivisions) under emergency situations] Karniz AF, et al. **Voen Med Zh** 1996 Feb;317(2):38–45 **(Rus)**

[Traumatology is neglected. The number of professional years lost due to accidents is higher than the loss caused by cancer and heart diseases] Brismar B. **Lakartidningen** 1996 Jul 24;93(30–31):2651–2 **(Swe)**

[Lessons learned from the Råneälv accident. Role distribution important during crisis intervention] Johansson B.
Lakartidningen 1995 Oct 25;92(43):3995–7 **(Swe)**

ECONOMICS

One-year economic consequences of accidents in a Swedish municipality. Lindqvist KS, et al. **Accid Anal Prev** 1996 Mar;28(2):209–19

[Comment on W. Brand: Ambulatory rehabilitation—effectiveness and cost savings (letter; comment)] Emde, et al. **Versicherungsmedizin** 1995 Dec 1;47(6):234–5. Comment on: Versicherungsmedizin 1995 Jun 1;47(3):95–6. **(Ger)**

LEGISLATION & JURISPRUDENCE

[Accidental CO poisoning by operating a charcoal grill] Raule P, et al. **Arch Kriminol** 1996 Mar–Apr;197(3–4):81–8 (Eng. Abstr.) **(Ger)**

MORTALITY

Accidents involving older people: a review of the literature. Lilley JM, et al. **Age Ageing** 1995 Jul;24(4):346–65 (153 ref.)

Almost 19 million childhood injuries result in 11 thousand deaths. Waldman HB. **ASDC J Dent Child** 1996 Jan–Feb; 63(1):54–9

The epidemiology of fatal unintentional child injuries in Denmark. Jørgensen IM. **Dan Med Bull** 1995 Jun; 42(3):285–90

The epidemiology of leisure accidents in Scotland. Campbell H, et al. **Health Bull (Edinb)** 1995 Sep;53(5):280–93

Firearm fatalities and injuries from hunting accidents in Germany. Karger B, et al. **Int J Legal Med** 1996; 108(5):252–5

Lethal accidents, 1979–1992. Doyle R. **Sci Am** 1996 Aug; 275(2):26

Unintentional deaths from carbon monoxide poisoning in New Mexico, 1980 to 1988. A comparison of medical examiner and national mortality data. Moolenaar RL, et al. **West J Med** 1995 Nov;163(5):431–4

[Analysis of causes of accidental deaths in several districts of Sichuan province] Liu M, et al.
Hua Hsi I Ko Ta Hsueh Hsueh Pao 1995 Sep;26(3):326–9 (Eng. Abstr.) **(Chi)**

[Accidents in children and adolescents: from analysis to prevention] Reinberg O. **Rev Med Suisse Romande** 1995 Nov;115(11):863–7 **(Fre)**

[The elderly as accident victims—an overview] Dankwarth G. **Versicherungsmedizin** 1996 Jun 1;48(3):93–5 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL see ACCIDENT PREVENTION

PSYCHOLOGY

Fatal hot coffee scald of the larynx. Case report. Mellen PF, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):117–9

Accident neurosis revisited [editorial] Mayou R.
Br J Psychiatry 1996 Apr;168(4):399–403 (26 ref.)

The acute psychological impact on survivors following a train accident. Hagström R. **J Trauma Stress** 1995 Jul; 8(3):391–402

Transportation disasters—a review. Lundin T.
J Trauma Stress 1995 Jul;8(3):381–9 (27 ref.)

Psychosocial aspects of accidental injuries—an overview [see comments] Schnyder U, et al. **Langenbecks Arch Chir** 1996; 381(3):125–31 (67 ref.). Comment in: Langenbecks Arch Chir 1996;381(3):123–4.

[Psychosomatic aspects of post-traumatic stress disorders (editorial;comment)] Trentz O. **Langenbecks Arch Chir** 1996;381(3):123–4. Comment on: Langenbecks Arch Chir 1996;38(3):125–31. **(Ger)**

STATISTICS & NUMERICAL DATA

Risk factors for injury: similarities and differences for traffic crashes and other causes. Chipman ML.
Accid Anal Prev 1995 Oct;27(5):699–706

Treated injuries in northern Vermont. Waller JA, et al.
Accid Anal Prev 1995 Dec;27(6):819–28

Accidents in childhood: relation to psychosocial conditions and mental development. Larsson JO, et al.
Acta Paediatr 1996 Mar;85(3):285–91

Accidental injury is a serious risk in children with typical absence epilepsy. Wirrell EC, et al. **Arch Neurol** 1996 Sep; 53(9):929–32

Relationship between behavioral problems and unintentional injuries in US children. Findings of the 1988 National Health Interview Survey. Bussing R, et al.
Arch Pediatr Adolesc Med 1996 Jan;150(1):50–56

Epidemiology of shopping cart-related injuries to children. An analysis of national data for 1990 to 1992. Smith GA, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1207–10

Social policy as a cause of childhood accidents: the children of lone mothers. Roberts I, et al. **BMJ** 1995 Oct 7; 311(7010):925–8

Less common causes of accidental drownings in Alberta. Ryan CA, et al. **Can J Public Health** 1995 Jul–Aug; 86(4):255–6

A population survey of childhood accidents in Andalusia (Spain). Sanchez-Cruz JJ, et al. **Eur J Epidemiol** 1995 Jun; 11(3):297–303

Accuracy of ICD-9 coding with regard to childhood accidents. Beattie TF. **Health Bull (Edinb)** 1995 Nov; 53(6):395–7

An accident and emergency based child accident surveillance system: is it possible? Beattie TF. **J Accid Emerg Med** 1996 Mar;13(2):116–8

A qualitative evaluation of the post accident notification system to health visitors. Reynolds L. **J Adv Nurs** 1996 Jan;23(1):97–105

Self-reported incidence of accidental exposures to patients' blood and body fluids by resident doctors in Nigeria. Olubuyide IO, et al. **J R Soc Health** 1995 Aug;115(4):235–6, 241–3

Incidence and characteristics of spinal cord injured patients with a family history of alcoholism. Schandler SL, et al. **J Stud Alcohol** 1995 Sep;56(5):522–7

Meeting the challenge of railway injury in a South African city. Lerer LB, et al. **Lancet** 1996 Sep 7;348(9028):664–6

Train over-runs in south-east Queensland [letter] Milne N,

et al. **Med J Aust** 1996 Aug 19;165(4):240

Perceptions of risks of drinking and boating among Massachusetts boaters. Howland J, et al. **Public Health Rep** 1996 Jul-Aug;111(4):372-7

[Epidemiology of accidents in Lebanese children (letter)] Gerbaka B. **Arch Pediatr** 1996 Apr;3(4):398-9 **(Fre)**

[Accident prevention in 0-to-5-year-old children in Vaud: implications of a population study for medical practice] Addor V, et al. **Rev Med Suisse Romande** 1995 Nov; 115(11):849-57 **(Fre)**

[Prospective study of accidents in children in the Vevey metropolitan area] Duperrex O, et al. **Rev Med Suisse Romande** 1995 Nov;115(11):841-8 **(Fre)**

[Accidents in children and adolescents. Introduction] Reinberg O. **Rev Med Suisse Romande** 1995 Nov; 115(11):839-40 **(Fre)**

[Comparison between ski and snowboarding accidents. Current overview from the ski area Arosa (Switzerland) (1988/89 to 1994/95)] Fischler L, et al. **Schweiz Rundsch Med Prax** 1996 Jun 11;85(24):777-82 (Eng. Abstr.) **(Ger)**

[Burn fatalities in advanced age] Sánchez-Hanke M, et al. **Z Gerontol Geriatr** 1996 May-Jun;29(3):185-90 (Eng. Abstr.) **(Ger)**

[Human failure--more frequent than expected? (letter)] Westin S. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1152 **(Nor)**

[Trauma epidemiology--a tool in trauma prevention] Ytterstad B. **Tidsskr Nor Laegeforen** 1996 Apr 20; 116(10):1205-6 **(Nor)**

[Children's accidents treated at health centers] Constan E, et al. **Aten Primaria** 1995 Dec;16(10):628-30, 632 (Eng. Abstr.) **(Spa)**

ACCIDENTS, AVIATION

The truth about wire strikes [news] **Aviat Space Environ Med** 1995 Nov;66(11):1122, 1130

U.S. Naval helicopter mishaps: cockpit egress problems. Barker CO, et al. **Aviat Space Environ Med** 1996 May; 67(5):480-5

China eastern MD-11 mass casualty--expect the unexpected: a case report. Towne LE. **Aviat Space Environ Med** 1995 Oct;66(10):998-1000

The aftermath of disaster. Swire J. **BMJ** 1995 Dec 23-30; 311(7021):1688-9

Odontological identification of the victims of flight A1.IT 5148 air disaster Lyon-Strasbourg 20.01.1992. Hutt JM, et al. **Int J Legal Med** 1995;107(6):275-9

Reduced fertility after the crash of a U.S. bomber carrying nuclear weapons? A register-based study on male fertility. Juel K. **J Clin Epidemiol** 1995 Oct;48(10):1261-7

Blunt traumatic injury of the thoracic aorta following commercial airline crashes. Pezzella AT. **Tex Heart Inst J** 1996;23(1):65-7

[The characteristics of the spinal trauma in catapulted pilots] Moiseev IuB. **Voen Med Zh** 1995 Jun;(6):56-61, 80 (Eng. Abstr.) **(Rus)**

MORTALITY

Cohort study of Air Canada pilots: mortality, cancer incidence, and leukemia risk. Band PR, et al. **Am J Epidemiol** 1996 Jan 15;143(2):137-43

Airplane crash. Traumatologic findings in cases of extreme body disintegration. Hellerich U, et al. **Am J Forensic Med Pathol** 1995 Dec;16(4):320-4

Deaths and injuries as a result of lightning strikes to aircraft. Cherington M, et al. **Aviat Space Environ Med** 1995 Jul; 66(7):687-9

PREVENTION & CONTROL

Human factors and aircraft accidents [letter; comment] Salazar GJ. **Aviat Space Environ Med** 1995 Nov;66(11):1120 . Comment on: Aviat Space Environ Med 1995 Jun;66(6):521.

[The importance of the human factor in the medical support for flight safety] Lapa VV, et al. **Voen Med Zh** 1996 Apr; 317(4):41-4, 79 (16 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Critical incident stress intervention following fatal aircraft mishaps. Cigrang JA, et al. **Aviat Space Environ Med** 1995 Sep;66(9):880-2

Transportation disasters--a review. Lundin T. **J Trauma Stress** 1995 Jul;8(3):381-9 (27 ref.)

Post-traumatic morbidity in a civilian community of litigants: a follow-up at 3 years. Scott RB, et al. **J Trauma Stress** 1995 Jul;8(3):403-17

Spatial disorientation episodes among F-15C pilots during Operation Desert Storm. Collins DL, et al. **J Vestib Res** 1995 Nov-Dec;5(6):405-10

Symptoms of stress disorder and depression among trauma counselors after an airline disaster. Lesaca T. **Psychiatr Serv** 1996 Apr;47(4):424-6

STATISTICS & NUMERICAL DATA

Crash and violation experience of pilots involved in prior commuter and air taxi crashes: a historical cohort study. Li G, et al. **Aviat Space Environ Med** 1995 Dec; 66(12):1131-5

The epidemiology of aircraft fire in commuter and air taxi crashes. Li G, et al. **Aviat Space Environ Med** 1996 May; 67(5):434-7

ACCIDENTS, HOME

Accidental fatal monochloroacetic acid poisoning. Rogers DR. **Am J Forensic Med Pathol** 1995 Jun;16(2):115-6

Near-hanging caused by a toy necklace. Chin N, et al. **Ann Emerg Med** 1995 Oct;26(4):522-5

A case of traumatic lens extraction [letter] DeBacker CM, et al. **Arch Ophthalmol** 1995 Dec;113(12):1568

Deep burns following epileptic seizures. Karacaoglan N, et al. **Burns** 1995 Nov;21(7):546-9

A potentially life-threatening upper eyelid laceration. Rhatigan MC, et al. **Injury** 1996 Apr;27(3):229-30

Injuries from propane gas grills. Schieber RA, et al. **JAMA** 1996 Mar 20;275(11):886

A report of accidental ethylene glycol ingestion in 2 siblings. De Leacy EA, et al. **Pathology** 1995 Jul;27(3):273-6

Accidental ingestion of vitamin A. de Francisco A, et al. **Trop Doct** 1995 Oct;25(4):187

[Landfill gas] Laursen E, et al. **Ugeskr Laeger** 1995 Nov 20; 157(47):6585-6 (Eng. Abstr.) **(Dan)**

[Accidental atropine poisoning. Anticholinergic syndrome in a child after intranasal overdose] Jelstad A, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3030-1 (Eng. Abstr.) **(Nor)**

ECONOMICS

Paraffin (kerosene) poisoning in childhood--is prevention affordable in South Africa? de Wet B, et al. **S Afr Med J** 1994 Nov;84(11):735-8

LEGISLATION & JURISPRUDENCE

Re: Auto-erotic asphyxial death [letter; comment] Cooper AJ. **Can J Psychiatry** 1995 Aug;40(6):363-4. Comment on: Can J Psychiatry 1994 Apr;39(3):157-60.

MORTALITY

Fire fatalities in elderly people. Elder AT, et al. **Age Ageing** 1996 May;25(3):214-6

Deaths of children in house fires [letter; comment] Whidden P. **BMJ** 1996 Feb 24;312(7029):511. Comment on: BMJ 1995 Nov 25;311(7017):1381-2.

Accidental death or sudden infant death syndrome? Beal SM, et al. **J Paediatr Child Health** 1995 Aug;31(4):269-71

Burning brides--a medicolegal study. Satpathy DK. **Med Law** 1995;14(7-8):547-52

PREVENTION & CONTROL

A standardized instrument to assess hazards for falls in the home of older persons. Rodriguez JG, et al. **Accid Anal Prev** 1995 Oct;27(5):625-31

Safe storage of handguns. What do the police recommend? Denno DM, et al. **Arch Pediatr Adolesc Med** 1996 Sep; 150(9):927-31

Adolescent and adult mothers' perceptions of hazardous situations for their children. McClure-Martinez K, et al. **J Adolesc Health** 1996 Mar;18(3):227-31

Health visitors' knowledge, attitudes and practices in childhood accident prevention. Marsh P, et al. **J Public Health Med** 1995 Jun;17(2):193-9

Preventing falls in the elderly at home: a community-based program [letter] Frank OR. **Med J Aust** 1996 Aug 19; 165(4):238

Preventing falls in the elderly at home: a community-based program. Thompson PG. **Med J Aust** 1996 May 6; 164(9):530-2

Paraffin (kerosene) poisoning in childhood--is prevention affordable in South Africa? de Wet B, et al. **S Afr Med J** 1994 Nov;84(11):735-8

Paraffin (kerosene) poisoning in South Africa--some errors in a poster designed for black viewers [editorial] de Wet B, et al. **S Afr Med J** 1994 Nov;84(11):722-3

Paraffin ingestion--the problem. Ellis JB, et al. **S Afr Med J** 1994 Nov;84(11):727-30

Behavioral determinants of mothers' safety measures to prevent injuries of pre-school children. Wortel E, et al. **Scand J Psychol** 1995 Sep;36(3):306-22

STATISTICS & NUMERICAL DATA

Population-based study of unintentional injuries in the home. Kopjar B, et al. **Am J Epidemiol** 1996 Sep 1;144(5):456-62

Home injuries among adults in Stavanger, Norway. Kopjar B, et al. **Am J Public Health** 1996 Mar;86(3):400-4

The association of vision-threatening ocular injury with infant walker use [letter] [see comments] Koser M, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1275-6. Comment in: Arch Pediatr Adolesc Med 1996 Jun;150(6):652.

Injury control in practice. Home radiator burns in inner-city children. Quinlan KP. **Arch Pediatr Adolesc Med** 1996 Sep; 150(9):954-7

Burns caused by domestic alkalis. Rider MA, et al. **J Accid Emerg Med** 1995 Jun;12(2):130-1

How safe are day care centers? Day care versus home injuries among children in Norway. Kopjar B, et al. **Pediatrics** 1996 Jan;97(1):43-7

Predictors for recurrent falls among the home-dwelling elderly. Luukinen H, et al. **Scand J Prim Health Care** 1995 Dec;13(4):294-9

[Accidents caused by inflatable bouncers in 0-19 year-olds in Denmark in 1993] Kirketerp-Møller K, et al. **Ugeskr Laeger** 1996 Apr 15;158(16):2251-3 (Eng. Abstr.) **(Dan)**

ACCIDENTS, INDUSTRIAL see **ACCIDENTS, OCCUPATIONAL**

ACCIDENTS, NUCLEAR see **ACCIDENTS, RADIATION**

ACCIDENTS, NUCLEAR REACTOR see **ACCIDENTS, RADIATION**

ACCIDENTS, OCCUPATIONAL

De-solv-it for hot paving asphalt burn: case report [letter] Tsou TJ, et al. **Acad Emerg Med** 1996 Jan;3(1):88-9

Fall-related occupational injuries on farms. Nordstrom DL, et al. **Am J Ind Med** 1996 May;29(5):509-15

Hidden sharps [letter] Pandya KS, et al. **Anaesthesia** 1996 May;51(5):515

Injury to an anaesthetist during patient transfer [letter] Toomey PJ. **Anaesthesia** 1996 Mar;51(3):294

Accidental prolonged mydriasis in anesthesiologists [letter] Tabboush ZS. **Anesth Analg** 1995 Dec;81(6):1312-3

Two-level intervertebral disc herniation in an adolescent. Schindler OS, et al. **Br J Clin Pract** 1996 Apr-May; 50(3):171-3

Case of carbon monoxide poisoning treated with oxygen hyperbarism. Olszański R, et al. **Bull Inst Marit Trop Med Gdynia** 1993-94;44-45(1-4):83-7

Farm-related injuries taken seriously [letter] Goertzen J. **Can Fam Physician** 1995 Oct;41:1670

Number of needlestick injuries still a concern [news] **Can Med Assoc J** 1995 Nov 15;153(10):1484

The injured worker: assessing "return-to-work" status. Mazanec DJ. **Cleve Clin J Med** 1996 May-Jun;63(3):166-71 (27 ref.)

Interactions of aniline with soil and groundwater at an industrial spill site. Kosson DS, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:71-3 (13 ref.)

On an accident by liquid nitrogen--histological changes of skin in cold. Tabata N, et al. **Forensic Sci Int** 1995 Nov 30;76(1):61-7

'Sand-blaster' injuries. Amir A, et al. **Injury** 1996 Apr; 27(3):223-4

Burns due to flammable solvents ignited with floor buffers. Still JM, et al. **J Burn Care Rehabil** 1996 Mar-Apr; 17(2):188-90

Anaphylaxis after laboratory rat bite: an occupational hazard. Hesford JD, et al. **J Emerg Med** 1995 Nov-Dec;13(6):765-8

Intracranial nail. A case report. Tancioni F, et al. **J Neurosurg Sci** 1994 Dec;38(4):239-43

A 23-year-old maintenance employee in a fertilizer manufacturing plant was exposed to a high concentration of ammonia vapor after a pipe ruptured. **J Occup Environ Med** 1995 Oct;37(10):1187-8

Occupational injury and stress. Johnston JJ. **J Occup Environ Med** 1995 Oct;37(10):1199-203 (25 ref.)

The occupational health of de-miners in Afghanistan. Peel M. **J R Soc Med** 1995 Dec;88(12):683-5

Hazard to pathologists and anatomists from vena-caval (Greenfield) filters [letter] Abraham JL, et al. **Lancet** 1995 Oct 21;346(8982):1100

Scalpel injury and HIV infection in a surgeon.The Studio Italiano Rischio Occupazionale da HIV (SIROH) [letter] Ippolito G, et al. **Lancet** 1996 Apr 13;347(9007):1042

New guidelines set for occupational HIV exposure [news] Rowe PM. **Lancet** 1996 Jul 6;348(9019):48

Down on the farm: health and safety in Australian agriculture [editorial] Fragar LJ. **Med J Aust** 1996 Jul 15;165(2):69-70

Case of torticollis occurring following electrical injury [letter] Boonkongchuen P, et al. **Mov Disord** 1996 Jan; 11(1):109-10

OOS--a new industrial malady [letter] Chew TC. **N Z Med J** 1996 Mar 22;109(1018):107

Stopping the burn. Smith KE. **Occup Health Saf** 1995 Oct; 64(10):159-60

Dealing with spilt mercury [letter] Kulshrestha MK, et al. **Occup Med (Oxf)** 1996 Feb;46(1):91-2

Accident history and perceived risk of injury as factors influencing fatalism about occupational accidents. Harrell WA. **Percept Mot Skills** 1995 Oct;81(2):665-6

Persistent neurotoxicity from a battery fire: is cadmium the culprit? Kilburn KH, et al. **South Med J** 1996 Jul; 89(7):693-8

Respiratory irritants encountered at work. Taylor AJ. **Thorax** 1996 May;51(5):541-5 (17 ref.)

[Acute arsenic poisoning] Johansen JB, et al. **Ugeskr Laeger** 1996 Jul 15;158(29):4201-2 (Eng. Abstr.) **(Dan)**

[Acute poisoning in the work situation in The Netherlands] Bosch E, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13; 140(15):850-3 **(Dut)**

[Chronic obstructive bronchopneumopathy after acute inhalation of sulfur anhydride. Apropos of a case] Ramakers M, et al. **Rev Pneumol Clin** 1995;51(6):343-7 (31 ref.) (Eng. Abstr.) **(Fre)**

[Accident with protective gloves. Case report (letter)] Schmidt A. **Hautarzt** 1995 Sep;46(9):663 **(Ger)**

[Means of individual protection in cleaning-up consequences of accidents at chemical industries] Selov AV, et al. **Med Tr Prom Ekol** 1995;(7):36-9 (Eng. Abstr.) **(Rus)**

[Wounds of the abdomen and pelvis with damage to the major vessels] Lokhvitskii SV, et al. **Vestn Khir Im I I Grek** 1995;154(3):65-7 (Eng. Abstr.) **(Rus)**

[The sequelae of accident situations on board ships of the Black Sea fleet and the organization of medical care for the victims] Demurov OD, et al. **Voen Med Zh** 1995 Aug; (8):44-9 **(Rus)**

[Disability, the risk of disability and changes in work capacity-- unacceptable conditions for insurance in occupational injuries and diseases] Kurajica L, et al. **Arh Hig Rada Toksikol** 1996 Mar;47(1):69-75 (Eng. Abstr.) **(Scr)**

[Acute lipoid pneumonia. Report of 2 cases] Lores L, et al. **Med Clin (Barc)** 1996 May 18;106(19):747-8 (Eng. Abstr.) **(Spa)**

[Accumulated years of potential productive life lost due industrial accidents in Petróleos Mexicanos] Güemez-Sandoval JC, et al. **Salud Publica Mex** 1996 Mar-Apr;38(2):110-7 (Eng. Abstr.) **(Spa)**

[Consider the nature of the disease! Prevent overutilization of insurance] Mikaelsson B. **Lakartidningen** 1996 Jul 10; 93(28-29):2562-3 **(Swe)**

ECONOMICS

Estimating the costs of occupational injury in the United States. Miller TR, et al. **Accid Anal Prev** 1995 Dec; 27(6):741-7

Why is the treatment of work-related injuries so costly? New evidence from California. Johnson WG, et al. **Inquiry** 1996 Spring;33(1):53-65

LEGISLATION & JURISPRUDENCE

Regional harmonization of occupational health rules: the European example. Raworth P. **Am J Law Med** 1995; 21(1):7-44 (339 ref.)

Predictors of returning to work. Ash P, et al. **Bull Am Acad Psychiatry Law** 1995;23(2):205-10

[The application of D.Lgs. 626/94 in USL (local health unit) enterprises and hospital enterprises: a proposal for organizing preventive activities. The Associazione Italiana di Medicina Preventiva dei Lavoratori della Sanità] **Med Lav** 1995 Jul-Aug;86(4):352-9 **(Ita)**

MORTALITY

Assessment of mortality in the construction industry in the United States, 1984-1986. Robinson C, et al. **Am J Ind Med** 1995 Jul;28(1):49-70

Occupational injury mortality rates in the United States: changes from 1980 to 1989. Stout NA, et al. **Am J Public Health** 1996 Jan;86(1):73-7

Occupational injury mortality in New Mexico. Fullerton L, et al. **Ann Emerg Med** 1995 Oct;26(4):447-54

Fatal farm injuries in Ontario, 1984 through 1992. Brison RJ, et al. **Can J Public Health** 1995 Jul-Aug;86(4):246-8

Tractor-related injuries in Ontario. Pickett W, et al. **Can J Public Health** 1995 Jul-Aug;86(4):243-6

Human errors in fatal and serious occupational accidents in Finland. Salminen S, et al. **Ergonomics** 1996 Jul;39(7):980-8

Mortality study of construction workers in the UK. Dong W, et al. **Int J Epidemiol** 1995 Aug;24(4):750-7

Fatalities associated with improper hitching to farm tractors--New York, 1991-1995. **MMWR Morb Mortal Wkly Rep** 1996 Apr 19; 45(15):307-11

Preventing deaths in Alaska's fishing industry. Conway GA, et al. **Public Health Rep** 1995 Nov-Dec;110(6):700

Occupational injury fatalities--1994. Toscano G, et al. **Stat Bull Metrop Insur Co** 1996 Apr-Jun;77(2):12-22

[Fatal occupational accidents in Lombardy] Pianosi G. **Med Lav** 1995 Nov-Dec;86(6):534-41 (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Farm-work hazard prevention efforts by school-based agricultural education instructors. Chapman LJ, et al. **Am J Ind Med** 1995 Oct;28(4):565-77

A method to help reduce the risk of serious knee sprains incurred in alpine skiing. Ettlinger CF, et al. **Am J Sports Med** 1995 Sep-Oct;23(5):531-7

Selected problems of health and safety of divers in the light of Polish regulations. Renke W, et al. **Bull Inst Marit Trop Med Gdynia** 1995;46(1-4):23-6

Home healthcare: a risky business. **Del Med J** 1995 Dec; 67(12):656

The integrated model: implications for worksite health promotion and occupational health and safety practice. Baker E, et al. **Health Educ Q** 1996 May;23(2):175-90 (61 ref.)

Effect of organization-level variables on differential employee participation in 10 federal worksite health promotion programs. Crump CE, et al. **Health Educ Q** 1996 May;23(2):204-23

Worksite health programs: working together to advance employee health. Heaney CA, et al. **Health Educ Q** 1996 May;23(2):133-6 (18 ref.)

The ecology of work and health: research and policy directions for the promotion of employee health. Stokols D, et al. **Health Educ Q** 1996 May;23(2):137-58 (162 ref.)

Application of CQI tools to the reduction in risk of needlestick injury [see comments] Burnett L, et al. **Infect Control Hosp Epidemiol** 1995 Sep;16(9):503-5. Comment in: Infect Control Hosp Epidemiol 1995 Sep'16(9):499-502.

Occupational injuries in a poor inner-city population. Frumkin H, et al. **J Occup Environ Med** 1995 Dec; 37(12):1374-82

A comprehensive initiative to manage the incidence and cost of occupational injury and illness. Report of an outcomes analysis. McGrail MP Jr, et al. **J Occup Environ Med** 1995 Nov;37(11):1263-8

From the Centers for Disease Control and Prevention. NIOSH alert: request for assistance in preventing deaths and injuries of adolescent workers. **JAMA** 1995 Oct 11; 274(14):1114

Surveillance systems and the role of a preventive medical team in chemical incidents [letter] Philipp R. **Occup Environ Med** 1996 Jul;53(7):502

Slip-and-fall accidents. Bell J. **Occup Health Saf** 1995 Dec; 64(12):40-1, 57

Wipe out slips and falls. Brock M. **Occup Health Saf** 1996 Jun;65(6):57

Proper fall protection training. David DA JR. **Occup Health Saf** 1996 Jun;65(6):54-6, 58-9

Head protection for industrial and construction applicants. Patton E. **Occup Health Saf** 1996 Jun;65(6):68-9

Management of sharps injuries and contamination incidents in health care workers: an audit in the Wessex and Oxford regions. Smedley J, et al. **Occup Med (Oxf)** 1995 Oct; 45(5):273-5

Evaluation of an Alaskan marine safety training program. Perkins R. **Public Health Rep** 1995 Nov-Dec;110(6):701-2

Best practice in workplace hazardous substances management. Winder C. **Qual Assur** 1995 Sep;4(3):211-25

Prevention of occupational musculo-skeletal injuries. Labour Inspectorate investigation. Kemmlert K. **Scand J Rehabil Med Suppl** 1996;35:1-34 (124 ref.)

Injury prevention in anesthesiology. Berry AJ. **Surg Clin North Am** 1995 Dec;75(6):1123-32 (21 ref.)

PSYCHOLOGY

The personal experience of Australian health-care workers accidentally exposed to risk of HIV infection [letter] Treloar CJ, et al. **AIDS** 1995 Dec;9(12):1385-6

Personality self-representations of patients with hand injury, and its relationship with work injury. Chau N, et al. **Eur J Epidemiol** 1995 Aug;11(4):373-82

Effects of age and level of work experience on occurrence of accidents. Cellier JM, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):931-40

Does pressure from the work community increase risk taking? Salminen S. **Psychol Rep** 1995 Dec;77(3 Pt 2):1247-50

STATISTICS & NUMERICAL DATA

Nonfatal farm injuries in Ontario: a population-based survey. Pickett W, et al. **Accid Anal Prev** 1995 Aug;27(4):425-33

Sex differences in work-related injury rates among electric utility workers. Keish MA, et al. **Am J Epidemiol** 1996 May 15;143(10):1050-8

Incidence of farm-work-related acute injury in a defined population. Nordstrom DL, et al. **Am J Ind Med** 1995 Oct; 28(4):551-64

Establishment size and risk of occupational injury. Oleinick A, et al. **Am J Ind Med** 1995 Jul;28(1):1-21

Effect of recall period on the reporting of occupational injuries among older workers in the Health and Retirement Study. Zwerling C, et al. **Am J Ind Med** 1995 Nov; 28(5):583-90

Demographic factors in a population-based survey of hospitalized, work-related, ocular injury. Baker RS, et al. **Am J Ophthalmol** 1996 Aug;122(2):213-9

A survey of injuries among Broadway performers. Evans RW, et al. **Am J Public Health** 1996 Jan;86(1):77-80

Risk factors for occupational injuries among older workers: an analysis of the health and retirement study. Zwerling C, et al. **Am J Public Health** 1996 Sep;86(9):1306-9

Machine-related occupational injuries in farm residents. Layde PM, et al. **Ann Epidemiol** 1995 Nov;5(6):419-26

Inhalation accidents reported to the SWORD surveillance project 1990-1993. Sallie B, et al. **Ann Occup Hyg** 1996 Apr;40(2):211-21

The role of eye protection in work-related eye injuries. Fong LP, et al. **Aust N Z J Ophthalmol** 1995 May;23(2):101-6

Auger injuries in the Wimmera region 1987-95. Read KO, et al. **Aust N Z J Surg** 1996 Apr;66(4):229-30

Common accidents among airport ground personnel. Ribak J, et al. **Aviat Space Environ Med** 1995 Dec;66(12):1188-90

Causes of horse-related injuries in a rural western community. Thompson JM, et al. **Can Fam Physician** 1996 Jun;42:1103-9

Tractor-related injuries in Ontario. Pickett W, et al. **Can J Public Health** 1995 Jul-Aug;86(4):243-6

The pattern of tissue damage in occupational trauma. Perera J. **Ceylon Med J** 1996 Mar;41(1):15-8

Linking stress and injury in the farming environment: a secondary analysis of qualitative data. Kidd P, et al. **Health Educ Q** 1996 May;23(2):224-37

Accidents in the aluminium smelting industry. Das BC, et al. **Ind Health** 1995;33(4):191-8

Factors associated with work-related accidents and sickness among maquiladora workers: the case of Nogales, Sonora, Mexico. Balcazar H, et al. **Int J Health Serv** 1995; 25(3):489-502

Case control study of agricultural injuries to older farmers in central Wisconsin [letter] Stueland DT, et al. **J Am Geriatr Soc** 1996 Apr;44(4):475-6

Needlesticks and cuts with sharp objects in Siriraj Hospital 1992. Danchaivijitr S, et al. **J Med Assoc Thai** 1995 Jul; 78 Suppl 2:S108-11

Occupational injury record keeping guidelines [letter; comment] Hall HL Jr. **J Occup Environ Med** 1995 Nov; 37(11):1261. Comment on: J Occup Environ Med 1995 Feb;37(2):124-5.

Patterns of injury and disability caused by forklift trucks. Born CT, et al. **J Trauma** 1996 Apr;40(4):636-9

From the Centers for Disease Control and Prevention. Agricultural auger-related injuries and fatalities--Minnesota, 1992-1994. **JAMA** 1995 Dec 13; 274(22):1754-5

Work-related injuries associated with falls during ice storms--National Institutes of Health, January 1994. From the Centers for Disease Control and Prevention. **JAMA** 1996 Jan 10;275(2):98

From the Centers for Disease Control and Prevention. Work-related injuries and illnesses associated with child labor--United States, 1993. **JAMA** 1996 Jul 3;276(1):16-7

Work-related injuries associated with falls during ice storms--National Institutes of Health, January 1994. **MMWR Morb Mortal Wkly Rep** 1995 Dec 15;44(49):920-2

Work-related injuries and illnesses associated with child labor--United States, 1993. **MMWR Morb Mortal Wkly Rep** 1996 Jun 7;45(22):464-8

Reports of work related musculoskeletal injury among home care service workers compared with nursery school workers and the general population of employed women in Sweden. Ono Y, et al. **Occup Environ Med** 1995 Oct; 52(10):686-93

Occupational injuries in Bahrain. al-Arrayed A, et al. **Occup Med (Oxf)** 1995 Oct;45(5):231-3

Epidemiology of injuries by needles and other sharp instruments. Minimizing sharp injuries in gynecologic and obstetric operations. Lewis FR Jr, et al. **Surg Clin North Am** 1995 Dec;75(6):1105-21 (34 ref.)

The incidence of needlestick and sharps injuries and use of safer devices in Wisconsin hospitals. Lulloff SJ, et al. **Wis Med J** 1996 Jun;95(6):379-81

[Claim review in occupational disability insurance] Stache G. **Versicherungsmedizin** 1995 Oct 1;47(5):178-81 (Eng. Abstr.) **(Ger)**

[Accidents at work among women: an example from the INAIL data. Istituto Nazionale per l'Assicurazione contro gli Infortuni sul Lavoro] Nesti M, et al. **Epidemiol Prev** 1996 Apr-Sep;20(2-3):208-10 **(Ita)**

[Work-related accidents in minors in Lombardy] Pianosi G, et al. **Med Lav** 1995 Jul-Aug;86(4):332-40 (Eng. Abstr.) **(Ita)**

[Causes and consequences of maxillofacial trauma due to occupational accidents in the north-east region of Poland] Hubert E, et al. **Med Pr** 1995;46(3):247-54 (Eng. Abstr.) **(Pol)**

[Occupational accidents and incidence of HIV infection and hepatitis B and C at a Mexican institution] Huertas MA, et al. **Rev Invest Clin** 1995 May-Jun;47(3):181-7 (Eng. Abstr.) **(Spa)**

TRENDS

Occupational injury mortality rates in the United States: changes from 1980 to 1989. Stout NA, et al. **Am J Public Health** 1996 Jan;86(1):73-7

ACCIDENTS, RADIATION

see related

RADIATION INJURIES

Effects of radiation on the production of immunoglobulins in children subsequent to the Chernobyl disaster. Titov LP, et al. **Allergy Proc** 1995 Jul-Aug;16(4):185-93

Characteristics of thyroid ultrasound pictures in children with nodular thyroid changes effected by radionuclides. Drozd VM, et al. **Bildgebung** 1995 Dec;62(4):236-41

Glycophorin A biodosimetry in Chernobyl cleanup workers from the Baltic countries [see comments] Bigbee WL, et al. **BMJ** 1996 Apr 27;312(7038):1078-9. Comment in: BMJ 1996 Apr 27;312(7038):1052-3.

Chernobyl 10 years on [editorial; comment] Henshaw DL. **BMJ** 1996 Apr 27;312(7038):1052-3. Comment on: BMJ 1996 Apr 27;312(7038):1078-9.

Is blood a better source of allogeneic hematopoietic stem cells for use after radiation accidents? Frickhofen N, et al. **Bone Marrow Transplant** 1996 Feb;17(2):131-5 (48 ref.)

Childhood leukaemia in Europe after Chernobyl: 5 year follow-up. Parkin DM, et al. **Br J Cancer** 1996 Apr; 73(8):1006-12

Chest wall reconstruction by free latissimus dorsi flap 25 years after accidental exposure to a source of industrial irradiation. Brenner P, et al. **Br J Plast Surg** 1995 Sep; 48(6):431-3

Characteristics of follicular tumors and nonneoplastic thyroid lesions in children and adolescents exposed to radiation as a result of the Chernobyl disaster. Nikiforov YE, et al. **Cancer** 1995 Sep 1;76(5):900-9

Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Fugazzola L, et al. **Cancer Res** 1995 Dec 1;55(23):5617-20

Radiation disasters and emergency department preparedness. Fong F, et al. **Emerg Med Clin North Am** 1996 May; 14(2):349-70 (18 ref.)

Children of Chernobyl [news] **Environ Health Perspect** 1995 Nov;103(11):990

Health effects in a casual sample of immigrants to Israel from areas contaminated by the Chernobyl explosion. Kordysh EA, et al. **Environ Health Perspect** 1995 Oct;103(10):936-41

An approach to detecting delayed effects of radioactive contamination on industrial-urban-area dwellers. Privalova LI, et al. **Environ Health Perspect** 1994 May;102(5):470-4

Monitoring hprt mutant frequency over time in T-lymphocytes of people accidentally exposed to high doses of ionizing radiation. da Cruz AD, et al. **Environ Mol Mutagen** 1996;27(3):165-75

A post-Chernobyl rise in thyroid cancer in Connecticut, USA. Mangano JJ. **Eur J Cancer Prev** 1996 Feb;5(1):75-81

Radiocesium distribution in undisturbed soil: measurements and diffusion-advection model. Antonopoulos-Domis M, et al. **Health Phys** 1995 Dec;69(6):949-53

Internal doses to Ukrainian populations using Dnieper River water. Berkovski V, et al. **Health Phys** 1996 Jul;71(1):37-44

Countermeasures for radiocesium in animal products in Norway after the Chernobyl accident--techniques, effectiveness, and costs. Brynildsen LI, et al. **Health Phys** 1996 May;70(5):665-72

Risks from radionuclide migration to groundwater in the Chernobyl 30-km zone. Bugai DA, et al. **Health Phys** 1996 Jul;71(1):9-18

Cancer risk estimation in Belarussian children due to thyroid irradiation as a consequence of the Chernobyl nuclear accident. Buglova EE, et al. **Health Phys** 1996 Jul; 71(1):45-9

The Chernobyl accident and the resultant long-term relocation of people. Filyushkin IV. **Health Phys** 1996 Jul; 71(1):4-8

Model testing using Chernobyl data: III. Atmospheric resuspension of radionuclides in Ukrainian regions impacted by Chernobyl fallout. Garger EK, et al. **Health Phys** 1996 Jan;70(1):18-24

Opportunities for the testing of environmental transport models using data obtained following the Chernobyl accident. Hoffman FO, et al. **Health Phys** 1996 Jan; 70(1):5-7

Model testing using Chernobyl data: I. Wash-off of 90Sr and 137Cs from two experimental plots established in the vicinity of the Chernobyl reactor. Konoplev AV, et al. **Health Phys** 1996 Jan;70(1):8-12

Further response to Watson [letter; comment] Kramer GH, et al. **Health Phys** 1995 Dec;69(6):987. Comment on: Health Phys 1995 May;68(5):733-5.

Dosimetry of an incident involving 14C. Kramer GH, et al. **Health Phys** 1996 Mar;70(3):418-24

Model testing using Chernobyl data: II. Assessment of the consequences of the radioactive contamination of the Chernobyl Nuclear Power Plant cooling pond. Kryshev II, et al. **Health Phys** 1996 Jan;70(1):13-7

Internal exposure from the ingestion of foods contaminated by 137Cs after the Chernobyl accident. Report 1. General model: ingestion doses and countermeasure effectiveness for the adults of Rovno Oblast of Ukraine. Likhtarev IA, et al. **Health Phys** 1996 Mar;70(3):297-317

Effective doses due to external irradiation from the Chernobyl accident for different population groups of Ukraine. Likhtariov I, et al. **Health Phys** 1996 Jan; 70(1):87-98

Summary of the BIOMOVS A4 scenario: testing models of the air-pasture-cow milk pathway using Chernobyl fallout data. Peterson SR, et al. **Health Phys** 1996 Aug; 71(2):149-59

The results of selective cytogenetic monitoring of Chernobyl accident victims in the Ukraine. Pilinskaya MA. **Health Phys** 1996 Jul;71(1):29-33

A dynamic model for evaluating radionuclide distribution in forests from nuclear accidents. Schell WR, et al. **Health Phys** 1996 Mar;70(3):318-35

Analysis of body-burden measurements of 137Cs and 40K in a Japanese group over a period of 5 years following the Chernobyl accident. Uchiyama M, et al. **Health Phys** 1996 Sep;71(3):320-5

Long-term behavior of radiocesium in dairy herds in the years following the Chernobyl accident. Voigt G, et al. **Health Phys** 1996 Sep;71(3):370-3

Present concept on current water protection and remediation activities for the areas contaminated by the 1986 Chernobyl accident. Voitsekhovitch O, et al. **Health Phys** 1996 Jul; 71(1):19-28

Response to Kramer, Hoshi, and Okajima [letter] Watson WS. **Health Phys** 1995 Dec;69(6):987-8

Cancer consequences of the Chernobyl accident in Europe outside the former USSR: a review. Sali D, et al. **Int J Cancer** 1996 Jul 29;67(3):343-52 (33 ref.)

Mutations in the p53 tumour suppressor gene in thyroid tumours of children from areas contaminated by the Chernobyl accident. Hillebrandt S, et al. **Int J Radiat Biol** 1996 Jan;69(1):39-45

Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis. Nikiforov Y, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):9-14

Thyroid cancer and the Chernobyl accident [editorial] Williams D. **J Clin Endocrinol Metab** 1996 Jan;81(1):6-8

Therapeutic use of an antibiotic-resistant Bifidobacterium preparation in men exposed to high-dose gamma-irradiation. Korschunov VM, et al. **J Med Microbiol** 1996 Jan;44(1):70-4

Health effects in survivors of the Chernobyl disaster [letter] Quastel MR, et al. **JAMA** 1996 Jun 26;275(24):1881-2

RET oncogene puzzle in Chernobyl thyroid tumours [news] Bonn D. **Lancet** 1996 Apr 27;347(9009):1176

Chernobyl and hypothyroidism [letter] Mangano JJ. **Lancet** 1996 May 25;347(9013):1482-3

Chernobyl's dirty legacy lives on [news] Rich V. **Lancet** 1996 Apr 27;347(9009):1178

Chernobyl and hypothyroidism [letter] Williams D. **Lancet** 1996 Aug 17;348(9025):476-7

Retrospective dose estimates in Estonian Chernobyl clean-up workers by means of FISH. Granath F, et al. **Mutat Res** 1996 Jul 10;369(1-2):7-12

Yearly variation of spontaneous somatic mutation frequency in the stamen hairs of Tradescantia clone KU 9 grown outdoors, which showed a significant increase after the Chernobyl accident. Ichikawa S, et al. **Mutat Res** 1996 Feb 1;349(2):249-59

Chromosome aberrations and rogue cells in lymphocytes of Chernobyl clean-up workers. Lazutka JR. **Mutat Res** 1996 Mar 9;350(2):315-29

Do human lymphocytes exposed to the fallout of the Chernobyl accident exhibit an adaptive response? 1. Challenge with ionizing radiation. Padovani L, et al. **Mutat Res** 1995 Nov;332(1-2):33-8

Do human lymphocytes exposed to the fallout of the Chernobyl accident exhibit an adaptive response? 2. Challenge with bleomycin. Tedeschi B, et al. **Mutat Res** 1995 Nov;332(1-2):39-44

Do human lymphocytes exposed to the fallout of the Chernobyl accident exhibit an adaptive response? III. Challenge with bleomycin in lymphocytes from children hit by the initial acute dose of ionizing radiation. Tedeschi B, et al. **Mutat Res** 1996 Jul 5;354(1):77-80

Chernobyl's legacy to science [editorial] [see comments] **Nature** 1996 Apr 25;380(6576):653. Comment in: Nature 1996 Jun 20;381(6584):642.

Chernobyl damage 'underestimated' [news] Abbott A, et al. **Nature** 1996 Apr 25;380(o576):658

High levels of genetic change in rodents of Chernobyl [see comments] Baker RJ, et al. **Nature** 1996 Apr 25; 380(6576):707-8. Comment in: Nature 1996 Apr 25;380(6576):665-6.

Links in childhood leukaemia [news; comment] Darby SC, et al. **Nature** 1996 Jul 25;382(6589):303-4. Comment on: Nature 1996 Jul 25;382(6589):352-3.

Contamination [letter; comment] Dricks V. **Nature** 1995 Nov 2;378(6552):10. Comment on: Nature 1995 Oct 19;377(6550):563.

Human minisatellite mutation rate after the Chernobyl accident [see comments] Dubrova YE, et al. **Nature** 1996 Apr 25;380(6576):683-6. Comment in: Nature 1996 Apr 25;380(6576):665-6.

Life in the hot zone around Chernobyl [news; comment] Hillis DM. **Nature** 1996 Apr 25;380(6576):665-6. Comment on: Nature 1996 Apr 25;380(6576):683-6. Comment on: Nature 1996 Apr 25;380(6576):707-8.

Accidental contamination 'unlikely' [news] Macilwain C. **Nature** 1995 Nov 2;378(6552):9

NIH denies blame for radiation poisoning but tightens rules [news] Macilwain C. **Nature** 1995 Dec 21-28;378(6559):757

Call for more research into health effects of Chernobyl accident [news] Masood E. **Nature** 1995 Nov 30; 378(6556):429

Infant leukaemia after in utero exposure to radiation from Chernobyl [see comments] Petridou E, et al. **Nature** 1996 Jul 25;382(6589):352-3. Comment in: Nature 1996 Jul 25;382(6589):303-4.

Effects of radiation on children [letter] Satoh C, et al. **Nature** 1996 Sep 19;383(6597):226

Chernobyl legacy [letter; comment] Voice E. **Nature** 1996 Jun 20;381(6584):642. Comment on: Nature 1996 Apr 25;380(6576):653.

Unexpectedly slow decrease of Chernobyl-derived radiocesium in air and deposition in Bavaria/Germany. Bunzl K, et al. **Naturwissenschaften** 1995 Sep;82(9):417-20

High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Klugbauer S, et al. **Oncogene** 1995 Dec 21; 11(12):2459-67

Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Nikiforov YE, et al. **Oncogene** 1996 Aug 15;13(4):687-93

Evaluation of 137Cs activity in plant drugs and in some phytoderivatives from Chernobyl accident up to present (1986-1994). Curini M, et al. **Pharmacol Res** 1995 Jul-Aug; 32(1-2):69-74

Clastogenic factors in the plasma of Chernobyl accident recovery workers: anticlastogenic effect of Ginkgo biloba extract. Emerit I, et al. **Radiat Res** 1995 Nov;144(2):198-205

Lethal exposure [letter; comment] Smit BJ. **S Afr Med J** 1994 Nov;84(11):780. Comment on: S Afr Med J 1994 Mar;84(3):166.

Residual Chernobyl fallout and Sellafield pollutants found on the Isle of Man. McKenna P, et al. **Sci Total Environ** 1995 Dec 1;173-174:7-14

Atmospheric deposition of cosmogenic 7Be and 137Cs from fallout of the Chernobyl accident. Papastefanou C, et al. **Sci Total Environ** 1995 Aug 18;170(1-2):151-6

Children become the first victims of fallout [news] Balter M. **Science** 1996 Apr 19;272(5260):357-60

Chernobyl's thyroid cancer toll [news] Balter M. **Science** 1995 Dec 15;270(5243):1758-9

Chernobyl research becomes international growth industry [news] Williams N, et al. **Science** 1996 Apr 19; 272(5260):355-6

Leukemia studies continue to draw a blank [news] Williams N. **Science** 1996 Apr 19;272(5260):358

Health effects of radiation incidents in the southern Urais. Akleyev AV, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:58-68

Chernobyl experience: biological indicators of exposure to ionizing radiation. Baranov AE, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:69-77

Cytogenetic research after accidental radiation exposure. Bauchinger M. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:182-90 (36 ref.)

The delayed respiratory consequences of inhaled radionuclides in population exposed to nuclear catastrophe. Chuchalin AG, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:276-82

International program on the health effects of the Chernobyl accident. Kreisel W. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:33-9

Micronucleus determination as a means to assess radiation exposure. Müller WU, et al. **Stem Cells (Dayt)** 1995 May; 13 Suppl 1:199-206

Childhood thyroid diseases around Chernobyl evaluated by ultrasound examination and fine needle aspiration cytology. Ito M, et al. **Thyroid** 1995 Oct;5(5):365-8

Chernobyl and thyroid [editorial] Yamashita S, et al. **Thyroid** 1995 Jun;5(3):153-4

[Therapeutic approaches of hematopoietic syndrome following accidental total whole body irradiation] Thierry D, et al. **Bull Cancer (Paris)** 1996 May;83(5):361-70 (40 ref.) (Eng. Abstr.) **(Fre)**

[Medical management of radiation casualties] Dushnitsky T, et al. **Harefuah** 1995 Dec 1;129(11):481-4 (28 ref.) **(Heb)**

[A case of non-Hodgkin T-cell lymphoma with predominantly cutaneous manifestations] di Tondo U, et al. **Clin Ter** 1995 Aug-Sep;146(8-9):537-42 (Eng. Abstr.) **(Ita)**

[Consequences of the reactor breakdown at Chernobyl 10 years after the catastrophe] Jankowski J. **Med Pr** 1996; 47(4):319-29 (Eng. Abstr.) **(Pol)**

[Cytogenetic study of residents three years and more after the accident at the Chernobyl Atomic Power Plant] Bochkov NP, et al. **Dokl Akad Nauk** 1995 Dec;345(6):843-4 **(Rus)**

[Change in biological availability of 137Cs in grassland ecosystems after the accident at Chernobyl Atomic Energy Station] Fesenko SV, et al. **Dokl Akad Nauk** 1996 Apr; 347(6):847-9 **(Rus)**

[Detection and nature of melanin-containing centers in bronchoalveolar smears and blood of persons responsible for cleaning up after the accident at the Chernobyl Atomic Energy Station] Pulatova MK, et al. **Dokl Akad Nauk** 1995 Nov;345(1):130-4 **(Rus)**

[Adaptive changes in autonomic functions in liquidators of the accident at the Chernobyl nuclear power plant in the process of conducting rehabilitation measures] Fudin NA, et al. **Fiziol Cheloveka** 1995 Nov-Dec;21(6):137-45 **(Rus)**

[Dynamics of objective audiometry parameters in liquidators of the accident at the Chernobyl nuclear power plant] Zabolotnyi DI, et al. **Fiziol Cheloveka** 1995 Jul-Aug; 21(4):119-22 **(Rus)**

[Processing of screening data obtained for peripheral blood of children who were victims at the accident at the Chernobyl nuclear power plant] Sevast'anov PV, et al. **Gematol Transfuziol** 1996 Jan-Feb;41(1):33-6 (Eng. Abstr.) **(Rus)**

[Quantitative and cytologic changes in various types of blood leukocytes in liquidators 5-6 years after the accident at the Chernobyl power plant] Zak KP, et al. **Gematol Transfuziol** 1995 Jul-Aug;40(4):39-42 (Eng. Abstr.) **(Rus)**

[Hereditary chromosome instability in the common vole (Microtus arvalis) from the region of the Kyshtym nuclear accident--fact or hypothesis?] Gileva EA, et al. **Genetika** 1996 Jan;32(1):114-9 (Eng. Abstr.) **(Rus)**

[Genetic sequelae of the accident at the Chernobyl nuclear power plant in house mice (Mus musculus)] Pomerantseva MD, et al. **Genetika** 1996 Feb;32(2):298-303 (Eng. Abstr.) **(Rus)**

[Dna repair activity in children exposed to small doses of ionizing radiation as a result of the accident at the Chernobyl nuclear power station] Unizhakov SV, et al. **Genetika** 1995 Oct;31(10):1433-7 (Eng. Abstr.) **(Rus)**

[Assessment of radioactive irradiation of Kamensk-Uralski inhabitants and its impact on their descendants' health] Riabova NV, et al. **Gig Sanit** 1996 Mar-Apr;(2):28-31 (Eng. Abstr.) **(Rus)**

[State of the visual function in locomotive team personnel

working in zones of radioactive pollution] Sosnova TL, et al. **Gig Sanit** 1995 Sep–Oct;(5):43–5 (Eng. Abstr.) **(Rus)**

[The characteristics of the population of the deep waters of the Norwegian Sea in the region of the loss of the Komsomolets nuclear-powered submarine] Vinogradov ME, et al. **Izv Akad Nauk Ser Biol** 1995 Sep–Oct;(5):612–23 (Eng. Abstr.) **(Rus)**

[Immune and microcirculatory disorders and their correction in the participants in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station who have neurosomatic pathology] Frolov VM, et al. **Lik Sprava** 1995 May–Jun;(5–6):22–5 (Eng. Abstr.) **(Rus)**

[Tolerance for physical loading and its determinative factors in persons who took part in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Khomaziuk IN. **Lik Sprava** 1995 May–Jun;(5–6):31–5 **(Rus)**

[The clinical and biochemical characteristics of the status of stomach cancer patients who were exposed to ionizing radiation as a result of the accident at the Chernobyl Atomic Electric Power Station] Korobko VB, et al. **Lik Sprava** 1995 May–Jun;(5–6):19–22 (Eng. Abstr.) **(Rus)**

[The functional status of the hypophyseal–thyroid and hypophyseal–adrenal systems in breast cancer patients taking into account their exposure to the factors of the accident at the Chernobyl Atomic Electric Power Station] Maevskaia LP. **Lik Sprava** 1995 May–Jun;(5–6):29–31 (Eng. Abstr.) **(Rus)**

[The correction of free–radical oxidation processes in patients with chronic cholecystitis subjected to ionizing radiation exposure] Pasieshvili LM. **Lik Sprava** 1995 Jul–Aug;(7–8):54–6 (Eng. Abstr.) **(Rus)**

[The health status of children up to 14 years old living in an area of long–term post–accident exposure to low doses of ionizing radiation] Ponomarenko VM. **Lik Sprava** 1995 May–Jun;(5–6):12–5 (Eng. Abstr.) **(Rus)**

[Lipid indices in the expirate of persons subjected to ionizing radiation exposure] Protsiuk RG, et al. **Lik Sprava** 1995 Jul–Aug;(7–8):56–9 (Eng. Abstr.) **(Rus)**

[Low doses of ionizing radiation and short– and long–term hematologic changes (review of the literature)] Soldatov SK, et al. **Med Tr Prom Ekol** 1995;(9):20–3 **(Rus)**

[The genetic consequences of the radioactive contamination of populations of Arabidopsis thaliana growing in a 30–kilometer area of the accident at the Chernobyl Atomic Electric Power Station] Abramov VI, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):676–89 (Eng. Abstr.) **(Rus)**

[Regularities of changes in Cs–137 contents in animal products in the territory of the Russian Federation polluted as a consequence of the Chernobyl AES accident] Fesenko SV, et al. **Radiats Biol Radioecol** 1995 May–Jun; 35(3):316–27 (Eng. Abstr.) **(Rus)**

[Study of reproductive behavior in Russian and Byelarus populations exposed to ionizing radiation as a consequence of the Chernobyl AES accident] Golovko OV, et al. **Radiats Biol Radioecol** 1996 Jan–Feb;36(1):3–8 (Eng. Abstr.) **(Rus)**

[Endocrine function of the thymus and ionizing radiation] Grinevich IuA, et al. **Radiats Biol Radioecol** 1995 May–Jun; 35(3):391–404 (126 ref.) (Eng. Abstr.) **(Rus)**

[Radiosensitivity and postradiation kinetics of megakaryocyte release of the bone marrow (analysis based on data of the Chernobyl AES accident sequelae)] Gruzdev GP, et al. **Radiats Biol Radioecol** 1996 Mar–Apr;36(2):250–63 (Eng. Abstr.) **(Rus)**

[The genetic consequences of the Chernobyl accident. The monitoring of congenital developmental defects in newborn infants in Kaluga Province] Guzeev GG, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):640–6 (Eng. Abstr.) **(Rus)**

[An assessment of the absorbed doses in cattle over the course of the first year after the accident at the Chernobyl Atomic Electric Power Station] Iastrebkov IuA, et al. **Radiats Biol Radioecol** 1995 Nov–Dec;35(6):845–50 (Eng. Abstr.) **(Rus)**

[The genetic effect in Pinus sylvestris L. populations of the eastern Urals radioactive trace from the control area of the accident at the Chernobyl Atomic Electric Power Station and from the region of the nuclear device tests at the Semipalatinsk proving grounds] Kal'chenko VA, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):702–7 (Eng. Abstr.) **(Rus)**

[The cytogenetic examination of different groups of children living in regions of Bryansk Province contaminated as a result of the Chernobyl accident] Khandogina EK, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):618–25 (Eng. Abstr.) **(Rus)**

[The dynamics of the radiation damage and recovery processes in coniferous stands in a 10–kilometer control zone of the accident at the Chernobyl Atomic Electric Power Station] Kozubov GM, et al. **Radiats Biol Radioecol** 1995 Nov–Dec;35(6):836–44 (Eng. Abstr.) **(Rus)**

[Estimation of absorbed doses by dominant species of the ecosystem in Polesski state radio–ecological reserve] Kravchenko VA, et al. **Radiats Biol Radioecol** 1996 Mar–Apr;36(2):163–7 (Eng. Abstr.) **(Rus)**

[Soil–plant linkage and expected doses in humans from incorporated long–lived radionuclides] Kravets AP, et al. **Radiats Biol Radioecol** 1996 Jan–Feb;36(1):9–16 (Eng. Abstr.) **(Rus)**

[The sequelae of the Kyshtym and Chernobyl accidents for hydrobionts] Polikarpov GG, et al. **Radiats Biol Radioecol** 1995 Jul–Aug;35(4):536–49 (79 ref.) (Eng. Abstr.) **(Rus)**

[Modification of the genetic effect of radiation in mice exposed in the region of the Chernobyl Atomic Electric Power Station] Pomerantseva MD, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):765–73 (Eng. Abstr.) **(Rus)**

[Assessment of factors determining the dynamics of pollution by Cs–137 of agricultural production after the Chernobyl AES accident] Sanzharova NI, et al. **Radiats Biol Radioecol** 1995 May–Jun;35(3):307–15 (Eng. Abstr.) **(Rus)**

[UV–induced unscheduled DNA synthesis in the peripheral blood lymphocytes of participants in the clean–up of the aftereffects of Chernobyl accident] Semov AB. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):740–5 (Eng. Abstr.) **(Rus)**

[The relationship between respiratory system reactivity and neutrophil metabolism in hypoxia in persons subjected to ionizing radiation exposure] Serebrovskaia TV, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):400–4 (Eng. Abstr.) **(Rus)**

[Chemiluminescence, blood lipid peroxidation and neutrophil activity during the hypoxic training of persons subjected to ionizing radiation exposure] Serebrovskaia ZA, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):394–9 (Eng. Abstr.) **(Rus)**

[The monitoring of natural populations of Dactylis glomerata L. in the area of the accident at the Chernobyl Atomic Electric Power Station] Shershunova VI, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):690–5 (Eng. Abstr.) **(Rus)**

[The cytogenetic effects in persons who suffered as a result of the accident at the Chernobyl Atomic Electric Power Station] Shevchenko VA, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):646–54 (Eng. Abstr.) **(Rus)**

[The cytogenetic effects in natural populations of Crepis tectorum exposed to chronic irradiation in the region of the Chernobyl Atomic Electric Power Station. An analysis of the frequency of chromosome aberrations and karyotype changes in the 3rd and 4th years after the accident] Shevchenko VV, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):695–701 (Eng. Abstr.) **(Rus)**

[The cytogenetic effects in Crepis tectorum populations growing in Bryansk Province observed in the 7th year after the accident at the Chernobyl Atomic Electric Power Station] Shevchenko VV, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):720–5 (Eng. Abstr.) **(Rus)**

[The role of immunological changes in diseases in regions contaminated by radionuclides after the accident at the Chernobyl Atomic Electric Power Station] Shubik VM, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):332–7 (Eng. Abstr.) **(Rus)**

[The use of the FISH method for reconstructing the absorbed doses received by participants in the clean–up of the accident at the Chernobyl Atomic Electric Power Station] Snigireva GP, et al. **Radiats Biol Radioecol** 1995 Sep–Oct; 35(5):654–61 (Eng. Abstr.) **(Rus)**

[Radiation sensitivity of the seeds of winter wheat from chronically exposed agrocenosis] Ul'ianenko LN, et al. **Radiats Biol Radioecol** 1995 May–Jun;35(3):428–34 (Eng. Abstr.) **(Rus)**

[The cytogenetic examination of children in the Saint Petersburg region who suffered as a result of the accident at the Chernobyl Atomic Electric Power Station. The frequency of unstable chromosome aberrations in the peripheral blood lymphocytes] Vorobtsova IE, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):630–5 (Eng. Abstr.) **(Rus)**

[Stable chromosome aberrations in the lymphocytes of the peripheral blood in persons who suffered as a result of the accident at the Chernobyl Atomic Electric Power Station] Vorobtsova IE, et al. **Radiats Biol Radioecol** 1995 Sep–Oct; 35(5):636–40 (Eng. Abstr.) **(Rus)**

[Respiratory tract damage in those who cleaned up the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Antonov NS, et al. **Ter Arkh** 1996; 68(3):12–4 (Eng. Abstr.) **(Rus)**

[The prevalence of respiratory organ diseases among those who cleaned up the accident at the Chernobyl Atomic Electric Power Station] Antonov NS, et al. **Ter Arkh** 1996; 68(3):17–9 (Eng. Abstr.) **(Rus)**

[The rehabilitation under alpine conditions of the participants in the cleanup of the accident at the Chernobyl Atomic Electric Power Station who are ill with chronic bronchitis] Brimkulov NN, et al. **Ter Arkh** 1996;68(3):34–7 (Eng. Abstr.) **(Rus)**

[The morphological characteristics of the alveolar macrophages in those who cleaned up the aftermath of the accident at the Chernobyl Atomic Electric Power Station at a late period (1)] Cherniaev AL, et al. **Ter Arkh** 1996;68(3):19–23 (Eng. Abstr.) **(Rus)**

[Respiratory organ pathology in those who cleaned up the aftermath of the accident at the Chernobyl Atomic Electric Power Station (editorial)] Chuchalin AG. **Ter Arkh** 1996; 68(3):5–7 **(Rus)**

[The presence of cesium–137 in the tissue of a lung tumor in someone who cleaned up the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Grobova OM, et al. **Ter Arkh** 1996;68(3):26–30 (Eng. Abstr.) **(Rus)**

[Respiratory organ pathology in the participants in the cleanup of the accident at the Chernobyl Atomic Electric Power Station] Maracheva AV, et al. **Ter Arkh** 1996; 68(3):8–12 (Eng. Abstr.) **(Rus)**

[Respiratory and hemodynamic disorders in the participants in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Pashkova TL, et al. **Ter Arkh** 1996;68(3):14–6 (Eng. Abstr.) **(Rus)**

[The results of the combined programmed treatment of those who cleaned up the accident at the Chernobyl Atomic Electric Power Station who suffer from respiratory organ diseases] Tatarskii AR, et al. **Ter Arkh** 1996; 68(3):30–3 (Eng. Abstr.) **(Rus)**

[The pathomorphology of the pulmonary infectious complications in acute radiation sickness (based on the autopsy data from persons who died as a result of the accident at the Chernobyl Atomic Electric Power Station] Vlasov PA, et al. **Ter Arkh** 1996;68(3):23–6 (Eng. Abstr.) **(Rus)**

[Radiation–induced cytogenetic markers detected 8 years after the accident at the Chernobyl Atomic Electric Power Station by different methods of analyzing metaphase chromosome preparations in persons who have had acute radiation sickness] Pilinskaia MA, et al. **Tsitol Genet** 1995 Sep–Oct;29(5):3–11 (Eng. Abstr.) **(Rus)**

[The effect of chronic ionizing radiation at low doses on a number of reproductive indices in CC57W/Mv mice from an experimental Chernobyl population] Stolina MR, et al. **Tsitol Genet** 1996 Jan–Feb;30(1):53–8 (Eng. Abstr.) **(Rus)**

[The radiation factors impacting on people in accidents at atomic power installations] Cherniak SI, et al. **Voen Med Zh** 1992 Feb;(2):52–6 **(Rus)**

[The organization of health and hygiene measures among the troops working in the cleanup of the aftermath of the Chernobyl catastrophe in 1986] Chvyrev VG, et al. **Voen Med Zh** 1996 Apr;317(4):4–7, 79 (Eng. Abstr.) **(Rus)**

[131I as a factor in radiation exposure] Korolev VI. **Voen Med Zh** 1992 Feb;(2):56–8 **(Rus)**

[A hygienic analysis of the irradiation doses of those cleaning up the aftermath of the accident at the Chernobyl Atomic Electric Power Station (based on data from the All–Army Registry)] Shantyr' II, et al. **Voen Med Zh** 1995 Mar; (3):58–63, 80 (Eng. Abstr.) **(Rus)**

[The dynamic cytochemical indices of the blood in helicopter pilots who participated in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Smirnov NA, et al. **Voen Med Zh** 1995 Aug; (8):42–3 **(Rus)**

[The assessment at a sanatorium of the mental status of children who were victims of the Chernobyl catastrophe] Lysenko VI, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec; (6):31–3 (Eng. Abstr.) **(Rus)**

[Malignant thyroid neoplasms in the territories of the Russian Federation exposed as a consequence of the accident at the Chernobyl Atomic Electric Power Station] Remennik LV, et al. **Vopr Onkol** 1995;41(2):29–34 **(Rus)**

[A case of prolonged hematopoietic depression after acute radiation sickness in a man who worked in the cleanup of the aftereffects of the accident at the Chernobyl Atomic Electric Power Station] Klimenko VI, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):41–3 **(Rus)**

[The autonomic regulation of the cardiovascular system in subjects with the autonomic dystonia syndrome subjected to ionizing radiation exposure as a result of the accident at the Chernobyl Atomic Electric Power Station] Niagu AI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(4):32–5 (Eng. Abstr.) **(Rus)**

[From Hiroshima to Chernobyl. Increasing number of late fatal cases of cancer] Drottz–Sjöberg BM, et al. **Lakartidningen** 1995 Nov 1;92(44):4100–2, 4105 (18 ref.) **(Swe)**

[The most–attended meeting on Chernobyl ever. Markedly increasing number of thyroid cancer cases among children and adolescents] Landquist A. **Lakartidningen** 1996 Jan 3; 93(1–2):43–4 **(Swe)**

[The microwave therapy of patients with duodenal peptic ulcer who took part in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Babak OIa, et al. **Lik Sprava** 1995 Jul–Aug; (7–8):51–3 (Eng. Abstr.) **(Ukr)**

[The characteristics of disorders of general adaptation reactions in people who suffered as a consequence of the accident at the Chernobyl Atomic Electric Power Station and their correction by means of balneo– and phytotherapy] Sarancha SM, et al. **Lik Sprava** 1995 Jul–Aug;(7–8):47–51 (Eng. Abstr.) **(Ukr)**

[The metabolic aspects of the sequelae of the accident at the Chernobyl Atomic Electric Power Station in the course of kidney diseases] Vozianov OF, et al. **Lik Sprava** 1995 May–Jun;(5–6):15–9 (Eng. Abstr.) **(Ukr)**

LEGISLATION & JURISPRUDENCE

New NRC rule spurred by radiation incidents. Motivated by two recent acts of suspected radiation sabotage, the Nuclear Regulatory Commission wants any future events to be reported within 24 hours. Will the new rule prevent

international misadministrations or just cause unnecessary paperwork? [news] Kotz D. **J Nucl Med** 1996 Jun; 37(6):15N–9N

Nuclear watchdog tightens incident reporting rules [news] Macilwain C. **Nature** 1996 Feb 15;379(6566):572

PREVENTION & CONTROL

[Problems of radiation hygiene in railway transport] Freiman ES. **Gig Sanit** 1995 Sep–Oct;(5):40–2 (Eng. Abstr.) **(Rus)**

[Evaluation of the degree of radiation safety in the use of radioisotope devices in teaching and research centers] Aleksandrova AI. **Med Tr Prom Ekol** 1995;(7):30–3 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

[The systematics of mental disorders related to the sequelae of the accident at the Chernobyl Atomic Electric Power Station] Napreenko AK, et al. **Lik Sprava** 1995 May–Jun; (5–6):25–9 (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

[The irradiation levels of the participants in the cleanup of the aftermath of the Chernobyl accident in 1986–1987 and the verification of the dosimetric data] Il'in LA, et al. **Radiats Biol Radioecol** 1995 Nov–Dec;35(6):803–28 (Eng. Abstr.) **(Rus)**

[The results of a study of disability among those who participated in the cleanup of the aftereffects of the accident at the Chernobyl Atomic Electric Power Station (based on data from the Ukrainian National Registry)] Nagornaia AM, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):36–7 **(Rus)**

ACCIDENTS, TRAFFIC

see related
AIR BAGS
SEAT BELTS

A skeletal model for the efficacy of automobile safety restraints [letter] Adams SL, et al. **Acad Emerg Med** 1996 Mar;3(3):284

A challenge in injury prevention—the Hispanic population [editorial; comment] Martinez R, et al. **Acad Emerg Med** 1996 Mar;3(3):194–7. Comment on: Acad Emerg Med 1996 Mar;3(3):221–7.

Rejoinder to Hemenway [letter; comment] Peck RC. **Accid Anal Prev** 1995 Aug;27(4):617. Comment on: Accid Anal Prev 1994 Feb;26(1):127–9.

The nature and source of the head injuries sustained by restrained front-seat car occupants in frontal collisions. Thomas P, et al. **Accid Anal Prev** 1995 Aug;27(4):561–70

The geography of availability and driving after drinking. Gruenewald PJ, et al. **Addiction** 1996 Jul;91(7):967–83

Alcohol and road traffic accidents. Mayou R, et al. **Alcohol Alcohol** 1995 Nov;30(6):709–11

Case-control study of the effectiveness of different types of helmets for the prevention of head injuries among motorcycle riders in Taipei, Taiwan. Tsai YJ, et al. **Am J Epidemiol** 1995 Nov 1;142(9):974–81

Corneoscleral laceration caused by air-bag trauma. Baker RS, et al. **Am J Ophthalmol** 1996 Jun;121(6):709–11

The symbiosis between basic and applied research. Leibowitz HW. **Am Psychol** 1996 Apr;51(4):366–70

The study of the relationship between lifestyle characteristic self-reported drinking patterns and trauma. Brotman S, et al. **Am Surg** 1995 Nov;61(11):975–9

Syncope as etiology of road crashes involving elderly drivers. Rehm CG, et al. **Am Surg** 1995 Nov;61(11):1006–8

Infant involved in a motor vehicle accident. Steele AG, et al. **Ann Emerg Med** 1995 Oct;26(4):508–14

Staged reconstruction of abdominal wall defects after intra-abdominal catastrophes. Okunski WJ, et al. **Ann Plast Surg** 1996 May;36(5):475–8

Limb body wall defects the result of trauma? [letter] Moore L, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jul; 75(1):F71

Alcohol and injuries [letter; comment] Hamilton JT. **Arch Fam Med** 1996 Feb;5(2):67–8. Comment on: Arch Fam Med 1995 Jun;4(6):499–501.

Moose-motor vehicle collisions. An increasing hazard in northern New England. Farrell TM, et al. **Arch Surg** 1996 Apr;131(4):377–81

Who develops PTSD from motor vehicle accidents? Blanchard EB, et al. **Behav Res Ther** 1996 Jan;34(1):1–10

Depression, antidepressants, and accidents [letter; comment] Diamond PA. **BMJ** 1995 Dec 9;311(7019):1570. Comment on: BMJ 1995 Oct 7;311(7010):887–8.

Depression, antidepressants, and accidents [editorial] [see comments] Edwards JG. **BMJ** 1995 Oct 7;311(7010):887–8 . Comment in: BMJ 1995 Dec 9;311(7019):1570.

Bilateral corneal contusion and angle recession caused by an airbag [letter] Michaeli-Cohen A, et al. **Br J Ophthalmol** 1996 May;80(5):487

Airbag injury during low impact collision [letter] Molia LM, et al. **Br J Ophthalmol** 1996 May;80(5):487–8

Acetabular fractures and seat belts [editorial; comment] Waddell JP. **Can J Surg** 1996 Aug;39(4):266. Comment on: Can J Surg 1996 Aug;39(4):317–20.

Sleep apnea a risk factor for poor driving [letter] Lertzman M, et al. **Can Med Assoc J** 1995 Oct 15;153(8):1063

Case report: apical pleural cap mimicked by post-traumatic pseudomeningocele. McKillop G, et al. **Clin Radiol** 1995 Dec;50(12):870–2

The haunting memory of a trauma patient [clinical conference] Elder J, et al. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):147–50, 153–6

Development of transportable wheelchair design criteria using computer crash simulation. Bertocci GE, et al. **IEEE Trans Rehabil Eng** 1996 Sep;4(3):171–81

An unusual case of irreducible intra-articular patellar dislocation with vertical axis rotation. Gidden DJ, et al. **Injury** 1995 Nov;26(9):643–4

Injury reduction by the airbag in accidents. Kuner EH, et al. **Injury** 1996 Apr;27(3):185–8

Arthroscopy for acute knee haemarthrosis in road traffic accident victims. Lu KH, et al. **Injury** 1996 Jun;27(5):341–3

The injury impairment scale in pelvic and lower limb fractures sustained in road traffic accidents. Massoud SN, et al. **Injury** 1996 Mar;27(2):107–10

The epidemiology of pelvic fractures in the Mersey Region. Muir L, et al. **Injury** 1996 Apr;27(3):199–204

Volar perilunate dislocation of the carpus: a case report and elucidation of its mechanism of occurrence. Niazi TB. **Injury** 1996 Apr;27(3):209–11

Multiple cranial nerve palsies in a motorcyclist caused by the helmet. Smith JC. **Injury** 1995 Jul;26(6):405–6

Selective embolization of pseudo-aneurysms of the renal artery after blunt abdominal injury in a patient with a single kidney. Steffens MG, et al. **Injury** 1996 Apr;27(3):219–20

Isolated trans-trapezoid axial-radial carpal dislocation. Williams JR. **Injury** 1995 Jul;26(6):417–8

Vehicle entrapment rescue and pre-hospital trauma care. Wilmink AB, et al. **Injury** 1996 Jan;27(1):21–5

Rate, causes and prevention of deaths from injuries in south-east Scotland. Wyatt JP, et al. **Injury** 1996 Jun; 27(5):337–40

What is your diagnosis? Lateral condylar fracture of the tibial plateau, comminuted supracondylar and lateral condylar femoral fractures, fractured public bone, and craniodorsal coxofemoral luxation. Dixon BC. **J Am Vet Med Assoc** 1996 Jan 15;208(2):199–200

Air bag "tattoo," a lasting impression [letter] Beckerman B, et al. **J Emerg Med** 1995 Sep–Oct;13(5):680–2

Rupture of the gravid uterus secondary to motor vehicle trauma. Dittrich KC. **J Emerg Med** 1996 Mar–Apr; 14(2):177–80

An unusual fetal complication of traumatic uterine rupture. Rowe TF, et al. **J Emerg Med** 1996 Mar–Apr;14(2):173–6

Child pedestrian injury rates: the importance of "exposure to risk" relating to socioeconomic and ethnic differences, in Auckland, New Zealand. Roberts I, et al. **J Epidemiol Community Health** 1996 Apr;50(2):162–5

Commentary on Rosenbluth W, Hicks L. Evaluating low-speed rear-end impact severity and resultant occupant stress parameters J Forensic Sci, 1994;39 (6, Nov): 1393–1424 [letter] Bailey M. **J Forensic Sci** 1996 Jul; 41(4):551

DNA typing and blood transfusion. Brauner P. **J Forensic Sci** 1996 Sep;41(5):895–7

Risk of accidents in drivers with epilepsy. Taylor J, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):621–7

Vestibular hyperreactivity and hyperventilation after whiplash injury. Fischer AJ, et al. **J Neurol Sci** 1995 Sep; 132(1):35–43

The impact of two related prevention strategies on head injury reduction among nonfatally injured motorcycle riders, California, 1991–1993. Kraus JF, et al. **J Neurotrauma** 1995 Oct;12(5):873–81

Fracture of the trochlea. Foulk DA, et al. **J Orthop Trauma** 1995;9(6):530–2

Lumbar compression fractures secondary to lap-belt use in children. Sturm PF, et al. **J Pediatr Orthop** 1995 Jul–Aug; 15(4):521–3 (27 ref.)

Automobile-induced obstruction of the intrathoracic caudal vena cava in a dog. Lisciandro GR, et al. **J Small Anim Pract** 1995 Aug;36(8):368–72

Cardiac trauma and third degree AV block in a dog following a road accident. Nicholls PK, et al. **J Small Anim Pract** 1995 Sep;36(9):411–5

Airbag-induced eye injuries: a report of 25 cases. Duma SM, et al. **J Trauma** 1996 Jul;41(1):114–9

Children's traffic safety program: influence of early elementary school safety education on family seat belt use. Hazinski MF, et al. **J Trauma** 1995 Dec;39(6):1063–8

Effect of valvular heart diseases, migraine headaches, and perianal diseases on the risk of involvement in motor vehicle crashes. Lerman Y, et al. **J Trauma** 1995 Dec; 39(6):1058–62

Traumatic lumbar hernia: a seat belt injury. McCarthy MC, et al. **J Trauma** 1996 Jan;40(1):121–2 (10 ref.)

Intra-abdominal injury with handlebar hernia: case report and literature review. Yarbrough DR 3rd. **J Trauma** 1996 Jan;40(1):116–8 (21 ref.)

Older drivers and physicians [editorial; comment] Martinez R. **JAMA** 1995 Oct 4;274(13):1060. Comment on: JAMA 1995 Oct 4;274(13):1026–30.

Late whiplash syndrome [letter; comment] Bjørgen IA. **Lancet** 1996 Jul 13;348(9020):124; discussion 125–6. Comment on: Lancet 1996 May 4;347(9010):1207–11.

Airbags and fatal injuries to children. Bourke GJ. **Lancet** 1996 Mar 2;347(9001):560

Late whiplash syndrome [letter; comment] de Mol BA, et al. **Lancet** 1996 Jul 13;348(9020):124–5; discussion 125–6. Comment on: Lancet 1996 May 4;347(9010):1207–11.

Late whiplash syndrome [letter; comment] Freeman MD, et al. **Lancet** 1996 Jul 13;348(9020):125; discussion 125–6. Comment on: Lancet 1996 May 4;347(9010):1207–11.

Impact of daytime sleepiness underrated. Sharpley A. **Lancet** 1996 Jul 13;348(9020):71

Occupational handicap in victims of limb injuries. Magalhaes T, et al. **Med Law** 1996;15(1):135–41

Long-term outcome after whiplash injury. A 2-year follow-up considering features of injury mechanism and somatic, radiologic, and psychosocial findings. Radanov BP, et al. **Medicine (Baltimore)** 1995 Sep;74(5):281–97 (61 ref.)

Traffic accidents and daylight saving time [letter; comment] Bergner L. **N Engl J Med** 1996 Aug 1;335(5):356; discussion 356–7. Comment on: N Engl J Med 1996 Apr 4;334(14):924.

Daylight savings time and traffic accidents [letter] [see comments] Coren S. **N Engl J Med** 1996 Apr 4;334(14):924 . Comment in: N Engl J Med 1996 Aug 1;335(5):355–6; discussion 356–7. Comment in: N Engl J Med 1996 Aug 1;335(5):356; discussion 356–7.

Traffic accidents and daylight saving time [letter; comment] Grekin RJ. **N Engl J Med** 1996 Aug 1;335(5):356; discussion 356–7. Comment on: N Engl J Med 1996 Apr 4;334(14):924.

Lap seat belt injuries. Hingston GR. **N Z Med J** 1996 Aug 9;109(1027):301–2

Deterioration of the high-mounted brake light. Cameron DL. **Percept Mot Skills** 1995 Oct;81(2):418

Young children's judgments of relative mass of two objects in a head-on-collision event. Nakamura K. **Perception** 1995;24(10):1189–200

Automobile accidents during pregnancy [letter] Källén B, et al. **Reprod Toxicol** 1995 Nov–Dec;9(6):591

Isolated ureteral injury caused by blunt trauma. Kotkin L, et al. **Urology** 1996 Jan;47(1):111–3

A pilot study of alcohol and drug-related traffic accidents and death in two Jamaican parishes, 1991. Francis M, et al. **West Indian Med J** 1995 Sep;44(3):99–101

Automobile restraint systems and injury prevention. Hendey GW. **West J Med** 1996 Jan;164(1):63–4

[Is there a connection between alcoholism and the chance of traffic accidents? (see comments)] Korzec A, et al. **Ned Tijdschr Geneeskd** 1995 Oct 7;139(40):2020–3. Comment in: Ned Tijdschr Geneeskd 1995 Dec 30;139(52):2758. **(Dut)**

[Acute Budd-Chiari syndrome of traumatic origin] Izard G, et al. **Presse Med** 1995 Sep 16;24(26):1209–10 (Eng. Abstr.) **(Fre)**

[Pelvic ring fractures in children. Apropos of 47 cases] Sy MH, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(6):538–45 (Eng. Abstr.) **(Fre)**

[New airbag-associated injuries in traffic accidents] Rebel A, et al. **Anaesthesist** 1996 Apr;45(4):359–62 (Eng. Abstr.) **(Ger)**

[A causal relationship between a collision and an intervertebral disk prolapse?] Zimmer G. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1487 **(Ger)**

[Experience with 2 cases of traumatic diaphragmatic hernia occurred at the same time] Doi K, et al. **Kyobu Geka** 1996 Mar;49(3):251–3 (Eng. Abstr.) **(Jpn)**

[Airway management in complete transection of the trachea due to traffic accident] Komatsu H, et al. **Masui** 1996 May; 45(5):646–8 (Eng. Abstr.) **(Jpn)**

[Cardiovascular diseases in motor vehicle drivers and traffic safety] El'garov AA, et al. **Med Tr Prom Ekol** 1995;(6):10–3 (Eng. Abstr.) **(Rus)**

[The effect of drivers' health status on the occurrence of traffic accidents] Jovanović J, et al. **Vojnosanit Pregl** 1995 Jul–Aug;52(4):335–40 (Eng. Abstr.) **(Scr)**

[Alcohol level and injury risks in traffic accidents in Tudela (Navarre)] Cia Lecumberi MT, et al. **Gac Sanit** 1996 Mar–Apr;10(53):55–61 (Eng. Abstr.) **(Spa)**

[Alcohol measurement in traffic accidents: how long will the ostrich strategy last? (editorial)] Plasència A. **Gac Sanit** 1996 Mar–Apr;10(53):51–4 **(Spa)**

[Neurological diseases and driving] Mola S. **Rev Neurol** 1995 Mar–Apr;23(120):334–50 (139 ref.) (Eng. Abstr.) **(Spa)**

[Safety belt use and severity of injuries in traffic accidents] Hijar-Medina MC, et al. **Salud Publica Mex** 1996 Mar–Apr; 38(2):118–27 (Eng. Abstr.) **(Spa)**

[Streetcars in urban environment pose a great risk of accidents] Hedelin A, et al. **Lakartidningen** 1995 Dec 13; 92(50):4803–6 **(Swe)**

[Ruptured aneurysm without abdominal symptoms. Unexpected fatal intraabdominal bleeding after a traffic accident] Pedersen JC. **Lakartidningen** 1996 Mar 27; 93(13):1250 **(Swe)**

[Principal approach to medical assistance to victims with multiple trauma during the prehospital stage] Protsik AI. **Klin Khir** 1995;(4):28–9 **(Ukr)**

CLASSIFICATION

Behavioural characteristics and involvement in different types of traffic accident. Parker D, et al. **Accid Anal Prev** 1995 Aug;27(4):571–81

Can emergency physicians correlate between vehicle damage and velocity change? Ros SP, et al. **Pediatr Emerg Care** 1995 Oct;11(5):277–9

ECONOMICS

Low-threat-to-life motor vehicle injuries. National Highway

Traffic Safety Administration. **Ann Emerg Med** 1996 Jul; 28(1):100; discussion 101

Seat belt use, insurance status, and hospital bad debt. Clyde AT, et al. **J Trauma** 1996 Jul;41(1):100–4

Economic impact of motor-vehicle crashes involving teenaged drivers—Kentucky, 1994. **MMWR Morb Mortal Wkly Rep** 1996 Aug 23;45(33):715–9

LEGISLATION & JURISPRUDENCE

Driver licenses as a measure of older drivers' exposure: a methodological note. Hakamies-Blomqvist L, et al. **Accid Anal Prev** 1995 Dec;27(6):853–7

Helmet use by drivers and passengers of motorcycles in Pamplona (Spain), 1992. Guillén Grima F, et al. **Eur J Epidemiol** 1995 Feb;11(1):87–9

Detection and quantification of lorazepam in human hair by GC-MS/NCI in a case of traffic accident. Cirimele V, et al. **Int J Legal Med** 1996;108(5):265–7

Medico-legal aspects of road traffic accidents. Mayou R. **J Psychosom Res** 1995 Aug;39(6):789–98 (13 ref.)

[Initial experiences with the ‰0.8 promille regulation in Thüringen] Giebe W, et al. **Blutalkohol** 1995 Sep; 32(5):279–84 (Eng. Abstr.) **(Ger)**

[Use of the ADH/REA method (Abbott Tdx-REA) in forensic blood alcohol determination] Mebs D, et al. **Blutalkohol** 1996 Mar;33(2):71–7 (Eng. Abstr.) **(Ger)**

[Drinking trials for back calculation in long elapsed time intervals] Schröter A, et al. **Blutalkohol** 1995 Nov; 32(6):344–52 (Eng. Abstr.) **(Ger)**

[Reliability of back-calculation of blood alcohol concentration to the time of infraction] Schyma C, et al. **Blutalkohol** 1996 Mar;33(2):65–70 (Eng. Abstr.) **(Ger)**

[Alcohol and aggression—violence prone drivers preventing passing maneuvers] Zabel GE. **Blutalkohol** 1996 Mar; 33(2):84–93 (Eng. Abstr.) **(Ger)**

[Revoking the right to drive—a blunt weapon against alcohol intoxicated drivers, hit-and-run drivers and speed limit and red light offenders? (see comments)] Zabel GE. **Blutalkohol** 1995 Sep;32(5):254–67 (56 ref.) (Eng. Abstr.). Comment in: Blutalkohol 1995 Nov;32(6):314–6. **(Ger)**

[Severe perforating eye injury caused by an air bag in a traffic skid accident] Biechl-Lautenbach KS, et al. **Klin Monatsbl Augenheilkd** 1996 Mar;208(3):196–200 (Eng. Abstr.) **(Ger)**

MORTALITY

Estimating the consequences of accidents: the case of automatic train protection in Britain. Evans AW, et al. **Accid Anal Prev** 1996 Mar;28(2):181–91

Pedestrian exposure to risk of road accident in New Zealand. Keall MD. **Accid Anal Prev** 1995 Oct;27(5):729–40

Cyclist road deaths in London 1985–1992: drivers, vehicles, manoeuvres and injuries. McCarthy M, et al. **Accid Anal Prev** 1996 Mar;28(2):275–9

Characteristics of crashes attributed to the driver having fallen asleep. Pack AI, et al. **Accid Anal Prev** 1995 Dec; 27(6):769–75

Analysis of fatal motorcycle crashes: crash typing. Preusser DF, et al. **Accid Anal Prev** 1995 Dec;27(6):845–51

The hit-and-run in fatal pedestrian accidents: victims, circumstances and drivers. Solnick SJ, et al. **Accid Anal Prev** 1995 Oct;27(5):643–9

Lowering state legal blood alcohol limits to 0.08%: the effect on fatal motor vehicle crashes. Hingson R, et al. **Am J Public Health** 1996 Sep;86(9):1297–9

Reducing death on the road: the effects of minimum safety standards, publicized crash tests, seat belts, and alcohol. Robertson LS. **Am J Public Health** 1996 Jan;86(1):31–4

Northern Ontario MDs seek solution to region's huge accidental-death toll. Spears T. **Can Med Assoc J** 1996 Jul 1;155(1):101–2

Single road traffic deaths—accident or suicide? Connolly JF, et al. **Crisis** 1995;16(2):85–9

Alcohol and drugs (medical and illicit) in fatal road accidents in a city of 300,000 inhabitants. Hansen AC, et al. **Forensic Sci Int** 1996 May 17;79(1):49–52

Drug and alcohol use in fatally injured drivers in Washington State. Logan BK, et al. **J Forensic Sci** 1996 May; 41(3):505–10

A new epidemic is killing our children ... and everyone can help immunize them! Carr OB Jr. **J Med Assoc State Ala** 1981 Feb;50(8):49–50

Effects of law promulgation for compulsory use of protective helmets on death following motorcycle accidents. Panichaphongse V, et al. **J Med Assoc Thai** 1995 Oct; 78(10):521–5

Does routine child health surveillance reach children most at risk of accidental injury? [letter; comment] Cooper N. **J Public Health Med** 1995 Dec;17(4):492–3. Comment on: J Public Health Med 1995 Mar;17(1):39–45.

Characteristics of fatal crashes of 16-year-old drivers: implications for licensure policies. Williams AF, et al. **J Public Health Policy** 1995;16(3):347–60

Role of alcohol in traffic crashes involving women: passenger car fatalities in northern Sweden. Öström M, et al. **J Stud Alcohol** 1995 Sep;56(5):506–12

A population-based study of outcome after injury to car occupants and to pedestrians. Hill DA, et al. **J Trauma** 1996 Mar;40(3):351–5

Evaluation of the medical management and preventability of death in 137 road traffic fatalities in Victoria, Australia: an overview. Consultative Committee on Road Traffic Fatalities in Victoria. McDermott FT, et al. **J Trauma** 1996 Apr;40(4):520–33; discussion 533–5

Fatal motor vehicle crashes: variations of crash characteristics within rural regions of different population densities. Muelleman RL, et al. **J Trauma** 1996 Aug; 41(2):315–20

From the Centers for Disease Control and Prevention. Update: alcohol-related traffic crashes and fatalities among youth—United States, 1982–1994. **JAMA** 1995 Dec 27; 274(24):1904–5

Relationship between driver's license renewal policies and fatal crashes involving drivers 70 years or older [see comments] Levy DT, et al. **JAMA** 1995 Oct 4; 274(13):1026–30. Comment in: JAMA 1995 Oct 4;274(13):1060.

School bus related deaths and injuries in New South Wales. Cass DT, et al. **Med J Aust** 1996 Aug 5;165(3):134–7

Update: alcohol-related traffic crashes and fatalities among youth and young adults—United States, 1982–1994. **MMWR Morb Mortal Wkly Rep** 1995 Dec 1;44(47):869–74

Alcohol involvement in fatal motor-vehicle crashes—United States, 1993–1994. **MMWR Morb Mortal Wkly Rep** 1995 Dec 1;44(47):886–7

Hormones and highways: a dangerous mixture for teenage drivers [editorial] Thomas JR. **Mo Med** 1995 Sep; 92(9):561–2

The application of K-function analysis to the geographical distribution of road traffic accident outcomes in Norfolk, England. Jones AP, et al. **Soc Sci Med** 1996 Mar; 42(6):879–85

[Pediatric and adolescent accident victims (ICD-E 800 to 829) in Austria 1980 to 1989] Foltin E. **Unfallchirurgie** 1996 Jun;22(3):99–109 (Eng. Abstr.) **(Ger)**

[Falling asleep at the wheel: the chief cause of severe traffic accidents] Zulley J, et al. **Wien Med Wochenschr** 1995; 145(17–18):473 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

The safety value of guardrails and crash cushions: a meta-analysis of evidence from evaluation studies. Elvik R. **Accid Anal Prev** 1995 Aug;27(4):523–49

Effectiveness estimates for center high mounted stop lamps: a six-year study. Farmer CM. **Accid Anal Prev** 1996 Mar; 28(2):201–8

An evaluation of the New Zealand graduated driver licensing system. Langley JD, et al. **Accid Anal Prev** 1996 Mar; 28(2):139–46

Compatibility considerations for low-mass rigid-belt vehicles. Niederer PF, et al. **Accid Anal Prev** 1995 Aug; 27(4):551–60

How drivers sit in cars. Parkin S, et al. **Accid Anal Prev** 1995 Dec;27(6):777–83

Bicycle accidents and drivers' visual search at left and right turns. Summala H, et al. **Accid Anal Prev** 1996 Mar; 28(2):147–53

Daytime running lights as a vehicle collision countermeasure: the Swedish evidence reconsidered. Theeuwes J, et al. **Accid Anal Prev** 1995 Oct;27(5):633–42

Remediation can only give what it has, so do not ask too much. Assailly JP. **Addiction** 1995 Dec;90(12):1594–5; discussion 1595–601

Meta-analysis helps to define the policy-relevance of drink driving research. Hedlund J. **Addiction** 1995 Dec; 90(12):1593–4; discussion 1595–601

Meta-analysis of remedial interventions with drink/drive offenders: a useful clarification of what is and is not known. McKnight AJ. **Addiction** 1995 Dec;90(12):1591–2; discussion 1595–601

Settling old questions, stimulating new ones [comment] Mann RE. **Addiction** 1995 Dec;90(12):1587–9; discussion 1595–601 . Comment on: Addiction 1995 Jul;90(7):907–26.

The need to standardize methodology. Nickel WR. **Addiction** 1995 Dec;90(12):1595; discussion 1595–601

Inherent problems with meta-analysis [comment] Peck RC. **Addiction** 1995 Dec;90(12):1589–91; discussion 1595–601. Comment on: Addiction 1995 Jul;90(7):907–26.

The dominant role of driver behavior in traffic safety [comment] Evans L. **Am J Public Health** 1996 Jun; 86(6):784–6. Comment on: Am J Public Health 1996 Jun;86(6):791–7.

The effects of a 4-year program promoting bicycle helmet use among children in Quebec. Farley C, et al. **Am J Public Health** 1996 Jan;86(1):46–51

Reducing alcohol-impaired driving in Massachusetts: the Saving Lives Program [see comments] Hingson R, et al. **Am J Public Health** 1996 Jun;86(6):791–7. Comment in: Am J Public Health 1996 Jun;86(6):784–5.

Reduce drunk driving for everyone's sake [letter; comment] Jacobsen P. **Am J Public Health** 1996 Jun;86(6):890–1. Comment on: Am J Public Health 1994 Nov;84(11):1732–7.

Reducing death on the road: the effects of minimum safety standards, publicized crash tests, seat belts, and alcohol. Robertson LS. **Am J Public Health** 1996 Jan;86(1):31–4

Effect of integration of injury control information into a high school physics course. Martinez R, et al. **Ann Emerg Med** 1996 Feb;27(2):216–24

"Steering clear" of automobile accidents in patients with sleep disorders [editorial; comment] [published erratum appears in Chest 1995 Dec;108(6):1776] Collop NA. **Chest** 1995 Oct; 108(4):889. Comment on: Chest 1995 Oct;108(4):899–902.

Hazard surveillance and injury control: a university-based pedestrian-safety project. Wojtowicz GG, et al. **J Am Coll Health** 1996 Jul;45(1):43–6

Airbag safety: deployment in an automobile crash with a fall from height. Barton ED. **J Emerg Med** 1995 Jul–Aug; 13(4):481–4

After the party's over: evaluation of a drinking and driving prevention program. Kuthy S, et al. **J Neurosci Nurs** 1995 Oct;27(5):273–7

Characteristics of fatal crashes of 16-year-old drivers: implications for licensure policies. Williams AF, et al. **J Public Health Policy** 1995;16(3):347–60

Alcohol interventions in trauma centers [letter; comment] Gitlitz GF. **JAMA** 1996 Feb 7;275(5):358. Comment on: JAMA 1995 Oct 4;274(13):1043–8.

Collisions with animals. Pless IB. **Lancet** 1996 Aug 24; 348(9026):492

Roadside driver alcohol survey and hospital alcohol survey in Port Moresby, Papua New Guinea. Attah Johnson FY, et al. **Med Law** 1995;14(3–4):157–61

Drink driving legislation: medicine and the law. Marks P. **Med Leg J** 1995;63 (Pt 3):119–27 (17 ref.)

Diabetes mellitus and traffic incidents. Veneman TF. **Neth J Med** 1996 Jan;48(1):24–8 (27 ref.)

Evaluation of the effectiveness of a pavement stencil in promoting safe behavior among elementary school children boarding school buses. Burke GS, et al. **Pediatrics** 1996 Apr;97(4):520–3

The Harstad injury prevention study: hospital-based injury recording used for outcome evaluation of community-based prevention of bicyclist and pedestrian injury. Ytterstad B. **Scand J Prim Health Care** 1995 Jun; 13(2):141–9

Safety first—mostly [editorial] Thomison JB. **Tenn Med** 1996 Aug;89(8):278–9

[Automobile driving with alcohol impaired abilities in young people from rural areas in Quebec: a comparison of the years 1983 and 1992] Audet T, et al. **Can J Public Health** 1995 Sep–Oct;86(5):333–4 **(Fre)**

[Air bags: benefits and risks] Haddad R, et al. **Harefuah** 1996 Jan 15;130(2):120–2 (25 ref.) **(Heb)**

[Air bags—do they help?] Solheim K. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):471 **(Nor)**

PSYCHOLOGY

Personal and behavioral predictors of automobile crash and injury severity. Kim K, et al. **Accid Anal Prev** 1995 Aug; 27(4):469–81

Perceived risk and modal choice: risk compensation in transportation systems. Noland RB. **Accid Anal Prev** 1995 Aug;27(4):503–21

Behavioural characteristics and involvement in different types of traffic accident. Parker D, et al. **Accid Anal Prev** 1995 Aug;27(4):571–81

The effect of a moderate dose of alcohol on the traffic hazard perception profile of young drink-drivers. Deery HA, et al. **Addiction** 1996 Jun;91(6):815–27

Road traffic offending, stress, age, and accident history among male and female drivers. Simon F, et al. **Ergonomics** 1996 May;39(5):757–80

IQ loss and emotional dysfunctions after mild head injury incurred in a motor vehicle accident. Parker RS, et al. **J Clin Psychol** 1996 Jan;52(1):32–43

Initial posttraumatic stress responses following motor vehicle accidents. Bryant RA, et al. **J Trauma Stress** 1996 Apr; 9(2):223–34

Confrontations with reality: crisis intervention services for traumatized families after a school bus accident in Norway. Winje D, et al. **J Trauma Stress** 1995 Jul;8(3):429–44

Psychosocial factors in childhood pedestrian injury: a matched case-control study. Kid's 'n Cars Team. Christoffel KK, et al. **Pediatrics** 1996 Jan;97(1):33–42 (49 ref.)

Acute stress response: a comparison of head injured and non-head injured patients. Bryant RA, et al. **Psychol Med** 1995 Jul;25(4):869–73

STATISTICS & NUMERICAL DATA

Analysis of Hispanic motor vehicle trauma victims in Illinois, 1991–1992 [see comments] Lee P, et al. **Acad Emerg Med** 1996 Mar;3(3):221–7. Comment in: Acad Emerg Med 1996 Mar;3(3):194–7.

Thermal trauma resulting from motor vehicle operation or maintenance. Barillo DJ, et al. **Accid Anal Prev** 1995 Dec; 27(6):829–33

A case-control study of child bicycle injuries: relationship of risk to exposure. Carlin JB, et al. **Accid Anal Prev** 1995 Dec;27(6):839–44

Alcohol and non-fatal injury in the U.S. general population: a risk function analysis. Cherpitel CJ, et al. **Accid Anal Prev** 1995 Oct;27(5):651–61

Risk factors for injury: similarities and differences for traffic crashes and other causes. Chipman ML. **Accid Anal Prev** 1995 Oct;27(5):699–706

Helmets, injuries and cultural definitions: motorcycle injury in urban Indonesia. Conrad P, et al. **Accid Anal Prev** 1996 Mar;28(2):193–200

Lower extremity fractures in motor vehicle collisions: the role of driver gender and height. Dischinger PC, et al. **Accid Anal Prev** 1995 Aug;27(4):601–6

Differences in young driver crash involvement in states with varying licensure practices. Ferguson SA, et al. **Accid Anal Prev** 1996 Mar;28(2):171–80

Influence of fatigue in nonfatal nighttime car accidents involving young male drivers [letter; comment] Geuna S, et al. **Accid Anal Prev** 1995 Aug;27(4):618. Comment on: Accid Anal Prev 1994 Oct;26(5):617–24.
Young novice drivers: towards a model of their accident involvement. Gregersen NP, et al. **Accid Anal Prev** 1996 Mar;28(2):229–41
Rejoinder to Field and Clarke [letter; comment] Hazelbaker KL. **Accid Anal Prev** 1995 Aug;27(4):622. Comment on: Accid Anal Prev 1993 Jun;25(3):297–306.
Appropriate frontal barrier tests for belted occupants. Hill JR, et al. **Accid Anal Prev** 1995 Dec;27(6):807–17
The effects of seat belts on injury severity of front and rear seat occupants in the same frontal crash. Huelke DF, et al. **Accid Anal Prev** 1995 Dec;27(6):835–8
Personal and behavioral predictors of automobile crash and injury severity. Kim K, et al. **Accid Anal Prev** 1995 Aug; 27(4):469–81
Crash pulse recorder—validation in full scale crash tests. Kullgren A, et al. **Accid Anal Prev** 1995 Oct;27(5):717–27
Spatial analysis of Honolulu motor vehicle crashes: I. Spatial patterns. Levine N, et al. **Accid Anal Prev** 1995 Oct; 27(5):663–74
Spatial analysis of Honolulu motor vehicle crashes: II. Zonal generators. Levine N, et al. **Accid Anal Prev** 1995 Oct; 27(5):675–85
Daily fluctuations in honolulu motor vehicle accidents. Levine N, et al. **Accid Anal Prev** 1995 Dec;27(6):785–96
Head injuries in lateral impact collisions. Morris A, et al. **Accid Anal Prev** 1995 Dec;27(6):749–56
Some implications of driver training for road accidents in Gaborone. Oladiran MT, et al. **Accid Anal Prev** 1995 Aug; 27(4):583–90
Rejoinder to Mannering [letter; comment] Peck RC. **Accid Anal Prev** 1995 Aug;27(4):618–21. Comment on: Accid Anal Prev 1994 Feb;26(1):130–3.
Emergency department and hospital admissions and deaths from traffic injuries in Barcelona, Spain. A one-year population-based study. Plasència A, et al. **Accid Anal Prev** 1995 Aug;27(4):591–600
The feasibility of linking hospital and police road crash casualty records without names. Rosman DL. **Accid Anal Prev** 1996 Mar;28(2):271–4
An evaluation of road crash injury severity measures. Rosman DL, et al. **Accid Anal Prev** 1996 Mar;28(2):163–70
Field effectiveness of two restraint systems: the 3-point manual belt versus the 2-point motorized-shoulder/manual lap belt. Streff FM. **Accid Anal Prev** 1995 Aug;27(4):607–10
Spatial data aggregation: exploratory analysis of road accidents. Thomas I. **Accid Anal Prev** 1996 Mar; 28(2):251–64
Rollovers on sideslopes and ditches. Viner JG. **Accid Anal Prev** 1995 Aug;27(4):483–91
Cellular phones and traffic accidents: an epidemiological approach. Violanti JM, et al. **Accid Anal Prev** 1996 Mar; 28(2):265–70
A filter model to describe bias in official statistics on alcohol-related injuries. Webb GR. **Accid Anal Prev** 1995 Oct;27(5):687–97
The need for emergency department data in highway safety management systems [news] Weiss HB, et al. **Accid Anal Prev** 1995 Aug;27(4):621–2
Young female drivers in New Zealand. Wylie SJ. **Accid Anal Prev** 1995 Dec;27(6):797–805
Alcohol availability and alcohol-related crashes: does distance make a difference? Giacopassi D, et al. **Am J Drug Alcohol Abuse** 1995 Aug;21(3):407–16
Alcohol, the elderly, and motor vehicle crashes. Higgins JP, et al. **Am J Emerg Med** 1996 May;14(3):265–7
The dominant role of driver behavior in traffic safety [comment] Evans L. **Am J Public Health** 1996 Jun; 86(6):784–6. Comment on: Am J Public Health 1996 Jun;86(6):791–7.
Motorcycle helmet use and injury outcome and hospitalization costs from crashes in Washington State. Rowland J, et al. **Am J Public Health** 1996 Jan;86(1):41–5
Motorcycle trauma in the state of Illinois: analysis of the Illinois Department of Public Health Trauma Registry [see comments] Orsay E, et al. **Ann Emerg Med** 1995 Oct; 26(4):455–60. Comment in: Ann Emerg Med 1996 Mar;27(3):389–91.
Enforcement of drunken driving laws in cases involving injured intoxicated drivers. Runge JW, et al. **Ann Emerg Med** 1996 Jan;27(1):66–72
Crashes and violations among drivers with Alzheimer disease. Trobe JD, et al. **Arch Neurol** 1996 May;53(5):411–6
Evaluation of the prevalence of drug and alcohol abuse in motor vehicle trauma in south western Sydney. Sugrue M, et al. **Aust N Z J Surg** 1995 Dec;65(12):853–6
Northern Ontario MDs seek solution to region's huge accidental-death toll. Spears T. **Can Med Assoc J** 1996 Jul 1;155(1):101–2
Disablement resulting from motorcycle crashes. Clarke JA, et al. **Disabil Rehabil** 1995 Oct;17(7):377–85
Road traffic accidents in Kenya: an epidemiological appraisal. Odero W. **East Afr Med J** 1995 May;72(5):299–305
Motorcycle accidents in Strathclyde Region, Scotland during 1992: a study of the injuries sustained. Doyle D, et al. **Health Bull (Edinb)** 1995 Nov;53(6):386–94
Craniofacial injuries in unhelmeted riders of motorbikes. Lee MC, et al. **Injury** 1995 Sep;26(7):467–70
Injuries related to car crime: the joy-riding epidemic. Marshall C, et al. **Injury** 1996 Mar;27(2):79–80
Severe motorcycle injury in Mersey region and North Wales. Sinha AK, et al. **Injury** 1995 Oct;26(8):543–5
A case-control study of traffic risk factors and child pedestrian injury. Stevenson MR, et al. **Int J Epidemiol** 1995 Oct;24(5):957–64
Pedestrian-motor vehicle trauma: an analysis of injury profiles by age. Kong LB, et al. **J Am Coll Surg** 1996 Jan; 182(1):17–23
Medical screening of older drivers as a traffic safety measure—a comparative Finnish-Swedish evaluation study. Hakamies-Blomqvist L, et al. **J Am Geriatr Soc** 1996 Jun;44(6):650–3
Predictors of motor vehicle crashes in a dementia clinic population: the role of gender and arthritis [letter] Tuokko H, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1444–5
The effect of accident mechanisms and initial findings on the long-term course of whiplash injury. Sturzenegger M, et al. **J Neurol** 1995 Jul;242(7):443–9
Regional differences in alcohol and fatal injury: a comparison of data from two county coroners. Cherpitel CJ. **J Stud Alcohol** 1996 May;57(3):244–8
Demographic characteristics, drinking patterns and drink-driving behavior of injured male drivers and motorcycle riders. Holubowycz OT, et al. **J Stud Alcohol** 1995 Sep;56(5):513–21
Comparison of accident and emergency with police road injury data. Cercarelli LR, et al. **J Trauma** 1996 May; 40(5):805–9
Fatal motor vehicle crashes: variations of crash characteristics within rural regions of different population densities. Muelleman RL, et al. **J Trauma** 1996 Aug; 41(2):315–20
Traffic accidents and daylight saving time [letter; comment] Ferguson SA. **N Engl J Med** 1996 Aug 1;335(5):355–6; discussion 356–7. Comment on: N Engl J Med 1996 Apr 4;334(14):924.
Self-reported automobile accidents involving patients with obstructive sleep apnea. Wu H, et al. **Neurology** 1996 May; 46(5):1254–7
Psychosocial factors in childhood pedestrian injury: a matched case-control study. Kid's'n Cars Team. Christoffel KK, et al. **Pediatrics** 1996 Jan;97(1):33–42 (49 ref.)
Subway suicide rates and national suicide rates. Lester D. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):954
Accident experience and notification rates in people with recent seizures, epilepsy or undiagnosed episodes of loss of consciousness. Taylor J, et al. **QJM** 1995 Oct; 88(10):733–40
The age-dependent incidence of injuries due to road traffic accidents in Odense, Denmark from 1980 to 1992. Larsen LB, et al. **Scand J Soc Med** 1995 Sep;23(3):150–5
Traffic accident mapping in Bangkok metropolis: a case study. Ayuthya RS, et al. **Stat Med** 1995 Nov 15–30; 14(21–22):2445–58
[Mortality among victims of traffic accidents with multiple injuries. A descriptive study 1986–1990] Larsen MS, et al. **Ugeskr Laeger** 1995 Nov 27;157(48):6716–9 (Eng. Abstr.) **(Dan)**
[Abuse of psychotropic drugs during driving] Lemoine P, et al. **Encephale** 1996 Jan–Feb;22(1):1–6 (39 ref.) (Eng. Abstr.) **(Fre)**
[Traffic accidents in alcoholic intoxication] Erath D, et al. **Blutalkohol** 1996 Mar;33(2):57–64 (Eng. Abstr.) **(Ger)**
[Changes in the spectrum of alcohol-induced traffic accidents in relation to blood alcohol level] Haffner HT, et al. **Blutalkohol** 1996 Mar;33(2):78–83 (Eng. Abstr.) **(Ger)**
[Hyperkinetic syndrome and behavioral disorders in street traffic: a case control pilot study] Beck N, et al. **Z Kinder Jugenpsychiatr** 1996 Jun;24(2):82–91 (Eng. Abstr.) **(Ger)**
[Traffic accidents in the Spanish population] Prada C, et al. **Med Clin (Barc)** 1995 Nov 11;105(16):601–4 (Eng. Abstr.) **(Spa)**

TRENDS

Trends in highway safety: effects of an aging population on accident propensity. Stamatiadis N, et al. **Accid Anal Prev** 1995 Aug;27(4):443–59
The older driver—a review. Morgan R, et al. **Postgrad Med J** 1995 Sep;71(839):525–8 (30 ref.)

ACCLIMATION see **ACCLIMATIZATION**

ACCLIMATIZATION

Evaluation of the peripheral circulatory status of the neonate during homeothermal adjustment by plethysmo-time-interval. Oishi M, et al. **Acta Paediatr Jpn** 1996 Apr;38(2):147–50
Cold acclimation-recruited nonshivering thermogenesis: the Syrian hamster is not an exception. Dicker A, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R767–74
Expression of sarcoplasmic reticulum Ca2+ transport proteins in cold-acclimating ducklings. Dumonteil E, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C955–60
Cholesterol content of trout plasma membranes varies with acclimation temperature. Robertson JC, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1113–9
Circulating leptin levels are modulated by fasting, cold exposure and insulin administration in lean but not Zucker (fa/fa) rats as measured by ELISA. Hardie LJ, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):660–5
Biogenesis of thermogenic mitochondria in brown adipose tissue of Djungarian hamsters during cold adaptation. Klingenspor M, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):607–13
Cold-induced reduction in Gi alpha proteins in brown adipose tissue. Effects on the cellular hypersensitization to noradrenaline caused by pertussis-toxin treatment. Svoboda P, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):761–8
Poor ventilatory response to mild hypoxia may inhibit acclimatization at moderate altitude in elderly patients after carotid surgery. Roeggla G, et al. **Br J Sports Med** 1995 Jun;29(2):110–2
Heat strain in protective clothing following hot-wet or hot-dry heat acclimation. McLellan TM, et al. **Can J Appl Physiol** 1996 Apr;21(2):90–108
Effects of 6 versus 12 days of heat acclimation on heat tolerance in lightly exercising men wearing protective clothing. Aoyagi Y, et al. **Eur J Appl Physiol** 1995; 71(2–3):187–96
The characterisation of the 5' regulatory region of a temperature-induced myosin-heavy-chain gene associated with myotomal muscle growth in the carp. Gauvry L, et al. **Eur J Biochem** 1996 Mar 15;236(3):887–94
Acclimatization effect on the evening fall in core temperature under the influence of two types of clothing. Li X, et al. **Experientia** 1996 Jun 15;52(6):613–5
Estimation of the degree of acclimatization to high altitude by a rapid and simple physiological examination. Saito S, et al. **Int Arch Occup Environ Health** 1995;67(5):347–51
Role of vasoconstrictors in the systemic hypertension of rats acclimatized to hypoxia. Moue Y, et al. **J Appl Physiol** 1995 Nov;79(5):1657–67
Enhanced hypo-osmoregulation induced by warm-acclimation in antarctic fish is mediated by increased gill and kidney Na+/K(+)-ATPase activities. Gonzalez-Cabrera PJ, et al. **J Exp Biol** 1995 Nov;198 (Pt 11):2279–91
Lactotroph and somatotroph function in piglets reared in a constant hot environment. Matteri RL, et al. **Life Sci** 1996;58(8):711–7
Long-term potentiation at low temperature is stronger in hippocampal slices from hibernating Turkish hamsters compared to warm-acclimated hamsters and rats. Spangenberger H, et al. **Neurosci Lett** 1995 Jul 14; 194(1–2):127–9
ELISA measurements of vasotocin and isotocin in plasma and pituitary of the rainbow trout: effect of salinity. Pierson PM, et al. **Peptides** 1995;16(5):859–65
The correlation between heat-shock protein accumulation and persistence and chilling tolerance in tomato fruit. Sabehat A, et al. **Plant Physiol** 1996 Feb;110(2):531–7
31P magnetic resonance spectroscopy of the Sherpa heart: a phosphocreatine/adenosine triphosphate signature of metabolic defense against hypobaric hypoxia. Hochachka PW, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):1215–20
Leukotriene C4-stimulated contractions in bullfrog lung are affected by cold acclimation and calcium antagonists. Herman CA, et al. **Prostaglandins** 1995 Feb;49(2):117–29
Cold acclimation and endurance training in guinea pigs: changes in lung, muscle and brown fat tissue. Hoppeler H, et al. **Respir Physiol** 1995 Aug;101(2):189–98
Cold acclimation and endurance training in guinea pigs: changes in daily and maximal metabolism. Turner DL, et al. **Respir Physiol** 1995 Aug;101(2):183–8
[Results from measurements of nitrogen and energy metabolism in adaptive different cattle] Jentsch W, et al. **Arch Tierernahr** 1995;48(1–2):159–71 (Eng. Abstr.) **(Ger)**
[Clinical chemical and hematological blood values and adaptation reactions in suckling calves in the first weeks of life] Steinhardt M, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Oct; 102(10):399–405 (Eng. Abstr.) **(Ger)**
[Cardiorespiratory evaluation of athletes for competitions at high altitudes] Costa RV. **Arq Bras Cardiol** 1995 Feb; 64(2):183–6 **(Por)**
[Prediction of health status and adaptation of workers in the gas-production industry under conditions of the arid zone] Ammanepesov KA, et al. **Fiziol Cheloveka** 1995 Nov-Dec; 21(6):92–8 **(Rus)**
[Circadian rhythm of secretion of electrolytes with saliva during acute human adaptation to contrasting climatic conditions in the environment] Fedorova OI. **Fiziol Cheloveka** 1995 Nov-Dec;21(6):76–91 **(Rus)**
[The problem of human nutrition under the native-climatic conditions of Turkmenistan] Grafova VA, et al. **Fiziol Cheloveka** 1995 Nov-Dec;21(6):99–106 **(Rus)**
[Seasonal and social influences on the cardiorespiratory system in inhabitants of the North] Roshchevskiĭ MP, et al. **Fiziol Cheloveka** 1995 Nov-Dec;21(6):55–69 **(Rus)**
[Seasonal changes in physiologic functions in inhabitants of the North] Solonin IuG. **Fiziol Cheloveka** 1995 Nov-Dec; 21(6):70–5 **(Rus)**
[Functional activity of the hypophyseal-thyroid system in pregnant women under conditions of the town of Khabarovska] Uchakina RV, et al. **Fiziol Cheloveka** 1995 Nov-Dec;21(6):85–91 **(Rus)**

GENETICS

Induction of proteins in response to cold acclimation of rainbow trout cells. Yamashita M, et al. **FEBS Lett** 1996

Mar 18;382(3):261–4

PHYSIOLOGY

Cardiovascular response to exercise in humans following acclimatization to extreme altitude. Savard GK, et al. **Acta Physiol Scand** 1995 Aug;154(4):499–509

Physical performance and heat tolerance after chronic water loading and heat acclimation. Kristal-Boneh E, et al. **Aviat Space Environ Med** 1995 Aug;66(8):733–8

The effect of altitude pre-acclimatization on acute mountain sickness during reexposure. Lyons TP, et al. **Aviat Space Environ Med** 1995 Oct;66(10):957–62

Thermogenesis, myoclonic twitching, and ultrasonic vocalization in neonatal rats during moderate and extreme cold exposure. Blumberg MS, et al. **Behav Neurosci** 1996 Apr;110(2):305–14

The effects of soft-water acclimation on gill structure in the rainbow trout Oncorhynchus mykiss. Greco AM, et al. **Cell Tissue Res** 1996 Jul;285(1):75–82

Thermal control of rod outer segment length and shedding in a fish, Fundulus zebrinus. Allen DM. **Exp Eye Res** 1995 Aug;61(2):165–71

Effects of growth hormone and insulin-like growth factor I on salinity tolerance and gill Na+, K+-ATPase in Atlantic salmon (Salmo salar): interaction with cortisol. McCormick SD. **Gen Comp Endocrinol** 1996 Jan; 101(1):3–11

Changes in blood cell numbers and formation of eicosanoids during clotting in warm- and cold-acclimated bullfrogs (Rana catesbeiana). Wang X, et al. **Gen Comp Endocrinol** 1996 Feb;101(2):211–9

Evidence for contribution of effector organ cellular responses to the biphasic dynamics of heat acclimation. Horowitz M, et al. **J Appl Physiol** 1996 Jan;80(1):77–85

Acclimatization at high altitude in gradual and acute induction. Purkayastha SS, et al. **J Appl Physiol** 1995 Aug; 79(2):487–92

Mechanical and metabolic performance of the rat heart: effects of combined stress of heat acclimation and swimming training. Horowitz M, et al. **J Basic Clin Physiol Pharmacol** 1993 Apr-Jun; 4(1–2):139–56

Mechanism of heat acclimation induced bradycardia in the sand rat. Horowitz M, et al. **J Basic Clin Physiol Pharmacol** 1993 Apr-Jun;4(1–2):37–46

Differences in protein patterns of gill epithelial cells of the fish Gillichthys mirabilis after osmotic and thermal acclimation. Kültz D, et al. **J Comp Physiol [B]** 1996; 166(2):88–100

Freezing tolerance/intolerance and cryoprotectant synthesis in terrestrially overwintering anurans in the Great Plains, USA. Swanson DL, et al. **J Comp Physiol [B]** 1996; 166(2):110–9

Thermotolerance attenuates heat-induced increases in [Ca2+]i and HSP-72 synthesis but not heat-induced intracellular acidification in human A-431 cells. Kiang JG, et al. **J Investig Med** 1996 Feb;44(2):53–63

Adaptation to heat. Hori S. **Jpn J Physiol** 1995;45(6):921–46 (82 ref.)

ACCOMMODATION, OCULAR

Dynamics of accommodative vergence movements controlled by the dominant and non-dominant eye. Han Y, et al. **Acta Ophthalmol Scand** 1995 Aug;73(4):319–24

Partly accommodative esotropia. Should you overcorrect and cut the plus? Kushner BJ. **Arch Ophthalmol** 1995 Dec; 113(12):1530–4

The effects of Qi-Qong ocular exercise on accommodation. Shih YF, et al. **Chin J Physiol** 1995;38(1):35–42

Accommodation to monochromatic and white-light targets. Aggarwala KR, et al. **Invest Ophthalmol Vis Sci** 1995 Dec; 36(13):2695–705

Descending projections from the cortical accommodation area in the cat. Ohtsuka K, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1429–36

Effect of accommodation of the lens on ocular pressure. Blake J, et al. **Ir J Med Sci** 1995 Oct-Dec;164(4):269–70

Dissociated horizontal deviation and accommodative esotropia: treatment options when an eso- and an exodeviation co-exist. Wilson ME, et al. **J Pediatr Ophthalmol Strabismus** 1995 Jul-Aug; 32(4):228–30

Spectacle lenses alter eye growth and the refractive status of young monkeys [see comments] Hung LF, et al. **Nat Med** 1995 Aug;1(8):761–5. Comment in: Nat Med 1995 Aug;1(8):737–9.

Gain changes in the accommodative convergence cross-link. Bobier WR, et al. **Ophthalmic Physiol Opt** 1996 Jul; 16(4):318–25

Proximal contribution to a linear static model of accommodation and vergence. Hung GK, et al. **Ophthalmic Physiol Opt** 1996 Jan;16(1):31–41

Spasm of the near reflex: a spectrum of anomalies. Goldstein JH, et al. **Surv Ophthalmol** 1996 Jan-Feb;40(4):269–78 (50 ref.)

Refractive emergency. Khan A. **Surv Ophthalmol** 1996 Mar-Apr;40(5):405–6

Effects on the compensatory responses to positive and negative lenses of intermittent lens wear and ciliary nerve section in chicks. Schmid KL, et al. **Vision Res** 1996 Apr; 36(7):1023–36

[Measuring the level of tonic accomodation as a function of wavelength] Dechriste S, et al. **J Fr Ophtalmol** 1995; 18(6–7):439–46 (26 ref.) (Eng. Abstr.) **(Fre)**

[Use of laser speckle in occupational eye diseases] Feigin AA, et al. **Vestn Oftalmol** 1996 Jan-Mar;112(1):33–4 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Aging effects on accommodation and outflow facility responses to pilocarpine in humans. Croft MA, et al. **Arch Ophthalmol** 1996 May;114(5):586–92

PGF2 alpha/pilocarpine interactions on IOP and accommodation in monkeys. Millar JC, et al. **Exp Eye Res** 1995 Dec;61(6):677–83

Seronegative myasthenia gravis associated with atonic urinary bladder and accommodative insufficiency. Matsui M, et al. **J Neurol Sci** 1995 Nov;133(1–2):197–9

Dapiprazole's effect upon accommodative recovery: is it due entirely to changes in depth of field? Molinari JF, et al. **Optom Vis Sci** 1995 Aug;72(8):552–6 (18 ref.)

[Effects of topical application of isopropyl unoprostone on refraction and accommodation] Otsuka N, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jul;100(7):531–4 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Accommodation in primate eyes after implantation of refilled endocapsular balloon. Sakka Y, et al. **Am J Ophthalmol** 1996 Feb;121(2):210–2

The symbiosis between basic and applied research. Leibowitz HW. **Am Psychol** 1996 Apr;51(4):366–70

Neuronal circuitry controlling the near response. Mays LE, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):763–8 (29 ref.)

Accommodation power determined with visual evoked cortical potentials in psychogenic visual disturbances. Yamazaki H, et al. **Doc Ophthalmol** 1995;90(3):271–7

Viewing distance variation and related ophthalmological changes in office activities with and without VDUs. Piccoli B, et al. **Ergonomics** 1996 May;39(5):719–28

Theoretical analysis of image defocus with intraocular lens decentration. Kozaki J, et al. **J Cataract Refract Surg** 1995 Sep;21(5):552–5

Projection from the accommodation-related area in the superior colliculus of the cat. Sato A, et al. **J Comp Neurol** 1996 Apr 8;367(3):465–76

Evolution of control system models of ocular accommodation, vergence and their interaction. Eadie AS, et al. **Med Biol Eng Comput** 1995 Jul;33(4):517–24 (84 ref.)

The fluctuations of accommodation and ageing. Heron G, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):445–9

Dark focus and dark vergence: an experimental verification of the configuration of the dual-interactive feedback model. Jiang BC, et al. **Ophthalmic Physiol Opt** 1996 Jul; 16(4):342–7

Effect of age on the interaction between the AC/A and CA/C ratios. Rosenfield M, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):451–5

Accommodation and iridotomy in the pigment dispersion syndrome. Pavlin CJ, et al. **Ophthalmic Surg Lasers** 1996 Feb;27(2):113–20

Abnormal transient myopia in symptomatic individuals after sustained nearwork. Ciuffreda KJ, et al. **Optom Vis Sci** 1995 Jul;72(7):506–10

Small amounts of chromatic aberration influence dynamic accommodation. Kruger PB, et al. **Optom Vis Sci** 1995 Sep; 72(9):656–66

Accommodative amplitudes in the Early Treatment Diabetic Retinopathy Study. Braun CI, et al. **Retina** 1995; 15(4):275–81

Microfluctuations of steady-state accommodation and the cardiopulmonary system. Collins M, et al. **Vision Res** 1995 Sep;35(17):2491–502

Absence of adaptive plasticity after voluntary vergence and accommodation. Ebenholtz SM, et al. **Vision Res** 1995 Oct; 35(19):2773–83

Accommodative vergence is driven by the phasic component of the accommodative controller. Jiang BC. **Vision Res** 1996 Jan;36(1):97–102

Accommodation responds to changing contrast of long, middle and short spectral-waveband components of the retinal image. Kruger PB, et al. **Vision Res** 1995 Sep; 35(17):2415–29

[Partly accommodative convergent strabismus with and without excess convergence. Surgical treatment] Klainguti G, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):352–5 (Eng. Abstr.) **(Fre)**

[Continuous ultrasound biomicroscopic imaging of accommodative changes in the human ciliary body] Bacskulin A, et al. **Klin Monatsbl Augenheilkd** 1995 Oct; 207(4):247–52 (Eng. Abstr.) **(Ger)**

[Ultrasound biomicroscopy imaging of accommodative configuration changes in the presbyopic ciliary body] Bacskulin A, et al. **Ophthalmologe** 1996 Apr;93(2):199–203 (Eng. Abstr.) **(Ger)**

ACCOUNTABLE HEALTH PLANS see **MANAGED COMPETITION**

ACCOUNTING

The quality of cost data. A caution from the Department of Veterans Affairs experience. Swindle RW Jr, et al. **Med Care** 1996 Mar;34(3 Suppl):MS83–90

The imposter phenomenon in teachers and accountants. Byrnes KD, et al. **Psychol Rep** 1995 Aug;77(1):350

[30 million dollars as the highest compensation so far. American hospitals salt the bills] Bergström L. **Lakartidningen** 1996 May 22;93(21):2019 **(Swe)**

METHODS

A multifactorial approach to understanding anesthesia selection. Suver JD, et al. **Health Care Manage Rev** 1995 Summer;20(3):7–15

ACCREDITATION

see related
CERTIFICATION
LICENSURE

ELPAT program report: background and current status (April 1996). Environmental Lead Proficiency Analytical Testing. Esche CA, et al. **Am Ind Hyg Assoc J** 1996 Jul; 57(7):697–703

Standards, accreditation and proficiency testing in the management of blood and blood products in hospitals [letter] Growe GH. **Can Med Assoc J** 1996 Mar 15; 154(6):755

Clinical sports medicine training and accreditation: the United States experience [editorial] Lombardo JA, et al. **Clin J Sport Med** 1996 Apr;6(2):76–7

Quality and accreditation systems in clinical biochemistry in the European Union. Jansen RT, et al. **Eur J Clin Chem Clin Biochem** 1995 Jun;33(6):393–8

The nature of quality assurance in nuclear medicine and the American College of Nuclear Physicians' quality assurance programs. Abreu SH. **Eur J Nucl Med** 1996 Jan; 23(1):99–103

Accreditation of postdoctoral general dentistry programs. Glassman P. **J Am Coll Dent** 1995 Fall;62(3):27–30 (33 ref.)

The 1995 JCAHO mental health manual--an overview for dietetics professionals. Foiles RA. **J Am Diet Assoc** 1996 Apr;96(4):403–4 (6 ref.)

Applying the 1996 JCAHO nutrition care standards in a long-term-care setting. Robinson GE. **J Am Diet Assoc** 1996 Apr;96(4):400–3 (8 ref.)

Applying the 1995 JCAHO standards to dietetics practice in home care. Westbrook NH. **J Am Diet Assoc** 1996 Apr; 96(4):404–6 (5 ref.)

Accreditation in the UK for pesticide residue analysis in foods. Thorpe SA, et al. **J Chromatogr A** 1996 Jun 14; 737(1):3–7 (4 ref.)

Nurses go to the home [letter; comment] Kobs AE. **J Nurs Adm** 1996 Mar;26(3):8. Comment on: J Nurs Adm 1995 Sep;25(9):7, 26.

Accountability through accreditation [editorial] Laskin DM. **J Oral Maxillofac Surg** 1996 Mar;54(3):249

Discrediting accreditation [letter] Ronald JB. **J Oral Maxillofac Surg** 1996 Sep;54(9):1142

From the Joint Commission on Accreditation of Healthcare Organizations. Loeb JM, et al. **JAMA** 1996 Feb 21; 275(7):508

The development of an accreditation scheme for the application of computerized information systems using the National Child Health System. Nolder CR, et al. **Medinfo** 1995;8 Pt 2:1612–5

The National Committee for Quality Assurance. Iglehart JK. **N Engl J Med** 1996 Sep 26;335(13):995–9

U.S. EPA challenges and review--highlights of the Fiscal Year 1994 Inspection Program and EPA's laboratory accreditation considerations. Dull D. **Qual Assur** 1995 Mar; 4(1):20–8

What's in it for me (and my program)? Fay M. **Radiol Technol** 1996 Mar-Apr;67(4):355–7

The South African Pilot Hospital Accreditation Programme [letter] Muller M, et al. **S Afr Med J** 1995 Oct;85(10):1034–5

Obstetrics and gynecology ultrasound laboratory accreditation in the USA [editorial] Copel JA. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):161–2

[Teaching digestive laparoscopic surgery in France: from education to accreditation?] Testas P, et al. **Bull Acad Natl Med** 1995 Oct;179(7):1507–14; discussion 1514–6 (Eng. Abstr.) **(Fre)**

[Accreditation. Priority and challenge] Imperatori E. **Acta Med Port** 1996 Jan;9(1):59–66 (16 ref.) (Eng. Abstr.) **(Por)**

[The accreditation of clinico-diagnostic laboratories on the territory of Kaluga Province] Titova LD. **Klin Lab Diagn** 1995 Nov-Dec;(6):61–2 **(Rus)**

[The JUS ISO 9000 Quality Control System. General requirements for laboratory accreditation] Miličević P. **Med Pregl** 1995;48(7–8):241–4 (Eng. Abstr.) **(Scr)**

[Requisites for accreditation of teaching units in pneumology] Alvarez- Sala Walther JL, et al. **Arch Bronconeumol** 1996 Mar;32(3):142–4 **(Spa)**

[The experience of 15 years in the accreditation of training centers for medical specialists] Vial S. **Rev Med Chil** 1995 Aug;123(8):1025–32 (Eng. Abstr.) **(Spa)**

[Accreditation in practice: "stimulation for personnel, good for competition"] Norbrink B. **Lakartidningen** 1996 Feb 14; 93(7):540 **(Swe)**

ACCREDITATION

HISTORY

The historical relationship of nursing program accreditation and public policy in Canada. Richardson SL. **Nurs Hist Rev** 1996;4:19–41

LEGISLATION & JURISPRUDENCE

New accrediting regs pose issues for schools, NLN. **Am J Nurs** 1996 Feb;96(2):63–64

National and regional regulations on minimal requirements, quality control and accreditation for clinical laboratories in Italy. Menditto A, et al. **Ann Ist Super Sanita** 1995; 31(1):149–55

Accreditation of those who arrange adoptions under the Hague Convention on intercountry adoption as a means of protecting, through private international law, the rights of children. Pierce WL. **J Contemp Health Law Policy** 1996 Spring;12(2):535–61 (31 ref.)

METHODS

General practitioner reaccreditation: use of performance indicators. Houghton G. **Br J Gen Pract** 1995 Dec; 45(401):677–81

ORGANIZATION & ADMINISTRATION

Compliance with ACHS standards in Australian hospitals. Australian Council on Healthcare Standards. Holt PE. **Aust Clin Rev** 1991;11:111–5

Improving continuing medical education and addressing the challenge of instituting reaccreditation. Westcott R. **Br J Gen Pract** 1996 Jan;46(402):43–5

Can educational accreditation drive interdisciplinary learning in the health professions? Gelmon SB. **Jt Comm J Qual Improv** 1996 Mar;22(3):213–22 (27 ref.)

STANDARDS

Relating autopsy requirements to the contemporary accreditation process. O'Leary DS. **Arch Pathol Lab Med** 1996 Aug;120(8):763–6 (5 ref.)

Accreditation standards proposed for managed-mental-health care in USA [news] Rovner J. **Lancet** 1996 Apr 20;347(9008):1108–9

ISO 9000 laboratory accreditation. International Organization for Standardization. Dunavant DW, et al. **Qual Assur** 1995 Mar;4(1):41–59

Standards are adopted by JRCERT. Fay M. **Radiol Technol** 1996 May-Jun;67(5):429–34

TRENDS

[Experience with the accreditation of the neurological and neurosurgical services of Saint Petersburg during the transition of public health to the principles of medical insurance] Poliakov IV, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):95–7 **(Rus)**

ACCULTURATION

The Anne Frank Haven in an Israeli Kibbutz. Dror Y. **Adolescence** 1995 Fall;30(119):617–29

Cultural orientation and psychological well-being in Chinese Americans. Ying YW. **Am J Community Psychol** 1995 Dec; 23(6):893–911

Health effects of westernization and migration among Chamorros. 1970 [classical article] Reed D, et al. **Am J Epidemiol** 1995 Oct 1;142(7):673–91; discussion 671–2

Acculturation style and psychological functioning in children of immigrants. Pawliuk N, et al. **Am J Orthopsychiatry** 1996 Jan;66(1):111–21

Acculturation and low-birthweight infants among Latino women: a reanalysis of HHANES data with structural equation models [see comments] Cobas JA, et al. **Am J Public Health** 1996 Mar;86(3):394–6. Comment in: Am J Public Health 1996 Mar;86(3):303–5.

Potential for intergenerational conflict in Cuban and Haitian immigrant families. De Santis L, et al. **Arch Psychiatr Nurs** 1995 Dec;9(6):354–64

Food intakes of adult Melbourne Chinese. Hsu-Hage BH, et al. **Aust J Public Health** 1995 Dec;19(6):623–8

Child and adolescent psychiatric presentations of second-generation Afro-Caribbeans in Britain. Goodman R, et al. **Br J Psychiatry** 1995 Sep;167(3):362–9

The effect of acculturation on low birthweight in immigrant women. Hyman I, et al. **Can J Public Health** 1996 May-Jun; 87(3):158–62

Effects of immigration on the mentally ill—does it produce psychological distress? Ritsner M, et al. **Compr Psychiatry** 1996 Jan-Feb;37(1):17–22

The role of gender and acculturation on determining the consumption of alcoholic beverages among Mexican-Americans and Central Americans in the United States. Marín G, et al. **Int J Addict** 1995 May;30(7):779–94

Acculturation and psychiatric morbidity among Cambodian refugees in New Zealand. Cheung P. **Int J Soc Psychiatry** 1995 Summer;41(2):108–19

Does acculturation influence psychosocial adaptation and well-being in Native Hawaiians? Streltzer J, et al. **Int J Soc Psychiatry** 1996 Spring;42(1):28–37

Cross-cultural differences between Russian immigrants and Israeli college students: the effect of the family on the sense of coherence. Ben-David A. **Isr J Psychiatry Relat Sci** 1996;33(1):13–20

"Aliya as a challenge": an innovative workshop for the sociocultural integration of immigrant students. Dreman S, et al. **Isr J Psychiatry Relat Sci** 1996;33(1):5–12

Psychosocial problems faced during absorption of Russian-speaking new immigrants into Israel: a systematic approach. Rotenberg V, et al. **Isr J Psychiatry Relat Sci** 1996;33(1):40–9

Asian immigrants and the stress process: a study of Koreans in Canada. Noh S, et al. **J Health Soc Behav** 1996 Jun; 37(2):192–206

Comparing acculturation scales and their relationship to cancer screening among older Mexican-American women. Suarez L, et al. **J Natl Cancer Inst Monogr** 1995;(18):41–7

Personality styles and dynamics of Alaska Native and nonnative incarcerated men. Glass MH, et al. **J Pers Assess** 1996 Jun;66(3):583–603

"Acculturating" heroin use [see comments] Gaughwin MD. **Med J Aust** 1996 Jun 3;164(11):692–3. Comment in: Med J Aust 1996 Jun 3;164(11):649–50.

Strangers in a strange land. Clement D. **Minn Med** 1996 May; 79(5):11–4, 17–9

Trading places. Clement D. **Minn Med** 1996 May;79(5):6–7, 10

Development of a new scale for measuring acculturation: the Taiwan Aboriginal Acculturation Scale (TAAS). Cheng AT, et al. **Psychol Med** 1995 Nov;25(6):1281–7

Psychological distress among recent immigrants from the former Soviet Union to Israel, II. The effects of the Gulf War. Lerner Y, et al. **Psychol Med** 1996 May;26(3):503–10

Psychological distress among recent immigrants from the former Soviet Union to Israel, I. Correlates of level of distress. Zilber N, et al. **Psychol Med** 1996 May; 26(3):493–501

Acculturation, perceived social support, and self-esteem in primigravida Puerto Rican teenagers. Orshan SA. **West J Nurs Res** 1996 Aug;18(4):460–73

ACE INHIBITORS see **ANGIOTENSIN-CONVERTING ENZYME INHIBITORS**

ACEBUTOLOL

CHEMISTRY

Improved static compression behaviors and tablettabilities of spherically agglomerated crystals produced by the spherical crystallization technique with a two-solvent system. Kawashima Y, et al. **Pharm Res** 1995 Jul; 12(7):1040–4

PHARMACOLOGY

Evidence for a dual effect of acebutolol, a beta blocker, on the mouse humoral immune response. In S, et al. **Immunopharmacol Immunotoxicol** 1995 Aug;17(3):529–50

Effects of the beta-adrenergic blockers propranolol and acebutolol on stress-induced learned helplessness behavior of rats. Danchev N, et al. **Methods Find Exp Clin Pharmacol** 1995 Sep;17(7):463–7

POISONING

[Acute voluntary poisoning with acebutolol (letter)] Darmanaden R, et al. **Therapie** 1995 Nov-Dec;50(6):591–3 (18 ref.) **(Fre)**

THERAPEUTIC USE

Beta adrenergic blockade does not improve effort tolerance in patients with mitral stenosis in sinus rhythm. Patel JJ, et al. **Eur Heart J** 1995 Sep;16(9):1264–8

ACECAINIDE

PHARMACOKINETICS

Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans. Tisdale JE, et al. **J Clin Pharmacol** 1995 Sep;35(9):902–10

Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. Kharidia J, et al. **J Pharm Sci** 1996 Jun;85(6):595–9

Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity. Low CL, et al. **Nephrol Dial Transplant** 1996 May;11(5):881–4

PHARMACOLOGY

Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. Kharidia J, et al. **J Pharm Sci** 1996 Jun;85(6):595–9

ACEMETHADONE see **METHADYL ACETATE**

ACENAPHTHENES

CHEMICAL SYNTHESIS

Synthesis of (+/-)-1-amino-6,7,8,8a-tetrahydro acenaphthene with possible central dopaminergic activity. Perez J, et al. **Boll Chim Farm** 1995 Jun;134(6):329–32

ACENOCOUMARIN see **ACENOCOUMAROL**

ACENOCOUMAROL

ADMINISTRATION & DOSAGE

[The effect of prolonged acenocoumarol therapy on bone density] Kiss J, et al. **Orv Hetil** 1995 Sep 24;136(39):2113–5 (Eng. Abstr.) **(Hun)**

ADVERSE EFFECTS

Retroperitoneal haematoma in a patient treated with acenocoumarol, phenytoin and paroxetine. Abad-Santos F, et al. **Clin Lab Haematol** 1995 Jun;17(2):195–7

[Prolonged fever following treatment with acenocoumarol (letter)] Renou C, et al. **Rev Med Interne** 1996;17(1):93–4 **(Fre)**

[Hypersensitivity to Sintrom, caused by cochineal red A (letter)] Guy C, et al. **Therapie** 1995 Sep-Oct;50(5):483–4 **(Fre)**

THERAPEUTIC USE

Reduction of migrainous headaches during the use of acenocoumarol. van Puijenbroek EP, et al. **Headache** 1996 Jan;36(1):48

Simvastatin-oral anticoagulant interaction [letter] Grau E, et al. **Lancet** 1996 Feb 10;347(8998):405–6

ACEPHEN see **MECLOFENOXATE**

ACEPROMAZINE

A standard water provocative test for dogs anaesthetized with acepromazine-ketamine. Martin E, et al. **Zentralbl Veterinarmed A** 1995 Jun;42(4):267–73

ACETABULARIA

GROWTH & DEVELOPMENT

Coordination of cellular events that precede reproductive onset in Acetabularia acetabulum: evidence for a 'loop' in development. Runft LL, et al. **Development** 1996 Apr; 122(4):1187–94

ACETABULUM

Measurement of polyethylene wear in metal-backed acetabular cups. I. Three-dimensional technique. Devane PA, et al. **Clin Orthop** 1995 Oct;(319):303–16

Prosthetic reconstruction for periacetabular malignant tumors. Uchida A, et al. **Clin Orthop** 1996 May; (326):238–45

Unusually located osteoid osteomas. Pikoulas C, et al. **Eur J Radiol** 1995 Jul;20(2):120–5

Bilateral primary cystic arthrosis of the acetabulum. A case report. Silas SI, et al. **J Bone Joint Surg Am** 1996 May; 78(5):775–8

Wear of polyethylene cups in total hip arthroplasty. A study of specimens retrieved post mortem. Sychterz CJ, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1193–200

The histological appearance of the periprosthetic capsule in failed total hip arthroplasty differs depending on the presence of polyethylene acetabulum destruction, iliac bone damage and presence of infection. Rudzki Z, et al. **Pol J Pathol** 1996;47(1):19–25

Malignant acetabular osteolyses: percutaneous injection of acrylic bone cement. Cotten A, et al. **Radiology** 1995 Oct; 197(1):307–10

[Ceramic acetabulum cup inserts for hip endoprostheses] Willmann G, et al. **Biomed Tech (Berl)** 1996 Apr; 41(4):98–105 (Eng. Abstr.) **(Ger)**

ANATOMY & HISTOLOGY

Anatomic considerations of plate-screw fixation of the anterior column of the acetabulum. Benedetti JA, et al. **J Orthop Trauma** 1996;10(4):264–72

Spherical assessment of the hip on standard AP radiographs: a simple method for the measurement of the contact area between acetabulum and femoral head and of acetabular orientation. Hefti F. **J Pediatr Orthop** 1995 Nov-Dec; 15(6):797–805

Errors in measurement of acetabular index. Portinaro NM, et al. **J Pediatr Orthop** 1995 Nov-Dec;15(6):780–4

[Anatomy and development of the hip joint during growth. I. anatomy and development of the acetabulum] Wierusz-Kozłowska M. **Chir Narzadow Ruchu Ortop Pol** 1995;60(6):477–83 (59 ref.) (Eng. Abstr.) **(Pol)**

GROWTH & DEVELOPMENT

Comparative development of the antitrochanter in three strains of domestic fowl. Hocking PM, et al. **Res Vet Sci** 1996 Jan;60(1):37–43

[Anatomy and development of the hip joint during growth. I. anatomy and development of the acetabulum] Wierusz-Kozłowska M. **Chir Narzadow Ruchu Ortop Pol** 1995;60(6):477–83 (59 ref.) (Eng. Abstr.) **(Pol)**

INJURIES

An acetabular fracture with superior gluteal artery disruption. Patel NH, et al. **AJR Am J Roentgenol** 1996 May;166(5):1074

The management of combined skeletal and arterial injuries of the lower extremity. Gates JD. **Am J Orthop** 1995 Sep; 24(9):674–80

Two cases of acetabular fractures sustained during competitive cycling. Bass A, et al. **Br J Sports Med** 1995 Sep;29(3):205–6

Acetabular fractures before and after the introduction of seatbelt legislation [see comments] al-Qahtani S, et al. **Can J Surg** 1996 Aug;39(4):317–20. Comment in: Can J Surg 1996 Aug;39(4):266.

Acetabular fractures and seat belts [editorial; comment] Waddell JP. **Can J Surg** 1996 Aug;39(4):266. Comment on: Can J Surg 1996 Aug;39(4):317–20.

Lesions of the sciatic nerve in fractures of the acetabulum. Bungaro P, et al. **Chir Organi Mov** 1995 Oct–Dec; 80(4):391–7 **(Eng, Ita)**

Bilateral central acetabular fracture dislocations secondary to sustained myoclonus. Van Heest A, et al. **Clin Orthop** 1996 Mar;(324):210–13

Incarcerated fragment of posterior acetabular wall fracture without hip dislocation. Guiral J, et al. **Injury** 1995 Nov; 26(9):647–8

Magnetic resonance venography to evaluate the deep venous system of the pelvis in patients who have an acetabular fracture. Montgomery KD, et al. **J Bone Joint Surg Am** 1995 Nov;77(11):1639–49

Periprosthetic fracture of the acetabulum after total hip arthroplasty. Peterson CA, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1206–13

Prevention of heterotopic bone formation after acetabular fracture fixation by single-dose radiation therapy: a preliminary report. Anglen JO, et al. **J Orthop Trauma** 1996;10(4):258–63

Unrecognized foreign body in the hip joint. Nassif JM, et al. **J Orthop Trauma** 1996;10(3):216–9

Retropubic vascular hazards of the ilioinguinal exposure: a cadaveric and clinical study. Teague DC, et al. **J Orthop Trauma** 1996;10(3):156–9

Optimal technique of screw placement in the ischial tuberosity for posterior acetabular fractures. Xu R, et al. **J Orthop Trauma** 1996;10(3):160–4

Posterior fracture–dislocation of the hip in a jogger. Wolfe MW, et al. **J South Orthop Assoc** 1995 Summer;4(2):91–5

Central acetabular fracture–dislocation following electroconvulsive therapy: report of two similar cases. Sarpel Y, et al. **J Trauma** 1996 Aug;41(2):342–4

Infection following acetabular and pelvic fractures. Skie MC, et al. **Orthopedics** 1996 Jan;19(1):68–72

Acetabular labral tears: contrast-enhanced MR imaging under continuous leg traction. Nishii T, et al. **Skeletal Radiol** 1996 May;25(4):349–56

[Three-dimensional imaging of acetabular fractures using spiral CT] Smet MH, et al. **J Belge Radiol** 1995 Oct; 78(5):308–10 (Eng. Abstr.) **(Dut)**

[clinical application of multiplanar and 3D reconstruction of spiral CT in diagnosis of acetabulum fractures] Stroszczynski C, et al. **Aktuelle Radiol** 1996 Mar;6(2):91–5 (23 ref.) (Eng. Abstr.) **(Ger)**

[Primary total endoprosthetic hip joint replacement in acetabulum fractures] Volkmann R, et al. **Unfallchirurgie** 1995 Dec;21(6):292–7 (Eng. Abstr.) **(Ger)**

INNERVATION

The nerve endings of the acetabular labrum. Kim YT, et al. **Clin Orthop** 1995 Nov;(320):176–81

PATHOLOGY

Hip osteoarthritis and dysplasia in Chinese men. Lau EM, et al. **Ann Rheum Dis** 1995 Dec;54(12):965–9

Rate of degeneration of human acetabular cartilage after hemiarthroplasty [letter; comment] Blasier RB. **J Bone Joint Surg Am** 1996 Apr;78(4):635. Comment on: J Bone Joint Surg Am 1995 Jun;77(6):877–82.

Osteolysis of the acetabulum associated with a bipolar hemiarthroplasty. A late complication. Bose WJ, et al. **J Bone Joint Surg Am** 1995 Nov;77(11):1733–5

Acetabular changes in an experimental model of developmental dysplasia of the hip (DDH). Greenhill BJ, et al. **J Pediatr Orthop** 1995 Nov–Dec;15(6):789–93

Lesions of the acetabular labrum: accuracy of MR imaging and MR arthrography in detection and staging. Czerny C, et al. **Radiology** 1996 Jul;200(1):225–30

Acetabular labral tears: evaluation with MR arthrography. Petersilge CA, et al. **Radiology** 1996 Jul;200(1):231–5

[Changes in the acetabular roof produced by Chiari pelvic osteotomy] Hayashi J. **Nippon Seikeigeka Gakkai Zasshi** 1995 Nov;69(11):1126–35 (Eng. Abstr.) **(Jpn)**

RADIATION EFFECTS

Early failure of acetabular components inserted without cement after previous pelvic irradiation. Jacobs JJ, et al. **J Bone Joint Surg Am** 1995 Dec;77(12):1829–35

[3-years results of endoprosthetic management of radiation-induced hip joint necrosis] Aigner C, et al. **Wien Klin Wochenschr** 1995;107(23):726–30 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Radiographic loosening of cementless threaded acetabular cups. No additional diagnostic value of arthrography in 30 patients. Seelen JL, et al. **Acta Orthop Scand** 1995 Oct; 66(5):415–7

An acetabular fracture with superior gluteal artery disruption. Patel NH, et al. **AJR Am J Roentgenol** 1996 May;166(5):1074

Acetabular rim pathology secondary to congenital hip dysplasia in the adult. A radiographic study. Pitto RP, et al. **Chir Organi Mov** 1995 Oct–Dec;80(4):361–8 **(Eng, Ita)**

Early radiographic results comparing cemented and cementless total hip arthroplasty. Mulliken BD, et al. **J Arthroplasty** 1996 Jan;11(1):24–33

Osteolysis in cemented versus cementless acetabular components. Nayak NK, et al. **J Arthroplasty** 1996 Feb; 11(2):135–40

Idiopathic osteolysis of the acetabulum: a case report. Nemec B, et al. **J Bone Joint Surg Br** 1996 Jul;78(4):666–7 (8 ref.)

[Three-dimensional imaging of acetabular fractures using spiral CT] Smet MH, et al. **J Belge Radiol** 1995 Oct; 78(5):308–10 (Eng. Abstr.) **(Dut)**

[Improved radiological imaging of acetabular screw socket] Rössig S, et al. **Z Orthop Ihre Grenzgeb** 1996 Jan–Feb; 134(1):36–43 (Eng. Abstr.) **(Ger)**

[Radiologic analysis of osseous changes in coxarthrosis] Jovanić s, et al. **Reumatizam** 1993;40(1):5–9 (Eng. Abstr.) **(Scr)**

RADIONUCLIDE IMAGING

Grafted bone used in acetabular reconstruction: assessment by SPECT scintigraphy. Fujikawa Y, et al. **Skeletal Radiol** 1995 Aug;24(6):441–5

SURGERY

Revision arthroplasty of the hip with extensive bone loss. Preliminary study. Lakatos J, et al. **Acta Chir Hung** 1995–96;35(1–2):103–11

Early experience with eccentric acetabular components in revision total hip arthroplasty. Sutherland CJ. **Am J Orthop** 1996 Apr;25(4):284–9

Femoral head bone grafting for reconstruction of the acetabular wall in dysplastic hip replacement. Hartwig CH, et al. **Arch Orthop Trauma Surg** 1995;114(5):269–73

Changes in growth of the ilium after sopraacetabular osteotomy. Long-term evaluation. Capelli A, et al. **Chir Organi Mov** 1995 Oct–Dec;80(4):369–76 **(Eng, Ita)**

Ten years of experience with porous acetabular components for revision surgery. Dorr LD, et al. **Clin Orthop** 1995 Oct;(319):191–200

Radiographic course after acetabuloplasty and femoral osteotomy in hip dysplasia. Fritsch EW, et al. **Clin Orthop** 1996 Feb;(323):215–25 (52 ref.)

Classification and reconstruction in revision acetabular arthroplasty with bone stock deficiency. Garbuz D, et al. **Clin Orthop** 1996 Mar;(324):98–107

Morselized allograft in acetabular reconstruction. A postmortem retrieval analysis. Heekin RD, et al. **Clin Orthop** 1995 Oct;(319):184–90

Acetabular reconstruction in total hip revision using a bone graft substitute. Early clinical and radiographic results. Levai JP, et al. **Clin Orthop** 1996 Sep;(330):108–14

Dega acetabuloplasty combined with intertrochanteric osteotomies. Reichel H, et al. **Clin Orthop** 1996 Feb; (323):234–42

Revision total hip arthroplasty using a cementless acetabular component. Technique and results. Silverton CD, et al. **Clin Orthop** 1995 Oct;(319):201–8

Acetabular allografts for restoration of bone stock in revision arthroplasty of the hip. Gross AE, et al. **Instr Course Lect** 1996;45:135–42 (41 ref.)

Acetabular reconstruction with massive acetabular allografts. Paprosky WG, et al. **Instr Course Lect** 1996;45:149–59

Metal ring supports for deficient acetabular bone in total hip replacement. Possai KW, et al. **Instr Course Lect** 1996; 45:161–9

Early failure of Hylamer acetabular inserts due to eccentric wear. Chmell MJ, et al. **J Arthroplasty** 1996 Apr; 11(3):351–3

Fixation of the acetabular component: the case for cementless bone ingrowth modular sockets. Dorr LD. **J Arthroplasty** 1996 Jan;11(1):3–5; discussion 5–6

Cementless hemispheric acetabular components. A 4- to 8-year follow-up report. Incavo SJ, et al. **J Arthroplasty** 1996 Apr;11(3):298–303

Total hip arthroplasty with shelf grafts using uncemented cups. A long-term follow-up study. Morsi E, et al. **J Arthroplasty** 1996 Jan;11(1):81–5

Revision total hip arthroplasty with shelf bulk allografts. A long-term follow-up study. Morsi E, et al. **J Arthroplasty** 1996 Jan;11(1):86–90

Removal and reinsertion of cemented femoral components during acetabular revision. Nabors ED, et al. **J Arthroplasty** 1996 Feb;11(2):146–52

Managing acetabular defects [letter] Sutherland CJ. **J Arthroplasty** 1996 Apr;11(3):357–8

Treatment of type III acetabular deficiencies in revision total hip arthroplasty without structural bone-graft. Sutherland CJ. **J Arthroplasty** 1996 Jan;11(1):91–8

Revision of the acetabular component of a total hip arthroplasty with a massive structural allograft. Study with a minimum five-year follow-up. Garbuz D, et al. **J Bone Joint Surg Am** 1996 May;78(5):693–7

Congenital hip disease in adults. Classification of acetabular deficiencies and operative treatment with acetabuloplasty combined with total hip arthroplasty. Hartofilakidis G, et al. **J Bone Joint Surg Am** 1996 May;78(5):683–92

Revision of the acetabular component without cement after total hip arthroplasty. A follow-up note regarding results at seven to eleven years. Silverton CD, et al. **J Bone Joint Surg Am** 1996 Sep;78(9):1366–70

Structural bulk allografts in acetabular reconstruction. Analysis of two grafts retrieved at post-mortem. Hooten JP Jr, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):270–5

Hydroxyapatite coating of an acetabular prosthesis. Effect on stability. Moilanen T, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):200–5

Adolescent and young adult hip dysplasia. The role of Bernese periacetabular osteotomy. McClellan JW 3rd, et al. **Nebr Med J** 1995 Aug;80(8):271–5; discussion 275–6

Structural grafting of the acetabulum. Chandler HP. **Orthopedics** 1995 Sep;18(9):863–4

Cementless acetabular components: optimums and outcomes. Engh CA Sr, et al. **Orthopedics** 1995 Sep;18(9):813–5

The lessons of acetabular component fixation. Harris WH. **Orthopedics** 1995 Sep;18(9):811–2

Management of acetabular deficiency. Morscher EW. **Orthopedics** 1995 Sep;18(9):859–62

Grafted bone used in acetabular reconstruction: assessment by SPECT scintigraphy. Fujikawa Y, et al. **Skeletal Radiol** 1995 Aug;24(6):441–5

[Reconstruction of the acetabulum after iterative surgery of the hip (report of 38 cases)] Poitout DG, et al. **Bull Acad Natl Med** 1996 Mar;180(3):515–28; discussion 528–31 (Eng. Abstr.) **(Fre)**

[Percutaneous cementoplasty for malignant osteolysis of the acetabulum] Cotten A, et al. **Presse Med** 1995 Sep 30; 24(28):1308–10 (Eng. Abstr.) **(Fre)**

[Acetabular implant in Charnley's total arthroplasty. Review of 309 cases with a minimum of 15 years follow-up] Avedikian J, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):116–24 (40 ref.) (Eng. Abstr.) **(Fre)**

[Allograft transplantation in pelvic instability following prosthesis exchange] Bettin D, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):380–6 (Eng. Abstr.) **(Ger)**

[Results of cementless acetabular revision surgery] Krüger-Franke M, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):374–9 (Eng. Abstr.) **(Ger)**

[Long-term outcome of Dega acetabulum-plasty] Reichel H, et al. **Z Orthop Ihre Grenzgeb** 1996 Mar–Apr; 134(2):131–6 (Eng. Abstr.) **(Ger)**

[Improved radiological imaging of acetabular screw socket] Rössig S, et al. **Z Orthop Ihre Grenzgeb** 1996 Jan–Feb; 134(1):36–43 (Eng. Abstr.) **(Ger)**

[Cementless cup anchorage in hip endoprostheses. Comparative study of 3 cup systems with titanium surface] Thomsen M, et al. **Z Orthop Ihre Grenzgeb** 1995 Nov–Dec; 133(6):551–7 (Eng. Abstr.) **(Ger)**

[Stabilization of the proximal femur in hip joint replacement using M.E. Müller's acetabular roof socket] Wessinghage D, et al. **Z Orthop Ihre Grenzgeb** 1996 Jan–Feb; 134(1):29–35 (Eng. Abstr.) **(Ger)**

ACETALDEHYDE

Ethanol-dependent oxygen consumption and acetaldehyde formation during vanadyl oxidation by H2O2. Ravishankar HN, et al. **Mol Cell Biochem** 1996 Jan 26;154(2):101–6

ANALOGS & DERIVATIVES

3,4,5-Trimethoxyphenylacetaldehyde, an intermediate metabolite of mescaline, is a substrate for microsomal aldehyde oxygenase in the mouse liver. Watanabe K, et al. **Biol Pharm Bull** 1995 May;18(5):696–9

Environmental impact of two molluscicides: niclosamide and metaldehyde in a rice paddy ecosystem. Calumpang SM, et al. **Bull Environ Contam Toxicol** 1995 Oct;55(4):494–501

Molecular analysis of mutations induced by 2-chloroacetaldehyde, the ultimate carcinogenic form of vinyl chloride, in human cells using shuttle vectors. Matsuda T, et al. **Carcinogenesis** 1995 Oct;16(10):2389–94

Cytochrome P450 catalyzed metabolism of 1,2-dibromoethane in liver microsomes of differentially induced rats. Wormhoudt LW, et al. **Chem Biol Interact** 1996 Jan 5;99(1–3):41–53

p-Hydroxyphenylacetaldehyde is the major product of L-tyrosine oxidation by activated human phagocytes. A chloride-dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase. Hazen SL, et al. **J Biol Chem** 1996 Jan 26;271(4):1861–7

Induction of deletion mutations by methoxyacetaldehyde in Chinese hamster ovary (CHO)-AS52 cells. Chiewchanwit T, et al. **Mutat Res** 1995 Oct;335(2):121–8

ANALYSIS

Static headspace gas chromatography of acetaldehyde in aqueous foods and polythene terephthalate. Linssen J, et al. **Z Lebensm Unters Forsch** 1995 Sep;201(3):253–5

ACETALDEHYDE

ANTAGONISTS & INHIBITORS

[The action of medichronal (glucose–glycine–formate) on the serotonin blood level in alcoholism patients] Bozhko GKh, et al. **Lik Sprava** 1995 May–Jun;(5–6):130–2 (Eng. Abstr.) **(Rus)**

BLOOD

Additional proof of reduction of ethanol absorption from rat intestine in vivo by high acetaldehyde concentrations. Kinoshita H, et al. **Alcohol Alcohol** 1995 Jul;30(4):419–21

Validated fluorimetric HPLC analysis of acetaldehyde in hemoglobin fractions separated by cation exchange chromatography: three new peaks associated with acetaldehyde. Chen HM, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):939–44

Investigation of the mechanism of alcohol–induced bronchial asthma. Shimoda T, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):74–84

Ethanol and acetaldehyde metabolism in chinese with different aldehyde dehydrogenase–2 genotypes. Luu SU, et al. **Proc Natl Sci Counc Repub China B** 1995 Jul; 19(3):129–36

[Biochemical characteristics of various adaptation mechanisms in acute alcoholic intoxication] Sinitskiĭ VN, et al. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):90–5 (Eng. Abstr.) **(Rus)**

[Medichronal lowers blood ethanol and acetaldehyde and restores the concentration of catecholamines in rat tissues] Bozhko HKZh, et al. **Ukr Biokhim Zh** 1995 Mar–Apr; 67(2):108–12 (Eng. Abstr.) **(Ukr)**

CHEMISTRY

The formation and stability of imidazolidinone adducts from acetaldehyde and model peptides. A kinetic study with implications for protein modification in alcohol abuse. Fowles LF, et al. **Biochem Pharmacol** 1996 May 17; 51(10):1259–67

Studies of the reaction of acetaldehyde with deoxynucleosides. Vaca CE, et al. **Chem Biol Interact** 1995 Oct 20;98(1):51–67

IMMUNOLOGY

Antibodies made against a formaldehyde–protein adduct cross react with an acetaldehyde–protein adduct. Implications for the origin of antibodies in human serum which recognize acetaldehyde–protein adducts. Pietrzak ER, et al. **Alcohol Alcohol** 1995 May;30(3):373–8

METABOLISM

Could bacterial acetaldehyde production explain the deleterious effect of alcohol on skin diseases? [letter] Höök–Nikanne J, et al. **Acta Derm Venereol** 1995 Jul; 75(4):330

Acetaldehyde metabolism by brain mitochondria from UChA and UChB rats. Quintanilla ME, et al. **Alcohol** 1995 Nov–Dec;12(6):519–24

Distribution of the thiamin diphosphate C(2)–proton during catalysis of acetaldehyde formation by brewers' yeast pyruvate decarboxylase. Harris TK, et al. **Biochemistry** 1995 Oct 31;34(43):13994–4000

Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism. Klyosov AA, et al. **Biochemistry** 1996 Apr 9;35(14):4445–56

Enzymes from Pseudomonas sp. strain NCIB 11097 participating in biotransformation of acetaldehyde and glycine to threonine isomers. Diaz–Diaz M, et al. **Can J Microbiol** 1995 Apr–May;41(4–5):438–43

Development of a 32P–postlabelling method for the analysis of adducts arising through the reaction of acetaldehyde with 2'–deoxyguanosine–3'–monophosphate and DNA. Fang JL, et al. **Carcinogenesis** 1995 Sep;16(9):2177–85

Sequential acetaldehyde production, lipid peroxidation, and fibrogenesis in micropig model of alcohol–induced liver disease. Niemelä O, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1208–14

Acetaldehyde and malondialdehyde react together to generate distinct protein adducts in the liver during long–term ethanol administration. Tuma DJ, et al. **Hepatology** 1996 Apr;23(4):872–80

Identification of the 37–kd rat liver protein that forms an acetaldehyde adduct in vivo as delta 4–3–ketosteroid 5 beta–reductase. Zhu Y, et al. **Hepatology** 1996 Jan; 23(1):115–22

p–Hydroxyphenylacetaldehyde is the major product of L–tyrosine oxidation by activated human phagocytes. A chloride–dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase. Hazen SL, et al. **J Biol Chem** 1996 Jan 26;271(4):1861–7

PHARMACOKINETICS

Measuring and reporting the concentration of acetaldehyde in human breath. Jones AW. **Alcohol Alcohol** 1995 May; 30(3):271–85 (45 ref.)

Analysis of ethanol and acetaldehyde recovery from perchloric acid–treated blood. Whitmire D, et al. **Alcohol Alcohol** 1995 Sep;30(5):623–8

Metabolism of acetaldehyde to acetate by rat hepatic P–450s: presence of different metabolic pathway from acetaldehyde dehydrogenase system. Kunitoh S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):22A–24A

Daidzin suppresses ethanol consumption by Syrian golden hamsters without blocking acetaldehyde metabolism. Keung WM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8990–3

PHARMACOLOGY

Inhibitory action of in vitro ethanol and acetaldehyde exposure on LHRH–and phorbol ester–stimulated testosterone secretion by rat testicular interstitial cells. Wanderley MI, et al. **Acta Physiol Pharmacol Ther Latinoam** 1994;44(4):135–41

Acetaldehyde inhibits serum aminopeptidases. Brecher AS, et al. **Alcohol** 1996 Mar–Apr;13(2):125–31

Role of acetaldehyde in the actions of ethanol on the brain––a review. Hunt WA. **Alcohol** 1996 Mar–Apr;13(2):147–51 (66 ref.)

Activation by acetaldehyde of the promoter of the mouse alpha2(I) collagen gene when transfected into rat activated stellate cells. Anania FA, et al. **Arch Biochem Biophys** 1996 Jul 15;331(2):187–93

Influence of acetaldehyde and ethanol on rat hepatic lipocyte characteristics in primary culture. Sato T, et al. **Cell Biol Int** 1995 Oct;19(10):879–81

Acetaldehyde mediates the synchronization of sustained glycolytic oscillations in populations of yeast cells. Richard P, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):238–41

Binding of apolipoprotein A–I and acetaldehyde–modified apolipoprotein A–I to liver extracellular matrix. Paradis V, et al. **Hepatology** 1996 May;23(5):1232–8

Effects of acetaldehyde on the isolated papillary muscle of diabetic rats. Savage AO, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):251–8

Inhibition of gastric cell proliferation by acetaldehyde. Matysiak–Budnik T, et al. **J Pathol** 1995 Nov;177(3):317–22

Intravenous injection of acetaldehyde but not ethanol induces histamine–mediated bronchoconstriction in guinea pigs. Myou S, et al. **Respiration** 1995;62(3):143–7

TOXICITY

Acetaldehyde involvement in ethanol–induced potentiation of rat hepatocyte damage due to the carcinogen 1,2–dibromoethane. Chiarpotto E, et al. **Alcohol Alcohol** 1995 Nov;30(6):721–8

In vitro comparison of the effects of ethanol and acetaldehyde on dorsal root ganglion neurons. Bradley DM, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1345–50

Changes in the nasal epithelium of rats exposed by inhalation to mixtures of formaldehyde, acetaldehyde, and acrolein. Cassee FR, et al. **Fundam Appl Toxicol** 1996 Feb; 29(2):208–18

Hepatotoxicity and absorption of extrahepatic acetaldehyde in rats. Matysiak–Budnik T, et al. **J Pathol** 1996 Apr; 178(4):469–74

Effects of acute acetaldehyde, chronic ethanol, and pargyline treatment on agonist responses of the rat aorta. Brown RA, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):170–8

The effects of some redox–active metals and reactive aldehydes on DNA–protein cross–links in vitro. Olin KL, et al. **Toxicology** 1996 Jun 17;110(1–3):1–8

ACETALS

CHEMICAL SYNTHESIS

Chemical synthesis of allysine ethylene acetal and conversion in situ into 1–piperideine–6–carboxylic acid: key intermediate of the alpha–aminoadipic acid for beta–lactam antibiotics biosynthesis. Rumbero A, et al. **Bioorg Med Chem** 1995 Sep;3(9):1237–40

CHEMISTRY

A mild and efficient procedure to remove acetal and dithioacetal protecting groups in carbohydrate derivatives using 2,3–dichloro–5,6–dicyano–1,4–benzoquinone. García Fernández JM, et al. **Carbohydr Res** 1995 Sep 8;274:263–8

Di–D–fructose dianhydrides and related oligomers from thermal treatments of inulin and sucrose. Manley–Harris M, et al. **Carbohydr Res** 1996 Jun 21;287(2):183–202

ACETAMIDES

ADVERSE EFFECTS

Remacemide hydrochloride and ARL 15896AR lack abuse potential: additional differences from other uncompetitive NMDA antagonists. Hudzik TJ, et al. **Epilepsia** 1996 Jun; 37(6):544–50

A new mask filter cartridge used to determine applicator inhalation exposure to an alachlor herbicide (Lasso) during normal spraying operations. Flaherty DK, et al. **J Occup Environ Med** 1995 Sep;37(9):1116–21

Monitoring acrylic fiber workers for liver toxicity and exposure to dimethylacetamide. 1. Assessing exposure to dimethylacetamide by air and biological monitoring. Spies GJ, et al. **J Occup Environ Med** 1995 Sep;37(9):1093–101

ANTAGONISTS & INHIBITORS

Activin A inhibits growth and hexamethylene bisacetamide–induced differentiation in human retinoblastoma Y–79 cells. Zhang Z, et al. **Anticancer Res** 1996 Jan–Feb;16(1):269–72

CHEMICAL SYNTHESIS

New 5–HT3 (serotonin–3) receptor antagonists. IV. Synthesis and structure–activity relationships of azabicycloalkaneacetamide derivatives. Kato M, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug;43(8):1351–7

(E)–(arylmethyleneaminoxy)acetamides as analogues of neuroleptic benzamides: synthesis and D2–dopaminergic binding affinity. Macchia M, et al. **Farmaco** 1995 Oct; 50(10):719–24

Identification of a novel oxazolidinone (U–100480) with potent antimycobacterial activity. Barbachyn MR, et al. **J Med Chem** 1996 Feb 2;39(3):680–5

Synthesis and antibacterial activity of U–100592 and U–100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug–resistant gram–positive bacterial infections. Brickner SJ, et al. **J Med Chem** 1996 Feb 2;39(3):673–9

Arylacetamide–derived fluorescent probes: synthesis, biological evaluation, and direct fluorescent labeling of kappa opioid receptors in mouse microglial cells. Chang AC, et al. **J Med Chem** 1996 Apr 12;39(8):1729–35

Synthesis and anticonvulsant activities of N–Benzyl–2–acetamidopropionamide derivatives. Choi D, et al. **J Med Chem** 1996 Apr 26;39(9):1907–16

A structure–activity relationship study of novel phenylacetamides which are sodium channel blockers. Roufos I, et al. **J Med Chem** 1996 Mar 29;39(7):1514–20

Synthesis and evaluation of aryl–substituted N–(arylethyl)–N–methyl–2–(1–pyrrolidinyl)ethylamines and corresponding arylacetamides for sigma receptor affinity. Zhang Y, et al. **J Med Chem** 1996 Aug 30; 39(18):3564–8

CHEMISTRY

Structure–based design of a potent transition state analogue for TEM–1 beta–lactamase. Strynadka NC, et al. **Nat Struct Biol** 1996 Aug;3(8):688–95

ISOLATION & PURIFICATION

Cytotoxicity and mode of action of aeroplysinin–1 and a related dienonefrom the sponge Aplysina aerophoba. Koulman A, et al. **J Nat Prod** 1996 Jun;59(6):591–4

METABOLISM

Determination and properties of acetyl conjugate of N–desisopropylpropranolol, AcNDP. Noda A, et al. **Biol Pharm Bull** 1995 Oct;18(10):1454–5

Effect of abrasion on protective properties of polyester and cotton/polyester blend fabrics. Shaw A, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):935–41

PHARMACOKINETICS

Disposition and pharmacokinetics of remacemide hydrochloride in male Sprague–Dawley rats. Curry S, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:330–1

13C–methacetin breath test parameter S for liver diseases diagnosis. Zeng W, et al. **Sci China C Life Sci** 1996 Feb; 39(1):87–98

PHARMACOLOGY

Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Palmer GC, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:236–47; discussion 248 (38 ref.)

Activin A inhibits growth and hexamethylene bisacetamide–induced differentiation in human retinoblastoma Y–79 cells. Zhang Z, et al. **Anticancer Res** 1996 Jan–Feb;16(1):269–72

In vitro activities of oxazolidinones U–100592 and U–100766 against penicillin–resistant and cephalosporin–resistant strains of Streptococcus pneumoniae. Mason EO Jr, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1039–40

In vitro activities of U–100592 and U–100766, novel oxazolidinone antibacterial agents. Zurenko GE, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):839–45

Hepatoprotective effect of SY–640, a novel acetamide derivative, on Propionibacterium acnes and lipopolysaccharide–induced liver injury in mice. Tanaka Y, et al. **Arch Int Pharmacodyn Ther** 1995 Mar–Apr; 329(2):319–30

Distinct temporal patterns of defensin mRNA regulation during drug–induced differentiation of human myeloid leukemia cells. Herwig S, et al. **Blood** 1996 Jan 1; 87(1):350–64

The in vivo melanocytotoxicity and depigmenting potency of N–2,4–acetoxyphenyl thioethyl acetamide in the skin and hair. Jimbow M, et al. **Br J Dermatol** 1995 Oct; 133(4):526–36

The effect of the desglycinyl metabolite of remacemide hydrochloride (FPL 12495AA) and dizocilpine (MK–801) on endogenous amino acid release from mouse cortex. Srinivasan J, et al. **Br J Pharmacol** 1995 Dec;116(8):3087–92

Melatonin and its new agonist S–20098 restore synchronized sleep fragmented by experimental trypanosome infection in the rat. Grassi–Zucconi G, et al. **Brain Res Bull** 1996; 39(2):63–8

Inhibitors of ADP–ribosylation suppress phenotypic

modulation and proliferation of smooth muscle cells cultured from rat aorta. Thyberg J, et al. **Differentiation** 1995 Nov;59(4):243–52

Induction of rodent hepatic drug–metabolizing enzyme activities by the novel anticonvulsant remacemide hydrochloride. Riley RJ, et al. **Drug Metab Dispos** 1995 Sep;23(9):922–8

The peripherally acting kappa–opiate agonist EMD 61753 and analogues: opioid activity versus peripheral selectivity. Gottschlich R, et al. **Drugs Exp Clin Res** 1995;21(5):171–4

Effects of anticonvulsants in a novel operant learning paradigm in rats: comparison of remacemide hydrochloride and FPL 15896AR to other anticonvulsant agents. Hudzik TJ, et al. **Epilepsy Res** 1995 Jul;21(3):183–93

Hexamethylene bisacetamide–induced differentiation of Friend virus–transformed murine erythroleukemia cells is associated with parallel changes in casein kinase II and guanine nucleotide exchange factor activities. Aroor AR, et al. **Exp Hematol** 1995 Oct;23(11):1204–11

Pulmonary pharmacology of WAY–126299A: a dual–acting 5–lipoxygenase inhibitor and leukotriene D4 antagonist. Howell RE, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S170–1

Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds. Marks PA, et al. **Int J Hematol** 1996 Jan;63(1):1–17 (152 ref.)

Identification of a novel oxazolidinone (U–100480) with potent antimycobacterial activity. Barbachyn MR, et al. **J Med Chem** 1996 Feb 2;39(3):680–5

Synthesis and antibacterial activity of U–100592 and U–100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug–resistant gram–positive bacterial infections. Brickner SJ, et al. **J Med Chem** 1996 Feb 2;39(3):673–9

Synthesis and anticonvulsant activities of N–Benzyl–2–acetamidopropionamide derivatives. Choi D, et al. **J Med Chem** 1996 Apr 26;39(9):1907–16

A structure–activity relationship study of novel phenylacetamides which are sodium channel blockers. Roufos I, et al. **J Med Chem** 1996 Mar 29;39(7):1514–20

Block of the N–methyl–D–aspartate receptor by remacemide and its des–glycine metabolite. Subramaniam S, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):161–8

Pharmacology of L–754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist. Williams DL Jr, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1518–26

Gastroprotective activity of FRG–8813, a novel histamine H2–receptor antagonist, in rats. Onodera S, et al. **Jpn J Pharmacol** 1995 Jun;68(2):161–73

Hexamethylenebisacetamide (HMBA) is a growth factor for human, ovine and porcine thyroid cells. Fayet G, et al. **Mol Cell Endocrinol** 1996 Mar 1;117(1):111–6

Identification of genetic factors for Alachlor tolerance in maize by molecular markers analysis. Sari–Gorla M, et al. **Mol Gen Genet** 1996 Jul 19;251(5):551–5

Novel pharmacological properties of transient potassium currents in central neurons revealed by N–bromoacetamide and other chemical modifiers. Huang RC. **Mol Pharmacol** 1995 Sep;48(3):451–8

Micronuclei induced by alachlor, mitomycin–C and vinblastine in human lymphocytes: presence of centromeres and kinetochores and influence of staining technique. Surrallés J, et al. **Mutagenesis** 1995 Sep;10(5):417–23

Effects of remacemide and its metabolite FPL 12495 on spike–wave discharges, electroencephalogram and behaviour in rats with absence epilepsy. van Luijtelaar EL, et al. **Neuropharmacology** 1995 Apr;34(4):419–25

Differentiation of murine embryonal carcinoma in vitro and in vivo with N,N–dimethyl acetamide. Meng X, et al. **Pathology** 1995 Oct;27(4):339–43

Pharmacokinetics and anticonvulsant effect of a new hypnotic, CL 284,846, in rats. Gaudreault J, et al. **Pharm Res** 1995 Nov;12(11):1592–7

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Richon VM, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5705–8

Dose dependent effects of S–20098, a melatonin agonist, on direction of re–entrainment of rat circadian activity rhythms. Redman JR, et al. **Psychopharmacology (Berl)** 1995 Apr;118(4):385–90

[Effect of FRG–8813, a new histamine H2–receptor antagonist, on gastric mucus production in rats] Kagoshima M, et al. **Nippon Yakurigaku Zasshi** 1995 Dec;106(6):385–92 (Eng. Abstr.) **(Jpn)**

POISONING

Metobromuron/metolachlor ingestion with late onset methemoglobinemia in a pregnant woman successfully treated with methylene blue. Yang CC, et al. **J Toxicol Clin Toxicol** 1995;33(6):713–6

THERAPEUTIC USE

Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV–1–infected patients. Staszewski S, et al. **AIDS** 1996 May;10(5):F1–7

Initial experience with remacemide hydrochloride in patients with acute ischemic stroke. Muir KW, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:322–3

Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. Li XN, et al. **J Neurosurg** 1996 May;84(5):831–8

TOXICITY

Initial experience with remacemide hydrochloride in patients with acute ischemic stroke. Muir KW, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:322–3

Evidence of chemical stimulation of hepatic metabolism by an experimental acetanilide (FOE 5043) indirectly mediating reductions in circulating thyroid hormone levels in the male rat. Christenson WR, et al. **Fundam Appl Toxicol** 1996 Feb;29(2):251–9

Chronic toxicity/oncogenicity of dimethylacetamide in rats and mice following inhalation exposure. Malley LA, et al. **Fundam Appl Toxicol** 1995 Nov;28(1):80–93

Activities of the rodent carcinogens thioacetamide and acetamide in the mouse bone marrow micronucleus assay. Mirkova ET. **Mutat Res** 1996 Jun 10;352(1–2):23–30

URINE

Identification of a major human urinary metabolite of alachlor by LC–MS/MS. Driskell WJ, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):853–9

2–ACETAMIDOFLUORENE see **2–ACETYLAMINOFLUORENE**

4–ACETAMIDO–4'–ISOTHIOCYANATOSTILBENE–2,2'–DISULFONIC ACID see **SITS**

ACETAMIDOPHENOL see **ACETAMINOPHEN**

ACETAMINOPHEN

Naming of drugs. BMJ should use "paracetamol" instead of "acetaminophen" in its index [letter] Bradley N. **BMJ** 1996 Sep 14;313(7058):689

Fatalities associated with ingestion of diethylene glycol–contaminated glycerin used to manufacture acetaminophen syrup—Haiti, November 1995–June 1996. **MMWR Morb Mortal Wkly Rep** 1996 Aug 2;45(30):649–50

ADMINISTRATION & DOSAGE

Additive analgesic effect of codeine and paracetamol can be detected in strong, but not moderate, pain after Caesarean section. Baseline pain–intensity is a determinant of assay–sensitivity in a postoperative analgesic trial [see comments] Bjune K, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):399–407. Comment in: Acta Anaesthesiol Scand 1996 Apr;40(4):397–8.

Plasma concentrations after high–dose (45 mg.kg–1) rectal acetaminophen in children. Montgomery CJ, et al. **Can J Anaesth** 1995 Nov;42(11):982–6

Treatment of advanced malignancies with high–dose acetaminophen and N–acetylcysteine rescue. Kobrinsky NL, et al. **Cancer Invest** 1996;14(3):202–10

Endoscopic assessment of the effects of dipyrone (metamizol) in comparison to paracetamol and placebo on the gastric and duodenal mucosa of healthy adult volunteers. Bianchi Porro G, et al. **Digestion** 1996;57(3):186–90

Pharmacokinetics of rectal paracetamol after major surgery in children. Anderson BJ, et al. **Paediatr Anaesth** 1995; 5(4):237–42

[Paracetamol and metoclopramide in fixed combination?] Chrubasik S, et al. **Med Monatsschr Pharm** 1996 Apr; 19(4):110 **(Ger)**

ADVERSE EFFECTS

Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population–based case–control study. Steineck G, et al. **Acta Oncol** 1995; 34(6):741–8

Delayed hypersensitivity reaction to paracetamol (acetaminophen). Ibáñez MD, et al. **Allergy** 1996 Feb; 51(2):121–3

The relationship between the content of aggressive and protective components in gastric juice and endoscopic findings after naproxen sodium and acetaminophen administration. Marcinkiewicz M, et al. **Am J Gastroenterol** 1996 Feb;91(2):360–5

Analgesic nephropathy. Proceedings of a symposium. June 1995. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S1–70

Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Barrett BJ. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S14–9 (15 ref.)

Acetaminophen: acute and chronic effects on renal function. Blantz RC. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S3–6 (23 ref.)

Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin. Buckalew VM Jr. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S7–13 (31 ref.)

Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti–inflammatory agents. Matzke GR. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S63–70 (38 ref.)

Other factors may have contributed to epidemic of renal failure [letter; comment] Hossain M. **BMJ** 1995 Oct 7; 311(7010):950–1. Comment on: BMJ 1995 Jul 8;311(6997):88–91.

Vasculitis in a fixed drug eruption due to paracetamol. Harris A, et al. **Br J Dermatol** 1995 Nov;133(5):790–1

In vivo murine studies on the biochemical mechanism of acetaminophen cataractogenicity. Wells PG, et al. **Can J Physiol Pharmacol** 1995 Aug;73(8):1123–9

Methemoglobinemia and anemia in a dog with acetaminophen toxicity. Schlesinger DP. **Can Vet J** 1995 Aug;36(8):515–7

Vaccine immune response and side effects with the use of acetaminophen with influenza vaccine. Gross PA, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):134–8

Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors. Kwan D, et al. **Dig Dis Sci** 1995 Sep;40(9):1951–5

Acetaminophen–induced hepatotoxicity: protection by enzyme inhibition [comment] Park BK. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):747–8. Comment on: Eur J Gastroenterol Hepatol 1995 Aug;7(8):757–62.

The selling of acetaminophen. Lee WM. **Gastroenterology** 1995 Dec;109(6):2043–5

Exacerbation of acetaminophen hepatotoxicity by thalidomide and protection by nicotinic acid amide. Kröger H, et al. **Gen Pharmacol** 1995 Oct;26(6):1243–7

Acetaminophen–induced hypotension. Brown G. **Heart Lung** 1996 Mar–Apr;25(2):137–40

Aspirin or acetaminophen? A comparison from data collected by the Spanish Drug Monitoring System. Carvajal A, et al. **J Clin Epidemiol** 1996 Feb;49(2):255–61

New ways of looking at an old molecule [editorial; comment] Brent J. **J Toxicol Clin Toxicol** 1996;34(2):149–53. Comment on: J Toxicol Clin Toxicol 1996;34(2):145–7.

Does acetaminophen damage the heart? [see comments] Lip GY, et al. **J Toxicol Clin Toxicol** 1996;34(2):145–7 (23 ref.) . Comment in: J Toxicol Clin Toxicol 1996;34(2):149–53. Comment in: J Toxicol Clin Toxicol 1996;34(2):155–6.

APAP–induced heart injury? Maybe yes, maybe no. Next question? [editorial; comment] Smilkstein MJ. **J Toxicol Clin Toxicol** 1996;34(2):155–6. Comment on: J Toxicol Clin Toxicol 1996;34(2):145–7.

Acetaminophen, NSAIDs and alcohol. **Med Lett Drugs Ther** 1996 Jun 21;38(977):55–6

Acetaminophen–induced toxicity to human epidermoid cell line A431 and hepatoblastoma cell line Hep G2, in vitro, is diminished by silymarin. Shear NH, et al. **Skin Pharmacol** 1995;8(6):279–91

[Rectal stenosis following prolonged use of suppositories of acetylsalicylic acid and paracetamol. Correction by perineal approach (letter)] Catheline JM, et al. **Ann Chir** 1995;49(6):551 **(Fre)**

[Paracetamol and leukocytoclastic vasculitis: apropos of a case (letter)] Bouhanick B, et al. **Therapie** 1995 Sep–Oct; 50(5):489–91 **(Fre)**

[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121–4 (50 ref.) (Eng. Abstr.) **(Hun)**

ANALOGS & DERIVATIVES

Hepatic glycogen accurately reflected by acetaminophen glucuronide in dogs refed after fasting. Rother KI, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):E766–73

3,5–Disubstituted analogues of paracetamol. Synthesis, analgesic activity and cytotoxicity. Bessems JG, et al. **Chem Biol Interact** 1995 Dec 22;98(3):237–50

Peroxidase–catalyzed oxidation of 3,5–dimethyl acetaminophen causes cell death by selective protein thiol modification in isolated rat hepatocytes. Weis M, et al. **Chem Biol Interact** 1996 May 6;100(3):255–65

Hemocompatible properties of polymeric derivative of paracetamol. De Queiroz AA, et al. **J Biomater Sci Polym Ed** 1995;7(6):523–30

Occupational allergy to propacetamol [letter] Barbaud A, et al. **Lancet** 1995 Sep 30;346(8979):902

[Comparative study of buprenorphine and its combination to ketoprofen or propacetamol for postoperative analgesia in urologic surgery] Tauzin–Fin P, et al. **Ann Fr Anesth Reanim** 1996;15(1):41–6 (Eng. Abstr.) **(Fre)**

[Efficacy of propacetamol in postoperative pain based on two modes of intravenous administration] Farhat F, et al. **Can Anesthesiol** 1995;43(4):351–6 (Eng. Abstr.) **(Fre)**

ANALYSIS

Assay of paracetamol and its metabolites in urine, plasma and saliva of children with chronic liver disease. al–Obaidy SS, et al. **J Pharm Biomed Anal** 1995 Jul;13(8):1033–9

Spectrofluorimetric determination of paracetamol in pharmaceuticals and biological fluids. Vilchez JL, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1119–25

[Determination of paracetmol caffeine and ephedrine hydrochloride in likeshu capsules] Wu C, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):443–6 (Eng. Abstr.) **(Chi)**

ANTAGONISTS & INHIBITORS

Protective effect of nifedipine against cytotoxicity and intracellular calcium alterations induced by acetaminophen in rat hepatocyte cultures. Ellouk–Achard S, et al. **Drug Chem Toxicol** 1995 May–Aug;18(2–3):105–17

Mechanism of protection of lobenzarit against paracetamol–induced toxicity in rat hepatocytes. Remirez D, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):301–8

Cytochrome P4502E1 inhibition by propylene glycol prevents acetaminophen (paracetamol) hepatotoxicity in mice without cytochrome P4501A2 inhibition. Thomsen

MS, et al. **Pharmacol Toxicol** 1995 Jun;76(6):395–9

BLOOD

Plasma concentrations after high-dose (45 mg.kg-1) rectal acetaminophen in children. Montgomery CJ, et al. **Can J Anaesth** 1995 Nov;42(11):982–6

Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. Gomez HF, et al. **J Forensic Sci** 1995 Nov;40(6):980–2

Unrestricted availability of a plasma paracetamol assay service resulting in an increased number of inappropriate requests. Chan TY, et al. **Postgrad Med J** 1995 Nov; 71(841):678–80

[Gastric emptying of semi-solid meal in normal man with special reference to relationship between plasma acetoaminophen concentrations and gastric emptying time] Koyama K, et al. **J Smooth Muscle Res** 1995 Apr;31(2):61–5 (Eng. Abstr.) **(Jpn)**

DIAGNOSTIC USE

Acetaminophen absorption test as a useful indicator of small intestinal rejection in rats. Ishikawa M, et al. **Transplant Proc** 1996 Jun;28(3):1845–6

[Gastric emptying of semi-solid meal in normal man with special reference to relationship between plasma acetoaminophen concentrations and gastric emptying time] Koyama K, et al. **J Smooth Muscle Res** 1995 Apr;31(2):61–5 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. Settipane RA, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):480–5

METABOLISM

Glutathione depletion kinetics with acetaminophen. A simulation study. Chiba M, et al. **Drug Metab Dispos** 1995 Jun;23(6):622–30

The price of silence. Park BK. **Hum Exp Toxicol** 1996 Apr; 15(4):362–3

Evidence for common binding of acetaminophen and bromobenzene to the 58-kDa acetaminophen-binding protein. Manautou JE, et al. **J Toxicol Environ Health** 1995 Nov;46(3):263–9

Identification of the mouse liver 44-kDa acetaminophen-binding protein as a subunit of glutamine synthetase. Bulera SJ, et al. **Toxicol Appl Pharmacol** 1995 Oct;134(2):313–20

Acetaminophen-arylated proteins are detected in hepatic subcellular fractions and numerous extra-hepatic tissues in CD-1 and C57B1/6J mice. Bulera SJ, et al. **Toxicology** 1996 May 17;109(2-3):85–99

PHARMACOKINETICS

Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Ueshima Y, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):25A–28A

The effect of caffeine on the pharmacokinetics of acetaminophen in man. Iqbal N, et al. **Biopharm Drug Dispos** 1995 Aug;16(6):481–7

The proportional cumulative area under the curve of paracetamol used as an index of gastric emptying in diabetic patients with symptoms of gastroparesis. van Wyk M, et al. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):637–40

Effect of total parenteral nutrition containing lipid calories on hepatic drug metabolism in rats. Raftogianis RB, et al. **Drug Metab Dispos** 1996 Apr;24(4):502–5

Metabolism of paracetamol in children with chronic liver disease. al-Obaidy SS, et al. **Eur J Clin Pharmacol** 1996; 50(1-2):69–76

Omeprazole has no effect on acetaminophen kinetics in the rat. Melzer E, et al. **Eur J Drug Metab Pharmacokinet** 1995 Apr-Jun;20(2):125–8

Postmortem acetaminophen pharmacokinetics: an experimental study of site and time-dependent concentration changes. Gomez HF, et al. **J Forensic Sci** 1995 Nov;40(6):980–2

Bioavailability of medication after laparoscopic cholecystectomy. Elfant AB, et al. **J Laparoendosc Surg** 1995 Aug;5(4):237–40

Cyclization-activated prodrugs: N-(substituted 2-hydroxyphenyl and 2-hydroxypropyl)carbamates based on ring-opened derivatives of active benzoxazolones and oxazolidinones as mutual prodrugs of acetaminophen. Vigroux A, et al. **J Med Chem** 1995 Sep 29;38(20):3983–94

Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. Lee CA, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):287–91

Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose. Stork CM, et al. **J Toxicol Clin Toxicol** 1996;34(2):157–62

The depression of hepatic drug conjugation reactions in rats after lipid-free total parenteral nutrition administered via the portal vein. Raftogianis RB, et al. **JPEN J Parenter Enteral Nutr** 1995 Jul-Aug;19(4):303–9

Pharmacokinetics of rectal paracetamol after major surgery in children. Anderson BJ, et al. **Paediatr Anaesth** 1995; 5(4):237–42

Relationship between gelation rate of controlled-release acetaminophen tablets containing polyethylene oxide and colonic drug release in dogs. Sako K, et al. **Pharm Res** 1996 Apr;13(4):594–8

Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasted and fed conditions in humans. Shameem M, et al. **Pharm Res** 1995 Jul;12(7):1049–54

[Influence of caffeine on toxicity and pharmacokinetics of paracetamol] Rańska-Giezek T. **Ann Acad Med Stetin** 1995;41:69–85 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Modulation of alpha-interferon's antiviral and clinical effects by aspirin, acetaminophen, and prednisone in healthy volunteers. Hendrix CW, et al. **Antiviral Res** 1995 Oct; 28(2):121–31

A comparative study of mouse liver proteins arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3'-hydroxyacetanilide. Myers TG, et al. **Chem Res Toxicol** 1995 Apr-May;8(3):403–13

Acetaminophen does not decrease hepatic 3'-phosphoadenosine 5'-phosphosulfate in mice. Kim HJ, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1506–11

Paracetamol exerts a spinal antinociceptive effect involving an indirect interaction with 5-hydroxytryptamine3 receptors: in vivo and in vitro evidence. Pelissier T, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):8–14

Lack of binding of acetaminophen to 5-HT receptor or uptake sites (or eleven other binding/uptake assays). Raffa RB, et al. **Life Sci** 1996;59(2):PL37–40

Determination of analgesic interaction between acetaminophen and d-propoxyphene obtained by means of the surface of synergistic interaction. López-Muñoz FJ, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun; 17(5):311–20

Evidence of a central antinociceptive effect of paracetamol involving spinal 5HT3 receptors. Pelissier T, et al. **Neuroreport** 1995 Jul 31;6(11):1546–8

Aspirin and acetaminophen reduced both Fos expression in rat lumbar spinal cord and inflammatory signs produced by carrageenin inflammation. Honoré P, et al. **Pain** 1995 Dec;63(3):365–75

[The effect of paracetamol and its combinations with acetylsalicylic and ascorbic acids on lipid peroxidation processes in the rat liver] Chaĭka LA, et al. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):43–6 (Eng. Abstr.) **(Rus)**

POISONING

Paracetamol intoxication and N-acetyl-cysteine treatment. De Groote J, et al. **Acta Gastroenterol Belg** 1995 May-Aug; 58(3-4):326–34 (78 ref.)

Management of acetaminophen toxicity. Larsen LC, et al. **Am Fam Physician** 1996 Jan;53(1):185–90 (25 ref.)

Acetaminophen and salicylate serum levels in patients with suicidal ingestion or altered mental status. Sporer KA, et al. **Am J Emerg Med** 1996 Sep;14(5):443–6

Acetaminophen overdose: need to consider intravenous preparation of N-acetylcysteine in the United States [letter] Dhawan A, et al. **Am J Gastroenterol** 1996 Jul;91(7):1476

Comparison of N-acetylcysteine and methylene blue, alone or in combination, for treatment of acetaminophen toxicosis in cats. Rumbeiha WK, et al. **Am J Vet Res** 1995 Nov; 56(11):1529–33

Parents beware of accidental overdose of acetaminophen [news] Laino C. **AORN J** 1995 Sep;62(3):429

Compound opioid/paracetamol analgesics: misuse and dependence. McBride AJ, et al. **Br J Clin Pract** 1995 Sep-Oct;49(5):268–9

Paracetamol overdose [letter] Friedman T. **Br J Psychiatry** 1996 Apr;168(4):519

Paracetamol self-poisoning. Characteristics, prevention and harm reduction. Hawton K, et al. **Br J Psychiatry** 1996 Jan;168(1):43–8

Media influence on parasuicide. A study of the effects of a television drama portrayal of paracetamol self-poisoning. Simkin S, et al. **Br J Psychiatry** 1995 Dec;167(6):754–9

Serial measurements of serum Gc-globulin in acetaminophen intoxication. Schiødt FV, et al. **Eur J Gastroenterol Hepatol** 1995 Jul;7(7):635–40

A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987–1993). Makin AJ, et al. **Gastroenterology** 1995 Dec;109(6):1907–16

Cholestasis as a liver protective factor in paracetamol acute overdose. Acevedo C, et al. **Gen Pharmacol** 1995 Nov; 26(7):1619–24

Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. Blakely P, et al. **J Am Soc Nephrol** 1995 Jul;6(1):48–53 (21 ref.)

Acetaminophen toxicity in children: diagnostic confirmation using a specific antigenic biomarker. Webster PA, et al. **J Clin Pharmacol** 1996 May;36(5):397–402

Acetaminophen hepatotoxicity [letter] Langdon DE. **J Fam Pract** 1996 Jul;43(1):13

Acetaminophen toxicity: report of case and review of the literature. Schueler L, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1208–12 (13 ref.)

The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning. Clark RF, et al. **J Toxicol Clin Toxicol** 1996;34(2):163–7

Extended-release acetaminophen overdose [letter] Cetaruk EW, et al. **JAMA** 1996 Mar 6;275(9):686

Management of paracetamol poisoning [letter; comment] Connor P. **Lancet** 1995 Nov 4;346(8984):1236. Comment on: Lancet 1995 Aug 26;346(8974):547–52.

Management of paracetamol poisoning [letter] Matthey F. **Lancet** 1995 Nov 4;346(8984):1237

Management of paracetamol poisoning [letter; comment] Ward SJ. **Lancet** 1995 Nov 4;346(8984):1236. Comment on: Lancet 1995 Aug 26;346(8974):547–52.

Management of paracetamol poisoning [letter; comment] Wendon JA, et al. **Lancet** 1995 Nov 4;346(8984):1236. Comment on: Lancet 1995 Aug 26;346(8974):547–52.

Drug-induced hepatotoxicity [letter; comment] De Roos FJ, et al. **N Engl J Med** 1996 Mar 28;334(13):863; discussion 864. Comment on: N Engl J Med 1995 Oct 26;333(17):1118–27.

More on extended-release acetaminophen [letter; comment] Temple AR, et al. **N Engl J Med** 1995 Nov 30; 333(22):1508–9. Comment on: N Engl J Med 1995 Jul 20;333(3):196.

Hyperglycaemia induced by paracetamol [letter] Lawrence IG, et al. **Postgrad Med J** 1995 Nov;71(841):702

Treating paracetamol overdose by charcoal haemoperfusion and long-hours high-flux dialysis. Higgins RM, et al. **QJM** 1996 Apr;89(4):297–306

The Danish liver transplantation program and patients with serious acetaminophen intoxication. Larsen FS, et al. **Transplant Proc** 1995 Dec;27(6):3519–20

[Paracetamol poisoning (letter)] Ring-Hansen H. **Ugeskr Laeger** 1995 Nov 27;157(48):6734–5 **(Dan)**

[Paracetamol poisoning (letter)] Ring-Larsen H. **Ugeskr Laeger** 1995 Aug 7;157(32):4470–1 **(Dan)**

[Clinical-toxicological case (1). Dosage of N-acetylcysteine in acute paracetamol poisoning] Kind B, et al. **Schweiz Rundsch Med Prax** 1996 Aug 2;85(31-32):935–8 (33 ref.) (Eng. Abstr.) **(Ger)**

[Paracetamol poisoning--case report] Filipović-Grčić B, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:91–2 (Eng. Abstr.) **(Scr)**

[Poisonings with analgesics. Paracetamol and dextropropoxyphene dominate and cause the most severe symptoms in a 3-year material] Torell E, et al. **Lakartidningen** 1996 May 15;93(20):1955–60 **(Swe)**

THERAPEUTIC USE

Comparing efficacy and tolerability of ibuprofen and paracetamol in fever. McIntyre J, et al. **Arch Dis Child** 1996 Feb;74(2):164–7

Analgesic efficacy and safety of paracetamol-codeine combinations versus paracetamol alone: a systematic review. de Craen AJ, et al. **BMJ** 1996 Aug 10; 313(7053):321–5

A double-blind placebo-controlled study to assess the efficacy of a compound analgesic to prevent postoperative pain following oral surgery. Sandhu S, et al. **Br Dent J** 1996 May 11;180(9):335–8

Paracetamol in childhood illness [letter] Cooney K. **Br J Gen Pract** 1995 Aug;45(397):439–40

Ketoprofen, paracetamol and placebo in the treatment of episodic tension-type headache. Dahlöf CG, et al. **Cephalalgia** 1996 Apr;16(2):117–23

A comparison of crossover versus parallel-group design in the evaluation of analgesic efficacy after molar extraction. Margarone JE, et al. **Clin Pharmacol Ther** 1995 Oct; 58(4):453–8

Comparative study of ibuprofen lysine and acetaminophen in patients with postoperative dental pain. Mehlisch DR, et al. **Clin Ther** 1995 Sep-Oct;17(5):852–60

Paracetamol prescribing--an epidemic? Dawson KP, et al. **Fam Pract** 1996 Apr;13(2):179–81

Choice of antipyretic in children. Khubchandani RP, et al. **J Assoc Physicians India** 1995 Sep;43(9):614–6

A comparison of 2 analgesic regimens for the control of postoperative periodontal discomfort. Tucker PW, et al. **J Periodontol** 1996 Feb;67(2):125–9

12 years on: co-proxamol revisited. Haigh S. **Lancet** 1996 Jun 29;347(9018):1840–1

Coproxamol revisited [letter] Sykes JV, et al. **Lancet** 1996 Aug 10;348(9024):408

The efficacy of amitriptyline and acetaminophen in the management of acute low back pain. Stein D, et al. **Psychosomatics** 1996 Jan-Feb;37(1):63–70

Fever in uncomplicated Plasmodium falciparum malaria: randomized double-'blind' comparison of ibuprofen and paracetamol treatment. Krishna S, et al. **Trans R Soc Trop Med Hyg** 1995 Sep-Oct;89(5):507–9

[Optimal use of non opioid analgesics] Fletcher D. **Cah Anesthesiol** 1995;43(3):239–49 (Eng. Abstr.) **(Fre)**

[Effectiveness of fixed analgesic combinations exemplified by thomapyrin] Aicher B, et al. **Wien Klin Wochenschr** 1996;108(8):219–33 (104 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Acetaminophen/aspirin mixtures: experimental data. Porter GA. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S30–3 (11 ref.)

Effect of nifedipine, verapamil, diltiazem and trifluoperazine on acetaminophen toxicity in mice. Dimova S, et al. **Arch Toxicol** 1995;70(2):112–8

Acute hepatotoxicity of acetaminophen in rats treated with ethanol plus isopentanol. Kostrubsky VE, et al.

Biochem Pharmacol 1995 Nov 27;50(11):1743–8

Maintenance of hepatic glutathione homeostasis and prevention of acetaminophen–induced cataract in mice by L–cysteine prodrugs. Rathbun WB, et al. **Biochem Pharmacol** 1996 May 3;51(9):1111–6

Mechanism of acetaminophen–induced hepatotoxicity: covalent binding versus oxidative stress. Gibson JD, et al. **Chem Res Toxicol** 1996 Apr–May;9(3):580–5

Actions of selected hepatotoxicants on freshly isolated and cryopreserved rat hepatocytes. Pang JM, et al. **Cryobiology** 1996 Apr;33(2):226–35

Ketoconazole inhibits acetaminophen–induced hepatotoxicity in mice [see comments] Culo F, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):757–62. Comment in: Eur J Gastroenterol Hepatol 1995 Aug;7(8):747–8.

Mitochondrial ATPase: a target for paracetamol–induced hepatotoxicity. Parmar DV, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):225–9

Evidence for potential application of zinc as an antidote to acetaminophen–induced hepatotoxicity. Woo PC, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):217–24

Comparative methods of toxicity testing. Consensus document following an International Life Sciences Institute–ILSI Europe Workshop held in May 1995. Huggett AC, et al. **Food Chem Toxicol** 1996 Feb; 34(2):183–92 (34 ref.)

Oxidative stress by acute acetaminophen administration in mouse liver. Lores Arnaiz S, et al. **Free Radic Biol Med** 1995 Sep;19(3):303–10

Protection against acetaminophen hepatotoxicity by a single dose of clofibrate: effects on selective protein arylation and glutathione depletion. Manautou JE, et al. **Fundam Appl Toxicol** 1996 Feb;29(2):229–37

Preventive and curative effects of Artemisia absinthium on acetaminophen and CCl4–induced hepatotoxicity. Gilani AH, et al. **Gen Pharmacol** 1995 Mar;26(2):309–15

The influence of antagonists of poly(ADP–ribose) metabolism on acetaminophen hepatotoxicity. Kröger H, et al. **Gen Pharmacol** 1996 Jan;27(1):167–70

Influence of diet free of NAD–precursors on acetaminophen hepatotoxicity in mice. Kröger H, et al. **Gen Pharmacol** 1996 Jan;27(1):79–82

Effect of Teucrium stocksianum on paracetamol–induced hepatotoxicity in mice. Rasheed RA, et al. **Gen Pharmacol** 1995 Mar;26(2):297–301

Acetaminophen–induced microvascular injury in the rat liver: protection with misoprostol. Lim SP, et al. **Hepatology** 1995 Dec;22(6):1776–81

In vivo effects of acetaminophen on rat RBC and role of vitamin E. Suhail M, et al. **Indian J Exp Biol** 1995 Apr; 33(4):269–71

Acetaminophen toxicity is substantially reduced by beta–carotene in mice. Baranowitz SA, et al. **Int J Vitam Nutr Res** 1995;65(3):175–80

Prevention of acetaminophen– and naphthalene–induced cataract and glutathione loss by CySSME. Rathbun WB, et al. **Invest Ophthalmol Vis Sci** 1996 Apr;37(5):923–9

Role of CYP2E1 in the hepatotoxicity of acetaminophen. Lee SS, et al. **J Biol Chem** 1996 May 17;271(20):12063–7

Susceptibility to hepatotoxicity in transgenic mice that express a dominant–negative human keratin 18 mutant. Ku NO, et al. **J Clin Invest** 1996 Aug 15;98(4):1034–46

Evaluation of the protective potential of Artemisia maritima extract on acetaminophen– and CCl4–induced liver damage. Janbaz KH, et al. **J Ethnopharmacol** 1995 Jun 23; 47(1):43–7

Comparison of thermally oxidized lipids and acetaminophen with concurrent consumption of ethanol as inducers of liver cirrhosis. Fouad FM, et al. **J Toxicol Environ Health** 1995 Oct;46(2):217–32

Series: current issues in mutagenesis and carcinogenesis, No. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view. Bergman K, et al. **Mutat Res** 1996 Feb 1;349(2):263–88 (103 ref.)

Evaluation of the ability of paracetamol to produce chromosome aberrations in man. Hantson P, et al. **Mutat Res** 1996 Jul 5;368(3–4):293–300

Effects of acetaminophen and hydroxyurea on spermatogenesis and sperm chromatin structure in laboratory mice. Wiger R, et al. **Reprod Toxicol** 1995 Jan–Feb;9(1):21–33

Induction of chromosome aberrations in vivo in bone–marrow cells of mice by paracetamol. Severin E, et al. **Rom J Morphol Embryol** 1995 Jul–Dec;41(3–4):117–20

Acetaminophen nephrotoxicity in the CD–1 mouse. II. Protection by probenecid and AT–125 without diminution of renal covalent binding. Emeigh Hart SG, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):161–9

Different mechanism of saturation of acetaminophen sulfate conjugation in mice and rats. Liu L, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):128–34

Protective effects of garlic and related organosulfur compounds on acetaminophen–induced hepatotoxicity in mice. Wang EJ, et al. **Toxicol Appl Pharmacol** 1996 Jan; 136(1):146–54

Inhibitory effect of cold stress against acetaminophen–induced hepatic injury in B6C3F1 and ICR mice. Yamamoto H, et al. **Toxicol Lett** 1995 Nov 15; 81(2–3):125–30

Protection in the late stages of paracetamol–induced liver cell injury with fructose, cyslosporin A and trifluoperazine. Beales D, et al. **Toxicology** 1996 Mar 18;107(3):201–8

Cell injury and protection in long–term incubation of liver slices after in vivo initiation with paracetamol: cell injury after in vivo initiation with paracetamol. Beales D, et al. **Toxicology** 1995 Nov 30;103(2):113–9

Cell protection by fructose is independent of adenosine triphosphate (ATP) levels in paracetamol injury to rat liver slices. Martin FL, et al. **Toxicology** 1996 Mar 18; 107(3):177–87

Adenosine triphosphate (ATP) levels in paracetamol–induced cell injury in the rat in vivo and in vitro. Martin FL, et al. **Toxicology** 1995 Dec 15;104(1–3):91–7

Comparison of protection by fructose against paracetamol injury with protection by glucose and fructose–1,6–diphosphate. Martin FL, et al. **Toxicology** 1996 Apr 30;108(3):175–84

Protective effects of Osbeckia octandra against paracetamol–induced liver injury. Thabrew MI, et al. **Xenobiotica** 1995 Sep;25(9):1009–17

[Influence of caffeine on toxicity and pharmacokinetics of paracetamol] Rańska–Giezek T. **Ann Acad Med Stetin** 1995;41:69–85 (Eng. Abstr.) **(Pol)**

[Effects of cholestasis on hepatotoxicity of acetaminophen in rats] Salas Coll CA, et al. **G E N** 1995 Jan–Mar; 49(1):42–9 (Eng. Abstr.) **(Spa)**

[Plasma levels of alanine aminotransferase in experimental liver necrosis induced by overdosage of paracetamol in mice] Carrasco R, et al. **Rev Esp Enferm Dig** 1995 Dec; 87(12):865–8 (Eng. Abstr.) **(Spa)**

ACETANILIDES

CHEMISTRY

P–azidoiodoacetanilide, a new short photocrosslinker that has greater cysteine specificity than p–azidophenacyl bromide and p–azidobromoacetanilide. Zhang J, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1177–84

PHARMACOLOGY

A comparative study of mouse liver proteins arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3'–hydroxyacetanilide. Myers TG, et al. **Chem Res Toxicol** 1995 Apr–May;8(3):403–13

Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Cameron NE, et al. **Diabetologia** 1996 Feb;39(2):172–82

Hypolipidemic and antiatherosclerotic effects of a novel ACAT inhibitor, HL–004, in stroke–prone spontaneously hypertensive rats. Murakami S, et al. **Exp Mol Pathol** 1995 Aug;63(1):23–32

TOXICITY

Identity and pathogenesis of stomach tumors in Sprague–Dawley rats associated with the dietary administration of butachlor. Hard GC, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):95–105

A study of the mechanism of butachlor–associated gastric neoplasms in Sprague–Dawley rats. Thake DC, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):107–16

Genotoxicity of the herbicide butachlor in cultured human lymphocytes. Sinha S, et al. **Mutat Res** 1995 Aug; 344(1–2):63–7

ACETATE–COA LIGASE

BIOSYNTHESIS

Acetate utilization is inhibited by benzoate in Alcaligenes eutrophus: evidence for transcriptional control of the expression of acoE coding for acetyl coenzyme A synthetase. Ampe F, et al. **J Bacteriol** 1995 Oct; 177(20):5826–33

CHEMISTRY

The putative acetyl–CoA synthetase gene of Cryptosporidium parvum and a new conserved protein motif in acetyl–CoA synthetases. Khramtsov NV, et al. **J Parasitol** 1996 Jun;82(3):423–7

GENETICS

The putative acetyl–CoA synthetase gene of Cryptosporidium parvum and a new conserved protein motif in acetyl–CoA synthetases. Khramtsov NV, et al. **J Parasitol** 1996 Jun;82(3):423–7

ISOLATION & PURIFICATION

Purification and characterization of the acetate forming enzyme, acetyl–CoA synthetase (ADP–forming) from the amitochondriate protist, Giardia lamblia. Sanchez LB, et al. **FEBS Lett** 1996 Jan 15;378(3):240–4

METABOLISM

Purification and characterization of the acetate forming enzyme, acetyl–CoA synthetase (ADP–forming) from the amitochondriate protist, Giardia lamblia. Sanchez LB, et al. **FEBS Lett** 1996 Jan 15;378(3):240–4

ACETATE–FREE BIOFILTRATION see **HEMODIAFILTRATION**

ACETATE KINASE

GENETICS

Cloning, sequencing, and expression of genes encoding phosphotransacetylase and acetate kinase from Clostridium acetobutylicum ATCC 824. Boynton ZL, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2758–66

ACETATE THIOKINASE see **ACETATE–COA LIGASE**

ACETATES

Treatment of ionic species in force–field calculations: sulfate and carboxylate groups in carbohydrates. Ferro DR, et al. **Int J Biol Macromol** 1995 Jun;17(3–4):131–6

ADVERSE EFFECTS

Single dose pharmacokinetics, safety and tolerability of MK–0476, a new leukotriene D4–receptor antagonist, in healthy volunteers. Schoors DF, et al. **Br J Clin Pharmacol** 1995 Sep;40(3):277–80

BLOOD

[Rapid assay of plasma acetate by gas chromatography: evaluation and comparison with two other methods] Boussairi A, et al. **Ann Biol Clin (Paris)** 1995;53(6):339–42 (Eng. Abstr.) **(Fre)**

[Acid–base equilibrium of peritoneal dialysis (CAPD) patients utilizing acetate, lactate, bicarbonate] Quellhorst E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct;30 Suppl 1:S69–72 **(Ger)**

[Acetate] Shimizu T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:590–2 (16 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Simple production of [1–carbon–11]acetate. Oberdorfer F, et al. **J Nucl Med** 1996 Feb;37(2):341–2

CHEMISTRY

(3E,8Z,11Z)–3,8,11–tetradecatrienyl acetate, major sex pheromone component of the tomato pest Scrobipalpuloides absoluta (Lepidoptera: Gelechiidae). Attygalle AB, et al. **Bioorg Med Chem** 1996 Mar; 4(3):305–14

Ab initio calculations on (Z)–5–decenyl acetate, a component of the pheromone complex of Agrotis segetum (Lepidoptera: Noctuidae) and electrophysiological studies with chain elongated analogues. Bestmann HJ, et al. **Bioorg Med Chem** 1996 Mar;4(3):473–7

Conformationally constrained analogues of (Z)–5–decenyl acetate, a pheromone component of Agrotis segetum. Jönsson S, et al. **Bioorg Med Chem** 1996 Mar;4(3):499–504

DIAGNOSTIC USE

Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. Irie T, et al. **J Nucl Med** 1996 Apr;37(4):649–55

Simple production of [1–carbon–11]acetate. Oberdorfer F, et al. **J Nucl Med** 1996 Feb;37(2):341–2

Myocardial oxidative metabolism in hyperthyroid patients assessed by PET with carbon–11–acetate. Torizuka T, et al. **J Nucl Med** 1995 Nov;36(11):1981–6

[The 13C–acetate breath test for the noninvasive assessment of the gastric emptying of a liquid/solid test meal in diabetics] Pfaffenbach B, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):713–8 (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

Gummiferol, a cytotoxic polyacetylene from the leaves of Adenia gummifera. Fullas F, et al. **J Nat Prod** 1995 Oct; 58(10):1625–8

METABOLISM

Anaplerotic effects of propionate on oxidations of acetate and long–chain fatty acids. Liedtke AJ, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2197–203

Metabolic rates during sporulation of Saccharomyces cerevisiae on acetate. Aon JC, et al. **Antonie Van Leeuwenhoek** 1996 Apr;69(3):257–65

Pathways of acetate, propionate, and butyrate formation by the human fecal microbial flora. Miller TL, et al. **Appl Environ Microbiol** 1996 May;62(5):1589–92

Acetate represents a major product of heptanoate and octanoate beta–oxidation in hepatocytes isolated from neonatal piglets. Lin X, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):235–40

Post–exercise gastric emptying of carbohydrate solutions determined using the 13C acetate breath test. Leese GP, et al. **Eur J Appl Physiol** 1995;71(4):306–10

Most probable number enumeration of H2–utilizing acetogenic bacteria from the digestive tract of animals and man. Doré J, et al. **FEMS Microbiol Lett** 1995 Jul 15; 130(1):7–12

Insulin and(or) dexamethasone regulation of glucose and acetate utilization in ovine and bovine adipose tissue explants incubated for seven days. Chilliard Y, et al.

J Anim Sci 1995 Jul;73(7):2063–70

Acetate utilization is inhibited by benzoate in Alcaligenes eutrophus: evidence for transcriptional control of the expression of acoE coding for acetyl coenzyme A synthetase. Ampe F, et al. **J Bacteriol** 1995 Oct; 177(20):5826–33

Oxidation of alanine, acetate, glutamate, and succinate by digitonin–permeabilized Leishmania major promastigotes. Blum JJ. **J Eukaryot Microbiol** 1996 Mar–Apr;43(2):144–50

Genetic manipulation of acid formation pathways by gene inactivation in Clostridium acetobutylicum ATCC 824. Green EM, et al. **Microbiology** 1996 Aug;142 (Pt 8):2079–86

Attempted induction of reductive acetogenesis into the rumen fermentation in vitro. Demeyer DI, et al. **Reprod Nutr Dev** 1996;36(3):233–40

Effect of thiosulphate as electron acceptor on glucose and xylose oxidation by Thermoanaerobacter finnii and a Thermoanaerobacter sp. isolated from oil field water. Fardeau ML, et al. **Res Microbiol** 1996 Mar–Apr; 147(3):159–65

PHARMACOKINETICS

Single dose pharmacokinetics, safety and tolerability of MK–0476, a new leukotriene D4–receptor antagonist, in healthy volunteers. Schoors DF, et al. **Br J Clin Pharmacol** 1995 Sep;40(3):277–80

Short chain fatty acid absorption from the human distal colon: interactions between acetate, propionate and calcium. Wolever TM, et al. **J Am Coll Nutr** 1995 Aug; 14(4):393–8

Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK–0476) in healthy males and females. Cheng H, et al. **Pharm Res** 1996 Mar;13(3):445–8

PHARMACOLOGY

Rat cerebral mitochondrial glutaminase activity is unaffected by moderate hyperammonemia in two models. Albrecht J, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):545–8

Effect of acetate and propionate on calcium absorption from the rectum and distal colon of humans. Trinidad TP, et al. **Am J Clin Nutr** 1996 Apr;63(4):574–8

Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig. André P, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):56–63

Oxidative folding of omega–conotoxin MVIIC: effects of temperature and salt. Kubo S, et al. **Biopolymers** 1996 Jun; 38(6):733–44

Single dose pharmacokinetics, safety and tolerability of MK–0476, a new leukotriene D4–receptor antagonist, in healthy volunteers. Schoors DF, et al. **Br J Clin Pharmacol** 1995 Sep;40(3):277–80

Plasma non–esterified fatty acid response to dialysate acetate concentration during haemodialysis in humans. Jackson JM, et al. **Clin Chim Acta** 1995 Jul 31;239(1):81–9

Transient inhibition of glucose uptake mimics ischemic preconditioning by salvaging ischemic myocardium in the rabbit heart. Goto M, et al. **J Mol Cell Cardiol** 1995 Sep; 27(9):1883–94

Brain quinolinic acid in chronic experimental hepatic encephalopathy: effects of an exogenous ammonium acetate challenge. Bergqvist PB, et al. **J Neurochem** 1995 Nov; 65(5):2235–40

Gel mobility shift scanning of the acetate–inducible promoters from Neurospora crassa reveals a common co–inducible DNA–binding protein. Mizote T, et al. **Mol Gen Genet** 1996 Mar 7;250(4):421–7

THERAPEUTIC USE

Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study [see comments] Théroux P, et al. **Circulation** 1996 Sep 1; 94(5):899–905. Comment in: Circulation 1996 Sep 1;94(5):866–8.

Comparison of antithrombotic effects of GPIIb–IIIa receptor antagonist and TXA2 receptor antagonist in the guinea–pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis. Takiguchi Y, et al. **Thromb Haemost** 1995 Apr;73(4):683–8

TOXICITY

Haloacetate–induced oxidative damage to DNA in the liver of male B6C3F1 mice. Parrish JM, et al. **Toxicology** 1996 Jun 17;110(1–3):103–11

Treatment of ammonia intoxication in rats through the use of amino acids from the urea cycle. Ortolani EL, et al. **Vet Hum Toxicol** 1995 Jun;37(3):217–20

ACETAZINE see **ACEPROMAZINE**

ACETAZOLAMIDE

ADMINISTRATION & DOSAGE

The use of low–dose acetazolamide to prevent mountain sickness [letter] Meyer BH. **S Afr Med J** 1995 Aug; 85(8):792–3

[Combination therapy of circumscribed choroid hemangioma in contralateral Sturge–Weber syndrome with acetazolamide and laser coagulation] Althaus C, et al. **Klin Monatsbl Augenheilkd** 1996 Apr;208(4):239–42 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Prevalence of chronic hypokalaemia amongst elderly patients using acetozolamide and diuretics [letter] Davis AR, et al. **Eye** 1995;9 (Pt 3):381–2

Pustular psoriasis precipitated by acetazolamide. Kuroda K, et al. **J Dermatol** 1995 Oct;22(10):784–7

Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis. Schwenk MH, et al. **Pharmacotherapy** 1995 Jul–Aug;15(4):522–7

DIAGNOSTIC USE

Hemodynamics of hypertensive putaminal hemorrhage evaluated by Xenon–enhanced computed tomography and acetazolamide test. Kitahara T, et al. **Acta Neurol Scand Suppl** 1996;166:139–43

Susceptibility–weighted MR for evaluation of vasodilatory capacity with acetazolamide challenge. Ohnishi T, et al. **AJNR Am J Neuroradiol** 1996 Apr;17(4):631–7

18FDG PET and acetazolamide–enhanced 99mTc–HMPAO SPET in systemic lupus erythematosus. Grünwald F, et al. **Eur J Nucl Med** 1995 Sep;22(9):1073–7

Use of transcranial Doppler sonography and acetazolamide test to demonstrate changes in cerebrovascular reserve capacity following carotid endarterectomy. Barzó P, et al. **Eur J Vasc Endovasc Surg** 1996 Jan;11(1):83–9

Cerebral blood flow alteration by acetazolamide during carotid balloon occlusion: parameters reflecting cerebral perfusion pressure in the acetazolamide test. Okudaira Y, et al. **Stroke** 1996 Apr;27(4):617–21

Preoperative and postoperative evaluation of cerebral perfusion and vasodilatory capacity with 99mTc–HMPAO SPECT and acetazolamide in childhood Moyamoya disease. Touho H, et al. **Stroke** 1996 Feb;27(2):282–9

[A time–saving approach for quantifying regional cerebral blood flow and application to split–dose method with 123I–IMP SPECT using a single–head rotating gamma–camera] Inoue T, et al. **Kaku Igaku** 1995 Nov; 32(11):1217–26 (Eng. Abstr.) **(Jpn)**

[Presurgical evaluation of cerebral perfusion reserve in patients for cardiovascular surgery using 99mTc–ECD SPECT with diamox enhancement] Matsumura K, et al. **Kaku Igaku** 1996 Mar;33(3):223–31 (Eng. Abstr.) **(Jpn)**

[Usefulness of change ratio map in 99mTc–HMPAO SPECT with acetazolamide enhancement] Yamamoto N. **Kaku Igaku** 1996 Apr;33(4):399–408 (Eng. Abstr.) **(Jpn)**

[Cerebral blood flow increase and P300 latency prolongation by intravenous injection of acetazolamide--investigation in lacunar cerebral infarction and healthy subjects] Oishi M, et al. **No To Shinkei** 1995 Oct;47(10):975–9 (Eng. Abstr.) **(Jpn)**

METABOLISM

Concentration–dependent tubular secretion of acetazolamide and its inhibition by salicylic acid in the isolated perfused rat kidney. Taft DR, et al. **Drug Metab Dispos** 1996 Apr; 24(4):456–61

PHARMACOLOGY

Acetazolamide produced blood flow velocity changes measured by laser Doppler in gerbils with reduced CBF. Czernicki Z, et al. **Acta Neurochir (Wien)** 1996;138(1):81–3

Adaptive changes of autoregulation in chronic cerebral hypotension with arteriovenous malformations: an acetazolamide–enhanced single–photon emission CT study. Hacein–Bey L, et al. **AJNR Am J Neuroradiol** 1995 Oct; 16(9):1865–74

Enalapril attenuates the renal hemodynamic effect of acetazolamide in patients with diabetes mellitus: possible implications for tubuloglomerular feedback. Slomowitz LA, et al. **Am J Nephrol** 1996;16(4):315–9

Effects of dietary sucrose and cortisone on hepatic acetazolamide–resistant carbonic anhydrase. Moynihan JB. **Biochem Soc Trans** 1996 Feb;24(1):145S

The effect of acetazolamide and carbon dioxide on cerebral hemodynamic changes on near–infrared spectroscopy in young rabbits. Kimoto H, et al. **Brain Dev** 1995 Jul–Aug; 17(4):261–3

Inhibitory mechanisms of H(+)–ATPase inhibitor bafilomycin A1 and carbonic anhydrase II inhibitor acetazolamide on experimental bone resorption. Ohba Y, et al. **FEBS Lett** 1996 Jun 3;387(2–3):175–8

Effect of acetazolamide on cough induced by low–chloride–ion solutions in normal subjects: comparison with furosemide. Foresi A, et al. **J Allergy Clin Immunol** 1996 May;97(5):1093–9

Acetazolamide–induced vasodilation in the carotid vascular bed in healthy volunteers. Démolis P, et al. **J Cardiovasc Pharmacol** 1995 Nov;26(5):841–4

Time course of acetazolamide effect in normal persons. Hamann GF, et al. **J Neuroimaging** 1996 Jan;6(1):29–31

Extracranial intravascular vasodilatory response to acetazolamide and magnetic resonance angiography. Levine RL, et al. **J Neuroimaging** 1996 Apr;6(2):126–30

Time course of the acetazolamide effect in patients with extracranial carotid artery disease. Stoll M, et al. **J Neuroimaging** 1996 Jul;6(3):144–9

Haemodynamic effects of acetazolamide in patients with cardiovascular disorders: correlation with calculated cerebral perfusion reserve. Vanninen E, et al. **Nucl Med Commun** 1996 Apr;17(4):325–30

Effects of acetazolamide on the sleep apnea syndrome and its therapeutic mechanism. Sakamoto T, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):59–64

Acetazolamide–induced inhibition of carbonic anhydrase influences energy metabolism and respiratory work in healthy subjects. Hirahara K, et al. **Res Commun Mol Pathol Pharmacol** 1995 Oct;90(1):125–31

Cerebral vasoreactivity assessed with transcranial Doppler and regional cerebral blood flow measurements. Dose, serum concentration, and time course of the response to acetazolamide. Dahl A, et al. **Stroke** 1995 Dec; 26(12):2302–6

Effect of acetazolamide on regional cerebral oxygen saturation and regional cerebral blood flow. Kaminogo M, et al. **Stroke** 1995 Dec;26(12):2358–60

Sex–related differences in acetazolamide–induced cerebral vasomotor reactivity. Karnik R, et al. **Stroke** 1996 Jan; 27(1):56–8

[Comparison of cerebral vasoreactivity to acetazolamide in normal volunteer among 123I–IMP, 99mTc–ECD and 99mTc–HMPAO] Makino K, et al. **Kaku Igaku** 1996 May; 33(5):551–5 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Acetazolamide in the treatment of seizures. Reiss WG, et al. **Ann Pharmacother** 1996 May;30(5):514–9 (68 ref.)

Intraocular pressure rise after phacoemulsification with posterior chamber lens implantation: effect of prophylactic medication, wound closure, and surgeon's experience. Bömer TG, et al. **Br J Ophthalmol** 1995 Sep;79(9):809–13

Follow–up of treatment of a cerebral arteriovenous malformation with acetazolamide and positron emission tomography. Argenyi EE, et al. **Clin Nucl Med** 1995 Jul; 20(7):639–41

The effect of prophylactic acetazolamide in patients undergoing extensive retinal detachment repair. Edmunds B, et al. **Eye** 1996;10 (Pt 3):328–30

Cystoid macular oedema in chronic myeloid leukaemia: treatment with acetazolamide and response to bone marrow transplantation [letter] Horgan SE, et al. **Eye** 1996;10 (Pt 3):394–6

Hereditary myokymia and paroxysmal ataxia linked to chromosome 12 is responsive to acetazolamide. Lubbers WJ, et al. **J Neurol Neurosurg Psychiatry** 1995 Oct; 59(4):400–5

A randomized, masked, cross–over trial of acetazolamide for cystoid macular edema in patients with uveitis. Whitcup SM, et al. **Ophthalmology** 1996 Jul; 103(7):1054–62;discussion 1062–3

Effects of acetazolamide on the sleep apnea syndrome and its therapeutic mechanism. Sakamoto T, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):59–64

Prophylactic efficacy of phenytoin, acetazolamide and hydrochlorothiazide in horses with hyperkalaemic periodic paralysis. Beech J, et al. **Res Vet Sci** 1995 Sep;59(2):95–101

Acetazolamide therapy evaluation in haemorrhagic stroke. Popa G, et al. **Rom J Neurol Psychiatry** 1995 Apr–Jun; 33(2):145–55

Time dependency of the acetazolamide effect on cerebral hemodynamics in patients with chronic occlusive cerebral arteries. Early steal phenomenon demonstrated by [15O]H2O positron emission tomography. Kuwabara Y, et al. **Stroke** 1995 Oct;26(10):1825–9

[Altitude illness] Bosch FH. **Ned Tijdschr Geneeskd** 1995 Dec 2;139(48):2465–7 **(Dut)**

[Acetazolamide treatment of a newborn infant with posthemorrhagic cerebral ventricular dilatation] Rubetti P, et al. **Pediatr Med Chir** 1995 Jul–Aug;17(4):359–63 (Eng. Abstr.) **(Ita)**

[Prevention of neurological disorders of high altitude disease] Carod FJ, et al. **Rev Neurol** 1995 Nov–Dec;23(124):1324 **(Spa)**

ACETIC ACID ESTERS

ADVERSE EFFECTS

Pulmonary toxicity following exposure to an aerosolized leather protector [see comments] Burkhart KK, et al. **J Toxicol Clin Toxicol** 1996;34(1):21–4. Comment in: J Toxicol Clin Toxicol 1996;34(1):25–6.

PHARMACOKINETICS

Postmortem diffusion of ingested and aspirated paint thinner. Fuke C, et al. **Forensic Sci Int** 1996 Apr 23;78(3):199–207

ACETIC ACIDS

Millisecond studies of calcium–dependent exocytosis in pituitary melanotrophs: comparison of the photolabile calcium chelators nitrophenyl–EGTA and DM–nitrophen. Parsons TD, et al. **Cell Calcium** 1996 Mar;19(3):185–92

Plasticity of myofibroblasts appearing in granulation tissues after acetic acid treatment. Effect of bFGF. Nakamura M, et al. **Dig Dis Sci** 1995 Nov;40(11):2477–80

The importance of tissue fixation for light microscopic immunohistochemical localization of peroxisomal proteins:

the superiority of Carnoy's fixative over Baker's formalin and Bouin's solution. Lehmann T, et al. **Histochem Cell Biol** 1995 Mar;103(3):187-95

Media for preservative resistant yeasts: a collaborative study. Hocking AD. **Int J Food Microbiol** 1996 Apr; 29(2-3):167-75

Protein extraction and western blotting from methacarn-fixed tissue. Lalani EN, et al. **J Pathol** 1995 Nov;177(3):323-8

[Prostacyclin mimetics with non-prostanoid structures] Kondo K, et al. **Nippon Yakurigaku Zasshi** 1995 Sep; 106(3):181-91 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Abdominal angiostrongyliasis: its prevention by the destruction of infecting larvae in food treated with salt, vinegar or sodium hypochlorite] Zanini GM, et al. **Rev Soc Bras Med Trop** 1995 Oct-Dec;28(4):389-92 (Eng. Abstr.) **(Por)**

ADMINISTRATION & DOSAGE

The management of chronic suppurative otitis media with acid media solution. Aminifarshidmehr N. **Am J Otol** 1996 Jan;17(1):24-5

Prognosis of small hepatocellular carcinoma (less than 3 cm) after percutaneous acetic acid injection: study of 91 cases. Ohnishi K, et al. **Hepatology** 1996 May;23(5):994-1002

Topical treatments for hydrofluoric acid dermal burns. Further assessment of efficacy using an experimental piq model. Dunn BJ, et al. **J Occup Environ Med** 1996 May; 38(5):507-14

Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857. Rübsamen K, et al. **Thromb Haemost** 1995 Nov; 74(5):1353-60

ADVERSE EFFECTS

Hypomania induced by gabapentin [letter] Hauck A, et al. **Br J Psychiatry** 1995 Oct;167(4):549

Gabapentin: pharmacokinetics, efficacy, and safety. Beydoun A, et al. **Clin Neuropharmacol** 1995 Dec;18(6):469-81 (61 ref.)

Behavioral side effects of gabapentin in children. Lee DO, et al. **Epilepsia** 1996 Jan;37(1):87-90

Movement disorders associated with the use of gabapentin. Reeves AL, et al. **Epilepsia** 1996 Oct;37(10):988-90

Gabapentin associated with aggressive behavior in pediatric patients with seizures. Tallian KB, et al. **Epilepsia** 1996 May;37(5):501-2

Gabapentin toxicity in children manifesting as behavioral changes. Wolf SM, et al. **Epilepsia** 1995 Dec;36(12):1203-5

Hemorrhagic cystitis caused by acetic acid instillation. Osorio AV, et al. **J Urol** 1996 Feb;155(2):685

Choreoathetotic movements: A possible side effect of gabapentin. Buetefisch CM, et al. **Neurology** 1996 Mar; 46(3):851-2

Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Vossler DG. **Neurology** 1996 Mar;46(3):852-3

[General argyria caused by administration of tobacco-withdrawal tablets containing silver acetate] Vau. Garsse L, et al. **Ned Tijdschr Geneeskd** 1995 Dec 23; 139(51):2658-61 (Eng. Abstr.) **(Dut)**

ANALYSIS

Acetate: a contaminant in Hepes buffer. Abas L, et al. **Anal Biochem** 1995 Jul 20;229(1):139-40

BLOOD

Determination of gabapentin in serum by capillary electrophoresis. Garcia LL, et al. **J Chromatogr B Biomed Appl** 1995 Jul 7;669(1):157-62

CEREBROSPINAL FLUID

Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. Ben-Menachem E, et al. **Epilepsy Res** 1995 Jul;21(3):231-6

CHEMICAL SYNTHESIS

Synthesis and antitumor activity of some analogues of flavone acetic acid. Valenti P, et al. **Anticancer Drug Des** 1996 Apr; 11(3):243-52

2-Anthracenonyl acetic acids as 5-lipoxygenase inhibitors. Prinz H, et al. **Arch Pharm (Weinheim)** 1996 May; 329(5):262-6

CHEMISTRY

750 MHz HPLC-NMR spectroscopic studies on the separation and characterization of the positional isomers of the glucuronides of 6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid. Sidelmann UG, et al. **Anal Chem** 1996 Jan 1;68(1):106-10

Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. Clerc S, et al. **Biochim Biophys Acta** 1995 Dec 13;1240(2):257-65

Modeling the structure of the combining site of an antisweet taste ligand monoclonal antibody NC10.14. Viswanathan M, et al. **Biopolymers** 1996 Sep;39(3):395-406

Phospholipid surface density determines the partitioning and permeability of acetic acid in DMPC:cholesterol bilayers. Xiang TX, et al. **J Membr Biol** 1995 Nov;148(2):157-67

Synthesis and in vitro transdermal penetration enhancing activity of lactam N-acetic acid esters. Michniak BB, et al. **J Pharm Sci** 1996 Feb;85(2):150-4

Acid binding and detritylation during oligonucleotide synthesis. Paul CH, et al. **Nucleic Acids Res** 1996 Aug 1; 24(15):3048-52

DIAGNOSTIC USE

Acetic acid visualization of the cervix: an alternative to cytologic screening. Megevand E, et al. **Obstet Gynecol** 1996 Sep;88(3):383-6

IMMUNOLOGY

Circular dichroism spectroscopy of monoclonal antibodies that bind a superpotent guanidinium sweetener ligand. Tetin SY, et al. **Biochemistry** 1996 Jan 30;35(4):1258-64

Structural predictions of the binding site architecture for monoclonal antibody NC6.8 using computer-aided molecular modeling, ligand binding, and spectroscopy. Viswanathan M, et al. **Biophys J** 1995 Sep;69(3):741-53

METABOLISM

Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. Demigné C, et al. **Br J Nutr** 1995 Aug;74(2):209-19

A reevaluation of the thermodynamics of growth of Saccharomyces cerevisiae on glucose, ethanol, and acetic acid. Battley EH. **Can J Microbiol** 1995 Apr-May; 41(4-5):388-98

Cytoplasmic calcium buffer capacity determined with Nitr-5 and DM-nitrophen. al-Baldawi NF, et al. **Cell Calcium** 1995 Jun;17(6):409-21

Metabolism of bromodichloroacetate in B6C3F1 mice. Xu G, et al. **Drug Metab Dispos** 1995 Dec;23(12):1412-6

Utilization of acetic acid and other short-chain monocarboxylic acids in the yeasts Torulaspora delbrueckii and Saccharomyces cerevisiae: transport and its regulation. Casal M, et al. **Folia Microbiol (Praha)** 1994;39(6):512-3

The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. Gee NS, et al. **J Biol Chem** 1996 Mar 8;271(10):5768-76

Mechanisms regulating the transport of acetic acid in Saccharomyces cerevisiae. Casal M, et al. **Microbiology** 1996 Jun;142 (Pt 6):1385-90

Expression of an amino acid biosynthesis gene in tomato flowers: developmental upregulation and MeJa response are parenchyma-specific and mutually compatible. Samach A, et al. **Plant J** 1995 Sep;8(3):391-406

PHARMACOKINETICS

Metabolism of acetaldehyde to acetate by rat hepatic P-450s: presence of different metabolic pathway from acetaldehyde dehydrogenase system. Kunitoh S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):22A-24A

Transport of acetic acid in Zygosaccharomyces bailii: effects of ethanol and their implications on the resistance of the yeast to acidic environments. Sousa MJ, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3152-7

Estimation of kinetic rate constants for biodegradation of chemicals in activated sludge wastewater treatment plants using short term batch experiments and microgram/L range spiked concentrations. Nyholm N, et al. **Chemosphere** 1996 Sep;33(5):851-64

Effect of intragastric pH on the absorption of oral zinc acetate and zinc oxide in young healthy volunteers. Henderson LM, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep-Oct;19(5):393-7

The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. Wang Y, et al. **Pharm Res** 1996 Mar;13(3):398-403

Physiologically based pharmacokinetics of methoxyacetic acid: dose-effect considerations in C57BL/6 mice. O'Flaherty EJ, et al. **Teratology** 1995 Aug;52(2):78-89

Physiologically based pharmacokinetic models applicable to organogenesis: extrapolation between species and potential use in prenatal toxicity risk assessments. Welsch F, et al. **Toxicol Lett** 1995 Dec;82-83:539-47

PHARMACOLOGY

The effects of disulfiram on equine hepatic alcohol dehydrogenase and its efficiency against alcoholism: vinegar effect. Langeland BT, et al. **Alcohol Alcohol** 1996 Jan;31(1):75-80

The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Petroff OA, et al. **Ann Neurol** 1996 Jan;39(1):95-9

Formation and decay of the S3 EPR signal species in acetate-inhibited photosystem II. Szalai VA, et al. **Biochemistry** 1996 Feb 13;35(6):1946-53

Magnesium acetate induces a conformational change in Escherichia coli primase. Urlacher TM, et al. **Biochemistry** 1995 Dec 26;34(51):16708-14

Cytoxicity of [(5,6-dichloro-9a-n-propyl-2,3,9,9a-tetrahydro-3-oxo-1H fluoren-7-yl)oxy]acetic acid, an agent known to reduce brain edema. Hall IH, et al. **Biomed Pharmacother** 1996; 50(1):19-23

The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Honmou O, et al. **Brain Res** 1995 Sep 18;692(1-2):273-7

Acute effect of intracerebroventricular administration of zinc on the drinking behavior of rats induced by dehydration or central cholinergic and angiotensinergic stimulation. Fregoneze JB, et al. **Braz J Med Biol Res** 1994 Nov; 27(11):2623-33

Gabapentin: pharmacokinetics, efficacy, and safety. Beydoun A, et al. **Clin Neuropharmacol** 1995 Dec;18(6):469-81 (61 ref.)

Zinc acetate and lyophilized aloe barbadensis as vaginal contraceptive. Fahim MS, et al. **Contraception** 1996 Apr; 53(4):231-6

Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. Ben-Menachem E, et al. **Epilepsy Res** 1995 Jul;21(3):231-6

Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Goldlust A, et al. **Epilepsy Res** 1995 Sep;22(1):1-11

Effect of acetate and propionate on fasting hepatic glucose production in humans. Laurent C, et al. **Eur J Clin Nutr** 1995 Jul;49(7):484-91

Studies with pre-treatment of milk with calcium acetata to reduce the phosphate content [letter] Schröder CH, et al. **Eur J Pediatr** 1995 Aug;154(8):689

Antimyoclonic effect of gabapentin in a posthypoxic animal model of myoclonus. Kanthasamy AG, et al. **Eur J Pharmacol** 1996 Feb 22;297(3):219-24

Induction of a novel cytochrome P450 (CYP93 family) by methyl jasmonate in soybean suspension-cultured cells. Suzuki G, et al. **FEBS Lett** 1996 Mar 25;383(1-2):83-6

In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. Midolo PD, et al. **J Appl Bacteriol** 1995 Oct;79(4):475-9

Investigations of the inhibitory effect of propranolol, chlorpromazine, quinine, and dicyclohexylcarbodiimide on the swelling of yeast mitochondria in potassium acetate. Evidences for indirect effects mediated by the lipid phase. Roucou X, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):353-62

Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids. Ishii A, et al. **J Med Chem** 1996 Apr 26;39(9):1924-7

N-methyl-D-aspartic acid receptor agonists: resolution, absolute stereochemistry, and pharmacology of the enantiomers of 2-amino-2-(3-hydroxy-5-methyl-4-isoxazolyl)acetic acid. Madsen U, et al. **J Med Chem** 1996 Jan 5;39(1):183-90

Identification of male germ cells undergoing apoptosis in adult rats. Brinkworth MH, et al. **J Reprod Fertil** 1995 Sep;105(1):25-33

Is phospholipase in vinegared oysters a casual agent for human poisoning? Sajiki J. **J Toxicol Environ Health** 1996 Feb 23;47(3):221-32

Effective acidification of traditional fermented foods. Simango C. **J Trop Med Hyg** 1995 Dec;98(6):465-8

Healing-promoting action of the zinc-cimetidine complex on acetic acid-induced gastric ulcers in rats. Ito M, et al. **Jpn J Pharmacol** 1995 Jul;68(3):287-95

The plant growth regulator methyl jasmonate inhibits aflatoxin production by Aspergillus flavus. Goodrich-Tanrikulu M, et al. **Microbiology** 1995 Nov;141 (Pt 11):2831-7

Manganese-induced reactive oxygen species: comparison between Mn+2 and Mn+3. Ali SF, et al. **Neurodegeneration** 1995 Sep;4(3):329-34

Effect of volatile methyl jasmonate on the oxylipin pathway in tobacco, cucumber, and arabidopsis. Avdiushko S, et al. **Plant Physiol** 1995 Dec;109(4):1227-30

Coi1-dependent expression of an Arabidopsis vegetative storage protein in flowers and siliques and in response to coronatine or methyl jasmonate. Benedetti CE, et al. **Plant Physiol** 1995 Oct;109(2):567-72

A wound- and methyl jasmonate-inducible transcript coding for a myrosinase-associated protein with similarities to an early nodulin. Taipalensuu J, et al. **Plant Physiol** 1996 Feb; 110(2):483-91

In vitro and in vivo comparative studies on chelation of aluminum by some polyaminocarboxylic acids. Graff L, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jun; 88(3):271-92

Evaluation of the effect of zinc acetate on the stratum corneum penetration kinetics of erythromycin in healthy male volunteers. van Hoogdalem EJ, et al. **Skin Pharmacol** 1996;9(2):104-10

[Antineurotic effect of the hydrazide of O-B-chloroethyl-para-N-dimethylaminophenylphosphinylacetic acid (amfazide)] Semin II, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):423-5 **(Rus)**

POISONING

Accidental fatal monochloroacetic acid poisoning. Rogers DR. **Am J Forensic Med Pathol** 1995 Jun;16(2):115-6

Gabapentin, valproic acid, and ethanol intoxication: elevated blood levels with mild clinical effects. Fernández MC, et al. **J Toxicol Clin Toxicol** 1996;34(4):437-9

ACETIC ACIDS

RADIATION EFFECTS

Laser photolysis of caged calcium: rates of calcium release by nitrophenyl-EGTA and DM-nitrophen. Ellis-Davies GC, et al. **Biophys J** 1996 Feb;70(2):1006-16

Electrical currents generated by a partially purified Na/Ca exchanger from lobster muscle reconstituted into liposomes and adsorbed on black lipid membranes: activation by photolysis of Ca2+. Eisenrauch A, et al. **J Membr Biol** 1995 May;145(2):151-64

THERAPEUTIC USE

Gabapentin in refractory partial epilepsy--a trial in India. Dixit SN, et al. **Acta Neurol Scand** 1996 Feb-Mar; 93(2-3):85-7

Postpoliomyelitis pain treated with gabapentin [letter] Zapp JJ. **Am Fam Physician** 1996 Jun;53(8):2442, 2445

Potential use of gabapentin and lamotrigine. Cory PR, et al. **Ann Pharmacother** 1995 Nov;29(11):1160-1 (10 ref.)

Weight gain and gabapentin therapy [letter] Gidal BE, et al. **Ann Pharmacother** 1995 Oct;29(10):1048

Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis. Welty DF, et al. **Ann Pharmacother** 1995 Nov;29(11):1164-7

Reduction of fasciculations in patients with amyotrophic lateral sclerosis with the use of gabapentin [letter] Romano JG. **Arch Neurol** 1996 Aug;53(8):716

Gabapentin adjunctive therapy in neuropathic pain states. Rosner H, et al. **Clin J Pain** 1996 Mar;12(1):56-8

Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Janssen MJ, et al. **Clin Nephrol** 1996 Feb;45(2):111-9

Gabapentin for the treatment of hemifacial spasm. Patel J, et al. **Clin Neuropharmacol** 1996 Apr;19(2):185-8

Efficacy and tolerability of gabapentin in clinical practice. Morris GL 3rd. **Clin Ther** 1995 Sep-Oct;17(5):891-900

Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs. French JA. **Epilepsia** 1996;37 Suppl 2:S23-S26

Gabapentin. McLean MJ. **Epilepsia** 1995;36 Suppl 2:S73-86 (70 ref.)

A double-blind controlled evaluation of the sebosuppressive activity of topical erythromycin-zinc complex. Piérard-Franchimont C, et al. **Eur J Clin Pharmacol** 1995; 49(1-2):57-60

Gabapentin for seizure control in organ transplant recipients [letter] Warner EG. **J Heart Lung Transplant** 1995 Sep-Oct;14(5):1011

Efficacy of gabapentin therapy in children with refractory partial seizures. Khurana DS, et al. **J Pediatr** 1996 Jun; 128(6):829-33

Restless legs syndrome [letter] Cochran JW, et al. **JAMA** 1996 Jan 17;275(3):187

Epilepsy in porphyria [letter; comment] Reynolds NC Jr. **Neurology** 1996 May;46(5):1497-8. Comment on: Neurology 1995 Mar;45(3 Pt 1):594-5. Comment on: Neurology 1995 Jun;45(6):1216-7.

Hypertonic sodium acetate treatment of hemorrhagic shock in awake rats. Krausz MM, et al. **Shock** 1995 Jul;4(1):56-60

[New medical treatment of epilepsy (editorial)] Loiseau P. **Presse Med** 1996 Mar 23;25(10):481-3 (Eng. Abstr.) **(Fre)**

[Gabapentin (Neurontin): a new possibility in the add-on therapy of partial epilepsies] Krämer G. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):84-93 (106 ref.) (Eng. Abstr.) **(Ger)**

[Recommendations on clinical epilepsy treatment using gabapentin] Krämer G, et al. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):99-101 (Eng. Abstr.) **(Ger)**

[Clinical studies on gabapentin in Switzerland] Shokry A. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):94-8 (Eng. Abstr.) **(Ger)**

[Gabapentin--a new add-on antiepileptic drug (editorial)] Vassella F. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):73 **(Ger)**

[Refractory epilepsy in adults and the new antiepileptic drugs: the role of gabapentin] Galdames D, et al. **Rev Med Chil** 1995 Apr;123(4):500-8 (34 ref.) (Eng. Abstr.) **(Spa)**

[Advances in the diagnostic and treatment of infantile epilepsy] Legido A. **Rev Neurol** 1996 Jun;24(130):688-93 (25 ref.) **(Spa)**

TOXICITY

Cytoxicity of [(5,6-dichloro-9a-n-propyl-2,3,9,9a-tetrahydro-3-oxo-1H fluoren-7-yl)oxy]acetic acid, an agent known to reduce brain edema. Hall IH, et al. **Biomed Pharmacother** 1996; 50(1):19-23

Dibromoacetic acid affects reproductive competence and sperm quality in the male rat. Linder RE, et al. **Fundam Appl Toxicol** 1995 Nov;28(1):9-17

Acute pancreatitis after ingestion of acetic acid [letter] Bergenfeldt M, et al. **Pancreas** 1996 Mar;12(2):207-9

Physiologically based pharmacokinetics of methoxyacetic acid: dose-effect considerations in C57BL/6 mice. O'Flaherty EJ, et al. **Teratology** 1995 Aug;52(2):78-89

Repeated high dose oral exposure or continuous subcutaneous infusion of 2-methoxyacetic acid does not suppress humoral immunity in the mouse. Riddle MM, et al. **Toxicology** 1996 May 3;109(1):67-74

ACETIC ANHYDRIDES

Facilitation of thin-layer chromatographic identification of opiates by derivatization with acetic anhydride or methoxyamine. Dietzen DJ, et al. **J Anal Toxicol** 1995 Sep; 19(5):299-303

ACETOACETATES

BLOOD

Determination of lactate, pyruvate, beta-hydroxybutyrate and acetoacetate with a centrifugal analyser. Artuch R, et al. **Eur J Clin Chem Clin Biochem** 1995 Aug;33(8):529-33

PHARMACOKINETICS

Substrate selection in the isolated working rat heart: effects of reperfusion, afterload, and concentration. Jeffrey FM, et al. **Basic Res Cardiol** 1995 Sep-Oct;90(5):388-96

ACETOACETYL COA THIOLASE see **ACETYL-COA ACETYLTRANSFERASE**

ACETOBACTER

ENZYMOLOGY

Cloning and nucleotide sequencing of the membrane-bound L-sorbosone dehydrogenase gene of Acetobacter liquefaciens IFO 12258 and its expression in Gluconobacter oxydans. Shinjoh M, et al. **Appl Environ Microbiol** 1995 Feb;61(2):413-20

Isolation and nucleotide sequence of the GDP-mannose:cellobiosyl-diphosphopolyprenol alpha-mannosyltransferase gene from Acetobacter xylinum. Petroni EA, et al. **J Bacteriol** 1996 Aug; 178(16):4814-21

Function of multiple heme c moieties in intramolecular electron transport and ubiquinone reduction in the quinohemoprotein alcohol dehydrogenase-cytochrome c complex of Gluconobacter suboxydans. Matsushita K, et al. **J Biol Chem** 1996 Mar 1;271(9):4850-7

GENETICS

Cloning and nucleotide sequencing of the membrane-bound L-sorbosone dehydrogenase gene of Acetobacter liquefaciens IFO 12258 and its expression in Gluconobacter oxydans. Shinjoh M, et al. **Appl Environ Microbiol** 1995 Feb;61(2):413-20

16S-23S ribosomal RNA spacer regions of Acetobacter europaeus and A. xylinum, tRNA genes and antitermination sequences. Sievers M, et al. **FEMS Microbiol Lett** 1996 Aug 15;142(1):43-8

Isolation and nucleotide sequence of the GDP-mannose:cellobiosyl-diphosphopolyprenol alpha-mannosyltransferase gene from Acetobacter xylinum. Petroni EA, et al. **J Bacteriol** 1996 Aug; 178(16):4814-21

Molecular characterization of the levansucrase gene from the endophytic sugarcane bacterium Acetobacter diazotrophicus SRT4. Arrieta J, et al. **Microbiology** 1996 May;142 (Pt 5):1077-85

ACETOBACTERACEAE

[Determination of glucose concentration in human blood serum using a microbial biosensor] Reshetilov AN, et al. **Biull Eksp Biol Med** 1995 Aug;120(8):218-21 **(Rus)**

[Sensor for rapid measurement of blood glucose] Reshetilov AN, et al. **Klin Lab Diagn** 1996 Mar-Apr;(2):26-9 (Eng. Abstr.) **(Rus)**

CYTOLOGY

FET-microbial sensor for xylose detection based on Gluconobacter oxydans cells. Reshetilov AN, et al. **Biosens Bioelectron** 1996;11(4):401-8

ENZYMOLOGY

Generation mechanism and purification of an inactive form convertible in vivo to the active form of quinoprotein alcohol dehydrogenase in Gluconobacter suboxydans. Matsushita K, et al. **J Bacteriol** 1995 Nov;177(22):6552-9

Function of multiple heme c moieties in intramolecular electron transport and ubiquinone reduction in the quinohemoprotein alcohol dehydrogenase-cytochrome c complex of Gluconobacter suboxydans. Matsushita K, et al. **J Biol Chem** 1996 Mar 1;271(9):4850-7

GENETICS

Cloning and nucleotide sequencing of the membrane-bound L-sorbosone dehydrogenase gene of Acetobacter liquefaciens IFO 12258 and its expression in Gluconobacter oxydans. Shinjoh M, et al. **Appl Environ Microbiol** 1995 Feb;61(2):413-20

ACETOHEXAMIDE

METABOLISM

Purification and catalytic properties of a novel acetohexamide-reducing enzyme from rabbit heart. Imamura Y, et al. **J Biochem (Tokyo)** 1996 Apr; 119(4):648-52

ACETOHYDROXY ACID SYNTHASE see **ACETOLACTATE SYNTHASE**

ACETOHYDROXY ACID SYNTHETASE see **ACETOLACTATE SYNTHASE**

ACETOLACTATE SYNTHASE

BIOSYNTHESIS

Metabolic engineering of Lactococcus lactis: influence of the overproduction of alpha-acetolactate synthase in strains deficient in lactate dehydrogenase as a function of culture conditions. Platteeuw C, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3967-71

GENETICS

Cloning, sequencing and expression of the ilvBNC gene cluster from Streptomyces avermitilis. De Rossi E, et al. **Gene** 1995 Dec 1;166(1):127-32

A naturally occurring point mutation confers broad range tolerance to herbicides that target acetolactate synthase. Bernasconi P, et al. **J Biol Chem** 1996 Jun 7;271(23):13925

A single amino acid change in acetolactate synthase confers resistance to valine in tobacco. Hervieu F, et al. **Mol Gen Genet** 1996 May 23;251(2):220-4

METABOLISM

Isolation and characterization of subunits of acetohydroxy acid synthase isozyme III and reconstitution of the holoenzyme. Vyazmensky M, et al. **Biochemistry** 1996 Aug 13;35(32):10339-46

End-product control of enzymes of branched-chain amino acid biosynthesis in Streptomyces coelicolor. Potter CA, et al. **Microbiology** 1996 Aug;142 (Pt 8):1945-52

ACETOLACTATE SYNTHETASE see **ACETOLACTATE SYNTHASE**

ACETONE

Modification of AOAC multiresidue method for determination of synthetic pyrethroid residues in fruits, vegetables, and grains. Part II: Acetone extraction system. Pang GF, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1489-96

ADMINISTRATION & DOSAGE

Removal of superglue from the external ear using acetone: case report and literature review. Abadir WF, et al. **J Laryngol Otol** 1995 Dec;109(12):1219-21 (5 ref.)

ADVERSE EFFECTS

[Interference of acetone in styrene metabolism in subjects exposed to both solvents] De Rosa E, et al. **G Ital Med Lav** 1994 Jan-Nov;16(1-6):43-7 (Eng. Abstr.) **(Ita)**

ANALOGS & DERIVATIVES

New trifluoromethyl ketones as potent inhibitors of esterases: 19F NMR spectroscopy of transition state analog complexes and structure-activity relationships. Rosell G, et al. **Biochem Biophys Res Commun** 1996 Sep 4; 226(1):287-92

Inhibition of glyceraldehyde 3-phosphate dehydrogenase in boar spermatozoa by bromohydroxypropanone. Porter LM, et al. **Reprod Fertil Dev** 1995;7(1):107-11

Toxicity of field bindweed (Convolvulus arvensis) to mice. Schultheiss PC, et al. **Vet Hum Toxicol** 1995 Oct; 37(5):452-4

ANALYSIS

Breath acetone in congestive heart failure. Kupari M, et al. **Am J Cardiol** 1995 Nov 15;76(14):1076-8

Accumulation of foreign gases during closed-system anaesthesia. Versichelen L, et al. **Br J Anaesth** 1996 May; 76(5):668-72

Behaviour of urinary 2,5-hexanedione in occupational co-exposure to n-hexane and acetone. Cardona A, et al. **Int Arch Occup Environ Health** 1996;68(2):88-93

Evaluation of additional acetone and urea analyses, and of the fat-lactose-quotient in cow milk samples in the herd recording system in Norway. Steen A, et al. **Zentralbl Veterinarmed A** 1996 May;43(3):181-91

METABOLISM

Involvement of an ATP-dependent carboxylase in a CO2-dependent pathway of acetone metabolism by Xanthobacter strain Py2. Sluis MK, et al. **J Bacteriol** 1996 Jul;178(14):4020-6

Biotransformation of acetone to isopropanol observed in a motorist involved in a sobriety check. Jones AW, et al. **J Forensic Sci** 1995 Jul;40(4):686-7

PHARMACOKINETICS

Inter-individual variability in blood/air partitioning of volatile organic compounds and correlation with blood

chemistry. Dills RL, et al.
J Expo Anal Environ Epidemiol 1994 Apr-Jun;4(2):229-45

PHARMACOLOGY

Cutaneous permeability barrier repair following various types of insults: kinetics and effects of occlusion. Taljebini M, et al. **Skin Pharmacol** 1996;9(2):111-9

ACETONE BODIES see KETONE BODIES

ACETONITRILES

Capillary electrophoresis of heparin and dermatan sulfate unsaturated disaccharides with triethylamine and acetonitrile as electrolyte additives. Scapol L, et al.
J Chromatogr A 1996 May 31;735(1-2):367-74

ISOLATION & PURIFICATION

Cytotoxicity and mode of action of aeroplysinin-1 and a related dienonefrom the sponge Aplysina aerophoba. Koulman A, et al. **J Nat Prod** 1996 Jun;59(6):591-4

PHARMACOLOGY

Effect of organic modifier concentrations on electrokinetic migrations in micellar electrokinetic chromatography. Chen N, et al. **Electrophoresis** 1995 Aug;16(8):1457-62

Influence of long-term simmondsin administration on thyroid hormone levels in adult rats. Cokelaere M, et al.
Horm Metab Res 1995 Jul;27(7):318-21

Devazepide reverses the anorexic effect of simmondsin in the rat. Cokelaere MM, et al. **J Endocrinol** 1995 Dec; 147(3):473-7

TOXICITY

Chronic toxicity of acrylonitrile and acetonitrile to Daphnia magna in 14-d and 21-d toxicity tests. Tong Z, et al.
Bull Environ Contam Toxicol 1996 Oct;57(4):655-9

Developmental effects of trichloroacetonitrile administered in corn oil to pregnant Long-Evans rats. Christ SA, et al. **J Toxicol Environ Health** 1996 Feb 23;47(3):233-47

ACETOPHENETIDIN see PHENACETIN

ACETOPHENONES

ANALYSIS

[Determination of paeonol in carbonized bark of Paeonia suffruticosa Andr. by HPLC] Ding A, et al.
Chung Kuo Chung Yao Tsa Chih 1996 Jan;21(1):23-4, 63 (Eng. Abstr.) **(Chi)**

PHARMACOKINETICS

Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery. Dow J, et al.
Arzneimittelforschung 1995 Dec;45(12):1245-52

PHARMACOLOGY

Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery. Dow J, et al.
Arzneimittelforschung 1995 Dec;45(12):1245-52

Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. Endoh T, et al. **Carcinogenesis** 1996 Mar; 17(3):467-75

Antinociceptive action of 2-(4-bromobenzoyl)-3-methyl-4,6-dimethoxy benzofuran, a novel xanthoxyline derivative on chemical and thermal models of nociception in mice. Vaz ZR, et al.
J Pharmacol Exp Ther 1996 Jul;278(1):304-12

Effect of acetosyringone on growth and oncogenic potential of Agrobacterium tumefaciens. Dion P, et al.
Methods Mol Biol 1995;44:37-45

Maternal ingestion of ortho-aminoacetophenone during gestation affects intake by offspring. Nolte DL, et al.
Physiol Behav 1995 Nov;58(5):925-8

The influence of an PGF2x analogue and of some peptidoleukotrienes and platelet activating factor antagonists in experimentally induced gastric ulcer in rats. Nechifor M, et al. **Rom J Physiol** 1993 Jul-Dec; 30(3-4):155-9

THERAPEUTIC USE

Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. Staszewski S, et al. **AIDS** 1996 May;10(5):F1-7

[Therapeutical mechanism of 3,4 dihydroxyacetophenone in treating chronic obstructive pulmonary disease] Lin C, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Apr; 18(2):97-8, 128 (Eng. Abstr.) **(Chi)**

TOXICITY

The effects of peroxisome proliferators on protein abundances in mouse liver. Anderson NL, et al.
Toxicol Appl Pharmacol 1996 Mar;137(1):75-89

ACETOPROMAZINE see ACEPROMAZINE

ACETOXYACETAMIDOFLUORENE see ACETOXYACETYLAMINOFLUORENE

ACETOXYACETYLAMINOFLUORENE

PHARMACOLOGY

Mutagenic synergy between paraoxon and plant-activated m-phenylenediamine or 2-acetoxyacetylaminofluorene. Gichner T, et al. **Environ Mol Mutagen** 1996;27(1):59-66

TOXICITY

Programmed cell death and N-acetoxy-2-acetylaminofluorene-induced apoptosis in the rat embryo. Thayer JM, et al. **Teratology** 1995 Jun; 51(6):418-29

ACETOXYFLUORENYLACETAMIDE see ACETOXYACETYLAMINOFLUORENE

ACETOXYPHENYLMERCURY see PHENYLMERCURIC ACETATE

ACETYL ACTIVATING ENZYME see ACETATE-COA LIGASE

N-ACETYL-BETA-D-GLUCOSAMINIDASE see ACETYLGLUCOSAMINIDASE

ACETYL CARNITINE see ACETYLCARNITINE

ACETYL COA see ACETYL COENZYME A

ACETYL-COA ACETYLTRANSFERASE

ANALYSIS

Localization of peroxisomal 3-oxoacyl-CoA thiolase in particles of varied density in rat liver: implications for peroxisome biogenesis. van Roermund CW, et al.
Biochim Biophys Acta 1995 Dec 14;1245(3):348-58

BIOSYNTHESIS

Differential induction of peroxisomal enzymes by hypolipidaemics in human (HepG2) and rat (MH1C1) hepatoma cell lines. Stangl H, et al.
Eur J Clin Chem Clin Biochem 1995 Nov;33(11):775-83

GENETICS

Comparative genome mapping of the ataxia-telangiectasia region in mouse, rat, and Syrian hamster. Matsuda Y, et al. **Genomics** 1996 Jun 15;34(3):347-52

Cloning of a cDNA encoding cytosolic acetoacetyl-coenzyme A thiolase from radish by functional expression in Saccharomyces cerevisiae. Vollack KU, et al. **Plant Physiol** 1996 Aug;111(4):1097-107

METABOLISM

Peb1p (Pas7p) is an intraperoxisomal receptor for the NH2-terminal, type 2, peroxisomal targeting sequence of thiolase: Peb1p itself is targeted to peroxisomes by an NH2-terminal peptide. Zhang JW, et al. **J Cell Biol** 1996 Feb;132(3):325-34

ACETYL COA ACYLTRANSFERASE

DEFICIENCY

Metabolic coma with ketoacidosis and hyperglycaemia in 2-methylacetoacetyl-CoA thiolase deficiency. Riudor E, et al. **J Inherit Metab Dis** 1995;18(6):748-9

[Ketoacidotic coma in an infant as the form of onset of a mitochondrial 2-methylacetoacetyl-CoA thiolase deficiency] Yeste Fernández D, et al. **An Esp Pediatr** 1996 Jun;44(6):620-2 (9 ref.) **(Spa)**

GENETICS

Analysis of beta-ketothiolase and acetoacetyl-CoA reductase genes of a methylotrophic bacterium, Paracoccus denitrificans, and their expression in Escherichia coli. Yabutani T, et al. **FEMS Microbiol Lett** 1995 Nov 1; 133(1-2):85-90

Repression of 4-hydroxybenzoate transport and degradation by benzoate: a new layer of regulatory control in the Pseudomonas putida beta-ketoadipate pathway. Nichols NN, et al. **J Bacteriol** 1995 Dec;177(24):7033-40

METABOLISM

Histidine-450 is the catalytic residue of L-3-hydroxyacyl coenzyme A dehydrogenase associated with the large alpha-subunit of the multienzyme complex of fatty acid oxidation from Escherichia coli. He XY, et al.
Biochemistry 1996 Jul 23;35(29):9625-30

ACETYL-COA CARBOXYLASE

ANTAGONISTS & INHIBITORS

Characterization of 5'AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Kudo N, et al. **Biochim Biophys Acta** 1996 May 31; 1301(1-2):67-75

BIOSYNTHESIS

Identification of a second human acetyl-CoA carboxylase gene. Widmer J, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):915-22

Obese gene expression alters the ability of 30A5 preadipocytes to respond to lipogenic hormones. Bai Y, et al. **J Biol Chem** 1996 Jun 14;271(24):13939-42

Dephosphorylation of Sp1 by protein phosphatase 1 is involved in the glucose-mediated activation of the acetyl-CoA carboxylase gene. Daniel S, et al.
J Biol Chem 1996 Jun 21;271(25):14692-7

Sp1 mediates glucose activation of the acetyl-CoA carboxylase promoter. Daniel S, et al. **J Biol Chem** 1996 Jan 19;271(3):1385-92

Molecular cloning and characterization of the cDNA coding for the biotin-containing subunit of the chloroplastic acetyl-coenzyme A carboxylase. Choi JK, et al.
Plant Physiol 1995 Oct;109(2):619-25

Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid. Lopez JM, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):1049-53

CHEMISTRY

Purification and characterization of intact and truncated forms of the Escherichia coli biotin carboxyl carrier subunit of acetyl-CoA carboxylase. Nenortas E, et al.
J Biol Chem 1996 Mar 29;271(13):7559-67

Molecular cloning and characterization of the cDNA coding for the biotin-containing subunit of the chloroplastic acetyl-coenzyme A carboxylase. Choi JK, et al.
Plant Physiol 1995 Oct;109(2):619-25

Structure of the biotinyl domain of acetyl-coenzyme A carboxylase determined by MAD phasing. Athappilly FK, et al. **Structure** 1995 Dec 15;3(12):1407-19

GENETICS

Promoter usage determines tissue specific responsiveness of the rat acetyl-CoA carboxylase gene. Kim TS, et al.
Biochem Biophys Res Commun 1996 Aug 14;225(2):647-53

Biotin carboxyl carrier protein and carboxyltransferase subunits of the multi-subunit form of acetyl-CoA carboxylase from Brassica napus: cloning and analysis of expression during oilseed rape embryogenesis. Elborough KM, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):103-12

Cloning and characterization of the 5' end and promoter region of the chicken acetyl-CoA carboxylase gene. El Khadir-Mounier C, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):613-9

Identification of a second human acetyl-CoA carboxylase gene. Widmer J, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):915-22

The genes encoding the biotin carboxyl carrier protein and biotin carboxylase subunits of Bacillus subtilis acetyl coenzyme A carboxylase, the first enzyme of fatty acid synthesis. Marini P, et al. **J Bacteriol** 1995 Dec; 177(23):7003-6

Sp1 mediates glucose activation of the acetyl-CoA carboxylase promoter. Daniel S, et al. **J Biol Chem** 1996 Jan 19;271(3):1385-92

Soybean protein suppresses hepatic lipogenic enzyme gene expression in Wistar fatty rats. Iritani N, et al. **J Nutr** 1996 Feb;126(2):380-8

The ACC1 gene, encoding acetyl-CoA carboxylase, is essential for growth in Ustilago maydis. Bailey A, et al.
Mol Gen Genet 1995 Nov 15;249(2):191-201

Genomic organization of 251 kDa acetyl-CoA carboxylase genes in Arabidopsis: tandem gene duplication has made two differentially expressed isozymes. Yanai Y, et al.
Plant Cell Physiol 1995 Jul;36(5):779-87

Structure of a gene encoding a cytosolic acetyl-CoA carboxylase of hexaploid wheat. Podkowinski J, et al.
Proc Natl Acad Sci U S A 1996 Mar 5;93(5):1870-4

Mapping of the ACC1/FAS3 gene to the right arm of chromosome XIV of Saccharomyces cerevisiae. Guerra CE, et al. **Yeast** 1995 Jun 15;11(7):697-700

METABOLISM

Acetyl coenzyme A carboxylase activity in neonatal rat cardiac myocytes in culture: citrate dependence and effects of hypoxia. Wang D, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):249-55

Activation of hepatic acetyl-CoA carboxylase by glutamate and Mg2+ is mediated by protein phosphatase-2A. Gaussin V, et al. **Biochem J** 1996 May 15;316 (Pt 1):217-24

Effects of acute exercise on hepatic lipogenic enzymes in fasted and refed rats. Griffiths MA, et al.
J Appl Physiol 1995 Sep;79(3):879-85

ACETYL-COA CARBOXYLASE

Protein kinase signaling pathway triggered by cell swelling and involved in the activation of glycogen synthase and acetyl-CoA carboxylase in isolated rat hepatocytes. Krause U, et al. **J Biol Chem** 1996 Jul 12;271(28):16668-73

Purification and characterization of intact and truncated forms of the Escherichia coli biotin carboxyl carrier subunit of acetyl-CoA carboxylase. Nenortas E, et al. **J Biol Chem** 1996 Mar 29;271(13):7559-67

Aberrant mitosis in fission yeast mutants defective in fatty acid synthetase and acetyl CoA carboxylase. Saitoh S, et al. **J Cell Biol** 1996 Aug;134(4):949-61

Glucose activation of acetyl-CoA carboxylase in association with insulin secretion in a pancreatic beta-cell line. Zhang S, et al. **J Endocrinol** 1995 Oct;147(1):33-41

Acetyl-CoA carboxylase activity in Helicobacter pylori and the requirement of increased CO2 for growth. Burns BP, et al. **Microbiology** 1995 Dec;141 (Pt 12):3113-8

Acetyl-CoA carboxylase in higher plants: most plants other than gramineae have both the prokaryotic and the eukaryotic forms of this enzyme. Konishi T, et al. **Plant Cell Physiol** 1996 Mar;37(2):117-22

ACETYL COA SYNTHETASE see **ACETATE-COA LIGASE**

ACETYL COENZYME A

BIOSYNTHESIS

A methylnickel intermediate in a bimetallic mechanism of acetyl-coenzyme A synthesis by anaerobic bacteria [see comments] Kumar M, et al. **Science** 1995 Oct 27; 270(5236):628-30. Comment in: Science 1995 Oct 27;270(5236):587-8.

CHEMISTRY

Reactivity of a paramagnetic enzyme--CO adduct in acetyl-CoA synthesis and cleavage. Grahame DA, et al. **Biochemistry** 1996 Jan 16;35(2):593-600

alpha-Fluoro acid and alpha-fluoro amide analogs of acetyl-CoA as inhibitors of citrate synthase: effect of pKa matching on binding affinity and hydrogen bond length. Schwartz B, et al. **Biochemistry** 1995 Nov 28; 34(47):15459-66

A conformational change in the methyltransferase from Clostridium thermoaceticum facilitates the methyl transfer from (6S)-methyltetrahydrofolate to the corrinoid/iron-sulfur protein in the Acetyl-CoA pathway. Zhao S, et al. **Biochemistry** 1996 Feb 20;35(7):2476-81

Kinetics of acetyl coenzyme A:arylamine N-acetyltransferase from rapid and slow acetylator frog tissues. Ho CC, et al. **Drug Metab Dispos** 1996 Feb;24(2):137-41

METABOLISM

Disturbances of acetyl-CoA, energy and acetylcholine metabolism in some encephalopathies. Szutowicz A, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):323-39 (110 ref.)

Effect of NADPH-associated keto-reducing domain on substrate entry into 6-hydroxymellein synthase, a multifunctional polyketide synthetic enzyme involved in phytoalexin biosynthesis in carrot. Kurosaki F. **Arch Biochem Biophys** 1996 Apr 1;328(1):213-7

Reactivity of a paramagnetic enzyme--CO adduct in acetyl-CoA synthesis and cleavage. Grahame DA, et al. **Biochemistry** 1996 Jan 16;35(2):593-600

RGFGIGS is an amino acid sequence required for acetyl coenzyme A binding and activity of human spermidine/spermine N1acetyltransferase. Lu L, et al. **J Biol Chem** 1996 Aug 2;271(31):18920-4

Hypothesis on cellular ATP depletion and adenosine release as causes of heart failure and vasodilatation in cardiovascular beriberi. Bakker SJ, et al. **Med Hypotheses** 1995 Sep;45(3):265-7

Molecular characterization of a chromosomal region involved in the oxidation of acetyl-CoA to glyoxylate in the isocitrate-lyase-negative methylotroph Methylobacterium extorquens AM1. Chistoserdova LV, et al. **Microbiology** 1996 Jun;142 (Pt 6):1459-68

Acetyl-CoA-dependent pyruvate carboxylase from the photosynthetic bacterium Rhodobacter capsulatus: rapid and efficient purification using dye-ligand affinity chromatography. Modak HV, et al. **Microbiology** 1995 Oct; 141 (Pt 10):2619-28

PHARMACOLOGY

Effects of acetyl CoA on the pre-steady-state kinetics of the biotin carboxylation reaction of pyruvate carboxylase. Legge GB, et al. **Biochemistry** 1996 Mar 26;35(12):3849-56

Effects of added l-carnitine, acetyl-CoA and CoA on peroxisomal beta-oxidation of [U-14C]hexadecanoate by isolated peroxisomal fractions. Sleboda J, et al. **Biochim Biophys Acta** 1995 Oct 5;1258(3):309-18

ACETYL COENZYME A ACETYLTRANSFERASE see **ACETYL-COA ACETYLTRANSFERASE**

ACETYL COENZYME A ACYLTRANSFERASE see **ACETYL COA ACYLTRANSFERASE**

ACETYL COENZYME A CARBOXYLASE see **ACETYL-COA CARBOXYLASE**

ACETYL GLYCERYL ETHER PHOSPHORYLCHOLINE see **PLATELET ACTIVATING FACTOR**

ACETYL HYDROPEROXIDE see **PERACETIC ACID**

2-ACETYLAMINOFLUORENE

ANALOGS & DERIVATIVES

Blast-like cell compartment in carcinogen-induced proliferating bile ductules. Novikoff PM, et al. **Am J Pathol** 1996 May;148(5):1473-92

Solution conformation of the N-(deoxyguanosin-8-yl)aminofluorene adduct opposite deoxyinosine and deoxyguanosine in DNA by NMR and computational characterization. Abuaf P, et al. **Chem Res Toxicol** 1995 Apr-May:8(3):369-78

IMMUNOLOGY

Selective induction of mucosal immune responses to 2-acetylaminofluorene. Silbart LK, et al. **Anticancer Res** 1996 Mar-Apr;16(2):651-60

PHARMACOLOGY

Down-regulation of protein kinase C in murine splenocytes: a potential mechanism for 2-acetylaminofluorene-mediated immunosuppression. Lee M, et al. **Cancer Lett** 1996 Mar 19;101(1):53-7

Oval cell differentiation into hepatocytes in the acetylaminofluorene-treated regenerating rat liver. Golding M, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1243-53

Sequence determinants for -2 frameshift mutagenesis at NarI-derived hot spots. Koffel-Schwartz N, et al. **J Mol Biol** 1995 Oct 6;252(5):507-13

TOXICITY

Early initiating and promoting effects in 2-AAF-induced rat liver carcinogenesis: an immunohistochemical study. Hadjiolov N, et al. **Cancer Lett** 1995 Nov 27;98(1):39-46

Influence of liver tumor promoters on apoptosis in rat hepatocytes induced by 2-acetylaminofluorene, ultraviolet light, or transforming growth factor beta 1. Worner W, et al. **Cancer Res** 1996 Mar 15;56(6):1272-8

Differential regulation of mdr genes in response to 2-acetylaminofluorene treatment in cultured rat and human hepatocytes. Lecureur V, et al. **Carcinogenesis** 1996 May; 17(5):1157-60

The BN rat strain carries dominant hepatocarcinogen resistance loci. Pascale RM, et al. **Carcinogenesis** 1996 Aug; 17(8):1765-8

Repair of DNA lesions induced by ultraviolet irradiation and aromatic amines in normal and repair-deficient human lymphoblastoid cell lines. Stevnsner T, et al. **Carcinogenesis** 1995 Nov;16(11):2855-8

Induction of humoral immunity toward 2-acetylaminofluorene in mice: modulation of DNA binding after 4 weeks dietary exposure to the carcinogen. Verdina A, et al. **Carcinogenesis** 1996 Aug;17(8):1705-9

NMR data show that the carcinogen N-2-acetylaminofluorene stabilises an intermediate of -2 frameshift mutagenesis in a region of high mutation frequency. Milhé C, et al. **Eur J Biochem** 1996 Jan 15; 235(1-2):120-7

In vivo infusion of growth factors enhances the mitogenic response of rat hepatic ductal (oval) cells after administration of 2-acetylaminofluorene. Nagy P, et al. **Hepatology** 1996 Jan;23(1):71-9

Effects of aminofluorene and acetylaminofluorene DNA adducts on transcriptional elongation by RNA polymerase II. Donahue BA, et al. **J Biol Chem** 1996 May 3; 271(18):10588-94

Mutagenic activation of aromatic amines by a human hepatoma cell (Hep G2) supernatant tested by means of Salmonella typhimurium strains with different acetyltransferase activities. Duverger-van Bogaert M, et al. **Mutat Res** 1995 Dec;335(3):219-27

Use of precision-cut liver slices to evaluate species differences in 2-acetylaminofluorene-induced unscheduled DNA synthesis. Lake BG, et al. **Toxicol Appl Pharmacol** 1996 Jun;138(2):231-41

Relationship of DNA adducts derived from 2-acetylaminofluorene to cell proliferation and the induction of rodent liver and bladder tumors. Cohen SM, et al. **Toxicol Pathol** 1995 Mar-Apr;23(2):136-42 (21 ref.)

ACETYLASE see **ACETYLESTERASE**

ACETYLATION

Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9). De Leon JH, et al. **Drug Metab Dispos** 1995 Dec;23(12):1354-61

ACETYLBENZOYLACONINE see **ACONITINE**

ACETYLCARNITINE

ADMINISTRATION & DOSAGE

Brain enzyme activities after intracerebroventricular injection of streptozotocin in rats receiving acetyl-L-carnitine. Terwel D, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):65-71

ANALYSIS

Quantification of carnitine, acetylcarnitine, and total carnitine in tissues by high-performance liquid chromatography: the effect of exercise on carnitine homeostasis in man. Minkler PE, et al. **Anal Biochem** 1995 Nov 1;231(2):315-22

Tissue acylcarnitine and acyl-coenzyme A profiles in chronically hyperammonemic mice treated with sodium benzoate and supplementary L-carnitine. Michalak A, et al. **Biomed Pharmacother** 1995;49(7-8):350-7

BLOOD

Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Rashed MS, et al. **Pediatr Res** 1995 Sep;38(3):324-31

DEFICIENCY

Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K-ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat. Stevens MJ, et al. **Metabolism** 1996 Jul;45(7):865-72

METABOLISM

Reye syndrome model in rats: protection against liver abnormalities by L-carnitine and acetyl-L-carnitine. Visentin M, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):1069-75

Prenatal diagnosis of organic acidemias based on amniotic fluid levels of acylcarnitines. Shigematsu Y, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):680-4

PHARMACOKINETICS

Disposition of L-carnitine and acetyl-L-carnitine in the isolated perfused rat kidney. Mancinelli A, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1122-8

PHARMACOLOGY

Alterations of the thalamo-cortical system in rats prenatally exposed to ethanol are prevented by concurrent administration of acetyl-L-carnitine. Santarelli M, et al. **Brain Res** 1995 Nov 6;698(1-2):241-7

Effect of intraventricular injection of 1-methyl-4-phenylpyridinium: protection by acetyl-L-carnitine. Steffen V, et al. **Hum Exp Toxicol** 1995 Nov;14(11):865-71

The aging process of skin and the increase in size of subcutaneous adipocytes. Baldassarri P, et al. **Int J Tissue React** 1994;16(5-6):229-41

Age- and trauma-dependent modifications of neuromuscular junction and skeletal muscle structure in the rat. Effects of long-term treatment with Acetyl-L-Carnitine. De Angelis C, et al. **Mech Ageing Dev** 1995 Nov 3;85(1):37-53

Carnitine-acylcarnitine translocase activity in cardiac mitochondria from aged rats: the effect of acetyl-L-carnitine. Paradies G, et al. **Mech Ageing Dev** 1995 Oct 13;84(2):103-12

The effects of acetyl-L-carnitine and sorbinil on peripheral nerve structure, chemistry, and function in experimental diabetes. Malone JI, et al. **Metabolism** 1996 Jul;45(7):902-7

Acetyl-L-carnitine attenuates neuronal damage in gerbils with transient forebrain ischemia only when given before the insult. Shuaib A, et al. **Neurochem Res** 1995 Sep; 20(9):1021-5

Effects of levo-acetylcarnitine on second motoneuron survival after axotomy. Fernandez E, et al. **Neurol Res** 1995 Oct;17(5):373-6

THERAPEUTIC USE

L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain. Onofrj M, et al. **Int J Clin Pharmacol Res** 1995;15(1):9-15

Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. Sima AA, et al. **J Clin Invest** 1996 Apr 15;97(8):1900-7

ACETYLCHOLINE

see related
CHOLINERGIC AGENTS
RECEPTORS, CHOLINERGIC

Differential regulation of neuronal nicotinic acetylcholine receptor subunit gene promoters by Brn-3 POU family transcription factors. Milton NG, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):419-23

Expression of a human insulin transgene in cholinergic neurons of the mouse medial habenula. Douhet P, et al. **Biol Cell** 1995;85(2-3):137-46

The emerging three-dimensional structure of a receptor. The nicotinic acetylcholine receptor. Hucho F, et al. **Eur J Biochem** 1996 Aug 1;239(3):539-57 (180 ref.)

Improvement of coronary vasomotion with eicosapentaenoic acid does not inhibit acetylcholine-induced coronary vasospasm in patients with variant angina. Yamamoto H, et al. **Jpn Circ J** 1995 Sep;59(9):608-16

ADMINISTRATION & DOSAGE

L-arginine restores dilator responses of the basilar artery to acetylcholine during chronic hypertension. Kitazono T, et al. **Hypertension** 1996 Apr;27(4):893-6

Effect of captopril on acetylcholine-induced relaxation in the presence of nitroglycerin tolerance in isolated rabbit aorta. Moroi M, et al. **J Vasc Res** 1995 Sep-Oct; 32(5):347-52

Pulmonary administration of vasoactive substances by perfluorochemical ventilation. Wolfson MR, et al. **Pediatrics** 1996 Apr;97(4):449-55

[The heterogeneity of the reaction of plasma renin activity in the arterial blood of rats to acetylcholine infusion into the systemic blood flow] Fedorov VI, et al. **Fiziol Zh Im I M Sechenova** 1995 Feb;81(2):59-66 (Eng. Abstr.) **(Rus)**

ANALOGS & DERIVATIVES

Bromoacetylcholine and acetylcholinesterase introduced via liposomes into motor nerve endings block increases in quantal size. Brailoiu E, et al. **Pflugers Arch** 1996 Jul; 432(3):413-8

ANALYSIS

Application of a novel, plastic formed carbon as a precolumn packing material for the liquid chromatographic determination of acetylcholine and choline in biological samples. Ikarashi Y, et al. **J Chromatogr A** 1995 Dec 22; 718(2):267-72

Detection of basal acetylcholine in rat brain microdialysate. Huang T, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):323-7

NGF mRNA is expressed by GABAergic but not cholinergic neurons in rat basal forebrain. Lauterborn JC, et al. **J Comp Neurol** 1995 Sep 25;360(3):454-62

Extraction of acetylcholine and choline from physiological solutions for analysis by HPLC. Shen A, et al. **J Pharmacol Toxicol Methods** 1995 Dec;34(4):215-8

All pelvic neurons in male rats contain immunoreactivity for the synthetic enzymes of either noradrenaline or acetylcholine. Keast JR, et al. **Neurosci Lett** 1995 Aug 25; 196(3):209-12

Ultrastructural characterization of the acetylcholine innervation in adult rat neostriatum. Contant C, et al. **Neuroscience** 1996 Apr;71(4):937-47

Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Togashi H, et al. **Stroke** 1996 Mar;27(3):520-5; discussion 525-6

ANTAGONISTS & INHIBITORS

Evidence for selective inhibition by lysophosphatidylcholine of acetylcholine-induced endothelium-dependent hyperpolarization and relaxation in rat mesenteric artery. Fukao M, et al. **Br J Pharmacol** 1995 Sep;116(1):1541-3

Control of locomotion in marine mollusc Clione limacina. X. Effects of acetylcholine antagonists. Panchin YV, et al. **Exp Brain Res** 1995;106(1):135-44

Histamine H3 receptor inhibition of K(+)-evoked release of acetylcholine from rat cortex in vivo. Blandina P, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S54-5

Nitric oxide synthase inhibitor blocks acetylcholine induced increase in brain blood flow in rainbow trout. Söderström V, et al. **Neurosci Lett** 1995 Sep 15;197(3):191-4

BIOSYNTHESIS

Differential effects of 2,4-dithiobiuret on the synthesis and release of acetylcholine and dopamine from rat pheochromocytoma (PC12) cells. Ireland LM, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1453-62

Synthesis and release of an acetylcholine-like compound by human myoblasts and myotubes. Hamann M, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):791-803

Regulation of acetylcholine synthesis in the presence of hemicholinium mustard. Gylys KH, et al. **Life Sci** 1996; 58(22):1937-46

Amygdala beta-noradrenergic influences on memory storage involve cholinergic activation. Introini-Collison IB, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):57-64

BLOOD

Variable response of the peripheral circulation to acetylcholine in patients with coronary artery disease. Testa M, et al. **Am J Cardiol** 1996 Jan 15;77(2):149-53

Species differences in the concentration of acetylcholine, a neurotransmitter, in whole blood and plasma. Fujii T, et al. **Neurosci Lett** 1995 Dec 15;201(3):207-10

CEREBROSPINAL FLUID

Cerebrospinal fluid norepinephrine and acetylcholine concentrations during acute pain. Eisenach JC, et al. **Anesth Analg** 1996 Mar;82(3):621-6

DIAGNOSTIC USE

Variable coronary vasomotor responses to acetylcholine in patients with normal coronary arteriograms: evidence for localised endothelial dysfunction. Tousoulis D, et al. **Heart** 1996 Mar;75(3):261-6

METABOLISM

Disturbances of acetyl-CoA, energy and acetylcholine metabolism in some encephalopathies. Szutowicz A, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):323-39 (110 ref.)

The D1 agonist dihydrexidine releases acetylcholine and improves cognition in rats. Steele TD, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:427-30

Covalent modification of engineered cysteines in the nicotinic acetylcholine receptor agonist-binding domain inhibits receptor activation. McLaughlin JT, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):765-9

Role of acetylcholine, corticoids and opioids in the rostral ventrolateral medulla in stress-induced hypertensive rats. Li P, et al. **Biol Signals** 1995 May-Jun;4(3):124-32

Paradoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by isoprenaline. Belvisi MG, et al. **Br J Pharmacol** 1996 Apr; 117(7):1413-20

Inhibition by halothane of potassium-stimulated acetylcholine release from rat cortical slices. Griffiths R, et al. **Br J Pharmacol** 1995 Oct;116(4):2310-4

Improvement by dynorphin A (1-13) of galanin-induced impairment of memory accompanied by blockade of reductions in acetylcholine release in rats. Hiramatsu M, et al. **Br J Pharmacol** 1996 May;118(2):255-60

Blockade of acetylcholine release at the motor endplate by a polypeptide from the venom of Phoneutria nigriventer. Souccar C, et al. **Br J Pharmacol** 1995 Dec;116(7):2817-23

Effect of vagal autotransplantation and bifemelane hydrochloride on cholinergic markers and event-related potentials in rats with lesions of the nucleus basalis magnocellularis. Ikeda K, et al. **Brain Res** 1995 Aug 7; 688(1-2):171-83

Enhanced release of acetylcholine in the rostral ventrolateral medulla of spontaneously hypertensive rats. Kubo T, et al. **Brain Res** 1995 Jul 17;686(1):1-9

Acute dopamine depletion potentiates independent stimulatory and inhibitory D1 DA receptor-mediated control of striatal acetylcholine release in vitro. Login IS, et al. **Brain Res** 1995 May 29;681(1-2):209-12

Acetylcholine release from dissociated striatal cells. Login IS, et al. **Brain Res** 1995 Oct 30;697(1-2):271-5

Extracellular acetylcholine is increased in the nucleus accumbens following the presentation of an aversively conditioned taste stimulus. Mark GP, et al. **Brain Res** 1995 Aug 7;688(1-2):184-8

Long-term time course of regional changes in cholinergic indices following transient ischemia in the spontaneously hypertensive rat brain. Ogawa N, et al. **Brain Res** 1996 Mar 11;712(1):60-8

Augmented pharmacologic stimulation of striatal acetylcholine release following developmental hypoxic-ischemic injury. Oo TF, et al. **Brain Res** 1996 Jan 8;706(1):145-50

Involvement of GABA systems in acetylcholine release induced by 5-HT3 receptor blockade in slices from rat entorhinal cortex. Ramírez MJ, et al. **Brain Res** 1996 Mar 18;712(2):274-80

L-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats. Ueda H, et al. **Brain Res** 1995 Nov 6;698(1-2):213-6

Hydroxyl radical scavengers enhance nitric oxide-evoked acetylcholine release from mouse cerebral cortical neurons. Ohkuma S, et al. **Brain Res Mol Brain Res** 1995 Dec 28; 34(2):347-50

Involvement of peroxynitrite in N-methyl-D-aspartate- and sodium nitroprusside-induced release of acetylcholine from mouse cerebral cortical neurons. Ohkuma S, et al. **Brain Res Mol Brain Res** 1995 Jul;31(1-2):185-93

Acetylcholine release in the rostral ventrolateral medulla of spontaneously hypertensive rats. Kubo T, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S40-2

Radioactive choline metabolism in guinea pig gallbladder. Is there measurable acetylcholine release? Brotschi EA, et al. **Dig Dis Sci** 1995 Sep;40(9):1982-9

Schistosoma: rate of glucose import is altered by acetylcholine interaction with tegumental acetylcholine receptors and acetylcholinesterase. Camacho M, et al. **Exp Parasitol** 1995 Dec;81(4):584-91

Effect of omega-conotoxin GVIA on tetrodotoxin-insensitive acetylcholine release by nicotine in guinea-pig bladder. Shinkai M, et al. **Gen Pharmacol** 1995 Sep;26(5):1077-81

Specific vesicular acetylcholine transporter promoters lie within the first intron of the rat choline acetyltransferase gene. Cervini R, et al. **J Biol Chem** 1995 Oct 20; 270(42):24654-7

Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits. Wang F, et al. **J Biol Chem** 1996 Jul 26;271(30):17656-65

Is in vivo striatal acetylcholine output under a tonic inhibitory control by dopamine? Imperato A, et al. **J Neural Transm Suppl** 1995;45:91-102

Inhibition of Na+,K+-ATPase by ouabain opens calcium channels coupled to acetylcholine release in guinea pig myenteric plexus. Gomez RS, et al. **J Neurochem** 1996 Apr; 66(4):1440-7

Septal and hippocampal glutamate receptors modulate the output of acetylcholine in hippocampus: a microdialysis study. Moor E, et al. **J Neurochem** 1996 Jul;67(1):310-6

Pharmacological characterization of tachykinin receptors controlling acetylcholine release from rat striatum: an in vivo microdialysis study. Steinberg R, et al. **J Neurochem** 1995 Dec;65(6):2543-8

Increased acetylcholine content induced by antidromic stimulation of a sympathetic ganglion: a possible retrograde action of adenosine. Tandon A, et al. **J Neurochem** 1995 Nov;65(5):2116-23

Conditioned and unconditioned stimuli increase frontal cortical and hippocampal acetylcholine release: effects of novelty, habituation, and fear. Acquas E, et al. **J Neurosci** 1996 May 1;16(9):3089-96

Staurosporine blocks evoked release of FM1-43 but not acetylcholine from frog motor nerve terminals. Henkel AW, et al. **J Neurosci** 1995 Dec;15(12):8246-58

Local modulation of hippocampal acetylcholine release by dopamine D1 receptors: a combined receptor autoradiography and in vivo dialysis study. Hersi AI, et al. **J Neurosci** 1995 Nov;15(11):7150-7

Functional reconstitution of KCl-evoked, Ca(2+)-dependent acetylcholine release system in Xenopus oocytes microinjected with presynaptic plasma membranes and synaptic vesicles. Canals JM, et al. **J Neurosci Res** 1996 Apr 15;44(2):106-14

ATP inhibits the synaptic release of acetylcholine in submucosal neurons. Barajas-López C, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1238-45

Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. Gifford AN, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1431-6

Inhibition of ACh release at an Aplysia synapse by neurotoxic phospholipases A2: specific receptors and mechanisms of action. Fossier P, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):29-40

Synchronous release of ATP and neurotransmitter within milliseconds of a motor nerve impulse in the frog. Silinsky EM, et al. **J Physiol (Lond)** 1996 May 1;492 (Pt 3):815-22

The role of non-quantal release of acetylcholine in regulation of postsynaptic membrane electrogenesis. Vyskočil F, et al. **J Physiol Paris** 1995;89(3):157-62

Overexpression of choline acetyltransferase reconstitutes discrete acetylcholine release in some but not all synapse formation-defective neuroblastoma cells. Zhong ZG, et al. **J Physiol Paris** 1995;89(3):137-45 (40 ref.)

Loxiglumide, L-364,718 and L-365,260 prevent the inhibition of spontaneous acetylcholine release from the frontal cerebral cortex of freely moving rat peripherally administered with cholecystokinin-8S. Kimura I, et al. **Jpn J Pharmacol** 1995 May;68(1):129-32

Minireview. Galanin-acetylcholine interactions: relevance to memory and Alzheimer's disease. Crawley JN. **Life Sci** 1996;58(24):2185-99 (112 ref.)

Differentiation agents enhance cholinergic characteristics of LA-N-2 human neuroblastoma cells. Crosland RD. **Life Sci** 1996;58(22):1987-94

Effects of dietary phosphatidylcholine on memory in memory deficient mice with low brain acetylcholine concentration. Moriyama T, et al. **Life Sci** 1996;58(6):PL111-8

Membrane delimited and intracellular soluble pathways in the somatostatin modulation of ACh release. Pilar G, et al. **Life Sci** 1996;58(22):1979-86

Postnatal development of methionine-enkephalin modulation of cholinergic transmission in cat ileum. Chernaeva L, et al. **Mech Ageing Dev** 1995 Sep 7;83(2):117-24

A unifying hypothesis for acetylcholine release. Israël M, et al. **Neurochem Int** 1996 Jan;28(1):1-9 (88 ref.)

Effects of adenosine on norepinephrine and acetylcholine release from guinea pig right atrium: role of A1-receptors. Nakatsuka H, et al. **Neurochem Int** 1995 Oct-Nov; 27(4-5):345-53

Metrifonate effects on acetylcholine and biogenic amines in rat cortex. Mori F, et al. **Neurochem Res** 1995 Sep; 20(9):1081-8

5-fluoronicotine, noranhydroecgonine, and pyridyl-methylpyrrolidine release acetylcholine and biogenic amines in rat cortex in vivo. Summers KL, et al. **Neurochem Res** 1995 Sep;20(9):1089-94

Effects of local and repeated systemic administration of (-)nicotine on extracellular levels of acetylcholine, norepinephrine, dopamine, and serotonin in rat cortex. Summers KL, et al. **Neurochem Res** 1995 Jun;20(6):753-9

SR 48692-sensitive neurotensin receptors modulate acetylcholine release in the rat striatum. Steinberg R, et al. **Neuropeptides** 1995 Jul;29(1):27-31

Modification of ionic currents underlying action potentials in mouse nerve terminals by the thiol-oxidizing agent diamide. Braga MF, et al. **Neuropharmacology** 1995 Nov; 34(11):1529-33

Facilitation of N-methyl-D-aspartate-evoked acetylcholine release by hydroxyl radical scavengers. Ohkuma S, et al. **Neuroreport** 1995 Oct 23;6(15):2033-6

Methionine sulfoximine increases acetylcholine level in the rat brain: no relation with epileptogenesis. Richard O, et al. **Neuroreport** 1995 Oct 23;6(15):2027-32

Modulation of hippocampal ACh release by chronic nicergoline treatment in freely moving young and aged rats. Carfagna N, et al. **Neurosci Lett** 1995 Sep 15; 197(3):195-8

Basal and scopolamine-evoked release of hippocampal acetylcholine following traumatic brain injury in rats. Dixon CE, et al. **Neurosci Lett** 1995 Sep 29;198(2):111-4

Botulinum toxin type A inhibits Ca(2+)-dependent transport

of acetylcholine in reconstituted giant liposomes made from presynaptic membranes from cholinergic nerve terminals. López-Alonso E, et al. **Neurosci Lett** 1995 Aug 18; 196(1-2):37-40

Peripherally injected scopolamine differentially modulates acetylcholine release in vivo in the young and aged rats. Scali C, et al. **Neurosci Lett** 1995 Sep 15;197(3):171-4

Synthesis, storage and release of acetylcholine at and from growth cones of rat central cholinergic neurons in culture. Tatsumi H, et al. **Neurosci Lett** 1995 Dec 29;202(1-2):25-8

Dopamine D1 receptor ligands modulate cognitive performance and hippocampal acetylcholine release in memory-impaired aged rats. Hersi AI, et al. **Neuroscience** 1995 Dec;69(4):1067-74

Physiological and regenerative acetylcholine release from motor nerve: differential inhibitions by vesamicol and omega-agatoxin IVA. Hong SJ, et al. **Neuroscience** 1995 Jul;67(1):169-75

A nitric oxide synthase activity is involved in the modulation of acetylcholine release in Aplysia ganglion neurons: a histological, voltammetric and electrophysiological study. Meulemans A, et al. **Neuroscience** 1995 Dec;69(3):985-95

Age-related changes in diurnal acetylcholine release in the prefrontal cortex of male rats as measured by microdialysis. Mitsushima D, et al. **Neuroscience** 1996 May;72(2):429-34

A1-receptor-mediated effect of adenosine on the release of acetylcholine from the myenteric plexus: role and localization of ecto-ATPase and 5'-nucleotidase. Nitahara K, et al. **Neuroscience** 1995 Jul;67(1):159-68

Glucose injections into the medial septum reverse the effects of intraseptal morphine infusions on hippocampal acetylcholine output and memory. Ragozzino ME, et al. **Neuroscience** 1995 Oct;68(4):981-8

Differential effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid and N-methyl-D-aspartate receptor antagonists applied to the basal forebrain on cortical acetylcholine release and electroencephalogram desynchronization. Rasmusson DD, et al. **Neuroscience** 1996 May;72(2):419-27

A syntaxin-related protein controls acetylcholine release by different mechanisms in Aplysia. Smirnova T, et al. **Neuroscience** 1995 Sep;68(1):125-33

Disorganisation of quantal acetylcholine release by zinc at the Torpedo nerve-electroplate junction. Corrèges P, et al. **Pflugers Arch** 1996 Sep;432(5):859-66

Activation and desensitisation of acetylcholine release by zinc at Torpedo nerve terminals. Dunant Y, et al. **Pflugers Arch** 1996 Sep;432(5):853-8

Decrease of acidity inside zymogen granules inhibits acetylcholine- or inositol trisphosphate-evoked cytosolic Ca2+ spiking in pancreatic acinar cells. Titievsky AV, et al. **Pflugers Arch** 1996 Sep;432(5):938-40

Morphine and naloxone, i.p. or locally, affect extracellular acetylcholine in the accumbens and prefrontal cortex. Rada PV, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):809-16

Tail pinch increases acetylcholine release in rat striatum even after toluene exposure. Stengård K. **Pharmacol Biochem Behav** 1995 Oct;52(2):261-4

Effects of honokiol and magnolol on acetylcholine release from rat hippocampal slices [letter] Tsai TH, et al. **Planta Med** 1995 Oct;61(5):477-9

Quantal acetylcholine release induced by mediatophore transfection. Falk-Vairant J, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5203-7

Miniature endplate current rise times less than 100 microseconds from improved dual recordings can be modeled with passive acetylcholine diffusion from a synaptic vesicle. Stiles JR, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5747-52

Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles. Weihe E, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3547-52

[Influences of capsaicin and electroacupuncture at "point" on acetylcholine (ACh) release in the spinal dorsal horn of rats] Shi J, et al. **Chen Tzu Yen Chiu** 1995;20(2):22-7 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Acetylcholine induces different cutaneous sensations in atopic and non-atopic subjects. Vogelsang M, et al. **Acta Derm Venereol** 1995 Nov;75(6):434-6

Acetylcholine-induced prolongation of the QT interval in idiopathic long QT syndrome. Aizawa Y, et al. **Am J Cardiol** 1996 Apr 15;77(10):879-82

Responses of internal mammary artery to local administration of acetylcholine. Tanaka T, et al. **Am J Cardiol** 1996 Feb 1;77(4):302-4

Cilazapril reverses endothelium-dependent vasodilator response to acetylcholine in mesenteric artery from spontaneously hypertensive rats. Young RH, et al. **Am J Hypertens** 1995 Sep;8(9):928-33

Enhanced vasodilation to acetylcholine in athletes is associated with lower plasma cholesterol. Kingwell BA, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2008-13

Infusions of pressor agents selectively attenuate depressor responses to ACh in anesthetized dogs. Nakahara T, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H273-81

KATP channels in rat heart: blockade of ischemic and acetylcholine-mediated preconditioning by glibenclamide. Qian YZ, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H23-8

Effect of ACh and calmodulin inhibitor on O2 transfer from exocrine pancreatic microvessels of rats. Seiyama A, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H1-7

Airway hyperresponsiveness to acetylcholine: segregation analysis and evidence for linkage to murine chromosome 6. Ewart SL, et al. **Am J Respir Cell Mol Biol** 1996 May; 14(5):487-95

Inhibition of acetylcholine-evoked Cl- currents by 14-membered macrolide antibiotics in isolated acinar cells of the guinea pig nasal gland. Ikeda K, et al. **Am J Respir Cell Mol Biol** 1995 Oct;13(4):449-54

Effects of alpha 2-adrenergic receptor agonist and antagonist drugs on cholinergic contraction in bovine tracheal smooth muscle in vitro. Manning MM, et al. **Am J Vet Res** 1995 Jul;56(7):930-5

Acetylcholine stimulates the release of nitric oxide from rat spinal cord. Xu Z, et al. **Anesthesiology** 1996 Jul; 85(1):107-11

Chemotaction of mouse spermatozoa induced by certain hormones. Sliwa L. **Arch Androl** 1995 Sep-Oct; 35(2):105-10

Acetylcholine activates latent pseudorabies virus in pigs. Tanaka S, et al. **Arch Virol** 1996;141(1):161-6

Effect of acetylcholine on the electrophysiology and proliferative response of human lymphocytes. Gáspár R Jr., et al. **Biochem Biophys Res Commun** 1996 Sep 13; 226(2):303-8

Muscarinic stimulation increases Na+ entry in pancreatic B-cells by a mechanism other than the emptying of intracellular Ca2+ pools. Miura Y, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):67-73

Activation of P2z purinoceptors diminishes the muscarinic cholinergic-induced release of inositol 1,4,5-trisphosphate and stored calcium in rat parotid acini. ATP as a co-transmitter in the stimulus-secretion coupling. Jørgensen TD, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):457-64

Amplification of the thapsigargin-evoked increase in the cytosolic free Ca2+ concentration by acetylcholine in acutely isolated mouse submandibular acinar cells. Smith PM, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):779-83

Activation of NO:cGMP pathway by acetylcholine in bovine chromaffin cells. Possible role of Ca2+ in the down-regulation of cGMP signaling. Rodriguez-Pascual F, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):763-9

Acetylcholine-induced Ca2+ flux across the sarcolemma of an echinoderm smooth muscle. Devlin CL, et al. **Biol Bull** 1995 Oct-Nov;189(2):207

Two groups of diabetic KK-CAy mice specifically bred for high and low sensitivity to exogenous acetylcholine and beta 1-adrenergic stimulation: interaction of higenamine and aconitine on pulse rate. Kimura I, et al. **Biol Pharm Bull** 1995 Oct;18(10):1356-61

Cholera toxin accentuates the antagonism by acetylcholine of higenamine-induced positive chronotropy is isolated right atria of mice. Kimura I, et al. **Biol Pharm Bull** 1995 Nov;18(11):1509-12

The cholinergic hypothesis revisited--an unfinished story. Fitzgerald RS, et al. **Biol Signals** 1995 Sep-Oct; 4(5):298-303

Central cardiovascular effects of acetylcholine in the conscious dog. Brefel C, et al. **Br J Pharmacol** 1995 Oct; 116(4):2175-82

Endothelium-dependent relaxation to acetylcholine in bovine oviductal arteries: mediation by nitric oxide and changes in apamin-sensitive K+ conductance. García-Pascual A, et al. **Br J Pharmacol** 1995 Aug;115(7):1221-30

Impaired endothelium-dependent relaxation in isolated resistance arteries of spontaneously diabetic rats. Heygate KM, et al. **Br J Pharmacol** 1995 Dec;116(8):3251-9

Differential sensitivity of basal and acetylcholine-stimulated activity of nitric oxide to destruction by superoxide anion in rat aorta. Mian KB, et al. **Br J Pharmacol** 1995 Jul; 115(6):993-1000

Myocardial and coronary endothelial protective effects of acetylcholine after myocardial ischaemia and reperfusion in rats: role of nitric oxide. Richard V, et al. **Br J Pharmacol** 1995 Aug;115(8):1532-8

Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery. Zygmunt PM, et al. **Br J Pharmacol** 1996 Apr; 117(7):1600-6

Effects of acetylcholine and adrenaline on axoplasmic transport at different regions of mouse superior cervical ganglion cells in culture. Kawakami T, et al. **Brain Res** 1995 Jun 12;683(1):88-92

Ethanol enhances muscarinic cholinergic neurotransmission in rat hippocampus in vitro. Madamba SG, et al. **Brain Res** 1995 Jul 10;685(1-2):21-32

PKC-dependent reduction of the acetylcholine-evoked inward Na current in Aplysia D-neurons: effect of injected PKC and PKC activators. Papp A, et al. **Brain Res** 1996 Feb 5;708(1-2):123-7

Prejunctional modulation of nitroxidergic nerve function in canine cerebral arteries. Toda N, et al. **Brain Res** 1995 Nov 27;700(1-2):213-8

Myocardial metabolic and functional responses to acetylcholine are altered in thyroxine-induced cardiac hypertrophy. Weiss HR, et al. **Can J Physiol Pharmacol** 1995 Jun;73(6):729-35

Vascular acetylcholine response during chronic NO synthase inhibition: in vivo versus in vitro. Zanchi A, et al. **Cardiovasc Res** 1995 Jul;30(1):122-9

Acetylcholine-activated inward current induces cytosolic Ca2+ mobilization in mouse C2C12 myotubes. Giovannelli A, et al. **Cell Calcium** 1995 Jul;18(1):41-50

Interplay of glucose-stimulated Ca2+ sequestration and acetylcholine-induced Ca2+ release at the endoplasmic reticulum in rat pancreatic beta-cells. Hamakawa N, et al. **Cell Calcium** 1995 Jan;17(1):21-31

Effect of membrane potential on the initiation of acetylcholine-induced Ca2+ transients in isolated guinea pig coronary myocytes. Ganitkevich VY, et al. **Circ Res** 1996 Apr;78(4):717-23

Characteristics of muscarinic cholinoceptors in airways of antigen-induced airway hyperresponsive rats. Chiba Y, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jul;111(3):351-7

Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Morris SJ, et al. **Diabetologia** 1995 Nov;38(11):1337-44

Acetylcholine induces oscillations in intracellular calcium in isolated bovine adrenal zona fasciculata/reticularis cells. Clyne CD, et al. **Endocr Res** 1995 Feb-May;21(1-2):53-60

Effect of acetylcholine on corticotropin-releasing factor gene expression in the hypothalamic paraventricular nucleus of conscious rats. Ohmori N, et al. **Endocrinology** 1995 Nov; 136(11):4858-63

Effect of flurbiprofen on acetylcholine-induced pupillary contraction. Tabandeh H, et al. **Eur J Ophthalmol** 1995 Jul-Sep;5(3):177-80

Characterization of the positive and negative inotropic effects of acetylcholine in the human myocardium. Du XY, et al. **Eur J Pharmacol** 1995 Sep 15;284(1-2):119-27

Acetylcholine as a mitogen: muscarinic receptor-mediated proliferation of rat astrocytes and human astrocytoma cells. Guizzetti M, et al. **Eur J Pharmacol** 1996 Feb 22; 297(3):265-73

K+ channel blockers do not modify relaxation of guinea-pig uterine artery evoked by acetylcholine. Jovanović A, et al. **Eur J Pharmacol** 1995 Jun 23;280(1):95-100

Acetylcholine modulation of the short-circuit current across the rabbit lens. Alvarez LJ, et al. **Exp Eye Res** 1995 Aug; 61(2):129-40

Effects of calcium antagonist drugs on acetylcholine and high K responses of a molluscan muscle Neptunea antiqua. Alohan FI. **Gen Physiol Biophys** 1995 Oct;14(5):419-26

Involvement of different Ca2+ sources in changes of responsiveness of guinea-pig trachea to repeated administration of histamine and acetylcholine. Mátyás S, et al. **Gen Physiol Biophys** 1995 Feb;14(1):51-60

Effect of pregnancy on mechanisms of relaxation in human omental microvessels. Pascoal IF, et al. **Hypertension** 1996 Aug;28(2):183-7

Effect of vasoactive intestinal peptide and acetylcholine on penile erection in the rat in vivo. Suh JK, et al. **Int J Impot Res** 1995 Jun;7(2):111-8

Recombinant human erythropoietin inhibits the cutaneous vasodilatation induced by acetylcholine. Buemi M, et al. **Int J Microcirc Clin Exp** 1995 Nov-Dec;15(6):283-6

Comparative adrenocholinergic control of intracellular Ca2+ in the layers of the ciliary body epithelium. Schütte M, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):212-20

Renal vasodilatory effect of endothelial stimulation in patients with chronic congestive heart failure. Elkayam U, et al. **J Am Coll Cardiol** 1996 Jul;28(1):176-82

Diffuse disorder of coronary artery vasomotility in patients with coronary spastic angina. Hyperreactivity to the constrictor effects of acetylcholine and the dilator effects of nitroglycerin. Okumura K, et al. **J Am Coll Cardiol** 1996 Jan;27(1):45-52

Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine. Tsurumi Y, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1242-50

Effect of inhaled and intravenous acetylcholine on bronchial blood flow in anesthetized sheep. Scuri M, et al. **J Appl Physiol** 1996 Jan;80(1):341-44

cGMP release in rat mesenteric arterioles and in conduit mesenteric artery. Dubois-Aubecq V, et al. **J Auton Pharmacol** 1996 Feb;16(1):7-11

Positive inotropic effect in the heart produced by acetylcholine. Nadler E, et al. **J Basic Clin Physiol Pharmacol** 1993 Jul-Sep;4(3):229-48

Low-dose i.v. acetylcholine acts as a "preconditioning-mimetic" in the canine model. Przyklenk K, et al. **J Card Surg** 1995 Jul;10(4 Suppl):389-95

Mechanism of acetylcholine-induced constriction enhanced by endothelial removal in isolated, perfused canine basilar arteries. Tsuji T, et al. **J Cardiovasc Pharmacol** 1995 Jun; 25(6):940-6

Effect of neuromimetics upon the release of atrial natriuretic peptide granules: are multiple pathways involved in secretion? Newman TM, et al. **J Cell Physiol** 1996 Jul; 168(1):134-40

Role of extracellular Ca2+ in acetylcholine-induced repetitive Ca2+ release in submandibular gland acinar cells of the rat. Zhang W, et al. **J Cell Physiol** 1996 May; 167(2):277-84

Role of nitric oxide in the elevation of cerebral blood flow induced by acetylcholine and anoxia in the turtle. Hylland P, et al. **J Cereb Blood Flow Metab** 1996 Mar;16(2):290-5

Effect of prostaglandins and nitric oxide on basal blood flow and acetylcholine-induced vasodilation in rat diaphragmatic microcirculation. Chang HY, et al.

J Formos Med Assoc 1995 Jun;94(6):332–40

Block by acetylcholine of mouse muscle nicotinic receptors, stably expressed in fibroblasts. Maconochie DJ, et al. J Gen Physiol 1995 Jul;106(1):113–47

Increased basal tone and hyperresponsiveness to acetylcholine and ergonovine in spasm related coronary arteries in patients with variant angina—basal coronary artery tone in patients with variant angina. Park SJ, et al. J Korean Med Sci 1996 Feb;11(1):17–25

The ACh–evoked, Ca2+–activated whole–cell K+ current in mouse mandibular secretory cells. Whole–cell and fluorescence studies. Hayashi T, et al. J Membr Biol 1996 Aug;152(3):253–9

Characterization of the acetylcholine–sensitive muscarinic K+ channel in isolated feline atrial and ventricular myocytes. Koumi S, et al. J Membr Biol 1995 May; 145(2):143–50

Cyclic AMP enhances acetylcholine (ACh)–induced ion fluxes and catecholamine release by inhibiting Na+, K(+)–ATPase and participates in the responses to ACh in cultured bovine adrenal medullary chromaffin cells. Morita K, et al. J Neural Transm Gen Sect 1995; 100(1):17–26

Ca2+ responses to acetylcholine and adenosine triphosphate in the otocyst of chick embryo. Nakaoka Y, et al. J Neurobiol 1995 Sep;28(1):23–34

Effects of inhibitory amino acid antagonists on reciprocal inhibitory interactions during rhythmic motor activity in the in vitro neonatal rat spinal cord. Cowley KC, et al. J Neurophysiol 1995 Sep;74(3):1109–17

Two ion currents activated by acetylcholine in the ARC muscle of Aplysia. Kozak JA, et al. J Neurophysiol 1996 Feb;75(2):660–77

Agonist and toxin sensitivities of ACh–evoked currents on neurons expressing multiple nicotinic ACh receptor subunits. Mandelzys A, et al. J Neurophysiol 1995 Sep; 74(3):1212–21

Acetylcholine–induced potassium current of guinea pig outer hair cells: its dependence on a calcium influx through nicotinic–like receptors. Blanchet C, et al. J Neurosci 1996 Apr 15;16(8):2574–84

Protein kinase C modulates exogenous acetylcholine current in Xenopus oocytes. Mileo AM, et al. J Neurosci Res 1995 Jul 1;41(4):443–51

Acetylcholine–induced chloride current oscillations in swine tracheal smooth muscle cells. Liu X, et al. J Pharmacol Exp Ther 1996 Jan;276(1):178–86

Depletion and refilling of acetylcholine– and caffeine–sensitive Ca++ stores in tracheal myocytes. Liu X, et al. J Pharmacol Exp Ther 1996 May;277(2):789–95

Acetylcholine–induced Ca++–dependent chloride current oscillations are mediated by inositol 1,4,5–trisphosphate in tracheal myocytes. Liu X, et al. J Pharmacol Exp Ther 1996 May;277(2):796–804

Frequency modulation of acetylcholine–induced oscillations in Ca++ and Ca(++)–activated Cl– current by cAMP in tracheal smooth muscle. Nuttle LC, et al. J Pharmacol Exp Ther 1996 May;277(2):753–60

Mechanisms underlying endothelium–independent relaxation by acetylcholine in canine retinal and cerebral arteries. Toda N, et al. J Pharmacol Exp Ther 1995 Sep; 274(3):1507–12

Acetylcholine inhibits Ca2+ current by acting exclusively at a site proximal to adenylyl cyclase in frog cardiac myocytes. Jurevičius J, et al. J Physiol (Lond) 1996 Mar 15;491 (Pt 3):669–75

Selective activation of exocytosis by low concentrations of ACh in rat pancreatic acinar cells. Maruyama Y. J Physiol (Lond) 1996 May 1;492 (Pt 3):807–14

Colocalization of ATP and nicotinic ACh receptors in the identified vagal preganglionic neurone of rat. Nabekura J, et al. J Physiol (Lond) 1995 Dec 1;489 (Pt 2):519–27

Cytosolic calcium concentration in resting and stimulated endothelium of excised intact rat aorta. Usachev YM, et al. J Physiol (Lond) 1995 Dec 1;489 (Pt 2):309–17

Regional differences in the negative inotropic effect of acetylcholine within the canine ventricle. Yang ZK, et al. J Physiol (Lond) 1996 May 1;492 (Pt 3):789–806

Activation of recombinant mouse acetylcholine receptors by acetylcholine, carbamylcholine and tetramethylammonium. Zhang Y, et al. J Physiol (Lond) 1995 Jul 1;486 (Pt 1):189–206

Heterogeneity of endothelium–dependent mechanisms in different rabbit arteries. Ferrer M, et al. J Vasc Res 1995 Sep–Oct;32(5):339–46

Spontaneous tone in different types of longitudinal muscle preparations of guinea pig ileum. Suzuki N, et al. Jpn J Pharmacol 1995 Sep;69(1):23–8

S–(–)–ET 126: a potent and selective M1 antagonist in vitro and in vivo. Ghelardini C, et al. Life Sci 1996; 58(12):991–1000

Reduction of acetylcholine–activated current by low concentrations of extracellular adenosine 5'–triphosphate. Nakazawa K, et al. Life Sci 1995;57(22):PL351–6

Evaluation of the mechanism of endothelial dysfunction in the genetically–diabetic BB rat. Pieper GM, et al. Life Sci 1996;58(9):PL147–52

Vasodilation in porcine ophthalmic artery: peptide interaction with acetylcholine and endothelial dependence. Bakken IJ, et al. Neuropeptides 1995 Aug;29(2):69–75

Acetylcholine contractures of skeletal muscles: inhibition by chlorpromazine and diltiazem. Lorković H. Neuropharmacology 1995 Jul;34(7):695–700

Acetylcholine as a regulator of neurite outgrowth and motility in cultured embryonic mouse spinal cord. Owen A, et al. Neuroreport 1995 Nov 27;6(17):2269–72

Nitric oxide synthase inhibitor blocks acetylcholine induced increase in brain blood flow in rainbow trout. Söderström V, et al. Neurosci Lett 1995 Sep 15;197(3):191–4

alpha 2–Adrenoreceptor–mediated inhibition of acetylcholine–induced noradrenaline release from rat sympathetic neurons: an action at voltage–gated Ca2+ channels. Boehm S, et al. Neuroscience 1995 Nov; 69(1):221–31

Relaxing effects of vasoactive intestinal peptide (VIP) on the contractile actions of endothelin–3, histamine, and acetylcholine in isolated guinea pig tracheal smooth muscle with or without epithelium. Uzuner K, et al. Peptides 1996; 17(2):299–303

Evidence that Ca/calmodulin–dependent protein kinase mediates the modulation of the Ca2+–dependent K+ current, IAHP, by acetylcholine, but not by glutamate, in hippocampal neurons. Pedarzani P, et al. Pflugers Arch 1996 Mar;431(5):723–8

Reduction of ACh–induced contraction of rat isolated ileum by coptisine, (+)–caffeoylmalic acid, Chelidonium majus, and Corydalis lutea extracts. Boegge SC, et al. Planta Med 1996 Apr;62(2):173–4

Strain and route differences in airway responsiveness to acetylcholine in mice. Chiba Y, et al. Res Commun Mol Pathol Pharmacol 1995 Oct;90(1):169–72

Differential significance of nitric oxide in hypotensive mechanisms of acetylcholine and histamine in dogs. Nakahara T, et al. Res Commun Mol Pathol Pharmacol 1995 Jul;89(1):77–84

Hippocampal cell death [letter; comment] Cahill L, et al. Science 1996 May 31;272(5266):1251. Comment on: Science 1996 Mar 1;271(5253):1229–30.

Nitric oxide regulates insulin secretion in the isolated perfused human pancreas via a cholinergic mechanism. Atiya A, et al. Surgery 1996 Aug;120(2):322–7

Facile production of native–like kappa–bungarotoxin in yeast: an enhanced system for the production of a neuronal nicotinic acetylcholine receptor probe. Fiordalisi JJ, et al. Toxicon 1996 Feb;34(2):213–24

Impaired endothelial–dependent relaxation by acetylcholine after preservation of the human hepatic artery with UW solution. Jeng LB, et al. Transplant Proc 1996 Jun; 28(3):1895–6

L–arginine restores suppressed acetylcholine–induced endothelium–dependent vascular relaxation in cyclosporine A–treated rats. Kim HS, et al. Transplant Proc 1996 Jun; 28(3):1372–4

Endothelium–dependent relaxation of the canine pulmonary artery is preserved after prolonged preservation with University of Wisconsin solution. Lin PJ, et al. Transplant Proc 1996 Jun;28(3):1897–8

Cholinergic and adrenergic effects on insulin secretion from islet transplants. Shi CL, et al. Transplant Proc 1995 Dec; 27(6):3255–6

[Effect of acetylcholine on the proliferation of T lymphocyte of rat spleen] Qiu YH, et al. Sheng Li Hsueh Pao 1995 Jun;47(3):275–80 (Eng. Abstr.) (Chi)

[Comparison of the infusion of acetylcholine into the artery of the sinoatrial node with the electric stimulation of cardiac parasympathetic nerves] Pagé PL, et al. Ann Chir 1995;49(8):719–27 (Eng. Abstr.) (Fre)

[Respiratory and cardiovascular effects of acetylcholine provocation after inhalation exposure to various occupational pollutants—studies in the rabbit] Marek W, et al. Pneumologie 1996 May;50(5):342–9 (Eng. Abstr.) (Ger)

[The electrical activity of the isolated rabbit cerebral cortex after acetylcholine application] Agladze NN, et al. Zh Vyssh Nerv Deiat Im I P Pavlova 1995 Jul–Aug; 45(4):782–90 (Eng. Abstr.) (Rus)

[An in–vitro study of the sources of intracellular calcium in Ach–induced contractions and electrical depolarization and of the capacity of calcium antagonists to influence them in the canine detrusor] Server Pastor G, et al. Actas Urol Esp 1996 Jan;20(1):13–21 (Eng. Abstr.) (Spa)

[The secretory function of the gastric glands under the joint action of acetylcholine, adenosine triphosphoric acid and histamine] Skliarov OIa. Fiziol Zh 1995 May–Aug; 41(3–4):9–13 (Eng. Abstr.) (Ukr)

PHYSIOLOGY

Cholinergic dimensions to carotid body chemotransduction. Fitzgerald RS, et al. Adv Exp Med Biol 1995;393:303–8

Role of acetylcholine as an essential neurotransmitter in central respiratory drive. Kazemi H, et al. Adv Exp Med Biol 1995;393:29–32

Neural, endocrine and immune regulation of secretory component production by lacrimal gland acinar cells. Lambert RW, et al. Adv Exp Med Biol 1995;371A:221–4

Role for 5–HT and ACh in submucosal reflexes mediating colonic secretion. Sidhu M, et al. Am J Physiol 1995 Sep; 269(3 Pt 1):G346–51

Vestibular influences on the histaminergic and cholinergic systems in the rat brain. Horii A, et al. Ann N Y Acad Sci 1996 Jun 19;781:633–4

Acetylcholine enhances optokinetic modulation of floccular Purkinje cells. Tan HS, et al. Ann N Y Acad Sci 1996 Jun 19;781:703–5

Pharmacological analysis of acute morphine dependence in infant rats: close molecular relationship of head–shaking precipitated by opiate antagonists and cholinergic neurotransmission. Pérez–Saad H, et al. Arch Med Res 1996 Summer;27(2):139–44

The effect of vitamin E deficiency on the plasticity of cholinergic synapses: a computer–assisted morphometric study. Fattoretti P, et al. Boll Soc Ital Biol Sper 1995 May–Jun;71(5–6):119–24

Acetylcholine and hallucinations: disease–related compared to drug–induced alterations in human consciousness. Perry EK, et al. Brain Cogn 1995 Aug;28(3):240–58 (65 ref.)

Involvement of sigma 1 receptor in (+)–N–allylnormetazocine–stimulated hippocampal cholinergic functions in rats. Matsuno K, et al. Brain Res 1995 Sep 4;690(2):200–6

The role of the cholinergic system in the development of the human cerebellum. Court JA, et al. Brain Res Dev Brain Res 1995 Dec 21;90(1–2):159–67

Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Müller EE, et al. Drugs 1995 Nov; 50(5):805–37 (285 ref.)

Effects of vasoactive intestinal peptide and its homologues on the acetylcholine–mediated secretion of fluid and protein from the rat submandibular gland. Iwabuchi Y, et al. Gen Pharmacol 1995 Sep;26(5):961–70

Effect of felodipine on cholinergic responses of the colonic smooth muscle of streptozotocin induced diabetic rats. Jaiprakash R, et al. Indian J Exp Biol 1995 Apr;33(4):297–9

Acetylcholine–induced calcium signaling associated with muscarinic receptor activation in cultured myenteric neurons. Simeone DM, et al. J Am Coll Surg 1996 Jun; 182(6):473–81

GABAergic neurons in the rat pontomesencephalic tegmentum: codistribution with cholinergic and other tegmental neurons projecting to the posterior lateral hypothalamus. Ford B, et al. J Comp Neurol 1995 Dec 11;363(2):177–96

Nerve growth factor prevents apoptotic cell death in injured central cholinergic neurons. Wilcox BJ, et al. J Comp Neurol 1995 Sep 4;359(4):573–85

The Ach–evoked Ca2+–activated K+ current in mouse mandibular secretory cells. Single channel studies. Hayashi T, et al. J Membr Biol 1996 May;151(1):19–27

Role of the afterhyperpolarization in control of discharge properties of septal cholinergic neurons in vitro. Gorelova N, et al. J Neurophysiol 1996 Feb;75(2):695–706

Histamine depolarizes cholinergic septal neurons. Gorelova N, et al. J Neurophysiol 1996 Feb;75(2):707–14

Characterization of GABA current in rat septal cholinergic neurons in culture and its modulation by metal cations. Kumamoto E, et al. J Neurophysiol 1995 Nov; 74(5):2012–27

Two distinct modes of Ca2+ signalling by ACh in rat pancreatic beta–cells: concentration, glucose dependence and Ca2+ origin. Yada T, et al. J Physiol (Lond) 1995 Oct 1;488 (Pt 1):13–24

Cholinergic and Related Mechanisms in Aging and Disease: a Tribute to Donald J. Jenden, M.D. Los Angeles, California, November 17–18, 1995. Life Sci 1996; 58(22):1909–2064

Optimal physical performance in athletes: key roles of dopamine in a specific neurotransmitter/hormonal mechanism. Gilbert C. Mech Ageing Dev 1995 Oct 13; 84(2):83–102 (85 ref.)

The problems with exocytosis. Marchbanks RM. Neurochem Int 1996 Jan;28(1):11–3

A neurochemical approach for studying response to acetylcholine in Alzheimer's disease. Alder JT, et al. Neurochem Res 1995 Jul;20(7):769–71

Neurobiology of Rett syndrome. Johnston MV, et al. Neuropediatrics 1995 Apr;26(2):119–22

Galanin inhibits the vasodilatatory basalocortical cholinergic system in the anaesthetized rat. Barbelivien A, et al. Neuroreport 1995 Oct 2;6(14):1849–52

Acetylcholine modulates ganglion cell activity in the trout pineal organ. Brandstätter R, et al. Neuroreport 1995 Jul 31;6(11):1553–6

Altered distribution of cholinergic cells in the narcoleptic dog. Nitz D, et al. Neuroreport 1995 Jul 31;6(11):1521–4

Acetylcholine activates a nicotinic receptor and an inward current in dorsal motor nucleus of the vagus neurons in vitro. Neff RA, et al. Neurosci Lett 1995 Aug 11; 195(3):163–6

Endogenous acetylcholine–induced Fos expression in magnocellular neurosecretory neurons in the supraoptic nucleus of the rat hypothalamus. Shen E, et al. Neurosci Lett 1995 Aug 11;195(3):191–4

Role of nitric oxide and acetylcholine in neocortical hyperemia elicited by basal forebrain stimulation: evidence for an involvement of endothelial nitric oxide. Zhang F, et al. Neuroscience 1995 Dec;69(4):1195–204

Cholinergic and vasoactive intestinal polypeptidergic innervation of the cerebral arteries. Dauphin F, et al. Pharmacol Ther 1995;67(3):385–417 (274 ref.)

Opposite actions of nitric oxide on cholinergic synapses: which pathways? Mothet JP, et al. Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8721–6

Requirement for cholinergic synaptic transmission in the propagation of spontaneous retinal waves. Feller MB, et

al. **Science** 1996 May 24;272(5265):1182–7

Arteriolar reactivity of endotoxin-tolerant rats after hemorrhage and reinfusion. Baker CH, et al. **Shock** 1995 Dec;4(6):455–60

[Role of cholinergic mechanisms in the functioning of specific structures of the visual analyzer] Aleksandrov MV, et al. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):64–8 **(Rus)**

SECRETION

Intravenous opioids stimulate norepinephrine and acetylcholine release in spinal cord dorsal horn. Systematic studies in sheep and an observation in a human. Bouaziz H, et al. **Anesthesiology** 1996 Jan;84(1):143–54

Reversed mode Na(+)–Ca2+ exchange activated by ciguatoxin (CTX–1b) enhances acetylcholine release from Torpedo cholinergic synaptosomes. Gaudry–Talarmain YM, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:404–6

Tetanus toxin inhibits spontaneous quantal release and cleaves VAMP/synaptobrevin. Herreros J, et al. **Brain Res** 1995 Nov 20;699(2):165–70

3,4–Diaminopyridine and choline increase in vivo acetylcholine release in rat striatum. Buyukuysal RL, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):179–85

Intermittent morphine treatment causes a protracted increase in cholinergic striatal neurotransmission measured ex vivo. Schoffelmeer AN, et al. **Eur J Pharmacol** 1995 Nov 24; 286(3):311–4

Intermittent and chronic morphine treatment induces long–lasting changes in delta–opioid receptor–regulated acetylcholine release in rat striatum and nucleus accumbens. Tjon GH, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):169–76

In vivo and in vitro effects of muscarinic receptor antagonists on contractions and release of [3H]acetylcholine in the rabbit urinary bladder. Tobin G, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):1–8

Homocysteate–evoked release of acetylcholine from the rabbit retina. Linn DM, et al. **J Neurochem** 1996 Jan; 66(1):153–60

Cd(2+)–and K(+)–evoked ACh release induce different synaptophysin and synaptobrevin immunolabelling at the frog neuromuscular junction. Colasante C, et al. **J Neurocytol** 1995 Aug;24(8):547–58

Beta–amyloid–related peptides inhibit potassium–evoked acetylcholine release from rat hippocampal slices. Kar S, et al. **J Neurosci** 1996 Feb 1;16(3):1034–40

Transmitter release by non–receptor activation of the alpha–subunit of guanine nucleotide regulatory protein in rat striatal slices. Zelles T, et al. **J Neurosci Res** 1995 Oct 1;42(2):242–51

A1, but not A2A, adenosine receptors modulate electrically stimulated [14C]acetylcholine release from rat cortex. Broad RM, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):193–7

Endogenous serotonin facilitates in vivo acetylcholine release in rat frontal cortex through 5–HT 1B receptors. Consolo S, et al. **J Pharmacol Exp Ther** 1996 May;277(2):823–30

Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes. DeBoer P, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):775–83

Arachidonic acid cascade and stimulation of acetylcholine release by human recombinant interleukin–1 beta in guinea pig ileum. Mameya S, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):319–24

Effects of H–89, an inhibitor of protein kinase A, on the acetylcholine release from myenteric plexus of guinea pig ileum. Takeuchi T, et al. **J Smooth Muscle Res** 1995 Aug; 31(4):143–51

Ca2+ antagonists reveal a novel inhibitory effect of caerulein on guinea pig ileum. Mantovani P, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun;17(5):321–5

Subclassification of presynaptic alpha 2–adrenoceptors: alpha 2D–autoreceptors and alpha 2D–adrenoceptors modulating release of acetylcholine in guinea–pig ileum. Funk L, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):58–66

Nitric oxide modulates the release of acetylcholine in the ventral striatum of the freely moving rat. Prast H, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):67–73

Calcium–dependent transmitter secretion from fibroblasts: modulation by synaptotagmin I. Morimoto T, et al. **Neuron** 1995 Sep;15(3):689–96

Differential effects of calcium channel antagonists on tityustoxin and ouabain–induced release of [3H]acetylcholine from brain cortical slices. Casali TA, et al. **Neuropharmacology** 1995 Jun;34(6):599–603

Adenosine A2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Cunha RA, et al. **Neurosci Lett** 1995 Aug 18;196(1–2):41–4

The effect of PhTx3 on the release of 3H–acetylcholine induced by tityustoxin and potassium in brain cortical slices and myenteric plexus. Gomez RS, et al. **Neurosci Lett** 1995 Aug 18;196(1–2):131–3

Hippocampal acetylcholine release during memory testing in rats: augmentation by glucose. Ragozzino ME, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4693–8

Enhancement of acetylcholine release by flumazenil in the hippocampus of rats chronically treated with diazepam but not with imidazenil or abecarnil. Dazzi L, et al. **Psychopharmacology (Berl)** 1995 Sep;121(2):180–5

Inhibitory effect of dopamine on gastric motility in rats. Nagahata Y, et al. **Scand J Gastroenterol** 1995 Sep; 30(9):880–5

TOXICITY

Modulation of acetylcholine, capsaicin and substance P effects by histamine H3 receptors in isolated perfused rabbit lungs. Delaunois A, et al. **Eur J Pharmacol** 1995 Apr 24; 277(2–3):243–50

Evaluation of retinal toxicity of acetylcholine in rabbit eyes. Ahn DS, et al. **Retina** 1995;15(4):327–31

ACETYLCHOLINE AGENTS see **CHOLINERGIC AGENTS**

ACETYLCHOLINE AGONISTS see **CHOLINERGIC AGONISTS**

ACETYLCHOLINE ANTAGONISTS see **CHOLINERGIC ANTAGONISTS**

ACETYLCHOLINE RECEPTORS see **RECEPTORS, CHOLINERGIC**

ACETYLCHOLINESTERASE

ANALYSIS

Activity of acetylcholinesterase and unspecific cholinesterase during differentiation of somites in mouse embryos. al–Fakhri N, et al. **Anat Embryol (Berl)** 1995 Sep; 192(3):257–64

Identification and isolation of two rat serum proteins with A–esterase activity toward paraoxon and chlorpyrifos–oxon. Pond AL, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):363–9

Monoclonal antibodies against a C–terminal peptide of human brain acetylcholinesterase distinguish between erythrocyte and brain acetylcholinesterases. Boschetti N, et al. **Clin Chem** 1996 Jan;42(1):19–23

Acetylcholinesterase of human intestinal tissue affected by Hirschsprung's disease: effect of magnesium chloride on isoforms. Johnson G, et al. **Clin Chim Acta** 1995 Dec 29; 243(2):115–28

Acetylcholinesterase from Bungarus venom: a monomeric species. Cousin X, et al. **FEBS Lett** 1996 Jun 3; 387(2–3):196–200

Colocalization of NADPH–diaphorase and acetylcholinesterase in the rat olfactory bulb. Crespo C, et al. **J Chem Neuroanat** 1995 Oct;9(3):207–16

Perfusion immunoassay for acetylcholinesterase: analyte detection based on intrinsic activity. Vanderlaan M, et al. **J Chromatogr A** 1995 Sep 8;711(1):23–31

Ultrastructural identification of cholinergic neurons in the external cuneate nucleus of the gerbil: acetylcholinesterase histochemistry and choline acetyltransferase immunocytochemistry. Lan CT, et al. **J Neurocytol** 1995 Nov;24(11):838–52

Acetylcholinesterase in tentacles of Octopus vulgaris (Cephalopoda). Histochemical localization and characterization of a specific high salt–soluble and heparin–soluble fraction of globular forms. Talesa V, et al. **Neurochem Int** 1995 Aug;27(2):201–11

Molecular forms of acetyl– and butyrylcholinesterase in human glioma. Sáez–Valero J, et al. **Neurosci Lett** 1996 Mar 15;206(2–3):173–6

Length density and total length of acetylcholinesterase positive nerves related to cystometry and in vitro studies of muscle strips in mini–pig urinary bladder after chronic outflow obstruction and recovery from obstruction. Nielsen KK, et al. **Neurourol Urodyn** 1995;14(4):379–95

Alpha–fetoprotein and acetylcholinesterase activity in first– and early second–trimester amniotic fluid. Jørgensen FS, et al. **Prenat Diagn** 1995 Jul;15(7):621–5

[Acetylcholinesterase–positive innervation of the thymus in old rats after ovariectomy] Dorko F, et al. **Bratisl Lek Listy** 1996 May;97(5):298–300 (Eng. Abstr.) **(Slo)**

ANTAGONISTS & INHIBITORS see **CHOLINESTERASE INHIBITORS**

BIOSYNTHESIS

Differential expression of acetylcholinesterase in the developing barrel cortex of three rodent species. Sendemir E, et al. **Cereb Cortex** 1996 May–Jun;6(3):377–87

Stable expression of acetylcholinesterase and associated collagenic subunits in transfected RBL cell lines: production of GPI–anchored dimers and collagen–tailed forms. Coussen F, et al. **Eur J Cell Biol** 1995 Jul; 67(3):254–60

Regulation of acetylcholinesterase expression during neuronal differentiation. Coleman BA, et al. **J Biol Chem** 1996 Feb 23;271(8):4410–6

Thyroid hormones stabilize acetylcholinesterase mRNA in neuro–2A cells that overexpress the beta 1 thyroid receptor. Puymirat J, et al. **J Biol Chem** 1995 Dec 22; 270(51):30651–6

Overexpression of alternative human acetylcholinesterase forms modulates process extensions in cultured glioma cells. Karpel R, et al. **J Neurochem** 1996 Jan;66(1):114–23

Truncated form of pro–acetylcholine receptor–inducing activity (ARIA) induces AChR alpha–subunit but not AChE transcripts in cultured chick myotubes. Pun S, et al. **Neurosci Lett** 1995 Sep 29;198(2):107–10

BLOOD

Glycoinositol phospholipid anchor and protein C–terminus of bovine erythrocyte acetylcholinesterase: analysis by mass spectrometry and by protein and DNA sequencing. Haas R, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):817–25

Mercuric chloride effects on the kinetic parameters of human erythrocyte membrane bound acetylcholinesterase. Aijafari AA. **Biochem Mol Biol Int** 1995 Aug;36(6):1243–53

Optimization and kinetic studies of human erythrocyte membrane–bound acetylcholinesterase. al–Jafari AA, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):577–86

Cholinesterase inhibition: complexities in interpretation. Lotti M. **Clin Chem** 1995 Dec;41(12 Pt 2):1814–8 (22 ref.)

Activities of acetylcholinesterase and NA+, K+ –ATP–ase in human erythrocytes after ethanol consumption. Dudek IM, et al. **Int J Occup Med Environ Health** 1995;8(2):109–14

Serum cholinesterase in obsessive–compulsive disorder. Erzegovesi S, et al. **Psychiatry Res** 1995 Oct 16;58(3):265–8

[Activity of cholinesterase of erythrocyte membrane in patients with hot or cold syndrome] Fu H, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun; 15(6):351–2 **(Chi)**

[Catalytic properties of cholinesterases immobilized in N–phthalylchitosan and gelatin] Kuznetsova LP, et al. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):49–54 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Increased acetylcholinesterase activity in the CSF of Alzheimer patients carrying apolipoprotein epsilon4 allele. Soininen H, et al. **Neuroreport** 1995 Dec 15;6(18):2518–20

CHEMISTRY

Conversion of acetylcholinesterase hydrophilic tetramers into amphiphilic dimers and monomers. Flores–Flores C, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):53–8

Glycoinositol phospholipid anchor and protein C–terminus of bovine erythrocyte acetylcholinesterase: analysis by mass spectrometry and by protein and DNA sequencing. Haas R, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):817–25

Allosteric modulation of acetylcholinesterase activity by peripheral ligands involves a conformational transition of the anionic subsite. Barak D, et al. **Biochemistry** 1995 Nov 28;34(47):15444–52

Specificity and orientation of trigonal carboxyl esters and tetrahedral alkylphosphonyl esters in cholinesterases. Hosea NA, et al. **Biochemistry** 1995 Sep 12;34(36):11528–36

Biochemical evaluation of photolabile precursors of choline and of carbamylcholine for potential time–resolved crystallographic studies on cholinesterases. Peng L, et al. **Biochemistry** 1996 Aug 20;35(33):10854–61

Residues in Torpedo californica acetylcholinesterase necessary for processing to a glycosyl phosphatidylinositol–anchored form. Bucht G, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):223–32

Effect of protamine on the solubilization of collagen–tailed acetylcholinesterase: potential heparin–binding consensus sequences in the tail of the enzyme. Deprez PN, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):53–8

Electrooptical measurements demonstrate a large permanent dipole moment associated with acetylcholinesterase. Porschke D, et al. **Biophys J** 1996 Apr;70(4):1603–8

The membrane anchor of mammalian brain acetylcholinesterase consists of a single glycosylated protein of 22 kDa. Boschetti N, et al. **FEBS Lett** 1996 Feb 12;380(1–2):133–6

Cloning and expression of acetylcholinesterase from Bungarus fasciatus venom. A new type of cooh–terminal domain; involvement of a positively charged residue in the peripheral site. Cousin X, et al. **J Biol Chem** 1996 Jun 21; 271(25):15099–108

The architecture of human acetylcholinesterase active center probed by interactions with selected organophosphate inhibitors. Ordentlich A, et al. **J Biol Chem** 1996 May 17; 271(20):11953–62

Transient interactions between collagen–tailed acetylcholinesterase and sulfated proteoglycans prior to immobilization on the extracellular matrix. Rossi SG, et al. **J Biol Chem** 1996 Jan 26;271(4):1979–87

Oligomerization of chicken acetylcholinesterase does not require intersubunit disulfide bonds. Gough NR, et al. **J Neurochem** 1995 Dec;65(6):2734–41

Irreversible thermal denaturation of Torpedo californica acetylcholinesterase. Kreimer DI, et al. **Protein Sci** 1995 Nov;4(11):2349–57

Soluble monomeric acetylcholinesterase from mouse: expression, purification, and crystallization in complex with fasciculin. Marchot P, et al. **Protein Sci** 1996 Apr;5(4):672–9

Interaction of partially unfolded forms of Torpedo acetylcholinesterase with liposomes. Shin I, et al. **Protein Sci** 1996 Jan;5(1):42–51

Crystal structure of an acetylcholinesterase–fasciculin complex: interaction of a three–fingered toxin from snake venom with its target. Harel M, et al. **Structure** 1995 Dec 15;3(12):1355–66

Differential inhibition of rat brain acetylcholinesterase

molecular forms by 7-methoxytacrine in vitro. Bajgar J, et al. **Toxicol Lett** 1995 Oct;80(1-3):109-14

DRUG EFFECTS

Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). Nochi S, et al. **Biol Pharm Bull** 1995 Aug;18(8):1145-7

Inhibition of acetylcholinesterase activity in the central nervous system of the red swamp crayfish, Procambarus clarkii, by mercury, cadmium, and lead. Devi M, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):746-50

The effect of ondansetron on pyridostigmine-induced blood acetylcholinesterase inhibition in the guinea pig. Capacio BR, et al. **Drug Chem Toxicol** 1996;19(1-2):1-19

Centrophenoxine activates acetylcholinesterase activity in hippocampus of aged rats. Sharma D, et al. **Indian J Exp Biol** 1995 May;33(5):365-8

Effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1 -H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models. Miyamoto M, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1292-304

GENETICS

Chronic enhancement of neuromuscular activity increases acetylcholinesterase gene expression in skeletal muscle. Sveistrup H, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C856-62

Developmental regulation of acetylcholinesterase transcripts in the mouse diaphragm: alternative splicing and focalization. Legay C, et al. **Eur J Neurosci** 1995 Aug 1; 7(8):1803-9

Antisense inhibition of acetylcholinesterase gene expression causes transient hematopoietic alterations in vivo. Lev-Lehman E, et al. **Gene Ther** 1994 Mar;1(2):127-35

Cloning and sequencing of a cDNA encoding acetylcholinesterase in Colorado potato beetle, Leptinotarsa decemlineata (Say). Zhu KY, et al. **Insect Biochem Mol Biol** 1995 Dec;25(10):1129-38

Transcription factor repression and activation of the human acetylcholinesterase gene. Getman DK, et al. **J Biol Chem** 1995 Oct 6;270(40):23511-9

Acetylcholinesterase and nicotinic acetylcholine receptor expression diverge in muscular dysgenic mice lacking the L-type calcium channel. Luo ZD, et al. **J Neurochem** 1996 Jul;67(1):111-8

Reinnervation of a denervated slow muscle triggers high extrajunctional expression of the asymmetric molecular forms of acetylcholinesterase. Crne-Finderle N, et al. **J Neurosci Res** 1995 Aug 15;41(6):745-52

Deletion of the acetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Stephenson J, et al. **Leuk Res** 1996 Mar; 20(3):235-41

Replacement of the glycoinositol phospholipid anchor of Drosophila acetylcholinesterase with a transmembrane domain does not alter sorting in neurons and epithelia but results in behavioral defects. Incardona JP, et al. **Mol Biol Cell** 1996 Apr;7(4):613-30

IMMUNOLOGY

Monoclonal antibodies against acetylcholinesterase of Schistosoma mansoni: production and characterization. Espinoza B, et al. **Hybridoma** 1995 Dec;14(6):577-86

Immunisation of guinea pigs against Dictyocaulus viviparus using adult ES products enriched for acetylcholinesterases. McKeand JB, et al. **Int J Parasitol** 1995 Jul;25(7):829-37

Lowered norepinephrine turnover as a sign of impaired ganglionic transmission after preganglionic lesioning by acetylcholinesterase antibodies. McKinzie S, et al. **J Pharmacol Exp Ther** 1996 May;277(2):817-22

Preparation and assay of acetylcholinesterase antibody. Friboulet A, et al. **Methods Mol Biol** 1995;51:211-22

ISOLATION & PURIFICATION

Acetylcholinesterase from desert cobra (Walterinnesia aegyptia) venom: optimization and kinetics study. AlJafari AA, et al. **Mol Cell Biochem** 1995 Oct 4;151(1):21-6

Purification of acetylcholinesterase by tacrine affinity chromatography. Carroll RT, et al. **Protein Expr Purif** 1995 Aug;6(4):389-93

METABOLISM

Post-inoculation changes in enzyme activity of Aedes aegypti infected with Chikungunya virus. Mourya DT, et al. **Acta Virol** 1995 Feb;39(1):31-5

Cholinesterases and the pathology of Alzheimer disease. Geula C, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:23-8

Methantheline improves the reactivation by HI 6 of human erythrocyte acetylcholinesterase inhibited by soman in vitro. Hallek M, et al. **Arch Toxicol** 1995;70(1):16-9

Ultrastructure of Psammobatis extenta (Rajidae) electrolytes and cytochemical localization of acetylcholinesterase, acetylcholine receptor and F-actin. Prado Figueroa M, et al. **Biocell** 1995 Aug;19(2):113-23

Protein ligand interactions 7 halogenated pyridinium salts as inhibitors of acetylcholinesterase from Electrophorus electricus. Whiteley CG, et al. **Biochem Mol Biol Int** 1995 Aug;36(5):1107-16

Temperature-nearly-independent binding constant in several biochemical systems. The underlying entropy-driven binding mechanism and its practical significance. Miklavc A. **Biochem Pharmacol** 1996 Mar 22;51(6):723-9

Aspartate 74 as a primary determinant in acetylcholinesterase governing specificity to cationic organophosphonates. Hosea NA, et al. **Biochemistry** 1996 Aug 20; 35(33):10995-1004

Binding of the neurotoxin fasciculin 2 to the acetylcholinesterase peripheral site drastically reduces the association and dissociation rate constants for N-methylacridinium binding to the active site. Rosenberry TL, et al. **Biochemistry** 1996 Jan 23;35(3):685-90

Residues in Torpedo californica acetylcholinesterase necessary for processing to a glycosyl phosphatidylinositol-anchored form. Bucht G, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):223-32

Binding of tacrine and 6-chlorotacrine by acetylcholinesterase. Wlodek ST, et al. **Biopolymers** 1996 Jan;38(1):109-17

Inhibition of bovine brain acetylcholinesterase by aluminum. Moraes MS, et al. **Braz J Med Biol Res** 1994 Nov; 27(11):2635-8

Cholinergic signaling in the rat pineal gland. Laitinen JT, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):177-92 (72 ref.)

Esterase comparison in neuroblastoma cells of human and rodent origin. Ehrich M, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):385-6

Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice. Beeri R, et al. **Curr Biol** 1995 Sep 1;5(9):1063-71

In vivo effects of deltamethrin exposure on activity and distribution of molecular forms of carp AChE. Szegletes T, et al. **Ecotoxicol Environ Saf** 1995 Aug;31(3):258-63

Acetylcholinesterase in Dendrobaena veneta (Oligochaeta: Opisthopora) is present with forms sensitive and insensitive to phosphatidylinositol phospholipase C. Biochemical characterization and histochemical localization in the nervous system. Talesa V, et al. **Eur J Biochem** 1996 Jun 1;238(2):538-48

Histochemical demonstration of acetylcholinesterase activity in human Meibomian glands. Perra MT, et al. **Eur J Histochem** 1996;40(1):39-44

Development of acetylcholinesterase-positive thalamic and basal forebrain afferents to embryonic rat neocortex. De Carlos JA, et al. **Exp Brain Res** 1995;104(3):385-401

Postnatal development of cortical acetylcholinesterase-rich neurons in the rat brain: permanent and transient patterns. Geula C, et al. **Exp Neurol** 1995 Aug;134(2):157-78

Murine and human mast cell express acetylcholinesterase. Nechushtan H, et al. **FEBS Lett** 1996 Jan 22;379(1):1-6

The rate of thermal inactivation of Torpedo acetylcholinesterase is not reduced in the C231S mutant. Wilson EJ, et al. **FEBS Lett** 1996 Jan 29;379(2):161-4

Acetylcholinesterase-positive afferent axons in mucosa of urinary bladder of adult cats: retrograde tracing and degeneration studies. Wakabayashi Y, et al. **Histol Histopathol** 1995 Jul;10(3):523-30

Parasympatholytic activity of psychoactive drugs in rat brain mitochondria. Nag M, et al. **Indian J Exp Biol** 1995 Jun; 33(6):462-3

Kinetics for the inhibition of acetylcholinesterase from human erythrocyte by cisplatin. Aljafari AA. **Int J Biochem Cell Biol** 1995 Sep;27(9):965-70

Effect of prolonged starvation on the activities of malic enzyme and acetylcholinesterase in tissues of Japanese quail. Kim HI, et al. **Int J Biochem Cell Biol** 1995 Nov; 27(11):1161-7

Physiological regulation of G4 ACh in fast-twitch muscle: effects of exercise and CGRP. Fernandez HL, et al. **J Appl Physiol** 1996 Jan;80(1):357-62

Cloning and expression of acetylcholinesterase from Bungarus fasciatus venom. A new type of cooh-terminal domain; involvement of a positively charged residue in the peripheral site. Cousin X, et al. **J Biol Chem** 1996 Jun 21; 271(25):15099-108

Protein ligand interactions. Part 5: Isoquinoline alkaloids as inhibitors of acetylcholinesterase from Electrophorus electricus. Whiteley CG, et al. **J Enzym Inhib** 1995; 9(4):285-94

In vivo imaging of human cerebral acetylcholinesterase. Pappata S, et al. **J Neurochem** 1996 Aug;67(2):876-9

Modulation in acetylcholinesterase of rat brain by pyrethroids in vivo and an in vitro kinetic study. Rao GV, et al. **J Neurochem** 1995 Nov;65(5):2259-66

Glutamate-receptor elicited acetylcholinesterase release in mouse spinal cord slice: a model of early excitotoxic injury. Rodríguez-Ithurralde D, et al. **J Neurol Sci** 1995 May;129 Suppl:104-6

Acetylcholinesterase expression in NTera 2 human neuronal cells: a model for developmental expression in the nervous system. Llanes C, et al. **J Neurosci Res** 1995 Dec 15; 42(6):791-802

Acetyl- and butyrylcholinesterase activities in the rat retina and retinal pigment epithelium. Sánchez-Chávez G, et al. **J Neurosci Res** 1995 Aug 1;41(5):655-62

Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. Irie T, et al. **J Nucl Med** 1996 Apr;37(4):649-55

Evaluation of the nature of rat retinal acetylcholinesterase using a specific substrate and a specific inhibitor. Sastry BV, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):401-9

Scanning electron microscopic observations of nerves in the guinea-pig gallbladder after an acetylcholinesterase histochemistry. Gonda T, et al. **J Smooth Muscle Res** 1995 Aug;31(4):153-62

Effects of tacrine (THA) on spatial reference memory and cholinergic enzymes in specific rat brain regions. Jackson JJ, et al. **Life Sci** 1996;58(1):47-54

Construction and characterization of secreted and chimeric transmembrane forms of Drosophila acetylcholinesterase: a large truncation of the C-terminal signal peptide does not eliminate glycoinositol phospholipid anchoring. Incardona JP, et al. **Mol Biol Cell** 1996 Apr;7(4):595-611

6-Coumarin diazonium salt: a specific affinity label of the Torpedo acetylcholinesterase peripheral site. Schalk I, et al. **Mol Pharmacol** 1995 Dec;48(6):1063-7

Properties of acetylcholinesterase reconstituted in liposomes of a different charge. Cho Y, et al. **Neurochem Res** 1995 Jun;20(6):681-7

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Inestrosa NC, et al. **Neuron** 1996 Apr;16(4):881-91

Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-beta-peptides. Alvarez A, et al. **Neurosci Lett** 1995 Dec 1;201(1):49-52

Inverse correlation of acetylcholinesterase (AChE) activity with the presence of neurofilament inclusions in dorsal root ganglion neurons cultured in the presence of a reversible inhibitor of AChE. Dupree JL, et al. **Neurosci Lett** 1995 Sep 1;197(1):37-40

Monomers and dimers of acetylcholinesterase in human meningioma are anchored to the membrane by glycosylphosphatidylinositol. Sáez-Valero J, et al. **Neurosci Lett** 1995 Aug 4;195(2):101-4

Phenobarbital in the anticonvulsant dose range does not impair learning and memory or alter brain AChE activity or monoamine levels. Sudha S, et al. **Pharmacol Biochem Behav** 1996 Jul;54(3):633-8

Chronic phenytoin induced impairment of learning and memory with associated changes in brain acetylcholine esterase activity and monoamine levels. Sudha S, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):119-24

Enzymological differences of AChE and diazinon hepatic metabolism: correlation of in vitro data with the selective toxicity of diazinon to fish species. Keizer J, et al. **Sci Total Environ** 1995 Oct 27;171(1-3):213-20

In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[11C]methylpiperdin-4-yl propionate ([11C]PMP). Kilbourn MR, et al. **Synapse** 1996 Feb; 22(2):123-31

Modification of acetylcholinesterase during adaptation to chronic, subacute paraoxon application in rat. Milatovic D, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):20-8

Fosinopril treatment of pregnant rats: developmental toxicity, fetal angiotensin-converting enzyme inhibition, and fetal angiotensin II receptor regulation. Grove KL, et al. **Toxicol Lett** 1995 Oct;80(1-3):85-95

Oxime-induced reactivation of acetylcholinesterase inhibited by phosphoramidates. Jokanović M, et al. **Toxicol Lett** 1996 Apr;85(1):35-9

PHARMACOLOGY

Acetylcholinesterase-induced respiratory burst in macrophages: evidence for the involvement of the macrophage mannose-fucose receptor. Klegeris A, et al. **Biochim Biophys Acta** 1996 Feb 9;1289(1):159-68

Recombinant acetylcholinesterase has behavioural effects in the rat substantia nigra not attributable to its enzymatic activity. Hawkins CA, et al. **Neurosci Lett** 1995 Sep 15; 197(3):203-6

Bromoacetylcholine and acetylcholinesterase introduced via liposomes into motor nerve endings block increases in quantal size. Brailoiu E, et al. **Pflugers Arch** 1996 Jul; 432(3):413-8

PHYSIOLOGY

Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. McGaughy J, et al. **Behav Neurosci** 1996 Apr; 110(2):247-65

Site-directed mutants designed to test back-door hypotheses of acetylcholinesterase function. Faerman C, et al. **FEBS Lett** 1996 May 13;386(1):65-71

Tetrameric (G4) acetylcholinesterase: structure, localization, and physiological regulation. Fernandez HL, et al. **J Neurochem** 1996 Apr;66(4):1335-46 (120 ref.)

Oligomerization of chicken acetylcholinesterase does not require intersubunit disulfide bonds. Gough NR, et al. **J Neurochem** 1995 Dec;65(6):2734-41

SECRETION

Release of acetylcholinesterase from guinea-pig substantia nigra: effects of tryptaminergic drugs and dorsal raphé nucleus stimulation. Dickie BG, et al. **Neuropharmacology** 1995 Sep;34(9):1191-200

ACETYLCHOLINESTERASE INHIBITORS see **CHOLINESTERASE INHIBITORS**

ACETYLCYSTEINE

New ET-Kyoto solution containing N-acetylcysteine, nitroglycerin, and dibutyryl cyclic AMP provides reliable 30-hour canine lung preservation. Liu CJ, et al. **Transplant Proc** 1996 Jun;28(3):1871-3

The use of N-acetylcysteine in solid-organ preservation solutions [letter; comment] Spaggiari L, et al. **Transplantation** 1996 Jan 15;61(1):172. Comment on: Transplantation 1995 Jan 15;59(1):6-9.

ADMINISTRATION & DOSAGE

Acetaminophen overdose: need to consider intravenous preparation of N-acetylcysteine in the United States [letter] Dhawan A, et al. **Am J Gastroenterol** 1996 Jul;91(7):1476

N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Arstall MA, et al. **Circulation** 1995 Nov 15;92(10):2855-62

Drug-induced hepatotoxicity [letter; comment] De Roos FJ, et al. **N Engl J Med** 1996 Mar 28;334(13):863; discussion 864. Comment on: N Engl J Med 1995 Oct 26;333(17):1118-27.

De medicamenteuze behandeling van chronisch obstructieve longziekte [Drug treatment of chronic obstructive lung disease (letter)] Cabolet P. **Ned Tijdschr Geneeskd** 1996 Aug 17;140(33):1705

Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy. Gallon AM. **Thorax** 1996 Apr;51(4):429-32

[Clinical-toxicological case (1). Dosage of N-acetylcysteine in acute paracetamol poisoning] Kind B, et al. **Schweiz Rundsch Med Prax** 1996 Aug 2;85(31-32):935-8 (33 ref.) (Eng. Abstr.) **(Ger)**

[The dissolution of cystine lithiasis with n-acetylcysteine] Benítez Navio J, et al. **Arch Esp Urol** 1995 Nov;48(9):944-8 (13 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Antidotes: benefits and risks. Proudfoot AT. **Toxicol Lett** 1995 Dec;82-83:779-83 (20 ref.)

ANALOGS & DERIVATIVES

Deprotection of S-acetamidomethyl cysteine-containing peptides by silver trifluoromethanesulfonate avoids the oxidation of methionines. Hunter MJ, et al. **Anal Biochem** 1995 Jun 10;228(1):173-7

Induction of a permeability transition in rat kidney mitochondria by pentachlorobutadienyl cysteine: a beta-lyase-independent process. Brown PC, et al. **Arch Biochem Biophys** 1996 Jul 15;331(2):225-31

Fate and distribution of (14C]S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine, an antimutagenic mixed disulfide from disulfiram, in rats. Lee BH, et al. **Arzneimittelforschung** 1995 Dec; 45(12):1319-23

Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Imajoh-Ohmi S, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):1070-7

Inhibitors of farnesyl and geranylgeranyl methyltransferases prevent beta 2 integrin-induced actin polymerization without affecting beta 2 integrin-induced Ca2+ signaling in neutrophils. Molony L, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):612-7

Lactacystin, an inhibitor of the proteasome, blocks the degradation of a mutant precursor of glycosylphosphatidylinositol-linked protein in a pre-Golgi compartment. Oda K, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):800-5

Neuronal differentiation of Neuro 2a cells by lactacystin and its partial inhibition by the protein phosphatase inhibitors calyculin A and okadaic acid. Tanaka H, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):291-7

Stimulation of erythrocyte membrane Mg(2+)-ATPase activity by glutathione S-conjugates. Sokal A, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):73-9

Prenylcysteine analogs mimicking the C-terminus of GTP-binding proteins stimulate exocytosis from permeabilized HIT-T15 cells: comparison with the effect of Rab3AL peptide. Regazzi R, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):269-78

Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Jensen TJ, et al. **Cell** 1995 Oct 6;83(1):129-35

Acrolein mercapturates: synthesis, characterization, and assessment of their role in the bladder toxicity of cyclophosphamide. Ramu K, et al. **Chem Res Toxicol** 1995 Jun;8(4):515-24

The sulfoxidation of the hexachlorobutadiene metabolite N-acetyl-S-(1,2,3,4,4-pentachlorobutadienyl)-L-cysteine is catalyzed by human cytochrome P450 3A enzymes. Werner M, et al. **Chem Res Toxicol** 1995 Oct-Nov; 8(7):917-23

Fourier-transform ion cyclotron resonance mass spectrometric evidence for the formation of alpha-chloroenethiolates and thioketenes from chloroalkene-derived, cytotoxic 4-thiaalkanoates. Zhang TL, et al. **Chem Res Toxicol** 1995 Oct-Nov;8(7):907-10

The role of cytochrome P4503A1/2 in the sex-specific sulfoxidation of the hexachlorobutadiene metabolite, N-acetyl-S-(pentachlorobutadienyl)-L-cysteine in rats. Werner M, et al. **Drug Metab Dispos** 1995 Aug;23(8):861-8

Biosynthesis of lactacystin. Takahashi S, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):1015-20

Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. Dick LR, et al. **J Biol Chem** 1996 Mar 29; 271(13):7273-6

Biological monitoring of exposure to benzene: a comparison between S-phenylmercapturic acid, trans,trans-muconic acid, and phenol. Boogaard PJ, et al. **Occup Environ Med** 1995 Sep;52(9):611-20

N-Acetyl-L-cysteine and its derivatives activate a Cl-conductance in epithelial cells. Köttgen M, et al. **Pflugers Arch** 1996 Feb;431(4):549-55

Nitric oxide inhibits creatine kinase and regulates rat heart contractile reserve. Gross WL, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5604-9

Biotransformation of acrolein in rat: excretion of mercapturic acids after inhalation and intraperitoneal injection. Linhart I, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):155-60

[Lactacystin: a tool for elucidation of proteasome functions] Omura S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(4):327-36 (57 ref.) **(Jpn)**

CHEMISTRY

Identification of N-acetylcysteine conjugates of 1,2-dibromo-3-chloropropane: evidence for cytochrome P450 and glutathione mediated bioactivation pathways. Weber GL, et al. **Chem Res Toxicol** 1995 Jun;8(4):560-73

Interactions between reactive oxygen species and sulfhydryl groups of cysteine, acetylcysteine and glutathione. Robak J, et al. **Pol J Pharmacol** 1995 Jan-Feb;47(1):59-62

[Biological monitoring of exposure to alkylating xenobiotics by determining them in complexes with plasma proteins, hemoglobin, mercapturic acids from urine of rats and industrial workers. I. Acrylonitrile] Ivanov VV, et al. **Vopr Med Khim** 1995 Jul-Aug;41(4):18-22 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Detection of human IgG antibodies against free N-acetyl-L-cysteine. Maes RF. **Immunol Lett** 1995 Nov; 48(1):49-52

METABOLISM

Inhibition of human leukaemia 60 cell growth by mercapturic acid metabolites of phenylethyl isothiocyanate. Adesida A, et al. **Food Chem Toxicol** 1996 Apr;34(4):385-92

4-hydroxynonenal is degraded to mercapturic acid conjugate in rat kidney. Petras T, et al. **Free Radic Biol Med** 1995 Nov;19(5):685-8

Mercapturic acid formation in cultured opossum kidney cells. Golenhofen N, et al. **Ren Physiol Biochem** 1995 Jul-Aug; 18(4):191-7

PHARMACOKINETICS

Bioavailability of cefpodoxime proxetil with co-administered acetylcysteine. Kees F, et al. **Arzneimittelforschung** 1996 Apr;46(4):435-8

Uptake and distribution of N-acetylcysteine in mice: tissue-specific effects on glutathione concentrations. McLellan LI, et al. **Carcinogenesis** 1995 Sep;16(9):2099-106

PHARMACOLOGY

Prevention of intracellular adenosine triphosphate depletion after sublethal oxidant injury to rat type II alveolar epithelial cells with exogenous glutathione and N-acetylcysteine. Pacht ER, et al. **Am J Med Sci** 1995 Oct;310(4):133-7

N-acetylcysteine inhibits loss of diaphragm function in streptozotocin-treated rats. Hida W, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1875-9

Effective 30-hour preservation of canine lungs with modified ET-Kyoto solution. Wada H, et al. **Ann Thorac Surg** 1996 Apr;61(4):1099-105

N-acetylcysteine inhibits production of tumor necrosis factor alpha and interleukin-1 beta [letter] Redondo P, et al. **Arch Intern Med** 1996 Jun 10;156(11):1238, 1241

Efficacy of topical tuaminoheptane combined with N-acetyl-cysteine in reducing nasal resistance. A double-blind rhinomanometric study versus xylometazoline and placebo. Cogo A, et al. **Arzneimittelforschung** 1996 Apr;46(4):385-8

Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Bostom AG, et al. **Atherosclerosis** 1996 Feb;120(1-2):241-4

Cyclic strain-induced plasminogen activator inhibitor-1 (PAI-1) release from endothelial cells involves reactive oxygen species. Cheng JJ, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):100-5

N-acetylcysteine diminishes injury induced by balloon angioplasty of the carotid artery in rabbits. Mass H, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):613-8

N-acetylcysteine protects lymphocytes from nitrogen mustard-induced apoptosis. Weltin D, et al. **Biochem Pharmacol** 1996 May 3;51(9):1123-9

In vitro antioxidant treatment recovers proliferative responses of anergic CD4+ lymphocytes from human immunodeficiency virus-infected individuals. Cayota A, et al. **Blood** 1996 Jun 1;87(11):4746-53

L-2-Oxothiazolidine-4-carboxylate and N-acetylcysteine as precursors of intracellular glutathione in human peritoneal mesothelial cells. Breborowicz A, et al. **Blood Purif** 1996; 14(1):1-7

Induction by carcinogens and chemoprevention by N-acetylcysteine of adducts to mitochondrial DNA in rat organs. Balansky R, et al. **Cancer Res** 1996 Apr 1; 56(7):1642-7

Biomarker alterations produced in rat lung by intratracheal instillations of air particulate extracts and chemoprevention with oral N-acetylcysteine. Izzotti A, et al. **Cancer Res** 1996 Apr 1;56(7):1533-8

Influence of the antioxidant N-acetylcysteine and its metabolites on damage induced by bleomycin in PM2 bacteriophage DNA. Cloos J, et al. **Carcinogenesis** 1996 Feb;17(2):327-31

N-acetyl-cysteine enhances cell adhesion properties of epithelial and lymphoid cells. Rivabene R, et al. **Cell Biol Int** 1995 Aug;19(8):681-6

N-acetylcysteine (NAC) enhances interleukin-2 but suppresses interleukin-4 secretion from normal and HIV+ CD4+ T-cells. Eylar EH, et al. **Cell Mol Biol (Noisy-le-grand)** 1995;41 Suppl 1:S35-40

Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Sagara M, et al. **Diabetologia** 1996 Mar;39(3):263-9

Effects of N-acetyl-L-cysteine on regional blood flow during endotoxic shock. Zhang H, et al. **Eur Surg Res** 1995; 27(5):292-300

Inhibition of human leukaemia 60 cell growth by mercapturic acid metabolites of phenylethyl isothiocyanate. Adesida A, et al. **Food Chem Toxicol** 1996 Apr;34(4):385-92

Effects of N-acetylcysteine in the rat heart reperfused after low-flow ischemia: evidence for a direct scavenging of hydroxyl radicals and a nitric oxide-dependent increase in coronary flow. Brunet J, et al. **Free Radic Biol Med** 1995 Nov;19(5):627-38

Effects of N-acetyl-L-cysteine on T-cell apoptosis are not mediated by increased cellular glutathione. Jones DP, et al. **Immunol Lett** 1995 Mar;45(3):205-9

The effect of N-acetylcysteine on exercise-induced priming of human neutrophils. A chemiluminescence study. Huupponen MR, et al. **Int J Sports Med** 1995 Aug; 16(6):399-403

N-acetylcysteine administration and loaded breathing. Supinski GS, et al. **J Appl Physiol** 1995 Jul;79(1):340-7

N-acetyl-L-cysteine abolishes the bromoethylamine-induced choline incorporation into renal papillary tissue. Thielemann LE, et al. **J Biochem Toxicol** 1995 Oct;10(5):251-257

Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. Tsai JC, et al. **J Biol Chem** 1996 Feb 16;271(7):3667-70

N-acetylcysteine-promoted survival of PC12 cells is glutathione-independent but transcription-dependent. Yan CY, et al. **J Biol Chem** 1995 Nov 10;270(45):26827-32

Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis. Jeannin P, et al. **J Exp Med** 1995 Dec 1;182(6):1785-92

In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. Blackwell TS, et al. **J Immunol** 1996 Aug 15;157(4):1630-7

N-acetylcysteine enhances antibody-dependent cellular cytotoxicity in neutrophils and mononuclear cells from healthy adults and human immunodeficiency virus-infected patients. Roberts RL, et al. **J Infect Dis** 1995 Dec; 172(6):1492-502

Adhesive mucous gel layer and mucus release as intestinal barrier in rats. Iiboshi Y, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar-Apr;20(2):98-104

Contact solvents for common bile duct stones. Study in an in vitro system. Guitaoui M, et al. **Liver** 1995 Oct; 15(5):247-52

Activity profiles of antimutagens: in vitro and in vivo data. Waters MD, et al. **Mutat Res** 1996 Feb 19;350(1):109-29 (117 ref.)

N-Acetyl-L-cysteine and its derivatives activate a Cl-conductance in epithelial cells. Köttgen M, et al. **Pflugers Arch** 1996 Feb;431(4):549-55

Scavenging of reactive oxygen species by letosteine, a molecule with two blocked-SH groups. Comparison with free-SH drugs. Gressier B, et al. **Pharm World Sci** 1995 May 26;17(3):76-80

N-acetylcysteine increases the glutathione content and protects rat alveolar type II cells against paraquat-induced cytotoxicity. Hoffer E, et al. **Toxicol Lett** 1996 Jan; 84(1):7-12

N-actylcysteine protects Chinese hamster ovary (CHO) cells from lead-induced oxidative stress. Ercal N, et al. **Toxicology** 1996 Apr 15;108(1-2):57-64

N-acetylcysteine failed to improve early microcirculatory alterations of the rat liver after transplantation. Walcher F, et al. **Transpl Int** 1995;8(4):317-23

Impact of N-acetylcysteine on the hepatic microcirculation after orthotopic liver transplantation. Koeppel TA, et al. **Transplantation** 1996 May 15;61(9):1397-402

[Radiation protection through cytokine release by N-acetylcysteine] Baier JE, et al. **Strahlenther Onkol** 1996 Feb;172(2):91-8 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Paracetamol intoxication and N-acetyl-cysteine treatment. De Groote J, et al. **Acta Gastroenterol Belg** 1995 May-Aug; 58(3-4):326-34 (78 ref.)

N-acetylcysteine potentiates the antihypertensive effect of angiotensin converting enzyme inhibitors [letter] Suárez C, et al. **Am J Hypertens** 1995 Aug;8(8):859

Comparison of N-acetylcysteine and methylene blue, alone or in combination, for treatment of acetaminophen toxicosis in cats. Rumbeiha WK, et al. **Am J Vet Res** 1995 Nov; 56(11):1529-33

Effects of intraoperative N-acetylcysteine in orthotopic liver transplantation. Bromley PN, et al. **Br J Anaesth** 1995 Sep; 75(3):352-4

Treatment of advanced malignancies with high-dose acetaminophen and N-acetylcysteine rescue. Kobrinsky NL, et al. **Cancer Invest** 1996;14(3):202-10

Chemopreventive efficacy of arylalkyl isothiocyanates and N-acetylcysteine for lung tumorigenesis in Fischer rats. Chung FL, et al. **Cancer Res** 1996 Feb 15;56(4):772-8

Oxidant-antioxidant balance in granulocytes during ARDS. Effect of N-acetylcysteine. Laurent T, et al. **Chest** 1996 Jan;109(1):163-6

N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock. Peake SL, et al. **Crit Care Med** 1996 Aug;24(8):1302-10

Hyperthermia, radiation carcinogenesis and the protective potential of vitamin A and N-acetylcysteine. Sminia P, et al. **J Cancer Res Clin Oncol** 1996;122(6):343-50

Chemopreventive properties and mechanisms of N-Acetylcysteine. The experimental background. De Flora S, et al. **J Cell Biochem Suppl** 1995;22:33-41 (37 ref.)

N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. van Zandwijk N. **J Cell Biochem Suppl** 1995; 22:24-32 (48 ref.)

The role of N-acetylcysteine in the treatment of chronic obstructive pulmonary disease [editorial] van Herwaarden CL, et al. **Neth J Med** 1995 Aug;47(2):45-8 (21 ref.)

[The application of n-acetylcysteine as an antioxidant and mucolytic in mechanical ventilation in intensive care patients. A prospective, randomized, placebo-controlled, double-blind study] Konrad F, et al. **Anaesthesist** 1995 Sep; 44(9):651-8 (Eng. Abstr.) **(Ger)**

[The effect of prophylactically administered n-acetylcysteine on clinical indicators for tissue oxygenation during hyperoxic ventilation in cardiac risk patients] Spies C, et al. **Anaesthesist** 1996 Apr;45(4):343-50 (Eng. Abstr.) **(Ger)**

[N-acetylcysteine: a functional oxygen radical scavenger in vitro and ex vivo in monocytes and neutrophilic granulocytes of patients with COPD] Jaworska M, et al. **Pneumologie** 1995 Oct;49(10):539-45 (Eng. Abstr.) **(Ger)**

[Antioxidants support the intrinsic physical response (interview by Heinz W. Weismann)] Magnussen H. **Pneumologie** 1996 Jan;50(1):VII **(Ger)**

[The acetylcysteine correction of disorders of the oxidative processes in a toxic liver lesion] Gonskiĭ IaI, et al. **Eksp Klin Farmakol** 1995 Nov-Dec;58(6):64-6 (Eng. Abstr.) **(Rus)**

URINE

Metabolism of illudin S, a toxic substance of Lampteromyces japonicus: urinary excretion of mercapturic acids in rat. Tanaka K, et al. **Xenobiotica** 1996 Mar;26(3):347-54

[Biological monitoring of exposure to alkylating xenobiotics by determining them using a new analytical approach in complexes with hemoglobin, plasma proteins and mercapturic acids in urine. II. Acrylamide] Hashimoto K, et al. **Vopr Med Khim** 1995 Jul-Aug;41(4):22-5 (Eng. Abstr.) **(Rus)**

ACETYLDIGOXINS

PHARMACOKINETICS

The effect of meloxicam on the pharmacokinetics of beta-acetyl-digoxin. Degner FL, et al. **Br J Clin Pharmacol** 1995 Nov;40(5):486-8

ACETYLENE

ANALOGS & DERIVATIVES

Marine natural products. XXXVI. Biologically active polyacetylenes, adociacetylenes A, B, C, and D, from an Okinawan Marine sponge of Adocia sp. Kobayashi M, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):720-4

ISOLATION & PURIFICATION

Marine natural products. XXXVI. Biologically active polyacetylenes, adociacetylenes A, B, C, and D, from an Okinawan Marine sponge of Adocia sp. Kobayashi M, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):720-4

METABOLISM

Biosynthesis of acetylenic compounds in cultured cells of Asparagus officinalis from [1-13C]- and [U-13C] Glucose. Terada K, et al. **Biol Pharm Bull** 1995 Nov;18(11):1472-5

Purification and characterization of acetylene hydratase of Pelobacter acetylenicus, a tungsten iron-sulfur protein. Rosner BM, et al. **J Bacteriol** 1995 Oct;177(20):5767-72

ACETYLESTERASE

The use of recombinant DNA technology in the design of a highly specific heroin sensor. Rathbone DA, et al. **Ann N Y Acad Sci** 1996 May 15;782:534-43

GENETICS

Glycosphingolipid composition of murine neuroblastoma cells: O-acetylesterase gene downregulates the expression of O-acetylated GD3. Ariga T, et al. **Biochemistry** 1995 Sep 12;34(36):11500-7

Acetyl xylan esterase from Trichoderma reesei contains an active-site serine residue and a cellulose-binding domain. Margolles-Clark E, et al. **Eur J Biochem** 1996 May 1; 237(3):553-60

Identification of a chromosomally encoded kanamycin acetylase in Porphyromonas gingivalis. Kato T, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):301-6

Molecular cloning and characterization of a rhamnogalacturonan acetylesterase from Aspergillus aculeatus. Synergism between rhamnogalacturonan degrading enzymes. Kauppinen S, et al. **J Biol Chem** 1995 Nov 10;270(45):27172-8

ISOLATION & PURIFICATION

Purification and characterization of two thermostable acetyl xylan esterases from Thermoanaerobacterium sp. strain JW/SL-YS485. Shao W, et al. **Appl Environ Microbiol** 1995 Feb;61(2):729-33

Purification and characterization of two acetyl xylan esterases from Penicillium purpurogenum. Egaña L, et al. **Biotechnol Appl Biochem** 1996 Aug;24 (Pt 1):33-9

METABOLISM

Acetyl xylan esterase from Trichoderma reesei contains an active-site serine residue and a cellulose-binding domain. Margolles-Clark E, et al. **Eur J Biochem** 1996 May 1; 237(3):553-60

Molecular cloning and characterization of a rhamnogalacturonan acetylesterase from Aspergillus aculeatus. Synergism between rhamnogalacturonan degrading enzymes. Kauppinen S, et al. **J Biol Chem** 1995 Nov 10;270(45):27172-8

ACETYLFORMALDEHYDE see **PYRUVALDEHYDE**

ACETYLGALACTOSAMINE

ANALOGS & DERIVATIVES

Inhibition of mucin synthesis by benzyl-alpha-GalNAc in KATO III gastric cancer and Caco-2 colon cancer cells. Byrd JC, et al. **Eur J Cancer** 1995;31A(9):1498-505

ANALYSIS

Bovine pituitary membrane glycoproteins contain beta-N-acetylgalactosaminylated N-linked sugar chains. Taka J, et al. **J Neurochem** 1996 Feb;66(2):852-9

S-laminin and N-acetylgalactosamine located at the synaptic basal lamina of skeletal muscle are involved in synaptic recognition by growing neurites. Iglesias M, et al. **J Neurocytol** 1995 Dec;24(12):903-15

Lectin binding and identification of sialic acid acceptor sugars in rabbit oviduct under hormone administration. Menghi G, et al. **Microsc Res Tech** 1995 Aug 15;31(6):488-96

METABOLISM

Binding studies on the combining site of a GalNAc alpha 1-->-specific lectin with Thomsen-Friedenreich activity prepared from green marine algae Codium fragile subspecies tomentosoides. Wu AM, et al. **Eur J Biochem** 1995 Oct 1;233(1):145-51

Oligosaccharides containing beta 1,4-linked N-acetylgalactosamine, a paradigm for protein-specific glycosylation. Manzella SM, et al. **J Biol Chem** 1996 May 24;271(21):12117-20 (54 ref.)

Kidney N-acetylgalactosamine (GalNAc)-1-phosphate kinase, a new pathway of GalNAc activation. Pastuszak I, et al. **J Biol Chem** 1996 Aug 23;271(34):20776-82

Characterization of an alternatively spliced GM2 activator protein, GM2A protein. An activator protein which stimulates the enzymatic hydrolysis of N-acetylneuraminic acid, but not N-acetylgalactosamine, from GM2. Wu YY, et al. **J Biol Chem** 1996 May 3;271(18):10611-5

Purification and characterization of galactose- and N-acetylgalactosamine-specific adhesin lectin of Entamoeba histolytica. Petri WA Jr, et al. **Methods Enzymol** 1995;253:98-104

Molybdate impairs glycosaminoglycan sulfation in rat cartilage. Oguro T, et al. **Toxicol Appl Pharmacol** 1996 Feb; 136(2):354-60

N-ACETYLGALACTOSAMINYLTRANSFERASES

ANALYSIS

A scintillation proximity assay for UDP-GalNAc:polypeptide, N-acetylgalactosaminyltransferase. Baker CA, et al. **Anal Biochem** 1996 Jul 15;239(1):20-4

BIOSYNTHESIS

cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine. Polypeptide N-acetylgalactosaminyltransferase, GalNAc-t3. Bennett EP, et al. **J Biol Chem** 1996 Jul 19;271(29):17006-12

Purification and cDNA cloning of a human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase. White T, et al. **J Biol Chem** 1995 Oct 13;270(41):24156-65

Heterogeneity in the expression pattern of two ganglioside synthase genes during mouse brain development. Yamamoto A, et al. **J Neurochem** 1996 Jan;66(1):26-34

BLOOD

Can blood group O red cells of donor origin acquire weak group A reactivity through serum A transferase of the recipient after bone marrow transplantation? Wichmann MG, et al. **Infusionsther Transfusionsmed** 1996 Feb; 23(1):29-31

Detection and characterization of UDP-GalNAc: chondroitin N-acetylgalactosaminyltransferase in bovine serum using a simple assay method. Kitagawa H, et al. **J Biochem (Tokyo)** 1995 May;117(5):1083-7

GENETICS

ABO glycosyltransferase genotyping by polymerase chain reaction using sequence-specific primers. Gassner C, et al. **Blood** 1996 Sep 1;88(5):1852-6

beta-1,4-N-Acetylgalactosaminyltransferase involved in ganglioside synthesis: cDNA sequence, expression, and chromosome mapping of the mouse gene. Sango K, et al. **Genomics** 1995 May 20;27(2):362-5

Organization of a human UDP-GalNAc:polypeptide, N-acetylgalactosaminyltransferase gene and a related processed pseudogene. Meurer JA, et al. **Glycobiology** 1996 Mar;6(2):231-41

Detection of N-acetylgalactosaminyltransferase mRNA which determines expression of Sda blood group carbohydrate structure in human gastrointestinal mucosa and cancer. Dohi T, et al. **Int J Cancer** 1996 Sep 4; 67(5):626-31

cDNA cloning, expression, and chromosomal localization of a human UDP-GalNAc:polypeptide, N-acetylgalactosaminyltransferase. Meurer JA, et al. **J Biochem (Tokyo)** 1995 Sep;118(3):568-74

Genomic organization and chromosomal assignment of the human beta1, 4-N-acetylgalactosaminyltransferase gene. Identification of multiple transcription units. Furukawa K, et al. **J Biol Chem** 1996 Aug 23;271(34):20836-44

Diverse expression of beta 1,4-N-acetylgalactosaminyltransferase gene in the adult mouse brain. Yamamoto A, et al. **J Neurochem** 1995 Dec; 65(6):2417-24

T-cell-specific deletion of a polypeptide N-acetylgalactosaminyl-transferase gene by site-directed recombination. Hennet T, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12070-4

ISOLATION & PURIFICATION

Purification and cDNA cloning of a human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase. White T, et al. **J Biol Chem** 1995 Oct 13;270(41):24156-65

METABOLISM

Analysis of melanoma cells stably transfected with beta 1,4GalNAc transferase (GM2/GD2 synthase) cDNA: relative glycosyltransferase levels play a dominant role in determining ganglioside expression. Ruan S, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):11-8

The effects of the site-directed removal of N-glycosylation sites from beta-1,4-N-acetylgalactosaminyltransferase on its function. Haraguchi M, et al. **Biochem J** 1995 Nov 15; 312 (Pt 1):273-80

Sequence of bovine carbonic anhydrase VI: potential recognition sites for N-acetylgalactosaminyltransferase. Jiang W, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):291-6

High expression of ganglioside alpha-2,8-sialyltransferase (GD3 synthase) gene in adult T-cell leukemia cells unrelated to the gene expression of human T-lymphotropic virus type I. Okada M, et al. **Cancer Res** 1996 Jun 15; 56(12):2844-8

Giardia lamblia: increased UDP-N-acetyl-D-glucosamine and N-acetyl-D-galactosamine transferase activities during encystation. Das S, et al. **Exp Parasitol** 1996 Jun; 83(1):19-29

Glycosylation in lepidopteran insect cells: identification of a beta 1-->4-N-acetylgalactosaminyltransferase involved

in the synthesis of complex-type oligosaccharide chains. van Die I, et al. **Glycobiology** 1996 Mar;6(2):157-64

Cloned beta 1,4N-acetylgalactosaminyltransferase: subcellular localization and formation of disulfide bonded species. Jaskiewicz E, et al. **Glycoconj J** 1996 Apr; 13(2):213-23

UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase. Identification and separation of two distinct transferase activities. Sørensen T, et al. **J Biol Chem** 1995 Oct 13;270(41):24166-73

Amino acid residue at codon 268 determines both activity and nucleotide-sugar donor substrate specificity of human histo-blood group A and B transferases. In vitro mutagenesis study. Yamamoto F, et al. **J Biol Chem** 1996 May 3;271(18):10515-20

ACETYLGLUCOSAMINE

An insecticidal N-acetylglucosamine-specific lectin gene from Griffonia simplicifolia (Leguminosae). Zhu K, et al. **Plant Physiol** 1996 Jan;110(1):195-202

ANALOGS & DERIVATIVES

Breast cancer-associated antibody LU BCRU G7 recognises the terminal disaccharide Gal beta 1-3GlcNAc and can be used to isolate tumour cells from body fluids by an immunomagnetic bead procedure. Rye PD, et al. **Biochem Soc Trans** 1995 Nov;23(4):584S

DNA-based carrier screening in primary healthcare: screening for aspartylglucosaminuria mutations in maternity health offices. Hietala M, et al. **Clin Chem** 1996 Sep;42(9):1398-404

Utility of 3-O-methyl-N-acetyl-D-glucosamine, an N-acetylglucosamine kinase inhibitor, for accurate assay of glucokinase in pancreatic islets and liver. Miwa I, et al. **Enzyme Protein** 1994-95;48(3):135-42

Characterization of four monosialo and a novel disialo Asn N-glycosides from the urine of a patient with aspartylglycosaminuria. Irie F, et al. **Glycoconj J** 1995 Jun; 12(3):290-7

Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer. Enomaa N, et al. **Hum Gene Ther** 1995 Jun;6(6):723-31

A lysosomal cysteine proteinase from Dictyostelium discoideum contains N-acetylglucosamine-1-phosphate bound to serine but not mannose-6-phosphate on N-linked oligosaccharides. Mehta DP, et al. **J Biol Chem** 1996 May 3;271(18):10897-903

Identification of two novel Dictyostelium discoideum cysteine proteinases that carry N-acetylglucosamine-1-P-modification. Souza GM, et al. **J Biol Chem** 1995 Dec 1;270(48):28938-45

Single base deletion in exon 7 of the glycosylasparaginase gene causes a mild form of aspartylglycosaminuria in a patient of Mauritian origin. Park H, et al. **J Inherit Metab Dis** 1996;19(1):76-83

[Contribution of ion exchange chromatography of amino acids to the diagnosis of aspartylglucosaminuria (letter)] Candito M, et al. **Ann Biol Clin (Paris)** 1995;53(3):145-6 **(Fre)**

ANALYSIS

Selective detection and site-analysis of O-GlcNAc-modified glycopeptides by beta-elimination and tandem electrospray mass spectrometry. Greis KD, et al. **Anal Biochem** 1996 Feb 1;234(1):38-49

High molecular weight microtubule-associated proteins contain O-linked-N-acetylglucosamine. Ding M, et al. **J Biol Chem** 1996 May 24;271(21):12555-61

LEC14, a dominant Chinese hamster ovary glycosylation mutant expresses complex N-glycans with a new N-acetylglucosamine residue in the core region. Raju TS, et al. **J Biol Chem** 1996 Mar 29;271(13):7484-93

BLOOD

Circulating malignant lymphocytes from Sezary syndrome express high level of glycoproteins carrying beta (1-6)N-acetylglucosamine-branched N-linked oligosaccharides. Derappe C, et al. **Leukemia** 1996 Jan; 10(1):138-41

CHEMISTRY

Towards oligosaccharide libraries: a study of the random galactosylation of unprotected N-acetylglucosamine. Ding Y, et al. **Bioorg Med Chem** 1996 May;4(5):683-92

The relationship between exposed galactose and N-acetylglucosamine residues on IgG in rheumatoid arthritis (RA), juvenile chronic arthritis (JCA) and Sjögren's syndrome (SS). Bond A, et al. **Clin Exp Immunol** 1996 Jul;105(1):99-103

Antibodies from patients with psoriasis recognize N-acetylglucosamine terminals in glycoproteins from Pityrosporum ovale. Mathov I, et al. **Clin Exp Immunol** 1996 Jul;105(1):79-83

Stereochemical requirements of chitin synthase for ligand binding at the allosteric site for N-acetylglucosamine. Horsch M, et al. **Eur J Biochem** 1996 Apr 15;237(2):476-82

A precise structural analysis of a fertilization-associated carbohydrate-rich glycopeptide isolated from the fertilized eggs of euryhaline killi fish (Fundulus heteroclitus). Novel penta-antennary N-glycan chains with a bisecting N-acetylglucosaminyl residue. Taguchi T, et al. **Glycobiology** 1995 Sep;5(6):611-24

Plant nuclear pore complex proteins are modified by novel oligosaccharides with terminal N-acetylglucosamine. Heese-Peck A, et al. **Plant Cell** 1995 Sep;7(9):1459-71

IMMUNOLOGY

Antibodies from patients with psoriasis recognize N-acetylglucosamine terminals in glycoproteins from Pityrosporum ovale. Mathov I, et al. **Clin Exp Immunol** 1996 Jul;105(1):79-83

Monoclonal antibody LU-BCRU-G7 against a breast tumour-associated glycoprotein recognizes the disaccharide Gal beta 1-3GlcNAc. Rye PD, et al. **Glycobiology** 1995 Jun;5(4):385-9

ISOLATION & PURIFICATION

Specific isolation of O-linked N-acetylglucosamine glycopeptides from complex mixtures. Hayes BK, et al. **Anal Biochem** 1995 Jun 10;228(1):115-22

The impact of fixatives on the binding of lectins to N-acetyl-glucosamine residues of human syncytiotrophoblast: a quantitative histochemical study. Høyer PE, et al. **J Histochem Cytochem** 1996 Aug; 44(8):855-63

METABOLISM

O-linked N-acetylglucosamine: the "yin-yang" of Ser/Thr phosphorylation? Nuclear and cytoplasmic glycosylation. Hart GW, et al. **Adv Exp Med Biol** 1995;376:115-23 (45 ref.)

Dynamic O-GlcNAcylation of the small heat shock protein alpha B-crystallin. Roquemore EP, et al. **Biochemistry** 1996 Mar 19;35(11):3578-86

Quantitative differences in GlcNAc:beta1—>3 and GlcNAc:beta1—>4 galactosyltransferase activities between human colonic adenocarcinomas and normal colonic mucosa. Seko A, et al. **Cancer Res** 1996 Aug 1; 56(15):3468-73

Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization. Yoshimura M, et al. **Cancer Res** 1996 Jan 15; 56(2):412-8

Stereochemical requirements of chitin synthase for ligand binding at the allosteric site for N-acetylglucosamine. Horsch M, et al. **Eur J Biochem** 1996 Apr 15;237(2):476-82

Identification of N-acetylglucosamine binding residues in Griffonia simplicifolia lectin II. Zhu K, et al. **FEBS Lett** 1996 Jul 29;390(3):271-4

Characterization of 20K fimbria, a new adhesin of septicemic and diarrhea-associated Escherichia coli strains, that belongs to a family of adhesins with N-acetyl-D-glucosamine recognition. Bertin Y, et al. **Infect Immun** 1996 Jan;64(1):332-42

Cytoplasmic O-GlcNAc modification of the head domain and the KSP repeat motif of the neurofilament protein neurofilament-H. Dong DL, et al. **J Biol Chem** 1996 Aug 23;271(34):20845-52

Binding capacities of two immunomodulatory lectins, carrier-immobilized glycoligands and steroid hormones in lung cancer and the concentration of nitrite/nitrate in pleural effusions. Timoshenko AV, et al. **Lung Cancer** 1996 Feb;14(1):75-84

Metabolism of glycoprotein-derived sialic acid and N-acetylglucosamine by Streptococcus oralis. Homer KA, et al. **Microbiology** 1996 May;142 (Pt 5):1221-30

Activity of ecdysone analogs in enhancing N-acetylglucosamine incorporation into the cultured integument of Chilo suppressalis. Nakagawa Y, et al. **Steroids** 1995 May;60(5):401-5

PHARMACOLOGY

Effects of C-1-substituted glucose analogue on the activation states of glycogen synthase and glycogen phosphorylase in rat hepatocytes. Board M, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):845-52

A new predictive test for in-vitro fertilization based on the induction of sperm acrosome reaction by N-acetylglucosamine-neoglycoprotein. Brandelli A, et al. **Hum Reprod** 1995 Jul;10(7):1751-6

Active site-directed inactivation of Escherichia coli glucosamine-6-phosphate synthase. Determination of the fructose 6-phosphate binding constant using a carbohydrate-based inactivator. Bearne SL. **J Biol Chem** 1996 Feb 9;271(6):3052-7

ACETYLGLUCOSAMINIDASE

The structure of the keratan sulphate chains attached to fibromodulin isolated from bovine tracheal cartilage: oligosaccharides generated by keratanase II digestion. Lauder RM, et al. **Glycoconj J** 1995 Oct;12(5):651-9

ANTAGONISTS & INHIBITORS

Synthesis and activity of 1-N-iminosugar inhibitors, siastatin B analogues for alpha-N-acetylgalactosaminidase and beta-N-acetylglucosaminidase. Nishimura Y, et al. **Bioorg Med Chem** 1996 Jan;4(1):91-6

BLOOD

Automated fluorimetric assay procedure for glucohydrolases using a routine centrifugal analyser assay of enzymes of lysosomal origin in plasma, II. Goi G, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):737-42

Lithium ion influence on N-acetyl-beta-glucosaminidase isoenzymes serum level. Stojkovic M, et al. **Rom J Physiol** 1994 Jan-Dec;31(1-4):91-6

CHEMISTRY

Bacterial chitobiase structure provides insight into catalytic mechanism and the basis of Tay-Sachs disease. Tews I, et al. **Nat Struct Biol** 1996 Jul;3(7):638-48

DRUG EFFECTS

Lithium ion influence on N-acetyl-beta-glucosaminidase isoenzymes serum level. Stojkovic M, et al. **Rom J Physiol** 1994 Jan-Dec;31(1-4):91-6

GENETICS

Molecular cloning of the gene which encodes beta-N-acetylglucosaminidase from a marine bacterium, Alteromonas sp. strain O-7. Tsujibo H, et al. **Appl Environ Microbiol** 1995 Feb;61(2):804-6

N-Acetylglucosaminidase (chitobiase) from Serratia marcescens: gene sequence, and protein production and purification in Escherichia coli. Tews I, et al. **Gene** 1996 Apr 17;170(1):63-7

Overexpression and purification of non-glycosylated recombinant endo-beta-N-acetylglucosaminidase F3. Tarentino AL, et al. **Glycobiology** 1995 Sep;5(6):599-601

Molecular dissection of a cosmid from a gene-rich region in 17q21 and characterization of a candidate gene for alpha-N-acetylglucosaminidase with two cDNA isoforms. Zhao Z, et al. **Mamm Genome** 1996 Sep;7(9):686-90

The molecular basis of Sanfilippo syndrome type B. Zhao HG, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11; 93(12):6101-5

ISOLATION & PURIFICATION

Differential extraction of N-acetylglucosaminidase and trehalase from the cell envelope of Candida albicans. Molloy C, et al. **Exp Mycol** 1995 Sep;19(3):178-85

Purification and characterization of N-acetylglucosaminidase from Trypanosoma cruzi. el Moudni B, et al. **Exp Parasitol** 1996 Jul;83(2):167-73

An autolysin ring associated with cell separation of Staphylococcus aureus. Yamada S, et al. **J Bacteriol** 1996 Mar;178(6):1565-71

METABOLISM

Vesicles in rat epididymal fluid. Existence of two populations differing in ultrastructure and enzymatic composition. Fornés WM, et al. **Andrologia** 1995 Jul-Aug;27(4):233-7

Effects of exposure to elemental mercury on the nervous system and the kidneys of workers producing natural gas. Boogaard PJ, et al. **Arch Environ Health** 1996 Mar-Apr; 51(2):108-15

Occurrence of a cytosolic neutral chitobiase activity involved in oligomannoside degradation: a study with Madin-Darby bovine kidney (MDBK) cells. Cacan R, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):597-602

Characterization of beta-N-acetylglucosaminidase from human epididymis. Miranda PV, et al. **Int J Androl** 1995 Oct;18(5):263-70

Are there biological functions for bacterial endo-N-acetyl-beta-D-glucosaminidases? Karamanos Y, et al. **Res Microbiol** 1995 Jul-Aug;146(6):437-43 (42 ref.)

Inhibition by lithium and rubidium of gentamicin-induced release of N-acetyl-beta-D-glucosaminidase from perfused rat kidney. Dehpour AR, et al. **Toxicology** 1996 Jun 17; 110(1-3):9-15

N-acetyl-beta-D-glucosaminidase (NAG) isoenzymes in primary cultures of rabbit kidney proximal tubule cells: a cellular model for studies on nephrotoxicity? Robic D, et al. **Toxicology** 1995 Nov 20;103(1):37-44

Exercise-induced changes in the activities of beta-glucuronidase and N-acetyl-beta-D-glucosaminidase in plasma and muscle of standardbred trotters. Raulo SM, et al. **Zentralbl Veterinarmed A** 1996 Apr;43(2):119-26

PHYSIOLOGY

N-acetyl-beta-glucosaminidase accounts for differences in glycosylation of influenza virus hemagglutinin expressed in insect cells from a baculovirus vector. Wagner R, et al. **J Virol** 1996 Jun;70(6):4103-9

SECRETION

Protein kinase C and intracellular pH regulate zymosan-induced lysosomal enzyme secretion in macrophages. Tapper H, et al. **J Leukoc Biol** 1995 Oct; 58(4):485-94

URINE

Urinary N-acetyl-beta-D-glucosaminidase activity in children with insulin-dependent diabetes mellitus. Hsiao PH, et al. **Am J Nephrol** 1996;16(4):300-3

N-acetyl-beta-D-glucosaminidase enzymuria as an indicator

in monitoring the therapy of some rheumatic diseases with potentially nephrotoxic drugs. Wiland P, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):331–6

Is carbamazepine associated with NAG elevations suggestive of renal disease? Garvey MJ, et al. **Brain Dev** 1995 May–Jun;17(3):222–4

Urinary activity of N-acetyl-beta-glycosaminidase (NAG) in arterial hypertension [letter] Pérez-Blanco FJ, et al. **Clin Nephrol** 1996 Jan;45(1):65–6

Urinary excretion of type IV collagen and laminin in the evaluation of nephropathy in NIDDM: comparison with urinary albumin and markers of tubular dysfunction and/or damage. Banu N, et al. **Diabetes Res Clin Pract** 1995 Jul; 29(1):57–67

Increased urinary N-acetyl-beta-glucosaminidase (NAG) excretion in young insulin-dependent diabetic patients. Lorini R, et al. **Diabetes Res Clin Pract** 1995 Aug; 29(2):99–105

Effect of proximal tubular glucose transport blockade on urinary enzyme excretions in hyperglycemic rats. Ishii N, et al. **Enzyme Protein** 1994–95;48(5–6):243–50

Diagnostic significance of urinary enzymes for diabetes mellitus and hypertension. Ishii N, et al. **Enzyme Protein** 1994–95;48(3):174–82

Urinary N-acetyl-beta-D-glucosaminidase determination in newborns and children: methods and diagnostic applications. Csáthy L, et al. **Eur J Clin Chem Clin Biochem** 1995 Sep;33(9):575–87 (188 ref.)

Urinary enzyme changes in children undergoing cineangiographic evaluation using iopromid. Kavukçu S, et al. **Int Urol Nephrol** 1995;27(2):131–5

Enzymatic evaluation of renal damage caused by different therapeutic procedures for kidney stone disease. Sakkas G, et al. **Int Urol Nephrol** 1995;27(6):669–77

Estimation of quantitative enzymuria in dogs with gentamicin-induced nephrotoxicosis using urine enzyme/creatinine ratios from spot urine samples. Grauer GF, et al. **J Vet Intern Med** 1995 Sep–Oct;9(5):324–7

Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Carraro M, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):444–8

The association of the serotonin metabolite, 5-HIAA, to the lysosomal enzyme N-acetyl-beta-glucosaminidase. Garvey MJ, et al. **Neuropsychobiology** 1995;32(2):75–8

Enzymuria in a population living near a cadmium battery plant. Järup L, et al. **Occup Environ Med** 1995 Nov; 52(11):770–2

Association of levels of N-acetyl-beta-glucosaminidase with severity of psychiatric symptoms in panic disorder. Garvey MJ, et al. **Psychiatry Res** 1996 Mar 29;60(2–3):185–90

Urinary NAG as an early indicator of renal damage in Russell's viper bite envenomation. Win-Aung, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr;90(2):169–72

Reduced renal allograft survival is related to low urinary N-acetyl-beta-D-glucosaminidase excretion during the first posttransplant month. Kotanko P, et al. **Transplantation** 1996 Feb 15;61(3):388–92

[Urinary N-acetyl-beta-D-glucosaminidase] Sugita O. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:447–9 (20 ref.) **(Jpn)**

[Nephrotoxicity evaluation of cytostatic agents in children with acute lymphoblastic leukemia] Tomaszewska B, et al. **Pediatr Pol** 1995 Nov;70(11):915–20 (Eng. Abstr.) **(Pol)**

TRANS-N-ACETYLGLUCOSAMINOSYLASE see **CHITIN SYNTHASE**

N-ACETYLGLUCOSAMINYLTRANSFERASES

ANALYSIS

Subcellular distribution of "intersecting" beta-N-acetylglucosaminyltransferase in Dictyostelium discoideum. A likely marker for the Golgi apparatus. Capasso JM, et al. **Biochim Biophys Acta** 1996 May 22; 1281(1):15–22

ANTAGONISTS & INHIBITORS

Substrate specificity and inhibition of UDP-GlcNAc:GlcNAc beta 1-2Man alpha 1-6R beta 1,6-N-acetylglucosaminyltransferase V using synthetic substrate analogues. Brockhausen I, et al. **Glycoconj J** 1995 Jun;12(3):371–9

[Synthesis of modified tetrasaccharides as analog acceptor-inhibitors of N-acetylglucosaminyltransferase II] Paulsen H, et al. **Carbohydr Res** 1995 Oct 2;275(2):403–11 **(Ger)**

BIOSYNTHESIS

Cloning and chromosomal mapping of the mouse Mgat3 gene encoding N-acetylglucosaminyltransferase III. Bhaumik M, et al. **Gene** 1995 Oct 27;164(2):295–300

Changes of beta-1,4-N-acetylglucosaminyltransferase III (GnT-III) in patients with leukaemia. Yoshimura M, et al. **Glycoconj J** 1995 Jun;12(3):234–40

Biosynthesis of Azorhizobium caulinodans Nod factors. Study of the activity of the NodABCS proteins by expression of the genes in Escherichia coli. Mergaer P, et al. **J Biol Chem** 1995 Dec 8;270(49):29217–23

CHEMISTRY

The C-terminal domain of the Rhizobium leguminosarum chitin synthase NodC is important for function and determines the orientation of the N-terminal region in the inner membrane. Barny MA, et al. **Mol Microbiol** 1996 Feb;19(3):443–53

[A theoretical analysis of the secondary structure and topology of dolichol-coupled enzymes] Shpakov AO. **Zh Evol Biokhim Fiziol** 1995 Mar–Apr;31(2):129–40 (Eng. Abstr.) **(Rus)**

GENETICS

Human N-acetylglucosaminyltransferase III gene is transcribed from multiple promoters. Koyama N, et al. **Eur J Biochem** 1996 Jun 15;238(3):853–61

Organization of the human N-acetylglucosaminyltransferase V gene. Saito H, et al. **Eur J Biochem** 1995 Oct 1; 233(1):18–26

Cloning and chromosomal mapping of the mouse Mgat3 gene encoding N-acetylglucosaminyltransferase III. Bhaumik M, et al. **Gene** 1995 Oct 27;164(2):295–300

Sequence analysis of the 5'-flanking region of the gene encoding human N-acetylglucosaminyltransferase III. Kim YJ, et al. **Gene** 1996 May 8;170(2):281–3

Genomic organization of core 2 and I branching beta-1,6-N-acetylglucosaminyltransferases. Implication for evolution of the beta-1,6-N-acetylglucosaminyltransferase gene family. Bierhuizen MF, et al. **Glycobiology** 1995 Jun; 5(4):417–25

Complex asparagine-linked oligosaccharides in Mgat1-null embryos. Campbell RM, et al. **Glycobiology** 1995 Jul; 5(5):535–43

Elongation of the N-glycans of fowl plague virus hemagglutinin expressed in Spodoptera frugiperda (Sf9) cells by coexpression of human beta 1,2-N-acetylglucosaminyltransferase I. Wagner R, et al. **Glycobiology** 1996 Mar;6(2):165–75

Insertion into Aspergillus nidulans of functional UDP-GlcNAc: alpha 3-D- mannoside beta-1,2-N-acetylglucosaminyl-transferase I, the enzyme catalysing the first committed step from oligomannose to hybrid and complex N-glycans. Kalsner I, et al. **Glycoconj J** 1995 Jun;12(3):360–70

Gene expression of N-acetylglucosaminyltransferases III and V: a possible implication for liver regeneration. Miyoshi E, et al. **Hepatology** 1995 Dec;22(6):1847–55

Inner core biosynthesis of lipooligosaccharide (LOS) in Neisseria meningitidis serogroup B: identification and role in LOS assembly of the alpha1,2 N-acetylglucosamine transferase (RfaK). Kahler CM, et al. **J Bacteriol** 1996 Mar; 178(5):1265–73

Identification and characterization of a gene regulating enzymatic glycosylation which is induced by diabetes and hyperglycemia specifically in rat cardiac tissue. Nishio Y, et al. **J Clin Invest** 1995 Oct;96(4):1759–67

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. Guilloux Y, et al. **J Exp Med** 1996 Mar 1;183(3):1173–83

[The identification of repetitive sequences and internal symmetry in the primary structure of N-acetylglucosaminyl-1-phosphotransferases] Shpakov AO. **Zh Evol Biokhim Fiziol** 1995 Sep–Dec;31(5–6):519–28 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

GlcNAc-transferase V and core 2 GlcNAc-transferase expression in the developing mouse embryo. Granovsky M, et al. **Glycobiology** 1995 Dec;5(8):797–806

METABOLISM

The characterization of a UDP-N-acetylglucosamine: Gal beta 1-4Glc(NAc) beta 1-3 N-acetylglucosaminyltransferase in fluids from rat rete testis. Tsuji Y, et al. **Biochim Biophys Acta** 1996 Feb 9; 1289(1):115–21

The CD43 130-kD peripheral T-cell activation antigen is downregulated in thymic positive selection. Ellies LG, et al. **Blood** 1996 Sep 1;88(5):1725–32

Synthesis of 2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1-->2)-alpha-D-mannopyranosyl-(1-->6)-beta-D-mannopyranosyl-(1-->4)-2-acetamido-2-d eox y-D-glucopyranose. Acceptor-substrate recognition by N-acetylglucosaminyltransferase-V (GnT-V). Khan SH, et al. **Carbohydr Res** 1995 Dec 20;278(2):351–62

Synthesis of pentasaccharide analogues of the N-glycan substrates of N-acetylglucosaminyltransferases III, IV and V using tetrasaccharide precursors and recombinant beta-(1-->2)-N-acetylglucosaminyltransferase II. Reck F, et al. **Carbohydr Res** 1995 Oct 2;275(2):221–9

Synthesis of uridine-5-propylamine derivatives and their use in affinity chromatography of N-acetylglucosaminyltransferases I and II. Reck F. **Carbohydr Res** 1995 Oct 23;276(2):321–35

In the biosynthesis of N-glycans in connective tissue of the snail Lymnaea stagnalis of incorporation GlcNAc by beta 2GlcNAc-transferase I is an essential prerequisite for the action of beta 2GlcNAc-transferase II and beta 2Xyl-transferase. Mulder H, et al. **Eur J Biochem** 1995 Aug 15;232(1):272–83

Giardia lamblia: increased UDP-N-acetyl-D-glucosamine and N-acetyl-D-galactosamine transferase activities during encystation. Das S, et al. **Exp Parasitol** 1996 Jun; 83(1):19–29

Mass spectrometric analysis of chitin oligosaccharides produced by Rhizobium NodC protein in Escherichia coli. Kamst E, et al. **J Bacteriol** 1995 Nov;177(21):6282–5

Evidence for recycling of the resident medial/trans Golgi enzyme, N-acetylglucosaminyltransferase I, in ldlD cells. Hoe MH, et al. **J Biol Chem** 1995 Oct 20;270(42):25057–63

Transfection of N-acetylglucosaminyltransferase III gene suppresses expression of hepatitis B virus in a human hepatoma cell line, HB611. Miyoshi E, et al. **J Biol Chem** 1995 Nov 24;270(47):28311–5

Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Yoshimura M, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8754–8

[Synthesis of modified tetrasaccharides as analog acceptor-inhibitors of N-acetylglucosaminyltransferase II] Paulsen H, et al. **Carbohydr Res** 1995 Oct 2;275(2):403–11 **(Ger)**

N-ACETYLLACTOSAMINE SYNTHASE

ANALYSIS

Immunocytochemical localization of the protein reactive to human beta-1, 4-galactosyltransferase antibodies during chick embryonic skin differentiation. Akimoto Y, et al. **Anat Rec** 1995 Sep;243(1):109–19

BIOSYNTHESIS

Enhanced galactosyltransferase expression in the failing hearts of spontaneously hypertensive rats. Humphries DE, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):320–4

Agalactosyl IgG and beta-1,4-galactosyltransferase gene expression in rheumatoid arthritis patients and in the arthritis-prone MRL lpr/lpr mouse. Jeddi PA, et al. **Immunology** 1996 Apr;87(4):654–9

Transcriptional regulation of murine beta1,4-galactosyltransferase in somatic cells. Analysis of a gene that serves both a housekeeping and a mammary gland-specific function. Rajput B, et al. **J Biol Chem** 1996 Mar 1;271(9):5131–42

Golgi localization and in vivo activity of a mammalian glycosyltransferase (human beta1,4-galactosyltransferase) in yeast. Schwientek T, et al. **J Biol Chem** 1996 Feb 16; 271(7):3398–405

BLOOD

beta 1,4-Galactosyltransferase activity in B cells detected using a simple ELISA-based assay. Keusch J, et al. **Glycobiology** 1995 Jun;5(4):365–700

GENETICS

Murine beta 1,4-galactosyltransferase. Analysis of a gene that serves both a housekeeping and a cell specific function. Shaper JH, et al. **Adv Exp Med Biol** 1995;376:95–104 (33 ref.)

The beta 1,4-galactosyltransferase gene is post-transcriptionally regulated during differentiation of mouse F9 teratocarcinoma cells. Kudo T, et al. **Glycobiology** 1995 Jun;5(4):397–403

Transcriptional regulation of murine beta1,4-galactosyltransferase in somatic cells. Analysis of a gene that serves both a housekeeping and a mammary gland-specific function. Rajput B, et al. **J Biol Chem** 1996 Mar 1;271(9):5131–42

IMMUNOLOGY

A lack of relationship between secretory component and galactosyltransferase in human milk. Kobayashi K, et al. **Adv Exp Med Biol** 1995;371A:637–42

ISOLATION & PURIFICATION

Recombinant soluble beta-1,4-galactosyltransferases expressed in Saccharomyces cerevisiae. Purification, characterization and comparison with human enzyme. Malissard M, et al. **Eur J Biochem** 1996 Jul 15;239(2):340–8

METABOLISM

Beta 1,4-galactosyltransferase variations in rheumatoid arthritis. Alavi A, et al. **Adv Exp Med Biol** 1995;376:185–92 (35 ref.)

Cell surface beta 1,4-galactosyltransferase. A signal transducing receptor? Dubois DH, et al. **Adv Exp Med Biol** 1995;376:105–14 (72 ref.)

Recombinant soluble beta-1,4-galactosyltransferases expressed in Saccharomyces cerevisiae. Purification, characterization and comparison with human enzyme.

Malissard M, et al. **Eur J Biochem** 1996 Jul 15;239(2):340–8
Diffusional mobility of Golgi proteins in membranes of living cells. Cole NB, et al. **Science** 1996 Aug 9;273(5276):797–801
Activation of a G protein complex by aggregation of beta-1,4-galactosyltransferase on the surface of sperm. Gong X, et al. **Science** 1995 Sep 22;269(5231):1718–21

PHYSIOLOGY

Evaluation of beta 1,4-galactosyltransferase in rheumatoid arthritis and its role in the glycosylation network associated with this disease. Alavi A, et al. **Glycoconj J** 1995 Jun; 12(3):206–10 (35 ref.)

N-ACETYLLACTOSAMINE SYNTHETASE see **N-ACETYLLACTOSAMINE SYNTHASE**

ACETYLMETHADOL see **METHADYL ACETATE**

N-ACETYLMURAMOYL-L-ALANINE AMIDASE

ANALYSIS

A major autolysin of Pseudomonas aeruginosa: subcellular distribution, potential role in cell growth and division and secretion in surface membrane vesicles. Li Z, et al. **J Bacteriol** 1996 May;178(9):2479–88

BIOSYNTHESIS

Effects of mecA and mecB (clpC) mutations on expression of sigD, which encodes an alternative sigma factor, and autolysin operons and on flagellin synthesis in Bacillus subtilis. Rashid MH, et al. **J Bacteriol** 1996 Aug; 178(16):4861–9

BLOOD

Purification and characterization of N-acetylmuramyl-L-alanine amidase from human plasma using monoclonal antibodies. Hoijer MA, et al. **Biochim Biophys Acta** 1996 Feb 9;1289(1):57–64

CHEMISTRY

Structural organization of the major autolysin from Streptococcus pneumoniae. Usobiaga P, et al. **J Biol Chem** 1996 Mar 22;271(12):6832–8

GENETICS

DNA sequence differences of ampD mutants of Citrobacter freundii. Stapleton P, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2494–8
Architecture and domain interchange of the pneumococcal cell wall lytic enzymes. López R, et al. **Dev Biol Stand** 1995;85:273–81
Construction of a multifunctional pneumococcal murein hydrolase by module assembly. Sanz JM, et al. **Eur J Biochem** 1996 Feb 1;235(3):601–5
Sequence analysis of the region upstream of a peptidoglycan hydrolase-encoding gene from bacteriophage phi 11 of Staphylococcus aureus. Weerakoon LK, et al. **FEMS Microbiol Lett** 1995 Nov 1;133(1-2):9–15
A gene (sleC) encoding a spore-cortex-lytic enzyme from Clostridium perfringens S40 spores; cloning, sequence analysis and molecular characterization. Miyata S, et al. **Microbiology** 1995 Oct;141 (Pt 10):2643–50
Cloning and expression of a murein hydrolase lipoprotein from Escherichia coli. Ehlert K, et al. **Mol Microbiol** 1995 May;16(4):761–8
Heterogeneous endolysins in Listeria monocytogenes bacteriophages: a new class of enzymes and evidence for conserved holin genes within the siphoviral lysis cassettes. Loessner MJ, et al. **Mol Microbiol** 1995 Jun;16(6):1231–41

IMMUNOLOGY

Two Listeria monocytogenes CTL epitopes are processed from the same antigen with different efficiencies. Sijts AJ, et al. **J Immunol** 1996 Jan 15;156(2):683–92

ISOLATION & PURIFICATION

Purification and characterization of N-acetylmuramyl-L-alanine amidase from human plasma using monoclonal antibodies. Hoijer MA, et al. **Biochim Biophys Acta** 1996 Feb 9;1289(1):57–64
An autolysin ring associated with cell separation of Staphylococcus aureus. Yamada S, et al. **J Bacteriol** 1996 Mar;178(6):1565–71
Alteration of bacteriolytic enzyme profile of Staphylococcus aureus during growth. Komatsuzawa H, et al. **Microbiol Immunol** 1995;39(8):629–33

METABOLISM

From growth to autolysis: the murein hydrolases in Escherichia coli. Höltje JV. **Arch Microbiol** 1995 Oct; 164(4):243–54 (94 ref.)
The human and mammalian N-acetylmuramyl-L-alanine amidase: distribution, action on different bacterial peptidoglycans, and comparison with the human lysozyme activities. Vanderwinkel E, et al. **Biochem Mol Med** 1995 Feb;54(1):26–32
Construction of a multifunctional pneumococcal murein hydrolase by module assembly. Sanz JM, et al. **Eur J Biochem** 1996 Feb 1;235(3):601–5
Molecular characterization and functional analysis of the major autolysin of Staphylococcus aureus 8325/4. Foster SJ. **J Bacteriol** 1995 Oct;177(19):5723–5

PHARMACOLOGY

Bacteriolytic effect of membrane vesicles from Pseudomonas aeruginosa on other bacteria including pathogens: conceptually new antibiotics. Kadurugamuwa JL, et al. **J Bacteriol** 1996 May;178(10):2767–74

TOXICITY

Roles of autolysin and pneumolysin in middle ear inflammation caused by a type 3 Streptococcus pneumoniae strain in the chinchilla otitis media model. Sato K, et al. **Infect Immun** 1996 Apr;64(4):1140–5

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE

Pericholangitis in a rabbit colitis model induced by injection of muramyl dipeptide emulsified with a long-chain fatty acid. Kuroe K, et al. **J Gastroenterol** 1996 Jun;31(3):347–52

ADMINISTRATION & DOSAGE

Rabbit granulomatous enterocolitis induced by injection of muramyl dipeptide emulsified with Freund's incomplete adjuvant. Kuroe K, et al. **J Gastroenterol** 1995 Aug; 30(4):472–7

ANALOGS & DERIVATIVES

In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide. Goldbach P, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):L429–34
Adverse effects at adjuvant treatment of liver metastases in rat with RSU-1069 + microspheres, or liposomal MTP-PE. Wang L, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):2077–80
Restorative effect of romurtide for thrombocytopenia associated with intensive anticancer drug treatment and/or irradiation in patients with gastrointestinal cancer. Yano K, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2883–7
Prevention of experimental endotoxin shock by a monocyte activator. Passlick B, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2535–40
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES. **Hematol Oncol Clin North Am** 1995 Aug;9(4):927–38 (37 ref.)
The occurrence of natural antibodies to minimal component of bacterial cell wall (N-acetylglucosaminyl-N-acetylmuramyl dipeptide) in sera from healthy humans. Pinegin BV, et al. **Immunol Lett** 1995 Jul-Aug;47(1-2):33–7
Different effect of cyclosporin A on arthritides induced by a muramyl dipeptide analogue or the complete adjuvant in rats. Sugawara T, et al. **Int J Exp Pathol** 1995 Jun; 76(3):191–9
Synergistic effects between recombinant interleukin-2 and the synthetic immunomodulator murabutide: selective enhancement of cytokine release and potentiation of antitumor activity. Bahr GM, et al. **J Interferon Cytokine Res** 1996 Feb;16(2):169–78
Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. Dinney CP, et al. **J Interferon Cytokine Res** 1995 Jun;15(6):585–92
Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes. Asano T, et al. **Oncol Res** 1995;7(5):253–7
Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP). Hornung RL, et al. **Ther Immunol** 1995 Feb; 2(1):7–14
Enhancement of nonspecific resistance by liposome-encapsulated immunomodulators does not affect skin graft rejection in mice. ten Hagen TL, et al. **Transplantation** 1995 Dec 15;60(11):1211–4
Soluble intercellular adhesion molecule-1 and serum cytokines in melanoma patients treated with liposomes containing muramyl tripeptide. Favaro D, et al. **Tumori** 1995 May-Jun;81(3):185–90
Protection of ruminants by Pasteurella haemolytica A1 capsular polysaccharide vaccines containing muramyl dipeptide analogs. Brogden KA, et al. **Vaccine** 1995 Dec; 13(17):1677–84
Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Ott G, et al. **Vaccine** 1995 Nov; 13(16):1557–62
Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice. Yoo YC, et al. **Vaccine** 1995 Oct; 13(14):1300–5

CHEMICAL SYNTHESIS

Development of an emulsion-based muramyl dipeptide adjuvant formulation for vaccines. Lidgate DM, et al. **Pharm Biotechnol** 1995;6:313–24 (34 ref.)

IMMUNOLOGY

Protection of ruminants by Pasteurella haemolytica A1 capsular polysaccharide vaccines containing muramyl dipeptide analogs. Brogden KA, et al. **Vaccine** 1995 Dec; 13(17):1677–84

PHARMACOLOGY

An interleukin-1 receptor fragment inhibits spontaneous sleep and muramyl dipeptide-induced sleep in rabbits. Takahashi S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R101–8
In vitro and in vivo production of interleukin-6 induced by muramyl peptides and lipopolysaccharide in normal dogs. Shi F, et al. **Cancer Biother** 1995 Winter;10(4):317–25
Modulation of expression of class II MHC and CD40 molecules in murine B cells by various muramyl dipeptides. Cohen LY, et al. **Cell Immunol** 1996 Apr 10;169(1):75–84
Regulation of lipopolysaccharide-induced tumor necrosis factor production by cyclosporin A in mice primed with muramyl dipeptide. Le Contel C, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):297–305
Modification of delayed-type hypersensitivity reactions by muramyldipeptide in guinea pigs. Nagao S, et al. **FEMS Immunol Med Microbiol** 1995 Jun;11(3):231–45
Differentiation of murine pre-B cell line by an adjuvant muramyl peptide via NF-kappa B activation. Cohen LY, et al. **Immunobiology** 1995 Aug;193(5):363–77
Differential regulation of surface immunoglobulin expression by various muramyl dipeptides in a murine pre-B cell line. Cohen LY, et al. **Immunol Lett** 1995 Mar;45(3):210–4
Muramyl dipeptide mimicry in the regulation of murine macrophage activation by serotonin. Polanski M, et al. **Int J Immunopharmacol** 1995 Mar;17(3):225–32
Extraintestinal manifestations of granulomatous enterocolitis induced in rabbits by long-term submucosal administration of muramyl dipeptide emulsified with Freund's incomplete adjuvant. Kuroe K, et al. **J Gastroenterol** 1996 Apr; 31(2):199–206
A tumor necrosis factor (TNF) receptor fragment attenuates TNF-alpha- and muramyl dipeptide-induced sleep and fever in rabbits. Takahashi S, et al. **J Sleep Res** 1996 Jun; 5(2):106–14

N-ACETYLNEURAMINIC ACIDS see **SIALIC ACIDS**

ACETYLPROCAINAMIDE see **ACECAINIDE**

ACETYLPROMAZINE see **ACEPROMAZINE**

ACETYLSALICYLIC ACID see **ASPIRIN**

O-ACETYLSERINE SULFHYDRYLASE see **CYSTEINE SYNTHASE**

ACETYLSEROTONIN METHYLTRANSFERASE

ANALYSIS

N-acetyltransferase, hydroxyindole-O-methyltransferase and melatonin in the optic lobes of the giant tiger shrimp Penaeus monodon. Withyachumnarnkul B, et al. **J Pineal Res** 1995 May;18(4):217–21

GENETICS

Hydroxyindole-O-methyltransferase gene expression in the pineal gland of chicken embryo: development of messenger RNA levels and regulation by serum. Grechez-Cassiau A, et al. **Brain Res Dev Brain Res** 1995 Sep 29;88(2):204–11
Retinoic acid increases hydroxyindole-O-methyltransferase activity and mRNA in human Y-79 retinoblastoma cells. Bernard M, et al. **J Neurochem** 1996 Sep;67(3):1032–8

METABOLISM

Human hydroxyindole-O-methyltransferase in pineal gland, retina and Y79 retinoblastoma cells. Bernard M, et al. **Brain Res** 1995 Oct 23;696(1-2):37–48
Retinoic acid increases hydroxyindole-O-methyltransferase activity and mRNA in human Y-79 retinoblastoma cells. Bernard M, et al. **J Neurochem** 1996 Sep;67(3):1032–8

ACETYLTHIOCHOLINE

METABOLISM

Evaluation of the nature of rat retinal acetylcholinesterase using a specific substrate and a specific inhibitor. Sastry BV, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):401–9

ACETYLTRANSFERASES

ANALYSIS

A simple assay for puromycin N-acetyltransferase: selectable marker and reporter. Mielke C, et al. **Trends Genet** 1995 Jul;11(7):258–9

BIOSYNTHESIS

Differential post-transcriptional control of ornithine decarboxylase and spermidine-spermine N1-acetyltransferase by polyamines. Fogel-Petrovic M, et al. **FEBS Lett** 1996 Aug 5;391(1-2):89-94

Significant induction of spermidine/spermine N1-acetyltransferase without cytotoxicity by the growth-supporting polyamine analogue 1,12-dimethylspermine. Yang J, et al. **J Cell Physiol** 1995 Oct;165(1):71-6

CHEMISTRY

Structure and critical residues at the active site of spermidine/spermine-N1-acetyltransferase. Coleman CS, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):697-701

Role of the carboxyl terminal MATEE sequence of spermidine/spermine N1-acetyltransferase in the activity and stabilization by the polyamine analog N1,N12-bis(ethyl)spermine. Coleman CS, et al. **Biochemistry** 1995 Oct 17;34(41):13423-30

Purification and characterization of the cytoplasmic histone acetyltransferase B of maize embryos. Eberharter A, et al. **FEBS Lett** 1996 May 13;386(1):75-81

Glycyl free radical in pyruvate formate-lyase: synthesis, structure characteristics, and involvement in catalysis. Knappe J, et al. **Methods Enzymol** 1995;258:343-62

GENETICS

Cloning and characterization of a 3-N-aminoglycoside acetyltransferase gene, aac(3)-Ib, from Pseudomonas aeruginosa. Schwocho LR, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1790-6

Isolation and characterization of Tri3, a gene encoding 15-O-acetyltransferase from Fusarium sporotrichioides. McCormick SP, et al. **Appl Environ Microbiol** 1996 Feb; 62(2):353-9

Genetic predisposition in occupational toxicology. Bolt HM. **Arch Toxicol Suppl** 1996;18:362-6 (32 ref.)

Cloning and expression of cDNA for O-acetylation of GD3 ganglioside. Ogura K, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):932-8

Differential transcription of the human spermidine/spermine N1-acetyltransferase (SSAT) gene in human lung carcinoma cells. Xiao L, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):691-6

Histological localization of messenger RNAs for rat acetyltransferases that acetylate serotonin and genotoxic arylamines. Debiec-Rychter M, et al. **Cancer Res** 1996 Apr 1;56(7):1517-25

Genetic analysis of two rat acetyltransferases. Land SJ, et al. **Carcinogenesis** 1996 May;17(5):1121-6

Effect of acetylator genotype on 3,2'-dimethyl-4-aminobiphenyl induced aberrant crypt foci in the colon of hamsters. Paulsen JE, et al. **Carcinogenesis** 1996 Mar;17(3):459-65

Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Brownell JE, et al. **Cell** 1996 Mar 22;84(6):843-51

Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9). De Leon JH, et al. **Drug Metab Dispos** 1995 Dec;23(12):1354-61

Analysis of two capreomycin-resistance determinants from Streptomyces capreolus and characterization of the action of their products. Thiara AS, et al. **Gene** 1995 Dec 29; 167(1-2):121-6

Cloning and sequence analysis of the pfl gene encoding pyruvate formate-lyase from Streptococcus mutans. Yamamoto Y, et al. **Infect Immun** 1996 Feb;64(2):385-91

Molecular characterization of the genes encoding pyruvate formate-lyase and its activating enzyme of Clostridium pasteurianum. Weidner G, et al. **J Bacteriol** 1996 Apr; 178(8):2440-4

Identification of a gene encoding a yeast histone H4 acetyltransferase. Kleff S, et al. **J Biol Chem** 1995 Oct 20; 270(42):24674-7

RGFGIGS is an amino acid sequence required for acetyl coenzyme A binding and activity of human spermidine/spermine N1acetyltransferase. Lu L, et al. **J Biol Chem** 1996 Aug 2;271(31):18920-4

Purification of ArcA and analysis of its specific interaction with the pfl promoter-regulatory region. Drapal N, et al. **Mol Microbiol** 1995 May;16(3):597-607

The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein [see comments] Borrow J, et al. **Nat Genet** 1996 Sep;14(1):33-41. Comment in: Nat Genet 1996 Sep;14(1):3-4.

Yeast SAS silencing genes and human genes associated with AML and HIV-1 Tat interactions are homologous with acetyltransferases [see comments] Reifsnyder C, et al. **Nat Genet** 1996 Sep;14(1):42-9. Comment in: Nat Genet 1996 Sep;14(1):3-4.

Something about silencing [news; comment] Roth SY. **Nat Genet** 1996 Sep;14(1):3-4. Comment on: Nat Genet 1996 Sep;14(1):33-41. Comment on: Nat Genet 1996 Sep;14(1):42-9.

Regional and cellular distribution of spermidine/spermine N1-acetyltransferase (SSAT) mRNA in the rat central nervous system. Zoli M, et al. **Neurosci Lett** 1996 Mar 22; 207(1):13-6

Cloning and characterization of an Arabidopsis thaliana cDNA clone encoding an organellar isoform of serine acetyltransferase. Roberts MA, et al. **Plant Mol Biol** 1996 Mar;30(5):1041-9

A simple assay for puromycin N-acetyltransferase: selectable marker and reporter. Mielke C, et al. **Trends Genet** 1995 Jul;11(7):258-9

[Human biodiversity and its effects on the pharmacological variability: CYP2D6 and NAT2 enzymes in Amerind populations of Panama, Colombia and Costa Rica] Jorge LF, et al. **Rev Med Panama** 1995 Sep;20(3):98-107 (Eng. Abstr.) (Spa)

ISOLATION & PURIFICATION

Purification and characterization of cysteine-S-conjugate N-acetyltransferase from pig kidney. Aigner A, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):213-8

Isolation, characterization and mode of neutralization of a potent antihemorrhagic factor from the serum of the snake Bothrops asper. Borkow G, et al. **Biochim Biophys Acta** 1995 Oct 19;1245(2):232-8

Different localization of spermidine/spermine N1-acetyltransferase and ornithine decarboxylase transcripts in the rat kidney. Bettuzzi S, et al. **FEBS Lett** 1995 Dec 27;377(3):321-4

METABOLISM

Diversity among the gram-positive acetyltransferases inactivating streptogramin A and structurally related compounds and characterization of a new staphylococcal determinant, vatB. Allignet J, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2027-36

Dissociation and reassembly of the dihydrolipoyl transacetylase component of the bovine heart pyruvate dehydrogenase complex. De Marcucci OL, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):169-76

Cloning and expression of cDNA for O-acetylation of GD3 ganglioside. Ogura K, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):932-8

Structure and critical residues at the active site of spermidine/spermine-N1-acetyltransferase. Coleman CS, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):697-701

Substrate specificity and kinetic studies of nodulation protein NodL of Rhizobium leguminosarum. Bloemberg GV, et al. **Biochemistry** 1995 Oct 3;34(39):12712-20

Role of the carboxyl terminal MATEE sequence of spermidine/spermine N1-acetyltransferase in the activity and stabilization by the polyamine analog N1,N12-bis(ethyl)spermine. Coleman CS, et al. **Biochemistry** 1995 Oct 17;34(41):13423-30

Stoichiometry of binding of mature and truncated forms of the dihydrolipoamide dehydrogenase-binding protein to the dihydrolipoamide acetyltransferase core of the pyruvate dehydrogenase complex from Saccharomyces cerevisiae. Maeng CY, et al. **Biochemistry** 1996 May 7;35(18):5879-82

Alkylglycerophosphate acetyltransferase and lyso platelet activating factor acetyltransferase, two key enzymes in the synthesis of platelet activating factor, are found in neuronal nuclei isolated from cerebral cortex. Baker RR, et al. **Biochim Biophys Acta** 1996 Aug 16;1302(3):257-63

N-acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. Sadrieh N, et al. **Cancer Res** 1996 Jun 15;56(12):2683-7

The role of acetylation in benzidine metabolism and DNA adduct formation in dog and rat liver. Lakshmi VM, et al. **Chem Res Toxicol** 1995 Jul-Aug;8(5):711-20

Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9). De Leon JH, et al. **Drug Metab Dispos** 1995 Dec;23(12):1354-61

Biosynthesis of N-acetylsphingosine by platelet-activating factor: sphingosine CoA-independent transacetylase in HL-60 cels. Lee TC, et al. **J Biol Chem** 1996 Jan 5; 271(1):209-17

Acetyl coenzyme A:salutaridinol-7-O-acetyltransferase from papaver somniferum plant cell cultures. The enzyme catalyzing the formation of thebaine in morphine biosynthesis. Lenz R, et al. **J Biol Chem** 1995 Dec 29; 270(52):31091-6

Structural and mechanistic studies of galactoside acetyltransferase, the Escherichia coli LacA gene product. Lewendon A, et al. **J Biol Chem** 1995 Nov 3; 270(44):26326-31

RGFGIGS is an amino acid sequence required for acetyl coenzyme A binding and activity of human spermidine/spermine N1acetyltransferase. Lu L, et al. **J Biol Chem** 1996 Aug 2;271(31):18920-4

Linkage-specific action of endogenous sialic acid O-acetyltransferase in Chinese hamster ovary cells. Shi WX, et al. **J Biol Chem** 1996 Jun 21;271(25):15130-8

Glycyl free radical in pyruvate formate-lyase: synthesis, structure characteristics, and involvement in catalysis. Knappe J, et al. **Methods Enzymol** 1995;258:343-62

Metabolic engineering in Escherichia coli: lowering the lipoyl domain content of the pyruvate dehydrogenase complex adversely affects the growth rate and yield. Dave E, et al. **Microbiology** 1995 Aug;141 (Pt 8):1839-49

Mutagenic activation of aromatic amines by a human hepatoma cell (Hep G2) supernatant tested by means of Salmonella typhimurium strains with different acetyltransferase activities. Duverger-van Bogaert M, et al. **Mutat Res** 1995 Dec;335(3):219-27

Role of O-acetyltransferase in activation of oxidised metabolites of the genotoxic environmental pollutant 1-nitropyrene. Rosser PF, et al. **Mutat Res** 1996 Aug 12; 369(3-4):209-20

Mutagenicity of nitrophenanthrene derivatives for Salmonella typhimurium: effects of nitroreductase and acetyltransferase. Sera N, et al. **Mutat Res** 1996 Jan 17; 349(1):137-44

Transcription-linked acetylation by Gcn5p of histones H3 and H4 at specific lysines. Kuo MH, et al. **Nature** 1996 Sep 19;383(6597):269-72

Identification of the polyamine N8-acetyltransferase involved in the pathway of 1,3-diaminopropane production in Acanthamoeba culbertsoni. Shukla OP, et al. **Parasitol Res** 1996;82(3):270-2

Metabolic activation of carcinogenic arylamines by rapid acetylator, slow acetylator, and chimeric recombinant Syrian hamster NAT2 allozymes. Hein DW, et al. **Proc West Pharmacol Soc** 1995;38:59-62

PHYSIOLOGY

Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Brownell JE, et al. **Curr Opin Genet Dev** 1996 Apr; 6(2):176-84 (83 ref.)

ACHALASIA, ESOPHAGEAL see **ESOPHAGEAL ACHALASIA**

ACHIEVEMENT

The effect of early performance on examiners' marking patterns during an oral examination. Brown MH, et al. **Acad Med** 1996 Jan;71(1 Suppl):S73-5

Consequences of shifting medical-student education to the outpatient setting: effects on performance and experiences. Grum CM, et al. **Acad Med** 1996 Jan;71(1 Suppl):S99-101

Use of a standardized-patient-based clinical performance examination as an outcome measure to evaluate medical school curricula. Richards BF, et al. **Acad Med** 1996 Jan; 71(1 Suppl):S49-51

Relationship between achievement in basic science coursework and performance on 1994 USMLE Step 1. 1994-95 Validity Study Group for USMLE Step 1/2 Pass/Fail Standards. Swanson DB, et al. **Acad Med** 1996 Jan;71(1 Suppl):S28-30

The deaf child and solving problems of arithmetic. The importance of comprehensive reading. Serrano Pau C. **Am Ann Deaf** 1995 Jul;140(3):287-90

Validity of the WISC-III for deaf and hard of hearing persons. Slate JR, et al. **Am Ann Deaf** 1995 Jul;140(3):250-4

The concept of fractional number among deaf and hard of hearing students. Titus JC. **Am Ann Deaf** 1995 Jul; 140(3):255-62

Finding the 'I' in the 'we'. Gordon S, et al. **Am J Nurs** 1996 Jan;96(1):21-2

High rates of violence, crime, academic problems, and behavioral problems in males with both early neuromotor deficits and unstable family environments. Raine A, et al. **Arch Gen Psychiatry** 1996 Jun;53(6):544-9

Cognitive and motivational determinants of academic achievement and behaviour in third and fourth grade disadvantaged children. Kreitler S, et al. **Br J Educ Psychol** 1995 Sep;65 (Pt 3):297-316

Perceptions of mathematics ability versus actual mathematics performance: Canadian and Hong Kong Chinese children. Kwok DC, et al. **Br J Educ Psychol** 1996 Jun;66 (Pt 2):209-22

Self-perceptions, motivation, and school functioning of low-income maltreated and comparison children. Barnett D, et al. **Child Abuse Negl** 1996 May;20(5):397-410

Helplessness in early childhood: the role of contingent worth. Burhans KK, et al. **Child Dev** 1995 Dec;66(6):1719-38

Perceptions and attitudes of black students toward school, achievement, and other educational variables. Ford DY, et al. **Child Dev** 1996 Jun;67(3):1141-52

A multiperspective comparison of peer sociometric status groups in childhood and adolescence. Hatzichristou C, et al. **Child Dev** 1996 Jun;67(3):1085-102

The effects of work intensity on adolescent mental health, achievement, and behavioral adjustment: new evidence from a prospective study. Mortimer JT, et al. **Child Dev** 1996 Jun;67(3):1243-61

Cognitive and family-support mediators of preschool effectiveness: a confirmatory analysis. Reynolds AJ, et al. **Child Dev** 1996 Jun;67(3):1119-40

School attainment, cognitive ability and motor function in a total Scottish very-low-birthweight population at eight years: a controlled study. Hall A, et al. **Dev Med Child Neurol** 1995 Dec;37(12):1037-50

Modeling causal relations between academic and social competence and depression: a multitrait-multimethod longitudinal study of children. Cole DA, et al. **J Abnorm Psychol** 1996 May;105(2):258-70

Differential family environments of bulimics and victims of childhood sexual abuse: achievement orientation. Kern JM, et al. **J Clin Psychol** 1995 Jul;51(4):499-506

Predicting antisocial behavior in youngsters displaying poor academic achievement: a review of risk factors. Brier N. **J Dev Behav Pediatr** 1995 Aug;16(4):271-6 (90 ref.)

Ethnicity, family achievement syndrome, and adolescents' aspirations: Rosen's framework revisited. Marjoribanks K.

ACHIEVEMENT

J Genet Psychol 1996 Sep;157(3):349–59

The relationship of HIV status, type of coagulation disorder, and school absenteeism to cognition, educational performance, mood, and behavior of boys with hemophilia. Mayes SD, et al. **J Genet Psychol** 1996 Jun;157(2):137–51

The relevance of Vygotsky's theory of the "zone of proximal development" to the assessment of children with intellectual disabilities. Rutland AF, et al. **J Intellect Disabil Res** 1996 Apr;40 (Pt 2):151–8

The effectiveness of admission criteria in predicting achievement in a master's degree program in nursing. Hansen MJ, et al. **J Nurs Educ** 1995 Dec;34(9):433–7

Mastery motivation and cognitive development in 4–year–old children born at various degrees of medical risk. McGrath M, et al. **J Pediatr Nurs** 1995 Oct;10(5):287–95

Neuropsychological deficit and academic performance in children and adolescents following traumatic brain injury. Kinsella G, et al. **J Pediatr Psychol** 1995 Dec;20(6):753–67

Achievement in children with birth weights less than 750 grams with normal cognitive abilities: evidence for specific learning disabilities. Taylor HG, et al. **J Pediatr Psychol** 1995 Dec;20(6):703–19

Does research during general surgery residency correlate with academic pursuits after pediatric surgery residency? Lessin MS, et al. **J Pediatr Surg** 1995 Sep;30(9):1310–3

Racial identity, academic achievement, and the psychological well–being of economically disadvantaged adolescents. Arroyo CG, et al. **J Pers Soc Psychol** 1995 Nov; 69(5):903–14

Self–handicapping and intrinsic motivation: buffering intrinsic motivation from the threat of failure. Deppe RK, et al. **J Pers Soc Psychol** 1996 Apr;70(4):868–76

Repressive emotional discreteness after failure. Egloff B, et al. **J Pers Soc Psychol** 1996 Jun;70(6):1318–26

Predicting student success: a 10–year review using integrative review and meta–analysis. Campbell AR, et al. **J Prof Nurs** 1996 Jan–Feb;12(1):47–59

The birth order factor: ordinal position, social strata, and educational achievement. Travis R, et al. **J Soc Psychol** 1995 Aug;135(4):499–507

Maturity in medical students [letter; comment] Alexander H, et al. **Lancet** 1996 Jan 6;347(8993):55. Comment on: Lancet 1995 Nov 18;346(8986):1329–33.

Maturity in medical students [letter; comment] Epstein R. **Lancet** 1996 Jan 6;347(8993):55–6. Comment on: Lancet 1995 Nov 18;346(8986):1329–33.

Maturity in medical students [letter; comment] Judson I. **Lancet** 1996 Jan 6;347(8993):55. Comment on: Lancet 1995 Nov 18;346(8986):1329–33.

Children who have difficulty in school: a primary pediatrician's approach. McInerny TK. **Pediatr Rev** 1995 Sep;16(9):325–32; quiz 332 (18 ref.)

Relationship between the Luria–Nebraska Neuropsychological Battery and Woodcock–Johnson Tests of Achievement–Revised in children with psychiatric impairment. Hooper SR. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1353–4

Fear of success among business students. Rothman M. **Psychol Rep** 1996 Jun;78(3 Pt 1):863–9

Effect of goal orientation on achievement beliefs, cognition and strategies in team sport. Roberts GC, et al. **Scand J Med Sci Sports** 1996 Feb;6(1):46–56

[Medical student traits associated with future success as physicians (see comments)] Garduño–Espinosa J, et al. **Rev Invest Clin** 1995 Sep–Oct;47(5):355–64 (Eng. Abstr.) . Comment in: Rev Invest Clin 1996 Mar–Apr;48(2):165–7. **(Spa)**

[Medical students' future success as physicians (letter; comment)] López–Jiménez F, et al. **Rev Invest Clin** 1996 Mar–Apr;48(2):165–7. Comment on: Rev Invest Clin 1995 Sep–Oct;47(5):355–64. **(Spa)**

[Academic performance in the 1st year and its relationship with admission variables in medical schools. Comparative study] García RE. **Rev Med Chil** 1995 Jan;123(1):28–36 (Eng. Abstr.) **(Spa)**

ACHILLES TENDON

Management of ulcers with exposed Achilles tendon using occlusive dressings. Omidi J, et al. **Arch Dermatol** 1996 Sep;132(9):1007–8

Long survival with metastatic clear cell sarcoma of the Achilles tendon. Yip KM, et al. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):109–11; discussion 187

Lower leg overuse injuries in athletes. Järvinen M. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):126–30 (33 ref.)

Chronic Achilles peritendinitis and retrocalcanear bursitis. Long–term follow–up of surgically treated cases. Lehto MU, et al. **Knee Surg Sports Traumatol Arthrosc** 1994; 2(3):182–5

[Surgically treated chronic bilateral Achilles tendon disease, without spontaneous rupture, caused by perfloxacin (letter)] Beuchard J, et al. **Presse Med** 1996 Jun 29;25(23):1083 **(Fre)**

[Ciprofloxacin–associated bilateral acute achilles tendinitis] Mirovsky Y, et al. **Harefuah** 1995 Dec 1;129(11):470–2, 535 (Eng. Abstr.) **(Heb)**

ANATOMY & HISTOLOGY

Anatomy of the Achilles tendon and plantar fascia in relation to the calcaneus in various age groups. Snow SW, et al. **Foot Ankle Int** 1995 Jul;16(7):418–21

Adapted techniques for clinical MR imaging of tendons. Schick F, et al. **MAGMA** 1995 Jul;3(2):103–7

Anatomy of the Achilles tendon (tendo calcaneus) with respect to tendon thickness measurements. Koivunen–Niemelä T, et al. **Surg Radiol Anat** 1995; 17(3):263–8

[Structural MRI study of the Achilles tendon. Correlation with microanatomy and histology] Mantel D, et al. **J Radiol** 1996 Apr;77(4):261–5 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Crosslinking characteristics of porcine tendons: effects of fixation with glutaraldehyde or epoxy. Sung HW, et al. **J Biomed Mater Res** 1996 Mar;30(3):361–7

DRUG EFFECTS

[Tendinopathy and fluoroquinolones] Castagnola C, et al. **Ann Urol (Paris)** 1996;30(3):129–30 (Eng. Abstr.) **(Fre)**

INJURIES

Incidence of Achilles tendon rupture. Leppilahti J, et al. **Acta Orthop Scand** 1996 Jun;67(3):277–9

Achilles tendon ruptures. A new method of repair, early range of motion, and functional rehabilitation. Mandelbaum BR, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):392–5

Surgical treatment of ruptures of the Achilles tendon: a review of long–term results. Krueger–Franke M, et al. **Br J Sports Med** 1995 Jun;29(2):121–5

Bilateral simultaneous rupture of the Achilles tendon. A rare traumatic injury. Habusta SF. **Clin Orthop** 1995 Nov; (320):231–4

Free tissue coverage of wound complications following Achilles tendon rupture surgery. Leppilahti J, et al. **Clin Orthop** 1996 Jul;(328):171–6

Diagnosis and treatment of Achilles tendon rupture. Kuwada GT. **Clin Podiatr Med Surg** 1995 Oct;12(4):633–52 (75 ref.)

Treatment of ruptures of Achilles' tendons by an external fixator. Tokmakov P. **Folia Med (Plovdiv)** 1995;37(4A Suppl):92

A method for combined percutaneous and open surgical repair of Achilles tendon ruptures: a report of three cases. Esemenli BT, et al. **Foot Ankle Int** 1996 Apr;17(4):217–20

Early motion after repair of Achilles tendon ruptures. Troop RL, et al. **Foot Ankle Int** 1995 Nov;16(11):705–9

Repair of neglected Achilles tendon ruptures with Marlex mesh. Choksey A, et al. **Injury** 1996 Apr;27(3):215–7

Roentgenographic assessment of Achilles tendon rupture [letter; comment] Combalia A, et al. **J Accid Emerg Med** 1995 Sep;12(3):230–1. Comment on: Arch Emerg Med 1993 Dec;10(4):336–8.

Stress in the Achilles tendon during a topple–over movement in the ankle joint. Wallenböck E, et al. **J Biomech** 1995 Sep;28(9):1091–101

A severe acute Achilles rupture and repair. Kuwada GT. **J Foot Ankle Surg** 1995 May–Jun;34(3):262–5

Reconstruction of an Achilles tendon defect utilizing an Achilles tendon allograft. Nellas ZJ, et al. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):144–8; discussion 190

A composite lateral arm flap for the secondary repair of a multiply ruptured Achilles tendon. Sylaidis P, et al. **Plast Reconstr Surg** 1995 Dec;96(7):1719–23

[Fracture of an ossified Achilles tendon] Krause K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):171–2 (9 ref.) **(Ger)**

[Functional treatment of acute rupture of the Achilles tendon. An experimental biomechanical study] Thermann H, et al. **Unfallchirurg** 1995 Oct;98(10):507–13 (Eng. Abstr.) **(Ger)**

[Biomechanical studies of human Achilles tendon rupture] Thermann H, et al. **Unfallchirurg** 1995 Nov;98(11):570–5 (Eng. Abstr.) **(Ger)**

[Surgical therapy of Achilles tendon rupture] Winter E, et al. **Unfallchirurg** 1995 Sep;98(9):468–73 (Eng. Abstr.) **(Ger)**

[The echographic and clinical follow–up of patients operated on for subcutaneous rupture of the Achilles tendon] Cinotti A, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):28–32 (Eng. Abstr.) **(Ita)**

[Rupture of the Achilles tendon after ciproxine therapy] Hugo–Persson M. **Lakartidningen** 1996 Apr 17;93(16):1520 **(Swe)**

INNERVATION

Human root and cord potentials evoked by Achilles tendon tap. Ertekin C, et al. **Electromyogr Clin Neurophysiol** 1995 Aug–Sep;35(5):259–71

PATHOLOGY

Relation of cholesterol–year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia. Schmidt HH, et al. **Am J Cardiol** 1996 Mar 15;77(8):575–80

PHYSIOLOGY

Human myotatic reflex development of the lower extremities. Leonard CT, et al. **Early Hum Dev** 1995 Aug 30;43(1):75–93

In vivo Achilles tendon loading during jumping in humans. Fukashiro S, et al. **Eur J Appl Physiol** 1995;71(5):453–8

Stress in the Achilles tendon during a topple–over movement in the ankle joint. Wallenböck E, et al. **J Biomech** 1995 Sep;28(9):1091–101

The use of xenogeneic small intestinal submucosa as a biomaterial for Achilles tendon repair in a dog model. Badylak SF, et al. **J Biomed Mater Res** 1995 Aug; 29(8):977–85

The influence of strength training, swim training and ageing on the Achilles tendon and m. soleus of the rat. Simonsen EB, et al. **J Sports Sci** 1995 Aug;13(4):291–5

Range of motion, muscle torque and training habits in runners with and without Achilles tendon problems. Haglund–Akerlind Y, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):195–9

SURGERY

Surgical treatment of ruptures of the Achilles tendon: a review of long–term results. Krueger–Franke M, et al. **Br J Sports Med** 1995 Jun;29(2):121–5

Free tissue coverage of wound complications following Achilles tendon rupture surgery. Leppilahti J, et al. **Clin Orthop** 1996 Jul;(328):171–6

Early motion after repair of Achilles tendon ruptures. Troop RL, et al. **Foot Ankle Int** 1995 Nov;16(11):705–9

Surgery for chronic Achilles tendon problems. Saxena A. **J Foot Ankle Surg** 1995 May–Jun;34(3):294–300

Comparison of tendo–Achilles lengthening alone and combined with neurectomy of the gastrocnemius muscle in the treatment of equinus deformity of the foot associated with clonus in children with cerebral palsy. Camacho FJ, et al. **Orthopedics** 1996 Apr;19(4):319–22

Plantar forefoot ulceration with equinus deformity of the ankle in diabetic patients: the effect of tendo–Achilles lengthening and total contact casting. Lin SS, et al. **Orthopedics** 1996 May;19(5):465–75

[Cover of the Achilles tendon by peroneus brevis and flexor hallucis longus flaps. Apropos of 5 clinical cases] Braye F, et al. **Ann Chir Plast Esthet** 1996 Apr;41(2):137–44 (Eng. Abstr.) **(Fre)**

[Distal reconstruction of the Achilles tendon with a bone–tendon graft from extensor system of the knee] Besse JL, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(5):453–7 (Eng. Abstr.) **(Fre)**

[Treatment results of Imhäuser's method of treating neonatal clubfeet] Kausch T, et al. **Z Orthop Ihre Grenzgeb** 1995 Nov–Dec;133(6):524–9 (Eng. Abstr.) **(Ger)**

[Percutaneous method for achilles tendon lengthening in treatment of spastic equinus deformity with progressive muscular dystrophy] Lejman T, et al. **Chir Narzadow Ruchu Ortop Pol** 1993;58(6):485–8 (Eng. Abstr.) **(Pol)**

TRANSPLANTATION

Subcutaneous pretibial cyst formation associated with anterior cruciate ligament allografts: a report of four cases and literature review. Victoroff BN, et al. **Arthroscopy** 1995 Aug;11(4):486–94 (25 ref.)

Reconstruction of an Achilles tendon defect utilizing an Achilles tendon allograft. Nellas ZJ, et al. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):144–8; discussion 190

ULTRASONOGRAPHY

High resolution ultrasound anatomy of normal Achilles tendon. Bertolotto M, et al. **Br J Radiol** 1995 Sep; 68(813):986–91

Ultrasound of the Achilles tendon after surgical repair: morphology and function [letter] Maffulli N. **Br J Radiol** 1995 Dec;68(816):1372–3

Anisotropy of the transverse mode ultrasonic properties of fixed tendon and fixed myocardium. Hoffmeister BK, et al. **J Acoust Soc Am** 1996 Jun;99(6):3826–36

[The echographic and clinical follow–up of patients operated on for subcutaneous rupture of the Achilles tendon] Cinotti A, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):28–32 (Eng. Abstr.) **(Ita)**

ACHLORHYDRIA

BLOOD

Effect of omeprazole and feeding on plasma gastrin in patients with achlorhydria. Banerjee S, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):507–12

CHEMICALLY INDUCED

Hypochlorhydria from short–term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. Serfaty–Lacrosniere C, et al. **J Am Coll Nutr** 1995 Aug; 14(4):364–8

COMPLICATIONS

Bacteria in the aetio–pathogenesis of gastric cancer: a review. Houben GM, et al. **Scand J Gastroenterol Suppl** 1995; 212:13–8 (61 ref.)

ETIOLOGY

[A Chinese patient with pernicious anemia; a medical experience from the Indonesian period] Zuidema PJ.

Ned Tijdschr Geneeskd 1996 Mar 9;140(10):561-3 (Eng. Abstr.) (Dut)

METABOLISM

Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. Serfaty-Lacrosniere C, et al. J Am Coll Nutr 1995 Aug; 14(4):364-8

ACHOLEPLASMA LAIDLAWII

[A factor to enhance HIV replication in serum bearing a resemblance to membranes of Acholeplasma laidlawii] Hayashi R. Kansenshogaku Zasshi 1995 Dec;69(12):1389-95 (Eng. Abstr.) (Jpn)

CHEMISTRY

New aspects on membrane lipid regulation in Acholeplasma laidlawii A and phase equilibria of monoacyldiglucosyldiacylglycerol. Andersson AS, et al. Biochemistry 1996 Aug 27;35(34):11119-30

Quantitation of the phase preferences of the major lipids of the Acholeplasma laidlawii B membrane. Foht PJ, et al. Biochemistry 1995 Oct 24;34(42):13811-7

Acholeplasma laidlawii B membranes contain a lipid (glycerylphosphoryldiglucosyldiacylglycerol) which forms micelles rather than lamellar or reversed phases when dispersed in water. Lewis RN, et al. Biochemistry 1995 Oct 24;34(42):13818-24

Fluctuations in IR spectral parameters detected in mixed acyl chain membranes of Acholeplasma laidlawii B. Moore DJ, et al. Biochim Biophys Acta 1996 Feb 21;1279(1):49-57

Chromatographic resolution of partially perdeuterated diglucosyldiacylglycerols from Acholeplasma laidlawii. Bergqvist MH. J Chromatogr A 1996 Jun 7;736(1-2):83-9

DRUG EFFECTS

Influence of monoglucosyldiacylglycerol and monoacylmonoglucosyldiacylglycerol on the lipid bilayer of the membrane from Acholeplasma laidlawii strain A-EF22. Niemi AR, et al. Biochim Biophys Acta 1995 Nov 1;1239(2):186-94

ENZYMOLOGY

Efficient modulation of glucolipid enzyme activities in membranes of Acholeplasma laidlawii by the type of lipids in the bilayer matrix. Dahlqvist A, et al. Biochemistry 1995 Oct 17;34(41):13381-9

Correlation between bilayer lipid dynamics and activity of the diglucosyldiacylglycerol synthase from Acholeplasma laidlawii membranes. Karlsson OP, et al. Biochemistry 1996 Aug 6;35(31):10094-102

GENETICS

Expression of foreign genes and selection of promoter sequences in Acholeplasma laidlawii. Jarhede TK, et al. Microbiology 1995 Sep;141 (Pt 9):2071-9

PATHOGENICITY

[Clastogenic effect of mycoplasma on human chromosomes] Chernov VM, et al. Dokl Akad Nauk 1995 Sep;344(1):130-2 (Rus)

[The effect of the Mycoplasma contamination of 2 kidney cell sublines from the kangaroo rat on their karyotypic structure] Polianskaia GG, et al. Tsitologiia 1996; 38(1):75-84 (Eng. Abstr.) (Rus)

ACHONDROPLASIA

COMPLICATIONS

Treatment of obstructive sleep apnea in achondroplasia: evaluation of sleep, breathing, and somatosensory-evoked potentials. Waters KA, et al. Am J Med Genet 1995 Dec 4;59(4):460-6

Gallbladder carcinoma in an achondroplastic boy. Eire PF, et al. Eur J Pediatr Surg 1995 Oct;5(5):313-4

DIAGNOSIS

Foramen magnum stenosis and bilateral benign subdural collections in achondroplasia: case report. Mancuso P, et al. J Neurosurg Sci 1994 Dec;38(4):259-62

[DNA diagnosis for short limb dwarfism, possibility of prenatal diagnosis for achondroplasia] Komori S, et al. Nippon Sanka Fujinka Gakkai Zasshi 1996 Mar; 48(3):229-32 (Jpn)

GENETICS

Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism. Bonaventure J, et al. Am J Med Genet 1996 May 3; 63(1):148-54

Atypical radiological findings in achondroplasia with uncommon mutation of the fibroblast growth factor receptor-3 (FGFR-3) gene (Gly to Cys transition at codon 375) [letter] Nishimura G, et al. Am J Med Genet 1995 Nov 20;59(3):393-5

Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta. Orioli IM, et al. Am J Med Genet 1995 Nov 6;59(2):209-17

Cardiac malformation in two infants with hypochondrogenesis. Potocki L, et al. Am J Med Genet 1995 Nov 20;59(3):295-9 (17 ref.)

Lung hypoplasia and severe pulmonary hypertension in an infant with double heterozygosity for spondyloepiphyseal dysplasia congenita and achondroplasia. Günthard J, et al. Clin Genet 1995 Jul;48(1):35-40

Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. Webster MK, et al. EMBO J 1996 Feb 1;15(3):520-7

Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia. Rousseau F, et al. Horm Res 1996; 45(1-2):108-10 (18 ref.)

Chinese achondroplasia is also defined by recurrent G380R mutations of the fibroblast growth factor receptor-3 gene. Niu DM, et al. Hum Genet 1996 Jul;98(1):65-7

Undersulfation of proteoglycans synthesized by chondrocytes from a patient with achondrogenesis type 1B homozygous for an L483P substitution in the diastrophic dysplasia sulfate transporter. Rossi A, et al. J Biol Chem 1996 Aug 2;271(31):18456-64

Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Colvin JS, et al. Nat Genet 1996 Apr;12(4):390-7

Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Naski MC, et al. Nat Genet 1996 Jun;13(2):233-7

Achondrogenesis type IB is caused by mutations in the diastrophic dysplasia sulphate transporter gene. Superti-Furga A, et al. Nat Genet 1996 Jan;12(1):100-2

METABOLISM

Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. Webster MK, et al. EMBO J 1996 Feb 1;15(3):520-7

Undersulfation of proteoglycans synthesized by chondrocytes from a patient with achondrogenesis type 1B homozygous for an L483P substitution in the diastrophic dysplasia sulfate transporter. Rossi A, et al. J Biol Chem 1996 Aug 2;271(31):18456-64

Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Colvin JS, et al. Nat Genet 1996 Apr;12(4):390-7

PATHOLOGY

Craniocervical stenosis and apnea spells in a 2-month-old baby with achondroplasia. Najjar JA, et al. J Child Neurol 1995 Nov;10(6):484-6

PHYSIOPATHOLOGY

Standard curves of chest circumference in achondroplasia and the relationship of chest circumference to respiratory problems. Hunter AG, et al. Am J Med Genet 1996 Mar 1;62(1):91-7

RADIOGRAPHY

[X-ray diagnosis of the state of soft tissues in patients with achondroplasia in limb lengthening using Ilizarov technique] D'iachkova GV. Vestn Rentgenol Radiol 1995 Mar-Apr;(2):46-9 (Eng. Abstr.) (Rus)

SURGERY

Callus formation in femur and tibia during leg lengthening: 7 patients examined with DXA. Tanaka K, et al. Acta Orthop Scand 1996 Apr;67(2):158-60

Foramen magnum stenosis and bilateral benign subdural collections in achondroplasia: case report. Mancuso P, et al. J Neurosurg Sci 1994 Dec;38(4):259-62

Coronary artery bypass grafting in an achondroplastic dwarf. Balaguer JM, et al. Tex Heart Inst J 1995;22(3):258-60

[X-ray diagnosis of the state of soft tissues in patients with achondroplasia in limb lengthening using Ilizarov technique] D'iachkova GV. Vestn Rentgenol Radiol 1995 Mar-Apr;(2):46-9 (Eng. Abstr.) (Rus)

ACHROMOBACTER see **ALCALIGENES**

ACHROMOBACTERIACEAE see **GRAM-NEGATIVE AEROBIC BACTERIA**

ACHYLIA GASTRICA see **ACHLORHYDRIA**

ACID ANHYDRIDE HYDROLASES

BIOSYNTHESIS

Differential modulation of expression of the two acylphosphatase isoenzymes by thyroid hormone. Chiarugi P, et al. Biochem J 1995 Oct 15;311 (Pt 2):567-73

CHEMISTRY

Use of fluorogenic substrates for detection and investigation of ectoenzymatic hydrolysis of diadenosine polyphosphates: a fluorometric study on chromaffin cells. Ramos A, et al. Anal Biochem 1995 Jun 10;228(1):74-82

Looking for residues involved in the muscle acylphosphatase catalytic mechanism and structural stabilization: role of Asn41, Thr42, and Thr46. Taddei N, et al. Biochemistry 1996 Jun 4;35(22):7077-83

C-terminal region contributes to muscle acylphosphatase three-dimensional structure stabilisation. Taddei N, et al. FEBS Lett 1996 Apr 15;384(2):172-6

Localization and in vitro mutagenesis of the active site in the Saccharomyces cerevisiae mRNA capping enzyme. Shibagaki Y, et al. J Biochem (Tokyo) 1995 Dec; 118(6):1303-9

Domain structure of the vaccinia virus mRNA capping enzyme. Expression in Escherichia coli of a subdomain possessing the RNA 5'-triphosphatase and guanylyltransferase activities and a kinetic comparison to the full-size enzyme. Myette JR, et al. J Biol Chem 1996 May 17;271(20):11936-44

GENETICS

Cloning of the Schizosaccharomyces pombe gene encoding diadenosine 5',5"'-P1,P4-tetraphosphate (Ap4A) asymmetrical hydrolase: sequence similarity with the histidine triad (HIT) protein family. Huang Y, et al. Biochem J 1995 Dec 15;312 (Pt 3):925-32

Expression of acylphosphatase in Saccharomyces cerevisiae enhances ethanol fermentation rate. Raugei G, et al. Biotechnol Appl Biochem 1996 Jun;23 (Pt 3):273-8

Light-modulated abundance of an mRNA encoding a calmodulin-regulated, chromatin-associated NTPase in pea. Hsieh HL, et al. Plant Mol Biol 1996 Jan;30(1):135-47

METABOLISM

Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase. Millard CB, et al. Biochemistry 1995 Dec 12;34(49):15925-33

Specific dinucleoside polyphosphate cleaving enzymes from chromaffin cells: a fluorimetric study. Ramos A, et al. Biochim Biophys Acta 1995 Nov 15;1253(1):103-11

Ultracytochemical study of trimetaphosphatase activity during acrosomal formation in the mouse testis. Jin QS, et al. Histol Histopathol 1995 Jul;10(3):681-9

Localization and in vitro mutagenesis of the active site in the Saccharomyces cerevisiae mRNA capping enzyme. Shibagaki Y, et al. J Biochem (Tokyo) 1995 Dec; 118(6):1303-9

Characterization of the vaccinia virus RNA 5'-triphosphatase and nucleotide triphosphate phosphohydrolase activities. Demonstrate that both activities are carried out at the same active site. Myette JR, et al. J Biol Chem 1996 May 17; 271(20):11945-52

Stimulation of cardiac sarcoplasmic reticulum calcium pump by acylphosphatase. Relationship to phospholamban phosphorylation. Nediani C, et al. J Biol Chem 1996 Aug 9;271(32):19066-73

Partial purification and immunohistochemical localization of ATP diphosphohydrolase from Schistosoma mansoni. Immunological cross-reactivities with potato apyrase and Toxoplasma gondii nucleoside triphosphate hydrolase. Vasconcelos EG, et al. J Biol Chem 1996 Sep 6; 271(36):22139-45

Morphology and distribution of microglial cells in the young and adult mouse cerebellum. Vela JM, et al. J Comp Neurol 1995 Oct 30;361(4):602-16

Thiamine, thiamine phosphates, and their metabolizing enzymes in human brain. Bettendorff L, et al. J Neurochem 1996 Jan;66(1):250-8

Double-stranded RNA bacteriophage phi 6 protein P4 is an unspecific nucleoside triphosphatase activated by calcium ions. Paatero AO, et al. J Virol 1995 Nov;69(11):6729-34

Mutational analysis of the RNA triphosphatase component of vaccinia virus mRNA capping enzyme. Yu L, et al. J Virol 1996 Sep;70(9):6162-8

Identification of an RNA-stimulated NTPase in the predicted helicase sequence of the Rubella virus nonstructural polyprotein. Gros C, et al. Virology 1996 Mar 1; 217(1):367-72

[Organelle specificity of yeast cell polyphosphatases] Kulaev IS, et al. Biokhimiia 1995 Sep;60(9):1396-402 (34 ref.) (Eng. Abstr.) (Rus)

[Immunoenzyme analysis of polyphosphatases from various compartments of yeast cells] Kulakovskaia TV, et al. Biokhimiia 1995 Dec;60(12):2040-4 (Eng. Abstr.) (Rus)

[Characteristics of Saccharomyces cerevisiae nuclear polyphosphatase activity] Lichko LP, et al. Biokhimiia 1996 Mar;61(3):488-95 (Eng. Abstr.) (Rus)

[Detection of polyphosphatase activity in isolated Saccharomyces cerevisiae nuclei] Lichko LP, et al. Biokhimiia 1995 Nov;60(11):1911-6 (Eng. Abstr.) (Rus)

ACID ASPIRATION SYNDROME see **PNEUMONIA, ASPIRATION**

ACID-BASE EQUILIBRIUM

see related
ACIDOSIS
ALKALOSIS
BUFFERS

Early cerebral functional outcome after coronary artery bypass surgery using different acid-base management during hypothermic cardiopulmonary bypass. Engelhardt

W, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):457–65

Phenylephrine in treating maternal hypotension due to spinal anaesthesia for caesarean delivery: effects on neonatal catecholamine concentrations, acid base status and Apgar scores. LaPorta RF, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):901–5

Modelling of acid–base equilibria. Jabor A, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:119–22

Oxygen and acid–base parameters of arterial and mixed venous blood, relevant versus redundant. Siggaard–Andersen O, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:21–7

Effect of casein–based semi–synthetic food on renal acid excretion and acid–base state of blood in dogs. Zijlstra WG, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:179–83

Umbilical cord blood acid–base state: what is normal? Helwig JT, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1807–12; discussion 1812–4

Acid–base homeostasis parallels anabolism in surgically stressed rats treated with GH and IGF–I. Evans SJ, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E968–74

Expression of colonic H–K–ATPase mRNA in cortical collecting duct: regulation by acid/base balance. Fejes–Tóth G, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):F551–7

Oxygen consumption, acid–base status, and behavior during and after acute, severe hemorrhage in fetal lambs. Kwan E, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R758–66

Acid–base management during cardiopulmonary bypass. Current trends in the United Kingdom. Goldsack C, et al. **Anaesthesia** 1996 Apr;51(4):396–8

Acid–base metabolism after bladder substitution with the ileal urethral Kock reservoir. Poulsen AL, et al. **Br J Urol** 1996 Jul;78(1):47–53

Anion gap in turpentine–induced pleural effusions. Correlation with pH and protein level. Paulson WD, et al. **Chest** 1996 Feb;109(2):504–9

Metabolic base production and mucosal vulnerability during acid inhibition in a mammalian stomach in vitro. Glauser M, et al. **Dig Dis Sci** 1996 May;41(5):964–71

Effects of multibuffer supplementation on acid–base balance and 2,3–diphosphoglycerate following repetitive anaerobic exercise. Kraemer WJ, et al. **Int J Sport Nutr** 1995 Dec; 5(4):300–14

Acid–base variables during incremental exercise in sprint–trained horses fed a high–fat diet. Taylor LE, et al. **J Anim Sci** 1995 Jul;73(7):2009–18

The effects of changing ration ingredients on acid–base status, renal function, and macromineral metabolism. Delaquis AM, et al. **J Dairy Sci** 1995 Sep;78(9):2024–39

Dietary cation–anion difference, acid–base status, mineral metabolism, renal function, and milk production of lactating cows. Delaquis AM, et al. **J Dairy Sci** 1995 Oct; 78(10):2259–84

Cell saver autologous transfusion: metabolic consequences of washing blood with normal saline. Halpern NA, et al. **J Trauma** 1996 Sep;41(3):407–15

Serum lactate is not predicted by anion gap or base excess after trauma resuscitation. Mikulaschek A, et al. **J Trauma** 1996 Feb;40(2):218–22; discussion 222–4

Quantitative acid base chemistry [letter; comment] Duval D. **J Vet Intern Med** 1995 Jul–Aug;9(4):289. Comment on: J Vet Intern Med 1995 Jan–Feb;9(1):1–11.

Relationship between degree of dehydration and serum electrolytes and acid–base status in cows with various abomasal disorders. Taguchi K. **J Vet Med Sci** 1995 Apr; 57(2):257–60

Effect of acid/base balance on H–ATPase 31 kD subunit mRNA levels in collecting duct cells. Fejes–Tóth G, et al. **Kidney Int** 1995 Nov;48(5):1420–6

Third–trimester arterial blood gas and acid base values in normal pregnancy at moderate altitude. Hankins GD, et al. **Obstet Gynecol** 1996 Sep;88(3):347–50

Moving more closely to acid–base relationships in the body as a whole. Gamble JL Jr. **Perspect Biol Med** 1996 Summer; 39(4):593–600 (9 ref.)

A computer program for the multivariate and graphical monitoring of acid–base data in an intensive care unit. Hekking M, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:52–6

[Determination of serum lactic acid and the acid–base equilibrium in carbon monoxide poisoning] Kubát K, et al. **Vnitr Lek** 1995 Aug;41(8):545–8 (Eng. Abstr.) **(Cze)**

[2nd CPA Symposium: Liver function and acid–base balance. Mainz, September 1994] **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S1–77 **(Ger)**

[The acid–base balance in the blood of calves of different breeds in a mother cow herd raised on deep straw and strawless conditions] Thielscher HH, et al. **Berl Munch Tierarztl Wochenschr** 1995 Sep;108(9):339–43 (Eng. Abstr.) **(Ger)**

[Base excess and buffer base] Matsuzaki K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:782–6 (4 ref.) **(Jpn)**

[Arterial pH] Matsuzaki K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:800–3 (5 ref.) **(Jpn)**

[Role of acid–base balance of the blood in the pathogenesis of acute gastroduodenal ulcers in surgery patients] Skriabin ON, et al. **Klin Med (Mosk)** 1995;73(4):100 **(Rus)**

[The reaction of the kidneys and acid–base and osmotic homeostasis to moderate physical exertion in patients with chronic pyelonephritis in the pre–azotemia period] Kaiukov IG, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):13–5 (Eng. Abstr.) **(Rus)**

[The effect of vitamin E on cortisol and lactate levels and on the acid–base equilibrium in calves exposed to transportation stress] Mudroň P, et al. **Vet Med (Praha)** 1996 Mar;41(3):71–6 (Eng. Abstr.) **(Slo)**

[Role of low molecular weight metabolites as natural regulators of metabolism] Mel'nychuk DO, et al. **Ukr Biokhim Zh** 1995 May–Jun;67(3):84–92 (Eng. Abstr.) **(Ukr)**

DRUG EFFECTS

The effect of sodium bicarbonate on CBF and intracellular pH in man: stable Xe–CT and 31P–MRS. Nakashima K, et al. **Acta Neurol Scand Suppl** 1996;166:96–8

Effects of protein, methionine, or chloride on acid–base balance and on cysteine catabolism. Bella DL, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E910–7

Investigation into intraerythrocytic and extraerythrocytic acid–base and electrolyte changes after long–term ammonium chloride administration in dogs. Schober KE. **Am J Vet Res** 1996 May;57(5):743–9

The effect of physostigmine on acid–base status in arterial and venous blood of anaesthetized rabbits following hypovolemic shock. Zunić G, et al. **Gen Pharmacol** 1995 Mar;26(2):291–5

Effects of stobadine on survival, histopathologic outcome and acid–base status after global brain ischemia in dogs. Pomfy M, et al. **J Hirnforsch** 1995;36(3):365–78

Effects of Carbicarb and sodium bicarbonate on hypoxic lactic acidosis in newborn pigs. Basir MA, et al. **J Investig Med** 1996 Feb;44(2):70–4

Acid–base status and cardiovascular function in mink (Mustela vison) anaesthetized with ketamine/midazolam. Wamberg S, et al. **Lab Anim** 1996 Jan;30(1):55–66

The effects of dopamine and adrenaline infusions on acid–base balance and systemic haemodynamics in severe infection. Day NP, et al. **Lancet** 1996 Jul 27; 348(9022):219–23

Acid–base balance with different CAPD solutions. Feriani M, et al. **Perit Dial Int** 1996;16 Suppl 1:S126–9

Effect of different buffers on the biocompatibility of CAPD solutions. Schambye HT. **Perit Dial Int** 1996;16 Suppl 1:S130–6 (48 ref.)

Induction of alkalinization in cultured renal cells (MDCK line) by prostaglandin E2. Rodriguez MG, et al. **Prostaglandins** 1995 Feb;49(2):79–91

Gastric alkalinization, pneumonia, and systemic infections: the controversy. Tryba M, et al. **Scand J Gastroenterol Suppl** 1995;210:53–9 (69 ref.)

[Therapy of candiduria by alkalinization of urine. Oral treatment with potassium–sodium–hydrogen citrate] Strassner C, et al. **Fortschr Med** 1995 Sep 10;113(25):359–62 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

"Physiologic" intracellular acidosis in pregnancy. Bardicef O, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):879–80

The liver: the forgotten organ in acid–base balance? [editorial] Zander R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S2–9 **(Eng, Ger)**

Acid–base balance affects dietary choice in cats. Cook NE, et al. **Appetite** 1996 Apr;26(2):175–92

The effect of xylazine epidural anaesthesia on blood gas and acid–base parameters in rams. Aminkov BY, et al. **Br Vet J** 1995 Sep–Oct;151(5):579–85

Effects of sodium bicarbonate on fluid, electrolyte and acid–base balance in racehorses [see comments] Lloyd DR, et al. **Br Vet J** 1995 Sep–Oct;151(5):523–45. Comment in: Br Vet J 1995 Sep–Oct;151(5):473–5.

Extreme derangements of acid–base balance in exercise: advantages and limitations of the Stewart analysis. Fedde MR, et al. **Can J Appl Physiol** 1995 Sep;20(3):369–79 (10 ref.)

Contribution of acid–base changes to control of breathing during exercise. Forster HV, et al. **Can J Appl Physiol** 1995 Sep;20(3):380–94 (97 ref.)

A quantitative approach to acid–base chemistry. Heigenhauser GJ. **Can J Appl Physiol** 1995 Sep; 20(3):333–40 (20 ref.)

Acid–base balance: origin of plasma [H+] during exercise. Kowalchuk JM, et al. **Can J Appl Physiol** 1995 Sep; 20(3):341–56 (33 ref.)

Origins of [H+] changes in exercising skeletal muscle. Lindinger MI. **Can J Appl Physiol** 1995 Sep;20(3):357–68 (38 ref.)

Regulation of intracellular pH by cell–cell adhesive interactions. Galkina SI, et al. **FEBS Lett** 1995 Oct 23; 374(1):17–20

Age and systemic acid–base equilibrium: analysis of published data. Frassetto L, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B91–9

Thermotolerance attenuates heat–induced increases in [Ca2+]i and HSP–72 synthesis but not heat–induced intracellular acidification in human A–431 cells. Kiang JG, et al. **J Investig Med** 1996 Feb;44(2):53–63

Alpha–stat acid–base regulation during cardiopulmonary bypass improves neuropsychologic outcome in patients undergoing coronary artery bypass grafting. Patel RL, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1267–79

Ontogeny of proximal tubule acidification [editorial] Baum M, et al. **Kidney Int** 1995 Dec;48(6):1697–704 (90 ref.)

The influence of pH on surface properties of lung surfactants. Amirkhanian JD, et al. **Lung** 1995;173(4):243–54

Liver and kidney in acid–base regulation. Hüssinger D. **Nephrol Dial Transplant** 1995;10(9):1536 (5 ref.)

Brain oxygen, CO2, pH, and temperature monitoring: evaluation in the feline brain. Zauner A, et al. **Neurosurgery** 1995 Dec;37(6):1168–76; discussion 1176–7

The kidney in acid–base balance. Hanna JD, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1365–95 (85 ref.)

Aortic pH oscillations in conscious humans and anaesthetised cats and rabbits. Cross BA, et al. **Respir Physiol** 1995 Oct; 102(1):51–62

Hemodynamics and oxygen metabolism in the pig during long–term hypothermia: comparison of 2 pH strategies. Kornberger E, et al. **Resuscitation** 1995 Aug;30(1):43–50

[Basic indicators characterizing the acid–base equilibrium and its disorders] Kubát K. **Vnitr Lek** 1996 Mar;42(3):181–7 (Eng. Abstr.) **(Cze)**

[Determination of base excess (BE, mmol/l) in urine] Blöck TM, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S41–2 **(Ger)**

[Lactate versus intramucosal pCO2 or pH?] Mertzlufft F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S27–33 (41 ref.) **(Ger)**

[Base imbalance: definition and conventional values] Müller–Plathe O. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S34–5 **(Ger)**

[Experimental studies of acid–base balance and lactate metabolism by the liver] Nöldge–Schomburg G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S43–7 **(Ger)**

[Mucosa–pH as a parameter of mucosa oxygenation in liver transplantation] Pichler B, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S22–3 **(Ger)**

[Acid–base equilibrium of peritoneal dialysis (CAPD) patients utilizing acetate, lactate, bicarbonate] Quellhorst E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct;30 Suppl 1:S69–72 **(Ger)**

[Dilution acidosis in clinical conditions] Singbartl G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S58–61 **(Ger)**

[Effect of organ preservation conditions on reperfusion after liver transplantation] Walcher F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S55–7 (27 ref.) **(Ger)**

[Liver metabolism and acid–base balance] Zander R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S48–51 (26 ref.) **(Ger)**

[Quality control of base excess (BE, mmol/l) with the blood gas analyzer] Zander R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S39–40 **(Ger)**

[Declaring infusion solutions with base excess and potential base excess] Zander R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S73–7 **(Ger)**

[Correct determination of blood base excess (BE, mmol/l)] Zander R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S36–8 **(Ger)**

[Verification of KTG recording in states of perinatal partial asphyxia using fetal capillary blood pH] Głąb G, et al. **Ginekol Pol** 1995 May;66(5):272–6 (Eng. Abstr.) **(Pol)**

[Acid–base balance in capillary blood of newborns with perinatal hypoxemia symptoms] Grudzińska M, et al. **Ginekol Pol** 1995 Mar;66(3):151–7 (Eng. Abstr.) **(Pol)**

[Analysis of mean differences for acid–base balance parameters in blood from umbilical arteries and veins of newborns with perinatal hypoxemia] Grudzińska M, et al. **Ginekol Pol** 1995 Apr;66(4):198–204 (Eng. Abstr.) **(Pol)**

[Parameters of acid–base equilibrium and blood gases in the female body during the process of physiologic childbirth] Agadzhanian NA, et al. **Fiziol Cheloveka** 1995 Nov–Dec; 21(6):160–2 **(Rus)**

[The relationship of the acid–base status of the blood to the electrophoretic mobility of the erythrocytes in liver pathology] Matiushichev VB, et al. **Tsitologiia** 1995; 37(5–6):444–8 (Eng. Abstr.) **(Rus)**

[Acid–base equilibrium and nitrogen metabolism in rats in a state of artificial hibernation] Mel'nychuk SD, et al. **Ukr Biokhim Zh** 1995 Jul–Aug;67(4):67–75 (Eng. Abstr.) **(Ukr)**

RADIATION EFFECTS

[The acid–base properties of hemoglobin in the laboratory mouse after gamma irradiation] Irzhak LI, et al. **Zh Evol Biokhim Fiziol** 1996 Jan–Feb;32(1):104–6 (Eng. Abstr.) **(Rus)**

ACID–BASE IMBALANCE

Acid–base disorders in medicine. Laski ME, et al. **Dis Mon** 1996 Feb;42(2):51–125 (200 ref.)

Brain tissue acid–base response to hypercapnia in neurosurgical patients. Hoffman WE, et al. **Neurol Res** 1995 Dec;17(6):417–20

[2nd CPA Symposium: Liver function and acid–base balance.

Mainz, September 1994]
Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Oct; 30 Suppl 1:S1-77 **(Ger)**

BLOOD

Base excess or buffer base (strong ion difference) as measure of a non-respiratory acid-base disturbance.
Siggaard-Andersen O, et al.
Acta Anaesthesiol Scand Suppl 1995;107:123-8
Design and representation of multivariate patient-based reference regions for arterial pH, PCO2 and base excess values. Hekking M, et al. **Clin Biochem** 1995 Dec; 28(6):581-5
Effect of acute pH change on serum anion gap. Paulson WD. **J Am Soc Nephrol** 1996 Feb;7(2):357-63
Siggaard-Andersen algorithm-derived p50 parameters: perturbation by abnormal hemoglobin-oxygen affinity and acid-base disturbances. Morgan TJ, et al.
J Lab Clin Med 1995 Oct;126(4):365-72
Evaluation of the effect of whole-blood transfusion on the oxygen status and acid-base balance of Babesia canis infected dogs using the oxygen status algorithm. Leisewitz AL, et al. **J S Afr Vet Assoc** 1996 Mar;67(1):20-6
[Disorders of acid-base balance caused by blood products] Schmitt HJ.
Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Oct; 30 Suppl 1:S62-4 (20 ref.) **(Ger)**
[Base excess and buffer base] Matsuzaki K.
Nippon Rinsho 1995 Feb;53 Su Pt 1:782-6 (4 ref.) **(Jpn)**

COMPLICATIONS

Amniotic fluid meconium: a fetal environmental hazard. Ramin KD, et al. **Obstet Gynecol** 1996 Feb;87(2):181-4

DRUG THERAPY

[Correction of disturbances in acid-base status and metabolism of metabolites of the oxidative-reductive reaction in rickets] Skorik LV, et al. **Ukr Biokhim Zh** 1995 Jan-Feb;67(1):76-81 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Alterations in the systemic acid-base status and blood gas dynamics during progressive hypocalcaemia in cow calves. Setia MS, et al. **Indian J Exp Biol** 1996 Apr;34(4):375-6
Effect of vacuum extraction on umbilical cord blood acid-base measurements. Vintzileos AM, et al.
J Matern Fetal Med 1996 Jan-Feb;5(1):11-7

METABOLISM

The skeleton as an ion exchange system: implications for the role of acid-base imbalance in the genesis of osteoporosis. Barzel US. **J Bone Miner Res** 1995 Oct;10(10):1431-6 (31 ref.)
Tubular function and acid-base disturbances. Bleich M.
Nephrol Dial Transplant 1995;10(9):1540-1 (13 ref.)
Acid-base and potassium homeostasis. Krapf R.
Nephrol Dial Transplant 1995;10(9):1537-9
[Basic indicators characterizing the acid-base equilibrium and its disorders] Kubát K. **Vnitr Lek** 1996 Mar;42(3):181-7 (Eng. Abstr.) **(Cze)**

PHYSIOPATHOLOGY

The liver: the forgotten organ in acid-base balance? [editorial] Zander R, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Oct; 30 Suppl 1:S2-9 **(Eng, Ger)**
Impact of respiratory acid-base status in patients with pulmonary hypertension. Fullerton DA, et al.
Ann Thorac Surg 1996 Feb;61(2):696-701
Acid-base changes after severe birth acidaemia. Farkas AG, et al. **J Perinat Med** 1995;23(4):249-55

THERAPY

Ethylene glycol acute poisoning treatment results in Kraków in the years 1990-1994. Stompór T, et al. **Przegl Lek** 1996; 53(4):360-4

VETERINARY

[The effect of experimental metabolic stress on ovulation and blood progesterone levels in cows] Vinkler A, et al.
Vet Med (Praha) 1996 Mar;41(3):65-9 (Eng. Abstr.) **(Cze)**

ACID ETCHING, DENTAL

Scanning electron microscopic study and shear bond strength measurement with 5% and 37% phosphoric acid. Bhad WA, et al. **Am J Orthod Dentofacial Orthop** 1995 Oct; 108(4):410-4
Split-mouth study of sealant retention with carbon dioxide laser versus acid etch conditioning. Walsh LJ.
Aust Dent J 1996 Apr;41(2):124-7
The effect of etch time and debond interval upon the shear bond strength of metallic orthodontic brackets. Bin Abdullah M, et al. **Br J Orthod** 1996 May;23(2):121-4
Structural changes of acid etched enamel examined under confocal laser scanning microscope. Zentner A, et al.
Fortschr Kieferorthop 1996 Aug;57(4):202-9 **(Eng, Ger)**
Root cementum appearance in healthy monkeys and periodontitis-prone patients after different etching modalities. Blomlöf J. **J Clin Periodontol** 1996 Jan; 23(1):12-8
Root surface etching at neutral pH promotes periodontal healing. Blomlöf J, et al. **J Clin Periodontol** 1996 Jan; 23(1):50-5
Duration of cleaning and priming of dentine and contraction gap formation. Ohhashi M, et al. **J Dent** 1995 Dec; 23(6):365-9
The effect of ultrasonic irrigation before and after citric acid treatment on collagen fibril exposure: an in vitro SEM study. Higashi T, et al. **J Periodontol** 1995 Oct; 66(10):887-91

ADVERSE EFFECTS

In vitro study on the dimensional changes of human dentine after demineralization. Carvalho RM, et al.
Arch Oral Biol 1996 Apr;41(4):369-77
An SEM examination of etched dentin and the structure of the hybrid layer. Titley KC, et al. **J Can Dent Assoc** 1995 Oct;61(10):887-94
Long-time etching at low pH jeopardizes periodontal healing. Blomlöf J, et al. **J Clin Periodontol** 1995 Jun; 22(6):459-63

METHODS

The effect of etch duration on the microstructure of molar enamel: an in vitro study. Johnston CD, et al.
Am J Orthod Dentofacial Orthop 1996 May;109(5):531-4
Effect of varying etching times on the bond strength of ceramic brackets. Olsen ME, et al.
Am J Orthod Dentofacial Orthop 1996 Apr;109(4):403-9 (49 ref.)
Air abrasion of failed bonded metal brackets: a study of shear bond strength and surface characteristics as determined by scanning electron microscopy. Sonis AL.
Am J Orthod Dentofacial Orthop 1996 Jul;110(1):96-8
Comment on concentration and etch time for phosphoric acid [letter] Unruh MD. **Am J Orthod Dentofacial Orthop** 1996 Jul;110(1):15A-16A
Four-year evaluation of the effect of 10% polyacrylic acid or water rinsing pretreatment on retention of glass polyalkenoate cement. van Dijken JW. **Eur J Oral Sci** 1996 Feb;104(1):64-6
Periodontal tissue-vitality after different etching modalities. Blomlöf J, et al. **J Clin Periodontol** 1995 Jun;22(6):464-8
Citric acid demineralization of cementum and dentin: the effect of application pressure. Sterrett JD, et al.
J Clin Periodontol 1995 Jun;22(6):434-41
Effects of acidic conditioners on dentine demineralization and dimension of hybrid layers. Uno S, et al. **J Dent** 1996 May;24(3):211-6
Evaluation of a no-rinse enamel conditioning prior to sealant application: an in vitro study of comparison to traditional etching technique. Vijayaraghavan TV, et al.
Pediatr Dent 1995 Jul-Aug;17(4):301-4

ACID MALTASE see GLUCAN 1,4-ALPHA-GLUCOSIDASE

ACID PHOSPHATASE

ANALYSIS

Effect of KCA-098 on the function of osteoblast-like cells and the formation of TRAP-positive multinucleated cells in a mouse bone marrow cell population. Kawashima K, et al. **Biochem Pharmacol** 1996 Jan 26;51(2):133-9
Ultrastructural cytochemistry of human gastric cancer: electron microscopic observations of five organellae marker enzymes. Yang G, et al. **Chin Med J (Engl)** 1995 Nov;108(11):859-63
Phenotyping of esterase D and acid phosphatase by rapid isoelectric focusing on PhastSystem. Guo Y, et al.
Electrophoresis 1996 Mar;17(3):535-6
Localization of tartrate-resistant acid phosphatase in human placenta. Janckila AJ, et al. **Histochem J** 1996 Mar; 28(3):195-200
Correlation of survival with quantitative tissue staining of prostate specific acid phosphatase in patients with prostate carcinoma by using microscopic image analysis: a preliminary report of correlative studies on RTOG protocols 75-06, 77-06, and 83-07. Zhou R, et al.
Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):823-9
Human osteoclast and giant cell differentiation: the apparent switch from nonspecific esterase to tartrate resistant acid phosphatase activity coincides with the in situ expression of osteopontin mRNA. Connor JR, et al.
J Histochem Cytochem 1995 Dec;43(12):1193-201
Epitope enhancement for immunohistochemical demonstration of tartrate-resistant acid phosphatase. Janckila AJ, et al. **J Histochem Cytochem** 1996 Mar; 44(3):235-44
An enzyme linked immunosorbent assay (ELISA) for detection of seminal fluid using a monoclonal antibody to prostatic acid phosphatase. Allen SM. **J Immunoassay** 1995 Aug;16(3):297-308
Prostatic acid phosphatase levels (enzymatic method) from completely sectioned, clinically benign, whole prostates. Brawn PN, et al. **Prostate** 1996 May;28(5):295-9
The influence of carbon particles on the concentration of acid phosphatase and lysozyme enzymes within alveolar macrophages during the killing and degradation of Mycobacterium bovis. Attwood EM, et al.
Tuber Lung Dis 1996 Aug;77(4):341-7
[Various immunohistochemical markers of precancer and variants of prostate cancer] Romanenko AM, et al.
Arkh Patol 1995 Jul-Aug;57(4):38-41 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Inhibition of tartrate-resistant acid phosphatase gene expression by hemin and protoporphyrin IX. Identification of a hemin-responsive inhibitor of transcription. Reddy SV, et al. **Blood** 1996 Sep 15;88(6):2288-97

BIOSYNTHESIS

Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Hsieh TY, et al.
Biochem Biophys Res Commun 1996 Jun 5;223(1):141-6
Acid phosphatase synthesis in Aspergillus flavus. Famurewa O, et al. **Folia Microbiol (Praha)** 1994;39(6):475-80
An inducible acid phosphatase from the yeast Pichia pastoris: characterization of the gene and its product. Payne WE, et al. **Gene** 1995 Sep 22;163(1):19-26
Effect of growth conditions on expression of the acid phosphatase (cyx-appA) operon and the appY gene, which encodes a transcriptional activator of Escherichia coli. Brøndsted L, et al. **J Bacteriol** 1996 Mar;178(6):1556-64
Cloning and characterization of the human tartrate-resistant acid phosphatase (TRAP) gene. Fleckenstein E, et al.
Leukemia 1996 Apr;10(4):637-43
Phosphatase production and activity in Citrobacter freundii and a naturally occurring, heavy-metal-accumulating Citrobacter sp. Montgomery DM, et al. **Microbiology** 1995 Oct;141 (Pt 10):2433-41

BLOOD

Generation and characterization of monoclonal antibodies to human type-5 tartrate-resistant acid phosphatase: development of a specific immunoassay of the isoenzyme in serum. Chamberlain P, et al. **Clin Chem** 1995 Oct; 41(10):1495-9
Tartrate resistant acid phosphatase in the serum of patients with larynx carcinoma--a marker of osteoclast activation. Jarkowska-Kozłowska J, et al. **Clin Chim Acta** 1995 Sep 15;240(2):213-9
Phosphotyrosine protein phosphatases and diabetic pregnancy: an association between low molecular weight acid phosphatase and degree of glycemic control. Gloria-Bottini F, et al. **Experientia** 1996 Apr 15;52(4):340-3
ACP1 and human adaptability. 1. Association with common diseases: a case-control study. Bottini E, et al.
Hum Genet 1995 Dec;96(6):629-37
Prostatic acid phosphatase and prostate specific antigen in liver disease. Kadayifci A, et al. **Int Urol Nephrol** 1996; 28(1):67-71
Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation. Sasagawa I, et al.
Int Urol Nephrol 1995;27(6):769-74
Neuroendocrine tumors of the liver and pancreas associated with elevated serum prostatic acid phosphatase. Kaneko Y, et al. **Intern Med** 1995 Sep;34(9):886-91 (35 ref.)
Biological variation in bone-derived biochemical markers in serum. Panteghini M, et al. **Scand J Clin Lab Invest** 1995 Nov;55(7):609-16
Acid phosphatase: defining a role in androgen-independent prostate cancer. Steineck G, et al. **Urology** 1996 May; 47(5):719-26
[Acid phosphatase] Kishi H, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:338-41 (13 ref.) **(Jpn)**
[Acid phosphatase] Otani K, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:247-50 (8 ref.) **(Jpn)**
[Myeloperoxidase] Saito K, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:251-3 (6 ref.) **(Jpn)**
[The lysosomal acid phosphatase activity of the peripheral blood neutrophils of women in the dynamics of the menstrual cycle] Gerasimov IG, et al. **Tsitologiia** 1995; 37(7):574-8 (Eng. Abstr.) **(Rus)**
[Prognosis significance of prostatic markers in patients with prostatic adenocarcinoma undergoing total hormonal blockade] Regueiro López JC, et al. **Actas Urol Esp** 1995 May;19(5):357-62 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Identity of zinc ion-dependent acid phosphatase from bovine brain and myo-inositol 1-phosphatase. Caselli A, et al.
Biochim Biophys Acta 1996 Aug 13;1290(3):241-9
Role of the intersubunit disulfide bond in the unfolding pathway of dimeric red kidney bean purple acid phosphatase. Cashikar AG, et al. **Biochim Biophys Acta** 1996 Aug 15;1296(1):76-84
Relationship between the acid phosphatases of the Kurloff body and the major 30-35 kDa glycoproteins of the Kurloff cell. Oulhaj N, et al. **Biol Cell** 1995;83(2-3):141-7
Unique structural features of red kidney bean purple acid phosphatase. Cashikar AG, et al.

Indian J Biochem Biophys 1995 Jun;32(3):130–6
The folding intermediate of reversibly denatured human prostatic acid phosphatase. Kuciel R, et al. **Int J Biol Macromol** 1996 Apr;18(3):167–75
Unfolding pathway in red kidney bean acid phosphatase is dependent on ligand binding. Cashikar AG, et al. **J Biol Chem** 1996 Mar 1;271(9):4741–6
Mechanism of Fe(III)–Zn(II) purple acid phosphatase based on crystal structures. Klabunde T, et al. **J Mol Biol** 1996 Jun 21;259(4):737–48

DRUG EFFECTS

Short treatment of osteoclasts in bone marrow culture with calcitonin causes prolonged suppression of calcitonin receptor mRNA. Rakopoulos M, et al. **Bone** 1995 Nov; 17(5):447–53

GENETICS

The Aspergillus niger (ficuum) aphA gene encodes a pH 6.0–optimum acid phosphatase. Mullaney EJ, et al. **Gene** 1995 Aug 30;162(1):117–21
An inducible acid phosphatase from the yeast Pichia pastoris: characterization of the gene and its product. Payne WE, et al. **Gene** 1995 Sep 22;163(1):19–26
Distribution of ACP1, AK1 and ALAD polymorphisms in northern Portugal. Amorim A, et al. **Gene Geogr** 1994 Aug; 8(2):147–50
ACP1 and human adaptability. 1. Association with common diseases: a case–control study. Bottini E, et al. **Hum Genet** 1995 Dec;96(6):629–37
Human prostatic acid phosphatase and prostate specific antigen: protein structure, gene organization, and expression in neoplastic and benign tissues. Li SS. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Aug; 12(8):441–7
Evidence for transcriptional modulation but not acid phosphatase expression during programmed cell death in the colonial tunicate Botryllus schlosseri. Lauzon RJ, et al. **Microsc Res Tech** 1996 Jun 15;34(3):218–27
Molecular characterization of the lysosomal acid phosphatase from Drosophila melanogaster. Chung HJ, et al. **Mol Gen Genet** 1996 Mar 20;250(5):635–46
Regulation of acid phosphatases in an Aspergillus niger pacC disruption strain. van den Hombergh JP, et al. **Mol Gen Genet** 1996 Jul 19;251(5):542–50
[Studies on the cloning, expression and function of the yeast PHO 80 gene] Zhao Y, et al. **I Chuan Hsueh Pao** 1996; 23(2):142–8 (Eng. Abstr.) **(Chi)**
[Study of biochemical gene markers in the Mongolian gerbil (Meriones unguiculatus)] Okumura K, et al. **Exp Anim** 1995 Oct;43(5):719–23 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Investigation of acid phosphatase as a possible IgE–binding marker for pollen allergens and their polymerized derivatives. Berrens L, et al. **Allergol Immunopathol (Madr)** 1995 Mar–Apr;23(2):79–84
Generation and characterization of monoclonal antibodies to human type-5 tartrate-resistant acid phosphatase: development of a specific immunoassay of the isoenzyme in serum. Chamberlain P, et al. **Clin Chem** 1995 Oct; 41(10):1495–9
Toxoplasma gondii: characterization of a monoclonal antibody recognizing antigens of 36 and 38 kDa with acid phosphatase activity located in dense granules and rhoptries. Metsis A, et al. **Exp Parasitol** 1995 Dec; 81(4):472–9

ISOLATION & PURIFICATION

Purification and characterization of an acid phosphatase from Arachis hypogaea. Srivastava R, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):949–56
Acid phosphatase synthesis in Aspergillus flavus. Famurewa O, et al. **Folia Microbiol (Praha)** 1994;39(6):475–80
Single-step purification of prostatic acid phosphatase: immunoaffinity chromatography with a monoclonal antibody. Yoshiki T, et al. **Int J Urol** 1995 Sep;2(4):261–6

METABOLISM

The tartrate-resistant purple acid phosphatase of bone osteoclasts—a protein phosphatase with multivalent substrate specificity and regulation. Andersson G, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:189–94 (28 ref.)
Immunohistochemical detection of tartrate-resistant acid phosphatase in non-hematopoietic human tissues. Yaziji H, et al. **Am J Clin Pathol** 1995 Oct;104(4):397–402
The measurement of acid and alkaline phosphatase in gingival crevicular fluid during orthodontic tooth movement. Insoft M, et al. **Am J Orthod Dentofacial Orthop** 1996 Mar; 109(3):287–96
The effect of anti–bursa serum (ABS) on the intensity of acid phosphatase reaction in bursa-dependent structures of the chicken spleen and on the level of antibodies in the blood serum. Graczyk S. **Arch Vet Pol** 1994;34(1–2):25–36
Tyrosine phosphorylation of a 185 kDa phosphoprotein (pp185) inversely correlates with the cellular activity of human prostatic acid phosphatase. Lin MF, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):206–13
Participation of a proton-translocating plasma membrane ATPase, acid phosphatase and alkaline phosphatase in ATP degradation by Aspergillus niger extracts. Elzainy TA, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):91–7
Detection of alkaline and acid phosphatases around titanium implants: a light microscopical and histochemical study in rabbits. Piattelli A, et al. **Biomaterials** 1995 Nov; 16(17):1333–8
An in vitro procedure for studying enzymic dephosphorylation of phytate in maize–soyabean feeds for turkey poults. Zyła K, et al. **Br J Nutr** 1995 Jul;74(1):3–17
Bone resorption by tartrate-resistant acid phosphatase-positive multinuclear cells isolated from rheumatoid synovium. Fujikawa Y, et al. **Br J Rheumatol** 1996 Mar;35(3):213–7
Alterations of low molecular weight acid phosphatase protein level in Alzheimer's disease. Shimohama S, et al. **Brain Res** 1995 Nov 13;699(1):125–9
Does gene palB regulate the transcription or the post-translational modification of Pi-repressible phosphatases of Aspergillus nidulans? Maccheroni Júnior W, et al. **Braz J Med Biol Res** 1995 Jan;28(1):31–8
Clinical and biological aspects of acid phosphatase. Moss DW, et al. **Crit Rev Clin Lab Sci** 1995;32(4):431–67 (285 ref.)
Acid phosphatase activity in mating type I and mating type II cell lines of Paramecium primaurelia. Ramoino P, et al. **Eur J Histochem** 1995;39(2):157–64
The effect of sublethal lead exposure on the ultrastructure and on the distribution of acid phosphatase activity in chloragocytes of earthworms (Annelida, Oligochaeta). Cancio I, et al. **Histochem J** 1995 Dec;27(12):965–73
Lysosomal origin of the chloragosomes in the chloragogenous tissue of the earthworm Eisenia foetida: cytochemical demonstration of acid phosphatase activity. Cancio I, et al. **Histochem J** 1995 Aug;27(8):591–6
Receptor–mediated regulation by histamine of the acid phosphatase activity in cultured cerebral endothelial cells. Szabó CA, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S60–1
Unfolding pathway in red kidney bean acid phosphatase is dependent on ligand binding. Cashikar AG, et al. **J Biol Chem** 1996 Mar 1;271(9):4741–6
Characterization and sequencing of a respiratory burst–inhibiting acid phosphatase from Francisella tularensis. Reilly TJ, et al. **J Biol Chem** 1996 May 3; 271(18):10973–83
Influence of butibufen on enzyme activity and lysosomal stabilization ex vivo: a comparative study with hydrocortisone and acetylsalicylic acid. Alamo C, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun;17(5):303–10
Congenital muscular dystrophy syndromes distinguished by alkaline and acid phosphatase, merosin, and dystrophin staining. Connolly AM, et al. **Neurology** 1996 Mar; 46(3):810–14
[Biosynthesis, processing, and lysosome targeting of acid phosphatase] Himeno M, et al. **Nippon Rinsho** 1995 Dec; 53(12):2898–903 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Cellular interactions in the intracellular parasitism of cryptosporidia. I. The effect of Cryptosporidium parvum on the phosphatase activity in the small intestine enterocytes of experimentally infected newborn rat pups] Beier TV, et al. **Tsitologiia** 1995;37(8):829–37 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Birth dates in Florence... [letter] Boddi V, et al. **Nature** 1996 Feb 1;379(6564):394

ACID RAIN

[Atmospheric pollution: acid depositions] De Luca D'Alessandro E. **Ann Ig** 1994 Jul–Dec;6(4–6):793–802 (27 ref.) (Eng. Abstr.) **(Ita)**

ANALYSIS

Intercommunity differences in acid aerosol (H+)/sulfate (SO_4^{2-}) ratios. Ozkaynak H, et al. **J Expo Anal Environ Epidemiol** 1996 Jan–Mar;6(1):35–55

ACID SEROMUCOID see **OROSOMUCOID**

ACIDIC FIBROBLAST GROWTH FACTOR see **FIBROBLAST GROWTH FACTOR, ACIDIC**

ACIDIC PANCREATIC TRYPSIN INHIBITOR see **TRYPSIN INHIBITOR, KAZAL PANCREATIC**

ACIDOSIS

Response of LLC-PK1-F+ cells to metabolic acidosis. Mu X, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C920–5
Effects of serosal-side acidosis on cell pH (pHi) and membrane electrical properties in gastric mucosa. Soybel DI, et al. **J Surg Res** 1996 Jun;63(1):147–51
Metabolic acidosis stimulates protein metabolism in uremia. Mitch WE. **Miner Electrolyte Metab** 1996;22(1–3):62–5 (20 ref.)
Acidosis-induced modifications of high-affinity choline uptake by synaptosomes: effects of pH readjustment. Cancela JM, et al. **Neurochem Res** 1995 Jul;20(7):863–7

BLOOD

Liquid chromatographic–atmospheric pressure chemical ionization mass spectrometric analysis of glycine conjugates and urinary isovalerylglycine in isovaleric acidemia. Ito T, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18; 670(2):317–22
Acid–base changes after severe birth acidaemia. Farkas AG, et al. **J Perinat Med** 1995;23(4):249–55
Influence of metabolic acidosis on serum 1,25(OH)2D3 levels in chronic renal failure. Lu KC, et al. **Miner Electrolyte Metab** 1995;21(6):398–402
[Diagnosis of organic aciduria] García L, et al. **Rev Neurol** 1995;23 Suppl 3:S325–9 (16 ref.) **(Spa)**

CHEMICALLY INDUCED

Shock, metabolic acidosis, and coma following ibuprofen overdose in a child. Zuckerman GB, et al. **Ann Pharmacother** 1995 Sep;29(9):869–71
Salicylism from topical salicylates: review of the literature. Brubacher JR, et al. **J Toxicol Clin Toxicol** 1996; 34(4):431–6 (31 ref.)
Severe acute metabolic acidosis and Wernicke's encephalopathy following chemotherapy with 5-fluorouracil and cisplatin: case report and review of the literature. Kondo K, et al. **Jpn J Clin Oncol** 1996 Aug; 26(4):234–6
[Metabolic acidosis caused by injectable sodium valproate. 6 postoperative cases in neurosurgery (letter)] Riche H, et al. **Presse Med** 1996 Apr 13;25(13):642 **(Fre)**

COMPLICATIONS

Follow-up of children born with an umbilical arterial blood pH < 7 [see comments] Nagel HT, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1758–64 (26 ref.). Comment in: Am J Obstet Gynecol 1996 Jul;175(1):229.
Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: effect of calcitriol treatment. Coen G, et al. **Miner Electrolyte Metab** 1995; 21(6):375–82
Renal osteodystrophy [letter; comment] Barzel US. **N Engl J Med** 1995 Nov 23;333(21):1428. Comment on: N Engl J Med 1995 Jul 20;333(3):166–74.
Is it necessary to treat metabolic acidosis in chronic renal insufficiency? Hörl WH. **Nephrol Dial Transplant** 1995; 10(9):1542–3 (27 ref.)
Methemoglobinemia in an infant: case report and review of the literature. Jolly BT, et al. **Pediatr Emerg Care** 1995 Oct;11(5):294–7 (22 ref.)
More questions than answers [letter; comment] Raju TN. **Pediatrics** 1996 Apr;97(4):602–3. Comment on: Pediatrics 1995 Feb;95(2):238–43.
Metabolic acidosis as a uremic toxin. Bailey JL, et al. **Semin Nephrol** 1996 May;16(3):160–6 (37 ref.)

DIAGNOSIS

Comparison of intrapartum electronic fetal heart rate monitoring versus intermittent auscultation in detecting fetal acidemia at birth [see comments] Vintzileos AM, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1021–4. Comment in: Am J Obstet Gynecol 1996 Apr;174(4):1395–6.
A new range for the anion gap [letter] Sadjadi SA. **Ann Intern Med** 1995 Nov 15;123(10):807
The prediction of fetal acidosis at birth by computerised analysis of intrapartum cardiotocography [letter; comment] Keith RD, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):94–5 . Comment on: Br J Obstet Gynaecol 1995 Jun;102(6):454–60.
The prediction of fetal acidosis at birth by computerised analysis of intrapartum cardiotocography [letter; comment] Persad PS, et al. **Br J Obstet Gynaecol** 1996 Feb; 103(2):190–1. Comment on: Br J Obstet Gynaecol 1995 Jun;102(6):454–60.
The value of fetal arterial, cardiac and venous flows in predicting pH and blood gases measured in umbilical blood at cordocentesis in growth retarded fetuses. Rizzo G, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):963–9
Intrapartum amniotic fluid index for predicting fetal acidemia. Results of receiver operating characteristic curve analysis. Chauhan SP, et al. **J Reprod Med** 1995 Aug; 40(8):561–4
The efficacy of individual computer heart rate indices in detecting acidemia at birth in growth-restricted fetuses. Guzman ER, et al. **Obstet Gynecol** 1996 Jun;87(6):969–74
Prenatal diagnosis of organic acidemias based on amniotic fluid levels of acylcarnitines. Shigematsu Y, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):680–4

DRUG THERAPY

The correction of acidosis does not increase dietary protein intake in chronic renal failure patients. Roberts RG, et al. **Am J Kidney Dis** 1996 Sep;28(3):350–3
Influence of rapid correction of metabolic acidosis on serum osteocalcin level in chronic renal failure. Lin YF, et al. **ASAIO J** 1994 Jul–Sep;40(3):M440–4
The acute impact of $NaHCO_3$ in treatment of metabolic acidosis on back-titration of non-bicarbonate buffers: a quantitative analysis. Kamel KS. **Clin Nephrol** 1996 Jan; 45(1):51–5
Topical acetylsalicylic, salicylic acid and indomethacin suppress pain from experimental tissue acidosis in human skin. Steen KH, et al. **Pain** 1995 Sep;62(3):339–47
Amelioration of impaired cerebral metabolism after severe

acidotic ischemia by tirilazad posttreatment in dogs. Kim H, et al. **Stroke** 1996 Jan;27(1):114–21

ENZYMOLOGY

The role of H(+)-ATPases in urinary acidification. Constantinescu A. **Pediatr Nephrol** 1995 Aug;9(4):510–3 (24 ref.)

ETIOLOGY

Hyperkalemic hyperchloremic metabolic acidosis in a patient with sickle cell beta-thalassemia [letter] Elisaf M, et al. **Am J Hematol** 1995 Oct;50(2):151–2

Severe acidosis alone does not predict mortality in the trauma patient. Robertson R, et al. **Am J Surg** 1995 Dec; 170(6):691–4; discussion 694–5

Mechanism of hyperchloremic metabolic acidosis [letter; comment] Miller LR, et al. **Anesthesiology** 1996 Feb; 84(2):482–3. Comment on: Anesthesiology 1995 Jul;83(1):198–200.

Endotoxemia causes ileal mucosal [correction of musocal] acidosis in the absence of mucosal hypoxia [letter] Germann R, et al. **Crit Care Med** 1996 Jun;24(6):1091–2

Does peritoneal mobilization increase laparoscopic acidosis? Ortega AE, et al. **Dis Colon Rectum** 1995 Dec; 38(12):1296–300

Diet-induced ketosis does not cause cerebral acidosis. Al-Mudallal AS, et al. **Epilepsia** 1996 Mar;37(3):258–61

Unusual cause of hypotension associated with penetrating trauma. Ma OJ, et al. **J Trauma** 1996 Jan;40(1):161–4

Metabolic acidosis: an emerging problem in patients with intestinal segments as part of urinary diversion. A report of two cases. Lundbeck F, et al. **Scand J Urol Nephrol Suppl** 1995;172:37–41

Hemodynamic and arterial blood gas changes during carbon dioxide and helium pneumoperitoneum in pigs. Shuto K, et al. **Surg Endosc** 1995 Nov;9(11):1173–8

[Clinical, biological and developmental aspects of alcoholic ketoacidosis] Gaches F, et al. **Presse Med** 1996 Jun 8; 25(20):924–8 (Eng. Abstr.) **(Fre)**

[Clinical case of the month. Physiopathology, symptoms, complications and treatment of alcoholic ketoacidosis: apropos of a fatal case] Lambermont B, et al. **Rev Med Liege** 1996 Apr;51(4):266–9 **(Fre)**

[Methemoglobinemia, acidemia and diarrhea induced by hypersensitivity to cow's milk proteins] Catalán Muñoz M, et al. **An Esp Pediatr** 1996 Mar;44(3):295–6 (6 ref.) **(Spa)**

[Ketoacidotic coma in an infant as the form of onset of a mitochondrial 2-methylacetoacetyl-CoA thiolase deficiency] Yeste Fernández D, et al. **An Esp Pediatr** 1996 Jun;44(6):620–2 (9 ref.) **(Spa)**

METABOLISM

Attenuation of low pH-, but not capsaicin- or PGI2-evoked CGRP-release by endothelium removal using saponin. Källner G, et al. **Acta Physiol Scand** 1995 Nov;155(3):251–6

Experimental acidemia and muscle cell pH in chronic acidosis and renal failure. Bailey JL, et al. **Am J Physiol** 1995 Sep; 269(3 Pt 1):C706–12

Response of hepatic amino acid consumption to chronic metabolic acidosis. Boon L, et al. **Am J Physiol** 1996 Jul; 271(1 Pt 2):F198–202

Transient pre-ischemic acidosis protects the isolated rabbit heart subjected to 30 minutes, but not 60 minutes, of global ischemia. Simkhovich BZ, et al. **Basic Res Cardiol** 1995 Sep-Oct;90(5):397–403

Protein catabolism in metabolic acidosis: inhibition of glycolysis by low pH suggests a role for glucose. Bevington A, et al. **Biochem Soc Trans** 1995 Aug;23(3):464S

Intracellular alkalosis during hypoxia in newborn mouse brain in the presence of systemic acidosis: a phosphorus magnetic resonance spectroscopic study. Mitsufuji N, et al. **Brain Dev** 1995 Jul-Aug;17(4):256–60

Acute acidosis elevates malonaldehyde in rat brain in vivo. Waterfall AH, et al. **Brain Res** 1996 Mar 11;712(1):102–6

The acute impact of NaHCO3 in treatment of metabolic acidosis on back-titration of non-bicarbonate buffers: a quantitative analysis. Kamel KS. **Clin Nephrol** 1996 Jan; 45(1):51–5

Uremic acidosis and protein metabolism. Mitch WE. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):488–92 (41 ref.)

Regulation of the insulin-like growth factor system by acute acidosis. Bereket A, et al. **Endocrinology** 1996 Jun; 137(6):2238–45

Potential effect of metabolic acidosis on beta 2-microglobulin generation: in vivo and in vitro studies. Sonikian M, et al. **J Am Soc Nephrol** 1996 Feb;7(2):350–6

Changes in muscle proton transverse relaxation times and acidosis during exercise and recovery. Cheng HA, et al. **J Appl Physiol** 1995 Oct;79(4):1370–8

The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. Bailey JL, et al. **J Clin Invest** 1996 Mar 15;97(6):1447–53

Adaptation of rabbit cortical collecting duct HCO3- transport to metabolic acidosis in vitro. Tsuruoka S, et al. **J Clin Invest** 1996 Feb 15;97(4):1076–84

Glutaric aciduria mediated by gut bacteria. Wendel U, et al. **J Inherit Metab Dis** 1995;18(3):358–9

Correction of acidosis in CAPD decreases whole body protein degradation. Graham KA, et al. **Kidney Int** 1996 May;49(5):1396–400

Glucocorticoids and acidosis stimulate protein and amino acid catabolism in vivo. May RC, et al. **Kidney Int** 1996 Mar;49(3):679–83

Influence of acid loading, extracellular pH and uremia on intracellular pH in muscle. Bailey JL, et al. **Miner Electrolyte Metab** 1996;22(1-3):66–8

Acidosis and glucocorticoids induce branched-chain amino acid catabolism. England BK, et al. **Miner Electrolyte Metab** 1996;22(1-3):69–71 (26 ref.)

Muscle protein turnover in chronic renal failure patients with metabolic acidosis or normal acid-base balance. Garibotto G, et al. **Miner Electrolyte Metab** 1996;22(1-3):58–61

Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1-3):72–5 (14 ref.)

Influence of acidosis on protein metabolism. Ballmer PE, et al. **Nutrition** 1995 Sep-Oct;11(5):462–8; discussion 470 (66 ref.)

"Neonatal variant" of Bartter syndrome presenting with acidosis. Ammenti A, et al. **Pediatr Nephrol** 1996 Feb; 10(1):79–80

Metabolic acidosis and uremia. Walls J. **Perit Dial Int** 1995; 15(5 Suppl):S36–8

Amelioration of impaired cerebral metabolism after severe acidotic ischemia by tirilazad posttreatment in dogs. Kim H, et al. **Stroke** 1996 Jan;27(1):114–21

PHYSIOPATHOLOGY

The role of intracellular acidosis in muscle fatigue. Allen DG, et al. **Adv Exp Med Biol** 1995;384:57–68 (54 ref.)

Respiratory compensation for the metabolic acidosis of severe exercise as a modulator of muscular capillary O2-unloading. Fukuba Y, et al. **Adv Exp Med Biol** 1995; 393:153–8

Additive effects of acidosis and parathyroid hormone on mouse osteoblastic and osteoclastic function. Bushinsky DA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1364–70

Effect of stretch on contraction and the Ca2+ transient in ferret ventricular muscles during hypoxia and acidosis. Hongo K, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C690–7

Low gastric intramucosal pH: incidence and significance in intensive care patients [see comments] Trinder TJ, et al. **Anaesth Intensive Care** 1995 Jun;23(3):315–21. Comment in: Anaesth Intensive Care 1996 Feb;24(1):120–2.

Acidosis accentuates thiopental-induced myocardial depression in vitro. Thurston TA, et al. **Anesth Analg** 1996 Sep;83(3):636–8

Role of minor electrolytes when applied to Stewart's acid-base approach in an acidotic rabbit model. Waters JH, et al. **Anesth Analg** 1995 Nov;81(5):1043–51

Neonatal cerebral arterial flow velocity waveforms in term infants with and without metabolic acidosis at delivery. Morrison FK, et al. **Early Hum Dev** 1995 Aug 18; 42(3):155–68

The effect of mechanical loading on the response of rat ventricular myocytes to acidosis. Hongo K, et al. **Exp Physiol** 1995 Sep;80(5):701–12

Exercise-induced gastric mucosal acidosis. Nielsen HB, et al. **Med Sci Sports Exerc** 1995 Jul;27(7):1003–6

Improvement of muscular oxidative capacity by training is associated with slight acidosis and ATP depletion in exercising muscles. Ravalec X, et al. **Muscle Nerve** 1996 Mar;19(3):355–61

Pain due to experimental acidosis in human skin: evidence for non-adapting nociceptor excitation. Steen KH, et al. **Neurosci Lett** 1995 Oct 13;199(1):29–32

pHi in piglet cerebral microvascular endothelial cells: recovery from an acid load. Hsu P, et al. **Proc Soc Exp Biol Med** 1996 Jul;212(3):256–62

[Dilution acidosis in clinical conditions] Singbartl G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S58–61 **(Ger)**

PREVENTION & CONTROL

Nitric oxide synthase inhibition by L-NAME prevents brain acidosis during focal cerebral ischemia in rabbits. Regli L, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):988–95

SURGERY

Hypermetabolism during bilateral single-lung transplantation requiring cardiopulmonary bypass. Chaney MA. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):565–70

Liver transplantation in two cases of propionic acidaemia. Schlenzig JS, et al. **J Inherit Metab Dis** 1995;18(4):448–61

THERAPY

Correction of acidosis in CAPD decreases whole body protein degradation. Graham KA, et al. **Kidney Int** 1996 May;49(5):1396–400

Correction of chronic metabolic acidosis in haemodialysed patients by acetate-free biofiltration does not influence parathyroid function. de Précigout V, et al. **Nephrol Dial Transplant** 1995;10(6):821–4

Is it necessary to treat metabolic acidosis in chronic renal insufficiency? Hörl WH. **Nephrol Dial Transplant** 1995; 10(9):1542–3 (27 ref.)

URINE

Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric analysis of glycine conjugates and urinary isovalerylglycine in isovaleric acidemia. Ito T, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18; 670(2):317–22

The role of H(+)-ATPases in urinary acidification. Constantinescu A. **Pediatr Nephrol** 1995 Aug;9(4):510–3 (24 ref.)

[Diagnosis of organic aciduria] García L, et al. **Rev Neurol** 1995;23 Suppl 3:S325–9 (16 ref.) **(Spa)**

VETERINARY

Induced acute ruminal acidosis in goats treated with yeast (Saccharomyces cerevisiae) and bicarbonate. Aslan V, et al. **Acta Vet Scand** 1995;36(1):65–77

Forestomach acidosis in six New World camelids. Cebra CK, et al. **J Am Vet Med Assoc** 1996 Mar 15;208(6):901–4

Efficacy of laidlomycin propionate to reduce ruminal acidosis in cattle. Bauer ML, et al. **J Anim Sci** 1995 Nov; 73(11):3445–54

Feeding wet corn gluten feed to reduce subacute acidosis in cattle. Krehbiel CR, et al. **J Anim Sci** 1995 Oct; 73(10):2931–9

The effects of ruminal acidosis on volatile fatty acid absorption and plasma activities of pancreatic enzymes in lambs. Krehbiel CR, et al. **J Anim Sci** 1995 Oct; 73(10):3111–21

Effect of level and type of fat on subacute acidosis in cattle fed dry-rolled corn finishing diets. Krehbiel CR, et al. **J Anim Sci** 1995 Aug;73(8):2438–46

'Stupid calves' [letter] [see comments] Grove-White DH. **Vet Rec** 1995 Jul 8;137(2):52. Comment in: Vet Rec 1995 Aug 12;137(7):176. Comment in: Vet Rec 1995 Sep 16;137(12):300.

ACIDOSIS, DIABETIC see **DIABETIC KETOACIDOSIS**

ACIDOSIS, LACTIC

BLOOD

Contribution of the respiratory muscles to the lactic acidosis of heavy exercise in COPD. Engelen MP, et al. **Chest** 1995 Nov;108(5):1246–51

CHEMICALLY INDUCED

Metformin-associated lactic acidosis. Pearlman BL, et al. **Am J Med** 1996 Jul;101(1):109–10

Phenformin-induced lactic acidosis: an almost forgotten complication of treatment with biguanides. Ko GT, et al. **Br J Hosp Med** 1995 Nov 1-14;54(9):469–70

Lactic acidosis associated with propofol [letter] Marinella MA. **Chest** 1996 Jan;109(1):292

Role of metformin accumulation in metformin-associated lactic acidosis. Lalau JD, et al. **Diabetes Care** 1995 Jun; 18(6):779–84

A case of life-threatening lactic acidosis after smoke inhalation - interference between beta-adrenergic agents and ethanol? Taboulet P, et al. **Intensive Care Med** 1995 Dec;21(12):1039–41

Efficacy of metformin in non-insulin-dependent diabetes mellitus [letter; comment] Gueriguian J, et al. **N Engl J Med** 1996 Jan 25;334(4):269; discussion 269–70 . Comment on: N Engl J Med 1995 Aug 31;333(9):541–9.

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B [see comments] McKenzie R, et al. **N Engl J Med** 1995 Oct 26;333(17):1099–105. Comment in: N Engl J Med 1995 Oct 26;333(17):1146–8. Comment in: N Engl J Med 1996 Apr 25;334(17):1135; discussion 1137–8. Comment in: N Engl J Med 1996 Apr 25;334(17):1135–6; discussion 1137–8. Comment in: N Engl J Med 1996 Apr 25;334(17):1136; discussion 1137–8. Comment in: N Engl J Med 1996 Apr 25;334(17):1136–7; discussion 1137–8.

Metformin and lactic acid acidosis [letter; comment] Salter FJ. **N Z Med J** 1996 Mar 8;109(1017):82. Comment on: N Z Med J 1995 Jun 14;108(1001):230–1.

[Lactic acidosis associated with biguanides] Safadi R, et al. **Harefuah** 1996 Feb 15;130(4):280–3 (40 ref.) **(Heb)**

COMPLICATIONS

Depletion of mitochondrial DNA in the liver of a patient with lactic acidemia and hypoketotic hypoglycemia [see comments] Maaswinkel-Mooij PD, et al. **J Pediatr** 1996 May;128(5 Pt 1):679–83. Comment in: J Pediatr 1996 May;128(5 Pt 1):597–9.

DIAGNOSIS

[Measuring lactate concentration with electrodes] Biedler A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct;30 Suppl 1:S24–6 **(Ger)**

[Kubát: Lactic acidosis--a rare or common disease? (letter)] Rosival V. **Vnitr Lek** 1996 Jan;42(1):62 **(Slo)**

ENZYMOLOGY

Defect in the X-lipoyl-containing component of the pyruvate dehydrogenase complex in a patient with neonatal lactic

acidemia. Geoffroy V, et al. **Pediatrics** 1996 Feb; 97(2):267–72

ETIOLOGY

The chemical pathology of AIDS [letter] Crowley VE, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):511–2

Lactic acidosis and hypoglycemia in a patient with high-grade non-Hodgkin's lymphoma and elevated circulating TNF-alpha. Durig J, et al. **Ann Hematol** 1996 Feb;72(2):97–9

Lactic acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. Gore DC, et al. **Ann Surg** 1995 Jul;224(1):97–102

Unexplained severe illness possibly associated with consumption of Kombucha tea--Iowa, 1995. From the Centers for Disease Control and Prevention. **JAMA** 1996 Jan 10;275(2):96–8

Unexplained severe illness possibly associated with consumption of Kombucha tea--Iowa, 1995. **MMWR Morb Mortal Wkly Rep** 1995 Dec 8;44(48):892–3, 899–900

GENETICS

Fatal mitochondrial myopathy, lactic acidosis, and complex I deficiency associated with a heteroplasmic A —> G mutation at position 3251 in the mitochondrial tRNALeu(UUR) gne. Houshmand M, et al. **Hum Genet** 1996 Mar;97(3):269–73

A mitochondrial DNA microdeletion in a newborn girl with transient lactic acidosis. Seneca S, et al. **J Inherit Metab Dis** 1996;19(2):115–8

MERRF syndrome with overwhelming lactic acidosis. Sanger TD, et al. **Pediatr Neurol** 1996 Jan;14(1):57–61

METABOLISM

Oxidative phosphorylation defect associated with primary adrenal insufficiency. North K, et al. **J Pediatr** 1996 May; 128(5 Pt 1):688–92

PHYSIOPATHOLOGY

Lactic acidosis and diaphragmatic function in vitro. Coast JR, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1648–52

Effects of Carbicarb and sodium bicarbonate on hypoxic lactic acidosis in newborn pigs. Basir MA, et al. **J Investig Med** 1996 Feb;44(2):70–4

Association of cerebral dysgenesis and lactic acidemia with X-linked PDH E1 alpha subunit mutations in females. Otero LJ, et al. **Pediatr Neurol** 1995 Nov;13(4):327–32

[Is sepsis and septic shock due to a global oxygen insufficiency? A review in 2 parts. 2: Sepsis and lactate] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):205–15 (175 ref.) **(Ger)**

PREVENTION & CONTROL

Hypoglycemia prevents increase in lactic acidosis during reperfusion after temporary cerebral ischemia in rats. Sappey-Marinier D, et al. **NMR Biomed** 1995 Jun; 8(4):171–8

[Anesthesia in a case of mitochondrial myopathy (letter)] Torres MD, et al. **Rev Esp Anestesiol Reanim** 1996 Mar; 43(3):114–5 **(Spa)**

VETERINARY

Lactic acidosis in a Clumber spaniel. Järvinen AK, et al. **Acta Vet Scand** 1996;37(1):119–21

Induction of lactic acidosis in cattle with sucrose: relationship between dose, rumen fluid pH and animal size. Ortolani EL. **Vet Hum Toxicol** 1995 Oct;37(5):462–4

ACIDOSIS, RENAL TUBULAR

CHEMICALLY INDUCED

Renal tubular acidosis following treatment with foscarnet [letter] Navarro JF, et al. **AIDS** 1995 Dec;9(12):1389–90

Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Navarro JF, et al. **Am J Kidney Dis** 1996 Mar;27(3):431–4 (16 ref.)

Proximal renal tubular acidosis secondary to FK506 in pediatric liver transplant patients. O'Gorman MA, et al. **Clin Transplant** 1995 Aug;9(4):312–6

COMPLICATIONS

Renal tubular acidosis and deafness: report of a large family. Bajaj G, et al. **Am J Kidney Dis** 1996 Jun;27(6):880–2

Thyrotoxicosis and renal tubular acidosis presenting as hypokalaemic paralysis. Szeto CC, et al. **Br J Rheumatol** 1996 Mar;35(3):289–91

Spontaneous steinstrasse due to renal tubular acidosis. Homayoon K. **Br J Urol** 1996 Apr;77(4):610–11

Metabolic acidosis does not contribute to chronic renal injury in the rat. Throssell D, et al. **Clin Sci (Colch)** 1995 Dec; 89(6):643–50

Hearing impairment in association with distal renal tubular acidosis among Saudi children. Zakzouk SM, et al. **J Laryngol Otol** 1995 Oct;109(10):930–4

Concurrent gradient defect renal tubular acidosis and autoimmune lymphocytic thyroiditis. Wu MS, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2122–3

Renal tubular acidosis complicated with hypokalemic periodic paralysis. Chang YC, et al. **Pediatr Neurol** 1995 Jul;13(1):52–4

Osteomalacia as a presenting manifestation of Sjögren's syndrome. Hajjaj-Hassouni N, et al. **Rev Rhum Engl Ed** 1995 Jul–Sep;62(7–8):529–32 (30 ref.)

A study of recurrent stone formers with special reference to renal tubular acidosis. Singh PP, et al. **Urol Res** 1995; 23(3):201–3

[Distal renal tubular acidosis in patients with Wilson's disease] Tesař V, et al. **Sb Lek** 1991;93(9–10):315–23 (Eng. Abstr.) **(Cze)**

[Rapidly progressive paresis and hypokalemia] Koistinen A, et al. **Duodecim** 1995;111(9):850–2 **(Fin)**

[Renal acidification mechanism disorders in patients with osteoporosis] Sánchez A, et al. **Medicina (B Aires)** 1995; 55(3):197–202 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Renal tubular acidosis. Pathophysiology and diagnosis. Smulders YM, et al. **Arch Intern Med** 1996 Aug 12–26; 156(15):1629–36 (63 ref.)

Biochemical markers of renal disease in primary Sjögren's syndrome. Eriksson P, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):383–92

[The significance of citrate, uromucoid and GAG for diagnosis of renal tubular acidosis in patients with urinary calculi] Bichler KH, et al. **Urologe A** 1995 Nov; 34(6):437–43 (Eng. Abstr.) **(Ger)**

[Renal tubular acidosis: pathomechanism, clinical diagnosis and treatment] Zawadzki J. **Pediatr Pol** 1995 Dec; 70(12):suppl 1–7 **(Pol)**

DRUG THERAPY

Renal tubular acidosis [letter; comment] Wolf JS Jr. **N Engl J Med** 1996 Aug 29;335(9):675. Comment on: N Engl J Med 1996 Apr 25;334(17):1105.

ENZYMOLOGY

Absence of vacuolar H(+)-ATPase pump in the collecting duct of a patient with hypokalemic distal renal tubular acidosis and Sjögren's syndrome. DeFranco PE, et al. **J Am Soc Nephrol** 1995 Aug;6(2):295–301

EPIDEMIOLOGY

Prevalence of endemic distal renal tubular acidosis and renal stone in the northeast of Thailand. Nimmannit S, et al. **Nephron** 1996;72(4):604–10

ETIOLOGY

Primary distal renal tubular acidosis as a result of a gradient defect. Bonilla-Felix M. **Am J Kidney Dis** 1996 Mar; 27(3):428–30 (10 ref.)

Renal tubular acidosis in children with vesicoureteral reflux. Guizar JM, et al. **J Urol** 1996 Jul;156(1):193–5

Lack of H-ATPase in distal nephron causing hypokalaemic distal RTA in a patient with Sjögren's syndrome [letter; comment] Bastani B, et al. **Nephrol Dial Transplant** 1995; 10(6):908–9. Comment on: Nephrol Dial Transplant 1994;9(8):1176–8.

Renal tubular dysfunction and acidosis. Sharma AM. **Nephrol Dial Transplant** 1995;10(9):1544–45 (4 ref.)

Nephrocalcinosis is associated with renal tubular acidosis in children with X-linked hypophosphatemia. Seikaly M, et al. **Pediatrics** 1996 Jan;97(1):91–3

[A case of Sjögren's syndrome complicated with cryoglobulinemia, nephrogenic diabetes insipidus, and renal tubular acidosis] Koura T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr;18(2):221–7 (Eng. Abstr.) **(Jpn)**

[Renal tubular acidosis] Zawadzki J. **Pediatr Pol** 1995 Dec; 70(12):1059–64 (36 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Renal tubular acidosis and deafness: report of a large family. Bajaj G, et al. **Am J Kidney Dis** 1996 Jun;27(6):880–2

Arthrogryposis, renal dysfunction and cholestasis syndrome: report of five patients from three Italian families. Di Rocco M, et al. **Eur J Pediatr** 1995 Oct;154(10):835–9 (8 ref.)

IMMUNOLOGY

Urolithiasis and distal renal tubular acidosis preceding primary Sjögren's syndrome: a retrospective study 5–53 years after the presentation of urolithiasis. Eriksson P, et al. **J Intern Med** 1996 Jun;239(6):483–8

METABOLISM

Nitric oxide kinetics during hypoxia in proximal tubules: effects of acidosis and glycine. Yaqoob M, et al. **Kidney Int** 1996 May;49(5):1314–9

PHYSIOPATHOLOGY

Underlying defects in distal renal tubular acidosis: new understandings. Batlle D, et al. **Am J Kidney Dis** 1996 Jun; 27(6):896–915 (120 ref.)

Renal tubular acidosis. Pathophysiology and diagnosis. Smulders YM, et al. **Arch Intern Med** 1996 Aug 12–26; 156(15):1629–36 (63 ref.)

THERAPY

[Renal tubular acidosis: pathomechanism, clinical diagnosis and treatment] Zawadzki J. **Pediatr Pol** 1995 Dec; 70(12):suppl 1–7 **(Pol)**

URINE

Evaluation of urine acidification by urine anion gap and urine osmolal gap in chronic metabolic acidosis. Kim GH, et al. **Am J Kidney Dis** 1996 Jan;27(1):42–7

ACIDOSIS, RESPIRATORY

DIAGNOSIS

Intrapartum amniotic fluid index for predicting fetal acidemia. Results of receiver operating characteristic curve analysis. Chauhan SP, et al. **J Reprod Med** 1995 Aug; 40(8):561–4

DRUG THERAPY

Heliox inhalation in status asthmaticus and respiratory acidemia: a brief report. Austan F. **Heart Lung** 1996 Mar–Apr;25(2):155–7

Sodium bicarbonate does not correct respiratory acidosis [letter] Sutin KM. **Lancet** 1995 Nov 4;346(8984):1226–7

METABOLISM

Increased resistance to acute respiratory acidosis in isolated cardiac muscle following chronic hypoxia-induced hypertrophy. Neville E, et al. **Cardiovasc Res** 1996 May; 31(5):739–46

ACIDS

Isolates of Salmonella enterica Enteritidis PT4 with enhanced heat and acid tolerance are more virulent in mice and more invasive in chickens. Humphrey TJ, et al. **Epidemiol Infect** 1996 Aug;117(1):79–88

Investigation of the impurities found in methamphetamine synthesised from pseudoephedrine by reduction with hydriodic acid and red phosphorus. Windahl KL, et al. **Forensic Sci Int** 1995 Dec 18;76(2):97–114

Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline-3-carboxylic acid at position 2. Capasso S, et al. **Int J Pept Protein Res** 1995 Jun;45(6):567–73

[Stereochemistry of highly selective transition metal or Lewis acid-catalyzed asymmetric reactions] Hiroi K. **Yakugaku Zasshi** 1995 Aug;115(8):553–69 (63 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Histopathologic evaluation of the therapeutic efficacy of water and milk dilution for esophageal acid injury. Homan CS, et al. **Acad Emerg Med** 1995 Jul;2(7):587–91

Two-year follow-up study of the effect of acid fog on adult asthma patients. Tanaka H, et al. **Intern Med** 1996 Feb; 35(2):100–4

BLOOD

Experimental acidemia and muscle cell pH in chronic acidosis and renal failure. Bailey JL, et al. **Am J Physiol** 1995 Sep; 269(3 Pt 1):C706–12

Capillary zone electrophoresis of organic acids in serum of critically ill children. Dolník V, et al. **J Chromatogr A** 1995 Nov 17;716(1–2):269–77

Quantitative contribution of the acid production to the intracellular acidification in human neutrophils stimulated by N-formyl-methionyl-leucyl-phenylalanine. Satoh M, et al. **Mol Cell Biochem** 1995 Nov 22;152(2):159–65

CEREBROSPINAL FLUID

[The acid-base balance of cerebrospinal fluid] Kępa L. **Neurol Neurochir Pol** 1996 Jan–Feb;30(1):113–21 (27 ref.) (Eng. Abstr.) **(Pol)**

CHEMISTRY

Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. Clerc S, et al. **Biochim Biophys Acta** 1995 Dec 13;1240(2):257–65

Partition coefficients by curve fitting: the use of two different octanol volumes in a dual-phase potentiometric titration. Clarke FH, et al. **J Pharm Sci** 1996 Feb;85(2):178–83

An organic acid-induced sigmoidal release system for oral controlled-release preparations. 2. Permeability enhancement of Eudragit RS coating led by the physicochemical interactions with organic acid. Narisawa S, et al. **J Pharm Sci** 1996 Feb;85(2):184–8

ISOLATION & PURIFICATION

Rapid chiral separation methods development by cyclodextrin-mediated capillary electrophoresis for acidic and basic compounds. Guttman A, et al. **Chirality** 1995; 7(6):409–14

METABOLISM

Mechanisms of acid release in isolated gas gland cells of the European eel Anguilla anguilla. Pelster B. **Am J Physiol** 1995 Oct;269(4 Pt 2):R793–9

Regulation of luminal alkalinization and acidification in the cortical collecting duct by angiotensin II. Weiner ID, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):F730–8

rpoS regulation of acid, heat, and salt tolerance in Escherichia coli O157:H7. Cheville AM, et al. **Appl Environ Microbiol** 1996 May;62(5):1822–4

Mechanism of hydrogen peroxide and hydroxyl free radical–induced intracellular acidification in cultured rat cardiac myoblasts. Wu ML, et al. **Circ Res** 1996 Apr; 78(4):564–72

Inhibition of acid production in Streptococcus mutans R9: inhibition constants and reversibility. Assinder SJ, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2–3):287–92

Accumulation of acidic renin isoforms in kidneys of cyclosporine–A–treated rats. Norling LL, et al. **J Am Soc Nephrol** 1996 Feb;7(2):331–7

The involvement of protein phosphatases in the activation of ICE/CED–3 protease, intracellular acidification, DNA digestion, and apoptosis. Morana SJ, et al. **J Biol Chem** 1996 Jul 26;271(30):18263–71

Acid efflux from retinal glial cells generated by sodium bicarbonate cotransport. Newman EA. **J Neurosci** 1996 Jan;16(1):159–68

PHARMACOKINETICS

Quantitative relationship between structure and peritoneal membrane transport based on physiological pharmacokinetic concepts for acidic drugs. Nakashima E, et al. **Drug Metab Dispos** 1995 Nov;23(11):1220–4

PHARMACOLOGY

Weak acid effects and fluoride inhibition of glycolysis by Streptococcus mutans GS–5. Belli WA, et al. **Can J Microbiol** 1995 Sep;41(9):785–91

Micelle–like conformation of humic substances as revealed by size exclusion chromatography. Piccolo A, et al. **Chemosphere** 1996 Aug;33(4):595–602

Low pH adaptation and the acid tolerance response of Salmonella typhimurium. Foster JW. **Crit Rev Microbiol** 1995;21(4):215–37 (90 ref.)

Response of Mycobacterium smegmatis to acid stress. O'Brien LM, et al. **FEMS Microbiol Lett** 1996 May 15; 139(1):11–7

Mucus and alkali secretion in the rat duodenum: effects of indomethacin, N omega–nitro–L–arginine, and luminal acid. Sababi M, et al. **Gastroenterology** 1995 Nov; 109(5):1526–34

Capacitance measurement to assess acid–induced injury to Salmonella enteritidis PT4. Alexandrou O, et al. **Int J Food Microbiol** 1995 Sep;27(1):27–36

Acid shock induction of RpoS is mediated by the mouse virulence gene mviA of Salmonella typhimurium. Bearson SM, et al. **J Bacteriol** 1996 May;178(9):2572–9

A glutamate–dependent acid resistance gene in Escherichia coli. Hersh BM, et al. **J Bacteriol** 1996 Jul;178(13):3978–81

Gustatory neural coding in the monkey cortex: acid stimuli. Plata–Salamán CR, et al. **J Neurophysiol** 1995 Aug; 74(2):556–64

The stationary–phase sigma factor sigma S (RpoS) is required for a sustained acid tolerance response in virulent Salmonella typhimurium. Lee IS, et al. **Mol Microbiol** 1995 Jul;17(1):155–67

Continuous infusion of acidified saline around the rat sciatic nerve produces thermal hyperalgesia. Maves TJ, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):45–8

[The effect of acidification on Salmonella enteritidis in a defined medium] Ružičková V. **Vet Med (Praha)** 1996 Jan; 41(1):25–31 (Eng. Abstr.) **(Cze)**

POISONING

Corrosive injuries of the oesophagus and stomach: experience in management at a regional paediatric centre. Stiff G, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2):119–23 (68 ref.)

Elective surgery for corrosive–induced gastric injury. Chaudhary A, et al. **World J Surg** 1996 Jul–Aug; 20(6):703–6; discussion 706

THERAPEUTIC USE

Effective treatment for acute alkali injury to the esophagus using weak–acid neutralization therapy: an ex–vivo study. Homan CS, et al. **Acad Emerg Med** 1995 Nov;2(11):952–8

Should we add an acid to an alkali injury? For now, let's remain neutral! [editorial] Smilkstein MJ. **Acad Emerg Med** 1995 Nov;2(11):945–6

URINE

3–Methylglutaconic aciduria, type 3 [letter; comment] Costeff H, et al. **Brain Dev** 1995 May–Jun;17(3):226. Comment on: Brain Dev 1994 Nov;16 Suppl:23–32.

Organic acidurias and related abnormalities. Lehotay DC, et al. **Crit Rev Clin Lab Sci** 1995;32(4):377–429 (262 ref.)

Effect of luminal calcium on proximal tubule bicarbonate reabsorption in the rat. Gil FZ, et al. **Ren Physiol Biochem** 1995 Nov–Dec;18(6):271–7

ACIDULATED PHOSPHATE FLUORIDE

ADMINISTRATION & DOSAGE

In vitro evaluation of fluoride uptake with application of acidulated phosphate fluoride to interproximal enamel of primary teeth using dental floss. Us Z, et al. **ASDC J Dent Child** 1995 Jul–Aug;62(4):274–8

CHEMISTRY

The effect of topical APF foam and other fluorides on veneer porcelain surfaces. Kula K, et al. **Pediatr Dent** 1995 Sep–Oct;17(5):356–61

THERAPEUTIC USE

Three–year randomized trial of professionally applied topical fluoride gel comparing annual and biannual applications with/without prior prophylaxis. Johnston DW, et al. **Caries Res** 1995;29(5):331–6

Fluoride varnish versus acidulated phosphate fluoride gel: a 3–year clinical trial. Seppä L, et al. **Caries Res** 1995; 29(5):327–30

ACINETOBACTER

Resistant nosocomial gram–negative bacillary pathogens: Acinetobacter baumannii, Xanthomonas maltophilia, and Pseudomonas cepacia. Fang FC, et al. **Curr Clin Top Infect Dis** 1996;16:52–83 (363 ref.)

CHEMISTRY

Structural studies of the putative O–specific polysaccharide of Acinetobacter baumannii O2 containing 3,6–dideoxy–3–N–(D–3–hydroxybutyryl)amino–D–galactose. Haseley SR, et al. **Eur J Biochem** 1995 Nov 1; 233(3):899–906

Structure of the O–specific polysaccharide of Acinetobacter baumannii O5 containing 2–acetamido–2–deoxy–D–galacturonic acid. Haseley SR, et al. **Eur J Biochem** 1996 Apr 1;237(1):229–33

Structural studies of the putative O–specific polysaccharide of Acinetobacter baumannii O11. Haseley SR, et al. **Eur J Biochem** 1996 Apr 1;237(1):266–71

Structural and serological characterisation of two O–specific polysaccharides of Acinetobacter. Vinogradov EV, et al. **Eur J Biochem** 1996 Aug 1;239(3):602–10

CLASSIFICATION

Validation of use of whole–cell repetitive extragenic palindromic sequence–based PCR (REP–PCR) for typing strains belonging to the Acinetobacter calcoaceticus–Acinetobacter baumannii complex and application of the method to the investigation of a hospital outbreak. Snelling AM, et al. **J Clin Microbiol** 1996 May; 34(5):1193–202

Identification and biotyping of Acinetobacter spp. isolated in Chilean hospitals. Dominguez M, et al. **J Hosp Infect** 1995 Aug;30(4):267–71

Outbreak caused by two multi–resistant Acinetobacter baumannii clones in a burns unit: emergence of resistance to imipenem. Lyytikäinen O, et al. **J Hosp Infect** 1995 Sep; 31(1):41–54

Genomic fingerprinting Acinetobacter baumannii: amplification of multiple inter–repetitive extragenic palindromic sequences. Sheehan C, et al. **J Hosp Infect** 1995 Sep;31(1):33–40

A comparative study of different PCR–based DNA fingerprinting techniques for typing of the Acinetobacter calcoaceticus–A. baumannii complex. Vila J, et al. **J Med Microbiol** 1996 Jun;44(6):482–9

Comparison of rapid automated laser fluorescence analysis of DNA fingerprints with four other computer–assisted approaches for studying relationships between Acinetobacter baumannii isolates. Webster CA, et al. **J Med Microbiol** 1996 Mar;44(3):185–94

Differentiation of Acinetobacter calcoaceticus sensu stricto from related Acinetobacter species by electrophoretic polymorphism of malate dehydrogenase, glutamate dehydrogenase and catalase. Bouvet PJ, et al. **Res Microbiol** 1995 Nov–Dec;146(9):773–85

[Identification and typing of hospital strains of Acinetobacter calcoaceticus–Acinetobacter baumanni complex] Nemec A, et al. **Epidemiol Mikrobiol Imunol** 1996 May;45(2):71–82 (Eng. Abstr.) **(Cze)**

[Taxonomy of the genus Acinetobacter] Nemec A. **Epidemiol Mikrobiol Imunol** 1996 Mar;45(1):23–9 (Eng. Abstr.) **(Cze)**

DRUG EFFECTS

In–vitro activity of cephalosporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles. Aubert G, et al. **J Antimicrob Chemother** 1996 Jan; 37(1):155–60

Bactericidal in–vitro activity of beta–lactams and beta–lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. Joly–Guillou ML, et al. **J Antimicrob Chemother** 1995 Oct;36(4):619–29

Transferable imipenem–resistance in Acinetobacter species from a clinical source [letter] Scaife W, et al. **J Antimicrob Chemother** 1995 Sep;36(3):585–6

Outbreak caused by two multi–resistant Acinetobacter baumannii clones in a burns unit: emergence of resistance to imipenem. Lyytikäinen O, et al. **J Hosp Infect** 1995 Sep; 31(1):41–54

[In vitro antibacterial activity of a new fluoroquinolone, enoxacin against hospital bacteria and regression curve] Soussy CJ, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):274–80 (Eng. Abstr.) **(Fre)**

[In vitro study of antibacterial activity of cefepime (Axepim) against gram negative bacteria: comparison with cephalosporins and other beta–lactams] Vachée A, et al. **Pathol Biol (Paris)** 1996 Feb;44(2):132–7 (Eng. Abstr.) **(Fre)**

[Biological characteristics and antibiotic sensitivity of Acinetobacter strains] Maruashvili IA, et al. **Antibiot Khimioter** 1995 Aug;40(8):28–31 (Eng. Abstr.) **(Rus)**

[Variation in transfer resistance to cefotaxime, ceftazidime and aztreonam in strains of Acinetobacter sp., Enterobacter sp. and Citrobacter sp. isolated from the same university hospitals] Babálová M, et al. **Cas Lek Cesk** 1996 Mar 20; 135(6):181–4 (Eng. Abstr.) **(Slo)**

ENZYMOLOGY

The beta–lactamase secreted by the antarctic psychrophile Psychrobacter immobilis A8. Feller G, et al. **Appl Environ Microbiol** 1995 Dec;61(12):4474–6

Occurrence and antigenic heterogeneity of L–2,4–diaminobutyrate decarboxylase in Acinetobacter species. Yamamoto S, et al. **Biol Pharm Bull** 1995 Mar; 18(3):454–6

Detection of alpha/beta–hydrolase fold in the cell surface esterases of Acinetobacter species using an analysis of 3D profiles. Alon RN, et al. **FEBS Lett** 1995 Sep 11; 371(3):231–5

Isolation and characterization of a novel oxygenase that catalyzes the first step of n–alkane oxidation in Acinetobacter sp. strain M–1. Maeng JH, et al. **J Bacteriol** 1996 Jul;178(13):3695–700

GENETICS

Validation of use of whole–cell repetitive extragenic palindromic sequence–based PCR (REP–PCR) for typing strains belonging to the Acinetobacter calcoaceticus–Acinetobacter baumannii complex and application of the method to the investigation of a hospital outbreak. Snelling AM, et al. **J Clin Microbiol** 1996 May; 34(5):1193–202

Genomic fingerprinting Acinetobacter baumannii: amplification of multiple inter–repetitive extragenic palindromic sequences. Sheehan C, et al. **J Hosp Infect** 1995 Sep;31(1):33–40

Automated laser fluorescence analysis of randomly amplified polymorphic DNA: a rapid method for investigating nosocomial transmission of Acinetobacter baumannii. Grundmann H, et al. **J Med Microbiol** 1995 Dec; 43(6):446–51

ISOLATION & PURIFICATION

Epidemiological analysis of Acinetobacter baumannii strains isolated from a surgical intensive care unit. Ben Hassen A, et al. **Ann Biol Clin (Paris)** 1995;53(9):491–7

Acinetobacter baumannii outbreak isolates characterized by three typing methods. Aubert G, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec;14(12):1095–9

Molecular heterogeneity of Acinetobacter baumannii isolates during seasonal increase in prevalence. Christie C, et al. **Infect Control Hosp Epidemiol** 1995 Oct;16(10):590–4

Infective endocarditis of an interventricular patch caused by Acinetobacter haemolyticus. Castellanos Martínez E, et al. **Infection** 1995 Jul–Aug;23(4):243–5

Comparison of arbitrarily primed polymerase chain reaction and cell envelope protein electrophoresis for analysis of Acinetobacter baumannii and A. junii outbreaks. Vaneechoutte M, et al. **Res Microbiol** 1995 Jul–Aug; 146(6):457–65

METABOLISM

Alasan, a new bioemulsifier from Acinetobacter radioresistens. Navon–Venezia S, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3240–4

Identification of a 13–kDa protein associated with the polyhydroxyalkanoic acid granules from Acinetobacter spp. Schembri MA, et al. **FEMS Microbiol Lett** 1995 Nov 15;133(3):277–83

Autophosphorylation of a bacterial protein at tyrosine. Duclos B, et al. **J Mol Biol** 1996 Jun 28;259(5):891–5

ACINETOBACTER CALCOACETICUS

Acinetobacter endocarditis in children: a case report and review of the literature. Malik AS. **Infection** 1995 Sep–Oct; 23(5):306–8 (18 ref.)

Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Seifert H, et al. **Medicine (Baltimore)** 1995 Nov;74(6):340–9 (46 ref.)

ACINETOBACTER CALCOACETICUS

[The efficacy of sulbactam-ampicillin in a urinary infection due to Acinetobacter calcoaceticus var. anitratus (letter)] Telenti Asensio M, et al. **Med Clin (Barc)** 1995 Oct 7; 105(11):438–9 **(Spa)**

CHEMISTRY

Detection of alpha/beta-hydrolase fold in the cell surface esterases of Acinetobacter species using an analysis of 3D profiles. Alon RN, et al. **FEBS Lett** 1995 Sep 11; 371(3):231–5

CLASSIFICATION

Validation of use of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for typing strains belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex and application of the method to the investigation of a hospital outbreak. Snelling AM, et al. **J Clin Microbiol** 1996 May; 34(5):1193–202

A comparative study of different PCR-based DNA fingerprinting techniques for typing of the Acinetobacter calcoaceticus-A. baumannii complex. Vila J, et al. **J Med Microbiol** 1996 Jun;44(6):482–9

DRUG EFFECTS

Antibiotic resistance of Acinetobacter calcoaceticus strains isolated from patients treated in intensive care units. Kiss L, et al. **Acta Microbiol Immunol Hung** 1995;42(4):381–7

[Biological characteristics and antibiotic sensitivity of Acinetobacter strains] Maruashvili IA, et al. **Antibiot Khimioter** 1995 Aug;40(8):28–31 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Cloning and expression of dipeptidase from Acinetobacter calcoaceticus ATCC 23055. Adachi H, et al. **J Biochem (Tokyo)** 1995 Sep;118(3):555–61

Purification and characterization of Acinetobacter calcoaceticus 4-hydroxybenzoate 3-hydroxylase after its overexpression in Escherichia coli. Fernandez J, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1261–6

GENETICS

Natural transformation in river epilithon. Williams HG, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2994–8

Unusual ancestry of dehydratases associated with quinate catabolism in Acinetobacter calcoaceticus. Elsemore DA, et al. **J Bacteriol** 1995 Oct;177(20):5971–8

Distance between alleles as a determinant of linkage in natural transformation of Acinetobacter calcoaceticus. Kloos DU, et al. **J Bacteriol** 1995 Oct;177(20):6015–7

catM encodes a LysR-type transcriptional activator regulating catechol degradation in Acinetobacter calcoaceticus. Romero-Arroyo CE, et al. **J Bacteriol** 1995 Oct;177(20):5891–8

Validation of use of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for typing strains belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex and application of the method to the investigation of a hospital outbreak. Snelling AM, et al. **J Clin Microbiol** 1996 May; 34(5):1193–202

IS1236, a newly discovered member of the IS3 family, exhibits varied patterns of insertion into the Acinetobacter calcoaceticus chromosome. Gerischer U, et al. **Microbiology** 1996 Jul;142 (Pt 7):1825–31

Genetic organization, nucleotide sequence and regulation of expression of genes encoding phenol hydroxylase and catechol 1,2-dioxygenase in Acinetobacter calcoaceticus NCIB8250. Ehrt S, et al. **Mol Microbiol** 1995 Oct; 18(1):13–20

ISOLATION & PURIFICATION

Study of a hydrocarbon-utilizing and emulsifier-producing Acinetobacter calcoaceticus strain isolated from heating oil. Marín MM, et al. **Microbiologia** 1995 Dec;11(4):447–54

Differentiation of Acinetobacter calcoaceticus sensu stricto from related Acinetobacter species by electrophoretic polymorphism of malate dehydrogenase, glutamate dehydrogenase and catalase. Bouvet PJ, et al. **Res Microbiol** 1995 Nov-Dec;146(9):773–85

METABOLISM

Phenol degradation by Acinetobacter calcoaceticus NCIB 8250. Paller G, et al. **J Basic Microbiol** 1995;35(5):325–35

ACINETOBACTER INFECTIONS

[Bacteremia with Acinetobacter species—clinicopathological characteristics of 27 cases] Kurosu I. **Kansenshogaku Zasshi** 1995 Aug;69(8):895–902 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Acinetobacter endocarditis in children: a case report and review of the literature. Malik AS. **Infection** 1995 Sep-Oct; 23(5):306–8 (18 ref.)

DRUG THERAPY

[The efficacy of sulbactam-ampicillin in a urinary infection due to Acinetobacter calcoaceticus var. anitratus (letter)] Telenti Asensio M, et al. **Med Clin (Barc)** 1995 Oct 7; 105(11):438–9 **(Spa)**

EPIDEMIOLOGY

Epidemiological analysis of Acinetobacter baumannii strains isolated from a surgical intensive care unit. Ben Hassen A, et al. **Ann Biol Clin (Paris)** 1995;53(9):491–7

Molecular heterogeneity of Acinetobacter baumanii isolates during seasonal increase in prevalence. Christie C, et al. **Infect Control Hosp Epidemiol** 1995 Oct;16(10):590–4

Validation of use of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for typing strains belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex and application of the method to the investigation of a hospital outbreak. Snelling AM, et al. **J Clin Microbiol** 1996 May; 34(5):1193–202

The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents. Bergogne-Bérézin E. **J Hosp Infect** 1995 Jun;30 Suppl:441–52

The epidemiology of acinetobacter infections in Hong Kong. Siau H, et al. **J Med Microbiol** 1996 May;44(5):340–7

Comparison of arbitrarily primed polymerase chain reaction and cell envelope protein electrophoresis for analysis of Acinetobacter baumannii and A. junii outbreaks. Vaneechoutte M, et al. **Res Microbiol** 1995 Jul-Aug; 146(6):457–65

ETIOLOGY

Risk factors for nosocomial colonization with multiresistant Acinetobacter baumannii. Mulin B, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):569–76

MICROBIOLOGY

Acinetobacter baumannii outbreak isolates characterized by three typing methods. Aubert G, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec;14(12):1095–9

Infective endocarditis of an interventricular patch caused by Acinetobacter haemolyticus. Castellanos Martínez E, et al. **Infection** 1995 Jul-Aug;23(4):243–5

Bactericidal in-vitro activity of beta-lactams and beta-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. Joly-Guillou ML, et al. **J Antimicrob Chemother** 1995 Oct;36(4):619–29

Validation of use of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for typing strains belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex and application of the method to the investigation of a hospital outbreak. Snelling AM, et al. **J Clin Microbiol** 1996 May; 34(5):1193–202

Identification and biotyping of Acinetobacter spp. isolated in Chilean hospitals. Dominguez M, et al. **J Hosp Infect** 1995 Aug;30(4):267–71

Outbreak caused by two multi-resistant Acinetobacter baumannii clones in a burns unit: emergence of resistance to imipenem. Lyytikäinen O, et al. **J Hosp Infect** 1995 Sep; 31(1):41–54

Genomic fingerprinting Acinetobacter baumannii: amplification of multiple inter-repetitive extragenic palindromic sequences. Sheehan C, et al. **J Hosp Infect** 1995 Sep;31(1):33–40

Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Seifert H, et al. **Medicine (Baltimore)** 1995 Nov;74(6):340–9 (46 ref.)

[Sensitivity of Acinetobacter baumannii to antibiotics and disinfectants used in a Tunisian hospital milieu] Jennane S, et al. **Med Trop (Mars)** 1995;55(3):255–7 (Eng. Abstr.) **(Fre)**

TRANSMISSION

Automated laser fluorescence analysis of randomly amplified polymorphic DNA: a rapid method for investigating nosocomial transmission of Acinetobacter baumannii. Grundmann H, et al. **J Med Microbiol** 1995 Dec; 43(6):446–51

ACITRETIN

ADVERSE EFFECTS

Pseudoallergic hepatitis after a single intake of 10 mg acitretin (Neotigason) for treatment of psoriasis pustulosa [letter] Blum A, et al. **Acta Derm Venereol** 1995 Jul;75(4):332

Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study. Vahlquist C, et al. **Acta Derm Venereol** 1995 Sep;75(5):377–80

Acitretin-induced myopathy [letter] Lister RK, et al. **Br J Dermatol** 1996 May;134(5):989–90

Skeletal side-effects of 5 years' acitretin treatment [letter] Mørk NJ, et al. **Br J Dermatol** 1996 Jun;134(6):1156–7

Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Van Dooren-Greebe RJ, et al. **Br J Dermatol** 1996 Jan;134(1):71–6 (30 ref.)

METABOLISM

Mechanistic studies on the ethyl-esterification of acitretin by human liver preparations in vitro. Schmitt-Hoffmann AH, et al. **Life Sci** 1995 Nov 17;57(26):PL407–12

PHARMACOKINETICS

[Trans-acitretin is metabolized back to etretinate. Importance for oral retinoid therapy] Almond-Roesler B, et al. **Hautarzt** 1996 Mar;47(3):173–7 (29 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Successful treatment of papillomatosis cutis lymphostatica with acitretin [letter] Feind-Koopmans A, et al. **Acta Derm Venereol** 1995 Sep;75(5):411

Response of the clinically uninvolved skin of psoriatic patients to tape stripping during acitretin treatment. Gerritsen MJ, et al. **Acta Derm Venereol** 1996 Jan;76(1):6–9

Coexistence of palmoplantar lichen planus and lupus erythematosus with response to treatment using acitretin. De Jong EM, et al. **Br J Dermatol** 1996 Mar;134(3):538–41

An appraisal of acitretin therapy in children with inherited disorders of keratinization. Lacour M, et al. **Br J Dermatol** 1996 Jun;134(6):1023–9

13-CIS-ACITRETIN see **ACITRETIN**

ACLACINOMYCIN A see **ACLARUBICIN**

ACLARUBICIN

ADMINISTRATION & DOSAGE

[Adsorption of aclacinomycin A onto polyisobutylcyanoacrylate nanoparticles] Jiang X, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Jun;26(2):163–6 (Eng. Abstr.) **(Chi)**

[Trial of a treatment for lymph node metastases in patients with breast cancer using aclarubicin bound to activated carbon particles] Imanishi T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1635–7 (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

Expression of Streptomyces peucetius genes for doxorubicin resistance and aklavinone 11-hydroxylase in Streptomyces galilaeus ATCC 31133 and production of a hybrid aclacinomycin. Hwang CK, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1616–20

Evidence for distinct regulation processes in the aclacinomycin- and doxorubicin-mediated differentiation of human erythroleukemic cells. Morceau F, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):839–45

Activation of erythroid-specific promoters during anthracycline-induced differentiation of K562 cells. Aries A, et al. **Blood** 1996 Apr 1;87(7):2885–90

New anthracycline metabolites produced by the aklavinone 11-hydroxylase gene in Streptomyces galilaeus ATCC 31133. Kim HS, et al. **J Antibiot (Tokyo)** 1996 Apr; 49(4):355–60

Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Dong J, et al. **Oncol Res** 1995;7(5):245–52

CHEMISTRY

Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains. Shelton CJ, et al. **Biochemistry** 1996 Jun 18;35(24):7974–82

PHARMACOLOGY

Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Sehested M, et al. **Biochem Pharmacol** 1996 Apr 12; 51(7):879–86

The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. Figueiredo-Pereira ME, et al. **J Biol Chem** 1996 Jul 12;271(28):16455–9

THERAPEUTIC USE

Relation of blast cell survival and proliferation to chemotherapy resistance in AML. Nørgaard JM, et al. **Br J Haematol** 1996 Jun 2;93(4):888–97

ACNE see **ACNE VULGARIS**

ACNE ROSACEA

DIAGNOSIS

Demodicidosis or rosacea: what did we treat? Hoekzema R, et al. **Br J Dermatol** 1995 Aug;133(2):294–9

Crops of 'pimples': has her acne returned at age 64? Levine N. **Geriatrics** 1995 Nov;50(11):48

Tinea incognito mimicking red face and red ear [letter] Bose SK. **J Dermatol** 1995 Sep;22(9):706–7
[Morbihan disease—chronic persistent erythema and edema of the face] Hölzle E, et al. **Hautarzt** 1995 Nov;46(11):796–8 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea. Signore RJ. **Cutis** 1995 Sep;56(3):177–9
Acne rosacea and Helicobacter pylori betrothed [letter] Wolf R. **Int J Dermatol** 1996 Apr;35(4):302–3
[Pharma-clinics. How I treat... rosacea] Piérard-Franchimont C, et al. **Rev Med Liege** 1996 Jun; 51(6):393–5 (25 ref.) **(Fre)**
[The oral treatment of rosacea with isotretinoin] Jansen T, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1745–7 (32 ref.) **(Ger)**

ETIOLOGY

Multiple endocrine neoplasia type 1 presenting as rosacea. Creamer JD, et al. **Clin Exp Dermatol** 1996 Mar;21(2):170–1
Environmental factors influencing rosacea [letter] Mills CM, et al. **Clin Exp Dermatol** 1996 Mar;21(2):172–3
[Rosacea and Helicobacter pylori] Jansen T, et al. **Hautarzt** 1995 Oct;46(10):675 **(Ger)**

PARASITOLOGY

Rosacea-like demodicosis in an HIV-positive child. Barrio J, et al. **Dermatology** 1996;192(2):143–5 (23 ref.)
[Demodex in a needle puncture of the skin of the cheekbone area. Report of a case and short description of the parasite] Mihaescu A, et al. **Arch Anat Cytol Pathol** 1996; 44(2-3):113–6 (Eng. Abstr.) **(Fre)**

ACNE VULGARIS

Acne vulgaris: tricks and treatments. Part I. Kligman AM. **Cutis** 1995 Sep;56(3):141–3
Why the "SAPHO" syndrome? [editorial] Kahn MF. **J Rheumatol** 1995 Nov;22(11):2017–9 (20 ref.)
SAPHO syndrome: a followup study of 19 cases with special emphasis on enthesis involvement. Maugars Y, et al. **J Rheumatol** 1995 Nov;22(11):2135–41
SAPHO syndrome. Cotten A, et al. **Radiographics** 1995 Sep; 15(5):1147–54

BLOOD

Raised serum androgens and increased responsiveness to luteinizing hormone in men with acne vulgaris. Ramsay B, et al. **Acta Derm Venereol** 1995 Jul;75(4):293–6
Raised serum 11-deoxycortisol in men with persistent acne vulgaris. Ramsay B, et al. **Clin Endocrinol (Oxf)** 1995 Sep; 43(3):305–10
Androgen status in adolescent women with acne vulgaris. Aizawa H, et al. **J Dermatol** 1995 Jul;22(7):530–2

CHEMICALLY INDUCED

Steroid acne sparing an area of previous irradiation [letter] Nasca MR, et al. **Acta Derm Venereol** 1995 Nov;75(6):495
Recurrent exacerbation of acne by granulocyte colony-stimulating factor administration. Lee PK, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):855–6
Acne: a potential side effect of cyclosporine A therapy. el-Shahawy MA, et al. **Nephron** 1996;72(4):679–82
[Acne fulminans in adolescents and isotretinoin (letter)] Faverge B, et al. **Arch Pediatr** 1996 Feb;3(2):188–9 **(Fre)**

COMPLICATIONS

Resurfacing of atrophic facial acne scars with a high-energy, pulsed carbon dioxide laser. Alster TS, et al. **Dermatol Surg** 1996 Feb;22(2):151–4; discussion 154–5
Recollagenation of acne scars. Burres SA. **Dermatol Surg** 1996 Apr;22(4):364–7
Acne fulminans coexisting with pyoderma gangrenosum-like eruptions and posterior scleritis. Kurokawa S, et al. **J Dermatol** 1996 Jan;23(1):37–41
SAPHO syndrome: a new pulmonary manifestation? [letter] Vaile JH, et al. **J Rheumatol** 1995 Nov;22(11):2190–1
Sapho syndrome associated with acne fulminans and prominent acromioclavicular joint involvement. Bölükbaş N, et al. **Scand J Rheumatol** 1996;25(3):180–2
[Sapho syndrome] Cotten A, et al. **Rev Med Interne** 1996; 17(4):341–3 **(Fre)**
[Multifocal periostitis in SAPHO syndrome] Steinborn M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jun;164(6):514–6 **(Ger)**

DIAGNOSIS

Crops of 'pimples': has her acne returned at age 64? Levine N. **Geriatrics** 1995 Nov;50(11):48
[Use of primary care services by adolescents and detection of health problems other than those for which they came] Colino Nevot R, et al. **Aten Primaria** 1995 Dec; 16(10):594–600 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Ocular side effects associated with 13-cis-retinoic acid therapy for acne vulgaris: clinical features, alterations of tearfilm and conjunctival flora. Egger SF, et al. **Acta Ophthalmol Scand** 1995 Aug;73(4):355–7
Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris. Margolis DJ, et al. **Arch Dermatol** 1996 Jul;132(7):769–74
Acne therapy. Medication use and sources of care in office-based practice [see comments] Stern RS. **Arch Dermatol** 1996 Jul;132(7):776–80. Comment in: Arch Dermatol 1996 Jul;132(7):819–20.
Is it reasonable for a dermatologist to treat acne? [editorial; comment] Webster GF. **Arch Dermatol** 1996 Jul; 132(7):819–20. Comment on: Arch Dermatol 1996 Jul;132(7):776–807.
Pregnancy, abortion and the dangers of prescribing vitamin A analogs in Australia [letter] Lipson T. **Australas J Dermatol** 1996 May;37(2):114–5
Minocycline for acne. Doctors should not change the way they prescribe for acne [letter; comment] Cunliffe WJ. **BMJ** 1996 Apr 27;312(7038):1101. Comment on: BMJ 1996 Jan 20;312(7024):138. Comment on: BMJ 1996 Jan 20;312(7024):169–72.
Minocycline for acne [editorial; comment] [see comments] Ferner RE, et al. **BMJ** 1996 Jan 20;312(7024):138. Comment on: BMJ 1996 Jan 20;312(7024):169–72. Comment in: BMJ 1996 Apr 27;312(7038):1101.
Minocycline for acne. Food reduces minocycline's bioavailability [letter; comment] Meyer FP. **BMJ** 1996 Apr 27;312(7038):1101. Comment on: BMJ 1996 Jan 20;312(7024):138.
The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Eady EA, et al. **Br J Dermatol** 1996 Jan;134(1):107–13
Safety of long-term high-dose minocycline in the treatment of acne. Goulden V, et al. **Br J Dermatol** 1996 Apr; 134(4):693–5
The Mexican hairless dog as a model for assessing the comedolytic and morphogenic activity of retinoids. Schwartzman RM, et al. **Br J Dermatol** 1996 Jan; 134(1):64–70
Depression associated with isotretinoin therapy [letter] Byrne A, et al. **Can J Psychiatry** 1995 Nov;40(9):567
Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Mango D, et al. **Contraception** 1996 Mar; 53(3):163–70
Antibiotic resistance in acne patients under antibiotic treatment in comparison to an untreated control group with retrospective assessment of therapy. Forssman T. **Curr Probl Dermatol** 1995;22:91–7
Rationale for the development of new topical treatments for acne vulgaris. Gibson JR. **Cutis** 1996 Jan;57(1 Suppl):13–9 (47 ref.)
The treatment of acne. Part III: antibacterials. Kligman AM. **Cutis** 1995 Dec;56(6):315–6
How to use topical tretinoin in treating acne. Kligman AM. **Cutis** 1995 Aug;56(2):83–4
Treating severe inflammatory acne: the last word. Kligman AM. **Cutis** 1996 Jan;57(1):26–7
Acne vulgaris: tricks and treatments. Part II: The benzoyl peroxide saga. Kligman AM. **Cutis** 1995 Nov;56(5):260–1
New approaches in dermatology: a clinical profile of azelaic acid [editorial] Lowe NJ. **Cutis** 1996 Jan;57(1 Suppl):7
Benzamycin gel for acne. **Drug Ther Bull** 1995 Aug; 33(8):62–4 (13 ref.)
In vivo effects of 13-cis retinoic acid treatment on the concentration of proteins and lipids in serum. Fex GA, et al. **Eur J Clin Chem Clin Biochem** 1996 Jan;34(1):3–7
Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. van Wayjen RG, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(4):241–51
Isotretinoin for acne vulgaris. al-Khawajah MM. **Int J Dermatol** 1996 Mar;35(3):212–5
13-cis-retinoic acid and bone density. Kocijančič M. **Int J Dermatol** 1995 Oct;34(10):733–4
Effect of systemic administration of isotretinoin on blood lipids and fatty acids in acne patients. Ostlere LS, et al. **Int J Dermatol** 1996 Mar;35(3):216–8
Treatment of acne vulgaris: combination of 3% erythromycin and 5% benzoyl peroxide in a gel compared to clindamycin phosphate lotion. Packman AM, et al. **Int J Dermatol** 1996 Mar;35(3):209–11
Bacteria and antimicrobial agents in the treatment of acne. Parry EJ, et al. **Int J Dermatol** 1996 Apr;35(4):249–51 (15 ref.)
A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. Shalita A, et al. **J Am Acad Dermatol** 1996 Mar;34(3):482–5
Minocycline vs tetracycline [letter] Shubin JA. **J Fam Pract** 1995 Dec;41(6):538
Clinical evaluation of roxithromycin in patients with acne. Akamatsu H, et al. **J Int Med Res** 1996 Jan-Feb; 24(1):109–14
Isotretinoin for severe acne. James M. **Lancet** 1996 Jun 22; 347(9017):1749–50
Isotretinoin dosage [letter] Saurat JH. **Lancet** 1996 Aug 31; 348(9027):623
Pantothenic acid deficiency as the pathogenesis of acne vulgaris. Leung LH. **Med Hypotheses** 1995 Jun;44(6):490–2
Azelaic acid-a new topical drug for acne. **Med Lett Drugs Ther** 1996 Jun 7;38(976):52–3
Optimization of topical erythromycin formulations by ion pairing. Matschiner S, et al. **Skin Pharmacol** 1995; 8(6):319–25
[Comparative study of the efficacy and tolerability of 0.1 and 0.03 p.100 adapalene gel and 0.025 p.100 tretinoin gel in the treatment of acne] Alirezai M, et al. **Ann Dermatol Venereol** 1996;123(3):165–70 (Eng. Abstr.) **(Fre)**
[Probable acute hemorrhagic colitis caused by isotretinoin with a test of repeated administration (letter)] Deplaix P, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):113–4 **(Fre)**
[Clinical treatment results of treating androgenization symptoms in women with preparation Diane-35] Marianowski L, et al. **Wiad Lek** 1994 Oct;47(19–20):745–6 (Eng. Abstr.) **(Pol)**
[Acne, hirsutism and androgenic alopecia] Dobrić I, et al. **Lijec Vjesn** 1996 Mar;118 Suppl 1:48–51 (Eng. Abstr.) **(Scr)**
[New recommendations on treatment of acne] **Lakartidningen** 1996 May 29;93(22):2171–2 **(Swe)**

ETIOLOGY

Pantothenic acid deficiency as the pathogenesis of acne vulgaris. Leung LH. **Med Hypotheses** 1995 Jun;44(6):490–2

GENETICS

Acne tetrad in a family. Zisova L, et al. **Folia Med (Plovdiv)** 1994;36(4):51–7

METABOLISM

Keratin expression in pilosebaceous epithelia in truncal skin of acne patients. Hughes BR, et al. **Br J Dermatol** 1996 Feb;134(2):247–56
In situ hybridization analysis of CRABP II expression in sebaceous follicles from 13-cis retinoic acid-treated acne patients. Sitzmann JH, et al. **Br J Dermatol** 1995 Aug; 133(2):241–8
Clinical, ultrasound and hormonal markers of androgenicity in acne vulgaris. Walton S, et al. **Br J Dermatol** 1995 Aug; 133(2):249–53

MICROBIOLOGY

Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Bojar RA, et al. **Drugs** 1995;49 Suppl 2:164–7
Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris. Vogt K, et al. **Drugs** 1995;49 Suppl 2:266–8

PATHOLOGY

Squamous cell carcinoma arising from the follicular occlusion triad. Dufresne RG Jr, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):475–7
Fluorescence photography in the evaluation of acne. Lucchina LC, et al. **J Am Acad Dermatol** 1996 Jul; 35(1):58–63
Modeling acne in vitro. Guy R, et al. **J Invest Dermatol** 1996 Jan;106(1):176–82

SURGERY

[Removal of wrinkles and acne scars with the ultra-pulse CO2 laser] Raulin C, et al. **Hautarzt** 1996 Jun;47(6):443–6 (Eng. Abstr.) **(Ger)**

THERAPY

An overview of acne and its treatment. Thiboutot DM. **Cutis** 1996 Jan;57(1 Suppl):8–12 (16 ref.)
Improvement of facial acne scars by the 585 nm flashlamp-pumped pulsed dye laser. Alster TS, et al. **J Am Acad Dermatol** 1996 Jul;35(1):79–81
Acne: what's new? Cargnello JA. **Med J Aust** 1996 Aug 5;165(3):153–8
[A survey on the treatment of acne] Huang ZM. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun; 15(6):379–81 (20 ref.) **(Chi)**
[Alpha hydroxy acids in acne therapy] Michelsen S, et al. **Hautarzt** 1996 Apr;47(4):311–2 **(Ger)**

ACNU see **NIMUSTINE**

ACOCANTHERIN see **OUABAIN**

ACOMYS see **MURIDAE**

ACONITASE see **ACONITATE HYDRATASE**

ACONITATE HYDRATASE

ANALYSIS

Relationship between duodenal cytosolic aconitase activity and iron status in the mouse. Rabie A, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):414–20

ACONITATE HYDRATASE

BIOSYNTHESIS

Testosterone stimulates the biosynthesis of m-aconitase and citrate oxidation in prostate epithelial cells. Costello LC, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):45–51

CHEMISTRY

Magnetic circular dichroism study of the selenium-substituted form (Fe3Se4) of bovine heart aconitase. Breton JL, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):197–202

Spectroscopic characterisation of an aconitase (AcnA) of Escherichia coli. Bennett B, et al. **Eur J Biochem** 1995 Oct 1;233(1):317–26

Conservation of aconitase residues revealed by multiple sequence analysis. Implications for structure/function relationships. Frishman D, et al. **Eur J Biochem** 1996 Jul 1;239(1):197–200

METABOLISM

Conservation of aconitase residues revealed by multiple sequence analysis. Implications for structure/function relationships. Frishman D, et al. **Eur J Biochem** 1996 Jul 1;239(1):197–200

Prolactin specifically regulates citrate oxidation and m-aconitase of rat prostate epithelial cells. Liu Y, et al. **Metabolism** 1996 Apr;45(4):442–9

ACONITINE

ANALOGS & DERIVATIVES

Effect of diterpenoid alkaloids on cardiac sympathetic efferent and vagal afferent nerve activity. Chiao H, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):103–6

A sensitive technique for the detection of the alpha 7 neuronal nicotinic acetylcholine receptor antagonist, methyllycaconitine, in rat plasma and brain. Turek JW, et al. **J Neurosci Methods** 1995 Sep–Oct;61(1–2):113–8

Nicotinic acetylcholine receptors in separate brain regions exhibit different affinities for methyllycaconitine. Yum L, et al. **Neuroscience** 1996 May;72(2):545–55

ANALYSIS

[Correlativity analysis of detoxicating effect of radix Glycyrrhizae on radix Aconiti preparata in sini decoction] Pei M, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Jan; 21(1):50–2, inside back cover (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Expression of major histocompatibility complex in mouse peritoneal macrophages increasingly depends on plasma corticosterone levels: stimulation by aconitine. Kimura I, et al. **Biol Pharm Bull** 1995 Nov;18(11):1504–8

Electrophysiological effects of aconitine in rat hippocampal slices. Ameri A, et al. **Neuropharmacology** 1996 Jan; 35(1):13–22

Effects of aconitine on neurotransmitter release in the rat neuromuscular junction. Onur R, et al. **Neuropharmacology** 1995 Sep;34(9):1139–45

[Ia antigen expression of peritoneal macrophage in mice model of yang deficiency and the effect of aconitine] Ma J, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Sep;15(9):544–6 (Eng. Abstr.) **(Chi)**

ACOUSTIC EVOKED BRAIN STEM POTENTIALS see **EVOKED POTENTIALS, AUDITORY, BRAIN STEM**

ACOUSTIC IMPEDANCE TESTS

The accuracy of tympanometry assessed by its sensitivity and specificity. Szucs E, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):287–92

Tympanogram recorded under cervical compression. Nakashima T. **Audiology** 1995 Jan–Feb;34(1):13–6

Tympanometric screening in elementary school children. Page A, et al. **Audiology** 1995 Jan–Feb;34(1):6–12

What middle ear parameters tell about impedance matching and high frequency hearing. Hemilä S, et al. **Hear Res** 1995 May;85(1–2):31–44

Comparison of acoustic immittance measures obtained with different commercial instruments. De Chicchis AR, et al. **J Am Acad Audiol** 1996 Apr;7(2):120–4

Developmental changes in static admittance and tympanometric width in infants and toddlers. Roush J, et al. **J Am Acad Audiol** 1995 Jul;6(4):334–8

The length of the referral chain after failing preschool tympanometry. Claridge O, et al. **N Z Med J** 1995 Nov 24;108(1012):479–81

[Effect of variations in middle ear pressure on ruptures of the round window membrane of the inner ear of the guinea pig (Cavia porcellus)] Mertens J. **HNO** 1995 Oct; 43(10):611–8 (Eng. Abstr.) **(Ger)**

[Postmortem changes in ear canal resonance and tympanic membrane impedance in the human ear] Vitzthum HG, et al. **Laryngorhinootologie** 1996 May;75(5):270–4 (Eng. Abstr.) **(Ger)**

[Study on middle ear ventilation using positional tympanometry—post mastoidectomy ear] Ebihara H. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Dec;98(12):1887–93 (Eng. Abstr.) **(Jpn)**

[The usefulness of impedance audiometry for the diagnosis of occupational hearing loss] Kowalska S, et al. **Otolaryngol Pol** 1995;49(3):243–51 (Eng. Abstr.) **(Pol)**

HISTORY

Bluestone et al.: Audiometry and tympanometry in relation to middle ear effusions in children. (Laryngoscope. 1973;83;594–604). Meyerhoff WL. **Laryngoscope** 1996 Jun; 106(6):684–7

METHODS

Biomechanical characteristics of the middle ear system measured by a new method. III: Comparisons with tympanometric measurements. Gaihede M, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):522–7

ACOUSTIC MACULAE

PHYSIOLOGY

Evidence of a sensory processing unit in the mammalian macula. Chimento TC, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:196–212

ACOUSTIC NERVE

Acoustic neuroma [letter; comment] Morr ML. **J Am Acad Audiol** 1995 Sep;6(5):396–8. Comment on: J Am Acad Audiol 1994 Sep;5(5):349–54.

Water excitation MPRAGE MRI of VII and VIII cranial nerves. Litt AW, et al. **J Comput Assist Tomogr** 1996 Mar–Apr;20(2):194–200

Pineal germinoma with cranial nerve metastasis. Incesu L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):471–2 (11 ref.)

ANATOMY & HISTOLOGY

Connections of octaval and lateral line nuclei of the medulla in the goldfish, including the cytoarchitecture of the secondary octaval population in goldfish and catfish. McCormick CA, et al. **Brain Behav Evol** 1996;47(3):113–37

Structural diversity in the inner ear of teleost fishes: implications for connections to the Mauthner cell. Popper AN, et al. **Brain Behav Evol** 1995;46(3):131–40 (70 ref.)

DRUG EFFECTS

Laminin promotes differentiation, adhesion and proliferation of cell cultures derived from human acoustic nerve schwannoma. Baur AM, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):517–21

A model for long-term intracochlear administration of pharmacologic agents. Davies E, et al. **Am J Otol** 1994 Nov;15(6):757–61

Enhanced preservation of the auditory nerve following cochlear perfusion with nerve growth factors. Schindler RA, et al. **Am J Otol** 1995 May;16(3):304–9

An extended study: protective effects of nerve growth factor in neomycin-induced auditory neural degeneration. Shah SB, et al. **Am J Otol** 1995 May;16(3):310–4

Alpha 1-adrenergic receptor antagonist blocks acute cocaine action on the compound action potential of the auditory nerve in the chinchilla. Shivapuja BG, et al. **Drug Alcohol Depend** 1995 Nov;40(1):43–8

Effects of metamfetamine on auditory P3 component of event-related potentials in rats. Iwanami A, et al. **Eur Neuropsychopharmacol** 1995 Jun;5(2):103–6

Ototoxicity and irradiation: additional etiologies of hearing loss in adults. Mencher GT, et al. **J Am Acad Audiol** 1995 Sep;6(5):351–7

ENZYMOLOGY

Guanylate cyclase activity in the inner ear and auditory nerve of the rat. Zubin P, et al. **J Biochem (Tokyo)** 1995 Aug; 118(2):418–21

GROWTH & DEVELOPMENT

Distortion generated by the ear: its emergence and evolution during development. Tubach M, et al. **Laryngoscope** 1996 Jul;106(7):822–30

INJURIES

Changes in brainstem calcitonin gene-related peptide after VIIth and VIIIth cranial nerve lesions in guinea pig. Thompson GC, et al. **Brain Res** 1995 Jun 12;683(1):140–8

PATHOLOGY

Normal hearing in acoustic neuroma patients: a critical evaluation. Saleh EA, et al. **Am J Otol** 1996 Jan; 17(1):127–32

Evaluating hearing threshold differences between ears as a screen for acoustic neuroma. Schlauch RS, et al. **J Speech Hear Res** 1995 Oct;38(5):1168–75

Eighth cranial nerve lipoma manifesting as intractable vertigo—Case report. Kawaguchi S, et al. **Neurol Med Chir (Tokyo)** 1995 Nov;35(11):818–21

[New protocol for the early diagnosis of acoustic schwannoma in the outpatient clinic] Soto Sánchez C, et al. **Acta Otorrinolaringol Esp** 1995 Sep–Oct;46(5):353–5 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Short latency vestibular evoked responses to linear acceleration stimuli in small mammals: masking effects and experimental applications. Böhmer A. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:120–3

Hearing loss in Paget's disease of bone: evidence of auditory nerve integrity. Monsell EM, et al. **Am J Otol** 1995 Jan; 16(1):27–33

Nonlinear feedback models for the tuning of auditory nerve fibers. Carney LH, et al. **Ann Biomed Eng** 1996 May–Jun; 24(3):440–50

Left-right discrimination of sound onset by the Mauthner system. Eaton RC, et al. **Brain Behav Evol** 1995; 46(3):165–79

The octavolateralis system and Mauthner cell: interactions and questions. Eaton RC, et al. **Brain Behav Evol** 1995; 46(3):124–30 (60 ref.)

Physiology of primary saccular afferents of goldfish: implications for Mauthner cell response. Fay RR. **Brain Behav Evol** 1995;46(3):141–50 (54 ref.)

Comparative studies on the Mauthner cell of teleost fish in relation to sensory input. Zottoli SJ, et al. **Brain Behav Evol** 1995;46(3):151–64 (115 ref.)

Physiological identification of the auditory nerve during surgery for acoustic neuroma. Butler S, et al. **Clin Otolaryngol** 1995 Aug;20(4):312–7

Development of the VIIIth nerve compound action potential evoked by low-intensity tone pips in the Mongolian gerbil. Huang JM, et al. **Hear Res** 1995 Aug;88(1–2):14–8

Phase effects in forward masking of the compound action potential: a comparison of responses to stimulus and distortion frequencies. McAnally KI, et al. **Hear Res** 1995 Nov;91(1–2):110–8

Functional responses from guinea pigs with cochlear implants. I. Electrophysiological and psychophysical measures. Miller CA, et al. **Hear Res** 1995 Dec; 92(1–2):85–99

A functional map of the pigeon basilar papilla: correlation of the properties of single auditory nerve fibres and their peripheral origin. Smolders JW, et al. **Hear Res** 1995 Dec; 92(1–2):151–69

Reduction in excitability of the auditory nerve following electrical stimulation at high stimulus rates. Tykocinski M, et al. **Hear Res** 1995 Aug;88(1–2):124–42

One-tone suppression in the frog auditory nerve. Christensen-Dalsgaard J, et al. **J Acoust Soc Am** 1996 Jul; 100(1):451–7

Rate representation and discriminability of second formant frequencies for /epsilon/-like steady-state vowels in cat auditory nerve. Conley RA, et al. **J Acoust Soc Am** 1995 Dec;98(6):3223–34

Preservation of amplitude modulation coding in the presence of background noise by chinchilla auditory-nerve fibers. Frisina RD, et al. **J Acoust Soc Am** 1996 Jan;99(1):475–90

Long-term adaptation in cat auditory-nerve fiber responses. Javel E. **J Acoust Soc Am** 1996 Feb;99(2):1040–52

The periodogram and Allan variance reveal fractal exponents greater than unity in auditory-nerve spike trains. Lowen SB, et al. **J Acoust Soc Am** 1996 Jun;99(6):3585–91

ABR interpeak latencies in rats are shorter at low click intensities. Levi H, et al. **J Basic Clin Physiol Pharmacol** 1995;6(2):129–38

Spatial and spectral dependence of the auditory periphery in the northern leopard frog. Wang J, et al. **J Comp Physiol [A]** 1996 Feb;178(2):159–72

Activity-dependent short-term enhancement of intercellular coupling. Pereda AE, et al. **J Neurosci** 1996 Feb 1; 16(3):983–92

Age-related alterations in the auditory brainstem responses and the compound action potentials in guinea pigs. Nozawa I, et al. **Laryngoscope** 1996 Aug;106(8):1034–9

Distortion generated by the ear: its emergence and evolution during development. Tubach M, et al. **Laryngoscope** 1996 Jul;106(7):822–30

Deafness-induced plasticity in the mature central auditory system. Bledsoe SC Jr, et al. **Neuroreport** 1995 Dec 29; 7(1):225–9

Naturalistic stimuli increase the rate and efficiency of information transmission by primary auditory afferents. Rieke F, et al. **Proc R Soc Lond B Biol Sci** 1995 Dec 22; 262(1365):259–65

PHYSIOPATHOLOGY

The auditory, vestibular, and oculomotor system in facioscapulohumeral dystrophy. Verhagen WI, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:140–2

Superficial siderosis of the central nervous system: an underdiagnosed cause of sensorineural hearing loss and ataxia. Pribitkin EA, et al. **Am J Otol** 1994 May;15(3):415–8

Acoustic nerve in peripheral neuropathy: a BAEP study. Brainstem Auditory Evoked Potentials. Pareyson D, et al. **Electromyogr Clin Neurophysiol** 1995 Oct;35(6):359–64

Auditory nerve–brainstem responses in cystic fibrosis patients. Ozcelik T, et al. **Int J Pediatr Otorhinolaryngol** 1996 Apr;35(2):165–9

RADIATION EFFECTS

Ototoxicity and irradiation: additional etiologies of hearing loss in adults. Mencher GT, et al. **J Am Acad Audiol** 1995 Sep;6(5):351–7

SURGERY

Facial nerve outcome in acoustic tumor surgery. Esses BA, et al. **Am J Otol** 1994 Nov;15(6):810–2

Far-field auditory brainstem response in neurotologic surgery. Harner SG, et al. **Am J Otol** 1996 Jan;17(1):150–3

Determinants and impact of headache after acoustic neuroma surgery. Pedrosa CA, et al. **Am J Otol** 1994 Nov; 15(6):793–7

Acoustic neuroma recurrence after suboccipital resection: management with translabyrinthine resection. Roberson JB Jr, et al. **Am J Otol** 1996 Mar;17(2):307–11

Delayed and progressive hearing loss after microvascular decompression of cranial nerves. Fuse T, et al. **Ann Otol Rhinol Laryngol** 1996 Feb;105(2):158–61

Quality of life after acoustic neuroma surgery. van Leeuwen JP, et al. **Ann Otol Rhinol Laryngol** 1996 Jun;105(6):423–30

Physiological identification of the auditory nerve during surgery for acoustic neuroma. Butler S, et al. **Clin Otolaryngol** 1995 Aug;20(4):312–7

Gamma knife radiosurgery for acoustic schwannoma: early effects and preservation of hearing. Hirato M, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):737–41

[Report on the 2nd International Conference on the surgery of acoustic nerve neuromas and from 2nd European Congress of the Society of cranial base surgery, Paris, April 22–26, 1995] Pietruski J. **Neurol Neurochir Pol** 1996 Jan–Feb;30(1):163–5 **(Pol)**

ULTRASTRUCTURE

Laminin promotes differentiation, adhesion and proliferation of cell cultures derived from human acoustic nerve schwannoma. Baur AM, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):517–21

ACOUSTIC NERVE DISEASES

COMPLICATIONS

Hearing loss in multiple sclerosis: localization of the auditory pathway lesion according to electrocochleographic findings. Marangos N. **J Laryngol Otol** 1996 Mar; 110(3):252–7

DIAGNOSIS

Discrimination of patients with acoustic neuroma and peripheral vestibular lesions with human posture dynamics. Johansson R, et al. **Acta Otolaryngol Suppl (Stockh)** 1995; 520 Pt 1:27–8

VIIIth cranial nerve involvement in sarcoidosis. O'Reilly BJ, et al. **J Laryngol Otol** 1995 Nov;109(11):1089–93

ETIOLOGY

Pineal germinoma with cranial nerve metastasis. Incesu L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):471–2 (11 ref.)

SURGERY

Ectomesenchymal hamartoma (benign "ectomesenchymoma") of the VIIIth nerve: case report. Apostolides PJ, et al. **Neurosurgery** 1995 Dec;37(6):1204–7

ACOUSTIC NEUROMA see **NEUROMA, ACOUSTIC**

ACOUSTIC STIMULATION

see related
EVOKED POTENTIALS, AUDITORY

Changes in auditory P300 event-related potentials and brainstem evoked potentials in diabetes mellitus. Kurita A, et al. **Acta Neurol Scand** 1995 Oct;92(4):319–23

Effect of lidocaine injection of EOAE in patients with tinnitus. Haginomori S, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):488–92

Clinical and electrophysiological findings in the Tullio phenomenon. Bronstein AM, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:209–11

Effects of ethanol and auditory distraction on forced choice reaction time. Jääskeläinen IP, et al. **Alcohol** 1996 Mar–Apr; 13(2):153–6

Fetal acoustic stimulation test: stimulus features of three artificial larynges recorded in sheep. Abrams RM, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1372–6

Fetal acoustic stimulation, an adjunct to external cephalic version: a blinded, randomized crossover study. Johnson RL, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1369–72

Effect of vibroacoustic stimulation on fetal meconium passage in labor. Zimmer EZ, et al. **Am J Perinatol** 1996 Feb; 13(2):81–3

Processing familiar and unfamiliar auditory stimuli during general anesthesia. Donker AG, et al. **Anesth Analg** 1996 Mar;82(3):452–5

The mismatch negativity to novel stimuli reflects cognitive decline. Schroeder MM, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:399–401

Low-frequency biasing of round window responses in guinea pigs and chinchillas. Tono T, et al. **Audiology** 1995 Jan–Feb; 34(1):47–56

Analysis of auditory brainstem response waveforms derived ipsilaterally and contralaterally to monaural stimulation. Kato T, et al. **Auris Nasus Larynx** 1995;22(2):96–102

The effect of the sympathetic nervous system upon susceptibility to acoustic trauma. Wada T, et al. **Auris Nasus Larynx** 1995;22(2):86–92

Is intrapartum vibratory acoustic stimulation a valid alternative to fetal scalp pH determination? Irion O, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):642–7

Learning to ignore: psychophysics and computational modeling of fast learning of direction in noisy motion stimuli. Vaina LM, et al. **Brain Res Cogn Brain Res** 1995 Jul;2(3):155–63

Influence of intense sound stimuli on skin microcirculation. Kolev OI, et al. **Clin Auton Res** 1995 Sep;5(4):187–90

Tinnitus and otoacoustic emissions. Ceranic BJ, et al. **Clin Otolaryngol** 1995 Jun;20(3):192–200 (89 ref.)

The accuracy of acoustic rhinometry using a pulse train signal. Hamilton JW, et al. **Clin Otolaryngol** 1995 Jun; 20(3):279–82

Auditory priming for nonverbal information: Implicit and explicit memory for environmental sounds. Chiu CY, et al. **Conscious Cogn** 1995 Dec;4(4):440–58

A comparison of binaural interactions using traditional and maximum length sequence evoked response paradigms. Lasky RE, et al. **Ear Hear** 1995 Aug;16(4):354–60

COAEs and SSOAEs in adults with increased age. Prieve BA, et al. **Ear Hear** 1995 Oct;16(5):521–8

Effect of high-frequency interrupted noise exposures on evoked-potential thresholds, distortion-product otoacoustic emissions, and outer hair cell loss. Subramaniam M, et al. **Ear Hear** 1995 Aug;16(4):372–81

Antecedent tone presentation significantly delays rate of amygdala kindling. Hernandez TD, et al. **Epilepsy Res** 1995 Sep;22(1):35–41

Limitations in the use of distortion product otoacoustic emissions in objective audiometry as the result of fine structure. Heitmann J, et al. **Eur Arch Otorhinolaryngol** 1996;253(3):167–71

Selecting the best tone-pip stimulus-envelope time for estimating an objective middle-latency response threshold for low- and middle-tone sensorineural hearing losses. Xu ZM, et al. **Eur Arch Otorhinolaryngol** 1995;252(5):275–9

Auditory responsive cortex in the squirrel monkey: neural responses to amplitude-modulated sounds. Bieser A, et al. **Exp Brain Res** 1996 Mar;108(2):273–84

Influence of auditory precuing on automatic postural responses. McChesney JW, et al. **Exp Brain Res** 1996 Mar; 108(2):315–20

Detection of hearing loss in young children and adults using otoacoustic emissions. Herer GR, et al. **Folia Phoniatr Logop** 1996;48(3):117–21

Binaural noise suppresses linear click-evoked otoacoustic emissions more than ipsilateral or contralateral noise. Berlin CI, et al. **Hear Res** 1995 Jul;87(1–2):96–103

Noise exposure alters the response of outer hair cells to ATP. Chen C, et al. **Hear Res** 1995 Aug;88(1–2):215–21

The effect of contralateral stimulation on cochlear resonance and damping in the mustached bat: the role of the medial efferent system. Henson OW Jr, et al. **Hear Res** 1995 Jun; 86(1–2):111–24

Sensorineural hearing loss alters recovery from short-term adaptation in the C57BL/6 mouse. Walton JP, et al. **Hear Res** 1995 Aug;88(1–2):19–26

Sensing platform for acoustic startle responses from rat forelimbs and hindlimbs. Seaman RL, et al. **IEEE Trans Biomed Eng** 1996 Feb;43(2):221–5

Spontaneous and evoked otoacoustic emissions in pre-term and full-term neonates: is there a clinical application? Morlet T, et al. **Int J Pediatr Otorhinolaryngol** 1995 Nov; 33(3):207–11

Behavioral and hippocampal evoked responses in an auditory oddball situation when an unconditioned stimulus is paired with deviant tones in the cat: experiment II. Ruusuvirta T, et al. **Int J Psychophysiol** 1995 Jun;20(1):41–7

Hippocampal event-related potentials to pitch deviances in an auditory oddball situation in the cat: experiment I. Ruusuvirta T, et al. **Int J Psychophysiol** 1995 Jun;20(1):33–9

Two-tone suppression in cochlear mechanics. Cooper NP. **J Acoust Soc Am** 1996 May;99(5):3087–98

The cubic distortion product otoacoustic emissions from the normal and noise-damaged chinchilla cochlea. Hamernik RP, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1003–12

The ipsilaterally evoked olivocochlear reflex causes rapid adaptation of the 2f1–f2 distortion product otoacoustic emission. Liberman MC, et al. **J Acoust Soc Am** 1996 Jun; 99(6):3572–84

Slopes of distortion-product otoacoustic emission growth curves corrected for noise-floor levels. Nelson DA, et al. **J Acoust Soc Am** 1996 Jan;99(1):468–74

Click- and tone-burst-evoked otoacoustic emissions in normal-hearing and hearing-impaired ears. Prieve BA, et al. **J Acoust Soc Am** 1996 May;99(5):3077–86

Olivocochlear reflex assays: effects of contralateral sound on compound action potentials versus ear-canal distortion products. Puria S, et al. **J Acoust Soc Am** 1996 Jan; 99(1):500–7

Lateralization of comodulated complex waveforms. Saberi K. **J Acoust Soc Am** 1995 Dec;98(6):3146–56

Filtering and spectral characteristics of averaged auditory brain-stem response and background noise in infants. Sininger YS. **J Acoust Soc Am** 1995 Oct;98(4):2048–55

Latency and multiple sources of distortion product otoacoustic emissions. Stover LJ, et al. **J Acoust Soc Am** 1996 Feb;99(2):1016–24

Effects of ear-canal standing waves on measurements of distortion-product otoacoustic emissions. Whitehead ML, et al. **J Acoust Soc Am** 1995 Dec;98(6):3200–14

Transient effects during the chopping response of LSO neurons. Zacksenhouse M, et al. **J Acoust Soc Am** 1995 Sep;98(3):1410–22

The origin of periodicity in the spectrum of evoked otoacoustic emissions. Zweig G, et al. **J Acoust Soc Am** 1995 Oct;98(4):2018–47

An in-situ calibration procedure for click stimuli. Chertoff ME, et al. **J Am Acad Audiol** 1996 Apr;7(2):130–6

Clinical applications of otoacoustic emissions [editorial] Jerger J. **J Am Acad Audiol** 1995 Jul;6(4):270

Referral rates and cost efficiency in a universal newborn hearing screening program using transient evoked otoacoustic emissions. Maxon AB, et al. **J Am Acad Audiol** 1995 Jul;6(4):271–7

Transient evoked otoacoustic emissions and pseudohypacusis. Musiek FE, et al. **J Am Acad Audiol** 1995 Jul;6(4):293–301

Effects of exam procedures on transient evoked otoacoustic emissions (TEOAEs) in neonates. Vohr BR, et al. **J Am Acad Audiol** 1996 Apr;7(2):77–82

Responses to simulated echoes by neurons in the barn owl's auditory space map. Keller CH, et al. **J Comp Physiol [A]** 1996 Apr;178(4):499–512

Aging and the segregation of auditory stimulus sequences. Alain C, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Mar; 51(2):P91–3

Neural responses to simple simulated echoes in the auditory brain stem of the unanesthetized rabbit. Fitzpatrick DC, et al. **J Neurophysiol** 1995 Dec;74(6):2469–86

Vibratory acoustic stimulation and fetal gasping. Marks F, et al. **J Reprod Med** 1995 Jul;40(7):513–5

Effect of labor analgesia with nalbuphine hydrochloride on fetal response to vibroacoustic stimulation. Poehlmann S, et al. **J Reprod Med** 1995 Oct;40(10):707–10

Comparison of horizontal head movements evoked by auditory and visual targets. Fuller JH. **J Vestib Res** 1996 Jan–Feb;6(1):1–13

Functional magnetic resonance imaging of the central auditory pathway following speech and pure-tone stimuli. Millen SJ, et al. **Laryngoscope** 1995 Dec;105(12 Pt 1):1305–10

Rhythmic auditory stimulation in gait training for Parkinson's disease patients. Thaut MH, et al. **Mov Disord** 1996 Mar; 11(2):193–200

Acoustic myography during isometric fatigue in postpolio and control subjects. Rodriguez AA, et al. **Muscle Nerve** 1996 Mar;19(3):384–7

Contingent and non-contingent auditory cueing in Parkinson's disease. Kritikos A, et al. **Neuropsychologia** 1995 Oct;33(10):1193–203

Spatial, bioelectrical, and neurochemical characteristics of the early afferent reaction of the caudate nucleus to an acoustic signal. Khasabov GA, et al. **Neurosci Behav Physiol** 1995 Jul–Aug;25(4):319–21

Mismatch between anticipated and actually presented sound stimuli in humans. Remijn GB, et al. **Neurosci Lett** 1996 Jan 5;202(3):169–72

Neonatal methamphetamine-induced long-term acoustic startle facilitation in rats as a function of prepulse stimulus intensity. Vorhees CV, et al. **Neurotoxicol Teratol** 1996 Mar–Apr;18(2):135–9

Dorsal cochlear nucleus blood flow during acoustic stimulation. Quirk WS, et al. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):613–9

Decreased cardiac responses to auditory stimulation during prone sleep. Franco P, et al. **Pediatrics** 1996 Feb; 97(2):174–8

P3(00) habituation from auditory and visual stimuli. Romero R, et al. **Physiol Behav** 1996 Mar;59(3):517–22

Sound does not entrain the motor activity circadian rhythm of rats. Vilaplana J, et al. **Physiol Behav** 1995 Nov; 58(5):975–8

Naming norms for brief environmental sounds: effects of age and dementia. Fabiani M, et al. **Psychophysiology** 1996 Jul; 33(4):462–75

Developmental and pharmacological analysis of the cardiac response to an acoustic startle stimulus. Richardson R, et al. **Psychophysiology** 1996 Jan;33(1):31–41

Transient evoked otoacoustic emissions as screening for hearing losses at the school for military training. Engdahl B, et al. **Scand Audiol** 1996;25(1):71–8

Acoustic cues and postural control. Petersen H, et al. **Scand J Rehabil Med** 1995 Jun;27(2):99–104

Sound stimulation-induced vasomotor reflex in the central artery of the rabbit ear. Takeoka M, et al. **Tohoku J Exp Med** 1996 Feb;178(2):101–11

Effects of developmental hypothyroidism on auditory and motor function in the rat. Goldey ES, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):67–76

[Modulation of evoked potentials following electrical tooth stimulation by pre-auditory stimulus] Inada M. **Kokubyo Gakkai Zasshi** 1996 Jun;63(2):313–33 (Eng. Abstr.) **(Jpn)**

[Transitory evoked otoacoustic emissions in children with impaired middle ear ventilation] Rogowski M. **Otolaryngol Pol** 1995;49(3):238–42 (Eng. Abstr.) **(Pol)**

[Hemispheric functional specialization in motor aphasia. Neurophysiologic findings with computerized electroencephalographic brain mapping during musical and oral sound stimulation. Study of 2 cases] Muszkat M, et al. **Arq Neuropsiquiatr** 1995 Mar;53(1):88–93 (Eng. Abstr.)

(Por)
[Model for isolating spectral maxima of an acoustic signal at the first levels of the hearing system] Arkhipenko SA, et al. **Biofizika** 1996 Mar-Apr;41(2):463-70 (Eng. Abstr.) (Rus)
[Parameters of normalcy in transient otoacoustic emissions] Martínez Ibargüen A, et al. **Acta Otorrinolaringol Esp** 1995 Sep-Oct;46(5):339-44 (Eng. Abstr.) (Spa)
[Recording of evoked otoacoustic emissions in adult normal hearing population. Percentile of normalcy] Morant Ventura A, et al. **An Otorrinolaringol Ibero Am** 1995; 22(4):363-77 (Eng. Abstr.) (Spa)

ADVERSE EFFECTS

Tectorial membrane regeneration in acoustically damaged birds: an immunocytochemical technique. Adler HJ, et al. **Hear Res** 1995 Jun;86(1-2):43-6
Migration of hyaline cells into the chick basilar papilla during severe noise damage. Cotanche DA, et al. **Hear Res** 1995 Nov;91(1-2):148-59

INSTRUMENTATION

Characterization of vestibular potentials evoked by linear acceleration pulses in the chinchilla. Böhmer A, et al. **Am J Otol** 1995 Jul;16(4):498-504
Metronome in Parkinson's disease [letter] Enzensberger W, et al. **Lancet** 1996 May 11;347(9011):1337
[Phantom responses and early auditory evoked potentials. Comparison of the TDH39 hearing aid and an intra-canal hearing device] Jezequel JA. **Ann Otolaryngol Chir Cervicofac** 1995;112(4):151-7 (Eng. Abstr.) (Fre)

METHODS

Behaviour of surface acoustic wave interdigitated array electrode sensor in non-aqueous solution and determination of blood plasma recalcification time. Chen K, et al. **Biosens Bioelectron** 1996;11(5):515-21
The effect of noise trauma following training exposures in the mouse. Fowler T, et al. **Hear Res** 1995 Aug; 88(1-2):1-13
Fetal acoustic stimulation as an adjunct to external cephalic version. Johnson RL, et al. **J Reprod Med** 1995 Oct; 40(10):696-8

ACOUSTIC TRAUMA see **HEARING LOSS, NOISE-INDUCED**

ACOUSTICS

see related
PSYCHOACOUSTICS
SPEECH ACOUSTICS

Noninvasive diagnosis of mechanical failure of the implanted total artificial heart using neural network analysis of acoustic signals. Kim HC, et al. **ASAIO J** 1995 Jul-Sep; 41(3):M271-6
Changes in acoustic distortion during long term electrical stimulation of the guinea pig cochlea: a preliminary study. Dodson HC, et al. **Br J Audiol** 1995 Aug;29(4):209-18
Selecting the gain for radio microphone (FM) systems: theoretical considerations and practical limitations. Rowson VJ, et al. **Br J Audiol** 1995 Jun;29(3):161-71
An assessment of the intrauterine sound intensity level during obstetric echo-planar magnetic resonance imaging. Glover P, et al. **Br J Radiol** 1995 Oct;68(814):1090-4
An acoustic screening test for obstructive sleep apnoea. McCombe AW, et al. **Clin Otolaryngol** 1995 Aug; 20(4):348-51
Phonomyogram from single motor units during voluntary isometric contraction. Petitjean M, et al. **Eur J Appl Physiol** 1995;71(2-3):215-22
The acoustic properties of snores. Beck R, et al. **Eur Respir J** 1995 Dec;8(12):2120-8
Acoustic features of normal-hearing pre-term infant cry. Cacace AT, et al. **Int J Pediatr Otorhinolaryngol** 1995 Nov; 33(3):213-24
The Acoustical Society of America 130th meeting. Saint Louis, Missouri, 27 November-1 December, 1995. Abstracts. **J Acoust Soc Am** 1995 Nov;98(5 Pt 2):2863-994
Acoustic properties of selected bovine tissues in the frequency range 20-200 MHz. Akashi N, et al. **J Acoust Soc Am** 1995 Dec;98(6):3035-9
Measurements of harmonic generation in a focused finite-amplitude sound beam. Averkiou MA, et al. **J Acoust Soc Am** 1995 Dec;98(6):3439-42
Acoustically enhanced bubble growth at low frequencies and its implications for human diver and marine mammal safety. Crum LA, et al. **J Acoust Soc Am** 1996 May;99(5):2898-907
An interferometric technique for B/A measurement. Everbach EC, et al. **J Acoust Soc Am** 1995 Dec; 98(6):3428-38
Effects of aging on the fine structure of the 2f1-f2 acoustic distortion product. He NJ, et al. **J Acoust Soc Am** 1996 Feb;99(2):1002-15
Acoustic radiation pressure in a three-dimensional lossy medium. Jiang ZY, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):741-7
Wave space resolution in ultrasonic scattering measurements. Mast TD, et al. **J Acoust Soc Am** 1995 Dec;98(6):3050-8
Acoustic characterization of mechanical valve condition and loading. Eberhardt AC, et al. **J Heart Valve Dis** 1995 Nov; 4(6):649-58; discussion 658-9
Bio-acoustic signals from stenotic tube flow: state of the art and perspectives for future methodological development. Ask P, et al. **Med Biol Eng Comput** 1995 Sep;33(5):669-75 (29 ref.)
Ambient noise interferes with auscultatory blood pressure measurement during exercise. Lightfoot JT, et al. **Med Sci Sports Exerc** 1996 Apr;28(4):502-8
Magnetic resonance elastography. Muthupillai R, et al. **Nat Med** 1996 May;2(5):601-3 (16 ref.)
Clinical and acoustic measures of the negative syndrome. Alpert M, et al. **Psychopharmacol Bull** 1995;31(2):321-6
Acoustic properties of some biocompatible polymers at body temperature. Guess JF, et al. **Ultrasound Med Biol** 1995; 21(2):273-7
Acoustic generation of intra-arterial contrast boluses. Ivey JA, et al. **Ultrasound Med Biol** 1995;21(6):757-67

INSTRUMENTATION

Performance evaluation of implantable artificial organs by sound spectrum analysis. Lee SH, et al. **ASAIO J** 1994 Jul-Sep;40(3):M762-6
A new urea sensor based on combining the surface acoustic wave device with urease extracted from green soya bean and its application--determination of urea in human urine. Liu D, et al. **Biosens Bioelectron** 1996;11(4):435-42
Evaluation of acoustic rhinometry and posterior rhinomanometry as tools for inhalation challenge studies. Kesavanathan J, et al. **J Toxicol Environ Health** 1996 Jun 28;48(3):295-307
[Device for examining the state of bronchial patency using the acoustic method] Kulakov IuV, et al. **Med Tekh** 1995 Sep-Oct;(5):20-3 (Eng. Abstr.) (Rus)

ACOUSTICS, SPEECH see **SPEECH ACOUSTICS**

ACQUIRED IMMUNODEFICIENCY SYNDROME

see related
AIDS SERODIAGNOSIS
HIV SEROPOSITIVITY
HIV SEROPREVALENCE
LYMPHOMA, AIDS-RELATED

The snout and palmomental reflexes in HIV disease in Tanzania. Howlett WP, et al. **Acta Neurol Scand** 1995 Jun; 91(6):470-6
The need to preserve historical material [letter] Berridge V. **Addiction** 1995 Dec;90(12):1683
Support service use by persons with AIDS and their caregivers. Wight RG, et al. **AIDS Care** 1995;7(4):509-20
AIDS service organizations and the gay community. Andriote JM. **AIDS Educ Prev** 1995;7(5 Suppl):91-5
A typology of AIDS volunteers. Cassel JB, et al. **AIDS Educ Prev** 1995;7(5 Suppl):80-90
What African-American women know, do, and feel about AIDS: a function of age and education. Dancy B. **AIDS Educ Prev** 1996 Feb;8(1):26-36
GMHC volunteers and the challenges and hopes for the second decade of AIDS. Ouellette SC, et al. **AIDS Educ Prev** 1995;7(5 Suppl):64-79
Mental health-related calls to the CDC National AIDS Hotline. Safran MA, et al. **AIDS Educ Prev** 1996 Feb; 8(1):37-43
Special service for education of physicians about HIV and AIDS [news] **Am Fam Physician** 1995 Nov 1;52(6):1935
Short course dexamethasone for thrombocytopenia in AIDS. Ramratnam B, et al. **Am J Med** 1996 Jan;100(1):117-8
Surfing the World Wide Web for AIDS information. **Am J Nurs** 1996 Jun;96(6):12
AIDS phobia, public health warnings, and lawsuits: deterring harm or rewarding ignorance? Mariner WK. **Am J Public Health** 1995 Nov;85(11):1562-8 (42 ref.)
The risk of domestic violence and women with HIV infection: implications for partner notification, public policy, and the law. Rothenberg KH, et al. **Am J Public Health** 1995 Nov;85(11):1569-76 (98 ref.)
Nurses on Presidential Advisory Council on HIV/AIDS [news] **AORN J** 1996 Apr;63(4):778
Contract minimum dataset includes confidential data [letter; comment] Goodyear OM. **BMJ** 1996 Jan 20;312(7024):185 . Comment on: BMJ 1995 Sep 16;311(7007):754.
Government agents raid the Cannabis Buyers' Club [news] Macready N. **BMJ** 1996 Aug 24;313(7055):444
AIDS now more chronic than fatal [news] Roberts J. **BMJ** 1996 Mar 30;312(7034):796-7
A new agenda for AIDS research [editorial] Walker BD. **BMJ** 1995 Dec 2;311(7018):1448-9
Historical and analytical overview of policy issues affecting women living with AIDS: a blueprint for learning from our past. Cooper EB. **Bull N Y Acad Med** 1995 Summer; 72(1 Suppl):283-99 (59 ref.)
Miles to go before we sleep. Goosby EP. **Bull N Y Acad Med** 1995 Summer;72(1 Suppl):309-15
A view from the front lines of bioethics. Levine C. **Bull N Y Acad Med** 1995 Summer;72(1 Suppl):187-201
The provider as advocate. Zealand TP. **Bull N Y Acad Med** 1995 Summer;72(1 Suppl):300-8
AIDS networking in Canada, US [news] **Can Med Assoc J** 1995 Dec 15;153(12):1772
Visit to Zambia offers humbling reminder of privileges Canadians enjoy. Needham D. **Can Med Assoc J** 1996 Sep 1;155(5):579-80
A surgeon with AIDS made the most of borrowed time. Robb N. **Can Med Assoc J** 1996 Jan 15;154(2):223-5
Special issue on AIDS. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):345-452
Special issue on AIDS. **Cell Mol Biol (Noisy-le-grand)** 1995; 41 Suppl 1:S1-161
The role of the dentist in the era of AIDS. Glick M. **Dent Clin North Am** 1996 Apr;40(2):343-57 (52 ref.)
AIDS: awareness and blood handling practices of health care workers in Lagos, Nigeria. Odujinrin OM, et al. **Eur J Epidemiol** 1995 Aug;11(4):425-30
Ceramide, AIDS and long-term survivors [letter; comment] De Simone C, et al. **Immunol Today** 1996 Jan;17(1):48. Comment on: Immunol Today 1995 Jun;16(6):294-7. Comment on: Immunol Today 1995 Jun;16(6):297-302.
Immunologic and virologic markers determining progression to AIDS. Schellekens PT, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S62-6 (30 ref.)
State Dental Boards' policies on a practitioner's duty to care for HIV seropositive or AIDS patients. Friedland B, et al. **J Am Coll Dent** 1995 Fall;62(3):37-40
AIDS awareness among nursing students of Delhi. Kumar A, et al. **J Commun Dis** 1996 Mar;28(1):20-7
Knowledge, attitudes, and professional behaviors of third- and fourth-year dental students concerning AIDS and hepatitis B. Chehaitly A, et al. **J Dent Educ** 1995 Aug; 59(8):844-9
Problems of AIDS in developing countries [letter; comment] Mehra DS. **J Indian Med Assoc** 1995 Mar;93(3):115. Comment on: J Indian Med Assoc 1992 Oct;90(10):254-6.
13th annual symposium on nonhuman primate models for AIDS. Monterey, California, November 5-8, 1994. Abstracts. **J Med Primatol** 1995 Dec;24(4):169-229
Informal caregivers of persons with AIDS [letter] Clipp EC. **J Palliat Care** 1995 Autumn;11(3):53
Treatment of resistant oral aphthous ulcers in children with acquired immunodeficiency syndrome. de Asis ML, et al. **J Pediatr** 1995 Oct;127(4):663-5
Heterozygosity for long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency and deterioration in liver function in a newborn infant infected with human immunodeficiency virus. Hicks P, et al. **J Pediatr** 1995 Oct; 127(4):599-602
The mythology of modern medicine--IV. HIV: heuristically important virus. AIDS: advances induced deficiency syndromes. Kothari MV, et al. **J Postgrad Med** 1994 Jan-Mar;40(1):42-5 (31 ref.)
AIDS' nomenclature's spelling or style [letter] Rafiquzzman M. **J R Soc Health** 1995 Oct;115(5):331
AIDS: where do we stand? [editorial] Bryan CS. **J S C Med Assoc** 1995 Sep;91(9):389-90
Infection and disease due to human immunodeficiency virus and the acquired immunodeficiency syndrome. Postic B, et al. **J S C Med Assoc** 1995 Sep;91(9):371-88
AIDS in 1996. Much accomplished, much to do [editorial] Fauci AS. **JAMA** 1996 Jul 10;276(2):155-6
Politicians, AIDS experts wage budget debate [news] Voelker R. **JAMA** 1996 May 8;275(18):1390-1
AIDS and human rights [news] Voelker R. **JAMA** 1995 Nov 22-29;274(20):1577
Restructure for federal AIDS research [news] Voelker R. **JAMA** 1996 Apr 10;275(14):1065
India's railways relent over AIDS passengers [news] Kumar S. **Lancet** 1996 Apr 27;347(9009):1178
South Africa's AIDS play provokes controversy. Lee N. **Lancet** 1996 Mar 2;347(9001):610
Report calls on US to revamp AIDS research effort [news] McCarthy M. **Lancet** 1996 Mar 23;347(9004):823
Vancouver conference marks viral-load era of AIDS [news] Sharp D. **Lancet** 1996 Jul 20;348(9021):183
Netherlands revises HIV coordination efforts [news] Spanjer M. **Lancet** 1995 Nov 18;346(8986):1358
Free access to electronic AIDS information [news] **MCN Am J Matern Child Nurs** 1995 Jan-Feb;20(1):52
Prevention of AIDS and living together with an HIV-infected patient. Fahik FT, et al. **Medinfo** 1995;8 Pt 2:1191
A standards-based clinical information system for HIV/AIDS. Stitt FW. **Medinfo** 1995;8 Pt 1:402
The story behind the creation of the Michigan AIDS Fund. Strumwasser I. **Mich Med** 1995 Nov;94(11):11-3
The evolution of the Michigan AIDS Fund. Strumwasser I. **Mich Med** 1995 Dec;94(12):20-2
Viral load and response to treatment of HIV [letter; comment] Fessel WJ. **N Engl J Med** 1996 Jun 20; 334(25):1672; discussion 1672-3. Comment on: N Engl J Med 1996 Feb 15;334(7):426-31.
Dingell disavows 'Dingell' report on Gallo [news] Culliton BJ. **Nat Med** 1995 Mar;1(3):188
Japan to open first AIDS clinic [news] Hannay T. **Nat Med** 1995 Feb;1(2):104-5
AIDS summit approaches [news] Steele FR. **Nat Med** 1995 Dec;1(12):1230
HIV summit is a good show [news] Steele FR. **Nat Med** 1996 Jan;2(1):9
AIDS myths that need eradicating [editorial] **Nature** 1996 Jul 25;382(6589):283
Japanese AIDS expert files law suits for damages [news]

Nature 1996 Jul 25;382(6589):292
Rockefeller link for AIDS centre [news] **Nature** 1996 Jun 20;381(6584):641
Indian budget boosts AIDS research [news] Jayaraman KS. **Nature** 1996 Aug 1;382(6590):382
Advisers deny pressure over Japan's 'first' AIDS case [news] Swinbanks D. **Nature** 1996 May 16;381(6579):181
AIDS survey traces shifting attitudes [news] Tastemain C. **Nature** 1995 Dec 7;378(6557):530
Planning of US AIDS research [letter; comment] Varmus H, et al. **Nature** 1996 May 23;381(6580):270. Comment on: Nature 1996 May 2;381(6577):5.
Panel calls for overhaul of AIDS research [news] Wadman M. **Nature** 1996 Mar 21;380(6571):190
NIH institute limits scope of 'AIDS research' [news] Wadman M. **Nature** 1996 May 16;381(6579):179
NIH agrees to temporary by-pass of AIDS office in allocation of grants [news] Wadman M. **Nature** 1996 Feb 8;379(6565):475
AIDS office opposes outside planning [news] [see comments] Wadman M. **Nature** 1996 May 2;381(6577):5. Comment in: Nature 1996 May 23;381(6580):270.
Advance directives: matters of life and death [news] Klaus BD. **Nurse Pract** 1995 Oct;20(10):88–90
Nutritional alterations in high-risk groups in relationship to HIV-1 disease progression [editorial] Baum MK. **Nutrition** 1996 Feb;12(2):124–5
AIDS: newer concepts in the immunopathogenic mechanisms of human immunodeficiency virus disease. Fauci AS. **Proc Assoc Am Physicians** 1995 Apr;107(1):1–7 (25 ref.)
Actors play patients. Using surrogate patients to look into private practice [see comments] Hazelkorn HM, et al. **Public Health Rep** 1996 Mar–Apr;111(2):129–32. Comment in: Public Health Rep 1996 Mar–Apr;111(2):133–4.
AIDS: clinical and scientific issues past, present and future. Dalgleish AG, et al. **Q J Nucl Med** 1995 Sep;39(3):156–62 (44 ref.)
AIDS in older patients: a problem of increasing concern. Stein WM, et al. **R I Med** 1995 Nov;78(11):324–5
HIV/AIDS activists want blacklist for discriminators [news] van der Linde I. **S Afr Med J** 1994 Dec;84(12):11
Socio-economic status of AIDS patients. Laursen E, et al. **Scand J Soc Med** 1995 Sep;23(3):189–92
NCI AIDS budget under microscope [news] **Science** 1995 Dec 8;270(5242):1559
Chimp finally shows AIDS symptoms [news] **Science** 1995 Oct 13;270(5234):223
Potential animal model for AIDS [news] **Science** 1995 Sep 29;269(5232):1819, 1821
NIH budget trouble for AIDS office? [news] **Science** 1996 Jan 19;271(5247):281
The changing of the guard [news] [see comments] Cohen J. **Science** 1996 Jun 28;272(5270):1876–9. Comment in: Science 1996 Aug 16;273(5277):859.
Overhauling AIDS research: views from the community [news] [see comments] Cohen J. **Science** 1996 Feb 2; 271(5249):590–1. Comment in: Science 1996 Apr 26;272(5261):469–70.
Panel urges NIH to loosen its grip on AIDS research [news] Cohen J. **Science** 1996 Mar 15;271(5255):1491
Clinton holds first AIDS summit [news] Cohen J. **Science** 1995 Dec 15;270(5243):1752
NIH Regional Primate Centers [letter; comment] Dukelow WR. **Science** 1996 Apr 26;272(5261):469–70. Comment on: Science 1996 Feb 2;271(5249):590–1. Comment on: Science 1996 Mar 15;271(5255):1491.
AIDS politics [letter; comment] Fox CH. **Science** 1996 Aug 16;273(5277):859. Comment on: Science 1996 Jun 28;272(5270):1876–9.
Gallo's institute at the last hurdle [news] Marshall E. **Science** 1996 Mar 8;271(5254):1359
Human immunodeficiency virus and acquired immunodeficiency syndrome: recent developments and their implications for pediatric surgeons. Cooper A. **Semin Pediatr Surg** 1995 Nov;4(4):252–61 (88 ref.)
Depressive symptoms over the course of HIV infection before AIDS. Lyketsos CG, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jun;31(3–4):212–9
Ethics, AIDS, and the neurosurgeon [editorial] Heifetz MD. **Surg Neurol** 1996 Mar;45(3):299–300
Virology before and after HIV. Cossart Y. **Vet Microbiol** 1995 Sep;46(1–3):243–7
Cuba's national AIDS program. The first decade. Granich R, et al. **West J Med** 1995 Aug;163(2):139–44
[Construction and expression of the gene CD4V1V2-PE40, coding for a molecular targeted protein against AIDS] Zhao X, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Aug; 17(4):248–52 (Eng. Abstr.) **(Chi)**
[Sexuality and AIDS. KAPB study accomplished in 1989 in a school environment in Ouagadougou (Burkina Faso)] Ouedraogo A, et al. **Bull Soc Pathol Exot** 1996;89(1):41–4 (Eng. Abstr.) **(Fre)**
[AIDS: current epidemiology, diagnosis and therapy] Chidiac C. **Rev Stomatol Chir Maxillofac** 1995;96(4):227–9 **(Fre)**
[The Aids Research Prize 1996 (news)] **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):A37 **(Ger)**
[11th International AIDS Conference (news)] Schenk M. **Dtsch Med Wochenschr** 1996 Aug 23;121(34–35):A9 **(Ger)**
[DFG promotes AIDS research (news)] Schmidt D. **Dtsch Med Wochenschr** 1996 Aug 16;121(33):A11–2 **(Ger)**
[Acquired immunodeficiency syndrome—1995 (Part II)] Lasry Y, et al. **Harefuah** 1995 Dec 15;129(12):596–602 (97 ref.) **(Heb)**
[The level of information on AIDS among the university and secondary school students of Camerino] Grappasonni I, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):717–21 (Eng. Abstr.) **(Ita)**
[New anti-HIV drug which binds the oligosaccharides of HIV envelope glycoprotein] Mizuochi T, et al. **Nippon Rinsho** 1995 Sep;53(9):2340–9 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Hepatitis induced by HIV (human immunodeficiency virus)] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):141–3 (14 ref.) **(Jpn)**
[MUTAN—an AIDS project in Tanzania] Bergsjø P. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3233–4 **(Nor)**
[The global offensive against AIDS: together for the future (materials of the 10th International AIDS Congress) (news)] Shcherbinskaia AM. **Mikrobiol Z** 1995 Jul–Aug; 57(4):108–11 **(Rus)**
[Basic results of studies on AIDS from 1994] Pokrovskiĭ VI, et al. **Vopr Virusol** 1995 Nov–Dec;40(6):242–6 (0 ref.) **(Rus)**
[AIDS: the Spanish view] Schüller DA. **An R Acad Nac Med (Madr)** 1996;Spec No:157–81; discussion 181–2 (73 ref.) **(Spa)**
[The development of a test for evaluating the knowledge of and attitudes on human immunodeficiency virus infection in primary health care professionals] Llobera Serentill A, et al. **Aten Primaria** 1996 May 31;17(9):564–9 (Eng. Abstr.) **(Spa)**
[The impact of AIDS in the global mortality in Catalonia, 1981–1993] Blanch Mur C, et al. **Med Clin (Barc)** 1995 Oct 28;105(14):528–31 (Eng. Abstr.) **(Spa)**
[Sidoso and sídico: 2 Spanish adjectives for AIDS (letter)] Navarro FA. **Med Clin (Barc)** 1996 May 25;106(20):797 **(Spa)**
[AIDS and human rights] Rico B, et al. **Salud Publica Mex** 1995 Nov–Dec;37(6):661–8 (Eng. Abstr.) **(Spa)**
[Two different HIV types are known. The differences may explain mechanisms of the infection] Andersson S, et al. **Lakartidningen** 1996 Jun 5;93(23):2230, 2235–6 (37 ref.) **(Swe)**
[10 years of experiences with HIV and AIDS care. A report from a dermato-venereological clinic] Bergbrant IM, et al. **Lakartidningen** 1995 Nov 8;92(45):4172–4 **(Swe)**
[The First National Scientific and Practical Conference on the Problems of HIV/AIDS with international participation] Spivak MIa. **Mikrobiol Z** 1996 Jan–Feb; 58(1):108–11 **(Ukr)**

BLOOD

Serum nitrite concentration suggests a role for nitric oxide in AIDS [letter] Baldeweg T, et al. **AIDS** 1996 Apr; 10(4):451–2
Evaluation of murine leukemia virus infection as a model for thrombocytopenia of HIV/AIDS: mechanism of thrombocytopenia and modulation of thrombocytopenia by thrombopoietin. Sullivan PS, et al. **AIDS Res Hum Retroviruses** 1995 Jul;11(7):837–42
Predicting progression to AIDS [editorial; comment] Greene WC. **Ann Intern Med** 1995 Nov 1;123(9):726–7. Comment on: Ann Intern Med 1995 Nov 1;123(9):641–8.
Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1. Thea DM, et al. **Ann Intern Med** 1996 Apr 15;124(8):757–62
Abnormal serum porphyrin levels in patients with the acquired immunodeficiency syndrome with or without hepatitis C virus infection. Nomura N, et al. **Arch Dermatol** 1996 Aug;132(8):906–10
Interferon and tumor necrosis factor responses of HIV+ patients as markers for monitoring of the AIDS progression. Piasecki E, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(5–6):439–45
Impairment of circulating lactoferrin in HIV-1 infection. Defer MC, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May; 41(3):417–21
Blood monocytes from most human immunodeficiency virus type 1-infected patients do not carry proviral DNA. Shen Y, et al. **Clin Diagn Lab Immunol** 1994 Sep;1(5):531–7
Reversal of immunosuppression of lymphocyte proliferation caused by sera from persons with AIDS. Tomar RH, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):408–11
Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Frost RA, et al. **Clin Endocrinol (Oxf)** 1996 May;44(5):501–14
Increased levels of nitrite in the sera of children infected with human immunodeficiency virus type 1. Torre D, et al. **Clin Infect Dis** 1996 Apr;22(4):650–3
Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with the CD4 cell counts. Laudat A, et al. **Eur J Endocrinol** 1995 Oct;133(4):418–24
Clastogenic factors in plasma of HIV-1 infected patients. Fuchs J, et al. **Free Radic Biol Med** 1995 Dec;19(6):843–8
Levels of the circulating cell adhesion molecule E-selectin and disease progression in HIV infection. Sfikakis PP, et al. **Infection** 1995 Jul–Aug;23(4):207–11
Cross-linking of Fc gamma receptors activates HIV-1 long terminal repeat-driven transcription in human monocytes. Tsitsikov EN, et al. **Int Immunol** 1995 Oct;7(10):1665–70
T-lymphocytes from AIDS patients are unable to synthesize ribonucleotides de novo in response to mitogenic stimulation. Impaired pyrimidine responses are already evident at early stages of HIV-1 infection. Bofil M, et al. **J Biol Chem** 1995 Dec 15;270(50):29690–7
Pseudouridine and 1-ribosylpyridin-4-one-3-carboxamide (PCNR) serum concentrations in human immunodeficiency virus type 1-infected patients are independent predictors for AIDS progression. Intrieri M, et al. **J Infect Dis** 1996 Jul;174(1):199–203
Interleukin-10 enhances human immunodeficiency virus type 1 expression in a chronically infected promonocytic cell line (U1) by a tumor necrosis factor alpha-independent mechanism. Angel JB, et al. **J Interferon Cytokine Res** 1995 Jun;15(6):575–84
Increased soluble tumor necrosis factor receptor expression and release by human immunodeficiency virus type 1 infection. Kalinkovich A, et al. **J Interferon Cytokine Res** 1995 Sep;15(9):749–57
Regulation and characterization of the interferon-alpha present in patients with advanced human immunodeficiency virus type 1 disease. Swindells S, et al. **J Interferon Cytokine Res** 1996 Feb;16(2):127–37
Longitudinal study of adrenal steroids in a cohort of HIV-infected patients with hemophilia [see comments] Chatterton RT Jr, et al. **J Lab Clin Med** 1996 Jun; 127(6):545–52. Comment in: J Lab Clin Med 1996 Jun;127(6):522–3.
[Reversed electrophoresis] Grasland A, et al. **Rev Med Interne** 1995;16(10):790–1 **(Fre)**
[Methemoglobin in AIDS (letter)] Ansovini R. **Recenti Prog Med** 1995 Nov;86(11):463–4 **(Ita)**
[Serological evaluation for human immunodeficiency virus (HIV) and for hepatitis B (HBV) among candidates who have passed the admission tests at a hospital institution in São Paulo] Uip DE, et al. **Rev Assoc Med Bras** 1995 Mar–Apr;41(2):141–3 (Eng. Abstr.) **(Por)**

CEREBROSPINAL FLUID

Mycobacterium avium complex (MAC): an unusual potential pathogen in cerebrospinal fluid of AIDS patients. Hadad DJ, et al. **Rev Inst Med Trop Sao Paulo** 1995 Mar–Apr; 37(2):93–8
Bacterial agents isolated from cerebrospinal fluid of patients with acquired immunodeficiency syndrome (AIDS) and neurological complications. Landgraf IM, et al. **Rev Inst Med Trop Sao Paulo** 1994 Nov–Dec;36(6):491–6
[Beta-2 microglobulin in cerebrospinal fluid in neurology] Beyne P, et al. **Presse Med** 1995 Jun 24;24(23):1071–4 (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Clinical staging system for AIDS patients [letter; comment] Cozzi Lepri A, et al. **Lancet** 1995 Oct 21;346(8982):1103 . Comment on: Lancet 1995 Jul 1;346(8966):12–7.
Clinical staging system for AIDS patients [letter; comment] Hill AM. **Lancet** 1995 Sep 30;346(8979):911. Comment on: Lancet 1995 Jul 1;346(8966):12–7.
Clinical staging system for AIDS in Edinburgh [letter; comment] Hutchinson SJ, et al. **Lancet** 1996 May 11; 347(9011):1341. Comment on: Lancet 1995 Jul 1;346(8966):12–7.
The severity classification system for acquired immunodeficiency syndrome hospitalizations. Association with survival after discharge and inpatient resource use. Friedman LA, et al. **Med Care** 1996 Feb;34(2):178–89
[The clinical laboratory in the diagnosis, classification, and follow-up of patients with HIV/AIDS infection] **Gac Med Mex** 1994 Jan–Feb;130(1):26–7 **(Spa)**

COMPLICATIONS

Rapidly developing neurological symptoms in a 40-year-old man with AIDS [clinical conference] Brohée P, et al. **Acta Neurol Belg** 1995 Dec;95(4):239–43
Role of HIV in the pathogenesis of distal symmetrical peripheral neuropathy. Rizzuto N, et al. **Acta Neuropathol (Berl)** 1995;90(3):244–50
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antinori A, et al. **AIDS** 1995 Dec; 9(12):1343–50
Metronidazole treatment in a patient with AIDS and visceral leishmaniasis [letter] Arranz-Caso JA, et al. **AIDS** 1995 Dec;9(12):1377–8
Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. Bell JE, et al. **AIDS** 1996 May; 10(5):493–9
Employment of recombinant human granulocyte-macrophage colony stimulating factor in oesophageal candidiasis in AIDS patients [letter] Capetti A, et al. **AIDS** 1995 Dec;9(12):1378–9
AIDS behind bars: preventing HIV spread among incarcerated drug injectors [editorial] Dolan K, et al. **AIDS** 1995 Aug;9(8):825–32 (72 ref.)
Diagnosis and prognosis of AIDS-related cholangitis.

Ducreux M, et al. **AIDS** 1995 Aug;9(8):875–80

Survival after AIDS among Italian haemophiliacs with HIV infection. The Italian Group on Congenital Coagulopathies. Ghirardini A, et al. **AIDS** 1995 Dec;9(12):1351–6

Non-Hodgkin's lymphoma and Kaposi's sarcoma causing cavitary lung lesions in a patient with AIDS: an HIV-associated collision tumor [letter] Ko AH, et al. **AIDS** 1995 Oct;9(10):1195–7

Necrotizing maxillary sinus mucormycosis related to candidiasis and microsporidiosis in an AIDS patient [letter] Pedro-de-Lelis FJ, et al. **AIDS** 1995 Dec;9(12):1386–8

Interest and reliability of a polymerase chain reaction on bone-marrow samples in the diagnosis of visceral leishmaniasis in AIDS [letter] Piarroux R, et al. **AIDS** 1996 Apr;10(4):452–3

Tuberculous brain abscess should be considered in HIV/AIDS patients [letter] Velasco-Martínez JJ, et al. **AIDS** 1995 Oct;9(10):1197–9 (16 ref.)

Pathophysiology and treatment of the AIDS wasting syndrome. Kotler DP, et al. **AIDS Clin Rev** 1995–96; :229–75 (211 ref.)

HIV type 1 V3 sequences and the development of dementia during AIDS. Di Stefano M, et al. **AIDS Res Hum Retroviruses** 1996 Apr 10;12(6):471–6

Peripheral blood T cell subsets as prognostic indicators of chemotherapy outcome in AIDS patients with large cell lymphoma. Patarca R, et al. **AIDS Res Hum Retroviruses** 1996 May 20;12(8):645–9

Sequence analysis of the V3 loop in brain and spleen of patients with HIV encephalitis. Reddy RT, et al. **AIDS Res Hum Retroviruses** 1996 Apr 10;12(6):477–82

Detection and differential diagnosis of pulmonary infections and tumors in patients with AIDS: value of chest radiography versus CT. Kang EY, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):15–9

Pancreaticobiliary manifestations of AIDS. Miller FH, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1269–74

AIDS diarrhea: new kid on the paraffin-block. Flemmer M, et al. **Am J Gastroenterol** 1996 Feb;91(2):402–3

Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration. Guillaume MP, et al. **Am J Gastroenterol** 1996 Jan;91(1):165–8 (14 ref.)

AIDS and esophageal tuberculosis. Quader Z, et al. **Am J Gastroenterol** 1995 Dec;90(12):2237–8

Doxorubicin liposome formulation gains marketing approval [news] **Am J Health Syst Pharm** 1996 Jan 15;53(2):116, 119

Abnormal chromatin clumping in polymorphonuclears from a patient with AIDS [letter] Ciaudo M, et al. **Am J Hematol** 1996 May;52(1):62–3

AIDS-related pure red cell aplasia [letter] Majluf-Cruz A, et al. **Am J Hematol** 1996 Feb;51(2):171

Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an HIV-positive patient: case report and review of the literature. Yospur LS, et al. **Am J Hematol** 1996 Jan;51(1):73–8 (29 ref.)

Long-term follow-up of endoscopic retrograde cholangiopancreatography sphincterotomy for patients with acquired immune deficiency syndrome papillary stenosis. Cello JP, et al. **Am J Med** 1995 Dec;99(6):600–3

Deterioration and death in a 30-year old male with AIDS [clinical conference] Ludmerer KM, et al. **Am J Med** 1996 May;100(5):571–8

Acquired immunodeficiency syndrome-related Kaposi's sarcoma: two cervical cases [letter] Darai E, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):979

Corneal lipidosis in patients with the acquired immunodeficiency syndrome [letter; comment] Diesenhouse MC, et al. **Am J Ophthalmol** 1995 Oct; 120(4):545–6. Comment on: Am J Ophthalmol 1995 Jan;119(1):14–9.

Squamous cell carcinoma of the conjunctiva in a patient with the acquired immunodeficiency syndrome. Muccioli C, et al. **Am J Ophthalmol** 1996 Jan;121(1):94–6

The ear in the acquired immunodeficiency syndrome: II. Clinical and audiologic investigation. Soucek S, et al. **Am J Otol** 1996 Jan;17(1):35–9

Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Brown LF, et al. **Am J Pathol** 1996 Apr;148(4):1065–74

Charting a new course through the chaos of KS (Kaposi's sarcoma) [comment] Nickoloff BJ, et al. **Am J Pathol** 1996 May;148(5):1323–9 (82 ref.). Comment on: Am J Pathol 1996 May;148(5):1387–96.

Tuberculosis screening among homeless persons with AIDS living in single-room-occupancy hotels. Layton MC, et al. **Am J Public Health** 1995 Nov;85(11):1556–9

Presentation of AIDS-related pulmonary Kaposi's sarcoma diagnosed by bronchoscopy. Huang L, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1385–90

Penetrating trauma and emergency surgery in patients with AIDS. Carrillo EH, et al. **Am J Surg** 1995 Oct;170(4):341–4

Small bowel obstruction from gastrointestinal histoplasmosis in acquired immune deficiency syndrome. Spivak H, et al. **Am Surg** 1996 May;62(5):369–72

Fifth Seah Cheng Siang Memorial Lecture. Human immunodeficiency virus and the respiratory system—pulmonary manifestations of acquired immunodeficiency syndrome. Dudley A, et al. **Ann Acad Med Singapore** 1995 May;24(3):482–9 (35 ref.)

The chemical pathology of AIDS [letter] Crowley VE, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):511–2

Esophageal ulcers in AIDS [letter; comment] Couderc LJ, et al. **Ann Intern Med** 1996 May 15;124(10):928; discussion 928–9. Comment on: Ann Intern Med 1995 Jul 15;123(2):143–9.

Esophageal ulcers in AIDS [letter; comment] Domingo P, et al. **Ann Intern Med** 1996 May 15;124(10):928; discussion 928–9. Comment on: Ann Intern Med 1995 Jul 15;123(2):143–9.

Morphologic patterns and molecular pathways of AIDS-related head and neck and other systemic lymphomas [clinical conference] Carbone A, et al. **Ann Otol Rhinol Laryngol** 1996 Jun;105(6):495–9

Intralesional vinblastine for treating AIDS-associated Kaposi's sarcoma of the oropharynx and larynx. Friedman M, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):272–4

Widespread papules and nodules in a Ugandan man with acquired immunodeficiency syndrome. African blastomycosis. Cohen LM, et al. **Arch Dermatol** 1996 Jul; 132(7):821–2, 824

Disseminated strongyloidiasis in a patient with acquired immunodeficiency syndrome [letter] Kao D, et al. **Arch Dermatol** 1996 Aug;132(8):977–8

Disseminated acanthamebiasis in patients with AIDS. A report of five cases and a review of the literature. Murakawa GJ, et al. **Arch Dermatol** 1995 Nov; 131(11):1291–6

Appendicitis due to Mycobacterium avium complex in a patient with AIDS [letter] Domingo P, et al. **Arch Intern Med** 1996 May 27;156(10):1114

Anterior-segment ultrasound biomicroscopy in a patient with AIDS and bilateral angle-closure glaucoma secondary to uveal effusions [letter] Krzystolik MG, et al. **Arch Ophthalmol** 1996 Jul;114(7):878–9

Metastatic choroidal abscess in the acquired immunodeficiency syndrome [letter] Walton RC, et al. **Arch Ophthalmol** 1996 Jul;114(7):880–1

Cytomegalovirus keratitis in acquired immunodeficiency syndrome [clinical conference] Wilhelmus KR, et al. **Arch Ophthalmol** 1996 Jul;114(7):869–72

Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Albrecht H, et al. **Arch Pathol Lab Med** 1996 Feb;120(2):189–98 (53 ref.)

Pathology of microsporidiosis: emerging parasitic infections in patients with acquired immunodeficiency syndrome. Schwartz DA, et al. **Arch Pathol Lab Med** 1996 Feb; 120(2):173–88 (72 ref.)

Primary adrenal leiomyosarcoma in a man with acquired immunodeficiency syndrome (AIDS). Further evidence for an increase in smooth muscle tumors related to Epstein-Barr infection in AIDS. Zetler PJ, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1164–7 (19 ref.)

The relationship between rheumatoid arthritis and the acquired immunodeficiency syndrome: comment on the article by Ornstein et al [letter; comment] Adebajo AO, et al. **Arthritis Rheum** 1996 Aug;39(8):1437–9. Comment on: Arthritis Rheum 1995 Nov;38(11):1701–6.

A reexamination of the relationship between active rheumatoid arthritis and the acquired immunodeficiency syndrome [see comments] Ornstein MH, et al. **Arthritis Rheum** 1995 Nov;38(11):1701–6. Comment in: Arthritis Rheum 1996 Aug;39(8):1437–9.

AIDS and the eye. A 10-year experience. Maclean H, et al. **Aust N Z J Ophthalmol** 1996 Feb;24(1):61–7 (18 ref.)

Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs. Humphrey RW, et al. **Blood** 1996 Jul 1;88(1):297–301

Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Nador RG, et al. **Blood** 1996 Jul 15; 88(2):645–56

Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial. Kelly P, et al. **BMJ** 1996 May 11; 312(7040):1187–91

Recent insights into the pathogenesis of Kaposi's sarcoma. Fife K, et al. **Br J Cancer** 1996 Jun;73(11):1317–22 (68 ref.)

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Goebel FD, et al. **Br J Cancer** 1996 Apr;73(8):989–94

Disseminated varioliform pustular eruption due to Mycobacterium avium intracellulare in an HIV-infected patient. Bachelez H, et al. **Br J Dermatol** 1996 Apr; 134(4):801–3

Muir-Torré syndrome in a patient with acquired immunodeficiency syndrome [letter] Graells J, et al. **Br J Dermatol** 1996 Jul;135(1):159–61

Cutaneous Pneumocystis carinii and Cryptococcus neoformans in AIDS. Sandler B, et al. **Br J Dermatol** 1996 Jan;134(1):159–63

Lichen myxoedematosus in a patient with AIDS. Tarantini G, et al. **Br J Dermatol** 1996 Jun;134(6):1122–4

Cytomegalovirus retinitis in an AIDS patient without severe depletion in CD4 cell count [letter] Baglivo E, et al. **Br J Ophthalmol** 1995 Oct;79(10):962–3

The challenge of HIV/AIDS related eye disease [editorial; comment] Courtright P. **Br J Ophthalmol** 1996 Jun; 80(6):496–7. Comment on: Br J Ophthalmol 1996 Jun;80(6):503–8.

Ultrastructural features and prevalence of tubuloreticular structures in the ocular vasculature of patients with AIDS: a study of 23 cases. Maturi RK, et al. **Br J Ophthalmol** 1996 Mar;80(3):252–5

Case report: Kaposi's sarcoma of the rectum--treatment with radiation therapy. Kaufmann T, et al. **Br J Radiol** 1996 Jun;69(822):573–4

Successful treatment of Reiter's syndrome in a patient with AIDS with methotrexate and corticosteroids [letter] Berenbaum F, et al. **Br J Rheumatol** 1996 Mar;35(3):295

Acute right iliac fossa pain in acquired immunodeficiency: a comparison between patients with and without acquired immune deficiency syndrome. Savioz D, et al. **Br J Surg** 1996 May;83(5):644–6

AIDS-associated vacuolar myelopathy. A morphometric study. Tan SV, et al. **Brain** 1995 Oct;118 (Pt 5):1247–61

Management of primary central nervous system lymphoma for the patient with acquired immunodeficiency syndrome. Confronting a clinical catch-22 [editorial; comment] Corn BW, et al. **Cancer** 1995 Jul 15;76(2):163–6. Comment on: Cancer 1995 Jul 15;76(2):328–32.

Combination chemotherapy with doxorubicin, bleomycin, and vindesine for AIDS-related Kaposi's sarcoma. Tavio M, et al. **Cancer** 1996 May 15;77(10):2117–22

AIDS-associated malignancies. Krown SE. **Cancer Chemother Biol Response Modif** 1996;16:441–61 (141 ref.)

Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Mori S, et al. **Cancer Res** 1996 Apr 15;56(8):1874–9

Kaposi's sarcoma in patients infected with human virus (HIV): an overview. Hermans P, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):357–64 (43 ref.)

Upper airway obstruction in a woman with AIDS-related laryngeal Kaposi's sarcoma. Beitler AJ, et al. **Chest** 1996 Mar;109(3):836–7

Intrathoracic Kaposi's sarcoma. CT findings. Khalil AM, et al. **Chest** 1995 Dec;108(6):1622–6

AIDS-related spontaneous pneumothorax. Risk factors and treatment. Metersky ML, et al. **Chest** 1995 Oct; 108(4):946–51

Spontaneous pneumothorax in children with AIDS. Schroeder SA, et al. **Chest** 1995 Oct;108(4):1173–6 (25 ref.)

Outcome of AIDS patients requiring mechanical ventilation predicted by recursive partitioning. El-Solh, AA, et al. **Chest** 1996 Jun;109(6):1584–90

Pericardial effusion in AIDS. Incidence and survival. Heidenreich PA, et al. **Circulation** 1995 Dec 1; 92(11):3229–34

Use of zidovudine in human immunodeficiency virus-induced hepatitis. Wertheim DL, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):361–3

Clinical features of adrenal insufficiency in patients with acquired immunodeficiency syndrome. Piédrola G, et al. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):97–101

Multiple pilomatricomas and myotonic dystrophy in a patient with AIDS. Farrell AM, et al. **Clin Exp Dermatol** 1995 Sep;20(5):423–4

Disappearance of cryoglobulins and remission of symptoms in a patient with HCV-associated type II mixed cryoglobulinemia after HIV-1 infection. Antinori S, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S157–9

Elevated cytokine levels in a patient with AIDS and hypercalcemia: effects of therapy with pamidronate [letter] Carbone LD, et al. **Clin Infect Dis** 1995 Sep;21(3):699

Fatal toxic epidermal necrolysis in patients with AIDS [letter; comment] Caumes E, et al. **Clin Infect Dis** 1995 Jul; 21(1):240. Comment on: Clin Infect Dis 1994 Aug;19(2):358–9.

Strongyloides stercoralis first-stage larvae in the lungs of a patient with AIDS: primary localization or a noninvasive form of dissemination? Cirioni O, et al. **Clin Infect Dis** 1996 Apr;22(4):737

Pasteurella pneumotropica pneumonia in a patient with AIDS [letter] Cuadrado-Gómez LM, et al. **Clin Infect Dis** 1995 Aug;21(2):445–6

Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS. Dautzenberg B, et al. **Clin Infect Dis** 1996 Apr;22(4):705–8

Progressive multifocal leukoencephalopathy as an AIDS-defining condition in a patient with human immunodeficiency virus infection [letter] Drexler JA, et al. **Clin Infect Dis** 1996 May;22(5):882–3

Unusual presentation of cryptococcosis in a patient with AIDS. Finazzi R, et al. **Clin Infect Dis** 1996 Apr;22(4):709

Cytomegalovirus-induced alveolar hemorrhage in patients with AIDS: a new clinical entity? Herry I, et al. **Clin Infect Dis** 1996 Apr;22(4):616–20

Diarrhea associated with Vibrio fluvialis infection in a patient with AIDS [letter] Hodge TW Jr, et al. **Clin Infect Dis** 1995 Jul;21(1):237–8

Factors associated with the development of Pneumocystis carinii pneumonia [letter] Hoover DR. **Clin Infect Dis** 1996 Apr;22(4):738–9

Rhodococcus equi mastoiditis in a patient with AIDS. Lopes Cardoso FL, et al. **Clin Infect Dis** 1996 Apr;22(4):713

Chronic varicella-zoster virus myelitis without cutaneous

eruption in a patient with AIDS: report of a fatal case. Manian FA, et al. **Clin Infect Dis** 1995 Oct;21(4):986–8

AIDS–associated cytomegalovirus infection mimicking central nervous system tumors: a diagnostic challenge. Moulignier A, et al. **Clin Infect Dis** 1996 Apr;22(4):626–31

Strongyloides stercoralis hyperinfection syndrome in a patient with AIDS: diagnosis by fluorescent microscopy. Nomura J, et al. **Clin Infect Dis** 1996 Apr;22(4):736

Simultaneous occurrence of acute myocarditis and reactivated Chagas' disease in a patient with AIDS. Sartori AM, et al. **Clin Infect Dis** 1995 Nov;21(5):1297–9

Cryptococcosis in the era of AIDS—100 years after the discovery of Cryptococcus neoformans. Mitchell TG, et al. **Clin Microbiol Rev** 1995 Oct;8(4):515–48 (529 ref.)

Sonographic prediction of a normal or abnormal ERCP in suspected AIDS related sclerosing cholangitis. Daly CA, et al. **Clin Radiol** 1996 Sep;51(9):618–21

Intraocular silicone oil for retinal detachment in AIDS: CT and MR appearances. Murray JG, et al. **Clin Radiol** 1996 Jun;51(6):415–7

Verruga peruana: an infectious endemic angiomatosis. Cáceres–Ríos H, et al. **Crit Rev Oncog** 1995;6(1):47–56 (96 ref.)

Cancer in AIDS. **Curr Opin Oncol** 1995 Sep;7(5):B89–90

An integrated approach to the epidemiology of Kaposi's sarcoma. Jacobson LP, et al. **Curr Opin Oncol** 1995 Sep; 7(5):450–5 (71 ref.)

Malignancies in pediatric AIDS. Mueller BU, et al. **Curr Opin Pediatr** 1996 Feb;8(1):45–9 (42 ref.)

Kaposi's sarcoma with an intense parasitization by Leishmania. Gallego MA, et al. **Cutis** 1996 Feb;57(2):103–5

Blue nails and acquired immunodeficiency syndrome: not always associated with azidothymidine use. Glaser DA, et al. **Cutis** 1996 Apr;57(4):243–4

Ofuji papuloerythroderma in a patient with the acquired immunodeficiency syndrome. García–Patos V, et al. **Dermatology** 1996;192(2):164–6 (23 ref.)

Rahnella aquatilis bacteremia in an HIV–infected intravenous drug abuser. Funke G, et al. **Diagn Microbiol Infect Dis** 1995 Jul;22(3):293–6 (8 ref.)

Diarrhea and quality of life in ambulatory HIV–infected patients. Watson A, et al. **Dig Dis Sci** 1996 Sep; 41(9):1794–800

Is the human immunodeficiency virus–related Kaposi's sarcoma epidemic coming to an end? Insights from the Tricontinental Seroconverter Study. Veugelers PJ, et al. **Epidemiology** 1995 Jul;6(4):382–6

Role of intralesional vinblastine administration in treatment of intraoral Kaposi's sarcoma in AIDS. Flaitz CM, et al. **Eur J Cancer B Oral Oncol** 1995 Jul;31B(4):280–5

Tuberculosis cutis miliaris disseminata due to multidrug–resistant Mycobacterium tuberculosis in AIDS patients. Antinori S, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):911–4

Role of antigenemia assay in the early diagnosis and prediction of human cytomegalovirus organ involvement in AIDS patients. Francisci D, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):498–503

Multiple myeloma associated with Epstein–Barr virus in an AIDS patient: a case report [letter] Ventura G, et al. **Eur J Haematol** 1995 Nov;55(5):332–4

Squamous cell carcinomas of the anus and infection with human papillomavirus in patients with AIDS. Muñoz–Jiménez F, et al. **Eur J Surg** 1996 Mar;162(3):251–3

Aetiology and prognostic factors of patients with AIDS presenting life–threatening acute respiratory failure. Torres A, et al. **Eur Respir J** 1995 Nov;8(11):1922–8

Progressive outer retinal necrosis (PORN) in AIDS patients: a different appearance of varicella–zoster retinitis. Pavesio CE, et al. **Eye** 1995;9 (Pt 3):271–6

Retinal detachment in AIDS–related cytomegalovirus retinitis. Sandy CJ, et al. **Eye** 1995;9 (Pt 3):277–81

Gastric toxoplasmosis in acquired immunodeficiency syndrome: antemortem diagnosis with histopathologic characterization. Alpert L, et al. **Gastroenterology** 1996 Jan; 110(1):258–64

Investigating diarrhea in patients with acquired immunodeficiency syndrome [editorial; comment] Crotty B, et al. **Gastroenterology** 1996 Jan;110(1):296–8. Comment on: Gastroenterology 1996 Jan;110(1):30–7.

Weight loss in acquired immunodeficiency syndrome: wasting or wanting not? Koretz RL. **Gastroenterology** 1996 Apr;110(4):1316–7

Disseminated cutaneous Mycobacterium tuberculosis infection in a patient with AIDS. Corbett EL, et al. **Genitourin Med** 1995 Oct;71(5):308–10

The haemolytic uraemic syndrome in patients with AIDS. Kelleher P, et al. **Genitourin Med** 1996 Jun;72(3):172–5

Non surgical treatment of empyema thoracis with intrapleural streptokinase in a patient with AIDS. Miller RF, et al. **Genitourin Med** 1995 Aug;71(4):259–61

Herpes simplex virus type 2 encephalitis and concomitant cytomegalovirus infection in a patient with AIDS: detection of virus–specific DNA in CSF by nested polymerase chain reaction. Miller RF, et al. **Genitourin Med** 1995 Aug;71(4):262–4

AIDS–related optic neuropathy: a histological, virological and ultrastructural study. Sadun AA, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Jul;233(7):387–98

Vulvar intraepithelial neoplasia in women infected with human immunodeficiency virus–1. Korn AP, et al. **Gynecol Oncol** 1996 Jun;61(3):384–6

Etiology, evaluation, and outcome of jaundice in patients with acquired immunodeficiency syndrome. Chalasani N, et al. **Hepatology** 1996 Apr;23(4):728–33

Hyperglycemia in an AIDS patient taking megestrol. Pimentel G, et al. **Hosp Pract (Off Ed)** 1996 Apr 15; 31(4):27–8

Ocular lesions in AIDS: a report of first two cases in India. Biswas J, et al. **Indian J Ophthalmol** 1995 Jun;43(2):69–72

Clinical and microscopical features of small–intestinal microsporidiosis in patients with AIDS. Caramello P, et al. **Infection** 1995 Nov–Dec;23(6):362–8

High risk of Kaposi's sarcoma and central nervous system lymphoma in the same individuals: a finding related to acquired immunodeficiency syndrome. Ahsan H, et al. **Int J Cancer** 1996 Apr 10;66(2):176–8

Kawasaki syndrome in an adult AIDS patient. Porneuf M, et al. **Int J Dermatol** 1996 Apr;35(4):292–4

Leprosy and AIDS in the Amazon basin [letter] Schettini AP, et al. **Int J Lepr Other Mycobact Dis** 1996 Jun; 64(2):171–3

Spectrum of opportunistic infections among AIDS patients in Tamil Nadu, India. Kumarasamy N, et al. **Int J STD AIDS** 1995 Nov–Dec;6(6):447–9

Chlamydia trachomatis as a possible cofactor for Kaposi's sarcoma in AIDS. Peters BS, et al. **Int J STD AIDS** 1995 Nov–Dec;6(6):422–5

Kaposi's sarcoma in the kidney. Pollok RC, et al. **Int J STD AIDS** 1995 Jul–Aug;6(4):289–90

Posterior uveitis in the acquired immunodeficiency syndrome. McCluskey PJ, et al. **Int Ophthalmol Clin** 1995 Spring;35(2):1–14 (20 ref.)

A hemophiliac with human immunodeficiency virus (HIV)–1–associated dementia complex [see comments] Arimura H, et al. **Intern Med** 1995 Oct;34(10):995–9 (12 ref.). Comment in: Intern Med 1995 Oct;34(10):935.

Comparison of therapeutic activity of fluconazole and itraconazole in the treatment of oesophageal candidiasis in AIDS patients: a double–blind, randomized, controlled clinical study. Barbaro G, et al. **Ital J Gastroenterol** 1995 May;27(4):175–80

Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. Chiesi A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):39–44

A phase II study of recombinant human interferon–alpha 2a and zidovudine in patients with AIDS–related Kaposi's sarcoma. AIDS Clinical Trials Group. Fischl MA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 1;11(4):379–84

IL–6 and b–FGF overproductions precede development of AIDS–associated Kaposi's sarcoma [letter] Lafeuillade A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):95–6

Efficacy, safety, and tolerance of low–dose, long–term interferon–alpha 2b and zidovudine in early–stage AIDS–associated Kaposi's sarcoma. Mauss S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):157–62

Mycobacterial infection in Mexican AIDS patients. Molina–Gamboa JD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):53–8

Campylobacter spp. bacteremia in AIDS patients [letter; comment] Pigrau C, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):93–5. Comment on: J Acquir Immune Defic Syndr Hum Retrovirol 1995 Jan 1;8(1):51–7.

Neurologic manifestations of AIDS: a comparative study of two populations from Mexico and the United States. Trujillo JR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Jan 1;8(1):23–9

Human immunodeficiency virus and acquired immune deficiency syndrome AIDS–related hearing disorders. Madriz JJ, et al. **J Am Acad Audiol** 1995 Sep;6(5):358–64 (48 ref.)

Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. Berger TG, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):837–8

Cutaneous cryptococcosis and histoplasmosis coinfection in a patient with AIDS. Myers SA, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):898–900

Epidermal expression of 65 and 72 kd heat shock proteins in psoriasis and AIDS–associated psoriasiform dermatitis. Puig L, et al. **J Am Acad Dermatol** 1995 Dec;33(6):985–9

Clinical and histopathologic features of hair loss in patients with HIV–1 infection. Smith KJ, et al. **J Am Acad Dermatol** 1996 Jan;34(1):63–8

Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. Doucet–Populaire F, et al. **J Antimicrob Chemother** 1995 Jul;36(1):129–36

Correlation of in–vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. Rodríguez–Tudela JL, et al. **J Antimicrob Chemother** 1995 Jun;35(6):793–804

Marked variation in pyrimethamine disposition in AIDS patients treated for cerebral toxoplasmosis. Winstanley P, et al. **J Antimicrob Chemother** 1995 Aug;36(2):435–9

Total knee arthroplasty in human immunodeficiency virus–infected hemophiliacs. Unger AS, et al. **J Arthroplasty** 1995 Aug;10(4):448–52

Ethical aspects of assisted reproduction in AIDS patients. Rojansky N, et al. **J Assist Reprod Genet** 1995 Sep; 12(8):537–42

Liposomal doxorubicin (Doxil). Porche DJ. **J Assoc Nurses AIDS Care** 1996 Mar–Apr;7(2):55–9 (6 ref.)

Cultured AIDS–related Kaposi's sarcoma (AIDS–KS) cells demonstrate impaired bioenergetic adaptation to oxidant challenge: implication for oxidant stress in AIDS–KS pathogenesis. Mallery SR, et al. **J Cell Biochem** 1995 Nov; 59(3):317–28

AIDS–associated intussusception in young adults. Wood BJ, et al. **J Clin Gastroenterol** 1995 Sep;21(2):158–62

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS–related Kaposi's sarcoma. Gill PS, et al. **J Clin Oncol** 1996 Aug; 14(8):2353–64

Observations on two cases of apparent submandibular gland cysts in HIV positive patients: MR and CT findings. Gottesman RI, et al. **J Comput Assist Tomogr** 1996 May–Jun;20(3):444–7

CT of disseminated plasmacytoma in an AIDS patient. Leder DS, et al. **J Comput Assist Tomogr** 1996 May–Jun; 20(3):468–70

Human herpesvirus–8/Kaposi's sarcoma–associated herpesvirus is a new transmissible virus that infects B cells. Mesri EA, et al. **J Exp Med** 1996 May 1;183(5):2385–90

Detection and sequence analysis of a new herpesvirus–like agent in AIDS and non–AIDS Kaposi's sarcoma in Taiwan. Su IJ, et al. **J Formos Med Assoc** 1996 Jan;95(1):13–8

Mucormycosis of the upper limb. al–Qattan MM, et al. **J Hand Surg [Br]** 1996 Apr;21(2):261–2

Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. Goletti D, et al. **J Immunol** 1996 Aug 1;157(3):1271–8

Intestinal microsporidiosis with Septata intestinalis in a patient with AIDS—response to albendazole. Franzen C, et al. **J Infect** 1995 Nov;31(3):237–9

Toxoplasma pneumonia in a patient with AIDS [letter] Halme M, et al. **J Infect** 1995 Nov;31(3):252–3

Epstein–Barr virus (EBV) DNA in saliva and EBV serology of HIV–1–infected persons with and without hairy leukoplakia. Lucht E, et al. **J Infect** 1995 Nov;31(3):189–94

Acute myelogenous leukaemia followed by non–Hodgkin's lymphoma in a patient with AIDs. Rabaud C, et al. **J Infect** 1995 Jul;31(1):69–70

Better efficacy of twice–monthly than monthly aerosolised pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. An Italian multicentric randomised controlled trial. The Italian PCP Study Group. Rizzardi GP, et al. **J Infect** 1995 Sep; 31(2):99–105

Once–weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome. Hodge WG, et al. **J Infect Dis** 1996 Aug;174(2):393–6

Synthesis of tumor necrosis factor–alpha mRNA in bronchoalveolar lavage cells from human immunodeficiency virus–infected persons with Pneumocystis carinii pneumonia. Rayment N, et al. **J Infect Dis** 1996 Sep;174(3):654–9

Disseminated Mycobacterium avium complex: correlation between blood and tissue burden. Torriani FJ, et al. **J Infect Dis** 1996 Apr;173(4):942–9

High prevalence of human T cell lymphotropic virus type II infection in patients affected by human immunodeficiency virus type 1—associated predominantly sensory polyneuropathy. Zehender G, et al. **J Infect Dis** 1995 Dec;172(6):1595–8

The spectrum of non–AIDS–defining neoplastic disease in HIV infection. Remick SC. **J Investig Med** 1996 Jun; 44(5):205–15 (183 ref.)

Acute Sjögren–like syndrome as the first manifestation of a generalized CMV infection in a patient with AIDS. Van Vooren JP, et al. **J Laryngol Otol** 1995 Nov;109(11):1113–4

Candida albicans isolates from HIV–infected and AIDS patients exhibit enhanced adherence to epithelial cells. Sweet SP, et al. **J Med Microbiol** 1995 Dec;43(6):452–7

Herpesvirus–like DNA sequences in classic Kaposi's sarcomas. Rady PL, et al. **J Med Virol** 1995 Oct; 47(2):179–83

AIDS malignancy research gets a home at NCI [news] McNeil C. **J Natl Cancer Inst** 1996 Mar 20;88(6):320–1

Subacute sclerosing panencephalitis and acquired immunodeficiency syndrome: role of electroencephalography and magnetic resonance imaging. Koppel BS, et al. **J Neuroimaging** 1996 Apr;6(2):122–5

Necrotizing fasciitis of the cervical region in an AIDS patient: report of a case. Chidzonga MM. **J Oral Maxillofac Surg** 1996 May;54(5):638–40

Uganda: status of cancer pain and palliative care. Merriman A. **J Pain Symptom Manage** 1996 Aug;12(2):141–3

Cardiomyopathy related to acquired immunodeficiency syndrome in children [letter; comment] Steinherz LJ. **J Pediatr** 1996 May;128(5 Pt 1):721. Comment on: J Pediatr 1995 Jul;127(1):137–46.

AIDS–related malignancies. Spittle MF. **J R Soc Med** 1996 Jan;89(1):35P–6P (0 ref.)

Rheumatoid papules in a patient with acquired immune deficiency syndrome and symmetric polyarthritis. Golden BD, et al. **J Rheumatol** 1996 Apr;23(4):760–2

Clinical investigation of traditional Chinese medicine and pharmacy in treating respiratory tract infections in AIDS.

Li G, et al. **J Tradit Chin Med** 1996 Mar;16(1):3–6

Impact of the human immunodeficiency virus type–1 on common pediatric illnesses in Zambia. Chintu C, et al. **J Trop Pediatr** 1995 Dec;41(6):348–53

Micturition disturbances and human immunodeficiency virus infection. Hermieu JF, et al. **J Urol** 1996 Jul;156(1):157–9

Kaposi sarcoma of the conjunctiva [letter; comment] Flowers CW Jr, et al. **JAMA** 1996 May 22–29;275(20):1545. Comment on: JAMA 1996 Jan 10;275(2):142–4.

Megestrol acetate in patients with AIDS–related cachexia. Bell SJ, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar–Apr;20(2):165–6

A young child with Kawasaki syndrome and AIDS [letter] [see comments] Aladhami SMS, et al. **Lancet** 1996 Mar 30;347(9005):912–3. Comment in: Lancet 1996 Jul 20;348(9021):202.

Porphyria cutanea tarda preceding AIDS [letter] Ash S, et al. **Lancet** 1996 Jan 20;347(8995):190

Erythema elevatum diutinum with HIV–2 infection [letter] Bachmeyer C, et al. **Lancet** 1996 Apr 13;347(9007):1041–2

'Chicane–like' airway as a complication of lingual tonsils [letter] Conacher ID, et al. **Lancet** 1996 Aug 17; 348(9025):475

Invasive pneumococcal disease in a cohort of predominantly HIV–1 infected female sex–workers in Nairobi, Kenya [see comments] Gilks CF, et al. **Lancet** 1996 Mar 16; 347(9003):718–23. Comment in: Lancet 1996 May 18;347(9012):1414.

HIV–related oral disease. Greenspan D, et al. **Lancet** 1996 Sep 14;348(9029):729–33 (38 ref.)

Kaposi's sarcoma and KSHV [letter; comment] Ioachim HL. **Lancet** 1995 Nov 18;346(8986):1360. Comment on: Lancet 1995 Sep 23;346(8978):799–802.

HIV–associated diarrhoea and wasting [letter; comment] Malnick SD. **Lancet** 1995 Nov 11;346(8985):1304. Comment on: Lancet 1995 Aug 5;346(8971):352–6.

HIV infection and neoplasia. Schulz TF, et al. **Lancet** 1996 Aug 31;348(9027):587–91 (50 ref.)

Thalidomide effective for AIDS–related oral ulcers [news] Thompson C. **Lancet** 1995 Nov 11;346(8985):1289

Microsporidian sinusitis in patients with the acquired immunodeficiency syndrome. Rossi RM, et al. **Laryngoscope** 1996 Aug;106(8):966–71

Nodal inclusion cysts of the parotid gland and parapharyngeal space: a discussion of lymphoepithelial, AIDS–related parotid, and branchial cysts, cystic Warthin's tumors, and cysts in Sjögren's syndrome. Som PM, et al. **Laryngoscope** 1995 Oct;105(10):1122–8

Detection of HHV–8/KSHV DNA sequences in AIDS–associated extranodal lymphoid malignancies. Otsuki T, et al. **Leukemia** 1996 Aug;10(8):1358–62

Correlation between AIDS–related Kaposi sarcoma histological grade and in vitro behavior: reduced exogenous growth factor requirements for isolates from high grade lesions. Bailer RT, et al. **Lymphology** 1995 Sep;28(3):126–37

Hodgkin's disease as an indicator of AIDS. Gerold M, et al. **Med Hypotheses** 1995 Jul;45(1):76–82 (113 ref.)

Typothesis explaining simultaneous development of acquired immunodeficiency syndrome and malignant tumors. Gogichadze GK, et al. **Med Hypotheses** 1995 May; 44(5):307–8

Managing HIV. Part 5: Treating secondary outcomes. 5.17 HIV, weight loss and wasting syndrome. Kelly MD, et al. **Med J Aust** 1996 May 6;164(9):549–50 (9 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.14 HIV and Kaposi's sarcoma. Millar JL, et al. **Med J Aust** 1996 May 6;164(9):539–42 (16 ref.)

Massive gastrointestinal hemorrhage from AIDS–related Kaposi's sarcoma confined to the small bowel managed with radiation. Neville CR, et al. **Med Pediatr Oncol** 1996 Feb;26(2):135–8

Sulfadiazine–associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Becker K, et al. **Medicine (Baltimore)** 1996 Jul;75(4):185–94 (56 ref.)

Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV–infected individuals. Sullivan DJ, et al. **Microbiology** 1995 Jul;141 (Pt 7):1507–21

Simultaneous development of two different B–cell lymphomas in a patient with acquired immune deficiency syndrome evidenced by molecular analysis. Dubus P, et al. **Mod Pathol** 1995 Oct;8(8):825–9

Leprosy in five human immunodeficiency virus–infected patients. Moran CA, et al. **Mod Pathol** 1995 Aug;8(6):662–4

Testosterone wasting and AIDS [news] Holzman D. **Mol Med Today** 1996 Mar;2(3):93

The lung in HIV infection: can pulmonary function testing help? Mitchell DM, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):214–22 (30 ref.)

Phialophora verrucosa infection in an AIDS patient. Duggan JM, et al. **Mycoses** 1995 May–Jun;38(5–6):215–8

A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome [see comments] Pierce M, et al. **N Engl J Med** 1996 Aug 8;335(6):384–91. Comment in: N Engl J Med 1996 Aug 8;335(6):428–30.

A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma. Schalling M, et al. **Nat Med** 1995 Jul;1(7):707–8

Keeping a lid on marijuana research [news] Steele FR. **Nat Med** 1995 Sep;1(9):853–4

AIDS, drugs, and the adolescent. Steel E. **NIDA Res Monogr** 1995;156:130–45 (34 ref.)

Characteristics of women with AIDS and invasive cervical cancer. Klevens RM, et al. **Obstet Gynecol** 1996 Aug; 88(2):269–73

Acquired immunodeficiency syndrome (AIDS) and the eye. Armstrong RA. **Ophthalmic Physiol Opt** 1995 Sep;15 Suppl 2:S42–8 (25 ref.)

Large oral ulcers leading to the destruction of the tonsils in patients with AIDS. Chaudhry R, et al. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):474–8

Tuberculous and nontuberculous mycobacterial infection of the pancreas in a patient with AIDS [letter] Albu E, et al. **Pancreas** 1996 May;12(4):412–3

Acute pancreatitis in an octreotide–treated AIDS patient—suggested alternative mechanisms [letter; comment] Harris AG, et al. **Pancreas** 1995 Oct;11(3):318–9 . Comment on: Pancreas 1994 May;9(3):395–7.

CMV–IGG avidity and CMV–IGM concentration in both immunocompromised and immunocompetent patients. Dussaix E, et al. **Pathol Biol (Paris)** 1996 May;44(5):405–10

Gastrointestinal and nutritional problems in children with immunodeficiency and AIDS. Winter H, et al. **Pediatr Clin North Am** 1996 Apr;43(2):573–90 (40 ref.)

Kaposi sarcoma in a Thai boy with acquired immunodeficiency syndrome. Pruksachatkunakorn C, et al. **Pediatr Dermatol** 1995 Sep;12(3):252–5

Life–threatening gastrointestinal bleeding caused by aphthous ulcers in a patient with perinatal acquired immunodeficiency syndrome. Bonafede MC, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1117–9

Fatal ceftriaxone–induced hemolysis in a child with acquired immunodeficiency syndrome. Borgna–Pignatti C, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1116–7

Multilocular thymic cyst in a child with acquired immunodeficiency syndrome. Shalaby–Rana E, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):83–6

Adrenal gland leiomyoma in a child with acquired immunodeficiency syndrome. Jimenez–Heffernan JA, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):923–9 (22 ref.)

Application of thin–section low–dose chest CT (TSCT) in the management of pediatric AIDS. Ambrosino MM, et al. **Pediatr Radiol** 1995;25(5):393–400

Extensive vascular calcification in a patient with perinatally acquired AIDS. Marquis JR, et al. **Pediatr Radiol** 1996; 26(5):365–6

The role of clarithromycin in the prophylaxis of disseminated Mycobacterium avium–intracellulare infection in patients with AIDS. Mertl SL. **Pharmacotherapy** 1996 May–Jun; 16(3):393–400

Hyperkalemia associated with high–dose trimethoprim–sulfamethoxazole in a patient with the acquired immunodeficiency syndrome. Mihm LB, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):793–7

Massive reversible pulmonary cysts in a patient with AIDS. Collazos J, et al. **Postgrad Med J** 1995 Dec;71(842):753–4

AIDS–associated Kaposi's sarcoma: a new perspective of its pathogenesis and treatment. Ensoli B, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):8–18 (90 ref.)

HIV–associated renal disease in London hospitals. Connolly JO, et al. **QJM** 1995 Sep;88(9):627–34

Disseminated disease due to Mycobacterium avium complex in AIDS. Flegg PJ, et al. **QJM** 1995 Sep;88(9):617–26

Screening for cytomegalovirus retinitis in HIV–positive and AIDS patients. Sandy CJ, et al. **QJM** 1995 Dec; 88(12):899–903

Gastrointestinal manifestations of acquired immunodeficiency syndrome: radiologic–pathologic correlation. Pantongrag–Brown L, et al. **Radiographics** 1995 Sep; 15(5):1155–78 (105 ref.)

Human immunodeficiency virus infection and multilocular thymic cysts. Leonidas JC, et al. **Radiology** 1996 Feb; 198(2):377–9

Unusual lymphoproliferative disorders in nine adults with HIV or AIDS: CT and pathologic findings. McGuinness G, et al. **Radiology** 1995 Oct;197(1):59–65

Bacillary angiomatosis in patients with AIDS: multiorgan imaging findings [published erratum appears in Radiology 1995 Nov;197(2):549] Moore EH, et al. **Radiology** 1995 Oct; 197(1):67–72

Use of furazolidone for the treatment of microsporidiosis due to Enterocytozoon bieneusi in patients with AIDS. Dionisio D, et al. **Recenti Prog Med** 1995 Oct;86(10):394–7

Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective. Benson CA. **Res Microbiol** 1996 Jan–Feb;147(1–2):16–24 (43 ref.)

Current problems with tuberculosis treatment. Grosset J. **Res Microbiol** 1996 Jan–Feb;147(1–2):10–6 (32 ref.)

Solving the dilemma of antimycobacterial chemotherapy. Rastogi N, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):7–10 (30 ref.)

Poorly differentiated non–small cell carcinoma of the lung in acquired immunodeficiency syndrome. Mady BJ. **Respiration** 1995;62(4):232–3

Simultaneous syphilitic necrotizing retinitis and placoid chorioretinitis in acquired immune deficiency syndrome. Dodds EM, et al. **Retina** 1995;15(4):354–6

Paracoccidioidomycosis associated with acquired immunodeficiency syndrome. Report of seven cases. Marques SA, et al. **Rev Inst Med Trop Sao Paulo** 1995 May–Jun;37(3):261–5

AIDS tumor bank [news] **Science** 1995 Dec 8;270(5242):1571, 1573

Reports bolster viral cause of KS [news] Cohen J. **Science** 1996 Aug 2;273(5275):573

AIDS related cholangitis [letter; comment] Staines JD, et al. **Scott Med J** 1995 Jun;40(3):73. Comment on: Scott Med J 1995 Apr;40(2):53–4.

CT/MRI of musculoskeletal complications of AIDS. Wyatt SH, et al. **Skeletal Radiol** 1995 Oct;24(7):481–8 (21 ref.)

Hyponatremia in pediatric patients with HIV–1 infection. Tolaymat A, et al. **South Med J** 1995 Oct;88(10):1039–42

AIDS and cerebrovascular disease. Pinto AN. **Stroke** 1996 Mar;27(3):538–43 (61 ref.)

Complications of laparoscopic cholecystectomy in HIV and AIDS patients. Carroll BJ, et al. **Surg Endosc** 1995 Aug; 9(8):874–8

AIDS and hemophilia—current issues. Evatt BL. **Thromb Haemost** 1995 Jul;74(1):36–9 (46 ref.)

Epidemic AIDS–related Kaposi's sarcoma in southern Africa: experience at the Johannesburg General Hospital (1980–1990). Stein ME, et al. **Trans R Soc Trop Med Hyg** 1994 Jul–Aug;88(4):434–6

Factors associated with extrapulmonary tuberculosis as an AIDS–defining disease in Europe. The Coordinators of AIDS surveillance in Austria, Belgium, France, Germany, Italy, Portugal, Switzerland, United Kingdom and the city of Amsterdam. Schwoebel V, et al. **Tuber Lung Dis** 1995 Aug;76(4):281–5

Tuberculosis among European patients with the acquired immune deficiency syndrome. The AIDS in Europe Study Group. Sudre P, et al. **Tuber Lung Dis** 1996 Aug; 77(4):322–8

Pott's disease of the cervico–occipital junction in an AIDS patient. Ventura G, et al. **Tuber Lung Dis** 1996 Apr; 77(2):188–90

Linkage between AIDS surveillance system and population–based cancer registry data in Italy: a pilot study in Florence, 1985–90. Barchielli A, et al. **Tumori** 1995 May–Jun;81(3):169–72

Epididymocutaneous fistula in a patient with the acquired immunodeficiency syndrome and Marfan's syndrome. Weiner DM, et al. **Urology** 1996 May;47(5):766–8 (14 ref.)

[What to do in a 60–year–old HIV–positive woman with a cerebral arteriovenous malformation? Decision analysis (see comments)] Dippel DW, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2362–9 (52 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1996 Feb 17;140(7):386–7. **(Dut)**

[HIV infection and AIDS in women and children (letter; comment)] Verkuyl DA. **Ned Tijdschr Geneeskd** 1995 Aug 26;139(34):1758–9. Comment on: Ned Tijdschr Geneeskd 1995 May 13;139(19):964–6. **(Dut)**

[Abdominal surgical emergencies in human immunodeficiency virus (HIV) infected patients. Apropos of 34 cases] Hammoud R, et al. **Ann Chir** 1995;49(10):922–7 (Eng. Abstr.) **(Fre)**

[Pigmented erythroderma in AIDS. 5 cases] Picard–Dahan C, et al. **Ann Dermatol Venereol** 1996;123(5):307–13 (Eng. Abstr.) **(Fre)**

[Local treatments of AIDS–related Kaposi disease] Saiag P, et al. **Ann Dermatol Venereol** 1995;122(8):551–7 (56 ref.) **(Fre)**

[Muscular involvement in the course of AIDS. Anatomo–clinical study of 17 cases] Butori C, et al. **Ann Pathol** 1995;15(6):424–30 (Eng. Abstr.) **(Fre)**

[Colonic Histoplasma capsulatum pseudotumor in AIDS. Morphological and immunohistochemical diagnosis of an isolated lesion] Hofman P, et al. **Arch Anat Cytol Pathol** 1995;43(3):140–6 (Eng. Abstr.) **(Fre)**

[A clinical study of cardiac manifestations related to acquired immunodeficiency syndrome (AIDS) in Kinsaha] Longo–Mbenza B, et al. **Arch Mal Coeur Vaiss** 1995 Oct; 88(10):1437–43 (Eng. Abstr.) **(Fre)**

[A case of disseminated Encephalitozoon intestinalis microsporidiosis in an AIDS patient in Nîmes] Delage A, et al. **Bull Soc Pathol Exot** 1995 Apr;88(5):229–33 (Eng. Abstr.) **(Fre)**

[ORL manifestations observed in AIDS. Apropos of 65 cases] Sacko HB, et al. **Bull Soc Pathol Exot** 1995 Apr;88(5):234–5 (Eng. Abstr.) **(Fre)**

[Prevalence of Cryptosporidium sp and Isospora belli in patients with acquired immunodeficiency syndrome (AIDS) in Dakar (Senegal] Dieng T, et al. **Dakar Med** 1994;39(2):121–4 (Eng. Abstr.) **(Fre)**

[Diagnostic and therapeutic management of diarrhea in human immunodeficiency virus infected patients] Benhamou Y, et al. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B136–44 **(Fre)**

[Helicobacter pylori, gastric acid secretion, ulcer disease and HIV infection] Blondon H, et al. **Gastroenterol Clin Biol** 1996;20(3):248–53 (49 ref.) **(Fre)**

[Esophago–gastroduodenal involvement in human immunodeficiency virus infection] Bouchaud O, et al. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B125–9 **(Fre)**

[Primary non–Hodgkin's lymphomas of the liver in human immunodeficiency virus infected patients. Three cases] Brugière O, et al. **Gastroenterol Clin Biol** 1996;20(3):307–11 (18 ref.) (Eng. Abstr.) **(Fre)**

[Parasitic and viral enteritis in human immunodeficiency virus infection] Cotte L, et al. **Gastroenterol Clin Biol** 1995; 19(5 Pt 2):B130–5 **(Fre)**

[New parasitoses and news in parasitology] Gérard A. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B119–24 **(Fre)**

[Nutrition and human immunodeficiency virus infection] Melchior JC, et al. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B157–60 **(Fre)**

[Proctology and human immunodeficiency virus] Puy–Montbrun T. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B145–9 **(Fre)**

[Hepatobiliary and pancreatic diseases in human immunodeficiency virus infection] Roulot D. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B150–6 **(Fre)**

[Hepatic peliosis, a still current disease (editorial)] Scoazec JY. **Gastroenterol Clin Biol** 1995 May;19(5):505–7 **(Fre)**

[Liver, biliary tracts and human immunodeficiency virus infection. 1:q liver, HIV and hepatitis B, C and D viruses] Vuitton DA, et al. **Gastroenterol Clin Biol** 1996; 20(3):269–80 (146 ref.) **(Fre)**

[Liver, biliary tracts and human immunodeficiency virus infection. 2: hepatobiliary complications of AIDS] Vuitton DA, et al. **Gastroenterol Clin Biol** 1996;20(3):281–93 (146 ref.) **(Fre)**

[Bilateral acute retinal necrosis in a patient with acquired immunodeficiency syndrome] Menerath JM, et al. **J Fr Ophtalmol** 1995;18(10):625–33 (39 ref.) (Eng. Abstr.) **(Fre)**

[Spontaneous corneal perforation and conjunctival molluscum contagiosum in a AIDS patient] Williamson W, et al. **J Fr Ophtalmol** 1995;18(11):703–7 (Eng. Abstr.) **(Fre)**

[Cerebral arteritis in AIDS. Demonstration with MRA in 2 patients] Brunereau L, et al. **J Radiol** 1996 May; 77(5):367–71 (Eng. Abstr.) **(Fre)**

[Spinal cord toxoplasmosis and AIDS] Carteret M, et al. **J Radiol** 1995 Jul;76(7):453–5 (Eng. Abstr.) **(Fre)**

[Resistance of cytomegalovirus to ganciclovir: rapid detection of the mutations 460 of the UL97 phosphotransferase] Alain S, et al. **Pathol Biol (Paris)** 1996 May;44(5):456–60 (Eng. Abstr.) **(Fre)**

[Isolation of an acid–alcohol resistant bacillus (BAAR) in the febrile HIV infected patients: Mycobacterium tuberculosis (MT) or Mycobacterium avium complex (MAC)?] Brel F, et al. **Pathol Biol (Paris)** 1995 Apr; 43(4):380–4 (Eng. Abstr.) **(Fre)**

[Azithromycin: new orientations] Coulaud JP. **Pathol Biol (Paris)** 1995 Jun;43(6):547–50 **(Fre)**

[Analysis of restriction fragment length polymorphism (RFLP) of Mycobacterium tuberculosis strains isolated from patients with several episodes of tuberculosis] Lemaitre N, et al. **Pathol Biol (Paris)** 1996 May;44(5):452–5 (Eng. Abstr.) **(Fre)**

[Reactivation of hepatitis B in AIDS (letter)] Berthelot P, et al. **Presse Med** 1996 Jan 27;25(3):128 **(Fre)**

[Reactivation of hepatitis B in AIDS (letter)] Blanche P, et al. **Presse Med** 1995 Sep 16;24(26):1221 **(Fre)**

[Bacterial esophagitis in AIDS (letter)] Blanche P, et al. **Presse Med** 1995 Nov 11;24(34):1624 **(Fre)**

[Induced expectoration: its role in the diagnosis of pneumocystis carinii pneumonia] Cabié A, et al. **Presse Med** 1995 Jul 1–8;24(24):1119–20 (Eng. Abstr.) **(Fre)**

[Prostatic tuberculous abscess in AIDS. 2 cases (letter)] Greder–Belan A, et al. **Presse Med** 1995 Sep 30;24(28):1315 **(Fre)**

[Tuberculosis in a Parisian internal medicine hospital unit. 50 cases (letter)] Haas C, et al. **Presse Med** 1995 Dec 16–23; 24(39):1911 **(Fre)**

[Urination disorders in HIV infected patients] Hermieu JF, et al. **Presse Med** 1995 Sep 30;24(28):1287–90 (Eng. Abstr.) **(Fre)**

[Parvovirus B19 infection. New physiopathological approaches] Labau E, et al. **Presse Med** 1996 Feb 3; 25(4):162–6 (26 ref.) (Eng. Abstr.) **(Fre)**

[Acid–alcohol–resistant bacilli detected by microscopic analysis of exhaled air from HIV–infected patients: tuberculosis or mycobacteriosis?] Meynard JL, et al. **Presse Med** 1996 Feb 10;25(5):193–6 (Eng. Abstr.) **(Fre)**

[Absence of regular medical follow–up: main cause of pneumocystosis diagnosed in patients with HIV infection in France in 1992 (letter)] Pradier C, et al. **Presse Med** 1995 Nov 11;24(34):1623 **(Fre)**

[Cyclospora infection in a HIV infected patient (letter)] Raguin G, et al. **Presse Med** 1995 Jul 1–8;24(24):1134 **(Fre)**

[Seroprevalence of cytomegalovirus infection in human immunodeficiency virus infected subjects (letter)] Rey D, et al. **Presse Med** 1995 Oct 21;24(31):1445 **(Fre)**

[Cerebral ischemic accidents in AIDS. Two new cases (letter)] Rogez JP, et al. **Presse Med** 1995 Sep 23; 24(27):1272 **(Fre)**

[Nonketotic hyperglycemic coma induced by somatostatin in an AIDS patient] Vandercam B, et al. **Presse Med** 1995 Oct 14;24(30):1389–90 (Eng. Abstr.) **(Fre)**

[Disseminated aspergillosis with pulmonary and cardiac localization in an HIV–infected patient] Escamilla R, et al. **Rev Mal Respir** 1995;12(4):380–2 (Eng. Abstr.) **(Fre)**

[Prevention of opportunistic infections in HIV infection] Pesce A. **Rev Med Interne** 1995;16 Suppl 3:315s–319s (20 ref.) **(Fre)**

[Cerebrovascular complications and AIDS: prethrombotic state? (letter)] Rogez JP, et al. **Rev Med Interne** 1996; 17(5):428 **(Fre)**

[Cerebrovascular accidents and AIDS] Strobel M, et al. **Rev Med Interne** 1995;16(10):743–6 (Eng. Abstr.) **(Fre)**

[AIDS and diabetes] Blanc MH. **Rev Med Suisse Romande** 1995 Sep;115(9):667–70 (29 ref.) **(Fre)**

[Prevalence of skin manifestations in AIDS patients in the Lome–Tokoin University Hospital (Togo)] Pitche P, et al. **Sante** 1995 Nov–Dec;5(6):349–52 (Eng. Abstr.) **(Fre)**

[HIV–associated Pneumocystis carinii pneumonia, primary pentamidine inhalation prophylaxis notwithstanding. Are there differences with Pneumocystis carinii pneumonia without prophylaxis?] Ewig S, et al. **Dtsch Med Wochenschr** 1996 Jan 26;121(4):83–9 (Eng. Abstr.) **(Ger)**

[Crohn disease in an AIDS patient] Armbruster C, et al. **Schweiz Med Wochenschr** 1995 Oct 21;125(42):1999–2002 (Eng. Abstr.) **(Ger)**

[Kaposi sarcoma of the glans penis with meatal obstruction. Case report and literature review] John H, et al. **Swiss Surg** 1996;(3):134–6 (3 ref.) (Eng. Abstr.) **(Ger)**

[Why are AIDS patients frequently visually impaired?] Fabricius EM. **Ther Umsch** 1996 Jan;53(1):49–57 (13 ref.) (Eng. Abstr.) **(Ger)**

[Hepatitis and posthepatic cirrhosis in AIDS] Bierhoff E, et al. **Verh Dtsch Ges Pathol** 1995;79:249–53 (Eng. Abstr.) **(Ger)**

[Diseases of the gallbladder and biliary tract in patients with AIDS] Regev A, et al. **Harefuah** 1996 Mar 1;130(5):330–2 (15 ref.) **(Heb)**

[Magnetic resonance in AIDS–related encephalopathy] Gualdi GF, et al. **Clin Ter** 1995 Dec;146(12):843–56 (42 ref.) (Eng. Abstr.) **(Ita)**

[Oral lesions in Kaposi sarcoma: clinical and radiotherapeutic considerations] Barberis M, et al. **Minerva Stomatol** 1996 Jan–Feb;45(1–2):17–27 (62 ref.) (Eng. Abstr.) **(Ita)**

[AIDS–related neoplasms: a clinico–radiological study] Ferrozzi F, et al. **Radiol Med (Torino)** 1996 Apr;91(4):434–9 (Eng. Abstr.) **(Ita)**

[Echographic and magnetic resonance aspects in a case of bacterial myositis in AIDS] Midiri M, et al. **Radiol Med (Torino)** 1995 Oct;90(4):489–91 **(Ita)**

[Progressive multifocal leukoencephalopathy in patients with AIDS. Findings with computerized tomography and magnetic resonance] Tartaglione T, et al. **Radiol Med (Torino)** 1995 Jul–Aug;90(1–2):8–15 (Eng. Abstr.) **(Ita)**

[Cytomegalovirus infection in HIV] Ferone U, et al. **Riv Eur Sci Med Farmacol** 1994 May–Aug;16(3–4):55–60 (Eng. Abstr.) **(Ita)**

[Efficiency of combination chemotherapy and interferon–alpha therapy in a patient with AIDS–related cutaneous and gastrointestinal Kaposi's sarcoma] Sawayama Y, et al. **Kansenshogaku Zasshi** 1996 Jun; 70(6):621–6 (Eng. Abstr.) **(Jpn)**

[A case report of the atypical tuberculosis associated with AIDS] Arai Y, et al. **Kekkaku** 1995 Jul;70(7):431–7 (Eng. Abstr.) **(Jpn)**

[Massive and progressive hepatosplenomegaly caused by disseminated nontuberculous mycobacteriosis in a patient with acquired immunodeficiency syndrome] Hagiwara T, et al. **Kekkaku** 1995 Jul;70(7):423–9 (Eng. Abstr.) **(Jpn)**

[A case of AIDS with bronchial tuberculosis] Naganuma M, et al. **Kekkaku** 1996 May;71(5):345–9 (Eng. Abstr.) **(Jpn)**

[Two cases of sensory neural hearing loss as a manifestation of HIV infection] Ohashi S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Sep;98(9):1399–406 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Nodular and cavitary pneumocystosis in a patient with hemophilia A and the acquired immunodeficiency syndrome] Yamakawa H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan; 34(1):117–20 (Eng. Abstr.) **(Jpn)**

[An AIDS case of probable pentamidine–induced diabetic ketoacidosis and severe acute pancreatitis] Pae Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):226–30 **(Jpn)**

[HIV (human immunodeficiency virus) disease and AIDS (acquired immunodeficiency syndrome)] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):255–7 (10 ref.) **(Jpn)**

[Cerebellar abscess by Nocardia: a case report] Aguiar PH, et al. **Arq Neuropsiquiatr** 1995 Jun;53(2):307–11 (Eng. Abstr.) **(Por)**

[The knowledge of neurological changes in patients with AIDS] Cămara VD, et al. **Arq Neuropsiquiatr** 1995 Mar; 53(1):53–9 (Eng. Abstr.) **(Por)**

[Hemichorea associated with cerebral toxoplasmosis and AIDS (letter; comment)] de Mattos JP, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3–A):534. Comment on: Arq Neuropsiquiatr 1995 Mar;53(1):118–22. **(Por)**

[Infection caused by Mycobacterium tuberculosis with primary resistance to multiple drugs: a case report of a patient with AIDS] Grinbaum RS, et al. **Rev Assoc Med Bras** 1995 May–Jun;41(3):255–6 (Eng. Abstr.) **(Por)**

[Facial and cervical manifestations of AIDS] Gebrim EM, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul–Aug; 50(4):222–6 (22 ref.) (Eng. Abstr.) **(Por)**

[Treatment of bacterial infections in patients with AIDS] Lewi DS. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:22–6 **(Por)**

[Tuberculosis in patients with HIV infections and AIDS] Alekseeva LP, et al. **Probl Tuberk** 1996;(2):16–7 (Eng. Abstr.) **(Rus)**

[Central nervous system involvement in the acquired immunodeficiency syndrome] Gavura VV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(2):96–100 (87 ref.) **(Rus)**

[Tuberculous prostatic abscess in a patient with AIDS] Duarte Ojeda JM, et al. **Actas Urol Esp** 1995 Sep; 19(8):655–61 (22 ref.) (Eng. Abstr.) **(Spa)**

[Epidemic Kaposi's sarcoma. Apropos of 14 cases] Figueras Villalba MP, et al. **An Med Interna** 1996 Apr;13(4):163–7 (Eng. Abstr.) **(Spa)**

[Usefulness of lithium in neutropenia associated with AIDS (letter)] Martinez Ruiz M, et al. **An Med Interna** 1996 Jan; 13(1):49 **(Spa)**

[Spontaneous perinephric hematoma in a case of AIDS] Sánchez–Chapado M, et al. **Arch Esp Urol** 1995 Dec; 48(10):1050–2 (Eng. Abstr.) **(Spa)**

[Hemichorea associated with cerebral toxoplasmosis and AIDS (see comments)] Garretto NS, et al. **Arq Neuropsiquiatr** 1995 Mar;53(1):118–22 (Eng. Abstr.). Comment in: Arq Neuropsiquiatr 1995 Sep;53(3–A):534. **(Spa)**

[AIDS and tuberculosis (editorial)] Giménez i Masat A. **Aten Primaria** 1996 Mar 31;17(5):307–8 **(Spa)**

[Impact of AIDS on premature mortality in La Rioja] Ramalle–Gómara E, et al. **Aten Primaria** 1996 May 15; 17(8):517–20 (Eng. Abstr.) **(Spa)**

[Current status of the management of cytomegalovirus retinitis in patients with AIDS (editorial)] López–Cortés LF, et al. **Enferm Infecc Microbiol Clin** 1996 Mar; 14(3):137–41 **(Spa)**

[Aspergillus tracheobronchitis in a patient with AIDS (letter)] Arizcorreta Yarza A, et al. **Med Clin (Barc)** 1995 Nov 25;105(18):717 **(Spa)**

[Disseminated histoplasmosis and AIDS. Report of 4 cases] Bayés B, et al. **Med Clin (Barc)** 1996 May 11;106(18):700–3 (Eng. Abstr.) **(Spa)**

[Hypocalcemia and hypomagnesemia associated with the treatment with pentamidine in 2 patients with HIV infection (letter)] Cortés E, et al. **Med Clin (Barc)** 1996 May 11;106(18):717 **(Spa)**

[AIDS and primary lateral sclerosis? (letter)] de la Fuente–Fernández R. **Med Clin (Barc)** 1996 Jan 13; 106(1):36 **(Spa)**

[Granulomatous pneumonitis: a clinical manifestation and atypical pathology of pneumocystosis in AIDS (letter)] Macías J, et al. **Med Clin (Barc)** 1995 Dec 8;105(20):797 **(Spa)**

[Pleural cryptococcosis in patients with human immunodeficiency virus infection] Mauri M, et al. **Med Clin (Barc)** 1996 Mar 16;106(10):380–2 (Eng. Abstr.) **(Spa)**

[Cancer and AIDS: an odd couple (editorial)] QUAB1go M, et al. **Med Clin (Barc)** 1996 May 4;106(17):659–60 **(Spa)**

[Movement disorders and AIDS] Iranzo A, et al. **Neurologia** 1996 Feb;11(2):70–5 (Eng. Abstr.) **(Spa)**

[Surgical abdomen in a patient with human immunodeficiency virus infection (clinical conference)] **Rev Clin Esp** 1996 Apr;196(4):264–9 **(Spa)**

[Intravitreal ganciclovir in cytomegalovirus retinitis in AIDS] Olea JL, et al. **Rev Clin Esp** 1996 Apr;196(4):208–12 (Eng. Abstr.) **(Spa)**

[Visceral leishmaniasis in a patient with HIV–2 infection (letter)] Sarmento e Castro R, et al. **Rev Clin Esp** 1995 Aug;195(8):591–2 **(Spa)**

[Cytomegalovirus retinitis in patients with AIDS (editorial)] Verdejo Ortés J. **Rev Clin Esp** 1996 Apr;196(4):205–7 **(Spa)**

[Acute pancreatitis and acquired immunodeficiency syndrome] Talens A, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):155–9 (Eng. Abstr.) **(Spa)**

[Extra meningeal cryptococcosis in a patient with AIDS] Srur E, et al. **Rev Med Chil** 1995 Aug;123(8):1009–12 (Eng. Abstr.) **(Spa)**

[Microsporidiosis in patients with chronic diarrhea and AIDS, in HIV asymptomatic patients and in patients with acute diarrhea] Weitz JC, et al. **Rev Med Chil** 1995 Jul; 123(7):849–56 (Eng. Abstr.) **(Spa)**

CONGENITAL

Spectrum of chest radiographic abnormalities in children with AIDS and Pneumocystis carinii pneumonia. Sivit CJ, et al. **Pediatr Radiol** 1995;25(5):389–92

DIAGNOSIS

Predictors of repeat HIV testing among gay and bisexual men. Phillips KA, et al. **AIDS** 1995 Jul;9(7):769–75

Precipitous visual loss secondary to optic nerve toxoplasmosis as an unusual presentation of AIDS. Wei ME, et al. **Aust N Z J Ophthalmol** 1996 Feb;24(1):75–7

HIV testing at a gay men's clinic, Melbourne [letter] Carmody C, et al. **Aust N Z J Public Health** 1996 Jun; 20(3):323–4

HIV in plasma is best predictor of progression to AIDS [news] Roberts J. **BMJ** 1996 Jun 8;312(7044):1437–8

Fluorometric detection of HIV–1 genome through use of an internal control, inosine–substituted primers, and microtiter plate format. Gérard B, et al. **Clin Chem** 1996 May;42(5):696–703

Laboratory tests for detection of human immunodeficiency

virus type 1 infection. Nuwayhid NF.
Clin Diagn Lab Immunol 1995 Nov;2(6):637–45 (126 ref.)

Toxoplasmosis localized to the bladder is diagnostic of human immunodeficiency virus infection: case report [letter] Chemlal K, et al. **Clin Infect Dis** 1996 Apr;22(4):740–1

Pediatric AIDS with severe T-cell depression and hypogammaglobulinemia. Koutsonikolis A, et al.
Clin Pediatr (Phila) 1995 Nov;34(11):605–7

CD4 Lymphocyte enumeration: comparison between flow cytometry and enzyme immunoassay. Cordiali Fei P, et al. **Cytometry** 1995 Mar 15;22(1):70–4

Accuracy of a saliva test for HIV antibody [letter] [see comments] Frerichs RR.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Dec 1;10(4):484–5. Comment in: J Acquir Immune Defic Syndr Hum Retrovirol 1996 Mar 1;11(3):309–10.

Review of invasive cervical cancer cases for AIDS surveillance [letter; comment] Kelley KF, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Jan 1;8(1):102–3. Comment on: J Acquir Immune Defic Syndr 1994 Jun;7(6):631.

Replacing time since human immunodeficiency virus infection by marker values in predicting residual time to acquired immunodeficiency syndrome diagnosis. Multicenter AIDS Cohort Study. Shi M, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jul; 12(3):309–16

False-negative polymerase chain reaction-based diagnosis of human immunodeficiency virus (HIV) type 1 in children infected with HIV strains of African origin [letter; comment] Haas J, et al. **J Infect Dis** 1996 Jul;174(1):244–5 . Comment on: J Infect Dis 1996 Jan;173(1):68–76.

HIV and the paediatrician as the child's advocate. Duke C, et al. **Lancet** 1996 Jul 27;348(9022):247–9

US specialists object to AMA's call for mandatory HIV testing [news] Rovner J. **Lancet** 1996 Aug 3;348(9023):330

AIDS-resembling disease in a non-HIV-infected African born to an HIV-positive mother. Irova T, et al.
Pediatr Hematol Oncol 1995 Sep-Oct;12(5):495–8

Myelopathy as a presenting sign of acquired immunodeficiency syndrome. Fiser RT, et al.
Pediatr Infect Dis J 1995 Sep;14(9):808–9

HIV/AIDS report. Gleeson RK.
Proc Annu Meet Med Sect Am Counc Life Insur 1995;:181–2

Correlative morphologic and functional imaging for diagnosis, staging and follow up in AIDS: an overview. Brunetti A, et al. **Q J Nucl Med** 1995 Sep;39(3):201–11 (90 ref.)

Antigen testing for human immunodeficiency virus (HIV) and the magnet effect: will the benefit of a new HIV test be offset by the numbers of higher risk, test-seeking donors attracted to blood centers? Retrovirus Epidemiology Donor Study. Korelitz JJ, et al. **Transfusion** 1996 Mar; 36(3):203–8

Neurology of human immunodeficiency virus infection--past, present, and future. Jay C. **West J Med** 1995 Nov;163(5):470–1

[HIV infections in Germany (editorial)] Goebel FD.
Bildgebung 1995 Dec;62(4):242–3 **(Ger)**

[AIDS: infections of the retina and choroid] Schimkat M, et al. **Bildgebung** 1995 Dec;62(4):288–301 (100 ref.) (Eng. Abstr.) **(Ger)**

[Kaposi sarcoma in Caucasian women. Clinical, chemical laboratory and endocrinologic examination of 8 women with HIV associated or classical Kaposi sarcoma (letter)] Schmoeckel C. **Hautarzt** 1996 May;47(5):394 **(Ger)**

[Kaposi sarcoma in Caucasian women. Clinical, chemical laboratory and endocrinologic studies in 8 women with HIV-associated or classical Kaposi sarcoma] Schöfer H, et al. **Hautarzt** 1995 Sep;46(9):632–7 (Eng. Abstr.) **(Ger)**

[Information from the American Academy of Ophthalmology: how AIDS affects the eye (news)]
Klin Monatsbl Augenheilkd 1996 Feb;208(2):aA7 **(Ger)**

[Ocular microangiopathy syndrome in patients with AIDS is associated with increased plasma levels of the vasoconstrictor endothelin-1] Geier SA, et al.
Klin Monatsbl Augenheilkd 1995 Dec;207(6):353–60 (Eng. Abstr.) **(Ger)**

[Dementia-paranoid syndrome as the initial manifestation of AIDS. Case report and diagnostic overview] Sobanski T, et al. **Nervenarzt** 1996 Jan;67(1):68–71 (Eng. Abstr.) **(Ger)**

[Incidence and differential diagnosis of cholestasis in AIDS--a retrospective analysis of 73 patients] Klinker H, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:126–8 (Eng. Abstr.) **(Ger)**

[A case of AIDS patient who was hard to diagnose from an initial symptom of interstitial pneumonitis] Hakoda S, et al. **Kansenshogaku Zasshi** 1995 Sep;69(9):1007–11 (Eng. Abstr.) **(Jpn)**

[Questionnaire survey of AIDS examination recipients at government-run public health center regarding AIDS awareness promotion and HIV examinations] Hasegawa S, et al. **Nippon Koshu Eisei Zasshi** 1996 Apr;43(4):276–85 (Eng. Abstr.) **(Jpn)**

[Alpha tumor necrosis factor in central nervous system disease associated with HIV infection] Calvo Manuel E, et al. **An Med Interna** 1995 Jun;12(6):263–6 (Eng. Abstr.) **(Spa)**

[Adenosine deaminase (ADA) and beta 2-microglobulin (beta 2M) as discriminating serum markers of progression to AIDS] Pérez de Oteyza C, et al. **An Med Interna** 1996 May;13(5):217–21 (Eng. Abstr.) **(Spa)**

[The role of the primary care physician in AIDS (editorial)] da Pena Alvarez JM. **Aten Primaria** 1996 Jul-Aug; 18(3):103–4 **(Spa)**

[Evaluation of an informative leaflet on AIDS/HIV infection aimed at primary health care professionals in Catalonia] Rodés A, et al. **Aten Primaria** 1996 Jan;17(1):4–10 (Eng. Abstr.) **(Spa)**

[The clinical laboratory in the diagnosis, classification, and follow-up of patients with HIV/AIDS infection]
Gac Med Mex 1994 Jan-Feb;130(1):26–7 **(Spa)**

[Changes in the spectrum of AIDS-defining diseases in Spain] Castilla J, et al. **Med Clin (Barc)** 1996 May 18;106(19):730–3 (Eng. Abstr.) **(Spa)**

[Unexpected cryptococcosis and AIDS in an elderly patient (clinical conference)] **Medicina (B Aires)** 1995;55(2):147–54 **(Spa)**

[Clinical characteristics and natural history of human immunodeficiency virus infection. Study in a Chilean population served at a multiprofessional pilot center] Wolff M, et al. **Rev Med Chil** 1995 Jan;123(1):61–73 (Eng. Abstr.) **(Spa)**

DIET THERAPY

The effect of supplemental beta-carotene on immunologic indices in patients with AIDS: a pilot study. Fryburg DA, et al. **Yale J Biol Med** 1995 Jan-Apr;68(1-2):19–23

DRUG THERAPY

Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals. Rice WG, et al. **Adv Pharmacol** 1995;33:389–438 (204 ref.)

Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in patients with AIDS [letter] Engelson ES, et al. **AIDS** 1995 Sep; 9(9):1107–8

The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. Jacobson MA, et al. **AIDS** 1995 Jul;9(7):727–34

Hydroxyurea and HIV-1 viraemia [letter] Lafeuillade A, et al. **AIDS** 1995 Nov;9(11):1290–1

Changing incidence of HIV-induced brain lesions in Oslo, 1983–1994: effects of zidovudine treatment. Maehlen J, et al. **AIDS** 1995 Oct;9(10):1165–9

Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. Roberts NA. **AIDS** 1995 Dec;9 Suppl 2:27–S32 (34 ref.)

New developments in antiretroviral drug therapy for HIV-1 infections. Johnson VA. **AIDS Clin Rev** 1995–96;:305–46 (106 ref.)

Hydroxyurea and AIDS: an old drug finds a new application? Lori F, et al. **AIDS Res Hum Retroviruses** 1995 Oct; 11(10):1149–51

Antiretroviral drug treatment for HIV/AIDS. Goldschmidt RH, et al. **Am Fam Physician** 1996 Aug;54(2):574–80, 587–8

Lotteries set up for two experimental AIDS drugs [news] **Am J Health Syst Pharm** 1995 Sep 1;52(17):1848

Negotiating AIDS drug assistance programs [news] **Am J Nurs** 1995 Dec;95(12):11

Survivor treatment selection bias in observational studies: examples from the AIDS literature. Glesby MJ, et al.
Ann Intern Med 1996 Jun 1;124(11):999–1005 (46 ref.)

Recombinant erythropoietin for zidovudine-induced anemia in AIDS. Kuehl AK, et al. **Ann Pharmacother** 1995 Jul-Aug;29(7-8):778–9 (15 ref.)

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Horton CM, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2309–15

A penile ulceration in a patient with the acquired immunodeficiency syndrome. Foscarnet-induced penile ulceration. Fitzgerald E, et al. **Arch Dermatol** 1995 Dec; 131(12):1449, 1452

The antiinflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis. Ornstein MH, et al. **Arthritis Rheum** 1996 Jan; 39(1):157–61

New strategies for treating AIDS. Sandstrom PA, et al.
Bioessays 1996 May;18(5):343–6 (20 ref.)

Role of zidovudine antiretroviral therapy in the pathogenesis of acquired immunodeficiency syndrome-related lymphoma. Levine AM, et al. **Blood** 1995 Dec 15; 86(12):4612–6

Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Hengge UR, et al. **Br J Nutr** 1996 Jan; 75(1):129–38

A model for treatment strategy in the chemotherapy of AIDS. Kirschner D, et al. **Bull Math Biol** 1996 Mar; 58(2):376–90

The politics of despair: AIDS and the failure of treatment [see comments] Mackie ID. **Can Med Assoc J** 1995 Oct 1;153(7):967–8. Comment in: Can Med Assoc J 1996 Jan 15;154(2):139; discussion 140. Comment in: Can Med Assoc J 1996 Jan 15;154(2):139–40. Comment in: Can Med Assoc J 1996 Jan 15;154(2):140.

A report on 8 seronegative converted HIV/AIDS patients with traditional Chinese medicine. Lu W, et al.
Chin Med J (Engl) 1995 Aug;108(8):634–7

Effect of clarithromycin on the pharmacokinetics of 2',3'-dideoxyinosine in patients who are seropositive for human immunodeficiency virus. Gillum JG, et al.
Clin Infect Dis 1996 Apr;22(4):716–8

Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Olano JP, et al.
Clin Infect Dis 1995 Oct;21(4):973–6

Clinical significance of drug resistance in human immunodeficiency virus. Richman DD. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S166–9 (26 ref.)

Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Sperber K, et al.
Clin Ther 1995 Jul-Aug;17(4):622–36

The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. Crystal S, et al.
Health Serv Res 1995 Oct;30(4):593–614

Erythema multiforme secondary to dideoxycytidine (ddC). Wardropper AG, et al. **Int J STD AIDS** 1995 Nov-Dec; 6(6):450

Differences in participation in experimental drug trials among persons with AIDS. Diaz T, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Dec 15;10(5):562–8

Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. Fichtenbaum CJ, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Oct 1;10(2):169–74

Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group. Gatell JM, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jul; 12(3):249–58

Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model. Harvie P, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Aug 15;12(5):451–61

Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immune deficiency syndrome: Relation to indices of cytokine production. Hellerstein MK, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Mar 1;11(3):258–70

A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS. Vella S, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Aug 15;12(5):462–9

Treatment of AIDS and HIV-related conditions--1996. Goldschmidt RH, et al. **J Am Board Fam Pract** 1996 Mar-Apr;9(2):125–48 (88 ref.)

A new HIV/AIDS drug. **J Ark Med Soc** 1996 Jan;92(8):407

Drug leads from the Kallawaya herbalists of Bolivia. 1. Background, rationale, protocol and anti-HIV activity. Abdel-Malek S, et al. **J Ethnopharmacol** 1996 Mar; 50(3):157–66

Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. Arevalo JF, et al.
J Infect Dis 1995 Oct;172(4):951–6

Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy [see comments] Demeter LM, et al. **J Infect Dis** 1995 Dec; 172(6):1480–5. Comment in: J Infect Dis 1996 Aug;174(2):448–9.

Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. Giacca M, et al. **J Infect Dis** 1996 Jul;174(1):204–9

Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group. Imrie A, et al. **J Infect Dis** 1996 Jul;174(1):195–8

Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy [see comments] Livington DJ, et al.
J Infect Dis 1995 Nov;172(5):1238–45. Comment in: J Infect Dis 1996 Jun;173(6):1524–6.

Inhibition of human immunodeficiency virus type 1 multiplication by transforming growth factor beta 1 and AZT in HIV-1-infected myeloid cells. McKiel V, et al.
J Interferon Cytokine Res 1995 Oct;15(10):849–55

AIDS malignancy consortium plans first clinical trials.[news] McNeil C. **J Natl Cancer Inst** 1996 Mar 20;88(6):321

Controlling infantile AIDS with natural remedies--a Romanian case study. Tani M. **J Tradit Chin Med** 1995 Dec;15(4):277–88

Other AIDS drug regimens beat AZT alone, reduce clinical progression and mortality [news] Stephenson J. **JAMA** 1995 Oct 18;274(15):1183–4

Predominance of codon 215 mutation in reverse transcriptase-coding region of 3'-azido-3'-deoxythymidine (AZT)-resistant HIV-1 isolates after long-term AZT therapy. Kondo M. **Kansenshogaku Zasshi** 1995 Nov; 69(11):1278–85

US states must cover protease inhibitors [news] Barnett AA. **Lancet** 1996 Jul 6;348(9019):52

French patients will get protease inhibitors [news] Gozlan M. **Lancet** 1996 Mar 23;347(9004):821

Impact of treatment and prophylaxis on presentation and survival of patients with AIDS in Milan [letter] Monforte A, et al. **Lancet** 1995 Dec 2;346(8988):1488

Vancouver AIDS meeting highlights combination attack on

HIV [news] Sharp D. **Lancet** 1996 Jul 13;348(9020):115
Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity. Yang SS, et al. **Leukemia** 1995 Oct;9 Suppl 1:S75–85
The NCI's AIDS antiviral drug screening program. Yang SS. **Leukemia** 1995 Oct;9 Suppl 1:S9–11
Drugs for AIDS and associated infections.
Med Lett Drugs Ther 1995 Oct 13;37(959):87–94
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. de Clercq E. **Med Res Rev** 1996 Mar;16(2):125–57 (180 ref.)
Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS [see comments] Saravolatz LD, et al. **N Engl J Med** 1996 Oct 10;335(15):1099–106. Comment in: N Engl J Med 1996 Oct 10;335(15):1142–9.
HIV therapy—what's new? [letter] Chew GS.
N Z Med J 1996 May 10;109(1021):172
A fight to the death. Short N. **Nat Med** 1995 Feb;1(2):122–4
AIDS drugs lurch towards market [news] Steele F.
Nat Med 1995 Apr;1(4):285–6
What direction for AIDS drug task force? [news] Steele FR.
Nat Med 1995 Aug;1(8):725
Confusion reigns over compassionate use of AIDS drug [news] Tastemain C. **Nat Med** 1995 Oct;1(10):986
Protestors say "non" to HIV drug lottery [news] Tastemain C. **Nat Med** 1996 Apr;2(4):376
AZT combination trial shows positive results [news]
Nature 1995 Sep 28;377(6547):277
Plants and AIDS [letter] Atta-ur-Rahman. **Nature** 1996 Sep 26;383(6598):294
'Beware of hype,' AIDS conference told [news] Macilwain C. **Nature** 1996 Jul 11;382(6587):101
Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Herz AV, et al.
Proc Natl Acad Sci U S A 1996 Jul 9;93(14):7247–51
Augmentation of CD8 and CD4 lymphocytes subsets in AIDS infected children after treatment with a non-toxic chelating agents compound—Rodilemid. Dinu R, et al.
Rom J Intern Med 1995 Jul–Dec;33(3–4):205–10
Confirmation for combination AIDS therapy [news]
Science 1995 Oct 6;270(5233):33
AIDS task force fizzles out [news] Cohen J. **Science** 1996 Jan 26;271(5248):438–9
Protease inhibitors: a tale of two companies [news] Cohen J. **Science** 1996 Jun 28;272(5270):1882–3
Results on new AIDS drugs bring cautious optimism [news] Cohen J. **Science** 1996 Feb 9;271(5250):755–6
AIDS trials take on peer review [news] Cohen J. **Science** 1996 Jan 5;271(5245):20–1
AIDS conference. Chemokines share center stage with drug therapies [news] Cohen J. **Science** 1996 Jul 19; 273(5273):302–3
AIDS researchers, activists fight crisis in clinical trials [news] Nowak R. **Science** 1995 Sep 22;269(5231):1666–7
[Occurrence of anterior uveitis in a HIV patient treated with rifabutin, ethambutol, clarithromycin (letter)] Pinzani V, et al. **Therapie** 1995 Sep–Oct;50(5):482–3 **(Fre)**
[AIDS studies with didanosine and stavudine (news)]
Dtsch Med Wochenschr 1996 May 31;121(22):A30 **(Ger)**
[A new antiviral substance against AIDS is already tested by phase II trial (news)] Diehl M.
Dtsch Med Wochenschr 1996 Jan 5;121(1–2):A21 **(Ger)**
[Protease inhibitors are effective only on HIV-infected cells (news)] **Fortschr Med** 1996 May 30;114(15):12 **(Ger)**
[New therapeutic possibilities in AIDS (editorial)] Heinzl S. **Med Monatsschr Pharm** 1996 May;19(5):121 **(Ger)**
[New treatments in HIV] Turner D, et al. **Harefuah** 1996 Apr 1;130(7):467–70 (32 ref.) **(Heb)**
[Prognosis and evaluation of drug therapy by V3 and RT gene analysis of HIV-1] Morimoto M, et al.
Kansenshogaku Zasshi 1996 Apr;70(4):347–53 (Eng. Abstr.) **(Jpn)**
[Advances in the treatment of human immunodeficiency virus (HIV) infection (editorial)] Amato Neto V, et al.
Rev Assoc Med Bras 1995 Mar–Apr;41(2):81–2 **(Por)**
[Policy of the Health Ministry on anti-retroviral therapy] del Bianco R. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:18–22 **(Por)**
[Care for the patient with AIDS] Ponce-de León S, et al.
Salud Publica Mex 1995 Nov–Dec;37(6):525–32 (30 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

The usage and costs of health services for HIV infection in Australia. Hurley SF, et al. **AIDS** 1995 Jul;9(7):777–85
Hospital costs of treating haemophilic patients infected with HIV. Kennelly JM, et al. **AIDS** 1995 Jul;9(7):787–93
AIDS and politics: death and taxes. Westmoreland TM.
Bull N Y Acad Med 1995 Summer;72(1 Suppl):273–82
Cost effectiveness and AIDS: science or marketing? Proceedings of a workshop. Washington, D.C., January 28, 1995. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 4:S1–32
Specific considerations for cost-effectiveness studies in AIDS. Bozzette SA.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 4:S23–7 (14 ref.)
Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. Gable CB, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Aug 1;12(4):413–20
Design and assessment of cost-effectiveness studies in AIDS populations. Simpson KN.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 4:S28–32 (17 ref.)
Is new AIDS report just another piece of paper? [news] Kedar I. **Nat Med** 1996 May;2(5):501
Buying life insurance from the dying gets riskier [news] Steele FR. **Nat Med** 1996 May;2(5):500–1
'Bypass' budget reveals AIDS research funding priorities [news] Steele FR. **Nat Med** 1995 Jun;1(6):499
Less cash from French AIDS event [news] **Nature** 1996 Sep 19;383(6597):210
Health secretary backs AIDS office's budget authority [news] Wadman M. **Nature** 1996 Feb 15;379(6566):570
AIDS office budget morass settled [news] **Science** 1996 Mar 1;271(5253):1221
The marketplace of HIV/AIDS [news] Cohen J. **Science** 1996 Jun 28;272(5270):1880–1
[The epidemiology and cost of AIDS in France] Trotot PM, et al. **J Neuroradiol** 1995 Sep;22(3):136–41 (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

The chemical pathology of AIDS [letter] Crowley VE, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):511–2
Adenosine deaminase isoenzyme levels in patients with human T-cell lymphotropic virus type 1 and human immunodeficiency virus type 1 infections. Tsuboi I, et al.
Clin Diagn Lab Immunol 1995 Sep;2(5):626–30
[Study on reverse transcriptase inhibiting antibody in plasma of HIV-1 seropositive subjects] Saito T, et al.
Kansenshogaku Zasshi 1995 Aug;69(8):851–7 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Statistics from the World Health Organization. **AIDS** 1995 Nov;9(11):1297–8
Statistics from the Centers for Disease Control and Prevention. **AIDS** 1995 Oct;9(10):1207–9
Sexual behaviour and HIV epidemiology: comparative analysis in France and Britain. The ACSF Group. Bajos N, et al. **AIDS** 1995 Jul;9(7):735–43
Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. Bloland PB, et al. **AIDS** 1995 Jul;9(7):721–6
AIDS: a major health problem among young Italian women. Conti S, et al. **AIDS** 1996 Apr;10(4):407–11
The HIV/AIDS epidemic in Jamaica. Figueroa JP, et al.
AIDS 1995 Jul;9(7):761–8
WHO global AIDS statistics. AIDS cases reported to the World Health Organization as at 7 July 1995.
AIDS Care 1995;7(5):689–90
WHO Global AIDS Statistics. **AIDS Care** 1996 Feb; 8(1):127–8
WHO Global AIDS Statistics. **AIDS Care** 1995;7(3):397–8
World Health Organization Global AIDS Statistics.
AIDS Care 1995;7(4):543–7
Responding to the AIDS epidemic in Asia and the Pacific: report on the Third International Conference on AIDS in Asia and the Pacific, Chiang Mai, Thailand, 17–21 September, 1995. Ford NJ. **AIDS Care** 1996 Feb; 8(1):117–24 (7 ref.)
Unmet needs for help among persons with AIDS. Smith MY, et al. **AIDS Care** 1995;7(3):353–63
Update on epidemiology of AIDS in Asia. Li PC, et al.
AIDS Clin Rev 1995–96;:347–86 (151 ref.)
Trends in the AIDS epidemic among men who reported sex with men in New York City: 1981–1993. Fordyce EJ, et al. **AIDS Educ Prev** 1995;7(5 Suppl):3–12
Social and sexual networks: their role in the spread of HIV/AIDS among young gay men. Morris M, et al.
AIDS Educ Prev 1995;7(5 Suppl):24–35
Patterns of HIV/AIDS in Zimbabwe: implications for health education. Munodawafa D, et al. **AIDS Educ Prev** 1996 Feb;8(1):1–10
Re: "Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study" and "Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978–1991" [letter; comment] Zwahlen M, et al.
Am J Epidemiol 1996 Mar 1;143(5):523–5; discussion 525–6 . Comment on: Am J Epidemiol 1994 Jun 1;139(11):1077–87. Comment on: Am J Epidemiol 1994 Oct 15;140(8):747–58.
Tuberculosis and HIV among mentally ill men in a New York City shelter [letter] Saez H, et al.
Am J Public Health 1996 Sep;86(9):1318–9
Using administratively collected hospital discharge data for AIDS surveillance. Payne SM, et al. **Ann Epidemiol** 1995 Sep;5(5):337–46
Has the incidence of AIDS reached its peak? [news]
Ann Oncol 1996 Feb;7(2):108
HIV-1 subtype O: epidemiology, pathogenesis, diagnosis, and perspectives of the evolution of HIV. Gürtler LG, et al.
Arch Virol Suppl 1996;11:195–202 (15 ref.)
Pediatric AIDS epidemic reflects the first half million AIDS cases in the U.S. Waldman HB. **ASDC J Dent Child** 1996 Mar–Apr;63(2):89–94 (6 ref.)
Hazard function estimation using B-splines. Rosenberg PS.
Biometrics 1995 Sep;51(3):874–87
AIDS rates rise in younger groups [news] Boulton A.
BMJ 1995 Dec 2;311(7018):1455
Trends in incidence of AIDS associated with transfusion of blood and blood products in Europe and the United States, 1985–93 [see comments] Franceschi S, et al. **BMJ** 1995 Dec 9;311(7019):1534–6. Comment in: BMJ 1996 Mar 30;312(7034):847–8.
Russia is on brink of AIDS epidemic [news] Ingram M.
BMJ 1996 Aug 3;313(7052):252
AIDS-related lymphoma: an emerging epidemic. Denton AS, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):282–8 (27 ref.)
A journey through the epidemic. Friedland GH.
Bull N Y Acad Med 1995 Summer;72(1 Suppl):178–86
HIV and AIDS: where is the epidemic going? Mertens TE, et al. **Bull World Health Organ** 1996;74(2):121–9
Pending problem of "silent" human immunodeficiency virus infection. Bentwich Z, et al.
Cell Mol Biol (Noisy-le-grand) 1995 May;41(3):345–50 (42 ref.)
AIDS, Ebola and other new epidemics: theme of European Conference on Tropical Medicine in Hamburg [news] Papendorf J. **Cent Afr J Med** 1995 Aug;41(8):264
The incidence and prevalence of AIDS and prevalence of other severe HIV disease in England and Wales for 1995 to 1999: projections using data to the end of 1994.
Commun Dis Rep CDR Rev 1996 Jan 5;6(1):R1–21
'Soundex' codes of surnames provide confidentiality and accuracy in a national HIV database. Mortimer JY, et al.
Commun Dis Rep CDR Rev 1995 Nov 10;5(12):R183–6
AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1996 Apr 19; 6(16):141–4
AIDS and HIV-1 infection worldwide.
Commun Dis Rep CDR Wkly 1995 Nov 17;5(46):253–4
AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1995 Sep 22; 5(38):183–4
Sociodemographic profile of children affected by AIDS in Addis Abeba. Bedri A, et al. **Ethiop Med J** 1995 Oct; 33(4):227–34
Completeness of AIDS reporting and quality of AIDS death certification in Tuscany (Italy): a linkage study between surveillance system of cases and death certificates. Barchielli A, et al. **Eur J Epidemiol** 1995 Oct;11(5):513–7
HIV-related non-Hodgkin's lymphoma among European AIDS patients. AIDS in Europe Study Group. AIDS in Europe Study Group. Pedersen C, et al.
Eur J Haematol 1995 Oct;55(4):245–50
Public health. AIDS invades rural Maine. MacPherson P.
Hosp Health Netw 1995 Dec 5;69(23):60, 62
Patterns and predictability in emerging infections. Morse SS.
Hosp Pract (Off Ed) 1996 Apr 15;31(4):85–91, 96–101, 104 passim (11 ref.)
Estimation of adult HIV prevalence as of the end of 1994 in India. Anthony B, et al. **Indian J Public Health** 1995 Jul–Sep;39(3):79–85
HIV and AIDS [editorial] Lal S, et al.
Indian J Public Health 1995 Jul–Sep;39(3):77–8
Use of AIDS surveillance data to describe subepidemic dynamics. Cantoni M, et al. **Int J Epidemiol** 1995 Aug; 24(4):804–12
Marital status in relation to Kaposi's sarcoma, non-Hodgkin's lymphoma, and anal cancer in the pre-AIDS era. Biggar RJ, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Feb 1;11(2):178–82
The epidemic of HIV/AIDS in Abidjan, Côte d'Ivoire: a review of data collected by Projet RETRO-CI from 1987 to 1993. Djomand G, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Nov 1;10(3):358–65
How important is race/ethnicity as an indicator of risk for specific AIDS-defining conditions? Hu DJ, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Nov 1;10(3):374–80
AIDS in transfusion recipients and hemophiliacs in France and other European countries [letter] La Vecchia C, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 15;11(5):512–4
Back-projection and sensitivity analysis of the HIV-AIDS epidemic in the Caribbean. Newton EA, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jan 1;11(1):69–76
Arkansas HIV/AIDS report 1983–1995. **J Ark Med Soc** 1995 Dec;92(7):348–9
Arkansas HIV/AIDS report 1983–1996. **J Ark Med Soc** 1996 Feb;92(9):460–1
The changing face of HIV infection: charting the pattern of AIDS in Canada and the United States. Epstein JB, et al. **J Can Dent Assoc** 1995 Nov;61(11):985–7
AIDS in the elderly: New York City vital statistics. Gaeta TJ, et al. **J Emerg Med** 1996 Jan–Feb;14(1):19–23
Epidemiology of AIDS/HIV in Japan. Tajima K, et al.
J Epidemiol 1996 Aug;6(3 Suppl):S67–74

The impact of bacteraemia on HIV infection. Nine years experience in a large Italian university hospital. Tumbarello M, et al. **J Infect** 1995 Sep;31(2):123–31

AIDS in Côte d'Ivoire—ten years on. Watson P, et al. **J Public Health Med** 1996 Mar;18(1):107–11

AIDS in San Francisco. The Medicine Gilliland Travelling Fellowship 1995. Jackson DH. **J R Coll Physicians Lond** 1996 Mar–Apr;30(2):178–81

From the Centers for Disease Control and Prevention. First 500,000 AIDS cases—United States, 1995. **JAMA** 1995 Dec 20;274(23):1827–8

The changing face of AIDS in Argentina. Betts CD, et al. **JAMA** 1996 Jul 10;276(2):94–6

HIV–1 subtype B in west Africa [letter; comment] Ariyoshi K, et al. **Lancet** 1996 Feb 3;347(8997):328. Comment on: Lancet 1995 Sep 16;346(8977):782.

Multiple introductions of HIV–1 subtype E into the western hemisphere [published erratum appears in Lancet 1995 Nov 18;346(8986):1376] Artenstein AW, et al. **Lancet** 1995 Nov 4;346(8984):1197–8

HIV epidemic in India [letter] Jain M, et al. **Lancet** 1996 Aug 10;348(9024):412–3

Global burden of the HIV pandemic [see comments] Quinn TC. **Lancet** 1996 Jul 13;348(9020):99–106 (50 ref.). Comment in: Lancet 1996 Aug 17;348(9025):480–1.

English HIV and AIDS projections made [news] Ramsay S. **Lancet** 1996 Jan 13;347(8994):109

Hodgkin's disease as an indicator of AIDS. Gerold M, et al. **Med Hypotheses** 1995 Jul;45(1):76–82 (113 ref.)

Managing HIV. Part 8: Controlling an epidemic. 8.6 Epidemiological surveillance for HIV and AIDS. Kaldor JM, et al. **Med J Aust** 1996 Sep 2;165(5):268–71

First 500,000 AIDS cases—United States, 1995. **MMWR Morb Mortal Wkly Rep** 1995 Nov 24; 44(46):849–53

Surveillance of tuberculosis and AIDS co–morbidity—Florida, 1981–1993. **MMWR Morb Mortal Wkly Rep** 1996 Jan 19;45(2):38–41

Tuberculosis, AIDS, and death among substance abusers on welfare in New York City [see comments] Friedman LN, et al. **N Engl J Med** 1996 Mar 28;334(13):828–33. Comment in: N Engl J Med 1996 Mar 28;334(13):859–60.

The march of AIDS through Asia [editorial; comment] Weniger BG, et al. **N Engl J Med** 1996 Aug 1;335(5):343–5 . Comment on: N Engl J Med 1996 Aug 1;335(5):297–303.

AIDS [news] **N Z Med J** 1996 May 24;109(1022):196

AIDS [news] **N Z Med J** 1996 Aug 23;109(1028):326

AIDS in position to ravage India [news] Jayaraman KS. **Nat Med** 1996 Sep;2(9):951

Bringing the context in from the cold: substantive, technical, and statistical issues for AIDS research in the second decade. Brunswick AF. **NIDA Res Monogr** 1994; 143:187–201 (21 ref.)

AIDS and cancer registry linkage: measurement and enhancement of registry completeness. The National AIDS/Cancer Match Study Group. Coté TR, et al. **Prev Med** 1995 Jul;24(4):375–7

Toward a unified–field theory of the pathogenesis of acquired immune deficiency syndrome [editorial] Jonas S. **Prev Med** 1995 Sep;24(5):423–4

The AIDS epidemic. Galli M, et al. **Q J Nucl Med** 1995 Sep;39(3):147–55

HIV/AIDS in South Africa—a relentless progression? [editorial] McIntyre J. **S Afr Med J** 1996 Jan;86(1):27–8 (12 ref.)

The African AIDS epidemic [see comments] Caldwell JC, et al. **Sci Am** 1996 Mar;274(3):62–3, 66–8. Comment in: Sci Am 1996 Jul;275(1):8.

AIDS cases reported, 1994–1995 [news] Doyle R. **Sci Am** 1996 Jun;274(6):28

AIDS: a global response [editorial] [see comments] Piot P. **Science** 1996 Jun 28;272(5270):1855. Comment in: Science 1996 Aug 16;273(5277):861.

Scope of the AIDS epidemic in the United States [see comments] Rosenberg PS. **Science** 1995 Nov 24; 270(5240):1372–5. Comment in: Science 1996 Mar 15;271(5255):1479–80; discussion 1480–1. Comment in: Science 1996 Mar 15;271(5255):1480; discussion 1480–1.

The epidemiology of HIV/AIDS. Hughes MJ, et al. **Semin Dermatol** 1995 Sep;14(3):191–201 (123 ref.)

Forecasting the AIDS epidemic in Puerto Rico. Löytönen M, et al. **Soc Sci Med** 1996 Apr;42(7):997–1010

Trends of AIDS incidence in Europe and the United States. Dal Maso L, et al. **Soz Praventivmed** 1995;40(4):239–65

Computing back–calculation estimates of AIDS epidemic. Ding Y. **Stat Med** 1995 Jul 30;14(14):1505–12

The shape of the distribution of the number of sexual partners. Kault D. **Stat Med** 1996 Jan 30;15(2):221–30

Assessment of HIV testing rates among HIV infected individuals using incidence data on HIV and AIDS diagnoses. Marschner IC. **Stat Med** 1996 Mar 15; 15(5):497–511

Reporting delay: a review with a simulation study and application to Spanish AIDS data. Sánchez Sellero C, et al. **Stat Med** 1996 Feb 15;15(3):305–21

A back–calculation method to estimate the age and period HIV infection intensity, considering the susceptible population. Verdecchia A, et al. **Stat Med** 1995 Jul 30; 14(14):1513–30

Behavioural risk factors for HIV infection amongst blood donors in London. Cowan FM, et al. **Transfus Med** 1996 Mar;6(1):31–6

Surveillance for human immunodeficiency virus type 1 group O infections in the United States. Pau CP, et al. **Transfusion** 1996 May;36(5):398–400

Malawi has the highest number of reported cases of AIDS [letter] Wilbrink J. **Trop Geogr Med** 1995;47(6):310–1

AIDS–related experiences of primary care physicians in rural California, 1995. Lewis CE. **West J Med** 1996 May; 164(5):415–8

Acquired immunodeficiency syndrome (AIDS)—data as at 15 December 1995. **Wkly Epidemiol Rec** 1995 Dec 15; 70(50):353–4 **(Eng, Fre)**

[Outcome of the HIV/AIDS pandemic in Africa and in Asia] Lepage P. **Arch Pediatr** 1996;3 Suppl 1:13s–16s **(Fre)**

[AIDS and childhood] Courpotin C, et al. **Bull Acad Natl Med** 1996 Mar;180(3):709–25 (27 ref.) **(Fre)**

[The epidemiology and cost of AIDS in France] Trotot PM, et al. **J Neuroradiol** 1995 Sep;22(3):136–41 (Eng. Abstr.) **(Fre)**

[Effect of primary prevention of Pneumocystis carinii pneumonia on the inaugural clinical and biological presentation of AIDS: 624 cases (Aquitaine Cohort, 1985–1994)] Morlat P, et al. **Rev Med Interne** 1995; 16(11):815–7 (Eng. Abstr.) **(Fre)**

[AIDS epidemiology in French–speaking, central Africa] Kapita B. **Sante** 1995 Sep–Oct;5(5):287–90 **(Fre)**

[The spread of HIV and AIDS: current numbers and trends (news)] **Dtsch Med Wochenschr** 1996 Aug 23; 121(34–35):A10–A11 **(Ger)**

[1994 annual report on the development of the HIV–AIDS epidemic in Germany (news)] **Pharm Unserer Zeit** 1995 Sep;24(5):285 **(Ger)**

[AIDS as a problem of great relevance for women's health] Conti S, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):133–5 **(Ita)**

[Analysis of cause of recent rise in number of foreigners reported to HIV/AIDS surveillance in Japan] Kihara M, et al. **Nippon Koshu Eisei Zasshi** 1995 Aug;42(8):569–78 (Eng. Abstr.) **(Jpn)**

[Prevalence of HIV and STD infection among foreign STD clinic attendants in Ibaragi prefecture, Japan] Kihara M, et al. **Nippon Koshu Eisei Zasshi** 1995 Aug;42(8):579–85 **(Jpn)**

[Medical care of AIDS patients by hospitals in Tokyo] Okajima F, et al. **Nippon Koshu Eisei Zasshi** 1995 Sep; 42(9):799–807 (Eng. Abstr.) **(Jpn)**

[The AIDS epidemic in Norway—where did it go?] Eskild A, et al. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):382–6 (26 ref.) (Eng. Abstr.) **(Nor)**

[AIDS and HIV infections in 1994] Szata W. **Przegl Epidemiol** 1996;50(1–2):205–12 **(Pol)**

[HIV/AIDS infection. The Brazilian view. AIDS in Brazil] Gonçalves AP, et al. **An R Acad Nac Med (Madr)** 1996; Spec No:145–56 (Eng. Abstr.) **(Por)**

[The social geography of AIDS in Brazil] Bastos FI, et al. **Rev Saude Publica** 1995 Feb;29(1):52–62 (38 ref.) (Eng. Abstr.) **(Por)**

[Evolution of the epidemiologic pattern of the cases of AIDS in Spain] Castilla Catalán J, et al. **Gac Sanit** 1995 May–Jun; 9(48):159–65 (Eng. Abstr.) **(Spa)**

[Comparative study of the prevalence of hepatitis B virus infection and human immunodeficiency virus type 1 infection in the prison population between 1985 and 1992] del Olmo JA, et al. **Gastroenterol Hepatol** 1995 Oct; 18(8):405–9 (Eng. Abstr.) **(Spa)**

[Changes in the spectrum of AIDS–defining diseases in Spain] Castilla J, et al. **Med Clin (Barc)** 1996 May 18;106(19):730–3 (Eng. Abstr.) **(Spa)**

[Retrovirus, drugs, and sex: a reflection beyond medicine (editorial)] Leal M. **Med Clin (Barc)** 1995 Sep 9; 105(7):255–6 **(Spa)**

[Type 2 human immunodeficiency virus infection (HIV–2) in Spain: analysis of the first 50 cases. Spanish Group for the Study of HIV–2] Soriano V, et al. **Med Clin (Barc)** 1995 Sep 9;105(7):241–5 (Eng. Abstr.) **(Spa)**

[The HIV/AIDS epidemic and women in Mexico] del Río–Zolezzi A, et al. **Salud Publica Mex** 1995 Nov–Dec; 37(6):581–91 (Eng. Abstr.) **(Spa)**

[AIDS cases in the rural area in Mexico] Magis–Rodríguez C, et al. **Salud Publica Mex** 1995 Nov–Dec;37(6):615–23 (Eng. Abstr.) **(Spa)**

[AIDS and neoplasms in Mexico] Mohar A, et al. **Salud Publica Mex** 1995 Nov–Dec;37(6):533–8 (Eng. Abstr.) **(Spa)**

[Sexually transmitted diseases and the HIV/AIDS epidemic] Valdespino–Gómez JL, et al. **Salud Publica Mex** 1995 Nov–Dec;37(6):549–55 (Eng. Abstr.) **(Spa)**

[The epidemiology of AIDS/HIV in Mexico: from 1983 to March 1995] Valdespino–Gómez JL, et al. **Salud Publica Mex** 1995 Nov–Dec;37(6):556–71 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Perceived function of and barriers to condom use in Arusha and Kilimanjaro regions of Tanzania. Mnyika KS, et al. **AIDS Care** 1995;7(3):295–305

Perception of AIDS risk and high–risk behaviors in African–American methadone–dependent women. Harris RM, et al. **AIDS Educ Prev** 1995 Oct;7(5):415–28

Overview of the Canadian study on the determinants of ethnoculturally specific behaviours related to HIV/AIDS. Adrien A, et al. **Can J Public Health** 1996 May–Jun;87 Suppl 1:S4–10 **(Eng, Fre)**

HIV/AIDS in the context of culture: selection of ethnocultural communities for study in Canada. Cappon P, et al. **Can J Public Health** 1996 May–Jun;87 Suppl 1:S11–4, S11–5 (50 ref.) **(Eng, Fre)**

HIV/AIDS in the context of culture [editorial] de Burger R. **Can J Public Health** 1996 May–Jun;87 Suppl 1:S3 **(Eng, Fre)**

Understanding use of condoms among Canadian ethnocultural communities: methods and main findings of the survey. Godin G, et al. **Can J Public Health** 1996 May–Jun;87 Suppl 1:S33–7, S36–41 **(Eng, Fre)**

Canadian ethnocultural communities facing AIDS: overview and summary of survey results from phase III. Maticka–Tyndale E, et al. **Can J Public Health** 1996 May–Jun;87 Suppl 1:S38–43, S42–8 **(Eng, Fre)**

Many voices—sociocultural results of the ethnocultural communities facing AIDS study in Canada. Singer SM, et al. **Can J Public Health** 1996 May–Jun;87 Suppl 1:S26–32, S28–35 **(Eng, Fre)**

Participatory aspects in the qualitative research design of phase II of the ethnocultural communities facing AIDS study. Willms D, et al. **Can J Public Health** 1996 May–Jun; 87 Suppl 1:S15–25, S16–27 **(Eng, Fre)**

Five conversations: reflections of stakeholders on the impact of the ethnocultural communities facing AIDS study. Willms D, et al. **Can J Public Health** 1996 May–Jun;87 Suppl 1:S44–8, S49–53 **(Eng, Fre)**

AIDS in Africans living in London. O'Farrell N, et al. **Genitourin Med** 1995 Dec;71(6):358–62

AIDS defining conditions in Africans resident in the United Kingdom. Del Amo J, et al. **Int J STD AIDS** 1996 Jan–Feb; 7(1):44–7

Alcohol, sexual practices, and risk of AIDS among blacks, Hispanics, and whites. Caetano R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 15;10(5):554–61

Epidemiology of AIDS among Hispanics in Chicago. Murphy J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):83–7

Latino women and AIDS risk. Peragallo N. **Public Health Nurs** 1996 Jun;13(3):217–22

AIDS and ethnicity [letter; comment] McMillan S. **Science** 1996 Mar 15;271(5255):1480; discussion 1480–1. Comment on: Science 1995 Nov 24;270(5240):1372–5.

AIDS and ethnicity [letter; comment] Males M. **Science** 1996 Mar 15;271(5255):1479–80; discussion 1480–1. Comment on: Science 1995 Nov 24;270(5240):1372–5.

ETIOLOGY

Retrospective versus prospective estimates of number of sexual partners [letter] Feldblum PJ, et al. **AIDS** 1995 Nov; 9(11):1294–5

Smoking marijuana before sex: a high–risk behavior in Jamaica? [letter] Simeon DT, et al. **AIDS** 1995 Nov; 9(11):1293–4

HIV risk factors and behaviors among men in a Milwaukee homeless shelter [letter] Kelly JA, et al. **Am J Public Health** 1995 Nov;85(11):1585

Network between main protagonists and events leading to AIDS. Larralde C, et al. **Arch Med Res** 1996 Summer; 27(2):107–13 (87 ref.)

The potential importance of MHC mimicry by HIV in the pathogenesis of AIDS. Sheikh J, et al. **Biochem Soc Trans** 1995 Aug;23(3):471S

Cause of AIDS [letter] Cook GC. **BMJ** 1996 May 11; 312(7040):1231

Commentary: non–HIV hypotheses must be studied more carefully [comment] Duesberg P. **BMJ** 1996 Jan 27; 312(7025):210–1. Comment on: BMJ 1996 Jan 27;312(7025):207–10.

Response: arguments contradict the "foreign protein–zidovudine" hypothesis. Sabin CA, et al. **BMJ** 1996 Jan 27;312(7025):211–2

Factors associated with progression to AIDS and mortality in a cohort of HIV–infected patients with hemophilia followed up since seroconversion. Santagostino E, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 May;41(3):371–80

AIDS pathogenesis: from models to viral dynamics in patients. Nowak MA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S1–5 (14 ref.)

Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. Dorrucci M, et al. **J Infect Dis** 1995 Dec;172(6):1503–8

An international collaborative study of the effects of coinfection with human T–lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. Hershow RC, et al. **J Infect Dis** 1996 Aug;174(2):309–17

From the Centers for Disease Control and Prevention. AIDS associated with injecting–drug use—United States, 1995. **JAMA** 1996 Jun 5;275(21):1628–9

Is HIV the cause of AIDS? [letter] Duesberg PH. **Lancet** 1995 Nov 18;346(8986):1371–2

AIDS associated with injecting–drug use—United States, 1995. **MMWR Morb Mortal Wkly Rep** 1996 May 17; 45(19):392–8

Duesberg and AIDS [letter] Derbyshire SW. **Nature** 1995 Oct 26;377(6551):672

Linkages between sexual risk taking, substance use, and AIDS knowledge among pregnant adolescents and young mothers. Koniak-Griffin D, et al. **Nurs Res** 1995 Nov-Dec; 44(6):340-6

Positively healthy. Moore W. **Nutr Health** 1995;10(3):209-16

Toward a unified-field theory of the pathogenesis of acquired immune deficiency syndrome [editorial] Jonas S. **Prev Med** 1995 Sep;24(5):423-4

My response to "polio vaccines and the origin of AIDS" [letter; comment] Koprowski H. **Res Virol** 1995 May-Jun; 146(3):233-4. Comment on: Res Virol 1993 Mar-Apr;144(2):175-7.

Risk of acquiring AIDS from salivary exchange through cardiopulmonary resuscitation courses and mouth-to-mouth resuscitation. Sun D, et al. **Semin Dermatol** 1995 Sep;14(3):205-11 (76 ref.)

Absence of human immunodeficiency virus type 2 infection among patients in a hospital serving a New York community at high risk for infection. Centers for Disease Control and Prevention/Bronx-Lebanon Hospital Center HIV Serosurvey Team. Irwin KL, et al. **Transfusion** 1996 Aug;36(8):731-3

Transfusion and cytomegalovirus-associated AIDS-defining disease in hemophiliacs. Hemophilia Malignancy Study. Ragni MV, et al. **Transfusion** 1996 Aug;36(8):681-4

GENETICS

Distinct HIV-1 long terminal repeat quasispecies present in nervous tissues compared to that in lung, blood and lymphoid tissues of an AIDS patient. Ait-Khaled M, et al. **AIDS** 1995 Jul;9(7):675-83

A genetic analysis of HIV-1 from Punjab, India reveals the presence of multiple variants. Jameel S, et al. **AIDS** 1995 Jul;9(7):685-90

Polymerase chain reaction in situ hybridization--opening Pandora's box? [editorial] Wiley CA. **Ann Neurol** 1996 Jun; 39(6):691-2

Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome A review of the literature examining associations with HLA. Just JJ. **Hum Immunol** 1995 Nov;44(3):156-69 (92 ref.)

Implications of genetic variability in HIV for epidemiology and public health. Anderson RM, et al. **Lancet** 1996 Jun 29;347(9018):1778-9

AIDS research. Receptor mutations help slow disease progression [news; comment] Cohen J. **Science** 1996 Sep 27;273(5283):1797-8. Comment on: Science 1996 Sep 27;273(5283):1856-62.

Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study [see comments] Dean M, et al. **Science** 1996 Sep 27; 273(5283):1856-62. Comment in: Science 1996 Sep 27;273(5283):1797-8.

HISTORY

The Pastorian: a legacy of Louis Pasteur. Varmus H. **Adv Cancer Res** 1996;69:1-16

In memoriam: David Byar as an AIDS activist. Harrington M. **Control Clin Trials** 1995 Aug;16(4):270-5

Was HIV present in 1959? [letter] Bailey AS, et al. **Lancet** 1996 Jan 20;347(8995):189

IMMUNOLOGY

From cell activation to cell depletion. The programmed cell death hypothesis of AIDS pathogenesis. Ameisen JC. **Adv Exp Med Biol** 1995;374:139-63 (159 ref.)

AIDS as immune system activation. Key questions that remain. Ascher MS, et al. **Adv Exp Med Biol** 1995; 374:203-10 (89 ref.)

Immunosuppression by a noncytolytic virus via T cell mediated immunopathology. Implication for AIDS. Zinkernagel RM. **Adv Exp Med Biol** 1995;374:165-71 (78 ref.)

Serum and saliva immunoglobulin A concentrations show an inverse relationship in HIV infection and AIDS [letter] Sweet SP, et al. **AIDS** 1995 Nov;9(11):1288-9

Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. Rivière Y, et al. **AIDS Res Hum Retroviruses** 1995 Aug;11(8):903-7

HLA class II on HIV particles is functional in superantigen presentation to human T cells: implications for HIV pathogenesis. Rossio JL, et al. **AIDS Res Hum Retroviruses** 1995 Dec;11(12):1433-9

Genetically engineered HIV type 1 peptides as tools for the determination of anti-V3 loop antibody titers in sera from HIV type 1-infected patients. Von Brunn A, et al. **AIDS Res Hum Retroviruses** 1995 Dec;11(12):1459-65

Preparation and characterization of human HIV type 1 neutralizing reference sera. Vujcic LK, et al. **AIDS Res Hum Retroviruses** 1995 Jul;11(7):783-7

Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients. Yamamoto N, et al. **AIDS Res Hum Retroviruses** 1995 Nov;11(11):1373-8

Molecular mechanisms of APO-1/Fas(CD95)-mediated apoptosis in tolerance and AIDS. Dhein J, et al. **Behring Inst Mitt** 1995 Jun;(96):13-20 (37 ref.)

Repair of the in vitro HIV-1-induced immunosuppression and blockade of the generation of functional suppressive CD8 cells by anti-alpha interferon and anti-Tat antibodies. Lachgar A, et al. **Biomed Pharmacother** 1996;50(1):13-8

Evidence for an antiviral effect and interferon neutralizing capacity in human sera; variability and implications for HIV infection. Fall LS, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):409-16

Contribution of alpha interferon (alpha IFN) to HIV-induced immunosuppression. Lachgar A, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):431-7

Cytotoxic T lymphocytes specific for the synthetic VEINCTR peptide, a sequence found within the Fas molecule and env gp120 in the blood of HIV-1 seropositive individuals. Moukrim Z, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):439-44

Differential elevation of circulating interleukin-1 beta, tumor necrosis factor alpha, and interleukin-6 in AIDS-associated cachectic states. Bélec L, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):117-20

Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS. Brenner BG, et al. **Clin Diagn Lab Immunol** 1994 Sep;1(5):538-44

Dysregulated production of interleukin-10 (IL-10) and IL-12 by peripheral blood lymphocytes from human immunodeficiency virus-infected individuals is associated with altered proliferative responses to recall antigens. Daftarian MP, et al. **Clin Diagn Lab Immunol** 1995 Nov; 2(6):712-8

Antineurofilament and antiretinal antibodies in AIDS patients with cytomegalovirus retinitis. Rosberger DF, et al. **Clin Diagn Lab Immunol** 1994 Jul;1(4):445-9

Decreased T-cell proliferative response to common environmental antigens could be an indicator of early human immunodeficiency virus-mediated lymphocyte lesions. Tassinari P, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):404-7

In vitro anti-HIV-1 antibody production in subjects in different stages of HIV-1 infection. Rusconi S, et al. **Clin Exp Immunol** 1995 Oct;102(1):26-30

CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Zanussi S, et al. **Clin Exp Immunol** 1996 Aug;105(2):220-4

Normal levels of allo- but increased levels of potentially autoreactive antibodies against ABO histo-blood group antigens in AIDS patients. Friedli F, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):96-100

Existence and failure of T-cell homeostasis prior to AIDS onset in HIV-infected injection drug users. Galai N, et al. **Clin Immunol Immunopathol** 1996 May;79(2):134-41

During HIV infection, CD4+ CD38+ T-cells are the predominant circulating CD4+ subset whose HLA-DR positivity increases with disease progression and whose V beta repertoire is similar to that of CD4+ CD38- T-cells. Ramzaoui S, et al. **Clin Immunol Immunopathol** 1995 Oct; 77(1):33-41

Elevated cytokine levels in a patient with AIDS and hypercalcemia: effects of therapy with pamidronate [letter] Carbone LD, et al. **Clin Infect Dis** 1995 Sep;21(3):699

Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome A review of the literature examining associations with HLA. Just JJ. **Hum Immunol** 1995 Nov;44(3):156-69 (92 ref.)

Selective inhibitory effects of stress hormones on natural killer (NK) cell activity of lymphocytes from AIDS patients. Nair MP, et al. **Immunol Invest** 1995 Aug; 24(5):689-99

AIDS: a disease of impaired Th-cell renewal? Heeney JL. **Immunol Today** 1995 Nov;16(11):515-20 (44 ref.)

Heat-shock protein expression on the membrane of T cells undergoing apoptosis. Poccia F, et al. **Immunology** 1996 May;88(1):6-12

Cerebrospinal fluid antiganglioside antibodies in patients with AIDS. Sorice M, et al. **Infection** 1995 Sep-Oct;23(5):288-91

Cytokines in the acquired immunodeficiency syndrome and other infectious diseases. Poli G, et al. **Int J Clin Lab Res** 1995;25(3):128-34 (58 ref.)

Increased radiosensitivity of normal tissue fibroblasts in patients with acquired immunodeficiency syndrome (AIDS) and with Kaposi's sarcoma. Formenti SC, et al. **Int J Radiat Biol** 1995 Oct;68(4):411-2

Increase in percentage of CD45RO+/CD8+ cells is associated with previous severe primary HIV infection [see comments] Bruunsgaard H, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):107-14. Comment in: J Acquir Immune Defic Syndr Hum Retrovirol 1996 Apr 1;11(4):411.

T-cell homeostasis, competition, and drift: AIDS as HIV-accelerated senescence of the immune repertoire. Mittler JE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jul; 12(3):233-48

Postoperative infection following orthopaedic surgery in human immunodeficiency virus-infected hemophiliacs with CD4 counts < or = 200/mm3. Ragni MV, et al. **J Arthroplasty** 1995 Dec;10(6):716-21

T-lymphocytes from AIDS patients are unable to synthesize ribonucleotides de novo in response to mitogenic stimulation. Impaired pyrimidine responses are already evident at early stages of HIV-1 infection. Bofil M, et al. **J Biol Chem** 1995 Dec 15;270(50):29690-7

Pathogenic and protective correlates of T cell proliferation in AIDS. HNRC Group. HIV Neurobehavioral Research Center. Schrier RD, et al. **J Clin Invest** 1996 Aug 1; 98(3):731-40

Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia [see comments] Simon HU, et al. **J Exp Med** 1996 Mar 1;183(3):1071-82. Comment in: J Exp Med 1996 Mar 1;183(3):721-4.

IL-12 expression in AIDS-related lymphoma B cell lines. Benjamin D, et al. **J Immunol** 1996 Feb 15;156(4):1626-37

Cytokine patterns during progression to AIDS in children with perinatal HIV infection. Hyjek E, et al. **J Immunol** 1995 Oct 15;155(8):4060-71

Antibodies to p24 antigen do not specifically detect HIV-infected lymphocytes in AIDS patients. Kux A, et al. **J Immunol Methods** 1996 May 27;191(2):179-86

Human studies in the development of human immunodeficiency virus vaccines. Dolin R. **J Infect Dis** 1995 Nov;172(5):1175-83 (91 ref.)

Human immunodeficiency virus type 1 (HIV-1)--and Epstein-Barr virus--specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1--infected persons. Geretti AM, et al. **J Infect Dis** 1996 Jul; 174(1):34-45

Relationship between infectious cell-associated human immunodeficiency virus type 1 load, T lymphocyte subsets, and stage of infection in homosexual men. Margolick JB, et al. **J Infect Dis** 1996 Feb;173(2):468-71

Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. Nyambi PN, et al. **J Infect Dis** 1995 Nov;172(5):1228-37

Synthesis of tumor necrosis factor-alpha mRNA in bronchoalveolar lavage cells from human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia. Rayment N, et al. **J Infect Dis** 1996 Sep;174(3):654-9

Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. Walker RE, et al. **J Infect Dis** 1996 Jul;174(1):63-8

Nonclassical mucosal antibodies predominate in genital secretions of HIV-1 infected chimpanzees. Israel ZR, et al. **J Med Primatol** 1995 Feb;24(2):53-60

T-helper reactivity to simian immunodeficiency virus gag synthetic peptides in human immunodeficiency virus type 2 infected individuals. Pinto LA, et al. **J Med Virol** 1995 Oct;47(2):139-44

Malignant testicular neoplasms in immunosuppressed patients. Leibovitch I, et al. **J Urol** 1996 Jun;155(6):1938-42 (41 ref.)

Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. Joag SV, et al. **J Virol** 1996 May;70(5):3189-97

Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. Lukashov VV, et al. **J Virol** 1995 Nov;69(11):6911-6

Intraepithelial gamma/delta T cells in duodenal mucosa are related to the immune state and survival time in AIDS. Nilssen DE, et al. **J Virol** 1996 Jun;70(6):3545-50

Multivariate analysis of human immunodeficiency virus type 1 neutralization data. Nyambi PN, et al. **J Virol** 1996 Sep; 70(9):6235-43

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. Trkola A, et al. **J Virol** 1995 Nov;69(11):6609-17

Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. Yang OO, et al. **J Virol** 1996 Sep;70(9):5799-806

Percentage of CD4 lymphocytes and risk of AIDS [letter; comment] Mocroft A, et al. **JAMA** 1995 Dec 20; 274(23):1836. Comment on: JAMA 1995 Aug 16;274(7):554-8.

9-year-old child with falling CD4 count after neonatal HIV [letter] Giaquinto C, et al. **Lancet** 1995 Oct 7;346(8980):963

AIDS--beyond helper T cells. Knight SC, et al. **Lancet** 1996 Sep 7;348(9028):631

Complete nucleotide sequence of Ig V genes in three cases of Burkitt lymphoma associated with AIDS. Eclache V, et al. **Leuk Lymphoma** 1996 Jan;20(3-4):281-90

Leukocyte adhesion molecules as a cofactor in AIDS: basic science and pilot study. Allen AD, et al. **Med Hypotheses** 1995 Aug;45(2):164-8

TNF and AIDS: two sides of the same coin? Pallarés-Trujillo J, et al. **Med Res Rev** 1995 Nov;15(6):533-46 (128 ref.)

Molecular biological bases of resistance to HIV/AIDS (the hypothesis with elements of the theory). Skripal IG. **Mikrobiol Z** 1995 Jul-Aug;57(4):89-105 (45 ref.)

Directions in HIV/AIDS research. A Minnesota perspective. Henry K, et al. **Minn Med** 1995 Nov;78(11):26-34 (17 ref.)

Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection [see comments] Kaslow RA, et al. **Nat Med** 1996 Apr; 2(4):405-11. Comment in: Nat Med 1996 Apr;2(4):395-6.

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women [published erratum appears in Nat Med 1995 Jun;1(6):598] Rowland-Jones S, et al. **Nat Med** 1995 Jan;1(1):59-64

Increased expression of activation markers on CD8 lymphocytes in children with human immunodeficiency

virus-1 infection. Schlesinger M, et al. **Pediatr Res** 1995 Sep;38(3):390-6

Major histocompatibility complex class II DR alleles DRB1*1501 and those encoding HLA-DR13 are preferentially associated with a diminution in maternally transmitted human immunodeficiency virus 1 infection in different ethnic groups: determination by an automated sequence-based typing method. Winchester R, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12374-8

Anti-CD4 therapy for AIDS suggested by mathematical models. De Boer RJ, et al. **Proc R Soc Lond B Biol Sci** 1996 Jul 22;263(1372):899-905

Augmentation of CD8 and CD4 lymphocytes subsets in AIDS infected children after treatment with a non-toxic chelating agents compound--Rodilemid. Dinu R, et al. **Rom J Intern Med** 1995 Jul-Dec;33(3-4):205-10

IFN-gamma restores HIV- and non-HIV-specific cell mediated immune response in vitro and its activity is neutralized by antibodies from patients with AIDS. De Francesco MA, et al. **Scand J Immunol** 1996 Jan; 43(1):94-100

AIDS conference. Chemokines share center stage with drug therapies [news] Cohen J. **Science** 1996 Jul 19; 273(5273):302-3

Toward an understanding of the correlates of protective immunity to HIV infection [see comments] Haynes BF, et al. **Science** 1996 Jan 19;271(5247):324-8 (73 ref.). Comment in: Science 1996 Feb 23;371(5252):1043. Comment in: Science 1996 May 31;272(5266):1362. Comment in: Science 1996 Jul 26;273(5274):415-6.

AIDS pathogenesis: a finite immune response to blame? [comment] Miedema F, et al. **Science** 1996 Apr 26; 272(5261):505-6 (18 ref.). Comment on: Science 1996 Apr 26;272(5261):537-42.

Overview: practical insights from comparative immunology and pathogenesis of AIDS, hepatitis B, and measles for developing an HIV vaccine. Hilleman MR. **Vaccine** 1995 Dec;13(18):1733-40 (41 ref.)

[Resisting AIDS?] Bonard EC. **Rev Med Suisse Romande** 1996 Mar;116(3):229-30 **(Fre)**

[Apoptosis of T-helper cells is massively increased in AIDS] Weismann H. **Dtsch Med Wochenschr** 1996 Jan 26; 121(4):A14 **(Ger)**

[The cytotoxic activity in intestinal lamina propria and peripheral blood in AIDS and Crohn disease] Fink CO, et al. **Z Gastroenterol** 1996 Feb;34(2):111-5 (Eng. Abstr.) **(Ger)**

[Self-defence power fighting against AIDS. Cellular immunity and its activation] Takahashi H. **Nippon Ika Daigaku Zasshi** 1995 Oct;62(5):539-46 (23 ref.) **(Jpn)**

[The relevance of phenotypic markers for progression in AIDS in HIV-1+ children] Zugun F, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul-Dec; 40(3-4):253-6 **(Rum)**

[Latent specific antibodies are found in the serum of patients with acquired immunodeficiency syndrome] Siziakina LP, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):315-6 **(Rus)**

[A comparison of lymphocyte populations of the blood and bronchoalveolar lavage in AIDS patients] Fernández E, et al. **Arch Bronconeumol** 1996 Jun-Jul;32(6):271-4 (Eng. Abstr.) **(Spa)**

[Relationship between AIDS and atopy (editorial)] Hernández Bautista VM, et al. **Rev Alerg Mex** 1995 Nov-Dec;42(6):96-7 **(Spa)**

[Simplified CD4+ T-lymphocyte count in patients with HIV/AIDS in Mexico] Guarner J, et al. **Salud Publica Mex** 1996 May-Jun;38(3):207-11 (Eng. Abstr.) **(Spa)**

METABOLISM

Oxytocin mRNA in the human paraventricular nucleus in AIDS. Guldenaar SE, et al. **Adv Exp Med Biol** 1995;395:91

Expression and cytokine regulation of glucocorticoid receptors in Kaposi's sarcoma. Guo WX, et al. **Am J Pathol** 1996 Jun;148(6):1999-2008

Immunihistochemical detection of Bcl-2 in AIDS-associated and classical Kaposi's sarcoma. Morris CB, et al. **Am J Pathol** 1996 Apr;148(4):1055-63

Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Vance E, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1355-60

Beta 2-microglobulin expression of AIDS-related and classical Kaposi's sarcoma. Petersen BL, et al. **APMIS** 1995 Jul-Aug;103(7-8):553-7

Clinical and pharmacokinetic evaluation of a new lipid-based delivery system of amphotericin B in AIDS patients. Villani P, et al. **Arzneimittelforschung** 1996 Apr;46(4):445-9

Estimation of oxytocin mRNA in the human paraventricular nucleus in AIDS by means of quantitative in situ hybridization. Guldenaar SE, et al. **Brain Res** 1995 Nov 27;700(1-2):107-14

Prealbumin, retinol-binding protein, and total salivary IgA in children with AIDS. Slobodianik NH, et al. **Clin Chem** 1996 Mar;42(3):471-2

Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1. Wolfe EJ, et al. **Clin Pharmacol Ther** 1996 Jun; 59(6):662-7

The coat protein gp120 of HIV-1 inhibits astrocyte uptake of excitatory amino acids via macrophage arachidonic acid. Dreyer EB, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2502-7

Histological study of oxalosis in the eye and adnexa of AIDS patients. Pecorella I, et al. **Histopathology** 1995 Nov; 27(5):431-8 (22 ref.)

Glucocorticoid reserve in patients with acquired immunodeficiency syndrome. Peter SA, et al. **Horm Res** 1995;44(2):85-8

Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS. Burger D, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):163-8

CD4+ and CD8+ lymphocytes of patients with AIDS synthesize increased amounts of interferon-gamma. Caruso A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):462-70

Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS. Sippy BD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 15;10(5):511-21

Marked variation in pyrimethamine disposition in AIDS patients treated for cerebral toxoplasmosis. Winstanley P, et al. **J Antimicrob Chemother** 1995 Aug;36(2):435-9

Glucocorticoids and interferon-alpha in the acquired immunodeficiency syndrome. Norbiato G, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2601-6

Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor. Aweeka FT, et al. **J Clin Pharmacol** 1995 Sep;35(9):856-64

Impaired hepatic protein synthesis in AIDS patients with low vitamin A levels [letter; comment] Haas DW, et al. **J Infect Dis** 1995 Oct;172(4):1167-9. Comment on: J Infect Dis 1995 May;171(5):1196-202.

Increased NADPH-diaphorase reactivity and cytokine expression in dorsal root ganglia in acquired immunodeficiency syndrome. Nagano I, et al. **J Neurol Sci** 1996 Mar;136(1-2):117-28

Study of receptor-mediated neurotoxins released by HIV-1-infected mononuclear phagocytes found in human brain. Giulian D, et al. **J Neurosci** 1996 May 15; 16(10):3139-53

Neuronal expression of human immunodeficiency virus type 1 env proteins in transgenic mice: distribution in the central nervous system and pathological alterations. Berrada F, et al. **J Virol** 1995 Nov;69(11):6770-8

Decreased expression of AMPA receptor messenger RNA and protein in AIDS: a model for HIV-associated neurotoxicity. Everall IP, et al. **Nat Med** 1995 Nov; 1(11):1174-8

Plasma concentration of cytokine antagonists in patients with HIV infection. Catania A, et al. **Neuroimmunomodulation** 1994 Jan;1(1):42-9

TNF alpha production by whole blood from HIV-1 infected patients. Benyoucef S, et al. **Pathol Biol (Paris)** 1996 May; 44(5):393-6

The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients. Nazareno LA, et al. **Pharm Res** 1995 Oct;12(10):1462-5

[Thyroid and AIDS] Bonnyns M, et al. **Rev Med Brux** 1995 Nov;16(5):361-3 (16 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Bone marrow cryptococcosis in an AIDS hemophiliac (morphological aspect in routine hematology) [letter] Fillola G, et al. **Ann Biol Clin (Paris)** 1995;53(10-11):561-2

Multiple serovars of Mycobacterium avium complex in patients with AIDS. Julander I, et al. **APMIS** 1996 Apr; 104(4):318-20

Mycobacterium genavense invasive infection in two children with AIDS: long-term followup. Reymond D, et al. **Eur J Pediatr** 1995;154(9 Suppl 4):S74-6

AIDS-associated mycoplasmas possess phospholipases C in the membrane. Shibata K, et al. **Infect Immun** 1995 Oct; 63(10):4174-7

A new group (type 3) of Mycobacterium celatum isolated from AIDS patients in the London area. Bull TJ, et al. **Int J Syst Bacteriol** 1995 Oct;45(4):861-2

Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. Le Guennec R, et al. **J Clin Microbiol** 1995 Oct;33(10):2732-7

Identification of virulence-associated antigens and plasmids in Rhodococcus equi from patients with AIDS. Takai S, et al. **J Infect Dis** 1995 Nov;172(5):1306-11

Molecular karyotyping of multiple yeast species isolated from nine patients with AIDS during prolonged fluconazole therapy. Espinel-Ingroff A, et al. **J Med Vet Mycol** 1996 Mar-Apr;34(2):111-6

HIV-1 subtype B in west Africa [letter; comment] Ariyoshi K, et al. **Lancet** 1996 Feb 3;347(8997):328. Comment on: Lancet 1995 Sep 16;346(8977):782.

Plant bacterial spores, active systemically as a separate entity, play a significant role in human illnesses such as cancer, granulomas, AIDS, and milky white abdominal ascites that currently defies recognition. White MW. **Med Hypotheses** 1995 Jun;44(6):493-503

Ribosomal internal transcribed spacer sequences are identical among Mycobacterium avium-intracellulare complex isolates from AIDS patients, but vary among isolates from elderly pulmonary disease patients. De Smet KA, et al. **Microbiology** 1995 Oct;141 (Pt 10):2739-47

Mycobacterium avium complex (MAC): an unusual potential pathogen in cerebrospinal fluid of AIDS patients. Hadad DJ, et al. **Rev Inst Med Trop Sao Paulo** 1995 Mar-Apr; 37(2):93-8

MORTALITY

Relationship between cytomegalovirus cells and survival in acquired immunodeficiency syndrome patients. Lemert CM, et al. **Acta Cytol** 1996 Mar-Apr;40(2):205-10

Survival after AIDS among Italian haemophiliacs with HIV infection. The Italian Group on Congenital Coagulopathies. Ghirardini A, et al. **AIDS** 1995 Dec;9(12):1351-6

Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. Moore RD, et al. **AIDS** 1995 Dec;9(12):1337-42

Effects of AIDS-related bereavement on HIV progression among New York City gay men. Kemeny ME, et al. **AIDS Educ Prev** 1995;7(5 Suppl):36-47

Causes of death in Florida prisons: the dominance of AIDS [letter] Amankwaa AA. **Am J Public Health** 1995 Dec; 85(12):1710-1

The migration of persons with AIDS: data from 12 states, 1985 to 1992. AIDS Mortality Project Group. Buehler JW, et al. **Am J Public Health** 1995 Nov;85(11):1552-5

Mortality attributable to HIV infection among persons aged 25-44 years--US, 1994 [news] **Ann Pharmacother** 1996 May;30(5):564

Empirical estimation of a distribution function with truncated and doubly interval-censored data and its application to AIDS studies. Sun J. **Biometrics** 1995 Sep;51(3):1096-104

Tuberculosis as a predictor of survival in AIDS. Study had several flaws [letter; comment] Holmes WC, et al. **BMJ** 1996 Mar 23;312(7033):776. Comment on: BMJ 1995 Dec 2;311(7018):1468-71.

Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. AIDS in Europe Study Group [see comments] Perneger TV, et al. **BMJ** 1995 Dec 2; 311(7018):1468-71. Comment in: BMJ 1996 Mar 23;312(7033):776.

Factors associated with progression to AIDS and mortality in a cohort of HIV-infected patients with hemophilia followed up since seroconversion. Santagostino E, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):371-80

Acquired immunodeficiency syndrome, Pneumocystis carinii pneumonia, and futility [editorial; comment] Notterman DA. **Crit Care Med** 1996 Jun;24(6):907-9. Comment on: Crit Care Med 1996 Jun;24(6):963-7.

Completeness of AIDS reporting and quality of AIDS death certification in Tuscany (Italy): a linkage study between surveillance system of cases and death certificates. Barchielli A, et al. **Eur J Epidemiol** 1995 Oct;11(5):513-7

Survival differences in Austrian patients with the acquired immunodeficiency syndrome. Zangerle R, et al. **Eur J Epidemiol** 1995 Oct;11(5):519-26

AIDS survival and progression in black Africans living in south London, 1986-1994. Low N, et al. **Genitourin Med** 1996 Feb;72(1):12-6

Survival of AIDS patients in the emerging epidemic in Bangkok, Thailand. Kitayaporn D, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):77-82

Weight loss prior to clinical AIDS as a predictor of survival. Multicenter AIDS Cohort Study Investigators. Palenicek JP, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Nov 1;10(3):366-73

On the use of auxiliary data to estimate the survival function and its variance: an application to acquired immunodeficiency syndrome. Flandre P. **J Clin Epidemiol** 1996 Aug;49(8):899-905

The role of functional status in predicting inpatient mortality with AIDS: a comparison with current predictors. Justice AC, et al. **J Clin Epidemiol** 1996 Feb;49(2):193-201

Estimation of survival after AIDS diagnosis: CD4 T lymphocyte count versus clinical severity. Turner BJ, et al. **J Clin Epidemiol** 1996 Jan;49(1):59-65

Iron overload as a mechanism for the lowered survival in AIDS patients receiving dapsone-iron protoxalate for secondary prophylaxis of Pneumocystis carinii pneumonia [letter; comment] Weinberg GA. **J Infect Dis** 1996 Jul; 174(1):241-2. Comment on: J Infect Dis 1995 Sep;172(3):656-64.

Impact of the human immunodeficiency virus type-1 on common pediatric illnesses in Zambia. Chintu C, et al. **J Trop Pediatr** 1995 Dec;41(6):348-53

Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. O'Brien TR, et al. **JAMA** 1996 Jul 10;276(2):105-10

Survival of patients with AIDS depends on physicians' experience treating the disease [news] Stephenson J. **JAMA** 1996 Mar 13;275(10):745-6

Euthanasia and physician-assisted suicide in homosexual men with AIDS [see comments] Bindels PJ, et al. **Lancet** 1996 Feb 24;347(9000):499-504. Comment in: Lancet 1996 Apr 13;347(9007):1046.

Unnatural death, AIDS, and coroners. Brahams D. **Lancet** 1996 Mar 23;347(9004):777

Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. UK Haemophilia Centre Directors' Organisation [see comments] Darby SC, et al. **Lancet** 1996 Jun 8; 347(9015):1573-9. Comment in: Lancet 1996 Jun 8;347(9015):1569-70.

Mortality and haemophilia [letter] Goedert JJ. **Lancet** 1995

Nov 25;346(8987):1425–6

Global burden of the HIV epidemic [letter; comment] Stewart GT. **Lancet** 1996 Aug 17;348(9025):480–1. Comment on: Lancet 1996 Jul 13;348(9020):99–106.

Age as a prognostic factor in AIDS [letter] Tumbarello M, et al. **Lancet** 1996 Aug 31;348(9027):623–4

The severity classification system for acquired immunodeficiency syndrome hospitalizations. Association with survival after discharge and inpatient resource use. Friedman LA, et al. **Med Care** 1996 Feb;34(2):178–89

Life time expectancy of hemophilia patients infected with HIV–1 with the risk of hepatocellular carcinoma after HCV infection. Tatsunami S, et al. **Medinfo** 1995;8 Pt 2:912

Physicians' experience and survival in patients with AIDS [letter; comment] Bach PB. **N Engl J Med** 1996 Aug 1; 335(5):349–50; discussion 350–1. Comment on: N Engl J Med 1996 Mar 14;334(11):701–6.

Physicians' experience and survival in patients with AIDS [letter; comment] Coker RJ, et al. **N Engl J Med** 1996 Aug 1;335(5):349; discussion 350–1. Comment on: N Engl J Med 1996 Mar 14;334(11):701–6.

Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival [see comments] Kitahata MM, et al. **N Engl J Med** 1996 Mar 14; 334(11):701–6. Comment in: N Engl J Med 1996 Mar 14;334(11):729–31. Comment in: N Engl J Med 1996 Aug 1;335(5):349; discussion 350–1. Comment in: N Engl J Med 1996 Aug 1;335(5):349–50; discussion 350–1.

Race, sex, drug use, and human immunodeficiency virus disease [letter; comment] Turner BJ, et al. **N Engl J Med** 1996 Jan 11;334(2):123–4. Comment on: N Engl J Med 1995 Sep 21;333(12):751–6.

Improving the outcomes of care for patients with human immunodeficiency virus infection [editorial; comment] [see comments] Volberding PA. **N Engl J Med** 1996 Mar 14; 334(11):729–31. Comment on: N Engl J Med 1996 Mar 14;334(11):701–6. Comment in: N Engl J Med 1996 Aug 1;335(5):350; discussion 350–1. Comment in: N Engl J Med 1996 Aug 1;335(5):350; discussion 351.

A comparison of two computer–based prognostic systems for AIDS. Ohno–Machado L, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:737–41

Characterization of HIV incubation distributions and some comparative studies. Tan WY, et al. **Stat Med** 1996 Jan 30;15(2):197–220

[AIDS—the leading cause of death among young adult men in Copenhagen and Frederiksberg] Fouchard JR, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3448–50 (Eng. Abstr.) **(Dan)**

[Survival time after the diagnosis of AIDS in the county of Funen] Hornstrup MK, et al. **Ugeskr Laeger** 1996 Mar 18;158(12):1667–9 (Eng. Abstr.) **(Dan)**

[Incidence of AIDS in the mortality of young women in the UHC (University Hospital Center) of Nice (letter)] Bongain A, et al. **Presse Med** 1996 Apr 27;25(15):731 **(Fre)**

[World Health Report shows children as the sad losers. Almost 10 million AIDS orphans can be expected (news)] Knauer RH. **Fortschr Med** 1995 Dec 10;113(34):18–9 **(Ger)**

[HIV infections in Switzerland] Schneider RE. **Internist (Berl)** 1996 Apr;37(4):419–21 **(Ger)**

NURSING

Jordanian and Canadian nursing students' knowledge about AIDS. al–Ma'aitah R, et al. **Int Nurs Rev** 1996 May–Jun; 43(3):89–92

Nurses' knowledge and beliefs about AIDS: comparing nurses in hospital, community and hospice settings. Steele A, et al. **J Adv Nurs** 1995 Nov;22(5):879–87

Perceived barriers to getting published: results of the JANAC survey. Meisenhelder JB, et al. **J Assoc Nurses AIDS Care** 1995 Nov–Dec;6(6):57–62

Stigma: baccalaureate nursing students' attitudes toward persons living with AIDS. Leasure R, et al. **J Nurs Educ** 1996 May;35(5):234–6

A critical experiential teaching strategy: student and faculty participation in an AIDS walk. Patsdaughter CA, et al. **J Nurs Educ** 1996 May;35(5):223–6

Nurses' attitudes about acquired immunodeficiency syndrome care: what research tells us. Bennett JA. **J Prof Nurs** 1995 Nov–Dec;11(6):339–50 (67 ref.)

Factors associated with student nurses' intent to provide physical and psychosocial care to persons with acquired immunodeficiency syndrome. Cole FL. **J Prof Nurs** 1996 Jul–Aug;12(4):217–24

Re: Cole and Slocumb's response to "AIDS, nurses' intentions, and the interpretation of findings" [letter; comment] Bennett JA. **Res Nurs Health** 1996 Feb; 19(1):83–4. Comment on: Res Nurs Health 1995 Apr;18(2):185–9.

Quality of life in nurse case management of persons with AIDS receiving home care. Nickel JT, et al. **Res Nurs Health** 1996 Apr;19(2):91–9

[Hygienic aspects with regard to nursing of home care patients with AIDS, chronic diseases and mental handicaps] Sonntag HG, et al. **Zentralbl Hyg Umweltmed** 1995 Apr; 197(1–3):26–44 (Eng. Abstr.) **(Ger)**

PARASITOLOGY

Specific detection of the microsporidia Encephalitozoon intestinalis in AIDS patients. Ombrouck C, et al. **C R Acad Sci III** 1996 Jan;319(1):39–43

Disseminated Encephalitozoon (Septata) intestinalis infection in a patient with AIDS: novel diagnostic approaches and autopsy–confirmed parasitological cure following treatment with albendazole. Sobottka I, et al. **J Clin Microbiol** 1995 Nov;33(11):2948–52

Detection and identification of gastrointestinal microsporidia using non–invasive techniques. Corcoran GD, et al. **J Clin Pathol** 1995 Aug;48(8):725–7

Comparative development of two microsporidian species: Enterocytozoon bieneusi and Enterocytozoon salmonis, reported in AIDS patients and salmonid fish, respectively. Desportes–Livage I, et al. **J Eukaryot Microbiol** 1996 Jan–Feb;43(1):49–60

Characterization of Encephalitozoon (Septata) intestinalis isolates cultured from nasal mucosa and bronchoalveolar lavage fluids of two AIDS patients. Didier ES, et al. **J Eukaryot Microbiol** 1996 Jan–Feb;43(1):34–43

PATHOLOGY

Diagnostic value of stereotactic biopsy of cerebral lesions in patients with AIDS. Alesch F, et al. **Acta Neurochir (Wien)** 1995;134(3–4):214–9

Programmed cell death in brains of HIV–1–positive AIDS and pre–AIDS patients. An SF, et al. **Acta Neuropathol (Berl)** 1996;91(2):169–73

Cytomegalovirus infection of the brain in AIDS: a clinicopathological study. Setinek U, et al. **Acta Neuropathol (Berl)** 1995;90(5):511–5

The role of the cell cycle in HIV–1 infection. Zack JA. **Adv Exp Med Biol** 1995;374:27–31 (26 ref.)

The ear in the acquired immunodeficiency syndrome: I. Temporal bone histopathologic study. Michaels L, et al. **Am J Otol** 1994 Jul;15(4):515–22

Ultrastructural findings in the vestibular end–organs of AIDS cases. Pappas DG Jr, et al. **Am J Otol** 1995 Mar;16(2):140–5

Immunihistochemical detection of Bcl–2 in AIDS–associated and classical Kaposi's sarcoma. Morris CB, et al. **Am J Pathol** 1996 Apr;148(4):1055–63

Six billion neurons lost in AIDS. A stereological study of the neocortex. Oster S, et al. **APMIS** 1995 Jul–Aug; 103(7–8):525–9

Changing patterns of autopsy findings among persons with acquired immunodeficiency syndrome in an inner–city population. A 12–year retrospective study. Sehonanda A, et al. **Arch Pathol Lab Med** 1996 May;120(5):459–64

The CD4+ T–cell network and the cytokine profile after HIV–1 infection. Caterino–de–Araujo A. **Braz J Med Biol Res** 1995 Jan;28(1):2–6

A sonographic–pathological correlation of liver biopsies in patients with the acquired immune deficiency syndrome (AIDS). Beale TJ, et al. **Clin Radiol** 1995 Nov;50(11):761–4

Primary brain tumors in the acquired immunodeficiency syndrome. DeAngelis LM. **Curr Opin Neurol** 1995 Dec; 8(6):419–23 (35 ref.)

Open lung biopsy for investigation of acute respiratory episodes in patients with HIV infection and AIDS. Miller RF, et al. **Genitourin Med** 1995 Oct;71(5):280–5

Histological study of oxalosis in the eye and adnexa of AIDS patients. Pecorella I, et al. **Histopathology** 1995 Nov; 27(5):431–8 (22 ref.)

In situ amplification and detection of HIV–1 DNA in fixed pediatric AIDS brain tissue. Sharer LR, et al. **Hum Pathol** 1996 Jun;27(6):614–7

AIDS: a disease of impaired Th–cell renewal? Heeney JL. **Immunol Today** 1995 Nov;16(11):515–20 (44 ref.)

Autopsy report of a case of perinatal AIDS. Lanjewar DN, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S24–5

Mixed cerebral pathology in AIDS patients [letter] Laing RB, et al. **J Infect** 1996 Mar;32(2):174

Paraneoplastic necrotising myelopathy in a case of AIDS with lymphoma [letter] Drach LM, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb;60(2):237

Con A cytotoxicity: a model for the study of key signaling steps leading to lymphocyte apoptosis in AIDS? Pitts OM. **Med Hypotheses** 1995 Sep;45(3):311–5

Association of hepatic veno–occlusive disease with the acquired immunodeficiency syndrome. Buckley JA, et al. **Mod Pathol** 1995 May;8(4):398–401

Clinical viral infections and temporal bone histologic studies of patients with AIDS. Davis LE, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):695–701

The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases. Martinez AJ, et al. **Pathol Res Pract** 1995 Jun;191(5):427–43

Pneumocystis carinii pneumonia with an atypical granulomatous response. Flannery MT, et al. **South Med J** 1996 Apr;89(4):409–10

[Maxillofacial manifestations of AIDS] Dompmartin A, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):230–3 **(Fre)**

[Disseminated Kaposi's sarcoma with hepatosplenic involvement in AIDS] González–López A, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):622–3 (15 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Molecular basis of cell cycle dependent HIV–1 replication. Implications for control of virus burden. Stevenson M, et al. **Adv Exp Med Biol** 1995;374:33–45 (56 ref.)

Alcohol consumption as a cofactor in the progression of HIV infection and AIDS. Penkower L, et al. **Alcohol** 1995 Nov–Dec;12(6):547–52

Myocardial atrophy in acquired immunodeficiency syndrome--associated wasting. Samaan SA, et al. **Am Heart J** 1995 Oct;130(4):823–7

Induction of adrenal suppression by megestrol acetate [letter] Khoo SH, et al. **Ann Intern Med** 1996 Mar 15;124(6):613

No evidence of a higher risk of progression to AIDS in patients with HIV–1–related severe thrombocytopenia. Galli M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jul; 12(3):268–75

14–year follow–up of HIV–infected homosexual men with lymphadenopathy syndrome [letter] Kaplan JE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):206–8

Replacing time since human immunodeficiency virus infection by marker values in predicting residual time to acquired immunodeficiency syndrome diagnosis. Multicenter AIDS Cohort Study. Shi M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jul; 12(3):309–16

Clinical profile of AIDS in India: a review of 61 cases. Chacko S, et al. **J Assoc Physicians India** 1995 Aug; 43(8):535–8 (25 ref.)

Hypothalamo–pituitary–adrenal function in human immunodeficiency virus–infected men. Lortholary O, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):791–6

Quantitative measures of human immunodeficiency virus–specific antibodies predict progression to AIDS. Strathdee SA, et al. **J Infect Dis** 1995 Nov;172(5):1375–9

AIDS is a multifactorial neuroimmunoendocrine disorder due to energy crisis in the 'Milieu Interieur' [letter] Spartalis MA. **J Natl Med Assoc** 1995 Oct;87(10):729, 731

Clinical evaluation of 451 patients with HIV related non–Hodgkin's lymphoma: experience on the Italian cooperative group on AIDS and tumors (GICAT). Tirelli U, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):91–6

Clinical predictors of functioning in persons with acquired immunodeficiency syndrome. Wilson IB, et al. **Med Care** 1996 Jun;34(6):610–23

HIV and the cortisol connection: a feasible concept of the process of AIDS. Corley PA. **Med Hypotheses** 1995 Jun; 44(6):483–9

Anterior pituitary and pituitary–dependent target organ function in men infected with the human immunodeficiency virus. Wilson LD, et al. **Metabolism** 1996 Jun;45(6):738–46

Changes in plasma HIV–1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS [see comments] O'Brien WA, et al. **N Engl J Med** 1996 Feb 15; 334(7):426–31. Comment in: N Engl J Med 1996 Jun 20;334(25):1671; discussion 1672–3. Comment in: N Engl J Med 1996 Jun 20;334(25):1671–2; discussion 1672–3. Comment in: N Engl J Med 1996 Jun 20;334(25):1672; discussion 1672–3.

Failure of T–cell homeostasis preceding AIDS in HIV–1 infection. The Multicenter AIDS Cohort Study [see comments] Margolick JB, et al. **Nat Med** 1995 Jul; 1(7):674–80. Comment in: Nat Med 1995 Jul;1(7):621–2.

Growth hormone and AIDS–related wasting [news] Steele FR. **Nat Med** 1996 Apr;2(4):369–70

Ocular motor dysfunction in HIV–1–infected subjects: a quantitative oculographic analysis. Johnston JL, et al. **Neurology** 1996 Feb;46(2):451–7

Taste and smell losses in HIV infected patients. Graham CS, et al. **Physiol Behav** 1995 Aug;58(2):287–93

Catabolic hormones and growth hormone resistance in acquired immunodeficiency syndrome and other catabolic states. Rodgers BD. **Proc Soc Exp Biol Med** 1996 Sep; 212(4):324–31 (106 ref.)

Opportunistic and non–opportunistic parasites in HIV–positive and negative patients with diarrhoea in Tanzania. Gomez Morales MA, et al. **Trop Med Parasitol** 1995 Jun;46(2):109–14

[Cofactors in the course of HIV infection] Meyer L, et al. **Presse Med** 1996 Mar 2–9;25(8):379–80, 382–4 (35 ref.) (Eng. Abstr.) **(Fre)**

[Stimulus of the hypophyseal–adrenocortical axis with corticotropin releasing hormone (CRH) in acquired immunodeficiency syndrome. Evidence for activation of the immune–neuroendocrine system] Lewi DS, et al. **Rev Assoc Med Bras** 1995 Mar–Apr;41(2):109–18 (Eng. Abstr.) **(Por)**

[Vesicourethral dysfunction in the acquired immunodeficiency syndrome (AIDS)] Begara Morillas FJ, et al. **Arch Esp Urol** 1995 Nov;48(9):915–21 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Is there a role for contact tracing in preventing HIV transmission among injecting drug users? [editorial] Hall W, et al. **Addiction** 1996 Jul;91(7):917–9

The relationship of moral reasoning and AIDS knowledge to risky sexual behavior. Hubbs–Tait L, et al. **Adolescence** 1995 Fall;30(119):549–64

AIDS prevention research in the developing world. **AIDS** 1995 Jul;9 Suppl 1:S1–77

Results of a model AIDS prevention program for high school students in the Philippines. Aplasca MR, et al. **AIDS** 1995 Jul;9 Suppl 1:S7–13

Female partners of AIDS patients in Uganda: reported

knowledge, perceptions and plans. Baingana G, et al. **AIDS** 1995 Jul;9 Suppl 1:S15–9

Impact of an intervention on HIV, sexually transmitted diseases, and condom use among sex workers in Bombay, India. Bhave G, et al. **AIDS** 1995 Jul;9 Suppl 1:S21–30

Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. Celentano DD, et al. **AIDS** 1995 Sep;9(9):1079–83

AIDS behind bars: preventing HIV spread among incarcerated drug injectors [editorial] Dolan K, et al. **AIDS** 1995 Aug;9(8):825–32 (72 ref.)

Collaborative AIDS prevention research in the developing world: the CAPS experience. Hearst N, et al. **AIDS** 1995 Jul;9 Suppl 1:S1–5

Adolescent sexuality in Saint Petersburg, Russia. Lunin I, et al. **AIDS** 1995 Jul;9 Suppl 1:S53–60

'Superstar' and 'model brothel': developing and evaluating a condom promotion program for sex establishments in Chiang Mai, Thailand. Visrutaratna S, et al. **AIDS** 1995 Jul;9 Suppl 1:S69–75

Responding to the AIDS epidemic in Asia and the Pacific: report on the Third International Conference on AIDS in Asia and the Pacific, Chiang Mai, Thailand, 17–21 September, 1995. Ford NJ. **AIDS Care** 1996 Feb; 8(1):117–24 (7 ref.)

AIDS prevention training for pharmacy workers in Mexico City. Pick S, et al. **AIDS Care** 1996 Feb;8(1):55–69

Regional training in AIDS prevention for health and behavioural science leaders in north-eastern Brazil. Sipan CL, et al. **AIDS Care** 1996 Feb;8(1):71–84

Outcomes of a risk-reduction intervention with high-risk populations: the Harlem AIDS project. Deren S, et al. **AIDS Educ Prev** 1995 Oct;7(5):379–90

My guardian angel: a learning exercise for adolescent AIDS education. Geiger BF, et al. **AIDS Educ Prev** 1996 Feb; 8(1):86–91

Childhood sexual abuse linked with adult substance use, victimization, and AIDS-risk. Johnsen LW, et al. **AIDS Educ Prev** 1996 Feb;8(1):44–57

Assisting gay men to maintain safer sex: an evaluation of an AIDS service organization's safer sex maintenance program. Miller RL. **AIDS Educ Prev** 1995;7(5 Suppl):48–63

AIDS education for college students: review and proposal for a research-based curriculum. Mulvihill CK. **AIDS Educ Prev** 1996 Feb;8(1):11–25 (72 ref.)

Patterns of HIV/AIDS in Zimbabwe: implications for health education. Munodawafa D, et al. **AIDS Educ Prev** 1996 Feb;8(1):1–10

AIDS prevention with adolescents. Rotheram-Borus MJ, et al. **AIDS Educ Prev** 1995 Aug;7(4):320–36 (125 ref.)

Early childhood differentials in mother-child AIDS-information interaction. Sly DF, et al. **AIDS Educ Prev** 1995 Aug;7(4):337–54

Quasi-experimental evaluation of three AIDS prevention activities for maintaining knowledge, improving attitudes, and changing risk behaviors of high school seniors. Smith MU, et al. **AIDS Educ Prev** 1995 Oct;7(5):391–402

HIV/AIDS knowledge among the U.S. population. Sweat MD, et al. **AIDS Educ Prev** 1995 Aug;7(4):355–72

New insights into the role of host cell proteins in antiviral vaccine protection [letter] Montefiori DC. **AIDS Res Hum Retroviruses** 1995 Dec;11(12):1429–31

Public health policies for HIV/AIDS prevention [letter; comment] Handsfield HH. **Am Fam Physician** 1996 Jul; 54(1):66, 68. Comment on: Am Fam Physician 1995 Nov 1;52(6):1682.

Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs [see comments] Des Jarlais DC, et al. **Am J Public Health** 1995 Nov;85(11):1577–84 (39 ref.). Comment in: Am J Public Health 1995 Nov;85(11):1490–1.

Improving HIV/AIDS prevention in prisons is good public health policy [editorial; comment] Gaiter J, et al. **Am J Public Health** 1996 Sep;86(9):1201–3. Comment on: Am J Public Health 1996 Sep;86(9):1211–5.

Family planning, sexually transmitted diseases, and the prevention of AIDS—divided we fail? [editorial] Stein Z. **Am J Public Health** 1996 Jun;86(6):783–4

Project youth inform—a school-based sexually transmitted disease/acquired immune deficiency syndrome education programme. Soon T, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):541–6

A randomized, controlled effectiveness trial of an AIDS prevention program for low-income African-American youths. Stanton BF, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):363–72

The control of communicable diseases in Australia [editorial; comment] Douglas B. **Aust J Public Health** 1995 Dec; 19(6):545–6. Comment on: Aust J Public Health 1995 Dec;19(6):634–8.

French bishops ease ban on condoms [news] [see comments] Dorozynski A. **BMJ** 1996 Feb 24;312(7029):462. Comment in: BMJ 1996 Jun 8;312(7044):1478.

AIDS message not getting through to young gay men [news] Sheldon T. **BMJ** 1996 Jul 13;313(7049):72–3

China steps up battle against AIDS [news] Tomlinson R. **BMJ** 1996 Apr 27;312(7038):1056

Australia launches third AIDS strategy [news] Zinn C. **BMJ** 1995 Oct 21;311(7012):1045–6

AIDS-related behaviour in adolescents: intervention programme with international application. Nikolopoulos TP, et al. **Br J Clin Pract** 1995 Sep-Oct;49(5):229–31

Knowledge of seafarers about AIDS problems and their vulnerability to HIV infection. Sesar Z, et al. **Bull Inst Marit Trop Med Gdynia** 1995;46(1–4):19–22

Understanding use of condoms among Canadian ethnocultural communities: methods and main findings of the survey. Godin G, et al. **Can J Public Health** 1996 May-Jun;87 Suppl 1:S33–7, S36–41 **(Eng, Fre)**

Canadian ethnocultural communities facing AIDS: overview and summary of survey results from phase III. Maticka-Tyndale E, et al. **Can J Public Health** 1996 May-Jun;87 Suppl 1:S38–43, S42–8 **(Eng, Fre)**

The reality of despair: AIDS in Malawi. Needham D. **Can Med Assoc J** 1996 Jul 1;155(1):91–2

Prevention of AIDS in Sri Lanka: are we doing the best for our people? [letter; comment] [see comments] Arulanantham T. **Ceylon Med J** 1995 Sep;40(3):127–8. Comment on: Ceylon Med J 1995 Mar;40(1):5–7. Comment in: Ceylon Med J 1995 Dec;40(4):160–1.

Prevention of AIDS in Sri Lanka, the debate continues [letter; comment] Vitarana T. **Ceylon Med J** 1995 Dec; 40(4):160–1. Comment on: Ceylon Med J 1995 Sep;40(3):127–8.

Mexican-American and Anglo-American children's responsiveness to a theory-centered AIDS education program. Sigelman C, et al. **Child Dev** 1996 Apr; 67(2):253–66

Sexually transmitted disease prevention services for female chronically mentally ill patients. Coverdale JH, et al. **Community Ment Health J** 1995 Aug;31(4):303–15

HIV/AIDS awareness, knowledge and practice in patients with sexually transmitted diseases. Ashebir DZ. **Ethiop Med J** 1996 Jan;34(1):25–32

Condom availability in the schools: lessons from the courtroom. Mahler K. **Fam Plann Perspect** 1996 Mar-Apr; 28(2):75–7

Introduction: blood safety in the age of AIDS. Engleman EG. **FASEB J** 1996 Mar;10(4):390

Blood safety in the age of AIDS. Roberts SS. **FASEB J** 1996 Mar;10(4):391–402

Changing AIDS risk behavior: effects of an intervention emphasizing AIDS risk reduction information, motivation, and behavioral skills in a college student population. Fisher JD, et al. **Health Psychol** 1996 Mar;15(2):114–23

Chronic care. The military's assault on AIDS. MacPherson P. **Hosp Health Netw** 1996 Jul 5;70(13):38

Factors influencing safer sexual behaviors in heterosexual late adolescent and young adult collegiate males. Cole FL, et al. **Image J Nurs Sch** 1995 Fall;27(3):217–23

Counselling in HIV/AIDS—an Indian perspective. Banerjee K, et al. **Indian J Public Health** 1995 Jul-Sep;39(3):121–4

Awareness on AIDS among health care professionals. Dobe M. **Indian J Public Health** 1995 Jul-Sep;39(3):105–8

Sexually transmitted disease services in Madras: could their role in AIDS prevention be strengthened? Kantharaj K, et al. **Indian J Public Health** 1995 Jul-Sep;39(3):93–9

AIDS awareness among nursing students. Kubde SS, et al. **Indian J Public Health** 1995 Jul-Sep;39(3):109–12

An assessment of AIDS awareness program—for I.C.D.S. functionaries. Ray SK, et al. **Indian J Public Health** 1995 Jul-Sep;39(3):100–4

Progress in AIDS vaccine development. Johnston MI. **Int Arch Allergy Immunol** 1995 Dec;108(4):313–7 (29 ref.)

Controlled heroin availability in Australia? How and to what end? Bammer G, et al. **Int J Addict** 1995 Jun;30(8):991–1007

An integrated rule- and case-based approach to AIDS initial assessment. Xu LD. **Int J Biomed Comput** 1996 Jan; 40(3):197–207

The effects of peer education on STD and AIDS knowledge among prisoners in Mozambique. Vaz RG, et al. **Int J STD AIDS** 1996 Jan-Feb;7(1):51–4

AIDS knowledge, risk behaviors, and condom use among four groups of female sex workers in Bali, Indonesia. Ford K, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 15;10(5):569–76

Opportunities for targeting publicly funded human immunodeficiency virus counseling and testing. Peterman TA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):69–74

Interest in HIV vaccines among Italian injection drug users. The Network Interregionale SERT [letter] Serpelloni G, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):206–7

Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: implications for secondary prevention efforts. Stall R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):151–60

College women's sexuality in an era of AIDS. Uddin M. **J Am Coll Health** 1996 May;44(6):252–61

Increased attention to human sexuality can improve HIV-AIDS prevention efforts: key research issues and directions. Kelly JA, et al. **J Consult Clin Psychol** 1995 Dec;63(6):907–18 (120 ref.)

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). Valentine FT, et al. **J Infect Dis** 1996 Jun;173(6):1336–46

Fourth annual survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates. Warren JT, et al. **J Med Primatol** 1995 May;24(3):150–68

Why screen for HIV infection in pregnancy? [editorial; comment] Newell ML. **J Med Screen** 1994 Jul;1(3):143. Comment on: J Med Screen 1994 Jul;1(3):176–9.

Combating the illusion of adolescent invincibility to HIV/AIDS. Crosby RA. **J Sch Health** 1996 May; 66(5):186–90

A peer-led AIDS prevention program for students in an alternative school. O'Hara P, et al. **J Sch Health** 1996 May; 66(5):176–82

AIDS prevention in high-risk African American women: behavioral, psychological, and gender issues. Hetherington SE, et al. **J Sex Marital Ther** 1996 Spring;22(1):9–21

Norway's policy on targeting AIDS prevention [letter] Alvik A. **Lancet** 1996 Sep 14;348(9029):762–3

Reconsidering an attenuated vaccine for AIDS. Beale J. **Lancet** 1996 Feb 10;347(8998):344–5

AIDS vaccines are the way to halt epidemic [news] Bradbury J. **Lancet** 1996 Jun 15;347(9016):1683

AIDS education dollars cause upset in Texas [news] Firshein J. **Lancet** 1995 Dec 9;346(8989):1548

Returning home: reflections on the USA's response to the HIV/AIDS epidemic. Merson MH. **Lancet** 1996 Jun 15; 347(9016):1673–6

Case for behavioural studies for AIDS prevention [news] Rowe PM. **Lancet** 1996 Mar 16;347(9003):750

Two candidates for a live AIDS vaccine emerge [news] Rowe PM. **Lancet** 1996 Sep 14;348(9029):742

Candidate AIDS vaccine inspires hope [news] Rowe PM. **Lancet** 1996 Aug 31;348(9027):603

Danes' AIDS education criticised [news] Skovmand K. **Lancet** 1996 Jan 13;347(8994):114

Messages of distinction: the HIV/AIDS media campaign in Thailand. Lyttleton C. **Med Anthropol** 1996 Mar; 16(4):363–89

Mandatory HIV testing of patients and professionals: bringing ethics into practice. Berglund CA. **Med Educ** 1995 Sep;29(5):360–3

AIDS and tuberculosis control programmes: an integrated approach at educational level. Migliori GB, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):102–7

AIDS prevention—sexual ethics and responsibility. Bayer R. **N Engl J Med** 1996 Jun 6;334(23):1540–2

Candidate AIDS vaccines. Graham BS, et al. **N Engl J Med** 1995 Nov 16;333(20):1331–9 (100 ref.)

HIV-1 Tat protein as a potential AIDS vaccine. Goldstein G. **Nat Med** 1996 Sep;2(9):960–4 (34 ref.)

Whether and when an AIDS vaccine? Hilleman MR. **Nat Med** 1995 Nov;1(11):1126–9

gp 120: good, bad or indifferent? [news] Steele FR. **Nat Med** 1995 Nov;1(11):1105–6

Assessing animal models of AIDS [comment] Stott J, et al. **Nat Med** 1995 Apr;1(4):295–7. Comment on: Nat Med 1995 Apr;1(4):321–9.

New global AIDS programme trying to break with the past [news] Tastemain C. **Nat Med** 1995 Sep;1(9):862

Qualitative research methods in drug abuse and AIDS prevention research: an overview. Carlson RG, et al. **NIDA Res Monogr** 1995;157:6–26 (75 ref.)

Hitting a moving target: the use of ethnographic methods in the development of sampling strategies for the evaluation of AIDS outreach programs for homeless youth in New York City. Clatts MC, et al. **NIDA Res Monogr** 1995; 157:117–35

A personal network approach to AIDS prevention: an experimental peer group intervention for street-injecting drug users: the SAFE study. Latkin CA. **NIDA Res Monogr** 1995;151:181–95

The role of qualitative research in the Global Programme on AIDS at the World Health Organization. O'Reilly KR. **NIDA Res Monogr** 1995;157:27–37 (17 ref.)

AIDS programmes at the workplace: a scoresheet for assessing the quality of services. London L. **Occup Med (Oxf)** 1996 Jun;46(3):216–20

Cancer resources in the United States. Kinsey R, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1421–32

A candidate live inactivatable attenuated vaccine for AIDS. Chakrabarti BK, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9810–5

A school fight against AIDS in the Caribbean. McBean G. **Promot Educ** 1996 Jun;3(2):13–7, 45

Zimbabwe's AIDS action programme for schools: a case study. O'Donoghue J. **Promot Educ** 1996 Jun;3(2):7–12, 45

Religiosity, AIDS, and sexuality knowledge, attitudes, beliefs, and practices of black South-African first-year university students. Nicholas L, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1328–30

WHO's primer on AIDS [news] **Public Health Rep** 1996 Jan-Feb;111(1):7

AIDS—knowledge, attitudes and practices among STD clinic attenders in the Cape Peninsula. Blecher MS, et al. **S Afr Med J** 1995 Dec;85(12):1281–6

Academic research and HIV/AIDS in South Africa. Campbell CM, et al. **S Afr Med J** 1996 Jan;86(1):55–60 (63 ref.)

Role of Danish general practitioners in AIDS prevention. Sandbaek A, et al. **Scand J Prim Health Care** 1995 Dec; 13(4):307–15

HIV's Achilles' heel. Drugs and education are starting to slow the AIDS virus [news] Beardsley T. **Sci Am** 1996 Sep;275(3):16, 18

Preventing AIDS [letter; comment] Benarde MA. **Science** 1996 Aug 16;273(5277):861. Comment on: Science 1996 Jun 28;272(5270):1855.

A perspective on AIDS vaccines. Bloom BR. **Science** 1996 Jun 28;272(5270):1888–90

Thailand weighs AIDS vaccine tests [news] Cohen J. **Science** 1995 Nov 10;270(5238):904–7

AIDS vaccine therapy trial launched [news] Holden C. **Science** 1996 Mar 15;271(5255):1501

AIDS intervention in Uganda [letter] Wawer MJ, et al. **Science** 1995 Oct 27;270(5236):564–5

Understanding the AIDS epidemic and reacting sensibly to it [editorial] Caldwell JC. **Soc Sci Med** 1995 Aug; 41(3):299–302

AIDS knowledge and risk behaviors among domestic clients of female sex workers in Bali, Indonesia. Fajans P, et al. **Soc Sci Med** 1995 Aug;41(3):409–17

Sexual communication in the age of AIDS: the construction of risk and trust among young adults. Lear D. **Soc Sci Med** 1995 Nov;41(9):1311–23

Learning to listen: formative research in the development of AIDS education for secondary school students. Mathews C, et al. **Soc Sci Med** 1995 Dec;41(12):1715–24

AIDS and injecting drug use in the United Kingdom, 1987–1993: the policy response and the prevention of the epidemic. Stimson GV. **Soc Sci Med** 1995 Sep; 41(5):699–716

Introducing a first AIDS vaccine in Switzerland: a Policy Delphi analysis. Zuber PL, et al. **Soz Praventivmed** 1996; 41(2):126–7

AIDS awareness in blood donors in north India. Choudhury N, et al. **Transfus Med** 1995 Dec;5(4):267–71

Sexual behaviour and condom acceptance among Nigerian drivers. Araoye MO, et al. **West Afr J Med** 1996 Jan–Mar; 15(1):6–10

[Progress in vaccination against AIDS] Burny A. **Bull Mem Acad R Med Belg** 1995;150(3–4):145–53; discussion 153–5 (Eng. Abstr.) **(Fre)**

[World AIDS year: final declaration] **J Med Liban** 1995; 43(1):43–4 **(Fre)**

[Evaluation of a new AIDS communication and prevention model. Analysis of reactions to the program "3000 scenarios against a virus"] Bajos N, et al. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):237–47 (Eng. Abstr.) **(Fre)**

[Research in Africa] Lévy JP. **Sante** 1995 Sep–Oct;5(5):283–5 **(Fre)**

[Exchange of syringes or apprenticeship? The buses of Bienne and Geneva] Malatesta D, et al. **Soz Praventivmed** 1996; 41 Suppl 1:S15–21 (Eng. Abstr.) **(Fre)**

[AIDS prevention in homosexuals in Switzerland: adaptation to risks according to type of partner] Moreau-Gruet F, et al. **Soz Praventivmed** 1996;41(1):1–10 (Eng. Abstr.) **(Fre)**

[AIDS prevention in European prisons] Schaller G, et al. **Soz Praventivmed** 1995;40(5):298–301 (Eng. Abstr.) **(Fre)**

[Nucleic acid vaccines for study in AIDS patients are approved. Vaccines of genetic molecules--humoral and cellular immune response (news)] Hobom B. **Fortschr Med** 1995 Dec 20;113(35–36):12 **(Ger)**

[AIDS vaccine: who should be selected for the test?] Marcus U. **Fortschr Med** 1995 Nov 20;113(32):16–7 **(Ger)**

[Vaccines against AIDS finally in sight? Vaccination campaigns in China and Uganda in preliminary stages (news)] Wolf HJ. **Fortschr Med** 1995 Nov 10;113(31):20, 22 **(Ger)**

[Acquired immunodeficiency syndrome--1995 (Part I)] Lasry Y, et al. **Harefuah** 1995 Dec 1;129(11):520–5 (50 ref.) **(Heb)**

[AIDS-related knowledge and sex behavior: a review of Italian studies of young people] Aloisi MS, et al. **Ann Ig** 1995 Sep–Oct;7(5):349–58 (38 ref.) (Eng. Abstr.) **(Ita)**

[Use of the condom for the prevention of AIDS: a review of 10 studies from Europe and the United States] Zantedeschi E, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):709–16 (Eng. Abstr.) **(Ita)**

[A survey on infection control practices, knowledge and attitudes toward AIDS/HIV among dental practitioners] Aizawa F, et al. **Nippon Koshu Eisei Zasshi** 1996 May; 43(5):364–73 (Eng. Abstr.) **(Jpn)**

[AIDS preventive work in Arusha and Kilimanjaro--health education] Klepp KI, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3278–80 (Eng. Abstr.) **(Nor)**

[Failing fight against AIDS (letter)] Wessel I. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):111 **(Nor)**

[Gdansk HIV-AIDS project, yesterday, today and future (editorial)] Zielińska W. **Pol Tyg Lek** 1995 Sep; 50(36–39):4–8, 15 (Eng. Abstr.) **(Pol)**

[AIDS and women: is a more effective prevention possible? (editorial)] Gordillo Alvarez-Valdés MV. **Med Clin (Barc)** 1996 May 18;106(19):734–6 **(Spa)**

[The National Council for AIDS Prevention and Control (CONASIDA). Report of activities, 1988–1994] **Salud Publica Mex** 1995 Nov–Dec;37(6):669–76 **(Spa)**

[Opinion about the special issue, "Ten years of AIDS in Mexico" (letter)] Gómez Alcalá AV. **Salud Publica Mex** 1996 May–Jun;38(3):153–4 **(Spa)**

[The HIV/AIDS work of Mexican nongovernmental organizations] Hernández-Chávez JJ. **Salud Publica Mex** 1995 Nov–Dec;37(6):654–60 (Eng. Abstr.) **(Spa)**

[Campaigns against AIDS in Mexico: the sounds of silence or a bridge over troubled waters?] Rico B, et al. **Salud Publica Mex** 1995 Nov–Dec;37(6):643–53 (Eng. Abstr.) **(Spa)**

[The strategy for preventing HIV/AIDS transmission via the blood and its derivatives in Mexico] Sepúlveda-Amor J, et al. **Salud Publica Mex** 1995 Nov–Dec;37(6):624–35 (Eng. Abstr.) **(Spa)**

[The health worker and counseling about HIV and AIDS] Vallejo-Aguilar OJ, et al. **Salud Publica Mex** 1995 Nov–Dec;37(6):636–42 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Fear of AIDS and suicide in Finland: a review. Aro AR, et al. **AIDS Care** 1995;7 Suppl 2:5187–97 (60 ref.)

AIDS and suicide issues in Spain. Carvajal MJ, et al. **AIDS Care** 1995;7 Suppl 2:S135–8

AIDS and euthanasia. Green G. **AIDS Care** 1995;7 Suppl 2:S169–73

Psychological distress among gay men supporting a lover or partner with AIDS: a pilot study. Irving G, et al. **AIDS Care** 1995;7(5):605–17

Reliance by gay men and intravenous drug users on friends and family for AIDS-related care. Johnston D, et al. **AIDS Care** 1995;7(3):307–19

Euthanasia, assisted suicide and AIDS. Laane HM. **AIDS Care** 1995;7 Suppl 2:S163–7

HIV and suicide in Hamburg. Pueschel K, et al. **AIDS Care** 1995;7 Suppl 2:S129–34

Suicide and AIDS: lessons from a case note audit in London. Sherr L. **AIDS Care** 1995;7 Suppl 2:S109–16

Group intervention to improve coping with AIDS-related bereavement: model development and an illustrative clinical example. Sikkema KJ, et al. **AIDS Care** 1995; 7(4):463–75

Epidemiology of suicide among persons with AIDS. Starace F. **AIDS Care** 1995;7 Suppl 2:S123–8 (15 ref.)

AIDS, euthanasia and grief. van den Boom F. **AIDS Care** 1995;7 Suppl 2:5175–85

The perceived social context of AIDS: study of inner-city sexually transmitted disease clinic patients. Kalichman SC, et al. **AIDS Educ Prev** 1995 Aug;7(4):298–307

The Nurses' Attitudes About AIDS Scale (NAAS): development and psychometric analysis. Preston DB, et al. **AIDS Educ Prev** 1995 Oct;7(5):443–54

Pet ownership among persons with AIDS in three Florida counties. Conti L, et al. **Am J Public Health** 1995 Nov; 85(11):1559–61

A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS [see comments] Hickey AM, et al. **BMJ** 1996 Jul 6;313(7048):29–33. Comment in: BMJ 1996 Jul 6;313(7048):6.

Concerns about AIDS in general practice. Moons MA, et al. **BMJ** 1996 Feb 3;312(7026):285–6

Revisiting the psychological aspects of AIDS: has the crisis passed? [editorial] Ratigan BJ. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):158–9

Illness and compassion: AIDS in an American Zen community. Nakasone RY. **Camb Q Healthc Ethics** 1995 Fall;4(4):488–93

Treating AIDS: hope and despair [letter; comment] Brown RH. **Can Med Assoc J** 1996 Jan 15;154(2):139; discussion 140. Comment on: Can Med Assoc J 1995 Oct 1;153(7):967–8.

Treating AIDS: hope and despair [letter; comment] Sauls R. **Can Med Assoc J** 1996 Jan 15;154(2):140. Comment on: Can Med Assoc J 1995 Oct 1;153(7):967–8.

AIDS related information, attitudes and behaviours among Italian male young people. Carducci A, et al. **Eur J Epidemiol** 1995 Feb;11(1):23–31

Changes in heterosexual university undergraduates' HIV-related knowledge, attitudes and behaviour: Melbourne, 1989–1994. Rosenthal DA, et al. **Genitourin Med** 1996 Apr;72(2):123–7

Gay men with AIDS and their families of origin: an analysis of social support. Kadushin G. **Health Soc Work** 1996 May; 21(2):141–9 (100 ref.)

Anticipatory grief and AIDS: strategies for intervening with caregivers. Walker RJ, et al. **Health Soc Work** 1996 Feb; 21(1):49–57 (43 ref.)

AIDS phobia--a case report. Latha KS. **Indian J Public Health** 1995 Jan–Mar;39(1):27–8

A comparison of the psychosocial aspects of AIDS and cancer-related bereavement. Kelly B, et al. **Int J Psychiatry Med** 1996;26(1):35–49

Patients misrepresenting their risk factors for AIDS [editorial] Brody S. **Int J STD AIDS** 1995 Nov–Dec; 6(6):392–8 (75 ref.)

Psychological dysfunction and HIV/AIDS risk behavior. Camacho LM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):198–202

AIDS phobia [letter] Sood AK, et al. **J Assoc Physicians India** 1996 Jan;44(1):70–1

AIDS and suicide. Kirchner JT. **J Fam Pract** 1995 Nov; 41(5):493–6 (19 ref.)

Changes in physicians' attitudes toward AIDS during residency training: a longitudinal study of medical school graduates. Yedidia MJ, et al. **J Health Soc Behav** 1996 Jun; 37(2):179–91

On the road to recovery for emotional harm. Is the fear of AIDS a legally compensable injury? Bollinger RC. **J Leg Med** 1995 Sep;16(3):417–45

Misconceptions about AIDS among children who can identify the major routes of HIV transmission. Wells EA, et al. **J Pediatr Psychol** 1995 Oct;20(5):671–86

Postbereavement depressive mood and its prebereavement predictors in HIV+ and HIV- gay men. Folkman S, et al. **J Pers Soc Psychol** 1996 Feb;70(2):336–48

Nurses' attitudes toward caring for patients with acquired immunodeficiency syndrome. Baylor RA, et al. **J Prof Nurs** 1996 Mar–Apr;12(2):99–105

Factors influencing baccalaureate nursing students' attitudes towards persons living with AIDS. Leasure R, et al. **J Prof Nurs** 1995 Sep–Oct;11(5):299–305

Assessing suffering [letter] Bayes R, et al. **Lancet** 1995 Dec 2;346(8988):1492

Playing doctors: refiguring the doctor-patient relationship in Hervé Guibert's AIDS novels. Caron D. **Lit Med** 1995 Fall;14(2):237–49

Clinical predictors of functioning in persons with acquired immunodeficiency syndrome. Wilson IB, et al. **Med Care** 1996 Jun;34(6):610–23

The role of reluctance to give up life in the measurement of the values of health states [see comments] Fowler FJ Jr, et al. **Med Decis Making** 1995 Jul–Sep;15(3):195–200. Comment in: Med Decis Making 1995 Jul–Sep;15(3):286–7.

Training medical students in HIV/AIDS test counselling: results of a randomized trial. Campbell E, et al. **Med Educ** 1996 Mar;30(2):134–41

Managing HIV. Part 7: Professional issues. 7.5 HIV and choosing to die. van Reyk P. **Med J Aust** 1996 Aug 5; 165(3):146

Attitude adjustment. A complacent public tunes out the AIDS epidemic. Feldman MK. **Minn Med** 1995 Nov; 78(11):10–4, 64–5

AIDS. Public perceptions obscure medical discourse [editorial] Meyer CR. **Minn Med** 1995 Nov;78(11):5

Assessing the reliability and validity of self-reported risk behavior. Gibson DR, et al. **NIDA Res Monogr** 1994; 143:218–36 (13 ref.)

A personal network approach to AIDS prevention: an experimental peer group intervention for street-injecting drug users: the SAFE study. Latkin CA. **NIDA Res Monogr** 1995;151:181–95

Using focus groups in drug abuse and HIV/AIDS research. Shedlin MG, et al. **NIDA Res Monogr** 1995;157:136–55 (13 ref.)

Compassionate mental health care for persons with HIV and AIDS. Grady HIV/AIDS Mental Health Program, Grady Health System Infectious Disease Program and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta. **Psychiatr Serv** 1995 Oct;46(10):1061–4

Managing diazepam abuse in an AIDS-related psychiatric clinic with a high percentage of substance abusers. Freedman JB, et al. **Psychosomatics** 1996 Jan–Feb; 37(1):43–7

A study of the reliability, validity and responsiveness of the HIV overview of problems evaluation system (HOPES) in assessing the quality of life of patients with AIDS and symptomatic HIV infection. De Boer JB, et al. **Qual Life Res** 1996 Jun;5(3):339–47

HIV/AIDS testing remains prickly affair [news] van der Linde I. **S Afr Med J** 1995 Aug;85(8):725–6

Stigma, HIV and AIDS: an exploration and elaboration of a stigma trajectory. Alonzo AA, et al. **Soc Sci Med** 1995 Aug;41(3):303–15 (79 ref.)

Suicide risk among people living with AIDS. Mancoske RJ, et al. **Soc Work** 1995 Nov;40(6):783–7

Fear of AIDS and homophobia: implications for direct practice and advocacy. O'Hare T, et al. **Soc Work** 1996 Jan;41(1):51–8 (22 ref.)

Occupational stress among AIDS social service providers. Cushman LF, et al. **Soc Work Health Care** 1995; 21(3):115–31

Racial minorities and other high-risk groups with HIV and AIDS at increased risk for psychological adjustment problems in association with health locus of control orientation. Spalding AD. **Soc Work Health Care** 1995; 21(3):81–114

[AIDS and AIDS: anthropological analysis of opinions relative to the death of AIDS patients in a district of Bangui (June 1994)] Epelboin A, et al. **Bull Soc Pathol Exot** 1996; 89(1):48–56 (Eng. Abstr.) **(Fre)**

[Attitude of established physicians to treating HIV-infected patients and to "acquired immunodeficiency syndrome". An empirical study] Loew TH, et al. **Med Klin** 1996 May 15; 91(5):272–6 (Eng. Abstr.) **(Ger)**

[Coping with AIDS in a support group--an encounter with the health system] Weishut DJ. **Harefuah** 1996 Apr 15; 130(8):521–3, 583 (Eng. Abstr.) **(Heb)**

[Health care seeking behavior of patients with AIDS] Talle A, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3284–5 (Eng. Abstr.) **(Nor)**

RADIOGRAPHY

Pneumatosis intestinalis in adults with AIDS: clinical significance and imaging findings. Wood BJ, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1387–90

Radiographic evaluation of AIDS patients. Le Blang SD, et al. **Q J Nucl Med** 1995 Sep;39(3):187–200 (101 ref.)

The gastrointestinal manifestations of pediatric AIDS. Stoane

JM, et al. **Radiol Clin North Am** 1996 Jul;34(4):779–90 (44 ref.)

[Standard radiological characteristics of thoracic sites of tuberculosis in patients with AIDS in a Tunisian population] Tiouiri H, et al. **Rev Pneumol Clin** 1995; 51(6):321–4 (12 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Radionuclide brain imaging in acquired immunodeficiency syndrome (AIDS). Costa DC, et al. **Q J Nucl Med** 1995 Sep;39(3):243–9

Role of nuclear medicine and AIDS: overview and perspective for the future. Ganz WI, et al. **Q J Nucl Med** 1995 Sep;39(3):169–86 (51 ref.)

AIDS and nuclear medicine [editorial] Lucignani G, et al. **Q J Nucl Med** 1995 Sep;39(3):145–6

The role of gallium and labeled leukocyte scintigraphy in the AIDS patient. Palestro CJ, et al. **Q J Nucl Med** 1995 Sep;39(3):221–30

REHABILITATION

State housing program recognized [news] **Minn Med** 1995 Sep;78(9):52

SURGERY

HIV-1 viraemia and splenectomy [letter] Lafeuillade A, et al. **AIDS** 1995 Jul;9(7):821–2

THERAPY

Idiotype manipulation in disease management. Kohler H, et al. **Adv Exp Med Biol** 1995;383:117–22 (38 ref.)

Enhancing HIV-1 specific immunity as a therapeutic strategy in AIDS. Schooley RT. **Adv Exp Med Biol** 1996;394:405–10 (24 ref.)

Investigations on autologous T-cells for adoptive immunotherapy of AIDS. van Lunzen J, et al. **Adv Exp Med Biol** 1995;374:57–70

Efficacy of 2-month total parenteral nutrition in AIDS patients: a controlled randomized prospective trial. The French Multicenter Total Parenteral Nutrition Cooperative Group Study. Melchior JC, et al. **AIDS** 1996 Apr; 10(4):379–84

Percutaneous endoscopic gastrostomy in AIDS and control patients: risks and outcome. Ockenga J, et al. **Am J Gastroenterol** 1996 Sep;91(9):1817–22

The treatment of AIDS and cancer in the third millennium. Gallo RC. **Am J Med** 1995 Dec 29;99(6A):6S–10S

General principles for AIDS research [editorial] Kupfer C. **Arch Ophthalmol** 1996 Jul;114(7):862

Health care of children and adults with acquired immunodeficiency syndrome. A population-based analysis. Turner BJ, et al. **Arch Pediatr Adolesc Med** 1996 Jun; 150(6):615–22

Biological effect of active anti-IFN alpha immunization in HIV-infected patients. Fall LS, et al. **Biomed Pharmacother** 1995;49(9):422–8

Whole body hyperthermia associated with beta-carotene supplementation in patients with AIDS. Pontiggia P, et al. **Biomed Pharmacother** 1995;49(5):263–5

Understanding the needs of children. Garcia A. **Bull N Y Acad Med** 1995 Summer;72(1 Suppl):217–25

The challenge of treating gay men with AIDS. Sheran M. **Bull N Y Acad Med** 1995 Summer;72(1 Suppl):202–10

National Advisory Committee on Immunization (NACI). Interim advisory on measles revaccination of persons with acquired immunodeficiency syndrome (AIDS). **Can Commun Dis Rep** 1996 Jul 15;22(14):116–7 **(Eng, Fre)**

The XI International Conference on AIDS: at the crossroads of hope and urgency [editorial] Schechter MT. **Can Med Assoc J** 1996 Jul 1;155(1):53–4

"Kinoids": the basis for anticytokine immunization and their use in HIV infection. Bizzini B, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):351–6 (38 ref.)

Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression. Gringeri A, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):381–7

Relationships between humoral factors in HIV-1-infected mothers and the occurrence of HIV infection in their infants. Mabondzo A, et al. **Clin Exp Immunol** 1995 Dec; 102(3):476–80

Prospective, controlled study of the outcome of human immunodeficiency virus-1 antibody-positive children admitted to an intensive care unit [see comments] Jeena PM, et al. **Crit Care Med** 1996 Jun;24(6):963–7. Comment in: Crit Care Med 1996 Jun;24(6):907–9.

Passive HIV-hyperimmunoglobulin therapy in paediatric AIDS [letter] Kreuz W, et al. **Eur J Pediatr** 1995 Oct; 154(10):865

Baboon marrow transplant given OK [news] **Hastings Cent Rep** 1995 Sep-Oct;25(5):47

Steps toward gene therapy: 2. Cancer and AIDS. Blaese RM. **Hosp Pract (Off Ed)** 1995 Dec 15;30(12):37–45 (6 ref.)

Free telephone service offers HIV information [news] **Indiana Med** 1996 Jan-Feb;89(1):92

Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. Collier AC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):150–6

Whole-body hyperthermia [letter; comment] Shecterle LM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Nov 1;10(3):391. Comment on: J Acquir Immune Defic Syndr Hum Retrovirol 1995 Apr 1;8(4):321–9.

Effect of whole-body hyperthermia on AIDS patients with Kaposi's sarcoma: a pilot study. Steinhart CR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):271–81

Acquired immune deficiency syndrome resource. **J Nurs Adm** 1996 Feb;26(2):3–4

Catalonia WHO Demonstration Project on Palliative Care Implementation 1990–1995: results in 1995. Gómez-Batiste X, et al. **J Pain Symptom Manage** 1996 Aug;12(2):73–8

A statewide program to evaluate the quality of care provided to persons with HIV infection. Agins BD, et al. **Jt Comm J Qual Improv** 1995 Sep;21(9):439–56

Patients sue "AIDS-cure" Kenyan scientist [news] Dodd R. **Lancet** 1996 Jun 15;347(9016):1688

Baboon xenotransplant fails but patient improves [news] Fricker J. **Lancet** 1996 Feb 17;347(8999):457

Xenotransplantation for AIDS [letter; comment] Ildstad ST. **Lancet** 1996 Mar 16;347(9003):761. Comment on: Lancet 1995 Aug 5;346(8971):369–70.

Gene therapy against retroviral diseases. Essex M, et al. **Leukemia** 1995 Oct;9 Suppl 1:S71–4 (13 ref.)

Development of a knowledge-based electronic patient record. Safran C, et al. **MD Comput** 1996 Jan-Feb; 13(1):46–54, 63

Update of HIV and AIDS in North America. Flanigan TP, et al. **Med Health R I** 1996 May;79(5):180–7 (18 ref.)

Leukocyte adhesion molecules as a cofactor in AIDS: basic science and pilot study. Allen AD, et al. **Med Hypotheses** 1995 Aug;45(2):164–8

Mechanism of the effect of thermotherapy as applied to AIDS. Moreira MB. **Med Hypotheses** 1995 Jul;45(1):5–6

Managing HIV. Part 7: Professional issues. 7.4 HIV and complementary medicine. McKnight I, et al. **Med J Aust** 1996 Aug 5;165(3):143–5

Managing HIV. Part 2: Phases of disease. 2.4 HIV and advanced immune deficiency. Marriott D, et al. **Med J Aust** 1996 Jan 15;164(2):111–2

Managing HIV. Part 1: Principles. 1.2 Strategies of care in managing HIV. Stewart GJ, et al. **Med J Aust** 1996 Jan 15;164(2):99–104

Managing HIV. Part 7: Professional issues. 7.8 Continuing HIV education for health care workers. Stewart GJ, et al. **Med J Aust** 1996 Aug 5;165(3):151–2

More than medicine: caring for the AIDS patient. Simpson M, et al. **Minn Med** 1995 Nov;78(11):6–7, 62–3

HIV accessory proteins: emerging therapeutic targets. Miller RH, et al. **Mol Med** 1995 Jul;1(5):479–85 (11 ref.)

Physicians' experience and survival in patients with AIDS [letter; comment] Macher AM, et al. **N Engl J Med** 1996 Aug 1;335(5):350; discussion 350–1. Comment on: N Engl J Med 1996 Mar 14;334(11):729–31.

Xenotransplantation at a crossroads: prevention versus progress. Allan JS. **Nat Med** 1996 Jan;2(1):18–21 (19 ref.)

AIDS — a treatable disease at last [editorial] Culliton BJ. **Nat Med** 1996 Mar;2(3):253

FDA panel reluctantly approves AIDS vaccine trial [news] Fox JL. **Nat Med** 1995 Mar;1(3):191–2

AIDS physicians find support in the trenches [news] Kedar I. **Nat Med** 1996 Feb;2(2):140

Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression [see comments] Koenig S, et al. **Nat Med** 1995 Apr;1(4):330–6. Comment in: Nat Med 1995 Apr;1(4):304–5.

Baboon bone marrow transplanted to AIDS patient [news] Steele FR. **Nat Med** 1996 Jan;2(1):17

Controversial AIDS vaccine fails to delay disease [news] **Nature** 1996 Apr 25;380(6576):662

Baboon cells fail to combat AIDS [news] **Nature** 1996 Feb 15;379(6566):577

France backs off promise to boost UN AIDS programme [news] Butler D. **Nature** 1995 Nov 16;378(6554):224

AIDS patient given baboon bone marrow [news] Lehrman S. **Nature** 1995 Dec 21-28;378(6559):756

Forum to advance trials for AIDS therapies [news] Macilwain C. **Nature** 1996 Aug 15;382(6592):566

Nebraska physicians and AIDS. Swindells S. **Nebr Med J** 1996 Jan;81(1):10–3

A magnetic approach to AIDS. Jacobson JI. **Panminerva Med** 1995 Mar;37(1):22–7 (21 ref.)

Therapeutic applications of ribozymes. Kijima H, et al. **Pharmacol Ther** 1995;68(2):247–67 (200 ref.)

Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: a new approach to gene therapy of HIV-infection. Arya SK, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4486–91

Anti-CD4 therapy for AIDS suggested by mathematical models. De Boer RJ, et al. **Proc R Soc Lond B Biol Sci** 1996 Jul 22;263(1372):899–905

AIDS clinic at the ACI. Khawaja M. **R I Med** 1995 Oct; 78(10):296–7

Patient rights and physician responsibility: four problems in AIDS care. Cooke M. **Semin Dermatol** 1995 Sep; 14(3):252–8

Stem cells as vehicles for gene therapy: novel strategy for HIV infection. Ho AD, et al. **Stem Cells** 1995 Dec;13 Suppl 3:100–5

Quantitation of passively acquired human immunodeficiency virus (HIV) antibodies in AIDS patients transfused with a plasma that is rich in HIV antibodies. Lefrère JJ, et al. **Transfusion** 1996 Aug;36(8):734–8

Inactivation of human immunodeficiency virus by high hydrostatic pressure [letter] Nakagami T, et al. **Transfusion** 1996 May;36(5):475–6

Cellular xenografting: from diabetes to AIDS. Ricordi C, et al. **Transplant Proc** 1996 Apr;28(2):533

[Gene therapy for hereditary and acquired human diseases] Mehtali M, et al. **Ann Endocrinol (Paris)** 1995;56(6):571–4 (15 ref.) (Eng. Abstr.) **(Fre)**

[Management of children infected by human immunodeficiency virus and of the family in the frame work of humanitarian mission in Tanzania] Faye A. **Arch Pediatr** 1996;3 Suppl 1:27s–31s **(Fre)**

[AIDS therapy on the upwind (news)] Weismann H. **Dtsch Med Wochenschr** 1996 Mar 15;121(11):A7–A8 **(Ger)**

[Gene therapy for AIDS in an animal experiment (news)] **Fortschr Med** 1995 Oct 20;113(29):14 **(Ger)**

[Robert Koch Institute information on new AIDS therapies] **Pharm Unserer Zeit** 1996 May;25(3):155 **(Ger)**

[Use of complimentary medical therapies in HIV/AIDS in Switzerland] Brauchli P, et al. **Schweiz Med Wochenschr** 1996 Jul 27;126(30):1297–305 (Eng. Abstr.) **(Ger)**

[The health care problems of planning services in a sample of persons with AIDS in Naples] Marazzi MC, et al. **Ann Ig** 1994 Jul-Dec;6(4–6):399–407 (Eng. Abstr.) **(Ita)**

[Controversial developments in AIDS[news]] Vecchia C. **Boll Chim Farm** 1995 Oct;134(9):534 **(Ita)**

[Safer trials of vaccine and gene therapy against HIV] Ikuta K. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):21–6 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Gene therapy for AIDS] Matsukura M. **Nippon Ika Daigaku Zasshi** 1995 Oct;62(5):528–9 **(Jpn)**

[Gene therapy for AIDS: current trends] Takatsuki K, et al. **Nippon Rinsho** 1996 Jan;54(1):233–41 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Gene therapy of AIDS by a Rev mutant without nucleolar dysfunction] Hatanaka M. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2753–8 (8 ref.) **(Jpn)**

TRANSMISSION

Prospective effects of perceived risk of developing HIV/AIDS on risk behaviors among injection drug users in Puerto Rico. Robles RR, et al. **Addiction** 1995 Aug; 90(8):1105–11

Biological phenotype of HIV-1 and transmission [letter] Albert J, et al. **AIDS** 1995 Jul;9(7):822–3

AIDS knowledge, risk behaviors, and factors related to condom use among male commercial sex workers and male tourist clients in Bali, Indonesia. Ford K, et al. **AIDS** 1995 Jul;9(7):751–9

AIDS risk-taking behavior during carnival in São Paulo, Brazil. Hughes V, et al. **AIDS** 1995 Jul;9 Suppl 1:S39–44

The social dynamics of HIV transmission as reflected through discordant couples in rural Uganda. Serwadda D, et al. **AIDS** 1995 Jul;9(7):745–50

Women and AIDS in Zambia: a review of the psychosocial factors implicated in the transmission of HIV. Campbell T, et al. **AIDS Care** 1995;7(3):365–73 (26 ref.)

Female prostitutes in south London: use of heroin, cocaine and alcohol, and their relationship to health risk behaviours. Gossop M, et al. **AIDS Care** 1995;7(3):253–60

Friends and lovers: needle sharing in young people in Western Australia. Loxley W, et al. **AIDS Care** 1995; 7(3):337–51

Physicians & AIDS: discrimination and the Rehabilitation Act—Doe v. Attorney General. **Am J Law Med** 1995; 21(1):167–9

New York inmates' HIV risk behaviors: the implications for prevention policy and programs [see comments] Mahon N. **Am J Public Health** 1996 Sep;86(9):1211–5. Comment in: Am J Public Health 1996 Sep;86(9):1201–3.

The 1990 Florida Dental Investigation: is the case really closed? [see comments] Barr S. **Ann Intern Med** 1996 Jan 15;124(2):250–4. Comment in: Ann Intern Med 1996 Jan 15;124(2):255–6.

The 1990 Florida Dental Investigation: theory and fact [comment] Brown D. **Ann Intern Med** 1996 Jan 15; 124(2):255–6. Comment on: Ann Intern Med 1996 Jan 15;124(2):250–4.

Vertical transmission of Kaposi's sarcoma. McCarthy GA, et al. **Arch Dis Child** 1996 May;74(5):455–7

Empirical estimation of a distribution function with truncated and doubly interval-censored data and its application to AIDS studies. Sun J. **Biometrics** 1995 Sep;51(3):1096–104

AIDS associated with blood transfusion and haemophilia in Europe [letter; comment] Hamers F. **BMJ** 1996 Mar 30; 312(7034):847–8. Comment on: BMJ 1995 Dec 9;311(7019):1534–6.

The mysterious Florida AIDS mystery [letter; comment] Lim M. **Br Dent J** 1996 May 25;180(10):367. Comment on: Br Dent J 1994 Dec 10-24;177(11-12):423–7.

Kaposi's sarcoma in a two week old infant born to a mother with Kaposi's sarcoma/AIDS. McCarty KA, et al. **Cent Afr J Med** 1995 Oct;41(10):330–1

AIDS and the contact lens practice. Slonim CB. **CLAO J** 1995 Oct;21(4):233–5 (19 ref.)

Relationships between humoral factors in HIV-1-infected mothers and the occurrence of HIV infection in their infants. Mabondzo A, et al. **Clin Exp Immunol** 1995 Dec; 102(3):476–80

AIDS-related knowledge and misconceptions among high secondary school teachers and students in Kassala, Sudan. Elzubier AG, et al. **East Afr Med J** 1996 May;73(5):295–7

High-risk sexual behavior among young urban students. Barone C, et al. **Fam Plann Perspect** 1996 Mar–Apr; 28(2):69–74

Using HIV/AIDS surveillance to monitor public health efforts to reduce perinatal transmission of HIV [letter] Wortley PM, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Feb 1;11(2):205–6

Transmission of HIV-1 in the breast-feeding process. Black RF. **J Am Diet Assoc** 1996 Mar;96(3):267–74; quiz 275–6 (61 ref.)

I do not understand it [editorial] Crawford PR.
J Can Dent Assoc 1995 Oct;61(10):827

Infection control [letter; comment] Hardie J.
J Can Dent Assoc 1995 Oct;61(10):824. Comment on: J Can Dent Assoc 1995 Jun;61(6):469.

Ottawa discrimination case [letter] Schutz AJ.
J Can Dent Assoc 1995 Oct;61(10):824

Teachers' awareness and opinion about AIDS: implications for school based AIDS education. Kumar A, et al.
J Commun Dis 1995 Jun;27(2):101–6

Transfusion-acquired AIDS in Taiwan. Yao C, et al.
J Formos Med Assoc 1996 Jan;95(1):51–5

Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. Transfusion Safety Study Group. Busch MP, et al. **J Infect Dis** 1996 Jul;174(1):26–33

Mother-to-child transmission of human immunodeficiency virus type 1 in Nairobi [letter; comment] Dunn D, et al. **J Infect Dis** 1995 Nov;172(5):1418–9. Comment on: J Infect Dis 1994 Nov;170(5):1134–40.

HIV-1 spreads from lymphocytes to normal human keratinocytes suitable for autologous and allogenic transplantation. Ramarli D, et al. **J Invest Dermatol** 1995 Nov;105(5):644–7

An ethical approach to HIV carriage and AIDS [letter] Nores JM. **J Med Ethics** 1995 Oct;21(5):311–2

Balancing judicial interests in HIV cases. Part 1, Issues for nurse administrators. Zachary MK. **J Nurs Adm** 1995 Oct; 25(10):51–5

Attitudes of baccalaureate nursing students toward persons with acquired immunodeficiency syndrome according to mode of human immunodeficiency virus transmission. West AM, et al. **J Prof Nurs** 1996 Jul–Aug;12(4):225–32

Knowledge level of youth in India regarding human sexuality and AIDS. Tikoo M, et al. **J Sex Marital Ther** 1995 Winter; 21(4):248–54

Vaginal transmission of chimeric simian/human immunodeficiency viruses in rhesus macaques. Lu Y, et al. **J Virol** 1996 May;70(5):3045–50

Blood safety issues working group convened [news] Bayer R. **Lancet** 1996 Aug 24;348(9026):540

Detection of diverse HIV-1 genetic subtypes in the USA [see comments] Brodine SK, et al. **Lancet** 1995 Nov 4; 346(8984):1198–9. Comment in: Lancet 1996 Mar 9;347(9002):697. Comment in: Lancet 1996 Mar 9;347(9002):697–8.

Migration and AIDS [letter; comment] Colvin M, et al. **Lancet** 1995 Nov 11;346(8985):1303–4. Comment on: Lancet 1995 Sep 23;346(8978):826–8.

Bad news travels fast in Chile? [news] Duery L. **Lancet** 1996 Aug 31;348(9027):605

Revelations rock Canada's tainted-blood inquiry [news] Kondro W. **Lancet** 1996 Apr 27;347(9009):1178

Timing of fetal membrane rupture predicts HIV risk [news] McCarthy M. **Lancet** 1996 Jun 29;347(9018):1821

HIV transmission by donor semen [letter] [see comments] Papadopulos-Eleopulos E, et al. **Lancet** 1996 Jan 20; 347(8995):190–1. Comment in: Lancet 1996 Apr 6;347(9006):970.

Global burden of the HIV pandemic [see comments] Quinn TC. **Lancet** 1996 Jul 13;348(9020):99–106 (50 ref.). Comment in: Lancet 1996 Aug 17;348(9025):480–1.

AIDS shakes up Japan's status quo [news] Ross C.
Lancet 1996 Apr 6;347(9006):961

Risk of HIV transmission in infected US military personnel [letter; comment] Ruppach H, et al. **Lancet** 1996 Mar 9; 347(9002):697–8. Comment on: Lancet 1995 Nov 4;346(8984):1198–9.

Transmission of HIV-1 by donor semen [letter; comment] [see comments] Stewart G, et al. **Lancet** 1996 Apr 6; 347(9006):970. Comment on: Lancet 1996 Jan 20;347(8995):190–1. Comment in: Lancet 1996 Jul 6;348(9019):59–60.

Risk of HIV transmission in infected US military personnel [letter; comment] Temoshok LR, et al. **Lancet** 1996 Mar 9;347(9002):697. Comment on: Lancet 1995 Nov 4;346(8984):1198–9.

Transmission of HIV-1 by human bite [letter] Vidmar L, et al. **Lancet** 1996 Jun 22;347(9017):1762

Migration and AIDS [letter; comment] [see comments] Wolffers I, et al. **Lancet** 1995 Nov 11;346(8985):1303. Comment on: Lancet 1995 Sep 23;346(8978):826–8. Comment in: Lancet 1996 Mar 2;347(9001):620.

HIV: the more things change, the more they stay the same. Osborn JE. **Nat Med** 1995 Oct;1(10):991–3

AIDS--reply to J. Nandi [letter; comment] Priya R.
Natl Med J India 1995 Nov–Dec;8(6):296. Comment on: Natl Med J India 1995 Mar–Apr;8(2):95.

Ministry 'knew high risk' of AIDS transmission [news] Swinbanks D. **Nature** 1996 Feb 15;379(6566):572

Documents confirm delays in Japanese HIV blood scandal [news] Swinbanks D. **Nature** 1996 Feb 29;379(6568):760

AIDS advisers disagree over events in HIV blood scandal [news] Swinbanks D. **Nature** 1996 Apr 25;380(6576):660

Assessing the reliability and validity of self-reported risk behavior. Gibson DR, et al. **NIDA Res Monogr** 1994; 143:218–36 (13 ref.)

HIV/AIDS risks among male, heterosexual noninjecting drug users who exchange crack for sex. Inciardi JA.
NIDA Res Monogr 1994;143:26–40 (66 ref.)

Factors associated with sexual risk of AIDS in women. O'Leary A. **NIDA Res Monogr** 1994;143:64–81 (82 ref.)

Cross-species transmission and recombination of 'AIDS' viruses. Sharp PM, et al.
Philos Trans R Soc Lond B Biol Sci 1995 Jul 29; 349(1327):41–7

Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Fang G, et al.
Proc Natl Acad Sci U S A 1995 Dec 19;92(26):12100–4

Major histocompatibility complex class II DR alleles DRB1*1501 and those encoding HLA-DR13 are preferentially associated with a diminution in maternally transmitted human immunodeficiency virus 1 infection in different ethnic groups: determination by an automated sequence-based typing method. Winchester R, et al.
Proc Natl Acad Sci U S A 1995 Dec 19;92(26):12374–8

Alcohol use and risky sex among college students [see comments] Carroll JL, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):723–6. Comment in: Psychol Rep 1995 Oct;77(2):421–2.

Comments on "Alcohol use and risky sex among college students" [comment] Ridley DR, et al. **Psychol Rep** 1995 Oct;77(2):421–2. Comment on: Psychol Rep 1995 Jun;76(3 Pt 1):723–6.

The African AIDS epidemic [see comments] Caldwell JC, et al. **Sci Am** 1996 Mar;274(3):62–3, 66–8. Comment in: Sci Am 1996 Jul;275(1):8.

AIDS and circumcision [letter; comment] Fleiss PM, et al. **Sci Am** 1996 Jul;275(1):8. Comment on: Sci Am 1996 Mar;274(3):62–3, 66–8.

AIDS and circumcision [letter; comment] Padian N.
Sci Am 1996 Jul;275(1):8. Comment on: Sci Am 1996 Mar;274(3):62–3, 66–8.

Pasteur implicated in blood scandal? [news] Kaiser J.
Science 1996 Apr 12;272(5259):185

Dermatologic surgery and AIDS. Introduction. Harahap M.
Semin Dermatol 1995 Sep;14(3):187–90

Dermatologic surgery personnel with AIDS. Resnik SS, et al. **Semin Dermatol** 1995 Sep;14(3):240–2 (22 ref.)

Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Grund JP, et al.
Soc Sci Med 1996 Mar;42(5):691–703 (89 ref.)

U.S. apartheid and the spread of AIDS to the suburbs: a multi-city analysis of the political economy of spatial epidemic threshold. Wallace R, et al. **Soc Sci Med** 1995 Aug;41(3):333–45

Malawi has the highest number of reported cases of AIDS [letter] Wilbrink J. **Trop Geogr Med** 1995;47(6):310–1

Changing face of HIV/AIDS care--mother-fetal and maternal-child HIV transmission. Frascino RJ.
West J Med 1995 Oct;163(4):368–9

[Infection with human immunodeficiency virus type 2--HIV-2] Christiansen CB. **Ugeskr Laeger** 1996 Mar 18; 158(12):1662–6 (37 ref.) (Eng. Abstr.) **(Dan)**

[Perforations and porosity of surgical gloves. Frequency, mechanism, risk] Johanet H, et al. **Ann Chir** 1996; 50(4):352–5 (35 ref.) (Eng. Abstr.) **(Fre)**

[In the name of Commission VII (Sexually transmissible diseases and AIDS). Heterosexual transmission of HIV in France] Montagnier L. **Bull Acad Natl Med** 1995 Jun; 179(6):1209–24 (22 ref.) **(Fre)**

[Ethical reflections on HIV infection] Nores JM.
Presse Med 1995 Sep 30;24(28):1280–3 **(Fre)**

[The sexual transmission of the acquired immunodeficiency virus: the reasons for greater male-to-female than female-to-male transmission efficiency] Nicolosi A, et al.
Ann Ig 1994 Jul–Dec;6(4–6):641–8 (88 ref.) (Eng. Abstr.) **(Ita)**

[Salivary HIV antibodies. Review of current data and future prospectives] Polimeni A, et al. **Minerva Stomatol** 1995 Dec;44(12):583–90 (20 ref.) (Eng. Abstr.) **(Ita)**

[Human immunodeficiency virus (HIV) infection in obstetrics and gynaecology] Balsdon MJ. **Rev Chil Obstet Ginecol** 1994;59(6):476–84 (0 ref.) (Eng. Abstr.) **(Spa)**

[The homosexual transmission of HIV/AIDS in Mexico] Izazola-Licea JA, et al. **Salud Publica Mex** 1995 Nov–Dec; 37(6):602–14 (Eng. Abstr.) **(Spa)**

[Prostitution and AIDS in the city of Mexico] Uribe-Zúñiga P, et al. **Salud Publica Mex** 1995 Nov–Dec;37(6):592–601 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

A sonographic-pathological correlation of liver biopsies in patients with the acquired immune deficiency syndrome (AIDS). Beale TJ, et al. **Clin Radiol** 1995 Nov;50(11):761–4

VIROLOGY

Discontinuous distribution of HIV-1 quasispecies in epidermal Langerhans cells of an AIDS patient and evidence for double infection. Sala M, et al.
Adv Exp Med Biol 1995;378:481–3

Analysis of the V3 loop sequences from 10 HIV type 1-infected AIDS patients from Paraguay. Cabello A, et al. **AIDS Res Hum Retroviruses** 1995 Sep;11(9):1135–7

Restricted tissue distribution of extralesional Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS patients with Kaposi's sarcoma. Corbellino M, et al. **AIDS Res Hum Retroviruses** 1996 May 20;12(8):651–7

Nucleotide sequence of the HIV-2 EHO genome, a divergent HIV-2 isolate. Galabru J, et al.
AIDS Res Hum Retroviruses 1995 Jul;11(7):873–4

Diversity of HIV type 1 envelope V3 loop region in saliva. Kakizawa J, et al. **AIDS Res Hum Retroviruses** 1996 Apr 10;12(6):561–3

env gene sequences of primary HIV type 1 isolates of subtypes B, C, D, E, and F obtained from the World Health Organization Network for HIV Isolation and Characterization. Penny MA, et al.
AIDS Res Hum Retroviruses 1996 May 20;12(8):741–7

A direct association between HIV and AIDS in blood transfusion donors and recipients. Sullivan JS, et al.
AIDS Res Hum Retroviruses 1995 Oct;11(10):1147–8

Sequence analysis of the V1/V2 and V3 domains in an HIV-seronegative AIDS patient. Vallejo A, et al.
AIDS Res Hum Retroviruses 1995 Dec;11(12):1539–41

Highly divergent env sequences of HIV-1 B subtype with two novel V3 loop motifs detected in an AIDS patient in Miami, Florida. Xin KQ, et al.
AIDS Res Hum Retroviruses 1995 Sep;11(9):1139–41

Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) DNA in Kaposi's sarcoma lesions, AIDS Kaposi's sarcoma cell lines, endothelial Kaposi's sarcoma simulators, and the skin of immunosuppressed patients. Dictor M, et al. **Am J Pathol** 1996 Jun;148(6):2009–16

HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS [comment] Saksela K, et al. **Ann Intern Med** 1995 Nov 1;123(9):641–8. Comment on: Ann Intern Med 1995 Nov 1;123(9):726–7.

Quantitation of human immunodeficiency virus in brains of demented and nondemented patients with acquired immunodeficiency syndrome. Johnson RT, et al.
Ann Neurol 1996 Mar;39(3):392–5

Novel assay system favorable for the study of cell-to-cell transmission of HIV-1 and its application to the evaluation of anti-HIV drugs. Inouye Y, et al. **Biol Pharm Bull** 1995 Jun;18(6):920–2

HIV virus does cause AIDS, research shows [news] Kingman S. **BMJ** 1995 Sep 9;311(7006):645

Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time. Levine AM, et al. **Cancer** 1996 Aug 1; 78(3):517–26

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Choe H, et al.
Cell 1996 Jun 28;85(7):1135–48

The subcellular distribution of eukaryotic translation initiation factor, eIF-5A, in cultured cells. Shi XP, et al.
Exp Cell Res 1996 Jun 15;225(2):348–56

In situ amplification and detection of HIV-1 DNA in fixed pediatric AIDS brain tissue. Sharer LR, et al.
Hum Pathol 1996 Jun;27(6):614–7

First case of HIV-1 subtype 0 infection in Germany. Hampl H, et al. **Infection** 1995 Nov–Dec;23(6):369–70

JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. Vago L, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jun 1;12(2):139–46 (43 ref.)

Herpes virus-like sequences are specifically found in Kaposi sarcoma lesions. O'Neill E, et al. **J Clin Pathol** 1996 Apr; 49(4):306–8

HIV-2 strikes injecting drug users (IDUs) in India. Singh NB, et al. **J Infect** 1995 Jul;31(1):49–50

Human herpesvirus 8 is present in the lymphoid system of healthy persons and can reactivate in the course of AIDS. Bigoni B, et al. **J Infect Dis** 1996 Mar;173(3):542–9

Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. Donovan RM, et al.
J Infect Dis 1996 Aug;174(2):401–3

False-negative polymerase chain reaction-based diagnosis of human immunodeficiency virus (HIV) type 1 in children infected with HIV strains of African origin [letter; comment] Haas J, et al. **J Infect Dis** 1996 Jul;174(1):244–5 . Comment on: J Infect Dis 1996 Jan;173(1):68–76.

Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. Gurusinghe AD, et al.
J Med Virol 1995 Jul;46(3):238–43

Quantitation of human cytomegalovirus genomes in the brain of AIDS patients. Kühn JE, et al. **J Med Virol** 1995 Sep; 47(1):70–82

Influence of host genotype on progression to acquired immunodeficiency syndrome among children infected with human immunodeficiency virus type 1. Just JJ, et al.

J Pediatr 1995 Oct;127(4):544–9

Human immunodeficiency virus type 1 long terminal repeat variants from 42 patients representing all stages of infection display a wide range of sequence polymorphism and transcription activity. Estable MC, et al. **J Virol** 1996 Jun; 70(6):4053–62

Biological characterization of nef in long-term survivors of human immunodeficiency virus type 1 infection. Huang Y, et al. **J Virol** 1995 Dec;69(12):8142–6

Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type 1 infection in perinatally infected twins with discordant disease courses. Hutto C, et al. **J Virol** 1996 Jun;70(6):3589–98

Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. Joag SV, et al. **J Virol** 1996 May;70(5):3189–97

Persistent infection of macaques with simian-human immunodeficiency viruses. Li JT, et al. **J Virol** 1995 Nov; 69(11):7061–7

Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression. Strunnikova N, et al. **J Virol** 1995 Dec; 69(12):7548–58

Predominance of codon 215 mutation in reverse transcriptase-coding region of 3'-azido-3'-deoxythymidine (AZT)-resistant HIV-1 isolates after long-term AZT therapy. Kondo M. **Kansenshogaku Zasshi** 1995 Nov; 69(11):1278–85

HIV as the cause of AIDS. Barré-Sinoussi F. **Lancet** 1996 Jul 6;348(9019):31–5 (50 ref.)

HIV-1 group O infection identified in USA [news] Rowe PM. **Lancet** 1996 Jul 13;348(9020):116

Risk of HIV transmission in infected US military personnel [letter; comment] Ruppach H, et al. **Lancet** 1996 Mar 9; 347(9002):697–8. Comment on: Lancet 1995 Nov 4;346(8984):1198–9.

Dual infection with HIV-1 Thai subtype B and E [letter] Xin KQ, et al. **Lancet** 1995 Nov 18;346(8986):1372–3

Can evolutionary principles help resolve the acquired immune deficiency syndrome crisis? Powell PD. **Med Hypotheses** 1996 Feb;46(2):130–4 (40 ref.)

Kaposi's sarcoma and herpesvirus-like DNA sequences in sensory ganglia [letter] Corbellino M, et al. **N Engl J Med** 1996 May 16;334(20):1341–2

Physicians' experience and survival in patients with AIDS [letter; comment] Guerra-Romero L, et al. **N Engl J Med** 1996 Aug 1;335(5):350; discussion 351. Comment on: N Engl J Med 1996 Mar 14;334(11):729–31.

Plasma HIV viremia and viral load in lymph nodes [letter; comment] Dianzani F, et al. **Nat Med** 1996 Aug;2(8):832–3 . Comment on: Nat Med 1996 May;2(5):502.

Pathway to understanding AIDS [news] Stevenson M. **Nat Struct Biol** 1996 Apr;3(4):303–6

HIV and AIDS [letter; comment] Sullivan JS, et al. **Nature** 1995 Nov 2;378(6552):10. Comment on: Nature 1995 Sep 7;377(6544):79–82.

Clinical viral infections and temporal bone histologic studies of patients with AIDS. Davis LE, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):695–701

All about AIDS [news] **Science** 1995 Nov 10;270(5238):919

Viral counts count in HIV infection [see comments] Ho DD. **Science** 1996 May 24;272(5265):1124–5 (13 ref.). Comment in: Science 1996 May 24;272(5265):1167–70.

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma [see comments] Mellors JW, et al. **Science** 1996 May 24;272(5265):1167–70. Comment in: Science 1996 May 24;272(5265):1124–5.

HIV receptors and the pathogenesis of AIDS. Weiss RA. **Science** 1996 Jun 28;272(5270):1885–6

Modeling HIV concentration during acute AIDS infection [letter; comment] Wilson SE, et al. **Science** 1996 Jun 28; 272(5270):1960–2. Comment on: Science 1996 Jan 26;271(5248):497–9.

[Risks of accidental exposure to blood in the operating room. Results of a multicenter prospective study. Groupe d'Etude sur les Risques d'Exposition au Sang] Johanet H, et al. **Ann Chir** 1995;49(5):403–10 (Eng. Abstr.) **(Fre)**

[Epithelial dendritic cells and HIV-1 infection in vivo and in vitro] Dezutter-Dambuyant C, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):882–8 (71 ref.) (Eng. Abstr.) **(Fre)**

[Dendritic cells of spleen and blood and HIV-1 infection] Hosmalin A. **Pathol Biol (Paris)** 1995 Dec;43(10):889–96 (54 ref.) (Eng. Abstr.) **(Fre)**

[HIV: virus burden as a prognostic factor and for monitoring of therapy (news)] Schenk M. **Dtsch Med Wochenschr** 1996 Sep 6;121(36):A9 **(Ger)**

[African histoplasmosis in a patient with HIV-2 infection] Eichmann A, et al. **Schweiz Med Wochenschr** 1996 May 4;126(18):765–9 (Eng. Abstr.) **(Ger)**

[Follow-up of HIV carriers by a laboratory method. I: Virus isolation is useful for prognostication of the onset of symptoms] Otake T, et al. **Kansenshogaku Zasshi** 1996 Apr; 70(4):338–46 (Eng. Abstr.) **(Jpn)**

[Nervous system infections by retroviruses] Román GC. **Rev Neurol** 1996 Jun;24(130):703–7 (9 ref.) **(Spa)**

ACQUISITION, HEALTH FACILITY see **HEALTH FACILITY MERGER**

ACREMONIUM

Pulmonary acremonium abscesses and gastrointestinal tuberculosis manifested as massive upper gastrointestinal bleeding. Miró O, et al. **Nephrol Dial Transplant** 1995; 10(8):1444–6 (17 ref.)

Management of postoperative Acremonium endophthalmitis. Weissgold DJ, et al. **Ophthalmology** 1996 May; 103(5):749–56

Kerionlike lesion of the scalp due to Acremonium kiliense in a noncompromised boy. Lopes JO, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jul-Aug;37(4):365–8

ENZYMOLOGY

Purification and characterization of an extracellular (1 --> 6)-beta-glucanase from the filamentous fungus Acremonium persicinum. Pitson SM, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):841–6

Functional analysis of conserved histidine residues in Cephalosporium acremonium isopenicillin N synthase by site-directed mutagenesis. Tan DS, et al. **J Biol Chem** 1996 Jan 12;271(2):889–94

Mutualistic fungal endophytes express a proteinase that is homologous to proteases suspected to be important in fungal pathogenicity. Reddy PV, et al. **Plant Physiol** 1996 Aug;111(4):1209–18

GENETICS

Rapid identification of Acremonium lolii and Acremonium coenophialum endophytes through arbitrarily primed PCR. Liu D, et al. **FEMS Microbiol Lett** 1995 Nov 1; 133(1-2):95–8

ISOLATION & PURIFICATION

Supplemental protein and energy for beef cows consuming endophyte-infected tall fescue. Forcherio JC, et al. **J Anim Sci** 1995 Nov;73(11):3427–36

Acremonium kiliense peritonitis complicating continuous ambulatory peritoneal dialysis: report of two cases. Lopes JO, et al. **Mycopathologia** 1995 Aug;131(2):83–5

Subcutaneous hyalohyphomycosis caused by Acremonium recifei: case report. Zaitz C, et al. **Rev Inst Med Trop Sao Paulo** 1995 May-Jun;37(3):267–70

PATHOGENICITY

Fatal, disseminated Acremonium strictum infection in a neutropenic host. Schell WA, et al. **J Clin Microbiol** 1996 May;34(5):1333–6 (27 ref.)

ACRIDINAMINE see **AMINACRINE**

ACRIDINE ORANGE

Chromatin condensation in cat spermatozoa during epididymal transit as studied by aniline blue and acridine orange staining. Hingst O, et al. **Andrologia** 1995 Sep-Oct; 27(5):275–9

Detection of borreliacidal antibody by using acridine orange and flow cytometry. Lim LC, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):44–50

Phenolic acridine orange fluorescent stain for mycobacteria. Smithwick RW, et al. **J Clin Microbiol** 1995 Oct; 33(10):2763–4

A fast and easy fluorescent counterstaining method for neuroanatomical studies by using Acridine Orange. López-Román A, et al. **J Neurosci Methods** 1995 Aug; 60(1-2):39–42

Comparison of acridine orange and giemsa stains for malaria diagnosis. Kong HH, et al. **Korean J Parasitol** 1995 Dec; 33(4):391–4 (18 ref.)

Immediate detection of malaria parasites by acridine orange staining [letter] Metzger WG, et al. **Trans R Soc Trop Med Hyg** 1995 Sep-Oct;89(5):577

DIAGNOSTIC USE

The relationship between acridine orange fluorescence of sperm nuclei and the fertilizing ability of human sperm. Hoshi K, et al. **Fertil Steril** 1996 Oct;66(4):634–9

[The quantitative buffy coat technique in detecting trypanosomes (letter)] Rogalle T, et al. **Med Trop (Mars)** 1995;55(3):288 **(Fre)**

PHARMACOKINETICS

A color image analysis method for assessment of germination based on differential fluorescence staining of bacterial spores and vegetative cells using acridine orange. Bruno JG, et al. **Biotech Histochem** 1995 Jul;70(4):175–84

ACRIDINES

High-performance liquid chromatography of amino acids after derivatization with 9-isothiocyanatoacridine. Oravec P, et al. **J Biochem Biophys Methods** 1995 Jun; 30(2-3):145–52

A general assay for antibody catalysis using acridone as a fluorescent tag. Reymond JL, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4251–6

CHEMICAL SYNTHESIS

Pyrimido [4,5,6-kl] acridines, a new class of potential anticancer agents. Synthesis and biological evaluation. Antonini I, et al. **Anticancer Drug Des** 1996 Jun; 11(4):339–49

In vitro evaluation of the potential antitumor activity of an N-acridyl-pentanoyloxypyridine-2-thione derivative. Nocentini G, et al. **Arzneimittelforschung** 1995 Oct; 45(10):1127–30

CHEMISTRY

Interactions of acridine antitumor agents with DNA: binding energies and groove preferences. Crenshaw JM, et al. **Biochemistry** 1995 Oct 17;34(41):13682–7

Spectroscopic studies on the interaction of three partially hydrogenated acridine dyes with calf thymus DNA and their structural comparison. Sivaraman J, et al. **J Biomol Struct Dyn** 1995 Aug;13(1):119–34

DIAGNOSTIC USE

Simultaneous detection of multiple nucleic acid targets in a homogeneous format. Nelson NC, et al. **Biochemistry** 1996 Jun 25;35(25):8429–38

METABOLISM

Interactions of intercalative and minor groove binding ligands with triplex poly(dA).[poly(dT)]2 and with duplex poly(dA).poly(dT) and poly[d(A-T)]2 studied by CD, LD, and normal absorption. Kim HK, et al. **Biochemistry** 1996 Jan 30;35(4):1187–94

Binding of the neurotoxin fasciculin 2 to the acetylcholinesterase peripheral site drastically reduces the association and dissociation rate constants for N-methylacridinium binding to the active site. Rosenberry TL, et al. **Biochemistry** 1996 Jan 23;35(3):685–90

9-Hydroxymethyl-10-carbamoylacridan in human serum is one of the major metabolites of carbamazepine. Eto S, et al. **Biol Pharm Bull** 1995 Jun;18(6):926–8

Stereoselective and regioselective hydration of 7-methylbenz[c]acridine-5,6-oxide enantiomers by rodent and human microsomal epoxide hydrolases. Roberts-Thomson SJ, et al. **Mol Pharmacol** 1996 Jan; 49(1):105–11

PHARMACOKINETICS

Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC-366140). Palomino E, et al. **Cancer Chemother Pharmacol** 1996;38(5):453–8

PHARMACOLOGY

Immunomodulating effect of acridine tautomers on eukaryotic cells. Petri IB, et al. **Acta Microbiol Immunol Hung** 1995;42(2):203–8

Pyrimido [4,5,6-kl] acridines, a new class of potential anticancer agents. Synthesis and biological evaluation. Antonini I, et al. **Anticancer Drug Des** 1996 Jun; 11(4):339–49

Induction of DNA fragmentation in human myelogenous leukaemic cell lines by phenothiazine-related compounds. Sakagami H, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2533–40

Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. Kuśnierczyk H, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(5-6):415–23

Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells. Grem JL, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1649–59

Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Berger B, et al. **Cancer Res** 1996 May 1;56(9):2094–104

Status of new anthrapyrazole and pyrazoloacridine derivatives. Berg SL. **Crit Rev Oncol Hematol** 1996 Mar; 22(2):79–87 (57 ref.)

From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Finlay GJ, et al. **Eur J Cancer** 1996 Apr; 32A(4):708–14

The effect of carbamazepine and its reactive metabolite, 9-acridine carboxaldehyde, on immune cell function in vitro. Furst SM, et al. **Int J Immunopharmacol** 1995 May; 17(5):445–52

Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. Lee HH, et al. **J Med Chem** 1996 Jun 21; 39(13):2508–17

Activity of 9-acridanone-hydrazone drugs detected at the pre-postural phase, in the experimental schistosomiasis mansoni. Pereira LH, et al. **Mem Inst Oswaldo Cruz** 1995 May-Jun;90(3):425–8

Mutagenicity of acridines in a reversion assay based on tetracycline resistance in plasmid pBR322 in Escherichia coli. Hoffman GR, et al. **Mutat Res** 1996 Mar 26; 351(1):33–43

Photolysis of N-hydroxpyridinethiones: a new source of hydroxyl radicals for the direct damage of cell-free and cellular DNA. Epe B, et al. **Nucleic Acids Res** 1996 May

1;24(9):1625-31
Studies on the inhibitory effects of some acridone alkaloids on Epstein-Barr virus activation [letter] Takemura Y, et al. **Planta Med** 1995 Aug;61(4):366-8
[Trypanocidal structure- activity relationship in 9-thioalkylacridines] Bsiri N, et al. **Ann Pharm Fr** 1996; 54(1):27-33 (Eng. Abstr.) **(Fre)**
[A disorder in the energy-conversion processes in the liver mitochondria of rats under the action of sanguinarin and AFMA] Beliaeva TN, et al. **Tsitologiia** 1995;37(3):237-48 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Antischistosomal activity of acridanone-hydrazones in Cebus monkeys experimentally infected with the SJ strain of Schistosoma mansoni. Coelho PM, et al.
Rev Soc Bras Med Trop 1995 Jul-Sep;28(3):179-83
Plasmodium berghei mouse model: antimalarial activity of new alkaloid salts and of thiosemicarbazone and acridine derivatives. Loiseau PM, et al. **Trop Med Int Health** 1996 Jun;1(3):379-84
[The interferon inducer neovir (kamedon) in the combined treatment of chronic inflammatory diseases of the adnexa uteri of chlamydial etiology (a clinical electron-microscopic study)] Delektorskii VV, et al. **Antibiot Khimioter** 1995 May;40(5):42-7 (Eng. Abstr.) **(Rus)**

TOXICITY

Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Berger B, et al.
Cancer Res 1996 May 1;56(9):2094-104
Comparative carcinogenicity, metabolism, mutagenicity, and DNA binding of 7H-dibenzo[c,g]carbazole and dibenz[a,j]acridine. Warshawsky D, et al.
Crit Rev Toxicol 1996;26(2):213-49 (101 ref.)

ACRIFLAVINE

PHARMACOLOGY

Molecular cloning of the acr-2 gene which controls acriflavine sensitivity in Neurospora crassa. Akiyama M, et al. **Biochim Biophys Acta** 1996 Jun 7;1307(2):187-92

ACRO-OSTEOLYSIS SYNDROMES see **OSTEOLYSIS, ESSENTIAL**

ACROCEPHALOSYNDACTYLIA

CLASSIFICATION

Classification of hand anomalies in Apert's syndrome. al-Qattan MM, et al. **J Hand Surg [Br]** 1996 Apr; 21(2):266-8

COMPLICATIONS

Morbidity associated with increased intracranial pressure in Apert and Pfeiffer syndromes: the need for long-term evaluation. Gosain AK, et al. **Plast Reconstr Surg** 1996 Feb;97(2):292-301

DIAGNOSIS

Skull base and calvarial deformities: association with intracranial changes in craniofacial syndromes. Tokumaru AM, et al. **AJNR Am J Neuroradiol** 1996 Apr;17(4):619-30

GENETICS

Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome. Slaney SF, et al.
Am J Hum Genet 1996 May;58(5):923-32
Asymmetrical coronal synostosis, cutaneous syndactyly of the fingers and toes, and jejunal atresia in a male infant. Pfeiffer RA, et al. **Am J Med Genet** 1996 May 3;63(1):175-6
Craniosynostosis suggestive of Saethre-Chotzen syndrome: clinical description of a large kindred and exclusion of candidate regions on 7p. von Gernet S, et al.
Am J Med Genet 1996 May 3;63(1):177-84
Assignment of FGF8 to human chromosome 10q25-q26: mutations in FGF8 may be responsible for some types of acrocephalosyndactyly linked to this region. White RA, et al. **Genomics** 1995 Nov 1;30(1):109-11
Possible genetic heterogeneity in the Saethre-Chotzen syndrome. Ma HW, et al. **Hum Genet** 1996 Aug; 98(2):228-32
Exclusive paternal origin of new mutations in Apert syndrome [see comments] Moloney DM, et al.
Nat Genet 1996 May;13(1):48-53. Comment in: Nat Genet 1996 May;13(1):9-10.
A paternal wash in Apert syndrome [news; comment] Sapienza C. **Nat Genet** 1996 May;13(1):9-10. Comment on: Nat Genet 1996 May;13(1):48-53.
Annual genetics meeting: some puzzles, some answers [news] [see comments] Nowak R. **Science** 1995 Nov 17; 270(5239):1120-1. Comment in: Science 1996 Mar 8;271(5254):1347-8.
[Nucleotide sequences at intron 6 and exon 7 junction of fibroblast growth factor receptor 2 and rapid mutational analysis in Apert syndrome] Wada C, et al.
Rinsho Byori 1996 May;44(5):435-8 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Cutaneous manifestations of Apert syndrome [letter; comment] Cohen MM Jr, et al. **Am J Med Genet** 1995 Jul 31;58(1):94-6. Comment on: Am J Med Genet 1993 Mar 15;45(6):758-60.
Suture formation, premature sutural fusion, and suture default zones in Apert syndrome. Cohen MM Jr, et al.
Am J Med Genet 1996 Apr 24;62(4):339-44

RADIOGRAPHY

[X-ray diagnosis of Pfeiffer's syndrome (type V of acrocephalosyndactyly)] Vatolin KV, et al.
Vestn Rentgenol Radiol 1995 Jul-Aug;(4):39-41 **(Rus)**

SURGERY

Extradural deadspace after infant fronto-orbital advancement in Apert syndrome. Moore MH, et al.
Cleft Palate Craniofac J 1996 May;33(3):202-5

THERAPY

Prognosis for mental function in Apert's syndrome. Renier D, et al. **J Neurosurg** 1996 Jul;85(1):66-72
[Apert syndrome. Ultrasonic diagnosis, obstetrical management] Delinière F, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(6):613-7 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[Apert syndrome. Ultrasonic diagnosis, obstetrical management] Delinière F, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(6):613-7 (Eng. Abstr.) **(Fre)**

ACROCEPHALY see **CRANIOSYNOSTOSES**

ACRODERMATITIS

[Gianotti disease and Gianotti-Crosti syndrome] Toda G. **Ryoikibetsu Shokogun Shirizu** 1995;(7):24-6 (11 ref.) **(Jpn)**

COMPLICATIONS

Acrodermatitis continua of Hallopeau in a patient with myelodysplastic syndrome. van der Kerkhof PC, et al.
Br J Dermatol 1996 Apr;134(4):754-7

DIAGNOSIS

Acro-angiodermatitis: review of the literature and report of a case. Rashkovsky I, et al. **Acta Derm Venereol** 1995 Nov; 75(6):475-8 (55 ref.)
Expression of the CD34 antigen distinguishes Kaposi's sarcoma from pseudo-Kaposi's sarcoma (acroangiodermatitis). Kanitakis J, et al. **Br J Dermatol** 1996 Jan;134(1):44-6
[Lyme borreliosis in hand surgery. A case report] Ebert B, et al. **Handchir Mikrochir Plast Chir** 1995 Sep;27(5):242-6 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Picture of the month. Acrodermatitis enteropathica-like rash in cystic fibrosis. Ghali FE, et al.
Arch Pediatr Adolesc Med 1996 Jan;150(1):99-100
Gianotti-Crosti syndrome as a result of vaccination and Epstein-Barr virus infection [letter] Lacour M, et al.
Eur J Pediatr 1995 Aug;154(8):688-9
Etiology of the acrodermatitis chronica atrophicans lesion in Lyme disease. Ohlenbusch A, et al. **J Infect Dis** 1996 Aug;174(2):421-3
Acrodermatitis enteropathica-like syndrome in a dialysis patient [letter] Parra E, et al. **Nephron** 1995;70(3):389-90
[Gianotti-Crosti syndrome due to a mixed infection produced by the mumps virus and the parainfluenza virus type 2] Hergueta Lendínez R, et al. **An Esp Pediatr** 1996 Jan; 44(1):65-6 (17 ref.) **(Spa)**

GENETICS

The acrodermatitis enteropathica mutation transiently affects zinc metabolism in human fibroblasts. Grider A, et al.
J Nutr 1996 Jan;126(1):219-24

IMMUNOLOGY

Gloves and socks syndrome [letter] Person DA. **Lancet** 1996 Apr 20;347(9008):1125-6

METABOLISM

The effect of the acrodermatitis enteropathica mutation on zinc uptake in human fibroblasts. Vazquez F, et al.
Biol Trace Elem Res 1995 Nov;50(2):109-17
The acrodermatitis enteropathica mutation transiently affects zinc metabolism in human fibroblasts. Grider A, et al.
J Nutr 1996 Jan;126(1):219-24

MICROBIOLOGY

Identification of Borrelia afzelii in a juxta-articular fibroid nodule from a human immunodeficiency virus-positive patient with acrodermatitis chronica atrophicans [letter] Lübbe J, et al. **Arch Dermatol** 1995 Nov;131(11):1341-2
Etiology of the acrodermatitis chronica atrophicans lesion in Lyme disease. Ohlenbusch A, et al. **J Infect Dis** 1996 Aug;174(2):421-3

VIROLOGY

Case report: Gianotti-Crosti syndrome associated with human herpesvirus-6 infection. Yasumoto S, et al.
J Dermatol 1996 Jul;23(7):499-501

ACRODYNIA

CHEMICALLY INDUCED

Dental amalgam and Feer disease [comment] von Mühlendahl KE. **Eur J Pediatr** 1995 Jul;154(7):585-6. Comment on: Eur J Pediatr 1994 Aug;153(8):607-10.

ACRODYSPLASIA V see **LANGER-GIEDION SYNDROME**

ACROLEIN

Covalent enzyme immobilization on paramagnetic polyacrolein beads. Varlan AR, et al.
Biosens Bioelectron 1996;11(4):443-8
Fate and effects of acrolein. Ghilarducci DP, et al.
Rev Environ Contam Toxicol 1995;144:95-146 (222 ref.)

ANALOGS & DERIVATIVES

An intermediate for chloroquine analogs: (E)-2-(4,7-dichloro-2-quinolinyl)-3-(dimethylamino)-2-propenal. Mague JT, et al. **Acta Crystallogr C** 1995 Jul 15;51 (Pt 7):1423-5
Acrolein mercapturates: synthesis, characterization, and assessment of their role in the bladder toxicity of cyclophosphamide. Ramu K, et al. **Chem Res Toxicol** 1995 Jun;8(4):515-24
[Eating cinnamon in cinnamaldehyde allergy] Hürlimann AF, et al. **Hautarzt** 1995 Sep;46(9):660-1 **(Ger)**
[Microbiological studies of stomatological periodontal films containing a derivative of chlorocinnamic aldehyde] Davtian LL, et al. **Mikrobiol Z** 1995 Sep-Oct;57(5):78-83 (Eng. Abstr.) **(Rus)**

METABOLISM

Effect of Magnacide(R) H herbicide residuals on water quality within wildlife refuges of the Klamath Basin, CA. Nordone AJ, et al. **Bull Environ Contam Toxicol** 1996 Jun; 56(6):964-70

PHARMACOKINETICS

Biotransformation of acrolein in rat: excretion of mercapturic acids after inhalation and intraperitoneal injection. Linhart I, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):155-60

PHARMACOLOGY

Inactivation of DNA polymerase alpha-primase by acrolein: loss of activity depends on the DNA substrate. Catalano CE, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):971-7

TOXICITY

Changes in the nasal epithelium of rats exposed by inhalation to mixtures of formaldehyde, acetaldehyde, and acrolein. Cassee FR, et al. **Fundam Appl Toxicol** 1996 Feb; 29(2):208-18
Acrolein-induced smooth muscle hyperresponsiveness and eicosanoid release in excised ferret tracheae. Ben-Jebria A, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):35-44

ACROMEGALY

Large lungs and growth hormone: an increased alveolar number? Donnelly PM, et al. **Eur Respir J** 1995 Jun; 8(6):938-47
Acromegaly: unravelling a complex disease. O'Halloran DJ, et al. **Growth Regul** 1995 Sep;5(3):119-24 (60 ref.)

BLOOD

The magnitude of growth hormone elevation is related with the proportion of monomeric form in acromegaly. Ochoa R, et al. **Arch Med Res** 1995;26 Spec No:S17-21
Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients. Ciccarelli E, et al.
Clin Endocrinol (Oxf) 1996 Jan;44(1):67-71
IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. de Herder WW, et al.
Clin Endocrinol (Oxf) 1995 Oct;43(4):501-5
True insulin and intact proinsulin levels in acromegalic patients. Tavares EF, et al. **Eur J Endocrinol** 1996 May; 134(5):549-53
Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Frystyk J, et al. **Growth Regul** 1995 Dec;5(4):169-76
GH response to oral and intravenous glucose load in acromegalic patients. Mancini A, et al.
Horm Metab Res 1995 Jul;27(7):322-5
Assessment of growth hormone (GH) plasma clearance rate,

half-life, and volume of distribution in acromegalic patients: the combined GH-octreotide infusion. Lanzi R, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3279–83

Effect of 4 weeks of octreotide treatment on prolactin, thyroid stimulating hormone and thyroid hormones in acromegalic patients. A double blind placebo-controlled cross-over study. Andersen M, et al. **J Endocrinol Invest** 1995 Dec;18(11):840–6

Sumatriptan does not stimulate PRL and GH secretion in acromegaly. Cuttica CM, et al. **Minerva Endocrinol** 1995 Jun;20(2):141–4

COMPLICATIONS

Acromegaly and large cell lymphoma. Intebi AD, et al. **Acta Haematol** 1995;94(4):214–5

Increased epithelial cell proliferation in the colon of patients with acromegaly. Cats A, et al. **Cancer Res** 1996 Feb 1; 56(3):523–6

Nocturnal breathing abnormalities in acromegaly after adenomectomy. Pelttari L, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):175–82

Case report: giant synovial osteochondromatosis in association with acromegaly. Breitenseher M, et al. **Clin Radiol** 1995 Sep;50(9):657–9

Acromegaly with cavernous haemangioma of the liver and colonic polyps [letter; comment] Ujj G, et al. **Horm Metab Res** 1995 Sep;27(9):438. Comment on: Horm Metab Res 1994 Dec;26(12):609–10.

The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. Delhougne B, et al. **J Clin Endocrinol Metab** 1995 Nov; 80(11):3223–6

Clomiphene-induced pituitary apoplexy in a patient with acromegaly. Walker AB, et al. **Postgrad Med J** 1996 Mar; 72(845):172–3

Heart disease in acromegaly. Hradec J, et al. **Sb Lek** 1995; 96(4):433–5

[Coronary artery bypass grafting for ischemic heart disease associated with acromegaly: a case report] Ichikawa S, et al. **Kyobu Geka** 1996 Mar;49(3):214–7 (Eng. Abstr.) **(Jpn)**

[Successful treatment of splenomegaly and anemia by VP therapy in idiopathic myelofibrosis complicated with acromegaly: a case report] Imai Y, et al. **Rinsho Ketsueki** 1995 Oct;36(10):1233–6 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. Melmed S, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3395–402 (69 ref.)

Pachydermoperiostosis in a 13 year-old boy presenting as an acromegaly-like syndrome. Singh GR, et al. **J Pediatr Endocrinol Metab** 1995 Jan–Mar;8(1):51–4

[Acromegaly; diagnosis and treatment] van der Lely AJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1436–40 (52 ref.) **(Dut)**

DRUG THERAPY

Prevalence of Helicobacter pylori in acromegalic patients during treatment with octreotide. Jones SL, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):683–7

Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group. Arosio M, et al. **Eur J Endocrinol** 1995 Oct;133(4):430–9

Octreotide treatment increases exercise capacity in patients with acromegaly. Padayatty SJ, et al. **Eur J Endocrinol** 1996 May;134(5):554–9

Medical therapy with somatostatin analogues for acromegaly [comment] Sassolas G. **Eur J Endocrinol** 1995 Dec; 133(6):675–7. Comment on: Eur J Endocrinol 1995 Dec;133(6):686–90.

Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. Hussaini SH, et al. **Gut** 1996 May;38(5):775–83

Sandostatin LAR in acromegalic patients: a dose-range study. Fløgstad AK, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3601–7

Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase. Simsolo RB, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3233–8

Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. Stewart PM, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3267–72

The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients. Tauber JP, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3262–6

A prospective multicenter octreotide dose response study in the treatment of acromegaly. Ezzat S, et al. **J Endocrinol Invest** 1995 May;18(5):364–9

Assessment of functional liver mass and plasma flow in acromegaly before and after long-term treatment with octreotide. Avagnina P, et al. **Metabolism** 1996 Jan; 45(1):109–13

ETIOLOGY

Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly. Tsukamoto N, et al. **Endocr J** 1994 Aug;41(4):437–44

Acromegaly caused by growth hormone-relating hormone in a patient with multiple endocrine neoplasia type I. Liu SW, et al. **Jpn J Clin Oncol** 1996 Feb;26(1):49–52

[Sarcoidosis-lymphoma syndrome in a woman with acromegaly] Siekierska-Hellmann M, et al. **Pol Arch Med Wewn** 1995 Dec;94(6):539–43 (Eng. Abstr.) **(Pol)**

GENETICS

Familial acromegaly: a specific clinical entity--further evidence from the genetic study of a three-generation family. Benlian P, et al. **Eur J Endocrinol** 1995 Oct; 133(4):451–6

[Surgical treatment of familial acromegaly] Xu L, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul;33(7):435–6 (Eng. Abstr.) **(Chi)**

HISTORY

Did the model for Polyphemus have acromegalic arthritis? [letter] Denko CW. **J Rheumatol** 1995 Nov;22(11):2191–2

Acromegaly and pituitary tumors: early anatomoclinical observations. Brunori A, et al. **Surg Neurol** 1995 Jul; 44(1):83–7

METABOLISM

Growth hormone pulsatility in active and cured acromegalic subjects. Semer M, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3767–70

Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase. Simsolo RB, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3233–8

Growth hormone (GH) secretory dynamics in a case of acromegalic gigantism associated with hyperprolactinemia: nonpulsatile secretion of GH may induce elevated insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 levels. Yoshida T, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):310–3

Prolactin receptor expression in lymphocytes from patients with hyperprolactinemia or acromegaly. Leite-de-Moraes MC, et al. **J Endocrinol** 1995 Nov;147(2):353–9

Growth hormone secretion in human acromegalic pituitary adenomas: cyclic adenosine monophosphate and protein kinase C responses. Ishizuka T, et al. **Metabolism** 1996 Feb; 45(2):206–10

PHYSIOPATHOLOGY

Nocturnal monitoring of growth hormone, insulin, C-peptide, and glucose in patients with acromegaly. Tsai JS, et al. **Am J Med Sci** 1996 Jun;311(6):281–5

Systolic and diastolic cardiac function in acromegaly. An echocardiographic study. Galanti G, et al. **Ann Ital Med Int** 1996 Jan–Mar;11(1):27–32

Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly. Giustina A, et al. **Endocr Res** 1995 Aug;21(3):569–82

Octreotide treatment increases exercise capacity in patients with acromegaly. Padayatty SJ, et al. **Eur J Endocrinol** 1996 May;134(5):554–9

Naloxone influence on the growth hormone, prolactin and thyrotropin response to thyrotropin releasing hormone in acromegalic patients. De Marinis L, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):67–71

Assessment of functional liver mass and plasma flow in acromegaly before and after long-term treatment with octreotide. Avagnina P, et al. **Metabolism** 1996 Jan; 45(1):109–13

SURGERY

Remission of polycythemia vera after surgical cure of acromegaly. Grellier P, et al. **Ann Intern Med** 1996 Mar 1;124(5):495–6

Use of modern craniofacial techniques for comprehensive reconstruction of the acromegalic face. Chung KC, et al. **Ann Plast Surg** 1996 Apr;36(4):403–8; discussion 408–9

Biochemical cure of recurrent acromegaly by resection of cervical spinal canal metastases. Dayan C, et al. **Clin Endocrinol (Oxf)** 1996 May;44(5):597–602

[Surgical treatment of familial acromegaly] Xu L, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul;33(7):435–6 (Eng. Abstr.) **(Chi)**

[Surgery of hypophyseal tumors via lateral rhinotomy. Reduced risk of recurrence and the impact on vision] Petruson B, et al. **Lakartidningen** 1996 Jun 12; 93(24):2337–40 **(Swe)**

THERAPY

Clinical presentations and results of therapy of 63 acromegalic patients Chang Gung Memorial Hospital. Lin JD, et al. **Chang Keng I Hsueh** 1995 Sep;18(3):231–9

The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Jenkins D, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):517–22

Acromegaly: what constitutes optimal therapy? [editorial] Frohman LA. **J Clin Endocrinol Metab** 1996 Feb; 81(2):443–5 (22 ref.)

Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-indium pentetreotide scan. Greenman Y, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1628–33 (29 ref.)

Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. Melmed S, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3395–402 (69 ref.)

[Acromegaly; diagnosis and treatment] van der Lely AJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1436–40 (52 ref.) **(Dut)**

ULTRASONOGRAPHY

Systolic and diastolic cardiac function in acromegaly. An echocardiographic study. Galanti G, et al. **Ann Ital Med Int** 1996 Jan–Mar;11(1):27–32

Doppler echocardiographic patterns in patients with acromegaly. Terzolo M, et al. **J Endocrinol Invest** 1995 Sep;18(8):613–20

VETERINARY

[A dog named Wanda and comparative pathobiology] Riinberk A. **Tijdschr Diergeneeskd** 1996 Apr 15; 121(8):224–8 **(Dut)**

ACROMIOCLAVICULAR JOINT

Mantle radiation induced symmetrical basal cell carcinomas over the acromioclavicular joints [letter] Grammer-West NY, et al. **Dermatol Surg** 1996 May;22(5):481–2

Combined arthroscopic management of impingement syndrome and acromioclavicular joint arthritis. Lozman PR, et al. **J South Orthop Assoc** 1995 Fall;4(3):177–81

Sapho syndrome associated with acne fulminans and prominent acromioclavicular joint involvement. Bölükbaş N, et al. **Scand J Rheumatol** 1996;25(3):180–2

ANATOMY & HISTOLOGY

Anatomic variants of the coracoacromial ligament. Holt EM, et al. **J Shoulder Elbow Surg** 1995 Sep-Oct;4(5):370–5

INJURIES

Surgical treatment of dislocations of the acromioclavicular joint in the athlete [letter] Combalia-Aleu A. **Br J Sports Med** 1995 Sep;29(3):210

Treatment of unstable distal clavicular fractures with and without lesions of the acromioclavicular joint. Hessmann M, et al. **Injury** 1996 Jan;27(1):47–52

A new drill guide to simplify coraco-clavicular screw fixation. Hubble MJ, et al. **Injury** 1995 Oct;26(8):572–3

Fracture of the acromion associated with acromioclavicular dislocation. Kurdy NM, et al. **Injury** 1995 Nov;26(9):636–7

Long-term results of conservative treatment for acromioclavicular dislocation. Rawes ML, et al. **J Bone Joint Surg Br** 1996 May;78(3):410–2

Surgical treatment of complete acromioclavicular dislocation using the coracoacromial ligament and coracoclavicular fixation: report of a technique in 14 patients. Kumar S, et al. **J Orthop Trauma** 1995;9(6):507–10

Acromioclavicular joint injuries. McCluskey GM 3rd, et al. **J South Orthop Assoc** 1995 Fall;4(3):206–13

Scapulothoracic dissociation: a devastating injury. Clements RH, et al. **J Trauma** 1996 Jan;40(1):146–9

[Reconstruction of chronic symptomatic acromioclavicular joint dislocation (Rockwood III-V) using the modified Weaver-Dunn method. 24 operated patients (1988–95), surgical technique, results] Bircher HP, et al. **Swiss Surg** 1996;(2):46–50 (Eng. Abstr.) **(Ger)**

[Morphometry of the sub-acromial space and its clinical relevance] Anetzberger H, et al. **Unfallchirurg** 1995 Aug; 98(8):407–14 (Eng. Abstr.) **(Ger)**

[Surgical treatment of acute, complete acromioclavicular joint dislocation. Indications, technique and results] Fremerey RW, et al. **Unfallchirurg** 1996 May;99(5):341–5 (Eng. Abstr.) **(Ger)**

[Late results of surgical treatment of Tossy III acromioclavicular joint separation with the Balser plate] Graupe F, et al. **Unfallchirurg** 1995 Aug;98(8):422–6 (Eng. Abstr.) **(Ger)**

[Coraco-clavicular screw fixation: a simple treatment of acromioclavicular joint dislocation] Tanner A, et al. **Unfallchirurg** 1995 Oct;98(10):518–21 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Patterns of degenerative change in the acromioclavicular joint. Edelson JG. **J Bone Joint Surg Br** 1996 Mar; 78(2):242–3

Arthroscopy of the acromioclavicular joint. Corso SJ, et al. **Orthop Clin North Am** 1995 Oct;26(4):661–70

PHYSIOLOGY

The role of the acromioclavicular ligaments and the effect of distal clavicle resection. Branch TP, et al. **Am J Sports Med** 1996 May-Jun;24(3):293–7

Acromial compromise with use of a transacromial portal: a biomechanical study. Coen MJ, et al. **J Shoulder Elbow Surg** 1995 Jul-Aug;4(4):249–53

RADIOGRAPHY

Gouty arthropathy of the acromioclavicular joint. Blotter

RH, et al. **Am J Orthop** 1995 Nov;24(11):859–60

SURGERY

Acromioclavicular reconstruction augmented with polydioxanonsulphate bands. Surgical technique and results. Hessmann M, et al. **Am J Sports Med** 1995 Sep–Oct; 23(5):552–6

Experimental models for microsurgical joint reconstruction in the upper extremity. Vilkki SK, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):58–62

Arthroscopic subacromial decompression with and without the Holmium: YAG–laser [letter] Brillhart AT. **Arthroscopy** 1996 Apr;12(2):263–4

The results of operative resection of the lateral end of the clavicle. Eskola A, et al. **J Bone Joint Surg Am** 1996 Apr; 78(4):584–7

Arthroscopic resection of the acromioclavicular joint (ARAC). Jerosch J, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):209–15

[Acromio–clavicular joint cyst. Surgical treatment] Le Huec JC, et al. **Acta Orthop Belg** 1996 Jun;62(2):107–12 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

A comparison of the methods of distraction for stress examination of the acromioclavicular joint. Sluming VA. **Br J Radiol** 1995 Nov;68(815):1181–4

ACROMION

Unusually located osteoid osteomas. Pikoulas C, et al. **Eur J Radiol** 1995 Jul;20(2):120–5

Apophysitis of the acromion. Morisawa K, et al. **J Shoulder Elbow Surg** 1996 Mar–Apr;5(2 Pt 1):153–6

Aneurysmal bone cyst of the acromion: a case report. Ruggieri M, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S147–9

ANATOMY & HISTOLOGY

Aspects of coracoacromial ligament anatomy of interest to the arthroscopic surgeon. Edelson JG, et al. **Arthroscopy** 1995 Dec;11(6):715–9

Morphologic variants of acromion in neonatal cadavers. Yazici M, et al. **J Pediatr Orthop** 1995 Sep–Oct;15(5):644–7

Acromial structure and tears of the rotator cuff. Toivonen DA, et al. **J Shoulder Elbow Surg** 1995 Sep–Oct;4(5):376–83

Acromial morphology: relation to sex, age, symmetry, and subacromial enthesophytes. Getz JD, et al. **Radiology** 1996 Jun;199(3):737–42

Subacromial fat pad. Vahlensieck M, et al. **Surg Radiol Anat** 1996;18(1):33–6

INJURIES

Fracture of the acromion associated with acromioclavicular dislocation. Kurdy NM, et al. **Injury** 1995 Nov;26(9):636–7

INNERVATION

Neurohistology of the subacromial space. Soifer TB, et al. **Arthroscopy** 1996 Apr;12(2):182–6

PATHOLOGY

Relationship between the lateral acromion angle and rotator cuff disease. Banas MP, et al. **J Shoulder Elbow Surg** 1995 Nov–Dec;4(6):454–61

Recurrent acromial bone spur after open subacromial decompression. Friedman RL, et al. **J Shoulder Elbow Surg** 1995 Nov–Dec;4(6):468–71

PHYSIOLOGY

Coracoacromial pressure recordings in a cadaveric model. Wuelker N, et al. **J Shoulder Elbow Surg** 1995 Nov–Dec; 4(6):462–7

RADIOGRAPHY

Reliability of radiographic assessment of acromial morphology. Jacobson SR, et al. **J Shoulder Elbow Surg** 1995 Nov–Dec;4(6):449–53

Roentgenographic assessment of acromial morphologic condition in rotator cuff impingement syndrome. Kitay GS, et al. **J Shoulder Elbow Surg** 1995 Nov–Dec;4(6):441–8

SURGERY

Comparison between open and arthroscopic acromioplasties: evaluation of absenteeism [see comments] Kinnard P, et al. **Can J Surg** 1996 Feb;39(1):21–3. Comment in: Can J Surg 1996 Jun;39(3):254.

Open versus arthroscopic acromioplasty [letter; comment] O'Driscoll SW. **Can J Surg** 1996 Jun;39(3):254. Comment on: Can J Surg 1996 Feb;39(1):21–3.

Surgical treatment of complete acromioclavicular dislocation using the coracoacromial ligament and coracoclavicular fixation: report of a technique in 14 patients. Kumar S, et al. **J Orthop Trauma** 1995;9(6):507–10

Heterotopic ossification after acromioplasty and distal clavicle resection. Berg EE, et al. **J Shoulder Elbow Surg** 1995 May–Jun;4(3):188–93

Anterior acromioplasty: effect of litigation and workers' compensation. Frieman BG, et al. **J Shoulder Elbow Surg** 1995 May–Jun;4(3):175–81

[Multicenter study of 210 rotator cuff ruptures treated with arthroscopic acromioplasty] Kempf JF, et al. **Acta Orthop Belg** 1995;61 Suppl 1:23–31 **(Fre)**

[Antero–superior impingement of the shoulder. Indications for and options in surgical treatment] Noorbergen M. **Rev Med Brux** 1995 Jul–Aug;16(4):178–80 (Eng. Abstr.) **(Fre)**

[Acromion resection for shoulder impingement syndrome. Results after an open and a percutaneous surgical method] Iversen T, et al. **Tidsskr Nor Laegeforen** 1996 Jun 20; 116(16):1879–82 (Eng. Abstr.) **(Nor)**

ACROSIN

ANALYSIS

Correlation of semen characteristics with acrosin, hyaluronidase, tubulin, dynein, and actin of spermatozoa. Hoshi K, et al. **Arch Androl** 1995 Nov–Dec;35(3):165–72

CHEMISTRY

Analysis of polysulfate–binding domains in porcine proacrosin, a putative zona adhesion protein from mammalian spermatozoa. Jansen S, et al. **Int J Dev Biol** 1995 Jun;39(3):501–10

METABOLISM

Analysis of polysulfate–binding domains in porcine proacrosin, a putative zona adhesion protein from mammalian spermatozoa. Jansen S, et al. **Int J Dev Biol** 1995 Jun;39(3):501–10

Acrosin activity of human spermatozoa by means of a simple gelatinolytic technique: a method useful for IVF. Henkel R, et al. **J Androl** 1995 May–Jun;16(3):272–7

ACROSOMAL PROTEINASE see **ACROSIN**

ACROSOME

Evaluation of the acrosome in oligozoospermic patients by simplified triple stain technique. Sánchez R, et al. **Andrologia** 1995 Sep–Oct;27(5):249–51

Intracellular calcium reaches different levels of elevation in hyperactivated and acrosome–reacted hamster sperm. Suarez SS, et al. **Mol Reprod Dev** 1995 Nov;42(3):325–33

CHEMISTRY

Delayed translation and posttranslational processing of cyritestin, an integral transmembrane protein of the mouse acrosome. Linder B, et al. **Exp Cell Res** 1995 Nov; 221(1):66–72

Plasminogen activator inhibitor type 1 in rat spermatozoa: localisation in the tail, in the acrosome and on the surface of the head. Manske M, et al. **Zygote** 1994 Aug;2(3):243–52

DRUG EFFECTS

Acrosome content release in streptolysin O permeabilized mouse spermatozoa. Díaz A, et al. **Andrologia** 1996 Jan–Feb;28(1):21–6

Effect of cytokines on sperm motility and ionophore–stimulated acrosome reaction. Fedder J, et al. **Arch Androl** 1995 Nov–Dec;35(3):173–85

Progesterone–induced acrosome reaction: one receptor is not enough [letter; comment] Tesarik J. **Fertil Steril** 1996 Jun; 65(6):1265–7. Comment on: Fertil Steril 1995 Dec;64(6):1213–5.

Modulation of prostaglandin synthesis in mammalian sperm acrosome reaction. Breitbart H, et al. **Hum Reprod** 1995 Aug;10(8):2079–84

Progesterone does not potentiate the acrosome reaction in human spermatozoa: flow cytometric analysis using CD46 antibody. Carver–Ward JA, et al. **Hum Reprod** 1996 Jan; 11(1):121–6

A simple method for assessment of the human acrosome reaction of spermatozoa bound to the zona pellucida: lack of relationship with ionophore A23187–induced acrosome reaction. Liu DY, et al. **Hum Reprod** 1996 Mar;11(3):551–7

Variations in spontaneous and induced acrosome reaction: correlations with semen parameters and in–vitro fertilization results. Parinaud J, et al. **Hum Reprod** 1995 Aug;10(8):2085–9

Comparative study of the effect of human cervical mucus and a cervical mucus substitute, Healonid, on capacitation and the acrosome reaction of human spermatozoa in vitro. Perry RL, et al. **Hum Reprod** 1996 May;11(5):1055–62

Acrosome reaction induced in a limited population of human spermatozoa by progesterone (Ca(2+)–dependent) and ATP (Ca(2+)–independent). Tomiyama T, et al. **Hum Reprod** 1995 Aug;10(8):2052–5

Reagents that activate GTP–binding proteins trigger the acrosome reaction in human spermatozoa. Dominguez L, et al. **Int J Androl** 1995 Aug;18(4):203–7

Effect on sperm–immobilizing antibodies on the spontaneous and calcium–ionophore (A23187)–induced acrosome reaction. Tasdemir I, et al. **Int J Fertil Menopausal Stud** 1995 Jul–Aug;40(4):192–5

Importance of bicarbonate to the progesterone–initiated human sperm acrosome reaction [published erratum appears in J Androl 1995 Sep–Oct;16(5):416] Sabeur K, et al. **J Androl** 1995 May–Jun;16(3):266–71

Effects of glucose and other energy substrates on the hyperactivated motility of macaque sperm and the zona pellucida–induced acrosome reaction. Vandevoort CA, et al. **J Androl** 1995 Jul–Aug;16(4):327–33

The effect of alpha–amylase on the acrosomal membrane of human sperm. Esterhuizen AD, et al. **J Assist Reprod Genet** 1995 Apr;12(4):283–7

Further indications of the multicomponent nature of the acrosome reaction–inducing substance of human follicular fluid. Fehl P, et al. **Mol Reprod Dev** 1995 Sep;42(1):80–8

Nuclear alterations during acrosomal cap formation in spermatids of lead–treated rats. Murthy RC, et al. **Reprod Toxicol** 1995 Sep–Oct;9(5):483–9

ENZYMOLOGY

Purification and characterization of procathepsin L, a self–processing zymogen of guinea pig spermatozoa that acts on a cathepsin D assay substrate. McDonald JK, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):409–22

Intracytoplasmic sperm injection for treatment of infertility due to acrosomal enzyme deficiency. Abdul–Aziz M, et al. **Fertil Steril** 1996 May;65(5):977–80

Ultracytochemical study of trimetaphosphatase activity during acrosomal formation in the mouse testis. Jin QS, et al. **Histol Histopathol** 1995 Jul;10(3):681–9

IMMUNOLOGY

A strategy for identifying candidate sperm antigens for immunocontraception: isolation of human testis cDNA clones using polyclonal antisera directed against hamster acrosomal membrane preparation. Adoyo PA, et al. **Int J Androl** 1995 Jun;18 Suppl 1:32–8

Functional characterization of the primate sperm acrosomal antigen (PSA–63). Archibong AE, et al. **J Androl** 1995 Jul–Aug;16(4):318–26

Study of the acrosome reaction and the fertilizing ability of hamster epididymal cauda spermatozoa treated with antibodies against phospholipase A2 and/or lysophosphatidylcholine. Riffo MS, et al. **J Exp Zool** 1996 Aug 15;275(6):459–68

Intra–acrosomal 155,000 dalton protein increases the antigenicity during mouse sperm maturation in the epididymis: a study using a monoclonal antibody MC101. Toshimori K, et al. **Mol Reprod Dev** 1995 Sep;42(1):72–9

[Selection and characterization of human acrosome–reacted sperm: application to subzonal insemination] Parinaud J, et al. **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):468–70 (Eng. Abstr.) **(Fre)**

METABOLISM

Co–expression of mannose–ligand and non–nuclear progesterone receptors on motile human sperm identifies an acrosome–reaction inducible subpopulation. Benoff S, et al. **Am J Reprod Immunol** 1995 Aug;34(2):100–15

Liposome fusion induced by a M(r) 18,000 protein localized to the acrosomal region of acrosome–reacted abalone spermatozoa. Swanson WJ, et al. **Biochemistry** 1995 Oct 31;34(43):14202–8

Isolation of a novel cDNA that encodes a protein localized to the pre–acrosome region of spermatids. Aoto H, et al. **Eur J Biochem** 1995 Nov 15;234(1):8–15

rab 3–peptide stimulates exocytosis of the ram sperm acrosome via interaction with cyclic AMP and phospholipase A2 metabolites. Garde J, et al. **FEBS Lett** 1996 Aug 12;391(3):263–8

T–type Ca2+ channels and alpha1E expression in spermatogenic cells, and their possible relevance to the sperm acrosome reaction. Liévano A, et al. **FEBS Lett** 1996 Jun 17;388(2–3):150–4

Release of angiotensin–converting enzyme (ACE) from human spermatozoa during capacitation and acrosome reaction. Köhn FM, et al. **J Androl** 1995 May–Jun; 16(3):259–65

Characterization of the actin cross–linking properties of the scruin–calmodulin complex from the acrosomal process of Limulus sperm. Sanders MC, et al. **J Biol Chem** 1996 Feb 2;271(5):2651–7

PHYSIOLOGY

Mechanism of human sperm activation by extracellular ATP. Foresta C, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1709–14

Selective isolation of acrosome–reacted human spermatozoa with progressive motility by using cell affinity chromatography on concanavalin A Sepharose. Kuroda Y, et al. **Andrologia** 1996 Jan–Feb;28(1):7–13

Effect of cytokines on sperm motility and ionophore–stimulated acrosome reaction. Fedder J, et al. **Arch Androl** 1995 Nov–Dec;35(3):173–85

Lectin–binding sites on human sperm during acrosome reaction: modifications judged by electron microscopy/flow cytometry. Fierro R, et al. **Arch Androl** 1996 May–Jun;36(3):187–96

In vitro fertilization: increased VLA (very late antigen) integrins and fibronectin after acrosome reaction. Glander HJ, et al. **Arch Androl** 1996 May–Jun;36(3):177–85

Characterization of mouse ZP3–derived glycopeptide, gp55, that exhibits sperm receptor and acrosome reaction–inducing activity in vitro. Litscher ES, et al. **Biochemistry** 1996 Apr 2;35(13):3980–5

ACROSOME

Surface localization of P34H an epididymal protein, during maturation, capacitation, and acrosome reaction of human spermatozoa. Boué F, et al. **Biol Reprod** 1996 May; 54(5):1009–17

Studies of porcine and human sperm suggesting a role for a sperm glycine receptor/Cl– channel in the zona pellucida–initiated acrosome reaction. Melendrez CS, et al. **Biol Reprod** 1995 Sep;53(3):676–83

Human sperm plasma membrane progesterone receptor(s) and the acrosome reaction. Sabeur K, et al. **Biol Reprod** 1996 May;54(5):993–1001

Fluorescence-labeled fucolectins are superior markers for flow cytometric quantitation of the human sperm acrosome reaction. D'Cruz OJ, et al. **Fertil Steril** 1996 Apr; 65(4):843–51

Relationship between the zona pellucida (ZP) and ionophore A23187–induced acrosome reaction and the ability of sperm to penetrate the ZP in men with normal sperm–ZP binding. Liu DY, et al. **Fertil Steril** 1996 Aug;66(2):312–5

Progesterone–induced acrosome reaction: one receptor is not enough [letter; comment] Tesarik J. **Fertil Steril** 1996 Jun; 65(6):1265–7. Comment on: Fertil Steril 1995 Dec;64(6):1213–5.

A new predictive test for in–vitro fertilization based on the induction of sperm acrosome reaction by N–acetylglucosamine–neoglycoprotein. Brandelli A, et al. **Hum Reprod** 1995 Jul;10(7):1751–6

Progesterone does not potentiate the acrosome reaction in human spermatozoa: flow cytometric analysis using CD46 antibody. Carver–Ward JA, et al. **Hum Reprod** 1996 Jan; 11(1):121–6

Cellular biology of capacitation and the acrosome reaction. Fraser LR. **Hum Reprod** 1995 Oct;10 Suppl 1:22–30 (50 ref.)

Intracytoplasmic sperm injection in mice: increased fertilization and development to term after induction of the acrosome reaction. Lacham–Kaplan O, et al. **Hum Reprod** 1995 Oct;10(10):2642–9

A simple method for assessment of the human acrosome reaction of spermatozoa bound to the zona pellucida: lack of relationship with ionophore A23187–induced acrosome reaction. Liu DY, et al. **Hum Reprod** 1996 Mar;11(3):551–7

Selection and characterization of human acrosome reacted spermatozoa. Moutaffian H, et al. **Hum Reprod** 1995 Nov; 10(11):2948–51

Relationships between motility parameters, morphology and acrosomal status of human spermatozoa. Parinaud J, et al. **Hum Reprod** 1996 Jun;11(6):1240–3

Effect of peritoneal fluid from infertile women with endometriosis on ionophore–stimulated acrosome loss. Tasdemir M, et al. **Hum Reprod** 1995 Sep;10(9):2419–22

In vitro fertilization and the effect of progesterone and 17 alpha–hydroxyprogesterone on acrosome reaction of mouse epididymal spermatozoa. Kholkute SK, et al. **Int J Androl** 1995 Jun;18(3):146–50

Assessment of the vitality and acrosomal status of human spermatozoa using fluorescent probes. Kinger S, et al. **Int J Androl** 1995 Jun;18 Suppl 1:12–8

Regulatory mechanisms of the acrosome reaction revealed by multiview microscopy of single starfish sperm. Sase I, et al. **J Cell Biol** 1995 Nov;131(4):963–73

Evidence for a nonlysosomal origin of the acrosome. Martínez–Menárguez JA, et al. **J Histochem Cytochem** 1996 Apr;44(4):313–20

LL95 monoclonal antibody mimics functional effects of ZP3 on mouse sperm: evidence that the antigen recognized is not hexokinase. Leyton L, et al. **Mol Reprod Dev** 1995 Nov; 42(3):347–58

Localization of intracellular calcium during the acrosome reaction in ram spermatozoa. Watson PF, et al. **Mol Reprod Dev** 1995 Aug;41(4):513–20

Motility, acrosome integrity and fertility of frozen ram spermatozoa treated with caffeine, pentoxifylline, cAMP, 2–deoxyadenosine and kallikrein. Maxwell WM, et al. **Reprod Fertil Dev** 1995;7(5):1081–7

Comparison of the acrosome reaction–inducing ability of the outer and inner surfaces of the zona pellucida and oolemma: a study using the golden hamster. Yazawa H, et al. **Zygote** 1995 Nov;3(4):295–303

[Spermatozoa antigen SAA–1 and co–precipitating molecules: regulation of human acrosome reaction] Brucker C, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:57–62 (Eng. Abstr.) **(Ger)**

SECRETION

Sperm membrane potential: hyperpolarization during capacitation regulates zona pellucida–dependent acrosomal secretion. Zeng Y, et al. **Dev Biol** 1995 Oct;171(2):554–63

ZP3–dependent activation of sperm cation channels regulates acrosomal secretion during mammalian fertilization. Arnoult C, et al. **J Cell Biol** 1996 Aug;134(3):637–45

ULTRASTRUCTURE

Ultracytochemical study of trimetaphosphatase activity during acrosomal formation in the mouse testis. Jin QS, et al. **Histol Histopathol** 1995 Jul;10(3):681–9

Assessment of the vitality and acrosomal status of human spermatozoa using fluorescent probes. Kinger S, et al. **Int J Androl** 1995 Jun;18 Suppl 1:12–8

A 7–A projection map of frozen, hydrated acrosomal bundle from Limulus sperm. Schmid MF, et al. **J Struct Biol** 1995 Sep–Oct;115(2):209–13

Sperm–egg interactions in an Australian dasyurid marsupial with official reference to changes in acrosomal morphology. Breed WG. **Zygote** 1994 Aug;2(3):201–11

ACROSPIROMA, ECCRINE

Eccrine acrospiroma in a young African male: case report. Nmadu PT. **East Afr Med J** 1995 Sep;72(9):613–4

CHEMISTRY

[Clear–cell eccrine carcinoma of the plantar region. Follow–up of a case using histochemistry, immunohistochemistry, and flow cytometry] Gamboa–Domínguez A, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):43–8 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Pigmented eccrine porocarcinoma: a mimic of malignant melanoma. Hara K, et al. **Histopathology** 1995 Jul; 27(1):86–8

Pigmented eccrine poroma: a simulant of nodular melanoma. Mousawi A, et al. **Int J Dermatol** 1995 Dec;34(12):857–8

ETIOLOGY

Malignant eccrine poroma in a patient with Rothmund–Thomson syndrome [letter] Van Hees CL, et al. **Br J Dermatol** 1996 Apr;134(4):813–5

PATHOLOGY

Cytologic findings in a case of malignant eccrine poroma [letter] López JI, et al. **Acta Cytol** 1996 Mar–Apr; 40(2):386–7

p53 protein and proliferating cell nuclear antigen in eccrine poroma and porocarcinoma. an immunohistochemical study. Tateyama H, et al. **Am J Dermatopathol** 1995 Oct; 17(5):457–64

Porocarcinoma of the heel. A case report with unusual histologic features. D'Amato MS, et al. **Cancer** 1996 Aug 15;78(4):751–7 (27 ref.)

Eccrine poroma. A case report. Hayes SW, et al. **J Am Podiatr Med Assoc** 1995 Sep;85(9):500–1

Multiple malignant eccrine poroma and a linear epidermal nevus. Hamanaka S, et al. **J Dermatol** 1996 Jul;23(7):469–71

A single lesion demonstrating features of eccrine poroma and poroid hidradenoma. Misago N, et al. **J Dermatol** 1995 Oct; 22(10):773–9

SURGERY

Recurrent eccrine acrospiroma of the hand. Kalainov DM, et al. **J Hand Surg [Br]** 1996 Apr;21(2):280–2

ACRYLAMIDES

Amine effect on phenylboronic acid complex with glucose under physiological pH in aqueous solution. Shiino D, et al. **J Biomater Sci Polym Ed** 1996;7(8):697–705

ADMINISTRATION & DOSAGE

Antibody–targeted polymer–bound drugs. Říhová B. **Folia Microbiol (Praha)** 1995;40(4):367–84 (121 ref.)

ADVERSE EFFECTS

Effects of 4–methylcatechol, a stimulator of endogenous nerve growth factor synthesis, on experimental acrylamide–induced neuropathy in rats. Saita K, et al. **Neurotoxicology** 1995 Fall;16(3):403–12

ANALYSIS

Studies on the origin and distribution of palytoxin in a Caribbean coral reef. Gleibs S, et al. **Toxicon** 1995 Nov; 33(11):1531–7

CHEMISTRY

5–Fluorouracil release from copolymeric hydrogels of itaconic acid monoester. I. Acrylamide–co–monomethyl itaconate. Blanco MD, et al. **Biomaterials** 1996 Jun; 17(11):1061–7

Cell attachment to laser–induced AAm– and HEMA–grafted ethylene–propylene rubber as biomaterial: in vivo study. Mirzadeh H, et al. **Biomaterials** 1995 May;16(8):641–8

Regioselective immobilization of short oligonucleotides to acrylic copolymer gels. Timofeev E, et al. **Nucleic Acids Res** 1996 Aug 15;24(16):3142–8

Lophozozymus pictor toxin: a fluorescent structural isomer of palytoxin. Lau CO, et al. **Toxicon** 1995 Oct;33(10):1373–7 (18 ref.)

[Biological monitoring of exposure to alkylating xenobiotics by determining them using a new analytical approach in complexes with hemoglobin, plasma proteins and mercapturic acids in urine. II. Acrylamide] Hashimoto K, et al. **Vopr Med Khim** 1995 Jul–Aug;41(4):22–5 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Toxicokinetics of a single 50 mg/kg oral dose of [2,3–14C]acrylamide in White Leghorn hens. Blumenthal GM, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):149–53

PHARMACOLOGY

Actions of palytoxin on Na+ and Ca2+ homeostasis in human osteoblast–like Saos–2 cells. Monroe JJ, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C582–9

Activation of stress–activator protein kinase/c–Jun N–terminal kinase by the non–TPA–type tumor promoter palytoxin. Kuroki DW, et al. **Cancer Res** 1996 Feb 1; 56(3):637–44

Inhibitory action of palytoxin on ascorbic acid transport into cultured bovine adrenal chromaffin cells. Morita K, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):996–1001

Palytoxin–induced Na+ influx into yeast cells expressing the mammalian sodium pump is due to the formation of a channel within the enzyme. Redondo J, et al. **Mol Pharmacol** 1996 Jan;49(1):49–57

Induction of hypoploidy and cell cycle delay by acrylamide in somatic and germinal cells of male mice. Gassner P, et al. **Mutat Res** 1996 Apr 6;367(4):195–202

POISONING

Creatine kinase activities in brain and blood:possible neurotoxic indicator of acrylamide intoxication. Matsuoka M, et al. **Occup Environ Med** 1996 Jul;53(7):468–71

TOXICITY

The reproductive and neural toxicities of acrylamide and three analogues in Swiss mice, evaluated using the continuous breeding protocol. Chapin RE, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):9–24

A lifetime oncogenicity study in rats with acrylamide. Friedman MA, et al. **Fundam Appl Toxicol** 1995 Aug; 27(1):95–105

Acrylamide–induced neuropathic changes in rat enteric nerves: similarities with effects of streptozotocin–diabetes. Belai A, et al. **J Auton Nerv Syst** 1996 Apr 20;58(1–2):56–62

A catechol derivative (4–methylcatechol) accelerates the recovery from experimental acrylamide–induced neuropathy. Saita K, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):231–7

The impact of dose rate on the neurotoxicity of acrylamide: the interaction of administered dose, target tissue concentrations, tissue damage, and functional effects. Crofton KM, et al. **Toxicol Appl Pharmacol** 1996 Jul; 139(1):163–76

The effects of 2,5–hexanedione and acrylamide on myosin heavy chain isoforms of slow and fast skeletal muscles of the rat. Oishi Y, et al. **Toxicol Appl Pharmacol** 1996 Jul; 139(1):15–21

ACRYLATES

Stress fractures after folding an acrylic intraocular lens. Pfister DR. **Am J Ophthalmol** 1996 May;121(5):572–4

Acrylic nails and pulse oximemtry [letter] Edelist G. **Anesth Analg** 1995 Oct;81(4):884–5

Forceps–induced scratching of a foldable acrylic intraocular lens [letter] Vrabec MP, et al. **Arch Ophthalmol** 1996 Jun; 114(6):777

Mechanical properties of vacuum–mixed acrylic bone cement. Lewis G, et al. **J Appl Biomater** 1994 Winter; 5(4):307–14

Two year clinical study of a soft acrylic intraocular lens. Oshika T, et al. **J Cataract Refract Surg** 1996 Jan–Feb; 22(1):104–9

Optimization of microencapsulation of acrylic adhesives. Giroud F, et al. **J Microencapsul** 1995 Jul–Aug; 12(4):389–400

Cracking of acrylic intraocular lenses during capsular bag insertion. Carlson KH, et al. **Ophthalmic Surg Lasers** 1995 Nov–Dec;26(6):572–3

ADVERSE EFFECTS

Adverse contact reactions to sculptured acrylic nails: 4 case reports and a literature review. Freeman S, et al. **Contact Dermatitis** 1995 Dec;33(6):381–5 (48 ref.)

Methyl acrylate: a new sensitizer in nail lacquer. Kanerva L, et al. **Contact Dermatitis** 1995 Sep;33(3):203–4

Glycidyl methacrylate and ethoxyethyl acrylate: new allergens in emulsions used to impregnate paper and textile materials. Matura M, et al. **Contact Dermatitis** 1995 Aug; 33(2):123–4

Rapid increase in skin problems among dental technician trainees working with acrylates. Mürer AJ, et al. **Contact Dermatitis** 1995 Aug;33(2):106–11

Visual significance of glistenings seen in the AcrySof intraocular lens. Dhaliwal DK, et al. **J Cataract Refract Surg** 1996 May;22(4):452–7

CHEMISTRY

Kinetics of membrane micellization by the hydrophobic polyelectrolyte poly(2–ethylacrylic acid). Thomas JL, et al. **Biochim Biophys Acta** 1996 Jan 12;1278(1):73–8

METABOLISM

The tryptophan synthase alpha 2 beta 2 complex: kinetic studies with a mutant enzyme (beta K87T) to provide evidence for allosteric activation by an aminoacrylate intermediate. Banik U, et al. **Biochemistry** 1995 Oct 3; 34(39):12704–11

PHARMACOLOGY

An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Wang KK, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6687-92

[The antimutagenic activity of ternary diallyl copolymers] Aleksandrova VA, et al. **Radiats Biol Radioecol** 1995 Sep-Oct;35(5):746-51 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Malignant acetabular osteolyses: percutaneous injection of acrylic bone cement. Cotten A, et al. **Radiology** 1995 Oct; 197(1):307-10

Anterior cervical discectomy with or without fusion with acrylate. A randomized trial. van den Bent MJ, et al. **Spine** 1996 Apr 1;21(7):834-9; discussion 840

ACRYLIC RESINS

see related

DENTAL MATERIALS

Mastique laminate veneers: results after 4 and 10 years of service. Høffding J. **Acta Odontol Scand** 1995 Oct; 53(5):283-6

Detection of protein kinase activities toward oligopeptides in sodium dodecyl sulfate-polyacrylamide gel. Kameshita I, et al. **Anal Biochem** 1996 Jun 1;237(2):198-203

The effect of oral commensal bacteria on candidal adhesion to denture acrylic surfaces. An in vitro study. Nair RG, et al. **APMIS** 1996 May;104(5):339-49

Temperature-controlled release property of phospholipid vesicles bearing a thermo-sensitive polymer. Hayashi H, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):127-34

Synthesis and purification of thermally sensitive oligomer-enzyme conjugates of poly(N-isopropylacrylamide)-trypsin. Ding Z, et al. **Bioconjug Chem** 1996 Jan-Feb;7(1):121-6

Effect of molecular architecture of poly(N-isopropylacrylamide)-trypsin conjugates on their solution and enzymatic properties. Matsukata M, et al. **Bioconjug Chem** 1996 Jan-Feb;7(1):96-101

Prevention of dialysis-related amyloidosis using the polyacrylonitrile AN69 membrane. Chanard J. **Contrib Nephrol** 1995;112:137-44 (23 ref.)

Effective blotting of ultrathin polyacrylamide gels anchored to a solid matrix. Heukeshoven J, et al. **Electrophoresis** 1995 May;16(5):748-56

Clinical evaluation of five adhesive systems: three-year results. Tyas MJ. **Int Dent J** 1996 Feb;46(1):10-4

A clinical evaluation of a resin-modified. Glass ionomer restorative material. Barnes DM, et al. **J Am Dent Assoc** 1995 Sep;126(9):1245-53

Provisional restorations for fixed prosthodontics. Christensen GJ. **J Am Dent Assoc** 1996 Feb;127(2):249-52

Esthetic consideration of a labial bar major connector. Ansari IH. **J Prosthet Dent** 1995 Sep;74(3):321-2

In-depth disinfection of acrylic resins. Chau VB, et al. **J Prosthet Dent** 1995 Sep;74(3):309-13

Tensile bond strength of enamel-resin-metal joints. Cötert HS, et al. **J Prosthet Dent** 1996 Jun;75(6):609-16

Improved method to construct an anterior deprogramming device. Hack G, et al. **J Prosthet Dent** 1996 Mar;75(3):337

Acrylic resin labial flange for a Kennedy Class I partial denture: a clinical report. Keng SB. **J Prosthet Dent** 1996 Feb;75(2):114-6

Transverse bond strength of repaired acrylic resin strips and temperature rise of dentures relined with VLC reline resin. Lewinstein I, et al. **J Prosthet Dent** 1995 Oct;74(4):392-9

Repair of an eight-unit fixed partial denture with a resin-bonded overcasting: a clinical report. Matsumura H, et al. **J Prosthet Dent** 1996 Jun;75(6):594-6

Acrylic resin denture repair with adhesive resin and metal wires: effects on strength parameters. Polyzois GL, et al. **J Prosthet Dent** 1996 Apr;75(4):381-7

Moderate-temperature polymerization of LR White in a nitrogen atmosphere. Harris KF, et al. **Microsc Res Tech** 1995 Oct 15;32(3):264-5

Improved antigenic preservation of plant tissue by low temperature processing in LR white resin. Mashadian DY, et al. **Microsc Res Tech** 1995 Aug 15;31(6):531-2

No generation of bradykinin with a new polyacrylonitrile membrane (SPAN) in haemodialysis patients treated with ACE inhibitors. Mannstadt M, et al. **Nephrol Dial Transplant** 1995;10(9):1696-700

The safety and effectiveness of brain arteriovenous malformation embolization using acrylic and particles: the experiences of a single institution. Wallace RC, et al. **Neurosurgery** 1995 Oct;37(4):606-15; discussion 615-8

Cervical dilation from laminaria tents and synthetic osmotic dilators used for 6 hours before abortion. Kline SB, et al. **Obstet Gynecol** 1995 Dec;86(6):931-5

Cracking of acrylic intraocular lenses during capsular bag insertion [letter] Bee JA. **Ophthalmic Surg Lasers** 1996 Apr; 27(4):327

The influence of buffer species and strength on diltiazem HCl release from beads coated with the aqueous cationic polymer dispersions, Eudragit RS, RL 30D. Bodmeier R, et al. **Pharm Res** 1996 Jan;13(1):52-6

High resolution electron microscopy of the interface between dental calculus and denture resin. Hayashi Y. **Scanning Microsc** 1995 Jun;9(2):419-25; discussion 425-7

Application of AN69 hydrogel to islet encapsulation: evaluation in the streptozotocin-induced diabetic rat model. Prevost P, et al. **Transplant Proc** 1995 Dec; 27(6):3393-5

ADVERSE EFFECTS

Allergic contact dermatitis to artificial fingernails prepared from UV light-cured acrylates. Hemmer W, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):377-80

Monomer allergy [letter; comment] Donohoo SF. **J Am Dent Assoc** 1995 Oct;126(10):1338, 1340. Comment on: J Am Dent Assoc 1995 Aug;126(8):1094, 1096.

Traumatic stomatitis following an intraoral denture reline: a clinical report. Bohnenkamp DM. **J Prosthet Dent** 1996 Aug;76(2):113-4

Kinin kinetics during different dialysis protocols with AN69 dialyser in ACEI-treated patients. Van der Niepen P, et al. **Nephrol Dial Transplant** 1995;10(9):1689-95

CHEMICAL SYNTHESIS

Cyclosporin analogs modified in the 3,7,8-positions: substituent effects on peptidylprolyl isomerase inhibition and immunosuppressive activity are nonadditive. Hu MK, et al. **J Med Chem** 1995 Oct 13;38(21):4164-70

CHEMISTRY

The bonding of cold-cured acrylic resin to acrylic denture teeth. Chung RW, et al. **Aust Dent J** 1995 Aug;40(4):241-5

Blends of synthetic and natural polymers as drug delivery systems for growth hormone. Cascone MG, et al. **Biomaterials** 1995 May;16(7):569-74

Influence of mucin type on polymer-mucin rheological interactions. Rossi S, et al. **Biomaterials** 1995 Sep; 16(14):1073-9

Direct bonding to typodont teeth. Titshall MJ, et al. **Br J Orthod** 1996 Feb;23(1):65-7

Rheological studies of the interaction of mucins with alginate and polyacrylate. Fuongfuchat A, et al. **Carbohydr Res** 1996 Apr 18;284(1):85-99

A new drug delivery system using plasma-irradiated pharmaceutical aids. VI. Controlled release of theophylline from plasma-irradiated double-compressed tablet composed of water-soluble polymers as a wall material. Kuzuya M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):192-5

Chemical stability of polyacrylamide-coating on fused silica capillary. Nakatani M, et al. **Electrophoresis** 1995 Aug; 16(8):1451-6

The creep behavior of acrylic denture base resins. Sadiku ER, et al. **J Biomater Appl** 1996 Jan;10(3):250-61

The effect of modification of acrylic resins on controlled release and bioadhesion. Vlachou M, et al. **J Biomater Appl** 1996 Jan;10(3):217-29

Composite poly(methyl methacrylate-methacrylic acid-2-hydroxyethyl methacrylate) latex for immunoassay. The case of plasminogen. Miksa B, et al. **J Biomater Sci Polym Ed** 1995;7(6):503-13

Heparin release from thermosensitive polymer coatings: in vivo studies. Gutowska A, et al. **J Biomed Mater Res** 1995 Jul;29(7):811-21

The effect of preparation conditions of acrylic denture base materials on the level of residual monomer, mechanical properties and water absorption. Doğan A, et al. **J Dent** 1995 Oct;23(5):313-8

Laboratory evaluation of three visible light-cured resinous liners. Kakaboura AI, et al. **J Dent** 1996 May;24(3):223-31

The effects of cross-linking agents on some properties of HEMA-based resins. Arima T, et al. **J Dent Res** 1995 Sep; 74(9):1597-601

Quantitative and morphological aspects of Unicryl versus Lowicryl K4M embedding in immunoelectron microscopic studies. Bogers JJ, et al. **J Histochem Cytochem** 1996 Jan; 44(1):43-8

Analysis of composition and structure of hard autopolymerizing reline resins. Arima T, et al. **J Oral Rehabil** 1996 May;23(5):346-52

A new technique for determining the denture tooth bond. Cunningham JL, et al. **J Oral Rehabil** 1996 Mar;23(3):202-9

Posterior palatal seal adaptation: influence of a high expansion stone. Sykora O, et al. **J Oral Rehabil** 1996 May; 23(5):342-5

Composition and effect of denture base resin surface primers for reline acrylic resins. Arima T, et al. **J Prosthet Dent** 1996 Apr;75(4):457-62

Dimensional stability of occlusal splints. Bohnenkamp DM. **J Prosthet Dent** 1996 Mar;75(3):262-8

Effects of chlorine-containing disinfecting compounds on shade guides made of acrylic resin. Cernavin I. **J Prosthet Dent** 1996 May;75(5):574

Tensile bond strength of enamel-resin-metal joints. Cötert HS, et al. **J Prosthet Dent** 1996 Jun;75(6):609-16

Bond strength of permanent soft denture liners bonded to the denture base. Emmer TJ Jr, et al. **J Prosthet Dent** 1995 Dec;74(6):595-601

Twelve-month results of a clinical wear study of three artificial tooth materials. Lindquist TJ, et al. **J Prosthet Dent** 1995 Aug;74(2):156-61

Consistency and softness of soft liners. Yoeli Z, et al. **J Prosthet Dent** 1996 Apr;75(4):412-8

Ionic strength dependence of dissolution for Eudragit S-100 coated pellets. Kararli TT, et al. **Pharm Res** 1995 Nov; 12(11):1813-6

Investigations on preparation and properties of modified polyacrylamide hydrogels for application as wound dressing materials. Lukaszczyk J. **Polim Med** 1995; 25(1-2):15-23

A study of collagen-hyaluronan interaction through swelling in polyacrylamide gels. Nagorski C, et al. **Res Commun Mol Pathol Pharmacol** 1995 Aug;89(2):179-88

DIAGNOSTIC USE

Quantitative and morphological aspects of Unicryl versus Lowicryl K4M embedding in immunoelectron microscopic studies. Bogers JJ, et al. **J Histochem Cytochem** 1996 Jan; 44(1):43-8

METABOLISM

Receptor-mediated endocytosis of poly(acrylic acid)-conjugated liposomes by macrophages. Fujiwara M, et al. **Biochim Biophys Acta** 1996 Jan 12;1278(1):59-67

Cytoplasmic calcium level and membrane fluidity of platelets contacting poly(acrylamide-co-methacrylic acid) particles with different surface properties. Yui N, et al. **J Biomater Sci Polym Ed** 1995;7(3):253-64

Prolonged blood circulation in rats of nanospheres surface-modified with semitelechelic poly[N-(2-hydroxypropyl)methacrylamide]. Kamei S, et al. **Pharm Res** 1995 May;12(5):663-8

PHARMACOLOGY

Temperature-modulated platelet and lymphocyte interactions with poly(N-isopropylacrylamide)-grafted surfaces. Takei YG, et al. **Biomaterials** 1995 Jun; 16(9):667-73

The effects of orthopaedic cements on osteoblastic cells cultured in vitro. Ciapetti G, et al. **Chir Organi Mov** 1995 Oct-Dec;80(4):409-15 **(Eng, Ita)**

Four-year evaluation of the effect of 10% polyacrylic acid or water rinsing pretreatment on retention of glass polyalkenoate cement. van Dijken JW. **Eur J Oral Sci** 1996 Feb;104(1):64-6

Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Luessen HL, et al. **Pharm Res** 1995 Sep;12(9):1293-8

RADIATION EFFECTS

A new drug delivery system using plasma-irradiated pharmaceutical aids. VI. Controlled release of theophylline from plasma-irradiated double-compressed tablet composed of water-soluble polymers as a wall material. Kuzuya M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):192-5

THERAPEUTIC USE

Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren's syndrome. van der Reijden WA, et al. **Arthritis Rheum** 1996 Jan;39(1):57-63

ACRYLONITRILE

ANALOGS & DERIVATIVES

Kinin kinetics during different dialysis protocols with AN69 dialyser in ACEI-treated patients. Van der Niepen P, et al. **Nephrol Dial Transplant** 1995;10(9):1689-95

Application of AN69 hydrogel to islet encapsulation: evaluation in the streptozotocin-induced diabetic rat model. Prevost P, et al. **Transplant Proc** 1995 Dec; 27(6):3393-5

CHEMISTRY

[Biological monitoring of exposure to alkylating xenobiotics by determining them in complexes with plasma proteins, hemoglobin, mercapturic acids from urine of rats and industrial workers. I. Acrylonitrile] Ivanov VV, et al. **Vopr Med Khim** 1995 Jul-Aug;41(4):18-22 (Eng. Abstr.) **(Rus)**

METABOLISM

Binding of acrylonitrile to parvalbumin. Lech JJ, et al. **Fundam Appl Toxicol** 1996 Feb;29(2):260-6

A physiologically based dosimetry description of acrylonitrile and cyanoethylene oxide in the rat. Gargas ML, et al. **Toxicol Appl Pharmacol** 1995 Oct;134(2):185-94

Conjugation of acrylonitrile and 2-cyanoethylene oxide with hepatic glutathione. Kedderis GL, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):9-17

PHARMACOKINETICS

Uptake, disposition, and persistence of acrylonitrile in rainbow trout. Lech JJ, et al. **Fundam Appl Toxicol** 1995 Sep;27(2):291-4

Intestinal toxicity of acrylonitrile: in vitro metabolism by intestinal cytochrome P450 2E1. Subramanian U, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):1-8

TOXICITY

Chronic toxicity of acrylonitrile and acetonitrile to Daphnia

magna in 14-d and 21-d toxicity tests. Tong Z, et al. **Bull Environ Contam Toxicol** 1996 Oct;57(4):655-9
Intestinal toxicity of acrylonitrile: in vitro metabolism by intestinal cytochrome P450 2E1. Subramanian U, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):1-8

ACTH see **CORTICOTROPIN**

ACTH 1-24 see **COSYNTROPIN**

ACTH RECEPTORS see **RECEPTORS, CORTICOTROPIN**

ACTH-RELEASING FACTOR see **CORTICOTROPIN-RELEASING HORMONE**

ACTH SYNDROME, ECTOPIC

BLOOD

Ectopic ACTH syndrome: redefinition and case report. Jolobe OM. **Postgrad Med J** 1996 Mar;72(845):174-5

COMPLICATIONS

[Thymic carcinoid associated with ectopic ACTH syndrome] Ishikawa T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr;34(4):471-6 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Use of somatostatin analog for localization and treatment of ACTH secreting bronchial carcinoid tumor. Christin-Maitre S, et al. **Chest** 1996 Mar;109(3):845-6

ETIOLOGY

Colonic adenocarcinoma associated ectopic ACTH secretion: a case history. Anthoney DA, et al. **Eur J Cancer** 1995 Nov;31A(12):2109-12
[Small cell lung cancer associated with ectopic ACTH syndrome] Takano K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb;34(2):220-5 (Eng. Abstr.) **(Jpn)**

METABOLISM

11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. Stewart PM, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3617-20
The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. de Keyzer Y, et al. **J Clin Invest** 1996 Mar 1;97(5):1311-8

PATHOLOGY

Ectopic adrenocorticotropin syndrome associated with undifferentiated carcinoma of the colon showing multidirectional neuroendocrine, exocrine, and squamous differentiation. Onishi R, et al. **Virchows Arch** 1996 Feb; 427(5):537-41 (14 ref.)

RADIONUCLIDE IMAGING

Successful localization of an occult ACTH-secreting bronchial carcinoid tumour with 111indium-DTPA labelled octreotide. Tsagarakis S, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):763-7

RADIOTHERAPY

Radiotherapy of ectopic ACTH syndrome due to thoracic carcinoids. He J, et al. **Chin Med J (Engl)** 1995 May; 108(5):338-41

SURGERY

Role of surgery in management of adrenocorticotropic hormone-producing islet cell tumors of the pancreas. Amikura K, et al. **Surgery** 1995 Dec;118(6):1125-30

1-24-ACTH see **COSYNTROPIN**

ACTIN-BINDING PROTEINS see **MICROFILAMENT PROTEINS**

ACTING OUT

Enactments: an evolving dyadic concept of acting out. Frayn DH. **Am J Psychother** 1996 Spring;50(2):194-207 (35 ref.)
Acting out and the narrative function: reconsidering Peter Blos's concept of the second individuation process. Lock J. **Am J Psychother** 1995 Fall;49(4):548-57
Changes in daily mood and self-restraint among undercontrolled preadolescents: a time-series analysis of "acting out". Weinberger DA, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1473-82
Problem behaviors in inner-city adolescents with chronic illness. Alderman EM, et al. **J Dev Behav Pediatr** 1995 Oct;16(5):339-44

ACTINIC RAYS see **ULTRAVIOLET RAYS**

ACTINIC RETICULOID SYNDROME see **PHOTOSENSITIVITY DISORDERS**

ACTINIDES see **METALS, ACTINOID**

ACTININ

A novel intermediate filament-associated protein: further characterization of the G.3.5 antigen. Jeffcoat S, et al. **Cytobios** 1995;82(329):81-99

ANALYSIS

Determination of the protein components of native thin filaments isolated from natural actomyosin: nebulin and alpha-actinin are associated with actin filaments. Meng Y, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):422-7

CHEMISTRY

Viscoelastic properties of F-actin solutions in the presence of normal and mutated actin-binding proteins. Janssen KP, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):183-9
Association of structural repeats in alpha-actinin. Flood GJ, et al. **Biochem Soc Trans** 1995 Aug;23(3):399S
Strength and lifetime of the bond between actin and skeletal muscle alpha-actinin studied with an optical trapping technique. Miyata H, et al. **Biochim Biophys Acta** 1996 May 21;1290(1):83-8
Molecular model of an actin filament capped by a severing protein. McGough A, et al. **J Struct Biol** 1995 Sep-Oct; 115(2):144-50

DRUG EFFECTS

Cation effects on the conformations of muscle and non-muscle alpha-actinins. Wenegieme EF, et al. **Biometals** 1996 Jul;9(3):259-65
Proteolytic cleavage of alpha-actinin by calpain in T cells stimulated with anti-CD3 monoclonal antibody. Selliah N, et al. **J Immunol** 1996 May 1;156(9):3215-21

GENETICS

Fibroblast growth factor-1-inducible gene FR-17 encodes a nonmuscle alpha-actinin isoform. Hsu DK, et al. **J Cell Physiol** 1996 May;167(2):261-8

IMMUNOLOGY

AAMP, a newly identified protein, shares a common epitope with alpha-actinin and a fast skeletal muscle fiber protein. Beckner ME, et al. **Exp Cell Res** 1996 Jun 15;225(2):306-14

ISOLATION & PURIFICATION

Isolation and properties of white skeletal muscle alpha-actinin from sea-trout (Salmo trutta) and bass (Dicentrarchus labrax). Papa I, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):271-82

METABOLISM

Identification of the 70kD heat shock cognate protein (Hsc70) and alpha-actinin-1 as novel phosphotyrosine-containing proteins in T lymphocytes. Egerton M, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):666-74
DXR depresses the alpha-actinin-induced formation of actin bundles. Dalledonne I, et al. **Cancer Biochem Biophys** 1993 Sep;13(4):245-54
Identification of a phosphatidylinositol 4,5-bisphosphate-binding site in chicken skeletal muscle alpha-actinin. Fukami K, et al. **J Biol Chem** 1996 Feb 2; 271(5):2646-50
Mapping the human erythrocyte beta-spectrin dimer initiation site using recombinant peptides and correlation of its phasing with the alpha-actinin dimer site. Ursitti JA, et al. **J Biol Chem** 1996 Mar 22;271(12):6636-44
The cytoplasmic domains of E- and P-selectin do not constitutively interact with alpha-actinin and are not essential for leukocyte adhesion. Kansas GS, et al. **J Immunol** 1996 Jul 1;157(1):321-5
Proteolytic cleavage of alpha-actinin by calpain in T cells stimulated with anti-CD3 monoclonal antibody. Selliah N, et al. **J Immunol** 1996 May 1;156(9):3215-21
Alpha-actinin accumulation in epithelial cells infected with attaching and effacing gastrointestinal pathogens. Ismaili A, et al. **J Infect Dis** 1995 Nov;172(5):1393-6

ACTINOBACILLOSIS

DIAGNOSIS

An atypical case of actinobacillosis in a cow. Aslani MR, et al. **Zentralbl Veterinarmed A** 1995 Oct;42(8):485-8

ACTINOBACILLUS

CLASSIFICATION

Actinobacillus delphinicola sp. nov., a new member of the family Pasteurellaceae Pohl (1979) 1981 isolated from sea mammals. Foster G, et al. **Int J Syst Bacteriol** 1996 Jul; 46(3):648-52
Reclassification of 30 Pasteurellaceae strains isolated from rodents. Boot R, et al. **Lab Anim** 1995 Jul;29(3):314-9

GENETICS

Construction of pYGK, an Actinobacillus actinomycetemcomitans-Escherichia coli shuttle vector. Brogan JM, et al. **Gene** 1996 Feb 22;169(1):141-2
New shuttle vectors for Actinobacillus actinomycetemcomitans and Escherichia coli. Nakano Y, et al. **Gene** 1996 Feb 22;169(1):139-40

IMMUNOLOGY

Enhancement of host resistance to bacterial infections in normal and immunosuppressed mice with Actinobacillus suis. Watanabe T. **Kansenshogaku Zasshi** 1996 Jun; 70(6):574-83

ISOLATION & PURIFICATION

Actinobacillus suis septicaemia in two foals. Nelson KM, et al. **Vet Rec** 1996 Jan 13;138(2):39-40
[Actinobacillus ureae isolated from a patient with chronic bronchitis (letter)] Vay C, et al. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):569-70 **(Spa)**

ACTINOBACILLUS ACTINOMYCETEMCOMITANS

Cerebral abscess complicating dental treatment. Case report and review of the literature. Renton TF, et al. **Aust Dent J** 1996 Feb;41(1):12-5 (32 ref.)
Actinobacillus actinomycetemcomitans septicemia during pregnancy [letter] Shalini S, et al. **Int J Gynaecol Obstet** 1995 Oct;51(1):57-8

CHEMISTRY

Relative cytokine-stimulating activities of surface components of the oral periodontopathogenic bacterium Actinobacillus actinomycetemcomitans. Reddi K, et al. **Cytokine** 1995 Aug;7(6):534-41
Characterization of the O-polysaccharide structure of lipopolysaccharide from Actinobacillus actinomycetemcomitans serotype b. Perry MB, et al. **Infect Immun** 1996 Apr;64(4):1215-9

CLASSIFICATION

Arbitrarily primed polymerase chain reaction analysis of periodontal pathogens: discriminative primers and genetic diversity. Chen C, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S301-3
[Purification of serotype d-- and e--specific antigens from Actinobacillus actinomycetemcomitans and seroclassification of clinical isolates from periodontal patients] Yamamoto M. **Kokubyo Gakkai Zasshi** 1996 Mar; 63(1):174-87 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

In vitro activity of tetracyclines, macrolides, quinolones, clindamycin and metronidazole against periodontopathic bacteria. Miyake Y, et al. **J Periodontal Res** 1995 Jul; 30(4):290-3

GENETICS

Differential regulation of the leukotoxin operon in highly leukotoxic and minimally leukotoxic strains of Actinobacillus actinomycetemcomitans. Hritz M, et al. **Infect Immun** 1996 Jul;64(7):2724-9
cis Elements and trans factors are both important in strain-specific regulation of the leukotoxin gene in Actinobacillus actinomycetemcomitans. Kolodrubetz D, et al. **Infect Immun** 1996 Sep;64(9):3451-60
Identification of Actinobacillus actinomycetemcomitans in subgingival plaque by PCR. Flemmig TF, et al. **J Clin Microbiol** 1995 Dec;33(12):3102-5
Mutational analysis of the putative leukotoxin transport genes in Actinobacillus actinomycetemcomitans. Guthmiller JM, et al. **Microb Pathog** 1995 May;18(5):307-21

IMMUNOLOGY

Membrane-associated interleukin-1 on macrophages stimulated with Actinobacillus actinomycetemcomitans lipopolysaccharide induces osteoclastic bone resorption in vivo. Nishihara T, et al. **Cytobios** 1995;81(327):229-37
Surface-associated material from the bacterium Actinobacillus actinomycetemcomitans contains a peptide which, in contrast to lipopolysaccharide, directly stimulates fibroblast interleukin-6 gene transcription. Reddi K, et al. **Eur J Biochem** 1996 Mar 15;236(3):871-6
Immunosuppressive factor from Actinobacillus actinomycetemcomitans down regulates cytokine production. Kurita-Ochiai T, et al. **Infect Immun** 1996 Jan; 64(1):50-4
Actinobacillus actinomycetemcomitans serotype b-specific polysaccharide antigen stimulates production of chemotactic factors and inflammatory cytokines by human monocytes. Yamaguchi N, et al. **Infect Immun** 1996 Jul; 64(7):2563-70
Role of the capsular polysaccharide-like serotype-specific antigen in resistance of Actinobacillus actinomycetemcomitans to phagocytosis by human polymorphonuclear leukocytes. Yamaguchi N, et al.

Infect Immun 1995 Dec;63(12):4589–94

Longitudinal changes in antibody avidity to Actinobacillus actinomycetemcomitans in periodontitis. O'Dell DS, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):203–11

Influence of periodontal bacteria and disease status on V beta expression in T cells. Mathur A, et al. **J Periodontal Res** 1995 Sep;30(5):369–73

Occurrence of Actinobacillus actinomycetemcomitans and anti-leukotoxin antibodies in some members of an extended family affected by Papillon-Lefèvre syndrome. Stabholz A, et al. **J Periodontol** 1995 Jul;66(7):653–7

Humoral immunity to commensal oral bacteria: quantitation, specificity and avidity of serum IgG and IgM antibodies reactive with Actinobacillus actinomycetemcomitans in children. Cole MF, et al. **Microbiol Immunol** 1995; 39(8):591–8

ISOLATION & PURIFICATION

Identification of Actinobacillus actinomycetemcomitans in subgingival plaque by PCR. Flemmig TF, et al. **J Clin Microbiol** 1995 Dec;33(12):3102–5

Putative periodontal pathogens colonizing oral mucous membranes in denture-wearing subjects with a past history of periodontitis. Danser MM, et al. **J Clin Periodontol** 1995 Nov;22(11):854–9

The effect of a single mechanical treatment on the subgingival microflora in patients with HIV-associated gingivitis. Hofer D, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):180–7

The natural history of periodontal disease. The correlation of selected microbiological parameters with disease severity in Sri Lankan tea workers. Preus HR, et al. **J Clin Periodontol** 1995 Sep;22(9):674–8

Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans and Treponema denticola detection in oral plaque samples using the polymerase chain reaction. Watanabe K, et al. **J Clin Periodontol** 1996 Mar; 23(3 Pt 1):212–9

Simultaneous detection of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis by a rapid PCR method. Wahlfors J, et al. **J Dent Res** 1995 Nov;74(11):1796–801

Bacterial colonization of the external and internal sulci and of cellulose membranes at time of retrieval. Novaes AB Jr, et al. **J Periodontol** 1995 Oct;66(10):864–9

Analytical performance of an immunologic-based periodontal bacterial test for simultaneous detection and differentiation of Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, and Prevotella intermedia. Snyder B, et al. **J Periodontol** 1996 May;67(5):497–505

Occurrence of Actinobacillus actinomycetemcomitans and anti-leukotoxin antibodies in some members of an extended family affected by Papillon-Lefèvre syndrome. Stabholz A, et al. **J Periodontol** 1995 Jul;66(7):653–7

Semiquantitative analysis of periodontopathogens by gene amplification. Sumi Y, et al. **Jpn J Med Sci Biol** 1995 Aug; 48(4):177–91

Actinobacillus actinomycetemcomitans pneumonia with chest wall and subphrenic abscess. Chen AC, et al. **Scand J Infect Dis** 1995;27(3):289–90

[The prognostic significance of the presence of Actinobacillus actinomycetemcomitans in the subgingival plaque of young orthodontic patients] Paolantonio M, et al. **Minerva Stomatol** 1995 May;44(5):195–203 (Eng. Abstr.) **(Ita)**

PATHOGENICITY

Virulence factors of Actinobacillus actinomycetemcomitans relevant to the pathogenesis of inflammatory periodontal diseases. Wilson M, et al. **FEMS Microbiol Rev** 1995 Dec; 17(4):365–79 (108 ref.)

Influence of anti-Actinobacillus actinomycetemcomitans Y4 (serotype b) lipopolysaccharide on severity of generalized early-onset periodontitis. Califano JV, et al. **Infect Immun** 1996 Sep;64(9):3908–10

Evidence for apoptosis of murine macrophages by Actinobacillus actinomycetemcomitans infection. Kato S, et al. **Infect Immun** 1995 Oct;63(10):3914–9

Invasion of epithelial cells by Actinobacillus actinomycetemcomitans: a dynamic, multistep process. Meyer DH, et al. **Infect Immun** 1996 Aug;64(8):2988–97

PHYSIOLOGY

Production of inflammatory mediators and cytokines by human gingival fibroblasts following bacterial challenge. Dongari-Bagtzoglou AI, et al. **J Periodontal Res** 1996 Feb; 31(2):90–8

Repopulation of periodontal pockets by microbial pathogens in the absence of supportive therapy. Shiloah J, et al. **J Periodontol** 1996 Feb;67(2):130–9

Haemolytic activity of Actinobacillus actinomycetemcomitans strains on different blood types. Avila-Campos MJ. **Rev Inst Med Trop Sao Paulo** 1995 May-Jun;37(3):215–7

VIROLOGY

Temperate bacteriophages are common among Actinobacillus actinomycetemcomitans isolates from periodontal pockets. Sandmeier H, et al. **J Periodontal Res** 1995 Nov;30(6):418–25

ACTINOBACILLUS INFECTIONS

Cerebral abscess complicating dental treatment. Case report and review of the literature. Renton TF, et al. **Aust Dent J** 1996 Feb;41(1):12–5 (32 ref.)

Actinobacillus ureae meningitis: case report and review of the literature. Kingsland RC, et al. **J Emerg Med** 1995 Sep-Oct;13(5):623–7 (37 ref.)

DIAGNOSIS

Actinobacillus actinomycetemcomitans pneumonia with chest wall and subphrenic abscess. Chen AC, et al. **Scand J Infect Dis** 1995;27(3):289–90

DRUG THERAPY

Efficacy of florfenicol on experimental Actinobacillus pleuropneumonia in pigs. Ueda Y, et al. **J Vet Med Sci** 1995 Apr;57(2):261–5

ETIOLOGY

Evidence for apoptosis of murine macrophages by Actinobacillus actinomycetemcomitans infection. Kato S, et al. **Infect Immun** 1995 Oct;63(10):3914–9

IMMUNOLOGY

Humoral immunity to commensal oral bacteria: quantitation, specificity and avidity of serum IgG and IgM antibodies reactive with Actinobacillus actinomycetemcomitans in children. Cole MF, et al. **Microbiol Immunol** 1995; 39(8):591–8

METABOLISM

Selective effects of a bacterial infection (Actinobacillus pleuropneumoniae) on the hepatic clearances of caffeine, antipyrine, paracetamol, and indocyanine green in the pig. Monshouwer M, et al. **Xenobiotica** 1995 May;25(5):491–9

MICROBIOLOGY

Virulence factors of Actinobacillus actinomycetemcomitans relevant to the pathogenesis of inflammatory periodontal diseases. Wilson M, et al. **FEMS Microbiol Rev** 1995 Dec; 17(4):365–79 (108 ref.)

Simplified procedure for preparation of sensitized latex particles to detect capsular polysaccharides: application to typing and diagnosis of Actinobacillus pleuropneumoniae. Inzana TJ. **J Clin Microbiol** 1995 Sep;33(9):2297–303

PREVENTION & CONTROL

Protective efficacy of cell-free-antigen of Actinobacillus pleuropneumoniae in mice. Oishi E, et al. **J Vet Med Sci** 1995 Aug;57(4):727–31

VETERINARY

Oral immunization with lung-pathogenic bacteria is protective against defined challenge in a pig aerosol infection model. Hensel A, et al. **Adv Exp Med Biol** 1995; 371B:803–6

Mucosal and serum IgA antibodies in pigs following infection with Actinobacillus pleuropneumoniae. Loftager MK, et al. **Adv Exp Med Biol** 1995;371B:935–8

Efficacy dose determination study of tilmicosin phosphate in feed for control of pneumonia caused by Actinobacillus pleuropneumoniae in swine. Moore GM, et al. **Am J Vet Res** 1996 Feb;57(2):220–3

Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine. Moore GM, et al. **Am J Vet Res** 1996 Feb;57(2):224–8

Characterisation of porcine haemophili isolated from Australian pigs between 1988 and 1992. Blackall PJ, et al. **Aust Vet J** 1995 Jan;72(1):18–21

In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs. Blackall PJ, et al. **Aust Vet J** 1995 Jan;72(1):35–6

Tissue reaction and immunity in swine immunized with Actinobacillus pleuropneumoniae vaccines. Willson PJ, et al. **Can J Vet Res** 1995 Oct;59(4):299–305

Evaluation of pig lungs following an experimental challenge with Actinobacillus pleuropneumoniae serotype 1 and 5 in pigs inoculated with either hemolysin protein and/or outer membrane proteins. Madsen ME, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):329–35

Serotypes and antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolated from piglets with pleuropneumonia. Asawa T, et al. **J Vet Med Sci** 1995 Aug; 57(4):757–9

Effect of physical defenses of the respiratory tract on the development of pneumonia in pigs inoculated endobronchially with Actinobacillus pleuropneumoniae. Narita M, et al. **J Vet Med Sci** 1995 Oct;57(5):839–44

Protective effect of the combined vaccine prepared from cell-free-antigen of Actinobacillus pleuropneumoniae serotypes 1, 2 and 5 in pigs. Oishi E, et al. **J Vet Med Sci** 1995 Dec;57(6):1125–8

In vitro antibacterial activity of florfenicol against Actinobacillus pleuropneumoniae. Ueda Y, et al. **J Vet Med Sci** 1995 Apr;57(2):363–4

Lymphocyte subsets in bronchoalveolar lavage after exposure to Actinobacillus pleuropneumoniae in pigs previously immunized orally or by aerosol. Pabst R, et al. **Lung** 1995;173(4):233–41

Susceptibility to Actinobacillus pleuropneumoniae infection in pigs from an endemically infected herd is related to the presence of toxin-neutralizing antibodies. Cruijsen T, et al. **Vet Microbiol** 1995 Dec;47(3–4):219–28

Aerosol exposure of pigs to viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces antibodies in bronchoalveolar lining fluids and serum, and protects against homologous challenge. Hensel A, et al. **Vet Microbiol** 1995 Nov;47(1–2):27–41

Development and evaluation of a selective and indicative medium for isolation of Actinobacillus pleuropneumoniae from tonsils. Jacobsen MJ, et al. **Vet Microbiol** 1995 Nov; 47(1–2):191–7

Comparison of virulence of different Actinobacillus pleuropneumoniae serotypes and biotypes using an aerosol infection model. Jacobsen MJ, et al. **Vet Microbiol** 1996 Apr;49(3–4):159–68

Cross-protection experiments in pigs vaccinated with Actinobacillus pleuropneumoniae subtypes 1A and 1B. Jolie RA, et al. **Vet Microbiol** 1995 Aug;45(4):383–91

Characterization of tetracycline and erythromycin resistance in Actinobacillus pleuropneumoniae. Wasteson Y, et al. **Vet Microbiol** 1996 Jan;48(1–2):41–50

Prevalence and development of antibodies neutralizing the haemolysin and cytotoxin of Actinobacillus pleuropneumoniae in three infected pig herds. Cruijsen T, et al. **Vet Q** 1995 Sep;17(3):96–100

Serological characterisation and antimicrobial susceptibility of Actinobacillus pleuropneumoniae strains isolated from pigs in Spain. Gutiérrez CB, et al. **Vet Rec** 1995 Jul 15; 137(3):62–4

Actinobacillus suis septicaemia in two foals. Nelson KM, et al. **Vet Rec** 1996 Jan 13;138(2):39–40

[Induction of polyvalent immunity against Actinobacillus pleuropneumoniae in an experimental rat model] Herrera L, et al. **Rev Latinoam Microbiol** 1995 Apr-Jun; 37(2):147–52 (Eng. Abstr.) **(Spa)**

ACTINOBACILLUS PLEUROPNEUMONIAE

Mucosal and serum IgA antibodies in pigs following infection with Actinobacillus pleuropneumoniae. Loftager MK, et al. **Adv Exp Med Biol** 1995;371B:935–8

Efficacy dose determination study of tilmicosin phosphate in feed for control of pneumonia caused by Actinobacillus pleuropneumoniae in swine. Moore GM, et al. **Am J Vet Res** 1996 Feb;57(2):220–3

Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine. Moore GM, et al. **Am J Vet Res** 1996 Feb;57(2):224–8

Effect of physical defenses of the respiratory tract on the development of pneumonia in pigs inoculated endobronchially with Actinobacillus pleuropneumoniae. Narita M, et al. **J Vet Med Sci** 1995 Oct;57(5):839–44

Protective effect of the combined vaccine prepared from cell-free-antigen of Actinobacillus pleuropneumoniae serotypes 1, 2 and 5 in pigs. Oishi E, et al. **J Vet Med Sci** 1995 Dec;57(6):1125–8

Efficacy of florfenicol on experimental Actinobacillus pleuropneumonia in pigs. Ueda Y, et al. **J Vet Med Sci** 1995 Apr;57(2):261–5

Susceptibility to Actinobacillus pleuropneumoniae infection in pigs from an endemically infected herd is related to the presence of toxin-neutralizing antibodies. Cruijsen T, et al. **Vet Microbiol** 1995 Dec;47(3–4):219–28

Selective effects of a bacterial infection (Actinobacillus pleuropneumoniae) on the hepatic clearances of caffeine, antipyrine, paracetamol, and indocyanine green in the pig. Monshouwer M, et al. **Xenobiotica** 1995 May;25(5):491–9

CHEMISTRY

Cloning and characterization of an Actinobacillus pleuropneumoniae outer membrane protein belonging to the family of PAL lipoproteins. Frey J, et al. **Res Microbiol** 1996 Jun;147(5):351–61

Isolation of the major outer-membrane protein of Actinobacillus pleuropneumoniae and Haemophilus parasuis. Hartmann L, et al. **Zentralbl Veterinarmed [B]** 1995 Mar;42(1):59–63

CLASSIFICATION

Characterisation of porcine haemophili isolated from Australian pigs between 1988 and 1992. Blackall PJ, et al. **Aust Vet J** 1995 Jan;72(1):18–21

Evidence obtained with monoclonal antibodies that O antigen is the major antigen responsible for the cross-reactivities between serotypes 4 and 7 of Actinobacillus (Haemophilus) pleuropneumoniae. Rodríguez Barbosa JI, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):563–8

Serotypes and antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolated from piglets with pleuropneumonia. Asawa T, et al. **J Vet Med Sci** 1995 Aug; 57(4):757–9

Development of an efficient PCR method for toxin typing

of Actinobacillus pleuropneumoniae strains. Frey J, et al. **Mol Cell Probes** 1995 Aug;9(4):277–82

Serological characterisation and antimicrobial susceptibility of Actinobacillus pleuropneumoniae strains isolated from pigs in Spain. Gutiérrez CB, et al. **Vet Rec** 1995 Jul 15; 137(3):62–4

DRUG EFFECTS

Efficacy of a variety of disinfectants against Actinobacillus pleuropneumoniae serotype 1. Gutiérrez CB, et al. **Am J Vet Res** 1995 Aug;56(8):1025–9

In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs. Blackall PJ, et al. **Aust Vet J** 1995 Jan;72(1):35–6

Serotypes and antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolated from piglets with pleuropneumonia. Asawa T, et al. **J Vet Med Sci** 1995 Aug; 57(4):757–9

In vitro antibacterial activity of florfenicol against Actinobacillus pleuropneumoniae. Ueda Y, et al. **J Vet Med Sci** 1995 Apr;57(2):363–4

Characterization of tetracycline and erythromycin resistance in Actinobacillus pleuropneumoniae. Wasteson Y, et al. **Vet Microbiol** 1996 Jan;48(1–2):41–50

GENETICS

Cloning, sequencing and expression of the transferrin–binding protein 1 gene from Actinobacillus pleuropneumoniae. Daban M, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):257–64

A targeted mutagenesis system for Actinobacillus pleuropneumoniae. Mulks MH, et al. **Gene** 1995 Nov 7; 165(1):61–6

Molecular characterization of a common 48–kilodalton outer membrane protein of Actinobacillus pleuropneumoniae. Cruz WT, et al. **Infect Immun** 1996 Jan;64(1):83–90

Characterization of Actinobacillus pleuropneumoniae riboflavin biosynthesis genes. Fuller TE, et al. **J Bacteriol** 1995 Dec;177(24):7265–70

Sequence, genetic analysis, and expression of Actinobacillus pleuropneumoniae transferrin receptor genes. Gonzalez GC, et al. **Microbiology** 1995 Oct;141 (Pt 10):2405–16

IMMUNOLOGY

Oral immunization with lung–pathogenic bacteria is protective against defined challenge in a pig aerosol infection model. Hensel A, et al. **Adv Exp Med Biol** 1995; 371B:803–6

Aerosol treatment of pigs with Actinobacillus pleuropneumoniae serotype 2: mucosal immunity and resistance against challenge. Loftager MK, et al. **Adv Exp Med Biol** 1995;371B:1611–4

Immunization by the enteral and respiratory route with viable and inactivated bacteria results in a differential increase in lymphocyte subsets in the bronchoalveolar space. Pabst R, et al. **Adv Exp Med Biol** 1995;371B:1459–61

Production and characterization of monoclonal antibodies to Actinobacillus pleuropneumoniae serotype 5b. Altman E, et al. **Can J Vet Res** 1995 Oct;59(4):279–84

Tissue reaction and immunity in swine immunized with Actinobacillus pleuropneumoniae vaccines. Willson PJ, et al. **Can J Vet Res** 1995 Oct;59(4):299–305

Evidence obtained with monoclonal antibodies that O antigen is the major antigen responsible for the cross–reactivities between serotypes 4 and 7 of Actinobacillus (Haemophilus) pleuropneumoniae. Rodríguez Barbosa JI, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):563–8

Evaluation of pig lungs following an experimental challenge with Actinobacillus pleuropneumoniae serotype 1 and 5 in pigs inoculated with either hemolysin protein and/or outer membrane proteins. Madsen ME, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):329–35

Protective efficacy of cell–free–antigen of Actinobacillus pleuropneumoniae in mice. Oishi E, et al. **J Vet Med Sci** 1995 Aug;57(4):727–31

Lymphocyte subsets in bronchoalveolar lavage after exposure to Actinobacillus pleuropneumoniae in pigs previously immunized orally or by aerosol. Pabst R, et al. **Lung** 1995;173(4):233–41

Aerosol exposure of pigs to viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces antibodies in bronchoalveolar lining fluids and serum, and protects against homologous challenge. Hensel A, et al. **Vet Microbiol** 1995 Nov;47(1–2):27–41

Cross–protection experiments in pigs vaccinated with Actinobacillus pleuropneumoniae subtypes 1A and 1B. Jolie RA, et al. **Vet Microbiol** 1995 Aug;45(4):383–91

Prevalence and development of antibodies neutralizing the haemolysin and cytotoxin of Actinobacillus pleuropneumoniae in three infected pig herds. Cruijsen T, et al. **Vet Q** 1995 Sep;17(3):96–100

[Induction of polyvalent immunity against Actinobacillus pleuropneumoniae in an experimental rat model] Herrera L, et al. **Rev Latinoam Microbiol** 1995 Apr–Jun; 37(2):147–52 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Simplified procedure for preparation of sensitized latex particles to detect capsular polysaccharides: application to typing and diagnosis of Actinobacillus pleuropneumoniae. Inzana TJ. **J Clin Microbiol** 1995 Sep;33(9):2297–303

Development and evaluation of a selective and indicative medium for isolation of Actinobacillus pleuropneumoniae from tonsils. Jacobsen MJ, et al. **Vet Microbiol** 1995 Nov; 47(1–2):191–7

Production and characterization of monoclonal antibodies against Actinobacillus pleuropneumoniae serotype 1. Lairini K, et al. **Vet Microbiol** 1995 Oct;46(4):369–81

METABOLISM

Characterisation of haemolytic RTX toxins produced by Australian isolates of Actinobacillus pleuropneumoniae. Tarigan S, et al. **Aust Vet J** 1996 May;73(5):164–9

Cloning, sequencing and expression of the transferrin–binding protein 1 gene from Actinobacillus pleuropneumoniae. Daban M, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):257–64

Mapping of functional regions on the transferrin–binding protein (TfbA) of Actinobacillus pleuropneumoniae. Strutzberg K, et al. **Infect Immun** 1995 Oct;63(10):3846–50

PATHOGENICITY

Influence of Actinobacillus pleuropneumoniae and its metabolites on porcine alveolar epithelial cells. van de Kerkhof A, et al. **Infect Immun** 1996 Sep;64(9):3905–7

Molecular investigation of the role of ApxI and ApxII in the virulence of Actinobacillus pleuropneumoniae serotype 5. Reimer D, et al. **Microb Pathog** 1995 Mar;18(3):197–209

Virulence in Actinobacillus pleuropneumoniae and RTX toxins. Frey J. **Trends Microbiol** 1995 Jul;3(7):257–61 (50 ref.)

Comparison of virulence of different Actinobacillus pleuropneumoniae serotypes and biotypes using an aerosol infection model. Jacobsen MJ, et al. **Vet Microbiol** 1996 Apr;49(3–4):159–68

ACTINOIDS see **METALS, ACTINOID**

ACTINOMYCES

DRUG EFFECTS

Antibacterial action of dental cements: an in vitro study. Morrier JJ, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct; 38(3–4):87–93

ENZYMOLOGY

Phosphorylating enzymes involved in glucose fermentation of Actinomyces naeslundii. Takahashi N, et al. **J Bacteriol** 1995 Oct;177(20):5806–11

Assay of proteases from Actinomyces pyogenes isolated from pigs and cows by zymography. Takeuchi S, et al. **J Vet Med Sci** 1995 Oct;57(5):977–9

ISOLATION & PURIFICATION

Muscular actinomycosis in the back. Coppens L, et al. **Acta Clin Belg** 1996;51(2):94–6

Microbiological and serological investigations of oral lesions in Papillon–Lefèvre syndrome. Clerehugh V, et al. **J Clin Pathol** 1996 Mar;49(3):255–7

[Primary hepatic actinomycosis: current management of a rare disease (letter)] Combes R, et al. **Presse Med** 1995 Oct 21;24(31):1445 **(Fre)**

[Clinical manifestations of actinomycosis: literature review apropos of a case] Liaudet L, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):423–8 **(Fre)**

[Microbiologic detection of pelvic actinomycosis (letter)] Vukadinović MV, et al. **Lijec Vjesn** 1995 Jul–Aug; 117(7–8):201–2 **(Scr)**

METABOLISM

Microbial biosorption of copper and lead from aqueous systems. Pradhan AA, et al. **Sci Total Environ** 1995 Sep 29;170(3):209–20

PHYSIOLOGY

Co–adhesion of oral microbial pairs under flow in the presence of saliva and lactose. Bos R, et al. **J Dent Res** 1996 Feb;75(2):809–15

ACTINOMYCES INFECTIONS see **ACTINOMYCOSIS**

ACTINOMYCES VISCOSUS

Cervicofacial Actinomyces viscosus infection in a Brazilian fila: a case report and literature review. Donohue DE, et al. **J Am Anim Hosp Assoc** 1995 Nov–Dec;31(6):501–5 (20 ref.)

CHEMISTRY

Effects of Actinomyces amphiphile on the fluidity of endothelial cells: a spin label study. Hamada Y. **J Dent Res** 1996 Apr;75(4):1002–7

PATHOGENICITY

Experimental root surface caries in hamsters the development of the disease after inoculations of two types of cariogenic bacteria. de Oliveira Cordeiro JG. **Bull Tokyo Med Dent Univ** 1995 Dec;42(3):83–103

ACTINOMYCETACEAE

ISOLATION & PURIFICATION

Images in clinical medicine. Tropheryma whippelii. Fricker EJ, et al. **N Engl J Med** 1996 Jul 4;335(1):26

METABOLISM

Production of trehalose phosphorylase by Catellatospora ferruginea. Aisaka K, et al. **FEMS Microbiol Lett** 1995 Aug 15;131(1):47–51

Antibiotics A21459 A and B, new inhibitors of bacterial protein synthesis. I. Taxonomy, isolation and characterization. Selva E, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):145–9

BE–40644, a new human thioredoxin system inhibitor isolated from Actinoplanes sp. A40644. Torigoe K, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):314–7

ACTINOMYCETALES

Occurrence and clinical significance of thermophilic actinomycetes in cane–sugar mills. Gangwar M, et al. **Arch Environ Health** 1995 Sep–Oct;50(5):393–4

Treatment of eumycetoma and actinomycetoma. Welsh O, et al. **Curr Top Med Mycol** 1995;6:47–71 (105 ref.)

CHEMISTRY

Distribution of thiols in microorganisms: mycothiol is a major thiol in most actinomycetes. Newton GL, et al. **J Bacteriol** 1996 Apr;178(7):1990–5

CLASSIFICATION

Morphological, physiological, and molecular characterization of actinomycetes isolated from dry soil, rocks, and monument surfaces. Eppard M, et al. **Arch Microbiol** 1996 Jul;166(1):12–22

Microbiology terminology update: clinically significant anaerobic gram–positive and gram–negative bacteria (excluding spirochetes). Summanen P. **Clin Infect Dis** 1995 Aug;21(2):273–6

Heterogeneity within human–derived centers for disease control and prevention (CDC) coryneform group ANF–1–like bacteria and description of Corynebacterium auris sp. nov. Funke G, et al. **Int J Syst Bacteriol** 1995 Oct;45(4):735–9

Agrococcus jenensis gen. nov., sp. nov., a new genus of actinomycetes with diaminobutyric acid in the cell wall. Groth I, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):234–9

Molecular phylogeny of the genus Frankia and related genera and emendation of the family Frankiaceae. Normand P, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):1–9

Phylogenetic analysis of mycolic acid–containing wall–chemotype IV actinomycetes and allied taxa by partial sequencing of ribosomal protein AT–L30. Ochi K. **Int J Syst Bacteriol** 1995 Oct;45(4):653–60

Sanguibacter inulinus sp. nov. Pascual C, et al. **Int J Syst Bacteriol** 1996 Jul;46(3):811–3

Phylogenetic analysis of the genera Cellulomonas, Promicromonospora, and Jonesia and proposal to exclude the genus Jonesia from the family Cellulomonadaceae. Rainey FA, et al. **Int J Syst Bacteriol** 1995 Oct;45(4):649–52

Two coryneform bacteria isolated from the surface of French Gruyère and Beaufort cheeses are new species of the genus Brachybacterium: Brachybacterium alimentarium sp. nov. and Brachybacterium tyrofermentans sp. nov. Schubert K, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):81–7

Agromyces mediolanus sp. nov., nom. rev., comb. nov., a species for "Corynebacterium mediolanum" Mamoli 1939 and for some aniline–assimilating bacteria which contain 2,4–diaminobutyric acid in the cell wall peptidoglycan. Suzuki K, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):88–93

Phylogenetic analysis reveals new relationships among members of the genera Microtetraspora and Microbispora. Wang Y, et al. **Int J Syst Bacteriol** 1996 Jul;46(3):658–63

Tsukamurella inchonensis sp. nov. Yassin AF, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):522–7

Identification of some clinical strains of CDC coryneform group A–3 and A–4 bacteria as Cellulomonas species and proposal of Cellulomonas hominis sp. nov. for some group A–3 strains. Funke G, et al. **J Clin Microbiol** 1995 Aug; 33(8):2091–7

[Importance of taxonomic and immunologic lipid markers of actinomycetes and similar bacteria] Szponar B. **Postepy Hig Med Dosw** 1995;49(1):161–70 (25 ref.) (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

A mass spectrometry–based approach for probing enzyme active sites: identification of Glu 127 in Cellulomonas fimi exoglycanase as the residue modified by N–bromoacetyl cellobiosylamine. Tull D, et al. **Anal Biochem** 1996 Feb 15;234(2):119–25

Purification and characterization of two different xylanases from the thermophilic actinomycete Microtetraspora flexuosa SIIX. Berens S, et al. **Antonie Van Leeuwenhoek** 1996 Apr;69(3):235–41

Purification and characterization of an extracellular pectate lyase from an Amycolata sp. Brühlmann F. **Appl Environ Microbiol** 1995 Oct;61(10):3580–5

Chorismate mutase and 3–deoxy–D–arabino–heptulosonate

7-phosphate synthase of the methylotrophic actinomycete Amycolatopsis methanolica. Euverink GJ, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3796-803
Structure-function relationship of xylanase: fluorimetric analysis of the tryptophan environment. Bandivadekar KR, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):583-7
Substrate specificity of endoglucanase A from Cellulomonas fimi: fundamental differences between endoglucanases and exoglucanases from family 6. Damude HG, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):467-72
Structural environment of an essential cysteine residue of xylanase from Chainia sp. (NCL 82.5.1). Rao M, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):771-5
Cellobiohydrolase B, a second exo-cellobiohydrolase from the cellulolytic bacterium Cellulomonas fimi. Shen H, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):67-74
Maltokinase (ATP:maltose 1-phosphotransferase) from Actinoplanes sp.: demonstration of enzyme activity and characterization of the reaction product. Drepper A, et al. **FEBS Lett** 1996 Jun 17;388(2-3):177-9
A modular xylanase from mesophilic Cellulomonas fimi contains the same cellulose-binding and thermostabilizing domains as xylanases from thermophilic bacteria. Clarke JH, et al. **FEMS Microbiol Lett** 1996 May 15;139(1):27-35
Cloning, sequencing and analysis of the ggh-A gene encoding a 1,4-beta-D-glucan glucohydrolase from Microbispora bispora. Goyal AK, et al. **Gene** 1996 Jun 12;172(1):93-8
Purification and characterization of the major beta-1,4-endoglucanase from Thermomonospora curvata. Lin SB, et al. **J Appl Bacteriol** 1995 Oct;79(4):447-53
Nucleotide sequence of a beta-1,3-glucanase isoenzyme IIA gene of Oerskovia xanthineolytica LL G109 (Cellulomonas cellulans) and initial characterization of the recombinant enzyme expressed in Bacillus subtilis. Ferrer P, et al. **J Bacteriol** 1996 Aug;178(15):4751-7

GENETICS

Amplification of 16S rRNA genes from Frankia strains in root nodules of Ceanothus griseus, Coriaria arborea, Coriaria plumosa, Discaria toumatou, and Purshia tridentata. Benson DR, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2904-9
Purification and characterization of an extracellular pectate lyase from an Amycolata sp. Brühlmann F. **Appl Environ Microbiol** 1995 Oct;61(10):3580-5
Analysis of partial sequences of genes coding for 16S rRNA of actinomycetes isolated from Casuarina equisetifolia nodules in Mexico. Niner BM, et al. **Appl Environ Microbiol** 1996 Aug;62(8):3034-6
Isolation of strong promoters from Clavibacter xyli subsp. cynodontis using a promoter probe plasmid. Haapalainen M, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):130-4
Restriction analysis of actinomycetes chromosomal DNA. Novella IS, et al. **Can J Microbiol** 1996 Feb;42(2):201-6
The factors affecting transformation efficiency of coryneform bacteria by electroporation. Na S, et al. **Chin J Biotechnol** 1995;11(3):193-8
Rifamycins: strain improvement program. Lal R, et al. **Crit Rev Microbiol** 1995;21(1):19-30 (42 ref.)
Nucleotide sequence of a beta-1,3-glucanase isoenzyme IIA gene of Oerskovia xanthineolytica LL G109 (Cellulomonas cellulans) and initial characterization of the recombinant enzyme expressed in Bacillus subtilis. Ferrer P, et al. **J Bacteriol** 1996 Aug;178(15):4751-7
A deduced Thermomonospora curvata protein containing serine/threonine protein kinase and WD-repeat domains. Janda L, et al. **J Bacteriol** 1996 Mar;178(5):1487-9
Limited role for PCR-based diagnosis of Whipple's disease from peripheral blood mononuclear cells [letter] Marth T, et al. **Lancet** 1996 Jul 6;348(9019):66-7
Molecular identification of pathogenic actinomycetes: a new approach. Fernández-Garayzábal JF. **Microbiologia** 1995 Sep;11(3):403-4
Molecular structure of the Frankia spp. nifD-K intergenic spacer and design of Frankia genus compatible primer. Nalin R, et al. **Mol Ecol** 1995 Aug;4(4):483-91

IMMUNOLOGY

Thermophilic actinomycetes in cane sugar mills: an aeromicrobiologic and seroepidemiologic study. Khan ZU, et al. **Antonie Van Leeuwenhoek** 1995;67(4):339-44

ISOLATION & PURIFICATION

Tsukamurella and HIV infection [letter] Rey D, et al. **AIDS** 1995 Dec;9(12):1379
Thermophilic actinomycetes in cane sugar mills: an aeromicrobiologic and seroepidemiologic study. Khan ZU, et al. **Antonie Van Leeuwenhoek** 1995;67(4):339-44
PCR-restriction fragment length polymorphism identification and host range of single-spore isolates of the flexible Frankia sp. strain UFI 132715. Lumini E, et al. **Appl Environ Microbiol** 1996 Aug;62(8):3026-9
Development of a specific biotinylated DNA probe for the detection of Renibacterium salmoninarum. Hariharan H, et al. **Can J Vet Res** 1995 Oct;59(4):306-10
Selective recovery of Streptosporangium fragile from soil by indirect immunomagnetic capture. Mullins PH, et al. **Microbiology** 1995 Sep;141 (Pt 9):2149-56

METABOLISM

Tetracyclines. Běhal V, et al. **Biotechnology** 1995;28:359-84 (99 ref.)
Aminoglycosides and aminocyclitols (other than streptomycin). Hotta K, et al. **Biotechnology** 1995;28:571-95 (82 ref.)
Macrolides. Katz L, et al. **Biotechnology** 1995;28:385-420 (136 ref.)
Streptomycin and related aminoglycosides. Piepersberg W. **Biotechnology** 1995;28:531-70 (179 ref.)
Rifamycins: strain improvement program. Lal R, et al. **Crit Rev Microbiol** 1995;21(1):19-30 (42 ref.)
4'-Deacetyl-(-)-griseusins A and B, new naphthoquinone antibiotics from an actinomycete. Igarashi M, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1502-5
2-Demethylazalomycins F4a and F5a, two new antifungal metabolites from Actinomycete sp. HIL Y-9120362. Mukhopadhyay T, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1350-2
AH17, a new non-polyenic antifungal antibiotic produced by a strain of Spirillospora. Hacène H, et al. **Microbios** 1995;83(336):199-205
[Induction of antibiotic production in inactive cultures of actinomycetes. Monensin production by a mutant strain 2608 EB-1] Malkina ND, et al. **Antibiot Khimioter** 1995 Oct;40(10):3-6 (Eng. Abstr.) **(Rus)**

PATHOGENICITY

Sepsis due to coryneform group A-4 in an immunocompromised host. Bizette GA, et al. **Clin Infect Dis** 1995 Nov;21(5):1334-6

PHYSIOLOGY

Douglas-fir root-associated microorganisms with inhibitory activity towards fungal plant pathogens and human bacterial pathogens. Axelrood PE, et al. **Can J Microbiol** 1996 Jul;42(7):690-700
[Infectivity and effectiveness of different strains of Frankia spp. on Atriplex cordobensis plants] Fabri S, et al. **Rev Argent Microbiol** 1996 Jan-Mar;28(1):31-8 (Eng. Abstr.) **(Spa)**

ACTINOMYCETALES INFECTIONS

An unusual case of untreated chronic lymphocytic leukemia patient presenting with Rhodococcus equi bacteriemia [letter] Matteo Rigolin G, et al. **Am J Hematol** 1996 Jun; 52(2):126

COMPLICATIONS

Sequential involvement of NK cells and CD8+ T cells in granuloma formation of Rhodococcus aurantiacus-infected mice. Asano M, et al. **Microbiol Immunol** 1995; 39(7):499-507
[Rhodococcus equi pneumonia in patients with HIV infection: report of 2 cases and review of the literature] Berna JD, et al. **Enferm Infecc Microbiol Clin** 1996 Mar; 14(3):177-80 (57 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Rhodococcus equi infection in HIV-infected patients. Donisi A, et al. **AIDS** 1996 Apr;10(4):359-62

EPIDEMIOLOGY

Prevalence in India of Dermatophilus congolensis infection in clinical specimens from animals and humans. Pal M. **Rev Sci Tech** 1995 Sep;14(3):857-63

ETIOLOGY

Sepsis due to coryneform group A-4 in an immunocompromised host. Bizette GA, et al. **Clin Infect Dis** 1995 Nov;21(5):1334-6
Meningitis caused by mixed anaerobic species complicating tethered cord syndrome [letter] Borowsky AD, et al. **Clin Infect Dis** 1995 Sep;21(3):706-7
Pathogenesis of Rhodococcus equi infection in mice: roles of virulence plasmids and granulomagenic activity of bacteria. Takai S, et al. **FEMS Immunol Med Microbiol** 1995 Jun;11(3):181-90
Rhodococcus peritonitis in continuous ambulatory peritoneal dialysis. Tang S, et al. **Nephrol Dial Transplant** 1996 Jan; 11(1):201-2
Rhodococcus equi infection after liver transplantation. Sabater L, et al. **Transplantation** 1996 Mar 27;61(6):980-2
[Rhodococcus equi pulmonary abscess in HIV infection] About I, et al. **Rev Med Interne** 1996;17(5):410-4 (25 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Reciprocal action of interferon-gamma and interleukin-4 promotes granulomatous inflammation induced by Rhodococcus aurantiacus in mice. Asano M, et al. **Immunology** 1996 Jul;88(3):394-9

MICROBIOLOGY

Rhodococcus equi infection in 3 AIDS patients. Colebunders R, et al. **Acta Clin Belg** 1996;51(2):101-5
Identification of virulence-associated antigens and plasmids in Rhodococcus equi from patients with AIDS. Takai S, et al. **J Infect Dis** 1995 Nov;172(5):1306-11
Ribosomal DNA polymorphism in the genus Bifidobacterium. Mangin I, et al. **Res Microbiol** 1996 Mar-Apr;147(3):183-92

PATHOLOGY

Fine needle aspiration cytology of mycetoma. EL Hag IA, et al. **Acta Cytol** 1996 May-Jun;40(3):461-4

RADIOGRAPHY

[Rhodococcus equi lung infection in AIDS patients. A report of 4 cases] Carli Moretti C, et al. **Radiol Med (Torino)** 1996 Apr;91(4):477-80 (13 ref.) **(Ita)**

VETERINARY

An amino acid sequence coded by the exon 2 of the BoLA DRB3 gene associated with a BoLA class I specificity constitutes a likely genetic marker of resistance to dermatophilosis in Brahman zebu cattle of Martinique (FWI). Maillard JC, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:185-97
Treatment of ovine dermatophilosis with long-acting oxytetracycline or a lincomycin-spectinomycin combination. Jordan D, et al. **Aust Vet J** 1995 Jun; 72(6):234-6
Development of a specific biotinylated DNA probe for the detection of Renibacterium salmoninarum. Hariharan H, et al. **Can J Vet Res** 1995 Oct;59(4):306-10
Development of reactive arthritis and resistance to erythromycin and rifampin in a foal during treatment for Rhodococcus equi pneumonia. Kenney DG, et al. **Equine Vet J** 1994 May;26(3):246-8
Comparison of diagnostic tests for bacterial kidney disease in juvenile steelhead trout (Oncorhynchus mykiss). White MR, et al. **J Vet Diagn Invest** 1995 Oct;7(4):494-9
Association with HeLa cells by Rhodococcus equi with and without the virulence plasmid. de la Peña-Moctezuma A, et al. **Vet Microbiol** 1995 Oct;46(4):383-92
Immunohistochemical detection of virulence-associated antigens of Rhodococcus equi in pulmonary lesions of foals. Madarame H, et al. **Vet Pathol** 1996 May;33(3):341-3
Blastogenic response of lymphocytes from foals infected with Rhodococcus equi. Sanada Y, et al. **Zentralbl Veterinarmed [B]** 1996 Apr;43(2):97-107

ACTINOMYCETE INFECTIONS see **ACTINOMYCETALES INFECTIONS**

ACTINOMYCIN see **DACTINOMYCIN**

ACTINOMYCIN D see **DACTINOMYCIN**

ACTINOMYCOSIS

Actinomycosis in Alabama. Harris LF. **J Med Assoc State Ala** 1981 Feb;50(8):39-40
Colonic actinomycosis: report of a case and review of the literature. Kaya E, et al. **Surg Today** 1995;25(10):923-6 (12 ref.)
[Actinomycetes canaliculitis--case reports] Hass C, et al. **Immun Infekt** 1995 Dec;23(6):222-3 (Eng. Abstr.) **(Ger)**
[Hepatic actinomycosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):104-5 (8 ref.) **(Jpn)**
[Hepatic actinomycosis: radiologic findings and percutaneous drainage] Sandoval Polo E, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):590-2 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Extensive colonic stricture due to pelvic actinomycosis. Kim JC, et al. **J Korean Med Sci** 1995 Apr;10(2):142-6
Postoperative carotid artery rupture caused by actinomyces infection. Friedman HD, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):145-7
Primary actinomycotic lung abscess. Mohan A, et al. **Postgrad Med J** 1995 Nov;71(841):699-700
Transphrenic dissemination of actinomycosis. Zeebregts CJ, et al. **Thorax** 1996 Apr;51(4):449-50
[A rare cause of retroperitoneal fibrosis: actinomycosis] Koutani A, et al. **Ann Urol (Paris)** 1996;30(2):89-93 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

'Lumpy jaw' syndrome. Golledge C. **Aust Fam Physician** 1995 Sep;24(9):1703, quiz 1752-3
Actinomyces odontolyticus thoracopulmonary infections. Two cases in lung and heart-lung transplant recipients and a review of the literature. Bassiri AG, et al. **Chest** 1996 Apr;109(4):1109-11 (10 ref.)
Hepatic actinomycosis: a case report. Shiau YR, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Jul;56(1):62-5
Disseminated infection due to Actinomyces meyeri: case report and review. Apothéloz C, et al. **Clin Infect Dis** 1996 Apr;22(4):621-5 (32 ref.)
Abdominal actinomycosis. Cintron JR, et al. **Dis Colon Rectum** 1996 Jan;39(1):105-8 (10 ref.)
Primary perianal actinomycosis. Posnik MR, et al. **Eur J Surg** 1996 Feb;162(2):153-4
MRI of thoracic actinomycosis. Wand A, et al.

J Comput Assist Tomogr 1996 Sep–Oct;20(5):770–2
Pulmonary actinomycosis—a master of disguise. Shannon HM, et al. **J Infect** 1995 Sep;31(2):165–9
Diagnosis of actinomycosis by fine–needle aspiration [letter] Gerbino G, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Apr;81(4):381–2
Actinomycosis presenting as carcinoma. Hinnie J, et al.
Postgrad Med J 1995 Dec;71(842):749–50
[Actinomycosis an infectious disease, simulating malignancy] Koskela A. **Duodecim** 1994;110(8):819–22 **(Fin)**
[Actinomycotic abscess of the spleen (letter)] Lipsker D, et al. **Ann Med Interne (Paris)** 1995;146(5):336–7 **(Fre)**
[When should genital actinomycosis be considered? (letter)] Boutboul R, et al. **Presse Med** 1996 Jan 20;25(2):83 **(Fre)**
[Pseudotumoral pelvic actinomycosis (letter)] Collard O, et al. **Presse Med** 1996 May 4–11;25(16):776 **(Fre)**
[Primary hepatic actinomycosis: current management of a rare disease (letter)] Combes R, et al. **Presse Med** 1995 Oct 21;24(31):1445 **(Fre)**
[Bronchial actinomycosis of pseudo–tumor form (letter)] Guichenez P, et al. **Presse Med** 1996 Mar 16;25(9):459 **(Fre)**
[Thoracic actinomycosis] Mohr VD, et al. **Chirurg** 1995 Aug; 66(8):818–22 (Eng. Abstr.) **(Ger)**
[Rare manifestation of actinomycosis as retroperitoneal space–occupying lesion] Seelig MH, et al. **Chirurg** 1995 Aug;66(8):823–5 (Eng. Abstr.) **(Ger)**
[Acute abdomen in abdominal actinomycosis] Müller R, et al. **Leber Magen Darm** 1996 Mar;26(2):109–12 (Eng. Abstr.) **(Ger)**
[Pleuro–mediastinitis in pulmonary actinomycosis as a rare differential bronchial carcinoma diagnosis] Orth M, et al. **Pneumologie** 1995 Sep;49(9):505–8 (Eng. Abstr.) **(Ger)**
[Reactive and areactive actinomycosis infection of the female genitals and differentiation of pseudoactinomycosis] Horn LC, et al. **Zentralbl Gynakol** 1995;117(9):466–71 (Eng. Abstr.) **(Ger)**
[Abdominal actinomycosis in tubo–ovarian abscess] Theodoropoulos G, et al. **Zentralbl Gynakol** 1995; 117(9):494–7 (Eng. Abstr.) **(Ger)**
[Actinomycotic abscess of the cerebellum: a case report] Tsubouchi MH, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3–A):498–502 (Eng. Abstr.) **(Por)**
[Microbiologic detection of pelvic actinomycosis (letter)] Vukadinović MV, et al. **Lijec Vjesn** 1995 Jul–Aug; 117(7–8):201–2 **(Scr)**
[Pulmonary actinomycosis. The difficulties in its diagnosis and treatment] Márquez Rivas FJ, et al.
An Esp Pediatr 1996 Jun;44(6):588–90 (12 ref.) **(Spa)**
[Recurrent hemoptysis as a presentation form of thoracic actinomycosis (letter)] Pastorín J, et al.
Arch Bronconeumol 1996 Mar;32(3):157 **(Spa)**

DRUG THERAPY

[Pulmonary actinomycosis. The difficulties in its diagnosis and treatment] Márquez Rivas FJ, et al.
An Esp Pediatr 1996 Jun;44(6):588–90 (12 ref.) **(Spa)**

ETIOLOGY

Thoracic actinomycosis in a patient with pulmonary involvement caused by non–Hodgkin's lymphoma. Batt JA, et al. **Clin Infect Dis** 1996 Apr;22(4):731–2
Intrauterine contraceptive device–associated actinomycotic abscess and Actinomyces detection on cervical smear. Fiorino AS. **Obstet Gynecol** 1996 Jan;87(1):142–9 (107 ref.)
Actinomycosis of the paranasal sinuses: a case report and review. Roth M, et al. **Otolaryngol Head Neck Surg** 1996 Jun;114(6):818–21

METABOLISM

[The observation of sulfur granules in noninfectious processes (letter; comment)] Diaz Morant V, et al.
Med Clin (Barc) 1996 Jun 8;107(2):75. Comment on: Med Clin (Barc) 1995 Jun 10;105(2):68–75. **(Spa)**

MICROBIOLOGY

Muscular actinomycosis in the back. Coppens L, et al.
Acta Clin Belg 1996;51(2):94–6
[Clinical manifestations of actinomycosis: literature review apropos of a case] Liaudet L, et al.
Rev Med Suisse Romande 1996 Jun;116(6):423–8 **(Fre)**

PATHOLOGY

Actinomycosis—an unusual presentation. Appiah–Anane S, et al. **Br J Oral Maxillofac Surg** 1995 Aug;33(4):248–9
[A case of ileocecal actinomycosis with marked swelling of ileocecal valve] Kyogoku T, et al.
Nippon Shokakibyo Gakkai Zasshi 1995 Dec;92(12):1971–4 **(Jpn)**

PHYSIOPATHOLOGY

Progressive intractable actinomycosis in patients with AIDS. Manfredi R, et al. **Scand J Infect Dis** 1995;27(4):405–7

RADIOGRAPHY

Retroperitoneal actinomycosis with intraperitoneal spread. Stellate pattern on CT. Ko SF, et al. **Clin Imaging** 1996 Apr–Jun;20(2):133–6
Gastric actinomycosis. Lee CM, et al.
J Formos Med Assoc 1996 Jan;95(1):66–8
Pulmonary actinomycosis appearing as a "ball–in–hole" on chest radiography and bronchoscopy [see comments] Hsieh MJ, et al. **Thorax** 1996 Feb;51(2):221–2. Comment in: Thorax 1996 Feb;51(2):226–7.
[X–ray computed tomographic and radiographic aspects of thoracic actinomycosis] Poey C, et al. **J Radiol** 1996 Mar; 77(3):177–83 (Eng. Abstr.) **(Fre)**

SURGERY

Abdominal actinomycosis. Cintron JR, et al.
Dis Colon Rectum 1996 Jan;39(1):105–8 (10 ref.)
Childhood actinomycosis: report of two cases. Benammar S, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):180–3
[Abscess of the skull base—therapy and reconstruction after zygoma resection] Prochno T, et al.
Zentralbl Neurochir 1996;57(2):97–102 (Eng. Abstr.) **(Ger)**

TRANSMISSION

Salivary glands and saliva of Amblyomma variegatum ticks: comparison of immatures and adults in relation to the pathogenesis of dermatophilosis. Lloyd CM, et al.
Vet Parasitol 1995 Aug;59(1):59–67

VETERINARY

Cervicofacial Actinomyces viscosus infection in a Brazilian fila: a case report and literature review. Donohue DE, et al. **J Am Anim Hosp Assoc** 1995 Nov–Dec;31(6):501–5 (20 ref.)
What is your diagnosis? Right maxillary sinusitis or sinus cyst in a cow. Miller M, et al. **J Am Vet Med Assoc** 1996 Mar 15;208(6):829–30
Assay of proteases from Actinomyces pyogenes isolated from pigs and cows by zymography. Takeuchi S, et al.
J Vet Med Sci 1995 Oct;57(5):977–9
A survey of dermatophilosis in Israeli dairy cattle. Yeruham I, et al. **Rev Elev Med Vet Pays Trop** 1995;48(1):25–9
Suppurative pleuropneumonia and a pulmonary abscess in a ram: ultrasonographic and radiographic findings. Braun U, et al. **Schweiz Arch Tierheilkd** 1995;137(6):272–8

ACTINOMYCOSIS, CERVICOFACIAL

DIAGNOSIS

[Actinomycosis of the tonsils with a pseudotumoral presentation: a clinical case] Vallés Fontanet J, et al.
Acta Otorrinolaringol Esp 1995 Nov–Dec;46(6):444–6 (Eng. Abstr.) **(Spa)**

ACTINOSPECTACIN see **SPECTINOMYCIN**

ACTINOTHERAPY see **ULTRAVIOLET THERAPY**

ACTINS

Evolution of a dynamic cytoskeleton. Mitchison TJ.
Philos Trans R Soc Lond B Biol Sci 1995 Sep 29; 349(1329):299–304 (18 ref.)
Actin. Sheterline P, et al. **Protein Profile** 1994;1(1):1–121 (1838 ref.)

ANALYSIS

Contractile proteins in human fetoplacental vessels. Cavaillé F, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1793–9
The organization of microtubules and filamentous actin in cytospin preparations of Sertoli cells from w/wwei mutant mice devoid of germ cells. Wolf KW, et al.
Anat Embryol (Berl) 1996 Apr;193(4):413–7
Increased cell diameter precedes chondrocyte terminal differentiation, whereas cell–matrix attachment complex proteins appear constant. Hirsch MS, et al. **Anat Rec** 1996 Mar;244(3):284–96
Correlation of semen characteristics with acrosin, hyaluronidase, tubulin, dynein, and actin of spermatozoa. Hoshi K, et al. **Arch Androl** 1995 Nov–Dec;35(3):165–72
Altered expression of alpha–smooth muscle isoactin in Hirschsprung's disease. Fromont–Hankard G, et al.
Arch Pathol Lab Med 1996 Mar;120(3):270–4
Immunohistochemical observation of foci of muscle actin–positive tumor cells in meningiomas. Tsuchida T, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):267–9
Biliary secretion and actin–cytokeratin filament distribution in rat hepatocytes during phalloidin–induced cholestasis. Loranger A, et al. **Biochem Cell Biol** 1995 Sep–Oct; 73(9–10):641–9
Immunocytochemical localization of actin in the nucleolus of rat oocytes. Funaki K, et al. **Biol Cell** 1995;84(3):139–46
The instability of the membrane skeleton in thalassemic red blood cells. Yuan J, et al. **Blood** 1995 Nov 15; 86(10):3945–50
Comparison of anti–desmin and anti–actin staining for the computerized analysis of cavernous smooth muscle density. Sattar AA, et al. **Br J Urol** 1996 Feb;77(2):266–70
F–actin in mitotic spindles of synchronized suspension culture cells of tobacco visualized by confocal laser scanning microscopy. Kengen HM, et al. **Cell Biol Int** 1995 Jul; 19(7):585–92
Molecular environment of ZO–1 in epithelial and non–epithelial cells. Howarth AG, et al.
Cell Motil Cytoskeleton 1995;31(4):323–32
Vinculin localization and actin stress fibers differ in thyroid cells organized as monolayers or follicles. Yap AS, et al.
Cell Motil Cytoskeleton 1995;32(4):318–31
Actin bundles in human hair follicles as revealed by confocal laser microscopy. Furumura M, et al. **Cell Tissue Res** 1996 Mar;283(3):425–34
Effects of latrunculin A on immunological phagocytosis and macrophage spreading–associated changes in the F–actin/G–actin content of the cells. Oliveira CA, et al. **Chem Biol Interact** 1996 Mar 25;100(2):141–53
Application of immunostaining for muscle specific actin in detection of myoepithelial cells in breast fine–needle aspirates. Masood S, et al. **Diagn Cytopathol** 1995 Jul; 13(1):71–4
Heterogeneity in the progeny of single human muscle satellite cells. Baroffio A, et al. **Differentiation** 1995 Nov; 59(4):259–68
Desmin expressing nonhematopoietic liver cells during rat liver development: an immunohistochemical and morphometric study. Kiassov AP, et al. **Differentiation** 1995 Nov;59(4):253–8
Detection of beta–actin mRNA by RT–PCR in normal and regenerating chicken cochleae. Lee KH, et al.
Hear Res 1995 Jul;87(1–2):9–15
Immunocytochemical localisation of actin and profilin in the generative cell of angiosperm pollen: TEM studies on high–pressure frozen and freeze–substituted Ledebouria socialis Roth (Hyacinthaceae). Hess MW, et al.
Histochem Cell Biol 1995 Dec;104(6):443–51
Characterization and immunocytochemical localization of actin and fibronectin in haemocytes of the mussel Mytilus galloprovincialis. Panara F, et al. **Histochem J** 1996 Feb; 28(2):123–31
Vascular smooth muscle alpha–actin distribution around endometrial arterioles during the menstrual cycle: increased expression during the perimenopause and lack of correlation with menorrhagia. Abberton KM, et al.
Hum Reprod 1996 Jan;11(1):204–11
Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB–1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Amada S, et al. **Int J Gynecol Pathol** 1995 Apr;14(2):134–42
Determination of the protein components of native thin filaments isolated from natural actomyosin: nebulin and alpha–actinin are associated with actin filaments. Meng Y, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):422–7
Synthetic lethality screen identifies a novel yeast myosin I gene (MYO5): myosin I proteins are required for polarization of the actin cytoskeleton. Goodson HV, et al.
J Cell Biol 1996 Jun;133(6):1277–91
Actin organization, bristle morphology, and viability are affected by actin capping protein mutations in Drosophila. Hopmann R, et al. **J Cell Biol** 1996 Jun;133(6):1293–305
Changes in cytoskeletal actin content, F–actin distribution, and surface morphology during HL–60 cell volume regulation. Hallows KR, et al. **J Cell Physiol** 1996 Apr; 167(1):60–71
S100, alpha–smooth muscle actin and cytokeratin 19 immunohistochemistry in odontogenic and soft tissue myxomas. Lombardi T, et al. **J Clin Pathol** 1995 Aug; 48(8):759–62
Bifunctional protein cross–linking reagents improve labeling of cytoskeletal proteins for qualitative and quantitative fluorescence microscopy. Safiejko–Mroczka B, et al.
J Histochem Cytochem 1996 Jun;44(6):641–56
Cytoskeletal disruption in A6 kidney cells: impact on endo/exocytosis and NaCl transport regulation by antidiuretic hormone. Verrey F, et al. **J Membr Biol** 1995 May;145(2):193–204
Fluorescence polarization study of the rigor complexes formed at different degrees of saturation of actin filaments with myosin subfragment–1. Andreev OA, et al.
J Muscle Res Cell Motil 1995 Aug;16(4):353–67
Localization of actin and myosin in Cryptosporidium parvum using immunogold staining. Yu JR, et al.
Korean J Parasitol 1995 Sep;33(3):155–64
Bleb formation and F–actin distribution during mitosis and tumor necrosis factor–induced apoptosis. Laster SM, et al.
Microsc Res Tech 1996 Jun 15;34(3):272–80
The actin–related protein Act3p of Saccharomyces cerevisiae is located in the nucleus. Weber V, et al.
Mol Biol Cell 1995 Oct;6(10):1263–70
Contractile protein system in the asexual stages of the malaria parasite Plasmodium falciparum. Webb SE, et al.
Parasitology 1996 May;112 (Pt 5):451–7
Mandibular osteosarcoma with unusual expression of alpha–actin smooth muscle antibody. Remadi S, et al.
Pathol Res Pract 1996 Feb;192(2):148–53
Improved methods for preserving macromolecular structures and visualizing them by fluorescence and scanning electron microscopy. Bell PB Jr, et al. **Scanning Microsc** 1995 Sep; 9(3):843–57; discussion 858–60
Identification of two types of smooth muscle cells from rabbit urinary bladder. Lau CL, et al. **Tissue Cell** 1996 Jun; 28(3):339–55
A case with small cell carcinoma of the lung expressing alpha–smooth muscle actin. Sassa K, et al. **Tumori** 1995 Nov–Dec;81(6):475–6

ANTAGONISTS & INHIBITORS

Antagonistic regulation of tight junction dynamics by glucocorticoids and transforming growth factor-beta in mouse mammary epithelial cells. Woo PL, et al. **J Biol Chem** 1996 Jan 5;271(1):404–12

Delay of HeLa cell cleavage into interphase using dihydrocytochalasin B: retention of a postmitotic spindle and telophase disc correlates with synchronous cleavage recovery. Martineau SN, et al. **J Cell Biol** 1995 Oct; 131(1):191–205

BIOSYNTHESIS

Lung fibroblast alpha-smooth muscle actin expression and contractile phenotype in bleomycin-induced pulmonary fibrosis. Zhang HY, et al. **Am J Pathol** 1996 Feb; 148(2):527–37

Decrease in actin gene expression in melanoma cells compared to melanocytes is partly counteracted by BrdU-induced cell adhesion and antagonized by L-tyrosine induction of terminal differentiation. Gómez LA, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):84–9

The serum response factor (SRF) is needed for muscle-specific activation of CArG boxes. Soulez M, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):418–22

Smooth muscle myosin II and alpha smooth muscle actin expression in the baboon (Papio anubis) uterus is associated with glandular secretory activity and stromal cell transformation. Christensen S, et al. **Biol Reprod** 1995 Sep; 53(3):598–608

Regulation of actin and tubulin gene expression by thyroid hormone during rat brain development. Poddar R, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):111–8

Expression of alpha SM actin in terrestrial ectothermic vertebrates. Di Rosa I, et al. **Cell Tissue Res** 1995 Sep; 281(3):501–5

Comparison of the cell cycle regulated synthesis and phosphorylation of stress proteins, actin isoforms and a novel actin-like protein following drug administration in cultured rat lymphocytes. Pipkin JL, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):549–59

Developmental and tissue-specific regulation of the murine cardiac actin gene in vivo depends on distinct skeletal and cardiac muscle-specific enhancer elements in addition to the proximal promoter. Biben C, et al. **Dev Biol** 1996 Jan 10;173(1):200–12

Expression of the actin gene family in embryos of the sea urchin Lytechinus pictus. Fang H, et al. **Dev Biol** 1996 Jan 10;173(1):306–17

Smooth muscle alpha-actin downregulation in cultured chick aortic smooth muscle and neural crest cells is associated with altered cell shape. Mishima N, et al. **Exp Cell Res** 1996 Apr 10;224(1):204–7

Transforming growth factor-beta 1 induces alpha-smooth muscle-actin expression in cultured human and monkey trabecular meshwork. Tamm ER, et al. **Exp Eye Res** 1996 Apr;62(4):389–97

Fimbrin expression in the developing rat cochlea. Zine A, et al. **Hear Res** 1995 Jul;87(1–2):165–9

Actin cytoskeletal isoforms in human endothelial cells in vitro: alteration with cell passage. Galustian C, et al. **In Vitro Cell Dev Biol Anim** 1995 Nov;31(10):796–802

Escherichia coli cytotoxic necrotizing factor 1: evidence for induction of actin assembly by constitutive activation of the p21 Rho GTPase. Fiorentini C, et al. **Infect Immun** 1995 Oct;63(10):3936–44

Activation of smooth muscle alpha-actin promoter in ras-transformed cells by treatments with antimitotic agents: correlation with stimulation of SRF:SRE mediated gene transcription. Kumar CC, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1285–92

Formation of actin filament bundles in the ring canals of developing Drosophila follicles. Tilney LG, et al. **J Cell Biol** 1996 Apr;133(1):61–74

Myosin II filament assemblies in the active lamella of fibroblasts: their morphogenesis and role in the formation of actin filament bundles. Verkhovsky AB, et al. **J Cell Biol** 1995 Nov;131(4):989–1002

Changes in beta-actin mRNA expression in remodeling canine myocardium. Carlyle WC, et al. **J Mol Cell Cardiol** 1996 Jan;28(1):53–63

High glucose alters actin assembly in glomerular mesangial and epithelial cells. Zhou X, et al. **Lab Invest** 1995 Sep; 73(3):372–83

end5, end6, and end7: mutations that cause actin delocalization and block the internalization step of endocytosis in Saccharomyces cerevisiae. Munn AL, et al. **Mol Biol Cell** 1995 Dec;6(12):1721–42

A Drosophila homolog of the Rac- and Cdc42-activated serine/threonine kinase PAK is a potential focal adhesion and focal complex protein that colocalizes with dynamic actin structures. Harden N, et al. **Mol Cell Biol** 1996 May; 16(5):1896–908

Cholecystokinin-B/gastrin receptors mediate rapid formation of actin stress fibers. Taniguchi T, et al. **Oncogene** 1996 Mar 21;12(6):1357–60

The arabidopsis ACT7 actin gene is expressed in rapidly developing tissues and responds to several external stimuli. McDowell JM, et al. **Plant Physiol** 1996 Jul;111(3):699–711

BLOOD

Association of localized Ca2+ gradients with redistribution of glycoprotein IIb-IIIa and F-actin in activated human blood platelets. Ariyoshi H, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):230–5

Cell polarization as a possible mechanism of response termination. Model MA, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):516–21

Serial measurements of serum Gc-globulin in acetaminophen intoxication. Schiødt FV, et al. **Eur J Gastroenterol Hepatol** 1995 Jul;7(7):635–40

Direct measurement of neutrophil F-actin content in microvolume whole blood samples. Chen WY, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):325–31

Circulating alpha-actin in non-insulin-dependent diabetics with autonomic dysfunction. Prados J, et al. **Int J Cardiol** 1995 Sep;51(2):127–30

Actin filament barbed-end capping activity in neutrophil lysates: the role of capping protein-beta 2. DiNubile MJ, et al. **Mol Biol Cell** 1995 Dec;6(12):1659–71

CHEMISTRY

Viscoelastic properties of F-actin solutions in the presence of normal and mutated actin-binding proteins. Janssen KP, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):183–9

Comparison of the effects of calponin and a 38-kDa caldesmon fragment on formation of the "strong-binding" state in ghost muscle fibers. Borovikov YS, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):240–4

Fluctuation analysis of myosin-coated bead movement along actin bundles of Nitella. Yamasaki H, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):831–6

Talin can crosslink actin filaments into both networks and bundles. Zhang J, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):530–7

Structural changes in subdomain 2 of G-actin observed by fluorescence spectroscopy. Moraczewska J, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):605–11

Effects of the type of divalent cation, Ca2+ or Mg2+, bound at the high-affinity site and of the ionic composition of the solution on the structure of F-actin. Strzelecka-Golaszewska H, et al. **Biochem J** 1996 Jun 15; 316 (Pt 3):713–21

Dilution beyond a transition concentration and the enhanced filaments' formation of actin in the low ionic strength buffer. Ikkai T, et al. **Biochem Mol Biol Int** 1995 Dec; 37(6):1153–61

Identification of the disulfide-linked peptide in irreversibly sickled cell beta-actin. Bencsath FA, et al. **Biochemistry** 1996 Apr 9;35(14):4403–8

Cross-link between cys 374 and cys 10 of actin abolishes polymerizability and allows study of the properties of the "F-actin monomer". Heintz D, et al. **Biochemistry** 1996 Jan 9;35(1):258–65

Inhibition of smooth muscle actomyosin ATPase by caldesmon is associated with caldesmon-induced conformational changes in tropomyosin bound to actin. Horiuchi KY, et al. **Biochemistry** 1995 Dec 26; 34(51):16815–20

Purification and characterization of subtilisin cleaved actin lacking the segment of residues 43–47 in the DNase I binding loop. Kiessling P, et al. **Biochemistry** 1995 Nov 14;34(45):14834–42

Mutational analysis of the role of hydrophobic residues in the 338–348 helix on actin in actomyosin interactions. Miller CJ, et al. **Biochemistry** 1996 Mar 26;35(12):3670–6

The end of a polymerizing actin filament contains numerous ATP-subunit segments that are disconnected by ADP-subunits resulting from ATP hydrolysis. Pieper U, et al. **Biochemistry** 1996 Apr 9;35(14):4396–402

Polymorphism of F-actin assembly. 1. A quantitative phase diagram of F-actin. Suzuki A, et al. **Biochemistry** 1996 Apr 23;35(16):5238–44

Polymorphism of F-actin assembly. 2. Effects of barbed end capping on F-actin assembly. Suzuki A, et al. **Biochemistry** 1996 Apr 23;35(16):5245–9

Strength and lifetime of the bond between actin and skeletal muscle alpha-actinin studied with an optical trapping technique. Miyata H, et al. **Biochim Biophys Acta** 1996 May 21;1290(1):83–8

Mg- and Ca-actin filaments appear virtually identical in steady-state as determined by dynamic light scattering. Scharf RE, et al. **Biochim Biophys Acta** 1995 Dec 6; 1253(2):129–32

Compressibility and specific volume of actin decrease upon G to F transformation. Suzuki N, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):265–72

Sequences of actin implicated in the polymerization process: a simplified mathematical approach to probe the role of these segments. Houmeida A, et al. **Biophys Chem** 1995 Nov;56(3):201–14

H2O2-treated actin: assembly and polymer interactions with cross-linking proteins. DalleDonne I, et al. **Biophys J** 1995 Dec;69(6):2710–9

F-actin, a model polymer for semiflexible chains in dilute, semidilute, and liquid crystalline solutions. Käs J, et al. **Biophys J** 1996 Feb;70(2):609–25

Conformational changes in subdomain 2 of G-actin: fluorescence probing by dansyl ethylenediamine attached to Gln-41. Kim E, et al. **Biophys J** 1995 Nov;69(5):2024–32

Myosin-induced changes in F-actin: fluorescence probing of subdomain 2 by dansyl ethylenediamine attached to Gln-41 Kim E, et al. **Biophys J** 1996 Mar;70(3):1439–46

Real time imaging of single fluorophores on moving actin with an epifluorescence microscope. Sase I, et al. **Biophys J** 1995 Aug;69(2):323–8

Preparation of bead-tailed actin filaments: estimation of the torque produced by the sliding force in an in vitro motility assay. Suzuki N, et al. **Biophys J** 1996 Jan;70(1):401–8

Interpreting photoactivated fluorescence microscopy measurements of steady-state actin dynamics. Tardy Y, et al. **Biophys J** 1995 Nov;69(5):1674–82

Deletion of amino acids from the carboxy-terminal end of actin. Xia D, et al. **Cell Motil Cytoskeleton** 1995; 32(3):163–72

The actin binding site of thymosin beta 4 mapped by mutational analysis. Van Troys M, et al. **EMBO J** 1996 Jan 15;15(2):201–10

Shear field mapping in actin networks by using magnetic tweezers. Schmidt FG, et al. **Eur Biophys J** 1996; 24(5):348–53

The stiffness of the crossbridge is a function of the intrinsic protein osmotic pressure generated by the crossbridge itself. Grazi E, et al. **FEBS Lett** 1996 Jun 3;387(2–3):101–4

Conformational changes in subdomain I of actin induced by proteolytic cleavage within the DNase I-binding loop: energy transfer from tryptophan to AEDANS. Kuznetsova I, et al. **FEBS Lett** 1996 Mar 25;383(1–2):105–8

Two identical hydrophobic clusters are present on the same actin monomer: interaction between one myosin subfragment-1 and two actin monomers. Labbé JP, et al. **FEBS Lett** 1995 Oct 16;373(3):221–4

Studies on the thermokinetic characterisation of actin polymerization and the effect of cisplatin. Zeng HH, et al. **Int J Biol Macromol** 1996 Apr;18(3):161–6

Conformational behaviour of a synthetic peptide of the C-terminus of villin that interacts with actin: an NMR, CD and stimulated annealing study. Simenel C, et al. **Int J Pept Protein Res** 1995 Jun;45(6):574–86

Actin-actin contact: chemical cross-linking between actin and the 2.6-kDa peptide from subdomain 4 of actin. Hori K, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1232–8

Crosslinking of a 28-residue N-terminal peptide of actin to myosin subfragment 1. Kunori S, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1239–47

Kinetics of association of myosin subfragment-1 to unlabeled and pyrenyl-labeled actin. Blanchoin L, et al. **J Biol Chem** 1996 May 24;271(21):12380–6

Integral repeats and a continuous coiled coil are required for binding of striated muscle tropomyosin to the regulated actin filament. Hitchcock-DeGregori SE, et al. **J Biol Chem** 1996 Feb 16;271(7):3600–3

Identification of the spectrin subunit and domains required for formation of spectrin/adducin/actin complexes. Li X, et al. **J Biol Chem** 1996 Jun 28;271(26):15695–702

Identification of contact sites in the actin-thymosin beta 4 complex by distance-dependent thiol cross-linking. Reichert A, et al. **J Biol Chem** 1996 Jan 19;271(3):1301–8

The polyelectrolyte nature of F-actin and the mechanism of actin bundle formation. Tang JX, et al. **J Biol Chem** 1996 Apr 12;271(15):8556–63

Structural changes in actin-tropomyosin during muscle regulation: computer modelling of low-angle X-ray diffraction data. al-Khayat HA, et al. **J Mol Biol** 1995 Oct 6;252(5):611–32

Microsecond rotational dynamics of actin: spectroscopic detection and theoretical simulation. Prochniewicz E, et al. **J Mol Biol** 1996 Jan 26;255(3):446–57

Cooperativity in F-actin: binding of gelsolin at the barbed end affects structure and dynamics of the whole filament. Prochniewicz E, et al. **J Mol Biol** 1996 Aug 2;260(5):756–66

Allostery, cooperativity, and different structural states in F-actin. Egleman EH, et al. **J Struct Biol** 1995 Sep-Oct; 115(2):159–62 (16 ref.)

Solving the structure of macromolecular complexes with the help of X-ray fiber diffraction diagrams. Holmes KC. **J Struct Biol** 1995 Sep-Oct;115(2):151–8

Molecular model of an actin filament capped by a severing protein. McGough A, et al. **J Struct Biol** 1995 Sep-Oct; 115(2):144–50

A discourse on modeling F-actin. Schutt CE, et al. **J Struct Biol** 1995 Sep-Oct;115(2):186–98 (69 ref.)

Proteins associated with purified human cytomegalovirus particles. Baldick CJ Jr, et al. **J Virol** 1996 Sep; 70(9):6097–105

Actin-related proteins in Anabaena spp. and Escherichia coli. Guerrero-Barrera AL, et al. **Microbiology** 1996 May;142 (Pt 5):1133–40

The ADF/cofilin proteins: stimulus-responsive modulators of actin dynamics. Moon A, et al. **Mol Biol Cell** 1995 Nov; 6(11):1423–31 (84 ref.)

Actin isoforms in the parasitic nematode Haemonchus contortus. Criado-Fornelio A, et al. **Parasitol Res** 1995; 81(8):700–2

Yeast actin: polymerization kinetic studies of wild type and a poorly polymerizing mutant. Buzan JM, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):91–5

Protein-protein interactions in the rigor actomyosin complex. Milligan RA. **Proc Natl Acad Sci U S A** 1996 Jan 9; 93(1):21–6 (31 ref.)

Actin. Sheterline P, et al. **Protein Profile** 1995;2(1):1–103 (2085 ref.)

Principles of chaperone-assisted protein folding: differences

between in vitro and in vivo mechanisms [see comments] Frydman J, et al. **Science** 1996 Jun 7;272(5267):1497–502 . Comment in: Science 1996 Jun 7;272(5267):1448–9.
[Statistics on actin globule chains, stretched by hydrogen bonds, and the Hill law in quantum mechanics theory of muscle contraction] Bespalova SV, et al. **Biofizika** 1996 Jan–Feb;41(1):22–32 (Eng. Abstr.) **(Rus)**
[Structural changes in actin filaments during binding with phosphofructokinase (F–protein), detected using an optical diffraction method] Podlubnaia ZA, et al. **Biofizika** 1996 Jan–Feb;41(1):73–7 (Eng. Abstr.) **(Rus)**
[The effect of phalloidin on stability of F– and G–actin] Vedenkina NS, et al. **Mol Biol (Mosk)** 1995 May–Jun; 29(3):597–602 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Calcium–independent effects of cadmium on actin assembly in mesangial and vascular smooth muscle cells. Wang Z, et al. **Cell Motil Cytoskeleton** 1996;33(3):208–22
Involvement of nitric oxide in permeability alteration and F–actin redistribution induced by phorbol myristate acetate in endothelial cells. Liu SM, et al. **Exp Cell Res** 1995 Dec; 221(2):289–93
Coactosin interferes with the capping of actin filaments. Röhrig U, et al. **FEBS Lett** 1995 Oct 30;374(2):284–6
Exposure of tumor necrosis factor–alpha to luminal membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation of actin. Deli MA, et al. **J Neurosci Res** 1995 Aug 15;41(6):717–26
The actin filament disrupter cytochalasin D activates the recombinant cystic fibrosis transmembrane conductance regulator Cl– channel in mouse 3T3 fibroblasts. Fischer H, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):745–54
Effect of maternal labor and mode of delivery on neutrophil actin response to N–formylmethionyl–leucyl–phenylalanine in healthy neonates. Chen WY, et al.
Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1996 Feb; 12(2):83–7
High glucose alters actin assembly in glomerular mesangial and epithelial cells. Zhou X, et al. **Lab Invest** 1995 Sep; 73(3):372–83
[The effect of calponin on the rate of actin filament movement] Borovikov IuS, et al. **Tsitologiia** 1996; 38(3):351–4 (Eng. Abstr.) **(Rus)**
[The effect of a caldesmon fragment with a mol. weight of 38 kDa and calponin on the capacity of actin to form a "strong" form of binding with myosin heads] Khoroshev MI, et al. **Tsitologiia** 1996;38(3):346–50 (Eng. Abstr.) **(Rus)**

GENETICS

SRF and TEF–1 control of chicken skeletal alpha–actin gene during slow–muscle hypertrophy. Carson JA, et al.
Am J Physiol 1996 Jun;270(6 Pt 1):C1624–33
Simultaneous amplification of four DNA repair genes and beta–actin in human lymphocytes by multiplex reverse transcriptase–PCR. Wei Q, et al. **Cancer Res** 1995 Nov 1;55(21):5025–9
Structural features and phylogeny of the actin gene of Chondrus crispus (Gigartinales, Rhodophyta). Bouget FY, et al. **Curr Genet** 1995 Jul;28(2):164–72
Isolation, characterization and chromosomal mapping of an actin gene from the primitive red alga Cyanidioschyzon merolae. Takahashi H, et al. **Curr Genet** 1995 Oct; 28(5):484–90
SpRunt–1, a new member of the runt domain family of transcription factors, is a positive regulator of the aboral ectoderm–specific CyIIIA gene in sea urchin embryos. Coffman JA, et al. **Dev Biol** 1996 Feb 25;174(1):43–54
Avian serum response factor expression restricted primarily to muscle cell lineages is required for alpha–actin gene transcription. Croissant JD, et al. **Dev Biol** 1996 Jul 10; 177(1):250–64
Spatial and temporal information processing in the sea urchin embryo: modular and intramodular organization of the CyIIIa gene cis–regulatory system. Kirchhamer CV, et al. **Development** 1996 Jan;122(1):333–48
Introns and protein revolution—an analysis of the exon/intron organisation of actin genes. Bagavathi S, et al. **FEBS Lett** 1996 Aug 19;392(1):63–5
An actin point–mutation neighboring the 'hydrophobic plug' causes defects in the maintenance of cell polarity and septum organization in the fission yeast Schizosaccharomyces pombe. Ishiguro J, et al.
FEBS Lett 1996 Sep 2;392(3):237–41
Cloning and characterization of the actin–encoding gene of Chlamydomonas reinhardtii. Sugase Y, et al. **Gene** 1996 Feb 2;168(1):117–21
Actin–encoding cDNAs and gene expression during the intermolt cycle of the Bermuda land crab Gecarcinus lateralis. Varadaraj K, et al. **Gene** 1996 Jun 1;171(2):177–84
Epigenetic effects on yeast transcription caused by mutations in an actin–related protein present in the nucleus. Jiang YW, et al. **Genes Dev** 1996 Mar 1;10(5):604–19
Cloning and sequence analysis of the mouse smooth muscle gamma–enteric actin gene. Szucsik JC, et al. **Genomics** 1995 Jul 20;28(2):154–62
Actin isoform and alpha 1B–adrenoceptor gene expression in aortic and coronary smooth muscle is influenced by cyclical stretch. Lundberg MS, et al.
In Vitro Cell Dev Biol Anim 1995 Sep;31(8):595–600
Activation of smooth muscle alpha–actin promoter in ras–transformed cells by treatments with antimitotic agents: correlation with stimulation of SRF:SRE mediated gene transcription. Kumar CC, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1285–92
Serum response factor mediates AP–1–dependent induction of the skeletal alpha–actin promoter in ventricular myocytes. Paradis P, et al. **J Biol Chem** 1996 May 3; 271(18):10827–33
Sequences, structural models, and cellular localization of the actin–related proteins Arp2 and Arp3 from Acanthamoeba. Kelleher JF, et al. **J Cell Biol** 1995 Oct;131(2):385–97
The actin gene from Cryptococcus neoformans: structure and phylogenetic analysis. Cox GM, et al.
J Med Vet Mycol 1995 Jul–Aug;33(4):261–6
Isolation of 88F actin mutants of Drosophila melanogaster and possible alterations in the mutant actin structures. An HS, et al. **J Mol Biol** 1996 Jul 26;260(4):492–505
Isolation, characterization and evolution of nine pufferfish (Fugu rubripes) actin genes. Venkatesh B, et al.
J Mol Biol 1996 Jun 21;259(4):655–65
Characterization of cardiac gene cis–regulatory elements in the early stages of chicken heart morphogenesis. Fisher SA, et al. **J Mol Cell Cardiol** 1996 Jan;28(1):113–22
The Giardia lamblia actin gene and the phylogeny of eukaryotes. Drouin G, et al. **J Mol Evol** 1995 Dec; 41(6):841–9
Control genes in reverse transcriptase–polymerase chain reaction assays. Lion T. **Leukemia** 1996 Sep;10(9):1527–8
Endothelin–1 induces an increase in total protein synthesis and expression of the smooth muscle alpha–actin gene in vascular smooth muscle cells. Andrawis NS, et al.
Life Sci 1996;59(7):523–8
Mapping of a replication origin within the promoter region of two unlinked, abundantly transcribed actin genes of Physarum polycephalum. Bénard M, et al.
Mol Cell Biol 1996 Mar;16(3):968–76
Hypothermia preserves expression of beta–actin mRNA in ischemic brain. Wu X, et al. **Neuroreport** 1995 Dec 29; 7(1):302–4
Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. Livak KJ, et al.
PCR Methods Appl 1995 Jun;4(6):357–62
A method for rapid generation of competitive standard molecules for RT–PCR avoiding the problem of competitor/probe cross–reactions. Ross R, et al.
PCR Methods Appl 1995 Jun;4(6):371–5
Conserved expression of the Arabidopsis ACT1 and ACT 3 actin subclass in organ primordia and mature pollen. An YQ, et al. **Plant Cell** 1996 Jan;8(1):15–30
Strong, constitutive expression of the Arabidopsis ACT2/ACT8 actin subclass in vegetative tissues. An YQ, et al. **Plant J** 1996 Jul;10(1):107–21
Sequence–based identification of T–DNA insertion mutations in Arabidopsis: actin mutants act2–1 and act4–1. McKinney EC, et al. **Plant J** 1995 Oct;8(4):613–22
Modular cis–regulatory organization of developmentally expressed genes: two genes transcribed territorially in the sea urchin embryo, and additional examples. Kirchhamer CV, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3; 93(18):9322–8 (67 ref.)
No effect of 60 Hz electromagnetic fields on MYC or beta–actin expression in human leukemic cells. Lacy–Hulbert A, et al. **Radiat Res** 1995 Oct;144(1):9–17
Human beta–actin retropseudogenes interfere with RT–PCR. Dirnhofer S, et al. **Trends Genet** 1995 Oct;11(10):380–1
Trans–activation of a cell housekeeping gene promoter by the IE1 gene product of baculoviruses. Lu M, et al.
Virology 1996 Apr 1;218(1):103–13

IMMUNOLOGY

Heat serum inactivation as a mandatory procedure for antiactin antibody detection in cell culture. Cançado EL, et al. **Hepatology** 1996 May;23(5):1098–104
Anti–actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA. Leibovitch L, et al. **Immunol Lett** 1995 Dec;48(2):129–32
Effect of a neuron–specific actin–binding protein, drebrin A, on cell–substratum adhesion. Ikeda K, et al.
Neurosci Lett 1995 Jul 21;194(3):197–200
[Serum smooth muscle antibodies with anti–actin specificity appeared during treatment with interferon alpha (letter)] Grimbert S, et al. **Gastroenterol Clin Biol** 1996;20(4):404–5 **(Fre)**

METABOLISM

Distribution pattern of F–actin, vimentin and alpha–tubulin in the bovine testis during postnatal development. Wrobel KH, et al. **Acta Anat (Basel)** 1995;153(4):263–72
Microfilament dynamics: regulation of actin polymerization by actin–fragmin kinase and phosphatases. Waelkens E, et al. **Adv Enzyme Regul** 1995;35:199–227 (60 ref.)
Early recovery of the actin cytoskeleton during renal ischemic injury in vivo. Kellerman PS, et al.
Am J Kidney Dis 1996 May;27(5):709–14
Changes in neutrophil actin and shape during sequestration induced by complement fragments in rabbits. Motosugi H, et al. **Am J Pathol** 1996 Sep;149(3):963–73
Electrophoretic analysis of contractile proteins of the diaphragm in chronically hypoxic rats. Mortola JP, et al.
Am J Physiol 1995 Sep;269(3 Pt 1):L371–6
Control of actin assembly at filament ends. Schafer DA, et al. **Ann Rev Cell Dev Biol** 1995;11:497–518 (143 ref.)
Ultrastructure of Psammobatis extenta (Rajidae) electrolytes and cytochemical localization of acetylcholinesterase, acetylcholine receptor and F–actin. Prado Figueroa M, et al. **Biocell** 1995 Aug;19(2):113–23
Profilin forms tetramers that bind to G–actin. Babich M, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):125–31
Comparison of the effects of calponin and a 38–kDa caldesmon fragment on formation of the "strong–binding" state in ghost muscle fibers. Borovikov YS, et al.
Biochem Biophys Res Commun 1996 Jun 14;223(2):240–4
Differential effects of retinoic acid (RA) and N–(4–hydroxyphenyl) retinamide (4–HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl–2, and actin expression in the human promyelocytic HL–60 leukemic cells. Dipietrantonio A, et al.
Biochem Biophys Res Commun 1996 Jul 25;224(3):837–42
The N–terminal sequences (5–20) of thymosin beta 4 binds to monomeric actin in an alpha–helical conformation. Feinberg J, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):127–32
The mechanism for mechanochemical energy transduction in actin–myosin interaction revealed by in vitro motility assay with ATP analogues. Higashi–Fujime S, et al.
Biochem Biophys Res Commun 1996 Apr 25;221(3):773–8
Elastic properties of single titin molecules made visible through fluorescent F–actin binding. Kellermayer MS, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):491–7
Direct binding of F actin to the cytoplasmic domain of the alpha 2 integrin chain in vitro. Kieffer JD, et al.
Biochem Biophys Res Commun 1995 Dec 14;217(2):466–74
Inhibition of vanadate–induced astrocytic stress fiber formation by C3 ADP–ribosyltransferase. Koyama Y, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):331–6
The neuronal EF–hand Ca(2+)–binding protein VILIP: interaction with cell membrane and actin–based cytoskeleton. Lenz SE, et al.
Biochem Biophys Res Commun 1996 Aug 23;225(3):1078–83
Identification of actin as a substrate of ICE and an ICE–like protease and involvement of an ICE–like protease but not ICE in VP–16–induced U937 apoptosis. Mashima T, et al.
Biochem Biophys Res Commun 1995 Dec 26;217(3):1185–92
Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. Miquel K, et al.
Biochem Biophys Res Commun 1996 Aug 23;225(3):869–76
Inhibitors of farnesyl and geranylgeranyl methyltransferases prevent beta 2 integrin–induced actin polymerization without affecting beta 2 integrin–induced Ca2+ signaling in neutrophils. Molony L, et al.
Biochem Biophys Res Commun 1996 Jun 25;223(3):612–7
Is actin polymerization relevant to neurosecretion? A study on neuroblastoma cells. Viviani B, et al.
Biochem Biophys Res Commun 1996 Jun 25;223(3):712–7
Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat–shock protein 27. Landry J, et al.
Biochem Cell Biol 1995 Sep–Oct;73(9–10):703–7 (42 ref.)
Modulation of gelsolin–induced actin–filament severing by caldesmon and tropomyosin and the effect of these proteins on the actin activation of myosin Mg(2+)–ATPase activity. Dąbrowska R, et al. **Biochem J** 1996 May 1;315 (Pt 3):753–9
Calponin induces actin polymerization at low ionic strength and inhibits depolymerization of actin filaments. Kake T, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):587–92
Na+/Pi co–transport alters rapidly cytoskeletal protein polymerization dynamics in opossum kidney cells. Papakonstanti EA, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):241–7
Acidic phospholipids inhibit the intramolecular association between the N– and C–terminal regions of vinculin, exposing actin–binding and protein kinase C phosphorylation sites. Weekes J, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):827–32
The influence of regulatory light chains on structural organization of cardiac myosin heads interacting with actin and ATP. Moczarska A, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):765–72
Interaction of purified protein kinase C with key proteins of energy metabolism and cellular motility. Reiss N, et al.
Biochem Mol Biol Int 1996 Apr;38(4):711–9
Rho, rac and cdc42 GTPases: regulators of actin structures, cell adhesion and motility. Nobes CD, et al.
Biochem Soc Trans 1995 Aug;23(3):456–9 (16 ref.)
Calmodulin regulation of utrophin actin binding. Winder SJ, et al. **Biochem Soc Trans** 1995 Aug;23(3):397S
Binding of heavy–chain and essential light–chain 1 of S1 to actin depends on the degree of saturation of F–actin filaments with S1. Andreev OA, et al. **Biochemistry** 1995 Nov 14;34(45):14829–33
The actin–binding protein hisactophilin binds in vitro to partially charged membranes and mediates actin coupling to membranes. Behrisch A, et al. **Biochemistry** 1995 Nov 21;34(46):15182–90
Role of the Dictyostelium 30 kDa protein in actin bundle formation. Furukawa R, et al. **Biochemistry** 1996 Jun 4; 35(22):7224–32
Chemomechanical transduction in the actomyosin molecular

motor by 2',3'-dideoxydidehydro-ATP and characterization of its interaction with myosin subfragment 1 in the presence and absence of actin. Gopal D, et al. **Biochemistry** 1996 Aug 6;35(31):10149-57

Cross-link between cys 374 and cys 10 of actin abolishes polymerizability and allows study of the properties of the "F-actin monomer". Heintz D, et al. **Biochemistry** 1996 Jan 9;35(1):258-65

Comparative studies of the monomeric and filamentous actin-myosin head complexes. Lheureux K, et al. **Biochemistry** 1995 Sep 12;34(36):11435-44

Functional significance of the binding of one myosin head to two actin monomers. Lheureux K, et al. **Biochemistry** 1995 Sep 12;34(36):11445-52

Characterization of calponin binding to actin. Lu FW, et al. **Biochemistry** 1995 Sep 19;34(37):11864-71

Light-directed generation of the actin-activated ATPase activity of caged heavy meromyosin. Marriott G, et al. **Biochemistry** 1996 Mar 12;35(10):3170-4

Purification and properties of a Ca(2+)-independent barbed-end actin filament capping protein, CapZ, from human polymorphonuclear leukocytes. Maun NA, et al. **Biochemistry** 1996 Mar 19;35(11):3518-24

Expressing functional domains of mouse calponin: involvement of the region around alanine 145 in the actomyosin ATPase inhibitory activity of calponin. el-Mezgueldi M, et al. **Biochemistry** 1996 Mar 26; 35(12):3654-61

Separation and characterization of the two functional regions of troponin involved in muscle thin filament regulation. Schaertl S, et al. **Biochemistry** 1995 Dec 12;34(49):15890-4

The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Wen D, et al. **Biochemistry** 1996 Jul 30;35(30):9700-9

Binding of S1(A1) and S1(A2) to F-actin. Xiao M, et al. **Biochemistry** 1996 Jan 16;35(2):523-30

A soluble motor from the alga Nitella supports fast movement of actin filaments in vitro. Rivolta MN, et al. **Biochim Biophys Acta** 1995 Nov 21;1232(1-2):1-4

Compressibility and specific volume of actin decrease upon G to F transformation. Suzuki N, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):265-72

Communicative interaction of myosins along an actin filament in the presence of ATP. Hatori K, et al. **Biophys Chem** 1996 Jun 11;60(3):149-52

Cross-bridge binding to actin and force generation in skinned fibers of the rabbit psoas muscle in the presence of antibody fragments against the N-terminus of actin. Brenner B, et al. **Biophys J** 1996 Jan;70(1):48-56

H2O2-treated actin: assembly and polymer interactions with cross-linking proteins. DalleDonne I, et al. **Biophys J** 1995 Dec;69(6):2710-9

The effect of genetically expressed cardiac titin fragments on in vitro actin motility. Li Q, et al. **Biophys J** 1995 Oct; 69(4):1508-18

Release of oxygen metabolites from chemoattractant-stimulated neutrophils is inhibited by resting platelets: role of extracellular adenosine and actin polymerization. Bengtsson T, et al. **Blood** 1996 May 15; 87(10):4411-23

Recombinant scinderin, an F-actin severing protein, increases calcium-induced release of serotonin from permeabilized platelets, an effect blocked by two scinderin-derived actin-binding peptides and phosphatidylinositol 4,5-bisphosphate. Marcu MG, et al. **Blood** 1996 Jan 1; 87(1):20-4

Evolutionarily conserved alternative pre-mRNA splicing regulates structure and function of the spectrin-actin binding domain of erythroid protein 4.1. Winardi R, et al. **Blood** 1995 Dec 1;86(11):4315-22

Expression of the adhesion molecule CD11b and polymerization of actin by polymorphonuclear granulocytes of patients endangered by sepsis. Brom J, et al. **Burns** 1995 Sep;21(6):427-31

DXR depresses the alpha-actinin-induced formation of actin bundles. Dalledonne I, et al. **Cancer Biochem Biophys** 1993 Sep;13(4):245-54

HSP27 phosphorylation-mediated resistance against actin fragmentation and cell death induced by oxidative stress. Huot J, et al. **Cancer Res** 1996 Jan 15;56(2):273-9

Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Symons M, et al. **Cell** 1996 Mar 8;84(5):723-34

Partial characterization of a putative 110 kDa myosin from the green alga Chara corallina by in vitro binding of fluorescent F-actin. Grolig F, et al. **Cell Biol Int** 1996 May; 20(5):365-73

The induction of protrusion by neomycin in human glioma cells is correlated with a decrease followed by an increase in filamentous actin. Safiejko-Mroczka B, et al. **Cell Biol Int** 1995 Aug;19(8):655-74

Living adult rat cardiomyocytes in culture: evidence for dissociation of costameric distribution of vinculin from costameric distributions of attachments. Imanaka-Yoshida K, et al. **Cell Motil Cytoskeleton** 1996;33(4):263-75

EJ-Ras inhibits phospholipase C gamma 1 but not actin polymerization induced by platelet-derived growth factor-BB via phosphatidylinositol 3-kinase. Heldman AW, et al. **Circ Res** 1996 Feb;78(2):312-21

EGF stimulates lamellipod extension in metastatic mammary adenocarcinoma cells by an actin-dependent mechanism. Segall JE, et al. **Clin Exp Metastasis** 1996 Jan;14(1):61-72

Microvillus assembly. Not actin alone. Fath KR, et al. **Curr Biol** 1995 Jun 1;5(6):591-3 (22 ref.)

Actin-membrane cytoskeletal dynamics in early sea urchin development. Bonder EM, et al. **Curr Top Dev Biol** 1995; 31:101-37 (131 ref.)

Occurrence and a possible mechanism of penetration of natural killer cells into K562 target cells during the cytotoxic interaction. Radošević K, et al. **Cytometry** 1995 Aug 1;20(4):273-80

Characterization of changes in F-actin during maturation of starfish oocytes. Heil-Chapdelaine RA, et al. **Dev Biol** 1996 Jul 10;177(1):204-16

Rac GTPase interacts with GAPs and target proteins through multiple effector sites. Diekmann D, et al. **EMBO J** 1995 Nov 1;14(21):5297-305

The actin binding site of thymosin beta 4 mapped by mutational analysis. Van Troys M, et al. **EMBO J** 1996 Jan 15;15(2):201-10

Neurothelin: amino acid sequence, cell surface dynamics and actin colocalization. Schlosshauer B, et al. **Eur J Cell Biol** 1995 Oct;68(2):159-66

Distribution of actin and tubulin in outer hair cells isolated from developing rat cochlea: a quantitative study. Vago P, et al. **Eur J Cell Biol** 1996 Apr;69(4):308-15

Autoregulation of actin synthesis by physiological alterations of the G-actin level in hepatocytes. Reuner KH, et al. **Eur J Clin Chem Clin Biochem** 1995 Sep;33(9):569-74

Physical association and functional relationship between protein kinase C zeta and the actin cytoskeleton. Gómez J, et al. **Eur J Immunol** 1995 Sep;25(9):2673-8

CD31-triggered rearrangement of the actin cytoskeleton in human natural killer cells. Poggi A, et al. **Eur J Immunol** 1996 Apr;26(4):817-24

Translocation of cortactin (p80/85) to the actin-based cytoskeleton during thrombin receptor-mediated platelet activation. Ozawa K, et al. **Exp Cell Res** 1995 Nov; 221(1):197-204

The Dictyostelium cytoskeleton. Noegel AA, et al. **Experientia** 1995 Dec 18;51(12):1135-43 (135 ref.)

Functional interaction of hexokinase with ATP requires participation by both small and large lobes of the enzyme: implications for other proteins using the actin fold as a nucleotide binding motif. Wilson JE, et al. **FASEB J** 1996 May;10(7):799-801

Does Vav bind to F-actin through a CH domain? Castresana J, et al. **FEBS Lett** 1995 Oct 30;374(2):149-51

ADP-ribosylation of Rho enhances actin polymerization-coupled shape oscillations in human neutrophils. Ehrengruber MU, et al. **FEBS Lett** 1995 Sep 25;372(2-3):161-4

The fastest actin-based motor protein from the green algae, Chara, and its distinct mode of interaction with actin. Higashi-Fujime S, et al. **FEBS Lett** 1995 Nov 13; 375(1-2):151-4

Dual role of tropomyosin on chemically modified actin filaments from skeletal muscle. Honda H, et al. **FEBS Lett** 1996 Mar 25;383(1-2):55-8

Human mineralocorticoid receptor interacts with actin under mineralocorticoid ligand modulation. Jalaguier S, et al. **FEBS Lett** 1996 Apr 15;384(2):112-6

Stress-induced tyrosine phosphorylation of actin in Dictyostelium cells and localization of the phosphorylation site to tyrosine-53 adjacent to the DNase I binding loop. Jungbluth A, et al. **FEBS Lett** 1995 Nov 13;375(1-2):87-90

Conformational changes in subdomain I of actin induced by proteolytic cleavage within the DNase I-binding loop: energy transfer from tryptophan to AEDANS. Kuznetsova I, et al. **FEBS Lett** 1996 Mar 25;383(1-2):105-8

Phase specific association of heterotrimeric GTP-binding proteins with the actin-based cytoskeleton during thrombin receptor-mediated platelet activation. Ozawa K, et al. **FEBS Lett** 1996 Mar 11;382(1-2):159-63

Dephosphorylated but not phosphorylated microtubule associated protein MAP1B binds to microfilaments. Pedrotti B, et al. **FEBS Lett** 1996 Jun 17;388(2-3):131-3

The ternary complex of DNase I, actin and thymosin beta4. Reichert A, et al. **FEBS Lett** 1996 Jun 3;387(2-3):132-6

Analysis of the catalytic site of the actin ADP-ribosylating Clostridium perfringens iota toxin. van Damme J, et al. **FEBS Lett** 1996 Feb 19;380(3):291-5

Insulin and ATP stimulate actin polymerization in U937 cells by a wortmannin-sensitive mechanism. Walters RJ, et al. **FEBS Lett** 1996 Aug 19;392(1):66-70

Sphingosine-1-phosphate inhibits actin nucleation and pseudopodium formation to control cell motility of mouse melanoma cells. Yamamura S, et al. **FEBS Lett** 1996 Mar 11;382(1-2):193-7

Protein kinase C and F-actin are essential for stimulation of neuronal FAK tyrosine phosphorylation by G-proteins and amyloid beta protein. Zhang C, et al. **FEBS Lett** 1996 May 20;386(2-3):185-8

Comparison of cytosolic levels of calcium and G actin in diffuse and localised adherent Escherichia coli-infected HeLa cells. Karmaker S, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2-3):245-9

Changes in actin cytoskeleton are involved in the cytopathic action of Candida albicans upon human skin fibroblasts. Marewicz E, et al. **Folia Histochem Cytobiol** 1995; 33(3):157-62

Specificity of single LIM motifs in targeting and LIM/LIM interactions in situ. Arber S, et al. **Genes Dev** 1996 Feb 1;10(3):289-300

Single amino acid mutations in Drosophila fascin disrupt actin bundling function in vivo. Cant K, et al. **Genetics** 1996 May;143(1):249-58

Endothelin-induced cytoskeletal actin re-organization in cultured astrocytes: inhibition by C3 ADP-ribosyltransferase. Koyama Y, et al. **Glia** 1996 Apr; 16(4):342-50

The rosette complex in gerbil Deiters cells contains gamma actin. Nakazawa K, et al. **Hear Res** 1995 Sep;89(1-2):121-9

Heat serum inactivation as a mandatory procedure for antiactin antibody detection in cell culture. Cançado EL, et al. **Hepatology** 1996 May;23(5):1098-104

Tyrosine-phosphorylated T cell receptor zeta chain associates with the actin cytoskeleton upon activation of mature T lymphocytes. Rozdzial MM, et al. **Immunity** 1995 Nov;3(5):623-33

Modification of actin in peritoneal macrophages after diazepam treatment. De Martino L, et al. **Immunopharmacol Immunotoxicol** 1995 Aug;17(3):551-64

Pathogenicity of the diffusely adhering strain Escherichia coli C1845: F1845 adhesin-decay accelerating factor interaction, brush border microvillus injury, and actin disassembly in cultured human intestinal epithelial cells. Bernet-Camard MF, et al. **Infect Immun** 1996 Jun; 64(6):1918-28

Gonococcal opacity protein promotes bacterial entry-associated rearrangements of the epithelial cell actin cytoskeleton. Grassmé HU, et al. **Infect Immun** 1996 May; 64(5):1621-30

Reconstitution of chemokine-induced actin polymerization in undifferentiated human leukemia cells (HL-60) by heterologous expression of interleukin-8 receptors. Norgauer J, et al. **Inflamm Res** 1996 Mar;45(3):127-31

ADP-ribosylation in adrenal glands: purification and characterization of mono-ADP-ribosyltransferases and ADP-ribosylhydrolase affecting cytoskeletal actin. Fujita H, et al. **Int J Biochem Cell Biol** 1995 Oct;27(10):1065-78

Assessment of f-actin organization and apical-basal polarity during in vivo cat endothelial wound healing. Petroll WM, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2492-502

Actin-actin contact: chemical cross-linking between actin and the 2.6-kDa peptide from subdomain 4 of actin. Hori K, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1232-8

F-actin bundling activity of Tetrahymena elongation factor 1 alpha is regulated by Ca2+/calmodulin. Kurasawa Y, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):791-8

Methanol traps the troponin-tropomyosin-actin complex in an "off-state". Matsuura Y, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1293-8

Myosin light chain kinase from vascular smooth muscle inhibits the ATP-dependent interaction between actin and myosin by binding to actin. Sato M, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):1-3

Enhancement of gamma-actin protein during liver regeneration: its accumulation in a region adjacent to the hepatocyte plasma membrane. Tanahashi T, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):355-63

Binding of phosphate, aluminum fluoride, or beryllium fluoride to F-actin inhibits severing by gelsolin. Allen PG, et al. **J Biol Chem** 1996 Mar 1;271(9):4665-70

Regulation of epithelial sodium channels by short actin filaments. Berdiev BK, et al. **J Biol Chem** 1996 Jul 26; 271(30):17704-10

Protein kinase C betaII specifically binds to and is activated by F-actin. Blobe GC, et al. **J Biol Chem** 1996 Jun 28; 271(26):15823-30

G alpha 12 and G alpha 13 stimulate Rho-dependent stress fiber formation and focal adhesion assembly. Buhl AM, et al. **J Biol Chem** 1995 Oct 20;270(42):24631-4

Tbeta 4 is not a simple G-actin sequestering protein and interacts with F-actin at high concentration. Carlier MF, et al. **J Biol Chem** 1996 Apr 19;271(16):9231-9

Syk tyrosine kinase is required for immunoreceptor tyrosine activation motif-dependent actin assembly. Cox D, et al. **J Biol Chem** 1996 Jul 12;271(28):16597-602

Cross-linking and fluorescence study of the COOH- and NH2-terminal domains of intact caldesmon bound to actin. Graceffa P. **J Biol Chem** 1995 Dec 15;270(50):30187-93

Integral repeats and a continuous coiled coil are required for binding of striated muscle tropomyosin to the regulated actin filament. Hitchcock-DeGregori SE, et al. **J Biol Chem** 1996 Feb 16;271(7):3600-3

A new function for adducin. Calcium/calmodulin-regulated capping of the barbed ends of actin filaments. Kuhlman PA, et al. **J Biol Chem** 1996 Apr 5;271(14):7986-91

Pasteurella multocida toxin, a potent intracellularly acting mitogen, induces p125FAK and paxillin tyrosine phosphorylation, actin stress fiber formation, and focal contact assembly in Swiss 3T3 cells. Lacerda HM, et al. **J Biol Chem** 1996 Jan 5;271(1):439-45

A kinase anchor protein 75 targets regulatory (RII) subunits of cAMP-dependent protein kinase II to the cortical actin cytoskeleton in non-neuronal cells. Li Y, et al. **J Biol Chem** 1996 Jul 12;271(28):16862-9

Activated phosphatidylinositol 3-kinase is sufficient to mediate actin rearrangement and GLUT4 translocation in 3T3-L1 adipocytes. Martin SS, et al. **J Biol Chem** 1996 Jul 26;271(30):17605-8

Phosphorylation of threonine 558 in the carboxyl-terminal actin-binding domain of moesin by thrombin activation of human platelets. Nakamura F, et al. **J Biol Chem** 1995 Dec 29;270(52):31377-85

Enzymatic characterization and functional domain mapping of brain myosin-V. Nascimento AAC, et al. **J Biol Chem** 1996 Jul 19;271(29):17561-9

Role of nucleotide exchange and hydrolysis in the function of profilin in action assembly. Perelroizen I, et al. **J Biol Chem** 1996 May 24;271(21):12302-9

Renal epithelial protein (Apx) is an actin cytoskeleton-regulated Na+ channel. Prat AG, et al. **J Biol Chem** 1996 Jul 26;271(30):18045-53

Identification of contact sites in the actin-thymosin beta 4 complex by distance-dependent thiol cross-linking. Reichert A, et al. **J Biol Chem** 1996 Jan 19;271(3):1301-8

Chimeric substitutions of the actin-binding loop activate dephosphorylated but not phosphorylated smooth muscle heavy meromyosin. Rovner AS, et al. **J Biol Chem** 1995 Dec 22;270(51):30260-3

Characterization of the actin cross-linking properties of the scruin-calmodulin complex from the acrosomal process of Limulus sperm. Sanders MC, et al. **J Biol Chem** 1996 Feb 2;271(5):2651-7

Sphingosylphosphorylcholine rapidly induces tyrosine phosphorylation of p125FAK and paxillin, rearrangement of the actin cytoskeleton and focal contact assembly. Requirement of p21rho in the signaling pathway. Seufferlein T, et al. **J Biol Chem** 1995 Oct 13; 270(41):24343-51

beta-Thymosins are not simple actin monomer buffering proteins. Insights from overexpression studies. Sun HQ, et al. **J Biol Chem** 1996 Apr 19;271(16):9223-30

Functional analysis of Shigella VirG domains essential for interaction with vinculin and actin-based motility. Suzuki T, et al. **J Biol Chem** 1996 Sep 6;271(36):21878-85

Actin polymerization induced by GTP gamma S in permeabilized neutrophils is induced and maintained by free barbed ends. Tardif M, et al. **J Biol Chem** 1995 Nov 24; 270(47):28075-83

Src homologous and collagen (Shc) protein binds to F-actin and translocates to the cytoskeleton upon nerve growth factor stimulation in PC12 cells. Thomas D, et al. **J Biol Chem** 1995 Dec 1;270(48):28924-31

The molecular nature of the F-actin binding activity of aldolase revealed with site-directed mutants. Wang J, et al. **J Biol Chem** 1996 Mar 22;271(12):6861-5

Phosphorylation of human fascin inhibits its actin binding and bundling activities. Yamakita Y, et al. **J Biol Chem** 1996 May 24;271(21):12632-8

Biochemical characterization of ezrin-actin interaction. Yao X, et al. **J Biol Chem** 1996 Mar 22;271(12):7224-9

Two separate functions are encoded by the carboxyl-terminal domains of the yeast cyclase-associated protein and its mammalian homologs. Dimerization and actin binding. Zelicof A, et al. **J Biol Chem** 1996 Jul 26;271(30):18243-52

Coordinated regulation of platelet actin filament barbed ends by gelsolin and capping protein. Barkalow K, et al. **J Cell Biol** 1996 Jul;134(2):389-99

Essential role of caldesmon in the actin filament reorganization induced by glucocorticoids. Castellino F, et al. **J Cell Biol** 1995 Dec;131(5):1223-30

Endocytosis of GPI-anchored proteins in human lymphocytes: role of glycolipid-based domains, actin cytoskeleton, and protein kinases. Deckert M, et al. **J Cell Biol** 1996 May;133(4):791-9

Actin filaments in yeast are unstable in the absence of capping protein or fimbrin. Karpova TS, et al. **J Cell Biol** 1995 Dec;131(6 Pt 1):1483-93

Chaperonin-mediated folding of actin and tubulin. Lewis SA, et al. **J Cell Biol** 1996 Jan;132(1-2):1-4 (32 ref.)

Axonal transport of mitochondria along microtubules and F-actin in living vertebrate neurons. Morris RL, et al. **J Cell Biol** 1995 Dec;131(5):1315-26

Identification and localization of an actin-binding motif that is unique to the epsilon isoform of protein kinase C and participates in the regulation of synaptic function. Prekeris R, et al. **J Cell Biol** 1996 Jan;132(1-2):77-90

beta-Catenin associates with the actin-bundling protein fascin in a noncadherin complex. Tao YS, et al. **J Cell Biol** 1996 Sep;134(5):1271-81

Movement of cortical actin patches in yeast. Waddle JA, et al. **J Cell Biol** 1996 Mar;132(5):861-70

Leukocyte adhesion to vascular endothelium induces E-selectin linkage to the actin cytoskeleton. Yoshida M, et al. **J Cell Biol** 1996 Apr;133(2):445-55

Recognition of two classes of oligoproline sequences in profilin-mediated acceleration of actin-based Shigella motility. Zeile WL, et al. **J Cell Biol** 1996 Apr;133(1):49-59

Actin polymerization in human eosinophils, unlike human neutrophils, depends on intracellular calcium mobilization. Elsner J, et al. **J Cell Physiol** 1996 Jun;167(3):548-55

Phalloidin unzips nebulin from thin filaments in skeletal myofibrils. Ao X, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3397-403

Alternatively spliced exons of the beta tropomyosin gene exhibit different affinities for F-actin and effects with nonmuscle caldesmon. Pittenger MF, et al. **J Cell Sci** 1995 Oct;108 (Pt 10):3253-65

beta-Scruin, a homologue of the actin crosslinking protein scruin, is localized to the acrosomal vesicle of Limulus sperm. Way M, et al. **J Cell Sci** 1995 Oct;108 (Pt 10):3155-62

Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport [see comments] Tripodi G, et al. **J Clin Invest** 1996 Jun 15;97(12):2815-22. Comment in: **J Clin Invest** 1996 Jun 15;97(12):2691.

Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. Guido M, et al. **J Hepatol** 1996 Mar; 24(3):301-7

Rapid oscillations of actin polymerization/depolymerization in polymorphonuclear leukocytes stimulated by leukotriene B4 and platelet-activating factor. Omann GM, et al. **J Immunol** 1995 Dec 1;155(11):5375-81

Modulation of a volume-regulated chloride current by F-actin. Levitan I, et al. **J Membr Biol** 1995 Oct; 147(3):283-94

Cooperativity in F-actin: binding of gelsolin at the barbed end affects structure and dynamics of the whole filament. Prochniewicz E, et al. **J Mol Biol** 1996 Aug 2;260(5):756-66

Thin filament activation by phalloidin in skinned cardiac muscle. Bukatina AE, et al. **J Mol Cell Cardiol** 1995 Jun; 27(6):1311-5

Actin interaction with purified dystrophin from electric organ of Torpedo marmorata: possible resemblance with filamin-actin interface. Lebart MC, et al. **J Muscle Res Cell Motil** 1995 Oct;16(5):543-52

2',3'-Cyclic nucleotide 3'-phosphodiesterase binds to actin-based cytoskeletal elements in an isoprenylation-independent manner. De Angelis DA, et al. **J Neurochem** 1996 Sep;67(3):943-51

Slow axonal transport of soluble actin with actin depolymerizing factor, cofilin, and profilin suggests actin moves in an unassembled form. Mills RG, et al. **J Neurochem** 1996 Sep;67(3):1225-34

Assembly of microfilaments and microtubules from axonally transported actin and tubulin after axotomy. Jacob JM, et al. **J Neurosci Res** 1996 Feb 15;43(4):412-9

Defective neutrophil actin polymerisation and chemotaxis in stressed newborns. Merry C, et al. **J Pediatr Surg** 1996 Apr;31(4):481-5

The subcellular localization of 17 beta-hydroxysteroid dehydrogenase type 4 and its interaction with actin. Markus M, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(5-6):617-21

Role of the actin cytoskeleton on epithelial Na+ channel regulation. Cantiello HF. **Kidney Int** 1995 Oct;48(4):970-84 (91 ref.)

Actin and villin compartmentation during ATP depletion and recovery in renal cultured cells. Golenhofen N, et al. **Kidney Int** 1995 Dec;48(6):1837-45

Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Gary R, et al. **Mol Biol Cell** 1995 Aug;6(8):1061-75

Identification of a cyclase-associated protein (CAP) homologue in Dictyostelium discoideum and characterization of its interaction with actin. Gottwald U, et al. **Mol Biol Cell** 1996 Feb;7(2):261-72

Organelle-cytoskeletal interactions: actin mutations inhibit meiosis-dependent mitochondrial rearrangement in the budding yeast Saccharomyces cerevisiae. Smith MG, et al. **Mol Biol Cell** 1995 Oct;6(10):1381-96

The Ras GTPase-activating-protein-related human protein IQGAP2 harbors a potential actin binding domain and interacts with calmodulin and Rho family GTPases. Brill S, et al. **Mol Cell Biol** 1996 Sep;16(9):4869-78

The EH-domain-containing protein Pan1 is required for normal organization of the actin cytoskeleton in Saccharomyces cerevisiae. Tang HY, et al. **Mol Cell Biol** 1996 Sep;16(9):4897-914

Mutations altering the mitochondrial-cytoplasmic distribution of Mod5p implicate the actin cytoskeleton and mRNA 3' ends and/or protein synthesis in mitochondrial delivery. Zoladek T, et al. **Mol Cell Biol** 1995 Dec; 15(12):6884-94

Regulation of vinculin binding to talin and actin by phosphatidyl-inositol-4-5-bisphosphate. Gilmore AP, et al. **Nature** 1996 Jun 6;381(6582):531-5

Myosin drives retrograde F-actin flow in neuronal growth cones. Lin CH, et al. **Neuron** 1996 Apr;16(4):769-82

Two actin binding proteins, actin depolymerizing factor and cofilin, are associated with Hirano bodies. Maciver SK, et al. **Neuroreport** 1995 Oct 23;6(15):1985-8

Delivery of membrane-impermeant fluorescent probes into living neural cell populations by lipotransfer. Barber K, et al. **Neurosci Lett** 1996 Mar 22;207(1):17-20

Tomato annexins p34 and p35 bind to F-actin and display nucleotide phosphodiesterase activity inhibited by phospholipid binding. Calvert CM, et al. **Plant Cell** 1996 Feb;8(2):333-42

Movement of yeast cortical actin cytoskeleton visualized in vivo. Doyle T, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):3886-91

Neurotrophins stimulate phosphorylation of synapsin I by MAP kinase and regulate synapsin I-actin interactions. Jovanovic JN, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3679-83

Cleavage of actin by interleukin 1 beta-converting enzyme to reverse DNase I inhibition. Kayalar C, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2234-8

The putative actin-binding role of hydrophobic residues Trp546 and Phe547 in chicken gizzard heavy meromyosin. Onishi H, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19; 92(26):11965-9

Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Rimm DL, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8813-7

Actin. Sheterline P, et al. **Protein Profile** 1995;2(1):1-103 (2085 ref.)

Rho returns: its targets in focal adhesions [comment] Bussey H. **Science** 1996 Jul 12;273(5272):203. Comment on: Science 1996 Jul 12;273(5272):245-8.

Cellular microbiology emerging. Cossart P, et al. **Science** 1996 Jan 19;271(5247):315-6 (22 ref.)

Pheromone response in yeast: association of Bem1p with proteins of the MAP kinase cascade and actin. Leeuw T, et al. **Science** 1995 Nov 17;270(5239):1210-3

Regulation of the actin cytoskeleton by inositol phospholipid pathways. Kandzari DE, et al. **Subcell Biochem** 1996; 26:97-114 (91 ref.)

Cellular factors mediate cadmium-dependent actin depolymerization. Wang Z, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):115-21

Actin binding and proteolysis by the baculovirus AcMNPV: the role of virion-associated V-CATH. Lanier LM, et al. **Virology** 1996 Feb 15;216(2):380-8

HIV-1 Gag protein associates with F-actin present in microfilaments. Rey O, et al. **Virology** 1996 Jun 15; 220(2):530-4

[Correlation between Ca2+-dependent movement of crosslinks in myosin filaments and Ca2+-sensitive actin-activated ATPase of skeletal muscle myosin] Podlubnaia ZA, et al. **Biofizika** 1996 Jan-Feb;41(1):58-63 (Eng. Abstr.) **(Rus)**

[Calponin inhibits the strong type of myosin binding with actin] Borovikov IuS, et al. **Biokhimiia** 1995 Oct; 60(10):1654-8 (Eng. Abstr.) **(Rus)**

[Effect of phosphorylating myosin light chains and ionic strength on actin-myosin interaction in a relaxed skeletal muscle fiber] Efimov NN, et al. **Biokhimiia** 1995 Nov; 60(11):1799-802 (Eng. Abstr.) **(Rus)**

[DNA-methylase activity in human cardiac muscle. Association of DNA methylase activity with actin protein fractions] Lopatina NG, et al. **Mol Biol (Mosk)** 1995 Jul-Aug;29(4):884-92 (Eng. Abstr.) **(Rus)**

[The effect of a caldesmon fragment with a mol. weight of 38 kDa and calponin on the capacity of actin to form a "strong" form of binding with myosin heads] Khoroshev MI, et al. **Tsitologiia** 1996;38(3):346-50 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Actin filaments stimulate the Na(+)-K(+)-ATPase. Cantiello HF. **Am J Physiol** 1995 Nov;269(5 Pt 2):F637-43

Effects on Ca(2+)-activated tension due to a synthetic NH2-terminal actin peptide in single skeletal muscle fibers. Metzger JM. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1193-9

Engineering actin-resistant human DNase I for treatment of cystic fibrosis. Ulmer JS, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8225-9

PHYSIOLOGY

Growth factors and the glomerulus: relationships between development and injury. Alpers CE, et al. **Adv Nephrol Necker Hosp** 1995;24:33-52 (85 ref.)

Is gamma-actin a regulator of amino acid transport? Lin G, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1647-55

Regulation of the cross-bridge transition from a weakly to strongly bound state in skinned rabbit muscle fibers. Regnier M, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1532-9

Constitutive expression of hepatocyte growth factor may maintain the sheet construction of gastric epithelial cells through facilitating actin-myosin contractile system. Takahashi M, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):40-6

The role of actin filament barbed-end exposure in cytoskeletal dynamics and cell motility. Barkalow K, et al. **Biochem Soc Trans** 1995 Aug;23(3):451-6 (40 ref.)

Different cardiac myosin isoforms exhibit equal force-generating ability in vitro. Sugiura S, et al. **Biochim Biophys Acta** 1996 Feb 15;1273(2):73-6

Force generation and work production by covalently cross-linked actin-myosin cross-bridges in rabbit muscle fibers. Bershitsky SY, et al. **Biophys J** 1995 Sep; 69(3):1011-21

Preparation of bead-tailed actin filaments: estimation of the torque produced by the sliding force in an in vitro motility assay. Suzuki N, et al. **Biophys J** 1996 Jan;70(1):401-8

Thrombin-induced GPIb-IX centralization on the platelet surface requires actin assembly and myosin II activation. Kovacsovics TJ, et al. **Blood** 1996 Jan 15;87(2):618-29

Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite. Dobrowolski JM, et al. **Cell** 1996 Mar 22;84(6):933-9

Actin-based cell motility and cell locomotion. Mitchison TJ, et al. **Cell** 1996 Feb 9;84(3):371-9 (76 ref.)

Differences in the motility of Amoeba proteus isolated fragments are determined by F-actin arrangement and cell nucleus presence. Grębecka L, et al. **Cell Biol Int** 1995 Oct;19(10):847-54

Cell cycle-dependent morphological changes in the actin cytoskeleton induced by agents which elevate cyclic AMP. McNamee CJ, et al. **Cell Biol Int** 1995 Sep;19(9):769-75

Actin-based motility of isolated axoplasmic organelles. Bearer EL, et al. **Cell Motil Cytoskeleton** 1996;33(2):106-14

F-actin forms transient perinuclear shells at the mitosis-interphase transition. Clubb BH, et al. **Cell Motil Cytoskeleton** 1996;33(2):151-62

Actin filaments in honeybee-flight muscle move collectively. Trombitás K, et al. **Cell Motil Cytoskeleton** 1995; 32(2):145-50

Actin cytoskeleton. Setting the pace of cell movement. Barkalow K, et al. **Curr Biol** 1995 Sep 1;5(9):1000-2 (11 ref.)

Actin cytoskeleton. Missing link for intracellular bacterial motility? Pollard TD. **Curr Biol** 1995 Aug 1;5(8):837-40

Molecular motors, membrane movements and physiology: emerging roles for myosins. Hasson T, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):587-94 (49 ref.)

Role of the actin cytoskeleton in early Drosophila development. Miller KG. **Curr Top Dev Biol** 1995; 31:167-96 (59 ref.)

A pathogenic bacterium triggers epithelial signals to form a functional bacterial receptor that mediates actin pseudopod formation. Rosenshine I, et al. **EMBO J** 1996 Jun 3;15(11):2613-24

Reorganization of actin microfilaments and microtubules in regenerating retinal pigment epithelium. Korte GE, et al. **Exp Eye Res** 1995 Aug;61(2):189-203

Stimulation of catecholamine secretion from adrenal chromaffin cells by 14-3-3 proteins is due to reorganisation of the cortical actin network. Roth D, et al. **FEBS Lett** 1995 Oct 23;374(1):77-81

A stringent role of F-actin in the ascogonial differentiation of Neurospora crassa fluffy mutant. Liu JW, et al. **Folia Microbiol (Praha)** 1995;40(6):665-8

Dependence of fibroblast migration on actin severing activity of gelsolin. Arora PD, et al. **J Biol Chem** 1996 Aug 23; 271(34):20516-23

P2U agonists induce chemotaxis and actin polymerization in human neutrophils and differentiated HL60 cells. Verghese MW, et al. **J Biol Chem** 1996 Jun 28; 271(26):15597-601

Heterogeneous distribution and organization of cytoskeletal proteins drive differential modulation of metabolic fluxes. Aon MA, et al. **J Cell Biochem** 1996 Feb;60(2):271-8

Overexpression of cofilin stimulates bundling of actin filaments, membrane ruffling, and cell movement in Dictyostelium. Aizawa H, et al. **J Cell Biol** 1996 Feb; 132(3):335-44

CDC42 and Rac1 control different actin-dependent processes in the Drosophila wing disc epithelium. Eaton S, et al. **J Cell Biol** 1995 Oct;131(1):151-64

The Saccharomyces cerevisiae actin-related protein Arp2 is involved in the actin cytoskeleton. Moreau V, et al. **J Cell Biol** 1996 Jul;134(1):117-32

A function for filamentous alpha-smooth muscle actin: retardation of motility in fibroblasts. Rønnov-Jessen L, et al. **J Cell Biol** 1996 Jul;134(1):67-80

Ponticulin plays a role in the positional stabilization of pseudopods. Shutt DC, et al. **J Cell Biol** 1995 Dec;131(6 Pt 1):1495-506

Dominant negative effect of cytoplasmic actin isoproteins on cardiomyocyte cytoarchitecture and function. von Arx P, et al. **J Cell Biol** 1995 Dec;131(6 Pt 2):1759-73

Bordetella bronchiseptica dermonecrotizing toxin stimulates assembly of actin stress fibers and focal adhesions by modifying the small GTP-binding protein rho. Horiguchi Y, et al. **J Cell Sci** 1995 Oct;108 (Pt 10):3243-51

Lysophosphatidic acid-induced neurite retraction in PC12 cells: control by phosphoinositide-Ca2+ signaling and Rho. Tigyi G, et al. **J Neurochem** 1996 Feb;66(2):537-48

Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125FAK) in prostate carcinoma. Duncan MD, et al. **J Surg Res** 1996 Jun;63(1):359-63

Linear electric traction as an alternative model of the actin/myosin motor. Edmonds DT. **J Theor Biol** 1996 Mar 7;179(1):55-60

The ADF/cofilin proteins: stimulus-responsive modulators of actin dynamics. Moon A, et al. **Mol Biol Cell** 1995 Nov; 6(11):1423-31 (84 ref.)

Asymmetric distribution of the Listeria monocytogenes ActA protein is required and sufficient to direct actin-based motility. Smith GA, et al. **Mol Microbiol** 1995 Sep; 17(5):945-51

F-actin is involved in control of bovine cumulus expansion. Sutovský P, et al. **Mol Reprod Dev** 1995 Aug;41(4):521-9

Actin-based motility of vaccinia virus. Cudmore S, et al. **Nature** 1995 Dec 7;378(6557):636-8

Muscle. Hops, steps and jumps [news; comment] Surridge C. **Nature** 1995 Dec 14;378(6558):664. Comment on: Nature 1995 Dec 14;378(6558):748-51. Comment on: Nature 1995 Dec 14;378(6558):751-3.

Functional linkage of the cardiac ATP-sensitive K+ channel to the actin cytoskeleton. Furukawa T, et al. **Pflugers Arch** 1996 Feb;431(4):504-12

Particles move along actin filament bundles in nerve growth cones. Evans LL, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10954-8

Rho protein regulates tight junctions and perijunctional actin organization in polarized epithelia. Nusrat A, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10629-33

[Statistics on actin globule chains, stretched by hydrogen bonds, and the Hill law in quantum mechanics theory of muscle contraction] Bespalova SV, et al. **Biofizika** 1996 Jan-Feb;41(1):22-32 (Eng. Abstr.) **(Rus)**

[The interaction of actin with myosin in fast and slow muscles of the mouse] Borovikov IuS, et al. **Tsitologiia** 1996; 38(3):355-8 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Effects of ultraviolet B irradiation on cell-cell interaction; implication of morphological changes and actin filaments in irradiated cells. Maekawa TL, et al. **Clin Exp Immunol** 1996 Aug;105(2):389-96

ULTRASTRUCTURE

Changes in endothelial actin cytoskeleton in venules with time after histamine treatment. Baldwin AL, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1528-37

Control of actin assembly at filament ends. Schafer DA, et al. **Ann Rev Cell Dev Biol** 1995;11:497-518 (143 ref.)

Calponin induces actin polymerization at low ionic strength and inhibits depolymerization of actin filaments. Kake T, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):587-92

F-actin, a model polymer for semiflexible chains in dilute, semidilute, and liquid crystalline solutions. Käs J, et al. **Biophys J** 1996 Feb;70(2):609-25

Role of the cytoskeleton in the generation of spatial patterns in Tubifex eggs. Shimizu T. **Curr Top Dev Biol** 1995; 31:197-235 (57 ref.)

Heterogeneous responsiveness of the in situ rat vascular endothelial cells to mechanical stretching in vitro. Sugimoto K, et al. **Eur J Cell Biol** 1995 Sep;68(1):70-7

Organization of F-actin filaments in human glioma cell lines cultured on extracellular matrix proteins. Nagano N, et al. **J Neurooncol** 1996 Mar;27(3):215-24

Image analysis of helical objects: the Brandeis Helical Package. Owen CH, et al. **J Struct Biol** 1996 Jan-Feb; 116(1):167-75

Extensible and object-oriented system Eos supplies a new environment for image analysis of electron micrographs of macromolecules. Yasunaga T, et al. **J Struct Biol** 1996 Jan-Feb;116(1):155-60

Growth factor-induced actin reorganization in Swiss 3T3 cells. Ridley AJ. **Methods Enzymol** 1995;256:306-13

Microinjection of Rho and Rac into quiescent Swiss 3T3 cells. Ridley AJ. **Methods Enzymol** 1995;256:313-20

ACTION POTENTIALS

Monophasic action potential recordings during T-wave alternans in congenital long QT syndrome. Shimizu W, et al. **Am Heart J** 1996 Sep;132(3):699-701

Generation of slow wave type action potentials in the mouse small intestine involves a non-L-type calcium channel. Malysz J, et al. **Can J Physiol Pharmacol** 1995 Oct; 73(10):1502-11

The electrophysiology of rabbit hearts with left ventricular hypertrophy under normal and ischaemic conditions. Hicks MN, et al. **Cardiovasc Res** 1995 Aug;30(2):181-6

Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Kääb S, et al. **Circ Res** 1996 Feb;78(2):262-73

Signal-to-noise ratio enhancement of cardiac late potentials using ensemble correlation. Atarius R, et al. **IEEE Trans Biomed Eng** 1995 Nov;42(11):1132-7

Analysis of alternans in late potentials. Correlations between epicardial and body surface recordings. Romberg D, et al. **J Electrocardiol** 1995;28 Suppl:198-201

Effect of noise in maximum likelihood analysis of late potentials. Sörnmo L, et al. **J Electrocardiol** 1995;28 Suppl:50-3

Repolarization gradients derived by subtraction of monophasic action potential recordings in the human heart. Studies incorporating altered mechanical loading and ischemia. Taggart P, et al. **J Electrocardiol** 1995;28 Suppl:156-61 (25 ref.)

Advantages of using microfabricated extracellular electrodes for in vitro neuronal recording. Breckenridge LJ, et al. **J Neurosci Res** 1995 Oct 1;42(2):266-76

Proximal-to-distal facial amplitude ratios as predictors of facial nerve function after acoustic neuroma excision. Taha JM, et al. **J Neurosurg** 1995 Dec;83(6):994-8

Spontaneous excitations in the visual cortex: stripes, spirals, rings, and collective bursts. Fohlmeister C, et al. **Neural Comput** 1995 Sep;7(5):905-14

Computer analysis of monophasic action potentials: manual validation and clinically pertinent applications. Franz MR, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1666-78

Clinical application of a microcomputer system for analysis of monophasic action potentials. Yuan S, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):297-308

[Clinical importance of monophasic action potential registration in long QT syndrome] Merkely B, et al. **Orv Hetil** 1996 Feb 11;137(6):283-6 (Eng. Abstr.) **(Hun)**

[Midmotoraxonal reexcitation observed in a patient with hereditary motor and sensory neuropathy (HMSN) type IA] Hasegawa O, et al. **Rinsho Shinkeigaku** 1996 Jan; 36(1):65-7 (Eng. Abstr.) **(Jpn)**

[Splitting of the back edge of a propagating excitation pulse] Mornev OA, et al. **Biofizika** 1996 Jan-Feb;41(1):191-7 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

In vivo reversal of depolarizing neuromuscular blockade. Riker WF Jr, et al. **Arch Int Pharmacodyn Ther** 1995 Jul-Aug;330(1):90-101

Effect of gadolinium on stretch-induced changes in contraction and intracellularly recorded action- and afterpotentials of rat isolated atrium. Tavi P, et al. **Br J Pharmacol** 1996 May;118(2):407-13

Electrophysiological evidence for oxytocin receptors on sympathetic preganglionic neurones--an in vitro study on the neonatal rat. Desaulles E, et al. **Brain Res** 1995 Nov 13;699(1):139-42

Electrophysiological properties and their modulation by norepinephrine in the ambiguus neurons of the guinea pig. Nishimura Y, et al. **Brain Res** 1995 Dec 8;702(1-2):213-22

Age-related changes in electrophysiological responses to muscarinic receptor stimulation in rat myocardium. Su N, et al. **Can J Physiol Pharmacol** 1995 Oct;73(10):1430-6

Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes. Cheng J, et al. **Cardiovasc Res** 1996 Jun;31(6):963-74

Outward currents underlying repolarization in human atrial myocytes. Firek L, et al. **Cardiovasc Res** 1995 Jul;30(1):31-8

Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening. Grover GJ, et al. **Cardiovasc Res** 1995 Nov;30(5):731-8

Sympathomimetic modulation of load-dependent changes in the action potential duration in the in situ porcine heart. Horner SM, et al. **Cardiovasc Res** 1996 Jul;32(1):148-57

Negative dromotropic effects of class I antiarrhythmic drugs in anisotropic ventricular muscle. Iida M, et al. **Cardiovasc Res** 1996 Apr;31(4):640-50

The vulnerable period for low and high energy T-wave shocks: role of dispersion of repolarisation and effect of d-sotalol. Kirchhof PF, et al. **Cardiovasc Res** 1996 Jun; 31(6):953-62

Calcium and mechanically induced potentials in fibroblasts of rat atrium. Kiseleva I, et al. **Cardiovasc Res** 1996 Jul; 32(1):98-111

EMG spike trains of succinylcholine-induced fasciculations in myalgic patients. Poon PW, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jun; 101(3):206-10

Muscarinic receptors modulate the afterhyperpolarizing potential in neostriatal neurons. Pineda JC, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):271-7

Three distinct components of the negative inotropic action of lidocaine in dog Purkinje fiber. Pankucsi C, et al. **Gen Pharmacol** 1996 Jan;27(1):69-71

Effects of piperazine derivatives on the activity of frog skeletal muscle fibers. Radicheva N, et al. **Gen Pharmacol** 1995 Oct;26(6):1431-9

Nitroprusside suppresses cochlear potentials and outer hair cell responses. Chen C, et al. **Hear Res** 1995 Jul;87(1-2):1-8

Electromechanical effects of caffeine in failing human ventricular myocardium. Chang CY, et al. **Int J Cardiol** 1995 Jun 2;50(1):43-50

Excitable properties and underlying Na+ and K+ currents in neurons from the guinea-pig jugular ganglion. Christian EP, et al. **J Auton Nerv Syst** 1995 Dec 5;56(1-2):75-86

Selective Ik blocker almokalant exhibits class III--specific effects on the repolarization and refractoriness of the human heart: a study of healthy volunteers using right ventricular monophasic action potential recordings [see comments] Darpö B, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):530-40. Comment in: J Cardiovasc Pharmacol 1995 Oct;26(4):524-7.

Serotonin-induced changes in the excitability of cultured antennal-lobe neurons of the sphinx moth Manduca sexta. Mercer AR, et al. **J Comp Physiol [A]** 1996 Jan; 178(1):21-31

Evidence for the induction of repetitive action potentials in synaptosomes by K+-channel inhibitors: an analysis of plasma membrane ion fluxes. Tibbs GR, et al. **J Neurochem** 1996 Jul;67(1):389-97

Mechanism of alpha-2 adrenergic modulation of canine cardiac Purkinje action potential. Lee HC, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):597-606

Comparison of bidisomide, flecainide and dofetilide on action potential duration in isolated canine atria: effect of isoproterenol. Martin CL, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):154-62

Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle. Muraki K, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):555-63

Use of chloride blockers: a novel approach for cardioprotection against ischemia-reperfusion damage. Tanaka H, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):854-61

Osmo- and mechanosensitivity of the transient outward K+ current in a mammalian neuronal cell line. Schoenmakers TJ, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):419-30

Cellular mechanisms of 4-aminopyridine-induced synchronized after-discharges in the rat hippocampal slice. Traub RD, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):127-40

Regional differences in the negative inotropic effect of acetylcholine within the canine ventricle. Yang ZK, et al. **J Physiol (Lond)** 1996 May 1;492 (Pt 3):789-806

The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Cichon JV Jr, et al. **Laryngoscope** 1995 Feb;105(2):144-8

Role of inward and delayed rectifier currents in generation of early afterdepolarization in guinea pig ventricular

myocytes under K(+)-free or low K+ superfusion. Fan JS, et al. **Methods Find Exp Clin Pharmacol** 1996 Jan-Feb; 18(1):25-32

Frequency-dependent effect of ethanol on action potentials of frog skeletal muscle fibers. Oz M, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun;17(5):295-8

Further evidence on the contribution of GABAA receptors to the GABA-mediated inhibition of medial vestibular nucleus neurones in vitro. Hutchinson M, et al. **Neuroreport** 1995 Aug 21;6(12):1649-52

Excitatory amino acid-induced currents in rat septal cholinergic neurons in culture. Kumamoto E, et al. **Neuroscience** 1995 Nov;69(2):477-93

Chronic corticosterone treatment maintains synaptic activity of CA1 hippocampal pyramidal cells: acute high corticosterone administration increases action potential number. Birnstiel S, et al. **Synapse** 1995 Jun;20(2):117-24

Effects of the antihypoxic and neuroprotective drug, lubeluzole, on repolarization phase of canine heart assessed by monophasic action potential recording. Sugiyama A, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):109-14

Cholinergic effects on cat retina In vitro: changes in rod- and cone-driven b-wave and optic nerve response. Jurklies B, et al. **Vision Res** 1996 Mar;36(6):797-816

[Variability of antiarrhythmic drug action in prolonging action potential duration during various rates of heart action] Zakrzewski D, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):383-7 (20 ref.) **(Pol)**

PHYSIOLOGY

Human central neurocytoma cells show neuronal physiological properties in vitro. Patt S, et al. **Acta Neuropathol (Berl)** 1996;91(2):209-214

The role of the sarcolemma action potential in fatigue. Fuglevand AJ. **Adv Exp Med Biol** 1995;384:101-8 (56 ref.)

Human motor units studied by spike-triggered averaging and intraneural motor axon stimulation. Thomas CK. **Adv Exp Med Biol** 1995;384:147-60 (75 ref.)

Generator sources for the early and late ulnar hypothenar premotor potentials: short segment electrophysiologic studies and cadaveric dissection. Park TA, et al. **Arch Phys Med Rehabil** 1996 May;77(5):467-72

Determination of the precision of spike timing in the visual cortex of anaesthetised cats. Lestienne R. **Biol Cybern** 1996 Jan;74(1):55-61

Backpropagation of action potentials generated at ectopic axonal loci: hypothesis that axon terminals integrate local environmental signals. Pinault D. **Brain Res Brain Res Rev** 1995 Jul;21(1):42-92 (484 ref.)

Mechano-electrical feedback in ventricular myocardium. Franz MR. **Cardiovasc Res** 1996 Jul;32(1):15-24 (40 ref.)

Nitric oxide and prostacyclin modulate the alterations in cardiac action potential duration mediated by platelets during ischaemia. Goulielmos NV, et al. **Cardiovasc Res** 1995 Nov;30(5):788-98

The role of Na-Ca exchange current in the cardiac action potential. Janvier NC, et al. **Cardiovasc Res** 1996 Jul; 32(1):69-84 (74 ref.)

Electrical alternans and the onset of rate-induced pulsus alternans during acute regional ischaemia in the anaesthetised pig heart. Murphy CF, et al. **Cardiovasc Res** 1996 Jul;32(1):138-47

Ionic basis of the action potential prolongation in ventricular myocytes from Syrian hamsters with dilated cardiomyopathy. Thuringer D, et al. **Cardiovasc Res** 1996 May;31(5):747-57

High frequency discharge of a fraction (f) of motor unit action potential. Soichot P, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jun; 101(3):201-5

Development of the VIIIth nerve compound action potential evoked by low-intensity tone pips in the Mongolian gerbil. Huang JM, et al. **Hear Res** 1995 Aug;88(1-2):14-8

Computer simulation of epicardial potentials using a heart-torso model with realistic geometry. Weixue L, et al. **IEEE Trans Biomed Eng** 1996 Feb;43(2):211-7

Presynaptic excitability. Jackson MB. **Int Rev Neurobiol** 1995; 38:201-51 (296 ref.)

Excitable properties and underlying Na+ and K+ currents in neurons from the guinea-pig jugular ganglion. Christian EP, et al. **J Auton Nerv Syst** 1995 Dec 5;56(1-2):75-86

Action potential duration and force-frequency relationship in isolated rabbit, guinea pig and rat cardiac muscle. Szigligeti P, et al. **J Comp Physiol [B]** 1996;166(2):150-5

Diagnostic usefulness of activation-recovery interval for reciprocal ECG changes. Effects of regional myocardial cooling, warming, or coronary occlusion on epicardial electrograms in dogs. Ikeno E, et al. **J Electrocardiol** 1995 Jul;28(3):237-43

Involvement of cochlear efferent pathways in protective effects elicited with binaural loud sound exposure in cats. Rajan R. **J Neurophysiol** 1995 Aug;74(2):582-97

Frequency and loss dependence of the protective effects of the olivocochlear pathways in cats. Rajan R. **J Neurophysiol** 1995 Aug;74(2):598-615

Serial E-M and simulation study of presynaptic inhibition along a group Ia collateral in the spinal cord. Walmsley B, et al. **J Neurophysiol** 1995 Aug;74(2):616-23

Chemically mediated cross-excitation in rat dorsal root ganglia. Amir R, et al. **J Neurosci** 1996 Aug 1; 16(15):4733-41

Action potential initiation site depends on neuronal excitation. Melinek R, et al. **J Neurosci** 1996 Apr 15; 16(8):2585-91

Apical dendritic location of slow afterhyperpolarization current in hippocampal pyramidal neurons: implications for the integration of long-term potentiation. Sah P, et al. **J Neurosci** 1996 Aug 1;16(15):4537-42

Kinetics of stimulus-coupled secretion in dialyzed bovine chromaffin cells in response to trains of depolarizing pulses. Seward EP, et al. **J Neurosci** 1996 Jan 15;16(2):553-62

Synchronization of fast (30-40 Hz) spontaneous oscillations in intrathalamic and thalamocortical networks. Steriade M, et al. **J Neurosci** 1996 Apr 15;16(8):2788-808

Changes in action potential duration alter reliance of excitatory synaptic transmission on multiple types of Ca2+ channels in rat hippocampus. Wheeler DB, et al. **J Neurosci** 1996 Apr 1;16(7):2226-37

The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons. Wilson CJ, et al. **J Neurosci** 1996 Apr 1;16(7):2397-410

Sampling variation caused by A/D cards due to external trigger. Jaw FS, et al. **J Neurosci Methods** 1995 Nov; 62(1-2):175-8

Poisson-process electrical stimulation: circuit and axonal responses. Moradmand K, et al. **J Neurosci Methods** 1995 Dec;63(1-2):113-20

Spike-train acquisition, analysis and real-time experimental control using a graphical programming language (LabView). Nordstrom MA, et al. **J Neurosci Methods** 1995 Nov;62(1-2):93-102

A rapid correlation method for the analysis of spectro-temporal receptive fields of auditory neurons. Richard JP, et al. **J Neurosci Methods** 1995 Sep-Oct; 61(1-2):99-103

Electrical and morphological factors influencing the depolarizing after-potential in rat and lizard myelinated axons. David G, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):141-57

Effects of diaphragm shortening on the mean action potential conduction velocity in canines. Sinderby C, et al. **J Physiol (Lond)** 1996 Jan 1;490 (Pt 1):207-14

Na+ current and Ca2+ release from the sarcoplasmic reticulum during action potentials in guinea-pig ventricular myocytes. Sipido KR, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):1-17

Role of the steady-state Na+ channel current in pacemaker depolarizations in young embryonic chick ventricular myocytes. Sada H, et al. **Jpn J Pharmacol** 1995 Oct; 69(2):159-66

Does recurrent inhibition exist in the paraventricular magnocellular neurosecretory cells in the male rat? Ueta Y, et al. **Jpn J Physiol** 1995;45(5):913-9

Calcium-dependent afterhyperpolarization and learning in young and aging hippocampus. Disterhoft JF, et al. **Life Sci** 1996;59(5-6):413-20 (54 ref.)

The influence of the reference electrode on CMAP configuration: leg nerve observations and an alternative reference site [letter] Bilbao A, et al. **Muscle Nerve** 1996 Aug;19(8):1055-6

Cortical and spinal mechanisms of facilitation to brain stimulation. Mills KR, et al. **Muscle Nerve** 1996 Aug; 19(8):953-8

Primary cortical representation of sounds by the coordination of action-potential timing. deCharms RC, et al. **Nature** 1996 Jun 13;381(6583):610-3

Multiple spike-initiation zones in single neurons revealed by voltage-sensitive dyes. Zečević D. **Nature** 1996 May 23; 381(6580):322-5

Encoding with bursting, subthreshold oscillations, and noise in mammalian cold receptors. Longtin A, et al. **Neural Comput** 1996 Feb 15;8(2):215-55 (75 ref.)

Action potentials in axonless horizontal cells isolated from the rabbit retina. Blanco R, et al. **Neurosci Lett** 1996 Jan 12;203(1):57-60

Decompaction of CNS myelin leads to a reduction of the conduction velocity of action potentials in optic nerve. Gutiérrez R, et al. **Neurosci Lett** 1995 Aug 4;195(2):93-6

Basic concepts in cellular cardiac electrophysiology: Part I: Ion channels, membrane currents, and the action potential. Whalley DW, et al. **Pacing Clin Electrophysiol** 1995 Aug; 18(8):1556-74 (72 ref.)

Magnetic-evoked compound muscle action potential neuromonitoring in spine surgery. Kitagawa H, et al. **Spine** 1995 Oct 15;20(20):2233-9

[Developmental changes in the pacemaker current and membrane currents of the guinea pig myocardium] Shigenobu K, et al. **Nippon Yakurigaku Zasshi** 1996 Jun; 107(6):259-72 (48 ref.) (Eng. Abstr.) **(Jpn)**

[Emergence of minute rhythms of small intestinal smooth muscle spike activity during adaptation] Tropskaia NS, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):36-8 **(Rus)**

ACTIVATED CHARCOAL see **CHARCOAL**

ACTIVATED COAGULATION TIME, WHOLE BLOOD see **WHOLE BLOOD COAGULATION TIME**

ACTIVATED PARTIAL THROMBOPLASTIN TIME see **PARTIAL THROMBOPLASTIN TIME**

ACTIVATION ANALYSIS

METHODS

Proton activation analysis of stable isotopes for a molybdenum biokinetics study in humans. Cantone MC, et al. **Med Phys** 1995 Aug;22(8):1293-8

ACTIVATOR APPLIANCES

Combination of bionator and high-pull headgear therapy in a skeletal open bite case. Closs L, et al. **Am J Orthod Dentofacial Orthop** 1996 Apr;109(4):341-7

Maxillary and cranial base changes during treatment with functional appliances. Courtney M, et al. **Am J Orthod Dentofacial Orthop** 1996 Jun;109(6):616-24

Orthodontic and orthopedic effects of Activator, Activator-HG combination, and Bass appliances: a comparative study. Cura N, et al. **Am J Orthod Dentofacial Orthop** 1996 Jul;110(1):36-45

Active vertical corrector treatment—long-term follow-up of anterior open bite treated by the intrusion of posterior teeth. Dellinger EL, et al. **Am J Orthod Dentofacial Orthop** 1996 Aug;110(2):145-54

The correction of interarch malocclusions using a fixed force module. Jasper JJ, et al. **Am J Orthod Dentofacial Orthop** 1995 Dec;108(6):641-50

Effects of buccal shields on the maxillary dentoalveolar structures and the midpalatal suture--histologic and biometric studies in rabbits. Kalogirou K, et al. **Am J Orthod Dentofacial Orthop** 1996 May;109(5):521-30

Treatment of Class II malocclusions with the Jasper Jumper appliance--a preliminary report. Weiland FJ, et al. **Am J Orthod Dentofacial Orthop** 1995 Oct;108(4):341-50

Treatment of a Class II, Division 1 malocclusion with the Jasper Jumper: a case report. Weiland FJ, et al. **Am J Orthod Dentofacial Orthop** 1996 Jan;109(1):1-7

Treatment needs following activator-headgear therapy. Bondevik O. **Angle Orthod** 1995;65(6):417-22

Changes in soft tissue profile following treatment with the bionator. Lange DW, et al. **Angle Orthod** 1995;65(6):423-30

Follow-up of electromyographic and cephalometric findings in patients with unilateral cleft lip and palate after fifteen months of continuous wearing of a special removable appliance. Carvajal R, et al. **Cleft Palate Craniofac J** 1995 Jul;32(4):323-7

A cephalometric investigation of the effects of the Elastic Bite-block in the treatment of Class II division 1 malocclusions. Erverdi N, et al. **Eur J Orthod** 1995 Oct; 17(5):375-84

Functional therapy in hemifacial microsomia: therapeutic protocol for growing children. Silvestri A, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):271-8; discussion 278-80

[Fractures of the mandibular collum in childhood--a long-term follow-up with orthopantomography] Röthler G, et al. **Fortschr Kiefer Gesichtschir** 1996;41:146-7 (Eng. Abstr.) **(Ger)**

[The dental and skeletal changes in early Class II treatment with a Klammt open activator] Eckardt L, et al. **Fortschr Kieferorthop** 1995 Nov;56(6):339-46 (Eng. Abstr.) **(Ger)**

ACTIVE LEARNING see **PROBLEM-BASED LEARNING**

ACTIVE SITE see **BINDING SITES**

ACTIVE TRANSPORT see **BIOLOGICAL TRANSPORT, ACTIVE**

ACTIVITIES OF DAILY LIVING

see related
SICKNESS IMPACT PROFILE

Activity levels and cognitive functioning in an elderly community sample. Christensen H, et al. **Age Ageing** 1996 Jan;25(1):72-80

Reliability of the revised functional autonomy measurement system (SMAF) for epidemiological research. Desrosiers J, et al. **Age Ageing** 1995 Sep;24(5):402-6

Is medication use by community-dwelling elderly people influenced by cognitive function? Hanlon JT, et al. **Age Ageing** 1996 May;25(3):190-6

The Barthel ADL index: factor structure depends upon the category of patient. Laake K, et al. **Age Ageing** 1995 Sep; 24(5):393-7

The Barthel ADL index one year after stroke: comparison between relatives' and occupational therapist's scores. Wyller TB, et al. **Age Ageing** 1995 Sep;24(5):398-401

The Adelaide Activities Profile: a measure of the life-style activities of elderly people. Clark MS, et al. **Aging (Milano)** 1995 Aug;7(4):174-84

Development of a hierarchical activities of daily living scale for Chinese stroke patients in geriatric day hospitals. Kong TK, et al. **Aging (Milano)** 1995 Jun;7(3):173-8

The Timed Test of Money Counting: a simple method of recognizing geriatric patients at risk for increased health care. Nikolaus T, et al. **Aging (Milano)** 1995 Jun;7(3):179-83

Quantifying functional ability to predict health-care use of elderly persons. Nikolaus T, et al. **Aging (Milano)** 1995 Jun; 7(3):258-60

Increased heart rate response to laboratory-induced mental

stress predicts frequency and duration of daily life ambulatory myocardial ischemia in patients with coronary artery disease. Krittayaphong R, et al. **Am J Cardiol** 1995 Oct 1;76(10):657–60

Relation of patient characteristics to cardiac ischemia during daily life activity (an Asymptomatic Cardiac Ischemia Pilot Data Bank Study). Pepine CJ, et al. **Am J Cardiol** 1996 Jun 15;77(15):1267–72

A specific activity questionnaire to measure the functional capacity of cardiac patients. Rankin SL, et al. **Am J Cardiol** 1996 Jun 1;77(14):1220–3

Analysis of change in self-reported physical function among older persons in four population studies. Beckett LA, et al. **Am J Epidemiol** 1996 Apr 15;143(8):766–78

Exercise, employment, other daily activities, and adverse pregnancy outcomes. Schramm WF, et al. **Am J Epidemiol** 1996 Feb 1;143(3):211–8

Successful aging: predictors and associated activities. Strawbridge WJ, et al. **Am J Epidemiol** 1996 Jul 15; 144(2):135–41

Assessment tools: functional health status and patient satisfaction. Ware JE Jr, et al. **Am J Med Qual** 1996 Spring; 11(1):S50–3

Effects of afternoon rest on the performance of geriatric patients in a rehabilitation hospital;: a pilot study. Creighton C. **Am J Occup Ther** 1995 Sep;49(8):775–9

Pulse oximetry for an adult with a pulmonary disorder. Hogan BM. **Am J Occup Ther** 1995 Nov–Dec; 49(10):1062–4

Sexual orientation: its relevance to occupational science and the practice of occupational therapy. Jackson J. **Am J Occup Ther** 1995 Jul–Aug;49(7):669–79

Functional considerations in evaluation and treatment of the client with low vision. Lampert J, et al. **Am J Occup Ther** 1995 Oct;49(9):885–90

Assistive devices used by home-based elderly persons with arthritis. Mann WC, et al. **Am J Occup Ther** 1995 Sep; 49(8):810–20

Living with low vision: a personal and professional perspective. Rosenthal SB. **Am J Occup Ther** 1995 Oct; 49(9):861–4

Adaptation to macular scotomas in persons with low vision. Schuchard RA. **Am J Occup Ther** 1995 Oct;49(9):870–6

Telephone and in-person proxy agreement between stroke patients and caregivers for the functional independence measure. Segal ME, et al. **Am J Phys Med Rehabil** 1996 May–Jun;75(3):208–12

Outdoor winter activities of spinal cord-injured patients. With special reference to outdoor mobility. Shirado O, et al. **Am J Phys Med Rehabil** 1995 Nov–Dec;74(6):408–14

ADL structure for stroke patients in Japan based on the functional independence measure. Tsuji T, et al. **Am J Phys Med Rehabil** 1995 Nov–Dec;74(6):432–8

Disability in geriatric depression. Alexopoulos GS, et al. **Am J Psychiatry** 1996 Jul;153(7):877–85

The loss of independence in activities of daily living: the role of low normal cognitive function in elderly nuns. Greiner PA, et al. **Am J Public Health** 1996 Jan;86(1):62–6

Health and activity after intensive care. Munn J, et al. **Anaesthesia** 1995 Dec;50(12):1017–21

Survival and functional independence after implantation of a permanent pacemaker in octogenarians and nonagenarians. A population-based study. Shen WK, et al. **Ann Intern Med** 1996 Sep 15;125(6):476–80

Functional performance in people with chronic obstructive pulmonary disease: a qualitative analysis. Leidy NK, et al. **ANS Adv Nurs Sci** 1996 Mar;18(3):77–89

Pediatric Functional Independence Measure: clinical trials with disabled and nondisabled children. McCabe MA. **Appl Nurs Res** 1996 Aug;9(3):136–8

Generalizability of the Preoperative Self-Efficacy Scale. Oetker-Black SL. **Appl Nurs Res** 1996 Feb;9(1):40–4

Functional outcomes of acute medical illness and hospitalization in older persons. Sager MA, et al. **Arch Intern Med** 1996 Mar 25;156(6):645–52

The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I–II Study Group. **Arch Neurol** 1996 Feb;53(2):141–7

Development of the Tinnitus Handicap Inventory. Newman CW, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb; 122(2):143–8

Differences between persons with right or left cerebral vascular accident on the Assessment of Motor and Process Skills. Bernspång B, et al. **Arch Phys Med Rehabil** 1995 Dec;76(12):1144–51

Standing balance and function over the course of acute rehabilitation. Bohannon RW, et al. **Arch Phys Med Rehabil** 1995 Nov;76(11):994–6

Functional outcome in brain stem stroke patients after rehabilitation. Chua KS, et al. **Arch Phys Med Rehabil** 1996 Feb;77(2):194–7

Recombinant human erythropoietin: effect on the functional performance of anemic orthopedic patients. Green D, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3):242–6

Maximal effort during functional capacity evaluations: an examination of psychological factors. Kaplan GM, et al. **Arch Phys Med Rehabil** 1996 Feb;77(2):161–4

Validation of a neurobehavioral functioning inventory for adults with traumatic brain injury. Kreutzer JS, et al. **Arch Phys Med Rehabil** 1996 Feb;77(2):116–24

Functional outcome following rehabilitation of the cancer patient. Marciniak CM, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):54–7

Predicting discharge destination of stroke patients using a mathematical model based on six items from the Functional Independence Measure. Mauthe RW, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):10–3

The performance of a limited set of items from the Functional Independence Measure for use in acute trauma care and rehabilitation. Mortifee PR, et al. **Arch Phys Med Rehabil** 1996 May;77(5):436–9

Orientation in the acute and chronic stroke patient: impact on ADL and social activities. The Copenhagen Stroke Study. Pedersen PM, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):336–9

The SIP68: a measure of health-related functional status in rehabilitation medicine. Post MW, et al. **Arch Phys Med Rehabil** 1996 May;77(5):440–5

Gait speed and activities of daily living function in geriatric patients. Potter JM, et al. **Arch Phys Med Rehabil** 1995 Nov;76(11):997–9

Measuring functional limitations in rising and sitting down: development of a questionnaire. Roorda LD, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):663–9

Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson disease. Sabaté M, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):29–34

Intermodal agreement of follow-up telephone functional assessment using the Functional Independence Measure in patients with stroke. Smith PM, et al. **Arch Phys Med Rehabil** 1996 May;77(5):431–5

Function-based payment model for inpatient medical rehabilitation: an evaluation. Sutton JP, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):693–701

Failure of "effective" treatment for heart failure to improve normal customary activity. Walsh JT, et al. **Br Heart J** 1995 Oct;74(4):373–6

Young adults with arthritis: meeting their transitional needs [see comments] Chamberlain MA, et al. **Br J Rheumatol** 1996 Jan;35(1):84–90. Comment in: Br J Rheumatol 1996 Jan;35(1):80–3.

Discordance between objective and subjective assessment of functional ability of patients with rheumatoid arthritis. van den Ende CH, et al. **Br J Rheumatol** 1995 Oct;34(10):951–5

Future expectations: adolescents with rheumatic diseases and their transition into adulthood [editorial; comment] White PH. **Br J Rheumatol** 1996 Jan;35(1):80–3. Comment on: Br J Rheumatol 1996 Jan;35(1):84–90.

Dilemmas in care of the elderly. Koren G. **Can Fam Physician** 1995 Sep;41:1480

Frailty: a public health perspective [see comments] Raphael D, et al. **Can J Public Health** 1995 Jul–Aug;86(4):224–7. Comment in: Can J Public Health 1995 Jul–Aug;86(4):221–3.

The development of a socio-dental measure of dental impacts on daily living. Leao A, et al. **Community Dent Health** 1996 Mar;13(1):22–6

Ability and dependency in adolescents with severe learning disabilities. McKinlay I, et al. **Dev Med Child Neurol** 1996 Jan;38(1):48–58

Adults born with high anorectal atresia--how do they manage? Hassink EA, et al. **Dis Colon Rectum** 1996 Jun; 39(6):695–9

The Functional Independence Measure: a comparative validity and reliability study [letter; comment] Dickson HG, et al. **Disabil Rehabil** 1995 Nov–Dec;17(8):456. Comment on: Disabil Rehabil 1995 Jan;17(1):10–4.

Impact of fibromyalgia on everyday life: a study of women in the USA and Sweden. Henriksson C, et al. **Disabil Rehabil** 1996 May;18(5):241–8

Measuring activities of daily living among haemophiliacs. Iwata N, et al. **Disabil Rehabil** 1996 May;18(5):217–23

Physically disabled and frail elderly: assessing their external environments. Tranter RT, et al. **Disabil Rehabil** 1995 Aug–Sep;17(6):305–11

Does physical improvement reduce depressive symptoms in HIV-infected medical inpatients? Mierlak D, et al. **Gen Hosp Psychiatry** 1995 Sep;17(5):380–4

Low vision: physician screening helps to improve patient function. Castor TD, et al. **Geriatrics** 1995 Dec;50(12):51–2, 55–7; quiz 58–9 (5 ref.)

Medical conditions differentially affect the development of IADL disability: implications for medical care and research. Furner SE, et al. **Gerontologist** 1995 Aug; 35(4):444–50

Effect on physical functioning of care in adult foster homes and nursing homes. Stark AJ, et al. **Gerontologist** 1995 Oct; 35(5):648–55

Predictors of functioning of patients with chronic obstructive pulmonary disease. Graydon JE, et al. **Heart Lung** 1995 Sep–Oct;24(5):369–75

Children with fractures ... should they attend school? Hyder N, et al. **Injury** 1995 Nov;26(9):609–10

Sensory impairments and physical disability in aged women living at home. Dargent-Molina P, et al. **Int J Epidemiol** 1996 Jun;25(3):621–9

Choice and daily activities for people with disabilities. Frost PA. **Int J Rehabil Res** 1996 Mar;19(1):89–91

The economics of independent living: efficiency, equity and ethics. O'Shea E, et al. **Int J Rehabil Res** 1996 Mar; 19(1):13–26 (28 ref.)

Busy doing nothing: activity and interaction levels amongst differing populations of elderly patients. Nolan M, et al. **J Adv Nurs** 1995 Sep;22(3):528–38

Functional health status and instrumental activities of daily living performance in noninstitutionalized elderly people. Whittle H, et al. **J Adv Nurs** 1996 Feb;23(2):220–7

Triggers of myocardial ischemia during daily life in patients with coronary artery disease: physical and mental activities, anger and smoking. Gabbay FH, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):585–92

Successful recruitment and interview techniques of free-living elderly [letter; comment] Greenwell C, et al. **J Am Diet Assoc** 1996 Jun;96(6):558. Comment on: J Am Diet Assoc 1995 Dec;95(12):1381–6.

Cognitive and functional status of the oldest old. Corey-Bloom J, et al. **J Am Geriatr Soc** 1996 Jun; 44(6):671–4

Determinants of functional abilities in dementia. Hill RD, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1092–7

Could aspirin/NSAID treatment preserve independence and decrease the need for institutionalization of older rheumatoid arthritis patients [letter] Leibovitz A, et al. **J Am Geriatr Soc** 1996 Feb;44(2):216

A walking program for nursing home residents: effects on walk endurance, physical activity, mobility, and quality of life. MacRae PG, et al. **J Am Geriatr Soc** 1996 Feb; 44(2):175–80

Function and medical comorbidity in south Texas nursing home residents: variations by ethnic group. Mulrow CD, et al. **J Am Geriatr Soc** 1996 Mar;44(3):279–84

Insulin-like growth factor 1 and functional status in healthy older men. Papadakis MA, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1350–5

Factors associated with institutionalization of older people in Canada: testing a multifactorial definition of frailty. Rockwood K, et al. **J Am Geriatr Soc** 1996 May; 44(5):578–82

Hospital admission risk profile (HARP): identifying older patients at risk for functional decline following acute medical illness and hospitalization. Sager MA, et al. **J Am Geriatr Soc** 1996 Mar;44(3):251–7

Functional Incidental Training, mobility performance, and incontinence care with nursing home residents [see comments] Schnelle JF, et al. **J Am Geriatr Soc** 1995 Dec; 43(12):1356–62. Comment in: J Am Geriatr Soc 1995 Dec;43(12):1439–40.

Effects of resistance training on strength, power, and selected functional abilities of women aged 75 and older. Skelton DA, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1081–7

Injurious falls in nonambulatory nursing home residents: a comparative study of circumstances, incidence, and risk factors. Thapa PB, et al. **J Am Geriatr Soc** 1996 Mar; 44(3):273–8

Weight change and physical function in older women: findings from the Nun Study. Tully CL, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1394–7

Functional abilities of elderly survivors of intensive care [see comments] Broslawski GE, et al. **J Am Osteopath Assoc** 1995 Dec;95(12):712–7. Comment in: J Am Osteopath Assoc 1995 Dec;95(12):708, 710.

Ability of the Caltrac accelerometer to assess daily physical activity levels. Richardson MT, et al. **J Cardpulm Rehabil** 1995 Mar–Apr;15(2):107–13

The evaluation of changes in functional health status in patients with abdominal complaints. Jacobs HM, et al. **J Clin Epidemiol** 1996 Feb;49(2):163–71

The role of functional status in predicting inpatient mortality with AIDS: a comparison with current predictors. Justice AC, et al. **J Clin Epidemiol** 1996 Feb;49(2):193–201

Hierarchical structure in ADL and IADL: analytical assumptions and applications for clinicians and researchers. Kempen GI, et al. **J Clin Epidemiol** 1995 Nov; 48(11):1299–305

The Quebec Back Pain Disability Scale: conceptualization and development. Kopec JA, et al. **J Clin Epidemiol** 1996 Feb;49(2):151–61

Responsiveness of the rehabilitation activities profile and the Barthel index. van Bennekom CA, et al. **J Clin Epidemiol** 1996 Jan;49(1):39–44

Comparing survey data on functional disability: the impact of some methodological differences. Picavet HS, et al. **J Epidemiol Community Health** 1996 Feb;50(1):86–93

The relationship of strength to function in the older adult. Brown M, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov; 50 Spec No:55–9

Effects of exercise on body composition and functional capacity of the elderly. Evans WJ. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:147–50 (23 ref.)

Progressive versus catastrophic disability: a longitudinal view of the disablement process. Ferrucci L, et al. **J Gerontol A Biol Sci Med Sci** 1996 May;51(3):M123–30

Utility of Mini-Mental State Exam scores in predicting functional impairment among white and African American dementia patients. Ford GR, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):M185–8

Functional decline in older adults: expanding methods of ascertainment. Fried LP, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):M206–14

Functional and residential status transitions among nursing home residents. Gillen P, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):M29–36

Upper-body strength and breast cancer: a comparison of the

effects of age and disease. Satariano WA, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):M215–9

The predictors of surgical procedure and the effects on functional recovery in elderly with subcapital fractures. Young Y, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul; 51(4):M158–64

The relationship of self–rated function and self–rated health to concurrent functional ability, functional decline, and mortality: findings from the Nun Study. Greiner PA, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Sep;51(5):S234–41

The assessment of ADL among frail elderly in an interview survey: self–report versus performance–based tests and determinants of discrepancies. Kempen GI, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Sep;51(5):P254–60

A longitudinal study of change in domain–specific self–efficacy among older adults. McAvay GJ, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Sep;51(5):P243–53

Self–efficacy and pain in disability with osteoarthritis of the knee. Rejeski WJ, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):P24–9

Social network characteristics and onset of ADL disability: MacArthur studies of successful aging. Seeman TE, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul;51(4):S191–200

Physical function and perceived health: cohort differences and interrelationships in older people. Spiers N, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Sep;51(5):S226–33

Age differences and age changes in activities: Baltimore Longitudinal Study of Aging. Verbrugge LM, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):S30–41

Upper extremity function after wrist arthrodesis. Weiss AC, et al. **J Hand Surg [Am]** 1995 Sep;20(5):813–7

Attention to adl needs. Easy cutlery holder. Benaglia PG, et al. **J Hand Ther** 1996 Jan–Mar;9(1):59–60

The relationships of motor function, education, age and cognitive function to the physical activities of daily living. Park JH, et al. **J Korean Med Sci** 1995 Jun;10(3):195–9

The Functional Limitations Profile may be a valid, reliable and sensitive measure of disability in multiple sclerosis. Hutchinson J, et al. **J Neurol** 1995 Oct;242(10):650–7

Reliability and validity of a new preadmission acuity tool for long–term care. Swanson EA, et al. **J Nurs Meas** 1995 Summer;3(1):77–88

Pediatric femur fractures: effects of spica cast treatment on family and community. Hughes BF, et al. **J Pediatr Orthop** 1995 Jul–Aug;15(4):457–60

Determinants of hand function in patients with rheumatoid arthritis. Vliet Vlieland TP, et al. **J Rheumatol** 1996 May; 23(5):835–40

Effects of age, education, and living environment on Boston Naming Test performance. Neils J, et al. **J Speech Hear Res** 1995 Oct;38(5):1143–9

Serious traumatic brain injury: an evaluation of functional outcomes. Hawkins ML, et al. **J Trauma** 1996 Aug; 41(2):237–63; discussion 263–4

Functional status following orthopedic trauma in young women. McCarthy ML, et al. **J Trauma** 1995 Nov; 39(5):828–36; discussion 836–7

The value of service dogs for people with severe ambulatory disabilities. A randomized controlled trial. Allen K, et al. **JAMA** 1996 Apr 3;275(13):1001–6

Secular improvement in self–care independence of old people living in community in Kahoku, Japan [letter] Matsubayashi K, et al. **Lancet** 1996 Jan 6;347(8993):60

Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. Tsevat J, et al. **Med Care** 1996 Jan; 34(1):44–57

Clinical predictors of functioning in persons with acquired immunodeficiency syndrome. Wilson IB, et al. **Med Care** 1996 Jun;34(6):610–23

Relationship between mean habitual daily energy expenditure and maximal oxygen uptake. Berthouze SE, et al. **Med Sci Sports Exerc** 1995 Aug;27(8):1170–9

Autobiographical memory and daily schemas at work. Eldridge MA, et al. **Memory** 1994 Mar;2(1):51–74

Prevalence and impact of arthritis by race and ethnicity—United States, 1989–1991. **MMWR Morb Mortal Wkly Rep** 1996 May 10;45(18):373–8

A trial of annual in–home comprehensive geriatric assessments for elderly people living in the community [see comments] Stuck AE, et al. **N Engl J Med** 1995 Nov 2; 333(18):1184–9. Comment in: N Engl J Med 1995 Nov 2;333(18):1213–4. Comment in: N Engl J Med 1996 Mar 7;334(10):665; discussion 666.

Re: "Motor performance correlates of functional dependence in long–term care residents' [letter; comment] Knapp TR, et al. **Nurs Res** 1995 Nov–Dec;44(6):382. Comment on: Nurs Res 1995 Jan–Feb;44(1):4–8.

Prevalence of cognitive and functional impairment in an elderly Puerto Rican population. Alonso Serra ML, et al. **P R Health Sci J** 1995 Dec;14(4):279–83

Functional disability and mental impairment as predictors of mortality in community–dwelling elderly Puerto Ricans. De Andino RM, et al. **P R Health Sci J** 1995 Dec; 14(4):285–7

The long term outcome in 149 patients with spinal cord injury. Daverat P, et al. **Paraplegia** 1995 Nov;33(11):665–8

The effect of botulinum toxin A on the function if a person with poststroke quadriplegia. Cromwell SJ, et al. **Phys Ther** 1996 Apr;76(4):395–402

Initial health status of patients at outpatient physical therapy clinics. Mossberg KA, et al. **Phys Ther** 1995 Dec; 75(12):1043–51; discussion 1051–3

Three–dimensional joint co–ordination strategies of the upper limb during functional activities. Barker TM, et al. **Proc Inst Mech Eng [H]** 1996;210(1):17–26

Functional ability and nutritional status of free–living elderly people. Manandhar MC. **Proc Nutr Soc** 1996 Nov; 54(3):677–91 (99 ref.)

Angina, functional impairment and physical inactivity among Mexican–American women with depressive symptoms. Portillo CJ, et al. **Prog Cardiovasc Nurs** 1995 Summer; 10(3):18–25

Neighborhood locations of Section 8 housing certificate users with and without mental illness. Newman SJ, et al. **Psychiatr Serv** 1996 Apr;47(4):392–7

Activity restriction mediates the association between pain and depressed affect: a study of younger and older adult cancer patients. Williamson GM, et al. **Psychol Aging** 1995 Sep;10(3):369–78

The relationship between visual acuity and functioning and well–being among diabetics. Lee PP, et al. **Qual Life Res** 1995 Aug;4(4):319–23

Chronic obstructive pulmonary disease and self–maintaining functions in the elderly—a population–based study. Isoaho R, et al. **Scand J Prim Health Care** 1995 Jun;13(2):122–7

Care for demented patients in different living conditions. Effects on cognitive function, ADL–capacity and behaviour. Wimo A, et al. **Scand J Prim Health Care** 1995 Sep;13(3):205–10

Interrater reliability of the 7–level functional independence measure (FIM) [letter; comment] Dickson HG, et al. **Scand J Rehabil Med** 1995 Dec;27(4):253–6. Comment on: Scand J Rehabil Med 1994 Sep;26(3):115–9.

Functional balance tests in 76–year–olds in relation to performance, activities of daily living and platform tests. Frändin K, et al. **Scand J Rehabil Med** 1995 Dec; 27(4):231–41

Instrumental activities of daily living related to impairments and functional limitations in 70–year–olds and changes between 70 and 76 years of age. Sonn U, et al. **Scand J Rehabil Med** 1995 Jun;27(2):119–28

Longitudinal studies of dependence in daily life activities among elderly persons. Sonn U. **Scand J Rehabil Med Suppl** 1996;34:1–35 (168 ref.)

Ambulatory elderly patients of primary care physicians: functional, psychosocial and environmental predictors of need for social work care management. Berkman B, et al. **Soc Work Health Care** 1996;22(3):1–20

Measurement of instrumental activities of daily living in stroke [letter; comment] Gladman JR. **Stroke** 1995 Nov; 26(11):2197. Comment on: Stroke 1995 Jun;26(6):1119–22.

Day–to–day demands of Parkinson's disease. Habermann B. **West J Nurs Res** 1996 Aug;18(4):397–413

[Favorable development of ability to function in patients during admission in a geriatric unit of a psychiatric hospital] Maas HA, et al. **Ned Tijdschr Geneeskd** 1995 Dec 2; 139(48):2494–8 (Eng. Abstr.) **(Dut)**

[Future prospects for children with spina bifida aperta] Staal–Schreinemachers AL, et al. **Ned Tijdschr Geneeskd** 1996 Jun 15;140(24):1268–72 (Eng. Abstr.) **(Dut)**

[Effects of technical aids on the utilization of professional care. A study among single 75–year olds] de Klerk MM, et al. **Tijdschr Gerontol Geriatr** 1996 Jun;27(3):105–14 (Eng. Abstr.) **(Dut)**

[Standardized behavior assessment plays a minor role in arriving at indications for admission to a psychogeriatric nursing home] Janzing JG, et al. **Tijdschr Gerontol Geriatr** 1995 Oct;26(5):200–4 (Eng. Abstr.) **(Dut)**

[Unidimensionality of a functional measure for patient with an injured upper limb] Luquet C, et al. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):248–61 (Eng. Abstr.) **(Fre)**

[Modeling vestibulo–ocular reflexes in everyday activities] Ossig J, et al. **Biomed Tech (Berl)** 1996 May;41(5):123–31 (Eng. Abstr.) **(Ger)**

[Singer—and no end in sight? Or: can severely handicapped patients be "persons"?] Grüning J. **Rehabilitation (Stuttg)** 1996 May;35(2):126–8 (Eng. Abstr.) **(Ger)**

[Factors affecting continuation of home medical care—based on the relationship between patient and caregiver status] Yamagishi K, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:326–30 (Eng. Abstr.) **(Jpn)**

[Factors related to ADL of stroke patients three months after discharge] Ishikawa R, et al. **Nippon Koshu Eisei Zasshi** 1996 May;43(5):354–63 (Eng. Abstr.) **(Jpn)**

[Characteristics of participants in community–based rehabilitation programs and their levels of independence in activities of daily living] Okamura T, et al. **Nippon Koshu Eisei Zasshi** 1995 Oct;42(10):878–87 (Eng. Abstr.) **(Jpn)**

[Comparison of activities of daily living (ADL), medical treatment and blood pressure of elderly participants and non–participants in health examinations] Yamakawa M, et al. **Nippon Koshu Eisei Zasshi** 1995 Sep;42(9):769–76 (Eng. Abstr.) **(Jpn)**

[Sociomedical study of centenarians in Nagoya City] Inagaki T, et al. **Nippon Ronen Igakkai Zasshi** 1996 Feb;33(2):84–94 (Eng. Abstr.) **(Jpn)**

[Chronological study concerning ADL among Okinawan centenarians] Suzuki M, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jun;32(6):416–23 (Eng. Abstr.) **(Jpn)**

[Rheumatoid arthritis and quality of life] Kawai S. **Ryumachi** 1995 Jun;35(3):609–20 (43 ref.) **(Jpn)**

[Rehabilitation in rheumatoid arthritis (RA) patients—assessment of effects of rehabilitation based on activities of daily living (ADL)] Konno T, et al. **Ryumachi** 1995 Jun;35(3):595–9 (Eng. Abstr.) **(Jpn)**

[The assessment of functional status in hospitalized elderly patients: the Plutchik scale] Perlado F, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):45–9 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Bucks RS, et al. **Age Ageing** 1996 Mar;25(2):113–20

Predictive validity of a postal questionnaire for screening community–dwelling elderly individuals at risk of functional decline. Hébert R, et al. **Age Ageing** 1996 Mar; 25(2):159–67

The effect of tumour associated epilepsy on performance/handicap scales used in cerebral glioma. Macleod M, et al. **Br J Neurosurg** 1995;9(5):653–7

Migraine impact and functional disability. Lipton RB, et al. **Cephalalgia** 1995 Oct;15 Suppl 15:4–9 (33 ref.)

A cluster analytic study of functional outcome after psychiatric hospitalization. Goethe JW, et al. **Compr Psychiatry** 1996 Mar–Apr;37(2):115–21

Usefulness of the SF–36 Health Survey in measuring health outcomes in the depressed elderly. Beusterien KM, et al. **J Geriatr Psychiatry Neurol** 1996 Jan;9(1):13–21

Longitudinal changes in cognitive functioning in adult day care participants. Cohen–Mansfield J, et al. **J Geriatr Psychiatry Neurol** 1996 Jan;9(1):30–8

Rate of progression in familial Alzheimer's disease. Swearer JM, et al. **J Geriatr Psychiatry Neurol** 1996 Jan;9(1):22–5

Care dependence and individual care provision. Maaskant MA, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):306–15

Pilot project on functional outcome in stroke. Hinkle JL, et al. **J Neurosci Nurs** 1996 Feb;28(1):13–8

Benefits of rehabilitation for traumatic spinal cord injury: a case report. Lu AC, et al. **J Spinal Cord Med** 1996 Jan; 19(1):17–9

Interventionalists' guide to the patient's experience of lower extremity arterial occlusive disease. McDaniel MD, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):30S–35S (27 ref.)

Development of an ambulatory physical activity memory device and its application for the categorization of actions in daily life. Makikawa M, et al. **Medinfo** 1995;8 Pt 1:747–50

Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale. Louis ED, et al. **Mov Disord** 1996 Mar;11(2):185–92

Adult screening for cognitive and functional impairment. **Nurse Pract** 1996 Apr;21(4):112–5

Assessing functional status of elderly adults via microcomputer. Yarnold PR, et al. **Percept Mot Skills** 1996 Apr;82(2):689–90

Maternal activity budgets: feasibility of exclusive breastfeeding for six months among urban women in Honduras. Cohen RJ, et al. **Soc Sci Med** 1995 Aug; 41(4):527–36

[Quality of life in peripheral arterial occlusive disease. Multicenter study of quality of life characteristics with a newly developed disease–specific questionnaire] Heidrich H, et al. **Med Klin** 1995 Dec 15;90(12):693–7 (Eng. Abstr.) **(Ger)**

[Concept for a functional status and handicap–adjustment treatment and rehabilitation service chain in neurologic and neurosurgical management in Germany ("phase model")] Schupp W. **Nervenarzt** 1995 Dec;66(12):907–14 (Eng. Abstr.) **(Ger)**

[Hannover Functional Questionnaire in ambulatory diagnosis of functional disability caused by backache] Kohlmann T, et al. **Rehabilitation (Stuttg)** 1996 Feb;35(1):I–VIII (Eng. Abstr.) **(Ger)**

[Measuring functional capacity in backache patients in rehabilitation: a comparison of standardized questionnaires] Roese I, et al. **Rehabilitation (Stuttg)** 1996 May;35(2):103–8 (Eng. Abstr.) **(Ger)**

[International Classification of Impairments, Disabilities and Handicaps ICIDH—results and problems] Schuntermann MF. **Rehabilitation (Stuttg)** 1996 Feb;35(1):6–13 (Eng. Abstr.) **(Ger)**

[Quantification of dementia–related disabilities in daily behavior with the DAFS (Direct Assessment of Functional Status): reliability and validity of a German test version] Hochrein A, et al. **Z Gerontol Geriatr** 1996 May–Jun; 29(3):216–22 (Eng. Abstr.) **(Ger)**

[Inpatient length of stay and physical capacity after aortocoronary bypass operation, after heart valve replacement and myocardial infarct] Köhler E, et al. **Z Kardiol** 1995 Nov;84(11):911–20 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Self–reported functioning and well–being in patients with Parkinson's disease: comparison of the short–form health survey (SF–36) and the Parkinson's Disease Questionnaire (PDQ–39). Jenkinson C, et al. **Age Ageing** 1995 Nov; 24(6):505–9

"Taking another route": daily survival narratives from mothers who are homeless. Banyard VL. **Am J Community Psychol** 1995 Dec;23(6):871–91

Effects of children with Down syndrome on parents' activities. Barnett WS, et al. **Am J Ment Retard** 1995 Sep; 100(2):115–27

Preventing restrictive placements through community support services. Colond JS, et al. **Am J Ment Retard** 1995 Sep;100(2):201–6

Discontinuation of neuroleptics in community–dwelling individuals with mental retardation and mental illness. Pary RJ. **Am J Ment Retard** 1995 Sep;100(2):207–12

Impact of size revisited: relation of number of residents to self–determination and deprivatization. Tossebro J. **Am J Ment Retard** 1995 Jul;100(1):59–67

The Life Skills Profile: a study of its psychometric properties. Trauer T, et al. **Aust N Z J Psychiatry** 1995 Sep;29(3):492–9

The Maine and Vermont three–decade studies of serious mental illness. I. Matched comparison of cross–sectional outcome. DeSisto MJ, et al. **Br J Psychiatry** 1995 Sep; 167(3):331–8

One and two year outcomes for adults with learning disabilities discharged to the community. Donnelly M, et al. **Br J Psychiatry** 1996 May;168(5):598–606

Self–awareness of deficits in adults with traumatic brain injury: how best to measure? Fleming JM, et al. **Brain Inj** 1996 Jan;10(1):1–15

Neuropsychological problems in everyday life: a 5–year follow–up study of young severely closed–head–injured patients. Kaitaro T, et al. **Brain Inj** 1995 Oct;9(7):713–27

A validity study of the St. Louis Inventory of Community Living Skills. Fitz D, et al. **Community Ment Health J** 1995 Aug;31(4):369–77

Better than expected: improvements in borderline personality disorder in a 3–year prospective outcome study. Najavits LM, et al. **Compr Psychiatry** 1995 Jul–Aug;36(4):296–302

Economic incentives for financial and residential independence. Whittington LA, et al. **Demography** 1996 Feb;33(1):82–97

Ecological measures of cognitive functioning: a validation study. Goodman CR, et al. **Int Psychogeriatr** 1995 Spring; 7(1):39–50

Acute effects of fluoxetine versus placebo on functional health and well–being in late–life depression. Heiligenstein JH, et al. **Int Psychogeriatr** 1995;7 Suppl:125–37

Increasing self–determination: teaching people with mental retardation to evaluate residential options. Faw GD, et al. **J Appl Behav Anal** 1996 Summer;29(2):173–88

The social and community involvement of older Australians with intellectual disabilities. Ashman AF, et al. **J Intellect Disabil Res** 1996 Apr;40 (Pt 2):120–9

The effects of deinstitutionalization on adults with learning disabilities. Cullen C, et al. **J Intellect Disabil Res** 1995 Dec;39 (Pt 6):484–94

Community care for adults with learning disability and their carers: needs and outcomes from the Leicestershire register. McGrother CW, et al. **J Intellect Disabil Res** 1996 Apr; 40 (Pt 2):183–90

Ageing in adults with Down's syndrome in institutionally based and community–based residences. Roeden JM, et al. **J Intellect Disabil Res** 1995 Oct;39 (Pt 5):399–407

Follow–up studies of a representative sample of children with severe mental handicap in Poland. Wald I, et al. **J Intellect Disabil Res** 1995 Dec;39 (Pt 6):465–73

"This is your meeting": a qualitative study of person–centered planning. Hagner D, et al. **Ment Retard** 1996 Jun; 34(3):159–71

The Community Living Attitudes Scale, Mental Retardation Form: development and psychometric properties. Henry D, et al. **Ment Retard** 1996 Jun;34(3):149–58

Factors contributing to the stability of social relationships between individuals with mental retardation and other community members. Newton JS, et al. **Ment Retard** 1995 Dec;33(6):383–93

Enhancing the participation and independence of students with severe physical and multiple disabilities in performing community activities. Sowers JA, et al. **Ment Retard** 1995 Aug;33(4):209–20

An acoustic orientation system to promote independent indoor travel in blind persons with severe mental retardation. Lancioni GE, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):747–54

Effects of parental involvement on the functioning of noninstitutionalized adults with schizophrenia. Brekke JS, et al. **Psychiatr Serv** 1995 Nov;46(11):1149–55

Functional capabilities of depressed patients one year after hospitalization. Goethe JW, et al. **Psychiatr Serv** 1995 Nov; 46(11):1187–8

Comparison of clinicians' housing recommendations and preferences of homeless mentally ill persons. Goldfinger SM, et al. **Psychiatr Serv** 1996 Apr;47(4):413–5

Preliminary results from a psychoeducational program to rehabilitate chronic patients. Halford WK, et al. **Psychiatr Serv** 1995 Nov;46(11):1189–91

Therapeutic alliance and outcome in a VA intensive case management program. Neale MS, et al. **Psychiatr Serv** 1995 Jul;46(7):719–21

The experiences of long–stay inpatients returning to the community. Davidson L, et al. **Psychiatry** 1995 May; 58(2):122–32; discussion 133–5

Social support as a mediator in the relation between functional status and quality of life in older adults. Newsom JT, et al. **Psychol Aging** 1996 Mar;11(1):34–44

Factors affecting the success of community placement: the TAPS project 26. Gooch C, et al. **Psychol Med** 1996 May; 26(3):511–20

Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Bonomi AE, et al. **Qual Life Res** 1996 Jun; 5(3):309–20

A study of the reliability, validity and responsiveness of the HIV overview of problems evaluation system (HOPES) in assessing the quality of life of patients with AIDS and symptomatic HIV infection. De Boer JB, et al. **Qual Life Res** 1996 Jun;5(3):339–47

Functional Assessment of Cancer Therapy (FACT–G): non–response to individual questions. Fairclough DL, et al. **Qual Life Res** 1996 Jun;5(3):321–9

Teaching key use to persons with severe disabilities in congregate living settings. Ivancic MT, et al. **Res Dev Disabil** 1995 Sep–Oct;16(5):415–23

[Evaluation of autonomy in chronic mental patients. Problems, assessment tools, results] Leguay D. **Encephale** 1995 Nov–Dec;21(6):425–35 (98 ref.) (Eng. Abstr.) **(Fre)**

[Computer–assisted individualized memory training in Alzheimer patients] Hofmann M, et al. **Nervenarzt** 1995 Sep;66(9):703–7 (Eng. Abstr.) **(Ger)**

[Can disabled persons have "full social value"?] Finck W. **Rehabilitation (Stuttg)** 1995 Nov;34(4):175–8 (Eng. Abstr.) **(Ger)**

[Pain, independence and subjective attitude to aging––an empirical contribution from the study "Possibilities and limits of independent living by the elderly"] Hofer J, et al. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):358–68 (Eng. Abstr.) **(Ger)**

[Leisure interest activities within the context of mobility environments] Karl F. **Z Gerontol Geriatr** 1995 Sep–Oct; 28(5):374–7 (Eng. Abstr.) **(Ger)**

[Aspects of physical capacity and quality of life in old age (editorial)] Kruse A. **Z Gerontol Geriatr** 1996 Mar–Apr; 29(2):93–4 **(Ger)**

[Wellbeing, health and autonomy in old age: the Basal IDA Study (Interdisciplinary Aging Study)] Perrig–Chiello P, et al. **Z Gerontol Geriatr** 1996 Mar–Apr;29(2):95–109 (Eng. Abstr.) **(Ger)**

ACTIVITY CYCLES

Circadian rhythms of temperature and activity in obese and lean Zucker rats. Murakami DM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1038–43

Expression of daily torpor in the Djungarian hamster (Phodopus sungorus) is correlated with the testosterone–driven vasopressin content in the lateral septum. Ouarour A, et al. **Biol Signals** 1995 Jan–Feb; 4(1):42–50

Alterations in the ultradian oscillations of insulin secretion and plasma glucose in aging. Scheen AJ, et al. **Diabetologia** 1996 May;39(5):564–72

Differences in the nyctohemeral secretion of TSH and PRL in healthy euthyroid men. Dericks–Tan JS, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):145–50

Women's patterns of activity over 6 months after coronary artery bypass surgery. Redeker NS, et al. **Heart Lung** 1995 Nov–Dec;24(6):502–11

Entrainment of ultradian oscillations in the secretion of insulin and glucagon to the nonrapid eye movement/rapid eye movement sleep rhythm in humans. Kern W, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1541–7

GENETICS

Genes that control a temperature–compensated ultradian clock in Caenorhabditis elegans. Iwasaki K, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10317–21

IMMUNOLOGY

Urinary leukotriene E4 in the assessment of nocturnal asthma. Bellia V, et al. **J Allergy Clin Immunol** 1996 Mar; 97(3):735–41

PHYSIOLOGY

Circadian and ultradian rhythms of peripheral growth hormone concentrations in lactating dairy cows. Lefcourt AM, et al. **Domest Anim Endocrinol** 1995 Jul;12(3):247–56

Secretory rhythm of vasopressin in healthy subjects with inversed sleep––wake cycle: evidence for the existence of an intrinsic regulation. Nadal M. **Eur J Endocrinol** 1996 Feb;134(2):174–6

Rhythmic variations in reaction times and evoked potentials. Conte S, et al. **Int J Neurosci** 1995 May;82(1–2):127–33

Analysis of twenty–four–hour ambulatory blood pressure monitoring: what time period to assess blood pressures during waking and sleeping? van Ittersum FJ, et al. **J Hypertens** 1995 Sep;13(9):1053–8

Ultradian aspects of sleep in narcolepsy. Nobili L, et al. **Neurophysiol Clin** 1996;26(1):51–9

Stress induced disorganization of circadian and ultradian rhythms: comparisons of effects of surgery and social stress. Harper DG, et al. **Physiol Behav** 1996 Mar;59(3):409–19

Reconstruction of insulin secretion rate by deconvolution: domain of validity of a monoexponential C–peptide impulse response model. Sparacino G, et al. **Technol Health Care** 1996 Apr;4(1):87–95

ACTOMYOSIN

CHEMISTRY

Effects of nucleotide on skeletal muscle myosin unfolding in myofibrils by DSC. Lőrinczy D, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):592–8

Multiple– and single–molecule analysis of the actomyosin motor by nanometer–piconewton manipulation with a microneedle: unitary steps and forces. Ishijima A, et al. **Biophys J** 1996 Jan;70(1):383–400

The osmotic properties and free energy of formation of the actomyosin rigor complexes from rabbit muscle. Magri E, et al. **Eur J Biochem** 1996 Jul 1;239(1):165–71

Determination of the protein components of native thin filaments isolated from natural actomyosin: nebulin and alpha–actinin are associated with actin filaments. Meng Y, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):422–7

Protein–protein interactions in the rigor actomyosin complex. Milligan RA. **Proc Natl Acad Sci U S A** 1996 Jan 9; 93(1):21–6 (31 ref.)

METABOLISM

Observation of ATP turnover during in vitro motility assays. Conibear PB, et al. **Biochem Soc Trans** 1995 Aug;23(3):400S

Structural basis for actomyosin chemomechanical transduction by non–nucleoside triphosphate analogues. Gopal D, et al. **Biochemistry** 1995 Sep 26;34(38):12178–84

Chemomechanical transduction in the actomyosin molecular motor by 2',3'–dideoxydidehydro–ATP and characterization of its interaction with myosin subfragment 1 in the presence and absence of actin. Gopal D, et al. **Biochemistry** 1996 Aug 6;35(31):10149–57

Mutational analysis of the role of hydrophobic residues in the 338–348 helix on actin in actomyosin interactions. Miller CJ, et al. **Biochemistry** 1996 Mar 26;35(12):3670–6

Evidence for increased low force cross–bridge population in shortening skinned skeletal muscle fibers: implications for actomyosin kinetics. Iwamoto H. **Biophys J** 1995 Sep; 69(3):1022–35

The effect of genetically expressed cardiac titin fragments on in vitro actin motility. Li Q, et al. **Biophys J** 1995 Oct; 69(4):1508–18

Coupling between myosin ATPase cycle and creatinine kinase cycle facilitates cardiac actomyosin sliding in vitro. A clue to mechanical dysfunction during myocardial ischemia. Sata M, et al. **Circulation** 1996 Jan 15;93(2):310–7

Cardiac troponin I mutants. Phosphorylation by protein kinases C and A and regulation of Ca(2+)–stimulated MgATPase of reconstituted actomyosin S–1. Noland TA Jr, et al. **J Biol Chem** 1995 Oct 27;270(43):25445–54

Nucleotide binding by actomyosin as a determinant of relaxation kinetics of rabbit phasic and tonic smooth muscle. Khromov AS, et al. **J Physiol (Lond)** 1996 May 1;492 (Pt 3):669–73

Postnatal changes in size and actomyosin content of rabbit gastric myocytes. Tomomasa T, et al. **Reprod Fertil Dev** 1995;7(5):1305–10

[Biomechanics of actomyosin–dependent mobility of keratinocytes] Alt W. **Biofizika** 1996 Jan–Feb;41(1):169–77 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Actomyosin–based motility of endoplasmic reticulum and chloroplasts in Vallisneria mesophyll cells. Liebe S, et al. **Biol Cell** 1995;85(2–3):207–22

Multiple– and single–molecule analysis of the actomyosin motor by nanometer–piconewton manipulation with a microneedle: unitary steps and forces. Ishijima A, et al. **Biophys J** 1996 Jan;70(1):383–400

ACTOMYOSIN ADENOSINETRIPHOSPHATASE see **MYOSIN ATPASE**

ACTOMYOSIN SUBFRAGMENTS see **MYOSIN SUBFRAGMENTS**

ACTUARIAL ANALYSIS

Royal Society plans genetics meeting with actuarial profession [news] Dickson D. **Nature** 1995 Oct 5; 377(6548):375–6

[Actuarial survival analysis of patients in dialysis] Douthat W, et al. **Medicina (B Aires)** 1995;55(2):97–105 (Eng. Abstr.) **(Spa)**

ECONOMICS

Genetic discrimination: actuarial aspects [letter; comment] Dicke A. **Science** 1995 Dec 1;270(5241):1423–4. Comment on: Science 1995 Oct 20;270(5235):391–3.

HISTORY

Actuarial Society of America. Transactions. 1901–1903 [classical article] McClintock E, et al. **Obes Res** 1996 Mar; 4(2):196–200

STATISTICS & NUMERICAL DATA

How are net health insurance benefits distributed in the

employment-related insurance market? Monheit AC, et al. **Inquiry** 1995-96 Winter;32(4):379-91

ACUPOINTS see **ACUPUNCTURE POINTS**

ACUPRESSURE

Effect of P-6 acupressure on prevention of nausea and vomiting after epidural morphine for post-cesarean section pain relief. Ho CM, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):372-5

Efficacy of P6 acupressure in the treatment of nausea and vomiting during pregnancy. O'Brien B, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):708-15

Ear point tapping and pressing therapy for giving up smoking in 45 cases. Lei X. **J Tradit Chin Med** 1996 Mar;16(1):33-4

Periomarthritis treated with pain point pressure in combination with local exercises. Ma J. **J Tradit Chin Med** 1995 Dec;15(4):289

External approach to the treatment of pediatric asthma. Sun Y. **J Tradit Chin Med** 1995 Dec;15(4):290-1

INSTRUMENTATION

Efficacy of a portable acustimulation device in controlling seasickness. Bertolucci LE, et al. **Aviat Space Environ Med** 1995 Dec;66(12):1155-8

A randomised placebo-controlled clinical trial of an acupressure device for weight loss. Allison DB, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19(9):653-8

METHODS

CHROMASSI: a therapy advice system based on chrono-massage and acupression using the method of ZiWuLiuZhu. Nguyen HP, et al. **Medinfo** 1995;8 Pt 2:998

ACUPUNCTURE

2nd International Symposium on the Bi-Digital O-Ring Test. Tokyo, Japan, July 8-9, 1995. Abstracts. **Acupunct Electrother Res** 1995 Aug-Dec;20(3-4):231-312

Changes of cerebral endogenous evoked potentials by acupunciure stimulation: a P300 study. Abad-Alegria F, et al. **Am J Chin Med** 1995;23(2):115-9

Effect of acupuncture at the Hoku point on vibration-induced finger flexion reflex in man: comparison between press needle technique, electroacupuncture, and in-situ technique. Takakura N, et al. **Am J Chin Med** 1995; 23(3-4):313-8

Non-invasive measurement of brain activity using functional MRI: toward the study of brain response to acupuncture stimulation. Yoshida T, et al. **Am J Chin Med** 1995; 23(3-4):319-25

Electrical stimulation at traditional acupuncture sites in periphery produces brain opioid-receptor-mediated antinociception in rats. Chen XH, et al. **J Pharmacol Exp Ther** 1996 May;277(2):654-60

Placebo controls [letter; comment] Vahrman J. **J R Soc Med** 1995 Oct;88(10):603. Comment on: J R Soc Med 1995 Apr;88(4):199-202.

Transient increase in human muscle sympathetic nerve activity during manual acupuncture. Sugiyama Y, et al. **Jpn J Physiol** 1995;45(2):337-45

Acupuncture--from empiricism to science: functional background to acupuncture effects in pain and disease. Andersson S, et al. **Med Hypotheses** 1995 Sep;45(3):271-81 (96 ref.)

Long-lasting facilitation and depression of periurethral skeletal muscle following acupuncture-like stimulation in anesthetized rats. Morrison JF, et al. **Neurosci Res** 1995 Sep;23(2):159-69

Effects of auricular acupuncture stimulation on nonobese, healthy volunteer subjects. Shiraishi T, et al. **Obes Res** 1995 Dec;3 Suppl 5:667S-673S

The language of acupuncture: should Western physicians learn it? Erickson JK. **Pharos** 1995 Fall;58(4):21-5 (14 ref.)

Neurobiological mechanisms of the meridian and the propagation of needle feeling along the meridian pathway. Xie Y, et al. **Sci China C Life Sci** 1996 Feb;39(1):99-112

[Confocal laser scan microscope system and its applications on studying acupuncture and meridian] Li R, et al. **Chen Tzu Yen Chiu** 1995;20(2):76-8 (Eng. Abstr.) **(Chi)**

ADVERSE EFFECTS

[Hazards of infectious diseases in acupuncture (editorial)] Israeli E. **Harefuah** 1995 Jun 15;128(12):769-70 **(Heb)**

[Complications of acupuncture (letter)] Norheim AJ, et al. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1153 **(Nor)**

METHODS

Innovations in acumoxa: acupuncture analgesia, scalp and ear acupuncture in the People's Republic of China. Hsu E. **Soc Sci Med** 1996 Feb;42(3):421-30

VETERINARY

AAEP acupuncture lecture gets point across [news] Meehan SK. **J Am Vet Med Assoc** 1996 Feb 1;208(3):325-6

ACUPUNCTURE ANALGESIA

Involvement of opioid peptides of the preoptic area during electroacupuncture analgesia. Wu GC, et al. **Acupunct Electrother Res** 1995 Jan-Mar;20(1):1-6

Role of opioid peptides of rat's nucleus reticularis paragigantocellularis lateralis (RPGL) in acupuncture analgesia. Zhou L, et al. **Acupunct Electrother Res** 1995 Apr-Jul;20(2):89-100

The use of acupuncture in dentistry [letter] Rosted P. **Aust Dent J** 1996 Feb;41(1):61

The use of acupuncture in dentistry [letter] Rosted P. **Br Dent J** 1996 May 11;180(9):325

A concept in analgesic mechanisms of acupuncture. Lin JG. **Chin Med J (Engl)** 1996 Mar;109(3):185-8 (8 ref.)

Expressions of preproenkephalin mRNA during electroacupuncture analgesia enhanced by fenfluramine. Li XY, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep; 16(5):431-4

Acupuncture: can it take the pain away? Senior K. **Mol Med Today** 1996 Apr;2(4):150-3

Innovations in acumoxa: acupuncture analgesia, scalp and ear acupuncture in the People's Republic of China. Hsu E. **Soc Sci Med** 1996 Feb;42(3):421-30

[The effect of intrathecal injection of neurotensin on acupuncture analgesia in rats] Liu W, et al. **Chen Tzu Yen Chiu** 1995;20(3):13-7 (Eng. Abstr.) **(Chi)**

[Effect of electrical stimulation of red nucleus on acupuncture analgesia] Yu Q, et al. **Chen Tzu Yen Chiu** 1995;20(2):7-11 (Eng. Abstr.) **(Chi)**

[Effect of brain somatostatin on electroacupuncture analgesia of rat] Zheng L, et al. **Chen Tzu Yen Chiu** 1995;20(3):22-5 (Eng. Abstr.) **(Chi)**

[Study on a role of substance P in the spinal mechanisms of electroacupuncture analgesia] Bian JT. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):325-8 (Eng. Abstr.) **(Chi)**

ACUPUNCTURE ANESTHESIA

The use of acupuncture in dentistry [letter] Rosted P. **Aust Dent J** 1996 Feb;41(1):61

Combined acupuncture and medicinal anesthesia for neolarynx reconstruction. Huang H. **Chin Med J (Engl)** 1995 Nov;108(11):870-1

Decrease of anesthetics activity by electroacupuncture on Jen-Chung point in rabbits. Chang CL, et al. **Neurosci Lett** 1995 Dec 29;202(1-2):93-6

[Application of acupuncture anesthesia combining with drugs during neolarynx reconstruction] Huang H. **Chen Tzu Yen Chiu** 1995;20(2):3-6 (Eng. Abstr.) **(Chi)**

[Clinical study and application of auricular magnet anesthesia for the operation of the thyroid] Jiang J. **Chen Tzu Yen Chiu** 1995;20(3):4-8 **(Chi)**

[Afferent projections to the central superior raphe nucleus of brain stem and its relation to acupuncture anesthesia] Wang J, et al. **Chen Tzu Yen Chiu** 1995;20(3):9-12 (Eng. Abstr.) **(Chi)**

ACUPUNCTURE POINTS

A single-blind investigation of four auricular needle puncture configurations. Margolin A, et al. **Am J Chin Med** 1995; 23(2):105-14

Effect of acupuncture at Tsu San Li (St-36) on the pulse spectrum. Wang WK, et al. **Am J Chin Med** 1995; 23(2):121-30

P6 acupressure reduces symptoms of vection-induced motion sickness. Hu S, et al. **Aviat Space Environ Med** 1995 Jul; 66(7):631-4

Somatosensory evoked potential elicited by acupoint's stimulus. Abad-Alegria F, et al. **Clin Electroencephalogr** 1995 Oct;26(4):219-24

Detection of pelvic deep vein thrombosis by subcutaneous radionuclide venography utilizing an acupuncture point. Chiu NT, et al. **Clin Nucl Med** 1995 Oct;20(10):899-901

Treatment of biliary colic by water injection in the region of Qimen, Riyue, and Juque points. Jiang Y, et al. **J Tradit Chin Med** 1995 Sep;15(3):185-8

An exploration of eight-liao points. Wang L. **J Tradit Chin Med** 1995 Sep;15(3):195-7

Anti-inflammatory effects of tianrong acupoint on blood vessels of dura mater. Yu S, et al. **J Tradit Chin Med** 1995 Sep;15(3):209-13

Experience of Prof. Wei Jia in using acupoint fengchi. Zhang Q, et al. **J Tradit Chin Med** 1995 Dec;15(4):265-9

Effects of the weather conditions on mood and behaviour: the role of acupuncture points. Sher L. **Med Hypotheses** 1996 Jan;46(1):19-20

Decrease of anesthetics activity by electroacupuncture on Jen-Chung point in rabbits. Chang CL, et al. **Neurosci Lett** 1995 Dec 29;202(1-2):93-6

[The effect of electro-acupuncture at auricular & body acupoints on the curve changes of the pressure-volume of urinary bladder and the electric activity of pelvic nerves of rat] Ben H, et al. **Chen Tzu Yen Chiu** 1995;20(2):51-4 (Eng. Abstr.) **(Chi)**

[The functional connection among the "zusanli"-spinal dorsal horn neurons-trigeminal sensory nucleus of rats] Meng Z. **Chen Tzu Yen Chiu** 1995;20(3):29-32 (Eng. Abstr.) **(Chi)**

[Effect of electroacupuncture at "shenshu" point on renal blood flow in rabbits] Xu N, et al. **Chen Tzu Yen Chiu** 1995;20(2):48-50 (Eng. Abstr.) **(Chi)**

[Influence of changing Ca++ concentration in neiguan (PC 6) on the effect of acupuncture treating experimental arrhythmia of rabbits] Zhang Y, et al. **Chen Tzu Yen Chiu** 1995;20(2):63-7 (Eng. Abstr.) **(Chi)**

[Therapy of cantharides extract for perennial allergic rhinitis and its effect on total IgE in serum] Tang ZM, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun; 15(6):334-6 (Eng. Abstr.) **(Chi)**

[Biotics of human blood after applying microcurrents (letter)] Zorich OI, et al. **Biofizika** 1992 Mar-Apr;37(2):388-90 (Eng. Abstr.) **(Rus)**

[Cluster analysis of the course of regeneration of the rat submaxillary gland during treatment of acupuncture points] Denisov AB, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):659-62 **(Rus)**

[The clinico-physiological characteristics of biologically active points] Panasiuk IeM, et al. **Fiziol Zh** 1995 Jan-Apr; 41(1-2):117-21 (19 ref.) (Eng. Abstr.) **(Ukr)**

ACUPUNCTURE THERAPY

Acupuncture in angina pectoris: do psycho-social and neurophysiological factors relate to the effect? Ballegaard S, et al. **Acupunct Electrother Res** 1995 Apr-Jul; 20(2):101-16

Application of intensified (+) Qi Gong energy, (-) electrical field, (S) magnetic field, electrical pulses (1-2 pulses/sec), strong Shiatsu massage or acupuncture on the accurate organ representation areas of the hands to improve circulation and enhance drug uptake in pathological organs: clinical applications with special emphasis on the "Chlamydia-(Lyme)-uric acid syndrome" and "Chlamydia-(cytomegalovirus)-uric acid syndrome". Omura Y, et al. **Acupunct Electrother Res** 1995 Jan-Mar; 20(1):21-72

A neuromagnetic study of acupuncturing LI-4 (Hegu). Yang ZL, et al. **Acupunct Electrother Res** 1995 Jan-Mar; 20(1):15-20

Second-line and 'alternative' treatments for alcohol withdrawal: alpha-agonists, beta-blockers, anticonvulsants, acupuncture and neuro-electric therapy. Brewer C. **Alcohol Alcohol** 1995 Nov;30(6):799-803 (25 ref.)

Further discussion on foundation for acupuncture [letter] Lipinski B. **Altern Ther Health Med** 1996 Jan;2(1):14

Conditioned healing with electroacupuncture. Ulett GA. **Altern Ther Health Med** 1996 Sep;2(5):56-60 (52 ref.)

Another theory available for explaining acupuncture [letter] Zilberter T. **Altern Ther Health Med** 1996 May;2(3):17

Acupuncture protection against experimental hyperbilirubinemia and cholangitis in rats. Lin JG, et al. **Am J Chin Med** 1995;23(2):131-7

A single-blind investigation of four auricular needle puncture configurations. Margolin A, et al. **Am J Chin Med** 1995; 23(2):105-14

The effect of acupuncture on spinal motor neuron excitability in stroke patients. Yu YH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Oct; 56(4):258-63

Acupuncture treatment of patients with radiation-induced xerostomia. Blom M, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):182-90

Migration of an acupuncture needle into the medulla oblongata. Abumi K, et al. **Eur Spine J** 1996;5(2):137-9

Acupuncture in migraine: long-term outcome and predicting factors. Baischer W. **Headache** 1995 Sep;35(8):472-4

Acupuncture and migraine [letter] Duncan MR, et al. **Headache** 1996 Jun;36(6):397

Consistency of rotator-cuff calcifications. Observations on plain radiography, sonography, computed tomography, and at needle treatment. Farin PU. **Invest Radiol** 1996 May; 31(5):300-4

Enhanced bone metabolism induced by acupuncture. Kuno RC, et al. **J Nucl Med** 1995 Dec;36(12):2246-7

A nonconventional approach to the treatment of "environmental illness". Arnetz BB, et al. **J Occup Environ Med** 1995 Jul;37(7):838-44

Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. Vickers AJ. **J R Soc Med** 1996 Jun;89(6):303-11 (49 ref.)

Acupuncture for the treatment of cocaine addiction. Investigation of a needle puncture control. Avants SK, et al. **J Subst Abuse Treat** 1995 May-Jun;12(3):195-205

Effectiveness of adjunct therapies in crack cocaine treatment. Richard AJ, et al. **J Subst Abuse Treat** 1995 Nov-Dec; 12(6):401-13

Personal experience with acupuncture therapy. Chen K. **J Tradit Chin Med** 1995 Sep;15(3):203-8

Treatment of ulcerative colitis with acupuncture. Chen Z. **J Tradit Chin Med** 1995 Sep;15(3):231-3

206 cases of spinogenic dizziness treated by contralateral acupuncture. Cheng B. **J Tradit Chin Med** 1996 Mar; 16(1):35-6

Advanced in studies on acupuncture abstinence. Cui M. **J Tradit Chin Med** 1996 Mar;16(1):65-9 concl (38 ref.)

Advances in studies on acupuncture abstinence. Cui M. **J Tradit Chin Med** 1995 Dec;15(4):301-7, contd (32 ref.)

The treatment of pain in bone metastasis of cancer with the analgesic decoction of cancer and the acupoint therapeutic apparatus. Guo R, et al. **J Tradit Chin Med** 1995 Dec; 15(4):262-4

Acupuncture treatment of epigastric pain [clinical conference] Hu J. **J Tradit Chin Med** 1995 Sep;15(3):238-40

Observation of curative effect of acupuncture therapy plus scalp acupuncture for restoring consciousness and inducing

resuscitation in 80 cases of acute apoplexy. Liu C, et al. **J Tradit Chin Med** 1996 Mar;16(1):18–22

Recent progress in the studies on weight reduction by acupuncture and moxibustion. Liu Z, et al. **J Tradit Chin Med** 1995 Sep;15(3):224–30 (42 ref.)

23 cases of summer fever treated by needling huatuojiaji points. Shen X, et al. **J Tradit Chin Med** 1995 Sep; 15(3):192–4

3-directional penetration needling for the treatment of paralysis. Shi N. **J Tradit Chin Med** 1996 Mar;16(1):37–40

An exploration of eight-liao points. Wang L. **J Tradit Chin Med** 1995 Sep;15(3):195–7

Clinical experience of Dr. Shao Jingming in treatment of diseases by puncturing back-shu points. Wang M, et al. **J Tradit Chin Med** 1996 Mar;16(1):23–6

Treatment of cancerous abdominal pain by acupuncture on zusanli (ST 36)--a report of 92 cases. Xu S, et al. **J Tradit Chin Med** 1995 Sep;15(3):189–91

Anti-inflammatory effects of tianrong acupoint on blood vessels of dura mater. Yu S, et al. **J Tradit Chin Med** 1995 Sep;15(3):209–13

Experience of Prof. Wei Jia in using acupoint fengchi. Zhang Q, et al. **J Tradit Chin Med** 1995 Dec;15(4):265–9

Indications and contraindications in emergency acupuncture treatment. Zhang X. **J Tradit Chin Med** 1996 Mar; 16(1):70–7

Efficacy of traditional Chinese acupuncture in the treatment of symptomatic knee osteoarthritis: a pilot study. Berman BM, et al. **Osteoarthritis Cartilage** 1995 Jun;3(2):139–42

Acupuncture for the relief of cancer-related breathlessness. Filshie J, et al. **Palliat Med** 1996 Apr;10(2):145–50

[A study on factors of acupuncture methods affecting effects through acupuncture treatments for experimental gastric ulcer in rats] Fu Z. **Chen Tzu Yen Chiu** 1995;20(2):40–4 (Eng. Abstr.) **(Chi)**

[Influence of thoracic spinal subarachnoid microinjection of noradrenaline on the effect of electroacupuncture] Liu J, et al. **Chen Tzu Yen Chiu** 1995;20(2):28–32 (Eng. Abstr.) **(Chi)**

[A study of relation between rheumatoid arthritis (RA) and blood stasis--the effect of acupuncture promoting blood circulation to remove blood stasis] Sun Z. **Chen Tzu Yen Chiu** 1995;20(2):71–5 (Eng. Abstr.) **(Chi)**

[Effect of acupuncture on the regulation of cell-mediated immunity in the patients with malignant tumors] Wu B. **Chen Tzu Yen Chiu** 1995;20(3):67–71 (Eng. Abstr.) **(Chi)**

[Studies on regulatory effects of acupuncture on mucosal secretory IgA in patients with allergic asthma] Yang Y, et al. **Chen Tzu Yen Chiu** 1995;20(2):68–70 (Eng. Abstr.) **(Chi)**

[Influence of changing Ca++ concentration in neiguan (PC 6) on the effect of acupuncture treating experimental arrhythmia of rabbits] Zhang Y, et al. **Chen Tzu Yen Chiu** 1995;20(2):63–7 (Eng. Abstr.) **(Chi)**

[Effect of acupuncture on immunologic function and histopathology of transplanted mammary cancer in mice] Liu LJ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):615–7 (Eng. Abstr.) **(Chi)**

[Effect of acupuncture on heart rate variability in coronary heart disease patients] Shi X, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Sep; 15(9):536–8 (Eng. Abstr.) **(Chi)**

[Progress in the treatment of opiate dependence] Wu LZ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Sep;15(9):569–73 (38 ref.) **(Chi)**

[Effect of acupuncturing houxi and shenmen in treating cerebral traumatic dementia] Zhang AR, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Sep; 15(9):519–21 (Eng. Abstr.) **(Chi)**

[Treatment of esophageal motility disorders with acupuncture of the ear (preliminary report)] Hep A, et al. **Vnitr Lek** 1995 Jul;41(7):473–5 (Eng. Abstr.) **(Cze)**

[Value of acupuncture in treatment of migraine] Chrubasik S, et al. **Anaesthesiol Reanim** 1995;20(6):150–2 (25 ref.) (Eng. Abstr.) **(Ger)**

[Ancient Chinese prescriptions for hay fever. Herbs and acupuncture instead of desensitizing Western medicine?] Gendo U. **Fortschr Med** 1996 Apr 10;114(10):50–2 **(Ger)**

[Quality assurance in acupuncture therapy] Kubiena G. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):159–62 (Eng. Abstr.) **(Ger)**

[Effect of acupuncture on the overactive bladder] Kitakoji H, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct; 86(10):1514–9 (Eng. Abstr.) **(Jpn)**

[Acupuncture against stroke?] Abildgaard U. **Tidsskr Nor Laegeforen** 1995 Sep 30;115(23):2877 **(Nor)**

[Acupuncture therapy in stroke during the subacute phase. A randomized controlled trial] Sällström S, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30;115(23):2884–7 (Eng. Abstr.) **(Nor)**

[Effect of the antistressor effect of acupuncture on the functional state of aqualung divers] Apchel VIa. **Fiziol Cheloveka** 1996 Mar-Apr;22(2):136–8 **(Rus)**

[Bronchial nonspecific reactivity in patients with bronchial asthma and in the preasthmatic state and its alteration under the influence of acupuncture] Aleksandrova RA, et al. **Ter Arkh** 1995;67(8):42–5 (Eng. Abstr.) **(Rus)**

[The use of auricular puncture in the combined treatment of acute cholecystitis in elderly persons] Antonov AM, et al. **Vestn Khir Im I I Grek** 1995;154(3):104–5 **(Rus)**

[An analysis of the acupuncture treatment results in bronchial asthma patients] Aleksandrova RA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May-Jun; (3):10–2 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Transverse myelopathy after acupuncture therapy: a case report. Ilhan A, et al. **Acupunct Electrother Res** 1995 Aug-Dec;20(3-4):191–4

Localised lipoatrophy after acupuncture [letter; comment] Drago F, et al. **Lancet** 1996 May 25;347(9013):1484. Comment on: Lancet 1995 Jun 17;345(8964):1576.

[A case of posterior tuberculous spondylitis of the lumbar vertebra with the skull inoculated by acupuncture] Sasaki Y, et al. **Kekkaku** 1996 May;71(5):357–61 (Eng. Abstr.) **(Jpn)**

METHODS

P6 acupressure reduces symptoms of vection-induced motion sickness. Hu S, et al. **Aviat Space Environ Med** 1995 Jul; 66(7):631–4

PSYCHOLOGY

Why do patients turn to complementary medicine? An empirical study. Vincent C, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):37–48

ACUTE DISEASE

Functional outcomes of acute medical illness and hospitalization in older persons. Sager MA, et al. **Arch Intern Med** 1996 Mar 25;156(6):645–52

Alternatives to hospital care: what are they and who should decide? [see comments] Coast J, et al. **BMJ** 1996 Jan 20; 312(7024):162–6. Comment in: BMJ 1996 Apr 27;312(7038):1102.

T-lymphocyte subsets in acute illness. Feeney C, et al. **Crit Care Med** 1995 Oct;23(10):1680–5

Strategies for potential manipulation of anorexia during acute and chronic disease. Plata-Salamán CR. **Nutrition** 1995 Sep-Oct;11(5 Suppl):702–4 (39 ref.)

Anorexia during acute and chronic disease. Plata-Salamán CR. **Nutrition** 1996 Feb;12(2):69–78 (147 ref.)

ECONOMICS

Cost recovery and improved drug availability in Niger--implications for total patient treatment costs. Wouters A, et al. **Health Econ** 1996 Jan-Feb;5(1):37–59

NURSING

The changing profile of acute childhood illness: a need for the development of family nursing knowledge. Rennick JE. **J Adv Nurs** 1995 Aug;22(2):258–66 (57 ref.)

A model for collegiality among staff nurses in acute care. Hansen HE. **J Nurs Adm** 1995 Dec;25(12):11–20

PSYCHOLOGY

The essence of enduring and expressions of suffering: the reformulation of self. Morse JM, et al. **Sch Inq Nurs Pract** 1996 Spring;10(1):43–60; discussion 61–74

THERAPY

Evaluation of the appropriate use of parenteral nutrition in an acute care setting. Hester DD, et al. **J Am Diet Assoc** 1996 Jun;96(6):602–3

On-site acute care for residents of long-term care facilities. Gordon M. **J Am Geriatr Soc** 1996 May;44(5):606–7

Extended hospital stays with increasing age: the impact of an acute geriatric unit [see comments] Flamer HE, et al. **Med J Aust** 1996 Jan 1;164(1):10–3. Comment in: Med J Aust 1996 Jan 1;164(1):5–6.

Optimum care of the elderly in an acute general hospital [editorial; comment] Lipski P. **Med J Aust** 1996 Jan 1; 164(1):5–6. Comment on: Med J Aust 1996 Jan 1;164(1):10–3.

Gene therapy in acute critical illness. Brigham KL, et al. **New Horiz** 1995 May;3(2):321–9 (34 ref.)

ACUTE LARYNGOTRACHEOBRONCHITIS VIRUS see **PARAINFLUENZA VIRUS TYPE 2**

ACUTE LUNG INJURY see **RESPIRATORY DISTRESS SYNDROME, ADULT**

ACUTE PAIN SERVICE see **PAIN CLINICS**

ACUTE-PHASE PROTEINS

[Acute phase proteins] Mašek Z, et al. **Sb Lek** 1995; 96(4):451–4 (Eng. Abstr.) **(Cze)**

ANALYSIS

Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons. Ballou SP, et al. **Age Ageing** 1996 May;25(3):224–30

Isolation of acute-phase proteins from plasma for determination of fractional synthesis rates by a stable isotope tracer technique. Jahoor F, et al. **Anal Biochem** 1996 Apr 5;236(1):95–100

Identification of acute-phase proteins (APP) in circulating immune complexes (CIC) in esophageal cancer patients' sera. Croce MV, et al. **Cancer Invest** 1996;14(5):421–6

Concentrations of acute-phase proteins in infants [letter; comment] Johnson AM. **Clin Chem** 1995 Nov;41(11):1673 . Comment on: Clin Chem 1995 Apr;41(4):605–8.

Two-dimensional electrophoretic patterns of acute-phase human serum proteins in the course of bacterial and viral diseases. Bini L, et al. **Electrophoresis** 1996 Mar;17(3):612–6

The major acute phase serum protein in pigs is homologous to human plasma kallikrein sensitive PK-120. González-Ramón N, et al. **FEBS Lett** 1995 Sep 11; 371(3):227–30

Detection of neopterin, interleukin-6 and acute-phase proteins as parameters of potential monocyte activation in preoperative patients. Haupt W, et al. **Infection** 1995 Sep-Oct;23(5):263–6

Alterations in serum lipids in lepromatous leprosy patients with and without ENL reactions and their relationship to acute phase proteins. Memon RA, et al. **Int J Lepr Other Mycobact Dis** 1996 Jun;64(2):115–22

Close relationship between hemostatic factors and acute-phase reaction as normal aging process [letter] Kario K, et al. **J Am Geriatr Soc** 1996 May;44(5):614–5

Detection of stable and active periodontitis sites by clinical assessment and gingival crevicular acute-phase protein levels. Adonogianaki E, et al. **J Periodontal Res** 1996 Feb; 31(2):135–43

Acute-phase proteins in osteoarthritis. Sipe JD. **Semin Arthritis Rheum** 1995 Oct;25(2):75–86 (115 ref.)

Acute-phase plasma proteins in gastric cancer: association with metastatic potential and prognosis. Ogoshi K, et al. **Tumour Biol** 1996;17(5):281–9

[Initial personal experiences with alpha-1-antitrypsin determination in feces] Schwery S, et al. **Schweiz Med Wochenschr** 1995 Sep 23;125(38):1783–7 (Eng. Abstr.) **(Ger)**

[Usefulness of the determination of C reactive protein and other acute phase proteins in rheumatoid arthritis] Galeazzi M, et al. **Recenti Prog Med** 1995 Nov;86(11):456–62 (40 ref.) (Eng. Abstr.) **(Ita)**

[Acid-soluble blood glycoproteins in patients with diffuse purulent peritonitis] Riabov GA, et al. **Anesteziol Reanimatol** 1995 Jul-Aug;(4):44–6 (Eng. Abstr.) **(Rus)**

[Clinical significance of alpha-1 acid glycoprotein and antiprotease blood proteins in salmonellosis and food poisoning] Mironova OG, et al. **Klin Med (Mosk)** 1995; 73(4):78–80 **(Rus)**

ANTAGONISTS & INHIBITORS

ADP-ribosylation of Rho enhances actin polymerization-coupled shape oscillations in human neutrophils. Ehrengruber MU, et al. **FEBS Lett** 1995 Sep 25;372(2-3):161–4

BIOSYNTHESIS

Immunohistochemical demonstration of interleukin-1 beta induced changes in acute-phase proteins and albumin in rat liver. Ballmer PE, et al. **Acta Histochem** 1995 Jul; 97(3):281–9

The acute phase protein response in patients receiving subcutaneous IL-6. Banks RE, et al. **Clin Exp Immunol** 1995 Oct;102(1):217–23

Circulating levels of IL-11 and leukaemia inhibitory factor (LIF) do not significantly participate in the production of acute-phase proteins by the liver. Gabay C, et al. **Clin Exp Immunol** 1996 Aug;105(2):260–5

The effect of nutritional status on the cytokine and acute phase protein responses to elective surgery. Curtis GE, et al. **Cytokine** 1995 May;7(4):380–8

A new hepatocyte stimulating factor: cardiotrophin-1 (CT-1). Peters M, et al. **FEBS Lett** 1995 Sep 25; 372(2-3):177–80

The hepatocyte growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: divergent effect on interleukin-6-stimulated genes. Guillén MI, et al. **Hepatology** 1996 Jun;23(6):1345–52

The effect of WSEWS pentapeptide and WSEWS-specific monoclonal antibodies on constitutive and IL-6 induced acute-phase protein production by a human hepatoma cell line, HEPG-2. Biró J, et al. **Immunol Lett** 1995 May; 46(1-2):183–7

Transcription factors Stat3 and Stat5b are present in rat liver nuclei late in an acute phase response and bind interleukin-6 response elements. Ripperger JA, et al. **J Biol Chem** 1995 Dec 15;270(50):29998–30006

Hypoxia, a novel inducer of acute phase gene expression in a human hepatoma cell line. Wenger RH, et al. **J Biol Chem** 1995 Nov 17;270(46):27865–70

Interleukin-6 production by human liver (myo)fibroblasts in culture. Evidence for a regulatory role of LPS, IL-1 beta and TNF alpha. Tiggelman AM, et al. **J Hepatol** 1995 Sep; 23(3):295–306

The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteins. Schumann RR, et al. **Mol Cell Biol** 1996 Jul;16(7):3490–503

HI-6 therapy and the acute phase response in the rat. Ivanović-Matić S, et al. **Toxicology** 1996 Jan 8;

106(1-3):11-7

CHEMISTRY

Inflammatory cytokines controlling branching of N-heteroglycans of acute phase protein. Gryska K, et al. **Adv Exp Med Biol** 1995;376:239-45

Demonstration of a glycoprotein derived from the 24p3 gene in mouse uterine luminal fluid. Chu ST, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):545-50

Primary structure of the pig homologue of human IHRP: inter-alpha-trypsin inhibitor family heavy chain-related protein. Hashimoto K, et al. **J Biochem (Tokyo)** 1996 Mar; 119(3):577-84

Posttranslational folding of alpha 1-inhibitor 3. Evidence for a compaction process. Wassler M, et al. **J Biol Chem** 1995 Oct 13;270(41):24598-603

DRUG EFFECTS

Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. McMillan DC, et al. **Eur J Surg Oncol** 1995 Oct;21(5):531-4

GENETICS

Hepatic heat shock and acute-phase gene expression are induced simultaneously after celiotomy in the anesthetized pig. Pannen BH, et al. **Anesthesiology** 1995 Oct;83(4):850-9

Demonstration of a glycoprotein derived from the 24p3 gene in mouse uterine luminal fluid. Chu ST, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):545-50

Identification of a transcriptional regulatory region of the rat pancreatitis-associated protein I (PAP I) gene that confers tissue specificity. Dusetti NJ, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):643-7

The rat genes encoding the pancreatitis-associated proteins I, II and III (Pap1, Pap2, Pap3), and the lithostathin/pancreatic stone protein/regeneration protein (Reg) colocalize at 4q33-->q34. Stephanova E, et al. **Cytogenet Cell Genet** 1996;72(1):83-5

Ribozyme mediated cleavage of acute phase serum amyloid A (A-SAA) mRNA in vitro. Gaughan DJ, et al. **FEBS Lett** 1995 Oct 30;374(2):241-5

An apparent autocrine mechanism amplifies the dexamethasone- and retinoic acid-induced expression of mouse lipocalin-encoding gene 24p3. Garay-Rojas E, et al. **Gene** 1996 May 8;170(2):173-80

Identification of estrogen regulated genes in Fe33 rat hepatoma cells by differential display polymerase chain reaction and their hormonal regulation in rat liver and uterus. Diel P, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(3-4):363-73

Changes in gene expression of pancreatitis-associated protein and pancreatic secretory trypsin inhibitors in experimental pancreatitis produced by pancreatic duct occlusion in rats: comparison with gene expression of cholecystokinin and secretin. Funakoshi A, et al. **Pancreas** 1995 Aug; 11(2):147-53

Mechanisms of transcriptional activation of lipopolysaccharide binding protein (LBP). Schumann RR. **Prog Clin Biol Res** 1995;392:297-304

IMMUNOLOGY

Non specific resistance against malaria pre-erythrocytic stages: involvement of acute phase proteins. Pied S, et al. **Parasite** 1995 Sep;2(3):263-8

ISOLATION & PURIFICATION

Characterisation of bovine lipopolysaccharide binding protein and the in vivo acute phase response to Pasteurella haemolytica Type A. Horadagoda NU, et al. **Vet Immunol Immunopathol** 1995 Nov;49(1-2):61-74

METABOLISM

Inflammatory cytokines controlling branching of N-heteroglycans of acute phase protein. Gryska K, et al. **Adv Exp Med Biol** 1995;376:239-45

Altitude-dependent decrease in plasma fibronectin [letter] Wenisch C, et al. **Arch Intern Med** 1995 Oct 9; 155(18):2012-3

The role of Stat and C/EBP transcription factors in the synergistic activation of rat serine protease inhibitor-3 gene by interleukin-6 and dexamethasone. Kordula T, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):1019-27

Differences in the binding of transforming growth factor beta 1 to the acute-phase reactant and constitutively synthesized alpha-macroglobulins of rat. Webb DJ, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):579-86

Serum acute phase reactants and prognosis in renal cell carcinoma. Ljungberg B, et al. **Cancer** 1995 Oct 15; 76(8):1435-9

Diagnostic usefulness of acute-phase protein measurement in hepatocellular carcinoma. Fabris C, et al. **Cancer Invest** 1996;14(2):103-8

Acute phase proteins in serum and cerebrospinal fluid in the course of bacterial meningitis. Paradowski M, et al. **Clin Biochem** 1995 Aug;28(4):459-66

Quantitative cytochemistry of human leukocyte elastase compared with plasma elastase and acute phase proteins in inflammatory diseases. Pradella M, et al. **Clin Chim Acta** 1995 Jul 31;239(1):91-101

Whole-body protein turnover and hepatic protein synthesis are increased by vaccination in man. Cayol M, et al. **Clin Sci (Colch)** 1995 Oct;89(4):389-96

Regulation of pancreatitis-associated protein (HIP/PAP) mRNA levels in mouse pancreas and small intestine. McKie AT, et al. **Clin Sci (Colch)** 1996 Aug;91(2):213-8

Haematological and acute-phase responses associated with delayed-onset muscle soreness in humans. Gleeson M, et al. **Eur J Appl Physiol** 1995;71(2-3):137-42

Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseases [see comments] Propst A, et al. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1031-6. Comment in: Eur J Gastroenterol Hepatol 1995 Nov;7(11):1021-3.

Expression of beta-2-integrins and L-selectin by leukocytes and changes in acute-phase reactants in total hip replacement surgery. Høgevold HE, et al. **Eur Surg Res** 1996;28(3):190-200

Interactions of human mannose-binding protein with lipoteichoic acids. Polotsky VY, et al. **Infect Immun** 1996 Jan;64(1):380-3

Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. Hemmann U, et al. **J Biol Chem** 1996 May 31;271(22):12999-3007

Posttranslational folding of alpha 1-inhibitor 3. Evidence for a compaction process. Wassler M, et al. **J Biol Chem** 1995 Oct 13;270(41):24598-603

Induction of neurite outgrowth by interleukin-6 is accompanied by activation of Stat3 signaling pathway in a variant PC12 cell (E2) line. Wu YY, et al. **J Biol Chem** 1996 May 31;271(22):13023-32

STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. Zhang D, et al. **J Biol Chem** 1996 Apr 19;271(16):9503-9

Binding of rat alpha 1-inhibitor-3-methylamine to the alpha 2-macroglobulin signaling receptor induces second messengers. Misra UK, et al. **J Cell Biochem** 1996 Apr; 61(1):61-71

The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. Burlingame RW, et al. **J Immunol** 1996 Jun 15;156(12):4783-8

Lipopolysaccharide binding protein as a marker of inflammation in synovial fluid of patients with arthritis: correlation with interleukin 6 and C-reactive protein. Heumann D, et al. **J Rheumatol** 1995 Jul;22(7):1224-9

Effect of fentanyl citrate anesthesia on protein turnover in patients with esophagectomy. Yoshida S, et al. **J Surg Res** 1996 Aug;64(2):120-7

Lipoprotein(a) in relation to acute phase reaction in patients with rheumatoid arthritis and polymyalgia rheumatica. Wållberg-Jonsson S, et al. **Scand J Clin Lab Invest** 1995 Jul;55(4):309-15

Developmental, nutritional, and hormonal regulation of the pancreatitis-associated protein I and III gene expression in the rat small intestine. Sansonetti A, et al. **Scand J Gastroenterol** 1995 Jul;30(7):664-9

Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Kossmann T, et al. **Shock** 1995 Nov;4(5):311-7

Metabolic responses after laparoscopic or open hernia repair. Schrenk P, et al. **Surg Endosc** 1996 Jun;10(6):628-32

Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Schols AM, et al. **Thorax** 1996 Aug;51(8):819-24

Acute phase protein concentrations predict parasite clearance rate during therapy for visceral leishmaniasis. Wasunna KM, et al. **Trans R Soc Trop Med Hyg** 1995 Nov-Dec; 89(6):678-81

[Acute-phase proteins in inflammation] Engler R. **C R Seances Soc Biol Fil** 1995;189(4):563-78 (20 ref.) (Eng. Abstr.) **(Fre)**

[The effect of an antimalarial agent (chloroquine) on acute phase reactants in patients with rheumatoid arthritis] Jajić Z, et al. **Reumatizam** 1994;41(2):5-7 (Eng. Abstr.) **(Scr)**

PHYSIOLOGY

Hip, a novel cochaperone involved in the eukaryotic Hsc70/Hsp40 reaction cycle. Höhfeld J, et al. **Cell** 1995 Nov 17;83(4):589-98

Isoforms of human C4b-binding protein. II. Differential modulation of the C4BPA and C4BPB genes by acute phase cytokines. Criado García O, et al. **J Immunol** 1995 Oct 15;155(8):4037-43

The acute-phase response. Pannen BH, et al. **New Horiz** 1995 May;3(2):183-97 (84 ref.)

ACUTE-PHASE REACTANTS see **ACUTE-PHASE PROTEINS**

ACUTE-PHASE REACTION

Circadian variation of human acute phase response. Perdiz P, et al. **Arch Med Res** 1996 Summer;27(2):157-63

Specific expression in brain and liver driven by the hemopexin promoter in transgenic mice. Tolosano E, et al. **Biochem Biophys Res Commun** 1996 Jan 26; 218(3):694-703

The effect of nutritional status on the cytokine and acute phase protein responses to elective surgery. Curtis GE, et al. **Cytokine** 1995 May;7(4):380-8

Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapy-induced leucopenia. Bruserud O, et al. **Eur J Haematol** 1996 Jul;57(1):87-95

Stimulation of megakaryocytopoiesis in mice by human modified C-reactive protein (mCRP). Potempa LA, et al. **Exp Hematol** 1996 Feb;24(2):258-64

Incidence and pathophysiological relevance of postoperative endotoxemia. Berger D, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):285-90

The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. Peters M, et al. **J Exp Med** 1996 Apr 1;183(4):1399-406

The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. Burlingame RW, et al. **J Immunol** 1996 Jun 15;156(12):4783-8

Acute phase levels of C-reactive protein enhance IL-1 beta and IL-1ra production by human blood monocytes but inhibit IL-1 beta and IL-1ra production by alveolar macrophages. Pue CA, et al. **J Immunol** 1996 Feb 15; 156(4):1594-600

The acute-phase response. Pannen BH, et al. **New Horiz** 1995 May;3(2):183-97 (84 ref.)

Susceptibility to Plasmodium berghei infection in rats is modulated by the acute phase response. Vreden SG, et al. **Parasite Immunol** 1995 Sep;17(9):445-50

Lipoprotein(a) in relation to acute phase reaction in patients with rheumatoid arthritis and polymyalgia rheumatica. Wållberg-Jonsson S, et al. **Scand J Clin Lab Invest** 1995 Jul;55(4):309-15

[Consequences of surgery on nutritional status] Chioléro R. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:39-46 (Eng. Abstr.) **(Fre)**

BLOOD

Effect of dietary protein concentration on responses to Escherichia coli endotoxin in broiler chickens. Takahashi K, et al. **Br J Nutr** 1995 Aug;74(2):173-82

Extrapancreatic origin of the pancreatic secretory trypsin inhibitor as an acute-phase reactant. Jönsson P, et al. **Pancreas** 1996 Apr;12(3):303-7

Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction. Results of the ECAT Angina Pectoris Study Group. Haverkate F, et al. **Thromb Haemost** 1995 Apr;73(4):561-7

High lipoprotein (a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Kario K, et al. **Thromb Haemost** 1995 Oct;74(4):1020-4

[Serum protein binding of fentanyl. The effect of postoperative acute phase reaction with elevated alpha 1-acid glycoprotein and methodologic problems in determination by equilibrium dialysis] Wiesner G, et al. **Anaesthesist** 1996 Apr;45(4):323-9 (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Interleukin-1 beta induces production of granulocyte colony-stimulating factor in human hepatoma cells. Lai CF, et al. **Blood** 1996 May 15;87(10):4143-8

Regulation of bovine acute phase responses by recombinant interleukin-1 beta. Godson DL, et al. **Can J Vet Res** 1995 Oct;59(4):249-55

Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. Schweitzer DH, et al. **J Bone Miner Res** 1995 Jun; 10(6):956-62

Murine cardiotrophin-1 stimulates the acute-phase response in rat hepatocytes and H35 hepatoma cells. Richards CD, et al. **J Interferon Cytokine Res** 1996 Jan;16(1):69-75

HI-6 therapy and the acute phase response in the rat. Ivanović-Matić S, et al. **Toxicology** 1996 Jan 8; 106(1-3):11-7

DIAGNOSIS

Increase of interleukin-6 plasma levels after elective craniotomy: influence of interleukin-10 and catecholamines. Heesen M, et al. **Acta Neurochir (Wien)** 1996;138(1):77-80

ENZYMOLOGY

Discordant regulation of proteins of cholesterol metabolism during the acute phase response. Feingold KR, et al. **J Lipid Res** 1995 Jul;36(7):1474-82

ETIOLOGY

Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Biasucci LM, et al. **Am J Cardiol** 1996 Jan 1;77(1):85-7

A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. McMillan DC, et al. **Am J Surg** 1995 Oct; 170(4):319-22

Acute-phase responses to cardiopulmonary bypass in children weighing less than 10 kilograms. Butler J, et al. **Ann Thorac Surg** 1996 Aug;62(2):538-42

Acute phase responses of vasoactive hormones to non pulsatile systemic circulation. Tatsumi E, et al. **ASAIO J** 1995 Jul-Sep;41(3):M460-5

Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. Robson SC, et al. **Br J Haematol** 1996 Jun 2;93(4):943-9

Inflammatory reaction and capillary leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations. Seghaye MC, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):687-97

Acute-phase response in rat to carbon tetrachloride-azathioprine induced cirrhosis and partial hepatectomy of cirrhotic liver. Fouad FM, et al. **J Toxicol Environ Health** 1996 Apr 19;47(6):601-15

Acute-phase response in snakebite [letter; comment] Barraviera B. **Rev Inst Med Trop Sao Paulo** 1994 Sep-Oct; 36(5):479. Comment on: Rev Inst Med Trop Sao Paulo 1994 Mar-Apr;36(2):149-51.

Acute phase response after liver transplantation for fulminant hepatic failure and cirrhosis. Izumi S, et al. **Transpl Int** 1995;8(5):340-5

GENETICS

Ferritin translation by interleukin-6: the role of sequences upstream of the start codons of the heavy and light subunit genes. Rogers JT. **Blood** 1996 Mar 15;87(6):2525-37

Two genes controlling acute phase responses by the antitumor polysacch aride, lentinan. Maeda YY, et al. **Immunogenetics** 1996;43(4):215-9

Effect of thermal injury on the expression of transcription factors that regulate acute phase response genes: the response of C/EBP alpha, C/EBP beta, and C/EBP delta to thermal injury. Gilpin DA, et al. **Surgery** 1996 Jun; 119(6):674-83

IMMUNOLOGY

Neuronal activity and neuropeptide gene transcription in the brains of immune-challenged rats. Rivest S, et al. **J Neuroendocrinol** 1995 Jul;7(7):501-25

The influence of trauma on changes in neutrophil granulocyte function assessed by an analysis of granulocyte migration. Hofer HP, et al. **Langenbecks Arch Chir** 1996;381(3):148-54

METABOLISM

Haptoglobin. A potential reporter molecule for glycosylation changes in disease. Turner GA. **Adv Exp Med Biol** 1995; 376:231-8 (26 ref.)

Interleukin 10 inhibits interleukin 6 production and acute phase response in rheumatoid arthritis. Łącki JK, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(1):11-4

Changes in protein distribution in normal and protein-deficient rats during an acute-phase 'injury' response. Jennings G, et al. **Br J Nutr** 1996 Jul;76(1):123-32

Whole-body protein turnover and hepatic protein synthesis are increased by vaccination in man. Cayol M, et al. **Clin Sci (Colch)** 1995 Oct;89(4):389-96

Interleukin 1 binding to its type I, but not type II receptor, modulates the in vivo acute phase response. Oldenburg HS, et al. **Cytokine** 1995 Aug;7(6):510-6

Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Kossmann T, et al. **Shock** 1995 Nov;4(5):311-7

[The role of proteins and amino acids in acute phase response] Rakarić-Poznanović M, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:107-9 (Eng. Abstr.) **(Scr)**

PHYSIOPATHOLOGY

Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Biasucci LM, et al. **Am J Cardiol** 1996 Jan 1;77(1):85-7

Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Espat NJ, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R185-90

Acute phase responses of vasoactive hormones to non pulsatile systemic circulation. Tatsumi E, et al. **ASAIO J** 1995 Jul-Sep;41(3):M460-5

New aspects concerning the regulation of the post-operative acute phase reaction during cardiac surgery. Berger D, et al. **Clin Chim Acta** 1995 Aug 14;239(2):121-30

Peroxides in human leucocytes in acute septic shock: a preliminary study of acute phase changes and mortality. Leaver HA, et al. **Eur J Clin Invest** 1995 Oct;25(10):777-83

Inflammatory cell response to acute muscle injury. Tidball JG. **Med Sci Sports Exerc** 1995 Jul;27(7):1022-32 (118 ref.)

Injury in laparoscopic surgery. Bolufer JM, et al. **Surg Laparosc Endosc** 1995 Aug;5(4):318-23

[Postoperative homeostatic imbalance after trauma surgical interventions of various degrees in polytrauma] Waydhas C, et al. **Unfallchirurg** 1995 Sep;98(9):455-63 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Reduced hepatic acute-phase response after simultaneous resection for gastrointestinal cancer with synchronous liver metastases. Kimura F, et al. **Br J Surg** 1996 Jul;83(7):1002-6

URINE

Urinary zinc excretion in patients with different disorders: the acute phase response in the kidney. Melichar B, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl** 1993;36(4-5):325-35

VETERINARY

The influence of supplemental chromium and vaccines on the acute phase response of newly arrived feeder calves. Wright AJ, et al. **Can J Vet Res** 1995 Oct;59(4):311-5

ACUTE-PHASE STATE see **ACUTE-PHASE REACTION**

ACUTE PHYSIOLOGY AND CHRONIC HEALTH EVALUATION see **APACHE**

ACUTE RESPIRATORY DISEASE VIRUSES see **ADENOVIRUSES, HUMAN**

ACUTE RETINAL NECROSIS see **RETINAL NECROSIS SYNDROME, ACUTE**

ACYCLOGUANOSINE see **ACYCLOVIR**

ACYCLOVIR

ADMINISTRATION & DOSAGE

Topical acyclovir is beneficial in recurrent herpes labialis [letter; comment] [see comments] Lamey PJ. **BMJ** 1996 Apr 13;312(7036):975. Comment on: BMJ 1996 Jan 6;312(7022):6. Comment in: BMJ 1996 Jul 6;313(7048):46.

Evidence for efficacy of topical acyclovir in recurrent herpes labialis is weak [letter; comment] Worrall G. **BMJ** 1996 Jul 6;313(7048):46. Comment on: BMJ 1996 Apr 13;312(7036):975.

Randomized case-controlled trial of oral low-dose acyclovir for prevention of virus infections in recipients of renal allografts. Jiang J, et al. **Chin Med J (Engl)** 1995 Jun; 108(6):459-61

Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. Kletzmayr J, et al. **J Am Soc Nephrol** 1996 Feb;7(2):325-30

Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. Valenza M, et al. **J Heart Lung Transplant** 1995 Jul-Aug;14(4):659-65

Herpes simplex encephalitis [letter; comment] Shafran SD. **N Engl J Med** 1996 Jul 18;335(3):209. Comment on: N Engl J Med 1996 Mar 7;334(10):634.

Prospective epidemiologic study of painful and neurologic sequelae induced by herpes zoster in patients treated early with oral acyclovir. Bruxelle J. **Neurology** 1995 Dec;45(12 Suppl 8):S78-9

[Treatment of herpes simplex keratouveitis with systemic and local administration of acyclovir] Říhová E, et al. **Cesk Slov Oftalmol** 1996 Apr;52(2):109-14 (Eng. Abstr.) **(Cze)**

[My experiences with Zovir herpes tablets (letter)] Ambjørn A. **Ugeskr Laeger** 1996 May 13;158(20):2867-8 **(Dan)**

ADVERSE EFFECTS

Acyclovir in chickenpox [letter] Jenks PJ, et al. **Arch Dis Child** 1996 Feb;74(2):184

Stevens-Johnson syndrome induced by treatment with acyclovir. Fazal BA, et al. **Clin Infect Dis** 1995 Oct; 21(4):1038-9

Acyclovir-induced neutropenia in an infant with herpes simplex encephalitis: case report. Feder HM Jr, et al. **Clin Infect Dis** 1995 Jun;20(6):1557-9

Delirium associated with acyclovir treatment in a patient with renal failure. Revankar SG, et al. **Clin Infect Dis** 1995 Aug;21(2):435-6 (14 ref.)

No evidence of contact sensitization to acyclovir in acute dermatitis of the lips following local application of Zovirax cream. Koch P. **Contact Dermatitis** 1995 Oct;33(4):255-7

A pharmacokinetic and safety evaluation of a 28 day course of oral acyclovir in elderly patients with herpes zoster [letter] Moss PJ, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):271-3

Acyclovir-associated encephalopathy, lack of relationship between acyclovir levels and symptoms. de Knegt RJ, et al. **Nephrol Dial Transplant** 1995;10(9):1775-7

Acyclovir-associated encephalopathy in haemodialysis [letter] Peces R, et al. **Nephrol Dial Transplant** 1996 Apr; 11(4):752

Hemodialysis removal of acyclovir. Leikin JB, et al. **Vet Hum Toxicol** 1995 Jun;37(3):233-4

[Acyclovir nephrotoxicity] Briso-Montiano JM, et al. **An Med Interna** 1995 Oct;12(10):501-2 (Eng. Abstr.) **(Spa)**

ANALOGS & DERIVATIVES

Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Smiley ML, et al. **Adv Exp Med Biol** 1996;394:33-9 (23 ref.)

Activity of penciclovir against Epstein-Barr virus. Bacon TH, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1599-602

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Beutner KR, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1546-53

Antiviral effect in human cytomegalovirus-infected cells, pharmacokinetics, and intravitreal toxicology in rabbits of acyclovir diphosphate dimyristoylglycerol. Shakiba S, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1383-5

Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Soul-Lawton J, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2759-64

Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Thackray AM, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):846-51

Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Beutner KR. **Antiviral Res** 1995 Dec;28(4):281-90 (29 ref.)

Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV. Hasegawa T, et al. **Antiviral Res** 1995 Jun;27(3):271-9

A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Spruance SL, et al. **Arch Intern Med** 1996 Aug 12-26;156(15):1729-35

New drugs--reports of new drugs recently approved by the FDA. Valacyclovir. Shinkai I, et al. **Bioorg Med Chem** 1996 Jan;4(1):1-2

Use of famciclovir and valaciclovir in the treatment of viral keratitis [letter] Gatchel S. **Clin Infect Dis** 1996 May; 22(5):886

Use of penciclovir and famciclovir in the management of genital herpes. Sacks SL. **Curr Probl Dermatol** 1996; 24:219-26 (34 ref.)

Aciclovir and its l-valyl ester, valaciclovir. Smiley ML, et al. **Curr Probl Dermatol** 1996;24:209-18 (56 ref.)

Activity of penciclovir in antiviral assays against herpes simplex virus. Bacon TH, et al. **J Antimicrob Chemother** 1996 Feb;37(2):303-13

Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid. de Bony F, et al. **J Antimicrob Chemother** 1996 Feb;37(2):383-7

Comparison of high-performance liquid chromatography and capillary zone electrophoresis in penciclovir biodegradation kinetic studies. Hsu LC, et al. **J Chromatogr B Biomed Appl** 1995 Jul 7;669(1):85-92

Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. Thackray AM, et al. **J Infect Dis** 1996 Feb;173(2):291-9

Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir. Standring-Cox R, et al. **J Virol Methods** 1996 Jan; 56(1):3-11

Valacyclovir. **Med Lett Drugs Ther** 1996 Jan 5;38(965):3-4

Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. Haynes P, et al. **Mutat Res** 1996 Jul 10;369(1-2):65-74

Acyclovir triphosphate inhibits the diagnostic polymerase chain reaction for cytomegalovirus. Yedidag EN, et al. **Transplantation** 1996 Jul 27;62(2):238-42

[Compounds similar to acyclovir. IX. Synthesis of 7-hydroxy-2,5-dioxaheptyl nucleic acid derivatives] Smirnov IP, et al. **Bioorg Khim** 1995 Oct;21(10):790-4 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

A pharmacokinetic and safety evaluation of a 28 day course of oral acyclovir in elderly patients with herpes zoster [letter] Moss PJ, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):271-3

Single dose and steady state pharmacokinetics of intravenous acyclovir in children undergoing bone marrow and liver transplant. Joshi P, et al. **Pediatr Infect Dis J** 1995 Aug; 14(8):717-9

Theoretical design of prodrug-enhancer combination based on a skin diffusion model: prediction of permeation of acyclovir prodrugs treated with 1-geranylazacycloheptan-2-one. Bando H, et al. **Pharm Res** 1996 Mar;13(3):427-32

Iontophoresis enhances the transport of acyclovir through nude mouse skin by electrorepulsion and electroosmosis. Volpato NM, et al. **Pharm Res** 1995 Nov;12(11):1623-7

PHARMACOLOGY

Treatment of acyclovir-resistant herpes simplex and varicella zoster virus infections. Safrin S. **Adv Exp Med Biol** 1996; 394:59-66 (44 ref.)

In vitro effects of a combination of zidovudine and acyclovir on growth of normal human myeloid progenitor cells [letter] Shaked Y, et al. **Am J Hematol** 1996 Apr; 51(4):329-30

Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Wald A, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):8-15

Comparative evaluation of microplate enzyme-linked immunosorbent assay versus plaque reduction assay for antiviral susceptibility testing of herpes simplex virus isolates. Safrin S, et al. **Antimicrob Agents Chemother** 1996

Apr;40(4):1017-9
Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV. Hasegawa T, et al. **Antiviral Res** 1995 Jun;27(3):271-9
Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Kim JH, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):861-8
Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. Boeckh M, et al. **J Infect Dis** 1995 Oct;172(4):939-43
Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type-2 herpes simplex virus: masked heterogeneity or reversion? Sasadeusz JJ, et al. **J Infect Dis** 1996 Sep;174(3):476-82
A blinded comparison of two methods of viral susceptibility testing: plaque reduction assay versus microplate in situ ELISA. Leahy BJ, et al. **J Virol Methods** 1996 Jan; 56(1):85-90
Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir. Standring-Cox R, et al. **J Virol Methods** 1996 Jan; 56(1):3-11
Inhibitory effect of a nucleoside analog, acyclovir, on leukemia cells. Nishimaki J, et al. **Leuk Res** 1996 May; 20(5):415-20
Antiviral drugs from the nucleoside analog family block volume-activated chloride channels. Gschwentner M, et al. **Mol Med** 1995 May;1(4):407-17
Does acyclovir increase serum lithium levels? Sylvester RK, et al. **Pharmacotherapy** 1996 May-Jun;16(3):466-8
[Acyclovir and guinea-pig airway smooth muscle] Nasuhara Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul; 33(7):728-32 (Eng. Abstr.) **(Jpn)**
[Resistance of herpes simplex virus to acyclovir: laboratory and clinical aspects] Briazzhikova TS, et al. **Antibiot Khimioter** 1995 Nov-Dec;40(11-12):29-33 (Eng. Abstr.) **(Rus)**
[Varying sensitivity to acyclovir of different years' clinical isolates of herpes simplex virus] Briazhikova TS, et al. **Vestn Ross Akad Med Nauk** 1995;(9):12-5 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Treatment of acyclovir-resistant herpes simplex and varicella zoster virus infections. Safrin S. **Adv Exp Med Biol** 1996; 394:59-66 (44 ref.)
Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Wald A, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):8-15
Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Whitley RJ, et al. **Ann Intern Med** 1996 Sep 1;125(5):376-83
Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. Adour KK, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):371-8
Failure of acyclovir sodium therapy in herpes simplex encephalitis. Gürses N, et al. **Ann Trop Paediatr** 1996 Jun; 16(2):173-5
Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Beutner KR, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1546-53
Efficacy of traditional herbal medicines in combination with acyclovir against herpes simplex virus type 1 infection in vitro and in vivo. Kurokawa M, et al. **Antiviral Res** 1995 May;27(1-2):19-37
Unique clinical trial design: combination acyclovir plus prednisone therapy of localized zoster in the normal host. Whitley RJ, et al. **Antiviral Res** 1996 Jan;29(1):67-8
Herpetic trigeminal trophic syndrome. Treatment with acyclovir and sublesional triamcinolone. Shea CR, et al. **Arch Dermatol** 1996 Jun;132(6):613-4
A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. The Herpetic Eye Disease Study Group. **Arch Ophthalmol** 1996 Sep;114(9):1065-72
Herpetic eye disease study. You can help [editorial] Dawson CR, et al. **Arch Ophthalmol** 1996 Jan;114(1):89-90 (8 ref.)
Serous retinal detachments in a patient with clinically resistant cytomegalovirus retinitis. Dodds EM, et al. **Arch Ophthalmol** 1996 Jul;114(7):896-7
Acyclovir in recurrent herpes labialis [editorial] [see comments] Worrall G. **BMJ** 1996 Jan 6;312(7022):6. Comment in: BMJ 1996 Apr 13;312(7036):975.
Acyclovir-resistant chronic cutaneous herpes simplex in Wiskott-Aldrich syndrome. Modiano P, et al. **Br J Dermatol** 1995 Sep;133(3):475-8
Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Hoh HB, et al. **Br J Ophthalmol** 1996 Feb;80(2):140-3
Aciclovir and its l-valyl ester, valaciclovir. Smiley ML, et al. **Curr Probl Dermatol** 1996;24:209-18 (56 ref.)
Acyclovir in the treatment of hand-foot-and-mouth disease. Shelley WB, et al. **Cutis** 1996 Apr;57(4):232-4
Successful empiric treatment of HSV hepatitis in pregnancy. Case report and review of the literature. Glorioso DV, et al. **Dig Dis Sci** 1996 Jun;41(6):1273-5
Recurrence rate of herpetic uveitis in patients on long-term oral acyclovir. Rodriguez A, et al. **Doc Ophthalmol** 1995; 90(4):331-40
Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation. Epstein JB, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):158-62
Oral acyclovir in herpes zoster ophthalmicus [letter; comment] Harding SP. **Eye** 1995;9 (Pt 3):390-2. Comment on: Eye 1994;8 (Pt 1):70-4.
Oral acyclovir in treatment of suspected herpes simplex encephalitis. Awasthi S, et al. **Indian Pediatr** 1995 Apr; 32(4):485-7
Herpes simplex virus resistance to acyclovir: clinical relevance. Pottage JC Jr, et al. **Infect Agents Dis** 1995 Sep; 4(3):115-24 (111 ref.)
Antiviral chemotherapy in genital herpes simplex virus infections. Patel R, et al. **Int J STD AIDS** 1995 Sep-Oct; 6(5):320-8 (78 ref.)
Efficacy of herpes vaccine and acyclovir (ACV) in a rabbit model following intraocular inoculation of herpes simplex virus. Narang HK. **J Chemother** 1995 Jun;7(3):210-5
Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs. Bravo FJ, et al. **J Infect Dis** 1996 Jan;173(1):1-6
Acyclovir in human immunodeficiency virus patients [letter; comment] Stein DS, et al. **J Infect Dis** 1996 Feb; 173(2):504-7. Comment on: J Infect Dis 1995 Aug;172(2):346-52.
Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. Tynell E, et al. **J Infect Dis** 1996 Aug;174(2):324-31
Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. Wutzler P, et al. **J Med Virol** 1995 Jul;46(3):252-7
Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. Rosengren LE, et al. **J Neurol Sci** 1995 Nov;133(1-2):61-5
Class-specific antibody response in acyclovir-treated and adenine arabinoside-treated patients with primary genital herpes simplex virus infection. Kawana T, et al. **Microbiol Immunol** 1995;39(10):795-9
Immunocompromised patients, herpes zoster and acyclovir [letter] Elder M, et al. **N Z Med J** 1996 May 24; 109(1022):196
Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Scott LL, et al. **Obstet Gynecol** 1996 Jan;87(1):69-73
Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes [letter] Watts H, et al. **Obstet Gynecol** 1996 Jun;87(6):1064-5
Perinatal herpes: current status and obstetric management strategies. Scott LL. **Pediatr Infect Dis J** 1995 Oct; 14(10):827-32; discussion 832-5 (73 ref.)
Postexposure prophylaxis of varicella in children with leukemia by oral acyclovir [letter; comment] Ishida Y, et al. **Pediatrics** 1996 Jan;97(1):150-1. Comment on: Pediatrics 1993 Aug;92(2):219-22.
Prevention of facial herpetic infections after chemical peel and dermabrasion: new treatment strategies in the prophylaxis of patients undergoing procedures of the perioral area. Perkins SW, et al. **Plast Reconstr Surg** 1996 Sep;98(3):427-33; discussion 434-5
Chronic ulcerating acyclovir-resistant varicella zoster lesions in an AIDS patient. Bernhard P, et al. **Scand J Infect Dis** 1995;27(6):623-5
Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction. Ham JM, et al. **Transplant Proc** 1995 Oct;27(5 Suppl 1):31-3
Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient. Uber L, et al. **Transplant Proc** 1995 Oct;27(5 Suppl 1):42-3
[Acyclovir freely obtainable (letter)] Kroes AC, et al. **Ned Tijdschr Geneeskd** 1996 Jul 6;140(27):1412-3 **(Dut)**
[Acyclovir in the treatment of varicella in immunocompetent children] Catania S, et al. **Riv Eur Sci Med Farmacol** 1995 Jul-Aug;17(4):115-23 (Eng. Abstr.) **(Ita)**
[Action of para-aminobenzoic acid and its combination with acyclovir in herpetic infection] Akberova SI, et al. **Antibiot Khimioter** 1995 Oct;40(10):25-9 (Eng. Abstr.) **(Rus)**
[Varicella pneumonia in adults (letter)] Marti J, et al. **An Med Interna** 1995 Dec;12(12):618-9 **(Spa)**
[Periodical EEG pattern modifications in herpetic encephalitis treated with acyclovir] Benetó A, et al. **Rev Neurol** 1996 Jul;24(131):829-32 (Eng. Abstr.) **(Spa)**

TOXICITY

Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. Haynes P, et al. **Mutat Res** 1996 Jul 10;369(1-2):65-74

ACYL CARRIER PROTEIN

BIOSYNTHESIS

The apparent coupling between synthesis and posttranslational modification of Escherichia coli acyl carrier protein is due to inhibition of amino acid biosynthesis. Keating DH, et al. **J Bacteriol** 1996 May; 178(9):2662-7

CHEMISTRY

Conserved secondary structure in the actinorhodin polyketide synthase acyl carrier protein from Streptomyces coelicolor A3(2) and the fatty acid synthase acyl carrier protein from Escherichia coli. Crump MP, et al. **FEBS Lett** 1996 Aug 12;391(3):302-6
NMR investigations of the structural properties of the nodulation protein, NodF, from Rhizobium leguminosarum and its homology with Escherichia coli acyl carrier protein. Ghose R, et al. **FEBS Lett** 1996 Jun 10;388(1):66-72
An isoleucine to valine substitution in Escherichia coli acyl carrier protein results in a functional protein of decreased molecular radius at elevated pH. Keating DH, et al. **J Biol Chem** 1996 Jul 5;271(27):15905-10

GENETICS

Different respiratory-defective phenotypes of Neurospora crassa and Saccharomyces cerevisiae after inactivation of the gene encoding the mitochondrial acyl carrier protein. Schneider R, et al. **Curr Genet** 1995 Dec;29(1):10-7
Bacillus subtilis acyl carrier protein is encoded in a cluster of lipid biosynthesis genes. Morbidoni HR, et al. **J Bacteriol** 1996 Aug;178(16):4794-800
Acyl carrier protein of Azospirillum brasilense: properties of the purified protein and sequencing of the corresponding gene, acpP. Maiti MK, et al. **Microbiology** 1996 Aug;142 (Pt 8):2097-103
Overexpression, purification, and characterization of Escherichia coli acyl carrier protein and two mutant proteins. Hill RB, et al. **Protein Expr Purif** 1995 Aug; 6(4):394-400

ISOLATION & PURIFICATION

Isolation of Vibrio harveyi acyl carrier protein and the fabG, acpP, and fabF genes involved in fatty acid biosynthesis. Shen Z, et al. **J Bacteriol** 1996 Jan;178(2):571-3

METABOLISM

The acyl carrier protein of malonate decarboxylase of Malonomonas rubra contains 2'-(5"-phosphoribosyl)-3'-dephosphocoenzyme A as a prosthetic group. Berg M, et al. **Biochemistry** 1996 Apr 16;35(15):4689-96
The apparent coupling between synthesis and posttranslational modification of Escherichia coli acyl carrier protein is due to inhibition of amino acid biosynthesis. Keating DH, et al. **J Bacteriol** 1996 May; 178(9):2662-7
Regulation of fatty acid elongation and initiation by acyl-acyl carrier protein in Escherichia coli. Heath RJ, et al. **J Biol Chem** 1996 Jan 26;271(4):1833-6
An isoleucine to valine substitution in Escherichia coli acyl carrier protein results in a functional protein of decreased molecular radius at elevated pH. Keating DH, et al. **J Biol Chem** 1996 Jul 5;271(27):15905-10
Acyl carrier protein of Azospirillum brasilense: properties of the purified protein and sequencing of the corresponding gene, acpP. Maiti MK, et al. **Microbiology** 1996 Aug;142 (Pt 8):2097-103

PHYSIOLOGY

Inhibition of beta-ketoacyl-acyl carrier protein synthase III (FabH) by acyl-acyl carrier protein in Escherichia coli. Heath RJ, et al. **J Biol Chem** 1996 May 3; 271(18):10996-1000

ACYL COA see **ACYL COENZYME A**

ACYL-COA-CHOLESTEROL ACYLTRANSFERASE see **CHOLESTEROL ACYLTRANSFERASE**

ACYL COA DEHYDROGENASES see **FATTY ACID DESATURASES**

ACYL COA DESATURASES see **FATTY ACID DESATURASES**

ACYL COA HYDROLASE see **PALMITOYL-COA HYDROLASE**

ACYL COA LYSOLECITHIN ACYLTRANSFERASE see **LYSOLECITHIN ACYLTRANSFERASE**

ACYL COA SYNTHETASES see **COENZYME A SYNTHETASES**

ACYL COENZYME A

ANALYSIS

Tissue acylcarnitine and acyl-coenzyme A profiles in chronically hyperammonemic mice treated with sodium benzoate and supplementary L-carnitine. Michalak A, et al. **Biomed Pharmacother** 1995;49(7-8):350-7

ANTAGONISTS & INHIBITORS

Structural alterations of human immortal astrocytes after inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase by lovastatin. Bobryshev YV, et al. **J Submicrosc Cytol Pathol** 1995 Oct;27(4):435-44

BIOSYNTHESIS

Evidence for the interaction of avian 3-hydroxy-3-methylglutaryl-CoA synthase histidine 264 with acetoacetyl-CoA. Misra I, et al. **Biochemistry** 1996 Jul 23;35(29):9610-6

Benzoate-coenzyme A ligase, encoded by badA, is one of three ligases able to catalyze benzoyl-coenzyme A formation during anaerobic growth of Rhodopseudomonas palustris on benzoate. Egland PG, et al. **J Bacteriol** 1995 Nov;177(22):6545-51

To be free or not: the fate of pimelate in Bacillus sphaericus and in Escherichia coli [letter] Lemoine Y, et al. **Mol Microbiol** 1996 Feb;19(3):645-7

CHEMICAL SYNTHESIS

Preparative synthesis of beta-L-malyl-coenzyme A assisted by malyl-coenzyme A synthetase from Pseudomonas AM1. Willibald B, et al. **Anal Biochem** 1995 May 20;227(2):363-7

CHEMISTRY

Structure of 4-chlorobenzoyl coenzyme A dehalogenase determined to 1.8 A resolution: an enzyme catalyst generated via adaptive mutation. Benning MM, et al. **Biochemistry** 1996 Jun 25;35(25):8103-9

Structural modulation of 2-enoyl-CoA bound to reduced acyl-CoA dehydrogenases: a resonance Raman study of a catalytic intermediate. Nishina Y, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):800-8

GENETICS

Reversion of transformed phenotype of human adenocarcinoma A549 cells by expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase complementary DNA. Seronie-Vivien S, et al. **Cell Growth Differ** 1995 Nov;6(11):1415-23

Lysophosphatidylcholine increases 3-Hydroxy-3-methylglutaryl-coenzyme A reductase gene expression in CaCo-2 cells. Muir LV, et al. **Gastroenterology** 1996 Apr;110(4):1068-76

METABOLISM

Acyl CoA and lipid synthesis from ketone bodies by the extramitochondrial fraction of hepatoma tissue. Hildebrandt L, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):307-12

Substrate stereospecificity in oxidation of (25S)-3 alpha, 7 alpha, 12 alpha-trihydroxy-5 beta-cholestanoyl-CoA by peroxisomal trihydroxy-5 beta-cholestanoyl-CoA oxidase. Pedersen JI, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):37-42

Acyl-CoA binding and acylation of UDP-glucuronosyltransferase isoforms of rat liver: their effect on enzyme activity. Yamashita A, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):301-8

Long-chain acyl-CoA profiles in cultured fibroblasts from patients with defects in fatty acid oxidation. Tamvakopoulos CS, et al. **Biochem Mol Med** 1995 Jun; 55(1):15-21

Evidence for the interaction of avian 3-hydroxy-3-methylglutaryl-CoA synthase histidine 264 with acetoacetyl-CoA. Misra I, et al. **Biochemistry** 1996 Jul 23;35(29):9610-6

Evidence for electrophilic catalysis in the 4-chlorobenzoyl-CoA dehalogenase reaction: UV, Raman, and 13C-NMR spectral studies of dehalogenase complexes of benzoyl-CoA adducts. Taylor KL, et al. **Biochemistry** 1995 Oct 24;34(42):13881-8

Substrate specificity of microsomal 1-acyl-sn-glycero-3-phosphoinositol acyltransferase in rat submandibular gland for polyunsaturated long-chain acyl-CoAs. Yashiro K, et al. **Biochim Biophys Acta** 1995 Oct 5;1258(3):288-96

Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Prentki M, et al. **Diabetes** 1996 Mar;45(3):273-83 (163 ref.)

Benzoyl-coenzyme A reductase (dearomatizing), a key enzyme of anaerobic aromatic metabolism. ATP dependence of the reaction, purification and some properties of the enzyme from Thauera aromatica strain K172. Boll M, et al. **Eur J Biochem** 1995 Dec 15; 234(3):921-33

Mechanisms by which fatty-acyl-CoA esters inhibit or activate glucose-6-phosphatase in intact and detergent-treated rat liver microsomes. Mithieux G, et al. **Eur J Biochem** 1996 Feb 1;235(3):799-803

Characterization and isolation of enzymes that hydrolyze short-chain acyl-CoA in rat-liver mitochondria. Svensson LT, et al. **Eur J Biochem** 1996 Jul 15;239(2):526-31

Unusual dehydrations in anaerobic bacteria: considering ketyls (radical anions) as reactive intermediates in enzymatic reactions. Buckel W. **FEBS Lett** 1996 Jun 24; 389(1):20-4 (43 ref.)

Photolabeling acyl CoA binding proteins in microsome preparations. Hare JF. **FEBS Lett** 1995 Nov 20; 375(3):188-92

Oligomerization of VIP21-caveolin in vitro is stabilized by long chain fatty acylation or cholesterol. Monier S, et al. **FEBS Lett** 1996 Jun 17;388(2-3):143-9

Peroxisomal beta-oxidation of 2-methyl-branched acyl-CoA esters: stereospecific recognition of the 2S-methyl compounds by trihydroxycoprostanoyl-CoA oxidase and pristanoyl-CoA oxidase. Van Veldhoven PP, et al. **FEBS Lett** 1996 Jun 10;388(1):80-4

C-NMR study on the interaction of medium-chain acyl-CoA dehydrogenase with acetoacetyl-CoA. Miura R, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):512-9

Structural modulation of 2-enoyl-CoA bound to reduced acyl-CoA dehydrogenases: a resonance Raman study of a catalytic intermediate. Nishina Y, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):800-8

Activation of the ATP-sensitive K+ channel by long chain acyl-CoA. A role in modulation of pancreatic beta-cell glucose sensitivity. Larsson O, et al. **J Biol Chem** 1996 May 3;271(18):10623-6

Heterozygosity for long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency and deterioration in liver function in a newborn infant infected with human immunodeficiency virus. Hicks P, et al. **J Pediatr** 1995 Oct; 127(4):599-602

Analysis of the regulation of the Aspergillus nidulans penicillin biosynthesis gene aat (penDE), which encodes acyl coenzyme A:6-aminopenicillanic acid acyltransferase. Litzka O, et al. **Mol Gen Genet** 1995 Dec 15;249(5):557-69

Saturable binding sites for the coenzyme A ester of nafenopin, a peroxisome proliferator, in rat liver cytosol. Morgan C, et al. **Xenobiotica** 1995 Dec;25(12):1293-300

PHARMACOLOGY

Effect of pH and acyl-CoA chain length on the conversion of heart mitochondrial CPT-I/CPTo to a high affinity, malonyl-CoA-inhibited state. Bieber LL, et al. **Biochim Biophys Acta** 1996 Aug 13;1290(3):261-6

Effects of fatty acids and fatty acyl CoA esters on Cu(2+)-induced conversion of xanthine dehydrogenase to oxidase in rabbit liver. Fujita T, et al. **Free Radic Biol Med** 1995 Oct;19(4):487-91

Inhibitory effect of 3-hydroxyacyl-CoAs and other long-chain fatty acid beta-oxidation intermediates on mitochondrial oxidative phosphorylation. Ventura FV, et al. **J Inherit Metab Dis** 1996;19(2):161-4

ACYL COENZYME A SYNTHETASES see **COENZYME A SYNTHETASES**

ACYLATION

Mechanisms of phosphoryl and acyl transfer. Cleland WW, et al. **FASEB J** 1995 Dec;9(15):1585-94 (50 ref.)

ACYLNEURAMINATE CYTIDYLYLTRANSFERASE

GENETICS

Lec32 is a new mutation in Chinese hamster ovary cells that essentially abrogates CMP-N-acetylneuraminic acid synthetase activity. Potvin B, et al. **J Biol Chem** 1995 Dec 22;270(51):30415-21

Characterization of cpsF and its product CMP-N-acetylneuraminic acid synthetase, a group B streptococcal enzyme that can function in K1 capsular polysaccharide biosynthesis in Escherichia coli. Haft RF, et al. **Mol Microbiol** 1996 Feb;19(3):555-63

ISOLATION & PURIFICATION

Purification, cloning, and expression of a cytidine 5'-monophosphate N-acetylneuraminic acid synthetase from Haemophilus ducreyi. Tullius MV, et al. **J Biol Chem** 1996 Jun 28;271(26):15373-80

METABOLISM

Characterization of cpsF and its product CMP-N-acetylneuraminic acid synthetase, a group B streptococcal enzyme that can function in K1 capsular polysaccharide biosynthesis in Escherichia coli. Haft RF, et al. **Mol Microbiol** 1996 Feb;19(3):555-63

ACYLTRANSFERASES

ANALYSIS

Immunocytochemical characterization and subcellular localization of human myristoyl-CoA: protein N-myristoyltransferase in HeLa cells. McIlhinney RA, et al. **Exp Cell Res** 1996 Mar 15;223(2):348-56

Glutaminyl-cyclase expression in the bovine/porcine hypothalamus and pituitary. Böckers TM, et al. **J Neuroendocrinol** 1995 Jun;7(6):445-53

ANTAGONISTS & INHIBITORS

Relationship between arachidonate--phospholipid remodeling and apoptosis. Surette ME, et al. **Biochemistry** 1996 Jul 16;35(28):9187-96

Photolabeling acyl CoA binding proteins in microsome preparations. Hare JF. **FEBS Lett** 1995 Nov 20; 375(3):188-92

Amidepsines, inhibitors of diacylglycerol acyltransferase produced by Humicola sp. FO-2942. I. Production, isolation and biological properties. Tomoda H, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):937-41

Amidepsines, inhibitors of diacylglycerol acyltransferase produced by Humicola sp. FO-2942. II. Structure elucidation of amidepsines A, B and C. Tomoda H, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):942-7

New isochromophilones VII and VIII produced by Penicillium sp. FO-4164. Yang DJ, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):223-9

Reduction of oncoprotein transformation in vitro by albumin [letter] Raju PV, et al. **J Natl Cancer Inst** 1996 Apr 17; 88(8):556-7

Effects of CoA-independent transacylase inhibitors on the production of lipid inflammatory mediators. Winkler JD, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1338-47

Lipid peroxidation inhibits acyl-CoA:-1-acyl-sn-glycero-3-phosphocholine O-acyltransferase but not CTP: phosphocholine cytidylyltransferase activity in rat brain membranes. Alberghina M, et al. **Neurochem Int** 1995 May;26(5):477-87

BIOSYNTHESIS

Biosynthesis of Azorhizobium caulinodans Nod factors. Study of the activity of the NodABCS proteins by expression of the genes in Escherichia coli. Mergaer P, et al. **J Biol Chem** 1995 Dec 8;270(49):29217-23

Isolation of Arabidopsis mutants altered in the light-regulation of chalcone synthase gene expression using a transgenic screening approach. Jackson JA, et al. **Plant J** 1995 Sep;8(3):369-80

Analysis of cis-regulatory elements involved in the activation of a member of chalcone synthase gene family (PsChs1) in pea. Seki H, et al. **Plant Mol Biol** 1996 Jun;31(3):479-91

BLOOD

Reduced fatty acid ethyl ester synthase activity in the white blood cells of alcoholics. Gorski NP, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):268-74

Fatty acid ethyl ester synthase, an enzyme for nonoxidative ethanol metabolism, is present in serum after liver and pancreatic injury. Aleryani S, et al. **Clin Chem** 1996 Jan; 42(1):24-7

CHEMISTRY

Fatty acid ethyl ester synthesis by human liver microsomes. Treloar T, et al. **Biochim Biophys Acta** 1996 Jan 19; 1299(2):160-6

Conserved secondary structure in the actinorhodin polyketide synthase acyl carrier protein from Streptomyces coelicolor A3(2) and the fatty acid synthase acyl carrier protein from Escherichia coli. Crump MP, et al. **FEBS Lett** 1996 Aug 12;391(3):302-6

Divergent sequence motifs correlated with the substrate specificity of (methyl)malonyl-CoA:acyl carrier protein transacylase domains in modular polyketide synthases. Haydock SF, et al. **FEBS Lett** 1995 Oct 30;374(2):246-8

Transacylase-like structure and its role in substrate channeling of 6-hydroxymellein synthase, a multifunctional polyketide biosynthetic enzyme in carrot cell extracts. Kurosaki F. **FEBS Lett** 1996 Jan 22;379(1):97-102

Lysophosphatidic acid acyltransferase from meadowfoam mediates insertion of erucic acid at the sn-2 position of triacylglycerol in transgenic rapeseed oil. Lassner MW, et al. **Plant Physiol** 1995 Dec;109(4):1389-94

Crystallization of UDP-N-acetylglucosamine O-acyltransferase from Escherichia coli. Pfitzner U, et al. **Proteins** 1995 Jun;22(2):191-2

A left-handed parallel beta helix in the structure of UDP-N-acetylglucosamine acyltransferase. Raetz CR, et al. **Science** 1995 Nov 10;270(5238):997-1000

DEFICIENCY

[Biotinidase deficiency. Its form of presentation and response to treatment] Campistol J, et al. **An Esp Pediatr** 1996 Apr; 44(4):389-92 (22 ref.) **(Spa)**

GENETICS

Reduced expression of kan-1 (encoding putative bile acid-CoA-amino acid N-acyltransferase) mRNA in livers of rats after partial hepatectomy and during sepsis. Furutani M, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):203-8

A rapid screen of active site mutants in glycinamide ribonucleotide transformylase. Warren MS, et al. **Biochemistry** 1996 Jul 9;35(27):8855-62

Molecular cloning of the murine branched chain alpha-ketoacid dehydrogenase E2 subunit: presence of 3' B1 repeat elements. Costeas PA, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1-2):25-8

Application of an optimized electroporation procedure for replacement of the polyhydroxyalkanoate synthase I gene in Nocardia corallina. Valentin HE, et al. **Can J Microbiol** 1996 Jul;42(7):715-9

Molecular cloning, sequencing, and expression in Escherichia coli of the chalcone synthase gene. Shao L, et al.

Chin J Biotechnol 1995;11(2):131-5
Suppression of flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense and sense genes. de Lange P, et al. Curr Top Microbiol Immunol 1995; 197:57-75 (88 ref.)
Developmental regulation of co-suppression in Petunia hybrida. Flavell RB, et al. Curr Top Microbiol Immunol 1995;197:43-56 (63 ref.)
A plant acyltransferase involved in triacylglycerol biosynthesis complements an Escherichia coli sn-1-acylglycerol-3-phosphate acyltransferase mutant. Hanke C, et al. Eur J Biochem 1995 Sep 15;232(3):806-10
The Aspergillus nidulans penicillin-biosynthesis gene aat (penDE) is controlled by a CCAAT-containing DNA element. Litzka O, et al. Eur J Biochem 1996 Jun 15; 238(3):675-82
Co-transcription of a homologue of the formamidopyrimidine-DNA glycosylase (fpg) and lysophosphatidic acid acyltransferase (nlaA) in Neisseria meningitidis. Swartley JS, et al. FEMS Microbiol Lett 1995 Dec 15;134(2-3):171-6
Comparison of the phenotypes of the lpxA and lpxD mutants of Escherichia coli. Vuorio R, et al. FEMS Microbiol Lett 1995 Dec 15;134(2-3):227-32
Genetic and physiological characterization of a Rhizobium etli mutant strain unable to synthesize poly-beta-hydroxybutyrate. Cevallos MA, et al. J Bacteriol 1996 Mar;178(6):1646-54
Molecular analysis of the poly(3-hydroxyalkanoate) synthase gene from a methylotrophic bacterium, Paracoccus denitrificans. Ueda S, et al. J Bacteriol 1996 Feb; 178(3):774-9
Function of the htrB high temperature requirement gene of Escherchia coli in the acylation of lipid A: HtrB catalyzed incorporation of laurate. Clementz T, et al. J Biol Chem 1996 May 17;271(20):12095-102
The human purH gene product, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase. Cloning, sequencing, expression, purification, kinetic analysis, and domain mapping. Rayl EA, et al. J Biol Chem 1996 Jan 26;271(4):2225-33
Genetic regulation of fatty acid modifying enzyme from Staphylococcus aureus. Chamberlain NR, et al. J Med Microbiol 1996 Feb;44(2):125-9
Functional analysis of the Bacillus subtilis purT gene encoding formate-dependent glycinamide ribonucleotide transformylase. Saxild HH, et al. Microbiology 1995 Sep; 141 (Pt 9):2211-8
Analysis of the regulation of the Aspergillus nidulans penicillin biosynthesis gene aat (penDE), which encodes acyl coenzyme A:6-aminopenicillanic acid acyltransferase. Litzka O, et al. Mol Gen Genet 1995 Dec 15;249(5):557-69
Genetic studies reveal that myristoylCoA:protein N-myristoyltransferase is an essential enzyme in Candida albicans. Weinberg RA, et al. Mol Microbiol 1995 Apr; 16(2):241-50
Mutation analysis of the chromosome 14q24.3 dihydrolipoyl succinyltransferase (DLST) gene in patients with early-onset Alzheimer disease. Cruts M, et al. Neurosci Lett 1995 Oct 13;199(1):73-7
Isolation of Arabidopsis mutants altered in the light-regulation of chalcone synthase gene expression using a transgenic screening approach. Jackson JA, et al. Plant J 1995 Sep;8(3):369-80
Organization of soybean chalcone synthase gene clusters and characterization of a new member of the family. Akada S, et al. Plant Mol Biol 1995 Oct;29(2):189-99
Identification of a cDNA that encodes a 1-acyl-sn-glycerol-3-phosphate acyltransferase from Limnanthes douglasii. Brown AP, et al. Plant Mol Biol 1995 Oct;29(2):267-78
Cis elements and potential trans-acting factors for the developmental regulation of the Phaseolus vulgaris CHS15 promoter. Hotter GS, et al. Plant Mol Biol 1995 Sep; 28(6):967-81
Cloning of a coconut endosperm cDNA encoding a 1-acyl-sn-glycerol-3-phosphate acyltransferase that accepts medium-chain-length substrates. Knutzon DS, et al. Plant Physiol 1995 Nov;109(3):999-1006
Targeted replacement of the mycocerosic acid synthase gene in Mycobacterium bovis BCG produces a mutant that lacks mycosides. Azad AK, et al. Proc Natl Acad Sci U S A 1996 May 14;93(10):4787-92
Sterol esterification in yeast: a two-gene process. Yang H, et al. Science 1996 May 31;272(5266):1353-6

ISOLATION & PURIFICATION

Identification and characterization of multiple forms of bovine brain N-myristoyltransferase. Glover CJ, et al. J Biol Chem 1995 Sep 29;270(39):23226-33

METABOLISM

Production of poly(hydroxyalkanoic acid). Lee SY, et al. Adv Biochem Eng Biotechnol 1995;52:27-58 (131 ref.)
Effect of NADPH-associated keto-reducing domain on substrate entry into 6-hydroxymellein synthase, a multifunctional polyketide synthetic enzyme involved in phytoalexin biosynthesis in carrot. Kurosaki F. Arch Biochem Biophys 1996 Apr 1;328(1):213-7
Fatty acid amide biosynthesis: a possible new role for peptidylglycine alpha-amidating enzyme and acyl-coenzyme A: glycine N-acyltransferase. Merkler DJ, et al. Arch Biochem Biophys 1996 Jun 15;330(2):430-4
Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: involvement of Ca(2+)-dependent transacylase and phosphodiesterase activities. Sugiura T, et al. Biochem Biophys Res Commun 1996 Jan 5;218(1):113-7
Characterization and cellular localization of human myristoyl-COA: protein N-myristoyltransferase. McIlhinney RA. Biochem Soc Trans 1995 Aug;23(3):549-53
Fatty acids and anionic phospholipids alter the palmitoyl coenzyme A kinetics of hepatic monoacylglycerol acyltransferase in Triton X-100 mixed micelles. Coleman RA, et al. Biochemistry 1996 Jul 23;35(29):9576-83
Binding of phenylarsenoxide to Arg-tRNA protein transferase is independent of vicinal thiols. Li J, et al. Biochemistry 1995 Dec 5;34(48):15829-37
A rapid screen of active site mutants in glycinamide ribonucleotide transformylase. Warren MS, et al. Biochemistry 1996 Jul 9;35(27):8855-62
Distribution of myristoyl-CoA:protein N-myristoyl transferase activity in rabbit intestine. Magnuson BA, et al. Biochim Biophys Acta 1996 Apr 19;1300(2):119-24
Comparison of acceptor and donor substrates in the CoA-independent transacylase reaction in human neutrophils. Nixon AB, et al. Biochim Biophys Acta 1996 May 20;1300(3):187-96
Thioesterase and protein deacylase activities of porcine pancreatic phospholipase A2. Nocito M, et al. Biochim Biophys Acta 1996 Jan 5;1299(1):17-22
Fatty acid ethyl ester synthesis by human liver microsomes. Treloar T, et al. Biochim Biophys Acta 1996 Jan 19; 1299(2):160-6
Substrate specificity of microsomal 1-acyl-sn-glycero-3-phosphoinositol acyltransferase in rat submandibular gland for polyunsaturated long-chain acyl-CoAs. Yashiro K, et al. Biochim Biophys Acta 1995 Oct 5;1258(3):288-96
Fatty acyl-Co A: sphingosine acyltransferase in bovine brain mitochondria: its solubilization and reconstitution onto the membrane lipid liposomes. Shimeno H, et al. Biol Pharm Bull 1995 Oct;18(10):1335-9
Mechanistic studies on the 8-amino-7-oxopelargonate synthase, a pyridoxal-5'-phosphate-dependent enzyme involved in biotin biosynthesis. Ploux O, et al. Eur J Biochem 1996 Feb 15;236(1):301-8
Transacylase-like structure and its role in substrate channeling of 6-hydroxymellein synthase, a multifunctional polyketide biosynthetic enzyme in carrot cell extracts. Kurosaki F. FEBS Lett 1996 Jan 22;379(1):97-102
Amino-acid substitutions in the cleavage site of acyl-coenzyme A:isopenicillin N acyltransferase from Penicillium chrysogenum: effect on proenzyme cleavage and activity. Tobin MB, et al. Gene 1995 Aug 30; 162(1):29-35
Identification of the catalytic triad of the lipase/acyltransferase from Aeromonas hydrophila. Brumlik MJ, et al. J Bacteriol 1996 Apr;178(7):2060-4
Activation of detergent-solubilized diacylglycerol acyltransferase by anionic phospholipids. Kamisaka Y, et al. J Biochem (Tokyo) 1996 Mar;119(3):520-3
A novel enzyme that catalyzes the esterification of N-acetylsphingosine. Metabolism of C2-ceramides. Abe A, et al. J Biol Chem 1996 Jun 14;271(24):14383-9
Substrate specificity of glycinamide ribonucleotide transformylase from chicken liver. Antle VD, et al. J Biol Chem 1996 Mar 15;271(11):6045-9
G-protein palmitoyltransferase activity is enriched in plasma membranes. Dunphy JT, et al. J Biol Chem 1996 Mar 22; 271(12):7154-9
Lipoylation of acyltransferase components of alpha-ketoacid dehydrogenase complexes. Fujiwara K, et al. J Biol Chem 1996 May 31;271(22):12932-6
Identification and characterization of multiple forms of bovine brain N-myristoyltransferase. Glover CJ, et al. J Biol Chem 1995 Sep 29;270(39):23226-33
Auto-regulation of retinoic acid biosynthesis through regulation of retinol esterification in human keratinocytes. Kurlandsky SB, et al. J Biol Chem 1996 Jun 28; 271(26):15346-52
Coenzyme A-independent monoacylglycerol acyltransferase from rat intestinal mucosa. Tsujita T, et al. J Biol Chem 1996 Jan 26;271(4):2156-61
Lipid-modified, cysteinyl-containing peptides of diverse structures are efficiently S-acylated at the plasma membrane of mammalian cells. Schroeder H, et al. J Cell Biol 1996 Aug;134(3):647-60
Protein N-myristoylation as a chemotherapeutic target for cancer [editorial] Felsted RL, et al. J Natl Cancer Inst 1995 Nov 1;87(21):1571-3
Increased N-myristoyltransferase activity observed in rat and human colonic tumors. Magnuson BA, et al. J Natl Cancer Inst 1995 Nov 1;87(21):1630-5
Saccharomyces cerevisiae expressing bacterial polyhydroxybutyrate synthase produces poly-3-hydroxybutyrate. Leaf TA, et al. Microbiology 1996 May;142 (Pt 5):1169-80
Mammalian myristoyl CoA: protein N-myristoyltransferase. Raju RV, et al. Mol Cell Biochem 1995 Aug-Sep; 149-150:191-202 (89 ref.)
Rhizobium nodulation protein NodA is a host-specific determinant of the transfer of fatty acids in Nod factor biosynthesis. Ritsema T, et al. Mol Gen Genet 1996 Apr 24;251(1):44-51
Cloning of a cDNA encoding the 21.2 kDa oleosin isoform from Arabidopsis thaliana and a study of its expression in a mutant defective in diacylglycerol acyltransferase activity. Zou J, et al. Plant Mol Biol 1996 May;31(2):429-33
Lysophosphatidic acid acyltransferase from meadowfoam mediates insertion of erucic acid at the sn-2 position of triacylglycerol in transgenic rapeseed oil. Lassner MW, et al. Plant Physiol 1995 Dec;109(4):1389-94

PHYSIOLOGY

Regulation of FFA by the acyltransferase pathway in focal cerebral ischemia-reperfusion. Zhang JP, et al. Neurochem Res 1995 Nov;20(11):1279-86

ADAMANTANE

Synthesis, hybridization properties, nuclease stability, and cellular uptake of the oligonucleotide--amino-beta-cyclodextrins and adamantane conjugates. Habus I, et al. Bioconjug Chem 1995 Jul-Aug;6(4):327-31

ANALOGS & DERIVATIVES

Probing the cytochrome P-450 2B1 active site with diamantoid compounds. Hodek P, et al. Gen Physiol Biophys 1995 Jun;14(3):225-39
A quantitative luminescence assay for nonradioactive nucleic acid probes. Didenko VV, et al. J Histochem Cytochem 1996 Jun;44(6):657-60
3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. Chan FC, et al. J Med Chem 1996 Aug 16;39(17):3319-23
Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2. Kolocouris N, et al. J Med Chem 1996 Aug 16;39(17):3307-18
Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. Rowlands MG, et al. J Med Chem 1995 Oct 13; 38(21):4191-7
LY353433, a potent, orally effective, long-acting 5-HT(4) receptor antagonist: comparison to cisapride and RS23597-190. Cohen ML, et al. J Pharmacol Exp Ther 1996 Apr;277(1):97-104
Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636. Lin CW, et al. J Pharmacol Exp Ther 1996 Mar; 276(3):1022-9
Effects of the adenosine A1-receptor antagonist on defecation, small intestinal propulsion and gastric emptying in rats. Suzuki M, et al. Jpn J Pharmacol 1995 May; 68(1):119-23
Diuretic activity of N'-disubstituted morpholinoguanidine analogs of U-37883A in rats and dogs. Humphrey SJ, et al. Methods Find Exp Clin Pharmacol 1995 May; 17(4):255-66
Effects of K-ATP blocking guanidine diuretics during experimental kaliuresis in rats and dogs. Humphrey SJ. Methods Find Exp Clin Pharmacol 1995 Oct;17(8):519-28
AQ-0145, a newly developed histamine H3 antagonist, decreased seizure susceptibility of electrically induced convulsions in mice. Murakami K, et al. Methods Find Exp Clin Pharmacol 1995 Nov;17 Suppl C:70-3
Non-radioactive detection of oligonucleotide probes by photochemical amplification of dioxetanes. Schubert F, et al. Nucleic Acids Res 1995 Nov 25;23(22):4657-63
Guanidine derivative U-37883A, inhibits mitochondrial K+ uniport. Szewczyk A, et al. Pol J Pharmacol 1995 Jul-Aug; 47(4):339-44
Pharmacological profile of (-)HT-90B, a novel 5-HT1A receptor agonist/5-HT2 receptor antagonist. Uchida H, et al. Prog Neuropsychopharmacol Biol Psychiatry 1995 Nov; 19(7):1201-16
[Preparation and antiviral properties of Bacillus intermedius ribonuclease modified by chloranhydride of adamantanecarboxylic acid] Kurinenko BM, et al. Antibiot Khimioter 1995 Sep;40(9):17-9 (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. Chan FC, et al. J Med Chem 1996 Aug 16;39(17):3319-23
Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2. Kolocouris N, et al. J Med Chem 1996 Aug 16;39(17):3307-18
[Synthesis and pharmacological study of adamantyl benzene propanamines and propenamines] Pouli N, et al. Ann Pharm Fr 1995;53(4):163-9 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

[Synthesis and pharmacological study of adamantyl benzene propanamines and propenamines] Pouli N, et al. **Ann Pharm Fr** 1995;53(4):163–9 (Eng. Abstr.) **(Fre)**

ADAMANTINOMA see AMELOBLASTOMA

ADAPTATION, BIOLOGICAL

Structural adaptations for gliding in mammals with implications for locomotor behavior in paromomyids. Runestad JA, et al. **Am J Phys Anthropol** 1995 Oct; 98(2):101–19

Adaptive significance of amylase polymorphism in Drosophila. X. Analysis of alpha-amylase activity of two amylase variants in individual Drosophila subobscura flies. Stojiljković V, et al. **Jpn J Genet** 1995 Aug;70(4):487–95

Insights into protein adaptation to a saturated salt environment from the crystal structure of a halophilic 2Fe–2S ferredoxin. Frolow F, et al. **Nat Struct Biol** 1996 May;3(5):452–8

The Leeuwenhoek Lecture, 1995. Adaptation to life without oxygen. Guest JR. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29;350(1332):189–202 (61 ref.)

Immunological evidence for accumulation of two high-molecular-weight (104 and 90 kDa) HSPs in response to different stresses in rice and in response to high temperature stress in diverse plant genera. Pareek A, et al. **Plant Mol Biol** 1995 Oct;29(2):293–301

Smoothness within ruggedness: the role of neutrality in adaptation. Huynen MA, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):397–401

Sexual potency and adaptive mutation in bacteria. Bridges BA. **Trends Microbiol** 1995 Aug;3(8):291–2; discussion 292–4 (16 ref.)

[Adaptability and modulation in shoulder prosthesis] Boileau P, et al. **Acta Orthop Belg** 1995;61 Suppl 1:49–61 **(Fre)**

[Radiobiological constant in irradiation stimulation of cells for the subsequent adaptive response] Spitkovskiĭ DM. **Radiats Biol Radioecol** 1995 May–Jun;35(3):346–8 (Eng. Abstr.) **(Rus)**

GENETICS

Increasing genotypic and phenotypic selection from the original genomic RNA populations of HIV-1 strains LAI and MN (NM) by peripheral blood mononuclear cell culture, B-cell–line propagation and T-cell–line adaptation. Lukashov VV, et al. **AIDS** 1995 Dec;9(12):1307–11

The adaptive advantage of phenotypic memory in changing environments. Jablonka E, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29; 350(1332):133–41

A salinity-induced gene from the halophyte M. crystallinum encodes a glycolytic enzyme, cofactor-independent phosphoglyceromutase. Forsthoefel NR, et al. **Plant Mol Biol** 1995 Oct;29(2):213–26

PHYSIOLOGY

Accumulation of glutamate by osmotically stressed Escherichia coli is dependent on pH. Ogahara T, et al. **J Bacteriol** 1995 Oct;177(20):5987–90

ADAPTATION, MARGINAL (DENTISTRY) see MARGINAL ADAPTATION (DENTISTRY)

ADAPTATION, OCULAR

Receptor and neural visual readaptation after exposure to colored flash. Wang L, et al. **Acta Ophthalmol Scand** 1995 Aug;73(4):313–8

Automated perimetry with bright and dark stimuli. Wabbels B, et al. **Ger J Ophthalmol** 1995 Jul;4(4):217–21

Foveal adaptation abnormalities in early glaucoma. Eisner A, et al. **J Opt Soc Am A** 1995 Oct;12(10):2318–28

Analysis of retinal light adaptation with the flicker electroretinogram. Wu S, et al. **J Opt Soc Am A** 1996 Mar; 13(3):649–57

The one-year surgical outcome after prism adaptation for the management of acquired esotropia. Repka MX, et al. **Ophthalmology** 1996 Jun;103(6):922–8

Adaptive changes in saccade amplitude: oculocentric or orbitocentric mapping? Albano JE. **Vision Res** 1996 Jul; 36(14):2087–98

Contrast discrimination at high contrasts reveals the influence of local light adaptation on contrast processing. Kingdom FA, et al. **Vision Res** 1996 Mar;36(6):817–29

The effect of dark and equiluminant occlusion on the interocular transfer of visual aftereffects. Timney B, et al. **Vision Res** 1996 Mar;36(5):707–15

The time course of adaptation in macaque retinal ganglion cells. Yeh T, et al. **Vision Res** 1996 Apr;36(7):913–31

DRUG EFFECTS

ERG OFF response in frog retina: light adaptation and effect of 2-amino-4-phosphonobutyrate. Popova E, et al. **Acta Physiol Scand** 1995 Jul;154(3):377–86

Ca2+ dependence of dark- and light-adapted flash responses in rod photoreceptors. Gray-Keller MP, et al. **Neuron** 1996 Aug;17(2):323–31

PHYSIOLOGY

Sensory adaptations in Duane's retraction syndrome. Orton HP, et al. **Acta Ophthalmol Scand** 1995 Oct;73(5):417–20

Left and right visual field advantages are a function of scotopic and photopic retinal adaptation, respectively, in simple reaction time to near-threshold targets. Braun C, et al. **Acta Psychol (Amst)** 1996 Feb;91(1):3–14

Effect of blocking the Na+/K+ ATPase on Ca2+ extrusion and light adaptation in mammalian retinal rods. Demontis GC, et al. **Biophys J** 1995 Aug;69(2):439–50

Light adaptation of bovine retinas in situ stimulates phosphatidylinositol synthesis in rod outer segments in vitro. Ghalayini AJ, et al. **Curr Eye Res** 1995 Nov; 14(11):1025–9

Light adaptation of the human photopic oscillatory potentials: influence of the length of the dark adaptation period. Benoit J, et al. **Doc Ophthalmol** 1995;89(3):267–76

The 'light scattering factor'. Importance of stimulus geometry, contrast definition, and adaptation. Thaung J, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2313–7

Retinoid cycling proteins redistribute in light-/dark-adapted octopus retinas. Robles LJ, et al. **J Comp Neurol** 1995 Aug 7;358(4):605–14

Nonlinear models of the first synapse in the light-adapted fly retina. Juusola M, et al. **J Neurophysiol** 1995 Dec; 74(6):2538–47

Light adaptation and the rising phase of the flash photocurrent of salamander retinal rods. Jones GJ. **J Physiol (Lond)** 1995 Sep 1;487 (Pt 2):441–51

Effects of panretinal photocoagulation on photopic ERG in normal rabbit eyes. Imai M, et al. **Jpn J Ophthalmol** 1995; 39(2):120–3

The source of disparity vergence innervation determines prism adaptation. McCormack G, et al. **Ophthalmic Physiol Opt** 1996 Jan;16(1):73–82

Distance cues for vertical vergence adaptation. Schor CM, et al. **Optom Vis Sci** 1995 Jul;72(7):478–86

Short-term adaptation of eye movements in patients with visual hemifield defects indicates high level control of human scanpath. Zangemeister WH, et al. **Optom Vis Sci** 1995 Jul;72(7):467–77

Segmenting textures using cells with adaptive receptive fields. Meśrobian E, et al. **Spat Vis** 1995;9(2):163–90

Grating detection and identification dissociated by pattern adaptation. Vassilev A, et al. **Spat Vis** 1995;9(2):221–34

Dark-suppression and light-sensitization of horizontal cell responses in the hybrid bass retina. Baldridge WH, et al. **Vis Neurosci** 1995 Jul–Aug;12(4):611–20

Human cones appear to adapt at low light levels: measurements on the red-green detection mechanism. Chaparro A, et al. **Vision Res** 1995 Nov;35(22):3103–18

Changes in retinal time scale under background light: observations on rods and ganglion cells in the frog retina. Donner K, et al. **Vision Res** 1995 Aug;35(16):2255–66

Absence of adaptive plasticity after voluntary vergence and accommodation. Ebenholtz SM, et al. **Vision Res** 1995 Oct; 35(19):2773–83

Fast disconjugate adaptations of saccades in microstrabismic subjects. Kapoula Z, et al. **Vision Res** 1996 Jan;36(1):103–4

Direction-selective adaptation and simultaneous contrast induced by stereoscopic (cyclopean) motion. Patterson R, et al. **Vision Res** 1996 Jun;36(12):1773–81

Perceived contrast following adaptation to gratings of different orientations. Ross J, et al. **Vision Res** 1996 Jun; 36(12):1811–8

Spatial frequency adaptation: threshold elevation and perceived contrast. Snowden RJ, et al. **Vision Res** 1996 Jun;36(12):1797–809

Brightness of uniform stabilized fields. Tulunay-Keesey U, et al. **Vision Res** 1996 Feb;36(3):351–9

Recovery from adaptation for dynamic and static motion aftereffects: evidence for two mechanisms. Verstraten FA, et al. **Vision Res** 1996 Feb;36(3):421–4

Testing a computational model of light-adaptation dynamics. von Wiegand TE, et al. **Vision Res** 1995 Nov; 35(21):3037–51

Visual motion aftereffects: critical adaptation and test conditions. Wade NJ, et al. **Vision Res** 1996 Jul; 36(14):2167–75

Effects of flicker adaptation and temporal gain control on the flicker ERG. Wu S, et al. **Vision Res** 1995 Nov; 35(21):2943–53

RADIATION EFFECTS

Effect of blocking the Na+/K+ ATPase on Ca2+ extrusion and light adaptation in mammalian retinal rods. Demontis GC, et al. **Biophys J** 1995 Aug;69(2):439–50

ADAPTATION, PHYSIOLOGICAL

Adaptations of diaphragm neuromuscular junction following inactivity. Prakash YS, et al. **Acta Anat (Basel)** 1995; 154(2):147–61

Mucosal adaptation and destruction in response to lamina propria T cell activation in explants of human fetal intestine. Lionetti P, et al. **Adv Exp Med Biol** 1995; 371A:493–6

Is the slow component of exercise VO2 a respiratory adaptation to anaerobiosis? Wasserman K, et al. **Adv Exp Med Biol** 1995;393:187–94 (11 ref.)

Adaptive changes of autoregulation in chronic cerebral hypotension with arteriovenous malformations: an acetazolamide-enhanced single-photon emission CT study. Hacein-Bey L, et al. **AJNR Am J Neuroradiol** 1995 Oct; 16(9):1865–74

Echocardiographic characterization of left ventricular adaptation in a genetically determined heart failure rat model. Haas GJ, et al. **Am Heart J** 1995 Oct;130(4):806–11

Rapid adaptation of myocardial calcium homeostasis to short episodes of ischemia in isolated rat hearts. Smith GB, et al. **Am Heart J** 1996 Jun;131(6):1106–12

Colonic adaptation to daily lactose feeding in lactose maldigesters reduces lactose intolerance. Hertzler SR, et al. **Am J Clin Nutr** 1996 Aug;64(2):232–6

Extrarenal potassium adaptation: review of a concept [editorial] Spital A, et al. **Am J Nephrol** 1995;15(5):367–73 (29 ref.)

Limb skeleton and locomotor adaptations of Apidium phiomense, an Oligocene anthropoid from Egypt. Fleagle JG, et al. **Am J Phys Anthropol** 1995 Jul;97(3):235–89

Structural adaptations for gliding in mammals with implications for locomotor behavior in paromomyids. Runestad JA, et al. **Am J Phys Anthropol** 1995 Oct; 98(2):101–19

Single-nephron adaptations to partial renal ablation in cats. Brown SA, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1002–8

Diurnal rhythmicity of human cholesterol synthesis: normal pattern and adaptation to simulated "jet lag". Cella LK, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E489–98

Adaptation of the skeletal muscle calcium-release mechanism to weight-bearing condition. Kandarian SC, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1588–94

Resection-induced colonic adaptation is augmented by IGF-I and associated with upregulation of colonic IGF-I mRNA. Mantell MP, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G974–80

Diurnal changes and adaptation by the liver of hamsters to an atherogenic diet. Robins SJ, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1327–32

Compensatory enlargement of angiographically normal coronary segments in patients with coronary artery disease. In vivo documentation using intravascular ultrasound. Nakamura Y, et al. **Angiology** 1996 Aug;47(8):775–81

Involvement of heat shock proteins and cellular membranes in the development of thermotolerance. Jóźwiak Z. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):247–52 (70 ref.)

Role of membrane lipids in temperature acclimatization of carp. Buda C, et al. **Arch Tierernahr** 1996;49(1):61–2 (7 ref.)

Adaptation of tissue to a chronic heat load. Davies CR, et al. **ASAIO J** 1994 Jul–Sep;40(3):M514–7

Does the colon adopt small bowel features in a small bowel environment? King DR, et al. **Aust N Z J Surg** 1996 Aug; 66(8):543–6

Salt excretory capacity in natives adapted to moderate high altitude living after acute mobilization to sea level. Ramirez G, et al. **Aviat Space Environ Med** 1995 Nov;66(11):1063–70

The economy of winter: phenotypic plasticity in behavior and brain structure. Jacobs LF. **Biol Bull** 1996 Aug; 191(1):92–100 (61 ref.)

A model of the cerebellum in adaptive control of saccadic gain. I. The model and its biological substrate. Schweighofer N, et al. **Biol Cybern** 1996 Jul;75(1):19–28

A model of the cerebellum in adaptive control of saccadic gain. II. Simulation results. Schweighofer N, et al. **Biol Cybern** 1996 Jul;75(1):29–36

Carotid body adaptation to hypoxia: cellular and molecular mechanisms in vitro. Nurse CA. **Biol Signals** 1995 Sep–Oct; 4(5):286–91

Skeletal adaptations to mechanical usage: results from tibial loading studies in rats. Forwood MR, et al. **Bone** 1995 Oct; 17(4 Suppl):197S–205S (56 ref.)

Adaptation of non-growing former epiphysis and metaphyseal trabecular bones to aging and immobilization in rat. Ijiri K, et al. **Bone** 1995 Oct;17(4 Suppl):207S–212S

Using functional loading to influence bone mass and architecture: objectives, mechanisms, and relationship with estrogen of the mechanically adaptive process in bone. Lanyon LE. **Bone** 1996 Jan;18(1 Suppl):37S–43S (74 ref.)

Adaptation in the oculomotor response to caloric irrigation and the merits of bithermal stimulation [see comments] Barnes G. **Br J Audiol** 1995 Apr;29(2):95–106 (22 ref.). Comment in: Br J Audiol 1995 Apr;29(2):83–6.

The influence of the period of adaptation on the digestibility of diets containing different types of indigestible polysaccharides in rats. Brunsgaard G, et al. **Br J Nutr** 1995 Dec;74(6):833–48

Digestive adaptations of rats given white bread and cooked haricot beans (Phaseolus vulgaris): large-bowel fermentation and digestion of complex carbohydrates. Key FB, et al. **Br J Nutr** 1995 Sep;74(3):393–406

Influence of caecal microflora and of two dietary protein levels on the adaptation of the exocrine pancreas: comparative study in germ-free and conventional rats. Lhoste EF, et al. **Br J Nutr** 1996 Mar;75(3):433–44

On the mechanism and possible therapeutic application of delayed cardiac adaptation to stress. Szekeres L. **Can J Cardiol** 1996 Feb;12(2):177–85 (49 ref.)

Cross-adaptation of sweaty-smelling 3-methyl-2-hexenoic acid by a structurally-similar, pleasant-smelling odorant. Pierce JD Jr, et al. **Chem Senses** 1995 Aug;20(4):401–11

Contractility of longitudinal smooth muscle after massive intestinal resection in rat. Chin BC, et al.

Clin Invest Med 1996 Apr;19(2):101–10

Autonomic regulation of heart rate and peripheral circulation: comparison of high altitude and sea level residents. Passino C, et al. **Clin Sci (Colch)** 1996;91 Suppl:81–3

Metabolic and ventilatory adjustments and tolerance of the bat Pteropus poliocephalus to acute hypoxic stress. Thomas SP, et al. **Comp Biochem Physiol A Physiol** 1995 Sep; 112(1):43–54

The effect of inositol hexaphosphate in the high-affinity hemoglobin of the Andean chicken (Gallus gallus). Mejia O, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov;109(2–3):437–41

Biophysical modulation of cell and tissue structure and function. Rubin J, et al. **Crit Rev Eukaryot Gene Expr** 1995; 5(2):177–91 (81 ref.)

Maternal adaptation to pregnancy. Sibai BM, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):420–6 (55 ref.)

Towards understanding the process of intestinal adaptation. Wolvekamp MC, et al. **Dig Dis** 1996 Jan–Feb;14(1):59–72 (106 ref.)

Time course of adaptive regulatory peptide changes following massive small bowel resection in the dog. Adrian TE, et al. **Dig Dis Sci** 1996 Jun;41(6):1194–203

Aminophylline inhibits adaptation to ischaemia during angioplasty. Role of adenosine in ischaemic preconditioning [see comments] Claeys MJ, et al. **Eur Heart J** 1996 Apr; 17(4):539–44. Comment in: Eur Heart J 1996 Apr;17(4):490–1.

Biological adaptation of the myocardium to chronic mechanical overload. Molecular determinants of the autonomic nervous system. Mondry A, et al. **Eur Heart J** 1995 Aug;16 Suppl I:64–73 (96 ref.)

Thyroid function during a prolonged stay in Antarctica. Sawhney RC, et al. **Eur J Appl Physiol** 1995;72(1–2):127–33

On the mechanism of selenium tolerance in selenium-accumulating plants. Purification and characterization of a specific selenocysteine methyltransferase from cultured cells of Astragalus bisculatus. Neuhierl B, et al. **Eur J Biochem** 1996 Jul 1; 239(1):235–8

Thyroid hormone: modulation of muscle structure, function, and adaptive responses to mechanical loading. Caiozzo VJ, et al. **Exerc Sport Sci Rev** 1996;24:321–61 (159 ref.)

Muscle mechanics: adaptations with exercise-training. Fitts RH, et al. **Exerc Sport Sci Rev** 1996;24:427–73 (139 ref.)

Strength and power training: physiological mechanisms of adaptation. Kraemer WJ, et al. **Exerc Sport Sci Rev** 1996; 24:363–97 (158 ref.)

Exercise training and the cross-stressor adaptation hypothesis. Sothmann MS, et al. **Exerc Sport Sci Rev** 1996; 24:267–87 (89 ref.)

The development of adaptive head movements following enucleation. Marotta JJ, et al. **Eye** 1995;9 (Pt 3):333–6

Mechanical strain-induced NO production by bone cells: a possible role in adaptive bone (re)modeling? Pitsillides AA, et al. **FASEB J** 1995 Dec;9(15):1614–22

Increased gastroduodenal concentrations of transforming growth factor alpha in adaptation to aspirin in monkeys and rats. Romano M, et al. **Gastroenterology** 1996 May; 110(5):1448–55

Gastric adaptation to injury by repeated doses of aspirin strengthens mucosal defence against subsequent exposure to various strong irritants in rats. Brzozowski T, et al. **Gut** 1995 Dec;37(6):749–57

Adaptive response of the enterohepatic circulation of bile acids to extrahepatic cholestasis. Dumaswala R, et al. **Hepatology** 1996 Mar;23(3):623–9

Chronic kinin blockade and effect of ramipril in renal adaptation to sodium restriction. Jover B, et al. **Hypertension** 1996 Jan;27(1):79–84

Specialized surface adaptations of Giardia lamblia. Aley SB, et al. **Infect Agents Dis** 1995 Sep;4(3):161–6 (32 ref.)

The adaptive value of fever. Kluger MJ, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):1–20 (96 ref.)

The role of protein kinases in adaptational growth of the heart. Bogoyevitch MA, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):1–12 (101 ref.)

Acid adaptation and food poisoning microorganisms. Hill C, et al. **Int J Food Microbiol** 1995 Dec;28(2):245–54

The significance of bacteria in stationary phase to food microbiology. Rees CE, et al. **Int J Food Microbiol** 1995 Dec;28(2):263–75 (74 ref.)

Vascular thermal adaptation in tumors and normal tissue in rats. Nah BS, et al. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):95–101

Adaptive response to ionizing radiation induced by low doses of gamma rays in human cell lines. Seong J, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):869–74

Rapid adaptation to eccentric exercise-induced muscle damage. Mair J, et al. **Int J Sports Med** 1995 Aug; 16(6):352–6

Calcium absorption in rats with distal intestinal resection: influence of type of dietary fat, cholecalciferol and nature of the adaptative response. Alférez MJ, et al. **Int J Vitam Nutr Res** 1996;66(1):59–65

How the two sides of the heart adapt to graded impedance to venous return with head-up tilting. Guazzi M, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1732–40

Central blood volume: a determinant of early cardiac adaptation in arterial hypertension? Schmieder RE, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1692–8

Mechanisms of adaptation to hypoxia in energy metabolism in rats. Mimura Y, et al. **J Am Coll Surg** 1995 Nov; 181(5):437–43

Renal adaptation to dietary sodium restriction in moderate renal failure resulting from chronic glomerular disease. Cianciaruso B, et al. **J Am Soc Nephrol** 1996 Feb; 7(2):306–13

Ultrastructural features of left ventricular myocytes in active and torpid hamsters compared with rats: a morphometric study. Skepper JN, et al. **J Anat** 1995 Jun;186 (Pt 3):585–92

Enhanced cardiac metabolism of plasma glucose in high-altitude natives: adaptation against chronic hypoxia. Holden JE, et al. **J Appl Physiol** 1995 Jul;79(1):222–8

Pulmonary vascular adaptations to augmented polycythemia during chronic hypoxia. Petit RD, et al. **J Appl Physiol** 1995 Jul;79(1):229–35

Early adaptations in collateral and microvascular resistances after ligation of the rat femoral artery. Unthank JL, et al. **J Appl Physiol** 1995 Jul;79(1):73–82

Effect of physical training on bone adaptation in three zones of the rat tibia. Bourrin S, et al. **J Bone Miner Res** 1995 Nov;10(11):1745–52

Thermotolerance and intracellular pH in two Chinese hamster cell lines adapted to growth at low pH. Wahl ML, et al. **J Cell Physiol** 1996 Feb;166(2):438–45

Adaptive preservation of ATP and tolerance to hypoxia following carotid artery ligation in the immature rat. Hylton CM, et al. **J Cereb Blood Flow Metab** 1995 Nov; 15(6):1137–40

Progressive elevation of plasma thyrotropin during adaptation to simulated jet lag: effects of treatment with bright light or zolpidem. Hirschfeld U, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3270–7

Neural simulations of adaptive reafference suppression in the elasmobranch electrosensory system. Nelson ME, et al. **J Comp Physiol [A]** 1995 Dec;177(6):723–36

Blood vessel adaptation to gravity in a semi-arboreal snake. Conklin DJ, et al. **J Comp Physiol [B]** 1996;165(7):518–26

Survival of Shigella flexneri in artificial aquatic environment: effects of different physicochemical stress factors. Islam MS, et al. **J Diarrhoeal Dis Res** 1996 Mar;14(1):37–40

Migratory fat deposition in European quail: a role for prolactin? Boswell T, et al. **J Endocrinol** 1995 Jul; 146(1):71–9

Differential acetylation of pro-opiomelanocortin-derived peptides in the pituitary gland of Xenopus laevis in relation to background adaptation. van Strien FJ, et al. **J Endocrinol** 1995 Jul;146(1):159–67

Salinity change and cell volume: the response of tissues from the estuarine mussel Geukensia demissa. Neufeld DS, et al. **J Exp Biol** 1996 Jul;199 (Pt 7):1619–30

Gravity, blood circulation, and the adaptation of form and function in lower vertebrates. Lillywhite HB. **J Exp Zool** 1996 Jun 1–15;275(2–3):217–25 (37 ref.)

Adaptation of the gastric epithelium to injury is maintained in vitro and is associated with increased TGF-alpha expression. Doljanin K, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):259–63

Time course of hypertrophic adaptations of the anterior latissimus dorsi muscle to stretch overload in aged Japanese quail. Carson JA, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):B391–8

Characterization of intracellular calcium pools and their desensitization in thermotoierant human A-431 cells. Kiang JG, et al. **J Investig Med** 1996 Aug;44(6):352–61

Inability of the heat-shocked heart to adjust its pre-ischemic and post-ischemic performance to variable loading conditions. Cornelussen R, et al. **J Mol Cell Cardiol** 1996 Feb;28(2):291–8

Influence of instruction, prediction, and afferent sensory information on the postural organization of step initiation. Burleigh A, et al. **J Neurophysiol** 1996 Apr;75(4):1619–28

Trajectory adaptation to a nonlinear visuomotor transformation: evidence of motion planning in visually perceived space. Flanagan JR, et al. **J Neurophysiol** 1995 Nov;74(5):2174–8

Adaptive control for backward quadrupedal walking V. Mutable activation of bifunctional thigh muscles. Pratt CA, et al. **J Neurophysiol** 1996 Feb;75(2):832–42

Adaptive control for backward quadrupedal walking VI. metatarsophalangeal joint dynamics and motor patterns of digit muscles. Trank TV, et al. **J Neurophysiol** 1996 Feb; 75(2):678–9

Effects of delayed visual information on the rate and amount of prism adaptation in the human. Kitazawa S, et al. **J Neurosci** 1995 Nov;15(11):7644–52

Transduction and adaptation in sensory receptor cells. Torre V, et al. **J Neurosci** 1995 Dec;15(12):7757–68 (105 ref.)

Spatiotemporal adaptation model for retinal ganglion cells. Dahari R, et al. **J Opt Soc Am A** 1996 Mar;13(3):419–35

Studies on adaptation to complete dentures. Part I: Oral and manual motor ability. Müller F, et al. **J Oral Rehabil** 1995 Jul;22(7):501–7

Skin response to mechanical stress: adaptation rather than breakdown—a review of the literature. Sanders JE, et al. **J Rehabil Res Dev** 1995 Oct;32(3):214–26 (71 ref.)

Enterocyte functional adaptation following intestinal resection. Whang EE, et al. **J Surg Res** 1996 Feb 1; 60(2):370–4

The consequences of phenotypic plasticity in cyclically varying environments: a genetic algorithm study. Behera N, et al. **J Theor Biol** 1996 Jan 21;178(2):135–44

Application of morphological trends of evolution to phylogenetic interpretation of chemotaxonomic data. Kalinin VI, et al. **J Theor Biol** 1996 May 7;180(1):1–10

The inheritance of phenotypes: an adaptation to fluctuating environments. Lachmann M, et al. **J Theor Biol** 1996 Jul 7;181(1):1–9

Preconceptual programming and sexual orientation: a hypothesis. Pollard I. **J Theor Biol** 1996 Apr 7; 179(3):269–73

Clinical features of mal de debarquement: adaptation and habituation to sea conditions. Gordon CR, et al. **J Vestib Res** 1995 Sep–Oct;5(5):363–9

Assessment of training-induced autonomic adaptations in athletes with spectral analysis of cardiovascular variability signals. Shin K, et al. **Jpn J Physiol** 1995;45(6):1053–69

Bifemelane hydrochloride enhances 'ischemic tolerance' phenomenon in gerbil hippocampal CA1 neurons. Ohtsuki T, et al. **Life Sci** 1996;59(12):979–85

Molecular architecture and biophysical properties of phospholipids during thermal adaptation in fish: an experimental and model study. Fodor E, et al. **Lipids** 1995 Dec;30(12):1119–26

Bed rest induces neural and contractile adaptations in triceps surae. Duchateau J. **Med Sci Sports Exerc** 1995 Dec; 27(12):1581–9

Adaptations of immature trabecular bone to exercise and augmented dietary protein. Zernicke RF, et al. **Med Sci Sports Exerc** 1995 Nov;27(11):1486–93

The purification of a GroEL-like stress protein from aerobically adapted Campylobacter jejuni. Takata T, et al. **Microbiol Immunol** 1995;39(9):639–45

On the mechanism and possible therapeutic application of delayed adaptation of the heart to stress situations. Krause EG, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):115–22

Adaptation of the heart to ischemia by preconditioning: effects on energy equilibrium, properties of sarcolemmal ATPases and release of cardioprotective proteins. Ziegelhöffer A, et al. **Mol Cell Biochem** 1995 Jun 7–21; 147(1–2):129–37

Cardiopulmonary adaptation to exercise after acute weight loss in severely obese subjects. Boni E, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):264–8

Decreased sensitivity to the cytogenetic effects of bleomycin in individuals occupationally exposed to ionizing radiation. Barquinero JF, et al. **Mutat Res** 1996 Jul 5;354(1):81–6

The adaptive response of peripheral blood lymphocytes to low doses of mutagenic agents in patients with ataxia telangiectasia. Némethová G, et al. **Mutat Res** 1995 Nov; 348(3):101–4

Do human lymphocytes exposed to the fallout of the Chernobyl accident exhibit an adaptive response? III. Challenge with bleomycin in lymphocytes from children hit by the initial acute dose of ionizing radiation. Tedeschi B, et al. **Mutat Res** 1996 Jul 5;354(1):77–80

The limit of human adaptation to starvation. Collins S. **Nat Med** 1995 Aug;1(8):810–4

Rapid adaptive camouflage in tropical flounders. Ramachandran VS, et al. **Nature** 1996 Feb 29; 379(6568):815–8

Sexually antagonistic male adaptation triggered by experimental arrest of female evolution [see comments] Rice WR. **Nature** 1996 May 16;381(6579):232–4. Comment in: Nature 1996 May 16;381(6579):189–90.

Reducing antibiotic resistance [letter] Schrag SJ, et al. **Nature** 1996 May 9;381(6578):120–1

Global plasticity in adult visual cortex following reversal of visual input. Sugita Y. **Nature** 1996 Apr 11; 380(6574):523–6

Systemic vascular adaptation to increases in blood volume: the role of the blood-vessel wall [editorial] MacAllister RJ, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):231–4

Alzheimer's disease: maladaptive synaptoplasticity hypothesis. Neill D. **Neurodegeneration** 1995 Jun; 4(2):217–32 (250 ref.)

Modifications in end positions of arm movements following short-term saccadic adaptation. de Graaf JB, et al. **Neuroreport** 1995 Sep 11;6(13):1733–6

Mechanisms for sensory adaptation in frog vestibular organs. Masetto S, et al. **Neuroreport** 1995 Dec 29;7(1):230–2

Evidence for a cooperative learning mechanism in the vestibulo-ocular reflex. Ratnam R, et al. **Neuroreport** 1995 Nov 13;6(16):2129–33

Effects of different patterns of light adaptation on cellular and synaptic plasticity in teleost retina: comparison of flickering and steady lights. Haamedi SN, et al. **Neurosci Lett** 1996 Mar 15;206(2–3):93–6

Influence of environmental adaptation on the sensitivity of micromycetes to pentachlorophenol toxicity in microcosms. Onochie-Okeke BC, et al. **New Microbiol** 1996 Jan;19(1):77–84

Perinatal benzodiazepine modulation of GABAA receptor function: influence on adaptive responses. Kellogg CK. **NIDA Res Monogr** 1995;158:202–26 (78 ref.)

Impaired compensatory adaption to B-cell mass reduction in young spontaneously hypertensive rats (SHR). Tanigawa K, et al. **Pancreas** 1996 Apr;12(3):237–42

Structure and function of the abdominal muscles in primigravid subjects during pregnancy and the immediate postbirth period. Gilleard WL, et al. **Phys Ther** 1996 Jul; 76(7):750–62

Transformation of Synechococcus with a gene for choline oxidase enhances tolerance to salt stress. Deshnium P, et

al. **Plant Mol Biol** 1995 Dec;29(5):897–907

Ability of broilers to resist heat following neonatal exposure to high environmental temperature. May JD. **Poult Sci** 1995 Nov;74(11):1905–7

31P magnetic resonance spectroscopy of the Sherpa heart: a phosphocreatine/adenosine triphosphate signature of metabolic defense against hypobaric hypoxia. Hochachka PW, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):1215–20

Fuel selection by the kidney: adaptation to starvation. Baverel G, et al. **Proc Nutr Soc** 1995 Mar;54(1):197–212 (116 ref.)

Colour vision as an adaptation to frugivory in primates. Osorio D, et al. **Proc R Soc Lond B Biol Sci** 1996 May 22;263(1370):593–9

Correlation between proto-oncogene, fibroblast growth factor and adaptive response in brain infarct. Liu HM. **Prog Brain Res** 1995;105:239–44 (44 ref.)

EEG power spectral densities during and after cycle ergometer exercise. Kubitz KA, et al. **Res Q Exerc Sport** 1996 Mar;67(1):91–6

HCO3(–)-ATPase and Ca2+ dependent ATPase activities in the gills of the rainbow trout after the transfer to brackishwater and seawater. Fuentes J, et al. **Rev Esp Fisiol** 1995 Jun;51(2):93–100

Aging of human muscle: structure, function and adaptability [see comments] Porter MM, et al. **Scand J Med Sci Sports** 1995 Jun;5(3):129–42 (122 ref.). Comment in: Scand J Med Sci Sports 1995 Jun;5(3):127–8.

Arterial Windkessels in marine mammals. Shadwick RE, et al. **Symp Soc Exp Biol** 1995;49:243–52

Body surface adaptations to boundary-layer dynamics. Videler JJ. **Symp Soc Exp Biol** 1995;49:1–20

An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system. Perrin P, et al. **Vaccine** 1995 Sep;13(13):1244–50

Virus and host-specific adaptations in the BL1 and BR1 genes of bipartite geminiviruses. Schaffer RL, et al. **Virology** 1995 Dec 20;214(2):330–8

Binocular interactions in rapid saccadic adaptation. Albano JE, et al. **Vision Res** 1995 Dec;35(23–24):3439–50

Separate adaptive mechanisms for the control of reactive and volitional saccadic eye movements. Deubel H. **Vision Res** 1995 Dec;35(23–24):3529–40

Disparity tuning of the stereoscopic (cyclopean) motion aftereffect. Patterson R, et al. **Vision Res** 1996 Apr; 36(7):975–83

An adaptable association between vertical and horizontal vergence. Schor CM, et al. **Vision Res** 1995 Dec; 35(23–24):3519–27

Color perception with test and adapting lights perceived in different depth planes. Shevell SK, et al. **Vision Res** 1996 Apr;36(7):949–54

Rapid gain adaptation affects the dynamics of saccadic eye movements in humans. Straube A, et al. **Vision Res** 1995 Dec;35(23–24):3451–8

[Changes in the status of the adaptation of workers at the television relay station on top of Botev Peak] Nikolova R, et al. **Probl Khig** 1995;20:68–73 (Eng. Abstr.) **(Bul)**

[Post-polio syndrome; the limit of neuromuscular adaptation?] Nollet F, et al. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1169–73 (39 ref.) **(Dut)**

[Cardiac adaptation to muscular exercise in children after complete repair of tetralogy of Fallot] Guillaumont S, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):587–92 (Eng. Abstr.) **(Fre)**

[Bone hypertrophy as a results of training] Krahl H, et al. **Orthopade** 1995 Sep;24(5):441–5 (Eng. Abstr.) **(Ger)**

[Factors limiting adaptation to exercise after the Fontan operation: role of altered pulmonary function] Vignati G, et al. **G Ital Cardiol** 1996 Apr;26(4):399–405 (Eng. Abstr.) **(Ita)**

[An electromyographic study on functional adaptations--associated with herbst appliance] Hiyama S. **Kokubyo Gakkai Zasshi** 1996 Mar;63(1):18–30 (Eng. Abstr.) **(Jpn)**

[Evaluation of gastric adaptive relaxation in isolated stomach from the guinea-pig] Uno H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov;92(11):1832–8 (Eng. Abstr.) **(Jpn)**

[Adaptation and protection systems against chemical substances in living body] Ariyoshi T. **Yakugaku Zasshi** 1996 Mar;116(3):192–208 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Characteristics of adaptive reactions of pregnant women with chronic inflammatory gynecologic diseases and in their newborn in the early neonatal period] Krylov VI, et al. **Akush Ginekol (Mosk)** 1995;(4):24–6 (Eng. Abstr.) **(Rus)**

[Adaptive processes in heart failure (correlation and recombination)] Khmel'nitskiĭ OK, et al. **Arkh Patol** 1995 Jul–Aug;57(4):56–62 (Eng. Abstr.) **(Rus)**

[Morphology of adaptive-compensatory processes in the myocardium as affected by contrasting temperatures] Nepomniashchikh LM, et al. **Arkh Patol** 1995 Jul–Aug; 57(4):62–7 (Eng. Abstr.) **(Rus)**

[Comparative study of adaptive responses of the cardiorespiratory system in inhabitants of different climatic-geographic regions] Agadzhanian NA, et al. **Aviakosm Ekolog Med** 1995;29(5):10–4 (Eng. Abstr.) **(Rus)**

[Ecology, adaptation and biorhythms] Agadzhanian NA, et al. **Aviakosm Ekolog Med** 1995;29(3):16–9 (17 ref.) (Eng. Abstr.) **(Rus)**

[Changes in the structures of the kidney medullary layer in rats during adaptation to high altitude] Iangalycheva EA, et al. **Aviakosm Ekolog Med** 1995;29(3):55–7 **(Rus)**

[New methodological approaches in assessing adaptive body reactions in the system of flight medicine expertise] Karlov VN, et al. **Aviakosm Ekolog Med** 1995;29(2):28–31 (Eng. Abstr.) **(Rus)**

[Neurophysiological patterns of vestibular adaptation to microgravity] Kornilova LN, et al. **Aviakosm Ekolog Med** 1995;29(5):23–30 (Eng. Abstr.) **(Rus)**

[A method of evaluation of the adaptation process] Myznikov IL, et al. **Aviakosm Ekolog Med** 1995;29(4):54–8 (Eng. Abstr.) **(Rus)**

[The reactions to weightlessness exposure: adaptation or disease?] Pestov ID. **Aviakosm Ekolog Med** 1995;29(2):56–9 (Eng. Abstr.) **(Rus)**

[The ecological-morphological aspects of adaptation and the role of the macrophages in body dehydration] Proshina LG. **Aviakosm Ekolog Med** 1995;29(3):31–5 (Eng. Abstr.) **(Rus)**

[Several mechanisms of adaptation to combined action of weak varying magnetic fields and hypokinesia] Temur'iants NA. **Aviakosm Ekolog Med** 1995;29(6):49–54 (Eng. Abstr.) **(Rus)**

[The adaptive-compensatory reactions in adjusting to space flights] Volozhin AI. **Aviakosm Ekolog Med** 1995; 29(2):6–12 (Eng. Abstr.) **(Rus)**

[Seasonal features of the mitotic activity of the duodenal epithelium in two representatives of a family of squirrels with different ecological specialization] Dubinin EV, et al. **Biull Eksp Biol Med** 1995 Jun;119(6):642–3 **(Rus)**

[Effect of adapting to periodic hypoxia on kinetic parameters of respiratory chain enzymes in the rat brain] Dudchenko AM, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):252–5 **(Rus)**

[Adaptation to hypoxia, as opposed to adaptation to stress, does not protect the isolated heart from reperfusion after total ischemia. A nuclear magnetic resonance study] Golubeva LIu, et al. **Biull Eksp Biol Med** 1995 Nov; 120(11):481–4 **(Rus)**

[The effect of adaptation to interrupted normobaric hypoxia on the ultrastructure of pregnant rat cardiomyocytes] Lebkova NP, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):597–602 **(Rus)**

[Adaptation to high altitude hypoxia facilitates a limitation of lipid peroxidation activation in inflammation and stress] Malyshev VV, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):590–3 **(Rus)**

[Functional status of endothelium and production of nitric oxide in the rat, adapted to periodic hypoxia] Manukhina EB, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):495–8 **(Rus)**

[Participation of endogenous mu- and delta-opiate receptor agonists in mechanisms of the anti-arrhythmia effect of adaptation] Maslov LN, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):24–5 **(Rus)**

[Seasonal differences in formation of increased resistance of the isolated heart during adaptation to physical stress] Prodius PA, et al. **Biull Eksp Biol Med** 1995 Sep; 120(9):299–301 **(Rus)**

[The role of cholinergic regulation of the heart in the protective antiarrhythmic effect of adaptation to continuous moderate stress] Pshennikova MG, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):36–9 **(Rus)**

[Adaptation to periodic hypoxia and diet with omega-3 polyunsaturated fatty acids increases the stability of myocardial sarcoplasmic reticulum Ca2+ transport to free radical oxidation] Sazontova TG, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):42–5 **(Rus)**

[Opposite effect of adaptation to short exposure to stressors and adaptation to periodic hypoxia on liver cell membrane Na,K-ATPase activity] Sazontova TG. **Biull Eksp Biol Med** 1996 Apr;121(4):383–6 **(Rus)**

[Induced sensitivity to odorants: a new phenomenon] Sokolov VE, et al. **Dokl Akad Nauk** 1996 Apr;347(6):843–6 **(Rus)**

[Chronobiologic study of cardiac activity regulation in the course of urgent adaptation of healthy persons to high altitude conditions] Fedorova OI. **Fiziol Cheloveka** 1995 Jul–Aug;21(4):100–10 **(Rus)**

[Adaptive changes in autonomic functions in liquidators of the accident at the Chernobyl nuclear power plant in the process of conducting rehabilitation measures] Fudin NA, et al. **Fiziol Cheloveka** 1995 Nov–Dec;21(6):137–45 **(Rus)**

[Mechanisms of respiratory responses to external and internal resistive load] Isaev GG, et al. **Fiziol Cheloveka** 1995 Sep–Oct;21(5):96–105 **(Rus)**

[Hormonal reorganization in sailors with varying levels of non-specific resistance] Maksimov AL, et al. **Fiziol Cheloveka** 1995 Nov–Dec;21(6):107–12 **(Rus)**

[Macro- and microrheologic properties of blood in people with varying levels of training] Murav'ev AV, et al. **Fiziol Cheloveka** 1995 Jul–Aug;21(4):137–42 **(Rus)**

[Immunophysiologic mechanisms of adaptation to extreme conditions] Novikov VS. **Fiziol Cheloveka** 1996 Mar–Apr; 22(2):25–34 (44 ref.) **(Rus)**

[Cardiorespiratory system adaptation after surgical correction of intracardiac hemodynamics] Shevchenko IuL. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):20–4 (14 ref.) **(Rus)**

[Feasibility of directed rearrangement of human EEG parameters using adaptive biocontrol] Soroko SI, et al. **Fiziol Cheloveka** 1995 Sep–Oct;21(5):5–17 **(Rus)**

[Effect of individual-adaptive psychophysiological correction on operator working capacity] Turzin PS, et al. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):112–7 **(Rus)**

[Energy metabolism and autonomic function in students under study and examination stress] Umiriukhin EA, et al. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):108–11 **(Rus)**

[The role of neurotrophic factors in adaptational processes in the nervous system] Akoev GN, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):12–7 (Eng. Abstr.) **(Rus)**

[The microvascular permeability of the skin and mesentery in rats adapting to hypoxia] Gavrisheva NA, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):81–6 (Eng. Abstr.) **(Rus)**

[The basic molecular cellular mechanisms of adaptive reactions in the brain] Samoĭlov MO. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):3–11 (32 ref.) **(Rus)**

[Neuroendocrine mechanisms in the shaping of adaptive behavior] Shaliapina VG, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):94–100 (25 ref.) (Eng. Abstr.) **(Rus)**

[The formation of blood system tolerance in rats to the repeated action of a stressor stimulus] Tseĭlikman VE, et al. **Fiziol Zh Im I M Sechenova** 1995 Dec;81(12):88–94 (Eng. Abstr.) **(Rus)**

[Effect of preliminary chronic low-dose gamma-irradiation on the compensatory potentialities of the hematopoietic system] Deshevoĭ IuB, et al. **Gematol Transfuziol** 1995 Sep–Oct;40(5):3–6 (Eng. Abstr.) **(Rus)**

[Genetic-demographic study of mountain populations from Dagestan and their migrants to the lowlands. Comparison of basic parameters of fitness] Bulaeva KB, et al. **Genetika** 1995 Sep;31(9):1300–7 (Eng. Abstr.) **(Rus)**

[A genetic and demographic study of Dagestan highland populations and migrants to the lowlands. The relationship between levels of consanguinity, homozygosity and physiologic sensitivity] Bulaeva KB, et al. **Genetika** 1996 Jan;32(1):93–102 (Eng. Abstr.) **(Rus)**

[Adaptive mechanisms in the ecology of the pseudotuberculosis microbe] Tafel'shtein EE, et al. **Med Parazitol (Mosk)** 1995 Oct–Dec;(4):30–4 (Eng. Abstr.) **(Rus)**

[Distribution of polyamines in Escherichia coli and their role in potassium exchange between the cell and the environment during aerobiosis-anaerobiosis transitions] Tkachenko AG, et al. **Mikrobiologiia** 1996 Jan–Feb; 65(1):10–4 (Eng. Abstr.) **(Rus)**

[Changes in the endocrine pancreas of laboratory white rats with diabetes mellitus, adaptation to hypoxia and their combination (an immunohistochemical study)] Kolesnik IuM, et al. **Morfologiia** 1996;109(1):91–4 (Eng. Abstr.) **(Rus)**

[The adaptation of the microcirculatory bed of the major veins to the intermittent action of high-altitude hypoxia] Kramar NI, et al. **Morfologiia** 1995;108(2):39–40 (Eng. Abstr.) **(Rus)**

[The compensatory-adaptive reactions of the thyroid and adrenal adrenergic structures in the postnatal ontogeny of sympathectomized rats] Markov VN, et al. **Morfologiia** 1994 Jul–Dec;107(7–12):89–96 (Eng. Abstr.) **(Rus)**

[The adaptation of human skeletal muscle fibers during aerobic training] Nemirovskaia TL, et al. **Morfologiia** 1994 Apr–Jun;106(4–6):151–6 (Eng. Abstr.) **(Rus)**

[Acute renal insufficiency in rats in compensatory renal hypertrophy] Bakhateeva VT, et al. **Patol Fiziol Eksp Ter** 1995 Oct–Dec;(4):40–3 (Eng. Abstr.) **(Rus)**

[Compensatory potential of the hematopoietic system under conditions of exposure of the body to gamma-irradiation at a dose of 0.9 Gy and prolonged emotional stress] Deshevoĭ IuB, et al. **Patol Fiziol Eksp Ter** 1996 Jan–Mar; (1):3–5 (Eng. Abstr.) **(Rus)**

[The role of adaptation to new medicogeographical conditions in mandibular fractures] Ruzin GP. **Stomatologiia (Mosk)** 1995;74(3):41–3 (Eng. Abstr.) **(Rus)**

[The bioenergetic, cytochemical, and staining properties of normal hepatocytes and under functional loads, adaptations to environmental changes and in nonspecific injuries] Chentsov IuS, et al. **Tsitologiia** 1995;37(12):1123–35 (Eng. Abstr.) **(Rus)**

[Cooperative effect of high density lipoproteins and adaptive hormones in chromatin activation in rat liver] Panin LE, et al. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):64–70 (Eng. Abstr.) **(Rus)**

[Biochemical characteristics of various adaptation mechanisms in acute alcoholic intoxication] Sinitskiĭ VN, et al. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):90–5 (Eng. Abstr.) **(Rus)**

[The effect of adaptation to hypoxia on the results of the health resort treatment of children with bronchial asthma] Legkikh MV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec;(6):42 **(Rus)**

[Tocopherol level and lipid peroxidation in Wistar rat tissues during adaptation to cold] Kolosova NG, et al. **Vopr Med Khim** 1995 Nov–Dec;41(6):16–9 (Eng. Abstr.)

(Rus)
[Changes in glycolysis and glycogenolysis in tissues and level of certain hormones in blood and urine from rats with varying lengths of cold adaptation] Panin LE, et al. **Vopr Med Khim** 1995 Jul-Aug;41(4):14-8 (Eng. Abstr.) (Rus)

[Adaptation of hepatitis A virus to nonprimate cells] Bychenko AB, et al. **Vopr Virusol** 1996 Mar-Apr; 41(2):58-61 (Eng. Abstr.) (Rus)

[Changes in biological and physico-chemical properties of avian influenza virus A hemagglutinin H2 during adaptation to a new host] Lipatov AS, et al. **Vopr Virusol** 1995 Sep-Oct;40(5):208-11 (Eng. Abstr.) (Rus)

[Adaptive biocontrol in the system of treating epilepsy patients] Akimenko MA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):45-8 (Eng. Abstr.) (Rus)

[Intestinal adaptation in the short and ultrashort bowel syndrome. Nutritional support] Galiano Segovia MJ, et al. **An Esp Pediatr** 1996 Jun;44(6):605-8 (16 ref.) (Spa)

[Changes in erythrocyte rigidity and neonatal relative viscosity during the adaptation of the newborn to extrauterine life. Observations on term and premature newborns] Uberos-Fernández J, et al. **An Esp Pediatr** 1996 Mar;44(3):262-6 (Eng. Abstr.) (Spa)

[The physiological basis of the compensatory-adaptive significance of expiratory bronchospasm] Marin AM. **Fiziol Zh** 1994 Sep-Dec;40(5-6):82-7 (Eng. Abstr.) (Ukr)

[The functional organization of the adaptive and compensatory reactions of the endocrine glands] Reznikov OH. **Fiziol Zh** 1994 Sep-Dec;40(5-6):121-7 (22 ref.) (Eng. Abstr.) (Ukr)

[Role of low molecular weight metabolites as natural regulators of metabolism] Mel'nychuk DO, et al. **Ukr Biokhim Zh** 1995 May-Jun;67(3):84-92 (Eng. Abstr.) (Ukr)

DRUG EFFECTS

Impairment of stress adaptive behaviours in rats by the CCKA receptor antagonist, devazepide. Hernando F, et al. **Br J Pharmacol** 1996 May;118(2):400-6

Contingent tolerance to the anticonvulsant effects of carbamazepine: relationship to loss of endogenous adaptive mechanisms. Weiss SR, et al. **Brain Res Brain Res Rev** 1995 Mar;20(3):305-25 (96 ref.)

Biochemical changes associated with the adaptive response of human keratinocytes to N-methyl-N'-nitro-N-nitrosoguanidine. Kleczkowska HE, et al. **Mutat Res** 1996 Jun 12;368(2):121-31

Hypothalamic neuronal histamine modulates adaptive behavior and thermogenesis in response to endogenous pyrogen. Sakata T, et al. **Obes Res** 1995 Dec;3 Suppl 5:707S-712S (26 ref.)

Gastric adaptation to aspirin and stress enhances gastric mucosal resistance against the damage by strong irritants. Brzozowski T, et al. **Scand J Gastroenterol** 1996 Feb; 31(2):118-25

GENETICS

Molecular cloning of delta 9 fatty acid desaturase from the protozoan Tetrahymena thermophila and its mRNA expression during thermal membrane adaptation. Nakashima S, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):29-34

Commensalism, adaptation and gene flow: mosquitoes of the Culex pipiens complex in different habitats. Chevillon C, et al. **Genet Res** 1995 Oct;66(2):147-57

Long-term experimental evolution in Escherichia coli. IV. Targets of selection and the specificity of adaptation. Travisano M, et al. **Genetics** 1996 May;143(1):15-26

Genetics of larval urea tolerance in Drosophila melanogaster. Joshi A, et al. **Heredity** 1996 Jul;77 (Pt 1):33-9

Two classes of plant cDNA clones differentially complement yeast calcineurin mutants and increase salt tolerance of wild-type yeast. Lippuner V, et al. **J Biol Chem** 1996 May 31;271(22):12859-66

Adaptational response in transcription factors during development of myocardial hypertrophy. Doud SK, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2359-72

Differential stress protein mRNA expression during early ischaemic preconditioning in the rabbit heart and its relationship to adenosine receptor function. Heads RJ, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2133-48

Mutual adaptation of bacteriophage fd, pfd plasmids and their host strains. Geider K, et al. **Microbiol Res** 1995 Nov; 150(4):337-46

An unusual group 2 LEA gene family in citrus responsive to low temperature. Cai Q, et al. **Plant Mol Biol** 1995 Oct; 29(1):11-23

Isolation of mutations affecting the development of freezing tolerance in Arabidopsis thaliana (L.) Heynh. Warren G, et al. **Plant Physiol** 1996 Aug;111(4):1011-9

Group selection for adaptation to multiple-hen cages: beak-related mortality, feathering, and body weight responses. Craig JV, et al. **Poult Sci** 1996 Mar;75(3):294-302

Group selection for adaptation to multiple-hen cages: selection program and direct responses. Muir WM. **Poult Sci** 1996 Apr;75(4):447-58

[Fluctuating asymmetry as a marker of phenotypic adaptiveness (modelled on the neurological manifestations of lumbar osteochondrosis)] Verenich SV. **Ontogenez** 1996 Mar-Apr;27(2):137-40 (Eng. Abstr.) (Rus)

[Alcohol dehydrogenase polymorphism and the genotypic adaptation of D. melanogaster to the action of selective factors] Totskil VN, et al. **Tsitol Genet** 1995 Nov-Dec; 29(6):54-9 (Eng. Abstr.) (Rus)

IMMUNOLOGY

Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Trinchieri G. **Semin Immunol** 1995 Apr; 7(2):83-8 (43 ref.)

[Characteristics of adaptive reactions of the body's immune system following operations for vascular anomalies] Starchenko AA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Oct-Dec; (4):13-6 (Eng. Abstr.) (Rus)

PHYSIOLOGY

Effects of swimming training on the lysosomal enzyme system in brown adipose tissue of rats: an analogy between swimming exercise and cold acclimation. Ohno H, et al. **Acta Physiol Scand** 1995 Nov;155(3):333-4

Effect of sickness severity on habituation to repeated motion challenges in aircrew referred for airsickness treatment. Golding JF, et al. **Aviat Space Environ Med** 1995 Jul; 66(7):625-30

A hot topic: the origin of hyperthermophiles. Forterre P. **Cell** 1996 Jun 14;85(6):789-92 (20 ref.)

Fontan physiology [letter] Kiani A, et al. **Circulation** 1995 Nov 15;92(10):3148-50

Antecedent hypoglycaemia in non-diabetic subjects reduces the adrenaline response for 6 days but does not affect the catecholamine response to other stimuli. Robinson AM, et al. **Clin Sci (Colch)** 1995 Oct;89(4):359-66

Effect of water restriction during adaptation to a low-sodium diet in man. Sutters M, et al. **Clin Sci (Colch)** 1995 Sep; 89(3):305-10

Low pH adaptation and the acid tolerance response of Salmonella typhimurium. Foster JW. **Crit Rev Microbiol** 1995;21(4):215-37 (90 ref.)

Role of the cerebellum in movement control and adaptation. Robinson FR. **Curr Opin Neurobiol** 1995 Dec;5(6):755-62 (49 ref.)

Limb movement adaptations in horses with experimentally induced fore- or hindlimb lameness. Buchner HH, et al. **Equine Vet J** 1996 Jan;28(1):63-70

Head and trunk movement adaptations in horses with experimentally induced fore- or hindlimb lameness. Buchner HH, et al. **Equine Vet J** 1996 Jan;28(1):71-6

Postural adaptations to workbench modifications in standing workers. Whistance RS, et al. **Ergonomics** 1995 Dec; 38(12):2485-503

Seasonal variations in energy balance among agriculturalists in central Mali: compromise or adaptation? Adams AM. **Eur J Clin Nutr** 1995 Nov;49(11):809-23

Cardiorespiratory adaptation of COPD patients to physical training on land and in water. Perk J, et al. **Eur Respir J** 1996 Feb;9(2):248-52

Synaptic depression in visual cortex tissue slices: an in vitro model for cortical neuron adaptation. Finlayson PG, et al. **Exp Brain Res** 1995;106(1):145-55

Adaptation to life at micromolar nutrient levels: the regulation of Escherichia coli glucose transport by endoinduction and cAMP. Ferenci T. **FEMS Microbiol Rev** 1996 Jul;18(4):301-17 (92 ref.)

Increased adipose tissue glyceroneogenesis in rats adapted to a high protein, carbohydrate-free diet. Botion LM, et al. **Horm Metab Res** 1995 Jul;27(7):310-3

The importance of gastric emptying and mucosal folds in the adaptive cytoprotection of mild irritants in rats. Ko JK, et al. **Inflamm Res** 1995 Dec;44(12):518-22

Adaptation of human skeletal muscle to exercise-training. Simoneau JA. **Int J Obes Relat Metab Disord** 1995 Oct; 19 Suppl 4:S9-13 (47 ref.)

Spectral indices of cardiovascular adaptations to short-term simulated microgravity exposure. Patwardhan AR, et al. **Integr Physiol Behav Sci** 1995 Jul-Sep;30(3):201-14

Discrete, patterned and purposeful adaptive physiological adjustments integrated by forebrain influences. Wolf S. **Integr Physiol Behav Sci** 1995 Jul-Sep;30(3):190-9 (21 ref.)

Heat tolerance in two tropically adapted Bos taurus breeds, Senepol and Romosinuano, compared with Brahman, Angus, and Hereford cattle in Florida. Hammond AC, et al. **J Anim Sci** 1996 Feb;74(2):295-303

Myoneural interactions affect diaphragm muscle adaptations to inactivity. Miyata H, et al. **J Appl Physiol** 1995 Nov; 79(5):1640-9

Adaptation to eccentric exercise: effect on CD64 and CD11b/CD18 expression. Pizza FX, et al. **J Appl Physiol** 1996 Jan;80(1):47-55

Slow component of O2 uptake during heavy exercise: adaptation to endurance training. Womack CJ, et al. **J Appl Physiol** 1995 Sep;79(3):838-45

Regional adaptations of rabbit diaphragm muscle fibers to unilateral denervation. Zhan WZ, et al. **J Appl Physiol** 1995 Sep;79(3):941-50

Cellular changes during cold acclimatation in adipose tissues. Cousin B, et al. **J Cell Physiol** 1996 May;167(2):285-9

Altered polyamine biosynthesis with aging after massive proximal small bowel resection in rat. Sakamoto K, et al. **J Gastroenterol** 1996 Jun;31(3):338-46

The effect of exercise training on cold tolerance in adult and old C57BL/6J mice. Schaefer VI, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B38-42

Transduction and adaptation in spider slit sense organ mechanoreceptors. Juusola M, et al. **J Neurophysiol** 1995 Dec;74(6):2513-23

Adaptation of carotid chemoreceptors to step increases in PaCO2 in anesthetized cats. Linton RA, et al. **J Neurophysiol** 1995 Dec;74(6):2707-12

Adaptation to high-salt stress in Saccharomyces cerevisiae is regulated by Ca2+/calmodulin-dependent phosphoprotein phosphatase (calcineurin) and cAMP-dependent protein kinase. Hirata D, et al. **Mol Gen Genet** 1995 Nov 27;249(3):257-64

Influence of the thyroid status of the organism in the realization of the adaptational effect of cold. Bozhko AP, et al. **Neurosci Behav Physiol** 1995 Jul-Aug;25(4):311-8

Central mechanism of neural activation with cold acclimation of rats using Fos immunohistochemistry. Miyata S, et al. **Neurosci Res** 1995 May;22(2):209-18

Induction of thermotolerance in male broiler chickens by temperature conditioning at an early age. Yahav S, et al. **Poult Sci** 1996 Mar;75(3):402-6

Signal transduction in ischemic preconditioning. Downey JM, et al. **Z Kardiol** 1995;84 Suppl 4:77-86 (68 ref.)

[Morphologic adaptation of the vertebrate eye to the environment] Puzzolo D. **Arch Ital Anat Embriol** 1994 Oct-Dec;99(4):17-100 (250 ref.) (Ita)

[The participation of gastric afferents in the reflex mechanisms of immediate adaptation to stress exposures] Serdiuk SE, et al. **Fiziol Zh Im I M Sechenova** 1995 Sep; 81(9):40-51 (Eng. Abstr.) (Rus)

[The effect of temperature and cold adaptation on slow-muscle contractile activity in rats] Uspenskii AN, et al. **Fiziol Zh Im I M Sechenova** 1995 Sep;81(9):95-100 (Eng. Abstr.) (Rus)

RADIATION EFFECTS

Variability in adaptive response to low dose radiation in human blood lymphocytes: consistent results from chromosome aberrations and micronuclei. Vijayalaxmi, et al. **Mutat Res** 1995 Sep;348(1):45-50

[Modification of reactions of rats to the effect of weak variable magnetic fields using a stress factor] Temur'iants NA, et al. **Biofizika** 1995 Sep-Oct;40(5):969-73 (Eng. Abstr.) (Rus)

[The pathological mechanisms of central nervous system dysadaptation in subjects exposed to radiation] Sinitskiĭ VN, et al. **Fiziol Zh** 1995 May-Aug;41(3-4):55-66 (Eng. Abstr.) (Rus)

[The assessment of the effect of radiation on the body adaptation potentials in people living on the Techa River] Lemiasev MF, et al. **Gig Sanit** 1996 Jan-Feb;(1):31-3 (Eng. Abstr.) (Rus)

[The cytogenetic analysis of the adaptive response in the lymphocytes of donors living in areas with different levels of radioactive contamination] Riabchenko NI, et al. **Radiats Biol Radioecol** 1995 Sep-Oct;35(5):670-5 (Eng. Abstr.) (Rus)

[The radioadaptive response in the lymphocytes of schizophrenia patients] Tskhovrebova LV, et al. **Radiats Biol Radioecol** 1995 Sep-Oct;35(5):665-9 (Eng. Abstr.) (Rus)

[The adaptive response in the lymphocytes of children from an area with an elevated background of ionizing radiation] Vasil'eva IM, et al. **Radiats Biol Radioecol** 1995 Sep-Oct; 35(5):662-5 (Eng. Abstr.) (Rus)

ADAPTATION, PSYCHOLOGICAL

see related

SOCIAL ADJUSTMENT

Helping medical students develop lifelong strategies to cope with stress. Rathbun J. **Acad Med** 1995 Nov;70(11):955-6

Psychological long-term coping with experience of disease and treatment in childhood cancer survivors. Boman K, et al. **Acta Paediatr** 1995 Dec;84(12):1395-402

Psychological long-term coping with experience of disease and treatment in childhood cancer survivors. Larsson B, et al. **Acta Paediatr** 1996 Apr;85(4):404-6

Life satisfaction as a mediator between distressing events and neurotic impairment in a general population. Baruffol E, et al. **Acta Psychiatr Scand** 1995 Jul;92(1):56-62

Mental well-being in people with non-insulin-dependent diabetes. Viinamäki H, et al. **Acta Psychiatr Scand** 1995 Nov;92(5):392-7

Aggression and hostility in substance abusers: the relationship to abuse patterns, coping style, and relapse triggers. McCormick RA, et al. **Addict Behav** 1995 Sep-Oct; 20(5):555-62

Coping capacity in female adolescent substance abusers. Mezzich AC, et al. **Addict Behav** 1995 Mar-Apr;20(2):181-7

Entering treatment for alcohol abuse: a stress and coping model. Finney JW, et al. **Addiction** 1995 Sep;90(9):1223-40

Self-perception in late adolescence: an interactive perspective. Klein HA. **Adolescence** 1995 Fall; 30(119):579-91

Strategies for coping with sexually transmitted diseases by adolescent females. Rosenthal SL, et al. **Adolescence** 1995 Fall;30(119):655-66

Coping by the carers of dementia sufferers. Saad K, et al.

Age Ageing 1995 Nov;24(6):495–8
Coping and social support as determinants of quality of life in HIV/AIDS. Friedland J, et al. **AIDS Care** 1996 Feb; 8(1):15–31
The stressors and stress of being HIV-positive. Thompson SC, et al. **AIDS Care** 1996 Feb;8(1):5–14
Stress, coping, and attitudes toward HIV treatment in injecting drug users: a qualitative study. Demas P, et al. **AIDS Educ Prev** 1995 Oct;7(5):429–42
Alcohol consumption, life context, and coping predict mortality among late-middle-aged drinkers and former drinkers. Mertens JR, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):313–9
"Taking another route": daily survival narratives from mothers who are homeless. Banyard VL. **Am J Community Psychol** 1995 Dec;23(6):871–91
Race, gender, and the response to stress: autoworkers' vulnerability to long-term unemployment. Broman CL, et al. **Am J Community Psychol** 1995 Dec;23(6):813–42
Protective processes in adolescence: matching stressors with social resources. Gore S, et al. **Am J Community Psychol** 1995 Jun;23(3):301–27
Evaluation of a preventive intervention for a self-selected subpopulation of children. Short JL, et al. **Am J Community Psychol** 1995 Apr;23(2):223–47
Cultural orientation and psychological well-being in Chinese Americans. Ying YW. **Am J Community Psychol** 1995 Dec; 23(6):893–911
Impact of aborted sudden cardiac death on survivors and their spouses: the phenomenon of different reference points. Doolittle ND, et al. **Am J Crit Care** 1995 Sep;4(5):389–96 (24 ref.)
Correlates of crack abuse among drug-using incarcerated women: psychological trauma, social support, and coping behavior. el-Bassel N, et al. **Am J Drug Alcohol Abuse** 1996 Feb;22(1):41–56
Coping with the personal and professional frustrations of epidemiologic research. Harlow BL. **Am J Epidemiol** 1995 Oct 15;142(8):785–7
John Henryism, education, and blood pressure in young adults. The CARDIA study. Coronary Artery Risk Development in Young Adults Study. McKetney EC, et al. **Am J Epidemiol** 1996 Apr 15;143(8):787–91
Patients' perceived control over their health care: an outcome assessment of their psychological adjustment to renal failure. Bremer BA, et al. **Am J Med Qual** 1995 Fall; 10(3):149–54
Alma: coping with culture, poverty, and disability. Blanche EI. **Am J Occup Ther** 1996 Apr;50(4):265–76
Transformative narratives: from victimic to agentic life plots. Polkinghorne DE. **Am J Occup Ther** 1996 Apr; 50(4):299–305 (34 ref.)
Jenny's story: reinventing oneself through occupation and narrative configuration. Price-Lackey P, et al. **Am J Occup Ther** 1996 Apr;50(4):306–14
Impact of spinal cord injury on the life roles of women. Quigley MC. **Am J Occup Ther** 1995 Sep;49(8):780–6
The meaning of sea kayaking for persons with spinal cord injuries. Taylor LP, et al. **Am J Occup Ther** 1996 Jan; 50(1):39–46
The role of work identity in women's adjustment to divorce. Bisagni GM, et al. **Am J Orthopsychiatry** 1995 Oct; 65(4):574–83
Long-term follow-up of outpatient interdisciplinary pain management with a no-treatment comparison group. Lynch RT, et al. **Am J Phys Med Rehabil** 1996 May-Jun; 75(3):213–22
Defense mechanisms and adjustment in normal adolescents. Erickson SJ, et al. **Am J Psychiatry** 1996 Jun;153(6):826–8
The Melbourne Family Grief Study, I: Perceptions of family functioning in bereavement. Kissane DW, et al. **Am J Psychiatry** 1996 May;153(5):650–8
The Melbourne Family Grief Study, II: Psychosocial morbidity and grief in bereaved families. Kissane DW, et al. **Am J Psychiatry** 1996 May;153(5):659–66
Research update on the psychosocial treatment of schizophrenia. Penn DL, et al. **Am J Psychiatry** 1996 May; 153(5):607–17 (89 ref.)
Dissociation, somatization, and affect dysregulation: the complexity of adaptation of trauma. van der Kolk BA, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):83–93 (90 ref.)
Anger theory and management: a historical analysis. Kemp S, et al. **Am J Psychol** 1995 Fall;108(3):397–417
Basic behavioral science research for mental health. Vulnerability and resilience. Basic Behavioral Science Task Force of the National Advisory Mental Health Council. **Am Psychol** 1996 Jan;51(1):22–8 (7 ref.)
A life span model of successful aging. Schulz R, et al. **Am Psychol** 1996 Jul;51(7):702–14
Living with chronic illness [editorial] Chinn PL. **ANS Adv Nurs Sci** 1996 Mar;18(3):vi
Testing an uncertainty model for women with multiple sclerosis. Crigger NJ. **ANS Adv Nurs Sci** 1996 Mar; 18(3):37–47
Functional performance in people with chronic obstructive pulmonary disease: a qualitative analysis. Leidy NK, et al. **ANS Adv Nurs Sci** 1996 Mar;18(3):77–89
Creating health with chronic illness. McWilliam CL, et al. **ANS Adv Nurs Sci** 1996 Mar;18(3):1–15
Struggling to gain meaning: living with the uncertainty of breast cancer. Nelson JP. **ANS Adv Nurs Sci** 1996 Mar; 18(3):59–76
Specter of the crone: the experience of vertebral fracture. Paier GS. **ANS Adv Nurs Sci** 1996 Mar;18(3):27–36
Womanspirit: a journey into healing through art in breast cancer. Predeger E. **ANS Adv Nurs Sci** 1996 Mar; 18(3):48–58
Working-out caregiving systems in African American families. Nkongho NO, et al. **Appl Nurs Res** 1996 Aug; 9(3):108–14
Running and its effect on family life. Fick DS, et al. **Arch Fam Med** 1996 Jul-Aug;5(7):385–8; discussion 389
Harrison's. Lemkau JP. **Arch Fam Med** 1995 Nov;4(11):920–1
Israeli preschoolers under Scud missile attacks. A developmental perspective on risk-modifying factors. Laor N, et al. **Arch Gen Psychiatry** 1996 May;53(5):416–23
Violence in the health care environment. Gregg CM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jan;122(1):11–6 (19 ref.)
Tympanic temperature asymmetry and stress behavior in rhesus macaques and children. Boyce WT, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):518–23
Changes in the execution of a complex manual task after ipsilateral ischemic cerebral hemispheric stroke. Yelnik A, et al. **Arch Phys Med Rehabil** 1996 Aug;77(8):806–10
Dispositional optimism, dysphoria, health, and coping with hearing impairment in elderly adults. Andersson G, et al. **Audiology** 1995 Mar-Apr;34(2):76–84
Psychological first-aid: a practical aide-memoire. Leach J. **Aviat Space Environ Med** 1995 Jul;66(7):668–74 (22 ref.)
Psychological functioning among members of a small polar expedition. Palinkas LA, et al. **Aviat Space Environ Med** 1995 Oct;66(10):943–50
The effects of short-term exercise on the cognitive orientation for health and adjustment in myocardial infarction patients. Greif H, et al. **Behav Med** 1995 Summer; 21(2):75–85
Computer modeling of adaptive depression. Webster C. **Behav Sci** 1995 Oct;40(4):314–30 (52 ref.)
A behavioral animal model of posttraumatic stress disorder featuring repeated exposure to situational reminders. Pynoos RS, et al. **Biol Psychiatry** 1996 Jan 15;39(2):129–34
Coping with a diagnosis of breast cancer [letter] **BMJ** 1995 Sep 9;311(7006):692
Gonadal function and psychosexual adjustment in male long-term survivors of bone marrow transplantation. Molassiotis A, et al. **Bone Marrow Transplant** 1995 Aug; 16(2):253–9
Coping with noise-induced hearing loss: experiences from the perspective of middle-aged male victims. Hallberg LR, et al. **Br J Audiol** 1995 Aug;29(4):219–30
Coping strategies and phobias: the relationship between fears, phobias and methods of coping with stressors. Davey GC, et al. **Br J Clin Psychol** 1995 Sep;34 (Pt 3):423–34
A psychological analysis of menopausal hot flushes. Hunter MS, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):589–99
Measurement of psychological distress in asthma and asthma management programmes. Hyland ME, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):601–11
Traumatic spinal cord injury and psychological impact: a cross-sectional analysis of coping strategies. Kennedy P, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):627–39
Childhood onset of spinal cord injury: self-esteem and self-perception. Kennedy P, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):581–8
Revisiting the psychological aspects of AIDS: has the crisis passed? [editorial] Ratigan BJ. **Br J Hosp Med** 1996 Feb 21-Mar 5;55(4):158–9
Miscarriage experience and the role of support systems: a pilot study. Conway K. **Br J Med Psychol** 1995 Sep;68 (Pt 3):259–67
The influence of psychological debriefing on emotional adaptation in women following early miscarriage: a preliminary study. Lee C, et al. **Br J Med Psychol** 1996 Mar;69 (Pt 1):47–58
Case report: psychological response of a woman with schizo-affective disorder on discovering she had ovarian cancer. Morris MR, et al. **Br J Med Psychol** 1995 Dec;68 (Pt 4):349–51
Adapting cognitive analytic therapy to make sense of psychologically harmful work environments. Walsh S. **Br J Med Psychol** 1996 Mar;69 (Pt 1):3–20
Incorporating psychological debriefing techniques within a brief group psychotherapy programme for the treatment of post-traumatic stress disorder. Busuttil W, et al. **Br J Psychiatry** 1995 Oct;167(4):495–502
Psychological interventions in infection with the human immunodeficiency virus. Catalan J. **Br J Psychiatry** 1995 Jul;167(1):104–11 (65 ref.)
Women's response to adversity [letter; comment] Mezey GC. **Br J Psychiatry** 1995 Aug;167(2):266. Comment on: Br J Psychiatry 1995 May;166(5):583–94.
Immigrant families coping with schizophrenia. Behavioral family intervention v. case management with a low-income Spanish-speaking population. Telles C, et al. **Br J Psychiatry** 1995 Oct;167(4):473–9
Coping and psychosocial function after brain injury. Malia K, et al. **Brain Inj** 1995 Aug-Sep;9(6):607–18
Post-concussion syndrome and the coping hypothesis. Marsh NV, et al. **Brain Inj** 1995 Aug-Sep;9(6):553–62
Screening prison inmates for mental disorder: an examination of the relationship between mental disorder and prison adjustment. DiCataldo F, et al. **Bull Am Acad Psychiatry Law** 1995;23(4):573–85
Ticket on the Titanic. Perils and pitfalls of junior faculty development [editorial] Graham JE. **Can Fam Physician** 1996 Jul;42:1271–4, 1281–4 **(Eng, Fre)**
Self-esteem and cancer: theory and research. Katz MR, et al. **Can J Psychiatry** 1995 Dec;40(10):608–15 (120 ref.)
Treating AIDS: hope and despair [letter; comment] Brown MG. **Can Med Assoc J** 1996 Jan 15;154(2):139–40. Comment on: Can Med Assoc J 1995 Oct 1;153(7):967–8.
Female family physicians in obstetrics: achieving personal balance. Carroll JC, et al. **Can Med Assoc J** 1995 Nov 1;153(9):1283–9
Managing erotic feelings in the physician-patient relationship [see comments] Golden GA, et al. **Can Med Assoc J** 1995 Nov 1;153(9):1241–5 (52 ref.). Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149; discussion 1150. Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149–50.
A surgeon with AIDS made the most of borrowed time. Robb N. **Can Med Assoc J** 1996 Jan 15;154(2):223–5
Treating AIDS: hope and despair [letter; comment] Sauls R. **Can Med Assoc J** 1996 Jan 15;154(2):140. Comment on: Can Med Assoc J 1995 Oct 1;153(7):967–8.
A psychoeducational nursing intervention to enhance coping and affective state in newly diagnosed malignant melanoma patients. Fawzy NW. **Cancer Nurs** 1995 Dec;18(6):427–38
Coping patterns among bone marrow transplant patients: a hermeneutical inquiry. Shuster GF, et al. **Cancer Nurs** 1996 Aug;19(4):290–7
Sexual functioning in women with breast cancer after treatment with adjuvant therapy. Young-McCaughan S. **Cancer Nurs** 1996 Aug;19(4):308–19
Coping and learning with data systems in the information age. Brandstetter RW, et al. **Chest** 1996 Jan;109(1):238–40
A meta-analysis of the relationship of child sexual abuse to adult psychological adjustment. Jumper SA. **Child Abuse Negl** 1995 Jun;19(6):715–28
Trauma history and personal narratives: some clues to coping among survivors of child abuse. Klein I, et al. **Child Abuse Negl** 1996 Jan;20(1):45–54
Moderating effects of physical abuse and perceived social support on the potential to abuse. Litty CG, et al. **Child Abuse Negl** 1996 Apr;20(4):305–14
Ethnic differences in psychological functioning among black and Latino sexually abused girls. Sanders-Phillips K, et al. **Child Abuse Negl** 1995 Jun;19(6):691–706
Resilience criteria and factors associated with resilience in sexually abused girls. Spaccarelli S, et al. **Child Abuse Negl** 1995 Sep;19(9):1171–82
Sibling empathy and behavioural adjustment of children with chronic illness. Janus M, et al. **Child Care Health Dev** 1995 Sep;21(5):321–31
It takes two to replicate: a mediational model for the impact of parents' stress on adolescent adjustment. Conger RD, et al. **Child Dev** 1995 Feb;66(1):80–97
Friendship quality as a predictor of young children's early school adjustment. Ladd GW, et al. **Child Dev** 1996 Jun; 67(3):1103–18
Congruence between mothers' and fathers' differential treatment of siblings: links with family relations and children's well-being. McHale SM, et al. **Child Dev** 1995 Feb;66(1):116–28
Can ideological commitment protect children's psychological well-being in situations of political violence? Punamäki RL. **Child Dev** 1996 Feb;67(1):55–69
Physician job satisfaction: reversing the decline. Suchman AL. **Cleve Clin J Med** 1996 May-Jun;63(3):137–8
Do changes in patient beliefs and coping strategies predict temporomandibular disorder treatment outcomes? Turner JA, et al. **Clin J Pain** 1995 Sep;11(3):177–88
Behavioral management of children's seizure activity. Intervention guidelines for primary-care providers. Kuhn BR, et al. **Clin Pediatr (Phila)** 1995 Nov;34(11):570–5
Ability and dependency in adolescents with severe learning disabilities. McKinlay I, et al. **Dev Med Child Neurol** 1996 Jan;38(1):48–58
The long-term effects of children's early-onset disability on marital relationships. Taanila A, et al. **Dev Med Child Neurol** 1996 Jul;38(7):567–77
Long-term effects of Hurricane Andrew: revisiting mental health indicators. McDonnell S, et al. **Disasters** 1995 Sep; 19(3):235–46
Factors associated with coping in persons undergoing alcohol and drug detoxification. Madden C, et al. **Drug Alcohol Depend** 1995 Jun;38(3):229–35
Neuroticism in temporal lobe epilepsy: assessment and implications for pre- and postoperative psychosocial adjustment and health-related quality of life. Rose KJ, et al. **Epilepsia** 1996 May;37(5):484–91
Partners in adversity. V: Support, personality and coping behaviour at the time of crisis. Miller PM, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(4–5):245–54
Well-being and coping in oral and pharyngeal cancer patients. Langius A, et al. **Eur J Cancer B Oral Oncol** 1995 Jul;31B(4):242–9
Inflammatory Bowel Disease Questionnaire: cross-cultural adaptation and further validation. de Boer AG, et al. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1043–50
Prenatal exposure to diethylstilbestrol and the mother-daughter relationship. Cahen F, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):181–7
Psychosocial adaptation after liver transplantation with particular reference to recipients aware of their cancer. Filiberti A, et al. **Eur J Surg Oncol** 1996 Jun;22(3):240–4

Short-term adaptation of the phase of the vestibulo-ocular reflex (VOR) in normal human subjects. Kramer PD, et al. **Exp Brain Res** 1995;106(2):318-26

Surviving the 'heartsink' experience. Mathers NJ, et al. **Fam Pract** 1995 Jun;12(2):176-83

Illness and family functioning: theoretical and practical considerations from the primary care point of view. Tansella CZ. **Fam Pract** 1995 Jun;12(2):214-20 (14 ref.)

The excitation-adaptation model of pediatric chronic illness. Meijer AM, et al. **Fam Process** 1995 Dec;34(4):441-54

Depression in patients with coronary heart disease. A 12-month follow-up. Hance M, et al. **Gen Hosp Psychiatry** 1996 Jan;18(1):61-5

Coping and the decision to hospitalize in emergency psychiatry. Schnyder U, et al. **Gen Hosp Psychiatry** 1995 Sep;17(5):362-70

The impact of mood on time perception, memorization, and acceptance of waiting. Chebat JC, et al. **Genet Soc Gen Psychol Monogr** 1995 Nov;121(4):411-24

The long-term effects of later life spousal and parental bereavement on personal functioning. Arbuckle NW, et al. **Gerontologist** 1995 Oct;35(5):637-47

The effects of poverty environments on elders' subjective well-being: a conceptual model. Brown V. **Gerontologist** 1995 Aug;35(4):541-8 (48 ref.)

Last rites [letter; comment] Jackson CM. **Hastings Cent Rep** 1995 Nov-Dec;25(6):3. Comment on: Hastings Cent Rep 1995 Mar-Apr;25(2):22-3.

Subjective stress and coping in recurrent tension-type headache. Ficek SK, et al. **Headache** 1995 Sep;35(8):455-60

When mom or dad has cancer: II. Coping, cognitive appraisals, and psychological distress in children of cancer patients [see comments] Compas BE, et al. **Health Psychol** 1996 May;15(3):167-75. Comment in: Health Psychol 1996 May;15(3):155-7.

Effects of cognitive coping skills training on coping strategies and experimental pain sensitivity in African American adults with sickle cell disease. Gil KM, et al. **Health Psychol** 1996 Jan;15(1):3-10

Social support and adjustment to cancer: reconciling descriptive, correlational, and intervention research. Helgeson VS, et al. **Health Psychol** 1996 Mar;15(2):135-48 (80 ref.)

Applications of the monitoring process model to coping with severe long-term medical threats. Miller SM, et al. **Health Psychol** 1996 May;15(3):216-25

Financial stress, social support, and alcohol involvement: a longitudinal test of the buffering hypothesis in a general population survey. Peirce RS, et al. **Health Psychol** 1996 Jan;15(1):38-47

Establishing the study of development as a dynamic force in health psychology [editorial; comment] Peterson L. **Health Psychol** 1996 May;15(3):155-7. Comment on: Health Psychol 1996 May;15(3):158-66. Comment on: Health Psychol 1996 May;15(3):167-75.

Association between daily coping and end-of-day mood. Stone AA, et al. **Health Psychol** 1995 Jul;14(4):341-9

Preventive health psychology from a developmental perspective: an extension of protection motivation theory [see comments] Sturges JW, et al. **Health Psychol** 1996 May;15(3):158-66. Comment in: Health Psychol 1996 May;15(3):155-7.

Pain perception and coping in female tension headache sufferers and headache-free controls. Ukestad LK, et al. **Health Psychol** 1996 Jan;15(1):65-8

Parental education related to adolescent stress-coping and substance use: development of a mediational model. Wills TA, et al. **Health Psychol** 1995 Sep;14(5):464-78

Does apologizing help? The role of self-blame and making amends in recovery from bereavement. Weinberg N. **Health Soc Work** 1995 Nov;20(4):294-9

Psychological reactions and family adjustment in shock versus no shock groups after implantation of internal cardioverter defibrillator. Dougherty CM. **Heart Lung** 1995 Jul-Aug;24(4):281-91

Life after a cardiac event: women's experience in healing. Fleury J, et al. **Heart Lung** 1995 Nov-Dec;24(6):474-82

Psychosocial recovery from a cardiac event: the influence of perceived control. Moser DK, et al. **Heart Lung** 1995 Jul-Aug;24(4):273-80

Links between growth hormone deficiency, adaptation and social phobia. Stabler B, et al. **Horm Res** 1996;45(1-2):30-3 (27 ref.)

Delineating the concept of hope. Morse JM, et al. **Image J Nurs Sch** 1995 Winter;27(4):277-85

The lived experience of women military nurses in Vietnam during the Vietnam War. Scannell-Desch EA. **Image J Nurs Sch** 1996 Summer;28(2):119-24

Problem-focused coping in HIV-infected mothers in relation to self-efficacy, uncertainty, social support, and psychological distress. Sharts-Hopko NC, et al. **Image J Nurs Sch** 1996 Summer;28(2):107-11

The Pinwheel Model of Bereavement. Solari-Twadell PA, et al. **Image J Nurs Sch** 1995 Winter;27(4):323-6 (21 ref.)

Smoking cessation leads to reduced stress, but why? Parrott AC. **Int J Addict** 1995 Sep;30(11):1509-16 (17 ref.)

Caregiving and dementia: predicting negative and positive outcomes for caregivers. Gold DP, et al. **Int J Aging Hum Dev** 1995;41(3):183-201

Centenarians: their memories and future ambitions. Merriam SB, et al. **Int J Aging Hum Dev** 1995;41(2):117-32

Psychological and hypnotic preparation for anesthesia and surgery: an individual differences perspective. Kessler R, et al. **Int J Clin Exp Hypn** 1996 Jul;44(3):189-207 (60 ref.)

Development of body image, eating disturbance, and general psychological functioning in female adolescents: covariance structure modeling and longitudinal investigations. Thompson JK, et al. **Int J Eat Disord** 1995 Nov; 18(3):221-36

Coping and depression in bulimia nervosa. Tobin DL, et al. **Int J Eat Disord** 1995 Dec;18(4):359-63

Wellness and HIV: developing a model for progression from theoretical knowledge about psychosocial factors to application. Rayner-Brosnan D. **Int J Immunopharmacol** 1995 Aug;17(8):663-76 (95 ref.)

Managing occupational HIV exposures: a Canadian study. Reutter LI, et al. **Int J Nurs Stud** 1995 Oct;32(5):493-505

The spiritual dimension: its importance to patients' health, well-being and quality of life and its implications for nursing practice. Ross L. **Int J Nurs Stud** 1995 Oct; 32(5):457-68 (66 ref.)

"Adaptive" changes in the behaviour of parasitized animals: a critical review. Poulin R. **Int J Parasitol** 1995 Dec; 25(12):1371-83 (102 ref.)

Does acculturation influence psychosocial adaptation and well-being in Native Hawaiians? Streltzer J, et al. **Int J Soc Psychiatry** 1996 Spring;42(1):28-37

Structural sources of the sense of coherence. Two life stories of Holocaust survivors in Israel. Sagy S, et al. **Isr J Med Sci** 1996 Mar-Apr;32(3-4):200-5

The impact of Jewish identity on the psychological adjustment of Soviet Jewish immigrants to Israel. Epstein A, et al. **Isr J Psychiatry Relat Sci** 1996;33(1):21-31

Psychological adjustment among Soviet immigrant physicians: distress and self-assessments of its sources. Factourovich A, et al. **Isr J Psychiatry Relat Sci** 1996; 33(1):32-9

Psychosocial problems faced during absorption of Russian-speaking new immigrants into Israel: a systematic approach. Rotenberg V, et al. **Isr J Psychiatry Relat Sci** 1996;33(1):40-9

Depressive symptomatology in new mothers: a stress and coping perspective. Terry DJ, et al. **J Abnorm Psychol** 1996 May;105(2):220-31

Coping strategies and posttraumatic stress disorder in female victims of sexual and nonsexual assault. Valentiner DP, et al. **J Abnorm Psychol** 1996 Aug;105(3):455-8

Postpartum psychiatric disorders: their relationship to psychological adjustment and marital satisfaction in the spouses. Zelkowitz P, et al. **J Abnorm Psychol** 1996 May; 105(2):281-5

Coping, social support, and depressive symptoms in adolescent mothers. Panzarine S, et al. **J Adolesc Health** 1995 Aug;17(2):113-9

The experience of bereavement in older adults. Anderson KL, et al. **J Adv Nurs** 1995 Aug;22(2):308-15

Living with ulcerative colitis: experiences of adolescents and young adults. Brydolf M, et al. **J Adv Nurs** 1996 Jan; 23(1):39-47

Unbearable incidents: failure to endure the experience of illness. Dewar AL, et al. **J Adv Nurs** 1995 Nov;22(5):957-64

The lived experience of clinical educators. Ferguson DS. **J Adv Nurs** 1996 Apr;23(4):835-41

Patient suffering: a taxonomy from the nurse's perspective. Flaming D. **J Adv Nurs** 1995 Dec;22(6):1120-7

Parents' perceptions of caring for an infant or toddler with diabetes. Hatton DL, et al. **J Adv Nurs** 1995 Sep; 22(3):569-77

Social support and the patient with cancer: a consideration of the literature. Krishnasamy M. **J Adv Nurs** 1996 Apr; 23(4):757-62 (29 ref.)

Adjustment and social behaviour in older adults with chronic obstructive pulmonary disease: the family's perspective. Leidy NK, et al. **J Adv Nurs** 1996 Feb;23(2):252-9

Stressors, coping mechanisms and quality of life among dialysis patients in Australia. Lok P. **J Adv Nurs** 1996 May; 23(5):873-81

Ongoing work of older adults at home after hospitalization. Lough MA. **J Adv Nurs** 1996 Apr;23(4):804-9

Alternative therapies as control behaviours used by cancer patients. Montbriand MJ. **J Adv Nurs** 1995 Oct; 22(4):646-54

Chronic illness and the family life-cycle. Newby NM. **J Adv Nurs** 1996 Apr;23(4):786-91 (29 ref.)

The effect of a senior preceptorship on the adaptive competencies of community college nursing students. Ridley MJ, et al. **J Adv Nurs** 1995 Jul;22(1):58-65

The moderating effect of demographic variables on coping effectiveness. Spitzer A, et al. **J Adv Nurs** 1995 Sep; 22(3):578-85

Social support: how does it really work? Spitzer A, et al. **J Adv Nurs** 1995 Nov;22(5):850-4

Living with haemophilia and HIV/AIDS: support and coping. Stewart MJ, et al. **J Adv Nurs** 1995 Dec; 22(6):1101-11

The experiences of patients and their partners 1 month after a heart attack. Thompson DR, et al. **J Adv Nurs** 1995 Oct; 22(4):707-14

Management of conflict: do nurses/women handle it differently? Valentine PE. **J Adv Nurs** 1995 Jul;22(1):142-9 (77 ref.)

The transformational experience of liver transplantation. Wainwright SP. **J Adv Nurs** 1995 Dec;22(6):1068-76

Nursing as the promotion of well-being: the client's experience. Wallace CL, et al. **J Adv Nurs** 1995 Aug; 22(2):285-9

Caring, curing, coping: towards an integrated model. Webb C. **J Adv Nurs** 1996 May;23(5):960-8 (44 ref.)

Young children's behavioural responses to acute pain: strategies for getting better. Woodgate R, et al. **J Adv Nurs** 1995 Aug;22(2):243-9

The relationship of health locus of control and cardiac rehabilitation to mastery of illness-related stress. Younger J, et al. **J Adv Nurs** 1995 Aug;22(2):294-9

Families created through ovum donation: a preliminary investigation of obstetrical outcome and psychosocial adjustment. Applegarth L, et al. **J Assist Reprod Genet** 1995 Oct;12(9):574-80

Quality of life and coping styles of HIV-positive women with children. Rose MA, et al. **J Assoc Nurses AIDS Care** 1996 Mar-Apr;7(2):28-34

Psychosocial adjustment and the role of functional status for children with asthma. Padur JS, et al. **J Asthma** 1995; 32(5):345-53

Poor sleepers who do not complain of insomnia: myths and realities about psychological and lifestyle characteristics of older good and poor sleepers. Fichten CS, et al. **J Behav Med** 1995 Apr;18(2):189-223

The physical and psychosocial predictors of adolescents' recovery from oral surgery. Gidron Y, et al. **J Behav Med** 1995 Aug;18(4):385-99

Preparation for oral surgery: evaluating elements of coping. Litt MD, et al. **J Behav Med** 1995 Oct;18(5):435-59

Cognitive factors in adjustment to cancer: attributions of self-blame and perceptions of control. Malcarne VL, et al. **J Behav Med** 1995 Oct;18(5):401-17

School reentry for the patient with burn injuries: video and/or on-site intervention. Bishop B, et al. **J Burn Care Rehabil** 1995 Jul-Aug;16(4):455-7

Efficacy of school reentry programs. Blakeney P, et al. **J Burn Care Rehabil** 1995 Jul-Aug;16(4):469-72; discussion 466-8

Diminished adaptive behaviors among pediatric survivors of burns. Meyer WJ 3rd, et al. **J Burn Care Rehabil** 1995 Sep-Oct;16(5):511-8

Inconsistencies in psychosocial assessment of children after severe burns. Meyer WJ 3rd, et al. **J Burn Care Rehabil** 1995 Sep-Oct;16(5):559-68; discussion 557-8

Gender differences in the psychological adjustment of parents of young, developmentally disabled children. Trute B. **J Child Psychol Psychiatry** 1995 Oct;36(7):1225-42

Family functioning predictors of adjustment in children with newly diagnosed cancer: a prospective analysis. Varni JW, et al. **J Child Psychol Psychiatry** 1996 Mar;37(3):321-8

Psychosocial adjustment and quality of life in women with breast cancer and benign breast problems: a controlled comparison. Andrykowski MA, et al. **J Clin Epidemiol** 1996 Aug;49(8):827-34

Psychological response to the Oklahoma City bombing [editorial] Krug RS, et al. **J Clin Psychol** 1996 Jan; 52(1):103-5

Psychosocial consequences of weight cycling. Bartlett SJ, et al. **J Consult Clin Psychol** 1996 Jun;64(3):587-92

Task analysis exemplified: the process of resolving unfinished business. Greenberg LS, et al. **J Consult Clin Psychol** 1996 Jun;64(3):439-46

Acceleration of changes in session impact during contrasting time-limited psychotherapies. Reynolds S, et al. **J Consult Clin Psychol** 1996 Jun;64(3):577-86

The resolution of ruptures in the therapeutic alliance. Safran JD, et al. **J Consult Clin Psychol** 1996 Jun;64(3):447-58

Psychological distress in mothers of preterm infants. Meyer EC, et al. **J Dev Behav Pediatr** 1995 Dec;16(6):412-7

Psychological adjustment of children evaluated for short stature: a preliminary report. Zimet GD, et al. **J Dev Behav Pediatr** 1995 Aug;16(4):264-70

Camping with a friend. Helping adolescents cope with diabetes. Silverstein JH, et al. **J Fla Med Assoc** 1995 Dec; 82(12):817-20

Toddlers' emotion regulation behaviors: the roles of social context and family expressiveness. Garner PW. **J Genet Psychol** 1995 Dec;156(4):417-30

Age differences in stress, coping, and appraisal: findings from the Normative Aging Study. Aldwin CM, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul;51(4):P179-88

The importance of friendship and family support in adaptation to chronic vision impairment. Reinhardt JP. **J Gerontol B Psychol Sci Soc Sci** 1996 Sep;51(5):P268-78

Psychosocial consequences of upper limb injury. Paterson MC, et al. **J Hand Surg [Br]** 1995 Dec;20(6):776-81

Epilepsy and children's social and psychological adjustment. Carlton-Ford S, et al. **J Health Soc Behav** 1995 Sep; 36(3):285-301

Caregiving and women's well-being: a life course approach. Moen P, et al. **J Health Soc Behav** 1995 Sep;36(3):259-73

Job autonomy and control over one's spouse: a compensatory process. Stets JE. **J Health Soc Behav** 1995 Sep; 36(3):244-58

Stress, coping, and social support processes: where are we? What next? Thoits PA. **J Health Soc Behav** 1995;Spec No:53-79 (220 ref.)

Impact of psychologic functioning, medical severity, and family functioning in pediatric heart transplantation. DeMaso DR, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 1):1102-8

Psychological distress and disease course for women with breast cancer: one answer, many questions [editorial; comment] Spiegel D. **J Natl Cancer Inst** 1996 May 15; 88(10):629–31. Comment on: J Natl Cancer Inst 1996 May 15;88(10):661–7.

Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B [see comments] Tross S, et al. **J Natl Cancer Inst** 1996 May 15;88(10):661–7. Comment in: J Natl Cancer Inst 1996 May 15;88(10):629–31.

Patients' strategies for coping with auditory hallucinations. Carter DM, et al. **J Nerv Ment Dis** 1996 Mar;184(3):159–64

A model of family adaptation to new-onset childhood epilepsy. Austin JK. **J Neurosci Nurs** 1996 Apr;28(2):82–92 (55 ref.)

Stress and coping: first-year Nepalese nursing students in clinical settings. Mahat G. **J Nurs Educ** 1996 Apr; 35(4):163–9

Creating paths: living with a very-low-birth-weight infant. Vasquez E. **J Obstet Gynecol Neonatal Nurs** 1995 Sep; 24(7):619–24

Child witnesses in Oklahoma. Pfefferbaum B, et al. **J Okla State Med Assoc** 1995 Nov;88(11):479–86

Studies on adaptation to complete dentures. Part II: Oral stereognosis and tactile sensibility. Müller F, et al. **J Oral Rehabil** 1995 Oct;22(10):759–67

Pain, coping, and adjustment in patients with burns: preliminary findings from a prospective study. Ptacek JT, et al. **J Pain Symptom Manage** 1995 Aug;10(6):446–55

Rehearsing one's death. Sirois F. **J Palliat Care** 1995 Autumn; 11(3):50–2

Spiritual care of the school-age child with a chronic condition. Fulton RA, et al. **J Pediatr Nurs** 1995 Aug; 10(4):224–31 (56 ref.)

Perceived stressors and coping strategies of parents who have children with developmental disabilities: a comparison of mothers with fathers. Heaman DJ. **J Pediatr Nurs** 1995 Oct;10(5):311–20

Evolution of parental stress and coping processes: a framework for critical care practice. LaMontagne LL, et al. **J Pediatr Nurs** 1995 Aug;10(4):212–8 (13 ref.)

Maintaining the creative edge during health care reform. Martin BS. **J Pediatr Nurs** 1996 Jun;11(3):200–1

Psychological distress in adolescents with cancer. Neville K. **J Pediatr Nurs** 1996 Aug;11(4):243–51

When cancer strikes home. Neville K. **J Pediatr Oncol Nurs** 1996 Jul;13(3):153–4

Family coping with pediatric leukemia: ten years after treatment. Kupst MJ, et al. **J Pediatr Psychol** 1995 Oct; 20(5):601–17

Late psychosocial consequences for parents of children who survived cancer. Van Dongen-Melman JE, et al. **J Pediatr Psychol** 1995 Oct;20(5):567–86

Coping strategies of children with faecal incontinence. Ludman L, et al. **J Pediatr Surg** 1996 Apr;31(4):563–7

Realities of a premature infant's first year: helping parents cope. Maroney DI. **J Perinatol** 1995 Sep–Oct;15(5):418–22

Repressive coping style and the experience and recall of emotion: a naturalistic study of daily affect. Cutler SE, et al. **J Pers** 1996 Jun;64(2):379–405

Assessment and prediction of stress-related growth. Park CL, et al. **J Pers** 1996 Mar;64(1):71–105

Self-concept clarity and preferred coping styles. Smith M, et al. **J Pers** 1996 Jun;64(2):407–34

Beliefs in realistic and unrealistic control: assessment and implications. Zuckerman M, et al. **J Pers** 1996 Jun; 64(2):435–64

Validation evidence for three coping measures. Clark KK, et al. **J Pers Assess** 1995 Dec;65(3):434–55

IQ and ego-resiliency: conceptual and empirical connections and separateness. Block J, et al. **J Pers Soc Psychol** 1996 Feb;70(2):349–61

Close relationships and adjustment to a life crisis: the case of breast cancer. Bolger N, et al. **J Pers Soc Psychol** 1996 Feb;70(2):283–94

Major life events and minor stressors: identifying mediational links in the stress process. Pillow DR, et al. **J Pers Soc Psychol** 1996 Feb;70(2):381–94

The structure of psychological well-being revisited. Ryff CD, et al. **J Pers Soc Psychol** 1995 Oct;69(4):719–27

The role of loneliness and social support in adjustment to loss: a test of attachment versus stress theory. Stroebe W, et al. **J Pers Soc Psychol** 1996 Jun;70(6):1241–9

Assessing individual differences in constructive versus destructive responses to anger across the lifespan. Tangney JP, et al. **J Pers Soc Psychol** 1996 Apr;70(4):780–96

Relation of shame and guilt to constructive versus destructive responses to anger across the lifespan. Tangney JP, et al. **J Pers Soc Psychol** 1996 Apr;70(4):797–809

Social evaluation and cardiovascular response: an active coping approach. Wright RA, et al. **J Pers Soc Psychol** 1995 Sep;69(3):530–43

The relation between overly positive self-evaluation and adjustment: a comment on Colvin, Block, and Funder (1995) [comment] Zuckerman M, et al. **J Pers Soc Psychol** 1996 Jun;70(6):1250–1; discussion 1252–5. Comment on: J Pers Soc Psychol 1995 Jun;68(6):1152–62.

Living with depression: family members' experiences and treatment needs. Badger TA. **J Psychosoc Nurs Ment Health Serv** 1996 Jan;34(1):21–9

Suicidal thought and self-transcendence in older adults. Buchanan D, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Oct;33(10):31–4

The transition from victim to victor: application of the theory of mastery. White KR. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):41–4

Causal attribution and adaptation among lung cancer patients. Faller H, et al. **J Psychosom Res** 1995 Jul;39(5):619–27

Coping strategies and defense mechanisms and their relevance for the recovery after discectomy. Fulde E, et al. **J Psychosom Res** 1995 Oct;39(7):819–26

The effects of stress and coping upon the diagnostic intracavernous injection in men with erectile dysfunction. van der Borght W, et al. **J Psychosom Res** 1995 Oct; 39(7):865–73

Psychological morbidity and the availability of assisted conception: a group comparison study. Atherton F, et al. **J Public Health Med** 1995 Jun;17(2):157–60

Change and coping with change. Benatar SR. **J R Coll Physicians Lond** 1995 Sep–Oct;29(5):436–41

Children coping with the death of a sibling [editorial; comment] Kroll L, et al. **J R Soc Med** 1995 Aug; 88(8):426–7. Comment on: J R Soc Med 1995 Aug;88(8):474–5.

Pain coping mechanisms in fibromyalgia: relationship to pain and functional outcomes. Nicassio PM, et al. **J Rheumatol** 1995 Aug;22(8):1552–8

Coping styles among adolescent competitive athletes. Anshel M. **J Soc Psychol** 1996 Jun;136(3):311–23

Demographic differences in coping with uncertainty about the future. van der Sijde PC, et al. **J Soc Psychol** 1996 Apr;136(2):159–64

Problem solving and coping strategies in persons with spinal cord injury who have and do not have a family history of alcoholism. Schandler SL, et al. **J Spinal Cord Med** 1996 Apr;19(2):78–86

The role of stress and family relationships in mediating problem drinking and fathers' personal adjustment. Dumka LE, et al. **J Stud Alcohol** 1995 Sep;56(5):528–37

The Adolescent Relapse Coping Questionnaire: psychometric validation. Myers MG, et al. **J Stud Alcohol** 1996 Jan; 57(1):40–6

Gender roles and alcohol abuse across the transition to parenthood. Richman JA, et al. **J Stud Alcohol** 1995 Sep; 56(5):553–7

The impact of coping styles and family communication on the social skills of children of alcoholics. Segrin C, et al. **J Stud Alcohol** 1996 Jan;57(1):29–33

Situational analysis of coping in substance-abusing patients. Schmitz JM, et al. **J Subst Abuse** 1995;7(2):189–204

A need to study utilization of inhospital volunteer manpower for hospitalized adult cancer patients. Hagmann CE. **J Tenn Med Assoc** 1996 Feb;89(2):56–7

Appraisal of control and coping with air-raids. Arambasic L. **J Trauma Stress** 1996 Apr;9(2):325–33

Modes of long-term coping with trauma memories: relative use and associations with personality among Vietnam veterans with chronic PTSD. Hyer L, et al. **J Trauma Stress** 1996 Apr;9(2):299–316

Psychological adaptation of anxiety disorder patients following repeated exposure to emergency situation. Somer E, et al. **J Trauma Stress** 1996 Apr;9(2):207–21

Psychosexual adjustment of children and adolescents after different types of hypospadias surgery: a norm-related study. Mureau MA, et al. **J Urol** 1995 Nov;154(5):1902–7

Patients' needs and their coping strategies transition to cardiac surgery. Shih FJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Feb; 12(2):114–27

Adaptation to pregnancy and motherhood among subfecund and fecund primiparous women. Halman LJ, et al. **Matern Child Nurs J** 1995 Jul–Sep;23(3):90–100

Hardiness and stress: a critical review. Huang C. **Matern Child Nurs J** 1995 Jul–Sep;23(3):82–9 (36 ref.)

Teaching pregnant adolescents to cope with environmental smoke. Winkelstein ML. **MCN Am J Matern Child Nurs** 1995 Jan–Feb;20(1):38–42

Teaching the principles of behaviour change to medical students: evaluation of a programme. Nairn RG, et al. **Med Educ** 1995 Nov;29(6):443–8

The biology of deception: the evolution of cognitive coping as a denial-like process. Stefano GB, et al. **Med Hypotheses** 1995 May;44(5):311–4

Managing HIV. Part 3: Mechanisms of disease. 3.8 How psychosocial aspects of HIV infection can affect health. Ross MW. **Med J Aust** 1996 Feb 19;164(4):235–7 (5 ref.)

Exploration of a self-protective strategy in pediatric oncology staff. Grootenhuis MA, et al. **Med Pediatr Oncol** 1996 Jul;27(1):40–7

Sibling adaptation to childhood cancer collaborative study: health outcomes of siblings of children with cancer. Zeltzer LK, et al. **Med Pediatr Oncol** 1996 Aug;27(2):98–107

African American families, religion, and disability: a conceptual framework. Rogers-Dulan J, et al. **Ment Retard** 1995 Aug;33(4):226–38 (65 ref.)

Grandparents as a source of support for parents of children with disabilities: a brief report. Sandler AG, et al. **Ment Retard** 1995 Aug;33(4):248–50

A day in the life of Gregory L. Walker, MD [interview by Karen Bouffard] Walker GL. **Mich Med** 1996 May; 95(5):30–3

Survival of the fittest [letter] Crowley WJ Jr. **Mo Med** 1995 Sep;92(9):562

Attachment security, affect regulation, and defensive responses to mood induction. Lay KL, et al. **Monogr Soc Res Child Dev** 1995;60(2–3):179–96

Geographical distance from parents and adjustment during adolescence and young adulthood. Dubas JS, et al. **New Dir Child Dev** 1996 Spring;(71):3–19

Pediatric and family HIV. Psychosocial concerns across the continuum of disease. Lewis SL, et al. **Nurs Clin North Am** 1996 Mar;31(1):221–30 (29 ref.)

Coping, diabetes, and the older African-American. Degazon CE. **Nurs Outlook** 1995 Nov–Dec;43(6):254–9

Coming to terms: parents' response to a first cancer recurrence in their child. Hinds PS, et al. **Nurs Res** 1996 May–Jun;45(3):148–53

Stress mediation in caregivers of cognitively impaired adults: theoretical model testing. Irvin BL, et al. **Nurs Res** 1996 May–Jun;45(3):160–6

Children's preoperative coping and its effects on postoperative anxiety and return to normal activity. LaMontagne LL, et al. **Nurs Res** 1996 May–Jun;45(3):141–7

Factor analysis of the Ways of Coping Questionnaire for African American women. Smyth K, et al. **Nurs Res** 1996 Jan–Feb;45(1):25–9

Getting back to normal: the family experience during early stage breast cancer. Hilton BA. **Oncol Nurs Forum** 1996 May;23(4):605–14

Self-blame and adjustment to breast cancer. Houldin AD, et al. **Oncol Nurs Forum** 1996 Jan–Feb;23(1):75–9

Balancing our lives: a study of the married couple's experience with breast cancer recurrence. Lewis FM, et al. **Oncol Nurs Forum** 1995 Jul;22(6):943–53

Development and initial validation of a scale to measure self-efficacy beliefs in patients with chronic pain. Anderson KO, et al. **Pain** 1995 Oct;63(1):77–84

The attentional control of pain: methodological and theoretical concerns. Eccleston C. **Pain** 1995 Oct; 63(1):3–10 (45 ref.)

The role of coping in adjustment to phantom limb pain. Hill A, et al. **Pain** 1995 Jul;62(1):79–86

Family behavior, adaptation, and treatment adherence of pediatric nephrology patients. Davis MC, et al. **Pediatr Nephrol** 1996 Apr;10(2):160–6

School adjustment of children with end-stage renal disease. Fukunishi I, et al. **Pediatr Nephrol** 1995 Oct;9(5):553–7

Management of fatal illness and death in children or their parents. Barakat LP, et al. **Pediatr Rev** 1995 Nov; 16(11):419–23; quiz 424

Divorce: consequences for children. Emery RE, et al. **Pediatr Rev** 1995 Aug;16(8):306–10 (8 ref.)

Coping processes in competitive gymnasts: gender differences. Kolt G, et al. **Percept Mot Skills** 1995 Dec; 81(3 Pt 2):1139–45

Stress, coping, and injuries in male and female high school basketball players. Rider SP, et al. **Percept Mot Skills** 1995 Oct;81(2):499–503

Psychosocial complications in PD. Dingwall RR. **Perit Dial Int** 1996;16 Suppl 1:S472–4

Trends in research on temperament. Bates JE, et al. **Psychiatr Serv** 1995 Jul;46(7):661–3 (21 ref.)

Adaptive coping among family members of persons with serious mental illness. Solomon P, et al. **Psychiatr Serv** 1995 Nov;46(11):1156–60

Preliminary evaluation of cognitive adaptation training to compensate for cognitive deficits in schizophrenia. Velligan DI, et al. **Psychiatr Serv** 1996 Apr;47(4):415–7

The vital role of adaptive grandiosity in artistic creativity. Wolson P. **Psychoanal Rev** 1995 Aug;82(4):577–97

Post-traumatic stress and coping in an inner-city child. Traumatogenic witnessing of interparental violence and murder. Parson ER. **Psychoanal Study Child** 1995; 50:272–307

Helping foster children to mourn past relationships. Samuels SC. **Psychoanal Study Child** 1995;50:308–26

Age and sex differences in strategies of coping and defense across the life span. Diehl M, et al. **Psychol Aging** 1996 Mar;11(1):127–39

Psychological impact of illness downturns: a comparison of new and chronic conditions. Erdal KJ, et al. **Psychol Aging** 1995 Dec;10(4):570–7

Role of family adaptability in the psychological adjustment of spouse caregivers to patients with dementia. Majerovitz SD. **Psychol Aging** 1995 Sep;10(3):447–57

Determinants and consequences of children's coping in the medical setting: conceptualization, review, and critique. Rudolph KD, et al. **Psychol Bull** 1995 Nov;118(3):328–57 (130 ref.)

The family life cycle: a forgotten variable in the study of women's employment and well-being. Haw CE. **Psychol Med** 1995 Jul;25(4):727–38

Coping with chronic fatigue syndrome: illness responses and their relationship with fatigue, functional impairment and emotional status. Ray C, et al. **Psychol Med** 1995 Sep; 25(5):937–45

The effect of prior stressful experience on coping with war trauma and captivity. Solomon Z. **Psychol Med** 1995 Nov; 25(6):1289–94

Importance of central issues and students positive evaluation of life events. Bernstein BL, et al. **Psychol Rep** 1995 Dec; 77(3 Pt 1):848–50

A behavioral nosology for tinnitus. Briner W. **Psychol Rep** 1995 Aug;77(1):27–34

Retrospective appraisals of fathers' effectiveness and

psychological health of adults. Brost L, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):803–7

Psychological adjustment to hospitalization: factorial structure, antecedents, and outcome. Bruchon-Schweitzer M, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1091–100

Alexithymia and coping with stress in healthy persons: alexithymia as a personality trait is associated with low social support and poor responses to stress. Fukunishi I, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1299–304

College maladjustment may be related to alexithymia constructs with weakness of ego strength. Fukunishi I. **Psychol Rep** 1996 Jun;78(3 Pt 1):735–8

Pretense and hidden feelings in the Humane Society environment: a source of stress. Hart LA, et al. **Psychol Rep** 1995 Oct;77(2):554

Adjustment to breast cancer in couples. Hoskins CN. **Psychol Rep** 1995 Oct;77(2):435–54

Patterns of adjustment among women with breast cancer and their partners. Hoskins CN. **Psychol Rep** 1995 Dec;77(3 Pt 1):1017–8

Accounting for variance shared by measures of personality and stress-related variables: a canonical correlation analysis. Jelinek J, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):959–62

Applicability of the goodness-of-fit hypothesis to coping with daily hassles. Roberts SM. **Psychol Rep** 1995 Dec;77(3 Pt 1):943–54

Coping and personality. Saklofske DH, et al. **Psychol Rep** 1995 Oct;77(2):481–2

An exploration of the relationship between interpersonal problems and psychological health. Sheffield M, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):947–56

Adaptation to homelessness: self-actualization, loneliness, and depression in street homeless men. Sumerlin JR. **Psychol Rep** 1995 Aug;77(1):295–314

Cognitive determinants of quality of life after onset of cancer. Wagner MK, et al. **Psychol Rep** 1995 Aug;77(1):147–54

Adaptation strategies and transient niches of one middle-class inmate in prison. Wooden WS, et al. **Psychol Rep** 1996 Jun;78(3 Pt 1):870

Physical fitness and perceived stress. Relationships with coronary artery disease risk factors. Labbate LA, et al. **Psychosomatics** 1995 Nov-Dec;36(6):555–60

Alexithymia: a further exploration of its nomological network. Vingerhoets AJ, et al. **Psychother Psychosom** 1995;64(1):32–42

Coping with fear of long-term complications in diabetes mellitus: a model clinical program. Zettler A, et al. **Psychother Psychosom** 1995;64(3–4):178–84

The relationship between visual acuity and functioning and well-being among diabetics. Lee PP, et al. **Qual Life Res** 1995 Aug;4(4):319–23

Life style intervention in general practice: effects on psychological well-being and patient satisfaction. Meland E, et al. **Qual Life Res** 1996 Jun;5(3):348–54

Determinants of health-related quality of life after temporal lobe epilepsy surgery. Rose KJ, et al. **Qual Life Res** 1996 Jun;5(3):395–402

Development and testing of a quality of life model for long-term female cancer survivors. Wyatt GK, et al. **Qual Life Res** 1996 Jun;5(3):387–94

Influence of symptoms, lung function, mood, and social support on level of functioning of patients with COPD. Graydon JE, et al. **Res Nurs Health** 1995 Dec;18(6):525–33

Coping with radiation therapy: optimism and the effect of preparatory interventions. Johnson JE. **Res Nurs Health** 1996 Feb;19(1):3–12

Perceived self-efficacy and outcome expectancies in coping with chronic low back pain. Lin CC, et al. **Res Nurs Health** 1996 Aug;19(4):299–310

Adjustment of women and their husbands to recurrent breast cancer. Northouse LL, et al. **Res Nurs Health** 1995 Dec;18(6):515–24

Development of a short scale for self-assessment of experiences of hearing loss. The hearing coping assessment. Andersson G, et al. **Scand Audiol** 1995;24(3):147–54

Psychosocial adjustment in Norwegian adults who had undergone standardised treatment of complete cleft lip and palate. II. Self-reported problems and concerns with appearance. Ramstad T, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Dec;29(4):329–36

Migration and health. A study of Latin American refugees, their exile in Sweden and repatriation. Sundquist J, et al. **Scand J Prim Health Care** 1995 Jun;13(2):135–40

Smoking in pregnancy: a way to cope with excessive workload? Wergeland E, et al. **Scand J Prim Health Care** 1996 Mar;14(1):21–8

Physical strength and endurance in relation to perceived psychosocial work environment, sleep disturbance and coping strategies in men. Stockholm MUSIC I (MUsculo-Skeletal Intervention Centre) Study Group, Stockholm. Theorell T, et al. **Scand J Rehabil Med** 1995 Jun;27(2):67–71

Coping with conflicting agendas: the bathing experience of cognitively impaired older adults. Kovach CR, et al. **Sch Inq Nurs Pract** 1996 Spring;10(1):23–36; discussion 37–42

The essence of enduring and expressions of suffering: the reformulation of self. Morse JM, et al. **Sch Inq Nurs Pract** 1996 Spring;10(1):43–60; discussion 61–74

Development of a scale to measure core beliefs and perceived self efficacy in adults with epilepsy. Tedman S, et al. **Seizure** 1995 Sep;4(3):221–31

Coping with laryngeal cancer. Shanks JC. **Semin Speech Lang** 1995 Aug;16(3):180–90 (37 ref.)

Cognitive coping response to crises and onset of depression. Bifulco A, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jun;31(3–4):163–72

Coping with additional stresses: comparative study of healthy and cancer patient new immigrants. Baider L, et al. **Soc Sci Med** 1996 Apr;42(7):1077–84

Stress responsivity in exercisers and non-exercisers during different phases of the menstrual cycle. Choi PY, et al. **Soc Sci Med** 1995 Sep;41(6):769–77

Traditional reaction to modern stress [editorial] Lee RP. **Soc Sci Med** 1996 Mar;42(5):639–41

Structural relationships between social support and coping. McColl MA, et al. **Soc Sci Med** 1995 Aug;41(3):395–407

Sociological dimensions of illness behavior. Mechanic D. **Soc Sci Med** 1995 Nov;41(9):1207–16 (54 ref.)

The creation of protection and hope in patients with malignant brain tumours. Salander P, et al. **Soc Sci Med** 1996 Apr;42(7):985–96

Exposure to missile attacks: the impact of the Persian Gulf War on physical health behaviours and psychological distress in high and low risk areas in Israel. Soskolne V, et al. **Soc Sci Med** 1996 Apr;42(7):1039–47

Perceived social support and adjustment to mastectomy in socioeconomically disadvantaged black women. Beder J. **Soc Work Health Care** 1995;22(2):55–71

A model for group intervention with the chronically ill: cystic fibrosis and the family. Brown DG, et al. **Soc Work Health Care** 1995;21(1):81–94

Stressors, social support, and adjustment in kidney transplant patients and their spouses. Frazier PA, et al. **Soc Work Health Care** 1995;21(2):93–108

Parent and professional perceptions about stress and coping strategies during a child's lengthy hospitalization. Horn JD, et al. **Soc Work Health Care** 1995;21(1):107–27

Psychosocial outcomes of HIV illness in male and female African American clients. Linn JG, et al. **Soc Work Health Care** 1995;21(3):43–60

Racial minorities and other high-risk groups with HIV and AIDS at increased risk for psychological adjustment problems in association with health locus of control orientation. Spalding AD. **Soc Work Health Care** 1995;21(3):81–114

Codependency and family cohesion and adaptability: changes during treatment in a therapeutic community. Teichman M, et al. **Subst Use Misuse** 1996 Apr;31(5):599–615

Problem solving, stress, and coping in adolescent suicide attempts. Wilson KG, et al. **Suicide Life Threat Behav** 1995 Summer;25(2):241–52

Concerns, coping and quality of life in head and neck cancer patients. Chaturvedi SK, et al. **Support Care Cancer** 1996 May;4(3):186–90

Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I. A descriptive pilot study [see comments] Fosså SD, et al. **Support Care Cancer** 1996 Mar;4(2):118–28. Comment in: Support Care Cancer 1996 Mar;4(2):73–4.

Helping children cope when a family member has cancer. Rittenberg CN. **Support Care Cancer** 1996 May;4(3):196–9

The tar reduction study: randomised trial of the effect of cigarette tar yield reduction on compensatory smoking. Frost C, et al. **Thorax** 1995 Oct;50(10):1038–43

Impact of sexual and nonsexual assault on secondary victims. Davis R, et al. **Violence Vict** 1995 Spring;10(1):73–84

Relationship between multiple exposures to violence and coping strategies among African-American mothers. Hill HM, et al. **Violence Vict** 1995 Spring;10(1):55–71

Control, coping, and victimization in dating relationships. Pape KT, et al. **Violence Vict** 1995 Spring;10(1):43–54

Family members' experiences living with members with depression. Badger TA. **West J Nurs Res** 1996 Apr;18(2):149–71

Redefining smoking and the self as a nonsmoker. Brown JM. **West J Nurs Res** 1996 Aug;18(4):414–28

A grounded theory of balancing alcohol recovery and pregnancy. Brudenell I. **West J Nurs Res** 1996 Aug;18(4):429–40

Day-to-day demands of Parkinson's disease. Habermann B. **West J Nurs Res** 1996 Aug;18(4):397–413

Illness experiences and health recovery behaviors of patients in southern Appalachia. Rosswurm MA, et al. **West J Nurs Res** 1996 Aug;18(4):441–59

[The 'pleasant events schedule' for the elderly] Cuijpers P, et al. **Tijdschr Gerontol Geriatr** 1996 Apr;27(2):54–61 (Eng. Abstr.) **(Dut)**

[Psychological factors associated with organ transplantation] Kronqvist K, et al. **Duodecim** 1994;110(19):1771–5 (13 ref.) **(Fin)**

[Systemic approach to families dealing with cancer diagnosis, its treatment and its prognosis] Bodart A, et al. **Acta Psychiatr Belg** 1996 Jan-Feb;96(1):30–57 (73 ref.) (Eng. Abstr.) **(Fre)**

[Anti-hallucinatory coping strategies in schizophrenia] Brazo P, et al. **Ann Med Psychol (Paris)** 1995 Aug-Sep;153(7):456–9; discussion 459–60 (Eng. Abstr.) **(Fre)**

[Stabilized psychoses and psychopathology] Samacher R, et al. **Ann Med Psychol (Paris)** 1995 Oct;153(8):551–4 (Eng. Abstr.) **(Fre)**

[Hysterectomy. Indications, abuse, psychological impact] Barrat J, et al. **Bull Acad Natl Med** 1995 Dec; 179(9):1855–69; discussion 1869–70 (Eng. Abstr.) **(Fre)**

[Grief experience by 154 young adults in the general population (value of the TRIG grief scale). Texas Revised Inventory of Grief] Paulhan I, et al. **Encephale** 1995 Jul-Aug;21(4):263–71 (Eng. Abstr.) **(Fre)**

[Psychological aspects of breast cancer] Daune F. **Rev Med Brux** 1995 Jul-Aug;16(4):245–7 (Eng. Abstr.) **(Fre)**

[Discussion group: for caregivers confronted with death in the hospital environment] Reich M, et al. **Rev Med Brux** 1996 Feb;17(1):4–6 (Eng. Abstr.) **(Fre)**

[Psycho-oncology in gynecology] **Arch Gynecol Obstet** 1995; 257(1–4):270–7 (28 ref.) **(Ger)**

[Psychological coping with abortion by the woman] Petersen P. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):M143–5 **(Ger)**

[Breast and genital cancer patients--psychosocial examination in the pre- and postoperative phase] Stauber M. **Geburtshilfe Frauenheilkd** 1996 May;56(5):M66–8 **(Ger)**

[Coping with illness/quality of life and immunologic parameters of patients with breast carcinoma and benign tumors] Neises M, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:166–71 (Eng. Abstr.) **(Ger)**

[Psychiatric manifestations in climacteric. Diagnostic difficulties and therapeutic possibilities] Nijs P, et al. **Gynakologe** 1995 Dec;28(6):420–5 (22 ref.) **(Ger)**

[Cancer prognosis, psychosocial stress and attitude of melanoma patients to supportive psychotherapy] Söllner W, et al. **Hautarzt** 1996 Mar;47(3):200–5 (Eng. Abstr.) **(Ger)**

[Clinical aspects of coping with tinnitus] Nieschalk M, et al. **Laryngorhinootologie** 1995 Oct;74(10):594–600 (Eng. Abstr.) **(Ger)**

[Coping pattern and adjustment in multiple sclerosis] Rumpf HJ, et al. **Nervenarzt** 1995 Aug;66(8):624–9 (Eng. Abstr.) **(Ger)**

[Coping in the family context: active and avoidance strategies in adolescents from divorced families] Huss M, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar-Apr; 45(3–4):123–30 (Eng. Abstr.) **(Ger)**

[Huntington disease (comment)] Dose M. **Psychiatr Prax** 1996 May;23(3):107–8. Comment on: Psychiatr Prax 1996 May;23(3):117–20. Comment on: Psychiatr Prax 1996 May;23(3):121–5. **(Ger)**

[Psychosocial problems in Huntington chorea. 1: Overview, project description. social and illness-related data (see comments)] Jarka M, et al. **Psychiatr Prax** 1996 May; 23(3):117–20 (Eng. Abstr.). Comment in: Psychiatr Prax 1996 May;23(3):107–8. **(Ger)**

[Psychosocial problems in Huntington chorea. 2: Results and experiences from a 5-year project (see comments)] Jarka M, et al. **Psychiatr Prax** 1996 May;23(3):121–5 (Eng. Abstr.) . Comment in: Psychiatr Prax 1996 May;23(3):107–8. **(Ger)**

[Coping strategies and stress of family and follow-up of schizophrenia] Scherrmann TE. **Psychiatr Prax** 1995 Nov; 22(6):244–8 (Eng. Abstr.) **(Ger)**

["Filtered normality": psychological causes and sequelae of specific retinal diseases] Franke GH, et al. **Psychother Psychosom Med Psychol** 1996 May;46(5):159–68 (Eng. Abstr.) **(Ger)**

[Between isolation and new hope: the psychosocial status of HIV-infected women] Franke GH, et al. **Psychother Psychosom Med Psychol** 1995 Sep-Oct; 45(9–10):310–20 (Eng. Abstr.) **(Ger)**

[Psychosocial causal attributions by myasthenia gravis patients. A longitudinal study of the significance of subjective illness theories after diagnosis and in follow-up] Knieling J, et al. **Psychother Psychosom Med Psychol** 1995 Nov;45(11):373–80 (Eng. Abstr.) **(Ger)**

[Effects of mastectomy on dimensions of psychological and psychosocial experience and behavior of affected women] Fries A, et al. **Rehabilitation (Stuttg)** 1996 Feb;35(1):54–64 (Eng. Abstr.) **(Ger)**

[References for evaluation scales in quality assurance in rehabilitation--6. Assessment of coping processes with the Freiburg Questionnaire of Illness Coping] Muthny FA. **Rehabilitation (Stuttg)** 1996 May;35(2):IX–XVI (Eng. Abstr.) **(Ger)**

[Bad news and the successful life] Baumann-Hölzle R. **Schweiz Rundsch Med Prax** 1996 Apr 2;85(14):445–50 (Eng. Abstr.) **(Ger)**

[Therapists' coping with his own abilities] Joss R. **Schweiz Rundsch Med Prax** 1996 Jul 16;85(29–30):904–10 (25 ref.) (Eng. Abstr.) **(Ger)**

[Effect of treatment of patients with sleep apnea with a nCPAP device on stress coping and well-being] Weissenberg A, et al. **Wien Med Wochenschr** 1995; 145(17–18):523–4 (Eng. Abstr.) **(Ger)**

[Interaction of differential anxiety states with analytic cognitive style] Otto JH, et al. **Z Exp Psychol** 1995; 42(2):302–23 (Eng. Abstr.) **(Ger)**

[Experimental analysis of processing stressful information: differential and age-related psychological aspects] Wentura D, et al. **Z Exp Psychol** 1995;42(1):152–75 (Eng. Abstr.) **(Ger)**

[Coping with illness in the postoperative phase following gastrectomy] Theissen HH. **Z Gastroenterol** 1996 Jun;34

Suppl 2:29–31 **(Ger)**

[Patients in the terminal phase and their caregivers as a "dyad": how do they perceive the finite stage of life, how do they cope with it?—Results of a longitudinal study] Kruse A. **Z Gerontol Geriatr** 1995 Jul–Aug;28(4):264–72 (Eng. Abstr.) **(Ger)**

[Life review: promoting the developmental potentials in aging] Lohmann R, et al. **Z Gerontol Geriatr** 1995 Jul–Aug; 28(4):236–41 (35 ref.) (Eng. Abstr.) **(Ger)**

[Pain and psychological disorders in the elderly] Wojnar J, et al. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):369–73 (22 ref.) (Eng. Abstr.) **(Ger)**

[Psychological aspects of Prader–Willi syndrome. Results of a parent survey] Sarimski K. **Z Kinder Jugenpsychiatr** 1995 Dec;23(4):267–74 (Eng. Abstr.) **(Ger)**

[Causal "cancer personality" attribution—an expression of maladaptive coping with illness?] Faller H, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):104–16 (Eng. Abstr.) **(Ger)**

[Coping strategies of children and adolescents with diabetes mellitus: the German language version of KIDCOPE] Rathner G, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):49–74 (Eng. Abstr.) **(Ger)**

[Measuring scales for assessment of coping behavior: a critical evaluation] Wendt A, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):3–32 (90 ref.) (Eng. Abstr.) **(Ger)**

[Trauma of illness—crises in self concept regulation by cancer patients] Kruse J, et al. **Z Psychosom Med Psychoanal** 1995; 41(4):370–85 (Eng. Abstr.) **(Ger)**

[Bio–psychosocial interactions in follow–up of Crohn disease] Küchenhoff J. **Z Psychosom Med Psychoanal** 1995; 41(4):306–28 (Eng. Abstr.) **(Ger)**

[Psychodynamic and coping processes in patients with physical illnesses] Rüger U. **Z Psychosom Med Psychoanal** 1996;42(2):169–78 (Eng. Abstr.) **(Ger)**

[Causal attributions and coping with illness by breast cancer patients: results of a longitudinal study] Wolf C, et al. **Z Psychosom Med Psychoanal** 1995;41(4):356–69 (Eng. Abstr.) **(Ger)**

[Coping with the illness by patients with chronic polyarthritis. Forms of coping and therapeutic implications] Csef H, et al. **Z Rheumatol** 1995 Sep–Oct;54(5):310–8 (Eng. Abstr.) **(Ger)**

[Effect of treated genital cancer on sexual functions of the woman] Urbánek V, et al. **Zentralbl Gynakol** 1996; 118(1):9–17 (Eng. Abstr.) **(Ger)**

[Psychological assessment of patients who have ++undergone breast reconstruction using 2 different technics: autologous tissue versus prosthesis] Franchelli S, et al. **Minerva Chir** 1995 May;50(5):481–8 (Eng. Abstr.) **(Ita)**

[The assessment of individual differences in self–control in daily life] Sugiwaka H. **Shinrigaku Kenkyu** 1995 Aug; 66(3):169–75 (Eng. Abstr.) **(Jpn)**

[Coping with certain symptoms of acute schizophrenic psychosis] Krzyżanowska–Zbucka J, et al. **Psychiatr Pol** 1996 May–Jun;30(3):429–44 (Eng. Abstr.) **(Pol)**

[Coping strategies and psychological well–being in mothers of children with disabilities] Pisula E. **Psychiatr Pol** 1996 Mar–Apr;30(2):221–32 (Eng. Abstr.) **(Pol)**

[Phenomenology of spatial illusory reactions in weightlessness] Kornilova LN, et al. **Fiziol Cheloveka** 1995 Jul–Aug;21(4):50–62 **(Rus)**

[Information model of adaptation development] Myznikov IL. **Fiziol Cheloveka** 1995 Jul–Aug;21(4):63–8 **(Rus)**

[Adaptive functions of the emotions] Simonov PV. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):5–9 **(Rus)**

[Automated information system for controlling the sociopsychological adaptation of junior grade schoolchildren during learning activities] Serdiukovskaia GN, et al. **Gig Sanit** 1996 Mar–Apr;(2):19–22 (Eng. Abstr.) **(Rus)**

[The effect of the individual character traits of servicemen on their adaptation to military professional training] Ignatkin VN, et al. **Voen Med Zh** 1995 Feb;(2):54–7 **(Rus)**

[The social psychological adaptation of patients with borderline mental disorders] Veshchugina TS. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):67–71 (Eng. Abstr.) **(Rus)**

[Spontaneous use of active and passive coping strategies for pain in patients with rheumatoid arthritis] Sebro B, et al. **Reumatizam** 1993;40(1):1–4 (Eng. Abstr.) **(Scr)**

[Stress and adjustment at the beginning of postgraduate medical training] Pino Morales Socorro M, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Sep–Oct;23(5):241–8 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Psychological and sexual symptoms associated with the menopause and the effects of hormone replacement therapy. Pearce J, et al. **Br J Psychiatry** 1995 Aug; 167(2):163–73 (60 ref.)

The perception of saltiness is eliminated by NaCl adaptation: implications for gustatory transduction and coding. Smith DV, et al. **Chem Senses** 1995 Oct;20(5):545–57

Effects of surgical menopause on psychological characteristics and lipid levels: the Healthy Women Study. Everson SA, et al. **Health Psychol** 1995 Sep;14(5):435–43

PHYSIOLOGY

The relationship between habitual anger coping style and serum lipid and lipoprotein concentrations. Müller MM, et al. **Biol Psychol** 1995 Aug;41(1):69–81

Intra–individual patterns of hormonal and affective adaptation to work demands: an n = 2 study of junior doctors. Robert G, et al. **Biol Psychol** 1996 Feb 5; 42(3):393–411

Gangliosides attenuate stress–induced changes on body weight, motor activity and on the behavioral response to 5–methoxy–N,N–dimethyltryptamine. Cancela LM, et al. **Brain Res Bull** 1996;40(2):105–10

Effects of lifestyle, coping and work–related stress on blood pressure in office workers. Lindquist TL, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):580–2

Cholesterol and psychological well–being. Wardle J. **J Psychosom Res** 1995 Jul;39(5):549–62 (72 ref.)

Cognitive coping and appraisal processes in the treatment of chronic headaches. ter Kuile MM, et al. **Pain** 1996 Feb; 64(2):257–64

NGF regulatory role in stress and coping of rodents and humans. Alleva E, et al. **Pharmacol Biochem Behav** 1996 May;54(1):65–72 (110 ref.)

Abnormal behaviors in the stargazer rat are maladaptive, but not anxiety related. Brock JW, et al. **Physiol Behav** 1996 Apr–May;59(4–5):1011–4

Stress management for the cardiovascular patient: a look at current treatment and trends. Ulmer D. **Prog Cardiovasc Nurs** 1996 Winter;11(1):21–9 (31 ref.)

Stressful life events and coping styles in relation to dysthymia and major depressive disorder: variations associated with alleviation of symptoms following pharmacotherapy. Ravindran AV, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):637–53

High self–esteem, hardiness and affective stability are associated with higher basal pituitary–adrenal hormone levels. Zorrilla EP, et al. **Psychoneuroendocrinology** 1995; 20(6):591–601

Psychophysiologic factors contributing to functional performance in people with COPD: are there gender differences? Leidy NK, et al. **Res Nurs Health** 1995 Dec; 18(6):535–46

[Ontogenesis of affect regulation] Beckmann D, et al. **Psychother Psychosom Med Psychol** 1995 Dec; 45(12):427–35 (60 ref.) (Eng. Abstr.) **(Ger)**

[Coping with stress and rheumatoid factor—a comparative study] Mur E, et al. **Z Rheumatol** 1995 Sep–Oct; 54(5):319–23 (Eng. Abstr.) **(Ger)**

[Proceedings of the symposium on molecular–cellular and genetic mechanisms of adaptive behaviour] **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):1–192 **(Rus)**

RADIATION EFFECTS

[Intellectual and psychosocial functions in children treated with radiation for brain tumor] Fossen A. **Tidsskr Nor Laegeforen** 1995 Nov 20;115(28):3490–3 (Eng. Abstr.) **(Nor)**

[The pathological mechanisms of central nervous system dysadaptation in subjects exposed to radiation] Sinitskiĭ VN, et al. **Fiziol Zh** 1995 May–Aug;41(3–4):55–66 (Eng. Abstr.) **(Rus)**

ADCC see **ANTIBODY–DEPENDENT CELL CYTOTOXICITY**

ADDICTIVE BEHAVIOR see **BEHAVIOR, ADDICTIVE**

ADDISON'S ANEMIA see **ANEMIA, PERNICIOUS**

ADDISON'S DISEASE

[Addison's disease in pregnancy: a report of six cases] Xia Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Apr; 31(4):226–8 (Eng. Abstr.) **(Chi)**

BLOOD

Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease. Cohen N, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1411–5

COMPLICATIONS

Addison's disease presenting as reduced insulin requirement in insulin dependent diabetes. Armstrong L, et al. **BMJ** 1996 Jun 22;312(7046):1601–2

Silent myocardial rupture in a patient with diabetes and Addison's disease. Östermaier R, et al. **Int J Cardiol** 1995 Jun 2;50(1):75–8

Pseudotumor cerebri as presenting syndrome of Addisonian crisis. Leggio MG, et al. **Ital J Neurol Sci** 1995 Sep; 16(6):387–9

Pituitary macroadenoma in Addison's disease. Akçay G, et al. **J Int Med Res** 1996 Mar–Apr;24(2):221–7

Hyponatraemic rhabdomyolysis in Addison's disease [letter] Jolobe O, et al. **Postgrad Med J** 1995 Sep;71(839):574

[A case of Addison's disease complicated by lung carcinoma treated with surgical resection—a case report] Sasamoto S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Nov; 43(11):1879–83 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Addison's disease. Brosnan CM, et al. **BMJ** 1996 Apr 27; 312(7038):1085–7

Addison's disease. Secondary adrenal failure in critically ill patients is underrecognised [letter] Granger C. **BMJ** 1996 Aug 17;313(7054):426–7

Addison's disease. Adrenal insufficiency should be excluded before thyroxine replacement is started [letter] Osman IA, et al. **BMJ** 1996 Aug 17;313(7054):427

An 11–year–old boy with vomiting, dehydration, and a tan complexion. Woods M, et al. **Curr Opin Pediatr** 1995 Aug; 7(4):472–6

Clinical problem–solving: identifying Addison's disease [letter; comment] Babich DJ. **N Engl J Med** 1996 May 23;334(21):1403–4; discussion 1404–5. Comment on: N Engl J Med 1996 Jan 4;334(1):46–8.

Clinical problem–solving: identifying Addison's disease [letter; comment] Baxter DG. **N Engl J Med** 1996 May 23;334(21):1404; discussion 1404–5. Comment on: N Engl J Med 1996 Jan 4;334(1):46–8.

Clinical problem–solving: identifying Addison's disease [letter; comment] de Loos WS. **N Engl J Med** 1996 May 23;334(21):1403; discussion 1404–5. Comment on: N Engl J Med 1996 Jan 4;334(1):46–8.

Clinical problem–solving: identifying Addison's disease [letter; comment] Hoffer EP. **N Engl J Med** 1996 May 23;334(21):1404; discussion 1404–5. Comment on: N Engl J Med 1996 Jan 4;334(1):46–8.

Clinical problem–solving. Just in time [see comments] Keljo DJ, et al. **N Engl J Med** 1996 Jan 4;334(1):46–8. Comment in: N Engl J Med 1996 May 23;334(21):1403; discussion 1404–5. Comment in: N Engl J Med 1996 May 23;334(21):1403–4; discussion 1404–5. Comment in: N Engl J Med 1996 May 23;334(21):1404; discussion 1404–5.

Clinical problem–solving: identifying Addison's disease [letter; comment] Shannon DC. **N Engl J Med** 1996 May 23;334(21):1404; discussion 1404–5. Comment on: N Engl J Med 1996 Jan 4;334(1):46–8.

DRUG THERAPY

Addison's disease. Hydrocortisone should be started immediately adrenal insufficiency is considered [letter] Leman P. **BMJ** 1996 Aug 17;313(7054):427

Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease. Cohen N, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1411–5

Pulsatile thyrotropin secretion in patients with Addison's disease during variable glucocorticoid therapy. Hangaard J, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2502–7

[A case of Addison's disease complicated by lung carcinoma treated with surgical resection—a case report] Sasamoto S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Nov; 43(11):1879–83 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Subclinical Addison's disease: a cause of persistent abnormalities in transaminase values. Boulton R, et al. **Gastroenterology** 1995 Oct;109(4):1324–7

[Addison disease: a rare cause of elevated serum aminotransferase activity (letter)] Lesur G, et al. **Gastroenterol Clin Biol** 1996;20(5):515–6 **(Fre)**

ETIOLOGY

Addison's disease caused by adrenal blastomycosis: a case report with fine needle aspiration (FNA) cytology. Rimondi AP, et al. **Cytopathology** 1995 Aug;6(4):277–9

Addison disease 10 years after bone marrow transplantation for Wiskott–Aldrich syndrome. Latal Hajnal B, et al. **Eur J Pediatr** 1995 Sep;154(9):729–31

X–linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. Laureti S, et al. **J Clin Endocrinol Metab** 1996 Feb; 81(2):470–4

Clinical problem–solving: identifying Addison's disease [letter; comment] Baum GL. **N Engl J Med** 1996 May 23; 334(21):1404; discussion 1404–5. Comment on: N Engl J Med 1996 Jan 4;334(1):46–8.

[Addisonian crisis as initial manifestation of bilateral metastatic adrenal tumor (letter)] Fuentes Jimenez FJ, et al. **An Med Interna** 1995 Dec;12(12):619–20 **(Spa)**

[Bilateral primary adrenal lymphoma with atypical presentation as an addisonian crisis (letter)] Sanjuán F, et al. **Med Clin (Barc)** 1995 Dec 8;105(20):798 **(Spa)**

GENETICS

Steroid 21–hydroxylase gene polymorphism in Addison's disease patients. Peterson P, et al. **Tissue Antigens** 1995 Jul;46(1):63–7

IMMUNOLOGY

Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. Chen S, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1871–6

[Autoimmune Addison's disease. Current knowledge and prospects] De Bellis A, et al. **Minerva Endocrinol** 1996 Mar;

ADDISON'S DISEASE

21(1):1-6 (35 ref.) (Ita)

MICROBIOLOGY

Addison's disease caused by Paracoccidioides brasiliensis: diagnosis by needle aspiration biopsy of the adrenal gland [letter] Faiçal S, et al. **AJR Am J Roentgenol** 1996 Feb; 166(2):461-2

PATHOLOGY

Autopsy findings of Addison's disease caused by systemic cytomegalovirus infection in a patient with acquired immunodeficiency syndrome. Takasawa A, et al. **Intern Med** 1995 Jun;34(6):533-6

PHYSIOPATHOLOGY

Pulsatile thyrotropin secretion in patients with Addison's disease during variable glucocorticoid therapy. Hangaard J, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2502-7

VETERINARY

Atypical Addison's disease in the dog: a retrospective survey of 14 cases. Sadek D, et al. **J Am Anim Hosp Assoc** 1996 Mar-Apr;32(2):159-63

ADENINE

The expanding clinical phenotype of the tRNA(Leu(UUR)) A-->G mutation at np 3243 associated with mitochondrial DNA: diabetic embryopathy associated with mitochondrial cytopathy. Feigenbaum A, et al. **Am J Med Genet** 1996 Apr 24;62(4):404-9

Chain folding and A:T pairing in human telomeric DNA: a model-building and molecular dynamics study. Mohanty D, et al. **Biophys J** 1995 Sep;69(3):1046-67

Three recognition events at the branch-site adenine. Query CC, et al. **EMBO J** 1996 Mar 15;15(6):1392-402

Inhibition of hydroxyl radical production by lactobionate, adenine, and tempol. Charloux C, et al. **Free Radic Biol Med** 1995 Nov;19(5):699-704

Analysis of action of the wobble adenine on codon reading within the ribosome. Lim VI. **J Mol Biol** 1995 Sep 22; 252(3):277-82

ANALOGS & DERIVATIVES

Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Cundy KC, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2401-5

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Gu Z, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1888-91

Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Robbins BL, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2304-8

Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Balzarini J, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):337-41

Plant growth hormone kinetin delays ageing, prolongs the lifespan and slows down development of the fruitfly Zaprionus paravittiger. Sharma SP, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):1067-71

Major groove (R)-alpha-(N6-adenyl)styrene oxide adducts in an oligodeoxynucleotide containing the human N-ras codon 61 sequence: conformations of the R(61,2) and R(61,3) sequence isomers from 1H NMR. Feng B, et al. **Biochemistry** 1995 Oct 31;34(43):14021-36

Major groove (S)-alpha-(N6-adenyl)styrene oxide adducts in an oligodeoxynucleotide containing the human N-ras codon 61 sequence: conformations of the S(61,2) and S(61,3) sequence isomers from 1H NMR. Feng B, et al. **Biochemistry** 1996 Jun 11;35(23):7316-29

Conformational studies of depurinating DNA adducts from syn-dibenzo[a,l]pyrene diolepoxide. Ariese F, et al. **Carcinogenesis** 1996 Apr;17(4):829-37

1,N6-ethenoadenine and 3,N4-ethenocytosine are excised by separate human DNA glycosylases. Hang B, et al. **Carcinogenesis** 1996 Jan;17(1):155-7

Preparation, characterization and 32P-postlabeling of butadiene monoepoxide N6-adenine adducts. Koivisto P, et al. **Carcinogenesis** 1995 Dec;16(12):2999-3007

Urinary excretion of 3-methyladenine and 3-ethyladenine after controlled exposure to tobacco smoke. Kopplin A, et al. **Carcinogenesis** 1995 Nov;16(11):2637-41

Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Michie AM, et al. **Cell Signal** 1996 Feb;8(2):97-110

Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Podzuweit T, et al. **Cell Signal** 1995 Sep;7(7):733-8

Synthesis and antitumor activity of phenyl carbocyclic oxetanocin and related compounds. Maruyama T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul;44(7):1407-11

The in vitro methylation of DNA by a minor groove binding methyl sulfonate ester. Encell L, et al. **Chem Res Toxicol** 1996 Apr-May;9(3):563-7

Selective attenuation by N-0861 (N6-endonorboran-2-yl-9-methyladenine) of cardiac A1 adenosine receptor-mediated effects in humans. Bertolet BD, et al. **Circulation** 1996 May 15;93(10):1871-6

A fast and simple screening method for detection of 2,8-dihydroxyadenine urolithiasis by capillary zone electrophoresis. Sevčík J, et al. **Clin Chim Acta** 1996 Feb 9;245(1):85-92

Suppression of rat adjuvant arthritis by some acyclic nucleotide analogs. Zídek A, et al. **Eur J Pharmacol** 1995 Nov 24;286(3):307-10

N(6) or N(9) substituted 2-phenyl-8-azaadenines: affinity for A1 adenosine receptors. VII. Biagi G, et al. **Farmaco** 1995 Oct;50(10):659-67

DNA damage in human respiratory tract epithelial cells: damage by gas phase cigarette smoke apparently involves attack by reactive nitrogen species in addition to oxygen radicals. Spencer JP, et al. **FEBS Lett** 1995 Nov 20; 375(3):179-82

The controversial role of cAMP on amnionic prostaglandin release: effect of adenylate cyclase inhibition. Vesce F, et al. **Gynecol Obstet Invest** 1995;40(2):73-9

Acyclic oligonucleotide analogues. Merle Y, et al. **Int J Biol Macromol** 1995 Oct;17(5):239-46

Efficacy of (S)-HPMPA against thymidine kinase-deficient herpes simplex virus-keratitis. Maudgal PC, et al. **Invest Ophthalmol Vis Sci** 1987 Feb;28(2):243-8

Effects of cell-cycle-arrest agents on cleavage and development of mouse embryos. Samaké S, et al. **J Exp Zool** 1996 Feb 1;274(2):111-20

Effects of the anthelmintics clorsulon, rafoxanide, mebendazole and arprinocid on Echinostoma caproni in ICR mice. Maurer K, et al. **J Helminthol** 1995 Dec; 69(4):373-4

Carbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl)adenines. Borcherding DR, et al. **J Med Chem** 1996 Jun 21; 39(13):2615-20

Helix rigidity of DNA: the meroduplex as an experimental paradigm. Hagerman KR, et al. **J Mol Biol** 1996 Jul 12; 260(2):207-23

Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3',5'-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung. Haynes J Jr, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):752-7

Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy-endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. Martin PL, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):490-9

Effect of a dynein inhibitor on vasopressin action in toad urinary bladder. Marples D, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):767-74

Drug prevents SIV infection [news] McCarthy M. **Lancet** 1995 Dec 2;346(8988):1482

Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines. Perno CF, et al. **Mol Pharmacol** 1996 Aug;50(2):359-66

Base analog 6-N-hydroxylaminopurine mutagenesis in the yeast Saccharomyces cerevisiae is controlled by replicative DNA polymerases. Shcherbakova PV, et al. **Mutat Res** 1996 Jul 10;369(1-2):33-44

Enhancement of the anti-HIV-1 activity of ddAdo by coformycin, EHNA and deaza-EHNA derivatives. Marongiu ME, et al. **New Microbiol** 1995 Oct;18(4):359-70

Escherichia coli, Saccharomyces cerevisiae, rat and human 3-methyladenine DNA glycosylases repair 1,N6-ethenoadenine when present in DNA. Saparbaev M, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3750-5

Cytokinin induces a rapid decrease in the levels of mRNAs for catalase, 3-hydroxy-3-methylglutaryl CoA reductase, lectin and other unidentified proteins in etiolated cotyledons of cucumber. Toyama T, et al. **Plant Cell Physiol** 1995 Oct;36(7):1349-59

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Schulze-Gahmen U, et al. **Proteins** 1995 Aug;22(4):378-91

Free radical formation in single crystals of 9-methyladenine X-irradiated at 10 K. An electron paramagnetic resonance and electron nuclear double resonance study. Hole EO, et al. **Radiat Res** 1995 Dec;144(3):258-65

AIDS research. New drug shows promise in monkeys [news; comment] Cohen J. **Science** 1995 Nov 17;270(5239):1121-2 . Comment on: Science 1995 Nov 17;270(5239):1197-9.

Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine [see comments] Tsai CC, et al. **Science** 1995 Nov 17; 270(5239):1197-9. Comment in: Science 1995 Nov 17;270(5239):1121-2.

(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]: a purine analogue with trypanocidal activity in vitro and in vivo. Kaminsky R, et al. **Trop Med Int Health** 1996 Apr;1(2):255-63

HAM1, the gene controlling 6-N-hydroxylaminopurine sensitivity and mutagenesis in the yeast Saccharomyces cerevisiae. Noskov VN, et al. **Yeast** 1996 Jan;12(1):17-29

The effect of 6-dimethylaminopurine (6-DMAP) on DNA synthesis in activated mammalian oocytes. Ledda S, et al. **Zygote** 1996 Feb;4(1):7-9

BIOSYNTHESIS

[Transfer of S. typhimurium strains with mutation to a noncultured state, disrupting synthesis of purine bases] Romanov IuM, et al. **Mol Gen Mikrobiol Virusol** 1996 Jan-Mar;(1):26-8 (Eng. Abstr.) (Rus)

CHEMICAL SYNTHESIS

N(9)-Substituted 2-phenyl-N(6)-benzyl-8-azaadenines: A1 adenosine receptor affinity. A comparison with the corresponding N(6)-substituted 2-phenyl-N(9)-benzyl-8-azaadenines. Biagi G, et al. **Farmaco** 1996 Jun;51(6):395-9

[Synthesis and some biochemical properties of phosphonyl acyclic analogs of 2'-deoxyadenosine nucleotides] Malakhov DV, et al. **Bioorg Khim** 1995 Jul;21(7):539-44 (Eng. Abstr.) (Rus)

CHEMISTRY

Fluorescence spectroscopic study of the interaction of adenine and nucleotide with trichosanthin. Hao Q, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):889-95

A free energy analysis of nucleic acid base stacking in aqueous solution. Friedman RA, et al. **Biophys J** 1995 Oct; 69(4):1528-35

Preparation, characterization and 32P-postlabeling of butadiene monoepoxide N6-adenine adducts. Koivisto P, et al. **Carcinogenesis** 1995 Dec;16(12):2999-3007

What is the basis of sequence-directed curvature in DNAs containing A tracts? Harvey SC, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):301-7 (55 ref.)

Helix rigidity of DNA: the meroduplex as an experimental paradigm. Hagerman KR, et al. **J Mol Biol** 1996 Jul 12; 260(2):207-23

The effects of sequence context on base dynamics at TpA steps in DNA studied by NMR. McAteer K, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):3962-6

Synthesis and coupling reactions of alpha,alpha-dialkylated amino acids with nucleobase side chains. Azumaya I, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12013-6

AU-rich elements: characterization and importance in mRNA degradation. Chen CY, et al. **Trends Biochem Sci** 1995 Nov;20(11):465-70 (42 ref.)

[Oxidative reactions of the base moiety in purine nucleosides and their applications] Maki Y, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1211-8 (30 ref.) (Jpn)

[Modeling DNA hydration using the Monte Carlo method. Interaction of adenines with water in a nonglycoside A-tract grove stabilizes the B'- conformation] Teplukhin AV, et al. **Mol Biol (Mosk)** 1996 Jan-Feb;30(1):121-35 (Rus)

METABOLISM

Effect of adenine methylation on the structure and dynamics of TpA steps in DNA: NMR structure determination of [d(CGAGGTTTAAACCTCG)]2 and its A9-methylated derivative at 750 MHz. Lingbeck J, et al. **Biochemistry** 1996 Jan 23;35(3):719-34

Identification of adenine binding domain peptides of the ADP regulatory site within glutamate dehydrogenase. Shoemaker MT, et al. **Bioconjug Chem** 1996 May-Jun; 7(3):302-10

Observation and prevention of an artefactual formation of oxidized DNA bases and nucleosides in the GC-EIMS method. Douki T, et al. **Carcinogenesis** 1996 Feb; 17(2):347-53

Activities associated with the presence of ribosome-inactivating proteins increase in senescent and stressed leaves. Stirpe F, et al. **FEBS Lett** 1996 Mar 18; 382(3):309-12

Role of adenine deaminase in purine salvage and nitrogen metabolism and characterization of the ade gene in Bacillus subtilis. Nygaard P, et al. **J Bacteriol** 1996 Feb; 178(3):846-53

AUF1 binding affinity to A+U-rich elements correlates with rapid mRNA degradation. DeMaria CT, et al. **J Biol Chem** 1996 May 24;271(21):12179-84

Schizosaccharomyces pombe rds1, an adenine-repressible gene regulated by glucose, ammonium, phosphate, carbon dioxide and temperature. Ludin KM, et al. **Mol Gen Genet** 1995 Aug 30;248(4):439-45

Adenine methylation at dam sites increases transient gene expression in plant cells. Graham MW, et al. **Transgenic Res** 1995 Sep;4(5):324-31

The red ade mutants of Kluyveromyces lactis and their classification by complementation with cloned ADE1 or ADE2 genes from Saccharomyces cerevisiae. Zonneveld BJ, et al. **Yeast** 1995 Jul;11(9):823-7

ADENINE ARABINOSIDE see **VIDARABINE**

ADENINE ARABINOSIDE MONOPHOSPHATE see **VIDARABINE PHOSPHATE**

ADENINE DEOXYRIBONUCLEOSIDES see **DEOXYADENOSINES**

ADENINE NUCLEOTIDE TRANSLOCASE

ANALYSIS

Fluorometric titration of the mitochondrial ADP/ATP carrier protein in muscle homogenate with atractyloside derivatives. Roux P, et al. **Anal Biochem** 1996 Feb 1; 234(1):31–7

ANTAGONISTS & INHIBITORS

Inhibition of adenine nucleotide translocator by lipid peroxidation products. Chen JJ, et al. **Free Radic Biol Med** 1995 Nov;19(5):583–90

CHEMISTRY

The yeast ADP/ATP carrier. Mutagenesis and second-site revertants. Nelson DR. **Biochim Biophys Acta** 1996 Jul 18; 1275(1–2):133–7 (27 ref.)

Translocation of loops regulates transport activity of mitochondrial ADP/ATP carrier deduced from formation of a specific intermolecular disulfide bridge catalyzed by copper–o-phenanthroline. Majima E, et al. **J Biol Chem** 1995 Dec 8;270(49):29548–54

GENETICS

Regulation of adenine nucleotide translocase and glycerol 3-phosphate dehydrogenase expression by thyroid hormones in different rat tissues. Dümmler K, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):913–8

Molecular biological and quantitative abnormalities of ADP/ATP carrier protein in cardiomyopathic hamsters. Kato M, et al. **Eur Heart J** 1995 Dec;16 Suppl O:78–80

Transcription of the AAC1 gene encoding an isoform of mitochondrial ADP/ATP carrier in Saccharomyces cerevisiae is regulated by oxygen in a heme-independent manner. Gavurníková G, et al. **Eur J Biochem** 1996 Aug 1;239(3):759–63

Molecular characterization of an Arabidopsis thaliana cDNA encoding a novel putative adenylate translocator of higher plants. Kampfenkel K, et al. **FEBS Lett** 1995 Nov 6; 374(3):351–5

Sp1 activates and inhibits transcription from separate elements in the proximal promoter of the human adenine nucleotide translocase 2 (ANT2) gene. Li R, et al. **J Biol Chem** 1996 Aug 2;271(31):18925–30

The Ant1 gene maps near Klk3 on proximal mouse chromosome 8. Mills KA, et al. **Mamm Genome** 1996 Sep; 7(9):707

IMMUNOLOGY

Cardiac cytotoxic mechanism mediated by antibodies against myocardial mitochondrial ADP/ATP carrier in patients with dilated cardiomyopathy. Liao Y, et al. **Chin Med J (Engl)** 1996 Mar;109(3):193–6

The role of the ADP/ATP carrier in the pathogenesis of viral heart disease. Schulze K, et al. **Eur Heart J** 1995 Dec; 16 Suppl O:64–7

ISOLATION & PURIFICATION

ADP/ATP carrier and uncoupling protein. Klingenberg M, et al. **Methods Enzymol** 1995;260:369–89

METABOLISM

Calcium indirectly increases the control exerted by the adenine nucleotide translocator over 2-oxoglutarate oxidation in rat heart mitochondria. Mildaziene V, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):130–4

Mitochondrial ADP/ATP carrier can be reversibly converted into a large channel by Ca2+. Brustovetsky N, et al. **Biochemistry** 1996 Jul 2;35(26):8483–8

Dependence of flux size and efficiency of oxidative phosphorylation on external osmolarity in isolated rat liver mitochondria: role of adenine nucleotide carrier. Devin A, et al. **Biochim Biophys Acta** 1996 Jan 11;1273(1):13–20

Modulation of matrix Ca2+ content by the ADP/ATP carrier in brown adipose tissue mitochondria. Influence of membrane lipid composition. Chávez E, et al. **J Bioenerg Biomembr** 1996 Feb;28(1):69–76

Activity of the mitochondrial multiple conductance channel is independent of the adenine nucleotide translocator. Lohret TA, et al. **J Biol Chem** 1996 Mar 1;271(9):4846–9

ADP/ATP carrier and uncoupling protein. Klingenberg M, et al. **Methods Enzymol** 1995;260:369–89

Electrical currents associated with nucleotide transport by the reconstituted mitochondrial ADP/ATP carrier. Brustovetsky N, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):664–8

[Participation of the ADP/ATP-antiporter in the uncoupling action of fatty acids in liver mitochondria] Bodrova ME, et al. **Biokhimiia** 1995 Aug;60(8):1349–57 (Eng. Abstr.) **(Rus)**

ADENINE NUCLEOTIDES

RNase L and 2-5A to enhance antisense technology and target the destruction of mRNA [news] Glaser V. **Mol Med Today** 1996 May;2(5):183

ANALYSIS

Applicability of small endomyocardial biopsies for evaluation of high energy phosphates and glycogen in the heart. Bøtker HE, et al. **J Mol Cell Cardiol** 1995 Oct; 27(10):2081–9

BIOSYNTHESIS

Agrocins. Clare BG. **Biotechnology** 1995;28:619–32 (53 ref.)

The functional and metabolic responses of the heart to catecholamines are attenuated in diabetic rats. Irlbeck M, et al. **Cardioscience** 1995 Jun;6(2):131–8

BLOOD

[Energy-dependent processes and metabolism of adenylates in human erythrocytes] Ataullakhanov FI, et al. **Biokhimiia** 1996 Feb;61(2):266–74 (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

Inhibition of adenylyl cyclase by a family of newly synthesized adenine nucleoside 3'-polyphosphates. Désaubry L, et al. **J Biol Chem** 1996 Jun 14; 271(24):14028–34

Chemical synthesis of benzamide adenine dinucleotide: inhibition of inosine monophosphate dehydrogenase (types I and II). Zatorski A, et al. **J Med Chem** 1996 Jun 7; 39(12):2422–6

CHEMISTRY

Use of fluorogenic substrates for detection and investigation of ectoenzymatic hydrolysis of diadenosine polyphosphates: a fluorometric study on chromaffin cells. Ramos A, et al. **Anal Biochem** 1995 Jun 10;228(1):74–82

Does the sulfhydryl or the adenine moiety of CoA enhance firefly luciferase activity? Ford SR, et al. **Biochim Biophys Acta** 1995 Oct 25;1252(2):180–4

Agrocins. Clare BG. **Biotechnology** 1995;28:619–32 (53 ref.)

Synthesis and biological activities of a phosphorodithioate analog of 2',5'-oligoadenylate. Beigelman L, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):3989–94

METABOLISM

The number of nucleotide binding sites in cytochrome C oxidase. Rieger T, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):34–40

Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Rogers MJ, et al. **Biochem Biophys Res Commun** 1996 Jul 25; 224(3):863–9

Photoaffinity labeling of a P3 purinoceptor-like protein purified from rat brain membranes. Saitoh Y, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):469–74

Effects of P2-purinoceptor antagonists on degradation of adenine nucleotides by ecto-nucleotidases in folliculated oocytes of Xenopus laevis. Ziganshin AU, et al. **Biochem Pharmacol** 1996 Apr 12;51(7):897–901

Nucleotide-binding sites in F1-ATPase: different pockets for different types of nucleotide analogues. Berden JA, et al. **Biochem Soc Trans** 1995 Nov;23(4):741–7

Determination of the nucleotide binding site within Clostridium symbiosum pyruvate phosphate dikinase by photoaffinity labeling, site-directed mutagenesis, and structural analysis. McGuire M, et al. **Biochemistry** 1996 Jul 2;35(26):8544–52

An intracellular adenine nucleotide binding site inhibits guanyly cyclase C by a guanine nucleotide-dependent mechanism. Parkinson SJ, et al. **Biochemistry** 1996 Mar 12;35(10):3213–21

5'-(p-fluorosulfonylbenzoyl)-2'(or 3')-(methylanthraniloyl)adenosine, fluorescent affinity labels for adenine nucleotide binding sites: interaction with the kinase active site of the receptor for epidermal growth factor. Scoggins RM, et al. **Biochemistry** 1996 Jul 16; 35(28):9197–203

Developmental changes of the adenine nucleotide translocation in rat brain. Schönfeld P, et al. **Biochim Biophys Acta** 1995 Nov 21;1232(1–2):75–80

Differences in nucleotide compartmentation and energy state in isolated and in situ rat heart: assessment by 31P-NMR spectroscopy. Williams JP, et al. **Biochim Biophys Acta** 1996 Aug 7;1276(1):71–9

Hepatic adenine nucleotides and DNA synthesis during the regenerative and atrophic process of the liver lobes after selective portal vein ligation. Kameoka N, et al. **Eur Surg Res** 1996;28(3):212–21

Control of adenine nucleotide metabolism and glycolysis in vertebrate skeletal muscle during exercise. Krause U, et al. **Experientia** 1996 May 15;52(5):396–403 (51 ref.)

Is there a critical tissue oxygen tension for bioenergetic status and cellular pH regulation in solid tumors? Vaupel P. **Experientia** 1996 May 15;52(5):464–8 (33 ref.)

Presence of epsilon-adenosine tetraphosphate in chromaffin granules after transport of epsilon-ATP. Gualix J, et al. **FEBS Lett** 1996 Aug 5;391(1–2):195–8

The effect of prostaglandin E1 on liver adenine nucleotides and cytoplasmic enzymes in a porcine model of normothermic hepatic ischemia. Helling TS, et al. **Hepatology** 1995 Nov;22(5):1554–9

Concentration dependence and time course of the effects of glucose on adenine and guanine nucleotides in mouse pancreatic islets. Detimary P, et al. **J Biol Chem** 1996 Aug 23;271(34):20559–65

Nucleotide vesicular transporter of bovine chromaffin granules. Evidence for a mnemonic regulation. Gualix J, et al. **J Biol Chem** 1996 Jan 26;271(4):1957–65

Adaptation of Ehrlich ascites carcinoma cells to energy deprivation in vivo can be associated with heat shock protein accumulation. Kabakov AE, et al. **J Cell Physiol** 1995 Oct;165(1):1–6

Dynamics of the GroEL-protein complex: effects of nucleotides and folding mutants. Sparrer H, et al. **J Mol Biol** 1996 Apr 26;258(1):74–87

Brain regional levels of adenosine and adenosine nucleotides in rats killed by high-energy focused microwave irradiation. Delaney SM, et al. **J Neurosci Methods** 1996 Feb;64(2):151–6

The effects of age on the release of adenine nucleosides and nucleotides from rat caudal artery. Hashimoto M, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):841–8

When does the lung die? Time course of high energy phosphate depletion and relationship to lung viability after "death". D'Armini AM, et al. **J Surg Res** 1995 Oct; 59(4):468–74

A possible role of adenylate metabolism in human erythrocytes: simple mathematical model. Ataullakhanov FI, et al. **J Theor Biol** 1996 Mar 7;179(1):75–86

The source of brain adenosine outflow during ischemia and electrical stimulation. Latini S, et al. **Neurochem Int** 1995 Sep;27(3):239–44

Electrical currents associated with nucleotide transport by the reconstituted mitochondrial ADP/ATP carrier. Brustovetsky N, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):664–8

Nucleotide binding-promoted conformational changes release a nonnative polypeptide from the Escherichia coli chaperonin GroEL. Lin Z, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1977–81

A mammalian 2-5A system functions as an antiviral pathway in transgenic plants. Mitra A, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6780–5

Intracellular high energy metabolite depletion and cell membrane injury with antioxidant enzymes during oxidant exposure in vitro. Aalto K, et al. **Toxicol Lett** 1996 May; 85(2):93–9

Hydroperoxide-induced nucleotide degradation and adenosine formation in isolated rat cardiomyocytes. Andersson BS, et al. **Toxicology** 1996 Jan 8;106(1–3):39–48

PHARMACOLOGY

Allosteric regulation of liver phosphorylase a: revisited under approximated physiological conditions. Ercan N, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):255–64

ATP activates the potassium channel and enhances cytosolic Ca2+ release via a P2Y purinoceptor linked to pertussis toxin-insensitive G-protein in brain artery endothelial cells. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1022–8

Stimulation of rat liver AMP-activated protein kinase by AMP analogues. Henin N, et al. **Biochim Biophys Acta** 1996 Jun 4;1290(2):197–203

Potent agonist action of 2-thioether derivatives of adenine nucleotides at adenylyl cyclase-linked P2Y-purinoceptors. Boyer JL, et al. **Br J Pharmacol** 1995 Nov;116(6):2611–6

Regulation of Na+/H+ exchange by diadenosine polyphosphates, angiotensin II, and vasopressin in rat cortical collecting duct. Schlatter E, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1223–9

Stoichiometry of 2',5'-oligoadenylate-induced dimerization of ribonuclease L. A sedimentation equilibrium study. Cole JL, et al. **J Biol Chem** 1996 Feb 23;271(8):3979–81

Inhibition of adenylyl cyclase by a family of newly synthesized adenine nucleoside 3'-polyphosphates. Désaubry L, et al. **J Biol Chem** 1996 Jun 14; 271(24):14028–34

Nucleotides increase the internal flexibility of filaments of dephosphorylated Acanthamoeba myosin II. Redowicz MJ, et al. **J Biol Chem** 1996 May 24;271(21):12401–7

Fluid flow modulates vascular endothelial cytosolic calcium responses to adenine nucleotides. Shen J, et al. **Microcirculation** 1994 Apr;1(1):67–78

Frameshift mutagenesis by 9-aminoacridine: antimutagenic effects of adenosine compounds. Kopsidas G, et al. **Mutat Res** 1996 Jun 10;352(1–2):135–42

Inhibition of growth of estrogen receptor positive and estrogen receptor negative breast cancer cells in culture by AA-etherA, a stable 2-5A derivative. Latham KE, et al. **Oncogene** 1996 Feb 15;12(4):827–37

Effect of "core" 2'5'-oligoadenylates on the phosphorylation-dependent calcium channels in GH3 cells. Kostyuk PG, et al. **Ukr Biokhim Zh** 1995 Jan-Feb; 67(1):26–32

[The effect of 2',5'-oligoadenylates on the expression of the cellular proto-oncogene c-myc during the development of Svec's leukemia in rats] Prima VI, et al. **Tsitol Genet** 1995 Nov-Dec;29(6):8–13 (Eng. Abstr.) **(Rus)**

ADENINE NUCLEOTIDES

PHYSIOLOGY

Adenine nucleotide and protein kinase C regulation of renal tubular epithelial cell wound healing. Sponsel HT, et al. **Kidney Int** 1995 Jul;48(1):85–92

ADENINE PHOSPHORIBOSYLTRANSFERASE

BIOSYNTHESIS

Efficient modification of the APRT gene by FLP/FRT site-specific targeting. RV Merrihew, et al. **Somat Cell Mol Genet** 1995 Sep;21(5):299–307

DEFICIENCY

Differential cytotoxic effects of mizoribine and its aglycone on human and murine cells and on normal and enzyme-deficient human cells. Terai C, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1099–102

Adenine phosphoribosyltransferase-deficient mice develop 2,8-dihydroxyadenine nephrolithiasis. Engle SJ, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5307–12

GENETICS

Analysis of mutations at the adenine phosphoribosyltransferase gene locus in wild-type and thymidine kinase-deficient Friend cells. Hyland PL, et al. **Biochem Soc Trans** 1996 Feb;24(1):105S

High-efficiency triple-helix-mediated photo-cross-linking at a targeted site within a selectable mammalian gene. Vasquez KM, et al. **Biochemistry** 1996 Aug 20; 35(33):10712–9

Aflatoxin B1, 2-aminoanthracene, and 7,12-dimethylbenz[a]anthracene-induced frameshift mutations in human APRT. Zhu Y, et al. **Environ Mol Mutagen** 1995;26(3):234–9

Cloning and expression of the adenine phosphoribosyltransferase gene from Leishmania donovani. Allen T, et al. **Mol Biochem Parasitol** 1995 Oct; 74(1):99–103

Effects of nonsense mutations on nuclear and cytoplasmic adenine phosphoribosyltransferase RNA. Kessler O, et al. **Mol Cell Biol** 1996 Aug;16(8):4426–35

Characterization of an apparent hotspot for spontaneous mutation in exon 5 of the Chinese hamster APRT gene. Smith DG, et al. **Mutat Res** 1996 Jun 10;352(1–2):87–96

Effect of third strand composition on the triple helix formation: purine versus pyrimidine oligodeoxynucleotides. Faucon B, et al. **Nucleic Acids Res** 1996 Aug 15; 24(16):3181–8

The influence of a (GT)29 microsatellite sequence on homologous recombination in the hamster adenine phosphoribosyltransferase gene. Sargent RG, et al. **Nucleic Acids Res** 1996 Feb 15;24(4):746–53

A second form of adenine phosphoribosyltransferase in Arabidopsis thaliana with relative specificity towards cytokinins. Schnorr KM, et al. **Plant J** 1996 Jun;9(6):891–8

Adenine phosphoribosyltransferase-deficient mice develop 2,8-dihydroxyadenine nephrolithiasis. Engle SJ, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5307–12

Deletion mapping of highly conserved transcribed sequence downstream from APRT locus. Harwood J, et al. **Somat Cell Mol Genet** 1995 May;21(3):151–60

Efficient modification of the APRT gene by FLP/FRT site-specific targeting. RV Merrihew, et al. **Somat Cell Mol Genet** 1995 Sep;21(5):299–307

METABOLISM

A second form of adenine phosphoribosyltransferase in Arabidopsis thaliana with relative specificity towards cytokinins. Schnorr KM, et al. **Plant J** 1996 Jun;9(6):891–8

ADENINE POLYNUCLEOTIDES see **POLY A**

ADENITIS see **LYMPHADENITIS**

ADENO-ASSOCIATED VIRUSES see **DEPENDOVIRUS**

ADENOCARCINOMA

Clinical behavior and prognostic factors of periampullary adenocarcinoma. Chan C, et al. **Ann Surg** 1995 Nov; 222(5):632–7

ABC of Urology. Urological malignancy—II: Urothelial tumours. Dawson C, et al. **BMJ** 1996 Apr 27; 312(7038):1090–4 (0 ref.)

Appendiceal mucocele with concomitant colonic cancer. Report of two cases. Fujiwara T, et al. **Dis Colon Rectum** 1996 Feb;39(2):232–6

Periampullary tumours: report of two cases. Kassa E. **East Afr Med J** 1996 May;73(5):333–5 (17 ref.)

Endometrial adenocarcinoma and life expectancy in elderly women. Chiarelli S, et al. **Eur J Gynaecol Oncol** 1996; 17(1):43–7

Mixed adenocarcinoma and neuroendocrine carcinoma arising in the urachus. A case report and review of the literature. Munichor M, et al. **Eur Urol** 1995;28(4):345–7 (22 ref.)

Krukenberg tumor complicated by pregnancy. Mackey JR, et al. **Gynecol Oncol** 1996 Apr;61(1):153–5

Adenocarcinoma of the lung and mesothelioma [letter] Wolfe KQ, et al. **Histopathology** 1995 Oct;27(4):393–4

Asymptomatic endometrial carcinoma after endometrial ablation. Margolis MT, et al. **Int J Gynaecol Obstet** 1995 Dec;51(3):255–8

Elevation of intracellular cyclic adenosine monophosphate inhibits the epidermal growth factor signal transduction pathway and cellular growth in pancreatic adenocarcinoma cell lines. Lieberman MD, et al. **Surgery** 1996 Aug; 120(2):354–9

Adenocarcinoma of the rete testis. Sánchez-Chapado M, et al. **Urology** 1995 Oct;46(4):468–75 (48 ref.)

Malignant gastroesophageal polyp: a case report. Cavanaugh DG, et al. **Wis Med J** 1995;94(8):443–5

[Cancer of the anal canal] Gérard JP, et al. **Bull Cancer Radiother** 1990;77(1):23–31 (41 ref.) **(Fre)**

[Muscular metastasis of cancer of the pancreas. A propos of a case] Wafflart E, et al. **J Chir (Paris)** 1996 Jun; 133(4):167–70 (16 ref.) (Eng. Abstr.) **(Fre)**

[Wermer syndrome associated with a bilateral renal tumor] Jeddi A, et al. **Prog Urol** 1996 Feb;6(1):103–6 (Eng. Abstr.) **(Fre)**

[Urachal adenocarcinoma associated with urothelial tumor of the bladder. Report of a case] Payen E, et al. **Prog Urol** 1996 Apr;6(2):288–91 (13 ref.) (Eng. Abstr.) **(Fre)**

[Evolving identities of bronchopulmonary adenocarcinomas (editorial)] Lebeau B. **Rev Mal Respir** 1995;12(4):325–6 **(Fre)**

["N2" carcinoma of the lung. Therapeutic considerations] Ugolini D, et al. **Minerva Chir** 1996 Mar;51(3):97–102 (Eng. Abstr.) **(Ita)**

[Appearance in 2 brothers of double primary neoplasms: right renal carcinoma and gastric adenocarcinoma] Casetta G, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):49–51 (11 ref.) (Eng. Abstr.) **(Ita)**

[Natural history of prostatic adenocarcinoma. Recent advances in prognostic parameters and biological behavior] Mirone V, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):171–5 (11 ref.) (Eng. Abstr.) **(Ita)**

[Duodenal cancer] Morales Linares JC, et al. **Rev Gastroenterol Mex** 1995 Jul–Sep;60(3):154–7 (Eng. Abstr.) **(Ita)**

[Adenoacanthoma] Honda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):303–4 (17 ref.) **(Jpn)**

[Carcinoma in adenoma of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):311–3 (6 ref.) **(Jpn)**

[Adenoacanthoma, adenosquamous carcinoma of the extrahepatic bile duct] Kimoto E, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):47–9 (36 ref.) **(Jpn)**

[Adenocarcinoma of the gallbladder] Nakamura S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):299–302 (16 ref.) **(Jpn)**

[Diffuse bile duct carcinoma] Nakao A. **Ryoikibetsu Shokogun Shirizu** 1996;(9):74–6 (14 ref.) **(Jpn)**

[Adenocarcinoma of the extra bile duct] Noguchi T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):43–6 (8 ref.) **(Jpn)**

[Pleomorphic giant cell adenocarcinoma (PGCA-Ca)] Seki S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):318–20 (20 ref.) **(Jpn)**

[Intrahepatic bile duct adenocarcinoma] Terada T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):402–4 (7 ref.) **(Jpn)**

[Anal cancer. A review] Tanum G. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1567–70 (31 ref.) (Eng. Abstr.) **(Nor)**

[A case report of unusual metastasis in malignant carcinoid of the cecum] Volobuev NN, et al. **Klin Khir** 1996;(1):51–2 **(Rus)**

[Synchronous-metachronous malignant neoformations of the larynx and kidneys] Klochikhin AL, et al. **Vestn Otorinolaringol** 1996 Mar–Apr;(2):50–1 **(Rus)**

[Spontaneous tumor regression and gastric cancer (letter)] Zambrana Garcia JL, et al. **An Med Interna** 1996 Jan; 13(1):47–8 **(Spa)**

[Synchronous colonic adenocarcinoma and hypernephroma (letter)] Broto A, et al. **Med Clin (Barc)** 1995 Sep 9; 105(7):276–7 **(Spa)**

[Gastric cancer in children: report of a case] Berrospi Espinoza F, et al. **Rev Gastroenterol Peru** 1995 Sep–Dec; 15(3):296–8 (16 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Colon cancer with a high serum alpha-fetoprotein level. Kato K, et al. **Am J Gastroenterol** 1996 May;91(5):1045–6

Serum interleukin-6 levels reflect disease status of gastric cancer. Wu CW, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1417–22

Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. Olt G, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1316–9

Estimation of serum level of pS2 protein in patients with lung adenocarcinoma. Higashiyama M, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2351–5

Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma. Horie Y, et al. **Cancer** 1996 May 15; 77(10):1991–7 (21 ref.)

Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Pollack A, et al. **Cancer** 1996 Apr 15;77(8):1515–23

Tumor necrosis factor and coagulopathy in patients with prostate cancer. Nakashima J, et al. **Cancer Res** 1995 Nov 1;55(21):4881–5

Prothrombin fragment F1+2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer. Gadducci A, et al. **Gynecol Oncol** 1996 May;61(2):215–7

Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy. D'Amico AV, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):273–9

Serum prostate specific antigen and prostate specific antigen density in patients receiving radical prostatectomy. Masai M, et al. **Int J Urol** 1996 Mar;3(2):118–23

Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival [see comments] Lee WR, et al. **J Urol** 1996 Aug; 156(2 Pt 1):450–3. Comment in: J Urol 1996 Aug;156(2 Pt 1):459.

Biochemical characterization of alpha-fetoprotein and other serum proteins produced by a uterine endometrial adenocarcinoma. Koyama Y, et al. **Jpn J Cancer Res** 1996 Jun;87(6):612–7

Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer [letter] Ivanovic V, et al. **Nat Med** 1995 Apr;1(4):282–4

Elevated serum prostate-specific antigen and pancreatic carcinoma. Ranganath LR, et al. **Postgrad Med J** 1996 Jun; 72(848):363–4

Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Lerner SE, et al. **Urology** 1996 Aug;48(2):240–8

[Usefulness of prostate-specific antigen in the diagnosis of lymphatic metastases in cancer of the prostate] Saad F, et al. **Ann Chir** 1995;49(8):680–4 (Eng. Abstr.) **(Fre)**

[Detection of prostatic cancer in symptomatic patients with serum levels of prostate-specific antigen between 4 and 10 ng/ml] Ravery V, et al. **Presse Med** 1996 Feb 24; 25(7):272–6 (Eng. Abstr.) **(Fre)**

[PSA and hormone-refractory period in prostatic cancer] Ojea Calvo A, et al. **Actas Urol Esp** 1996 Feb;20(2):168–71 (Eng. Abstr.) **(Spa)**

[Prognosis significance of prostatic markers in patients with prostatic adenocarcinoma undergoing total hormonal blockade] Regueiro López JC, et al. **Actas Urol Esp** 1995 May;19(5):357–62 (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer [see comments] Frank RE, et al. **Ann Surg** 1995 Dec;222(6):695–9. Comment in: Ann Surg 1995 Dec;222(6):693–4.

The absence of autonomic perivascular nerves in human colorectal liver metastases. Ashraf S, et al. **Br J Cancer** 1996 Feb;73(3):349–59

Tumor angiogenesis in human lung adenocarcinoma [letter; comment] Kolin A. **Cancer** 1995 Jul 1;76(1):151. Comment on: Cancer 1994 Oct 15;74(8):2245–50.

Tumor angiogenesis in human lung adenocarcinoma [letter; comment] Sikora J. **Cancer** 1995 Sep 1;76(5):915–6. Comment on: Cancer 1994 Oct 15;74(8):2245–50.

Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Bossi P, et al. **Cancer Res** 1995 Nov 1; 55(21):5049–53

Tumor angiogenesis and interstitial hypertension. Boucher Y, et al. **Cancer Res** 1996 Sep 15;56(18):4264–6

Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Tanigawa N, et al. **Cancer Res** 1996 Jun 1;56(11):2671–6

Tumor vascularity—a novel prognostic factor in advanced cervical carcinoma. Schlenger K, et al. **Gynecol Oncol** 1995 Oct;59(1):57–66

Ultrastructural study of the vascular response in small early gastric cancer. Caruso RA, et al. **Histol Histopathol** 1996 Jan;11(1):17–25

Blood vessel morphometry in human colorectal lesions. Tipoe GL, et al. **Histol Histopathol** 1995 Jul;10(3):589–96

Influence of hepatic artery occlusion and desferrioxamine on liver-tumour growth. Lindnér P, et al. **Int J Cancer** 1995 Nov 15;63(4):592–6

Vascular thermal adaptation in tumors and normal tissue in rats. Nah BS, et al. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):95–101

Vascular manifestations of small solitary pulmonary masses. Angiographic-pathologic correlations and clinical significance. Yang X, et al. **Invest Radiol** 1996 May; 31(5):275–9

Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin). Thurman GB, et al. **J Cancer Res Clin Oncol** 1996; 122(9):549–53

Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Patan S, et al. **Microvasc Res** 1996 Mar; 51(2):260–72

Correlation of intratumoral microvessel density and p53

protein overexpression in human colorectal adenocarcinoma. Vermeulen PB, et al. **Microvasc Res** 1996 Mar;51(2):164–74

Registration of three-dimensional compound ultrasound scans of the breast for refraction and motion correction. Moskalik A, et al. **Ultrasound Med Biol** 1995;21(6):769–78

CHEMICALLY INDUCED

Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Thomas DB, et al. **Am J Epidemiol** 1996 Aug 1;144(3):281–9

Oxidative stress response in iron-induced renal carcinogenesis: acute nephrotoxicity mediates the enhanced expression of glutathione S-transferase Yp isozyme. Fukuda A, et al. **Arch Biochem Biophys** 1996 May 1; 329(1):39–46

Induction of adenocarcinomas in the submandibular salivary glands of female Wistar rats treated with 7,12-dimethylbenz(a)anthracene. Zaman A, et al. **Arch Oral Biol** 1996 Feb;41(2):221–4

Distribution of lymphoid nodules, aberrant crypt foci and tumours in the colon of carcinogen-treated rats. Cameron IL, et al. **Br J Cancer** 1996 Apr;73(7):893–8

Inhibitory potential of pregnancy and lactation on mammary carcinogenesis induced by a food-derived carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, in Sprague-Dawley rats. Kimura J, et al. **Cancer Lett** 1996 Mar 19;101(1):73–8

Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status. McGonigle KF, et al. **Cancer Lett** 1996 Mar 19; 101(1):59–66

Rapid and high yield induction of endometrial adenocarcinomas in CD-1 mice by a single intrauterine administration of N-ethyl-N-nitrosourea combined with chronic 17 beta-estradiol treatment. Takahashi M, et al. **Cancer Lett** 1996 Jun 24;104(1):7–12

Phenobarbital promotes the development of adenocarcinomas in the accessory sex glands of MNU-inoculated L-W rats. Pollard M, et al. **Carcinogenesis** 1995 Oct;16(10):2419–21

Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Thomas DB, et al. **Contraception** 1995 Nov;52(5):307–12

Synchronous endometrial and ovarian cancer in young woman taking oral contraception. Fishman A, et al. **Eur J Gynaecol Oncol** 1995;16(5):346–8

Lack of influence of diethylstilbestrol on induced pancreatic ductal carcinomas in Syrian hamsters. Baum A, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):117–20

A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Robinson DC, et al. **Gynecol Oncol** 1995 Nov;59(2):186–90

Primary non-clear cell adenocarcinoma of the vagina in older DES-exposed women [letter; comment] Townsend DE. **Gynecol Oncol** 1996 Jun;61(3):454. Comment on: Gynecol Oncol 1995 Sep;58(3):389–92.

Combined continuous hormone replacement therapy: a critical review [letter; comment] Gambrell RD Jr. **Obstet Gynecol** 1995 Nov;86(5):869–70. Comment on: Obstet Gynecol 1995 Aug;86(2):306–16.

Intravenous vs. intraprostatic administration of N-methyl-N-nitrosourea to induce prostate cancer in rats. Schleicher RL, et al. **Prostate** 1996 Jan;28(1):32–43

[Adenocarcinoma of the cervix and the use of oral contraceptives] **Dtsch Med Wochenschr** 1995 Sep 29; 120(39):1341 **(Ger)**

[3 different malignancies of the aerodigestive tract after chronic abuse of cannabis products] Richter B, et al. **HNO** 1995 Dec;43(12):728–31 (Eng. Abstr.) **(Ger)**

[Tamoxifen and endometrial cancer. A case report (see comments)] Orbo A, et al. **Tidsskr Nor Laegeforen** 1996 Jun 20;116(16):1877–8 (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1996 Jun 20;116(16):1872. **(Nor)**

CHEMISTRY

Nonhistone chromosomal proteins (NHCP) in adenocarcinoma of human endometrium. Miturski R. **Acta Biochim Pol** 1995;42(2):191–5

Microglandular carcinoma of the pancreas: immunohistochemical and ultrastructural study of an unusual variant of pancreatic carcinoma that may closely resemble a neuroendocrine neoplasm. Berho M, et al. **Am J Clin Pathol** 1996 Jun;105(6):727–32

c-erbB-2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease. Costa MJ, et al. **Am J Clin Pathol** 1995 Dec;104(6):634–42

Aromatase in human common epithelial ovarian neoplasms. Kaga K, et al. **Am J Pathol** 1996 Jul;149(1):45–51

Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Krajewska M, et al. **Am J Pathol** 1996 May;148(5):1567–76

Beta-catenin expression in human cancers. Takayama T, et al. **Am J Pathol** 1996 Jan;148(1):39–46

RNA isolation from solid tumor tissue. Kitlińska J, et al. **Anal Biochem** 1995 Jun 10;228(1):170–2

Expression of c-erbB-2 and p53 in colorectal adenocarcinoma. Sun XF, et al. **Anal Cell Pathol** 1995 Apr; 8(3):203–11

Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen. Yu CC, et al. **Anal Cell Pathol** 1995 Jul;9(1):45–52

C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. Giatromanolaki A, et al. **Anticancer Res** 1996 Mar-Apr;16(2):987–93

Immunohistochemical detection of ras p21 oncoprotein in undifferentiated and well-differentiated epithelial carcinomas of the human ovary. Kuwashima Y, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2847–50

Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Lundin J, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2659–68

Folate receptor in malignant effusions of ovarian carcinoma. Holm J, et al. **APMIS** 1995 Sep;103(9):663–70

Neuroendocrine differentiation in gastric adenocarcinomas. An immunohistochemical study. Blumenfeld W, et al. **Arch Pathol Lab Med** 1996 May;120(5):478–81

Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Slebos RJ, et al. **Br J Cancer** 1996 Jul;74(2):165–71

Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Smith DR, et al. **Br J Cancer** 1996 Jul;74(2):216–23

Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Watson AJ, et al. **Br J Cancer** 1996 Apr;73(8):889–95

Prostatic adenocarcinoma labelled with a monoclonal antibody and polyclonal serum: a quantitative assessment. Gray E, et al. **Br J Urol** 1996 Jul;78(1):104–8

Alpha-1-antichymotrypsin expression in lung adenocarcinoma and its possible association with tumor progression. Higashiyama M, et al. **Cancer** 1995 Oct 15; 76(8):1368–76

Immunocytochemical detection of p53 protein from pancreatic duct brushings in patients with pancreatic carcinoma. Ishimaru S, et al. **Cancer** 1996 Jun 1; 77(11):2233–9

Cysteine and serine proteases in gastric cancer. Plebani M, et al. **Cancer** 1995 Aug 1;76(3):367–75

A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Sonoda K, et al. **Cancer** 1996 Apr 15;77(8):1501–9

Transferrin receptor expression in nonsmall cell lung cancer. Histopathologic and clinical correlates [see comments] Whitney JF, et al. **Cancer** 1995 Jul 1;76(1):20–5. Comment in: Cancer 1996 Jul 1;78(1):178–9.

The differential expression of cytokeratin 18 in cisplatin-sensitive and -resistant human ovarian adenocarcinoma cells and its association with drug sensitivity. Parekh HK, et al. **Cancer Res** 1995 Nov 15; 55(22):5203–6

High levels of DNA adducts in human colon are associated with colorectal cancer. Pfohl-Leszkowicz A, et al. **Cancer Res** 1995 Dec 1;55(23):5611–6

Immunohistochemically defined lymphocyte function-associated antigen 1 (LFA-1) on an adenocarcinoma cell line is a distinct molecule from LFA-1 on leukocytes. Yamada A, et al. **Cell Immunol** 1995 Dec; 166(2):254–60

Epidermal growth factor receptor expression: is it the same in normal and malignant endometria? Zarcone R, et al. **Clin Exp Obstet Gynecol** 1995;22(4):298–300

Tissue potassium, selenium, and iron levels associated with gastric cancer progression. Wu CW, et al. **Dig Dis Sci** 1996 Jan;41(1):119–25

Immunohistochemical analysis of statin in colorectal adenocarcinoma, polyps, and normal mucosa. Kyzer SD, et al. **Dis Colon Rectum** 1996 May;39(5):546–51

p53 immunoreactive stain and early colorectal adenocarcinomas. Hirota S, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2220–2

The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer. Webb A, et al. **Eur J Cancer** 1996 Jan;32A(1):63–8

E-cadherin and OB-cadherin mRNA levels in normal human colon and colon carcinoma. Munro SB, et al. **Exp Mol Pathol** 1995 Apr;62(2):118–22

p53 protein overexpression in early stage endometrial cancer. Kohlberger P, et al. **Gynecol Oncol** 1996 Aug;62(2):213–7

Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Buø L, et al. **Hum Pathol** 1995 Oct;26(10):1133–8

Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Day JD, et al. **Hum Pathol** 1996 Feb; 27(2):119–24

Distribution of lipochrome pigment in the prostate gland: biological and diagnostic implications. Leung CS, et al. **Hum Pathol** 1995 Dec;26(12):1302–7

Immunohistochemical localization of cathepsins D and E in human gastric cancer: a possible correlation with local invasive and metastatic activities of carcinoma cells. Matsuo K, et al. **Hum Pathol** 1996 Feb;27(2):184–90

Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Ohtani H, et al. **Int J Cancer** 1995 Sep 15;62(6):691–6

Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung. Sugawara I, et al. **Int J Cancer** 1995 Oct 20;64(5):322–5

Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2,p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. Sun XF, et al. **Int J Cancer** 1996 Feb 20;69(1):5–8

Altered expression of extracellular matrix molecules and their receptors in chronic pancreatitis and pancreatic adenocarcinoma in comparison with normal pancreas. Shimoyama S, et al. **Int J Pancreatol** 1995 Dec;18(3):227–34

The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary. van der Gaast A, et al. **J Cancer Res Clin Oncol** 1996;122(3):181–85

Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. Tennant MK, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):411–20

Significance of MUC1 and MUC2 mucin expression in colorectal cancer. Ajioka Y, et al. **J Clin Pathol** 1996 Jul; 49(7):560–4

beta hCG as a prognostic marker in adenocarcinoma of the prostate. Sheaff MT, et al. **J Clin Pathol** 1996 Apr; 49(4):329–32

An immunohistochemical study of the expression of p53 protein in colon cancer. Kim YW, et al. **J Korean Med Sci** 1995 Jun;10(3):176–82

Distribution of transforming growth factor-beta and its receptors in gastric carcinoma tissue. Kai T, et al. **Jpn J Cancer Res** 1996 Mar;87(3):296–304

Expression of sulfomucins in normal mucosae, colorectal adenocarcinomas, and metastases. Matsushita Y, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1060–7

Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix. Tsuda H, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1049–53

The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Derenzini M, et al. **Lab Invest** 1995 Oct;73(4):497–502

Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Eastham JA, et al. **Lab Invest** 1995 Nov;73(5):628–35

Nuclear DNA and nuclear protein content of tumor cell in adenocarcinoma of the lung. Gönüllü U, et al. **Lung Cancer** 1995 Aug;13(1):13–9

Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Takanami I, et al. **Oncology** 1996 Sep-Oct;53(5):392–7

Mucin mRNA expression in lung adenocarcinoma cell lines and tissues. Yu CJ, et al. **Oncology** 1996 Mar-Apr; 53(2):118–26

Primary adenocarcinoma of the ureter. Case report with immunohistochemical characterization. Haitel A, et al. **Pathol Res Pract** 1996 Jan;192(1):81–5; discussion 86–7

p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater. Lee CS, et al. **Pathology** 1995 Apr;27(2):117–20

Determination of Ki-67 defined growth fraction by monoclonal antibody MIB-1 in formalin-fixed, paraffin-embedded prostatic cancer tissues. Noordzij MA, et al. **Prostate** 1995 Sep;27(3):154–9

DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma--necessitating multiple site analysis. Warzynski MJ, et al. **Prostate** 1995 Dec; 27(6):329–35

Expression of the proliferative cell nuclear antigen (PCNA) in adenocarcinoma of the gallbladder, and its relationship to prognosis. Hanada K, et al. **Scand J Clin Lab Invest** 1995 Aug;55(5):377–82

Clinical implication of neuroendocrine differentiation in prostatic adenocarcinomas. Constantinides C, et al. **Urol Int** 1995;55(3):134–6

Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Stricker HJ, et al. **Urology** 1996 Mar;47(3):366–9

Immunohistochemical expression of metallothioneins in colorectal adenocarcinoma [letter] Tuccari G, et al. **Virchows Arch** 1996 Feb;427(5):547–8

[Correlation between expression of RB protein and prognosis of gastric cancer] Ogawa M, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:148–50 (Eng. Abstr.) **(Jpn)**

[Establishment of a new human endometrial adenocarcinoma cell line, Watanabe cells, containing estrogen receptor] Satoh T, et al. **Hum Cell** 1995 Dec;8(4):195–201 (Eng. Abstr.) **(Jpn)**

[Immunohistochemical study of collagen in gastric cancer tissue] Kondou S, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr;18(2):168–77 (Eng. Abstr.) **(Jpn)**

[Immunohistochemistry of hormone receptors in pancreatic cancer (letter)] Truán Alonso N, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):832–3 **(Spa)**

ADENOCARCINOMA

CLASSIFICATION

[A new histological classification of cancers of the stomach] Paraf F. **Gastroenterol Clin Biol** 1995 Oct;19(10):858–60 (12 ref.) **(Fre)**

COMPLICATIONS

Obstructive jaundice in gastric carcinoma: cause, site, and relationship to the primary lesion. Lee BH, et al. **Abdom Imaging** 1995 Jul–Aug;20(4):307–11

A possible role of interleukin-8 in the induction of psoriasis-like lesions in Torre-Muir syndrome [letter] Yamamoto T, et al. **Acta Derm Venereol** 1996 Jan; 76(1):75–7

Simultaneous metastasis of pulmonary adenocarcinoma and bone tuberculosis. Carpintero P, et al. **Acta Orthop Scand** 1996 Aug;67(4):403–4

Radiologic features of carcinomas arising in hiatal hernias. Maglinte DD, et al. **AJR Am J Roentgenol** 1996 Apr; 166(4):789–94

Mirizzi syndrome associated with gallbladder cancer and biliary–enteric fistulas. Miller FH, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):95–7

Esophageal adenocarcinoma associated with Barrett's esophagus: long-term management with laser ablation. Ertan A, et al. **Am J Gastroenterol** 1995 Dec;90(12):2201–3

Contemporaneous diagnosis of Crohn's disease and adenocarcinoma of the jejunum [letter] Lock G, et al. **Am J Gastroenterol** 1996 May;91(5):1060–2

Chronic hyponatremia due to reset osmostat in a patient with colon cancer. Elisaf MS, et al. **Am J Nephrol** 1996; 16(4):349–51

Multiple polyposis and adenocarcinoma arising in Barrett's esophagus. Wong RS, et al. **Ann Thorac Surg** 1996 Jan; 61(1):216–8

Concurrent abdominal aortic aneurysm and urologic neoplasm: an argument for simultaneous intervention. Ginsberg DA, et al. **Ann Vasc Surg** 1995 Sep;9(5):428–33

Pulmonary sclerosing hemangioma in a woman with multiple uterine fibromas, cysts to thyroid and kidney. Rizzo S, et al. **Anticancer Res** 1996 May–Jun;16(3A):1297–9

Paraneoplastic cone dysfunction: an unusual visual remote effect of cancer [letter] Jacobson DM, et al. **Arch Ophthalmol** 1995 Dec;113(12):1580–2

Mucosal lymphangiectasia in gastric adenocarcinoma. Mak KL, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):78–80

Upper limb reflex sympathetic dystrophy associated with occult malignancy. Ku A, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):726–8

Adenocarcinoma in the distal esophagus with and without Barrett esophagus. Differences in symptoms and survival rates. Johansson J, et al. **Arch Surg** 1996 Jul;131(7):708–13

Meigs' syndrome in association with a locally invasive adenocarcinoma of the fallopian tube. Chen FC, et al. **Aust N Z J Surg** 1995 Oct;65(10):761–2

A case of Cowden's disease accompanied by prostatic cancer. Inagaki T, et al. **Br J Urol** 1996 Jun;77(6):918–9

Appendicular adenocarcinoma leading to appendiculo-vesical fistula. Rahman SI, et al. **Br J Urol** 1996 Aug;78(2):305–6

Nontraumatic subcutaneous emphysema in association with rectal carcinoma. Chow E, et al. **Can Assoc Radiol J** 1996 Apr;47(2):94–7 (12 ref.)

Chronological observation of mouse endometrial carcinogenesis induced by N-methyl-N-nitrosourea and 17 beta-estradiol. Niwa K, et al. **Cancer Lett** 1996 Jun 24; 104(1):115–9

A case of pancreatic carcinoma causing massive bronchial fluid production and electrolyte abnormalities. Lembo T, et al. **Chest** 1995 Oct;108(4):1161–3 (8 ref.)

Digital ischemia associated with lung cancer: a case report. Wang HC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 May;57(5):370–4

Pulmonary malignancy associated with granulomatous vasculitis in the maxillary sinus. Durand JM, et al. **Clin Rheumatol** 1995 Sep;14(5):572–3

Gallbladder carcinoma in an achondroplastic boy. Eire PF, et al. **Eur J Pediatr Surg** 1995 Oct;5(5):313–4

Non-small-cell lung cancer with multiple paraneoplastic syndromes. Monsieur I, et al. **Eur Respir J** 1995 Jul; 8(7):1231–4

Bilateral panuveitis in a patient with colonic adenocarcinoma and Streptococcus milleri liver abscesses [letter] Churchill AJ, et al. **Eye** 1995;9 (Pt 3):372–5

Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Cameron AJ, et al. **Gastroenterology** 1995 Nov;109(5):1541–6

Nitinol coil esophageal prosthesis: advantages of removable self-expanding metallic stents. Axelrad AM, et al. **Gastrointest Endosc** 1996 Feb;43(2 Pt 1):155–60

Marking clips for the accurate positioning of self-expandable esophageal stents. de Boer WA, et al. **Gastrointest Endosc** 1995 Jul;42(1):73–6

Tandem wire mesh stents for palliation of obstructing gastroduodenal adenocarcinoma. Ho SB, et al. **Gastrointest Endosc** 1995 Oct;42(4):363–6

An esophagopericardial fistula successfully treated with an expandable covered metal mesh stent. Tukkie R, et al. **Gastrointest Endosc** 1996 Feb;43(2 Pt 1):165–7

A novel technique for dilating difficult malignant biliary strictures during therapeutic ERCP. van Someren RN, et al. **Gastrointest Endosc** 1996 May;43(5):495–8

Facial pain as a symptom of nonmetastatic lung cancer. Capobianco DJ. **Headache** 1995 Nov–Dec;35(10):581–5 (18 ref.)

Duodenal obstruction due to annular pancreas associated with pancreatic head carcinoma. Yasui A, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):1017–22

Lymphoepithelioma-like carcinoma of the lung: analysis of two cases for Epstein-Barr virus infection. Higashiyama M, et al. **Hum Pathol** 1995 Nov;26(11):1278–82

Urachal adenocarcinoma accompanied by a large spherical calcified mass. Ando M, et al. **Int J Urol** 1995 Nov; 2(5):344–6

Vivre ou laisser mourir [letter] Rutschmann OT, et al. **J Am Geriatr Soc** 1996 Jan;44(1):104

Dermatomyositis with malignancy. Balakrishnan C, et al. **J Assoc Physicians India** 1995 Apr;43(4):287–8

Duodeno-jejunal adenocarcinoma as a first presentation of coeliac disease. MacGowan DJ, et al. **J Clin Pathol** 1996 Jul;49(7):602–4

Tripe palms: a cutaneous marker of internal malignancy. Requena L, et al. **J Dermatol** 1995 Jul;22(7):492–5

Pancreatic calculi superimposed upon slow growing pancreatic cancer. Noda A, et al. **J Gastroenterol Hepatol** 1996 Jan;11(1):97–101

Should nasopharyngeal biopsy be mandatory in adult unilateral glue ear? Lee WC, et al. **J Laryngol Otol** 1996 Jan;110(1):62–4

Fatal hemorrhage from additional primary esophageal squamous cell carcinoma in a patient previously having primary bronchogenic adenocarcinoma. Shuangshoti S, et al. **J Med Assoc Thai** 1995 Aug;78(8):443–8

Primary adenocarcinoma of the appendix. Hartley JE, et al. **J R Soc Med** 1996 Feb;89(2):111P–3P

A case of malignant rectoduodenal fistula: an unusual form of duodenum to large bowel fistula. Kirkpatrick WN, et al. **J R Soc Med** 1996 Feb;89(2):109P–11P

Primary adenocarcinoma of the endometrium associated with genital tuberculosis. A case report. Castelo-Branco C, et al. **J Reprod Med** 1995 Sep;40(9):673–5

Raynaud's phenomenon as a presenting sign of ovarian adenocarcinoma. Kohli M, et al. **J Rheumatol** 1995 Jul; 22(7):1393–4

Metastatic endometrial carcinoma: rare cause of extrahepatic obstructive jaundice. Ritota PC, et al. **J Surg Oncol** 1996 Jan;61(1):61–2

Barrett's esophagus: a review. Sawyer DR, et al. **Mo Med** 1995 Oct;92(10):645–7 (13 ref.)

Characterization of a cancer cachectic factor. Todorov P, et al. **Nature** 1996 Feb 22;379(6567):739–42

Deep venous thrombosis in haemodialysis patients – a pointer to the presence of malignancy? Wagner R, et al. **Nephrol Dial Transplant** 1996 May;11(5):879–80

Non-islet-cell tumour induced hypoglycaemia: a case report and review of literature. Kuenen BC, et al. **Neth J Med** 1996 May;48(5):175–9 (16 ref.)

Malignant acanthosis nigricans with florid papillary oral lesions. Tyler MT, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):445–9

CD68+ reactive histiocytosis complicating early gastric cancer [letter] Ogawa Y, et al. **Pathol Int** 1995 Sep; 45(9):698–701

Schistosomiasis and prostate cancer. Cohen RJ, et al. **Pathology** 1995 Apr;27(2):115–6

Polymyalgia rheumatica, temporal arteritis and malignancy. Speed CA, et al. **Postgrad Med J** 1995 Aug;71(838):500–2

Pulmonary cancer and hypertrophic osteoarthropathy. Brief recurrence of the osteoarticular symptoms after surgical resection. Pereira JR, et al. **Rev Paul Med** 1995 Jan–Feb; 113(1):726–8

Adenocarcinoma of the prostate and Eaton-Lambert syndrome. A previously unreported association. Agarawal SK, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):351–3 (8 ref.)

Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Nakahama H, et al. **Urol Int** 1995;55(1):38–40

Thrombocytopenia and pancreatic carcinoma. Sweeney CJ, et al. **Wis Med J** 1995 Nov;94(11):611–5

[Adenocarcinoma on villous tumor of the rectum in an adolescent] Chafai S, et al. **Arch Pediatr** 1995 Aug; 2(8):762–5 (Eng. Abstr.) **(Fre)**

[Ureteral obstruction caused by retroperitoneal metastasis of gastric carcinoma] Böszörményi-Nagy G, et al. **Prog Urol** 1995 Dec;5(6):965–7 (Eng. Abstr.) **(Fre)**

[Colon tumor and spontaneous clostridium myonecrosis (gas gangrene)] Kerz T. **Med Klin** 1995 Oct 15;90(10):608–12 **(Ger)**

[Cachexia, ascites and kidney failure (clinical conference)] Sieber C, et al. **Schweiz Rundsch Med Prax** 1996 Mar 26; 85(13):411–5 **(Ger)**

[A case of appendiceal mucocele associated with cancer of the colon] Zullo A, et al. **Minerva Chir** 1995 Dec; 50(12):1095–8 (Eng. Abstr.) **(Ita)**

[A case of carcinomatous peritonitis for which combination therapy of 5-FU, leucovorin and cisplatin was effective] Okabe T, et al. **Gan To Kagaku Ryoho** 1996 Feb; 23(3):349–53 (Eng. Abstr.) **(Jpn)**

[Primary adenocarcinoma of renal pelvis and ureter associated with incomplete ureteral duplication: a case report] Yasui T, et al. **Hinyokika Kiyo** 1996 Apr; 42(4):307–10 (Eng. Abstr.) **(Jpn)**

[Clinical analysis of lung cancer in patients with chondromatous hamartoma] Umemori Y, et al. **Kyobu Geka** 1995 Nov;48(12):1061–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Lung cancer manifested as cardiac tamponade: a case report] Watanabe S, et al. **Kyobu Geka** 1995 Sep;48(10):890–2 (Eng. Abstr.) **(Jpn)**

[Tracheal carcinoma causing severe tracheal stenosis] Kubo M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun; 34(6):710–5 (Eng. Abstr.) **(Jpn)**

[A case of uterine endometrial cancer complicated post transfusion fatal fulminant hepatitis caused by hepatitis B virus with DNA mutation in precore region] Itani Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Oct; 47(10):1075–8 **(Jpn)**

[Papuloerythroderma associated with gastric cancer; report of a case] Sunami K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep;92(9):1285–8 **(Jpn)**

[Peutz-Jeghers syndrome and adenocarcinoma. Report of a case] Castro RR, et al. **Arq Gastroenterol** 1994 Oct–Dec; 31(4):145–8 (Eng. Abstr.) **(Por)**

[Features of angioarchitectonics of gastric tumors in the etiology of hemorrhage] Zaitsev VT, et al. **Klin Khir** 1995; (5):13–4 **(Rus)**

[Case of primary hyperparathyroidism caused by parathyroid adenocarcinoma] Liashchuk PM. **Klin Med (Mosk)** 1995; 73(5):67 **(Rus)**

[Inappropriate antidiuretic hormone secretion syndrome: a rare manifestation of prostatic adenocarcinoma] Pereira Arias JG, et al. **Arch Esp Urol** 1995 Dec;48(10):1042–5 (Eng. Abstr.) **(Spa)**

[Gas gangrene as presentation of colonic carcinoma in familial adenomatous polyposis] Martin Vieira F, et al. **Gastroenterol Hepatol** 1995 Oct;18(8):425–7 (Eng. Abstr.) **(Spa)**

[Bronchogenic carcinoma in patients with human immunodeficiency virus infection] Estrada O, et al. **Med Clin (Barc)** 1996 May 4;106(17):661–4 (Eng. Abstr.) **(Spa)**

[Prevalence of Helicobacter pylori infection in gastric adenocarcinoma and chronic gastritis] Boixeda D, et al. **Rev Esp Enferm Dig** 1996 Jun;88(6):403–8 (Eng. Abstr.) **(Spa)**

[Ileocolic invagination in cecal carcinoma in an aged patient. Preoperative diagnosis by imaging methods (letter)] Cosme A, et al. **Rev Esp Enferm Dig** 1996 May;88(5):381–2 **(Spa)**

[Psoas abscess secondary to colonic neoplasm (letter)] Insua Vilariño SA, et al. **Rev Esp Enferm Dig** 1995 Nov; 87(11):830–1 **(Spa)**

[Ampulloma in a patient with type I neurofibromatosis (letter)] Viladàs L, et al. **Rev Esp Enferm Dig** 1995 Dec; 87(12):908–9 **(Spa)**

DIAGNOSIS

Simultaneous detection of esophageal and gastric carcinomas. van Gelderen WF. **Abdom Imaging** 1995 Jul–Aug; 20(4):299–301

Endocervical columnar cell intraepithelial neoplasia. II. Grades of expression of cytomorphologic criteria. van Aspert-van Erp AJ, et al. **Acta Cytol** 1995 Nov–Dec; 39(6):1216–32

Carcinoma of the urachus. Michielsen D, et al. **Acta Urol Belg** 1995 Dec;63(4):33–5

Two cases of early colorectal cancer associated with gastric adenoma detected by serum pepsinogen screening method. Shimizu Y, et al. **Adv Exp Med Biol** 1995;362:149–54

Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. Jager GJ, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):845–52

Genitourinary case of the day. Urachal adenocarcinoma. Moran RE, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):247, 251

Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears [see comments] Apple SK, et al. **Am J Clin Pathol** 1996 Mar;105(3):321–6. Comment in: Am J Clin Pathol 1996 Mar;105(3):257–9.

K-ras mutations and the diagnosis of pancreatic carcinoma [editorial; comment] Robinson RA. **Am J Clin Pathol** 1996 Mar;105(3):257–9. Comment on: Am J Clin Pathol 1996 Mar;105(3):321–6.

Multicentric primary adenocarcinomas of the midgut: the first case report. Liu KJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1239–43 (48 ref.)

Adenomatous polyposis coli presenting as adenocarcinoma of the appendix. Parker GM, et al. **Am J Gastroenterol** 1996 Apr;91(4):801–2

Management of gastric remnant carcinoma based on the results of a 15-year endoscopic screening program. Greene FL. **Ann Surg** 1996 Jun;223(6):701–6; discussion 706–8

National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Janes RH Jr, et al. **Ann Surg** 1996 Mar;223(3):261–72

Comparative study between sonography, pathology and UGP in women with perimenopausal bleeding. el-Ahmady O, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2309–13

A novel tree-structured analysis for non-invasive diagnosis of gastric adenocarcinoma. Wu MS, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2739–43

Prostate-specific antigen (PSA) immunohistochemistry in the presence of a normal serum PSA as an aid to diagnosis

of adenocarcinoma of unknown primary site. Harper CL, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):367–8

Comment: dilemmas of diagnosis and treatment of prostate cancer [see comments] Sandu DP. **Br J Hosp Med** 1996 Mar 6–19;55(5):233–4. Comment in: Br J Hosp Med 1996 Mar 6–19;55(5):232–3.

Prognosis of early esophageal cancer. Comparison between adeno- and squamous cell carcinoma. Hölscher AH, et al. **Cancer** 1995 Jul 15;76(2):178–86

Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Farrow DC, et al. **Cancer Causes Control** 1996 May;7(3):322–7

Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen [see comments] Loric S, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1698–704. Comment in: Clin Chem 1995 Dec;41(12 Pt 1):1687–8.

Second-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniques. Hida J, et al. **Dis Colon Rectum** 1996 Jan;39(1):74–9

Pyogenic liver abscess: warning indicator of silent colonic cancer. Report of a case and review of the literature. Teitz S, et al. **Dis Colon Rectum** 1995 Nov;38(11):1220–3 (18 ref.)

Flat neoplastic lesions of the colon and rectum detected by high-resolution video endoscopy and chromoscopy [see comments] Jaramillo E, et al. **Gastrointest Endosc** 1995 Aug;42(2):114–22. Comment in: Gastrointest Endosc 1995 Aug;42(2):182–4.

Small flat cancer of the rectum: clinicopathologic and endoscopic features [see comments] Tada S, et al. **Gastrointest Endosc** 1995 Aug;42(2):109–13. Comment in: Gastrointest Endosc 1995 Aug;42(2):184–7.

Missed hysteroscopic detection of uterine carcinoma before endometrial resection: report of three cases. Colafranceschi M, et al. **Gynecol Oncol** 1996 Aug;62(2):298–300

Coincidental renal cell and endometrial carcinoma: a case report. Lam SK, et al. **Gynecol Oncol** 1996 Feb; 60(2):319–24

Adenocarcinoma of the cervix presenting as ovarian cancer: diagnostic considerations. Rawlings KK, et al. **Gynecol Oncol** 1996 Aug;62(2):304–8

Duplication of the gallbladder with advanced adenocarcinoma: diagnostic value of MRI and angiography. Kin Y, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):405–8

The value of PE-10, a monoclonal antibody against pulmonary surfactant, in distinguishing primary and metastatic lung tumours. Nicholson AG, et al. **Histopathology** 1995 Jul;27(1):57–60

Headache, nausea, and vomiting in a heavy drinker and smoker. Dawood MM, et al. **Hosp Pract (Off Ed)** 1995 Sep 15;30(9):28W–28X

Prognostic factors in urachal adenocarcinoma. A study in 41 specimens of DNA status, proliferating cell-nuclear antigen immunostaining, and argyrophilic nucleolar-organizer region counts. Nakanishi K, et al. **Hum Pathol** 1996 Mar;27(3):240–7

The prognostic value of DNA ploidy and S-phase estimate in primary breast cancer: a prospective study. Dieterich B, et al. **Int J Cancer** 1995 Sep 27;63(1):49–54

Uterine adenomatoid tumors: immunohistochemical characteristics with emphasis on Ber-EP4 immunoreactivity and distinction from adenocarcinoma. Otis CN. **Int J Gynecol Pathol** 1996 Apr;15(2):146–51

Cytogenetic analysis of prostate carcinoma by fluorescence in situ hybridization. Takahashi S, et al. **Int J Urol** 1995 Sep;2(4):215–23 (49 ref.)

Central diabetes insipidus caused by pituitary metastasis of lung cancer. Matsuda R, et al. **Intern Med** 1995 Sep; 34(9):913–8

Differential expression of jackfruit-lectin-specific glycoconjugates in metastatic adenocarcinoma and reactive mesothelial cells-a diagnostic aid in effusion cytology. Sujathan K, et al. **J Cancer Res Clin Oncol** 1996; 122(7):433–6

Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. D'Amico AV, et al. **J Clin Oncol** 1996 Jun;14(6):1770–7

OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material. Edwards C, et al. **J Clin Pathol** 1995 Jul;48(7):626–30

Hypertensive intra-arterial chemotherapy for endometrial carcinoma assessed by transvaginal Doppler ultrasound and magnetic resonance imaging. Hata K, et al. **J Clin Ultrasound** 1995 Sep;23(7):407–11

Atypical glandular cells of undetermined significance and adenocarcinoma in situ: summoning colposcopic expertise? Ferris DG, et al. **J Fam Pract** 1996 Aug;43(2):181–7

False-negative endoscopic biopsy of colonic adenocarcinoma in a young man. Gillett E, et al. **J Fam Pract** 1996 Aug; 43(2):178–80

Multiple neoplasias: an oncologic reality [letter] Prados C, et al. **J Natl Cancer Inst** 1996 Mar 6;88(5):303

Raynaud's phenomenon as a presenting sign of ovarian adenocarcinoma [letter] Paira SO. **J Rheumatol** 1996 Apr; 23(4):792

Barretts's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? McDonald ML, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1135–8; discussion 1139–40

Prostate carcinoma metastatic to the penis: magnetic resonance imaging and brachytherapy. Griffin JH, et al. **J Urol** 1996 May;155(5):1701–2

Prostate cancer—improvements in detection and diagnosis [editorial; comment] Schmidt JD. **J Urol** 1996 Jan; 155(1):243. Comment on: J Urol 1996 Jan;155(1):228–31. Comment on: J Urol 1996 Jan;155(1):232–7. Comment on: J Urol 1996 Jan;155(1):238–42.

Adenocarcinoma of the endolymphatic sac: imaging features and preoperative embolization. Mukherji SK, et al. **Neuroradiology** 1996 Feb;38(2):179–80

Hysteroscopy and adenocarcinoma. Mencaglia L. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):573–9 (30 ref.)

Adenosis (atypical adenomatous hyperplasia): histopathology and relationship to carcinoma. Epstein JI. **Pathol Res Pract** 1995 Sep;191(9):888–98 (21 ref.)

Colorectal neoplasms. Screening can save lives. Truszkowski JA, et al. **Postgrad Med** 1995 Nov;98(5):97–9, 103–6, 109–12 (20 ref.)

Solid and papillary epithelial neoplasm of the pancreas: imaging-pathologic correlation on 56 cases. Buetow PC, et al. **Radiology** 1996 Jun;199(3):707–11

Invasive cervical carcinoma: role of MR imaging in pretreatment work-up—cost minimization and diagnostic efficacy analysis. Hricak H, et al. **Radiology** 1996 Feb; 198(2):403–9

Acinic cell tumour of the maxillary sinus: an unusual case initially diagnosed as parotid cancer. Yoshihara T, et al. **Rhinology** 1995 Sep;33(3):177–9

Bone metastasis from breast carcinoma with fluid-fluid level. Nguyen BD, et al. **Skeletal Radiol** 1996 Feb;25(2):189–92

Gastric cancer and pernicious anemia appearing as pseudoachalasia. el-Newihi HM, et al. **South Med J** 1996 Sep;89(9):906–10 (30 ref.)

Endometrial metastases from gastric adenocarcinoma: a case report. Pasini A, et al. **Tumori** 1995 Sep-Oct;81(5):383–6

Colorectal cancer in young adults. Yilmazlar T, et al. **Tumori** 1995 Jul-Aug;81(4):230–3

[Detection of micrometastases in the bone marrow in patients with gastric cancer] Liu F, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):554–6 (Eng. Abstr.) (Chi)

[Upper digestive duplications in adults] Frering V, et al. **Ann Chir** 1995;49(10):928–35 (Eng. Abstr.) (Fre)

[Evolvements in the presentation of primary bronchial adenocarcinomas observed in a pneumology service over an 11-year period] Jeanfaivre T, et al. **Rev Mal Respir** 1995; 12(4):365–9 (Eng. Abstr.) (Fre)

[A large kidney with lymph nodes] Coutant-Perronne V, et al. **Rev Med Interne** 1996;17 Suppl 2:228S–230S (Fre)

[Significance of serum beta-hCG as a tumor marker for stomach carcinoma] Rau B, et al. **Langenbecks Arch Chir** 1995;380(6):359–64 (Eng. Abstr.) (Ger)

[Choroid metastasis in a patient with adenocarcinoma of the cervix. A case report] Wiegel T, et al. **Strahlenther Onkol** 1995 Sep;171(9):539–42 (16 ref.) (Eng. Abstr.) (Ger)

[Synchronous carcinoma of the colon and rectum] La Ganga V, et al. **Minerva Chir** 1995 Dec;50(12):1069–72 (Eng. Abstr.) (Ita)

[Is it possible to screen for endometrial carcinoma? Incidence and risk factors] Broso PR, et al. **Minerva Ginecol** 1995 Dec;47(12):539–52 (70 ref.) (Eng. Abstr.) (Ita)

[Quantitative evaluation of endocervical cells in women with human papillomavirus infection] Giovagnoli MR, et al. **Minerva Ginecol** 1996 Mar;48(3):65–71 (Eng. Abstr.) (Ita)

[Nuclear Magnetic Resonance Imaging in the staging of adenocarcinoma of the uterine cervix] Pellegrino A, et al. **Minerva Ginecol** 1995 Dec;47(12):523–6 (Eng. Abstr.) (Ita)

[Meningeal carcinosis: early clinical manifestations of inflammatory cancer of the breast] Pandolfi C, et al. **Minerva Med** 1995 Jul-Aug;86(7–8):319–22 (Eng. Abstr.) (Ita)

[Computerized tomography and magnetic resonance in the diagnosis of recurrent rectal neoplasms: comparison of reliability and errors of both methods] Golfieri R, et al. **Radiol Med (Torino)** 1996 May;91(5):601–9 (Eng. Abstr.) (Ita)

[Magnetic resonance with endorectal coil in the locoregional staging of rectal carcinoma] Masi A, et al. **Radiol Med (Torino)** 1995 Oct;90(4):431–7 (Eng. Abstr.) (Ita)

[The imaging diagnosis of primary hyperparathyroidism due to parathyroid adenocarcinoma. A case report] Prato N, et al. **Radiol Med (Torino)** 1995 Sep;90(3):323–6 (11 ref.) (Ita)

[A case of genitourinary double cancers detected by health screening] Ito T, et al. **Hinyokika Kiyo** 1996 Jun; 42(6):461–4 (20 ref.) (Eng. Abstr.) (Jpn)

[Two operated cases of synchronous double cancer of the lung and digestive tract in patients over 80 years old and genetical diagnosis] Nosaka S, et al. **Kyobu Geka** 1996 Feb; 49(2):111–5 (Eng. Abstr.) (Jpn)

[Primary adenocarcinoma of the tunica vaginalis testis expressing CA19-9 antigen] Muraki J, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Aug;86(8):1398–401 (Eng. Abstr.) (Jpn)

[Stage IIIa endometrial carcinoma: MR findings] Nobusawa H, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Apr; 56(5):283–7 (Eng. Abstr.) (Jpn)

[Is CA125 useful in the management of recurrence of endometrial carcinoma?] Sato K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep;47(9):917–24 (Eng. Abstr.) (Jpn)

[Two cases of metastatic lung cancer examined by bronchoscopic cytology] Kakumu S, et al. **Rinsho Byori** 1996 Apr;44(4):390–5 (Eng. Abstr.) (Jpn)

[A rare case of concurrent endometrial carcinoma and PCO syndrome] Goluda M, et al. **Ginekol Pol** 1995 Aug; 66(8):484–5 (Eng. Abstr.) (Pol)

[The detection and treatment of cancer of the large intestine] Petrov VP, et al. **Voen Med Zh** 1995 Oct;(10):28–30 (Rus)

[The diagnostic utility of PSA density] Alcover J, et al. **Actas Urol Esp** 1995 Mar;19(3):192–5 (Eng. Abstr.) (Spa)

[Pericardial tamponade and carcinomatous lymphangitis as primary manifestation of lung neoplasm] del Toro Cervera J, et al. **An Med Interna** 1995 Jun;12(6):286–8 (Eng. Abstr.) (Spa)

[Bronchogenic carcinoma and human immunodeficiency virus infection] Carrasquer C, et al. **Arch Bronconeumol** 1995 Aug-Sep;31(7):362–4 (15 ref.) (Eng. Abstr.) (Spa)

[Clinical study of incidentally diagnosed renal adenocarcinoma] Herranz Amo F, et al. **Arch Esp Urol** 1995 Dec;48(10):991–8; discussion 998–9 (24 ref.) (Eng. Abstr.) (Spa)

[Adenoma of Vater's ampulla without clinical or analytical expression (letter)] Moreira VF, et al. **Rev Clin Esp** 1996 May;196(5):343–4 (11 ref.) (Spa)

[Pulmonary carcinomatous lymphangitis as initial manifestation of gastric cancer (letter)] Morillas MJ, et al. **Rev Esp Enferm Dig** 1996 May;88(5):379–80 (Spa)

[Colorectal cancer: its clinical picture and survival] Díaz-Plasencia J, et al. **Rev Gastroenterol Peru** 1996 Jan-Apr;16(1):48–56 (Eng. Abstr.) (Spa)

DRUG THERAPY

CT evaluation of the resectability of gastric cancer postchemotherapy. Gossios K, et al. **Abdom Imaging** 1996 Jul-Aug;21(4):293–8

Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results. Colozza M, et al. **Am J Clin Oncol** 1996 Feb;19(1):10–7

High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Di Costanzo F, et al. **Am J Clin Oncol** 1996 Jun;19(3):307–10

A phase II trial of gallium nitrate (NSC #15200) in nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Malfetano JH, et al. **Am J Clin Oncol** 1995 Dec;18(6):495–7

Phase II trial of CHIP for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group Study. Marshall ME, et al. **Am J Clin Oncol** 1995 Oct;18(5):400–2

Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Pazdur R, et al. **Am J Clin Oncol** 1995 Oct;18(5):436–8

Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study. Williamson SK, et al. **Am J Clin Oncol** 1995 Dec;18(6):484–7

Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. Williamson SK, et al. **Am J Clin Oncol** 1996 Aug; 19(4):368–70

Taxol is active in platinum-resistant endometrial adenocarcinoma. Woo HL, et al. **Am J Clin Oncol** 1996 Jun;19(3):290–1

Photodynamic therapy for Barrett's esophagus: clinical update. Overholt BF, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1719–23

Lung cancer chemotherapy. Response-survival relationship depends on the method of chest tumor response evaluation. Pujol JL, et al. **Am J Respir Crit Care Med** 1996 Jan; 153(1):243–9

Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. André T, et al. **Ann Oncol** 1996 Feb;7(2):173–8

Cisplatin and protracted venous infusion 5-fluorouracil (CF)—good symptom relief with low toxicity in advanced pancreatic carcinoma. Nicolson M, et al. **Ann Oncol** 1995 Oct;6(8):801–4

Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. Poorter RL, et al. **Ann Oncol** 1995 Dec; 6(10):1048–9

The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Webb A, et al. **Ann Oncol** 1995 Jul;6(6):581–7

Prognostic factors in resectable gastric cancer: results of

EORTC study no. 40813 on FAM adjuvant chemotherapy. Lise M, et al. **Ann Surg Oncol** 1995 Nov;2(6):495–501

Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Macdonald JS, et al. **Ann Surg Oncol** 1995 Nov;2(6):488–94

In vitro activity of titanocenedichloride versus cisplatin in four ovarian carcinoma cell lines evaluated by a microtiter plate ATP bioluminescence assay. Kurbacher CM, et al. **Anticancer Drugs** 1995 Oct;6(5):697–704

Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts. Smith JP, et al. **Anticancer Drugs** 1995 Dec; 6(6):717–26

A clinical nude mouse metastatic model for highly malignant human pancreatic cancer. An Z, et al. **Anticancer Res** 1996 Mar–Apr;16(2):627–31

Effects of retinoic acid on cell differentiation and reversion toward normal in human endometrial adenocarcinoma (RL95-2) cells. Carter CA, et al. **Anticancer Res** 1996 Jan–Feb;16(1):17–24

Effects of interferon-beta on steroid receptors, prostaglandins and enzymatic activities in human endometrial cancer. De Cicco Nardone F, et al. **Anticancer Res** 1996 Jan–Feb; 16(1):161–9

Endometrial cancer cell lines are sensitive to paclitaxel. Rantanen V, et al. **Anticancer Res** 1996 Jan–Feb;16(1):475–9

Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial. Salvati F, et al. **Anticancer Res** 1996 Mar–Apr;16(2):1001–4

In vitro antitumor activity of 4'-O-tetrahydropyranyladriamycin on human gastric cancer cells. Yamaue H, et al. **Anticancer Res** 1996 Jan–Feb; 16(1):243–6

Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base. Brasnu D, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):765–8

Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy. Schned AR, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):96–100

Preoperative "chemoradiation" for stages II and III rectal carcinoma. Stryker SJ, et al. **Arch Surg** 1996 May; 131(5):514–8; discussion 518–9

Increased tumor oxygenation and radiation sensitivity in two rat tumors by a hemoglobin-based, oxygen-carrying preparation. Robinson MF, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):431–8

Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer. Levi JA, et al. **Aust N Z J Med** 1995 Oct;25(5):474–8

Cytotoxic chemotherapy and radiotherapy in a patient with breast cancer and variegate porphyria (VP) [letter] Scarlett JD, et al. **Aust N Z J Med** 1995 Dec;25(6):742–3

Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Thornalley PJ, et al. **Biochem Pharmacol** 1996 May 17;51(10):1365–72

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Dieras V, et al. **Br J Cancer** 1996 Aug;74(4):650–6

A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Evans TR, et al. **Br J Cancer** 1996 May;73(10):1260–4

Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC). Hussey HJ, et al. **Br J Cancer** 1996 May; 73(10):1187–92

Inhibition of tumour growth by lipoxygenase inhibitors. Hussey HJ, et al. **Br J Cancer** 1996 Sep;74(5):683–7

The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Lartigau E, et al. **Br J Cancer** 1996 Jun;73(12):1480–5

Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Neri B, et al. **Br J Cancer** 1996 Feb;73(4):549–52

Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. Veenhuizen RB, et al. **Br J Cancer** 1996 Jun;73(11):1387–92

Borderline ovarian cancer, bilateral surgical castration, chemotherapy and a normal delivery after ovum donation and in vitro fertilisation-embryo transfer. Lawal AH, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):931–2

Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Bamias A, et al. **Cancer** 1996 May 15;77(10):1978–85

Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study. Berenberg JL, et al. **Cancer** 1995 Sep 1;76(5):715–9

Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma. Kornek G, et al. **Cancer** 1995 Oct 15;76(8):1356–62

Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. Marsh RD, et al. **Cancer** 1996 Jul 15; 78(2):217–25

Regional chemotherapy for inoperable pancreatic carcinoma. Muchmore JH, et al. **Cancer** 1996 Aug 1;78(3 Suppl):664–73

Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Thomas F, et al. **Cancer** 1995 Dec 1;76(11):2286–90

Phase II study of mitomycin, ifosfamide and cisplatin in adenocarcinoma of the oesophagus. Allen SM, et al. **Cancer Chemother Pharmacol** 1996;37(5):496–8

Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Chou TC, et al. **Cancer Chemother Pharmacol** 1996;37(3):222–8

Characteristic antitumor activity of cytarabine ocfosfate against human colorectal adenocarcinoma xenografts in nude mice. Koga K, et al. **Cancer Chemother Pharmacol** 1995;36(6):459–62

A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer. Nardi M, et al. **Cancer Chemother Pharmacol** 1996;38(3):298–301

Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. Polyzos A, et al. **Cancer Chemother Pharmacol** 1996;38(3):292–7

Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice. Shinkai H, et al. **Cancer Chemother Pharmacol** 1996;38(5):417–24

Effects of N(g)-methyl-L-arginine, an inhibitor of nitric oxide synthesis, on interleukin-2-induced capillary leakage and antitumor responses in healthy and tumor-bearing mice. Orucevic A, et al. **Cancer Immunol Immunother** 1996 Jan;42(1):38–46

Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil. Chiou TJ, et al. **Cancer Invest** 1996;14(3):197–201

Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. Figueredo AT, et al. **Cancer Invest** 1995;13(6):608–11

Loss of DNA mismatch repair in acquired resistance to cisplatin. Aebi S, et al. **Cancer Res** 1996 Jul 1; 56(13):3087–90

Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. Alati T, et al. **Cancer Res** 1996 May 15;56(10):331–5

Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. Kelner MJ, et al. **Cancer Res** 1995 Nov 1;55(21):4936–40

Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. Murray JL, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5925s–5928s

Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Shirasaka T, et al. **Cancer Res** 1996 Jun 1;56(11):2602–6

Extended intraarterial cisplatin infusion for treatment of gynecologic cancer after alteration of intrapelvic blood flow and implantation of a vascular access device. Yamada T, et al. **Cardiovasc Intervent Radiol** 1996 May-Jun; 19(3):139–45

Effects of preoperative chemotherapy on gastric carcinoma: the relationship between histopathologic response and prognosis. Kumagai K, et al. **Clin Ther** 1995 Sep-Oct; 17(5):936–45

Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Benedetti-Panici P, et al. **Eur J Cancer** 1995 Nov; 31A(12):1987–92

Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11) [letter] Boisseau M, et al. **Eur J Cancer** 1996 Apr;32A(4):737–8

Adenocarcinoma of the eccrine sweat gland: response to both combination chemotherapy and local field irradiation [letter] Mertens WC, et al. **Eur J Cancer** 1996 Feb; 32A(2):372–3

Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma. Penna C, et al. **Eur J Cancer** 1996 Jun;32A(7):1117–22 (47 ref.)

Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma. Scheithauer W, et al. **Eur J Cancer** 1995 Nov; 31A(12):1981–6

Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma. Wadler S, et al. **Eur J Cancer** 1996 Jun;32A(7):1254–6

The use of the tumour marker CA19-9 in evaluating the response to tamoxifen therapy in patients with unresectable adenocarcinoma of the pancreas [letter] Wong A, et al. **Eur J Cancer** 1995 Nov;31A(12):2118–9

Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department. Carey PD, et al. **Eur J Surg Oncol** 1995 Dec;21(6):653–7

Induction chemotherapy via hepatic artery for gallbladder carcinoma. Lai DT, et al. **Eur J Surg Oncol** 1995 Dec; 21(6):690–1

Intra-arterial liposomal adriamycin for metastatic adenocarcinoma of the liver. Konno H, et al. **Eur Surg Res** 1995;27(5):301–6

Photodynamic therapy: a new light on Barrett's esophagus [editorial; comment] Lightdale CJ. **Gastrointest Endosc** 1995 Jul;42(1):96–8. Comment on: Gastrointest Endosc 1995 Jul;42(1):59–63. Comment on: Gastrointest Endosc 1995 Jul;42(1):64–70.

Barrett's esophagus: photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer [see comments] Overholt BF, et al. **Gastrointest Endosc** 1995 Jul;42(1):64–70. Comment in: Gastrointest Endosc 1995 Jul;42(1):96–8.

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium. a Gynecologic Oncology Group study. Ball HG, et al. **Gynecol Oncol** 1996 Aug;62(2):278–81

Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study. Pierga JY, et al. **Gynecol Oncol** 1996 Jan;60(1):59–63

A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary. Reed E, et al. **Gynecol Oncol** 1996 Jun;61(3):349–53

Hyperglycemia secondary to megestrol acetate for endometrial neoplasia. Rose PG. **Gynecol Oncol** 1996 Apr; 61(1):139–41

The role of chemotherapy in the treatment of adenocarcinoma of the pancreas. Fennelly D, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):356–62 (30 ref.)

Chronome of urinary 6-sulfoxy-melatonin excretion, circulating CA125, cancer progression and therapeutic response. Cornélissen G, et al. **In Vivo** 1995 Jul–Aug; 9(4):375–8

Response of bidimensionally measurable metastases to flutamide withdrawal in a patient with advanced prostate cancer. Warren GP, et al. **Indiana Med** 1996 May–Jun; 89(3):274–7

p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Benhattar J, et al. **Int J Cancer** 1996 Jun 21;69(3):190–2

Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Hill SA, et al. **Int J Cancer** 1995 Sep 27;63(1):119–23

Flutamide-induced liver toxicity including fatal hepatic necrosis. Crownover RL, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):911–5

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913–8 (35 ref.). Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969–70.

Prospective trial of combined hyperfractionated radiotherapy and bronchial arterial infusion of chemotherapy for locally advanced nonsmall cell lung cancer. Wang G, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):309–13

The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Yang FE, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1009–17

Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results. Einzig AI, et al. **Invest New Drugs** 1995;13(3):223–7

Adenocarcinoma of unknown primary: retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system. Hanauske AR, et al. **Invest New Drugs** 1995;13(1):43–9

A phase II trial of doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma. Schwartz GK, et al. **Invest New Drugs** 1995;13(1):77–82

A phase II trial of paclitaxel (Taxol) as first line treatment in advanced breast cancer. Swain SM, et al. **Invest New Drugs** 1995;13(3):217–22

Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study. Williamson SK, et al. **Invest New Drugs** 1995; 13(2):167–70

Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. Clark J, et al. **J Cancer Res Clin Oncol** 1996; 122(9):554–8

Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Scheithauer W, et al. **J Cancer Res Clin Oncol** 1995;121 Suppl 3:R7–10

Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model. Van de Vrie W, et al. **J Cancer Res Clin Oncol** 1996;122(7):403–8

Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. Jones DV Jr, et al. **J Clin Oncol** 1996

Aug;14(8):2306–10

Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. Kelsen D, et al. **J Clin Oncol** 1996 Jun; 14(6):1818–28

Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. Kunitoh H, et al. **J Clin Oncol** 1996 May;14(5):1649–55

Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. Moertel CG, et al. **J Clin Oncol** 1995 Dec;13(12):2936–43

Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. Rosen PJ, et al. **J Clin Oncol** 1996 May;14(5):1626–36

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. Rothenberg ML, et al. **J Clin Oncol** 1996 Apr;14(4):1128–35

Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose. Shepherd FA, et al. **J Clin Oncol** 1996 May; 14(5):1656–62

Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. Small EJ, et al. **J Clin Oncol** 1996 May;14(5):1617–25

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points [see comments] Tannock IF, et al. **J Clin Oncol** 1996 Jun;14(6):1756–64. Comment in: J Clin Oncol 1996 Jun;14(6):1753–5.

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. Wasserheit C, et al. **J Clin Oncol** 1996 Jul; 14(7):1993–9

Hypertensive intra-arterial chemotherapy for endometrial carcinoma assessed by transvaginal Doppler ultrasound and magnetic resonance imaging. Hata K, et al. **J Clin Ultrasound** 1995 Sep;23(7):407–11

The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma. Kalechman Y, et al. **J Immunol** 1996 Feb 1;156(3):1101–9

Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. Leach SD, et al. **J Infus Chemother** 1995 Summer;5(3):104–11 (46 ref.)

Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE). Lokich J, et al. **J Infus Chemother** 1996 Winter;6(1):39–42

Response of brain metastases from breast cancer to megestrol acetate: a case report. Stewart DJ, et al. **J Neurooncol** 1995; 24(3):299–301

Combination treatment with cisplatin and schizophyllan for 7,12-dimethylbenz(a)anthracene-induced rat ovarian adenocarcinoma. Sugiyama T, et al. **J Obstet Gynaecol** 1995 Oct;21(5):521–7

Cytotoxicity, cell cycle kinetics and morphonuclear-induced effects of Vinca alkaloid anticancer agents. Pauwels O, et al. **J Pharm Pharmacol** 1995 Oct;47(10):870–5

Growth inhibitory effects on human colon adenocarcinoma-derived Caco-2 cells and calcemic potential of 1 alpha,25-dihydroxyvitamin D3 analogs: structure-function relationships. Bischof MG, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1254–60

P450-dependent enzymes as targets for prostate cancer therapy. De Coster R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):133–43 (101 ref.)

The combination 5-fluorouracil/levamisole induces enhanced rat Kupffer cell-mediated cytotoxicity in vitro against the syngeneic colon adenocarcinoma cell line CC531. Schuurman B, et al. **J Surg Oncol** 1995 Nov; 60(3):180–4

Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. Herrada J, et al. **J Urol** 1996 Feb;155(2):620–3

In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers. Sarosdy MF, et al. **J Urol** 1996 Jun;155(6):2085–9

An early phase II study of etoposide (VP-16) in advanced gastric cancer. Yamao T, et al. **Jpn J Clin Oncol** 1996 Feb; 26(1):36–41

Experimental intraperitoneal administration of cisplatin-activated carbon for rat ovarian adenocarcinomas. Sugiyama T, et al. **Kurume Med J** 1996;43(1):33–9

Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma [letter] Bower JH, et al. **Mov Disord** 1995 Sep;10(5):681–2

In vivo and in vitro studies of cyclophosphamide chemotherapy in a mouse mammary carcinoma by 31P NMR spectroscopy. Street JC, et al. **NMR Biomed** 1995 Jun;8(4):149–58

Patient experiences adverse drug reaction to etoposide for adenocarcinoma of the lung. Ives RK. **Oncol Nurs Forum** 1995 Sep;22(8):1289

Pentoxifylline potentiates the antitumor effect of cisplatin and etoposide on human lung cancer cell lines. Ohsaki Y, et al. **Oncology** 1996 Jul-Aug;53(4):327–33

Characterization of alkylating versus intercalating anticancer drug-induced effects on cell survival, cell cycle kinetic and morphonuclear pattern of three neoplastic cells lines growing in vitro. Pauwels O, et al. **Pharm Res** 1995 Jul; 12(7):1011–8

Quality of life in patients with metastatic colorectal cancer receiving chemotherapy: a randomized, double-blind trial comparing 5-FU versus 5-FU with leucovorin. Sullivan BA, et al. **Pharmacotherapy** 1995 Sep-Oct;15(5):600–7

Tumor oxygenation changes post-photodynamic therapy. Chen Q, et al. **Photochem Photobiol** 1996 Jan;63(1):128–31

Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. Kuan CT, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):974–8

Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor. Sutkowski DM, et al. **Prostate Suppl** 1996;6:62–6

Pancreatic cancer: treatment with neutron irradiation alone and with chemotherapy [see comments] Cohen L, et al. **Radiology** 1996 Sep;200(3):627–30. Comment in: Radiology 1996 Sep;200(3):608–9.

The activity of paclitaxel in gastrointestinal tumors. Ajani JA, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):46–50; discussion 51–3

Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Hudes GR, et al. **Semin Oncol** 1995 Oct; 22(5 Suppl 12):41–5

Chemotherapy of adenocarcinoma of the pancreas. Schnall SF, et al. **Semin Oncol** 1996 Apr;23(2):220–8 (81 ref.)

Photodynamic therapy in Barrett's esophagus: reduction of specialized mucosa, ablation of dysplasia, and treatment of superficial esophageal cancer. Overholt BF, et al. **Semin Surg Oncol** 1995 Sep-Oct;11(5):372–6

Complete response of transverse colon carcinoma to S1, a new chemotherapy agent: report of a case. Mimori K, et al. **Surg Today** 1995;25(8):741–4

Adenocarcinoma of the pancreas in childhood (pancreatoblastoma): report of a case with good response to chemotherapy. Caracciolo G, et al. **Tumori** 1995 Sep-Oct;81(5):391–4

Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Igawa M, et al. **Urol Int** 1995;55(2):74–7

Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine. Naik H, et al. **Urology** 1996 Sep;48(3):508–11

[Modification of the response to paclitaxel of human differentiated colon cancer line after long-term treatment at very low dose] Carles G, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):135–8 (Eng. Abstr.) **(Fre)**

[Chemotherapy of metastatic endometrial carcinoma. Review of the literature] Pierga JY, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):1005–18 (110 ref.) (Eng. Abstr.) **(Fre)**

[Fulminant hepatitis caused by flutamide (letter)] Andréjak M, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):121–2 **(Fre)**

[Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape] Barthélémy Y, et al. **Prog Urol** 1996 Feb;6(1):93–7 (Eng. Abstr.) **(Fre)**

[Convulsions in a patient treated for ovarian adenocarcinoma] Le Moing V, et al. **Rev Med Interne** 1996;17 Suppl 2:234s–236s **(Fre)**

[Photodynamic therapy of small adenocarcinomas with methylene blue] Orth K, et al. **Chirurg** 1995 Dec; 66(12):1254–7 (Eng. Abstr.) **(Ger)**

[5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?] Maurer U, et al. **Strahlenther Onkol** 1996 May;172(5):257–9 (Eng. Abstr.) **(Ger)**

[The combined radiochemotherapy of inoperable esophageal neoplasms: a feasibility study] Sola B, et al. **Radiol Med (Torino)** 1996 Apr;91(4):456–9 (Eng. Abstr.) **(Ita)**

[Hepatic arterial infusion therapy for gastric liver metastasis using implanted reservoir] Hoshima M, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1515–8 (Eng. Abstr.) **(Jpn)**

[Intra-arterial infusion chemotherapy for advanced liver metastases from lung cancer via implantable vascular access: report of six cases] Hyogo H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1577–81 (Eng. Abstr.) **(Jpn)**

[Combination therapy of doxifluridine, pirarubicin and cisplatin for human gastric cancers implanted in nude mice] Inaba M, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1793–8 (Eng. Abstr.) **(Jpn)**

[A case of intrahepatic infusion chemotherapy with angiotensin II human for liver metastasis from early gastric cancer] Iwasaki Y, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1674–8 (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer remarkably responding to preoperative UFT-E therapy] Iwazaki R, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):355–9 (Eng. Abstr.) **(Jpn)**

[A case of pancreatic cancer surviving for 7 years 11 months following intra-arterial and portal infusion chemotherapy] Kenmotsu M, et al. **Gan To Kagaku Ryoho** 1995 Nov; 22(13):1983–5 (Eng. Abstr.) **(Jpn)**

[Outcomes of effective treatment of cases of metastatic liver tumors by intra-arterial infusion chemotherapy] Koizumi T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1573–6 (Eng. Abstr.) **(Jpn)**

[A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin] Kondo K, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1839–42 (Eng. Abstr.) **(Jpn)**

[A case of gastric cancer responding well to MTX/5-FU (methotrexate/5-fluorouracil) and PMUE (CDDP, MMC, UFT, etoposide) therapies upon lymphnode recurrence] Konishi K, et al. **Gan To Kagaku Ryoho** 1995 Nov; 22(13):1969–72 (Eng. Abstr.) **(Jpn)**

[A case report of prostate cancer resistant to endocrine therapy successfully treated with intra-arterial chemotherapy] Mima H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1694–6 (Eng. Abstr.) **(Jpn)**

[Sclerosing cholangitis-induced biliary cyst formation: complication of hepatic artery infusion chemotherapy] Miyamoto S, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1684–6 (Eng. Abstr.) **(Jpn)**

[Three cases of uterine cervical adenocarcinoma successfully treated by neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil)] Narimatsu A, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):111–4 (Eng. Abstr.) **(Jpn)**

[Experience in intra-hepatic-arterial chemotherapy and hepatic resection for metastatic colorectal cancer] Shimada H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1570–2 (Eng. Abstr.) **(Jpn)**

[Highly effective preoperative intraarterial infusion chemotherapy with CDDP for progressive uterine corpus cancer with a Sister Mary Joseph's nodule] Shirai T, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):791–5 (Eng. Abstr.) **(Jpn)**

[A case of histological complete remission by preoperative intraarterial infusion chemotherapy] Taniguchi Y, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1702–5 (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer treated effectively with neo-adjuvant chemotherapy using l-leucovorin and 5-FU] Terada J, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1835–8 (Eng. Abstr.) **(Jpn)**

[A case of effective chemotherapy by combination of 5'-DFUR and MMC for recurrent colon cancer with multiple liver metastasis] Tsuji K, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1077–9 (Eng. Abstr.) **(Jpn)**

[Study of serum CDDP concentrations in patients with advanced or recurrent adeno-or squamous cell carcinoma under combination chemotherapy of 5-FU (CIV) and low-dose CDDP (IV)] Yagihashi A, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):63–7 (Eng. Abstr.) **(Jpn)**

[FAM as a palliative chemotherapy for gastric cancer with bone metastasis] Yumoto Y, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):107–10 (Eng. Abstr.) **(Jpn)**

[Combination therapy with estrogen and UFT in newly diagnosed prostatic cancer (poorly differentiated, stage D2)] Kondo I, et al. **Hinyokika Kiyo** 1996 Mar;42(3):201–6 (Eng. Abstr.) **(Jpn)**

[Comparison of hormone therapy alone and in combination with chemotherapy of cisplatin and methotrexate in newly diagnosed patients with stage D2 prostatic cancer] Komatus H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):789–96 (Eng. Abstr.) **(Jpn)**

[Intralymphatic administration of estramustine phosphate] Sakamoto H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1271–2 **(Jpn)**

[Nitroxyl radical Tempol as a modulator of toxic and antineoplastic effect of 6-mercaptopurine] Konovalova NP, et al. **Vopr Onkol** 1996;42(3):57–63 (Eng. Abstr.) **(Rus)**

[Cyto-reduction of rectal cancer after preoperative chemoradiotherapy] Sánchez Maldonado W, et al. **Rev Gastroenterol Mex** 1995 Jul-Sep;60(3):158 **(Spa)**

ECONOMICS

Invasive cervical carcinoma: role of MR imaging in pretreatment work-up--cost minimization and diagnostic efficacy analysis. Hricak H, et al. **Radiology** 1996 Feb; 198(2):403–9

ENZYMOLOGY

Quantitative immunocytochemical assays of topoisomerase II in lung adenocarcinoma cell lines. Correlation to topoisomerase II alpha content and topoisomerase II catalytic activity. Yamazaki K, et al. **Acta Oncol** 1996; 35(4):417–23

Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Yabuki N, et al. **Am J Pathol** 1996 Sep;149(3):997–1007

MAPK activity is down-regulated in human colon adenocarcinoma: correlation with PKC activity. Attar BM, et al. **Anticancer Res** 1996 Jan-Feb;16(1):395–9

Histochemically demonstrable protein tyrosine phosphatase in human breast and colorectal cancer: large decrease in its activity in colorectal cancer suggests a tumor suppressor role in colorectal mucosal cells. Partanen S. **Anticancer Res** 1996 Mar-Apr;16(2):943–6

Expression of 16 kDa proteolipid of vacuolar-type

H(+)-ATPase in human pancreatic cancer. Ohta T, et al. **Br J Cancer** 1996 Jun;73(12):1511-7

Decreased levels of 13-hydroxyoctadecadienoic acid (13-HODE) dehydrogenase in neoplastic tissue of human colon biopsies. Silverman AL, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jan;5(1):53-6

Plasmin-catalyzed proteolysis in colorectal neoplasia. Delbaldo C, et al. **Cancer Res** 1995 Oct 15;55(20):4688-95

Quantitative differences in GlcNAc:beta1—>3 and GlcNAc:beta1—>4 galactosyltransferase activities between human colonic adenocarcinomas and normal colonic mucosa. Seko A, et al. **Cancer Res** 1996 Aug 1; 56(15):3468-73

Reversion of transformed phenotype of human adenocarcinoma A549 cells by expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase complementary DNA. Seronie-Vivien S, et al. **Cell Growth Differ** 1995 Nov;6(11):1415-23

Regulation of estrogen sulfotransferase in human endometrial adenocarcinoma cells by progesterone. Falany JL, et al. **Endocrinology** 1996 Apr;137(4):1395-401

Human colon sialidase: characterization and activity levels in normal mucosa and colonic adenocarcinoma. Martínez-Zorzano VS, et al. **Enzyme Protein** 1994-95; 48(5-6):282-90

Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gustafson-Svärd C, et al. **Gut** 1996 Jan;38(1):79-84

Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Young TN, et al. **Gynecol Oncol** 1996 Jul;62(1):89-99

Influence of proliferative stimulation on the activity of rat intestinal diamine oxidase. Schwelberger HG, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S66-7

Elevation of acid glycosidase activities in thyroid and gastric tumors. Gil-Martín E, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):651-7

Decreased expression of nucleoside diphosphate kinase alpha isoform, an nm23-H2 gene homolog, is associated with metastatic potential of rat mammary-adenocarcinoma cells. Fukuda M, et al. **Int J Cancer** 1996 Feb 8;65(4):531-7

Trypsinogen expression in human ovarian carcinomas. Hirahara F, et al. **Int J Cancer** 1995 Oct 9;63(2):176-81

Expression and function of alpha 2,3-sialyl- and alpha 1,3/1,4-fucosyltransferases in colon adenocarcinoma cell lines: role in synthesis of E-selectin counter-receptors. Majuri ML, et al. **Int J Cancer** 1995 Nov 15;63(4):551-9

92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Nielsen BS, et al. **Int J Cancer** 1996 Jan 3;65(1):57-62

Adenylate cyclase activity in human pancreatic adenocarcinoma cell lines. al-Nakkash L, et al. **Int J Pancreatol** 1996 Feb;19(1):39-47

Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. Lenz HJ, et al. **J Clin Oncol** 1996 Jan; 14(1):176-82

Specificity of glucuronosyltransferase activity in the human cancer cell line LNCaP, evidence for the presence of at least two glucuronosyltransferase enzymes. Guillemette C, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3-4):355-62

Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Kutchera W, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4816-20

There are multiple forms of glyceraldehyde-3-phosphate dehydrogenase in prostate cancer cells and normal prostate tissue. Epner DE, et al. **Prostate** 1996 Jun;28(6):372-8

Deoxythymidine kinase in the staging of prostatic adenocarcinoma. Letocha H, et al. **Prostate** 1996 Jul; 29(1):15-9

Immunohistochemical study of arginase in cancer of the stomach. Wu CW, et al. **Virchows Arch** 1996 Aug; 428(6):325-31

EPIDEMIOLOGY

Incidence trends in oesophageal and proximal gastric carcinoma in Victoria. Thomas RJ, et al. **Aust N Z J Surg** 1996 May;66(5):271-5

Local recurrence following total mesorectal excision for rectal cancer. Arbman G, et al. **Br J Surg** 1996 Mar; 83(3):375-9

Incidence and treatment of periampullary duodenal cancer in the U.S. veteran patient population [see comments] Sexe RB, et al. **Cancer** 1996 Jan 15;77(2):251-4. Comment in: Cancer 1996 Aug 1;78(3):568.

Lung carcinoma in former smokers. Tong L, et al. **Cancer** 1996 Sep 1;78(5):1004-10

Sexual, reproductive, and other risk factors for adenocarcinoma of the cervix: results from a population-based case-control study (California, United States) [see comments] Ursin G, et al. **Cancer Causes Control** 1996 May;7(3):391-401. Comment in: Cancer Causes Control 1996 May;7(3):299-301.

Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. Orbuch M, et al. **Dig Dis Sci** 1996 Mar; 41(3):604-13

The changing epidemiology of smoking and lung cancer histology. Wynder EL, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:143-8 (67 ref.)

A case-control study of gastric cancer and nutritional factors in Marseille, France. Cornée J, et al. **Eur J Epidemiol** 1995 Feb;11(1):55-65

Nitrosamine, nitrate and nitrite in relation to gastric cancer: a case-control study in Marseille, France. Pobel D, et al. **Eur J Epidemiol** 1995 Feb;11(1):67-73

Changes in the site- and histology-specific incidence of gastric cancer during a 50-year period. Locke GR 3rd, et al. **Gastroenterology** 1995 Dec;109(6):1750-6

Small flat adenomas appear to have little clinical importance in Western countries [editorial; comment] Bond JH. **Gastrointest Endosc** 1995 Aug;42(2):184-7. Comment on: Gastrointest Endosc 1995 Aug;42(2):109-13.

Primary carcinoma of the gallbladder--review of 143 cases. Arnaud JP, et al. **Hepatogastroenterology** 1995 Nov-Dec; 42(6):811-5

Primary carcinoma of the gallbladder associated with anomalous pancreaticobiliary ductal junction. Chao TC, et al. **J Clin Gastroenterol** 1995 Dec;21(4):306-8

More evidence for the increasing prevalence of adenocarcinoma of the esophagus over an 18-year period. Chen MY, et al. **J Clin Gastroenterol** 1995 Oct;21(3):254-5

Comparison of prevalence and resection rates in patients with esophageal squamous cell carcinoma and adenocarcinoma. Heitmiller RF, et al. **J Thorac Cardiovasc Surg** 1996 Jul; 112(1):130-6

Epidemiology of high grade prostatic intraepithelial neoplasia. Sakr WA, et al. **Pathol Res Pract** 1995 Sep; 191(9):838-41

Colorectal cancer and ulcerative colitis [editorial; comment] Giardiello FM, et al. **Radiology** 1996 Apr;199(1):28-30. Comment on: Radiology 1996 Apr;199(1):85-90.

Adenocarcinoma of the lung--clinical features and survival. Dev D, et al. **Respir Med** 1996 Jul;90(6):333-7

Carcinoma of the gallbladder--a possible regional predisposition in the western Cape and northern Cape. Warren BL, et al. **S Afr J Surg** 1995 Dec;33(4):161-4

[Prevalence of cervical adenocarcinoma in Finland] Nieminen P, et al. **Duodecim** 1995;111(9):837-41 **(Fin)**

[Epidemiology and prognosis of gastric carcinomas at the province of Calvados. A 10-year study] Arsène D, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):797-803 (Eng. Abstr.) **(Fre)**

[Epidemiology of exocrine pancreatic cancer in the Principality of Asturias, 1973-1992] González Martínez J, et al. **Rev Esp Enferm Dig** 1995 Sep;87(9):653-7 (Eng. Abstr.) **(Spa)**

[Changes in the epidemiology of gastric cancer in the last 15 years] Herrero J, et al. **Rev Esp Enferm Dig** 1996 May; 88(5):323-7 (Eng. Abstr.) **(Spa)**

[7 cases of carcinoma of the distal choledochus] Gómez-Méndez TJ, et al. **Rev Invest Clin** 1995 Jul-Aug; 47(4):291-5 (11 ref.) (Eng. Abstr.) **(Spa)**

[Esophageal cancer on the increase. Is Barrett esophagus the cause?] Walther B, et al. **Lakartidningen** 1996 Apr 24; 93(17):1643-7 (Eng. Abstr.) **(Swe)**

ETHNOLOGY

Molecular changes of colorectal cancer in Singapore. Goh HS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):3-10 (93 ref.)

Bladder cancer in various population groups in the greater Durban area of KwaZulu-Natal, South Africa. Groeneveld AE, et al. **Br J Urol** 1996 Aug;78(2):205-8

Flat adenomas and flat adenocarcinomas of the colorectal mucosa in Japanese and Swedish patients. Comparative histologic study. Rubio CA, et al. **Dis Colon Rectum** 1995 Oct;38(10):1075-9

ETIOLOGY

Early esophageal adenocarcinoma arising in a short segment of Barrett's mucosa after total gastrectomy. Nishimaki T, et al. **Am J Gastroenterol** 1996 Sep;91(9):1856-7

Adenocarcinoma in an enterovesiculocutaneous fistula. Schoenfeld PS, et al. **Am J Gastroenterol** 1996 Mar; 91(3):608-9

Wood dust and sino-nasal cancer: pooled reanalysis of twelve case-control studies. Demers PA, et al. **Am J Ind Med** 1995 Aug;28(2):151-66

Transforming growth factor-alpha promotes mammary tumorigenesis through selective survival and growth of secretory epithelial cells. Smith GH, et al. **Am J Pathol** 1995 Oct;147(4):1081-96

Adenocarcinoma of the neo-esophagus after Collis gastroplasty. Maziak DE, et al. **Ann Thorac Surg** 1995 Dec; 60(6):1795-7

Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Chua KL, et al. **Cancer** 1996 Jan 1;77(1):121-7

Aberrant mammary tissue and nephrourinary malignancy. Urbani CE, et al. **Cancer Genet Cytogenet** 1996 Mar; 87(1):88-9

Lack of inhibitory effects of beta-carotene, vitamin C, vitamin E and selenium on development of ductular adenocarcinomas in exocrine pancreas of hamsters. Appel MJ, et al. **Cancer Lett** 1996 Jun 5;103(2):157-62

Hormone dependent and independent mammary tumor development form N-methyl-N-nitrosourea-treated rat mammary epithelial cell xenografts in the nude mouse: multiple pathways and H-ras activation. Hwang SI, et al. **Cancer Lett** 1996 Mar 19;101(1):123-34

Promotion of colon carcinogenesis through increasing lipid peroxidation induced in rats by a high cholesterol diet. Tseng TH, et al. **Cancer Lett** 1996 Feb 27;100(1-2):81-7

Dietary fat and fiber differentially alter intracellular second messengers during tumor development in rat colon. Jiang YH, et al. **Carcinogenesis** 1996 Jun;17(6):1227-33

Adenocarcinoma at ureterosigmoidostomy junction in a renal transplant recipient 15 years after conversion to ileal conduit. Weinstein T, et al. **Clin Nephrol** 1995 Aug; 44(2):125-7

Crohn's disease, calculi and cancer: a report of two cases. Wide JM, et al. **Clin Radiol** 1996 Sep;51(9):651-3

Barrett's esophagus: a model of human neoplastic progression. Neshat K, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:577-83 (58 ref.)

The biological significance of tobacco-specific N-nitrosamines: smoking and adenocarcinoma of the lung. Hoffmann D, et al. **Crit Rev Toxicol** 1996;26(2):199-211 (76 ref.)

Histology of gastric antrum in intestinal-type gastric adenocarcinoma from Asir Central Hospital, Saudi Arabia. Morad NA. **East Afr Med J** 1995 Sep;72(9):577-8

Lack of influence of diethylstilbestrol on induced pancreatic ductal carcinomas in Syrian hamsters. Baum A, et al. **Exp Toxicol Pathol** 1995 May;47(2-3):117-20

Flat adenomas and cancers [editorial; comment] Colton CG, et al. **Gastrointest Endosc** 1995 Aug;42(2):182-4. Comment on: Gastrointest Endosc 1995 Aug;42(2):114-22.

Ileostomy polyps, adenomas, and adenocarcinomas. Attanoos R, et al. **Gut** 1995 Dec;37(6):840-4

A case of adenocarcinoma arising within a urethral diverticulum diagnosed only by the surgical specimen. Nakamura Y, et al. **Gynecol Obstet Invest** 1995;40(1):69-70

"Microinvasive" adenocarcinoma of the cervix implanting in an episiotomy scar. Van den Broek NR, et al. **Gynecol Oncol** 1995 Nov;59(2):297-9

Malignant tumor developed in colon-esophagus. Altorjay A, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):797-9 (19 ref.)

Adenoma malignum of the uterine cervix associated with Peutz-Jeghers syndrome [letter] Fujiwaki R, et al. **Int J Gynaecol Obstet** 1996 May;53(2):171-2

Adenocarcinoma of the esophagus complicating Cornelia de Lange syndrome. DuVall GA, et al. **J Clin Gastroenterol** 1996 Mar;22(2):131-3

Relation of family history of cancer and environmental factors to the risk of colorectal cancer: a case-control study. Kotake K, et al. **Jpn J Clin Oncol** 1995 Oct; 25(5):195-202

A study of the association between squamous cell carcinoma and adenocarcinoma in the lung, and history of menstruation in Shanghai women, China. Liao ML, et al. **Lung Cancer** 1996 Mar;14 Suppl 1:S215-21

Summary of papers and research recommendations presented at the International Symposium on Lifestyle Factors and Human Lung Cancer, Guangzhou, China. Wu JM, et al. **Lung Cancer** 1996 Mar;14 Suppl 1:S223-34

Lifestyle, environmental pollution and lung cancer in cities of Liaoning in northeastern China. Xu ZY, et al. **Lung Cancer** 1996 Mar;14 Suppl 1:S149-60

Combined analysis of case-control studies of smoking and lung cancer in China. Yu SZ, et al. **Lung Cancer** 1996 Mar; 14 Suppl 1:S161-70

Helicobacter pylori and gastric neoplasia: evolving concepts. Bolin TD, et al. **Med J Aust** 1995 Sep 4;163(5):253-5 (18 ref.)

Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat. Belinsky SA, et al. **Radiat Res** 1996 Apr;145(4):449-56

Tumor induction and prophylaxis following different forms of intestinal urinary diversion in a rat model. Kälble T, et al. **Urol Res** 1995;23(6):365-70

Late malignancy in bowel segments exposed to urine without fecal stream. Shokeir AA, et al. **Urology** 1995 Nov; 46(5):657-61

[A case-control study on the risk factors of lung cancer in Guangdong] Wang SY, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1995 Oct; 16(5):295-8 (Eng. Abstr.) **(Chi)**

[Adenocarcinoma developing on an ileal loop after augmentation cystoplasty] Jung JL, et al. **Ann Urol (Paris)** 1996;30(2):69-71 (Eng. Abstr.) **(Fre)**

[Carcinomatous degeneration of a choledochal cyst (letter)] Nicolet J, et al. **Gastroenterol Clin Biol** 1996;20(3):324-6 **(Fre)**

[From Barrett esophagus to adenocarcinoma: can the dangers of natural history be overcome?] Robaszkiewicz M. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B89-97 (111 ref.) **(Fre)**

[Two complications of bullous emphysema. Apropos of a case] Guichenez P, et al. **Rev Pneumol Clin** 1995; 51(4):250-2 (14 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Pathways of chromosome alteration in human epithelial cancers. Dutrillaux B. **Adv Cancer Res** 1995;67:59-82 (80 ref.)

Familial risk of lung cancer among nonsmokers and their relatives. Schwartz AG, et al. **Am J Epidemiol** 1996 Sep 15;144(6):554-62

p53 Protein overexpression in colorectal tumors from patients with familial adenomatous polyposis: is it an early or late event? [see comments] Levi E, et al. **Am J Gastroenterol** 1996 Jan;91(1):11–4. Comment in: Am J Gastroenterol 1996 Jan;91(1):3–6.

Carcinoma arising in familial Barrett's esophagus. Poynton AR, et al. **Am J Gastroenterol** 1996 Sep;91(9):1855–6

Detection of K-ras point mutation at codon 12 in pure pancreatic juice collected 3 years and 6 months before the clinical diagnosis of pancreatic cancer. Wakabayashi T, et al. **Am J Gastroenterol** 1996 Sep;91(9):1848–51

Somatic mitochondrial mutation in gastric cancer. Burgart LJ, et al. **Am J Pathol** 1995 Oct;147(4):1105–11

Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas: association with degree of DNA aneuploidy. Giaretti W, et al. **Am J Pathol** 1996 Jul; 149(1):237–45

In situ mRNA hybridization technique for analysis of metastasis-related genes in human colon carcinoma cells. Kitadai Y, et al. **Am J Pathol** 1995 Nov;147(5):1238–47

Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Mazzucchelli L, et al. **Am J Pathol** 1996 Aug;149(2):501–9

The role of flow cytometric DNA analysis in determining prognosis of resectable ductal adenocarcinoma of the pancreas. Park CS, et al. **Am Surg** 1996 Jul;62(7):609–15; discussion 615–6

Molecular changes of colorectal cancer in Singapore. Goh HS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):3–10 (93 ref.)

p53 and prognosis in colorectal cancer. Smith DR, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):107–12 (97 ref.)

Colorectal adenoma progression and genetic change: is there a link? Jass JR. **Ann Med** 1995 Jun;27(3):301–6 (40 ref.)

Fetal and neoplastic expression of the neurotensin gene in the human colon. Evers BM, et al. **Ann Surg** 1996 May; 223(5):464–70; discussion 470–1

Isolation of differentially expressed genes in carcinoma of the esophagus. Graber MW, et al. **Ann Surg Oncol** 1996 Mar;3(2):192–7

Synchronous colon carcinomas: molecular-genetic evidence for multicentricity. Koness RJ, et al. **Ann Surg Oncol** 1996 Mar;3(2):136–43

Hypermethylation of the myogenic gene Myf-3 in human breast carcinomas. Hähnel R, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):2111–5

Ploidy as a prognostic feature in colonic adenocarcinoma. Takanishi DM Jr, et al. **Arch Surg** 1996 Jun;131(6):587–92

Basement membrane regulates gene expression in HEC1B(L) endometrial adenocarcinoma cells. Strunck E, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):346–50

Mucin expression in colon adenocarcinoma cell lines. Van Klinken BJ, et al. **Biochem Soc Trans** 1995 Nov;23(4):529S

Direct molecular analysis of archival tumor tissue for loss of heterozygosity. Johnson DR, et al. **Biotechniques** 1995 Aug;19(2):190–2

Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II) [see comments] Bates P, et al. **Br J Cancer** 1995 Nov;72(5):1189–93. Comment in: Br J Cancer 1995 Nov;72(5):1065–6.

P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer. Dahiya R, et al. **Br J Cancer** 1996 Jul;74(2):264–8

Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Slebos RJ, et al. **Br J Cancer** 1996 Jul;74(2):165–71

Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Smith DR, et al. **Br J Cancer** 1996 Jul;74(2):216–23

K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Hanada K, et al. **Cancer** 1996 Feb 1;77(3):452–8

Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. Kato M, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1729–35

High incidence of point mutation in K-ras codon 12 in carcinoma of the fallopian tube. Mizuuchi H, et al. **Cancer** 1995 Jul 1;76(1):86–90

Microsatellite instability in precancerous lesions and adenocarcinomas of the stomach. Semba S, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1620–7

Familial and nutritional risk factors for p53 overexpression in colorectal cancer. Freedman AN, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr;5(4):285–91

Genetic characteristics of prostate cancer. Huncharek M, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):681–7 (65 ref.)

p53 and K-ras in radon-associated lung adenocarcinoma. McDonald JW, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct-Nov; 4(7):791–3

Cytogenetic support for primary prostatic cancer in a patient presenting with a soft tissue mass in the leg. Molenaar WM, et al. **Cancer Genet Cytogenet** 1996 Feb;86(2):147–9

del(1)(q12) in adenocarcinomas of the prostate. Qi H, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):79–81

Chromosome abnormalities in primary endometrioid ovarian carcinoma. Yonescu R, et al. **Cancer Genet Cytogenet** 1996 Apr;87(2):167–71

Mxi1 tumor suppressor gene is not mutated in primary pancreatic adenocarcinoma. Bartsch D, et al. **Cancer Lett** 1996 Apr 19;102(1–2):73–6

Genomic methylation patterns of the Dunning R-3327 prostate adenocarcinoma system. Blount LV, et al. **Cancer Lett** 1996 Jan 2;98(2):213–8

Peritoneal exfoliative cytology and Ki-ras mutational analysis in patients with pancreatic adenocarcinoma. Rall CJ, et al. **Cancer Lett** 1995 Nov 6;97(2):203–11

Absence of p53 gene mutations in rat colon carcinomas induced by azoxymethane. Shivapurkar N, et al. **Cancer Lett** 1995 Sep 4;96(1):63–70

Loss of DNA mismatch repair in acquired resistance to cisplatin. Aebi S, et al. **Cancer Res** 1996 Jul 1; 56(13):3087–90

Loss of heterozygosity for chromosome 11 in adenocarcinoma of the stomach. Baffa R, et al. **Cancer Res** 1996 Jan 15;56(2):268–72

Ubiquitous somatic alterations at microsatellite alleles occur infrequently in Barrett's-associated esophageal adenocarcinoma. Gleeson CM, et al. **Cancer Res** 1996 Jan 15;56(2):259–63

p53 point mutation and survival in colorectal cancer patients. Goh HS, et al. **Cancer Res** 1995 Nov 15;55(22):5217–21

Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Hahn SA, et al. **Cancer Res** 1995 Oct 15; 55(20):4670–5

Microsatellite instability in colorectal adenocarcinoma cell lines that have full-length adenomatous polyposis coli protein. Heinen CD, et al. **Cancer Res** 1995 Nov 1; 55(21):4797–9

Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Huang L, et al. **Cancer Res** 1996 Mar 1;56(5):1137–41

Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Krajewska M, et al. **Cancer Res** 1996 May 15;56(10):2422–7

Allelic imbalance at NME1 in microdissected primary and metastatic human colorectal carcinomas is frequent but not associated with metastasis to lymph nodes or liver. Lamb RF, et al. **Cancer Res** 1996 Feb 15;56(4):916–20

Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Miozzo M, et al. **Cancer Res** 1996 May 15;56(10):2285–8

Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma. Schwerdtle RF, et al. **Cancer Res** 1996 Jul 1;56(13):2927–30

Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Solinas-Toldo S, et al. **Cancer Res** 1996 Aug 15; 56(16):3803–7

Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Tamura G, et al. **Cancer Res** 1996 Feb 1; 56(3):612–5

Human connexin 37 is polymorphic but not mutated in tumours. Krutovskikh V, et al. **Carcinogenesis** 1996 Aug; 17(8):1761–3

Association of cigarette smoking and CYP1A1 polymorphisms with adenocarcinoma of the lung by grades of differentiation. Nakachi K, et al. **Carcinogenesis** 1995 Sep;16(9):2209–13

K-ras gene mutation in sputum samples containing atypical cells and adenocarcinoma cells in the lung. Shiono S, et al. **Carcinogenesis** 1996 Aug;17(8):1683–6

Overexpression of transforming growth factor-alpha and epidermal growth factor receptor, but not epidermal growth factor, in exocrine pancreatic tumours in hamsters. Visser CJ, et al. **Carcinogenesis** 1996 Apr;17(4):779–85

p53 mutations in non-small cell lung carcinomas in Hong Kong. Lung ML, et al. **Chest** 1996 Mar;109(3):718–26

Cytogenetic heterogeneity and histologic tumor growth patterns in prostatic cancer. Alers JC, et al. **Cytometry** 1995 Sep 1;21(1):84–94

Assessing sequential oncogene amplification in human breast cancer. Janocko LE, et al. **Cytometry** 1995 Sep 1; 21(1):18–22

Frequent K-ras mutations in small bowel adenocarcinomas. Sutter T, et al. **Dig Dis Sci** 1996 Jan;41(1):115–8

Mutation of p53 tumor suppressor gene in flat neoplastic lesions of the colorectal mucosa. Rubio CA, et al. **Dis Colon Rectum** 1996 Feb;39(2):143–7

A human gene encoding diazepam-binding inhibitor/acyl-CoA-binding protein: transcription and hormonal regulation in the androgen-sensitive human prostatic adenocarcinoma cell line LNCaP. Swinnen JV, et al. **DNA Cell Biol** 1996 Mar;15(3):197–208

ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Karunagaran D, et al. **EMBO J** 1996 Jan 15;15(2):254–64

C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Elnatan J, et al. **Eur J Cancer** 1996 Mar;32A(3):491–7

Microsatellite instability in gastric carcinoma with special references to histopathology and cancer stages. Lin JT, et al. **Eur J Cancer** 1995 Oct;31A(11):1879–82

Prediction of recurrence in B-C stages of colorectal cancer by p53 nuclear overexpression in comparison with standard pathological features. Diez M, et al. **Eur J Surg Oncol** 1995 Dec;21(6):635–9

Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Bartsch D, et al. **Genes Chromosomes Cancer** 1995 Nov;14(3):189–95

Cytogenetic analysis of three primary Bellini duct carcinomas. Gregori-Romero MA, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):170–2

Allelic imbalance in gastric cancer: an affected site on chromosome arm 3p. Schneider BG, et al. **Genes Chromosomes Cancer** 1995 Aug;13(4):263–71

Sensitive detection of loss of heterozygosity in the TP53 gene in pancreatic adenocarcinoma by fluorescence-based single-strand conformation polymorphism analysis using blunt-end DNA fragments. Sugano K, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):157–64

Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages. Martinez JA, et al. **Gut** 1995 Nov; 37(5):712–20

Uterine cervix adenocarcinoma with both human papillomavirus type 18 and tumor suppressor gene p53 mutation from a woman having an intact hymen. Craigo J, et al. **Gynecol Oncol** 1995 Dec;59(3):423–6

Growth suppression of a cervical cancer cell line (TMCC-1) by the human wild-type p53 gene. Zheng PS, et al. **Gynecol Oncol** 1996 Feb;60(2):245–50

DNA ploidy as a prognostic factor for patients with an adenocarcinoma in Barrett's esophagus. Menke-Pluymers MB, et al. **Hepatogastroenterology** 1995 Nov-Dec; 42(6):786–8

Interphase in situ hybridization to disaggregated and intact tissue specimens of prostatic adenocarcinomas. Alers JC, et al. **Histochem Cell Biol** 1995 Dec;104(6):479–86

Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. Audrézet MP, et al. **Hum Mutat** 1996; 7(2):109–13

Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Ittmann MM, et al. **Hum Pathol** 1996 Jan;27(1):28–34

von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. Zhuang Z, et al. **Hum Pathol** 1996 Feb; 27(2):152–6

p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Benhattar J, et al. **Int J Cancer** 1996 Jun 21;69(3):190–2

Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. Esteve A, et al. **Int J Cancer** 1996 May 3; 66(3):301–4

Numerical aberration and point mutation of p53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR-SSCP. Gomyo Y, et al. **Int J Cancer** 1996 May 29;66(5):594–9

Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Milde-Langosch K, et al. **Int J Cancer** 1995 Nov 27;63(5):639–45

Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Montesano R, et al. **Int J Cancer** 1996 Jun 21;69(3):225–35 (120 ref.)

Expression of fibroblast growth factor-1 (FGF-1), FGF-2 and FGF receptor-1 in a human salivary-gland adenocarcinoma cell line: evidence of growth. Myoken Y, et al. **Int J Cancer** 1996 Mar 1;65(5):650–7

Frequent occurrence of c-Ki-ras gene mutations in well differentiated endometrial adenocarcinoma showing infiltrative local growth with fibrosing stromal response. Tsuda H, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):255–9

K-ras mutation and pancreatic adenocarcinoma. Caldas C, et al. **Int J Pancreatol** 1995 Aug;18(1):1–6 (66 ref.)

Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Lei S, et al. **Int J Pancreatol** 1995 Feb;17(1):15–21

p53 overexpression in flat serrated adenomas and flat tubular adenomas of the colorectal mucosa. Rubio CA, et al. **J Cancer Res Clin Oncol** 1995;121(9–10):571–6

The prognostic significance of DNA ploidy in adenocarcinomas of the esophagogastric junction. Sarbia M, et al. **J Cancer Res Clin Oncol** 1996;122(3):186–88

High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs. Tsuchiya E, et al. **J Cancer Res Clin Oncol** 1995;121(9–10):577–81

Coexistence of choriocarcinoma and adenocarcinoma in the rectum: molecular aspects. Tokisue M, et al. **J Gastroenterol** 1996 Jun;31(3):431–6

Establishment of new interferon-gamma-resistant mutant cells with dominant phenotypes. Ohta T, et al. **J Interferon Cytokine Res** 1995 Feb;15(2):153–60

Identification of CD44 splice variant in Korean colorectal cancers and cell lines. Suh SI, et al. **J Korean Med Sci** 1995 Jun;10(3):169–75

Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. Bartsch D, et al. **J Natl Cancer Inst** 1996 May 15; 88(10):680–2

Correlation of numerical chromosome 11 and 17 imbalance with metastasis of primary breast cancer to lymph nodes. Herrington CS, et al. **J Pathol** 1995 Aug;176(4):353–9

Familial giant hyperplastic polyposis predisposing to colorectal cancer: a new hereditary bowel cancer syndrome. Jeevaratnam P, et al. **J Pathol** 1996 May; 179(1):20–5

The sequential accumulation of genetic alterations

characteristic of the colorectal adenoma–carcinoma sequence does not occur between gastric adenoma and adenocarcinoma [letter; comment] Tahara E, et al. **J Pathol** 1996 Apr;178(4):475–6. Comment on: J Pathol 1995 Jul;176(3):249–58.

Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines. Pfeffer U, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):99–105 (37 ref.)

Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors. Kandioler D, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):827–31; discussion 832

Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. Schneider PM, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):323–31; discussion 331–3

p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. Prendergast NJ, et al. **J Urol** 1996 May;155(5):1685–92

Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma. Thigpen AE, et al. **J Urol** 1996 Mar;155(3):975–81

Role of point mutation of the K-ras gene in tumorigenesis of B6C3F1 mouse lung lesions induced by urethane. Kawano R, et al. **Jpn J Cancer Res** 1995 Sep;86(9):802–10

Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers. Shimizu T, et al. **Jpn J Cancer Res** 1996 Mar;87(3):275–8

Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis. Suwa H, et al. **Jpn J Cancer Res** 1996 Jun; 87(6):641–9

Microsatellite instability and other molecular abnormalities in human prostate cancer. Suzuki H, et al. **Jpn J Cancer Res** 1995 Oct;86(10):956–61

p16/CDKN2 gene and p53 gene alterations in Japanese non-smoking female lung adenocarcinoma. Takeshima Y, et al. **Jpn J Cancer Res** 1996 Feb;87(2):134–40

T-cell receptor gene structures of HLA-A26-restricted cytotoxic T lymphocyte lines against human autologous pancreatic adenocarcinoma. Ueda D, et al. **Jpn J Cancer Res** 1995 Jul;86(7):691–7

Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Musiani P, et al. **Lab Invest** 1996 Jan; 74(1):146–57

Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. Vermeulen PB, et al. **Microvasc Res** 1996 Mar;51(2):164–74

DNA aneuploidy in morphologically normal colons from patients with colon cancer. Fleischhacker M, et al. **Mod Pathol** 1995 May;8(4):360–5

K-ras-2 and p53 genotyping of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. Wu TT, et al. **Mod Pathol** 1996 Mar;9(3):199–204

High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. Galiana C, et al. **Mol Carcinog** 1995 Dec;14(4):286–93

Loss of heterozygosity on chromosomes 1, 11, 12, and 14 in hybrid mouse lung adenocarcinomas. Herzog CR, et al. **Mol Carcinog** 1996 Jun;16(2):83–90

Frequent mutations of Ki-ras but no mutations of Ha-ras and p53 in lung lesions induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Kitada H, et al. **Mol Carcinog** 1996 Apr;15(4):276–83

Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents. Yen L, et al. **Mutat Res** 1995 Nov;337(3):179–89

Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group [letter; comment] Ciotti P, et al. **N Engl J Med** 1996 Feb 15;334(7):469–70; discussion 471–2 . Comment on: N Engl J Med 1995 Oct 12;333(15):970–4. Comment on: N Engl J Med 1995 Oct 12;333(15):975–7.

Gastric carcinoma [letter; comment] Kullmann F, et al. **N Engl J Med** 1995 Nov 23;333(21):1427–8. Comment on: N Engl J Med 1995 Jul 6;333(1):32–41.

Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Boland CR, et al. **Nat Med** 1995 Sep; 1(9):902–9

Genotypic analysis of multiple loci in somatic cells by whole genome amplification. Barrett MT, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3488–92

Analysis of the retinoblastoma gene in human endometrial carcinoma. Yaginuma Y, et al. **Obstet Gynecol** 1996 May; 87(5 Pt 1):755–9

Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Barrett MT, et al. **Oncogene** 1996 May 2;12(9):1873–8

Expression of Mts1, a metastasis-associated gene, increases motility but not invasion of a nonmetastatic mouse mammary adenocarcinoma cell line. Ford HL, et al. **Oncogene** 1995 Nov 16;11(10):2067–75

Widespread microsatellite instability occurs infrequently in adenocarcinoma of the gastric cardia. Gleeson CM, et al. **Oncogene** 1996 Apr 18;12(8):1653–62

Allelic loss of distal chromosome 4 in mouse lung tumors localize a putative tumor suppressor gene to a region homologous with human chromosome 1p36. Herzog CR, et al. **Oncogene** 1995 Nov 2;11(9):1811–5

NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Krane IM, et al. **Oncogene** 1996 Apr 18;12(8):1781–8

Characterization of the APC gene in sporadic gastric adenocarcinomas. Powell SM, et al. **Oncogene** 1996 May 2;12(9):1953–9

Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Tamura T, et al. **Oncogene** 1995 Nov 16;11(10):1939–46

An improved method for semiquantification of gene amplification from archival material. Underwood MA, et al. **PCR Methods Appl** 1994 Dec;4(3):178–84

Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Kutchera W, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4816–20

Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11. Sanchez Y, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2551–6

Point mutations in the Ki-ras2 gene of codon 12 in the Dunning R-3327 Prostatic Adenocarcinoma system. Blount LV, et al. **Prostate** 1996 Jan;28(1):44–50

Selection toward diploid cells in prostatic carcinoma derived cell cultures. Ketter R, et al. **Prostate** 1996 Jun;28(6):364–71

Retinoblastoma gene mutations in primary human prostate cancer. Kubota Y, et al. **Prostate** 1995 Dec;27(6):314–20

Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Suzuki H, et al. **Prostate** 1996 May;28(5):318–24

Towards molecular oncology. Brentani RR, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul-Aug; 50(4):240–2

Prognostic significance of p53 expression, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (stages IB and II). Baretton GB, et al. **Scand J Gastroenterol** 1996 May;31(5):481–9

Simultaneous early gastric cancer in identical twins: report of a case. Kinugasa S, et al. **Surg Today** 1996;26(3):189–91

Ras oncogene activation in benign and malignant colorectal tumours. Spandidos DA, et al. **Tumori** 1995 May-Jun;81(3 Suppl):7–11

Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer. Nguyen PL, et al. **Tumour Biol** 1996;17(3):176–92

Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis. Bratt O, et al. **Urology** 1996 Feb;47(2):218–24

Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Meyer-Siegler K, et al. **Urology** 1996 Sep;48(3):448–52

Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization. Qian J, et al. **Urology** 1995 Dec;46(6):837–42

The relationship between aneuploidy and p53 overexpression during genesis of colorectal adenocarcinoma [letter; comment] Biesterfeld S, et al. **Virchows Arch** 1995; 427(4):459. Comment on: Virchows Arch 1994;424(4):343–7.

Gastric adenoma-carcinoma sequence with special reference to p53 and Ki-ras gene alterations. Sakurai S, et al. **Virchows Arch** 1995;427(2):119–24

[Immunohistochemical analysis of nm23 gene product/nucleoside-diphosphate kinase expression in human lung carcinoma] Jiang Y, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Aug; 18(4):209–11, 254 (Eng. Abstr.) **(Chi)**

[Expression of oncogene and anti-oncogene in mouse lung cancer induced by coal-burning smoke] Lin C, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov;17(6):432–4 (Eng. Abstr.) **(Chi)**

[The significance of p53 gene mutations and expressions in human colorectal tumors] Qian H, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep;17(5):332–5 (Eng. Abstr.) **(Chi)**

[A study on DNA content and cell cycle phase analysis in endometrial carcinoma] Xue F, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Apr;31(4):216–9 (Eng. Abstr.) **(Chi)**

[Reversal of malignant phenotype of cells of human pancreatic adenocarcinoma cell line by recombinant retroviral vector expressing antisense c-myc] Li H, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Feb;25(1):13–6 (Eng. Abstr.) **(Chi)**

[Reversal of malignant cell phenotype of human pancreatic adenocarcinoma cell line by recombinant retroviral vector expressing antisense Ki-ras] Li H, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Oct;24(5):288–91 (Eng. Abstr.) **(Chi)**

[Genetics of colorectal cancers (editorial)] Pocard M, et al. **Ann Chir** 1996;50(3):211–6 (19 ref.) **(Fre)**

[Profile of p53 mutations and abnormal expression of P53 protein in 2 forms of esophageal cancer] Muzeau F, et al. **Gastroenterol Clin Biol** 1996;20(5):430–7 (Eng. Abstr.) **(Fre)**

[Comparative study of mRNA expression of E-cadherin and collagenase IV in early and advanced cancers] Anzai H, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:143–7 (Eng. Abstr.) **(Jpn)**

[Clinical implication of p53 analysis on DNA-damaging therapies of human gastric and rectal cancers] Fujiwara T, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1081–3 **(Jpn)**

[Genetic alterations in stomach cancer] Tahara E, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):252–6 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of MIB-1/KI-67 and bcl-2 in gastric carcinoma. Relationship with clinico-pathological factors] Sundblad AS, et al. **Acta Gastroenterol Latinoam** 1995;25(2):67–72 (Eng. Abstr.) **(Spa)**

[A comparative study on the prognostic value of the nuclear expression of protein p53 vis-à-vis histopathology in colorectal cancer] Díez M, et al. **An Med Interna** 1996 May;13(5):222–6 (Eng. Abstr.) **(Spa)**

[Significance of ploidy in prostatic cancer, quantified by a prospectively applicable procedure] Valle Gerhold J, et al. **Arch Esp Urol** 1996 Mar;49(2):139–45 (Eng. Abstr.) **(Spa)**

[Molecular changes in adenocarcinoma of the small intestine associated with Peutz-Jeghers syndrome] Hidalgo L, et al. **Rev Esp Enferm Dig** 1996 Feb;88(2):137–40 (Eng. Abstr.) **(Spa)**

HISTORY

K-RAS mutation in the tumour of Ferrante I of Aragon, King of Naples [letter] Marchetti A, et al. **Lancet** 1996 May 4;347(9010):1272

IMMUNOLOGY

Nodal immune reactivity in FIGO (International Federation of Gyn-Ob) Stage I endometrial carcinoma: relationship with myometrial invasion. Garzetti GG, et al. **Acta Obstet Gynecol Scand** 1995 Oct;74(9):723–8

Anti-alpha1(IV) collagen autoantibodies associated with lung adenocarcinoma presenting as the Goodpasture syndrome. Kalluri R, et al. **Ann Intern Med** 1996 Apr 1;124(7):651–3

Neutrophil and monocyte phagocytic functions in patients with colorectal adenocarcinoma during fluorouracil therapy. Lukač J, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2805–9

Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma. Lumsden AJ, et al. **Anticancer Res** 1996 May-Jun; 16(3A):1145–54

Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases. Kuwana M, et al. **Arthritis Rheum** 1996 Apr;39(4):686–91

Immunohistochemical detection of p53 and the recurrence of rectal adenocarcinoma. Subramaniam P, et al. **Aust N Z J Surg** 1995 Oct;65(10):740–2

Impaired tumor phenotypes in class II major histocompatibility complex antigen-inducible cells originated from human lung adenocarcinoma. Kawamoto S, et al. **Biochem Biophys Res Commun** 1995 Oct 4; 215(1):280–5

Inhibition of tumor cell growth by a human B-cell line. Katano M, et al. **Biotherapy** 1994;8(1):1–6

Generation of human monoclonal antibodies recognising membranous antigens of the lung adenocarcinoma cell line A549 using an AMeX immunohistostaining method. Yoshinari K, et al. **Br J Cancer** 1996 Aug;74(3):359–67

Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity? Locker GJ, et al. **Breast Cancer Res Treat** 1995 Jun;34(3):213–9

A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Sonoda K, et al. **Cancer** 1996 Apr 15;77(8):1501–9

Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". Gagandeep S, et al. **Cancer Gene Ther** 1996 Mar-Apr; 3(2):83–8

Splenectomy before tumor inoculation prolongs the survival time of cachectic mice. Soda K, et al. **Cancer Immunol Immunother** 1995 Oct;41(4):203–9

Alterations in lymphocyte subsets in blood may predict resectability in carcinoma of cardia or oesophagus. Bentdal OH, et al. **Cancer Lett** 1996 Feb 27;100(1-2):133–8

Amount of interleukin 12 available at the tumor site is critical for tumor regression. Colombo MP, et al. **Cancer Res** 1996 Jun 1;56(11):2531–4

Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Vagliani M, et al. **Cancer Res** 1996 Feb 1;56(3):467–70

Immunohistochemical study of HNK-1 (Leu-7) antigen in prostate cancer and its clinical significance. Liu X, et al. **Chin Med J (Engl)** 1995 Jul;108(7):516–21

Expression of variant CD44-messenger RNA in colorectal adenocarcinomas and adenomatous polyps in humans. Imazeki F, et al. **Gastroenterology** 1996 Feb;110(2):362–8

Association of gastric adenocarcinoma with the HLA class II gene DQB10301 [see comments] Lee JE, et al. **Gastroenterology** 1996 Aug;111(2):426–32. Comment in: Gastroenterology 1996 Aug;111(2):523–6.

Lymphocyte subset infiltration patterns and HLA antigen

status in colorectal carcinomas and adenomas. Jackson PA, et al. **Gut** 1996 Jan;38(1):85–9

Natural killer cell activity in patients with invasive cervical carcinoma: importance of a longitudinal evaluation in follow-up. Garzetti GG, et al. **Gynecol Obstet Invest** 1995; 40(2):133–8

Comparison of the pattern of expression of Leu-M1 antigen in adenocarcinomas, neutrophils and Hodgkin's disease by immunoelectron microscopy. Valente AM, et al. **Histochem Cell Biol** 1995 Mar;103(3):181–6

Molecular cloning of yeast cytochrome c-like polypeptide expressed in human lung carcinoma: an antigen recognizable by lung cancer-specific human monoclonal antibody. Kawamoto S, et al. **In Vitro Cell Dev Biol Anim** 1995 Oct;31(9):724–9

Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen. Kishimoto T, et al. **Int J Cancer** 1996 Aug 22;69(4):290–4

Autoantibodies against insulin and beta-islet cells in pancreatic adenocarcinoma: a possible explanation for diabetes mellitus. Syrigos KN, et al. **Int J Cancer** 1996 May 29;66(5):624–6

Simple mucin-type carbohydrates in normal and malignant human endometrium. Ravn V, et al. **Int J Gynecol Pathol** 1995 Apr;14(2):158–66

Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA. Pezzilli R, et al. **Ital J Gastroenterol** 1995 Jul-Aug;27(6):296–9

Novel colorectal adenocarcinoma-associated 40- and 47-kDa protein antigens recognized by anti-60-kDa heat shock protein antibody. Otaka M, et al. **J Clin Gastroenterol** 1995 Oct;21(3):224–9

Natural killing activity is associated with progression of gastric cancer. Ono K, et al. **J Clin Immunol** 1995 Jul; 15(4):210–4

Autologous human B-cell immune response to pulmonary adenocarcinomatous polymorphic epithelial mucin. Xiang J, et al. **J Clin Immunol** 1995 Mar;15(2):74–9

Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. Roselli M, et al. **J Clin Oncol** 1996 Jul;14(7):2031–42

Lymphocyte infiltration in oesophageal carcinoma: lack of correlation with MHC antigens, ICAM-1, and tumour stage and grade. Rockett JC, et al. **J Clin Pathol** 1996 Mar; 49(3):264–7

The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. Dinapoli MR, et al. **J Exp Med** 1996 Apr 1;183(4):1323–9

Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. Berman RM, et al. **J Immunol** 1996 Jul 1;157(1):231–8

Role of host antigen receptor-bearing and antigen receptor-negative cells in immune response to rat adenocarcinoma 13762. Frey AB. **J Immunol** 1996 May 15;156(10):3841–9

Importance of different CD44v6 expression in human gastric intestinal and diffuse type cancers for metastatic lymphogenic spreading. Dämmrich J, et al. **J Mol Med** 1995 Aug;73(8):395–401

T-cell receptor gene structures of HLA-A26-restricted cytotoxic T lymphocyte lines against human autologous pancreatic adenocarcinoma. Ueda D, et al. **Jpn J Cancer Res** 1995 Jul;86(7):691–7

Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Musiani P, et al. **Lab Invest** 1996 Jan; 74(1):146–57

Expression of Epstein-Barr nuclear antigen 2 in kidney tubule cells induce tumors in transgenic mice. Törnell J, et al. **Oncogene** 1996 Apr 4;12(7):1521–8

Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisole. Bjørge L, et al. **Scand J Immunol** 1995 Nov;42(5):512–6

Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins [letter] Brasoveanu LI, et al. **Scand J Immunol** 1996 Mar; 43(3):351–3

[The expression and significance of proliferating cell nuclear antigen/cyclin in cholangiocarcinoma and gallbladder carcinoma] Yang Z, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul;33(7):437–8 (Eng. Abstr.) **(Chi)**

[Effects of Shenmai injection on immune function in stomach cancer patients after chemotherapy] Lin SY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):451–3 (Eng. Abstr.) **(Chi)**

[Cloning and sequencing of VH and VL genes of an anti-human lung adenocarcinoma monoclonal antibody] Wang Y, et al. **I Chuan Hsueh Pao** 1996;23(2):91–5 (Eng. Abstr.) **(Chi)**

[PSA and prostatic adenocarcinoma. Experience with 805 patients] Grasso-Leanza F, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):161–5 (Eng. Abstr.) **(Ita)**

[A case of urachal carcinoma associated with elevated levels of CA19-9] Koyama I, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct;86(10):1587–90 (Eng. Abstr.) **(Jpn)**

[The proliferative ability of stage I lung adenocarcinoma and the correlation between host immunity and prognosis] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):670–2 **(Jpn)**

[Changes in the immune status of patients with rectal cancer while using specific immunotherapy] Zagadarchuk NL, et al. **Klin Khir** 1995;(9-10):23–6 **(Rus)**

[Analysis of proliferating cell nuclear antigen (PCNA) expression in 24 cases of primary non-small cell pulmonary carcinomas and correlation with survival] Castellano VM, et al. **Arch Bronconeumol** 1996 Mar;32(3):127–31 (Eng. Abstr.) **(Spa)**

METABOLISM

Glucuronidation by human colorectal adenocarcinoma cells as a mechanism of resistance to mycophenolic acid. Franklin TJ, et al. **Adv Enzyme Regul** 1995;35:91–100

Parathyroid hormone-related protein expression in human gastric adenocarcinomas not associated with hypercalcemia. Abdeen O, et al. **Am J Gastroenterol** 1995 Oct;90(10):1864–7

E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study. Swami S, et al. **Am J Gastroenterol** 1995 Oct;90(10):1808–13

p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. DiGiuseppe JA, et al. **Am J Pathol** 1995 Oct;147(4):884–8

Highly metastatic 13762NF rat mammary adenocarcinoma cell clones stimulate bone marrow by secretion of granulocyte-macrophage colony-stimulating factor/interleukin-3 activity. McGary CT, et al. **Am J Pathol** 1995 Dec;147(6):1668–81

The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Webb A, et al. **Ann Oncol** 1995 Jul;6(6):581–7

Uptake and distribution of the boron-containing ether lipid B-Et-11-OMe in tumor-bearing mice. Lemmen P, et al. **Anticancer Drugs** 1995 Dec;6(6):744–8

Nitrobenzylthioinosine-binding protein overexpression in human breast, liver, stomach and colorectal tumour tissues. Goh LB, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2575–9

Up-regulation of heat shock protein 70 in adenocarcinomas of the lung in smokers. Volm M, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2607–9

Epidermal Langerhans cells from mice bearing a granulocyte macrophage-colony stimulating factor-producing mammary tumor display impaired accessory functions. Xie Y, et al. **Anticancer Res** 1996 Jan-Feb;16(1):9–16

Interleukin-6 (IL-6) production in carcinoma of the cervix. Takano H, et al. **Arch Gynecol Obstet** 1996;258(1):25–33

Retinoic acid enhances expression of bone morphogenetic protein-2 in human adenocarcinoma cell line (HSG-S8). Hatakeyama S, et al. **Biochem Mol Biol Int** 1996 May; 38(6):1235–43

Proliferative signal transduction by epidermal growth factor (EGF) in the human salivary gland adenocarcinoma (HSG) cell line. Sato N, et al. **Biochem Mol Biol Int** 1996 Mar; 38(3):597–606

Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues. Canada AT, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):87–90

Calcitriol and lexicalcitol (KH1060) inhibit the growth of human breast adenocarcinoma cells by enhancing transforming growth factor-beta production. Mercier T, et al. **Biochem Pharmacol** 1996 Aug 9;52(3):505–10

Enzymology of mitomycin C metabolic activation in tumour tissue. Characterization of a novel mitochondrial reductase. Spanswick VJ, et al. **Biochem Pharmacol** 1996 Jun 28; 51(12):1623–30

Metabolism of L-arginine through polyamine and nitric oxide synthase pathways in proliferative or differentiated human colon carcinoma cells. Blachier F, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):255–62

The H19 gene is expressed within both epithelial and stromal components of human invasive adenocarcinomas. Dugimont T, et al. **Biol Cell** 1995;85(2-3):117–24

Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin. Chiang HS, et al. **Br J Cancer** 1996 Apr;73(7):902–8

Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Robson H, et al. **Br J Cancer** 1996 Sep;74(5):753–8

A case of ovarian carcinoma with production of granulocyte colony-stimulating factor. Sudo S, et al. **Br J Haematol** 1996 Jan;92(1):137–9

Difference in expression of CD44 splice variants between proximal and distal adenocarcinoma of the large bowel. Mulder JW, et al. **Br J Surg** 1995 Nov;82(11):1468–70

Expression and localization of inhibin/activin subunits and activin receptors in MCF-7 cells, a human breast cancer cell line. Ying SY, et al. **Breast Cancer Res Treat** 1996; 37(2):151–60

Interferon-beta can induce progesterone receptors in human endometrial adenocarcinoma. Codegoni AM, et al. **Cancer** 1996 Aug 1;78(3):448–53

Homeostatic derangement in the CBA rodent host during the growth of the CaNT tumor. De Villiers N, et al. **Cancer Biochem Biophys** 1993 Sep;13(4):255–64

Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Bjørge L, et al. **Cancer Immunol Immunother** 1996 Mar;42(3):185–92

Genomic methylation patterns of the Dunning R-3327 prostate adenocarcinoma system. Blount LV, et al. **Cancer Lett** 1996 Jan 2;98(2):213–8

Induction of the transcription factor AP-1 in cultured human colon adenocarcinoma cells following exposure to bile acids. Hirano F, et al. **Carcinogenesis** 1996 Mar;17(3):427–33

Human endometrial carcinoma cells release factors which inhibit the growth of normal epithelial cells in culture. Albright CD, et al. **Cell Biol Toxicol** 1995 Oct;11(5):251–61

Secretion rates and levels of vascular endothelial growth factor in clone A or HCT-8 human colon tumour cells as a function of oxygen concentration. Leith JT, et al. **Cell Prolif** 1995 Aug;28(8):415–30

Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas. Lau HK, et al. **Clin Exp Metastasis** 1995 Nov;13(6):492–8

Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells. Merlin JL, et al. **Cytometry** 1995 Aug 1;20(4):315–23

Raf-1 kinase, epidermal growth factor receptors, and mutant Ras proteins in colonic carcinomas. Eggstein S, et al. **Dig Dis Sci** 1996 Jun;41(6):1069–75

Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by quantitative autoradiography. Baghdiguian S, et al. **Eur J Cancer** 1996 Mar;32A(3):525–32

The effect of different dose levels of degradable starch microspheres (Spherex) on the distribution of a cytotoxic drug after regional administration to tumour-bearing rats. Teder H, et al. **Eur J Cancer** 1995 Sep;31A(10):1701–5

Expression of p53 protein as a prognostic factor in patients with gastric cancer. Victorzon M, et al. **Eur J Cancer** 1996 Feb;32A(2):215–20

Prognostic implications of Sialosyl-Tn antigen expression in sinonasal intestinal-type adenocarcinoma. Franchi A, et al. **Eur J Cancer B Oral Oncol** 1996 Mar;32B(2):123–7

Abnormal A-type lamin organization in a human lung carcinoma cell line. Machiels BM, et al. **Eur J Cell Biol** 1995 Aug;67(4):328–35

Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients. Garzetti GG, et al. **Gynecol Oncol** 1996 Apr;61(1):16–21

Platelet-activating factor enhances production of insulin-like growth factor binding proteins in a human adenocarcinoma cell line (HEC-1A) Giannini S, et al. **Gynecol Oncol** 1996 Jun;61(3):333–40

Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Nyholm HC, et al. **Gynecol Oncol** 1995 Dec;59(3):347–51

Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Barboule N, et al. **Int J Cancer** 1995 Nov 27; 63(5):611–5

Implication of the alpha v beta 3 integrin in the adhesion of the ovarian-adenocarcinoma cell line IGROV1. Carreiras F, et al. **Int J Cancer** 1995 Nov 15;63(4):530–6

Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Guerra FK, et al. **Int J Cancer** 1996 Mar 15;65(6):812–20

Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Naef M, et al. **Int J Cancer** 1996 May 3;66(3):315–21

Epidermal growth factor expression in human colon and colon carcinomas: anti-sense epidermal growth factor receptor RNA down-regulates the proliferation of human colon cancer cells. Rajagopal S, et al. **Int J Cancer** 1995 Sep 15;62(6):661–7

Effects of cytokines combined with high-dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule-1 in human ovarian cancers. Santin AD, et al. **Int J Cancer** 1996 Mar 1;65(5):688–94

Sialyl Tn antigen is an independent predictor of outcome in patients with gastric cancer. Victorzon M, et al. **Int J Cancer** 1996 Jan 26;65(3):295–300

Endometrial adenocarcinoma of endometrioid subtype with squamous differentiation: an immunohistochemical study of MIB-1 (ki-67 paraffin), cathepsin D, and C-erbB-2 protein (p185). Nielsen AL, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):230–4

Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia. Merlin JL, et al. **Int J Hyperthermia** 1995 Nov-Dec;11(6):855–65

bcl-2 expression on prostate cancer and its relationship to cell cycle and prognosis. Matsushima H, et al. **Int J Urol** 1996 Mar;3(2):113–7

Expression of the alpha 6, beta 1 and beta 4 integrin subunits,

basement membrane organization and proteolytic capacities in low and high metastatic human colon carcinoma xenografts. Daémi N, et al. **Invasion Metastasis** 1995; 15(3–4):103–15

Effect of serum in the growth medium on mucin synthesis by colon cancer cell line. Niv Y, et al. **Isr J Med Sci** 1995 Oct;31(10):600–3

An alternative splicing product of the lamin A/C gene lacks exon 10. Machiels BM, et al. **J Biol Chem** 1996 Apr 19; 271(16):9249–53

Alpha-fetoprotein production by a hepatoid adenocarcinoma of the uterus. Yamamoto R, et al. **J Clin Pathol** 1996 May; 49(5):420–2

Alpha-fetoprotein-producing gastric carcinoma: biological properties of a cultured cell line. Sekiguchi M, et al. **J Gastroenterol** 1995 Oct;30(5):589–98

Immunolocalization of pS2, a putative growth factor, in pancreatic carcinoma. Collier JD, et al. **J Gastroenterol Hepatol** 1995 Jul–Aug;10(4):396–400

Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues. Hong SI, et al. **J Korean Med Sci** 1996 Feb;11(1):33–7

Characterization of SA-11 rotavirus receptorial structures on human colon carcinoma cell line HT-29. Superti F, et al. **J Med Virol** 1995 Dec;47(4):421–8

The transport of lysine across monolayers of human cultured intestinal cells (Caco-2) depends on Na(+)-dependent and Na(+)-independent mechanisms on different plasma membrane domains. Ferruzza S, et al. **J Nutr** 1995 Oct; 125(10):2577–85

The Caco-2 cell culture system can be used as a model to study food iron availability. Garcia MN, et al. **J Nutr** 1996 Jan;126(1):251–8

Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma. Chan WK, et al. **J Pathol** 1995 Nov;177(3):241–6

p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. Doglioni C, et al. **J Pathol** 1996 Jul;179(3):248–53

Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. Nakopoulou LL, et al. **J Pathol** 1996 May;179(1):31–8

Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma. Ueki T, et al. **J Pathol** 1995 Dec;177(4):353–61

Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma. Vaidya P, et al. **J Pathol** 1996 Feb;178(2):140–5

A rapid assay for measuring the metabolism of [3H]-retinoic acid in cell cultures. Garrabrant TA, et al. **J Pharmacol Toxicol Methods** 1995 Dec;34(4):219–23

Evidence for a role of glucuronosyltransferase in the regulation of androgen action in the human prostatic cancer cell line LNCaP. Guillemette C, et al. **J Steroid Biochem Mol Biol** 1996 Feb;57(3–4):225–31

Immunohistochemical analysis of the poorly differentiated stomach adenocarcinoma with medullary growth pattern. Umeda T, et al. **J Surg Oncol** 1996 May;62(1):34–9

Adenocarcinoma of duodenum and ampulla of Vater: clinicopathology study and expression of p53, c-neu, TGF-alpha, CEA, and EMA. Zhu L, et al. **J Surg Oncol** 1996 Feb;61(2):100–5

Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. Faas FH, et al. **J Urol** 1996 Jul;156(1):243–8

Inhibition of cell growth by transforming growth factor beta 1 is associated with p53-independent induction of p21 in gastric carcinoma cells. Akagi M, et al. **Jpn J Cancer Res** 1996 Apr;87(4):377–84

Regulation of cholesterol synthesis in four colonic adenocarcinoma cell lines. Cerda SR, et al. **Lipids** 1995 Dec;30(12):1083–92

Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Washington K, et al. **Liver** 1996 Apr; 16(2):99–104

Chromogranin gene expressions in colorectal adenocarcinomas. Pagani A, et al. **Mod Pathol** 1995 Aug; 8(6):626–32

Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. Ho YS, et al. **Mol Carcinog** 1996 May;16(1):20–31

Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Schuetz EG, et al. **Mol Pharmacol** 1996 Feb;49(2):311–8

Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Smith RC, et al. **Nat Med** 1995 Oct;1(10):1040–5

Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells. Dejardin E, et al. **Oncogene** 1995 Nov 2;11(9):1835–41

Expression of c-fms proto-oncogene product by ovarian cancer cell lines with effects of macrophage colony-stimulating factor on proliferation. Suzuki M, et al. **Oncology** 1996 Mar-Apr;53(2):99–103

Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells. Bamberger AM, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11; 93(12):6169–74

Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Clinton GM, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):316–20

Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Van der Kwast TH, et al. **Prostate** 1996 Apr;28(4):227–31

The pO2 in a murine tumor after irradiation: an in vivo electron paramagnetic resonance oximetry study. O'Hara JA, et al. **Radiat Res** 1995 Nov;144(2):222–9

Brief communication, P53 accumulation in N-methyl-N-nitrosourea-induced rat mammary tumors. Crist KA, et al. **Toxicol Pathol** 1996 May-Jun;24(3):370–5

[Detection of CgA mRNA in neuroendocrine cells in gastric carcinoma by in situ hybridization] Wang L, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Oct;24(5):303–5 (Eng. Abstr.) **(Chi)**

[Lectins in pulmonary adenocarcinomas] Mířejovský P, et al. **Cesk Patol** 1995 Dec;31(4):107–10 (Eng. Abstr.) **(Cze)**

[Immunohistochemical study of transforming growth factor-beta and central fibrosis in T1 adenocarcinoma of the lung] Asakura S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1924–8 (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Clinicopathologic characteristics of Helicobacter pyloric seropositive gastric adenocarcinomas. Lee WJ, et al. **J Clin Gastroenterol** 1995 Oct;21(3):203–7

Presence of Streptococcus DNA sequence in surgical specimens of gastric cancer. Sasaki H, et al. **Jpn J Cancer Res** 1995 Sep;86(9):791–4

MORTALITY

A review of carcinoma of the stomach at a tertiary care referral hospital. Walker MJ. **Am J Surg** 1996 Jul; 172(1):75–8

Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Fortner JG, et al. **Ann Surg** 1996 Feb;223(2):147–53

Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer [see comments] Frank RE, et al. **Ann Surg** 1995 Dec;222(6):695–9. Comment in: Ann Surg 1995 Dec;222(6):693–4.

Superficial esophageal carcinoma. Sabik JF, et al. **Ann Thorac Surg** 1995 Oct;60(4):896–901; discussion 902

Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Lundin J, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2659–68

Gender related survival in colorectal cancer. Wolters U, et al. **Anticancer Res** 1996 May-Jun;16(3A):1281–9

Adenocarcinoma in the distal esophagus with and without Barrett esophagus. Differences in symptoms and survival rates. Johansson J, et al. **Arch Surg** 1996 Jul;131(7):708–13

Postoperative mortality in rectal cancer treated with or without preoperative radiotherapy: causes and risk factors. Holm T, et al. **Br J Surg** 1996 Jul;83(7):964–8

Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Shingleton HM, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1948–55

Pathologic models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage--a Gynecologic Oncology Group study. Zaino RJ, et al. **Cancer** 1996 Mar 15;77(6):1115–21

Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Nyholm HC, et al. **Gynecol Oncol** 1995 Dec;59(3):347–51

Carcinoma of the head of the pancreas: review of 67 cases and comparison with 27 additional periampullary carcinomas. Taschieri AM, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):1023–5

Combined use of nuclear morphometry and DNA ploidy as prognostic indicators in nonresectable adenocarcinoma of the pancreas. Linder S, et al. **Int J Pancreatol** 1995 Dec; 18(3):241–8

Long-term results of operation for carcinoma of the stomach in T1/T2 stages: critical evaluation of the concept of early carcinoma of the stomach [see comments] Abe S, et al. **J Am Coll Surg** 1995 Nov;181(5):389–96. Comment in: J Am Coll Surg 1995 Nov;181(5):467–8.

Survival factors in 186 patients younger than 40 years old with colorectal adenocarcinoma. Cusack JC, et al. **J Am Coll Surg** 1996 Aug;183(2):105–12

Management of patients with carcinoma of the pancreas [editorial; comment] Gordon TA, et al. **J Am Coll Surg** 1995 Dec;181(6):558–60. Comment on: J Am Coll Surg 1995 Dec;181(6):483–503.

Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting [see comments] Gudjonsson B. **J Am Coll Surg** 1995 Dec; 181(6):483–503 (350 ref.). Comment in: J Am Coll Surg 1995 Dec;181(6):558–60.

Gastric remnant carcinoma after partial gastrectomy for benign and malignant gastric lesions. Kodera Y, et al. **J Am Coll Surg** 1996 Jan;182(1):1–6

Long-term survival after resection for advanced gastric carcinoma. Adachi Y, et al. **J Clin Gastroenterol** 1995 Oct; 21(3):208–10

Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. Bartsch D, et al. **J Natl Cancer Inst** 1996 May 15; 88(10):680–2

Survival and function after sleeve lobectomy for lung cancer. Gaissert HA, et al. **J Thorac Cardiovasc Surg** 1996 May; 111(5):948–53

Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. Steup WH, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):85–94; discussion 94–5

Parametrial involvement, regardless of nodal status: a poor prognostic factor for cervical cancer. Zreik TG, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):741–6

In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide. Cipolla B, et al. **Urol Res** 1996;24(2):93–8; discussion 99

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Zietman AL, et al. **Urology** 1996 Feb;47(2):236–9

[Therapeutic management and survival of gastric adenocarcinoma in the province of Finistère between 1984 and 1989] Le Page M, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):804–10 (Eng. Abstr.) **(Fre)**

[Possibilities and limitations of curative resections in cancers of the pancreas] Klempnauer J, et al. **J Chir (Paris)** 1996 May;133(3):117–22 (27 ref.) (Eng. Abstr.) **(Fre)**

[The late results of the combined hormonal chemoradiation treatment of prostatic cancer] Sviridova TV, et al. **Urol Nefrol (Mosk)** 1996 Jan-Feb;(1):31–4 (Eng. Abstr.) **(Rus)**

[Survival in colorectal adenocarcinoma in Cantabria. A population-based study (1989)] Hernánz de la Fuente F, et al. **Rev Esp Enferm Dig** 1996 May;88(5):329–33 (Eng. Abstr.) **(Spa)**

NURSING

Interventions for a progressing head and neck tumor. Leach K, et al. **Oncol Nurs Forum** 1995 Jul;22(6):990

PATHOLOGY

Barrett's esophagus and esophageal adenocarcinoma: the scope o: the problem. Levine MS, et al. **Abdom Imaging** 1995 Jul–Aug;20(4):291–8 (69 ref.)

Cytologic features of well-differentiated villoglandular adenocarcinoma of the cervix. Ballo MS, et al. **Acta Cytol** 1996 May-Jun;40(3):536–40

Cytologic characteristics of tubulolobular carcinoma of the breast. Boppana S, et al. **Acta Cytol** 1996 May-Jun; 40(3):465–71

Serous surface papillary carcinoma of the ovary metastatic to a cervical polyp. A case report. Jiménez-Ayala M, et al. **Acta Cytol** 1996 Jul-Aug;40(4):765–9

Fine needle aspiration of basal cell adenocarcinoma of the parotid gland. Report of a case with assessment of DNA ploidy in aspirates and tissue sections by image analysis. Moroz K, et al. **Acta Cytol** 1996 Jul-Aug;40(4):773–8

Endocervical columnar cell intraepithelial neoplasia. I. Discriminating cytomorphologic criteria. van Aspert-van Erp AJ, et al. **Acta Cytol** 1995 Nov-Dec;39(6):1199–215

Transpyloric spread of gastric tumors: comparison of adenocarcinoma and lymphoma. Cho KC, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):467–9

Clinicopathologic correlation of DNA flow cytometric content analysis (DFCA), surgical staging, and estrogen/progesterone receptor status in endometrial adenocarcinoma. Konski AA, et al. **Am J Clin Oncol** 1996 Apr;19(2):164–8

Lymph node recovery from colorectal resection specimens removed for adenocarcinoma. Trends over time and a recommendation for a minimum number of lymph nodes to be recovered. Goldstein NS, et al. **Am J Clin Pathol** 1996 Aug;106(2):209–16

p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival. Lanza G Jr, et al. **Am J Clin Pathol** 1996 May;105(5):604–12

Human papillomavirus types 16 and 18 infection in infiltrating adenocarcinoma of the cervix: PCR analysis of 138 cases and correlation with histologic type and grade. Tenti P, et al. **Am J Clin Pathol** 1996 Jul;106(1):52–6

Adenocarcinoma in situ in Barrett's esophagus with stricture of 10-yr duration: a cytological diagnosis. Bauer W, et al. **Am J Gastroenterol** 1996 Aug;91(8):1650–1

Variant of intraductal carcinoma (with scant mucin production) is of main pancreatic duct origin: a clinicopathological study of four patients. Suda K, et al. **Am J Gastroenterol** 1996 Apr;91(4):798–800

Ultrasound-guided percutaneous transhepatic fine needle aspiration cytology study of gallbladder polypoid lesions. Wu SS, et al. **Am J Gastroenterol** 1996 Aug;91(8):1591–4

Hypoxic tumor cell death and modulation of endothelial adhesion molecules in the regression of granulocyte colony-stimulating factor-transduced tumors. Colombo MP, et al. **Am J Pathol** 1996 Feb;148(2):473–83

P53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. Boers JE, et al.

Am J Respir Crit Care Med 1996 Jan;153(1):411–6

Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Thoracoscopic and mineralogic study. Boutin C, et al. **Am J Respir Crit Care Med** 1996 Jan; 153(1):444–9

Chromophobe cell carcinoma of the kidney. A clinicopathologic study of 21 cases. Akhtar M, et al. **Am J Surg Pathol** 1995 Nov;19(11):1245–56

Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. McNeal JE, et al. **Am J Surg Pathol** 1996 Jul;20(7):802–14

Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Nelson RS, et al. **Am J Surg Pathol** 1996 Apr;20(4):419–26

Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Papotti M, et al. **Am J Surg Pathol** 1996 Jun; 20(6):686–94

Pouch–anal cancer after restorative proctocolectomy for familial adenomatous polyposis. von Herbay A, et al. **Am J Surg Pathol** 1996 Aug;20(8):995–9

Heterogeneity of the chromatin fine structure in DNA–diploid breast cancer cells. Haroske G, et al. **Anal Cell Pathol** 1995 Apr;8(3):213–26

Endocervical columnar cell intraepithelial neoplasia (ECCIN). 3. Interobserver variability in feature use. van Aspert van Erp AJ, et al. **Anal Cell Pathol** 1996 Mar; 10(2):115–35

Comparison between image and flow cytometry. A priori factors that influence technique. Bowman R, et al. **Anal Quant Cytol Histol** 1995 Aug;17(4):276–83

Diagnosis of lymphangitic carcinoma to lung by sputum cytology: case report. Shanies HM, et al. **Angiology** 1995 Nov;46(11):1035–8

Intraoral salivary duct carcinoma: a clinicopathological study of four cases and review of the literature. Epivatianos A, et al. **Ann Dent** 1995 Summer–Fall;54(1–2):36–40 (21 ref.)

Perianal Paget's disease: a case report [letter] Handberg J, et al. **Ann Oncol** 1995 Oct;6(8):851–2

Colorectal adenocarcinoma in Crohn's disease. Ribeiro MB, et al. **Ann Surg** 1996 Feb;223(2):186–93

Tubular carcinoma of the breast. Predicting axillary nodal metastases and recurrence. Winchester DJ, et al. **Ann Surg** 1996 Mar;223(3):342–7 (20 ref.)

Mammographically detected breast cancer. Benefits of stereotactic core versus wire localization biopsy. Yim JH, et al. **Ann Surg** 1996 Jun;223(6):688–97; discussion 697–700

Pregnancy influences breast cancer stage at diagnosis in women 30 years of age and younger. Anderson BO, et al. **Ann Surg Oncol** 1996 Mar;3(2):204–11

Thoracoscopic staging of esophageal cancer: a prospective, multiinstitutional trial. Cancer and Leukemia Group B Thoracic Surgeons. Krasna MJ, et al. **Ann Thorac Surg** 1995 Nov;60(5):1337–40

Effect of progestin treatment on estradiol–and growth factor–stimulated breast cancer cell lines. Cappelletti V, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2551–5

Effects of retinoic acid on cell differentiation and reversion toward normal in human endometrial adenocarcinoma (RL95–2) cells. Carter CA, et al. **Anticancer Res** 1996 Jan–Feb;16(1):17–24

The effect of ICI 164384 and beta–interferon on the growth and steroid receptor profile of breast cancer cell lines. Coradini D, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2557–61

Dihydrotestosterone affects the growth of hormone–unresponsive breast cancer cells: an indirect action. Di Monaco M, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2581–4

Apoptosis in human breast and gastrointestinal carcinomas. Detection in histological sections with monoclonal antibody to single–stranded DNA. Frankfurt OS, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1979–88

Hypermethylation of the myogenic gene Myf–3 in human breast carcinomas. Hähnel R, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2111–5

Influence of cyclopropyl antiestrogens on the cell cycle kinetics of MCF–7 human breast cancer cells. Jain PT, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2529–32

A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour. Lipponen P, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2095–100

Apoptosis and necrosis occurring during different stages of primary and metastatic tumor growth of a rat mammary adenocarcinoma. Matsuda H, et al. **Anticancer Res** 1996 May–Jun;16(3A):1117–21

Modifications of tumor–associated antigen expression on human lung cancer cells by hyperthermia and cytokine. Takahashi T, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2601–6

Transforming growth factor alpha (TGF–alpha) expression in biopsies of colorectal carcinoma is a significant prognostic indicator. Younes M, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1999–2003

Adriamycin resistance modulation induced by lonidamine in human breast cancer cells. Zupi G, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2469–77

An experimental study of gastric stump carcinoma in Wistar rats. Ehrnström R, et al. **APMIS** 1995 Dec;103(12):878–84

Interrelations of clinicopathologic variables and their prognostic value in colorectal adenocarcinoma. Sun XF, et al. **APMIS** 1996 Jan;104(1):35–8

Bedsore of an unknown primary site. Fader DJ, et al. **Arch Dermatol** 1995 Oct;131(10):1115–6

Induction of adenocarcinomas in the submandibular salivary glands of female Wistar rats treated with 7,12–dimethylbenz(a)anthracene. Zaman A, et al. **Arch Oral Biol** 1996 Feb;41(2):221–4

Terminal duct carcinoma [letter; comment] Zohar Y, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):208. Comment on: Arch Otolaryngol Head Neck Surg 1994 Sep;120(9):1010–5.

Neuroendocrine differentiation in gastric adenocarcinomas. An immunohistochemical study. Blumenfeld W, et al. **Arch Pathol Lab Med** 1996 May;120(5):478–81

Multiple primary neoplasms. Ovarian carcinoid tumor, mucinous cystadenoma of low malignant potential tumor of left ovary, and adenocarcinoma of the colon. Capaldo GR, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):393–6

Effects of saturated, mono–, and polyunsaturated fatty acids on the secretion of apo B containing lipoproteins by Caco–2 cells. van Greevenbroek MM, et al. **Atherosclerosis** 1996 Mar;121(1):139–50

Immunohistochemical detection of p53 and the recurrence of rectal adenocarcinoma. Subramaniam P, et al. **Aust N Z J Surg** 1995 Oct;65(10):740–2

Selection of a peptide with affinity for the tumor–associated TAG72 antigen from a phage–displayed library. Gui J, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):414–9

Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Qiao L, et al. **Biochim Biophys Acta** 1995 Sep 14; 1258(2):215–23

8–Chloro–cAMP induces apoptotic cell death in a human mammary carcinoma cell (MCF–7) line. Bøe R, et al. **Br J Cancer** 1995 Nov;72(5):1151–9

Proliferative response of human prostate tumour xenografts to surgical trauma and the transurethral resection of the prostate controversy. Bogden AE, et al. **Br J Cancer** 1996 Jan;73(1):73–8

Distribution of lymphoid nodules, aberrant crypt foci and tumours in the colon of carcinogen–treated rats. Cameron IL, et al. **Br J Cancer** 1996 Apr;73(7):893–8

Enhancement of sensitivity of human lung adenocarcinoma cells to growth–inhibitory activity of interferon alpha by differentiation–inducing agents. Goto I, et al. **Br J Cancer** 1996 Aug;74(4):546–54

Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth. Lawson JA, et al. **Br J Cancer** 1996 Apr;73(7):872–6

Apoptosis and necrosis induced with light and 5–aminolaevulinic acid–derived protoporphyrin IX. Noodt BB, et al. **Br J Cancer** 1996 Jul;74(1):22–9

Outpatient endometrial biopsy: the pipelle. Youssif SN, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):198–201 (23 ref.)

Macroscopically node–negative but histologically node–positive gastric carcinoma. Adachi Y, et al. **Br J Surg** 1995 Sep;82(9):1254–6

Vitamin D3 analogue (EB 1089) inhibits in vitro cellular proliferation of human colon cancer cells. Akhter J, et al. **Br J Surg** 1996 Feb;83(2):229–30

The significance of prostatic intra–epithelial neoplasia. Aboseif S, et al. **Br J Urol** 1995 Sep;76(3):355–9

Adenocarcinoma in an ileal conduit. Ng FC, et al. **Br J Urol** 1996 Feb;77(2):321–2

Six chromophobe cell carcinomas and one mixed renal cell carcinoma with chromophobe cell features: clinical and pathological implications. Usubütün A, et al. **Br J Urol** 1996 Aug;78(2):183–6

Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography. Davis PL, et al. **Breast Cancer Res Treat** 1996;37(1):1–9

Choroidal biopsy in the diagnosis of a suspect intraocular lesions. Lefebvre A, et al. **Bull Soc Belge Ophtalmol** 1995; 255:93–7

Sebaceous carcinoma of the eyelid in an immunocompromised patient with Muir–Torre syndrome. Stockl FA, et al. **Can J Ophthalmol** 1995 Oct;30(6):324–6

Manual dissection of adenocarcinoma of the lower third of the rectum specimens for detection of lymph node metastases smaller than 5 mm. Andreola S, et al. **Cancer** 1996 Feb 15;77(4):607–12

The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens. Epstein JI. **Cancer** 1996 Jul 15;78(2):350–6 (39 ref.)

The changes of the stromal elastotic framework in the growth of peripheral lung adenocarcinomas. Eto T, et al. **Cancer** 1996 Feb 15;77(4):646–56

Prognostic criteria in patients with stage D2 prostate cancer. Correlation with mean nuclear volume. Fujikawa K, et al. **Cancer** 1995 Jul 1;76(1):91–5

Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Furukawa H, et al. **Cancer** 1996 Sep 1;78(5):986–90

Early gastric lymphoma: a clinicopathologic study of ten patients, literature review, and comparison with early gastric adenocarcinoma. Kitamura K, et al. **Cancer** 1996 Mar 1;77(5):850–7 (70 ref.)

Nonpolypoid adenomas and adenocarcinomas found in background mucosa of surgically resected colons. Kubota O, et al. **Cancer** 1996 Feb 15;77(4):621–6

Atypical adenomatous hyperplasia and adenocarcinoma of the human lung: their heterology in form and analogy in immunohistochemical characteristics. Mori M, et al. **Cancer** 1996 Feb 15;77(4):665–74

Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome–based analysis. Pinover WH, et al. **Cancer** 1996 Apr 1;77(7):1334–41

Gastric epithelial dysplasia. How clinicopathologic background relates to management. Rugge M, et al. **Cancer** 1995 Aug 1;76(3):376–82

Histopathological studies of superficial–type early colorectal carcinoma [see comments] Wada R, et al. **Cancer** 1996 Jan 1;77(1):44–50. Comment in: Cancer 1996 Jan 1;77(1):3–6.

Pathologic models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage—a Gynecologic Oncology Group study. Zaino RJ, et al. **Cancer** 1996 Mar 15;77(6):1115–21

Usefulness of coagulation markers in staging of gastric cancer. Abbasciano V, et al. **Cancer Detect Prev** 1995; 19(4):331–6

Increasing development of pepsinogen–altered pyloric glands and adenocarcinoma in glandular stomach of analbuminemic rats. Ogawa K, et al. **Cancer Lett** 1995 Sep 25;96(2):219–24

Metastatic prostate cancer in a transgenic mouse. Gingrich JR, et al. **Cancer Res** 1996 Sep 15;56(18):4096–102

Uteri of women with endometrial carcinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability. Jovanovic AS, et al. **Cancer Res** 1996 Apr 15;56(8):1917–21

Allelic imbalance at NME1 in microdissected primary and metastatic human colorectal carcinomas is frequent but not associated with metastasis to lymph nodes or liver. Lamb RF, et al. **Cancer Res** 1996 Feb 15;56(4):916–20

Expression of cell cycle–regulated proteins in prostate cancer. Mashal RD, et al. **Cancer Res** 1996 Sep 15; 56(18):4159–63

Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Zhuang Z, et al. **Cancer Res** 1996 May 1;56(9):1961–4

Differential effects of nitrogen mustard in vivo on the cancer and host cells in MCa–11 tumours. Bose KK, et al. **Cell Prolif** 1995 Jul;28(7):403–14

Quinone–induced apoptosis in human colon adenocarcinoma cells via DT–diaphorase mediated bioactivation. Sun X, et al. **Chem Biol Interact** 1996 May 6;100(3):267–76

Effects of antisense epidermal growth factor and its receptor retroviral expression vectors on cell growth of human pancreatic carcinoma cell line. Liu T, et al. **Chin Med J (Engl)** 1995 Sep;108(9):653–9

Detection of candidates for cancer cell motility inhibitory protein in the Dunning adenocarcinoma model. Mohler JL, et al. **Clin Exp Metastasis** 1995 Nov;13(6):474–80

Ultrastructural study of TPA–induced cell motility: human well–differentiated rectal adenocarcinoma cells move as coherent sheets via localized modulation of cell–cell adhesion. Nabeshima K, et al. **Clin Exp Metastasis** 1995 Nov;13(6):499–508

EGF stimulates lamellipod extension in metastatic mammary adenocarcinoma cells by an actin–dependent mechanism. Segall JE, et al. **Clin Exp Metastasis** 1996 Jan;14(1):61–72

Integrin–mediated entry into S phase of human gastric adenocarcinoma cells. Udagawa T, et al. **Clin Exp Metastasis** 1995 Nov;13(6):427–38

The pathology of cervical cancer. Walsh CB, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):653–61 (16 ref.)

Benign to malignant progression in cervical squamous epithelium. Ehrmann RL. **Compr Ther** 1996 Feb; 22(2):67–75 (43 ref.)

Prognostic factors in endometrial neoplasia: old and new. Nogales FF. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):74–8 (34 ref.)

Adenocarcinoma of the colon presenting with a Sister Mary Joseph's nodule and Trousseau's syndrome. Barnes J, et al. **Cutis** 1995 Nov;56(5):270–2

A study of induced genotoxicity in MCF–7 cells. Mark HF, et al. **Cytobios** 1995;84(338–339):171–7

Aspiration cytology of chromophobe cell carcinoma of the kidney. Akhtar M, et al. **Diagn Cytopathol** 1995 Nov; 13(4):287–94

Fine–needle aspiration of supraclavicular lymph nodes. Carson HJ, et al. **Diagn Cytopathol** 1996 May;14(3):216–20

Exfoliative cytology of adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. Vogelsang PJ, et al. **Diagn Cytopathol** 1995 Aug;13(2):146–50

Carcinoma in gastric hyperplastic polyps. A phenotypic study. Zea–Iriarte WL, et al. **Dig Dis Sci** 1996 Feb; 41(2):377–86

Colorectal cancers of rare histologic types compared with adenocarcinomas [letter] DiSario JA. **Dis Colon Rectum** 1995 Nov;38(11):1227

Colon surveillance after colorectal cancer surgery. Khoury DA, et al. **Dis Colon Rectum** 1996 Mar;39(3):252–6

Flat adenomas and flat adenocarcinomas of the colorectal mucosa in Japanese and Swedish patients. Comparative histologic study. Rubio CA, et al. **Dis Colon Rectum** 1995 Oct;38(10):1075–9

Colonoscopic appearance of an adenocarcinoid of the vermiform appendix. Jiménez–Pérez FJ, et al. **Endoscopy** 1996 Feb;28(2):270

A minute rectal carcinoma with massive submucosal invasion and lymph–node metastasis. Yagi K, et al. **Endoscopy** 1996 Feb;28(2):261

Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. Pantel K, et al. **Eur J Cancer** 1995 Sep; 31A(10):1627–32

Characterisation of platelet aggregation induced by PC–3 human prostate adenocarcinoma cells and inhibited by venom peptides, trigramin and rhodostomin. Swaim MW, et al. **Eur J Cancer** 1996 Apr;32A(4):715–21

Infiltrating cribriform carcinoma of the breast. A clinico–pathologic and immunohistochemical study of 5 cases. Marzullo F, et al. **Eur J Gynaecol Oncol** 1996; 17(3):228–31

Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Shiff SJ, et al. **Exp Cell Res** 1996 Jan 10; 222(1):179–88

Neoplastic endocrine cells in prostatic carcinoma: a case report with immunocytochemical and electron microscopic findings. Watanabe K, et al. **Fukushima J Med Sci** 1995 Jun;41(1):51–60

Hepatoid adenocarcinoma of the stomach: a case report. Ihling C, et al. **Gen Diagn Pathol** 1995 May;141(1):61–5

Gastric epithelial cell kinetics in the progression from normal mucosa to gastric carcinoma. Cahill RJ, et al. **Gut** 1996 Feb;38(2):177–81

Relation of number of positive lymph nodes to the prognosis of patients with primary gastric adenocarcinoma. Wu CW, et al. **Gut** 1996 Apr;38(4):525–7

Fallopian tube cancer: incidence and role of lymphatic spread. di Re E, et al. **Gynecol Oncol** 1996 Aug; 62(2):199–202

Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Eifel PJ, et al. **Gynecol Oncol** 1995 Oct;59(1):38–44

Surgical predictors of para–aortic metastases in early–stage cervical carcinoma. Hackett TE, et al. **Gynecol Oncol** 1995 Oct;59(1):15–9

Adequacy of conization margins in adenocarcinoma in situ of the cervix as a predictor of residual disease. Im DD, et al. **Gynecol Oncol** 1995 Nov;59(2):179–82 (20 ref.)

p53 protein overexpression in early stage endometrial cancer. Kohlberger P, et al. **Gynecol Oncol** 1996 Aug;62(2):213–7

Vulvar Merkel cell tumor with glandular and squamous differentiation. Scurry J, et al. **Gynecol Oncol** 1996 Aug; 62(2):292–7 (15 ref.)

Growth suppression of a cervical cancer cell line (TMCC–1) by the human wild–type p53 gene. Zheng PS, et al. **Gynecol Oncol** 1996 Feb;60(2):245–50

Histologic variant of the epithelial–myoepithelial carcinoma of the salivary gland: a case report. Cheung FM, et al. **Head Neck** 1995 Sep–Oct;17(5):437–44

Histopathological assessment of lymph node metastasis in patients with gastric cancer. Matsushita M, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):861–6

Margins of resection of the esophagus for gastric cancer with esophageal invasion. Tsujitani S, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):873–7

Ultrastructural study of the vascular response in small early gastric cancer. Caruso RA, et al. **Histol Histopathol** 1996 Jan;11(1):17–25

Prognostic significance of p53 and c–erbB–2 immunohistochemical evaluation in colorectal adenocarcinoma. Lazaris AC, et al. **Histol Histopathol** 1995 Jul;10(3):661–8

Association between the apoptotic index and established prognostic parameters in endometrial adenocarcinoma. Heatley MK. **Histopathology** 1995 Nov;27(5):469–72

Synchronous adenocarcinoma and low grade B–cell lymphoma of mucosa associated lymphoid tissue (MALT) of the stomach. Wotherspoon AC, et al. **Histopathology** 1995 Oct;27(4):325–31 (45 ref.)

The nuclear channel system in endometrial adenocarcinoma exposed to medroxyprogesterone acetate. Horbelt DV, et al. **Hum Pathol** 1996 Jan;27(1):9–14

Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. Jannink I, et al. **Hum Pathol** 1995 Oct;26(10):1086–92

Distribution of lipochrome pigment in the prostate gland: biological and diagnostic implications. Leung CS, et al. **Hum Pathol** 1995 Dec;26(12):1302–7

Atypical adenomatous hyperplasia (adenosis) of the prostate: development of a Bayesian belief network for its distinction from well–differentiated adenocarcinoma. Montironi R, et al. **Hum Pathol** 1996 Apr;27(4):396–407

Comparative morphometric studies of benign and malignant intraductal proliferative lesions of the breast by computerized image analysis. Ozaki D, et al. **Hum Pathol** 1995 Oct;26(10):1109–13

The differential expression of N–cadherin and E–cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Peralta Soler A, et al. **Hum Pathol** 1995 Dec;26(12):1363–9

Colorectal cancer and noncancer patients have similar labeling indices by microscopy and computed image analysis. Wong AJ, et al. **Hum Pathol** 1995 Dec; 26(12):1329–32

Adenocarcinoma in situ of the gall bladder––an incidental finding. Sharma S, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S32–3

Exogenous nitric oxide stimulates mucin secretion from LS174T colonic adenocarcinoma cells. Göttke M, et al. **Inflamm Res** 1996 Apr;45(4):209–12

Lack of expression of transforming growth factor–beta type II receptor associated with malignant progression in human salivary gland cell clones. Azuma M, et al. **Int J Cancer** 1996 Jun 11;66(6):802–5

Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Barboule N, et al. **Int J Cancer** 1995 Nov 27; 63(5):611–5

Varying patterns of expression of insulin–like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Guerra FK, et al. **Int J Cancer** 1996 Mar 15;65(6):812–20

Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF–beta 1 and its type–I and type–II receptors. Landström M, et al. **Int J Cancer** 1996 Aug 7;67(4):573–9

Influence of hepatic artery occlusion and desferrioxamine on liver–tumour growth. Lindnér P, et al. **Int J Cancer** 1995 Nov 15;63(4):592–6

Characterization of tumorigenic sub–lines from a poorly tumorigenic human colon–adenocarcinoma cell line. López–Conejo T, et al. **Int J Cancer** 1996 Sep 4; 67(5):668–75

Antagonists of bombesin/gastrin–releasing peptide inhibit growth of SW–1990 human pancreatic adenocarcinoma and production of cyclic AMP. Qin Y, et al. **Int J Cancer** 1995 Oct 9;63(2):257–62

Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer. Robertson JF, et al. **Int J Cancer** 1995 Sep 27;63(1):69–75

Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. van der Stappen JW, et al. **Int J Cancer** 1996 Aug 7; 67(4):547–54

Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Xing RH, et al. **Int J Cancer** 1996 Jul 29;67(3):423–9

Transvaginal trucut biopsy in patients with abdominopelvic mass. Sheth SS, et al. **Int J Gynaecol Obstet** 1995 Jul; 50(1):27–31

Sertoliform endometrial adenocarcinoma: a study of four cases. Eichhorn JH, et al. **Int J Gynecol Pathol** 1996 Apr; 15(2):119–26

Surface epithelial changes in endometrial adenocarcinoma: diagnostic pitfalls in curettage specimens. Jacques SM, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):191–7

Endometrial adenocarcinoma with choriocarcinomatous differentiation in an elderly virginal woman. Kalir T, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):266–9

Enteric differentiation in endometrial adenocarcinomas: a mucin histochemical study. McCluggage WG, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):250–4

Monoclonal antibodies Ki–67 and MIB1 in the distinction of tuboendometrial metaplasia from endocervical adenocarcinoma and adenocarcinoma in situ in formalin–fixed material. McCluggage WG, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):209–16

Pancreatic adenocarcinoma cell line, MDAPanc–28, with features of both acinar and ductal cells. Frazier ML, et al. **Int J Pancreatol** 1996 Feb;19(1):31–8

Prostate cancer volume adds significantly to prostate–specific antigen in the prediction of early biochemical failure after external beam radiation therapy. D'Amico AV, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):273–9

Prognostic characteristics of surgical stage I endometrial adenocarcinoma. Konski A, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):935–40

Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer. Stock RG, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1; 33(4):815–21

A case of prostate carcinoma metastasizing to renal cell carcinoma. Inatomi H, et al. **Int J Urol** 1996 Mar;3(2):155–7

Serum prostate specific antigen and prostate specific antigen density in patients receiving radical prostatectomy. Masai M, et al. **Int J Urol** 1996 Mar;3(2):118–23

Primary adenocarcinoma in an ileal conduit. Tsuboniwa N, et al. **Int J Urol** 1996 Jan;3(1):64–6

Collision metastasis of bladder and prostate carcinoma to a single pelvic lymph node. Ergen A, et al. **Int Urol Nephrol** 1995;27(6):743–5

Artificial graft patch reconstruction of infiltrated inferior vena cava in renal adenocarcinoma. Kontothanassis D, et al. **Int Urol Nephrol** 1995;27(4):369–73

Intraobserver and interobserver reproducibility of WHO and Gleason histologic grading systems in prostatic adenocarcinomas. Ozdamar SO, et al. **Int Urol Nephrol** 1996;28(1):73–7

Perineal prostatic cancer seeding following Urocut needle biopsy. Szentgyörgyi E. **Int Urol Nephrol** 1996;28(1):87–90

Adenocarcinoma and atypical carcinoid: morphological study of a gastric collision–type tumour in the carcinoma–carcinoid spectrum. Corsi A, et al. **Ital J Gastroenterol** 1995 Jul–Aug;27(6):303–8

Long–term results of operation for carcinoma of the stomach in T1/T2 stages: critical evaluation of the concept of early carcinoma of the stomach [see comments] Abe S, et al. **J Am Coll Surg** 1995 Nov;181(5):389–96. Comment in: J Am Coll Surg 1995 Nov;181(5):467–8.

Usefulness of Japanese staging in the prognosis of patients treated operatively for adenocarcinoma of the head of the pancreas. Kobari M, et al. **J Am Coll Surg** 1996 Jan; 182(1):24–32

Lymph node involvement in T1/T2 carcinoma of the stomach [editorial; comment] Lillemoe KD. **J Am Coll Surg** 1995 Nov;181(5):467–8. Comment on: J Am Coll Surg 1995 Nov;181(5):389–96.

Autocrine growth stimulation of SW403 colon carcinoma cell line is caused by transforming–growth–factor–alpha–mediated epidermal growth factor receptor activation. Hirsch T, et al. **J Cancer Res Clin Oncol** 1996;122(6):328–34

Suppression of the proliferation and migration of oncogenic ras–dependent cell lines, cultured in a three–dimensional collagen matrix, by flavonoid–structured molecules. Lü HQ, et al. **J Cancer Res Clin Oncol** 1996;122(6):335–42

Tumor embolism to LAD during pneumonectomy. A case report. Shah R, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):319–21 (13 ref.)

Clinicopathologic characteristics of Helicobacter pyloric seropositive gastric adenocarcinomas. Lee WJ, et al. **J Clin Gastroenterol** 1995 Oct;21(3):203–7

Association between thyroid cancer of cribriform variant and familial adenomatous polyposis. Hizawa K, et al. **J Clin Pathol** 1996 Jul;49(7):611–3

Assessment of the nucleolar organizer regions by automated image analysis in benign and malignant colonic tumours and adjacent tissues in rats. Nyska A, et al. **J Comp Pathol** 1995 Jul;113(1):45–50

Staging of rectal carcinoma using MR double surface coil, MR endorectal coil, and intrarectal ultrasound: correlation with histopathologic findings. Joosten FB, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):752–8

Pancreatic carcinoma: MR assessment of tumor invasion of the peripancreatic vessels. Sironi S, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):739–44

Atypical glandular cells of undetermined significance and adenocarcinoma in situ: summoning colposcopic expertise? Ferris DG, et al. **J Fam Pract** 1996 Aug;43(2):181–7

False–negative endoscopic biopsy of colonic adenocarcinoma in a young man. Gillett E, et al. **J Fam Pract** 1996 Aug; 43(2):178–80

Computed tomography, endoscopic ultrasonography and intraoperative assessment in TN staging of gastric carcinoma. Perng DS, et al. **J Formos Med Assoc** 1996 May;95(5):378–85

Adenocarcinoma of the gastric cardia: prognostic significance of pathologic and treatment factors. Tsai MK, et al. **J Formos Med Assoc** 1995 Sep;94(9):535–40

Primary tubular adenocarcinoma arising in the duodenal limb of reconstructed gastroduodenostomy for signet–ring cell carcinoma of the stomach. Koyama S, et al. **J Gastroenterol** 1995 Oct;30(5):657–60

Floating gallbladder associated with histologically distinct double cancers. Nakahama M, et al. **J Gastroenterol** 1996 Jun;31(3):465–9

Carcinoma ex–pleomorphic adenoma of the nasal cavity: a report of two cases. Cho KJ, et al. **J Laryngol Otol** 1995 Jul;109(7):677–9

Polymorphous low–grade adenocarcinoma of the tongue. de Diego JI, et al. **J Laryngol Otol** 1996 Jul;110(7):700–3

Clinicopathological features of well–differentiated cervical adenocarcinoma with abundant mucus secretion. Ueki M, et al. **J Med** 1995;26(1–2):17–30

The Caco–2 cell culture system can be used as a model to study food iron availability. Garcia MN, et al. **J Nutr** 1996 Jan;126(1):251–8

Caco–2 cell iron uptake from meat and casein digests parallels in vivo studies: use of a novel in vitro method for rapid estimation of iron bioavailability. Glahn RP, et al. **J Nutr** 1996 Jan;126(1):332–9

Basal cell adenocarcinoma of the sublingual gland: report of a case. Mima T, et al. **J Oral Maxillofac Surg** 1996 Sep; 54(9):1121–3 (6 ref.)

Controversies in the diagnosis and management of thyroid cancer. Thomas MJ. **J Otolaryngol** 1996 Feb;25(1):20–2 (11 ref.)

Cytotoxicity, cell cycle kinetics and morphonuclear–induced effects of Vinca alkaloid anticancer agents. Pauwels O, et al. **J Pharm Pharmacol** 1995 Oct;47(10):870–5

The rat endometrial adenocarcinoma cell line RUCA–I: a novel hormone–responsive in vivo/in vitro tumor model. Pöllmer G, et al. **J Steroid Biochem Mol Biol** 1996 Apr; 58(1):103–15

Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. Alonso DF, et al. **J Surg Oncol** 1996 Aug; 62(4):288–97

Collagen promotes perianastomotic tumour growth in an experimental animal model. Reinbach D, et al. **J Surg Oncol** 1995 Oct;60(2):112–5

Insulin–like growth factor–II as a prognostic factor in pulmonary adenocarcinoma. Takanami I, et al. **J Surg Oncol** 1996 Mar;61(3):205–8

Adenocarcinoma of duodenum and ampulla of Vater: clinicopathology study and expression of p53, c–neu, TGF–alpha, CEA, and EMA. Zhu L, et al. **J Surg Oncol** 1996 Feb;61(2):100–5

Endothelial leukocyte adhesion molecule–1–mediated vasoinvasion of human pancreatic adenocarcinoma. Takada M, et al. **J Surg Res** 1995 Dec;59(6):653–7

Metastatic pattern in adenocarcinoma of the lung. An autopsy study from a cohort of 137 consecutive patients with complete resection. Stenbygaard LE, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1130–5

Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. Bostwick DG, et al. **J Urol** 1996 Apr;155(4):1361–7

Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy [see comments] Langer JE, et al. **J Urol** 1996 Jan; 155(1):228–31. Comment in: J Urol 1996 Jan;155(1):243.

Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy [see comments] Oefelein MG, et al. **J Urol** 1996 Jan;155(1):238–42. Comment in: J Urol 1996 Jan;155(1):243.

Inhibition of cell growth by transforming growth factor beta 1 is associated with p53–independent induction of p21 in gastric carcinoma cells. Akagi M, et al. **Jpn J Cancer Res** 1996 Apr;87(4):377–84

Biomodulation by hyperthermia of topoisomerase II–targeting drugs in human colorectal cancer cells. Hirohashi Y, et al. **Jpn J Cancer Res** 1995 Nov; 86(11):1097–105

Triamterene suppresses bombesin–enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Iishi H, et al. **Jpn J Cancer Res** 1996 Jul; 87(7):730–4

Flat serrated adenomas of the colorectal mucosa. Rubio CA, et al. **Jpn J Cancer Res** 1996 Mar;87(3):305–9

A comparative study between the gastric mucosa of Chileans and other dwellers of the Pacific basin. Rubio CA, et al. **Jpn J Cancer Res** 1996 Feb;87(2):117–21

Establishment and characterization of high– and low–lung–metastatic cell lines derived from murine colon adenocarcinoma 26 tumor line. Sakata K, et al. **Jpn J Cancer Res** 1996 Jan;87(1):78–85

Induction of invasive growth in a gallbladder cancer cell line by hepatocyte growth factor in vitro. Shimura H, et al. **Jpn J Cancer Res** 1995 Jul;86(7):662–9

Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG–M cells in vitro. Ueda M, et al. **Jpn J Cancer Res** 1996 May; 87(5):524–33

Primary hepatocellular carcinoma and hepatoid adenocarcinoma of the stomach with liver metastasis: an unusual association. Morinaga S, et al. **Jpn J Clin Oncol** 1996 Aug;26(4):258–63

Clinicopathologic study of gastric carcinoma with duodenal invasion. Perng DS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Aug; 12(8):461–5

Early mucosal gastric cancer with lymph node metastasis. Aoyagi K, et al. **Kurume Med J** 1995;42(3):145–8

Clinicopathologic characteristics of stage I lung adenocarcinoma in women. Takamori S, et al. **Kurume Med J** 1995;42(2):67–70

The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Derenzini M, et al. **Lab Invest** 1995 Oct;73(4):497–502

Ex vivo MRI in extracorporeal liver surgery. Wolf RF, et al. **Magn Reson Imaging** 1995;13(7):1031–5

Pulmonary scar carcinoma: report of three cases and review of the literature. Lee BY, et al. **Mil Med** 1995 Oct; 160(10):537–41

Benign endocervical adenomyomas and adenoma malignum. Gilks CB, et al. **Mod Pathol** 1996 Mar;9(3):220–4

Gallbladder adenocarcinoma, acalculous chronic lymphoplasmacytic cholecystitis, ulcerative colitis. Herzog K, et al. **Mod Pathol** 1996 Mar;9(3):194–8 (26 ref.)

Low–grade papillary adenomatous tumors of the temporal bone: report of two cases and review of the literature. Lavoie M, et al. **Mod Pathol** 1995 Aug;8(6):603–8 (17 ref.)

Sinonasal intestinal–type adenocarcinoma: immunohistochemical profile and comparison with colonic adenocarcinoma. McKinney CD, et al. **Mod Pathol** 1995 May;8(4):421–6

Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate. Van de Voorde WM, et al. **Mod Pathol** 1995 Aug;8(6):591–8

Multiparameter digital image analysis of biliary, ampullary, and pancreatic adenocarcinomas. Yeaton P, et al. **Mod Pathol** 1995 Oct;8(8):843–7

Choroid plexus carcinoma in the lateral ventricle—case report. Hashizume A, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):742–4

Anti–Yo–associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of unknown origin. Krakauer J, et al. **Neurology** 1996 May;46(5):1486–7

Malignant lymphoma arising in the duodenum combined with gastric lymphoma and early gastric cancer: a case report. Uyama N, et al. **Nippon Geka Hokan** 1995 Sep 1; 64(5):115–22

RRR–alpha–tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Israel K, et al. **Nutr Cancer** 1995;24(2):161–9

Selective toxicity of compounds naturally present in food toward the transformed phenotype of human colorectal cell line HT29. Musk SR, et al. **Nutr Cancer** 1995; 24(3):289–98

Prognostic significance of gross myometrial invasion with endometrial cancer. Larson DM, et al. **Obstet Gynecol** 1996 Sep;88(3):394–8

Adenocarcinoma in situ of the cervix: significance of cone biopsy margins. Wolf JK, et al. **Obstet Gynecol** 1996 Jul; 88(1):82–6

Pathologic evaluation of prostatic carcinoma: critical information for the oncologist. Epstein JI. **Oncology (Huntingt)** 1996 Apr;10(4):527–34; discussion 539, 541–3 (50 ref.)

Oncocytic adenocarcinoma of the lacrimal sac: report of a case with paranasal sinus and orbital extension. Perlman JI, et al. **Ophthalmic Surg** 1995 Jul–Aug;26(4):377–9

Basal cell adenocarcinoma of the parotid gland. Kacker A, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):150–1

Extensive invasion of a ductal adenocarcinoma into the wall of a pancreatic pseudocyst [letter] Otani T, et al. **Pancreas** 1996 May;12(4):416–9

The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Staley CA, et al. **Pancreas** 1996 May;12(4):373–80

Boundary in the pathologic evaluation of premalignant prostatic lesions. Algaba F. **Pathol Res Pract** 1995 Sep; 191(9):856–9

Prostatic intraepithelial neoplasia and well differentiated adenocarcinoma maintain an intact basement membrane. Bostwick DG, et al. **Pathol Res Pract** 1995 Sep; 191(9):850–5

Nucleolar and AgNOR–analysis of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic carcinoma. Helpap B, et al. **Pathol Res Pract** 1995 Jun;191(5):381–90

Unusual endometrial stromal cell changes mimicking metastatic carcinoma. Jacques SM, et al. **Pathol Res Pract** 1996 Jan;192(1):33–6

Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Montironi R, et al. **Pathol Res Pract** 1995 Sep; 191(9):873–80

Radial scar versus tubular carcinoma of the breast. A comparative study with quantitative techniques (morphometry, image– and flow cytometry). Ruiz–Saurí A, et al. **Pathol Res Pract** 1995 Jul;191(6):547–54

Hairy cell leukemia without splenomegaly nor myelofibrosis in a patient with gastric adenocarcinoma: early phase of the disease or a variant? Zoldan MC, et al. **Pathologica** 1995 Feb;87(1):97–9

Alpha–fetoprotein–producing adenocarcinoma of the sigmoid colon with possible hepatoid differentiation. Hocking GR, et al. **Pathology** 1995 Jul;27(3):277–9

Imaging features of ovarian metastases from colonic adenocarcinoma in adolescents. Kauffman WM, et al. **Pediatr Radiol** 1995;25(4):286–8

Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Nakashima E, et al. **Pharm Res** 1995 Nov; 12(11):1598–604

Synchronous multiple lymphomatous polyposis and adenocarcinomata in the large bowel [letter] Hopster D, et al. **Postgrad Med J** 1995 Jul;71(837):443

Antisense RNA to the type I insulin–like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Burfeind P, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7263–8

Inhibitors of angiotensin–converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Reddy MK, et al. **Proc Soc Exp Biol Med** 1995 Dec; 210(3):221–6

Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Bonkhoff H, et al. **Prostate** 1996 Feb;28(2):98–106 (52 ref.)

Molecular biology of prostatic intraepithelial neoplasia. Bostwick DG, et al. **Prostate** 1996 Aug;29(2):117–34 (157 ref.)

Microvascular invasion of the seminal vesicles in adenocarcinoma of the prostate. Graham SD Jr, et al. **Prostate** 1996 Jun;28(6):359–63

Adenocarcinoma of the prostate metastatic to the choroid of the eye. Keizur JJ, et al. **Prostate** 1995 Dec;27(6):336–9

Stimulation of human prostate cancer cell lines by factors present in human osteoblast–like cells but not in bone marrow. Lang SH, et al. **Prostate** 1995 Nov;27(5):287–93

Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC–3. Liu DF, et al. **Prostate** 1995 Nov;27(5):269–76

Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. McNeal JE, et al. **Prostate** 1995 Nov;27(5):258–68

Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model. Neubauer BL, et al. **Prostate** 1995 Oct;27(4):220–9

Determination of Ki–67 defined growth fraction by monoclonal antibody MIB–1 in formalin–fixed, paraffin–embedded prostatic cancer tissues. Noordzij MA, et al. **Prostate** 1995 Sep;27(3):154–9

Comparative analysis of prognostic factors in men undergoing radical prostatectomy for adenocarcinoma of the prostate, including DNA ploidy, surgical tumor stage, prostatic specific antigen, Gleason grade, and age. Shockley KF, et al. **Prostate** 1996 Jul;29(1):46–50

DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma—necessitating multiple site analysis. Warzynski MJ, et al. **Prostate** 1995 Dec; 27(6):329–35

Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone? Lee WR, et al. **Radiology** 1996 Feb;198(2):439–42

Colon cancer: morphology detected with barium enema examination versus histopathologic stage. McCarthy PA, et al. **Radiology** 1995 Dec;197(3):683–7

Comparison of two techniques for detecting tumour hypoxia: a fluorescent immunochemical method and an in vitro colony assay. Stern S, et al. **Radiother Oncol** 1996 May; 39(2):129–35

He–Ne laser has no effect on cell cycle phases of human colon adenocarcinoma cells. Morales JA, et al. **Rev Esp Fisiol** 1995 Mar;51(1):43–7

Endometrial biopsy with uretral plastic No. 12 sonde. Guerreiro ID, et al. **Rev Paul Med** 1995 Jan–Feb; 113(1):698–700

Open versus laparoscopic diagnostic pelvic lymphadenectomy. Mommsen S. **Scand J Urol Nephrol Suppl** 1995;172:23–5

The effect of castration on tumor growth rate and cell kinetics in hormone sensitive and hormone insensitive rat prostatic adenocarcinomas. Salling LN, et al. **Scand J Urol Nephrol Suppl** 1995;172:73–9

Basal cell adenocarcinoma of minor salivary and seromucous glands of the head and neck region. Fonseca I, et al. **Semin Diagn Pathol** 1996 May;13(2):128–37 (30 ref.)

Colorectal adenocarcinoma: staging and histopathology. Johnson RD, et al. **Semin Roentgenol** 1996 Apr; 31(2):94–102 (36 ref.)

Poorly differentiated adenocarcinoma in a gastric hyperplastic polyp [letter] Gotoh Y, et al. **South Med J** 1996 Apr;89(4):453–4

Observations of aggressive, small, flat, and depressed colon cancer. Report of three cases. Kasumi A, et al. **Surg Endosc** 1995 Jun;9(6):690–4 (19 ref.)

Significance of laparoscopic excisional biopsy for polypoid lesions of the gallbladder. Toda K, et al. **Surg Laparosc Endosc** 1995 Aug;5(4):267–71

Adenocarcinoma of Meckel's cave: case report. Tacconi L, et al. **Surg Neurol** 1995 Dec;44(6):553–5

The modulating effect of interferon alpha–2a on the antitumor activity of UFT against a human gastric carcinoma xenograft, SC–1–NU, in nude mice. Kubota T, et al. **Surg Today** 1996;26(1):12–4

Composite carcinoid–adenocarcinoma tumor of the stomach: report of a case. Nagaoka S, et al. **Surg Today** 1996; 26(3):184–8

Venous invasion as a prognostic factor in colorectal cancer. Tsuchiya A, et al. **Surg Today** 1995;25(11):950–3

Alterations in DNA proliferation in gastric stump mucosa with special reference to topography. Fukuzawa K, et al. **Surgery** 1996 Feb;119(2):191–7

Application of monoclonal antibodies to histologic diagnosis of gastric cancers. Otsuji E, et al. **Tohoku J Exp Med** 1995 Aug;176(4):213–8

Establishment of a new extrahepatic bile duct carcinoma cell line, TFK–1. Saijyo S, et al. **Tohoku J Exp Med** 1995 Sep; 177(1):61–71

Flow cytometric DNA analysis of abnormal endometrium. Sato S, et al. **Tohoku J Exp Med** 1996 Feb;178(2):199–202

Spontaneously occurring mammary adenocarcinoma in a 10–wk–old female rat. Oishi Y, et al. **Toxicol Pathol** 1995 Nov–Dec;23(6):696–700

Helicobacter pylori infection in patients with gastric adenocarcinoma. Wu CW, et al. **Tumori** 1996 Jan–Feb; 82(1):40–4

Metastatic biphasic pulmonary adenocarcinoma mimicking malignant gastrointestinal stromal tumour. Allen DC, et al. **Ulster Med J** 1995 Oct;64(2):181–4

Polymorphous low–grade adenocarcinoma arising in the nasal cavities with an associated undifferentiated carcinoma. Lloreta J, et al. **Ultrastruct Pathol** 1995 Sep–Oct;19(5):365–70

Single focus of adenocarcinoma in the prostate biopsy specimen is not predictive of the pathologic stage of disease. Bruce RG, et al. **Urology** 1996 Jul;48(1):75–9

Free, complexed, and total serum prostate–specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Lerner SE, et al. **Urology** 1996 Aug;48(2):240–8

Benign ectopic prostatic tissue involving the seminal vesicle in a patient with prostate cancer: recognition and implications for staging. Salem CE, et al. **Urology** 1996 Sep;48(3):490–3

Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Tatsutani K, et al. **Urology** 1996 Sep;48(3):441–7

Combined choriocarcinoma, hepatoid adenocarcinoma, small cell carcinoma and tubular adenocarcinoma in the oesophagus. Motoyama T, et al. **Virchows Arch** 1995; 427(4):451–4

Simultaneous gastric adenocarcinoma and MALT–type lymphoma in Helicobacter pylori infection. von Herbay A, et al. **Virchows Arch** 1995;427(4):445–50 (62 ref.)

Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer. Szentirmai M, et al. **West J Med** 1995 Dec;163(6):577–8

Peritoneal carcinomatosis from adenocarcinoma of the colon.

Sugarbaker PH, et al. **World J Surg** 1996 Jun;20(5):585–91; discussion 592

Difference between carcinoma of the lower esophagus and the cardia. Tachimori Y, et al. **World J Surg** 1996 May; 20(4):507–10 discussion 511

Gastric carcinoma arising from a hyperplasiogenic polyp with a diameter of less than 2 centimeters. Gschwantler M, et al. **Z Gastroenterol** 1995 Oct;33(10):610–2 (15 ref.)

[Lymphatic metastasis in central direction and bowel axial direction in colonic cancers] Gao X, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep;17(5):387–90 (Eng. Abstr.) **(Chi)**

[Expression and clinical significance of the AgNOR and PCNA in Barrett's adenocarcinoma and its precancerous lesions] Li H, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):286–8 (Eng. Abstr.) **(Chi)**

[Gastric cancer with P53 overexpression and nm23 low–expression has high potential for lymph node metastasis] Zhang S, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov;17(6):418–21 (Eng. Abstr.) **(Chi)**

[Autocrine transforming growth factor–beta stimulates human ovarian cancer cell growth in vitro and in vivo] Xiong S, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan;31(1):22–4 (Eng. Abstr.) **(Chi)**

[Enhancement of antitumor effect of cisplatin on human ovarian cancer by cyclosporin A in vitro and in vivo] Zhou Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan; 31(1):25–8 (Eng. Abstr.) **(Chi)**

[Induction of differentiation by all–trans–retinoic acid in a human lung adenocarcinoma cell line] Li B, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Nov;75(11):683–5, 711 (Eng. Abstr.) **(Chi)**

[Inhibition of colorectal carcinoma induced by 1, 2–dimethylhydrazine in mice with tea polyphenols] Pan H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):356–9 (Eng. Abstr.) **(Chi)**

[Mixed carcinoid–carcinoma of the stomach] Mačák J, et al. **Cesk Patol** 1995 Dec;31(4):135–8 (Eng. Abstr.) **(Cze)**

[Adenocarcinoma in an ileal duplication] Ribaux C, et al. **Ann Pathol** 1995;15(6):443–5 (Eng. Abstr.) **(Fre)**

[Modulation of the tumoral progression by anti–idiotypic antibodies of angiogenesis factors] Ortéga N, et al. **C R Acad Sci III** 1996 May;319(5):411–5 (Eng. Abstr.) **(Fre)**

[Late and multiple endocrine metastases of an adenocarcinoma of the kidney] Avisse C, et al. **Chirurgie** 1994–95;120(11):50–3 (Eng. Abstr.) **(Fre)**

[Adenocarcinoma of the anal glands (letter)] Hoang C, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):854–5 **(Fre)**

[Peroperative biopsy of the sub–apical urethra during prostatectomy for cancer] Ponthieu A, et al. **Prog Urol** 1996 Apr;6(2):250–5; discussion 255–6 (Eng. Abstr.) **(Fre)**

[Anatomopathologic reassessment of prostatic tumors exclusively affecting the organ with biologic progression and survival study of prostatectomized patients, in terms of the histologic characteristics of the tumor] Ravery V, et al. **Prog Urol** 1995 Dec;5(6):968–73 (17 ref.) (Eng. Abstr.) **(Fre)**

[Tubular differentiated stomach carcinoma of the (Ming) infiltrating type] Dirschmid K, et al. **Pathologe** 1996 Mar; 17(2):122–6 (Eng. Abstr.) **(Ger)**

[Sclerosing adenosis of the prostate. Carcinoma simulation] Meister P. **Pathologe** 1996 Mar;17(2):157–62 (Eng. Abstr.) **(Ger)**

[Preoperative serum levels of CEA and CA19–9 in patients with gastric cancer] Roviello F, et al. **Minerva Chir** 1996 Mar;51(3):133–9 (Eng. Abstr.) **(Ita)**

[A case of huge prostate cancer] Miyajima A, et al. **Hinyokika Kiyo** 1995 Sep;41(9):683–5 (Eng. Abstr.) **(Jpn)**

[Prostatic adenocarcinoma showing features of endometrioid and mucinous carcinomas: a case report] Nishimura K, et al. **Hinyokika Kiyo** 1995 Oct;41(10):805–7 (Eng. Abstr.) **(Jpn)**

[A case report of prostate cancer with Paneth cell–like change] Soga N, et al. **Hinyokika Kiyo** 1995 Nov; 41(11):891–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Establishment of a cisplatin–resistant new human endometrial adenocarcinoma cell line, Sawano cells] Satoh T, et al. **Hum Cell** 1995 Jun;8(2):67–72 (Eng. Abstr.) **(Jpn)**

[Comparative study on biological difference between gastric cancer and colorectal cancer] Mai M, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):263–8 (24 ref.) (Eng. Abstr.) **(Jpn)**

[A case of gastric cancer developed in the gastric tube 11 years after subtotal esophagectomy for esophageal cancer] Kan T, et al. **Nippon Geka Hokan** 1995 Sep 1;64(5):123–7 (Eng. Abstr.) **(Jpn)**

[Comparisons of histological grading between biopsy and radical prostatectomy specimens in prostatic adenocarcinoma] Fujinami K, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1460–5 (Eng. Abstr.) **(Jpn)**

[The proliferative ability of stage I lung adenocarcinoma and the correlation between host immunity and prognosis] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):670–2 **(Jpn)**

[Moderately differentiated adenocarcinoma of the lung presenting as multiple intrapulmonary metastases with thin–walled cavities] Kojima K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan; 34(1):96–100 (Eng. Abstr.) **(Jpn)**

[A case of endocrine cell carcinoma in the duodenal bulb] Nishida K, et al. **Nippon Ronen Igakkai Zasshi** 1996 Apr; 33(4):278–83 (Eng. Abstr.) **(Jpn)**

[Experimental studies on the cell adhesion molecule E–cadherin and in vitro invasion of endometrial carcinoma cell lines] Okamura N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 May; 48(5):335–42 (Eng. Abstr.) **(Jpn)**

[Immunohistochemical demonstration of laminin in endometrial cancer of uterus in relation to it's invasion and metastasis] Ooishi M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep;47(9):955–6 **(Jpn)**

[Expression of Le(y) antigen in adenocarcinoma and its related lesions of the human uterine cervix] Umezaki K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep; 47(9):925–30 (Eng. Abstr.) **(Jpn)**

[Retrospective analysis of cytology in a case with early invasive cervical adenocarcinoma] Utsugi K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Dec; 47(12):1389–92 **(Jpn)**

[A clinicopathological study in clear cell adenocarcinoma of the endometrium] Yamawaki T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 May; 48(5):328–34 (Eng. Abstr.) **(Jpn)**

[A study on the association between glandular dysplasia and cervical squamous neoplasia in surgical specimens] Yasuda M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jan; 48(1):32–6 (Eng. Abstr.) **(Jpn)**

[A case of early cancer which consecutively spread on the stomach and duodenum] Matsumoto T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):255–9 **(Jpn)**

[A case of primary salpinx cancer—diagnostic difficulties] Błoch P, et al. **Ginekol Pol** 1995 Nov;66(11):646–8 (Eng. Abstr.) **(Pol)**

[Finding antigens using immunoenzyme methods characterized by nonhistone proteins in hyperplastic and neoplastic endometrium in women] Miturski R. **Ginekol Pol** 1995 May;66(5):277–9 (Eng. Abstr.) **(Pol)**

[A case of aspergilloma in a adenocarcinoma cavity in a patient with a history of pulmonary tuberculosis] Nalepa P. **Pneumonol Alergol Pol** 1995;63(9–10):553–5 **(Pol)**

[Adenocarcinoma of the cervix uteri (immunohistochemistry, ultrastructure, differential diagnosis from adenocarcinoma of the adjacent organs] Petrov SV, et al. **Arkh Patol** 1995 Sep–Oct;57(5):47–53 (Eng. Abstr.) **(Rus)**

[The presence of cesium–137 in the tissue of a lung tumor in someone who cleaned up the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Grobova OM, et al. **Ter Arkh** 1996;68(3):26–30 (Eng. Abstr.) **(Rus)**

[The clinico–morphological characteristics of cancer of the extrahepatic bile ducts (an analysis of 52 autopsy cases)] Samsonov VA, et al. **Ter Arkh** 1995;67(10):53–5 (Eng. Abstr.) **(Rus)**

[Regional metastasis of malignant tumors of the external acoustic meatus and middle ear] Pavlov AS, et al. **Vestn Otorinolaringol** 1995 Nov–Dec;(6):21–3 **(Rus)**

[Metastases to the temporal bone. A report of two cases] Grijalba Uche M, et al. **Acta Otorrinolaringol Esp** 1995 Nov–Dec;46(6):441–3 (Eng. Abstr.) **(Spa)**

[Disparity between cytohistopathological results of diagnostic specimens and the resected tumor piece in bronchopulmonary carcinoma] Sánchez Varilla JM, et al. **An Med Interna** 1996 Apr;13(4):168–70 (Eng. Abstr.) **(Spa)**

[The reliability of computed tomography (CT) in the local (T) and lymph node (N) staging of kidney adenocarcinoma] Herranz Amo F, et al. **Arch Esp Urol** 1995 Nov; 48(9):897–905; discussion 905–6 (Eng. Abstr.) **(Spa)**

[Streptococcus bovis in a surgical wound and a colonic neoplasm] Martínez Mas E, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):474–6 (19 ref.) (Eng. Abstr.) **(Spa)**

[Cyto–reduction of rectal cancer after preoperative chemoradiotherapy] Sánchez Maldonado W, et al. **Rev Gastroenterol Mex** 1995 Jul–Sep;60(3):158 **(Spa)**

PHYSIOPATHOLOGY

Down–regulation of beta 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. Fornaro M, et al. **Am J Pathol** 1996 Sep;149(3):765–73

Epidermal Langerhans cells from mice bearing a granulocyte macrophage–colony stimulating factor–producing mammary tumor display impaired accessory functions. Xie Y, et al. **Anticancer Res** 1996 Jan–Feb;16(1):9–16

Volume–sensitive chloride channels in the primary culture cells of human cervical carcinoma. Shen MR, et al. **Biochim Biophys Acta** 1996 Mar 1;1315(2):138–44

Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Lewis JE, et al. **Cancer** 1996 Jan 15;77(2):223–30 (35 ref.)

Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Znati CA, et al. **Cancer Res** 1996 Mar 1;56(5):964–68

Neurophysiological examination of end–plate function in patients with lung cancer. Jandolo B, et al. **Electromyogr Clin Neurophysiol** 1995 Jun–Jul;35(4):247–50

Dissociation of c–fos induction and mitogen–activated–protein kinase activation from the hepatocyte–growth–factor–induced motility response in human gastric carcinoma cells. Nagamine K, et al. **Eur J Biochem** 1996 Mar 1;236(2):476–81

Glutathione peroxidase activity in endometrium: effects of sex hormones and cancer. Ohwada M, et al. **Gynecol Oncol** 1996 Feb;60(2):277–82

[Study of circadian rhythms of activity by actometry: preliminary results in 30 patients with metastatic colorectal cancer] Mormont MC, et al. **Pathol Biol (Paris)** 1996 Mar; 44(3):165–71 (Eng. Abstr.) **(Fre)**

[Effects of intravenous laser irradiation of blood on the sympathoadrenal, antioxidant and immune system in patients with cancer of the stomach and large intestine] Lal'chenko NA, et al. **Klin Khir** 1996;(1):36–9 **(Rus)**

[Sympathetic denervation of an extremity as a presentation form of apical lung cancer] Campero M, et al. **Rev Med Chil** 1995 May;123(5):624–7 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Chemoprevention of colon cancer by dietary curcumin. Rao CV, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:201–4

Barrett's esophagus with high–grade dysplasia. An indication for prophylactic esophagectomy. Heitmiller RF, et al. **Ann Surg** 1996 Jul;224(1):66–71

Clinical impact of colonoscopic screening in first–degree relatives of patients with hereditary non–polyposis colorectal cancer. Green SE, et al. **Br J Surg** 1995 Oct; 82(10):1338–40

Chemopreventive effects of 24R,25–dihydroxyvitamin D3, a vitamin D3 derivative, on glandular stomach carcinogenesis induced in rats by N–methyl–N'–nitro–N–nitrosoguanidine and sodium chloride. Ikezaki S, et al. **Cancer Res** 1996 Jun 15; 56(12):2767–70

Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Murrill WB, et al. **Carcinogenesis** 1996 Jul;17(7):1451–7

Chemopreventive effects of phenethyl isothiocyanate on lung and pancreatic tumorigenesis in N–nitrosobis(2–oxopropyl)amine–treated hamsters. Nishikawa A, et al. **Carcinogenesis** 1996 Jun;17(6):1381–4

Effect of selective and non–selective muscarinic blockade on baclofen inhibition of gastric carcinogenesis induced by N–methyl–N'–nitro–N–nitrosoguanidine in Wistar rats. Tatsuta M, et al. **Carcinogenesis** 1996 Feb;17(2):293–6

Suppression by amiloride of bombesin–enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Iishi H, et al. **Int J Cancer** 1995 Nov 27; 63(5):716–9

Potential criteria for cohort selection in chemoprevention trials of uterine adenocarcinoma. Baker VV. **J Cell Biochem Suppl** 1995;23:184–8 (32 ref.)

Modelling cost–effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials [see comments] Parsonnet J, et al. **Lancet** 1996 Jul 20;348(9021):150–4. Comment in: Lancet 1996 Jul 20;348(9021):141.

The effect of dietary fermented milk products and lactic acid bacteria on the initiation and promotion stages of mammary carcinogenesis. Rice LJ, et al. **Nutr Cancer** 1995; 24(2):99–109

Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Reddy BS. **Prev Med** 1996 Jan–Feb;25(1):48–50 (13 ref.)

Protective capability of dietary Zizyphus mistol seed oil, rich in 18:3, n–3, on the development of two murine mammary gland adenocarcinomas with high or low metastatic potential. Muñoz SF, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Aug; 53(2):135–8

Discovery of early gastric remnant carcinoma. Results of a 14–year endoscopic screening program. Greene FL. **Surg Endosc** 1995 Nov;9(11):1199–203

PSYCHOLOGY

Save a seat on the bus for me. Cristo MG. **Am J Nurs** 1995 Sep;95(9):72

RADIOGRAPHY

Serum prostate–specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer. Huncharek M, et al. **Abdom Imaging** 1996 Jul–Aug;21(4):364–7

Vascular involvement in pancreatic adenocarcinoma: reassessment by thin–section CT [see comments] Loyer EM, et al. **Abdom Imaging** 1996 May–Jun;21(3):202–6. Comment in: Abdom Imaging 1996 May–Jun;21(3):207–10.

Pancreatic adenocarcinoma [editorial; comment] Stephens DH. **Abdom Imaging** 1996 May–Jun;21(3):207–10. Comment on: Abdom Imaging 1996 May–Jun;21(3):202–6.

Radiologic features of carcinomas arising in hiatal hernias. Maglinte DD, et al. **AJR Am J Roentgenol** 1996 Apr; 166(4):789–94

Case report: malignant haemobilia detected in the gallbladder—retrograde cholangiographic findings. Osawa H, et al. **Br J Radiol** 1996 Jan;69(817):79–81

Wessex regional radiology audit: barium enema in colo–rectal carcinoma [see comments] Thomas RD, et al. **Clin Radiol** 1995 Sep;50(9):647–50. Comment in: Clin

Radiol 1996 Apr;51(4):306.

Angiographic properties of Gd-DTPA-24-cascade-polymer--a new macromolecular MR contrast agent. Schwickert HC, et al. **Eur J Radiol** 1995 Jul;20(2):144-50

Air-space pattern in lung metastasis from adenocarcinoma of the GI tract. Gaeta M, et al. **J Comput Assist Tomogr** 1996 Mar-Apr;20(2):300-4

Pancreatic adenocarcinoma presenting as a splenic abscess: case report and diagnostic approach. Lastrapes RG, et al. **J Okla State Med Assoc** 1995 Aug;88(8):333-6

Metastatic adenocarcinoma mimicking unilateral sacroiliitis. Humphrey SM, et al. **J Rheumatol** 1995 May;22(5):970-2

Imaging features of ovarian metastases from colonic adenocarcinoma in adolescents. Kauffman WM, et al. **Pediatr Radiol** 1995;25(4):286-8

Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation. Bluemke DA, et al. **Radiology** 1995 Nov;197(2):381-5

Delayed enhanced CT for differentiation of benign from malignant adrenal masses. Korobkin M, et al. **Radiology** 1996 Sep;200(3):737-42

Two-phase helical CT for pancreatic tumors: pancreatic versus hepatic phase enhancement of tumor, pancreas, and vascular structures. Lu DS, et al. **Radiology** 1996 Jun; 199(3):697-701

Colon cancer: morphology detected with barium enema examination versus histopathologic stage. McCarthy PA, et al. **Radiology** 1995 Dec;197(3):683-7

Congenital bile duct cyst: a premalignant lesion of the biliary tract associated with adenocarcinoma--a case report. Holzinger F, et al. **Z Gastroenterol** 1996 Jun;34(6):382-5

[Intracerebral calcifications] Milesi-Lecat AM, et al. **Rev Med Interne** 1995;16(8):636-7 **(Fre)**

[Spiral computerized tomography with tridimensional reconstruction (spiral 3D CT) in the study of maxillofacial pathology] Mevio E, et al. **Acta Otorhinolaryngol Ital** 1995 Dec;15(6):443-8 (Eng. Abstr.) **(Ita)**

[Use of CT-guided metal wires in pre-thoracoscopic localization of peripheral pulmonary nodules] Garuti E, et al. **Radiol Med (Torino)** 1995 Oct;90(4):470-4 (Eng. Abstr.) **(Ita)**

[The reliability of computed tomography (CT) in the local (T) and lymph node (N) staging of kidney adenocarcinoma] Herranz Amo F, et al. **Arch Esp Urol** 1995 Nov; 48(9):897-905; discussion 905-6 (Eng. Abstr.) **(Spa)**

[Early gastric cancer staging by radiology (letter; comment)] Castro DJ. **G E N** 1994 Oct-Dec;48(4):281-2. Comment on: G E N 1994 Apr-Jun;48(2):98-104. **(Spa)**

[Acute respiratory failure and multiple pulmonary nodules. Pulmonary metastases of colonic adenocarcinoma] Cordero PJ, et al. **Rev Clin Esp** 1995 Dec;195(12):845-6 (7 ref.) **(Spa)**

RADIONUCLIDE IMAGING

Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Sazon DA, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):417-21

Octreotide scintigraphy. A new method for diagnosing pancreatic tumors [editorial; comment] Merrell. **Ann Surg** 1996 Aug;224(2):117-8. Comment on: Ann Surg 1996 Aug;224(2):119-24.

The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors [see comments] van Eijck CH, et al. **Ann Surg** 1996 Aug;224(2):119-24. Comment in: Ann Surg 1996 Aug;224(2):117-8.

Diagnostic accuracy and tumor-targeting kinetics of complete versus fragmented 99mTc-labeled anti-carcinoembryonic antigen antibodies: an intraindividual comparison. Behr TM, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5786s-5793s

Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Nilsson S, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5805s-5810s

Fortuitous imaging of a primary adrenocortical carcinoma with Tc-99m HDP. Pacheco EJ, et al. **Clin Nucl Med** 1995 Oct;20(10):906-8

Metastases seen on SPECT imaging despite a normal planar bone scan. Roland J, et al. **Clin Nucl Med** 1995 Dec; 20(12):1052-4

Case report: ossifying metastases from carcinoma of the large bowel demonstrated by bone scintigraphy. Stabler J. **Clin Radiol** 1995 Oct;50(10):730-1

111In-CYT-103 scanning in recurrent colorectal cancer--does it affect standard management? Dominguez JM, et al. **Dis Colon Rectum** 1996 May;39(5):514-9

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences. Alexander C, et al. **Eur J Nucl Med** 1995 Jul;22(7):645-51

Technetium-99m-tetrofosmin uptake in malignant lung tumours. Başoğlu T, et al. **Eur J Nucl Med** 1995 Jul; 22(7):687-9

RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. Philpott GW, et al. **J Nucl Med** 1995 Oct;36(10):1818-24

Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy. Raderer M, et al. **J Nucl Med** 1996 Sep;37(9):1480-7

Thallium-201 uptake, histopathological differentiation and Na-K ATPase in lung adenocarcinoma. Takekawa H, et al. **J Nucl Med** 1996 Jun;37(6):955-8

Vasoactive intestinal peptide receptor scintigraphy. Virgolini I, et al. **J Nucl Med** 1995 Oct;36(10):1732-9

A brain metastasis, with no uptake of 99mTc-ECD, secondary to Hurtle cell carcinoma of the thyroid. Orsolon P, et al. **Minerva Endocrinol** 1995 Dec;20(4):233-6

Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma. Benyounes H, et al. **Nucl Med Commun** 1995 Jul;16(7):575-80

Hürthle cell carcinoma in an autonomous thyroid nodule in an adolescent. Siddiqui AR, et al. **Pediatr Radiol** 1995; 25(7):568-9

[The prognostic effect of scintigraphy-guided lymphadenectomy in therapy of stage Ib cervix carcinoma] Schatten C, et al. **Geburtshilfe Frauenheilkd** 1995 Aug; 55(8):441-6 (Eng. Abstr.) **(Ger)**

[Clear skeletal visualization on whole body 201Tl-chloride scintigraphy: a case of prostatic cancer with diffuse bone metastases] Tsubuku M, et al. **Kaku Igaku** 1995 Nov; 32(11):1249-53 (Eng. Abstr.) **(Jpn)**

[Evaluation of pancreatic cancers using thallium-201 single photon emission computed tomography] Kume N, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Aug; 55(9):682-9 (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method. Garkavij M, et al. **Acta Oncol** 1996;35(3):309-12

External beam radiotherapy of localized prostatic adenocarcinoma. Evaluation of conformal therapy, field number and target margins. Lennernäs B, et al. **Acta Oncol** 1995;34(7):953-8

Field displacement during external radiotherapy in prostatic adenocarcinoma treated with radioactive 198Au implants and external irradiation. Lennernäs B, et al. **Acta Oncol** 1995;34(7):959-64

Adverse effects after radical external beam radiotherapy of localized prostatic adenocarcinoma using two-dimensional dose-planning and a limited field technique. Ljung G, et al. **Acta Oncol** 1996;35(4):445-50

The curative potential of radiation therapy in the treatment of primary vaginal carcinoma. Fine BA, et al. **Am J Clin Oncol** 1996 Feb;19(1):39-44

Preoperative "chemoradiation" for stages II and III rectal carcinoma. Stryker SJ, et al. **Arch Surg** 1996 May; 131(5):514-8; discussion 518-9

Percutaneous iodine-125 seed implantation for carcinoma of the prostate. Kaye KW, et al. **Aust N Z J Surg** 1995 Sep; 65(9):658-63

The management of endometrial carcinoma [editorial] Irwin CJ. **Br J Hosp Med** 1996 Mar 20-Apr 2;55(6):308-10

Case report: fracture of central intrauterine tube following insertion of high dose rate intracavitary applicator. Tyrie LK, et al. **Br J Radiol** 1996 Jul;69(823):671-2

Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. Marsh RD, et al. **Cancer** 1996 Jul 15; 78(2):217-25

Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma. Miller RJ Jr, et al. **Cancer** 1996 Apr 15; 77(8):1510-4

Prognostic significance of tumor fixation of rectal carcinoma. Implications for adjunctive radiation therapy. Mohiuddin M, et al. **Cancer** 1996 Aug 15;78(4):717-22

Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB-1 and PC10 labeling indices. Oka K, et al. **Cancer** 1996 Jun 1;77(11):2280-5

Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis. Pinover WH, et al. **Cancer** 1996 Apr 1;77(7):1334-41

Effects of external radiotherapy on uterine blood flow in patients with advanced cervical carcinoma assessed by color Doppler ultrasonography. Pirhonen JP, et al. **Cancer** 1995 Jul 1;76(1):67-71

Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Pollack A, et al. **Cancer** 1996 Apr 15;77(8):1515-23

Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG, et al. **Cancer** 1996 Jun 1;77(11):2386-92

Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Thomas F, et al. **Cancer** 1995 Dec 1;76(11):2286-90

In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Shih LB, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5857s-5863s

Long-term follow-up of local excision and radiation therapy for invasive rectal cancer. Fortunato L, et al. **Dis Colon Rectum** 1995 Nov;38(11):1193-9

Conservative and curative management of rectal adenocarcinomas by local radiotherapy alone. Horiot JC, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1340-2

Adenocarcinoma of the eccrine sweat gland: response to both combination chemotherapy and local field irradiation [letter] Mertens WC, et al. **Eur J Cancer** 1996 Feb; 32A(2):372-3

Multi-institutional clinical trials: 3-D conformal radiotherapy quality assurance. Guidelines in an NCI/RTOG study evaluating dose escalation in prostate cancer radiotherapy. Purdy JA, et al. **Front Radiat Ther Oncol** 1996;29:255-63

Adenocarcinoma of the cervix in a renal transplant patient. Ripley D, et al. **Gynecol Oncol** 1995 Oct;59(1):151-5

Radioimmunotherapy of prostatic adenocarcinomas: effects of 131I-labelled E4 antibodies on cells at different depth in DU 145 spheroids. Essand M, et al. **Int J Cancer** 1995 Nov 3;63(3):387-94

Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Zamora PO, et al. **Int J Cancer** 1996 Jan 17;65(2):214-20

Analysis of prostate and seminal vesicle motion: implications for treatment planning. Beard CJ, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):451-8

Three dimensional conformal treatment planning with multileaf collimators. Brewster L, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1081-9

Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Chyle V, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):891-905

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913-8 (35 ref.). Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969-70.

Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: preliminary estimates of the therapeutic ratio. Forman JD, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):259-66

Endocavitary irradiation for early rectal carcinomas T1 (T2). A series of 101 patients treated with the Papillon's technique [see comments] Gérard JP, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):775-83. Comment in: Int J Radiat Oncol Biol Phys 1996 Mar 1;34(4):961-2.

Potency following conformal neutron/photon irradiation for localized prostate cancer. Hart KB, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):881-4

Radiotherapy for regionally localized hormone refractory prostate cancer. Lankford SP, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):907-12

Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial. Martinez A, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1019-27

Conservative management of early rectal cancer [editorial; comment] Minsky BD. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):961-2. Comment on: Int J Radiat Oncol Biol Phys 1996 Mar 1;34(4):775-83.

Management of minor salivary gland carcinomas [see comments] Parsons JT, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):443-54. Comment in: Int J Radiat Oncol Biol Phys 1996 Jun 1;35(3):631-2.

Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Pollack A, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1; 34(3):555-64

A pilot survey of sexual function and quality of life following 3D conformal radiotherapy for clinically localized prostate cancer. Roach M 3rd, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):869-74

Pelvic control following external beam radiation for surgical stage I endometrial adenocarcinoma. Rush S, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):851-4

Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Sandler HM, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):797-801

Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Stock RG, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):267-72

An analysis of intratreatment and intertreatment displacements in pelvic radiotherapy using electronic portal imaging. Tinger A, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):683-90

Prospective trial of combined hyperfractionated radiotherapy and bronchial arterial infusion of chemotherapy for locally advanced nonsmall cell lung cancer. Wang G, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):309-13

RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer [see comments] Watkins-Bruner D, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):901-6. Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):965-6.

The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Yang FE, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1009-17

PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells. Yang JL, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 15;34(5):1073-9

Blood supply to the oral and maxillofacial tissues following radiation therapy: a prospective ultrasonographic study.

Semergidis T, et al. **J Craniomaxillofac Surg** 1996 Feb; 24(1):16–23

Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium–177–CC49. Meredith RF, et al. **J Nucl Med** 1996 Sep;37(9):1491–6

Palladium–103: a new radioactive source in the treatment of unresectable carcinoma of the pancreas: a phase I–II study. Nori D, et al. **J Surg Oncol** 1996 Apr;61(4):300–5

Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. Wallace HJ 3rd, et al. **J Surg Oncol** 1995 Oct;60(2):122–7

Prostate carcinoma metastatic to the penis: magnetic resonance imaging and brachytherapy. Griffin JH, et al. **J Urol** 1996 May;155(5):1701–2

Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease–free survival [see comments] Lee WR, et al. **J Urol** 1996 Aug; 156(2 Pt 1):450–3. Comment in: J Urol 1996 Aug;156(2 Pt 1):459.

p53 immunohistochemical and genetic alterations are associated at high incidence with post–irradiated locally persistent prostate carcinoma. Prendergast NJ, et al. **J Urol** 1996 May;155(5):1685–92

Surgical staging and high dose rate brachytherapy for endometrial cancer: limiting external radiotherapy to node–positive tumors. Fanning J, et al. **Obstet Gynecol** 1996 Jun;87(6):1041–4

High–dose–rate intraoperative radiation therapy for colorectal cancer. Harrison LB, et al. **Oncology (Huntingt)** 1995 Aug;9(8):737–41; discussion 742–8 passim

High grade prostatic intraepithelial neoplasia in prostates removed following irradiation failure in the treatment of prostatic adenocarcinoma. Arakawa A, et al. **Pathol Res Pract** 1995 Sep;191(9):868–72

Clinicopathologic features in rectal cancer treated by local excision and postoperative radiation therapy. Minsky BD, et al. **Radiat Med** 1995 Sep–Oct;13(5):235–41

Pancreatic cancer: treatment with neutron irradiation alone and with chemotherapy [see comments] Cohen L, et al. **Radiology** 1996 Sep;200(3):627–30. Comment in: Radiology 1996 Sep;200(3):608–9.

Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone? Lee WR, et al. **Radiology** 1996 Feb;198(2):439–42

Postoperative radiotherapy in carcinoma of the cervix: treatment results and prognostic factors. Atkovar G, et al. **Radiother Oncol** 1995 Jun;35(3):198–205

Reproducibility of conformal radiation therapy in localized carcinoma of the prostate without rigid immobilization. Bieri S, et al. **Radiother Oncol** 1996 Mar;38(3):223–30

Concurrent 5–fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer. Christie DR, et al. **Radiother Oncol** 1995 Dec;37(3):181–9

A single session of intraluminal brachytherapy in palliation of oesophageal cancer. Jager J, et al. **Radiother Oncol** 1995 Dec;37(3):237–40

Increased morbidity following the introduction of remote afterloading, with increased dose rate, for cancer of the cervix [see comments] Newman G. **Radiother Oncol** 1996 May;39(2):97–103. Comment in: Radiother Oncol 1996 May;39(2):95–6.

Optimization of intensity–modulated 3D conformal treatment plans based on biological indices. Wang XH, et al. **Radiother Oncol** 1995 Nov;37(2):140–52

Radiotherapy in rectal cancer: stage of the disease and therapeutic approach. Cellini N, et al. **Rays** 1995 Apr–Jun; 20(2):132–44 (72 ref.) **(Eng, Ita)**

Prophylactic irradiation of para–aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. Chatani M, et al. **Strahlenther Onkol** 1995 Nov; 171(11):655–60

Role of radiation therapy in carcinoma of the gall bladder—a preliminary indian experience. Mehta A, et al. **Trop Gastroenterol** 1996 Jan–Mar;17(1):22–5

Prevention of radiation related complications in the treatment of rectal adenocarcinoma. The importance of the dose volume relationship. Gerard JP, et al. **Tumori** 1995 May–Jun;81(3 Suppl):114–6 (20 ref.)

Do the results of systematic biopsies predict outcome in patients with T1–T2 prostate cancer treated with radiation therapy alone? Lee WR, et al. **Urology** 1996 May; 47(5):704–7

[Radiotherapy of inoperable esophageal cancer. Retrospective analysis apropos of 108 cases] Geara F, et al. **Bull Cancer Radiother** 1990;77(1):69–76 (Eng. Abstr.) **(Fre)**

[Role of percutaneous radiotherapy in male breast carcinoma] Schuchardt U, et al. **Strahlenther Onkol** 1996 Jul; 172(7):369–75 (Eng. Abstr.) **(Ger)**

[Local efficiency of percutaneous radiotherapy in lung cancer. Analysis of 215 repeated bronchoscopies in relation to applied radiation dosage] Schwegler N, et al. **Strahlenther Onkol** 1996 Feb;172(2):81–90 (Eng. Abstr.) **(Ger)**

[The results of sandwich adjuvant radiotherapy in 2nd– and 3rd–stage rectal adenocarcinoma. The authors' personal experience] Gabriele AM, et al. **Radiol Med (Torino)** 1995 Sep;90(3):307–10 (Eng. Abstr.) **(Ita)**

[The combined radiochemotherapy of inoperable esophageal neoplasms: a feasibility study] Sola B, et al. **Radiol Med (Torino)** 1996 Apr;91(4):456–9 (Eng. Abstr.) **(Ita)**

[Cyto–reduction of rectal cancer after preoperative chemoradiotherapy] Sánchez Maldonado W, et al. **Rev Gastroenterol Mex** 1995 Jul–Sep;60(3):158 **(Spa)**

SECONDARY

Metastatic pleural effusion as presenting sign of prostatic carcinoma. Druwé PM, et al. **Acta Clin Belg** 1995; 50(4):227–30

Enhancement of experimental metastasis by gamma–interferon in a murine adenocarcinoma. Hirano T, et al. **Acta Med Okayama** 1996 Feb;50(1):11–6

Orbital presentation of ethmoid sinus adenocarcinoma. Seregard S, et al. **Acta Ophthalmol Scand** 1995 Oct; 73(5):457–9

Urethral metastasis from a rectal carcinoma. Kupfer HW, et al. **Acta Urol Belg** 1995 Dec;63(4):31–2

Carcinoma of the prostate: treatment of bone metastasis. Scalliet P. **Acta Urol Belg** 1996 May;64(2):87–90 (13 ref.)

Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long–term results. Colozza M, et al. **Am J Clin Oncol** 1996 Feb;19(1):10–7

Phase II trial of CHIP for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group Study. Marshall ME, et al. **Am J Clin Oncol** 1995 Oct;18(5):400–2

Phase II trial of isotretinoin and recombinant interferon alfa–2a in metastatic colorectal carcinoma. Pazdur R, et al. **Am J Clin Oncol** 1995 Oct;18(5):436–8

Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. Williamson SK, et al. **Am J Clin Oncol** 1996 Aug; 19(4):368–70

Adenocarcinoma of the duodenum with liver metastases. Complete remission and long–term survival with 5–fluorouracil chemotherapy—a case report. Witham M, et al. **Am J Clin Oncol** 1996 Jun;19(3):305–6

Cutaneous metastasis from a parotid adenocarcinoma. Report of a case with immunohistochemical findings and review of the literature. Tok J, et al. **Am J Dermatopathol** 1995 Jun;17(3):303–6 (9 ref.)

Two cases of pancreatic cancer associated with skin metastases [letter] Nakano S, et al. **Am J Gastroenterol** 1996 Feb;91(2):410–1

Diagnosis of lymphangitic carcinoma to lung by sputum cytology: case report. Shanies HM, et al. **Angiology** 1995 Nov;46(11):1035–8

Prostate cancer metastatic to the orbit [see comments] Maschka DA, et al. **Ann Otol Rhinol Laryngol** 1996 Jan; 105(1):70–1. Comment in: Ann Otol Rhinol Laryngol 1996 Jul;105(7):584.

"Metastatic breast carcinoma" that is neither metastatic nor breast. Rudolph R, et al. **Ann Plast Surg** 1995 Nov; 35(5):537–40

Clinical significance of colorectal cancer: metastases in lymph nodes < 5 mm in size. Rodriguez–Bigas MA, et al. **Ann Surg Oncol** 1996 Mar;3(2):124–30

Budd–Chiari syndrome secondary to carcinoma: report of two cases. Chatel D, et al. **Ann Vasc Surg** 1995 Nov; 9(6):565–70

Treatment of liver metastases from colorectal cancer. Isenberg J, et al. **Anticancer Res** 1996 May–Jun; 16(3A):1291–5

Apoptosis and necrosis occurring during different stages of primary and metastatic tumor growth of a rat mammary adenocarcinoma. Matsuda H, et al. **Anticancer Res** 1996 May–Jun;16(3A):1117–21

Assessment of response to carboplatin in patients with hormone–refractory prostate cancer: a critical analysis of drug activity. Miglietta L, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2825–8

Breast carcinoma metastatic to the optic nerve. Newman NJ, et al. **Arch Ophthalmol** 1996 Jan;114(1):102–3

P53 tumour–suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer. Dahiya R, et al. **Br J Cancer** 1996 Jul;74(2):264–8

Carcinoma colon with mandible and liver metastases [letter] Babu KG, et al. **Br J Oral Maxillofac Surg** 1996 Feb; 34(1):133–4

Metastatic colonic adenocarcinoma in a pedicled omental flap used for sternal reconstruction: a case report. Telfer JR, et al. **Br J Plast Surg** 1996 Jan;49(1):67–9

Case of the month: hidden trouble. Obaro RO. **Br J Radiol** 1995 Dec;68(816):1369–70

Diagnostic laparoscopy combined with laparoscopic ultrasonography in staging of cancer of the pancreatic head region [letter; comment] Carmichael AR, et al. **Br J Surg** 1995 Dec;82(12):1703–4. Comment on: Br J Surg 1995 Jun;82(6):820–4.

Choroidal biopsy in the diagnosis of a suspect intraocular lesions. Lefebvre A, et al. **Bull Soc Belge Ophtalmol** 1995; 255:93–7

Detection of DCC and Ki–ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. Kato M, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1729–35

Surgical treatment for patients with pulmonary metastases after resection of primary colorectal carcinoma. Shirouzu K, et al. **Cancer** 1995 Aug 1;76(3):393–8

Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA–III) in L–W rats. Pollard M. **Cancer Lett** 1996 Mar 19;101(1):21–4

Heterotopic ossification in adenocarcinoma of the colon. Hui Y, et al. **Chin Med J (Engl)** 1995 Oct;108(10):798–800 (2 ref.)

EGF stimulates lamellipod extension in metastatic mammary adenocarcinoma cells by an actin–dependent mechanism. Segall JE, et al. **Clin Exp Metastasis** 1996 Jan;14(1):61–72

Fortuitous imaging of a primary adrenocortical carcinoma with Tc–99m HDP. Pacheco EJ, et al. **Clin Nucl Med** 1995 Oct;20(10):906–8

Metastases seen on SPECT imaging despite a normal planar bone scan. Roland J, et al. **Clin Nucl Med** 1995 Dec; 20(12):1052–4

Colonic adenocarcinoma metastatic to bone with gross heterotopic bone formation. Bone scan appearance with correlative imaging. Stuckey SL. **Clin Nucl Med** 1996 May; 21(5):396–7

Case report: ossifying metastases from carcinoma of the large bowel demonstrated by bone scintigraphy. Stabler J. **Clin Radiol** 1995 Oct;50(10):730–1

Adenocarcinoma of the colon presenting with a Sister Mary Joseph's nodule and Trousseau's syndrome. Barnes J, et al. **Cutis** 1995 Nov;56(5):270–2

Colonic adenocarcinoma associated ectopic ACTH secretion: a case history. Anthoney DA, et al. **Eur J Cancer** 1995 Nov;31A(12):2109–12

Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. Pantel K, et al. **Eur J Cancer** 1995 Sep; 31A(10):1627–32

Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by immunocytochemical staining. Thorban S, et al. **Eur J Cancer** 1996 Feb; 32A(2):363–5

Complete sternectomy for metastatic carcinoma with reconstruction using a latissimus dorsi musculocutaneous flap. Shimizu J, et al. **Eur J Cardiothorac Surg** 1995; 9(6):342–4

Effect of octreotide infusion on hepatic and tumour blood flow in two experimental models of liver metastases. Davies N, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):971–4

Solitary metastasis in the tarsus preceding the diagnosis of primary endometrial cancer. A case report. Petru E, et al. **Eur J Gynaecol Oncol** 1995;16(5):387–91

Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic–assisted colectomy for colon cancer. Jacquet P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):568–70 (25 ref.)

Intra–arterial liposomal adriamycin for metastatic adenocarcinoma of the liver. Konno H, et al. **Eur Surg Res** 1995;27(5):301–6

The final analysis of the EORTC Genito–Urinary Tract Cancer Co–Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Robinson MR, et al. **Eur Urol** 1995;28(4):273–83

Metastatic colonic adenocarcinoma of the orbit with intraneural extension from the brow to the brainstem [letter] Ezra E, et al. **Eye** 1995;9 (Pt 3):371–2

The eye and adenocarcinoma of the breast: metastases and meningiomas [letter] Hingorani M, et al. **Eye** 1995;9 (Pt 5):640–3

Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Bova GS, et al. **Genomics** 1996 Jul 1;35(1):46–54

Structure and methylation–associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. MacGrogan D, et al. **Genomics** 1996 Jul 1;35(1):55–65

Carcinomatous meningitis complicating cervical cancer: a clinicopathologic study and literature review. Aboulafia DM, et al. **Gynecol Oncol** 1996 Feb;60(2):313–8 (19 ref.)

Recurrent endometrial adenocarcinoma presenting as a solitary humeral metastasis. Schöls WA, et al. **Gynecol Oncol** 1995 Oct;59(1):148–50 (14 ref.)

Resection of metastatic liver cancer in a patient with an anomalous intrahepatic portal system: a case report. Hiei K, et al. **Hepatogastroenterology** 1995 Nov–Dec; 42(6):1002–7

Locoregional chemotherapy versus locoregional combined immuno–chemotherapy for patients with advanced metastatic liver disease of colorectal origin: a prospective randomized study. Lygidakis NJ, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):212–20

Histopathological assessment of lymph node metastasis in patients with gastric cancer. Matsushita M, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):861–6

Case in point. Metastatic carcinoma of the prostate. Fred HL, et al. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):76

Metastatic pattern of gastric carcinoma [letter; comment] Carneiro F, et al. **Hum Pathol** 1996 Feb;27(2):213–4. Comment on: Hum Pathol 1995 May;26(5):504–8.

Decreased expression of nucleoside diphosphate kinase alpha isoform, an nm23–H2 gene homolog, is associated with metastatic potential of rat mammary–adenocarcinoma cells. Fukuda M, et al. **Int J Cancer** 1996 Feb 8;65(4):531–7

Diffuse spinal leptomeningeal metastases from prostatic cancer. A case report. Matsui H, et al. **Int Orthop** 1995;

19(5):315–8 (18 ref.)
Metastatic breast cancer to the bladder: a case report. Schneidau T, et al. **Int Urol Nephrol** 1995;27(3):297–300 (11 ref.)
Phase I–II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum. Elias D, et al. **J Am Coll Surg** 1995 Oct;181(4):303–10
Vivre ou laisser mourir [letter] Rutschmann OT, et al. **J Am Geriatr Soc** 1996 Jan;44(1):104
Metastatic endometrial carcinoma of the foot. A case report. Clarke SJ, et al. **J Am Podiatr Med Assoc** 1996 Jul; 86(7):331–3 (6 ref.)
Differential expression of jackfruit-lectin-specific glycoconjugates in metastatic adenocarcinoma and reactive mesothelial cells–a diagnostic aid in effusion cytology. Sujathan K, et al. **J Cancer Res Clin Oncol** 1996; 122(7):433–6
Gastric cancer metastases to the gallbladder. Masamune A, et al. **J Clin Gastroenterol** 1995 Dec;21(4):338–40
Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. Girard P, et al. **J Clin Oncol** 1996 Jul;14(7):2047–53
Non-neoplastic glandular structures in bone marrow: a technical artefact. McCluggage WG, et al. **J Clin Pathol** 1995 Dec;48(12):1141–2
Air-space pattern in lung metastasis from adenocarcinoma of the GI tract. Gaeta M, et al. **J Comput Assist Tomogr** 1996 Mar–Apr;20(2):300–4
Progressive jaundice due to lymphangiosis carcinomatosa of the liver: CT appearance. Tada H, et al. **J Comput Assist Tomogr** 1996 Jul–Aug;20(4):650–2
Early splenic metastasis in a case of renal adenocarcinoma. Pal KK, et al. **J Indian Med Assoc** 1995 Jul;93(7):276–7
Rectal carcinoma metastatic to the thyroid gland. Mesko TW, et al. **J Laryngol Otol** 1996 Feb;110(2):192–5
Metastatic adenocarcinoma of the ethmoids in a patient with previous gastric adenocarcinoma: a case report. Owa AO, et al. **J Laryngol Otol** 1995 Aug;109(8):759–61
The deep parotid lymph nodes: an anatomical and oncological study. Pisani P, et al. **J Laryngol Otol** 1996 Feb;110(2):148–50
Orbital and skin metastases in a polymorphous low grade adenocarcinoma of the salivary gland. Thomas KM, et al. **J Laryngol Otol** 1995 Dec;109(12):1222–5
Magnetic resonance imaging of syrinx associated with intramedullary metastases and leptomeningeal disease. Phuphanich S, et al. **J Neuroimaging** 1996 Apr;6(2):115–7
Palliative care rounds: T12 epidural metastasis mimicks pelvic recurrence of cecal adenocarcinoma. Stübgen JP. **J Pain Symptom Manage** 1996 Jan;11(1):61–4
Bilateral patellar metastases as the clinical presentation of bronchogenic adenocarcinoma. Pauzner R, et al. **J Rheumatol** 1996 May;23(5):939–41 (22 ref.)
Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors. Kandioler D, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):827–31; discussion 832
Metastatic pattern in adenocarcinoma of the lung. An autopsy study from a cohort of 137 consecutive patients with complete resection. Stenbygaard LE, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1130–5
Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. Steup WH, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):85–94; discussion 94–5
Spontaneous remission of a bony metastasis in prostatic adenocarcinoma. Schurmans JR, et al. **J Urol** 1996 Feb; 155(2):653
Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two-stage polymerase chain reaction/restriction fragment length polymorphism analysis. Inoue S, et al. **Jpn J Cancer Res** 1995 Jul; 86(7):626–30
Establishment and characterization of high- and low-lung-metastatic cell lines derived from murine colon adenocarcinoma 26 tumor line. Sakata K, et al. **Jpn J Cancer Res** 1996 Jan;87(1):78–85
A woman with malignant bowel obstruction who did not want to die with tubes. Steadman K, et al. **Lancet** 1996 Apr 6;347(9006):944
Metastatic neoplasms to the larynx: report of three cases. Nicolai P, et al. **Laryngoscope** 1996 Jul;106(7):851–5
Lung cancer during pregnancy [editorial; comment] Bitar RJ, et al. **Mayo Clin Proc** 1995 Nov;70(11):1130. Comment on: Mayo Clin Proc 1995 Apr;70(4):384–7.
A brain metastasis, with no uptake of 99mTc-ECD, secondary to Hurtle cell carcinoma of the thyroid. Orsolon P, et al. **Minerva Endocrinol** 1995 Dec;20(4):233–6
Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma [letter] Bower JH, et al. **Mov Disord** 1995 Sep;10(5):681–2
Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nelson JB, et al. **Nat Med** 1995 Sep;1(9):944–9
Pelvic lymph node metastasis in endometrial cancer with no myometrial invasion. Takeshima N, et al. **Obstet Gynecol** 1996 Aug;88(2):280–2
Disseminated intravascular coagulopathy (DIC) complicating intramedullary fixation of impending femur fracture from metastatic prostate cancer. Ward WG, et al. **Orthopedics** 1995 Nov;18(11):1115–8; discussion 1118–9
Androgen receptor status of lymph node metastases from prostate cancer. Hobisch A, et al. **Prostate** 1996 Feb; 28(2):129–35
Gastric carcinoma metastasis to calf muscles: MR findings. Amano Y, et al. **Radiat Med** 1996 Jan–Feb;14(1):35–6
Clinics in diagnostic imaging (7). Omental caking due to ovarian carcinoma. Helpert C, et al. **Singapore Med J** 1995 Dec;36(6):667–9
Bone metastasis from breast carcinoma with fluid–fluid level. Nguyen BD, et al. **Skeletal Radiol** 1996 Feb;25(2):189–92
The influence of a pneumoperitoneum on the peritoneal implantation of free intraperitoneal colon cancer cells. Hubens G, et al. **Surg Endosc** 1996 Aug;10(8):809–12
Peritoneal seeding of gallbladder cancer after laparoscopic cholecystectomy. Sailer M, et al. **Surg Endosc** 1995 Dec; 9(12):1298–300
Unexpected gallbladder cancer and laparoscopic surgery. Sandor J, et al. **Surg Endosc** 1995 Nov;9(11):1207–10
Proliferation of osteoclast-like giant cells in a metastatic bone tumor from stomach cancer: report of a case and analysis of the autopsy findings. Saeki T, et al. **Surg Today** 1996; 26(4):276–80
A case of transverse colon cancer secondarily involving the liver, duodenum, and pancreas. Suzaki M, et al. **Surg Today** 1996;26(1):42–5
Pulmonary metastasis of polymorphous low-grade adenocarcinoma of the minor salivary gland. Tanaka F, et al. **Thorac Cardiovasc Surg** 1995 Jun;43(3):178–80
Immunosuppressive drugs and their effect on experimental tumor growth. Yokoyama I, et al. **Transpl Int** 1995; 8(4):251–5
Endometrial metastases from gastric adenocarcinoma: a case report. Pasini A, et al. **Tumori** 1995 Sep–Oct;81(5):383–6
Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Meyer-Siegler K, et al. **Urology** 1996 Sep;48(3):448–52
Metastatic carcinoma of the penis. Char G, et al. **West Indian Med J** 1996 Mar;45(1):37–8
Peritoneal carcinomatosis from adenocarcinoma of the colon. Sugarbaker PH, et al. **World J Surg** 1996 Jun;20(5):585–91; discussion 592
[VM-26 plus CCNU in the prevention of brain metastasis in lung cancer patients] Li J, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):314–5 (Eng. Abstr.) **(Chi)**
[Detection of micrometastases in the bone marrow in patients with gastric cancer] Liu F, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):554–6 (Eng. Abstr.) **(Chi)**
[Clinical and pathological analysis of patients with hepatic metastases from colorectal cancer] Zhou Z, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Aug;33(8):454–7 (Eng. Abstr.) **(Chi)**
[Multiple isolated hepatic metastases of cystic aspect of prostatic adenocarcinoma (letter)] Demarquay JF, et al. **Gastroenterol Clin Biol** 1996;20(5):511–2 **(Fre)**
[Uterine metastasis revealing gastric adenocarcinoma] Mambrini P, et al. **Gastroenterol Clin Biol** 1995 Aug–Sep; 19(8–9):725–8 (Eng. Abstr.) **(Fre)**
[Pulmonary metastases of cancer of the colon (letter)] Paraf F, et al. **Gastroenterol Clin Biol** 1996;20(5):509–10 **(Fre)**
[Bone and bone marrow metastases of prostatic adenocarcinoma: the serum level of prostate-specific antigen may be normal (letter)] Marlier S, et al. **Presse Med** 1996 May 4–11;25(16):777 **(Fre)**
[Ureteral obstruction caused by retroperitoneal metastasis of gastric carcinoma] Böszörményi-Nagy G, et al. **Prog Urol** 1995 Dec;5(6):965–7 (Eng. Abstr.) **(Fre)**
[Report of a case of penile metastasis. Review of the literature] Cuvillier X, et al. **Prog Urol** 1995 Dec; 5(6):1009–11 (17 ref.) (Eng. Abstr.) **(Fre)**
[Metastasis of renal adenocarcinoma to the spermatic cord and the epididymis: 2 cases] Fournier G, et al. **Prog Urol** 1995 Nov;5(5):714–6 (Eng. Abstr.) **(Fre)**
[Ipsilateral adrenalectomy in the surgical treatment of renal carcinoma] Marois C, et al. **Prog Urol** 1995 Dec;5(6):961–4 (Eng. Abstr.) **(Fre)**
[Fever, partial pituitary insufficiency and interstitial lung syndrome in a 35-year-old woman] Cosserat J, et al. **Rev Med Interne** 1996;17 Suppl 2:241s–244s **(Fre)**
[Right internal jugular venous thrombosis in a young women 32 years of age] Launay O, et al. **Rev Med Interne** 1996; 17 Suppl 2:237s–240s **(Fre)**
[Implantation metastases following laparoscopic cholecystectomy in gallbladder carcinoma] Buhr J, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):57–61; discussion 61–2 (36 ref.) (Eng. Abstr.) **(Ger)**
[Can monoclonal antibodies to a carcinoma-specific cell surface molecule prevent liver metastasis of human colorectal carcinoma and effectively treat already existing micrometastases?] Burkart C, et al. **Z Gastroenterol** 1996 Jan;34(1):41–2 **(Ger)**
[Therapy refractory atypical polyarthritis and cryoglobulinemia in a patient with colon carcinoma and palliative intestinal bypass. Differential diagnosis: carcinoma-polyarthritis or bypass arthritis] Kanzler S, et al. **Z Gastroenterol** 1995 Aug;33(8):449–53 (Eng. Abstr.) **(Ger)**
[Immunocytochemical detection and prognostic significance of epithelial tumor cells in bone marrow of patients with pancreatic carcinoma] Thorban S, et al. **Zentralbl Chir** 1996;121(6):487–9; discussion 490–2 (Eng. Abstr.) **(Ger)**
[Splenic metastases] Tiszlavicz L. **Orv Hetil** 1996 Feb 11; 137(6):295–8 (25 ref.) (Eng. Abstr.) **(Hun)**
[Meningeal carcinomatosis from pulmonary adenocarcinoma: two clinical cases with review of the literature] Rostagno C, et al. **Ann Ital Med Int** 1995 Oct–Dec;10(4):253–6 (11 ref.) (Eng. Abstr.) **(Ita)**
[Pulmonary metastasis of colorectal cancer: clinico-therapeutic considerations] Lucci S, et al. **G Chir** 1996 May;17(5):255–63 (Eng. Abstr.) **(Ita)**
[A case of advanced gastric cancer with lung and liver metastasis treated by CDDP and 5-FU] Sakata Y, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):627–30 (Eng. Abstr.) **(Jpn)**
[Highly effective preoperative intraarterial infusion chemotherapy with CDDP for progressive uterine corpus cancer with a Sister Mary Joseph's nodule] Shirai T, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):791–5 (Eng. Abstr.) **(Jpn)**
[A case of effective chemotherapy by combination of 5'-DFUR and MMC for recurrent colon cancer with multiple liver metastasis] Tsuji K, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1077–9 (Eng. Abstr.) **(Jpn)**
[FAM as a palliative chemotherapy for gastric cancer with bone metastasis] Yumoto Y, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):107–10 (Eng. Abstr.) **(Jpn)**
[Clear skeletal visualization on whole body 201Tl-chloride scintigraphy: a case of prostatic cancer with diffuse bone metastases] Tsubuku M, et al. **Kaku Igaku** 1995 Nov; 32(11):1249–53 (Eng. Abstr.) **(Jpn)**
[Empyema caused by perforation of metastatic colon cancer: a case report] Ishiwa N, et al. **Kyobu Geka** 1995 Oct; 48(11):971–4 (Eng. Abstr.) **(Jpn)**
[Ocular metastasis necessitating enucleation of an eyeball after surgery for primary lung cancer] Egusa Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):121–5 (Eng. Abstr.) **(Jpn)**
[Two cases of metastatic lung cancer examined by bronchoscopic cytology] Kakumu S, et al. **Rinsho Byori** 1996 Apr;44(4):390–5 (Eng. Abstr.) **(Jpn)**
[Metastasis of rectal cancer into the appendix in association with acute destructive appendicitis] Shpizel' RS. **Klin Khir** 1995;(7–8):33 **(Rus)**
[Repeat liver resection for metastases of colonic cancer] Granov DA, et al. **Vestn Khir Im I I Grek** 1995;154(3):45 **(Rus)**
[Single metastasis of renal adenocarcinoma in contralateral adrenal gland] Diego García A, et al. **Actas Urol Esp** 1995 Apr;19(4):314–8; discussion 318–9 (20 ref.) (Eng. Abstr.) **(Spa)**
[Bilateral synchronous adrenal metastasis of renal adenocarcinoma] Rodríguez-Rubio FI, et al. **Actas Urol Esp** 1995 Nov–Dec;19(10):795–7 (Eng. Abstr.) **(Spa)**
[Renal adenocarcinoma with venous tumor extension to the right atrium: diagnostic and therapeutic considerations] Herranz Amo F, et al. **Arch Esp Urol** 1996 Jan–Feb; 49(1):17–25 (61 ref.) (Eng. Abstr.) **(Spa)**
[Acute respiratory failure and multiple pulmonary nodules. Pulmonary metastases of colonic adenocarcinoma] Cordero PJ, et al. **Rev Clin Esp** 1995 Dec;195(12):845–6 (7 ref.) **(Spa)**
[Do diagnostic laparoscopy and the use of drains favor the appearance of cutaneous metastases after oncological surgery? (letter)] Rosado R, et al. **Rev Esp Enferm Dig** 1996 Mar;88(3):231–2 **(Spa)**
[Early cerebral metastasis of colonic adenocarcinoma] Serantes Gómez A, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):141–3 (Eng. Abstr.) **(Spa)**

SECRETION

Salivary duct carcinoma secreting prostate-specific antigen. James GK, et al. **Am J Clin Pathol** 1996 Aug;106(2):242–7
Regulated and unregulated pathways for MUC2 mucin secretion in human colonic LS180 adenocarcinoma cells are distinct. McCool DJ, et al. **Biochem J** 1995 Nov 15; 312 (Pt 1):125–33
Colonic adenocarcinoma associated ectopic ACTH secretion: a case history. Anthoney DA, et al. **Eur J Cancer** 1995 Nov;31A(12):2109–12
Modulation of human endothelial cell procoagulant activity in tumour models in vitro. Hewett PW, et al. **Int J Cancer** 1996 Jun 11;66(6):784–9
Clinicopathological features of well-differentiated cervical adenocarcinoma with abundant mucus secretion. Ueki M, et al. **J Med** 1995;26(1–2):17–30

SURGERY

Adenocarcinoma of the ileum. A case report, and review of the literature. Mboti B, et al. **Acta Chir Belg** 1995 Nov–Dec;95(6):298–300
Splenectomy for isolated splenic metastasis from endometrial carcinoma. Hamy A, et al. **Acta Obstet Gynecol Scand** 1995 Oct;74(9):745–6
Endocervical cell retrieval following excisional treatment of CIN: a comparison study between large loop excision of the transformation zone and laser cone excision. Urbaniak

KJ, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):63–7

Total androgenic blockade: a review. Bianchi G, et al. **Acta Urol Belg** 1995 Sep;63(3):11–9 (54 ref.)

Vascular resection and intraoperative radiation therapy during pancreaticoduodenectomy: rationale and technique. Evans DB, et al. **Adv Surg** 1996;29:235–62 (87 ref.)

Esophageal adenocarcinoma associated with Barrett's esophagus: long-term management with laser ablation. Ertan A, et al. **Am J Gastroenterol** 1995 Dec;90(12):2201–3

Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma [letter] Shurafa M, et al. **Am J Hematol** 1995 Oct;50(2):149–50

Vaginal hysterectomy versus abdominal hysterectomy for the treatment of stage I endometrial adenocarcinoma. Massi G, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1320–6

Surgical palliation for ductal adenocarcinoma of the pancreas. Deziel DJ, et al. **Am Surg** 1996 Jul;62(7):582–8

Methods to decrease the morbidity of abdominoperineal resection. Farid H, et al. **Am Surg** 1995 Dec;61(12):1061–4

The role of flow cytometric DNA analysis in determining prognosis of resectable ductal adenocarcinoma of the pancreas. Park CS, et al. **Am Surg** 1996 Jul;62(7):609–15; discussion 615–6

Retroperitoneal and abdominal wall emphysema after transanal excision of a rectal carcinoma. Petros JG, et al. **Am Surg** 1996 Sep;62(9):759–61 (8 ref.)

Carcinoma of the ampulla of Vater: a community hospital experience. Sticca RP, et al. **Am Surg** 1996 Mar; 62(3):197–202

Surgical management of Barrett's esophagus. Clark GW, et al. **Ann Chir Gynaecol** 1995;84(2):139–44 (30 ref.)

Management of adenocarcinoma of the body and tail of the pancreas. Brennan MF, et al. **Ann Surg** 1996 May; 223(5):506–11; discussion 511–2

Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Fuhrman GM, et al. **Ann Surg** 1996 Feb; 223(2):154–62

Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Lillemoe KD, et al. **Ann Surg** 1996 Jun;223(6):718–25; discussion 725–8

Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy. Lise M, et al. **Ann Surg Oncol** 1995 Nov;2(6):495–501

Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Macdonald JS, et al. **Ann Surg Oncol** 1995 Nov;2(6):488–94

Superficial esophageal carcinoma. Sabik JF, et al. **Ann Thorac Surg** 1995 Oct;60(4):896–901; discussion 902

Concurrent abdominal aortic aneurysm and urologic neoplasm: an argument for simultaneous intervention. Ginsberg DA, et al. **Ann Vasc Surg** 1995 Sep;9(5):428–33

A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour. Lipponen P, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):2095–100

Bilateral renal tumours: a hard surgical problem. Case report. Gulino G, et al. **Arch Ital Urol Androl** 1995 Sep;67(4):273–7

Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base. Brasnu D, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):765–8

Preservation of the eye in the treatment of sinonasal malignant neoplasms with orbital involvement. A confirmation of the original treatise. McCary WS, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):657–9

Racial factors cannot explain superior Japanese outcomes in stomach cancer. Hundahl SA, et al. **Arch Surg** 1996 Feb; 131(2):170–5

Use of transrectal ultrasonography to select type of surgery for villous tumors in the lower two thirds of the rectum. Kusunoki M, et al. **Arch Surg** 1996 Jul;131(7):714–7

Surgical aspects of patients with adenocarcinoma of the stomach operated on for cure. Söreide JA, et al. **Arch Surg** 1996 May;131(5):481–6; discussion 486–8

Gallbladder carcinoma in the era of laparoscopic cholecystectomy. Yamaguchi K, et al. **Arch Surg** 1996 Sep; 131(9):981–4; discussion 985

Proliferative response of human prostate tumour xenografts to surgical trauma and the transurethral resection of the prostate controversy. Bogden AE, et al. **Br J Cancer** 1996 Jan;73(1):73–8

Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Neri B, et al. **Br J Cancer** 1996 Feb;73(4):549–52

The management of endometrial carcinoma [editorial] Irwin CJ. **Br J Hosp Med** 1996 Mar 20-Apr 2;55(6):308–10

Borderline ovarian cancer, bilateral surgical castration, chemotherapy and a normal delivery after ovum donation and in vitro fertilisation-embryo transfer. Lawal AH, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):931–2

Early parietal recurrence of adenocarcinoma of the colon after laparoscopic colectomy. Port site metastasis after laparascopic colorectal surgery for cure of malignancy [letter; comment] Akle CA. **Br J Surg** 1996 Mar;83(3):427 . Comment on: Br J Surg 1995 Mar;82(3):295–8. Comment on: Br J Surg 1995 Aug;82(8):1036–7.

Randomized trial of fibrin glue to seal mechanical oesophagojejunal anastomosis. Fernandez Fernandez L, et al. **Br J Surg** 1996 Jan;83(1):40–1

Prospective randomized controlled study of clinical function and anorectal physiology after low anterior resection: comparison of straight and colonic J pouch anastomoses. Ho YH, et al. **Br J Surg** 1996 Jul;83(7):978–80

Pattern of recurrence after oesophageal resection for cancer: clinical implications. Law SY, et al. **Br J Surg** 1996 Jan; 83(1):107–11

Radical surgery for advanced gallbladder carcinoma. Miyazaki M, et al. **Br J Surg** 1996 Apr;83(4):478–81

Radical resection of locally advanced colorectal cancer. Poeze M, et al. **Br J Surg** 1995 Oct;82(10):1386–90

No obvious advantages for thoracoscopic two-stage oesophagectomy. Robertson GS, et al. **Br J Surg** 1996 May; 83(5):675–8

Total pelvic exenteration for locally advanced colorectal carcinoma. Shirouzu K, et al. **Br J Surg** 1996 Jan;83(1):32–5

Transanal endoscopic microsurgery--initial experience from three centres in the United Kingdom. Steele RJ, et al. **Br J Surg** 1996 Feb;83(2):207–10

Bladder injury during laparoscopic abdominoperineal resection [see comments] Williams IM, et al. **Br J Surg** 1995 Sep;82(9):1207. Comment in: Br J Surg 1996 Mar;83(3):426. Comment in: Br J Surg 1996 Apr;83(4):571.

The role of cystoscopy before radical prostatectomy. Schwartz BF, et al. **Br J Urol** 1996 Jan;77(1):93–5

Exenteration as palliation for patients with advanced pelvic malignancy. Woodhouse CR, et al. **Br J Urol** 1995 Sep; 76(3):315–20

Adenocarcinoma of the head of the pancreas [editorial; comment] MacFarlane JK. **Can J Surg** 1996 Aug; 39(4):265–6. Comment on: Can J Surg 1996 Aug;39(4):271–83.

1995 Roussel Lecture. Management of adenocarcinoma of the head of the pancreas: 10 questions for the 1990s [see comments] Taylor B. **Can J Surg** 1996 Aug;39(4):271–83 (129 ref.). Comment in: Can J Surg 1996 Aug;39(4):265–6.

Surgical strategy for patients with gastric carcinoma with submucosal invasion. A multivariate analysis. Ichikura T, et al. **Cancer** 1995 Sep 15;76(6):935–40

Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma. Miller RJ Jr, et al. **Cancer** 1996 Apr 15; 77(8):1510–4

Prognostic significance of tumor fixation of rectal carcinoma. Implications for adjunctive radiation therapy. Mohiuddin M, et al. **Cancer** 1996 Aug 15;78(4):717–22

Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate. Petrovich Z, et al. **Cancer** 1995 Nov 1;76(9):1621–8

Surgical treatment for patients with pulmonary metastases after resection of primary colorectal carcinoma. Shirouzu K, et al. **Cancer** 1995 Aug 1;76(3):393–8

The results of radical prostatectomy at a community hospital during the prostate specific antigen era. Smitt MC, et al. **Cancer** 1996 Mar 1;77(5):928–33

Wide perineal dissection and its effect on local recurrence following potentially curative abdominoperineal resection for rectal adenocarcinoma. Volpe C, et al. **Cancer Invest** 1996;14(1):1–5

Lung volume reduction surgery: new expectations in the surgical treatment of lung cancer [letter] Munoz JI, et al. **Chest** 1996 Jun;109(6):1664

Progress in the management of gastric cancer. Karpeh MS Jr, et al. **Curr Opin Gen Surg** 1994;:125–30 (47 ref.)

Neovaginal cytology after total pelvic exenteration for gynecological malignancies. Selvaggi SM, et al. **Diagn Cytopathol** 1995 Jul;13(1):22–5

Long-term follow-up of local excision and radiation therapy for invasive rectal cancer. Fortunato L, et al. **Dis Colon Rectum** 1995 Nov;38(11):1193–9

Second-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniques. Hida J, et al. **Dis Colon Rectum** 1996 Jan;39(1):74–9

Extended resections are beneficial for patients with locally advanced colorectal cancer. Izbicki JR, et al. **Dis Colon Rectum** 1995 Dec;38(12):1251–6

Cancer recurrence following laparoscopic colectomy. Report of two patients treated with heated intraperitoneal chemotherapy. Jacquet P, et al. **Dis Colon Rectum** 1995 Oct;38(10):1110–4

Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines [see comments] Kikuchi R, et al. **Dis Colon Rectum** 1995 Dec;38(12):1286–95. Comment in: Dis Colon Rectum 1996 Jul;39(7):827–8.

Patterns of recurrence after nerve-sparing surgery for rectal adenocarcinoma with special reference to loco-regional recurrence. Moriya Y, et al. **Dis Colon Rectum** 1995 Nov; 38(11):1162–8

Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection. Winde G, et al. **Dis Colon Rectum** 1996 Sep;39(9):969–76

Double dynamic graciloplasty and coloperineal pull-through after abdominoperineal resection. Geerdes BP, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1248–52

Complete sternectomy for metastatic carcinoma with reconstruction using a latissimus dorsi musculocutaneous flap. Shimizu J, et al. **Eur J Cardiothorac Surg** 1995; 9(6):342–4

Using FIGO histologic grade to determine when to perform lymphadenectomies in endometrioid adenocarcinoma of the endometrium. Geisler JP, et al. **Eur J Gynaecol Oncol** 1996; 17(3):204–7

Low molecular weight heparin-induced thrombocytopenia and thrombosis [letter] Peters FP, et al. **Eur J Haematol** 1996 May;56(5):329–30

Modified venovenous bypass technique for resection of renal and adrenal carcinomas with involvement of the inferior vena cava. Baumgartner F, et al. **Eur J Surg** 1996 Jan; 162(1):59–62

Morbidity, ability to swallow, and survival, after oesophagectomy for cancer of the oesophagus and cardia. Svanes K, et al. **Eur J Surg** 1995 Sep;161(9):669–75

Management and outcome of patients with invasive carcinoma arising in colorectal polyps [comment] Volk EE, et al. **Gastroenterology** 1995 Dec;109(6):1801–7. Comment on: Gastroenterology 1995 Dec;109(6):2034–5.

Endoscopic aspiration mucosectomy as curative endoscopic surgery; analysis of 24 cases of early gastric cancer. Torii A, et al. **Gastrointest Endosc** 1995 Nov;42(5):475–9

Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. Berchuck A, et al. **Gynecol Oncol** 1995 Oct;59(1):20–4

Missed hysteroscopic detection of uterine carcinoma before endometrial resection: report of three cases. Colafranceschi M, et al. **Gynecol Oncol** 1996 Aug;62(2):298–300

Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Morris M, et al. **Gynecol Oncol** 1996 Feb;60(2):288–91

Can cervical adenocarcinoma in situ be safely managed by conization alone? [editorial; comment] Muntz HG. **Gynecol Oncol** 1996 Jun;61(3):301–3. Comment on: Gynecol Oncol 1996 Jun;61(3):304–8.

Invasive adenocarcinoma of the cervix following Lletz for adenocarcinoma in situ [letter; comment] Townsend DE. **Gynecol Oncol** 1996 Feb;60(2):332. Comment on: Gynecol Oncol 1995 Aug;58(2):274–7.

Adenocarcinoma in situ of the uterine cervix: management and outcome [see comments] Widrich T, et al. **Gynecol Oncol** 1996 Jun;61(3):304–8. Comment in: Gynecol Oncol 1996 Jun;61(3):301–3.

Transhiatal versus transthoracic esophagectomy for clinical stage I esophageal carcinoma. Berdejo L. **Hepatogastroenterology** 1995 Nov-Dec;42(6):789–91

Surgical treatment of gastric adenocarcinoma: impact on survival and quality of life. A prospective ten year study. Braga M, et al. **Hepatogastroenterology** 1996 Jan-Feb; 43(7):187–93

Resection of metastatic liver cancer in a patient with an anomalous intrahepatic portal system: a case report. Hiei K, et al. **Hepatogastroenterology** 1995 Nov-Dec; 42(6):1002–7

Surgical technique, curability and postoperative quality of life in an extended pancreatectomy for adenocarcinoma of the pancreas. Ishikawa O. **Hepatogastroenterology** 1996 Mar-Apr;43(8):320–5

Vater's papilla and periampullary area villous adenoma: personal experience about nine cases and review of the literature. Motton G, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):448–55 (77 ref.)

Carcinoma of the head of the pancreas: review of 67 cases and comparison with 27 additional periampullary carcinomas. Taschieri AM, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):1023–5

Margins of resection of the esophagus for gastric cancer with esophageal invasion. Tsujitani S, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):873–7

Factor VIII inhibitor developed in a 60-year-old patient with mild hemophilia A after surgery for colon cancer. Suzuki T, et al. **Int J Hematol** 1995 Aug;62(2):127–32

Management of patients with carcinoma of the pancreas [editorial; comment] Gordon TA, et al. **J Am Coll Surg** 1995 Dec;181(6):558–60. Comment on: J Am Coll Surg 1995 Dec;181(6):483–503.

Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting [see comments] Gudjonsson B. **J Am Coll Surg** 1995 Dec; 181(6):483–503 (350 ref.). Comment in: J Am Coll Surg 1995 Dec;181(6):558–60.

Primary duodenal adenocarcinoma: role for aggressive resection [editorial; comment] Lillemoe KD. **J Am Coll Surg** 1996 Aug;183(2):155–6. Comment on: J Am Coll Surg 1996 Aug;183(2):89–96.

Primary duodenal adenocarcinoma: a ten-year experience with 79 patients [see comments] Rose DM, et al. **J Am Coll Surg** 1996 Aug;183(2):89–96. Comment in: J Am Coll Surg 1996 Aug;183(2):155–6.

Pancreatic adenocarcinoma: an update. Tan HP, et al. **J Am Coll Surg** 1996 Aug;183(2):164–84 (159 ref.)

Results of curative gastrectomy for carcinoma of the distal third of the stomach. Wu CW, et al. **J Am Coll Surg** 1996 Sep;183(3):201–7

Multiple surgery indications in an older woman undergoing stroke rehabilitation: the rationale of complex decision-making in geriatric medicine. Barbisoni P, et al. **J Am Geriatr Soc** 1996 Aug;44(8):982–5

Thoracoscopic surgery for lung cancer using the two small skin incisional method. Two windows method. Iwasaki M, et al. **J Cardiovasc Surg (Torino)** 1996 Feb;37(1):79–81

Tumor embolism to LAD during pneumonectomy. A case report. Shah R, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):319–21 (13 ref.)

Evolving strategies for the treatment of adenocarcinoma of the pancreas. A review. Ettinghausen SE, et al.

J Clin Gastroenterol 1995 Jul;21(1):48–60 (123 ref.)

Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. Girard P, et al. **J Clin Oncol** 1996 Jul;14(7):2047–53

Adenocarcinoma of the gastric cardia: prognostic significance of pathologic and treatment factors. Tsai MK, et al. **J Formos Med Assoc** 1995 Sep;94(9):535–40

Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. Leach SD, et al. **J Infus Chemother** 1995 Summer;5(3):104–11 (46 ref.)

Trocar site tumor recurrence after laparoscopic-assisted colectomy. Fodera M, et al. **J Laparoendosc Surg** 1995 Aug; 5(4):259–62 (12 ref.)

Laparoscopic minilaparotomy Billroth I gastrectomy with extraperigastric lymphadenectomy for early gastric cancer using an abdominal wall-lifting method. Uyama I, et al. **J Laparoendosc Surg** 1995 Jun;5(3):181–7

Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms. Evans OB, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):319–23

Follow-up of patients resected for gastric cancer. Lacueva FJ, et al. **J Surg Oncol** 1995 Nov;60(3):174–9

Synchronous cancers of the esophagus and the ampulla of Vater after distal gastrectomy: successful removal of the esophagus, gastric remnant, duodenum, and pancreatic head. Mafune K, et al. **J Surg Oncol** 1995 Dec;60(4):277–81

Survival and function after sleeve lobectomy for lung cancer. Gaissert HA, et al. **J Thorac Cardiovasc Surg** 1996 May; 111(5):948–53

Comparison of prevalence and resection rates in patients with esophageal squamous cell carcinoma and adenocarcinoma. Heitmiller RF, et al. **J Thorac Cardiovasc Surg** 1996 Jul; 112(1):130–6

Transcervical approach (Dartevelle technique) for resection of lung tumors invading the thoracic inlet, sparing the clavicle [letter] Nazari S. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):558–60

Results and prognostic factors in resections of primary tracheal tumors: a multicenter retrospective study. The French Society of Cardiovascular Surgery. Regnard JF, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):808–13; discussion 813–4

Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting [see comments] Moul JW, et al. **J Urol** 1996 May;155(5):1667–73. Comment in: J Urol 1996 May;155(5):1678–80.

Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy [see comments] Oefelein MG, et al. **J Urol** 1996 Jan;155(1):238–42. Comment in: J Urol 1996 Jan;155(1):243.

Extended followup of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation [see comments] Smith RC, et al. **J Urol** 1996 Aug;156(2 Pt 1):454–7; discussion 457–8. Comment in: J Urol 1996 Aug;156(2 Pt 1):459.

Cryosurgical ablation of the prostate for localized adenocarcinoma: a preliminary experience [see comments] Wake RW, et al. **J Urol** 1996 May;155(5):1663–6. Comment in: J Urol 1996 May;155(5):1678–80.

Re: Potency-sparing radical retropubic prostatectomy: a simplified anatomical approach [letter; comment] Walsh PC. **J Urol** 1996 Jan;155(1):294. Comment on: J Urol 1995 Jun;153(6):1875–7.

Detection of ras gene mutations in perioperative peripheral blood with pancreatic adenocarcinoma. Nomoto S, et al. **Jpn J Cancer Res** 1996 Aug;87(8):793–7

Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial.The Surgical Cooperative Group [see comments] Cuschieri A, et al. **Lancet** 1996 Apr 13;347(9007):995–9. Comment in: Lancet 1996 Apr 13;347(9007):984–5. Comment in: Lancet 1996 Jul 20;348(9021):195–6.

Ex vivo MRI in extracorporeal liver surgery. Wolf RF, et al. **Magn Reson Imaging** 1995;13(7):1031–5

Postsurgical changes of the breast that mimic inflammatory breast carcinoma. Loprinzi CL, et al. **Mayo Clin Proc** 1996 Jun;71(6):552–5

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma [see comments] Walsh TN, et al. **N Engl J Med** 1996 Aug 15;335(7):462–7. Comment in: N Engl J Med 1996 Aug 15;335(7):509–10.

MRI of spinal cord and vertebral body infarction in the anterior spinal artery syndrome. Haddad MC, et al. **Neuroradiology** 1996 Feb;38(2):161–2

The split gluteus maximus muscle turnover flap. Hagerty RC, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1459–62

Clinicopathologic features in rectal cancer treated by local excision and postoperative radiation therapy. Minsky BD, et al. **Radiat Med** 1995 Sep-Oct;13(5):235–41

Use of a jejunal island flap for repair of a large duodenal defect after resection of a malignant duodenocolic fistula [letter] Ipek T, et al. **S Afr J Surg** 1995 Dec;33(4):186

Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Iversen P, et al. **Scand J Urol Nephrol Suppl** 1995;172:65–72

Surgery for gastric cancer: the American view. Brennan MF, et al. **Semin Oncol** 1996 Jun;23(3):352–9 (31 ref.)

Histopathological effects of androgen deprivation in prostatic cancer. Civantos F, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):22–31

Gamma Knife stereotactic radiosurgery of ocular metastases: a case report. Marchini G, et al. **Stereotact Funct Neurosurg** 1995;64 Suppl 1:67–71

Laparoscopic surgery in the rat. Beneficial effect on body weight and tumor take. Bouvy ND, et al. **Surg Endosc** 1996 May;10(5):490–4

Prospective evaluation of laparoscopic colon resection versus open colon resection for adenocarcinoma. A multicenter study. Franklin ME Jr, et al. **Surg Endosc** 1995 Jul; 9(7):811–6

Short-term outcome analysis of a randomized study comparing laparoscopic vs open colectomy for colon cancer. Lacy AM, et al. **Surg Endosc** 1995 Oct;9(10):1101–5

Laparoscope-assisted Billroth I gastrectomy. Nagai Y, et al. **Surg Laparosc Endosc** 1995 Aug;5(4):281–7

Laparoscopic monitoring of cryosurgical ablation of the prostate. Sklar GN, et al. **Surg Laparosc Endosc** 1995 Oct; 5(5):376–81

Sphincter-saving surgery with and without pre-operative radiation therapy as treatment for adenocarcinoma of the mid-rectum. Luna-Perez P, et al. **Surg Oncol** 1995 Aug; 4(4):223–9

Adenocarcinoma of the gastric cardia. Mäkelä JT, et al. **Surg Oncol** 1995;4(2):75–81

Effectiveness of multivisceral resection in surgery for gastrointestinal cancers. Balogh A, et al. **Surg Today** 1996; 26(5):373–6

Synchronous double cancers of the remnant stomach and pancreas: report of a case. Miyaguni T, et al. **Surg Today** 1995;25(12):1038–42

Synchronous growth of triple lung cancer. Motohiro A, et al. **Surg Today** 1995;25(12):1054–6

Radical surgery for gastric cancer in Singapore. Ti TK. **Surg Today** 1995;25(7):573–8

Disease-free survival for 9 years after liver resection for stage IV gallbladder cancer: report of a case. Yamamoto M, et al. **Surg Today** 1995;25(8):750–3

Carcinoma of the fourth part of the duodenum: report of a case. Yildirim S, et al. **Surg Today** 1995;25(12):1034–7

Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Bertsch DJ, et al. **Surgery** 1995 Oct;118(4):634–8; discussion 638–9 (9 ref.)

Alterations in DNA proliferation in gastric stump mucosa with special reference to topography. Fukuzawa K, et al. **Surgery** 1996 Feb;119(2):191–7

Prognostic factors of resected adenocarcinoma of the esophagus. Hölscher AH, et al. **Surgery** 1995 Nov; 118(5):845–55

Chylopericardium following right thoracotomy for lung cancer. Mizushima Y, et al. **Tumori** 1996 May-Jun; 82(3):264–5

Adenocarcinoma of the distal duodenum: two cases managed by pylorus preserving pancreatico-duodenectomy and adjuvant chemotherapy. Fon LJ, et al. **Ulster Med J** 1994 Oct;63(2):241–5

Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results. Cohen JK, et al. **Urology** 1996 Mar;47(3):395–401

[Recurrences and metastases in differentiated thyroid cancer] Petkov R. **Khirurgiia (Sofiia)** 1995;48(2):8–10 (Eng. Abstr.) **(Bul)**

[An analysis of the surgical treatment of tumors of the upper urinary tract] Stratev S. **Khirurgiia (Sofiia)** 1994;47(3):13–5 (Eng. Abstr.) **(Bul)**

[Esophagogastrostomy covered by sero-muscular flap of gastric wall in the treatment of gastric cardia cancer in 100 cases] Ke Y, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep;17(5):391–3 (Eng. Abstr.) **(Chi)**

[Excision of mid-lower rectal carcinoma through abdomen and anogenital space] Wei F, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul;33(7):425–7 (Eng. Abstr.) **(Chi)**

[Estrogen therapy after uterine cancer? (letter)] Bock JE. **Ugeskr Laeger** 1996 Mar 18;158(12):1691 **(Dan)**

[Pancreaticoduodenectomy (Whipple's operation) for periampullary cancer] Burcharth F, et al. **Ugeskr Laeger** 1995 Oct 2;157(40):5544–8 (Eng. Abstr.) **(Dan)**

[Late recurrence of stomach cancer in a patient treated with a H2 receptor antagonist] Overgaard H, et al. **Ugeskr Laeger** 1996 May 6;158(19):2717–8 (Eng. Abstr.) **(Dan)**

[Extensive rectal cancer—preserved intestinal and urinary continence after en-block rectal resection and radical cystectomy] Rasmussen OO, et al. **Ugeskr Laeger** 1995 Nov 27;157(48):6728–9 (Eng. Abstr.) **(Dan)**

[Palliative treatment of cancer of the rectum using an urological prostate resectoscope] Debras B, et al. **Ann Chir** 1995;49(10):954–8 (Eng. Abstr.) **(Fre)**

[Primary adenocarcinoma of the duodenum. Study of three cases and review of the literature] Lachachi F, et al. **Ann Chir** 1996;50(4):333–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic factors of surgically treated colorectal cancer] Valleur P. **Ann Gastroenterol Hepatol (Paris)** 1996 Mar-Apr;32(2):63–4 **(Fre)**

[Oncocytic cancers of the thyroid. Hürthle cell cancers] Janser JC, et al. **Chirurgie** 1996;121(1):28–36 (40 ref.) (Eng. Abstr.) **(Fre)**

[Gastric adenocarcinomas (excluding linites). Prognostic factors apropos of a series of 101 cases] Visset J, et al. **Chirurgie** 1994–95;120(13):174–8 (Eng. Abstr.) **(Fre)**

[Cancer of the gallbladder. A surgical experience. A propos of 143 cases] Arnaud JP, et al. **J Chir (Paris)** 1996 Jun; 133(4):155–8 (Eng. Abstr.) **(Fre)**

[Treatment of esophageal fistulas after gastrectomy. Apropos of 4 cases] Collet D, et al. **J Chir (Paris)** 1995 Nov; 132(11):430–3 (Eng. Abstr.) **(Fre)**

[Total gastrectomy and viscerosynthesis] Descottes B, et al. **J Chir (Paris)** 1995 Aug-Sep;132(8–9):336–41 (Eng. Abstr.) **(Fre)**

[Surgical treatment of adenocarcinoma of the stomach: 1969–1994. Apropos of 261 cases] Meyer C, et al. **J Chir (Paris)** 1995 Nov;132(11):423–9 (Eng. Abstr.) **(Fre)**

[Treatment of endometrial clinical stage I adenocarcinoma by laparoscopic surgery. Seventeen cases] Mage G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):485–90 (Eng. Abstr.) **(Fre)**

[Ipsilateral adrenalectomy in the surgical treatment of renal carcinoma] Marois C, et al. **Prog Urol** 1995 Dec;5(6):961–4 (Eng. Abstr.) **(Fre)**

[Peroperative biopsy of the sub-apical urethra during prostatectomy for cancer] Ponthieu A, et al. **Prog Urol** 1996 Apr;6(2):250–5; discussion 255–6 (Eng. Abstr.) **(Fre)**

[Anatomopathologic reassessment of prostatic tumors exclusively affecting the organ with biologic progression and survival study of prostatectomized patients, in terms of the histologic characteristics of the tumor] Ravery V, et al. **Prog Urol** 1995 Dec;5(6):968–73 (17 ref.) (Eng. Abstr.) **(Fre)**

[Results of surgical therapy of esophageal carcinoma in a general hospital] Aleksic M, et al. **Chirurg** 1995 Dec; 66(12):1247–53 (Eng. Abstr.) **(Ger)**

[Suprahyoid pharyngotomy for surgical therapy of malignant and benign oral and hypopharyngeal tumors] Metternich FU, et al. **HNO** 1996 May;44(5):242–5 (Eng. Abstr.) **(Ger)**

[Effect of surgical trauma on NK cell activity in esophageal carcinoma after transmediastinal dissection vs. transthoracic en bloc resection] Bruns C, et al. **Langenbecks Arch Chir** 1996;381(3):175–81 (Eng. Abstr.) **(Ger)**

[Carcinoma of the temporal bone—current diagnostic and therapeutic aspects] Issing PR, et al. **Laryngorhinootologie** 1995 Nov;74(11):666–72 (Eng. Abstr.) **(Ger)**

[Adenocarcinoma of the esophagogastric junction: association with Barrett esophagus and gastroesophageal reflux—surgical results in 122 patients] Schumpelick V, et al. **Leber Magen Darm** 1996 Mar;26(2):75–6, 79–80, 83–6 (Eng. Abstr.) **(Ger)**

[Technique and results of laparoscopic rectum resection] Glättli A, et al. **Schweiz Med Wochenschr Suppl** 1996; 79:85S–88S (Eng. Abstr.) **(Ger)**

[A new concept in imaging pelvic recurrence of curatively operated rectal carcinoma—image fusion of nuclear magnetic resonance tomography and anti-CEA immunoscintigraphy (SPECT): technique and clinical example] Kronberger L Jr, et al. **Wien Klin Wochenschr** 1995;107(23):710–3 (Eng. Abstr.) **(Ger)**

[Laparoscopic cholecystectomy in gallbladder carcinoma: risk of tumor cell seeding] Hentsch S, et al. **Zentralbl Chir** 1995;120(12):974–6 (Eng. Abstr.) **(Ger)**

[Sclerosing adenocarcinomas of the hepatic hilum] Zoppi S, et al. **G Chir** 1996 Apr;17(4):155–7 (Eng. Abstr.) **(Ita)**

[Results of endoscopic Nd-Yag laser treatment of inoperable colorectal carcinoma] De Palma GD, et al. **Minerva Chir** 1996 Mar;51(3):87–91 (Eng. Abstr.) **(Ita)**

[The role of surgery in the management of diffuse (N3) lung cancer] Politi L, et al. **Minerva Chir** 1995 Dec; 50(12):1039–42 (Eng. Abstr.) **(Ita)**

[Malignant tumors of the pancreas and periampullary area. Our experience] Stabilini L, et al. **Minerva Chir** 1995 Oct; 50(10):835–41 (Eng. Abstr.) **(Ita)**

[Retroperitoneal laparoscopic pelvic lymphadenectomy for patients with prostate cancer] Ushiyama T, et al. **Hinyokika Kiyo** 1996 Jan;42(1):23–6 (Eng. Abstr.) **(Jpn)**

[A case of resected small-sized (4 mm in diameter) lung cancer and its way of surgical treatment] Morita H. **Kyobu Geka** 1996 Mar;49(3):175–8; discussion 179–81 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical problem of lung cancer with coexisting acute pulmonary tuberculosis] Nonaka M, et al. **Kyobu Geka** 1995 Nov;48(12):1019–24 (Eng. Abstr.) **(Jpn)**

[A case of idiopathic thrombocytopenic purpura combined with lung cancer] Ohura H, et al. **Kyobu Geka** 1996 Jun; 49(6):484–6 (Eng. Abstr.) **(Jpn)**

[A clinical study of radial prostatectomy] Hotta H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):760–5 (Eng. Abstr.) **(Jpn)**

[A clinical and pathological study of radical prostatectomy for prostate cancer] Taguchi I, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):772–9 (Eng. Abstr.) **(Jpn)**

[Prognosis after radical surgery in prostatic cancer patients with lymph nodes metastases] Tomita K, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Aug;86(8):1322–7

(Eng. Abstr.) **(Jpn)**
[A case of palatal polymorphous low grade adenocarcinoma] Ishimoto S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Jul;98(7):1092–6 (Eng. Abstr.) **(Jpn)**
[A case of resected lung cancer associated with bullous pemphigoid] Sato Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):524–8 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Staged bilateral upper lobectomy of pathologically different synchronous double primary cancer] Taira O, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Nov; 43(11):1858–64 (Eng. Abstr.) **(Jpn)**
[A case of pancreas carcinoma observed reflux of the bile juice on cut surface of the pancreas] Dohke M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov;92(11):1895–8 **(Jpn)**
[A case of postoperative hyponatremia caused by Sheehan syndrome associated with lung carcinoma] Ozaki S, et al. **Sangyo Ika Daigaku Zasshi** 1995 Sep 1;17(3):199–205 (Eng. Abstr.) **(Jpn)**
[Lymph node dissection in patients with cancer of the proximal part of the stomach] Davydov MI, et al. **Khirurgiia (Mosk)** 1995;(5):41–6 (Eng. Abstr.) **(Rus)**
[Prognostic factors in the surgical treatment of lung cancer] Davydov MI, et al. **Khirurgiia (Mosk)** 1996;(1):13–6 (Eng. Abstr.) **(Rus)**
[Significance of esophagojejunogastroplasty in the surgical treatment of chronic and malignant ulcers of the cardial part of the stomach] Sheleshko PV, et al. **Khirurgiia (Mosk)** 1995;(6):21–2 (Eng. Abstr.) **(Rus)**
[Long term results of the surgical treatment of patients with cancer of the stomach and duodenum at the early stage] Bereznitskiĭ IaS, et al. **Klin Khir** 1995;(7–8):50 **(Rus)**
[A repeat reconstructive intervention after performing an extensive Garlock operation for neoplasm of the cardia] Pavliuk AD, et al. **Klin Khir** 1995;(9–10):52 **(Rus)**
[Repeat liver resection for metastases of colonic cancer] Granov DA, et al. **Vestn Khir Im I I Grek** 1995;154(3):45 **(Rus)**
[The surgical treatment of stomach cancer] Petrov VP, et al. **Voen Med Zh** 1996 Jan;317(1):32–7, 78 (Eng. Abstr.) **(Rus)**
[Complications of radical hysterectomy during management of stage Ib and IIa cervix uteri cancer. Experience with 145 patients] Torres–Lobaton A, et al. **Ginecol Obstet Mex** 1996 Jun;64:265–71 (Eng. Abstr.) **(Spa)**
[Laparoscopy: an alternative to second–look laparotomy in ovarian cancer] Mayerson D, et al. **Rev Chil Obstet Ginecol** 1994;59(5):388–9 (Eng. Abstr.) **(Spa)**
[Experience with Wertheim–Meigs surgery at the Dr. Juan Noé de Arica Hospital] Rodríguez E, et al. **Rev Chil Obstet Ginecol** 1995;60(2):96–100 (Eng. Abstr.) **(Spa)**
[Self–expanding esophageal metal stents in the palliative treatment of esophageal cancer] Pellicer F, et al. **Rev Esp Enferm Dig** 1996 Feb;88(2):89–92 (Eng. Abstr.) **(Spa)**
[Cancer of the gastric stump] Pinatel Lopasso F. **Rev Gastroenterol Peru** 1996 Jan–Apr;16(1):57–63 (69 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Carcinoma of the prostate: treatment of bone metastasis. Scalliet P. **Acta Urol Belg** 1996 May;64(2):87–90 (13 ref.)
Pilot phase II trial of 13–cis–retinoic acid and interferon–alpha combination therapy for advanced pancreatic adenocarcinoma. Moore DF Jr, et al. **Am J Clin Oncol** 1995 Dec;18(6):525–7
Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Staley CA, et al. **Am J Surg** 1996 Jan;171(1):118–24; discussion 124–5
The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Jain V, et al. **Am Surg** 1996 Feb;62(2):162–5
National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Janes RH Jr, et al. **Ann Surg** 1996 Mar;223(3):261–72
Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Lowy AM, et al. **Ann Surg** 1996 Feb;223(2):177–85
Treatment of adenocarcinoma of the stomach with resection, intraoperative radiotherapy, and adjuvant external beam radiation: a phase II study from Radiation Therapy Oncology Group 85–04 [see comments] Avizonis VN, et al. **Ann Surg Oncol** 1995 Jul;2(4):295–302. Comment in: Ann Surg Oncol 1995 Jul;2(4):286–7.
Adoptive cellular immunotherapy of cancer in mice using allogeneic T–cells. Bartels CJ, et al. **Ann Surg Oncol** 1996 Jan;3(1):67–73
Benefit of aggressive multimodality treatment for gastric cancer [editorial] [comment] Brennan MF. **Ann Surg Oncol** 1995 Jul;2(4):286–7. Comment on: Ann Surg Oncol 1995 Jul;2(4):295–302.
Isolated incisional recurrence after curative resection for primary lung cancer. Yokoi K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1236–7 (9 ref.)
Treatment of liver metastases from colorectal cancer. Isenberg J, et al. **Anticancer Res** 1996 May–Jun; 16(3A):1291–5
Immunohistochemical characterisation of immunological changes at the tumour site after chemo–immunotherapy with doxorubicin, interleukin–2 and interferon–gamma. Lumsden AJ, et al. **Anticancer Res** 1996 May–Jun; 16(3A):1145–54
Feasibility of photodynamic therapy using endogenous photosensitization for colon cancer. Fromm D, et al. **Arch Surg** 1996 Jun;131(6):667–9
Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer. Lazarus HM, et al. **Bone Marrow Transplant** 1995 Jun;15(6):935–42
The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation. Brizel DM, et al. **Br J Cancer** 1995 Nov;72(5):1120–4
NG–nitro–L–arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2–induced capillary leakage and reduces tumour growth in adenocarcinoma–bearing mice. Orucevic A, et al. **Br J Cancer** 1996 Jan;73(2):189–96
The management of localized prostate cancer [editorial] [see comments] Clarke NW. **Br J Hosp Med** 1996 Mar 6–19; 55(5):232–3. Comment in: Br J Hosp Med 1996 Mar 6–19;55(5):233–4.
Is there any value in the long term follow up of women treated for endometrial cancer? Owen P, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):710–3
Treatment of carcinomas of the uterine cervix which remain bulky after initial external beam radiotherapy: a pilot study using integrated cytotoxic chemotherapy prior to brachytherapy. Tan LT, et al. **Br J Radiol** 1996 Feb; 69(818):165–71
Self–expanding metal stents for the palliation of dysphagia due to inoperable oesophageal carcinoma [see comments] Ellul JP, et al. **Br J Surg** 1995 Dec;82(12):1678–81. Comment in: Br J Surg 1996 May;83(5):714–5.
The feisty family. Brock G, et al. **Can Fam Physician** 1995 Sep;41:1483, 1485
Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Heller R, et al. **Cancer** 1996 Mar 1;77(5):964–71
Preoperative chemoradiotherapy for localized pancreatic carcinoma. A perspective. Hoffman JP, et al. **Cancer** 1996 Aug 1;78(3 Suppl):592–7 (36 ref.)
An aggressive therapeutic approach to carcinoma of the body and tail of the pancreas. Ozaki H, et al. **Cancer** 1996 Jun 1;77(11):2240–5
Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Schweitzer VG, et al. **Cancer** 1995 Sep 15;76(6):1069–72
Multi–chemothermoimmunotherapy for human colon adenocarcinoma in vitro. Klostergaard J, et al. **Cancer Chemother Pharmacol** 1996;37(3):235–41
Prodrug–activated gene therapy: involvement of an immunological component in the "bystander effect". Gagandeep S, et al. **Cancer Gene Ther** 1996 Mar–Apr; 3(2):83–8
Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Hoganson DK, et al. **Cancer Res** 1996 Mar 15;56(6):1315–23
Local tumor irradiation augments the response to IL–2 therapy in a murine renal adenocarcinoma. Younes E, et al. **Cell Immunol** 1995 Oct 15;165(2):243–51
Treatment of 23 patients with advanced gastric cancer by intravenously transfer of autologous tumor–infiltrating lymphocytes combined with rIL–2. Xu X, et al. **Chin Med Sci J** 1995 Sep;10(3):185–7
Anaphylactic reaction after a first filgrastim (granulocyte–colony stimulating factor) injection [letter] Batel–Copel L, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2428
Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate. Voges GE, et al. **Eur Urol** 1995; 28(3):209–14
Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Lightdale CJ, et al. **Gastrointest Endosc** 1995 Dec; 42(6):507–12
A phase I study of intraperitoneal interferon–alpha 2b and intravenous cis–platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study. Moore DH, et al. **Gynecol Oncol** 1995 Nov; 59(2):267–72 (25 ref.)
Locoregional chemotherapy versus locoregional combined immuno–chemotherapy for patients with advanced metastatic liver disease of colorectal origin: a prospective randomized study. Lygidakis NJ, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):212–20
Adenovirus–mediated gene therapy in an experimental model of breast cancer metastatic to the brain. Colak A, et al. **Hum Gene Ther** 1995 Oct;6(10):1317–22
A bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma. Bakács T, et al. **Int Immunol** 1995 Jun;7(6):947–55
Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Tibben JG, et al. **Int J Cancer** 1996 May 16;66(4):477–83
Modulation of daunorubicin intracellular accumulation in P–glycoprotein expressing MCF–7 human breast adenocarcinoma cells by thermosensitive–liposome encapsulation and hyperthermia. Merlin JL, et al. **Int J Hyperthermia** 1995 Nov–Dec;11(6):855–65
Early evaluation of abdominal/hepatic irradiation and 5–fluorouracil/leucovorin infusion after pancreaticoduodenectomy. Carducci MA, et al. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):143–50
Thermal treatment parameters are most predictive of outcome in patients with single tumor nodules per treatment field in recurrent adenocarcinoma of the breast [see comments] Kapp DS, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):887–99. Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):963–4.
Vascular thermal adaptation in tumors and normal tissue in rats. Nah BS, et al. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):95–101
Local excision and external beam radiotherapy in early rectal cancer. Valentini V, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 1;35(4):759–64
Phase I–II randomized study on prehepatectomy recombinant interleukin–2 immunotherapy in patients with metastatic carcinoma of the colon and rectum. Elias D, et al. **J Am Coll Surg** 1995 Oct;181(4):303–10
Clonal T cell expansion induced by interleukin 2 therapy in blood and tumors. Kumar A, et al. **J Clin Invest** 1996 Mar 1;97(5):1219–26
Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. Bates BA, et al. **J Clin Oncol** 1996 Jan;14(1):156–63 (48 ref.)
Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. Mohiuddin M, et al. **J Clin Oncol** 1995 Nov;13(11):2764–8
Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. Stahl M, et al. **J Clin Oncol** 1996 Mar;14(3):829–37
Systemic administration of cellular IL–10 induces an effective, specific, and long–lived immune response against established tumors in mice. Berman RM, et al. **J Immunol** 1996 Jul 1;157(1):231–8
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor–associated antigen. Chen PW, et al. **J Immunol** 1996 Jan 1;156(1):224–31
Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL–12. Tannenbaum CS, et al. **J Immunol** 1996 Jan 15;156(2):693–9
Management of malignant ureteral obstruction in the palliative care setting. Smith P, et al. **J Pain Symptom Manage** 1995 Aug;10(6):481–6
Adenocarcinoma of the uterine cervix: a study of 37 cases. Piura B, et al. **J Surg Oncol** 1996 Apr;61(4):249–55
A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. Goydos JS, et al. **J Surg Res** 1996 Jun; 63(1):298–304
Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. Dalkin BL, et al. **J Urol** 1996 Apr;155(4):1357–60
Severe thrombocytopenia in a man with prostatic cancer. Hamid S, et al. **JPMA J Pak Med Assoc** 1995 Sep; 45(9):252–4
Anti–ganglioside GM2 monoclonal antibody–dependent killing of human lung cancer cells by lymphocytes and monocytes. Hanibuchi M, et al. **Jpn J Cancer Res** 1996 May;87(5):497–504
Vaccination with mutant ras peptides and induction of T–cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Gjertsen MK, et al. **Lancet** 1995 Nov 25;346(8987):1399–400
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma [see comments] Walsh TN, et al. **N Engl J Med** 1996 Aug 15;335(7):462–7. Comment in: N Engl J Med 1996 Aug 15;335(7):509–10.
Multimodal therapy for adenocarcinoma of the esophagus and esophagogastric junction [editorial; comment] Wilke H, et al. **N Engl J Med** 1996 Aug 15;335(7):509–10. Comment on: N Engl J Med 1996 Aug 15;335(7):462–7.
Adenoviral–mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Mujoo K, et al. **Oncogene** 1996 Apr 18;12(8):1617–23
MoAb to block growth signals plus chemo may act synergistically to kill tumor cells [news] **Oncology (Huntingt)** 1996 Apr;10(4):591–2
The role of embolization in palliative care [letter] Riley J. **Palliat Med** 1996 Apr;10(2):168
Palliation of malignant esophageal strictures with self–expanding nitinol stents: drawbacks and complications. Acunaş B, et al. **Radiology** 1996 Jun;199(3):648–52
Combined modality therapy in low risk (T2N0) rectal cancer. Coco C, et al. **Rays** 1995 Apr–Jun;20(2):156–64 **(Eng, Ita)**
Inflammatory breast cancer: what is the appropriate therapy for patients who have a clinical response to induction chemotherapy? Peters GN, et al. **Semin Oncol** 1995 Oct;

22(5):xiv, xxi, xxvi, xxxii

Inflammatory breast cancer. Lopez MJ, et al. **Surg Clin North Am** 1996 Apr;76(2):411-29 (88 ref.)

Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Buzdar AU, et al. **Surg Oncol Clin N Am** 1995 Oct; 4(4):715-34

The role of bone marrow transplantation in the management of advanced local disease. Safah H, et al. **Surg Oncol Clin N Am** 1995 Oct;4(4):735-49 (83 ref.)

Interaction of tumour necrosis factor-alpha and radiation against human colon tumour cells. Gridley DS, et al. **Ther Immunol** 1994 Jan;1(1):25-31

Adjuvant treatment in operable stage II and III rectal cancer. Aurelio P, et al. **Tumori** 1995 May-Jun;81(3 Suppl):109-13

In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide. Cipolla B, et al. **Urol Res** 1996;24(2):93-8; discussion 99

[Endoscopic YAG laser and palliative therapy of cancer of the esophagus] Ferraro P, et al. **Ann Chir** 1995;49(8):669-73 (Eng. Abstr.) **(Fre)**

[Prognostic factors in endometrial cancer: apropos of 206 cases treated at the Curie Institute] Chen Q, et al. **Bull Cancer (Paris)** 1995 Sep;82(9):717-23 (Eng. Abstr.) **(Fre)**

[Vaccination with genetically modified IL-2 secreting cells in a rat model of colonic carcinoma] Patry Y, et al. **Bull Cancer (Paris)** 1996 Mar;83(3):218-26 (Eng. Abstr.) **(Fre)**

[Statistical study of a series of 672 cases of carcinoma of the uterine cervix. Results and complications according to age and modalities of treatment] Pernot M, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):568-81 (66 ref.) (Eng. Abstr.) **(Fre)**

[Feasibility of retroperitoneal pelvic lymph node exploration in cancers of the cervix treated by radiosurgery association or radiotherapy alone. Apropos of a series of 52 cases] Bolla M, et al. **Bull Cancer Radiother** 1995;82(3):326-31 (Eng. Abstr.) **(Fre)**

[Radiochemotherapy and simultaneous hormonal therapy of locally advanced prostatic carcinoma] Strnad V, et al. **Strahlenther Onkol** 1996 Apr;172(4):225-8 (Eng. Abstr.) **(Ger)**

[The use of self-expanding stents in the recanalization of gastric antrum neoplastic obstructions. The experience of a case] Profili S, et al. **Radiol Med (Torino)** 1995 Sep; 90(3):330-3 (23 ref.) **(Ita)**

[Therapeutic effect of adenovirus-mediated transfer of the wild-type p53 gene with cisplatin] Fujiwara T, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1085-8 **(Jpn)**

[Oral administration of OK-432 is an effective immunotherapy against colon cancer--a study in a murine mesenteric lymphnode metastasis model] Nukata Y, et al. **Nippon Geka Gakkai Zasshi** 1995 Oct;96(10):671-9 (Eng. Abstr.) **(Jpn)**

[Prognostic factors in patients with advanced prostatic cancer (stage D2) initially treated with endocrine therapy] Matsuda H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):688-94 (Eng. Abstr.) **(Jpn)**

[Changes in the immune status of patients with rectal cancer while using specific immunotherapy] Zagadarchuk NL, et al. **Klin Khir** 1995;(9-10):23-6 **(Rus)**

[The late results of the combined hormonal chemoradiation treatment of prostatic cancer] Sviridova TV, et al. **Urol Nefrol (Mosk)** 1996 Jan-Feb;(1):31-4 (Eng. Abstr.) **(Rus)**

[Combined treatment of malignant tumors of the external auditory canal and the middle ear] Pavlov AS, et al. **Vestn Otorinolaringol** 1995 Sep-Oct;(5):16-8 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Carcinoma of the colon associated with high extragenital production of beta-hCG--a case report. Mashiach R, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):845-8

Periurethral tumor involving the vagina: clinical and sonographic findings [letter] Sørensen JL, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):191-2

Value of uterine artery Doppler in endometrial cancer. Flam F, et al. **Acta Oncol** 1995;34(6):779-82

Diagnosis of gallbladder carcinoma with color Doppler ultrasonography. Ueno N, et al. **Am J Gastroenterol** 1996 Aug;91(8):1647-9

Use of transrectal ultrasonography to select type of surgery for villous tumors in the lower two thirds of the rectum. Kusunoki M, et al. **Arch Surg** 1996 Jul;131(7):714-7

A new method for early diagnosis of carcinoma in bile duct-sonography of common bile duct before and after injection of ceosunin. Chen M, et al. **Chin Med J (Engl)** 1995 May;108(5):355-60

Case report: renal adenocarcinoma with ultrasonographic appearances suggestive of angiomyolipoma. Morrison ID, et al. **Clin Radiol** 1995 Sep;50(9):659-61

Staging of rectal carcinoma using MR double surface coil, MR endorectal coil, and intrarectal ultrasound: correlation with histopathologic findings. Joosten FB, et al. **J Comput Assist Tomogr** 1995 Sep-Oct;19(5):752-8

Cystic carcinoma of the prostate. Agha AH, et al. **J Ultrasound Med** 1996 Jan;15(1):75-7

Preoperative assessment of myometrial invasion of endometrial carcinoma by transvaginal ultrasonography. Zorlu CG, et al. **Mater Med Pol** 1995 Jan-Mar;27(1):23-5

[The significance of focal hypoechoic lesions in the peripheral zone of the prostate] Oyen R, et al. **J Belge Radiol** 1995 Dec;78(6):356-8 (Eng. Abstr.) **(Dut)**

[High-grade intraepithelial prostatic neoplasms: diagnosis and association with prostate cancer] Raviv G, et al. **Acta Urol Belg** 1996 Mar;64(1):11-5 (Eng. Abstr.) **(Fre)**

[Ultrasonography and prostatic adenocarcinoma] Grasso-Leanza F, et al. **Arch Ital Urol Androl** 1995 Sep; 67(4):237-41 (Eng. Abstr.) **(Ita)**

[The growth process of nodular-invasive gallbladder cancer observed by ultrasonography: a case report] Okaniwa S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr; 93(4):287-92 **(Jpn)**

[A case of early carcinoma of the gall-bladder arising in adenomyomatosis detected by endoscopic ultrasonography] Sakurai T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep;92(9):1304-8 (18 ref.) **(Jpn)**

[Transrectal ultrasonography in the preoperative staging of rectal adenocarcinoma. Cross-sectional study 1991-1994] Isern AM, et al. **G E N** 1995 Apr-Jun;49(2):104-10 (Eng. Abstr.) **(Spa)**

[Cyto-histologic evaluation of parametrial involvement in cervico-uterine cancer using aspiration puncture guided by transvaginal echography] Aliste G, et al. **Rev Chil Obstet Ginecol** 1994;59(6):442-7 (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

Microglandular carcinoma of the pancreas: immunohistochemical and ultrastructural study of an unusual variant of pancreatic carcinoma that may closely resemble a neuroendocrine neoplasm. Berho M, et al. **Am J Clin Pathol** 1996 Jun;105(6):727-32

Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Alberts SR, et al. **Cancer** 1996 Aug 15;78(4):764-72

Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Ohtani H, et al. **Int J Cancer** 1995 Sep 15;62(6):691-6

Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Xing RH, et al. **Int J Cancer** 1996 Jul 29;67(3):423-9

Autocrine growth stimulation of SW403 colon carcinoma cell line is caused by transforming-growth-factor-alpha-mediated epidermal growth factor receptor activation. Hirsch T, et al. **J Cancer Res Clin Oncol** 1996;122(6):328-34

Subcellular localization of docosahexaenoic acid and arachidonic acid omega-hydroxylation activity in the brain, liver and colonic adenocarcinoma. Yamane M, et al. **J Chromatogr A** 1996 Apr 12;730(1-2):91-8

Basal cell adenocarcinoma of the parotid gland: a case report with immunohistochemical, ultrastructural findings and review of the literature. Raslan WF, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1457-62 (15 ref.)

Schwann cell differentiation of modified myoepithelial cells within adenoid cystic carcinomas and polymorphous low-grade adenocarcinomas: clinicopathologic assessment of immunohistochemical staining. Toth AA, et al. **J Otolaryngol** 1996 Apr;25(2):94-102

Establishment of a cell line from an adenocarcinoma of the lung producing carcinoembryonic antigen (CEA) and CA19-9. Miki M, et al. **Tohoku J Exp Med** 1995 Apr; 175(4):269-70

VETERINARY

Detection of fibrin in canine neoplasia. McEvoy FJ, et al. **Br Vet J** 1996 Jan;152(1):83-91

Intestinal adenocarcinomas in two beluga whales (Delphinapterus leucas) from the estuary of the St. Lawrence River. Martineau D, et al. **Can Vet J** 1995 Sep; 36(9):563-5 (14 ref.)

A prospective study of the epidemiology of colitis and colon cancer in cotton-top tamarins (Saguinus oedipus). Johnson LD, et al. **Gastroenterology** 1996 Jan;110(1):102-15

Presumptive, iatrogenic gastric outflow obstruction associated with prior gastric surgery. Fossum TW, et al. **J Am Anim Hosp Assoc** 1995 Sep-Oct;31(5):391-5

What is your diagnosis? Suspected caudal esophageal mass in a dog. Schwarz LA, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):347-8

Silver-stained nucleolar (Ag-NOR) cluster size in feline mammary carcinomas: lack of correlation with histological appearance, mitotic activity, tumour stage, and degree of nuclear atypia. De Vico G, et al. **J Comp Pathol** 1995 Jul; 113(1):69-73

Parotid salivary gland adenocarcinoma with bilateral ocular and osseous metastases in a dog. Habin DJ, et al. **J Small Anim Pract** 1995 Oct;36(10):445-9

Xenotransplantation and high tumorigenicity of feline tumors in SCID mice. Maruo K, et al. **J Vet Med Sci** 1995 Oct; 57(5):967-9

Spontaneously occurring mammary adenocarcinoma in a 10-wk-old female rat. Oishi Y, et al. **Toxicol Pathol** 1995 Nov-Dec;23(6):696-700

Lectin histochemistry and carcinoembryonic antigen in spontaneous colonic cancers of cotton-top tamarins (Saguinus oedipus). Brack M. **Vet Pathol** 1995 Nov; 32(6):668-73

Nasal adenocarcinoma with myoepithelial component in a CD-1 mouse. Chen HC, et al. **Vet Pathol** 1995 Nov; 32(6):710-3

Poorly differentiated pancreatic adenocarcinoma in a chicken. Abdul-Aziz TA. **Vet Rec** 1995 Oct 14;137(16):408

Ultrasonography of pancreatic neoplasia in the dog: a retrospective review of 16 cases. Lamb CR, et al. **Vet Rec** 1995 Jul 15;137(3):65-8

Two cases of pyloric adenocarcinoma in the ferret (Mustela putorius furo). Sleeman JM, et al. **Vet Rec** 1995 Sep 9; 137(11):272-3

A comparison of medullary thyroid carcinoma and thyroid adenocarcinoma in dogs: a retrospective study of 38 cases. Carver JR, et al. **Vet Surg** 1995 Jul-Aug;24(4):315-9

Incidence and pathomorphology of uterine tumours in the cow. Garcia-Iglesias MJ, et al. **Zentralbl Veterinarmed A** 1995 Sep;42(7):421-9

VIROLOGY

Epstein-Barr virus-associated gastric adenocarcinomas among Koreans. Shin WS, et al. **Am J Clin Pathol** 1996 Feb;105(2):174-81

Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Iwasawa A, et al. **Cancer** 1996 Jun 1; 77(11):2275-9

Immortalization of human adult prostatic adenocarcinoma cells by human papilloma virus HPV16 and -18 DNA. Naghashfar Z, et al. **Cancer Lett** 1996 Feb 27; 100(1-2):47-54

High incidence of human papillomavirus in 146 cervical carcinomas. A study using three different pairs of consensus primers, and detecting viral genomes with putative deletions. Karlsen F, et al. **Eur J Cancer** 1995; 31A(9):1511-6

Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Gulley ML, et al. **Hum Pathol** 1996 Jan; 27(1):20-7

Genomic organization of human papillomavirus type 18 in cervical cancer specimens. Kitagawa K, et al. **Jpn J Cancer Res** 1996 Mar;87(3):263-8

Localization of Epstein-Barr virus genome in lymphoid cells in poorly differentiated adenocarcinoma with lymphoid stroma of the colon [letter] Vilor M, et al. **Pathol Int** 1995 Sep;45(9):695-7

Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Suzuki H, et al. **Prostate** 1996 May;28(5):318-24

Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. Wideroff L, et al. **Prostate** 1996 Feb;28(2):117-23

ADENOCARCINOMA, BASAL CELL see **ADENOCARCINOMA**

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR

Bronchioloalveolar carcinoma. Barkley JE, et al. **J Clin Oncol** 1996 Aug;14(8):2377-86 (96 ref.)

Lung cancer during pregnancy [letter; comment] Cone LA, et al. **Mayo Clin Proc** 1995 Nov;70(11):1130. Comment on: Mayo Clin Proc 1995 Apr;70(4):384-7.

[Bronchioloalveolar carcinoma] De Frutos Arribas JF, et al. **An Med Interna** 1996 Mar;13(3):118-21 (Eng. Abstr.) **(Spa)**

[Bronchioloalveolar carcinoma in a young woman] Plaza Valía P, et al. **An Med Interna** 1996 Mar;13(3):122-4 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Bronchioloalveolar carcinoma and congenital cystic adenomatoid malformation. Ribet ME, et al. **Ann Thorac Surg** 1995 Oct;60(4):1126-8

Follicular mucinosis plus mycosis fungoides and acanthosis nigricans plus alveolar bronchiolar carcinoma. Cottoni F, et al. **Int J Dermatol** 1995 Dec;34(12):867-9

DIAGNOSIS

Bronchioloalveolar carcinoma in progressive systemic sclerosis. Report of a case diagnosed by fine needle aspiration cytology. Paksoy N, et al. **Acta Cytol** 1995 Nov-Dec;39(6):1182-6

Cardiac tamponade as the initial presentation of bronchioloalveolar cell carcinoma. Hourany J, et al. **Tenn Med** 1996 Jul;89(7):247-8 (12 ref.)

[Bronchiolo-alveolar carcinoma of the lung] Galil-Ogly GA, et al. **Arkh Patol** 1995 Sep-Oct;57(5):64-70 (Eng. Abstr.) **(Rus)**

[Bronchioalveolar carcinoma and the paraneoplastic syndrome (letter)] Pasto Aguila M, et al. **An Med Interna** 1996 May;13(5):251 **(Spa)**

[Choroidal metastases as the form of presentation of 2 bronchiolo-alveolar carcinomas] de Frutos Arribas JF, et al. **Rev Clin Esp** 1995 Dec;195(12):853-5 (19 ref.) (Eng. Abstr.) **(Spa)**

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR

GENETICS

Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. Marchetti A, et al. **J Pathol** 1996 Jul;179(3):254–9

IMMUNOLOGY

[A case of bronchiolo-alveolar carcinoma with high production of carbohydrate antigen (CA19–9)] Shioji Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):325–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

p53 protein accumulation and the presence of human papillomavirus DNA in bronchiolo-alveolar carcinoma correlate with poor prognosis. Nuorva K, et al. **Int J Cancer** 1995 Dec 20;64(6):424–9

MORTALITY

Bronchioloalveolar carcinoma: long-term survival of 23 resected patients. De Leyn P, et al. **Acta Chir Belg** 1995 Sep-Oct;95(5):220–2

PATHOLOGY

Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma. Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Kitamura H, et al. **Am J Surg Pathol** 1996 May;20(5):553–62

Adenoid cystic carcinoma of the maxilla--the value of histopathology in diagnosing a second primary. Hadfield PJ, et al. **J Laryngol Otol** 1996 May;110(5):503–6

[Problem cases in lung pathology] Müller KM. **Pathologe** 1996 Jan;17(1):98–101 **(Ger)**

[Proliferation kinetics of bronchioloalveolar tumorlets] Theile A, et al. **Pathologe** 1996 Mar;17(2):163–70 (Eng. Abstr.) **(Ger)**

[Disparity between cytohistopathological results of diagnostic specimens and the resected tumor piece in bronchopulmonary carcinoma] Sánchez Varilla JM, et al. **An Med Interna** 1996 Apr;13(4):168–70 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Bronchioloalveolar carcinoma accompanied by severe bronchorrhea. Hidaka N, et al. **Chest** 1996 Jul;110(1):281–2

RADIOGRAPHY

Bronchioloalveolar carcinoma: focal area of ground-glass attenuation at thin-section CT as an early sign. Jang HJ, et al. **Radiology** 1996 May;199(2):485–8

SECONDARY

Bronchioloalveolar carcinoma presenting aerogenous metastasis to the upper airway [letter] Hidaka N, et al. **Eur J Cancer** 1996 Jun;32A(7):1261–2

[Choroidal metastases as the form of presentation of 2 bronchiolo-alveolar carcinomas] de Frutos Arribas JF, et al. **Rev Clin Esp** 1995 Dec;195(12):853–5 (19 ref.) (Eng. Abstr.) **(Spa)**

VETERINARY

Development and application of an antibody ELISA for the marker protein of ovine pulmonary carcinoma. Kwang J, et al. **Vet Immunol Immunopathol** 1995 Aug;47(3–4):323–31

Primary bronchiolo-alveolar adenocarcinoma in a bull. Charan K, et al. **Vet Rec** 1996 Feb 17;138(7):163–4

ADENOCARCINOMA, CLEAR CELL

[Appearance in 2 brothers of double primary neoplasms: right renal carcinoma and gastric adenocarcinoma] Casetta G, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):49–51 (11 ref.) (Eng. Abstr.) **(Ita)**

[Clear cell carcinoma of the gallbladder] Nomura S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):345–7 (8 ref.) **(Jpn)**

CHEMICALLY INDUCED

Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. Boyd J, et al. **Cancer** 1996 Feb 1;77(3):507–13

CHEMISTRY

Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Kobayashi F, et al. **Gynecol Oncol** 1996 Aug; 62(2):309–13

COMPLICATIONS

[Favorable prognosis in a case of recurrent cerebral infarctions caused by chronic disseminated intravascular coagulation due to ovarian carcinoma] Izumi M, et al. **No To Shinkei** 1996 Jun;48(6):581–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Vesical clear cell adenocarcinoma. V. Nephrogenic adenoma: a diagnostic problem. Alsanjari N, et al. **Histopathology** 1995 Jul;27(1):43–9

Pelvic clear cell adenocarcinoma in a 14-year-old boy. Morgan TO Jr, et al. **J Urol** 1996 Jun;155(6):2062–3

[Vena cava invasion in adrenal gland tumors: findings in nuclear magnetic resonance tomography] Kolb M, et al. **Aktuelle Radiol** 1995 Nov;5(6):356–9 (Eng. Abstr.) **(Ger)**

[Clear cell carcinoma of the kidney in an 8-year-old boy] Bukowski M. **Pediatr Pol** 1995 Nov;70(11):973–5 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

[Successful treatment of clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT-11 and mitomycin C] Shimizu Y, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):587–93 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Vaginal clear cell adenocarcinoma in the United States. Trimble EL, et al. **Gynecol Oncol** 1996 Apr;61(1):113–5

ETIOLOGY

[Cancer on an ectopic kidney. Apropos of a case] el Moussaoui A, et al. **J Urol (Paris)** 1995;101(2):101–3 (Eng. Abstr.) **(Fre)**

GENETICS

Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. Boyd J, et al. **Cancer** 1996 Feb 1;77(3):507–13

Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal carcinomas. Druck T, et al. **Cancer Res** 1995 Nov 15;55(22):5348–53

Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. Gilcrease MZ, et al. **Hum Pathol** 1995 Dec;26(12):1341–6

Familial renal cell carcinoma: review of recent molecular genetics. Yao M, et al. **Int J Urol** 1995 May;2(2):61–70 (134 ref.)

Abnormalities of chromosome 5q correlate with morphologic features of better prognosis in clear cell renal carcinomas. Podolski J, et al. **Pol J Pathol** 1995;46(3):163–6

IMMUNOLOGY

Change in MIB-1 staining between primary and recurrent epithelial ovarian cancer. Geisler JP, et al. **Eur J Gynaecol Oncol** 1995;16(5):343–5

METABOLISM

Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Terpe HJ, et al. **Am J Pathol** 1996 Feb;148(2):453–63

DNA cytometry in renal cell carcinoma. Nenning H, et al. **Gen Diagn Pathol** 1996 Mar;141(3–4):243–7

MORTALITY

Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression. Nordström B, et al. **Anticancer Res** 1996 Mar-Apr;16(2):899–904

PATHOLOGY

Clear cell "sugar" tumor of the pancreas. A novel member of the family of lesions characterized by the presence of perivascular epithelioid cells. Zamboni G, et al. **Am J Surg Pathol** 1996 Jun;20(6):722–30

Effects of TNF-alpha and retinoic acid on the proliferation of the clear cell and chromophilic types of human renal cell carcinoma in vitro. Gerharz CD, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1633–41

Malignant transformation in endometriosis of the urinary bladder: case report of clear cell adenocarcinoma. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(1):13–6 (14 ref.)

Female urethral adenocarcinoma: evidence for more than one tissue of origin? Dodson MK, et al. **Gynecol Oncol** 1995 Dec;59(3):352–7

Late recurrences of vaginal clear cell adenocarcinoma. Fishman DA, et al. **Gynecol Oncol** 1996 Jul;62(1):128–32

Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Kobayashi F, et al. **Gynecol Oncol** 1996 Aug; 62(2):309–13

Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Sainz de la Cuesta R, et al. **Gynecol Oncol** 1996 Feb;60(2):238–44

The histogenesis of clear cell adenocarcinoma of the lower urinary tract. Case series and review of the literature. Drew PA, et al. **Hum Pathol** 1996 Mar;27(3):248–52 (32 ref.)

Clear cell adenocarcinoma of the colon. Rubio CA. **J Clin Pathol** 1995 Dec;48(12):1142–4

MR and CT appearance of urethral clear cell adenocarcinoma in a woman. Morikawa K, et al. **J Comput Assist Tomogr** 1995 Nov-Dec;19(6):1001–3

Clear cell carcinoma simulating the "endometrioid-like variant" of yolk sac tumor. Ballotta MR, et al. **Pathologica** 1995 Feb;87(1):87–90

Hyalinizing clear cell carcinoma of salivary gland. A case report. Okoń K, et al. **Pol J Pathol** 1996;47(1):33–6

Clinicopathological study of clear-cell tumors of the thyroid: an evaluation of 22 cases. Shimizu K, et al. **Surg Today** 1995;25(12):1015–22

[Clear cell cancer of the gallbladder and extrahepatic bile ducts] Paraf F. **Gastroenterol Clin Biol** 1996 Feb; 20(1):124–5 **(Fre)**

[Intracaval neoplastic thrombi from clear cell adenocarcinoma of the kidney involving the righ renal and spermatic veins. Report of a case] Hubert J, et al. **Prog Urol** 1995 Dec;5(6):997–1000 (Eng. Abstr.) **(Fre)**

[Hyalinizing clear cell carcinoma of the salivary glands] Seifert G, et al. **Pathologe** 1996 Mar;17(2):110–5 (26 ref.) (Eng. Abstr.) **(Ger)**

[The results of chemosensitivity test for clear cell adenocarcinoma of the ovary] Shimizu Y, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):945–7 **(Jpn)**

[A benign clear cell tumor of the lung that grew gradually over five years] Mishina T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):765–70 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

CT demonstration of liquid intratumoral fat layering in a necrotic renal cell carcinoma. Castoldi MC, et al. **Abdom Imaging** 1995 Sep-Oct;20(5):483–5

MR and CT appearance of urethral clear cell adenocarcinoma in a woman. Morikawa K, et al. **J Comput Assist Tomogr** 1995 Nov-Dec;19(6):1001–3

SECONDARY

Change in MIB-1 staining between primary and recurrent epithelial ovarian cancer. Geisler JP, et al. **Eur J Gynaecol Oncol** 1995;16(5):343–5

Cerebellopontine angle metastasis from clear-cell renal carcinoma presenting as bleeding from the ear. Bhatoe HS, et al. **J Laryngol Otol** 1996 Apr;110(4):370–2

Head and neck metastases of renal cancer after nephrectomy: a report of 2 cases. Airoldi M, et al. **Tumori** 1995 May-Jun; 81(3):213–4

Solitary thyroid metastasis from a renal cell carcinoma diagnosed and treated 12 years before: a case report. Innocente R, et al. **Tumori** 1995 Nov-Dec;81(6):450–3

[Metachronous metastasis in ureteral stump secondary to ipsilateral renal adenocarcinoma] Pereira Arias JG, et al. **Arch Esp Urol** 1995 Sep;48(7):746–8 (9 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[Pregnancy after transposition and repositioning of the ovaries in a patient with clear-cell adenocarcinoma] Gerbaulet A, et al. **Rev Fr Gynecol Obstet** 1995 Dec; 90(12):534–8 (Eng. Abstr.) **(Fre)**

VIROLOGY

Clear cell adenosquamous carcinoma of the cervix. An aggressive tumor associated with human papillomavirus-18. Fujiwara H, et al. **Cancer** 1995 Nov 1;76(9):1591–600

ADENOCARCINOMA, FOLLICULAR

Follicular thyroid cancer. Grebe SK, et al. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):761–801 (184 ref.)

Adverse aspects of small thyroid cancer and need for treatment. Rosen IB, et al. **Head Neck** 1995 Sep-Oct; 17(5):373–6

[Distant metastases of thyroid tumors] Sterniuk IuM, et al. **Klin Khir** 1996;(1):46–8 **(Ukr)**

CHEMICALLY INDUCED

Mechanisms of chemically induced thyroid follicular carcinogenesis. Kanno J, et al. **Prog Clin Biol Res** 1996; 394:353–98 (176 ref.)

COMPLICATIONS

Carcinoma in Graves' disease. Thakur S, et al. **J Assoc Physicians India** 1995 Sep;43(9):600–1

Follicular thyroid carcinoma and mediastinal goiter in a case of situs inversus viscerum. Panza N, et al. **Q J Nucl Med** 1995 Jun;39(2):116–8

DIAGNOSIS

Metastatic follicular thyroid carcinoma masquerading as a chordoma. Casals MM, et al. **Thyroid** 1995 Jun;5(3):217–21

[Preoperative diagnosis of thyroid cancer by karyometry of thyrocytes] Kirillov VA, et al. **Klin Lab Diagn** 1996 Mar-Apr;(2):14–6 (Eng. Abstr.) **(Rus)**

[Follicular cancer of the thyroid: atypical presentation] Rodríguez Carballeira M, et al. **An Med Interna** 1995 Jun; 12(6):291–3 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Morbidity and mortality in follicular thyroid cancer. DeGroot LJ, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):2946–53

[Chronological changes in the representation of papillary and follicular carcinomas in our patient group 1960–1993] Němec J, et al. **Bratisl Lek Listy** 1995 Nov;96(11):619–21

(Eng. Abstr.) **(Cze)**

GENETICS

Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment [letter; comment] Takami H, et al. **Arch Surg** 1996 Jun;131(6):676. Comment on: Arch Surg 1995 Aug;130(8):892-7; discussion 898-9.

Contribution of p53 gene alterations to development of metastatic forms of follicular thyroid carcinoma. Sápi Z, et al. **Diagn Mol Pathol** 1995 Dec;4(4):256-60

Genetics of follicular thyroid cancer. Farid NR, et al. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):865-83 (87 ref.)

Molecular analysis of mutations in thyroid tumors with TGGE. Simon D, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(5):275-9 (36 ref.)

Deletions of the long arm of chromosome 10 in progression of follicular thyroid tumors. Zedenius J, et al. **Hum Genet** 1996 Mar;97(3):299-303

Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. Branet F, et al. **J Clin Endocrinol Metab** 1996 Jul; 81(7):2726-30

Infrequent CDKN2 mutation in human differentiated thyroid cancers. Tung WS, et al. **Mol Carcinog** 1996 Jan;15(1):5-10

[Gastric hamartoma and thyroid gland carcinoma with follicular and neuroendocrine differentiation in Cowden syndrome] Marth T, et al. **Z Gastroenterol** 1996 Jan; 34(1):30-5 (Eng. Abstr.) **(Ger)**

MORTALITY

Prognostic factors in follicular carcinoma of the thyroid: a study of 198 cases. Rao RS, et al. **Head Neck** 1996 Mar-Apr;18(2):118-24; discussion 124-6

PATHOLOGY

Solitary skin metastasis as the presenting feature of differentiated thyroid microcarcinoma: report of two cases. Lissak B, et al. **J Endocrinol Invest** 1995 Nov;18(10):813-6

Morule with biotin-containing intranuclear inclusions in thyroid carcinoma. Okamoto Y, et al. **Pathol Int** 1995 Aug; 45(8):573-9

Encapsulated follicular thyroid carcinoma exhibiting glandular and spindle cell components. A case report. Mizukami Y, et al. **Pathol Res Pract** 1996 Jan;192(1):67-71; discussion 72-4

Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Shaha AR, et al. **Surgery** 1995 Dec;118(6):1131-6; discussion 1136-8

Human follicular and papillary thyroid carcinoma cells interact differently with human venous endothelial cells. Grimm D, et al. **Thyroid** 1995 Jun;5(3):155-64

Follicular thyroid carcinoma with a predominant insular component in a child: a case report. Kotiloglu E, et al. **Tumori** 1995 Jul-Aug;81(4):296-8

[Differentiated thyroid cancer--a study of the pathomorphological variants in 216 patients] Petkov R, et al. **Khirurgiia (Sofiia)** 1995;48(2):11-2 (Eng. Abstr.) **(Bul)**

[Papillary carcinoma arising in thyroglossal duct cyst: a case report and review of the literature] Sorrenti G, et al. **Acta Otorhinolaryngol Ital** 1995 Dec;15(6):460-4 (40 ref.) (Eng. Abstr.) **(Ita)**

RADIONUCLIDE IMAGING

A false-positive localization of a parathyroid adenoma with technetium Tc 99m sestamibi scan secondary to a thyroid follicular carcinoma. Koss WG, et al. **Arch Surg** 1996 Feb; 131(2):216-7

False-positive I-131 images mimicking thyroid cancer metastasis. The nose ring sign. Dick C, et al. **Clin Nucl Med** 1995 Oct;20(10):876-7

Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma. Kosuda S, et al. **Eur J Nucl Med** 1995 Oct; 22(10):1218-20

Thallium-201 and iodine-131 scintigraphy in differentiated thyroid carcinoma. Lorberboym M, et al. **J Nucl Med** 1996 Sep;37(9):1487-91

Effect of lithium and oral thyrotrophin-releasing hormone (TRH) on serum thyrotrophin (TSH) and radioiodine uptake in patients with well differentiated thyroid carcinoma. Ang ES, et al. **Singapore Med J** 1995 Dec; 36(6):606-8

[Coincidence of unifocal thyroid autonomy and follicular carcinoma. Case report] Einert A, et al. **Radiologe** 1995 Aug;35(8):531-4 (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Farahati J, et al. **Cancer** 1996 Jan 1;77(1):172-80

"High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. Menzel C, et al. **J Nucl Med** 1996 Sep; 37(9):1496-503

SECONDARY

False-positive I-131 images mimicking thyroid cancer metastasis. The nose ring sign. Dick C, et al. **Clin Nucl Med** 1995 Oct;20(10):876-7

Isolated liver metastases from follicular thyroid cancer. Graves MW, et al. **Clin Nucl Med** 1996 Feb;21(2):147-8

Contribution of p53 gene alterations to development of metastatic forms of follicular thyroid carcinoma. Sápi Z, et al. **Diagn Mol Pathol** 1995 Dec;4(4):256-60

Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma. Kosuda S, et al. **Eur J Nucl Med** 1995 Oct; 22(10):1218-20

Solitary skin metastasis as the presenting feature of differentiated thyroid microcarcinoma: report of two cases. Lissak B, et al. **J Endocrinol Invest** 1995 Nov;18(10):813-6

Accelerated thyrotoxicosis induced by iodinated contrast media in metastatic differentiated thyroid carcinoma. Lorberboym M, et al. **J Nucl Med** 1996 Sep;37(9):1532-5

Thyroid carcinoma metastasized to the sternum: resection of the sternum and reconstruction with acrylic resin. Ozaki O, et al. **J Surg Oncol** 1995 Dec;60(4):282-5

Metastatic follicular thyroid carcinoma masquerading as a chordoma. Casals MM, et al. **Thyroid** 1995 Jun;5(3):217-21

[Functional activity of a metastatic differentiated carcinoma of the thyroid gland] Kraft O. **Vnitr Lek** 1995 Aug; 41(8):538-40 (Eng. Abstr.) **(Cze)**

SURGERY

An evaluation of prognostic scoring systems in patients with follicular thyroid cancer. Davis NL, et al. **Am J Surg** 1995 Nov;170(5):476-80

The role of total thyroidectomy in the management of differentiated thyroid cancer. Stephenson BM, et al. **Curr Opin Gen Surg** 1994;:53-9 (61 ref.)

Differentiated thyroid cancer: surgical treatments of 190 patients. Torre G, et al. **Eur J Surg Oncol** 1996 Jun; 22(3):276-81

Recurrence and mortality in patients with differentiated thyroid carcinoma. Noguchi M, et al. **Int Surg** 1995 Apr-Jun;80(2):162-6

Papillary and follicular thyroid carcinoma: the treatment results of 357 patients at the National Kyushu Cancer Centre of Japan. Yasumoto K, et al. **J Laryngol Otol** 1996 Jul;110(7):657-62

Prognostic factors associated with differentiated thyroid cancer. Tsuchiya A, et al. **Surg Today** 1995;25(9):778-82

[Struma nodosa and cancer of the thyroid] Gavrailov M, et al. **Khirurgiia (Sofiia)** 1995;48(2):5-7 (Eng. Abstr.) **(Bul)**

[Recurrences and metastases in differentiated thyroid cancer] Petkov R. **Khirurgiia (Sofiia)** 1995;48(2):8-10 (Eng. Abstr.) **(Bul)**

[Differentiated thyroid gland carcinomas in "autonomous adenomas" in childhood] Müller A, et al. **Chirurg** 1995 Oct; 66(10):1018-20 (Eng. Abstr.) **(Ger)**

[Prospective therapy study in differentiated thyroid carcinoma] Gemsenjäger E, et al. **Schweiz Med Wochenschr** 1995 Nov 18;125(46):2226-36 (41 ref.) (Eng. Abstr.) **(Ger)**

[Thyroid carcinoma in hyperthyroid syndromes] Ragni F, et al. **G Chir** 1996 Apr;17(4):158-65 (26 ref.) (Eng. Abstr.) **(Ita)**

VETERINARY

Response to high-dose radioactive iodine administration in cats with thyroid carcinoma that had previously undergone surgery. Guptill L, et al. **J Am Vet Med Assoc** 1995 Oct 15;207(8):1055-8

ADENOCARCINOMA, GRANULAR CELL see **ADENOCARCINOMA**

ADENOCARCINOMA, MUCINOUS

Different terms for the same disease: intraductal mucin-producing tumor versus mucinous tumor of the pancreas [letter; comment] Itai Y. **Radiology** 1996 Jul; 200(1):285. Comment on: Radiology 1996 Jan;198(1):249-57.

Mucinous carcinoma of sweat glands. Urso C, et al. **Tumori** 1995 Nov-Dec;81(6):457-9

[Adenocarcinoma of the appendix. A propos of a case complicated by double local and parietal recurrence] de Souza N, et al. **J Chir (Paris)** 1996 Jun;133(4):159-61 (10 ref.) (Eng. Abstr.) **(Fre)**

[Mucin producing gallbladder cancer] Araida T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):352-5 (15 ref.) **(Jpn)**

[Mucinous cholangiocarcinoma, mucus producing carcinoma] Sakamoto H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):414-6 (17 ref.) **(Jpn)**

[Mucinous cholangiocarcinoma] Sasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):423-5 (15 ref.) **(Jpn)**

[Mucin producing extrahepatic bile duct carcinoma] Yamanaka T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):92-4 (9 ref.) **(Jpn)**

[Association of cancer and non-Hodgkin's lymphoma of the stomach] Gorbunov GF. **Klin Khir** 1996;(1):53 **(Rus)**

[Primary mucinous adenocarcinoma of the prostate] Gomiz Léon JJ, et al. **Actas Urol Esp** 1995 Jun;19(6):473-5 (16 ref.) (Eng. Abstr.) **(Spa)**

[Mucinous adenocarcinoma of the anal region. Study of 4 cases] Sacristán F, et al. **Rev Esp Enferm Dig** 1995 Sep; 87(9):677-80 (Eng. Abstr.) **(Spa)**

BLOOD

Decreased branching, increased fucosylation and changed sialylation of alpha-1-proteinase inhibitor in breast and ovarian cancer. Goodarzi MT, et al. **Clin Chim Acta** 1995 May 15;236(2):161-71

Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Tamakoshi K, et al. **Gynecol Oncol** 1996 Jul;62(1):67-72

CHEMISTRY

Evaluation of mucinous metaplasia of the prostate gland by mucin histochemistry. Gal R, et al. **Br J Urol** 1996 Jan; 77(1):113-7

COMPLICATIONS

Pseudomyxoma peritonei. Fox H. **Br J Obstet Gynaecol** 1996 Mar;103(3):197-8

Sebaceous adenomas, squamous cell carcinoma and skin infections in a patient with carcinoma of the colon, rectum and bladder. Abraham Z, et al. **J Dermatol** 1995 Dec; 22(12):939-42

[A rare case of nonmetastatic paraneoplastic hypercalcemia (humoral hypercalcemia of malignancy) associated with mucinous carcinoma of the stomach] Mariani S, et al. **Minerva Gastroenterol Dietol** 1995 Dec;41(4):307-10 (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Mucinous carcinoma of the breast: potential false-negative MR imaging interpretation [letter] Miller RW, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):539-40

Mucinous carcinoma of the liver mimicking cavernous hemangioma on pre- and postcontrast MR imaging [letter] Ueda K, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):468-9

Colonic carcinoma presenting as an appendiceal abscess in a young woman. Ramsay JA, et al. **Can J Surg** 1996 Feb; 39(1):53-6

Mucinous eccrine carcinoma of the vulva with neuroendocrine differentiation. Rahilly MA, et al. **Histopathology** 1995 Jul;27(1):82-6

Imaging findings of mucinous type of cholangiocellular carcinoma. Hayashi M, et al. **J Comput Assist Tomogr** 1996 May-Jun;20(3):386-9

[Colloid cancer of the anus: value of anal ultrasonography and nuclear magnetic resonance imaging (letter)] De Parades V, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Oct;31(5):284-6 **(Fre)**

[Psoas abscess as initial manifestation of appendiceal tumor (letter)] Tabet J, et al. **Med Clin (Barc)** 1996 Apr 13; 106(14):556-7 **(Spa)**

EPIDEMIOLOGY

[Epidemiology and prognosis of gastric carcinomas at the province of Calvados. A 10-year study] Arsène D, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):797-803 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Cramer DW, et al. **Ann Epidemiol** 1995 Jul;5(4):310-4

GENETICS

Is mucinous carcinoma of the colorectum a distinct genetic entity? Hanski C. **Br J Cancer** 1995 Dec;72(6):1350-6 (124 ref.)

High yields of K-ras mutations in intraductal papillary mucinous tumors and invasive adenocarcinomas induced by N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine in the pancreas of female Syrian hamsters. Sugio K, et al. **Carcinogenesis** 1996 Feb;17(2):303-9

Genetic analysis of synchronous mucinous tumors of the ovary and appendix. Chuaqui RF, et al. **Hum Pathol** 1996 Feb;27(2):165-71

Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. Marchetti A, et al. **J Pathol** 1996 Jul;179(3):254-9

[Analysis of familial aggregation of ovarian and breast cancer in patients with ovarian cancer] Ichikawa Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep;47(9):901-6 (Eng. Abstr.) **(Jpn)**

METABOLISM

Image analysis quantification in hormone receptor assay of mucinous carcinoma of the breast. Comparison with biochemical analysis. Ballouk F, et al. **Anal Quant Cytol Histol** 1995 Jun;17(3):151-6

Low frequency of p53 gene mutation and protein expression in mucinous colorectal carcinomas. Hanski C, et al. **Cancer Lett** 1996 Jun 5;103(2):163-70

Antibody penetration of tumor GS-7 xenografts in nude mice: a model for mucinous adenocarcinoma of the colon. Blumenthal RD, et al. **Cancer Res** 1996 Aug 1; 56(15):3508-15

ADENOCARCINOMA, MUCINOUS

PATHOLOGY

Calcified splenic metastasis from gastric carcinoma. Williams L, et al. **Abdom Imaging** 1995 Jul–Aug;20(4):312–4

Cytologic findings in minimal deviation adenocarcinoma (adenoma malignum) of the cervix. A report of seven cases. Granter SR, et al. **Am J Clin Pathol** 1996 Mar;105(3):327–33

Mucinous carcinoma of the eyelid. An immunohistochemical study. Carson HJ, et al. **Am J Dermatopathol** 1995 Oct; 17(5):494–8

Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations. Cuatrecasas M, et al. **Am J Surg Pathol** 1996 Jun;20(6):739–46

Solid papillary carcinoma of the breast. A form of intraductal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma. Maluf HM, et al. **Am J Surg Pathol** 1995 Nov;19(11):1237–44

Mucus retention in heterotopic pancreas of the gastric antrum: a lesion mimicking mucinous carcinoma [letter; comment] Padberg BC, et al. **Am J Surg Pathol** 1995 Dec; 19(12):1445–7. Comment on: Am J Surg Pathol 1994 Sep;18(9):953–7.

Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Ronnett BM, et al. **Am J Surg Pathol** 1995 Dec;19(12):1390–408

Mucinous (colloid) carcinoma of urinary bladder following long-term cyclophosphamide therapy for Waldenstrom's macroglobulinemia. Siddiqui A, et al. **Am J Surg Pathol** 1996 Apr;20(4):500–4

Mucinous carcinoma of the skin [letter] Muramatsu T, et al. **Br J Dermatol** 1995 Nov;133(5):820–1

Mucinous (colloid) adenocarcinoma of the prostate. López JI, et al. **Br J Urol** 1995 Dec;76(6):805–6

An association between villous adenomas and mucinous ductal ectasia of the pancreas. Barthet M, et al. **Endoscopy** 1995 Oct;27(8):601–3

Female urethral adenocarcinoma: evidence for more than one tissue of origin? Dodson MK, et al. **Gynecol Oncol** 1995 Dec;59(3):352–7

Cystic neoplasms of the liver: a report of two cases with special reference to cystadenocarcinoma. Shimada M, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):249–54

Mucinous adenocarcinoma of the endometrium with intestinal differentiation: a case report. Zheng W, et al. **Hum Pathol** 1995 Dec;26(12):1385–8

Composite carcinoid carcinoma of the colon—a case report. Chaturvedi KU, et al. **Indian J Cancer** 1994 Sep;31(3):203–6

Eccrine carcinoma of the forearm. Prasad RR, et al. **Int J Dermatol** 1995 Dec;34(12):859–60

Mixed strumal and mucinous carcinoid tumor of the ovary. Matías-Guiu X, et al. **Int J Gynecol Pathol** 1995 Apr; 14(2):179–83

Ovarian mucinous tumors of low malignant potential: a clinicopathologic study of 54 tumors of intestinal and müllerian type. Siriaunkgul S, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):198–208

Gallbladder cancer associated with cholesterosis. Akiyama T, et al. **J Gastroenterol** 1996 Jun;31(3):470–4

Clinicopathological study of colorectal mucinous carcinoma in Taiwan: a multivariate analysis. Wu CS, et al. **J Gastroenterol Hepatol** 1996 Jan;11(1):77–81

Primary mucinous adencoarcinoma of the skin. Umap PS. **J Indian Med Assoc** 1995 Aug;93(8):328

Mucin-producing malignant meningioma with papillary and glandular patterns. Kasantikul V, et al. **J Med Assoc Thai** 1995 Nov;78(11):635–40

Increased incidence of second primary malignancy in patients with carcinoid tumors: case report and literature review. Rivadeneira DE, et al. **J Natl Med Assoc** 1996 May; 88(5):310–2 (12 ref.)

Mucinous carcinoma of the ovary. Clinicopathologic analysis. Kikkawa F, et al. **Oncology** 1996 Jul–Aug; 53(4):303–7

Pathological and immunohistochemical findings in a case of mucinous cholangiocarcinoma. Sasaki M, et al. **Pathol Int** 1995 Oct;45(10):781–6

Possible neoplastic transformation within gastric hyperplastic polyp. Application of endoscopic polypectomy. Hizawa K, et al. **Surg Endosc** 1995 Jun;9(6):714–8

Mucinous adenocarcinoma of the prostate: a report of a case of long-term survival. Olivas TP, et al. **Urology** 1996 Feb; 47(2):256–8 (7 ref.)

[Mucin histochemical analysis of mucin-forming carcinomas, metaplasias of the urothelium and in persistent urachus] Ebel K, et al. **Pathologe** 1996 May;17(3):208–12 (Eng. Abstr.) **(Ger)**

[Prostatic adenocarcinoma showing features of endometrioid and mucinous carcinomas: a case report] Nishimura K, et al. **Hinyokika Kiyo** 1995 Oct;41(10):805–7 (Eng. Abstr.) **(Jpn)**

[A case of mucinous adenocarcinoma of the prostate] Hayakawa K, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jan;87(1):78–81 (Eng. Abstr.) **(Jpn)**

[Metastasis of colon cancer to the larynx: a case report] Kruk-Zagajewska A, et al. **Otolaryngol Pol** 1995; 49(3):260–5 (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. Jacquet P, et al. **J Am Coll Surg** 1995 Dec;181(6):530–8

SECONDARY

Calcified splenic metastasis from gastric carcinoma. Williams L, et al. **Abdom Imaging** 1995 Jul–Aug;20(4):312–4

Recurrent parotid adenocarcinoma occurring within the cerebellopontine angle. Stravropoulos SW, et al. **AJNR Am J Neuroradiol** 1995 Aug;16(7):1529–31

Adenocarcinoma metastatic to the choroid: diagnosis by trans-scleral biopsy [letter] Isaacs TW, et al. **Eye** 1995;9 (Pt 5):643–7

Mucinous metastatic adenocarcinoma of spermatic cord. Reddy DS, et al. **J Indian Med Assoc** 1995 Mar;93(3):111, 102

SECRETION

[Mucinous pancreatic ductal ectasia: mucus secreting tumor of malignant potential] Michelin T, et al. **Presse Med** 1996 Apr 13;25(13):625–7 (10 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. Jacquet P, et al. **J Am Coll Surg** 1995 Dec;181(6):530–8

Mucinous eccrine carcinoma of the eyelid. Werner MS, et al. **Ophthal Plast Reconstr Surg** 1996 Mar;12(1):58–60

Synchronous double cancers of the remnant stomach and pancreas: report of a case. Miyaguni T, et al. **Surg Today** 1995;25(12):1038–42

[A case report: resection of the uncinate process of the pancreas for ultra-small pancreatic mucin-producing carcinoma of the branch type] Ichihara T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jun;93(6):445–50 **(Jpn)**

THERAPY

Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. de Kossodo S, et al. **Br J Cancer** 1995 Nov;72(5):1165–72

Combined modality therapy in low risk (T2N0) rectal cancer. Coco C, et al. **Rays** 1995 Apr–Jun;20(2):156–64 **(Eng, Ita)**

[Anastomotic recurrence with tumor stenosis after Billroth II gastrectomy for adenocarcinoma: implantation of 2 metal stents as palliative therapy] Krömer MU, et al. **Leber Magen Darm** 1995 Jul;25(4):176–9 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Preoperative diagnosis of mucinous gastric adenocarcinoma by endoscopic ultrasonography. Songür Y, et al. **Am J Gastroenterol** 1996 Aug;91(8):1586–90

Pure mucinous breast cancer–mammographic and ultrasound findings. Chopra S, et al. **Clin Radiol** 1996 Jun;51(6):421–4

Endosonographic features of a calcified mucinous gastric carcinoma. Songür Y, et al. **Endoscopy** 1995 May;27(4):347

ADENOCARCINOMA, OXYPHILIC see **ADENOCARCINOMA**

ADENOCARCINOMA, PAPILLARY

[Intrahepatic bile duct adenocarcinoma] Terada T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):402–4 (7 ref.) **(Jpn)**

BLOOD SUPPLY

[Usefulness of three-dimensional CT angiography for cervical tumor] Kumagai M, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Aug;98(8):1270–7 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Right hepatic lobe agenesis associated with bile duct carcinoma. Harada N, et al. **Abdom Imaging** 1995 Sep–Oct; 20(5):456–8

A patient with an autonomously functioning thyroid nodule with papillary adenocarcinoma associated with Graves' hyperthyroidism. Tsuboi M, et al. **Clin Nucl Med** 1995 Nov; 20(11):985–8

DIAGNOSIS

Upper airway obstruction caused by low-grade tracheal papillary adenocarcinoma: an usual flow-volume loop pattern. Clarke DE, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1286–8

[Primary carcinoma of the fallopian tubes—difficulties in its differential diagnosis and management] Raïcheva R, et al. **Akush Ginekol (Sofiia)** 1995;34(1):36–7 **(Bul)**

GENETICS

K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Hanada K, et al. **Cancer** 1996 Feb 1;77(3):452–8

Deregulated alternative splicing of CD44 messenger RNA transcripts in neoplastic and nonneoplastic lesions of the human thyroid. Ermak G, et al. **Cancer Res** 1995 Oct 15; 55(20):4594–8

[A case of intraductal papillary adenocarcinoma in adenoma of the pancreas presenting a mutation of Ki-ras codon 12 in the duodenal juice collected during a secretin test] Arao S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1327–30 **(Jpn)**

IMMUNOLOGY

[Two cases of CA19-9 producing pulmonary papillary adenocarcinoma] Hagiwara K, et al. **Kyobu Geka** 1995 Oct; 48(11):925–8 (Eng. Abstr.) **(Jpn)**

MORTALITY

Clinical and prognostic characteristics of papillary clear carcinoma of stomach. Uefuji K, et al. **Surg Today** 1996; 26(3):158–63

PATHOLOGY

Expression of mucin carbohydrate antigens (T, Tn and sialyl Tn) and MUC-1 gene product in intraductal papillary-mucinous neoplasm of the pancreas. Terada T, et al. **Am J Clin Pathol** 1996 May;105(5):613–20

Aggressive papillary tumors of the endolymphatic sac: clinical and tissue culture characteristics. Feghali JG, et al. **Am J Otol** 1995 Nov;16(6):778–82

Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. Coltrini D, et al. **Cancer Res** 1995 Oct 15;55(20):4729–38

Cystic neoplasms of the liver: a report of two cases with special reference to cystadenocarcinoma. Shimada M, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):249–54

Gallbladder cancer associated with cholesterosis. Akiyama T, et al. **J Gastroenterol** 1996 Jun;31(3):470–4

Venous tumor thrombosis and cavernous transformation of the portal vein in a patient with gastric carcinoma. Ishikawa M, et al. **J Gastroenterol** 1995 Aug;30(4):529–33

Floating gallbladder associated with histologically distinct double cancers. Nakahama M, et al. **J Gastroenterol** 1996 Jun;31(3):465–9

Familial adenomatous polyposis and lung cancer. Wong RP, et al. **J Surg Oncol** 1995 Nov;60(3):213–4 (11 ref.)

Aggressive papillary tumors of the temporal bone: an immunohistochemical analysis in tissue culture. Levin RJ, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):144–7

Orthotopic placement of the Dunning R3327 AT-3 prostate tumor in the Copenhagen X Fischer rat. Rubenstein M, et al. **Prostate** 1995 Sep;27(3):148–53

[Invasive thymoma associated with pure red cell aplasia and lung cancer] Morishima Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):236–40 (Eng. Abstr.) **(Jpn)**

[A case of gastric duplication cyst containing papillary adenocarcinoma] Mamiya N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):34–8 **(Jpn)**

[Bronchial obstruction due to carcinoma with psammoma and metastasis (clinical conference)] **Medicina (B Aires)** 1995;55(1):51–7 **(Spa)**

RADIONUCLIDE IMAGING

Thallium-201 and iodine-131 scintigraphy in differentiated thyroid carcinoma. Lorberboym M, et al. **J Nucl Med** 1996 Sep;37(9):1487–91

RADIOTHERAPY

Pancytopenia after repeated radioiodine treatment on metastatic thyroid cancer to bone. Tanigawa K, et al. **Chin Med J (Engl)** 1995 Oct;108(10):796–7

SECONDARY

Low-grade adenocarcinoma of probable endolymphatic sac origin: CT and MR appearance. Ho VT, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):168–70

Pancytopenia after repeated radioiodine treatment on metastatic thyroid cancer to bone. Tanigawa K, et al. **Chin Med J (Engl)** 1995 Oct;108(10):796–7

[A case of advanced gastric cancer with liver metastasis with no recurrence and long survival] Miyaji M, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):915–8 (Eng. Abstr.) **(Jpn)**

SECRETION

Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms. Shyr YM, et al. **Ann Surg** 1996 Feb;223(2):141–6 (27 ref.)

SURGERY

Pleuropneumonectomy and postoperative adjuvant chemotherapy for carcinomatous pleuritis in primary lung cancer: a case report of long-term survival. Yokoi K, et al. **Eur J Cardiothorac Surg** 1996;10(2):141–3

Hepatopancreatoduodenectomy for superficially spreading bile duct carcinoma: a report of two 5 year survivals. Nakamura S, et al. **Hepatogastroenterology** 1996 Jan–Feb;

43(7):138–42
Carcinoma of the cystic duct protruding into the common bile duct: report of a case. Shibata Y, et al. **Surg Today** 1995;25(12):1050–3

THERAPY

Leukemia developing after 131I treatment for thyroid cancer in a patient with Werner's syndrome: molecular and cytogenetic studies. Takemoto Y, et al. **Intern Med** 1995 Sep;34(9):863–7
[A case of advanced gastric cancer with liver metastasis with no recurrence and long survival] Miyaji M, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):915–8 (Eng. Abstr.) **(Jpn)**

ADENOCARCINOMA, RENAL CELL see **CARCINOMA, RENAL CELL**

ADENOCARCINOMA, SCIRRHOUS

DRUG THERAPY

Recurrent breast cancer treated successfully with mitomycin–C and vinblastine after failure of both doxorubicin–containing regimen and paclitaxel––a case report. Sekine I, et al. **Tohoku J Exp Med** 1996 Mar; 178(3):331–7
[A case of recurrent breast cancer responding to long–term treatment with 5'-DFUR combined with MPA] Kimura M, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1183–5 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. Yashiro M, et al. **Br J Cancer** 1995 Nov;72(5):1200–10
Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as "soil" for peritoneal dissemination. Yashiro M, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1668–75
Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Yashiro M, et al. **Clin Exp Metastasis** 1996 Jan;14(1):43–54
A low grade scirrhous carcinoma of eccrine gland origin in adolescence. Yamamoto O, et al. **J Dermatol** 1996 Jan; 23(1):47–52

RADIOGRAPHY

[Scirrhous gastric carcinoma: utility of computed tomographic diagnosis] Banba Y. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Nov; 55(14):961–7 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Incidental detection of breast cancer during T1–201 myocardial SPECT study. Arbab AS, et al. **Ann Nucl Med** 1995 Aug;9(3):143–4

SECONDARY

Long–term survival of 5 years following initial surgery for gastric cancer and simultaneous disseminated peritoneal metastasis: report of a case. Otani S, et al. **Surg Today** 1995; 25(11):959–61

SURGERY

Hepatopancreatoduodenectomy for superficially spreading bile duct carcinoma: a report of two 5 year survivals. Nakamura S, et al. **Hepatogastroenterology** 1996 Jan–Feb; 43(7):138–42

ULTRASONOGRAPHY

Short communication: detection of early scirrhous carcinoma of the stomach by endoscopic ultrasonography. Fujishima H, et al. **Br J Radiol** 1996 Jul;69(823):661–4

ULTRASTRUCTURE

Argyrophilic nucleolar organizer region (AgNOR) area per nucleus as a prognostic factor in breast cancer. Nakayama K, et al. **J Surg Oncol** 1995 Nov;60(3):160–7

ADENOCARCINOMA, SEBACEOUS

DIAGNOSIS

Genitourinary tumors in men with the Muir–Torre syndrome. Davis DA, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):909–12

ETIOLOGY

Sebaceous adenomas, squamous cell carcinoma and skin infections in a patient with carcinoma of the colon, rectum and bladder. Abraham Z, et al. **J Dermatol** 1995 Dec; 22(12):939–42

PATHOLOGY

Sebaceous epithelioma with sweat gland differentiation. Okuda C, et al. **Am J Dermatopathol** 1995 Oct;17(5):523–8
Extra–ocular sebaceous gland carcinoma [letter] Erverdi N, et al. **Eur J Cancer** 1995;31A(9):1546
Muir–Torre syndrome and defective DNA mismatch repair genes [letter] Fusaro RM, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):493–4
Sebaceous carcinoma of the vulva. Kawamoto M, et al. **Pathol Int** 1995 Oct;45(10):767–73 (32 ref.)

RADIOTHERAPY

Long–term follow–up of patients undergoing definitive radiation therapy for sebaceous carcinoma of the ocular adnexae [letter; comment] Pardo FS, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 15;34(5):1189–90 . Comment on: Int J Radiat Oncol Biol Phys 1989 Sep;17(3):643–7.

ADENOCARCINOMA, TUBULAR see **ADENOCARCINOMA**

ADENOFIBROMA

COMPLICATIONS

[Meigs syndrome presenting as diaphragmatic pleural nodules] Choh K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):80–4 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Benign adenomatous kidney neoplasms in children with polycythemia: imaging findings. Comerci SC, et al. **Radiology** 1996 Jan;198(1):265–8
Mammary hamartoma––an under–recognised breast lesion. Williams NP, et al. **West Indian Med J** 1996 Jun;45(2):67–9

PATHOLOGY

[Spontaneous expulsion of a uterine mass] Peoc'h M, et al. **Ann Pathol** 1995;15(6):451–2 **(Fre)**

ADENOHYPOPHYSIS see **PITUITARY GLAND, ANTERIOR**

ADENOIDECTOMY

Comparison of total intravenous, balanced inhalational and combined intravenous–inhalational anaesthesia for tympanoplasty, septorhinoplasty and adenotonsillectomy. Van den Berg AA, et al. **Anaesth Intensive Care** 1995 Oct; 23(5):574–82
Laryngeal mask airway in adeno–tonsillectomy in children [letter; comment] Howard–Griffin RM, et al. **Anaesthesia** 1996 Apr;51(4):409. Comment on: Anaesthesia 1995 Oct;50(10):898–900.
Sizing up the adenoid. Gates GA. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):239–40
The reproducibility of urinary growth hormone measurement in children undergoing adenotonsillectomy: a pilot study. Owen G, et al. **Clin Otolaryngol** 1996 Feb;21(1):54–8
Overnight pulse oximetry in normal children and in children undergoing adenotonsillectomy. Owen GO, et al. **Clin Otolaryngol** 1996 Feb;21(1):59–65
Polysomnography after adenotonsillectomy in mild pediatric obstructive sleep apnea. Helfaer MA, et al. **Crit Care Med** 1996 Aug;24(8):1323–7
Pediatric adenotonsillectomy for obstructive sleep apnea. Ruboyianes JM, et al. **Ear Nose Throat J** 1996 Jul; 75(7):430–3
Sleep disordered breathing: effects of adenotonsillectomy on behaviour and psychological functioning. Ali NJ, et al. **Eur J Pediatr** 1996 Jan;155(1):56–62
Tonsillectomy and adenoidectomy in patients with Down syndrome. Bower CM, et al. **Int J Pediatr Otorhinolaryngol** 1995 Oct;33(2):141–8
Comparison of sevoflurane and halothane anesthesia in children undergoing outpatient ear, nose, and throat surgery. Greenspun JC, et al. **J Clin Anesth** 1995 Aug; 7(5):398–402
Ambulatory tonsillectomy and adenoidectomy. Gabalski EC, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):77–80
General anesthesia with and without nitrous oxide (N2O) and the weight of middle ear effusion in children undergoing adenoidectomy and tympanostomy. Koivunen P, et al. **Laryngoscope** 1996 Jun;106(6):724–6
Processing of adenoid and tonsil specimens in children: a national survey of standard practices and a five–year review of the experience at the Children's Hospital of Pittsburgh. Dohar JE, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):94–7
Pediatric tympanoplasty: the role of adenoidectomy. Gianoli GJ, et al. **Otolaryngol Head Neck Surg** 1995 Oct; 113(4):380–6
[Sluder's adenotonsillectomy: with or without endotracheal intubation?] Mulder JJ, et al. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2730–2 (Eng. Abstr.) **(Dut)**
[Perioperative managements of a mentally retarded child with obstructive sleep apnea syndrome for adeno–tonsillectomy] Oohata H, et al. **Masui** 1996 Apr;45(4):458–63 (Eng. Abstr.) **(Jpn)**
[The effect of adenoidectomy on eustachian tube function] Sente M. **Med Pregl** 1996;49(1–2):45–7 (Eng. Abstr.) **(Scr)**

ADVERSE EFFECTS

Immunological effects of tonsillectomy/adenectomy in children. Del Rio–Navarro BE, et al. **Adv Exp Med Biol** 1995;371B:737–9
Atlanto–axial subluxation and cervical osteomyelitis: two unusual complications of adenoidectomy. Baker LL, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):295–9 (12 ref.)
Meningitis after adenoidectomy: an anatomic explanation. Isaacson G, et al. **Ann Otol Rhinol Laryngol** 1996 Sep; 105(9):684–8 (18 ref.)
The effect of intravenous dexamethasone in pediatric adenotonsillectomy. April MM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):117–20
Prevalence of IgE–mediated hypersensitivity in children with adenotonsillar disease [letter; comment] Cantani A. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):205–6 . Comment on: Arch Otolaryngol Head Neck Surg 1994 Feb;120(2):150–3.
Selected risk factors in pediatric adenotonsillectomy. Gerber ME, et al. **Arch Otolaryngol Head Neck Surg** 1996 Aug; 122(8):811–4
Mortality following adenotonsillectomy in a patient with Williams–Campbell syndrome. Kirse DJ, et al. **Arch Otolaryngol Head Neck Surg** 1996 Sep;122(9):1007–10
Velopharyngeal incompetence and persistent hypernasality after adenoidectomy in children without palatal defect. Ren YF, et al. **Cleft Palate Craniofac J** 1995 Nov;32(6):476–82
[Acute pulmonary edema as complication of adenotonsillectomy: a contribution of two cases] Grijalba Uche M, et al. **An Otorrinolaringol Ibero Am** 1996; 23(3):243–7 (Eng. Abstr.) **(Spa)**

METHODS

[Sluder's method of adenotonsillectomy; with or without endotracheal intubation? (letter)] Hoeve LJ. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):571–2 **(Dut)**

STATISTICS & NUMERICAL DATA

Education, practice reviews needed to reduce surgical intervention, Quebec report says. Rafuse J. **Can Med Assoc J** 1996 Aug 15;155(4):463–4

ADENOIDS

see related
ADENOIDECTOMY

Substance P and ciliary beat of human upper respiratory cilia in vitro. Schuil PJ, et al. **Ann Otol Rhinol Laryngol** 1995 Oct;104(10 Pt 1):798–802

ABNORMALITIES

Effects of adenotonsillar hypertrophy on snoring in children. Min YG, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Jul–Aug;57(4):214–9

CYTOLOGY

Cell suspension cultures and adenoid epithelium: an assessment of the source of material for human ciliary function experiments in vitro. Schuil PJ, et al. **Rhinology** 1995 Jun;33(2):66–9

IMMUNOLOGY

Spontaneous immunoglobulin production by adenoidal and tonsillar lymphocytes in relation to age and otitis media with effusion. Harabuchi Y, et al. **Int J Pediatr Otorhinolaryngol** 1996 Apr;35(2):117–25

METABOLISM

Concentrations of cefpodoxime in plasma, adenoid, and tonsillar tissue after repeated administrations of cefpodoxime proxetil in children. Bairamis TN, et al. **J Antimicrob Chemother** 1996 Apr;37(4):821–4

PATHOLOGY

Obstructive sleep apnea syndrome in children: an overview. Boudewyns AN, et al. **Acta Otorhinolaryngol Belg** 1995; 49(3):275–9 (15 ref.)
Lymphoid changes of the nasopharyngeal and palatine tonsils that are indicative of human immunodeficiency virus infection. A clinicopathologic study of 12 cases. Wenig BM, et al. **Am J Surg Pathol** 1996 May;20(5):572–87 (76 ref.)
Sizing up the adenoid. Gates GA. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):239–40
Adenotonsillar disease. Zalzal GH. **J Med Liban** 1994; 42(4):230–4 (18 ref.)
Processing of adenoid and tonsil specimens in children: a national survey of standard practices and a five–year review of the experience at the Children's Hospital of Pittsburgh. Dohar JE, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):94–7
Malignant transformation of nasopharyngeal lymphoid hyperplasia. Kieserman SP, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):474–6
Home testing for pediatric obstructive sleep apnea syndrome secondary to adenotonsillar hypertrophy. Jacob SV, et al. **Pediatr Pulmonol** 1995 Oct;20(4):241–52

ADENOIDS

PHYSIOLOGY

The functional role of the adenoids in speech. Finkelstein Y, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan; 34(1-2):61-74 (73 ref.)

PHYSIOPATHOLOGY

Pediatric adenotonsillectomy for obstructive sleep apnea. Ruboyianes JM, et al. **Ear Nose Throat J** 1996 Jul; 75(7):430-3

[The influence of nasopharyngeal obstruction on gasometric parameters in children] Namysłowski G, et al. **Otolaryngol Pol** 1995;49(3):220-4 (Eng. Abstr.) **(Pol)**

SURGERY

Pediatric adenotonsillectomy for obstructive sleep apnea. Ruboyianes JM, et al. **Ear Nose Throat J** 1996 Jul; 75(7):430-3

A comparison of sevoflurane with halothane in outpatient adenotomy in children with mild upper respiratory tract infections. Rieger A, et al. **J Clin Anesth** 1996 May; 8(3):188-97

[Outpatient surgery in pediatric ENT] Miró JL, et al. **Acta Otorrinolaringol Esp** 1995 Sep-Oct;46(5):345-8 (Eng. Abstr.) **(Spa)**

VIROLOGY

Growth of influenza A virus in primary, differentiated epithelial cells derived from adenoids. Endo Y, et al. **J Virol** 1996 Mar;70(3):2055-8

Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid. Frankel SS, et al. **Science** 1996 Apr 5;272(5258):115-7

ADENOLYMPHOMA

Extraparotid Warthin's tumor: clinical manifestations, challenges, and controversies. Astor FC, et al. **Otolaryngol Head Neck Surg** 1996 Jun;114(6):732-5

CLASSIFICATION

Multiple tumours of the salivary glands--terminology and nomenclature. Seifert G, et al. **Eur J Cancer B Oral Oncol** 1996 Jan;32B(1):3-7 (105 ref.)

DIAGNOSIS

Nodal inclusion cysts of the parotid gland and parapharyngeal space: a discussion of lymphoepithelial, AIDS-related parotid, and branchial cysts, cystic Warthin's tumors, and cysts in Sjögren's syndrome. Som PM, et al. **Laryngoscope** 1995 Oct;105(10):1122-8

ETIOLOGY

Cigarette smoking and Warthin's tumor. Pinkston JA, et al. **Am J Epidemiol** 1996 Jul 15;144(2):183-7

New insights into the pathogenesis of Warthin's tumour. Gallo O. **Eur J Cancer B Oral Oncol** 1995 Jul;31B(4):211-5 (54 ref.)

PATHOLOGY

Synchronous parotid myoepithelioma and Warthin's tumor. Slavin JL, et al. **Pathology** 1995 Apr;27(2):199-200

[Adenolymphoma of the salivary glands. The anatomicoclinical, epidemiological and therapeutic aspects of 76 cases] Favia G, et al. **Minerva Stomatol** 1995 Jul-Aug; 44(7-8):325-33 (Eng. Abstr.) **(Ita)**

[Bilateral Warthin tumors. Case report and review of literature] Sancipriano JA, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):157-9 (21 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Imaging quiz case 1. Warthin's tumor (papillary cystadenoma lymphomatosum). Mra Z. **Arch Otolaryngol Head Neck Surg** 1996 May;122(5):570, 572

SURGERY

[Bilateral Warthin tumors. Case report and review of literature] Sancipriano JA, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):157-9 (21 ref.) (Eng. Abstr.) **(Spa)**

ADENOMA

Bronchogenic carcinoma and coexistent bronchioloalveolar cell adenomas. Assessment of radiologic detection and follow-up in 28 patients. Logan PM, et al. **Chest** 1996 Mar; 109(3):713-7

Biochemical cure of recurrent acromegaly by resection of cervical spinal canal metastases. Dayan C, et al. **Clin Endocrinol (Oxf)** 1996 May;44(5):597-602

Pouch polyposis after ileal pouch-anal anastomosis for familial adenomatous polyposis: report of a case. Church JM, et al. **Dis Colon Rectum** 1996 May;39(5):584-6

Hypotonic lysis of red blood cell contamination from human anterior pituitary adenoma cell preparations [letter] Atkin SL, et al. **In Vitro Cell Dev Biol Anim** 1995 Oct;31(9):657-8

Tumor cells cultured in vivo in diffusion chambers induce hematological alterations. Diament M, et al. **In Vivo** 1995 May-Jun;9(3):203-6

Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Young WF Jr, et al. **Mayo Clin Proc** 1996 Jul;71(7):649-56

[Adenoma of the choledochus (letter)] Amar A, et al. **J Chir (Paris)** 1996 Jun;133(4):186-8 (Eng. Abstr.) **(Fre)**

[Carcinoma in adenoma of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):311-3 (6 ref.) **(Jpn)**

[Adenoma, cyst adenoma of the extrahepatic bile duct] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1996;(9):53-6 (21 ref.) **(Jpn)**

[Liver adenoma and hepatobiliary cystadenoma] Takahama T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):387-91 (7 ref.) **(Jpn)**

BLOOD

Another case of hypocholesterolemia associated with virilizing adrenal adenoma [letter; comment] Benvenga S. **J Clin Endocrinol Metab** 1995 Nov;80(11):3391-2. Comment on: J Clin Endocrinol Metab 1995 Jan;80(1):92-6.

Hyperprolactinemia caused by lactation and pituitary adenomas is associated with altered serum calcium, phosphate, parathyroid hormone (PTH), and PTH-related peptide levels. Kovacs CS, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3036-42

Intra-operative parathyroid hormone assay for simplified localization of parathyroid adenomas. Saharay M, et al. **J R Soc Med** 1996 May;89(5):261-4

BLOOD SUPPLY

Blood supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen-induced adenomatous hyperplasia. Jakubowski J. **Br J Neurosurg** 1995;9(3):331-46 (103 ref.)

Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Bossi P, et al. **Cancer Res** 1995 Nov 1; 55(21):5049-53

Blood vessel morphometry in human colorectal lesions. Tipoe GL, et al. **Histol Histopathol** 1995 Jul;10(3):589-96

CHEMICALLY INDUCED

Induction of benign and malignant pulmonary tumours in mice with benzo(a)pyrene. Kim SH, et al. **Anticancer Res** 1996 Jan-Feb;16(1):465-70

Synthesis of tobacco-specific N-nitrosamines and their metabolites and results of related bioassays. Amin S, et al. **Crit Rev Toxicol** 1996;26(2):139-47 (32 ref.)

Chronic nephropathy and renal carcinogenicity of o-benzyl-p-chlorophenol in F344/N rats and B6C3F1 mice. Marsman DS, et al. **Fundam Appl Toxicol** 1995 Sep; 27(2):252-62

Sequential appearance and ultrastructure of amphophilic cell foci, adenomas, and carcinomas in the liver of male and female rats treated with dehydroepiandrosterone. Metzger C, et al. **Toxicol Pathol** 1995 Sep-Oct;23(5):591-605

CHEMISTRY

Immunohistochemical demonstration of tenascin in human pituitary glands and adenomas. Ikeda H, et al. **Acta Histochem** 1995 Jul;97(3):273-80

Application of catalyzed signal amplification in immunodetection of gonadotropin subunits in clinically nonfunctioning pituitary adenomas. Sanno N, et al. **Am J Clin Pathol** 1996 Jul;106(1):16-21

K-ras mutations and HLA-DR expression in large bowel adenomas. Norheim Andersen S, et al. **Br J Cancer** 1996 Jul;74(1):99-108

Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Watson AJ, et al. **Br J Cancer** 1996 Apr;73(8):889-95

Peptide-containing nerve fibres in normal human parathyroid glands and in human parathyroid adenomas. Luts L, et al. **Eur J Endocrinol** 1995 Nov;133(5):543-51

Flow cytometric analysis of the DNA content in colorectal adenomas with focal cancers. Suzuki S, et al. **Gastroenterology** 1995 Oct;109(4):1098-104

Changes of the mucosal n3 and n6 fatty acid status occur early in the colorectal adenoma-carcinoma sequence. Fernández-Bañares F, et al. **Gut** 1996 Feb;38(2):254-9

Adenomatous transformation of the human anterior pituitary is associated with alterations in integrin expression. Farnoud MR, et al. **Int J Cancer** 1996 Jul 3;67(1):45-53

Expression of the steroidogenic acute regulatory protein mRNA in adrenal tumors and cultured adrenal cells. Liu J, et al. **J Endocrinol** 1996 Jul;150(1):43-50

An immunohistochemical study of the expression of p53 protein in colon cancer. Kim YW, et al. **J Korean Med Sci** 1995 Jun;10(3):176-82

Neural cell adhesion molecule expression in human pituitary adenomas. Kleinschmidt-DeMasters BK, et al. **J Neurooncol** 1995;25(3):205-13

Conserved expression of intestinal trefoil factor in the human colonic adenoma-carcinoma sequence. Taupin D, et al. **Lab Invest** 1996 Jul;75(1):25-32

Differential p53 protein expression in stomach adenomas of gastric and intestinal phenotypes: possible sequences of p53 alteration in stomach carcinogenesis. Kushima R, et al. **Virchows Arch** 1996 Jul;428(4-5):223-7

[The results of p53 immunostaining in colorectal adenomas, early cancers, advanced cancers and their hepatic metastasis] Saigusa N, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:159-63 (Eng. Abstr.) **(Jpn)**

[Analysis of duodenal bile acids in patients with colorectal tumors and control subjects] Taguchi F. **Nippon Ika Daigaku Zasshi** 1995 Dec;62(6):588-95 (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Classification of colorectal adenomas with quantitative pathology. Evaluation of morphometry, stereology, mitotic counts and syntactic structure analysis. Meijer GA, et al. **Anal Cell Pathol** 1995 Dec;9(4):311-23

Morphological classification of renal cancer. Störkel S, et al. **World J Urol** 1995;13(3):153-8

[Gallbladder adenoma (pyloric gland type, intestinal type, proper epithelial type, papillary type, mucinous cystic type) Ono T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):308-10 (16 ref.) **(Jpn)**

COMPLICATIONS

Visual disturbances in patients with pituitary adenoma. Ikeda H, et al. **Acta Neurol Scand** 1995 Aug;92(2):157-60

High cervical intravagal hypercellular parathyroid gland as the etiology of severe persistent primary hyperparathyroidism. Buell JF, et al. **Am Surg** 1995 Nov; 61(11):943-6

Patterns of visual loss associated with pituitary macroadenomas. Poon A, et al. **Aust N Z J Ophthalmol** 1995 May;23(2):107-15

Hypertension secondary to adrenal tumors ten years experience. Vázquez Quintana E, et al. **Bol Asoc Med P R** 1995 Jul-Sep;87(7-9):124-5

Pituitary microadenoma in Turner's syndrome. Pejaver RK, et al. **Br J Clin Pract** 1995 Jul-Aug;49(4):223-4

Muir-Torré syndrome in a patient with acquired immunodeficiency syndrome [letter] Graells J, et al. **Br J Dermatol** 1996 Jul;135(1):159-61

Hyperprolactinaemia in patients with pituitary adenomas. The pituitary stalk compression syndrome. Kruse A, et al. **Br J Neurosurg** 1995;9(4):453-7

Cushing's disease due to female gonadotroph adenoma of the pituitary. Ikeda H, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):383-6

Autonomous nodular hyperplasia of the adrenal cortex: tertiary hypercortisolism? Sturrock ND, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):753-8

Incarcerated bile duct adenoma as a rare cause of acute cholestatic pancreatitis. Körner T, et al. **Endoscopy** 1995 Oct;27(8):628

Fraternal sisters with adult polycystic kidney disease and adenoma of the ampulla of Vater. Norton ID, et al. **Gastroenterology** 1995 Dec;109(6):2007-10

Ischaemic stroke leading to left hemiparesis and autohypophysectomy in a case of pituitary macroadenoma. Mukherjee S, et al. **J Assoc Physicians India** 1995 Nov; 43(11):801-2

Another case of hypocholesterolemia associated with virilizing adrenal adenoma [letter; comment] Benvenga S. **J Clin Endocrinol Metab** 1995 Nov;80(11):3391-2. Comment on: J Clin Endocrinol Metab 1995 Jan;80(1):92-6.

Congenital adrenal hyperplasia presenting as massive adrenal incidentalomas in the sixth decade of life: report of two patients with 21-hydroxylase deficiency. Ravichandran R, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1776-9

Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. Takeda R, et al. **J Endocrinol Invest** 1995 May;18(5):370-3

Pituitary macroadenoma in Addison's disease. Akçay G, et al. **J Int Med Res** 1996 Mar-Apr;24(2):221-7

Pituitary tumor and low gonadotropins in a patient with Turner's syndrome. Mermilliod JA, et al. **J La State Med Soc** 1995 Dec;147(12):540-3

Severe acute pancreatitis as a first symptom of primary hyperparathyroid adenoma: a case report. Shimizu H, et al. **J Laryngol Otol** 1996 Jun;110(6):602-3

Thyrotropin secreting pituitary adenoma associated with hypopituitarism and diabetes insipidus in an adolescent boy. Phillip M, et al. **J Pediatr Endocrinol Metab** 1995 Jan-Mar; 8(1):47-50

Conn syndrome in a child, caused by adrenal adenoma. Abasiyanik A, et al. **J Pediatr Surg** 1996 Mar;31(3):430-2 (15 ref.)

Aldosteronoma in childhood [letter; comment] Etker S. **J Pediatr Surg** 1995 Jul;30(7):1113 (15 ref.). Comment on: J Pediatr Surg 1994 Oct;29(10):1388-91.

Primary hyperparathyroidism: an unusual cause of pancreatitis in adolescence [see comments] Nieves-Rivera F, et al. **P R Health Sci J** 1995 Sep;14(3):233-6. Comment in: P R Health Sci J 1995 Sep;14(3):191-3.

Unusual cases of hyperparathyroidism [see comments] Vázquez-Quintana E, et al. **P R Health Sci J** 1995 Sep; 14(3):227-32 (8 ref.). Comment in: P R Health Sci J 1995 Sep;14(3):191-3.

Increased prolactin level and pituitary adenoma as a cause of headache in two patients with sickle cell disease. Sabbagh R, et al. **Pediatr Hematol Oncol** 1996 Jan-Feb;

13(1):101–5

Persistent or recurrent hyperparathyroidism in patients with double adenomas. Tezelman S, et al. **Surgery** 1995 Dec; 118(6):1115–22; discussion 1122–4

Spontaneous hemorrhage of an adrenal cortical adenoma causing Cushing's syndrome. Saito T, et al. **Urol Int** 1996; 56(2):105–6

[Apropos of a case of nephrogenic adenoma in a urethral diverticulum in a woman] Materne R, et al. **Acta Urol Belg** 1995 Dec;63(4):13–8 (59 ref.) (Eng. Abstr.) **(Fre)**

[Bone pain revealing parathyroid adenoma (letter; comment)] Beauvais P. **Arch Pediatr** 1995 Oct;2(10):1022. Comment on: Arch Pediatr 1995 Jan;2(1):89. **(Fre)**

[Adenoma of Brunner's gland: a rare cause of duodenal obstruction] Rey P, et al. **J Chir (Paris)** 1996 Jun; 133(4):162–6 (41 ref.) (Eng. Abstr.) **(Fre)**

[State of shock and bilateral paralysis of the III cranial nerve revealing necrotic pituitary macroadenoma (letter; comment)] Dupont C, et al. **Presse Med** 1995 Oct 21; 24(31):1447. Comment on: Presse Med 1995 Mar 11;24(10):501–3. **(Fre)**

[Primary hyperparathyroidism. Relationships of symptoms to age, sex, calcemia, anatomical lesions and weight of the glands] Mellière D, et al. **Presse Med** 1995 Dec 16–23; 24(39):1889–93 (Eng. Abstr.) **(Fre)**

[The effect of neoplastic hyperprolactinemia on bone density] Baldelli R, et al. **Minerva Endocrinol** 1996 Mar;21(1):7–11 (Eng. Abstr.) **(Ita)**

[A case of oligozoospermia with marginal hyperprolactinemia due to pituitary microadenoma] Kawano M, et al. **Hinyokika Kiyo** 1996 Apr;42(4):319–21 (Eng. Abstr.) **(Jpn)**

[A case of pituitary adenoma progressing to pituitary apoplexy on the occasion of cerebral angiography] Suga T, et al. **No Shinkei Geka** 1996 May;24(5):475–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Penile erectile dysfunction secondary to hypophyseal adenoma] Franco Miranda E, et al. **Actas Urol Esp** 1995 Nov–Dec;19(10):805–7 (Eng. Abstr.) **(Spa)**

[Thymus carcinoid associated with type 1 multiple endocrine neoplasm syndrome] Martínez Cerezo FJ, et al. **Med Clin (Barc)** 1996 Jan 13;106(1):21–3 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Two cases of early colorectal cancer associated with gastric adenoma detected by serum pepsinogen screening method. Shimizu Y, et al. **Adv Exp Med Biol** 1995;362:149–54

Plain radiographic and MR imaging appearances of familial dermal cylindroma. Serra AD, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):615–6

Basal cell (monomorphic) and minimally pleomorphic adenomas of the salivary glands. Distinction from the solid (anaplastic) type of adenoid cystic carcinoma in fine-needle aspiration. Stanley MW, et al. **Am J Clin Pathol** 1996 Jul; 106(1):35–41 (35 ref.)

Depression and hypercalcemia [clinical conference] **Am J Med** 1996 Jul;101(1):111–7

A pigmented adenoma of the ciliary epithelium examined by magnetic resonance imaging. Greenberg PB, et al. **Am J Ophthalmol** 1995 Nov;120(5):679–81

Are papillary adenomas endolymphatic sac tumors? [letter; comment] Heffner DK. **Ann Otol Rhinol Laryngol** 1996 Mar;105(3):251–2. Comment on: Ann Otol Rhinol Laryngol 1995 Aug;104(8):613–9.

Are papillary adenomas endolymphatic sac tumors? [letter; comment] Megerian CA. **Ann Otol Rhinol Laryngol** 1996 Jan;105(1):83–4. Comment on: Ann Otol Rhinol Laryngol 1995 Aug;104(8):613–9.

Diagnosis and management of nonfunctioning pituitary tumors. Greenman Y, et al. **Annu Rev Med** 1996;47:95–106 (51 ref.)

Water-clear cell 'adenoma'. A new entity in the pathology of primary hyperparathyroidism [editorial; comment] Roth SI. **Arch Pathol Lab Med** 1995 Nov;119(11):996–7. Comment on: Arch Pathol Lab Med 1995 Nov;119(11):1072–4.

An 81-year-old woman with a cystic pancreatic mass. Katz DS, et al. **Clin Imaging** 1995 Oct–Dec;19(4):283–8

Ectopic parathyroid adenomas: multi-imaging modalities and its management. Moinuddin M, et al. **Clin Nucl Med** 1996 Jan;21(1):27–32

Preoperative endocrine tumor localization utilizing a cost-effective approach. Leight GS Jr, et al. **Curr Opin Gen Surg** 1993;:108–14 (19 ref.)

The characteristics of nine patients with adrenal incidentalomas. Kamel N, et al. **Endocr J** 1995 Aug; 42(4):497–503 (21 ref.)

Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Vasen HF, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1145–8

Follicular adenoma of the thyroid gland in children. Festen C, et al. **Eur J Pediatr Surg** 1995 Oct;5(5):262–4

Flexible sigmoidoscopy plus air-contrast barium enema versus colonoscopy for evaluation of symptomatic patients without evidence of bleeding. Rex DK, et al. **Gastrointest Endosc** 1995 Aug;42(2):132–8

Differential diagnosis and treatment of steroid-induced affective syndromes. Pies R. **Gen Hosp Psychiatry** 1995 Sep;17(5):353–61 (27 ref.)

A patient with a progesterone-producing adrenal adenoma who presented with primary amenorrhea. van Zonneveld P, et al. **Gynecol Endocrinol** 1995 Sep;9(3):189–94

Hepatic adenoma: an observation from asymptomatic stage to rupture. Cheng PN, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):245–8

Vesical clear cell adenocarcinoma. V. Nephrogenic adenoma: a diagnostic problem. Alsanjari N, et al. **Histopathology** 1995 Jul;27(1):43–9

Pituitary adenoma presenting as sinonasal tumor: pitfalls in diagnosis. Luk IS, et al. **Hum Pathol** 1996 Jun;27(6):605–9

Differentiation of spontaneous canine breast tumors using dynamic magnetic resonance imaging with 24-Gadolinium-DTPA-cascade-polymer, a new blood-pool agent. Preliminary experience. Adam G, et al. **Invest Radiol** 1996 May;31(5):267–74

CT of adenomas of the middle ear and mastoid cavity. Ho VT, et al. **J Comput Assist Tomogr** 1996 Mar–Apr; 20(2):219–20

MRI of mediastinal parathyroid cystic adenoma causing hyperparathyroidism. Soler R, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):166–8

Persistent/recurrent hyperparathyroidism: a comparison of sestamibi scintigraphy, MRI, and ultrasonography. Numerow LM, et al. **J Magn Reson Imaging** 1995 Nov–Dec;5(6):702–8

Intrasellar meningiomas. Wang CJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Aug; 12(8):486–90

A woman with bone pain, fractures, and malabsorption [see comments] Bertoli A, et al. **Lancet** 1996 Feb 3; 347(8997):300. Comment in: Lancet 1996 Mar 23;347(9004):829. Comment in: Lancet 1996 Mar 23;347(9004):829–30. Comment in: Lancet 1996 Apr 13;347(9007):1050.

The diagnosis I longed to make [letter] Churcher A. **Lancet** 1995 Sep 30;346(8979):915–6

The importance of monitoring colorectal adenomas by tumor markers (ROC analysis). Stajic S, et al. **Med Pregl** 1993; 46 Suppl 1:69–71

MRI of a pituitary cryptococcoma simulating an adenoma. Yu YQ, et al. **Neuroradiology** 1995 Aug;37(6):449–50

Cushing's disease due to a giant pituitary adenoma in early infancy: CT and MRI features. Maeder P, et al. **Pediatr Radiol** 1996;26(1):48–50

Colorectal neoplasms. Screening can save lives. Truszkowski JA, et al. **Postgrad Med** 1995 Nov;98(5):97–9, 103–6, 109–12 (20 ref.)

Dynamic MRI with slow injection of contrast material for the diagnosis of pituitary adenoma. Hayashi S, et al. **Radiat Med** 1995 Jul–Aug;13(4):167–70

MR imaging of macroadenomas. Mohammad-Zadeh L. **Radiol Technol** 1995 Sep–Oct;67(1):29–36; quiz 37–8

Benign adenomatous kidney neoplasms in children with polycythemia: imaging findings. Comerci SC, et al. **Radiology** 1996 Jan;198(1):265–8

Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Korobkin M, et al. **Radiology** 1995 Nov;197(2):411–8

Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Korobkin M, et al. **Radiology** 1996 Sep;200(3):743–7

Adrenal masses in patients with malignancy: prospective comparison of echo-planar, fast spin-echo, and chemical shift MR imaging. Schwartz LH, et al. **Radiology** 1995 Nov; 197(2):421–5

Renal adenoma and oncocytoma. Licht MR. **Semin Urol Oncol** 1995 Nov;13(4):262–6 (60 ref.)

Asymptomatic large pituitary adenomas discovered at autopsy. Auer RN, et al. **Surg Neurol** 1996 Jul;46(1):28–31

DNA index and ploidy distinguish normal human parathyroids from parathyroid adenomas and primary hyperplastic parathyroids. Chryssochoos JT, et al. **Surgery** 1995 Dec;118(6):1041–9; discussion 1049–50

[Comparitive study of three images examination in preoperative localization of parathyroid adenoma] Cai W. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):307–9 (Eng. Abstr.) **(Chi)**

[Favorable results of minimally invasive surgery in the treatment of primary hyperparathyroidism] van Vroonhoven TJ, et al. **Ned Tijdschr Geneeskd** 1996 Feb 10;140(6):304–8 (Eng. Abstr.) **(Dut)**

[Clinical imaging in psychiatry] Jabourian AP, et al. **Ann Med Psychol (Paris)** 1996 Jan;154(1):74–7 (Eng. Abstr.) **(Fre)**

[Parathyroid adenoma as an ectopic carotid mass. Apropos of a case] Suc B, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(4):190–3 (Eng. Abstr.) **(Fre)**

[Endoscopic diagnosis and treatment of flat colorectal neoplastic lesions] Saurin JC. **Gastroenterol Clin Biol** 1996; 20(5 Pt 2):B152–8 (44 ref.) **(Fre)**

[High-resolution magnetic resonance tomography by means of an endorectal coil--the results in rectal tumors] Pegios W, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):132–40 (Eng. Abstr.) **(Ger)**

[Nephrogenic adenoma after kidney transplantation] Colombo T, et al. **Urologe A** 1995 Nov;34(6):489–93 (Eng. Abstr.) **(Ger)**

[Incidental discovery of adrenal neoplasms: our experience] Bellantone R, et al. **Ann Ital Chir** 1995 Jul–Aug; 66(4):439–48 (Eng. Abstr.) **(Ita)**

[Adrenal adenoma or hyperplasia? Problems of differential diagnosis in an unusual case of primary hyperaldosteronism] Sanna AL, et al. **Minerva Med** 1996 Mar;87(3):93–7 (Eng. Abstr.) **(Ita)**

[MRI of the pituitary adenomas with reference to the hormonal activity] Masunaga S, et al. **No To Shinkei** 1995 Dec;47(12):1165–9 (Eng. Abstr.) **(Jpn)**

[An isolated parathyroid adenoma] Garlicka A, et al. **Pediatr Pol** 1995 Nov;70(11):965–71 (Eng. Abstr.) **(Pol)**

[Preoperative diagnosis of thyroid cancer by karyometry of thyrocytes] Kirillov VA, et al. **Klin Lab Diagn** 1996 Mar–Apr;(2):14–6 (Eng. Abstr.) **(Rus)**

[Adenomas and adenomyomatosis of the gallbladder] Sedov VM, et al. **Klin Med (Mosk)** 1996;74(1):21–2 **(Rus)**

["Nephrogenic adenoma" of the bladder] Pugachev AG, et al. **Urol Nefrol (Mosk)** 1995 Jul–Aug;(4):43–5 (Eng. Abstr.) **(Rus)**

[Early detection of adenomas in asymptomatic subjects: flexible sigmoidoscopy or colonoscopy] Farca Belsaguy A, et al. **Rev Gastroenterol Mex** 1996 Jan–Mar;61(1):27–30 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Adjuvant therapy for pituitary adenomas: the possible role of photodynamic therapy. Marks PV. **Ann R Coll Surg Engl** 1995 Jul;77(4):308–12 (25 ref.)

In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide [see comments] Ezzat S, et al. **Eur J Endocrinol** 1995 Dec; 133(6):686–90. Comment in: Eur J Endocrinol 1995 Dec;133(6):675–7.

NSAID trials, sporadic adenomas, and conservative inferences [letter; comment] Hawk E, et al. **Gastroenterology** 1996 Feb;110(2):654–5. Comment on: Gastroenterology 1995 Apr;108(4):1083–7.

Hyperglycemia secondary to megestrol acetate for endometrial neoplasia. Rose PG. **Gynecol Oncol** 1996 Apr; 61(1):139–41

ECONOMICS

Cost analysis of intermediate care versus intensive care for the neurosurgery patient. Cohen L, et al. **J Nurs Adm** 1996 Jul–Aug;26(7–8):3, 18

ENZYMOLOGY

Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Yabuki N, et al. **Am J Pathol** 1996 Sep;149(3):997–1007

Glyoxalase activities in tumor and non-tumor human urogenital tissues. Di Ilio C, et al. **Cancer Lett** 1995 Sep 25;96(2):189–93

Plasmin-catalyzed proteolysis in colorectal neoplasia. Delbaldo C, et al. **Cancer Res** 1995 Oct 15;55(20):4688–95

Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Liabakk NB, et al. **Cancer Res** 1996 Jan 1;56(1):190–6

Human adrenal CYP11B1: localization by in situ-hybridization and functional expression in cell cultures. Erdmann B, et al. **Endocr Res** 1995 Feb–May; 21(1–2):425–35

Zone-specific localization of cytochrome P45011B1 in human adrenal tissue by PCR-derived riboprobes. Erdmann B, et al. **Histochem Cell Biol** 1995 Oct; 104(4):301–7

Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. Derwahl M, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1898–904

Increased antioxidant enzyme activities in the colorectal adenoma and carcinoma. Beño I, et al. **Neoplasma** 1995; 42(5):265–9

Increased plasminogen activator and type IV collagenase activity in invasive follicular thyroid carcinoma cells. Packman KS, et al. **Surgery** 1995 Dec;118(6):1011–6; discussion 1016–7

EPIDEMIOLOGY

Characteristics of rectosigmoid adenomas as predictors of synchronous advanced proximal colon neoplasms. Papatheodoridis GV, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1809–13

Physical activity, obesity, and risk of colorectal adenoma in women (United States). Giovannucci E, et al. **Cancer Causes Control** 1996 Mar;7(2):253–63

Physical activity and the risk of colorectal adenomas. Sandler RS, et al. **Epidemiology** 1995 Nov;6(6):602–6

The measurement of adenoma occurrence. Aickin M, et al. **Eur J Cancer Prev** 1996 Feb;5(1):43–8

Pituitary adenomas in childhood and adolescence. Mindermann T, et al. **J Pediatr Endocrinol Metab** 1995 Apr–Jun;8(2):79–83 (39 ref.)

The relation of smoking, alcohol use and obesity to risk of sigmoid colon and rectal adenomas. Honjo S, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1019–26

A randomized surveillance study of patients with pedunculated and small sessile tubular and tubulovillous adenomas. The Funen Adenoma Follow-up Study. Jørgensen OD, et al. **Scand J Gastroenterol** 1995 Jul; 30(7):686–92

ADENOMA

ETHNOLOGY

Flat adenomas and flat adenocarcinomas of the colorectal mucosa in Japanese and Swedish patients. Comparative histologic study. Rubio CA, et al. **Dis Colon Rectum** 1995 Oct;38(10):1075–9

ETIOLOGY

Re: "Tobacco, alcohol, and colorectal tumors: a multistep process" [letter; comment] Neugut AI. **Am J Epidemiol** 1995 Dec 15;142(12):1346–7. Comment on: Am J Epidemiol 1995 Jun 1;141(11):1038–46.

Relationship of cigarette smoking, alcohol use, and dietary habits with sigmoid colon adenomas. Todoroki I, et al. **Ann Epidemiol** 1995 Nov;5(6):478–83

Differing proliferative responses in proximal and distal colons of growing rats fed food eaten by adenoma patients. Liberman V, et al. **Dig Dis Sci** 1996 Jun;41(6):1057–64

Adrenocortical nodules in post–mortem series. Development, functional significance, and differentiation from adenomas. Reinhard C, et al. **Gen Diagn Pathol** 1996 Mar; 141(3–4):203–8

Ileostomy polyps, adenomas, and adenocarcinomas. Attanoos R, et al. **Gut** 1995 Dec;37(6):840–4

The causes of ordinary colorectal adenomas: the key to the control of colorectal cancer? [see comments] Kune GA, et al. **J R Soc Med** 1995 Nov;88(11):625–8 (32 ref.). Comment in: J R Soc Med 1996 Apr;89(4):237.

Multicentre prospective controlled study of Barrett's oesophagus and colorectal adenomas. Groupe d'Etude de l'Oesophage de Barrett [see comments] Cauvin JM, et al. **Lancet** 1995 Nov 25;346(8987):1391–4. Comment in: Lancet 1996 Jan 6;347(8993):66–7.

Inflammatory bowel disease and adenomas in mice expressing a dominant negative N–cadherin. Hermiston ML, et al. **Science** 1995 Nov 17;270(5239):1203–7

[The effect of dosage strength on the induction of chromosome aberrations and lung tumors in mice under the combined action of ionizing radiation and chemical substances] Malenchenko AF, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):777–85 (Eng. Abstr.) **(Rus)**

GENETICS

The classification and molecular biology of pituitary adenomas. Thapar K, et al. **Adv Tech Stand Neurosurg** 1995; 22:3–53 (130 ref.)

The pathogenesis of familial multiple cylindromas, trichoepitheliomas, milia, and spiradenomas. van der Putte SC. **Am J Dermatopathol** 1995 Jun;17(3):271–80

K–ras mutation in a tubular adenoma originating at an ileostomy in a familial adenomatous polyposis patient. Herring JA, et al. **Am J Gastroenterol** 1996 Mar; 91(3):587–91 (38 ref.)

p53 Protein overexpression in colorectal tumors from patients with familial adenomatous polyposis: is it an early or late event? [see comments] Levi E, et al. **Am J Gastroenterol** 1996 Jan;91(1):11–4. Comment in: Am J Gastroenterol 1996 Jan;91(1):3–6.

Somatotrophinomas in multiple endocrine neoplasia type 1: a review of clinical phenotype and insulin–like growth factor–1 levels in a large multiple endocrine neoplasia type 1 kindred. Burgess JR, et al. **Am J Med** 1996 May; 100(5):544–7

DNA measurement in pituitary adenomas assessed on imprints by image analysis. Kontogeorgos G, et al. **Anal Quant Cytol Histol** 1996 Apr;18(2):144–50

Ha–ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors. Bouras M, et al. **Ann Biol Clin (Paris)** 1995; 53(10–11):549–55

K–ras2 mutation spectrum, DNA aneuploidy, and epithelial cell proliferation in colorectal adenomas. Giaretti W, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:261–3

K–ras gene mutation related to histological atypias in human colorectal adenomas. Ajiki T, et al. **Biotech Histochem** 1995 Mar;70(2):90–4

K–ras mutations and HLA–DR expression in large bowel adenomas. Norheim Andersen S, et al. **Br J Cancer** 1996 Jul;74(1):99–108

Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme–linked immunosorbent assay. Schroy PC 3rd, et al. **Cancer** 1995 Jul 15;76(2):201–9

Chromosomal abnormalities in tumor and lymphocyte cultures from patients with pituitary adenomas [letter] Capra E, et al. **Cancer Genet Cytogenet** 1995 Oct 1;84(1):89

A nonbalanced translocation (10;16) demonstrated by FISH analysis in a case of alveolar adenoma of the lung. Roque L, et al. **Cancer Genet Cytogenet** 1996 Jul 1;89(1):34–7

Deregulated alternative splicing of CD44 messenger RNA transcripts in neoplastic and nonneoplastic lesions of the human thyroid. Ermak G, et al. **Cancer Res** 1995 Oct 15; 55(20):4594–8

Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Kjellman M, et al. **Cancer Res** 1996 Sep 15;56(18):4219–23

Different genetic susceptibility to aberrant crypts and colon adenomas in mice. Moen CJ, et al. **Cancer Res** 1996 May 15;56(10):2382–6

Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Tahara H, et al. **Cancer Res** 1996 Feb 1;56(3):599–605

PCR–SSCP analysis of the angiotensin II type 1 receptor gene in patients with aldosterone–producing adenomas. Klemm SA, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul; 22(6–7):457–9

Adenoma–carcinoma sequence of colorectum. Prevalence of K–ras gene mutation in adenomas with increasing degree of dysplasia and aneuploidy. Ranaldi R, et al. **Diagn Mol Pathol** 1995 Sep;4(3):198–202

Mutation of p53 tumor suppressor gene in flat neoplastic lesions of the colorectal mucosa. Rubio CA, et al. **Dis Colon Rectum** 1996 Feb;39(2):143–7

Aneuploidy in salivary gland adenomas. Atula T, et al. **Eur Arch Otorhinolaryngol** 1995;252(7):395–400

Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas: new mutants, new second messenger and new frequency. Bertherat J. **Eur J Endocrinol** 1996 Jan; 134(1):114

Deletion of 1p loci and microsatellite instability in colorectal polyps. Lothe RA, et al. **Genes Chromosomes Cancer** 1995 Nov;14(3):182–8

Family history of colorectal tumours and implications for the adenoma–carcinoma sequence: a case control study. Boutron MC, et al. **Gut** 1995 Dec;37(6):830–4

Adenomas and a family history of colorectal cancer [letter; comment] Jass JR. **Gut** 1995 Aug;37(2):297–8. Comment on: Gut 1995 Mar;36(3):385–90.

Cytogenetical observations in a canalicular adenoma of the minor salivary glands. Havel G, et al. **Hereditas** 1996; 124(1):105–6

von Hippel–Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. Zhuang Z, et al. **Hum Pathol** 1996 Feb; 27(2):152–6

Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Higashikawa K, et al. **Int J Cancer** 1996 Mar 28;66(1):11–7

A detailed analysis of K–ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Span M, et al. **Int J Cancer** 1996 Jun 21;69(3):241–5

p53 overexpression in flat serrated adenomas and flat tubular adenomas of the colorectal mucosa. Rubio CA, et al. **J Cancer Res Clin Oncol** 1995;121(9–10):571–6

Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? Dotzenrath C, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3194–6

Mutational analysis of the extracellular Ca(2+)–sensing receptor gene in human parathyroid tumors. Hosokawa Y, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3107–10

Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. Hsi ED, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1736–9

Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. Russo D, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1548–51

Genetic abnormalities in sporadic parathyroid adenomas: loss of heterozygosity for chromosome 3q markers flanking the calcium receptor locus [see comments] Thompson DB, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3377–80. Comment in: J Clin Endocrinol Metab 1995 Nov;80(11):3105–6.

The cyclin D1/PRAD1 oncogene in human neoplasia. Arnold A. **J Investig Med** 1995 Dec;43(6):543–9 (44 ref.)

The sequential accumulation of genetic alterations characteristic of the colorectal adenoma–carcinoma sequence does not occur between gastric adenoma and adenocarcinoma [letter; comment] Tahara E, et al. **J Pathol** 1996 Apr;178(4):475–6. Comment on: J Pathol 1995 Jul;176(3):249–58.

Nephrogenic adenoma of the bladder in renal transplant recipients: a report of 9 cases with assessment of deoxyribonucleic acid ploidy and long–term followup. Fournier G, et al. **J Urol** 1996 Jul;156(1):41–4 (21 ref.)

Role of point mutation of the K–ras gene in tumorigenesis of B6C3F1 mouse lung lesions induced by urethane. Kawano R, et al. **Jpn J Cancer Res** 1995 Sep;86(9):802–10

Allelic loss at the tuberous sclerosis (Tsc2) gene locus in spontaneous uterine leiomyosarcomas and pituitary adenomas in the Eker rat model. Kubo Y, et al. **Jpn J Cancer Res** 1995 Sep;86(9):828–32

Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'–monophosphate and inositol phosphate–Ca2+ cascades. Parma J, et al. **Mol Endocrinol** 1995 Jun; 9(6):725–33

Genetic mapping of a pulmonary adenoma resistance (Par1) in mouse. Manenti G, et al. **Nat Genet** 1996 Apr;12(4):455–7

Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas. Porcellini A, et al. **Oncogene** 1995 Sep 21;11(6):1089–93

K–ras mutation and p53 protein accumulation in intraductal mucin–hypersecreting neoplasms of the pancreas. Satoh K, et al. **Pancreas** 1996 May;12(4):362–8

Metaphase analysis of metanephric adenoma reveals chromosome Y loss with chromosome 7 and 17 gain. Brown JA, et al. **Urology** 1996 Sep;48(3):473–5

Gastric adenoma–carcinoma sequence with special reference to p53 and Ki–ras gene alterations. Sakurai S, et al. **Virchows Arch** 1995;427(2):119–24

[K–ras gene mutations in adenomas from familial adenomatous polyposis] Ohki S, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:154–8 (Eng. Abstr.) **(Jpn)**

[Familial pituitary tumors] Yoshimoto K, et al. **Nippon Rinsho** 1995 Nov;53(11):2691–6 (21 ref.) (Eng. Abstr.) **(Jpn)**

[A case of intraductal papillary adenocarcinoma in adenoma of the pancreas presenting a mutation of Ki–ras codon 12 in the duodenal juice collected during a secretin test] Arao S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1327–30 **(Jpn)**

IMMUNOLOGY

Expression of alpha–3/4–monofucosylated polylactosaminoglycan epitope, as defined by monoclonal antibody FW6, is a marker of the colorectal adenoma–carcinoma sequence. Baldus SE, et al. **Cancer** 1995 Sep 15;76(6):954–60

Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas. Jackson PA, et al. **Gut** 1996 Jan;38(1):85–9

Characteristics of MHC antigen expression and tumor–infiltrating mononuclear cells in renal cell adenomas and carcinomas. Ohmori T, et al. **Histol Histopathol** 1995 Oct;10(4):789–94

Abnormal expression of the human CD44 gene in early colorectal malignancy with special reference to variant exon 9 (9v). Kawahara K, et al. **J Clin Pathol** 1996 Jun; 49(6):478–81

METABOLISM

Immunohistochemical demonstration of TGF–beta–receptor type II in human pituitary adenomas. Fujiwara K, et al. **Acta Histochem** 1995 Oct;97(4):445–54

Transforming growth factor–alpha promotes mammary tumorigenesis through selective survival and growth of secretory epithelial cells. Smith GH, et al. **Am J Pathol** 1995 Oct;147(4):1081–96

Tumor–related selection of calcium signals in vasopressin–stimulated human adenomatous corticotrophs. Corcuff JB, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E451–7

Immunohistochemical expression of insulin–like growth factor 1 and its receptor in normal and neoplastic human adrenal cortex. Backlin C, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2453–9

Expression of human Pit–1 product in the human pituitary and pituitary adenomas. Immunohistochemical studies using an antibody against synthetic human Pit–1 product. Sanno N, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):73–7

Long–PCR of the ANP gene and PCR–SSCP analysis of the proximal promoter region of the ANP gene in patients with aldosterone producing adenoma. Tunny TJ, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):172–8

Secretory component mRNA and protein expression in colorectal adenomas and carcinomas. Krajči P, et al. **Br J Cancer** 1996 Jun;73(12):1503–10

The prognostic importance of fibronectin and sialic acid levels in human pituitary adenomas. Ozyurt E, et al. **Cancer Lett** 1996 Feb 27;100(1–2):151–4

Expression of the transferrin receptor in human anterior pituitary adenomas is confined to gonadotrophinomas. Atkin SL, et al. **Clin Endocrinol (Oxf)** 1996 Apr; 44(4):467–71

Primary hyperparathyroidism masked by antituberculous therapy–induced vitamin D deficiency [letter; comment] Hutchesson AJ. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):511–3 . Comment on: Clin Endocrinol (Oxf) 1994 Dec;41(6):831–6; discussion 837–8.

Analysis of the renin gene in patients with aldosterone–producing adenomas by polymerase chain reaction–single stranded conformational polymorphisms and long polymerase chain reaction. Ballantine DM, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):484–6

Overexpression of p53 protein and histologic grades of dysplasia in colorectal adenomas. Sameshima S, et al. **Dis Colon Rectum** 1996 May;39(5):562–7

Cadherins, inflammatory bowel disease, and neoplasia. Shanahan F. **Gastroenterology** 1996 Jul;111(1):261–2

Faecal phytic acid and its relation to other putative markers of risk for colorectal cancer. Owen RW, et al. **Gut** 1996 Apr;38(4):591–7

Quantification of immunohistochemistry using an image analyser: correlation with hormone concentrations in pituitary adenomas. Matsuo T, et al. **Histochem J** 1995 Dec; 27(12):989–96

Tumor–specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor–beta receptors in human pituitary adenomas. Alexander JM, et al. **J Clin Endocrinol Metab** 1996 Feb; 81(2):783–90

Food–dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. de Herder WW, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3168–72

Impaired processing of proopiomelanocortin in corticotroph macroadenomas. Gibson S, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):497–502

Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone–releasing

hormone receptor in human pituitary adenomas. Hashimoto K, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2933–9

Epidermal growth factor and its receptor (EGF–R) in human pituitary adenomas: EGF–R correlates with tumor aggressiveness. LeRiche VK, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):656–62

Gonadotropin–releasing hormone messenger RNA expression in gonadotroph tumors and normal human pituitary. Miller GM, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):80–3

Pit–1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression. Pellegrini–Bouiller I, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3390–6

Decreased follistatin gene expression in gonadotroph adenomas. Penabad JL, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3397–403

Cell–specific expression of estrogen receptor in the human pituitary and its adenomas. Zafar M, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3621–7

Abnormal transduction of dopamine signal in human nonfunctioning pituitary adenomas. Lania A, et al. **J Endocrinol Invest** 1995 Apr;18(4):265–70

Mechanism of action of pituitary adenylate cyclase–activating polypeptide (PACAP) in human nonfunctioning pituitary tumors. Lania A, et al. **J Neuroendocrinol** 1995 Sep;7(9):695–702

S–100 antigen–positive folliculostellate cells are not the source of IL–6 gene expression in human pituitary adenomas. Ueta Y, et al. **J Neuroendocrinol** 1995 Jun; 7(6):467–74

p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. Doglioni C, et al. **J Pathol** 1996 Jul;179(3):248–53

Expression of Bcl–2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. Flohil CC, et al. **J Pathol** 1996 Apr;178(4):393–7

Early expression of bcl–2 protein in the adenoma–carcinoma sequence of colorectal neoplasia. Kaklamanis L, et al. **J Pathol** 1996 May;179(1):10–4

Quantitative analysis of messenger ribonucleic acid encoding natriuretic peptide receptors in aldosterone–producing adenoma. Chen YM, et al. **Mol Cell Endocrinol** 1995 Jun; 111(2):139–46

The cyclic adenosine 3',5'–monophosphate–responsive factor CREB is constitutively activated in human somatotroph adenomas. Bertherat J, et al. **Mol Endocrinol** 1995 Jul; 9(7):777–83

Expression of pituitary adenylate cyclase activating polypeptide and receptors in human brain tumors. Vertongen P, et al. **Peptides** 1995;16(4):713–9

Opioid and tachykinin neuropeptides in prolactin–secreting human pituitary adenomas. Zhu X, et al. **Peptides** 1995; 16(6):1097–107

Metanephric adenoma of the kidney: an electron microscopic and immunohistochemical study with quantitative DNA measurement by image analysis. Nonomura A, et al. **Ultrastruct Pathol** 1995 Nov–Dec;19(6):481–8

Correlation of p53 protein expression with apoptotic incidence in colorectal neoplasia. Kobayashi M, et al. **Virchows Arch** 1995;427(1):27–32

NURSING

Cost analysis of intermediate care versus intensive care for the neurosurgery patient. Cohen L, et al. **J Nurs Adm** 1996 Jul–Aug;26(7–8):3, 18

PATHOLOGY

Cytology of primary skin tumors. Dey P, et al. **Acta Cytol** 1996 Jul–Aug;40(4):708–13

Aspiration cytology of renal cell carcinoma and adenoma in childhood. Dey P, et al. **Acta Cytol** 1996 May–Jun; 40(3):457–60

Fine needle aspiration cytology of an ectopic parathyroid adenoma: a case report. Galloway A, et al. **Acta Cytol** 1996 Mar–Apr;40(2):315–8

Aspiration cytodiagnosis of dermal analogue tumor, a rare subtype of salivary gland monomorphic adenoma: a case report. Gupta RK. **Acta Cytol** 1996 Mar–Apr;40(2):331–4

Nondiagnostic fine needle aspiration biopsy of the thyroid gland: a diagnostic dilemma. MacDonald L, et al. **Acta Cytol** 1996 May–Jun;40(3):423–8

Pancreatic oncocytic endocrine tumors. Cytologic features of two cases. Pacchioni D, et al. **Acta Cytol** 1996 Jul–Aug; 40(4):742–6

Pituitary adenomas. Correlation of the cytologic appearance with biologic behavior. Pegolo G, et al. **Acta Cytol** 1995 Sep–Oct;39(5):887–92

Fine needle aspiration cytology of adenoma of the nipple. A case report. Pinto RG, et al. **Acta Cytol** 1996 Jul–Aug; 40(4):789–91

Size of thyrocyte nuclei in aspirates from follicular adenomas: correlation with patients' ages. Słowińska–Klencka D, et al. **Acta Cytol** 1996 May–Jun;40(3):414–6

Hyalinizing trabecular adenoma of the thyroid—morphology and differential diagnosis. Schmid KW, et al. **Acta Med Austriaca** 1996;23(1–2):65–8 (23 ref.)

Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Kawamoto H, et al. **Acta Neurochir (Wien)** 1995;136(1–2):37–43

Application of catalyzed signal amplification in immunodetection of gonadotropin subunits in clinically nonfunctioning pituitary adenomas. Sanno N, et al. **Am J Clin Pathol** 1996 Jul;106(1):16–21

Well–differentiated malignant cylindroma with partially preserved hyaline sheaths. A locally invasive neoplasm? Donner LR, et al. **Am J Dermatopathol** 1995 Apr; 17(2):169–73

Dermal cylindroma. An immunohistochemical study of thirteen cases. Tellechea O, et al. **Am J Dermatopathol** 1995 Jun;17(3):260–5

Tubular apocrine adenoma with eccrine and apocrine immunophenotypes or papillary tubular adenoma? Tellechea O, et al. **Am J Dermatopathol** 1995 Oct; 17(5):499–505

Adenomatous lesions of the temporal bone immunohistochemical analysis and theories of histogenesis. Bold EL, et al. **Am J Otol** 1995 Mar;16(2):146–52

Aggressive papillary tumors of the endolymphatic sac: clinical and tissue culture characteristics. Feghali JG, et al. **Am J Otol** 1995 Nov;16(6):778–82

The so–called bile duct adenoma is a peribiliary gland hamartoma. Bhathal PS, et al. **Am J Surg Pathol** 1996 Jul; 20(7):858–64

Metanephric adenoma. Clinicopathological study of fifty patients. Davis CJ Jr, et al. **Am J Surg Pathol** 1995 Oct; 19(10):1101–14

Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Ronnett BM, et al. **Am J Surg Pathol** 1995 Dec;19(12):1390–408

Esophageal submucosal gland duct adenoma. Rouse RV, et al. **Am J Surg Pathol** 1995 Oct;19(10):1191–6

Classification of colorectal adenomas with quantitative pathology. Evaluation of morphometry, stereology, mitotic counts and syntactic structure analysis. Meijer GA, et al. **Anal Cell Pathol** 1995 Dec;9(4):311–23

Knowledge–guided segmentation and morphometric analysis of colorectal dysplasia. Hamilton PW, et al. **Anal Quant Cytol Histol** 1995 Jun;17(3):172–82

K–ras2 mutation spectrum, DNA aneuploidy, and epithelial cell proliferation in colorectal adenomas. Giaretti W, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:261–3

A regional study of thyroidectomy: surgical pathology suggests scope to improve quality and reduce cost [letter] Sarela A. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):231

Canalicular adenoma of the palatal mucosa. Parvizi F, et al. **Br Dent J** 1996 Jul 6;181(1):27–8

Bilateral multifocal canalicular adenomas of buccal minor salivary glands: a case report. Nelson ZL, et al. **Br J Oral Maxillofac Surg** 1995 Oct;33(5):299–301

Apoptosis and immunohistochemical bcl–2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Baretton GB, et al. **Cancer** 1996 Jan 15;77(2):255–64

Nonpolypoid adenomas and adenocarcinomas found in background mucosa of surgically resected colons. Kubota O, et al. **Cancer** 1996 Feb 15;77(4):621–6

Atypical adenomatous hyperplasia and adenocarcinoma of the human lung: their heterology in form and analogy in immunohistochemical characteristics. Mori M, et al. **Cancer** 1996 Feb 15;77(4):665–74

Flat adenoma, flat carcinoma, and de novo carcinoma of the colon [editorial; comment] Owen DA. **Cancer** 1996 Jan 1;77(1):3–6 (40 ref.). Comment on: Cancer 1996 Jan 1;77(1):44–50.

Flat adenoma as a precursor of colorectal carcinoma in hereditary nonpolyposis colorectal carcinoma. Watanabe T, et al. **Cancer** 1996 Feb 15;77(4):627–34

Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro–transformed adenoma relative to adenoma relative to adenoma cell lines. Elder DJ, et al. **Cancer Res** 1996 May 15;56(10):2273–6

Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Kjellman M, et al. **Cancer Res** 1996 Sep 15;56(18):4219–23

Both transforming growth factor–beta and substrate release are inducers of apoptosis in a human colon adenoma cell line. Wang CY, et al. **Cancer Res** 1995 Nov 1;55(21):5101–5

Flat adenomas and flat adenocarcinomas of the colorectal mucosa in Japanese and Swedish patients. Comparative histologic study. Rubio CA, et al. **Dis Colon Rectum** 1995 Oct;38(10):1075–9

Natural history of aberrant crypt foci. A surgical approach. Shpitz B, et al. **Dis Colon Rectum** 1996 Jul;39(7):763–7

The problem of de novo colorectal carcinoma. Kudo S, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1118–20

Carcinomas of the pituitary: definition and review of the literature. Lübke D, et al. **Gen Diagn Pathol** 1995 Oct; 141(2):81–92 (83 ref.)

Cytogenetical observations in a canalicular adenoma of the minor salivary glands. Havel G, et al. **Hereditas** 1996; 124(1):105–6

Colonic tubular adenomas and intestinal spirochaetosis: an incompatible association. Coyne JD, et al. **Histopathology** 1995 Oct;27(4):377–9

Colorectal adenomas in surgical specimens from subjects with hereditary non–polyposis colorectal cancer. Jass JR. **Histopathology** 1995 Sep;27(3):263–7

Ultrastructural dynamics of mitochondrial morphology in varying functional forms of human adrenal cortical adenoma. Bornstein SR, et al. **Horm Metab Res** 1996 Apr; 28(4):177–82

Dysplasia in atypical liver nodes [letter; comment] Berman JJ, et al. **Hum Pathol** 1996 Feb;27(2):211–3. Comment on: Hum Pathol 1995 Aug;26(8):897–906.

Proliferative characteristics of differentiated cells in familial adenomatous polyposis–associated duodenal adenomas. Turner JR, et al. **Hum Pathol** 1996 Jan;27(1):63–9

Apoptosis in flat neoplasias of the colorectal mucosa. Rubio CA, et al. **In Vivo** 1995 May–Jun;9(3):173–6

Multiple gall bladder adenomas. Bhoria U, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S19–20

Paraganglioma–like adenoma of thyroid. Pinto RG, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S4

A detailed analysis of K–ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Span M, et al. **Int J Cancer** 1996 Jun 21;69(3):241–5

Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. van der Stappen JW, et al. **Int J Cancer** 1996 Aug 7; 67(4):547–54

Multiple lipomas, angiolipomas, and parathyroid adenomas in a patient with Birt–Hogg–Dube syndrome. Chung JY, et al. **Int J Dermatol** 1996 May;35(5):365–7

Tumor of the follicular infundibulum: a clinicopathologic study. Cribier B, et al. **J Am Acad Dermatol** 1995 Dec; 33(6):979–84

Muir–Torre syndrome and defective DNA mismatch repair genes [letter] Fusaro RM, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):493–4

Superficial papillary adenomatosis of the nipple: a case report and review of the literature. Montemarano AD, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):871–5 (24 ref.)

Reduced immunostaining for the extracellular Ca2+–sensing receptor in primary and uremic secondary hyperparathyroidism. Kifor O, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1598–606

Ectopic nonfunctioning pituitary adenoma in the sphenoid sinus [letter; comment] Siegert B, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):430–1. Comment on: J Clin Endocrinol Metab 1995 Jun;80(6):1774–7.

Papillary mucinous adenoma arising in adenomyomatous hyperplasia of the gall bladder. Lauwers GY, et al. **J Clin Pathol** 1995 Oct;48(10):965–7

Sebaceous adenoma with a cutaneous horn. Thornton CM, et al. **J Cutan Pathol** 1995 Apr;22(2):185–7

Ectopic aldosteronoma associated to another adrenocortical adenoma in the adrenal gland of the same side. Mazza E, et al. **J Endocrinol Invest** 1995 Nov;18(10):809–12

Proliferative activity of mixed hyperplastic adenomatous polyp/serrated adenoma in the large intestine, measured by PCNA (proliferating cell nuclear antigen). Fujishima N. **J Gastroenterol** 1996 Apr;31(2):207–13

Mucin–producing adenoma associated with pancreas divisum and hepatic hilar carcinoma: an autopsy case. Origuchi N, et al. **J Gastroenterol** 1996 Jun;31(3):455–9 (40 ref.)

Ectopic pituitary adenoma occurring in the interpeduncular cistern. Case report. Takahata T, et al. **J Neurosurg** 1995 Dec;83(6):1092–4

Nephrogenic adenoma occurring in an augmented bladder. Goldman HB, et al. **J Urol** 1996 Apr;155(4):1410

Flat serrated adenomas and flat tubular adenomas of the colorectal mucosa: differences in the pattern of cell proliferation. Rubio CA, et al. **Jpn J Cancer Res** 1995 Aug; 86(8):756–60

Flat serrated adenomas of the colorectal mucosa. Rubio CA, et al. **Jpn J Cancer Res** 1996 Mar;87(3):305–9

Paneth cell–rich flat adenoma of the rectum: report of a case. Rubio CA, et al. **Jpn J Cancer Res** 1996 Jan;87(1):109–12

Metanephric adenoma: histology, immunophenotype, cytogenetics, ultrastructure. Gatalica Z, et al. **Mod Pathol** 1996 Mar;9(3):329–33

Coexistence of nipple duct adenoma and breast carcinoma: a clinicopathologic study of five cases and review of the literature. Jones MW, et al. **Mod Pathol** 1995 Aug; 8(6):633–6 (13 ref.)

Low–grade papillary adenomatous tumors of the temporal bone: report of two cases and review of the literature. Lavoie M, et al. **Mod Pathol** 1995 Aug;8(6):603–8 (17 ref.)

Nephrogenic adenoma of the urinary tract: a review of the microscopic appearance of 80 cases with emphasis on unusual features. Oliva E, et al. **Mod Pathol** 1995 Sep; 8(7):722–30 (27 ref.)

Distribution of cytokeratin 19–positive biliary cells in cirrhotic nodules, hepatic borderline nodules (atypical adenomatous hyperplasia), and small hepatocellular carcinomas. Terada T, et al. **Mod Pathol** 1995 May; 8(4):371–9

Dural invasion and proliferative potential of pituitary adenomas. Daita G, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):211–4

p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Thapar K, et al. **Neurosurgery** 1996 Apr;38(4):763–70; discussion 770–1

Flat–elevated colorectal neoplasms exhibit a high malignant potential. Teixeira CR, et al. **Oncology** 1996 Mar–Apr; 53(2):89–93

Parathyroid lipoadenoma: case report and review of the

literature. Turner WJ, et al.
Otolaryngol Head Neck Surg 1996 Feb;114(2):313–6 (19 ref.)

K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Satoh K, et al. **Pancreas** 1996 May;12(4):362–8

Pituitary lesions in multiple endocrine neoplasia syndrome (MENS) type 1. Capella C, et al. **Pathol Res Pract** 1995 May;191(4):345–7 (27 ref.)

Double duplication in a nonrotational colon. Study of a case associated with mucinous adenoma. Diaz-Cano SJ, et al. **Pathol Res Pract** 1995 Jun;191(5):415–9

Null cell adenomas and oncocytomas of the pituitary gland. Holm R. **Pathol Res Pract** 1995 May;191(4):348–52 (38 ref.)

PCNA defined proliferative activity of epithelial tumor cells in adenomas of the colon. Bielicki D, et al.
Pol J Pathol 1995;46(3):151–4

Adenoma–carcinoma sequence in the papilla of Vater. Stolte M, et al. **Scand J Gastroenterol** 1996 Apr;31(4):376–82

Three-dimensional configuration of crypts of different types of colorectal adenomas. Araki K, et al.
Scanning Microsc 1995 Mar;9(1):149–56; discussion 156–8

Hereditary nonpolyposis colorectal cancer and colonic adenomas: aggressive adenomas? Lynch HT, et al.
Semin Surg Oncol 1995 Nov–Dec;11(6):406–10 (24 ref.)

Possible neoplastic transformation within gastric hyperplastic polyp. Application of endoscopic polypectomy. Hizawa K, et al. **Surg Endosc** 1995 Jun;9(6):714–8

Observations of aggressive, small, flat, and depressed colon cancer. Report of three cases. Kasumi A, et al.
Surg Endosc 1995 Jun;9(6):690–4 (19 ref.)

Asymptomatic large pituitary adenomas discovered at autopsy. Auer RN, et al. **Surg Neurol** 1996 Jul;46(1):28–31

A multicenter study of colorectal adenomas. Rationale, objectives, methods and characteristics of the study cohort. The Multicentric Study of Colorectal Adenomas (SMAC) Workgroup. **Tumori** 1995 May–Jun;81(3):157–63

Effects of gonadal steroids on the growth of human pituitary adenomas in vitro. Caronti B, et al. **Tumour Biol** 1995; 16(6):353–64

Monomorphic (basal cell) salivary adenoma of ovary: report of a case. Russell P, et al. **Ultrastruct Pathol** 1995 Sep–Oct; 19(5):431–8

Transforming growth factor beta 1 in human liver tumors. Vogelbruch M, et al. **Verh Dtsch Ges Pathol** 1995;79:132–6

Papillary adenoma of type II pneumocytes might have malignant potential. Mori M, et al. **Virchows Arch** 1996 Jun;428(3):195–200

[Current anatomopathological aspects of differentiated thyroid cancers of follicular (vesicular) origin: value and necessity of a common language] Franc B. **Ann Chir** 1995; 49(10):909–21 (65 ref.) (Eng. Abstr.) **(Fre)**

[Intraductal pancreatic adenomatosis. Apropos of a new case] Brassier D, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 Jan–Feb;32(1):19–23 (21 ref.) (Eng. Abstr.) **(Fre)**

[Multiple eccrine spiradenoma. Histological association with dermal cylindroma] Kawakubo Y, et al. **Hautarzt** 1995 Sep; 46(9):651–5 (Eng. Abstr.) **(Ger)**

[Tubular differentiated stomach carcinoma of the (Ming) infiltrating type] Dirschmid K, et al. **Pathologe** 1996 Mar; 17(2):122–6 (Eng. Abstr.) **(Ger)**

[Alveolar adenoma of the lung. Immunohistochemical characterization of type II pneumocytes] Köppl H, et al. **Pathologe** 1996 Mar;17(2):150–3 (Eng. Abstr.) **(Ger)**

[Hepatocellular nodular hyperplasias, adenomas and carcinomas] Altmann HW. **Verh Dtsch Ges Pathol** 1995; 79:84–108 (144 ref.) (Eng. Abstr.) **(Ger)**

[An unusual association: Jaffe-Linchtenstein syndrome, arcuate ligament syndrome and hepatic adenoma] Fontana D, et al. **Minerva Chir** 1996 Mar;51(3):167–9 (Eng. Abstr.) **(Ita)**

[Adenomatoid hyperplasia of the minor salivary glands. Report of a clinical case] Tucci E, et al.
Minerva Stomatol 1996 Jan–Feb;45(1-2):49–52 (9 ref.) (Eng. Abstr.) **(Ita)**

[The results of p53 immunostaining in colorectal adenomas, early cancers, advanced cancers and their hepatic metastasis] Saigusa N, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:159–63 (Eng. Abstr.) **(Jpn)**

[A morphological study of renal adenoma and latent renal cell carcinoma in autopsy cases] Hashine K, et al.
Nippon Hinyokika Gakkai Zasshi 1996 Mar;87(3):667–75 (Eng. Abstr.) **(Jpn)**

[A case report of intraductal papillary adenoma with carcinoma in situ of the pancreas with a repeated history of acute pancreatitis] Kinoshita M, et al.
Nippon Shokakibyo Gakkai Zasshi 1996 Jan;93(1):64–7 **(Jpn)**

[Brunner's gland adenoma of the duodenal bulb] Smirnov OA, et al. **Arkh Patol** 1995 Nov–Dec;57(6):71–3 (Eng. Abstr.) **(Rus)**

[Factors associated with high grade dysplasia and cancer in colorectal adenoma] Alonso G, et al.
Acta Gastroenterol Latinoam 1995;25(3):131–5 (Eng. Abstr.) **(Spa)**

[Parathyroid adenoma and carcinoma. A comparative morphologic study] Morelli A, et al.
Medicina (B Aires) 1991;51(6):507–10 (Eng. Abstr.) **(Spa)**

[Hypophyseal apoplexy] Sánchez Valiente S. **Neurologia** 1995 Jun–Jul;10(6):252–3 **(Spa)**

PHYSIOPATHOLOGY

Frontal intermittent rhythmic delta activity (FIRDA) in pituitary adenoma. Kameda K, et al.
Clin Electroencephalogr 1995 Jul;26(3):173–9

Hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-aldosterone systems. Gennari C, et al. **Miner Electrolyte Metab** 1995; 21(1-3):77–81

Hot flushes in men with pituitary adenoma. McReynolds SM, et al. **Surg Neurol** 1995 Jul;44(1):14–7; discussion 17–8

PREVENTION & CONTROL

Screening high-risk groups for colorectal neoplasia. Hardcastle JD, et al. **Am J Gastroenterol** 1996 May; 91(5):850–2 (34 ref.)

Lessons from the follow-up of patients with large colorectal adenomas: be or not be, that is the question [editorial; comment] Neugut AI, et al. **Am J Gastroenterol** 1996 Mar; 91(3):420–2 (45 ref.). Comment on: Am J Gastroenterol 1996 Mar;91(3):448–54.

Chemoprevention of diethylnitrosamine-induced liver foci and hepatocellular adenomas in C3H mice. Pereira MA. **Anticancer Res** 1995 Sep–Oct;15(5B):1953–6

Chemopreventive effects of green and black tea on pulmonary and hepatic carcinogenesis. Cao J, et al.
Fundam Appl Toxicol 1996 Feb;29(2):244–50

Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. The Australian Polyp Prevention Project [see comments] MacLennan R, et al. **J Natl Cancer Inst** 1995 Dec 6;87(23):1760–6. Comment in: J Natl Cancer Inst 1995 Dec 6;87(23):1733–5. Comment in: J Natl Cancer Inst 1996 Mar 20;88(6):377–8.

Re: Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas [letter; comment] Wynder EL. **J Natl Cancer Inst** 1996 Mar 20;88(6):377–8. Comment on: J Natl Cancer Inst 1995 Dec 6;87(23):1760–6.

Colorectal cancer in the Royal Navy--an opportunity to intervene? Cripps NP, et al. **J R Nav Med Serv** 1995 Spring; 81(1):16–26

Effect of methimazole on rat renal carcinogenesis induced by N-ethyl-N-hydroxyethylnitrosamine. Konishi N, et al. **Toxicol Pathol** 1995 Sep–Oct;23(5):606–11

[Mass screening for colorectal cancer in France. Experience in 165,000 people in the department of Calvados] Launoy G, et al. **Gastroenterol Clin Biol** 1996;20(3):228–36 (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Adrenal nonhyperfunctioning adenoma and nonadenoma: CT attenuation value as discriminative index. Miyake H, et al.
Abdom Imaging 1995 Nov–Dec;20(6):559–62

Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. Korobkin M, et al.
AJR Am J Roentgenol 1996 Mar;166(3):531–6

Radiologic manifestations of hyperparathyroidism. Vázquez Quintana E, et al. **Bol Asoc Med P R** 1995 Jul–Sep; 87(7-9):135–9

Incidentally discovered adrenal tumors. Saxe A.
Curr Opin Gen Surg 1993;:121–9 (50 ref.)

Delayed enhanced CT for differentiation of benign from malignant adrenal masses. Korobkin M, et al. **Radiology** 1996 Sep;200(3):737–42

[CT findings of the small polypoid lesions of the gallbladder (2cm or less PLG): differentiation between benign and malignant disease on unenhanced CT] Shindoh N.
Nippon Igaku Hoshasen Gakkai Zasshi 1996 Feb; 56(3):102–8 (Eng. Abstr.) **(Jpn)**

[Classical roentgenology and computerized tomography in the diagnosis of pituitary adenomas] Portnoĭ LM, et al. **Vestn Rentgenol Radiol** 1996 Jan–Feb;(1):5–9 (Eng. Abstr.) **(Rus)**

[Experience with using mobile x-ray computed tomography in the diagnosis of hypophyseal adenomas] Portnoĭ LM, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Jul–Sep; (3):28–30 **(Rus)**

RADIONUCLIDE IMAGING

Case report: failure of adrenal scintigraphy to exhibit 131I cholesterol uptake in a CT-demonstrated, surgically proven aldosteronoma. Salam Z, et al. **Am J Med Sci** 1996 Sep;312(3):130–2

Technetium 99m sestamibi scan is the useful procedure to locate parathyroid adenomas before surgery [letter; comment] Takami H, et al. **Am J Surg** 1996 Jul;172(1):93 . Comment on: Am J Surg 1995 Nov;170(5):488–91.

Tc-99m sestamibi scanning in the preoperative localization of mediastinal parathyroid adenomas. Chiu NT, et al.
Ann Nucl Med 1995 Aug;9(3):157–9

A false-positive localization of a parathyroid adenoma with technetium Tc 99m sestamibi scan secondary to a thyroid follicular carcinoma. Koss WG, et al. **Arch Surg** 1996 Feb; 131(2):216–7

131I-6 beta-iodomethylnorcholesterol scintigraphy: an assessment of its role in the investigation of adrenocortical incidentalomas. Bardet S, et al. **Clin Endocrinol (Oxf)** 1996 May;44(5):587–96

Localization of parathyroid tumours [comment] Heath DA. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):523–4. Comment on: Clin Endocrinol (Oxf) 1995 Nov;43(5):525–30.

Tc-99m sestamibi uptake by parathyroid carcinoma. False-positive localization of parathyroid adenoma. Achong DM, et al. **Clin Nucl Med** 1995 Aug;20(8):735

False-positive imaging of In-111 labeled monoclonal antibody conjugate CYT-103 in a patient with metastatic colorectal carcinoma. Bhatia M, et al. **Clin Nucl Med** 1995 Nov;20(11):979–80

Nuclear medicine imaging in a case of hyperfunctioning parathyroid carcinoma associated with a parathyroid adenoma. Ceriani L, et al. **Clin Nucl Med** 1995 Sep; 20(9):817–20

Tc-99m sestamibi imaging of brown tumors of primary hyperparathyroidism. Dinauer PA, et al. **Clin Nucl Med** 1996 Mar;21(3):192–6

Tc-99m tetrofosmin. A new diagnostic tracer for parathyroid imaging. Ishibashi M, et al. **Clin Nucl Med** 1995 Oct; 20(10):902–5

Parathyroid adenomas without sestamibi retention. Leslie WD, et al. **Clin Nucl Med** 1995 Aug;20(8):699–702

Ectopic parathyroid imaging with Tc-99m sestamibi. Pusuwan P, et al. **Clin Nucl Med** 1996 Jan;21(1):74

Accumulation of I-123 IMP in hepatic cell adenoma. Suto Y, et al. **Clin Nucl Med** 1995 Jul;20(7):643–4

The role of pre-operative thallium-technetium subtraction scintigraphy in the surgical management of patients with solitary parathyroid adenoma [see comments] Tsukamoto E, et al. **Clin Radiol** 1995 Oct;50(10):677–80. Comment in: Clin Radiol 1996 May;51(5):383.

The role of pre-operative thallium-technetium subtraction scintigraphy in the surgical management of patients with solitary parathyroid adenoma [letter; comment] Watura R, et al. **Clin Radiol** 1996 May;51(5):383. Comment on: Clin Radiol 1995 Oct;50(10):677–80.

Fluorine-18-fluorodeoxyglucose positron emission tomography for preoperative parathyroid imaging in primary hyperparathyroidism. Melon P, et al.
Eur J Nucl Med 1995 Jun;22(6):556–8

Technetium-99m-methoxyisobutylisonitrile in localization of ectopic parathyroid adenoma. Bernà L, et al.
J Nucl Med 1996 Apr;37(4):631–3

Localization of an ectopic parathyroid adenoma by double-phase technetium-99m-sestamibi scintigraphy. Caravalho J, et al. **J Nucl Med** 1995 Oct;36(10):1840–2

Technetium-99m-sestamibi imaging before reoperation for primary hyperparathyroidism. Chen CC, et al.
J Nucl Med 1995 Dec;36(12):2186–91

Rapid washout of technetium-99m-MIBI from a large parathyroid adenoma [letter; comment] Staudenherz A, et al. **J Nucl Med** 1995 Oct;36(10):1928–9. Comment on: J Nucl Med 1995 Feb;36(2):241–3.

Technetium-99m-sestamibi SPECT localization of mediastinal parathyroid adenoma. Teigen EL, et al.
J Nucl Med 1996 Sep;37(9):1535–7

Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands. van Royen EA, et al.
J Nucl Med 1996 Sep;37(9):1449–51

Intraoperative identification of parathyroid gland pathology: a new approach. Martinez DA, et al. **J Pediatr Surg** 1995 Sep;30(9):1306–9

Sestamibi parathyroid imaging. McBiles M, et al.
Semin Nucl Med 1995 Jul;25(3):221–34 (62 ref.)

[Preoperative localization of parathyroid adenomas using Tc-99m-sestamibi] Stilgren LS, et al. **Ugeskr Laeger** 1996 Mar 25;158(13):1832–4 (Eng. Abstr.) **(Dan)**

[Scintigraphy of the parathyroid glands with 99mTc-MIBI] Grünwald F, et al. **Med Klin** 1995 Aug 15;90(8):450–5 (Eng. Abstr.) **(Ger)**

[Usefulness of scintigraphy using 99mTc-MIBI for localization of parathyroid adenoma] Leowska E, et al.
Pol Tyg Lek 1995 Oct;50(40–44):23–5 (Eng. Abstr.) **(Pol)**

RADIOTHERAPY

The need for adjunctive focused radiation therapy in pituitary adenomas. Knosp E, et al. **Acta Neurochir Suppl (Wien)** 1995;63:81–4

Radiation therapy for pituitary adenomas. A retrospective study of the University of Louisville experience. Cornett MS, et al. **Am J Clin Oncol** 1996 Jun;19(3):292–5

High efficacy without visual damage: the current status of pituitary radiotherapy [editorial; comment] Goldsmith BJ, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):765–7 . Comment on: Int J Radiat Oncol Biol Phys 1995 Oct 15;33(3):599–605.

Long-term visual changes following pituitary irradiation [see comments] Movsas B, et al.
Int J Radiat Oncol Biol Phys 1995 Oct 15;33(3):599–605 . Comment in: Int J Radiat Oncol Biol Phys 1995 Oct 15;33(3):765–7.

Treatment of adenoma sebaceum with the copper vapor laser. Kaufman AJ, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):770–4

[Discrepancy between peripheral thyroid hormone values and TSH level] Heinze HG. **Dtsch Med Wochenschr** 1995 Nov 24;120(47):1639–40 **(Ger)**

[Hormonally inactive hypophyseal adenomas: the results and late sequelae after surgery and radiotherapy] Grabenbauer GG, et al. **Strahlenther Onkol** 1996 Apr;172(4):193–7 (Eng. Abstr.) **(Ger)**

SECRETION

Thyrotropin-secreting pituitary tumors in hyper- and

hypothyroidism. Beck-Peccoz P, et al. **Acta Med Austriaca** 1996;23(1-2):41-6 (45 ref.)

Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression. Jin L, et al. **Am J Pathol** 1996 Jun;148(6):2057-66

GHRH activates a nonselective cation current in human GH-secreting adenoma cells. Takano K, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E1050-7

A case of hyperthyroidism due to pituitary resistance to thyroid hormone. Hidaka Y, et al. **Endocr J** 1994 Aug; 41(4):339-43

Analysis of the in vitro secretory activity of human pituitary adenomas: modification of corticotropin release from adenoma tissue explant cultures by addition of a human plasma ultrafiltrate bioactive fraction. Zarković N, et al. **Eur J Clin Chem Clin Biochem** 1996 Jan;34(1):23-30

Adrenal tumor producing 11-deoxycorticosterone, 18-hydroxy-11-deoxycorticosterone and aldosterone. Toyoda Y, et al. **Intern Med** 1996 Feb;35(2):123-8

Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. Arafah BM, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3507-12

Venous angiography is needed to interpret inferior petrosal sinus and cavernous sinus sampling data for lateralizing adrenocorticotropin-secreting adenomas. Mamelak AN, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):475-81

Lack of effect of a gonadotropin-releasing hormone agonist in a patient with prostate cancer and a gonadotroph adenoma [letter] Schuval BJ, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):864

Different patterns of steroid secretion in patients with adrenal incidentaloma. Terzolo M, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):740-4

Thyrotropin secreting pituitary adenoma associated with hypopituitarism and diabetes insipidus in an adolescent boy. Phillip M, et al. **J Pediatr Endocrinol Metab** 1995 Jan-Mar; 8(1):47-50

Effect of galanin on growth hormone (GH) response to thyrotropin releasing hormone of rat pituitary GH-secreting adenomatous cells (GH1) in culture. Giustina A, et al. **Life Sci** 1996;58(1):83-90

Growth hormone secretion in human acromegalic pituitary adenomas: cyclic adenosine monophosphate and protein kinase C responses. Ishizuka T, et al. **Metabolism** 1996 Feb; 45(2):206-10

Mammosomatotroph adenoma cells secrete both growth hormone and prolactin. Kojima Y, et al. **Neurol Med Chir (Tokyo)** 1995 Nov;35(11):791-6

Opioid and tachykinin neuropeptides in prolactin-secreting human pituitary adenomas. Zhu X, et al. **Peptides** 1995; 16(6):1097-107

[Problems in thyroid function screening using thyroid stimulating hormone. A case of thyrotoxicosis caused by a thyroid stimulating hormone-secreting pituitary tumor] Nygaard B. **Ugeskr Laeger** 1995 Oct 9;157(41):5728-9 (Eng. Abstr.) **(Dan)**

[The relationship between cell proliferation activity and secretory activity in pituitary adenoma--a review of 63 cases] Asano K, et al. **No To Shinkei** 1996 Jun;48(6):543-9 (Eng. Abstr.) **(Jpn)**

[Molecular forms of human growth hormone and prolactin, secreted by cultured pituitary tumor cells] Bulatov AA, et al. **Biokhimiia** 1995 Oct;60(10):1637-46 (Eng. Abstr.) **(Rus)**

SURGERY

Tension pneumocephalus after transsphenoidal surgery: two case reports. Yüceer N, et al. **Acta Neurochir (Wien)** 1995; 137(1-2):58-61

Surgical management of hyperparathyroidism. A 24 years experience. Vázquez Quintana E. **Bol Asoc Med P R** 1995 Jul-Sep;87(7-9):126-9

Recovery of vision following transsphenoidal surgery for pituitary adenomas. Powell M. **Br J Neurosurg** 1995; 9(3):367-73 (7 ref.)

Initial experience with endoscopic retroperitoneal adrenalectomy. Parrilla P, et al. **Br J Surg** 1996 Jul; 83(7):987-8

Transanal endoscopic microsurgery--initial experience from three centres in the United Kingdom. Steele RJ, et al. **Br J Surg** 1996 Feb;83(2):207-10

Flat adenoma as a precursor of colorectal carcinoma in hereditary nonpolyposis colorectal carcinoma. Watanabe T, et al. **Cancer** 1996 Feb 15;77(4):627-34

A case of silent 21-hydroxylase deficiency with persistent adrenal insufficiency after removal of an adrenal incidentaloma. Nagasaka S, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):111-6

Local therapy of rectal tumors. Mentges B, et al. **Dis Colon Rectum** 1996 Aug;39(8):886-92

Interference with the adenoma-carcinoma sequence. Bond JH. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1115-7 (30 ref.)

Follow-up after polypectomy: consensus? Bond JH. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1141-4 (28 ref.)

Prognostic model for patients treated for colorectal adenomas with regard to development of recurrent adenomas and carcinoma. Jensen P, et al. **Eur J Surg** 1996 Mar; 162(3):229-34; discussion 235

Surgical treatments for oesophageal cancer concomitant with gastric adenoma with severe epithelial atypia. Ueo H, et al. **Eur J Surg Oncol** 1995 Oct;21(5):573-5

Endoscopic aspiration mucosectomy as curative endoscopic surgery; analysis of 24 cases of early gastric cancer. Torii A, et al. **Gastrointest Endosc** 1995 Nov;42(5):475-9

Intraoperative fall in plasma levels of intact parathyroid hormone in patients undergoing parathyroid adenomectomy. Tommasi M, et al. **Int J Biol Markers** 1995 Oct-Dec;10(4):206-10

Primary aldosteronism in pregnancy--should it be treated surgically? Aboud E, et al. **Ir J Med Sci** 1995 Oct-Dec; 164(4):279-80 (12 ref.)

Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing's disease. Considerations concerning preoperative medical treatment and the long-term follow-up [editorial; comment] Lamberts SW, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3111-3. Comment on: J Clin Endocrinol Metab 1995 Nov;80(11):3114-20.

Risk factors and long-term outcome in pituitary-dependent Cushing's disease. Sonino N, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2647-52

Endoscopic treatment of ampullary adenomas in familial adenomatous polyposis. Bleau BL, et al. **J Clin Gastroenterol** 1996 Apr;22(3):237-41

Endoscopic management of lesions of the sella turcica. Sethi DS, et al. **J Laryngol Otol** 1995 Oct;109(10):956-62

Delayed hyponatremia [letter; comment] Landolt AM. **J Neurosurg** 1996 Jan;84(1):150-1. Comment on: J Neurosurg 1995 Aug;83(2):363-7.

Intraoperative identification of parathyroid gland pathology: a new approach. Martinez DA, et al. **J Pediatr Surg** 1995 Sep;30(9):1306-9

Lateralization of parathyroid adenomas by intra-operative parathormone estimation. Taylor J, et al. **J R Coll Surg Edinb** 1996 Jun;41(3):174-7

Surgical management of breast masses in pregnant women. Collins JC, et al. **J Reprod Med** 1995 Nov;40(11):785-8

Resection of giant invasive pituitary tumors through a transfacial approach: technical case report. Anson JA, et al. **Neurosurgery** 1995 Sep;37(3):541-5; discussion 545-6

Gonadotropic pituitary carcinoma: case report. Beauchesne P, et al. **Neurosurgery** 1995 Oct;37(4):810-5; discussion 815-6

Aggressive papillary middle ear tumors: a report of two cases with review of the literature [letter; comment] Holness RO, et al. **Neurosurgery** 1996 Apr;38(4):849. Comment on: Neurosurgery 1994 Sep;35(3):493-7; discussion 497.

Delayed onset of hyponatremia after transsphenoidal surgery for pituitary adenomas. Taylor SL, et al. **Neurosurgery** 1995 Oct;37(4):649-53; discussion 653-4 (26 ref.)

Nonhemorrhagic pituitary macroadenoma producing reversible internal carotid artery occlusion: case report. Yaghmai R, et al. **Neurosurgery** 1996 Jun;38(6):1245-8

Intraoperative monitoring with pulse Doppler ultrasonography in transsphenoidal surgery: technique application. Yamasaki T, et al. **Neurosurgery** 1996 Jan; 38(1):95-7; discussion 97-8

Surgery of the incidentally discovered mass of the adrenal gland (incidentaloma). Fronticelli CM, et al. **Panminerva Med** 1995 Jun;37(2):60-4

Gamma Knife treatment of pituitary adenomas. Ganz JC. **Stereotact Funct Neurosurg** 1995;64 Suppl 1:3-10 (38 ref.)

Laparoscopic resection of a large hepatic tumor. Ferzli G, et al. **Surg Endosc** 1995 Jun;9(6):733-5 (9 ref.)

Laparoscopic resection of an adenoma of the urachus in combination with a laparoscopic cholecystectomy. Hubens G, et al. **Surg Endosc** 1995 Aug;9(8):914-6

Transanal endoscopic microsurgery in large, sessile adenomas of the rectum. A 10-year experience. Said S, et al. **Surg Endosc** 1995 Oct;9(10):1106-12

Endoscopically-assisted laparoscopic partial gastric resection for treatment of a large benign gastric adenoma. Trías M, et al. **Surg Endosc** 1996 Mar;10(3):344-6

The subxiphoid laparoscopic approach for resection of mediastinal parathyroid adenoma after successful localization with TC-99m-sestamibi radionuclide scan. Wei JP, et al. **Surg Laparosc Endosc** 1995 Oct;5(5):402-6

Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Massoud F, et al. **Surg Neurol** 1996 Apr;45(4):341-6

Persistent elevated serum levels of intact parathyroid hormone after operation for sporadic parathyroid adenoma: evidence of detrimental effects of severe parathyroid disease. Bergenfelz A, et al. **Surgery** 1996 Jun;119(6):624-33

[Clinical study and application of auricular magnet anesthesia for the operation of the thyroid] Jiang J. **Chen Tzu Yen Chiu** 1995;20(3):4-8 **(Chi)**

[Endoscopic mucosectomy for resection of early gastric cancer and precancerous lesions] Zhou L, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jul;34(7):443-5 (Eng. Abstr.) **(Chi)**

[Initial experience of an endocrinologist with the treatment of hypophyseal adenomas with the Leksell gamma knife] Marek J, et al. **Cas Lek Cesk** 1995 Sep 6;134(17):543-6 (Eng. Abstr.) **(Cze)**

[Use of the radiosurgery knife in the treatment of hypophyseal adenomas] Vladyka V, et al. **Cas Lek Cesk** 1995 Sep 6;134(17):539-42 (Eng. Abstr.) **(Cze)**

[Cushing's disease: successful surgery through improved preoperative tumor localization] van Aken MO, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1455-9 (Eng. Abstr.) **(Dut)**

[Excision of a parathyroid adenoma of the aorto-pulmonary window under thoracoscopy] Peix JL, et al. **Presse Med** 1996 Mar 23;25(10):494-6 (Eng. Abstr.) **(Fre)**

[Differentiated thyroid gland carcinomas in "autonomous adenomas" in childhood] Müller A, et al. **Chirurg** 1995 Oct; 66(10):1018-20 (Eng. Abstr.) **(Ger)**

[Scintigraphy of the parathyroid glands with 99mTc-MIBI] Grünwald F, et al. **Med Klin** 1995 Aug 15;90(8):450-5 (Eng. Abstr.) **(Ger)**

[Treatment of rectum adenoma. Retrospective study of the treatment of inpatients (1987-1991)] Richter M, et al. **Schweiz Med Wochenschr Suppl** 1996;79:80S-84S (Eng. Abstr.) **(Ger)**

[Hormonally inactive hypophyseal adenomas: the results and late sequelae after surgery and radiotherapy] Grabenbauer GG, et al. **Strahlenther Onkol** 1996 Apr;172(4):193-7 (Eng. Abstr.) **(Ger)**

[A new method for treating benign prostatic hypertrophy: transurethral prostatic vaporization] Tizzani A, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):53-4 **(Ita)**

[Transanal endoscopic microsurgery] Thoresen JE, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):52-3 (Eng. Abstr.) **(Nor)**

[Surgical treatment of toxic adenoma] Ignjatović M, et al. **Vojnosanit Pregl** 1995 Mar-Apr;52(2):128-34 (Eng. Abstr.) **(Scr)**

[Adenoma of the colon and rectum] Celestino A, et al. **Rev Gastroenterol Peru** 1995 Sep-Dec;15(3):224-9 (Eng. Abstr.) **(Spa)**

THERAPY

Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly. Tsukamoto N, et al. **Endocr J** 1994 Aug;41(4):437-44

Treatment and follow-up of large bowel adenoma. Rossini FP, et al. **Tumori** 1995 May-Jun;81(3 Suppl):38-44 (61 ref.)

[Localized transrectal hyperthermia. Transurethral hyperthermia and thermotherapy in the treatment of benign hyperplasia of the prostate] Mazo E, et al. **J Urol (Paris)** 1996;102(1):23-5 (Eng. Abstr.) **(Fre)**

[Normalization of the prolactin values during alfa-interferon therapy: the considerations with a female patient with anti-HCV-positive chronic hepatitis and prolactin-secreting hypophyseal microadenoma] Zennaro R, et al. **Clin Ter** 1996 Apr;147(4):169-71 (Eng. Abstr.) **(Ita)**

[Treatment of hypothalamic-pituitary tumors--experiences at Hiroshima University School of Medicine] Uozumi T. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1019-36 (43 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Underdiagnosis of parathyroid adenomas by sonography [letter] Lerner RM. **AJR Am J Roentgenol** 1996 Sep; 167(3):814-5

[Metanephric adenoma: an unusual tumor of the kidney. Apropos of a case] Chefchaouni MC, et al. **J Urol (Paris)** 1996;102(1):40-3 (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Water-clear cell adenoma of the parathyroid. A case report with immunohistochemistry and electron microscopy [see comments] Grenko RT, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1072-4. Comment in: Arch Pathol Lab Med 1995 Nov;119(11):996-7.

Leuchtenberger bodies in flat adenomas of the colorectal mucosa: a comparison between Japanese and Swedish patients. Rubio CA, et al. **Jpn J Cancer Res** 1996 Jun; 87(6):618-22

Metanephric adenoma of the kidney: an electron microscopic and immunohistochemical study with quantitative DNA measurement by image analysis. Nonomura A, et al. **Ultrastruct Pathol** 1995 Nov-Dec;19(6):481-8

[Ultrastructure of renal-cell tumors induced in mice by 1,2-dimethylhydrazine] Kondalenko VF, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):286-90 **(Rus)**

VETERINARY

Ectopic perianal gland tumor in a timber wolf. Wheler CL, et al. **Can Vet J** 1996 Jan;37(1):41-2

A light microscopical, ultrastructural and immunohistochemical study of spindle-cell adrenocortical tumours of ferrets. Gliatto JM, et al. **J Comp Pathol** 1995 Aug;113(2):175-83

Adrenal gland adenomas in raccoons (Procyon lotor) from the eastern United States. Hamir AN, et al. **J Vet Diagn Invest** 1995 Jul;7(3):413-6

Pancreatic adenocarcinoma in two grey collie dogs with cyclic hematopoiesis. Brabb T, et al. **Lab Anim Sci** 1995 Aug;45(4):357-62

VIROLOGY

Detection of polyomaviral DNA sequences in normal and adenomatous human pituitary tissues using the polymerase chain reaction. Woloschak M, et al. **Cancer** 1995 Aug 1; 76(3):490-6

ADENOMA, ACIDOPHIL

see related
ACROMEGALY
GIGANTISM

SURGERY

[Transsphenoidal microsurgical removal of GH-secreting pituitary adenoma in: a report of 200 cases] Su C, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):333-7 (Eng. Abstr.) **(Chi)**

ADENOMA, ADRENAL CORTICAL

BLOOD

Characteristics of aldosterone-producing adenoma responsive to upright posture. Toraya S, et al. **Endocr J** 1995 Aug;42(4):481-7

CHEMISTRY

[Ultrastructural and immunohistochemical localization of endothelin-1 in nonneoplastic, hyperplastic and neoplastic adrenal gland] Li Q, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):128-31 (Eng. Abstr.) **(Chi)**

COMPLICATIONS

Combined Conn's and Cushing's syndrome: an unusual presentation of adrenal adenoma. Baert D, et al. **Acta Clin Belg** 1995;50(5):310-3

Possible pre-Cushing's syndrome due to an adrenal adenoma incidentally discovered. Tsuboi Y, et al. **Endocr J** 1995 Aug;42(4):509-16

Conn's syndrome due to adrenocortical adenoma--a rare but rewarding cause of curable hypertension. Quarmby CJ, et al. **S Afr Med J** 1995 Dec;85(12 Pt 2):1353-6

Renal pathology in patients with primary hyperaldosteronism secondary to an adrenal cortical adenoma. Grady RW, et al. **Urology** 1996 Sep;48(3):369-72

[Hyperaldosteronism sensitive to dexamethasone with adrenal adenoma. Clinical, biological and genetic study] Jeunemaitre X, et al. **Presse Med** 1995 Sep 23;24(27):1243-8 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Adrenocortical adenoma containing a fat component: CT and MR image evaluation. Sato N, et al. **Abdom Imaging** 1995 Sep-Oct;20(5):489-90

An imaging algorithm for the differential diagnosis of adrenal adenomas and metastases. McNicholas MM, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1453-9

Calcified aldosterone-producing adrenocortical adenoma. Jelic TM, et al. **Clin Imaging** 1996 Jan-Mar;20(1):50-4

Case report. Adrenocortical oncocytoma: CT and MRI findings. Gandras EJ, et al. **J Comput Assist Tomogr** 1996 May-Jun;20(3):407-9

Adrenal cortical adenoma with extensive fat cell metaplasia. Feldberg E, et al. **Pathol Res Pract** 1996 Jan;192(1):62-5; discussion 66

Hyperaldosteronism: sampling the adrenal veins. Doppman JL, et al. **Radiology** 1996 Feb;198(2):309-12

[Dysfunction of the aldosterone synthesis pathway as a marker of malignity in symptomatic and asymptomatic adrenal masses] Aupetit-Faisant B, et al. **Bull Acad Natl Med** 1995 Oct;179(7):1355-65; discussion 1365-7 (Eng. Abstr.) **(Fre)**

METABOLISM

Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Rossi E, et al. **Am J Hypertens** 1995 Sep;8(9):884-93

PATHOLOGY

Adrenal cortical neoplasms. A study of 56 cases. Evans HL, et al. **Am J Clin Pathol** 1996 Jan;105(1):76-86

[Morphologic heterogeneity of adrenal cortical adenoma] Solov'eva NA. **Arkh Patol** 1995 Jul-Aug;57(4):45-50 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Adrenal nonhyperfunctioning adenoma and nonadenoma: CT attenuation value as discriminative index. Miyake H, et al. **Abdom Imaging** 1995 Nov-Dec;20(6):559-62

SECRETION

A case of deoxycorticosterone-producing adrenal adenoma. Wada N, et al. **Endocr J** 1995 Oct;42(5):637-42 (29 ref.)

SURGERY

Primary non-functioning tumours of the adrenal cortex: an eight-year experience in Turkey. Aydintuğ S, et al. **Eur J Surg** 1996 Apr;162(4):275-8

[Adrenalectomy by posterior approach for benign adrenocortical tumors. Apropos of 12 cases] Brunaud L, et al. **J Chir (Paris)** 1996 Jan;133(1):7-11 (Eng. Abstr.) **(Fre)**

ADENOMA, ALPHA-CELL see **GLUCAGONOMA**

ADENOMA, BASAL CELL see **ADENOMA**

ADENOMA, BASOPHIL

see related
CUSHING'S SYNDROME

ADENOMA, BETA-CELL see **INSULINOMA**

ADENOMA, BILE DUCT

Extrahepatic biliary cystadenomas and cystadenocarcinoma. Report of seven cases and review of the literature. Davies W, et al. **Ann Surg** 1995 Nov;222(5):619-25 (20 ref.)

DIAGNOSIS

Hepatobiliary cystadenoma protruding into the common bile duct, mimicking complicated hydatid cyst of the liver. Report of a case. Gadzijev E, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):1008-10

[A giant unifocal biliary cystadenoma: a chance finding in a young asymptomatic athlete] Busoni F, et al. **Radiol Med (Torino)** 1996 Apr;91(4):480-2 (12 ref.) **(Ita)**

PATHOLOGY

Hepatobiliary cystadenoma. Adam YG, et al. **South Med J** 1995 Nov;88(11):1140-3

ULTRASONOGRAPHY

Adenoma of the papilla of Vater: a possible role for intraductal ultrasound (IDUS). Menzel J, et al. **Z Gastroenterol** 1995 Sep;33(9):539-42

VETERINARY

Cholangioma in a goat. Puette M, et al. **J Vet Diagn Invest** 1995 Oct;7(4):574-5

Biliary cystadenoma of cats. Adler R, et al. **Vet Pathol** 1995 Jul;32(4):415-8 (23 ref.)

ADENOMA, CHROMOPHOBE

COMPLICATIONS

A case of central pontine myelinolysis after surgical removal of a pituitary tumor. Nakano H, et al. **Surg Neurol** 1996 Jul;46(1):32-6

DIAGNOSIS

[Cystic ectopic pituitary adenoma: report of a case] Akimoto J, et al. **No To Shinkei** 1995 Nov;47(11):1092-7 (12 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Intracranial dissemination of a pituitary adenoma: presentation as an unusual mass in the cerebellopontine angle [letter] Depper MH, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1500-1

SURGERY

Expanding intracerebral hematoma from pituitary adenoma: case report. Wakai S, et al. **Neurosurgery** 1995 Oct; 37(4):807-8; discussion 808-9 (2 ref.)

A case of central pontine myelinolysis after surgical removal of a pituitary tumor. Nakano H, et al. **Surg Neurol** 1996 Jul;46(1):32-6

[Surgery of hypophyseal tumors via lateral rhinotomy. Reduced risk of recurrence and the impact on vision] Petruson B, et al. **Lakartidningen** 1996 Jun 12; 93(24):2337-40 **(Swe)**

ADENOMA, EOSINOPHILIC see **ADENOMA, ACIDOPHIL**

ADENOMA, FOLLICULAR see **ADENOMA**

ADENOMA, HEPATOCELLULAR see **ADENOMA, LIVER CELL**

ADENOMA, ISLET CELL

COMPLICATIONS

Pancreatic duct stricture caused by islet cell tumors. Heller SJ, et al. **Am J Gastroenterol** 1996 Jan;91(1):147-9 (15 ref.)

Pancreatitis associated with neuroendocrine (islet cell) tumors of the pancreas. Mao C, et al. **Am J Surg** 1996 Jun;171(6):562-4

DIAGNOSIS

Islet cell tumors of the pancreas: pathologic-imaging correlation among size, necrosis and cysts, calcification, malignant behavior, and functional status. Buetow PC, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1175-9

[Endocrine pancreatic tumors] Goretzki PE, et al. **Ther Umsch** 1996 May;53(5):408-12 (18 ref.) (Eng. Abstr.) **(Ger)**

[A case study of nonfunctioning islet cell tumor in patient with splenic tumor and increased AFP] Zeki S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May;93(5):382-7 (20 ref.) **(Jpn)**

DRUG THERAPY

Deleterious effect of formycin A on tumor islet cells. Rasschaert J, et al. **Biochem Mol Med** 1995 Apr; 54(2):138-41

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. di Bartolomeo M, et al. **Cancer** 1996 Jan 15;77(2):402-8

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Arnold R, et al. **Gut** 1996 Mar;38(3):430-8

Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Parangi S, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2002-7

METABOLISM

mRNA profiling of rat islet tumors reveals nkx 6.1 as a beta-cell-specific homeodomain transcription factor. Jensen J, et al. **J Biol Chem** 1996 Aug 2;271(31):18749-58

Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Christofori G, et al. **Mol Endocrinol** 1995 Dec;9(12):1760-70

PATHOLOGY

A pancreatic endocrine tumor arising within a serous cystadenoma of the pancreas. Keel SB, et al. **Am J Surg Pathol** 1996 Apr;20(4):471-5

Pleomorphic nonfunctioning islet cell tumor of the pancreas. Taniguchi K, et al. **Int J Pancreatol** 1995 Feb;17(1):83-9

Duct-acinar-islet cell tumor of the pancreas. Okada Y, et al. **Pathol Int** 1995 Sep;45(9):669-76

Development of colonic and pancreatic endocrine tumours in mice expressing a glucagon-SV40 T antigen transgene. Asa SL, et al. **Virchows Arch** 1996 Mar;427(6):595-606

RADIOGRAPHY

Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. Van Hoe L, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1437-9

RADIONUCLIDE IMAGING

Octreotide scintigraphy. A new method for diagnosing pancreatic tumors [editorial; comment] Merrell. **Ann Surg** 1996 Aug;224(2):117-8. Comment on: Ann Surg 1996 Aug;224(2):119-24.

The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors [see comments] van Eijck CH, et al. **Ann Surg** 1996 Aug;224(2):119-24. Comment in: Ann Surg 1996 Aug;224(2):117-8.

SECRETION

Role of surgery in management of adrenocorticotropic hormone-producing islet cell tumors of the pancreas. Amikura K, et al. **Surgery** 1995 Dec;118(6):1125-30

SURGERY

Role of surgery in management of adrenocorticotropic hormone-producing islet cell tumors of the pancreas. Amikura K, et al. **Surgery** 1995 Dec;118(6):1125-30

[Is preoperative site diagnosis in organic hyperinsulinism from the viewpoint of the surgeon still necessary today? Results of a consecutive series and analysis of the literature] Böttger T, et al. **Chirurg** 1996 Mar;67(3):268-72 (17 ref.) (Eng. Abstr.) **(Ger)**

[Progress in pancreatic endocrine tumor surgery: with special reference to the Zollinger-Ellison syndrome] Imamura M. **Nippon Shokakibyo Gakkai Zasshi** 1995 Dec;92(12):1905-10 (10 ref.) **(Jpn)**

ULTRASONOGRAPHY

Utility of endoscopic ultrasonography with color Doppler function for the diagnosis of islet cell tumor. Ueno N, et al. **Am J Gastroenterol** 1996 Apr;91(4):772-6

ADENOMA, LIVER CELL

[Hepatic tumors resembling hepatocellular carcinoma] Kojiro M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):374-7 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

[The regression of a hepatocellular adenoma after the withdrawal of hormonal contraception] Daldrup HE, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):449-51 (12 ref.) **(Ger)**

DIAGNOSIS

Case report: hepatic adenoma with nodule-in-nodule appearance: CT and MR findings. Matsui M, et al. **Clin Radiol** 1996 Sep;51(9):662-4

Management of focal nodular hyperplasia and hepatocellular

adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Cherqui D, et al. **Hepatology** 1995 Dec;22(6):1674–81

Liver cell adenoma in a young man with elevated serum PIVKA-II level. Uto H, et al. **J Gastroenterol** 1996 Jun; 31(3):441–5

Hepatic adenomatosis. Arsenault TM, et al. **Mayo Clin Proc** 1996 May;71(5):478–80

PATHOLOGY

Hepatic adenoma in the pediatric age group. Clinicopathological observations and assessment of cell proliferative activity. Resnick MB, et al. **Am J Surg Pathol** 1995 Oct;19(10):1181–90

Benign myxoid hepatocellular tumor: a variant of liver cell adenoma. Galassi A, et al. **Liver** 1995 Oct;15(5):233–5

RADIOGRAPHY

Hepatocellular adenoma. al-Otaibi L, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1426 (6 ref.)

RADIONUCLIDE IMAGING

Hepatocellular adenoma case report with Tc-99m SC uptake and radiologic correlation. Davis DC, et al. **Clin Nucl Med** 1996 Jan;21(1):8–10

SURGERY

Laparoscopic anatomical (hepatic) left lateral segmentectomy–technical aspects. Azagra JS, et al. **Surg Endosc** 1996 Jul;10(7):758–61

Limited laparoscopic liver resection of benign tumors guided by laparoscopic ultrasonography: report of two cases. Cuesta MA, et al. **Surg Laparosc Endosc** 1995 Oct; 5(5):396–401

ADENOMA, MICROCYSTIC see **ADENOMA**

ADENOMA, MONOMORPHIC see **ADENOMA**

ADENOMA, OXYPHILIC

COMPLICATIONS

Bilateral renal oncocytomatosis in a patient with renal failure. Israeli RS, et al. **Urology** 1995 Dec;46(6):873–5 (15 ref.)

DIAGNOSIS

Renal oncocytomatosis. Katz DS, et al. **Am J Kidney Dis** 1996 Apr;27(4):579–82 (19 ref.)

Renal oncocytoma mimicking hemorrhagic renal cyst. Sekido N, et al. **Int J Urol** 1995 Nov;2(5):336–8

Case report. Adrenocortical oncocytoma: CT and MRI findings. Gandras EJ, et al. **J Comput Assist Tomogr** 1996 May–Jun;20(3):407–9

Renal adenoma and oncocytoma. Licht MR. **Semin Urol Oncol** 1995 Nov;13(4):262–6 (60 ref.)

EPIDEMIOLOGY

Morbidity and mortality in follicular thyroid cancer. DeGroot LJ, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):2946–53

GENETICS

Fluorescence in situ hybridization analysis of renal oncocytoma reveals frequent loss of chromosomes Y and 1 [see comments] Brown JA, et al. **J Urol** 1996 Jul; 156(1):31–5. Comment in: J Urol 1996 Jul;156(1):40.

Biological properties of renal oncocytoma cells in culture. Hawkins NJ, et al. **Urol Int** 1996;56(2):69–74

METABOLISM

Coordinate expression of nuclear and mitochondrial genes involved in energy production in carcinoma and oncocytoma. Heddi A, et al. **Biochim Biophys Acta** 1996 Aug 23;1316(3):203–9

Biological properties of renal oncocytoma cells in culture. Hawkins NJ, et al. **Urol Int** 1996;56(2):69–74

PATHOLOGY

Papillary Hürthle cell tumor of thyroid: report of a case with a cytomorphologic approach to diagnosis. Dzięcioł J, et al. **Acta Cytol** 1996 Mar–Apr;40(2):311–4

Renal oncocytoma. Pathological evaluation and clinical implications. Muzzonigro G, et al. **Arch Ital Urol Androl** 1996 Apr;68(2):107–13

Pathologic quiz case 2. Oncocytic cyst of the larynx. Kleidermacher P, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec; 121(12):1430–1, 1433 (5 ref.)

Fine needle aspiration (FNA)-induced necrosis of tumours of the thyroid. Ramp U, et al. **Cytopathology** 1995 Aug; 6(4):248–54 (13 ref.)

Soft tissue oncocytoma. Polk P, et al. **Hum Pathol** 1996 Feb; 27(2):206–8

Renal oncocytoma containing "chromophobe" cells. Noguchi S, et al. **Int J Urol** 1995 Sep;2(4):279–80

Hürthle cell adenoma of the thyroid: in 32 consecutive cases. Guadagni S, et al. **J R Coll Surg Edinb** 1996 Aug; 41(4):246–9

Renal oncocytoma: magnetic resonance imaging characteristics. Harmon WJ, et al. **J Urol** 1996 Mar; 155(3):863–7

Renal oncocytoma in a short-term renal transplant patient [letter; comment] Turney JH, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):395–6. Comment on: Nephrol Dial Transplant 1995;10(4):560–2.

Pulmonary oncocytoma: report of a case in conjunction with an immunohistochemical and ultrastructural study. Tashiro Y, et al. **Pathol Int** 1995 Jun;45(6):448–51

Null cell adenomas and oncocytomas of the pituitary gland. Holm R. **Pathol Res Pract** 1995 May;191(4):348–52 (38 ref.)

Oxyphil cell adenoma (oncocytoma) of the lacrimal caruncle: a case report. Dini M, et al. **Tumori** 1996 May–Jun; 82(3):276–9

[Oncocytoma of the nose. A case report and review of the literature] Förster C, et al. **Pathologe** 1995 Nov;16(6):431–3 (12 ref.) (Eng. Abstr.) **(Ger)**

[Immunohistochemistry: another criterion for typing oncocytomas of the salivary gland. A case report] Gálvez J, et al. **Acta Otorrinolaringol Esp** 1995 Nov–Dec; 46(6):462–4 (Eng. Abstr.) **(Spa)**

[Synchronous bilateral renal oncocytoma] Sánchez-Chapado M, et al. **Arch Esp Urol** 1995 Nov;48(9):909–13 (35 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

[Radiological diagnosis of renal oncocytoma] Sasaki S, et al. **Hinyokika Kiyo** 1995 Sep;41(9):731–5 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Renal oncocytoma: preoperative diagnosis using technetium 99m sestamibi imaging. Gormley TS, et al. **Urology** 1996 Jul;48(1):33–9

SURGERY

Management considerations in Hürthle cell carcinoma. Azadian A, et al. **Surgery** 1995 Oct;118(4):711–4; discussion 714–5 (23 ref.)

ULTRASTRUCTURE

Malignant oncocytoma of the lacrimal sac: ultrastructure and immunocytochemistry. Tomic S, et al. **Ear Nose Throat J** 1995 Oct;74(10):717–20

ADENOMA, PAPILLARY see **ADENOMA**

ADENOMA, PLEOMORPHIC

A case report of metachronous salivary gland neoplasia [letter] Shaw RJ. **Br J Oral Maxillofac Surg** 1996 Feb; 34(1):135

Chondroid syringoma of the abdominal wall. A case report and review of the literature. Sliwa-Hähnle K, et al. **S Afr J Surg** 1996 Feb;34(1):46–8 (15 ref.)

[Pleomorphic adenoma of the trachea] Carlsson M. **Ugeskr Laeger** 1996 Jun 17;158(25):3622–3 (Eng. Abstr.) **(Dan)**

[Metastasizing pleomorphic adenomas. Clinical and cytometric analysis] Junquera Gutiérrez LM, et al. **Rev Stomatol Chir Maxillofac** 1996;97(1):26–31 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Analysis of the interdependent localization of vimentin and microtubules in neoplastic myoepithelial cells. Jaeger RG, et al. **Cell Motil Cytoskeleton** 1995;32(4):289–98

The significance of PCNA and p53 protein in some oral tumors. Tsuji T, et al. **Int J Oral Maxillofac Surg** 1995 Jun;24(3):221–5

Parathyroid hormone-related peptide: immunolocalisation in normal salivary glands and in pleomorphic adenomas. Sunardhi-Widyaputra S, et al. **Pathol Res Pract** 1996 Jan; 192(1):15–9

CLASSIFICATION

Multiple tumours of the salivary glands—terminology and nomenclature. Seifert G, et al. **Eur J Cancer B Oral Oncol** 1996 Jan;32B(1):3–7 (105 ref.)

DIAGNOSIS

Basal cell (monomorphic) and minimally pleomorphic adenomas of the salivary glands. Distinction from the solid (anaplastic) type of adenoid cystic carcinoma in fine-needle aspiration. Stanley MW, et al. **Am J Clin Pathol** 1996 Jul; 106(1):35–41 (35 ref.)

GENETICS

Mapping of the translocation breakpoints of primary pleomorphic adenomas and lipomas within a common region of chromosome 12. Wanschura S, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):39–45

Regional fine mapping of the multiple-aberration region involved in uterine leiomyoma, lipoma, and pleomorphic adenoma of the salivary gland to 12q15. Wanschura S, et al. **Genes Chromosomes Cancer** 1995 Sep;14(1):68–70

Molecular characterization of a novel cancer cell line established from human carcinoma in pleomorphic adenoma (CaPA-4). Fujioka M, et al. **Int J Cancer** 1996 Jul 17;67(2):204–10

A fluorescence in situ hybridization (FISH) analysis with centromere-specific DNA probes of chromosomes 3 and 17 in pleomorphic adenomas and adenoid cystic carcinomas. Li X, et al. **J Oral Pathol Med** 1995 Oct; 24(9):398–401

METABOLISM

Radioimmunological and immunohistochemical study of carcinoembryonic antigen in pleomorphic adenoma and mucoepidermoid carcinoma of the salivary glands. Angelov A, et al. **Gen Diagn Pathol** 1996 Mar;141(3–4):229–34

[A study on expression of epidermal growth factor receptor in pleomorphic adenoma of lacrimal gland] Zheng L, et al. **Chung Hua Yen Ko Tsa Chih** 1995 May;31(3):212–4 (Eng. Abstr.) **(Chi)**

[Immunohistochemical localization of Type I, II and IX collagens in pleomorphic adenoma of human salivary glands] Luna MG. **Kokubyo Gakkai Zasshi** 1996 Mar; 63(1):122–30 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Benign mixed tumor (pleomorphic adenoma) of the lacrimal gland in a 6-year-old boy. Faktorovich EG, et al. **Am J Ophthalmol** 1996 Sep;122(3):446–7

Thomsen-Friedenreich (T) antigen as marker of myoepithelial and basal cells in the parotid gland, pleomorphic adenomas and adenoid cystic carcinomas. An immunohistological comparison between T and sialosyl-T antigens, alpha-smooth muscle actin and cytokeratin 14. Therkildsen MH, et al. **APMIS** 1995 Jul–Aug; 103(7–8):558–67

Malignant pleomorphic parotid adenoma with inflammatory cutaneous metastasis [letter] Soler E, et al. **Br J Dermatol** 1996 Jan;134(1):190–2

Demonstration of monoclonal origin of human parotid gland pleomorphic adenoma. Noguchi S, et al. **Cancer** 1996 Feb 1;77(3):431–5

Fine-needle sampling of salivary gland lesions. I. Cytology and histology correlation of 412 cases of pleomorphic adenoma. Klijanienko J, et al. **Diagn Cytopathol** 1996 May; 14(3):195–200

Cytomorphology of a mixed pigmented/nonpigmented pleomorphic adenoma of the ciliary body: a diagnostic pitfall in the evaluation of intraocular tumors. Laver NV, et al. **Diagn Cytopathol** 1996 May;14(3):259–62

Cell kinetics of pleomorphic adenomas of the parotid gland. Matturri L, et al. **Eur J Cancer B Oral Oncol** 1996 May; 32B(3):154–7

Pleomorphic adenoma with extensive lipometaplasia. Ng WK, et al. **Histopathology** 1995 Sep;27(3):285–8

Mixed tumour of breast—report of a rare case. Mathur DR, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S47–8

Pleomorphic adenoma of an unusual size in the deep lobe of the parotid gland. Uslu SS, et al. **Int J Pediatr Otorhinolaryngol** 1995 Oct;33(2):163–9

Metastatic pleomorphic adenoma. Olsha O, et al. **Invasion Metastasis** 1995;15(3–4):163–6

Giant mixed tumor of the face. Kakuta M, et al. **J Dermatol** 1996 May;23(5):369–71

Heterotopic pleomorphic adenoma of the external nose. Badia L, et al. **J Laryngol Otol** 1996 Apr;110(4):376–8

Carcinoma ex-pleomorphic adenoma of the nasal cavity: a report of two cases. Cho KJ, et al. **J Laryngol Otol** 1995 Jul;109(7):677–9

Seeding of a parotid pleomorphic adenoma. Commins DJ, et al. **J Laryngol Otol** 1995 Jul;109(7):671–3

Pleomorphic adenoma of the external auditory canal: a case report and review of the literature. Haraguchi H, et al. **J Laryngol Otol** 1996 Jan;110(1):52–6 (24 ref.)

The deep parotid lymph nodes: an anatomical and oncological study. Pisani P, et al. **J Laryngol Otol** 1996 Feb;110(2):148–50

Pleomorphic adenoma of the sublingual gland: report of a case. Okura M, et al. **J Oral Maxillofac Surg** 1996 Mar; 54(3):363–6

Hyaline cell-rich chondroid syringoma: epithelial nature of the hyaline cells. Nakayama H, et al. **Jpn J Clin Oncol** 1996 Aug;26(4):237–42

Myoepithelial carcinoma in pleomorphic adenoma of salivary gland type, occurring in the mandible of an infant. Asai S, et al. **Pathol Int** 1995 Sep;45(9):677–83

Pleomorphic adenoma of the breast: case report and review of the literature. Narita T, et al. **Pathol Int** 1995 Jun; 45(6):441–7 (40 ref.)

[Pleomorphic adenoma of the minor salivary gland] Campos A, et al. **Acta Otorrinolaringol Esp** 1995 Jul–Aug; 46(4):331–4 (Eng. Abstr.) **(Spa)**

[Paranasal sinus pleomorphic adenoma] Sánchez-Alcón MD, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):71–3 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Pleomorphic adenoma and adenoid-cystic carcinoma of salivary glands: immunohistochemical assessment of proliferative activity in comparison with flow-cytometric study. Daniele E, et al. **Cell Prolif** 1996 Mar;29(3):153–62

ADENOMA, PLEOMORPHIC

RADIOGRAPHY

[Primary pleomorphic adenoma of the principal paranasal sinus] Flöttmann T, et al. **HNO** 1995 Oct;43(10):624–6 (Eng. Abstr.) **(Ger)**

SURGERY

Resection of a recurrent nasal tumor via Le Fort I osteotomy approach. Alvi A, et al. **Am J Otolaryngol** 1995 Nov–Dec; 16(6):418–21

Giant pleomorphic adenoma of the parotid. Lomeo PE. **Ear Nose Throat J** 1996 Jul;75(7):402

[Long-term results of total conservative parotidectomy for pleomorphic adenoma] Laccourreye O, et al. **Presse Med** 1995 Nov 4;24(33):1563–5 (Eng. Abstr.) **(Fre)**

[Iatrogenic lesions of the facial nerve during parotid surgery for pleomorphic adenoma] Colella G, et al. **Minerva Stomatol** 1995 Dec;44(12):591–6 (40 ref.) (Eng. Abstr.) **(Ita)**

[A case of palatal polymorphous low grade adenocarcinoma] Ishimoto S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Jul;98(7):1092–6 (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Pleomorphic adenoma of the bronchus. Sweeney EC, et al. **J Clin Pathol** 1996 Jan;49(1):87–9

ADENOMA, PROLACTIN-SECRETING, PITUITARY see **PROLACTINOMA**

ADENOMA, PROSTATIC see **PROSTATIC HYPERPLASIA**

ADENOMA, SWEAT GLAND

Eccrine spiradenoma, not poroma [letter; comment] Beckman B. **Dermatol Surg** 1996 May;22(5):484. Comment on: Dermatol Surg 1995 Nov;21(11):925, 997–8.

BLOOD SUPPLY

Perivascular spaces in eccrine spiradenoma. A clue to its histological diagnosis. van den Oord JJ, et al. **Am J Dermatopathol** 1995 Jun;17(3):266–70

GENETICS

The pathogenesis of familial multiple cylindromas, trichoepitheliomas, milia, and spiradenomas. van der Putte SC. **Am J Dermatopathol** 1995 Jun;17(3):271–80

PATHOLOGY

Eccrine syringofibroadenoma. A clear-cell variant. Fretzin DF, et al. **Am J Dermatopathol** 1995 Dec;17(6):591–3

Giving credit where it is due [letter] Rosai J. **Am J Dermatopathol** 1996 Apr;18(2):218

Carcinosarcoma arising in eccrine spiradenoma of the breast. Report of a case and review of the literature. Saboorian MH, et al. **Arch Pathol Lab Med** 1996 May;120(5):501–4 (19 ref.)

Eccrine syringofibroadenoma. Report of a case and immunohistochemical study of keratin expression. Ohnishi T, et al. **Br J Dermatol** 1995 Sep;133(3):449–54

Multiple tumors of follicular infundibulum with sweat duct differentiation. Horn TD, et al. **J Cutan Pathol** 1995 Jun; 22(3):281–7

A single lesion demonstrating features of eccrine poroma and poroid hidradenoma. Misago N, et al. **J Dermatol** 1995 Oct; 22(10):773–9

[Multiple eccrine spiradenoma. Histological association with dermal cylindroma] Kawakubo Y, et al. **Hautarzt** 1995 Sep; 46(9):651–5 (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Eccrine syringofibroadenoma (Mascaro). An ultrastructural and immunohistochemical study. Ishida-Yamamoto A, et al. **Am J Dermatopathol** 1996 Apr;18(2):207–11

ADENOMA, TRABECULAR see **ADENOMA**

ADENOMA, VILLOUS

COMPLICATIONS

Gall bladder tumour, choledochal cyst and an anomalous pancreatico-biliary junction. Toufeeq Khan TF, et al. **HPB Surg** 1995 Jun;8(3):185–6

Spontaneous peritonitis caused by Streptococcus bovis: search for colonic neoplasia [letter] Ackerman Z, et al. **J Clin Gastroenterol** 1995 Oct;21(3):263

[Adenocarcinoma on villous tumor of the rectum in an adolescent] Chafai S, et al. **Arch Pediatr** 1995 Aug; 2(8):762–5 (Eng. Abstr.) **(Fre)**

[Villous adenoma of the appendix caused acute appendicitis] Guliás Piñeiro A, et al. **Rev Esp Enferm Dig** 1996 Jun; 88(6):435–7 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Photodynamic therapy for Barrett's esophagus: clinical update. Overholt BF, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1719–23

Complete regression of villous adenomas of the colon using piroxicam, a nonsteroidal anti-inflammatory drug. Gowen GF. **Dis Colon Rectum** 1996 Jan;39(1):101–2

EPIDEMIOLOGY

Characteristics of rectosigmoid adenomas as predictors of synchronous advanced proximal colon neoplasms. Papatheodoridis GV, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1809–13

A randomized surveillance study of patients with pedunculated and small sessile tubular and tubulovillous adenomas. The Funen Adenoma Follow-up Study. Jørgensen OD, et al. **Scand J Gastroenterol** 1995 Jul; 30(7):686–92

GENETICS

Aberrant expression of a human mucin gene (MUC5AC) in rectosigmoid villous adenoma. Buisine MP, et al. **Gastroenterology** 1996 Jan;110(1):84–91

PATHOLOGY

Cytologic features of well-differentiated villoglandular adenocarcinoma of the cervix. Ballo MS, et al. **Acta Cytol** 1996 May-Jun;40(3):536–40

Tubular apocrine adenoma with eccrine and apocrine immunophenotypes or papillary tubular adenoma? Tellechea O, et al. **Am J Dermatopathol** 1995 Oct; 17(5):499–505

Villous adenoma of the urinary bladder: a case report. Lin JW, et al. **Chang Keng I Hsueh** 1995 Sep;18(3):266–9

Villous adenoma of ampulla of Vater: a case report. Wu CJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Jul; 56(1):70–4

An association between villous adenomas and mucinous ductal ectasia of the pancreas. Barthet M, et al. **Endoscopy** 1995 Oct;27(8):601–3

Three-dimensional configuration of crypts of different types of colorectal adenomas. Araki K, et al. **Scanning Microsc** 1995 Mar;9(1):149–56; discussion 156–8

RADIOGRAPHY

Ampullary tumour. Leslie KA, et al. **Can J Surg** 1995 Dec; 38(6):478–9

[Degenerative villous adenoma of the intrapancreatic choledochus (letter)] Gainant A, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):850–1 **(Fre)**

SECRETION

[Diagnostic case: intraductal mucinous hypersecreting tumor or intraductal mucinous ectasia] Valette PJ, et al. **J Radiol** 1995 Dec;76(12):1133–5 **(Fre)**

SURGERY

Endoscopic Nd:YAG laser therapy for villous adenomas of the colon and rectum. Hyser MJ, et al. **Am Surg** 1996 Jul; 62(7):577–80; discussion 580–1

Laparoscopic endoluminal gastric surgery. Lai DT, et al. **Aust N Z J Surg** 1996 Jan;66(1):41–2

Vater's papilla and periampullary area villous adenoma: personal experience about nine cases and review of the literature. Motton G, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):448–55 (77 ref.)

Appendiceal intussusception due to an appendiceal malignant polyp--an association in a patient with Peutz-Jeghers syndrome: report of a case. Miyahara M, et al. **Surg Today** 1995;25(9):834–7

[The transphincteric approach excision of rectal villous adenomas] Qiu H, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Mar;33(3):170–2 (Eng. Abstr.) **(Chi)**

[A radical treatment of villous tumors of the duodenum] Zinzindohoué F, et al. **Ann Chir** 1996;50(4):330–2 (Eng. Abstr.) **(Fre)**

[Laparoscopic gastrectomy. A case report] Ablassmaier B, et al. **Chirurg** 1996 Jun;67(6):643–7 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Endorectal ultrasonic detection of malignancy within rectal villous lesions. Adams WJ, et al. **Dis Colon Rectum** 1995 Oct;38(10):1093–6

Adenoma of the papilla of Vater: a possible role for intraductal ultrasound (IDUS). Menzel J, et al. **Z Gastroenterol** 1995 Sep;33(9):539–42

ADENOMATOID TUMOR

Three consecutive cases of adenomatoid tumour of the epididymis: histological considerations and therapeutical implications. Review of the literature. Racioppi M, et al. **Arch Ital Urol Androl** 1996 Apr;68(2):115–9

DIAGNOSIS

Uterine adenomatoid tumors: immunohistochemical characteristics with emphasis on Ber-EP4 immunoreactivity and distinction from adenocarcinoma. Otis CN. **Int J Gynecol Pathol** 1996 Apr;15(2):146–51

PATHOLOGY

Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors. Goldblum J, et al. **Am J Surg Pathol** 1995 Oct;19(10):1124–37

Adenomatoid tumour of the uterus--a case report. Cooper R, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S58–9

Adenomatoid tumor of the female genital tract. Huang CC, et al. **Int J Gynaecol Obstet** 1995 Sep;50(3):275–80

ADENOMATOSIS, FAMILIAL ENDOCRINE see **MULTIPLE ENDOCRINE NEOPLASIA**

ADENOMATOSIS, PULMONARY

VETERINARY

Ovine pulmonary adenomatosis (jaagsiekte) [editorial; comment] Verwoerd DW. **Br Vet J** 1996 Jul;152(4):369–72 . Comment on: Br Vet J 1996 Jul;152(4):395–410.

ADENOMATOSIS, PULMONARY, OVINE see **PULMONARY ADENOMATOSIS, OVINE**

ADENOMATOUS POLYPOSIS COLI

see related
GENES, APC

Association between thyroid cancer of cribriform variant and familial adenomatous polyposis. Hizawa K, et al. **J Clin Pathol** 1996 Jul;49(7):611–3

[Hamartomatous polyposis syndrome] Tamura K, et al. **Nippon Rinsho** 1995 Nov;53(11):2728–33 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Mouse model for familial adenomatous polyposis coli] Ito M, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2668–73 (22 ref.) **(Jpn)**

BLOOD

Serum gastrin levels in patients with colorectal cancer and adenomatous polyps: a prospective study. Mihas AA, et al. **Res Commun Mol Pathol Pharmacol** 1995 Nov; 90(2):301–4

COMPLICATIONS

Diffuse juvenile non-adenomatous polyposis: a rare cause of severe hypoalbuminaemia in childhood. Nicholls S, et al. **Acta Paediatr** 1995 Dec;84(12):1447–8

Chemotherapy for desmoid tumours in association with familial adenomatous polyposis: a report of three cases. Hamilton L, et al. **Can J Surg** 1996 Jun;39(3):247–52 (21 ref.)

Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Giardiello FM, et al. **Gut** 1996 Apr;38(4):578–81

Endoscopic treatment of ampullary adenomas in familial adenomatous polyposis. Bleau BL, et al. **J Clin Gastroenterol** 1996 Apr;22(3):237–41

Mental retardation and colorectal disease: colonoscopic mass screening to determine whether the risk of adenomatous polyposis syndrome is increased in the mentally retarded. Uno Y. **J Gastroenterol Hepatol** 1996 Mar;11(3):275–8

Gastroduodenal polyps in familial adenomatous polyposis. Marcello PW, et al. **Surg Endosc** 1996 Apr;10(4):418–21

[Gas gangrene as presentation of colonic carcinoma in familial adenomatous polyposis] Martín Vieira F, et al. **Gastroenterol Hepatol** 1995 Oct;18(8):425–7 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Frequency of congenital hypertrophy of the retinal pigment epithelium in familial adenomatous polyposis. Olea JL, et al. **Acta Ophthalmol Scand** 1996 Feb;74(1):48–50

Adenomatous polyposis coli presenting as adenocarcinoma of the appendix. Parker GM, et al. **Am J Gastroenterol** 1996 Apr;91(4):801–2

Use of molecular methods in the early diagnosis of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. Khine K, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):64–70 (88 ref.)

[Prognosis in familial adenomatous polyposis. Results from the Polyposis Registry] Bülow C, et al. **Ugeskr Laeger** 1996 Jul 15;158(29):4188–90 (Eng. Abstr.) **(Dan)**

[Contribution of the ophthalmologist to presymptomatic diagnosis of familial adenomatous polyposis (FAP)] Sommer E, et al. **Ophthalmologe** 1995 Dec;92(6):809–16 (Eng. Abstr.) **(Ger)**

[Use of molecular genetics in the early diagnosis of familial adenomatous polyposis] Simko J, et al. **Vnitr Lek** 1996 Mar; 42(3):188–90 (Eng. Abstr.) **(Slo)**

DIET THERAPY

Randomized, double-blinded, placebo-controlled study of effect of wheat bran fiber and calcium on fecal bile acids in patients with resected adenomatous colon polyps [see comments] Alberts DS, et al. **J Natl Cancer Inst** 1996 Jan 17;88(2):81–92. Comment in: J Natl Cancer Inst 1996 Jan 17;88(2):67–9.

DRUG THERAPY

Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Boolbol SK, et al. **Cancer Res** 1996 Jun 1;56(11):2556-60

Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Nugent KP, et al. **Dis Colon Rectum** 1996 Jun;39(6):659-62

Photodynamic therapy for polyps in familial adenomatous polyposis--a pilot study. Mlkvy P, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1160-5

[Treatment with sulindac of adenomatous polyps in familial polyposis] Cerdán FJ, et al. **Rev Esp Enferm Dig** 1995 Aug; 87(8):574-6 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Three secretory phospholipase A(2) genes that map to human chromosome 1P35-36 are not mutated in individuals with attenuated adenomatous polyposis coli. Spirio LN, et al. **Cancer Res** 1996 Mar 1;56(5):955-8

EPIDEMIOLOGY

Centralized registration, prophylactic examination, and treatment results in improved prognosis in familial adenomatous polyposis. Results from the Danish Polyposis Register. Bülow S, et al. **Scand J Gastroenterol** 1995 Oct; 30(10):989-93

Clinical and biologic features of adenomatosis coli in Northern Italy. De Pietri S, et al. **Scand J Gastroenterol** 1995 Aug;30(8):771-9

Polyposis coli, craniofacial exostosis and astrocytoma: the concomitant occurrence of the Gardner's and Turcot syndromes. Koot RW, et al. **Surg Neurol** 1996 Mar; 45(3):213-8

Triple primary malignant neoplasms including a malignant brain tumor: report of two cases and review of the literature. Nagane M, et al. **Surg Neurol** 1996 Mar; 45(3):219-29 (44 ref.)

GENETICS

The genetic background of familial adenomatous polyposis. Linkage analysis, the APC gene identification and mutation screening. Kartheuser A, et al. **Acta Gastroenterol Belg** 1995 Sep-Dec;58(5-6):433-51 (112 ref.)

The technical background of familial adenomatous polyposis. History, epidemiology, diagnosis and treatment. Kartheuser A, et al. **Acta Gastroenterol Belg** 1995 Mar-Apr; 58(2):252-66 (136 ref.)

K-ras mutation in a tubular adenoma originating at an ileostomy in a familial adenomatous polyposis patient. Herring JA, et al. **Am J Gastroenterol** 1996 Mar; 91(3):587-91 (38 ref.)

p53 Protein overexpression in colorectal tumors from patients with familial adenomatous polyposis: is it an early or late event? [see comments] Levi E, et al. **Am J Gastroenterol** 1996 Jan;91(1):11-4. Comment in: Am J Gastroenterol 1996 Jan;91(1):3-6.

Genetic counseling in an extended attenauted familial adenomatous polyposis kindred. Lynch HT, et al. **Am J Gastroenterol** 1996 Mar;91(3):455-9

Genetic mapping of hereditary mixed polyposis syndrome to chromosome 6q. Thomas HJ, et al. **Am J Hum Genet** 1996 Apr;58(4):770-6

Familial segregation in the occurrence and severity of periampullary neoplasms in familial adenomatous polyposis. Sanabria JR, et al. **Am J Surg** 1996 Jan;171(1):136-40; discussion 140-1

Sisters with familial adenomatous polyposis affected with thyroid carcinoma, desmoid tumour and duodenal polyposis. Kashiwagi H, et al. **Br J Surg** 1996 Feb;83(2):228

Colorectal cancer genetics. Closing the gap between genotype and phenotype [editorial; comment] Bufill JA. **Cancer** 1995 Dec 15;76(12):2389-92. Comment on: Cancer 1995 Dec 15;76(12):2427-33.

Cranial desmoid tumor associated with homozygous inactivation of the adenomatous polyposis coli gene in a 2-year-old girl with familial adenomatous polyposis. de Silva DC, et al. **Cancer** 1996 Mar 1;77(5):972-6

Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP [see comments] Lynch HT, et al. **Cancer** 1995 Dec 15;76(12):2427-33. Comment in: Cancer 1995 Dec 15;76(12):2389-92.

Emergent issues in the genetics of intestinal neoplasia. Dove WF, et al. **Cancer Surv** 1995;25:335-55 (98 ref.)

The adenomatous polyposis coli gene of the mouse in development and neoplasia. Dove WF, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:501-8 (43 ref.)

Normal genetic response to gamma irradiation in familial adenomatous polyposis. Brás A, et al. **Eur J Cancer** 1995; 31A(9):1506-10

ApcMin: a mouse model for intestinal and mammary tumorigenesis. Moser AR, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1061-4 (30 ref.)

Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer [see comments] Konishi M, et al. **Gastroenterology** 1996 Aug;111(2):307-17. Comment in: Gastroenterology 1996 Aug;111(2):519-21.

The murine homolog of TB2/DP1, a gene of the familial adenomatous polyposis (FAP) locus. Prieschl EE, et al. **Gene** 1996 Mar 9;169(2):215-8

Presymptomatic diagnosis of familial adenomatous polyposis using intragenic polymorphisms and CA repeats flanking the APC gene. Hayes VM, et al. **Genet Couns** 1996;7(1):1-7

Evidence for a novel exon in the coding region of the adenomatous polyposis coli (APC) gene. Xia L, et al. **Genomics** 1995 Aug 10;28(3):589-91

Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study. Schnitzler M, et al. **Gut** 1996 May;38(5):707-13

Novel germline APC gene mutation in a large familial adenomatous polyposis kindred displaying variable phenotypes. Scott RJ, et al. **Gut** 1996 May;38(5):794

Secretory phospholipase A2 does not appear to be associated with phenotypic variation in familial adenomatous polyposis. Dobbie Z, et al. **Hum Genet** 1996 Sep; 98(3):386-90

Attenuated familial adenomatous polyposis due to a mutation in the 3' part of the APC gene. A clue for understanding the function of the APC protein. Friedl W, et al. **Hum Genet** 1996 May;97(5):579-84

Familial adenomatous polyposis: a submicroscopic deletion at the APC locus in a family with mentally normal patients. Mandl M, et al. **Hum Genet** 1996 Feb;97(2):204-8

A novel coding exon of the human adenomatous polyposis coli gene. Suleková Z, et al. **Hum Genet** 1995 Oct; 96(4):469-71

APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis. van der Luijt RB, et al. **Hum Genet** 1995 Dec;96(6):705-10

Identification of a novel single base insertion in the adenomatous polyposis coli gene. Kotze MJ, et al. **Hum Mutat** 1996;7(1):68-9

Oncogene expression in patients with familial polyposis coli/Gardner's syndrome. Yuwono M, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):89-95

Frequency and histological appearance of adenomas in multiple intestinal neoplasia mice are unaffected by severe combined immunodeficiency (scid) mutation. Dudley ME, et al. **Int J Cancer** 1996 Jan 17;65(2):249-53

Familial juvenile polyposis: patterns of recurrence and implications for surgical management. Scott-Conner CE, et al. **J Am Coll Surg** 1995 Nov;181(5):407-13

The adenomatous polyposis coli gene and human cancers. Nakamura Y. **J Cancer Res Clin Oncol** 1995; 121(9-10):529-34 (63 ref.)

Presymptomatic diagnosis in Portuguese FAP families using intragenic RFLPs and (CA)n flanking markers by fluorescence based semiautomated DNA analysis. Almeida R, et al. **J Med Genet** 1996 Mar;33(3):244-7

Genotype-phenotype correlations of new causative APC gene mutations in patients with familial adenomatous polyposis. Bunyan DJ, et al. **J Med Genet** 1995 Sep; 32(9):728-31

Correlation between the development of extracolonic manifestations in FAP patients and mutations beyond codon 1403 in the APC gene. Dobbie Z, et al. **J Med Genet** 1996 Apr;33(4):274-80

Rapid detection of rare variants and common polymorphisms in the APC gene by PCR-SSCP for presymptomatic diagnosis and showing allele loss. Gayther SA, et al. **J Med Genet** 1995 Jul;32(7):568-71

A novel deletion at codon 441 of the APC gene associated with ophthalmic lesions (CHRPE) in a South African family. Grobbelaar JJ, et al. **J Med Genet** 1996 May; 33(5):384-6

Parents' responses to predictive genetic testing in their children: report of a single case study. Michie S, et al. **J Med Genet** 1996 Apr;33(4):313-8

A modifying locus for familial adenomatous polyposis may be present on chromosome 1p35-p36. Tomlinson IP, et al. **J Med Genet** 1996 Apr;33(4):268-73

Developing strategies for intervention/prevention trials of individuals at risk of hereditary colon cancer. Blackburn GL, et al. **J Natl Cancer Inst Monogr** 1995;(17):107-10

Gene tests and counseling for colorectal cancer risk: lessons from familial polyposis. Petersen GM, et al. **J Natl Cancer Inst Monogr** 1995;(17):67-71

The Canadian Familial Adenomatous Polyposis Registry: past, present and future. Stern HS. **J R Soc Med** 1996 Mar; 89(3):153P-4P (10 ref.)

Familial adenomatous polyposis: an update. Wyman A, et al. **J R Soc Med** 1996 Apr;89(4):224P-8P (26 ref.)

Adenomatous polyposis coli and translational medicine [comment] Geraghty J. **Lancet** 1996 Aug 17;348(9025):422 . Comment on: Lancet 1996 Aug 17;348(9025):433-5.

Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis [see comments] Vasen HF, et al. **Lancet** 1996 Aug 17;348(9025):433-5. Comment in: Lancet 1996 Aug 17;348(9025):422.

Impact of molecular genetics on the management of familial adenomatous polyposis. Jass JR, et al. **N Z Med J** 1996 Aug 9;109(1027):285-6 (32 ref.)

Juvenile nasopharyngeal angiofibroma and familial adenomatous polyposis: an association? Ferouz AS, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):435-9

Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Novelli MR, et al. **Science** 1996 May 24; 272(5265):1187-90

Multistep carcinogenesis in colorectal cancers. Takami K, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:190-6 (28 ref.)

Screening by genomic linkage studies and mutation analysis of hereditary adenomatous polyposis coli: usefulness for clinical practice. Karner-Hanusch J, et al. **World J Surg** 1996 Jun;20(5):578-83; discussion 583-4

[Hereditary colorectal cancer (editorial)] Bülow S, et al. **Ugeskr Laeger** 1996 May 20;158(21):2959 **(Dan)**

[Genetics of colorectal cancers (editorial)] Pocard M, et al. **Ann Chir** 1996;50(3):211-6 (19 ref.) **(Fre)**

[Familial adenomatous polyposis] Constanda MT, et al. **Schweiz Rundsch Med Prax** 1996 Aug 27;85(35):1052-7 (61 ref.) (Eng. Abstr.) **(Fre)**

[Desmoid tumors in patients with familial adenomatous polyposis (FAP). Clinical and therapeutic observations from the Heidelberg polyposis register] Kadmon M, et al. **Chirurg** 1995 Oct;66(10):997-1005 (Eng. Abstr.) **(Ger)**

[Perifollicular fibroma of the skin and colonic polyps: Hornstein-Knickenberg syndrome] Schachtschabel AA, et al. **Hautarzt** 1996 Apr;47(4):304-6 (Eng. Abstr.) **(Ger)**

[K-ras gene mutations in adenomas from familial adenomatous polyposis] Ohki S, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:154-8 (Eng. Abstr.) **(Jpn)**

[Familial polyposis coli] Watanabe T, et al. **Nippon Rinsho** 1995 Nov;53(11):2722-7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Mouse model for familial adenomatous polyposis coli and APC gene] Ito M, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2035-44 (22 ref.) **(Jpn)**

[Juvenile polyposis in 2 patients of the same family] Alcaín G, et al. **Gastroenterol Hepatol** 1995 Oct;18(8):417-9 (Eng. Abstr.) **(Spa)**

HISTORY

[Scientific raisins from 125 years SMW (Swiss Medical Weekly). Familial colon carcinoma. A pedigree from canton Aargau. 1926. (classical article)] Mathis M. **Schweiz Med Wochenschr** 1995 Dec 16;125(50):2449-54 **(Ger)**

IMMUNOLOGY

Expression of variant CD44-messenger RNA in colorectal adenocarcinomas and adenomatous polyps in humans. Imazeki F, et al. **Gastroenterology** 1996 Feb;110(2):362-8

METABOLISM

Overexpression of p53 in duodenal tumours in patients with familial adenomatous polyposis. Kashiwagi H, et al. **Br J Surg** 1996 Feb;83(2):225-8

Alteration of beta-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Inomata M, et al. **Cancer Res** 1996 May 1;56(9):2213-7

Differences in the levels and pattern of DNA-adduct labelling in human cell lines MCL-5 and CCRF, proficient or deficient in carcinogen-metabolism, treated in vitro with bile from familial adenomatous polyposis patients and from unaffected controls. Scates DK, et al. **Carcinogenesis** 1996 Apr;17(4):707-13

Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Nugent KP, et al. **Dis Colon Rectum** 1996 Jun;39(6):659-62

Caffeine phenotyping in patients with familial adenomatous polyposis may shed light on sporadic colon cancer and acetylator status [letter; comment] Welfare MR, et al. **Gut** 1996 Jan;38(1):153. Comment on: Gut 1995 Feb;36(2):251-4.

PATHOLOGY

Growth factor expression and proliferation kinetics in periampullary neoplasms in familial adenomatous polyposis. Resnick MB, et al. **Cancer** 1995 Jul 15;76(2):187-94

Flat adenoma as a precursor of colorectal carcinoma in hereditary nonpolyposis colorectal carcinoma. Watanabe T, et al. **Cancer** 1996 Feb 15;77(4):627-34

Upper intestinal surveillance in familial adenomatous polyposis. Debinski HS, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1149-53

Serrated adenomatous polyposis: a new syndrome? [editorial; comment] Burt RW, et al. **Gastroenterology** 1996 Mar; 110(3):950-2. Comment on: Gastroenterology 1996 Mar;110(3):748-55.

Colorectal polyp counts and cancer risk in familial adenomatous polyposis. Debinski HS, et al. **Gastroenterology** 1996 Apr;110(4):1028-30

Apoptosis and proliferation: the balance [letter; comment] Khosraviani K, et al. **Gastroenterology** 1996 Apr; 110(4):1323-4. Comment on: Gastroenterology 1995 Sep;109(3):994-8.

Serrated adenomatous polyposis in humans [see comments] Torlakovic E, et al. **Gastroenterology** 1996 Mar; 110(3):748-55. Comment in: Gastroenterology 1996 Mar;110(3):950-2.

Intraoperative small bowel enteroscopy in familial adenomatous and familial juvenile polyposis. Rodriguez-Bigas MA, et al. **Gastrointest Endosc** 1995 Dec; 42(6):560-4

Leucocyte typing, cytokine expression, and epithelial turnover in the ileal pouch in patients with ulcerative colitis and familial adenomatous polyposis. Goldberg PA, et al. **Gut** 1996 Apr;38(4):549-53

ADENOMATOUS POLYPOSIS COLI

Cell proliferation and polyposis [letter; comment] **Jass JR. Gut** 1995 Sep;37(3):446–7. Comment on: Gut 1995 Mar;36(3):391–4.

In situ detection of enterocytic apoptosis in normal colonic mucosa and in familial adenomatous polyposis. Sträter J, et al. **Gut** 1995 Dec;37(6):819–25

Effect of longterm placebo controlled calcium supplementation on sigmoidal cell proliferation in patients with sporadic adenomatous polyps. Weisgerber UM, et al. **Gut** 1996 Mar;38(3):396–402

Proliferative characteristics of differentiated cells in familial adenomatous polyposis-associated duodenal adenomas. Turner JR, et al. **Hum Pathol** 1996 Jan;27(1):63–9

Establishment and characterization of a human colon cancer cell line, OUMS-23, from a patient with familial adenomatous polyposis. Miyazaki M, et al. **J Cancer Res Clin Oncol** 1996;122(2):95–101

Familial adenomatous polyposis and lung cancer. Wong RP, et al. **J Surg Oncol** 1995 Nov;60(3):213–4 (11 ref.)

Epithelial proliferation and differentiation in flat duodenal mucosa of patients with familial adenomatous polyposis. Odze RD. **Mod Pathol** 1995 Aug;8(6):648–53

PREVENTION & CONTROL

The protocol for a European double-blind trial of aspirin and resistant starch in familial adenomatous polyposis: the CAPP study. Concerted Action Polyposis Prevention. Burn J, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1385–6

Calcium chemoprevention in colorectal cancer. Duris I, et al. **Hepatogastroenterology** 1996 Jan-Feb;43(7):152–4

Developing strategies for intervention/prevention trials of individuals at risk of hereditary colon cancer. Blackburn GL, et al. **J Natl Cancer Inst Monogr** 1995;(17):107–10

[Effectiveness and costs of screening colonoscopy] Neuhaus H. **Fortschr Med** 1995 Sep 30;113(27):381–4 (Eng. Abstr.) **(Ger)**

SURGERY

Pouch-anal cancer after restorative proctocolectomy for familial adenomatous polyposis. von Herbay A, et al. **Am J Surg Pathol** 1996 Aug;20(8):995–9

Colorectal cancer: surgical prophylaxis and chemoprevention [see comments] Nugent KP. **Ann R Coll Surg Engl** 1995 Sep;77(5):372–6 (55 ref.). Comment in: Ann R Coll Surg Engl 1996 Mar;78(2):154–5.

Long-term results after colectomy and ileoanal pull-through procedure in children. Fonkalsrud EW. **Arch Surg** 1996 Aug;131(8):881–5; discussion 885–6

Carcinoma in an ileoanal pouch after restorative proctocolectomy for familial adenomatous polyposis. Bassuni MM, et al. **Br J Surg** 1996 Apr;83(4):506

Adenomatous polyps in the anal transitional zone after ileal pouch-anal anastomosis for familial adenomatous polyposis: treatment by transanal mucosectomy and ileal pouch advancement. Malassagne B, et al. **Br J Surg** 1995 Dec;82(12):1634

Can we safely delay or avoid prophylactic colectomy in familial adenomatous polyposis? Phillips RK, et al. **Br J Surg** 1996 Jun;83(6):769–70

Choice of prophylactic surgery for the large bowel component of familial adenomatous polyposis. Setti-Carraro P, et al. **Br J Surg** 1996 Jul;83(7):885–92 (88 ref.)

Flat adenoma as a precursor of colorectal carcinoma in hereditary nonpolyposis colorectal carcinoma. Watanabe T, et al. **Cancer** 1996 Feb 15;77(4):627–34

Pouch polyposis after ileal pouch-anal anastomosis for familial adenomatous polyposis: report of a case. Church JM, et al. **Dis Colon Rectum** 1996 May;39(5):584–6

Recurrent polyps in the ileo-anal pouch or rectum in familial adenomatous polyposis. Tytgat GN, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1154–9 (45 ref.)

Risk of cancer development in the rectal remnant of patients with familial adenomatous polyposis/Gardner's syndrome. Matsumoto T, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):765–70

A simplified method for mucosal proctectomy in children. Bickler SW, et al. **J Am Coll Surg** 1996 Mar;182(3):268–9

Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis [see comments] Vasen HF, et al. **Lancet** 1996 Aug 17;348(9025):433–5. Comment in: Lancet 1996 Aug 17;348(9025):422.

Surgical options for familial adenomatous polyposis. Ambroze WL Jr, et al. **Semin Surg Oncol** 1995 Nov-Dec; 11(6):423–7 (27 ref.)

Ileal pouch-anal anastomosis as the first choice operation in patients with familial adenomatous polyposis: a ten-year experience. Kartheuser AH, et al. **Surgery** 1996 Jun; 119(6):615–23

Treatment of malignant polyps. Spinelli P, et al. **Tumori** 1995 May-Jun;81(3 Suppl):45–9

[Results of ileoanal reservoir surgery] Boné J, et al. **Ugeskr Laeger** 1996 Apr 8;158(15):2105–8 (Eng. Abstr.) **(Dan)**

[Synchronous cancers. A case with three localizations: rectal cancer associated with familial polyposis, breast cancer and adrenal gland cancer (letter)] Eisinger F, et al. **Presse Med** 1995 Oct 21;24(31):1446 **(Fre)**

[Changes in fecal bile acid excretion after proctocolectomy] Brüwer M, et al. **Z Gastroenterol** 1996 Feb;34(2):105–10 (Eng. Abstr.) **(Ger)**

[Restorative proctocolectomy for ulcerative colitis and familial polyposis] Sofer D, et al. **Harefuah** 1995 Sep; 129(5–6):176–9, 223 (Eng. Abstr.) **(Heb)**

[The surgical treatment of diffuse polyposis coli in children] Lukin VV. **Vestn Khir Im I I Grek** 1992 Nov-Dec; 149(11–12):350–4 (Eng. Abstr.) **(Rus)**

[Follow-up of colorectal polyps--is it really beneficial? (letter)] Brevinge H. **Lakartidningen** 1996 May 22; 93(21):2044 **(Swe)**

THERAPY

Impact of molecular genetics on the management of familial adenomatous polyposis. Jass JR, et al. **N Z Med J** 1996 Aug 9;109(1027):285–6 (32 ref.)

VETERINARY

Clinical evaluation of in-feed zinc bacitracin for the control of porcine intestinal adenomatosis in growing/fattening pigs. Kyriakis SC, et al. **Vet Rec** 1996 May 18; 138(20):489–92

ADENOMATOUS POLYPS

Malignant gastroesophageal polyp: a case report. Cavanaugh DG, et al. **Wis Med J** 1995;94(8):443–5

BLOOD

Red cell and plasma folate, folate consumption, and the risk of colorectal adenomatous polyps. Bird CL, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct-Nov; 4(7):709–14

Somatostatin and large bowel polyps. Payer J Jr, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):775–7

Serum gastrin levels in patients with colorectal cancer and adenomatous polyps: a prospective study. Mihas AA, et al. **Res Commun Mol Pathol Pharmacol** 1995 Nov; 90(2):301–4

CHEMICALLY INDUCED

Oncogenic potential of inhaled hydrazine in the nose of rats and hamsters after 1 or 10 1-hr exposures. Latendresse JR, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):33–48

CHEMISTRY

Localization of transforming growth factor-beta 1 precursor and latent TGF-beta 1 binding protein in colorectal adenomas. Van Laethem JL, et al. **Dig Dis Sci** 1996 Sep; 41(9):1741–8

COMPLICATIONS

Multiple polyposis and adenocarcinoma arising in Barrett's esophagus. Wong RS, et al. **Ann Thorac Surg** 1996 Jan; 61(1):216–8

[Giant hyperplastic polyposis with adenomatous tissue] Beusnel C, et al. **Gastroenterol Clin Biol** 1996;20(3):294–7 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Sensitivity, specificity, and predictive value of fecal occult blood testing (Hemoccult II) for colorectal neoplasia in symptomatic patients: a prospective study with total colonoscopy. Niv Y, et al. **Am J Gastroenterol** 1995 Nov; 90(11):1974–7

Flat neoplastic lesions of the colon and rectum detected by high-resolution video endoscopy and chromoscopy [see comments] Jaramillo E, et al. **Gastrointest Endosc** 1995 Aug;42(2):114–22. Comment in: Gastrointest Endosc 1995 Aug;42(2):182–4.

Endoscopic evaluation of colon polyps. VanDerWerken BS, et al. **Semin Roentgenol** 1996 Apr;31(2):118–24 (43 ref.)

DRUG THERAPY

Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Giardiello FM, et al. **Gut** 1996 Apr;38(4):578–81

ENZYMOLOGY

Decreased levels of 13-hydroxyoctadecadienoic acid (13-HODE) dehydrogenase in neoplastic tissue of human colon biopsies. Silverman AL, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jan;5(1):53–6

Diet, acetylator phenotype, and risk of colorectal neoplasia. Roberts-Thomson IC, et al. **Lancet** 1996 May 18; 347(9012):1372–4

[Adenomatous and inflammatory colorectal polyps: antioxidative enzyme activity in the colon] Beňo I, et al. **Cas Lek Cesk** 1996 Apr 3;135(7):208–10 (Eng. Abstr.) **(Slo)**

EPIDEMIOLOGY

Metachronous colon cancer in persons who have had a large adenomatous polyp [see comments] Otchy DP, et al. **Am J Gastroenterol** 1996 Mar;91(3):448–54. Comment in: Am J Gastroenterol 1996 Mar;91(3):420–2.

The effect of calcium and vitamin supplements on the incidence and recurrence of colorectal adenomatous polyps. Neugut AI, et al. **Cancer** 1996 Aug 15;78(4):723–8

Reproductive risk factors for colorectal adenomatous polyps (New York City, NY, United States). Jacobson JS, et al. **Cancer Causes Control** 1995 Nov;6(6):513–8

Establishment of a colonic polyp registry in Rhode Island. Lev R, et al. **Dig Dis Sci** 1995 Dec;40(12):2526–31

Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. Orbuch M, et al. **Dig Dis Sci** 1996 Mar; 41(3):604–13

Small flat adenomas appear to have little clinical importance in Western countries [editorial; comment] Bond JH. **Gastrointest Endosc** 1995 Aug;42(2):184–7. Comment on: Gastrointest Endosc 1995 Aug;42(2):109–13.

ETIOLOGY

Recurrent adenomatous polyps and body mass index. Davidow AL, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr;5(4):313–5

Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Martínez ME, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct-Nov; 4(7):703–7

Malignant tumor developed in colon-esophagus. Altorjay A, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):797–9 (19 ref.)

GENETICS

Colorectal adenoma progression and genetic change: is there a link? Jass JR. **Ann Med** 1995 Jun;27(3):301–6 (40 ref.)

Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup [see comments] Winawer SJ, et al. **N Engl J Med** 1996 Jan 11;334(2):82–7. Comment in: N Engl J Med 1996 May 16;334(20):1339–40.

Risk of colorectal cancer in families of patients with adenomatous polyps [letter; comment] Zarchy TM, et al. **N Engl J Med** 1996 May 16;334(20):1339–40. Comment on: N Engl J Med 1996 Jan 11;334(2):82–7.

Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Boland CR, et al. **Nat Med** 1995 Sep; 1(9):902–9

Immunohistochemical analysis of p53 and ras p21 expression in colorectal adenomas and early carcinomas. Ieda S, et al. **Surg Today** 1996;26(4):230–5

[Hereditary solitary adenoma] Yoshikawa R, et al. **Nippon Rinsho** 1995 Nov;53(11):2734–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Reduced glutamine content in colonic polyps. Goldin E, et al. **Scand J Gastroenterol** 1996 Apr;31(4):345–8

PATHOLOGY

Gastric polyps: relationship of size and histology to cancer risk. Ginsberg GG, et al. **Am J Gastroenterol** 1996 Apr; 91(4):714–7

Ultrasound-guided percutaneous transhepatic fine needle aspiration cytology study of gallbladder polypoid lesions. Wu SS, et al. **Am J Gastroenterol** 1996 Aug;91(8):1591–4

Knowledge-guided segmentation and morphometric analysis of colorectal dysplasia. Hamilton PW, et al. **Anal Quant Cytol Histol** 1995 Jun;17(3):172–82

Flat adenomas and cancers [editorial; comment] Colton CG, et al. **Gastrointest Endosc** 1995 Aug;42(2):182–4. Comment on: Gastrointest Endosc 1995 Aug;42(2):114–22.

Quantification of proliferative activity in colorectal adenomas by mitotic counts: relationship to degree of dysplasia and histological type. Meijer GA, et al. **J Clin Pathol** 1995 Jul; 48(7):620–5

Gastrointestinal adenomatous polyps. Itzkowitz SH. **Semin Gastrointest Dis** 1996 Apr;7(2):105–16 (85 ref.)

Significance of laparoscopic excisional biopsy for polypoid lesions of the gallbladder. Toda K, et al. **Surg Laparosc Endosc** 1995 Aug;5(4):267–71

PREVENTION & CONTROL

The effect of calcium and vitamin supplements on the incidence and recurrence of colorectal adenomatous polyps. Neugut AI, et al. **Cancer** 1996 Aug 15;78(4):723–8

Fecal alpha 1-antitrypsin detection of colorectal neoplasia. An evaluation using HemoQuant. Moran A, et al. **Dig Dis Sci** 1995 Dec;40(12):2522–5

[Administration of acetylsalicylic acid and risk of colorectal adenoma and carcinoma] Möhler M, et al. **Z Gastroenterol** 1995 Aug;33(8):470–1 **(Ger)**

SURGERY

Transduodenal excision of premalignant duodenal lesions in patients with portal hypertension. Pruitt AL, et al. **J Clin Gastroenterol** 1995 Dec;21(4):334–5

Endoscopic band ligation for treatment of post-polypectomy bleeding. Pfaffenbach B, et al. **Z Gastroenterol** 1996 Apr; 34(4):241–2

[Hyperplastic gastric polyposis and familial colonic adenomas. Apropos of a case] Davion T, et al. **Gastroenterol Clin Biol** 1996;20(3):298–302 (Eng. Abstr.) **(Fre)**

[Transanal endoscopic microsurgery for local excision of

rectal neoplasms] Madhala O, et al. **Harefuah** 1995 Oct; 129(7–8):236–7, 295 (Eng. Abstr.) **(Heb)**

ADENOMYOMA

[Adenomyoma of the extrahepatic bile duct] Hoso M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):50–2 (19 ref.) **(Jpn)**

[Adenomyomatosis of the gallbladder] Yamaguchi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):305–7 (18 ref.) **(Jpn)**

COMPLICATIONS

Coexistence of anomalous pancreaticobiliary ductal union with adenomyomatosis of the gallbladder. Wu MS, et al. **Gastrointest Endosc** 1995 Sep;42(3):265–9

DIAGNOSIS

Large cervical adenomyoma occurring in a first-trimester gravid uterus: radiologic-pathology correlation. Athas JM, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):514–5

MR imaging of atypical polypoid adenomyoma. Yamashita Y, et al. **Comput Med Imaging Graph** 1995 Jul–Aug; 19(4):351–5

Adenomyoma of the common hepatic duct. Imai S, et al. **J Gastroenterol** 1995 Aug;30(4):547–50

[Adenomas and adenomyomatosis of the gallbladder] Sedov VM, et al. **Klin Med (Mosk)** 1996;74(1):21–2 **(Rus)**

PATHOLOGY

Papillary serous carcinoma of the uterus arising in an adenomyoma [letter] Griffin M, et al. **Acta Cytol** 1996 Jul–Aug;40(4):849–50

Atypical polypoid adenomyofibromas (atypical polypoid adenomyomas) of the uterus. A clinicopathologic study of 55 cases. Longacre TA, et al. **Am J Surg Pathol** 1996 Jan; 20(1):1–20

Atypical polypoid adenomyomas of the uterus. Fukunaga M, et al. **Histopathology** 1995 Jul;27(1):35–42 (18 ref.)

Papillary mucinous adenoma arising in adenomyomatous hyperplasia of the gall bladder. Lauwers GY, et al. **J Clin Pathol** 1995 Oct;48(10):965–7

Benign endocervical adenomyomas and adenoma malignum. Gilks CB, et al. **Mod Pathol** 1996 Mar;9(3):220–4

Significance of laparoscopic excisional biopsy for polypoid lesions of the gallbladder. Toda K, et al. **Surg Laparosc Endosc** 1995 Aug;5(4):267–71

[Spontaneous uterine rupture in the 18th week of pregnancy in a primigravida patient with adenomyosis] Mueller MD, et al. **Zentralbl Gynakol** 1996;118(1):42–4 (Eng. Abstr.) **(Ger)**

[Diffuse adenomyomatosis of the gallbladder] Perišić-Savić M, et al. **Acta Chir Iugosl** 1990;37(2):189–98 (Eng. Abstr.) **(Ser)**

ULTRASONOGRAPHY

[Bladder adenomyomatosis. Apropos of a case of segmental involvement. Correlation ultrasonography-MRI] Berger V, et al. **J Radiol** 1996 Mar;77(3):205–8 (Eng. Abstr.) **(Fre)**

[A case of early carcinoma of the gall-bladder arising in adenomyomatosis detected by endoscopic ultrasonography] Sakurai T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep;92(9):1304–8 (18 ref.) **(Jpn)**

ADENOMYOSIS see **ENDOMETRIOSIS**

ADENOSARCOMA

DIAGNOSIS

[Müllerian adenosarcoma] Bettini-Papon V, et al. **J Radiol** 1996 Jul;77(7):512–4 **(Fre)**

ETIOLOGY

Primary extrauterine mullerian adenosarcoma of the peritoneum [letter; comment] Thylan S. **Gynecol Oncol** 1996 Feb;60(2):333. Comment on: Gynecol Oncol 1995 Apr;57(1):126–30.

GENETICS

The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Swisher EM, et al. **Gynecol Oncol** 1996 Jan;60(1):81–8

PATHOLOGY

Two unusual presentations of müllerian adenosarcoma: case reports, literature review, and treatment considerations. Gollard R, et al. **Gynecol Oncol** 1995 Dec;59(3):412–22 (26 ref.)

Epithelial–mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor-beta1. Kitagawa K, et al. **Int J Cancer** 1996 Mar 28;66(1):91–7

Adenosarcoma of the uterine cervix: a clinicopathological study of 12 cases. Jones MW, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):223–9

Müllerian adenosarcoma of the cervix: differential diagnosis, histogenesis and review of the literature. García-Rostán y P erez GM, et al. **Pathol Int** 1995 Nov;45(11):890–4 (30 ref.)

SURGERY

[Heterologous adenosarcoma of the Müllerian ducts in adolescence. Presentation of clinical case and review of the literature] Juárez Azpilcueta A, et al. **Ginecol Obstet Mex** 1995 Sep;63:398–400 (15 ref.) (Eng. Abstr.) **(Spa)**

ADENOSINE

A safe, simple alternative for pressure reduction during aortic endograft deployment [comment] Diethrich EB. **J Endovasc Surg** 1996 Aug;3(3):275. Comment on: J Endovasc Surg 1996 Aug;3(3):270–2. Comment on: J Endovasc Surg 1996 Aug;3(3):273–4.

Adenosine-induced transient cardiac asystole enhances precise deployment of stent-grafts in the thoracic or abdominal aorta [see comments] Dorros G, et al. **J Endovasc Surg** 1996 Aug;3(3):270–2. Comment in: J Endovasc Surg 1996 Aug;3(3):275.

Transient asystole for aortic endograft deployment: a technique justified only in highly selected cases [see comments] White GH. **J Endovasc Surg** 1996 Aug; 3(3):273–4. Comment in: J Endovasc Surg 1996 Aug;3(3):275.

ADMINISTRATION & DOSAGE

Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain. Belfrage M, et al. **Anesth Analg** 1995 Oct; 81(4):713–7

Intraosseous adenosine for the termination of supraventricular tachycardia in an infant. Friedman FD. **Ann Emerg Med** 1996 Sep;28(3):356–8

Adenosine for refractory pulmonary hypertension. Fullerton DA, et al. **Ann Thorac Surg** 1996 Sep;62(3):874–7

Differential alteration of neuronal and cardiovascular responses to adenosine microinjected into the nucleus tractus solitarius of spontaneously hypertensive rats. Abdel-Rahman AA, et al. **Hypertension** 1996 Apr; 27(4):939–48

Adenosine and renal sodium handling: direct natriuresis and renal nerve-mediated antinatriuresis. Fransen R, et al. **J Am Soc Nephrol** 1995 Nov;6(5):1491–7

ADVERSE EFFECTS

Adenosine-induced atrial fibrillation. Silverman AJ, et al. **Am J Emerg Med** 1996 May;14(3):300–1

Adenosine thallium-201 scans in patients undergoing elective non-cardiac surgery. Ahluwalia U, et al. **Aust N Z J Surg** 1995 Nov;65(11):780–3

Non-sustained broad-complex tachycardia following intravenous adenosine. Hingorani AD, et al. **J Accid Emerg Med** 1995 Sep;12(3):208–9

Ventricular fibrillation following adenosine therapy for supraventricular tachycardia in a neonate with concealed Wolff-Parkinson-White syndrome treated with digoxin. Mulla N, et al. **Pediatr Emerg Care** 1995 Aug;11(4):238–9

[Ventricular fibrillation after administration of adenosine] Pella J, et al. **Vnitr Lek** 1995 Dec;41(12):832–5 (Eng. Abstr.) **(Slo)**

AGONISTS

Effects of adenosine drugs on apomorphine-induced licking in rats. Zarrindast MR, et al. **Gen Pharmacol** 1995 Sep; 26(5):1119–23

An adenosine agonist increases blood flow and density of capillary branches in the optic tectum of Xenopus laevis tadpoles. Jen SC, et al. **Microcirculation** 1994 Apr; 1(1):59–66

ANALOGS & DERIVATIVES

Adenosine-N6-diethylthioether-N1-pyridoximine 5'-phosphate. A novel marker for human cancer detection. Tryfiates GP. **Anticancer Res** 1996 Jul–Aug;16(4B):2201–4

Diazepam, adenosine analogues and calcium channel antagonists inhibit the contractile activity of the mouse urinary bladder. Schaufele P, et al. **Arch Int Pharmacodyn Ther** 1995 May–Jun;329(3):454–66

Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Boyle DL, et al. **Arthritis Rheum** 1996 Jun;39(6):923–30

Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. Kohno Y, et al. **Biochem Biophys Res Commun** 1996 Feb 27; 219(3):904–10

Purification of pancreas type-I ATP diphosphohydrolase and identification by affinity labelling with the 5'-p-fluorosulphonylbenzoyladenosine ATP analogue. Sévigny J, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):351–6

N6-methyladenosine inhibits murine erythroleukemia cell maturation by blocking methylation of RNA and memory via conversion to S-(N6-methyl)-adenosylhomocysteine. Vizirianakis IS, et al. **Biochem Pharmacol** 1995 Nov 27; 50(11):1807–14

2-Hydroxyethyl alpha-D-glucopyranoside 2,3',4'-trisphosphate: a novel metabolically resistant adenophostin A and myo-inositol 1,4,5-trisphosphate analogue potently interacts with the myo-inositol 1,4,5-trisphosphate receptor. Wilcox RA, et al. **Biochem Soc Trans** 1995 Aug;23(3):420S

5'-(p-fluorosulfonylbenzoyl)-2 (or 3')-(methylanthraniloyl)adenosine, fluorescent affinity labels for adenine nucleotide binding sites: interaction with the kinase active site of the receptor for epidermal growth factor. Scoggins RM, et al. **Biochemistry** 1996 Jul 16; 35(28):9197–203

The A1 agonist CCPA reduced bisoxonol-monitored membrane potential depolarization elicited by high K+ in cerebrocortical nerve endings. Amoroso S, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):67–73

Inhibition of ATP-diphosphohydrolase(apyrase) of Torpedo electric organ by 5'-p-fluorosulfonylbenzoyladenosine. Martí E, et al. **Biochim Biophys Acta** 1996 Jun 13; 1282(1):17–24

In vitro effect of adenosine agonist GR79236 on the insulin sensitivity of glucose utilisation in rat soleus and human rectus abdominus muscle. Webster JM, et al. **Biochim Biophys Acta** 1996 Jun 7;1316(2):109–13

Probing nucleic acid geometries: oligonucleotides containing 2'-O-phenethyladenosine at specific sites. Deshmukh HM, et al. **Bioconjug Chem** 1996 Jan–Feb;7(1):108–20

Synthesis and antiviral effects of 2-heteroaryl substituted adenosine and 8-heteroaryl substituted guanosine derivatives. Persson T, et al. **Bioorg Med Chem** 1995 Oct; 3(10):1377–82

Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. Appel S, et al. **Br J Pharmacol** 1995 Aug;115(7):1253–9

Anxiolytic activity of adenosine receptor activation in mice. Jain N, et al. **Br J Pharmacol** 1995 Oct;116(3):2127–33

Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo. Mathôt RA, et al. **Br J Pharmacol** 1995 Oct;116(3):1957–64

Stimulation of A1 adenosine receptors mimics the electroencephalographic effects of sleep deprivation. Benington JH, et al. **Brain Res** 1995 Sep 18;692(1–2):79–85

Effects of CGS 21680 in vivo on dopamine D2 agonist binding in the rat brain. Hillefors-Berglund M, et al. **Brain Res** 1995 Aug 28;690(1):34–40

Formation of etheno and oxoethyl adducts in liver DNA from rats exposed subchronically to urethane in drinking water and ethanol. Sotomayor RE, et al. **Cancer Lett** 1996 Feb 27;100(1–2):155–61

Vitamin B6 and cancer: synthesis and occurrence of adenosine-N6-diethylthioether-N-pyridoximine-5'-phosphate, a circulating human tumor marker. Tryfiates GP, et al. **Cancer Res** 1996 Aug 15;56(16):3670–7

Reaction of mucochloric acid with adenosine: formation of 8-(N6-adenosinyl)ethenoadenosine derivatives. Asplund D, et al. **Chem Res Toxicol** 1995 Sep;8(6):841–6

Preconditioning of bovine endothelial cells. The protective effect is mediated by an adenosine A2 receptor through a protein kinase C signaling pathway. Zhou X, et al. **Circ Res** 1996 Jan;78(1):73–81

Rationale and hurdles of inhibitors of hepatic gluconeogenesis in treatment of diabetes mellitus. Kashiwagi A. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S195–200 (30 ref.)

Disordered gastric motor function in diabetes mellitus [letter; comment] Mikhailidis DP, et al. **Diabetologia** 1995 May; 38(5):632. Comment on: Diabetologia 1994 Jun;37(6):543–51.

Crystal structure of histidyl-tRNA synthetase from Escherichia coli complexed with histidyl-adenylate. Arnez JG, et al. **EMBO J** 1995 Sep 1;14(17):4143–55

Pharmacokinetics of the antiviral agent 3-deazaneplanocin A. Coulombe RA Jr, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul–Sep; 20(3):197–202

Differential vasodilatory action of 2-octynyladenosine (YT-146), an adenosine A2 receptor agonist, in the isolated rat femoral artery and vein. Abiru T, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):9–15

Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Adami M, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):383–9

Mast cell degranulation following adenosine A3 receptor activation in rats. Fozard JR, et al. **Eur J Pharmacol** 1996 Mar 18;298(3):293–7

Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Popoli P, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):215–7

Early administration of YT-146, an adenosine A2 receptor agonist, inhibits neointimal thickening after rat femoral artery endothelium injury. Takiguchi Y, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):205–7

8-substituted adenosine and theophylline-7-riboside analogues as potential partial agonists for the adenosine A1 receptor. Van der Wenden EM, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):189–99

Sinefungin and taxol effects on cell cycle and cytoskeleton of Leishmania donovani promastigotes. Moulay L, et al. **Exp Cell Res** 1996 Aug 1;226(2):283–91

DNA methylation in mycobacteria: absence of methylation at GATC (Dam) and CCA/TGG (Dcm) sequences. Hemavathy KC, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):291–6

Characterization of ocular hypertension induced by adenosine agonists. Crosson CE, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1833–9

Molecular basis for subtype-specific desensitization of inhibitory adenosine receptors. Analysis of a chimeric A1–A3 adenosine receptor. Palmer TM, et al. **J Biol Chem** 1996 Jun 21;271(25):15272–8

Adenosine A2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. Revan S, et al. **J Biol Chem** 1996 Jul 19;271(29):17114–8

Nitric oxide participates in the hypotensive effect induced by adenosine A2 subtype receptor stimulation. Stella L, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):1001–5

Carbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl)adenines. Borcherding DR, et al. **J Med Chem** 1996 Jun 21; 39(13):2615–20

Aristeromycin-5'-carboxaldehyde: a potent inhibitor of S-adenosyl-L-homocysteine hydrolase. Liu S, et al. **J Med Chem** 1996 Jun 7;39(12):2347–53

N6,C8-distributed adenosine derivatives as partial agonists for adenosine A1 receptors. Roelen H, et al. **J Med Chem** 1996 Mar 29;39(7):1463–71

New neplanocin analogues. 6. Synthesis and potent antiviral activity of 6'-homoneplanocin A1. Shuto S, et al. **J Med Chem** 1996 Jun 7;39(12):2392–9

Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor. van der Wenden EM, et al. **J Med Chem** 1995 Sep 29;38(20):4000–6

Interaction of beta-adrenoceptor and adenosine receptor agonists on phosphorylation. Identification of target proteins in mammalian ventricles. Neumann J, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1655–67

Photoaffinity labeling with 2(–)[2-(4-azido-3(–)[125I]-iodophenyl)ethylamino]adenosine and autoradiography with 2(–)[2-(4-amino-3(–)[125I]iodophenyl) ethylamino]adenosine of A2a adenosine receptors in rat brain. Luthin DR, et al. **J Neurochem** 1995 Nov; 65(5):2072–9

Sustained activation of phospholipase D via adenosine A3 receptors is associated with enhancement of antigen- and Ca(2+)-ionophore-induced secretion in a rat mast cell line. Ali H, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):837–45

125I-APE binding to adenosine receptors in coronary artery: photoaffinity labeling with 125I-azidoAPE. Hussain T, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):284–8

Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists. Lee YW, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1642–8

Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine. Mathôt RA, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):245–53

Adenosine dialdehyde blocks the disappearance of two nerve growth factor-induced insoluble proteins. VanDenburg JY, et al. **J Protein Chem** 1995 Jul;14(5):291–7

Effects of diazepam and cyclohexyladenosine on open-field behavior in rats perinatally exposed to caffeine. Fisher CE, et al. **Life Sci** 1996;58(8):701–9

Modulation of erythropoietin production by selective adenosine agonists and antagonists in normal and anemic rats. Nagashima K, et al. **Life Sci** 1996;59(9):761–71

An adenosine agonist increases blood flow and density of capillary branches in the optic tectum of Xenopus laevis tadpoles. Jen SC, et al. **Microcirculation** 1994 Apr; 1(1):59–66

Selective enhancement by an adenosine A1 receptor agonist of agents inducing contraction of the rat vas deferens. Brownhill VR, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Apr; 353(5):499–504

Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors. Cunha RA, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Feb; 353(3):261–71

Functional characterization of adenosine A2 receptors in Jurkat cells and PC12 cells using adenosine receptor agonists. van der Ploeg I, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Feb; 353(3):250–60

Further characterization of the binding of the adenosine receptor agonist [3H]CGS 21680 to rat brain using autoradiography. Johansson B, et al. **Neuropharmacology** 1995 Apr;34(4):393–403

Adenosine A2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Morelli M, et al. **Neuroscience** 1995 Jul;67(1):49–55

A novel enzymatic pathway leading to 1-methylinosine modification in Haloferax volcanii tRNA. Grosjean H, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4312–9

Cardiovascular and antilipolytic effects of the adenosine agonist GR79236. Merkel LA, et al. **Pharmacology** 1995 Oct;51(4):224–36

Effects of adenosine agents on apomorphine-induced yawning in rats. Zarrindast MR, et al. **Psychopharmacology (Berl)** 1995 Dec;122(3):292–6

Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Ishiwata S, et al. **Tohoku J Exp Med** 1995 May;176(1):61–8

[Phosphodiesterase inhibitor: griseolic acid, its' derivatives and their biological activities] Kaneko M, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1268–76 (23 ref.) **(Jpn)**

[Design of S-adenosylhomocystein hydrolase (SHAase) inhibitors as potent anti-RNA viral agents] Shuto S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1261–7 (27 ref.) **(Jpn)**

[Serum 1-methyladenosine and pseudouridine as tumor markers in tumor-bearing mice] Ishiwata S, et al. **Yakugaku Zasshi** 1995 Jul;115(7):523–7 (Eng. Abstr.) **(Jpn)**

[Acyclic nucleoside analogs: synthesis and cytotoxic properties of acyl derivatives of 3'(5')-amino-3'(5')-deoxy-2',3'-secoadenosine] Goriunova OV, et al. **Bioorg Khim** 1995 Aug;21(8):617–24 (Eng. Abstr.) **(Rus)**

ANALYSIS

Sodium intake markedly alters renal interstitial fluid adenosine. Siragy HM, et al. **Hypertension** 1996 Mar;27(3 Pt 1):404–7

ANTAGONISTS & INHIBITORS

Effect of calcium channel antagonists in modifying the inhibitory influence of adenosine on insulin secretion. Ismail NA, et al. **Arzneimittelforschung** 1995 Aug;45(8):865–8

Effects of adenosine drugs on apomorphine-induced licking in rats. Zarrindast MR, et al. **Gen Pharmacol** 1995 Sep; 26(5):1119–23

Efficacy of an adenosine antagonist, theophylline, in essential tremor: comparison with placebo and propranolol. Mally J, et al. **J Neurol Sci** 1995 Oct;132(2):129–32

Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Pollack AE, et al. **Neuroscience** 1995 Oct;68(3):721–8

BIOSYNTHESIS

Activation of protein kinase C increases adenosine production in the hypoxic canine coronary artery through the extracellular pathway. Minamino T, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2298–304

Production of adenosine and nucleoside analogs by the exchange reaction catalyzed by rat liver adenosine kinase. Mimouni M, et al. **Biochem Pharmacol** 1995 Nov 9; 50(10):1587–91

Synergistic effect of granulocyte colony-stimulating factor and drugs elevating extracellular adenosine on neutrophil production in mice. Pospísil M, et al. **Blood** 1995 Nov 15; 86(10):3692–7

BLOOD

The relationship between uterine artery Doppler velocimetry and umbilical venous adenosine levels in pregnancies complicated by preeclampsia. Yoneyama Y, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):267–71

CHEMICAL SYNTHESIS

Comparative molecular field analysis of selective A3 adenosine receptor agonists. Siddiqi SM, et al. **Bioorg Med Chem** 1995 Oct;3(10):1331–43

Synthesis and biological evaluation of N6-cycloalkyl derivatives of 1-deazaadenine nucleosides: a new class of anti-human immunodeficiency virus agents. Cristalli G, et al. **J Med Chem** 1995 Sep 29;38(20):4019–25

CHEMISTRY

Reaction of mucochloric acid with adenosine: formation of 8-(N6-adenosinyl)ethenoadenosine derivatives. Asplund D, et al. **Chem Res Toxicol** 1995 Sep;8(6):841–6

Direct synthesis and characterization of site-specific adenosyl adducts derived from the binding of a 3,4-dihydroxy-1,2-epoxybenzo[c]phenanthrene stereoisomer to an 11-mer oligodeoxyribonucleotide. Laryea A, et al. **Chem Res Toxicol** 1995 Apr–May; 8(3):444–54

Different mechanisms of aralkylation of adenosine at the 1- and N6-positions. Qian C, et al. **Chem Res Toxicol** 1995 Apr–May;8(3):389–95

Characterization of adenosine-uridine-rich RNA binding factors. Nakamaki T, et al. **J Cell Physiol** 1995 Dec; 165(3):484–92

RNA tertiary structure mediation by adenosine platforms [see comments] Cate JH, et al. **Science** 1996 Sep 20; 273(5282):1696–9. Comment in: Science 1996 Sep 20;273(5282):1676–7.

DIAGNOSTIC USE

Detection of regional perfusion abnormalities during adenosine stress echocardiography with intravenous perfluorocarbon-exposed sonicated dextrose albumin. Porter TR, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):41–7

Adenosine radionuclide perfusion imaging in the preoperative evaluation of patients undergoing peripheral vascular surgery. Marshall ES, et al. **Am J Cardiol** 1995 Oct 15; 76(11):817–21

Adenosine approved for use in stress testing [news] **Am J Health Syst Pharm** 1995 Aug 1;52(15):1601, 1604

Adenosine thallium-201 scans in patients undergoing elective non-cardiac surgery. Ahluwalia U, et al. **Aust N Z J Surg** 1995 Nov;65(11):780–3

Avoidance of upward creep artifact during TI-201 myocardial perfusion tomography using adenosine infusion. A case report. Anagnostopoulos C, et al. **Clin Nucl Med** 1995 Aug;20(8):685–7

Adenosine technetium-99m sestamibi (SPECT) for the early assessment of jeopardized myocardium after acute myocardial infarction. Claeys MJ, et al. **Eur Heart J** 1995 Sep;16(9):1186–94

Adenosine technetium-99m sestamibi myocardial perfusion SPECT in women: diagnostic efficacy in detection of coronary artery disease. Amanullah AM, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):803–9

Stress echocardiography in elderly patients with coronary artery disease: applicability, safety and prognostic value of dobutamine and adenosine echocardiography in elderly patients. Anthopoulos LP, et al. **J Am Coll Cardiol** 1996 Jul;28(1):52–9

Detection of left anterior descending coronary artery stenosis in patients with left bundle branch block: exercise, adenosine or dobutamine imaging? Vaduganathan P, et al. **J Am Coll Cardiol** 1996 Sep;28(3):543–50

Comparison of adenosine echocardiography, with and without isometric handgrip, to exercise echocardiography in the detection of ischemia in patients with coronary artery disease. Tawa CB, et al. **J Am Soc Echocardiogr** 1996 Jan–Feb;9(1):33–43

Adenosine coronary vasodilation quantitative technetium 99m methoxy isobutyl isonitrile myocardial tomography in the identification and localization of coronary artery disease. Nicolai E, et al. **J Nucl Cardiol** 1996 Jan–Feb; 3(1):9–17

Comparison of adenosine and high-dose dipyridamole both combined with low-level exercise stress for 99Tcm-MIBI SPET myocardial perfusion imaging. Cramer MJ, et al. **Nucl Med Commun** 1996 Feb;17(2):97–104

Comparative value of effort and adenosine-testing in the evaluation of patients with old myocardial infarction. Zdrenghea D, et al. **Rom J Intern Med** 1995 Jan–Jun; 33(1–2):13–8

[Multiplane transesophageal echocardiography and adenosine in the study of coronary blood reserve] Galati A, et al. **G Ital Cardiol** 1995 Dec;25(12):1589–1600 (Eng. Abstr.) **(Ita)**

ISOLATION & PURIFICATION

[Chemical constituents of stems and leaves of Fritillaria ussuriensis Maxim] Cui D, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):298, 320 (Eng. Abstr.) **(Chi)**

METABOLISM

Equilibrative adenosine transport in rat hepatocytes after chronic ethanol feeding. Wannamaker VL, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):735–40

Comparison of myocardial ATP, blood flow, and cytosolic adenosine in demand ischemia and coronary occlusion. Kroll K, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H819–28

Simultaneous determination of adenosine, inosine, hypoxanthine, xanthine, and uric acid in microdialysis samples using microbore column high-performance liquid chromatography with a diode array detector. Mei DA, et al. **Anal Biochem** 1996 Jun 15;238(1):34–9

Effects of anesthesia and K+ ATP channel blockade on interstitial adenosine accumulation in ischemic rabbit myocardium. Cohen MV, et al. **Basic Res Cardiol** 1995 Sep–Oct;90(5):410–7

Activation of ecto-5'-nucleotidase and cardioprotection by ischemic preconditioning. Kitakaze M, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):23–6 (8 ref.)

Adenosine and bradykinin: are they independent triggers of preconditioning? Miura T. **Basic Res Cardiol** 1996 Jan–Feb; 91(1):20–2 (14 ref.)

Transient pre-ischemic acidosis protects the isolated rabbit heart subjected to 30 minutes, but not 60 minutes, of global ischemia. Simkhovich BZ, et al. **Basic Res Cardiol** 1995 Sep–Oct;90(5):397–403

Efflux of adenosine and total adenylate catabolites during alterations of the cellular energy state. An NMR study of continuous and discontinuous ischemia. Vuorinen KH, et al. **Basic Res Cardiol** 1995 May–Jun;90(3):211–9

Photoaffinity labeling of a P3 purinoceptor-like protein purified from rat brain membranes. Saitoh Y, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):469–74

Transport mechanisms of nucleosides and the derivative, 6-mercaptopurine riboside across rate intestinal brush-border membranes. Iseki K, et al. **Biochim Biophys Acta** 1996 Jan 12;1278(1):105–10

Magnesium activated adenosine formation in intact perfused heart: predominance of ecto 5'-nucleotidase during hypermagnesemia. Mallet RT, et al. **Biochim Biophys Acta** 1996 Jun 4;1290(2):165–76

The role of intracellular pH in the control of adenosine output from red skeletal muscle. Ballard HJ. **Biol Signals** 1995 May–Jun;4(3):168–73 (21 ref.)

Enhancement of NMDA-induced increases in levels of endogenous adenosine by adenosine deaminase and adenosine transport inhibition in rat striatum. Delaney SM,

et al. **Brain Res** 1995 Dec 8;702(1-2):72-6

Regulation of extracellular adenosine levels in the striatum of aging rats. Pazzagli M, et al. **Brain Res** 1995 Jun 26; 684(1):103-6

Adenylyl cyclase activation underlies intracellular cyclic AMP accumulation, cyclic AMP transport, and extracellular adenosine accumulation evoked by beta-adrenergic receptor stimulation in mixed cultures of neurons and astrocytes derived from rat cerebral cortex. Rosenberg PA, et al. **Brain Res** 1995 Sep 18; 692(1-2):227-32

Interstitial adenosine and cellular metabolism during beta-adrenergic stimulation of the in situ rabbit heart. Headrick JP, et al. **Cardiovasc Res** 1996 May;31(5):699-710

Adenosine A1 stimulation activates delta-protein kinase C in rat ventricular myocytes. Henry P, et al. **Circ Res** 1996 Jan;78(1):161-5

Kinetics of phosphorolysis of 3-(beta-D-ribofuranosyl)adenine and 3-(beta-D-ribofuranosyl)hypoxanthine, non-conventional substrates of purine-nucleoside phosphorylase. Bzowska A, et al. **Eur J Biochem** 1996 Jul 1;239(1):229-34

Smooth muscle cell-derived adenosine inhibits cell growth. Dubey RK, et al. **Hypertension** 1996 Mar;27(3 Pt 2):766-73

Presynaptic inhibition of norepinephrine release from sympathetic nerve endings by endogenous adenosine. Rongen GA, et al. **Hypertension** 1996 Apr;27(4):933-8

Microdialyzed adenosine in nucleus tractus solitarii and ventilatory response to hypoxia in piglets. Yan S, et al. **J Appl Physiol** 1995 Aug;79(2):405-10

Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. Carter NS, et al. **J Biol Chem** 1995 Nov 24; 270(47):28153-7

Adenosine-mediated inhibition of casein production by mouse mammary glands in culture. Hom YK, et al. **J Cell Physiol** 1996 Aug;168(2):314-21

The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. Gadangi P, et al. **J Immunol** 1996 Mar 1;156(5):1937-41

Hypoxia preconditions rabbit myocardium via adenosine and catecholamine release. Cohen MV, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1527-34

Release of adenosine from rat hippocampal slices by nitric oxide donors. Fallahi N, et al. **J Neurochem** 1996 Jul; 67(1):186-93

Characterization of inhibitor-sensitive and -resistant adenosine transporters in cultured human fetal astrocytes. Gu JG, et al. **J Neurochem** 1996 Sep;67(3):972-7

Adenosine release and uptake in cerebellar granule neurons both occur via an equilibrative nucleoside carrier that is modulated by G proteins. Sweeney MI. **J Neurochem** 1996 Jul;67(1):81-8

Brain regional levels of adenosine and adenosine nucleotides in rats killed by high-energy focused microwave irradiation. Delaney SM, et al. **J Neurosci Methods** 1996 Feb;64(2):151-6

Interactions between ethanol, endogenous adenosine and adenosine uptake in hippocampal brain slices. Diao L, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):542-6

Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA. Casey JL, et al. **J Virol** 1995 Dec;69(12):7593-600

Inhibition of adenosine kinase and adenosine uptake in guinea-pig CNS tissue by halogenated tubercidin analogues. Davies LP, et al. **Life Sci** 1995 Mar 17; 56(17):PL345-9

The effect of anoxia on cardiomyocyte glucose transport does not involve an adenosine release or a change in energy state. Eblenkamp M, et al. **Life Sci** 1996;59(2):141-51

Mode and extent of degradation of adenosine and guanosine by extracts of Aspergillus terricola. Elshafei AM, et al. **Microbiol Res** 1995 Sep;150(3):291-5

The source of brain adenosine outflow during ischemia and electrical stimulation. Latini S, et al. **Neurochem Int** 1996 Jan;28(1):113-8

The source of brain adenosine outflow during ischemia and electrical stimulation. Latini S, et al. **Neurochem Int** 1995 Sep;27(3):239-44

Adenosine A1 and A2A receptors and nitrobenzylthioinosine-sensitive transporters in gerbil brain: no changes following long-term treatment with the adenosine transport inhibitor propentofylline. Parkinson FE, et al. **Neuropharmacology** 1996 Jan;35(1):79-89

Choline substitution for sodium triggers glutamate and adenosine release from rat hippocampal slices. Fowler JC. **Neurosci Lett** 1995 Sep 8;197(2):97-100

Vasoactive intestinal peptide regulates extracellular adenosine levels in rat cortical cultures. Rosenberg PA, et al. **Neurosci Lett** 1995 Nov 17;200(2):93-6

The branch site adenosine is recognized differently for the two steps of pre-mRNA splicing. Query CC, et al. **Nucleic Acids Symp Ser** 1995;(33):224-5

Reduction in cerebral ischemic injury in the newborn rat by potentiation of endogenous adenosine. Gidday JM, et al. **Pediatr Res** 1995 Sep;38(3):306-11

Transport and metabolism of adenosine in the perfused human placenta. Acevedo CG, et al. **Placenta** 1995 Oct; 16(7):611-22

Effect of chlorpromazine as a sensitizer of rat brain on radiation-induced AMP and adenosine metabolism. Hasan SS, et al. **Q J Nucl Med** 1995 Dec;39(4):290-9

Transport and metabolism of adenosine in diabetic human placenta. Osses N, et al. **Reprod Fertil Dev** 1995; 7(6):1499-503

Adenosine scavenging: a novel mechanism of chloride secretory control in intestinal epithelial cells. Tally KJ, et al. **Surgery** 1996 Aug;120(2):248-54

Hydroperoxide-induced nucleotide degradation and adenosine formation in isolated rat cardiomyocytes. Andersson BS, et al. **Toxicology** 1996 Jan 8;106(1-3):39-48

Myocardial protection by nucleoside transport inhibition. Van Belle H. **Transplant Proc** 1995 Oct;27(5):2804-5

PHARMACOKINETICS

Effects of ischemic and adenosine preconditioning on interstitial fluid adenosine and myocardial infarct size. Lasley RD, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1460-6

Adenosine and carbachol are not equivalent in their effects on L-type calcium current in rabbit ventricular cells. Kumar R, et al. **J Mol Cell Cardiol** 1996 Feb;28(2):403-15

PHARMACOLOGY

Adenosine increases the cutaneous heat pain threshold in healthy volunteers. Ekblom A, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):717-22

Combined inhibitory effects of ethanol and adenosine on the responses of rabbit platelets to thrombin. Rand ML, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1279-85

Transesophageal echo phase imaging for localizing accessory pathways during adenosine-induced preexcitation in patients with the Wolff-Parkinson-White syndrome. Kuecherer HF, et al. **Am J Cardiol** 1996 Jan 1;77(1):64-71

Different adhesion types and active sensitivity of platelet subpopulations. Zhao B, et al. **Am J Hematol** 1996 Aug; 52(4):322-4

Fructose-1,6-diphosphate or adenosine attenuate leukocyte adherence in postischemic skeletal muscle. Akimitsu T, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1743-51

Effects of ischemic and adenosine preconditioning on interstitial fluid adenosine and myocardial infarct size. Lasley RD, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1460-6

Adenosine inhibits arginine vasopressin-stimulated chloride secretion in a mouse IMCD cell line (mIMCD-K2). Moyer BD, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):F884-91

Increased sensitivity of the renal vasculature to adenosine in streptozotocin-induced diabetes mellitus rats. Pflueger AC, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):F529-35

Adenosine: a prototherapeutic concept in neurodegeneration. von Lubitz DK, et al. **Ann N Y Acad Sci** 1995 Sep 15; 765:163-78; discussion 196-7 (123 ref.)

Effect of K-7259, a novel derivative of dilazep, on cardiovascular actions of adenosine: comparison with dilazep. Hara A, et al. **Arch Int Pharmacodyn Ther** 1995 Jul-Aug;330(1):66-75

Diazepam, adenosine analogues and calcium channel antagonists inhibit the contractile activity of the mouse urinary bladder. Schaufele P, et al. **Arch Int Pharmacodyn Ther** 1995 May-Jun;329(3):454-66

Inhibition of adenosine deaminase and administration of adenosine increase hypoxia induced ventricular ectopy. Leone RJ Jr, et al. **Basic Res Cardiol** 1995 May-Jun; 90(3):234-9

Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. Kohno Y, et al. **Biochem Biophys Res Commun** 1996 Feb 27; 219(3):904-10

Hormonal regulation of glucose transport in a brown adipose cell preparation isolated from rats that shows a large response to insulin. Omatsu-Kanbe M, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):25-31

Cross-talk between glucagon- and adenosine-mediated signalling systems in rat hepatocytes: effects on cyclic AMP-phosphodiesterase activity. Robles-Flores M, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):763-7

Homocysteine enhances the inhibitory effect of extracellular adenosine on the synthesis of proteins in isolated rat hepatocytes. Tinton S, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):893-6

Adenosine modulation of tumor necrosis factor-alpha-induced neutrophil activation. Barnes CR, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1851-7

Synthesis and antiviral effects of 2-heteroaryl substituted adenosine and 8-heteroaryl substituted guanosine derivatives. Persson T, et al. **Bioorg Med Chem** 1995 Oct; 3(10):1377-82

Modulation of calcium currents by G-proteins and adenosine receptors in myenteric neurones cultured from adult guinea-pig small intestine. Baidan LV, et al. **Br J Pharmacol** 1995 Sep;116(2):1882-6

Enhancement by benzodiazepines of the inhibitory effect of adenosine on skeletal neuromuscular transmission. Chiou LC, et al. **Br J Pharmacol** 1995 Sep;116(2):1870-4

Effects of pH on responses to adenosine, CGS 21680, carbachol and nitroprusside in the isolated perfused superior mesenteric arterial bed of the rat. Hiley CR, et al. **Br J Pharmacol** 1995 Nov;116(6):2641-6

The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist. Poucher SM, et al. **Br J Pharmacol** 1995 Jul; 115(6):1096-102

Pharmacological analysis of the interaction between purinoceptor agonists and antagonists in the guinea-pig taenia caecum. Prentice DJ, et al. **Br J Pharmacol** 1995 Jun;115(4):549-56

Contribution of P1-(A2b subtype) and P2-purinoceptors to the control of vascular tone in the rat isolated mesenteric arterial bed. Rubino A, et al. **Br J Pharmacol** 1995 Jun; 115(4):648-52

Adenosine modulates methylmercuric chloride (MeHgCl)-induced D-aspartate release from neonatal rat primary astrocyte cultures. Aschner M, et al. **Brain Res** 1995 Aug 14;689(1):1-8

Adrenergic, insulin, and work interactions with adenosine's effects on in situ myocardial glucose uptake. Law WR, et al. **Cardiovasc Res** 1996 May;31(5):691-8

Adenosine increases potassium conductance in isolated rabbit atrioventricular nodal myocytes. Martynyuk AE, et al. **Cardiovasc Res** 1995 Nov;30(5):668-75

Synergistic modulation of ATP-sensitive K+ currents by protein kinase C and adenosine. Implications for ischemic preconditioning. Liu Y, et al. **Circ Res** 1996 Mar; 78(3):443-54

Adenosine-induced vasoconstriction in vivo. Role of the mast cell and A3 adenosine receptor. Shepherd RK, et al. **Circ Res** 1996 Apr;78(4):627-34

Quantitative relation between interstitial adenosine concentration and coronary blood flow. Stepp DW, et al. **Circ Res** 1996 Sep;79(3):601-10

Cellular basis for the negative dromotropic effect of adenosine on rabbit single atrioventricular nodal cells. Wang D, et al. **Circ Res** 1996 Apr;78(4):697-706

Modulation of the hyperpolarization-activated current (I(f)) by adenosine in rabbit sinoatrial myocytes. Zaza A, et al. **Circulation** 1996 Aug 15;94(4):734-41

Glyceryl trinitrate enhances the adenosine-induced inhibition of platelet responses: a mechanism potentially involved in the in vivo anti-aggregating effects of organic nitrates. Anfossi G, et al. **Clin Exp Pharmacol Physiol** 1995 Nov; 22(11):803-11 (57 ref.)

Effects of adenosine on chick retinal pigment epithelium: membrane potentials and light-evoked responses. Maruiwa F, et al. **Curr Eye Res** 1995 Aug;14(8):685-91

Adenosine stimulates calcium influx in isolated rat hepatocytes. Tinton SA, et al. **Eur J Biochem** 1996 Jun 1;238(2):576-81

Complex role of peripheral adenosine in the genesis of the response to subcutaneous formalin in the rat. Doak GJ, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):311-8

Antinociception by adenosine analogs and an adenosine kinase inhibitor: dependence on formalin concentration. Poon A, et al. **Eur J Pharmacol** 1995 Nov 14;286(2):177-84

8-substituted adenosine and theophylline-7-riboside analogues as potential partial agonists for the adenosine A1 receptor. Van der Wenden EM, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):189-99

Adenosine and propentofylline inhibit the proliferation of cultured microglial cells. Si QS, et al. **Exp Neurol** 1996 Feb;137(2):345-9

Adenosine evokes potassium currents by protein kinase C activated via a novel signaling pathway in superior colliculus neurons. Nishizaki T, et al. **FEBS Lett** 1996 Jan 2;378(1):1-6

The effect of exogenous adenosine on functional injury caused by hydrogen peroxide in the isolated rat heart. Valen G, et al. **Free Radic Res** 1996 Jan;24(1):31-38

Effect of adenosine on bicuculline-resistant paired-pulse inhibition in the rat hippocampal slice. Higgins MJ, et al. **Hippocampus** 1995;5(3):209-16

Adenosine inhibits growth of rat aortic smooth muscle cells. Possible role of A2b receptor. Dubey RK, et al. **Hypertension** 1996 Mar;27(3 Pt 2):786-93

Methylxanthines with adenosine alter TNF alpha-primed PMN activation. Sullivan GW, et al. **Immunopharmacology** 1995 Nov;31(1):19-29

The effect of adenosine on histamine release from rat peritoneal mast cells induced by the calcium ionophore in buffers containing different calcium concentrations. Forsythe P, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S19-20

Effects of adenosine on cAMP production during early development in the optic tectum of chicks. Tasca CI, et al. **Int J Dev Neurosci** 1995 Oct;13(6):545-53

The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity. Sullivan GW, et al. **Int J Immunopharmacol** 1995 Oct;17(10):793-803

Adenosine promotes regulation of corneal hydration through cyclic adenosine monophosphate. Riley MV, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):1-10

Activation of adenosine receptors before ischemia enhances tolerance against myocardial stunning in the rabbit heart. Ogawa T, et al. **J Am Coll Cardiol** 1996 Jan;27(1):225-33

The potent relaxant effect of adenosine in rabbit corpora cavernosa is nitric oxide independent and mediated by A2 receptors. Mantelli L, et al. **J Androl** 1995 Jul-Aug; 16(4):312-7

Adenosine activates cardiac sympathetic afferent fibers and potentiates the excitation induced by coronary occlusion. Gnecchi-Ruscone T, et al. **J Auton Nerv Syst** 1995 Jun 25;53(2-3):175-84

Molecular basis for subtype-specific desensitization of inhibitory adenosine receptors. Analysis of a chimeric A1-A3 adenosine receptor. Palmer TM, et al.

J Biol Chem 1996 Jun 21;271(25):15272–8

Effects of adenosine and 2-chloroadenosine on cerebral collateral vessels. Muhonen MG, et al. **J Cereb Blood Flow Metab** 1995 Nov;15(6):1075–81

Adenosine modulates vasomotor tone in outer medullary descending vasa recta of the rat. Silldorff EP, et al. **J Clin Invest** 1996 Jul 1;98(1):18–23

Adenosine enhances IL-10 secretion by human monocytes. Le Moine O, et al. **J Immunol** 1996 Jun 1;156(11):4408–14

Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. Sajjadi FG, et al. **J Immunol** 1996 May 1;156(9):3435–42

Effect of adenosine on the expression of beta(2) integrins and L-selectin of human polymorphonuclear leukocytes in vitro. Thiel M, et al. **J Leukoc Biol** 1996 May; 59(5):671–82

Carbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl)adenines. Borcherding DR, et al. **J Med Chem** 1996 Jun 21; 39(13):2615–20

Effect of endothelin-1 and its combination with adenosine on myocardial contractility and myocardial energy metabolism in vivo. Beyer ME, et al. **J Mol Cell Cardiol** 1995 Sep;27(9):1989–97

Behavioural effects of adenosine locally applied into ventral hippocampus of adult male rats. Salas SL, et al. **J Neural Transm Gen Sect** 1995;100(1):63–72

Increased acetylcholine content induced by antidromic stimulation of a sympathetic ganglion: a possible retrograde action of adenosine. Tandon A, et al. **J Neurochem** 1995 Nov;65(5):2116–23

Adenosine facilitates in vivo neurotransmission in the superior colliculus of the rat. Hirai H, et al. **J Neurophysiol** 1995 Sep;74(3):950–60

Opioid and adenosine peripheral antinociception are subject to tolerance and withdrawal. Aley KO, et al. **J Neurosci** 1995 Dec;15(12):8031–8

Ischemic preconditioning, adenosine and bethanechol protect spontaneously hypertensive isolated rat hearts. Boutros A, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1148–56

Interactions between ethanol, endogenous adenosine and adenosine uptake in hippocampal brain slices. Diao L, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):542–6

Mechanisms of [Ca++]i elevation induced by erythrocyte components in endothelial cells. Zhang H, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1501–9

Influence of spasmogen inhalation by guinea pigs upon subsequent demonstration of ovalbumin-induced hyperreactivity in isolated airways tissues. Lewis CA, et al. **J Pharmacol Toxicol Methods** 1995 Dec;34(4):187–98

The role of adenosine in functional hyperaemia in the coronary circulation of anaesthetized dogs. Karim F, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):793–803

A-type potassium current modulated by A1 adenosine receptor in frog melanotrophs. Mei YA, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):431–42

The role of adenosine in mediating vasodilatation in mesenteric circulation of the rat in acute and chronic hypoxia. Mian R, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):225–34

Improvement in functional recovery of the isolated guinea pig heart after hyperkalemic reperfusion with adenosine. Habazettl H, et al. **J Thorac Cardiovasc Surg** 1996 Jan; 111(1):74–84

Local application of adenosine induces an increase of capillary diameter in skeletal muscle of anesthetized rabbits. Bosman J, et al. **J Vasc Res** 1996 Mar-Apr;33(2):111–8

Excitation and inhibition via adenosine receptors of the twitch response to electrical stimulation in isolated guinea pig ileum. Tomaru A, et al. **Jpn J Pharmacol** 1995 Dec; 69(4):429–33

Glutamate-independent long term depression in rat hippocampus by activation GABAA receptors. Akhondzadeh S, et al. **Life Sci** 1996;58(13):1024–30

Effect of adenosine and adenosine agonists on amylase release from rat pancreatic lobules. Rodriguez-Nodal F, et al. **Life Sci** 1995;57(17):PL253–8

Altered endothelium-mediated relaxation by sympathectomy in isolated rabbit carotid artery rings. Kaya T, et al. **Methods Find Exp Clin Pharmacol** 1995 Jul-Aug; 17(6):369–75

Frameshift mutagenesis by 9-aminoacridine: antimutagenic effects of adenosine compounds. Kopsidas G, et al. **Mutat Res** 1996 Jun 10;352(1–2):135–42

Vasodilatation produced by adenosine in isolated rat perfused mesenteric artery: a role for endothelium. Tabrizchi R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Oct; 352(4):412–8

Renal haemodynamic responses to adenosine in acute renal failure. Gould J, et al. **Nephron** 1995;71(2):184–9

Effects of adenosine on norepinephrine and acetylcholine release from guinea pig right atrium: role of A1-receptors. Nakatsuka H, et al. **Neurochem Int** 1995 Oct-Nov; 27(4–5):345–53

Modulation of adenosine-induced cAMP accumulation via metabotropic glutamate receptors in chick optic tectum. Tasca CI, et al. **Neurochem Res** 1995 Sep;20(9):1033–9

Purinergic inhibition of GABA and glutamate release in the thalamus: implications for thalamic network activity. Ulrich D, et al. **Neuron** 1995 Oct;15(4):909–18

Comparative sensitivity to adenosine of paired-pulse inhibition and single field potentials in the rat hippocampus. Higgins MJ, et al. **Neurosci Lett** 1996 May 3;209(1):69–72

Adenosine activates the potassium channel via a P2 purinoceptor but not via an adenosine receptor in cultured rat superior colliculus neurons. Ikeuchi Y, et al. **Neurosci Lett** 1995 Oct 6;198(3):205–8

Electrophysiological study on spinal antinociceptive interactions between adenosine and morphine in the dorsal horn of the rat. Reeve AJ, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):81–4

A1-receptor-mediated effect of adenosine on the release of acetylcholine from the myenteric plexus: role and localization of ecto-ATPase and 5'-nucleotidase. Nitahara K, et al. **Neuroscience** 1995 Jul;67(1):159–68

Nitric oxide mediates the anti-adrenergic effect of adenosine on calcium current in isolated rabbit atrioventricular nodal cells. Martynyuk AE, et al. **Pflugers Arch** 1996 Jan; 431(3):452–7

Spatial heterogeneity of blood flow in the dog heart. I. Glucose uptake, free adenosine and oxidative/glycolytic enzyme activity. Sonntag M, et al. **Pflugers Arch** 1996 Jul; 432(3):439–50

Adenosine activates ATP-sensitive potassium channels in arterial myocytes via A2 receptors and cAMP-dependent protein kinase. Kleppisch T, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12441–5

Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension. Brett SJ, et al. **Thorax** 1996 Jan;51(1):89–91

Supersensitivity mismatch of adenosine in the transplanted human heart: chrono- and dromotropy versus inotropy. Koglin J, et al. **Transpl Int** 1996;9(1):9–14

Adenosine, antioxidant enzymes and cytoprotection. Ramkumar V, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):283–5 (31 ref.)

[Effects of exogenous adenosine on myocardial recovery after acute hemorrhage] Yahagi M, et al. **Masui** 1995 Sep; 44(9):1218–23 (Eng. Abstr.) **(Jpn)**

[The effect of adenosine on the hypothalamo-hypophyseal-adrenal system] Kononenko Vla, et al. **Fiziol Zh** 1994 Sep-Dec;40(5–6):20–3 (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

Theophylline increases coronary vascular tone in humans: evidence for a role of endogenous adenosine in flow regulation. Edlund A, et al. **Acta Physiol Scand** 1995 Nov; 155(3):303–11

Possible central adenosinergic modulation of ethanol-induced alterations in [14C]glucose utilization in mice. Anwer J, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):777–83

Possible role of striatal adenosine in the modulation of acute ethanol-induced motor incoordination in rats. Meng ZH, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):892–901

Different properties of the atrial G protein-gated K+ channels activated by extracellular ATP and adenosine. Fu C, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1349–58

Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. **Anesthesiology** 1995 Oct; 83(4):658–73

Adenosine: a prototherapeutic concept in neurodegeneration. von Lubitz DK, et al. **Ann N Y Acad Sci** 1995 Sep 15; 765:163–78; discussion 196–7 (123 ref.)

Release of oxygen metabolites from chemoattractant-stimulated neutrophils is inhibited by resting platelets: role of extracellular adenosine and actin polymerization. Bengtsson T, et al. **Blood** 1996 May 15; 87(10):4411–23

The involvement of ATP-sensitive potassium channels and adenosine in the regulation of coronary flow in the isolated perfused rat heart. Randall MD. **Br J Pharmacol** 1995 Dec; 116(7):3068–74

Potentiation by neurosteroids of muscimol/adenosine interactions in rat hippocampus. Akhondzadeh S, et al. **Brain Res** 1995 Apr 24;677(2):311–8

Role of nitric oxide, adenosine, N-methyl-D-aspartate receptors, and neuronal activation in hypoxia-induced pial arteriolar dilation in rats. Pelligrino DA, et al. **Brain Res** 1995 Dec 15;704(1):61–70

Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Smits P, et al. **Circulation** 1995 Oct 15;92(8):2135–41

A role for adenosine in coronary vasoregulation in man. Effects of theophylline and enprofylline. Edlund A, et al. **Clin Physiol** 1995 Nov;15(6):623–36

The role of adenosine in the hypotensive actions of morphine. White PJ, et al. **Eur J Pharmacol** 1995 Nov 24; 286(3):315–19

Functional role of endogenous adenosine in human chronic renal disease. Balakrishnan VS, et al. **Exp Nephrol** 1996 Jan-Feb;4(1):26–36

Adenosine does not mediate renal sodium retention and peripheral vasodilation elicited by partial portal vein ligation in rats. Murakami S, et al. **Hepatology** 1996 Feb; 23(2):346–52

Role of nitric oxide, adenosine, and ATP-sensitive potassium channels in insulin-induced vasodilation. McKay MK, et al. **Hypertension** 1996 Aug;28(2):202–8

Hypoglycemic hyperemia in retina of newborn pigs. Involvement of adenosine. Zhu Y, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):86–92

Adenosine: potential modulator for vasovagal syncope. Shen WK, et al. **J Am Coll Cardiol** 1996 Jul;28(1):146–54

Role of K+ ATP channels and adenosine in the regulation of coronary blood flow during exercise with normal and restricted coronary blood flow. Duncker DJ, et al. **J Clin Invest** 1996 Feb 15;97(4):996–1009

Increased defibrillation threshold due to ventricular fibrillation duration. Potential mechanisms. Lerman BB, et al. **J Electrocardiol** 1995;28 Suppl:21–4

Effect of adenosine on Na+ and Cl- currents in A6 monolayers. Receptor localization and messenger involvement. Casavola V, et al. **J Membr Biol** 1996 Jun; 151(3):237–45

Endogenous adenosine reduces depression of cardiac function induced by beta-adrenergic stimulation during low flow perfusion. Fenton RA, et al. **J Mol Cell Cardiol** 1995 Oct; 27(10):2373–83

Differential stress protein mRNA expression during early ischaemic preconditioning in the rabbit heart and its relationship to adenosine receptor function. Heads RJ, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2133–48

Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. Mullane K, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):1041–54 (145 ref.)

Adenosine pre- and postsynaptic modulation of glutamate-dependent calcium activity in hypothalamic neurons. Obrietan K, et al. **J Neurophysiol** 1995 Nov; 74(5):2150–62

Adenosine mediates metabolic and cardiovascular responses to hypoxia in fetal sheep. Koos BJ, et al. **J Physiol (Lond)** 1995 Nov 1;488 (Pt 3):761–6

Adenosine-induced apoptosis in chick embryonic sympathetic neurons: a new physiological role for adenosine. Wakade TD, et al. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):123–38

Role of adenosine in the renal responses to contrast medium. Arakawa K, et al. **Kidney Int** 1996 May;49(5):1199–206

Ischaemic preconditioning [letter; comment] Andreotti F, et al. **Lancet** 1996 Jul 20;348(9021):204. Comment on: Lancet 1996 Apr 27;347(9009):1159–62.

Adenosine attenuation of isoproterenol-stimulated adenylyl cyclase activity is enhanced with aging in the adult heart. Romano FD, et al. **Life Sci** 1996;58(6):493–502

Modulation of protein kinase C by adenosine: involvement of adenosine A1 receptor-pertussis toxin sensitive nucleotide binding protein system. Marala RB, et al. **Mol Cell Biochem** 1995 Aug-Sep;149–150:51–8 (56 ref.)

Regulation of rhythmic movements by purinergic neurotransmitters in frog embryos. Dale N, et al. **Nature** 1996 Sep 19;383(6597):259–63

Purinergic inhibition of neurotransmitter release in the central nervous system. Ribeiro JA. **Pharmacol Toxicol** 1995 Nov; 77(5):299–305 (68 ref.)

SECRETION

Modulation of adenosine release from rat spinal cord by adenosine deaminase and adenosine kinase inhibitors. Golembiowska K, et al. **Brain Res** 1995 Nov 20; 699(2):315–20

Effect of antiarrhythmics on the release of adenosine in rat hearts with coronary occlusion and reperfusion. Bernauer W. **Eur J Pharmacol** 1995 Sep 5;283(1–3):91–8

Spinal opioid receptors and adenosine release: neurochemical and behavioral characterization of opioid subtypes. Cahill CM, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):84–93

Hypothesis on cellular ATP depletion and adenosine release as causes of heart failure and vasodilatation in cardiovascular beriberi. Bakker SJ, et al. **Med Hypotheses** 1995 Sep;45(3):265–7

THERAPEUTIC USE

Adenosine for per-operative blood pressure control in an infant with neuroblastoma. Selldén H, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):705–8

Intraoperative ventricular tachycardia responsive to adenosine. Wagner SR 4th, et al. **Anesth Analg** 1996 May; 82(5):1086–8

Magnesium sulfate for conversion of supraventricular tachycardia refractory to intravenous adenosine. LeDuc TJ, et al. **Ann Emerg Med** 1996 Mar;27(3):375–8

Effect of adenosine on the management of supraventricular tachycardia by urban paramedics. Lozano M Jr, et al. **Ann Emerg Med** 1995 Dec;26(6):691–6

Adenosine in acute theophylline intoxication. Blery JC, et al. **Ann Pharmacother** 1995 Dec;29(12):1285–7

Adenosine use in a pregnant patient with supraventricular tachycardia [letter] Hagley MT, et al. **Ann Pharmacother** 1995 Sep;29(9):938

Adenosine effectively controls pulmonary hypertension after cardiac operations [see comments] Fullerton DA, et al. **Ann Thorac Surg** 1996 Apr;61(4):1118–23; discussion 1123–4. Comment in: Ann Thorac Surg 1996 Apr;61(4):1051–2.

Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Vander Heide RS, et al. **Cardiovasc Res** 1996 May;31(5):711–8

Adenosine is a selective pulmonary vasodilator in cardiac surgical patients. Fullerton DA, et al. **Chest** 1996 Jan; 109(1):41–6

Intramyocardial injections and protection against myocardial ischemia. An attempt to examine the cardioprotective actions of adenosine. Whittaker P, et al. **Circulation** 1996 Jun 1;93(11):2043–57

Nodal re-entry tachycardia with angina treated with adenosine [letter] Nyberg G, et al. **Eur Heart J** 1996 Apr; 17(4):643

Adenosines scavenged hydroxyl radicals and prevented posttraumatic epilepsy. Yokoi I, et al. **Free Radic Biol Med** 1995 Oct;19(4):473–9

Pretreatment of human myocardium with adenosine during open heart surgery. Lee HT, et al. **J Card Surg** 1995 Nov; 10(6):665–76

Cardioprotection by adenosine: is it a question of effective dose, timing, or the target compartment? [letter; comment] Vinten-Johansen J, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):202–4. Comment on: J Thorac Cardiovasc Surg 1995 Jul;110(1):63–74.

Adenosine infusion improves oxygenation in term infants with respiratory failure. Konduri GG, et al. **Pediatrics** 1996 Mar;97(3):295–300

[Adenosine in the treatment of supraventricular arrhythmias] Lommi J, et al. **Duodecim** 1994;110(5):473–7 (27 ref.) **(Fin)**

[Adenosine as an anti-arrhythmia agent] Scheininger MJ, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):139–40 **(Ger)**

[Paroxysmal supraventricular tachycardia in pregnancy. Value of adenosine and other anti-arrhythmia agents] Hösl P, et al. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):313–6 (Eng. Abstr.) **(Ger)**

[Effects of adenosine on the heart—therapeutic and diagnostic possibilities] Stark U, et al. **Wien Klin Wochenschr** 1996;108(12):343–51 (61 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Quantitative analysis of similarities and differences in neurotoxicities caused by adenosine and 2'-deoxyadenosine in sympathetic neurons. Kulkarni JS, et al. **J Neurochem** 1996 Aug;67(2):778–86

ADENOSINE AMINOHYDROLASE see **ADENOSINE DEAMINASE**

ADENOSINE CYCLIC MONOPHOSPHATE-DEPENDENT PROTEIN KINASES see **CYCLIC AMP-DEPENDENT PROTEIN KINASES**

ADENOSINE CYCLIC 3',5'-MONOPHOSPHATE see **CYCLIC AMP**

ADENOSINE DEAMINASE

Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26/dipeptidyl peptidase IV (EC 3.4.14.5). de Meester I, et al. **J Immunol Methods** 1996 Jan 16;189(1):99–105

ANALYSIS

Adenosine deaminase (ADA) activity in tissues and sera from normal and leukaemic cattle. Yasuda J, et al. **Br Vet J** 1996 Jul;152(4):485–8

Adenosine deaminase in pericardial fluids. Which test is best? [letter] Miller KD. **Chest** 1995 Dec;108(6):1766

Rapid automated determination of adenosine deaminase and lysozyme for differentiating tuberculous and nontuberculous pleural effusions. Villena V, et al. **Clin Chem** 1996 Feb;42(2):218–21

Adenosine deaminase in the diagnosis of tuberculosis pleural effusion [editorial] Sharma SK, et al. **Indian J Chest Dis Allied Sci** 1996 Apr–Jun;38(2):69–71

Validation of the determination of the activity of adenosine deaminase in the body effusions of cats. Hirschberger J, et al. **Res Vet Sci** 1995 Nov;59(3):226–9

Tumour necrosis factor, interleukin-1 and adenosine deaminase in tuberculous pleural effusion. Orphanidou D, et al. **Respir Med** 1996 Feb;90(2):95–8

[Measurement of adenosine deaminase activity in bronchoalveolar lavage fluids as a tool for diagnosing miliary tuberculosis] Kubota M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):139–44 (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Inhibition of adenosine deaminase and administration of adenosine increase hypoxia induced ventricular ectopy. Leone RJ Jr, et al. **Basic Res Cardiol** 1995 May–Jun; 90(3):234–9

Adenosine deaminase inhibition prevents free radical–mediated injury in the postischemic heart. Xia Y, et al. **J Biol Chem** 1996 Apr 26;271(17):10096–102

Theoretical study of inhibition of adenosine deaminase by (8R)–coformycin and (8R)–deoxycoformycin. Marrone TJ, et al. **J Med Chem** 1996 Jan 5;39(1):277–84

Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3',5'-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung. Haynes J Jr, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):752–7

Induction of apoptosis by cordycepin in ADA-inhibited TdT-positive leukemia cells. Koç Y, et al. **Leukemia** 1996 Jun;10(6):1019–24

Enhancement of the anti-HIV-1 activity of ddAdo by coformycin, EHNA and deaza-EHNA derivatives. Marongiu ME, et al. **New Microbiol** 1995 Oct;18(4):359–70

Inhibition of adenosine deaminase activity of aortic endothelial cells by selected flavonoids. Melzig MF. **Planta Med** 1996 Feb;62(1):20–1

BIOSYNTHESIS

High-level expression from a cytomegalovirus promoter in macrophage cells. Ramesh N, et al. **Hum Gene Ther** 1995 Oct;6(10):1323–7

Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. Blackburn MR, et al. **J Biol Chem** 1996 Jun 21;271(25):15203–10

Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Patterson JB, et al. **Mol Cell Biol** 1995 Oct;15(10):5376–88

Regulation and function of adenosine deaminase in mice. Blackburn MR, et al. **Prog Nucleic Acid Res Mol Biol** 1996; 55:195–226

BLOOD

Adenosine deaminase in progressive systemic sclerosis. Meunier P, et al. **Acta Derm Venereol** 1995 Jul;75(4):297–9

Adenosine deaminase isoenzyme levels in patients with human T-cell lymphotropic virus type 1 and human immunodeficiency virus type 1 infections. Tsuboi I, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):626–30

A correlation study between serum adenosine deaminase activities and peripheral lymphocyte subsets in Parkinson's disease. Chiba S, et al. **J Neurol Sci** 1995 Oct;132(2):170–3

[Role of serum adenosine deaminase as an immune parameter of tuberculosis] Kelbel C, et al. **Pneumologie** 1995 Dec; 49(12):684–8 (Eng. Abstr.) **(Ger)**

[Adenosine deaminase] Sakura N. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:299–302 (20 ref.) **(Jpn)**

[Adenosine deaminase isoenzymes in patients with Graves' disease] Nishikawa Y, et al. **Rinsho Byori** 1995 Oct; 43(10):1057–60 (Eng. Abstr.) **(Jpn)**

[Pleural tuberculosis with negative ADA (letter)] Marcos Sánchez F, et al. **An Med Interna** 1996 Mar;13(3):149–50 **(Spa)**

[Adenosine deaminase (ADA) and beta 2-microglobulin (beta 2M) as discriminating serum markers of progression to AIDS] Pérez de Oteyza C, et al. **An Med Interna** 1996 May;13(5):217–21 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Cerebrospinal fluid adenosine deaminase activity and C-reactive protein in tuberculous and partially treated bacterial meningitis. Mishra OP, et al. **Indian Pediatr** 1995 Aug;32(8):886–9

Adenosine deaminase in cerebrospinal fluid during brucella meningitis [letter; comment] da Cunha S. **J Infect** 1995 Jul; 31(1):82–3. Comment on: J Infect 1994 Jul;29(1):41–4.

Cerebrospinal fluid adenosine deaminase activity for the diagnosis of tuberculous meningitis in children. Mishra OP, et al. **J Trop Pediatr** 1996 Jun;42(3):129–32

Adenosine deaminase levels in cerebrospinal fluid in tuberculosis and bacterial meningitis [letter; comment] Gakis C. **Tuber Lung Dis** 1995 Aug;76(4):372–3. Comment on: Tubercle 1991 Sep;72(3):190–2. Comment on: Tuber Lung Dis 1992 Oct;73(5):308–9.

[Cauda equina syndrome with elevated adenosine deaminase in a patient with HIV infection (letter)] Alonso JJ, et al. **Enferm Infecc Microbiol Clin** 1995 Aug–Sep;13(7):444–5 **(Spa)**

CHEMISTRY

Homogeneous assays for riboflavin mediated by the interaction between enzyme-biotin and avidin-riboflavin conjugates. Kim MJ, et al. **Anal Biochem** 1995 Nov 1; 231(2):400–6

Probing the functional role of two conserved active site aspartates in mouse adenosine deaminase. Sideraki V, et al. **Biochemistry** 1996 Jun 18;35(24):7862–72

DEFICIENCY

Granulocyte colony-stimulating factor recruitment of CD34+ progenitors to peripheral blood: impaired mobilization in chronic granulomatous disease and adenosine deaminase—deficient severe combined immunodeficiency disease patients. Sekhsaria S, et al. **Blood** 1996 Aug 1;88(3):1104–12

PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Hershfield MS. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S228–32

Adenosine deaminase deficiency: molecular basis and recent developments. Hirschhorn R. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S219–27 (66 ref.)

Steps toward gene therapy: 1. The initial trials. Blaese RM. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):33–40 (7 ref.)

Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. Blackburn MR, et al. **J Biol Chem** 1996 Jun 21;271(25):15203–10

Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency. Ramsey WJ, et al. **Leukemia** 1995 Oct;9 Suppl 1:S70

Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. Bollinger ME, et al. **N Engl J Med** 1996 May 23;334(21):1367–71

Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency [see comments] Hirschhorn R, et al. **Nat Genet** 1996 Jul; 13(3):290–5. Comment in: Nat Genet 1996 Jul;13(3):255–6.

Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Kohn DB, et al. **Nat Med** 1995 Oct;1(10):1017–23

T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Blaese RM, et al. **Science** 1995 Oct 20;270(5235):475–80

Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Bordignon C, et al. **Science** 1995 Oct 20;270(5235):470–5

A case of adenosine deaminase-negative severe combined immunodeficiency with neurological abnormalities. Tezcan I, et al. **Turk J Pediatr** 1995 Oct-Dec;37(4):383–9

[Gene therapy for adenosine deaminase deficiency] Sakiyama Y. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):27–32 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Gene therapy for ADA deficiency] Ariga T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2772–80 (13 ref.) **(Jpn)**

DRUG EFFECTS

Modulation of adenosine release from rat spinal cord by adenosine deaminase and adenosine kinase inhibitors. Golembiowska K, et al. **Brain Res** 1995 Nov 20; 699(2):315–20

Developmental expression and corticosterone inhibition of adenosine deaminase activity in different tissues of mice. Singh LS, et al. **Mech Ageing Dev** 1995 May 12;80(2):85–92

GENETICS

Adenosine deaminase deficiency: molecular basis and recent developments. Hirschhorn R. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S219–27 (66 ref.)

Exclusion of adenosine deaminase gene locus on chromosome 20q12–13.1 in familial NIDDM in Taiwanese patients [letter] Chuang LM, et al. **Diabetologia** 1995 Dec; 38(12):1490–1

Identification of a murine homolog of the human adenosine deaminase thymic enhancer. Brickner AG, et al. **Gene** 1995 Dec 29;167(1–2):261–6

Gene organization in the ada-rplL region of Streptomyces virginiae. Katayama M, et al. **Gene** 1996 May 24; 171(1):135–6

The interferon-inducible, double-stranded RNA-specific adenosine deaminase gene (DSRAD) maps to human chromosome 1q21.1–21.2. Weier HU, et al. **Genomics** 1995 Nov 20;30(2):372–5

Interaction between ABO blood groups and ADA genetic polymorphism during intrauterine life. A comparative analysis of couples with habitual abortion and normal puerperae delivering a live-born infant. Lucarini N, et al. **Hum Genet** 1995 Nov;96(5):527–31

Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA. Santisteban I, et al. **Hum Mol Genet** 1995 Nov;4(11):2081–7

Structural requirements for RNA editing in glutamate receptor pre-mRNAs by recombinant double-stranded RNA adenosine deaminase. Maas S, et al. **J Biol Chem** 1996 May 24;271(21):12221–6

Genomic organization and chromosomal location of the human dsRNA adenosine deaminase gene: the enzyme for glutamate-activated ion channel RNA editing. Wang Y, et al. **J Mol Biol** 1995 Nov 24;254(2):184–95

Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency. Ramsey WJ, et al. **Leukemia** 1995 Oct;9 Suppl 1:S70

Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency [see comments] Hirschhorn R, et al. **Nat Genet** 1996 Jul; 13(3):290–5. Comment in: Nat Genet 1996 Jul;13(3):255–6.

Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Kohn DB, et al. **Nat Med** 1995 Oct;1(10):1017–23

T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Blaese RM, et al. **Science** 1995 Oct 20;270(5235):475–80

Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Bordignon C, et al. **Science** 1995 Oct 20;270(5235):470–5

A 43.5 kb segment of yeast chromosome XIV, which contains MFA2, MEP2, CAP/SRV2, NAM9, FKB1/FPR1/RBP1, MOM22 and CPT1, predicts an adenosine deaminase gene and 14 new open reading frames. Mallet L, et al. **Yeast** 1995 Sep 30;11(12):1195–209

[The human adenosine deaminase gene contains a p53-responsive element] Kondratov RV, et al. **Dokl Akad Nauk** 1996 Jan;346(2):260–2 **(Rus)**

ADENOSINE DEAMINASE

ISOLATION & PURIFICATION

Adenosine deaminase from human thyroid purification and some properties. Jaroszewicz L, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1096–103

METABOLISM

Adenosine deaminase from human thyroid purification and some properties. Jaroszewicz L, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1096–103

Site-directed mutagenesis of active site glutamate-217 in mouse adenosine deaminase. Mohamedali KA, et al. **Biochemistry** 1996 Feb 6;35(5):1672–80

Enzyme-substrate complexes of adenosine and cytidine deaminases: absence of accumulation of water adducts. Shih P, et al. **Biochemistry** 1996 Apr 16;35(15):4697–703

Probing the functional role of two conserved active site aspartates in mouse adenosine deaminase. Sideraki V, et al. **Biochemistry** 1996 Jun 18;35(24):7862–72

Enhancement of NMDA-induced increases in levels of endogenous adenosine by adenosine deaminase and adenosine transport inhibition in rat striatum. Delaney SM, et al. **Brain Res** 1995 Dec 8;702(1–2):72–6

Activities of adenosine deaminase, 5'-nucleotidase, guanase, and cytidine deaminase enzymes in cancerous and non-cancerous human breast tissues. Canbolat O, et al. **Breast Cancer Res Treat** 1996;37(2):189–93

Combined use of pleural adenosine deaminase with lymphocyte/neutrophil ratio. Increased specificity for the diagnosis of tuberculous pleuritis. Burgess LJ, et al. **Chest** 1996 Feb;109(2):414–9

Editing of the GLuR-B ion channel RNA in vitro by recombinant double-stranded RNA adenosine deaminase. Dabiri GA, et al. **EMBO J** 1996 Jan 2;15(1):34–45

The diagnostic and prognostic value of adenosine deaminase in tuberculous pericarditis. Komsuoğlu B, et al. **Eur Heart J** 1995 Aug;16(8):1126–30

Specific binding of adenosine deaminase but not HIV-1 transactivator protein Tat to human CD26. Blanco J, et al. **Exp Cell Res** 1996 May 25;225(1):102–11

Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. Ciruela F, et al. **FEBS Lett** 1996 Feb 19;380(3):219–23

Tissue-specific rescue suggests that placental adenosine deaminase is important for fetal development in mice. Blackburn MR, et al. **J Biol Chem** 1995 Oct 13; 270(41):23891–4

Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. Dong RP, et al. **J Immunol** 1996 Feb 15;156(4):1349–55

Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. Martin M, et al. **J Immunol** 1995 Nov 15;155(10):4630–43

Adenosine deaminase isoenzymes and pleural tuberculosis [editorial; comment] Antony VB. **J Lab Clin Med** 1996 Apr;127(4):326–7. Comment on: J Lab Clin Med 1996 Apr;127(4):348–52.

Adenosine deaminase isozymes in tuberculous pleural effusion [see comments] Shibagaki T, et al. **J Lab Clin Med** 1996 Apr;127(4):348–52. Comment in: J Lab Clin Med 1996 Apr;127(4):326–7.

Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 3. 6-Amino prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine. Driscoll JS, et al. **J Med Chem** 1996 Apr 12;39(8):1619–25

Adenosine deaminase interacts with A1 adenosine receptors in pig brain cortical membranes. Saura C, et al. **J Neurochem** 1996 Apr;66(4):1675–82

Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA. Casey JL, et al. **J Virol** 1995 Dec;69(12):7593–600

Mechanism of interferon action: functionally distinct RNA-binding and catalytic domains in the interferon-inducible, double-stranded RNA-specific adenosine deaminase. Liu Y, et al. **J Virol** 1996 Mar; 70(3):1961–8

RNA editing. The long and the short of it [news; comment] Benne R. **Nature** 1996 Apr 4;380(6573):391–2. Comment on: Nature 1996 Apr 4;380(6573):454–6.

A mammalian RNA editing enzyme. Melcher T, et al. **Nature** 1996 Feb 1;379(6564):460–4

RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase [see comments] Polson AG, et al. **Nature** 1996 Apr 4;380(6573):454–6. Comment in: Nature 1996 Apr 4;380(6573):391.

A comparison of some leucocyte differentiation markers and the adenosine deaminase and purine nucleoside phosphorylase values in B and T cell leukemias and lymphomas. Mesárošová A, et al. **Neoplasma** 1995; 42(6):307–12

Double-stranded RNA adenosine deaminase binds Z-DNA in vitro. Herbert A, et al. **Nucleic Acids Symp Ser** 1995; (33):16–9

Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats. Anderson BD, et al. **Pharm Res** 1995 Aug;12(8):1126–33

Deamination of mammalian glutamate receptor RNA by Xenopus dsRNA adenosine deaminase: similarities to in vivo RNA editing. Hurst SR, et al. **RNA** 1995 Dec; 1(10):1051–60

[Adenosine deaminase activity in blood and tissues of horses of the Rassen Haflinger and Thüringer Kaltblut breeds] Leo M, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Oct; 102(10):405–7 (Eng. Abstr.) **(Ger)**

[Opposite effect of p53 on nucleotide metabolizing enzyme activity in Rat1 cells and their sublines, transformed by N-RAS or v-mos oncogenes] Khramtsova SN, et al. **Biokhimiia** 1995 Nov;60(11):1881–8 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

The role of adenosine in functional hyperaemia in the coronary circulation of anaesthetized dogs. Karim F, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):793–803

PHYSIOLOGY

RNA editing. An I for editing. Bass BL. **Curr Biol** 1995 Jun 1;5(6):598–600 (15 ref.)

THERAPEUTIC USE

PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Hershfield MS. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S228–32

ADENOSINE DEAMINASE-BINDING PROTEINS see **ANTIGENS, CD26**

ADENOSINE DIPHOSPHATASE see **APYRASE**

ADENOSINE DIPHOSPHATE

ANALOGS & DERIVATIVES

Endo 5'-nucleotidase in healthy peripheral blood lymphocytes. Inhibition by alpha beta methylene adenosine 5'-diphosphate. Pizzichini M, et al. **Biochem Soc Trans** 1996 Feb;24(1):48S

Mechanism-based inhibition of ribonucleoside diphosphate reductase from Corynebacterium nephridii by 2'-C-methyladenosine diphosphate. McFarlan SC, et al. **Biochemistry** 1996 Apr 9;35(14):4485–91

The end of a polymerizing actin filament contains numerous ATP-subunit segments that are disconnected by ADP-subunits resulting from ATP hydrolysis. Pieper U, et al. **Biochemistry** 1996 Apr 9;35(14):4396–402

Complexes of myosin subfragment-1 with adenosine diphosphate and phosphate analogs: probes of active site and protein conformation. Phan BC, et al. **Biophys Chem** 1996 Apr 16;59(3):341–9

Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Gachet C, et al. **Br J Haematol** 1995 Oct; 91(2):434–44

Platelet activation by 2-(4-bromo-2,3-dioxobutylthio)adenosine 5'-diphosphate is mediated by its binding to a putative ADP receptor, aggregin. Puri RN, et al. **Eur J Biochem** 1996 Mar 15; 236(3):862–70

Structural asymmetry of F1-ATPase caused by the gamma subunit generates a high affinity nucleotide binding site. Kaibara C, et al. **J Biol Chem** 1996 Feb 2;271(5):2433–8

Inhibition of ADP-induced platelet responses by covalent modification of aggregin, a putative ADP receptor, by 8-(4-bromo-2,3-dioxobutylthio)ADP. Puri RN, et al. **J Biol Chem** 1995 Oct 13;270(41):24482–8

Photoaffinity labeling of human recombinant sulfotransferases with 2-azidoadenosine 3',5'-[5'-32P]bisphosphate. Radominska A, et al. **J Biol Chem** 1996 Feb 9;271(6):3195–9

Binding of 2'(3')-O-(2,4-6-trinitrophenyl) ADP to soluble alpha beta protomers of Na, K-ATPase modified with fluorescein isothiocyanate. Evidence for two distinct nucleotide sites. Ward DG, et al. **J Biol Chem** 1996 May 24;271(21):12317–21

Mechanism of inhibition of poly(ADP-ribose) glycohydrolase by adenosine diphosphate (hydroxymethyl)pyrrolidinediol. Slama JT, et al. **J Med Chem** 1995 Oct 13;38(21):4332–6

Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation. Li M, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6902–6

[Calorimetric study of stable complexes of myosin subfragment I with adenosine diphosphate and phosphate analogs] Levitskii DI, et al. **Biofizika** 1996 Jan-Feb; 41(1):64–72 (29 ref.) (Eng. Abstr.) **(Rus)**

ANALYSIS

On-line Raman spectroscopy of ribonucleotides preconcentrated by capillary isotachophoresis. Walker PA 3rd, et al. **Anal Chem** 1995 Dec 1;67(23):4255–60

Modelization of coordinated changes of adenylate energy charge and ATP/ADP ratio: application to energy metabolism in invertebrate and vertebrate skeletal muscle. Raffin JP, et al. **C R Acad Sci III** 1996 Jan;319(1):9–15

Possible links between glucose-induced changes in the energy state of pancreatic B cells and insulin release. Unmasking by decreasing a stable pool of adenine nucleotides in mouse islets. Detimary P, et al. **J Clin Invest** 1995 Oct;96(4):1738–45

ANTAGONISTS & INHIBITORS

Two different inhibitory effects of pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid on adenosine diphosphate-induced human platelet aggregation. Windscheif U, et al. **Arzneimittelforschung** 1995 Sep;45(9):994–7

Inhibition of ADP-induced platelet activation by 7-chloro-4-nitrobenz-2-oxa-1,3-diazole: covalent modification of aggregin, a putative ADP receptor. Puri RN, et al. **J Cell Biochem** 1996 Apr;61(1):97–108

Effects of lomefloxacin and sparfloxacin on human platelet aggregation. Losasso C, et al. **J Chemother** 1995 Oct; 7(5):420–3

BIOSYNTHESIS

Purification and characterization of the acetate forming enzyme, acetyl-CoA synthetase (ADP-forming) from the amitochondriate protist, Giardia lamblia. Sanchez LB, et al. **FEBS Lett** 1996 Jan 15;378(3):240–4

BLOOD

[Nucleotides] Fujii H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:243–6 (5 ref.) **(Jpn)**

CHEMISTRY

Effects of nucleotide on skeletal muscle myosin unfolding in myofibrils by DSC. Lörinczy D, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):592–8

Proton NMR investigation of the [4Fe--4S]1+ cluster environment of nitrogenase iron protein from Azotobacter vinelandii: defining nucleotide-induced conformational changes. Lanzilotta WN, et al. **Biochemistry** 1995 Dec 5; 34(48):15646–53

Conformation of manganese(II)-nucleotide complexes bound to rabbit muscle creatine kinase: 13C NMR measurements using [2-13C]ATP and [2-13C]ADP. Ray BD, et al. **Biochemistry** 1996 Jun 4;35(22):7239–46

Complexes of myosin subfragment-1 with adenosine diphosphate and phosphate analogs: probes of active site and protein conformation. Phan BC, et al. **Biophys Chem** 1996 Apr 16;59(3):341–9

The difference between ADP-beryllium fluoride and ADP-aluminium fluoride complexes of the spin-labeled myosin subfragment 1. Ponomarev MA, et al. **FEBS Lett** 1995 Sep 11;371(3):261–3

Intracellular ADP modulates the Ca2+ release-activated Ca2+ current in a temperature- and Ca2+-dependent Way. Innocenti B, et al. **J Biol Chem** 1996 Apr 12; 271(15):8582–7

DEFICIENCY

Inherited platelet delta-storage pool disease in dogs causing severe bleeding: an animal model for a specific ADP deficiency. Callan MB, et al. **Thromb Haemost** 1995 Sep; 74(3):949–53

METABOLISM

Effects of long-term alcohol intake on ADP ribosylation in rat liver plasma membranes. Nomura F, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):60A–62A

Phosphocreatine synthesis by isolated rat skeletal muscle mitochondria is not dependent upon external ADP: a 31P NMR study. Kernec F, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):819–25

Two tight binding sites for ADP and their interactions during nucleotide exchange in chloroplast coupling factor 1. Digel JG, et al. **Biochemistry** 1995 Nov 7;34(44):14482–9

The alpha 3 beta 3 gamma complex of the F1-ATPase from thermophilic Bacillus PS3 containing the alpha D261N substitution fails to dissociate inhibitory MgADP from a catalytic site when ATP binds to noncatalytic sites. Jault JM, et al. **Biochemistry** 1995 Dec 19;34(50):16412–8

Initial rate and equilibrium isotope exchange studies on the ATP-dependent activity of polyphosphate Glucokinase from Propionibacterium shermanii. Kowalczyk TH, et al. **Biochemistry** 1996 May 28;35(21):6777–85

Phase partition analysis of nucleotide binding to axonemal dynein. Mocz G, et al. **Biochemistry** 1996 Jul 16; 35(28):9204–11

Effect of divalent cations on the formation and stability of myosin subfragment 1-ADP-phosphate analog complexes. Peyser YM, et al. **Biochemistry** 1996 Apr 9;35(14):4409–16

Elucidating the mechanism of nucleotide-dependent changes in the redox potential of the [4Fe-4S] cluster in nitrogenase iron protein: the role of phenylalanine 135. Ryle MJ, et al. **Biochemistry** 1996 Jul 23;35(29):9424–34

Vanadate inhibits vacuolar H(+)-ATPase-mediated proton transport in chicken kidney microsomes by an ADP-dependent mechanism. David P, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):155–60

Identification of adenine binding domain peptides of the ADP regulatory site within glutamate dehydrogenase. Shoemaker MT, et al. **Bioconjug Chem** 1996 May-Jun; 7(3):302–10

Binding of ADP to sarcoplasmic reticulum Ca(2+)-ATPase in the absence of Mg2+ is specifically inhibited by thapsigargin: observations on the ligand stoichiometry.

Hansen O, et al. **Cell Calcium** 1995 Dec;18(6):557-68

Evidence for elongation of the helical pitch of the RecA filament upon ATP and ADP binding using small-angle neutron scattering. Ellouze C, et al. **Eur J Biochem** 1995 Oct 15;233(2):579-83

Identification of two sites in gelsolin with different sensitivities to adenine nucleotides. Laham LE, et al. **Eur J Biochem** 1995 Nov 15;234(1):1-7

Macromolecules increase the channeling of ADP from externally associated hexokinase to the matrix of mitochondria. Laterveer FD, et al. **Eur J Biochem** 1995 Sep 1;232(2):569-77

Formation and characterization of a transition state complex of Azotobacter vinelandii nitrogenase. Duyvis MG, et al. **FEBS Lett** 1996 Feb 19;380(3):233-6

ADP delivery from adenylate kinase in the mitochondrial intermembrane space to oxidative phosphorylation increases in the presence of macromolecules. Laterveer FD, et al. **FEBS Lett** 1996 May 20;386(2-3):255-9

Changes in patterns of ADP-ribosylated proteins during differentiation of Streptomyces coelicolor A3(2) and its development mutants. Shima J, et al. **J Bacteriol** 1996 Jul; 178(13):3785-90

Differences between two tight ADP binding sites of the chloroplast coupling factor 1 and their effects on ATPase activity. Digel JG, et al. **J Biol Chem** 1996 Aug 16; 271(33):19976-82

The chaperonin GroEL is destabilized by binding of ADP. Gorovits BM, et al. **J Biol Chem** 1995 Dec 1; 270(48):28551-6

Global conformational transitions in Escherichia coli primary replicative helicase DnaB protein induced by ATP, ADP, and single-stranded DNA binding. Multiple conformational states of the helicase hexamer. Jezewska MJ, et al. **J Biol Chem** 1996 Feb 23;271(8):4261-5

Purification and characterization of a novel ADP-dependent glucokinase from the hyperthermophilic archaeon Pyrococcus furiosus. Kengen SW, et al. **J Biol Chem** 1995 Dec 22;270(51):30453-7

Equilibrium studies of kinesin-nucleotide intermediates. Rosenfeld SS, et al. **J Biol Chem** 1996 Apr 19; 271(16):9473-82

Respiratory control in heart muscle during fatty acid oxidation. Energy state or substrate-level regulation by Ca2+? Vuorinen KH, et al. **J Mol Cell Cardiol** 1995 Aug; 27(8):1581-91

ADP release produces a rotation of the neck region of smooth myosin but not skeletal myosin [see comments] Gollub J, et al. **Nat Struct Biol** 1996 Sep;3(9):796-802. Comment in: Nat Struct Biol 1996 Sep;3(9):737-9.

A 32 degree tail swing in brush border myosin I on ADP release [see comments] Jontes JD, et al. **Nature** 1995 Dec 14;378(6558):751-3. Comment in: Nature 1995 Dec 14;378(6558):664.

A 35-A movement of smooth muscle myosin on ADP release [see comments] Whittaker M, et al. **Nature** 1995 Dec 14; 378(6558):748-51. Comment in: Nature 1995 Dec 14;378(6558):664.

Adenylate kinase complements nucleoside diphosphate kinase deficiency in nucleotide metabolism. Lu Q, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5720-5

A recombinant peptide model of the first nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator: comparison of wild-type and delta F508 mutant forms. Yike I, et al. **Protein Sci** 1996 Jan;5(1):89-97

Adenosine diphosphate as an intracellular regulator of insulin secretion. Nichols CG, et al. **Science** 1996 Jun 21; 272(5269):1785-7

[The effect of p-chloromercuribenzoate on regulation of oxidative phosphorylation by ADP and ATP and stimulation of liver mitochondrial respiration by palmitate] Samartsev VN, et al. **Biokhimiia** 1995 Oct;60(10):1706-10 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: direct measurement of percent release of beta-thromboglobulin and assessment by flow cytometry of P-selectin expression. Rand ML, et al. **Am J Hematol** 1996 Aug;52(4):288-94

Moderate hypothermia reduces cardiopulmonary bypass-induced impairment of cerebrovascular responses to platelet products. Stamler A, et al. **Ann Thorac Surg** 1996 Jul;62(1):191-8

Internal motions in myosin head: effect of ADP and ATP. Belagyi J, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):936-40

Influence of nucleotides on the cold stability of chloroplast coupling factor 1. Hightower KE, et al. **Biochemistry** 1996 Aug 6;35(31):10051-7

Adenosine diphosphate inhibits the serotonin transporter. Anderson GM, et al. **Biochim Biophys Acta** 1996 Aug 14; 1283(1):14-20

Synergistic action of ADP and 2,3-bisphosphoglycerate on the modulation of cytosolic 5'-nucleotidase. Pesi R, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):191-4

Variability of the thrombin- and ADP-induced Ca2+ response among human platelets measured using fluo-3 and fluorescent videomicroscopy. Tao J, et al. **Biochim Biophys Acta** 1996 May 28;1311(3):164-74

Effect of inorganic phosphate and ADP on the myofilament sliding induced by laser flash photolysis of caged ATP. Wada H, et al. **Biochim Biophys Acta** 1996 Jun 13; 1274(3):89-93

The role of MgADP in force maintenance by dephosphorylated cross-bridges in smooth muscle: a flash photolysis study. Khromov A, et al. **Biophys J** 1995 Dec; 69(6):2611-22

Effects of phosphate and ADP on shortening velocity during maximal and submaximal calcium activation of the thin filament in skeletal muscle fibers. Metzger JM. **Biophys J** 1996 Jan;70(1):409-17

Effect of hematocrit on adenosine diphosphate-induced aggregation of human platelets in tube flow. Goldsmith HL, et al. **Biorheology** 1995 Sep-Oct;32(5):537-52

Actions of ADP, but not ATP, on cytosolic free Ca2+ in single rat hepatocytes mimicked by 2-methylthioATP. Dixon CJ, et al. **Br J Pharmacol** 1995 Oct;116(3):1979-84

Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo. Humphries RG, et al. **Br J Pharmacol** 1995 Jul;115(6):1110-6

Additive effect of ADP and CGRP in modulation of the acetylcholine receptor channel in Xenopus embryonic myocytes. Liou JC, et al. **Br J Pharmacol** 1995 Jun; 115(4):563-8

Influence of ADP, AMP-PNP and of depletion of nucleotides on the structural properties of F1ATPase: a Fourier transform infrared spectroscopic study. Lippe G, et al. **FEBS Lett** 1995 Oct 9;373(2):141-5

Effects of diltiazem and verapamil on ADP-induced rabbit platelet shape change and aggregation. Dehpour AR, et al. **Gen Pharmacol** 1995 Oct;26(6):1295-9

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. Kleiman NS, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1665-71

Inhibition of ADP-induced platelet responses by covalent modification of aggregin, a putative ADP receptor, by 8-(4-bromo-2,3-dioxobutylthio)ADP. Puri RN, et al. **J Biol Chem** 1995 Oct 13;270(41):24482-8

Effects of adenosine diphosphate on the structure of myosin cross-bridges: an X-ray diffraction study on a single skinned frog muscle fibre. Takemori S, et al. **J Muscle Res Cell Motil** 1995 Dec;16(6):571-7

Preconditioning with ischemia or adenosine protects skeletal muscle from ischemic tissue reperfusion injury. Lee HT, et al. **J Surg Res** 1996 Jun;63(1):29-34

A P2 purinoceptor activated by ADP in rat medullar neurons. Ikeuchi Y, et al. **Neurosci Lett** 1995 Sep 29; 198(2):71-4

ADP exerts a protective effect against rundown of the Ca2+ current in bovine chromaffin cells. Elhamdani A, et al. **Pflugers Arch** 1995 Jul;430(3):401-9

Protein tyrosine phosphorylation in human platelets during shear stress-induced platelet aggregation (SIPA) is regulated by glycoprotein (GP) Ib/IX as well as GP IIb/IIIa and requires intact cytoskeleton and endogenous ADP. Oda A, et al. **Thromb Haemost** 1995 Aug; 74(2):736-42

Cigarette smoking sensitizes and desensitizes impedance-measured ADP-induced platelet aggregation in whole blood. Sharp DS, et al. **Thromb Haemost** 1995 Aug; 74(2):730-5

Inhibition of ADP-induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion. Riddell DR, et al. **Thromb Res** 1995 Dec 15;80(6):499-508

Apyrase activity and adenosine diphosphate induced platelet aggregation inhibition by the salivary gland proteins of Culicoides variipennis, the North American vector of bluetongue viruses. Pérez de León AA, et al. **Vet Parasitol** 1996 Feb;61(3-4):327-38

[Mobilization of intracellular Ca2+ by ADP and thrombin in platelets of patients with diabetes mellitus with vascular complications] Kubatiev AA, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):112-5 **(Rus)**

[The effect of ADP on the contractile activity of guinea pig intestinal smooth muscle] Poriadin GV, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):361-5 **(Rus)**

PHYSIOLOGY

Correction of the platelet adhesion defect in delta-storage pool deficiency at elevated hematocrit--possible role of adenosine diphosphate. Weiss HJ, et al. **Blood** 1996 May 15;87(10):4214-22

Regulation of the H+/e- stoichiometry of cytochrome c oxidase from bovine heart by intramitochondrial ATP/ADP ratios. Frank V, et al. **FEBS Lett** 1996 Mar 11;382(1-2):121-4

ADENOSINE DIPHOSPHATE RIBOSE

ANALOGS & DERIVATIVES

Specific modulation of cyclic ADP-ribose-induced Ca2+ release by polyamines. Chini EN, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C1042-7

Inhibition of cADPR-Hydrolase by ADP-ribose potentiates cADPR synthesis from beta-NAD+. Genazzani AA, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):502-7

Fluorescent analogs of cyclic ADP-ribose: synthesis, spectral characterization, and use. Graeff RM, et al. **Biochemistry** 1996 Jan 16;35(2):379-86

NAD glycohydrolases and the metabolism of cyclic ADP-ribose. Jacobson MK, et al. **Biochimie** 1995; 77(5):341-4 (15 ref.)

Cyclic ADP-ribose and its metabolic enzymes. Lee HC, et al. **Biochimie** 1995;77(5):345-55 (42 ref.)

New aspects of the physiological significance of NAD, poly ADP-ribose and cyclic ADP-ribose. Okamoto H, et al. **Biochimie** 1995;77(5):356-63 (41 ref.)

Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane. Ramaschi G, et al. **Blood** 1996 Mar 15;87(6):2308-13

Inositol trisphosphate and cyclic ADP-ribose-mediated release of Ca2+ from single isolated pancreatic zymogen granules. Gerasimenko OV, et al. **Cell** 1996 Feb 9; 84(3):473-80

A cADP-ribose antagonist does not inhibit secretagogue-, caffeine- and nitric oxide-induced Ca2+ responses in rat pancreatic beta-cells. Willmott NJ, et al. **Cell Calcium** 1995 Nov;18(5):411-9

Cyclic aristeromycin diphosphate ribose: a potent and poorly hydrolysable Ca(2+)-mobilising mimic of cyclic adenosine diphosphate ribose. Bailey VC, et al. **FEBS Lett** 1996 Feb 5;379(3):227-30

Cyclic GMP potentiates phenylephrine but not cyclic ADP-ribose-evoked calcium release from rat lacrimal acinar cells. Jorgensen TD, et al. **FEBS Lett** 1996 Aug 5;391(1-2):117-20

HPLC analysis of cyclic adenosine diphosphate ribose and adenosine diphosphate ribose: determination of NAD+ metabolites in hippocampal membranes. Casabona G, et al. **Ital J Biochem** 1995 Sep-Oct;44(5):258-68

The type 2 ryanodine receptor of neurosecretory PC12 cells is activated by cyclic ADP-ribose. Role of the nitric oxide/cGMP pathway. Clementi E, et al. **J Biol Chem** 1996 Jul 26;271(30):17739-45

Agonist-stimulated cyclic ADP ribose. Endogenous modulator of Ca(2+)-induced Ca2+ release in intestinal longitudinal muscle. Kuemmerle JF, et al. **J Biol Chem** 1995 Oct 27;270(43):25488-94

Requirement of calmodulin-dependent protein kinase II in cyclic ADP-ribose-mediated intracellular Ca2+ mobilization. Takasawa S, et al. **J Biol Chem** 1995 Dec 22;270(51):30257-9

2'-Phospho-cyclic ADP-ribose, a calcium-mobilizing agent derived from NADP. Vu CQ, et al. **J Biol Chem** 1996 Mar 1;271(9):4747-54

Insulin exocytosis and glucose-mediated increase in cytoplasmic free Ca2+ concentration in the pancreatic beta-cell are independent of cyclic ADP-ribose. Webb DL, et al. **J Biol Chem** 1996 Aug 9;271(32):19074-9

Nitric oxide-induced mobilization of intracellular calcium via the cyclic ADP-ribose signaling pathway. Willmott N, et al. **J Biol Chem** 1996 Feb 16;271(7):3699-705

Characterization of cyclic adenosine diphosphate-ribose-induced Ca2+ release in T lymphocyte cell lines. Guse AH, et al. **J Immunol** 1995 Oct 1;155(7):3353-9

Inositol trisphosphate and cyclic ADP ribose as long range messengers generating local subcellular calcium signals. Petersen OH. **J Physiol Paris** 1995;89(3):125-7 (16 ref.)

Modulator and messenger functions of cyclic ADP-ribose in calcium signaling. Lee HC. **Recent Prog Horm Res** 1996; 51:355-88; discussion 389 (86 ref.)

Cyclic ADP-ribose, the ryanodine receptor and Ca2+ release. Sitsapesan R, et al. **Trends Pharmacol Sci** 1995 Nov; 16(11):386-91 (50 ref.)

ANALYSIS

HPLC analysis of cyclic adenosine diphosphate ribose and adenosine diphosphate ribose: determination of NAD+ metabolites in hippocampal membranes. Casabona G, et al. **Ital J Biochem** 1995 Sep-Oct;44(5):258-68

CHEMISTRY

Glycation and glycoxidation of histones by ADP-ribose. Cervantes-Laurean D, et al. **J Biol Chem** 1996 May 3; 271(18):10461-9

METABOLISM

Effects of long-term alcohol intake on ADP ribosylation in rat liver plasma membranes. Nomura F, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):60A-62A

Poly(ADP-ribose) quantification at the femtomole level in mammalian cells. Malanga M, et al. **Anal Biochem** 1995 Jul 1;228(2):245-51

Detection of arginine-ADP-ribosylated protein using recombinant ADP-ribosylarginine hydrolase. Ohno T, et al. **Anal Biochem** 1995 Oct 10;231(1):115-22

Reduction of mono(ADP-ribosyl)ation of histones in rat testis by gonadotropin-testosterone system. Kurokawa T, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):808-13

Calcium-dependent ADP-ribosylation of high-mobility-group I (HMGI) proteins. Giancotti V, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):865-70

Studies on the active-site structure of C3-like exoenzymes: involvement of glutamic acid in catalysis of ADP-ribosylation. Aktories K, et al. **Biochimie** 1995; 77(5):326-32 (62 ref.)

ADENOSINE DIPHOSPHATE RIBOSE

A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. Locht C, et al. **Biochimie** 1995;77(5):333–40 (56 ref.)
Characterization of mammalian ADP-ribosylation cycles. Okazaki IJ, et al. **Biochimie** 1995;77(5):319–25 (43 ref.)
ADP-ribosylation reactions. Shall S. **Biochimie** 1995; 77(5):313–8 (21 ref.)
Involvement of oxidative and L-arginine-NO pathways in the neurotoxicity of drugs of abuse in vitro. Cerruti C, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):381–2
Immunochemical detection of ADP-ribosylating enzymes in the archaeon Sulfolobus solfataricus. Faraone-Mennella MR, et al. **FEBS Lett** 1996 Jan 8;378(2):199–201
Analysis of the catalytic site of the actin ADP-ribosylating Clostridium perfringens iota toxin. van Damme J, et al. **FEBS Lett** 1996 Feb 19;380(3):291–5
Change of ADP-ribosylation in human kidney T1-cells by various external stimuli. Schneeweiss FH, et al. **Indian J Biochem Biophys** 1995 Jun;32(3):119–24
Iron starvation causes release from the group A streptococcus of the ADP-ribosylating protein called plasmin receptor or surface glyceraldehyde-3-phosphate-dehydrogenase. Eichenbaum Z, et al. **Infect Immun** 1996 Jun;64(6):1956–60
ADP-ribosylation of an approximately 70-kilodalton protein of Klebsiella pneumoniae. Geipel U, et al. **Infect Immun** 1996 May;64(5):1720–3
Pertussis toxin-catalyzed ADP-ribosylation of Gi-2 and Gi-3 in CHO cells is modulated by inhibitors of intracellular trafficking. Xu Y, et al. **Infect Immun** 1996 Feb;64(2):593–9
ADP-ribosylation of proteins in Bacillus subtilis and its possible importance in sporulation. Huh JW, et al. **J Bacteriol** 1996 Aug;178(16):4935–41
Mannose 6-phosphate receptors and ADP-ribosylation factors cooperate for high affinity interaction of the AP-1 Golgi assembly proteins with membranes. Le Borgne R, et al. **J Biol Chem** 1996 Jan 26;271(4):2162–70
NAD(+)-dependent ADP-ribosylation of T lymphocyte alloantigen RT6.1 reversibly proceeding in intact rat lymphocytes. Maehama T, et al. **J Biol Chem** 1995 Sep 29;270(39):22747–51
ADP-ribosylation of the G protein Rho inhibits integrin regulation of tumor cell growth. Udagawa T, et al. **J Biol Chem** 1996 May 24;271(21):12542–8
Poly(ADP-ribosyl)ation of histone H1 correlates with internucleosomal DNA fragmentation during apoptosis. Yoon YS, et al. **J Biol Chem** 1996 Apr 12;271(15):9129–34
Decreased heterogeneity of CS histone variants after hydrolysis of the ADP-ribose moiety. Imschenetzky M, et al. **J Cell Biochem** 1996 Apr;61(1):109–17
Enzymatic activities affecting exogenous nicotinamide adenine dinucleotide in human skin fibroblasts. Aleo MF, et al. **J Cell Physiol** 1996 Apr;167(1):173–6
Regulation of CTL by ecto-nictinamide adenine dinucleotide (NAD) involves ADP-ribosylation of a p56lck-associated protein. Wang J, et al. **J Immunol** 1996 Apr 15; 156(8):2819–27
In vitro ADP-ribosylation of Rho by bacterial ADP-ribosyltransferases. Aktories K, et al. **Methods Enzymol** 1995;256:184–95
Evidence for multisite ADP-ribosylation of neuronal phosphoprotein B-50/GAP-43. Philibert K, et al. **Mol Cell Biochem** 1995 Aug-Sep;149–150:183–90
Adenosine diphosphate ribosylation of fibroblast growth factor-2. Boulle N, et al. **Mol Endocrinol** 1995 Jun; 9(6):767–75
Adenylyl cyclase inhibition and altered G protein subunit expression and ADP-ribosylation patterns in tissues and cells from Gi2 alpha-/-mice. Rudolph U, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3209–14

PHARMACOLOGY

Inhibition of cADPR-Hydrolase by ADP-ribose potentiates cADPR synthesis from beta-NAD+. Genazzani AA, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):502–7

ADENOSINE DIPHOSPHORIBOSE see **ADENOSINE DIPHOSPHATE RIBOSE**

ADENOSINE KINASE

ANTAGONISTS & INHIBITORS

Antinociception by adenosine analogs and an adenosine kinase inhibitor: dependence on formalin concentration. Poon A, et al. **Eur J Pharmacol** 1995 Nov 14;286(2):177–84
Inhibition of adenosine kinase and adenosine uptake in guinea-pig CNS tissue by halogenated tubercidin analogues. Davies LP, et al. **Life Sci** 1995 Mar 17; 56(17):PL345–9

BIOSYNTHESIS

Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. Spychala J, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1232–7

CHEMISTRY

Two conformationally vicinal thiols at the active site of Leishmania donovani adenosine kinase. Bagui TK, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):439–45
Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. Spychala J, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1232–7

METABOLISM

Production of adenosine and nucleoside analogs by the exchange reaction catalyzed by rat liver adenosine kinase. Mimouni M, et al. **Biochem Pharmacol** 1995 Nov 9; 50(10):1587–91
Effects of iodotubercidin on adenosine kinase activity and nucleoside transport in DDT1 MF-2 smooth muscle cells. Parkinson FE, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1397–401

ADENOSINE MONOPHOSPHATE

ADMINISTRATION & DOSAGE

[Coenzyme metabolic therapy in infectious allergic myocarditis] Mazurets AF, et al. **Klin Med (Mosk)** 1995; 73(5):41–3 (Eng. Abstr.) **(Rus)**

ANALOGS & DERIVATIVES

Structure-activity relationship of cytoplasmic 5'-nucleotidase substrate sites. Skladanowski AC, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):1001–7
Thermodynamic analysis of small ligand binding to the Escherichia coli repressor of biotin biosynthesis. Xu Y, et al. **Biochemistry** 1996 Apr 30;35(17):5509–17
New enterocytic peptides with morphogenic effect. Trifonov B, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):30
Phosphodiester amidates of allenic nucleoside analogues: anti-HIV activity and possible mechanism of action. Winter H, et al. **J Med Chem** 1996 Aug 16;39(17):3300–6
Transition state stabilization by the 'high' motif of class I aminoacyl-tRNA synthetases: the case of Escherichia coli methionyl-tRNA synthetase. Schmitt E, et al. **Nucleic Acids Res** 1995 Dec 11;23(23):4793–8

ANALYSIS

On-line Raman spectroscopy of ribonucleotides preconcentrated by capillary isotachophoresis. Walker PA 3rd, et al. **Anal Chem** 1995 Dec 1;67(23):4255–60
Detection and quantitation of phosphorus metabolites in crude tissue extracts by 1H and 31P NMR: use of gradient assisted 1H-31P HMQC experiments, with selective pulses, for the assignment of less abundant metabolites. Pollesello P, et al. **NMR Biomed** 1995 Aug;8(5):190–6

BLOOD

[Nucleotides] Fujii H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:243–6 (5 ref.) **(Jpn)**

CHEMISTRY

Thermodynamic analysis of small ligand binding to the Escherichia coli repressor of biotin biosynthesis. Xu Y, et al. **Biochemistry** 1996 Apr 30;35(17):5509–17
Structural basis of RNA folding and recognition in an AMP-RNA aptamer complex [see comments] Jiang F, et al. **Nature** 1996 Jul 11;382(6587):183–6. Comment in: Nature 1996 Jul 11;382(6587):112.

METABOLISM

A study of subunit interface residues of fructose-1,6-bisphosphatase by site-directed mutagenesis: effects on AMP and Mg2+ affinities. Shyur LF, et al. **Biochemistry** 1996 Jun 11;35(23):7492–8
A calorimetric study of the binding of AMP to liver glycogen phosphorylase b. García-Fuentes L, et al. **Biochim Biophys Acta** 1996 May 2;1294(1):83–8
Modelization of coordinated changes of adenylate energy charge and ATP/ADP ratio: application to energy metabolism in invertebrate and vertebrate skeletal muscle. Raffin JP, et al. **C R Acad Sci III** 1996 Jan;319(1):9–15
High efficiency of glycerol 2-phosphate and sn-glycerol 3-phosphate as nucleotidyl acceptors in snake venom phosphodiesterase esterifications. Formation of primary and secondary AMP-O-glyceryl and AMP-O-glycerophosphoryl esters and evidence for an acceptor-binding enzyme site. Vergeles JM, et al. **Eur J Biochem** 1995 Oct 15;233(2):442–7
The dephosphorylation of AMP and IMP by a soluble low Km 5'nucleotidase from human seminal plasma: some regulatory aspects. Minelli A, et al. **Int J Biochem Cell Biol** 1995 Oct;27(10):1079–83
Enzymatic activities affecting exogenous nicotinamide adenine dinucleotide in human skin fibroblasts. Aleo MF, et al. **J Cell Physiol** 1996 Apr;167(1):173–6
Adenylate kinase complements nucleoside diphosphate kinase deficiency in nucleotide metabolism. Lu Q, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5720–5
Effect of chlorpromazine as a sensitizer of rat brain on radiation-induced AMP and adenosine metabolism. Hasan SS, et al. **Q J Nucl Med** 1995 Dec;39(4):290–9

PHARMACOLOGY

Synergistic effect of granulocyte colony-stimulating factor and drugs elevating extracellular adenosine on neutrophil production in mice. Pospísil M, et al. **Blood** 1995 Nov 15; 86(10):3692–7
Anti-lymphoproliferative activity of brown adipose tissue of hibernating ground squirrels is mainly caused by AMP. Atanassov CL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Sep;112(1):93–100
Inhaled lysine acetylsalicylate (L-ASA) attenuates the bronchoconstrictor response to adenosine 5'-monophosphate (AMP) in asthmatic subjects. Crimi N, et al. **Eur Respir J** 1995 Jun;8(6):905–12
5'-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. Davies SP, et al. **FEBS Lett** 1995 Dec 27;377(3):421–5
Vesicular monoamine uptake by digitonin-permeabilized PC12 cells: inhibitory effect of neuromodulators and drugs on the amine transport. Nakanishi N, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):291–6
5'-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. Hawley SA, et al. **J Biol Chem** 1995 Nov 10; 270(45):27186–91
Radioprotective efficacy of dipyridamole and AMP combination in fractionated radiation regimen, and its dependence on the time of administration of the drugs prior to irradiation. Hofer M, et al. **Physiol Res** 1995;44(2):93–98

ADENOSINE PHOSPHATES see **ADENINE NUCLEOTIDES**

ADENOSINE PYROPHOSPHATE see **ADENOSINE DIPHOSPHATE**

ADENOSINE RECEPTORS see **RECEPTORS, PURINERGIC P1**

ADENOSINE TRIPHOSPHATE

Messenger RNA expression and immunological quantification of phospholamban and SR-Ca(2+)-ATPase in failing and nonfailing human hearts. Linck B, et al. **Cardiovasc Res** 1996 Apr;31(4):625–32
Clinical relevance of ATP-dependent potassium channels. Ligtenberg JJ, et al. **Neth J Med** 1995 Nov;47(5):241–51 (82 ref.)

ADMINISTRATION & DOSAGE

Thallium-201 myocardial tomography with intravenous infusion of adenosine triphosphate in diagnosis of coronary artery disease. Miyagawa M, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1196–201

ANALOGS & DERIVATIVES

Rate of active tension development from rigor in skinned atrial and ventricular cardiac fibres from swine following photolytic release of ATP from caged ATP. Morano I, et al. **Acta Physiol Scand** 1995 Jul;154(3):343–53
Preservation of insulin secretory responses to P2 purinoceptor agonists in Zucker diabetic fatty rats. Tang J, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E504–12
Protein folding within and protein transport into mammalian microsomes are differentially affected by photoaffinity labeling of microsomes with 8-azido-ATP. Brunke M, et al. **Biochem Biophys Res Commun** 1996 Jan 17; 218(2):454–60
The mechanism for mechanochemical energy transduction in actin-myosin interaction revealed by in vitro motility assay with ATP analogues. Higashi-Fujime S, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):773–8
Regulation of the potassium current and cytosolic Ca2+ release induced by 2-methylthio ATP in hippocampal neurons. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):428–33
Photoaffinity labeling of a P3 purinoceptor-like protein purified from rat brain membranes. Saitoh Y, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):469–74
Caged FEDA-ATP: a new tool in the measurement of ATP turnover during the in vitro motility assay. Jeffreys DS, et al. **Biochem Soc Trans** 1995 Aug;23(3):401S
Protein kinase C isoforms in endothelial cells: role in agonist stimulated prostacyclin release. Patel V, et al. **Biochem Soc Trans** 1996 Feb;24(1):56S
Kinetic and spectroscopic characterization of fluorescent ribose-modified ATP analogs upon interaction with skeletal muscle myosin subfragment 1. Conibear PB, et al. **Biochemistry** 1996 Feb 20;35(7):2299–308
Interaction of nucleotide-free Hsc70 with clathrin and peptide and effect of ATP analogues. Gao B, et al. **Biochemistry** 1995 Sep 19;34(37):11882–8
Differentiation of catalytic sites on Escherichia coli F1ATPase by laser photoactivated labeling with [3H]-2-Azido-ATP using the mutant beta Glu381Cys:epsilonSer108Cys to identify different beta subunits by their interactions with gamma and epsilon subunits. Grüber G, et al. **Biochemistry** 1996 Apr 2; 35(13):3875–9
Identification of the ATP transporter of rat liver rough

endoplasmic reticulum via photoaffinity labeling and partial purification. Kim SH, et al. **Biochemistry** 1996 Apr 30; 35(17):5418–25

Utility of a novel spin–labeled nucleotide in investigation of the substrate and effector sites of phosphoribulokinase. Koteiche HA, et al. **Biochemistry** 1995 Nov 21; 34(46):15068–74

The end of a polymerizing actin filament contains numerous ATP–subunit segments that are disconnected by ADP–subunits resulting from ATP hydrolysis. Pieper U, et al. **Biochemistry** 1996 Apr 9;35(14):4396–402

Adenosine 5'–(gamma–thiotriphosphate): an ATP analog that should be used with caution in muscle contraction studies. Resetar AM, et al. **Biochemistry** 1995 Dec 12; 34(49):16039–45

Neutralizing antibodies to nucleoside diphosphate kinase inhibit the enzyme in vitro and in vivo: evidence for two distinct mechanisms of activation of atrial currents by ATPgammaS. Yi XB, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):334–42

Highly selective affinity labeling of DNA polymerase alpha–primase from human placenta by reactive analogs of ATP. Zakharova OD, et al. **Biochimie** 1995; 77(9):699–702

Orientation changes in myosin regulatory light chains following photorelease of ATP in skinned muscle fibers. Allen TS, et al. **Biophys J** 1996 Apr;70(4):1847–62

BDM compared with P(i) and low Ca2+ in the cross–bridge reaction initiated by flash photolysis of caged ATP. Kagawa K, et al. **Biophys J** 1995 Dec;69(6):2590–600

Actions of ADP, but not ATP, on cytosolic free Ca2+ in single rat hepatocytes mimicked by 2–methylthioATP. Dixon CJ, et al. **Br J Pharmacol** 1995 Oct;116(3):1979–84

Pharmacological profile of the novel P2T–purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo. Humphries RG, et al. **Br J Pharmacol** 1995 Jul;115(6):1110–6

Evidence that [3H]–alpha,beta–methylene ATP may label an endothelial–derived cell line 5'–nucleotidase with high affinity. Michel AD, et al. **Br J Pharmacol** 1995 Jul; 115(5):767–74

Effects of PPADS and suramin on contractions and cytoplasmic Ca2+ changes evoked by AP4A, ATP and alpha, beta–methylene ATP in guinea–pig urinary bladder. Usune S, et al. **Br J Pharmacol** 1996 Feb;117(4):698–702

Vasoconstrictor responses to the P2x–purinoceptor agonist beta, gamma–methylene–L–ATP in human cutaneous and renal blood vessels. von Kügelgen I, et al. **Br J Pharmacol** 1995 Sep;116(2):1932–6

Characterization and autoradiographic localization of [3H] alpha, beta–methylene adenosine 5'–triphosphate binding sites in human urinary bladder. Bo X, et al. **Br J Urol** 1995 Sep;76(3):297–302

Effects of Cr (VI) on ATPases in the brain and muscle of mudskipper, Boleophthalmus dentatus. Kundu R, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):723–9

Photoaffinity labeling of elongation factor–2 with 8–azido derivatives of GTP and ATP. Guillot D, et al. **Eur J Biochem** 1996 Feb 15;236(1):149–54

Interaction of mitochondrial F1–ATPase with trinitrophenyl derivatives of ATP. Photoaffinity labeling of binding sites with 2–azido–2',3'–O–(4,6–trinitrophenyl)adenosine 5'–triphosphate. Murataliev MB. **Eur J Biochem** 1995 Sep 1;232(2):578–85

Potentiating and inhibitory effects of periodate–oxidized ATP analogs on contractions of vas deferens to ATP. Fedan JS, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):213–7

A P2X purinoceptor cDNA conferring a novel pharmacological profile. Bo X, et al. **FEBS Lett** 1995 Nov 13;375(1–2):129–33

Measurement of nucleotide exchange kinetics with isolated synthetic myosin filaments using flash photolysis. Conibear PB, et al. **FEBS Lett** 1996 Feb 12;380(1–2):13–6

2,8–Diazido–ATP—a short–length bifunctional photoaffinity label for photoaffinity cross–linking of a stable F1 in ATP synthase (from thermophilic bacteria PS3). Schäfer HJ, et al. **FEBS Lett** 1995 Dec 27;377(3):408–12

Effects of ATP analogues and basic fibroblast growth factor on astroglial cell differentiation in primary cultures of rat striatum. Abbracchio MP, et al. **Int J Dev Neurosci** 1995 Nov;13(7):685–93

Preferential binding of Escherichia coli RecF protein to gapped DNA in the presence of adenosine (gamma–thio) triphosphate. Hegde SP, et al. **J Bacteriol** 1996 Jan; 178(1):184–90

Structural asymmetry of F1–ATPase caused by the gamma subunit generates a high affinity nucleotide binding site. Kaibara C, et al. **J Biol Chem** 1996 Feb 2;271(5):2433–8

The modulation of Ca2+ binding to sarcoplasmic reticulum ATPase by ATP analogues is pH–dependent. Mintz E, et al. **J Biol Chem** 1995 Nov 10;270(45):27160–4

3'–O–(4–Benzoyl)benzoyladenosine 5'–triphosphate inhibits activity of the vacuolar (H+)–ATPase from bovine brain clathrin–coated vesicles by modification of a rapidly exchangeable, noncatalytic nucleotide binding site on the B subunit. Vasilyeva E, et al. **J Biol Chem** 1996 May 31; 271(22):12775–82

Binding and hydrolysis of TNP–ATP by Escherichia coli F1–ATPase. Weber J, et al. **J Biol Chem** 1996 Feb 16; 271(7):3474–7

The guanylyl cyclase–A receptor transduces an atrial natriuretic peptide/ATP activation signal in the absence of other proteins. Wong SK, et al. **J Biol Chem** 1995 Dec 22;270(51):30818–22

Kinetics of prephosphorylation reactions and myosin light chain phosphorylation in smooth muscle. Flash photolysis studies with caged calcium and caged ATP. Zimmermann B, et al. **J Biol Chem** 1995 Oct 13;270(41):23966–74

Extracellular ATP binding proteins as potential receptors in mucociliary epithelium: characterization using [32P]3'–O–(4–benzoyl)benzoyl ATP, a photoaffinity label. Gheber L, et al. **J Membr Biol** 1995 Sep;147(1):83–93

Structure of a mutant adenylate kinase ligated with an ATP–analogue showing domain closure over ATP. Schlauderer GJ, et al. **J Mol Biol** 1996 Feb 23;256(2):223–7

Regional hemodynamic effects of purinergic P2 receptor subtype agonists in rats. Cox BF, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1492–500

Modified nucleotides as probes for dynein. Omoto CK. **Methods Cell Biol** 1995;47:507–10

The 2.4 A crystal structure of the bacterial chaperonin GroEL complexed with ATP gamma S [see comments] Boisvert DC, et al. **Nat Struct Biol** 1996 Feb;3(2):170–7. Comment in: Nat Struct Biol 1996 Feb;3(2):116–21.

Structural basis of cyclin–dependent kinase activation by phosphorylation. Russo AA, et al. **Nat Struct Biol** 1996 Aug;3(8):696–700

Cultured chick sympathetic neurons: modulation of electrically evoked noradrenaline release by P2–purinoceptors. Allgaier C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):17–24

The influence of ionic strength upon relaxation from rigor induced by flash photolysis of caged–ATP in skinned murine skeletal muscle fibres. Veigel C, et al. **Pflugers Arch** 1995 Oct;430(6):994–1003

A novel adenosine triphosphate analog with a heavy atom to target the nucleotide binding site of proteins. Naber N, et al. **Protein Sci** 1995 Sep;4(9):1824–31

ANALYSIS

On–line Raman spectroscopy of ribonucleotides preconcentrated by capillary isotachophoresis. Walker PA 3rd, et al. **Anal Chem** 1995 Dec 1;67(23):4255–60

Biochemical modulation of tumor cell energy. IV. Evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically–induced tumor regression. Colofiore JR, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1943–8

Metabolic imaging in tumours by means of bioluminescence. Tamulevicius P, et al. **Br J Cancer** 1995 Nov;72(5):1102–12

Modelization of coordinated changes of adenylate energy charge and ATP/ADP ratio: application to energy metabolism in invertebrate and vertebrate skeletal muscle. Raffin JP, et al. **C R Acad Sci III** 1996 Jan;319(1):9–15

Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Andreotti PE, et al. **Cancer Res** 1995 Nov 15; 55(22):5276–82

Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P– and 13C–nuclear magnetic resonance (NMR) spectroscopy study. Singer S, et al. **Cancer Res** 1995 Nov 15;55(22):5140–5

Possible links between glucose–induced changes in the energy state of pancreatic B cells and insulin release. Unmasking by decreasing a stable pool of adenine nucleotides in mouse islets. Detimary P, et al. **J Clin Invest** 1995 Oct;96(4):1738–45

Phosphorus J coupling constants of ATP in human myocardium and calf muscle. Jung WI, et al. **J Magn Reson B** 1996 Jan;110(1):39–46

Ischemic injury of the small intestine studied by 31P–MRS. Sato A, et al. **J Surg Res** 1996 Mar;61(2):373–8

[A semi–quantitative measurement of glycocalyx and an ATP bioluminescent assay for the analysis of Pseudomonas aeruginosa biofilm] Ono N. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1440–9 (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Genistein inhibits Ca2+ influx by extracellular ATP in PC12 pheochromocytoma cells. Kozawa O, et al. **Horm Metab Res** 1995 Jun;27(6):272–4

Myosin light chain kinase from vascular smooth muscle inhibits the ATP–dependent interaction between actin and myosin by binding to actin. Sato M, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):1–3

BIOSYNTHESIS

Mitochondrial ATP production rate in 55 to 73–year–old men: effect of endurance training. Berthon P, et al. **Acta Physiol Scand** 1995 Jun;154(2):269–74

Inhibition of alveolar type II cell ATP and surfactant synthesis by nitric oxide. Haddad IY, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):L898–906

Alteration of mitochondrial F0F1 ATP synthase during aging. Possible involvement of oxygen free radicals. Guerrieri F, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:62–71

Growth inhibition of Ureaplasma urealyticum by the proton pump inhibitor lansoprazole: direct attribution to inhibition by lansoprazole of urease activity and urea–induced ATP synthesis in U. urealyticum. Nagata K, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2187–92

ATP synthesis by purified ATP–synthase from beef heart mitochondria after coreconstitution with bacteriorhodopsin. Matuschka S, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):135–42

Calf muscle mitochondrial and glycogenolytic ATP synthesis in patients with claudication due to peripheral vascular disease analysed using 31P magnetic resonance spectroscopy. Kemp GJ, et al. **Clin Sci (Colch)** 1995 Dec; 89(6):581–90

ATP synthesis by the F0F1 ATP synthase from thermophilic Bacillus PS3 reconstituted into liposomes with bacteriorhodopsin. 1. Factors defining the optimal reconstitution of ATP synthases with bacteriorhodopsin. Pitard B, et al. **Eur J Biochem** 1996 Feb 1;235(3):769–78

ATP synthesis by the F0F1 ATP synthase from thermophilic Bacillus PS3 reconstituted into liposomes with bacteriorhodopsin. 2. Relationships between proton motive force and ATP synthesis. Pitard B, et al. **Eur J Biochem** 1996 Feb 1;235(3):779–88

Meta–iodobenzylguanidine (MIBG) inhibits malate and succinate driven mitochondrial ATP synthesis in the human neuroblastoma cell line SK–N–BE(2c). Cornelissen J, et al. **Eur J Cancer** 1995;31A(4):582–6

P/O ratios reassessed: mitochondrial P/O ratios consistently exceed 1.5 with succinate and 2.5 with NAD–linked substrates. Lee CP, et al. **FASEB J** 1996 Feb;10(2):345–50

Ammonium/urea–dependent generation of a proton electrochemical potential and synthesis of ATP in Bacillus pasteurii. Jahns T. **J Bacteriol** 1996 Jan;178(2):403–9

Endothelin–1 partially inhibits ATP–sensitive K+ current in guinea pig ventricular cells. Kobayashi S, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):12–9

Prenatal diagnosis of systemic disorders of the respiratory chain in cultured chorionic villus fibroblasts by study of ATP–synthesis in digitonin–permeabilized cells. Wanders RJ, et al. **J Inherit Metab Dis** 1996;19(2):133–6

A double mutation in subunit c of the Na(+)–specific F1F0–ATPase of Propionigenium modestum results in a switch from Na+ to H(+)–coupled ATP synthesis in the Escherichia coli host cells. Kaim G, et al. **J Mol Biol** 1995 Nov 10;253(5):726–38

Necessity of newly synthesized ATP by creatine kinase for contraction of permeabilized longitudinal muscle preparations of rat proximal colon. Takeuchi T, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):429–34

The mechanism of action of the two–layer cold storage method in canine pancreas preservation—protection of pancreatic microvascular endothelium. Fujita H, et al. **Kobe J Med Sci** 1995 Jun;41(3):47–61

Reducing equivalent shuttles in developing porcine myocardium: enhanced capacity in the newborn heart. Scholz TD, et al. **Pediatr Res** 1995 Aug;38(2):221–7

Hypothermic perfusion preservation of liver: the role of phosphate in stimulating ATP synthesis studied by 31P NMR. Lockett CJ, et al. **Transpl Int** 1995;8(6):440–5

[Lack of serum causes apoptosis of thymocytes not requiring protein synthesis and ATP generation] Gabai VL, et al. **Biokhimiia** 1995 Aug;60(8):1201–8 (Eng. Abstr.) **(Rus)**

BLOOD

Studies on the differential morphological alterations in human and goat erythrocytes against ATP depletion and Ca(2+)–induced stresses. Zaidi A, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):517–26

Glutathione regeneration in calcium–loaded erythrocytes: a possible relationship among calcium accumulation, ATP decrement and oxidative damage. Kurata M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov; 109(2–3):305–12

Platelet–neutrophil interaction and superoxide anion generation: involvement of purine nucleotides. Colli S, et al. **Free Radic Biol Med** 1996;20(3):271–8

Platelets enhance Fc(gamma) receptor–mediated phagocytosis and respiratory burst in neutrophils: the role of purinergic modulation and actin polymerization. Zalavary S, et al. **J Leukoc Biol** 1996 Jul;60(1):58–68

[Nucleotides] Fujii H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:243–6 (5 ref.) **(Jpn)**

[The effect of exogenous iron on levels of adenosinetriphosphate and 2,3–diphosphoglycerate in erythrocytes of men during extreme physical exertion] Pędzikiewicz J, et al. **Med Pr** 1995;46(5):479–84 (Eng. Abstr.) **(Pol)**

[Level of 2,3–diphosphoglycerate and adenosine triphosphate in erythrocytes and acid–base status in adult and newborn rats in acute hypoxia] Alatyrtsev VV, et al. **Biull Eksp Biol Med** 1995 Jun;119(6):631–3 **(Rus)**

CHEMISTRY

Standard free energy change for the hydrolysis of the alpha, beta–phosphoanhydride bridge in ATP. Frey PA, et al. **Biochemistry** 1995 Sep 12;34(36):11307–10

Kinetics of nucleotide–induced changes in the tryptophan fluorescence of the molecular chaperone Hsc70 and its subfragments suggest the ATP–induced conformational change follows initial ATP binding. Ha JH, et al. **Biochemistry** 1995 Sep 12;34(36):11635–44

Proton NMR investigation of the [4Fe—4S]1+ cluster environment of nitrogenase iron protein from Azotobacter

vinelandii: defining nucleotide-induced conformational changes. Lanzilotta WN, et al. **Biochemistry** 1995 Dec 5; 34(48):15646–53

Conformation of manganese(II)–nucleotide complexes bound to rabbit muscle creatine kinase: 13C NMR measurements using [2–13C]ATP and [2–13C]ADP. Ray BD, et al. **Biochemistry** 1996 Jun 4;35(22):7239–46

Mechanochemical coupling of the motion of molecular motors to ATP hydrolysis. Astumian RD, et al. **Biophys J** 1996 Feb;70(2):637–53

Crystal structure of bacteriophage T4 deoxynucleotide kinase with its substrates dGMP and ATP. Teplyakov A, et al. **EMBO J** 1996 Jul 15;15(14):3487–97

Characterisation of a recombinant P2Y purinoceptor. Simon J, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):281–9

The beta/alpha peak height ratio of ATP. A measure of free [Mg2+] using 31P NMR. Clarke K, et al. **J Biol Chem** 1996 Aug 30;271(35):21142–50

A comparative study of ATP and GTP complexation with trivalent Al, Ga and Fe cations. Determination of cation binding site and nucleotide conformation by FTIR difference spectroscopy. el-Mahdaoui L, et al. **J Biomol Struct Dyn** 1995 Aug;13(1):69–86

Crystal structure of the pertussis toxin–ATP complex: a molecular sensor. Hazes B, et al. **J Mol Biol** 1996 May 17;258(4):661–71

Snapshot of an enzyme reaction intermediate in the structure of the ATP-Mg2+–oxalate ternary complex of Escherichia coli PEP carboxykinase [see comments] Tari LW, et al. **Nat Struct Biol** 1996 Apr;3(4):355–63. Comment in: Nat Struct Biol 1996 Apr;3(4):307–9.

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Schulze-Gahmen U, et al. **Proteins** 1995 Aug;22(4):378–91

CONTRAINDICATIONS

[Contraindication of ATP related drugs for therapy of gout and uric acidemia (letter)] Domoto K. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1939–40 **(Jpn)**

DEFICIENCY

Preconditioning accelerates contracture and ATP depletion in blood-perfused rat hearts. Kolocassides KG, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1415–20

ATP depletion inhibits capacitative Ca2+ entry in rat thymic lymphocytes. Marriott I, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C766–74

Hyperpermeability and ATP depletion induced by chronic hypoxia or glycolytic inhibition in Caco-2BBe monolayers. Unno N, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):G1010–21

Effects of Ca++ and glycine on lipid breakdown and death of ATP-depleted MDCK cells. Venkatachalam MA, et al. **Kidney Int** 1995 Jul;48(1):118–28

DIAGNOSTIC USE

Adenosine triphosphate stress echocardiography in the detection of myocardial ischemia. Fukai T, et al. **Am J Card Imaging** 1995 Oct;9(4):237–44

[99mTc-MIBI myocardial tomography with intravenous infusion of adenosine triphosphate in the diagnosis of coronary artery disease] Kumano S. **Kaku Igaku** 1996 Feb; 33(2):153–9 (Eng. Abstr.) **(Jpn)**

GENETICS

Point mutation of adenosine triphosphate-binding motif generated rigor kinesin that selectively blocks anterograde lysosome membrane transport. Nakata T, et al. **J Cell Biol** 1995 Nov;131(4):1039–53

Pentagastrin selectively modulates levels of mRNAs encoding apical H/K adenosine triphosphatase and basolateral Na–K–Cl cotransporter in rat gastric fundic mucosa. Klingensmith ME, et al. **Surgery** 1996 Aug; 120(2):242–6; discussion 246–7

METABOLISM

Prevention of intracellular adenosine triphosphate depletion after sublethal oxidant injury to rat type II alveolar epithelial cells with exogenous glutathione and N-acetylcysteine. Pacht ER, et al. **Am J Med Sci** 1995 Oct;310(4):133–7

Comparison of myocardial ATP, blood flow, and cytosolic adenosine in demand ischemia and coronary occlusion. Kroll K, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H819–28

Prior heat stress enhances survival of renal epithelial cells after ATP depletion. Wang YH, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):F1057–65

A continuous spectrophotometric assay for simultaneous measurement of calcium uptake and ATP hydrolysis in sarcoplasmic reticulum. Karon BS, et al. **Anal Biochem** 1995 May 20;227(2):328–33

Isoflurane preserves adenosine triphosphate levels in anoxic isolated rat hepatocytes by stimulating glycolytic adenosine triphosphate formation. Matsushita M, et al. **Anesth Analg** 1996 Jun;82(6):1261–7

Metabolism of glucose, glycogen, and high-energy phosphates during transient forebrain ischemia in diabetic rats: effect of insulin treatment. Lanier WL, et al. **Anesthesiology** 1996 Apr;84(4):917–25

A new splicing variant in the frog heart sarcolemmal Na–Ca exchanger creates a putative ATP-binding site. Iwata T, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:37–45 (34 ref.)

Delay of adenosine triphosphate depletion and hypoxanthine formation in rabbit lung after death. Van Raemdonck DE, et al. **Ann Thorac Surg** 1996 Jul;62(1):233–40; discussion 240–1

Relationship of mitochondrial function and cellular adenosine triphosphate levels to pMC540 and merodantoin cytotoxicity in MCF-7 human breast cancer cells. Gulliya KS, et al. **Anticancer Drugs** 1995 Aug;6(4):545–52

Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate. García P, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1569–73

The effect of sulfite on the ATP hydrolysis and synthesis activities in chloroplasts and cyanobacterial membrane vesicles can be explained by competition with phosphate. Bakels RH, et al. **Arch Biochem Biophys** 1996 Aug 1; 332(1):170–4

Application of a double isotopic labeling method to a study of the interaction of mitochondrially bound rat brain hexokinase with intramitochondrial compartments of ATP generated by oxidative phosphorylation. de Cerqueira Cesar M, et al. **Arch Biochem Biophys** 1995 Dec 1; 324(1):9–14

G(o) protein does not regulate ATP-stimulated [Ca2+]i elevation or noradrenaline release in PC12 cells. Oda H, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):1–7

ATP hydrolysis is not required for the dissociation of a substance P.BiP complex. Vidal V, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):314–8

Transient pre-ischemic acidosis protects the isolated rabbit heart subjected to 30 minutes, but not 60 minutes, of global ischemia. Simkhovich BZ, et al. **Basic Res Cardiol** 1995 Sep–Oct;90(5):397–403

Characterization of the ATP-dependent LTC4 transporter in cisplatin-resistant human KB cells. Chuman Y, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):158–65

ATP depletion affects NPM translocation and exportation of rRNA from nuclei. Finch RA, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):553–8

Nucleoside triphosphate donors for nucleoside kinases: donor properties of UTP with human deoxycytidine kinase. Krawiec K, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):42–8

Binding and functions of extracellular ATP in cultured cerebellar granule neurons. Merlo D, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):907–14

Requirement of ATP hydrolysis for assembly of ClpA/ClpP complex, the ATP-dependent protease Ti in Escherichia coli. Seol JH, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):41–51

Phosphorylation of myosin-I from rat liver by protein kinase C reduces calmodulin binding. Williams R, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):90–102

A hierarchy of ATP-consuming processes in mammalian cells. Buttgereit F, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):163–7

Involvement of an arginyl residue in the nucleotide-binding site of Ca(2+)-ATPase from sarcoplasmic reticulum as seen by reaction with phenylglyoxal. Corbalán-García S, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):179–85

Top-down control analysis of temperature effect on oxidative phosphorylation. Dufour S, et al. **Biochem J** 1996 Mar 15; 314 (Pt 3):743–51

Glycerol 3-phosphate-induced ATP production in intact mitochondria from pancreatic B-cells. Idahl LA, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):287–92

Activation of P2z purinoceptors diminishes the muscarinic cholinergic-induced release of inositol 1,4,5-trisphosphate and stored calcium in rat parotid acini. ATP as a co-transmitter in the stimulus-secretion coupling. Jørgensen TD, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):457–64

ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Leier I, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):433–7

Temporal patterns of changes in ATP/ADP ratio, glucose 6-phosphate and cytoplasmic free Ca2+ in glucose-stimulated pancreatic beta-cells. Nilsson T, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):91–4

Protection of hypoxia-induced ATP decrease in endothelial cells by ginkgo biloba extract and bilobalide. Janssens D, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):991–9

A model for ATP hydrolysis catalysed by F1-ATPases based on kinetic and structural considerations. Allison WS, et al. **Biochem Soc Trans** 1995 Nov;23(4):752–6

Observation of ATP turnover during in vitro motility assays. Conibear PB, et al. **Biochem Soc Trans** 1995 Aug;23(3):400S

Caged FEDA-ATP: a new tool in the measurement of ATP turnover during the in vitro motility assay. Jeffreys DS, et al. **Biochem Soc Trans** 1995 Aug;23(3):401S

Human erythrocyte dematin and protein 4.2 (pallidin) are ATP binding proteins. Azim AC, et al. **Biochemistry** 1996 Mar 5;35(9):3001–6

Role of adenosine 5'-triphosphate hydrolysis in the assembly of the bacteriophage T4 DNA replication holoenzyme complex. Berdis AJ, et al. **Biochemistry** 1996 Jul 16; 35(28):9253–65

Substrate binding causes movement in the ATP binding domain of Escherichia coli adenylate kinase. Bilderback T, et al. **Biochemistry** 1996 May 14;35(19):6100–6

Characterization of the arachidonate and ATP binding sites of human 5-lipoxygenase using photoaffinity labeling and enzyme immobilization. Falgueyret JP, et al. **Biochemistry** 1995 Oct 17;34(41):13603–11

Biochemical evidence for the formation of a covalent acyl-phosphate linkage between UDP-N-acetylmuramate and ATP in the Escherichia coli UDP-N-acetylmuramate:L-alanine ligase-catalyzed reaction. Falk PJ, et al. **Biochemistry** 1996 Feb 6; 35(5):1417–22

A kinetic study on the influence of nucleoside triphosphate effectors on subunit interaction in mouse ribonucleotide reductase. Ingemarson R, et al. **Biochemistry** 1996 Jul 2; 35(26):8603–9

The alpha 3 beta 3 gamma complex of the F1-ATPase from thermophilic Bacillus PS3 containing the alpha D261N substitution fails to dissociate inhibitory MgADP from a catalytic site when ATP binds to noncatalytic sites. Jault JM, et al. **Biochemistry** 1995 Dec 19;34(50):16412–8

Identification of the ATP transporter of rat liver rough endoplasmic reticulum via photoaffinity labeling and partial purification. Kim SH, et al. **Biochemistry** 1996 Apr 30; 35(17):5418–25

Evidence for electron transfer from the nitrogenase iron protein to the molybdenum-iron protein without MgATP hydrolysis: characterization of a tight protein-protein complex. Lanzilotta WN, et al. **Biochemistry** 1996 Jun 4; 35(22):7188–96

Allosteric effects of RuvA protein, ATP, and DNA on RuvB protein-mediated ATP hydrolysis. Marrione PE, et al. **Biochemistry** 1996 Aug 27;35(34):11228–38

Phase partition analysis of nucleotide binding to axonemal dynein. Mocz G, et al. **Biochemistry** 1996 Jul 16; 35(28):9204–11

Structural investigation of the antibiotic and ATP-binding sites in kanamycin nucleotidyltransferase. Pedersen LC, et al. **Biochemistry** 1995 Oct 17;34(41):13305–11

Limited proteolysis of Salmonella typhimurium nicotinic acid phosphoribosyltransferase reveals ATP-linked conformational change. Rajavel M, et al. **Biochemistry** 1996 Apr 2;35(13):3909–16

Adenosine 5'-(gamma-thiotriphosphate): an ATP analog that should be used with caution in muscle contraction studies. Resetar AM, et al. **Biochemistry** 1995 Dec 12; 34(49):16039–45

Mutation of position 52 in ERK2 creates a nonproductive binding mode for adenosine 5'-triphosphate. Robinson MJ, et al. **Biochemistry** 1996 May 7;35(18):5641–6

Elucidation of a MgATP signal transduction pathway in the nitrogenase iron protein: formation of a conformation resembling the MgATP-bound state by protein engineering. Ryle MJ, et al. **Biochemistry** 1996 Apr 16; 35(15):4766–75

Elucidating the mechanism of nucleotide-dependent changes in the redox potential of the [4Fe-4S] cluster in nitrogenase iron protein: the role of phenylalanine 135. Ryle MJ, et al. **Biochemistry** 1996 Jul 23;35(29):9424–34

Differential effects of ubiquitin aldehyde on ubiquitin and ATP-dependent protein degradation. Shaeffer JR, et al. **Biochemistry** 1996 Aug 20;35(33):10886–93

Recovery from acute challenge with noradrenaline, vasopressin and angiotensin II in isolated rat hepatocytes. Aggarwal SR, et al. **Biochim Biophys Acta** 1996 Feb 29; 1310(3):284–92

A possible role of the ATP-sensitive potassium ion channel in determining the duration of spike-bursts in mouse pancreatic beta-cells. Ding WG, et al. **Biochim Biophys Acta** 1996 Mar 13;1279(2):219–26

NMR studies of the effect of Mg2+ on post-ischemic recovery of ATP and intracellular sodium in perfused kidney. Dowd TL, et al. **Biochim Biophys Acta** 1995 Dec 12;1272(3):133–9

Participation of a proton-translocating plasma membrane ATPase, acid phosphatase and alkaline phosphatase in ATP degradation by Aspergillus niger extracts. Elzainy TA, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):91–7

Regulation of ATP-sensitive potassium channels by phosphorylation. Light P. **Biochim Biophys Acta** 1996 May 6;1286(1):65–73 (139 ref.)

Effect of the ATP level on the overall protein biosynthesis rate in a wheat germ cell-free system. Matveev SV, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):207–12

Cleft containing reactive thiol of myosin closes during ATP hydrolysis. Park S, et al. **Biochim Biophys Acta** 1996 Aug 15;1296(1):1–4

Nucleotide binding to tubulin-investigations by nuclear magnetic resonance spectroscopy. Rai SS, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):77–88

A point mutation within each of two ATP-binding motifs inactivates the functions of elongation factor 3. Yang H, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):303–8

ATP hydrolysis by membrane-bound Escherichia coli F0F1 causes rotation of the gamma subunit relative to the beta subunits. Zhou Y, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1-2):96–100 (23 ref.)

Effect of a high alpha-linolenate and high linoleate diet on membrane-associated enzyme activities in rat brain--modulation of Na+, K+- ATPase activity at suboptimal concentrations of ATP. Tsutsumi T, et al. **Biol Pharm Bull** 1995 May;18(5):664–70

Communicative interaction of myosins along an actin

filament in the presence of ATP. Hatori K, et al. **Biophys Chem** 1996 Jun 11;60(3):149–52
Mechanochemical coupling of the motion of molecular motors to ATP hydrolysis. Astumian RD, et al. **Biophys J** 1996 Feb;70(2):637–53
Structural and functional similarities between the nucleotide-binding domains of CFTR and GTP-binding proteins. Carson MR, et al. **Biophys J** 1995 Dec; 69(6):2443–8
Sliding distance per ATP molecule hydrolyzed by myosin heads during isotonic shortening of skinned muscle fibers. Higuchi H, et al. **Biophys J** 1995 Oct;69(4):1491–507
Influence of inorganic phosphate and pH on ATP utilization in fast and slow skeletal muscle fibers. Potma EJ, et al. **Biophys J** 1995 Dec;69(6):2580–9
P2X1 receptor activation in HL60 cells. Buell G, et al. **Blood** 1996 Apr 1;87(7):2659–64
Full sensitivity of P2X2 purinoceptor to ATP revealed by changing extracellular pH. King BF, et al. **Br J Pharmacol** 1996 Apr;117(7):1371–3
Prevention by alpha-tocopherol and rutin of glutathione and ATP depletion induced by oxidized LDL in cultured endothelial cells. Schmitt A, et al. **Br J Pharmacol** 1995 Oct;116(3):1985–90
Lack of correlation between glutamate-induced depletion of ATP and neuronal death in primary cultures of cerebellum. Marcaida G, et al. **Brain Res** 1995 Oct 16;695(2):146–50
Intracellular ATP is required for actinomycin D-induced apoptotic cell death in HeLa cells. Chou CC, et al. **Cancer Lett** 1995 Sep 25;96(2):181–7
Accumulation of human promyelocytic leukemic (HL-60) cells at two energetic cell cycle checkpoints. Sweet S, et al. **Cancer Res** 1995 Nov 15;55(22):5164–7
Non-uniform recovery of segment shortening during reperfusion following regional myocardial ischaemia despite uniform recovery of ATP. Brunvand H, et al. **Cardiovasc Res** 1995 Jul;30(1):138–46
Regulation of glibenclamide-sensitive K+ current by nucleotide phosphates in isolated rabbit pulmonary myocytes. Clapp LH. **Cardiovasc Res** 1995 Sep;30(3):460–8
Lack of a pharmacologic interaction between ATP-sensitive potassium channels and adenosine A1 receptors in ischemic rat hearts. Grover GJ, et al. **Cardiovasc Res** 1996 Apr; 31(4):511–7
Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Hearse DJ. **Cardiovasc Res** 1995 Jul;30(1):1–17 (94 ref.)
Evidence for the involvement of the ATP-sensitive potassium channel in a novel model of hypoxic preconditioning in dogs. Mei DA, et al. **Cardiovasc Res** 1995 Aug;30(2):222–30
Myocardial Ca(2+)- and ATP-cycling imbalances in end-stage dilated and ischemic cardiomyopathies. O'Brien PJ, et al. **Cardiovasc Res** 1995 Sep;30(3):394–404
ATP-sensitive potassium channels, transmural ischemia and the ECG implications for the non-insulin dependent diabetic patient? [editorial] Wilde AA. **Cardiovasc Res** 1996 May;31(5):688–90
Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Liu X, et al. **Cell** 1996 Jul 12;86(1):147–57
ATP binding to the sigma 54-dependent activator XylR triggers a protein multimerization cycle catalyzed by UAS DNA. Pérez-Martín J, et al. **Cell** 1996 Jul 26;86(2):331–9
Protein kinase C-induced changes in the stoichiometry of ATP binding activate cardiac ATP-sensitive K+ channels. A possible mechanistic link to ischemic preconditioning. Light PE, et al. **Circ Res** 1996 Sep;79(3):399–406
Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Speechly-Dick ME, et al. **Circ Res** 1995 Nov;77(5):1030–5
31P nuclear magnetic resonance spectroscopic imaging of regions of remodeled myocardium in the infarcted rat heart. Friedrich J, et al. **Circulation** 1995 Dec 15;92(12):3527–38
ATP-dependent potassium channel in rat cardiomyocytes is blocked by lidocaine. Possible impact on the antiarrhythmic action of lidocaine. Olschewski A, et al. **Circulation** 1996 Feb 15;93(4):656–9
Mechanism of ischemic preconditioning [letter; comment] Zucchi R. **Circulation** 1996 Jan 1;93(1):200–2. Comment on: Circulation 1995 Jun 1;91(11):2810–8.
Regional difference of endogenous ATP release in the pulmonary artery of rabbits. Takeuchi K, et al. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):675–6
Adenosine triphosphate catabolism in bovine spermatozoa. Minelli A, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Mar; 110(3):605–11
Regional differences of endogenous ATP release in rabbit arteries. Ishii R, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Mar;113(3):387–91
Effect of antidepressants on ATP content, 3H-valine incorporation and cell morphometry of astrocytes cultured from rat brain. Trzeciak HI, et al. **Dev Neurosci** 1995; 17(5–6):292–9
The inhibition of the insulin receptor by the receptor protein PC-1 is not specific and results from the hydrolysis of ATP. Stefan C, et al. **Diabetes** 1996 Jul;45(7):980–3
Sulphonylurea stimulates glucose uptake in rats through an ATP-sensitive K+ channel dependent mechanism. Pulido N, et al. **Diabetologia** 1996 Jan;39(1):22–7
Calcitonin gene-related peptide rapidly inhibits calcium uptake in osteoblastic cell lines via activation of adenosine triphosphate-sensitive potassium channels. Kawase T, et al. **Endocrinology** 1996 Mar;137(3):984–90
Evidence for elongation of the helical pitch of the RecA filament upon ATP and ADP binding using small-angle neutron scattering. Ellouze C, et al. **Eur J Biochem** 1995 Oct 15;233(2):579–83
The synthesis of mRNA in isolated mitochondria can be maintained for several hours and is inhibited by high levels of ATP. Enriquez JA, et al. **Eur J Biochem** 1996 May 1; 237(3):601–10
Identification of two sites in gelsolin with different sensitivities to adenine nucleotides. Laham LE, et al. **Eur J Biochem** 1995 Nov 15;234(1):1–7
Possible neuronal origin of ATP release evoked by forskolin and ouabain from guinea-pig atrial segments. Katsuragi T, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):213–7
Neuroprotective effects of the pyrrolopyrimidine U-104067F in 3-acetylpyridine-treated rats. Sethy VH, et al. **Exp Neurol** 1996 Jul;140(1):79–83
Functional interaction of hexokinase with ATP requires participation by both small and large lobes of the enzyme: implications for other proteins using the actin fold as a nucleotide binding motif. Wilson JE, et al. **FASEB J** 1996 May;10(7):799–801
Maltokinase (ATP:maltose 1-phosphotransferase) from Actinoplanes sp.: demonstration of enzyme activity and characterization of the reaction product. Drepper A, et al. **FEBS Lett** 1996 Jun 17;388(2–3):177–9
Localisation of an ATP-binding site on adenylyl cyclase type I after chemical and enzymatic fragmentation. Droste M, et al. **FEBS Lett** 1996 Aug 5;391(1–2):209–14
Distinct effects of heat shock and ATP depletion on distribution and isoform patterns of human Hsp27 in endothelial cells. Loktionova SA, et al. **FEBS Lett** 1996 Aug 26;392(2):100–4
Control of apoptosis by the cellular ATP level. Richter C, et al. **FEBS Lett** 1996 Jan 8;378(2):107–10 (62 ref.)
The catalytic cycle of P-glycoprotein. Senior AE, et al. **FEBS Lett** 1995 Dec 27;377(3):285–9 (42 ref.)
Inhibition of astrocyte gap junctional communication by ATP depletion is reversed by calcium sequestration. Vera B, et al. **FEBS Lett** 1996 Sep 2;392(3):225–8
High potassium-evoked release of ATP from rabbit pulmonary artery via endogenous noradrenaline. Takeuchi K, et al. **Gen Pharmacol** 1995 Oct;26(6):1385–90
The effect of 2-chloroadenosine on the ATP level Na,K ATPase activity in experimental brain ischemia of gerbil. Türközkan N, et al. **Gen Pharmacol** 1996 Jan;27(1):165–6
Hypoxic preconditioning in isolated rat hearts: non-involvement of activation of adenosine A1 receptor, Gi protein, and ATP-sensitive K+ channel. Yabe K, et al. **Heart Vessels** 1995;10(6):294–303
Astrocyte survival in the absence of exogenous substrate: comparison of immature and mature cells. Hertz L, et al. **Int J Dev Neurosci** 1995 Oct;13(6):523–7
Proteolytic degradation of dinitrogenase reductase from Anabaena variabilis (ATCC 29413) as a consequence of ATP depletion and impact of oxygen. Durner J, et al. **J Bacteriol** 1996 Feb;178(3):606–10
ATP-dependent H+ -pump activity in inverted vesicles of Methanosarcina mazei Gö1 and characterization of membrane ATPase. Inatomi KI. **J Bacteriol** 1996 Apr; 178(8):2424–6
SecA proteins of Bacillus subtilis and Escherichia coli possess homologous amino-terminal ATP-binding domains regulating integration into the plasma membrane. McNicholas P, et al. **J Bacteriol** 1995 Dec;177(24):7231–7
Involvement of an ATP-dependent carboxylase in a CO2-dependent pathway of acetone metabolism by Xanthobacter strain Py2. Sluis MK, et al. **J Bacteriol** 1996 Jul;178(14):4020–6
ATP-dependent conformational changes of dynein: evidence for changes in the interaction of dynein heavy chain with the intermediate chain 1. Inaba K. **J Biochem (Tokyo)** 1995 Apr;117(4):903–7
Lysyl-tRNA synthetase from Bacillus stearothermophilus. Purification, and fluorometric and kinetic analysis of the binding of substrates, L-lysine and ATP. Takita T, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):680–9
An activating mutation in the ATP binding site of the ABL kinase domain. Allen PB, et al. **J Biol Chem** 1996 Aug 9;271(32):19585–91
Catalytic activities of alpha3beta3gamma complexes of F1-ATPase with 1, 2, or 3 incompetent catalytic sites. Amano T, et al. **J Biol Chem** 1996 Jul 26;271(30):18128–33
N-Ethylmaleimide-sensitive factor acts at a prefusion ATP-dependent step in Ca2+-activated exocytosis. Banerjee A, et al. **J Biol Chem** 1996 Aug 23;271(34):20223–6
Characterization of ATP transport into chromaffin granule ghosts. Synergy of ATP and serotonin accumulation in chromaffin granule ghosts. Bankston LA, et al. **J Biol Chem** 1996 Jul 19;271(29):17132–8
Evidence for the coupling of ATP hydrolysis to the final (extension) phase of RecA protein-mediated DNA strand exchange. Bedale WA, et al. **J Biol Chem** 1996 Mar 8; 271(10):5725–32
The maltose transport system of Escherichia coli displays positive cooperativity in ATP hydrolysis. Davidson AL, et al. **J Biol Chem** 1996 Mar 1;271(9):4858–63
Recombinant N-terminal nucleotide-binding domain from mouse P-glycoprotein. Overexpression, purification, and role of cysteine 430. Dayan G, et al. **J Biol Chem** 1996 May 17;271(20):11652–8
A role for ATP and TFIIH in activation of the RNA polymerase II preinitiation complex prior to transcription initiation. Dvir A, et al. **J Biol Chem** 1996 Mar 29; 271(13):7245–8
Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis. Eytan GD, et al. **J Biol Chem** 1996 Feb 9; 271(6):3172–8
An ATP-dependent iron transport system in isolated rat liver nuclei. Gurgueira SA, et al. **J Biol Chem** 1996 Jun 7; 271(23):13616–20
ATP binding and hydrolysis by the multifunctional protein disulfide isomerase. Guthapfel R, et al. **J Biol Chem** 1996 Feb 2;271(5):2663–6
Assessment of the ATP binding properties of Hsp90. Jakob U, et al. **J Biol Chem** 1996 Apr 26;271(17):10035–41
Global conformational transitions in Escherichia coli primary replicative helicase DnaB protein induced by ATP, ADP, and single-stranded DNA binding. Multiple conformational states of the helicase hexamer. Jezewska MJ, et al. **J Biol Chem** 1996 Feb 23;271(8):4261–5
Identification of the ATP binding domain of recombinant human 40-kDa 2',5'-oligoadenylate synthetase by photoaffinity labeling with 8-azido-[alpha-32P]ATP. Kon N, et al. **J Biol Chem** 1996 Aug 16;271(33):19983–90
Substitutions of glutamate 781 in the Na,K-ATPase alpha subunit demonstrate reduced cation selectivity and an increased affinity for ATP. Koster JC, et al. **J Biol Chem** 1996 Feb 2;271(5):2413–21
The cardiac inward rectifier K+ channel subunit, CIR, does not comprise the ATP-sensitive K+ channel, IKATP. Krapivinsky G, et al. **J Biol Chem** 1995 Dec 1; 270(48):28777–9
Activation of the ATP-sensitive K+ channel by long chain acyl-CoA. A role in modulation of pancreatic beta-cell glucose sensitivity. Larsson O, et al. **J Biol Chem** 1996 May 3;271(18):10623–6
C-terminal trimerization, but not N-terminal trimerization, of the reovirus cell attachment protein Is a posttranslational and Hsp70/ATP-dependent process. Leone G, et al. **J Biol Chem** 1996 Apr 5;271(14):8466–71
Purified cystic fibrosis transmembrane conductance regulator (CFTR) does not function as an ATP channel. Li C, et al. **J Biol Chem** 1996 May 17;271(20):11623–6
ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. Loe DW, et al. **J Biol Chem** 1996 Apr 19;271(16):9683–9
Sec-dependent thylakoid protein translocation. Delta pH requirement is dictated by passenger protein and ATP concentration. Mant A, et al. **J Biol Chem** 1995 Oct 6; 270(40):23275–81
Influence of cluster formation of acidic phospholipids on decrease in the affinity for ATP of DnaA protein. Mizushima T, et al. **J Biol Chem** 1996 Feb 16;271(7):3633–8
Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein. Müller M, et al. **J Biol Chem** 1996 Jan 26;271(4):1877–83
ATP and SH3 binding sites in the protein kinase of the large subunit of herpes simplex virus type 2 of ribonucleotide reductase (ICP10). Nelson JW, et al. **J Biol Chem** 1996 Jul 19;271(29):17021–7
Lysine 71 of the chaperone protein Hsc70 Is essential for ATP hydrolysis. O'Brien MC, et al. **J Biol Chem** 1996 Jul 5;271(27):15874–8
A mutation in the ATP binding domain of rho alters its RNA binding properties and uncouples ATP hydrolysis from helicase activity. Pereira S, et al. **J Biol Chem** 1995 Dec 22;270(51):30401–7
Role of nucleotide exchange and hydrolysis in the function of profilin in action assembly. Perelroizen I, et al. **J Biol Chem** 1996 May 24;271(21):12302–9
Equilibrium studies of kinesin-nucleotide intermediates. Rosenfeld SS, et al. **J Biol Chem** 1996 Apr 19; 271(16):9473–82
Characterization of a potential catalytic residue, Asp-133, in the high affinity ATP-binding site of Escherichia coli SecA, translocation ATPase. Sato K, et al. **J Biol Chem** 1996 Jul 19;271(29):17439–44
GrpE alters the affinity of DnaK for ATP and Mg2+. Implications for the mechanism of nucleotide exchange. Skowyra D, et al. **J Biol Chem** 1995 Nov 3;270(44):26282–5
Reduction in water activity greatly retards the phosphoryl transfer from ATP to enzyme protein in the catalytic cycle of sarcoplasmic reticulum Ca2+-ATPase. Suzuki H, et al. **J Biol Chem** 1996 Mar 8;271(10):5481–6
The ATP-binding site in the 2-kinase domain of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Study of the role of Lys-54 and Thr-55 by site-directed mutagenesis. Vertommen D, et al. **J Biol Chem** 1996 Jul 26;271(30):17875–80
The mitochondrial protein import machinery. Role of ATP in dissociation of the Hsp70.Mim44 complex. von Ahsen O, et al. **J Biol Chem** 1995 Dec 15;270(50):29848–53
An interaction between the Escherichia coli RecF and RecR proteins dependent on ATP and double-stranded DNA. Webb BL, et al. **J Biol Chem** 1995 Dec 29;

270(52):31397–404
In vitro dissociation of BiP–peptide complexes requires a conformational change in BiP after ATP binding but does not require ATP hydrolysis. Wei J, et al. **J Biol Chem** 1995 Nov 3;270(44):26677–82
Phosphocreatine–dependent glutamate uptake by synaptic vesicles. A comparison with atp–dependent glutamate uptake. Xu CJ, et al. **J Biol Chem** 1996 Jun 7; 271(23):13435–40
Assembly of ER–associated protein degradation in vitro: dependence on cytosol, calnexin, and ATP. McCracken AA, et al. **J Cell Biol** 1996 Feb;132(3):291–8
Sac1p mediates the adenosine triphosphate transport into yeast endoplasmic reticulum that is required for protein translocation. Mayinger P, et al. **J Cell Biol** 1995 Dec;131(6 Pt 1):1377–86
Adenine nucleotide metabolism by chondrocytes in vitro: role of ATP in chondrocyte maturation and matrix mineralization. Hatori M, et al. **J Cell Physiol** 1995 Dec; 165(3):468–74
Homologous desensitization of ATP–stimulated mitogenesis: mechanism involves desensitization of arachidonic acid release and cAMP elevation but not the activation of protein kinase A. Huang NN, et al. **J Cell Physiol** 1995 Dec;165(3):667–75
ATP depletion causes translational immobilization of cell surface transferrin receptors in K562 cells. Thatte HS, et al. **J Cell Physiol** 1996 Feb;166(2):446–52
Adaptive preservation of ATP and tolerance to hypoxia following carotid artery ligation in the immature rat. Hylton CM, et al. **J Cereb Blood Flow Metab** 1995 Nov; 15(6):1137–40
Regional alterations of ATP and heat–shock protein–72 mRNA following hypoxia–ischemia in neonatal rat brain. Kobayashi S, et al. **J Cereb Blood Flow Metab** 1995 Nov; 15(6):1047–56
Nucleotide turnover rate measured in fully relaxed rabbit skeletal muscle myofibrils. Myburgh KH, et al. **J Gen Physiol** 1995 Nov;106(5):957–73
The ATP–binding and ATPase activities of human papillomavirus type 16 E1 are significantly weakened by the absence of prolines in its ATP–binding domain. Raj K, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):2949–56
Lesch–Nyhan syndrome and its pathogenesis: normal nicotinamide–adenine dinucleotide but reduced ATP concentrations that correlate with reduced poly(ADP–ribose) synthetase activity in HPRT–deficient lymphoblasts. McCreanor GM, et al. **J Inherit Metab Dis** 1995;18(6):737–47
4–(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF–receptor protein tyrosine kinase. Traxler PM, et al. **J Med Chem** 1996 Jun 7;39(12):2285–92
Role of translocases in the generation of phosphatidylserine asymmetry. Diaz C, et al. **J Membr Biol** 1996 May; 151(1):1–9 (99 ref.)
Extracellular ATP binding proteins as potential receptors in mucociliary epithelium: characterization using [32P]3'–O–(4–benzoyl)benzoyl ATP, a photoaffinity label. Gheber L, et al. **J Membr Biol** 1995 Sep;147(1):83–93
CFTR channels expressed in CHO cells do not have detectable ATP conductance. Grygorczyk R, et al. **J Membr Biol** 1996 May;151(2):139–48
Inter–ring communication is disrupted in the GroEL mutant Arg13 —> Gly; Ala126 —> Val with known crystal structure. Aharoni A, et al. **J Mol Biol** 1996 May 24; 258(5):732–5
Role of adenosine nucleotides in the regulation of a stress–response transcription factor in Bacillus subtilis. Alper S, et al. **J Mol Biol** 1996 Jul 12;260(2):165–77
Structural and functional dissections of transcription termination factor rho by random mutagenesis. Miwa Y, et al. **J Mol Biol** 1995 Dec 15;254(5):815–37
Repressor forms of the enhancer–binding protein NrtC: some fail in coupling ATP hydrolysis to open complex formation by sigma 54–holoenzyme. North AK, et al. **J Mol Biol** 1996 Jul 19;260(3):317–31
RecA protein dynamics in the interior of RecA nucleoprotein filaments. Shan Q, et al. **J Mol Biol** 1996 Apr 12; 257(4):756–74
Allosteric control by ATP of non–folded protein binding to GroEL. Yifrach O, et al. **J Mol Biol** 1996 Jan 26; 255(3):356–61
Requirement of glycolytic substrate for metabolic recovery during moderate low flow ischemia. Schaefer S, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2167–76
Intrasynaptosomal free Mg2+ concentration measured with the fluorescent indicator mag–fura–2: modulation by Na+ gradient and by extrasynaptosomal ATP. García–Martín E, et al. **J Neurochem** 1995 Dec;65(6):2757–64
L–type voltage–dependent Ca2+ and ATP–sensitive K+ channels are not involved in the regulation of bovine ciliary muscle contractility. Kageyama M, et al. **J Ocul Pharmacol Ther** 1995 Winter;11(4):553–63
ATP depletion by iodoacetate and cyanide in renal distal tubular cells. Lash LH, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):194–205
Diabetes and ATP–sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts. Tosaki A, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1115–23
Synchronous release of ATP and neurotransmitter within milliseconds of a motor nerve impulse in the frog. Silinsky EM, et al. **J Physiol (Lond)** 1996 May 1;492 (Pt 3):815–22
Inorganic pyrophosphate generation from adenosine triphosphate by cell–free human synovial fluid. Park W, et al. **J Rheumatol** 1996 Apr;23(4):665–71
Myocardial glucose metabolism and ATP levels are decreased two days after global ischemia. Baldwin DR, et al. **J Surg Res** 1996 Jun;63(1):35–8
Evaluation of functional recovery of regenerating rat liver after partial hepatectomy using 31P–NMR spectroscopy. Nishida Y, et al. **J Surg Res** 1996 Mar;61(2):385–90
Energy depletion in the liver and in isolated hepatocytes of tumor–bearing animals. Tsuburaya A, et al. **J Surg Res** 1995 Oct;59(4):421–7
Dichloroacetate enhanced myocardial functional recovery post–ischemia : ATP and NADH recovery. Wahr JA, et al. **J Surg Res** 1996 Jun;63(1):220–4
Quantal transmission at purinergic synapses: stochastic interaction between ATP and its receptors. Bennett MR, et al. **J Theor Biol** 1995 Aug 7;175(3):397–404
ATP release from the isolated perfused guinea pig heart in response to increased flow. Vials AJ, et al. **J Vasc Res** 1996 Jan–Feb;33(1):1–4
The QRxGRxGRxxxG motif of the vaccinia virus DExH box RNA helicase NPH–II is required for ATP hydrolysis and RNA unwinding but not for RNA binding. Gross CH, et al. **J Virol** 1996 Mar;70(3):1706–13
Negative regulation of the adeno–associated virus (AAV) P5 promoter involves both the P5 rep binding site and the consensus ATP–binding motif of the AAV Rep68 protein. Kyöstiö SR, et al. **J Virol** 1995 Nov;69(11):6787–96
Participation of endogenous noradrenaline in the release of ATP by high potassium in the rat caudal artery. Shinozuka K, et al. **Jpn J Pharmacol** 1995 May;68(1):125–7
Actin and villin compartmentation during ATP depletion and recovery in renal cultured cells. Golenhofen N, et al. **Kidney Int** 1995 Dec;48(6):1837–45
An ATP–regulated, inwardly rectifying potassium channel from rat kidney (ROMK). Hebert SC. **Kidney Int** 1995 Oct; 48(4):1010–6 (66 ref.)
Cross–talk and the role of KATP channels in the proximal tubule. Welling PA. **Kidney Int** 1995 Oct;48(4):1017–23 (79 ref.)
A unifying purinergic hypothesis for the initiation of pain. Burnstock G. **Lancet** 1996 Jun 8;347(9015):1604–5
31P NMR studies of human soleus and gastrocnemius show differences in the J gamma beta coupling constant of ATP and in intracellular free magnesium. Widmaier S, et al. **MAGMA** 1996 Mar;4(1):47–53
Human cardiac high–energy phosphate metabolite concentrations by 1D–resolved NMR spectroscopy. Bottomley PA, et al. **Magn Reson Med** 1996 May; 35(5):664–70
Correlation of rapid changes in the average water diffusion constant and the concentrations of lactate and ATP breakdown products during global ischemia in cat brain. Decanniere C, et al. **Magn Reson Med** 1995 Sep; 34(3):343–52
Depletion of cytosolic GSH decreases the ATP levels and viability of synaptosomes from aged mice but not from young mice. Martínez M, et al. **Mech Ageing Dev** 1995 Sep 29;84(1):77–81
Hypothesis on cellular ATP depletion and adenosine release as causes of heart failure and vasodilatation in cardiovascular beriberi. Bakker SJ, et al. **Med Hypotheses** 1995 Sep;45(3):265–7
Nonradioactive method for ATPase assays. Kagami O, et al. **Methods Cell Biol** 1995;47:147–50
Analysis and purification of ATP–dependent mitochondrial lon protease of Saccharomyces cerevisiae. Suzuki CK, et al. **Methods Enzymol** 1995;260:486–94
Necessary but not sufficient: the role of glucocorticoids in the acidosis–induced increase in levels of mRNAs encoding proteins of the ATP–dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1–3):72–5 (14 ref.)
Biochemical and functional analysis of the YME1 gene product, an ATP and zinc–dependent mitochondrial protease from S. cerevisiae. Weber ER, et al. **Mol Biol Cell** 1996 Feb;7(2):307–17
ATP–dependent activation of phospholipase C by antigen, NECA, Na3VO4, and GTP–gamma–S in permeabilized RBL cell ghosts: differential augmentation by ATP, phosphoenolpyruvate and phosphocreatine. Dreskin SC. **Mol Cell Biochem** 1995 May 24;146(2):165–70
ATP modulation of the ligand binding and signal transduction activities of the type C natriuretic peptide receptor guanylate cyclase. Duda T, et al. **Mol Cell Biochem** 1995 Nov 22;152(2):179–83
ATP–dependent release of glucocorticoid receptors from the nuclear matrix. Tang Y, et al. **Mol Cell Biol** 1996 May; 16(5):1989–2001
Evidence for two aromatic amino acid–binding sites, one ATP–dependent and the other ATP–independent, in the Escherichia coli regulatory protein TyrR. Wilson TJ, et al. **Mol Microbiol** 1995 Aug;17(3):483–92
ATP depletion and inactivation of an ATP–sensitive taurine channel by classic ion channel blockers. Ballatori N, et al. **Mol Pharmacol** 1995 Sep;48(3):472–6
Improvement of muscular oxidative capacity by training is associated with slight acidosis and ATP depletion in exercising muscles. Ravalec X, et al. **Muscle Nerve** 1996 Mar;19(3):355–61
Structure of the multifunctional loops in the nonclassical ATP–binding fold of glutathione synthetase [letter] Hibi T, et al. **Nat Struct Biol** 1996 Jan;3(1):16–8
Balancing ATP in the cell [news] Stroud RM. **Nat Struct Biol** 1996 Jul;3(7):567–9
Minimal cost per twitch in rattlesnake tail muscle. Conley KE, et al. **Nature** 1996 Sep 5;383(6595):71–2
Highly processive microtubule–stimulated ATP hydrolysis by dimeric kinesin head domains. Hackney DD. **Nature** 1995 Oct 5;377(6548):448–50
Coexpression of P2X2 and P2X3 receptor subunits can account for ATP–gated currents in sensory neurons [see comments] Lewis C, et al. **Nature** 1995 Oct 5; 377(6548):432–5. Comment in: Nature 1995 Oct 5;377(6548):385–6. Comment in: Nature 1995 Dec 14;378(6558):658.
Aptly named aptamers display their aptitude [news; comment] Williamson JR. **Nature** 1996 Jul 11; 382(6587):112–3. Comment on: Nature 1996 Jul 11;382(6587):183–6.
Opposite modulation of noradrenaline and ATP release in guinea–pig vas deferens through prejunctional beta–adrenoceptors: evidence for the beta 2 subtype. Driessen B, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Apr; 353(5):564–71
Failure of tyramine to release neuronal ATP as a cotransmitter of noradrenaline in the guinea–pig vas deferens. Driessen B, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):175–83
Opposite modulation of cotransmitter release in guinea–pig vas deferens: increase of noradrenaline and decrease of ATP release by activation of prejunctional beta–adrenoceptors. Gonçalves J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):184–92
Comparison of corelease of noradrenaline and ATP evoked by hypogastric nerve stimulation and field stimulation in guinea–pig vas deferens. Gonçalves J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug; 352(2):229–35
Extracellular ATP augments mesangial cell growth induced by multiple growth factors. Schulze–Lohoff E, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2027–34
Docked granules, the exocytic burst, and the need for ATP hydrolysis in endocrine cells. Parsons TD, et al. **Neuron** 1995 Nov;15(5):1085–96
Hyperthermia depletes adenosine triphosphate and decreases glutamate uptake in rat hippocampal slices. Madl JE, et al. **Neuroscience** 1995 Nov;69(2):395–405
Application of homonuclear decoupling to measures of diffusion in biological 31P spin echo spectra. Hubley MJ, et al. **NMR Biomed** 1995 May;8(3):113–7
Diffusion coefficients of ATP and creatine phosphate in isolated muscle: pulsed gradient 31P NMR of small biological samples. Hubley MJ, et al. **NMR Biomed** 1995 Apr;8(2):72–8
Expression of an ATP binding mutant of PKC–delta inhibits Sis–induced transformation of NIH3T3 cells. Li W, et al. **Oncogene** 1996 Aug 15;13(4):731–7
Quantitative relationship between brain temperature and energy utilization rate measured in vivo using 31P and 1H magnetic resonance spectroscopy. Laptook AR, et al. **Pediatr Res** 1995 Dec;38(6):919–25
Atomic force microscopy visualizes ATP–dependent dissociation of multimeric TATA–binding protein before translocation into the cell nucleus. Oberleithner H, et al. **Pflugers Arch** 1996 Sep;432(5):839–44
31P magnetic resonance spectroscopy of the Sherpa heart: a phosphocreatine/adenosine triphosphate signature of metabolic defense against hypobaric hypoxia. Hochachka PW, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):1215–20
Oscillations in KATP channel activity promote oscillations in cytoplasmic free Ca2+ concentration in the pancreatic beta cell. Larsson O, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5161–5
ATP–dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Paul S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6929–34
31P NMR magnetization transfer study of the control of ATP turnover in Saccharomyces cerevisiae. Sheldon JG, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6399–404
P2X4: an ATP–activated ionotropic receptor cloned from rat brain. Soto F, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3684–8
Molecular cloning and expression of a cyclic AMP–activated chloride conductance regulator: a novel ATP–binding cassette transporter. van Kuijck MA, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5401–6
The mitochondrial protein import motor: dissociation of mitochondrial hsp70 from its membrane anchor requires ATP binding rather than ATP hydrolysis. Horst M, et al. **Protein Sci** 1996 Apr;5(4):759–67
A recombinant peptide model of the first nucleotide–binding fold of the cystic fibrosis transmembrane conductance regulator: comparison of wild–type and delta F508 mutant forms. Yike I, et al. **Protein Sci** 1996 Jan;5(1):89–97
Nucleoside triphosphate levels versus oxygen affinity of rattlesnake red cells. Ragsdale FR, et al. **Respir Physiol**

1995 Oct;102(1):63–9
Selecting apt RNAs for NMR. Cech TR, et al. **RNA** 1996 Jul;2(7):625–7
Solution structure of an ATP-binding RNA aptamer reveals a novel fold. Dieckmann T, et al. **RNA** 1996 Jul;2(7):628–40
Adenosine diphosphate as an intracellular regulator of insulin secretion. Nichols CG, et al. **Science** 1996 Jun 21; 272(5269):1785–7
Failure of the cystic fibrosis transmembrane conductance regulator to conduct ATP. Reddy MM, et al. **Science** 1996 Mar 29;271(5257):1876–9
The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Surprenant A, et al. **Science** 1996 May 3;272(5262):735–8
Relationships between ATP depletion, membrane potential, and the release of neurotransmitters in rat nerve terminals. An in vitro study under conditions that mimic anoxia, hypoglycemia, and ischemia. Santos MS, et al. **Stroke** 1996 May;27(5):941–50
Inositol trisphosphate, polyphosphoinositide turnover, and high-energy metabolites in focal cerebral ischemia and reperfusion. Sun GY, et al. **Stroke** 1995 Oct; 26(10):1893–900
Clinical usefulness of an ATP heat sensitivity test using endoscopic biopsy materials from esophageal cancer patients. Hirai T, et al. **Surg Today** 1995;25(8):684–9
Depletion of high energy phosphate compouds in the tumor-bearing state and reversal after tumor resection. Hochwald SN, et al. **Surgery** 1996 Sep;120(3):534–41
Cell protection by fructose is independent of adenosine triphosphate (ATP) levels in paracetamol injury to rat liver slices. Martin FL, et al. **Toxicology** 1996 Mar 18; 107(3):177–87
Adenosine triphosphate (ATP) levels in paracetamol-induced cell injury in the rat in vivo and in vitro. Martin FL, et al. **Toxicology** 1995 Dec 15;104(1–3):91–7
Regeneration of ATP in kidney slices after warm ischemia and hypothermic preservation. Stubenitsky BM, et al. **Transpl Int** 1995;8(4):293–7
Allopurinol improves postischemic skeletal muscle performance and endurance but not high-energy phosphate levels. Gürke L, et al. **Transplant Proc** 1995 Oct; 27(5):2840–1
Modulation of mitochondrial ATP synthesis and lipid peroxidation by Kupffer cells in liver grafts. Shibuya H, et al. **Transplant Proc** 1996 Feb;28(1):321–3
The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2. Peng T, et al. **Virology** 1996 Feb 1;216(1):184–96
[Effect of DL-butylphthalide (NBP) on mouse brain energy metabolism in complete brain ischemia induced by decapitation] Feng YP, et al. **Yao Hsueh Hsueh Pao** 1995; 30(10):741–4 (Eng. Abstr.) **(Chi)**
-Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay- Kurbacher CM, et al. **Geburtshilfe Frauenheilkd** 1996 Feb; 56(2):70–8 (Eng. Abstr.) **(Ger)**
[Oxidative energy metabolism and cardiac contractility in rat heart during graded reductions of coronary flow] Imamura E. **Hokkaido Igaku Zasshi** 1995 May;70(3):429–36 (Eng. Abstr.) **(Jpn)**
[Effects of exogenous adenosine on myocardial recovery after acute hemorrhage] Yahagi M, et al. **Masui** 1995 Sep; 44(9):1218–23 (Eng. Abstr.) **(Jpn)**
[Kinetic uniformity of the ATP hydrolysis reaction catalyzed by Mg2+-ATPase in smooth muscle cell membrane] Kosterin SA, et al. **Biokhimiia** 1995 Sep;60(9):1450–9 (Eng. Abstr.) **(Rus)**
[Mg2+,ATP-dependent transport of Ca2+ in the endoplasmic reticulum of myometrial cells] Kosterin SA, et al. **Biokhimiia** 1996 Jan;61(1):73–81 (Eng. Abstr.) **(Rus)**
[The effect of p-chloromercuribenzoate on regulation of oxidative phosphorylation by ADP and ATP and stimulation of liver mitochondrial respiration by palmitate] Samartsev VN, et al. **Biokhimiia** 1995 Oct;60(10):1706–10 (Eng. Abstr.) **(Rus)**
[Accumulation of ATP in rat and human hepatocyte cell membranes exposed to certain growth factors and phosphatidylcholine] Globa AG, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):271–4 **(Rus)**
[Effect of thapsigargin and cyclopiazonic acid on Mg2+,ATP-dependent Ca2+ accumulation stimulated by oxalate (phosphate) in permeabilized myometrial cells] Babich LG, et al. **Dokl Akad Nauk** 1995 Nov;345(2):259–62 **(Rus)**
[Coupling effect of 6-ketocholestanol on mitochondria, hydrolyzing adenosine triphosphate in the presence of uncoupling agents-protonophores] Mansurova SE, et al. **Mol Biol (Mosk)** 1995 Nov-Dec;29(6):1376–83 **(Rus)**
[Rapid accumulation of ATP in enriched cell membrane particle substances made from bovine aortic endothelial cells and human hemangioma under the influence of endothelial growth factor] Karelin AA, et al. **Vopr Med Khim** 1995 May-Jun;41(3):17–20 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Effects of zinc and divalent cation chelators on ATP hydrolysis and Ca deposition by rachitic rat matrix vesicles. Hsu HH, et al. **Bone** 1995 Nov;17(5):473–7
Artificial cell-spreading of permeabilized BHK cells on fibronectin-coated substratum. Hayashi M, et al. **Cell Struct Funct** 1995 Oct;20(5):311–7

PHARMACOLOGY

ATP a potent regulator of inositol phospholipids-phospholipase C and lipid mediators in brain cortex. Strosznajder J, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):527–34
Activation of L-type Ca2+ channels after purinoceptor stimulation by ATP in an alveolar epithelial cell (L2). Dietl P, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):L873–83
ATP-sensitive K+ channel opener pinacidil augments beta 1-adrenoceptor-induced coronary vasodilation in dogs. Katsuda Y, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2210–5
Regulation of ATP-sensitive K+ channel by membrane-bound protein phosphatases in rat principal tubule cell. Kubokawa M, et al. **Am J Physiol** 1995 Sep; 269(3 Pt 2):F355–62
An ATP-activated nonselective cation channel in guinea pig ventricular myocytes. Parker KE, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H789–97
KATP channels in rat heart: blockade of ischemic and acetylcholine-mediated preconditioning by glibenclamide. Qian YZ, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H23–8
Pharmacology of ATP-sensitive K+ currents in smooth muscle cells from rabbit mesenteric artery. Quayle JM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1112–8
Opioids contribute to hypoxia-induced pial artery dilation through activation of ATP-sensitive K+ channels. Shankar V, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H997–1002
Preservation of insulin secretory responses to P2 purinoceptor agonists in Zucker diabetic fatty rats. Tang J, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E504–12
Dual effects of arachidonic acid on ATP-sensitive K+ current of coronary smooth muscle cells. Xu X, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H1957–62
Eicosanoid production in rabbit tracheal epithelium by adenine nucleotides: mediation by P2-purinoceptors. Aksoy MO, et al. **Am J Respir Cell Mol Biol** 1995 Oct; 13(4):410–7
A nerve cytosolic factor is required for MgATP stimulation of a Na+ gradient-dependent Ca2+ uptake in plasma membrane vesicles from squid optic nerve. Beaugé L, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:208–16
ATP stimulation of a Na+ gradient-dependent Ca2+ uptake in cardiac sarcolemmal vesicles. Berberián G, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:282–3
Regulation of sodium-calcium exchange in intact myocytes by ATP and calcium. Haworth RA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:464–79 (42 ref.)
Internal motions in myosin head: effect of ADP and ATP. Belagyi J, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):936–40
Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5'-triphosphate. Bronte V, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):344–51
Role of the purinergic P2Z receptor in spontaneous cell death in J774 macrophage cultures. Chiozzi P, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):176–81
Sulfhydryl redox modulates ATP-sensitive K+ channels in rabbit ventricular myocytes. Han J, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):900–3
Dual effects of ATP on the potassium channel and intracellular Ca2+ release in smooth muscle cells of the bovine brain arteries. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1071–7
ATP activates the potassium channel and enhances cytosolic Ca2+ release via a P2Y purinoceptor linked to pertussis toxin-insensitive G-protein in brain artery endothelial cells. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1022–8
P2U purinergic activation leads to the cell cycle progression from the G1 to the S and M phases but not from the G0 to G1 phase in vascular smooth muscle cells in primary culture. Miyagi Y, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):652–8
ATP-stimulated degradation of oxidatively modified superoxide dismutase by cathepsin D in cardiac tissue extracts. Strack PR, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):348–53
P2u purinoceptor regulation of mucin secretion in SPOC1 cells, a goblet cell line from the airways. Abdullah LH, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):943–51
Reconstitution and characterization of ATP-dependent bile acid transport in human and rat placenta. Bravo P, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):479–85
Extracellular ATP activates different signalling pathways in rat Sertoli cells. Foresta C, et al. **Biochem J** 1995 Oct 1; 311 (Pt 1):269–74
Phospholipase D activation by P2Z-purinoceptor agonists in human lymphocytes is dependent on bivalent cation influx. Gargett CE, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):529–35
Activation of P2z purinoceptors diminishes the muscarinic cholinergic-induced release of inositol 1,4,5-trisphosphate and stored calcium in rat parotid acini. ATP as a co-transmitter in the stimulus-secretion coupling. Jørgensen TD, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):457–64
ATP-regulated activity of the plasmin-streptokinase complex: a novel mechanism involving phosphorylation of streptokinase. Serrano RL, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):171–7
Agonists for endothelial P2 purinoceptors trigger a signalling pathway producing Ca2+ responses in lymphocytes adherent to endothelial cells. Wiley JS, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):589–94
Biphasic effect of ATP on neutrophil functions mediated by P2U and adenosine A2A receptors. Zhang Y, et al. **Biochem Pharmacol** 1996 Apr 12;51(7):957–65
Protein kinase C isoform expression and ATP response change with smooth muscle cell differentiation. Assender JW, et al. **Biochem Soc Trans** 1995 Aug;23(3):453S
Distinct effects of ATP on transcription complex formation and initiation in a yeast in vitro transcription system. Coda-Zabetta F, et al. **Biochim Biophys Acta** 1996 May 2;1306(2-3):194–202
A cation non-selective channel induced by extracellular ATP in macrophages and phagocytic cells of the thymic reticulum. Coutinho-Silva R, et al. **Biochim Biophys Acta** 1996 Jan 12;1278(1):125–30
ATP increases Ca(2+)-activated K+ channel activity in isolated rat arterial smooth muscle cells. Hartley SA, et al. **Biochim Biophys Acta** 1996 Sep 4;1283(2):192–8
The role of thiols in ATP-dependent transport of S-(2,4-dinitrophenyl)glutathione by rat liver plasma membrane vesicles. Matsuda Y, et al. **Biochim Biophys Acta** 1996 Feb 21;1279(1):35–42
Effect of inorganic phosphate and ADP on the myofilament sliding induced by laser flash photolysis of caged ATP. Wada H, et al. **Biochim Biophys Acta** 1996 Jun 13; 1274(3):89–93
Purinergically induced membrane fluidization in ciliary cells: characterization and control by calcium and membrane potential. Alfahel E, et al. **Biophys J** 1996 Feb; 70(2):1045–53
The diadenosine polyphosphates Ap3A and Ap4A and adenosine triphosphate interact with granulocyte-macrophage colony-stimulating factor to delay neutrophil apoptosis: implications for neutrophil: platelet interactions during inflammation. Gasmi L, et al. **Blood** 1996 Apr 15;87(8):3442–9
UTP- and ATP-triggered transmitter release from rat sympathetic neurones via separate receptors. Boehm S, et al. **Br J Pharmacol** 1995 Nov;116(5):2341–3
Actions of ADP, but not ATP, on cytosolic free Ca2+ in single rat hepatocytes mimicked by 2-methylthioATP. Dixon CJ, et al. **Br J Pharmacol** 1995 Oct;116(3):1979–84
ATP, a partial agonist of atypical P2Y purinoceptors in rat brain microvascular endothelial cells. Feolde E, et al. **Br J Pharmacol** 1995 Aug;115(7):1199–203
Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Hide EJ, et al. **Br J Pharmacol** 1995 Nov;116(5):2435–40
Action of angiotensin II, 5-hydroxytryptamine and adenosine triphosphate on ionic currents in single ear artery cells of the rabbit. Hughes AD, et al. **Br J Pharmacol** 1995 Oct; 116(3):2148–54
Direct demonstration of sulphonylurea-sensitive KATP channels on nerve terminals of the rat motor cortex. Lee K, et al. **Br J Pharmacol** 1995 Jun;115(3):385–7
The involvement of ATP-sensitive potassium channels in beta-adrenoceptor-mediated vasorelaxation in the rat isolated mesenteric arterial bed. Randall MD, et al. **Br J Pharmacol** 1995 Jun;115(4):607–12
Contribution of P1-(A2b subtype) and P2-purinoceptors to the control of vascular tone in the rat isolated mesenteric arterial bed. Rubino A, et al. **Br J Pharmacol** 1995 Jun; 115(4):648–52
Vasoconstrictor responses to the P2x-purinoceptor agonist beta, gamma-methylene-L-ATP in human cutaneous and renal blood vessels. von Kügelgen I, et al. **Br J Pharmacol** 1995 Sep;116(2):1932–6
ATP increases extracellular dopamine level through stimulation of P2Y purinoceptors in the rat striatum. Zhang YX, et al. **Brain Res** 1995 Sep 11;691(1-2):205–12
A comparison of the effects of UTP and ATP on the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum. Suarez-Kurtz G. **Braz J Med Biol Res** 1994 Nov; 27(11):2661–6
Regulation of postsynaptic responses by calcitonin gene related peptide and ATP at developing neuromuscular junctions. Lu B, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):1050–6 (42 ref.)
Intracellular ATP is required for actinomycin D-induced apoptotic cell death in HeLa cells. Chou CC, et al. **Cancer Lett** 1995 Sep 25;96(2):181–7
Human cytomegalovirus modulates the Ca2+ response to vasopressin and ATP in fibroblast cultures. Himpens B, et al. **Cell Calcium** 1995 Aug;18(2):111–9
Calcium mobilization and entry induced by extracellular ATP in the non-sensory epithelial cell of the cochlear lateral wall. Ikeda K, et al. **Cell Calcium** 1995 Aug; 18(2):89–99
cAMP/ATP relationship in the activation of trout sperm motility: their interaction in membrane-deprived models and in live spermatozoa. Cosson MP, et al. **Cell Motil Cytoskeleton** 1995;31(2):159–76

ATP-induced beta-glucuronidase release from undifferentiated HL-60 cells is dependent on Ca2+ ions. Packham DE, et al. **Cell Signal** 1996 Jan;8(1):67–73

Changes in the endocochlear potential and cochlear blood flow induced by ATP infusion and arterial occlusion. Hu B, et al. **Chin Med J (Engl)** 1995 Jun;108(6):428–33

Protein kinase C activates ATP-sensitive K+ current in human and rabbit ventricular myocytes. Hu K, et al. **Circ Res** 1996 Mar;78(3):492–8

Protein kinase C-induced changes in the stoichiometry of ATP binding activate cardiac ATP-sensitive K+ channels. A possible mechanistic link to ischemic preconditioning. Light PE, et al. **Circ Res** 1996 Sep;79(3):399–406

Synergistic modulation of ATP-sensitive K+ currents by protein kinase C and adenosine. Implications for ischemic preconditioning. Liu Y, et al. **Circ Res** 1996 Mar; 78(3):443–54

Pharmacological evidence for the persistent activation of ATP-sensitive K+ channels in early phase of reperfusion and its protective role against myocardial stunning. Shigematsu S, et al. **Circulation** 1995 Oct 15;92(8):2266–75

Prolactin induced analgesia is dependent on ATP sensitive potassium channels. Shewade DG, et al. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):635–6

Characteristics of ATP-induced catecholamine secretion from adrenal chromaffin cells of the guinea-pig. Asano T, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):101–8

Changes in responsiveness to extracellular ATP in chick skeletal muscle during development and upon denervation. Wells DG, et al. **Dev Biol** 1995 Dec;172(2):585–90

An ATP-sensitive Cl- channel current that is activated by cell swelling, cAMP, and glyburide in insulin-secreting cells. Kinard TA, et al. **Diabetes** 1995 Dec;44(12):1461–6

The beta-cell response to oral hypoglycemic agents. Cook DL. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S81–9 (72 ref.)

The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Kramer W, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S67–80 (25 ref.)

Altered [Ca2+]i mobilization in diabetic cardiomyocytes: responses to caffeine, KCl, ouabain, and ATP. Yu JZ, et al. **Diabetes Res Clin Pract** 1995 Oct;30(1):9–20

The mechanism of action of hepatic sympathetic nerves on ketone-body output from perfused rat liver. The effect of the interaction of noradrenaline with ATP on the release of beta-hydroxybutyrate. Yamamoto T, et al. **Eur J Biochem** 1995 Dec 1;234(2):466–71

Potentiating and inhibitory effects of periodate-oxidized ATP analogs on contractions of vas deferens to ATP. Fedan JS, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):213–7

Pharmacological dissociation of UTP- and ATP-elicited contractions and relaxations in isolated rat aorta. Garcia-Velasco G, et al. **Eur J Pharmacol** 1995 Dec 29; 294(2–3):521–9

Effects of protein kinase A activation on endothelin- and ATP-induced signal transduction. Lin WW. **Eur J Pharmacol** 1995 Sep 15;291(1):1–7

Nucleotide-induced mucin release from primary hamster tracheal surface epithelial cells involves the P2u purinoceptor. Kim KC, et al. **Eur Respir J** 1996 Mar; 9(3):542–8

Renal vascular reactivity to ATP in hyper- and hypothyroid rats. Vargas F, et al. **Experientia** 1996 Mar 15;52(3):225–9

ATP regulates calcium leak from agonist-sensitive internal calcium stores. Hofer AM, et al. **FASEB J** 1996 Feb; 10(2):302–8

Combined effects of ATP and its analogs on the membrane permeability in transformed mouse fibroblasts. Arav R, et al. **FEBS Lett** 1996 Jun 3;387(2–3):149–51

A P2X purinoceptor cDNA conferring a novel pharmacological profile. Bo X, et al. **FEBS Lett** 1995 Nov 13;375(1–2):129–33

The 65-kDa protein derived from the internal translational start site of the clpA gene blocks autodegradation of ClpA by the ATP-dependent protease Ti in Escherichia coli. Seol JH, et al. **FEBS Lett** 1995 Dec 11;377(1):41–3

Ligands of purinergic receptors stimulate electrogenic H(+)-transport of neutrophils. Suszták K, et al. **FEBS Lett** 1995 Nov 13;375(1–2):79–82

Insulin and ATP stimulate actin polymerization in U937 cells by a wortmannin-sensitive mechanism. Walters RJ, et al. **FEBS Lett** 1996 Aug 19;392(1):66–70

Protective effects of the K+ ATP channel opener, aprikalim, against free radicals in isolated rabbit hearts. Pignac J, et al. **Free Radic Biol Med** 1996;20(3):383–9

Age-dependent changes in voltage-gated calcium channels and ATP-dependent potassium channels in Fischer 344 rats. Bangalore R, et al. **Gen Pharmacol** 1995 Oct; 26(6):1237–42

Cytokine-induced expression of type II nitric oxide synthase in astrocytes is downregulated by ATP and glutamate. Murphy S, et al. **Glia** 1995 Sep;15(1):77–82

Noise exposure alters the response of outer hair cells to ATP. Chen C, et al. **Hear Res** 1995 Aug;88(1–2):215–21

ATP modulation of L-type calcium channel currents in guinea pig outer hair cells. Chen C, et al. **Hear Res** 1995 Jun;86(1–2):25–33

ATP-induced increase in intracellular Ca2+ concentration in the cultured marginal cell of the stria vascularis of guinea-pigs. Suzuki M, et al. **Hear Res** 1995 Jun; 86(1–2):68–76

The role of a purinergic P2z receptor in calcium-dependent cell killing of isolated rat hepatocytes by extracellular adenosine triphosphate. Zoetewij JP, et al. **Hepatology** 1996 Apr;23(4):858–65

Human Fallopian tubal epithelial cells in vitro: establishment of polarity and potential role of intracellular calcium and extracellular ATP in fluid secretion. Dickens CJ, et al. **Hum Reprod** 1996 Jan;11(1):212–7

Acrosome reaction induced in a limited population of human spermatozoa by progesterone (Ca(2+)-dependent) and ATP (Ca(2+)-independent). Tomiyama T, et al. **Hum Reprod** 1995 Aug;10(8):2052–5

Effects of ATP analogues and basic fibroblast growth factor on astroglial cell differentiation in primary cultures of rat striatum. Abbracchio MP, et al. **Int J Dev Neurosci** 1995 Nov;13(7):685–93

ATP-sensitive K+ channels are not involved in ischemia-reperfusion lung endothelial injury. Khimenko PL, et al. **J Appl Physiol** 1995 Aug;79(2):554–9

ATP-sensitive K+ channel blockade impairs O2 extraction during progressive ischemia in pig hindlimb. Vallet B, et al. **J Appl Physiol** 1995 Dec;79(6):2035–42

The ATP-activated hexameric helicase of bacteriophage T4 (gp41) forms a stable primosome with a single subunit of T4-coded primase (gp61). Dong F, et al. **J Biol Chem** 1996 Aug 9;271(32):19625–31

SNAP prevents Mg(2+)-ATP-induced release of N-ethylmaleimide-sensitive factor from the Golgi apparatus in digitonin-permeabilized PC12 cells. Tagaya M, et al. **J Biol Chem** 1996 Jan 5;271(1):466–70

Strand specificity of nicking of DNA at Chi sites by RecBCD enzyme. Modulation by ATP and magnesium levels. Taylor AF, et al. **J Biol Chem** 1995 Oct 13;270(41):24459–67

Protective effect of K(ATP) openers in ischemic rat hearts treated with a potassium cardioplegic solution. Grover GJ, et al. **J Cardiovasc Pharmacol** 1995 Nov;26(5):698–706

Endothelin-1 contracts and increases motor responses to ATP in rat seminal vesicle. Luciano LG, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S91–4

Pharmacological analysis in rat of the role of the ATP-sensitive potassium channel as a potential target for antifibrillatory intervention in acute myocardial ischaemia. Rees SA, et al. **J Cardiovasc Pharmacol** 1995 Aug; 26(2):280–8

Neuropeptide-Y-ATP interactions at the vascular sympathetic neuroeffector junction. Westfall TC, et al. **J Cardiovasc Pharmacol** 1995 Nov;26(5):682–7

Regulation of changes in cytosolic Ca2+ and Na+ concentrations in rat submandibular gland acini exposed to carbachol and ATP. Hurley TW, et al. **J Cell Physiol** 1996 Aug;168(2):229–38

Extracellular ATP causes of loss of L-selectin from human lymphocytes via occupancy of P2Z purinocepters. Jamieson GP, et al. **J Cell Physiol** 1996 Mar;166(3):637–42

Low affinity purinergic receptor modulates the response of rat submandibular glands to carbachol and substance P. Métioui M, et al. **J Cell Physiol** 1996 Aug;168(2):462–75

Purinergic agonist ATP is a comitogen in thyroid FRTL-5 cells. Törnquist K, et al. **J Cell Physiol** 1996 Feb; 166(2):241–8

Elevating intracellular free Mg2+ preserves sensitivity of Na(+)-K+ pump to ATP at reduced temperatures in guinea pig red blood cells. Marjanovic M, et al. **J Comp Physiol [B]** 1995;165(6):428–32

Functional heterogeneity of human term cytotrophoblasts revealed by differential sensitivity to extracellular Ca2+ and nucleotides. Bradbury RA, et al. **J Endocrinol** 1996 Apr;149(1):135–44

Coronary vascular ATP-sensitive potassium channels are activated to a greater extent in spontaneously hypertensive rats than in Wistar-Kyoto rats. Numaguchi K, et al. **J Hypertens** 1996 Feb;14(2):183–9

Extracellular ATP activates mast cells via a mechanism that is different from the activation induced by the cross-linking of Fc receptors. Sudo N, et al. **J Immunol** 1996 May 15; 156(10):3970–9

Platelets enhance Fc(gamma) receptor-mediated phagocytosis and respiratory burst in neutrophils: the role of purinergic modulation and actin polymerization. Zalavary S, et al. **J Leukoc Biol** 1996 Jul;60(1):58–68

Extracellular ATP activates both Ca(2+)- and cAMP-dependent Cl- conductances in rat epididymal cells. Chan HC, et al. **J Membr Biol** 1995 Sep;147(2):185–93

Selectivity of ATP-activated GTP-dependent Ca(2+)-permeable channels in rat macrophage plasma membrane. Naumov AP, et al. **J Membr Biol** 1995 Nov; 148(1):91–8

Ca2+ responses to acetylcholine and adenosine triphosphate in the otocyst of chick embryo. Nakaoka Y, et al. **J Neurobiol** 1995 Sep;28(1):23–34

A strongly inwardly rectifying K+ channel that is sensitive to ATP. Collins A, et al. **J Neurosci** 1996 Jan;16(1):1–9

Cloning OF P2X5 and P2X6 receptors and the distribution and properties of an extended family of ATP-gated ion channels. Collo G, et al. **J Neurosci** 1996 Apr 15; 16(8):2495–507

ATP-induced cytoplasmic calcium mobilization in Bergmann glial cells. Kirischuk S, et al. **J Neurosci** 1995 Dec; 15(12):7861–71

Inhibition of the ATP-sensitive potassium channel in the guinea pig substantia nigra by BMS 181100 is not mediated by a sigma-binding site. O'Callaghan JF, et al. **J Neurosci Res** 1995 Sep 1;42(1):85–96

ATP inhibits the synaptic release of acetylcholine in submucosal neurons. Barajas-López C, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1238–45

Activation of ATP-dependent K+ channels and inhibition of insulin release: effect of BPDZ 62. Lebrun P, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):156–62

ATP-sensitive potassium channel modulators: both pinacidil and glibenclamide produce antiarrhythmic activity during acute myocardial infarction in conscious rats. Leprán I, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1215–20

Effects of high-energy phosphates on carbachol-evoked cationic current in single smooth muscle cells from guinea-pig ileum. Bakhramov A. **J Physiol (Lond)** 1995 Jun 15;485 (Pt 3):659–69

A rate theory model for Mg2+ block of ATP-dependent potassium channels of rat skeletal muscle. Davies NW, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):817–26

Calcium handling and purinoceptor subtypes involved in ATP-induced contraction in rat small mesenteric arteries. Lagaud GJ, et al. **J Physiol (Lond)** 1996 May 1;492 (Pt 3):689–703

Enhancement of delayed rectifier K+ current by P2-purinoceptor stimulation in guinea-pig atrial cells. Matsuura H, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):647–58

Activation of the muscarinic K+ channel by P2-purinoceptors via pertussis toxin-sensitive G proteins in guinea-pig atrial cells. Matsuura H, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):659–71

Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. Murphy ME, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):47–58

Colocalization of ATP and nicotinic ACh receptors in the identified vagal preganglionic neurone of rat. Nabekura J, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):519–27

ATP-activated inward current and calcium-permeable channels in rat macrophage plasma membranes. Naumov AP, et al. **J Physiol (Lond)** 1995 Jul 15;486 (Pt 2):323–37

ATP-operated calcium-permeable channels activated via a guanine nucleotide-dependent mechanism in rat macrophages. Naumov AP, et al. **J Physiol (Lond)** 1995 Jul 15;486 (Pt 2):339–47

Mechanism of action of ATP on canine pulmonary vagal C fibre nerve terminals. Pelleg A, et al. **J Physiol (Lond)** 1996 Jan 1;490 (Pt 1):265–75

Histamine and ATP mobilize calcium by activation of H1 and P2u receptors in human lens epithelial cells. Riach RA, et al. **J Physiol (Lond)** 1995 Jul 15;486 (Pt 2):273–82

Activation by intracellular ATP of a potassium channel in neurones from rat basomedial hypothalamus. Rowe IC, et al. **J Physiol (Lond)** 1996 Jan 1;490 (Pt 1):97–113

ATP receptor-mediated increase of Ca ionophore-stimulated arachidonic acid release from PC12 pheochromocytoma cells. Murayama T, et al. **Jpn J Pharmacol** 1995 Sep; 69(1):43–51

Modulation of phagocytosis by P2-purinergic receptors in mouse peritoneal macrophages. Ichinose M. **Jpn J Physiol** 1995;45(5):707–21

Effect of extracellular adenosine 5'-triphosphate on Ca2+ efflux from freshly isolated adult rat cardiomyocytes. Hori T, et al. **Life Sci** 1996;58(11):PL217–22

Reciprocal modulation of ATP-sensitive K+ channel activity in rat ventricular myocytes by phosphorylation of tyrosine and serine/threonine residues. Kwak YG, et al. **Life Sci** 1996;58(11):897–904

Reduction of acetylcholine-activated current by low concentrations of extracellular adenosine 5'-triphosphate. Nakazawa K, et al. **Life Sci** 1995;57(22):PL351–6

Reactivation of motility of demembranated sea urchin sperm flagella. Brokaw CJ. **Methods Cell Biol** 1995;47:231–8

Isolation and reactivation of newt lung respiratory cilia. Hard R. **Methods Cell Biol** 1995;47:225–30

Reactivation of Chlamydomonas cell models. Horst CJ, et al. **Methods Cell Biol** 1995;47:207–10

Preparation and reactivation of Spermatozopsis cytoskeletons. Lechtreck KF, et al. **Methods Cell Biol** 1995; 47:335–40

Reactivation of extracted Paramecium models. Naitoh Y. **Methods Cell Biol** 1995;47:211–24

Preparation and reactivation of demembranated, cytosol-free ram spermatozoa. San Agustin JT, et al. **Methods Cell Biol** 1995;47:251–5

Calcium-induced aggregation of neuroendocrine protein 7B2 in vitro and its modulation by ATP. Linard CG, et al. **Mol Cell Biochem** 1995 Oct 4;151(1):39–47

Regulation of bovine rod outer segment membrane guanylate cyclase by ATP, phosphodiesterase and metal ions. Sitaramayya A, et al. **Mol Cell Biochem** 1995 Jul 19; 148(2):139–45

Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells. Lee K, et al. **Mol Pharmacol** 1996 Apr;49(4):715–20

Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. Nicholas RA, et al. **Mol Pharmacol** 1996 Aug;50(2):224–9

Cystic fibrosis hetero- and homozygosity is associated with inhibition of breast cancer growth. Abraham EH, et al. **Nat Med** 1996 May;2(5):593–6

Cultured chick sympathetic neurons: modulation of electrically evoked noradrenaline release by P2-purinoceptors. Allgaier C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):17–24

Cultured chick sympathetic neurons: ATP-induced noradrenaline release and its blockade by nicotinic receptor antagonists. Allgaier C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):25–30

In vitro association of mitochondrial ATP- dependent protease with mitochondrial heat-shock proteins. Chloupková M, et al. **Neoplasma** 1995;42(6):325–9

Effects of arginine-lysine mixture, glucose and ATP on the autonomic outflows to the thymus and spleen. Niijima A, et al. **Neurobiology (Bp)** 1995;3(3–4):299–307

Modulation of mouse cerebral Na+,K(+)-ATPase activity by oxygen free radicals. Jamme I, et al. **Neuroreport** 1995 Dec 29;7(1):333–7

Regulatory mechanism of calcium efflux from cultured bovine adrenal chromaffin cells induced by extracellular ATP. Houchi H, et al. **Neurosci Lett** 1995 Oct 6; 198(3):177–80

Zn2+ potentiates steady-state ATP activated currents in rat nodose ganglion neurons by increasing the burst duration of a 35 pS channel. Wright JM, et al. **Neurosci Lett** 1995 Jul 7;193(3):177–80

ATP and G proteins affect the runup of the Ca2+ current in bovine chromaffin cells. Elhamdani A, et al. **Pflugers Arch** 1995 Jul;430(3):410–9

Functional linkage of the cardiac ATP-sensitive K+ channel to the actin cytoskeleton. Furukawa T, et al. **Pflugers Arch** 1996 Feb;431(4):504–12

Effects of diadenosine polyphosphates, ATP and angiotensin II on membrane voltage and membrane conductances of rat mesangial cells. Kleta R, et al. **Pflugers Arch** 1995 Sep; 430(5):713–20

Modulation of Ca2+-activated K+ channels by Mg2+ and ATP in frog oxyntic cells. Komatsu H, et al. **Pflugers Arch** 1996 Feb;431(4):494–503

Mechanism of the ATP-induced rise in cytosolic Ca2+ in freshly isolated smooth muscle cells from human saphenous vein. Loirand G, et al. **Pflugers Arch** 1995 Jul;430(3):429–36

Modulation of calcium current by ATP in guinea-pig adrenal chromaffin cells. Otsuguro Ki, et al. **Pflugers Arch** 1996 Jan;431(3):402–7

Effects of diadenosine polyphosphates, ATP and angiotensin II on cytosolic Ca2+ activity and contraction of rat mesangial cells. Schlatter E, et al. **Pflugers Arch** 1995 Sep; 430(5):721–8

The Ba2+ block of the ATP-sensitive K+ current of mouse pancreatic beta-cells. Takano M, et al. **Pflugers Arch** 1996 Feb;431(4):625–31

The role of ATP-sensitive potassium channels in striatal dopamine release: an in vivo microdialysis study. Tanaka T, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):831–5

Mammalian phospholipase D: activation by ammonium sulfate and nucleotides. Nakamura S, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12319–22

ATP-sensitive K+ channels: paradigm lost, paradigm regained [comment] Philipson LH. **Science** 1995 Nov 17; 270(5239):1159. Comment on: Science 1995 Nov 17;270(5239):1166–70.

[Mechanism of activation of Ehrlich ascites carcinoma cells using the total fraction of saponins from Korean ginseng] Nurieva RI, et al. **Antibiot Khimioter** 1995 Nov–Dec; 40(11–12):25–8 (Eng. Abstr.) **(Rus)**

[Role of ATP as a mediator of the sympathetic nervous system in smoothing out rapid changes in arterial pressure] Rodionov IM, et al. **Biull Eksp Biol Med** 1995 Nov; 120(11):461–4 **(Rus)**

[The secretory function of the gastric glands under the joint action of acetylcholine, adenosine triphosphoric acid and histamine] Skliarov OIa. **Fiziol Zh** 1995 May–Aug; 41(3–4):9–13 (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

Extracellular ATP as a neurotransmitter: its role in synaptic plasticity in the hippocampus. Wieraszko A. **Acta Neurobiol Exp (Warsz)** 1996;56(2):637–48 (85 ref.)

Modulation of muscle contractility during fatigue and recovery by ATP sensitive potassium channel. Renaud JM, et al. **Acta Physiol Scand** 1996 Mar;156(3):203–12 (50 ref.)

Effects of thiol-modifying agents on KATP channels in guinea pig ventricular cells. Coetzee WA, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1625–33

Mechanism of human sperm activation by extracellular ATP. Foresta C, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1709–14

Different properties of the atrial G protein-gated K+ channels activated by extracellular ATP and adenosine. Fu C, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1349–58

Stimulation of Cl- secretion by extracellular ATP does not depend on increased cytosolic Ca2+ in HT-29.cl16E. Guo X, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1457–63

Apical and basolateral ATP stimulates tracheal epithelial chloride secretion via multiple purinergic receptors. Hwang TH, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1611–23

ATP-sensitive K+ currents in cerebral arterial smooth muscle: pharmacological and hormonal modulation. Kleppisch T, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1634–40

Role of K+ATP channels and EDRF in reactive hyperemia in the hindquarters vascular bed of cats. Minkes RK, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1704–12

Different responses of epicardium and endocardium to KATP channel modulators during regional ischemia. Miyoshi S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H140–7

Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs. Terzic A, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C525–45 (196 ref.)

Do ATP-sensitive potassium channels play a role in myocardial stunning? Gross GJ. **Basic Res Cardiol** 1995 Jul–Aug;90(4):266–8 (10 ref.)

Effects of inhibitors and activators of ATP-regulated K+ channel on mitochondrial potassium uniport. Szewczyk A, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):477–84

The phosphocreatine overshoot occurs independent of myocardial work. Kaplan LJ, et al. **Biochimie** 1995; 77(4):245–8

An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Baricordi OR, et al. **Blood** 1996 Jan 15;87(2):682–90

Endothelin-1-induced reduction of myocardial infarct size by activation of ATP-sensitive potassium channels in a rabbit model of myocardial ischaemia and reperfusion. Hide EJ, et al. **Br J Pharmacol** 1995 Nov;116(6):2597–602

The involvement of ATP-sensitive potassium channels and adenosine in the regulation of coronary flow in the isolated perfused rat heart. Randall MD. **Br J Pharmacol** 1995 Dec; 116(7):3068–74

Two types of ATP-sensitive potassium channels in rat portal vein smooth muscle cells. Zhang HL, et al. **Br J Pharmacol** 1996 May;118(1):105–14

Activation or block of adenosine triphosphate-sensitive potassium channel have opposite effects on postcardioplegic myocardial dysfunction, "stunning". A multivariate prediction based on relative operating characteristic curve. Puddu PE, et al. **Cardiologia** 1995 Sep; 40(9):667–77

Modulation of Neisseria porin (PorB) by cytosolic ATP/GTP of target cells: parallels between pathogen accommodation and mitochondrial endosymbiosis. Rudel T, et al. **Cell** 1996 May 3;85(3):391–402

Divergent mechanisms of ATP-sensitive K+ channel-induced vasodilation in renal afferent and efferent arterioles. Evidence of L-type Ca2+ channel-dependent and -independent actions of pinacidil. Reslerova M, et al. **Circ Res** 1995 Dec;77(6):1114–20

Extracellular ATP inhibits adrenergic agonist-induced hypertrophy of neonatal cardiac myocytes. Zheng JS, et al. **Circ Res** 1996 Apr;78(4):525–35

Role of cerebral ATP-sensitive K+ channels in arterial pressure regulation during acute cerebral ischaemia in SHR and WKY rats. Nishimura M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S70–2

Potassium channels in the cardiovascular system. Pogátsa G. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S91–8 (48 ref.)

Inhibition of ATP-sensitive K+ channels of mouse skeletal muscle by disopyramide. Moser C, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):35–41

Regulation of the H+/e- stoichiometry of cytochrome c oxidase from bovine heart by intramitochondrial ATP/ADP ratios. Frank V, et al. **FEBS Lett** 1996 Mar 11;382(1–2):121–4

Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytotoxic T lymphocyte effector functions. Apasov S, et al. **Immunol Rev** 1995 Aug;146:5–19 (40 ref.)

A role for ATPase in the mechanisms of ATP-dependent Ca and phosphate deposition by isolated rachitic matrix vesicles. Hsu HH, et al. **Int J Biochem Cell Biol** 1995 Dec; 27(12):1349–56

Nucleosome disruption by human SWI/SNF is maintained in the absence of continued ATP hydrolysis. Imbalzano AN, et al. **J Biol Chem** 1996 Aug 23;271(34):20726–33

The role of ATP sensitive potassium channels in myocardial protection. Cason BA, et al. **J Card Surg** 1995 Jul;10(4 Suppl):441–4 (32 ref.)

Murine T lymphocytes modulate activity of an ATP-activated P2Z-type purinoceptor during differentiation. Chused TM, et al. **J Immunol** 1996 Aug 15;157(4):1371–80

Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. Ferrari D, et al. **J Immunol** 1996 Feb 15;156(4):1531–9

Nerve growth factor, epidermal growth factor, and insulin differentially potentiate ATP-induced [Ca2+]i rise and dopamine secretion in PC12 cells. Huang CM, et al. **J Neurochem** 1996 Jan;66(1):124–30

ATP-activated nonselective cation current in NG108-15 cells. Kaiho H, et al. **J Neurochem** 1996 Jul;67(1):398–406

Hypoxic relaxation in functionally intact cattle coronary artery segments involves K+ ATP channels. Kalsner S. **J Pharmacol Exp Ther** 1995 Dec;275(3):1219–26

Characterization of an ATP-modulated large conductance Ca(2+)-activated K+ channel present in rat cortical neurones. Lee K, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):319–37

Effect of intracellular calcium on ATP-activated, GTP-dependent calcium channels in rat macrophages. Mamin AG, et al. **J Physiol (Lond)** 1996 Mar 15;491 (Pt 3):697–705

ATP activates non-selective cation channels and calcium release in inner hair cells of the guinea-pig cochlea. Sugasawa M, et al. **J Physiol (Lond)** 1996 Mar 15;491 (Pt 3):707–18

KATP channel mediation of anoxia-induced outward current in rat dorsal vagal neurons in vitro. Trapp S, et al. **J Physiol (Lond)** 1995 Aug 15;487 (Pt 1):37–50

Modification by protons of frog skeletal muscle KATP channels: effects on ion conduction and nucleotide inhibition. Vivaudou M, et al. **J Physiol (Lond)** 1995 Aug 1;486 (Pt 3):629–45

Noradrenaline and ATP: cotransmitters and neuromodulators. Burnstock G. **J Physiol Pharmacol** 1995 Dec;46(4):365–84 (195 ref.)

Adenosine triphosphate-sensitive K+ channels mediate postcardioplegia coronary hyperemia. Wang SY, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1073–82

Regulation of rhythmic movements by purinergic neurotransmitters in frog embryos. Dale N, et al. **Nature** 1996 Sep 19;383(6597):259–63

Painful connection for ATP [news; comment] Kennedy C, et al. **Nature** 1995 Oct 5;377(6548):385–6. Comment on: Nature 1995 Oct 5;377(6548):428–31. Comment on: Nature 1995 Oct 5;377(6548):432–5.

ATP serves as a negative feedback inhibitor of voltage-gated Ca2+ channel currents in cultured bovine adrenal chromaffin cells. Currie KP, et al. **Neuron** 1996 May; 16(5):1027–36

An adenosine triphosphate (ATP)-sensitive K+ channel of rat neocortical neurons is bi-gated by intracellular ATP and voltage: a novel channel gating mechanism? Tang XD, et al. **Neurosci Lett** 1995 Jun 30;193(2):93–6

Coexistence of two classes of glibenclamide-inhibitable ATP-regulated K+ channels in avian skeletal muscle. Fosset M, et al. **Pflugers Arch** 1995 Nov;431(1):117–24

ATP-Dependent inhibition of Ca2+-activated K+ channels in vascular smooth muscle cells by neuropeptide Y. Xiong Z, et al. **Pflugers Arch** 1995 Nov;431(1):110–6

An ATP-activated, ligand-gated ion channel on a cholinergic presynaptic nerve terminal. Sun XP, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1859–63

Regulatory role of ATP at developing neuromuscular junctions. Fu WM. **Prog Neurobiol** 1995 Sep;47(1):31–44 (101 ref.)

Geometry, kinetics and plasticity of release and clearance of ATP and noradrenaline as sympathetic cotransmitters: roles for the neurogenic contraction. Stjärne L, et al. **Prog Neurobiol** 1995 Sep;47(1):45–94 (145 ref.)

SECRETION

A monitor of secretion from single pancreatic beta-cells. Kuromi H, et al. **Diabetes** 1995 Oct;44(10):1213–7

Modifications of platelet shape change and ATP release during cardiopulmonary bypass. Jung G, et al. **Haemostasis** 1995 Jul–Aug;25(4):149–57

Non-neuronal release of ATP and inositol 1,4,5-trisphosphate accumulation evoked by P2- and M-receptor stimulation in guinea pig ileal segments. Katsuragi T, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):747–52

Long-term guanethidine sympathectomy suppresses flow-induced release of ATP and endothelin from endothelial cells isolated from adult rat aorta. Milner P, et al. **J Vasc Res** 1996 Mar–Apr;33(2):139–45

THERAPEUTIC USE

Use of intravenous adenosine triphosphate (ATP) to terminate supraventricular tachycardia in a pregnant woman with Wolff-Parkinson-White syndrome. Kanai M, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):95–9

Phosphoenolpyruvate/adenosine triphosphate enhances post-ischemic survival of skeletal muscle. Hickey MJ, et al. **J Reconstr Microsurg** 1995 Nov;11(6):415–22

Phase I trial of extracellular adenosine 5'-triphosphate in patients with advanced cancer. Haskell CM, et al. **Med Pediatr Oncol** 1996 Sep;27(3):165–73

Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays. Estrela JM, et al. **Nat Med** 1995 Jan;1(1):84–8

Effects of ATP-magnesium chloride on the cardiopulmonary manifestations of group B streptococcal sepsis in the piglet. Ali A, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):609–15

ADENOSINETRIPHOSPHATASE

ANALYSIS

Entrapment by immobilized metal ion affinity chromatography of assembled yeast mitochondrial ATP synthase containing individual subunits tagged with hexahistidine. Bateson M, et al. **Anal Biochem** 1996 Jun 15;238(1):14–8

Identification and immunolocalization of ecto-ATPDase in chicken stomach. Stout JG, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):529–35

Autoradiography-based cytochemical detection of ecto-ATPase, ecto-ADPase, 5'-nucleotidase, and extracellular adenosine production, employing 141Ce3+ as a capturing agent. Culic O, et al. **Histochem J** 1995 Jul; 27(7):555–64

Functional expression and segmental localization of rat colonic K-adenosine triphosphatase. Lee J, et al. **J Clin Invest** 1995 Oct;96(4):2002-8

Cytochemical localization of ecto-ATPases in rat neurohypophysis. Thirion S, et al. **J Histochem Cytochem** 1996 Feb;44(2):103-11

The vacuolar ATPase proton pump is present on intracellular vacuoles induced by Helicobacter pylori. Papini E, et al. **J Med Microbiol** 1996 Aug;45(2):84-9

Renaissance of cytochemical localization of membrane ATPases in the myocardium. Slezák J, et al. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):169-72

Identification of an RNA-dependent ATPase activity in mammalian U5 snRNPs. Laggerbauer B, et al. **Nucleic Acids Res** 1996 Mar 1;24(5):868-75

ANTAGONISTS & INHIBITORS

Partial characterization and effect of omeprazole on ATPase activity in Helicobacter pylori by using permeabilized cells. Belli WA, et al. **Antimicrob Agents Chemother** 1995 Aug; 39(8):1717-20

Vanadate and bafilomycin A1 are potent inhibitors of the ATPase activity of the reconstituted bacterial ATP-binding cassette transporter for maltose (MalFGK2). Hunke S, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):589-94

Inhibition of purified chicken gizzard smooth muscle ecto-ATPAse by P2 purinoceptor antagonists. Stout JG, et al. **Biochem Mol Biol Int** 1995 Aug;36(5):927-34

Inhibitory mechanisms of H(+)-ATPase inhibitor bafilomycin A1 and carbonic anhydrase II inhibitor acetazolamide on experimental bone resorption. Ohba Y, et al. **FEBS Lett** 1996 Jun 3;387(2-3):175-8

Reactive red 2: a P2y-selective purinoceptor antagonist and an inhibitor of ecto-nucleotidase. Bültmann R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):477-82

Mobilization of gastric histamine during repeated administration of a proton potassium adenosine triphosphatase inhibitor in intact and antrectomized rats. Miyazaki Y, et al. **Regul Pept** 1995 Jul 21;58(1-2):47-54

BIOSYNTHESIS

Mutagenic specificity of ultraviolet light in the tonB gene on the chromosome of Escherichia coli uvrA cells. Kitamura K, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):496-501

Cloning of a secA homolog from Streptomyces lividans 1326 and overexpression in both S. lividans and Escherichia coli. Gilbert M, et al. **Biochim Biophys Acta** 1996 Aug 15; 1296(1):9-12

A tick homologue of the human DNA helicase II 70-kDa subunit. Paesen GC, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):120-4

In vivo synthesis of ATPase complexes of Propionigenium modestum and Escherichia coli and analysis of their function. Gerike U, et al. **Eur J Biochem** 1995 Sep 1; 232(2):596-602

The Saccharomyces cerevisiae OXA1 gene is required for the correct assembly of cytochrome c oxidase and oligomycin-sensitive ATP synthase. Altamura N, et al. **FEBS Lett** 1996 Mar 11;382(1-2):111-5

BLOOD

Measurement of ATPases in red cells: setting up and validation of a highly reproducible method. Matteucci E, et al. **Enzyme Protein** 1994-95;48(2):105-19

Alterations in intracellular cations and cell membrane ATPase activity in patients with malignant hypertension. Touyz RM, et al. **J Hypertens** 1995 Aug;13(8):867-74

CHEMISTRY

Structures of the rat proteasomal ATPases: determination of highly conserved structural motifs and rules for their spacing. Makino Y, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):1049-54

Identification of a new isoform of cell-cell adhesion molecule 105 (C-CAM), C-CAM4: a secretory protein with only one Ig domain. Earley K, et al. **Biochem J** 1996 May 1; 315 (Pt 3):799-806

Structure and function of C-CAM1: effects of the cytoplasmic domain on cell aggregation. Lin SH, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):239-45

Organization of P-type ATPases: significance of structural diversity. Lutsenko S, et al. **Biochemistry** 1995 Dec 5; 34(48):15607-13 (54 ref.)

ATPase activity of Escherichia coli Rep helicase is dramatically dependent on DNA ligation and protein oligomeric states. Wong I, et al. **Biochemistry** 1996 May 7;35(18):5726-34

Rotary DNA motors. Doering C, et al. **Biophys J** 1995 Dec; 69(6):2256-67

Calmodulin binds to specific sequences in the cytoplasmic domain of C-CAM and down-regulates C-CAM self-association. Edlund M, et al. **J Biol Chem** 1996 Jan 19;271(3):1393-9

BiP binding sequences in antibodies. Knarr G, et al. **J Biol Chem** 1995 Nov 17;270(46):27589-94

Lysine 71 of the chaperone protein Hsc70 Is essential for ATP hydrolysis. O'Brien MC, et al. **J Biol Chem** 1996 Jul 5;271(27):15874-8

Characterization of a potential catalytic residue, Asp-133, in the high affinity ATP-binding site of Escherichia coli SecA, translocation ATPase. Sato K, et al. **J Biol Chem** 1996 Jul 19;271(29):17439-44

Intragenic suppressors of P-loop mutations in the beta-subunit of the mitochondrial ATPase in the yeast Saccharomyces cerevisiae. Shen H, et al. **J Biol Chem** 1996 May 17;271(20):11844-51

Characterization of molecular aggregates of alpha 1 beta 1-integrin and other rat liver membrane proteins by combination of size-exclusion chromatography and chemical cross-linking. Löster K, et al. **J Chromatogr A** 1995 Sep 8;711(1):187-99

Characterization of the HeLa cell single-stranded DNA-dependent ATPase/DNA helicase II. Vishwanatha JK, et al. **Mol Cell Biochem** 1995 May 24;146(2):121-6

A novel adenosine triphosphate analog with a heavy atom to target the nucleotide binding site of proteins. Naber N, et al. **Protein Sci** 1995 Sep;4(9):1824-31

DEFICIENCY

Respiratory chain complex I deficiency in an infant with infantile spasms [letter] Verdú A, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):349

DRUG EFFECTS

Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Orlowski S, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):515-22

In vitro inhibition of rat heart sarcoplasmic reticular membrane ATPase activities by amphotericin B and their reversal by fructose-1,6-diphosphate. Rao MR, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):821-5

Impact of aluminium, fluoride and fluoroaluminate complex on ATPase activity of Nostoc linckia and Chlorella vulgaris. Husaini Y, et al. **Biometals** 1996 Jul;9(3):277-83

Direct depressant effect of phosphodiesterase inhibitors on ATPase activity of rat cardiac myofibrils. Polla B, et al. **Can J Physiol Pharmacol** 1995 May;73(5):661-4

Relationship of alcohol-induced changes in Mg(2+)-ATPase activity of rabbit intestinal brush border membrane with changes in fluidity of its lipid bilayer. Kitagawa S, et al. **J Membr Biol** 1995 Jul;146(2):193-9

GENETICS

Kinetic and mutational dissection of the two ATPase activities of terminase, the DNA packaging enzyme of bacteriophage Chi. Hwang Y, et al. **Biochemistry** 1996 Feb 27;35(8):2796-803

Cloning of a secA homolog from Streptomyces lividans 1326 and overexpression in both S. lividans and Escherichia coli. Gilbert M, et al. **Biochim Biophys Acta** 1996 Aug 15; 1296(1):9-12

Isolation of the vma-6 gene encoding a 41 kDa subunit of the Neurospora crassa vacuolar ATPase, and an adjoining gene encoding a ribosome-associated protein. Melnik VI, et al. **Biochim Biophys Acta** 1996 Feb 15;1273(2):77-83

A tick homologue of the human DNA helicase II 70-kDa subunit. Paesen GC, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):120-4

Expression of the Escherichia coli chromosomal ars operon. Cai J, et al. **Can J Microbiol** 1996 Jul;42(7):662-71

The Bloom's syndrome gene product is homologous to RecQ helicases. Ellis NA, et al. **Cell** 1995 Nov 17;83(4):655-66

Organisation of the mitochondrial genome of Trichophyton rubrum. DNA sequence analysis of the ND4 gene, the ATPase subunit-6 gene, the ribosomal RNA small-subunit gene, the ND6 gene, the COXIII gene, the ATPase subunit-8 gene and six tRNA genes that correspond respectively to the tyrosine, lysine, glutamine, asparagine, isoleucine and tryptophan isoacceptors. de Bièvre C, et al. **Curr Genet** 1995 Nov;28(6):553-9

The peroxisome biogenesis disorder group 4 gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the PTS1 receptor. Yahraus T, et al. **EMBO J** 1996 Jun 17; 15(12):2914-23

cDNA cloning of p42, a shared subunit of two proteasome regulatory proteins, reveals a novel member of the AAA protein family. Fujiwara T, et al. **FEBS Lett** 1996 Jun 3; 387(2-3):184-8

Multiple transduction pathways regulate the sodium-extrusion gene PMR2/ENA1 during salt stress in yeast. Márquez JA, et al. **FEBS Lett** 1996 Mar 11; 382(1-2):89-92

Mutations in RCA1 and AFG3 inhibit F1-ATPase assembly in Saccharomyces cerevisiae. Paul MF, et al. **FEBS Lett** 1995 Oct 2;373(1):66-70

Down-regulation of plant V-type H+ -ATPase genes after light-induced inhibition of growth. Viereck R, et al. **FEBS Lett** 1996 Apr 22;384(3):285-8

The arsenical resistance operon of IncN plasmid R46. Bruhn DF, et al. **FEMS Microbiol Lett** 1996 Jun 1;139(2-3):149-53

Functional characterization of the Staphylococcus carnosus SecA protein in Escherichia coli and Bacillus subtilis secA mutant strains. Klein M, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):271-7

The Drosophila melanogaster gene vha14 encoding a 14-kDa F-subunit of the vacuolar ATPase. Guo Y, et al. **Gene** 1996 Jun 26;172(2):239-43

The bovine PP3 gene is homologous to the murine GlyCAM 1 gene. Johnsen LB, et al. **Gene** 1996 Mar 9;169(2):297-8

Cloning, sequencing and expression of the uvrA gene from an extremely thermophilic bacterium, Thermus thermophilus HB8. Yamamoto N, et al. **Gene** 1996 May 24;171(1):103-6

Homeless is required for RNA localization in Drosophila oogenesis and encodes a new member of the DE-H family of RNA-dependent ATPases. Gillespie DE, et al. **Genes Dev** 1995 Oct 15;9(20):2495-508

Genetic analysis of delta helD and delta uvrD mutations in combination with other genes in the RecF recombination pathway in Escherichia coli: suppression of a ruvB mutation by a uvrD deletion. Mendonca VM, et al. **Genetics** 1995 Oct;141(2):443-52

Cloning of the cDNA for the human ATP synthase OSCP subunit (ATP5O) by exon trapping and mapping to chromosome 21q22.1-q22.2. Chen H, et al. **Genomics** 1995 Aug 10;28(3):470-6

Molecular structure of the Menkes disease gene (ATP7A). Dierick HA, et al. **Genomics** 1995 Aug 10;28(3):462-9

Genomic organization and mapping of the mouse P26s4 ATPase gene: a member of the remarkably conserved AAA gene family. Hoyle J, et al. **Genomics** 1996 Jan 1;31(1):115-8

Physical mapping of the bloom syndrome region by the identification of YAC and P1 clones from human chromosome 15 band q26.1. Straughen J, et al. **Genomics** 1996 Jul 1;35(1):118-28

Gene amplification of the Menkes (MNK; ATP7A) P-type ATPase gene of CHO cells is associated with copper resistance and enhanced copper efflux. Camakaris J, et al. **Hum Mol Genet** 1995 Nov;4(11):2117-23

The sequence and structure of the meadow grasshopper (Chorthippus parallelus) mitochondrial srRNA, ND2, COI, COII ATPase8 and 9 tRNA genes. Szymura JM, et al. **Insect Mol Biol** 1996 May;5(2):127-39

The Streptomyces peucetius drrC gene encodes a UvrA-like protein involved in daunorubicin resistance and production. Lomovskaya N, et al. **J Bacteriol** 1996 Jun;178(11):3238-45

SecA proteins of Bacillus subtilis and Escherichia coli possess homologous amino-terminal ATP-binding domains regulating integration into the plasma membrane. McNicholas P, et al. **J Bacteriol** 1995 Dec;177(24):7231-7

Effects of mecA and mecB (clpC) mutations on expression of sigD, which encodes an alternative sigma factor, and autolysin operons and on flagellin synthesis in Bacillus subtilis. Rashid MH, et al. **J Bacteriol** 1996 Aug; 178(16):4861-9

Suppression of ftsH mutant phenotypes by overproduction of molecular chaperones. Shirai Y, et al. **J Bacteriol** 1996 Feb;178(4):1141-5

Replacement of gly815 in helicase motif V alters the single-stranded DNA-dependent ATPase activity of the herpes simplex virus type 1 helicase-primase. Graves-Woodward KL, et al. **J Biol Chem** 1996 Jun 7; 271(23):13629-35

RAD26, the yeast homolog of human Cockayne's syndrome group B gene, encodes a DNA-dependent ATPase. Guzder SN, et al. **J Biol Chem** 1996 Aug 2;271(31):18314-7

Cloning and membrane topology of a P type ATPase from Helicobacter pylori. Melchers K, et al. **J Biol Chem** 1996 Jan 5;271(1):446-57

The ntpJ gene in the Enterococcus hirae ntp operon encodes a component of KtrII potassium transport system functionally independent of vacuolar Na+-ATPase. Murata T, et al. **J Biol Chem** 1996 Apr 26;271(17):10042-7

Intragenic suppressors of P-loop mutations in the beta-subunit of the mitochondrial ATPase in the yeast Saccharomyces cerevisiae. Shen H, et al. **J Biol Chem** 1996 May 17;271(20):11844-51

Cloning and characterization of an ATPase gene from Pneumocystis carinii which closely resembles fungal H+ ATPases. Meade JC, et al. **J Eukaryot Microbiol** 1995 May-Jun;42(3):298-307

Cloning, sequencing, and characterization of a complementary DNA from Haematobia irritans irritans (Diptera: Muscidae) that shares significant homology to a yeast ATPase. Guerrero FD. **J Med Entomol** 1995 Nov; 32(6):906-10

Mutations affecting the high affinity ATPase center of gpA, the large subunit of bacteriophage lambda terminase, inactivate the endonuclease activity of terminase. Hwang Y, et al. **J Mol Biol** 1996 Aug 30;261(4):524-35

Regulation of the expression of three housekeeping genes encoding subunits of the Neurospora crassa vacuolar ATPase. Wechser MA, et al. **Mol Gen Genet** 1995 Nov 27;249(3):317-27

The Mycobacterium leprae genome: systematic sequence analysis identifies key catabolic enzymes, ATP-dependent transport systems and a novel polA locus associated with genomic variability. Fsihi H, et al. **Mol Microbiol** 1995 Jun; 16(5):909-19

A cellulase/xylanase-negative mutant of Streptomyces lividans 1326 defective in cellobiose and xylobiose uptake is mutated in a gene encoding a protein homologous to ATP-binding proteins. Hurtubise Y, et al. **Mol Microbiol** 1995 Jul;17(2):367-77

Peroxisome assembly factor-2, a putative ATPase cloned by functional complementation on a peroxisome-deficient mammalian cell mutant. Tsukamoto T, et al. **Nat Genet** 1995 Dec;11(4):395-401

Mutation-causing mutations [news] Ellis NA. **Nature** 1996 May 9;381(6578):110-1
Bloom's syndrome. Mapping to the point [news] Korn R, et al. **Nature** 1995 Dec 7;378(6557):557-80
DNA repair in Escherichia coli: the dual function of uvr genes. Mašek F, et al. **Neoplasma** 1995;42(6):317-23
18S rRNA processing requires the RNA helicase-like protein Rrp3. O'Day CL, et al. **Nucleic Acids Res** 1996 Aug 15; 24(16):3201-7
Bilateral striatal necrosis with a novel point mutation in the mitochondrial ATPase 6 gene. De Meirleir L, et al. **Pediatr Neurol** 1995 Oct;13(3):242-6
The stroma of higher plant plastids contain ClpP and ClpC, functional homologs of Escherichia coli ClpP and ClpA: an archetypal two-component ATP-dependent protease. Shanklin J, et al. **Plant Cell** 1995 Oct;7(10):1713-22
Mutation of vaccinia virus gene G2R causes suppression of gene A18R ts mutants: implications for control of transcription. Condit RC, et al. **Virology** 1996 Jun 1; 220(1):10-9

IMMUNOLOGY

Characterization of two conformational epitopes of the Chlamydia trachomatis serovar L2 DnaK immunogen. Birkelund S, et al. **Infect Immun** 1996 Mar;64(3):810-7

ISOLATION & PURIFICATION

Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Jin L, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):47-53
Identification of a new isoform of cell-cell adhesion molecule 105 (C-CAM), C-CAM4: a secretory protein with only one Ig domain. Earley K, et al. **Biochem J** 1996 May 1; 315 (Pt 3):799-806
Chicken oviductal ecto-ATP-diphosphohydrolase. Purification and characterization. Strobel RS, et al. **J Biol Chem** 1996 Jul 5;271(27):16323-31
Detection of different adenosine triphosphatases in human placental brush border membranes. Brunette MG, et al. **J Membr Biol** 1995 Jun;145(3):285-93

METABOLISM

Maximum speed of shortening and ATPase activity in atrial and ventricular myocardia of hyperthyroid rats. Bottinelli R, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C785-90
Relation between contractile function and regulatory cardiac proteins in hypertrophied hearts. Stein B, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2021-8
The ATPase module and the process of cellular immortalization. Krøoll J. **Ann N Y Acad Sci** 1996 Jun 15;786:57-61 (36 ref.)
Identification and characterization of an ecto-ATPase activity in rat Sertoli cells. Barbacci E, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):273-9
A novel Cl(-)-pump: intracellular regulation of transport activity. Gerencser GA, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):994-1000
Cytochrome f encoded by the chloroplast genome is imported into thylakoids via the SecA-dependent pathway. Nohara T, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):474-8
Drug-stimulated ATPase activity of a deletion mutant of the human multidrug-resistance protein (MDR1). Welker E, et al. **Biochem Biophys Res Commun** 1995 Nov 13; 216(2):602-9
Role of PM-ATPase, amino acid transport and free amino acid pool in the salt stress of, Candida membranefaciens. Khaware RK, et al. **Biochem Mol Biol Int** 1996 Mar; 38(3):635-43
Identification of a novel ATP-dependent proteolytic activity in mitochondrial intermembrane space. Sitte N, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):871-81
Stimulation of erythrocyte membrane Mg(2+)-ATPase activity by glutathione S-conjugates. Sokal A, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):73-9
Effects of P2-purinoceptor antagonists on ecto-nucleotidase activity of guinea-pig vas deferens cultured smooth muscle cells. Ziganshin AU, et al. **Biochem Mol Biol Int** 1995 Jul; 36(4):863-9
SecA, a novel ATPase that converts chemical energy into a mechanical force to drive precursor protein translocation. Driessen AJ, et al. **Biochem Soc Trans** 1995 Nov; 23(4):981-5 (32 ref.)
Role of adenosine 5'-triphosphate hydrolysis in the assembly of the bacteriophage T4 DNA replication holoenzyme complex. Berdis AJ, et al. **Biochemistry** 1996 Jul 16; 35(28):9253-65
Kinetic mechanism of DNA binding and DNA-induced dimerization of the Escherichia coli Rep helicase. Bjornson KP, et al. **Biochemistry** 1996 Feb 20;35(7):2268-82
Phosphorylation on threonine-18 of the regulatory light chain dissociates the ATPase and motor properties of smooth muscle myosin II. Bresnick AR, et al. **Biochemistry** 1995 Oct 3;34(39):12576-83
Electrogenic K+ transport by the Kdp-ATPase of Escherichia coli. Fendler K, et al. **Biochemistry** 1996 Jun 18;35(24):8009-17
Kinetic and mutational dissection of the two ATPase activities of terminase, the DNA packaging enzyme of bacteriophage Chi. Hwang Y, et al. **Biochemistry** 1996 Feb 27;35(8):2796-803
Identification of an essential cysteinyl residue in the ArsC arsenate reductase of plasmid R773. Liu J, et al. **Biochemistry** 1995 Oct 17;34(41):13472-6
Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Liu R, et al. **Biochemistry** 1996 Sep 10;35(36):11865-73
Allosteric effects of RuvA protein, ATP, and DNA on RuvB protein-mediated ATP hydrolysis. Marrione PE, et al. **Biochemistry** 1996 Aug 27;35(34):11228-38
Light-directed generation of the actin-activated ATPase activity of caged heavy meromyosin. Marriott G, et al. **Biochemistry** 1996 Mar 12;35(10):3170-4
Expression, purification, ATPase properties, and microtubule-binding properties of the ncd motor domain. Shimizu T, et al. **Biochemistry** 1995 Oct 10;34(40):13259-66
Control of cell membrane ecto-ATPase by oligomerization state: intermolecular cross-linking modulates ATPase activity. Stout JG, et al. **Biochemistry** 1996 Jun 25; 35(25):8289-98
ATPase activity of Escherichia coli Rep helicase is dramatically dependent on DNA ligation and protein oligomeric states. Wong I, et al. **Biochemistry** 1996 May 7;35(18):5726-34
Interaction of substrate and effector binding sites in the ArsA ATPase. Zhou T, et al. **Biochemistry** 1995 Oct 17; 34(41):13622-6
The ATPase activity of purified CDC48p from Saccharomyces cerevisiae shows complex dependence on ATP-, ADP-, and NADH-concentrations and is completely inhibited by NEM. Fröhlich KU, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):25-32
Inactivation of ecto-ATPase activity of rat brain synaptosomes. Martín-Romero FJ, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):51-9
Structural organization, ion transport, and energy transduction of P-type ATPases. Møller JV, et al. **Biochim Biophys Acta** 1996 May 6;1286(1):1-51 (527 ref.)
A point mutation within each of two ATP-binding motifs inactivates the functions of elongation factor 3. Yang H, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):303-8
Comparative analysis of ATPase of yeast elongation factor 3 and ATPase associated with Tetrahymena ribosomes. Kovalchuke O, et al. **Biochimie** 1995;77(9):713-18
Immunocytochemical localization of vacuolar H+-ATPase and Cl--HCO3- anion exchanger (erythrocyte band-3 protein) in avian osteoclasts: effect of calcium-deficient diet on polar expression of the H+-ATPase pump. Bastani B, et al. **Calcif Tissue Int** 1996 May;58(5):332-6
Direct depressant effect of phosphodiesterase inhibitors on ATPase activity of rat cardiac myofibrils. Polla B, et al. **Can J Physiol Pharmacol** 1995 May;73(5):661-4
Quantitative analysis of multiple phenotype enzyme-altered foci in rat hepatocarcinogenesis experiments: the multipath/multistage model. Sherman CD, et al. **Carcinogenesis** 1995 Oct;16(10):2499-506
The YTA10-12 complex, an AAA protease with chaperone-like activity in the inner membrane of mitochondria. Arlt H, et al. **Cell** 1996 Jun 14;85(6):875-85
SecA membrane cycling at SecYEG is driven by distinct ATP binding and hydrolysis events and is regulated by SecD and SecF. Economou A, et al. **Cell** 1995 Dec 29; 83(7):1171-81
Inversion of the membrane topology of SecG coupled with SecA-dependent preprotein translocation. Nishiyama K, et al. **Cell** 1996 Apr 5;85(1):71-81
Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Schwinger RH, et al. **Circulation** 1995 Dec 1;92(11):3220-8
Mechanism of ischemic preconditioning [letter; comment] Zucchi R. **Circulation** 1996 Jan 1;93(1):200-2. Comment on: Circulation 1995 Jun 1;91(11):2810-8.
Effect of testosterone on carbonic anhydrase and MG(2+)-dependent HCO3-stimulated ATPase activities in rat kidney: comparison with estradiol effect. Suzuki S, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jun;114(2):105-12
Bacteriophage Mu reppressor as a target for the Escherichia coli ATP-dependent Clp Protease. Laachouch JE, et al. **EMBO J** 1996 Jan 15;15(2):437-44
The hemolysin B protein, expressed in Saccharomyces cerevisiae, accumulates in binding-protein (BiP)-containing structures. Kölling R, et al. **Eur J Biochem** 1996 Jul 15;239(2):356-61
Mitochondrial ATPase: a target for paracetamol-induced hepatotoxicity. Parmar DV, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):225-9
Afg3p, a mitochondrial ATP-dependent metalloprotease, is involved in degradation of mitochondrially-encoded Cox1, Cox3, Cob, Su6, Su8 and Su9 subunits of the inner membrane complexes III, IV and V. Guzélin E, et al. **FEBS Lett** 1996 Feb 26;381(1-2):42-6
The fastest actin-based motor protein from the green algae, Chara, and its distinct mode of interaction with actin. Higashi-Fujime S, et al. **FEBS Lett** 1995 Nov 13; 375(1-2):151-4
Association of yeast SAP1, a novel member of the 'AAA' ATPase family of proteins, with the chromatin protein SIN1. Liberzon A, et al. **FEBS Lett** 1996 Jun 10;388(1):5-10
The catalytic cycle of P-glycoprotein. Senior AE, et al. **FEBS Lett** 1995 Dec 27;377(3):285-9 (42 ref.)
Disassembly of the Mu transposase tetramer by the ClpX chaperone. Levchenko I, et al. **Genes Dev** 1995 Oct 1; 9(19):2399-408
Adhesion of K88ab to guinea pig erythrocytes: effect on membrane enzyme activities. Caloca MJ, et al. **Infect Immun** 1996 Aug;64(8):3416-8
Characterization of ATP-diphosphohydrolase from rat mammary gland. Alvarez A, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):75-9
Mutations in motif II of Escherichia coli DNA helicase II render the enzyme nonfunctional in both mismatch repair and excision repair with differential effects on the unwinding reaction. Brosh RM Jr, et al. **J Bacteriol** 1995 Oct;177(19):5612-21
PstB protein of the phosphate-specific transport system of Escherichia coli is an ATPase. Chan FY, et al. **J Bacteriol** 1996 Jul;178(13):3974-7
The Activity of the high-affinity K+ uptake system Kdp sensitizes cells of Escherichia coli to methylglyoxal. Ferguson GP, et al. **J Bacteriol** 1996 Jul;178(13):3957-61
ATP-dependent H+ -pump activity in inverted vesicles of Methanosarcina mazei Gö1 and characterization of membrane ATPase. Inatomi KI. **J Bacteriol** 1996 Apr; 178(8):2424-6
Methanol traps the troponin-tropomyosin-actin complex in an "off-state". Matsuura Y, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1293-8
RNA polymerase signals UvrAB landing sites. Ahn B, et al. **J Biol Chem** 1996 Aug 30;271(35):21453-61
The binding of UvrAB proteins to bubble and loop regions in duplex DNA. Ahn B, et al. **J Biol Chem** 1996 Aug 30; 271(35):21462-70
Differential effect of precursor ribose binding protein of Escherichia coli and its signal peptide on the SecA penetration of lipid bilayer. Ahn T, et al. **J Biol Chem** 1996 May 24;271(21):12372-9
FtsH, a membrane-bound ATPase, forms a complex in the cytoplasmic membrane of Escherichia coli. Akiyama Y, et al. **J Biol Chem** 1995 Oct 6;270(40):23485-90
Liganded and unliganded receptors interact with equal affinity with the membrane complex of periplasmic permeases, a subfamily of traffic ATPases. Ames GFL, et al. **J Biol Chem** 1996 Jun 14;271(24):14264-70
Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. Borgnia MJ, et al. **J Biol Chem** 1996 Feb 9;271(6):3163-71
Calmodulin binds to specific sequences in the cytoplasmic domain of C-CAM and down-regulates C-CAM self-association. Edlund M, et al. **J Biol Chem** 1996 Jan 19;271(3):1393-9
Binding of mitochondrial presequences to yeast cytosolic heat shock protein 70 depends on the amphiphilicity of the presequence. Endo T, et al. **J Biol Chem** 1996 Feb 23; 271(8):4161-7
Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis. Eytan GD, et al. **J Biol Chem** 1996 Feb 9; 271(6):3172-8
Isolation and sequencing of the rho gene from Streptomyces lividans ZX7 and characterization of the RNA-dependent NTPase activity of the overexpressed protein. Ingham CJ, et al. **J Biol Chem** 1996 Sep 6;271(36):21803-7
Analysis of three DnaK mutant proteins suggests that progression through the ATPase cycle requires conformational changes. Kamath-Loeb AS, et al. **J Biol Chem** 1995 Dec 15;270(50):30051-9
A bipartite signaling mechanism involved in DnaJ-mediated activation of the Escherichia coli DnaK protein. Karzai AW, et al. **J Biol Chem** 1996 May 10;271(19):11236-46
ATPase activity of UvrB protein form Thermus thermophilus HB8 and its interaction with DNA. Kato R, et al. **J Biol Chem** 1996 Apr 19;271(16):9612-8
Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. Loo TW, et al. **J Biol Chem** 1995 Sep 29;270(39):22957-61
Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein. Müller M, et al. **J Biol Chem** 1996 Jan 26;271(4):1877-83
Lysine 71 of the chaperone protein Hsc70 Is essential for ATP hydrolysis. O'Brien MC, et al. **J Biol Chem** 1996 Jul 5;271(27):15874-8
Mutations in the B subunit of Escherichia coli DNA gyrase that affect ATP-dependent reactions. O'Dea MH, et al. **J Biol Chem** 1996 Apr 19;271(16):9723-9
Equilibrium studies of kinesin-nucleotide intermediates. Rosenfeld SS, et al. **J Biol Chem** 1996 Apr 19; 271(16):9473-82
Characterization of a potential catalytic residue, Asp-133, in the high affinity ATP-binding site of Escherichia coli SecA, translocation ATPase. Sato K, et al. **J Biol Chem** 1996 Jul 19;271(29):17439-44
GrpE alters the affinity of DnaK for ATP and Mg2+. Implications for the mechanism of nucleotide exchange. Skowyra D, et al. **J Biol Chem** 1995 Nov 3;270(44):26282-5
Chicken oviductal ecto-ATP-diphosphohydrolase. Purification and characterization. Strobel RS, et al. **J Biol Chem** 1996 Jul 5;271(27):16323-31
Reconstitution of TFIIH and requirement of its DNA

helicase subunits, Rad3 and Rad25, in the incision step of nucleotide excision repair. Sung P, et al. **J Biol Chem** 1996 May 3;271(18):10821–6

A conserved HPD sequence of the J–domain is necessary for YDJ1 stimulation of Hsp70 ATPase activity at a site distinct from substrate binding. Tsai J, et al. **J Biol Chem** 1996 Apr 19;271(16):9347–54

Characterization of the nucleotide binding properties and ATPase activity of recombinant hamster BiP purified from bacteria. Wei J, et al. **J Biol Chem** 1995 Nov 3; 270(44):26670–6

In vitro dissociation of BiP–peptide complexes requires a conformational change in BiP after ATP binding but does not require ATP hydrolysis. Wei J, et al. **J Biol Chem** 1995 Nov 3;270(44):26677–82

Characterization of the helicase and ATPase activity of human papillomavirus type 6b E1 protein. Jenkins O, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1805–9

The ATP–binding and ATPase activities of human papillomavirus type 16 E1 are significantly weakened by the absence of prolines in its ATP–binding domain. Raj K, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):2949–56

Lack of conventional ATPase properties in CFTR chloride channel gating. Schultz BD, et al. **J Membr Biol** 1996 May; 151(1):63–75

ATPase activity of the type IC restriction–modification system EcoR124II. Dreier J, et al. **J Mol Biol** 1996 Apr 19;257(5):960–9

Effect of ischemic preconditioning on mitochondrial oxidative phosphorylation and high energy phosphates in rat hearts. Kobara M, et al. **J Mol Cell Cardiol** 1996 Feb; 28(2):417–28

Effect of reversible ischemia on the activity of the mitochondrial ATPase: relationship to ischemic preconditioning. Vander Heide RS, et al. **J Mol Cell Cardiol** 1996 Jan;28(1):103–12

Weakly–coupled models for motor enzyme function. Brokaw CJ. **J Muscle Res Cell Motil** 1995 Jun;16(3):197–211

Cytochemical evidence for redistribution of membrane pump calcium–ATPase and ecto–Ca–ATPase activity, and calcium influx in myelinated nerve fibres of the optic nerve after stretch injury. Maxwell WL, et al. **J Neurocytol** 1995 Dec;24(12):925–42

An ATP–sensitive potassium conductance in rabbit arterial endothelial cells. Katnik C, et al. **J Physiol (Lond)** 1995 Jun 15;485 (Pt 3):595–606

A component of the 26S proteasome binds on orphan member of the nuclear hormone receptor superfamily. Choi HS, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):23–30

Vaccinia virion protein I8R has both DNA and RNA helicase activities: implications for vaccinia virus transcription. Bayliss CD, et al. **J Virol** 1996 Feb;70(2):794–800

Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. Hong Z, et al. **J Virol** 1996 Jul;70(7):4261–8

E5 oncoprotein transmembrane mutants dissociate fibroblast transforming activity from 16–kilodalton protein binding and platelet–derived growth factor receptor binding and phosphorylation. Sparkowski J, et al. **J Virol** 1996 Apr; 70(4):2420–30

Morderate diabetes alters myosin isoenzyme distribution in cardiac but not skeletal muscle of male rats. Morris GS, et al. **Life Sci** 1996;58(10):833–8

Lack of major changes in ATPase activity in mitochondria from liver, heart, and skeletal muscle of rats upon ageing. Barogi S, et al. **Mech Ageing Dev** 1995 Oct 13;84(2):139–50

Purification and biochemical characterization of enzymes with DNA helicase activity. Matson SW, et al. **Methods Enzymol** 1995;262:389–405

Biochemical and functional analysis of the YME1 gene product, an ATP and zinc–dependent mitochondrial protease from S. cerevisiae. Weber ER, et al. **Mol Biol Cell** 1996 Feb;7(2):307–17

Influence of global ischemia on the sarcolemmal ATPases in the rat heart. Vrbjar N, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):99–103

Adaptation of the heart to ischemia by preconditioning: effects on energy equilibrium, properties of sarcolemmal ATPases and release of cardioprotective proteins. Ziegelhöffer A, et al. **Mol Cell Biochem** 1995 Jun 7–21; 147(1–2):129–37

Direct regulation of the ATPase activity of the transcriptional activator DmpR by aromatic compounds. Shingler V, et al. **Mol Microbiol** 1995 Aug;17(3):505–13

The Escherichia coli DNA repair protein UvrA can re–associate with the UvrB: aflatoxin B1–DNA complex in vitro. Allan JM, et al. **Mutat Res** 1996 Apr 2;362(3):261–8

An RNA–dependent ATPase associated with U2/U6 snRNAs in pre–mRNA splicing. Xu D, et al. **Nature** 1996 Jun 20;381(6584):709–13

Effect of thyrotropin–releasing hormone on Na(+)–K(+)–Adenosine triphosphatase activity following experimental spinal cord trauma. Baykal S, et al. **Neurol Med Chir (Tokyo)** 1996 May;36(5):296–9

Immunocytochemical localization of ecto–5'–nucleotidase in cultures of cerebellar granule cells. Maienschein V, et al. **Neuroscience** 1996 Jan;70(2):429–38

A1–receptor–mediated effect of adenosine on the release of acetylcholine from the myenteric plexus: role and localization of ecto–ATPase and 5'–nucleotidase. Nitahara K, et al. **Neuroscience** 1995 Jul;67(1):159–68

Tomato annexins p34 and p35 bind to F–actin and display nucleotide phosphodiesterase activity inhibited by phospholipid binding. Calvert CM, et al. **Plant Cell** 1996 Feb;8(2):333–42

ATPase activity and molecular chaperone function of the stress70 proteins. Miernyk JA, et al. **Plant Physiol** 1996 Feb;110(2):419–24

HCO3(–)–ATPase and Ca2+ dependent ATPase activities in the gills of the rainbow trout after the transfer to brackishwater and seawater. Fuentes J, et al. **Rev Esp Fisiol** 1995 Jun;51(2):93–100

Competition between ribosome and SecA binding promotes Escherichia coli secA translational regulation. Salavati R, et al. **RNA** 1995 Sep;1(7):745–53

Prp16p, Slu7p, and Prp8p interact with the 3' splice site in two distinct stages during the second catalytic step of pre–mRNA splicing. Umen JG, et al. **RNA** 1995 Aug; 1(6):584–97

Heterogeneous distribution of ecto–Ca–ATPases in primary cultures of human adenohypophyseal cells. Kittel A, et al. **Scanning Microsc** 1995 Jun;9(2):485–90; discussion 490–2

New ways to avoid organ rejection buoy hopes [news] Roush W. **Science** 1995 Oct 13;270(5234):234–5

A subfamily of P–type ATPases with aminophospholipid transporting activity. Tang X, et al. **Science** 1996 Jun 7; 272(5267):1495–7

Potential mechanism of abnormal thromboregulation in xenograft rejection: loss of ecto–ATPases upon endothelial cell activation. Robson SC, et al. **Transplant Proc** 1996 Apr; 28(2):536

[Changes in myocardial ATPase activity and Ca2+ content in burned rats] Huan J, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul;33(7):400–2 (Eng. Abstr.) **(Chi)**

[Change in prostaglandin levels and ATPase activity of cardiac membrane fractions during the formation of cerebral hematomas in animals with a hereditary predisposition to stroke] Vasil'eva EM, et al. **Patol Fiziol Eksp Ter** 1996 Jan–Mar;(1):16–9 (Eng. Abstr.) **(Rus)**

[Oligomeric assemblies of transport adenosine triphosphatases in a membrane bilayer] Boldyrev AA. **Zh Evol Biokhim Fiziol** 1995 Jul–Aug;31(4):375–86 (45 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Facile preparation of inside–out plasma membrane vesicles from tumor cells for functional studies of pharmacologically relevant translocating ATPases. Schlemmer SR, et al. **Anal Biochem** 1995 Jul 1; 228(2):226–31

Fpg and UvrA proteins participate in the repair of DNA lesions induced by hydrogen peroxide in low iron level in Escherichia coli. Asad NR, et al. **Biochimie** 1995; 77(4):262–4

PHYSIOLOGY

Sec–dependent preprotein translocation in bacteria. den Blaauwen T, et al. **Arch Microbiol** 1996 Jan;165(1):1–8 (73 ref.)

Structure and function of C–CAM1: effects of the cytoplasmic domain on cell aggregation. Lin SH, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):239–45

Suppression of human bladder cancer growth by increased expression of C–CAM1 gene in an orthotopic model. Kleinerman DI, et al. **Cancer Res** 1996 Aug 1;56(15):3431–5

An NSF–like ATPase, p97, and NSF mediate cisternal regrowth from mitotic Golgi fragments. Rabouille C, et al. **Cell** 1995 Sep 22;82(6):905–14

ClpX protein of Escherichia coli activates bacteriophage Mu transposase in the strand transfer complex for initiation of Mu DNA synthesis. Kruklitis, R, et al. **EMBO J** 1996 Feb 15;15(4):935–44

A short isoform of carcinoembryonic–antigen–related rat liver cell–cell adhesion molecule (C–CAM/gp110) mediates intercellular adhesion. Sequencing and recombinant functional analysis. Lucka L, et al. **Eur J Biochem** 1995 Dec 1;234(2):527–35

Functional characterization of the Staphylococcus carnosus SecA protein in Escherichia coli and Bacillus subtilis secA mutant strains. Klein M, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):271–7

A role for ATPase in the mechanisms of ATP–dependent Ca and phosphate deposition by isolated rachitic matrix vesicles. Hsu HH, et al. **Int J Biochem Cell Biol** 1995 Dec; 27(12):1349–56

Soft metal thiol chemistry is not involved in the transport of arsenite by the Ars pump. Chen Y, et al. **J Bacteriol** 1996 Feb;178(3):911–3

Site–specific proteolysis of the Escherichia coli SecA protein in vivo. Mondigler M, et al. **J Bacteriol** 1996 May; 178(10):2986–8

Regulation of Escherichia coli starvation sigma factor (sigma s) by ClpXP protease. Schweder T, et al. **J Bacteriol** 1996 Jan;178(2):470–6

Role of E. coli DNA helicase II in a umuCD–dependent Wiegle reactivation. Altshuler ML. **Mutat Res** 1996 Mar 26;351(1):3–7

Factors limiting adenosine triphosphatase function during high intensity exercise. Thermodynamic and regulatory considerations. Korge P. **Sports Med** 1995 Oct;20(4):215–25 (31 ref.)

ADENOSINETRIPHOSPHATASE, ACTOMYOSIN see **MYOSIN ATPASE**

ADENOSINETRIPHOSPHATASE, CALCIUM see **CA(2+)-TRANSPORTING ATPASE**

ADENOSINETRIPHOSPHATASE, CALCIUM, MAGNESIUM see **CA(2+) MG(2+)-ATPASE**

ADENOSINETRIPHOSPHATASE, DYNEIN see **DYNEIN ATPASE**

ADENOSINETRIPHOSPHATASE F1 see **H(+)-TRANSPORTING ATP SYNTHASE**

ADENOSINETRIPHOSPHATASE, HYDROGEN, POTASSIUM see **H(+)-K(+)-EXCHANGING ATPASE**

ADENOSINETRIPHOSPHATASE, MAGNESIUM see **CA(2+) MG(2+)-ATPASE**

ADENOSINETRIPHOSPHATASE, MYOSIN see **MYOSIN ATPASE**

ADENOSINETRIPHOSPHATASE, SODIUM, POTASSIUM see **NA(+)-K(+)-EXCHANGING ATPASE**

ADENOSIS OF BREAST see **FIBROCYSTIC DISEASE OF BREAST**

S-ADENOSYLHOMOCYSTEINE

ANALOGS & DERIVATIVES

N6–methyladenosine inhibits murine erythroleukemia cell maturation by blocking methylation of RNA and memory via conversion to S–(N6–methyl)–adenosylhomocysteine. Vizirianakis IS, et al. **Biochem Pharmacol** 1995 Nov 27; 50(11):1807–14

Methylation inhibitors can increase the rate of cytosine deamination by (cytosine–5)–DNA methyltransferase. Zingg JM, et al. **Nucleic Acids Res** 1996 Aug 15; 24(16):3267–75

BLOOD

Effect of methionine loading on 5–methyltetrahydrofolate, S–adenosylmethionine and S–adenosylhomocysteine in plasma of healthy humans. Loehrer FM, et al. **Clin Sci (Colch)** 1996 Jul;91(1):79–86

METABOLISM

Vaccinia virus mRNA (guanine–7–)methyltransferase: mutational effects on cap methylation and AdoHcy–dependent photo–cross–linking of the cap to the methyl acceptor site. Mao X, et al. **Biochemistry** 1996 May 28;35(21):6900–10

Effect of hypoxia on hepatic DNA methylation and tRNA methyltransferase in rat: similarities to effects of methyl–deficient diets. Chawla RK, et al. **J Cell Biochem** 1996 Apr;61(1):72–80

PHARMACOLOGY

S–adenosyl–L–homocysteine and 5'–methylthioadenosine inhibit binding of [3H]flunitrazepam to rat brain membranes. Tsvetnitsky V, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):255–8

S-ADENOSYLMETHIONINE

ANALOGS & DERIVATIVES

Methylation inhibitors can increase the rate of cytosine deamination by (cytosine–5)–DNA methyltransferase. Zingg JM, et al. **Nucleic Acids Res** 1996 Aug 15; 24(16):3267–75

ANALYSIS

Thiopeptides. Strohl WR, et al. **Biotechnology** 1995;28:223–38 (50 ref.)

BIOSYNTHESIS

Mutations affecting the biosynthesis of S–adenosylmethionine cause reduction of DNA methylation in Neurospora crassa. Roberts CJ, et al. **Nucleic Acids Res** 1995 Dec 11; 23(23):4818–26

BLOOD

Effect of methionine loading on 5–methyltetrahydrofolate, S–adenosylmethionine and S–adenosylhomocysteine in plasma of healthy humans. Loehrer FM, et al. **Clin Sci (Colch)** 1996 Jul;91(1):79–86

DEFICIENCY

Low whole–blood S–adenosylmethionine and correlation between 5–methyltetrahydrofolate and homocysteine in

coronary artery disease. Loehrer FM, et al. **Arterioscler Thromb Vasc Biol** 1996 Jun;16(6):727–33

GENETICS

Characterization of the smtA gene encoding an S-adenosylmethionine-dependent methyltransferase of Escherichia coli. Yamanaka K, et al. **FEMS Microbiol Lett** 1995 Nov 1;133(1–2):59–63

METABOLISM

Probing the S-adenosylmethionine-binding site of rat guanidinoacetate methyltransferase. Effect of site-directed mutagenesis of residues that are conserved across mammalian non-nucleic acid methyltransferases. Hamahata A, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):141–5

Evidence for a covalent intermediate in the S-adenosyl-L-methionine-dependent transmethylation reaction catalysed by sirohaem synthase. Woodcock SC, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):415–21

Mechanism and structural requirements for transformation of substrates by the (S)-adenosyl-L-methionine:delta 24(25)-sterol methyl transferase from Saccharomyces cerevisiae. Venkatramesh M, et al. **Biochim Biophys Acta** 1996 Feb 16;1299(3):313–24

Involvement of methionine in the synthesis of certain membrane-associated nucleotide sugars by human amnion (WISH) cells. Wood RC. **Cancer Lett** 1996 Feb 27; 100(1–2):37–40

Crithidia luciliae: effect of purine starvation on S-adenosyl-L-methionine uptake and protein methylation. Alleman MM, et al. **Exp Parasitol** 1995 Dec;81(4):519–28

S-Adenosylmethionine and methylation. Chiang PK, et al. **FASEB J** 1996 Mar;10(4):471–80 (99 ref.)

Purification of the KpnI DNA methyltransferase and photolabeling of the enzyme with S-adenosyl-L-methionine. Finta C, et al. **Gene** 1995 Oct 16;164(1):65–9

Effect of hypoxia on hepatic DNA methylation and tRNA methyltransferase in rat: similarities to effects of methyl-deficient diets. Chawla RK, et al. **J Cell Biochem** 1996 Apr;61(1):72–80

Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. Morrison LD, et al. **J Neurochem** 1996 Sep;67(3):1328–31

Nyctohemeral rhythm in the levels of S-adenosylmethionine in the rat pineal gland and its relationship to melatonin biosynthesis. Sitaram BR, et al. **J Neurochem** 1995 Oct; 65(4):1887–94

NodS is an S-adenosyl-L-methionine-dependent methyltransferase that methylates chitooligosaccharides deacetylated at the non-reducing end. Geelen D, et al. **Mol Microbiol** 1995 Jul;17(2):387–97

PHARMACOLOGY

Persistent chemopreventive effect of S-adenosyl-L-methionine on the development of liver putative preneoplastic lesions induced by thiobenzamide in diethylnitrosamine-initiated rats. Simile MM, et al. **Carcinogenesis** 1996 Jul;17(7):1533–7

Beneficial effect of S-adenosylmethionine during both cold storage and cryopreservation of isolated hepatocytes. Vara E, et al. **Cryobiology** 1995 Oct;32(5):422–7

Characterization of an Arabidopsis thaliana cDNA encoding an S-adenosylmethionine-sensitive threonine synthase. Threonine synthase from higher plants. Curien G, et al. **FEBS Lett** 1996 Jul 15;390(1):85–90

S-adenosyl-L-methionine prevents disruption of canalicular function and pericanalicular cytoskeleton integrity caused by cyclosporin A in isolated rat hepatocyte couplets. Román ID, et al. **Hepatology** 1996 Jul;24(1):134–40

Protective effect of S-adenosyl-L-methionine on bromobenzene- and D-galactosamine-induced toxicity to isolated rat hepatocytes. Wu J, et al. **Hepatology** 1996 Feb; 23(2):359–65

Defective cystathionine beta-synthase regulation by S-adenosylmethionine in a partially pyridoxine responsive homocystinuria patient. Kluijtmans LA, et al. **J Clin Invest** 1996 Jul 15;98(2):285–9

Microsomal function in biliary obstructed rats: effects of S-adenosylmethionine. Pastor A, et al. **J Hepatol** 1996 Mar; 24(3):353–9

Reversal of cyclosporine A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats. Fernández E, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):442–9

S-adenosylmethionine protects hepatocytes against the effects of cytokines. Arias-Díaz J, et al. **J Surg Res** 1996 Apr;62(1):79–84

Partial restoration of impaired alpha 1-adrenergic responsiveness in parotid cells of aged rats by S-adenosylmethionine treatment. Kowatch MA, et al. **Mol Cell Biochem** 1995 Jul 5;148(1):73–7

Met30p, a yeast transcriptional inhibitor that responds to S-adenosylmethionine, is an essential protein with WD40 repeats. Thomas D, et al. **Mol Cell Biol** 1995 Dec; 15(12):6526–34

Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of S-adenosylmethionine: a possible role of hypermethylation in parkinsonism. Charlton CG, et al. **Mol Chem Neuropathol** 1995 Dec;26(3):269–84

PHYSIOLOGY

Changes in rat liver gene expression induced by thioacetamide: protective role of S-adenosyl-L-methionine by a glutathione-dependent mechanism. Mesa ML, et al. **Hepatology** 1996 Mar;23(3):600–6

THERAPEUTIC USE

Carbon tetrachloride-induced hepatic injury is associated with global DNA hypomethylation and homocysteinemia: effect of S-adenosylmethionine treatment. Varela-Moreiras G, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1310–5

Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Fava M, et al. **Psychiatry Res** 1995 Apr 28;56(3):295–7

[Parenteral S-adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases] Diaz Belmont A, et al. **An Med Interna** 1996 Jan;13(1):9–15 (Eng. Abstr.) (Spa)

S-ADENOSYLMETHIONINE DECARBOXYLASE

BIOSYNTHESIS

S-adenosylmethionine decarboxylase gene expression in rat hepatoma cells: regulation by insulin and by inhibition of protein synthesis. Soininen T, et al. **Biochem J** 1996 May 15;316 (Pt 1):273–7

GENETICS

Maternal and zygotic expression of mRNA for S-adenosylmethionine decarboxylase and its relevance to the unique polyamine composition in Xenopus oocytes and embryos. Shinga J, et al. **Biochim Biophys Acta** 1996 Jul 31;1308(1):31–40

Isolation and characterization of a Tritordeum cDNA encoding S-adenosylmethionine decarboxylase that is circadian-clock-regulated. Dresselhaus T, et al. **Plant Mol Biol** 1996 Mar;30(5):1021–33

METABOLISM

Polyamines and their metabolizing enzymes in human frontal cortex and hippocampus: preliminary measurements in affective disorders. Gilad GM, et al. **Biol Psychiatry** 1995 Aug 15;38(4):227–34

S-ADENOSYLMETHIONINE SYNTHETASE see **METHIONINE ADENOSYLTRANSFERASE**

ADENOVIRIDAE

Adenovirus-mediated gene therapy for head and neck squamous cell carcinomas. Goebel EA, et al. **Ann Otol Rhinol Laryngol** 1996 Jul;105(7):562–7

Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir. Tong XW, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1611–7

Expression of exogenous protein and analysis of morphogenesis in the developing chicken heart using an adenoviral vector. Fisher SA, et al. **Cardiovasc Res** 1996 Feb;31 Spec No:E86–95

VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Mühlhauser J, et al. **Circ Res** 1995 Dec;77(6):1077–86

Adenovirus fiber. Chroboczek J, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):163–200 (125 ref.)

Non-replicating expression vectors: applications in vaccine development and gene therapy. Limbach KJ, et al. **Epidemiol Infect** 1996 Jun;116(3):241–56 (87 ref.)

Toxicity of replication-defective adenoviral recombinants in dissociated cultures of nervous tissue. Durham HD, et al. **Exp Neurol** 1996 Jul;140(1):14–20

Astrocytes infected with replication-defective adenovirus containing a secreted form of CNTF or NT3 show enhanced support of neuronal populations in vitro. Smith GM, et al. **Exp Neurol** 1996 May;139(1):156–66

Gene delivery into the central nervous system by nasal instillation in rats. Draghia R, et al. **Gene Ther** 1995 Aug; 2(6):418–23

Adenovirus-mediated transfer of CCAAT/enhancer-binding protein-alpha identifies a dominant antiproliferative role for this isoform in hepatocytes. Diehl AM, et al. **J Biol Chem** 1996 Mar 29;271(13):7343–50

Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. Chang MW, et al. **J Clin Invest** 1995 Nov; 96(5):2260–8

Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. Newman KD, et al. **J Clin Invest** 1995 Dec;96(6):2955–65

Inhibition of endothelial cell activation by adenovirus-mediated expression of I kappa B alpha, an inhibitor of the transcription factor NF-kappa B. Wrighton CJ, et al. **J Exp Med** 1996 Mar 1;183(3):1013–22

Adenovirus-mediated expression of ribozymes in mice. Lieber A, et al. **J Virol** 1996 May;70(5):3153–8

Transduction of LacZ gene into leukemia cells using viral vectors of retrovirus and adenovirus. Tani K, et al. **Leukemia** 1995 Oct;9 Suppl 1:S64–5

Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery. Chang MW, et al. **Mol Med** 1995 Jan;1(2):172–81

Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Kay MA, et al. **Nat Genet** 1995 Oct;11(2):191–7

Gene targeting in mouse embryonic stem cells with an adenoviral vector. Mitani K, et al. **Somat Cell Mol Genet** 1995 Jul;21(4):221–31

CHEMISTRY

Nucleoplasmic and nucleolar distribution of the adenovirus IVa2 gene product. Lutz P, et al. **J Virol** 1996 Jun; 70(6):3449–60

Epitopes and hemagglutination binding domain on subgenus B:2 adenovirus fibers. Mei YF, et al. **J Virol** 1996 Jun; 70(6):3688–97

Sequence characterization of the adenovirus 31 fibre and comparison with serotypes of subgenera A to F. Pring-Akerblom P, et al. **Res Virol** 1995 Sep–Oct; 146(5):343–54

ENZYMOLOGY

Transcription of adenovirus RNA polymerase III genes. Pruzan R, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):201–26 (116 ref.)

Adenovirus endopeptidase and its role in virus infection. Weber JM. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):227–35 (36 ref.)

GENETICS

Adenovirus vector technology: an efficient method for constructing recombinant adenovirus and on/off switching of gene expression. Kanegae Y, et al. **Acta Paediatr Jpn** 1996 Apr;38(2):182–8

Transgene expression in the rhesus cervix mediated by an adenovirus expressing beta-galactosidase. Mitchell MF, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1094–101

Adenovirus and adeno-associated virus as vectors for gene therapy. Berns KI, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:95–104 (48 ref.)

Prospects for gene therapy with direct injection of polynucleotides. Kass-Eisler A, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:232–40 (33 ref.)

Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector. Magovern CJ, et al. **Ann Thorac Surg** 1996 Aug;62(2):425–33; discussion 433–4

Genes for fowl adenovirus CELO penton base and core polypeptides. Akopian TA, et al. **Arch Virol** 1996; 141(2):357–65

Genomic location and nucleotide sequence of a porcine adenovirus penton base gene. McCoy RJ, et al. **Arch Virol** 1996;141(7):1367–75

Adenovirus-mediated gene transfer to normal and atherosclerotic arteries. A novel approach. Rios CD, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2241–5

Quantitative analysis of repeat adenovirus-mediated gene transfer into injured canine femoral arteries. Ueno H, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2246–53

Mutational analysis of the adenovirus E2-early promoter in fission yeast Schizosaccharomyces pombe. Manohar CF, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):653–63

Recombinant adenoviruses as vaccines. Randrianarison-Jewtoukoff V, et al. **Biologicals** 1995 Jun; 23(2):145–57 (82 ref.)

Gene transfer into human bone marrow hematopoietic cells mediated by adenovirus vectors. Watanabe T, et al. **Blood** 1996 Jun 15;87(12):5032–9

Adenovirus-mediated gene transfer of dopamine D2 receptor cDNA into rat striatum. Ikari H, et al. **Brain Res Mol Brain Res** 1995 Dec 28;34(2):315–20

Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Harris MP, et al. **Cancer Gene Ther** 1996 Mar–Apr;3(2):121–30

In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Toloza EM, et al. **Cancer Gene Ther** 1996 Jan–Feb;3(1):11–7

In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Eastham JA, et al. **Cancer Res** 1995 Nov 15; 55(22):5151–5

Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Kaneko S, et al. **Cancer Res** 1995 Nov 15;55(22):5283–7

Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. Seth P, et al. **Cancer Res** 1996 Mar 15; 56(6):1346–51

Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Tanaka T, et al. **Cancer Res** 1996 Mar 15;56(6):1341–5

Percutaneous transluminal gene transfer into canine myocardium in vivo by replication-defective adenovirus. Li JJ, et al. **Cardiovasc Res** 1995 Jul;30(1):97–105

Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis. Katayose D, et al. **Cell Growth Differ** 1995 Oct;6(10):1207–12

The use of adenoviral vectors for gene therapy and gene transfer in vivo. Bramson JL, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):590–5 (49 ref.)

Adenovirus–augmented, receptor–mediated gene delivery and some solutions to the common toxicity problems. Cotten M. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):283–95 (70 ref.)

The mechanism of adenovirus DNA integration: studies in a cell–free system. Fechteler K, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):109–37 (122 ref.)

Gene therapy using adenovirus vectors. Haddada H, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):297–306 (35 ref.)

Molecular interactions during adenovirus DNA replication. Hay RT, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):31–48 (114 ref.)

Post–transcriptional control of adenovirus gene expression. Imperiale MJ, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):139–71 (143 ref.)

Structure, function, and evolution of adenovirus virus–associated RNAs. Mathews MB. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):173–87 (35 ref.)

Expression, nuclear transport, and phosphorylation of adenovirus DNA replication proteins. Ramachandra M, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):50–88 (262 ref.)

Cap–independent translation in adenovirus infected cells. Schneider RJ. **Curr Top Microbiol Immunol** 1995; 203:117–29 (61 ref.)

Adenovirus DNA replication. Van der Vliet PC. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):1–30 (147 ref.)

Homologous recombination in the replicative cycle of adenovirus and its relationship to DNA replication. Young CS. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):89–108 (75 ref.)

Differential short–term transduction efficiency of adult versus newborn mouse tissues by adenoviral recombinants. Huard J, et al. **Exp Mol Pathol** 1995 Apr;62(2):131–43

Sequence of the mouse adenovirus type–1 DNA encoding the 100–kDa, 33–kDa and DNA–binding proteins. Cauthen AN, et al. **Gene** 1996 Feb 12;168(2):183–7

Cloning, sequence determination and functional expression of the genes encoding adenovirus type–4 polymerase and the terminal protein precursor. Stanglmaier M, et al. **Gene** 1996 Feb 12;168(2):177–82

Adenovirus vectors to transfer genes into neurones: implications for gene therapy of neurological disorders. Bain D, et al. **Gene Ther** 1994;1 Suppl 1:S68

Efficient catheter–mediated gene transfer into the heart using replication–defective adenovirus. Barr E, et al. **Gene Ther** 1994 Jan;1(1):51–8

In vivo adenovirus–mediated transfer of human CFTR cDNA to rhesus monkey airway epithelium: efficacy, toxicity and safety. Bout A, et al. **Gene Ther** 1994 Nov; 1(6):385–94

A recombinant adenoviral vector expressing a soluble form of VCAM–1 inhibits VCAM–1/VLA–4 adhesion in transduced synoviocytes. Chen SJ, et al. **Gene Ther** 1995 Sep;2(7):469–80

Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus. Cotten M, et al. **Gene Ther** 1994 Jul;1(4):239–46

Lack of persistence of E1– recombinant adenoviral vectors containing a temperature–sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Fang B, et al. **Gene Ther** 1996 Mar;3(3):217–22

An efficient procedure to select and recover recombinant adenovirus vectors. Imler JL, et al. **Gene Ther** 1995 Jun; 2(4):263–8

The impact of developmental stage, route of administration and the immune system on adenovirus–mediated gene transfer. Kass–Eisler A, et al. **Gene Ther** 1994 Nov; 1(6):395–402

The constitutive expression of the immunomodulatory gp19k protein in E1–, E3– adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Lee MG, et al. **Gene Ther** 1995 Jun;2(4):256–62

Expression of human interleukin–1 receptor antagonist in mouse lungs using a recombinant adenovirus: effects on vector–induced inflammation. McCoy RD, et al. **Gene Ther** 1995 Sep;2(7):437–42

Adenovirus mediated gene transfer to the central nervous system. Mallet J, et al. **Gene Ther** 1994;1 Suppl 1:S52

Increased titer of recombinant AAV vectors by gene transfer with adenovirus coupled to DNA–polylysine complexes. Mamounas M, et al. **Gene Ther** 1995 Aug;2(6):429–32

In vivo adenovirus–mediated gene transfer into ocular tissues. Mashhour B, et al. **Gene Ther** 1994 Mar;1(2):122–6

Adenovirus–mediated transfer of a human dystrophin gene to skeletal muscle of mdx mouse. Ragot T, et al. **Gene Ther** 1994;1 Suppl 1:S53–4

Generation of recombinant adeno–associated virus (rAAV) from an adenoviral vector and functional reconstitution of the NADPH–oxidase. Thrasher AJ, et al. **Gene Ther** 1995 Sep;2(7):481–5

In vivo adenovirus–mediated gene transfer into normal and cystic rat kidneys. Zhu G, et al. **Gene Ther** 1996 Apr; 3(4):298–304

Selective translation initiation by ribosome jumping in adenovirus–infected and heat–shocked cells. Yueh A, et al. **Genes Dev** 1996 Jun 15;10(12):1557–67

Adenovirus–based p53 gene therapy in ovarian cancer [see comments] Santoso JT, et al. **Gynecol Oncol** 1995 Nov; 59(2):171–8. Comment in: Gynecol Oncol 1995 Nov;59(2):169–70.

In vivo gene therapy of ovarian cancer by adenovirus–mediated thymidine kinase gene transduction and ganciclovir administration. Tong XW, et al. **Gynecol Oncol** 1996 May;61(2):175–9

A novel adenovirus–based system for facilitating retroviral hepatic gene transfer in vivo. Ott M, et al. **Hepatology** 1996 Mar;23(3):645–7

Characterization of an adenovirus gene transfer vector containing an E4 deletion. Armentano D, et al. **Hum Gene Ther** 1995 Oct;6(10):1343–53

Recombinant truncated dystrophin minigenes: construction, expression, and adenoviral delivery. Clemens PR, et al. **Hum Gene Ther** 1995 Nov;6(11):1477–85

A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung. Crystal RG, et al. **Hum Gene Ther** 1995 May;6(5):643–66

Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis. Crystal RG, et al. **Hum Gene Ther** 1995 May;6(5):667–703

Regenerating cells in human airway surface epithelium represent preferential targets for recombinant adenovirus. Dupuit F, et al. **Hum Gene Ther** 1995 Sep;6(9):1185–93

Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus–mediated factor IX expression. Fang B, et al. **Hum Gene Ther** 1995 Aug;6(8):1039–44

Transient expression of genes transferred in vivo into heart using first–generation adenoviral vectors: role of the immune response. Gilgenkrantz H, et al. **Hum Gene Ther** 1995 Oct;6(10):1265–74

Transfer of the CFTR gene to the lung of nonhuman primates with E1–deleted, E2a–defective recombinant adenoviruses: a preclinical toxicology study. Goldman MJ, et al. **Hum Gene Ther** 1995 Jul;6(7):839–51

Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hay JG, et al. **Hum Gene Ther** 1995 Nov; 6(11):1487–96

Trans–complementation of E1–deleted adenovirus: a new vector to reduce the possibility of codissemination of wild–type and recombinant adenoviruses. Imler JL, et al. **Hum Gene Ther** 1995 Jun;6(6):711–21

Aerosol delivery of a beta–galactosidase adenoviral vector to the lungs of rodents. Katkin JP, et al. **Hum Gene Ther** 1995 Aug;6(8):985–95

Ferrochelatase cDNA delivered by adenoviral vector corrects biochemical defect in protoporphyric cells. Magness ST, et al. **Hum Gene Ther** 1995 Oct;6(10):1285–90

In vivo marking of spontaneous or vaccine–induced fibrosarcomas in the domestic house cat, using an adenoviral vector containing a bifunctional fusion protein, GAL–TEK. Marini FC 3rd, et al. **Hum Gene Ther** 1995 Sep;6(9):1215–23

In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor. Mühlhauser J, et al. **Hum Gene Ther** 1995 Nov;6(11):1457–65

Efficient adenovirus–mediated gene transfer to basal but not columnar cells of cartilaginous airway epithelia. Pickles RJ, et al. **Hum Gene Ther** 1996 May 20;7(8):921–31

Modification of tumor suppressor gene expression and induction of apoptosis in non–small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Roth JA. **Hum Gene Ther** 1996 May 20;7(8):1013–30

Aerosol–mediated delivery of recombinant adenovirus to the airways of nonhuman primates. Sené C, et al. **Hum Gene Ther** 1995 Dec;6(12):1587–93

Adenovirus–mediated gene transfer to the respiratory tract of fetal sheep in utero. Vincent MC, et al. **Hum Gene Ther** 1995 Aug;6(8):1019–28

Heterogeneity of adenovirus–mediated gene transfer in cultured thoracic aorta and renal artery of rats. Yao A, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1046–50

In vitro evaluation of a p53–expressing adenovirus as an anti–cancer drug. Blagosklonny MV, et al. **Int J Cancer** 1996 Jul 29;67(3):386–92

Adenovirus–mediated gene transfer of wild–type p53 results in melanoma cell apoptosis in vitro and in vivo. Cirielli C, et al. **Int J Cancer** 1995 Nov 27;63(5):673–9

Induction of a cytolytic T–cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Warnier G, et al. **Int J Cancer** 1996 Jul 17;67(2):303–10

Adenovirus–mediated gene transfer to retinal ganglion cells. Cayouette M, et al. **Invest Ophthalmol Vis Sci** 1996 Sep; 37(10):2022–8

Adenovirus–mediated expression of aquaporin–5 in epithelial cells. Delporte C, et al. **J Biol Chem** 1996 Sep 6; 271(36):22070–5

Abortive initiation and first bond formation at an activated adenovirus E4 promoter. Jiang Y, et al. **J Biol Chem** 1995 Nov 10;270(45):27332–8

Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus–mediated gene transfer of the very low density lipoprotein receptor. Kobayashi K, et al. **J Biol Chem** 1996 Mar 22; 271(12):6852–60

Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor–associated antigen. Chen PW, et al. **J Immunol** 1996 Jan 1;156(1):224–31

Antigen–specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. Zhai Y, et al. **J Immunol** 1996 Jan 15;156(2):700–10

Strategies for cancer gene therapy using adenoviral vectors. Descamps V, et al. **J Mol Med** 1996 Apr;74(4):183–9 (80 ref.)

Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. Byrnes AP, et al. **J Neurosci** 1996 May 1;16(9):3045–55

Proneuropeptide Y processing in large dense–core vesicles: manipulation of prohormone convertase expression in sympathetic neurons using adenoviruses. Paquet L, et al. **J Neurosci** 1996 Feb 1;16(3):964–73

Adenovirus–mediated gene transfer into tendon and tendon sheath. Lou J, et al. **J Orthop Res** 1996 Jul;14(4):513–7

Cardiac gene transfer by intracoronary infusion of adenovirus vector–mediated reporter gene in the transplanted mouse heart. Lee J, et al. **J Thorac Cardiovasc Surg** 1996 Jan; 111(1):246–52

Adenoviral–p53 gene transfer to orthotopic and peritoneal murine bladder cancer. Werthman PE, et al. **J Urol** 1996 Feb;155(2):753–6

Analysis of early region 3 mutants of mouse adenovirus type 1. Beard CW, et al. **J Virol** 1996 Sep;70(9):5867–74

Adenovirus E4 open reading frame 4 protein autoregulates E4 transcription by inhibiting E1A transactivation of the E4 promoter. Bondesson M, et al. **J Virol** 1996 Jun; 70(6):3844–51

Second–strand synthesis is a rate–limiting step for efficient transduction by recombinant adeno–associated virus vectors. Ferrari FK, et al. **J Virol** 1996 May;70(5):3227–34

Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. Gorziglia MI, et al. **J Virol** 1996 Jun;70(6):4173–8

The structure of adenovirus type 12 DNA integration sites in the hamster cell genome. Knoblauch M, et al. **J Virol** 1996 Jun;70(6):3788–96

Enhanced splicing of nonconsensus 3' splice sites late during adenovirus infection. Mühlemann O, et al. **J Virol** 1995 Nov;69(11):7324–7

Specific growth inhibition of small–cell lung cancer cells by adenovirus vector expressing antisense c–kit transcripts. Yamanishi Y, et al. **Jpn J Cancer Res** 1996 May; 87(5):534–42

Gene transfer using replication–defective retroviral and adenoviral vectors. Leber SM, et al. **Methods Cell Biol** 1996;51:161–83 (42 ref.)

Methods for construction of adenovirus vectors. Graham FL, et al. **Mol Biotechnol** 1995 Jun;3(3):207–20

Gene transfer and expression in mouse preimplantation embryos by recombinant adenovirus vector. Tsukui T, et al. **Mol Reprod Dev** 1995 Nov;42(3):291–7

Local adenoviral–mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Rade JJ, et al. **Nat Med** 1996 Mar;2(3):293–8

Immune responses to transgene–encoded proteins limit the stability of gene expression after injection of replication–defective adenovirus vectors. Tripathy SK, et al. **Nat Med** 1996 May;2(5):545–50

Second–generation adenovirus vectors. Wang Q, et al. **Nat Med** 1996 Jun;2(6):714–6 (36 ref.)

Inhibition by SR proteins of splicing of a regulated adenovirus pre–mRNA. Kanopka A, et al. **Nature** 1996 Jun 6;381(6582):535–8

Specific and efficient gene transfer strategy offers new potentialities for the treatment of motor neurone diseases. Finiels F, et al. **Neuroreport** 1995 Dec 29;7(1):373–8

Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site–specific Cre recombinase. Kanegae Y, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):3816–21

Adenovirus–mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Fueyo J, et al. **Oncogene** 1996 Jan 4; 12(1):103–10

Adenoviral–mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Mujoo K, et al. **Oncogene** 1996 Apr 18;12(8):1617–23

Adenovirus–mediated in vivo gene transfer and expression in normal rat pancreas. Raper SE, et al. **Pancreas** 1996 May;12(4):401–10

A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full–length dystrophin and beta–galactosidase. Kochanek S, et al. **Proc Natl Acad Sci U S A** 1996 Jun

11;93(12):5731–6
Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood–brain barrier disruption. Nilaver G, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9829–33
Titration of serine/arginine (SR) splicing factors during adenoviral infection modulates E1A pre-mRNA alternative splicing. Himmelspach M, et al. **RNA** 1995 Oct; 1(8):794–806
High frequency recombination between loxP sites in human chromosomes mediated by an adenovirus vector expressing Cre recombinase. Wang P, et al. **Somat Cell Mol Genet** 1995 Nov;21(6):429–41
Expression of thyroid peroxidase in EBV-transformed B cell lines using adenovirus. Hidaka Y, et al. **Thyroid** 1996 Feb; 6(1):23–8
Adenovirus-mediated gene delivery to the corneal endothelium. Larkin DF, et al. **Transplantation** 1996 Feb 15;61(3):363–70
Adenovirus-mediated gene transfer into rat cardiac allografts. Comparison of direct injection and perfusion. Wang J, et al. **Transplantation** 1996 Jun 27;61(12):1726–9
Adenovirus vectors as recombinant viral vaccines. Imler JL. **Vaccine** 1995 Sep;13(13):1143–51 (72 ref.)
Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Fisher KJ, et al. **Virology** 1996 Mar 1;217(1):11–22
DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309. Bett AJ, et al. **Virus Res** 1995 Nov; 39(1):75–82
[Therapeutic effect of adenovirus-mediated transfer of the wild-type p53 gene with cisplatin] Fujiwara T, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1085–8 **(Jpn)**
[Expression of HCV genes using adenovirus vector with CAG promoter] Makimura M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:91–4 (9 ref.) **(Jpn)**
[Gene expression using adenovirus vector] Kanegae Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2525–31 (11 ref.) **(Jpn)**
[Expression of a gene encoding the porcine rotavirus VP7 capsid using a nondefective recombinant adenoviral genome] Doronin KK, et al. **Mol Gen Mikrobiol Virusol** 1995 Oct–Dec;(4):35–9 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

An adenovirus-herpes simplex virus glycoprotein B recombinant (Ad-HSV.gB) protects mice against a vaccinia HSV.gB and HSV challenge. Endresz V, et al. **Acta Microbiol Immunol Hung** 1995;42(3):247–54
Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Juillard V, et al. **Eur J Immunol** 1995 Dec;25(12):3467–73
Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. McCoy RD, et al. **Hum Gene Ther** 1995 Dec;6(12):1553–60
Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Van Ginkel FW, et al. **Hum Gene Ther** 1995 Jul;6(7):895–903
FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Vilquin JT, et al. **Hum Gene Ther** 1995 Nov; 6(11):1391–401
A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro. Morgan SM, et al. **J Virol** 1996 Apr;70(4):2394–402
Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. Yang Y, et al. **J Virol** 1996 Sep;70(9):6370–7
Immunomodulation to enhance gene therapy [comment] Wilson C, et al. **Nat Med** 1995 Sep;1(9):887–9. Comment on: Nat Med 1995 Sep;1(9):890–3.
Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung [see comments] Yang Y, et al. **Nat Med** 1995 Sep;1(9):890–3. Comment in: Nat Med 1995 Sep;1(9):887–9.
Occurrence of haemagglutination-inhibition antibodies against egg drop syndrome 1976 virus in broilers. Singh JK, et al. **Trop Anim Health Prod** 1995 Aug;27(3):167–70
Immunization trial of cats with a replication-defective adenovirus type 5 expressing the ENV gene of feline immunodeficiency virus. Gonin P, et al. **Vet Microbiol** 1995 Aug;45(4):393–401

ISOLATION & PURIFICATION

Natural infection with attaching and effacing Escherichia coli and adenovirus in the intestine of a pigeon with diarrhea. Wada Y, et al. **J Vet Med Sci** 1995 Jun;57(3):531–3
Seasonal distribution of adenoviruses, enteroviruses and reoviruses in urban river water. Tani N, et al. **Microbiol Immunol** 1995;39(8):577–80
Evaluation of WHO monoclonal antibody kit for diagnosis of acute respiratory viral infections. Khairullah NS, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):263–7
Coinfection of a bearded dragon, Pogona vitticeps, with adenovirus- and dependovirus-like viruses. Jacobson ER, et al. **Vet Pathol** 1996 May;33(3):343–6
Systemic adenovirus infection associated with high mortality in mule deer (Odocoileus hemionus) in California. Woods LW, et al. **Vet Pathol** 1996 Mar;33(2):125–32
Bovine adenovirus type 10: properties of viruses isolated from cases of bovine haemorrhagic enterocolitis. Adair BM, et al. **Vet Rec** 1996 Mar 16;138(11):250–2
Enteritis associated with adenovirus-like particles in a Spanish kid. Orós J, et al. **Vet Rec** 1996 Jan 13;138(2):43–4

METABOLISM

In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Blagosklonny MV, et al. **Int J Cancer** 1996 Jul 29;67(3):386–92
Abortive initiation and first bond formation at an activated adenovirus E4 promoter. Jiang Y, et al. **J Biol Chem** 1995 Nov 10;270(45):27332–8
Virus-mediated release of endosomal content in vitro: different behavior of adenovirus and rhinovirus serotype 2. Prchla E, et al. **J Cell Biol** 1995 Oct;131(1):111–23
Analysis of early region 3 mutants of mouse adenovirus type 1. Beard CW, et al. **J Virol** 1996 Sep;70(9):5867–74
Structural limitations of the Ad5 E1A 12S nuclear localization signal. Douglas JL, et al. **Virology** 1996 Jun 15;220(2):339–49

PATHOGENICITY

Model systems for studying the effects of adenovirus E3 genes on virulence in vivo. Horwitz MS, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):195–211 (63 ref.)
Adenovirus serotype 1 does not act synergistically with Moraxella (Branhamella) catarrhalis to induce otitis media in the chinchilla. Bakaletz LO, et al. **Infect Immun** 1995 Oct;63(10):4188–90
Mouse adenovirus type 1 causes a fatal hemorrhagic encephalomyelitis in adult C57BL/6 but not BALB/c mice. Guida JD, et al. **J Virol** 1995 Dec;69(12):7674–81
Adenovirus and Epstein-Barr virus in lung disease. Hogg JC, et al. **Semin Respir Infect** 1995 Dec;10(4):244–53 (34 ref.)
Pathogenesis and immunogenicity of bovine adenovirus type 3 in cotton rats (Sigmodon hispidus). Mittal SK, et al. **Virology** 1995 Oct 20;213(1):131–9

PHYSIOLOGY

A research shortcut from a common cold virus to human cancer. Harlow E. **Cancer** 1996 Aug 1;78(3):558–65
Nuclear organization of replication and gene expression in adenovirus-infected cells. Bridge E, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):99–117 (86 ref.)
Virus assembly. D'Halluin JC. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):47–66 (145 ref.)
Adenovirus--an eternal archetype. Philipson L. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):1–24 (138 ref.)
Selective encapsidation of adenovirus DNA. Schmid SI, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):67–80 (45 ref.)
CD5-mediated specific delivery of DNA to T lymphocytes: compartmentalization augmented by adenovirus. Merwin JR, et al. **J Immunol Methods** 1995 Oct 26;186(2):257–66
A human cell line selected for resistance to adenovirus infection has reduced levels of the virus receptor. Freimuth P. **J Virol** 1996 Jun;70(6):4081–5
Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. Gall J, et al. **J Virol** 1996 Apr; 70(4):2116–23
Enhanced splicing of nonconsensus 3' splice sites late during adenovirus infection. Mühlemann O, et al. **J Virol** 1995 Nov;69(11):7324–7
Adenovirus uncoating and nuclear establishment are not affected by weak base amines. Rodríguez E, et al. **J Virol** 1996 Jun;70(6):3470–7
E1A promotes association between p300 and pRB in multimeric complexes required for normal biological activity. Wang HG, et al. **J Virol** 1995 Dec;69(12):7917–24
Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers. Weitzman MD, et al. **J Virol** 1996 Mar;70(3):1845–54
In vitro replication of a reptilian adenovirus. Ahne W, et al. **Vet Res** 1995;26(5–6):443–8

ULTRASTRUCTURE

Adenovirus structure by X-ray crystallography and electron microscopy. Stewart PL, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):25–38 (51 ref.)

ADENOVIRIDAE INFECTIONS

Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bertheau P, et al. **Bone Marrow Transplant** 1996 Feb;17(2):295–8 (14 ref.)

DIAGNOSIS

Polymerase chain reaction for rapid diagnosis of respiratory adenovirus infection. Morris DJ, et al. **J Infect** 1996 Mar; 32(2):113–7
Comparison of agar-gel precipitin responses among strains of fowl adenovirus using antigens prepared from chorioallantoic membranes and chicken kidney cell cultures. Takase K, et al. **J Vet Med Sci** 1995 Apr; 57(2):327–30
Adenovirus endocarditis [letter; comment] Keltz TN. **Lancet** 1996 Jan 13;347(8994):125. Comment on: Lancet 1995 Dec 9;346(8989):1532.

DRUG THERAPY

Treatment of adenoviral pneumonitis with intravenous ribavirin and immunoglobulin. Sabroe I, et al. **Thorax** 1995 Nov;50(11):1219–20

ENZYMOLOGY

Adenovirus endopeptidase and its role in virus infection. Weber JM. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):227–35 (36 ref.)

EPIDEMIOLOGY

Two outbreaks of adenovirus type 8 keratoconjunctivitis with different outcome. Tabery HM. **Acta Ophthalmol Scand** 1995 Aug;73(4):358–60
Gastrointestinal adenovirus infections in a tertiary referral centre in Saudi Arabia. Akhter J, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):707–10

ETIOLOGY

Adenovirus pneumonia in lung transplant recipients. Ohori NP, et al. **Hum Pathol** 1995 Oct;26(10):1073–9
Pathogenesis and immunogenicity of bovine adenovirus type 3 in cotton rats (Sigmodon hispidus). Mittal SK, et al. **Virology** 1995 Oct 20;213(1):131–9

IMMUNOLOGY

Commentary: severe varicella/zoster and adenovirus infections in immunocompromised patients [comment] Weir WR. **Thorax** 1995 Nov;50(11):1222–3. Comment on: Thorax 1995 Apr;50(4):422–3. Comment on: Thorax 1995 Nov;50(11):1221–2.

METABOLISM

Astrocytes infected with replication-defective adenovirus containing a secreted form of CNTF or NT3 show enhanced support of neuronal populations in vitro. Smith GM, et al. **Exp Neurol** 1996 May;139(1):156–66
Expression of human interleukin-1 receptor antagonist in mouse lungs using a recombinant adenovirus: effects on vector-induced inflammation. McCoy RD, et al. **Gene Ther** 1995 Sep;2(7):437–42

PHYSIOPATHOLOGY

Susceptibility and signs associated with mouse adenovirus type 1 infection of adult outbred Swiss mice. Kring SC, et al. **J Virol** 1995 Dec;69(12):8084–8

PREVENTION & CONTROL

The effects of corticosteroids of adenoviral replication. Romanowski EG, et al. **Arch Ophthalmol** 1996 May; 114(5):581–5
Approaches to food-based vaccines for domestic chickens. Bensink Z, et al. **Vet Microbiol** 1995 Sep;46(1–3):29–35

TRANSMISSION

Nosocomial transmission of epidemic keratoconjunctivitis to food handlers in a nursing home. Chhabra BK. **J Am Geriatr Soc** 1995 Dec;43(12):1392–3

VETERINARY

Combined adenovirus and rotavirus enteritis with Escherichia coli septicemia in an emu chick (Dromaius novaehollandiae). Hines ME 2nd, et al. **Avian Dis** 1995 Jul–Sep;39(3):646–51
Immunosuppressive potential and pathogenicity of an avian adenovirus isolate involved in hydropericardium syndrome in broilers. Naeem K, et al. **Avian Dis** 1995 Oct–Dec; 39(4):723–8
Bovine adenovirus type 10 identified in fatal cases of adenovirus-associated enteric disease in cattle by in situ hybridization. Smyth JA, et al. **J Clin Microbiol** 1996 May; 34(5):1270–4
Gross and histologic lesions of adenovirus group I in guinea fowl. Charlton BR, et al. **J Vet Diagn Invest** 1995 Oct; 7(4):552–4
Natural infection with attaching and effacing Escherichia coli and adenovirus in the intestine of a pigeon with diarrhea. Wada Y, et al. **J Vet Med Sci** 1995 Jun;57(3):531–3
Pathogenesis of type II avian adenovirus infection in turkeys: in vivo immune cell tropism and tissue distribution of the virus. Suresh M, et al. **J Virol** 1996 Jan;70(1):30–6
Occurrence of haemagglutination-inhibition antibodies against egg drop syndrome 1976 virus in broilers. Singh JK, et al. **Trop Anim Health Prod** 1995 Aug;27(3):167–70
Coinfection of a bearded dragon, Pogona vitticeps, with adenovirus- and dependovirus-like viruses. Jacobson ER, et al. **Vet Pathol** 1996 May;33(3):343–6

ADENOVIRIDAE INFECTIONS

Disseminated adenovirus infection associated with cutaneous and visceral hemorrhages in a nursing piglet. Tang KN, et al. **Vet Pathol** 1995 Jul;32(4):433–7

Systemic adenovirus infection associated with high mortality in mule deer (Odocoileus hemionus) in California. Woods LW, et al. **Vet Pathol** 1996 Mar;33(2):125–32

Bovine adenovirus type 10: properties of viruses isolated from cases of bovine haemorrhagic enterocolitis. Adair BM, et al. **Vet Rec** 1996 Mar 16;138(11):250–2

Enteritis associated with adenovirus–like particles in a Spanish kid. Orós J, et al. **Vet Rec** 1996 Jan 13;138(2):43–4

Pathogenicity of quail's inclusion body hepatitis virus (avian adenovirus–1) for Japanese quails and broiler chicks. Singh A, et al. **Vet Res Commun** 1995;19(6):545–51

VIROLOGY

Nuclear organization of replication and gene expression in adenovirus–infected cells. Bridge E, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 1):99–117 (86 ref.)

Enteric adenoviruses. Mautner V, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 3):229–82 (189 ref.)

Role of adenovirus structural components in the regulation of adenovirus infection. Russell WC, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 1):81–98 (78 ref.)

Studies of adenovirus–induced eye disease in the rabbit model. Trousdale MD, et al. **Invest Ophthalmol Vis Sci** 1995 Dec;36(13):2740–8

Pathology and immunogenicity in the cotton rat (Sigmodon hispidus) model after infection with a bovine adenovirus type 3 recombinant virus expressing the firefly luciferase gene. Mittal SK, et al. **J Gen Virol** 1996 Jan;77 (Pt 1):1–9

Spontaneous, persistent infection of a B–cell lymphoma with adenovirus. Flomenberg P, et al. **J Med Virol** 1996 Mar; 48(3):267–72

The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. Sparer TE, et al. **J Virol** 1996 Apr;70(4):2431–9

Expression of early and late adenoviral proteins in fatal adenovirus bronchopneumonia. Ladenheim HS, et al.
Pediatr Pathol Lab Med 1995 Mar–Apr;15(2):291–8

ADENOVIRUS E1 PROTEINS

DRUG EFFECTS

Induction of polyploidy in adenovirus E1–transformed cells by the mitotic inhibitor colcemid. Kranenburg O, et al. **Virus Res** 1996 Feb;40(2):185–90

GENETICS

Lack of persistence of E1– recombinant adenoviral vectors containing a temperature–sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Fang B, et al. **Gene Ther** 1996 Mar;3(3):217–22

The constitutive expression of the immunomodulatory gp19k protein in E1–, E3– adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Lee MG, et al. **Gene Ther** 1995 Jun;2(4):256–62

Trans–complementation of E1–deleted adenovirus: a new vector to reduce the possibility of codissemination of wild–type and recombinant adenoviruses. Imler JL, et al. **Hum Gene Ther** 1995 Jun;6(6):711–21

Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Krougliak V, et al. **Hum Gene Ther** 1995 Dec;6(12):1575–86

A gene transfer vector–cell line system for complete functional complementation of adenovirus early regions E1 and E4. Brough DE, et al. **J Virol** 1996 Sep;70(9):6497–501

Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293–derived cell line expressing a minimal E4 functional unit. Yeh P, et al. **J Virol** 1996 Jan; 70(1):559–65

Second–generation adenovirus vectors. Wang Q, et al.
Nat Med 1996 Jun;2(6):714–6 (36 ref.)

[Inheritable phenotypic normalization of rodent cells transformed by simian adenovirus SA7 E1 oncogenes by singled–stranded oligonucleotides complementary to a long region of integrated oncogenes] Grineva NI, et al.
Genetika 1995 Aug;31(8):1043–51 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Hepatitis B virus X protein partially substitutes for E1A transcriptional function during adenovirus infection. Schaack J, et al. **Virology** 1996 Feb 15;216(2):425–30

ADENOVIRUS E1A PROTEIN DOMAIN 3 see **ADENOVIRUS E1A PROTEINS**

ADENOVIRUS E1A PROTEINS

ANALYSIS

Expression of early and late adenoviral proteins in fatal adenovirus bronchopneumonia. Ladenheim HS, et al.
Pediatr Pathol Lab Med 1995 Mar–Apr;15(2):291–8

CHEMISTRY

E2F1 and E1A(12S) have a homologous activation domain regulated by RB and CBP. Trouche D, et al.
Proc Natl Acad Sci U S A 1996 Feb 20;93(4):1439–42

GENETICS

A novel chimera gene between EWS and E1A–F, encoding the adenovirus E1A enhancer–binding protein, in extraosseous Ewing's sarcoma. Urano F, et al.
Biochem Biophys Res Commun 1996 Feb 15;219(2):608–12

E1A—oncogene or tumor suppressor? [letter; comment] Frisch SM. **Bioessays** 1995 Nov;17(11):1002. Comment on: Bioessays 1995 Jul;17(7):621–9.

Adenovirus E1a–mediated tumor suppression by a c–erbB–2/neu–independent mechanism. Frisch SM, et al. **Cancer Res** 1995 Dec 1;55(23):5551–5

Modulation of E–cadherin localization in cells expressing wild–type E1A 12S or hypertransforming mutants. Gopalakrishnan S, et al. **Cell Growth Differ** 1995 Aug; 6(8):985–98

Induction of differentiation–regulated transcription factor Oct–6 specifically accompanies major histocompatibility complex class I down–regulation by E1A of oncogenic adenovirus type 12. Peeper DS, et al.
Cell Growth Differ 1995 Aug;6(8):977–84

Transcriptional modulation by the adenovirus E1A gene. Jones N. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):59–80 (118 ref.)

Functional domains of adenovirus E1A oncogenes which control interactions with effectors of cellular immunity. Raška K Jr. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):131–48 (85 ref.)

Transcriptional regulation of the adenovirus E1A gene. Yoshida K, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):113–30 (107 ref.)

Assignment of the ets–related transcription factor E1A–F gene (ETV4) to human chromosome region 17q21. Isobe M, et al. **Genomics** 1995 Jul 20;28(2):357–9

A genetic model for undifferentiated cell tumor formation: similar tumors formed by different cell lines transformed by the E1A oncogene. Ramón y Cajal S, et al.
Histol Histopathol 1995 Oct;10(4):811–20

Transcriptional repression by human adenovirus E1A N terminus/conserved domain 1 polypeptides in vivo and in vitro in the absence of protein synthesis. Song CZ, et al. **J Biol Chem** 1995 Oct 6;270(40):23263–7

Efficient nuclear localization and immortalizing ability, two functions dependent on the adenovirus type 5 (Ad5) E1A second exon, are necessary for cotransformation with Ad5 E1B but not with T24ras. Douglas JL, et al. **J Virol** 1995 Dec;69(12):8061–5

Reversal of malignancy by the adenovirus E1a gene. Frisch SM. **Mutat Res** 1996 Feb 19;350(1):261–6 (31 ref.)

E1A oncogene expression in target cells induces cytolytic susceptibility at a post–recognition stage in the interaction with killer lymphocytes. Cook JL, et al. **Oncogene** 1996 Aug 15;13(4):833–42

The first exon of Ad12 E1A excluding the transactivation domain mediates differential binding of COUP–TF and NF–kappa B to the MHC class I enhancer in transformed cells. Kushner DB, et al. **Oncogene** 1996 Jan 4;12(1):143–51

S–phase induction by adenovirus E1A requires activation of cdc25a tyrosine phosphatase. Spitkovsky D, et al.
Oncogene 1996 Jun 20;12(12):2549–54

Induction of apoptosis by tamoxifen–activation of a p53–estrogen receptor fusion protein expressed in E1A and T24 H–ras transformed p53–/– mouse embryo fibroblasts. Vater CA, et al. **Oncogene** 1996 Aug 15;13(4):739–48

Liposome–mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER–2/neu. Yu D, et al. **Oncogene** 1995 Oct 5; 11(7):1383–8

Titration of serine/arginine (SR) splicing factors during adenoviral infection modulates E1A pre–mRNA alternative splicing. Himmelspach M, et al. **RNA** 1995 Oct; 1(8):794–806

Phenotypic determinants of adenovirus E1A gene autoregulation: variable region between conserved coding domains 2 and 3. Hamid R, et al. **Virology** 1995 Nov 10; 213(2):666–70

DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309. Bett AJ, et al. **Virus Res** 1995 Nov; 39(1):75–82

[Activity and composition of transcription factor AP–1 in rat embryonal fibroblasts transformed by oncogenes E1A plus Ha–ras] Pospelova TV, et al. **Mol Biol (Mosk)** 1996 May–Jun;30(3):662–72 **(Rus)**

IMMUNOLOGY

Natural killer cell ontogeny in the athymic rat. Relationship between functional maturation and acquired resistance to E1A oncogene–expressing sarcoma cells. Cook JL, et al. **J Immunol** 1995 Dec 15;155(12):5512–8

Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor–specific CTL induced by peptide vaccination can lead to the inability to reject tumors. Toes RE, et al. **J Immunol** 1996 May 15; 156(10):3911–8

METABOLISM

The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct isoforms of the transcriptional co–activator, p300. Avantaggiati ML, et al. **EMBO J** 1996 May 1;15(9):2236–48

CBP–induced stimulation of c–Fos activity is abrogated by E1A. Bannister AJ, et al. **EMBO J** 1995 Oct 2; 14(19):4758–62

Differential interactions of the CREB/ATF family of transcription factors with p300 and adenovirus E1A. Lee JS, et al. **J Biol Chem** 1996 Jul 26;271(30):17666–74

Targeting of adenovirus E1A and E4–ORF3 proteins to nuclear matrix–associated PML bodies. Carvalho T, et al. **J Cell Biol** 1995 Oct;131(1):45–56

Dominant negative mutants of Myc inhibit cooperation of both Myc and adenovirus serotype–5 E1a with Ras. MacGregor D, et al. **J Cell Physiol** 1996 Apr;167(1):95–105

The CR1 and CR3 domains of the adenovirus type 5 E1A proteins can independently mediate activation of ATF–2. Duyndam MC, et al. **J Virol** 1996 Sep;70(9):5852–9

Cyclin–dependent kinases phosphorylate the adenovirus E1A protein, enhancing its ability to bind pRb and disrupt pRb–E2F complexes. Mal A, et al. **J Virol** 1996 May; 70(5):2911–21

E1A promotes association between p300 and pRB in multimeric complexes required for normal biological activity. Wang HG, et al. **J Virol** 1995 Dec;69(12):7917–24

The human papillomavirus type 16 E7 protein complements adenovirus type 5 E1A amino–terminus–dependent transactivation of adenovirus type 5 early genes and increases ATF and Oct–1 DNA binding activity. Wong HK, et al. **J Virol** 1996 Jan;70(1):332–40

Adenovirus E1A243 disrupts the ATF/CREB–YY1 complex at the mouse c–fos promoter. Zhou Q, et al. **J Virol** 1995 Dec;69(12):7402–9

Adenovirus E1A functions as a cofactor for retinoic acid receptor beta (RAR beta) through direct interaction with RAR beta. Folkers GE, et al. **Mol Cell Biol** 1995 Nov; 15(11):5868–78

Subregions of the adenovirus E1A transactivation domain target multiple components of the TFIID complex. Geisberg JV, et al. **Mol Cell Biol** 1995 Nov;15(11):6283–90

Adenovirus E1A proteins inhibit activation of transcription by p53. Steegenga WT, et al. **Mol Cell Biol** 1996 May; 16(5):2101–9

A p300/CBP–associated factor that competes with the adenoviral oncoprotein E1A. Yang XJ, et al. **Nature** 1996 Jul 25;382(6589):319–24

Viral transactivators specifically target distinct cellular protein kinases that phosphorylate the RNA polymerase II C–terminal domain. Herrmann CH, et al.
Nucleic Acids Res 1996 Feb 1;24(3):501–8

The CtBP binding domain in the adenovirus E1A protein controls CR1–dependent transactivation. Sollerbrant K, et al. **Nucleic Acids Res** 1996 Jul 1;24(13):2578–84

Bcl–2 and adenovirus E1B 19 kDA protein prevent E1A–induced processing of CPP32 and cleavage of poly(ADP–ribose) polymerase. Boulakia CA, et al.
Oncogene 1996 Feb 1;12(3):529–35

HPV–16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Massimi P, et al. **Oncogene** 1996 Jun 6;12(11):2325–30

The viral oncoproteins Ad5 E1A, HPV16 E7 and SV40 TAg bind a common region of the TBP–associated factor–110. Mazzarelli JM, et al. **Oncogene** 1995 Nov 2;11(9):1859–64

TATA–dependent repression of human immunodeficiency virus type–1 transcription by the adenovirus E1A 243R oncoprotein. Tsang SX, et al. **Oncogene** 1996 Feb 15; 12(4):819–26

Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C–terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Schaeper U, et al.
Proc Natl Acad Sci U S A 1995 Nov 7;92(23):10467–71

Repression of a matrix metalloprotease gene by E1A correlates with its ability to bind to cell type–specific transcription factor AP–2. Somasundaram K, et al.
Proc Natl Acad Sci U S A 1996 Apr 2;93(7):3088–93

Transcription factor TFIID is a direct functional target of the adenovirus E1A transcription–repression domain. Song CZ, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24; 92(22):10330–3

Structural limitations of the Ad5 E1A 12S nuclear localization signal. Douglas JL, et al. **Virology** 1996 Jun 15;220(2):339–49

PHARMACOLOGY

Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFbeta–treated cells. Mal A, et al. **Nature** 1996 Mar 21; 380(6571):262–5

PHYSIOLOGY

Regulation of viral and cellular gene expression by E1A proteins encoded by the oncogenic adenovirus type 12. Brockmann D, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):81–112 (221 ref.)

Adenovirus E1A: transcription regulation and alteration of cell growth control. Nevins JR.
Curr Top Microbiol Immunol 1995;199 (Pt 3):25–32 (39 ref.)

Regulation of p53–dependent apoptosis by E1A and E1B. White E. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):34–58 (103 ref.)

Assessing the role of E1A in the differential oncogenicity

of group A and group C human adenoviruses. Williams J, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):149–75 (134 ref.)
Adenovirus E1A proteins regulate phosphoenolpyruvate carboxykinase gene transcription through multiple mechanisms. Klemm DJ, et al. **J Biol Chem** 1996 Apr 5; 271(14):8082–8
Induction of DNA synthesis and apoptosis in cardiac myocytes by E1A oncoprotein. Liu Y, et al. **J Cell Biol** 1996 Apr;133(2):325–34
Transactivation of adenovirus E2-early promoter by E1A and E4 6/7 in the context of viral chromosome. Swaminathan S, et al. **J Mol Biol** 1996 May 24; 258(5):736–46
Adenovirus E4 open reading frame 4 protein autoregulates E4 transcription by inhibiting E1A transactivation of the E4 promoter. Bondesson M, et al. **J Virol** 1996 Jun; 70(6):3844–51
Adenovirus type 5 early region 4 is responsible for E1A-induced p53-independent apoptosis. Marcellus RC, et al. **J Virol** 1996 Sep;70(9):6207–15
Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. Shisler J, et al. **J Virol** 1996 Jan;70(1):68–77
Adenovirus E1A downregulates cJun- and JunB-mediated transcription by targeting their coactivator p300. Lee JS, et al. **Mol Cell Biol** 1996 Aug;16(8):4312–26
The dual effect of adenovirus type 5 E1A 13S protein on NF-kappaB activation is antagonized by E1B 19K. Schmitz ML, et al. **Mol Cell Biol** 1996 Aug;16(8):4052–63
Transcription factors RFX1/EF-C and ATF-1 associate with the adenovirus E1A-responsive element of the human proliferating cell nuclear antigen promoter. Labrie C, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3732–41
Repression of c-Jun-induced mouse major histocompatibility class I promoter (H-2Kb) activity by the Adenovirus type 12-unique 52R E1A protein. Brockmann D, et al. **Oncogene** 1996 Apr 18;12(8):1715–25
Altered AP-1/ATF complexes in adenovirus-E1-transformed cells due to E1A-dependent induction of ATF3. Hagmeyer BM, et al. **Oncogene** 1996 Mar 7;12(5):1025–32
The adenovirus E1A-associated 300 kDa adaptor protein counteracts the inhibition of the collagenase promoter by E1A and represses transformation. Smits PH, et al. **Oncogene** 1996 Apr 4;12(7):1529–35
Control of p53 expression by adenovirus 12 early region 1A and early region 1B 54K proteins. Grand RJ, et al. **Virology** 1996 Apr 1;218(1):23–34
E1A second exon requirements for induction of target cell susceptibility to lysis by natural killer cells: implications for the mechanism of action. Krantz CK, et al. **Virology** 1996 Mar 1;217(1):23–32

ADENOVIRUS E1B 19K PROTEIN see **ADENOVIRUS E1B PROTEINS**

ADENOVIRUS E1B PROTEINS

ANALYSIS

Expression of early and late adenoviral proteins in fatal adenovirus bronchopneumonia. Ladenheim HS, et al. **Pediatr Pathol Lab Med** 1995 Mar-Apr;15(2):291–8

BIOSYNTHESIS

Adenovirus early region 4 34-kilodalton protein directs the nuclear localization of the early region 1B 55-kilodalton protein in primate cells. Goodrum FD, et al. **J Virol** 1996 Sep;70(9):6323–35

GENETICS

The function of the octamer-binding site in the DRA promoter. Voliva CF, et al. **Immunogenetics** 1996; 43(1-2):20–6
A hydrophobic region within the adenovirus E1B 19 kDa protein is necessary for the transient inhibition of NF-kappaB activated by different stimuli. Limbourg FP, et al. **J Biol Chem** 1996 Aug 23;271(34):20392–8
Efficient nuclear localization and immortalizing ability, two functions dependent on the adenovirus type 5 (Ad5) E1A second exon, are necessary for cotransformation with Ad5 E1B but not with T24ras. Douglas JL, et al. **J Virol** 1995 Dec;69(12):8061–5
Functional substitution identifies a cell survival promoting domain common to adenovirus E1B 19 kDa and Bcl-2 proteins. Subramanian T, et al. **Oncogene** 1995 Dec 7; 11(11):2403–9

METABOLISM

Differential sensitivity to Ad5 E1B-21kD and Bcl-2 proteins of apoptin-induced versus p53-induced apoptosis. Zhuang SM, et al. **Carcinogenesis** 1995 Dec;16(12):2939–44
The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Han J, et al. **Genes Dev** 1996 Feb 15;10(4):461–77
Bcl-2 and adenovirus E1B 19 kDA protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase. Boulakia CA, et al. **Oncogene** 1996 Feb 1;12(3):529–35

PHARMACOLOGY

Induction of p53-independent apoptosis by hygromycin B: suppression by Bcl-2 and adenovirus E1B 19-kDa protein. Chen G, et al. **Exp Cell Res** 1995 Nov;221(1):55–9

PHYSIOLOGY

Control of p53-dependent apoptosis by E1B, Bcl-2, and Ha-ras proteins. White E, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:395–402
Functional similarity between adenovirus E1B 19-kDa protein and proteins encoded by Bcl-2 proto-oncogene and Epstein-Barr virus BHRF1 gene. Subramanian T, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):153–61 (52 ref.)
Regulation of p53-dependent apoptosis by E1A and E1B. White E. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):34–58 (103 ref.)
The dual effect of adenovirus type 5 E1A 13S protein on NF-kappaB activation is antagonized by E1B 19K. Schmitz ML, et al. **Mol Cell Biol** 1996 Aug;16(8):4052–63
Control of p53 expression by adenovirus 12 early region 1A and early region 1B 54K proteins. Grand RJ, et al. **Virology** 1996 Apr 1;218(1):23–34
Distinct modulation of p53 activity in transcription and cell-cycle regulation by the large (54 kDa) and small (21 kDa) adenovirus E1B proteins. Steegenga WT, et al. **Virology** 1995 Oct 1;212(2):543–54

ADENOVIRUS E2 PROTEINS

GENETICS

Mutational analysis of the adenovirus E2-early promoter in fission yeast Schizosaccharomyces pombe. Manohar CF, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):653–63
Regulation of adenovirus E2 transcription unit. Swaminathan S, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):177–94 (46 ref.)
Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Fang B, et al. **Gene Ther** 1996 Mar;3(3):217–22
Transactivation of adenovirus E2-early promoter by E1A and E4 6/7 in the context of viral chromosome. Swaminathan S, et al. **J Mol Biol** 1996 May 24; 258(5):736–46
Second-generation adenovirus vectors. Wang Q, et al. **Nat Med** 1996 Jun;2(6):714–6 (36 ref.)

PHYSIOLOGY

DNA-binding by oncoprotein E2a-Pbx1 is important for blocking differentiation but dispensable for fibroblast transformation. Kamps MP, et al. **Oncogene** 1996 Jan 4; 12(1):19–30
Cyclic AMP signaling is required for function of the N-terminal and CR1 domains of adenovirus E1A in Saccharomyces cerevisiae. Miller ME, et al. **Oncogene** 1995 Oct 19;11(8):1623–30

ADENOVIRUS E2A DNA-BINDING PROTEINS see **ADENOVIRUS E2 PROTEINS**

ADENOVIRUS E2A 72K PROTEIN see **ADENOVIRUS E2 PROTEINS**

ADENOVIRUS E2A PROTEINS see **ADENOVIRUS E2 PROTEINS**

ADENOVIRUS E2F PROTEINS see **ADENOVIRUS E2 PROTEINS**

ADENOVIRUS E3 19K PROTEIN see **ADENOVIRUS E3 PROTEINS**

ADENOVIRUS E3 PROTEINS

BIOSYNTHESIS

Tumor necrosis factor alpha increases expression of adenovirus E3 proteins. Deryckere F, et al. **Immunobiology** 1995 Jul;193(2-4):186–92 (16 ref.)
Analysis of early region 3 mutants of mouse adenovirus type 1. Beard CW, et al. **J Virol** 1996 Sep;70(9):5867–74
Early region 3 of adenovirus type 19 (subgroup D) encodes an HLA-binding protein distinct from that of subgroups B and C. Deryckere F, et al. **J Virol** 1996 May; 70(5):2832–41

DRUG EFFECTS

Tumor necrosis factor alpha increases expression of adenovirus E3 proteins. Deryckere F, et al. **Immunobiology** 1995 Jul;193(2-4):186–92 (16 ref.)

GENETICS

Model systems for studying the effects of adenovirus E3 genes on virulence in vivo. Horwitz MS, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):195–211 (63 ref.)
E3 transcription unit of adenovirus. Wold WS, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):237–74 (196 ref.)
Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35. Basler CF, et al. **Gene** 1996 May 8;170(2):249–54
The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Lee MG, et al. **Gene Ther** 1995 Jun;2(4):256–62
Genetic organization, size, and complete sequence of early region 3 genes of human adenovirus type 41. Yeh HY, et al. **J Virol** 1996 Apr;70(4):2658–63
Subgroup B adenovirus type 35 early region 3 mRNAs differ from those of the subgroup C adenoviruses. Basler CF, et al. **Virology** 1996 Jan 15;215(2):165–77
Sequence analysis of the E3 region and fiber gene of human adenovirus genome type 7h. Kajon AE, et al. **Virology** 1996 Jan 15;215(2):190–6

IMMUNOLOGY

Human adenovirus-specific CD8+ T-cell responses are not inhibited by E3-19K in the presence of gamma interferon. Flomenberg P, et al. **J Virol** 1996 Sep;70(9):6314–22

METABOLISM

Activation of transcription factor NF-kappaB by the adenovirus E3/19K protein requires its ER retention. Pahl HL, et al. **J Cell Biol** 1996 Feb;132(4):511–22

PHYSIOLOGY

Pathology and immunogenicity in the cotton rat (Sigmodon hispidus) model after infection with a bovine adenovirus type 3 recombinant virus expressing the firefly luciferase gene. Mittal SK, et al. **J Gen Virol** 1996 Jan;77 (Pt 1):1–9
The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. Sparer TE, et al. **J Virol** 1996 Apr;70(4):2431–9
The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. Tollefson AE, et al. **J Virol** 1996 Apr;70(4):2296–306
The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Tollefson AE, et al. **Virology** 1996 Jun 1;220(1):152–62

ADENOVIRUS E4 PROTEINS

GENETICS

Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes. Scaria A, et al. **Gene Ther** 1995 Jun;2(4):295–8
Characterization of an adenovirus gene transfer vector containing an E4 deletion. Armentano D, et al. **Hum Gene Ther** 1995 Oct;6(10):1343–53
Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Krougliak V, et al. **Hum Gene Ther** 1995 Dec;6(12):1575–86
A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. Brough DE, et al. **J Virol** 1996 Sep;70(9):6497–501
Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. Yeh P, et al. **J Virol** 1996 Jan; 70(1):559–65

METABOLISM

Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. Carvalho T, et al. **J Cell Biol** 1995 Oct;131(1):45–56
Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Dobner T, et al. **Science** 1996 Jun 7;272(5267):1470–3
A conserved region of unknown function participates in the recognition of E2F family members by the adenovirus E4 ORF 6/7 protein. Jost CA, et al. **Virology** 1996 Jun 1; 220(1):78–90

PHYSIOLOGY

Transactivation of adenovirus E2-early promoter by E1A and E4 6/7 in the context of viral chromosome. Swaminathan S, et al. **J Mol Biol** 1996 May 24; 258(5):736–46
Adenovirus early region 4 34-kilodalton protein directs the nuclear localization of the early region 1B 55-kilodalton protein in primate cells. Goodrum FD, et al. **J Virol** 1996 Sep;70(9):6323–35
Human adenovirus type 9 E4 open reading frame 1 encodes a cytoplasmic transforming protein capable of increasing the oncogenicity of CREF cells. Weiss RS, et al. **J Virol** 1996 Feb;70(2):862–72

ADENOVIRUS E4F PROTEIN see **ADENOVIRUS E4 PROTEINS**

ADENOVIRUS 2, HUMAN see **ADENOVIRUSES, HUMAN**

ADENOVIRUS INFECTIONS see **ADENOVIRIDAE**

INFECTIONS

ADENOVIRUS INFECTIONS, HUMAN

A model of latent adenovirus 5 infection in the guinea pig (Cavia porcellus). Vitalis TZ, et al. **Am J Respir Cell Mol Biol** 1996 Mar;14(3):225–31

The spectrum of adult adenovirus pneumonia. Retalis P, et al. **Chest** 1996 Jun;109(6):1656–7

[A 12-year-old girl with acute respiratory disease with pneumonia caused by adenovirus type 7] Wada Y, et al. **Kansenshogaku Zasshi** 1996 May;70(5):500–5 (Eng. Abstr.) **(Jpn)**

[Autopsy case of type-3 adenovirus pneumonia] Mizutani A, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10; 84(8):1325–6 **(Jpn)**

[Adenovirus hepatitis] Nishiyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):27–9 (3 ref.) **(Jpn)**

COMPLICATIONS

Adenoviral infections in children. Singh-Naz N, et al. **Adv Pediatr Infect Dis** 1996;11:365–88 (106 ref.)

Fatal adenovirus 32 infection in a bone marrow transplant recipient. Charles AK, et al. **J Clin Pathol** 1995 Aug; 48(8):779–81

DIAGNOSIS

Prospective study of adenovirus antigen detection in eye swabs by radioimmune dot-blot. Morris DJ, et al. **Eye** 1995; 9 (Pt 5):629–32

Adenovirus masquerading as microsporidia. Visvesvara GS, et al. **J Parasitol** 1996 Apr;82(2):316–9

[Rapid diagnosis of adenoviral conjunctivitis by enzyme-linked immunosorbent assay (Adenoclone)] Nakagawa H, et al. **Nippon Ganka Gakkai Zasshi** 1995 Oct; 99(10):1164–9 (Eng. Abstr.) **(Jpn)**

[The clinical and epidemiological characteristics of adenovirus infection in adults] Kolodii NA, et al. **Vrach Delo** 1995 Jan-Feb;(1–2):125–7 **(Rus)**

DRUG THERAPY

Intravenous ribavirin therapy for adenovirus gastroenteritis after bone marrow transplantation. Kapelushnik J, et al. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):110–2

Intravenous ribavirin therapy for disseminated adenovirus infection. McCarthy AJ, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):1003–4

EPIDEMIOLOGY

Genome analysis of adenovirus type 3 isolated in Japan. Shiao S, et al. **J Clin Microbiol** 1996 Feb;34(2):413–6

Adenovirus types 2, 8, and 37 associated with genital infections in patients attending a sexually transmitted disease clinic. Swenson PD, et al. **J Clin Microbiol** 1995 Oct;33(10):2728–31

Adenovirus cross-infection: a continuing problem. Klapper PE, et al. **J Hosp Infect** 1995 Jun;30 Suppl:262–7

Adenovirus infections in compromised and other patients at a tertiary referral centre in Saudi Arabia [letter] Akhter J, et al. **J Infect** 1995 Jul;31(1):85–6

[Adenoviruses from stool samples in hospital units. Comparison with main pathogens in gastroenteritis (rotavirus, Campylobacter, Salmonella)] Durepaire N, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):601–10 (22 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Adenovirus type 12-induced fragility of the human RNU2 locus requires U2 small nuclear RNA transcriptional regulatory elements. Bailey AD, et al. **Mol Cell Biol** 1995 Nov;15(11):6246–55

The transcriptionally competent U2 gene is necessary and sufficient for adenovirus type 12 induction of the fragile site at 17q21–22. Gargano S, et al. **Mol Cell Biol** 1995 Nov; 15(11):6256–61

IMMUNOLOGY

Virus-specific, antibody-secreting cells during upper respiratory infections. Mäkelä MJ, et al. **J Med Virol** 1995 Dec;47(4):416–20

Adenoviral pericarditis: high levels of interleukin 6 in pericardial fluid. Mistchenko AS, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):1007–9

PREVENTION & CONTROL

Possible consequences of shaking hands with your patients with epidemic keratoconjunctivitis. Azar MJ, et al. **Am J Ophthalmol** 1996 Jun;121(6):711–2

VIROLOGY

Genome analysis of adenovirus type 3 isolated in Japan. Shiao S, et al. **J Clin Microbiol** 1996 Feb;34(2):413–6

Adenovirus cross-infection: a continuing problem. Klapper PE, et al. **J Hosp Infect** 1995 Jun;30 Suppl:262–7

Adenovirus mixture isolated from the brain of an AIDS patient with encephalitis. Schnurr D, et al. **J Med Virol** 1995 Oct;47(2):168–71

Multiplex polymerase chain reaction for adenovirus and herpes simplex virus in eye swabs. Jackson R, et al. **J Virol Methods** 1996 Jan;56(1):41–8

Clinical viral infections and temporal bone histologic studies of patients with AIDS. Davis LE, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):695–701

Acute hemorrhagic cystitis by adenovirus type 11 with and without type 37 after kidney transplantation. Umekawa T, et al. **Urol Int** 1996;56(2):114–6

[Adenoviruses as causative agents in gastroenteritis] de Jong JC. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):536–41 (48 ref.) **(Dut)**

ADENOVIRUSES, AVIAN see **AVIADENOVIRUS**

ADENOVIRUSES, HUMAN

Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Gomez-Manzano C, et al. **Cancer Res** 1996 Feb 15; 56(4):694–9

Enteric adenoviruses. Mautner V, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):229–82 (189 ref.)

Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. Chen L, et al. **J Clin Invest** 1995 Dec; 96(6):2775–82

Adenoviruses as gene-delivery vehicles. Wilson JM. **N Engl J Med** 1996 May 2;334(18):1185–7 (0 ref.)

CHEMISTRY

Structure of the receptor binding domain of adenovirus type 5 fiber protein. Xia D, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):39–46 (17 ref.)

Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. Crawford-Miksza L, et al. **J Virol** 1996 Mar;70(3):1836–44

CLASSIFICATION

Acute hemorrhagic cystitis by adenovirus type 11 with and without type 37 after kidney transplantation. Umekawa T, et al. **Urol Int** 1996;56(2):114–6

DRUG EFFECTS

Enhanced reactivation of nitrous acid treated adenovirus is not associated with enhanced mutagenesis in pretreated with heavy metals HeLa cells. Piperakis SM. **Mutat Res** 1995 Dec;348(4):201–4

ENZYMOLOGY

Crystal structure of the human adenovirus proteinase with its 11 amino acid cofactor. Ding J, et al. **EMBO J** 1996 Apr 15;15(8):1778–83

The role of the adenovirus protease on virus entry into cells. Greber UF, et al. **EMBO J** 1996 Apr 15;15(8):1766–77

Different modes of inhibition of human adenovirus proteinase, probably a cysteine proteinase, by bovine pancreatic trypsin inhibitor. Brown MT, et al. **FEBS Lett** 1996 Jun 17;388(2-3):233–7

Electrophoretic and spectral characterization of wild type and mutant adenovirus protease. Keyvani-Amineh H, et al. **J Biol Chem** 1995 Oct 6;270(40):23250–3

Characterization of three components of human adenovirus proteinase activity in vitro. Mangel WF, et al. **J Biol Chem** 1996 Jan 5;271(1):536–43

Activation of the protease from human adenovirus type 2 is accompanied by a conformational change that is dependent on cysteine-104. Jones SJ, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1821–4

Crystallization and preliminary X-ray diffraction studies of the human adenovirus serotype 2 proteinase with peptide cofactor. Keefe LJ, et al. **Protein Sci** 1995 Aug;4(8):1658–60

The adenovirus protease is required for virus entry into host cells. Cotten M, et al. **Virology** 1995 Nov 10;213(2):494–502

Characterization of human adenovirus proteinase activity in disrupted virus particles. McGrath WJ, et al. **Virology** 1996 Mar 1;217(1):131–8

Adenovirus protease expressed in insect cells cleaves adenovirus proteins, ovalbumin and baculovirus protease in the absence of activating peptide. Keyvani-Amineh H, et al. **Virus Res** 1995 Jul;37(2):87–97

GENETICS

Mucosal immunization with a recombinant adenovirus vector induces local and systemic immunity and protection from herpes simplex virus. Gallichan WS, et al. **Adv Exp Med Biol** 1995;371B:1581–5

Efficiency and functional consequences of adenovirus-mediated in vivo gene transfer to normal and dystrophic (mdx) mouse diaphragm. Petrof BJ, et al. **Am J Respir Cell Mol Biol** 1995 Nov;13(5):508–17

B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 (Ad-B7) expression vector. Dessureault S, et al. **Ann Surg Oncol** 1996 May;3(3):317–24

Genome polymorphism of human adenoviruses of subgenus C. Adrian T. **Arch Virol** 1996;141(6):1021–31

Efficient regulation of gene expression by adenovirus vector-mediated delivery of the CRE recombinase. Sakai K, et al. **Biochem Biophys Res Commun** 1995 Dec 14; 217(2):393–401

Simultaneous suppression of progression marker genes in the highly malignant human melanoma cell line BLM after transfection with the adenovirus-5 E1A gene. van Groningen JJ, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):808–16

Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors. Neering SJ, et al. **Blood** 1996 Aug 15;88(4):1147–55

In vivo adenovirus vector-mediated transfer of the human thrombopoietin cDNA maintains platelet levels during radiation-and chemotherapy-induced bone marrow suppression. Ohwada A, et al. **Blood** 1996 Aug 1; 88(3):778–84

Defective interleukin six expression and responsiveness in human mammary cells transformed by an adeno 5/SV40 hybrid virus. Basolo F, et al. **Br J Cancer** 1996 Jun; 73(11):1356–61

Mammary tumors induced by human adenovirus type 9: a role for the viral early region 4 gene. Javier R, et al. **Breast Cancer Res Treat** 1996;39(1):57–67

Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Xu HJ, et al. **Cancer Res** 1996 May 15;56(10):2245–9

Adenovirus mediated gene transfer of vascular smooth muscle cells and endothelial cells in vitro. Zhou H, et al. **Chin Med J (Engl)** 1995 Jul;108(7):493–6

Enhanced adeno-associated virus vector expression by adenovirus protein-cationic liposome complex. A novel and high efficient way to introduce foreign DNA into endothelial cells. Zhou H, et al. **Chin Med J (Engl)** 1995 May;108(5):332–7

Novel adenovirus component system that transfects cultured cardiac cells with high efficiency. Kohout TA, et al. **Circ Res** 1996 Jun;78(6):971–7

The complete nucleotide sequence of the DNA of human adenovirus type 12. Sprengel J, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):189–274 (45 ref.)

E3 transcription unit of adenovirus. Wold WS, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):237–74 (196 ref.)

Modulation of gene expression by adenovirus transformation. Zantema A, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):1–23 (158 ref.)

Efficient transfer of regulated genes in adipocytes and hepatoma cells by the combination of liposomes and replication-deficient adenovirus. Meunier-Durmort C, et al. **Eur J Biochem** 1996 May 1;237(3):660–7

A human B-box-binding protein downregulated in adenovirus 5-transformed human cells. Kropotov AV, et al. **FEBS Lett** 1996 May 13;386(1):43–6

Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35. Basler CF, et al. **Gene** 1996 May 8;170(2):249–54

Cloning, sequence determination and functional expression of the genes encoding adenovirus type-4 polymerase and the terminal protein precursor. Stanglmaier M, et al. **Gene** 1996 Feb 12;168(2):177–82

Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants. Acsadi G, et al. **Gene Ther** 1994 Sep;1(5):338–40

Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexes. Ebbinghaus SW, et al. **Gene Ther** 1996 Apr;3(4):287–97

Addition of a short peptide ligand to the adenovirus fiber protein. Michael SI, et al. **Gene Ther** 1995 Nov;2(9):660–8

Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Yei S, et al. **Gene Ther** 1994 May;1(3):192–200

High-level tissue-specific expression of functional human factor VIII in mice. Connelly S, et al. **Hum Gene Ther** 1996 Jan 20;7(2):183–95

Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Elshami AA, et al. **Hum Gene Ther** 1996 Jan 20;7(2):141–8

Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Fallaux FJ, et al. **Hum Gene Ther** 1996 Jan 20; 7(2):215–22

A neural cell-type-specific expression system using recombinant adenovirus vectors. Hashimoto M, et al. **Hum Gene Ther** 1996 Jan 20;7(2):149–58

Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Kolls JK, et al. **Hum Gene Ther** 1996 Mar 1;7(4):489–97

Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Krougliak V, et al. **Hum Gene Ther** 1995 Dec;6(12):1575–86

Adenovirus-mediated interferon-gamma transfer inhibits growth of transplanted HTLV-1 Tax tumors in mice. Xu X, et al. **Hum Gene Ther** 1996 Mar 1;7(4):471–7

Adenovirus-mediated heme oxygenase-1 gene transfer into rabbit ocular tissues. Abraham NG, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2202–10

Ocular adenovirus gene transfer varies in efficiency and inflammatory response. Borrás T, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1282–93

In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells. Budenz DL, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2211–5

Adenovirus–mediated gene transfer of ornithine aminotransferase in cultured human retinal pigment epithelium. Sullivan DM, et al. **Invest Ophthalmol Vis Sci** 1996 Apr;37(5):766–74

Electrophoretic and spectral characterization of wild type and mutant adenovirus protease. Keyvani–Amineh H, et al. **J Biol Chem** 1995 Oct 6;270(40):23250–3

A hydrophobic region within the adenovirus E1B 19 kDa protein is necessary for the transient inhibition of NF–kappaB activated by different stimuli. Limbourg FP, et al. **J Biol Chem** 1996 Aug 23;271(34):20392–8

Localization of subunits of transcription factors IIE and IIF immediately upstream of the transcriptional initiation site of the adenovirus major late promoter. Robert F, et al. **J Biol Chem** 1996 Apr 12;271(15):8517–20

Genome analysis of adenovirus type 3 isolated in Japan. Shiao S, et al. **J Clin Microbiol** 1996 Feb;34(2):413–6

Replication–defective adenovirus type 5 as an in vitro and in vivo gene transfer vector in chickens. Adam M, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3153–7

An adenovirus recombinant expressing the spike glycoprotein of porcine respiratory coronavirus is immunogenic in swine. Callebaut P, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):309–13

Transactivation of adenovirus E2–early promoter by E1A and E4 6/7 in the context of viral chromosome. Swaminathan S, et al. **J Mol Biol** 1996 May 24; 258(5):736–46

A gene transfer vector–cell line system for complete functional complementation of adenovirus early regions E1 and E4. Brough DE, et al. **J Virol** 1996 Sep;70(9):6497–501

Constitutive episomal expression of polypeptide IX (pIX) in a 293–based cell line complements the deficiency of pIX mutant adenovirus type 5. Caravokyri C, et al. **J Virol** 1995 Nov;69(11):6627–33

Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. Chartier C, et al. **J Virol** 1996 Jul;70(7):4805–10

Early region 3 of adenovirus type 19 (subgroup D) encodes an HLA–binding protein distinct from that of subgroups B and C. Deryckere F, et al. **J Virol** 1996 May; 70(5):2832–41

Sequences regulating poly(A) site selection within the adenovirus major late transcription unit influence the interaction of constitutive processing factors with the pre–mRNA. Gilmartin GM, et al. **J Virol** 1996 Mar; 70(3):1775–83

Properties of the adenovirus IVa2 gene product, an effector of late–phase–dependent activation of the major late promoter. Lutz P, et al. **J Virol** 1996 Mar;70(3):1396–405

Tropism of human adenovirus type 5–based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. Torres JM, et al. **J Virol** 1996 Jun;70(6):3770–80

The human papillomavirus type 16 E7 protein complements adenovirus type 5 E1A amino–terminus–dependent transactivation of adenovirus type 5 early genes and increases ATF and Oct–1 DNA binding activity. Wong HK, et al. **J Virol** 1996 Jan;70(1):332–40

mRNA export correlates with activation of transcription in human subgroup C adenovirus–infected cells. Yang UC, et al. **J Virol** 1996 Jun;70(6):4071–80

Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. Yang Y, et al. **J Virol** 1996 Sep;70(9):6370–7

Genetic organization, size, and complete sequence of early region 3 genes of human adenovirus type 41. Yeh HY, et al. **J Virol** 1996 Apr;70(4):2658–63

Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293–derived cell line expressing a minimal E4 functional unit. Yeh P, et al. **J Virol** 1996 Jan; 70(1):559–65

Differential efficacy of adenoviral mediated gene transfer into cells from hematological cell lines and fresh hematological malignancies. Wattel E, et al. **Leukemia** 1996 Jan; 10(1):171–4

Adenovirus DNA replication in a reconstituted system. Coenjaerts FE, et al. **Methods Enzymol** 1995;262:548–60

Adenovirus type 12–induced fragility of the human RNU2 locus requires U2 small nuclear RNA transcriptional regulatory elements. Bailey AD, et al. **Mol Cell Biol** 1995 Nov;15(11):6246–55

Two regions within the DNA binding domain of nuclear factor I interact with DNA and stimulate adenovirus DNA replication independently. Dekker J, et al. **Mol Cell Biol** 1996 Aug;16(8):4073–80

The transcriptionally competent U2 gene is necessary and sufficient for adenovirus type 12 induction of the fragile site at 17q21–22. Gargano S, et al. **Mol Cell Biol** 1995 Nov; 15(11):6256–61

Evidence for the involvement of a nuclear NF–kappa B inhibitor in global down–regulation of the major histocompatibility complex class I enhancer in adenovirus type 12–transformed cells. Liu X, et al. **Mol Cell Biol** 1996 Jan;16(1):398–404

The dual effect of adenovirus type 5 E1A 13S protein on NF–kappaB activation is antagonized by E1B 19K. Schmitz ML, et al. **Mol Cell Biol** 1996 Aug;16(8):4052–63

Adenovirus E1A proteins inhibit activation of transcription by p53. Steegenga WT, et al. **Mol Cell Biol** 1996 May; 16(5):2101–9

Splicing of two weak 3'splice sites from the adenovirus major late region is enhanced in nuclear extracts from adenovirus infected cells. Mühlemann O, et al. **Nucleic Acids Symp Ser** 1995;(33):220–3

Intraamniotic administration of an adenoviral vector for gene transfer to fetal sheep and mouse tissues. Holzinger A, et al. **Pediatr Res** 1995 Dec;38(6):844–50

Improved adenovirus packaging cell lines to support the growth of replication–defective gene–delivery vectors. Amalfitano A, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3352–6

Efficient generation of recombinant adenoviruses using adenovirus DNA–terminal protein complex and a cosmid bearing the full–length virus genome. Miyake S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1320–4

Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Zhang JF, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30; 93(9):4513–8

Recombinant adenovirus vector expressing wild–type p53 is a potent inhibitor of prostate cancer cell proliferation. Srivastava S, et al. **Urology** 1995 Dec;46(6):843–8

Subgroup B adenovirus type 35 early region 3 mRNAs differ from those of the subgroup C adenoviruses. Basler CF, et al. **Virology** 1996 Jan 15;215(2):165–77

Immunological adenovirus variant strains of subgenus D: comparison of the hexon and fiber sequences. Eiz B, et al. **Virology** 1995 Nov 10;213(2):313–20

Phenotypic determinants of adenovirus E1A gene autoregulation: variable region between conserved coding domains 2 and 3. Hamid R, et al. **Virology** 1995 Nov 10; 213(2):666–70

Sequence analysis of the E3 region and fiber gene of human adenovirus genome type 7h. Kajon AE, et al. **Virology** 1996 Jan 15;215(2):190–6

Induction of antibodies protecting against transmissible gastroenteritis coronavirus (TGEV) by recombinant adenovirus expressing TGEV spike protein. Torres JM, et al. **Virology** 1995 Nov 10;213(2):503–16

Selective loss of unmethylated segments of integrated Ad12 genomes in revertants of the adenovirus type 12–transformed cell line T637. Orend G, et al. **Virus Res** 1995 Oct;38(2–3):261–7

[Gene therapy in ophthalmology] Mashhour B. **Bull Acad Natl Med** 1996 Mar;180(3):645–57 (Eng. Abstr.) (Fre)

GROWTH & DEVELOPMENT

293 cell lines that inducibly express high levels of adenovirus type 5 precursor terminal protein. Langer SJ, et al. **Virology** 1996 Jul 1;221(1):172–9

IMMUNOLOGY

Prospective study of adenovirus antigen detection in eye swabs by radioimmune dot–blot. Morris DJ, et al. **Eye** 1995; 9 (Pt 5):629–32

Anti–T cell receptor monoclonal antibody prolongs transgene expression following adenovirus–mediated in vivo gene transfer to mouse synovium. Sawchuk SJ, et al. **Hum Gene Ther** 1996 Mar 1;7(4):499–506

Common epitope on protein VI of enteric adenoviruses from subgenera A and F. Grydsuk JD, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1811–9

Human T cell proliferative response to polypeptides from adenovirus type 2 [letter; comment] Souberbielle BE, et al. **J Infect Dis** 1995 Nov;172(5):1421–2. Comment on: J Infect Dis 1995 May;171(5):1090–6.

Virus–specific, antibody–secreting cells during upper respiratory infections. Mäkelä MJ, et al. **J Med Virol** 1995 Dec;47(4):416–20

Early region 3 of adenovirus type 19 (subgroup D) encodes an HLA–binding protein distinct from that of subgroups B and C. Deryckere F, et al. **J Virol** 1996 May; 70(5):2832–41

Human adenovirus–specific CD8+ T–cell responses are not inhibited by E3–19K in the presence of gamma interferon. Flomenberg P, et al. **J Virol** 1996 Sep;70(9):6314–22

Antigenic sites on the receptor–binding domain of human adenovirus type 2 fiber. Fender P, et al. **Virology** 1995 Dec 1;214(1):110–7

A replication–defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Xiang ZQ, et al. **Virology** 1996 May 1;219(1):220–7

ISOLATION & PURIFICATION

Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bertheau P, et al. **Bone Marrow Transplant** 1996 Feb;17(2):295–8 (14 ref.)

Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Huyghe BG, et al. **Hum Gene Ther** 1995 Nov;6(11):1403–16

Genome analysis of adenovirus type 3 isolated in Japan. Shiao S, et al. **J Clin Microbiol** 1996 Feb;34(2):413–6

Adenovirus types 2, 8, and 37 associated with genital infections in patients attending a sexually transmitted disease clinic. Swenson PD, et al. **J Clin Microbiol** 1995 Oct;33(10):2728–31

Spontaneous, persistent infection of a B–cell lymphoma with adenovirus. Flomenberg P, et al. **J Med Virol** 1996 Mar; 48(3):267–72

Adenovirus mixture isolated from the brain of an AIDS patient with encephalitis. Schnurr D, et al. **J Med Virol** 1995 Oct;47(2):168–71

Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus–contaminating recombinant adenovirus stocks. Dion LD, et al. **J Virol Methods** 1996 Jan;56(1):99–107

Multiplex polymerase chain reaction for adenovirus and herpes simplex virus in eye swabs. Jackson R, et al. **J Virol Methods** 1996 Jan;56(1):41–8

Adenovirus surveillance, 1982–1993, Japan. A report of the National Epidemiological Surveillance of Infectious Agents in Japan. Yamadera S, et al. **Jpn J Med Sci Biol** 1995 Aug; 48(4):199–210

METABOLISM

Protein ligands of the human adenovirus type 2 outer capsid identified by biopanning of a phage–displayed peptide library on separate domains of wild–type and mutant penton capsomers. Hong SS, et al. **EMBO J** 1995 Oct 2; 14(19):4714–27

Constitutive episomal expression of polypeptide IX (pIX) in a 293–based cell line complements the deficiency of pIX mutant adenovirus type 5. Caravokyri C, et al. **J Virol** 1995 Nov;69(11):6627–33

Adenovirus E1A activates cyclin A gene transcription in the absence of growth factors through interaction with p107. Zerfass K, et al. **J Virol** 1996 Apr;70(4):2637–42

Adenovirus DNA replication in a reconstituted system. Coenjaerts FE, et al. **Methods Enzymol** 1995;262:548–60

Host cell reactivation of irradiated adenovirus in UV–sensitive Chinese hamster ovary cell mutants. Arnold WR, et al. **Mutagenesis** 1996 Jan;11(1):89–94

Bcl–2 and adenovirus E1B 19 kDA protein prevent E1A–induced processing of CPP32 and cleavage of poly(ADP–ribose) polymerase. Boulakia CA, et al. **Oncogene** 1996 Feb 1;12(3):529–35

Human adenovirus serotype 3 (Ad3) and the Ad3 fiber protein bind to a 130–kDa membrane protein on HeLa cells. Di Guilmi AM, et al. **Virus Res** 1995 Sep;38(1):71–81

PATHOGENICITY

Oncogenicity of human papillomavirus– or adenovirus–transformed cells correlates with resistance to lysis by natural killer cells. Routes JM, et al. **J Virol** 1995 Dec;69(12):7639–47

PHYSIOLOGY

Cytokine production by cultured human bronchial epithelial cells infected with a replication–deficient adenoviral gene transfer vector or wild–type adenovirus type 5. Noah TL, et al. **Am J Respir Cell Mol Biol** 1996 May;14(5):417–24

The effects of corticosteroids of adenoviral replication. Romanowski EG, et al. **Arch Ophthalmol** 1996 May; 114(5):581–5

Regulation of viral and cellular gene expression by E1A proteins encoded by the oncogenic adenovirus type 12. Brockmann D, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):81–112 (221 ref.)

Abortive adenovirus infection and host range determinants. Lucher LA. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):119–52 (148 ref.)

Molecular determinants of adenovirus tropism. Mei YF, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):213–28 (55 ref.)

Role of adenovirus structural components in the regulation of adenovirus infection. Russell WC, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):81–98 (78 ref.)

Assessing the role of E1A in the differential oncogenicity of group A and group C human adenoviruses. Williams J, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):149–75 (134 ref.)

Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Doucas V, et al. **Genes Dev** 1996 Jan 15;10(2):196–207

Effect of adenoviral vector infection on cell proliferation in cultured primary human airway epithelial cells. Teramoto S, et al. **Hum Gene Ther** 1995 Aug;6(8):1045–53

Tyrosine kinase–dependent release of an adenovirus preterminal protein complex from the nuclear matrix. Angeletti PC, et al. **J Virol** 1996 May;70(5):3060–7

The CR1 and CR3 domains of the adenovirus type 5 E1A proteins can independently mediate activation of ATF–2. Duyndam MC, et al. **J Virol** 1996 Sep;70(9):5852–9

Adenovirus early region 4 34–kilodalton protein directs the nuclear localization of the early region 1B 55–kilodalton protein in primate cells. Goodrum FD, et al. **J Virol** 1996 Sep;70(9):6323–35

Interaction of the adenovirus L1 52/55–kilodalton protein with the IVa2 gene product during infection. Gustin KE, et al. **J Virol** 1996 Sep;70(9):6463–7

Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. Huang S, et al. **J Virol** 1996 Jul; 70(7):4502–8

Adenovirus type 5 early region 4 is responsible for E1A–induced p53–independent apoptosis. Marcellus RC, et al. **J Virol** 1996 Sep;70(9):6207–15

ADENOVIRUSES, HUMAN

Transcriptional transactivation of parvovirus B19 promoters in nonpermissive human cells by adenovirus type 2. Ponnazhagan S, et al. **J Virol** 1995 Dec;69(12):8096–101

Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105–Rb and induction of DNA synthesis. Shisler J, et al. **J Virol** 1996 Jan;70(1):68–77

The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. Sparer TE, et al. **J Virol** 1996 Apr;70(4):2431–9

The adenovirus death protein (E3–11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. Tollefson AE, et al. **J Virol** 1996 Apr;70(4):2296–306

Human adenovirus type 9 E4 open reading frame 1 encodes a cytoplasmic transforming protein capable of increasing the oncogenicity of CREF cells. Weiss RS, et al. **J Virol** 1996 Feb;70(2):862–72

Control of p53 expression by adenovirus 12 early region 1A and early region 1B 54K proteins. Grand RJ, et al. **Virology** 1996 Apr 1;218(1):23–34

E1A second exon requirements for induction of target cell susceptibility to lysis by natural killer cells: implications for the mechanism of action. Krantz CK, et al. **Virology** 1996 Mar 1;217(1):23–32

The E3–11.6–kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Tollefson AE, et al. **Virology** 1996 Jun 1;220(1):152–62

RADIATION EFFECTS

Host cell reactivation of irradiated adenovirus in UV–sensitive Chinese hamster ovary cell mutants. Arnold WR, et al. **Mutagenesis** 1996 Jan;11(1):89–94

ULTRASTRUCTURE

Adenovirus masquerading as microsporidia. Visvesvara GS, et al. **J Parasitol** 1996 Apr;82(2):316–9

[Adenoviruses as causative agents in gastroenteritis] de Jong JC. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):536–41 (48 ref.) **(Dut)**

ADENOVIRUSES, MAMMALIAN see **MASTADENOVIRUS**

ADENOVIRUSES, SIMIAN

GENETICS

[Inheritable phenotypic normalization of rodent cells transformed by simian adenovirus SA7 E1 oncogenes by singled–stranded oligonucleotides complementary to a long region of integrated oncogenes] Grineva NI, et al. **Genetika** 1995 Aug;31(8):1043–51 (Eng. Abstr.) **(Rus)**

ADENYL CYCLASE

AGONISTS

Effects of parathyroid hormone and agonists of the adenylyl cyclase and protein kinase C pathways on bone cell proliferation. Sabatini M, et al. **Bone** 1996 Jan;18(1):59–65

Tubulin stimulates adenylyl cyclase activity in rat striatal membranes via transfer of guanine nucleotide to Gs protein. Hatta S, et al. **Brain Res** 1995 Dec 15;704(1):23–30

Adrenocorticotropic hormone activation of adenylate cyclase in raphe neurons: multiple regulatory pathways control serotonergic neuronal differentiation. Eaton MJ, et al. **J Neurobiol** 1995 Dec;28(4):465–81

Post–translational regulation of neuronal acetylcholine receptors stably expressed in a mouse fibroblast cell line. Rothhut B, et al. **J Neurobiol** 1996 Jan;29(1):115–25

Experimental studies of the effect of Forskolin on the lowering of intraocular pressure. Zeng S, et al. **Yen Ko Hsueh Pao** 1995 Sep;11(3):173–6

ANALYSIS

A novel calmodulin–binding protein, belonging to the WD–repeat family, is localized in dendrites of a subset of CNS neurons. Castets F, et al. **J Cell Biol** 1996 Aug; 134(4):1051–62

Adrenergic desensitization in left ventricle from streptozotocin diabetic swine. Roth DA, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2315–25

Flagellar adenylyl cyclases in Chlamydomonas. Zhang Y, et al. **Methods Cell Biol** 1995;47:459–65

Yeast adenylyl cyclase assays. Mintzer KA, et al. **Methods Enzymol** 1995;255:468–76

Immunocytochemical studies of the Gi protein mediated muscarinic receptor–adenylyl cyclase system. Schulze W, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):161–8

Cytochemical localization of adenylyl cyclase activity within the sensory epithelium of the trout saccule. Drescher MJ, et al. **Neurosci Lett** 1995 Aug 25;196(3):145–8

Protein kinase C regulation of the adenylyl cyclase system in rat prostatic epithelium. Carmena MJ, et al. **Prostate** 1995 Oct;27(4):204–11

ANTAGONISTS & INHIBITORS

Role of protein synthesis on ethanol regulation of adenylyl cyclase activity in wild–type S49 murine lymphoma cells. Nakamura J. **Alcohol Clin Exp Res** 1996 Apr;20(2):302–6

Insulin and vasopressin elicit inhibition of cholera–toxin–stimulated adenylate cyclase activity in both hepatocytes and the P9 immortalized hepatocyte cell line through an action involving protein kinase C. Zeng L, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):769–74

Khellin, but not 8–methoxypsoralen, inhibits adenylyl cyclase system in HeLa cells. Di Stefano A, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):162–6

Stable GDP analog–induced inactivation of G(i) proteins promotes cardiac adenylyl cyclase inhibition by guanosine 5'–(beta gamma–imino)triphosphate and muscarinic acetylcholine receptor. Piacentini L, et al. **Biochim Biophys Acta** 1996 Jun 13;1282(1):11–6

Rat striatal muscarinic receptors coupled to the inhibition of adenylyl cyclase activity: potent block by the selective m4 ligand muscarinic toxin 3 (MT3). Olianas MC, et al. **Br J Pharmacol** 1996 May;118(2):283–8

Cannabinoid receptor down–regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940–tolerant mice. Fan F, et al. **Brain Res** 1996 Jan 8;706(1):13–20

Thiopentone inhibits beta–adrenergic responses in myocardial tissue. Thurston TA, et al. **Can J Anaesth** 1995 Oct; 42(10):944–7

Impairment of adenylyl cyclase signal transduction in mecobalamin–deficient rats. Hatta S, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):351–8

The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. Bayewitch M, et al. **FEBS Lett** 1995 Nov 13;375(1–2):143–7

The controversial role of cAMP on amnionic prostaglandin release: effect of adenylate cyclase inhibition. Vesce F, et al. **Gynecol Obstet Invest** 1995;40(2):73–9

Cytoplasmic domain of natriuretic peptide receptor–C inhibits adenylyl cyclase. Involvement of a pertussis toxin–sensitive G protein. Anand–Srivastava MB, et al. **J Biol Chem** 1996 Aug 9;271(32):19324–9

(–)–Delta9–tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor–mediated inhibition of adenylyl cyclase. Bayewitch M, et al. **J Biol Chem** 1996 Apr 26; 271(17):9902–5

Cannabinoid inhibition of adenylate cyclase–mediated signal transduction and interleukin 2 (IL–2) expression in the murine T–cell line, EL4.IL–2. Condie R, et al. **J Biol Chem** 1996 May 31;271(22):13175–83

2',5'–Dideoxyadenosine 3'–polyphosphates are potent inhibitors of adenylyl cyclases. Désaubry L, et al. **J Biol Chem** 1996 Feb 2;271(5):2380–2

Inhibition of adenylyl cyclase by a family of newly synthesized adenine nucleoside 3'–polyphosphates. Désaubry L, et al. **J Biol Chem** 1996 Jun 14; 271(24):14028–34

Identification and molecular characterization of a m5 muscarinic receptor in A2058 human melanoma cells. Coupling to inhibition of adenylyl cyclase and stimulation of phospholipase A2. Kohn EC, et al. **J Biol Chem** 1996 Jul 19;271(29):17476–84

Digoxin reduces beta–adrenergic contractile response in rabbit hearts. Ca(2+)–dependent inhibition of adenylyl cyclase activity via Na+/Ca2+ exchange. Nagai K, et al. **J Clin Invest** 1996 Jan 1;97(1):6–13

Chimeric D2/D3 dopamine receptors efficiently inhibit adenylyl cyclase in HEK 293 cells. Robinson SW, et al. **J Neurochem** 1996 Jul;67(1):212–9

Glycine increases the number of somatostatin receptors and somatostatin–mediated inhibition of the adenylate cyclase system in the rat hippocampus. Puebla L, et al. **J Neurosci Res** 1996 Feb 1;43(3):346–54

Both dynorphin A(1–17) [Des–Tyr1]dynorphin A(2–17) inhibit adenylyl cyclase activity in rat caudate putamen. Claye LH, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):359–65

Erythroid differentiation and growth inhibition of K562 cells by 2',5'–dideoxyadenosine: synergism with interferon–alpha. Ogawa K, et al. **Leuk Res** 1995 Oct; 19(10):749–55

Muscarinic agonist inhibition of rat striatal adenylate cyclase is enhanced by dopamine stimulation. DeLapp NW, et al. **Life Sci** 1996;59(7):565–72

Direct inhibitory effect of corticotropin releasing hormone on isolated caecal circular smooth muscle cells of guinea pig via adenylate cyclase system. Iwakiri Y, et al. **Life Sci** 1996;58(24):2243–9

Evidence against a regulation of Na+/K(+)–ATPase by Gi proteins. Failure to detect an influence of G proteins on Na+/Ca(2+)–exchange in cardiac sarcolemmal membranes. Mura RA, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Apr; 353(5):505–12

Adenylyl cyclase inhibition and altered G protein subunit expression and ADP–ribosylation patterns in tissues and cells from Gi2 alpha–/–mice. Rudolph U, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3209–14

Inhibition of adenylyl cyclase activity by the cholecystokinin analog SNF 9007 in neuroblastoma x glioma NG108–15 hybrid cells. Roerig SC, et al. **Regul Pept** 1996 Jan 16; 61(1):51–6

[Decrease in adenylate cyclase sensitivity to sodium ions in lymphocytes of patients with arterial hypertension] Krasnikova LT, et al. **Biull Eksp Biol Med** 1995 Aug; 120(8):206–7 **(Rus)**

BIOSYNTHESIS

Cell–free synthesis of functional type IV adenylyl cyclase. Warner DR, et al. **Anal Biochem** 1995 Nov 20;232(1):31–6

Control of a novel adenylyl cyclase by calcineurin. Paterson JM, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):1000–8

Synchronous patchy pattern of gene expression for adenylyl cyclase and phosphodiesterase but discrete expression for G–protein in developing rat striatum. Sakagami H, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):185–91

Cloning and expression of a bovine adenylyl cyclase type VII specific to the retinal pigment epithelium. Völkel H, et al. **FEBS Lett** 1996 Jan 15;378(3):245–9

Calcineurin feedback inhibition of agonist–evoked cAMP formation. Antoni FA, et al. **J Biol Chem** 1995 Nov 24; 270(47):28055–61

Expression of type V adenylyl cyclase is required for epidermal growth factor–mediated stimulation of cAMP accumulation. Chen Z, et al. **J Biol Chem** 1995 Nov 17; 270(46):27525–30

Type V, but not type VI, adenylyl cyclase mRNA accumulates in the rat heart during ontogenic development. Correlation with increased global adenylyl cyclase activity. Espinasse I, et al. **J Mol Cell Cardiol** 1995 Sep; 27(9):1789–95

G–proteins and adenylyl cyclase signalling in hypertension. Anand–Srivastava MB. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):163–70

BLOOD

Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN–1 on platelet cyclic AMP. Fisch A, et al. **Eur J Pharmacol** 1995 May 26;289(3):455–61

Aberrant adenylyl cyclase/cAMP signal transduction and G protein levels in platelets from hypertensive patients improve with antihypertensive drug therapy. Marcil J, et al. **Hypertension** 1996 Jul;28(1):83–90

Suppression of lipopolysaccharide–induced tumor necrosis factor–alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Seldon PM, et al. **Mol Pharmacol** 1995 Oct;48(4):747–57

CHEMISTRY

Truncation and alanine–scanning mutants of type I adenylyl cyclase. Tang WJ, et al. **Biochemistry** 1995 Nov 7; 34(44):14563–72

The stoichiometry of expression of protein components of the stimulatory adenylyl cyclase cascade and the regulation of information transfer. Milligan G. **Cell Signal** 1996 Feb; 8(2):87–95 (81 ref.)

Conformational transitions within the calmodulin–binding site of Bordetella pertussis adenylate cyclase studied by time–resolved fluorescence of Trp242 and circular dichroism. Bouhss A, et al. **Eur J Biochem** 1996 May 1; 237(3):619–28

Localisation of an ATP–binding site on adenylyl cyclase type I after chemical and enzymatic fragmentation. Droste M, et al. **FEBS Lett** 1996 Aug 5;391(1–2):209–14

Identification by in vitro complementation of regions required for cell–invasive activity of Bordetella pertussis adenylate cyclase toxin. Iwaki M, et al. **Mol Microbiol** 1995 Sep;17(6):1015–24

CLASSIFICATION

Identification and characterization of a widely expressed form of adenylyl cyclase. Premont RT, et al. **J Biol Chem** 1996 Jun 7;271(23):13900–7

DEFICIENCY

Decreased levels of adenylate cyclase contribute to the down–regulation of beta–adrenergic signal transduction in the salivary glands of the non–obese diabetic (NOD) mouse. Hu Y, et al. **Autoimmunity** 1995;21(2):137–42

DRUG EFFECTS

Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta–adrenoceptor and adenylate cyclase in rat heart. Chatelain P, et al. **Br J Pharmacol** 1995 Oct;116(3):1949–56

Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1–like' dopamine receptors not linked to adenylyl cyclase. Deveney AM, et al. **Br J Pharmacol** 1995 Oct;116(3):2120–6

Inhibition of bronchoconstriction by pituitary adenylate cyclase activating polypeptide (PACAP 1–27) in guinea–pigs in vivo. Lindén A, et al. **Br J Pharmacol** 1995 Jul;115(6):913–6

Refractory hypothalamic adenylate cyclase in anorectic tumor–bearing rats: implications for NPY–induced feeding. Chance WT, et al. **Brain Res** 1995 Sep 11;691(1–2):180–4

Involvement of the adenylyl cyclase signaling system in the action of insulin and mollusk insulin–like peptide. Pertseva MN, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec;112(4):689–95

The effect of GTP on the aluminum fluoride– and forskolin–activated adenylyl cyclase from human embryonic kidney 293 cells. Sanchez–Yagüe J, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov;

109(2-3):359-69

Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Barg J, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):145-52

Activation of adenylate cyclase by divalent cations and polyamines in saponin-treated Dictyostelium discoideum cells. Oyama M, et al. **J Biochem (Tokyo)** 1995 Jul; 118(1):117-21

Forskolin carbamates: binding and activation studies with type I adenylyl cyclase. Robbins JD, et al. **J Med Chem** 1996 Jul 5;39(14):2745-52

Gi-mediated stimulation of type II adenylyl cyclase is augmented by Gq-coupled receptor activation and phorbol ester treatment. Tsu RC, et al. **J Neurosci** 1996 Feb 15; 16(4):1317-23

Lack of 5-hydroxytryptamine1A-mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats. Clarke WP, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1259-66

Mechanism and properties of inhibition of purified rat brain adenylate cyclase by G protein beta gamma-subunits. Enomoto K, et al. **Jpn J Pharmacol** 1995 Nov;69(3):239-50

1-Acetyl-7-deacetylforskolin: a potential non-specific inactive analog of forskolin for estimation of its specific high-affinity binding and adenylyl cyclase stimulation in vitro. Sasaki T, et al. **Life Sci** 1995;57(14):1367-73

Loop diuretics act directly on adenylate cyclase in rat renal tubular basolateral membranes. Osajima A, et al. **Nippon Jinzo Gakkai Shi** 1995 Aug;37(8):436-41

GENETICS

Selective effects of ethanol on the generation of cAMP by particular members of the adenylyl cyclase family. Yoshimura M, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1435-40

Mapping domains in proteins: dissection and expression of Escherichia coli adenylyl cyclase. Reddy P, et al. **Anal Biochem** 1995 Nov 1;231(2):282-6

The stoichiometry of expression of protein components of the stimulatory adenylyl cyclase cascade and the regulation of information transfer. Milligan G. **Cell Signal** 1996 Feb; 8(2):87-95 (81 ref.)

A suppressor mutation which suppresses adenylyl cyclase mutations in Neurospora crassa. Murayama T, et al. **Exp Mycol** 1995 Dec;19(4):320-3

Cloning and expression of a bovine adenylyl cyclase type VII specific to the retinal pigment epithelium. Völkel H, et al. **FEBS Lett** 1996 Jan 15;378(3):245-9

Cloning and sequence of the Bordetella bronchiseptica adenylate cyclase-hemolysin-encoding gene: comparison with the Bordetella pertussis gene. Betsou F, et al. **Gene** 1995 Aug 30;162(1):165-6

An additional copy of the adenylate cyclase-encoding gene relieves developmental defects produced by a mutation in a vegetative incompatibility-controlling gene in Podospora anserina. Loubradou G, et al. **Gene** 1996 Apr 17; 170(1):119-23

Localization of mRNAs encoding Ca2+-inhibitable adenylyl cyclases along the renal tubule. Functional consequences for regulation of the cAMP content. Chabardès D, et al. **J Biol Chem** 1996 Aug 9;271(32):19264-71

Constitutively active adenylyl cyclase mutant requires neither G proteins nor cytosolic regulators. Parent CA, et al. **J Biol Chem** 1996 Aug 2;271(31):18333-6

Identification and characterization of a widely expressed form of adenylyl cyclase. Premont RT, et al. **J Biol Chem** 1996 Jun 7;271(23):13900-7

Adenylyl cyclases: mRNA and characteristics of enzyme activity in three areas of brain. Hellevuo K, et al. **J Neurochem** 1996 Jul;67(1):177-85

The gene encoding adenylyl cyclase VII is located in central mouse chromosome 8. Doyle J, et al. **Mamm Genome** 1996 Apr;7(4):320-1

Resistance to mecillinam produced by the co-operative action of mutations affecting lipopolysaccharide, spoT, and cya or crp genes of Salmonella typhimurium. Antón DN. **Mol Microbiol** 1995 May;16(3):587-95

Molecular characterization of an adenylate cyclase gene of the cyanobacterium Spirulina platensis. Yashiro K, et al. **Plant Mol Biol** 1996 Apr;31(1):175-81

Evidence for distinct signaling mechanisms in two mammalian olfactory sense organs. Berghard A, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2365-9

IMMUNOLOGY

In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. Fayolle C, et al. **J Immunol** 1996 Jun 15;156(12):4697-706

ISOLATION & PURIFICATION

Purification and characterization of a soluble form of mammalian adenylyl cyclase. Dessauer CW, et al. **J Biol Chem** 1996 Jul 12;271(28):16967-74

Soluble adenylyl cyclase from Spodoptera frugiperda (Sf9) cells. Purification and biochemical characterization. Kawabe Ji, et al. **J Biol Chem** 1996 Aug 16;271(33):20132-7

Isolation of inactive and G protein-resistant adenylyl cyclase mutants using random mutagenesis. Parent CA, et al. **J Biol Chem** 1995 Sep 29;270(39):22693-6

METABOLISM

Activation of adenylyl cyclase downregulates sodium/calcium exchanger of arterial myocytes. Smith L, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1379-84

Expression and function of the beta-adrenergic receptor coupled-adenylyl cyclase system on human airway epithelial cells. Kelsen SG, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1774-83

Complexity and diversity of mammalian adenylyl cyclases. Sunahara RK, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:461-80 (95 ref.)

Corpora allata of the larval tobacco hornworm contain a calcium/calmodulin-sensitive adenylyl cyclase. Granger NA, et al. **Arch Insect Biochem Physiol** 1995;30(2-3):149-64

Stimulation of Gs and inhibition of Gi protein functions by minimally oxidized LDL. Parhami F, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):2019-24

Adenylyl cyclase integrates multiple G protein signals to modulate calcium currents in neonatal rabbit heart. Chen F, et al. **Biochem Biophys Res Commun** 1995 Nov 2; 216(1):190-7

Pretreatment with 17 beta-estradiol attenuates basal- and PTH-stimulated membrane adenylyl cyclase activity in human osteoblast-like SAOS-2 cells. Monroe JJ, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):320-5

Inhibition of beta-adrenergic receptor-mediated signals by a synthetic peptide derived from the alpha subunit of the stimulatory G-protein. Novotny J, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):619-24

Adenylyl cyclase activity in turtle vomeronasal and olfactory epithelium. Okamoto K, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):98-101

Type I and type VIII adenylyl cyclases constitute a family whose activation is coupled to cellular deformation through the action of calcium-calmodulin. Watson PA, et al. **Biochem Cell Biol** 1995 Jul-Aug;73(7-8):367-72

Muscarinic m1 receptor-stimulated adenylate cyclase activity in Chinese hamster ovary cells is mediated by Gs alpha and is not a consequence of phosphoinositidase C activation. Burford NT, et al. **Biochem J** 1996 May 1;315 (Pt 3):883-8

Early alterations in the brown adipose tissue adenylate cyclase system of pre-obese Zucker rat fa/fa pups: decreased G-proteins and beta 3-adrenoceptor activities. Charon C, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):781-8

A rat skeletal muscle cell line (L6) expresses specific adrenomedullin binding sites but activates adenylate cyclase via calcitonin gene-related peptide receptors. Coppock HA, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):241-5

Cells retrovirally transfected with fibroblast growth factor-2 isoforms exhibit altered adenylate cyclase activity and G-protein functionality. Estival A, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):619-24

Quantification of signalling components and amplification in the beta-adrenergic-receptor-adenylate cyclase pathway in isolated adult rat ventricular myocytes. Post SR, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):75-80

Epidermal growth factor regulates adenylate cyclase activity via Gs and Gi1-2 proteins in pancreatic acinar membranes. Stryjek-Kaminska D, et al. **Biochem J** 1996 May 15;316 (Pt 1):87-91

Adenylyl cyclase system is affected differently by endurance physical training in heart and adipose tissue. Nieto JL, et al. **Biochem Pharmacol** 1996 May 17;51(10):1321-9

Dopamine receptor multiplicity: "D1-like"-"D2-like" interactions and " D1-like" receptors not linked to adenylate cyclase. Waddington JL, et al. **Biochem Soc Trans** 1996 Feb;24(1):177-82 (77 ref.)

Membrane potential regulates sea urchin sperm adenylylcyclase. Beltrán C, et al. **Biochemistry** 1996 Jun 11;35(23):7591-8

Calcium ionophore, A23187, alters the mode of cAMP formation in wild-type S49 murine lymphoma cells. Nakamura J. **Biochim Biophys Acta** 1996 Aug 21; 1313(1):6-10

Characterization of adenylyl cyclase stimulated by VIP in rat and mouse peritoneal macrophage membranes. Pozo D, et al. **Biochim Biophys Acta** 1996 Jul 24;1312(3):249-54

Involvement of the beta gamma subunits of inhibitory GTP-binding protein in chemoattractant receptor-mediated potentiation of cyclic AMP formation in guinea pig neutrophils. Suzuki T, et al. **Biochim Biophys Acta** 1996 Aug 21;1313(1):72-8

Modulation by 1,25(OH)2-vitamin D3 of the adenylyl cyclase/cyclic AMP pathway in rat and chick myoblasts. Vazquez G, et al. **Biochim Biophys Acta** 1995 Oct 19; 1269(1):91-7

Nobel Lecture. G proteins and regulation of adenylyl cyclase. Gilman AG. **Biosci Rep** 1995 Apr;15(2):65-97 (154 ref.)

Potent agonist action of 2-thioether derivatives of adenine nucleotides at adenylyl cyclase-linked P2Y-purinoceptors. Boyer JL, et al. **Br J Pharmacol** 1995 Nov;116(6):2611-6

Coupling of an endogenous 5-HT1B-like receptor to increases in intracellular calcium through a pertussis toxin-sensitive mechanism in CHO-K1 cells. Dickenson JM, et al. **Br J Pharmacol** 1995 Dec;116(7):2889-96

Potentiation of P1075-induced K+ channel opening by stimulation of adenylate cyclase in rat isolated aorta. Linde C, et al. **Br J Pharmacol** 1995 Jun;115(3):515-21

Adenylyl cyclase activation underlies intracellular cyclic AMP accumulation, cyclic AMP transport, and extracellular adenosine accumulation evoked by beta-adrenergic receptor stimulation in mixed cultures of neurons and astrocytes derived from rat cerebral cortex. Rosenberg PA, et al. **Brain Res** 1995 Sep 18; 692(1-2):227-32

Hippocampal somatostatin receptors and modulation of adenylyl cyclase activity in histamine-treated rats. Puebla L, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1-2):77-83

Binding sites for islet amyloid polypeptide in mammalian lung: species variation and effects on adenylyl cyclase. Bhogal R, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):1030-6

Functional activity and expression of the myocardial postreceptor adenylyl cyclase system in pressure overload hypertrophy in rat. Holmer SR, et al. **Cardiovasc Res** 1996 May;31(5):719-28

Nitric oxide inhibits the initiation of cAMP pulsing in D. discoideum without altering receptor-activated adenylate cyclase. Tao Y, et al. **Cell Signal** 1996 Jan;8(1):26-34

Cardiac beta-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury. Evidence for catecholamine-mediated myocardial damage. White M, et al. **Circulation** 1995 Oct 15;92(8):2183-9

Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates adenylate cyclase and promotes proliferation of mouse primordial germ cells. Pesce M, et al. **Development** 1996 Jan;122(1):215-21

The third cytoplasmic domain of the GLP-1[7-36 amide] receptor is required for coupling to the adenylyl cyclase system. Takhar S, et al. **Endocrinology** 1996 May; 137(5):2175-8

Transformation with vectors harboring the NEOR selection marker induces germination-specific adenylylcyclase activity in Dictyostelium cells. Schulkes CC, et al. **Exp Cell Res** 1995 Oct;220(2):505-8

Trypanosoma brucei: stimulation of adenylate cyclase by proventriculus and esophagus tissue of the tsetse fly, Glossina morsitans morsitans. van den Abbeele J, et al. **Exp Parasitol** 1995 Dec;81(4):618-20

Circadian rhythm in the Ca(2+)-inhibitable adenylyl activity of the rat striatum. Chern Y, et al. **FEBS Lett** 1996 May 6;385(3):205-8

Localisation of an ATP-binding site on adenylyl cyclase type I after chemical and enzymatic fragmentation. Droste M, et al. **FEBS Lett** 1996 Aug 5;391(1-2):209-14

Regulation of type V adenylyl cyclase by PMA-sensitive and -insensitive protein kinase C isoenzymes in intact cells. Kawabe Ji, et al. **FEBS Lett** 1996 Apr 22;384(3):273-6

Acylation of adenylyl cyclase catalyst is important for enzymic activity. Mollner S, et al. **FEBS Lett** 1995 Sep 11;371(3):241-4

Determination and cellular localization of adenylyl cyclase isozymes expressed in embryonic chick heart. Yu HJ, et al. **FEBS Lett** 1995 Oct 23;374(1):89-94

GM1 ganglioside modulates prostaglandin E1 stimulated adenylyl cyclase in neuro-2A cells. Wu G, et al. **Glycoconj J** 1996 Apr;13(2):235-9

G protein alterations in hypertension and aging. Feldman RD, et al. **Hypertension** 1995 Nov;26(5):725-32

Characterization of human and rat immortalized clones parotid acinar cells with respect to specific proteins and their mRNAs, and receptor-linked adenylate cyclase. Prasad KN, et al. **In Vitro Cell Dev Biol Anim** 1995 Nov; 31(10):767-72

Effects of sodium saccharin diet on fat-cell lipolysis: evidence for increased function of the adenylyl cyclase catalyst. Dib K, et al. **Int J Obes Relat Metab Disord** 1996 Jan; 20(1):15-20

Adenylate cyclase activity in human pancreatic adenocarcinoma cell lines. al-Nakkash L, et al. **Int J Pancreatol** 1996 Feb;19(1):39-47

Defect in potentiation of adenylyl cyclase correlates with bronchial hyperreactivity. Dooper MW, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):628-34

Differential structural requirements for interaction of Ras protein with its distinct downstream effectors. Akasaka K, et al. **J Biol Chem** 1996 Mar 8;271(10):5353-60

Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma. Avidor-Reiss T, et al. **J Biol Chem** 1996 Aug 30; 271(35):21309-15

Adenylylcyclase supersensitization in mu-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment. Avidor-Reiss T, et al. **J Biol Chem** 1995 Dec 15;270(50):29732-8

Splice variants of type VIII adenylyl cyclase. Differences in glycosylation and regulation by Ca2+/calmodulin. Cali JJ, et al. **J Biol Chem** 1996 Jan 12;271(2):1089-95

Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. Condie R, et al. **J Biol Chem** 1996 May 31;271(22):13175-83

Functional co-localization of transfected Ca(2+)-stimulable adenylyl cyclases with capacitative Ca2+ entry sites. Fagan KA, et al. **J Biol Chem** 1996 May 24; 271(21):12438-44

Involvement of Gs and Gi proteins in dual coupling of the luteinizing hormone receptor to adenylyl cyclase and phospholipase C. Herrlich A, et al. **J Biol Chem** 1996 Jul 12;271(28):16764-72

Truncation of the C-terminal tail of the follitropin receptor does not impair the agonist- or phorbol ester-induced

receptor phosphorylation and uncoupling. Hipkin RW, et al. **J Biol Chem** 1995 Nov 3;270(44):26683–9

Isolation of inactive and G protein–resistant adenylyl cyclase mutants using random mutagenesis. Parent CA, et al. **J Biol Chem** 1995 Sep 29;270(39):22693–6

Constitutively active adenylyl cyclase mutant requires neither G proteins nor cytosolic regulators. Parent CA, et al. **J Biol Chem** 1996 Aug 2;271(31):18333–6

Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. Pisegna JR, et al. **J Biol Chem** 1996 Jul 19;271(29):17267–74

Calcineurin mediates calcium–induced potentiation of adenylyl cyclase activity in dispersed chief cells from guinea pig stomach. Further evidence for cross–talk between signal transduction pathways that regulate pepsinogen secretion. Raufman JP, et al. **J Biol Chem** 1996 Aug 16;271(33):19877–82

Simultaneous but independent activation of adenylate cyclase and glycosylphosphatidylinositol–phospholipase C under stress conditions in Trypanosoma brucei. Rolin S, et al. **J Biol Chem** 1996 May 3;271(18):10844–52

Repression of adipogenesis by adenylyl cyclase stimulatory G–protein alpha subunit is expressed within region 146–220. Wang Hy, et al. **J Biol Chem** 1996 Sep 6;271(36):22022–9

Hormone stimulation of type III adenylyl cyclase induces Ca2+ oscillations in HEK–293 cells. Wayman GA, et al. **J Biol Chem** 1995 Oct 13;270(41):24108–15

A domain on the G protein beta subunit interacts with both adenylyl cyclase 2 and the muscarinic atrial potassium channel. Yan K, et al. **J Biol Chem** 1996 Jul 26; 271(30):17597–600

Two cytoplasmic domains of mammalian adenylyl cyclase form a Gs alpha– and forskolin–activated enzyme in vitro. Yan SZ, et al. **J Biol Chem** 1996 May 3;271(18):10941–5

Age–dependent changes in the beta–adrenoceptor–G–protein(s)–adenylyl cyclase system in human right atrium. Brodde OE, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):20–6

Myocardial adenylyl cyclase type V and VI mRNA: differential regulation with age. Scarpace PJ, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):86–90

Beta 3–adrenergic activation of adenylyl cyclase in mouse white adipocytes: modulation by GTP and effect of obesity. Bégin–Heick N. **J Cell Biochem** 1995 Aug;58(4):464–73

Constitutive activation of the Gs alpha protein–adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. Derwahl M, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1898–904

The biological activity of the corticotropin–releasing hormone receptor–adenylate cyclase complex in human myometrium is reduced at the end of pregnancy. Grammatopoulos D, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):745–51

Urinary cyclic adenosine 3',5'–monophosphate response in McCune–Albright syndrome: clinical evidence for altered renal adenylate cyclase activity. Zung A, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3576–81

Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. Hirata T, et al. **J Clin Invest** 1996 Feb 15;97(4):949–56

Phospholipase C and adenylate cyclase signalling systems in the action of hCG on porcine myometrial smooth muscle cells. Kisielewska J, et al. **J Endocrinol** 1996 Jan; 148(1):175–80

Abnormal transduction of dopamine signal in human nonfunctioning pituitary adenomas. Lania A, et al. **J Endocrinol Invest** 1995 Apr;18(4):265–70

Alterations in ovine myometrial beta–adrenergic cascade do not mediate tachyphylaxis to ritodrine. Daftary A, et al. **J Matern Fetal Med** 1996 May–Jun;5(3):155–60

Synthesis of the four isomers of 4–aminopyrrolidine–2,4–dicarboxylate: identification of a potent, highly selective, and systemically–active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase. Monn JA, et al. **J Med Chem** 1996 Jul 19;39(15):2990–3000

(2S,4S)–2–amino–4–(4,4–diphenylbut–1–yl)–pentane–1,5–dioic acid: a potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylate cyclase. Wermuth CG, et al. **J Med Chem** 1996 Feb 16;39(4):814–6

Effect of essential fatty acid deficiency on forskolin binding sites, adenylate cyclase and cyclic AMP–dependent protein kinase activity, the levels of G proteins and ventricular function in rat heart. Alam SQ, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1593–604

Mechanisms of the circadian regulation of beta–adrenoceptor density and adenylyl cyclase activity in cardiac tissue from normotensive and spontaneously hypertensive rats. Witte K, et al. **J Mol Cell Cardiol** 1995 May;27(5):1195–202

Activation of type II adenylyl cyclase by the cloned mu–opioid receptor: coupling to multiple G proteins. Chan JS, et al. **J Neurochem** 1995 Dec;65(6):2682–9

Adenylyl cyclases: mRNA and characteristics of enzyme activity in three areas of brain. Hellevuo K, et al. **J Neurochem** 1996 Jul;67(1):177–85

Very low protein diets induce a rapid decrease in hepatic cAMP–dependent protein kinase followed by a lower increase in adenylyl cyclase activity in rats. Stephen LL, et al. **J Nutr** 1996 Jul;126(7):1799–807

Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content. Chen J, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):509–17

Striatal dopamine receptors and adenylyl cyclase activity in a rat model of alcohol addiction: effects of ethanol and lisuride treatment. May T, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1195–203

Dopamine D2L receptor couples to G alpha i2 and G alpha i3 but not G alpha i1, leading to the inhibition of adenylate cyclase in transfected cell lines. O'Hara CM, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):354–60

Participation of delta opioid receptor subtypes in the stimulation of adenylyl cyclase activity in rat olfactory bulb. Olianas MC, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1560–7

Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor–desensitized than that of normal platelets: role of adenylylcyclase up–regulation. Vezza R, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1497–505

Acetylcholine inhibits Ca2+ current by acting exclusively at a site proximal to adenylyl cyclase in frog cardiac myocytes. Jurevičius J, et al. **J Physiol (Lond)** 1996 Mar 15;491 (Pt 3):669–75

Adenylyl cyclase activity in human decidua and myometrium during pregnancy and labour. Miyazaki K, et al. **J Reprod Fertil** 1995 Sep;105(1):141–5

Adenylate cyclase activity during exocrine pancreatic proliferation in the rat. Alvaro–Alonso I, et al. **Life Sci** 1995;57(25):2317–23

Adenosine attenuation of isoproterenol–stimulated adenylyl cyclase activity is enhanced with aging in the adult heart. Romano FD, et al. **Life Sci** 1996;58(6):493–502

Hyperpermeability of pulmonary endothelial monolayer: protective role of phosphodiesterase isoenzymes 3 and 4. Suttorp N, et al. **Lung** 1996;174(3):181–94

Effects of iloprost on salt–sensitive Dahl rats. Somova L. **Methods Find Exp Clin Pharmacol** 1995 Sep;17(7):443–7

Hydrogen peroxide–induced increase in lung endothelial and epithelial permeability—effect of adenylate cyclase stimulation and phosphodiesterase inhibition. Seeger W, et al. **Microvasc Res** 1995 Jul;50(1):1–17

Alterations of beta–adrenoceptor–G–protein–regulated adenylyl cyclase in heart failure. Böhm M. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):147–60 (84 ref.)

Beta–adrenoceptor mediated signal transduction in congestive heart failure in cardiomyopathic (UM–X7.1) hamsters. Kaura D, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):191–6

Regulation of cellular Gs alpha levels and basal adenylyl cyclase activity by expression of the beta 2–adrenoceptor in neuroblastoma cell lines. Milligan G, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:213–6

Stable activation and desensitization of beta 2–adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi–irreversible binding to an exosite. Clark RB, et al. **Mol Pharmacol** 1996 Jan;49(1):182–9

Characterization of the G protein involved in the muscarinic stimulation of adenylyl cyclase of rat olfactory bulb. Olianas MC, et al. **Mol Pharmacol** 1996 Jan;49(1):22–9

Distinct receptor domains determine subtype–specific coupling and desensitization phenotypes for human beta1– and beta2–adrenergic receptors. Rousseau G, et al. **Mol Pharmacol** 1996 Apr;49(4):752–60

Irreversible inhibition of forskolin interactions with type I adenylyl cyclase by a 6–isothiocyanate derivative of forskolin. Sutkowski EM, et al. **Mol Pharmacol** 1996 Aug; 50(2):299–305

Isoform–specific sensitization of adenylyl cyclase activity by prior activation of inhibitory receptors: role of beta gamma subunits in transducing enhanced activity of the type VI isoform. Thomas JM, et al. **Mol Pharmacol** 1996 May; 49(5):907–14

mu–Opioid receptors inhibit dopamine–stimulated activity of type V adenylyl cyclase but enhance dopamine–stimulated activity of type VII adenylyl cyclase. Yoshimura M, et al. **Mol Pharmacol** 1996 Jul;50(1):43–51

Identification of a novel dual angiotensin II/vasopressin receptor on the basis of molecular recognition theory. Ruiz–Opazo N, et al. **Nat Med** 1995 Oct;1(10):1074–81

Olfactory transduction mechanisms in sheep. Fabbri E, et al. **Neurochem Res** 1995 Jun;20(6):719–25

Effects of Ca2+ and calmodulin on adenylyl cyclase activity in sheep olfactory epithelium. Fabbri E, et al. **Neurochem Res** 1995 Dec;20(12):1511–7

Adenylate–cyclase–dependent pituitary adrenocorticotropin secretion is defective in the inflammatory–disease–susceptible Lewis rat. Bernardini R, et al. **Neuroendocrinology** 1996 May;63(5):468–74

In vitro effect of chlorpyrifos oxon on muscarinic receptors and adenylate cyclase. Huff RA, et al. **Neurotoxicology** 1995 Summer;16(2):281–90

Atypical regulation of hepatic adenylyl cyclase and adrenergic receptors during a critical developmental period: agonists evoke supersensitivity accompanied by failure of receptor down–regulation. Thai L, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):697–707

Activation of adenylate cyclase and phosphodiesterase inhibition enhance neutral endopeptidase activity in human endothelial cells. Graf K, et al. **Peptides** 1995;16(7):1273–8

Differential activation of yeast adenylyl cyclase by Ras1 and Ras2 depends on the conserved N terminus. Hurwitz N, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21; 92(24):11009–13

Agonist–induced desensitization of dopamine D1 receptor–stimulated adenylyl cyclase activity is temporally and biochemically separated from D1 receptor internalization. Ng GY, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10157–61

Targeted disruption of the mouse beta1–adrenergic receptor gene: developmental and cardiovascular effects. Rohrer DK, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):7375–80

Interaction of the two cytosolic domains of mammalian adenylyl cyclase. Whisnant RE, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6621–5

Regulation of phosducin phosphorylation in retinal rods by Ca2+/calmodulin–dependent adenylyl cyclase. Willardson BM, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20; 93(4):1475–9

Adenylate cyclase activity increases concomitantly with the onset of capacitation in heparin–treated bovine spermatozoa. Ijaz A, et al. **Reprod Nutr Dev** 1996; 36(2):221–32

The G2M arrest caused by iodide is unrelated to the effects of iodide at adenylate cyclase. Smerdely P, et al. **Thyroid** 1995 Aug;5(4):325–30

The influence of ageing on muscarinic receptors, beta–adrenoceptors and adenylate cyclase activity in the bovine lung. Roets E, et al. **Vet Res Commun** 1995; 19(3):221–30

[Stimulation of adenylate cyclase by the isoforms of human and rat beta–3 adrenergic receptor expressed in the CHO cells] Levasseur S, et al. **Gastroenterol Clin Biol** 1995 Aug–Sep;19(8–9):668–72 (Eng. Abstr.) **(Fre)**

[Changes in platelet adenylyl cyclase system in alcoholics] Katamura Y, et al. **Arukoru Kenkyuto Yakubutsu Ison** 1996 Apr;31(2):164–76 (Eng. Abstr.) **(Jpn)**

[Adenylate cyclase system and calcium channels] Shchegoleva TIu, et al. **Biofizika** 1995 Nov–Dec; 40(6):1281–4 (Eng. Abstr.) **(Rus)**

[Adenylate cyclase and 5'–nucleotidase activities in the sensorimotor and limbic structures of the rat brain after training in a manipulative skill] Zhuravin IA, et al. **Fiziol Zh Im I M Sechenova** 1995 Jan;81(1):40–7 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Calcitonin gene–related peptide activates the K+ channels of vascular smooth muscle cells via adenylate cyclase. Miyoshi H, et al. **Basic Res Cardiol** 1995 Jul–Aug; 90(4):332–6

Glutamate enhances the adenylyl cyclase–cAMP system–induced beta–endorphin secretion and POMC mRNA expression in rat hypothalamic neurons in culture: NMDA receptor–mediated modulation. Yang Z, et al. **Brain Res** 1995 Sep 18;692(1–2):129–36

Neural input and the development of adrenergic intracellular signaling: neonatal denervation evokes neither receptor upregulation nor persistent supersensitivity of adenylate cyclase. Slotkin TA, et al. **Brain Res Dev Brain Res** 1995 Aug 28;88(1):17–29

Oxidant stress enhances adenylyl cyclase activation. Tan CM, et al. **Circ Res** 1995 Oct;77(4):710–7

Immunomodulation by an adenylate cyclase activator, NKH477, in vivo and vitro. Furukawa Y, et al. **Clin Immunol Immunopathol** 1996 Apr;79(1):25–35

Activators of protein kinase C but not of phospholipase C modulate adenylate cyclase–responses of normal pig epidermis. Iizuka H, et al. **Epithelial Cell Biol** 1995; 4(1):35–41

Evidence that hormone receptors couple and activate a common signal transducer adenylyl cyclase in corpus luteum. Rojas FJ, et al. **Fertil Steril** 1996 Feb;65(2):275–9

The Gs alpha/Gi alpha 2 axis controls adipogenesis independently of adenylylcyclase. Wang HY, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S26–31 (62 ref.)

Pseudohypoparathyroidism, a novel mutation in the betagamma–contact region of Gsalpha impairs receptor stimulation. Farfel Z, et al. **J Biol Chem** 1996 Aug 16; 271(33):19653–5

Sensory transduction in vomeronasal neurons: evidence for G alpha o, G alpha i2, and adenylyl cyclase II as major components of a pheromone signaling cascade. Berghard A, et al. **J Neurosci** 1996 Feb 1;16(3):909–18

Beta–adrenergic responsiveness of adenylate cyclase in human adipocyte plasma membranes in obesity and after massive weight reduction. Kaartinen JM, et al. **Metabolism** 1995 Oct;44(10):1288–92

Long–term potentiation in mice lacking synapsins. Spillane DM, et al. **Neuropharmacology** 1995 Nov;34(11):1573–9

Adenylate cyclases: critical foci in neuronal signaling. Mons N, et al. **Trends Neurosci** 1995 Dec;18(12):536–42 (60 ref.)

TOXICITY

Cell–invasive activity of epitope–tagged adenylate cyclase of Bordetella pertussis allows in vitro presentation of a foreign epitope to CD8+ cytotoxic T cells. Sebo P, et al. **Infect Immun** 1995 Oct;63(10):3851–7

ADENYL IMIDODIPHOSPHATE see **ADENYLYL IMIDODIPHOSPHATE**

ADENYLATE CYCLASE see **ADENYL CYCLASE**

ADENYLATE DEAMINASE see **AMP DEAMINASE**

ADENYLATE KINASE

ANALYSIS

The hepatitis B virus X protein is a potent AMP kinase. Dopheide TA, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):173–6

ANTAGONISTS & INHIBITORS

Suppression of adenylate kinase catalyzed phosphotransfer precedes and is associated with glucose–induced insulin secretion in intact HIT–T15 cells. Olson LK, et al. **J Biol Chem** 1996 Jul 12;271(28):16544–52

Characteristics of rabbit muscle adenylate kinase inhibition by sulfur and recovery by dithiothreitol. Russell PJ, et al. **J Enzym Inhib** 1995;9(3):179–94

CEREBROSPINAL FLUID

Occurrence of adenylate kinase in cerebrospinal fluid after isoflurane anaesthesia and orthognathic surgery. Enlund M, et al. **Ups J Med Sci** 1996;101(1):97–111

CHEMISTRY

Domain closure in adenylate kinase. Sinev MA, et al. **Biochemistry** 1996 May 21;35(20):6425–37

Sequential unfolding of adenylate kinase during denaturation by guanidine hydrochloride. Zhang YL, et al. **Biochim Biophys Acta** 1996 Jul 18;1295(2):239–44

Ancient divergence of long and short isoforms of adenylate kinase: molecular evolution of the nucleoside monophosphate kinase family. Fukami–Kobayashi K, et al. **FEBS Lett** 1996 May 6;385(3):214–20

Structure of a mutant adenylate kinase ligated with an ATP–analogue showing domain closure over ATP. Schlauderer GJ, et al. **J Mol Biol** 1996 Feb 23;256(2):223–7

DEFICIENCY

Red cell enzyme deficiencies in the tribal population groups of the Bastar District, Madhya Pradesh, India. Basu S, et al. **Anthropol Anz** 1995 Dec;53(4):331–5

GENETICS

A secY homologous gene in the crenarchaeon Sulfolobus acidocaldarius. Kath T, et al. **Biochim Biophys Acta** 1995 Nov 7;1264(2):155–8

Distribution of ACP1, AK1 and ALAD polymorphisms in northern Portugal. Amorim A, et al. **Gene Geogr** 1994 Aug; 8(2):147–50

Primary structure of a putative adenylate kinase gene of Giardia lamblia. Rozario C, et al. **Mol Biochem Parasitol** 1995 May;71(2):279–83

Mapping functional chicken genes: an alternative approach. Smith EJ, et al. **Poult Sci** 1996 May;75(5):642–7

Electrophoretic variation in adenylate kinase of Neisseria meningitidis is due to inter– and intraspecies recombination. Feil E, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7; 92(23):10535–9

METABOLISM

Binding of adenylate kinase to RNA. Schlattner U, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):509–14

Substrate binding causes movement in the ATP binding domain of Escherichia coli adenylate kinase. Bilderback T, et al. **Biochemistry** 1996 May 14;35(19):6100–6

Domain closure in adenylate kinase. Sinev MA, et al. **Biochemistry** 1996 May 21;35(20):6425–37

Cytoplasmic and mitochondrial forms of yeast adenylate kinase 2 are N–acetylated. Klier H, et al. **Biochim Biophys Acta** 1996 Apr 26;1280(2):251–6

Activity changes of ATP synthase and adenylate kinase in rat–liver mitochondria during the early phase after burn injury. Wang XM, et al. **Burns** 1995 Aug;21(5):362–3

ADP delivery from adenylate kinase in the mitochondrial intermembrane space to oxidative phosphorylation increases in the presence of macromolecules. Laterveer FD, et al. **FEBS Lett** 1996 May 20;386(2–3):255–9

Adenylate kinase complements nucleoside diphosphate kinase deficiency in nucleotide metabolism. Lu Q, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5720–5

ADENYLATE PHOSPHATASE see **5'–NUCLEOTIDASE**

ADENYLIC ACID see **ADENOSINE MONOPHOSPHATE**

ADENYLOSUCCINASE see **ADENYLOSUCCINATE LYASE**

ADENYLOSUCCINATE LYASE

BLOOD

AMP–succinate lyase in lymphocytic leukemia. Marinello E, et al. **Biochem Soc Trans** 1996 Feb;24(1):121S

CHEMISTRY

Affinity Labeling of the active site of rabbit muscle adenylosuccinate lyase by 2–[(4–bromo–2,3–dioxobutyl)thio] adenosine 5'–monophosphate. Gite SU, et al. **Biochemistry** 1996 Feb 27;35(8):2658–67

Crystallization and preliminary structural analysis of Bacillus subtilis adenylosuccinate lyase, an enzyme implicated in infantile autism. Redinbo MR, et al. **Protein Sci** 1996 Apr; 5(4):786–8

DEFICIENCY

Capillary electrophoresis for screening of adenylosuccinate lyase deficiency. Gross M, et al. **Electrophoresis** 1995 Oct; 16(10):1927–9

A new diagnostic technique for adenylosuccinate lyase deficiency. Domkin VD, et al. **J Inherit Metab Dis** 1995; 18(3):291–4

Adenylosuccinase deficiency: a patient with impaired erythrocyte activity and anomalous response to intravenous fructose. Salerno C, et al. **J Inherit Metab Dis** 1995; 18(5):602–8

GENETICS

Characterization of the cDNA and the gene encoding murine adenylosuccinate lyase. Wong LJ, et al. **Genomics** 1995 Jul 20;28(2):341–3

ADENYLOSUCCINATE SYNTHETASE

CHEMISTRY

Involvement of arginine 143 in nucleotide substrate binding at the active site of adenylosuccinate synthetase from Escherichia coli. Moe OA, et al. **Biochemistry** 1996 Jul 16;35(28):9024–33

Refined crystal structures of unligated adenylosuccinate synthetase from Escherichia coli. Silva MM, et al. **J Mol Biol** 1995 Dec 1;254(3):431–46

GENETICS

The adenylosuccinate synthetase from the hyperthermophilic archaeon Pyrococcus species displays unusual structural features. Bouyoub A, et al. **J Mol Biol** 1996 Aug 16; 261(2):144–54

METABOLISM

Enzymatic properties and inhibition by single–stranded autonomously replicating sequences of adenylosuccinate synthase from Saccharomyces cerevisiae. Gallert KC, et al. **Eur J Biochem** 1996 Jul 15;239(2):487–93

The mode of action and the structure of a herbicide in complex with its target: binding of activated hydantocidin to the feedback regulation site of adenylosuccinate synthetase. Fonné–Pfister R, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9431–6

ULTRASTRUCTURE

Refined crystal structures of guanine nucleotide complexes of adenylosuccinate synthetase from Escherichia coli. Poland BW, et al. **J Biol Chem** 1996 Jun 28; 271(26):15407–13

ADENYLPYROPHOSPHATE see **ADENOSINE TRIPHOSPHATE**

ADENYLYL IMIDODIPHOSPHATE

CHEMISTRY

2.0 A resolution structure of a ternary complex of pig muscle phosphoglycerate kinase containing 3–phospho–D–glycerate and the nucleotide Mn adenylylimidodiphosphate. May A, et al. **Proteins** 1996 Mar;24(3):292–303

METABOLISM

Energy coupling in Escherichia coli DNA gyrase: the relationship between nucleotide binding, strand passage, and DNA supercoiling. Bates AD, et al. **Biochemistry** 1996 Feb 6;35(5):1408–16

Structure of the R65Q mutant of yeast 3–phosphoglycerate kinase complexed with Mg–AMP–PNP and 3–phospho–D–glycerate. McPhillips TM, et al. **Biochemistry** 1996 Apr 2;35(13):4118–27

PHARMACOLOGY

Influence of nucleotides on the cold stability of chloroplast coupling factor 1. Hightower KE, et al. **Biochemistry** 1996 Aug 6;35(31):10051–7

Influence of ADP, AMP–PNP and of depletion of nucleotides on the structural properties of F1ATPase: a Fourier transform infrared spectroscopic study. Lippe G, et al. **FEBS Lett** 1995 Oct 9;373(2):141–5

ADHESINS, BACTERIAL

see related
BACTERIAL ADHESION

ANALYSIS

Identification of a 100–kilodalton putative coaggregation–mediating adhesin of Streptococcus gordonii DL1 (Challis). Clemans DL, et al. **Infect Immun** 1995 Dec;63(12):4890–3

Pseudomonas aeruginosa strains possess specific adhesins for laminin. Plotkowski MC, et al. **Infect Immun** 1996 Feb; 64(2):600–5

CHEMISTRY

Characterization of CshA, a high molecular mass adhesin of Streptococcus gordonii. McNab R, et al. **Dev Biol Stand** 1995;85:371–5

Molecular characterization and adhesive properties of CF29K, an adhesin of Klebsiella pneumoniae strains involved in nosocomial infections. Di Martino P, et al. **Infect Immun** 1995 Nov;63(11):4336–44

The OmpU outer membrane protein, a potential adherence factor of Vibrio cholerae. Sperandio V, et al. **Infect Immun** 1995 Nov;63(11):4433–8

The galactosyl–(alpha 1–4)–galactose–binding adhesin of Streptococcus suis: occurrence in strains of different hemagglutination activities and induction of opsonic antibodies. Tikkanen K, et al. **Infect Immun** 1996 Sep; 64(9):3659–65

Porins of Vibrio cholerae: purification and characterization of OmpU. Chakrabarti SR, et al. **J Bacteriol** 1996 Jan; 178(2):524–30

The intercellular adhesin involved in biofilm accumulation of Staphylococcus epidermidis is a linear beta–1,6–linked glucosaminoglycan: purification and structural analysis. Mack D, et al. **J Bacteriol** 1996 Jan;178(1):175–83

Substitution of two histidine residues in YadA protein of Yersinia enterocolitica abrogates collagen binding, cell adherence and mouse virulence. Roggenkamp A, et al. **Mol Microbiol** 1995 Jun;16(6):1207–19

GENETICS

Characterization of a Porphyromonas gingivalis gene prtR that encodes an arginine–specific thiol proteinase and multiple adhesins. Slakeski N, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):605–10

Characterization of CshA, a high molecular mass adhesin of Streptococcus gordonii. McNab R, et al. **Dev Biol Stand** 1995;85:371–5

Genetic evidence for host specificity in the adhesin–encoding genes hxaA of Helicobacter acinonyx, hnaA of H. nemestrinae and hpaA of H. pylori. Evans DG, et al. **Gene** 1995 Sep 22;163(1):97–102

scbA from Streptococcus crista CC5A: an atypical member of the IraI gene family. Correla FF, et al. **Infect Immun** 1996 Jun;64(6):2114–21

Biofunctional domains of the Mycoplasma pneumoniae P30 adhesin. Dallo SF, et al. **Infect Immun** 1996 Jul; 64(7):2595–601

Cloning and characterization of a putative cytadhesin gene (mgc1) from Mycoplasma gallisepticum. Keeler CL Jr, et al. **Infect Immun** 1996 May;64(5):1541–7

Deletion of amino acids 29 to 81 in adhesion protein YadA of Yersinia enterocolitica serotype O:8 results in selective abrogation of adherence to neutrophils. Roggenkamp A, et al. **Infect Immun** 1996 Jul;64(7):2506–14

Molecular basis of size and antigenic variation of a Mycoplasma hominis adhesin encoded by divergent vaa genes. Zhang Q, et al. **Infect Immun** 1996 Jul;64(7):2737–44

Insertional inactivation of Streptococcus pyogenes sod suggests that prtF is regulated in response to a superoxide signal. Gibson CM, et al. **J Bacteriol** 1996 Aug; 178(15):4688–95

Epidemiological study of Mycoplasma pneumoniae infections in japan based on PCR–restriction fragment length polymorphism of the P1 cytadhesin gene. Sasaki T, et al. **J Clin Microbiol** 1996 Feb;34(2):447–9

Molecular cloning of adhesion genes. Hull SI, et al. **Methods Enzymol** 1995;253:258–69

Molecular analysis of the cso operon of enterotoxigenic Escherichia coli reveals that CsoA is the adhesin of CS1 fimbriae and that the accessory genes are interchangeable with those of the cfa operon. Marron MB, et al. **Microbiology** 1995 Nov;141 (Pt 11):2849–59

Chimeric FimH adhesin of type 1 fimbriae: a bacterial surface display system for heterologous sequences. Pallesen L, et al. **Microbiology** 1995 Nov;141 (Pt 11):2839–48

Identification of a second family of high–molecular–weight adhesion proteins expressed by non–typable Haemophilus influenzae. Barenkamp SJ, et al. **Mol Microbiol** 1996 Mar; 19(6):1215–23

A combinatorial library of an alpha–helical bacterial receptor domain. Nord K, et al. **Protein Eng** 1995 Jun;8(6):601–8

[Adhesins from Vibrio cholerae: phenotypic analysis and genetic control of synthesis] Smirnova NI. **Mol Gen Mikrobiol Virusol** 1995 Jul–Sep;(3):18–26 (80 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Distribution, gene sequence and expression in vivo of the plasmid encoded fimbrial antigen of Salmonella serotype Enteritidis. Woodward MJ, et al. **Epidemiol Infect** 1996 Aug;117(1):17–28

Immunochemical characterisation and epitope mapping of

a novel fimbrial protein (Pg-II fimbria) of Porphyromonas gingivalis. Ogawa T, et al.
FEMS Immunol Med Microbiol 1995 Jun;11(3):247-55

Identification of surface-exposed B-cell epitopes on high molecular-weight adhesion proteins of nontypeable Haemophilus influenzae. Barenkam SJ, et al.
Infect Immun 1996 Aug;64(8):3032-7

Persistence of serum and salivary antibody responses after oral immunization with a bacterial protein antigen genetically linked to the A2/B subunits of cholera toxin. Hajishengallis G, et al. **Infect Immun** 1996 Feb;64(2):665-7

Identification of surface-exposed linear B-cell epitopes of the nonfimbrial adhesin CS31A of Escherichia coli by using overlapping peptides and antipeptide antibodies. Méchin MC, et al. **Infect Immun** 1996 Sep;64(9):3555-64

Role of YadA in resistance to killing of Yersinia enterocolitica by antimicrobial polypeptides of human granulocytes. Visser LG, et al. **Infect Immun** 1996 May; 64(5):1653-8

Molecular basis of size and antigenic variation of a Mycoplasma hominis adhesin encoded by divergent vaa genes. Zhang Q, et al. **Infect Immun** 1996 Jul;64(7):2737-44

A monoclonal antibody enhances ligand binding of fibronectin MSCRAMM (adhesin) from Streptococcus dysgalactiae. Speziale P, et al. **J Biol Chem** 1996 Jan 19; 271(3):1371-8

Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old. Halperin SA, et al. **Scand J Infect Dis** 1995;27(3):279-87

Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. Isacson J, et al. **Scand J Infect Dis** 1995; 27(3):273-7

ISOLATION & PURIFICATION

Purification of a galactosyl-alpha 1-4-galactose-binding adhesin from the gram-positive meningitis-associated bacterium Streptococcus suis. Tikkanen K, et al.
J Biol Chem 1995 Dec 1;270(48):28874-8

Identifying and isolating fimbrial-associated adhesins of oral gram-negative bacteria. London J. **Methods Enzymol** 1995; 253:397-403

Isolation and characterization of teichoic acid-lake substance as an adhesin of Staphylococcus aureus to HeLa cells. Matsuura T, et al. **Microbiol Immunol** 1996;40(4):247-54

METABOLISM

Aqueous two-phase polymer systems as tools for the study of a recombinant surface-expressed Escherichia coli hemagglutinin. Lutwyche P, et al.
Appl Environ Microbiol 1995 Sep;61(9):3251-5

Characterization of the binding region for the Yersinia enterocolitica adhesin YadA on types I and II collagen. Schulze-Koops H, et al. **Arthritis Rheum** 1995 Sep; 38(9):1283-9

Anti-adhesin antibodies that recognize a receptor-binding motif (adhesintope) inhibit pilus/fimbrial-mediated adherence of Pseudomonas aeruginosa and Candida albicans to asialo-GM1 receptors and human buccal epithelial cell surface receptors. Lee KK, et al.
Can J Microbiol 1996 May;42(5):479-86

A two-domain mechanism for group A streptococcal adherence through protein F to the extracellular matrix. Ozeri V, et al. **EMBO J** 1996 Mar 1;15(5):989-98

Decreased expression of mannose-specific adhesins by Escherichia coli in the colonic microflora of immunoglobulin A-deficient individuals. Friman V, et al. **Infect Immun** 1996 Jul;64(7):2794-8

Cytokine production by human epithelial and endothelial cells following exposure to oral viridans streptococci involves lectin interactions between bacteria and cell surface receptors. Vernier A, et al. **Infect Immun** 1996 Aug; 64(8):3016-22

Characterization of the binding activities of proteinase-adhesin complexes from Porphyromonas gingivalis. Pike RN, et al. **J Bacteriol** 1996 May; 178(10):2876-82

Distinct roles of the N-terminal and C-terminal precursor domains in the biogenesis of the Bordetella pertussis filamentous hemagglutinin. Renauld-Mongénie G, et al. **J Bacteriol** 1996 Feb;178(4):1053-60

Isolation and structural characterization of adhesin polysaccharide receptors. Cassels FJ, et al.
Methods Enzymol 1995;253:69-91 (44 ref.)

Adhesin-dependent isolation and characterization of bacteria from their natural environment. Krogfelt KA.
Methods Enzymol 1995;253:50-3

Use of synthetic peptides in characterization of microbial adhesins. Lee KK, et al. **Methods Enzymol** 1995;253:115-31

Specificity mapping of bacterial lectins by inhibition of hemagglutination using deoxy and deoxyfluoro analogs of receptor-active saccharides. Magnusson G, et al.
Methods Enzymol 1995;253:105-14

Identifying bacterial receptor proteins and quantifying strength of interactions they mediate. Prakobphol A, et al. **Methods Enzymol** 1995;253:132-42

Characterization of glycoprotein glycan receptors for Escherichia coli F17 fimbrial lectin. Mouricout M, et al. **Microb Pathog** 1995 Apr;18(4):297-306

Use of synthetic peptides to confirm that the Pseudomonas aeruginosa PAK pilus adhesin and the Candida albicans fimbrial adhesin possess a homologous receptor-binding domain. Yu L, et al. **Mol Microbiol** 1996 Mar;19(5):1107-16

Differentiation between human red cells of Pk and p blood types using Pseudomonas aeruginosa PA-I lectin. Sudakevitz D, et al. **Transfusion** 1996 Feb;36(2):113-6

PHARMACOLOGY

Erythrocytes as target cells for testing bacterial adhesins. Goldhar J. **Methods Enzymol** 1995;253:43-50 (32 ref.)

PHYSIOLOGY

Adherence of Helicobacter pylori. Logan RP.
Aliment Pharmacol Ther 1996 Apr;10 Suppl 1:3-15

The urease enzyme of Helicobacter pylori does not function as an adhesin. Clyne M, et al. **Infect Immun** 1996 Jul; 64(7):2817-20

Biofunctional domains of the Mycoplasma pneumoniae P30 adhesin. Dallo SF, et al. **Infect Immun** 1996 Jul; 64(7):2595-601

Deletion of amino acids 29 to 81 in adhesion protein YadA of Yersinia enterocolitica serotype O:8 results in selective abrogation of adherence to neutrophils. Roggenkamp A, et al. **Infect Immun** 1996 Jul;64(7):2506-14

The GafD protein of the G (F17) fimbrial complex confers adhesiveness of Escherichia coli to laminin. Saarela S, et al. **Infect Immun** 1996 Jul;64(7):2857-60

Role of YadA in Yersinia-enterocolitica-induced reactive arthritis: a hypothesis [letter] Skurnik M.
Trends Microbiol 1995 Aug;3(8):318-9

[Prevention of cariogenic dental plaque. Study of the structures implicated in the adhesion and coaggregation in Streptococcus mutans and Streptococcus sobrinus] Jacquelin LF, et al. **Pathol Biol (Paris)** 1995 Apr; 43(4):371-9 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Synthetic peptide derived from the Bordetella pertussis bacterium reduces infarct volume after transient middle cerebral artery occlusion in the rat. Zhang RL, et al.
Neurology 1996 May;46(5):1437-41

TOXICITY

Purified Pseudomonas aeruginosa PA-I lectin induces gut growth when orally ingested by rats. Grant G, et al.
FEMS Immunol Med Microbiol 1995 Jun;11(3):191-5

ULTRASTRUCTURE

Ultrastructural organization and regulation of a biomaterial adhesin of Staphylococcus epidermidis. Veenstra GJ, et al. **J Bacteriol** 1996 Jan;178(2):537-41

ADHESINS, ESCHERICHIA COLI

The PapG-adhesin at the tip of P-fimbriae provides Escherichia coli with a competitive edge in experimental bladder infections of cynomolgus monkeys. Winberg J, et al. **J Exp Med** 1995 Dec 1;182(6):1695-702

BIOSYNTHESIS

Identification and functional differentiation of two type I fatty acid synthases in Brevibacterium ammoniagenes. Stuible HP, et al. **J Bacteriol** 1996 Aug;178(16):4787-93

CHEMISTRY

Characterization of 20K fimbria, a new adhesin of septicemic and diarrhea-associated Escherichia coli strains, that belongs to a family of adhesins with N-acetyl-D-glucosamine recognition. Bertin Y, et al.
Infect Immun 1996 Jan;64(1):332-42

GENETICS

Dr fimbriae coding region associated hemolytic activity of Escherichia coli. Goluszko P, et al.
FEMS Microbiol Lett 1995 Jul 15;130(1):13-7

Expression of the gene cluster associated with the Escherichia coli pilus adhesin K99. Lee JH, et al.
Infect Immun 1995 Oct;63(10):4143-9

The structural gene encoding human enterotoxigenic Escherichia coli PCFO20 is homologous to that for porcine 987P. Viboud GI, et al. **Infect Immun** 1996 Apr; 64(4):1233-9

A novel multiply primed polymerase chain reaction assay for identification of variant papG genes encoding the Gal(alpha 1-4)Gal-binding PapG adhesins of Escherichia coli. Johnson JR, et al. **J Infect Dis** 1996 Apr;173(4):920-6

Analysis of the fim cluster of an avian O2 strain of Escherichia coli: serogroup-specific sites within fimA and nucleotide sequence of fimI. Marc D, et al.
J Med Microbiol 1996 Jun;44(6):444-52

Strategies for employing molecular genetics to study tip adhesions. Vetter V, et al. **Methods Enzymol** 1995; 253:229-41 (48 ref.)

IMMUNOLOGY

Inhibition of enteropathogenic Escherichia coli (EPEC) adherence to HeLa cells by human colostrum. Detection of specific sIgA related to EPEC outer-membrane proteins. Câmara LM, et al. **Adv Exp Med Biol** 1995;371A:673-6

METABOLISM

Pathogenicity of the diffusely adhering strain Escherichia coli C1845: F1845 adhesin-decay accelerating factor interaction, brush border microvillus injury, and actin disassembly in cultured human intestinal epithelial cells. Bernet-Camard MF, et al. **Infect Immun** 1996 Jun; 64(6):1918-28

Porcine 987P glycolipid receptors on intestinal brush borders and their cognate bacterial ligands. Khan AS, et al.
Infect Immun 1996 Sep;64(9):3688-93

Identification of major and minor chaperone proteins involved in the export of 987P fimbriae. Edwards RA, et al. **J Bacteriol** 1996 Jun;178(12):3426-33

Adhesins of Escherichia coli associated with extra-intestinal pathogenicity confer binding to colonic epithelial cells. Adlerberth I, et al. **Microb Pathog** 1995 Jun;18(6):373-85

Structural requirements for the glycolipid receptor of human uropathogenic Escherichia coli. Striker R, et al.
Mol Microbiol 1995 Jun;16(5):1021-9

Molecular dissection of PapD interaction with PapG reveals two chaperone-binding sites. Xu Z, et al.
Mol Microbiol 1995 Jun;16(5):1011-20

PHARMACOLOGY

A peptide, ALTTE, within the fimbrial subunit protein from Porphyromonas gingivalis, induces production of interleukin 6, gene expression and protein phosphorylation in human peripheral blood mononuclear cells. Ogawa T, et al. **FEMS Immunol Med Microbiol** 1995 Jun; 11(3):197-205

PHYSIOLOGY

The PapG-adhesin at the tip of P-fimbriae provides Escherichia coli with a competitive edge in experimental bladder infections of cynomolgus monkeys. Winberg J, et al. **J Exp Med** 1995 Dec 1;182(6):1695-702

ADHESINS, FIMBRIAL see **ADHESINS, BACTERIAL**

ADHESION, BACTERIAL see **BACTERIAL ADHESION**

ADHESIONS

[Formation of adhesions and change in activity of tissue plasminogen activator in the parietal peritoneum of the anterior stomach wall in rats depending on the method of restoring it] Mynbaev OA, et al.
Biull Eksp Biol Med 1996 Mar;121(3):328-31 **(Rus)**

COMPLICATIONS

[Celioscopic treatment of acute obstructions caused by adhesions of the small intestine. Experience of 35 cases] Parent S, et al. **J Chir (Paris)** 1995 Oct;132(10):382-5 (Eng. Abstr.) **(Fre)**

CONGENITAL

Congenital oral adhesion (syngnathia) with total cleft palate in a Nigerian child. Akpata OS, et al.
Cleft Palate Craniofac J 1995 Nov;32(6):529-30

ETIOLOGY

Quantitative analysis of the inflammatory reaction surrounding sutures commonly used in operative procedures and the relation to postsurgical adhesion formation. Bakkum EA, et al. **Biomaterials** 1995 Nov; 16(17):1283-9

Etiology of and therapeutic approach to synechia uteri. Schenker JG. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):109-13 (20 ref.)

Adhesion formation from release of dermoid contents in the peritoneal cavity and effect of copious lavage: a prospective, randomized, blinded, controlled study in a rabbit model. Fielder EP, et al. **Fertil Steril** 1996 Apr; 65(4):852-9

Experimental model for neoangiogenesis in adhesion formation. Bigatti G, et al. **Hum Reprod** 1995 Sep; 10(9):2290-4

Laparoscopic findings after transvaginal ultrasound-guided aspiration of ovarian endometriomas. Muzii L, et al.
Hum Reprod 1995 Nov;10(11):2902-3

Melanoma cell spreading on fibronectin induced by 12(S)-HETE involves both protein kinase C- and protein tyrosine kinase-dependent focal adhesion formation and tyrosine phosphorylation of focal adhesion kinase (pp125FAK). Tang DG, et al. **J Cell Physiol** 1995 Nov; 165(2):291-306

Adhesion formation after transperitoneal nephrectomy: laparoscopic v open approach. Moore RG, et al.
J Endourol 1995 Jun;9(3):277-80

PATHOLOGY

In response to article by Drs. Devulder et al [letter; comment] Racz GB, et al. **Clin J Pain** 1995 Jun;11(2):151-4. Comment on: Clin J Pain 1995 Jun;11(2):147-50.

In response to article by Drs. Devulder et al [letter; comment] Reed KL, et al. **Clin J Pain** 1995 Jun;11(2):154-6. Comment on: Clin J Pain 1995 Jun;11(2):147-50.

Effect of rat mesenchymal stem cells on development of abdominal adhesions after surgery. Lucas PA, et al. **J Surg Res** 1996 May;62(2):229–32

PHYSIOPATHOLOGY

Effects of interleukin-6 and its neutralizing antibodies on peritoneal adhesion formation and wound healing. Saba AA, et al. **Am Surg** 1996 Jul;62(7):569–72

PREVENTION & CONTROL

Comparison of covalently and physically cross-linked polyethylene glycol-based hydrogels for the prevention of postoperative adhesions in a rat model. West JL, et al. **Biomaterials** 1995 Oct;16(15):1153–6

Reduction of postoperative adhesion formation after laparoscopic ovarian cystectomy. Keckstein J, et al. **Hum Reprod** 1996 Mar;11(3):579–82

Post-operative adhesions after laparoscopic electrosurgical treatment for polycystic ovarian syndrome with the application of Interceed to one ovary: a prospective randomized controlled study. Saravelos H, et al. **Hum Reprod** 1996 May;11(5):992–7

Laparoscopy for adhesion prevention following myomectomy. Uğur M, et al. **Int J Gynaecol Obstet** 1996 May;53(2):145–9

Prevention of adhesion formation [editorial] Paraskevaides EC, et al. **Ir Med J** 1993 May;86(3):79–80

Comparative efficacy of nonsteroidal anti-inflammatory drugs and anti-thromboxane agents in a rabbit adhesion-prevention model. LeGrand EK, et al. **J Invest Surg** 1995 May–Jun;8(3):187–94

Novel antiadhesion barrier does not prevent anastomotic healing in a rabbit model. Medina M, et al. **J Invest Surg** 1995 May–Jun;8(3):179–86

Preventing adhesions. Thompson JN. **Lancet** 1995 Nov 25; 346(8987):1382

Application of polyvinyl alcohol hydrogel membrane as anti-adhesive interposition after spinal surgery. Hiraizumi Y, et al. **Spine** 1995 Nov 1;20(21):2272–7

Adhesion formation after laparoscopic anterior resection in a porcine model: a pilot study. Reissman P, et al. **Surg Laparosc Endosc** 1996 Apr;6(2):136–9

SURGERY

An analysis of the outcome of microsurgical and laparoscopic adhesiolysis for infertility. Saravelos HG, et al. **Hum Reprod** 1995 Nov;10(11):2887–94

An analysis of the outcome of microsurgical and laparoscopic adhesiolysis for chronic pelvic pain. Saravelos HG, et al. **Hum Reprod** 1995 Nov;10(11):2895–901

THERAPY

Etiology of and therapeutic approach to synechia uteri. Schenker JG. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):109–13 (20 ref.)

Evaluation of CMC and HA solutions for adhesiolysis. Peck LS, et al. **J Invest Surg** 1995 Sep–Oct;8(5):337–48

ADHESIVE CAPSULITIS see **BURSITIS**

ADHESIVENESS

see related
PLATELET ADHESIVENESS

ADHESIVES

see related
TISSUE ADHESIVES

A clinical evaluation of the effectiveness of a fluoride-releasing visible light-activated bonding system to reduce demineralization around orthodontic brackets. Trimpeneers LM, et al. **Am J Orthod Dentofacial Orthop** 1996 Aug;110(2):218–22

Biomarkers of exposure to organic solvents from glues used in table tennis bats. Karačić V, et al. **Arh Hig Rada Toksikol** 1995 Sep;46(3):307–11

Denture fixatives--an update for general dental practice. Jagger DC, et al. **Br Dent J** 1996 Apr 20;180(8):311–3 (18 ref.)

Blu-Tack--a novel substance of abuse [letter] Walker-Kinnear M, et al. **Br J Psychiatry** 1995 Oct; 167(4):550–1

Clinical evaluation of five adhesive systems: three-year results. Tyas MJ. **Int Dent J** 1996 Feb;46(1):10–4

Denture adhesives [letter] Escoe R. **J Am Dent Assoc** 1996 Jun;127(6):724

Denture adhesives: changing attitudes. Grasso JE. **J Am Dent Assoc** 1996 Jan;127(1):90–6 (36 ref.)

Effects of acidic conditioners on dentine demineralization and dimension of hybrid layers. Uno S, et al. **J Dent** 1996 May;24(3):211–6

Optimization of microencapsulation of acrylic adhesives. Giroud F, et al. **J Microencapsul** 1995 Jul–Aug; 12(4):389–400

Biomarkers of exposure, antibodies, and respiratory symptoms in workers heating polyurethane glue. Skarping G, et al. **Occup Environ Med** 1996 Mar;53(3):180–7

[Embolization of AVM's of thoracic spinal cord with histoacryl glue] Radek A, et al. **Neurol Neurochir Pol** 1996 Mar–Apr;30(2):333–45 (Eng. Abstr.) **(Pol)**

ADMINISTRATION & DOSAGE

In vitro assessment of bioadhesion for periodontal and buccal drug delivery. Needleman IG, et al. **Biomaterials** 1995 May; 16(8):617–24

ADVERSE EFFECTS

Contact allergy to components of glue in insulin pump infusion sets. Busschots AM, et al. **Contact Dermatitis** 1995 Sep;33(3):205–6

Occupational allergic contact dermatitis from 2-hydroxyethyl methacrylate and ethylene glycol dimethacrylate in a modified acrylic structural adhesive. Kanerva L, et al. **Contact Dermatitis** 1995 Aug;33(2):84–9

Contact urticaria from abietic acid. el Sayed F, et al. **Contact Dermatitis** 1995 Jun;32(6):361–2

Analysis of patients with allergic patch test reactions to a plastics and glues series. Tarvainen K. **Contact Dermatitis** 1995 Jun;32(6):346–51

Superglue lids: possibly non-accidental and a medico-legal problem [letter] Landers A, et al. **Eye** 1996;10 (Pt 3):402–3

[Asthma, rhinitis and urticaria following occupational exposure to cyanoacrylate glues] Kopferschmit-Kubler MC, et al. **Rev Mal Respir** 1996 Jul;13(3):305–7 (Eng. Abstr.) **(Fre)**

ANALYSIS

[The identification of glues in cadaveric material] Muzhanovskiĭ EB, et al. **Sud Med Ekspert** 1995 Jul–Sep; 38(3):28–30 (Eng. Abstr.) **(Rus)**

CHEMISTRY

A microtensiometer for the analysis of bioadhesive microspheres. Chickering DE 3rd, et al. **Biomed Instrum Technol** 1995 Nov–Dec;29(6):501–12

Crystal bonding--an adhesive system with a future? Knox J, et al. **Br J Orthod** 1995 Nov;22(4):309–17

Effect of mechanical load cycling on the marginal integrity of adhesive Class I resin composite restorations. Abdalla AI, et al. **J Dent** 1996 Jan–Mar;24(1–2):87–90

Shear bond strength of four dentinal adhesives applied in vivo and in vitro. Mason PN, et al. **J Dent** 1996 May; 24(3):217–22

New surface-active comonomer for adhesive bonding. Bowen RL, et al. **J Dent Res** 1996 Jan;75(1):606–10

Design and development of isocyanatoacrylates as dental adhesives. Chappelow CC, et al. **J Dent Res** 1996 Feb; 75(2):761–7

Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design. Roy SD, et al. **J Pharm Sci** 1996 May; 85(5):491–5

Wresting the muscle from mussel beards: research and applications. Rzepecki LM, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):313–22 (45 ref.)

THERAPEUTIC USE

Fibrin glue used as an adhesive agent in CNS tissues. Cheng H, et al. **J Neural Transplant Plast** 1995;5(4):233–43

ADIE'S SYNDROME

HISTORY

[The man behind the syndrome: William John Adie. He won an involuntary victory in an academic dispute] Carlsson M. **Lakartidningen** 1996 May 15;93(20):1966–9 **(Swe)**

ADIPIC ACIDS

METABOLISM

Repression of 4-hydroxybenzoate transport and degradation by benzoate: a new layer of regulatory control in the Pseudomonas putida beta-ketoadipate pathway. Nichols NN, et al. **J Bacteriol** 1995 Dec;177(24):7033–40

From xenobiotic to antibiotic, formation of protoanemonin from 4-chlorocatechol by enzymes of the 3-oxoadipate pathway. Blasco R, et al. **J Biol Chem** 1995 Dec 8; 270(49):29229–35

RADIATION EFFECTS

Effect of gamma-radiation on migration behaviour of dioctyladipate and acetyltributylcitrate plasticizers from food-grade PVC and PVDC/PVC films into olive oil. Goulas AE, et al. **Z Lebensm Unters Forsch** 1995 Jul; 201(1):74–8

URINE

Benign adipic aciduria [letter] Hunneman DH, et al. **Lancet** 1996 Jun 22;347(9017):1772–3

ADIPOCERE see **POSTMORTEM CHANGES**

ADIPOCYTES

Cellular and Molecular Biology of Adipose Cell Development and Growth. Proceedings of an international symposium. Ottawa, Ontario, Canada, 17–18 August 1994. Dedicated to the memory of Daniel AK Roncari. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S1–130

CHEMISTRY

Determination of gaseous and dissolved oxygen in a closed fat cell culture system. Böttcher H, et al. **Anal Biochem** 1995 Sep 1;230(1):149–53

Quantity of Na/K-ATPase and glucose transporters in the plasma membrane of rat adipocytes is reduced by in vivo triiodothyronine. Voldstedlund M, et al. **Eur J Endocrinol** 1995 Nov;133(5):626–34

Beta-adrenergic receptors in porcine adipocyte membranes: modification by animal age, depot site, and dietary protein deficiency. Akanbi KA, et al. **J Anim Sci** 1996 Mar; 74(3):551–61

Evidence of classic beta 3-adrenergic receptors in porcine adipocytes. Mersmann HJ. **J Anim Sci** 1996 May; 74(5):984–92

The major integral membrane glycoprotein in adipocytes is a novel 200-kDa heterodimer. Jochen A, et al. **Mol Membr Biol** 1995 Jul–Sep;12(3):277–81

Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Scherer PE, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):131–5

CYTOLOGY

Site-related differences in G-protein alpha subunit expression during adipogenesis in vitro: possible key role for Gq/11 alpha in the control of preadipocyte differentiation. Denis-Henriot D, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):443–8

The expression of and insulin binding to cellular thyroid hormone binding protein, but not insulin degrading enzyme, is increased during 3T3-L1 adipocytes differentiation. Lee YH, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):839–43

Differentiation of rat brown adipocytes during late foetal development: role of insulin-like growth factor I. Teruel T, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):771–6

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Schoonjans K, et al. **Biochim Biophys Acta** 1996 Jul 26;1302(2):93–109 (259 ref.)

Interferon alpha/beta-induced abnormalities in adipocytes of suckling mice. Sbarbati A, et al. **Biol Cell** 1995; 83(2–3):163–7

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Forman BM, et al. **Cell** 1995 Dec 1;83(5):803–12

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Kliewer SA, et al. **Cell** 1995 Dec 1;83(5):813–9

Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Tontonoz P, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):571–6 (51 ref.)

Ras is involved in gap junction closure in proliferating fibroblasts or preadipocytes but not in differentiated adipocytes. Brownell HL, et al. **DNA Cell Biol** 1996 Jun; 15(6):443–51

Inhibition of adipogenesis by the stress-induced protein CHOP (Gadd153). Batchvarova N, et al. **EMBO J** 1995 Oct 2;14(19):4654–61

Regulation of preadipocyte factor-1 gene expression during 3T3-L1 cell differentiation. Boney CM, et al. **Endocrinology** 1996 Jul;137(7):2923–8

1,25-Dihydroxyvitamin D induces lipoprotein lipase expression in 3T3-L1 cells in association with adipocyte differentiation. Vu D, et al. **Endocrinology** 1996 May; 137(5):1540–4

Influence of growth factors on growth and differentiation of 3T3-L1 preadipocytes in serum-free conditions. Bachmeier M, et al. **Eur J Cell Biol** 1995 Nov;68(3):323–9

Peroxisome proliferator-activated receptors: a nuclear hormone receptor involved in adipocyte differentiation and lipid homeostasis. Shalev A, et al. **Eur J Endocrinol** 1996 May;134(5):541–2

Human osteogenic protein-1 induces chondroblastic, osteoblastic, and/or adipocytic differentiation of clonal murine target cells. Asahina I, et al. **Exp Cell Res** 1996 Jan 10;222(1):38–47

Temporal regulation of gene expression in adipocyte differentiation. Martino JJ, et al. **FEBS Lett** 1996 Apr 29; 385(1–2):1–3

ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Kim JB, et al. **Genes Dev** 1996 May 1;10(9):1096–107

Comparison of the adipoconversion of preadipocytes derived from lean and obese Zucker rats in serum-free cultures. Grégoire FM, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19(9):664–70

The possibility of active form of vitamins A and D as suppressors on adipocyte development via ligand-dependent transcriptional regulators. Kawada T, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S52–7 (22 ref.)

Control of adipocyte differentiation by CCAAT/enhancer binding protein alpha (C/EBP alpha). Lane MD, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S91–6

(16 ref.)
The insulin/Ras pathway of adipocytic differentiation of 3T3 L1 cells: dissociation between Raf-1 kinase and the MAPK/RSK cascade. Porras A, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S43-51 (47 ref.)
Endocrine and paracrine negative regulators of adipose differentiation. Serrero G, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S58-64 (33 ref.)
A novel method for studying preadipocyte differentiation in vitro. Shillabeer G, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S77-83
Characterization of Pref-1 and its inhibitory role in adipocyte differentiation. Smas CM, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S65-72 (44 ref.)
Increasing vimentin expression associated with differentiation of human and rat preadipocytes. Teichert-Kuliszewska K, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S108-13
The Gs alpha/Gi alpha 2 axis controls adipogenesis independently of adenylylcyclase. Wang HY, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S26-31 (62 ref.)
Growth and maturation of primary-cultured adipocytes from lean and ob/ob mice. Black MA, et al. **J Cell Biochem** 1995 Aug;58(4):455-63
Transforming growth factor beta 1 induces mitogenesis in fetal rat brown adipocytes. Teruel T, et al.
J Cell Physiol 1996 Mar;166(3):577-84
Functional assessment of white and brown adipocyte development and energy metabolism in cell culture. Dissociation of terminal differentiation and thermogenesis in brown adipocytes. Klaus S, et al. **J Cell Sci** 1995 Oct; 108 (Pt 10):3171-80
Cellular characterization of adipose tissue from various body sites of women. Rink JD, et al.
J Clin Endocrinol Metab 1996 Jul;81(7):2443-7
Effects of growth hormone antagonists on 3T3-F442A preadipocyte differentiation. Xu BC, et al. **J Endocrinol** 1995 Jul;146(1):131-9
The block of adipocyte differentiation by a C-terminally truncated, but not by full-length, simian virus 40 large tumor antigen is dependent on an intact retinoblastoma susceptibility protein family binding domain. Higgins C, et al. **J Virol** 1996 Feb;70(2):745-52
The role of growth hormone/insulin-like growth factors in adipocyte differentiation. Wabitsch M, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):45-9 (58 ref.)
Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Wu Z, et al. **Mol Cell Biol** 1996 Aug; 16(8):4128-36
Distinct stages in adipogenesis revealed by retinoid inhibition of differentiation after induction of PPARgamma. Xue JC, et al. **Mol Cell Biol** 1996 Apr;16(4):1567-75
Effect of full feed and early feed restriction on broiler performance, abdominal fat level, cellularity, and fat metabolism in broiler chickens. Zhong C, et al.
Poult Sci 1995 Oct;74(10):1636-43
Identification and characterization of an immunophilin expressed during the clonal expansion phase of adipocyte differentiation. Yeh WC, et al.
Proc Natl Acad Sci U S A 1995 Nov 21;92(24):11081-5
Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Yeh WC, et al.
Proc Natl Acad Sci U S A 1995 Nov 21;92(24):11086-90
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibition of fat cell differentiation. Brodie AE, et al. **Toxicol Lett** 1996 Jan;84(1):55-9
[Proliferation and differentiation of fat cells] Sugihara H, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:115-20 (9 ref.) **(Jpn)**

DRUG EFFECTS

Viability of fat obtained by syringe suction lipectomy: effects of local anesthesia with lidocaine. Moore JH Jr, et al.
Aesthetic Plast Surg 1995 Jul-Aug;19(4):335-9
Comparison of trophic effects of norepinephrine, insulin, and IGF-1 in mouse brown adipocytes. Desautels M, et al.
Am J Physiol 1996 Jun;270(6 Pt 2):R1287-95
Orally active and long-term acting insulin-mimetic vanadyl complex:bis(picolinato)oxovanadium (IV). Sakurai H, et al.
Biochem Biophys Res Commun 1995 Sep 25;214(3):1095-101
Cyclic AMP stimulates the phosphorylation and activation of p42 and p44 mitogen-activated protein kinases in 3T3-F442A preadipocytes. Yarwood SJ, et al.
Biochem Biophys Res Commun 1996 Jul 25;224(3):734-9
Effect of pentoxifylline on the fibrogenic functions of cultured rat liver fat-storing cells and myofibroblasts. Windmeier C, et al. **Biochem Pharmacol** 1996 Mar 8; 51(5):577-84
Evidence for the distinct vanadyl(+4)-dependent activating system for manifesting insulin-like effects. Li J, et al.
Biochemistry 1996 Jun 25;35(25):8314-8
Influence of acetaldehyde and ethanol on rat hepatic lipocyte characteristics in primary culture. Sato T, et al.
Cell Biol Int 1995 Oct;19(10):879-81
Effects of wortmannin on glucose uptake and protein kinase C activity in rat adipocytes. Ishizuka T, et al.
Diabetes Res Clin Pract 1995 Sep;29(3):143-52
Tyrosine phosphorylation of the growth hormone (GH) receptor and Janus tyrosine kinase-2 is involved in the insulin-like actions of GH in primary rat adipocytes. Eriksson H, et al. **Endocrinology** 1995 Nov; 136(11):5093-101
Insulin stimulates the expression of basic fibroblast growth factor in rat brown adipocyte primary culture. Yamashita H, et al. **Eur J Cell Biol** 1995 Sep;68(1):8-13
The acid metabolite of ZD7114 is a partial agonist of lipolysis mediated by the rat beta 3-adrenoceptor. Mayers RM, et al. **Eur J Pharmacol** 1996 Jan 11;295(2-3):199-205
Differential activation of beta 1-, beta 2- and beta 3-adrenoceptors by catecholamines in white and brown adipocytes. Galitzky J, et al. **Fundam Clin Pharmacol** 1995; 9(4):324-31 (54 ref.)
Physiological effect of glucagon in human isolated adipocytes. Perea A, et al. **Horm Metab Res** 1995 Aug; 27(8):372-5
Adipocyte insulin action during the normal menstrual cycle. Marsden PJ, et al. **Hum Reprod** 1996 May;11(5):968-74
Counter modulation of adipocyte mitochondrial processes by insulin and S-oxalylglutathione. Moore KH, et al.
Int J Biochem Cell Biol 1996 Feb;28(2):183-91
The possibility of active form of vitamins A and D as suppressors on adipocyte development via ligand-dependent transcriptional regulators. Kawada T, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S52-7 (22 ref.)
Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. Guido M, et al. **J Hepatol** 1996 Mar; 24(3):301-7
Effect of tumor necrosis factor-alpha on basal and insulin-stimulated glucose transport in cultured muscle and fat cells. Ranganathan S, et al. **Metabolism** 1996 Sep; 45(9):1089-94
Biological effects of human growth hormone in rat adipocyte precursor cells and newly differentiated adipocytes in primary culture. Wabitsch M, et al. **Metabolism** 1996 Jan; 45(1):34-42
Wortmannin and LY294002 inhibit the insulin-induced down-regulation of IRS-1 in 3T3-L1 adipocytes. Smith LK, et al. **Mol Cell Endocrinol** 1995 Aug 30;113(1):73-81
Enhanced desensitization and phosphorylation of the beta 1-adrenergic receptor in rat adipocytes by peroxovanadate. Bahouth SW, et al. **Mol Pharmacol** 1996 Jun;49(6):1049-57
Alteration by 2,3,7,8-Tetrachlorodibenzo-p-dioxin of CCAAT/enhancer binding protein correlates with suppression of adipocyte differentiation in 3T3-L1 cells. Liu PC, et al. **Mol Pharmacol** 1996 Jun;49(6):989-97
Functional studies of the first selective beta 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes. Nisoli E, et al. **Mol Pharmacol** 1996 Jan;49(1):7-14
Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Wakitani S, et al.
Muscle Nerve 1995 Dec;18(12):1417-26
Systolic blood pressure is related to catecholamine sensitivity in subcutaneous abdominal fat cells. Hoffstedt J, et al.
Obes Res 1996 Jan;4(1):21-6
Cardiovascular and antilipolytic effects of the adenosine agonist GR79236. Merkel LA, et al. **Pharmacology** 1995 Oct;51(4):224-36
Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Kallen CB, et al.
Proc Natl Acad Sci U S A 1996 Jun 11;93(12):5793-6
[A comparison of some methods for administering the Ca-dependent photoprotein obelin into the adipocytes of the brown fat in the rat] Elsukova EI, et al. **Tsitologiia** 1995;37(5-6):440-3 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Fatty acids regulate the expression of lipoprotein lipase gene and activity in preadipose and adipose cells. Amri EZ, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):541-6
Protein kinase C isoforms epsilon, eta, delta and zeta in murine adipocytes: expression, subcellular localization and tissue-specific regulation in insulin-resistant states. Frevert EU, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):865-71
Compartment-specific regulation of phosphoinositide 3-kinase by platelet-derived growth factor and insulin in 3T3-L1 adipocytes. Navé BT, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):55-60
Brefeldin A enables synthesis of active lipoprotein lipase in cld/cld and castanospermine-treated mouse brown adipocytes via translocation of Golgi components to endoplasmic reticulum. Park JW, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):125-34
Fatty acids and fibrates are potent inducers of transcription of the phosphenolpyruvate carboxykinase gene in adipocytes. Antras-Ferry J, et al. **Eur J Biochem** 1995 Dec 1;234(2):390-6
Endothelin-1, but not endothelin-3, suppresses lipoprotein lipase gene expression in brown adipocytes differentiated in culture. Uchida Y, et al. **Eur J Pharmacol** 1995 Sep 15; 291(1):33-41
Effects of phorbol esters on insulin-induced activation of phosphatidylinositol 3-kinase, glucose transport, and glycogen synthase in rat adipocytes. Standaert ML, et al. **FEBS Lett** 1996 Jun 10;388(1):26-8
A GC-rich region containing Sp1 and Sp1-like binding sites is a crucial regulatory motif for fatty acid synthase gene promoter activity in adipocytes. Implication In the overactivity of FAS promoter in obese Zucker rats. Rolland V, et al. **J Biol Chem** 1996 Aug 30; 271(35):21297-302
Characterization of the insulin-regulated membrane aminopeptidase in 3T3-L1 adipocytes. Ross SA, et al.
J Biol Chem 1996 Feb 9;271(6):3328-32
Beta 3-adrenergic activation of adenylyl cyclase in mouse white adipocytes: modulation by GTP and effect of obesity. Bégin-Heick N. **J Cell Biochem** 1995 Aug;58(4):464-73
Regulation of lipoprotein lipase translation by epinephrine in 3T3-L1 cells. Importance of the 3' untranslated region. Yukht A, et al. **J Clin Invest** 1995 Nov;96(5):2438-44
Insulin increases lipogenic enzyme activity in human adipocytes in primary culture. Moustaïd N, et al.
J Nutr 1996 Apr;126(4):865-70

METABOLISM

Relationship between adipose stromal-vascular cells and adipocytes in human adipose tissue. O'Brien SN, et al.
Anal Quant Cytol Histol 1996 Apr;18(2):137-43
Dexamethasone regulates obese expression in isolated rat adipocytes. Murakami T, et al.
Biochem Biophys Res Commun 1995 Sep 25;214(3):1260-7
Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes. Stouthard JM, et al.
Biochem Biophys Res Commun 1996 Mar 18;220(2):241-5
Cleavage of vesicle-associated membrane protein (VAMP)-2 and cellubrevin on GLUT4-containing vesicles inhibits the translocation of GLUT4 in 3T3-L1 adipocytes. Tamori Y, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):740-5
Overexpression of the obese gene in the genetically obese JCR:LA-corpulent rat. Vydelingum S, et al.
Biochem Biophys Res Commun 1995 Nov 2;216(1):148-53
Membrane permeation and intracellular trafficking of long chain fatty acids: insights from Escherichia coli and 3T3-L1 adipocytes. Mangroo D, et al.
Biochem Cell Biol 1995 May-Jun;73(5-6):223-34 (98 ref.)
Both rapamycin-sensitive and -insensitive pathways are involved in the phosphorylation of the initiation factor-4E-binding protein (4E-BP1) in response to insulin in rat epididymal fat-cells. Diggle TA, et al.
Biochem J 1996 Jun 1;316 (Pt 2):447-53
Multiple signalling pathways involved in the stimulation of fatty acid and glycogen synthesis by insulin in rat epididymal fat cells. Moule SK, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):595-601
Phorbol esters stimulate phosphatidylinositol 3,4,5-trisphosphate production in 3T3-L1 adipocytes: implications for stimulation of glucose transport. Navé BT, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):203-5
Hormonal regulation of glucose transport in a brown adipose cell preparation isolated from rats that shows a large response to insulin. Omatsu-Kanbe M, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):25-31
The selective mobilization of fatty acids is not based on their positional distribution in white-fat-cell triacylglycerols. Raclot T, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):911-6
Noradrenaline increases glucose transport into brown adipocytes in culture by a mechanism different from that of insulin. Shimizu Y, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):485-90
The effect of intracellular pH on long-chain fatty acid uptake in 3T3-L1 adipocytes: evidence that uptake involves the passive diffusion of protonated long-chain fatty acids across the plasma membrane. Trigatti BL, et al.
Biochem J 1996 Jan 15;313 (Pt 2):487-94
Involvement of phosphatidylinositol 3-kinase in stimulation of glucose transport by growth factors in 3T3-L1 adipocytes. Conricode KM. **Biochem Mol Biol Int** 1995 Jul;36(4):835-43
Insulinomimetic effects of myricetin on lipogenesis and glucose transport in rat adipocytes but not glucose transport translocation. Ong KC, et al.
Biochem Pharmacol 1996 Feb 23;51(4):423-9
Kinetic analysis of glucose transporter trafficking in fibroblasts and adipocytes. Yeh JI, et al. **Biochemistry** 1995 Nov 28;34(47):15523-31
Vitamin A contained in the lipid droplets of rat liver stellate cells is substrate for acid retinyl ester hydrolase. Azaïs-Braesco V, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):271-6
Inhibitory effects of cerulenin on protein palmitoylation and insulin internalization in rat adipocytes. Jochen AL, et al.
Biochim Biophys Acta 1995 Oct 26;1259(1):65-72
Phenylarsine oxide and vanadate: apparent paradox of inhibition of protein phosphotyrosine phosphatases in rat adipocytes. Li J, et al. **Biochim Biophys Acta** 1996 Jul 24; 1312(3):223-30
Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. Miki H, et al. **Biochim Biophys Acta** 1996 Jun 13;1312(2):132-6
Cryptic receptors for insulin-like growth factor II in the plasma membrane of rat adipocytes--a possible link to cellular insulin resistance. Yu ZW, et al.
Biochim Biophys Acta 1996 Jun 13;1282(1):57-62
Mechanism on insulin-like action of vanadyl sulfate: studies on interaction between rat adipocytes and vanadium compounds. Nakai M, et al. **Biol Pharm Bull** 1995 May; 18(5):719-25
Elaboration of type-1 plasminogen activator inhibitor from

adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Lundgren CH, et al. **Circulation** 1996 Jan 1;93(1):106–10

Tissue deposition rates in relation to muscle fibre and fat cell characteristics in lean female pigs (Sus scrofa) following treatment with porcine growth hormone (pGH). Sørensen MT, et al. **Comp Biochem Physiol A Physiol** 1996 Feb;113(2):91–6

The GTP-binding protein Rac does not couple PI 3-kinase to insulin-stimulated glucose transport in adipocytes. Marcusohn J, et al. **Curr Biol** 1995 Nov 1;5(11):1296–302

Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Tontonoz P, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):571–6 (51 ref.)

Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro. Kolaczynski JW, et al. **Diabetes** 1996 May;45(5):699–701

Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Nolan JJ, et al. **Diabetes** 1996 Sep; 45(9):1276–8

The antihyperglycemic agent englitazone prevents the defect in glucose transport in rats fed a high-fat diet. Stevenson RW, et al. **Diabetes** 1996 Jan;45(1):60–6

Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes. Christie AW, et al. **Diabetologia** 1996 Jan; 39(1):45–53

Expression of a dominant-negative Ras mutant does not affect stimulation of glucose uptake and glycogen synthesis by insulin. Dorrestijn J, et al. **Diabetologia** 1996 May; 39(5):558–63

Binding of human, porcine and bovine insulin to insulin receptors from human brain, muscle and adipocytes and to expressed recombinant alternatively spliced insulin receptor isoforms [see comments] Kotzke G, et al. **Diabetologia** 1995 Jul;38(7):757–63. Comment in: Diabetologia 1996 Feb;39(2):248–9.

A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Paolisso G, et al. **Diabetologia** 1995 Oct;38(10):1213–7

Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line. Boston BA, et al. **Endocrinology** 1996 May;137(5):2043–50

Regulation of glucose transporters in cultured rat adipocytes: synergistic effect of insulin and dexamethasone on GLUT4 gene expression through promoter activation. Hajduch E, et al. **Endocrinology** 1995 Nov;136(11):4782–9

Triiodothyronine regulates beta 3-adrenoceptor expression in 3T3-F442A differentiating adipocytes. el Hadri K, et al. **Eur J Biochem** 1996 Jul 15;239(2):519–25

Differentiation-induced production of ASP in human adipocytes. Cianflone K, et al. **Eur J Clin Invest** 1995 Nov; 25(11):817–25

Identification of oestrogen receptors and oestrogen receptor mRNA in human adipose tissue [see comments] Pedersen SB, et al. **Eur J Clin Invest** 1996 Apr;26(4):262–9. Comment in: Eur J Clin Invest 1996 Apr;26(4):259–31.

Translocation of insulin-regulated glucose transporter is stimulated by long-chain 1,2-diacylglycerol in rat adipocytes. Gustavsson J, et al. **Exp Cell Res** 1995 Dec; 221(2):438–42

Uptake and metabolism of long-chain 1,2-diacylglycerols by rat adipocytes and H4IIE hepatoma cells. Gustavsson J, et al. **Exp Cell Res** 1995 Dec;221(2):443–7

Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes. Hazen SA, et al. **FASEB J** 1996 Mar; 10(4):481–90

Expression and function of integrin receptors for collagen and laminin in cultured human hepatic stellate cells. Carloni V, et al. **Gastroenterology** 1996 Apr;110(4):1127–36

Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Pinzani M, et al. **Gastroenterology** 1996 Feb;110(2):534–48

Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. Wu Z, et al. **Genes Dev** 1995 Oct 1;9(19):2350–63

Effects of aging and antioxidants on glucose transport in rat adipocytes. Moustafa SA, et al. **Gerontology** 1995; 41(6):301–7

Transforming growth factor beta 1-regulated gene expression of Ito cells. Knittel T, et al. **Hepatology** 1996 Aug; 24(2):352–60

Physiological effect of glucagon in human isolated adipocytes. Perea A, et al. **Horm Metab Res** 1995 Aug; 27(8):372–5

Effects of sodium saccharin diet on fat-cell lipolysis: evidence for increased function of the adenylyl cyclase catalyst. Dib K, et al. **Int J Obes Relat Metab Disord** 1996 Jan; 20(1):15–20

Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Hoffstedt J, et al. **Int J Obes Relat Metab Disord** 1996 May;20(5):428–34

Effects of fat depot site on differentiation-dependent gene expression in rat preadipocytes. Kirkland JL, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S102–7

Perilipin: possible roles in structure and metabolism of intracellular neutral lipids in adipocytes and steroidogenic cells. Londos C, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S97–101 (13 ref.)

Dexfenfluramine inhibits catecholamine stimulated in vitro lipolysis in human fat cells. Richter WO, et al. **Int J Obes Relat Metab Disord** 1995 Jul;19(7):503–5

Metabolic disruptions in the adipocyte-hepatocyte fatty acid axis as causes of HyperapoB. Sniderman AD, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S27–33 (68 ref.)

Alpha 2A-adrenergic regulation of cyclic AMP accumulation and lipolysis in human omental and subcutaneous adipocytes. Vikman HL, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20(2):185–9

The effects of brefeldin A on the glucose transport system in rat adipocytes. Implications regarding the intracellular locus of insulin-sensitive Glut4. Bao S, et al. **J Biol Chem** 1995 Dec 15;270(50):30199–204

Translocation of GLUT1 does not account for elevated glucose transport in glucose-deprived 3T3-L1 adipocytes. Fisher MD, et al. **J Biol Chem** 1996 May 17; 271(20):11806–9

Tumor necrosis factor promotes phosphorylation and binding of insulin receptor substrate 1 to phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. Guo D, et al. **J Biol Chem** 1996 Jan 12;271(2):615–8

Insulin-stimulated GLUT4 translocation is mediated by a divergent intracellular signaling pathway. Haruta T, et al. **J Biol Chem** 1995 Nov 24;270(47):27991–4

Insulin regulation of membrane-associated insulin receptor substrate 1. Heller-Harrison RA, et al. **J Biol Chem** 1995 Oct 13;270(41):24442–50

Effect of the activation of phosphatidylinositol 3-kinase by a thiophosphotyrosine peptide on glucose transport in 3T3-L1 adipocytes. Herbst JJ, et al. **J Biol Chem** 1995 Oct 27;270(43):26000–5

AdipoQ is a novel adipose-specific gene dysregulated in obesity. Hu E, et al. **J Biol Chem** 1996 May 3; 271(18):10697–703

Overexpression of catalytic subunit p110alpha of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1 adipocytes. Katagiri H, et al. **J Biol Chem** 1996 Jul 19;271(29):16987–90

Expression of ob gene in adipose cells. Regulation by insulin. Leroy P, et al. **J Biol Chem** 1996 Feb 2;271(5):2365–8

Regulation of GLUT4 gene expression by arachidonic acid. Evidence for multiple pathways, one of which requires oxidation to prostaglandin E2. Long SD, et al. **J Biol Chem** 1996 Jan 12;271(2):1138–44

Activated phosphatidylinositol 3-kinase is sufficient to mediate actin rearrangement and GLUT4 translocation in 3T3-L1 adipocytes. Martin SS, et al. **J Biol Chem** 1996 Jul 26;271(30):17605–8

Identification of the site in the cGMP-inhibited phosphodiesterase phosphorylated in adipocytes in response to insulin and isoproterenol. Rahn T, et al. **J Biol Chem** 1996 May 10;271(19):11575–80

Kinetics of fatty acid interactions with fatty acid binding proteins from adipocyte, heart, and intestine. Richieri GV, et al. **J Biol Chem** 1996 May 10;271(19):11291–300

Okadaic acid exerts a full insulin-like effect on glucose transport and glucose transporter 4 translocation in human adipocytes. Evidence for a phosphatidylinositol 3-kinase-independent pathway. Rondinone CM, et al. **J Biol Chem** 1996 Jul 26;271(30):18148–53

A synthetic peptide corresponding to the Rab4 hypervariable carboxyl-terminal domain inhibits insulin action on glucose transport in rat adipocytes. Shibata H, et al. **J Biol Chem** 1996 Apr 19;271(16):9704–9

Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP. Slieker LJ, et al. **J Biol Chem** 1996 Mar 8;271(10):5301–4

The expression and regulation of STATs during 3T3-L1 adipocyte differentiation. Stephens JM, et al. **J Biol Chem** 1996 May 3;271(18):10441–4

Glut4 is targeted to specific vesicles in adipocytes of transgenic mice overexpressing Glut4 selectively in adipose tissue. Tozzo E, et al. **J Biol Chem** 1996 May 3; 271(18):10490–4

Protein kinase C isoform expression during the differentiation of 3T3-L1 preadipocytes: loss of protein kinase C-alpha isoform correlates with loss of phorbol 12-myristate 13-acetate activation of nuclear factor kappaB and acquisition of the adipocyte phenotype. McGowan K, et al. **J Cell Physiol** 1996 Apr;167(1):113–20

Characterization and regulation of the latent transforming growth factor-beta complex secreted by vascular pericytes. Marra F, et al. **J Cell Physiol** 1996 Mar;166(3):537–46

Functional assessment of white and brown adipocyte development and energy metabolism in cell culture. Dissociation of terminal differentiation and thermogenesis in brown adipocytes. Klaus S, et al. **J Cell Sci** 1995 Oct; 108 (Pt 10):3171–80

Effect of glucocorticosteroid treatment on glucocorticoid receptor expression in human adipocytes. Brönnegård M, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3608–12

Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. Grunfeld C, et al. **J Clin Invest** 1996 May 1;97(9):2152–7

Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. Lee KS, et al. **J Clin Invest** 1995 Nov; 96(5):2461–8

Additive effects of growth hormone and testosterone on lipolysis in adipocytes of hypophysectomized rats. Yang S, et al. **J Endocrinol** 1995 Oct;147(1):147–52

Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. Rockey DC, et al. **J Investig Med** 1994 Dec;42(4):660–70

Metabolism of fenbufen by cultured 3T3-L1 adipocytes: synthesis and metabolism of xenobiotic glycerolipids. Dodds PF, et al. **J Lipid Res** 1995 Dec;36(12):2493–503

Selective mobilization of adipose tissue fatty acids during energy depletion in the rat. Raclot T, et al. **J Lipid Res** 1995 Oct;36(10):2164–73

Dietary (n-3) polyunsaturated fatty acids improve adipocyte insulin action and glucose metabolism in insulin-resistant rats: relation to membrane fatty acids. Luo J, et al. **J Nutr** 1996 Aug;126(8):1951–8

Alpha-1 adrenergic regulation of lactate production by white adipocytes. Faintrenie G, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):235–8

Functional interactions of phosphatidylinositol 3-kinase with GTPase-activating protein in 3T3-L1 adipocytes. DePaolo D, et al. **Mol Cell Biol** 1996 Apr;16(4):1450–7

Roles of 1-phosphatidylinositol 3-kinase and ras in regulating translocation of GLUT4 in transfected rat adipose cells. Quon MJ, et al. **Mol Cell Biol** 1995 Oct;15(10):5403–11

Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma. Sears IB, et al. **Mol Cell Biol** 1996 Jul;16(7):3410–9

Wortmannin and LY294002 inhibit the insulin-induced down-regulation of IRS-1 in 3T3-L1 adipocytes. Smith LK, et al. **Mol Cell Endocrinol** 1995 Aug 30;113(1):73–81

A eukaryotic transcriptional repressor with carboxypeptidase activity. He GP, et al. **Nature** 1995 Nov 2;378(6552):92–6

Determination of beta 3-adrenoceptor mediated lipolysis in human fat cells. Hoffstedt J, et al. **Obes Res** 1995 Sep; 3(5):447–57

The 3-phosphorylated phosphoinositide response of 3T3-L1 preadipose cells exposed to insulin, insulin-like growth factor-1, or platelet-derived growth factor. Sorisky A, et al. **Obes Res** 1996 Jan;4(1):9–19

Mechanism of increase in basal lipolysis of enlarged adipocytes in obese animals. Tsujita T, et al. **Obes Res** 1995 Dec;3 Suppl 5:633S–636S

Growth hormone (GH) treatment up-regulates GH receptor mRNA levels in adipocytes from patients with GH deficiency and Prader-Willi syndrome. Kamel A, et al. **Pediatr Res** 1995 Sep;38(3):418–21

Increased plasma IGF-1 levels but lack of changes in adipocyte glucose transport in weanling rats with dorsomedial hypothalamic nucleus lesions 1 year after lesion production. Bernardis LL, et al. **Physiol Behav** 1996 Apr-May;59(4-5):689–97

Brazilin stimulates the glucose transport in 3T3-L1 cells. Kim YM, et al. **Planta Med** 1995 Aug;61(4):297–301

Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport. Ibrahimi A, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2646–51

The inability of phosphatidylinositol 3-kinase activation to stimulate GLUT4 translocation indicates additional signaling pathways are required for insulin-stimulated glucose uptake. Isakoff SJ, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10247–51

Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. MacDougald OA, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9034–7

The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression. Miller SG, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5507–11

Cellular aspects of fuel mobilization and selection in white adipocytes. Lafontan M, et al. **Proc Nutr Soc** 1995 Mar; 54(1):49–63 (81 ref.)

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Hotamisligil GS, et al. **Science** 1996 Feb 2; 271(5249):665–8

[Molecular biology of adipocyte metabolism and obese gene] Kagawa Y. **Nippon Rinsho** 1995 Jun;53 Suppl:93–9 (16 ref.) **(Jpn)**

[Role of peptide hormones in adipocyte metabolism] Kaneko T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:100–5 (20 ref.) **(Jpn)**

[Role of catecholamines in adipocyte metabolism] Nagasaka Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:106–10 (13 ref.) **(Jpn)**

[Role of steroid hormone in adipocyte metabolism] Nagasaka Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:111–4 (9 ref.) **(Jpn)**

[The effect of neonatal nutrition on lipolysis and catecholamine binding in rat adipocytes] Macho L, et al. **Bratisl Lek Listy** 1995 Nov;96(11):581–5 (Eng. Abstr.) **(Slo)**

PARASITOLOGY

Parasitism of adipocytes by Trypanosoma cruzi. Andrade ZA, et al. **Mem Inst Oswaldo Cruz** 1995 Jul-Aug; 90(4):521–2

PATHOLOGY

Chondroid lipoma, a tumor of white fat cells. A brief report of two cases with ultrastructural analysis. Nielsen GP, et al. **Am J Surg Pathol** 1995 Nov;19(11):1272–6

ADIPOCYTES

Molecular mechanisms of liver fibrogenesis--a homage to the role of activated fat-storing cells. Gressner AM, et al. **Digestion** 1995;56(5):335-46 (99 ref.)
Hepatic stellate cell nomenclature [letter] **Hepatology** 1996 Jan;23(1):193
Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Baroni GS, et al. **Hepatology** 1996 May;23(5):1189-99
Molecular dissection of the mitogenic effect of hepatocytes on cultured hepatic stellate cells. Gressner AM, et al. **Hepatology** 1995 Nov;22(5):1507-18
The aging process of skin and the increase in size of subcutaneous adipocytes. Baldassarri P, et al. **Int J Tissue React** 1994;16(5-6):229-41
Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. Sorisky A, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3428-31
Massive papillary dermal fatty infiltration in a patient with psoriasis. Lee J, et al. **J Cutan Pathol** 1995 Apr;22(2):182-4
Experimental biliary fibrosis correlates with increased numbers of fat-storing and Kupffer cells, and portal endotoxemia. Grinko I, et al. **J Hepatol** 1995 Oct; 23(4):449-58

PHYSIOLOGY

Vitamin A-poor lipocytes: a novel desmin-negative lipocyte subpopulation, which can be activated to myofibroblasts. Ramm GA, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):G532-41
The acute insulin-like effects of growth hormone in primary adipocyte-signaling mechanisms. Tornqvist H, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:469-71
Activation by acetaldehyde of the promoter of the mouse alpha2(I) collagen gene when transfected into rat activated stellate cells. Anania FA, et al. **Arch Biochem Biophys** 1996 Jul 15;331(2):187-93
Differential relevance of beta-adrenoceptor subtypes in modulating the rat brown adipocytes function. Nisoli E, et al. **Arch Int Pharmacodyn Ther** 1995 May-Jun; 329(3):436-53
Voltage-dependent potassium channels in white adipocytes. Ramirez-Ponce MP, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):250-6
Norepinephrine stimulates the expression of fibroblast growth factor 2 in rat brown adipocyte primary culture. Yamashita H, et al. **Cell Growth Differ** 1995 Nov;6(11):1457-62
Adrenoceptor heterogeneity in human white adipocytes differentiated in culture as assessed by cytosolic free calcium measurements. Seydoux J, et al. **Cell Signal** 1996 Feb;8(2):117-22
Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway. Isami S, et al. **Diabetologia** 1996 Apr; 39(4):412-20
Alterations in insulin signalling pathway induced by prolonged insulin treatment of 3T3-L1 adipocytes. Ricort JM, et al. **Diabetologia** 1995 Oct;38(10):1148-56
Fat cell alpha 2-adrenoceptors: the regulation of fat cell function and lipolysis. Lafontan M, et al. **Endocr Rev** 1995 Dec;16(6):716-38 (234 ref.)
Mediators of hepatic fibrogenesis. Gressner AM. **Hepatogastroenterology** 1996 Jan-Feb;43(7):92-103 (84 ref.)
Pathobiology of hepatic stellate cells. Mathew J, et al. **Hepatogastroenterology** 1996 Jan-Feb;43(7):72-91 (201 ref.)
Regulation of insulin-like growth factor-I expression in mouse preadipocyte Ob1771 cells. Kamai Y, et al. **J Biol Chem** 1996 Apr 26;271(17):9883-6
Desensitization effect of in vivo treatment with metaproterenol on beta1, beta2 and beta3-adrenergic responsiveness in rat adipocytes. Portillo MP, et al. **Life Sci** 1996;58(5):405-14
Adrenergic receptors and fat cells: differential recruitment by physiological amines and homologous regulation. Lafontan M, et al. **Obes Res** 1995 Nov;3 Suppl 4:507S-514S (56 ref.)
A cascade-mechanism of fat storing cell activation forms the basis of the fibrogenic reaction of the liver. Gressner AM, et al. **Verh Dtsch Ges Pathol** 1995;79:1-14 (80 ref.)
[Leptin--a peptide hormone from adipocytes. Sensation of the 23rd FEBS Meeting] Pankov IuA. **Bioorg Khim** 1996 Mar;22(3):228-33 (13 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Fat cells in red bone marrow of human rib: their size and spatial distribution with respect to the radon-derived dose to the haemopoietic tissue. Allen JE, et al. **Int J Radiat Biol** 1995 Dec;68(6):669-78
Microdosimetry of haemopoietic stem cells irradiated by alpha particles from the short-lived products of 222Rn decays in fat cells and haemopoietic tissue. Charlton DE, et al. **Int J Radiat Biol** 1996 May;69(5):585-92

ULTRASTRUCTURE

Ultrastructural changes in fat cells and blood capillaries of the mammary gland in starved mice. Matsumoto M, et al. **J Vet Med Sci** 1995 Aug;57(4):733-6

ADIPOGENESIS INHIBITORY FACTOR see **INTERLEUKIN-11**

ADIPOSE TISSUE

see related
ADIPOCYTES
BROWN FAT
LIPECTOMY
SKINFOLD THICKNESS

Associations of fat and muscle masses with bone mineral in elderly men and women. Baumgartner RN, et al. **Am J Clin Nutr** 1996 Mar;63(3):365-72
Fat distribution and cardiovascular risk factors in obese adolescent girls: importance of the intraabdominal fat depot. Caprio S, et al. **Am J Clin Nutr** 1996 Jul;64(1):12-7
Sex differences in measures of body fat and body distribution in the elderly. Goodman-Gruen D, et al. **Am J Epidemiol** 1996 May 1;143(9):898-906
Body fat distribution and dyslipidemia [editorial; comment] Brunzell JD, et al. **Am J Med** 1995 Nov;99(5):457-8. Comment on: Am J Med 1995 Nov;99(5):459-64.
Body fat distribution, rather than overall adiposity, influences serum lipids and lipoproteins in healthy men independently of age [see comments] Walton C, et al. **Am J Med** 1995 Nov;99(5):459-64. Comment in: Am J Med 1995 Nov;99(5):457-8.
Autologous fat injection for unilateral vocal fold paralysis. Shindo ML, et al. **Ann Otol Rhinol Laryngol** 1996 Aug; 105(8):602-6
Traumatic herniation of the buccal fat pad: report of case. Takenoshita Y, et al. **ASDC J Dent Child** 1995 May-Jun; 62(3):201-4
Influence of early feeding mode on body composition of infants. Butte NF, et al. **Biol Neonate** 1995;67(6):414-24
Measurement of body fat in young and elderly women: comparison between a four-compartment model and widely used reference methods. Bergsma-Kadijk JA, et al. **Br J Nutr** 1996 May;75(5):649-57
Experimental mammary epithelial morphogenesis in an in vivo model: evidence for distinct cellular progenitors of the ductal and lobular phenotype. Smith GH. **Breast Cancer Res Treat** 1996;39(1):21-31
The buccal pad of fat: a review. Tostevin PM, et al. **Clin Anat** 1995;8(6):403-6 (35 ref.)
Soft tissue augmentation by fibrosis: fat injections and other means [letter; comment] Field LM. **Dermatol Surg** 1996 Feb;22(2):192-3. Comment on: J Dermatol Surg Oncol 1993 Nov;19(11):1032-40.
Transgenic mice with muscle-specific insulin resistance develop increased adiposity, impaired glucose tolerance, and dyslipidemia. Moller DE, et al. **Endocrinology** 1996 Jun;137(6):2397-405
Submandibular tissue obstruction of tracheostomy tube: reversal with "chin sling". Mallepalli J, et al. **Heart Lung** 1996 Mar-Apr;25(2):158-60
The reliability of bioelectrical impedance analysis for measuring changes in the body composition of patients with anorexia nervosa. Birmingham CL, et al. **Int J Eat Disord** 1996 Apr;19(3):311-5
Relationship between hydration of lean body mass and visceral adipose tissue. A clinical study of women. Armellini F, et al. **Int J Obes Relat Metab Disord** 1996 Jan;20(1):37-40
Reproductive history in relation to relative weight and fat distribution. Björkelund C, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):213-9
The regulation of adipose tissue distribution in humans. Björntorp P. **Int J Obes Relat Metab Disord** 1996 Apr; 20(4):291-302 (117 ref.)
Cardiovascular risk profile in 38-year and 18-year-old men. Contribution of body fat content and regional fat distribution. Bonora E, et al. **Int J Obes Relat Metab Disord** 1996 Jan;20(1):28-36
Major gene for abdominal visceral fat area in the Québec Family Study. Bouchard C, et al. **Int J Obes Relat Metab Disord** 1996 May;20(5):420-7
Moderate alcohol consumption and its relation to visceral fat and plasma androgens in healthy women. Cigolini M, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):206-12
The female 'insulin advantage' in a biracial cohort: results from the Miami Community Health Study. Donahue RP, et al. **Int J Obes Relat Metab Disord** 1996 Jan;20(1):76-82
Incidence, increasing prevalence, and predictors of change in obesity and fat distribution over 5 years in the rapidly developing population of Mauritius. Hodge AM, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20(2):137-46
Association between cardiac pathology and fat tissue distribution in an autopsy series of men without premortem evidence of cardiovascular disease. Kortelainen ML. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):245-52
Adiposity and body mass indices in children: Benn's index and other weight for height indices as measures of relative adiposity. Lazarus R, et al. **Int J Obes Relat Metab Disord** 1996 May;20(5):406-12
Fat intake and adiposity in 8 to 11-year-old obese children. Maffeis C, et al. **Int J Obes Relat Metab Disord** 1996 Feb; 20(2):170-4
The concentrations of monoamine metabolites and neuropeptides in the cerebrospinal fluid of obese women with different body fat distribution. Strömbom U, et al. **Int J Obes Relat Metab Disord** 1996 Apr;20(4):361-8
Body fat distribution in South Asian women and children. Wardle J, et al. **Int J Obes Relat Metab Disord** 1996 Mar; 20(3):267-71
Genetic and environmental correlations among hormone levels and measures of body fat accumulation and topography. Comuzzie AG, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):597-600
Reliability of near-infrared interactance body fat assessment relative to standard anthropometric techniques. Schreiner PJ, et al. **J Clin Epidemiol** 1995 Nov;48(11):1361-7
Measures of adiposity and coronary heart disease mortality in the Chicago Western Electric Company Study. Spataro JA, et al. **J Clin Epidemiol** 1996 Aug;49(8):849-57
High-density lipoprotein-cholesterol: determining hygienic factors for intervention [published erratum appears in J Occup Environ Med 1995 Sep;37(9):1121] Anzalone DA, et al. **J Occup Environ Med** 1995 Jul;37(7):856-61 (32 ref.)
Orbital fat prolapse in the dog. Boydell P, et al. **J Small Anim Pract** 1996 Feb;37(2):61-3
Urethral pseudolipoma: a complication of periurethral lipo-injection for stress urinary incontinence in a woman. Palma PC, et al. **J Urol** 1996 Feb;155(2):646
More exercise, less central fat distribution in women [letter] Goulding A, et al. **JAMA** 1996 Jul 17;276(3):193-4
The effect of fat on the coherent-to-Compton scattering ratio in the calcaneus: a computational analysis. Guttmann GD, et al. **Med Phys** 1995 Aug;22(8):1229-34
Military body fat standards and equations applied to middle-aged women. Bathalon GP, et al. **Med Sci Sports Exerc** 1995 Jul;27(7):1079-85
Validity of bioelectrical impedance equations for estimating percent fat in males. Eckerson JM, et al. **Med Sci Sports Exerc** 1996 Apr;28(4):523-30
Dexfenfluramine and abdominal visceral fat [editorial; comment] Bouchard C. **Obes Res** 1996 Jan;4(1):77-9. Comment on: Obes Res 1996 Jan;4(1):1-7.
Dehydroepiandrosterone and body fat. Clore JN. **Obes Res** 1995 Nov;3 Suppl 4:613S-616S (46 ref.)
Autonomic activity assessed by heart rate spectral analysis varies with fat distribution in obese women. Gao YY, et al. **Obes Res** 1996 Jan;4(1):55-63
Topical fat reduction. Greenway FL, et al. **Obes Res** 1995 Nov;3 Suppl 4:561S-568S
Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM [see comments] Marks SJ, et al. **Obes Res** 1996 Jan;4(1):1-7. Comment in: Obes Res 1996 Jan;4(1):77-9.
Visceral fat accumulation and cardiovascular disease. Matsuzawa Y, et al. **Obes Res** 1995 Dec;3 Suppl 5:645S-647S (11 ref.)
Genetic pleiotropy for resting metabolic rate with fat-free mass and fat mass: the Québec Family Study. Rice T, et al. **Obes Res** 1996 Mar;4(2):125-31
The association among fat distribution, physical fitness, and the risk factors of cardiovascular disease in obese women. Tanaka H, et al. **Obes Res** 1995 Dec;3 Suppl 5:649S-653S
Fat accretion and growth in the rat [classical article] [see comments] Zucker TF, et al. **Obes Res** 1996 Jan;4(1):102-8. Comment in: Obes Res 1996 Jan;4(1):91-5.
Predicting self-esteem from perceptions of actual and ideal ratings of body fatness: is there only one ideal "supermodel"? Marsh HW, et al. **Res Q Exerc Sport** 1996 Mar;67(1):13-23
Subacromial fat pad. Vahlensieck M, et al. **Surg Radiol Anat** 1996;18(1):33-6
[Sclerosing lipogranuloma in a male] Gosselin P, et al. **Ann Dermatol Venereol** 1995;122(10):682-5 (Eng. Abstr.) **(Fre)**
[Lipedema] Herpertz U. **Z Lymphol** 1995 Aug;19(1):1-11 (5 ref.) (Eng. Abstr.) **(Ger)**

ANATOMY & HISTOLOGY

Insulin response during the oral glucose tolerance test: the role of age, sex, body fat and the pattern of fat distribution. Muller DC, et al. **Aging (Milano)** 1996 Feb;8(1):13-21
Body fat distribution and non-insulin-dependent diabetes: comparison of a fiber-rich, high-carbohydrate, low-fat (23%) diet and a 35% fat diet high in monounsaturated fat. Walker KZ, et al. **Am J Clin Nutr** 1996 Feb; 63(2):254-60
How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Gallagher D, et al. **Am J Epidemiol** 1996 Feb 1;143(3):228-39
Sex-specific associations of magnetic resonance imaging-derived intra-abdominal and subcutaneous fat areas with conventional anthropometric indices. The Atherosclerosis Risk in Communities Study. Schreiner PJ, et al. **Am J Epidemiol** 1996 Aug 15;144(4):335-45
The importance of body fat distribution in early life. Freedman DS. **Am J Med Sci** 1995 Dec;310 Suppl 1:S72-6 (47 ref.)
Interrelationships between muscle morphology, insulin action, and adiposity. Kriketos AD, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1332-9
Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Cigolini M, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):368-74
Do elevated levels of abdominal visceral adipose tissue contribute to age-related differences in plasma lipoprotein concentrations in men? Lemieux S, et al. **Atherosclerosis** 1995 Nov;118(1):155-64
Relationships between insulin metabolism, serum lipid profile, body fat distribution and blood pressure in healthy men. Walton C, et al. **Atherosclerosis** 1995 Nov;118(1):35-43
Maternal obesity and body composition of the neonate.

Silliman K, et al. **Biol Neonate** 1995;68(6):384–93

Body fat distribution before pregnancy and gestational diabetes: findings from coronary artery risk development in young adults (CARDIA) study. Zhang S, et al. **BMJ** 1995 Oct 28;311(7013):1139–40

Lymphatics and adipose tissue. Ryan TJ. **Clin Dermatol** 1995 Sep–Oct;13(5):493–8 (38 ref.)

Comparison of methods to estimate body fat in growth hormone deficient adults. Bosaeus I, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):395–402

Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Carey DG, et al. **Diabetes** 1996 May;45(5):633–8

Adipose tissue leptin production and plasma leptin kinetics in humans. Klein S, et al. **Diabetes** 1996 Jul;45(7):984–7

Insulin resistance and obesity. The role of fat distribution pattern. Abate N. **Diabetes Care** 1996 Mar;19(3):292–4 (25 ref.)

Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Chen KW, et al. **Diabetes Care** 1995 Jun;18(6):747–53

Effects of maternal gestational diabetes and adiposity on neonatal adiposity and blood pressure. Vohr BR, et al. **Diabetes Care** 1995 Apr;18(4):467–75

Insulin resistance and body fat distribution. Yamashita S, et al. **Diabetes Care** 1996 Mar;19(3):287–91

Detection of obesity QTLs on mouse chromosomes 1 and 7 by selective DNA pooling. Taylor BA, et al. **Genomics** 1996 Jun 15;34(3):389–98

Insulin response of women athletes in relation to body fat quantified by magnetic resonance imaging. Frisch RE, et al. **Gynecol Obstet Invest** 1995;40(3):195–9

Social class interacts with the association between macronutrient intake and subcutaneous fat. Buemann B, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19(11):770–5

Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men. de Boer H, et al. **Int J Obes Relat Metab Disord** 1996 Jun;20(6):580–7

Abdominal fat distribution and coronary heart disease risk factors in men–waist/height ratio as a simple and useful predictor. Hsieh SD, et al. **Int J Obes Relat Metab Disord** 1995 Aug;19(8):585–9

Subcutaneous adipose tissue distribution in adolescent girls of four ethnic groups. Malina RM, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19(11):793–7

Measuring visceral adipose tissue content from contrast enhanced computed tomography. Vehmas T, et al. **Int J Obes Relat Metab Disord** 1996 Jun;20(6):570–3

Diet composition related to body fat in a multivariate study of 203 men. Nelson LH, et al. **J Am Diet Assoc** 1996 Aug; 96(8):771–7

Enlargement of the lateral pharyngeal fat pad space in pigs increases upper airway resistance. Winter WC, et al. **J Appl Physiol** 1995 Sep;79(3):726–31

Fat suppression at 7T using a surface coil: application of an adiabatic half-passage chemical shift selective radiofrequency pulse. Yongbi MN, et al. **J Magn Reson Imaging** 1995 Nov–Dec;5(6):768–72

Pharmacokinetics of TCDD in veterans of Operation Ranch Hand: 10-year follow-up. Michalek JE, et al. **J Toxicol Environ Health** 1996 Feb 23;47(3):209–20

Is it possible to derive a reliable estimate of human visceral and subcutaneous abdominal adipose tissue from simple anthropometric measurements? Bonora E, et al. **Metabolism** 1995 Dec;44(12):1617–25

The effects of weight reduction to ideal body weight on body fat distribution. Hendler RG, et al. **Metabolism** 1995 Nov; 44(11):1413–6

Abdominal fat distribution and metabolic risk factors: effects of race. Lovejoy JC, et al. **Metabolism** 1996 Sep; 45(9):1119–24

Familial aggregation of abdominal visceral fat level: results from the Quebec family study. Pérusse L, et al. **Metabolism** 1996 Mar;45(3):378–82

Familial clustering of abdominal visceral fat and total fat mass: the Québec Family Study. Rice T, et al. **Obes Res** 1996 May;4(3):253–61

Fatty tissue on opposed-phase MR images: paradoxical suppression of signal intensity by paramagnetic contrast agents. Mitchell DG, et al. **Radiology** 1996 Feb; 198(2):351–7

Body fat assessment by a new bipedal bioimpedance instrument in normal weight and obese women. Hainer V, et al. **Sb Lek** 1995;96(3):249–56

The relationship of cardiorespiratory variables, blood lipids, amount and distribution of fat in middle aged men. Pařízková J, et al. **Sb Lek** 1995;96(3):243–8

The interrelationships of body fat, exercise, and hormonal status and their impact on reproduction and bone health. Ramos RH, et al. **Semin Perinatol** 1995 Jun;19(3):163–70 (53 ref.)

[Significance of fat distribution for metabolic risk factors in healthy males of normal weight] Richelsen B, et al. **Ugeskr Laeger** 1996 Mar 4;158(10):1373–7 (Eng. Abstr.) **(Dan)**

[Obesity, The ob gene product and control of adipose mass] Ferré P. **Diabete Metab** 1995 Jun;21(3):217–8 **(Fre)**

[Histologic characteristics of posterior lumbar epidural fatty tissue] Wolfram-Gabel R, et al. **J Neuroradiol** 1996 Jun; 23(1):19–25 (Eng. Abstr.) **(Fre)**

[Waist to hip circumference ratio] Abe T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:221–6 (16 ref.) **(Jpn)**

[Evaluation of obesity by anthropometry (weight and height)] Ishii J, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:194–9 **(Jpn)**

[Dual photon absorptiometry, dual energy X-ray absorptiometry for analysis of body fat mass] Itabashi A. **Nippon Rinsho** 1995 Jun;53 Suppl:174–8 (11 ref.) **(Jpn)**

[Techniques of measurement of human body fat mass: overview] Kataoka K. **Nippon Rinsho** 1995 Jun;53 Suppl:157–64 (42 ref.) **(Jpn)**

[Densitometry (hydrostatic weighing) for measurement of human body fat mass] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:165–9 (11 ref.) **(Jpn)**

[Total body water by D2O dilution] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:170–3 (10 ref.) **(Jpn)**

[Skinfold thickness for analysis of body fat mass] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:189–93 (21 ref.) **(Jpn)**

[Bio-electrical impedance analysis method for body fat mass] Sato T. **Nippon Rinsho** 1995 Jun;53 Suppl:179–82 (10 ref.) **(Jpn)**

[Near infrared interactance for measurement of body fat mass] Sawai S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:183–8 (11 ref.) **(Jpn)**

[Fat measurement using MRI] Yamaguchi K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:215–20 (9 ref.) **(Jpn)**

[The fat should be located in body regions on which we sit] Björntorp P. **Lakartidningen** 1996 Jan 3;93(1–2):33–5 **(Swe)**

BLOOD SUPPLY

Vascular supply of the palmar subcutaneous tissue of fingers. Voche P, et al. **Br J Plast Surg** 1996 Jul;49(5):315–8

The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. Jansson PA, et al. **Diabetes Care** 1996 Feb;19(2):160–4

Evaluation of the microdialysis ethanol technique for monitoring of subcutaneous adipose tissue blood flow in humans. Felländer G, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):220–6

Cytochemical studies of adipose tissue-associated blood vessels in untreated and thyroxine-treated hypophysectomized pig fetuses. Hausman GJ, et al. **J Anim Sci** 1996 Feb;74(2):354–62

Haemodynamic responses in muscle and adipose tissue and whole body metabolic responses during norepinephrine infusions in man. Kurpad A, et al. **J Auton Nerv Syst** 1995 Aug 4;54(2):163–70

Body position, age and mass effect of adiposity on adipose tissue red cell flux in morbid obesity. Klassen GA, et al. **Obes Res** 1996 Mar;4(2):145–51

CHEMISTRY

Fatty acid composition of porcine muscle and adipose tissue lipids as affected by anatomical location and cod liver oil supplementation of the diet. Taugbøl O, et al. **Acta Vet Scand** 1995;36(1):93–101

Visceral adiposity and lipid oxidation [letter; comment] Frayn KN. **Am J Clin Nutr** 1996 Jun;63(6):977–8. Comment on: Am J Clin Nutr 1995 Nov;62(5):918–22.

Semivolatile organic compounds in adipose tissue: estimated averages for the US population and selected subpopulations. Lordo RA, et al. **Am J Public Health** 1996 Sep;86(9):1253–9

Accumulation levels of organochlorine pesticides in human adipose tissue: a new sample survey in Abruzzo. Giuliani AR, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):539–44

The effect of adipose cell size on the measurement of GLUT 4 in white adipose tissue of obese mice. Fabres-Machado U, et al. **Braz J Med Biol Res** 1995 Mar;28(3):369–76

Levels of alpha-HCH, lindane, and enantiomeric ratios of alpha-HCH in marine mammals from the northern hemisphere. Hummert K, et al. **Chemosphere** 1995 Sep; 31(6):3489–500

Occurrence of nitro and non-nitro benzenoid musk compounds in human adipose tissue. Müller S, et al. **Chemosphere** 1996 Jul;33(1):17–28

Monitoring norepinephrine levels by microdialysis in the white adipose tissue of spontaneously hypertensive rats. Cabassi A, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22 Suppl 1:S83–5

Unusual fatty acids in the depot fat of the Canadian beaver (Castor canadensis). Käkelä R, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):625–9

Porphyrin concentrations in various human tissues. Goerz G, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 1):218–20

Species identification by the positional analysis of fatty acid composition in triacylglyceride of adipose and bone tissues. Kagawa M, et al. **Forensic Sci Int** 1996 Jun 14;79(3):215–26

Alpha-tocopherol and hydroperoxide content in breast adipose tissue from patients with breast tumors. Chajés V, et al. **Int J Cancer** 1996 Jul 17;67(2):170–5

Does visceral adipose tissue differ from subcutaneous adipose tissue in fatty acid content? Schoen RE, et al. **Int J Obes Relat Metab Disord** 1996 Apr;20(4):346–52

Cyclic AMP and glycerol concentrations in freeze-clamped human omental and subcutaneous adipose tissues. Vikman HL, et al. **Int J Obes Relat Metab Disord** 1995 Jun; 19(6):388–91

Beta-adrenergic receptor subtype transcripts in porcine adipose tissue. McNeel RL, et al. **J Anim Sci** 1995 Jul; 73(7):1962–71

Vitamin E supplementation and stress affect tissue alpha-tocopherol content of beef heifers. Nockels CF, et al. **J Anim Sci** 1996 Mar;74(3):672–7

Regulation of glucose transporter gene expression in mammary gland, muscle, and fat of lactating cows by administration of bovine growth hormone and bovine growth hormone-releasing factor. Zhao FQ, et al. **J Anim Sci** 1996 Jan;74(1):183–9

Determination of chlorobiphenyls in seal blubber, marine sediment, and fish: interlaboratory study. de Boer J, et al. **J AOAC Int** 1996 Jan–Feb;79(1):83–96

Isolation of cholesterol oxidation products from animal fat using aminopropyl solid-phase extraction. Johnson CB. **J Chromatogr A** 1996 Jun 7;736(1–2):205–10

Determination of ceftiofur and its desfuroylceftiofur-related metabolites in swine tissues by high-performance liquid chromatography. Beconi-Barker MG, et al. **J Chromatogr B Biomed Appl** 1995 Nov 17;673(2):231–44

Determination of melengestrol acetate in supercritical fluid-solid phase extracts of bovine fat tissue by HPLC-UV and GC-MS. Parks OW, et al. **J Chromatogr Sci** 1996 Aug; 34(8):353–7

Human type VI collagen: purification from human subcutaneous fat tissue and an immunohistochemical study of morphea and systemic sclerosis. Takasaki S, et al. **J Dermatol** 1995 Jul;22(7):480–5

A comparison of the concentrations of certain chlorinated hydrocarbons and polychlorinated biphenyls in bone marrow and fat tissue of children and their concentrations in breast milk. Scheele J, et al. **J Environ Pathol Toxicol Oncol** 1995;14(1):11–4

A rapid method for determination of Aroclor 1260 in cattle adipose tissue. Kumar Y, et al. **J Environ Sci Health B** 1996 Sep;31(5):1001–13

Demonstration that acid-ethanol extracts of rat adipose tissue contain an inhibitor of food intake in the mouse [see comments] Goodner GC, et al. **J Lab Clin Med** 1996 Sep; 128(3):246–50. Comment in: J Lab Clin Med 1996 Sep;128(3):232.

If we knew then what we know now...[editorial; comment] Jacob HS. **J Lab Clin Med** 1996 Sep;128(3):232. Comment on: J Lab Clin Med 1996 Sep;128(3):246–50.

Organochlorine residues in human adipose and hepatic tissues from autopsy sources in northern Italy. Gallelli G, et al. **J Toxicol Environ Health** 1995 Nov;46(3):293–300

Very long chain polyunsaturated fatty acids in the blubber of ringed seals (Phoca hispida sp.) from Lake Saimaa, Lake Ladoga, the Baltic Sea, and Spitsbergen. Käkelä R, et al. **Lipids** 1995 Aug;30(8):725–31

Distribution of basement membrane components in normal adipose tissue and in benign and malignant tumors of lipomatous origin. Haraida S, et al. **Mod Pathol** 1996 Feb; 9(2):137–44

Fatty acid composition of breast adipose tissue in breast cancer patients and in patients with benign breast disease. Zhu ZR, et al. **Nutr Cancer** 1995;24(2):151–60

Fatty acid composition of adipose tissue in humans. Implications for the dietary fat-serum cholesterol-CHD issue. Seidelin KN. **Prog Lipid Res** 1995;34(3):199–217 (158 ref.)

Diagnosing amyloidosis [editorial] Westermark P. **Scand J Rheumatol** 1995;24(6):327–9 (12 ref.)

[Hydrocarbon content in the fat of meat pigs after feeding "Fermosin"] Henk G, et al. **Arch Tierernahr** 1993; 45(1):35–47 (Eng. Abstr.) **(Ger)**

[Polychlorobiphenyl (PCB) levels in the adipose tissue of subjects living in the Province of Trento] Poli A, et al. **Ann Ig** 1995 Mar–Apr;7(2):83–90 **(Ita)**

[Stabilization of omega-3-polyunsaturated acids in fat from Mallotus villosus (Osmeridae) by the nontoxic, sulfur-containing antioxidant CO-3] Rezvukhin AI, et al. **Vopr Med Khim** 1995 May–Jun;41(3):37–9 (Eng. Abstr.) **(Rus)**

CYTOLOGY

Transcriptional regulation of gene expression during adipocyte differentiation. MacDougald OA, et al. **Annu Rev Biochem** 1995;64:345–73 (164 ref.)

Voltage-dependent potassium channels in white adipocytes. Ramírez-Ponce MP, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):250–6

Adipocyte differentiation. When precursors are also regulators. MacDougald OA, et al. **Curr Biol** 1995 Jun 1; 5(6):618–21 (16 ref.)

Regulation of adipose maturation and energy homeostasis. Yeh WC, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):885–90 (57 ref.)

Human capillary endothelial cells from abdominal wall adipose tissue: isolation using an anti-pecam antibody. Springhorn JP, et al. **In Vitro Cell Dev Biol Anim** 1995 Jun;31(6):473–81

Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. Teboul L, et al. **J Biol Chem** 1995 Nov 24;270(47):28183–7

Cellular characterization of adipose tissue from various body sites of women. Rink JD, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2443–7

The relationship between serum lipoprotein levels and marbling of muscle tissue in beef cattle. Noro A, et al.

J Vet Med Sci 1995 Aug;57(4):737–8

Stromal cells from subcutaneous adipose tissue seeded in a native collagen/elastin dermal substitute reduce wound contraction in full thickness skin defects. de Vries HJ, et al. **Lab Invest** 1995 Oct;73(4):532–40

Linking protein kinase C to the cell cycle: ectopic expression of PKC eta in NIH3T3 cells alters the expression of cyclins and Cdk inhibitors and induces adipogenesis. Livneh E, et al. **Oncogene** 1996 Apr 4;12(7):1545–55

Effect of full feed and early feed restriction on broiler performance, abdominal fat level, cellularity, and fat metabolism in broiler chickens. Zhong C, et al. **Poult Sci** 1995 Oct;74(10):1636–43

Cellular aspects of fuel mobilization and selection in white adipocytes. Lafontan M, et al. **Proc Nutr Soc** 1995 Mar; 54(1):49–63 (81 ref.)

[Toward the treatment of obesity: role of PPAR gamma in adipogenesis] Motojima K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1936–41 (32 ref.) **(Jpn)**

DRUG EFFECTS

Effect of energy compared with carbohydrate restriction on the lipolytic response to epinephrine. Carroll RM, et al. **Am J Clin Nutr** 1995 Oct;62(4):757–60

22-kDa and 20-kDa hGH isoforms show differential effects when assayed in 3T3-F442A and 3T3-F442A/C4 adipocytes. Juárez-Aguilar E, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):28–33

The phosphatidylinositol 3-kinase inhibitor, wortmannin, inhibits insulin-induced activation of phosphatidylcholine hydrolysis and associated protein kinase C translocation in rat adipocytes. Standaert ML, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):1039–46

Inducers of adipose conversion activate transcription promoted by a peroxisome proliferators response element in 3T3-L1 cells. Brandes R, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1949–51

Regulation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) of the DNA binding activity of transcriptional factors via nuclear protein phosphorylation in guinea pig adipose tissue. Enan E, et al. **Biochem Pharmacol** 1995 Oct 12; 50(8):1199–206

Zinc supplementation aggravates body fat accumulation in genetically obese mice and dietary-obese mice. Chen MD, et al. **Biol Trace Elem Res** 1996 May;52(2):125–32

Cholinoceptor-mediated effects on glycerol output from human adipose tissue using in situ microdialysis. Andersson K, et al. **Br J Pharmacol** 1995 Aug;115(7):1155–62

The metabolic effects of interleukin 1 beta on human bone marrow adipocytes. Delikat SE, et al. **Cytokine** 1995 May; 7(4):338–43

Role of Ca2+ in the early stages of murine adipocyte differentiation as evidenced by calcium mobilizing agents. Ntambi JM, et al. **Differentiation** 1996 Jun;60(3):151–8

An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissues. Berger J, et al. **Endocrinology** 1996 May;137(5):1984–90

A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Lambe KG, et al. **Eur J Biochem** 1996 Jul 1;239(1):1–7

Influence of age and fetal hypophysectomy on porcine preadipocytes: insulin-like growth factor-I (IGF-I) response, receptor binding and IGF binding proteins secretion. Chen NX, et al. **Growth Dev Aging** 1995 Winter; 59(4):193–206

Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Lovejoy JC, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19(9):614–24

Oleoyl-estrone induces the loss of body fat in rats. Sanchis D, et al. **Int J Obes Relat Metab Disord** 1996 Jun; 20(6):588–94

Bone morphogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells. Gimble JM, et al. **J Cell Biochem** 1995 Jul;58(3):393–402

Effect of somatotropin treatment on lipogenesis, lipolysis, and related cellular mechanisms in adipose tissue of lactating cows. Lanna DP, et al. **J Dairy Sci** 1995 Aug; 78(8):1703–12

Interactions between adipose tissue around lymph nodes and lymphoid cells in vitro. Pond CM, et al. **J Lipid Res** 1995 Oct;36(10):2219–31

Effect of hypothermia on the insulin-receptor interaction in adipose plasma membranes. Torlińska T, et al. **J Physiol Pharmacol** 1995 Sep;46(3):341–9

Magnesium deficiency and glucose metabolism in rat adipocytes. Kandeel FR, et al. **Metabolism** 1996 Jul; 45(7):838–43

Effect of lipectomy and long-term dexamethasone on visceral fat and metabolic variables in rats. Palacios E, et al. **Metabolism** 1995 Dec;44(12):1631–8

Dietary oils with added tocopherols: effects on egg or tissue tocopherols, fatty acids, and oxidative stability. Cherian G, et al. **Poult Sci** 1996 Mar;75(3):423–31

Prolonged in vitro exposure of broiler adipocytes to somatostatin enhances lipolysis and induces desensitization of antilipolysis. Oscar TP. **Poult Sci** 1996 Mar; 75(3):393–401

EMBRYOLOGY

Ontogeny of the response to thyroxine (T4) in the porcine fetus: interrelationships between serum T4, serum insulin-like growth factor-1 (IGF-1) and differentiation of skin and several adipose tissues. Hausman GJ, et al. **Obes Res** 1996 May;4(3):283–92

ENZYMOLOGY

Coordinated regulation of hormone-sensitive lipase and lipoprotein lipase in human adipose tissue in vivo: implications for the control of fat storage and fat mobilization. Frayn KN, et al. **Adv Enzyme Regul** 1995; 35:163–78

Zeta PKC in rat preadipocytes: modulation by insulin and serum mitogenic factors and possible role in adipogenesis. Lacasa D, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):123–30

White adipose tissue nitric oxide synthase: a potential source for NO production. Ribiere C, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):706–12

Forms of lipoprotein lipase in rat tissues: in adipose tissue the proportion of inactive lipase increases on fasting. Bergö M, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):893–8

Pretranslational regulation of pyruvate dehydrogenase complex subunits in white adipose tissue during the suckling-weaning transition in the rat. Maury J, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):531–5

Differential responses of hormone-sensitive lipase gene to nutritional transition in adipose tissue, liver, and skeletal muscle of pigs. Liu CY, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):689–94

Lipoprotein lipase and glucose-6-phosphate dehydrogenase activities in bovine and ovine adipose tissue incubated for 7 days: effects of insulin and/or dexamethasone. Faulconnier Y, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Feb; 113(2):421–6

Kinetic properties of ovine adipose tissue fructose-1,6-bisphosphatase. Koekemoer TC, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct-Nov; 109(2-3):443–50

An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissues. Berger J, et al. **Endocrinology** 1996 May;137(5):1984–90

Differential activation of adipogenesis by multiple PPAR isoforms. Brun RP, et al. **Genes Dev** 1996 Apr 15; 10(8):974–84

Regulation of lipoprotein lipase activity by growth hormone in differentiated adipocytes from sheep. de la Hoz L, et al. **Horm Metab Res** 1996 Apr;28(4):202–4

Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells. Zhou D, et al. **J Biol Chem** 1996 Jun 21; 271(25):15194–202

Beta 3-adrenergic activation of adenylyl cyclase in mouse white adipocytes: modulation by GTP and effect of obesity. Bégin-Heick N. **J Cell Biochem** 1995 Aug;58(4):464–73

Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase. Simsolo RB, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3233–8

Semicarbazide-sensitive amine oxidase activity in white adipose tissue of the insulin-deficient rat. Conforti L, et al. **J Pharm Pharmacol** 1995 May;47(5):420–4

Glycohemoglobin levels relate to the response of adipose tissue lipoprotein lipase to insulin/glucose in obese non-insulin-dependent diabetes mellitus. Yost TJ, et al. **Metabolism** 1995 Nov;44(11):1475–80

Quantitative detection of alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in aromatase-expressing human cells by competitive RT-PCR. Agarwal VR, et al. **Mol Cell Probes** 1995 Dec; 9(6):453–64

GROWTH & DEVELOPMENT

Lesion of central nucleus of amygdala promotes fat gain without preventing effect of exercise on energy balance. Bovetto S, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R781–6

Standards for total body fat and fat-free mass in infants. de Bruin NC, et al. **Arch Dis Child** 1996 May;74(5):386–99

Interrelationship of day length and temperature on the control of gonadal development, body mass, and fat score in white-crowned sparrows, Zonotrichia leucophrys gambelii. Wingfield JC, et al. **Gen Comp Endocrinol** 1996 Mar;101(3):242–55

Paracrine interactions in adipose tissue development and growth. Lau DC, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S16–25 (57 ref.)

Influence of macronutrients on adiposity development: a follow up study of nutrition and growth from 10 months to 8 years of age. Rolland-Cachera MF, et al. **Int J Obes Relat Metab Disord** 1995 Aug;19(8):573–8

Biological maturation and the distribution of subcutaneous fat from adolescence into adulthood: the Amsterdam Growth and Health Study. van Lenthe FJ, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20(2):121–9

Effects of a dexamethasone implant on deposition of intramuscular fat in genetically identical cattle. Corah TJ, et al. **J Anim Sci** 1995 Nov;73(11):3310–6

Characterization of carcass development from 14 to 145 days of age in turkey hens from two strains. Barbour GW, et al. **Poult Sci** 1995 Oct;74(10):1650–8

Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha. Hu E, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9856–60

IMMUNOLOGY

Effect of syringe-assisted liposuction on activation of cascade systems and circulating cells when using the superwet or tumescent technique. Samdal F, et al. **Ann Plast Surg** 1995 Sep;35(3):242–8

METABOLISM

Microdialysis as a tool to assess interstitial norepinephrine levels in adipose tissue of spontaneously hypertensive rats. Bergamaschi E, et al. **Acta Biomed Ateneo Parmense** 1995; 66(3-4):105–10

Changes in the fatty acid profile of plasma and adipose tissue in rats after long-term ethanol feeding. Gómez-Tubío A, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):747–52

Ethnicity and energy stores. Conway JM. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1067S–1071S (35 ref.)

Biomarkers of habitual fish intake in adipose tissue. Marckmann P, et al. **Am J Clin Nutr** 1995 Nov;62(5):956–9

Visceral adiposity is associated with increased lipid oxidation in obese, postmenopausal women [see comments] Nicklas BJ, et al. **Am J Clin Nutr** 1995 Nov;62(5):918–22. Comment in: Am J Clin Nutr 1996 Jun;63(6):977–8.

Measuring body fat [letter] Walton C, et al. **Am J Med** 1996 Aug;101(2):236–7

Glucocorticoid deprivation alters in vivo glucose uptake by muscle and adipose tissues of GTG-obese mice. Blair SC, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E927–33

Selectivity of fatty acid mobilization: a general metabolic feature of adipose tissue. Raclot T, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1060–7

Rapid enhancement of acyl-CoA synthetase, LPL, and GLUT-4 mRNAs in adipose tissue of VMH rats. Shimomura I, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E995–1002

Effect of training on epinephrine-stimulated lipolysis determined by microdialysis in human adipose tissue. Stallknecht B, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):E1059–66

Relationship between adipose stromal-vascular cells and adipocytes in human adipose tissue. O'Brien SN, et al. **Anal Quant Cytol Histol** 1996 Apr;18(2):137–43

Differences in lipolysis between human subcutaneous and omental adipose tissues. Arner P. **Ann Med** 1995 Aug; 27(4):435–8 (27 ref.)

7 alpha-Hydroxylation of the adrenal androgens dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol predominates in differentiating human adipose stromal cells. Khalil MW, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:316–8

Estrogen biosynthesis in adipose. Significance in breast cancer development. Simpson ER, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:18–26 (60 ref.)

Transcriptional regulation of gene expression during adipocyte differentiation. MacDougald OA, et al. **Annu Rev Biochem** 1995;64:345–73 (164 ref.)

Magnetic resonance imaging-assessed adipose tissue and serum lipid and insulin concentrations in growth hormone-deficient adults. Effect of growth hormone replacement. Snel YE, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1543–8

Mutation screening and identification of a sequence variation in the human ob gene coding region. Considine RV, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):735–9

Characterization of a mutant GLUT4 lacking the N-glycosylation site: studies in transfected rat adipose cells. Ing BL, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):76–82

cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Maeda K, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):286–9

Augmented expression of the obese gene in the adipose tissue from rats fed high-fat diet. Masuzaki H, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):355–8

Dexamethasone regulates obese expression in isolated rat adipocytes. Murakami T, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1260–7

Unique subcellular distribution of five annexins in resting and insulin-stimulated rat adipose cells. Raynal P, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):116–21

Rat adipose ob mRNA levels in states of altered circulating glucose and insulin. Sivitz WI, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):520–5

Meal-feeding specifically induces obese mRNA expression. Thompson MP. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):332–7

Overexpression of the obese gene in the genetically obese JCR:LA-corpulent rat. Vydelingum S, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):148–53

Compartment ablation analysis of the insulin-responsive glucose transporter (GLUT4) in 3T3-L1 adipocytes. Livingstone C, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):487–95

The phosphatidylinositol 3-kinase inhibitor, wortmannin, inhibits insulin-induced activation of phosphatidylcholine

hydrolysis and associated protein kinase C translocation in rat adipocytes. Standaert ML, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):1039–46

Acute cold-induced suppression of ob (obese) gene expression in white adipose tissue of mice: mediation by the sympathetic system. Trayhurn P, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):729–33

Fatty acid synthesis from glutamate in the adipose tissue of normal subjects and obese patients: an enzyme study. Belfiore F, et al. **Biochem Mol Med** 1995 Feb;54(1):19–25

Adenylyl cyclase system is affected differently by endurance physical training in heart and adipose tissue. Nieto JL, et al. **Biochem Pharmacol** 1996 May 17;51(10):1321–9

Candidate proteins involved in the targeting of the insulin-sensitive glucose transporter GLUT4 in adipocytes. Barros LF, et al. **Biochem Soc Trans** 1995 Aug;23(3):414S

Lipolysis in rat adipose tissue in vitro is dependent on the quantity and not the quality of dietary fat. Carr RE, et al. **Biochem Soc Trans** 1995 Aug;23(3):486S

Surface lysine residues modulate the collisional transfer of fatty acid from adipocyte fatty acid binding protein to membranes. Herr FM, et al. **Biochemistry** 1995 Sep 19; 34(37):11840–5

Age-related changes in the percentage of oleate in adipose tissue of male and female Fischer rats. Thorling EB, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):195–8

Pontine and basal forebrain transections disinhibit brown fat thermogenesis in neonatal rats. Blumberg MS, et al. **Brain Res** 1995 Nov 20;699(2):214–20

Similar distribution of trans fatty acid isomers in partially hydrogenated vegetable oils and adipose tissue of Canadians. Chen ZY, et al. **Can J Physiol Pharmacol** 1995 Jun;73(6):718–23

The effect of amount of body fat and loss of fat on breeding soundness classification of beef bulls. Barth AD, et al. **Can Vet J** 1995 Dec;36(12):758–64

Evaluation of toxicity and sex-related variation of PCB levels in Mediterranean striped dolphins affected by an epizootic. Borrell A, et al. **Chemosphere** 1996 Jun;32(12):2359–69

Organochlorine compounds in blubber, liver and brain in neonatal grey seal pups. Jenssen BM, et al. **Chemosphere** 1996 Jun;32(11):2115–25

Carbohydrate metabolism in insulin resistance: glucose uptake and lactate production by adipose and forearm tissues in vivo before and after a mixed meal. Coppack SW, et al. **Clin Sci (Colch)** 1996 May;90(5):409–15

Interstitial glycerol concentration in human skeletal muscle and adipose tissue is close to the concentration in blood. Samra JS, et al. **Clin Sci (Colch)** 1996 Jun;90(6):453–6

Regulation of adipose maturation and energy homeostasis. Yeh WC, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):885–90 (57 ref.)

Role of phosphodiesterase III in the antilipolytic effect of insulin in vivo. Hagström-Toft E, et al. **Diabetes** 1995 Oct; 44(10):1170–5

The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. Jansson PA, et al. **Diabetes Care** 1996 Feb;19(2):160–4

A stable peroxovanadium compound with insulin-like action in human fat cells. Eriksson JW, et al. **Diabetologia** 1996 Feb;39(2):235–42

Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Hauner H, et al. **Diabetologia** 1995 Jul;38(7):764–71

Binding of human, porcine and bovine insulin to insulin receptors from human brain, muscle and adipocytes and to expressed recombinant alternatively spliced insulin receptor isoforms [see comments] Kotzke G, et al. **Diabetologia** 1995 Jul;38(7):757–63. Comment in: Diabetologia 1996 Feb;39(2):248–9.

A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Paolisso G, et al. **Diabetologia** 1995 Oct;38(10):1213–7

Intracerebroventricular administration of neuropeptide Y to normal rats increases obese gene expression in white adipose tissue. Sainsbury A, et al. **Diabetologia** 1996 Mar; 39(3):353–6

Effect of bovine somatotropin and food deprivation on beta-adrenergic and A1 adenosine receptor binding in adipose tissue of lactating cows. Houseknecht KL, et al. **Domest Anim Endocrinol** 1995 Oct;12(4):325–36

Normalization of insulin secretion by a selective alpha 2-adrenoceptor antagonist restores GLUT-4 glucose transporter expression in adipose tissue of type II diabetic rats. Angel I, et al. **Endocrinology** 1996 May;137(5):2022–7

Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line. Boston BA, et al. **Endocrinology** 1996 May;137(5):2043–50

Insulin-induced GLUT4 recycling in rat adipose cells by a pathway insensitive to brefeldin A. Kono-Sugita E, et al. **Eur J Biochem** 1996 Mar 15;236(3):1033–7

Microdialysis assessment of adipose tissue metabolism in post-absorptive obese NIDDM subjects. Jansson PA, et al. **Eur J Clin Invest** 1995 Aug;25(8):584–9

Identification of oestrogen receptors and oestrogen receptor mRNA in human adipose tissue [see comments] Pedersen SB, et al. **Eur J Clin Invest** 1996 Apr;26(4):262–9. Comment in: Eur J Clin Invest 1996 Apr;26(4):259–31.

Diet- and diabetes-induced changes of ob gene expression in rat adipose tissue. Becker DJ, et al. **FEBS Lett** 1995 Sep 11;371(3):324–8

Modulation of obese gene expression in rat brown and white adipose tissues. Moinat M, et al. **FEBS Lett** 1995 Oct 9; 373(2):131–4

Regulation of ob gene mRNA levels in cultured adipocytes. Rentsch J, et al. **FEBS Lett** 1996 Jan 22;379(1):55–9

Investigations on the mechanism of adipocere formation and its relation to other biochemical reactions. Takatori T. **Forensic Sci Int** 1996 Jun 28;80(1–2):49–61 (25 ref.)

Estrogen binding sites in hamster white adipose tissue: sex- and site-related variations; modulation by testosterone. Jaubert AM, et al. **Gen Comp Endocrinol** 1995 Nov; 100(2):179–87

The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. Zorad S, et al. **Gen Physiol Biophys** 1995 Oct;14(5):383–91 (43 ref.)

Influence of age and fetal hypophysectomy on porcine preadipocytes: insulin-like growth factor-I (IGF-I) response, receptor binding and IGF binding proteins secretion. Chen NX, et al. **Growth Dev Aging** 1995 Winter; 59(4):193–206

Increased adipose tissue glyceroneogenesis in rats adapted to a high protein, carbohydrate-free diet. Botion LM, et al. **Horm Metab Res** 1995 Jul;27(7):310–3

Techniques for the measurement of white adipose tissue metabolism: a practical guide. Arner P. **Int J Obes Relat Metab Disord** 1995 Jul;19(7):435–42 (50 ref.)

Impact of exercise on adipose tissue metabolism in humans. Arner P. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S18–21 (25 ref.)

Beta-adrenergic receptors and G-proteins in the ob/ob mouse. Bégin-Heick N. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S32–5 (21 ref.)

Analysis of cholesteryl ester transfer activity in adipose tissue. Shen GX, et al. **Int J Obes Relat Metab Disord** 1996 Mar; 20 Suppl 3:S114–20

Dietary effects on fat deposition and fatty acid profiles in muscle and fat depots of Friesian bull calves. Aharoni Y, et al. **J Anim Sci** 1995 Sep;73(9):2712–20

Insulin and(or) dexamethasone regulation of glucose and acetate utilization in ovine and bovine adipose tissue explants incubated for seven days. Chilliard Y, et al. **J Anim Sci** 1995 Jul;73(7):2063–70

Chronic effects of somatotropin treatment on response of subcutaneous adipose tissue lipolysis to acutely acting factors in vivo and in vitro. Doris RA, et al. **J Anim Sci** 1996 Mar;74(3):562–8

Depression of lipogenesis in swine adipose tissue by specific dietary fatty acids. Smith DR, et al. **J Anim Sci** 1996 May; 74(5):975–83

The effects of brefeldin A on the glucose transport system in rat adipocytes. Implications regarding the intracellular locus of insulin-sensitive Glut4. Bao S, et al. **J Biol Chem** 1995 Dec 15;270(50):30199–204

Genomic structure and promoter analysis of the human obese gene. Gong DW, et al. **J Biol Chem** 1996 Feb 23; 271(8):3971–4

Overexpression of Ha-ras selectively in adipose tissue of transgenic mice. Evidence for enhanced sensitivity to insulin. Houseknecht KL, et al. **J Biol Chem** 1996 May 10;271(19):11347–55

The insulin-like growth factor II/mannose 6-phosphate receptor utilizes the same membrane compartments as GLUT4 for insulin-dependent trafficking to and from the rat adipocyte cell surface. Kandror KV, et al. **J Biol Chem** 1996 Sep 6;271(36):21703–8

A novel serum protein similar to C1q, produced exclusively in adipocytes. Scherer PE, et al. **J Biol Chem** 1995 Nov 10;270(45):26746–9

The rat epididymal fat pad as an implantation site for the study of microcapsule biocompatibility: validation of the method. Pariseau JF, et al. **J Biomed Mater Res** 1995 Nov; 29(11):1331–5

Soft tissue body composition: familial resemblance and independent influences on bone mineral density. Krall EA, et al. **J Bone Miner Res** 1995 Dec;10(12):1944–50

Relationship between insulin-mediated glucose disposal by muscle and adipose tissue lipolysis in healthy volunteers. Pei D, et al. **J Clin Endocrinol Metab** 1995 Nov; 80(11):3368–72

Aromatase activity and interleukin-6 production by normal and malignant breast tissues. Purohit A, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3052–8

Phenylalanine kinetics in human adipose tissue. Coppack SW, et al. **J Clin Invest** 1996 Aug 1;98(3):692–7

Gender differences in regional fatty acid metabolism before and after meal ingestion. Jensen MD. **J Clin Invest** 1995 Nov;96(5):2297–303

Expression of the mitochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic obesity. Kopecky J, et al. **J Clin Invest** 1995 Dec;96(6):2914–23

Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic beta 3-adrenergic agonist. Nagase I, et al. **J Clin Invest** 1996 Jun 15;97(12):2898–904

Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. Samad F, et al. **J Clin Invest** 1996 Jan 1;97(1):37–46

The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. Vidal H, et al. **J Clin Invest** 1996 Jul 15;98(2):251–5

Lipid metabolism in adipose tissue of cows fed high fat diets during lactation. McNamara JP, et al. **J Dairy Sci** 1995 Dec;78(12):2782–96

Regional differences and up-regulation of progesterone receptors in adipose tissues from oestrogen-treated sheep. Mayes JS, et al. **J Endocrinol** 1996 Jan;148(1):19–25

GH inhibition of lipogenesis and stimulation of lipolysis in sheep adipose tissue: involvement of protein serine phosphorylation and dephosphorylation and phospholipase C. Vernon RG. **J Endocrinol** 1996 Jul;150(1):129–40

1994 Aspen Bile Acid/Cholesterol/Lipoprotein Conference: fatty acid metabolism in liver and adipose tissue. Ockner RK, et al. **J Lipid Res** 1995 Jul;36(7):1629–38

Cholesteryl ester transfer protein (CETP) mRNA abundance in human adipose tissue: relationship to cell size and membrane cholesterol content. Radeau T, et al. **J Lipid Res** 1995 Dec;36(12):2552–61

Rates of lipid metabolism in adipose tissue of pigs adapt to lactational state and dietary energy restriction. Parmley KL, et al. **J Nutr** 1996 Jun;126(6):1644–56

Adrenergic regulation of the heat shock response in brown adipose tissue. Matz JM, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1751–8

Modulation of calcium-activated non-selective cation channel activity by nitric oxide in rat brown adipose tissue. Koivisto A, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):59–65

Desensitization effect of in vivo treatment with metaproterenol on beta1, beta2 and beta3-adrenergic responsiveness in rat adipocytes. Portillo MP, et al. **Life Sci** 1996;58(5):405–14

Specific potentiation by cyclic AMP of natriuretic peptide-mediated cyclic GMP production in adipose tissue. Thibault G, et al. **Life Sci** 1996;58(25):2345–53

The relationship between plasma insulin level, prostaglandin production by adipose tissue, and blood pressure in normal rats and rats with diabetes mellitus and diabetic ketoacidosis. Chatzipanteli K, et al. **Metabolism** 1996 Jun; 45(6):691–8

Weight loss reduces abdominal fat and improves insulin action in middle-aged and older men with impaired glucose tolerance. Colman E, et al. **Metabolism** 1995 Nov; 44(11):1502–8

Magnesium deficiency and glucose metabolism in rat adipocytes. Kandeel FR, et al. **Metabolism** 1996 Jul; 45(7):838–43

Beef tallow diet decreases beta-adrenergic receptor binding and lipolytic activities in different adipose tissues of rat. Matsuo T, et al. **Metabolism** 1995 Oct;44(10):1271–7

Changes in adenosine A1- and A2-receptor expression during adipose cell differentiation. Børglum JD, et al. **Mol Cell Endocrinol** 1996 Mar 1;117(1):17–25

Increased obese mRNA expression in omental fat cells from massively obese humans. Hamilton BS, et al. **Nat Med** 1995 Sep;1(9):953–6

Overexpression of the obese (ob) gene in adipose tissue of human obese subjects [see comments] Lönnqvist F, et al. **Nat Med** 1995 Sep;1(9):950–3. Comment in: Nat Med 1996 Feb;2(2):130.

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Shimomura I, et al. **Nat Med** 1996 Jul;2(7):800–3

Developing Yoshida sarcoma does not influence the fatty acid composition of adipose tissues in the rat. Groscolas R, et al. **Nutr Cancer** 1995;24(1):77–84

Time-course study of adipose tissue fatty acid composition during mammary tumor growth in rats with controlled fat intake. Lhuillery C, et al. **Nutr Cancer** 1995;24(3):299–309

Testosterone and regional fat distribution. Mårin P. **Obes Res** 1995 Nov;3 Suppl 4:609S–612S

Short day-induced depletion of lipid stores is fat pad- and gender-specific in Siberian hamsters. Bartness TJ. **Physiol Behav** 1995 Sep;58(3):539–50

Chronic heat exposure enhances fat deposition and modifies muscle and fat partition in broiler carcasses. Ain Baziz H, et al. **Poult Sci** 1996 Apr;75(4):505–13

Identification of the promoter of the mouse obese gene. de la Brousse FC, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4096–101

Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. MacDougald OA, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9034–7

The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression. Miller SG, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5507–11

Fuel selection in white adipose tissue. Frayn KN, et al. **Proc Nutr Soc** 1995 Mar;54(1):177–89 (50 ref.)

Association of cadmium with human breast cancer. Antila E, et al. **Sci Total Environ** 1996 Jul 30;186(3):251–6

Organochlorine residues in marine mammals from the northern hemisphere--a consideration of the composition of organochlorine residues in the blubber of marine mammals. Vetter W, et al. **Sci Total Environ** 1996 Jul 16; 186(1–2):29–39

A tissue composition-based algorithm for predicting tissue:air partition coefficients of organic chemicals. Poulin P, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):126–30

[The effect of adrenotropic agents on lipolysis in rat adipose tissue; the effect of nonselective alpha adrenomimetics and alpha adrenolytics under in vitro experimental conditions] Lincová D, et al. **Sb Lek** 1991;93(9–10):351–63 (Eng.

Abstr.) **(Cze)**

[Pathogenesis of visceral fat accumulation] Keno Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:121–6 (20 ref.) **(Jpn)**

[Characteristics of adipose] Yamamura M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:133–7 (7 ref.) **(Jpn)**

PATHOLOGY

Adrenocortical adenoma containing a fat component: CT and MR image evaluation. Sato N, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):489–90

Postliposuction histologic alterations of adipose tissue. Carpaneda CA. **Aesthetic Plast Surg** 1996 May–Jun; 20(3):207–11

Effect of total adipose weight and systemic hypertension on left ventricular mass in children. Yoshinaga M, et al. **Am J Cardiol** 1995 Oct 15;76(11):785–7

Body mass index in screening for adiposity in children and adolescents: systematic evaluation using receiver operating characteristic curves. Lazarus R, et al. **Am J Clin Nutr** 1996 Apr;63(4):500–6

Fat intake and adiposity in children of lean and obese parents. Nguyen VT, et al. **Am J Clin Nutr** 1996 Apr;63(4):507–13

Quantitative assessment of fat cells in subcutaneous metastatic melanoma. Correlation with outcome. Smolle J, et al. **Am J Dermatopathol** 1995 Dec;17(6):555–9

Unreliability of the abdominal fat pad biopsy in the evaluation of nephrosis: report of 3 consecutive cases. Lipschutz JH, et al. **Am J Nephrol** 1995;15(5):431–5

Immunohistologic analysis of synovium in infrapatellar fat pad after anterior cruciate ligament injury. Murakami S, et al. **Am J Sports Med** 1995 Nov–Dec;23(6):763–8

Lipomatous medulloblastoma in adults. A distinct clinicopathological entity. Soylemezoglu F, et al. **Am J Surg Pathol** 1996 Apr;20(4):413–8 (33 ref.)

Imaging quiz case 2. Arteriovenous malformation (AVM) of the buccal fat pad. Cullen MM, et al. **Arch Otolaryngol Head Neck Surg** 1996 May; 122(5):571–573

The effect of adipose cell size on the measurement of GLUT 4 in white adipose tissue of obese mice. Fabres–Machado U, et al. **Braz J Med Biol Res** 1995 Mar;28(3):369–76

Magnetic resonance imaging of primary osteosarcoma of the lumbar vertebra with metastasis to the perirenal fat. Tehranzadeh J, et al. **Can Assoc Radiol J** 1996 Aug; 47(4):275–8

Right heart failure due to ventricular adiposity: 'adipositas cordis'—an old diagnosis revisited. House AA, et al. **Can J Cardiol** 1996 May;12(5):485–9

Changes in liver and fat depots of west African dwarf goats (Capra aegagus hircus) after an infection with T. vivax. Hamminga BJ, et al. **Comp Biochem Physiol A Physiol** 1996 Apr;113(4):401–6

Involutional lipoatrophy: macrophage–related involution of fat lobules. Zalla MJ, et al. **Dermatology** 1995;191(2):149–53

Modified staining technique for the on–site evaluation of fine–needle aspiration specimens from fatty tissues. Logan LS, et al. **Diagn Cytopathol** 1995 Nov;13(4):345–6

The obese growth hormone (GH)–deficient dwarf rat: body fat responses to patterned delivery of GH and insulin–like growth factor–I. Clark RG, et al. **Endocrinology** 1996 May; 137(5):1904–12

Pleomorphic adenoma with extensive lipometaplasia. Ng WK, et al. **Histopathology** 1995 Sep;27(3):285–8

Reproducibility of computed tomography measurement of visceral adipose tissue area. Thaete FL, et al. **Int J Obes Relat Metab Disord** 1995 Jul;19(7):464–7

Possible origin of pancreatic fat necrosis as a septal panniculitis. Ball NJ, et al. **J Am Acad Dermatol** 1996 Feb; 34(2 Pt 2):362–4

Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. Wabitsch M, et al. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3469–75

Ten–year changes in the obesity, abdominal adiposity, and serum lipoprotein cholesterol measures of Western Samoan men. Galanis DJ, et al. **J Clin Epidemiol** 1995 Dec; 48(12):1485–93

Localised lipoatrophy after acupuncture [letter; comment] Drago F, et al. **Lancet** 1996 May 25;347(9013):1484. Comment on: Lancet 1995 Jun 17;345(8964):1576.

Objective quantification of muscle and fat in human dystrophic muscle by magnetic resonance image analysis. Phoenix J, et al. **Muscle Nerve** 1996 Mar;19(3):302–10

MRI of idiopathic orbital inflammatory syndrome using fat saturation and Gd–DTPA. Hardman JA, et al. **Neuroradiology** 1995 Aug;37(6):475–8

Development of fat within a meningioma. Okamoto K, et al. **Neuroradiology** 1996 Apr;38(3):214–6

Pathophysiology and pathogenesis of visceral fat obesity. Matsuzawa Y, et al. **Obes Res** 1995 Sep;3 Suppl 2:187S–194S (14 ref.)

Quantitative analysis of stromal fat content of human parathyroid glands associated with thyroid diseases using computer image analysis. Iwasaki A, et al. **Pathol Int** 1995 Jul;45(7):483–6

A case of myospherulosis occurring in the perirenal adipose tissue. Le Gall F, et al. **Pathol Res Pract** 1996 Feb; 192(2):172–8; discussion 179–81

Fatty infiltration of disrupted rotator cuff muscles. Goutallier D, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):415–22

Ultrastructure of the adipose tissue matrix in children with malnutrition. Alexa A, et al. **Rom J Morphol Embryol** 1995 Jul–Dec;41(3–4):121–4

Simple anthropometric measurements—relation to body fat mass, visceral adipose tissue and risk factors of atherogenesis. Kunešová M, et al. **Sb Lek** 1995;96(3):257–67

The effects of race and body fat distribution on insulin sensitivity. Pi–Sunyer FX, et al. **Trans Am Clin Climatol Assoc** 1995;107:175–85; discussion 185–6

[MR appearance of fat distribution in ovarian teratoma: pathologic correlation] Hatanaka Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jun; 56(7):477–81 (Eng. Abstr.) **(Jpn)**

[The detection of secondary amyloidosis in rheumatoid arthritis by aspiration biopsy of the subcutaneous fatty tissue] Päi S, et al. **Ter Arkh** 1995;67(11):73–5 (Eng. Abstr.) **(Rus)**

[The role and significance of sagittal abdominal diameter in the determination of adipose tissue distribution] Stokić E, et al. **Med Pregl** 1996;49(5–6):217–20 (Eng. Abstr.) **(Scr)**

PHYSIOLOGY

New model for the regulation of energy balance and adiposity by the central nervous system. Kaiyala KJ, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1123S–1134S (130 ref.)

Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI–1 in postmenopausal women. Meilahn EN, et al. **Am J Epidemiol** 1996 Jan 15; 143(2):159–66

Physiological predictors of increasing total and central adiposity in aging men and women. Poehlman ET, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2443–8

Differential expression of ob mRNA in rat adipose tissues in response to insulin. Zheng D, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):434–7

Tissue impedance as a function of temperature and time. Dadd JS, et al. **Biomed Sci Instrum** 1996;32:205–14

Unexpected relationship between fat mass and basal metabolic rate in pregnant women. Bronstein MN, et al. **Br J Nutr** 1996 May;75(5):659–68

Adipose tissue leptin production and plasma leptin kinetics in humans. Klein S, et al. **Diabetes** 1996 Jul;45(7):984–7

Relation of steroid hormones to glucose tolerance and plasma insulin levels in men. Importance of visceral adipose tissue. Tchernof A, et al. **Diabetes Care** 1995 Mar;18(3):292–9

Steroid hormones and adipose tissue [comment] Prins JB, et al. **Eur J Clin Invest** 1996 Apr;26(4):259–61 (24 ref.). Comment on: Eur J Clin Invest 1996 Apr;26(4):262–9.

Is the intra–uterine period really a critical period for the development of adiposity? Allison DB, et al. **Int J Obes Relat Metab Disord** 1995 Jun;19(6):397–402

Response of total and regional lean tissue and skeletal muscle to a program of energy restriction and resistance exercise. Ross R, et al. **Int J Obes Relat Metab Disord** 1995 Nov; 19(11):781–7

Sensitivity associated with the identification of visceral adipose tissue levels using waist circumference in men and women: effects of weight loss. Ross R, et al. **Int J Obes Relat Metab Disord** 1996 Jun;20(6):533–8

Measuring visceral adipose tissue content from contrast enhanced computed tomography. Vehmas T, et al. **Int J Obes Relat Metab Disord** 1996 Jun;20(6):570–3

Inhomogeneity in body fat distribution may result in inaccuracy in the measurement of vertebral bone mass. Formica C, et al. **J Bone Miner Res** 1995 Oct; 10(10):1504–11

Skeletal muscle membrane lipid composition is related to adiposity and insulin action. Pan DA, et al. **J Clin Invest** 1995 Dec;96(6):2802–8

Involvement of epidermal growth factor in inducing adiposity of age female mice. Adachi H, et al. **J Endocrinol** 1995 Sep;146(3):381–93

Migratory fat deposition in European quail: a role for prolactin? Boswell T, et al. **J Endocrinol** 1995 Jul; 146(1):71–9

Generalised obesity and regional adiposity in adult white and migrant Muslim males from Pakistan in Peterborough. Bose K. **J R Soc Health** 1996 Jun;116(3):161–7

Optimizing exercise for fat loss. McCarty MF. **Med Hypotheses** 1995 May;44(5):325–30

Malonyl coenzyme A and adiposity in the Dahl salt–sensitive rat: effects of pioglitazone. Kurowski TG, et al. **Metabolism** 1996 Apr;45(4):519–25

Effects of exercise training and feeding on lipoprotein lipase gene expression in adipose tissue, heart, and skeletal muscle of the rat. Ong JM, et al. **Metabolism** 1995 Dec; 44(12):1596–605

Leptin and nerve growth factor regulate adipose tissue [letter; comment] Nisoli E, et al. **Nat Med** 1996 Feb;2(2):130. Comment on: Nat Med 1995 Sep;1(9):950–3.

Role of leptin in fat regulation [letter] Collins S, et al. **Nature** 1996 Apr 25;380(6576):677

The accumulation of visceral adipose tissue may be influenced by intra–abdominal temperature. Kahn HS. **Obes Res** 1996 May;4(3):297–9

Hologic QDR 2000 whole–body scans: a comparison of three combinations of scan modes and analysis software. Spector E, et al. **Osteoporos Int** 1995;5(6):440–5

Body fat reserves attenuate gastric ulcers induced by restricted feeding in rats. Yi I, et al. **Physiol Behav** 1996 Apr–May;59(4–5):931–6

[The role of muscle, adipose tissue and liver in development of metabolic syndrome] Krotkiewski M. **Pol Tyg Lek** 1996 Jan;51(1–5):40–5 (55 ref.) **(Pol)**

PHYSIOPATHOLOGY

Association of the waist–to–hip ratio is different with wine than with beer or hard liquor consumption. Atherosclerosis Risk in Communities Study Investigators. Duncan BB, et al. **Am J Epidemiol** 1995 Nov 15;142(10):1034–8

Possible role of bone marrow fat in the development of an inflammatory response to sickled erythrocytes: comment on the article by Mann and Schumacher [letter; comment] McCarty DJ, et al. **Arthritis Rheum** 1995 Sep;38(9):1349–50 . Comment on: Arthritis Rheum 1995 Feb;38(2):284–7.

Changes in autonomic nervous system activity and consecutive hyperinsulinaemia: respective roles in the development of obesity in rodents. Pénicaud L, et al. **Diabetes Metab** 1996 Feb;22(1):15–24 (67 ref.)

Loss of abdominal fat and improvement of the cardiovascular risk profile by regular moderate exercise training in patients with NIDDM. Lehmann R, et al. **Diabetologia** 1995 Nov; 38(11):1313–9

Beta–adrenergic responsiveness of adenylate cyclase in human adipocyte plasma membranes in obesity and after massive weight reduction. Kaartinen JM, et al. **Metabolism** 1995 Oct;44(10):1288–92

RADIOGRAPHY

CT demonstration of liquid intratumoral fat layering in a necrotic renal cell carcinoma. Castoldi MC, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):483–5

Intra–abdominal fat in obese children. Iwata F, et al. **Acta Paediatr Jpn** 1995 Oct;37(5):617–20

Case report: mobile fatty globules in benign cystic teratoma of the mediastinum. Hession PR, et al. **Br J Radiol** 1996 Feb;69(818):186–8

Case report: the CT demonstration of soft tissue involvement in multicentric reticulohistiocytosis. Kamel H, et al. **Clin Radiol** 1996 Jun;51(6):440–1

Computed tomography visceral adipose tissue volume measurements of Italians. Predictive equations. Armellini F, et al. **Eur J Clin Nutr** 1996 May;50(5):290–4

Decrease in intra–abdominal visceral fat may reduce blood pressure in obese hypertensive women. Kanai H, et al. **Hypertension** 1996 Jan;27(1):125–9

Computed tomographic observations on subcutaneous fat: implications for liposuction. Johnson D, et al. **Plast Reconstr Surg** 1996 Feb;97(2):387–96

[The measurement of fat distribution by computed tomography] Nakamura T, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:209–14 (10 ref.) **(Jpn)**

SECRETION

[Leptin—a new way to diet?] Holst JJ. **Ugeskr Laeger** 1996 Aug 5;158(32):4505–8 (25 ref.) (Eng. Abstr.) **(Dan)**

SURGERY

Superficial liposuction. Bolivar de Souza Pinto E, et al. **Aesthetic Plast Surg** 1996 Mar–Apr;20(2):111–22

Ventral hernia repair with simultaneous panniculectomy. Hughes KC, et al. **Am Surg** 1996 Aug;62(8):678–81

The soft–tissue shaving procedure for removal of adipose tissue. A new, less traumatic approach than liposuction. Gross CW, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct;121(10):1117–20

The role of orbital fat preservation in facial aesthetic surgery. A new concept. Hamra ST. **Clin Plast Surg** 1996 Jan; 23(1):17–28

Application of the buccal fat pad to the surgical treatment of oral submucous fibrosis. Yeh CJ. **Int J Oral Maxillofac Surg** 1996 Apr;25(2):130–3

Use of pedicled fat pad graft as an adjunct in the reconstruction of palatal cleft defects. Hudson JW, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):24–7

Subcutaneous approach for elevation of the malar fat pad through a prehairline incision. Collawn SS, et al. **Plast Reconstr Surg** 1996 Apr;97(4):836–41

Suborbicularis oculi fat pads [letter; comment] Hamra ST. **Plast Reconstr Surg** 1996 Feb;97(2):484–6. Comment on: Plast Reconstr Surg 1995 Jan;95(1):37–42.

[Drainage of the fatty tissues of the lesser pelvis] Iudin IaB. **Vestn Khir Im I I Grek** 1992 Mar;148(3):359–62 **(Rus)**

[Myringoplasty using a fat graft] Hernández Madorrán JM, et al. **Acta Otorrinolaringol Esp** 1995 Nov–Dec; 46(6):469–70 (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

Autologous periurethral fat injections for the creation of bladder outlet obstruction. Canning DA. **Adv Exp Med Biol** 1995;385:261–3

Long–term survival of fat transplants: controlled demonstrations. Coleman SR. **Aesthetic Plast Surg** 1995 Sep–Oct;19(5):421–5

Liposuction fat–fillant implant for breast augmentation and reconstruction. Hang–Fu L, et al. **Aesthetic Plast Surg** 1995 Sep–Oct;19(5):427–37

MR evaluation of frontal sinus osteoplastic flaps with autogenous fat grafts. Loevner LA, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1721–6

Long–term result of vocal cord augmentation with

autogenous fat. Bauer CA, et al.
Ann Otol Rhinol Laryngol 1995 Nov;104(11):871–4
Free fat autotransplantation for the cosmetic treatment of first web space atrophy. Ghobadi F, et al.
Ann Plast Surg 1995 Aug;35(2):197–200
The use of dermal–fat grafts. McClinton MA. **Hand Clin** 1996 May;12(2):357–64
Guidelines of care for soft tissue augmentation: fat transplantation. American Academy of Dermatology.
J Am Acad Dermatol 1996 Apr;34(4):690–4
Free fat transplantation in the face. Drommer RB, et al.
J Craniomaxillofac Surg 1995 Aug;23(4):228–32
Magnetic resonance imaging after frontal sinus surgery with fat obliteration. Keerl R, et al. **J Laryngol Otol** 1995 Nov; 109(11):1115–9
Vocal cord injection with autogenous fat: a long–term magnetic resonance imaging evaluation. Brandenburg JH, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):174–80
Fat cylinder transplantation: an experimental comparative study of three different kinds of fat transplants. Fagrell D, et al. **Plast Reconstr Surg** 1996 Jul;98(1):90–6; discussion 97–8
SMAS autografts for the nasal dorsum. Leaf N.
Plast Reconstr Surg 1996 May;97(6):1249–52
First–time operation for lumbar disc herniation with or without free fat transplantation. Prospective triple–blind randomized study with reference to clinical factors and enhanced computed tomographic scan 1 year after operation. Jensen TT, et al. **Spine** 1996 May 1;21(9):1072–6
Complication of epidural fat graft in lumbar spine disc surgery: case report. Cobanoğlu S, et al. **Surg Neurol** 1995 Nov;44(5):479–81; discussion 481–2
Use of a pericardial fat pad flap for preventing bronchopleural fistula: an experimental study focusing on the angiogenesis and cytokine production of the fat pad. Ichinose Y, et al. **Surg Today** 1995;25(9):811–5
[The Bichat ball. The surgical value of oro–sinus communications] Adam P, et al.
Rev Stomatol Chir Maxillofac 1995;96(6):379–84 (Eng. Abstr.) **(Fre)**
[Free fatty tissue transplantation in the area of the face] Drommer RB, et al. **Hautarzt** 1995 Sep;46(9):628–31 (Eng. Abstr.) **(Ger)**
[Dermal fat transplant as autologous orbital implant] Hintschich CR, et al. **Klin Monatsbl Augenheilkd** 1996 Mar; 208(3):135–41 (Eng. Abstr.) **(Ger)**
[Injected fat for correction of soft tissue defects] Shoshani O, et al. **Harefuah** 1995 Dec 1;129(11):489–93 (40 ref.) **(Heb)**
[The adipose Bichat bolla flaps in repair of oroantral fistulas] Cannistrà C, et al. **Acta Otorhinolaryngol Ital** 1995 Dec; 15(6):424–30 (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Hypoechoic fat: another location [letter; comment] Norris MA, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):214–5. Comment on: AJR Am J Roentgenol 1995 May;164(5):1277–80.
Performance of ultrasonic speckle tracking in various tissues. Chen EJ, et al. **J Acoust Soc Am** 1995 Sep;98(3):1273–8
Validation of body condition scores with ultrasound measurements of subcutaneous fat of dairy cows. Domecq JJ, et al. **J Dairy Sci** 1995 Oct;78(10):2308–13
Perirenal capsula adiposa—is it a sign indicating diabetes mellitus? Nahm AM, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):548–9
[Pitfall: decreased echo contrast of the processus uncinatus in ultrasound] Brambs HJ. **Rontgenpraxis** 1996 Jun; 49(6):139–40 **(Ger)**
[Ultrasonic diagnosis of visceral type obesity] Murano S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:203–8 (10 ref.) **(Jpn)**

ADIPOSE TISSUE, BROWN see **BROWN FAT**

ADIPOSIS DOLOROSA

[Dercum's disease. Fatty tissue rheumatism caused by immune defense reaction?] Brorson H, et al.
Lakartidningen 1996 Apr 10;93(15):1430, 1433–6 **(Swe)**

ADJUSTMENT DISORDERS

COMPLICATIONS

Koro–like syndrome associated with brief reactive psychosis in an Irish male. Phelan D, et al. **Ir Med J** 1996 Mar–Apr; 89(2):75–6

DIAGNOSIS

A test of the hopelessness theory of depression in unemployed young adults. Lynd–Stevenson RM. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):117–32
The prevalence of major depressive disorder and low self–esteem in medical inpatients [see comments] Silverstone PH, et al. **Can J Psychiatry** 1996 Mar; 41(2):67–74. Comment in: Can J Psychiatry 1996 Mar;41(2):65–6.
Depression in the medically ill [editorial; comment] Stenn PG. **Can J Psychiatry** 1996 Mar;41(2):65–6. Comment on: Can J Psychiatry 1996 Mar;41(2):67–74.
Clinical relevance of adjustment disorder in DSM–III–4 and DSM–IV. Despland JN, et al. **Compr Psychiatry** 1995 Nov–Dec;36(6):454–60
Psychiatric evaluation of physical rehabilitation patients. Aoki T, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):440–3
Reliability of diagnosing complicated grief: a preliminary investigation. Marwit SJ. **J Consult Clin Psychol** 1996 Jun; 64(3):563–8
Symptoms of stress disorder and depression among trauma counselors after an airline disaster. Lesaca T.
Psychiatr Serv 1996 Apr;47(4):424–6
Inventory of Complicated Grief: a scale to measure maladaptive symptoms of loss. Prigerson HG, et al.
Psychiatry Res 1995 Nov 29;59(1–2):65–79
Psychological distress among recent immigrants from the former Soviet Union to Israel, II. The effects of the Gulf War. Lerner Y, et al. **Psychol Med** 1996 May;26(3):503–10
Psychological distress among recent immigrants from the former Soviet Union to Israel, I. Correlates of level of distress. Zilber N, et al. **Psychol Med** 1996 May; 26(3):493–501

DRUG THERAPY

Fluoxetine treatment of depressed patients with HIV infection. Judd FK, et al. **Aust N Z J Psychiatry** 1995 Sep; 29(3):433–6
[SSRI–induced akathesia] Hofmann M, et al.
Psychiatr Prax 1996 May;23(3):143–4 **(Ger)**

EPIDEMIOLOGY

Kindergarten predictors of boys' stable behavior problems at the end of elementary school. Gagnon C, et al.
J Abnorm Child Psychol 1995 Dec;23(6):751–66
Urban stress in China. Lin N, et al. **Soc Sci Med** 1995 Oct; 41(8):1131–45
[Psychiatric disorders in hospitalized internal medicine and surgical patients. Prevalence and need for treatment] Arolt V, et al. **Nervenarzt** 1995 Sep;66(9):670–7 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Life events and symptomatic recovery of army spouses following Operation Desert Storm. Rosen LN.
Behav Med 1995 Fall;21(3):131–9
Termination of pregnancy and psychiatric morbidity. Gilchrist AC, et al. **Br J Psychiatry** 1995 Aug;167(2):243–8
Vulnerability to depressive mood reactions: retesting the hopelessness model of depression. Houston DM.
Br J Soc Psychol 1995 Sep;34 (Pt 3):293–302
Sustaining fantasies, daydreams, and psychopathology. Greenwald DF, et al. **J Clin Psychol** 1995 Nov;51(6):719–26

REHABILITATION

Postdischarge follow–up of psychiatric inpatients and readmission in an HMO setting. Schoenbaum SC, et al.
Psychiatr Serv 1995 Sep;46(9):943–5

THERAPY

[Medical management after spontaneous abortion] Beutel M, et al. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):M93–5 **(Ger)**

ADJUSTMENT, SOCIAL see **SOCIAL ADJUSTMENT**

ADJUVANT ARTHRITIS see **ARTHRITIS, ADJUVANT**

ADJUVANTS, IMMUNOLOGIC

Copolymer adjuvants. Brey RN. **Adv Exp Med Biol** 1995; 383:23–34 (47 ref.)
Glucans as immunological adjuvants. Mohagheghpour N, et al. **Adv Exp Med Biol** 1995;383:13–22
The effect of molecular weight and gel preparation on humoral adjuvancy of silicone oils and silicone gels. Naim JO, et al. **Adv Exp Med Biol** 1995;383:7–12
Myelopeptides: new immunoregulatory peptides. Petrov R. **Allergy Proc** 1995 Jul–Aug;16(4):177–84 (14 ref.)
DHEAS as an effective vaccine adjuvant in elderly humans. Proof–of–principle studies. Araneo B, et al.
Ann N Y Acad Sci 1995 Dec 29;774:232–48
A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212–26 (23 ref.)
Relationship between humoral immunoaugmenting properties of DHEAS and IgD–receptor expression in young and aged mice. Swenson CD, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:249–58
Selective induction of mucosal immune responses to 2–acetylaminofluorene. Silbart LK, et al. **Anticancer Res** 1996 Mar–Apr;16(2):651–60
Morphological demonstration of the immune privilege in the testis using adjuvants: tissue responses of male reproductive organs in mice injected with Bordetella pertussigens. Itoh M, et al. **Arch Histol Cytol** 1995 Dec;58(5):575–9
Augmentation of anti–influenza virus hemagglutinin antibody production by Peyer's patch cells with Bifidobacterium breve YIT4064. Yasui H, et al.
Clin Diagn Lab Immunol 1994 Mar;1(2):244–6
A royal jelly as a new potential immunomodulator in rats and mice. Sver L, et al.
Comp Immunol Microbiol Infect Dis 1996 Jan;19(1):31–8
Immunogenicity and safety of recombinant Helicobacter pylori urease in a nonhuman primate. Stadtländer CT, et al. **Dig Dis Sci** 1996 Sep;41(9):1853–62
CD8–deficient mice exhibit augmented mucosal immune responses and intact adjuvant effects to cholera toxin. Hörnquist E, et al. **Immunology** 1996 Feb;87(2):220–9
Immunomodulation: role of intravenous immunoglobulins. Symposium proceedings. Boston, Massachusetts, October 1988. **Int Rev Immunol** 1989;5(2):1–202
Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. Soiffer RJ, et al. **J Clin Apheresis** 1995;10(3):139–43 (36 ref.)
Dendritic cells as adjuvants for class I major histocompatibility complex–restricted antitumor immunity [comment] Young JW, et al. **J Exp Med** 1996 Jan 1; 183(1):7–11. Comment on: J Exp Med 1996 Jan 1;183(1):87–97. Comment on: J Exp Med 1996 Jan 1;183(1):283–7. Comment on: J Exp Med 1996 Jan 1;183(1):317–22.
Pericholangitis in a rabbit colitis model induced by injection of muramyl dipeptide emulsified with a long–chain fatty acid. Kuroe K, et al. **J Gastroenterol** 1996 Jun;31(3):347–52
Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL–4. Marinaro M, et al. **J Immunol** 1995 Nov 15;155(10):4621–9
Induction of Th1 cell–mediated protective immunity to Schistosoma mansoni by co–administration of larval antigens and IL–12 as an adjuvant. Mountford AP, et al. **J Immunol** 1996 Jun 15;156(12):4739–45
Effects of immunostimulators on involution of lymphoid organs in mice exposed to heat and cold stress. Kimura M, et al. **J Vet Med Sci** 1996 Mar;58(3):255–7
Modulation by gamma interferon of antiviral cell–mediated immune responses in vivo. Utermöhlen O, et al. **J Virol** 1996 Mar;70(3):1521–6
Variation in protection by BCG [letter; comment] Fraser DW. **Lancet** 1996 Feb 3;347(8997):333–4. Comment on: Lancet 1995 Nov 18;346(8986):1339–45.
Alpha interferon as an immunomodulator in the treatment of patients with tumors. Alvarez–Mon M, et al.
Med Oncol 1995 Mar;12(1):15–21 (45 ref.)
Immunomodulatory effects of Maharishi Amrit Kalash 4 and 5 in mice. Inaba R, et al. **Nippon Eiseigaku Zasshi** 1995 Oct;50(4):901–5
Vaccine adjuvants based on gamma inulin. Cooper PD.
Pharm Biotechnol 1995;6:559–80 (73 ref.)
Adjuvant properties of aluminum and calcium compounds. Gupta RK, et al. **Pharm Biotechnol** 1995;6:229–48 (126 ref.)
Structural and immunological characterization of the vaccine adjuvant QS–21. Kensil CR, et al. **Pharm Biotechnol** 1995; 6:525–41 (41 ref.)
Nanoparticles as adjuvants for vaccines. Kreuter J.
Pharm Biotechnol 1995;6:463–72 (32 ref.)
Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Ulrich JT, et al. **Pharm Biotechnol** 1995;6:495–524 (150 ref.)
A compendium of vaccine adjuvants and excipients. Vogel FR, et al. **Pharm Biotechnol** 1995;6:141–228 (284 ref.)
C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Dempsey PW, et al. **Science** 1996 Jan 19;271(5247):348–50
Induced regression of bovine papillomas by intralesional immunotherapy. Hall H, et al. **Ther Immunol** 1994 Dec; 1(6):319–24
Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Ivins B, et al. **Vaccine** 1995 Dec;13(18):1779–84
Immune response of calves to foot–and–mouth disease virus vaccine emulsified with oil adjuvant. Strategies of vaccination. Späth EJ, et al. **Vaccine** 1995 Jul;13(10):909–14
Adjuvant treatment of locally advanced renal cancer with autologous virus–modified tumor vaccines. Kirchner HH, et al. **World J Urol** 1995;13(3):171–3
[Physicochemical properties of a beta–glucan from Sclerotinia sclerotiorum] Liu R, et al.
Wei Sheng Wu Hsueh Pao 1995 Apr;35(2):103–8 (Eng. Abstr.) **(Chi)**

ADMINISTRATION & DOSAGE

Specific antibody–producing cells in humans after oral immunization with a ribosomal vaccine Ribomunyl. Bene MC, et al. **Adv Exp Med Biol** 1995;371B:1563–6
Cholera toxin–mediated cellular immune responses against ovalbumin administered orally. Bowen JC, et al.
Adv Exp Med Biol 1995;371B:1531–3
Cholera toxin enhances antigen presentation. Bromander AK, et al. **Adv Exp Med Biol** 1995;371B:1501–6
Cholera toxin increases T lymphocyte responses to unrelated antigens. Hornquist E, et al. **Adv Exp Med Biol** 1995; 371B:1507–12
Effect of cholera toxin and its B subunit on intestinal permeability for ovalbumin. Pierre PG, et al.
Adv Exp Med Biol 1995;371B:1519–21
Vaccine adjuvancy: a new potential area of development for GM–CSF. Taglietti M. **Adv Exp Med Biol** 1995;378:565–9 (22 ref.)
Cholera and pertussis toxins, but not forskolin or LT–B, adjuvant IgA antibody responses to orally administered antigen. Wilson AD, et al. **Adv Exp Med Biol** 1995; 371B:1523–6

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. Keefer MC, et al. **AIDS Res Hum Retroviruses** 1996 May 20;12(8):683-93

Immunological alterations induced by adjuvant treatment of postoperative colon carcinoma Duke's B or C with levamisole in combination with 5-FU. De Brabander M, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2271-7

Potential advantages in therapeutic index of OK-432 ointment to abdominal skin over systemic applied in a mouse model. Matsuoka H, et al. **Cancer Lett** 1996 Mar 19;101(1):15-20

Intratumoral administration of sizofiran activates Langerhans cell and T-cell infiltration in cervical cancer. Nakano T, et al. **Clin Immunol Immunopathol** 1996 Apr;79(1):79-86

A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. Seymour AM, et al. **Eur J Cancer** 1995 Dec; 31A(13-14):2157-63

Urinary interleukin-1 alpha levels are increased by intravesical instillation with keyhole limpet hemocyanin in patients with superficial transitional cell carcinoma of the bladder. Jurincic-Winkler CD, et al. **Eur Urol** 1995; 28(4):334-9

The impact of immunonutrition. Koretz RL. **Gastroenterology** 1995 Nov;109(5):1713-4

Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Daly TM, et al. **Infect Immun** 1996 Jul;64(7):2602-8

Is oral levamisole immunostimulation in rats mediated by reduced levels of free plasma corticosterone? Stogaus R, et al. **Int J Immunopharmacol** 1995 Aug;17(8):635-40

Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. Takahashi I, et al. **J Infect Dis** 1996 Mar;173(3):627-35

The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma. Böhle A, et al. **J Urol** 1996 Jun; 155(6):1892-6

Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors [see comments] Lüftenegger W, et al. **J Urol** 1996 Feb; 155(2):483-7. Comment in: J Urol 1996 Feb;155(2):488-9.

A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma [see comments] Lundholm C, et al. **J Urol** 1996 Aug;156(2 Pt 1):372-6. Comment in: J Urol 1996 Aug;156(2 Pt 1):389-90.

Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. Rintala E, et al. **J Urol** 1995 Dec; 154(6):2050-3

Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group [see comments] Rintala E, et al. **J Urol** 1996 Jul;156(1):56-9; discussion 59-60. Comment in: J Urol 1996 Jul;156(1):61-2.

Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder [see comments] Zhang GK, et al. **J Urol** 1996 Jun;155(6):1907-9. Comment in: J Urol 1996 Jun;155(6):1910-1.

Variation in protection by BCG [letter; comment] Lunn JA. **Lancet** 1996 Feb 3;347(8997):334. Comment on: Lancet 1995 Nov 18;346(8986):1339-45.

Tuberculosis screening in adults who have received bacille Calmette-Guérin vaccine. Ballew KA, et al. **South Med J** 1995 Oct;88(10):1025-30

Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP). Hornung RL, et al. **Ther Immunol** 1995 Feb; 2(1):7-14

Nutritional immunomodulation enhances cardiac allograft survival in rats treated with donor-specific transfusion and cyclosporine. Levy AE, et al. **Transplantation** 1995 Oct 27;60(8):812-5

Enhancement of nonspecific resistance by liposome-encapsulated immunomodulators does not affect skin graft rejection in mice. ten Hagen TL, et al. **Transplantation** 1995 Dec 15;60(11):1211-4

Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. de Haan A, et al. **Vaccine** 1995 Oct;13(14):1320-4

Humoral and cellular responses induced by intradermally administered cytokine and conventional adjuvants. Lofthouse SA, et al. **Vaccine** 1995 Aug;13(12):1131-7

[Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects] Walther EU, et al. **Nervenarzt** 1996 Jun;67(6):452-6 (16 ref.) (Eng. Abstr.) **(Ger)**

[Wobenzyme and diuretic therapy in lymphedema after breast operation] Korpan MI, et al. **Wien Med Wochenschr** 1996; 146(4):67-72; discussion 74 (Eng. Abstr.) **(Ger)**

[Results of a double-blind, randomized comparative study of Wobenzym-placebo in patients with cervical syndrome] Tilscher H, et al. **Wien Med Wochenschr** 1996;146(5):91-5 (Eng. Abstr.) **(Ger)**

[Prevention and treatment of acute suppurative infection in emergency abdominal surgery] Ashrafov AA, et al. **Klin Khir** 1995;(4):29-31 **(Rus)**

[Endolymphatic therapy in the treatment of patients with acute appendicitis] Komarov NV, et al. **Klin Khir** 1996; (1):53 **(Rus)**

[A comparative evaluation of the efficacy of immunocorrection in children with bronchial asthma living in ecologically contrasted regions] Trishina SV, et al. **Lik Sprava** 1995 Jul-Aug;(7-8):59-61 (Eng. Abstr.) **(Rus)**

[The use of leukinferon in treating measles in adult patients] Nikolaeva IN, et al. **Stomatologiia (Mosk)** 1995;74(3):32-5 (Eng. Abstr.) **(Rus)**

[The use of BCG vaccine for preventing recurrences of superficial bladder cancer] Tkachuk VN, et al. **Urol Nefrol (Mosk)** 1996 Mar-Apr;(2):23-5 (Eng. Abstr.) **(Rus)**

[The antibacterial and immunocorrective action of ozone therapy in peritonitis] Vasil'ev IT, et al. **Vestn Khir Im I I Grek** 1995;154(3):56-60 (Eng. Abstr.) **(Rus)**

[The use of pilastin for treating patients with chronic suppurative otitis media] Popova AE, et al. **Vestn Otorinolaringol** 1996 Jan-Feb;(1):42-3 (Eng. Abstr.) **(Rus)**

[Study of immunomodulating properties of beta-carotene in patients] Pletsityi KD, et al. **Vopr Pitan** 1995;(6):14-6 (Eng. Abstr.) **(Rus)**

[The effect of natural immunomodulators on the lymphocytic natural killer activity in patients with malignant lymphoproliferative diseases] Kindzel'skiĭ LP, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):146-8 (Eng. Abstr.) **(Rus)**

[Density of adhesive proteins after oral administration of proteolytic enzymes in multiple myeloma] Sakalová A, et al. **Vnitr Lek** 1995 Dec;41(12):822-6 (Eng. Abstr.) **(Slo)**

ADVERSE EFFECTS

Silicone gels as adjuvants. Effects on humoral and cell-mediated immune responses. Naim JO, et al. **Adv Exp Med Biol** 1995;383:1-6

Adverse effects at adjuvant treatment of liver metastases in rat with RSU-1069 + microspheres, or liposomal MTP-PE. Wang L, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):2077-80

A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole. Wehbe TW, et al. **Clin Pharmacol Ther** 1996 Mar; 59(3):360-2

Bacillus Calmette-Guerin (BCG) balanitis as a complication of intravesical BCG immunotherapy: a case report. Erol A, et al. **Int Urol Nephrol** 1995;27(3):307-10

Roquinimex-induced graft-versus-host reaction after autologous bone marrow transplantation. Gaspari AA, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):711-7

Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. Webster GF, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):365-7

An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis. Logan-Clubb L, et al. **J Neurosci Nurs** 1995 Dec; 27(6):344-7

An open labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis [letter] Ozuma J. **J Neurosci Nurs** 1996 Apr;28(2):72

The quality of life during intravesical bacillus Calmette-Guerin therapy. Bohle A, et al. **J Urol** 1996 Apr; 155(4):1221-6

Fever following intracavitary bacillus Calmette-Guerin therapy for upper tract transitional cell carcinoma [see comments] Schnapp DS, et al. **J Urol** 1996 Aug;156(2 Pt 1):386-8. Comment in: J Urol 1996 Aug;156(2 Pt 1):389-90.

Is silicone safe? Let science decide [editorial; comment] Shack RB. **South Med J** 1996 Feb;89(2):251-2. Comment on: South Med J 1996 Feb;89(2):179-88.

Human adjuvant disease: presentation as a multiple sclerosis-like syndrome [see comments] Shoaib BO, et al. **South Med J** 1996 Feb;89(2):179-88. Comment in: South Med J 1996 Feb;89(2):251-2.

Penile edema and meatal ulceration after intravesical instillation with bacillus Calmette-Guerin. Baniel J, et al. **Urology** 1996 Jun;47(6):932-4

Comparison of adjuvants for immune potentiating properties and side effects in mice. Leenaars PP, et al. **Vet Immunol Immunopathol** 1995 Sep;48(1-2):123-38

[Severe myalgias: an unusual undesirable effect of levamisole combined with 5-fluorouracil (letter)] Buecher B, et al. **Gastroenterol Clin Biol** 1996;20(4):407-8 **(Fre)**

[Complications of immunotherapy with BCG. Report of a case with retractile bladder] Torrubia Romero FJ, et al. **Arch Esp Urol** 1996 Jan-Feb;49(1):74-8 (Eng. Abstr.) **(Spa)**

ANALYSIS

Isoelectric focusing of Tamm-Horsfall glycoproteins: a simple tool for recognizing recurrent calcium oxalate renal stone formers. Schnierle P, et al. **Urol Res** 1996;24(2):79-82

Accurate determination of adjuvant-associated protein or peptide by ninhydrin assay. Brewer JM, et al. **Vaccine** 1995; 13(15):1441-4

Oral immunoadjuvant activity of lipophilic derivatives of N-acetylglucosaminyl-beta(1-->4)-N-acetylmuramyl-L-alanyl-D-isoglutamin yl-(L)- 2,6-meso-diaminopimeric acid-(D)-amide. Ogawa T, et al. **Vaccine** 1995 Jul; 13(10):887-9

[Colorimetric method for the determination of carboxymethyl pachyman] Chen G, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep;20(9):543-4, 576 (Eng. Abstr.) **(Chi)**

ANTAGONISTS & INHIBITORS

Anti-oxidants inhibit the enhancement of the immune response caused by oil adjuvants. Di Gianni P, et al. **Scand J Immunol** 1996 Apr;43(4):413-20

BLOOD

The expression of a progesterone-induced immunomodulatory protein in pregnancy lymphocytes. Szekeres-Bartho J, et al. **Am J Reprod Immunol** 1995 Dec; 34(6):342-8

Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Hoffmann JN, et al. **Kidney Int** 1995 Nov;48(5):1563-70

CHEMICAL SYNTHESIS

Syntheses and effect of bursin and it analogs on the reduced B lymphocytes of uremic patients. Abiko T, et al. **Biotechnol Ther** 1994-95;5(3-4):163-70

Development of an emulsion-based muramyl dipeptide adjuvant formulation for vaccines. Lidgate DM, et al. **Pharm Biotechnol** 1995;6:313-24 (34 ref.)

MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Ott G, et al. **Pharm Biotechnol** 1995; 6:277-96 (36 ref.)

CHEMISTRY

Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy. Jacobsen NE, et al. **Carbohydr Res** 1996 Jan 4;280(1):1-14

New oral dosage form for elderly patients. II. Release behavior of benfotiamine from silk fibroin gel. Hanawa T, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):872-6

Characterization of carbohydrate-peptide linkage of acidic heteroglycopeptide with immuno-stimulating activity from mycelium of Phellinus linteus. Lee JH, et al. **Chem Pharm Bull (Tokyo)** 1996 May;44(5):1093-5

Antibacterial and immunostimulating casein-derived substances from milk: casecidin, isracidin peptides. Lahov E, et al. **Food Chem Toxicol** 1996 Jan;34(1):131-45 (49 ref.)

Preparation and characterization of poly-(D,L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres with entrapped pneumotropic bacterial antigens. Kofler N, et al. **J Immunol Methods** 1996 Jun 10;192(1-2):25-35

Antibody production in rabbits and chickens immunized with human IgG. A comparison of titre and avidity development in rabbit serum, chicken serum and egg yolk using three different adjuvants. Svendsen Bollen L, et al. **J Immunol Methods** 1996 May 27;191(2):113-20

Structure and properties of aluminum-containing adjuvants. Hem SL, et al. **Pharm Biotechnol** 1995;6:249-76 (36 ref.)

Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Payne LG, et al. **Pharm Biotechnol** 1995;6:473-93 (15 ref.)

The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates. Chisholm PL, et al. **Ther Immunol** 1994 Aug;1(4):205-16

Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. Fernando GJ, et al. **Vaccine** 1995;13(15):1460-7

Synthetic peptide vaccines: success at last. Meloen RH, et al. **Vaccine** 1995 Jul;13(10):885-6

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Ott G, et al. **Vaccine** 1995 Nov; 13(16):1557-62

Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins. Rinella JV Jr, et al. **Vaccine** 1996 Mar;14(4):298-300

Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Soltysik S, et al. **Vaccine** 1995;13(15):1403-10

GENETICS

A molecular strategy to identify molecules that are specific for dendritic cells and/or critical to their unique immunostimulatory function. Heufler C, et al. **Adv Exp Med Biol** 1995;378:367-9

ISOLATION & PURIFICATION

Purification of a 92 kDa human immunostimulating glycoprotein obtained from the Tamm-Horsfall glycoprotein. Fontan E, et al. **J Immunol Methods** 1995 Nov 16;187(1):81-4

Lipopolysaccharides of oral black pigmented bacteria and

periodontal diseases. A novel immunomodulator different from endotoxin was extracted from Prevotella intermedia ATCC 25611 with hot phenol–water. Takada H, et al. **Prog Clin Biol Res** 1995;392:59–68

METABOLISM

Polyarthritis in the rat: effects of tolerance and sensitization to the bacterial extract OM–89 with a possible mode of action. Willis D, et al. **Br J Rheumatol** 1995 Dec; 34(12):1135–8

PHARMACOKINETICS

Bioavailability of bropirimine 250 mg tablet in dogs: effect of food. Emori H, et al. **J Pharm Pharmacol** 1995 Oct; 47(10):822–6

PHARMACOLOGY

Immunomodulating effect of acridine tautomers on eukaryotic cells. Petri IB, et al. **Acta Microbiol Immunol Hung** 1995;42(2):203–8

In vivo modulators of antibody kinetics. Jekunen A, et al. **Acta Oncol** 1996;35(3):267–71

Effects of Nocardia–delipidated cell mitogen on intestinal mucosa and spleen lymphocytes of germ–free rats. Kozáková H, et al. **Adv Exp Med Biol** 1995;371A:483–7

Analysis of the second messenger systems involved in the synergistic effect of cholera toxin and interleukin–4 on B cell isotype–switching. Lycke N. **Adv Exp Med Biol** 1995; 371A:15–20

Substance P mediated stimulation of cytokine levels in cultured murine bone marrow stromal cells. Manske JM, et al. **Adv Exp Med Biol** 1995;383:53–64

Stimulation of galt by Nocardia delipidated cell mitogen (NDCM) in irradiated germfree piglets. Trebichavsky I, et al. **Adv Exp Med Biol** 1995;371A:489–92

Immunoglobulin isotype modulation after administration of IL–12. Van Cleave V, et al. **Adv Exp Med Biol** 1995; 383:43–52

Calcium uptake by ACTH–stimulated lymphocytes: what is the physiological significance? Clarke BL. **Adv Neuroimmunol** 1995;5(3):271–81 (48 ref.)

Morphine stimulates phagocytosis of Mycobacterium tuberculosis by human microglial cells: involvement of a G protein–coupled opiate receptor. Peterson PK, et al. **Adv Neuroimmunol** 1995;5(3):299–309

Immunomodulatory properties of maxadilan, the vasodilator peptide from sand fly salivary gland extracts. Qureshi AA, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):665–71

Specific immune responses of dairy cattle after primary inoculation with recombinant bovine interferon–gamma as an adjuvant when vaccinating against mastitis. Pighetti GM, et al. **Am J Vet Res** 1996 Jun;57(6):819–24

Definition of chemiluminescence and superoxide production responses of bovine neutrophils to selected soluble and particulate stimulants, and comparisons with the responses to Pasteurella haemolytica. Watson GL, et al. **Am J Vet Res** 1995 Aug;56(8):1045–54

Anti–inflammatory effects of theophylline: modulation of cytokine production. Mascali JJ, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):34–8

IL–12–mediated activation of MHC–unrestricted cytotoxicity of human PBMC subpopulations: synergic action of a plant rhamnogalacturonan. Klein–Franke A, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2511–6

Differences in reactivity to cyclosporin A and interferon–gamma of normal and HPV–transformed keratinocytes. Marionnet AV, et al. **Anticancer Res** 1996 Jan–Feb;16(1):257–67

Usefulness of lymphocyte subset change as an indicator for predicting survival time and effectiveness of treatment with the immunopotentiator lentinan. Matsuoka H, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2291–6

Immunomodulating activities on cellular cytotoxicity and the blast transformation of human lymphocytes by 10–[n–(phthalimido)alkyl–2–substituted–10H–phenothiazines and 1–(2–chloroethyl)–3–(2–substituted–10H–phenothiazin–10–yl)alkyl–1–ureas. Petri IB, et al. **Anticancer Res** 1996 May–Jun;16(3A):1247–50

In vitro reactivity to a protein–bound polysaccharide PSK of peripheral blood lymphocytes from patients with gastrointestinal cancer. Sugimachi K, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2175–9

Immunotropic activities of benzisoselenazolones and organic diselenides in mice. Błaszczyk B, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(5–6):305–11

Immunotropic activity of lupin seeds extracts and fractions from Lupinus angustifolius and Lupinus albus. Błaszczyk B, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(2):147–53

Heparin enhances generation of natural killer activity in vitro. Wąsik M, et al. **Arch Immunol Ther Exp (Warsz)** 1994; 42(1):73–6

In vitro studies on the immunomodulating effects of polypodium leucotomos extract on human leukocyte fractions. Bernd A, et al. **Arzneimittelforschung** 1995 Aug; 45(8):901–4

Immunoregulatory effects of the herba Epimediia glycoside icariin. He W, et al. **Arzneimittelforschung** 1995 Aug; 45(8):910–3

Evaluation of the stimulatory activity of a fermented mistletoe lectin–1 free mistletoe extract on T–helper cells and monocytes in healthy individuals in vitro. Stein GM, et al. **Arzneimittelforschung** 1996 Jun;46(6):635–9

Antitumor mechanisms of Eubacterium lentum and its components. Hatta M. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):129–37

Selective induction of the glucose–regulated protein grp78 in human monocytes by bacterial extracts (OM–85): a role for calcium as second messenger. Jacquier–Sarlin MR, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):166–71

Adenosine modulation of tumor necrosis factor–alpha–induced neutrophil activation. Barnes CR, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1851–7

Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Zhao Q, et al. **Biochem Pharmacol** 1996 Jan 26;51(2):173–82

Augmentation of tumor immunity by 6–mercaptopurine (6–MP) and its analogs in the double grafted tumor system in mice. Kashida T, et al. **Biol Pharm Bull** 1995 Nov; 18(11):1492–7

Oral tolerance to ovalbumin in mice as a model for detecting modulators of the immunologic tolerance to a specific antigen. Kim JH, et al. **Biol Pharm Bull** 1995 Jun; 18(6):854–8

Immunostimulatory and antitumor activities of monoglycosylceramides having various sugar moieties. Motoki K, et al. **Biol Pharm Bull** 1995 Nov;18(11):1487–91

Comparison of the immunopharmacological activities of triple and single–helical schizophyllan in mice. Ohno N, et al. **Biol Pharm Bull** 1995 Sep;18(9):1242–7

Structure–activity relationship of (1–>3)–beta–D–glucans in the induction of cytokine production from macrophages, in vitro. Okazaki M, et al. **Biol Pharm Bull** 1995 Oct; 18(10):1320–7

A trace element preparation containing zinc increases the production of interleukin–6 in human monocytes and glial cells. Falus A, et al. **Biol Trace Elem Res** 1996 Mar; 51(3):293–301

Triggering effects of BCG vaccine on antitumor and interleukin–1 secretory activity of T cell lymphokine–primed macrophages. Seledtsova GV, et al. **Biomed Pharmacother** 1995;49(7–8):369–74

Effect of saponin from Quillaja saponaria (molina) on antibody, tumour necrosis factor and interferon–gamma production. Gebara VC, et al. **Biotechnol Appl Biochem** 1995 Aug;22 (Pt 1):31–7

Syntheses and effect of bursin and it analogs on the reduced B lymphocytes of uremic patients. Abiko T, et al. **Biotechnol Ther** 1994–95;5(3–4):163–70

Granulocyte–macrophage colony–stimulating factor: an effective adjuvant for protein and peptide–based vaccines. Disis ML, et al. **Blood** 1996 Jul 1;88(1):202–10

Inhibition of CD4 cross–linking–induced lymphocytes apoptosis by vesnarinone as a novel immunomodulating agent: vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion. Oyaizu N, et al. **Blood** 1996 Mar 15;87(6):2361–8

Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy. Katsumoto Y, et al. **Br J Cancer** 1996 Jan;73(1):110–6

Enhanced lymphokine–activated killer cell activity by an immunomodulator, Roquinimex. Vaz F, et al. **Br J Cancer** 1995 Dec;72(6):1498–503

In vitro and in vivo production of interleukin–6 induced by muramyl peptides and lipopolysaccharide in normal dogs. Shi F, et al. **Cancer Biother** 1995 Winter;10(4):317–25

The immunomodulatory effect of levamisole is influenced by postoperative changes and type of lymphocyte stimulant. Abdalla EE, et al. **Cancer Immunol Immunother** 1995 Sep;41(3):193–8

Induction of gene expression for nitric oxide synthase by immunomodulating drugs in the RAW264.7 murine macrophage cell line. Asai K, et al. **Cancer Immunol Immunother** 1996 Jun;42(5):275–9

Immune modulation by interleukin–12 in tumor–bearing mice receiving vitamin D3 treatments to block induction of immunosuppressive granulocyte/macrophage progenitor cells. Prechel MM, et al. **Cancer Immunol Immunother** 1996 May;42(4):213–20

Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. Young MR, et al. **Cancer Lett** 1996 Jul 12; 104(2):153–61

Modulation of expression of class II MHC and CD40 molecules in murine B cells by various muramyl dipeptides. Cohen LY, et al. **Cell Immunol** 1996 Apr 10;169(1):75–84

Differential activation of cell–mediated immune functions by encapsulated and surface–linked liposomal antigens. Fortin A, et al. **Cell Immunol** 1996 May 1;169(2):208–17

Endogenous cytokine expression profiles in retinoic acid–induced IgA production by LPS–stimulated murine splenocytes. Tokuyama H, et al. **Cell Immunol** 1995 Dec; 166(2):247–53

In vitro enhancement of antibody responses by T delta cells expressing IgD receptors. Yang YJ, et al. **Cell Immunol** 1996 Feb 25;168(1):107–16

Changes in viral expression and cytokine profile induced by a polyantigenic immunomodulator in HIV–infected peripheral blood mononuclear cells. Ríos Z, et al. **Cell Mol Biol (Noisy–le–grand)** 1995;41 Suppl 1:S93–101

Immunomodulation with intrathymic grafts or anti–lymphocyte serum promotes long–term intraspinal allograft survival. Theele DP, et al. **Cell Transplant** 1996 Mar–Apr;5(2):243–55

Effects of artesunate on immune function in mice. Lin PY, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):441–4

Effect of pineal body and melatonin on chemiluminescence of peritoneal macrophages via hypothalamus in rats. Wei W, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep; 16(5):435–7

Immunomodulatory effects of alpha interferon and thymostimulin in patients with neoplasias. Munno I, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):503–5

Effects of pretreatment with SDZ MRL 953, a novel immunostimulatory lipid A analog, on endotoxin–induced acute lung injury in guinea pigs. Nakamura H, et al. **Clin Diagn Lab Immunol** 1995 Nov;2(6):672–7

Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours. Algarra I, et al. **Clin Exp Immunol** 1996 Mar;103(3):499–505

Modulation of complement–mediated immune damage by intravenous immune globulin. Basta M. **Clin Exp Immunol** 1996 May;104 Suppl 1:21–5

Lipopolysaccharide (LPS) down–regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor (TNF) and IL–1 beta. Herbein G, et al. **Clin Exp Immunol** 1995 Nov;102(2):430–7

Mechanisms of action of intravenous immune globulin in immune–mediated diseases. Mouthon L, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:3–9 (63 ref.)

Effect of adjuvants on immunization with dengue virus–induced cytotoxic factor. Mukerjee R, et al. **Clin Exp Immunol** 1995 Dec;102(3):496–500

Potentiation of in vitro synthesis of human IgE by cyclosporin A (CsA). Wheeler DJ, et al. **Clin Exp Immunol** 1995 Oct;102(1):85–90

Modulation of B–cell immunoglobulin synthesis by retinoic acid. Ballow M, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S73–81 (37 ref.)

Immunomodulation by an adenylate cyclase activator, NKH477, in vivo and vitro. Furukawa Y, et al. **Clin Immunol Immunopathol** 1996 Apr;79(1):25–35

In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor–associated antigens is augmented by the iron chelator deferoxamine. Hsieh–Ma ST, et al. **Clin Immunol Immunopathol** 1996 Aug; 80(2):185–93

Sensitization of mice to paraphenylenediamine and structurally–related compounds: adjuvant effects of vitamin A supplementation. Kalish RS, et al. **Contact Dermatitis** 1995 Dec;33(6):407–13

Immunomodulatory effects of 1,25–dihydroxyvitamin D3. Casteels K, et al. **Curr Opin Nephrol Hypertens** 1995 Jul; 4(4):313–8 (75 ref.)

The adjuvant effect of silicone gel and silicone elastomer particles in rats. Hill SL, et al. **Curr Top Microbiol Immunol** 1996;210:123–37

The adjuvancy of silicones: dependency on compartmentalization. Klykken PC, et al. **Curr Top Microbiol Immunol** 1996;210:113–21

Induction of type II collagen arthritis in the DA rat using silicone gel as adjuvant. Naim JO, et al. **Curr Top Microbiol Immunol** 1996;210:103–11

Silicone gel and octamethylcyclotetrasiloxane potentiate antibody production to bovine serum albumin in mice. Nicholson JJ 3rd, et al. **Curr Top Microbiol Immunol** 1996; 210:139–44

Testing of immunomodulatory properties in vitro. Hartung T, et al. **Dev Biol Stand** 1996;86:85–96

Restorative effect of ofloxacin on inhibited chemiluminescence response of PMNs by sera from uraemic patients. Matsumoto T, et al. **Drugs** 1995;49 Suppl 2:289–90

Radioprotective effects of combination broncho–vaxom, a macrophage activator, and indomethacin, an inhibitor of prostaglandin production: relationship to myelopoiesis. Fedoročko P, et al. **Eur J Haematol** 1996 Jan–Feb; 56(1–2):54–61

Induction of T cell unresponsiveness by anti–CD3 antibodies occurs independently of co–stimulatory functions. Andris F, et al. **Eur J Immunol** 1996 May;26(5):1187–95

In interleukin–4–deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Brewer JM, et al. **Eur J Immunol** 1996 Sep; 26(9):2062–6

Interleukin–13 is produced by activated human CD45RA+ and CD45RO+ T cells: modulation by interleukin–4 and interleukin–12. Jung T, et al. **Eur J Immunol** 1996 Mar; 26(3):571–7

Lipid vesicle–entrapped influenza A antigen modulates the influenza A–specific human antibody response in immune reconstituted SCID–human mice. Walker W, et al. **Eur J Immunol** 1996 Jul;26(7):1664–7

Effects of vitamin A on immunological deficiencies in rats with obstructive jaundice. Karan B, et al. **Eur J Surg** 1996 Mar;162(3):217–22

Effect of the immunomodulator AS101 on chemotherapy–induced multilineage myelosuppression, thrombocytopenia, and anemia in mice. Kalechman Y, et al. **Exp Hematol** 1995 Dec;23(13):1358–66

Modification of delayed–type hypersensitivity reactions by muramyldipeptide in guinea pigs. Nagao S, et al. **FEMS Immunol Med Microbiol** 1995 Jun;11(3):231–45

Anti-metastatic activity induced by the in vivo activation of purified protein derivative (PPD)-recognizing Th1 type CD4+ T cells. Shinomiya Y, et al. **Immunobiology** 1995 Aug;193(5):439-55

IL-8 enhances antibody-dependent cellular cytotoxicity in human neutrophils. Reali E, et al. **Immunol Cell Biol** 1995 Jun;73(3):234-8

Prolactin and insulin regulate the release of IL-1-alpha and IFN-gamma from murine splenocytes activated with porins or LPS of Salmonella typhimurium. Vitiello M, et al. **Immunol Cell Biol** 1995 Oct;73(5):452-6

Interferon gamma potentiates human coronavirus OC43 infection of neuronal cells by modulation of HLA class I expression. Collins AR. **Immunol Invest** 1995 Nov; 24(6):977-86

In vitro modulation of preleukemic AKR mouse macrophage function by bacterial immunomodulators. Burek B, et al. **Immunol Lett** 1995 Mar;45(3):185-8

Polytuftsin: its possible effects and mechanism during macrophage activation. Dhawan P, et al. **Immunol Lett** 1995 May;46(1-2):177-82

Modulation of LIF expression in human melanoma cells by oncostatin M. Heymann D, et al. **Immunol Lett** 1995 Jun; 46(3):245-51

Enhancement and inhibition of cellular responsiveness mediated by the anti-leucocyte monoclonal antibody NDS 71. Higgins RM, et al. **Immunol Lett** 1995 May; 46(1-2):37-42

In vitro evaluation of fentanyl and meperidine for immunomodulatory activity. House RV, et al. **Immunol Lett** 1995 May;46(1-2):117-24

Immunogenicity of immunoliposomes: reactivity against species-specific IgG and liposomal phospholipids. Phillips NC, et al. **Immunol Lett** 1995 Mar;45(3):149-52

Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells. Qi CF, et al. **Immunol Lett** 1995 Jul-Aug;47(1-2):15-24

Immunoregulatory effects of a synthetic monosaccharide. Chang DM. **Immunopharmacol Immunotoxicol** 1995 Aug; 17(3):437-50

Effect of mechlorethamine on SRBC-induced secondary antibody response in mice. Obmińska-Domoradzka B, et al. **Immunopharmacol Immunotoxicol** 1995 Aug; 17(3):585-93

Modulating effect of sodium diethyldithiocarbamate on neutrophils in normal, febrile and cold-stressed rabbits. Obmińska-Domoradzka B, et al. **Immunopharmacol Immunotoxicol** 1995 Nov;17(4):733-44

PGE2-induced immunoregulation mediated by cytokine production from cultures of human peripheral T lymphocytes. Sottile A, et al. **Immunopharmacol Immunotoxicol** 1996 Feb;18(1):27-36

Tumor necrosis factor and interferon-gamma augment anticolon antibody- dependent cellular cytotoxicity in ulcerative colitis. Watanabe N, et al. **Immunopharmacol Immunotoxicol** 1996 Feb;18(1):15-26

Modulatory effect of plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) on macrophage functions in BALB/c mice. I. Potentiation of macrophage bactericidal activity. Abdul KM, et al. **Immunopharmacology** 1995 Sep;30(3):231-6

Exogenous and endogenous opioids as biological response modifiers. Carr DJJ, et al. **Immunopharmacology** 1995 Nov; 31(1):59-71 (118 ref.)

Activation of the anti-tumor effector cells by Radix bupleuri. Kok LD, et al. **Immunopharmacology** 1995 Jun;30(1):79-87

Reversal of multiple-site tumor cell-induced immunosuppression by specific cytokines and pharmacological agents. Ting CC, et al. **Immunopharmacology** 1995 Aug;30(2):119-30

The modulation of IL-2 dependent proliferation of CTLL-2 cells by 2-methyl-thiazolidine-2,4-dicarboxylic acid. Włodek L, et al. **Immunopharmacology** 1995 Jun;30(1):51-8

Designing of peptides with immuno-modulatory properties using protein A as a probe. Ray PK, et al. **Indian J Biochem Biophys** 1995 Dec;32(6):372-7

Passive transfer of poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose glucan protection against lethal infection in an animal model of intra-abdominal sepsis. Cisneros RL, et al. **Infect Immun** 1996 Jun;64(6):2201-5

Induction of common mucosal immunity by hormonally immunomodulated peripheral immunization. Daynes RA, et al. **Infect Immun** 1996 Apr;64(4):1100-9

Human glycoprotein HGP92 induces cytokine synthesis in mouse mononuclear phagocytes. Briend E, et al. **Int Immunol** 1995 Nov;7(11):1753-61

Suppression of adult T cell leukemia-derived factor/human thioredoxin induction by FK506 and cyclosporin A: a new mechanism of immune modulation via redox control. Furuke K, et al. **Int Immunol** 1995 Jun;7(6):985-93

Structure and mitogenic activities of corn cob heteroxylans. Ebringerová A, et al. **Int J Biol Macromol** 1995 Dec; 17(6):327-31

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Jäger E, et al. **Int J Cancer** 1996 Jul 3; 67(1):54-62

Immunomodulatory activity of met-enkephalin and its two potent analogs. Bajpai K, et al. **Int J Immunopharmacol** 1995 Mar;17(3):207-12

Inhibition by cholesterylphosphorylserine of T-cell-mediated immune responses in mice. Bruni A, et al. **Int J Immunopharmacol** 1995 Jun;17(6):517-21

Immunoactivating potential of multilamellar liposome vesicles (MLV) in murine popliteal lymph node (PLN) test. Desjardins R, et al. **Int J Immunopharmacol** 1995 May; 17(5):367-74

Adrenocorticotropic hormone as a potential enhancer of T-lymphocyte function in the rat mixed lymphocyte reaction. Gonsalkorale WM, et al. **Int J Immunopharmacol** 1995 Mar;17(3):197-206

Nitric oxide production by chicken macrophages activated by Acemannan, a complex carbohydrate extracted from Aloe vera. Karaca K, et al. **Int J Immunopharmacol** 1995 Mar;17(3):183-8

In vivo study of the immunomodulating activity of OM-85 using the plaque-forming cells technique (PFC) in mice. Mimouni J, et al. **Int J Immunopharmacol** 1995 Sep; 17(9):787-92

Muramyl dipeptide mimicry in the regulation of murine macrophage activation by serotonin. Polanski M, et al. **Int J Immunopharmacol** 1995 Mar;17(3):225-32

Is oral levamisole immunostimulation in rats mediated by reduced levels of free plasma corticosterone? Stogaus R, et al. **Int J Immunopharmacol** 1995 Aug;17(8):635-40

The immunomodulatory diversity of the proteins of the transforming growth factor beta (TGF beta) family. Wieczorek Z, et al. **Int J Pept Protein Res** 1995 Aug; 46(2):113-8

Immunomodulatory action of propolis. VI. Influence of a water soluble derivative on complement activity in vivo. Ivanovska ND, et al. **J Ethnopharmacol** 1995 Jul 28; 47(3):145-7

The immuno-stimulant OK-432 enhances liver regeneration after 70% hepatectomy. Kato K, et al. **J Hepatol** 1995 Jul; 23(1):87-94

IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. Bliss J, et al. **J Immunol** 1996 Feb 1;156(3):887-94

IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-alpha. Daftarian PM, et al. **J Immunol** 1996 Jul 1;157(1):12-20

IL-3 augments TCR-mediated responses of type 2 CD4 T cells. Dan Y, et al. **J Immunol** 1996 Jan 1;156(1):27-34

Requirements of a costimulus for IL-4-induced IgE class switching in murine B cells activated via antigen receptors: effectiveness of 8-mercaptoguanosine. Hikida M, et al. **J Immunol** 1996 Apr 15;156(8):2730-6

Dehydroepiandrosterone modulation of lipopolysaccharide-stimulated monocyte cytotoxicity. McLachlan JA, et al. **J Immunol** 1996 Jan 1;156(1):328-35

TNF-alpha enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease. Moore KJ, et al. **J Immunol** 1996 Jul 1;157(1):427-32

IL-12 as mediator and adjuvant for the induction of contact sensitivity in vivo. Müller G, et al. **J Immunol** 1995 Nov 15;155(10):4661-8

Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. Tanaka H, et al. **J Immunol** 1996 Feb 15;156(4):1601-8

Human IL-13 production is negatively influenced by CD3 engagement. Enhancement of IL-13 production by cyclosporin A. van der Pouw Kraan TC, et al. **J Immunol** 1996 Mar 1;156(5):1818-23

Diethylcarbamazine-related immunity [letter; comment] Kitchen LW. **J Infect Dis** 1995 Dec;172(6):1639-40. Comment on: J Infect Dis 1995 Jun;171(6):1683-7.

Comparative effects of interferon-consensus 1, interferon-alpha 2a, and interferon-beta 1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis. Dhib-Jalbut S, et al. **J Interferon Cytokine Res** 1996 Mar;16(3):195-200

Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. Gibson SJ, et al. **J Interferon Cytokine Res** 1995 Jun;15(6):537-45

Levamisole effects on major histocompatibility complex and adhesion molecule expression and on myeloid cell adhesion to human colon tumor cell lines. Kimball ES, et al. **J Natl Cancer Inst** 1996 Jan 17;88(2):109-16

Poloxamer-188 revisited: a potentially valuable immune modulator [letter] Moghimi SM, et al. **J Natl Cancer Inst** 1996 Jun 5;88(11):766-8

Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells. Jiang H, et al. **J Neuroimmunol** 1995 Aug;61(1):17-25

Intracerebral targets and immunomodulation of murine Listeria monocytogenes meningoencephalitis [see comments] Schlüter D, et al. **J Neuropathol Exp Neurol** 1996 Jan;55(1):14-24. Comment in: J Neuropathol Exp Neurol 1996 May;55(5):603.

Selective modulation of elements of the immune system by low molecular weight nucleosides. Goodman MG, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1552-7

Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF-beta 1 in vivo. Lagadec P, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):926-33

Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. Lee M, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):529-36

Cis-diamminedichloroplatinum(II) augments expression of tumor-associated antigens on human gastric cancer cell line KATO-3 and increases susceptibility and binding of tumor cells to various cytotoxic effector cells. Hayashi H, et al. **J Surg Oncol** 1996 Jul;62(3):162-70

The combination 5-fluorouracil/levamisole induces enhanced rat Kupffer cell-mediated cytotoxicity in vitro against the syngeneic colon adenocarcinoma cell line CC531. Schuurman B, et al. **J Surg Oncol** 1995 Nov; 60(3):180-4

Thymopentin modulates Th1 and Th2 cytokine response and host survival in experimental injury. Braga M, et al. **J Surg Res** 1996 May;62(2):197-200

Immunoregulatory effects of indomethacin on rats with trauma. Pan YC, et al. **J Tongji Med Univ** 1995;15(4):234-7

Enhancing effects of chicken egg white derivatives on the phagocytic response in the dog. Hirota Y, et al. **J Vet Med Sci** 1995 Oct;57(5):825-9

Enhancement of host resistance to bacterial infections in normal and immunosuppressed mice with Actinobacillus suis. Watanabe T. **Kansenshogaku Zasshi** 1996 Jun; 70(6):574-83

Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs. Robuccio JA, et al. **Lab Anim Sci** 1995 Aug;45(4):420-6

The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors. Condiotti R, et al. **Leuk Res** 1996 Jan;20(1):57-63

Immunomodulation by pycnogenol in retrovirus-infected or ethanol-fed mice. Cheshier JE, et al. **Life Sci** 1996;58(5):PL 87-96

Effects of calcium channel antagonists on the induction of nitric oxide synthase in cultured cells by immunostimulants. Hattori Y, et al. **Life Sci** 1995;57(20):1833-40

Histogranin, a modified histone H4 fragment endowed with N-methyl-D-aspartate antagonist and immunostimulatory activities. Lemaire S, et al. **Life Sci** 1995 Mar 3; 56(15):1233-41 (34 ref.)

Immunomodulating effects of synchronised plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Hanly JG, et al. **Lupus** 1995 Dec; 4(6):457-63

Immunomodulatory actions of xanthines and isoenzyme selective phosphodiesterase inhibitors. Banner KH, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):286-92 (96 ref.)

Fumonisin B1 alters sphingolipid metabolism and immune function in BALB/c mice: immunological responses to fumonisin B1. Martinova EA, et al. **Mycopathologia** 1995 Jun;130(3):163-70

Role of hormonal-cytokine interactions in the formation of the humoral immune response. Shirshev SV. **Neurosci Behav Physiol** 1995 Sep-Oct;25(5):345-7

Modulatory effects of hen egg-white lysozyme on immune response in mice. Valisena S, et al. **New Microbiol** 1996 Jan;19(1):15-24

Lysozyme inhibitors enhance immune response in mice. Valisena S, et al. **New Microbiol** 1996 Jan;19(1):25-30

Effect on leukemia cell numbers of in vivo administration of immunotherapeutic agents is age-dependent. Dussault I, et al. **Oncology** 1996 May-Jun;53(3):241-6

Lyme vaccine enhancement. N-terminal acylation of a protein antigen and inclusion of a saponin adjuvant. Coughlin RT, et al. **Pharm Biotechnol** 1995;6:719-35 (126 ref.)

Cytokines as vaccine adjuvants. Current status and potential applications. Dong P, et al. **Pharm Biotechnol** 1995;6:625-43 (122 ref.)

A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine. Goodman MG. **Pharm Biotechnol** 1995; 6:581-609 (73 ref.)

Cytokines as immunological adjuvants. Heath AW. **Pharm Biotechnol** 1995;6:645-58 (66 ref.)

Cytokine-containing liposomes as adjuvants for subunit vaccines. Lachman LB, et al. **Pharm Biotechnol** 1995; 6:659-71 (37 ref.)

Stearyl tyrosine. An organic equivalent of aluminum-based immunoadjuvants. Penney C. **Pharm Biotechnol** 1995; 6:611-24 (26 ref.)

Comparison of the hallucinogenic indole alkaloids ibogaine and harmaline for potential immunomodulatory activity. House RV, et al. **Pharmacology** 1995 Jun;51(1):56-65

Evaluation of an economical sunlamp that emits a near solar UV power spectrum for conducting photoimmunological and sunscreen immune protection studies. Beasley DG, et al. **Photochem Photobiol** 1996 Aug;64(2):303-9

Effect of oral administration of a pectic polysaccharide fraction from a kampo (Japanese herbal) medicine "juzen-taiho-to" on antibody response of mice. Kiyohara H, et al. **Planta Med** 1995 Oct;61(5):429-34

Immunomodulating activity of Echinacea gloriosa L., Echinacea angustifolia DC. and Rudbeckia speciosa Wenderoth ethanol-water extracts. Bukovský M, et al. **Pol J Pharmacol** 1995 Mar-Apr;47(2):175-7

Monophosphoryl lipid A as a prophylactic for sepsis and septic shock. Gustafson GL, et al. **Prog Clin Biol Res** 1995; 392:567-79

SDZ MRL 953, a lipid A analog as selective cytokine inducer. Stern A, et al. **Prog Clin Biol Res** 1995;392:549-65

Immunopharmacological and biochemical bases of Chinese

herbal medicine. Lien EJ, et al. **Prog Drug Res** 1996; 46:263–80 (29 ref.)

Intravenous immunoglobulin (IVIg) modulates the expansion of V beta 3+ and V beta 17+ T cells induced by staphylococcal enterotoxin B superantigen in vitro. Baudet V, et al. **Scand J Immunol** 1996 Mar;43(3):277–82

Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisole. Bjørge L, et al. **Scand J Immunol** 1995 Nov;42(5):512–6

Anti-oxidants inhibit the enhancement of the immune response caused by oil adjuvants. Di Gianni P, et al. **Scand J Immunol** 1996 Apr;43(4):413–20

Nordihydroguaiaretic acid blocks IL-2-independent lymphocyte proliferation and enhances responses to PPD. Esa AH, et al. **Scand J Immunol** 1996 Feb;43(2):127–33

Adjuvant properties of montanide CSA 720 with a recombinant HIV P17 gag protein and synthetic peptide antigens. Kirkley JE, et al. **Scand J Immunol** 1996 Apr; 43(4):431–8

A non-competitive P55 TNF receptor antibody enhances the specific activity of lymphotoxin-alpha. Medvedev AE, et al. **Scand J Immunol** 1996 Apr;43(4):439–48

Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-85 BV) via C-Fos/serum responsive element. Keul R, et al. **Thorax** 1996 Feb; 51(2):150–4

Modulation of interleukin-1 secretion by immunosuppressive drugs, alone and in combination. Reisman L, et al. **Transpl Immunol** 1995 Mar;3(1):45–9

Inhibition of ATG-induced experimental transplantation tolerance with LS2616. Olausson M, et al. **Transplant Proc** 1995 Dec;27(6):3541–3

Prevention and treatment of type I diabetes in NOD mice by linomide. Slavin S, et al. **Transplant Proc** 1995 Dec; 27(6):3240

Adjuvanticity of aluminium hydroxide and calcium phosphate in diphtheria-tetanus vaccines--I. Aggerbeck H, et al. **Vaccine** 1995 Oct;13(14):1360–5

Interferon-gamma inductive effect of liposomes as an immunoadjuvant. Aramaki Y, et al. **Vaccine** 1995 Dec; 13(18):1809–14

Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Fattom A, et al. **Vaccine** 1995 Oct;13(14):1288–93

Enhancement of protective immune responses to Venezuelan equine encephalitis (VEE) virus with microencapsulated vaccine. Greenway TE, et al. **Vaccine** 1995;13(15):1411–20

Adjuvants for human vaccines--current status, problems and future prospects. Gupta RK, et al. **Vaccine** 1995 Oct; 13(14):1263–76 (123 ref.)

Parameters related to the application of recombinant ovine interleukin-1 beta as an adjuvant. Lofthouse SA, et al. **Vaccine** 1995 Oct;13(14):1277–87

Effects of aluminum adjuvant on systemic reactions of lipopolysaccharides in swine. Norimatsu M, et al. **Vaccine** 1995 Oct;13(14):1325–9

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Ott G, et al. **Vaccine** 1995 Nov; 13(16):1557–62

In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant. Powers DC, et al. **Vaccine** 1995 Oct;13(14):1330–5

Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Rönnberg B, et al. **Vaccine** 1995 Oct;13(14):1375–82

Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice. Yoo YC, et al. **Vaccine** 1995 Oct; 13(14):1300–5

Gliding bacterial adjuvant stimulates feline cytokines in vitro and antigen-specific IgG in vivo. Zeidner NS, et al. **Vaccine** 1995 Oct;13(14):1294–9

Comparison of adjuvants for immune potentiating properties and side effects in mice. Leenaars PP, et al. **Vet Immunol Immunopathol** 1995 Sep;48(1–2):123–38

Enhancement of antibody response to bovine herpesvirus 1 with non-specific immunostimulants. Hampl J, et al. **Vet Med (Praha)** 1996 May;41(5):143–7

Enhancement of CTL response induced by a viral peptide using cationized BSA, a Th1-stimulating adjuvant. Vasilakos JP, et al. **Viral Immunol** 1994;7(4):179–88

Effects of levamisole, DTC and low-dose mechlorethamine on humoral response of SRBC-immunized rabbits exposed to cold stress. Obminska-Domoradzka B, et al. **Zentralbl Veterinarmed [B]** 1995 Mar;42(1):12–8

[The effects of zhuling-duotang, hepatitis B vaccine and bacillus Calmette-Guerin on immunoactivities of peripheral blood mononuclear cells: an in vitro research] Li L, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jun;34(6):392–5 (Eng. Abstr.) **(Chi)**

[Effects of Shenmai injection on immune function in stomach cancer patients after chemotherapy] Lin SY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):451–3 (Eng. Abstr.) **(Chi)**

[Effect of thyroid immune liquor on erythrocyte immune function in patients with autoimmune thyroiditis] Lu YC, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jul;15(7):414–5 (Eng. Abstr.) **(Chi)**

[Ia antigen expression of peritoneal macrophage in mice model of yang deficiency and the effect of aconitine] Ma J, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Sep;15(9):544–6 (Eng. Abstr.) **(Chi)**

[Effects of osthol and total-coumarins from Cnidium monnieri on immunological function in kidney yang deficiency mice] Qin LP, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Sep; 15(9):547–9 (Eng. Abstr.) **(Chi)**

[Effect of tetramethylpyrazine on lymphocytes proliferation response of murine splenocytes] Liu J, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Jun;26(2):177–9 (Eng. Abstr.) **(Chi)**

[Studies on the mechanisms of immunoregulatory effects of ginsenoside Rg1 in aged rats] Liu M, et al. **Yao Hsueh Hsueh Pao** 1996;31(2):95–100 (Eng. Abstr.) **(Chi)**

[Immunoregulatory effects of ginsenoside Rg1 in aged rats] Liu M, et al. **Yao Hsueh Hsueh Pao** 1995 Nov;30(11):818–23 (Eng. Abstr.) **(Chi)**

[The immunomodulatory effect of lentinan] Wang GL, et al. **Yao Hsueh Hsueh Pao** 1996;31(2):86–90 (Eng. Abstr.) **(Chi)**

[Imidazo(2,1-b)thiazole XII derivatives. Synthesis and research of immunoactivity in vitro on human T lymphocyte of 3-aroylmethyl and 2-aroyl-3-methyl(aryl)-5,6-dihydroimidaz o(2,1-b)thiazoles] Robert JF, et al. **Ann Pharm Fr** 1995; 53(6):261–71 (Eng. Abstr.) **(Fre)**

[Effects of morphine on murine infection with Friend retrovirus] Rouveix B, et al. **Bull Acad Natl Med** 1995 May; 179(5):1069–80 (Eng. Abstr.) **(Fre)**

[Levels of interleukin-2)IL-2 and tumor necrosis factor alpha (TNF-alpha) mRNA in aged rat spleen under physiological conditions and in septic shock: possible role of pidotimod in gene expression modulation] Arosio B, et al. **Drugs Exp Clin Res** 1993;19 Suppl:9–14 **(Ita)**

[Effect of pidotimod on the function of the human immune system: in vitro and ex vivo study] Borghi MO, et al. **Drugs Exp Clin Res** 1993;19 Suppl:37–43 **(Ita)**

[Potentiation of the resistance to viral and bacterial infections after pidotimod administration in mice] Marelli P, et al. **Drugs Exp Clin Res** 1993;19 Suppl:15–21 **(Ita)**

[Pidotimod causes apoptotic cell death and inhibits the proliferative activity of YAC-1 tumor cells in vitro] Migliorati G, et al. **Drugs Exp Clin Res** 1993;19 Suppl:1–7 **(Ita)**

[Effect of pidotimod on phagocytosis and intracellular killing of Staphylococcus aureus by human circulating polymorphonuclear neutrophils and alveolar macrophages] Oddera S, et al. **Drugs Exp Clin Res** 1993;19 Suppl:27–35 **(Ita)**

[Stimulation of B-cell immunity in the nude mice by pidotimod: immunohistochemical stucy of various lymphoid organs] Vacca A, et al. **Drugs Exp Clin Res** 1993; 19 Suppl:23–6 **(Ita)**

[Immunopotentiation by OK-432 ointment to apply to the mouse abdominal skin] Matsuoka H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1644–6 (Eng. Abstr.) **(Jpn)**

[Immunomodulating properties of synthetic fragments of human interleukin-2] Onoprienko LV, et al. **Bioorg Khim** 1996 Mar;22(3):180–90 (Eng. Abstr.) **(Rus)**

[The effect of thymoptin on development of a conditioned passive avoidance reaction in 18-month old and castrated rats] Burov IuV, et al. **Biull Eksp Biol Med** 1995 Aug; 120(8):167–8 **(Rus)**

[Stimulating effect of a polypeptide substance (Cuban stimulator) on hemopoiesis and formation of humoral immunity to murine thymus-dependent antigen] Shurygin AIa, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):511–4 **(Rus)**

[Immunomodulating properties of biologically active substances from embryonic tissue from birds of the chicken family] Masycheva VI, et al. **Dokl Akad Nauk** 1995 Sep; 344(1):140–2 **(Rus)**

[The immunotropic properties of biologically active products obtained from Klamath weed (Hypericum perforatum L.)] Evstifeeva TA, et al. **Eksp Klin Farmakol** 1996 Jan-Feb; 59(1):51–4 (Eng. Abstr.) **(Rus)**

[The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain] Kudrin VS, et al. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):8–11 (Eng. Abstr.) **(Rus)**

[The immunocorrective activity of myelopeptide-1 and myelopeptide-2 in cyclophosphane-treated mice] Shanurin SIu, et al. **Eksp Klin Farmakol** 1995 Sep-Oct;58(5):53–6 **(Rus)**

[Prodigiozan modulation of the specific activity of antidepressants] Sibiriak SV, et al. **Eksp Klin Farmakol** 1995 Sep-Oct;58(5):9–12 (Eng. Abstr.) **(Rus)**

[The efficacy of the immunomodulating action of Essentiale and the modified animal erythrocytes] Uteshev BS, et al. **Eksp Klin Farmakol** 1995 Nov-Dec;58(6):52–5 (Eng. Abstr.) **(Rus)**

[The immunomodulating action of preparations possessing membrane-protective properties under intensive physical loading] Uteshev BS, et al. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):47–50 (Eng. Abstr.) **(Rus)**

[The immunomodulating action of polyunsaturated phospholipids] Uteshev BS, et al. **Eksp Klin Farmakol** 1995 Sep-Oct;58(5):49–52 (Eng. Abstr.) **(Rus)**

[The anti-infective properties of mammalian earwax] Sokolov VE, et al. **Izv Akad Nauk Ser Biol** 1995 Sep-Oct; (5):579–85 (Eng. Abstr.) **(Rus)**

[The mechanism of the immunomodulating action of Béres Drops Plus] Grinevich IuA, et al. **Lik Sprava** 1995 May-Jun;(5–6):133–5 (Eng. Abstr.) **(Rus)**

[The use of immunomodulators to enhance postvaccinal immunity to experimental poliomyelitis] Bondarenko VI, et al. **Mikrobiol Z** 1995 Nov-Dec;57(6):41–5 (Eng. Abstr.) **(Rus)**

[Immunomodulating action of essentiale during prolonged intake of dietary cholesterol] Bart EV, et al. **Patol Fiziol Eksp Ter** 1995 Oct-Dec;(4):15–8 (Eng. Abstr.) **(Rus)**

[Immunomodulating action of hyaluronic acid and its hydrolysis products in health and in Staphylococcus infection] Lazarev AI, et al. **Patol Fiziol Eksp Ter** 1995 Oct-Dec;(4):18–21 (Eng. Abstr.) **(Rus)**

[Effects of MIGI-K on general resistance of the body] Kundriashov IuB, et al. **Radiats Biol Radioecol** 1995 May-Jun;35(3):418–23 (Eng. Abstr.) **(Rus)**

[Radiation-protective effectiveness of MIGI-K preparation in irradiation of animals with medium-lethal and sublethal doses of x-ray and gamma irradiation] Mazhul' VM, et al. **Radiats Biol Radioecol** 1995 May-Jun;35(3):424–7 (Eng. Abstr.) **(Rus)**

[The effect of sodium nucleinate on the precursors of antigen-dependent suppressors following irradiation] Surinov BP, et al. **Radiats Biol Radioecol** 1996 May-Jun; 36(3):355–8 (Eng. Abstr.) **(Rus)**

[The immunoadjuvant properties of hydroxyapatite with ultrahigh dispersity] Zuev VP, et al. **Stomatologiia (Mosk)** 1995;74(4):11–2 (Eng. Abstr.) **(Rus)**

[The characteristics of the neurophysiological mechanisms of the acquisition and extinction of defensive behavior in rabbits under the action of the immunomodulator neurotropin] Murtazina EP. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul-Aug; 45(4):748–56 (Eng. Abstr.) **(Rus)**

[Study of immunomodulators on isolated organs] Huković N, et al. **Glas Srp Akad Nauka [Med]** 1994;(44):13–9 (Eng. Abstr.) **(Scc)**

[Neuromodulation of synaptic transmission with thymopentin] Maličević Z, et al. **Vojnosanit Pregl** 1994 May-Jun;51(3):192–200 (Eng. Abstr.) **(Ser)**

PHYSIOLOGY

The heterogeneity of the osteopetroses reflects the diversity of cellular influences during skeletal development. Popoff SN, et al. **Bone** 1995 Nov;17(5):437–45 (131 ref.)

Differential effects of interleukin-2 and interleukin-4 on immunomodulatory role of platelet-activating factor in human B cells. Patke CL, et al. **Clin Diagn Lab Immunol** 1994 Jul;1(4):424–32

Exogenous and endogenous opioids as biological response modifiers. Carr DJJ, et al. **Immunopharmacology** 1995 Nov; 31(1):59–71 (118 ref.)

Immunoregulatory properties of ISG15, an interferon-induced cytokine. D'Cunha J, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):211–5

[Immunostimulating protein 90K in ovarian carcinoma] Zeimet AG, et al. **Gynakol Geburtshilfliche Rundsch** 1996; 36(1):44–5 (Eng. Abstr.) **(Ger)**

[Food-acquisition and avoidance behaviors: the role of immunomodulators in their systemic organization] Zhuravlev BV, et al. **Usp Fiziol Nauk** 1996 Apr-Jun; 27(2):90–106 (107 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

Chemical mediators released by primary-cultured human hepatic macrophages in patients with and without cirrhosis: a study in tumor-bearing patients. Funaki N, et al. **Hepatology** 1996 Jun;23(6):1353–8

[The effect of tetrachloromethane and ethanol on the release by rat splenocytes of immunomodulating factors] Smakhtin MIu, et al. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):48–50 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Response to oral beta-carotene supplementation in patients with cystic fibrosis: a 16-month follow-up study. Winklhofer-Roob BM, et al. **Acta Paediatr** 1995 Oct; 84(10):1132–6

Assessment of the clinical value of using an immunomodulator in recurrent respiratory infections. Bergmann KC. **Adv Exp Med Biol** 1995;371B:795–7 (15 ref.)

Reduction of the number and severity of respiratory tract infections in children by oral immunostimulation. Riedl-Seifert RJ, et al. **Adv Exp Med Biol** 1995; 371B:799–802

Orally administered bacterial lysate Broncho-Vaxom for the treatment of common variable immunodeficiency. Litzman J, et al. **Allerg Immunol (Paris)** 1996 Mar;28(3):81–5

Chloroquine for mild to moderately active ulcerative colitis: comparison with sulfasalazine. Goenka MK, et al. **Am J Gastroenterol** 1996 May;91(5):917–21

Case report: successful treatment with cimetidine and zinc sulphate in chronic mucocutaneous candidiasis. Polizzi B, et al. **Am J Med Sci** 1996 Apr;311(4):189–90

Effect of locally injected medications on healing of pad wounds in dogs. Swaim SF, et al. **Am J Vet Res** 1996 Mar;

57(3):394–9
Effect of polysaccharide–peptide (PSP), an extract from yun–zhi, on chemotherapy–induced cytopenias. Zhou LQ, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):143–6
Earlier methods of antibiotics administered prophylactically perioperatively [letter; comment] Lord JW Jr. **Ann Surg** 1995 Nov;222(5):689–90. Comment on: Arch Surg 1994 Nov;129(11):1204–10.
Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Iino Y, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2907–11
Immunostimulation by propionibacteria––effects on immune status and antineoplastic treatment. Isenberg J, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2363–8
Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette–Guérin (BCG) instillation on carcinoma in situ of the urinary bladder. Jurincic–Winkler C, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2771–6
Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma. Jurincic–Winkler CD, et al. **Anticancer Res** 1996 Jul–Aug; 16(4A):2105–10
Combined treatment with thymosin–alpha1 and low–dose interferon–alpha after ifosfamide in non–small cell lung cancer: a phase–II controlled trial. Salvati F, et al. **Anticancer Res** 1996 Mar–Apr;16(2):1001–4
Restorative effect of romurtide for thrombocytopenia associated with intensive anticancer drug treatment and/or irradiation in patients with gastrointestinal cancer. Yano K, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2883–7
Effect of macrophage–modulating agents on in vivo growth of transplantable Lewis lung cancer in mice. Nowicki A, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):313–7
Association of lymphomatoid granulomatosis with Epstein–Barr viral infection of B lymphocytes and response to interferon–alpha 2b. Wilson WH, et al. **Blood** 1996 Jun 1;87(11):4531–7
Safety and effectiveness of long–term interferon gamma therapy in patients with chronic granulomatous disease. Bemiller LS, et al. **Blood Cells Mol Dis** 1995;21(3):239–47
Why interferon beta 1b was licensed is a mystery [letter] Harvey P. **BMJ** 1996 Aug 3;313(7052):297–8
Melatonin: implications at the oral level. Cutando A, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct; 38(3–4):81–6 (29 ref.)
Suppressive effects of Lactobacillus casei cells, a bacterial immunostimulant, on the incidence of spontaneous thymic lymphoma in AKR mice. Watanabe T. **Cancer Immunol Immunother** 1996 Jun;42(5):285–90
Prophylactic intervention in radiation–leukemia–virus–induced murine lymphoma by the biological response modifier polysaccharide K. Yefenof E, et al. **Cancer Immunol Immunother** 1995 Dec; 41(6):389–96
Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin–2. McLaughlin JP, et al. **Cancer Res** 1996 May 15;56(10):2361–7
Adhesion molecules on intermediate TCR cells. II. Hepatoprotective effects of hyaluronic acid on acute liver injury. Nakayama M, et al. **Cell Immunol** 1995 Dec; 166(2):275–85
A 71–kD heat shock protein (hsp) from Mycobacterium tuberculosis has modulatory effects on experimental rat arthritis. Kingston AE, et al. **Clin Exp Immunol** 1996 Jan; 103(1):77–82
Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Leung DY. **Clin Exp Immunol** 1996 May;104 Suppl 1:49–54 (41 ref.)
HMGCoA reductase inhibitors and omega–3 fatty acids as adjunctive agents in maintenance immunosuppression after solid organ transplantation. Katznelson S, et al. **Clin Transplant** 1995 Jun;9(3 Pt 1):197–200
Post hoc analyses in sepsis trials: a formula for disappointment? [editorial; comment] Dellinger RP. **Crit Care Med** 1996 May;24(5):727–9. Comment on: Crit Care Med 1996 May;24(5):733–42.
The treatment of multiple sclerosis: current and future. Polman CH, et al. **Curr Opin Neurol** 1995 Jun;8(3):200–9 (87 ref.)
In vivo effects of thymostimulin treatment on monocyte polarization, dendritic cell clustering and serum p15E–like trans–membrane factors in operable head and neck squamous cell carcinoma patients. Kerrebijn JD, et al. **Eur Arch Otorhinolaryngol** 1995;252(7):409–16
Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy––lessons from animal experiments. Matsumori A, et al. **Eur Heart J** 1995 Dec;16 Suppl O:140–3 (10 ref.)
Effects of short–term zinc supplementation on cellular immunity, respiratory symptoms, and growth of malnourished Equadorian children. Sempértegui F, et al. **Eur J Clin Nutr** 1996 Jan;50(1):42–6
Marker tumour responses to the sequential combination of intravesical therapy with mitomycin–C and BCG–RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer–Genitourinary Group (EORTC 30897). Van der Meijden AP, et al. **Eur Urol** 1996;29(2):199–203
Pharmacological aspects and therapeutic applications of lysozymes. Sava G. **EXS** 1996;75:433–49 (79 ref.)
Hypocholesterolemic and immunostimulatory effects of orally applied Enterococcus faecium M–74 in man. Mikeš A, et al. **Folia Microbiol (Praha)** 1995;40(6):639–46
Prolonged survival of AVN Wistar rats with transplanted Yoshida sarcoma and increase of granular lymphocytes after administration of Bacillus firmus and their crude lipids. Stěpánková R, et al. **Folia Microbiol (Praha)** 1995; 40(4):413–6
Immunonutrition: we are what we eat [letter] Atkinson S, et al. **Gastroenterology** 1996 May;110(5):1676, 1678
The impact of immunonutrition [letter] Bernstein LH. **Gastroenterology** 1996 May;110(5):1677–8
Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine–125 in the adjuvant treatment of high–grade astrocytomas. Snelling L, et al. **Hybridoma** 1995 Apr;14(2):111–4
Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside–KLH conjugate vaccines. Livingston PO. **Immunol Rev** 1995 Jun;145:147–66 (68 ref.)
Concomitant immunity against tumor development is enhanced by the oral administration of a kampo medicine, Hochu–ekki–to (TJ–41: Bu–Zhong–Yi–Qi–Tang). Harada M, et al. **Immunopharmacol Immunotoxicol** 1995 Nov; 17(4):687–703
Pulmonary metastases neutralization and tumor rejection by in vivo administration of beta glucan and bispecific antibody. Penna C, et al. **Int J Cancer** 1996 Jan 26; 65(3):377–82
Lithium chloride enhances survival of NZB/W lupus mice: influence of melatonin and timing of treatment. Lenz SP, et al. **Int J Immunopharmacol** 1995 Jul;17(7):581–92
Experimental investigations on the immunomodulating activity of polybacterial preparation for peroral immunotherapy and immunoprophylaxis of uroinfections. Nenkov P, et al. **Int J Immunopharmacol** 1995 Jun; 17(6):489–96
Adjuvant effect of polyadenylic.polyuridylic acid on antibody production of recombinant hepatitis B surface antigen in mice. Park SJ, et al. **Int J Immunopharmacol** 1995 Jun;17(6):513–6
New treatments for multiple sclerosis [editorial] Hutchinson M. **Ir Med J** 1996 Mar–Apr;89(2):44
Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM–T412. Prinz JC, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):244–52
The effect of Acemannan Immunostimulant in combination with surgery and radiation therapy on spontaneous canine and feline fibrosarcomas. King GK, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct;31(5):439–47
Dietary omega–3 lipids delay the onset and progression of autoimmune lupus nephritis by inhibiting transforming growth factor beta mRNA and protein expression. Chandrasekar B, et al. **J Autoimmun** 1995 Jun;8(3):381–93
Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin–2 gene expression. Kaempfer R, et al. **J Clin Oncol** 1996 Jun; 14(6):1778–86
Efficacy of a Propionibacterium acnes immunostimulant for treatment of chronic Staphylococcus aureus mastitis. Dinsmore RP, et al. **J Dairy Sci** 1995 Sep;78(9):1932–6
The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma. Kalechman Y, et al. **J Immunol** 1996 Feb 1;156(3):1101–9
IL–12 is an effective adjuvant to recombinant vaccinia virus–based tumor vaccines: enhancement by simultaneous B7–1 expression. Rao JB, et al. **J Immunol** 1996 May 1; 156(9):3357–65
Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant–combined recombinant nucleoprotein. Tamura S, et al. **J Immunol** 1996 May 15;156(10):3892–900
Synergistic effects between recombinant interleukin–2 and the synthetic immunomodulator murabutide: selective enhancement of cytokine release and potentiation of antitumor activity. Bahr GM, et al. **J Interferon Cytokine Res** 1996 Feb;16(2):169–78
Predominance of TH1 response in tumor–bearing mice and cancer patients treated with AS101. Sredni B, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1276–84
The role of interferons in the treatment of multiple sclerosis. Kelley CL. **J Neurosci Nurs** 1996 Apr;28(2):114–20 (21 ref.)
Effect of diethyldithiocarbamate on Cryptosporidium parvum infection in immunosuppressed rats. Rehg JE. **J Parasitol** 1996 Feb;82(1):158–62
The beneficial effects of immunostimulation in posttraumatic sepsis. Austin OM, et al. **J Surg Res** 1995 Oct;59(4):446–9
Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. Chin JL, et al. **J Urol** 1996 Sep; 156(3):1189–93
Urinary cytokines during intravesical bacillus Calmette–Guerin therapy for superficial bladder cancer: processing, stability and prognostic value [see comments] de Reijke TM, et al. **J Urol** 1996 Feb;155(2):477–82. Comment in: J Urol 1996 Feb;155(2):488–9.
A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette–Guerin. Participating Clinics [see comments] Krege S, et al. **J Urol** 1996 Sep;156(3):962–6. Comment in: J Urol 1996 Sep;156(3):972–4.
Transitional cell carcinoma [editorial; comment] Narayan P. **J Urol** 1996 Aug;156(2 Pt 1):389–90. Comment on: J Urol 1996 Aug;156(2 Pt 1):372–6. Comment on: J Urol 1996 Aug;156(2 Pt 1):377–85. Comment on: J Urol 1996 Aug;156(2 Pt 1):386–8.
Bacillus Calmette–Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long–term results. Pansadoro V, et al. **J Urol** 1995 Dec;154(6):2054–8
Development of synthetic immunoadjuvants as cytokine inducers for cancer therapy. Mihich E. **Jpn J Cancer Res** 1996 Jul;87(7):inside front cover
Safety of topical dinitrochlorobenzene [letter; comment] Stricker RB, et al. **Lancet** 1995 Nov 11;346(8985):1293. Comment on: Lancet 1995 Oct 7;346(8980):975–6.
Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B cell chronic lymphocytic leukemia. Jurlander J, et al. **Leukemia** 1995 Nov;9(11):1902–9
A new approach to antiviral therapy. Peuschel KE. **Med Hypotheses** 1995 Oct;45(4):375–9
Biological activity and clinical efficacy of intravenous high–dose thymopentin in metastatic melanoma patients. Clemente C, et al. **Melanoma Res** 1996 Feb;6(1):63–9
Recombinant granulocyte colony–stimulating factor in acute myelogenous leukemia [letter; comment] Munck JN, et al. **N Engl J Med** 1995 Oct 26;333(17):1155–6. Comment on: N Engl J Med 1995 Jun 22;332(25):1678–83.
Trihexyphenidyl and isoprinosine in the treatment of subacute sclerosing panencephalitis. Nunes ML, et al. **Pediatr Neurol** 1995 Sep;13(2):153–6
Beta interferon and multiple sclerosis: why the fuss? [editorial] Mumford CJ. **QJM** 1996 Jan;89(1):1–3
Biologic interventions in rheumatoid arthritis. Cush JJ, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):797–816 (74 ref.)
Marine and botanical lipids as immunomodulatory and therapeutic agents in the treatment of rheumatoid arthritis. DeLuca P, et al. **Rheum Dis Clin North Am** 1995 Aug; 21(3):759–77 (91 ref.)
Complete remission of metastatic breast cancer by non–specific immunostimulation with a Nocardia opaca cell–wall extract after failure of conventional therapy. Ehrenfeld U, et al. **Sb Lek** 1994;95(1):1–5
Prolongation of discordant cardiac xenotransplantation survival by Lisofylline, a phosphatidic acid inhibitor. Aziz S, et al. **Transplant Proc** 1996 Apr;28(2):740
Perioperative treatment with phosphatidic acid inhibitor (Lisofylline leads to prolonged survival of hearts in the guinea pig to rat xenotransplant model. Valdivia LA, et al. **Transplant Proc** 1996 Apr;28(2):738–9
Immunological controls of postoperative infections in colorectal tumours. Farina EC, et al. **Tumori** 1995 May–Jun;81(3 Suppl):84–8
Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Sarosdy MF, et al. **Urology** 1996 Jul;48(1):21–7
Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Sarosdy MF, et al. **Urology** 1996 Jul;48(1):28–32
Booster vaccination against diphtheria and tetanus in man. Comparison of calcium phosphate and aluminium hydroxide as adjuvants––II. Aggerbeck H, et al. **Vaccine** 1995 Oct;13(14):1366–74
Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Danenberg HD, et al. **Vaccine** 1995;13(15):1445–8
A novel adjuvant for use with a blood–stage malaria vaccine. de Souza JB, et al. **Vaccine** 1995 Oct;13(14):1316–9
Immunomodulatory effects of HSV2 glycoprotein D in HSV1 infected mice: implications for immunotherapy of recurrent HSV infection. York LJ, et al. **Vaccine** 1995 Dec; 13(17):1706–12
Biochemotherapy of advanced metastatic renal–cell carcinoma: results of the combination of interleukin–2, alpha–interferon, 5–fluorouracil, vinblastine, and 13–cis–retinoic acid. Atzpodien J, et al. **World J Urol** 1995; 13(3):174–7
The effect of supplemental beta–carotene on immunologic indices in patients with AIDS: a pilot study. Fryburg DA, et al. **Yale J Biol Med** 1995 Jan–Apr;68(1–2):19–23
[Effect of zhuchun pill on immunity and endocrine function of elderly with kidney–yang deficiency] Yin GY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):601–3 (Eng. Abstr.) **(Chi)**
[Effect of Jinshuibao capsule on the immunological function of 36 patients with advanced cancer] Zhou DH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):476–8 (Eng. Abstr.) **(Chi)**
[Immunomodulatory treatment of septic conditions] Tønnesen E, et al. **Ugeskr Laeger** 1996 Aug 26; 158(35):4931–2 **(Dan)**
[BCG therapy. Its role in the treatment of tumors of the bladder] Patard JJ, et al. **Ann Urol (Paris)** 1995;29(5):292–3 **(Fre)**
[Immunomodulator treatments in HIV infection: rational bases and therapeutic prospects] Durant J, et al. **Rev Med Interne** 1995;16 Suppl 3:308s–312s (30 ref.) **(Fre)**
[Echinacea drugs––effects and active ingredients] Bauer R. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):111–5 (23 ref.) (Eng.

Abstr.) (Ger)
[Clinical application of extracts of Echinacea purpurea or Echinacea pallida. Critical evaluation of controlled clinical studies] Dorsch W. **Z Arztl Fortbild (Jena)** 1996 Apr; 90(2):117–22 (20 ref.) (Eng. Abstr.) (Ger)
[The mistletoe myth—claims, reality and provable perspectives] Gabius HJ, et al. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):103–10 (Eng. Abstr.) (Ger)
[Pidotimod, a new biological response modifier, is able to partially prevent immune response changes related to surgical stress] Pasqui AL, et al. **Drugs Exp Clin Res** 1993; 19 Suppl:45–53 (Ita)
[A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder] Iavarone C, et al. **G Chir** 1996 May;17(5):289–91 (Eng. Abstr.) (Ita)
[Multiple sclerosis. A report of a case treated with thymopentin] Borromei A, et al. **Minerva Med** 1995 May; 86(5):227–32 (Eng. Abstr.) (Ita)
[Clinical evaluation of Uro-Vaxom in treatment of recurrent urinary tract infections in girls] Gołąbek B, et al. **Pediatr Pol** 1995 Dec;70(12):1053–7 (Eng. Abstr.) (Pol)
[Evaluation of the efficacy of levamisole in corticosteroid-dependent nephrotic syndrome in children] Książek J, et al. **Pediatr Pol** 1995 Dec;70(12):1037–42 (Eng. Abstr.) (Pol)
[Production of selected cytokines by monocytes (IL-1 beta, IL-6) and lymphocytes (IL-2, IL-4) in peripheral blood of patients with nonallergic bronchial asthma treated with Broncho-Vaxom] Moniuszko T, et al. **Pneumonol Alergol Pol** 1995;63 Suppl 2:66–70 (Eng. Abstr.) (Pol)
[Assessment of the Mitsuda reaction in lepromatous patients inactive before and after immunotherapy] de Arruda MS, et al. **Rev Soc Bras Med Trop** 1995 Jul–Sep;28(3):233–6 (Eng. Abstr.) (Por)
[The beneficial effect of immunological and antiviral preparations in herpetic and papillomatosis infections] Topciu V, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul–Dec;40(3–4):257–60 (Rum)
[The efficacy of the therapeutic and prophylactic actions of immunomodulators in experimental infection due to the causative agent of Venezuelan equine encephalomyelitis] Bulychev LE, et al. **Antibiot Khimioter** 1995 May; 40(5):28–31 (Eng. Abstr.) (Rus)
[Correction of the immunomodulating action of antibiotics in health and in staphylococcal infection] Prokopenko LG, et al. **Antibiot Khimioter** 1995 Nov-Dec;40(11–12):50–4 (Eng. Abstr.) (Rus)
[The efficacy of the emergency prophylactic and therapeutic actions of immunomodulators in experimental filovirus infections] Sergeev AN, et al. **Antibiot Khimioter** 1995 May; 40(5):24–7 (Eng. Abstr.) (Rus)
[Immunomodulating action of antibiotics in health and in staphylococcal infection] Siplivaia LE, et al. **Antibiot Khimioter** 1995 Nov-Dec;40(11–12):45–9 (Eng. Abstr.) (Rus)
[Effect of T-activin and irradiation with a helium-neon laser on the status of the interleukin-2-dependent component of the proliferative response of mononuclear cells in rheumatoid arthritis] Parnes Ela, et al. **Fiziol Cheloveka** 1995 Jul–Aug;21(4):143–9 (Rus)
[Comparative study of the effectiveness of immunomodulating preparations in combined therapy of chronic obstructive bronchitis] Shilov VA, et al. **Klin Med (Mosk)** 1995;73(4):88–90 (Rus)
[Treatment with thymogen and myelopid of patients with bronchial asthma] Zoloedov VI, et al. **Klin Med (Mosk)** 1995;73(6):43–5 (Eng. Abstr.) (Rus)
[Immunocorrective therapy in the treatment of chronic herpetic stomatitis by using magnetic autohemotherapy] Grebnev EN, et al. **Stomatologiia (Mosk)** 1995;74(2):37–9 (Eng. Abstr.) (Rus)
[The characteristics of the immunogenesis and immunocorrection of diabetes mellitus] Galenok VA, et al. **Ter Arkh** 1995;67(10):7–12 (61 ref.) (Eng. Abstr.) (Rus)
[The use of tactivin for treating patients with IHD] Klimov AN, et al. **Ter Arkh** 1995;67(9):24–7 (Eng. Abstr.) (Rus)
[The immunocorrective action of the new synthetic hexapeptide imunofan in pharmacologically induced and ecological immunodeficiency] Pisarev VM, et al. **Vestn Ross Akad Med Nauk** 1995;(12):22–7 (Rus)
[Vitamin E: immunocorrecting effect in bronchial asthma patients] Pletsityĭ KD, et al. **Vopr Med Khim** 1995 Jul–Aug; 41(4):33–6 (Eng. Abstr.) (Rus)
[Interferon and tactivin in the treatment program for non-Hodgkin's lymphomas in children during remission] Makhonova LA, et al. **Vopr Onkol** 1995;41(2):80–1 (Rus)
[The effect of thymalin, dalargin and "Mucosalin" on the course of an experimental duodenal ulcer] Lukash NV, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):53–5 (Eng. Abstr.) (Rus)
[An evaluation of the efficacy of the new Ukrainian preparation Erbisol in patients with chronic hepatitis] Shipulin VP, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):55–9 (Eng. Abstr.) (Rus)
[Thymus hormones in the treatment and prevention of flavivirus infection under experimental conditions] Liubimova NB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep–Oct; (5):105–8 (Eng. Abstr.) (Rus)
[The effect of recombinant alfa-2 interferon (reaferon) on the functional activity of natural killers in acute viral hepatitis B] Petrovskaia IA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec; (6):56–7 (Rus)
[The effect on Coxsackie B3 viral infection of these different immunomodifiers: pertussis corpuscular vaccine, purified staphylococcal anatoxin and their combination] Semenova IB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec;(6):54–5 (Rus)
[The effect of thymoptin in the specific immunotherapy of experimental microbial allergy] Sukhodoeva GS, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):58–9 (Rus)
[Local immunomodulation in atopic and nonatopic children with nonspecific respiratory tract diseases] Cernelč D, et al. **Glas Srp Akad Nauka [Med]** 1994;(44):1–12 (Eng. Abstr.) (Sec)

TOXICITY

Tilorone-induced lysosomal lesions: the bisbasic character of the drug is essential for its high potency to cause storage of sulphated glycosaminoglycans. Fischer J, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):369–75
Different effect of cyclosporin A on arthritides induced by a muramyl dipeptide analogue or the complete adjuvant in rats. Sugawara T, et al. **Int J Exp Pathol** 1995 Jun; 76(3):191–9
Cytometric profile of molybdenum-induced contact sensitization versus a strong allergen reaction to oxazolone in murine auricular lymph node (ALN) test. Abdouh M, et al. **Int J Immunopharmacol** 1995 Jul;17(7):545–54
Induction of type II collagen arthritis in the DA rat using silicone gels and oils as adjuvant. Naim JO, et al. **J Autoimmun** 1995 Oct;8(5):751–61
Lack of carcinogenicity of daminozide, alone or in combination with its contaminant 1,1-dimethylhydrazine, in a medium-term bioassay. Cabral R, et al. **Teratog Carcinog Mutagen** 1995–96;15(6):307–12
Immunomodulatory effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin tested by the popliteal lymph node assay. Fan F, et al. **Toxicol Pathol** 1995 Jul–Aug;23(4):513–7
Evaluation of local toxicity after repeated intranasal vaccination of guinea-pigs. Gizurarson S, et al. **Toxicology** 1996 Jan 22;107(1):61–8
An investigation into the immunogenicity of a GnRH analogue in male rats: a comparison of the toxicity of various adjuvants used in conjunction with GnRH-glycys. Ferro VA, et al. **Vaccine** 1996 Apr;14(5):451–7

ADJUVANTS, PHARMACEUTIC

ADMINISTRATION & DOSAGE

Cytokine-containing liposomes as adjuvants for HIV subunit vaccines. Lachman LB, et al. **AIDS Res Hum Retroviruses** 1995 Aug;11(8):921–32

PHARMACOLOGY

Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides. Hughes JA, et al. **Pharm Res** 1996 Mar;13(3):404–10
Lymphatic transfer of macromolecules after intrapulmonary administration in the presence or absence of various absorption enhancers in rats. Muranishi S, et al. **Pharmazie** 1996 May;51(5):331–6

ADL see **ACTIVITIES OF DAILY LIVING**

ADMINISTRATION see **ORGANIZATION AND ADMINISTRATION**

ADMINISTRATION, CUTANEOUS

see related
SKIN ABSORPTION

Transcutaneous intracordal silicon injection for unilateral vocal cord paralysis. Iwatake H, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:133–7
The team approach to percutaneous endoscopic gastrostomy feeding. Hussain A, et al. **Br J Hosp Med** 1995 Oct 4–17; 54(7):308–12
Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin. Kemp EB, et al. **J Infect Dis** 1996 Jul;174(1):113–9
A mechanistic study of ultrasonically-enhanced transdermal drug delivery. Mitragotri S, et al. **J Pharm Sci** 1995 Jun; 84(6):697–706
Transdermal drug delivery using low-frequency sonophoresis. Mitragotri S, et al. **Pharm Res** 1996 Mar; 13(3):411–20
[Therapeutic range of transdermal nitro-patches] Lazebnik LB. **Klin Med (Mosk)** 1995;73(5):47–50 (Rus)
[Comparative evaluation of long-acting nitro preparations in patients with ischemic heart disease and stable angina pectoris of different functional classes] Zhebel' VN, et al. **Klin Med (Mosk)** 1995;73(5):74 (Rus)

ADMINISTRATION, INHALATION

see related
ADMINISTRATION, INTRANASAL
AEROSOLS
ANESTHESIA, INHALATION
RESPIRATORY THERAPY

Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers. Wennergren G, et al. **Acta Paediatr** 1996 Feb;85(2):183–9
Aerosolized drug delivery in the 90s [editorial; comment] Smaldone GC. **Chest** 1996 Aug;110(2):316–7. Comment on: Chest 1996 Aug;110(2):498–505.
Effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms. Lunell E, et al. **Eur J Clin Pharmacol** 1995;48(3–4):235–40
Bioequivalence of inhaled drugs [editorial] Derom E, et al. **Eur Respir J** 1995 Oct;8(10):1634–6
Molecular toxicology endpoints in rodent inhalation studies. Brown BG, et al. **Exp Toxicol Pathol** 1995 May; 47(2–3):183–91 (29 ref.)
Leucoencephalopathy after inhalation of heroin: a case report [letter] Celius EG, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):694–5
Hypertrophy of the tongue associated with inhaled corticosteroid therapy in premature infants [see comments] Linder N, et al. **J Pediatr** 1995 Oct;127(4):651–3. Comment in: J Pediatr 1996 Jun;128(6):865.
Nonantibiotic inhaled therapy in cystic fibrosis: new data. Lindemann H. **Pediatr Pulmonol Suppl** 1995;11:70–1
[Inhalation techniques] Huchon GJ. **Rev Med Suisse Romande** 1996 May;116(5):319–23 (32 ref.) (Fre)

ADMINISTRATION, INTRANASAL

see related
NEBULIZERS AND VAPORIZERS

Intranasal salbutamol has no effect on mucociliary clearance in normal subjects. Roberts DN, et al. **Clin Otolaryngol** 1995 Jun;20(3):246–8
Intranasal--enteral or parenteral? [letter] Houpt M. **Pediatr Dent** 1995 Nov-Dec;17(7):405

ADMINISTRATION, INTRAVAGINAL

The induction of mucosal immunity in the female genital tract using gene-gun technology. Part 1: Antigen expression. Livingston JB, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:265–7

ADMINISTRATION, INTRAVESICAL

A novel approach to endoscopic injection at the bladder neck in childhood. Abel C, et al. **Br J Urol** 1996 Feb;77(2):302–3

ADMINISTRATION, ORAL

The ratio of first to zeroth moments of the plasma profile of an oral drug undergoing first-pass and linear reversible metabolism. Cheng H. **Biopharm Drug Dispos** 1995 Dec; 16(9):791–6
Prediction of complications following caustic ingestion in adults. Christesen HB. **Clin Otolaryngol** 1995 Jun; 20(3):272–8
Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. Bareggi SR, et al. **Eur J Clin Pharmacol** 1995;48(3–4):265–8
Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection. Nahata MC, et al. **Eur J Clin Pharmacol** 1995;48(3–4):291–3
Oral immunization of mice against candidiasis. Jensen J, et al. **J Infect Dis** 1996 Jul;174(1):133–40
Oral self-administration of sweetened nicotine solutions by rats. Smith A, et al. **Psychopharmacology (Berl)** 1995 Aug; 120(3):341–6
[Intramuscular injections are unavoidable, but not the trend anymore. Physicians prefer orally administered drugs (interview by Dr. rer. nat. Anita Schweiger)] Muss R. **Fortschr Med** 1996 Jun 20;114(17):20, 22 (Ger)

ADMINISTRATION, RECTAL

see related
ANESTHESIA, RECTAL
SUPPOSITORIES

Patient consent and rectal drug administration [letter; comment] Barker I, et al. **Anaesthesia** 1996 Apr;51(4):402 . Comment on: Anaesthesia 1995 Nov;50(11):983–4.
Patient consent and rectal drug administration [letter; comment] Bonner S, et al. **Anaesthesia** 1996 Apr; 51(4):401–2. Comment on: Anaesthesia 1995 Nov;50(11):983–4.
Patient consent and rectal administration [letter; comment] Griffith NW. **Anaesthesia** 1996 Apr;51(4):402. Comment on: Anaesthesia 1995 Nov;50(11):983–4.
Attitudes and preferences of patients to routes of analgesic administration [letter] Skinner TA, et al. **Anaesthesia** 1996 Mar;51(3):290–1
Patients' attitudes to rectal drug administration [see comments] Vyvyan HA, et al. **Anaesthesia** 1995 Nov; 50(11):983–4. Comment in: Anaesthesia 1996

ADMINISTRATION, RECTAL

Apr;51(4):401–2. Comment in: Anaesthesia 1996 Apr;51(4):402.

ADMINISTRATION RESEARCH, NURSING see **NURSING ADMINISTRATION RESEARCH**

ADMINISTRATION SCHEDULE, DRUG see **DRUG ADMINISTRATION SCHEDULE**

ADMINISTRATION, TOPICAL

The effect of topical fluticasone propionate on intranasal histamine challenge in subjects with perennial allergic rhinitis. Birchall MA, et al. **Clin Otolaryngol** 1995 Jun; 20(3):204–10

The use of topical 5% lignocaine ointment for the relief of pain associated with post-operative nasal packing. Kuo MJ, et al. **Clin Otolaryngol** 1995 Aug;20(4):357–9

[Multicenter study comparing the efficacy and tolerance of topical ciprofloxacin (0.3%) versus topical gentamicin (0.3%) in the treatment of simple, non-cholesteatomaous chronic otitis media in the suppurative phase] Lorente J, et al. **An Otorrinolaringol Ibero Am** 1995;22(5):521–33 (Eng. Abstr.) **(Spa)**

ADMINISTRATION, VAGINAL see **ADMINISTRATION, INTRAVAGINAL**

ADMINISTRATIVE PERSONNEL

Is the Surgeon General obsolete? MacPherson P. **Hosp Health Netw** 1995 Nov 5;69(21):48

Program directors' opinions on the competency of postdoctoral general dentistry program graduates. Glassman P, et al. **J Dent Educ** 1996 Sep;60(9):747–54

Budget savvy dental administrators of the '90s [letter; comment] Wojtowicz DE. **J Dent Educ** 1996 May;60(5):409 . Comment on: J Dent Educ 1996 Mar;60(3):274–79.

The JIM interview. Jordan J. Cohen, MD [interview] Cohen JJ. **J Investig Med** 1995 Dec;43(6):510–5

The budget process in schools of nursing: a primer for the novice administrator. Starck PL, et al. **J Prof Nurs** 1996 Mar–Apr;12(2):69–75 (7 ref.)

Tokyo professor accused of perjury over evidence of HIV infection [news] **Nature** 1996 Feb 1;379(6564):388

New director for Cambridge biology laboratory [news] **Nature** 1996 Jan 18;379(6562):193

Australian institute gets new director [news] **Nature** 1995 Dec 14;378(6558):650

Charity head faces resignation calls [news] Butler D. **Nature** 1996 Jan 18;379(6562):195

French genome pioneer goes private [news] Butler D. **Nature** 1996 Feb 8;379(6565):478

Geneticist quits in protest at 'genes and violence' claim [news] Butler D. **Nature** 1995 Nov 16;378(6554):224

Cancer charity installs former critic as head [news] Butler D. **Nature** 1996 Feb 1;379(6564):385

Rockefeller biologist tipped for the top at Salk [news] Macilwain C. **Nature** 1996 Feb 8;379(6565):475

Cancer fund likely to boost basic research under new director [news] Masood E. **Nature** 1996 Jan 11;379(6561):106

Minor psychiatric morbidity, its prevalence and outcome in a cohort of civil servants—a seven-year follow-up study. Jenkins R, et al. **Occup Med (Oxf)** 1996 Jun;46(3):209–15

Cost shifting—insurance company style [editorial] Heilman RS. **Radiographics** 1995 Nov;15(6):1298

Managers' expectations of radiographers: a survey. Terrell-Nance S, et al. **Radiol Technol** 1995 Jul–Aug; 66(6):359–64

Gifted public servants [letter] Atkins JF. **Science** 1996 May 17;272(5264):938

Bureaucrats save lives [editorial] [see comments] Fink GR. **Science** 1996 Mar 1;271(5253):1213. Comment in: Science 1996 May 3;272(5262):633–4.

Gifted public servants [letter] Geiduschek EP. **Science** 1996 May 17;272(5264):937–8

New NIMH director offers institutional stimulant [news] Marshall E. **Science** 1996 Mar 22;271(5256):1662–3

[Working conditions, living conditions and physical health problems declared among penitentiary administration personnel in France] Goldberg P, et al. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):200–13 (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Study of the status and certification of transplant coordinators in Japan. Hiraga S, et al. **Transplant Proc** 1996 Feb; 28(1):260–3

ECONOMICS

Human resources. Rewards over the long haul [news] **Hosp Health Netw** 1996 Feb 20;70(4):17

Big bucks for managed care CEOs [news] **Hosp Health Netw** 1996 Apr 5;70(7):12

EDUCATION

Executive advancement ... College of Managed Care [news] **Hosp Health Netw** 1996 Feb 5;70(3):18–9

Executives. Sharing insights on the inside. Turner S. **Hosp Health Netw** 1995 Dec 5;69(23):58

PSYCHOLOGY

Work-site variation in managerial drinking. Howland J, et al. **Addiction** 1996 Jul;91(7):1007–17

False metaphors. Sports, competition, and the new leadership paradigm in health care. Adams DC. **Hosp Health Netw** 1995 Nov 5;69(21):42–4

Nutrition knowledge and attitudes of hotel and restaurant management students. Hamm MW, et al. **J Am Diet Assoc** 1995 Oct;95(10):1158–9

Stress in the emergency department clerical staff. Zautcke JL, et al. **J Emerg Med** 1996 Mar–Apr;14(2):247–9

Sickness absence in the Whitehall II study, London: the role of social support and material problems. Rael EG, et al. **J Epidemiol Community Health** 1995 Oct;49(5):474–81

STANDARDS

Child and adolescent mental disorders and the search for an NIMH director. Quo Vadis? [editorial] Barchas JD, et al. **Arch Gen Psychiatry** 1995 Oct;52(10):873

Coordinated program directors: activities and perceptions about research, tenure, and promotion. Gabel KA, et al. **J Am Diet Assoc** 1995 Oct;95(10):1156–7

Clinical nutrition management position: responsibilities and skill development strategies. Witte SS, et al. **J Am Diet Assoc** 1995 Oct;95(10):1113–20

ADMINISTRATORS see **ADMINISTRATIVE PERSONNEL**

ADMISSION TESTS, ROUTINE see **DIAGNOSTIC TESTS, ROUTINE**

ADMITTING DEPARTMENT, HOSPITAL

Computer-generated admission forms have greater accuracy. Dombrowski MP, et al. **Am J Obstet Gynecol** 1995 Sep; 173(3 Pt 1):847–8

ADNEXA UTERI

ANATOMY & HISTOLOGY

An anatomical approach to oophorectomy during vaginal hysterectomy. Jelen I, et al. **Obstet Gynecol** 1996 Jan; 87(1):137–9

PATHOLOGY

MR diagnosis of a rare adnexal mass: lithokelyphopedion [letter] Chako AC, et al. **AJR Am J Roentgenol** 1996 Feb; 166(2):462

Paratubal cystic leiomyoma: radiologic and pathologic analyses. Carabias E, et al. **Eur J Radiol** 1995 May; 20(1):28–31

SURGERY

Intraabdominal bleeding following laparoscopic adnexal surgery. A report of three cases. Wong SM, et al. **J Reprod Med** 1996 Apr;41(4):294–6

[Laparoscopic operation of adnexal tumors] Takeuchi H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1277–80 **(Jpn)**

ADNEXAL DISEASES

The female pelvic mass. Diagnosis and management. Russell DJ. **Med Clin North Am** 1995 Nov;79(6):1481–93 (19 ref.)

[Endometriosis. Analysis of laparoscopic findings at the A.B.C. (American-British Cowdray) Hospital] Rojas Poceros G, et al. **Ginecol Obstet Mex** 1995 Sep;63:401–5 (Eng. Abstr.) **(Spa)**

BLOOD

Color and pulsed Doppler sonography, gray-scale imaging, and serum CA 125 in the assessment of adnexal disease. Predanic M, et al. **Obstet Gynecol** 1996 Aug;88(2):283–8

CLASSIFICATION

Correlation between the American Fertility Society classifications of adnexal adhesions and distal tubal occlusion, salpingoscopy, and reproductive outcome in tubal surgery. Marana R, et al. **Fertil Steril** 1995 Nov; 64(5):924–9

[A proposal for improving the classification of endometriosis] Zheliazkova E. **Akush Ginekol (Sofiia)** 1995;34(1):32–3 **(Bul)**

DIAGNOSIS

Paratubal cystic leiomyoma: radiologic and pathologic analyses. Carabias E, et al. **Eur J Radiol** 1995 May; 20(1):28–31

Right-sided low inguinal pain in young women. Kumar S. **J R Coll Surg Edinb** 1996 Apr;41(2):93–4

Magnetic resonance imaging of benign adnexal conditions. Thickman D, et al. **Magn Reson Imaging Clin N Am** 1994 May;2(2):275–89 (30 ref.)

Laparoscopic management of adnexal masses in women with a history of nongynecologic malignancy. Chi DS, et al. **Obstet Gynecol** 1995 Dec;86(6):964–8

Adnexal masses: transvaginal US and gadolinium-enhanced MR imaging assessment of intratumoral structure. Komatsu T, et al. **Radiology** 1996 Jan;198(1):109–15

[Aspiration of the adnexal mass—is it reliable?] Lavie O, et al. **Harefuah** 1995 Dec 1;129(11):502–7 (45 ref.) **(Heb)**

ETIOLOGY

Castleman disease presenting as a pelvic mass. MacDonald SR, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):875–7

Case records of the Medical College of Virginia: a 10-year-old girl presenting with an acute onset of abdominal pain [clinical conference] Cunnion KM, et al. **Pediatr Emerg Care** 1996 Feb;12(1):52–5

[Adnexial torsion caused by ovarian hyperstimulation syndrome] Grønlund LA, et al. **Ugeskr Laeger** 1995 Dec 4;157(49):6881–2 (Eng. Abstr.) **(Dan)**

HISTORY

[The historical stages in the conservative treatment of endometriosis] Karag'ozov I, et al. **Akush Ginekol (Sofiia)** 1995;34(1):30–2 (12 ref.) **(Bul)**

PATHOLOGY

[Histopathological findings of malacoplakia of the adnexa uteri] Fujimoto T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jan;48(1):61–4 **(Jpn)**

PREVENTION & CONTROL

Laparoscopy for adhesion prevention following myomectomy. Uğur M, et al. **Int J Gynaecol Obstet** 1996 May;53(2):145–9

SURGERY

The case for laparoscopic management of the adnexal mass. Parker WH. **Clin Obstet Gynecol** 1995 Jun;38(2):362–9 (32 ref.)

Laparoscopic oophorectomy. Russell JB. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):295–8 (20 ref.)

Adnexal torsion: the contribution of color Doppler sonography to diagnosis and post-operative follow-up. Tepper R, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):121–3

Correlation between the American Fertility Society classifications of adnexal adhesions and distal tubal occlusion, salpingoscopy, and reproductive outcome in tubal surgery. Marana R, et al. **Fertil Steril** 1995 Nov; 64(5):924–9

Treatment of adnexal torsion using operative laparoscopy. Chapron C, et al. **Hum Reprod** 1996 May;11(5):998–1003

An analysis of the outcome of microsurgical and laparoscopic adhesiolysis for infertility. Saravelos HG, et al. **Hum Reprod** 1995 Nov;10(11):2887–94

Recovery of ovarian function after laparoscopic detorsion. Shalev E, et al. **Hum Reprod** 1995 Nov;10(11):2965–6

[Indications for celioscopic surgery in children (editorial)] Heloury Y. **Presse Med** 1995 Oct 14;24(30):1374–5 (9 ref.) **(Fre)**

[Surgical pathology of the adnexa uteri in girls] Koval'kov VF, et al. **Vestn Khir Im I I Grek** 1992 Nov–Dec; 149(11–12):354–9 (Eng. Abstr.) **(Rus)**

[Occurrence of pregnancy after microsurgical treatment of sterile patients with tubo-ovarian adhesive diseases] Lopez-Ortiz CS, et al. **Ginecol Obstet Mex** 1996 Jun; 64:256–60 (Eng. Abstr.) **(Spa)**

THERAPY

The management of a persistent adnexal mass in pregnancy. Platek DN, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1236–40

Laparoscopic management of adnexal masses in women with a history of nongynecologic malignancy. Chi DS, et al. **Obstet Gynecol** 1995 Dec;86(6):964–8

[The treatment of endometriosis in women with sterility. A prospective study over a 2-year period] Nalbanski B, et al. **Akush Ginekol (Sofiia)** 1995;34(1):18–20 (Eng. Abstr.) **(Bul)**

[Aspiration of the adnexal mass—is it reliable?] Lavie O, et al. **Harefuah** 1995 Dec 1;129(11):502–7 (45 ref.) **(Heb)**

ULTRASONOGRAPHY

Characterization of adnexal masses: combination of color Doppler and conventional sonography compared with spectral Doppler analysis alone and conventional sonography alone. Buy JN, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):385–93

Adnexal torsion: the contribution of color Doppler sonography to diagnosis and post-operative follow-up. Tepper R, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):121–3

Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. Strigini FA, et al. **Gynecol Oncol** 1996 Apr;61(1):68–72

The engorged fallopian tube: a new sonographic sign for adnexal torsion. Caspi B, et al. **J Clin Ultrasound** 1995 Oct; 23(8):505–7

Color and pulsed Doppler sonography, gray-scale imaging, and serum CA 125 in the assessment of adnexal disease.

Predanic M, et al. **Obstet Gynecol** 1996 Aug;88(2):283–8
Serial assessment of adnexal masses with transvaginal color Doppler sonography. Fleischer AC, et al. **Ultrasound Med Biol** 1995;21(4):435–41
[Pelvic emergencies in women] Noblinski B, et al. **Ann Radiol (Paris)** 1996;39(2):65–71 (Eng. Abstr.) **(Fre)**
[Transvaginal diagnosis of adnexal diseases] Osmers R. **Gynakologe** 1995 Aug;28(4):233–9 (52 ref.) **(Ger)**

ADNEXITIS

Pelvic inflammatory disease in adolescents. Wald ER. **Curr Probl Pediatr** 1996 Mar;26(3):86–97 (78 ref.)
Pelvic inflammatory disease: clinical overview. Kottmann LM. **J Obstet Gynecol Neonatal Nurs** 1995 Oct; 24(8):759–67 (33 ref.)
The coincident diagnosis of pelvic inflammatory disease and pregnancy: are they compatible? Acquavella AP, et al. **J Pediatr Adolesc Gynecol** 1996 Aug;9(3):129–32
[Upper genital tract infections in women infected with HIV: epidemiologic, diagnostic and therapeutic aspects] Panel P, et al. **Contracept Fertil Sex** 1996 Jun;24(6):488–94 (22 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Doppler ultrasound findings in female infertility. With special reference to pelvic inflammatory disease and endocrinological factors. Tinkanen H. **Acta Obstet Gynecol Scand** 1995 Oct;74(9):762–3
Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Risch HA, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul–Aug; 4(5):447–51
Lethal outcome of pelvic inflammatory disease in five women who were seropositive for HIV. Quazi MA. **Eur J Surg** 1996 Jan;162(1):67–9
Extensive colonic stricture due to pelvic actinomycosis. Kim JC, et al. **J Korean Med Sci** 1995 Apr;10(2):142–6
Occult infection as a cause of hip pain in a patient with metastatic breast cancer. Mackey JR, et al. **J Pain Symptom Manage** 1995 Oct;10(7):569–72
HIV–1 infection and the female genital tract [letter; comment] Donovan B. **Lancet** 1996 Jul 6;348(9019):59–60 . Comment on: Lancet 1996 Apr 6;347(9006):970.
The relationship of vaginal trichomoniasis and pelvic inflammatory disease among women colonized with Chlamydia trachomatis. Paisarntantiwong R, et al. **Sex Transm Dis** 1995 Nov–Dec;22(6):344–7
[Fitz–Hugh–Curtis syndrome] Sakai H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):430–3 (7 ref.) **(Jpn)**

DIAGNOSIS

Laparoscopic and cystopic findings in patients with chronic pelvic pain in Eshowe, South Africa. Krolikowski A, et al. **Cent Afr J Med** 1995 Jul;41(7):225–6
Pelvic inflammatory disease: an ongoing epidemic. Augenbraun MH, et al. **Hosp Pract (Off Ed)** 1995 Sep 15; 30(9):61–6 (6 ref.)
The Fitz–Hugh–Curtis syndrome, an unusual presentation. Schrander–v.d. Meer AM, et al. **Neth J Med** 1995 Dec; 47(6):278–80
Laboratory evaluation of acute upper genital tract infection. Peipert JF, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):730–6
Actinomycosis presenting as carcinoma. Hinnie J, et al. **Postgrad Med J** 1995 Dec;71(842):749–50
[Current concepts in the diagnosis and treatment of pelvic inflammatory disease] Borisov I. **Akush Ginekol (Sofiia)** 1995;34(2):47–51 (10 ref.) **(Bul)**
[Pseudotumoral pelvic actinomycosis (letter)] Collard O, et al. **Presse Med** 1996 May 4–11;25(16):776 **(Fre)**
[Chlamydia infections in gynecology and obstetrics] Dieterle S. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):510–7 (65 ref.) (Eng. Abstr.) **(Ger)**
[Reactive and areactive actinomycosis infection of the female genitals and differentiation of pseudoactinomycosis] Horn LC, et al. **Zentralbl Gynakol** 1995;117(9):466–71 (Eng. Abstr.) **(Ger)**
[Microbiologic detection of pelvic actinomycosis (letter)] Vukadinović MV, et al. **Lijec Vjesn** 1995 Jul–Aug; 117(7–8):201–2 **(Scr)**

DRUG THERAPY

Chlamydia trachomatis: a major cause of mucopurulent cervicitis and pelvic inflammatory disease in women. Paavonen J. **Curr Probl Dermatol** 1996;24:110–22 (78 ref.)
Pelvic inflammatory disease: an ongoing epidemic. Augenbraun MH, et al. **Hosp Pract (Off Ed)** 1995 Sep 15; 30(9):61–6 (6 ref.)
[Current concepts in the diagnosis and treatment of pelvic inflammatory disease] Borisov I. **Akush Ginekol (Sofiia)** 1995;34(2):47–51 (10 ref.) **(Bul)**
[Our experience in treating pelvic inflammatory disease caused by Chlamydia trachomatis with the preparation roxithromycin] Damianov L, et al. **Akush Ginekol (Sofiia)** 1995;34(1):16–8 (Eng. Abstr.) **(Bul)**
[Acute pelvic inflammatory disease: comparison of therapeutic protocols] Balbi G, et al. **Minerva Ginecol** 1996 Jan–Feb;48(1–2):19–23 (Eng. Abstr.) **(Ita)**
[The interferon inducer neovir (kamedon) in the combined treatment of chronic inflammatory diseases of the adnexa uteri of chlamydial etiology (a clinical electron–microscopic study)] Delektorskiĭ VV, et al. **Antibiot Khimioter** 1995 May;40(5):42–7 (Eng. Abstr.) **(Rus)**

ECONOMICS

Consequences of incomplete antibacterial treatment for chlamydial pelvic inflammatory disease. Rosenberg MJ, et al. **Drugs** 1995;49 Suppl 2:504–5

EPIDEMIOLOGY

Pelvic inflammatory disease: a contemporary approach. Newkirk GR. **Am Fam Physician** 1996 Mar;53(4):1127–35 (49 ref.)
Evidence against tailstrings increasing the rate of pelvic inflammatory disease among IUD users. Ebi KL, et al. **Contraception** 1996 Jan;53(1):25–32
Risk factors for Chlamydia trachomatis pelvic inflammatory disease among sex workers in Nairobi, Kenya. Kimani J, et al. **J Infect Dis** 1996 Jun;173(6):1437–44

ETIOLOGY

Pelvic abscess caused by Salmonella: a case report. Hung TH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jun; 57(6):457–9
Evidence against tailstrings increasing the rate of pelvic inflammatory disease among IUD users. Ebi KL, et al. **Contraception** 1996 Jan;53(1):25–32
[Intrauterine pessaries and acute genital inflammation in women] Nalbanski B. **Akush Ginekol (Sofiia)** 1995; 34(3):45–7 (Eng. Abstr.) **(Bul)**
[Pelvic inflammatory disease and the use of intrauterine contraceptive devices] Durdević S, et al. **Med Pregl** 1995; 48(7–8):264–7 (Eng. Abstr.) **(Scr)**

MICROBIOLOGY

Role of bacterial vaginosis in pelvic inflammatory disease. Sweet RL. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S271–5 (46 ref.)
Streptococcus pneumoniae pelvic inflammatory disease. A case report. Chudacoff RM, et al. **J Reprod Med** 1995 Sep; 40(9):649–51
[Two case of Fitz–Hugh–Curtis syndrome with Chlamydia trachomatis infection] Mizuguchi Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):195–200 **(Jpn)**
[Chlamydia trachomatis during genital tract infection and in imminent abortion] Elias M, et al. **Ginekol Pol** 1995 Sep; 66(9):513–7 (Eng. Abstr.) **(Pol)**

PATHOLOGY

Transvaginal trucut biopsy in patients with abdominopelvic mass. Sheth SS, et al. **Int J Gynaecol Obstet** 1995 Jul; 50(1):27–31
Commonly used diagnostic criteria for pelvic inflammatory disease have poor sensitivity for plasma cell endometritis [see comments] Korn AP, et al. **Sex Transm Dis** 1995 Nov–Dec;22(6):335–41. Comment in: Sex Transm Dis 1995 Nov–Dec;22(6):342–3.
The semantics of pelvic inflammatory disease [editorial; comment] Soper DE. **Sex Transm Dis** 1995 Nov–Dec; 22(6):342–3. Comment on: Sex Transm Dis 1995 Nov–Dec;22(6):335–41.

PREVENTION & CONTROL

Prevention of recurrent pelvic infection by contact tracing: a commonsense approach. Robinson AJ, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):859–61 (21 ref.)
Preventing pelvic infection after abortion [editorial] Stevenson MM, et al. **Int J STD AIDS** 1995 Sep–Oct; 6(5):305–12 (61 ref.)
Screening for chlamydia—a key to the prevention of pelvic inflammatory disease [editorial; comment] Hillis SD, et al. **N Engl J Med** 1996 May 23;334(21):1399–401. Comment on: N Engl J Med 1996 May 23;334(21):1362–6.
Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection [see comments] Scholes D, et al. **N Engl J Med** 1996 May 23;334(21):1362–6. Comment in: N Engl J Med 1996 May 23;334(21):1399–401.

THERAPY

Pelvic abscesses: transvaginal US–guided drainage with the trocar method. McGahan JP, et al. **Radiology** 1996 Aug; 200(2):579–81
[The management of severe pelvioperitonitis of an inflammatory genital origin] Pranchev N. **Akush Ginekol (Sofiia)** 1995;34(2):55–7 (Eng. Abstr.) **(Bul)**
[Synopsis of the standard 'Pelvic inflammatory disease' of the Dutch Society of Family Physicians] Burgers JS, et al. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):77–80 **(Dut)**
[Standard 'Pelvic inflammatory disease' of the Dutch Society of Family Physicians, from the viewpoint of gynecology] Essed GG. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):64 **(Dut)**
[Standard 'Pelvic inflammatory disease' of the Dutch Society of Family Physicians; reaction from the viewpoint of family practice] Meijman FJ. **Ned Tijdschr Geneeskd** 1996 Jan 13; 140(2):63–4 **(Dut)**

ULTRASONOGRAPHY

The value of transvaginal color Doppler in the assessment of pelvic inflammatory disease. Kupesic S, et al. **Ultrasound Med Biol** 1995;21(6):733–8

ADOLESCENCE

Rites of passage in adolescence. Delaney CH. **Adolescence** 1995 Winter;30(120):891–7
Variations in parenting practices: gender– and age–related differences in African adolescents. Mboya MM. **Adolescence** 1995 Winter;30(120):955–62
Identity development, parental and peer support in adolescence: results of a national Dutch survey. Meeus W, et al. **Adolescence** 1995 Winter;30(120):931–44
Voices of Korean–American students. Park EJ. **Adolescence** 1995 Winter;30(120):945–53
Heidegger's "authenticity" in the psychotherapy of adolescents. Chessick RD. **Am J Psychother** 1996 Spring; 50(2):208–16
Morbidity and mortality among US adolescents: An overview of data and trends [see comments] Sells CW, et al. **Am J Public Health** 1996 Apr;86(4):513–9. Comment in: Am J Public Health 1996 Apr;86(4):473–4.
Gambling among adolescents. Buchta RM. **Clin Pediatr (Phila)** 1995 Jul;34(7):346–8
International Conference on Conflict and Development in Adolescence. Deković M. **Crisis** 1996;17(1):44–5
Ability and dependency in adolescents with severe learning disabilities. McKinlay I, et al. **Dev Med Child Neurol** 1996 Jan;38(1):48–58
The youth role in creating a healthy future for the earth: an examination of the link between collective action for the environment and the emotional health of children. Alimahomed S, et al. **Environ Health Perspect** 1995 Sep; 103 Suppl 6:63–6
Effects of welfare reform on teenage parents and their children. Aber JL, et al. **Future Child** 1995 Summer–Fall; 5(2):53–71 (60 ref.)
Role of anthropometric indexes and blood pressure as determinants of left ventricular mass and geometry in adolescents. The Rio de Janeiro Study. Brandão AA, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1190–4
Calcium–ATPase and insulin in adolescent offspring of essential hypertensive parents. Grunfeld B, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1070–3
Insulin effect on renal sodium reabsorption in adolescent offspring of essential hypertensive parents. Grunfeld B, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1089–92
Adolescent health: a Middle East and North African perspective. Ozcebe H, et al. **Int J Gynaecol Obstet** 1995 Nov;51(2):151–7
Impact of tobacco–free policy on recruitment and retention of adolescents in residential substance abuse treatment. Kempf J, et al. **J Addict Dis** 1996;15(2):1–11
Posttraumatic stress disorder in adolescents after Hurricane Andrew. Garrison CZ, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1193–201
Ethnic, socioeconomic, and sex differences in physical activity among adolescents. Sallis JF, et al. **J Clin Epidemiol** 1996 Feb;49(2):125–34
Adolescents as victims of family violence. Council on Scientific Affairs. American Medical Association. **J Miss State Med Assoc** 1995 Oct–Nov;36(10):307–16
Racial identity, academic achievement, and the psychological well–being of economically disadvantaged adolescents. Arroyo CG, et al. **J Pers Soc Psychol** 1995 Nov; 69(5):903–14
Characteristics of fatal crashes of 16–year–old drivers: implications for licensure policies. Williams AF, et al. **J Public Health Policy** 1995;16(3):347–60
Youth in health campaigns. Sandoval F. **Promot Educ** 1996 Jun;3(2):18–9, 46
Great transitions [editorial] Abelson PH. **Science** 1995 Nov 10;270(5238):895
The self–image of Greek, Greek–migrant and German adolescents. Siefen G, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jun;31(3–4):241–7
Reasons for living among Chinese adolescents in Hong Kong. Chan DW. **Suicide Life Threat Behav** 1995 Fall; 25(3):347–57
Research on the sale of smokeless tobacco to adolescents [letter] Xaverius PK, et al. **Tob Control** 1996 Spring; 5(1):69–70
[Medico–social problems of young adolescents in Guediawaye (suburban area of Dakar–Senegal)] Camara B, et al. **Dakar Med** 1994;39(2):153–8 (Eng. Abstr.) **(Fre)**
[Acute lymphoblastic leukemia in adolescents] Barisone E, et al. **Minerva Pediatr** 1995 Jul–Aug;47(7–8):277–83 (Eng. Abstr.) **(Ita)**
[Use of primary care services by adolescents and detection of health problems other than those for which they came] Colino Nevot R, et al. **Aten Primaria** 1995 Dec; 16(10):594–600 (Eng. Abstr.) **(Spa)**

ADOLESCENCE

PHYSIOLOGY

Correlation between systolic blood pressure and physical development in adolescence. Akahoshi M, et al. **Am J Epidemiol** 1996 Jul 1;144(1):51–8

Growth and development of male gymnasts, swimmers, soccer and tennis players: a longitudinal study. Baxter-Jones AD, et al. **Ann Hum Biol** 1995 Sep–Oct; 22(5):381–94

Determinants of femoral geometry and structure during adolescent growth. van der Meulen MC, et al. **J Orthop Res** 1996 Jan;14(1):22–9

Critical anthropometry for menarche. Gonzales GF, et al. **J Pediatr Adolesc Gynecol** 1996 Aug;9(3):139–43

Salivary testosterone levels in male adolescents with cystic fibrosis. Boas SR, et al. **Pediatrics** 1996 Mar;97(3):361–3

Racial (black-white) differences in insulin secretion and clearance in adolescents: the Bogalusa heart study. Jiang X, et al. **Pediatrics** 1996 Mar;97(3):357–60

Medical problems of adolescent female athletes. Timmerman MG. **Wis Med J** 1996 Jun;95(6):351–4

[The characteristics of the formation and development of psychophysiological functions in ontogeny (Cherkassy, 24–27 October 1995)] Makarenko MV, et al. **Fiziol Zh** 1995 May-Aug;41(3–4):121–5 **(Ukr)**

PSYCHOLOGY see ADOLESCENT PSYCHOLOGY

ADOLESCENT BEHAVIOR

Effectiveness in adolescent health. Macfarlane A. **Acta Paediatr** 1995 Oct;84(10):1089–93 (19 ref.)

Transitions to cigarette smoking during adolescence. Fergusson DM, et al. **Addict Behav** 1995 Sep–Oct; 20(5):627–42

DSM-III-R tobacco dependence and quitting during late adolescence. Stanton WR. **Addict Behav** 1995 Sep–Oct; 20(5):595–603

Adolescents' promotion of nonsmoking and smoking. Stanton WR, et al. **Addict Behav** 1996 Jan–Feb;21(1):47–56

Sex under the influence of alcohol among Norwegian adolescents. Traeen B, et al. **Addiction** 1996 Jul; 91(7):995–1006

Changes in the telephone calling patterns of adolescent girls. Anderson PB, et al. **Adolescence** 1995 Winter; 30(120):779–84

Adolescents calling a peer-listening phone service: variations in calls by gender, age, and season of the year. Boehm KE, et al. **Adolescence** 1995 Winter;30(120):863–71

Adolescent depressed mood, reports of suicide attempts, and asking for help. Culp AM, et al. **Adolescence** 1995 Winter; 30(120):827–37

Actual and perceived parental social status: effects on adolescent self-concept. Orr E, et al. **Adolescence** 1995 Fall; 30(119):603–16

Sexual abstinence counseling of adolescents by physicians. Patton D, et al. **Adolescence** 1995 Winter;30(120):963–9

Fathers' and mothers' participation in research. Phares V. **Adolescence** 1995 Fall;30(119):593–602

Strategies for coping with sexually transmitted diseases by adolescent females. Rosenthal SL, et al. **Adolescence** 1995 Fall;30(119):655–66

Sociodemographic analysis of drug use among adolescent athletes: observations-perceptions of athletic directors-coaches. Shields EW Jr. **Adolescence** 1995 Winter;30(120):839–61

Gender and family as moderators of the relationship between music video exposure and adolescent sexual permissiveness. Strouse JS, et al. **Adolescence** 1995 Fall;30(119):505–21

Perceived control and treatment outcome with chronic adolescent offenders. Swenson CC, et al. **Adolescence** 1995 Fall;30(119):565–78

In search of effective programs to address students' emotional distress and behavioral problems. Part I: Defining the problem. Wassef A, et al. **Adolescence** 1995 Fall; 30(119):523–38 (22 ref.)

In search of effective programs to address students' emotional distress and behavioral problems. Part II: Critique of school- and community-based programs. Wassef A, et al. **Adolescence** 1995 Winter;30(120):757–77 (29 ref.)

Personal and situational factors in drug use as perceived by kibbutz youth. Wolf Y, et al. **Adolescence** 1995 Winter; 30(120):909–30

My guardian angel: a learning exercise for adolescent AIDS education. Geiger BF, et al. **AIDS Educ Prev** 1996 Feb; 8(1):86–91

Teenage drinking: a 4-year comparative study. Foxcroft DR, et al. **Alcohol Alcohol** 1995 Nov;30(6):713–9

Patterns of psychoactive substance use among adolescents. Nunes JV, et al. **Am Fam Physician** 1995 Nov 1; 52(6):1693–6, 1699

Protective processes in adolescence: matching stressors with social resources. Gore S, et al. **Am J Community Psychol** 1995 Jun;23(3):301–27

Adolescent suicidal behaviors as a function of depression, hopelessness, alcohol use, and social support: a longitudinal investigation. Reifman A, et al. **Am J Community Psychol** 1995 Jun;23(3):329–54

Correlates of gun-carrying among adolescents in south Louisiana. McNabb SJ, et al. **Am J Prev Med** 1996 Mar-Apr;12(2):96–102

Can conflict resolution training increase aggressive behavior in young adolescents? [letter] Colyer E, et al. **Am J Public Health** 1996 Jul;86(7):1028–9

Project Northland: outcomes of a communitywide alcohol use prevention program during early adolescence [see comments] Perry CL, et al. **Am J Public Health** 1996 Jul; 86(7):956–65. Comment in: Am J Public Health 1996 Jul;86(7):923–4.

Community solutions to community problems--preventing adolescent alcohol use [editorial; comment] Wechsler H, et al. **Am J Public Health** 1996 Jul;86(7):923–4. Comment on: Am J Public Health 1996 Jul;86(7):956–65.

Sex education and sexual behaviour of adolescents in Japan. Matsumoto S. **Ann Acad Med Singapore** 1995 Sep; 24(5):696–9

Adolescent sexuality and its problems. Yang M. **Ann Acad Med Singapore** 1995 Sep;24(5):736–40 (40 ref.)

Asthma deaths [letter] Randolph C. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):81–2

Health concerns and prevalence of abuse and sexual activity in adolescents at a runaway shelter. Bradford MS. **Appl Nurs Res** 1995 Nov;8(4):187–90

An intervention for preventing alcohol use among inner-city middle school students. Werch CE, et al. **Arch Fam Med** 1996 Mar;5(3):146–52

Covariations of unhealthy weight loss behaviors and other high-risk behaviors among adolescents. Neumark-Sztainer D, et al. **Arch Pediatr Adolesc Med** 1996 Mar;150(3):304–8

Communication between adolescents and physicians about sexual behavior and risk prevention. Schuster MA, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):906–13

Healthy masculinity starts in boyhood. Biddulph S. **Aust Fam Physician** 1995 Nov;24(11):2047–50, 2052

Compliance issues in adolescence: practical strategies. Blair S, et al. **Aust Fam Physician** 1995 Nov;24(11):2037–40

Engaging the adolescent patient. Sanci L, et al. **Aust Fam Physician** 1995 Nov;24(11):2027–31

Teenage sex. Trend towards earlier menarche stopped 30 years ago [letter; comment] Dann TC. **BMJ** 1996 Jun 1; 312(7043):1419. Comment on: BMJ 1996 Feb 17;312(7028):390–1.

Teenage sex. Teenagers can be helped to behave responsibly [letter; comment] Graham P. **BMJ** 1996 Jun 1; 312(7043):1420. Comment on: BMJ 1996 Feb 17;312(7028):390–1.

Teenage sex. Image of various providers of sexual health care varies [letter; comment] Pallecaros A, et al. **BMJ** 1996 Jun 1;312(7043):1419–20. Comment on: BMJ 1996 Feb 17;312(7028):390–1.

Teenage sex [editorial] [see comments] Stuart-Smith S. **BMJ** 1996 Feb 17;312(7028):390–1. Comment in: BMJ 1996 Jun 1;312(7043):1419. Comment in: BMJ 1996 Jun 1;312(7043):1419–20. Comment in: BMJ 1996 Jun 1;312(7043):1420.

Violence among children and adolescents and the role of the pediatrician. Dukarm CP, et al. **Bull N Y Acad Med** 1995 Summer;72(1):5–15 (38 ref.)

Time for a new societal norm for sexuality [news] Kermode-Scott B. **Can Fam Physician** 1996 Apr; 42:799–800

Predicting the timing of first sexual intercourse for at-risk adolescent males. Capaldi DM, et al. **Child Dev** 1996 Apr; 67(2):344–59

The younger sisters of childbearing adolescents: their attitudes, expectations, and behaviors. East PL. **Child Dev** 1996 Apr;67(2):267–82

A model of the effects of perceived parent and peer support on adolescent false self behavior. Harter S, et al. **Child Dev** 1996 Apr;67(2):360–74

Presurgical anxiety treated with cognitive behavioral therapy in a 13-year-old female with cleft lip and palate: a psychological case report. Whitehead TD, et al. **Cleft Palate Craniofac J** 1996 May;33(3):258–61

The effects of family structure and family relations on adolescent marijuana use. Hoffmann JP. **Int J Addict** 1995 Aug;30(10):1207–41 (106 ref.)

Drug use patterns and risk factors of adolescents with physical disabilities. Kessler DT, et al. **Int J Addict** 1995 Aug;30(10):1243–70

STDs: Screening, therapy, and long-term implications for the adolescent patient. Bishop-Townsend V. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):109–14 (41 ref.)

Adolescent health-threatening and health-enhancing behaviors: a study of word association and imagery. Benthin A, et al. **J Adolesc Health** 1995 Sep;17(3):143–52

The associations between immigrant status and risk-behavior patterns in Latino adolescents. Brindis C, et al. **J Adolesc Health** 1995 Aug;17(2):99–105

Prevalence of HIV-related risk behaviors and STDs among incarcerated adolescents. Canterbury RJ, et al. **J Adolesc Health** 1995 Sep;17(3):173–7

Dieting and "watching" behaviors among adolescent females: report of a multimethod study. Nichter M, et al. **J Adolesc Health** 1995 Sep;17(3):153–62

Concerns and risk behaviors and the association between them among high-school students in Jerusalem. Palti H, et al. **J Adolesc Health** 1995 Jul;17(1):51–7

The effectiveness of selected risk factors in mediating gender differences in drinking and it problems. Thomas BS. **J Adolesc Health** 1995 Aug;17(2):91–8

Durations of adolescent sexual relationships before and after conception. Toledo-Dreves V, et al. **J Adolesc Health** 1995 Sep;17(3):163–72

Suicide among female adolescents: characteristics and comparison with males in the age group 13 to 22 years. Marttunen MJ, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1297–307

Cigarette packaging appeals to teens [news] **J Am Dent Assoc** 1995 Dec;126(12):1604

Invest now for the future [letter; comment] Ginsburg KR, et al. **J Am Dent Assoc** 1996 Feb;127(2):158. Comment on: J Am Dent Assoc 1995 Sep;126(9):1200, 1202.

Reexamination of the paradigm of HIV risk reduction in adolescents. Earl DT. **J Am Osteopath Assoc** 1995 Dec; 95(12):725–8 (32 ref.)

Asthma, health behaviors, social adjustment, and psychosomatic symptoms in adolescence. Forero R, et al. **J Asthma** 1996;33(3):157–64

Adolescent resiliency to family adversity. Fergusson DM, et al. **J Child Psychol Psychiatry** 1996 Mar;37(3):281–92

Influence of tobacco marketing and exposure to smokers on adolescent susceptibility to smoking. Evans N, et al. **J Natl Cancer Inst** 1995 Oct 18;87(20):1538–45

Comments on a positive health practice observed in African-American youth [editorial] Dawson G. **J Natl Med Assoc** 1996 Aug;88(8):483–6

Opposing opinions on abstinence programs for adolescents. Abstinence only: negative position. Kantor LM, et al. **J Pediatr Adolesc Gynecol** 1996 Aug;9(3):166–8

Prevalence of abnormal eating attitudes and behaviors in hospital-based primary and tertiary care clinics: a window of opportunity? Rome ES, et al. **J Pediatr Adolesc Gynecol** 1996 Aug;9(3):133–8

Opposing opinions on abstinence programs for adolescents. Abstinence only: pro position. Weed SE. **J Pediatr Adolesc Gynecol** 1996 Aug;9(3):165–6

Opposing opinions on abstinence programs for adolescents. Weed SE, et al. **J Pediatr Adolesc Gynecol** 1996 Aug; 9(3):165–8

Having a future: sexual decision making in early adolescence. Monsen RB, et al. **J Pediatr Nurs** 1996 Jun;11(3):183–8

Decision making and risk behaviors of cancer-surviving adolescents and their peers. Hollen PJ, et al. **J Pediatr Oncol Nurs** 1996 Jul;13(3):121–33; discussion 135–7

MMPI-A profiles of adolescent boys with a history of firesetting. Moore JM Jr, et al. **J Pers Assess** 1996 Aug; 67(1):116–26

Factor analysis of the suicide intent scale with adolescent suicide attempters. Spirito A, et al. **J Pers Assess** 1996 Aug; 67(1):90–101

Drug use, sexual activity, and suicidal behavior in U.S. high school students. Burge V, et al. **J Sch Health** 1995 Aug; 65(6):222–7

Combating the illusion of adolescent invincibility to HIV/AIDS. Crosby RA. **J Sch Health** 1996 May; 66(5):186–90

The motivation of Australian adolescent schoolchildren to engage in group discussions about bullying. Rigby K. **J Soc Psychol** 1995 Dec;135(6):773–4

Conduct disorder among adolescent alcohol and drug abusers. Brown SA, et al. **J Stud Alcohol** 1996 May; 57(3):314–24

Gun acquisition and use by juvenile offenders. Ash P, et al. **JAMA** 1996 Jun 12;275(22):1754–8

Some schools agree to let sleeping teens lie [news] Lamberg L. **JAMA** 1996 Sep 18;276(11):859

The effect of socioeconomic status on chronic disease risk behaviors among US adolescents. Lowry R, et al. **JAMA** 1996 Sep 11;276(10):792–7

An investigation of junior high students' attitudes toward amphetamine use and related forms of behavior. Chen JW, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Oct; 11(10):557–63

Measuring the self-care practice of children and adolescents: instrument development. Moore JB. **Matern Child Nurs J** 1995 Jul-Sep;23(3):101–8

Physical activity and the initiation of high-risk health behaviors in adolescents. Aaron DJ, et al. **Med Sci Sports Exerc** 1995 Dec;27(12):1639–45

Youth Risk Behavior Surveillance--United States, 1995. Kann L, et al. **MMWR CDC Surveill Summ** 1996 Sep 27; 45(4):1–84

The minor side of smoking. Berlin B. **N J Med** 1996 Jun; 93(6):21–4

A national survey of cigarette smoking in fourth-form school children in New Zealand. Ford DJ, et al. **N Z Med J** 1995 Nov 10;108(1011):454–7

Sexual behavior of Nebraska adolescents. Courtney K, et al. **Nebr Med J** 1995 Sep;80(9):287–9

Adolescent Drug Abuse: Clinical Assessment and Therapeutic Interventions. Proceedings of a meeting. Bethesda, Maryland, May 13–14, 1993. **NIDA Res Monogr** 1995;156:1–374

Adolescent substance use disorder with conduct disorder and comorbid conditions. Crowley TJ, et al. **NIDA Res Monogr** 1995;156:49–111 (178 ref.)

Youth Evaluation Services (YES): assessment, systems of referral, and treatment effects. Del Boca FK, et al. **NIDA Res Monogr** 1995;156:325–40 (11 ref.)

Service delivery strategies for treating high-risk youth: delinquents, homeless, runaways, and sexual minorities. Farrow JA. **NIDA Res Monogr** 1995;156:39–48 (23 ref.)

Skills training for pregnant and parenting adolescents. Hall

JA. **NIDA Res Monogr** 1995;156:255–90 (70 ref.)
Therapeutic communities for adolescents. Jainchill N, et al. **NIDA Res Monogr** 1995;156:190–217 (19 ref.)
Pharmacotherapy for adolescents with psychoactive substance use disorders. Kaminer Y. **NIDA Res Monogr** 1995;156:291–324 (101 ref.)
Physical health problems associated with adolescent substance abuse. Kokotailo P. **NIDA Res Monogr** 1995; 156:112–29 (52 ref.)
Cultural competence in assessing Hispanic youths and families: challenges in the assessment of treatment needs and treatment evaluation for Hispanic drug-abusing adolescents. Kurtines WM, et al. **NIDA Res Monogr** 1995; 156:172–89 (30 ref.)
Family-based treatment for adolescent drug use: state of the science. Liddle HA, et al. **NIDA Res Monogr** 1995; 156:218–54 (153 ref.)
Identifying high-risk youth: prevalence and patterns of adolescent drug abuse. Newcomb MD. **NIDA Res Monogr** 1995;156:7–38 (68 ref.)
Advances in adolescent drug abuse treatment. Rahdert E, et al. **NIDA Res Monogr** 1995;156:1–6 (5 ref.)
Posttreatment services for chemically dependent adolescents. Spear SF, et al. **NIDA Res Monogr** 1995;156:341–64 (73 ref.)
AIDS, drugs, and the adolescent. Steel E. **NIDA Res Monogr** 1995;156:130–45 (34 ref.)
Current issues and future needs in the assessment of adolescent drug abuse. Winters KC, et al. **NIDA Res Monogr** 1995;156:146–71 (60 ref.)
Adolescent contraceptive behavior: the impact of the provider and the structure of clinic-based programs. Jaccard J. **Obstet Gynecol** 1996 Sep;88(3 Suppl):57S–64S (68 ref.)
Adolescents and the contraceptive pill: the impact of beliefs on intentions and use. Moore PJ, et al. **Obstet Gynecol** 1996 Sep;88(3 Suppl):48S–56S
Smoke screen [editorial] Carroll-Johnson RM. **Oncol Nurs Forum** 1995 Oct;22(9):1331
Medical students tackle adolescent health. Hoepfer M. **Pa Med** 1995 Sep;98(9):30–1
Eating disorders among children and adolescents. Kreipe RE. **Pediatr Rev** 1995 Oct;16(10):370–9
Alcohol misuse and adolescent sexual behaviors and risk taking. Fergusson DM, et al. **Pediatrics** 1996 Jul;98(1):91–6
Adverse factors associated with forced sex among southern adolescent girls. Nagy S, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):944–6
Male adolescents involved in pregnancy: associated health risk and problem behaviors. Spingarn RW, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):262–8
An investigation into why adolescents may reject Norplant. Wiemann CM, et al. **Pediatrics** 1996 Feb;97(2):185–91
Recognition and liking of tobacco and alcohol advertisements among adolescents: relationships with susceptibility to substance use. Unger JB, et al. **Prev Med** 1995 Sep; 24(5):461–6
Female adolescent contraceptive use or nonuse at first and most recent coitus. Felton GM. **Public Health Nurs** 1996 Jun;13(3):223–30
Pathways of influence on fifth and eighth graders' reports about having had sexual intercourse. Porter CP, et al. **Res Nurs Health** 1996 Jun;19(3):193–204 (55 ref.)
Sexual behaviour, contraceptive practice and reproductive health among school adolescents in rural Transkei. Buga GA, et al. **S Afr Med J** 1996 May;86(5):523–7
New studies trace the impact of tobacco advertising [news] Nowak R. **Science** 1995 Oct 27;270(5236):573–4
Anabolic steroid use and associated health risk behaviours. Middleman AB, et al. **Sports Med** 1996 Apr;21(4):251–5 (26 ref.)
Cigarette smoking among Chinese adolescents and its association with demographic characteristics, social activities, and problem behaviors. Li X, et al. **Subst Use Misuse** 1996 Apr;31(5):545–63
Helping children cope when a family member has cancer. Rittenberg CN. **Support Care Cancer** 1996 May;4(3):196–9
Tobacco use: Tennessee youths at risk. Pearson CM. **Tenn Med** 1996 Aug;89(8):299–300
Adolescents' perceptions about smoking prevention strategies: a comparison of the programmes of the American Lung Association and the Tobacco Institute. DeBon M, et al. **Tob Control** 1996 Spring;5(1):19–25
Absolute and relative involvement in homicide offending: contemporary youth and the baby boom cohorts. Smith MD, et al. **Violence Vict** 1995 Winter;10(4):327–33
[The medicosocial aspects of contraception for teenagers] Kolarov G, et al. **Akush Ginekol (Sofiia)** 1995;34(1):22–3 (Eng. Abstr.) **(Bul)**
[Elements in the communication and social contacts of chronically ill and healthy pupils in the upper school ages (a questionnaire study)] Popivanova Ts, et al. **Probl Khig** 1995;20:210–4 (Eng. Abstr.) **(Bul)**
[Health behavior in Hualien city high school students] Li YM, et al. **J Formos Med Assoc** 1995 Dec;94 Suppl 2:S81–6 (Eng. Abstr.) **(Chi)**
[Sexual development in urban and rural girls] Raboch J Jr, et al. **Ceska Gynekol** 1995 Oct;60(5):234–6 (Eng. Abstr.) **(Cze)**
[Rate of precocious sexual intercourse in adolescents in disadvantaged socioeconomic environments. (University of Quebec in Montreal)] Thériault J, et al. **Contracept Fertil Sex** 1995 Sep;23(9):545–51 (Eng. Abstr.) **(Fre)**
[The adolescent's lexicon: study of lexical variations in normal adolescents depending upon the listener] Granboulan V, et al. **Psychiatr Enfant** 1995;38(2):655–91 (Eng. Abstr.) **(Fre)**
[Art therapy as an assisting psychotherapeutic method for adolescents] Skowron J, et al. **Psychiatr Pol** 1996 Mar-Apr; 30(2):247–54 (Eng. Abstr.) **(Pol)**
[The psychological meaning of the female friend among Mexican adolescents: a gender comparison] González Forteza CF, et al. **Acta Psiquiatr Psicol Am Lat** 1994 Dec; 40(4):308–13 (Eng. Abstr.) **(Spa)**
[Design of a program to prevent adolescent suicide] González-Seijo JC, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1994 May-Jun;22(3):100–8 (59 ref.) (Eng. Abstr.) **(Spa)**
[Use of primary care services by adolescents and detection of health problems other than those for which they came] Colino Nevot R, et al. **Aten Primaria** 1995 Dec; 16(10):594–600 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Psychosocial correlates of smoking among immigrant Latina adolescents. Otero-Sabogal R, et al. **J Natl Cancer Inst Monogr** 1995;(18):65–71
Role of cigarette smoking as a gateway drug to alcohol use in Hispanic junior high school students. Parra-Medina DM, et al. **J Natl Cancer Inst Monogr** 1995;(18):83–6

PSYCHOLOGY

Teacher and parent perceptions of behavior problems among a sample of African American, Hispanic, and non-Hispanic white students. Zimmerman RS, et al. **Am J Community Psychol** 1995 Apr;23(2):181–97
Violent juvenile delinquents. Treatment effectiveness and implications for future action. Tate DC, et al. **Am Psychol** 1995 Sep;50(9):777–81
Recreational patterns, body composition and socioeconomic status of Western Australian secondary school students. Blanksby BA, et al. **Ann Hum Biol** 1996 Mar-Apr; 23(2):101–12
Adolescent food choice criteria: role of weight and dieting status. Contento IR, et al. **Appetite** 1995 Aug;25(1):51–76
AIDS-related behaviour in adolescents: intervention programme with international application. Nikolopoulos TP, et al. **Br J Clin Pract** 1995 Sep-Oct;49(5):229–31
Restrained eating among adolescents: dieters are not always bingers and bingers are not always dieters. Williams SS, et al. **Health Psychol** 1996 May;15(3):176–84
Facial expressions of emotion and psychopathology in adolescent boys. Keltner D, et al. **J Abnorm Psychol** 1995 Nov;104(4):644–52
Sexual abuse histories of adolescent male sex offenders: differences on the basis of the age and gender of their victims. Worling JR. **J Abnorm Psychol** 1995 Nov; 104(4):610–3
A pilot study of factors associated with resilience to substance abuse in adolescent sons of alcoholic fathers. Springer SA, et al. **J Addict Dis** 1995;14(2):53–66

ADOLESCENT HEALTH SERVICES

In search of effective programs to address students' emotional distress and behavioral problems. Part II: Critique of school- and community-based programs. Wassef A, et al. **Adolescence** 1995 Winter;30(120):757–77 (29 ref.)
Intentional injury surveillance in a primary care pediatric setting. Sege R, et al. **Arch Pediatr Adolesc Med** 1996 Mar; 150(3):277–83
Perspectives on adolescent health in the 1990s [editorial] Tresidder J. **Aust N Z J Public Health** 1996 Jun; 20(3):229–30
Primary health care and adolescence [editorial] [see comments] Macfarlane A, et al. **BMJ** 1995 Sep 30; 311(7009):825–6. Comment in: BMJ 1995 Dec 2;311(7018):1500.
School-based health clinics in the mid-1990s. Klein JD, et al. **Curr Opin Pediatr** 1995 Aug;7(4):353–9 (31 ref.)
Condom availability and prevention issues for adolescents. Spingarn RW. **Curr Opin Pediatr** 1995 Aug;7(4):360–5 (53 ref.)
Prevention. In the dark about safe sex. MacPherson P. **Hosp Health Netw** 1996 Mar 5;70(5):42
Patterns of ICD-9 diagnoses among adolescents using school-based clinics: diagnostic categories by school level and gender. Borenstein PE, et al. **J Adolesc Health** 1996 Mar;18(3):203–10
Adolescent pap smear screening: yes or no. Hillard P. **J Pediatr Adolesc Gynecol** 1996 Apr;9(2):93–7
Family involvement in the gynecologic care of adolescents. Rosenthal SL, et al. **J Pediatr Adolesc Gynecol** 1996 Apr; 9(2):59–65
Transferring to adult health care: experiences of adolescents with cystic fibrosis. Russell MT, et al. **J Pediatr Nurs** 1996 Aug;11(4):262–8 (44 ref.)
Changing populations in the public sector: responding to the needs of Texas youth. Johnson BS, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):7–11
Paediatric hospital services: are we satisfying our adolescent patients? Black W, et al. **J Qual Clin Pract** 1995 Sep; 15(3):161–7
Barriers to effective primary health care for adolescents. Veit FC, et al. **Med J Aust** 1996 Aug 5;165(3):131–3
Adolescent contraceptive behavior: the impact of the provider and the structure of clinic-based programs. Jaccard J. **Obstet Gynecol** 1996 Sep;88(3 Suppl):57S–64S (68 ref.)
Meeting the needs of young adults. McCauley AP, et al. **Popul Rep J** 1995 Oct;(41):1–43 (595 ref.)
Preventive health care for teenagers and young adults. Schaff EA, et al. **Prim Care** 1995 Dec;22(4):637–52 (27 ref.)
Promising approaches for adolescent reproductive health service delivery. The role of school-based health centers in a managed care environment. Brindis C. **West J Med** 1995 Sep;163(3 Suppl):50–6
[A survey on sex knowledge and medical demand of the cases in Kaohsiung city adolescent health clinic] Chung TC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Mar;12(3):174–82 (Eng. Abstr.) **(Chi)**
[Special health services for adolescents?] Hanstad AM. **Tidsskr Nor Laegeforen** 1996 Jun 30;116(17):1993 **(Nor)**
[A local health center for adolescents] Knoph IV, et al. **Tidsskr Nor Laegeforen** 1996 Jun 30;116(17):2030–1 (Eng. Abstr.) **(Nor)**
[Follow-up of health status of young girls by primary health care. Preventive work is the target of the health care center in Lilla Edet] Olsson I. **Lakartidningen** 1996 Aug 7; 93(32–33):2719–20 **(Swe)**

ECONOMICS

[Quality assurance in child and adolescent health care] Schirm H. **Gesundheitswesen** 1995 Nov;57(11):725–8 (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Pattern of prenatal care and infant immunization status in a comprehensive adolescent-oriented maternity program. Stevens-Simon C, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):829–33
Review of teenage health: time for a new direction. Jacobson LD, et al. **Br J Gen Pract** 1994 Sep;44(386):420–4 (64 ref.)
Mental health promotion for young adolescents in primary care: a feasibility study [letter] Westman A, et al. **Br J Gen Pract** 1996 May;46(406):317
Adolescent health: moving from prevention to promotion through a quality of life approach. Raphael D, et al. **Can J Public Health** 1996 Mar-Apr;87(2):81–3
Outreach. Practice parenting. Hudson T. **Hosp Health Netw** 1996 Sep 5;70(17):68
Targeting young people for sexual health counselling [letter] Williams E, et al. **Int J STD AIDS** 1995 Sep-Oct; 6(5):369–70
A pilot program of contraceptive continuation in six school-based clinics. Bearss N, et al. **J Adolesc Health** 1995 Sep;17(3):178–83
A hepatitis B vaccination program targeting adolescents. Cassiday WA, et al. **J Adolesc Health** 1995 Oct;17(4):244–7
Moving on: who is on-board? [editorial] Litt IF. **J Adolesc Health** 1995 Jul;17(1):1
The benefits of school-based condom availability: cross-sectional analysis of a comprehensive high school-based program. Wolk LI, et al. **J Adolesc Health** 1995 Sep;17(3):184–8
An evaluation of a Canadian peer-driven injury prevention programme for high-risk adolescents. Tenn L, et al. **J Adv Nurs** 1996 Feb;23(2):329–37
A school-linked health service for adolescents in Jerusalem. Halevy A, et al. **J Sch Health** 1995 Dec;65(10):416–9
Collaborative social and medical service application. Petermann CA, et al. **Medinfo** 1995;8 Pt 2:1671

STANDARDS

Quality management in a school-based nursing center: program development and implementation. Verhey MP, et al. **J Nurs Care Qual** 1996 Apr;10(3):59–67

STATISTICS & NUMERICAL DATA

[Achieving uniformity of documentation in child and adolescent health care. Child and adolescent medicine electronic data processing scope convention as the basis of GBE, Dresden Public Health Service Congress, May 1995] Meireis H. **Gesundheitswesen** 1995 Nov;57(11):729–33 (Eng. Abstr.) **(Ger)**

SUPPLY & DISTRIBUTION

Primary health care and adolescence [letter; comment] Kramer T, et al. **BMJ** 1995 Dec 2;311(7018):1500. Comment on: BMJ 1995 Sep 30;311(7009):825–6.
[Adolescents and rehabilitation] Kokkonen J, et al. **Duodecim** 1994;110(15):1410–6 (20 ref.) **(Fin)**

TRENDS

Approaches to delivering child and adolescent mental health services: the South Australian experience. Sawyer MG, et al. **Aust N Z J Psychiatry** 1995 Jun;29(2):230–7

UTILIZATION

Adolescent health care in a pediatric emergency department. Melzer-Lange M, et al. **Ann Emerg Med** 1996 May;

27(5):633–7
The role of community health centers in providing preventive care to adolescents. Hedberg VA, et al. **Arch Pediatr Adolesc Med** 1996 Jun;150(6):603–8
Utilization of ambulatory health services by urban adolescents [see comments] Ryan SA, et al. **J Adolesc Health** 1996 Mar;18(3):192–202. Comment in: Nippon Koshu Eisei Zasshi 1996 Mar;18(3):165.
The use of general practice services by 18 year olds in New Zealand. Murdoch JC, et al. **N Z Med J** 1996 Apr 12; 109(1019):113–5
Comprehensive school–based health care: high school students' use of medical, mental health, and substance abuse services. Anglin TM, et al. **Pediatrics** 1996 Mar; 97(3):318–30
Exploring the relationship between purpose in life and African American adolescents' use of prenatal care services. Spence SA, et al. **Soc Work Health Care** 1995; 22(2):43–53

ADOLESCENT, HOSPITALIZED

PSYCHOLOGY

Sensitivity of clinically hospitalized adolescents' self–report measures to change over time. Nelson WM 3rd, et al. **J Clin Psychol** 1995 Nov;51(6):753–60
Suicide contagion among adolescents during acute psychiatric hospitalization. King CA, et al. **Psychiatr Serv** 1995 Sep;46(9):915–8
[Anxiety and reconstructive surgery in children and adolescents] de Carmoy R. **Psychiatr Enfant** 1995; 38(1):141–202 (Eng. Abstr.) **(Fre)**

ADOLESCENT, INSTITUTIONALIZED

Perceived control and treatment outcome with chronic adolescent offenders. Swenson CC, et al. **Adolescence** 1995 Fall;30(119):565–78
Analysis of drug abuse among adolescent psychiatric inpatients at Veterans General Hospital–Taipei. Yeh HS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Nov; 56(5):325–30

ADOLESCENT MEDICINE

Prevention dollars and sense [editorial] Joffe A. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1203–4
Chronic illness in the adolescent. Harris RA. **Aust Fam Physician** 1995 Nov;24(11):2021–5
Abstracts of research presentations presented at the annual meeting of the Society for Adolescent Medicine. March 1996. **J Adolesc Health** 1996 Feb;18(2):111–59
Fellowships in adolescent medicine–1996. **J Adolesc Health** 1995 Jul;17(1):59–63
Bibliography of recent journal articles (July–December 1993). Brookman RR. **J Adolesc Health** 1996 Mar; 18(3):232–42
Health promotion in minority adolescents: a Healthy People 2000 pilot study. Fardy PS, et al. **J Cardpulm Rehabil** 1995 Jan–Feb;15(1):65–72

ECONOMICS

The cost of comprehensive preventive medical services for adolescents. Gans JE, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1226–34 (52 ref.)

EDUCATION

The need for adolescent health education and training among health professionals [letter] Gordon TE. **Am J Public Health** 1996 Jun;86(6):889–90
Barriers to effective primary health care for adolescents. Veit FC, et al. **Med J Aust** 1996 Aug 5;165(3):131–3

HISTORY

[History of the establishment and development of the Department of Child and Adolescent Health, Russian Medical Academy of Postgraduate Training] Fokina NS, et al. **Gig Sanit** 1996 Mar–Apr;(2):44–6 **(Rus)**

TRENDS

Engaging the adolescent patient. Sanci L, et al. **Aust Fam Physician** 1995 Nov;24(11):2027–31
Adolescent health research as we proceed into the twenty–first century. DuRant RH. **J Adolesc Health** 1995 Sep;17(3):199–203
Pediatrics and adolescent medicine. Walker AR, et al. **JAMA** 1996 Jun 19;275(23):1841–2
[Adolescentology—a new direction even in adolescent medicine?] Hamanová J, et al. **Sb Lek** 1996;97(1):167–8 **(Cze)**
[The basic research results and outlook of the Institute on the Problems of Child and Adolescent Hygiene] Makarova LP, et al. **Med Tr Prom Ekol** 1995;(11):6–8 (Eng. Abstr.) **(Rus)**

ADOLESCENT NUTRITION

Dietary sources of calcium and the contribution of flour fortification to total calcium intake in the diets of Northumbrian adolescents. Moynihan P, et al. **Br J Nutr** 1996 Mar;75(3):495–505
Evaluation of a quantitative food frequency questionnaire used in a group of Norwegian adolescents. Andersen LF, et al. **Eur J Clin Nutr** 1995 Aug;49(8):543–54
Dietary intake among Norwegian adolescents. Andersen LF, et al. **Eur J Clin Nutr** 1995 Aug;49(8):555–64
Iron and zinc status of young women aged 14 to 19 years consuming vegetarian and omnivorous diets. Donovan UM, et al. **J Am Coll Nutr** 1995 Oct;14(5):463–72
Position of the American Dietetic Association: child and adolescent food and nutrition programs. **J Am Diet Assoc** 1996 Sep;96(9):913–7
Adolescent milk consumption, menarche, birth weight, and ethnicity influence height of women in Hawaii. Novotny R, et al. **J Am Diet Assoc** 1996 Aug;96(8):802–4
Eating disorders in adolescents: a model for broadening our perspective. Rees JM. **J Am Diet Assoc** 1996 Jan;96(1):22–3 (4 ref.)
Timely statement of The American Dietetic Association: nutrition guidance for adolescent athletes in organized sports. Steen SN. **J Am Diet Assoc** 1996 Jun;96(6):611–2
Nutrition knowledge of adolescents in a family setting in Geelong, Australia. Tienboon P, et al. **J Med Assoc Thai** 1996 Apr;79(4):253–7
School food service. Pateman BC, et al. **J Sch Health** 1995 Oct;65(8):327–32
Contribution of street foods to nutrient intakes by Nigerian adolescents. Oguntona CR, et al. **Nutr Health** 1995; 10(2):165–71
A new recommendation for dietary fiber in childhood. Williams CL, et al. **Pediatrics** 1995 Nov;96(5 Pt 2):985–8
[Nutritional habits of adolescents in the Paris suburbs] Chauliac M, et al. **Arch Pediatr** 1996 Mar;3(3):227–34 (Eng. Abstr.) **(Fre)**
[The food habits and energy and nutrient intake in overweight adolescents compared to those with normal weight] Ortega Anta RM, et al. **An Esp Pediatr** 1996 Mar; 44(3):203–8 (Eng. Abstr.) **(Spa)**

ADOLESCENT PREGNANCY see **PREGNANCY IN ADOLESCENCE**

ADOLESCENT PSYCHIATRY

The prevalence of prodromal features of schizophrenia in adolescence: a preliminary survey. McGorry PD, et al. **Acta Psychiatr Scand** 1995 Oct;92(4):241–9
Survey of lead levels in patients presenting to child and adolescent psychiatry. Lavigne K, et al. **Hawaii Med J** 1995 Jul;54(7):671–2
Practice parameters for the psychiatric assessment of children and adolescents. American Academy of Child and Adolescent Psychiatry. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1386–402
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1124–32 (132 ref.)
Psychiatric emergencies in children and adolescents. Sadka S. **New Dir Ment Health Serv** 1995 Fall;(67):65–74
Psychiatric disorder among adolescents attending a psychiatric out–patient clinic in Accra, Ghana: a seven year review study (1987–1994). Turkson SN. **West Afr J Med** 1996 Jan–Mar;15(1):31–5
[Reflections on transference, countertransference, session frequency and the analytic process] Holder A. **Psychiatr Enfant** 1995;38(2):603–23 (5 ref.) (Eng. Abstr.) **(Fre)**
[Suicidal adolescents: psychotherapy and treatment interruption. Results of a controlled study] Ottino J. **Psychiatr Enfant** 1995;38(2):573–602 (Eng. Abstr.) **(Fre)**
[Managing violence: cooperation between adolescent welfare and child and adolescent psychiatry as a chance for improvements (editorial)] Martinius J. **Z Kinder Jugenpsychiatr** 1995 Sep;23(3):147–8 **(Ger)**
[Quality assurance in child and adolescent psychiatry and psychotherapy (editorial)] Remschmidt H. **Z Kinder Jugenpsychiatr** 1996 Jun;24(2):65–6 **(Ger)**
[Children of psychiatric patients—what to do?] Hestmann E, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30;115(23):2891–2 (Eng. Abstr.) **(Nor)**
[Depressions among adolescents are not always correctly diagnosed (letter)] Agren H. **Lakartidningen** 1996 Feb 7; 93(6):448 **(Swe)**
[Children of mentally ill parents must get more support] Axelsson–Ostman M, et al. **Lakartidningen** 1995 Oct 18; 92(42):3877–8 **(Swe)**
[Adolescents manage their crises without "happy pills" (letter)] Berggren I. **Lakartidningen** 1996 Jan 17;93(3):123 **(Swe)**
[Examination of children and adolescents who attempted suicide. No overmortality could be detected] Haitkin RM, et al. **Lakartidningen** 1996 Jan 17;93(3):144–7 **(Swe)**
[Let us not forget children of the mentally ill!] Trost von Werder AC, et al. **Lakartidningen** 1995 Oct 18;92(42):3876 **(Swe)**

EDUCATION

Exploration of failure on the subspecialty examination for child and adolescent psychiatry. Shapiro T, et al. **Am J Psychiatry** 1996 May;153(5):693–7
The function of the multidisciplinary team in child psychiatry—clinical and educational aspects. Benierakis CE. **Can J Psychiatry** 1995 Aug;40(6):348–53
A training guideline of cultural competence for child and adolescent psychiatric residencies. Kim WJ. **Child Psychiatry Hum Dev** 1995 Winter;26(2):125–36
The extent and importance of research to developmental and behavioral pediatrics. Wolraich ML. **J Dev Behav Pediatr** 1996 Apr;17(2):133–6

LEGISLATION & JURISPRUDENCE

The American Academy of Child and Adolescent Psychiatry's managed care strategy. Graham MD. **Psychiatr Serv** 1995 Jul;46(7):659–60

STATISTICS & NUMERICAL DATA

Immigrant child and adolescent psychiatric referrals: a five–year retrospective study of Asian and Caucasian families. Roberts N, et al. **Can J Psychiatry** 1995 Jun; 40(5):252–6

ADOLESCENT PSYCHOLOGY

Short stature and psychosocial assessment. Voss LD, et al. **Acta Paediatr Suppl** 1995 Sep;411:69–74
Epidemiology of eating behaviour and weight distribution in 14– to 19–year–old Swiss students. Buddeberg–Fischer B, et al. **Acta Psychiatr Scand** 1996 Apr;93(4):296–304
Adolescents' perceived risk and personal experience with natural disasters: an evaluation of cognitive heuristics. Greening L, et al. **Acta Psychol (Amst)** 1996 Feb; 91(1):27–38
DSM–III–R tobacco dependence and quitting during late adolescence. Stanton WR. **Addict Behav** 1995 Sep–Oct; 20(5):595–603
Constructivist developmental theory and therapy: implications for counseling adolescents. Crespi TD, et al. **Adolescence** 1995 Fall;30(119):735–43 (20 ref.)
Adolescent identity exploration: a test of Erikson's theory of transitional crisis. Kidwell JS, et al. **Adolescence** 1995 Winter;30(120):785–93
Modes of moral judgment among early adolescents. Perry CM, et al. **Adolescence** 1995 Fall;30(119):707–15
Development and validation of adolescent–perceived microsystem scales: social support, daily hassles, and involvement. Seidman E, et al. **Am J Community Psychol** 1995 Jun;23(3):355–88
Defense mechanisms and adjustment in normal adolescents. Erickson SJ, et al. **Am J Psychiatry** 1996 Jun;153(6):826–8
Children's memories in the wake of Challenger. Terr LC, et al. **Am J Psychiatry** 1996 May;153(5):618–25
Adolescent character formation and psychoanalytic theory. McCarthy JB. **Am J Psychoanal** 1995 Sep;55(3):245–67
The myth of the invulnerable self of adolescence. Rucker N, et al. **Am J Psychoanal** 1995 Dec;55(4):369–79
Affective comorbidity in children and adolescents with attention deficit hyperactivity disorder. Butler SF, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):51–5
Lasting success in teenage reduction mammaplasty. McMahan JD, et al. **Ann Plast Surg** 1995 Sep;35(3):227–31
Youth with chronic conditions and their transition to adulthood. Findings from a Finnish cohort study. Bussing R, et al. **Arch Pediatr Adolesc Med** 1996 Feb;150(2):181–6
Illicit substance use, gender, and the risk of violent behavior among adolescents. Dukarm CP, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):797–801
Body dissatisfaction and unhealthy weight–control practices among adolescents with and without chronic illness: a population–based study. Neumark–Sztainer D, et al. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1330–5
Communication between adolescents and physicians about sexual behavior and risk prevention. Schuster MA, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):906–13
Therapeutical management of depression during adolescence. Corcos M, et al. **Biomed Pharmacother** 1996;50(1):3–6
Teenage smokers fail to recognise health risks [news] Goldbeck–Wood S. **BMJ** 1996 Jun 15;312(7045):1501
The effects of forced sexual intercourse on white female adolescents. Miller BC, et al. **Child Abuse Negl** 1995 Oct; 19(10):1289–301
Friendships and social networks in childhood and adolescence: fluidity, reliability, and interrelations. Cairns RB, et al. **Child Dev** 1995 Oct;66(5):1330–45
Helpfulness and the development of competence in adolescence. Call KT, et al. **Child Dev** 1995 Feb; 66(1):129–38
Predicting the timing of first sexual intercourse for at–risk adolescent males. Capaldi DM, et al. **Child Dev** 1996 Apr; 67(2):344–59
The younger sisters of childbearing adolescents: their attitudes, expectations, and behaviors. East PL. **Child Dev** 1996 Apr;67(2):267–82
Adolescent girls' relationships with mothers and best friends. Gavin LA, et al. **Child Dev** 1996 Apr;67(2):375–86
Prosocial behavior and caring in adolescence: relations to self–understanding and social judgment. Hart D, et al. **Child Dev** 1995 Oct;66(5):1346–59
A model of the effects of perceived parent and peer support on adolescent false self behavior. Harter S, et al. **Child Dev** 1996 Apr;67(2):360–74
Grade–level differences in the social value of effort:

implication for self-presentation tactics of early adolescents. Juvonen J, et al. **Child Dev** 1995 Dec; 66(6):1694–705

Kinship support and maternal and adolescent well-being in economically disadvantaged African-American families. Taylor RD, et al. **Child Dev** 1995 Dec;66(6):1585–97

The onset and cross-temporal patterning of sexual intercourse in middle adolescence: prospective relations with behavioral and emotional problems. Tubman JG, et al. **Child Dev** 1996 Apr;67(2):327–43

Deviation from developmentally appropriate self-care autonomy. Association with diabetes outcomes. Wysocki T, et al. **Diabetes Care** 1996 Feb;19(2):119–25

The structure of family perceptions among adolescents and their parents: individual satisfaction factors and family system factors. Benson MJ, et al. **Fam Process** 1995 Sep; 34(3):323–36

Relational processes and identity formation in adolescence: the example of A Separate Peace. Flum H, et al. **Genet Soc Gen Psychol Monogr** 1995 Nov;121(4):369–89

Pediatric headaches: what do the children want? Lewis DW, et al. **Headache** 1996 Apr;36(4):224–30

Dieting behaviors and weight change history in female adolescents. French SA, et al. **Health Psychol** 1995 Nov; 14(6):548–55

Adolescents' views of sexual decision-making. Keller ML, et al. **Image J Nurs Sch** 1996 Summer;28(2):125–30

The importance of dreams and action in the adolescent process. Ladame F. **Int J Psychoanal** 1995 Dec;76 (Pt 6):1143–53

Worldly and workday worries: contemporary concerns of children and young adolescents. Henker B, et al. **J Abnorm Child Psychol** 1995 Dec;23(6):685–702

Poor interpersonal problem solving as a mechanism of stress generation in depression among adolescent women. Davila J, et al. **J Abnorm Psychol** 1995 Nov;104(4):592–600

Adolescent health-threatening and health-enhancing behaviors: a study of word association and imagery. Benthin A, et al. **J Adolesc Health** 1995 Sep;17(3):143–52

Hepatitis B vaccine acceptance among adolescents and their parents. Rosenthal SL, et al. **J Adolesc Health** 1995 Oct; 17(4):248–54

Durations of adolescent sexual relationships before and after conception. Toledo-Dreves V, et al. **J Adolesc Health** 1995 Sep;17(3):163–72

Living with ulcerative colitis: experiences of adolescents and young adults. Brydolf M, et al. **J Adv Nurs** 1996 Jan; 23(1):39–47

Diabetes: an adolescent's perspective. Kyngäs H, et al. **J Adv Nurs** 1995 Nov;22(5):941–7

The subculture of adolescence: beliefs about care, health and individuation within Leininger's theory. Rosenbaum JN, et al. **J Adv Nurs** 1996 Apr;23(4):741–6

The cyclic dilemma: organic, functional, and environmental interaction in a young teenager. Adinamis A, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1544–50

Attention-deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? Biederman J, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug; 35(8):997–1008

Adolescent psychopathology: IV. Specificity of psychosocial risk factors for depression and substance abuse in older adolescents. Lewinsohn PM, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep;34(9):1221–9

Frequency of phobic disorder in a community sample of young adolescents. Milne JM, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1202–11

Course of obsessive-compulsive disorder in children and adolescents: a prospective follow-up study of 23 Danish cases. Thomsen PH, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1432–40

Family structure, family functioning and adolescent well-being: the transcendent influence of parental style. McFarlane AH, et al. **J Child Psychol Psychiatry** 1995 Jul; 36(5):847–64

Fears in American, Australian, Chinese, and Nigerian children and adolescents: a cross-cultural study. Ollendick TH, et al. **J Child Psychol Psychiatry** 1996 Feb;37(2):213–20

Ethnicity, family achievement syndrome, and adolescents' aspirations: Rosen's framework revisited. Marjoribanks K. **J Genet Psychol** 1996 Sep;157(3):349–59

Adolescents' attachment representations and moral reasoning. van Ijzendoorn MH, et al. **J Genet Psychol** 1995 Sep; 156(3):359–72

Adolescents' opinions about genetic risk information, prenatal diagnosis, and pregnancy termination. Decruyenaere M, et al. **J Med Genet** 1995 Oct;32(10):799–804; discussion 805

Sexuality and related issues in the preadolescent and adolescent female with epilepsy. Mims J. **J Neurosci Nurs** 1996 Apr;28(2):102–6 (34 ref.)

Adolescent condom use, the health belief model, and the prevention of sexually transmitted disease. Hiltabiddle SJ. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):61–6 (36 ref.)

Persistent visceral pain in adolescents. Zeltzer L, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):92–8

Having a future: sexual decision making in early adolescence. Monsen RB, et al. **J Pediatr Nurs** 1996 Jun;11(3):183–8

Decision making and risk behaviors of cancer-surviving adolescents and their peers. Hollen PJ, et al. **J Pediatr Oncol Nurs** 1996 Jul;13(3):121–33; discussion 135–7

Combating the illusion of adolescent invincibility to HIV/AIDS. Crosby RA. **J Sch Health** 1996 May; 66(5):186–90

Coping styles among adolescent competitive athletes. Anshel M. **J Soc Psychol** 1996 Jun;136(3):311–23

Effect of sex role identity on academic achievement of late adolescents in India. Basu J, et al. **J Soc Psychol** 1996 Apr; 136(2):257–9

Sports participation and emotional wellbeing in adolescents [see comments] Steptoe A, et al. **Lancet** 1996 Jun 29; 347(9018):1789–92. Comment in: Lancet 1996 Jun 29;347(9018):1779.

Marketing adolescent tobacco addiction. Tye J, et al. **Md Med J** 1995 Oct;44(10):767–73 (29 ref.)

Geographical distance from parents and adjustment during adolescence and young adulthood. Dubas JS, et al. **New Dir Child Dev** 1996 Spring;(71):3–19

Timing of childhood events early-adult household formation. Hill MS, et al. **New Dir Child Dev** 1996 Spring;(71):87–109

Precepts and practices: researching identity formation among Indian Hindu adolescents in the United States. Miller BD. **New Dir Child Dev** 1995 Spring;(67):71–85

Adolescent-parent relationships and leaving home in young adulthood. O'Connor TG, et al. **New Dir Child Dev** 1996 Spring;(71):39–52

Leaving the parental home: predictors for young adults raised in former East and West Germany. Silbereisen RK, et al. **New Dir Child Dev** 1996 Spring;(71):71–86

Leaving home at an early age among females. Stattin H, et al. **New Dir Child Dev** 1996 Spring;(71):53–69

Negative self-perception and components of stress in Canadian, British, and Hong Kong adolescents. Bagley C, et al. **Percept Mot Skills** 1995 Aug;81(1):123–7

Adolescent perceptions of body weight and weight satisfaction. Page RM, et al. **Percept Mot Skills** 1995 Aug; 81(1):81–2

Gender differences in teachers' behaviors in relation to adolescents' self-concepts. Mboya MM. **Psychol Rep** 1995 Dec;77(3 Pt 1):831–9

Fear of weight gain: its correlates among school-aged adolescents. Moore SM, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1305–6

Response to Sputa and Paulson's "Birth order and family size: influences on adolescents' achievement and related parenting behaviors" [comment] Nystul MS. **Psychol Rep** 1995 Jun;76(3 Pt 2):1241–2. Comment on: Psychol Rep 1995 Feb;76(1):43–51.

Relationship of optimism, knowledge, attitudes, and beliefs to use of HIV antibody testing by at-risk female adolescents. Goodman E, et al. **Psychosom Med** 1995 Nov-Dec;57(6):541–6

Adolescent suicide. **Rep Group Adv Psychiatry** 1996; (140):1–184

Predicting self-esteem from perceptions of actual and ideal ratings of body fatness: is there only one ideal "supermodel"? Marsh HW, et al. **Res Q Exerc Sport** 1996 Mar;67(1):13–23

A prospective study of adolescent suicidal behavior following hospitalization. King CA, et al. **Suicide Life Threat Behav** 1995 Fall;25(3):327–38

Psychosocial correlates of suicidal ideation in adolescent psychiatric inpatients. Kumar G, et al. **Suicide Life Threat Behav** 1995 Fall;25(3):339–46

Psychological intervention, spontaneous remission, hopelessness, and psychiatric disturbance in adolescent parasuicides. Pillay AL, et al. **Suicide Life Threat Behav** 1995 Fall;25(3):386–92

[Risk factors related to alcohol use among adolescents of fathers with alcoholism] Yang MS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Dec; 11(12):686–96 (Eng. Abstr.) **(Chi)**

[The effect of violence in the media on children and adolescents from the viewpoint adolescent psychiatry] Malá E. **Ceska Slov Psychiatr** 1995 Feb;91(1):3–6 **(Cze)**

[Depression amd depressive feelings in childhood and adolescence--problems in diagnosis and assessment] Solantaus T. **Duodecim** 1994;110(3):239–51 (69 ref.) **(Fin)**

[White walls for black holes: essay on graffiti psychopathology] Catheline-Antipoff N, et al. **Psychiatr Enfant** 1995;38(2):625–53 (16 ref.) (Eng. Abstr.) **(Fre)**

["I non-exist". Paradoxes of death in adolescence] Chabert C. **Psychiatr Enfant** 1995;38(2):555–71 (Eng. Abstr.) **(Fre)**

[Adolescence: child psychiatry aspects] Steck B. **Rev Med Suisse Romande** 1995 Nov;115(11):869–74 **(Fre)**

[Self image in adolescence: gender differences and areas of psychological distress] Benvenuti P, et al. **Epidemiol Prev** 1996 Apr-Sep;20(2-3):269–71 **(Ita)**

[The social factor that influences the psychological development of childhood and adolescence] Kasahara T. **Seishin Shinkeigaku Zasshi** 1996;98(4):213–21 **(Jpn)**

[Modern family and adolescence] Takikawa K. **Seishin Shinkeigaku Zasshi** 1995;97(8):586–98 (7 ref.) **(Jpn)**

[Children of psychiatric patients--what to do?] Hestmann E, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30;115(23):2891–2 (Eng. Abstr.) **(Nor)**

[Art therapy as an assisting psychotherapeutic method for adolescents] Skowron J, et al. **Psychiatr Pol** 1996 Mar-Apr; 30(2):247–54 (Eng. Abstr.) **(Pol)**

[The personality characteristics of today's adolescents and means for their correction] Sergeta IV, et al. **Gig Sanit** 1996 Jan-Feb;(1):29–31 (Eng. Abstr.) **(Rus)**

[The psychological meaning of the female friend among Mexican adolescents: a gender comparison] González Forteza CF, et al. **Acta Psiquiatr Psicol Am Lat** 1994 Dec; 40(4):308–13 (Eng. Abstr.) **(Spa)**

[Adolescents manage their crises without "happy pills" (letter)] Berggren I. **Lakartidningen** 1996 Jan 17;93(3):123 **(Swe)**

[The characteristics of the formation and development of psychophysiological functions in ontogeny (Cherkassy, 24-27 October 1995)] Makarenko MV, et al. **Fiziol Zh** 1995 May-Aug;41(3-4):121-5 **(Ukr)**

STATISTICS & NUMERICAL DATA

Perception of dental and other individual problems: adolescents versus young adults. Assink MH, et al. **Community Dent Oral Epidemiol** 1995 Dec;23(6):369–73

ADOPTION

Depression spectrum disease, I: The role of gene-environment interaction. Cadoret RJ, et al. **Am J Psychiatry** 1996 Jul;153(7):892–9

Genetic-environmental interaction in the genesis of aggressivity and conduct disorders. Cadoret RJ, et al. **Arch Gen Psychiatry** 1995 Nov;52(11):916–24

Replication of the Stockholm Adoption Study of alcoholism. Confirmatory cross-fostering analysis. Sigvardsson S, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):681–7

Should older women be offered in vitro fertilisation? Existing children are treated differently from embryos [letter; comment] Stammers TG. **BMJ** 1995 Sep 9;311(7006):690 . Comment on: BMJ 1995 Jun 3;310(6992):1455–8.

Problems seen in two cases of illegal adoption. de Silva DG, et al. **Ceylon Med J** 1996 Jun;41(2):65–6

An adoption study of drug abuse/dependency in females. Cadoret RJ, et al. **Compr Psychiatry** 1996 Mar-Apr; 37(2):88–94

Preimplantation adoption: establishing pregnancy using donated oocytes and spermatozoa. Sauer MV, et al. **Hum Reprod** 1995 Jun;10(6):1419–22

Health and moral responsibility [letter] Meerstadt PW. **Lancet** 1996 Jun 22;347(9017):1768

The role of the perinatal nurse in open adoption. Fister S, et al. **MCN Am J Matern Child Nurs** 1995 Jan-Feb; 20(1):9–12 (11 ref.)

Medical examination of the internationally adopted child: screening for infectious diseases and developmental delay. Hostetter MK, et al. **Postgrad Med** 1996 Apr;99(4):70–2, 75–7, 81–2

Helping foster children to mourn past relationships. Samuels SC. **Psychoanal Study Child** 1995;50:308–26

Hepatitis B infection in black children from residential care facilities in KwaZulu-Natal. Implications for adoption and foster care. Solarsh GC, et al. **S Afr Med J** 1996 Apr; 86(4):345–9

LEGISLATION & JURISPRUDENCE

Forensic and policy implications of the transracial adoption debate. Griffith EE. **Bull Am Acad Psychiatry Law** 1995; 23(4):501–12

Biological parents regaining their rights: a psycholegal analysis of a new era in custody disputes. Kermani EJ, et al. **Bull Am Acad Psychiatry Law** 1995;23(2):261–7

Accreditation of those who arrange adoptions under the Hague Convention on intercountry adoption as a means of protecting, through private international law, the rights of children. Pierce WL. **J Contemp Health Law Policy** 1996 Spring;12(2):535–61 (31 ref.)

Adoption: an overview. Rhodes AM. **MCN Am J Matern Child Nurs** 1995 Jan-Feb;20(1):7

PSYCHOLOGY

Adoption as a risk factor for mental disorders. Sullivan PF, et al. **Acta Psychiatr Scand** 1995 Aug;92(2):119–24

Adoption and mental health: a theoretical critique of the psychopathological model. Wegar K. **Am J Orthopsychiatry** 1995 Oct;65(4):540–8 (55 ref.)

Genetic and environmental influences on temperament in middle childhood: analyses of teacher and tester ratings. Schmitz S, et al. **Child Dev** 1996 Apr;67(2):409–22

Like father, like son: young children's understanding of how and why offspring resemble their parents. Solomon GE, et al. **Child Dev** 1996 Feb;67(1):151–71

Kids speak out on adoption: a multiage bookwriting group for adopted children with special needs. Moroz KJ. **Child Welfare** 1996 May-Jun;75(3):235–51

Parent and sibling influences on adolescent alcohol use and misuse: evidence from a U.S. adoption cohort. McGue M, et al. **J Stud Alcohol** 1996 Jan;57(1):8–18

[Reflections on international adoption] Laurent A, et al. **Ann Med Psychol (Paris)** 1995 Oct;153(8):528–30; discussion 531 (2 ref.) (Eng. Abstr.) **(Fre)**

[The presence of absent persons: the identification changes of an adopted child] Sanzana A, et al. **Psychiatr Enfant** 1995;38(1):69–107 (Eng. Abstr.) **(Fre)**

ADOPTIVE CELL TRANSFER

ADOPTIVE CELL TRANSFER see **IMMUNOTHERAPY, ADOPTIVE**

ADOPTIVE CELLULAR IMMUNOTHERAPY see **IMMUNOTHERAPY, ADOPTIVE**

ADOSTEROL

DIAGNOSTIC USE

131I-6 beta-iodomethylnorcholesterol scintigraphy: an assessment of its role in the investigation of adrenocortical incidentalomas. Bardet S, et al. **Clin Endocrinol (Oxf)** 1996 May;44(5):587-96

Atlas of iodocholesterol scintigraphy (NP-59) in Cushing's syndrome with CT and MR correlation. Yu KC, et al. **Clin Nucl Med** 1996 Feb;21(2):136-41

Role of preoperative iodocholesterol scintiscanning in patients undergoing adrenalectomy for Cushing's syndrome. Yu KC, et al. **Surgery** 1995 Dec;118(6):981-6; discussion 986-7

ADP see **ADENOSINE DIPHOSPHATE**

ADP,ATP CARRIER see **ADENINE NUCLEOTIDE TRANSLOCASE**

ADP,ATP TRANSLOCATOR PROTEIN see **ADENINE NUCLEOTIDE TRANSLOCASE**

ADP GLUCOSE STARCH GLUCOSYLTRANSFERASE see **STARCH (BACTERIAL GLYCOGEN) SYNTHASE**

ADP RECEPTORS see **RECEPTORS, PURINERGIC P2**

ADP RIBOSE see **ADENOSINE DIPHOSPHATE RIBOSE**

ADP-RIBOSYLTRANSFERASE (POLYMERIZING) see **NAD+ ADP-RIBOSYLTRANSFERASE**

ADPASE see **APYRASE**

ADRENAL CORTEX

Papers presented at the 6th Conference on the Adrenal Cortex. Ardmore, Oklahoma, June 21-24, 1994. **Endocr Res** 1995 Feb-May;21(1-2):v-xx, 1-524

Infection with Mycobacterium abscessus associated with intramuscular injection of adrenal cortex extract--Colorado and Wyoming, 1995-1996. **MMWR Morb Mortal Wkly Rep** 1996 Aug 23;45(33):713-5

Pituitary choristoma composed of corticotrophs and adrenocortical cells in the sella turcica. Oka H, et al. **Virchows Arch** 1996 Mar;427(6):613-7

ANATOMY & HISTOLOGY

Comparison of adrenocortical zonation in C57BL/6J and DDD mice. Tanaka S, et al. **Exp Anim** 1995 Oct; 44(4):285-91

Genetic regulation of border zone formation in female mastomys (Praomys coucha) adrenal cortex. Tanaka S, et al. **J Hered** 1996 Jan-Feb;87(1):70-4

CHEMISTRY

Evidence for presence of a reduced form of digoxin-like immunoreactive factor (dihydro-DLIF) in mammalian tissues. Qazzaz HM, et al. **Clin Chem** 1996 Jul;42(7):1092-9

Sequences promoting the transcription of the human XA gene overlapping P450c21A correctly predict the presence of a novel, adrenal-specific, truncated form of tenascin-X. Tee MK, et al. **Genomics** 1995 Jul 20;28(2):171-8

Localization and regulation of corticotropin receptor expression in the midgestation human fetal adrenal cortex: implications for in utero homeostasis. Mesiano S, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):340-5

[Adrenal cortical lipids in sudden death from ischemic heart disease and death from mechanical trauma (the forensic medical diagnosis of stress)] Alisievich VI. **Sud Med Ekspert** 1995 Oct-Dec;38(4):3-8 (Eng. Abstr.) **(Rus)**

CYTOLOGY

Apoptotic cell death in the rat adrenal gland: an in vivo and in vitro investigation. Carsia RV, et al. **Cell Tissue Res** 1996 Feb;283(2):247-54

Rapid ras-oncogene-mediated transformation maintains steroidogenic differentiation in adrenocortical parenchymal cells. Roskelley CD, et al. **Differentiation** 1995 Sep; 59(2):103-11

Increased expression of p21Sdi1 in adrenocortical cells when they are placed in culture. Yang L, et al. **Exp Cell Res** 1995 Nov;221(1):126-31

Reactivity of the cells of the adrenal cortex under experimental conditions. Popova L, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):61

Cell proliferation and renewal of mouse adrenal cortex. Kataoka Y, et al. **J Anat** 1996 Apr;188 (Pt 2):375-81

Variegated expression of a mouse steroid 21-hydroxylase/beta- galactosidase transgene suggests centripetal migration of adrenocortical cells. Morley SD, et al. **Mol Endocrinol** 1996 May;10(5):585-98

DRUG EFFECTS

Ultrastructural variations of the rat fetal adrenal cortex after maternal bilateral adrenalectomy and exogen glucocorticoid administration. Machin C, et al. **Acta Biol Hung** 1995;46(1):87-98

Activation of the baboon fetal pituitary-adrenocortical axis at midgestation by estrogen: responsivity of the fetal adrenal gland to adrenocorticotropic hormone in vitro. Berghorn KA, et al. **Biol Reprod** 1995 Nov;53(5):996-1002

Interleukin-1 beta, but not IL-1 alpha, stimulates cell proliferation in the adrenal cortex. Zieleniewski W, et al. **Cytobios** 1995;84(338-339):199-204

Hormonal regulation of angiotensin II type 1 receptor expression and AT1-R mRNA levels in human adrenocortical cells. Bird IM, et al. **Endocr Res** 1995 Feb-May;21(1-2):169-82

The effects of KN62, a Ca2+/calmodulin-dependent protein kinase II inhibitor, on adrenocortical cell aldosterone production. Clyne CD, et al. **Endocr Res** 1995 Feb-May; 21(1-2):259-65

Acetylcholine induces oscillations in intracellular calcium in isolated bovine adrenal zona fasciculata/reticularis cells. Clyne CD, et al. **Endocr Res** 1995 Feb-May;21(1-2):53-60

Sex differences in the steroidogenic and respiratory electron transport chains in the rat adrenal cortex. el-Migdadi F, et al. **Endocr Res** 1995 Feb-May;21(1-2):109-14

A comparison of effects of triamcinolone acetonide aqueous nasal spray, oral prednisone, and placebo on adrenocortical function in male patients with allergic rhinitis. Howland WC 3rd, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):32-8

Effects of phenobarbital administration on results of serum biochemical analyses and adrenocortical function tests in epileptic dogs. Chauvet AE, et al. **J Am Vet Med Assoc** 1995 Nov 15;207(10):1305-7

Repression of transforming growth factor beta 1 protein by antisense oligonucleotide-induced increase of adrenal cell differentiated functions. Le Roy C, et al. **J Biol Chem** 1996 May 3;271(18):11027-33

Pituitary adenylate-cyclase activating peptide enhances aldosterone secretion of human adrenal gland: evidence for an indirect mechanism, probably involving the local release of catecholamines. Neri G, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):169-73

Cholera toxin directly stimulates pregnenolone generation with increasing Ca2+ efflux in bovine adrenocortical mitochondria. Nishikawa T, et al. **J Steroid Biochem Mol Biol** 1993 Aug;46(2):203-8

Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Todd G, et al. **Lancet** 1996 Jul 6;348(9019):27-9

Effect of indomethacin on the CRH- and VP-induced pituitary-adrenocortical response during social stress. Bugajski J, et al. **Life Sci** 1996;58(5):PL 67-72

Transplacental toxicity of 3-methylsulphonyl-DDE in the developing adrenal cortex in mice. Jönsson J, et al. **Reprod Toxicol** 1995 May-Jun;9(3):257-64

Effects of oxytocin on the function and morphology of the rat adrenal cortex: in vitro and in vivo investigations. Stachowiak A, et al. **Res Exp Med (Berl)** 1995; 195(5):265-74

Increased plasma corticosterone levels in bovine growth hormone (bGH) transgenic mice: effects of ACTH, GH and IGF-I on in vitro adrenal corticosterone production. Cecim M, et al. **Transgenic Res** 1996 May;5(3):187-92

Toxic effects of butylated triphenyl phosphate-based hydraulic fluid and tricresyl phosphate in female F344 rats. Latendresse JR, et al. **Vet Pathol** 1995 Jul;32(4):394-402

[Clinical manifestation of adrenal cortex insufficiency during thyroid hormone substitution] Soest R, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):406-8 (Eng. Abstr.) **(Ger)**

[The effect of reserpine on epiphysial-adrenocortical relations] Arushanian EB, et al. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):17-8 (Eng. Abstr.) **(Rus)**

[The antihypertensive activity of benazepril in the long-term treatment of hypertension patients and its effect on adrenal cortical function] Ol'binskaia LI, et al. **Ter Arkh** 1995; 67(9):56-8 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Inhibition of ACTH secretion blocks hypoxia-induced increase of adrenal cortical blood flow in fetal sheep. Carter AM, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E598-604

Activation of the baboon fetal pituitary-adrenocortical axis at midgestation by estrogen: responsivity of the fetal adrenal gland to adrenocorticotropic hormone in vitro. Berghorn KA, et al. **Biol Reprod** 1995 Nov;53(5):996-1002

ENZYMOLOGY

Electron paramagnetic resonance investigation of cytochrome P-450c21 from bovine adrenocortical microsomes: a new enzymatic activity. Tsubaki M, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):89-98

Human adrenal CYP11B1: localization by in situ-hybridization and functional expression in cell cultures. Erdmann B, et al. **Endocr Res** 1995 Feb-May; 21(1-2):425-35

P450aldo in hamster adrenal cortex: immunofluorescent and immuno-gold electron microscopic studies. LeHoux JG, et al. **Endocr Res** 1995 Feb-May;21(1-2):275-80

Cytochrome c oxidase in rat adrenal and liver: effects of anti-androgen treatment and studies in testicular feminized rats. el-Migdadi F, et al. **Endocr Res** 1996 Feb;22(1):59-75

Ca(2+)-regulated expression of steroid hydroxylases in H295R human adrenocortical cells. Bird IM, et al. **Endocrinology** 1995 Dec;136(12):5677-84

Regulation of cytochrome P4501B1 in cultured rat adrenocortical cells by cyclic adenosine 3',5'-monophosphate and 2,3,7,8-tetrachlorodibenzo-p-dioxin. Brake PB, et al. **Endocrinology** 1995 Nov;136(11):5034-41

Adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia: immunohistochemical studies of steroidogenic enzymes and post-operative course in two men. Wada N, et al. **Eur J Endocrinol** 1996 May; 134(5):583-7

Zone-specific localization of cytochrome P45011B1 in human adrenal tissue by PCR-derived riboprobes. Erdmann B, et al. **Histochem Cell Biol** 1995 Oct; 104(4):301-7

Expression and regulation of the lipoprotein lipase gene in human adrenal cortex. Staels B, et al. **J Biol Chem** 1996 Jul 19;271(29):17425-32

Some effects of a low sodium intake on the expression of P450 aldosterone synthase in the hamster adrenal cortex: immunoblotting, immunofluorescent and immuno-gold electron microscopic studies. LeHoux JG, et al. **J Endocrinol** 1996 May;149(2):341-9

Organization of 3 beta-hydroxysteroid dehydrogenase/isomerase and cytochrome P450scc into a catalytically active molecular complex in bovine adrenocortical mitochondria. Cherradi N, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(5-6):507-14

Differentiation of the expression of aldosterone synthase and 11 beta-hydroxylase mRNA in the rat adrenal cortex by reverse transcriptase-polymerase chain reaction. Oaks MK, et al. **J Steroid Biochem Mol Biol** 1995 Sep;54(5-6):193-9

Molecular cloning and nucleotide sequences of cDNA clones of sheep and goat adrenocortical cytochromes P450scc (CYP11A1). Okuyama E, et al. **J Steroid Biochem Mol Biol** 1996 Feb;57(3-4):179-85

Effect of glycosylation on cloned ANF-sensitive guanylyl cyclase. Heim JM, et al. **Life Sci** 1996;59(4):PL61-8

Sex differences in cytochromes oxidase and P-45011 beta in the rat adrenal cortex. el-Migdadi F, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):185-94

Ontogeny of immunoreactive and bioactive microsomal steroidogenic enzymes during adrenocortical development in rats. Nagaya M, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1-2):27-34

Transcriptional regulation of P450scc gene expression in neural and steroidogenic cells: implications for regulation of neurosteroidogenesis. Zhang P, et al. **Mol Endocrinol** 1995 Nov;9(11):1571-82

GROWTH & DEVELOPMENT

The development of the adrenal cortex in the rat. An immunohistochemical study. Pignatelli D, et al. **Endocr Res** 1995 Feb-May;21(1-2):129-36

Blunted adrenarche in patients with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Sellers EP, et al. **Endocr Res** 1995 Aug;21(3):537-44

Ontogeny of immunoreactive and bioactive microsomal steroidogenic enzymes during adrenocortical development in rats. Nagaya M, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1-2):27-34

IMMUNOLOGY

ACTH response to a low dose but not a high dose of bacterial endotoxin in rats is completely mediated by corticotropin-releasing hormone. Schotanus K, et al. **Neuroimmunomodulation** 1994 Sep-Oct;1(5):300-7

Sex steroid regulation of the hypothalamo-pituitary-adrenal axis activity in middle-aged mice during endotoxic shock. Suescun M, et al. **Neuroimmunomodulation** 1994 Sep-Oct; 1(5):315-20

Scintigraphy and biodistribution of monoclonal adrenocortical antibody in mice grafted with human adrenocortical carcinoma. Ohrvall U, et al. **Surgery** 1995 Nov;118(5):893-900

INJURIES

Expression of p21(WAF1/CIP1/SDI1) and p53 in apoptotic cells in the adrenal cortex and induction by ischemia/reperfusion injury. Didenko VV, et al. **J Clin Invest** 1996 Apr 1;97(7):1723-31

METABOLISM

Indomethacin, esculetin and nordihydroguaiaretic acid modify arachidonate biosynthesis in rat adrenocortical cells. de Gómez Dumm NT, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(3):155-64

Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Hornsby PJ. **Ann N Y Acad Sci** 1995 Dec 29;774:29-46 (64 ref.)

Immunohistochemical expression of insulin-like growth factor 1 and its receptor in normal and neoplastic human adrenal cortex. Backlin C, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2453-9

A lipid droplet-specific capsule is present in rat adrenal cells: evidence from a monoclonal antibody. Wang SM, et al.

Biochem Biophys Res Commun 1995 Dec 5;217(1):81–8

Expression of DAX–1, the gene responsible for X–linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism, in the hypothalamic–pituitary–adrenal/gonadal axis. Guo W, et al. **Biochem Mol Med** 1995 Oct;56(1):8–13

An inositol phosphoglycan from Trypanosoma cruzi inhibits ACTH action in calf adrenocortical cells. Vila MC, et al. **Cell Signal** 1995 May;7(4):331–9

Rapid ras–oncogene–mediated transformation maintains steroidogenic differentiation in adrenocortical parenchymal cells. Roskelley CD, et al. **Differentiation** 1995 Sep; 59(2):103–11

Adrenocorticotropic hormone–independent bilateral adrenocortical macronodular hyperplasia: a case report and immunohistochemical studies. Koizumi S, et al. **Endocr J** 1994 Aug;41(4):429–35

Sympathoadrenal regulation of adrenocortical steroidogenesis. Ehrhart–Bornstein M, et al. **Endocr Res** 1995 Feb–May;21(1–2):13–24

Evidence for fibroblast growth factor mediation of compensatory adrenocortical proliferation. Holzwarth MA. **Endocr Res** 1995 Feb–May;21(1–2):115–9

In vivo studies of the control of DNA synthesis in the rat adrenal cortex and medulla. McEwan PE, et al. **Endocr Res** 1995 Feb–May;21(1–2):91–102

Adrenal–specific transgene expression and derivation of conditionally immortal rat adrenocortical cell lines. Morley SD, et al. **Endocr Res** 1995 Feb–May;21(1–2):353–7

Characterization and identification of an adrenal age–related nonpolar fluorescent substance. Cheng B, et al. **Endocrinology** 1996 Jun;137(6):2447–56

Ouabain production by cultured adrenal cells. Doris PA, et al. **Endocrinology** 1996 Feb;137(2):533–9

Thrombospondins selectively activate one of the two latent forms of transforming growth factor–beta present in adrenocortical cell–conditioned medium. Souchelnitskiy S, et al. **Endocrinology** 1995 Nov;136(11):5118–26

Selective increases in adrenal steroidogenic capacity during acute respiratory disease in infants. Hanukoglu A, et al. **Eur J Endocrinol** 1995 Nov;133(5):552–6

Expression of sterol carrier protein 2 (SCP2) in human adrenocortical tissue. Yanase T, et al. **Eur J Endocrinol** 1996 Apr;134(4):501–7

Effect of interleukin–1a, IL–1b and IL–1 receptor antibody on the proliferation and steroidogenesis of regenerating rat adrenal cortex. Zieleniewski W, et al. **Exp Clin Endocrinol Diabetes** 1995;103(6):373–7

Effect of histamine on corticosteroid secretion of isolated human and rat adrenocortical cells. Orsó E, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S48–9

Expression of p21(WAF1/CIP1/SDI1) and p53 in apoptotic cells in the adrenal cortex and induction by ischemia/reperfusion injury. Didenko VV, et al. **J Clin Invest** 1996 Apr 1;97(7):1723–31

Specific inhibition of the last steps of aldosterone biosynthesis by 18–vinylprogesterone in bovine adrenocortical cells. Defaye G, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1–2):141–7

Glucocorticoids enhance the cholesterol side–chain cleavage activity of ovine adrenocortical mitochondria. Picard–Hagen N, et al. **J Steroid Biochem Mol Biol** 1995 Oct;55(1):57–65

Physiological significance of plasma sulfoconjugated dopamine in patients with hypertension—clinical and experimental studies. Yoshizumi M, et al. **Life Sci** 1996; 59(4):324–30

Protein import into mammalian mitochondria. Mihara K, et al. **Methods Enzymol** 1995;260:302–10

Impairment of adrenocortical function associated with increased plasma tumor necrosis factor–alpha and interleukin–6 concentrations in African trypanosomiasis. Reincke M, et al. **Neuroimmunomodulation** 1994 Jan; 1(1):14–22

Uncoupling of the noradrenergic–hypothalamic–pituitary–adrenal axis in panic disorder patients. Coplan JD, et al. **Neuropsychopharmacology** 1995 Aug;13(1):65–73

Expression of c–fos oncogenes in adrenal cortex of the rat with renal hypertension. Gao JY, et al. **Tissue Cell** 1995 Oct;27(5):499–503

[Interaction of 2Fe–2S–ferredoxins from plants and adrenal cortex with detergents] Mardanian SS, et al. **Biokhimiia** 1995 Jul;60(7):1055–61 (Eng. Abstr.) **(Rus)**

[Phosphorylation of adrenal cortex proteins by protein kinase C induced by prolactin] Sautin IuIu, et al. **Biokhimiia** 1996 Jan;61(1):34–41 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Adrenocortical adenoma containing a fat component: CT and MR image evaluation. Sato N, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):489–90

ACTH independent Cushing's syndrome occurring in siblings. Minami S, et al. **Clin Endocrinol (Oxf)** 1996 Apr; 44(4):483–8

Autonomous nodular hyperplasia of the adrenal cortex: tertiary hypercortisolism? Sturrock ND, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):753–8

Adrenocorticotropin–independent bilateral macronodular adrenocortical hyperplasia: immunohistochemical studies of steroidogenic enzymes and post–operative course in two men. Wada N, et al. **Eur J Endocrinol** 1996 May; 134(5):583–7

Comparison of the histological changes in the dog after treatment with the progestins medroxyprogesterone acetate and proligestone. Selman PJ, et al. **Vet Q** 1995 Dec; 17(4):128–33

[Morphological typing, evaluation of tumor dignity and prognosis and etiologic classification of adrenomedullary and adrenocortical neoplasias] Schröder S, et al. **Pathologe** 1995 Sep;16(5):307–14 (57 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Potential interactions between nimodipine and adrenal hormones. Isaacson RL, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:134–42; discussion 160–2 (29 ref.)

Emotional response and corticoadrenal function in anterodorsal thalami nuclei lesioned rats. Dal Zotto S, et al. **Arch Physiol Biochem** 1995 Aug;103(4):497–501

Regulation of angiotensinogen gene expression in the rat forebrain by adrenal steroids and relation to salt appetite. Riftina F, et al. **Brain Res Mol Brain Res** 1995 Nov; 33(2):201–8

The 1994 Upjohn Award Lecture. Molecular and genetic approaches to the study of signal transduction in the adrenal cortex. Schimmer BP. **Can J Physiol Pharmacol** 1995 Aug;73(8):1097–107 (83 ref.)

Dampening of adrenocortical responses during infancy: normative changes and individual differences. Gunnar MR, et al. **Child Dev** 1996 Jun;67(3):877–89

Localization of P450aldo and P45011 beta in normal and regenerating rat adrenal cortex. Mitani F, et al. **Endocr Res** 1995 Feb–May;21(1–2):413–23

Seasonal and acute changes in adrenocortical responsiveness in an arctic–breeding bird. Astheimer LB, et al. **Horm Behav** 1995 Dec;29(4):442–57

Effect of adrenalectomy and adrenalectomy + hydrocortisone treatment on histopathological, biochemical and zinc and copper profiles in rat testes. Nair N, et al. **Indian J Exp Biol** 1995 Sep;33(9):655–63

The transient outward current of isolated bovine adrenal zona fasciculata cells: comparison between standard and perforated patch recording methods. Bilbaut A, et al. **J Membr Biol** 1996 Feb;149(3):233–47

Contribution of the ventral subiculum to inhibitory regulation of the hypothalamo–pituitary–adrenocortical axis. Herman JP, et al. **J Neuroendocrinol** 1995 Jun;7(6):475–82

The effect of bilateral fetal adrenalectomy on fluid balance in the ovine fetus. Benson CA, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):235–41

The roles of microfilaments and intermediate filaments in the regulation of steroid synthesis. Hall PF. **J Steroid Biochem Mol Biol** 1995 Dec;55(5–6):601–5

Serotonin and the regulation of hypothalamic–pituitary–adrenal axis function. Dinan TG. **Life Sci** 1996;58(20):1683–94 (146 ref.)

Local transfer of hormones between blood vessels within the adrenal gland may explain the functional interaction between the adrenal cortex and medulla. Einer–Jensen N, et al. **Med Hypotheses** 1995 Jun;44(6):471–4

Targeted ablation of pituitary pre–proopiomelanocortin cells by herpes simplex virus–1 thymidine kinase differentially regulates mRNAs encoding the adrenocorticotropin receptor and aldosterone synthase in the mouse adrenal gland. Allen RG, et al. **Mol Endocrinol** 1995 Aug; 9(8):1005–16

Angiotensin II regulates both adrenocortical and adrenomedullary function in isolated perfused pig adrenals. Breidert M, et al. **Peptides** 1996;17(2):287–92

PHYSIOPATHOLOGY

Adult male rats exposed to an alcohol diet exhibit a blunted adrenocorticotropic hormone response to immune or physical stress: possible role of nitric oxide. Rivier C. **Alcohol Clin Exp Res** 1995 Dec;19(6):1474–9

Antidepressants and hypothalamic–pituitary–adrenocortical regulation. Holsboer F, et al. **Endocr Rev** 1996 Apr; 17(2):187–205 (237 ref.)

Adrenocortical function during septic shock. Bouachour G, et al. **Intensive Care Med** 1995 Jan;21(1):57–62

Evidence for a hypothalamic–pituitary versus adrenal cortical effect of glycemic control on counterregulatory hormone responses to hypoglycemia in insulin–dependent diabetes mellitus. Kinsley BT, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):684–91

Short–term night–shift working mimics the pituitary–adrenocortical dysfunction in chronic fatigue syndrome. Leese G, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1867–70

Stress–induced changes in blood leukocyte distribution. Role of adrenal steroid hormones. Dhabhar FS, et al. **J Immunol** 1996 Aug 15;157(4):1638–44

Hypothalamic–pituitary–adrenal response to chronic stress in five inbred rat strains: differential responses are mainly located at the adrenocortical level. Gómez F, et al. **Neuroendocrinology** 1996 Apr;63(4):327–37

Adrenocortical and behavioral predictors of immune responses to starting school. Boyce WT, et al. **Pediatr Res** 1995 Dec;38(6):1009–17

RADIONUCLIDE IMAGING

Scintigraphic diagnosis of subclinical Cushing's syndrome in patients with adrenal incidentalomas. Dominguez–Gadea L, et al. **Nucl Med Commun** 1996 Jan;17(1):29–32

SECRETION

Comprehensive adrenocortical steroid measurements in two cases of Schmidt's syndrome. Tanaka T, et al. **Endocr J** 1994 Aug;41(4):379–86

Zonation, paracrine function and aldosterone secretion in the rat adrenal cortex. Vinson GP, et al. **Endocr Res** 1995 Feb–May;21(1–2):1–12

Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Belloni AS, et al. **Hypertension** 1996 May;27(5):1153–9

Adrenocortical suppression blocks the memory–enhancing effects of amphetamine and epinephrine. Roozendaal B, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1429–33

Increase of aldosterone secretion in adrenal cortex suspensions derived from pregnant rats. Brochu M, et al. **Proc Soc Exp Biol Med** 1996 Jun;212(2):147–52

Stimulation of gastric proteases in the neonatal pig by a rise in adrenocortical secretion at parturition. Sangild PT. **Reprod Fertil Dev** 1995;7(5):1293–8

TRANSPLANTATION

Update on cellular transplantation into the CNS as a novel therapy for chronic pain. Czech KA, et al. **Prog Neurobiol** 1995 Aug;46(5):507–29 (126 ref.)

ULTRASTRUCTURE

Ultrastructural variations of the rat fetal adrenal cortex after maternal bilateral adrenalectomy and exogen glucocorticoid administration. Machin C, et al. **Acta Biol Hung** 1995;46(1):87–98

Novel nuclear ribonucleoprotein structural components in the dormouse adrenal cortex during hibernation. Malatesta M, et al. **Chromosoma** 1995 Nov;104(2):121–8

Activation of 5–hydroxytryptamine4 receptors causes calcium influx in adrenocortical cells: involvement of calcium in 5–hydroxytryptamine–induced steroid secretion. Contesse V, et al. **Mol Pharmacol** 1996 Mar;49(3):481–93

ADRENAL CORTEX DISEASES

BLOOD

Corticosteroids in human blood: IX. Evidence for adrenal secretion of sulfate–conjugated cortisol, 11 beta,17 alpha–dihydroxy–4–pregnene–3,20–dione–21–yl–sulfate. Kornel L, et al. **Steroids** 1995 Dec;60(12):817–23

DIAGNOSIS

Adrenal cortical and medullary imaging. Freitas JE. **Semin Nucl Med** 1995 Jul;25(3):235–30 (63 ref.)

[Acute adrenal cortex insufficiency and spondylodiscitis caused by reactivated pulmonary tuberculosis] Roth J, et al. **Med Klin** 1995 Dec 15;90(12):698–700 **(Ger)**

METABOLISM

Molecular mechanisms of glucocorticoid resistance. Ray DW. **J Endocrinol** 1996 Apr;149(1):1–5

VETERINARY

Polyglandular deficiency syndrome in a boxer dog: thyroid hormone and glucocorticoid deficiency. Kooistra HS, et al. **Vet Q** 1995 Jun;17(2):59–63

ADRENAL CORTEX FUNCTION TESTS

[Tests of adrenal gland and ovarian function in the hyperandrogenemia syndrome] Giljević Z. **Lijec Vjesn** 1996 Mar;118 Suppl 1:53–6 (Eng. Abstr.) **(Scr)**

VETERINARY

Effect of exogenous adrenocorticotropic hormone administration on plasma corticosterone concentrations in American black ducks (Anas rubripes). Spelman LH, et al. **J Wildl Dis** 1995 Apr;31(2):136–41

Use of ACTH stimulation tests to monitor the treatment of canine hyperadrenocorticism. Dunn KJ, et al. **Vet Rec** 1995 Aug 12;137(7):161–5

ADRENAL CORTEX HORMONES

see related
ADRENAL GLAND HYPERFUNCTION
ADRENAL GLAND HYPOFUNCTION
RECEPTORS, GLUCOCORTICOID

History of chicken pox and steroid cards: a new warning? [see comments] Feher MD, et al. **BMJ** 1996 Mar 2; 312(7030):542–3. Comment in: BMJ 1996 Jun 22;312(7046):1608. Comment in: BMJ 1996 Jun 22;312(7046):1608–9.

Four decades of topical corticosteroid assessment. Smith EW. **Curr Probl Dermatol** 1995;22:124–31 (10 ref.)

Ouabain: a new steroid hormone? Nicholls MG, et al. **Lancet** 1995 Nov 25;346(8987):1381–2

[Corticoid resistance in asthma] Perrin–Fayolle M, et al. **Rev Pneumol Clin** 1996;52(2):150–8 (43 ref.) (Eng. Abstr.)

ADRENAL CORTEX HORMONES

(Fre)

ADMINISTRATION & DOSAGE

Asthma treatment in pregnancy: a randomized controlled study. Wendel PJ, et al. **Am J Obstet Gynecol** 1996 Jul; 175(1):150–4

A meta-analysis on the efficacy of epidural corticosteroids in the treatment of sciatica. Watts RW, et al. **Anaesth Intensive Care** 1995 Oct;23(5):564–9

Inhaled steroids in acute asthma [letter] Kao NL. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):214

Methotrexate as a steroid-sparing agent in Cogan's syndrome: comment on the concise communication by Richardson [letter; comment] Pouchot J, et al. **Arthritis Rheum** 1995 Sep;38(9):1348–9. Comment on: Arthritis Rheum 1994 Oct;37(10):1559–61.

DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Yu C, et al. **Blood** 1995 Dec 1;86(11):4376–81

High-dose cyclosporine and corticosteroids for prophylaxis of acute and chronic graft-versus-host disease. Schwinghammer TL, et al. **Bone Marrow Transplant** 1995 Jul;16(1):147–54

Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Maugars Y, et al. **Br J Rheumatol** 1996 Aug;35(8):767–70

Inhaled corticosteroids in COPD. A light at the end of the tunnel? [editorial; comment] de Guia TS. **Chest** 1995 Dec; 108(6):1486–7. Comment on: Chest 1995 Dec;108(6):1568–71.

Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Firooz A, et al. **Clin Exp Dermatol** 1995 Sep;20(5):363–70 (79 ref.)

Use of antenatal corticosteroids for fetal maturation. Gardner MO, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):106–9 (37 ref.)

Acute irritant dermatitis: effect of short-term topical corticoid treatment. Berardesca E, et al. **Curr Probl Dermatol** 1995;22:86–90

Articular and periarticular corticosteroid injections. **Drug Ther Bull** 1995 Sep;33(9):67–70 (31 ref.)

High dose and low dose systematic corticosteroids are equally efficient in acute severe asthma [letter; comment] Carter E. **Eur Respir J** 1995 Aug;8(8):1435. Comment on: Eur Respir J 1995 Jan;8(1):22–7.

Differences in output from corticosteroid inhalers used with a volumatic spacer. Miller MR, et al. **Eur Respir J** 1995 Oct;8(10):1637–8

Counseling patients about allergic rhinitis. Swanson KA. **J Am Pharm Assoc (Wash)** 1996 May;NS36(5):300–7 (40 ref.)

Inhaled corticosteroids in asthma—star wars [editorial; comment] Sachs MI. **J Asthma** 1996;33(1):1–3. Comment on: J Asthma 1996;33(1):5–16.

Carpal tunnel syndrome: a case of median nerve injection injury and a safe and effective method for injecting the carpal tunnel. Kasten SJ, et al. **J Fam Pract** 1996 Jul; 43(1):79–82

Hypertrophy of the tongue associated with inhaled corticosteroid therapy in premature infants [see comments] Linder N, et al. **J Pediatr** 1995 Oct;127(4):651–3. Comment in: J Pediatr 1996 Jun;128(6):865.

Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. Nikolaizik WH, et al. **J Pediatr** 1996 Feb;128(2):271–4

In-vitro release from corticosteroid ointments [letter] Shah VP, et al. **J Pharm Sci** 1995 Sep;84(9):1139–40

Lumbar and caudal epidural corticosteroid injections. Spaccarelli KC. **Mayo Clin Proc** 1996 Feb;71(2):169–78 (109 ref.)

Prenatal and postnatal: use of corticosteroids. Corbett JV, et al. **MCN Am J Matern Child Nurs** 1995 Nov-Dec; 20(6):346 (9 ref.)

Spine update: epidural steroids [letter; comment] Cabot W. **Spine** 1995 Oct 1;20(19):2173. Comment on: Spine 1995 Apr 1;20(7):845–8.

Contemporary concepts in spine care. Epidural steroid injections. Weinstein SM, et al. **Spine** 1995 Aug 15; 20(16):1842–6 (46 ref.)

Corticosteroid withdrawal after liver transplantation. Punch JD, et al. **Surgery** 1995 Oct;118(4):783–6; discussion 786–8

Corticosteroids inhibit expression of inducible nitric oxide synthase during acute cardiac allograft rejection. Worrall NK, et al. **Transplantation** 1996 Jan 27;61(2):324–8

[Treatment of asthma; are there still questions? (letter; comment)] Ponsioen BP. **Ned Tijdschr Geneeskd** 1996 Mar 2;140(9):508–9. Comment on: Ned Tijdschr Geneeskd 1996 Jan 13;140(2):72–7. **(Dut)**

[Radioguided injection of the lumbar and the first sacral intervertebral foramina] Wybier M, et al. **Ann Radiol (Paris)** 1995;38(4):211–3 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Histopathologic and MRI findings in hypokalemic myopathy induced by glycyrrhizin. Hayashi K, et al. **Acta Neurol Scand** 1995 Aug;92(2):127–31

Steroids do not enhance the risk of developing tuberculosis or other AIDS-related diseases in HIV-infected patients treated for Pneumocystis carinii pneumonia. Martos A, et al. **AIDS** 1995 Sep;9(9):1037–41

Lipocortin-1 autoantibody concentration in children with inflammatory bowel disease. Beattie RM, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):541–5

Cutaneous-mucosal allergic contact reaction due to topical corticosteroids. Gonzalo Garijo MA, et al. **Allergy** 1995 Oct;50(10):833–6

Renal dysplasia associated with in utero exposure to gentamicin and corticosteroids. Hulton SA, et al. **Am J Med Genet** 1995 Jul 31;58(1):91–3

Effect of corticosteroid use before preterm delivery: outcome of periventricular hemorrhage [letter; comment] Ohlsson A, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1078–9. Comment on: Am J Obstet Gynecol 1995 Jul;173(1):322–35.

Inhaled and oral corticosteroids: their effects on bone mineral density in older adults. Marystone JF, et al. **Am J Public Health** 1995 Dec;85(12):1693–5

Adrenal suppression among asthmatic children receiving chronic therapy with inhaled corticosteroid with and without spacer device. Goldberg S, et al. **Ann Allergy Asthma Immunol** 1996 Mar;76(3):234–8

Corticosteroid-induced pancreatitis [letter] Felig DM, et al. **Ann Intern Med** 1996 Jun 1;124(11):1016

Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Sherertz EF. **Arch Dermatol** 1996 Apr;132(4):461, 464 (11 ref.)

Side-effects of drugs used in the treatment of rheumatoid arthritis. Evans PJ, et al. **Biochem Soc Symp** 1995; 61:195–207 (49 ref.)

Chickenpox and steroid cards. Patients need information [letter; comment] Calland D, et al. **BMJ** 1996 Jun 22; 312(7046):1608. Comment on: BMJ 1996 Mar 2;312(7030):542–3.

Chickenpox and steroid cards. Amended card is used in Oxford [letter; comment] Reynolds J, et al. **BMJ** 1996 Jun 22;312(7046):1608–9. Comment on: BMJ 1996 Mar 2;312(7030):542–3.

Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. Walsh LJ, et al. **BMJ** 1996 Aug 10;313(7053):344–6

Bacterial meningitis and cauda equina syndrome after epidural steroid injections. Cooper AB, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):471–4

A case-control study of corticosteroid exposure as a risk factor for clinically-diagnosed depressive disorders in a hospitalized population. Patten SB, et al. **Can J Psychiatry** 1995 Sep;40(7):396–400

Self-reported depressive symptoms in association with medication exposures among medical inpatients: a cross-sectional study. Patten SB, et al. **Can J Psychiatry** 1995 Jun;40(5):264–9

Unusual etiology of cough in a woman with asthma. Sorhage F, et al. **Chest** 1996 Sep;110(3):852–4

Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma. Fahy JV, et al. **Clin Chest Med** 1995 Dec;16(4):715–33 (145 ref.)

Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Firooz A, et al. **Clin Exp Dermatol** 1995 Sep;20(5):363–70 (79 ref.)

The neuropsychiatric complications of corticosteroid therapy. Vincent FM. **Compr Ther** 1995 Sep;21(9):524–8 (22 ref.)

Corticosteroid allergy. Freeman S. **Contact Dermatitis** 1995 Oct;33(4):240–2

Fluticasone propionate sensitivity in a patient with contact allergy to multiple corticosteroids. Venning VA. **Contact Dermatitis** 1995 Jul;33(1):48–9

Contact hypersensitivity to corticosteroids in routine patch test patients. A multi-centre study of the Swiss Contact Dermatitis Research Group. Bircher AJ, et al. **Dermatology** 1995;191(2):109–14

Sensitisation to corticosteroids. Consequences for anti-inflammatory therapy. Dooms-Goossens A. **Drug Saf** 1995 Aug;13(2):123–9 (47 ref.)

Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation. Tarantino A, et al. **Drug Saf** 1995 Sep;13(3):145–56 (120 ref.)

Aortic aneurysms in patients with autoimmune disorders treated with corticosteroids. Sato O, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):366–9 (17 ref.)

Self-reported depressive symptoms following treatment with corticosteroids and sedative-hypnotics. Patten SB, et al. **Int J Psychiatry Med** 1996;26(1):15–24

Reactions to other corticosteroids in patients with positive patch test reactions to budesonide. Wilkinson M, et al. **J Am Acad Dermatol** 1995 Dec;33(6):963–8

Physiologic basis of steroid-induced immunosuppression. Effects on lymphocyte migration to lymph nodes. Sackstein R. **J Fla Med Assoc** 1995 Sep;82(9):613–5 (22 ref.)

Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. Schiff D. **J Neurooncol** 1996 Mar; 27(3):235–40

Spinal epidural lipomatosis as a complication of prolonged corticosteroid therapy. Zentner J, et al. **J Neurosurg Sci** 1995 Mar;39(1):81–5 (23 ref.)

Hypertrophy of the tongue associated with inhaled corticosteroid therapy in premature infants [see comments] Linder N, et al. **J Pediatr** 1995 Oct;127(4):651–3. Comment in: J Pediatr 1996 Jun;128(6):865.

Macroglossia: more than meets the eye [letter; comment] Scheuerle AE. **J Pediatr** 1996 Jun;128(6):865. Comment on: J Pediatr 1995 Oct;127(4):651–3.

Pneumocystis carinii pneumonia associated with inhaled corticosteroids in an immunocompetent child with asthma. Sy ML, et al. **J Pediatr** 1995 Dec;127(6):1000–2

Leukaemia risk in Crohn's disease [letter; comment] Hatake K, et al. **Lancet** 1996 Apr 13;347(9007):1049–50. Comment on: Lancet 1996 Jan 27;347(8996):215–9.

The risk of standardized regimens of corticosteroids for the treatment of leprosy reactions in the field [letter; comment] Richardus JH, et al. **Lepr Rev** 1995 Dec;66(4):328–9. Comment on: Lepr Rev 1991 Jun;62(2):113–21.

Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? [editorial; comment] Sepkowitz KA. **Mayo Clin Proc** 1996 Jan;71(1):102–3. Comment on: Mayo Clin Proc 1996 Jan;71(1):5–13.

Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy [see comments] Yale SH, et al. **Mayo Clin Proc** 1996 Jan;71(1):5–13. Comment in: Mayo Clin Proc 1996 Jan;71(1):102–3.

Peracute disseminated fatal Aspergillus fumigatus sepsis as a complication of corticoid-treated systemic lupus erythematosus. Nenoff P, et al. **Mycoses** 1995 Nov-Dec; 38(11–12):467–71 (21 ref.)

Hypoglycemia and cortisol deficiency associated with low-dose corticosteroid therapy for asthma. Carrel AL, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):921–4

Bacterial pneumonia associated with corticosteroid therapy in three horses. Mair TS. **Vet Rec** 1996 Mar 2;138(9):205–7

[Opportunistic lung infections in patients with chronic obstructive lung disease; a side effect of inhalation steroids? (letter; comment)] Vooren PH. **Ned Tijdschr Geneeskd** 1996 Mar 2;140(9):511–2. Comment on: Ned Tijdschr Geneeskd 1996 Jan 13;140(2):94–8. **(Dut)**

[Growth retardation in an asthmatic child] Saha MT, et al. **Duodecim** 1995;111(5):444–6 **(Fin)**

[Cutaneous candidiasis due to Candida parapsilosis occurring in the course of idiopathic aplastic anemia] Machet MC, et al. **Ann Pathol** 1995;15(4):276–9 (Eng. Abstr.) **(Fre)**

[Maternal corticotherapy . Pharmacology and effect on the fetus] Guillonneau M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):160–7 (53 ref.) (Eng. Abstr.) **(Fre)**

[Benign colonic ulcer. Case report and differential diagnosis] Rexroth G. **Fortschr Med** 1995 Oct 30;113(30):427–30 (Eng. Abstr.) **(Ger)**

[Steroid-induced psychoses] Whitworth AB, et al. **Hautarzt** 1995 Sep;46(9):666–73; quiz 672 (34 ref.) **(Ger)**

[Reactivation of tuberculosis by use of inhaled steroid (letter)] Kropp R. **Pneumologie** 1995 Dec;49(12):704 **(Ger)**

[Drug induced obesity] Murakami T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:425–9 (16 ref.) **(Jpn)**

[Long-term corticosteroid therapy as a risk factor of osteoporosis in patients with asthma and chronic bronchitis] Kołaczkowska M, et al. **Pneumonol Alergol Pol** 1996; 64(3–4):196–203 (Eng. Abstr.) **(Pol)**

[Corticosteroid therapy and aseptic bone necrosis in patients with rheumatoid arthritis] Tsurko VV, et al. **Ter Arkh** 1995; 67(7):71–4 (Eng. Abstr.) **(Rus)**

[Fever as expression of corticoid withdrawal syndrome in chronic obstructive pulmonary disease (letter)] Suárez Ortega S, et al. **An Med Interna** 1996 Mar;13(3):153–4 **(Spa)**

[Dysphonia produced by corticoid inhalation: truth or myth?] Bonet Agustí M, et al. **Arch Bronconeumol** 1995 Oct; 31(8):415–7 (10 ref.) (Eng. Abstr.) **(Spa)**

[Intranasal steroids and perforation of the septum. An overlooked complication?] Cervin A, et al. **Lakartidningen** 1996 Jun 26;93(26–27):2515–7 **(Swe)**

[Drug induced tetraparesis and loss of myosin. Mild types are probably overlooked] Larsson L, et al. **Lakartidningen** 1996 Jun 5;93(23):2249–54 **(Swe)**

ANALYSIS

Steroids in human intrauterine fluids of early pregnancy. Atkinson G, et al. **Clin Endocrinol (Oxf)** 1996 Apr; 44(4):435–40

High-performance liquid chromatographic analysis of corticosteroids. Volin P. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):319–40 (162 ref.)

ANTAGONISTS & INHIBITORS

[Corticoid-resistant rejection and humoral rejection. The diagnostic criteria and therapeutic management] Crespo Leiro MG, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:77–85 (29 ref.) (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Sympathoadrenal regulation of adrenocortical steroidogenesis. Ehrhart-Bornstein M, et al. **Endocr Res** 1995 Feb-May;21(1–2):13–24

Potassium induces multiple steroidogenic enzymes in cultured rat zona glomerulosa cells. Yagci A, et al. **Endocrinology** 1996 Jun;137(6):2406–14

[Biosynthesis of steroids in the adrenal gland] Plavšić V. **Lijec Vjesn** 1996 Mar;118 Suppl 1:9–10 (Eng. Abstr.) **(Scr)**

BLOOD

Vital exhaustion, anger expression, and pituitary and

adrenocortical hormones. Implications for the insulin resistance syndrome. Keltikangas-Järvinen L, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):275-80

Responses of plasma adrenocortical steroids to low dose ACTH in normal subjects. Daidoh H, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):311-5

Effects of gonadal androgens and oestrogens on adrenal androgen levels [see comments] Polderman KH, et al. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):415-21. Comment in: Clin Endocrinol (Oxf) 1996 Apr;44(4):490-1.

Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with the CD4 cell counts. Laudat A, et al. **Eur J Endocrinol** 1995 Oct;133(4):418-24

Factitious hypercortisoluria. Workman RJ, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3050-1

Do the salutary effects of food restriction occur because of or despite of the accompanying hyperadrenocorticism? Sapolsky RM. **Neurobiol Aging** 1995 Sep-Oct;16(5):849-50; discussion 855-6 (5 ref.)

Corticosteroids in human blood: IX. Evidence for adrenal secretion of sulfate-conjugated cortisol, 11 beta,17 alpha-dihydroxy-4-pregnene-3,20-dione-21-yl-sulfate. Kornel L, et al. **Steroids** 1995 Dec;60(12):817-23

CHEMISTRY

In-vitro release from corticosteroid ointments [letter] Shah VP, et al. **J Pharm Sci** 1995 Sep;84(9):1139-40

DEFICIENCY

Comprehensive adrenocortical steroid measurements in two cases of Schmidt's syndrome. Tanaka T, et al. **Endocr J** 1994 Aug;41(4):379-86

Effect of exercise and adrenal insufficiency on urea production in rats. Litvinova L, et al. **Eur J Appl Physiol** 1995;70(6):536-40

GENETICS

Genetic disorders of steroid hormone synthesis and metabolism. New MI, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):525-54 (127 ref.)

Molecular biology in reproductive endocrinology. Layman LC. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):328-39 (104 ref.)

IMMUNOLOGY

Corticosteroids and IgE. Dutch CNSLD Study Group [letter; comment] Kerstjens HA, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):138. Comment on: J Allergy Clin Immunol 1994 Aug;94(2 Pt 1):222-30.

ISOLATION & PURIFICATION

Mixed micelles of short chain alkyl surfactants and bile salts in electrokinetic chromatography: enhanced separation of corticosteroids. Bumgarner JG, et al. **J Chromatogr A** 1996 Jul 12;738(2):275-83

Biocompatible sample pretreatment for immunochemical techniques using micellar liquid chromatography for separation of corticosteroids. Lövgren U, et al. **J Chromatogr B Biomed Appl** 1995 Oct 6;672(1):33-44

METABOLISM

Corticosteroid metabolism in isolated perfused rat liver and kidney. Experimental studies with emphasis on aldosterone. Egfjord M. **Acta Physiol Scand Suppl** 1995;627:1-42 (226 ref.)

Alcohol, corticosteroids, energy utilization, and hippocampal endangerment. Eskay RL, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:105-14

Sex differences in corticosteroid binding in the rat brain: an in vitro autoradiographic study. MacLusky NJ, et al. **Brain Res** 1996 Feb 5;708(1-2):71-81

Corticosteroid hypertension. Funder JW. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):432-7 (39 ref.)

Why we should give a qualified welcome to ouabain: a whole new family of adrenal steroid hormones? Hinson JP, et al. **J Endocrinol** 1995 Sep;146(3):369-72

Biotransformation of corticosteroids by Penicillium decumbens ATCC 10436. Holland HL, et al. **Steroids** 1995 Sep;60(9):646-9

PHARMACOKINETICS

Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. Xu ZX, et al. **J Pharmacokinet Biopharm** 1995 Apr; 23(2):163-81

PHARMACOLOGY

Effects of K+, Mg2+ deficiency and adrenal steroids on Na+, K(+)-pump concentration in skeletal muscle. Dørup I. **Acta Physiol Scand** 1996 Mar;156(3):305-11 (51 ref.)

Cortisol levels after single local steroid injection [letter] Maillefert JF, et al. **Am J Med** 1996 May;100(5):586-7

Differential regulation of Na+-K+-ATPase gene expression by corticosteriods in vascular smooth muscle cells. Muto S, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C731-9

Prolactin inhibits corticoid-induced differentiation of active Na+ transport across cultured frog tadpole skin. Takada M, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1326-31

Lung epithelial Na channel subunits are differentially regulated during development and by steroids. Tchepichev S, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C805-12

Expression of RANTES by human bronchial epithelial cells in vitro and in vivo and the effect of corticosteroids. Wang JH, et al. **Am J Respir Cell Mol Biol** 1996 Jan;14(1):27-35

Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia. Maung ZT, et al. **Br J Haematol** 1995 Sep;91(1):93-100

Plasma protein leakage and local secretion of proteins assessed in sputum in asthma and COPD. The effect of inhaled corticosteroids. Schoonbrood DF, et al. **Clin Chim Acta** 1995 Sep 15;240(2):163-78

Bioassay of steroids [letter; comment] Stempel DA. **Clin Pharmacol Ther** 1996 Apr;59(4):482-3. Comment on: Clin Pharmacol Ther 1995 Apr;57(4):455-60.

Inhibitory effects of corticoids on reductive halothane dehalogenation. Fujii K. **Drug Metabol Drug Interact** 1995; 12(1):37-43

Endogenous corticosteroids mediate the neutrophilia caused by platelet-activating factor in the mouse. Harris JG, et al. **Eur J Pharmacol** 1995 Sep 5;283(1-3):9-18

Modulation of the anchorage-independent phenotype of human lung fibroblasts obtained from fibrotic tissue following culture with retinoid and corticosteroid. Torry DJ, et al. **Exp Lung Res** 1996 Mar-Apr;22(2):231-44

The effect of glucocorticoids on the activity of monoamine oxidase, copper-zinc superoxide dismutase and catalase in the rat hypothalamus. Cvijić G, et al. **Funct Neurol** 1995 Jul-Oct;10(4-5):175-81

Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors. Van Wauwe J, et al. **Inflamm Res** 1995 Sep;44(9):400-5

Aquaporin-1 water channel protein in lung: ontogeny, steroid-induced expression, and distribution in rat. King LS, et al. **J Clin Invest** 1996 May 15;97(10):2183-91

Effects of infusion of combinations of adrenocorticosteroids on systemic and regional haemodynamics in conscious sheep. May CN, et al. **J Hypertens** 1996 Apr;14(4):475-82

Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO- and CD45RO+ subsets. Brinkmann V, et al. **J Immunol** 1995 Oct 1;155(7):3322-8

Transcriptional regulation of Na/K-ATPase by corticosteroids, glycyrrhetinic acid and second messenger pathways in rat kidney epithelial cells. Whorwood CB, et al. **J Mol Endocrinol** 1995 Aug;15(1):93-103

Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. Nikolaizik WH, et al. **J Pediatr** 1996 Feb;128(2):271-4

Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. Milad MA, et al. **J Pharmacokinet Biopharm** 1994 Dec;22(6):469-80

Type II collagen-induced arthritis in the diabetic-resistant biobreeding rat: inflammatory and histopathological features of joint pathology and effects of antiinflammatory and antirheumatic drugs on this chronic arthritic process. Smith RJ, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1801-13

Hippocampal homosynaptic long-term depression/depotentiation induced by adrenal steroids. Pavlides C, et al. **Neuroscience** 1995 Sep;68(2):379-85

[The effect of steroids on organ-cultured porcine trabecular meshwork--an ultrastructural, biochemical, and lectin histochemical study] Amaya J. **Nippon Ganka Gakkai Zasshi** 1995 Sep;99(9):995-1004 (Eng. Abstr.) **(Jpn)**

[Therapeutic approach to steroid resistant idiopathic nephrotic syndrome in childhood (editorial)] Wyszyńska T. **Pediatr Pol** 1995 Dec;70(12):1003-10 (Eng. Abstr.) **(Pol)**

[The effect of stress and corticosteroids on the rate of blood flow in the microvessels of the gastric muscular coat of rats] Filaretova LP, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):66-75 (Eng. Abstr.) **(Rus)**

[Corticosteroids limit the decrease in blood flow velocity in the microvessels of the gastric submucosal layer during stress in rats] Filaretova LP, et al. **Fiziol Zh Im I M Sechenova** 1996 Jan;82(1):71-8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Adrenocorticoid hormones and the development and expression of mammalian monogamy. Carter CS, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:82-91

Role of IL-1 beta and corticosteroids in the regulation of the C/EBP-alpha, beta and delta genes in vivo. Magalini A, et al. **Cytokine** 1995 Nov;7(8):753-8

Zonation, paracrine function and aldosterone secretion in the rat adrenal cortex. Vinson GP, et al. **Endocr Res** 1995 Feb-May;21(1-2):1-12

Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Pepe GJ, et al. **Endocr Rev** 1995 Oct; 16(5):608-48 (617 ref.)

Steroids, stability and stress. de Kloet ER. **Front Neuroendocrinol** 1995 Oct;16(4):416-25 (41 ref.)

Regulation of 5-HT receptors by corticosteroids: where do we stand? Chaouloff F. **Fundam Clin Pharmacol** 1995; 9(3):219-33 (82 ref.)

Exposure of postnatal rats to glucocorticoids suppresses the development of choline acetyltransferase-immunoreactive neurons: role of adrenal steroids in the development of forebrain cholinergic neurons. Hu Z, et al. **J Chem Neuroanat** 1996 Feb;10(1):1-10

Expression of cardiac angiotensin II AT1 receptor genes in rat hearts is regulated by steroids but not by angiotensin II. Della Bruna R, et al. **J Hypertens** 1995 Jul;13(7):763-9

Stress-induced changes in blood leukocyte distribution. Role of adrenal steroid hormones. Dhabhar FS, et al. **J Immunol** 1996 Aug 15;157(4):1638-44

Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. Milad MA, et al. **J Pharmacokinet Biopharm** 1994 Dec;22(6):469-80

Opposing roles of type I and type II adrenal steroid receptors in hippocampal long-term potentiation. Pavlides C, et al. **Neuroscience** 1995 Sep;68(2):387-94

Corticosteroids and performance. Prokop L. **Sb Lek** 1994; 95(2):101-4

Corticosteroid-mediated modulation of carbachol responsiveness in CA1 pyramidal neurons: a voltage clamp analysis. Hesen W, et al. **Synapse** 1995 Aug;20(4):299-304

Stress and the brain: a paradoxical role for adrenal steroids. McEwen BS, et al. **Vitam Horm** 1995;51:371-402 (113 ref.)

[Stress-induced analgesia. The role of corticosteroids] Bogdanov AI, et al. **Fiziol Zh Im I M Sechenova** 1995 Mar;81(3):61-7 (Eng. Abstr.) **(Rus)**

[Stress-induced analgesia. The role of the hormones of the hypophyseal-adrenocortical system] Filaretov AA, et al. **Fiziol Zh Im I M Sechenova** 1995 Feb;81(2):40-6 (Eng. Abstr.) **(Rus)**

[Gastric stress ulcers: the protective role of hormones of the hypothalamo-hypophyseal-adrenocortical system] Filaretova LP. **Fiziol Zh Im I M Sechenova** 1995 Mar; 81(3):50-60 (80 ref.) (Eng. Abstr.) **(Rus)**

[The antiulcer effect of corticosteroids and the blood flow in the gastric mucosa] Filaretova LP, et al. **Fiziol Zh Im I M Sechenova** 1996 Feb;82(2):61-70 (Eng. Abstr.) **(Rus)**

SECRETION

Effect of histamine on corticosteroid secretion of isolated human and rat adrenocortical cells. Orsó E, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S48-9

Pharmacological profile of the tachykinin receptor involved in the stimulation of corticosteroid secretion in the frog Rana ridibunda. Kodjo MK, et al. **J Steroid Biochem Mol Biol** 1996 Mar;57(5-6):329-35

Activation of 5-hydroxytryptamine4 receptors causes calcium influx in adrenocortical cells: involvement of calcium in 5-hydroxytryptamine-induced steroid secretion. Contesse V, et al. **Mol Pharmacol** 1996 Mar;49(3):481-93

Significance of adrenal corticosteroid secretion for the food restriction-induced enhancement of alcohol drinking in the rat. Hansen S, et al. **Psychopharmacology (Berl)** 1995 Sep; 121(2):213-21

STANDARDS

Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. Zanen P, et al. **Eur J Clin Pharmacol** 1995;48(3-4):179-84

THERAPEUTIC USE

Factors affecting prognosis of idiopathic interstitial pneumonia. Matsuo K, et al. **Acta Med Okayama** 1996 Feb; 50(1):37-46

Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. Jørgensen M, et al. **Acta Oncol** 1996;35(2):159-63

The outcome of Stevens-Johnson syndrome treated with corticosteroids. Cheriyan S, et al. **Allergy Proc** 1995 Jul-Aug;16(4):151-5

Corticosteroid injection therapy for overuse injuries. Nelson KH, et al. **Am Fam Physician** 1995 Nov 1;52(6):1811-6 (31 ref.)

Steroid therapy of chronic hepatitis: characteristics associated with response in anti-hepatitis C virus-positive and -negative patients. Thiele DL, et al. **Am J Gastroenterol** 1996 Feb;91(2):300-8

Steroid-responsive pulmonary disorders associated with myelodysplastic syndromes with der(1q;7p) chromosomal abnormality. Matsushima T, et al. **Am J Hematol** 1995 Oct; 50(2):110-5

Childhood steroid-sensitive nephrotic syndrome: does the histology matter? Webb NJ, et al. **Am J Kidney Dis** 1996 Apr;27(4):484-8

Comprehensive long-term management program for asthma: effect on outcomes in adult African-Americans. Kelso TM, et al. **Am J Med Sci** 1996 Jun;311(6):272-80

Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Busse WW, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):122-7

Treatment of osteitis pubis in athletes. Results of corticosteroid injections. Holt MA, et al. **Am J Sports Med** 1995 Sep-Oct;23(5):601-6

Salmeterol xinafoate in children on high dose inhaled steroids. Russell G, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):423–8

Comment: steroid treatment of mild chronic asthma [letter; comment] Grigg CF. **Ann Pharmacother** 1995 Nov; 29(11):1170, 1173. Comment on: Ann Pharmacother 1994 Nov;28(11):1285–9.

The adjuvant therapy of pemphigus. An update. Bystryn JC, et al. **Arch Dermatol** 1996 Feb;132(2):203–12 (89 ref.)

Beneficial effects of corticosteroids on ocular myasthenia gravis. Kupersmith MJ, et al. **Arch Neurol** 1996 Aug; 53(8):802–4

Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Schwid SR, et al. **Arch Neurol** 1996 Aug; 53(8):753–7

Corticosteroids for croup. Reconciling town and gown [editorial; comment] Rowe PC, et al.
Arch Pediatr Adolesc Med 1996 Apr;150(4):344–6. Comment on: Arch Pediatr Adolesc Med 1996 Apr;150(4):349–55.

Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg–Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Guillevin L, et al.
Arthritis Rheum 1995 Nov;38(11):1638–45

Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Meliconi R, et al. **Arthritis Rheum** 1996 Jul;39(7):1199–207

Prevention of preterm birth. Owen P, et al.
Baillieres Clin Obstet Gynaecol 1995 Sep;9(3):465–79 (96 ref.)

Corticosteroids in the management of croup [editorial] [see comments] Doull I. **BMJ** 1995 Nov 11;311(7015):1244. Comment in: BMJ 1996 Feb 24;312(7029):510; discussion 510–1. Comment in: BMJ 1996 Feb 24;312(7029):510–11.

Problems with the penis and prepuce in children. Lichen sclerosus should be treated with corticosteroids to reduce need for surgery [letter] Jorgensen ET, et al. **BMJ** 1996 Sep 14;313(7058):692

Corticosteroid injections for lateral epicondylitis: a systematic overview. Assendelft WJ, et al.
Br J Gen Pract 1996 Apr;46(405):209–16

The role of corticosteroids in rheumatoid arthritis [editorial] Byron M. **Br J Hosp Med** 1996 Mar 6–19;55(5):235–6

Trends and variations in use of antenatal corticosteroids to prevent neonatal respiratory distress syndrome: recommendations for national and international comparative audit. Scottish Neonatal Consultants' Collaborative Study Group, International Neonatal Network. **Br J Obstet Gynaecol** 1996 Jun;103(6):534–40

Successful treatment of Reiter's syndrome in a patient with AIDS with methotrexate and corticosteroids [letter] Berenbaum F, et al. **Br J Rheumatol** 1996 Mar;35(3):295

Corticosteroids in the management of rheumatoid arthritis [editorial] Morrison E, et al. **Br J Rheumatol** 1996 Jan; 35(1):2–4

A 32-year-old man with hematuria and acute respiratory failure. **Chest** 1995 Nov;108(5):1449–50

Pulmonary tuberculosis and steroids [letter; comment] Clarke P, et al. **Chest** 1996 Feb;109(2):582. Comment on: Chest 1995 Jun;107(6):1486–7. Comment on: Chest 1995 Jun;107(6):1621–30.

Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids. Kubiet MA, et al.
Chest 1996 Aug;110(2):367–70

Vocal cord dysfunction syndrome and "steroid-dependent" asthmatics [letter; comment] Pacht ER, et al. **Chest** 1995 Dec;108(6):1772–3. Comment on: Chest 1995 Mar;107(3):817–25.

Long-acting beta-agonists, tachyphylaxis, and corticosteroids [editorial; comment] Sears MR. **Chest** 1996 Apr;109(4):862–4. Comment on: Chest 1996 Apr;109(4):953–6.

When should inhaled corticosteroids be started for asthma? [editorial; comment] Tarpy R, et al. **Chest** 1995 Nov; 108(5):1188–90. Comment on: Chest 1995 Nov;108(5):1228–34.

Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Gelfand EW, et al.
Clin Exp Immunol 1996 May;104 Suppl 1:61–6 (56 ref.)

The clinical use of antenatal corticosteroids. Gardner MO, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):746–54 (39 ref.)

Steroid replacement in sepsis: an unexplored side of a multifaceted drug class. Annane D, et al.
Crit Care Med 1996 May;24(5):899–900

Treatment of scleroderma. Gelber AC, et al.
Curr Opin Rheumatol 1995 Nov;7(6):551–9 (66 ref.)

Articular and periarticular corticosteroid injections.
Drug Ther Bull 1995 Sep;33(9):67–70 (31 ref.)

What is the role of corticosteroids in meningitis? Harvey DR, et al. **Drugs** 1995 Dec;50(6):945–50 (58 ref.)

Alternative epilepsy therapies: the ketogenic diet, immunoglobulins, and steroids. Prasad AN, et al.
Epilepsia 1996;37 Suppl 1:S81–95 (106 ref.)

Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. Zanen P, et al. **Eur J Clin Pharmacol** 1995;48(3–4):179–84

Cytologic examination of broncho-alveolar fluid during the retinoic acid syndrome [letter] Maloisel F, et al.
Eur J Haematol 1996 May;56(5):319–20

Long-term effects of therapy on respiratory health. Fuhrman C, et al. **Eur Respir J** 1996 Mar;9(3):436–43

The efficacy of immunotherapy in patients who underwent superovulation with intrauterine insemination. Kim CH, et al. **Fertil Steril** 1996 Jan;65(1):133–8

Allergic rhinoconjunctivitis: current therapy. Hollingsworth HM. **Hosp Pract (Off Ed)** 1996 Jun 15;31(6):61–2, 65–7, 71–3 (12 ref.)

Adjuncts to antibacterial therapy. Frank MO, et al.
Infect Dis Clin North Am 1995 Sep;9(3):769–81 (63 ref.)

A novel contact hypersensitivity model for rank-ordering formulated corticosteroids. Bailey SC, et al.
Inflamm Res 1995 Aug;44 Suppl 2:S162–3

New therapeutic approaches in sepsis: a critical review. Eidelman LA, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S269–72 (18 ref.)

A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. Bernstein IL, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):317–24

Albumin and immunoglobulin levels in nasal secretions of patients with nasal polyps treated with endoscopic sinus surgery and topical corticosteroids. Biewenga J, et al.
J Allergy Clin Immunol 1995 Sep;96(3):334–40

The effects of prednisolone on the cutaneous tuberculin response in patients with corticosteroid-resistant bronchial asthma. Sousa AR, et al. **J Allergy Clin Immunol** 1996 Feb; 97(2):698–706

The pattern of topical corticosteroid prescribing in the United States, 1989–1991. Stern RS. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):183–6

Inhaled corticosteroids: benefits and risks [see comments] Robinson DS, et al. **J Asthma** 1996;33(1):5–16 (103 ref.). Comment in: J Asthma 1996;33(1):1–3.

Dissociation between serum interleukin-6 rise and other parameters of disease activity in subacute thyroiditis during treatment with corticosteroid. Yamada T, et al.
J Clin Endocrinol Metab 1996 Feb;81(2):577–9

Analysis of wild-type and e antigen-defective hepatitis B viruses during the course of a short-term corticosteroid therapy in chronic hepatitis B. Daikoku M, et al.
J Med Virol 1995 Oct;47(2):184–8

Treatment of resistant oral aphthous ulcers in children with acquired immunodeficiency syndrome. de Asis ML, et al.
J Pediatr 1995 Oct;127(4):663–5

Corticosteroid therapy for Pneumocystis carinii pneumonia [letter; comment] Marriage SC, et al. **J Pediatr** 1995 Dec; 127(6):1007–8. Comment on: J Pediatr 1995 May;126(5 Pt 1):821–4.

Pneumocystis carinii pneumonia associated with inhaled corticosteroids in an immunocompetent child with asthma. Sy ML, et al. **J Pediatr** 1995 Dec;127(6):1000–2

Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. Beattie RM, et al. **J Pediatr Gastroenterol Nutr** 1996 May; 22(4):373–9

Role of corticosteroids in cystic fibrosis lung disease. Balfour-Lynn IM, et al. **J R Soc Med** 1996;89 Suppl 27:8–13 (37 ref.)

Management of acquired bullous skin diseases [letter; comment] Guibal F, et al. **N Engl J Med** 1996 Mar 28; 334(13):864–5. Comment on: N Engl J Med 1995 Nov 30;333(22):1475–84.

Are corticosteroids really necessary in renal transplantation? Ponticelli C, et al. **Nephrol Dial Transplant** 1995; 10(9):1587–91 (36 ref.)

Does the treatment of cryptogenic fibrosing alveolitis influence prognosis? Egan JJ, et al. **Respir Med** 1996 Mar; 90(3):127–30 (26 ref.)

Reasons for failure to administer antenatal corticosteroids in preterm labour. Ballot DE, et al. **S Afr Med J** 1995 Oct;85(10):1005–7

Reasons for failure to administer antenatal corticosteroids in preterm labour [letter] Tregoning S. **S Afr Med J** 1996 May;86(5):570–2

Adjunctive corticosteroid therapy in bacterial meningitis. Lauritsen A, et al. **Scand J Infect Dis** 1995;27(5):431–4 (25 ref.)

Enhanced risk of steroid-resistant acute rejection following pretransplant steroid therapy in liver graft recipients. Conti F, et al. **Transplantation** 1995 Nov 27;60(10):1104–8

Reversal of steroid-resistant rejection in renal allograft recipients using FK506. Mathew A, et al.
Transplantation 1995 Nov 27;60(10):1182–4

[Is there any indication for general cortisosteroid therapy in urticaria?] **Ann Dermatol Venereol** 1995;122(10):735–8 **(Fre)**

[Thrombopenia resistant to corticosteroids revealing a non-hematologic disorder] Copin MC, et al. **Ann Pathol** 1995;15(6):453–4 **(Fre)**

[Indication of corticotherapy for fetal pulmonary maturation] Tchobroutsky C. **Contracept Fertil Sex** 1996 May; 24(5):413–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Pharma clinics: how I treat... Inflammatory intestinal diseases and pregnancy] Belaiche J. **Rev Med Liege** 1995 Nov;50(11):449–50 **(Fre)**

[Corticotherapy: half a century of fortune and misfortune] Scheen AJ. **Rev Med Liege** 1996 Jan;51(1):111–5 **(Fre)**

[Value of corticoids in hematology/oncology in adulthood] Schlimok G, et al. **Med Klin** 1995 Oct 15;90(10):579–84 (23 ref.) **(Ger)**

[Pemphigus vulgaris. Clinical aspects, pathophysiology and therapy of a bullous autoimmune dermatosis] Sunderkötter CH, et al. **Med Monatsschr Pharm** 1995 Sep;18(9):255–63 (39 ref.) **(Ger)**

[Immunosuppressive therapy of vasculitis: current aspects and perspectives] Giacomelli R, et al.
Recenti Prog Med 1996 Mar;87(3):124–34 (74 ref.) (Eng. Abstr.) **(Ita)**

[Pharmacological treatment of migraine: other treatments] Gómez Aranda F, et al. **Rev Neurol** 1995;23 Suppl 2:S198–200 (43 ref.) **(Spa)**

[Approach to the diagnosis and therapy of vascular neuropathy] Hernández MA, et al. **Rev Neurol** 1995 Sep–Oct;23(123):1008–12 (40 ref.) (Eng. Abstr.) **(Spa)**

[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525–9 (29 ref.) **(Spa)**

URINE

Alterations in cortisol metabolism in insulin-dependent diabetes mellitus: relationship with metabolic control and estimated blood volume and effect of angiotensin-converting enzyme inhibition. Dullaart RP, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3002–8

Factitious hypercortisoluria. Workman RJ, et al.
J Clin Endocrinol Metab 1995 Oct;80(10):3050–1

ADRENAL CORTEX NEOPLASMS

Clinical, hormonal and pathological findings in a comparative study of adrenocortical neoplasms in childhood and adulthood. Mendonca BB, et al. **J Urol** 1995 Dec; 154(6):2004–9

A functioning adrenocortical hemangioma. Stumvoll M, et al. **J Urol** 1996 Feb;155(2):638

BLOOD

Characteristics of aldosterone-producing adenoma responsive to upright posture. Toraya S, et al.
Endocr J 1995 Aug;42(4):481–7

CHEMISTRY

Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy. Sasano H, et al.
Hum Pathol 1995 Oct;26(10):1154–6

Expression of the steroidogenic acute regulatory protein mRNA in adrenal tumors and cultured adrenal cells. Liu J, et al. **J Endocrinol** 1996 Jul;150(1):43–50

[Ultrastructural and immunohistochemical localization of endothelin-1 in nonneoplastic, hyperplastic and neoplastic adrenal gland] Li Q, et al.
Chung Hua I Hsueh Tsa Chih 1996 Feb;76(2):128–31 (Eng. Abstr.) **(Chi)**

COMPLICATIONS

Combined Conn's and Cushing's syndrome: an unusual presentation of adrenal adenoma. Baert D, et al.
Acta Clin Belg 1995;50(5):310–3

Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Abdelhamid S, et al.
Arch Intern Med 1996 Jun 10;156(11):1190–5

Possible pre-Cushing's syndrome due to an adrenal adenoma incidentally discovered. Tsuboi Y, et al. **Endocr J** 1995 Aug;42(4):509–16

Malignant acanthosis nigricans in adrenal carcinoma. Hiranandani M, et al. **Indian Pediatr** 1995 Aug;32(8):920–3

Congenital adrenal hyperplasia presenting as massive adrenal incidentalomas in the sixth decade of life: report of two patients with 21-hydroxylase deficiency. Ravichandran R, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1776–9

Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. Takeda R, et al. **J Endocrinol Invest** 1995 May;18(5):370–3

Conn's syndrome due to adrenocortical adenoma—a rare but rewarding cause of curable hypertension. Quarmby CJ, et al. **S Afr Med J** 1995 Dec;85(12 Pt 2):1353–6

Spontaneous hemorrhage of an adrenal cortical adenoma causing Cushing's syndrome. Saito T, et al. **Urol Int** 1996; 56(2):105–6

Isolated clinical syndrome of primary aldosteronism in a patient with adrenocortical carcinoma. Case report and review of the literature. Weingärtner K, et al. **Urol Int** 1995;55(4):232–5 (15 ref.)

Renal pathology in patients with primary hyperaldosteronism secondary to an adrenal cortical adenoma. Grady RW, et al. **Urology** 1996 Sep;48(3):369–72

[Hyperaldosteronism sensitive to dexamethasone with adrenal adenoma. Clinical, biological and genetic study] Jeunemaitre X, et al. **Presse Med** 1995 Sep 23;24(27):1243–8 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Adrenocortical adenoma containing a fat component: CT and MR image evaluation. Sato N, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):489–90

An imaging algorithm for the differential diagnosis of adrenal adenomas and metastases. McNicholas MM, et al.
AJR Am J Roentgenol 1995 Dec;165(6):1453–9

Adrenal carcinoma in a patient with Gardner's syndrome: imaging findings. Traill Z, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1460–1 (8 ref.)
Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Abdelhamid S, et al. **Arch Intern Med** 1996 Jun 10;156(11):1190–5
Calcified aldosterone-producing adrenocortical adenoma. Jelic TM, et al. **Clin Imaging** 1996 Jan–Mar;20(1):50–4
A patient with a progesterone-producing adrenal adenoma who presented with primary amenorrhea. van Zonneveld P, et al. **Gynecol Endocrinol** 1995 Sep;9(3):189–94
Adrenocortical neoplasm disguised as a post-traumatic perinephric hematoma. Blake DP, et al. **Mil Med** 1996 Mar; 161(3):173–5
Adrenal cortical adenoma with extensive fat cell metaplasia. Feldberg E, et al. **Pathol Res Pract** 1996 Jan;192(1):62–5; discussion 66
Hyperaldosteronism: sampling the adrenal veins. Doppman JL, et al. **Radiology** 1996 Feb;198(2):309–12
[Dysfunction of the aldosterone synthesis pathway as a marker of malignity in symptomatic and asymptomatic adrenal masses] Aupetit-Faisant B, et al. **Bull Acad Natl Med** 1995 Oct;179(7):1355–65; discussion 1365–7 (Eng. Abstr.) **(Fre)**
[Adrenal cortex carcinoma—progress in diagnosis and therapy] Lizakowska-Kmieć M, et al. **Pol Arch Med Wewn** 1995 Dec;94(6):525–32 (32 ref.) **(Pol)**

ENZYMOLOGY

Type beta 1 transforming growth factor is an inhibitor of 3 beta-hydroxysteroid dehydrogenase isomerase in mouse adrenal tumor cell line Y1. Cherradi N, et al. **Endocr Res** 1995 Feb–May;21(1–2):61–6
Zone-specific localization of cytochrome P45011B1 in human adrenal tissue by PCR-derived riboprobes. Erdmann B, et al. **Histochem Cell Biol** 1995 Oct; 104(4):301–7
Aromatase expression in a feminizing adrenocortical tumor. Young J, et al. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3173–6

EPIDEMIOLOGY

Tumours of the adrenal cortex. Breza J, et al. **Ann Urol (Paris)** 1996;30(1):26–32
The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Crucitti F, et al. **Surgery** 1996 Feb;119(2):161–70
[Adrenocortical carcinoma in children: retrospective study of 54 cases] Teinturier C, et al. **Arch Pediatr** 1996 Mar; 3(3):235–40 (Eng. Abstr.) **(Fre)**

GENETICS

Bilateral adrenocortical carcinoma showing loss of heterozygosity at the p53 and RB gene loci. Miyamoto H, et al. **Cancer Genet Cytogenet** 1996 Jun;88(2):181–3
Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Kjellman M, et al. **Cancer Res** 1996 Sep 15;56(18):4219–23
[Insulin-like growth factor II (IGF II) and adrenocortical tumorigenesis] Gicquel C, et al. **Ann Endocrinol (Paris)** 1995;56(6):617–8 **(Fre)**

METABOLISM

Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Rossi E, et al. **Am J Hypertens** 1995 Sep;8(9):884–93
Immunohistochemical expression of insulin-like growth factor 1 and its receptor in normal and neoplastic human adrenal cortex. Backlin C, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2453–9
Long-PCR of the ANP gene and PCR-SSCP analysis of the proximal promoter region of the ANP gene in patients with aldosterone producing adenoma. Tunny TJ, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):172–8

PATHOLOGY

Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports. Zidan J, et al. **Am J Clin Oncol** 1996 Jun;19(3):229–31
Adrenal cortical tumors clinically mimicking pheochromocytoma. Alsabeh R, et al. **Am J Clin Pathol** 1995 Oct;104(4):382–90
Adrenal cortical neoplasms. A study of 56 cases. Evans HL, et al. **Am J Clin Pathol** 1996 Jan;105(1):76–86
Functional adrenal cortical tumors in pediatric patients: a clinicopathologic and immunohistochemical study of a long term follow-up series. Bergadá I, et al. **Cancer** 1996 Feb 15;77(4):771–7
Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Kjellman M, et al. **Cancer Res** 1996 Sep 15;56(18):4219–23
Ultrastructural dynamics of mitochondrial morphology in varying functional forms of human adrenal cortical adenoma. Bornstein SR, et al. **Horm Metab Res** 1996 Apr; 28(4):177–82
Ectopic aldosteronoma associated to another adrenocortical adenoma in the adrenal gland of the same side. Mazza E, et al. **J Endocrinol Invest** 1995 Nov;18(10):809–12
Spontaneous regression of pulmonary metastasis from nonfunctioning adrenocortical carcinoma after removal of the primary lesion: a case report. Gohji K, et al. **J Urol** 1995 Nov;154(5):1854–5
[Malignant adrenocortical tumors. Apropos of 9 cases] Benchekroun A, et al. **Ann Urol (Paris)** 1996;30(1):33–7 (Eng. Abstr.) **(Fre)**
[Morphological typing, evaluation of tumor dignity and prognosis and etiologic classification of adrenomedullary and adrenocortical neoplasias] Schröder S, et al. **Pathologe** 1995 Sep;16(5):307–14 (57 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

ACTH-receptor deficient mutants of the Y1 mouse adrenocortical tumor cell line. Schimmer BP, et al. **Endocr Res** 1995 Feb–May;21(1–2):139–56
[Role of hormonal receptor abnormalities in the physiopathology of adrenocortical tumors] Lacroix A. **Ann Endocrinol (Paris)** 1995;56(6):614–6 (21 ref.) **(Fre)**

RADIONUCLIDE IMAGING

131I-6 beta-iodomethylnorcholesterol scintigraphy: an assessment of its role in the investigation of adrenocortical incidentalomas. Bardet S, et al. **Clin Endocrinol (Oxf)** 1996 May;44(5):587–96
Fortuitous imaging of a primary adrenocortical carcinoma with Tc-99m HDP. Pacheco EJ, et al. **Clin Nucl Med** 1995 Oct;20(10):906–8
Scintigraphy and biodistribution of monoclonal adrenocortical antibody in mice grafted with human adrenocortical carcinoma. Ohrvall U, et al. **Surgery** 1995 Nov;118(5):893–900

SECRETION

A case of deoxycorticosterone-producing adrenal adenoma. Wada N, et al. **Endocr J** 1995 Oct;42(5):637–42 (29 ref.)
Optimizing ACTH-stimulated steroid secretion by cultured adrenocortical tumor cells. Mathias S, et al. **Endocr Res** 1995 Feb–May;21(1–2):121–7
Expression of type 1 angiotensin II receptors in human aldosteronomas. Sarzani R, et al. **Endocr Res** 1995 Feb–May;21(1–2):189–95

SURGERY

Functional adrenal cortical tumors in pediatric patients: a clinicopathologic and immunohistochemical study of a long term follow-up series. Bergadá I, et al. **Cancer** 1996 Feb 15;77(4):771–7
A case of silent 21-hydroxylase deficiency with persistent adrenal insufficiency after removal of an adrenal incidentaloma. Nagasaka S, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):111–6
Primary non-functioning tumours of the adrenal cortex: an eight-year experience in Turkey. Aydintuğ S, et al. **Eur J Surg** 1996 Apr;162(4):275–8
Adrenalectomy via the dorsal approach: a benchmark for laparoscopic adrenalectomy [see comments] Nash PA, et al. **J Urol** 1995 Nov;154(5):1652–4. Comment in: J Urol 1996 Sep;156(3):1136.
Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Lee JE, et al. **Surgery** 1995 Dec;118(6):1090–8
[Adrenalectomy by posterior approach for benign adrenocortical tumors. Apropos of 12 cases] Brunaud L, et al. **J Chir (Paris)** 1996 Jan;133(1):7–11 (Eng. Abstr.) **(Fre)**

THERAPY

The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Crucitti F, et al. **Surgery** 1996 Feb;119(2):161–70
[Adrenal cortex carcinoma—progress in diagnosis and therapy] Lizakowska-Kmieć M, et al. **Pol Arch Med Wewn** 1995 Dec;94(6):525–32 (32 ref.) **(Pol)**

URINE

Heterogeneity of urinary steroid profiles in children with adrenocortical tumors. Małunowicz EM, et al. **Horm Res** 1995;44(4):182–8

VETERINARY

A light microscopical, ultrastructural and immunohistochemical study of spindle-cell adrenocortical tumours of ferrets. Gliatto JM, et al. **J Comp Pathol** 1995 Aug;113(2):175–83
Effect of bursal anti-steroidogenic peptide (BASP) on cortisol biosynthesis in ACTH-stimulated canine adrenocortical carcinoma cells in vitro. Byrd JA, et al. **Vet Immunol Immunopathol** 1995 Jul;47(1–2):35–42
Results of adrenalectomy in 36 dogs with hyperadrenocorticism caused by adreno-cortical tumour. van Sluijs FJ, et al. **Vet Q** 1995 Sep;17(3):113–6

ADRENAL CORTICAL REST TUMOR see **ADRENAL REST TUMOR**

ADRENAL FASCICULATA see **ZONA FASCICULATA**

ADRENAL GLAND DISEASES

Bleeding to adrenal glands in adults. Baše J, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(2):95–8
Bleeding to adrenal gland in adults. Baše J, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl** 1995;38(2):95–8
[Spontaneous unilateral adrenal gland hematoma in the postpartum period (letter)] Badaoui R, et al. **Presse Med** 1995 Nov 11;24(34):1625 **(Fre)**

COMPLICATIONS

Addison's disease caused by adrenal blastomycosis: a case report with fine needle aspiration (FNA) cytology. Rimondi AP, et al. **Cytopathology** 1995 Aug;6(4):277–9
Adrenal pseudocyst in pregnancy. A case report. Trauffer PM, et al. **J Reprod Med** 1996 Mar;41(3):195–7
[Anticardiolipin antibodies, cerebral ischemia and adrenal hemorrhage in a newborn infant] Teyssier G, et al. **Arch Pediatr** 1995 Nov;2(11):1086–8 (Eng. Abstr.) **(Fre)**
[Unilateral spontaneous adrenal hematoma: an unusual cause of retroperitoneal hemorrhage] Vendrell JR, et al. **Actas Urol Esp** 1996 Jan;20(1):59–62 (12 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

[Congenital adrenal hypoplasia and hearing loss. A case report] Liotta A, et al. **Minerva Pediatr** 1995 Nov; 47(11):471–6 (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Incidentally discovered adrenal masses. Kloos RT, et al. **Endocr Rev** 1995 Aug;16(4):460–84 (253 ref.)
Symptomatic adrenal pseudocyst. Moons P, et al. **J Belge Radiol** 1996 Feb;79(1):23–5
Spontaneous unilateral adrenal hemorrhage: computerized tomography and magnetic resonance imaging findings in 8 cases. Hoeffel C, et al. **J Urol** 1995 Nov;154(5):1647–51 (24 ref.)
Contrast-enhanced MR imaging of the kidneys and adrenal glands. Huch Böni RA, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):101–31 (61 ref.)
Lymphangiomatous cyst of the adrenal gland: an unusual cause of flank pain. Jagusch CR, et al. **Nebr Med J** 1996 Jul;81(7):186–90
The incidental adrenal mass. Korobkin M, et al. **Radiol Clin North Am** 1996 Sep;34(5):1037–54 (54 ref.)
Adrenal imaging. Korobkin M, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):317–30 (45 ref.)
Bilateral adrenal hemorrhage following laparoscopic cholecystectomy. Belmore DJ, et al. **Surg Endosc** 1995 Aug;9(8):919–20
Adrenal lesion in multiple endocrine neoplasia type 1. Skogseid B, et al. **Surgery** 1995 Dec;118(6):1077–82
[Imaging of adrenal gland diseases] Taillefer R, et al. **Ann Endocrinol (Paris)** 1995;56(5):507–8 (4 ref.) **(Fre)**
[Bilateral cysts of the adrenal glands. Apropos of a case] Benchekroun A, et al. **Ann Urol (Paris)** 1996;30(1):40–3 (Eng. Abstr.) **(Fre)**
[New diagnostic possibilities (editorial)] Zvara V. **Ann Urol (Paris)** 1996;30(1):6 **(Fre)**
[Unilateral adrenal hematoma in adults. Contribution of MRI in follow-up] Meyer X, et al. **J Radiol** 1996 Mar; 77(3):197–200 (Eng. Abstr.) **(Fre)**
[Atypical overgrowth of the left suprarenal gland imitating pheochromocytoma] Orzeł M, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:133–6 (Eng. Abstr.) **(Pol)**

ETIOLOGY

Case report: 17 alpha-hydroxylase/17,20-lyase deficiency: a rare cause of endocrine hypertension. Hermans C, et al. **Am J Med Sci** 1996 Sep;312(3):126–9
Acute bilateral adrenal hemorrhage secondary to rough truck ride. Ikekpeazzu N, et al. **J Emerg Med** 1996 Jan–Feb; 14(1):15–8
[Bilateral hemorrhage of the adrenal glands and antiphospholipid syndrome disclosing cancer (letter)] Horusitzky A, et al. **Ann Med Interne (Paris)** 1996; 147(1):64–6 **(Fre)**
[Adrenal histoplasmosis in a non-insulin-dependent diabetic patient] Sert C, et al. **Rev Med Interne** 1995;16(10):771–4 (Eng. Abstr.) **(Fre)**
[Case of Sheehan syndrome with hypoglycemia and adrenal crisis despite normal labor] Ishii H, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1158–60 **(Jpn)**
[Diagnostic and therapeutic problems in a newborn with aortic coarctation, adrenal and intracranial hemorrhages and renal failure] Wróblewska-Kałużewska M, et al. **Pediatr Pol** 1995 Dec;70(12):1065–8 (Eng. Abstr.) **(Pol)**

ADRENAL GLAND DISEASES

IMMUNOLOGY

Spontaneous adrenal gland haematoma in a patient with antiphospholipid antibodies [letter] Luppi M, et al. **Eur J Haematol** 1995 Nov;55(5):335–8

PARASITOLOGY

Hydatid disease: a rare cause of adrenal cyst. Bastounis E, et al. **Am Surg** 1996 May;62(5):383–5

PATHOLOGY

Splenunculus masquerading as an adrenal mass. Dawson C, et al. **Br J Urol** 1995 Sep;76(3):404–5

Ectopic thyroid tissue in a cystic adrenal mass. Tsujimura A, et al. **Br J Urol** 1996 Apr;77(4):605–6

Giant adrenal cysts. Sahu KK, et al. **Indian J Pathol Microbiol** 1994 Dec;37 Suppl:S12–3

[A giant adrenal mass: the anatomicopathological surprise finding] Mármol Navarro S, et al. **Arch Esp Urol** 1995 Nov; 48(9):949–51 (8 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Abdominal pain after breast cancer surgery. Yale SH, et al. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):18, 21–2

SURGERY

Laparoscopic adrenalectomy. Comparison of the lateral and posterior approaches. Duh QY, et al. **Arch Surg** 1996 Aug; 131(8):870–5; discussion 875–6

Laparoscopic adrenal surgery. Fernández-Cruz L. **Br J Surg** 1996 Jun;83(6):721–3

Laparoscopic adrenalectomy: review of 14 cases and comparison with open adrenalectomy. Naito S, et al. **J Endourol** 1995 Dec;9(6):491–5

Laparoscopic surgery for adrenal lesions. Brown JP, et al. **Semin Surg Oncol** 1996 Mar–Apr;12(2):96–9 (12 ref.)

Laparoscopic resection of a large right adrenal gland cyst. Klimopoulos S, et al. **Surg Endosc** 1995 Dec;9(12):1295–7

[Adrenal gland epithelial cyst. Apropos of a case (letter)] Thognon P, et al. **Ann Chir** 1996;50(1):76 **(Fre)**

[Laparoscopic adrenalectomy. Experiences with 50 patients] Suzuki K, et al. **Urologe A** 1996 May;35(3):233–7 (Eng. Abstr.) **(Ger)**

[Adrenal cysts: therapeutic indications] De Toma G, et al. **Minerva Chir** 1995 Oct;50(10):925–8 (Eng. Abstr.) **(Ita)**

THERAPY

[Puncture of adrenal cyst and anaphylaxis (letter)] López P, et al. **Enferm Infecc Microbiol Clin** 1996 Mar;14(3):201–2 **(Spa)**

ULTRASONOGRAPHY

Ultrasound in screening for neonatal adrenal hemorrhage. Felc Z. **Am J Perinatol** 1995 Sep;12(5):363–6

Antenatal sonographic findings of fetal adrenal hemorrhage. Strouse PJ, et al. **J Clin Ultrasound** 1995 Sep;23(7):442–6

[Bilateral adrenal hemorrhage induced by stress. Radiological diagnosis. Apropos of a case] Armand JP, et al. **Ann Radiol (Paris)** 1995;38(3):153–6 (Eng. Abstr.) **(Fre)**

[Unilateral adrenal hemorrhage—a Waterhouse–Friderichsen syndrome?] Mühlig K, et al. **Ultraschall Med** 1995 Dec; 16(6):293–6 (Eng. Abstr.) **(Ger)**

VETERINARY

[Ultrasonography of the adrenal gland in dogs] Kaser-Hotz B, et al. **Schweiz Arch Tierheilkd** 1995;137(6):258–64 (Eng. Abstr.) **(Ger)**

VIROLOGY

Clinico-pathological study of cytomegalovirus (CMV) in AIDS autopsies: under-recognition of CMV pneumonitis and CMV adrenalitis. Dore GJ, et al. **Aust N Z J Med** 1995 Oct;25(5):503–6

ADRENAL GLAND HYPERFUNCTION

see related
HYPERANDROGENISM

COMPLICATIONS

Do the salutary effects of food restriction occur because of or despite of the accompanying hyperadrenocorticism? Sapolsky RM. **Neurobiol Aging** 1995 Sep–Oct;16(5):849–50; discussion 855–6 (5 ref.)

[Critical study of the characterization of hyperandrogenism in a group of obese women] Cordray JP, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):403–8 (Eng. Abstr.) **(Fre)**

CONGENITAL see ADRENAL HYPERPLASIA, CONGENITAL

DRUG THERAPY

Canine pituitary-dependent hyperadrenocorticism: a spontaneous animal model for neurodegenerative disorders and their treatment with l-deprenyl. Bruyette DS, et al. **Prog Brain Res** 1995;106:207–15 (30 ref.)

ETIOLOGY

Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome. Gonzalez F, et al. **Fertil Steril** 1996 Sep;66(3):354–61

[Food-dependent Cushing syndrome: a new entity of organic hypercorticism] Matejka G, et al. **Rev Med Interne** 1996; 17(6):461–6 (23 ref.) (Eng. Abstr.) **(Fre)**

[Subclinical hypercortisolism in incidentally detected adrenal adenoma] Seppel T, et al. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):503–7; discussion 508 (Eng. Abstr.) **(Ger)**

METABOLISM

Hypercorticism induces neurotensin mRNA in rat periventricular hypothalamus. Nicot A, et al. **Neuroreport** 1995 Nov 13;6(16):2158–60

PHYSIOPATHOLOGY

Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome. Gonzalez F, et al. **Fertil Steril** 1996 Sep;66(3):354–61

VETERINARY

Diagnostic ophthalmology. Idiopathic endophthalmitis with secondary retinal detachment. Wolfer J, et al. **Can Vet J** 1996 Jun;37(6):377–8

Urinary excretion of glucocorticoids in the diagnosis of hyperadrenocorticism in cats. Goossens MM, et al. **Domest Anim Endocrinol** 1995 Oct;12(4):355–62

Ultrasonographic evaluation of the adrenal glands in dogs. Barthez PY, et al. **J Am Vet Med Assoc** 1995 Nov 1; 207(9):1180–3

One-year follow-up evaluation of magnetic resonance imaging of the brain in dogs with pituitary-dependent hyperadrenocorticism. Bertoy EH, et al. **J Am Vet Med Assoc** 1996 Apr 15;208(8):1268–73

Adrenalectomy for treatment of hyperadrenocorticism in cats: 10 cases (1988–1992). Duesberg CA, et al. **J Am Vet Med Assoc** 1995 Oct 15;207(8):1066–70

Effects of disease on the results of diagnostic tests for use in detecting hyperadrenocorticism in dogs [see comments] Kaplan AJ, et al. **J Am Vet Med Assoc** 1995 Aug 15; 207(4):445–51. Comment in: J Am Vet Med Assoc 1995 Nov 1;207(9):1160–1.

Testing for hyperadrenocorticism [letter; comment] Rhody J. **J Am Vet Med Assoc** 1995 Nov 1;207(9):1160–1. Comment on: J Am Vet Med Assoc 1995 Aug 15;207(4):445–51.

Ultrasonographic characteristics of the adrenal glands in dogs with pituitary-dependent hyperadrenocorticism: comparison with normal dogs. Grooters AM, et al. **J Vet Intern Med** 1996 May-Jun;10(3):110–5

Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism. Montgomery TM, et al. **J Vet Intern Med** 1996 May-Jun;10(3):116–22

Results of adrenalectomy in 36 dogs with hyperadrenocorticism caused by adreno-cortical tumour. van Sluijs FJ, et al. **Vet Q** 1995 Sep;17(3):113–6

Use of ACTH stimulation tests to monitor the treatment of canine hyperadrenocorticism. Dunn KJ, et al. **Vet Rec** 1995 Aug 12;137(7):161–5

ADRENAL GLAND HYPOFUNCTION

BLOOD

Filter paper cortisol profiles in secondary adrenocortical insufficiency. Sieratzki JS, et al. **Arch Dis Child** 1995 Oct; 73(4):351–3

CHEMICALLY INDUCED

Induction of adrenal suppression by megestrol acetate [letter] Khoo SH, et al. **Ann Intern Med** 1996 Mar 15;124(6):613

Induction of adrenal suppression by megestrol acetate [letter] Loprinzi CL, et al. **Ann Intern Med** 1996 Mar 15;124(6):613

Induction of adrenal suppression by megestrol acetate [letter] Stoffer SS, et al. **Ann Intern Med** 1996 Mar 15;124(6):613–4

Use of supplemental steroids in patients having orthopaedic operations. Friedman RJ, et al. **J Bone Joint Surg Am** 1995 Dec;77(12):1801–6

[Growth retardation in an asthmatic child] Saha MT, et al. **Duodecim** 1995;111(5):444–6 **(Fin)**

[Clinical manifestation of adrenal cortex insufficiency during thyroid hormone substitution] Soest R, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):406–8 (Eng. Abstr.) **(Ger)**

[Increased risk of adrenal cortex failure after treatment of allergic rhinitis (letter)] Rolandsson O. **Lakartidningen** 1996 Jul 10;93(28–29):2564 **(Swe)**

COMPLICATIONS

A case of silent 21-hydroxylase deficiency with persistent adrenal insufficiency after removal of an adrenal incidentaloma. Nagasaka S, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):111–6

Clinical features of adrenal insufficiency in patients with acquired immunodeficiency syndrome. Piédrola G, et al. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):97–101

Adrenal insufficiency in the antiphospholipid antibody syndrome. Arnason JA, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):109–16 (27 ref.)

CONGENITAL

The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Burris TP, et al. **Recent Prog Horm Res** 1996;51:241–59; discussion 259–60 (94 ref.)

DIAGNOSIS

The repetitive short corticotropin stimulation test in patients with septic shock [letter] Bouachour G, et al. **Ann Intern Med** 1995 Dec 15;123(12):962–3

Diagnostic significance of dopamine estimation using plasma and urine in patients with adrenal and renal insufficiency, renal transplantation and hypertension. Yoshimura M, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S87–92 (31 ref.)

[Clinical manifestation of adrenal cortex insufficiency during thyroid hormone substitution] Soest R, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):406–8 (Eng. Abstr.) **(Ger)**

[Adrenal cortex insufficiency and hypothyroidism in advanced age] Schürmeyer TH, et al. **Fortschr Med** 1995 Oct 10;113(28):401–3 (Eng. Abstr.) **(Ger)**

[Acute adrenal cortex insufficiency and spondylodiscitis caused by reactivated pulmonary tuberculosis] Roth J, et al. **Med Klin** 1995 Dec 15;90(12):698–700 **(Ger)**

DRUG THERAPY

Successful treatment of CMV-induced adrenal insufficiency by ganciclovir in a patient with the acquired immunodeficiency syndrome. Sanhes L, et al. **Nephrol Dial Transplant** 1995;10(5):704–5

[Glucocorticoid treatment] Kauppinen-Mäkelin R. **Duodecim** 1995;111(8):725–31 (28 ref.) **(Fin)**

ETIOLOGY

Hypercalcaemia and secondary hypoadrenalism due to Sheehan's syndrome [letter] Kelestimur F, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):769–70

Occult adrenal insufficiency secondary to amyloidosis in the context of chronic renal failure. Harvey CJ, et al. **Nephrol Dial Transplant** 1995;10(7):1237–9

[Fulminant, rapidly reversible hepatitis and life-threatening anaphylaxis following rifampicin in an HIV-positive female patient with latent adrenal cortex insufficiency] Canova CR, et al. **Schweiz Med Wochenschr** 1996 Mar 9; 126(10):392–7 (Eng. Abstr.) **(Ger)**

[Hypocorticism due to selected deficiency of CRH with spontaneous resolution. A case report] López JM, et al. **Rev Med Chil** 1995 Mar;123(3):341–4 (Eng. Abstr.) **(Spa)**

GENETICS

A special case of congenital adrenal hypoplasia and acute bilateral infantile striatal necrosis. van der Ent CK, et al. **Acta Paediatr** 1995 Aug;84(8):957–60

Genomic sequence of the DAX1 gene: an orphan nuclear receptor responsible for X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Guo W, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2481–6

New mutations of DAX-1 genes in two Japanese patients with X-linked congenital adrenal hypoplasia and hypogonadotropic hypogonadism. Yanase T, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):530–5

The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Burris TP, et al. **Recent Prog Horm Res** 1996;51:241–59; discussion 259–60 (94 ref.)

PATHOLOGY

Angiotropic large cell lymphoma presenting as primary adrenal insufficiency. Chu P, et al. **Hum Pathol** 1996 Feb; 27(2):209–11 (24 ref.)

RADIOGRAPHY

Adrenal insufficiency with enlarged adrenals. Efremidis SC, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):168–71

VETERINARY

Hypoadrenocorticism [letter; comment] Aronson L. **J Am Anim Hosp Assoc** 1996 Mar–Apr;32(2):90. Comment on: J Am Anim Hosp Assoc 1995 Jul–Aug;31(4):301–5.

Concurrent hypoadrenocorticism and hypoalbuminemia in dogs: a retrospective study. Langlais-Burgess L, et al. **J Am Anim Hosp Assoc** 1995 Jul–Aug;31(4):307–11

Hypoadrenocorticism in a family of leonbergers [see comments] Smallwood LJ, et al. **J Am Anim Hosp Assoc** 1995 Jul–Aug;31(4):301–5. Comment in: J Am Anim Hosp Assoc 1996 Mar–Apr;32(2):90.

Pretreatment clinical and laboratory findings in dogs with hypoadrenocorticism: 225 cases (1979–1993). Peterson ME, et al. **J Am Vet Med Assoc** 1996 Jan 1;208(1):85–91

ADRENAL GLAND NEOPLASMS

Beneficial effects of octreotide in a patient with a metastatic

paraganglioma [letter] Tenenbaum F, et al. **Eur J Cancer** 1996 Apr;32A(4):737

Phaeochromocytoma in pregnancy: a case report. Atan A, et al. **Int Urol Nephrol** 1996;28(1):11–3

Phaeochromocytoma in various disguises. Monkelbaan JF, et al. **Neth J Med** 1995 Aug;47(2):70–5

Left ventricular myxoma, adrenal tumour and cutaneous vasculitis—a case report. Koh WH, et al. **Singapore Med J** 1995 Jun;36(3):328–30

[Pheochromocytoma and pregnancy. Two case reports] Barhmi R, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):543–8 (24 ref.) (Eng. Abstr.) **(Fre)**

[Adrenal hemangioma: review of the literature] Llado Carbonell C, et al. **Prog Urol** 1996 Apr;6(2):292–6 (38 ref.) (Eng. Abstr.) **(Fre)**

[Clinical and therapeutic features of MEN II] De Toma G, et al. **G Chir** 1995 Jun–Jul;16(6–7):297–301 (Eng. Abstr.) **(Ita)**

[A case of adrenal neoplasm] Petrone U, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):185–8 (Eng. Abstr.) **(Ita)**

[Cutaneous vasculitis, mixed cryoglobulinemia in a patient with non-secreting monolateral pheochromocytoma. A likely paraneoplastic syndrome] Perrone A, et al. **Recenti Prog Med** 1995 Dec;86(12):499–502 (Eng. Abstr.) **(Ita)**

[Adrenal myelolipoma. Report of a case and review of the literature] Bordallo Cortina A, et al. **Arch Esp Urol** 1996 Mar;49(2):184–7 (18 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Malignant phaeochromocytoma with high circulating DOPA, and clonidine-suppressible noradrenaline. McClean DR, et al. **Blood Press** 1995 Jul;4(4):215–7

Does plasma neuropeptide-Y immunoreactivity in patients with pheochromocytoma depend on hormonal activity of the tumor? Pruszczyk P, et al. **Clin Chim Acta** 1995 Dec 29;243(2):205–12

Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected adrenal tumors. Bencsik Z, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1726–9

Another case of hypocholesterolemia associated with virilizing adrenal adenoma [letter; comment] Benvenga S. **J Clin Endocrinol Metab** 1995 Nov;80(11):3391–2. Comment on: J Clin Endocrinol Metab 1995 Jan;80(1):92–6.

Selective venous catheterization and plasma catecholamine analysis in the diagnosis of phaeochromocytoma. Walker IA. **J R Soc Med** 1996 Apr;89(4):216P–8P

CHEMICALLY INDUCED

Pseudo-phaeochromocytoma and the serotonin syndrome [letter; comment] Brown TM, et al. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):513. Comment on: Clin Endocrinol (Oxf) 1995 Jan;42(1):95–8; discussion 98–9.

Experimental studies on the long-term effects of methylphenidate hydrochloride. Dunnick JK, et al. **Toxicology** 1995 Nov 30;103(2):77–84

CHEMISTRY

Stage-specific expression of integrin alphaVbeta3 in neuroblastic tumors. Gladson CL, et al. **Am J Pathol** 1996 May;148(5):1423–34

Ultrastructural localization of endothelin-1 in nonneoplastic, hyperplastic, and neoplastic adrenal gland. Li Q, et al. **Ultrastruct Pathol** 1995 Nov–Dec;19(6):489–94

COMPLICATIONS

Pheochromocytoma with reversible focal cardiac dysfunction. Scott IU, et al. **Am Heart J** 1995 Oct; 130(4):909–11

Phaeochromocytoma associated with myasthenia gravis precipitated by propranolol treatment [letter] Choi KL, et al. **Aust N Z J Med** 1995 Jun;25(3):257

Hypertension secondary to adrenal tumors ten years experience. Vázquez Quintana E, et al. **Bol Asoc Med P R** 1995 Jul–Sep;87(7–9):124–5

Pheochromocytoma associated with clinical and echocardiographic features simulating hypertrophic obstructive cardiomyopathy. Huddle KR, et al. **Chest** 1996 May;109(5):1394–7

Acute reversal of pheochromocytoma-induced catecholamine cardiomyopathy. Nanda AS, et al. **Clin Cardiol** 1995 Jul;18(7):421–3 (8 ref.)

Coexistence of bilateral adrenal phaeochromocytoma and idiopathic hyperaldosteronism. Tan GH, et al. **Clin Endocrinol (Oxf)** 1996 May;44(5):603–9

Cushing's disease associated with adrenal myelolipoma, adrenal calcification and thyroid cancer. Yoshioka M, et al. **Endocr J** 1994 Aug;41(4):461–6

Anaesthetic management of a patient with von Hippel–Lindau disease: a combination of bilateral phaeochromocytoma and spinal cord haemangioblastoma. Ercan M, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):81–3

Another case of hypocholesterolemia associated with virilizing adrenal adenoma [letter; comment] Benvenga S. **J Clin Endocrinol Metab** 1995 Nov;80(11):3391–2. Comment on: J Clin Endocrinol Metab 1995 Jan;80(1):92–6.

Heart rate variability before sudden blood pressure elevations or complex cardiac arrhythmias in phaeochromocytoma. Dabrowska B, et al. **J Hypertens** 1996 Jan;10(1):43–50

Conn syndrome in a child, caused by adrenal adenoma. Abasiyanik A, et al. **J Pediatr Surg** 1996 Mar;31(3):430–2 (15 ref.)

Aldosteronoma in childhood [letter; comment] Etker S. **J Pediatr Surg** 1995 Jul;30(7):1113 (15 ref.). Comment on: J Pediatr Surg 1994 Oct;29(10):1388–91.

Spontaneous retroperitoneal hemorrhage from a giant adrenal myelolipoma. Goldman HB, et al. **J Urol** 1996 Feb; 155(2):639

Hypomelanosis of Ito associated with neuroblastoma. Oguma E, et al. **Pediatr Radiol** 1996;26(4):273–5

Pressor effect of metoclopramide in phaeochromocytoma [letter] Freestone S, et al. **Postgrad Med J** 1996 Mar; 72(845):188–9

Pheochromocytoma associated with polycythemia: case report. Rezkalla MA, et al. **S D J Med** 1995 Oct; 48(10):349–51

[Tumors outside of the central nervous system in Von Hippel–Lindau disease] Veltman GA, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13;140(15):823–6 (33 ref.) **(Dut)**

[Infrahepatic ectopic non-secreting chromaffin tumor] Pfister C, et al. **Ann Chir** 1995;49(10):963–7 (Eng. Abstr.) (Fre)

[Granulosis rubra nasi and pheochromocytoma] Heid E, et al. **Ann Dermatol Venereol** 1996;123(2):106–8 (Eng. Abstr.) **(Fre)**

[Pheochromocytoma in Von Hippel Lindau disease. 3 cases] Tourniaire J, et al. **Ann Endocrinol (Paris)** 1995; 56(6):609–12 (Eng. Abstr.) **(Fre)**

[Pheochromocytoma-induced multiorgan failure. An internal medicine and surgical emergency] Lamberts R, et al. **Dtsch Med Wochenschr** 1996 Apr 12;121(15):479–84 (Eng. Abstr.) **(Ger)**

[Subclinical hypercortisolism in incidentally detected adrenal adenoma] Seppel T, et al. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):503–7; discussion 508 (Eng. Abstr.) **(Ger)**

[Tachycardia and hypotension attacks as the main symptoms of pheochromocytoma—case report] Sayali E, et al. **Wien Med Wochenschr** 1995;145(14):333–6 (Eng. Abstr.) **(Ger)**

[Pheochromocytoma-gastric leiomyoblastoma association. A possible expression of Carney's triad. A case report] Amoroso A, et al. **Recenti Prog Med** 1995 Sep;86(9):348–52 (Eng. Abstr.) **(Ita)**

[Pheochromocytoma, acute myocardial infarction and silent postprandial ischemia] Juncal A, et al. **Rev Esp Cardiol** 1996 Jan;49(1):73–6 (Eng. Abstr.) **(Spa)**

CONGENITAL

Spontaneous resolution of antenatally diagnosed adrenal masses. Holgersen LO, et al. **J Pediatr Surg** 1996 Jan; 31(1):153–5

The complete spectrum of neurocristopathy in an infant with congenital hypoventilation, Hirschsprung's disease, and neuroblastoma. Stovroff M, et al. **J Pediatr Surg** 1995 Aug; 30(8):1218–21

Urinary excretion of methylated catecholamine metabolites in a child with neuroblastoma maturing into ganglioneuroma. Candito M, et al. **Med Pediatr Oncol** 1996 Jan;26(1):57–60

DIAGNOSIS

Fine needle aspiration cytology of primary and metastatic lesions of the adrenal gland. A series of 188 biopsies with radiologic correlation. Saboorian MH, et al. **Acta Cytol** 1995 Sep–Oct;39(5):843–51

Magnetic resonance imaging of neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Wang YM, et al. **Acta Paediatr Sin** 1995 Nov–Dec;36(6):420–4

CT and MR imaging of adrenal hemangioma. A case report. Rieber A, et al. **Acta Radiol** 1995 Nov;36(6):659–61

Adrenal myelolipoma. Cyran KM, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):395–400

Hypertension and myocardial and cerebral infarctions. **Am J Med** 1996 Mar;100(3):357–64

The incidental adrenal mass. Cook DM, et al. **Am J Med** 1996 Jul;101(1):88–94 (03 ref.)

Phaeochromocytoma diagnosis [letter] Tormey WP. **Ann Clin Biochem** 1995 Nov;32 (Pt 6):595–7

Plasma metanephrines in the diagnosis of pheochromocytoma [letter] Elijovich F. **Ann Intern Med** 1996 Apr 1; 124(7):694–5

The urinary metanephrine-to-creatinine ratio for the diagnosis of pheochromocytoma [see comments] Héron E, et al. **Ann Intern Med** 1996 Aug 15;125(4):300–3. Comment in: Ann Intern Med 1996 Aug 16;125(4):331–2.

Phaeochromocytoma. Foo M, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):318–21

Investigation of phaeochromocytoma. Bouloux PG, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):657–64 (31 ref.)

MR imaging of primary adrenal lymphoma. Kato H, et al. **Clin Imaging** 1996 Apr–Jun;20(2):126–8

Preoperative endocrine tumor localization utilizing a cost-effective approach. Leight GS Jr, et al. **Curr Opin Gen Surg** 1993;:108–14 (19 ref.)

Incidentally discovered adrenal tumors. Saxe A. **Curr Opin Gen Surg** 1993;:121–9 (50 ref.)

The characteristics of nine patients with adrenal incidentalomas. Kamel N, et al. **Endocr J** 1995 Aug; 42(4):497–503 (21 ref.)

Incidentally discovered adrenal masses. Kloos RT, et al. **Endocr Rev** 1995 Aug;16(4):460–84 (253 ref.)

Hemorrhage in cavernous hemangioma of the adrenal gland: US, CT and MRI appearances with pathologic correlation. Boraschi P, et al. **Eur J Radiol** 1995 Nov;21(1):41–3

Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected adrenal tumors. Bencsik Z, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1726–9

Overnight excretion of urinary catecholamines and metabolites in the detection of pheochromocytoma. Peaston RT, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1378–84

Eight echo T2 measurements of adrenal masses: limitations of differential diagnosis by relaxation time determination. Gruss LP, et al. **J Comput Assist Tomogr** 1996 Sep–Oct; 20(5):792–7

Paroxystic hypertension in a long-term hemodialyzed patient. Successful adrenalectomy for a dopamine-producing pheochromocytoma. Ferrante A, et al. **J Endocrinol Invest** 1995 Sep;18(8):656–62

MR demonstration of a cystic pheochromocytoma. Belden CJ, et al. **J Magn Reson Imaging** 1995 Nov–Dec;5(6):778–80

Diencephalic epilepsy resembling pheochromocytoma: a first reported case in Thailand. Charoenlarp K, et al. **J Med Assoc Thai** 1995 Jun;78(6):332–6

Pheochromocytoma in pregnancy: a case report. Kunthonkitidej K. **J Med Assoc Thai** 1996 Apr; 79(4):258–62

Death from phaeochromocytoma: lessons from a post-mortem survey. Platts JK, et al. **J R Coll Physicians Lond** 1995 Jul–Aug;29(4):299–306

Pheochromocytoma and pseudovasculitis [letter] McColl GJ, et al. **J Rheumatol** 1995 Jul;22(7):1442–3

Dihydroxyphenylglycol in pheochromocytoma: its diagnostic use for norepinephrine dominant tumor. Nakada T, et al. **J Urol** 1996 Jan;155(1):14–8

Contrast-enhanced MR imaging of the kidneys and adrenal glands. Huch Böni RA, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):101–31 (61 ref.)

Pheochromocytoma: on the verge of extinction under managed care. Gross JS, et al. **N J Med** 1996 Jul; 93(7):39–40

Surgical excision of adrenal masses; a ten-year experience. Kogire M, et al. **Nippon Geka Hokan** 1995 Mar 1;64(2):45–9

Bilateral adrenal masses. Lopez E, et al. **Postgrad Med J** 1995 Sep;71(839):567–8

Abdominal tumours and neurofibromatosis. Martin AJ, et al. **Postgrad Med J** 1996 Jan;72(843):59–60

Adrenal incidentaloma: subclinical Cushing's syndrome. Newell-Price J, et al. **Postgrad Med J** 1996 Apr; 72(846):207–10 (27 ref.)

Myelolipoma of the adrenal gland found incidentally during abdominal ultrasound and computed tomography examinations. Nonomura A, et al. **Radiat Med** 1996 Jan–Feb;14(1):37–42

Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Korobkin M, et al. **Radiology** 1995 Nov;197(2):411–8

Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Korobkin M, et al. **Radiology** 1996 Sep;200(3):743–7

Adrenal masses: correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Outwater EK, et al. **Radiology** 1996 Sep;200(3):749–52

Adrenal masses in patients with malignancy: prospective comparison of echo-planar, fast spin-echo, and chemical shift MR imaging. Schwartz LH, et al. **Radiology** 1995 Nov; 197(2):421–5

[Non-functioning adrenal tumor: clinical analysis of 29 cases] Kong C, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep; 33(9):557–8 (Eng. Abstr.) **(Chi)**

[Pheochromocytoma, pulmonary nodule and hypercalcemia (clinical conference)] Kauppinen-Mäkelin R, et al. **Duodecim** 1995;111(7):644–51 **(Fin)**

[Detection of patients with pheochromocytoma using a cybernetic analysis method of the signs and symptoms of the disease] Balažovjech I, et al. **Ann Urol (Paris)** 1996; 30(1):7–13 (Eng. Abstr.) **(Fre)**

[Problems posed by asymptomatic pheochromocytoma and malignant tumors of the adrenal medulla] Zvara V, et al. **Ann Urol (Paris)** 1996;30(1):14–9 (Eng. Abstr.) **(Fre)**

[Dysfunction of the aldosterone synthesis pathway as a marker of malignity in symptomatic and asymptomatic adrenal masses] Aupetit-Faisant B, et al. **Bull Acad Natl Med** 1995 Oct;179(7):1355–65; discussion 1365–7 (Eng. Abstr.) **(Fre)**

[Vena cava invasion in adrenal gland tumors: findings in nuclear magnetic resonance tomography] Kolb M, et al. **Aktuelle Radiol** 1995 Nov;5(6):356–9 (Eng. Abstr.) **(Ger)**

[Subclinical hypercortisolism in incidentally detected adrenal adenoma] Seppel T, et al. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):503–7; discussion 508 (Eng. Abstr.) **(Ger)**

[Abdominal space-occupying lesion. Bilateral pheochromocytoma in MEN IIa and well differentiated retroperitoneal liposarcoma] Lohr F, et al. **Radiologe** 1995 Aug;35(8):543–5 **(Ger)**

[Adrenal gland carcinoma—status of diagnostic and therapeutic possibilities] Wunderlich H, et al. **Z Arztl Fortbild (Jena)** 1996 May;90(3):221–6 (16 ref.) (Eng. Abstr.) **(Ger)**

[Multiple "incidentalomas" (clinical conference)] Ben-Chetrit E, et al. **Harefuah** 1996 Mar 15;130(6):433–6 **(Heb)**

[Incidental discovery of adrenal neoplasms: our experience] Bellantone R, et al. **Ann Ital Chir** 1995 Jul–Aug; 66(4):439–48 (Eng. Abstr.) **(Ita)**

[Diagnostic and therapeutic approach to incidentally detected adrenal tumors] Tridico F, et al. **Minerva Chir** 1995 Nov; 50(11):943–8 (Eng. Abstr.) **(Ita)**

[Adrenal adenoma or hyperplasia? Problems of differential diagnosis in an unusual case of primary hyperaldosteronism] Sanna AL, et al. **Minerva Med** 1996 Mar;87(3):93–7 (Eng. Abstr.) **(Ita)**

[Scintigraphic characterization of expansive lesions located in the adrenals. Comparison with magnetic resonance imaging] Maurea S, et al. **Radiol Med (Torino)** 1995 Dec; 90(6):756–65 (Eng. Abstr.) **(Ita)**

[Imaging diagnosis in a case of adrenal cystic ganglioneuroblastoma in a child] Miele V, et al. **Radiol Med (Torino)** 1996 Apr;91(4):485–8 (11 ref.) **(Ita)**

[Primary malignant lymphoma of the adrenal gland: a case report] Mizusawa H, et al. **Hinyokika Kiyo** 1995 Dec; 41(12):991–4 (Eng. Abstr.) **(Jpn)**

[Atypical overgrowth of the left suprarenal gland imitating pheochromocytoma] Orzel M, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:133–6 (Eng. Abstr.) **(Pol)**

[Familial occurrence of pheochromocytoma] Feltynowski T, et al. **Pol Arch Med Wewn** 1995 May;93(5):427–32 (Eng. Abstr.) **(Pol)**

[A false diagnosis of hypertrophic myocardiopathy in pheochromocytoma] Lopes HF, et al. **Arq Bras Cardiol** 1995 Aug;65(2):167–9 (Eng. Abstr.) **(Por)**

[Cystic lymphangioma of the adrenal gland] Duca S, et al. **Chirurgia (Bucur)** 1995;44(1):43–7 (8 ref.) **(Rum)**

[25 years' experience with diagnosis of pheochromocytoma] Balažovjech I. **Vnitr Lek** 1995 Aug;41(8):513–6 (Eng. Abstr.) **(Slo)**

[Pheochromocytoma: a review of our own cases] Blasco Alfonso JE, et al. **Actas Urol Esp** 1996 Jan;20(1):43–9 (Eng. Abstr.) **(Spa)**

[Hemangioma of the adrenal gland] Martín Martínez JC, et al. **Actas Urol Esp** 1995 Oct;19(9):729–32 (Eng. Abstr.) **(Spa)**

[Adrenal myelolipoma: apropos a case with urologic symptomatology. A review of the literature] Pérez Arbej JA, et al. **Actas Urol Esp** 1995 Mar;19(3):243–6 (27 ref.) (Eng. Abstr.) **(Spa)**

[Pheochromocytoma in children: 2 cases] Fernández Córdoba MS, et al. **An Esp Pediatr** 1996 Mar;44(3):277–8 (6 ref.) **(Spa)**

[Addisonian crisis as initial manifestation of bilateral metastatic adrenal tumor (letter)] Fuentes Jimenez FJ, et al. **An Med Interna** 1995 Dec;12(12):619–20 **(Spa)**

[Laboratory contribution to the diagnosis of pheochromocytoma] Rivero Marcotegui A, et al. **An Med Interna** 1996 Jan;13(1):40–4 (60 ref.) **(Spa)**

[Bilateral primary adrenal lymphoma with atypical presentation as an addisonian crisis (letter)] Sanjuán F, et al. **Med Clin (Barc)** 1995 Dec 8;105(20):798 **(Spa)**

[Incidental adrenal masses] López Hernández E, et al. **Rev Clin Esp** 1995 Dec;195(12):873–81 (85 ref.) **(Spa)**

[Adrenal incidentalomas are a diagnostic dilemma. New guidelines for investigation and treatment. Medical Research Council] Ahrén B, et al. **Lakartidningen** 1996 Sep 4;93(36):3041–5 **(Swe)**

DRUG THERAPY

Dexamethasone-suppressible adrenal tumour in untreated 21-hydroxylase deficiency [letter] Bevan JS, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):733–7

Influence of alpha-adrenergic blockade on ventricular arrhythmias, QTc interval and heart rate variability in phaeochromocytoma. Dąbrowska B, et al. **J Hum Hypertens** 1995 Nov;9(11):925–9

Hypervitaminosis A as a complication of treatment for neuroblastoma. Grissom LE, et al. **Pediatr Radiol** 1996; 26(3):200–2

[Follow-up of malignant metastatic pheochromocytoma. Discussion of the therapeutic strategy] Fett W, et al. **Med Klin** 1995 Nov 15;90(11):661–4, 672 **(Ger)**

[Combination chemotherapy of ifosfamide and etoposide for advanced neuroblastoma] Matsumoto K, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2119–21 **(Jpn)**

ENZYMOLOGY

Correlating telomerase activity levels with human neuroblastoma outcomes [see comments] Hiyama E, et al. **Nat Med** 1995 Mar;1(3):249–55. Comment in: Nat Med 1995 Mar;1(3):203–5.

ETIOLOGY

Primary adrenal leiomyosarcoma in a man with acquired immunodeficiency syndrome (AIDS). Further evidence for an increase in smooth muscle tumors related to Epstein–Barr infection in AIDS. Zetler PJ, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1164–7 (19 ref.)

Adrenocortical nodules in post-mortem series. Development, functional significance, and differentiation from adenomas. Reinhard C, et al. **Gen Diagn Pathol** 1996 Mar; 141(3–4):203–8

Risk factors for adrenal cancer: an exploratory study. Hsing AW, et al. **Int J Cancer** 1996 Feb 8;65(4):432–6

GENETICS

Primary adrenal lymphoma with chromosomal abnormalities. Sasagawa I, et al. **Acta Haematol** 1995;94(3):156–62 (34 ref.)

RET proto-oncogene mutations and rearrangements in endocrine diseases [comment] Lloyd RV. **Am J Pathol** 1995 Dec;147(6):1539–44. Comment on: Am J Pathol 1995 Dec;147(6):1600–7.

Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Burgess JR, et al. **Arch Surg** 1996 Jul; 131(7):699–702

Molecular and immunohistochemical analysis of P53 in phaeochromocytoma. Dahia PL, et al. **Br J Cancer** 1995 Nov;72(5):1211–3

Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma. Eng C, et al. **Br J Cancer** 1996 Aug;74(3):339–41

Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Maris JM, et al. **Cancer Res** 1995 Oct 15; 55(20):4664–9

Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas. Aguiar RC, et al. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):93–6

PCR-SSCP analysis of the angiotensin II type 1 receptor gene in patients with aldosterone-producing adenomas. Klemm SA, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul; 22(6–7):457–9

Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma. Kimura T, et al. **Endocr J** 1995 Aug;42(4):517–25

Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome). Oishi S, et al. **Endocr J** 1995 Aug;42(4):527–36

Complex congenital heart disease, microcephaly, pheochromocytoma and neurofibromatosis type I in a girl born from consanguineous parents. Stoll C, et al. **Genet Couns** 1995;6(3):217–20

RET mutation screening in sporadic pheochromocytoma [letter; comment] Arnold A. **J Clin Endocrinol Metab** 1996 Jan;81(1):430. Comment on: J Clin Endocrinol Metab 1995 Jul;80(7):2063–8.

Familial pheochromocytoma associated with a novel mutation in the von Hippel–Lindau gene. Gross DJ, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):147–9

Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. Pascoe L, et al. **J Clin Invest** 1995 Nov;96(5):2236–46

Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. Modigliani E, et al. **J Intern Med** 1995 Oct;238(4):363–7

Molecular genetic diagnosis of von Hippel–Lindau disease in familial phaeochromocytoma. Crossey PA, et al. **J Med Genet** 1995 Nov;32(11):885–6

Von Hippel–Lindau disease and pheochromocytoma [letter; comment] Walther MM, et al. **JAMA** 1996 Mar 20; 275(11):839–40. Comment on: JAMA 1995 Oct 11;274(14):1149–51.

Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas. Komminoth P. **Verh Dtsch Ges Pathol** 1995;79:L–LV

[Multiple familial pheochromocytomas: sonographic demonstration of multiple adrenal, celiac and bladder localizations in a child] Arroja JM, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1231–4 (Eng. Abstr.) **(Fre)**

[Prognostic factors in neuroblastoma. Usefulness of DNA analysis using flow cytometry on paraffin-embedded material] Massara FM, et al. **Pediatr Med Chir** 1996 Mar–Apr;18(2):141–8 (Eng. Abstr.) **(Ita)**

[Familial neuroblastoma] Nakamura M, et al. **Nippon Rinsho** 1995 Nov;53(11):2684–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Proliferating cell nuclear antigen immunoreaction in adrenal tumors. Damiani D, et al. **Tumori** 1995 Jul–Aug;81(4):273–7

METABOLISM

Double effect of ethanol on intracellular Ca2+ levels in undifferentiated PC12 cells. Belia S, et al. **Cell Signal** 1995 May;7(4):389–95

Does plasma neuropeptide-Y immunoreactivity in patients with pheochromocytoma depend on hormonal activity of the tumor? Pruszczyk P, et al. **Clin Chim Acta** 1995 Dec 29;243(2):205–12

Analysis of the renin gene in patients with aldosterone-producing adenomas by polymerase chain reaction-single stranded conformational polymorphisms and long polymerase chain reaction. Ballantine DM, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):484–6

Assessment of adrenal surgery on creatinine clearance in patients with phaeochromocytoma. Nakada T, et al. **Int Urol Nephrol** 1995;27(2):121–30

Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. de Herder WW, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3168–72

Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. deS Senanayake P, et al. **J Clin Invest** 1995 Nov;96(5):2503–9

Quantitative analysis of messenger ribonucleic acid encoding natriuretic peptide receptors in aldosterone-producing adenoma. Chen YM, et al. **Mol Cell Endocrinol** 1995 Jun; 111(2):139–46

Nck inhibits NGF and basic FGF induced PC12 cell differentiation via mitogen-activated protein kinase-independent pathway. Rockow S, et al. **Oncogene** 1996 Jun 6;12(11):2351–9

MORTALITY

Death from phaeochromocytoma: lessons from a post-mortem survey. Platts JK, et al. **J R Coll Physicians Lond** 1995 Jul–Aug;29(4):299–306

PATHOLOGY

Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Yu L, et al. **Am J Clin Oncol** 1996 Aug;19(4):389–93 (29 ref.)

A case of von Recklinghausen's disease with bilateral pheochromocytoma-malignant peripheral nerve sheath tumors of the adrenal and gastrointestinal autonomic nerve tumors. Sakaguchi N, et al. **Am J Surg Pathol** 1996 Jul; 20(7):889–97

A unique dysembryonic neoplasm of the adrenal gland composed of nephrogenic rests in a child. Santonja C, et al. **Am J Surg Pathol** 1996 Jan;20(1):118–24

Pheochromocytomas with extension into central vascular structures. Rötker J, et al. **Ann Thorac Surg** 1996 Jan; 61(1):222–4

Adrenal ganglioneuroma. Celik V, et al. **Br J Surg** 1996 Feb; 83(2):263

Connatal localized neuroblastoma. The case to delay treatment. Kerbl R, et al. **Cancer** 1996 Apr 1;77(7):1395–401

Potentiation of enediyne-induced apoptosis and differentiation by Bcl-2. Cortazzo M, et al. **Cancer Res** 1996 Mar 15;56(6):1199–203

Histologic, flow cytometric, and genetic criteria in endocrine surgery. Flynn SD, et al. **Curr Opin Gen Surg** 1993;:115–20 (45 ref.)

Metastatic liposarcoma in the adrenal gland: report of two cases diagnosed by fine-needle aspiration. McCutcheon J, et al. **Diagn Cytopathol** 1995 Nov;13(4):330–2

Adrenal and extra-adrenal phaeochromocytomas. contribution of histology, immunochemistry and DNA flow cytometry in the diagnosis of malignancy [letter; comment] Gosset P, et al. **Eur J Surg** 1996 Jan;162(1):77 . Comment on: Eur J Surg 1994 Oct;160(10):547–52.

Two cases of pheochromocytoma diagnosed histopathologically as mixed neuroendocrine–neural tumor. Watanabe T, et al. **Intern Med** 1995 Jul;34(7):683–7 (47 ref.)

Neuroblastoma metastatic to brain [clinical conference] Xaidara A, et al. **Med Pediatr Oncol** 1996 Mar;26(3):208–14

Adrenal gland leiomyoma in a child with acquired immunodeficiency syndrome. Jimenez-Heffernan JA, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):923–9 (22 ref.)

[Unusual relapse for neuroblastoma. Case of an intracranial relapse] Frappaz D, et al. **Bull Cancer (Paris)** 1996 Mar; 83(3):239–42 (Eng. Abstr.) **(Fre)**

[Retrospective analysis of 44 adrenal puncture biopsies under x-ray computed tomographic guidance] Mesurolle B, et al. **J Radiol** 1996 Jan;77(1):17–21 (Eng. Abstr.) **(Fre)**

[Morphological typing, evaluation of tumor dignity and prognosis and etiologic classification of adrenomedullary and adrenocortical neoplasias] Schröder S, et al. **Pathologe** 1995 Sep;16(5):307–14 (57 ref.) (Eng. Abstr.) **(Ger)**

[Characteristics of the morphological structure of malignant tumors of the adrenal medulla] Kalashnikov SA, et al. **Klin Khir** 1995;(5):26–8 **(Rus)**

[A giant adrenal mass: the anatomicopathological surprise finding] Mármol Navarro S, et al. **Arch Esp Urol** 1995 Nov; 48(9):949–51 (8 ref.) (Eng. Abstr.) **(Spa)**

[Insulin-dependent diabetes mellitus and a malignant pheochromocytoma with a long-term evolution (letter)] Catalina PF, et al. **Rev Clin Esp** 1995 Oct;195(10):737 **(Spa)**

PHYSIOPATHOLOGY

Heart rate variability in pheochromocytoma. Dabrowska B, et al. **Am J Cardiol** 1995 Dec 1;76(16):1202–4

Heart rate variability before sudden blood pressure elevations or complex cardiac arrhythmias in phaeochromocytoma. Dabrowska B, et al. **J Hypertens** 1996 Jan;10(1):43–50

PREVENTION & CONTROL

Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Potmesil M, et al. **Cancer Res** 1995 Dec 1;55(23):5637–41

[Screening of multiple endocrine neoplasias type 1. Reflexions of the Study Group on Multiple Endocrine Neoplasias type 1] Cougard P, et al. **Ann Chir** 1995; 49(6):500–6 (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Adrenal nonhyperfunctioning adenoma and nonadenoma: CT attenuation value as discriminative index. Miyake H, et al. **Abdom Imaging** 1995 Nov–Dec;20(6):559–62

Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. Korobkin M, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):531–6

Genitourinary case of the day. Giant adrenal myelolipoma. Moran RE, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):246, 248

Segmented areas of increased attenuation in the liver caused by right adrenal tumors: CT features. Itai Y, et al. **J Comput Assist Tomogr** 1995 Nov–Dec;19(6):959–62

Scintigraphic diagnosis of subclinical Cushing's syndrome in patients with adrenal incidentalomas. Dominguez–Gadea L, et al. **Nucl Med Commun** 1996 Jan;17(1):29–32

Delayed enhanced CT for differentiation of benign from malignant adrenal masses. Korobkin M, et al. **Radiology** 1996 Sep;200(3):737–42

[Giant myelolipoma of the adrenals. A report of 3 cases studied by CT and a review of the literature] Catalano O, et al. **Radiol Med (Torino)** 1995 Dec;90(6):842–6 (53 ref.) **(Ita)**

[The computed tomographic characteristics of adrenal tumors] Cheremisin VM, et al. **Vestn Rentgenol Radiol** 1996 Mar–Apr;(2):22–5 (Eng. Abstr.) **(Rus)**

[A woman with a unilateral adrenal mass. The adrenal metastasis of a medullary carcinoma of the thyroid] Maroto P, et al. **Rev Clin Esp** 1995 Dec;195(12):847–8 (5 ref.) **(Spa)**

RADIONUCLIDE IMAGING

Pheochromocytoma with catecholamine–induced impairment of cardiac neuronal function. Agostini D, et al. **Am Heart J** 1995 Nov;130(5):1128–30

Case report: failure of adrenal scintigraphy to exhibit 131I cholesterol uptake in a CT–demonstrated, surgically proven aldosteronoma. Salam Z, et al. **Am J Med Sci** 1996 Sep;312(3):130–2

False–positive imaging of In–111 labeled monoclonal antibody conjugate CYT–103 in a patient with metastatic colorectal carcinoma. Bhatia M, et al. **Clin Nucl Med** 1995 Nov;20(11):979–80

Delayed presentation of adrenal neuroblastoma. Nye PJ, et al. **Clin Nucl Med** 1996 May;21(5):416–7

Abnormal cardiac sympathetic nerve function in a patient with pheochromocytoma. An analysis using 123I metaiodobenzylguanidine scintigraphy. Izumi C, et al. **Int J Cardiol** 1995 Jun 30;50(2):189–92

Usefulness of 123I–metaiodobenzylguanidine (MIBG) scintiscan in the diagnosis of juxta–adrenal schwannoma. Tommaselli AP, et al. **J Clin Endocrinol Metab** 1996 Feb; 81(2):843–6

Iodine–123–MIBG imaging in pheochromocytoma with cardiomyopathy and pulmonary edema. Suga K, et al. **J Nucl Med** 1996 Aug;37(8):1361–4

SECONDARY

Clinical impact of adrenal expansive lesions in bronchial carcinoma. Eggesbø HB, et al. **Acta Radiol** 1996 May;37(3 Pt 1):343–7

Renal cell carcinoma and erythropoietin [letter; comment] Sungur C. **Ann Intern Med** 1995 Nov 1;123(9):732–3. Comment on: Ann Intern Med 1995 May 1;122(9):676–7.

Case of the month: hidden trouble. Obaro RO. **Br J Radiol** 1995 Dec;68(816):1369–70

Adrenalectomy for metastatic disease to the adrenal glands. Lo CY, et al. **Br J Surg** 1996 Apr;83(4):528–31

Detection of adrenal metastasis from osteosarcoma by Tc–99m MDP scintigraphy. Kauffman WM, et al. **Clin Nucl Med** 1995 Aug;20(8):741

Renal cell carcinoma with synchronous bilateral adrenal metastases. Tsuboniwa N, et al. **Int J Urol** 1995 Jul; 2(3):208–10

Surgical treatment of adrenal metastasis following pulmonary resection for lung cancer: comparison of adrenalectomy with palliative therapy [letter; comment] Dieter RA. **Int Surg** 1995 Apr–Jun;80(2):195. Comment on: Int Surg 1994 Apr–Jun;79(2):124–9.

Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. Kletscher BA, et al. **J Urol** 1996 Jun;155(6):1844–6

Clinics in diagnostic imaging (8). Adrenal metastasis from bronchial carcinoma. Helpert C, et al. **Singapore Med J** 1995 Dec;36(6):671–3

[Treatment of non–small–cell lung cancer and solitary adrenal gland metastasis] Andreasen JJ, et al. **Ugeskr Laeger** 1996 May 27;158(22):3167–8 (Eng. Abstr.) **(Dan)**

[A case of adrenal gland metastasis of a cutaneous melanoma treated by excision with 3–year survival] Claude R, et al. **Ann Urol (Paris)** 1996;30(1):44–5 (Eng. Abstr.) **(Fre)**

[Late and multiple endocrine metastases of an adenocarcinoma of the kidney] Avisse C, et al. **Chirurgie** 1994–95;120(11):50–3 (Eng. Abstr.) **(Fre)**

[Ipsilateral adrenalectomy in the surgical treatment of renal carcinoma] Marois C, et al. **Prog Urol** 1995 Dec;5(6):961–4 (Eng. Abstr.) **(Fre)**

[Renal cell carcinoma with solitary asynchronous adrenal metastasis] Maeda Y, et al. **Hinyokika Kiyo** 1996 Jan; 42(1):39–42 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Asynchronous metastases solely to the bilateral adrenal glands from bladder cancer: a case report] Watanabe J, et al. **Hinyokika Kiyo** 1996 Jan;42(1):63–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Single metastasis of renal adenocarcinoma in contralateral adrenal gland] Diego García A, et al. **Actas Urol Esp** 1995 Apr;19(4):314–8; discussion 318–9 (20 ref.) (Eng. Abstr.) **(Spa)**

[Bilateral synchronous adrenal metastasis of renal adenocarcinoma] Rodríguez–Rubio FI, et al. **Actas Urol Esp** 1995 Nov–Dec;19(10):795–7 (Eng. Abstr.) **(Spa)**

[A woman with a unilateral adrenal mass. The adrenal metastasis of a medullary carcinoma of the thyroid] Maroto P, et al. **Rev Clin Esp** 1995 Dec;195(12):847–8 (5 ref.) **(Spa)**

SECRETION

Masked hyperprolactinemia in a case of aldosterone–producing adrenal adenoma [letter] Oki Y, et al. **Ann Intern Med** 1995 Dec 1;123(11):893–4

Adrenal tumor producing 11–deoxycorticosterone, 18–hydroxy–11–deoxycorticosterone and aldosterone. Toyoda Y, et al. **Intern Med** 1996 Feb;35(2):123–8

Different patterns of steroid secretion in patients with adrenal incidentaloma. Terzolo M, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):740–4

Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Drénou B, et al. **Nouv Rev Fr Hematol** 1995;37(3):197–9 (18 ref.)

Adrenocorticotropic hormone–secreting pheochromocytomas: the exception to the rule. Chen H, et al. **Surgery** 1995 Dec;118(6):988–94; discussion 994–5

SURGERY

Pre–operative management for surgery of pheochromocytoma. Májek M, et al. **Ann Urol (Paris)** 1996; 30(1):20–4

Initial experience with endoscopic retroperitoneal adrenalectomy. Parrilla P, et al. **Br J Surg** 1996 Jul; 83(7):987–8

Laparoscopic adrenalectomy. Stuart RC, et al. **Br J Surg** 1995 Nov;82(11):1498–9

Phaeochromocytoma and calcium channel block [letter; comment] Tobias JD. **Can J Anaesth** 1995 Sep;42(9):837–8 . Comment on: Can J Anaesth 1995 Mar;42(3):228–30.

Connatal localized neuroblastoma. The case to delay treatment. Kerbl R, et al. **Cancer** 1996 Apr 1;77(7):1395–401

Endoscopic adrenalectomy: the adrenals under the scope? Cuesta MA, et al. **Clin Endocrinol (Oxf)** 1996 Mar; 44(3):349–51

Laparoscopic adrenalectomy for adrenal tumours causing hypertension and for 'incidentalomas' of the adrenal on computerized tomography scanning. Rutherford JC, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):490–2

Modified venovenous bypass technique for resection of renal and adrenal carcinomas with involvement of the inferior vena cava. Baumgartner F, et al. **Eur J Surg** 1996 Jan; 162(1):59–62

A case of massive adrenal malignant pheochromocytoma: management of a large pheochromocytoma. Kondo T, et al. **Hinyokika Kiyo** 1995 Sep;41(9):669–73

Assessment of adrenal surgery on creatinine clearance in patients with phaeochromocytoma. Nakada T, et al. **Int Urol Nephrol** 1995;27(2):121–30

Primary aldosteronism in pregnancy—should it be treated surgically? Aboud E, et al. **Ir J Med Sci** 1995 Oct–Dec; 164(4):279–80 (12 ref.)

Laparoscopic adrenalectomy compared to open adrenalectomy for benign adrenal neoplasms [see comments] Brunt LM, et al. **J Am Coll Surg** 1996 Jul; 183(1):1–10. Comment in: J Am Coll Surg 1996 Jul;183(1):71–3.

Resection of primary tumor at diagnosis in stage IV–S neuroblastoma: does it affect the clinical course? Guglielmi M, et al. **J Clin Oncol** 1996 May;14(5):1537–44

Laparoscopic adrenalectomy: review of 14 cases and comparison with open adrenalectomy. Naito S, et al. **J Endourol** 1995 Dec;9(6):491–5

Laparoscopic adrenalectomy: clinical results in 25 patients. Nakagawa K, et al. **J Endourol** 1995 Jun;9(3):265–7

Cystic neuroblastoma of infancy. Richards ML, et al. **J Pediatr Surg** 1995 Sep;30(9):1354–7 (16 ref.)

Laparoscopic surgery for neuroblastoma identified by mass screening. Yamamoto H, et al. **J Pediatr Surg** 1996 Mar; 31(3):385–8

Surgical excision of adrenal masses; a ten–year experience. Kogire M, et al. **Nippon Geka Hokan** 1995 Mar 1;64(2):45–9

Surgery of the incidentally discovered mass of the adrenal gland (incidentaloma). Fronticelli CM, et al. **Panminerva Med** 1995 Jun;37(2):60–4

Results of endoscopic retroperitoneal adrenalectomy. Heintz A, et al. **Surg Endosc** 1996 Jun;10(6):633–5

Surgical strategy for pheochromocytoma: emphasis on the pledge of flank extraperitoneal approach in selected patients. Obara T, et al. **Surgery** 1995 Dec;118(6):1083–9

Removal of large adrenal tumor on the right side with liver mobilization. Nakada T, et al. **Urol Int** 1995;55(4):209–14

Retroperitoneoscopy: a laparoscopic approach for adrenal and renal surgery. Gasman D, et al. **Urology** 1996 Jun; 47(6):801–6

[Role of laparoscopy in surgery of the adrenal glands] Henry JF, et al. **J Chir (Paris)** 1996 May;133(3):111–6 (Eng. Abstr.) **(Fre)**

[Adrenal myelolipoma. Apropos of 3 cases] el Mezni F, et al. **J Urol (Paris)** 1995;101(4):203–6 (Eng. Abstr.) **(Fre)**

[Synchronous cancers. A case with three localizations: rectal cancer associated with familial polyposis, breast cancer and adrenal gland cancer (letter)] Eisinger F, et al. **Presse Med** 1995 Oct 21;24(31):1446 **(Fre)**

[Ipsilateral adrenalectomy in the surgical treatment of renal carcinoma] Marois C, et al. **Prog Urol** 1995 Dec;5(6):961–4 (Eng. Abstr.) **(Fre)**

[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery] Schüttler J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):341–9 (Eng. Abstr.) **(Ger)**

[Laparoscopic adrenalectomy in pheochromocytoma] Vogelbach P, et al. **Schweiz Med Wochenschr** 1995 Sep 16;125(37):1735–9 (25 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic adrenalectomy. Experiences with 50 patients] Suzuki K, et al. **Urologe A** 1996 May;35(3):233–7 (Eng. Abstr.) **(Ger)**

[Adrenal incidentaloma] Schmid M, et al. **Zentralbl Chir** 1995;120(9):702–6 (Eng. Abstr.) **(Ger)**

[Diagnostic and therapeutic approach to incidentally detected adrenal tumors] Tridico F, et al. **Minerva Chir** 1995 Nov; 50(11):943–8 (Eng. Abstr.) **(Ita)**

[123I–metaiodobenzylguanidine myocardial scintigraphy in a case of pheochromocytoma before and after resection of it] Matsumoto K, et al. **Kaku Igaku** 1995 Sep; 32(9):1023–8 (Eng. Abstr.) **(Jpn)**

[Anesthesia with transesophageal echocardiography for removal of pheochromocytoma] Matsuura T, et al. **Masui** 1995 Oct;44(10):1388–90 (Eng. Abstr.) **(Jpn)**

[Extraperitoneal laparoscopic adrenalectomy: the initial 9 cases] Suzuki K, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 May;87(5):809–14 (Eng. Abstr.) **(Jpn)**

[Perioperative course of 17 cases of pheochromocytoma] González R, et al. **Rev Invest Clin** 1996 Mar–Apr; 48(2):97–103 (Eng. Abstr.) **(Spa)**

THERAPY

Comprehensive treatment of advanced neuroblastoma involving autologous bone marrow transplant. Mugishima H, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):493–9

URINE

The clinical and laboratory correlates of an increased urinary 5–hydroxyindoleacetic acid. Tormey WP, et al. **Postgrad Med J** 1995 Sep;71(839):542–5 (16 ref.)

VETERINARY

Adrenal gland adenomas in raccoons (Procyon lotor) from the eastern United States. Hamir AN, et al. **J Vet Diagn Invest** 1995 Jul;7(3):413–6

Malignant melanocytic neural crest tumor in a young chicken (Gallus domesticus). Hafner S, et al. **Vet Pathol** 1995 Sep; 32(5):535–7

ADRENAL GLANDS

see related

ADRENALECTOMY

Ectopic adrenal tissue in the inguinal region in children. Okur H, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct;15(5):763–7

Testicular adrenal rest tissue in congenital adrenal hyperplasia: findings at Gray–scale and color Doppler US. Avila NA, et al. **Radiology** 1996 Jan;198(1):99–104

ABNORMALITIES

Zinner's syndrome associated with adrenal gland and vena cava malformation: a very rare case. Kyriakidis A, et al. **Br J Urol** 1995 Oct;76(4):523–4

Sex and the single DAX1: too little is bad, but can we have too much? [editorial; comment] McCabe ER. **J Clin Invest** 1996 Aug 15;98(4):881–2. Comment on: J Clin Invest 1996 Aug 15;98(4):1055–62.

Horseshoe adrenal in Ivemark (asplenia) syndrome. Horgan JG, et al. **J Ultrasound Med** 1995 Oct;14(10):785–6

Monosomy 7 syndrome associated with congenital adrenal hypoplasia and male pseudohermaphroditism. Le SQ, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):854–6

Mice deficient in the orphan receptor steroidogenic factor 1 lack adrenal glands and gonads but express P450 side–chain–cleavage enzyme in the placenta and have normal embryonic serum levels of corticosteroids. Sadovsky Y, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10939–43

ANATOMY & HISTOLOGY

The influence of stress on the adrenals of the springbok (Antidorcas marsupialis). Van Rijswijk AW, et al. **J S Afr Vet Assoc** 1995 Dec;66(4):251–3

Adrenal medullary ganglion neurons project into the splanchnic nerve. Dagerlind A, et al. **Neuroscience** 1995 Dec;69(4):1019–1023

[Electroacupuncture promotes enlargement of adrenals and enhances level of blood corticosterone in ovariectomized rats] Gao H, et al. **Chen Tzu Yen Chiu** 1995;20(2):55–8 (Eng.

Abstr.) **(Chi)**

BLOOD SUPPLY

Vascular architecture of the human fetal adrenal gland: a SEM study of corrosion casts. Pityński K, et al. **Anat Anz** 1996 Jun;178(3):215–22

Blood supply of the ovine adrenal gland and its relevance in adrenal autotransplantation. Hardy KJ, et al. **Aust Vet J** 1995 Jul;72(7):262–5

Effect of arginine vasopressin on regional adrenal blood flow and plasma cortisol concentration in fetal sheep. Carter AM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct; 62(2):235–9

Regional adrenal blood flow responses to adrenocorticotropic hormone after chronic embolization of the fetal placental circulation in sheep. Carter AM, et al. **J Endocrinol** 1996 Mar;148(3):517–22

Local transfer of hormones between blood vessels within the adrenal gland may explain the functional interaction between the adrenal cortex and medulla. Einer-Jensen N, et al. **Med Hypotheses** 1995 Jun;44(6):471–4

An anatomical study on the arteries to the left adrenal gland of sheep and goat. Karadağ H. **Schweiz Arch Tierheilkd** 1995;137(8):391–4

[Opening of the left V. spermatica interna into the left V. suprarenalis] Risse JH, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):364–6 (9 ref.) **(Ger)**

[Cardiac weight in patients with chronic Chagas disease with Trypanosoma cruzi nests in the central vein of the adrenal glands] Teixeira V de P, et al. **Arq Bras Cardiol** 1995 Apr; 64(4):315–7 (Eng. Abstr.) **(Por)**

CHEMISTRY

Simultaneous measurement of enzyme activity, protein, mRNA, and metabolites in small samples. Burke WJ, et al. **Anal Biochem** 1995 Sep 20;230(2):345–8

Comparative effects of two dithiocarbamates disulfiram and thiram, on adrenal catecholamine content and on plasma dopamine-beta-hydroxylase activity. Caroldi S, et al. **Arch Toxicol** 1995;69(10):690–3

Localization of diazepam-binding inhibitor-related peptides and peripheral type benzodiazepine receptors in the frog adrenal gland. Lesouhaitier O, et al. **Cell Tissue Res** 1996 Mar;283(3):403–12

Stress-induced elevation of ouabainlike compound in rat plasma and adrenal. Goto A, et al. **Hypertension** 1995 Dec; 26(6 Pt 2):1173–6

Expression of the steroidogenic acute regulatory protein mRNA in adrenal tumors and cultured adrenal cells. Liu J, et al. **J Endocrinol** 1996 Jul;150(1):43–50

Leucine enkephalin level in rat hypothalamus, striatum, hippocampus and adrenal glands in experimental rat uremia. Waluga M, et al. **Pol J Pathol** 1995;46(4):235–8

Ultrastructural localization of endothelin-1 in nonneoplastic, hyperplastic, and neoplastic adrenal gland. Li Q, et al. **Ultrastruct Pathol** 1995 Nov–Dec;19(6):489–94

[Ultrastructural and immunohistochemical localization of endothelin-1 in nonneoplastic, hyperplastic and neoplastic adrenal gland] Li Q, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):128–31 (Eng. Abstr.) **(Chi)**

CYTOLOGY

Immunohistochemical analysis of adrenal proliferation and corticosterone expression in experimental adrenal regeneration. Sarría R, et al. **Histol Histopathol** 1995 Jul; 10(3):603–9

Voltage-dependent currents and modulation of calcium channel expression in zona fasciculata cells from rat adrenal gland. Barbara JG, et al. **J Physiol (Lond)** 1995 Nov 1;488 (Pt 3):609–22

DRUG EFFECTS

Adrenal suppression among asthmatic children receiving chronic therapy with inhaled corticosteroid with and without spacer device. Goldberg S, et al. **Ann Allergy Asthma Immunol** 1996 Mar;76(3):234–8

Hexachlorocyclohexanes inhibit steroidogenesis in Y1 cells. Absence of correlation with binding to the peripheral-type benzodiazepine binding site. Zisterer DM, et al. **Biochem Pharmacol** 1996 May 17;51(10):1303–8

Effects of yohimbine and desipramine on adrenal catecholamine release in response to splanchnic nerve stimulation in anesthetized dogs. Koganei H, et al. **Biol Pharm Bull** 1995 Sep;18(9):1207–10

Properties of trichosporin-B-VIa-induced catecholamine secretion from bovine adrenal chromaffin cells. Tachikawa E, et al. **Biol Pharm Bull** 1995 Aug;18(8):1165–7

Pharmacological modulation of adrenal medullary GABAA receptor: consistent with its subunit composition. Parramón M, et al. **Br J Pharmacol** 1995 Sep;116(2):1875–81

Regionally specific induction of ICE mRNA and enzyme activity in the rat brain and adrenal gland by LPS. Tingsborg S, et al. **Brain Res** 1996 Mar 11;712(1):153–8

Effects of gonadal androgens on adrenal androgen levels [letter; comment] Cutolo M. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):490–1. Comment on: Clin Endocrinol (Oxf) 1995 Oct;43(4):415–21.

Regulation of 21-hydroxylase activity by steroids. Bélanger A, et al. **Endocr Res** 1995 Feb–May;21(1–2):329–41

Mechanisms of interleukin-1-induced hormone secretion from the rat adrenal gland. Gwosdow AR. **Endocr Res** 1995 Feb–May;21(1–2):25–37

In vivo effects of adrenocorticotropin on c-jun, jun-B, c-fos and fos-B in rat adrenal. LeHoux JG, et al. **Endocr Res** 1995 Feb–May;21(1–2):267–74

The effect of cytochrome b5 on progesterone metabolism in the ovine adrenal. Swart P, et al. **Endocr Res** 1995 Feb–May;21(1–2):297–306

Diurnal variation in resting levels of corticosterone is not mediated by variation in adrenal responsiveness to adrenocorticotropin but involves splanchnic nerve integrity. Dijkstra I, et al. **Endocrinology** 1996 Feb; 137(2):540–7

Renal and adrenal mechanisms in cyclosporine-induced hyperkalaemia after renal transplantation. Laine J, et al. **Eur J Clin Invest** 1995 Sep;25(9):670–6

Randomised crossover comparison of adrenal suppressive effects of dermal creams containing glucocorticosteroids. Visscher HW, et al. **Eur J Clin Pharmacol** 1995;48(2):123–5

Intraperitoneal administration of bacterial endotoxin enhances noradrenergic neurotransmission in the rat preoptic area: relationship with body temperature and hypothalamic--pituitary--adrenocortical axis activity. Linthorst AC, et al. **Eur J Neurosci** 1995 Dec 1; 7(12):2418–30

Differential effects of endogenous and exogenous nitric oxide on the release of endothelin-1 from the intact perfused rat adrenal gland in situ. Hinson JP, et al. **FEBS Lett** 1996 Jan 22;379(1):7–10

Hepatic and adrenal toxicity of a novel lipid regulator in beagle dogs. Wolfgang GH, et al. **Fundam Appl Toxicol** 1995 Jul;26(2):272–81

Atrial natriuretic peptide stimulates aldosterone production by turkey (Meleagris gallopavo) adrenal steroidogenic cells. Kocsis JF, et al. **Gen Comp Endocrinol** 1995 Sep; 99(3):364–72

Effects of dopaminergic drugs on the sympathoadrenal system. Damase-Michel C, et al. **Hypertens Res** 1995 Jun; 18 Suppl 1:S119–24

Effect of long-term administration of melatonin on adrenal histomorphology of the Indian desert gerbil Meriones hurrianae Jerdon. Joshi BN, et al. **Indian J Exp Biol** 1995 Nov;33(11):833–6

Effects of a long acting somatostatin analog on pituitary, adrenal, and testicular function during rest and acute exercise: unexpected stimulation of testosterone secretion. Vasankari T, et al. **J Clin Endocrinol Metab** 1995 Nov; 80(11):3298–303

Megestrol acetate-induced adrenal suppression [letter] Loprinzi CL, et al. **J Clin Oncol** 1996 Feb;14(2):689

Extracellular inhibition and intracellular enhancement of Ca2+ currents by Pb2+ in bovine adrenal chromaffin cells. Sun LR, et al. **J Neurophysiol** 1995 Aug;74(2):574–81

Influence of the central histaminergic systems on the pituitary-adrenocortical response to met-enkephalinamide. Bugajski J, et al. **J Physiol Pharmacol** 1995 Sep; 46(3):313–22

Cigarette smoking is associated with elevated adrenal androgen response to adrenocorticotropin. Hautanen A, et al. **J Steroid Biochem Mol Biol** 1993 Aug;46(2):245–51

Stimulation of the secretion of dehydroepiandrosterone by melatonin in mouse adrenals in vitro. Haus E, et al. **Life Sci** 1996;58(14):PL263–7

Effect of dietary chloride on aldosterone synthase induction and angiotensin II receptors in rat adrenals. Shibata H, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):167–75

Repeated endotoxin treatment decreases immune and hypothalamo-pituitary-adrenal axis responses: effects of orchidectomy and testosterone therapy. Hadid R, et al. **Neuroendocrinology** 1995 Oct;62(4):348–55

Hormonal control of rat adrenal phenylethanolamine N-methyltransferase. Enzyme activity, the final critical pathway. Wong DL, et al. **Neuropsychopharmacology** 1995 Nov;13(3):223–34

Regulatory mechanism of calcium efflux from cultured bovine adrenal chromaffin cells induced by extracellular ATP. Houchi H, et al. **Neurosci Lett** 1995 Oct 6; 198(3):177–80

Effects of beta-FNA on sympathoadrenal, cardiovascular, and analgesic responses to DAMPGO at rest and during stress. Houdi AA, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):927–33

Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Clark DJ, et al. **Thorax** 1996 Mar;51(3):262–6

[Changes in the weight of the uterus, ovaries and adrenal glands in sexually mature rats treated with estradiol and reserpine] Borisov I, et al. **Akush Ginekol (Sofiia)** 1994; 33(2):18–20 (Eng. Abstr.) **(Bul)**

[An experimental study of the effect of an artichoke preparation on the activity of the sympathetic-adrenal system in carbon disulfide exposure] Khalkova Zh, et al. **Probl Khig** 1995;20:162–71 (Eng. Abstr.) **(Bul)**

[The central hemodynamic changes and reaction of the sympathoadrenal system with the use of an original Russian analgesic fenaridin as the analgetic component of general anesthesia during aortocoronary bypass operations in patients with chronic ischemic heart disease] Tenshibaeva DA, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):51–5 (Eng. Abstr.) **(Rus)**

[The effect of antidepressants on the catecholamine content of the rat hypothalamus and adrenals] Arushanian EB, et al. **Eksp Klin Farmakol** 1995 Nov–Dec;58(6):14–6 (Eng. Abstr.) **(Rus)**

[The effect of epiphysectomy and melatonin administration on the catecholamine content of rat hypothalamic and adrenal tissue] Arushanian EB, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):173–5 **(Rus)**

[Biochemical-histological study of the effects of lithium on various organs of vizcacha (Lagostomus maximus maximus)] García Aseff S, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(2):87–95 (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Development of the sympathoadrenal system in the chick embryo: an immunocytochemical study with antibodies to pan-neuroendocrine markers, catecholamine-synthesizing enzymes, proprotein-processing enzymes, and neuropeptides. Sánchez-Montesinos I, et al. **Anat Rec** 1996 May;245(1):94–101

A cell-specific nuclear receptor plays essential roles in adrenal and gonadal development. Luo X, et al. **Endocr Res** 1995 Feb–May;21(1–2):517–24

Biphasic developmental expression of adrenocorticotropin receptor messenger ribonucleic acid levels in the baboon fetal adrenal gland. Albrecht ED, et al. **Endocrinology** 1996 Apr;137(4):1292–8

Developmentally regulated expression of adrenal 17 alpha-hydroxylase cytochrome P450 in the mouse embryo. Keeney DS, et al. **Endocrinology** 1995 Nov;136(11):4872–9

Continuous intrafetal infusion of prostaglandin E2 prematurely activates the hypothalamo-pituitary-adrenal axis and induces parturition in sheep. Young IR, et al. **Endocrinology** 1996 Jun;137(6):2424–31

Sympathoadrenal and other endocrine and metabolic responses to hypoglycaemia in the fetal foal during late gestation. Silver M, et al. **Exp Physiol** 1995 Jul;80(4):651–62

Type 2 11 beta-hydroxysteroid dehydrogenase in foetal and adult life. Stewart PM, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(5–6):465–71

Human fetal adrenal hydroxysteroid sulphotransferase: cDNA cloning, stable expression in V79 cells and functional characterisation of the expressed enzyme. Forbes KJ, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):53–60

Hypothalamic pituitary adrenal function in the sheep fetus. Matthews SG, et al. **Reprod Fertil Dev** 1995;7(3):509–16 (52 ref.)

[Morphology of an additional (pharyngeal) adenohypophysis and its interrelationship with pharyngeal tonsils in the human fetus] Khlystova ZS, et al. **Biull Eksp Biol Med** 1995 Aug;120(8):211–4 **(Rus)**

[The biosynthesis of cortisol and its regulation by the adrenocorticotropic hormone in the adrenals of silver fox embryos] Osadchuk LV. **Ontogenez** 1996 May–Jun; 27(3):218–21 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Effect of Ca2+ on the activity of mitochondrial NADP-specific isocitrate dehydrogenase from rabbit adrenals. Strumiło E. **Acta Biochim Pol** 1995;42(3):325–8

Effect of TGF-beta on dehydroepiandrosterone sulfotransferase in cultured human fetal adrenal cells. Parker CR Jr, et al. **Ann N Y Acad Sci** 1995 Dec 29; 774:326–8

Aldose reductase is a major reductase for isocaproaldehyde, a product of side-chain cleavage of cholesterol, in human and animal adrenal glands. Matsuura K, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):265–71

Effect of estrogen and progesterone on the expression of hepatic and extrahepatic sterol 27-hydroxylase in baboons (Papio sp). Kushwaha RS, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1088–94

Tissue-specific expression of two aldose reductase-like genes in mice: abundant expression of mouse vas deferens protein and fibroblast growth factor-regulated protein in the adrenal gland. Lau ET, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):609–15

Localization and activity of adrenal carbonyl reductase during the estrous cycle. Inazu N, et al. **Biol Pharm Bull** 1995 May;18(5):671–6

3-Deoxyglucosone reductase in dog adrenal glands. Identification as aldose reductase. Matsuura K, et al. **Biol Pharm Bull** 1995 Dec;18(12):1765–7

Functional aromatase expression in porcine adrenal gland and testis. Conley AJ, et al. **Biol Reprod** 1996 Feb;54(2):497–505

Nicotine elicits changes in expression of adrenal catecholamine biosynthetic enzymes, neuropeptide Y and immediate early genes by injection but not continuous administration. Hiremagalur B, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):109–15

Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 Chinese hamster cells. Denner K, et al. **Endocr Res** 1995 Feb–May;21(1–2):443–8

Immunohistochemical evaluation of the cellular localization and ontogeny of 3 beta-hydroxysteroid dehydrogenase/delta 5-4 isomerase in the human fetal adrenal gland. Parker CR Jr, et al. **Endocr Res** 1995 Feb–May;21(1–2):69–80

Developmentally regulated expression of adrenal 17 alpha-hydroxylase cytochrome P450 in the mouse embryo. Keeney DS, et al. **Endocrinology** 1995 Nov;136(11):4872-9

Increase in nitric oxide synthase and NADPH-diaphorase in the adrenal gland of streptozotocin-diabetic Wistar rats and its prevention by ganglioside. Afework M, et al. **Int J Dev Neurosci** 1996 Apr;14(2):111-23

Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. Pascoe L, et al. **J Clin Invest** 1995 Nov;96(5):2236-46

The hamster adrenal cytochrome P450C11 has equipotent 11beta-hydroxylase and 19-hydroxylase activities, but no aldosterone synthase activity. Véronneau S, et al. **J Steroid Biochem Mol Biol** 1996 Jan;57(1-2):125-39

Lysosomal enzyme activity in rat adrenal gland related to the postnatal development. Bianchi RA, et al. **Mech Ageing Dev** 1995 Oct 13;84(2):151-6

Human fetal adrenal hydroxysteroid sulphotransferase: cDNA cloning, stable expression in V79 cells and functional characterisation of the expressed enzyme. Forbes KJ, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):53-60

Cellular localization of 11 beta-hydroxysteroid dehydrogenase 2 gene expression in the ovine adrenal gland. Yang K, et al. **Mol Cell Endocrinol** 1995 Jun; 111(2):R19-23

Age-related changes in tetrahydrobiopterin and GTP-cyclohydrolase activity in the brain and adrenal gland of rats. Hossain MA, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):627-32

The rat hepatic lipase gene is expressed into two different proteins in liver, adrenals and ovaries. Verhoeven AJ, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:54-5

GROWTH & DEVELOPMENT

Immunoreactive inhibin concentrations in human gonads and adrenals during the first years of life. Brennemann W, et al. **Horm Res** 1995;44(3):115-20

The peptide ACTH(1-39), adrenal growth and steroidogenesis in the sheep fetus after disconnection of the hypothalamus and pituitary. Phillips ID, et al. **J Physiol (Lond)** 1996 Mar 15;491 (Pt 3):871-9

IMMUNOLOGY

Association of arginine vasopressin-secreting cell, steroid-secreting cell, adrenal and islet cell antibodies in a patient presenting with central diabetes insipidus, empty sella, subclinical adrenocortical failure and impaired glucose tolerance. De Bellis A, et al. **Horm Res** 1995; 44(3):142-6

Interaction between endocrine and immune system. Tsushima T. **J Toxicol Sci** 1995 Sep;20(4):474-6

INJURIES

Organ injury scaling VII: cervical vascular, peripheral vascular, adrenal, penis, testis, and scrotum. Moore EE, et al. **J Trauma** 1996 Sep;41(3):523-4

[Post-traumatic hemorrhage of the right adrenal gland with late clinical onset. A case report] Romiti S, et al. **Radiol Med (Torino)** 1995 Oct;90(4):516-9 **(Ita)**

INNERVATION

A case of von Recklinghausen's disease with bilateral pheochromocytoma-malignant peripheral nerve sheath tumors of the adrenal and gastrointestinal autonomic nerve tumors. Sakaguchi N, et al. **Am J Surg Pathol** 1996 Jul; 20(7):889-97

Effects of exposure to stressors of varying predictability on adrenal function in rats. Pitman DL, et al. **Behav Neurosci** 1995 Aug;109(4):767-76

Stimulation of neurite growth rat adrenal chromaffin cells infected with a defective herpes simplex virus carrying an NGF minigene. Bohn MC, et al. **Gene Ther** 1994;1 Suppl 1:S70

Immunohistochemical distribution of S-100 protein and type IV collagen in human embryonic and fetal sympathetic neuroblasts. Magro G, et al. **Histochem J** 1995 Sep; 27(9):694-701

Immunohistochemical heterogeneity of nerve cells in the human adrenal gland with special reference to substance P. Colombo-Benkmann M, et al. **J Histochem Cytochem** 1996 Apr;44(4):369-75

METABOLISM

Comparison of the effects of 2-deoxyglucose and immobilization on secretion and synthesis rate of catecholamines in the adrenal gland: a microdialysis study in conscious rats. Kuzmin AI, et al. **Acta Physiol Scand** 1995 Oct;155(2):147-55

Role of [Na+]i and [Ca2+]i in nicotine-induced norepinephrine release from bovine adrenal chromaffin cells. Gerber SH, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C572-81

Regulation of human dehydroepiandrosterone metabolism by insulin. Nestler JE. **Ann N Y Acad Sci** 1995 Dec 29; 774:73-81

Effects of HSV-1, a neurotropic virus, on the hypothalamic-pituitary-adrenocortical axis in rats. Ben-Hur T, et al. **Brain Res** 1995 Dec 8;702(1-2):17-22

Radioautographic studies on aging change of DNA synthesis and the ultrastructural development of mouse adrenal gland. Ito M. **Cell Mol Biol (Noisy-le-grand)** 1996 Mar; 42(2):279-92

Increased expression of proopiomelanocortin (POMC) mRNA in adrenal glands of mice undergoing graft-versus-host disease (GVHD): association with persistent elevated plasma corticosterone levels. You-Ten KE, et al. **Clin Exp Immunol** 1995 Dec;102(3):596-602

Characteristics of ATP-induced catecholamine secretion from adrenal chromaffin cells of the guinea-pig. Asano T, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):101-8

Intraadrenal steroid metabolism in the guinea pig: guinea pig adrenal microsomes metabolize androstenedione in a manner distinct from liver microsomes. Black VH, et al. **Endocr Res** 1995 Feb-May;21(1-2):315-28

Cortisol: a tool to study aldosterone biosynthesis in rats. Matković L, et al. **Endocr Res** 1995 Feb-May;21(1-2):471-5

Biphasic developmental expression of adrenocorticotropin receptor messenger ribonucleic acid levels in the baboon fetal adrenal gland. Albrecht ED, et al. **Endocrinology** 1996 Apr;137(4):1292-8

Regulation of immunoreactive androgen receptor in the adrenal gland of the adult rat. Bentvelsen FM, et al. **Endocrinology** 1996 Jul;137(7):2659-63

Different 5'-flanking regions of the inhibin-alpha gene target transgenes to the gonad and adrenal in an age-dependent manner in transgenic mice. Hsu SY, et al. **Endocrinology** 1995 Dec;136(12):5577-86

Specific binding sites for proadrenomedullin N-terminal 20 peptide (PAMP) in the rat. Iwasaki H, et al. **Endocrinology** 1996 Jul;137(7):3045-50

Effect of transforming growth factor beta-1 on the cholesterol side-chain cleavage system in the adrenal gland of sheep fetuses and newborns. Naaman-Reperant E, et al. **Endocrinology** 1996 Mar;137(3):886-92

Adrenal androgen production in polycystic ovary syndrome. McKenna TJ, et al. **Eur J Endocrinol** 1995 Oct;133(4):383-9 (35 ref.)

Impact of gestational age on the catecholamine responses of the fetal sheep adrenal to cholinergic stimulation in vitro. Butler TG, et al. **Exp Physiol** 1995 Sep;80(5):767-77

Rat renin gene transcription is initiated at a single start site. Della Bruna R, et al. **FEBS Lett** 1995 Sep 25; 372(2-3):157-60

Adrenal steroidogenesis is related to insulin in hyperandrogenic women. Martikainen H, et al. **Fertil Steril** 1996 Oct;66(4):564-70

Immunohistochemical correlation of human adrenal nerve fibres and thoracic dorsal root neurons with special reference to substance P. Heym C, et al. **Histochem Cell Biol** 1995 Sep;104(3):233-43

Immunohistochemical analysis of adrenal proliferation and corticosterone expression in experimental adrenal regeneration. Sarría R, et al. **Histol Histopathol** 1995 Jul; 10(3):603-9

Immunoreactive inhibin concentrations in human gonads and adrenals during the first years of life. Brennemann W, et al. **Horm Res** 1995;44(3):115-20

A promoter within intron 35 of the human C4A gene initiates abundant adrenal-specific transcription of a 1 kb RNA: location of a cryptic CYP21 promoter element? Tee MK, et al. **Hum Mol Genet** 1995 Nov;4(11):2109-16

Genetic analysis of renin gene expression in rat adrenal gland. Iwai N, et al. **Hypertension** 1996 Apr;27(4):975-8

Distinct mechanisms of upregulation of type 1A angiotensin II receptor gene expression in kidney and adrenal gland. Wang DH, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1134-7

Calretinin immunoreactivity in adrenal glands of developing, adult and ageing Sprague-Dawley rats. Afework M, et al. **Int J Dev Neurosci** 1995 Oct;13(6):515-21

Proliferating cell nuclear antigen in ACTH-independent bilateral macronodular adrenal hyperplasia. Nomata K, et al. **Int J Urol** 1995 Jul;2(3):203-5

Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control. Wang N, et al. **J Biol Chem** 1996 Aug 30;271(35):21001-4

Opposite regulation of thrombospondin-1 and corticotropin-induced secreted protein/thrombospondin-2 expression by adrenocorticotropic hormone in adrenocortical cells. Lafeuillade B, et al. **J Cell Physiol** 1996 Apr;167(1):164-72

Suppression of maternal adrenal dehydroepiandrosterone and dehydroepiandrosterone sulfate production by estrogen during baboon pregnancy. Albrecht ED, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3201-8

Human adrenal cells express tumor necrosis factor-alpha messenger ribonucleic acid: evidence for paracrine control of adrenal function. González-Hernández JA, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):807-13

Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production [see comments] Plump AS, et al. **J Clin Invest** 1996 Jun 1;97(11):2660-71. Comment in: J Clin Invest 1996 Jun 1;97(11):2405-6.

Why we should give a qualified welcome to ouabain: a whole new family of adrenal steroid hormones? Hinson JP, et al. **J Endocrinol** 1995 Sep;146(3):369-72

Expression of the c-myc gene in human adrenals: regulation by adrenocorticotropin in primary cultures. Liu J, et al. **J Endocrinol** 1996 Mar;148(3):523-9

The effect of constant light on the concentration of catecholamines of the hypothalamus and adrenal glands, circulatory hadrenocorticotropin hormone and progesterone. Ivanišević-Milovanović OK, et al. **J Endocrinol Invest** 1995 May;18(5):378-83

A comparison between short synacthen test and depot synacthen test in the evaluation of cortisol reserve of adrenal gland in normal subjects. Kelestimur F, et al. **J Endocrinol Invest** 1995 Dec;18(11):823-6

The adrenal renin-angiotensin system: a local hormonal regulator of aldosterone production. Mulrow PJ, et al. **J Hypertens** 1996 Feb;14(2):173-6 (41 ref.)

Structural requirements for cocaine-sensitive and -i sensitive uptake of phenethylamines into the adrenal chromaffin cell. Powers JL, et al. **J Neurochem** 1995 Nov;65(5):2031-42

Multiple tyrosine hydroxylase transcripts and immunoreactive forms in the rat: differential expression in the anterior pituitary and adrenal gland. Schussler N, et al. **J Neurosci Res** 1995 Dec 15;42(6):846-54

Effect of phonophoresis with dexamethasone on adrenal function. Franklin ME, et al. **J Orthop Sports Phys Ther** 1995 Sep;22(3):103-7

Inhibition of adrenal steroid metabolism by administration of 1-aminobenzotriazole to guinea pigs. Xu D, et al. **J Steroid Biochem Mol Biol** 1995 Sep;54(5-6):281-5

Angiotensin II receptor subtypes in the adrenals of pregnant rats. Forcier I, et al. **Mol Cell Endocrinol** 1995 Oct 30; 114(1-2):177-86

Effect of dietary chloride on aldosterone synthase induction and angiotensin II receptors in rat adrenals. Shibata H, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1-2):167-75

Stimulation of the amygdala by glutamate facilitates corticotropin-releasing factor release from the median eminence and activation of the hypothalamic-pituitary-adrenal axis in stressed rats. Gabr RW, et al. **Neuroendocrinology** 1995 Oct;62(4):333-9

Induction of interleukin-1 beta mRNA and enkephalin mRNA in the rat adrenal gland by lipopolysaccharides studied by in situ hybridization histochemistry. Nobel CS, et al. **Neuroimmunomodulation** 1995 Mar-Apr;2(2):61-73

The cholinergic innervation of the adrenal gland and its relation to enkephalin and nitric oxide synthase. Holgert H, et al. **Neuroreport** 1995 Dec 15;6(18):2576-80

Developmental expression of GAP43 mRNA in chromaffin cells and intra-adrenal neurons. Holgert H. **Neuroreport** 1995 Dec 15;6(18):2581-4

Differential regulation of c-fos, proenkephalin and tyrosine hydroxylase gene expression by metrazole in the hamster adrenal and hippocampus. Zhu YS, et al. **Neurosci Lett** 1995 Aug 25;196(3):197-200

Rat corticostatin R4: synthesis, disulfide bridge assignment, and in vivo activity. Cervini LA, et al. **Peptides** 1995; 16(5):837-42

The effects of hydrocortisone-acetate on some biochemical parameters in the liver, thymus, thymocytes and adrenals of white Wistar rats. Giurgea R, et al. **Rom J Physiol** 1993 Jul-Dec;30(3-4):249-52

[The biosynthesis of cortisol and its regulation by the adrenocorticotropic hormone in the adrenals of silver fox embryos] Osadchuk LV. **Ontogenez** 1996 May-Jun; 27(3):218-21 (Eng. Abstr.) **(Rus)**

[Biosynthesis of steroids in the adrenal gland] Plavšić V. **Lijec Vjesn** 1996 Mar;118 Suppl 1:9-10 (Eng. Abstr.) **(Scr)**

PATHOLOGY

Adrenal insufficiency with enlarged adrenals. Efremidis SC, et al. **Abdom Imaging** 1996 Mar-Apr;21(2):168-71

Addison's disease caused by Paracoccidioides brasiliensis: diagnosis by needle aspiration biopsy of the adrenal gland [letter] Faiçal S, et al. **AJR Am J Roentgenol** 1996 Feb; 166(2):461-2

Gantry angulation in CT-guided percutaneous adrenal biopsy. Hussain S. **AJR Am J Roentgenol** 1996 Mar; 166(3):537-9

Phaeochromocytoma. Foo M, et al. **Br J Hosp Med** 1995 Oct 4-17;54(7):318-21

'Til death do us part: a case of failed affection. Weber KT, et al. **Cardiovasc Res** 1995 Jul;30(1):26-30 (32 ref.)

Adrenal changes in murine pulmonary tuberculosis; a clue to pathogenesis? Hernandez-Pando R, et al. **FEMS Immunol Med Microbiol** 1995 Sep;12(1):63-72

Adrenocortical nodules in post-mortem series. Development, functional significance, and differentiation from adenomas. Reinhard C, et al. **Gen Diagn Pathol** 1996 Mar; 141(3-4):203-8

Angiotropic large cell lymphoma presenting as primary adrenal insufficiency. Chu P, et al. **Hum Pathol** 1996 Feb; 27(2):209-11 (24 ref.)

Effect of long-term administration of melatonin on adrenal histomorphology of the Indian desert gerbil Meriones hurrianae Jerdon. Joshi BN, et al. **Indian J Exp Biol** 1995 Nov;33(11):833-6

Coexistence of unilateral adrenal macronodule and Cushing's disease. Report of two cases. Borretta G, et al. **J Endocrinol Invest** 1996 Feb;19(2):131-5

Hepatic and adrenal changes in rabbits associated with hyperlipidemia caused by a semi-synthetic diet. Hausner EA, et al. **Lab Anim Sci** 1995 Dec;45(6):663-70

Contrast-enhanced MR imaging of the kidneys and adrenal

glands. Huch Böni RA, et al.
Magn Reson Imaging Clin N Am 1996 Feb;4(1):101–31 (61 ref.)

Effects of acute and chronic restraint on the adrenal gland weight and serum corticosterone concentration of mice and their faecal output of oocysts after infection with Eimeria apionodes. Tuli JS, et al. **Res Vet Sci** 1995 Jul;59(1):82–6

[Retrospective analysis of 44 adrenal puncture biopsies under x-ray computed tomographic guidance] Mesurolle B, et al. **J Radiol** 1996 Jan;77(1):17–21 (Eng. Abstr.) **(Fre)**

[Adrenal adenoma or hyperplasia? Problems of differential diagnosis in an unusual case of primary hyperaldosteronism] Sanna AL, et al. **Minerva Med** 1996 Mar;87(3):93–7 (Eng. Abstr.) **(Ita)**

[Scintigraphic characterization of expansive lesions located in the adrenals. Comparison with magnetic resonance imaging] Maurea S, et al. **Radiol Med (Torino)** 1995 Dec; 90(6):756–65 (Eng. Abstr.) **(Ita)**

[Cushing syndrome caused by macronodular hyperplasia ACTH-independent] Monnerat R, et al. **Actas Urol Esp** 1996 Apr;20(4):384–7 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

The adrenal renin/angiotensin system. Vinson GP.
Adv Exp Med Biol 1995;377:237–51 (135 ref.)

The relationship between the adrenal tissue renin–angiotensin system, internalization of the type I angiotensin II receptor (AT1) and angiotensin II function in the rat adrenal zona glomerulosa cell. Vinson GP, et al. **Adv Exp Med Biol** 1995; 377:319–29

Absence of enhanced sympathoadrenal activity and behaviorally evoked cardiovascular reactivity among offspring of hypertensives. Manuck SB, et al.
Am J Hypertens 1996 Mar;9(3):248–55

Ovarian and adrenal contributions to postnatal growth and differentiation of the rat uterus. Branham WS, et al.
Biol Reprod 1995 Oct;53(4):863–72

Adrenalectomy increases reduced nicotinamide adenine dinucleotide phosphate–diaphorase activity in the rat spinal trigeminal subnucleus caudalis. Hathaway CB, et al.
Brain Res 1996 Mar 11;712(1):143–7

The effect of adrenalectomy on stress-induced c-fos mRNA expression in the rat brain. Helmreich DL, et al.
Brain Res 1996 Jan 8;706(1):137–44

A cell-specific role for the adrenal gland in regulating CRH mRNA levels in rat hypothalamic neurosecretory neurons after cellular dehydration. Watts AG, et al. **Brain Res** 1995 Jul 31;687(1–2):63–70

Distinction between binding of [3H]triamcinolone acetonide to a ligand binding domain on the glucocorticoid receptor complex in cytosol fractions of brain and liver from the rat with intact adrenals. Yoneda Y, et al. **Brain Res** 1995 Jul 10;685(1–2):105–16

Adrenalectomy reduces FGF-1 and FGF-2 gene expression in specific rat brain regions and differently affects their induction by seizures. Riva MA, et al.
Brain Res Mol Brain Res 1995 Dec 28;34(2):190–6

Sympathoadrenal regulation of adrenocortical steroidogenesis. Ehrhart-Bornstein M, et al. **Endocr Res** 1995 Feb–May;21(1–2):13–24

Expression of cytochrome P450 aldosterone synthase and 11 beta-hydroxylase mRNA during adrenal regeneration. Engeland WC, et al. **Endocr Res** 1995 Feb–May; 21(1–2):449–54

Characterization of gap junction expression in the adrenal gland. Murray SA, et al. **Endocr Res** 1995 Feb–May; 21(1–2):221–9

Regulation and function of the fetal adrenal gland in sheep. Wintour EM, et al. **Endocr Res** 1995 Feb–May;21(1–2):81–9

Pituitary adenylate cyclase-activating polypeptide causes rapid Ca2+ release from intracellular stores and long lasting Ca2+ influx mediated by Na+ influx-dependent membrane depolarization in bovine adrenal chromaffin cells. Tanaka K, et al. **Endocrinology** 1996 Mar; 137(3):956–66

8-OH-DPAT stimulates gastric acid secretion through a vagal-independent, adrenal-mediated mechanism. Gidener S, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):19–24

Adrenalectomy does not prevent the ability of 8-OH-DPAT to decrease the ejaculatory threshold in male rats. Vega-Matuszczyk J, et al. **Eur Neuropsychopharmacol** 1995 Jun;5(2):115–8

Dynamics of the regulation of the hypothalamo-pituitary-adrenal (HPA) axis determined using a nonsurgical method for collecting pituitary venous blood from horses. Alexander SL, et al.
Front Neuroendocrinol 1996 Jan;17(1):1–50 (220 ref.)

Comparative aspects of regulation and function of the adrenal complex in different groups of vertebrates. Hanke W, et al. **Horm Metab Res** 1995 Sep;27(9):389–97 (29 ref.)

Role for endogenous dopamine in modulating sympathetic-adrenal activity in humans. Mannelli M, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S79–86 (92 ref.)

Inhibition of nitric oxide synthase reduces Sephadex-induced oedema formation in the rat lung: dependence on intact adrenal function. Andersson SE, et al. **Inflamm Res** 1995 Oct;44(10):418–22

Changes in sympathoadrenal response to standing in humans after spaceflight. Whitson PA, et al. **J Appl Physiol** 1995 Aug;79(2):428–33

Reaction of pituitary-adrenal and autonomic nervous systems to stress in trained and untrained elderly people. Korkushko OV, et al. **J Auton Nerv Syst** 1995 Jul 14;54(1):27–32

Arcuate nucleus neurons that project to the hypothalamic paraventricular nucleus: neuropeptidergic identity and consequences of adrenalectomy on mRNA levels in the rat. Baker RA, et al. **J Comp Neurol** 1995 Aug 7; 358(4):518–30

New insights into zonal differentiation of adrenal autotransplants in the rat: an immunohistochemical study. Vendeira P, et al. **J Endocrinol** 1996 Jun;149(3):497–502

Acute stimulation of the hypothalamic-pituitary-adrenal axis by IL-1 beta, TNF alpha and IL-6: a dose response study. van der Meer MJ, et al. **J Endocrinol Invest** 1996 Mar; 19(3):175–82

A 5-day estradiol therapy, in amounts reproducing concentrations of the early-mid follicular phase, prevents the activation of the hypothalamo-pituitary-adrenal axis by interleukin-1 alpha in the ovariectomized rhesus monkey. Xia-Zhang L, et al. **J Neuroendocrinol** 1995 May; 7(5):387–92

The effect of the adrenocortical axis upon recovery from closed head injury. Shohami E, et al. **J Neurotrauma** 1995 Dec;12(6):1069–77

Maternal protein restriction influences the programming of the rat hypothalamic-pituitary-adrenal axis.
Langley-Evans SC, et al. **J Nutr** 1996 Jun;126(6):1578–85

Contribution of SK and BK channels in the control of catecholamine release by electrical stimulation of the cat adrenal gland. Montiel C, et al. **J Physiol (Lond)** 1995 Jul 15;486 (Pt 2):427–37

Adrenergic regulation of the hypothalamic-pituitary-adrenal axis under basal and social stress conditions. Bugajski J, et al. **J Physiol Pharmacol** 1995 Sep;46(3):297–312

Mechanisms of catecholamine secretion from adrenal chromaffin cells. Burgoyne RD. **J Physiol Pharmacol** 1995 Sep;46(3):273–83 (45 ref.)

Effects of bilateral adrenalectomy on initiation of fur growth cycles in the deer mouse (Peromyscus maniculatus). Garwood T, et al. **Lab Anim Sci** 1995 Oct;45(5):564–6

Mouse Dax1 expression is consistent with a role in sex determination as well as in adrenal and hypothalamus function. Swain A, et al. **Nat Genet** 1996 Apr;12(4):404–9

Regulation of neuropeptide Y and its mRNA by glucocorticoids in the rat adrenal gland. Laborie C, et al. **Neuroendocrinology** 1995 Dec;62(6):601–10

Adrenalectomy increases serotonin turnover in brains of obese Zucker rats. Routh VH, et al. **Physiol Behav** 1995 Sep;58(3):491–9

Regulation of insulin-like growth factor-binding proteins in rats with insulin-dependent diabetes mellitus. Rodgers BD, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):234–41

[Activity of some indicator enzymes in myocardium of rats after adrenalectomy, stimulation and inhibition of adrenal function] Słodowska-Hajduk Z, et al. **Folia Med Cracov** 1994;35(1–4):91–5 (Eng. Abstr.) **(Pol)**

[Alkaline phosphatase isoforms in murine organs after bilateral adrenalectomy] Tsirel'nikov NI, et al.
Biull Eksp Biol Med 1996 Mar;121(3):262–4 **(Rus)**

[The evaluation of corticosteroid hormone receptor status in the brain structures of stressed and adrenalectomized rats] Efimov SV, et al. **Fiziol Zh Im I M Sechenova** 1995 Feb;81(2):33–9 (Eng. Abstr.) **(Rus)**

[The role of the sympathoadrenal system in the development of acute muscle fatigue] Makarenko NA. **Lik Sprava** 1995 May-Jun;(5–6):140–4 (Eng. Abstr.) **(Rus)**

[The compensatory-adaptive reactions of the thyroid and adrenal adrenergic structures in the postnatal ontogeny of sympathectomized rats] Markov VN, et al. **Morfologiia** 1994 Jul-Dec;107(7–12):89–96 (Eng. Abstr.) **(Rus)**

[Changes in the cytochemical and morphometric characteristics of the myocytes in the right heart of the rat in adrenal-regeneration hypertension] Selivanova GV, et al. **Tsitologiia** 1995;37(5–6):415–23 (Eng. Abstr.) **(Rus)**

[The participation of enteral mechanisms in the sympathetic-adrenal inhibition of gastric secretion] Trefilov AB. **Usp Fiziol Nauk** 1995 Jan-Mar;26(1):76–92 (79 ref.) (Eng. Abstr.) **(Rus)**

[Adrenal function in the mink Mustela vison selected for the type of behavior] Gulevich RG, et al.
Zh Evol Biokhim Fiziol 1995 Jul-Aug;31(4):444–8 (Eng. Abstr.) **(Rus)**

[The effect of epiphysectomy and melatonin administration on the catecholamine content of rat hypothalamic and adrenal tissue] Arushanian EB, et al.
Zh Vyssh Nerv Deiat Im I P Pavlova 1996 Jan-Feb; 46(1):173–5 **(Rus)**

[New approaches in the evaluation of sympathoadrenal system activity during periods of rest and stress] Kvetňanský R. **Bratisl Lek Listy** 1996 Feb;97(2):72–83 (Eng. Abstr.) **(Slo)**

PHYSIOPATHOLOGY

Cyclosporine A-induced hypertension in SHR and WKY: role of the sympatho-adrenal system. Grobecker HF, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S94–5

Divergent prolactin and pituitary-adrenal activity in rats selectively bred for different dopamine responsiveness. Rots NY, et al. **Endocrinology** 1996 May;137(5):1678–86

Early polycystic ovary-like syndrome in girls with central precocious puberty and exaggerated adrenal response [see comments] Lazar L, et al. **Eur J Endocrinol** 1995 Oct; 133(4):403–6. Comment in: Eur J Endocrinol 1995 Oct;133(4):399–400.

High prevalence of abnormal adrenal response in girls with central precocious puberty at early pubertal stages [see comments] Lazar L, et al. **Eur J Endocrinol** 1995 Oct; 133(4):407–11. Comment in: Eur J Endocrinol 1995 Oct;133(4):399–400.

Are adrenal and ovarian function normal in true precocious puberty? [comment] Rosenfield RL. **Eur J Endocrinol** 1995 Oct;133(4):399–400. Comment on: Eur J Endocrinol 1995 Oct;133(4):403–6. Comment on: Eur J Endocrinol 1995 Oct;133(4):407–11.

Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency and association with adrenal function. Roy A, et al. **Eur Respir J** 1996 Feb;9(2):226–31

Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome. Gonzalez F, et al.
Fertil Steril 1996 Sep;66(3):354–61

Adrenal responses of Angus x Hereford cattle to the stress of weaning. Lefcourt AM, et al. **J Anim Sci** 1995 Sep; 73(9):2669–76

Hypothalamo-pituitary-adrenal function in human immunodeficiency virus-infected men. Lortholary O, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):791–6

Primary hyperaldosteronism in pregnancy. A case report. Solomon CG, et al. **J Reprod Med** 1996 Apr;41(4):255–8

Augmented sympathoadrenal activity during treadmill exercise in patients with Wolff-Parkinson-White syndrome and atrial fibrillation. Honda T, et al. **Jpn Circ J** 1996 Jan; 60(1):43–9

Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Holsboer F, et al. **Neuroendocrinology** 1995 Oct;62(4):340–7

Interleukin 6 modulates interleukin-1-and stress-induced activation of the hypothalamic-pituitary-adrenal axis in male rats. Zhou D, et al. **Neuroendocrinology** 1996 Mar; 63(3):227–36

Adrenal secretion during major depression in 8- to 16-year-olds, I. Altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentation. Goodyer IM, et al. **Psychol Med** 1996 Mar;26(2):245–56

Adrenal secretion and major depression in 8- to 16-year-olds, II. Influence of co-morbidity at presentation. Herbert J, et al. **Psychol Med** 1996 Mar;26(2):257–63

[Endocrine function (pituitary, thyroid, adrenal gland) of obesity] Ogino Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:316–9 (13 ref.) **(Jpn)**

[Functional asymmetry of adrenal glands in (CBA x C57BL/6)F1 mice] Abramov VV, et al.
Doki Akad Nauk 1996 Apr;347(6):831–3 **(Rus)**

[Plasma cortisol and adrenal response to ACTH stimulation in diabetes mellitus with moderate decompensation] Rubio Pérez P, et al. **An Med Interna** 1995 Jun;12(6):267–9 (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

[Effects of intravenous laser irradiation of blood on the sympathoadrenal, antioxidant and immune system in patients with cancer of the stomach and large intestine] Ial'chenko NA, et al. **Klin Khir** 1996;(1):36–9 **(Rus)**

RADIOGRAPHY

Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Korobkin M, et al. **Radiology** 1996 Sep;200(3):743–7

Adrenal masses: correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Outwater EK, et al.
Radiology 1996 Sep;200(3):749–52

RADIONUCLIDE IMAGING

[Scintigraphic characterization of expansive lesions located in the adrenals. Comparison with magnetic resonance imaging] Maurea S, et al. **Radiol Med (Torino)** 1995 Dec; 90(6):756–65 (Eng. Abstr.) **(Ita)**

SECRETION

Tumor necrosis factor-alpha stimulates adrenal glucocorticoid secretion in cholestatic rats. Swain MG, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):G987–91

Adrenal androgen action in breast cancer. Boccuzzi G, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:349–61 (55 ref.)

Rab3A delayed catecholamine secretion from bovine adrenal chromaffin cells. Lin CG, et al.
Biochem Biophys Res Commun 1996 Apr 25;221(3):675–81

C-type natriuretic peptide as a possible local modulator of aldosterone secretion in bovine adrenal zona glomerulosa. Kawai M, et al. **Endocrinology** 1996 Jan;137(1):42–6

Differential effects of endogenous and exogenous nitric oxide on the release of endothelin-1 from the intact perfused rat adrenal gland in situ. Hinson JP, et al. **FEBS Lett** 1996 Jan 22;379(1):7–10

A non-cholinergic transmitter, pituitary adenylate cyclase-activating polypeptide, utilizes a novel mechanism to evoke catecholamine secretion in rat adrenal chromaffin cells. Przywara DA, et al. **J Biol Chem** 1996 May 3; 271(18):10545–50

Combined amplification of the pulsatile and basal modes of adrenocorticotropin and cortisol secretion in patients with Cushing's disease: evidence for decreased responsiveness of the adrenal glands. van den Berg G, et al.
J Clin Endocrinol Metab 1995 Dec;80(12):3750–7

Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion. Vesely DL, et al. **J Endocrinol** 1995 Sep;146(3):373–80

Stimulation of the secretion of dehydroepiandrosterone by melatonin in mouse adrenals in vitro. Haus E, et al. **Life Sci** 1996;58(14):PL263–7

Corticosteroids in human blood: IX. Evidence for adrenal secretion of sulfate-conjugated cortisol, 11 beta,17 alpha-dihydroxy-4-pregnene-3,20-dione-21-yl-sulfate. Kornel L, et al. **Steroids** 1995 Dec;60(12):817–23

SURGERY

From laparoscopic training on an animal model to retroperitoneoscopic or coelioscopic adrenal and renal surgery in human. de Cannière L, et al. **Surg Endosc** 1995 Jun;9(6):699–701

TRANSPLANTATION

Study of ACTH-immunoreactive cells after transplantation of neonatal adrenal glands into adult adrenalectomized rats. Sarria R, et al. **Anat Histol Embryol** 1995 Sep;24(3):185–90

Blood supply of the ovine adrenal gland and its relevance in adrenal autotransplantation. Hardy KJ, et al. **Aust Vet J** 1995 Jul;72(7):262–5

Intradermal implants of histotypic adrenal gland rotary cultures. Palacios-Prü E, et al. **Dev Neurosci** 1995; 17(2):118–26

ULTRASONOGRAPHY

Ultrasonographic evaluation of the adrenal glands in dogs. Barthez PY, et al. **J Am Vet Med Assoc** 1995 Nov 1; 207(9):1180–3

Horseshoe adrenal in Ivemark (asplenia) syndrome. Horgan JG, et al. **J Ultrasound Med** 1995 Oct;14(10):785–6

Ultrasonographic characteristics of the adrenal glands in dogs with pituitary-dependent hyperadrenocorticism: comparison with normal dogs. Grooters AM, et al. **J Vet Intern Med** 1996 May–Jun;10(3):110–5

[Ultrasonography of the adrenal gland in dogs] Kaser-Hotz B, et al. **Schweiz Arch Tierheilkd** 1995;137(6):258–64 (Eng. Abstr.) **(Ger)**

[Ultrasound in the study of the adrenal glands] Kuznetsov NS, et al. **Khirurgiia (Mosk)** 1996;(1):75–6 (44 ref.) **(Rus)**

[The methodological problems of ultrasonic study of the adrenals in children] Filippkin MA, et al. **Vestn Rentgenol Radiol** 1996 Mar–Apr;(2):49–50 **(Rus)**

ULTRASTRUCTURE

Na-Ca exchange in Ca2+ signaling and neurohormone secretion. Secretory vesicle contributions in adrenal chromaffin cells. Schneider AS, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:356–65 (17 ref.)

VIROLOGY

Generation of recombinant herpes simplex virus type 1 to be used for automatic tract tracing. LeVatte MA, et al. **Gene Ther** 1994;1 Suppl 1:S77

ADRENAL GLOMERULOSA see **ZONA GLOMERULOSA**

ADRENAL HYPERPLASIA, CONGENITAL

see related
PUBERTY, PRECOCIOUS
VIRILISM

[Congenital adrenal hyperplasia due to 21-hydroxylase enzyme deficiency] Dumić M. **Lijec Vjesn** 1996 Mar;118 Suppl 1:13–6 (Eng. Abstr.) **(Scr)**

BLOOD

Thrombocytosis in congenital adrenal hyperplasia at diagnosis. Gasparini N, et al. **Clin Pediatr (Phila)** 1996 May; 35(5):267–9

Screening for congenital adrenal hyperplasia: the Delfia Screening Test overestimates serum 17-hydroxyprogesterone in preterm infants. al Saedi S, et al. **Pediatrics** 1996 Jan;97(1):100–2

CLASSIFICATION

A contribution to the classification of cases of non-classic 21-hydroxylase-deficient congenital adrenal hyperplasia. Phocas I, et al. **Gynecol Endocrinol** 1995 Sep;9(3):229–38

COMPLICATIONS

Thrombocytosis in congenital adrenal hyperplasia at diagnosis. Gasparini N, et al. **Clin Pediatr (Phila)** 1996 May; 35(5):267–9

Congenital adrenal hyperplasia presenting as massive adrenal incidentalomas in the sixth decade of life: report of two patients with 21-hydroxylase deficiency. Ravichandran R, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1776–9

Testicular adrenal rest tissue in congenital adrenal hyperplasia: findings at Gray-scale and color Doppler US. Avila NA, et al. **Radiology** 1996 Jan;198(1):99–104

[Congenital adrenal hyperplasia and testicular hypertrophy] Dieckmann K, et al. **Arch Pediatr** 1995 Dec;2(12):1167–72 (20 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Congenital adrenal hyperplasia: molecular genetics and alternative approaches to treatment. Laue L, et al. **Adv Pediatr** 1995;42:113–43 (55 ref.)

Case report: 17 alpha-hydroxylase/17,20-lyase deficiency: a rare cause of endocrine hypertension. Hermans C, et al. **Am J Med Sci** 1996 Sep;312(3):126–9

Delay in diagnosis of congenital adrenal hyperplasia in an acutely ill infant. The confounding effect of unrelated medical therapies. Zeitler P. **Clin Pediatr (Phila)** 1995 Nov; 34(11):603–4

Macronodular congenital adrenal hyperplasia in an adult with female pseudohermaphroditism. Norris AM, et al. **Eur Radiol** 1996;6(4):470–2

Overdiagnosis of 21-hydroxylase late onset congenital adrenal hyperplasia: correlation of corticotropin test and human leukocyte antigen typing. Avivi I, et al. **Fertil Steril** 1996 Oct;66(4):557–63

Testicular masses associated with congenital adrenal hyperplasia: MRI findings. Berg NB, et al. **Urology** 1996 Feb;47(2):252–3

[21-hydroxylase deficiency. Review of the biochemical characteristics and their diagnostic implications] Campos López-Carrión M, et al. **Rev Clin Esp** 1995 Aug; 195(8):571–7 (81 ref.) **(Spa)**

DRUG THERAPY

Bone density in young patients with congenital adrenal hyperplasia. Mora S, et al. **Bone** 1996 Apr;18(4):337–40

Dexamethasone-suppressible adrenal tumour in untreated 21-hydroxylase deficiency [letter] Bevan JS, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):733–7

Chlormadinone acetate as a possible effective agent for congenital adrenal hyperplasia to suppress elevated ACTH and antagonize masculinization. Kageyama Y, et al. **Endocr J** 1995 Aug;42(4):505–8

Rapid occurrence of thelarche and menarche induced by hydrocortisone in a teenage girl with previously untreated congenital adrenal hyperplasia. Schwarz HP, et al. **Eur J Pediatr** 1995 Aug;154(8):617–20

Failure of steroid replacement to consistently normalize pituitary function in congenital adrenal hyperplasia: hormonal and MRI data. Speiser PW, et al. **Horm Res** 1995; 44(6):241–6

ENZYMOLOGY

Congenital adrenal hyperplasia presenting as massive adrenal incidentalomas in the sixth decade of life: report of two patients with 21-hydroxylase deficiency. Ravichandran R, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1776–9

Direct molecular diagnosis of CYP21 mutations in congenital adrenal hyperplasia. Lee HH, et al. **J Med Genet** 1996 May; 33(5):371–5

ETIOLOGY

Identification of enzyme deficiencies resulting in congenital adrenal hyperplasia. Sólyom J. **Acta Biomed Ateneo Parmense** 1995;66(3–4):99–104

Characterization of zona glomerulosa function in patients with classic and non-classic forms of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Castro-Magana M, et al. **J Pediatr Endocrinol Metab** 1995 Jan–Mar;8(1):19–25

GENETICS

Congenital adrenal hyperplasia: molecular genetics and alternative approaches to treatment. Laue L, et al. **Adv Pediatr** 1995;42:113–43 (55 ref.)

Who is a carrier? Detection of unsuspected mutations in 21-hydroxylase deficiency. Witchel SS, et al. **Am J Med Genet** 1996 Jan 2;61(1):2–9

Endocrinology and auxology of sibships with non-classical congenital adrenal hyperplasia. Cameron FJ, et al. **Arch Dis Child** 1996 May;74(5):406–11

Classic steroid 11 beta-hydroxylase deficiency caused by a C-->G transversion in exon 7 of CYP11B1. Yang LX, et al. **Biochem Biophys Res Commun** 1995 Nov 13; 216(2):723–8

Expression of DAX-1, the gene responsible for X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism, in the hypothalamic-pituitary-adrenal/gonadal axis. Guo W, et al. **Biochem Mol Med** 1995 Oct;56(1):8–13

Hormonal and genetic analysis of a patient with congenital adrenal hyperplasia. Summers RH, et al. **Clin Chem** 1996 Sep;42(9):1483–7

Phenotypic evolution of classic 21-hydroxylase deficiency. Hoffman WH, et al. **Clin Endocrinol (Oxf)** 1996 Jul; 45(1):103–9

Structure and expression of the CYP21 (P450c21, steroid 21-hydroxylase) gene with respect to its deficiency. Chung BC, et al. **Endocr Res** 1995 Feb–May;21(1–2):343–52

Constitutive human steroid 21-hydroxylase promoter gene and pseudogene activity in steroidogenic and nonsteroidogenic cells with the luciferase gene as a reporter. Kyllo JH, et al. **Endocr Res** 1995 Nov; 21(4):777–91

Divergence between genotype and phenotype in relatives of patients with the intron 2 mutation of steroid-21-hydroxylase. Schulze E, et al. **Endocr Res** 1995 Feb–May;21(1–2):359–64

An intron 1 splice mutation and a nonsense mutation (W23X) in CYP21 causing severe congenital adrenal hyperplasia. Lajic S, et al. **Hum Genet** 1996 Aug;98(2):182–4

T-->A transversion 11 bp from a splice acceptor site in the human gene for steroidogenic acute regulatory protein causes congenial lipoid adrenal hyperplasia. Tee MK, et al. **Hum Mol Genet** 1995 Dec;4(12):2299–305

A new compound heterozygous frameshift mutation in the type II 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) gene causes salt-wasting 3 beta-HSD deficiency congenital adrenal hyperplasia. Zhang L, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):291–5

Consanguinity in two seemingly unrelated patients with congenital adrenal hyperplasia [letter] Vierhapper H, et al. **Lancet** 1996 Mar 9;347(9002):699

Gene conversions and unequal crossovers between CYP21 (steroid 21-hydroxylase gene) and CYP21P involve different mechanisms. Tusié-Luna MT, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10796–800

[Hirsutism. Two familial cases of 21-hydroxylase deficiency] Roux S, et al. **Ann Dermatol Venereol** 1995;122(10):697–700 (Eng. Abstr.) **(Fre)**

HISTORY

Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency. Zachmann M. **Eur J Pediatr** 1996 Apr;155(4):259–61

[Scientific raisins from 125 years SMW (Swiss Medical Weekly. On the familiar occurrence of intersexuality and adrenal gland hyperplasia. 1941. (classical article)] Werthemann A. **Schweiz Med Wochenschr** 1995 Sep 9; 125(36):1697–701 **(Ger)**

METABOLISM

Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Holmes-Walker DJ, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):291–6

Elevated androgen, brain development and language/learning disabilities in children with congenital adrenal hyperplasia. Plante E, et al. **Dev Med Child Neurol** 1996 May;38(5):423–37

PATHOLOGY

Failure of steroid replacement to consistently normalize pituitary function in congenital adrenal hyperplasia: hormonal and MRI data. Speiser PW, et al. **Horm Res** 1995; 44(6):241–6

PHYSIOPATHOLOGY

Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): relation to body mass index in earlier childhood. Yu AC, et al. **Acta Paediatr** 1995 Aug;84(8):899–903

Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ghizzoni L, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):601–6

Characterization of zona glomerulosa function in patients with classic and non-classic forms of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Castro-Magana M, et al. **J Pediatr Endocrinol Metab** 1995 Jan–Mar;8(1):19–25

Congenital adrenal hyperplasia: is there an effect on penile growth? Levy JB, et al. **J Urol** 1996 Aug;156(2 Pt 2):780–2

The effect of prepubertal androgen exposure on adult penile length. Sutherland RS, et al. **J Urol** 1996 Aug;156(2 Pt 2):783–7; discussion 787

[Growth and adult height in patients with congenital adrenal hyperplasia] Koloušková S, et al. **Cas Lek Cesk** 1995 Nov 1;134(21):689–91 (Eng. Abstr.) **(Cze)**

PREVENTION & CONTROL

Newborn screening for congenital adrenal hyperplasia: testing to commence in New South Wales [letter] Wilcken B, et al. **J Paediatr Child Health** 1996 Feb;32(1):76

Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980–1995. Balsamo A, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):362–7

PSYCHOLOGY

The quality of life in adult female patients with congenital adrenal hyperplasia: a comprehensive study of the impact of genital malformations and chronic disease on female patients life. Kuhnle U, et al. **Eur J Pediatr** 1995 Sep; 154(9):708–16

SURGERY

The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. Van Wyk JJ, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3180–90

[Sporadic unilateral adrenal medullary hyperplasia--a rare cause of hypertension] Stenger AM, et al. **Chirurg** 1996 Apr;67(4):448–50 (Eng. Abstr.) **(Ger)**

ADRENAL MEDULLA

Neuroblastoma metastatic to brain [clinical conference] Xaidara A, et al. **Med Pediatr Oncol** 1996 Mar;26(3):208–14

Adrenal cortical and medullary imaging. Freitas JE. **Semin Nucl Med** 1995 Jul;25(3):235–30 (63 ref.)

[Characteristics of the morphological structure of malignant tumors of the adrenal medulla] Kalashnikov SA, et al. **Klin Khir** 1995;(5):26–8 **(Rus)**

BLOOD SUPPLY

The bovine central adrenomedullary vein: a target for endothelins. Lønning K, et al. **Acta Physiol Scand** 1995 Dec;155(4):415–25

Specific 125I neuropeptide Y binding to intact cultured bovine adrenal medulla capillary endothelial cells. Sanabria P, et al. **Microcirculation** 1994 Dec;1(4):267–73

CHEMISTRY

Immunocytochemical localization of the renal neutral and basic amino acid transporter in rat adrenal gland, brainstem, and spinal cord. Nirenberg MJ, et al. **J Comp Neurol** 1995 Jun 12;356(4):505–22

Interleukin-1 receptor antagonist protein and mRNA in the rat adrenal gland. Schultzberg M, et al. **J Interferon Cytokine Res** 1995 Aug;15(8):721–9

CYTOLOGY

Simultaneous amperometric measurement of ascorbate and catecholamine secretion from individual bovine adrenal medullary cells. Cahill PS, et al. **Anal Chem** 1995 Aug 1; 67(15):2599–605

Similarities and differences in supporting and chromaffin cells in the mammalian adrenal medullae: an immunohistochemical study. Suzuki T, et al. **Anat Rec** 1996 Mar;244(3):358–65

Ciliary neurotrophic factor promotes the terminal differentiation of v-myc immortalized sympathoadrenal progenitor cells in vivo. Doering LC, et al. **Brain Res Dev Brain Res** 1995 Oct 27;89(1):56–66

Ca(2+)/calmodulin-dependent protein kinase II inhibitor KN-62 inhibits adrenal medullary chromaffin cell functions independent of its action on the kinase. Tsutsui M, et al. **J Neurochem** 1996 Jun;66(6):2517–22

Sustained stimulation of rat adrenal chromaffin cell proliferation by reserpine. Tischler AS, et al. **Toxicol Appl Pharmacol** 1995 Dec;135(2):254–7

DRUG EFFECTS

Effects of atrial natriuretic factor on norepinephrine release evoked by angiotensins II and III in the rat adrenal medulla. Papouchado ML, et al. **Arch Physiol Biochem** 1995 Apr; 103(1):55–8

Acute repeated nicotine injections increase enkephalin and decrease AP-1 DNA binding activity in rat adrenal medulla. McMillian MK, et al. **Brain Res Mol Brain Res** 1995 Jul;31(1-2):210–4

The protein phosphatase inhibitor calyculin-A affects catecholamine secretion and granular distribution in cultured adrenomedullary chromaffin cells. Gutierrez LM, et al. **Eur J Cell Biol** 1995 Sep;68(1):88–95

Effect of human galanin on the response of circulating catecholamines to hypoglycemia in man. degli Uberti EC, et al. **Eur J Endocrinol** 1995 Dec;133(6):723–8

Effects of caffeine on Ca2+ fluxes and secretion in bovine chromaffin cells. Liu PS, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):265–72

Botulinum neurotoxin light chains inhibit both Ca(2+)-induced and GTP analogue-induced catecholamine release from permeabilised adrenal chromaffin cells. Glenn DE, et al. **FEBS Lett** 1996 May 20;386(2-3):137–40

Cyclic AMP enhances acetylcholine (ACh)-induced ion fluxes and catecholamine release by inhibiting Na+, K(+)-ATPase and participates in the responses to ACh in cultured bovine adrenal medullary chromaffin cells. Morita K, et al. **J Neural Transm Gen Sect** 1995; 100(1):17–26

Dopaminergic inhibition of catecholamine secretion from chromaffin cells: evidence that inhibition is mediated by D4 and D5 dopamine receptors. Dahmer MK, et al. **J Neurochem** 1996 Jan;66(1):222–32

Effects of protein kinase inhibitors on morphology and function of cultured bovine adrenal chromaffin cells: KN-62 inhibits secretory function by blocking stimulated Ca2+ entry. Maurer JA, et al. **J Neurochem** 1996 Jan; 66(1):105–13

Long-term stimulation of nicotinic receptors is required to increase proenkephalin A mRNA levels and the delayed secretion of [Met5]-enkephalin in bovine adrenal medullary chromaffin cells. Suh HW, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1663–70

The mechanism of lactitol (NS-4) in inducing adrenomedullary proliferative lesion in rats. Yoshida M, et al. **J Toxicol Sci** 1995 Oct;20 Suppl 1:37–45

Insulin-induced hypoglycemia stimulates both adrenaline and noradrenaline release from adrenal medulla in 21-day-old rats. Fujino Y, et al. **Jpn J Pharmacol** 1995 Dec; 69(4):413–20

Adrenomedullin stimulates calcium efflux from adrenal chromaffin cells in culture: possible involvement of an Na+/Ca2+ exchange mechanism. Houchi H, et al. **Life Sci** 1996;58(2):PL 35–40

Strychnine affects catecholamine secretion from bovine adrenal medulla chromaffin cells. Dar DE, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):11–6

Inhibitory effects of propofol on catecholamine secretion and uptake in cultured bovine adrenal medullary cells. Minami K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Apr; 353(5):572–8

Large- and small-conductance Ca(2+)-activated K+ channels: their role in the nicotinic receptor-mediated catecholamine secretion in bovine adrenal medulla. Wada A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):545–9

Inhibition by carbamazepine of various ion channels-mediated catecholamine secretion in cultured bovine adrenal medullary cells. Yoshimura R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):297–303

Innervation-independent changes in the mRNAs encoding tyrosine hydroxylase and the norepinephrine transporter in rat adrenal medulla after high-dose reserpine. Cubells JF, et al. **Neurosci Lett** 1995 Jul 7;193(3):189–92

2-Deoxy-D-glucose but not 2-mercaptoacetate increases Fos-like immunoreactivity in adrenal medulla and sympathetic preganglionic neurons. Ritter S, et al. **Obes Res** 1995 Dec;3 Suppl 5:729S–734S

ENZYMOLOGY

Chromaffin granule aspartic proteinase processes recombinant proopiomelanocortin (POMC). Azaryan AV, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):937–44

Specific dinucleoside polyphosphate cleaving enzymes from chromaffin cells: a fluorimetric study. Ramos A, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):103–11

The reduction of membrane-bound dopamine beta-monooxygenase in resealed chromaffin granule ghosts. Is intragranular ascorbic acid a mediator for extragranular reducing equivalents? Wimalasena K, et al. **J Biol Chem** 1995 Nov 17;270(46):27516–24

New species of human tyrosine hydroxylase mRNA are produced in variable amounts in adrenal medulla and are overexpressed in progressive supranuclear palsy. Dumas S, et al. **J Neurochem** 1996 Jul;67(1):19–25

Induction of adrenal tyrosine hydroxylase mRNA by single immobilization stress occurs even after splanchnic transection and in the presence of cholinergic antagonists. Kvetňanský R, et al. **J Neurochem** 1996 Jan;66(1):138–46

IMMUNOLOGY

Autoantibodies against adrenal medulla in type 1 and type 2 diabetes mellitus: no evidence for an association with autonomic neuropathy. Husebye ES, et al. **J Intern Med** 1996 Feb;239(2):139–46

INNERVATION

Preganglionic fibres of the adrenal medulla and cervical sympathetic ganglia: differential involvement during experimental American trypanosomiasis in rats. Camargos ER, et al. **Int J Exp Pathol** 1996 Jun;77(3):115–24

Centrally applied bombesin increases nerve activity of both sympathetic and adrenal branch of the splanchnic nerves. Okuma Y, et al. **Jpn J Pharmacol** 1995 Jun;68(2):227–30

Quantal release at a neuronal nicotinic synapse from rat adrenal gland. Barbara JG, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9905–9

METABOLISM

PACAP stimulates catecholamine release from adrenal medulla: a novel noncholinergic secretagogue. Watanabe T, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E903–9

Simultaneous amperometric measurement of ascorbate and catecholamine secretion from individual bovine adrenal medullary cells. Cahill PS, et al. **Anal Chem** 1995 Aug 1; 67(15):2599–605

Processing of chromogranins in chromaffin cell culture: effects of reserpine and alpha-methyl-p-tyrosine. Wolkersdorfer M, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):953–8

Tyrosine hydroxylase phosphorylation in bovine adrenal chromaffin cells. Clonidine stimulates basal but inhibits nicotinic receptor evoked phosphorylation. Dunkley PR, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):239–45

The low-affinity dihydropyridine receptor and Na+/Ca2+ exchanger are associated in adrenal medullary mitochondria. Palmero M, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):879–83

The interaction of 1-methyl-4-phenylpyridinium (MPP+) with bovine adrenal medulla chromaffin vesicle ghosts. Farmer MK, et al. **Biochem Soc Trans** 1996 Feb;24(1):60S

Angiotensin II receptor subtypes and phosphoinositide hydrolysis in rat adrenal medulla. Israel A, et al. **Brain Res Bull** 1995;38(5):441–6

In vivo studies of the control of DNA synthesis in the rat adrenal cortex and medulla. McEwan PE, et al. **Endocr Res** 1995 Feb-May;21(1-2):91–102

Conversion of angiotensin II into active fragments by an endosomal pathway in bovine adrenal medullary cells in primary culture. Wang JM, et al. **Endocrinology** 1995 Dec; 136(12):5274–82

The C-terminal bisphosphorylated proenkephalin-A-(209–237)-peptide from adrenal medullary chromaffin granules possesses antibacterial activity. Goumon Y, et al. **Eur J Biochem** 1996 Feb 1; 235(3):516–25

Distinct exocytotic responses of intact and permeabilised chromaffin cells after cleavage of the 25-kDa synaptosomal-associated protein (SNAP-25) or synaptobrevin by botulinum toxin A or B. Lawrence GW, et al. **Eur J Biochem** 1996 Mar 15;236(3):877–86

Staurosporine inhibits inositol phosphate formation in bovine adrenal medullary cells. Bunn SJ, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):227–36

Inhibition of catecholamine synthesis by proadrenomedullin N-terminal 20 peptide in cultured bovine adrenal medullary cells. Niina H, et al. **Eur J Pharmacol** 1995 Nov 3; 286(1):95–7

A peptide that mimics the carboxy-terminal domain of SNAP-25 blocks Ca(2+)-dependent exocytosis in chromaffin cells. Gutiérrez LM, et al. **FEBS Lett** 1995 Sep 18;372(1):39–43

SNAP-25 is differentially expressed by noradrenergic and adrenergic chromaffin cells. Kannan R, et al. **FEBS Lett** 1996 May 6;385(3):159–64

ADP-ribosylation in adrenal glands: purification and characterization of mono-ADP-ribosyltransferases and ADP-ribosylhydrolase affecting cytoskeletal actin. Fujita H, et al. **Int J Biochem Cell Biol** 1995 Oct;27(10):1065–78

Nerves containing nitric oxide synthase and their possible function in the control of catecholamine secretion in the bovine adrenal medulla. Marley PD, et al. **J Auton Nerv Syst** 1995 Sep 5;54(3):184–94

Characterization of ATP transport into chromaffin granule ghosts. Synergy of ATP and serotonin accumulation in chromaffin granule ghosts. Bankston LA, et al. **J Biol Chem** 1996 Jul 19;271(29):17132–8

Identification of a novel cysteine string protein variant and expression of cysteine string proteins in non-neuronal cells. Chamberlain LH, et al. **J Biol Chem** 1996 Mar 29; 271(13):7320–3

pH- and Ca(2+)-dependent aggregation property of secretory vesicle matrix proteins and the potential role of chromogranins A and B in secretory vesicle biogenesis. Yoo SH. **J Biol Chem** 1996 Jan 19;271(3):1558–65

Annexin II in exocytosis: catecholamine secretion requires the translocation of p36 to the subplasmalemmal region in chromaffin cells. Chasserot-Golaz S, et al. **J Cell Biol** 1996 Jun;133(6):1217–36

Immunohistochemical heterogeneity of nerve cells in the human adrenal gland with special reference to substance P. Colombo-Benkmann M, et al. **J Histochem Cytochem** 1996 Apr;44(4):369–75

Direct control of a large conductance K(+)-selective channel by G-proteins in adrenal chromaffin granule membranes. Arispe N, et al. **J Membr Biol** 1995 Sep; 147(2):109–19

Nicotine-induced exocytotic norepinephrine release in guinea-pig heart, human atrium and bovine adrenal chromaffin cells: modulation by single components of ischaemia. Krüger C, et al. **J Mol Cell Cardiol** 1995 Aug; 27(8):1491–506

Two distinct ATP receptors activate calcium entry and internal calcium release in bovine chromaffin cells. Reichsman F, et al. **J Neurochem** 1995 Nov;65(5):2080–6

Metal selectivity of exocytosis in alpha-toxin-permeabilized bovine chromaffin cells. Tomsig JL, et al. **J Neurochem** 1996 Feb;66(2):644–50

Insulin-induced hypoglycemia stimulates both adrenaline and noradrenaline release from adrenal medulla in 21-day-old rats. Fujino Y, et al. **Jpn J Pharmacol** 1995 Dec; 69(4):413–20

Adrenomedullin stimulates calcium efflux from adrenal chromaffin cells in culture: possible involvement of an Na+/Ca2+ exchange mechanism. Houchi H, et al. **Life Sci** 1996;58(2):PL 35–40

Investigation by transient transfection of the effects on regulated exocytosis of Rab3a. Holz RW, et al. **Methods Enzymol** 1995;257:221–31

The uptake of calcium by isolated chromaffin granules of the adrenal medulla. Fitzpatrick S, et al. **Mol Cell Biochem** 1996 Feb 23;155(2):121–30

Differential requirements for Ca2+ concentrations for catecholamine release and biosynthesis in isolated bovine adrenal chromaffin cells. Houchi H, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Apr; 353(5):596–8

Rapid and long-lasting increase in galanin mRNA levels in rat adrenal medulla following insulin-induced reflex splanchnic nerve stimulation. Anouar Y, et al. **Neuroendocrinology** 1995 Dec;62(6):611–8

Dominant role of mitochondria in clearance of large Ca2+ loads from rat adrenal chromaffin cells. Herrington J, et al. **Neuron** 1996 Jan;16(1):219–28

Expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat adrenal medulla. Gadient RA, et al. **Neurosci Lett** 1995 Jul 14;194(1-2):17–20

Immunohistochemical localization of pituitary adenylate cyclase-activating polypeptide (PACAP) in the adrenal medulla of the rat. Shiotani Y, et al. **Peptides** 1995;

16(6):1045–50
Temperature dependence of release of vesicular content in bovine chromaffin cells. Walker A, et al. **Pflugers Arch** 1996 Sep;432(5):885–92
Changes in enkephalin and neuropeptide Y-like immunoreactivity in rabbit chromaffin tissues during perinatal development. Wikström LM, et al. **Regul Pept** 1996 Jan 16;61(1):37–44

PATHOLOGY

[Problems posed by asymptomatic pheochromocytoma and malignant tumors of the adrenal medulla] Zvara V, et al. **Ann Urol (Paris)** 1996;30(1):14–9 (Eng. Abstr.) **(Fre)**
[Sporadic unilateral adrenal medullary hyperplasia--a rare cause of hypertension] Stenger AM, et al. **Chirurg** 1996 Apr;67(4):448–50 (Eng. Abstr.) **(Ger)**
[Morphological typing, evaluation of tumor dignity and prognosis and etiologic classification of adrenomedullary and adrenocortical neoplasias] Schröder S, et al. **Pathologe** 1995 Sep;16(5):307–14 (57 ref.) (Eng. Abstr.) **(Ger)**
[Asymptomatic unilateral adrenal medullary hyperplasia with a cyst: case report] Kise H, et al. **Hinyokika Kiyo** 1995 Oct;41(10):793–6 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Properties of intracellular calcium stores and their role in receptor-mediated catecholamine secretion in rat adrenal chromaffin cells. Warashina A, et al. **Biol Signals** 1995 Jul–Aug;4(4):195–205
Serotonin and stress-induced increases in renin secretion are not blocked by sympathectomy/adrenal medullectomy but are blocked by beta antagonists. Morton KD, et al. **Brain Res** 1995 Nov 6;698(1–2):185–92
Recombinant interleukin-1 beta inhibits gastric acid secretion by activation of central sympatho-adrenomedullary outflow in rats. Yokotani K, et al. **Eur J Pharmacol** 1995 Jun 12;279(2–3):233–9
Cocaine and exercise: alteration in carbohydrate metabolism in adrenodemedullated rats. Ojuka EO, et al. **J Appl Physiol** 1996 Jan;80(1):124–32
Phosphorylation of chromogranin A and catecholamine secretion stimulated by elevation of intracellular Ca2+ in cultured bovine adrenal medullary cells. Yanagihara N, et al. **J Biol Chem** 1996 Jul 19;271(29):17463–8
Activation of magnocellular vasopressin responses to non-osmotic stress after chronic adrenal demedullation in rats. Aguilera G, et al. **J Neuroendocrinol** 1993 Oct; 5(5):501–7
Role of CRH in glucopenia-induced adrenomedullary activation in rats. Goldstein DS, et al. **J Neuroendocrinol** 1993 Oct;5(5):475–86
Muscarinic receptor subtypes mediating catecholamine secretion and increase in intracellular Ca2+ concentration in adrenal chromaffin cells of the guinea pig. Asano T, et al. **J Vet Med Sci** 1995 Dec;57(6):1067–71
Local transfer of hormones between blood vessels within the adrenal gland may explain the functional interaction between the adrenal cortex and medulla. Einer-Jensen N, et al. **Med Hypotheses** 1995 Jun;44(6):471–4
Stimulatory regulation of the large-conductance, calcium-activated potassium channel by G proteins in bovine adrenal chromaffin cells. Walsh KB, et al. **Mol Pharmacol** 1996 Feb;49(2):379–86
Effects of expression of a mouse brain L-type calcium channel alpha 1 subunit on secretion from bovine adrenal chromaffin cells. Wick PF, et al. **Mol Pharmacol** 1996 Feb; 49(2):295–302
ATP serves as a negative feedback inhibitor of voltage-gated Ca2+ channel currents in cultured bovine adrenal chromaffin cells. Currie KP, et al. **Neuron** 1996 May; 16(5):1027–36
Angiotensin II regulates both adrenocortical and adrenomedullary function in isolated perfused pig adrenals. Breidert M, et al. **Peptides** 1996;17(2):287–92
Beta-adrenoceptor stimulation increases neuropeptide Y release from sympathetic nerves in intact rats. Évéquoz D, et al. **Regul Pept** 1995 Aug 22;58(3):163–6
Effect of [1-Sar,8-Thr]-angiotensin II on the hyperglycemic response to hemorrhage in adrenodemedullated and guanethidine-treated rats. Machado LJ, et al. **Regul Pept** 1995 Dec 7;60(1):69–77

PHYSIOPATHOLOGY

Selective hypoglycemia in the liver induces adrenomedullary counterregulatory response. Lamarche L, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1307–16
Nocturnal blood pressure elevation is related to adrenomedullary hyperactivity, but not to hyperinsulinemia, in nonobese normoalbuminuric type 1 diabetes. Peters A, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):507–12

SECRETION

Effects of atrial natriuretic factor on norepinephrine release evoked by angiotensins II and III in the rat adrenal medulla. Papouchado ML, et al. **Arch Physiol Biochem** 1995 Apr; 103(1):55–8
Enhanced cAMP production mediates the stimulatory action of pituitary adenylate cyclase activating polypeptide (PACAP) on in vitro catecholamine secretion from bovine adrenal chromaffin cells. Perrin D, et al. **Exp Clin Endocrinol Diabetes** 1995;103(2):81–7
Stimulation of catecholamine secretion from adrenal chromaffin cells by 14-3-3 proteins is due to reorganisation of the cortical actin network. Roth D, et al. **FEBS Lett** 1995 Oct 23;374(1):77–81
Calmodulin is the divalent cation receptor for rapid endocytosis, but not exocytosis, in adrenal chromaffin cells. Artalejo CR, et al. **Neuron** 1996 Jan;16(1):195–205

TRANSPLANTATION

Transplantation of human chromaffin cells for control of intractable cancer pain. Lazorthes Y, et al. **Acta Neurochir Suppl (Wien)** 1995;64:97–100
Modulation of NMDA receptor expression in the rat spinal cord by peripheral nerve injury and adrenal medullary grafting. Hama AT, et al. **Brain Res** 1995 Jul 31; 687(1–2):103–13
Bovine chromaffin cells for CNS transplantation do not elicit xenogeneic T cell proliferative responses in vitro. Czech KA, et al. **Cell Transplant** 1996 Mar–Apr;5(2):257–67
Effects of adrenal medulla transplantation into the third ventricle on the onset of puberty in female rhesus monkeys. Gore AC, et al. **Exp Neurol** 1996 Aug;140(2):172–83
Adrenal medullary implants reduce transsynaptic degeneration in the spinal cord of rats following chronic constriction nerve injury. Hama AT, et al. **Exp Neurol** 1996 Jan;137(1):81–93
Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report. Date I, et al. **J Neurosurg** 1996 Apr; 84(4):685–9 (33 ref.)
Adrenal medullary grafts suppress c-fos induction in spinal neurons of arthritic rats. Sagen J, et al. **Neurosci Lett** 1995 Jun 16;192(3):181–4
Two-year follow-up study of a patient with Parkinson's disease and severe motor fluctuations treated by co-grafts of adrenal medulla and peripheral nerve into bilateral caudate nuclei: case report. Date I, et al. **Neurosurgery** 1995 Sep;37(3):515–8; discussion 518–9
Attenuation of pain-related hyperventilation in adjuvant arthritic rats with adrenal medullary transplants in the spinal subarachnoid space. Wang H, et al. **Pain** 1995 Dec; 63(3):313–20
Peripheral xenogeneic immunological response to encapsulated bovine adrenal chromaffin cells implanted within the sheep lumbar intrathecal space. Kaplan FA, et al. **Transplantation** 1996 Apr 27;61(8):1215–21

ULTRASTRUCTURE

Thapsigargin discriminates strongly between Ca(2+)-ATPase phosphorylated intermediates with different subcellular distributions in bovine adrenal chromaffin cells. Caspersen C, et al. **FEBS Lett** 1995 Dec 11;377(1):31–6

ADRENAL REST TUMOR

[Adrenal rest tumor of the liver] Miyazaki I, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):285–7 (10 ref.) **(Jpn)**

PATHOLOGY

Proliferation and maturation indices in nephrogenic rests and Wilms tumor; the emergence of heterogeneity from dormant nodular renal blastema. Bove KE, et al. **Pediatr Pathol Lab Med** 1995 Mar–Apr;15(2):223–44

ADRENAL RETICULARIS see **ZONA RETICULARIS**

ADRENALECTOMY

Adrenalectomy prevents the development of alcohol preference in male rats. Lamblin F, et al. **Alcohol** 1996 May–Jun;13(3):233–8
Comparison of effects of adrenalectomy and RU-486 in rats given a choice of maintenance diet and fat supplement. Trocki O, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R708–19
Influence of maternal adrenalectomy and glucocorticoid administration on the development of rat cerebral cortex. Trejo JL, et al. **Anat Embryol (Berl)** 1995 Jul;192(1):89–99
Study of ACTH-immunoreactive cells after transplantation of neonatal adrenal glands into adult adrenalectomized rats. Sarria R, et al. **Anat Histol Embryol** 1995 Sep;24(3):185–90
Factors influencing outcome of surgery for primary aldosteronism. Celen O, et al. **Arch Surg** 1996 Jun; 131(6):646–50
Adrenalectomy for metastatic disease to the adrenal glands. Lo CY, et al. **Br J Surg** 1996 Apr;83(4):528–31
Adrenalectomy--still a must in radical renal surgery? Kozak W, et al. **Br J Urol** 1996 Jan;77(1):27–31
Region-specific alterations of calbindin-D28k immunoreactivity in the rat hippocampus following adrenalectomy and corticosterone treatment. Krugers HJ, et al. **Brain Res** 1995 Oct 23;696(1–2):89–96
Effects of adrenalectomy and corticosterone replacement on glucocorticoid receptor levels in rat brain tissue: a comparison between western blotting and receptor binding assays. O'Donnell D, et al. **Brain Res** 1995 Jul 31; 687(1–2):133–42
Hippocampal dentate granule cell degeneration after adrenalectomy in the rat is not reversed by dexamethasone. Sloviter RS, et al. **Brain Res** 1995 Jun 5;682(1–2):227–30
Effect of adrenal steroids on preproneurokinin-A gene expression in discrete regions of the rat brain. Pompei P, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):209–16
Regulation of angiotensinogen gene expression in the rat forebrain by adrenal steroids and relation to salt appetite. Riftina F, et al. **Brain Res Mol Brain Res** 1995 Nov; 33(2):201–8
Inhibition of 7,12-dimethylbenz[a]anthracene-induced lung tumorigenesis in A/J mice by food restriction is reversed by adrenalectomy. Pashko LL, et al. **Carcinogenesis** 1996 Feb;17(2):209–12
Endoscopic adrenalectomy: the adrenals under the scope? Cuesta MA, et al. **Clin Endocrinol (Oxf)** 1996 Mar; 44(3):349–51
Laparoscopic adrenalectomy for adrenal tumours causing hypertension and for 'incidentalomas' of the adrenal on computerized tomography scanning. Rutherford JC, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):490–2
Bilateral adrenalectomy induces early onset of summer fur growth in mink (Mustela vison). Rose J. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):243–7
Role of IL-1 beta and corticosteroids in the regulation of the C/EBP-alpha, beta and delta genes in vivo. Magalini A, et al. **Cytokine** 1995 Nov;7(8):753–8
Effect of adrenalectomy on the development of a pancreatic islet lesion in fa/fa rats. Kibenge MT, et al. **Diabetologia** 1996 Feb;39(2):190–8
Adrenalectomy reverses pre-existing obesity in adult genetically obese (ob/ob) mice. Feldkircher KM, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):232–5
Surgical treatment of adrenal metastasis following pulmonary resection for lung cancer: comparison of adrenalectomy with palliative therapy [letter; comment] Dieter RA. **Int Surg** 1995 Apr–Jun;80(2):195. Comment on: Int Surg 1994 Apr–Jun;79(2):124–9.
Laparoscopic adrenalectomy. Lee DW, et al. **Int Surg** 1995 Oct–Dec;80(4):311–4
Laparoscopic adrenalectomy [editorial; comment] Prinz RA. **J Am Coll Surg** 1996 Jul;183(1):71–3 (9 ref.). Comment on: J Am Coll Surg 1996 Jul;183(1):1–10.
The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. Van Wyk JJ, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3180–90
Glucose tolerance and insulin secretion after adrenalectomy in mice made obese with gold thioglucose. Blair SC, et al. **J Endocrinol** 1996 Mar;148(3):391–8
Adrenalectomy induces a decrease in the light scatter properties and amylase content of isolated zymogen granules from rat pancreas as analyzed by flow cytometry. Garcia-Montero AC, et al. **J Endocrinol** 1995 Dec; 147(3):431–40
Evidence for axonal sprouting in the anterior pituitary following adrenalectomy in the rat. Lu CR, et al. **J Endocrinol** 1995 Oct;147(1):161–6
Changes in glucocorticoid receptor immunoreactivity after adrenalectomy and corticosterone treatment in the rat testis. Biagini G, et al. **J Endocrinol Invest** 1995 May; 18(5):384–90
Laparoscopic adrenalectomy: clinical results in 25 patients. Nakagawa K, et al. **J Endourol** 1995 Jun;9(3):265–7
Effects of maternal adrenalectomy and glucocorticoid administration on the development of rat hippocampus. Rúa C, et al. **J Hirnforsch** 1995;36(4):473–83
The effect of bilateral fetal adrenalectomy on fluid balance in the ovine fetus. Benson CA, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):235–41
Adrenalectomy potentiates the morphine--but not cocaine-induced place preference in rats. Suzuki T, et al. **Life Sci** 1995 Mar 17;56(17):PL339–44
Alteration of antioxidant status following sympathectomy: differential effects of modified plasma levels of adrenaline and noradrenaline. Toleikis PM, et al. **Mol Cell Biochem** 1995 Nov 8;152(1):39–49
Behavioural deficits in adult rats following long-term adrenalectomy. Islam A, et al. **Neurosci Lett** 1995 Jul 14; 194(1–2):49–52
Cell-specific modulation of basal and seizure-induced neurotrophin expression by adrenalectomy. Lauterborn J, et al. **Neuroscience** 1995 Sep;68(2):363–78
Beta-adrenoceptor stimulation increases neuropeptide Y release from sympathetic nerves in intact rats. Évéquoz D, et al. **Regul Pept** 1995 Aug 22;58(3):163–6
Laparoscopic adrenalectomy. Gagner M. **Surg Clin North Am** 1996 Jun;76(3):523–37 (25 ref.)
The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Crucitti F, et al. **Surgery** 1996 Feb;119(2):161–70
Role of preoperative iodocholesterol scintiscanning in patients undergoing adrenalectomy for Cushing's syndrome. Yu KC, et al. **Surgery** 1995 Dec;118(6):981–6; discussion 986–7
The effects of inhibitors of cyclo-oxygenase, lipoxygenase and nitric oxide synthase pathways on the toxicity of hydroxyurea in adrenalectomized rats. Navarra P, et al. **Toxicol Lett** 1996 Jul;86(1):13–18
Radical surgery for renal-cell carcinoma: caval neoplastic

excision, adrenalectomy, lymphadenectomy, adjacent organ resection. Marshall FF, et al. **World J Urol** 1995; 13(3):159–62

[Ipsilateral adrenalectomy in the surgical treatment of renal carcinoma] Marois C, et al. **Prog Urol** 1995 Dec;5(6):961–4 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Primary aldosteronism. Results of surgical treatment. Lo CY, et al. **Ann Surg** 1996 Aug;224(2):125–30 (23 ref.)

Time course of the effects of steroid hormone deprivation elicited by ovariectomy or ovariectomy plus adrenalectomy on the affinity and density of GABA binding sites in distinct rat brain areas. Jussofie A, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):196–204

Combined effects of adrenalectomy and noise exposure on compound action potentials, endocochlear potentials and endolymphatic potassium concentrations. Ma YL, et al. **Hear Res** 1995 Nov;91(1–2):79–86

INSTRUMENTATION

[Laparoscopic adrenalectomy. Experiences with 50 patients] Suzuki K, et al. **Urologe A** 1996 May;35(3):233–7 (Eng. Abstr.) **(Ger)**

METHODS

Hemodynamic changes after retroperitoneal CO2 insufflation for posterior retroperitoneoscopic adrenalectomy. Giebler RM, et al. **Anesth Analg** 1996 Apr;82(4):827–31

Laparoscopic adrenalectomy. Comparison of the lateral and posterior approaches. Duh QY, et al. **Arch Surg** 1996 Aug; 131(8):870–5; discussion 875–6

Initial experience with endoscopic retroperitoneal adrenalectomy. Parrilla P, et al. **Br J Surg** 1996 Jul; 83(7):987–8

Laparoscopic adrenalectomy. Stuart RC, et al. **Br J Surg** 1995 Nov;82(11):1498–9

Retroperitoneal endoscopic adrenalectomy [letter; comment] Taylor RS, et al. **Br J Surg** 1995 Sep;82(9):1282. Comment on: Br J Surg 1995 Feb;82(2):215.

Microwave ablation of the adrenal gland: experimental study and clinical application. Kigure T, et al. **Br J Urol** 1996 Feb;77(2):215–20

Laparoscopic adrenalectomy compared to open adrenalectomy for benign adrenal neoplasms [see comments] Brunt LM, et al. **J Am Coll Surg** 1996 Jul; 183(1):1–10. Comment in: J Am Coll Surg 1996 Jul;183(1):71–3.

Laparoscopic adrenalectomy: review of 14 cases and comparison with open adrenalectomy. Naito S, et al. **J Endourol** 1995 Dec;9(6):491–5

Laparoscopic adrenalectomy. Miccoli P, et al. **J Laparoendosc Surg** 1995 Aug;5(4):221–6

Laparoscopic surgery for neuroblastoma identified by mass screening. Yamamoto H, et al. **J Pediatr Surg** 1996 Mar; 31(3):385–8

Adrenalectomy via the dorsal approach: a benchmark for laparoscopic adrenalectomy [see comments] Nash PA, et al. **J Urol** 1995 Nov;154(5):1652–4. Comment in: J Urol 1996 Sep;156(3):1136.

Re: Adrenalectomy via the dorsal approach: a benchmark for laparoscopic adrenalectomy [letter; comment] Schulam P, et al. **J Urol** 1996 Sep;156(3):1136. Comment on: J Urol 1995 Nov;154(5):1652–4.

Results of endoscopic retroperitoneal adrenalectomy. Heintz A, et al. **Surg Endosc** 1996 Jun;10(6):633–5

A porcine model for laparoscopic adrenalectomy. Park A, et al. **Surg Endosc** 1995 Jul;9(7):807–10

Endoscopic retroperitoneal adrenalectomy. Mercan S, et al. **Surgery** 1995 Dec;118(6):1071–5; discussion 1075–6

Surgical strategy for pheochromocytoma: emphasis on the pledge of flank extraperitoneal approach in selected patients. Obara T, et al. **Surgery** 1995 Dec;118(6):1083–9

Removal of large adrenal tumor on the right side with liver mobilization. Nakada T, et al. **Urol Int** 1995;55(4):209–14

[Adrenalectomy by laparoscopy] Gagner M. **Ann Endocrinol (Paris)** 1995;56(6):630–1 **(Fre)**

[Adrenalectomy by posterior approach for benign adrenocortical tumors. Apropos of 12 cases] Brunaud L, et al. **J Chir (Paris)** 1996 Jan;133(1):7–11 (Eng. Abstr.) **(Fre)**

[Role of laparoscopy in surgery of the adrenal glands] Henry JF, et al. **J Chir (Paris)** 1996 May;133(3):111–6 (Eng. Abstr.) **(Fre)**

[Endoscopic retroperitoneal adrenalectomy] Heintz A, et al. **Dtsch Med Wochenschr** 1995 Dec 8;120(49):1685–8 (Eng. Abstr.) **(Ger)**

[Laparoscopic adrenalectomy in pheochromocytoma] Vogelbach P, et al. **Schweiz Med Wochenschr** 1995 Sep 16;125(37):1735–9 (25 ref.) (Eng. Abstr.) **(Ger)**

[Extraperitoneal laparoscopic adrenalectomy: the initial 9 cases] Suzuki K, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 May;87(5):809–14 (Eng. Abstr.) **(Jpn)**

MORTALITY

[Brain death caused by catecholamine crisis during adrenalectomy] Ponomarev AB. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):76–9 **(Rus)**

VETERINARY

Adrenalectomy for treatment of hyperadrenocorticism in cats: 10 cases (1988–1992). Duesberg CA, et al. **J Am Vet Med Assoc** 1995 Oct 15;207(8):1066–70

Effects of bilateral adrenalectomy on initiation of fur growth cycles in the deer mouse (Peromyscus maniculatus). Garwood T, et al. **Lab Anim Sci** 1995 Oct;45(5):564–6

Results of adrenalectomy in 36 dogs with hyperadrenocorticism caused by adreno-cortical tumour. van Sluijs FJ, et al. **Vet Q** 1995 Sep;17(3):113–6

ADRENALINE see **EPINEPHRINE**

ADRENERGIC AGENTS

see related
SYMPATHOLYTICS
SYMPATHOMIMETICS

PHARMACOKINETICS

Bioavailability of pseudoephedrine from controlled release formulations in the presence of guaifenesin in human volunteers. Pade V, et al. **Biopharm Drug Dispos** 1995 Jul; 16(5):381–91

PHARMACOLOGY

Effects of ephedrine on oxygen consumption and cardiac output. Rådström M, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1084–7

Constant-pressure perfusion of rat hindlimb shows alpha- and beta-adrenergic stimulation of oxygen consumption. Ye JM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E960–8

Intrathecal amitriptyline. Antinociceptive interactions with intravenous morphine and intrathecal clonidine, neostigmine, and carbamylcholine in rats. Eisenach JC, et al. **Anesthesiology** 1995 Nov;83(5):1036–45

DSP-4 treatment influences olfactory preferences of developing rats. Cornwell CA, et al. **Brain Res** 1996 Mar 4;711(1–2):26–33

Autonomic receptor—effector coupling during post-natal development. Robinson RB. **Cardiovasc Res** 1996 Feb;31 Spec No:E68–76 (68 ref.)

Suppression of oocyte release in rats by local administration of the noradrenergic neurotoxin DSP4. Goldman JM, et al. **J Reprod Fertil** 1996 Mar;106(2):275–83

Hypotensive and bradycardic effects of dl-tetrahydropalmatine mediated by decrease in hypothalamic serotonin release in the rat. Chueh FY, et al. **Jpn J Pharmacol** 1995 Oct;69(2):177–80

Thermal, mechanical and chemical peripheral sensation in amphibians: opioid and adrenergic effects. Willenbring S, et al. **Life Sci** 1996;58(2):125–33

Effect of neurotoxin DSP4 on EEG power spectra in the rat acute model of epilepsy. Culić M, et al. **Neurosci Lett** 1995 Aug 18;196(1–2):49–52

Discriminative-stimulus effects of morphine in combination with alpha- and beta-noradrenergic agonists and antagonists in rats. Hughes CE, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):979–86

Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Grove A, et al. **Thorax** 1996 Jan;51(1):54–8

[The role of adrenergic mechanisms in the anticonvulsive action of the new preparation acetylaminoazaleptin] Tregubov AL. **Eksp Klin Farmakol** 1996 Jan–Feb; 59(1):19–20 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Adjunctive treatment of murine neuroblastoma with 6-hydroxydopamine and Tempol. Purpura P, et al. **Cancer Res** 1996 May 15;56(10):2336–42

Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Walker-Batson D, et al. **Stroke** 1995 Dec;26(12):2254–9

[Drug treatment of obesity] Yoshida T. **Nippon Rinsho** 1995 Jun;53 Suppl:481–6 (20 ref.) **(Jpn)**

TOXICITY

Methylphenidate studies give "weak signal" of carcinogenic potential [news] **Am J Health Syst Pharm** 1996 Mar 15; 53(6):610

Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on intravenous cocaine self-administration under a progressive ratio schedule of reinforcement. McGregor A, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):5–9

URINE

Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population. Wanwimolruk S, et al. **Br J Clin Pharmacol** 1995 Aug; 40(2):166–9

ADRENERGIC AGONISTS

Extracellular ATP inhibits adrenergic agonist-induced hypertrophy of neonatal cardiac myocytes. Zheng JS, et al. **Circ Res** 1996 Apr;78(4):525–35

ADMINISTRATION & DOSAGE

Accidental intra-arterial adrenaline administration. Young RJ, et al. **Anaesth Intensive Care** 1995 Aug;23(4):488–9

Efficacy of simulated epidural test doses in adult patients anesthetized with isoflurane: a dose-response study [see comments] Tanaka M, et al. **Anesth Analg** 1995 Nov; 81(5):987–92. Comment in: Anesth Analg 1996 Jun;82(6):1304–5.

The use of high doses of adrenaline in paediatric cardiac resuscitation. Higginson I, et al. **J Paediatr Child Health** 1996 Feb;32(1):1–3

The effect of inhaled adrenaline on lung function of recurrently wheezy infants less than 18 months old. Henderson AJ, et al. **Pediatr Pulmonol** 1995 Jul;20(1):9–15

Epinephrine prolongs duration of subcutaneous infiltration of local anesthesia in a dose-related manner. Correlation with magnitude of vasoconstriction. Liu S, et al. **Reg Anesth** 1995 Sep–Oct;20(5):378–84

ADVERSE EFFECTS

Effects of antiglaucoma drugs on ocular surface. Yalvaç IS, et al. **Acta Ophthalmol Scand** 1995 Jun;73(3):246–8

Accidental intra-arterial adrenaline administration. Young RJ, et al. **Anaesth Intensive Care** 1995 Aug;23(4):488–9

Epinephrine increases the severity of postresuscitation myocardial dysfunction. Tang W, et al. **Circulation** 1995 Nov 15;92(10):3089–93

Nonpigmenting fixed drug eruption after pseudoephedrine. Quan MB, et al. **Int J Dermatol** 1996 May;35(5):367–70

BLOOD

Plasma catecholamine and ventilatory responses to cycling after propranolol treatment. Schneider DA, et al. **Med Sci Sports Exerc** 1995 Dec;27(12):1616–20

PHARMACOLOGY

Influence of adrenergic and cholinergic mediators on the equine jejunum in vitro. Malone ED, et al. **Am J Vet Res** 1996 Jun;57(6):884–90

Influence of adrenoceptor agonists and antagonists on fluid secretion in small bowel obstruction. Nellgård P, et al. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1059–63

Indomethacin and epinephrine effects on outflow facility and cyclic adenosine monophosphate formation in monkeys. Crawford KS, et al. **Invest Ophthalmol Vis Sci** 1996 Jun; 37(7):1348–59

Adreno-cholinergic modulation of junctional communications between the pigmented and nonpigmented layers of the ciliary body epithelium. Shi XP, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1037–46

Early action potential shortening in hypoxic hearts: role of chloride current(s) mediated by catecholamine release. Ruiz Petrich E, et al. **J Mol Cell Cardiol** 1996 Feb; 28(2):279–90

Somatotropin treatment does not affect nonesterified fatty acid response to adrenergic injections in underfed or overfed nonlactating cows. Ferlay A, et al. **J Nutr** 1996 Apr;126(4):945–54

Functional characterization of alpha-1-adrenoceptor subtypes in the prostatic urethra and trigone of male rabbit. Deplanne V, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):527–34

Local modulation of adrenergic responses in the hindlimb vasculature of the intact conscious rat. DiCarlo SE, et al. **J Physiol (Lond)** 1995 Jun 15;485 (Pt 3):817–25

Interaction of epinephrine and beta-blockers. Jay GT, et al. **JAMA** 1995 Dec 20;274(23):1830, 1832

Spatial heterogeneity of blood flow in the dog heart. II. Temporal stability in response to adrenergic stimulation. Deussen A, et al. **Pflugers Arch** 1996 Jul;432(3):451–61

Temporary increase of plasma epinephrine affects stress responses 24 h later. Porta S, et al. **Physiol Behav** 1995 Aug;58(2):223–8

[Inhibitory effects of calcium channel antagonist on the proliferation of vascular smooth muscle cells induced by adrenoceptor activators] Li Y, et al. **Sheng Li Hsueh Pao** 1995 Jun;47(3):269–74 (Eng. Abstr.) **(Chi)**

[Effect of topical adrenergic agents on tissue circulation in human optic nerve head evaluated with a laser speckle microcirculation analyser] Tamaki Y, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jan;100(1):55–62 (Eng. Abstr.) **(Jpn)**

[The action of adrenergic agonists and antagonists on kidney function and arterial pressure depending on the mineral component of the diet] Shtrygol' SIu, et al. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):31–3 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Out-of-hospital provider use of epinephrine for allergic reactions: pilot program. Lindbeck GH, et al. **Acad Emerg Med** 1995 Jul;2(7):592–6

Hemodynamic effects of intravenous ephedrine in infants and children anesthetized with halothane and nitrous oxide. Taguchi N, et al. **Anesth Analg** 1996 Mar;82(3):568–73

Serial administration of adrenergic antagonist and agonist ("pulsatile therapy") reduces the incidence of long-term drift to timolol in humans. Gandolfi SA, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):684–8

Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. Chappell PB, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep;34(9):1140-6

Nebulized budesonide is as effective as nebulized adrenaline in moderately severe croup. Fitzgerald D, et al. **Pediatrics** 1996 May;97(5):722-5

Effects of epinephrine and vasopressin on median fibrillation frequency and defibrillation success in a porcine model of cardiopulmonary resuscitation. Strohmenger HU, et al. **Resuscitation** 1996 Feb;31(1):65-73

Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Wagner ML, et al. **Sleep** 1996 Jan;19(1):52-8

Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Prengel AW, et al. **Stroke** 1996 Jul;27(7):1241-8

ADRENERGIC ALPHA-AGONISTS

Extradural clonidine for postoperative pain relief [letter; comment] Cook B, et al. **Br J Anaesth** 1996 Jun;76(6):881-2 . Comment on: Br J Anaesth 1994 Mar;72(3):258-62. Comment on: Br J Anaesth 1996 Jan;76(1):171.

Effect of oral clonidine premedication on anesthetic requirement, hormonal response, hemodynamics, and recovery in coronary artery bypass graft surgery patients. Howie MB, et al. **J Clin Anesth** 1996 Jun;8(4):263-72

Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. Ruffolo RR Jr, et al. **J Med Chem** 1995 Sep 15;38(19):3681-716 (317 ref.)

Clonidine-mepivacaine mixture vs plain mepivacaine in paediatric surgery. Ivani G, et al. **Paediatr Anaesth** 1996; 6(2):111-4

[0.15 mg clonidine as oral premedication in retrobulbar anesthesia] Weindler J, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):410-3 (Eng. Abstr.) **(Ger)**

[Anesthesia using clofelin in different types of arterial hypertension in middle-aged and elderly patients] Dolina OA, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):4-6 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

The effects of imipramine, amitriptyline and clonidine administered by iontophoresis on the pain threshold. Taniguchi K, et al. **Acta Anaesthesiol Belg** 1995; 46(3-4):121-5

Effect of topical apraclonidine on flow properties of central retinal and ophthalmic arteries. Celiker UO, et al. **Acta Ophthalmol Scand** 1996 Apr;74(2):151-4

Oral clonidine premedication enhances the quality of postoperative analgesia by intrathecal morphine. Goyagi T, et al. **Anesth Analg** 1996 Jun;82(6):1192-6

Postoperative alpha 2-adrenergic stimulation attenuates protein catabolism. Mertes N, et al. **Anesth Analg** 1996 Feb; 82(2):258-63

The effects of alpha 2-adrenergic stimulation with mivazerol on myocardial blood flow and function during coronary artery stenosis in anesthetized dogs. Roekaerts PM, et al. **Anesth Analg** 1996 Apr;82(4):702-11

Chronic alpha 1-adrenoreceptor stimulation increases DNA synthesis in rat arterial wall. Modulation of responsiveness after vascular injury. deBlois D, et al. **Arterioscler Thromb Vasc Biol** 1996 Sep;16(9):1122-9

Efficacy of transdermal clonidine in short-term treatment of cluster headache: a pilot study. D'Andrea G, et al. **Cephalalgia** 1995 Oct;15(5):430-3

Clonidine plus haloperidol in the treatment of schizophrenia/psychosis. Maas JW, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):361-4

Intracorporeal phenylephrine in the treatment of priapism [see comments] Muruve N, et al. **J Urol** 1996 Jan; 155(1):141-3. Comment in: J Urol 1996 Jan;155(1):147. Comment in: J Urol 1996 Aug;156(2 Pt 1):483.

Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine. Virag R, et al. **Urology** 1996 May;47(5):777-81; discussion 781

[Postoperative analgesia with epidural administration of a combination of tramadol and clonidine] Masár O, et al. **Bratisl Lek Listy** 1995 Dec;96(12):669-70 (Eng. Abstr.) **(Slo)**

ADVERSE EFFECTS

Rebound hypertension and withdrawal associated with discontinuation of an infusion of epidural clonidine. Fitzgibbon D, et al. **Anesthesiology** 1996 Mar;84(3):729-31

Coronary artery spasm after ephedrine in a patient with high spinal anesthesia. Hirabayashi Y, et al. **Anesthesiology** 1996 Jan;84(1):221-4

High incidence of topical allergic reactions to 1% apraclonidine [letter] Feibel RM. **Arch Ophthalmol** 1995 Dec;113(12):1579-80

Correct treatment for accidental epinephrine auto-injector-induced digital ischemia [letter; comment] Brenner GM. **J Am Osteopath Assoc** 1995 Sep;95(9):510. Comment on: J Am Osteopath Assoc 1995 Jun;95(6):377-8.

Epidemiology of the adverse hemodynamic events occurring during "clonidine anesthesia": a prospective open trial of intraoperative intravenous clonidine. De Kock M, et al. **J Clin Anesth** 1995 Aug;7(5):403-10

Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution. Lin SL, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):267-78

Medications used to prevent migraine headaches and their potential ocular adverse effects. Doughty MJ, et al. **Optom Vis Sci** 1995 Dec;72(12):879-91 (176 ref.)

Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls. Gann H, et al. **Pharmacopsychiatry** 1995 May;28(3):80-3

BLOOD

Comparative stress hormone changes during helium versus carbon dioxide laparoscopic cholecystectomy. Naude GP, et al. **J Laparoendosc Surg** 1996 Apr;6(2):93-8

Measurement of brimonidine concentrations in human plasma by a highly sensitive gas chromatography/mass spectrometric assay. Acheampong A, et al. **J Pharm Biomed Anal** 1995 Jul;13(8):995-1002

High-performance liquid chromatographic determination of phenylephrine and its conjugates in human plasma using solid-phase extraction and electrochemical detection. Gumbhir K, et al. **J Pharm Biomed Anal** 1996 Mar; 14(5):623-30

Lymphocyte subset composition in peripheral blood from normal subjects may be influenced by both spleen size and plasma norepinephrine. Knudsen JH, et al. **Scand J Clin Lab Invest** 1995 Nov;55(7):643-8

CEREBROSPINAL FLUID

Cerebrospinal fluid norepinephrine and acetylcholine concentrations during acute pain. Eisenach JC, et al. **Anesth Analg** 1996 Mar;82(3):621-6

CHEMICAL SYNTHESIS

Design, synthesis, and structure-activity relationships of a new series of alpha-adrenergic agonists: spiro[(1,3-diazacyclopent-1-ene)-5,2'-(1',2',3',4'-tetrahydronaphthalene)]. Cordi AA, et al. **J Med Chem** 1995 Sep 29;38(20):4056-69

Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. Munk SA, et al. **J Med Chem** 1996 Mar 15;39(6):1193-5

Synthesis and evaluation of 2-[(5-methylbenz-1-ox-4-azin-6-yl)imino]imidazoline, a potent, peripherally acting alpha 2 adrenoceptor agonist. Munk SA, et al. **J Med Chem** 1996 Aug 30;39(18):3533-8

Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene derivatives of medetomidine. Zhang X, et al. **J Med Chem** 1996 Jul 19; 39(15):3001-13

DIAGNOSTIC USE

Growth hormone response to growth hormone-releasing hormone and clonidine in depression. Gann H, et al. **Biol Psychiatry** 1995 Sep 1;38(5):325-9

Nocturnal growth hormone (GH) secretion and GH response to clonidine provocation in children before and after long-term prednisone therapy. Soliman AT, et al. **J Trop Pediatr** 1995 Dec;41(6):344-7

METABOLISM

Imidazoline receptors and their endogenous ligands. Regunathan S, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:511-44 (168 ref.)

The unique nature of the serine interactions fpr alpha1-adrenergic receptor agonist binding and activation. Hwa J, et al. **J Biol Chem** 1996 Mar 15;271(11):6322-7

Identification of critical determinants of alpha 1-adrenergic receptor subtype selective agonist binding. Hwa J, et al. **J Biol Chem** 1995 Sep 29;270(39):23189-95

Selectivity of rilmenidine for I1-imidazoline-binding sites in rabbit proximal tubule cells. Gargalidis-Moudanos C, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S59-62

Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants. Galli A, et al. **J Exp Biol** 1995 Oct;198 (Pt 10):2197-212

PHARMACOKINETICS

Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension. Blowey DL, et al. **Am J Kidney Dis** 1996 Jul;28(1):132-6

Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Acheampong AA, et al. **Drug Metab Dispos** 1995 Jul;23(7):708-12

Atipamezole increases medetomidine clearance in the dog: an agonist-antagonist interaction. Salonen S, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):328-32

PHARMACOLOGY

Can alpha 2-adrenoceptor agonists reverse or prevent tolerance to the antinociceptive activity of opioids in rats? De Kock M, et al. **Acta Anaesthesiol Belg** 1995; 46(3-4):141-52

The metabolic effects of oral tizanidine in healthy volunteers. Taittonen M, et al. **Acta Anaesthesiol Scand** 1995 Jul; 39(5):628-32

Alpha 2-adrenergic stimulation counteracts glucose-induced rise of sodium in pancreatic islets exposed to ouabain. Saha S, et al. **Acta Diabetol** 1995 Jun;32(2):82-5

Diminished inhibitory effect of noradrenaline on insulin release from mouse islets transplanted to kidney. Shi CL, et al. **Acta Diabetol** 1995 Jun;32(2):116-20

Comparative responses to propofol anaesthesia alone and with alpha 2-adrenergic medications in a canine model. Bufalari A, et al. **Acta Vet Scand** 1996;37(2):187-201

Prevention of ethanol-induced sympathetic overactivity and degeneration by dexmedetomidine. Jaatinen P, et al. **Alcohol** 1995 Sep-Oct;12(5):439-46

Inotropic effects of alpha 1-adrenergic agonists in myocardium from rats with postinfarction heart failure. Litwin SE, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1553-63

Effects of alpha 2-adrenergic receptor agonist and antagonist drugs on cholinergic contraction in bovine tracheal smooth muscle in vitro. Manning MM, et al. **Am J Vet Res** 1995 Jul;56(7):930-5

The effect of prophylactic clonidine on postoperative shivering. A large prospective double-blind study. Vanderstappen I, et al. **Anaesthesia** 1996 Apr;51(4):351-5

Hypnotic and analgesic effects of the alpha 2-adrenergic agonist dexmedetomidine in morphine-tolerant rats. Hayashi Y, et al. **Anesth Analg** 1996 Sep;83(3):606-10

Mechanisms of dexmedetomidine-induced cerebrovascular effects in canine in vivo experiments. Ishiyama T, et al. **Anesth Analg** 1995 Dec;81(6):1208-15

Intrathecal clonidine and tizanidine in conscious dogs: comparison of analgesic and hemodynamic effects. Kroin JS, et al. **Anesth Analg** 1996 Mar;82(3):627-35

The effect of dexmedetomidine on the balance of myocardial energy requirement and oxygen supply and demand. Lawrence CJ, et al. **Anesth Analg** 1996 Mar;82(3):544-50

The effects of dobutamine and phenylephrine on atrioventricular conduction during combined use of halothane and thoracic epidural lidocaine. Nishikawa K, et al. **Anesth Analg** 1996 Mar;82(3):551-7

Renal sympathetic nerve activity after dexmedetomidine in nerve-intact and baroreceptor-denervated rabbits. Oku S, et al. **Anesth Analg** 1996 Sep;83(3):477-81

Dexmedetomidine injection into the locus ceruleus produces antinociception. Guo TZ, et al. **Anesthesiology** 1996 Apr; 84(4):873-81

Role of pertussis toxin-sensitive G-proteins in the analgesic and anesthetic actions of alpha 2-adrenergic agonists in the rat. Hayashi Y, et al. **Anesthesiology** 1995 Oct; 83(4):816-22

Interaction between intrathecal neostigmine and epidural clonidine in human volunteers. Hood DD, et al. **Anesthesiology** 1996 Aug;85(2):315-25

Role of the vagus nerve in the antidysrhythmic effect of dexmedetomidine on halothane/epinephrine dysrhythmias in dogs. Kamibayashi T, et al. **Anesthesiology** 1995 Nov; 83(5):992-9

Clonidine modulation of hemodynamic and catecholamine responses associated with hypoxia or hypercapnia in dogs. Nishikawa T, et al. **Anesthesiology** 1996 Mar;84(3):672-85

Phenylephrine increases cerebral blood flow during low-flow hypothermic cardiopulmonary bypass in baboons. Schwartz AE, et al. **Anesthesiology** 1996 Aug;85(2):380-4

Location and characteristics of nitric oxide synthase in sheep spinal cord and its interaction with alpha(2)-adrenergic and cholinergic antinociception. Xu Z, et al. **Anesthesiology** 1996 Apr;84(4):890-9

Reactivity to alpha agonists is heightened in immature porcine pulmonary arteries. Kadletz M, et al. **Ann Thorac Surg** 1996 May;61(5):1359-62

Effects of brimonidine on aqueous humor dynamics in human eyes. Toris CB, et al. **Arch Ophthalmol** 1995 Dec; 113(12):1514-7

Epinephrine dose-response of the isolated working heart in O2-exposed rats. Arieli R, et al. **Aviat Space Environ Med** 1995 Nov;66(11):1071-8

Clonidine antagonizes the aversive effects of opiate withdrawal and the rewarding effects of morphine only in opiate withdrawn rats. Nader K, et al. **Behav Neurosci** 1996 Apr;110(2):389-400

Protein kinase C inhibitor, chelerythrine, potentiates the adrenaline-mediated aggregation of human platelets through calcium influx. Shah BH, et al. **Biochem Mol Biol Int** 1996 May;38(6):1135-41

Activation by alpha 1-adrenergic agonists of the progression phase in the proliferation of primary cultures of smooth muscle cells in mouse and rat aorta. Mimura Y, et al. **Biol Pharm Bull** 1995 Oct;18(10):1373-6

Separation of alpha-adrenergic and imidazoline/guanidinium receptive sites (IGRS) activity in a series of imidazoline analogues of cirazoline. Brasili L, et al. **Bioorg Med Chem** 1995 Nov;3(11):1503-9

Opposite influences of hypertension and diabetes mellitus on pressor responses induced by different alpha-adrenoceptor agonists and angiotensin II in pithed rats. Beenen OH, et al. **Blood Press** 1996 Jan;5(1):57-63

Influence of oral clonidine on the ventilatory response to acute and sustained isocapnic hypoxia in human males. Foo IT, et al. **Br J Anaesth** 1996 Feb;76(2):214-20

Antinociceptive actions of intrathecal xylazine: interactions

with spinal cord opioid pathways. Goodchild CS, et al. **Br J Anaesth** 1996 Apr;76(4):544–51

Effects of clonidine premedication on the pressor response to alpha-adrenergic agonists. Tanaka M, et al. **Br J Anaesth** 1995 Nov;75(5):593–7

Optic nerve vasomotor effects of topical apraclonidine hydrochloride. Orgül S, et al. **Br J Ophthalmol** 1996 Jan; 80(1):82–4

The role of capacitative Ca2+ influx in the alpha 1B-adrenoceptor-mediated contraction to phenylephrine of the rat spleen. Burt RP, et al. **Br J Pharmacol** 1995 Oct;116(4):2327–33

Evidence for a functional alpha 1A- (alpha 1C-) adrenoceptor mediating contraction of the rat epididymal vas deferens and an alpha 1B-adrenoceptor mediating contraction of the rat spleen. Burt RP, et al. **Br J Pharmacol** 1995 Jun;115(3):467–75

Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system alpha 2-adrenoceptors. Evans RG, et al. **Br J Pharmacol** 1995 Sep;116(1):1557–70

Impaired endothelium-dependent relaxation in isolated resistance arteries of spontaneously diabetic rats. Heygate KM, et al. **Br J Pharmacol** 1995 Dec;116(8):3251–9

Selectivity of the imidazoline alpha-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned alpha 1-adrenoceptor subtypes. Horie K, et al. **Br J Pharmacol** 1995 Sep;116(1):1611–8

The mechanism of action of alpha 2-adrenoceptors in human isolated subcutaneous resistance arteries. Parkinson NA, et al. **Br J Pharmacol** 1995 Aug;115(8):1463–8

Exposure and characterization of the action of noradrenaline at dopamine receptors mediating endothelium-independent relaxation of rat isolated small mesenteric arteries. Van der Graaf PH, et al. **Br J Pharmacol** 1995 Dec;116(8):3237–42

Changes in [3H]-UK 14304 binding to alpha 2-adrenoceptors in morphine-dependent guinea-pigs. Varani K, et al. **Br J Pharmacol** 1995 Dec;116(8):3125–32

Postjunctional alpha 1- and beta-adrenoceptor effects of noradrenaline on electrical slow waves and phasic contractions of cat colon circular muscle. Venkova K, et al. **Br J Pharmacol** 1995 Dec;116(8):3265–73

Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage. Halonen T, et al. **Brain Res** 1995 Sep 25; 693(1–2):217–24

Attenuation of the catecholamine response to tracheal intubation with oral clonidine in children. Mikawa K, et al. **Can J Anaesth** 1995 Oct;42(10):869–74

Effect of sympathectomy on inotropic responsiveness to alpha-adrenoceptor stimulation in developing mouse myocardia. Tanaka H, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1285–8

Alpha-adrenergic agonist and endothelin-1 induced intracellular Ca2+ response in the presence of a Ca2+ entry blocker in cultured rat ventricular myocytes. De Jonge HW, et al. **Cell Calcium** 1995 Dec;18(6):515–25

The amphiphilic peptide adenoregulin enhances agonist binding to A1-adenosine receptors and [35S]GTP gamma S to brain membranes. Moni RW, et al. **Cell Mol Neurobiol** 1995 Aug;15(4):465–93

Involvement of multiple cis elements in basal- and alpha-adrenergic agonist-inducible atrial natriuretic factor transcription. Roles for serum response elements and an SP-1-like element. Sprenkle AB, et al. **Circ Res** 1995 Dec; 77(6):1060–9

The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Chandler WL, et al. **Circulation** 1995 Nov 15;92(10):2984–94

Gene regulation of brain natriuretic peptide in cardiocyte hypertrophy by alpha 1-adrenergic stimulation. Nakagawa O, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S183–5

Alteration in the release of endothelium-derived relaxing factors by alpha-adrenoceptor stimulation in the aorta of stroke-prone spontaneously hypertensive rats. Shimamura K, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S144–5

Effect of methoxamine on noradrenaline release in the caudal artery of hypertensive rats. Shinozuka K, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S88–90

Stimulation of nonshivering thermogenesis in the Syrian hamster by norepinephrine and beta-selective adrenergic agents: a phenomenon of refractoriness. Dicker A, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jan;113(1):37–43

The effect of the alpha 2-adrenoceptor agonist, guanfacin, on energy expenditure, intake and deposition in rats. Gazzola C. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Sep;112(1):29–34

Drug-dependent Ca2+ mobilization in organ-cultured rabbit ciliary processes. Yoshimura N, et al. **Curr Eye Res** 1995 Aug;14(8):629–35

Adrenergic effects on the corneal and intraretinal direct-current electroretinogram and on the standing potential of albino rabbit eyes. Jarkman S, et al. **Doc Ophthalmol** 1995;89(3):251–66

Effect of alpha 2-adrenergic agonist clonidine on plasma growth hormone and insulin-like growth factor-I concentrations in barrows. Ozawa A, et al. **Endocr J** 1995 Oct;42(5):669–73

Adrenergic and cholinergic involvement in basal and growth hormone-releasing hormone-stimulated growth hormone secretion in glucocorticoid-treated rats. Giustina A, et al. **Endocr Res** 1995 Nov;21(4):719–32

Alpha 1-adrenergic stimulation of isolated rat atria results in discoordinate increases in natriuretic peptide secretion and gene expression and enhances Egr-1 and c-Myc expression. Bruneau BG, et al. **Endocrinology** 1996 Jan; 137(1):137–43

Pharmacological characterization of a recently described human beta 3-adrenergic receptor mutant. Candelore MR, et al. **Endocrinology** 1996 Jun;137(6):2638–41

The alpha 2-adrenoreceptor agonist clonidine suppresses seizures, whereas the alpha 2-adrenoreceptor antagonist idazoxan promotes seizures in amygdala-kindled kittens: a comparison of amygdala and pontine microinfusion effects. Shouse MN, et al. **Epilepsia** 1996 Aug;37(8):709–17

Effects of propranolol compared with clonidine on portal haemodynamics: a double-blind cross-over study using duplex-Doppler ultrasonography. Tincani E, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):893–7

Characterization of contractile adrenoceptors in the human umbilical artery. Bodelsson G, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):95–101

Identification of alpha 1-adrenoceptor subtypes involved in the antinatriuretic response to intrarenal infusion of phenylephrine. Chen C, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):1–6

Action of dexmedetomidine on rat locus coeruleus neurones: intracellular recording in vitro. Chiu TH, et al. **Eur J Pharmacol** 1995 Oct 24;285(3):261–8

Denopamine as an alpha 1H-adrenoceptor antagonist in isolated blood vessels. Fujimoto S, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):143–7

Evidence for a 5-HT1D receptor-mediated hypothermic effect of the alpha 1-adrenoceptor agonist, SDZ NVI-085, in guinea-pigs. Kalkman HO, et al. **Eur J Pharmacol** 1995 Oct 24;285(3):313–5

Hypothalamic alpha 2A-adrenoceptors stimulate growth hormone release in the rat. Makara GB, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):43–8

Influence of selective alpha 2-adrenergic agents on mustard oil-induced central hyperalgesia in rats. Mansikka H, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):43–8

NS-49, a novel alpha 1a-adrenoceptor-selective agonist characterization using recombinant human alpha 1-adrenoceptors. Obika K, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):327–34

Effect of alpha 2-adrenergic drugs dexmedetomidine and atipamezole on extracellular amino acid levels in vivo. Valtonen P, et al. **Eur J Pharmacol** 1995 Oct 24; 285(3):239–46

The influence of hyperthyroidism on pharmacologically induced contractions of isolated resistance arteries. Zwaveling J, et al. **Eur J Pharmacol** 1996 Apr 4; 300(1–2):91–7

Analysis of the mechanisms underlying the antinociceptive effect of the extracts of plants from the genus Phyllanthus. Santos AR, et al. **Gen Pharmacol** 1995 Nov;26(7):1499–1506

Vascular smooth muscle reactivity to norepinephrine in ovariectomized rats: relationship to vascular PGE2/PGF2 alpha ratio. Zamorano B, et al. **Gen Pharmacol** 1995 Nov; 26(7):1613–8

Alpha 2-adrenergic agonists increase cellular lactate efflux. Lockette W, et al. **Hypertension** 1996 May;27(5):1104–7

Hypotensive effect of intracerebroventricular injection of norepinephrine and its modulation by alpha and beta adrenergic blockers in conscious rabbits. Krishna B, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):361–8

Cardiovascular and catecholamine response to clonidine in obese subjects. Del Rio G, et al. **Int J Obes Relat Metab Disord** 1995 Jul;19(7):475–9

Comparative adrenocholinergic control of intracellular Ca2+ in the layers of the ciliary body epithelium. Schütte M, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):212–20

Alpha1-adrenergic receptor subtype mRNAs are differentially regulated by alpha1-adrenergic and other hypertrophic stimuli in cardiac myocytes in culture and in vivo. Repression of alpha1B and alpha1D but induction of alpha1C. Rokosh DG, et al. **J Biol Chem** 1996 Mar 8; 271(10):5839–43

Effects of dexmedetomidine on coronary hemodynamics and myocardial oxygen balance. Jalonen J, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):519–24

Contractile responses to various stimuli in isolated resistance vessels from simultaneously hypertensive and streptozotocin-diabetic rats. Kam KL, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):167–75

Dopaminergic and alpha-adrenergic control of neurotransmission in human right atrium. Rump LC, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):462–70

Activation of protein kinase C as a modulator of potentiated UK-14304-induced contractions in dog mesenteric artery and vein. Shimamoto H, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):923–31

Regulation of protein synthesis by alpha 1-adrenergic receptor subtypes in cultured rabbit aortic vascular smooth muscle cells. Siwik DA, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):508–18

Renal I1-imidazoline receptor-selective compounds mediate natriuresis in the rat. Smyth DD, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S63–7

The effects of losartan and captopril on vasopressor actions of cirazoline in the absence and presence of SZL-49 and nifedipine. Tabrizchi R, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):137–44

Subcellular fractions of cyclic AMP and cyclic AMP-dependent protein kinase and the positive inotropic effects of selective beta 1- and beta 2-adrenoceptor agonists in guinea pig hearts. Yabana H, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):893–8

Effect of neuromimetics upon the release of atrial natriuretic peptide granules: are multiple pathways involved in secretion? Newman TM, et al. **J Cell Physiol** 1996 Jul; 168(1):134–40

Activation of heat shock protein (hsp)70 and proto-oncogene expression by alpha1 adrenergic agonist in rat aorta with age. Chin JH, et al. **J Clin Invest** 1996 May 15; 97(10):2316–23

Interaction of salbutamol and galanin on both basal and growth hormone releasing hormone-stimulated growth hormone secretion in humans. Arvat E, et al. **J Endocrinol Invest** 1995 May;18(5):324–8

Haemodynamic effects of a combination of propranolol and clonidine in patients with post-hepatitic cirrhosis. Lin HC, et al. **J Gastroenterol Hepatol** 1995 May-Jun;10(3):281–6

Alpha-adrenergic stimulation activates a calcium-sensitive chloride current in brown fat cells. Pappone PA, et al. **J Gen Physiol** 1995 Aug;106(2):231–58

Modulation of the inwardly rectifying K+ channel in isolated human atrial myocytes by alpha 1-adrenergic stimulation. Sato R, et al. **J Membr Biol** 1995 Nov; 148(2):185–91

The norepinephrine-stimulated inositol phosphate response in human atria. Anderson KE, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2415–9

Mivazerol, a novel alpha2-agonist and potential anti-ischemic drug, inhibits KC1-stimulated neurotransmitter release in rat nervous tissue preparations. El Tamer A, et al. **J Neurochem** 1996 Aug;67(2):636–44

Norepinephrine but not epinephrine stimulates the release of corticotropin-releasing factor from in vitro superfused rat hypothalamus. Orliaguet G, et al. **J Neurosci Res** 1995 Oct 1;42(2):236–41

Effect of clonidine on ICP and on the hemodynamic responses to nociceptive stimuli in patients with brain tumors. Favre JB, et al. **J Neurosurg Anesthesiol** 1995 Jul; 7(3):159–67

Apraclonidine protection of the blood-aqueous barrier from traumatic break-down. Bonomi L, et al. **J Ocul Pharmacol Ther** 1995 Spring;11(1):25–35

The influence of 17-beta-oestradiol and the natural oestrous cycle on alpha-adrenoceptor-mediated responses of the cardiovascular system in the rat. Austin C, et al. **J Pharm Pharmacol** 1995 Aug;47(8):656–60

Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo. Cuadra G, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):228–36

Effects of single and short-term administration of clonidine on hypothalamic-pituitary somatotropic function of the adult male rat: an in situ hybridization study. De Gennaro Colonna V, et al. **J Pharmacol Exp Ther** 1996 Feb; 276(2):795–800

To what extent do spinal interactions between an alpha-2 adrenoceptor agonist and a mu opioid agonist influence noxiously evoked c-Fos expression in the rat? A pharmacological study. Honoré P, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):393–403

Alpha-2 adrenergic modulation of sleep: time-of-day-dependent pharmacodynamic profiles of dexmedetomidine and clonidine in the rat. Seidel WF, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):263–73

Dual effect of clonidine on mesenteric artery adrenoceptors: agonistic (alpha-2) and antagonistic (alpha-1). Silva EG, et al. **J Pharmacol Exp Ther** 1996 May;277(2):872–6

Sedative effects of romifidine in the dog. England GC, et al. **J Small Anim Pract** 1996 Jan;37(1):19–25

Effects of NG-nitro-L-arginine on alpha-agonists-induced contraction of aortae from Wistar Kyoto rats and stroke-prone spontaneously hypertensive rats. Matsuda K, et al. **J Smooth Muscle Res** 1995 Apr;31(2):51–60

Effects of phenylephrine on the contractile tension and cytosolic Ca2+ level in rat anococcygeus muscle. Shimizu K, et al. **J Smooth Muscle Res** 1995 Aug;31(4):163–73

Pharmacological characterization of the isolated canine prostate. Normandin DE, et al. **J Urol** 1996 May; 155(5):1758–61

The effect of xylazine on equine muscle surface capillary blood flow. Hennig GE, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):388–90

The effect of xylazine on plasma thromboxane B2 concentration in sheep. Raptopoulos D, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):438–41

Alpha-adrenoceptors and angiotensinogen gene expression in opossum kidney cells. Wang TT, et al. **Kidney Int** 1995 Jul;48(1):139–45

Alpha-subunit G-protein antisense oligodeoxynucleotide effects on supraspinal (i.c.v.) alpha2-adrenoceptor antinociception in mice. Raffa RB, et al. **Life Sci** 1996; 58(5):PL 77–80

Partial restoration of impaired alpha 1-adrenergic responsiveness in parotid cells of aged rats by

S-adenosylmethionine treatment. Kowatch MA, et al. **Mol Cell Biochem** 1995 Jul 5;148(1):73-7

Alpha-adrenergic reactivity of the microcirculation in conscious spontaneously hypertensive rats. Struijker-Boudier HA, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):239-44

Genetic evidence for involvement of multiple effector systems in alpha 2A-adrenergic receptor inhibition of stimulus-secretion coupling. Lakhlani PP, et al. **Mol Pharmacol** 1996 Jul;50(1):96-103

Effect of phorbol myristate acetate on alpha 1-adrenergic action in cells expressing recombinant alpha 1-adrenoceptor subtypes. Vázquez-Prado J, et al. **Mol Pharmacol** 1996 Jul;50(1):17-22

No evidence for functional imidazoline receptors on locus coeruleus neurons. Szabo B, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Apr; 353(5):557-63

Abolition of spindle oscillations by serotonin and norepinephrine in the ferret lateral geniculate and perigeniculate nuclei in vitro. Lee KH, et al. **Neuron** 1996 Aug;17(2):309-21

Effects of immobilization stress on hippocampal monoamine release: modification by mivazerol, a new alpha 2-adrenoceptor agonist. Zhang X, et al. **Neuropharmacology** 1995 Dec;34(12):1661-72

alpha 2 adrenergic agonists prevent MK-801 neurotoxicity. Farber NB, et al. **Neuropsychopharmacology** 1995 Jul; 12(4):347-9

Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Vaupel DB, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):315-22 (27 ref.)

Effect of administration of high dose intrathecal clonidine or morphine prior to sciatic nerve section on c-Fos expression in rat lumbar spinal cord. Luo L, et al. **Neuroscience** 1995 Oct;68(4):1219-27

Effect of phenylephrine and prazosin on the somatostatinergic system in the rat frontoparietal cortex. López-Sañudo S, et al. **Peptides** 1995;16(8):1453-9

Effects of valproate and lorazepam on experimental anxiety: tolerance, withdrawal, and role of clonidine. de Angelis L. **Pharmacol Biochem Behav** 1995 Oct;52(2):329-33

Characteristics of depression by clonidine of the pressor response to alpha 1-adrenoceptor agonists in pithed rats. Nomura S, et al. **Res Commun Mol Pathol Pharmacol** 1996 Mar;91(3):273-86

Phosphatidylinositol 3-kinase inhibitor, wortmannin, inhibits 5-hydroxytryptamine-mediated potentiation of platelet aggregation induced by epinephrine. Shah BH, et al. **Res Commun Mol Pathol Pharmacol** 1995 Aug;89(2):157-64

Recurrent laryngeal nerve activation by alpha 2 adrenergic agonists in goats. Hedrick MS, et al. **Respir Physiol** 1995 Aug;101(2):129-37

Contrast medium induced renal vasoconstriction, role of alpha receptors. Drescher P, et al. **Scand J Urol Nephrol Suppl** 1995;172:103-8

Effects of noradrenaline and dopamine infusions on arachidonic acid metabolism in man. Kerttula T, et al. **Thromb Res** 1995 Oct 15;80(2):169-78

The effects of medetomidine on cardiac contractility in autonomically blocked dogs. de Morais HS, et al. **Vet Surg** 1995 Jul-Aug;24(4):356-64

The effects of intracoeliac injections of alpha-adrenergic agonists and veratridine on reticuloruminal motility and the evocation of rumination in sheep. Campion DP, et al. **Zentralbl Veterinarmed A** 1995 Sep;42(7):443-51

[The effect of adrenotropic agents on lipolysis in rat adipose tissue; the effect of nonselective alpha adrenomimetics and alpha adrenolytics under in vitro experimental conditions] Lincová D, et al. **Sb Lek** 1991;93(9-10):351-63 (Eng. Abstr.) **(Cze)**

[Clonidine increases the anesthetic effectiveness of thiopental] Tonner PH, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):357-60 (Eng. Abstr.) **(Ger)**

[The effect of clonidine on the duration of vecuronium-induced neuromuscular blockade in humans] Nakahara T, et al. **Masui** 1995 Nov;44(11):1458-63 (Eng. Abstr.) **(Jpn)**

[The experimental evaluation of the difference in closing dynamics of internal urethral ostium on the urinary continence and on the ejaculation induced by an administration of phenylephrine] Morita T, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec;86(12):1761-9 (Eng. Abstr.) **(Jpn)**

[Effect of alpha and beta-adrenergic agonists on methacholine-induced nasal secretion in man] Morishita A. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Sep;98(9):1387-98 (Eng. Abstr.) **(Jpn)**

[Effects of desipramine and clomipramine on alpha 2-adrenergic receptor function in nucleus accumbens: studies with intracerebral dialysis in freely moving rats] Sekiya Y, et al. **Seishin Shinkeigaku Zasshi** 1995; 97(8):605-22 (Eng. Abstr.) **(Jpn)**

[Clonidine and its renal effects (letter; comment)] Suárez L, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):399-400 . Comment on: Rev Esp Anestesiol Reanim 1994 Mar-Apr;41(2):75-6. **(Spa)**

THERAPEUTIC USE

Second-line and 'alternative' treatments for alcohol withdrawal: alpha-agonists, beta-blockers, anticonvulsants, acupuncture and neuro-electric therapy. Brewer C. **Alcohol Alcohol** 1995 Nov;30(6):799-803 (25 ref.)

Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension. Blowey DL, et al. **Am J Kidney Dis** 1996 Jul;28(1):132-6

Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Fouad-Tarazi FM, et al. **Am J Med** 1995 Dec;99(6):604-10

Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group. Robin AL, et al. **Am J Ophthalmol** 1995 Oct;120(4):423-32

Hypotension resistant to therapy with alpha receptor agonists complicating cardiopulmonary bypass: lithium as a potential cause. Berkowitz DE, et al. **Anesth Analg** 1996 May;82(5):1082-5

Oral clonidine premedication reduces postoperative pain in children. Mikawa K, et al. **Anesth Analg** 1996 Feb; 82(2):225-30

Further characterization of the receptor mechanism involved in the antidysrhythmic effect of dexmedetomidine on halothane/epinephrine dysrhythmias in dogs. Kamibayashi T, et al. **Anesthesiology** 1995 Nov;83(5):1082-9

A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group. Stewart WC, et al. **Arch Ophthalmol** 1996 Aug;114(8):938-42

Clonidine in the management of asymmetrical gustatory facial sweating: an N-of-1 trial. Nesathurai S, et al. **Arch Phys Med Rehabil** 1996 Sep;77(9):906-8

Contractile responses to various inotropic agents in isolated hearts obtained from hypertensive diabetic rats. Beenen OH, et al. **Blood Press** 1995 Nov;4(6):372-8

Malignant phaeochromocytoma with high circulating DOPA, and clonidine-suppressible noradrenaline. McClean DR, et al. **Blood Press** 1995 Jul;4(4):215-7

Treatment of priapism during transurethral resection of the prostate. Quinney N, et al. **Br J Hosp Med** 1995 Oct 18-31; 54(8):393-4

Use of clonidine for treatment of spasticity arising from various forms of brain injury: a case series. Dall JT, et al. **Brain Inj** 1996 Jun;10(6):453-8

Oral clonidine premedication reduces vomiting in children after strabismus surgery. Mikawa K, et al. **Can J Anaesth** 1995 Nov;42(11):977-81

Observations on midodrine in a case of vasodepressor neurogenic syncope. Ward C, et al. **Clin Auton Res** 1995 Oct;5(5):257-60

Preoperative alpha2-adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: results of a randomized, controlled trial. Kulka PJ, et al. **Crit Care Med** 1996 Jun;24(6):947-52

Adrenergic vasopressor agents and mechanical ventilation for the treatment of experimental septic shock. Tang W, et al. **Crit Care Med** 1996 Jan;24(1):125-30

Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts. Dawe S, et al. **Drug Alcohol Depend** 1995 Oct;39(3):207-12

Is clonidine an effective smoking cessation therapy? Gourlay SG, et al. **Drugs** 1995 Aug;50(2):197-207 (83 ref.)

Pain relief with low-dose intravenous clonidine in a child with severe burns. Lyons B, et al. **Intensive Care Med** 1996 Mar;22(3):249-51

Guanfacine for Tourette's disorder [letter; comment] Fras I. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):3-4 . Comment on: J Am Acad Child Adolesc Psychiatry 1995 Jan;34(1):50-4.

Guanfacine for PTSD nightmares [letter] Horrigan JP. **J Am Acad Child Adolesc Psychiatry** 1996 Aug;35(8):975-6

Preliminary observations on the use of midodrine in treating orthostatic hypotension in familial dysautonomia. Axelrod FB, et al. **J Auton Nerv Syst** 1995 Oct 5;55(1-2):29-35

New directions in the treatment of heart failure: some paradoxical observations. Merin RG. **J Card Surg** 1995 Jul; 10(4 Suppl):509-13

Rilmenidine prevents epinephrine-induced arrhythmias in halothane-anesthetized dogs. Mammoto T, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S40-3

Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril. Scemama M, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 2:S34-9

The suppression of nightmares with guanfacine [letter] Horrigan JP, et al. **J Clin Psychiatry** 1996 Aug;57(8):371

Blood pressure responses to phenylephrine infusions in subjects with Cushing's syndrome. McKnight JA, et al. **J Hum Hypertens** 1995 Oct;9(10):855-8

Re: Intracorporeal phenylephrine in the treatment of priapism [letter; comment] Seftel AD. **J Urol** 1996 Aug;156(2 Pt 1):483. Comment on: J Urol 1996 Jan;155(1):141-3.

Management of alcohol withdrawal [letter; comment] Gorelick DA. **Mayo Clin Proc** 1995 Dec;70(12):1224. Comment on: Mayo Clin Proc 1995 Aug;70(8):777-82.

Management of alcohol withdrawal [letter; comment] Strickland RA, et al. **Mayo Clin Proc** 1995 Dec;70(12):1224 . Comment on: Mayo Clin Proc 1995 Aug;70(8):777-82.

A double-blind randomised comparison of the effects of epidural clonidine, lignocaine and the combination of clonidine and lignocaine in patients with chronic pain. Glynn C, et al. **Pain** 1996 Feb;64(2):337-43

Efficacy of apraclonidine ophthalmic solution (iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma. Flach AJ. **Surv Ophthalmol** 1995 Jul-Aug;40(1):84-5

Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group. Robin AL, et al. **Trans Am Ophthalmol Soc** 1995;93:421-38; discussion 439-41

Efficacy of oxybutynin, pseudoephedrine and indomethacin in the treatment of primary nocturnal enuresis. Varan B, et al. **Turk J Pediatr** 1996 Apr-Jun;38(2):155-9

TOXICITY

Induction of DNA breaks in cardiac myoblast cells by norepinephrine. Okamoto T, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):821-7

URINE

Clenbuterol extraction by diphasic-dialysis and determination in bovine urine by GC-MS [letter] González Gigosos P, et al. **Rapid Commun Mass Spectrom** 1995;Spec No:S210-2

ADRENERGIC ALPHA-ANTAGONISTS

Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. Ruffolo RR Jr, et al. **J Med Chem** 1995 Sep 15;38(19):3681-716 (317 ref.)

[Discovery and development of tamsulosin hydrochloride, a new alpha 1-adrenoceptor antagonist] Takenaka T, et al. **Yakugaku Zasshi** 1995 Oct;115(10):773-89 (42 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Administration of terazosin capsules through feeding tubes [letter] Cheng L. **Am J Health Syst Pharm** 1995 Sep 15; 52(18):2031

Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Litman RE, et al. **Br J Psychiatry** 1996 May;168(5):571-9

Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Albillos A, et al. **Gastroenterology** 1995 Oct; 109(4):1257-65

Preweanling administration of terazosin decreases blood pressure of hypertensive rats in adulthood. McCarty R, et al. **Hypertension** 1996 May;27(5):1115-20

Efficacy and safety of terazosin to improve voiding in spinal cord injury patients. Perkash I. **J Spinal Cord Med** 1995 Oct;18(4):236-9

Pulmonary administration of vasoactive substances by perfluorochemical ventilation. Wolfson MR, et al. **Pediatrics** 1996 Apr;97(4):449-55

Peak pain relief is delayed and duration of relief is extended following intravenous phentolamine infusion. Preliminary report. Galer BS. **Reg Anesth** 1995 Sep-Oct;20(5):444-7

[Metazosin tablets (Kenosin) in the treatment of chronic congestive heart failure] Vokrouhlický L, et al. **Cas Lek Cesk** 1995 Sep 20;134(18):590-3 (Eng. Abstr.) **(Cze)**

[Relationship between the quantitative morphometry and the clinical response to alpha adrenergic blocker in benign prostatic hyperplasia] Sakai S, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):695-701 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Polyarthralgia associated with prazosin use [letter] Bell A, et al. **Ann Pharmacother** 1995 Sep;29(9):937

BLOOD

High-performance liquid chromatography using electrochemical detection for the determination of prazosin in biological samples. Rathinavelu A, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):177-82

[Alpha-blocker] Mikami H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:974-7 (19 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Synthesis of a selective alpha-2A adrenoceptor antagonist, BRL 48962, and its characterization at cloned human alpha-adrenoceptors. Beeley LJ, et al. **Bioorg Med Chem** 1995 Dec;3(12):1693-8

Synthesis and alpha-adrenoreceptor blocking properties of phenoxybenzamine-related (2-chloroethyl)-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)-(2-phenoxyethyl) amines. Giardinà D, et al. **Bioorg Med Chem** 1995 Jan;3(1):85-94

Synthesis of benzodioxinopyrroles as selective alpha 2-adrenoceptor antagonists. Kitchin J, et al. **Bioorg Med Chem** 1995 Dec;3(12):1595-603

Synthesis and alpha,beta-adrenergic blocking potency of 2,3-dihydro-1,4-benzodioxin derivatives. (I). Khouili M, et al. **Farmaco** 1996 Mar;51(3):175-84

Synthesis and alpha,beta-adrenergic blocking potency of 2,3-dihydro-1,4-benzodioxin derivatives. (II). Khouili M,

et al. **Farmaco** 1996 Mar;51(3):185–8
Synthesis, absolute configuration, and biological profile of the enantiomers of trans-[2-(2,6-dimethoxyphenoxy)ethyl][(3-p-tolyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amine (mephendioxan), a potent competitive alpha 1A-adrenoreceptor antagonist. Quaglia W, et al. **J Med Chem** 1996 May 24;39(11):2253–8

CHEMISTRY

Synthesis, absolute configuration, and biological profile of the enantiomers of trans-[2-(2,6-dimethoxyphenoxy)ethyl][(3-p-tolyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amine (mephendioxan), a potent competitive alpha 1A-adrenoreceptor antagonist. Quaglia W, et al. **J Med Chem** 1996 May 24;39(11):2253–8

CLASSIFICATION

Alpha 1-adrenoceptors: pharmacological classification and newer therapeutic applications. Ruffolo RR Jr, et al. **Proc West Pharmacol Soc** 1995;38:121–6 (59 ref.)

CONTRAINDICATIONS

Don't get stung with the adrenergic blockers (beta or alpha)! Watson A. **Aust Fam Physician** 1995 Oct;24(10):1879

DIAGNOSTIC USE

Growth hormone responses to growth hormone-releasing hormone and clonidine in patients with type I diabetes and in normal controls: effect of age, body mass index and sex. Jacobs ML, et al. **Clin Endocrinol (Oxf)** 1996 May; 44(5):547–53
Quantitative autoradiography of alpha 1 adrenoceptors with [3H]tamsulosin in human hypertrophied prostate using computerized image analysis. Kurimoto S, et al. **Histochem J** 1995 Dec;27(12):1007–13

ECONOMICS

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Hillman AL, et al. **Urology** 1996 Feb; 47(2):169–78

METABOLISM

Imidazoline receptors and their endogenous ligands. Regunathan S, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:511–44 (168 ref.)
Subtype selectivity of a new alpha 1-adrenoceptor antagonist, JTH-601: comparison with prazosin. Muramatsu I, et al. **Eur J Pharmacol** 1996 Apr 4; 300(1-2):155–7
Identification of alpha 1-adrenoceptor subtypes in the rabbit prostate. Hiraoka Y, et al. **J Auton Pharmacol** 1995 Aug; 15(4):271–8
Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. Michel MC, et al. **J Auton Pharmacol** 1996 Feb;16(1):21–8
RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Ford AP, et al. **Mol Pharmacol** 1996 Feb;49(2):209–15
Comparison of the binding activities of some drugs on alpha 2A, alpha 2B and alpha 2C-adrenoceptors and non-adrenergic imidazoline sites in the guinea pig. Uhlén S, et al. **Pharmacol Toxicol** 1995 Jun;76(6):353–64
Metabolism of tamsulosin in rat and dog. Soeishi Y, et al. **Xenobiotica** 1996 Mar;26(3):355–65

PHARMACOKINETICS

Studies on calcium antagonistic and alpha 1-adrenergic receptor blocking activities of monatepil maleate, its metabolites and their enantiomers. Honda Y, et al. **Arzneimittelforschung** 1995 Oct;45(10):1057–60
Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans. Huupponen R, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):506–11
The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Andros E, et al. **Eur J Clin Pharmacol** 1996;50(1-2):41–6
Disposition of a new rate-controlled formulation of prazosin in the treatment of hypertension during pregnancy: transplacental passage of prazosin. Bourget P, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul-Sep; 20(3):233–41
Bioequivalence study of alpha-dihydroergocryptine: utility of metabolite evaluation. Ezan E, et al. **Int J Clin Pharmacol Ther** 1996 Jan;34(1):32–7
Effect of time of administration on the pharmacokinetics and tolerance of doxazosin in healthy male volunteers. Vashi V, et al. **J Clin Pharmacol** 1996 Apr;36(4):325–31

PHARMACOLOGY

Influence of CCK-8 and yohimbine on supraspinal modulation of nociceptive process. Szymbor B, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):243–8
Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. Hernández Hernández R, et al. **Am J Hypertens** 1996 May;9(5):437–44
Hemodynamic effects of medetomidine-midazolam-butorphanol and medetomidine-midazolam-buprenorphine combinations and reversibility by atipamezole in dogs. Pypendop B, et al. **Am J Vet Res** 1996 May;57(5):724–30
Anesthesia induced in pigs by use of a combination of medetomidine, butorphanol, and ketamine and its reversal by administration of atipamezole. Sakaguchi M, et al. **Am J Vet Res** 1996 Apr;57(4):529–34
Inhibition of lipid hydroperoxidation of low density lipoprotein by the Ca(2+)-channel and alpha 1-adrenoceptor antagonist monatepil maleate. Hayashi K, et al. **Arzneimittelforschung** 1996 Apr;46(4):378–81
Specific effects of idazoxan in a distraction task: evidence that endogenous norepinephrine plays a role in selective attention in rats. Bunsey MD, et al. **Behav Neurosci** 1995 Oct;109(5):903–11
Effects of yohimbine and desipramine on adrenal catecholamine release in response to splanchnic nerve stimulation in anesthetized dogs. Koganei H, et al. **Biol Pharm Bull** 1995 Sep;18(9):1207–10
Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Goddard AW, et al. **Biol Psychiatry** 1995 Jul 15;38(2):74–85
Synthesis of a selective alpha-2A adrenoceptor antagonist, BRL 48962, and its characterization at cloned human alpha-adrenoceptors. Beeley LJ, et al. **Bioorg Med Chem** 1995 Dec;3(12):1693–8
Synthesis of benzodioxinopyrroles as selective alpha 2-adrenoceptor antagonists. Kitchin J, et al. **Bioorg Med Chem** 1995 Dec;3(12):1595–603
RS-45041-190: a selective, high-affinity ligand for I2 imidazoline receptors. Brown CM, et al. **Br J Pharmacol** 1995 Sep;116(2):1737–44
Evidence for a functional alpha 1A- (alpha 1C-) adrenoceptor mediating contraction of the rat epididymal vas deferens and an alpha 1B-adrenoceptor mediating contraction of the rat spleen. Burt RP, et al. **Br J Pharmacol** 1995 Jun;115(3):467–75
[3H]-RS-45041-190: a selective high-affinity radioligand for I2 imidazoline receptors. MacKinnon AC, et al. **Br J Pharmacol** 1995 Sep;116(2):1729–36
Investigation of the actions of chloroethylclonidine in rat aorta. O'Rourke M, et al. **Br J Pharmacol** 1995 Aug; 115(8):1399–406
Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens. Palea S, et al. **Br J Pharmacol** 1995 Nov;116(5):2401–6
A re-evaluation of the role of alpha 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat. Redfern WS, et al. **Br J Pharmacol** 1995 Oct;116(3):2081–9
Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197). Tallentire D, et al. **Br J Pharmacol** 1996 May;118(1):63–72
Analysis of the activity of alpha 1-adrenoceptor antagonists in rat aorta. Van der Graaf PH, et al. **Br J Pharmacol** 1996 May;118(2):299–310
Role of alpha-adrenoceptors in the maintenance of core temperature in humans. Frank SM, et al. **Clin Sci (Colch)** 1995 Sep;89(3):219–25
Alpha 1-adrenergic receptor antagonist blocks acute cocaine action on the compound action potential of the auditory nerve in the chinchilla. Shivapuja BG, et al. **Drug Alcohol Depend** 1995 Nov;40(1):43–8
Normalization of insulin secretion by a selective alpha 2-adrenoceptor antagonist restores GLUT-4 glucose transporter expression in adipose tissue of type II diabetic rats. Angel I, et al. **Endocrinology** 1996 May;137(5):2022–7
The alpha 2-adrenoreceptor agonist clonidine suppresses seizures, whereas the alpha 2-adrenoreceptor antagonist idazoxan promotes seizures in amygdala-kindled kittens: a comparison of amygdala and pontine microinfusion effects. Shouse MN, et al. **Epilepsia** 1996 Aug;37(8):709–17
The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Andros E, et al. **Eur J Clin Pharmacol** 1996;50(1-2):41–6
The alpha 1-adrenoceptor antagonist, doxazosin, modulates the lower limit of autoregulation of cerebral blood flow during hemorrhagic hypotension in anesthetized hypertensive rats. Cai H, et al. **Eur J Pharmacol** 1995 Nov 24;286(3):249–53
Is alpha-adrenoceptor blockade responsible for atropine flush? Chang KC, et al. **Eur J Pharmacol** 1995 Sep 25; 284(3):331–4
Denopamine as an alpha 1H-adrenoceptor antagonist in isolated blood vessels. Fujimoto S, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):143–7
Chloroethylclonidine increases the incidence of lethal arrhythmias during coronary occlusion in anesthetized dogs. Geller JC, et al. **Eur J Pharmacol** 1995 Dec 29; 294(2-3):423–8
Receptor binding profile of cyclazosin, a new alpha 1B-adrenoceptor antagonist. Giardinà D, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):13–6
Pharmacological evaluation of N-methyl-actinodaphnine, a new vascular alpha-adrenoceptor antagonist, isolated from Illigera luzonensis. Guh JH, et al. **Eur J Pharmacol** 1995 Jun 6;279(1):33–41
alpha 1-Adrenoceptor stimulation inhibits the isoproterenol-induced effects on myocardial contractility and protein phosphorylation. Hartmann M, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):57–64
Receptor binding and functional evidence suggest that postsynaptic alpha 2-adrenoceptors in rat brain are of the alpha 2D subtype. Heal DJ, et al. **Eur J Pharmacol** 1995 Apr 24;277(2-3):215–21
Differential characteristics and localisation of [3H]oxazoline and [3H]imidazoline binding sites in rat kidney. King PR, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):341–6
Effects of a selective alpha 2-adrenoceptor antagonist, atipamezole, on hypothalamic histamine and noradrenaline release in vivo. Laitinen KS, et al. **Eur J Pharmacol** 1995 Oct 24;285(3):255–60
Influence of selective alpha 2-adrenergic agents on mustard oil-induced central hyperalgesia in rats. Mansikka H, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):43–8
Involvement of neurohumoral factors in the pressor mechanism of NG-nitro-L-arginine. Nakahara T, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):49–56
NS-49, a novel alpha 1a-adrenoceptor-selective agonist characterization using recombinant human alpha 1-adrenoceptors. Obika K, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):327–34
A comparison of the effects of doxazosin and terazosin on the spontaneous sympathetic drive to the bladder and related organs in anaesthetized cats. Ramage AG, et al. **Eur J Pharmacol** 1995 Dec 29;294(2-3):645–50
Effects of combined block of alpha 1-adrenoceptors and NMDA receptors on spatial and passive avoidance behavior in rats. Riekkinen M, et al. **Eur J Pharmacol** 1996 Apr 4;300(1-2):9–16
Effect of alpha 2-adrenergic drugs dexmedetomidine and atipamezole on extracellular amino acid levels in vivo. Valtonen P, et al. **Eur J Pharmacol** 1995 Oct 24; 285(3):239–46
The alpha 2-adrenergic antagonist idazoxan enhances the frequency selectivity and increases the threshold of auditory cortex neurons. Edeline JM. **Exp Brain Res** 1995; 107(2):221–40
Evidence for activation of both adrenergic and cholinergic nervous pathways by yohimbine, an alpha 2-adrenoceptor antagonist. Bagheri H, et al. **Fundam Clin Pharmacol** 1995; 9(3):248–54
Effect of bunazosin, alpha 1-adrenoceptor blocker, on multidirectional contractile response and localization of bunazosin binding sites in human hypertrophied prostate. Moriyama N, et al. **Gen Pharmacol** 1995 Sep;26(5):1033–7
The additive miotic effects of dapiprazole and pilocarpine. Geyer O, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Jul;233(7):448–51
Doxazosin prevents proteinuria and glomerular loss of heparan sulfate in diabetic rats. Jyothirmayi GN, et al. **Hypertension** 1996 May;27(5):1108–14
Hypotensive effect of intracerebroventricular injection of norepinephrine and its modulation by alpha and beta adrenergic blockers in conscious rabbits. Krishna B, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):361–8
Induction of the synthesis of hsp27 and alpha B crystallin in tissues of heat-stressed rats and its suppression by ethanol or an alpha 1-adrenergic antagonist. Inaguma Y, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1238–43
Effects of alpha-adrenergic blockade on regional myocardial function in canine ischemic myocardium during beta-adrenergic blockade. Kono M, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):525–33
Effects of dicentrine on the mechanical properties of systemic arterial trees in dogs. Chang KC, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):169–76
Dopaminergic and alpha-adrenergic control of neurotransmission in human right atrium. Rump LC, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):462–70
Relative contribution of alpha 1-adrenoceptor blocking activity to the hypotensive effect of the novel calcium antagonist monatepil. Sugimoto T, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):55–60
The effects of losartan and captopril on vasopressor actions of cirazoline in the absence and presence of SZL-49 and nifedipine. Tabrizchi R, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):137–44
The furoxan system as a useful tool for balancing "hybrids" with mixed alpha 1-antagonist and NO-like vasodilator activities. Fruttero R, et al. **J Med Chem** 1995 Dec 8; 38(25):4944–9
The yohimbine-induced anticonflict effect in the rat, Part I. Involvement of noradrenergic, serotonergic and endozepinergic(?) mechanisms. Söderpalm A, et al. **J Neural Transm Gen Sect** 1995;100(3):175–89
The yohimbine-induced anticonflict effect in the rat, Part II. Neurochemical findings. Söderpalm A, et al. **J Neural Transm Gen Sect** 1995;100(3):191–206
Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by selective alpha- and beta-adrenergic drugs in mice. Elenkov IJ, et al. **J Neuroimmunol** 1995 Sep;61(2):123–31
Prazosin-induced blockade of extraneuronal uptake facilitates dopaminergic modulation of muscle twitches in rat vas deferens. Elmallah AI, et al. **J Pharm Pharmacol** 1995 Nov; 47(11):932–6

The prejunctional inhibitory effect of alpha-methylnoradrenaline in the rat vas deferens is not mediated via alpha 2-adrenoceptors. Oriowo MA. **J Pharm Pharmacol** 1995 Aug;47(8):661-4

Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. de Boer TH, et al. **J Pharmacol Exp Ther** 1996 May;277(2):852-60

Pharmacologic characterization of CHIR 2279, an N-substituted glycine peptoid with high-affinity binding for alpha 1-adrenoceptors. Gibbons JA, et al. **J Pharmacol Exp Ther** 1996 May;277(2):885-99

Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. Haddjeri N, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):861-71

Dual effect of clonidine on mesenteric artery adrenoceptors: agonistic (alpha-2) and antagonistic (alpha-1). Silva EG, et al. **J Pharmacol Exp Ther** 1996 May;277(2):872-6

Alpha 1- and alpha 2-adrenoreceptor actions of phentolamine and prazosin on breathing movements in fetal sheep in utero. Giussani DA, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):249-55

Actions of terazosin and its enantiomers at subtypes of alpha 1- and alpha 2-adrenoceptors in vitro. Hancock AA, et al. **J Recept Signal Transduct Res** 1995 Sep-Dec; 15(7-8):863-85

Circulatory and metabolic effects of alpha-adrenergic blockade in the hyperinsulinemic ovine fetus. Stonestreet BS, et al. **J Soc Gynecol Investig** 1996 Sep-Oct;3(5):241-9

Atipamezole increases medetomidine clearance in the dog: an agonist-antagonist interaction. Salonen S, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):328-32

Metabolic and hormonal responses to adrenoceptor antagonists in 48-hour-starved exercising rats. Benthem L, et al. **Metabolism** 1995 Oct;44(10):1332-9

Microwave-induced lethal heat stress: effects of phentolamine, prazosin and metoprolol. Jauchem JR, et al. **Methods Find Exp Clin Pharmacol** 1995 May;17(4):241-8

Alpha-adrenergic reactivity of the microcirculation in conscious spontaneously hypertensive rats. Struijker-Boudier HA, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):239-44

Effects of selective alpha 1A-adrenoceptor antagonists on reperfusion arrhythmias in isolated rat hearts. Yasutake M, et al. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):173-80

Antagonists that differentiate between alpha 2A-and alpha 2D-adrenoceptors. Trendelenburg AU, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Feb; 353(3):245-9

dazoxan-induced reductions in cortical glucose use are accompanied by an increase in noradrenaline release: complementary [14C]2-deoxyglucose and microdialysis studies. French N, et al. **Neuropharmacology** 1995 Jun; 34(6):605-13

nhibition by intrathecal prazosin but not yohimbine of fentanyl-induced muscular rigidity in the rat. Lui PW, et al. **Neurosci Lett** 1995 Dec 8;201(2):167-70

Analysis of the relative biomechanical effects of alpha 1 and alpha 2 antagonists in modifying the compliance of the prostate and micturition parameters of the hormonally manipulated male rat. Constantinou CE, et al. **Neurourol Urodyn** 1996;15(1):85-101

Effect of phenylephrine and prazosin on the somatostatinergic system in the rat frontoparietal cortex. López-Sañudo S, et al. **Peptides** 1995;16(8):1453-9

Presynaptic alpha 2A-adrenoceptors regulate the 3H-noradrenaline secretion in the guinea-pig urethra. Alberts P. **Pharmacol Toxicol** 1995 Aug;77(2):95-101

Tolazoline decreases survival time during microwave-induced lethal heat stress in anesthetized rats. Jauchem JR, et al. **Proc Soc Exp Biol Med** 1996 Mar; 211(3):236-43

Influence of the alpha 2 noradrenergic antagonist piperoxane on longevity in the Fischer-344 rat: a preliminary report. Compton DM, et al. **Psychol Rep** 1995 Aug;77(1):139-42

Do alpha-2 adrenoceptors modify coping strategies in rats? Haller J, et al. **Psychopharmacology (Berl)** 1995 Dec; 122(4):379-85

Adrenergic blockade ameliorates cellular immune responses to mental stress in humans. Bachen EA, et al. **Psychosom Med** 1995 Jul-Aug;57(4):366-72

Acute effects of alpha-1 adrenoceptor antagonist, doxazosin on circulating vasoactive hormones. Veglio F, et al. **Riv Eur Sci Med Farmacol** 1994 May-Aug;16(3-4):85-90

Contrast medium induced renal vasoconstriction, role of alpha receptors. Drescher P, et al. **Scand J Urol Nephrol Suppl** 1995;172:103-8

Effects of alpha-blocker on daily testicular sperm production and sperm concentration, motility, intraluminal pressure and fluid movement in the rat epididymis. Yamamoto M, et al. **Tohoku J Exp Med** 1995 Sep;177(1):25-37

Prevention of cyclosporine-induced nephrotoxicity by prazosin hydrochloride, an alpha-1-adrenoreceptor blocker. Ishikawa A, et al. **Transplant Proc** 1996 Jun; 28(3):1360-1

An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Gerber GS, et al. **Urology** 1996 Jun;47(6):840-4

Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Kaplan SA, et al. **Urology** 1995 Oct;46(4):512-7

[The effect of adrenotropic agents on lipolysis in rat adipose tissue; the effect of nonselective alpha adrenomimetics and alpha adrenolytics under in vitro experimental conditions] Lincová D, et al. **Sb Lek** 1991;93(9-10):351-63 (Eng. Abstr.) **(Cze)**

[Effects of amosulalol hydrochloride on intraocular pressure and aqueous humor dynamics in the rabbit eye] Taniguchi T, et al. **Nippon Ganka Gakkai Zasshi** 1996 Apr; 100(4):279-83 (Eng. Abstr.) **(Jpn)**

[Effect of 1-alpha blockader on maximal oxygen consumption and physical endurance in hypertensive men] Tomten SE, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10; 116(1):37-40 (Eng. Abstr.) **(Nor)**

[The effect of the alpha-adrenoblocker tropafen on the microcirculation and the hematocrit index in the capillaries of rats with ischemia] Khugaeva VK, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):113-21 (Eng. Abstr.) **(Rus)**

POISONING

Poisoning with anti-hypertensive drugs: alpha-adrenoceptor antagonists. Lip GY, et al. **J Hum Hypertens** 1995 Jul; 9(7):523-6 (21 ref.)

THERAPEUTIC USE

Alpha blockers: a reassessment of their role in therapy. Cauffield JS, et al. **Am Fam Physician** 1996 Jul;54(1):263-6, 269-70 (22 ref.)

Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure. Kukin ML, et al. **Am J Cardiol** 1996 Mar 1;77(7):486-91

Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trail comparing doxazosin and hydrochlorothiazide. Grimm RH Jr, et al. **Am J Hypertens** 1996 May;9(5):445-54

Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. Hernández Hernández R, et al. **Am J Hypertens** 1996 May;9(5):437-44

Pre-operative management for surgery of pheochromocytoma. Májek M, et al. **Ann Urol (Paris)** 1996; 30(1):20-4

Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Pisarik P. **Arch Fam Med** 1996 Jul-Aug;5(7):413-6 (17 ref.)

Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study. Cappiello A, et al. **Biol Psychiatry** 1995 Dec 1;38(11):765-7

Doxazosin: a new approach to hypertension and benign prostatic hyperplasia. Pool JL. **Br J Clin Pract** 1996 Apr-May;50(3):154-63 (70 ref.)

Phentolamine abolishes the pain of chronic pancreatitis. McCleane GJ. **Br J Hosp Med** 1996 Apr 17-30;55(8):521

Long term effect of apraclonidine. Araujo SV, et al. **Br J Ophthalmol** 1995 Dec;79(12):1098-101

Intraocular pressure rise after phacoemulsification with posterior chamber lens implantation: effect of prophylactic medication, wound closure, and surgeon's experience. Bömer TG, et al. **Br J Ophthalmol** 1995 Sep;79(9):809-13

Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Abrams P, et al. **Br J Urol** 1995 Sep;76(3):325-36

Benign prostatic hyperplasia: pathophysiology and pharmacological treatment. Madsen FA, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):455-9 (23 ref.)

Acute effects of the alpha 2-adrenoreceptor antagonist idazoxan on hormonal responses and symptoms of hypoglycaemia in patients with type 1 diabetes mellitus. Moberg E, et al. **Diabetes Metab** 1996 Feb;22(1):31-6

Consensus meeting on new approaches in the pharmacotherapy of benign prostatic hyperplasia (BPH). Proceedings of the meeting held on the 8th and 9th October 1994 in St. Tropez, France, under the patronage of the International Academy of Biomedical and Drug Research. **Eur Urol** 1996;29(3):374-84 (52 ref.)

Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. Cavallini G. **Eur Urol** 1995;28(2):126-30

Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Chapple CR. **Eur Urol** 1996;29(2):129-44 (67 ref.)

Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Chapple CR, et al. **Eur Urol** 1996;29(2):155-67

Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. Kaplan SA, et al. **Eur Urol** 1995;28(3):223-8

Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Schulman CC, et al. **Eur Urol** 1996; 29(2):145-54

Differential effects of an alpha 1-blocker (doxazosin) on diurnal blood pressure variation in dipper and non-dipper type hypertension. Ebata H, et al. **Hypertens Res** 1995 Jun; 18(2):125-30

Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients. Ishimitsu T, et al. **Hypertens Res** 1996 Mar;19(1):43-9

Hypertension and CHD risk: whither alpha-1 blockers? Pandit RB. **Indian Heart J** 1996 May-Jun;48(3):265-71 (41 ref.)

Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (Part Two). Dutkiewicz S, et al. **Int Urol Nephrol** 1995;27(4):413-7

Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One). Dutkiewicz S, et al. **Int Urol Nephrol** 1995; 27(3):311-8

Medical treatment as an alternative to surgery in the management of benign prostatic hypertrophy [editorial] Bredin HC. **Ir Med J** 1996 May-Jun;89(3):86, 88

Correct treatment for accidental epinephrine auto-injector-induced digital ischemia [letter; comment] Brenner GM. **J Am Osteopath Assoc** 1995 Sep;95(9):510. Comment on: J Am Osteopath Assoc 1995 Jun;95(6):377-8.

Influence of alpha-adrenergic blockade on ventricular arrhythmias, QTc interval and heart rate variability in phaeochromocytoma. Dąbrowska B, et al. **J Hum Hypertens** 1995 Nov;9(11):925-9

Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. Brown MJ, et al. **J Hypertens** 1995 Jun; 13(6):701-7

Antihypertensive and metabolic effects of doxazosin in hypertensive patients with concomitant non-insulin-dependent diabetes mellitus. Inoue Y, et al. **J Int Med Res** 1996 Jan-Feb;24(1):138-46

Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms [letter; comment] Frankel G. **J Urol** 1996 Mar; 155(3):1039. Comment on: J Urol 1995 Jul;154(1):116-8.

Re: Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia [letter; comment] Hansen BJ. **J Urol** 1996 Jul;156(1):184-5. Comment on: J Urol 1995 Sep;154(3):923-34.

Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. Witjes WP, et al. **J Urol** 1996 Apr;155(4):1117-23

The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study. Yasuda K, et al. **J Urol** 1996 Sep;156(3):1125-30

Benign prostatic hyperplasia. Current strategy and pharmacotherapeutical potential. Dutkiewicz S. **Mater Med Pol** 1995 Jan-Mar;27(1):3-6 (41 ref.)

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group [see comments] Lepor H, et al. **N Engl J Med** 1996 Aug 22;335(8):533-9 . Comment in: N Engl J Med 1996 Aug 22;335(8):586-7.

Treatment of benign prostatic hyperplasia [editorial; comment] Walsh PC. **N Engl J Med** 1996 Aug 22; 335(8):586-7. Comment on: N Engl J Med 1996 Aug 22;335(8):533-9.

Alpha 1-adrenoceptors: pharmacological classification and newer therapeutic applications. Ruffolo RR Jr, et al. **Proc West Pharmacol Soc** 1995;38:121-6 (59 ref.)

The effects of a new alpha-2 adrenoceptor antagonist on sleep and nocturnal penile tumescence in normal male volunteers and men with erectile dysfunction. Bancroft J, et al. **Psychosom Med** 1995 Jul-Aug;57(4):345-56

1st Congress of the European Association for Clinical Pharmacology and Therapeutics, Paris, France, 27-30 September 1995, and Synthelabo Symposium Alpha 1-blockers in BPH Uroselectivity and Quality of Life. Abstracts. **Therapie** 1995;Suppl:S1-191

Reflux pancreatitis after simultaneous pancreas-kidney transplantation treated by alpha 1 blocker. Ciancio G, et al. **Transplantation** 1995 Oct 15;60(7):760-1

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Elhilali MM, et al. **Urology** 1996 Mar;47(3):335-42

Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia [see comments] Lowe FC, et al. **Urology** 1995 Oct;46(4):477-83. Comment in: Urology 1996 Jan;47(1):152.

Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Roehrborn CG, et al. **Urology** 1996 Sep;48(3):406-15

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Roehrborn CG, et al. **Urology** 1996 Feb;47(2):159-68

[Medical treatment of benign hypertrophy of the prostate] Bensadoun H. **Presse Med** 1995 Oct 28;24(32):1485-9 (16 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of erectile insufficiency] Bondil P. **Presse Med** 1995 Oct 28;24(32):1531-6 (Eng. Abstr.) **(Fre)**

ADRENERGIC ALPHA-ANTAGONISTS

[Treatment of stress urinary incontinence in women] Buzelin JM. **Presse Med** 1995 Oct 28;24(32):1499–500 (Eng. Abstr.) **(Fre)**

[Pharma-clinics. Drug of the month. Terazosine (Hytrin)] Scheen AJ. **Rev Med Liege** 1995 Dec;50(12):540–1 **(Fre)**

[Drug treatment of benign prostatic hyperplasia (editorial)] Schmid HP. **Schweiz Rundsch Med Prax** 1995 Sep 26; 84(39):1061–2 **(Ger)**

[Current drug therapy of benign prostatic hyperplasia] Schmidbauer CP, et al. **Wien Med Wochenschr** 1996; 146(8):161–4 (12 ref.) (Eng. Abstr.) **(Ger)**

[Balanced beta-–alpha-blocker treatment with carvedilol in mild-moderate arterial hypertension] Perocchio M, et al. **Minerva Cardioangiol** 1996 Mar;44(3):115–21 (Eng. Abstr.) **(Ita)**

[Pharmacologic treatment of mild proliferation of prostatic cancer (editorial)] Dutkiewicz S. **Pol Tyg Lek** 1996 Feb; 51(6–9):67–72 (Eng. Abstr.) **(Pol)**

[A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia] Pushkar' DIu, et al. **Urol Nefrol (Mosk)** 1995 Jul–Aug;(4):32–5 (Eng. Abstr.) **(Rus)**

[Controversies in the treatment of arterial hypertension: other drugs as the first step (calcium antagonists, ACE inhibitors and alpha-blockers)] Castro Beiras A, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:72–80 (31 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Effects of endophyte-infected tall fescue, environmental temperature and prazosin injection on the rat. Larson BT, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 May;114(1):39–44

ADRENERGIC ALPHA-RECEPTOR AGONISTS see **ADRENERGIC ALPHA-AGONISTS**

ADRENERGIC ALPHA RECEPTOR BLOCKADERS see **ADRENERGIC ALPHA-ANTAGONISTS**

ADRENERGIC ALPHA-RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA**

ADRENERGIC ALPHA-1 RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA-1**

ADRENERGIC ALPHA-2 RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA-2**

ADRENERGIC ANTAGONISTS

see related
SYMPATHOLYTICS

PHARMACOLOGY

Influence of adrenergic and cholinergic mediators on the equine jejunum in vitro. Malone ED, et al. **Am J Vet Res** 1996 Jun;57(6):884–90

Regional haemodynamic effects of antagonists of angiotensin II, endothelin and adrenoceptors in conscious, vasopressin-deficient, genetically hypertensive rats. Gardiner SM, et al. **Br J Pharmacol** 1996 May; 118(2):325–34

Extracellular ATP inhibits adrenergic agonist-induced hypertrophy of neonatal cardiac myocytes. Zheng JS, et al. **Circ Res** 1996 Apr;78(4):525–35

Influence of adrenoceptor agonists and antagonists on fluid secretion in small bowel obstruction. Nellgård P, et al. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1059–63

SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Hodeige D, et al. **Eur J Pharmacol** 1995 Jun 6; 279(1):25–32

Nitric oxide mediates the anti-adrenergic effect of adenosine on calcium current in isolated rabbit atrioventricular nodal cells. Martynyuk AE, et al. **Pflugers Arch** 1996 Jan; 431(3):452–7

[A comparative study of the pharmacologic effects of combined use of strophanthin with certain antiadrenergic substances] Sergeev PV, et al. **Biull Eksp Biol Med** 1995 May;119(5):502–5 **(Rus)**

[The action of adrenergic agonists and antagonists on kidney function and arterial pressure depending on the mineral component of the diet] Shtrygol' SIu, et al. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):31–3 (Eng. Abstr.) **(Rus)**

[The role of adrenergic mechanisms in the anticonvulsive action of the new preparation acetylaminoazaleptin] Tregubov AL. **Eksp Klin Farmakol** 1996 Jan–Feb; 59(1):19–20 (Eng. Abstr.) **(Rus)**

[Interaction of the serotoninergic and noradrenergic systems in the brain and its role in regulating animal behavior] Semenova TP, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):101–3 (Eng. Abstr.) **(Rus)**

ADRENERGIC BETA-AGONISTS

Recent trends in the use of inhaled beta 2-adrenergic agonists and inhaled corticosteroids in Saskatchewan. Habbick B, et al. **Can Med Assoc J** 1995 Nov 15;153(10):1437–43

alpha 1-Adrenoceptor stimulation inhibits the isoproterenol-induced effects on myocardial contractility and protein phosphorylation. Hartmann M, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):57–64

Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses. Pizzichini MM, et al. **Eur Respir J** 1996 Mar;9(3):449–55

Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. Ruffolo RR Jr, et al. **J Med Chem** 1995 Sep 15;38(19):3681–716 (317 ref.)

Beta 2 agonist/antagonist activity of salbutamol [letter; comment] Jonkers RE, et al. **Thorax** 1995 Nov; 50(11):1227–8. Comment on: Thorax 1995 Feb;50(2):134–8.

[Evaluation of the beta-adrenergic receptor agonists] Liang B, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Jun;18(3):133–5 (17 ref.) **(Chi)**

ADMINISTRATION & DOSAGE

Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Steffensen I, et al. **Allergy** 1995 Aug; 50(8):657–63

Treatment of proctalgia fugax with salbutamol inhalation. Eckardt VF, et al. **Am J Gastroenterol** 1996 Apr; 91(4):686–9

Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Colice GL. **Am J Med** 1996 Jan 29;100(1A):11S–18S

Asthma treatment in pregnancy: a randomized controlled study. Wendel PJ, et al. **Am J Obstet Gynecol** 1996 Jul; 175(1):150–4

Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Cockcroft DW, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1485–9

The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Inman MD, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):65–9

The direct and interactive effects of phosphodiesterase inhibition and beta-adrenergic stimulation on myocyte contractile function after hypothermic cardioplegic arrest. Dorman BH, et al. **Anesth Analg** 1995 Nov;81(5):925–31

Simulation of an epidural test dose with intravenous isoproterenol in awake and in halothane-anesthetized children. Kozek-Langenecker S, et al. **Anesthesiology** 1996 Aug;85(2):277–80

Efficacy of once daily extended-release theophylline in decreasing the use of inhaled beta 2-agonists in stable, mild-to-moderate asthma patients. Edwards TB, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):409–16

Comparison of volume output from two different continuous nebulizer systems. Reisner C, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):209–13

Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconstriction. Schaanning J, et al. **Ann Allergy Asthma Immunol** 1996 Jan;76(1):57–60

Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Gilbert EM, et al. **Chest** 1995 Dec;108(6):1524–32

Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Newhouse MT, et al. **Chest** 1996 Sep;110(3):595–603

A 1-year comparison of turbuhaler vs pressurized metered-dose inhaler in asthmatic patients. Pauwels RA, et al. **Chest** 1996 Jul;110(1):53–7

Inhalation of single vs multiple metered-dose bronchodilator actuations from reservoir devices. An in vitro study. Rau JL, et al. **Chest** 1996 Apr;109(4):969–74

Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults. Shrestha M, et al. **Chest** 1996 Jul;110(1):42–7

A week-long course of inhaled beta-agonist or anticholinergic agent may reduce dyspnea during exercise in COPD [letter] Teramoto S, et al. **Chest** 1996 Jun; 109(6):1666–7

Reduced dose salbutamol in comparison with standard dosage for symptom relief in asthma. Yates DH, et al. **Eur Respir J** 1995 Nov;8(11):1847–51

Comparison of Diskus inhaler, a new multidose powder inhaler, with Diskhaler inhaler for the delivery of salmeterol to asthmatic patients. Canadian Study Group. Boulet LP, et al. **J Asthma** 1995;32(6):429–36

Treatment of nocturnal asthma by addition of oral slow-release albuterol to standard treatment in stable asthma patients. Van Keimpema AR, et al. **J Asthma** 1996; 33(2):119–24

Long-acting inhaled beta agonists in the treatment of bronchial asthma [editorial; comment] Wellman JJ. **J Asthma** 1995;32(6):395–6. Comment on: J Asthma 1995;32(6):397–404.

Oral albuterol for acute cough. Hickner JM. **J Fam Pract** 1996 Feb;42(2):111–2

A randomized controlled trial of oral albuterol in acute cough. Littenberg B, et al. **J Fam Pract** 1996 Jan; 42(1):49–53

MDI with spacer vs nebulizer in pediatric asthma. Shaughnessy AF, et al. **J Fam Pract** 1996 Jan;42(1):29–30

Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. Tal A, et al. **J Pediatr** 1996 Apr;128(4):479–84

Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network [see comments] Drazen JM, et al. **N Engl J Med** 1996 Sep 19;335(12):841–7. Comment in: N Engl J Med 1996 Sep 19;335(12):886–8.

Inhaled beta 2-agonists in the treatment of asthma [editorial; comment] O'Byrne PM, et al. **N Engl J Med** 1996 Sep 19;335(12):886–8. Comment on: N Engl J Med 1996 Sep 19;335(12):841–7.

Prehospital management of asthmatic children [letter; comment] Perry RF, et al. **Pediatr Emerg Care** 1996 Feb; 12(1):71–2. Comment on: Pediatr Emerg Care 1995 Aug;11(4):217–9.

Effects of isoproterenol infusions on heart rate variability in patients with panic disorder. Yeragani VK, et al. **Psychiatry Res** 1995 Apr 28;56(3):289–93

[Modes of administration of beta agonists in asthma] Salmeron S, et al. **Rev Pneumol Clin** 1996;52(2):119–27 (76 ref.) (Eng. Abstr.) **(Fre)**

[Therapy of asthma using bronchodilator agents--special reference to adrenergic beta 2-receptor agonists] Kurosawa M, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10; 85(2):210–5 (5 ref.) **(Jpn)**

ADVERSE EFFECTS

B2 agonists and their safety in the treatment of asthma. Fireman P. **Allergy Proc** 1995 Sep–Oct;16(5):235–9 (22 ref.)

Re: "Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy: the Washington, DC, Dilated Cardiomyopathy Study" [letter] Lanes SF, et al. **Am J Epidemiol** 1996 Sep 1;144(5):528–9

Incidence of adverse cardiopulmonary effects with low-dose continuous terbutaline infusion. Perry KG Jr, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1273–7

Aerosolized beta 2-agonists do not induce bronchial hyperreactivity in healthy adults. Kelly HW, et al. **Ann Pharmacother** 1995 Sep;29(9):848–51

Factors associated with prolonged hospitalization of children with asthma [letter; comment] Needles CF. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1401. Comment on: Arch Pediatr Adolesc Med 1995 Mar;149(3):276–9.

Asthma mortality and beta-agonists [letter; comment] Skorodin MS. **Chest** 1995 Dec;108(6):1768. Comment on: Chest 1995 Apr;107(4):1116–24.

Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma. Fahy JV, et al. **Clin Chest Med** 1995 Dec;16(4):715–33 (145 ref.)

Asthma and the beta 2-agonist controversy: much ado about something. Lieberman JS, et al. **Del Med J** 1995 Dec; 67(12):624–8 (28 ref.)

Diuretic-related hypokalaemia: the role of diuretics, potassium supplements, glucocorticoids and beta 2-adrenoceptor agonists. Results from the comprehensive hospital drug monitoring programme, berne (CHDM). Widmer P, et al. **Eur J Clin Pharmacol** 1995;49(1-2):31–6

A case of life-threatening lactic acidosis after smoke inhalation – interference between beta-adrenergic agents and ethanol? Taboulet P, et al. **Intensive Care Med** 1995 Dec;21(12):1039–41

Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. Bhagat R, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):47–52

Asthma and the beta agonist debate. Crane J, et al. **Thorax** 1995 Sep;50 Suppl 1:S5–10 (37 ref.)

[Injury claim in the administration of clenbuterol-containing drugs (letter)] van der Weg CP. **Tijdschr Diergeneeskd** 1996 Jul 1;121(13):394–5 **(Dut)**

[Maculopapular exanthema caused by ritodrine, accompanied by transaminase increase (letter)] del Pozo Hernando LJ, et al. **Med Clin (Barc)** 1995 Sep 9;105(7):277–8 **(Spa)**

[Salmeterol-induced enuresis in children] **Lakartidningen** 1996 May 22;93(21):2083 **(Swe)**

[Fever and shivering during dobutamine infusions] **Lakartidningen** 1995 Oct 18;92(42):3919 **(Swe)**

[Depression caused by beta-blockers--an exception (letter)] Artén B. **Lakartidningen** 1996 Feb 28;93(9):760–1 **(Swe)**

ANALYSIS

Detection and confirmation of beta-agonists in bovine retina using LC/APCI-MS. Doerge DR, et al. **Anal Chem** 1996 Jun 1;68(11):1918–23

Chiral separation and detection of terbutaline and ephedrine by capillary electrophoresis coupled with ion spray mass spectrometry. Sheppard RL, et al. **Anal Chem** 1995 Jul 1; 67(13):2054–8

Methods for the determination of beta-agonists in biological matrices. A review. Boyd D, et al. **Analyst** 1996 Jan; 121(1):1R–10R (115 ref.)

Evaluation of ractopamine cross-reactivity in several commercially available beta-agonist enzyme immunoassay kits. Wicker AL, et al. **Analyst** 1995 Dec;120(12):2879–81

Determination of ractopamine hydrochloride in swine and turkey tissues by liquid chromatography with coulometric detection. Turberg MP, et al. **J AOAC Int** 1995 Nov–Dec; 78(6):1394–402

Polarographic determination of prenalterol hydrochloride through treatment with nitrous acid. Aly FA, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1127-31

Determination of salmeterol in metered-dose and dry-powder inhalers by reversed-phase high performance liquid chromatography. Nayak VG, et al. **J Pharm Biomed Anal** 1996 Feb;14(4):511-3

An improved method for clenbuterol screening using high resolution selected ion recording. Kingston R, et al. **Rapid Commun Mass Spectrom** 1995;9(14):1395-9

Detection of beta 2-agonists in milk replacer. Caloni F, et al. **Vet Res Commun** 1995;19(4):285-93

BLOOD

Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis. Demnati R, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):319-24

Effect of hypoxia and beta 2-agonists on the activity of the renin-angiotensin system in normal subjects. Millar EA, et al. **Clin Sci (Colch)** 1995 Sep;89(3):273-6

Determination of salbutamol enantiomers in human plasma and urine by chiral high-performance liquid chromatography. Boulton DW, et al. **J Chromatogr B Biomed Appl** 1995 Oct 6;672(1):103-9

Detection of clenbuterol (Ventipulmin) in the horse. Hagedorn HW, et al. **Zentralbl Veterinarmed A** 1995 May; 42(3):209-19

CHEMICAL SYNTHESIS

Synthesis and pharmacological investigations of 1,2,3,4-tetrahydroisoquinoline derivatives. Brzezinska E, et al. **Pharmazie** 1996 Jun;51(6):397-9

New perhydro-1,4-oxazine derivatives of arylethanolamine with beta 3-adrenoceptor agonist activity. Monge A, et al. **Pharmazie** 1995 Nov;50(11):768-9

CHEMISTRY

Factors behind the functional beta 2-adrenoceptor selectivity of terbutaline. Johansson LH. **Pharmacol Toxicol** 1995;77 Suppl 3:21-4

CONTRAINDICATIONS

Don't get stung with the adrenergic blockers (beta or alpha)! Watson A. **Aust Fam Physician** 1995 Oct;24(10):1879

DIAGNOSTIC USE

Dobutamine stress echocardiography [letter; comment] Bach DS. **Am Heart J** 1996 Jun;131(6):1232-3. Comment on: Am Heart J 1995 May;129(5):1047-50.

Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction. Elhendy A, et al. **Am Heart J** 1996 Jun;131(6):1088-96

Assessment of reversible dyssynergic segments after acute myocardial infarction: Dobutamine echocardiography versus thallium-201 single photon emission computed tomography. Le Feuvre C, et al. **Am Heart J** 1996 Apr; 131(4):668-75

Myocardial perfusion abnormalities during low-dose dobutamine after coronary reperfusion can be demonstrated with intravenous perfluorocarbon-exposed sonicated dextrose albumin ultrasound contrast. Porter TR, et al. **Am Heart J** 1996 Jun;131(6):1079-87

Effect of beta-blockade on dobutamine stress echocardiography. Weissman NJ, et al. **Am Heart J** 1996 Apr;131(4):698-703

Comparison of dobutamine transesophageal echocardiography and dobutamine magnetic resonance imaging for detection of residual myocardial viability. Baer FM, et al. **Am J Cardiol** 1996 Aug 15;78(4):415-9

Value of dobutamine stress echocardiography in determining the prognosis of patients with known or suspected coronary artery disease. Marcovitz PA, et al. **Am J Cardiol** 1996 Aug 15;78(4):404-8

Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test. Sheldon R, et al. **Am J Cardiol** 1996 Sep 1;78(5):536-9

Head-up tilt testing: do we need to give an added push? [letter; comment] Barron H, et al. **Am J Med** 1995 Dec; 99(6):689-90. Comment on: Am J Med 1994 Jul;97(1):78-88.

Sustained nonischemic ventricular tachycardia during dobutamine stress echocardiography. Madu EC, et al. **Cardiology** 1996 Jan-Feb;87(1):82-5

Factors influencing regional myocardial contractile response to inotropic stimulation. Analysis in humans with stable ischemic heart disease. Skopicki HA, et al. **Circulation** 1996 Aug 15;94(4):643-50

Left ventricular outflow tract obstruction as a cause for hypotension and symptoms during dobutamine stress echocardiography. Sorrentino MJ, et al. **Clin Cardiol** 1996 Mar;19(3):225-30

Dobutamine stress echocardiography: a new, noninvasive method for detecting ischemic heart disease. Thompson EJ, et al. **Heart Lung** 1996 Mar-Apr;25(2):87-97

Dobutamine stress echocardiography in orthotopic heart transplant recipients [letter; comment] Akosah KO, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):953-4. Comment on: J Am Coll Cardiol 1995 Jun;25(7):1665-72.

Stress echocardiography in elderly patients with coronary artery disease: applicability, safety and prognostic value of dobutamine and adenosine echocardiography in elderly patients. Anthopoulos LP, et al. **J Am Coll Cardiol** 1996 Jul;28(1):52-9

Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization. Baer FM, et al. **J Am Coll Cardiol** 1996 Jul;28(1):60-9

Meta-analysis of intravenous dipyridamole-thallium-201 imaging (1985 to 1994) and dobutamine echocardiography (1991 to 1994) for risk stratification before vascular surgery [see comments] Shaw LJ, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):787-98. Comment in: J Am Coll Cardiol 1996 Mar 15;27(4):799-802.

Safety and feasibility of dobutamine-atropine stress echocardiography in patients with ischemic left ventricular dysfunction. Cornel JH, et al. **J Am Soc Echocardiogr** 1996 Jan-Feb;9(1):27-32

Normal changes in left ventricular filling and hemodynamics during dobutamine stress echocardiography. Tanimoto M, et al. **J Am Soc Echocardiogr** 1995 Jul-Aug;8(4):488-93

[Tilt-table study in vasovagal syncope. The diagnostic gain from isoprenaline administration] Bräuninger S, et al. **Dtsch Med Wochenschr** 1996 Aug 2;121(31-32):971-7 (Eng. Abstr.) **(Ger)**

[Responder and non-responder in the bronchodilator test?] Vollmer M, et al. **Pneumologie** 1995 Nov;49(11):584-9 (Eng. Abstr.) **(Ger)**

[Echocardiography with pharmacological stress: dobutamine or dipyridamole?] Salustri A, et al. **G Ital Cardiol** 1996 Apr;26(4):447-53 (45 ref.) **(Ita)**

[Dobutamine stress echocardiography in the diagnosis of myocardial ischemia in patients with implanted pacemakers: report of two cases] Yamamoto T, et al. **J Cardiol** 1995 Dec;26(6):367-72 (Eng. Abstr.) **(Jpn)**

[Echocardiography and MIBI-SPECT scintigraphy during dobutamine infusion in the diagnosis of coronary disease] San Román JA, et al. **Rev Esp Cardiol** 1995 Sep; 48(9):606-14 (Eng. Abstr.) **(Spa)**

ECONOMICS

Drug utilization evaluation identifies costs associated with high use of beta-adrenergic agonists. Stempel DA, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):153-8

Cost comparison of beta 2-agonist bronchodilators used in the treatment of asthma. Nightingale CH. **Pharmacotherapy** 1995 Sep-Oct;15(5):677-81

A cost comparison of beta 2-agonist bronchodilators is not a cost-effectiveness comparison. Rickard K, et al. **Pharmacotherapy** 1996 May-Jun;16(3):484-5; discussion 486-7

HISTORY

Astute observers discover anti-asthma drugs. Persson CG. **Pharmacol Toxicol** 1995;77 Suppl 3:7-15

The research behind terbutaline. Persson H. **Pharmacol Toxicol** 1995;77 Suppl 3:16-20

beta-Adrenoceptor agonists after terbutaline. Waldeck B. **Pharmacol Toxicol** 1995;77 Suppl 3:25-9

ISOLATION & PURIFICATION

Optimization of the separation of beta-agonists by capillary electrophoresis on untreated and C18 bonded silica capillaries. Chevolleau S, et al. **J Chromatogr A** 1995 Nov 3;715(2):345-54

Development of a rapid screening test to detect beta-agonist residues in bovine eye and hair. Elliott CT, et al. **Vet Rec** 1995 Dec 16;137(25):643-4

METABOLISM

Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women. Walle T, et al. **Br J Clin Pharmacol** 1996 Apr; 41(4):305-9

Identification of ractopamine hydrochloride metabolites excreted in rat bile. Smith DJ, et al. **Xenobiotica** 1995 May; 25(5):511-20

[Role of hormonal receptor abnormalities in the physiopathology of adrenocortical tumors] Lacroix A. **Ann Endocrinol (Paris)** 1995;56(6):614-6 (21 ref.) **(Fre)**

PHARMACOKINETICS

Pharmacodynamic modelling of the drug-induced downregulation of a beta 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone. Jonkers RE, et al. **Eur J Clin Pharmacol** 1995;49(1-2):37-44

Accumulation of the beta-agonist clenbuterol by pigmented tissues in rat eye and hair of veal calves. Dürsch I, et al. **J Anim Sci** 1995 Jul;73(7):2050-3

Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men. Salazar DE, et al. **J Clin Pharmacol** 1995 Nov; 35(11):1109-18

Relaxation kinetics of formoterol and salmeterol in the guinea pig trachea in vitro. Anderson P, et al. **Lung** 1996; 174(3):159-70

Terbutaline prodrugs and oral beta 2-agonist therapy. Svensson LA. **Pharmacol Toxicol** 1995;77 Suppl 3:30-3

Pharmacokinetics and pharmacodynamics of beta 2-agonists (in the light of fenoterol). Schmidt EW, et al. **Respiration** 1995;62(4):190-200

Residues of clenbuterol in cattle receiving therapeutic doses: implications for differentiating between legal and illegal use. Elliot CT, et al. **Vet Q** 1995 Sep;17(3):100-2

PHARMACOLOGY

Effect of dopexamine on calculated low gastric intramucosal pH following valve replacement. Gårdebäck M, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):599-604

Dopexamine and dopamine in the prevention of low gastric mucosal pH following cardiopulmonary by-pass. Gårdebäck M, et al. **Acta Anaesthesiol Scand** 1995 Nov; 39(8):1066-70

Differential effects of dobutamine, dopamine, and noradrenaline on splanchnic haemodynamics and oxygenation in the pig. Priebe HJ, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1088-96

Possible roles of nitric oxide and vasoactive intestinal polypeptide on relaxation induced by isoprenaline in isolated muscle strips of the mouse gastric fundus. Ogülener N, et al. **Acta Med Okayama** 1995 Oct;49(5):231-6

Subsensitivity to the bronchodilator action of beta 2-adrenergic agonists [letter; comment] Nelson HS. **Am J Med** 1995 Oct;99(4):449-50. Comment on: Am J Med 1994 Jul;97(1):29-37.

K+ balance during exercise and role of beta-adrenergic stimulation. Hallén J, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1347-54

Induction of hypertrophic responsiveness to isoproterenol by TGF-beta in adult rat cardiomyocytes. Schlüter KD, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1311-6

Human lung cell beta 2-adrenergic receptors desensitize in response to in vivo administered beta-agonist. Turki J, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):L709-14

Functional desensitization of beta agonist responses in human lung mast cells. Chong LK, et al. **Am J Respir Cell Mol Biol** 1995 Nov;13(5):540-6

Tracheal microvascular responses to beta-adrenergic stimulation in anesthetized rats. Corboz MR, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1093-7

Beta 2-agonist treatment reduces beta 2-sensitivity in alveolar macrophages despite corticosteroid treatment. Hjemdahl P, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):576-81

Salbutamol reduces pulmonary neutrophil sequestration of platelet-activating factor in humans. Masclans JR, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):529-32

Functional and binding characteristics of long-acting beta 2-agonists in lung and heart. Roux FJ, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1489-95

Effect of chronic antigen and beta 2 agonist exposure on airway remodeling in guinea pigs. Wang ZL, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2097-104

Down-regulation of beta-adrenergic receptors and up-regulation of estrogen and progesterone receptors induced in the reproductive system of female veal calves by dietary clenbuterol. Re G, et al. **Am J Vet Res** 1995 Nov;56(11):1493-7

Real-time monitoring of reduced beta-adrenergic response in fibroblasts from patients with pseudohypoparathyroidism. Ong OC, et al. **Anal Biochem** 1996 Jun 15;238(1):76-81

Hemodynamic effects of intravenous isoproterenol versus epinephrine in the chronic maternal-fetal sheep preparation. Marcus MA, et al. **Anesth Analg** 1996 May; 82(5):1023-6

The effects of dobutamine and phenylephrine on atrioventricular conduction during combined use of halothane and thoracic epidural lidocaine. Nishikawa K, et al. **Anesth Analg** 1996 Mar;82(3):551-7

Effects of the beta-adrenergic agonist salbutamol and its withdrawal on protein metabolism of lambs. del Barrio AS, et al. **Ann Nutr Metab** 1995;39(5):317-24

Long-and short-acting beta 2-adrenergic agonists. Effects on airway function in patients with asthma. Busse WW. **Arch Intern Med** 1996 Jul 22;156(14):1514-20 (63 ref.)

Adrenergic ligands trigger intracellular differentiation of trypanosoma cruzi. Zavala-Castro JE, et al. **Arch Med Res** 1995 Winter;26(4):449-50

Mononuclear cells in salivary glands of normal and isoproterenol-treated rats. Cohen RE, et al. **Arch Oral Biol** 1995 Nov;40(11):1015-21

Quantitative protein and fat metabolism in bull calves treated with beta-adrenergic agonist. Chwalibog A, et al. **Arch Tierernahr** 1996;49(2):159-67

Effect of duration of a beta-agonist treatment on growth, feed intake and carcass characteristics in finishing bulls. Fiems LO, et al. **Arch Tierernahr** 1993;45(2):101-9

Decreased levels of adenylate cyclase contribute to the down-regulation of beta-adrenergic signal transduction in the salivary glands of the non-obese diabetic (NOD) mouse. Hu Y, et al. **Autoimmunity** 1995;21(2):137-42

Epinephrine dose-response of the isolated working heart in O2-exposed rats. Arieli R, et al. **Aviat Space Environ Med** 1995 Nov;66(11):1071-8

Effects of chemical denervation with 6-hydroxydopamine on myocardial responsiveness to isoproterenol in rabbits. Tse J, et al. **Basic Res Cardiol** 1995 Sep-Oct;90(5):380-7

Decreased beta-adrenergic stimulation of glycoprotein

secretion in CF mice submandibular glands: reversal by the methylxanthine, IBMX. Mills CL, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):674–81

In vivo isoproterenol treatment leads to downregulation of the mRNA encoding the cAMP response element binding protein in the rat heart. Müller FU, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1043–9

PP2C phosphatase activity is coupled to cAMP-mediated pathway in rat parotid acinar cells. Yokoyama N, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):845–53

Isoprenaline induction of cAMP–phosphodiesterase in guinea–pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram. Kochetkova M, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2033–8

Simultaneous measurement of Ca2+ transients and changes in the cell volume and microviscosity of the plasma membrane in smooth muscle cells. Evaluation of the effect of formoterol. Ochsner M. **Biochem Pharmacol** 1996 Jul 12;52(1):49–63

Secretagogue–induced proteolysis of cAMP–dependent protein kinase in intact rat alveolar epithelial type II cells. Zimmerman UJ, et al. **Biochim Biophys Acta** 1996 Apr 24; 1311(2):117–23

Two groups of diabetic KK–CAy mice specifically bred for high and low sensitivity to exogenous acetylcholine and beta 1–adrenergic stimulation: interaction of higenamine and aconitine on pulse rate. Kimura I, et al. **Biol Pharm Bull** 1995 Oct;18(10):1356–61

Diminished responsiveness to cardiac beta 1–adrenoceptor agonists in rats with chronic heart failure following myocardial infarction. Sanbe A, et al. **Biol Pharm Bull** 1995 Oct;18(10):1362–6

Differential effects of selective beta 1–agonist stimulation on epi– and endocardial oxygen tension in anesthetized dogs. Tagami H, et al. **Biol Pharm Bull** 1995 Jul;18(7):951–6

Membrane–mediated effects of catecholamines on the DNA of human leukocytes: the role of reactive oxygen species. Crespo ME, et al. **Biol Signals** 1995 Mar–Apr;4(2):78–85

Antibronchospasmic, tachycardiac, and hypokalaemic effects of L–isoproterenol in guinea–pigs. Ohtani H, et al. **Biopharm Drug Dispos** 1995 Dec;16(9):745–53

Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers. Kiely DG, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):313–8

Effect of isoproterenol, phenylephrine, and sodium nitroprusside on fundus pulsations in healthy volunteers. Schmetterer L, et al. **Br J Ophthalmol** 1996 Mar; 80(3):217–23

Anti–inflammatory, membrane–stabilizing interactions of salmeterol with human neutrophils in vitro. Anderson R, et al. **Br J Pharmacol** 1996 Apr;117(7):1387–94

Paradoxical facilitation of acetylcholine release from parasy.npathetic nerves innervating guinea–pig trachea by isoprenaline. Belvisi MG, et al. **Br J Pharmacol** 1996 Apr; 117(7):1413–20

Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle. Ellis KE, et al. **Br J Pharmacol** 1995 Nov; 116(5):2510–6

The lack of a role for potassium channel opening in the action of relaxin in the rat isolated uterus; a comparison with levcromakalim and salbutamol. Hughes SJ, et al. **Br J Pharmacol** 1996 Apr;117(7):1435–42

Relaxant actions of isoprenaline on guinea–pig isolated tracheal smooth muscle. Ito Y, et al. **Br J Pharmacol** 1995 Nov;116(6):2738–42

The effects of formoterol on plasma exudation produced by a localized acute inflammatory response to bradykinin in the tracheal mucosa of rats in vivo. O'Donnell SR, et al. **Br J Pharmacol** 1995 Sep;116(1):1571–6

The involvement of ATP–sensitive potassium channels in beta–adrenoceptor–mediated vasorelaxation in the rat isolated mesenteric arterial bed. Randall MD, et al. **Br J Pharmacol** 1995 Jun;115(4):607–12

Postjunctional alpha 1– and beta–adrenoceptor effects of noradrenaline on electrical slow waves and phasic contractions of cat colon circular muscle. Venkova K, et al. **Br J Pharmacol** 1995 Dec;116(8):3265–73

Adenylyl cyclase activation underlies intracellular cyclic AMP accumulation, cyclic AMP transport, and extracellular adenosine accumulation evoked by beta–adrenergic receptor stimulation in mixed cultures of neurons and astrocytes derived from rat cerebral cortex. Rosenberg PA, et al. **Brain Res** 1995 Sep 18; 692(1–2):227–32

Interstitial adenosine and cellular metabolism during beta–adrenergic stimulation of the in situ rabbit heart. Headrick JP, et al. **Cardiovasc Res** 1996 May;31(5):699–710

Short–term effects of secretagogues on the mouse parotid and sublingual gland tissular water. Materazzi S, et al. **Cell Mol Biol (Noisy–le–grand)** 1996 Mar;42(2):179–88

Partial vs full beta–receptor agonism. A clinical study of inhaled albuterol and fenoterol. Bremner P, et al. **Chest** 1996 Apr;109(4):957–62

Metaproterenol responsiveness after methacholine– and histamine–induced bronchoconstriction. Elsasser S, et al. **Chest** 1996 Sep;110(3):617–23

Dopexamine hydrochloride in septic shock. Hannemann L, et al. **Chest** 1996 Mar;109(3):756–60

Relative efficacy and potency of beta–adrenoceptor agonists for generating cAMP in human lymphocytes. MacGregor DA, et al. **Chest** 1996 Jan;109(1):194–200

Short–term effects of inhaled beta–adrenergic agonist on breathlessness and central inspiratory drive in patients with nonreversible COPD. Pino–García JM, et al. **Chest** 1996 Sep;110(3):637–41

Interaction of phosphodiesterase inhibitor and isoproterenol in human and guinea–pig ventricular tissues and myocytes. Cheng PY, et al. **Chin J Physiol** 1995;38(3):185–91

beta–Adrenoceptor activates endothelium–dependent release of nitric oxide in rat aorta. Zheng XF, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):385–90

Developmental changes in beta–adrenergic modulation of L–type Ca2+ channels in embryonic mouse heart. An RH, et al. **Circ Res** 1996 Mar;78(3):371–8

The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Chandler WL, et al. **Circulation** 1995 Nov 15;92(10):2984–94

Nitric oxide inhibits the positive inotropic response to beta–adrenergic stimulation in humans with left ventricular dysfunction. Hare JM, et al. **Circulation** 1995 Oct 15; 92(8):2198–203

Long–term treatment with angiotensin I–converting enzyme inhibitors attenuates the loss of cardiac beta–adrenoceptor responses in rats with chronic heart failure. Sanbe A, et al. **Circulation** 1995 Nov 1;92(9):2666–75

Cardiovascular effects of dobutamine stress testing in healthy women. Blomstrand P, et al. **Clin Cardiol** 1995 Nov; 18(11):659–63

Comparison of the attenuating effects of four beta–adrenoceptor agonists on rat isolated uterus and aorta. Doggrell SA. **Clin Exp Pharmacol Physiol** 1995 Sep; 22(9):670–4

Decreased sensitivity to beta–adrenergic stimulation of the ventricular cells isolated from the spontaneously hypertensive rat heart. Habuchi Y, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S105–6

Impaired beta 2–adrenergic agonist–induced venodilation in Indians of Asian origin. Kapoor C, et al. **Clin Pharmacol Ther** 1996 May;59(5):569–76

The effects of the menstrual cycle, race, and gender on adrenergic receptors and agonists. Mills PJ, et al. **Clin Pharmacol Ther** 1996 Jul;60(1):99–104

Effect of the beta 2–adrenergic agonist clenbuterol on the growth of fast– and slow–twitch skeletal muscle of the dystrophic (C57BL6J dy2J/dy2J) mouse. Agbenyega ET, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jul;111(3):397–403

Stimulation of nonshivering thermogenesis in the Syrian hamster by norepinephrine and beta–selective adrenergic agents: a phenomenon of refractoriness. Dicker A, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jan;113(1):37–43

Dopexamine maintains intestinal villus blood flow during endotoxemia in rats. Schmidt H, et al. **Crit Care Med** 1996 Jul;24(7):1233–7

Effects of timolol, terbutaline and forskolin on IOP, aqueous humour formation and ciliary cyclic AMP levels in the bovine eye. Shahidullah M, et al. **Curr Eye Res** 1995 Jul; 14(7):519–28

Effect of carbachol on phospholipase C–mediated phosphatidylinositol 4,5–bisphosphate hydrolysis, and its modulation by isoproterenol in rabbit corneal epithelial cells. Zhang Y, et al. **Curr Eye Res** 1995 Jul;14(7):563–71

Does dobutamine prevent the rise in left ventricular filling pressures observed during exercise after heart transplantation? Vantrimpont PJ, et al. **Eur Heart J** 1995 Sep;16(9):1300–6

Isoproterenol inhibits insulin–stimulated tyrosine phosphorylation of the insulin receptor without increasing its serine/threonine phosphorylation. Issad T, et al. **Eur J Biochem** 1995 Nov 15;234(1):108–15

Influence of age on venodilator effect of isoproterenol and amrinone. Harada K, et al. **Eur J Clin Pharmacol** 1996; 50(1–2):37–40

Pharmacological effects of concomitant administration of beta–adrenoceptor blocker and agonist in normal subjects: characterization by heart rate response to exercise. Effects of beta–blocker combined with beta–agonist. Karita M, et al. **Eur J Clin Pharmacol** 1995;48(6):467–71

A specific beta 3–adrenoceptor agonist induces increased pancreatic islet blood flow and insulin secretion in rats. Atef N, et al. **Eur J Pharmacol** 1996 Mar 18;298(3):287–92

Effects of ageing and adrenergic stimulation on alpha 1– and beta–adrenoceptors and phospholipid fatty acids in rat heart. Benediktsdóttir VE, et al. **Eur J Pharmacol** 1995 May 26;289(3):419–27

Salbutamol–induced airway hyperreactivity in guinea pigs is not due to a loss of its bronchodilator effect. Buchheit KH, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):85–8

Antagonism of beta–adrenergic stimulation of L–type Ca2+ current by endothelin in guinea–pig atrial cells. Delpech N, et al. **Eur J Pharmacol** 1995 Oct 16;285(2):217–20

Different effects of isoproterenol and dihydroouabain on cardiac Ca2+ transients. Hotta Y, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):121–30

The effects of formoterol, a long–acting beta 2–adrenoceptor agonist, on mucociliary activity. Lindberg S, et al. **Eur J Pharmacol** 1995 Oct 24;285(3):275–80

Diazepam potentiates the positive inotropic effect of isoprenaline in rat ventricle strips: role of cyclic AMP. Martinez E, et al. **Eur J Pharmacol** 1995 Aug 25; 282(1–3):169–75

The acid metabolite of ZD7114 is a partial agonist of lipolysis mediated by the rat beta 3–adrenoceptor. Mayers RM, et al. **Eur J Pharmacol** 1996 Jan 11;295(2–3):199–205

Carazolol: a potent, selective beta 3–adrenoceptor agonist. Méjean A, et al. **Eur J Pharmacol** 1995 Nov 30; 291(3):359–66

Role of cyclic AMP in the modulation of IgE production by the beta 2–adrenoceptor agonist, fenoterol. Coqueret O, et al. **Eur Respir J** 1996 Feb;9(2):220–5

Beta 3–adrenoceptors and intestinal motility. Manara L, et al. **Fundam Clin Pharmacol** 1995;9(4):332–42 (70 ref.)

Effects on metabolic rate and fuel selection of a selective beta–3 agonist (ICI D7114) in healthy lean men. Goldberg GR, et al. **Int J Obes Relat Metab Disord** 1995 Sep; 19(9):625–31

Effects of several putative beta 3–adrenoceptor agonists on lipolysis in human omental adipocytes. Hoffstedt J, et al. **Int J Obes Relat Metab Disord** 1996 May;20(5):428–34

Beta–adrenergic stimulation of Na+, K+, Cl– cotransport in fetal nonpigmented ciliary epithelial cells. Crook RB, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1047–57

Effect of ractopamine on growth performance, carcass composition, and cutting yields of pigs slaughtered at 107 and 125 kilograms. Crome PK, et al. **J Anim Sci** 1996 Apr; 74(4):709–16

Effects of a beta–adrenergic agonist (L–644,969) and male sex condition on muscle growth and meat quality of callipyge lambs. Koohmaraie M, et al. **J Anim Sci** 1996 Jan;74(1):70–9

The effects of in utero exposure of lambs to a beta–adrenergic agonist on prenatal and postnatal muscle growth, carcass cutability, and meat tenderness. Shackelford SD, et al. **J Anim Sci** 1995 Oct;73(10):2986–93

Suppression of immune response in lambs during treatment with the beta–adrenergic agonist clenbuterol. Spencer GS, et al. **J Anim Sci** 1996 Jan;74(1):151–3

The role of insulin–like growth factor I in clenbuterol–stimulated growth in growing lambs. Young OA, et al. **J Anim Sci** 1995 Oct;73(10):3069–77

Effects of dietary protein percentage and beta–agonist administered to prepubertal ewes on mammary gland growth and hormone secretions. Zhang J, et al. **J Anim Sci** 1995 Sep;73(9):2655–61

A beta 2–agonist, procaterol, inhibits basophil migration. Yamaguchi M, et al. **J Asthma** 1995;32(2):125–30

Effects of chronic infusion of (–)–isoprenaline on rat cardiac muscarinic (M2)–cholinoceptors and beta 1– and beta 2–adrenoceptors. Sarsero D, et al. **J Auton Pharmacol** 1995 Aug;15(4):239–55

Calcineurin feedback inhibition of agonist–evoked cAMP formation. Antoni FA, et al. **J Biol Chem** 1995 Nov 24; 270(47):28055–61

Effect of different G protein–coupled receptor kinases on phosphorylation and desensitization of the alpha1B–adrenergic receptor. Diviani D, et al. **J Biol Chem** 1996 Mar 1;271(9):5049–58

Role of phosphorylation in agonist–promoted beta 2–adrenergic receptor sequestration. Rescue of a sequestration–defective mutant receptor by beta ARK1. Ferguson SS, et al. **J Biol Chem** 1995 Oct 20; 270(42):24782–9

Protein kinase C deficiency blocks recovery from agonist–induced desensitization. Shih M, et al. **J Biol Chem** 1996 Aug 30;271(35):21478–83

Role of nitric oxide in systemic hemodynamic responses to dobutamine, epinephrine, and amrinone. Hemida MR, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):627–33

Vascular smooth muscle relaxation by alpha–adrenoceptor blocking action of dobutamine in isolated rabbit aorta. Aikawa J, et al. **J Cardiovasc Pharmacol** 1996 Jan; 27(1):33–6

Beta 3–adrenergic activation of adenylyl cyclase in mouse white adipocytes: modulation by GTP and effect of obesity. Bégin–Heick N. **J Cell Biochem** 1995 Aug;58(4):464–73

Effect of neuromimetics upon the release of atrial natriuretic peptide granules: are multiple pathways involved in secretion? Newman TM, et al. **J Cell Physiol** 1996 Jul; 168(1):134–40

Functional beta3–adrenoceptor in the human heart [see comments] Gauthier C, et al. **J Clin Invest** 1996 Jul 15; 98(2):556–62. Comment in: J Clin Invest 1996 Jul 15;98(2):241.

beta–Adrenergic modulation of the inwardly rectifying potassium channel in isolated human ventricular myocytes. Alteration in channel response to beta–adrenergic stimulation in failing human hearts. Koumi S, et al. **J Clin Invest** 1995 Dec;96(6):2870–81

Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic beta 3–adrenergic agonist. Nagase I, et al. **J Clin Invest** 1996 Jun 15;97(12):2898–904

Duodenal infusion of oil in midlactation cows. 7. Interaction with niacin on responses to glucose, insulin, and beta–agonist challenges. Chilliard Y, et al. **J Dairy Sci** 1995 Nov;78(11):2452–63

Effect of two beta 2–agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis. Giustina A, et al. **J Endocrinol Invest** 1995 Dec;18(11):847–52

Loss of maximum attenuation and receptor reserve for

isoprenaline at the beta 2-adrenoceptors of the portal veins of hypertensive rats. Doggrell SA, et al. **J Hypertens** 1995 Sep;13(9):1023-9

Alterations in ovine myometrial beta-adrenergic cascade do not mediate tachyphylaxis to ritodrine. Daftary A, et al. **J Matern Fetal Med** 1996 May-Jun;5(3):155-60

Regulation of cell volume by beta2-adrenergic stimulation in rat fetal distal lung epithelial cells. Nakahari T, et al. **J Membr Biol** 1996 May;151(1):91-100

Endogenous adenosine reduces depression of cardiac function induced by beta-adrenergic stimulation during low flow perfusion. Fenton RA, et al. **J Mol Cell Cardiol** 1995 Oct; 27(10):2373-83

Decreased contractile responses to isoproterenol in isolated cardiac myocytes from aging guinea-pigs. Ferrara N, et al. **J Mol Cell Cardiol** 1995 May;27(5):1141-50

Decreased inotropic response to beta-adrenergic stimulation and normal sarcoplasmic reticulum calcium stores in the spontaneously hypertensive rat heart. Moravec CS, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2101-9

Interaction of beta-adrenoceptor and adenosine receptor agonists on phosphorylation. Identification of target proteins in mammalian ventricles. Neumann J, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1655-67

Adaptation to chronic hypoxia alters cardiac metabolic response to beta stimulation: novel face of phosphocreatine overshoot phenomenon. Novel-Chaté V, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1679-87

Adrenergic desensitization in left ventricle from streptozotocin diabetic swine. Roth DA, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2315-25

Acidosis masks beta-adrenergic control of cardiac L-type calcium current. Rozanski GJ, et al. **J Mol Cell Cardiol** 1995 Sep;27(9):1781-8

Alterations in sarcoplasmic reticulum calcium uptake, relaxation parameters and their responses to beta-adrenergic agonists in the developing rabbit heart. Szymanska G, et al. **J Mol Cell Cardiol** 1995 Sep; 27(9):1819-29

Rat frontal cortex beta 1-adrenoceptors are activated by the beta 3-adrenoceptor agonists SR 58611A and SR 58878A but not by BRL 37344 or ICI 215,001. Nisoli E, et al. **J Neurochem** 1995 Oct;65(4):1580-7

Regulation of macrophage-derived tumor necrosis factor production by modification of adrenergic receptor sensitivity. Ignatowski TA, et al. **J Neuroimmunol** 1995 Aug;61(1):61-70

Isoproterenol potentiates synaptic transmission primarily by enhancing presynaptic calcium influx via P- and/or Q-type calcium channels in the rat amygdala. Huang CC, et al. **J Neurosci** 1996 Feb 1;16(3):1026-33

Norepinephrine but not epinephrine stimulates the release of corticotropin-releasing factor from in vitro superfused rat hypothalamus. Orliaguet G, et al. **J Neurosci Res** 1995 Oct 1;42(2):236-41

The selectivity in vitro of the stereoisomers of the beta-3 adrenoceptor agonist BRL 37344. Oriowo MA, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):22-7

Slowing of shortening velocity of rat cardiac myocytes by adenosine receptor stimulation regardless of beta-adrenergic stimulation. Strang KT, et al. **J Physiol (Lond)** 1995 Aug 1;486 (Pt 3):679-88

Effects of clenbuterol on rabbit vesicourethral muscle contractility. Morita T, et al. **J Smooth Muscle Res** 1995 Aug;31(4):119-27

Desensitization and selective down-regulation of rat cardiac beta 1-adrenoceptors by prolonged in vivo infusion of T-0509, a beta 1-adrenoceptor full agonist. Sato Y, et al. **Jpn J Pharmacol** 1995 Dec;69(4):343-50

Beta-adrenoceptor agonists do not stimulate daytime melatonin secretion in healthy subjects. A double blind placebo controlled study. Berlin I, et al. **Life Sci** 1995 Mar 17;56(17):PL325-31

Different atypical beta-adrenoceptors mediate isoprenaline-induced relaxation in vascular and non-vascular smooth muscles. Oriowo MA. **Life Sci** 1995 Mar 3;56(15):PL269-75

Desensitization effect of in vivo treatment with metaproterenol on beta1, beta2 and beta3-adrenergic responsiveness in rat adipocytes. Portillo MP, et al. **Life Sci** 1996;58(5):405-14

Adenosine attenuation of isoproterenol-stimulated adenylyl cyclase activity is enhanced with aging in the adult heart. Romano FD, et al. **Life Sci** 1996;58(6):493-502

Relaxation kinetics of formoterol and salmeterol in the guinea pig trachea in vitro. Anderson P, et al. **Lung** 1996; 174(3):159-70

Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lindén A, et al. **Lung** 1996;174(1):1-22 (52 ref.)

Age-dependent changes in response of rat prostatic tissues to isoproterenol and forskolin: changes with sexual maturation in function of G proteins. Chen C, et al. **Mech Ageing Dev** 1995 Jun 30;81(1):1-13

The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Caruso JF, et al. **Med Sci Sports Exerc** 1995 Nov;27(11):1471-6

Effects of oral albuterol on serum lipids and carbohydrate metabolism in healthy men. Maki KC, et al. **Metabolism** 1996 Jun;45(6):712-7

Effect of CL316,243, a highly specific beta3-adrenoceptor agonist, on sympathetic nervous system activity in mice. Yoshida T, et al. **Metabolism** 1996 Jun;45(6):787-91

Enhanced ornithine decarboxylase activity of chick muscle cells in culture by beta-adrenergic agonists. Juráni M, et al. **Methods Find Exp Clin Pharmacol** 1996 Jan-Feb; 18(1):13-7

Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. Clark RB, et al. **Mol Pharmacol** 1996 Jan;49(1):182-9

Comparison of duration of agonist action at beta 1- and beta 2- adrenoceptors in C6 glioma cells: evidence that the long duration of action of salmeterol is specific to the beta 2-adrenoceptor. McCrea KE, et al. **Mol Pharmacol** 1996 May;49(5):927-37

Cyclic AMP-dependent regulation of fibroblast growth factor-2 messenger RNA levels in rat cortical astrocytes: comparison with fibroblast growth factor-1 and ciliary neurotrophic factor. Riva MA, et al. **Mol Pharmacol** 1996 Apr;49(4):699-706

Agonist-induced effects on cyclic AMP metabolism are affected in pigment epithelial cells of the Royal College of Surgeons rat. Nash MS, et al. **Neurochem Int** 1995 Sep; 27(3):253-62

Relaxant effects of pituitary adenylate cyclase activating polypeptide (PACAP) on epithelium-intact and -denuded guinea-pig trachea: a comparison with vasoactive intestinal peptide (VIP). Conroy DM, et al. **Neuropeptides** 1995 Sep; 29(3):121-7

Modulation of CCK mRNA in cell lines in response to isoproterenol and retinoic acid. Mania-Farnell BL, et al. **Neuropeptides** 1995 Oct;29(4):221-7

Beta-adrenoreceptor activation reduces dye-coupling between immature rat neocortical neurones. Rörig B, et al. **Neuroreport** 1995 Sep 11;6(13):1811-5

Combined corticosteroid and catecholamine stimulation of aqueous humor flow. Jacob E, et al. **Ophthalmology** 1996 Aug;103(8):1303-8

Catecholamines modulate growth and differentiation of human preosteoclastic cells. Frediani U, et al. **Osteoporos Int** 1996;6(1):14-21

Altered cAMP response after isoprenaline stimulation of mononuclear leucocytes from insulin-dependent diabetic patients with hypoglycaemia unawareness. Trovik TS, et al. **Pharmacol Toxicol** 1995 Oct;77(4):270-5

Chronic Losartan treatment blocks isoproterenol-induced dipsogenesis. Iyer SN, et al. **Physiol Behav** 1995 Aug; 58(2):283-6

Regulation of cardiac sodium-calcium exchanger by beta-adrenergic agonists. Fan J, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5527-32

cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists. Jurevičius J, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):295-9

Thermoregulation with age: restoration of beta(3)-adrenergic responsiveness in brown adipose tissue by cold exposure. Scarpace PJ, et al. **Proc Soc Exp Biol Med** 1996 Apr; 211(4):374-80

Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta 2-selective sympathomimetics. Mazzoni L, et al. **Pulm Pharmacol** 1994 Dec;7(6):367-76

Beta-adrenoceptor stimulation increases neuropeptide Y release from sympathetic nerves in intact rats. Évéquoz D, et al. **Regul Pept** 1995 Aug 22;58(3):163-6

Inhibitory potency of isoprenaline on guinea-pig and gravid human myometrium following extraneuronal uptake blockade. Kousides M, et al. **Reprod Fertil Dev** 1995; 7(1):59-66

Changes in the activities of hepatic xenobiotic metabolising enzymes after the administration of clenbuterol to female broilers. Nebbia C, et al. **Res Vet Sci** 1996 Jan;60(1):33-6

Analysis of the interactions between growth hormone and metaproterenol on lipid mobilization. Portillo MP, et al. **Rev Esp Fisiol** 1995 Sep;51(3):147-54

Salbutamol and high-intensity treadmill running in nonasthmatic highly conditioned athletes. Heir T, et al. **Scand J Med Sci Sports** 1995 Aug;5(4):231-6

Inhibitory effects of isoproterenol on PAF-induced endothelial cell permeability and morphological changes. Ding Z, et al. **Sci China C Life Sci** 1996 Feb;39(1):80-6

Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Ferguson SS, et al. **Science** 1996 Jan 19;271(5247):363-6

Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol. Grove A, et al. **Thorax** 1996 Jun;51(6):585-9

Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. Kiely DG, et al. **Thorax** 1995 Oct;50(10):1062-6

Effect of the adrenergic beta 3-agonist, BRL37344, on heat production by brown adipocytes in obese and in older rats. Yamakawa A, et al. **Tokai J Exp Clin Med** 1994 Dec; 19(3-6):139-42

Ozone-induced alteration in beta-adrenergic pharmacological modulation of pulmonary macrophages. McGovern TJ, et al. **Toxicol Appl Pharmacol** 1996 Mar; 137(1):51-6

Prevention of cyclosporine-induced nephrotoxicity by clenbuterol, a beta 2-adrenoreceptor stimulant. Ishikawa A, et al. **Transplant Proc** 1996 Jun;28(3):1976-7

[An observation on the pacemaker current I(f) in sheep cardiac Purkinje fibers under ischemia-mimic condition] Zhang Z, et al. **Sheng Li Hsueh Pao** 1995 Jun;47(3):209-17 (Eng. Abstr.) **(Chi)**

[Effects of beta-adrenergic compounds on IgE production] Coqueret O, et al. **Allerg Immunol (Paris)** 1995 Dec; 27(10):358-62 (Eng. Abstr.) **(Fre)**

[Stimulation of adenylate cyclase by the isoforms of human and rat beta-3 adrenergic receptor expressed in the CHO cells] Levasseur S, et al. **Gastroenterol Clin Biol** 1995 Aug-Sep;19(8-9):668-72 (Eng. Abstr.) **(Fre)**

[Study of control of the production of melatonin by perifusion of pineal bodies in rats] Zhao ZY, et al. **Pathol Biol (Paris)** 1996 Mar;44(3):157-64 (Eng. Abstr.) **(Fre)**

[The effect of the beta-adrenergic agonist clenbuterol on the growth of skeletal muscles of rats] Rehfeldt C, et al. **Arch Tierernahr** 1994;45(4):333-44 (Eng. Abstr.) **(Ger)**

[Effect of a beta-agonist and a beta-agonist/beta-antagonist combination on muscle growth, body composition and protein metabolism in rats] Reichel K, et al. **Arch Tierernahr** 1993;45(3):211-25 (Eng. Abstr.) **(Ger)**

[Effect of alpha and beta-adrenergic agonists on methacholine-induced nasal secretion in man] Morishita A. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Sep;98(9):1387-98 (Eng. Abstr.) **(Jpn)**

[Effects of a beta 2-agonist, sodium cromoglycate, and an anticholinergic agent on hyperventilation-induced bronchoconstriction in sensitized rabbits] Suguro H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Aug; 33(8):856-61 (Eng. Abstr.) **(Jpn)**

[Long-term effect of a beta-adrenergic agonist on sodium uptake into cultured rat alveolar type II cells] Suzuki S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Mar; 34(3):297-303 (Eng. Abstr.) **(Jpn)**

[Effect of ritodrine hydrochloride on fetal perfusion pressure in dually perfused human placenta] Ohashi M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1237-42 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Xamoterol improves the control of chronic atrial fibrillation in elderly patients. Lawson-Matthew PJ, et al. **Age Ageing** 1995 Jul;24(4):321-5

The efficacy and safety of inhaled salmeterol 50 microg bd in older patients with reversible airflow obstruction. Starke ID, et al. **Age Ageing** 1996 Jan;25(1):67-71

Antiallergic actions of high topical doses of terbutaline in human nasal airways. Svensson C, et al. **Allergy** 1995 Nov; 50(11):884-90

A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease. Friedman M. **Am J Med** 1996 Jan 29;100(1A):30S-39S

Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. Levin DC, et al. **Am J Med** 1996 Jan 29;100(1A):40S-48S

Results of a multicenter study of nebulized inhalant bronchodilator solutions. Tashkin DP, et al. **Am J Med** 1996 Jan 29;100(1A):62S-69

Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Belman MJ, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):967-75

Rebound airway obstruction and responsiveness after cessation of terbutaline: effects of budesonide. de Jong JW, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):70-5

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Woolcock A, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1481-8

Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Yates DH, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1170-4

A comparison of the efficacy of dopexamine and dobutamine for increasing oxygen delivery in high-risk surgical patients. Boyd O, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):478-84

A study of the combined haemodynamic effects of dobutamine and enoximone in patients taking beta adrenoceptor antagonists. Harvey WR, et al. **Anaesth Intensive Care** 1995 Dec;23(6):673-7

Isoflurane anesthesia does not add to the bronchodilating effect of a beta 2-adrenergic agonist after tracheal intubation. Wu RS, et al. **Anesth Analg** 1996 Aug; 83(2):238-41

Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma. Bousquet J, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):189-94

Safety of salmeterol in the maintenance treatment of asthma [see comments] Nathan RA, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):243-8. Comment in: Ann Allergy Asthma Immunol 1995 Sep;75(3):209-11.

High beta-agonist users in five HMOs: implications beyond high beta-agonist use [editorial] Pearlman DS. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):125-7

Salmeterol xinafoate in children on high dose inhaled steroids. Russell G, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):423-8

Salmeterol for the treatment of asthma [editorial; comment] Weinberger M. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):209-11 (26 ref.). Comment on: Ann Allergy Asthma

Immunol 1995 Sep;75(3):243–8.
Prospective, randomized trial of epinephrine, metaproterenol, and both in the prehospital treatment of asthma in the adult patient. Quadrel M, et al. **Ann Emerg Med** 1995 Oct; 26(4):469–73
Salmeterol for emphysema? [letter] Healey D. **Aust Fam Physician** 1996 Aug;25(8):1340
Beta–2 agonists in asthma—the Thoracic Society of Australia and New Zealand. Wilson J, et al. **Aust N Z J Med** 1995 Aug;25(4):358–61 (39 ref.)
Beta blockers have important role in pulmonary oedema due to mitral stenosis [letter; comment] Oakley CM. **BMJ** 1996 Feb 10;312(7027):376. Comment on: BMJ 1995 Oct 21;311(7012):1083–4.
Double blind randomised controlled trial of effect of metoprolol on myocardial ischaemia during endoscopic cholangiopancreatography. Rosenberg J, et al. **BMJ** 1996 Aug 3;313(7052):258–61
Are young adults with asthma treated sufficiently with inhaled steroids? A population-based study of prescription data from 1991 and 1994. Gaist D, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):285–9
Eformoterol in elderly patients: a follow-up. Brambilla R. **Br J Clin Pract Symp Suppl** 1995 Sep;81:6–7
Eformoterol and bronchial hyperresponsiveness in mild asthma. Chung KF. **Br J Clin Pract Symp Suppl** 1995 Sep; 81:14–5
Eformoterol versus salbutamol in elderly patients with ROAD. Hendrick DJ. **Br J Clin Pract Symp Suppl** 1995 Sep;81:4–5
Eformoterol versus salbutamol in patients with ROAD. Maesen FP. **Br J Clin Pract Symp Suppl** 1995 Sep;81:8–10
The place of long-acting beta 2 agonists in primary care. Stott PC. **Br J Clin Pract Symp Suppl** 1995 Sep;81:20–1
Continuous eformoterol and beta 2-receptor responsiveness. Sussman HS. **Br J Clin Pract Symp Suppl** 1995 Sep;81:16–7
Cardiovascular and metabolic effects of eformoterol in adults. Till MD. **Br J Clin Pract Symp Suppl** 1995 Sep;81:2–3
Rapid onset of tolerance to the bronchoprotective effect of salmeterol [see comments] Bhagat R, et al. **Chest** 1995 Nov; 108(5):1235–9. Comment in: Chest 1996 Jul;110(1):305–6. Comment in: Chest 1996 Jul;110(1):306.
Is the result of methacholine challenge accurate for assessing the bronchoprotective effects of long-acting beta-adrenergic bronchodilators? [letter; comment] Bumbacea D, et al. **Chest** 1996 Jul;110(1):305–6. Comment on: Chest 1995 Nov;108(5):1235–9.
Determination of post-salbutamol methacholine dose shift [letter] Cockcroft DW, et al. **Chest** 1996 Aug;110(2):579–80
Loss of bronchoprotection with salmeterol [letter; comment] D'Urzo AD. **Chest** 1996 Jul;110(1):306. Comment on: Chest 1995 Nov;108(5):1235–9.
Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD [letter] Ikeda A, et al. **Chest** 1996 Jan;109(1):294
Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD [letter; comment] Ingram RH Jr. **Chest** 1996 Jan; 109(1):293. Comment on: Chest 1995 Feb;107(2):401–5.
Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol [see comments] Kalra S, et al. **Chest** 1996 Apr;109(4):953–6. Comment in: Chest 1996 Apr;109(4):862–4.
A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma. Karpel JP, et al. **Chest** 1996 Sep;110(3):611–6
Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Kleerup EC, et al. **Chest** 1996 Mar; 109(3):702–7
Sleep quality and nocturnal respiratory function with once-daily theophylline (Uniphyl) and inhaled salbutamol in patients with COPD. Man GC, et al. **Chest** 1996 Sep; 110(3):648–53
Long-acting beta-agonists, tachyphylaxis, and corticosteroids [editorial; comment] Sears MR. **Chest** 1996 Apr;109(4):862–4. Comment on: Chest 1996 Apr;109(4):953–6.
Ventilation-perfusion response after fenoterol in hypoxemic patients with stable COPD. Viegas CA, et al. **Chest** 1996 Jul;110(1):71–7
Anti-inflammatory effects of long-acting beta-agonists in asthma [editorial] Bradding P. **Clin Exp Allergy** 1995 Oct; 25(10):912–4 (36 ref.)
Beta-adrenergic agonists. Boyle JG. **Clin Obstet Gynecol** 1995 Dec;38(4):688–96 (36 ref.)
Bronchodilator therapy in the management of acute asthma. Moan MJ, et al. **Compr Ther** 1995 Aug;21(8):421–7 (39 ref.)
Goal-directed therapy with dopexamine, dobutamine, and volume expansion: effects of systemic oxygen transport on hepatic ultrastructure in porcine sepsis. Tighe D, et al. **Crit Care Med** 1995 Dec;23(12):1997–2007
Dopexamine after cardiac surgery. **Drug Ther Bull** 1995 Apr; 33(4):30–2 (17 ref.)
Efficacy and safety of salmeterol in childhood asthma. Lenney W, et al. **Eur J Pediatr** 1995 Dec;154(12):983–90
Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group. Boyd G. **Eur Respir J** 1995 Sep; 8(9):1494–8
Overnight protection by inhaled salmeterol on exercise-induced asthma in children. Carlsen KH, et al. **Eur Respir J** 1995 Nov;8(11):1852–5
Long-term effects of therapy on respiratory health. Fuhrman C, et al. **Eur Respir J** 1996 Mar;9(3):436–43
Skeletal muscle magnesium and potassium in asthmatics treated with oral beta 2-agonists. Gustafson T, et al. **Eur Respir J** 1996 Feb;9(2):237–40
Reduced survival after isoprenaline/dopamine in d,l-propranolol intoxicated rats. Toet AE, et al. **Hum Exp Toxicol** 1996 Feb;15(2):120–8
Left ventricular volume in thrombolysed patients with acute anterior myocardial infarction: the effect of captopril and xamoterol. Darasz KH, et al. **Int J Cardiol** 1995 Sep; 51(2):137–42
Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes. Arch JR, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):191–9 (90 ref.)
Inhaled beta 2-agonists and allergen-induced airway responses [letter; comment] Cockcroft DW, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):1013–4. Comment on: J Allergy Clin Immunol 1995 Mar;95(3):641–51.
Try using binoculars [letter; comment] Costello J, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):1014–7. Comment on: J Allergy Clin Immunol 1995 Mar;95(3):641–51.
Long-acting inhaled beta agonists [see comments] Tilles SA, et al. **J Asthma** 1995;32(6):397–404 (51 ref.). Comment in: J Asthma 1995;32(6):395–6.
Terbutaline improves efficiency of oxygenation after coronary artery bypass surgery. Waller DA, et al. **J Cardiovasc Surg (Torino)** 1996 Feb;37(1):59–62
The beta 3-adrenoceptor agonist CL316243 prevents indomethacin-induced jejunal ulceration in the rat by reversing early villous shortening. Anthony A, et al. **J Pathol** 1996 Jul;179(3):340–6
Myocardial stunning: a therapeutic conundrum. Zhou Z, et al. **J Thorac Cardiovasc Surg** 1995 Nov;110(5):1391–400; discussion 1400–1
Potential anti-diabetic applications of a new molecule with affinity for beta 3-adrenoceptors. Barrionuevo M, et al. **Life Sci** 1996;59(11):PL141–6
The beta-agonist controversy. Taylor DR, et al. **Med Clin North Am** 1996 Jul;80(4):719–48 (126 ref.)
Beta-agonists as antiobesity, antidiabetic and nutrient partitioning agents. Yen TT. **Obes Res** 1995 Nov;3 Suppl 4:531S–536S (57 ref.)
Therapeutic regimens in acute experimental pancreatitis in rats: effects of a protease inhibitor, a beta-agonist, and antibiotics. Araida T, et al. **Pancreas** 1995 Aug;11(2):132–40
Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. König P, et al. **Pediatr Pulmonol** 1995 Oct;20(4):205–14
The use of beta 2-adrenoceptor agonists in the treatment of bronchial asthma. Svedmyr N, et al. **Pharmacol Toxicol** 1996 Jan;78(1):3–11 (94 ref.)
beta-Adrenoceptor agonists in future asthma therapy. Ullman A. **Pharmacol Toxicol** 1995;77 Suppl 3:36–9
Pharmacokinetics and pharmacodynamics of beta 2-agonists (in the light of fenoterol). Schmidt EW, et al. **Respiration** 1995;62(4):190–200
Beta 2 adrenoceptor polymorphisms: are they clinically important? [editorial] Hall IP. **Thorax** 1996 Apr;51(4):351–3
Long-acting beta 2-agonists and their role in asthma management. Galant SP. **West J Med** 1995 Oct;163(4):372
[The effect of salmeterol in the treatment of smokers with chronic obstructive lung disease] Ulrik CS. **Ugeskr Laeger** 1996 Jun 17;158(25):3604–7 (Eng. Abstr.) **(Dan)**
[Salmeterol no longer banned in Olympic Games (letter)] van Dam JG. **Ned Tijdschr Geneeskd** 1996 Aug 3; 140(31):1612 **(Dut)**
[Beta-2 adrenergic receptor agonists in asthma treatment] Haahtela T, et al. **Duodecim** 1995;111(8):744–8 (28 ref.) **(Fin)**
[Beta 2-sympathomimetic drugs] Criée CP, et al. **Internist (Berl)** 1995 Sep;36(9):918–23 (28 ref.) **(Ger)**
[Effect of the beta receptor blockader carazolol on the dropping and retention of the placenta in the camel (C. dromedarius)] Nasr MT, et al. **Tierarztl Prax** 1996 Jun; 24(3):319–21 (Eng. Abstr.) **(Ger)**
[Beta-2 agonists, exposure to allergens and bronchial hyperreactivity in children with allergic asthma] Piacentini GL, et al. **Pediatr Med Chir** 1995 Nov-Dec;17(6):515–7 (Eng. Abstr.) **(Ita)**
[The role of long-acting beta-mimetics in patients with chronic bronchial spasm and bronchial asthma] Chazan R, et al. **Pol Arch Med Wewn** 1995 Jul;94(1):59–63 (47 ref.) **(Pol)**

TOXICITY

The biochemical effects of clenbuterol: with particular reference to taurine and muscle damage. Waterfield CJ, et al. **Eur J Pharmacol** 1995 Jul 1;293(2):141–9
Structural and biochemical remodelling in catecholamine-induced cardiomyopathy: comparative and ontogenetic aspects. Oštádal B, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):83–8 (49 ref.)

URINE

Development of a tube enzyme immunoassay for "on-site" screening of urine samples in the presence of beta-agonists. Haasnoot W, et al. **Analyst** 1996 Aug;121(8):1111–4
Evaluation of commercially available ELISA test kits for the detection of clenbuterol and other beta 2-agonists. Hahnau S, et al. **Food Addit Contam** 1996 Apr;13(3):259–74
Rapid analysis of beta-agonists in urine by thermospray tandem mass spectrometry. van Rhijn JA, et al. **J Chromatogr A** 1995 Sep 29;712(1):67–73
Determination of salbutamol enantiomers in human plasma and urine by chiral high-performance liquid chromatography. Boulton DW, et al. **J Chromatogr B Biomed Appl** 1995 Oct 6;672(1):103–9
Detection of clenbuterol (Ventipulmin) in the horse. Hagedorn HW, et al. **Zentralbl Veterinarmed A** 1995 May; 42(3):209–19

ADRENERGIC BETA-ANTAGONISTS

Hazards of beta blockade. Pressor effects may be important [letter; comment] Cleophas TJ. **BMJ** 1995 Dec 2; 311(7018):1501–2. Comment on: BMJ 1995 Sep 16;311(7007):701–2.
beta-blockers. Drug interactions of clinical significance. Blaufarb I, et al. **Drug Saf** 1995 Dec;13(6):359–70 (114 ref.)
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. Ruffolo RR Jr, et al. **J Med Chem** 1995 Sep 15;38(19):3681–716 (317 ref.)
Beta 2 agonist/antagonist activity of salbutamol [letter; comment] Jonkers RE, et al. **Thorax** 1995 Nov; 50(11):1227–8. Comment on: Thorax 1995 Feb;50(2):134–8.

ADMINISTRATION & DOSAGE

The intraocular pressure lowering effect of timolol in gel-forming solution. Rosenlund EF. **Acta Ophthalmol Scand** 1996 Apr;74(2):160–2
Systemic beta-adrenoceptor function and ophthalmic beta-adrenergic blockers. Lippert FK, et al. **Anesth Analg** 1996 Jan;82(1):211–3
Brevibloc drug errors [letter] Pearce DJ. **Can J Anaesth** 1996 Apr;43(4):419
A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension. Chen MF, et al. **Cardiovasc Drugs Ther** 1995 Jun;9(3):401–6
A cross-over study comparing the efficacy of a combination of atenolol and nifedipine at different doses in angina pectoris. Metcalfe MJ, et al. **Curr Med Res Opin** 1995; 13(5):251–6
Increase in plasma propranolol caused by nicardipine is dependent on the delivery rate of propranolol. Vercruysse I, et al. **Eur J Clin Pharmacol** 1995;49(1–2):121–5
Atrial ectopic activity and atrial fibrillation/flutter after coronary artery bypass surgery. A case-base study controlling for confounding from age, beta-blocker treatment, and time distance from operation. Frost L, et al. **Int J Cardiol** 1995 Jun 30;50(2):153–62
Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope. Cox MM, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1293–8
Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope [letter] Vigh AG, et al. **J Am Coll Cardiol** 1996 Sep;28(3):798
Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation. Kalman J, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 1):1212–7
Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. Schneider M, et al. **J Hypertens** 1996 May;14(5):669–77
Comparison of perioperative myocardial protection with nifedipine versus nifedipine and metoprolol in patients undergoing elective coronary artery bypass grafting. Podesser BK, et al. **J Thorac Cardiovasc Surg** 1995 Nov; 110(5):1461–9
The safety of topical beta-blockers in glaucoma treatment. Goldberg I. **Med J Aust** 1996 Apr 15;164(8):498–9
[Treatment of hypertension with a fixed combination of bopindolol and chlorthalidone (Sandoretic)] Widimský J, et al. **Vnitr Lek** 1996 Apr;42(4):223–8 (Eng. Abstr.) **(Cze)**
[Multicenter double-blind study with 0.25% timolol in Gelrite (TG) once daily vs. 0.25% timolol solution (TS) twice daily. German Study Group] Hommer A, et al. **Ophthalmologe** 1995 Aug;92(4):546–9 (Eng. Abstr.) **(Ger)**
[Long-term selective beta 1-blockade therapy for a patient with anthracycline-induced cardiomyopathy] Okamoto M, et al. **Rinsho Ketsueki** 1995 Nov;36(11):1305–10 (Eng. Abstr.) **(Jpn)**
[Effect of 1-alpha blockader on maximal oxygen consumption and physical endurance in hypertensive men] Tomten SE, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10; 116(1):37–40 (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Conjunctival damage induced by long-term topical anti-glaucoma therapy [letter; comment] Broadway D, et al. **Acta Ophthalmol Scand** 1996 Feb;74(1):97. Comment on: Acta Ophthalmol Scand 1995 Jun;73(3):242–5.
Effects of antiglaucoma drugs on ocular surface. Yalvaç IS,

et al. **Acta Ophthalmol Scand** 1995 Jun;73(3):246–8
Association of metoprolol and retroperitoneal fibrosis. Ahmad S. **Am Heart J** 1996 Jan;131(1):202–3
Persistent hypoglycemia and hyperinsulinemia: caution in using glucagon [letter] Thoma ME, et al. **Am J Emerg Med** 1996 Jan;14(1):99–101
Lichen planus associated with topical beta-blocker therapy. Beckman KA, et al. **Am J Ophthalmol** 1995 Oct; 120(4):530–1
Diuretics and sudden cardiac death [letter; comment] Aursnes A. **Ann Intern Med** 1996 Aug 15;125(4):346;discussion 348–9. Comment on: Ann Intern Med 1995 Oct 1;123(7):481–7.
Diuretics and sudden cardiac death [letter; comment] Buck DS. **Ann Intern Med** 1996 Aug 15;125(4):347; discussion 348–9. Comment on: Ann Intern Med 1995 Oct 1;123(7):481–7.
Diuretics and sudden cardiac death [letter; comment] Cabell CH, et al. **Ann Intern Med** 1996 Aug 15;125(4):347; discussion 347–8. Comment on: Ann Intern Med 1995 Oct 1;123(7):481–7.
Diuretics and sudden cardiac death [letter; comment] Maun AR. **Ann Intern Med** 1996 Aug 15;125(4):348; discussion 348–9. Comment on: Ann Intern Med 1995 Oct 1;123(7):481–7.
Beta-blockers and sudden cardiac death [letter; comment] Messerli FH. **Ann Intern Med** 1996 Aug 15;125(4):349. Comment on: Ann Intern Med 1995 Sep 1;123(5):358–67.
Diuretics and sudden cardiac death [letter; comment] Winkelmann BR. **Ann Intern Med** 1996 Aug 15; 125(4):347–8; discussion 348–9. Comment on: Ann Intern Med 1995 Oct 1;123(7):481–7.
Portal-systemic encephalopathy and gastrointestinal bleeding after cardioselective beta-blocker (metoprolol) administration to patients with portal hypertension. Uribe M, et al. **Arch Med Res** 1995 Autumn;26(3):221–6
Reversal of topical antiglaucoma medication effects on the conjunctiva. Broadway DC, et al. **Arch Ophthalmol** 1996 Mar;114(3):262–7
Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults [see comments] Prince MJ, et al. **BMJ** 1996 Mar 30;312(7034):801–5. Comment in: BMJ 1996 Mar 30;312(7034):793–4. Comment in: BMJ 1996 Jul 20;313(7050):166–7.
Medical treatment of glaucoma--a reappraisal of the risks. Diggory P, et al. **Br J Ophthalmol** 1996 Jan;80(1):85–9 (38 ref.)
Beta blockers and the elderly with glaucoma: are we adding insult to injury? O'Donoghue E. **Br J Ophthalmol** 1995 Sep;79(9):794–6 (48 ref.)
Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought. Burvenich H. **Bull Soc Belge Ophtalmol** 1995;257:63–6; discussion 66–7
Allergic contact dermatitis from levobunolol eyedrops. di Lernia V, et al. **Contact Dermatitis** 1995 Jul;33(1):57
Allergic contact dermatitis due to timolol and levobunolol in eyedrops, with no cross-sensitivity to other ophthalmic beta-blockers. Koch P. **Contact Dermatitis** 1995 Aug; 33(2):140–1
Contact dermatitis from levobunolol and befunolol. Zucchelli V, et al. **Contact Dermatitis** 1995 Jul;33(1):66–7
Fulminant hepatitis after carbimazole and propranolol administration. Epeirier JM, et al. **Eur J Gastroenterol Hepatol** 1996 Mar;8(3):287–8
Uterine and fetal hemodynamics and fetal cardiac function after atenolol and pindolol infusion. A randomized study. Räsänen J, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):195–201
Beta-blockers and their effects on protein metabolism and resting energy expenditure. Lamont LS. **J Cardpulm Rehabil** 1995 May-Jun;15(3):183–5 (21 ref.)
The incidence of depression in new users of beta-blockers and selected antihypertensives. Gerstman BB, et al. **J Clin Epidemiol** 1996 Jul;49(7):809–15
Hypothyroidism-induced bradycardia [letter] Ahmad S. **J Fam Pract** 1995 Nov;41(5):432–3
Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy. Yamada Y, et al. **J Pharmacokinet Biopharm** 1995 Apr; 23(2):131–45
Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy. Yamada Y, et al. **J Pharmacokinet Biopharm** 1995 Oct;23(5):463–78 (30 ref.)
The safety of topical beta-blockers in glaucoma treatment [letter] Gale AE. **Med J Aust** 1996 Aug 5;165(3):175
Medications used to prevent migraine headaches and their potential ocular adverse effects. Doughty MJ, et al. **Optom Vis Sci** 1995 Dec;72(12):879–91 (176 ref.)
[Sotalol and torsades de pointes ventricular tachycardia] Petersen HH, et al. **Ugeskr Laeger** 1996 May 6; 158(19):2711–6 (Eng. Abstr.) **(Dan)**
[Are beta-blockers really depressogenic?] Pélissolo A, et al. **Ann Med Psychol (Paris)** 1995 Aug-Sep;153(7):441–7 (26 ref.) (Eng. Abstr.) **(Fre)**
[Fibrosing pneumopathy caused by labetalol] Kheir A, et al. **Rev Pneumol Clin** 1996;52(1):33–5 (Eng. Abstr.) **(Fre)**
[Does chronic oral treatment with beta-receptor blockers have an effect on positive inotropic therapy of coronary patients with adrenaline after extracorporeal circulation?] Günnicker M, et al. **Herz** 1995 Dec;20(6):399–411 (Eng. Abstr.) **(Ger)**
[Depression caused by beta blockaders. Unknown mechanisms behind well-known adverse effects] Hägg S, et al. **Lakartidningen** 1995 Dec 6;92(49):4681–3 **(Swe)**

ANALYSIS

High-performance liquid chromatographic analysis of pindolol enantiomers in human serum and urine using a reversed-phase cellulose-based chiral column. Zhang H, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23; 668(2):309–13
Determination of analytical error function for beta-blockers as a possible weighting method for the estimation of the regression parameters. Modamio P, et al. **J Pharm Biomed Anal** 1996 Feb;14(4):401–8
[Analysis of some neuroleptics and carazolol in pork kidneys] Arneth W. **Z Lebensm Unters Forsch** 1995 Sep;201(3):261–5 (Eng. Abstr.) **(Ger)**

BLOOD

Stereoselective analysis of nadolol in human plasma. Srinivas NR, et al. **Biomed Chromatogr** 1995 Sep-Oct;9(5):226–8
Protein binding of sotalol enantiomers in young and elderly human and rat serum using ultrafiltration. Carr RA, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):705–12
Increase in plasma propranolol caused by nicardipine is dependent on the delivery rate of propranolol. Vercruysse I, et al. **Eur J Clin Pharmacol** 1995;49(1–2):121–5
Ion-pair chromatography and micellar electrokinetic capillary chromatography in analyzing beta-adrenergic blocking agents from human biological fluids. Lukkari P, et al. **J Chromatogr A** 1995 Nov 24;717(1–2):211–7
Enantioselective analysis of sotalol in plasma by reversed-phase high-performance liquid chromatography using diastereomeric derivatives. Hooper WD, et al. **J Chromatogr B Biomed Appl** 1995 Oct 6;672(1):89–96
Determination of the beta-blocker carteolol in human plasma by a sensitive gas chromatographic-negative-ion chemical ionization high-resolution mass spectrometric method. Nagasawa M, et al. **J Chromatogr B Biomed Appl** 1995 Nov 17;673(2):294–8
Selective extraction of beta-blockers from biological fluids by column-switching high-performance liquid chromatography using an internal-surface phenylboronic acid precolumn. Ohta T, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):168–73
[Beta-blocking agents] Suzuki M. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:978–82 (16 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Studies on agents with vasodilator and beta-blocking activities. III. Synthesis and activity of optical isomers of TZC-1370. Seki T, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1719–23
Synthesis and alpha,beta-adrenergic blocking potency of 2,3-dihydro-1,4-benzodioxin derivatives. (II). Khouili M, et al. **Farmaco** 1996 Mar;51(3):185–8
Synthesis and alpha,beta-adrenergic blocking potency of 2,3-dihydro-1,4-benzodioxin derivatives. (I). Khouili M, et al. **Farmaco** 1996 Mar;51(3):175–84
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol. Dubois EA, et al. **J Med Chem** 1996 Aug 16; 39(17):3256–62
Synthesis and pharmacological investigations of 1,2,3,4-tetrahydroisoquinoline derivatives. Brzezinska E, et al. **Pharmazie** 1996 Jun;51(6):397–9

CHEMISTRY

X-ray structure investigations of potential beta-blockers. II.6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline. Olszak TA, et al. **Acta Crystallogr C** 1996 Apr 15;52 (Pt 4):1038–40
Conformational structure of some beta 1-blockers, their partitioning in lipid and the role of parasubstituents. Nandel FS, et al. **Indian J Biochem Biophys** 1995 Aug;32(4):207–12
Determination of the optical purity of timolol maleate by proton nuclear magnetic resonance spectroscopy with a chiral Pr(III) shift reagent. Hanna GM, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1313–9
Antagonist conformations with the beta(2)-adrenergic receptor ligand binding pocket. Hockerman GH, et al. **Mol Pharmacol** 1996 Jun;49(6):1021–32
Interaction between bile salts and beta-adrenoceptor antagonists. Grosvenor MP, et al. **Pharm Res** 1995 May; 12(5):682–6

CONTRAINDICATIONS

Don't get stung with the adrenergic blockers (beta or alpha)! Watson A. **Aust Fam Physician** 1995 Oct;24(10):1879
Exercise guidelines for patients with high blood pressure: an update [letter] Pescatello LS, et al. **J Cardpulm Rehabil** 1995 May-Jun;15(3):239–40
[Administration of beta-blockers and ACE inhibitors in this indication is frequently limited by hypotensive cardiovascular parameters] **Internist (Berl)** 1996 Jul; 37(7):739–40 **(Ger)**
[Are beta-blockers generally contraindicated in patients with peripheral arterial occlusive disease?] Schweizer J, et al. **Z Kardiol** 1996 Mar;85(3):193–7 (Eng. Abstr.) **(Ger)**

DIAGNOSTIC USE

Myocardial beta-adrenoceptor density and plasma catecholamines in syndrome X. Rosen SD, et al. **Am J Cardiol** 1996 Jul 1;78(1):37–42
In vivo quantification of human pulmonary beta-adrenoceptor density using PET: comparison with in vitro radioligand binding. Qing F, et al. **J Nucl Med** 1996 Aug;37(8):1275–81

ECONOMICS

Drop size of ocular timolol solutions [letter] Koe MA. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2469

HISTORY

[Beta-blockers] Kulbertus H. **Rev Med Liege** 1996 Jan; 51(1):19–23 **(Fre)**

ISOLATION & PURIFICATION

Comparison of two extraction methods for determination of propranolol and furosemide in human plasma by mixed-mode chromatography. Walshe M, et al. **J Pharm Biomed Anal** 1996 Feb;14(4):475–81

METABOLISM

Temperature-nearly-independent binding constant in several biochemical systems. The underlying entropy-driven binding mechanism and its practical significance. Miklavc A. **Biochem Pharmacol** 1996 Mar 22;51(6):723–9
(+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver. Prueksaritanont T, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1521–5
Effects of the ester moiety on stereoselective hydrolysis of several propranolol prodrugs in rat tissues. Takahashi K, et al. **Biol Pharm Bull** 1995 Oct;18(10):1401–4
Effect of pH and lidocaine on beta-adrenergic receptor binding. Interaction during resuscitation? Modest VE, et al. **Chest** 1995 Nov;108(5):1373–9
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol. Dubois EA, et al. **J Med Chem** 1996 Aug 16; 39(17):3256–62
Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy. Yamada Y, et al. **J Pharmacokinet Biopharm** 1995 Apr; 23(2):131–45
The binding of propranolol at 5-hydroxytryptamine1D beta T355N mutant receptors may involve formation of two hydrogen bonds to asparagine. Glennon RA, et al. **Mol Pharmacol** 1996 Jan;49(1):198–206
[Analysis of penbutolol and its metabolites in human body fluid by gas chromatography--mass spectrometry] Shen L, et al. **Yao Hsueh Hsueh Pao** 1995;30(9):702–5 (Eng. Abstr.) **(Chi)**
[The metabolism of the beta receptor blocker talinolol in humans--relationship between structure, polarity and amount excreted] Oertel R, et al. **Pharmazie** 1995 Sep; 50(9):637–8 **(Ger)**

PHARMACOKINETICS

Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Dickstein K, et al. **Am J Ophthalmol** 1996 Apr; 121(4):367–71
Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Trausch B, et al. **Biopharm Drug Dispos** 1995 Jul;16(5):403–14
Toxicokinetics of a single intravenous dose of rac-propranolol versus optically pure propranolol in the rat. Bode W, et al. **Chirality** 1995;7(8):626–31
Stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil: species differences and influence of endotoxin. Laethem ME, et al. **Chirality** 1995;7(8):616–22
Sex differences in pharmacokinetics of oral propranolol in healthy Chinese volunteers. Xie HG, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):468–70
Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Gramatté T, et al. **Clin Pharmacol Ther** 1996 May; 59(5):541–9
Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Lai ML, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):264–8
Interaction between propranolol and amino acids in the single-pass isolated, perfused rat liver. Semple HA, et al. **Drug Metab Dispos** 1995 Aug;23(8):794–8
Residues of some veterinary drugs in animals and foods. Monographs prepared by the forty-third meeting of the Joint FAO/WHO Expert Committee on Food Additives. **FAO Food Nutr Pap** 1995;41(7):1–112
Influence of aging on the oxidative and conjugative metabolism of propranolol. Tateishi T, et al. **Int J Clin Pharmacol Res** 1995;15(3):95–101
The lack of effect of aerobic exercise training on propranolol pharmacokinetics in young and elderly adults. Panton LB, et al. **J Clin Pharmacol** 1995 Sep;35(9):885–94

Effect of aging on atenolol pharmacokinetics and pharmacodynamics. Sowinski KM, et al. **J Clin Pharmacol** 1995 Aug;35(8):807–14

Comparison of concentration–time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits. Acheampong AA, et al. **J Ocul Pharmacol Ther** 1995 Winter;11(4):489–502

Sequential bioactivation of methoxime analogs of beta-adrenergic antagonists in the eye. Bodor N, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):305–18

The secretion of propranolol enantiomers in human saliva: evidence for active transport? Hölđ KM, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1401–7

Ophthalmic preservatives as absorption promoters for ocular drug delivery. Sasaki H, et al. **J Pharm Pharmacol** 1995 Sep;47(9):703–7

Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. Adson A, et al. **J Pharm Sci** 1995 Oct;84(10):1197–204

Quantitative structure–pharmacokinetic relationships (QSPR) of beta blockers derived using neural networks. Gobburu JV, et al. **J Pharm Sci** 1995 Jul;84(7):862–5

Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy. Yamada Y, et al. **J Pharmacokinet Biopharm** 1995 Apr; 23(2):131–45

Interaction between bile salts and beta-adrenoceptor antagonists. Grosvenor MP, et al. **Pharm Res** 1995 May; 12(5):682–6

Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers. Sasaki H, et al. **Pharm Res** 1995 Aug;12(8):1146–50

Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Wetterich U, et al. **Pharm Res** 1996 Apr;13(4):514–22

[Adrenergic betablockers] Alvarez Sabín J. **Rev Neurol** 1995; 23 Suppl 2:S185–9 (23 ref.) **(Spa)**

PHARMACOLOGY

QT interval of the ECG, heart rate and arterial pressure during anaesthetic induction: comparative effects of alfentanil and esmolol. Korpinen R, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):809–13

Effects of beta-blockade with bisoprolol on heart rate variability in advanced heart failure: analysis of scatterplots of R–R intervals at selected heart rates. Copie X, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):369–75

Effect of beta-blockade on left atrial contribution to ventricular filling in dogs with moderate heart failure. Shimoyama H, et al. **Am Heart J** 1996 Apr;131(4):772–7

Effect of beta-blockade on dobutamine stress echocardiography. Weissman NJ, et al. **Am Heart J** 1996 Apr;131(4):698–703

Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. Darbar D, et al. **Am J Cardiol** 1996 Jun 15;77(15):1351–5

Effects of bisoprolol on heart rate variability in heart failure. Pousset F, et al. **Am J Cardiol** 1996 Mar 15;77(8):612–7

Optic nerve vasomotor effects of topical beta-adrenergic antagonists in rabbits [see comments] Orgül S, et al. **Am J Ophthalmol** 1995 Oct;120(4):441–7. Comment in: Am J Ophthalmol 1996 Apr;121(4):456–7.

Optic nerve vasomotor effects of topical beta-adrenergic antagonists in rabbits [letter; comment] Spaeth GL. **Am J Ophthalmol** 1996 Apr;121(4):456–7. Comment on: Am J Ophthalmol 1995 Oct;120(4):441–7.

Blockade of beta-adrenoceptor in control of blood pressure in fowl. Kamimura K, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R914–22

Effect of bethanechol, neostigmine, metoclopramide, and propranolol on myoelectric activity of the ileocecocolic area in cows. Steiner A, et al. **Am J Vet Res** 1995 Aug; 56(8):1081–6

Beta-blockade lowers peripheral lipolysis in burn patients receiving growth hormone. Rate of hepatic very low density lipoprotein triglyceride secretion remains unchanged. Aarsland A, et al. **Ann Surg** 1996 Jun; 223(6):777–87; discussion 787–9

Cardiac surgical conditions induced by beta-blockade: effect on myocardial fluid balance. Mehlhorn U, et al. **Ann Thorac Surg** 1996 Jul;62(1):143–50

Propranolol suppresses reactivation of herpesvirus. Gebhardt BM, et al. **Antiviral Res** 1995 Jun;27(3):255–61

Topical beta-adrenergic antagonists and quinidine. A risky interaction [editorial] Higginbotham EJ. **Arch Ophthalmol** 1996 Jun;114(6):745–6 (7 ref.)

Ryanodine receptor/calcium release channel conformations as reflected in the different effects of propranolol on its ryanodine binding and channel activity. Zchut S, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):377–83

Bopindolol is a slowly dissociating beta 1-adrenoceptor antagonist when compared to other beta-blockers. Hosohata Y, et al. **Biol Pharm Bull** 1995 Aug;18(8):1066–71

Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. Meltzer HY, et al. **Biol Psychiatry** 1995 Sep 1;38(5):310–8

Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Sanderson JE, et al. **Br Heart J** 1995 Nov;74(5):502–7

Haemodynamic effects of molsidomine and propranolol in patients with cirrhosis. Combis JM, et al. **Br J Clin Pharmacol** 1996 May;41(5):409–13

The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomic function in mild to moderate hypertension. Panfilov V, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):563–9

A placebo controlled comparison of the effects of metoprolol and celiprolol on echo-Doppler measurements of cardiovascular function in normal volunteers. Silke B, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):37–42

The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man. Tham TC, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):19–23

Postextrasystolic potentiation in patients with ischaemic heart disease: influence of inotropic agents. Zhang YI, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):25–30

Noradrenaline-induced relaxation of rat oesophageal muscularis mucosae: mediation solely by innervated beta 3-adrenoceptors. de Boer RE, et al. **Br J Pharmacol** 1995 Oct;116(3):1945–7

Functional evidence of atypical beta 3-adrenoceptors in the human colon using the beta 3-selective adrenoceptor antagonist, SR 59230A. De Ponti F, et al. **Br J Pharmacol** 1996 Apr;117(7):1374–6

Atypical responses of rat ileum to pindolol, cyanopindolol and iodocyanopindolol. Hoey A, et al. **Br J Pharmacol** 1996 Feb;117(4):712–6

Determination of beta-adrenoceptor subtype on rat isolated ventricular myocytes by use of highly selective beta-antagonists. Kitagawa Y, et al. **Br J Pharmacol** 1995 Sep;116(1):1635–43

Serotonin and stress-induced increases in renin secretion are not blocked by sympathectomy/adrenal medullectomy but are blocked by beta antagonists. Morton KD, et al. **Brain Res** 1995 Nov 6;698(1–2):185–92

Thiopentone inhibits beta-adrenergic responses in myocardial tissue. Thurston TA, et al. **Can J Anaesth** 1995 Oct; 42(10):944–7

Experimental rat model representing both acute and chronic heart failure related to autoimmune myocarditis. Koyama S, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):701–7

Tilisolol hydrochloride dilates coronary arteries through an ATP-sensitive K(+)-channel opening mechanism in dogs. Liu Q, et al. **Cardiovasc Drugs Ther** 1996 Mar;10(1):23–30

Interactions of a new beta-blocker, celiprolol, with the calcium antagonists, diltiazem and nifedipine, on atrioventricular conduction. Motomura S, et al. **Cardiovasc Drugs Ther** 1995 Jun;9(3):445–57

Effects of beta-blockers on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts. Yoshida H, et al. **Cardiovasc Drugs Ther** 1996 Mar; 10(1):67–74

Adrenergic, insulin, and work interactions with adenosine's effects on in situ myocardial glucose uptake. Law WR, et al. **Cardiovasc Res** 1996 May;31(5):691–8

Studies on agents with vasodilator and beta-blocking activities. III. Synthesis and activity of optical isomers of TZC-1370. Seki T, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1719–23

Differential regulation of circulating Mg2+ in the rat by beta 1- and beta 2-adrenergic receptor stimulation. Keenan D, et al. **Circ Res** 1995 Nov;77(5):973–83

Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions. Holubarsch C, et al. **Circulation** 1995 Nov 15;92(10):2904–10

Sensitization of human atrial 5-HT4 receptors by chronic beta-blocker treatment. Sanders L, et al. **Circulation** 1995 Nov 1;92(9):2526–39

Beta blockers in pregnancy and their effect on regional Doppler ultrasound and fetal weight. Crichton F. **Clin Exp Obstet Gynecol** 1996;23(1):15–7

Sympathetic regulation in rabbits with heart failure: experience using power spectral analysis of heart rate variability. Moguilevski V, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):475–7

Effects of lisinopril and bisoprolol on lipoprotein metabolism in patients with mild-to-moderate essential hypertension. Saku K, et al. **Clin Ther** 1995 Nov–Dec;17(6):1136–46

Stimulation of nonshivering thermogenesis in the Syrian hamster by norepinephrine and beta-selective adrenergic agents: a phenomenon of refractoriness. Dicker A, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jan;113(1):37–43

Propranolol suppression of ocular HSV-1 recurrence and associated corneal lesions following spontaneous reactivation in the rabbit. Kaufman HE, et al. **Curr Eye Res** 1996 Jun·15(6):680–4

Effects of timolol, terbutafine and forskolin on IOP, aqueous humour formation and ciliary cyclic AMP levels in the bovine eye. Shahidullah M, et al. **Curr Eye Res** 1995 Jul; 14(7):519–28

Activation of beta(3) adrenergic receptors suppresses leptin expression and mediates a leptin-independent inhibition of food intake in mice. Mantzoros CS, et al. **Diabetes** 1996 Jul;45(7):909–14

Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective beta-blocker. Vachiery F, et al. **Dig Dis Sci** 1996 Sep;41(9):1722–6

Too many beta-blockers. **Drug Ther Bull** 1996 Jul;34(7):49–52 (37 ref.)

Beta-adrenergic mechanisms in the nasal mucosa vascular bed. Lacroix JS, et al. **Eur Arch Otorhinolaryngol** 1995; 252(5):298–303

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Feuerstein GZ, et al. **Eur Heart J** 1996 Apr;17 Suppl B:24–9 (24 ref.)

Pathophysiological targets for beta-blocker therapy in congestive heart failure. Just H. **Eur Heart J** 1996 Apr;17 Suppl B:2–7

Cardiac adrenergic receptor effects of carvedilol. Yoshikawa T, et al. **Eur Heart J** 1996 Apr;17 Suppl B:8–16 (37 ref.)

Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. Heinemann L, et al. **Eur J Clin Invest** 1995 Aug;25(8):595–600

Pharmacological effects of concomitant administration of beta-adrenoceptor blocker and agonist in normal subjects: characterization by heart rate response to exercise. Effects of beta-blocker combined with beta-agonist. Karita M, et al. **Eur J Clin Pharmacol** 1995;48(6):467–71

Rapid increase in plasma nitrite concentration following intravenous administration of nipradilol. Adachi T, et al. **Eur J Pharmacol** 1995 Nov 14;286(2):201–4

Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Yue TL, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):585–91

The effect of topical beta-adrenoceptor blocking agents on pulsatile ocular blood flow. Morsman CD, et al. **Eye** 1995; 9 (Pt 3):344–7

Doppler ultrasonography of the central retinal artery in patients with diabetes and vascular disease treated with topical timolol. Steigerwalt RD Jr, et al. **Eye** 1995;9 (Pt 4):495–501

Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines. Benschop RJ, et al. **FASEB J** 1996 Mar;10(4):517–24

Beta 3-adrenoceptors and intestinal motility. Manara L, et al. **Fundam Clin Pharmacol** 1995;9(4):332–42 (70 ref.)

Effect of bupranolol on CGP 12177-induced relaxation and cAMP accumulation in the guinea pig taenia caecum. Koike K, et al. **Gen Pharmacol** 1995 Dec;26(8):1791–4

Inhibition of rats adjuvant arthritis by a bradykinin antagonist Hoe 140 and its influence on kallikreins. Sharma JN, et al. **Gen Pharmacol** 1996 Jan;27(1):133–6

Evidence for a dual effect of acebutolol, a beta blocker, on the mouse humoral immune response. In S, et al. **Immunopharmacol Immunotoxicol** 1995 Aug;17(3):529–50

Topical timolol and lipid profile. Manoher JM, et al. **Indian J Ophthalmol** 1995 Jun;43(2):73–4

Hypotensive effect of intracerebroventricular injection of norepinephrine and its modulation by alpha and beta adrenergic blockers in conscious rabbits. Krishna B, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):361–8

Lack of a role for bradykinin in allergen-induced airway microvascular leakage and bronchoconstriction in the guinea pig. Sakamoto T, et al. **Inflamm Res** 1996 Mar; 45(3):123–6

Catecholamine and beta-adrenoceptor influences on airway reactivity to antigen in guinea pigs. Underwood DC, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):286–94

Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Blier P, et al. **Int Clin Psychopharmacol** 1996 Mar;11(1):37–44

beta-blockade, atrial natriuretic peptide and exercise. Kantola I, et al. **Int J Clin Pharmacol Ther** 1996 Jan;34(1):12–6

Effects of acute non-selective beta-adrenergic blockade on plasma ammonia levels in exercising dogs. Matthys D, et al. **Int J Sports Med** 1995 Aug;16(6):373–7

The effect of beta-adrenergic blockade on non-esterified fatty acid uptake of exercising skeletal muscle during arm cranking. Schrauwen P, et al. **Int J Sports Med** 1995 Oct; 16(7):439–44

Functional, angiographic and intracoronary Doppler flow characteristics in symptomatic patients with myocardial bridging: effect of short-term intravenous beta-blocker medication. Schwarz ER, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1637–45

Interactions of the cardiac chronotropic effects of rilmenidine with the autonomic nervous system in conscious dogs: comparison with clonidine. Boucher M, et al. **J Auton Pharmacol** 1996 Feb;16(1):13–20

Chronic administration of oxprenolol and metoprolol attenuate sympathetic cardiovascular responses only in non-adrenalectomized pithed rats. Vila E, et al. **J Auton Pharmacol** 1995 Oct;15(5):393–402

Reduced ambulatory heart rate response to physical work and complaints of fatigue among hypertensive males treated with beta-blockers. Kristal-Boneh E, et al. **J Behav Med** 1995 Apr;18(2):113–26

Dose-effect and kinetic-dynamic relationships of the beta-adrenoceptor blocking properties of various doses of talinolol in healthy humans. de Mey C, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):879–8

Different actions between pindolol and propranolol on the ionic currents in spontaneously beating rabbit sino-atrial node cells. Satoh H. **J Cardiovasc Pharmacol** 1995 Jun; 25(6):967–72

Effects of angiotensin-converting enzyme inhibition versus

beta-adrenergic blockade on aortic stiffness in essential hypertension. Savolainen A, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):99-104

Sertraline does not alter the beta-adrenergic blocking activity of atenolol in healthy male volunteers. Ziegler MG, et al. **J Clin Psychiatry** 1996;57 Suppl 1:12-5

Multiple mechanisms of heterologous beta-adrenoceptor regulation in rat uterus. Nimmo AJ, et al. **J Endocrinol** 1995 Nov;147(2):303-9

Protective effects of propranolol on experimentally head-injured mouse brains. Liu MY. **J Formos Med Assoc** 1995 Jul;94(7):386-90

Weakness of mucosal barrier in portal hypertensive gastropathy of alcoholic cirrhosis. Effects of propranolol and enprostil. Payen JL, et al. **J Hepatol** 1995 Dec; 23(6):689-96

Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. Jacob S, et al. **J Hypertens** 1996 Apr;14(4):489-94

Acute administration of metoprolol and enalaprilat reduces insulin-stimulated thermogenesis and skin blood flow. Tuominen JA, et al. **J Intern Med** 1996 May;239(5):399-406

Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by selective alpha- and beta-adrenergic drugs in mice. Elenkov IJ, et al. **J Neuroimmunol** 1995 Sep;61(2):123-31

Beta-blockade enhances adrenergic immunosuppression in rats via inhibition of melatonin release. Liebmann PM, et al. **J Neuroimmunol** 1996 Jul;67(2):137-42

Drug effects on intraocular pressure and vascular flow in the bovine perfused eye using radiolabelled microspheres. Millar JC, et al. **J Ocul Pharmacol Ther** 1995 Spring; 11(1):11-23

Vaninolol: a novel compound for the treatment of glaucoma and ischemic retinopathy. Wu BN, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):213-20

Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. Cockcroft JR, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1067-71

Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. Ma XL, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):128-36

Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle. Muraki K, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):555-63

Propranolol inhibits the spontaneous closure of the ductus arteriosus in newborn rats. Arishima K, et al. **J Vet Med Sci** 1995 Oct;57(5):943-4

Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction [see comments] Edeki TI, et al. **JAMA** 1995 Nov 22-29;274(20):1611-3. Comment in: JAMA 1996 Apr 3;275(13):985; discussion 986.

Excessive beta-blockade with timolol eye drops [letter; comment] Kalenak JW. **JAMA** 1996 Apr 3;275(13):985; discussion 986. Comment on: JAMA 1995 Nov 22-29;274(20):1611-3.

Excessive beta-blockade with timolol eye drops [letter; comment] Novack GD. **JAMA** 1996 Apr 3;275(13):985; discussion 986. Comment on: JAMA 1995 Nov 22-29;274(20):1611-3.

Antioxidative action of the beta-adrenoceptor antagonist bopindolol and its metabolite 18-502. Aniya Y, et al. **Jpn J Pharmacol** 1995 Jul;68(3):323-9

Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular beta-blocker, in dogs. Polgar P, et al. **Life Sci** 1995;56(14):1207-13

Comparison of two bolus doses of esmolol for attenuation of haemodynamic response to tracheal intubation. Sharma S, et al. **Med J Malaysia** 1995 Dec;50(4):372-6

Plasma catecholamine and ventilatory responses to cycling after propranolol treatment. Schneider DA, et al. **Med Sci Sports Exerc** 1995 Dec;27(12):1616-20

Metabolic and hormonal responses to adrenoceptor antagonists in 48-hour-starved exercising rats. Benthem L, et al. **Metabolism** 1995 Oct;44(10):1332-9

Effects of the beta-adrenergic blockers propranolol and acebutolol on stress-induced learned helplessness behavior of rats. Danchev N, et al. **Methods Find Exp Clin Pharmacol** 1995 Sep;17(7):463-7

Microwave-induced lethal heat stress: effects of phentolamine, prazosin and metoprolol. Jauchem JR, et al. **Methods Find Exp Clin Pharmacol** 1995 May;17(4):241-8

Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Schmitz W, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):251-8 (91 ref.)

Functional studies of the first selective beta 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes. Nisoli E, et al. **Mol Pharmacol** 1996 Jan;49(1):7-14

New systematically active antimycotics from the beta-blocker category. Hänel H, et al. **Mycoses** 1995 Jul-Aug;38(7-8):251-64

Beta-adrenoceptor antagonists suppress elevation in body temperature and increase in plasma IL-6 in rats exposed to open field. Soszynski D, et al. **Neuroendocrinology** 1996 May;63(5):459-67

Effect of drugs on chemoreceptor responsiveness in fetal sheep. Boekkooi PF, et al. **Pediatr Res** 1995 Dec; 38(6):938-43

Sleep and waking in 5,7-DHT-lesioned or (-)-pindolol-pretreated rats after administration of buspirone, ipsapirone, or gepirone. Monti JM, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):305-12

The inhibitory effects of propranolol on genital reflexes in male rats. Smith ER, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):541-6

Comparison of coronary microvascular response to nipradilol and nitroglycerin. Lamping KG, et al. **Pharmacology** 1995 Nov;51(5):315-22

Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Lopez BL, et al. **Pharmacology** 1995 Sep;51(3):165-73

Effects of beta adrenergic receptor blockade on hemodynamic changes associated with obstructive sleep apnea. Kirby DA, et al. **Physiol Behav** 1995 Nov; 58(5):919-23

Concurrent blockade of beta-adrenergic and muscarinic receptors disrupts working memory but not reference memory in rats. Kobayashi M, et al. **Physiol Behav** 1995 Aug;58(2):307-14

Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men. Meltzer HY, et al. **Psychiatry Res** 1995 Sep 29;58(2):89-98

Adrenergic blockade ameliorates cellular immune responses to mental stress in humans. Bachen EA, et al. **Psychosom Med** 1995 Jul-Aug;57(4):366-72

[Effect of puerarin on cerebral blood flow in dogs] Chen L, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep; 20(9):560-2, inside backcover (Eng. Abstr.) (Chi)

[Prevention of increase of blood pressure and intracranial pressure during endotracheal intubation in neurosurgery: esmolol versus lidocaine] Samaha T, et al. **Ann Fr Anesth Reanim** 1996;15(1):36-40 (Eng. Abstr.) (Fre)

[Effect of a beta-agonist and a beta-agonist/beta-antagonist combination on muscle growth, body composition and protein metabolism in rats] Reichel K, et al. **Arch Tierernahr** 1993;45(3):211-25 (Eng. Abstr.) (Ger)

[Effect of topical adrenergic agents on tissue circulation in human optic nerve head evaluated with a laser speckle microcirculation analyser] Tamaki Y, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jan;100(1):55-62 (Eng. Abstr.) (Jpn)

[Effects of amosulalol hydrochloride on intraocular pressure and aqueous humor dynamics in the rabbit eye] Taniguchi T, et al. **Nippon Ganka Gakkai Zasshi** 1996 Apr; 100(4):279-83 (Eng. Abstr.) (Jpn)

[Analysis of the effect of anapriline on circulatory system function] Syrenskiĭ AV, et al. **Biull Eksp Biol Med** 1995 May;119(5):510-2 (Rus)

[Poststress lesions of the gastric mucosa in inbred mice after the peripheral administration of cyproheptadine and propranolol] Koriakina LA. **Fiziol Zh Im I M Sechenova** 1995 Feb;81(2):19-25 (Eng. Abstr.) (Rus)

[The effect of beta-adrenoblockaders on the lipid composition of the blood] Veĭkin AK, et al. **Ter Arkh** 1995; 67(8):30-3 (28 ref.) (Rus)

[Adrenergic betablockers] Alvarez Sabín J. **Rev Neurol** 1995; 23 Suppl 2:S185-9 (23 ref.) (Spa)

POISONING

Hemodynamic effects of calcium chloride in a canine model of acute propranolol intoxication. Love JN, et al. **Ann Emerg Med** 1996 Jul;28(1):1-6

Reduced survival after isoprenaline/dopamine in d,l-propranolol intoxicated rats. Toet AE, et al. **Hum Exp Toxicol** 1996 Feb;15(2):120-8

Relative toxicity of beta blockers in overdose. Reith DM, et al. **J Toxicol Clin Toxicol** 1996;34(3):273-8

THERAPEUTIC USE

A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension. Fristrom B. **Acta Ophthalmol Scand** 1996 Apr;74(2):140-4

Influence of the beta-blocker therapy on neutrophil superoxide generation and platelet aggregation in experimental myocardial ischemia and reflow. Röth E, et al. **Acta Physiol Hung** 1995;83(2):163-70

Second-line and 'alternative' treatments for alcohol withdrawal: alpha-agonists, beta-blockers, anticonvulsants, acupuncture and neuro-electric therapy. Brewer C. **Alcohol Alcohol** 1995 Nov;30(6):799-803 (25 ref.)

Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction. CONSENSUS II multiecho study group. Bonarjee VV, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):71-7

Clinical assessment of adrenergic tone and responsiveness to beta-blocker therapy in patients with symptomatic ventricular tachycardia and no apparent structural heart disease. Brodsky MA, et al. **Am Heart J** 1996 Jan; 131(1):51-8

Suppression of ventricular tachycardia by sotalol in myotonic dystrophy. Cohen MB, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):446-9

Efficacy of pindolol for treatment of vasovagal syncope. Cohen MB, et al. **Am Heart J** 1995 Oct;130(4):786-90

Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Krum H, et al. **Am Heart J** 1996 Feb;131(2):337-41

Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. Mahanonda N, et al. **Am Heart J** 1995 Dec;130(6):1250-3

Holter-guided identification of premature ventricular contractions susceptible to suppression by beta-blockers. Pitzalis MV, et al. **Am Heart J** 1996 Mar;131(3):508-15

Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure. Yoshikawa T, et al. **Am Heart J** 1996 Feb;131(2):329-36

Effect of beta blockade on heart rate variability during vessel occlusion at the time of coronary angioplasty. Airaksinen KE, et al. **Am J Cardiol** 1996 Jan 1;77(1):20-4

Usefulness of heart rate variability in predicting drug efficacy (metoprolol vs diltiazem) in patients with stable angina pectoris. Brouwer J, et al. **Am J Cardiol** 1995 Oct 15; 76(11):759-63

Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Jonas M, et al. **Am J Cardiol** 1996 Jun 15; 77(15):1273-7

Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. Kontopoulos AG, et al. **Am J Cardiol** 1996 Feb 1;77(4):242-6

Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure. Kukin ML, et al. **Am J Cardiol** 1996 Mar 1;77(7):486-91

Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test. Sheldon R, et al. **Am J Cardiol** 1996 Sep 1;78(5):536-9

Meta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic or ischemic dilated cardiomyopathy. Zarembski DG, et al. **Am J Cardiol** 1996 Jun 1;77(14):1247-50

Timolol hemihydrate vs timolol maleate to treat ocular hypertension and open-angle glaucoma. DuBiner HB, et al. **Am J Ophthalmol** 1996 May;121(5):522-8

A management trial for Duchenne cardiomyopathy. Ishikawa Y, et al. **Am J Phys Med Rehabil** 1995 Sep-Oct; 74(5):345-50

A study of the combined haemodynamic effects of dobutamine and enoximone in patients taking beta adrenoceptor antagonists. Harvey WR, et al. **Anaesth Intensive Care** 1995 Dec;23(6):673-7

Esmolol aids extubation in intensive care patient with ischaemic pulmonary oedema. Duane DT, et al. **Anaesthesia** 1996 May;51(5):474-7

The effect of esmolol pretreatment on the incidence of regional wall motion abnormalities during electroconvulsive therapy [see comments] O'Connor CJ, et al. **Anesth Analg** 1996 Jan;82(1):143-7. Comment in: Anesth Analg 1996 Jul;83(1):199.

Hemodilution tolerance in patients with coronary artery disease who are receiving chronic beta-adrenergic blocker therapy. Spahn DR, et al. **Anesth Analg** 1996 Apr; 82(4):687-94

Sotalol prophylaxis and treatment of atrial fibrillation. Pill MW, et al. **Ann Pharmacother** 1996 Apr;30(4):399-401

Comparison of the ocular beta-blockers. Sorensen SJ, et al. **Ann Pharmacother** 1996 Jan;30(1):43-54 (85 ref.)

Beta-blockers in hypertensive and coronary heart disease. Goldstein S. **Arch Intern Med** 1996 Jun 24;156(12):1267-76 (89 ref.)

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study [see comments] Mishima HK, et al. **Arch Ophthalmol** 1996 Aug;114(8):929-32. Comment in: Arch Ophthalmol 1996 Aug;114(8):998-9.

Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Rácz P, et al. **Arch Ophthalmol** 1996 Mar;114(3):268-73

A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group. Stewart WC, et al. **Arch Ophthalmol** 1996 Aug;114(8):938-42

Different hemodynamic effects of celipropol and atenolol in patients with mild to moderate hypertension. Saner H, et al. **Arzneimittelforschung** 1995 Jul;45(7):790-5

Combination monoamine oxidase inhibitor and beta-blocker treatment of migraine, with anxiety and depression. Merikangas KR, et al. **Biol Psychiatry** 1995 Nov 1; 38(9):603-10

Cost-benefit aspects of treatment of hypertension in the elderly. Lindholm LH, et al. **Blood Press** 1995;Suppl 3:11-4

To beta block or better block? [editorial] [see comments] Brown MJ. **BMJ** 1995 Sep 16;311(7007):701-2. Comment in: BMJ 1995 Dec 2;311(7018):1501-2.

Increasing prescription of drugs for secondary prevention of myocardial infarction. Authors' recommendations are too restrictive [letter; comment] Sapsford RJ, et al. **BMJ** 1996 Jan 27;312(7025):252. Comment on: BMJ 1995 Oct 7;311(7010):917-8.

Increasing prescription of drugs for secondary prevention after myocardial infarction [see comments] Smith J, et al.

BMJ 1995 Oct 7;311(7010):917–8. Comment in: BMJ 1996 Jan 27;312(7025):252.

Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol. Persson H, et al. **Br Heart J** 1995 Aug;74(2):140–8

Reductions in muscle sympathetic nerve activity after long-term metoprolol for dilated cardiomyopathy: preliminary observations. Rahman MA, et al. **Br Heart J** 1995 Oct;74(4):431–6

Metoprolol treatment for two years after coronary bypass grafting: effects on exercise capacity and signs of myocardial ischaemia. Sjöland H, et al. **Br Heart J** 1995 Sep;74(3):235–41

Use of esmolol in a parturient with hypertrophic obstructive cardiomyopathy. Fairley CJ, et al. **Br J Anaesth** 1995 Dec; 75(6):801–4

Reduction by beta-adrenoceptor blockade of hypoxia-induced right heart hypertrophy in the rat. Ostman-Smith I. **Br J Pharmacol** 1995 Nov; 116(6):2698–702

Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure-overload in the rat. Ostman-Smith I. **Br J Pharmacol** 1995 Nov;116(6):2703–9

Beneficial effect of long-term use of a beta-blocker in patients before acute myocardial infarction. Bortolotto LA, et al. **Braz J Med Biol Res** 1995 Jun;28(6):637–42

The place of beta-blockers in cardiovascular medicine. Cruickshank JM. **Cardiologia** 1995 Nov;40(11):829–43 (81 ref.)

Prophylactic treatment of migraine: evaluation of clinical trials and choice among drugs. Tfelt-Hansen P. **Cephalalgia** 1995 Oct;15 Suppl 15:29–32 (15 ref.)

Diurnal variation of ischemic response to exercise in patients receiving a once-daily dose of beta-blockers. Implications for exercise testing and prescription of exercise and training heart rates. Franklin BA, et al. **Chest** 1996 Jan;109(1):253–7

Effect of carvedilol on mortality and morbidity in patients with chronic heart failure [news] **Circulation** 1996 Aug 15; 94(4):592

Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy. Andersson B, et al. **Circulation** 1996 Aug 15;94(4):673–82

Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients. Tuininga YS, et al. **Circulation** 1995 Dec 15;92(12):3415–23

The effect of beta-blockade therapy on the response to exercise training in postmyocardial infarction patients. Pavia L, et al. **Clin Cardiol** 1995 Dec;18(12):716–20

Treatment of silent ischemia in unstable angina: a randomized comparison of sustained-release verapamil versus metoprolol. Singh N, et al. **Clin Cardiol** 1995 Nov; 18(11):653–8

Low circulating IGF-I levels in hyperthyroidism are associated with decreased GH response to GH-releasing hormone. Ramos-Dias JC, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):583–9

Effects of chronic treatment with carvedilol on abnormalities of endothelium-dependent relaxation and structure of endothelium in resistance arteries of SHRSP. Sasaki F, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S329–30

Efficacy of long-term treatment with nipradilol, a nitroester-containing beta-blocker, in patients with mild-to-moderate essential hypertension. Haneda T, et al. **Clin Ther** 1995 Jul-Aug;17(4):667–79

The actions of talinolol, a beta 1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction. Assmann I. **Curr Med Res Opin** 1995;13(6):325–42 (43 ref.)

Too many beta-blockers. **Drug Ther Bull** 1996 Jul;34(7):49–52 (37 ref.)

Drug treatment of esophageal variceal bleeding: alternative or supplement to endoscopic therapy? Zoller WG, et al. **Endoscopy** 1995 Oct;27(8):616–21 (65 ref.)

Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. The MACB Study Group. **Eur Heart J** 1995 Dec; 16(12):1825–32

Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Bristow MR, et al. **Eur Heart J** 1995 Jul; 16 Suppl F:20–31 (93 ref.)

Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Dargie HJ, et al. **Eur Heart J** 1996 Jan;17(1):104–12

Protective effect of beta-blockade on dipyridamole-induced myocardial ischaemia. Role of heart rate. Ferrara N, et al. **Eur Heart J** 1995 Jul;16(7):903–8

The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Fox KM, et al. **Eur Heart J** 1996 Jan;17(1):96–103

Beta-blockers in heart failure--the evidence from clinical trials. Hampton JR. **Eur Heart J** 1996 Apr;17 Suppl B:17–20 (23 ref.)

Pathophysiological targets for beta-blocker therapy in congestive heart failure. Just H. **Eur Heart J** 1996 Apr;17 Suppl B:2–7

Effects of amlodipine on transient myocardial ischaemia in patients with a severe coronary condition treated with a beta-blocker. Amlor-Holter Study Investigators [see comments] Madjlessi-Simon T, et al. **Eur Heart J** 1995 Dec;16(12):1780–8. Comment in: Eur Heart J 1995 Dec;16(12):1754–6.

Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease. Packer M. **Eur Heart J** 1996 Apr;17 Suppl B:21–3 (23 ref.)

Beta adrenergic blockade does not improve effort tolerance in patients with mitral stenosis in sinus rhythm. Patel JJ, et al. **Eur Heart J** 1995 Sep;16(9):1264–8

Vasodilating beta-blockers in heart failure. Raftery EB. **Eur Heart J** 1995 Jul;16 Suppl F:32–7

The preventative effects of vasodilating beta-blockers in cardiovascular disease. Raftery EB. **Eur Heart J** 1996 Apr; 17 Suppl B:30–8

Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Rehnqvist N, et al. **Eur Heart J** 1996 Jan; 17(1):76–81

Calcium channel blockers or beta receptor antagonists for patients with ischaemic heart disease. What is the best choice? [editorial] Rydén L, et al. **Eur Heart J** 1996 Jan; 17(1):1–3

Beta-blockers in heart failure. Future directions. Sharpe N. **Eur Heart J** 1996 Apr;17 Suppl B:39–42 (23 ref.)

Adrenergic beta-blocking agents in congestive heart failure due to idiopathic dilated cardiomyopathy. Waagstein F. **Eur Heart J** 1995 Dec;16 Suppl O:128–32 (37 ref.)

A cross-over trial comparing once daily levobunolol with once and twice daily timolol. Akafo SK, et al. **Eur J Ophthalmol** 1995 Jul-Sep;5(3):172–6

Propranolol reduces the anxiety associated with day case surgery. Mealy K, et al. **Eur J Surg** 1996 Jan;162(1):11–4

The role of renal dopamine in the reduction of high blood pressure by beta 1-selective beta-blocker with intrinsic sympathomimetic activity in spontaneously hypertensive rats. Haneda T, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S215–9

A diuretic is more effective than a beta-blocker in hypertensive patients not controlled on amlodipine and lisinopril. Antonios TF, et al. **Hypertension** 1996 Jun; 27(6):1325–8

Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. Koh KK, et al. **Int J Cardiol** 1995 Nov 24;52(2):167–74

Serial administration of adrenergic antagonist and agonist ("pulsatile therapy") reduces the incidence of long-term drift to timolol in humans. Gandolfi SA, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):684–8

Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction [see comments] Brand DA, et al. **J Am Coll Cardiol** 1995 Nov 15;26(6):1432–6. Comment in: J Am Coll Cardiol 1995 Nov 15;26(6):1437–9.

Carvedilol therapy in heart failure--II [letter; comment] Carbajal EV. **J Am Coll Cardiol** 1995 Nov 1; 26(5):1399–400; discussion 1400–1. Comment on: J Am Coll Cardiol 1995 May;25(6):1225–31.

Carvedilol therapy in heart failure--I [letter; comment] Ghali JK. **J Am Coll Cardiol** 1995 Nov 1;26(5):1399; discussion 1400–1. Comment on: J Am Coll Cardiol 1995 May;25(6):1225–31.

Long-term beta-blocker treatment prevents chronic creatine kinase and lactate dehydrogenase system changes in rat hearts after myocardial infarction. Laser A, et al. **J Am Coll Cardiol** 1996 Feb;27(2):487–93

Carvedilol therapy in heart failure--III [letter; comment] Lee YC. **J Am Coll Cardiol** 1995 Nov 1;26(5):1400–1. Comment on: J Am Coll Cardiol 1995 May;25(6):1225–31.

Persistent transient myocardial ischemia despite beta-adrenergic blockade predicts a higher risk of adverse cardiac events in patients with coronary artery disease. Madjlessi-Simon T, et al. **J Am Coll Cardiol** 1996 Jun; 27(7):1586–91

Are beta-blockers really underutilized in postinfarction patients? [editorial; comment] O'Rourke RA. **J Am Coll Cardiol** 1995 Nov 15;26(6):1437–9. Comment on: J Am Coll Cardiol 1995 Nov 15;26(6):1432–6.

Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. Savonitto S, et al. **J Am Coll Cardiol** 1996 Feb; 27(2):311–6

Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. Shimizu W, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1299–309

Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up. Von Arnim T. **J Am Coll Cardiol** 1996 Jul; 28(1):20–4

Prevalence of use of beta blockers and of calcium channel blockers in older patients with prior myocardial infarction at the time of admission to a nursing home. Aronow WS. **J Am Geriatr Soc** 1996 Sep;44(9):1075–7

Long-term survival and use of antihypertensive medications in older persons [see comments] Pahor M, et al. **J Am Geriatr Soc** 1995 Nov;43(11):1191–7. Comment in: J Am Geriatr Soc 1995 Nov;43(11):1309–10. Comment in: J Am Geriatr Soc 1996 Jul;44(7):881–2.

Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. Rousseau MF, et al. **J Card Fail** 1996 Mar;2(1):15–23

New directions in the treatment of heart failure: some paradoxical observations. Merin RG. **J Card Surg** 1995 Jul; 10(4 Suppl):509–13

Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia. Antz M, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):627–35

Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. Maggi E, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):532–8

Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. Morel Y, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):306–11

The effects of beta 1-adrenergic blockade on the growth response to growth hormone (GH)-releasing hormone therapy in GH-deficient children. Cassorla F, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2997–3001

Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. Horwitz RI, et al. **J Clin Epidemiol** 1996 Apr;49(4):395–400

Preventing sudden cardiac death: the impact of beta-blockers on the brain [editorial] Townend JN, et al. **J Clin Pharm Ther** 1995 Dec;20(6):307–10

Individuals who swallow crack cocaine do not develop significant toxic reactions [letter; comment] Hollander JE. **J Emerg Med** 1995 Jul-Aug;13(4):538–9; discussion 539–43 . Comment on: J Emerg Med 1994 Jul-Aug;12(4):485–90.

Effect of beta-blockade on chronic heart failure. Bloomenthal R. **J Fam Pract** 1996 Aug;43(2):116–7

Medium-term effects of betaxolol monotherapy and combination therapy with nitrendipine on lipoprotein and apolipoprotein metabolism in patients with mild to moderate essential hypertension. Saku K, et al. **J Hum Hypertens** 1996 Apr;10(4):263–8

Treatment of hypertension in the elderly. Lever AF, et al. **J Hypertens** 1995 Jun;13(6):571–9 (44 ref.)

Efficacy of an adenosine antagonist, theophylline, in essential tremor: comparison with placebo and propranolol. Mally J, et al. **J Neurol Sci** 1995 Oct;132(2):129–32

Intraocular pressure after a two-week washout following long-term timolol or levobunolol. Hong YJ, et al. **J Ocul Pharmacol Ther** 1995 Summer;11(2):107–12

Effect of selected beta-blockers on supragingival calculus formation. Breuer MM, et al. **J Periodontol** 1996 Apr; 67(4):428–32

The use of corticosteroid/beta-blocker combinations in the management of regression after PRK for high myopia. MacRobert IJ, et al. **J Refract Surg** 1995 May-Jun;11(3 Suppl):S321–6

Esmolol and percutaneous cardiopulmonary bypass enhance myocardial salvage during ischemia in a dog model. Laub GW, et al. **J Thorac Cardiovasc Surg** 1996 May; 111(5):1085–91

Medical control of abdominal aortic aneurysm expansion rate [letter] Schneiderman J, et al. **J Vasc Surg** 1996 Aug; 24(2):297

Interaction of epinephrine and beta-blockers. Jay GT, et al. **JAMA** 1995 Dec 20;274(23):1830, 1832

Rationale for treatment of patients with chronic heart failure with adrenergic blockade. Sackner-Bernstein JD, et al. **JAMA** 1995 Nov 8;274(18):1462–7 (71 ref.)

Carvedilol for heart failure, with care. Cleland JG, et al. **Lancet** 1996 May 4;347(9010):1199–201

Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis [see comments] Feu F, et al. **Lancet** 1995 Oct 21;346(8982):1056–9. Comment in: Lancet 1995 Oct 21;346(8982):1046–7.

Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. van Essen GG, et al. **Lancet** 1996 Jan 13;347(8994):94–5

A sustained increase in beta-adrenoceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy. Yamada S, et al. **Life Sci** 1996;58(20):1737–44

A new approach to antiviral therapy. Peuschel KE. **Med Hypotheses** 1995 Oct;45(4):375–9

Beta-blockers in chronic heart failure: paradox proven? [editorial] Krum H. **Med J Aust** 1996 May 20;164(10):581–2

Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Schmitz W, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):251–8 (91 ref.)

Clinical problem-solving: mitral stenosis--silent? [letter; comment] Baker DW. **N Engl J Med** 1996 Jan 4;334(1):58 . Comment on: N Engl J Med 1995 Sep 7;333(10):648–52.

Cocaine-associated myocardial ischemia [letter] Blaho K, et al. **N Engl J Med** 1996 Feb 22;334(8):536; discussion 536–7

Cocaine-associated myocardial ischemia [letter; comment] Derlet RW, et al. **N Engl J Med** 1996 Feb 22;334(8):535–6; discussion 536–7. Comment on: N Engl J Med 1995 Nov

9;333(19):1267–72.
Trandolapril in patients with left ventricular dysfunction after myocardial infarction [letter; comment] Neumayr G, et al. **N Engl J Med** 1996 Jun 6;334(23):1546. Comment on: N Engl J Med 1995 Dec 21;333(25):1670–6.
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group [see comments] Packer M, et al. **N Engl J Med** 1996 May 23;334(21):1349–55. Comment in: N Engl J Med 1996 May 23;334(21):1396–7.
Beta-adrenergic blockers and survival in heart failure [editorial; comment] Pfeffer MA, et al. **N Engl J Med** 1996 May 23;334(21):1396–7. Comment on: N Engl J Med 1996 May 23;334(21):1349–55.
Cocaine-associated myocardial ischemia [letter; comment] Rajput V, et al. **N Engl J Med** 1996 Feb 22;334(8):536; discussion 536–7. Comment on: N Engl J Med 1995 Nov 9;333(19):1267–72.
Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. Villanueva C, et al. **N Engl J Med** 1996 Jun 20; 334(25):1624–9
Regional variation across the United States in the management of acute myocardial infarction [letter; comment] Viskin S, et al. **N Engl J Med** 1996 Jan 18; 334(3):194; discussion 194–5. Comment on: N Engl J Med 1995 Aug 31;333(9):565–72.
Propranolol or sclerotherapy to prevent variceal rebleeding. Dwivedi M, et al. **Natl Med J India** 1995 Sep–Oct;8(5):222
New arguments in favour of cardioselective beta-blockers [letter] Cleophas TJ, et al. **Neth J Med** 1995 Dec; 47(6):308–10
Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Carpentier AF, et al. **Neurology** 1996 Jun;46(6):1548–51
Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Camras CB. **Ophthalmology** 1996 Jan;103(1):138–47
The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group. Strahlman ER, et al. **Ophthalmology** 1996 Aug;103(8):1283–93
A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Watson P, et al. **Ophthalmology** 1996 Jan;103(1):126–37
Effect of beta adrenergic receptor blockade on cardiac autonomic tone in patients with chronic stable angina. Burger AJ, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):411–7
Beta2-adrenergic agents in asthma. Turcios NL. **Pediatr Rev** 1996 Mar;17(3):103–4
Current perspectives on beta-receptor antagonists in the treatment of symptomatic ventricular dysfunction. Adams KF Jr. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):69S–77S (46 ref.)
A perspective on the ESVEM trial current knowledge: sotalol should not be the first-line agent in the management of ventricular arrhythmias. Garan H. **Prog Cardiovasc Dis** 1996 May–Jun;38(6):455–6
Management of patients with life-threatening sustained ventricular tachyarrhythmias—the role of guided antiarrhythmic drug therapy. Steinbeck G, et al. **Prog Cardiovasc Dis** 1996 May–Jun;38(6):419–28
Pharmacological therapy for portal hypertension: rationale and results. Burroughs AK, et al. **Semin Gastrointest Dis** 1995 Jul;6(3):148–64 (148 ref.)
The efficacy of amrinone or adrenaline on low cardiac output following cardiopulmonary bypass in patients with coronary artery disease undergoing preoperative beta-blockade. Günnicker M, et al. **Thorac Cardiovasc Surg** 1995 Jun;43(3):153–60
[Glycemia increases during treatment of hypertension. 13 years' experience in the treatment of middle-aged men, randomized for treatment with beta blockers and diuretics] Válek J, et al. **Cas Lek Cesk** 1996 May 29;135(11):344–7 (Eng. Abstr.) **(Cze)**
[Betaxolol hydrochloride in the treatment of mild and medium hypertension—long-term effects] Souček M, et al. **Vnitr Lek** 1995 Sep;41(9):605–8 (Eng. Abstr.) **(Cze)**
[Should beta-adrenergic blockade be part of drug therapy for heart failure? (editorial)] Leinonen H. **Duodecim** 1995; 111(3):209–13 (18 ref.) **(Fin)**
[Beta blockers, calcium channel blockers and psyche] Strandberg T, et al. **Duodecim** 1994;110(4):397–402 (29 ref.) **(Fin)**
[Treatments of ischemic cardiopathies (IC) and modalities of prescription of aspirin in the three French MONICA centers in 1990] Cambou JP, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):578–86 (Eng. Abstr.) **(Fre)**
[Combination of celiprolol and amiodarone in the treatment of recurrent ventricular tachycardia] Tonet J, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jan;45(1):18–23 (Eng. Abstr.) **(Fre)**
[Hypertrophic cardiomyopathy: place and limitations of medical therapy] Desnos M, et al. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):573–5 (Eng. Abstr.) **(Fre)**
[Adrenergic betablockers and heart failure] Lechat P. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):611–5 (Eng. Abstr.) **(Fre)**
[Efficacy and tolerability of 2 presentations of eyedrops combining carteolol 2% and pilocarpine 2% in primary open-angle glaucoma and simple ocular hypertension] Sirbat D, et al. **J Fr Ophtalmol** 1995;18(10):589–96 (Eng. Abstr.) **(Fre)**
[Medical treatment of aortic aneurysms using beta-blockers] Chakkour K, et al. **J Mal Vasc** 1995;20(4):288–9 (Eng. Abstr.) **(Fre)**
[Medical treatment of aortic abdominal aneurysms. Outstanding questions] Cacoub P, et al. **Presse Med** 1996 Apr 20;25(14):683–5 (15 ref.) (Eng. Abstr.) **(Fre)**
[Carvedilol in cardiac decompensation] Dib J. **Rev Med Liege** 1996 Feb;51(2):198–200 **(Fre)**
[Beta-blockers in cardiac insufficiency. Time to reconsider? (editorial)] Follath F. **Schweiz Med Wochenschr** 1996 May 4;126(18):747–9 (12 ref.) **(Ger)**
[Esophageal varices. Drug treatment of recurrent bleeding and its prevention: beta blockers] Eigenmann F. **Schweiz Rundsch Med Prax** 1995 Dec 19;84(51–52):1544 **(Ger)**
[Beta blockers and diuretics: therapeutic drugs of first choice in diabetes mellitus and hypertension] Sawicki PT. **Wien Klin Wochenschr** 1995;107(21):629–39 (98 ref.) (Eng. Abstr.) **(Ger)**
[Beta receptor blockade in heart failure: a new look at an old topic (editorial)] Klein W. **Wien Med Wochenschr** 1996; 146(5):96–7 **(Ger)**
[Beta receptor blockers in chronic heart failure] Sigmund M, et al. **Z Kardiol** 1995 Oct;84(10):820–6 (74 ref.) (Eng. Abstr.) **(Ger)**
[Beta-blockers in congestive heart failure—a therapeutic paradox] Jonas M, et al. **Harefuah** 1995 Sep;129(5–6):192–7 (44 ref.) **(Heb)**
[Safety and tolerability of beta-blockers in severe cardiac decompensation from dilated cardiomyopathy] Sinagra G, et al. **G Ital Cardiol** 1995 Oct;25(10):1255–63 (Eng. Abstr.) **(Ita)**
[Balanced beta-–alpha-blocker treatment with carvedilol in mild-moderate arterial hypertension] Perocchio M, et al. **Minerva Cardioangiol** 1996 Mar;44(3):115–21 (Eng. Abstr.) **(Ita)**
[The relationship between the improvement of cardiac function and the myocardial uptake of I-123 metaiodobenzylguanidine in patients with dilated cardiomyopathy treated by beta-blocker] Wakita T, et al. **J Cardiol** 1995 Sep;26(3):177–83 (Eng. Abstr.) **(Jpn)**
[Coronary artery bypass grafting under bradycardia induced by ultra-short acting beta blocker] Miyamoto Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):801–5 (Eng. Abstr.) **(Jpn)**
[Sodium valproate versus propranolol in the prophylactic treatment of migraine] Kozubski W, et al. **Neurol Neurochir Pol** 1995 Nov–Dec;29(6):937–47 (Eng. Abstr.) **(Pol)**
[Use of beta-blockers in the treatment of chronic heart failure] Sutka J, et al. **Vnitr Lek** 1996 Jan;42(1):37–42 (30 ref.) (Eng. Abstr.) **(Slo)**
[Diuretics and beta-blockers as the first option in the treatment of arterial hypertension] Ferreira Montero IJ, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:66–71 (41 ref.) (Eng. Abstr.) **(Spa)**
[The effect of gallopamil and propranolol in patients with ischemic cardiopathy and moderate depression of ventricular function] Simarro E, et al. **Rev Esp Cardiol** 1995 Nov;48(11):741–5 (Eng. Abstr.) **(Spa)**

TOXICITY

Toxicokinetics of a single intravenous dose of rac-propranolol versus optically pure propranolol in the rat. Bode W, et al. **Chirality** 1995;7(8):626–31
The effects of extracellular ions on beta-blocker cardiotoxicity. Kerns W 2nd, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):1–7

URINE

Ion-pair chromatography and micellar electrokinetic capillary chromatography in analyzing beta-adrenergic blocking agents from human biological fluids. Lukkari P, et al. **J Chromatogr A** 1995 Nov 24;717(1–2):211–7
Selective extraction of beta-blockers from biological fluids by column-switching high-performance liquid chromatography using an internal-surface phenylboronic acid precolumn. Ohta T, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):168–73

ADRENERGIC BETA-RECEPTOR AGONISTS see **ADRENERGIC BETA-AGONISTS**

ADRENERGIC BETA-RECEPTOR BLOCKADERS see **ADRENERGIC BETA-ANTAGONISTS**

ADRENERGIC BETA-RECEPTORS see **RECEPTORS, ADRENERGIC, BETA**

ADRENERGIC BETA-1 RECEPTORS see **RECEPTORS, ADRENERGIC, BETA-1**

ADRENERGIC BETA-2 RECEPTORS see **RECEPTORS, ADRENERGIC, BETA-2**

ADRENERGIC-BLOCKING AGENTS see **ADRENERGIC ANTAGONISTS**

ADRENERGIC FIBERS

Basic innervation pattern and distribution of classic autonomic neurotransmitters in human nasal mucosal vasculature. Riederer A, et al. **Laryngoscope** 1996 Mar; 106(3 Pt 1):286–91
[Changes in adrenergic innervation of the choroid during aging] Nuzzi R, et al. **J Fr Ophtalmol** 1996;19(2):89–96 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Endogenous opioid peptides in parasympathetic, sympathetic and sensory nerves in the guinea-pig heart. Steele PA, et al. **Cell Tissue Res** 1996 May;284(2):331–9
Non-dopaminergic catecholaminergic neurons of mesencephalic and medullary nuclei contain different levels of dopamine. Alonso G, et al. **J Chem Neuroanat** 1995 Oct; 9(3):195–205

DRUG EFFECTS

Clinical assessment of adrenergic tone and responsiveness to beta-blocker therapy in patients with symptomatic ventricular tachycardia and no apparent structural heart disease. Brodsky MA, et al. **Am Heart J** 1996 Jan; 131(1):51–8
Modulation of somatocardiac sympathetic reflexes mediated by opioid receptors at the spinal and brainstem level. Sato A, et al. **Exp Brain Res** 1995;105(1):1–6
BMP-2 and BMP-4, but not BMP-6, increase the number of adrenergic cells which develop in quail trunk neural crest cultures. Varley JE, et al. **Exp Neurol** 1996 Jul; 140(1):84–94
Influence of diazepam on rat cardiac noradrenergic innervation in response to noise stress. Pellegrini A, et al. **In Vivo** 1995 May–Jun;9(3):211–4
Effect of metoclopramide on muscle sympathetic nerve activity in humans. Takeuchi Y, et al. **J Auton Nerv Syst** 1996 Apr 20;58(1–2):115–20
Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Sauer H, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8935–9

IMMUNOLOGY

Tyrosine hydroxylase- and nitric oxide synthase-immunoreactive nerve fibers in mitral valve of young adult and aged Fischer 344 rats. Jew JY, et al. **J Auton Nerv Syst** 1996 Apr 20;58(1–2):35–43
Noradrenergic system in the chicken brain: immunocytochemical study with antibodies to noradrenaline and dopamine-beta-hydroxylase. Moons L, et al. **J Comp Neurol** 1995 Sep 18;360(2):331–48

METABOLISM

Vasostatins, N-terminal products of chromogranin A, are released from the stimulated calf spleen in vitro. Liang F, et al. **Acta Physiol Scand** 1995 Sep;155(1):23–30
Chronic arthritis increases tyrosine hydroxylase mRNA levels in the pontine noradrenergic cell groups. Cho HJ, et al. **Brain Res** 1995 Oct 9;695(1):96–9
Nerve growth factor delivery by gene transfer induces differential outgrowth of sensory, motor, and noradrenergic neurites after adult spinal cord injury. Tuszynski MH, et al. **Exp Neurol** 1996 Jan;137(1):157–73
Histochemical demonstration of adrenergic nerves in the stroma of human cornea. Toivanen M, et al. **Invest Ophthalmol Vis Sci** 1987 Feb;28(2):398–400
Cardiac cells control transmitter release and calcium homeostasis in sympathetic neurons cultured from embryonic chick. Wakade AR, et al. **J Physiol (Lond)** 1995 Nov 1;488 (Pt 3):587–600

PHYSIOLOGY

Transcranial Doppler sonography in experimental Cushing response. Stępińska G, et al. **Acta Neurochir (Wien)** 1995; 133(1–2):80–2
Facilitation of the human nociceptive reflex by stimulation of A beta-fibres in a secondary hyperalgesic area sustained by nociceptive input from the primary hyperalgesic area. Andersen OK, et al. **Acta Physiol Scand** 1995 Sep; 155(1):87–97
Central blood volume influences sympathetic sudomotor nerve traffic in warm humans. Dodt C, et al. **Acta Physiol Scand** 1995 Sep;155(1):41–51
Endogenous NPY acting on the Y1 receptor accounts for the long-lasting part of the sympathetic contraction in guinea-pig vena cava: evidence using SR 120107A. Malmström RE, et al. **Acta Physiol Scand** 1995 Nov; 155(3):329–30
Septal lesions block sympathetic activation following frontal cortex stimulation in the rat. Monda M, et al. **Acta Physiol Scand** 1995 Nov;155(3):275–82
Sympathetic reinnervation of unilaterally denervated rat lung. Takachi T, et al. **Acta Physiol Scand** 1995 May; 154(1):43–50
Neuroendocrine insights from the laboratory to the clinic.

Ahlman H, et al. **Am J Surg** 1996 Jul;172(1):61–7 (40 ref.)
Involvement of bone morphogenetic protein–4 and bone morphogenetic protein–7 in the differentiation of the adrenergic phenotype in developing sympathetic neurons. Reissmann E, et al. **Development** 1996 Jul;122(7):2079–88
Properties of the ryanodine–sensitive release channels that underlie caffeine–induced Ca2+ mobilization from intracellular stores in mammalian sympathetic neurons. Hernández–Cruz A, et al. **Eur J Neurosci** 1995 Aug 1; 7(8):1684–99
Effects of chronic sympathetic stimulation on corneal wound healing. Perez E, et al. **Invest Ophthalmol Vis Sci** 1987 Feb;28(2):221–4
Altered beta–adrenergic and cholinergic pulmonary vascular responses after total cardiopulmonary bypass. Friedman M, et al. **J Appl Physiol** 1995 Dec;79(6):1998–2006
Sympathetic skin response and regeneration of sudomotor fibers after complete division of peripheral nerves. Ahčan U, et al. **J Auton Nerv Syst** 1996 Apr 20;58(1–2):69–75
Nitric oxide synthase–immunoreactive, adrenergic, cholinergic, and peptidergic nerves of the female rat urinary tract: a comparative study. Alm P, et al. **J Auton Nerv Syst** 1995 Dec 5;56(1–2):105–114
Renal sympathetic nerve responses to somato–sensory nerve stimulation in normotensive rats. Davis G, et al. **J Auton Nerv Syst** 1995 Jul 14;54(1):59–70
Adenosine activates cardiac sympathetic afferent fibers and potentiates the excitation induced by coronary occlusion. Gnecchi–Ruscone T, et al. **J Auton Nerv Syst** 1995 Jun 25;53(2–3):175–84
Monosynaptic projections from the medullary gigantocellular reticular formation to sympathetic preganglionic neurons in the thoracic spinal cord. Aicher SA, et al. **J Comp Neurol** 1995 Dec 25;363(4):563–580
Calcium–activated release of nitric oxide potentiates excitatory synaptic potentials in immature rat sympathetic preganglionic neurons. Wu SY, et al. **J Neurophysiol** 1995 Dec;74(6):2600–3
Effects of hypothalamic thermal stimuli on sympathetic neurones innervating skin and skeletal muscle of the cat hindlimb. Grewe W, et al. **J Physiol (Lond)** 1995 Oct 1; 488 (Pt 1):139–62
Adenosine–induced apoptosis in chick embryonic sympathetic neurons: a new physiological role for adenosine. Wakade TD, et al. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):123–38
Adrenergic regulation of the hypothalamic–pituitary–adrenal axis under basal and social stress conditions. Bugajski J, et al. **J Physiol Pharmacol** 1995 Sep;46(3):297–312
Cardiac adrenergic responses and electrophysiology during ischemia: effect of exercise. Hamra M, et al. **Med Sci Sports Exerc** 1995 Jul;27(7):993–1002
Cultured chick sympathetic neurons: ATP–induced noradrenaline release and its blockade by nicotinic receptor antagonists. Allgaier C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):25–30
Cultured chick sympathetic neurons: modulation of electrically evoked noradrenaline release by P2–purinoceptors. Allgaier C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):17–24
Developmental changes in the noradrenergic innervations of spinal motoneurons in neonatal rats. Tanaka H, et al. **Pediatr Neurol** 1996 Jan;14(1):21–7
Anaphylactic reactions to bee–sting challenges in allergic children are not modified by endogenous catecholamines. Hauk P, et al. **Pediatr Res** 1995 Dec;38(6):998–1002

ULTRASTRUCTURE

Noradrenergic system in the chicken brain: immunocytochemical study with antibodies to noradrenaline and dopamine–beta–hydroxylase. Moons L, et al. **J Comp Neurol** 1995 Sep 18;360(2):331–48
Differential regulation of adrenergic receptor development by sympathetic innervation. Habecker BA, et al. **J Neurosci** 1996 Jan;16(1):229–37
[Changes in the adrenergic innervation of the large intestine in the postnatal ontogeny of the white rat] Amvros'ev AP, et al. **Morfologiia** 1995;108(1):17–21 (Eng. Abstr.) **(Rus)**

ADRENERGIC NEURON AGENTS see **ADRENERGIC AGENTS**

ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC**

ADRENERGIC REUPTAKE INHIBITORS see **ADRENERGIC UPTAKE INHIBITORS**

ADRENERGIC SYNTHESIS INHIBITORS see **ADRENERGIC AGENTS**

ADRENERGIC UPTAKE INHIBITORS

see related
AMPHETAMINES
ANTIDEPRESSIVE AGENTS, TRICYCLIC
DOPAMINE UPTAKE INHIBITORS

ADVERSE EFFECTS

Methamphetamine and childhood and adolescent caries [letter] Howe AM. **Aust Dent J** 1995 Oct;40(5):340
Does reserpine induce parkinsonian rigidity? Lorenc–Koci E, et al. **J Neural Transm Park Dis Dement Sect** 1995; 9(2–3):211–23

CHEMICAL SYNTHESIS

Synthesis and enantioselectivity of optically active 1– and 3–substituted 4–phenyl–1,2,3,4–tetrahydroisoquinolin–4–ols and related compounds as norepinephrine potentiators. Kihara M, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep; 43(9):1543–6

DIAGNOSTIC USE

Biological and clinical validation of atypical depression. McGinn LK, et al. **Psychiatry Res** 1996 Mar 29; 60(2–3):191–8

PHARMACOLOGY

The role of L–threo DOPS in the control of Na–K ATPase activity of the marginal cells in the stria vascularis of reserpinized guinea pigs. Kanoh N, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:381–3
Effects of yohimbine and desipramine on adrenal catecholamine release in response to splanchnic nerve stimulation in anesthetized dogs. Koganei H, et al. **Biol Pharm Bull** 1995 Sep;18(9):1207–10
Comparison of the effects of desipramine on noradrenaline– and methoxamine–evoked venoconstriction in man. Abdelmawla AH, et al. **Br J Clin Pharmacol** 1995 Nov; 40(5):445–51
Effect of catecholamine depletion on myocardial infarct size in dogs: role of catecholamines in ischemic preconditioning. Vander Heide RS, et al. **Cardiovasc Res** 1995 Nov; 30(5):656–62
Desipramine treatment differently down–regulates beta–adrenoceptors of freshly isolated neurons and astrocytes. Sapena R, et al. **Eur J Pharmacol** 1996 Apr 4;300(1–2):159–62
Pharmacological properties of 403U76, a new chemical class of 5–hydroxytryptamine– and noradrenaline–reuptake inhibitor. Ferris RM, et al. **J Pharm Pharmacol** 1995 Sep; 47(9):775–81
Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. Kasamo K, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):278–86
Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Engleman EA, et al. **Neuropsychopharmacology** 1995 Jul;12(4):287–95
Some behavioural and neurochemical aspects of subacute (+/–)3,4–methylenedioxymethamphetamine administration in rats. McNamara MG, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):479–84
The effect of imipramine on lipid peroxidation in the rat cerebral cortex. Melzacka M, et al. **Pol J Pharmacol** 1995 Jan–Feb;47(1):25–30

THERAPEUTIC USE

Intrathecal amitriptyline acts as an N–methyl–D–aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Eisenach JC, et al. **Anesthesiology** 1995 Nov;83(5):1046–54
The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. Drake LA, et al. **Arch Dermatol** 1995 Dec;131(12):1403–8
The use of methylphenidate in Michigan [letter; comment] Kaufman G, et al. **Arch Pediatr Adolesc Med** 1996 May; 150(5):558–9. Comment on: Arch Pediatr Adolesc Med 1995 Jun;149(6):675–9.
Use of imipramine hydrochloride for treatment of urospermia in a stallion with a dysfunctional bladder. Turner RM, et al. **J Am Vet Med Assoc** 1995 Dec 15;207(12):1602–6
A double–blind, placebo–controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression [see comments] Mason BJ, et al. **JAMA** 1996 Mar 13;275(10):761–7. Comment in: JAMA 1996 Mar 13;275(10):803–4.
Polyuric and non–polyuric bedwetting––pathogenic differences in nocturnal enuresis. Hunsballe JM, et al. **Scand J Urol Nephrol Suppl** 1995;173:77–8; discussion 79
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Dam M, et al. **Stroke** 1996 Jul;27(7):1211–4

ADRENOCEPTORS see **RECEPTORS, ADRENERGIC**

ADRENOCHROME

ANALOGS & DERIVATIVES

Effects of carbazochrome sodium sulfonate (AC–17) on oleic acid–induced lung injury. Moriuchi H, et al. **Pharmacol Toxicol** 1995;77:238–40

METABOLISM

Effects of superoxide dismutase and catalase during reduction of adrenochrome by DT–diaphorase and NADPH–cytochrome P450 reductase. Baez S, et al. **Biochem Mol Med** 1995 Oct;56(1):37–44

TOXICITY

Functional effects of adrenochrome in isolated rabbit heart. Rump AF, et al. **Pharmacol Toxicol** 1995 Aug;77(2):102–5
Effects of adrenochrome and epinephrine on human arterial endothelial cells in vitro. Zhou Q, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jul;89(1):111–26

ADRENOCORTICOTROPIC HORMONE see **CORTICOTROPIN**

ADRENOCORTICOTROPIC HORMONE RECEPTORS see **RECEPTORS, CORTICOTROPIN**

ADRENOCORTICOTROPIN see **CORTICOTROPIN**

ADRENODOXIN

CHEMISTRY

Reversible, non–denaturing metal substitution in bovine adrenodoxin and spinach ferredoxin and the different reactivities of [2Fe–2S]–cluster–containing proteins. Iametti S, et al. **Eur J Biochem** 1996 Aug 1;239(3):818–26
The role of threonine 54 in adrenodoxin for the properties of its iron–sulfur cluster and its electron transfer function. Uhlmann H, et al. **J Biol Chem** 1995 Dec 15; 270(50):29959–66

GENETICS

Structure–function studies on mutants of adrenal ferredoxin. Uhlmann H, et al. **Endocr Res** 1995 Feb–May; 21(1–2):307–12

ISOLATION & PURIFICATION

Purification and characterization of rat adrenodoxin. Sagara Y, et al. **Biochimie** 1995;77(9):719–23

METABOLISM

Pyridoxal phosphate induced association reactions of adrenodoxin and adrenodoxin–reductase. Behlke J, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):663–7
Purification and characterization of rat adrenodoxin. Sagara Y, et al. **Biochimie** 1995;77(9):719–23
Cytoplasmic chaperones determine the targeting pathway of precursor proteins to mitochondria. Komiya T, et al. **EMBO J** 1996 Jan 15;15(2):399–407
Effect of transforming growth factor beta–1 on the cholesterol side–chain cleavage system in the adrenal gland of sheep fetuses and newborns. Naaman–Reperant E, et al. **Endocrinology** 1996 Mar;137(3):886–92
The role of threonine 54 in adrenodoxin for the properties of its iron–sulfur cluster and its electron transfer function. Uhlmann H, et al. **J Biol Chem** 1995 Dec 15; 270(50):29959–66

ADRENODOXIN REDUCTASE see **FERREDOXIN–NADP REDUCTASE**

ADRENOGENITAL SYNDROME see **ADRENAL HYPERPLASIA, CONGENITAL**

ADRENOLEUKODYSTROPHY

BLOOD

Plasma phospholipid fatty acids in X–linked adrenoleukodystrophy. Aveldaño MI, et al. **Clin Chem** 1996 Mar;42(3):454–61
Platelets in treated adrenoleukodystrophy: a brief report. Revell P, et al. **J Inherit Metab Dis** 1995;18(5):635–7

COMPLICATIONS

Circadian rhythm abnormalities in adrenoleukodystrophy and methyl B12 treatment. Tomoda A, et al. **Brain Dev** 1995 Nov–Dec;17(6):428–31
X–linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. Laureti S, et al. **J Clin Endocrinol Metab** 1996 Feb; 81(2):470–4

CONGENITAL see **PEROXISOMAL DISORDERS**

DIAGNOSIS

Adrenoleukodystrophy. A case report. Rosenkilde M, et al. **Acta Radiol** 1995 Nov;36(6):610–2
Improved tissue characterization in adrenoleukodystrophy using magnetization transfer imaging. Melhem ER, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):689–95
Adrenoleukodystrophy: magnetic resonance follow–up after Lorenzo's oil therapy. Duchesne N, et al. **Can Assoc Radiol J** 1995 Oct;46(5):386–91
Adrenoleukodystrophy: a link between adrenal insufficiency and school performance. Bakos JT, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2869–72
Differentiation of rare leukodystrophies by post–mortem morphological and biochemical studies: female

adrenoleukodystrophy-like disease and late-onset Krabbe disease. Gullotta F, et al. **Neuropediatrics** 1996 Feb; 27(1):37–41

Adrenoleukodystrophy: CT and MRI findings. Patel PJ, et al. **Pediatr Radiol** 1995;25(4):256–8

Prenatal diagnosis of adrenoleukodystrophy by means of mutation analysis. Imamura A, et al. **Prenat Diagn** 1996 Mar;16(3):259–61

[Athymhormic syndrome and progressive paraplegia disclosing adrenoleukomyeloneuropathy in an adult] Brosset C, et al. **Rev Neurol (Paris)** 1995 Jun–Jul; 151(6–7):388–91 (Eng. Abstr.) **(Fre)**

DIET THERAPY

Dietary management of X-linked adrenoleukodystrophy. Moser HW, et al. **Annu Rev Nutr** 1995;15:379–97 (77 ref.)

Platelets in treated adrenoleukodystrophy: a brief report. Revell P, et al. **J Inherit Metab Dis** 1995;18(5):635–7

DRUG THERAPY

Adrenoleukodystrophy: magnetic resonance follow-up after Lorenzo's oil therapy. Duchesne N, et al. **Can Assoc Radiol J** 1995 Oct;46(5):386–91

Glycerol trioleate/glycerol trierucate therapy in X-linked adrenoleukodystrophy: saturated and unsaturated fatty acids in blood cells. Implications for the follow-up. Ruiz M, et al. **J Inherit Metab Dis** 1996;19(2):188–92

GENETICS

Mutational and protein analysis of patients and heterozygous women with X-linked adrenoleukodystrophy. Feigenbaum V, et al. **Am J Hum Genet** 1996 Jun;58(6):1135–44

Cerebral adrenoleukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype. Korenke GC, et al. **Ann Neurol** 1996 Aug;40(2):254–7

Dietary management of X-linked adrenoleukodystrophy. Moser HW, et al. **Annu Rev Nutr** 1995;15:379–97 (77 ref.)

Association of X-linked adrenoleukodystrophy with HLA DRB1 alleles. Berger J, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):447–51

Adrenoleukodystrophy. Moser HW. **Curr Opin Neurol** 1995 Jun;8(3):221–6 (37 ref.)

Identification of mutations in the ALD-gene of 20 families with adrenoleukodystrophy/adrenomyeloneuropathy. Krasemann EW, et al. **Hum Genet** 1996 Feb;97(2):194–7

Characterization of a partial pseudogene homologous to the adrenoleukodystrophy gene and application to mutation detection. Braun A, et al. **Hum Mutat** 1996;7(2):105–8

Two intronic mutations in the adrenoleukodystrophy gene. Kemp S, et al. **Hum Mutat** 1995;6(3):272–3

Partial deletions of putative adrenoleukodystrophy (ALD) gene in Japanese ALD patients. Koike R, et al. **Hum Mutat** 1995;6(3):263–7

Mutational analysis of patients with X-linked adrenoleukodystrophy. Kok F, et al. **Hum Mutat** 1995; 6(2):104–15

X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. Laureti S, et al. **J Clin Endocrinol Metab** 1996 Feb; 81(2):470–4

Glycerol trioleate/glycerol trierucate therapy in X-linked adrenoleukodystrophy: saturated and unsaturated fatty acids in blood cells. Implications for the follow-up. Ruiz M, et al. **J Inherit Metab Dis** 1996;19(2):188–92

Molecular analysis of X-linked adrenoleukodystrophy patients. Yasutake T, et al. **J Neurol Sci** 1995 Jul; 131(1):58–64

DNA-based diagnostics for adrenoleukodystrophy in a large New Zealand family. Rowland SA, et al. **N Z Med J** 1996 Aug 23;109(1028):312–5

Late-onset generalized disorder of peroxisomes. Burdette DE, et al. **Neurology** 1996 Mar;46(3):829–31

Localised proton magnetic resonance spectroscopy in X-linked adrenoleukodystrophy. Confort-Gouny S, et al. **Neuroradiology** 1995 Oct;37(7):568–75

[Phenotype variability in adrenoleukodystrophy. Presentation of three new cases and a review of literature] Ara JR, et al. **Rev Neurol** 1996 Jul;24(131):843–7 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Association of X-linked adrenoleukodystrophy with HLA DRB1 alleles. Berger J, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):447–51

METABOLISM

Localization of mRNAs for adrenoleukodystrophy and the 70 kDa peroxisomal (PMP70) proteins in the rat brain during post-natal development. Pollard H, et al. **J Neurosci Res** 1995 Oct 15;42(3):433–7

PATHOLOGY

[Frontal type adrenoleukodystrophy: the progress of the white matter lesion—a neuroradiological and pathological study] Nagumo K, et al. **Rinsho Shinkeigaku** 1995 Sep; 35(9):983–90 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome. Moser HW. **J Inherit Metab Dis** 1995;18(4):435–47 (47 ref.)

Tumor necrosis factor-alpha and X-linked adrenoleukodystrophy. McGuinness MC, et al. **J Neuroimmunol** 1995 Sep;61(2):161–9

Nerve conduction studies in adrenomyeloneuropathy. Chaudhry V, et al. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):181–5

Late-onset generalized disorder of peroxisomes. Burdette DE, et al. **Neurology** 1996 Mar;46(3):829–31

Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study. van Geel BM, et al. **Neurology** 1996 Jan;46(1):112–8

PSYCHOLOGY

Adrenoleukodystrophy: a link between adrenal insufficiency and school performance. Bakos JT, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2869–72

Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. Shapiro EG, et al. **J Inherit Metab Dis** 1995;18(4):413–29 (29 ref.)

SURGERY

The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. Krivit W, et al. **J Inherit Metab Dis** 1995;18(4):398–412 (23 ref.)

Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. Shapiro EG, et al. **J Inherit Metab Dis** 1995;18(4):413–29 (29 ref.)

THERAPY

Bone marrow transplantation for metabolic diseases. Parkman R, et al. **Cancer Treat Res** 1995;76:87–96 (33 ref.)

Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome. Moser HW. **J Inherit Metab Dis** 1995;18(4):435–47 (47 ref.)

[Gene therapy of adrenoleukodystrophy] Cartier N, et al. **Arch Pediatr** 1996;3 Suppl 1:77s–81s (18 ref.) **(Fre)**

ADRENOLEUKODYSTROPHY, NEONATAL see **PEROXISOMAL DISORDERS**

ADRENOLYTICS see **ADRENERGIC AGENTS**

ADRENOMIMETICS see **ADRENERGIC AGENTS**

ADRENOMYELONEUROPATHY see **ADRENOLEUKODYSTROPHY**

ADRENRGIC RELEASE INHIBITORS see **ADRENERGIC AGENTS**

ADRIAMYCIN see **DOXORUBICIN**

ADULT RESPIRATORY DISTRESS SYNDROME see **RESPIRATORY DISTRESS SYNDROME, ADULT**

ADULT T-CELL LEUKEMIA-LYMPHOMA VIRUS I see **HTLV-I**

ADULTERY see **EXTRAMARITAL RELATIONS**

ADVANCE DIRECTIVES

see related
RESUSCITATION ORDERS
RIGHT TO DIE

Advance directives in the emergency department: too few, too late. Ishihara KK, et al. **Acad Emerg Med** 1996 Jan; 3(1):50–3

Choosing resuscitation late in life: problems with the paradigm [editorial; comment] Finucane TE. **Am J Med** 1996 Feb;100(2):126–7. Comment on: Am J Med 1996 Feb;100(2):128–37.

Advance directives. Most patients don't have one. Do yours? Berrio MW, et al. **Am J Nurs** 1996 Aug;96(8):24–8; quiz 29 (7 ref.)

Jehovah's Witnesses and advance directives. Ferdinand R. **Am J Nurs** 1996 Mar;96(3):64

No code. Lake DF. **Am J Nurs** 1996 Feb;96(2):38–9

Advance medical planning [letter; comment] Lipkin KM. **Ann Intern Med** 1996 Jun 1;124(11):1017. Comment on: Ann Intern Med 1995 Oct 15;123(8):621–4.

Advance medical planning [letter; comment] Potter HP Jr. **Ann Intern Med** 1996 Jun 1;124(11):1017. Comment on: Ann Intern Med 1995 Oct 15;123(8):621–4.

Promoting the use of advance directives: an empirical study [letter; comment] Coleman MT, et al. **Arch Fam Med** 1996 Jul–Aug;5(7):382–3. Comment on: Arch Fam Med 1995 Jul;4(7):609–15.

Involvement of cardiovascular rehabilitation programs in advance directive education. Heffner JE, et al. **Arch Intern Med** 1996 Aug 12–26;156(15):1746–51

On advancing advance directives. Why should we believe the promise? [editorial; comment] McIntyre KM. **Arch Intern Med** 1995 Nov 27;155(21):2271–3 (12 ref.). Comment on: Arch Intern Med 1994 Oct 24;154(20):2299–308.

Marked improvement in recognition and completion of health care proxies. A randomized controlled trial of counseling by hospital patient representatives. Meier DE, et al. **Arch Intern Med** 1996 Jun 10;156(11):1227–32

Advance end-of-life treatment planning. A research review. Miles SH, et al. **Arch Intern Med** 1996 May 27; 156(10):1062–8 (120 ref.)

Promoting inpatient directives about life-sustaining treatments in a community hospital. Results of a 3-year time-series intervention trial. Reilly BM, et al. **Arch Intern Med** 1995 Nov 27;155(21):2317–23

Promoting completion of health care proxies following hospitalization. A randomized controlled trial in a community hospital. Reilly BM, et al. **Arch Intern Med** 1995 Nov 13;155(20):2202–6

Advance directives are compatible with good medical practice [letter] Finfer S. **BMJ** 1996 Jun 15; 312(7045):1538–9

BMA division disagrees with association's stance over advance directives [letter] Jessiman IM. **BMJ** 1996 Mar 30;312(7034):850–1

Don't treat me; do treat me: against living wills [editorial] Millard PH. **Br J Hosp Med** 1996 May 15–Jun 4; 55(10):605–6

Advance directives in the intensive care unit of a tertiary cancer center. Ewer MS, et al. **Cancer** 1995 Oct 1; 76(7):1268–74

Advance directives. Changing our expectations [editorial; comment] Drought TS, et al. **Chest** 1996 Sep;110(3):589–91 . Comment on: Chest 1996 Sep;110(3):816–22.

Advance directive education during pulmonary rehabilitation [see comments] Heffner JE, et al. **Chest** 1996 Feb; 109(2):373–9. Comment in: Chest 1996 Feb;109(2):299.

Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation. Advance care planning and outcomes. Moss AH, et al. **Chest** 1996 Jul;110(1):249–55

Are advance directives becoming an endangered species? [editorial; comment] Perkins HS. **Chest** 1996 Feb;109(2):299 . Comment on: Chest 1996 Feb;109(2):373–9.

Pulling the plug on living wills. A critical analysis of advance directives [see comments] Tonelli MR. **Chest** 1996 Sep; 110(3):816–22. Comment in: Chest 1996 Sep;110(3):589–91.

Dworkin on dementia. Elegant theory, questionable policy. Dresser R. **Hastings Cent Rep** 1995 Nov–Dec;25(6):32–8 (17 ref.)

End-of-life care after termination of SUPPORT. Lo B. **Hastings Cent Rep** 1995 Nov–Dec;25(6):S6–8

Preservation of life or property? [letter; comment] Welsh F. **Hastings Cent Rep** 1995 Nov–Dec;25(6):2. Comment on: Hastings Cent Rep 1994 Nov–Dec;24(6):S1.

Older people's responses to education about advance directives. Bailly DJ, et al. **Health Soc Work** 1995 Aug; 20(3):223–8

Advance directives and opportunities for nurses. Johns JL. **Image J Nurs Sch** 1996 Summer;28(2):149–53 (52 ref.)

Making treatment decisions for incapacitated older adults without advance directives. AGS Ethics Committee. American Geriatrics Society [see comments] **J Am Geriatr Soc** 1996 Aug;44(8):986–7. Comment in: J Am Geriatr Soc 1996 Aug;44(8):994–6.

A method to communicate patient preferences about medically indicated life-sustaining treatment in the out-of-hospital setting. Dunn PM, et al. **J Am Geriatr Soc** 1996 Jul;44(7):785–91

Physicians, ethics, advance directives, and long-term care [letter] Gordon M, et al. **J Am Geriatr Soc** 1996 Apr; 44(4):471–2

Enhancement of proxy appointment for older persons: physician counselling in the ambulatory setting. Meier DE, et al. **J Am Geriatr Soc** 1996 Jan;44(1):37–43

Measuring capacity to complete an advance directive. Molloy DW, et al. **J Am Geriatr Soc** 1996 Jun;44(6):660–4

Advance directives and older adults: a critical care perspective [letter] Nuckton TJ. **J Am Geriatr Soc** 1996 Jun;44(6):733–4

Challenges facing physicians and healthcare institutions caring for patients with mental incapacity [editorial; comment] Pearlman RA. **J Am Geriatr Soc** 1996 Aug; 44(8):994–6. Comment on: J Am Geriatr Soc 1996 Aug;44(8):986–7.

Life-sustaining treatment preferences of hemodialysis patients: implications for advance directives. Singer PA, et al. **J Am Soc Nephrol** 1995 Nov;6(5):1410–7

Public awareness of the nature of CPR: a case for values-centered advance directives. Thurber CF. **J Clin Ethics** 1996 Spring;7(1):55–9

The completion of advance directives in primary care. Duffield P, et al. **J Fam Pract** 1996 Apr;42(4):378–84

Advance directives. Population prevalence and demand in Florida. Burg MA, et al. **J Fla Med Assoc** 1995 Dec; 82(12):811–4

AMA survey—American's know little or nothing about health care advance directives. **J Miss State Med Assoc** 1995 Dec;36(11):387–8

America's failure to use advance directives—helping your patients shape their health care future. **J Miss State Med Assoc** 1995 Dec;36(11):389–93

Exercising your health care rights [editorial] Laskin DM. **J Oral Maxillofac Surg** 1995 Oct;53(10):1133

Need exists for advance directives from parents [letter; comment] Alecson DG. **J Perinatol** 1995 Nov–Dec; 15(6):520–2. Comment on: J Perinatol 1995 May–Jun;15(3):232–6.

Need exists for advance directives from parents [letter]

Harrison H. **J Perinatol** 1995 Nov-Dec;15(6):522

Need exists for advance directives from parents [letter; comment] Perrotta L. **J Perinatol** 1995 Nov-Dec; 15(6):519-20. Comment on: J Perinatol 1995 May-Jun;15(3):232-6.

Advance directive decision making among medical inpatients. Rein AJ, et al. **J Prof Nurs** 1996 Jan-Feb;12(1):39-46

The SUPPORT project and improving care for seriously ill patients [letter; comment] Donnelly WJ. **JAMA** 1996 Apr 24;275(16):1228; discussion 1230-1. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Dougherty PJ. **JAMA** 1996 Apr 24;275(16):1227-8; discussion 1230-1. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Frank RR. **JAMA** 1996 Apr 24;275(16):1228-9; discussion 1230-1. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Godec MS. **JAMA** 1996 Apr 24;275(16):1230-1. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

Improving care near the end of life. Why is it so hard? [editorial; comment] Lo B. **JAMA** 1995 Nov 22-29; 274(20):1634-6. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Parrillo JE. **JAMA** 1996 Apr 24;275(16):1229; discussion 1230-1. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Prendergast TJ. **JAMA** 1996 Apr 24;275(16):1227; discussion 1230-1. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Sachs GA. **JAMA** 1996 Apr 24;275(16):1229; discussion 1230-1. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Solomon MZ, et al. **JAMA** 1996 Apr 24;275(16):1229-31. Comment on: JAMA 1995 Nov 22-39;274(20):1591-8.

The SUPPORT project and improving care for seriously ill patients [letter; comment] Strong MS. **JAMA** 1996 Apr 24;275(16):1231-2. Comment on: JAMA 1995 Nov 22-29;274(20):1591-8.

Advance directives: a policy-capturing approach. Raymark PH, et al. **Med Decis Making** 1995 Jul-Sep;15(3):217-26

Conflict resolution with end of life decisions in critical care settings. Murphy C, et al. **Medinfo** 1995;8 Pt 2:1696

The purpose of advance medical planning--autonomy for patients or limitation of care? Levinsky NG. **N Engl J Med** 1996 Sep 5;335(10):741-3

Advance directive for health care. The Medical Society of New Jersey. **N J Med** 1995 Oct;92(10):635-9

Advance directives: matters of life and death [news] Klaus BD. **Nurse Pract** 1995 Oct;20(10):88-90

"Toothanasia" or oral health care advance directive? [editorial] Casamassimo PS. **Pediatr Dent** 1995 Nov-Dec; 17(7):404

Advance care planning for children with special health care needs: a survey of parental attitudes. Wharton RH, et al. **Pediatrics** 1996 May;97(5):682-7

Nemawashi essential for conducting research in Japan. Fetters MD. **Soc Sci Med** 1995 Aug;41(3):375-81

Public opinion regarding end-of-life decisions: influence of prognosis, practice and process. Singer PA, et al. **Soc Sci Med** 1995 Dec;41(11):1517-21

Supporting patient autonomy: decision making in home care. Davitt JK, et al. **Soc Work** 1996 Jan;41(1):41-50

ECONOMICS

Cost savings at the end of life. What do the data show? Emanuel EJ. **JAMA** 1996 Jun 26;275(24):1907-14 (42 ref.)

ETHNOLOGY

The relationship between ethnicity and advance directives in a frail older population. Eleazer GP, et al. **J Am Geriatr Soc** 1996 Aug;44(8):938-43

LEGISLATION & JURISPRUDENCE

New laws mean MDs must keep up to date on living-will and related legislation. Capen K. **Can Med Assoc J** 1996 Feb 15;154(4):576-8

Plans in advance [news] Kessel R. **Hastings Cent Rep** 1995 Jul-Aug;25(4):47

Social work and end-of-life decisions: self-determination and the common good. Wesley CA. **Health Soc Work** 1996 May;21(2):115-21 (52 ref.)

The application of health care surrogate laws to older populations: how good a match? Hayley DC, et al. **J Am Geriatr Soc** 1996 Feb;44(2):185-8

Advance directives [editorial; comment] Hope T. **J Med Ethics** 1996 Apr;22(2):67-8. Comment on: J Med Ethics 1996 Apr;22(2):95-9. Comment on: J Med Ethics 1996 Apr;22(2):100-4.

Limiting risks by curtailing rights: a response to Dr Ryan [comment] [see comments] Luttrell S, et al. **J Med Ethics** 1996 Apr;22(2):100-4. Comment on: J Med Ethics 1996 Apr;22(2):95-9. Comment in: J Med Ethics 1996 Apr;22(2):67-8.

Betting your life: an argument against certain advance directives [see comments] Ryan CJ. **J Med Ethics** 1996 Apr;22(2):95-9. Comment in: J Med Ethics 1996 Apr;22(2):67-8. Comment in: J Med Ethics 1996 Apr;22(2):100-4.

Legal and ethical issues. Flexibility and faithfulness. Oldaker S. **J Prof Nurs** 1996 May-Jun;12(3):129

Advance directives [letter] Uzych L. **J R Coll Physicians Lond** 1996 Mar-Apr;30(2):188-9

New EMS Palliative Care/DNR protocol will replace existing hospice protocol. Smith G. **Md Med J** 1995 Sep; 44(9):717-22

Self-determination for life and death. Ladimer I. **Med Law** 1996;15(1):83-92

Wild death [letter; comment] Brechtelsbauer DA. **S D J Med** 1995 Sep;48(9):300. Comment on: S D J Med 1995 Jun;48(6):181-2.

[Limits of intensive care medicine. Medical and legal aspects] Effert S. **Versicherungsmedizin** 1996 Apr 1;48(2):40-2 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Advance directives in Utah. Information from death certificates and informants. Jacobson JA, et al. **Arch Intern Med** 1996 Sep 9;156(16):1862-8

A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators [see comments] **JAMA** 1995 Nov 22-29;274(20):1591-8. Comment in: JAMA 1995 Nov 22-29;274(20):1634-6. Comment in: JAMA 1996 Apr 24;275(16):1227; discussion 1230-1. Comment in: JAMA 1996 Apr 24;275(16):1227-8; discussion 1230-1. Comment in: JAMA 1996 Apr 24;275(16):1228; discussion 1230-1. Comment in: JAMA 1996 Apr 24;275(16):1228-9; discussion 1230-1. Comment in: JAMA 1996 Apr 24;275(16):1229; discussion 1230-1. Comment in: JAMA 1996 Apr 24;275(16):1229-30; discussion 1230-1. Comment in: JAMA 1996 Apr 24;275(16):1230-1. Comment in: JAMA 1996 Apr 24;275(16):1231-2.

ADVERSE DRUG REACTION REPORTING SYSTEMS

Medication-related adverse reactions and the elderly: a literature review. Atkin PA, et al. **Adverse Drug React Toxicol Rev** 1995 Autumn;14(3):175-91 (125 ref.)

Case series analysis of adverse reactions to vaccines: a comparative evaluation. Farrington CP, et al. **Am J Epidemiol** 1996 Jun 1;143(11):1165-73 (18 ref.)

Reporting adverse drug reactions in an ambulatory care setting. Finn B, et al. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2704-6

Drug reactions identified at resident physicians' morning report [letter] Kaufman MB. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2031

Potential drug interactions in a physical medicine and rehabilitation clinic. Braverman SE, et al. **Am J Phys Med Rehabil** 1996 Jan-Feb;75(1):44-9

Reporting vaccine-associated paralytic poliomyelitis: concordance between the CDC and the National Vaccine Injury Compensation Program. Weibel RE, et al. **Am J Public Health** 1996 May;86(5):734-7

Computer-assisted pharmacovigilance in hospitalized patients [letter] Chan TY. **Ann Pharmacother** 1995 Jul-Aug; 29(7-8):788-9

Impact of preexisting health conditions on the outcome of an adverse drug reaction alerting program: gastrointestinal disorders before piroxicam and sulindac therapy. Rawson NS. **Ann Pharmacother** 1995 Jul-Aug;29(7-8):676-80

3rd European workshop on drug information Helsinki, Finland, June 14-16, 1995. Wallenius K. **Biol Neonate** 1995; 68(6):426-8

Standardized coding is needed for reports of adverse drug reactions [letter] Bonnetblanc JM, et al. **BMJ** 1996 Mar 23;312(7033):776-7

Drug companies should report side effects in terms of frequency [letter] [see comments] Bracchi R. **BMJ** 1996 Feb 17;312(7028):442. Comment in: BMJ 1996 Jun 1;312(7043):1418-9. Comment in: BMJ 1996 Jun 1;312(7043):1419.

Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. Egberts TC, et al. **BMJ** 1996 Aug 31;313(7056):530-1

Monitoring the frequency of side effects of drugs. Reasons for stopping drugs could be recorded in general practice [letter; comment] Martin R, et al. **BMJ** 1996 Jun 1; 312(7043):1418-9. Comment on: BMJ 1996 Feb 17;312(7028):442.

Avoiding drug errors. Reporting of critical incidents shows how errors occur [letter; comment] Nandwani N. **BMJ** 1995 Nov 18;311(7016):1368. Comment on: BMJ 1995 Aug 19;311(7003):463-4.

Monitoring the frequency of side effects of drugs. Data from several sources are needed to show numbers taking drugs [letter; comment] St George DA. **BMJ** 1996 Jun 1; 312(7043):1419. Comment on: BMJ 1996 Feb 17;312(7028):442.

Avoiding drug errors. Reporting of errors should be free of recrimination [letter; comment] Upton DR, et al. **BMJ** 1995 Nov 18;311(7016):1367. Comment on: BMJ 1995 Aug 19;311(7003):463-4.

Failed emergency contraception [letter] Cardy GC. **Br J Gen Pract** 1994 Sep;44(386):428

Self-measure of neuroleptic side-effects [letter; comment] Sikdar S. **Br J Psychiatry** 1995 Jul;167(1):113-4. Comment on: Br J Psychiatry 1995 May;166(5):650-3.

Lessons from clinical research: adverse events or complications? [editorial] McLaughlin JF. **Dev Med Child Neurol** 1996 Jul;38(7):565-6

Cross-cultural miscommunication [news] Kang-Yum E. **Hastings Cent Rep** 1996 May-Jun;26(3):46

Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. Barber BL, et al. **Int J Clin Pharmacol Ther** 1995 Nov;33(11):598-604

Methods for monitoring and documenting adverse drug reactions. Venulet J, et al. **Int J Clin Pharmacol Ther** 1996 Mar;34(3):112-29 (48 ref.)

Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. Cooper JW. **J Am Geriatr Soc** 1996 Feb;44(2):194-7

The United States Pharmacopeia Veterinary Practitioners' Reporting Program. Meyer EK, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):361-3

System for reporting adverse reactions [letter] Meyer EK. **J Am Vet Med Assoc** 1996 Feb 1;208(3):339

Reminder about organized reporting of adverse reactions [letter] Meyer EK. **J Am Vet Med Assoc** 1996 Aug 1; 209(3):536

Aspirin or acetaminophen? A comparison from data collected by the Spanish Drug Monitoring System. Carvajal A, et al. **J Clin Epidemiol** 1996 Feb;49(2):255-61

Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. Mann RD, et al. **J Clin Epidemiol** 1996 Feb;49(2):247-50

Comparing the toxicity of two drugs in the framework of spontaneous reporting: a confidence interval approach. Tubert-Bitter P, et al. **J Clin Epidemiol** 1996 Jan; 49(1):121-3

ARAMIS and toxicity measurement. (Arthritis Rheumatism and Aging Medical Information System). Fries JF. **J Rheumatol** 1995 May;22(5):995-7

Red man syndrome and the red button system: where next for inpatient adverse drug reaction reporting? [comment] Schiff GD. **Jt Comm J Qual Improv** 1995 Oct;21(10):549-52 . Comment on: Jt Comm J Qual Improv 1995 Oct;21(10):541-8.

Morning report: a forum for reporting adverse drug reactions. Sivaram CA, et al. **Jt Comm J Qual Improv** 1996 Apr; 22(4):259-63

Sensible alerts [editorial] [see comments] **Lancet** 1995 Dec 16;346(8990):1569. Comment in: Lancet 1996 Jan 27;347(8996):257. Comment in: Lancet 1996 Jan 27;347(8996):257-8. Comment in: Lancet 1996 Jan 27;347(8996):258. Comment in: Lancet 1996 Jan 27;347(8996):258-9. Comment in: Lancet 1996 Jan 27;347(8996):259. Comment in: Lancet 1996 Jan 27;347(8996):259-60. Comment in: Lancet 1996 Jan 27;347(8996):260.

MedHelp: a Windows system offering drug information and selection. Purswani K, et al. **MD Comput** 1995 Sep-Oct; 12(5):402-4, 406-7

Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Beeler J, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):88-90

Using computerized individual medication data to detect drug effects on clinical laboratory tests. Grönroos P, et al. **Scand J Clin Lab Invest Suppl** 1995;222:31-6

Epidemiological identification and evaluation of hepatic adverse drug reactions. Bruppacher R. **Semin Liver Dis** 1995 Aug;15(3):301-8 (40 ref.)

National Association of Medical Examiner's Pediatric Toxicology (PedTox) Registry. Hanzlick R. **Toxicology** 1996 Feb 22;107(2):153-8

Suspected adverse reactions, 1994 [news] **Vet Rec** 1996 Jan 13;138(2):26

[Drug induced fatal anaphylactic shock in Denmark 1968-1990] Lenler-Petersen P, et al. **Ugeskr Laeger** 1996 Jun 3;158(23):3316-8 (Eng. Abstr.) **(Dan)**

[Drug monitoring] Roos JC. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1168-9 **(Dut)**

[Drug monitoring] Royer RJ. **Bull Soc Sci Med Grand Duche Luxemb** 1995;132(3):33-4 **(Fre)**

[The practice of drug monitoring in the Lorraine Regional Center of Drug Monitoring (CRPV)] Trechot P. **Bull Soc Sci Med Grand Duche Luxemb** 1995;132(3):41-2 **(Fre)**

[Good practices in pharmacovigilance. Drugs for human use] **Therapie** 1995 Nov-Dec;50(6):547-55 **(Fre)**

A 2-year evaluation of questions concerning "Drugs--Pregnancy" at the CRPV in Nantes March 1992--March 1994] Chiffoleau A, et al. **Therapie** 1995 Sep-Oct;50(5):429-38 (Eng. Abstr.) **(Fre)**

[What kind of pharmacovigilance applies to drugs derived from blood? (letter)] Gil P, et al. **Therapie** 1995 Sep-Oct; 50(5):463-4 **(Fre)**

[Evaluation of reports on "pregnancy and drugs" received during a period of 39 months by the Regional

Pharmacovigilance Center, Lorraine (Nancy) (letter)] Hanesse B, et al. **Therapie** 1995 Sep–Oct;50(5):471–2 **(Fre)**

[Movement disorders induced by drugs: experience at a pharmaco–vigilance center over five years] Llau ME, et al. **Therapie** 1995 Sep–Oct;50(5):425–7 (Eng. Abstr.) **(Fre)**

[French pharmacovigilance database system: examples of utilisation] Moore N, et al. **Therapie** 1995 Nov–Dec; 50(6):557–62 (Eng. Abstr.) **(Fre)**

[Adverse drug effect notifications by nurses and comparison with cases reported by physicians] Sacilotto K, et al. **Therapie** 1995 Sep–Oct;50(5):455–8 (Eng. Abstr.) **(Fre)**

[Use of databases in pharmacovigilance: two examples] Van Ganse E. **Therapie** 1995 Sep–Oct;50(5):409–12 (Eng. Abstr.) **(Fre)**

[Drug side–effects of the eye—a contribution to quality assurance in ophthalmology] Dangelmaier S, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):385–8 (4 ref.) (Eng. Abstr.) **(Ger)**

[Reduced number of reported cases. Natural products caused eczema] **Lakartidningen** 1996 Jul 10;93(28–29):2604–5 **(Swe)**

[Information about adverse effects of drugs is not included in Fass (Swedish drug catalog) (letter)] Jacks B. **Lakartidningen** 1995 Oct 11;92(41):3772 **(Swe)**

[Evaluation of calcium antagonists—a question for the SBU (letter) (see comments)] Philip–Shansky A, et al. **Lakartidningen** 1995 Nov 1;92(44):4076. Comment in: Lakartidningen 1995 Nov 22;92(47):4404. **(Swe)**

[Thrombosis caused by oracl contraceptives. Underreporting to the adverse effects registry] Samuelsson E, et al. **Lakartidningen** 1996 Sep 11;93(37):3117–8, 3121–4 **(Swe)**

LEGISLATION & JURISPRUDENCE

FDA warns Pfizer on failure to report drug problems [news] Barnett AA. **Lancet** 1996 Jun 1;347(9014):1546

[Current regulations for reporting of side effects in The Netherlands after 1995] Broekmans AW, et al. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1166–7 **(Dut)**

[Drug indications and the physician's treatment choice] Deutsch E. **Internist (Berl)** 1995 Aug;36(8):837–9 **(Ger)**

ORGANIZATION & ADMINISTRATION

Estimating the rate of adverse drug reactions with capture–recapture analysis. Seeger JD, et al. **Am J Health Syst Pharm** 1996 Jan 15;53(2):178–81

The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Rosenthal S, et al. **Am J Public Health** 1995 Dec;85(12):1706–9

Experience in the development of a postmarketing surveillance network: the pharmacy medication monitoring program. Willison DJ, et al. **Ann Pharmacother** 1995 Dec; 29(12):1208–13

Limited adverse event screening: using medical record review to reduce hospital adverse patient events [letter] Branley P, et al. **Med J Aust** 1996 Aug 5;165(3):176

Adverse drug reactions: the role of the internist [editorial] Kerremans AL, et al. **Neth J Med** 1995 Dec;47(6):261–4

[Official systems of pharmacovigilance in France and in Spain. Comparison of spontaneous reporting in two regional centers: Pays Basque and Bordeaux] Aguirre C, et al. **Therapie** 1995 Nov–Dec;50(6):563–9 (Eng. Abstr.) **(Fre)**

STANDARDS

Adverse drug event reporting at Veterans Affairs facilities [letter] Corr K, et al. **Am J Health Syst Pharm** 1996 Feb 1;53(3):314–5

Commentary on endometrial cancer deaths in tamoxifen–treated breast cancer patients. Fisher B. **J Clin Oncol** 1996 Mar;14(3):1027–39

A critical appraisal of toxicity indexes in rheumatology. Peloso PM, et al. **J Rheumatol** 1995 May;22(5):989–94

The incident reporting system does not detect adverse drug events: a problem for quality improvement [see comments] Cullen DJ, et al. **Jt Comm J Qual Improv** 1995 Oct; 21(10):541–8. Comment in: Jt Comm J Qual Improv 1995 Oct;21(10):549–52.

STATISTICS & NUMERICAL DATA

[Can the sub–notification of drug adverse effects by capture/recapture method be evaluated?] Jonville–Béra AP, et al. **Therapie** 1996 Mar–Apr;51(2):169–75 (Eng. Abstr.) **(Fre)**

[Pharmacovigilance seen by a selected group of general practitioners and of residents in the Midi–Pyrénées region] Pouget–Zago P, et al. **Therapie** 1995 Sep–Oct;50(5):459–62 (Eng. Abstr.) **(Fre)**

TRENDS

Attitudes to adverse drug reaction reporting [letter] Inman WH. **Br J Clin Pharmacol** 1996 May;41(5):434–5

UTILIZATION

The spontaneous reporting of adverse drug reactions by nurses. Hall M, et al. **Br J Clin Pharmacol** 1995 Aug; 40(2):173–5

ADVERTISING

Harm reduction, not alcohol consumption reduction [letter] Pittman DJ. **Addiction** 1995 Nov;90(11):1550–1

Florida goes statewide with alcohol health warning signs. Cleary D. **Am J Public Health** 1996 Jun;86(6):882–3

Smokers' knowledge and understanding of advertised tar numbers: health policy implications. Cohen JB. **Am J Public Health** 1996 Jan;86(1):18–24

Revealing and reversing tobacco industry strategies [editorial; comment] Fielding JE. **Am J Public Health** 1996 Aug;86(8 Pt 1):1073–5. Comment on: Am J Public Health 1996 Aug;86(8 Pt 1):1137–42.

Preventing tobacco use—the youth access trap [editorial] Glantz SA. **Am J Public Health** 1996 Feb;86(2):156–8

Seventh graders' self–reported exposure to cigarette marketing and its relationship to their smoking behavior. Schooler C, et al. **Am J Public Health** 1996 Sep; 86(9):1216–21

Job auction [editorial] Leach RE. **Am J Sports Med** 1995 Jul–Aug;23(4):379

Internet sees growth of unverified health claims [news] Bower H. **BMJ** 1996 Aug 17;313(7054):381

Factors influencing the response to advertisements for general practice vacancies. Carlisle R, et al. **BMJ** 1996 Aug 24;313(7055):468–71

Meat and Livestock Commission's advertising campaign. Commission emphasises nutritional value of meat in booklet for new mothers [letter] Glynn JR. **BMJ** 1996 Jan 20; 312(7024):181

Meat and Livestock Commission's advertising campaign. Commission defends campaign [letter] Lamb C. **BMJ** 1996 Jan 20;312(7024):181

Effect of sports sponsorship by tobacco companies on children's experimentation with tobacco [see comments] Vaidya SG, et al. **BMJ** 1996 Aug 17;313(7054):400. Comment in: BMJ 1996 Aug 17;313(7054):375.

Cigarette advertising and onset of smoking in children: questionnaire survey [see comments] While D, et al. **BMJ** 1996 Aug 17;313(7054):398–9. Comment in: BMJ 1996 Aug 17;313(7054):375.

The ethics of tobacco advertising and advertising bans. Chapman S. **Br Med Bull** 1996 Jan;52(1):121–31

Time to apply pressure [letter] Bell W. **Can Fam Physician** 1996 May;42:850; 852

US ad uses lure of prompt treatment to entice Canadians needing joint replacement. Johnston C. **Can Med Assoc J** 1996 Apr 1;154(7):1071–2

Violence sells [letter] Soltan HC. **Can Med Assoc J** 1996 Mar 15;154(6):756, 758

Teaching information mastery: evaluating information provided by pharmaceutical representatives. Shaughnessy AF, et al. **Fam Med** 1995 Oct;27(9):581–5

Marketing. A pitch for organ donations. MacPherson P. **Hosp Health Netw** 1996 Feb 20;70(4):76

Body shape ideals across gender, sexual orientation, socioeconomic status, race, and age in personal advertisements. Epel ES, et al. **Int J Eat Disord** 1996 Apr; 19(3):265–73

The rational use of medicines. Werkö L. **Int J Technol Assess Health Care** 1995 Summer;11(3):391–8

Promoting the profession [letter] Durick RJ. **J Am Dent Assoc** 1996 May;127(5):558, 560

Advertising health risk products: ethics vs. economics. Gupta S, et al. **J Am Pharm Assoc (Wash)** 1996 Jun;NS36(6):381–2

An atmosphere of mistrust. Ponte CD. **J Am Pharm Assoc (Wash)** 1996 May;NS36(5):322

Guilt appeals in advertising: what are their effects? Coulter RH, et al. **J Appl Psychol** 1995 Dec;80(6):697–705

Everybody's doing it: a P.E.T. peeve or a public service? [editorial] Abel L. **J Ark Med Soc** 1995 Nov;92(6):268–9

Tobacco advertising in pharmacies [letter] Brenner SA. **J Fam Pract** 1996 Mar;42(3):308–9

Harry and Louise go to Washington: political advertising and health care reform. West DM, et al. **J Health Polit Policy Law** 1996 Spring;21(1):35–68 (57 ref.)

Pharmaceutical sales representatives and physicians: ethical considerations of a relationship. Peppin JF. **J Med Philos** 1996 Feb;21(1):83–99

Influence of tobacco marketing and exposure to smokers on adolescent susceptibility to smoking. Evans N, et al. **J Natl Cancer Inst** 1995 Oct 18;87(20):1538–45

The role of UK tobacco advertising: no effect on the nation's health? Part II: The political economy and marketing of tobacco. Kinman BF, et al. **J R Soc Health** 1995 Dec; 115(6):356–62

The role of UK tobacco advertising: no effect on the nation's health? Kinman BF, et al. **J R Soc Health** 1995 Oct; 115(5):296–302 (27 ref.)

Affect and memory in advertising: an empirical study of the compensatory processes. Chebat JC, et al. **J Soc Psychol** 1995 Aug;135(4):425–37

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Jul 3;276(1):14

Bayer promotional publications misleading about effect of ciprofloxacin on hospital admissions [letter] Barton SB, et al. **Lancet** 1995 Oct 21;346(8982):1102

Epidemiology versus a smoke screen [letter] Boffetta P, et al. **Lancet** 1996 Aug 10;348(9024):410

Will today be the day YOU hear from "J"? [letter] Booy R, et al. **Lancet** 1996 Jun 15;347(9016):1706

Promotion of Coversyl by Servier [letter] Vitry A, et al. **Lancet** 1996 May 18;347(9012):1411

Drug advertisements that go straight to the hippocampus. Wolfe S. **Lancet** 1996 Sep 7;348(9028):632

Smoking in Russia: what do Stalin and Western tobacco companies have in common? [see comments] Hurt RD. **Mayo Clin Proc** 1995 Oct;70(10):1007–11. Comment in: Mayo Clin Proc 1996 Mar;71(3):317; discussion 317–8. Comment in: Mayo Clin Proc 1996 Mar;71(3):317–8.

Marketing adolescent tobacco addiction. Tye J, et al. **Md Med J** 1995 Oct;44(10):767–73 (29 ref.)

Three rear ends on the beach. Debating the ethics of medical advertising. Halperin EC. **N C Med J** 1995 Aug; 56(8):402–3; discussion 403–5

An advertising conundrum [editorial] Albert SB. **N Y State Dent J** 1996 May;62(5):4–5

Dentists to get green light on more creative advertising. Plunkett LR. **N Y State Dent J** 1996 Apr;62(4):12–4

Advertising. The Ethics Committee of the American Academy of Otolaryngology–Head and Neck Surgery. **Otolaryngol Head Neck Surg** 1996 Sep;115(3):228–34

Recognition and liking of tobacco and alcohol advertisements among adolescents: relationships with susceptibility to substance use. Unger JB, et al. **Prev Med** 1995 Sep; 24(5):461–6

Smoking cessation: physician responsibility and government's role [letter] Kawane H. **Respir Med** 1996 Aug;90(7):440

Attack on the private sector—the real reason? [letter] [see comments] Ferreira AL. **S Afr Med J** 1995 Aug;85(8):788–9 . Comment in: S Afr Med J 1995 Sep;85(9):929.

New studies trace the impact of tobacco advertising [news] Nowak R. **Science** 1995 Oct 27;270(5236):573–4

Advertising in Cambodia. Smith M. **Tob Control** 1996 Spring; 5(1):66–8

The Marlboro Man on coral beaches. Stanton HJ. **Tob Control** 1996 Spring;5(1):7–8

[Legal and ethical problems in drug advertising and their resolution in practice] Opletalová V, et al. **Cas Lek Cesk** 1995 Jun 14;134(12):393–6 (Eng. Abstr.) **(Cze)**

[Unacceptable aggressive marketing (letter)] Eldrup J, et al. **Ugeskr Laeger** 1996 Jan 8;158(2):176–7 **(Dan)**

[Nutrition committee in Denmark (letter)] Jensen NH. **Ugeskr Laeger** 1996 Jun 17;158(25):3630–2 **(Dan)**

[Misleading advertisment of pneumococcal vaccine! (letter)] Andersen BM. **Tidsskr Nor Laegeforen** 1996 Aug 20; 116(19):2355 **(Nor)**

[Doubtful advertising (letter)] Bredal W. **Tidsskr Nor Laegeforen** 1996 Jun 30;116(17):2084 **(Nor)**

[Misleading advertising on a new NSAID (letter)] Hammer J. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):301 **(Nor)**

[When your needs are most urgent, you will be denied help. Indistinct borderlines between advertisment, campaigns and information] Waal H. **Tidsskr Nor Laegeforen** 1996 Apr 30;116(11):1370–1 **(Nor)**

[Drug advertising (letter)] Gómez Martín O, et al. **Aten Primaria** 1995 Nov 15;16(8):510 **(Spa)**

[Drug advertising in medical journals] Madridejos R, et al. **Aten Primaria** 1996 Apr 15;17(6):408–10 (Eng. Abstr.) **(Spa)**

[Violence and sexism in television cartoons for children. Analysis of the contents] Prieto Rodríguez MA, et al. **Aten Primaria** 1996 Apr 15;17(6):382–8 (Eng. Abstr.) **(Spa)**

[Advertising of drugs: risk or benefits?] Barros JA. **Gac Sanit** 1996 Mar–Apr;10(53):81–90 (Eng. Abstr.) **(Spa)**

[Reporting by the IGM (Information Inspection Team). Marketing of Clarityn disguised as an inquiry] **Lakartidningen** 1996 Sep 11;93(37):3168 **(Swe)**

[The inspection of information: "Hidden" comparison, words of evaluation often cause notifications] **Lakartidningen** 1996 Aug 7;93(32–33):2763–5 **(Swe)**

[Advertising of soap for feminine hygiene is being over–done(letter)] Larsson PG. **Lakartidningen** 1996 Mar 20;93(12):1108 **(Swe)**

[Chubby women absolutely do not sell] Leander G. **Lakartidningen** 1996 Apr 24;93(17):1632–3 **(Swe)**

[Melatonin—uncritical use after unserious advertising (letter)] Wetterberg L. **Lakartidningen** 1996 Sep 4;93(36):3019–21 **(Swe)**

HISTORY

Images of madness: a portfolio of nineteenth–century women. Gamwell L. **Ann N Y Acad Sci** 1996 Jun 18;789:79–81

A historical analysis of tobacco marketing and the uptake of smoking by youth in the United States: 1890–1977. Pierce JP, et al. **Health Psychol** 1995 Nov;14(6):500–8

Bombastic ballyhoo: the extraordinary, advertising life of Painless Parker. Curtis EK. **J Am Coll Dent** 1995 Fall; 62(3):55–7

Advertisements in the Laryngoscope. The merits of cocaine—1896. **Laryngoscope** 1996 Jun;106(6):680

Advertisements in The Laryngoscope. Arsenauro, 1901–1904. **Laryngoscope** 1996 Aug;106(8):928

LEGISLATION & JURISPRUDENCE

Intervention to limit advertising of tobacco products [letter] Hatzi S, et al. **Aust N Z J Public Health** 1996 Jun; 20(3):324–5

Government secrecy. Baby milk advertising is a case in point [letter; comment] Banatvala N, et al. **BMJ** 1996 Jun 8;

ADVERTISING

312(7044):1475. Comment on: BMJ 1996 Feb 24;312(7029):455–6.
Tobacco companies violated advertising restriction [letter] [see comments] Guthrie B. **BMJ** 1995 Dec 2;311(7018):1501 . Comment in: BMJ 1996 Mar 16;312(7032):705. Comment in: BMJ 1996 Mar 16;312(7032):705–6.
Tobacco advertising. Cigarette advertisements are still allowed on television in Japan [letter; comment] Kawane H. **BMJ** 1996 Mar 16;312(7032):705. Comment on: BMJ 1995 Dec 2;311(7018):1501.
India cracks down on traditional drugs advertisements [news] Mudur G. **BMJ** 1996 May 25;312(7042):1318
Brazil takes steps to control tobacco [news] Raw M, et al. **BMJ** 1995 Oct 21;311(7012):1046
Tobacco advertising. Committee exists to monitor agreements on tobacco advertising [letter; comment] Whitmore C. **BMJ** 1996 Mar 16;312(7032):705–6. Comment on: BMJ 1995 Dec 2;311(7018):1501.
"Leveling the playing field" [letter] Jones HW Jr. **Fertil Steril** 1996 Apr;65(4):891
Community mobilization to reduce point-of-purchase advertising of tobacco products. Rogers T, et al. **Health Educ Q** 1995 Nov;22(4):427–42
Advertising medicines to the public [editorial; comment] George CF. **J R Coll Physicians Lond** 1996 Mar–Apr; 30(2):102–3. Comment on: J R Coll Physicians Lond 1996 Mar–Apr;30(2):104–6. Comment on: J R Coll Physicians Lond 1996 Mar–Apr;30(2):107–11.
The role of UK tobacco advertising: no effect on the nation's health? Part III: Government influence on cigarette advertising. Kinman BF, et al. **J R Soc Health** 1996 Feb; 116(1):21–6
Banning tobacco billboards: The case for municipal action. Garner DW. **JAMA** 1996 Apr 24;275(16):1263–9
The Food and Drug Administration's regulation of tobacco products. Kessler DA, et al. **N Engl J Med** 1996 Sep 26; 335(13):988–94
Prevent sports sponsorship by the tobacco industry [editorial] Yach D, et al. **S Afr Med J** 1994 Dec;84(12):823–6
[Legal and ethical problems in drug advertising and their resolution in practice] Opletalová V, et al. **Cas Lek Cesk** 1995 Jun 14;134(12):393–6 (Eng. Abstr.) **(Cze)**
[Solicitation for excimer laser by the ophthalmologist] Rieger HJ. **Dtsch Med Wochenschr** 1996 Jan 26;121(4):110–2 **(Ger)**
[Drug promotion, scientific promotion, and conflict of interest. On the royal decree 1416/1994, which regulates drug advertising] Camí J. **Gac Sanit** 1995 Jul–Aug; 9(49):273–5 **(Spa)**

STANDARDS

Tobacco advertising damages dental health [letter; comment] McCaul JA, et al. **Br Dent J** 1996 Apr 20;180(8):284. Comment on: Br Dent J 1995 Dec 9–23;179(11–12):402–3.
ADA advertising++ standards. **J Am Dent Assoc** 1996 Apr; 127(4):491–2
MADD's position on alcohol advertising: a response to Marshall and Oleson [comment] DeJong W, et al. **J Public Health Policy** 1995;16(2):231–8. Comment on: J Public Health Policy 1994 Spring;15(1):54–70.
From the Food and Drug Administration. Nightingale SL. **JAMA** 1995 Oct 11;274(14):1109

STATISTICS & NUMERICAL DATA

Tobacco and alcohol billboards in 50 Chicago neighborhoods: market segmentation to sell dangerous products to the poor. Hackbarth DP, et al. **J Public Health Policy** 1995;16(2):213–30
Using panel data to determine the effect of advertising on brand-level distilled spirits sales. Gius MP. **J Stud Alcohol** 1996 Jan;57(1):73–6

TRENDS

Health-related messages in consumer magazine advertising. Wofford JL, et al. **J Gen Intern Med** 1995 Sep;10(9):488–90
Truth in advertising. Aronson SM. **R I Med** 1995 Oct; 78(10):276–7
Tobacco advertising in South Africa with specific reference to magazines. Yach D, et al. **S Afr Med J** 1994 Dec; 84(12):838–41
[Nutritional health messages transmitted through television advertising. Trends and errors] Ortega RM, et al. **Nutr Hosp** 1995 Nov–Dec;10(6):331–9 (Eng. Abstr.) **(Spa)**

AEDES

Community involvement in the control of Aedes aegypti. Gubler DJ, et al. **Acta Trop** 1996 Apr;61(2):169–79 (21 ref.)
Aedes aegypti control in the Lao People's Democratic Republic, with reference to copepods. Jennings CD, et al. **Am J Trop Med Hyg** 1995 Oct;53(4):324–30
The Premise Condition Index: a tool for streamlining surveys of Aedes aegypti. Tun-Lin W, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):591–4
Understanding productivity, a key to Aedes aegypti surveillance. Tun-Lin W, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):595–601
Activity of novel juvenoids on arthropods of veterinary importance. Londershausen M, et al. **Arch Insect Biochem Physiol** 1996;32(3–4):651–8
Public service deficiencies and Aedes aegypti breeding sites in Venezuela. Barrera R, et al. **Bull Pan Am Health Organ** 1995 Sep;29(3):193–205
Possible contributing factors to the paucity of yellow fever epidemics in the Ashanti region of Ghana, west Africa. Addy PA, et al. **East Afr Med J** 1996 Jan;73(1):3–9
A placebo controlled clinical trial investigating the efficacy of a homeopathic after-bite gel in reducing mosquito bite induced erythema. Hill N, et al. **Eur J Clin Pharmacol** 1995; 49(1–2):103–8
Geographic spread of Aedes albopictus in Europe and the concern among public health authorities. Report and recommendations of a workshop, held in Rome, December 1994. Knudsen AB. **Eur J Epidemiol** 1995 Jun;11(3):345–8
Effect of ethylene bis isobutyl xanthate isolated from a marine green alga Dictyosphaeria favulosa on mosquito Aedes aegypti. Rao JV, et al. **Indian J Exp Biol** 1995 May; 33(5):399–40
Mosquito sensitivity to a scorpion neurotoxin expressed using an infectious Sindbis virus vector. Higgs S, et al. **Insect Mol Biol** 1995 May;4(2):97–103
Residual activity of three slow-release temephos formulations against Aedes aegypti larvae. Cilek JE, et al. **J Am Mosq Control Assoc** 1995 Sep;11(3):358–9
Attraction of Aedes albopictus adults in sod infusion. Lampman RL, et al. **J Am Mosq Control Assoc** 1996 Mar; 12(1):119–24
Essential oil analysis and field evaluation of the citrosa plant "Pelargonium citrosum" as a repellent against populations of Aedes mosquitoes. Matsuda BM, et al. **J Am Mosq Control Assoc** 1996 Mar;12(1):69–74
Characterization of resistance to organophosphate, carbamate, and pyrethroid insecticides in field populations of Aedes aegypti from Venezuela. Mazzarri MB, et al. **J Am Mosq Control Assoc** 1995 Sep;11(3):315–22
Isolation of the insecticidal components of Tagetes minuta (Compositae) against mosquito larvae and adults. Perich MJ, et al. **J Am Mosq Control Assoc** 1995 Sep;11(3):307–10
Evaluation of controlled-release mosquito repellent formulations. Rutledge LC, et al. **J Am Mosq Control Assoc** 1996 Mar;12(1):39–44
Distribution of Aedes albopictus in Georgia, USA. Womack ML, et al. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 1):237
Human host avidity in Aedes albopictus: influence of mosquito body size, age, parity, and time of day. Xue RD, et al. **J Am Mosq Control Assoc** 1996 Mar;12(1):58–63
Distribution and ecology of the mosquito fauna in the southwestern Saudi Arabia. Abdullah MA, et al. **J Egypt Soc Parasitol** 1995 Dec;25(3):815–37
Assignment of the crystal toxin genes of the mosquitocidal bacterium, Bacillus thuringiensis israelensis to a specific plasmid. Rady MH, et al. **J Egypt Soc Parasitol** 1996 Aug; 26(2):525–37
Aedes albopictus (Diptera: Culicidae) eggs: field survivorship during northern Indiana winters. Hanson SM, et al. **J Med Entomol** 1995 Sep;32(5):599–604
Yellowfever mosquito (Diptera:Culicidae) introduced into Landi Kotal, Pakistan, by tire importation. Suleman M, et al. **J Med Entomol** 1996 Jul;33(4):689–93
Mosquitoes, models, and dengue. Lifson AR. **Lancet** 1996 May 4;347(9010):1201–2
Workshop on the geographic spread of Aedes albopictus in Europe and the concern among public health authorities. Proceedings of a workshop held at the Istituto Superiore di Sanità, Rome, Italy, 19–20 December 1994. **Parassitologia** 1995 Dec;37(2–3):87–90
Aedes albopictus: a potential problem in the United Kingdom. Burgess NR. **Parassitologia** 1995 Dec; 37(2–3):121–2
Global distribution and continuing spread of Aedes albopictus. Knudsen AB. **Parassitologia** 1995 Dec; 37(2–3):91–7 (44 ref.)
The role of Aedes albopictus as an arbovirus vector. Mitchell CJ. **Parassitologia** 1995 Dec;37(2–3):109–13 (17 ref.)
Control of Aedes albopictus from the perspective of North America. Nasci RS. **Parassitologia** 1995 Dec;37(2–3):123–7 (6 ref.)
A North American model to contain the spread of Aedes albopictus through tire legislation. Novak RJ. **Parassitologia** 1995 Dec;37(2–3):129–39 (17 ref.)
Aedes albopictus: a potential problem in France. Rodhain F. **Parassitologia** 1995 Dec;37(2–3):115–9 (31 ref.)
History and updating on the spread of Aedes albopictus in Italy. Romi R. **Parassitologia** 1995 Dec;37(2–3):99–103 (16 ref.)
Aminopropeptide of human procollagen type I: a marker for the identification of blood from children in the mosquito blood meal. Bødker R, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):449–53
[The correct writing and pronunciation of the generic name Aedes Meigen, 1818] Zamburlini R. **Parassitologia** 1995 Dec;37(2–3):147–8 (Eng. Abstr.) **(Ita)**
[Single larva sampling for Aedes aegypti surveillance] Bracco JE, et al. **Rev Saude Publica** 1995 Apr;29(2):144–6 (Eng. Abstr.) **(Por)**
[The residual effect of temephos on Aedes aegypti larvae] Macoris M de L, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):375–7 (Eng. Abstr.) **(Por)**
[The role of the Aedes aegypti vector in the epidemiology of dengue in Mexico] Fernández-Salas I, et al. **Salud Publica Mex** 1995;37 Suppl:S45–52 (17 ref.) (Eng. Abstr.) **(Spa)**
[Vectors of dengue in Mexico: a critical review)] Ibáñez-Bernal S, et al. **Salud Publica Mex** 1995;37 Suppl:S53–63 (34 ref.) (Eng. Abstr.) **(Spa)**
[Yellow fever in Mexico. The eradication of Aëdes aegypti. 1966 (classical article)] Torres Muñoz A. **Salud Publica Mex** 1995;37 Suppl:S103–10; discussion S98 **(Spa)**

CHEMISTRY

A factor Xa-directed anticoagulant from the salivary glands of the yellow fever mosquito Aedes aegypti. Stark KR, et al. **Exp Parasitol** 1995 Nov;81(3):321–31
Immunohistological localization of regulatory peptides in the midgut of the female mosquito Aedes aegypti. Veenstra JA, et al. **Histochem Cell Biol** 1995 Nov;104(5):337–47

CLASSIFICATION

Aedes albopictus and other Aedes (Stegomyia) species in Fiji. Kay BH, et al. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 1):230–4

CYTOLOGY

Distention and sugar feeding induce autogenous egg development by the Asian tiger mosquito (Diptera:Culicidae). Chambers GM, et al. **J Med Entomol** 1996 May;33(3):372–8
Establishment and characterization of three cell lines from Aedes triseriatus (Diptera: Culicidae). Charpentier G, et al. **J Med Entomol** 1995 Nov;32(6):793–800

DRUG EFFECTS

Effects of two insect growth regulators on ecdysteroid production in Aedes aegypti (Diptera: Culicidae). Fournet F, et al. **J Med Entomol** 1995 Sep;32(5):588–93
Feeding the mosquito Aedes aegypti with TMOF and its analogs; effect on trypsin biosynthesis and egg development. Borovsky D, et al. **Regul Pept** 1995 Jun 27; 57(3):273–81

EMBRYOLOGY

[The duration of embryogenesis in mosquitoes of the genus Aedes] Iakubovich VIa. **Med Parazitol (Mosk)** 1995 Apr–Jun;(2):12–4 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Post-inoculation changes in enzyme activity of Aedes aegypti infected with Chikungunya virus. Mourya DT, et al. **Acta Virol** 1995 Feb;39(1):31–5
Partial purification of plasma phenoloxidase of the yellow fever mosquito Aedes aegypti L. (Diptera: Culicidae). Burks CS, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Mar; 110(3):641–7
The expression of chloramphenicol acetyltransferase in mosquitoes and mosquito cells using a packaged Sindbis replicon system. Kamrud KI, et al. **Exp Parasitol** 1995 Nov; 81(3):394–403
Mosquito dopa decarboxylase cDNA characterization and blood-meal-induced ovarian expression. Ferdig MT, et al. **Insect Mol Biol** 1996 May;5(2):119–26
Aedes aegypti midgut early trypsin is post-transcriptionally regulated by blood feeding. Noriega FG, et al. **Insect Mol Biol** 1996 Feb;5(1):25–9

GENETICS

Aedes aegypti: a quantitative trait locus (QTL) influencing filarial worm intensity is linked to QTL for susceptibility to other mosquito-borne pathogens. Beerntsen BT, et al. **Exp Parasitol** 1995 Nov;81(3):355–62
The Apyrase gene of the vector mosquito, Aedes aegypti, is expressed specifically in the adult female salivary glands. Smartt CT, et al. **Exp Parasitol** 1995 Nov;81(3):239–48
Stable expression of insect GABA receptors in insect cell lines. Promoters for efficient expression of Drosophila and mosquito Rdl GABA receptors in stably transformed mosquito cell lines. Shotkoski F, et al. **FEBS Lett** 1996 Feb 19;380(3):257–62
Population genetics with RAPD-PCR markers: the breeding structure of Aedes aegypti in Puerto Rico. Apostol BL, et al. **Heredity** 1996 Apr;76 (Pt 4):325–34
Cloning and characterization of cDNAs encoding the antibacterial peptide, defensin A, from the mosquito, Aedes aegypti. Cho WL, et al. **Insect Biochem Mol Biol** 1996 Apr; 26(4):395–402
Analysis of a vitellogenin gene of the mosquito, Aedes aegypti and comparisons to vitellogenins from other organisms. Romans P, et al. **Insect Biochem Mol Biol** 1995 Sep;25(8):939–58
Toward a physical map of Aedes aegypti. Brown SE, et al. **Insect Mol Biol** 1995 Aug;4(3):161–7
Evaluation of a viral thymidine kinase gene for suicide selection in transfected mosquito cells. Mazzacano CA, et al. **Insect Mol Biol** 1995 May;4(2):125–34
Genetic structure of Aedes albifasciatus (Diptera:Culicidae) from a marsh ecosystem in Córdoba, Argentina. de Sousa GB, et al. **J Med Entomol** 1996 Jul;33(4):531–6
Full sequence and characterization of two insect defensins:

immune peptides from the mosquito Aedes aegypti. Chalk R, et al. **Proc R Soc Lond B Biol Sci** 1995 Aug 22; 261(1361):217–21

GROWTH & DEVELOPMENT

Critical examination of Aedes aegypti indices: correlations with abundance. Tun-Lin W, et al.
Am J Trop Med Hyg 1996 May;54(5):543–7

Duration of larval and pupal development stages of Aedes albopictus in natural and artificial containers. Gomes A de C, et al. **Rev Saude Publica** 1995 Feb;29(1):15–9

IMMUNOLOGY

Monoclonal antibodies against Manduca sexta hemocytes bind Aedes aegypti hemocytes: characterization of six monoclonal antibodies that bind hemocytes from both species. Willott E, et al. **Dev Comp Immunol** 1995 Nov–Dec;19(6):451–61

Immunoblot analysis of IgE and IgG binding antigens in extracts of mosquitos Aedes vexans, Culex tarsalis and Culiseta inornata. Peng Z, et al.
Int Arch Allergy Immunol 1996 May;110(1):46–51

Histamine and leukotriene C4 release in cutaneous mosquito–bite reactions. Horsmanheimo L, et al.
J Allergy Clin Immunol 1996 Aug;98(2):408–11

Failure of immune sera to neutralize dengue–2 virus in intrathoracically inoculated Aedes aegypti. Putnam JL, et al. **J Am Mosq Control Assoc** 1995 Sep;11(3):372–4

Mosquito homolog of the La autoantigen binds to Sindbis virus RNA. Pardigon N, et al. **J Virol** 1996 Feb; 70(2):1173–81

MICROBIOLOGY

Wolbachia pipientis: bacterial density and unidirectional cytoplasmic incompatibility between infected populations of Aedes albopictus. Sinkins SP, et al. **Exp Parasitol** 1995 Nov;81(3):284–91

Serological and molecular characterization of Mesoplasma seiffertii strains isolated from hematophagous dipterans in France. Gros O, et al. **Int J Syst Bacteriol** 1996 Jan; 46(1):112–5

PARASITOLOGY

Plasmodium gallinaceum: sporozoite invasion of Aedes aegypti salivary glands is inhibited by anti–gland antibodies and by lectins. Barreau C, et al. **Exp Parasitol** 1995 Nov; 81(3):332–43

Aedes aegypti: a quantitative trait locus (QTL) influencing filarial worm intensity is linked to QTL for susceptibility to other mosquito–borne pathogens. Beerntsen BT, et al. **Exp Parasitol** 1995 Nov;81(3):355–62

Aedes aegypti: induced antibacterial proteins reduce the establishment and development of Brugia malayi. Lowenberger CA, et al. **Exp Parasitol** 1996 Jul; 83(2):191–201

Plasmodium gallinaceum: mosquito peritrophic matrix and the parasite–vector compatibility. Shahabuddin M, et al. **Exp Parasitol** 1995 Nov;81(3):386–93

Plasmodium: a quantitative molecular assay for detection of sporogonic–stage malaria parasites. Vernick KD, et al.
Exp Parasitol 1995 Dec;81(4):436–44

Antibody–mediated inhibition of Aedes aegypti midgut trypsins blocks sporogonic development of Plasmodium gallinaceum. Shahabuddin M, et al. **Infect Immun** 1996 Mar; 64(3):739–43

Host–parasite relationships of Wuchereria bancrofti and mosquito hosts, Culex pipiens L. and Aedes caspius pallas. Gad AM, et al. **J Egypt Soc Parasitol** 1996 Apr; 26(1):93–104

Uptake and development of Wuchereria bancrofti in Culex pipiens L. and Aedes caspius pallas. Gad AM, et al.
J Egypt Soc Parasitol 1996 Aug;26(2):305–14

Infection of Aedes albopictus (Diptera: Culicidae) and Ae. aegypti with Lambornella stegomyiae (Ciliophora: Tetrahymenidae). Arshad HH, et al. **J Invertebr Pathol** 1995 Nov;66(3):303–6

Parasitism of Aedes aegypti and Ae. albopictus (Diptera: Culicidae) by Ascogregarina spp. (Apicomplexa: Lecudinidae) in Florida. Blackmore MS, et al.
J Med Entomol 1995 Nov;32(6):847–52

Dirofilaria (Filarioidea: Onchocercidae) infection in Aedes albopictus (Diptera: Culicidae) collected in Louisiana. Comiskey N, et al. **J Med Entomol** 1995 Sep;32(5):734–7

Behavior of Wuchereria bancrofti (Filariidea: Onchocercidae) infective larvae in the vector Aedes polynesiensis (Diptera:Culicidae) in relation to parasite transmission. Lardeux F, et al. **J Med Entomol** 1996 Jul; 33(4):516–24

Release of Romanomermis iyengari (Nematoda:Mermithidae) to control Aedes taeniorhynchus (Diptera:Culicidae) in Punta del Este, Isla de la Juventud, Cuba. Santamarina Mijares A, et al. **J Med Entomol** 1996 Jul;33(4):680–2

Behaviors associated with egg and parasite deposition by gravid and Lambornella clarki–infected Aedes sierrensis. Yee WL. **J Parasitol** 1995 Oct;81(5):694–7

Interactions between parasites and insects vectors. Hurd H. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:27–30 (20 ref.)

Development of Dirofilaria and Setaria nematodes in Aedes albopictus. Cancrini G, et al. **Parassitologia** 1995 Dec; 37(2–3):141–5 (24 ref.)

A polymerase chain reaction assay to determine infection of Aedes polynesiensis by Wuchereria bancrofti. Nicolas L, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr; 90(2):136–9

PHYSIOLOGY

Probing and gorging responses of three mosquito species to a membrane feeding system at a range of temperatures. Cosgrove JB, et al. **J Am Mosq Control Assoc** 1995 Sep; 11(3):339–42

Field overwinter survivorship of Aedes albopictus eggs in Japan. Hanson SM. **J Am Mosq Control Assoc** 1995 Sep; 11(3):354–7

Non–linear dynamics of neurochemical modulation of mosquito oviduct and hindgut contractions. Messer AC, et al. **J Exp Biol** 1995 Nov;198 (Pt 11):2325–36

Differential lipid reserves influence host–seeking behaviour in the mosquitoes Aedes cantans and Aedes punctor. Renshaw M, et al. **Med Vet Entomol** 1995 Oct;9(4):381–7

Daily pattern of flight activity of Aedes albifasciatus in central Argentina. Almeida FF, et al.
Mem Inst Oswaldo Cruz 1995 Sep–Oct;90(5):639–44

Development of a cyanobacterial biolarvicide. Murphy RC, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):109–13

Studies on mosquitoes (Diptera: Culicidae) and anthropic environment. 9–Synanthropy and epidemiological vector role of Aedes scapularis in south–eastern Brazil. Forattini OP, et al. **Rev Saude Publica** 1995 Jun;29(3):199–207

VIROLOGY

Geographic distribution and serologic and genomic characterization of Morro Bay virus, a newly recognized bunyavirus. Fulhorst CF, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):563–9

Dual host infections: enhanced infectivity of eastern equine encephalitis virus to Aedes mosquitoes mediated by Brugia microfilariae. Vaughan JA, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):105–9

Prostaglandin A1 inhibits replication of Mayaro virus in Aedes albopictus cells. Barbosa JA, et al.
Braz J Med Biol Res 1995 Jan;28(1):27–30

Serum concentration and increased temperature alter Mayaro virus RNA and protein synthesis in Aedes albopictus (mosquito)–infected cells. Motta MC, et al.
Braz J Med Biol Res 1995 Jan;28(1):18–26

Isolation of potosi virus from Aedes albopictus in North Carolina. Harrison BA, et al.
J Am Mosq Control Assoc 1995 Jun;11(2 Pt 1):225–9

Evaluation of enemas for exposing Aedes aegypti to suspensions of dengue–2 virus. Putnam JL, et al.
J Am Mosq Control Assoc 1995 Sep;11(3):369–71

Laboratory transmission of Sindbis virus by Aedes albopictus, Ae. aegypti, and Culex pipiens (Diptera: Culicidae). Dohm DJ, et al. **J Med Entomol** 1995 Nov;32(6):818–21

Experimental evidence against replication or dissemination of hepatitis C virus in mosquitoes (Diptera:Culicidae) using detection by reverse transcriptase polymerase chain reaction. Silverman AL, et al. **J Med Entomol** 1996 May; 33(3):398–401

Molecularly engineered resistance to California serogroup virus replication in mosquito cells and mosquitoes. Powers AM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30; 93(9):4187–91

Dengue hemorrhagic fever [comment] James AA. **Science** 1996 May 10;272(5263):829. Comment on: Science 1996 May 10;272(5263):884–6.

Genetically engineered resistance to dengue–2 virus transmission in mosquitoes [see comments] Olson KE, et al. **Science** 1996 May 10;272(5263):884–6. Comment in: Science 1996 May 10;272(5263):829.

AEQUORIN

Calcium imaging shows differential sensitivity to cooling and communication in luminous transgenic plants. Campbell AK, et al. **Cell Calcium** 1996 Mar;19(3):211–8

Recombinant aequorin methods for intracellular calcium measurement in plants. Knight H, et al.
Methods Cell Biol 1995;49:201–16 (29 ref.)

Photoprotein–mediated measurement of calcium ion concentration in mitochondria of living cells. Rizzuto R, et al. **Methods Enzymol** 1995;260:417–28

BIOSYNTHESIS

Expression of membrane targeted aequorin in Xenopus laevis oocytes. Daguzan C, et al. **Int J Dev Biol** 1995 Aug; 39(4):653–7

Subcellular imaging of intramitochondrial Ca2+ with recombinant targeted aequorin: significance for the regulation of pyruvate dehydrogenase activity. Rutter GA, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5489–94

CHEMISTRY

Differences in stability of recombinant apoaequorin within subcellular compartments. Badminton MN, et al.
Biochem Biophys Res Commun 1995 Dec 26;217(3):950–7

Titration of recombinant aequorin with calcium chloride. Shimomura O, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):77–81

GENETICS

Agonist–stimulated free calcium in subcellular compartments. Delivery of recombinant aequorin to organelles using a replication deficient adenovirus vector. Kendall JM, et al. **Cell Calcium** 1996 Feb;19(2):133–42

The moss, Physcomitrella patens, transformed with apoaequorin cDNA responds to cold shock, mechanical perturbation and pH with transient increases in cytoplasmic calcium. Russell AJ, et al. **Transgenic Res** 1996 May; 5(3):167–70

METABOLISM

Targeting aequorin and green fluorescent protein to intracellular organelles. De Giorgi F, et al. **Gene** 1996;173(1 Spec No):113–7

Transgenic AEQUORIN reveals organ–specific cytosolic Ca2+ responses to anoxia and Arabidopsis thaliana seedlings. Sedbrook JC, et al. **Plant Physiol** 1996 May; 111(1):243–57

PHARMACOLOGY

Effects of thapsigargin on aequorin–injected and skinned preparations of ferret ventricular muscles. Tanaka T, et al. **Cardiovasc Res** 1995 Sep;30(3):357–62

Agonist–stimulated free calcium in subcellular compartments. Delivery of recombinant aequorin to organelles using a replication deficient adenovirus vector. Kendall JM, et al. **Cell Calcium** 1996 Feb;19(2):133–42

AEROBACTER see **ENTEROBACTER**

AEROBACTER AEROGENES see **KLEBSIELLA PNEUMONIAE**

AEROBIC BACTERIA see **BACTERIA, AEROBIC**

AEROBIC EXERCISE see **EXERCISE**

AEROCOCCUS see **STREPTOCOCCACEAE**

AEROMONAS

Infections in the cirrhotic patient [letter; comment] Garcia–Gonzalez MJ, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1475–6. Comment on: Am J Gastroenterol 1995 Dec;90(12):2234–5.

Endotoxin in Aeromonas sobria infection: speculative pathogenesis and treatment strategies in advanced liver disease with soft–tissue infection [letter; comment] Hokama A, et al. **Am J Gastroenterol** 1996 Jul;91(7):1475. Comment on: Am J Gastroenterol 1995 Dec;90(12):2234–5.

Aeromonas sobria infection with severe muscle degeneration in a patient with alcoholic liver cirrhosis [see comments] Kohashi T, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2234–5. Comment in: Am J Gastroenterol 1996 Jul;91(7):1475. Comment in: Am J Gastroenterol 1996 Jul;91(7):1475–6.

Aetiological role of Aeromonas and Plesiomonas species in human diarrhoeal illness in Nigeria [letter] Agbodaze D. **Cent Afr J Med** 1996 May;42(5):156–7

Development of Aeromonas hydrophila bacteremia in a patient recovering from cholera. Riley PA, et al.
Clin Infect Dis 1996 May;22(5):867–8

Indications and complications of medicinal leech therapy. Haycox CL, et al. **J Am Acad Dermatol** 1995 Dec; 33(6):1053–5 (10 ref.)

Motile Aeromonas as agent of infections of the foot. Wakabongo M. **J Am Podiatr Med Assoc** 1995 Sep; 85(9):505–8 (53 ref.)

Study of the humoral response of Atlantic salmon (Salmo salar L.), naturally infected with Aeromonas salmonicida ssp. achromogenes. Magnadóttir B, et al.
Vet Immunol Immunopathol 1995 Nov;49(1–2):127–42

[Gastroenteritis due to Aeromonas in pediatrics] Gómez Campdera J, et al. **An Esp Pediatr** 1996 Jun;44(6):548–52 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Structure of the O–specific polysaccharide of an Aeromonas trota strain cross–reactive with Vibrio cholerae O139 Bengal. Knirel YA, et al. **Eur J Biochem** 1996 May 15; 238(1):160–5

CLASSIFICATION

Aeromonas encheleia sp. nov., isolated from European eels. Esteve C, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):462–6

RAPD analysis of Aeromonas salmonicida and Aeromonas hydrophila. Miyata M, et al. **J Appl Bacteriol** 1995 Aug; 79(2):181–5

Non–enteritic aeromonas infections in hospitalized patients. Murphy OM, et al. **J Hosp Infect** 1995 Sep;31(1):55–60

DRUG EFFECTS

Differential susceptibility of aeromonads and coliforms to cefsulodin. Alonso JL, et al. **Appl Environ Microbiol** 1996 Jun;62(6):1885–8

Relationship between enterotoxicity and multiple drug resistance in Aeromonas spp. Singh DV, et al.
J Diarrhoeal Dis Res 1995 Sep;13(3):172–5

AEROMONAS

ENZYMOLOGY

Cloning of a cluster of chitinase genes from Aeromonas sp. No. 10S-24. Shiro M, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1-2):44-8

The structure of the Aeromonas proteolytica aminopeptidase complexed with a hydroxamate inhibitor. Involvement in catalysis of Glu151 and two zinc ions of the co-catalytic unit. Chevrier B, et al. **Eur J Biochem** 1996 Apr 15; 237(2):393-8

Sequence analysis of two chromosomally mediated inducible beta-lactamases from Aeromonas sobria, strain 163a, one a class D penicillinase, the other an AmpC cephalosporinase. Walsh TR, et al. **J Antimicrob Chemother** 1995 Jul;36(1):41-52

GENETICS

Cloning of a cluster of chitinase genes from Aeromonas sp. No. 10S-24. Shiro M, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1-2):44-8

Sequence analysis of two chromosomally mediated inducible beta-lactamases from Aeromonas sobria, strain 163a, one a class D penicillinase, the other an AmpC cephalosporinase. Walsh TR, et al. **J Antimicrob Chemother** 1995 Jul;36(1):41-52

Characterization of atypical Aeromonas salmonicida isolates by ribotyping and plasmid profiling. Pedersen K, et al. **J Appl Bacteriol** 1996 Jan;80(1):37-44

Aeromonas salmonicida possesses two genes encoding homologs of the major outer membrane protein, OmpA. Costello GM, et al. **J Bacteriol** 1996 Mar;178(6):1623-30

The leucine zipper of Aeromonas salmonicida AbcA is required for the transcriptional activation of the P2 promoter of the surface-layer structural gene, vapA, in Escherichia coli. Noonan B, et al. **Mol Microbiol** 1995 Jul; 17(2):379-86

GROWTH & DEVELOPMENT

Capsulated cells of Aeromonas salmonicida grown in vitro have different functional properties than capsulated cells grown in vivo. Garduño RA, et al. **Can J Microbiol** 1995 Oct;41(10):941-5

Emerging pathogens: Aeromonas spp. Merino S, et al. **Int J Food Microbiol** 1995 Dec;28(2):157-68

IMMUNOLOGY

Serum antibody responses of divers to waterborne pathogens. Losonsky GA, et al. **Clin Diagn Lab Immunol** 1994 Mar; 1(2):182-5

A live (delta aroA) Aeromonas salmonicida vaccine for furunculosis preferentially stimulates T-cell responses relative to B-cell responses in rainbow trout (Oncorhynchus mykiss). Marsden MJ, et al. **Infect Immun** 1996 Sep;64(9):3863-9

Characterization of Aeromonas trota strains that cross-react with Vibrio cholerae O139 Bengal. Albert MJ, et al. **J Clin Microbiol** 1995 Dec;33(12):3119-23

ISOLATION & PURIFICATION

Atypical Aeromonas salmonicida isolated from diseased turbot (Scophtalmus maximus L.). Larsen JL, et al. **Acta Vet Scand** 1996;37(2):139-46

Aeromonas encheleia sp. nov., isolated from European eels. Esteve C, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):462-6

Gastroenteritis caused by Aeromonas trota in a child. Reina J, et al. **J Clin Pathol** 1996 Feb;49(2):173-5

Abundance of Aeromonas spp. in river and lake waters in and around Dhaka, Bangladesh. Parveen S, et al. **J Diarrhoeal Dis Res** 1995 Sep;13(3):183-6

An alternative bacteriological medium for the isolation of Aeromonas spp. Jenkins JA, et al. **J Wildl Dis** 1995 Apr; 31(2):272-5

Presence of Aeromonas trota in aquatic environment. Almeida VC, et al. **Mem Inst Oswaldo Cruz** 1995 Jul-Aug; 90(4):449

Aeromonas hydrophila lung abscess in a previously healthy man. Hur T, et al. **Scand J Infect Dis** 1995;27(3):295

Role of aeromonas isolated from feces of Finnish patients. Rautelin H, et al. **Scand J Infect Dis** 1995;27(3):207-10

[Aeromonas spp. as an indicator of the trophic state of bodies of water] Reali D, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):921-5 (Eng. Abstr.) **(Ita)**

METABOLISM

Proteolytic activity of Aeromonas caviae. Karunakaran T, et al. **J Basic Microbiol** 1995;35(4):241-7

Utilization of transferrin and salmon serum as sources of iron by typical and atypical strains of Aeromonas salmonicida. Hirst ID, et al. **Microbiology** 1996 Jun;142 (Pt 6):1543-50

Growth and exotoxin production at low temperatures by Aeromonas strains in meat slurries. Majeed KN. **Microbios** 1996;85(343):105-15

PATHOGENICITY

Attachment of non-culturable toxigenic Vibrio cholerae O1 and non-O1 and Aeromonas spp. to the aquatic arthropod Gerris spinolae and plants in the River Ganga, Varanasi. Shukla BN, et al. **FEMS Immunol Med Microbiol** 1995 Oct; 12(2):113-20

Emerging pathogens: Aeromonas spp. Merino S, et al. **Int J Food Microbiol** 1995 Dec;28(2):157-68

Colonization of streptomycin-treated mice by Aeromonas species. Sanderson K, et al. **J Diarrhoeal Dis Res** 1996 Mar; 14(1):27-32

PHYSIOLOGY

Adhesion of Aeromonas sp. to cell lines used as models for intestinal adhesion. Kirov SM, et al. **Epidemiol Infect** 1995 Dec;115(3):465-73

Biochemical characterisation, enteropathogenicity and antimicrobial resistance plasmids of clinical and environmental Aeromonas isolates. Chaudhury A, et al. **J Med Microbiol** 1996 Jun;44(6):434-7

Vibrio spp. secrete proaerolysin as a folded dimer without the need for disulphide bond formation. Hardie KR, et al. **Mol Microbiol** 1995 Sep;17(6):1035-44

ULTRASTRUCTURE

Scanning electron microscopy analysis of bacterial colonization in crustaceans. Tedioli G, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):927-34

Electron microscopic examination of factors influencing the expression of filamentous surface structures on clinical and environmental isolates of Aeromonas veronii Biotype sobria. Kirov SM, et al. **Microbiol Immunol** 1995; 39(5):329-38

AEROMONAS HYDROPHILA

Fatal Aeromonas hydrophila bacteremia in a hemodialysis patient treated with deferoxamine. Lin SH, et al. **Am J Kidney Dis** 1996 May;27(5):733-5

Aeromonas hydrophila--its implications in freshwater injuries. Weber CA, et al. **J Foot Ankle Surg** 1995 Sep-Oct; 34(5):442-6

Platelet activating factor mediates cardiopulmonary dysfunction during graded bacteremic shock. Woolley DS, et al. **J Trauma** 1996 Aug;41(2):291-6; discussion 296-7

Treatment of Aeromonas hydrophila infection in a deep tissue wound. Archer BJ, et al. **S D J Med** 1995 Dec;48(12):405-7

[Serogroups, virulence and hemolytic activity of Aeromon as hydrophila which caused fish bacterial septicaemia] Qian D, et al. **Wei Sheng Wu Hsueh Pao** 1995 Dec;35(6):460-4 (Eng. Abstr.) **(Chi)**

[Bacteremic peritonitis caused by Aeromonas hydrophila in a woman with cirrhosis (letter)] Ramos Rincón JM, et al. **An Med Interna** 1996 Mar;13(3):154 **(Spa)**

CHEMISTRY

Characterisation of the heptameric pore-forming complex of the Aeromonas toxin aerolysin using MALDI-TOF mass spectrometry. Moniatte M, et al. **FEBS Lett** 1996 Apr 22;384(3):269-72

CLASSIFICATION

RAPD analysis of Aeromonas salmonicida and Aeromonas hydrophila. Miyata M, et al. **J Appl Bacteriol** 1995 Aug; 79(2):181-5

ENZYMOLOGY

The 'hidden' carbapenemase of Aeromonas hydrophila. Hayes MV, et al. **J Antimicrob Chemother** 1996 Jan; 37(1):33-44

Identification of the catalytic triad of the lipase/acyltransferase from Aeromonas hydrophila. Brumlik MJ, et al. **J Bacteriol** 1996 Apr;178(7):2060-4

Cloning, sequencing, and characterization of the nucH gene encoding an extracellular nuclease from Aeromonas hydrophila JMP636. Dodd HN, et al. **J Bacteriol** 1996 Jul; 178(13):3926-33

GENETICS

The O:34-antigen lipopolysaccharide as an adhesin in Aeromonas hydrophila. Merino S, et al. **FEMS Microbiol Lett** 1996 Jun 1;139(2-3):97-101

GROWTH & DEVELOPMENT

Survival and growth of Aeromonas hydrophila on modified atmosphere packaged normal and high pH lamb. Doherty A, et al. **Int J Food Microbiol** 1996 Jan;28(3):379-92

Growth/survival of psychrotrophic pathogens on meat packaged under modified atmospheres. García de Fernando GD, et al. **Int J Food Microbiol** 1995 Dec;28(2):221-31

Combined effect of gamma-irradiation and conventional cooking on Aeromonas hydrophila in meatball. Ozbaş ZY, et al. **Z Lebensm Unters Forsch** 1996 Jan;202(1):60-2

ISOLATION & PURIFICATION

Aeromonas hydrophila isolated from food and drinking water: hemagglutination, hemolysis, and cytotoxicity for a human intestinal cell line (HT-29). Handfield M, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3459-61

Differential media for quantitative recovery of waterborne Aeromonas hydrophila. Handfield M, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3544-7

A multiplicity of bowel problems. Luchsinger A, et al. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):27-8

Isolation, and virulence profiles, of Aeromonas hydrophila implicated in an outbreak of food poisoning in Sweden. Krovacek K, et al. **Microbiol Immunol** 1995;39(9):655-61

Improved glutaminate-starch-penicillin agar for the isolation and enumeration of Aeromonas hydrophila from seawater by membrane filtration. Papapetropoulou M, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):622-7

[Soft-tissue infection caused by Aeromonas hydrophila] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1995 Oct; 13(8):469-72 (27 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Purification and characterization of a CHO cell-elongating toxin produced by Aeromonas hydrophila. McCardell BA, et al. **Microb Pathog** 1995 Jul;19(1):1-9

PATHOGENICITY

Isolation, and virulence profiles, of Aeromonas hydrophila implicated in an outbreak of food poisoning in Sweden. Krovacek K, et al. **Microbiol Immunol** 1995;39(9):655-61

PHYSIOLOGY

Inactivation of Aeromonas hydrophila by Fe(II)-related-radical generation in oxidizing groundwaters. Kersters I, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3277-83

Behaviour of Yersinia enterocolitica and Aeromonas hydrophila in skim milk during fermentation by various lactobacilli. Ozbaş ZY, et al. **Z Lebensm Unters Forsch** 1996 Apr;202(4):324-8

RADIATION EFFECTS

Combined effect of gamma-irradiation and conventional cooking on Aeromonas hydrophila in meatball. Ozbaş ZY, et al. **Z Lebensm Unters Forsch** 1996 Jan;202(1):60-2

AEROSOL PROPELLANTS

ADVERSE EFFECTS

Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler. Donnell D, et al. **Eur J Clin Pharmacol** 1995;48(6):473-7

[Position paper on propellants in measured dose aerosol dispensers. The German Respiratory League] Wettengel R. **Med Klin** 1995 Nov 15;90(11):617 **(Ger)**

PHARMACOKINETICS

Disposition of inhaled 1,1,1,2-tetrafluoroethane (HFA134A) in healthy subjects and in patients with chronic airflow limitation. Measurement by 18F-labeling and whole-body gamma-counting. Pike VW, et al. **Drug Metab Dispos** 1995 Aug;23(8):832-9

TOXICITY

HFA-134a (1,1,1,2-tetrafluoroethane); lack of oncogenicity in rodents after inhalation. Alexander DJ, et al. **Hum Exp Toxicol** 1995 Sep;14(9):706-14

An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane). Alexander DJ, et al. **Hum Exp Toxicol** 1995 Sep;14(9):715-20 (8 ref.)

General toxicity and reproductive screen of liquid propellant XM46 administered in the drinking water of Sprague-Dawley rats. Kinkead ER, et al. **Toxicol Ind Health** 1995 Mar-Apr;11(2):199-215

AEROSOLS

Study on the ability of a new barrier to reduce airborne mite allergens. Rigamonti IE, et al. **Allerg Immunol (Paris)** 1996 Mar;28(3):70-3

Aerosolized drug delivery in the 90s [editorial; comment] Smaldone GC. **Chest** 1996 Aug;110(2):316-7. Comment on: Chest 1996 Aug;110(2):498-505.

Inhalant abuse. American Academy of Pediatrics, Committee on Substance Abuse and Committee on Native American Child Health. **Pediatrics** 1996 Mar;97(3):420-3

[Hygienic assessment of dust and gas factors at the enterprises using phosphoric acid production wastes] Rumiantsev GI, et al. **Gig Sanit** 1996 Mar-Apr;(2):13-5 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Aerosol delivery from a metered-dose inhaler during mechanical ventilation. An in vitro model. Fink JB, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):382-7

A non-electrostatic spacer for aerosol delivery. Bisgaard H, et al. **Arch Dis Child** 1995 Sep;73(3):226-30

Dispersion of aerosol boluses in the human lung: dependence on lung volume, bolus volume, and gender. Brown JS, et al. **J Appl Physiol** 1995 Nov;79(5):1787-95

Particle size selection device for use with the Turbohaler. Everard ML, et al. **Thorax** 1996 May;51(5):537-9

CHEMISTRY

The distribution of oleic acid between salbutamol base drug and different propellant blends. Eriksson PM, et al. **Pharm Res** 1995 May;12(5):715-9

Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. McCallion ON, et al. **Pharm Res** 1995 Nov;12(11):1682-8

DIAGNOSTIC USE

Aerosol derived airway morphometry in healthy subjects. Brand P, et al. **Eur Respir J** 1995 Oct;8(10):1639–46

THERAPEUTIC USE

Inhalation therapy. Jindal SK, et al.
Indian J Chest Dis Allied Sci 1996 Apr–Jun;38(2):95–109
Aerosol inhalation before reading age [letter] Faurisson F, et al. **Lancet** 1995 Nov 11;346(8985):1298
[Assessment of respiratory function in patients with chronic obstructive pulmonary diseases treated with budesonide] Kozak–Szkopek E. **Pneumonol Alergol Pol** 1995; 63(9–10):532–8 (Eng. Abstr.) **(Pol)**

TOXICITY

Development of pituitary lesions in ND4 Swiss Webster mice when estimating the sensory irritancy of airborne chemicals using ASTM method E981–84. Werley MS, et al.
Am Ind Hyg Assoc J 1996 Aug;57(8):712–6
Pulmonary collapse and pneumonia due to inhalation of a waterproofing aerosol in female CD–1 mice. Yamashita M, et al. **J Toxicol Clin Toxicol** 1995;33(6):631–7

AEROSPACE MEDICINE

see related
ACCIDENTS, AVIATION
ALTITUDE
DECOMPRESSION SICKNESS
SPACE FLIGHT

The hazards of reproduction in space. Sullivan R.
Acta Obstet Gynecol Scand 1996 Apr;75(4):372–7 (72 ref.)
Effects of high gravity on cardiac dimensions in trained air crew. Harpaz D, et al. **Am J Cardiol** 1996 Jun 1; 77(14):1258–60
Airline policy relating to passengers with epilepsy [see comments] Mumford CJ, et al. **Arch Neurol** 1995 Dec; 52(12):1215–8. Comment in: Arch Neurol 1996 May;53(5):405–6.
First aid in the air. Donaldson E, et al.
Aust N Z J Surg 1996 Jul;66(7):431–4
John Paul Stapp Award—1995 presented to James W. Brinkley [news] **Aviat Space Environ Med** 1995 Jul; 66(7):709
1995 award winners of the Aerospace Medical Association [news] **Aviat Space Environ Med** 1995 Jul;66(7):708–15
Aerospace medicine in the literature.
Aviat Space Environ Med 1995 Nov;66(11):1113–4
Directory issue of the Aerospace Medical Association.
Aviat Space Environ Med 1995 Sep;66(9 Suppl):A1–117
Greyout, blackout, and G-loss of consciousness in the Brazilian Air Force: a 1991–92 survey. Alvim KM.
Aviat Space Environ Med 1995 Jul;66(7):675–7
The effect of varying time at –Gz on subsequent +Gz physiological tolerance (push–pull effect). Banks RD, et al. **Aviat Space Environ Med** 1995 Aug;66(8):723–7
Comparison of airline passenger oxygen systems. Byrne NJ.
Aviat Space Environ Med 1995 Aug;66(8):780–3
Alcohol & tobacco: some good news & some bad news. Dille JR. **Aviat Space Environ Med** 1995 Jul;66(7):704
Magnetic resonance imaging as an aid to the diagnosis and treatment evaluation of suspected myocardial sarcoidosis in a fighter pilot. Eliasch H, et al.
Aviat Space Environ Med 1995 Oct;66(10):1010–3
Inflight arterial saturation [letter; comment] Fowler B.
Aviat Space Environ Med 1995 Nov;66(11):1119–20. Comment on: Aviat Space Environ Med 1995 Feb;66(2):126–30.
The flight engineer had one of the worst headaches in his life. Hattrup LM. **Aviat Space Environ Med** 1995 Oct; 66(10):1015–6
Spontaneous resolution of retained renal calculi in USAF aviators. Keefer KM, et al. **Aviat Space Environ Med** 1995 Oct;66(10):1001–4
Undetected neuropsychophysiological sequelae of khat chewing in standard aviation medical examination. Khattab NY, et al. **Aviat Space Environ Med** 1995 Aug;66(8):739–44
Defining and measuring the "right stuff": neuropsychiatrically enhanced flight screening (N–EFS). King RE, et al.
Aviat Space Environ Med 1995 Oct;66(10):951–6
Aeromedical certification of a pilot with bi–lateral prosthetic hands—a case report. Ospina EM, et al.
Aviat Space Environ Med 1996 May;67(5):491–3
A review of articles published in Aviation, Space, and Environmental Medicine, 1975–94. Rudge FW.
Aviat Space Environ Med 1995 Oct;66(10):1005–9 (4 ref.)
Back pain in aircrew—an initial survey. Sheard SC, et al.
Aviat Space Environ Med 1996 May;67(5):474–7
High performance supine flight assessment using the NAWC dynamic flight simulator. Shender BS.
Aviat Space Environ Med 1996 May;67(5):414–22
Alcohol elimination and simulator performance of male and female aviators: a preliminary report. Taylor JL, et al.
Aviat Space Environ Med 1996 May;67(5):407–13
China eastern MD–11 mass casualty—expect the unexpected: a case report. Towne LE. **Aviat Space Environ Med** 1995 Oct;66(10):998–1000
The role of anaerobic power in human tolerance to simulated aerial combat maneuvers. Wiegman JF, et al.
Aviat Space Environ Med 1995 Oct;66(10):938–42
You're the flight surgeon. Thoracic outlet syndrome. Wyman DO. **Aviat Space Environ Med** 1996 May;67(5):494–5
Electrooculographic and performance indices of fatigue during simulated flight. Morris TL, et al. **Biol Psychol** 1996 Feb 5;42(3):343–60
Managing in flight emergencies. Plane should not have left the ground [letter; comment] Buisseret PD. **BMJ** 1995 Dec 2;311(7018):1507–8. Comment on: BMJ 1995 Aug 5;311(7001):374–6.
Managing in flight emergencies. Glove and cannula approach is easier [letter; comment] Crawshaw CC. **BMJ** 1995 Dec 2;311(7018):1507. Comment on: BMJ 1995 Aug 5;311(7001):374–6.
Managing in flight emergencies. Emergency kit will now contain fatal dose of lignocaine [letter; comment] Gwinnutt CL, et al. **BMJ** 1995 Dec 2;311(7018):1507. Comment on: BMJ 1995 Aug 5;311(7001):374–6.
UBC researcher's back–pain studies focus on space travel. Robinson M. **Can Med Assoc J** 1996 Jan 1;154(1):94–5
Air travel and adults with cyanotic congenital heart disease. Harinck E, et al. **Circulation** 1996 Jan 15;93(2):272–6
Venous thromboembolism in association with prolonged air travel. Eklof B, et al. **Dermatol Surg** 1996 Jul;22(7):637–41
Microdosimetric–based risk factors for radiation received in space activities during a trip to Mars. Zaider M.
Health Phys 1996 Jun;70(6):845–51
Implications of automation surprises in aviation for the future of total intravenous anesthesia (TIVA). Cook RI, et al.
J Clin Anesth 1996 May;8(3 Suppl):29S–37S (49 ref.)
Barotitis in children after aviation; prevalence and treatment with Otovent. Stangerup SE, et al. **J Laryngol Otol** 1996 Jul;110(7):625–8
Options for screening for colorectal cancer in the Royal Air Force: a cost–effectiveness evaluation. Daniels K, et al.
J R Army Med Corps 1995 Oct;141(3):142–50
Noise induced hearing loss in military helicopter aircrew—a review of the evidence. Owen JP.
J R Army Med Corps 1995 Jun;141(2):98–101 (19 ref.)
Exercise ECG's [letter; comment] Perry I.
J R Army Med Corps 1995 Oct;141(3):183. Comment on: J R Army Med Corps 1995 Jun;141(2):71–4.
The United States Air Force Spatial Orientation Program [editorial] Collins DL, et al. **J Vestib Res** 1995 Nov–Dec; 5(6):389–91
Spatial disorientation episodes among F–15C pilots during Operation Desert Storm. Collins DL, et al.
J Vestib Res 1995 Nov–Dec;5(6):405–10
Auditory localization for spatial orientation. Endsley MR, et al. **J Vestib Res** 1995 Nov–Dec;5(6):473–85
Spatial orientation in aviation: visual contributions. Regan D. **J Vestib Res** 1995 Nov–Dec;5(6):455–71
Pulmonary embolism on non–stop flights between France and Reunion Island [letter] Paganin F, et al. **Lancet** 1996 Apr 27;347(9009):1195–6
Exposure to cosmic radiation of British Airways flying crew on ultralonghaul routes. Bagshaw M, et al.
Occup Environ Med 1996 Jul;53(7):495–8
Aerospace air pollution issues. Patterson RE, et al.
Otolaryngol Head Neck Surg 1996 Feb;114(2):277–80
Medical examinations for pilots. Nicholson PJ.
Postgrad Med J 1995 Nov;71(841):649–52
[Aviation medicine] Liu G.
Chung Hua I Hsueh Tsa Chih 1996 Jan;76(1):72–3 (0 ref.) **(Chi)**
[Medical aspects of space flight] Frimout D.
Bull Mem Acad R Med Belg 1994;149(12):423–8 **(Fre)**
[The work experience of the Central Military Aviation Research Hospital in the occupational rehabilitation of flight personnel after lithotripsy] Baraudinov KG, et al.
Aviakosm Ekolog Med 1995;29(2):40–2 (Eng. Abstr.) **(Rus)**
[An approach to formalized description of the spacecraft radiation safety task] Bengin VV, et al.
Aviakosm Ekolog Med 1995;29(5):40–2 (Eng. Abstr.) **(Rus)**
[Use of discriminant equations for individual evaluation of the effectiveness of phytotherapy in flying personnel] Denisov SL, et al. **Aviakosm Ekolog Med** 1995;29(6):68–72 (Eng. Abstr.) **(Rus)**
[The contribution of space biology and medicine to the solution of ecological problems] Grigor'ev AI, et al.
Aviakosm Ekolog Med 1995;29(3):21–4 (14 ref.) (Eng. Abstr.) **(Rus)**
[The international cooperation of the Institute of Biomedical Problems in 1994 (news)] Kuzin RA, et al.
Aviakosm Ekolog Med 1995;29(3):61–3 **(Rus)**
[Bases of differentiated evaluation of mental health of flying personnel] Ponomarenko VA, et al.
Aviakosm Ekolog Med 1995;29(4):12–8 (Eng. Abstr.) **(Rus)**
[Role of vestibular and visual analyzers in changes of postural activity of patients with childhood cerebral palsy in the process of treatment with space technology] Sologubov EG, et al. **Aviakosm Ekolog Med** 1995;29(5):30–4 (Eng. Abstr.) **(Rus)**
[Psychophysiological aspects of decision making by the dyad of operators] Turzin PS, et al. **Aviakosm Ekolog Med** 1995; 29(4):18–21 (Eng. Abstr.) **(Rus)**
[Man in aviation and cosmonautics: past, present and future] Ushakov IB, et al. **Aviakosm Ekolog Med** 1995;29(4):58–64 **(Rus)**
[Theoretical aspects of rehabilitation and occupational health of pilots] Vartbaronov RA, et al.
Aviakosm Ekolog Med 1995;29(5):15–9 (Eng. Abstr.) **(Rus)**
[Current problems of microbial safety of the interior environment of orbital stations after extended period of operation] Viktorov AN, et al. **Aviakosm Ekolog Med** 1995; 29(5):51–5 (Eng. Abstr.) **(Rus)**
[The concept of risk factors and flight certificate examination] Vlasov VV. **Aviakosm Ekolog Med** 1995;29(5):4–9 (60 ref.) (Eng. Abstr.) **(Rus)**
[Plasmo–catalytic removal of oxygen–containing organic compounds from the spacecraft air] Zlotopol'skiĭ VM, et al. **Aviakosm Ekolog Med** 1995;29(5):56–9 (Eng. Abstr.) **(Rus)**
[Combined effects of prolonged hypokinesia and ionizing radiation on the hematopoietic system and lymphatic organs of rats] Zukhbaia TM, et al.
Aviakosm Ekolog Med 1995;29(5):42–6 (Eng. Abstr.) **(Rus)**
[Value of several hormone indicators and cyclic nucleotides in the assessment and prognosis of resistance to acute hypoxia during operator activities] Bobrovnitskiĭ IP, et al.
Kosm Biol Aviakosm Med 1991 Sep–Oct;25(5):43–6 (Eng. Abstr.) **(Rus)**
[Specific features of humoral immunity and nonspecific resistance in pilots] Bochenkov AA, et al.
Kosm Biol Aviakosm Med 1991 Sep–Oct;25(5):8–10 (Eng. Abstr.) **(Rus)**
[Glycemia as a risk factor of reduced tolerance of hypoxic hypoxia in flight personnel] Ivanchikov AP, et al.
Kosm Biol Aviakosm Med 1991 Sep–Oct;25(5):10–2 (Eng. Abstr.) **(Rus)**
[Adrenergic reactivity of cell membranes as a criterion of occupational health of pilots] Dlusskaia IG, et al.
Med Tr Prom Ekol 1995;(9):43–6 **(Rus)**
[Early diagnosis of metabolic disorders in the gastric mucosa of flight personnel] Vasil'ev VA, et al.
Med Tr Prom Ekol 1996;(3):38–9 **(Rus)**
[The problem of myopia in pilots (causes and characteristics of development and comprehensive correction)] Ovechkin IG, et al. **Vestn Oftalmol** 1995 Oct–Dec;111(4):38–40 (45 ref.) **(Rus)**
[Current problems in aviation medical expertise] Slepenkov PL. **Voen Med Zh** 1992 Feb;(2):25–7 **(Rus)**
[The lung and trips by plane] Ibáñez Cuerda MD, et al.
Arch Bronconeumol 1995 Dec;31(10):526–33 (65 ref.) **(Spa)**

EDUCATION

Space shuttle operations at the NASA Kennedy Space Center: the role of emergency medicine. Rodenberg H, et al. **J Emerg Med** 1995 Jul–Aug;13(4):553–61
Elective report: summer 1994—American Airlines. Bland S.
J R Nav Med Serv 1995 Summer;81(2):138–41

HISTORY

Looking around: 35 years of oculomotor modeling. Young LR. **Ann Biomed Eng** 1995 Jul–Aug;23(4):456–66
[The Tsiolkovskiĭ Lectures over 30 years (1966–1995):the problems of space biomedicine] Kosmolinskiĭ FP, et al.
Aviakosm Ekolog Med 1995;29(2):64–6 **(Rus)**
[The 60th anniversary of the Institute of Aviation and Space Medicine] Stupakov GP, et al. **Aviakosm Ekolog Med** 1995; 29(2):4–6 **(Rus)**
[Aerospace radiobiology: the problems and the colleagues (on the 60th anniversary of the Institute of Aviation and Space Medicine)] Ushakov IB, et al.
Aviakosm Ekolog Med 1995;29(2):59–63 **(Rus)**
[The formation and development of pharmacological research in Russian aviation and space medicine (on the 60th anniversary of the Institute of Aviation and Space Medicine of the Ministry of Defense of the Russian Federation)] Vasil'ev PV, et al. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):72–3 **(Rus)**
[The 50th anniversary of the 114th District Military Hospital of the Moscow Air Defense District] Shichanin VV.
Voen Med Zh 1996 Apr;317(4):56–7 **(Rus)**

ORGANIZATION & ADMINISTRATION

Increased flight surgeon role in military aeromedical evacuation. Lyons TJ, et al. **Aviat Space Environ Med** 1995 Oct;66(10):927–9 (16 ref.)
Space shuttle operations at the NASA Kennedy Space Center: the role of emergency medicine. Rodenberg H, et al. **J Emerg Med** 1995 Jul–Aug;13(4):553–61
[The peripheral offices of naval and aviation health administration] Squarcione S, et al. **Ann Ig** 1994 Jul–Dec; 6(4–6):453–61 (Eng. Abstr.) **(Ita)**

STANDARDS

Excimer laser photorefractive keratectomy (PRK) for myopia—present status: aerospace considerations. Diamond S. **Aviat Space Environ Med** 1995 Jul;66(7):690–3 (38 ref.)

STATISTICS & NUMERICAL DATA

Cohort study of Air Canada pilots: mortality, cancer incidence, and leukemia risk. Band PR, et al.
Am J Epidemiol 1996 Jan 15;143(2):137–43
Vision impairment and corrective considerations of civil airmen [published erratum appears in J Am Optom Assoc 1995 Oct;66(10):602] Nakagawara VB, et al.

AEROSPACE MEDICINE

J Am Optom Assoc 1995 Aug;66(8):489–94

AESCIN see ESCIN

AET

PHARMACOLOGY

Guanidine thiol—a new activator of soluble guanylate cyclase with antihypertensive and antiaggregatory properties. Severina IS, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):913–25

[A new activator of soluble guanylate cyclase generated by nitric oxide and having antihypertensive and anti-aggregation properties] Busygina OG, et al. **Binkhimiia** 1995 Sep;60(9):1460–7 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Thiemermann C, et al. **Br J Pharmacol** 1995 Dec;116(7):2845–51

AFFECT

On the relationship between emotional and external eating behavior. Van Strien T, et al. **Addict Behav** 1995 Sep–Oct; 20(5):585–94

The effects of imagery on attitudes and moods in multiple sclerosis patients. Maguire BL. **Altern Ther Health Med** 1996 Sep;2(5):75–9

Dissociation, somatization, and affect dysregulation: the complexity of adaptation of trauma. van der Kolk BA, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):83–93 (90 ref.)

Understanding and differentiating clients' positive feelings in psychotherapy. Chance SE, et al. **Am J Psychother** 1995 Fall;49(4):514–25 (23 ref.)

Disorders of affective and linguistic prosody in children after early unilateral brain damage. Trauner DA, et al. **Ann Neurol** 1996 Mar;39(3):361–7

Chaos and complexity. Can it help us to understand mood and behavior? Ehlers CL. **Arch Gen Psychiatry** 1995 Nov; 52(11):960–4 (57 ref.)

Evidence of chaotic mood variation in bipolar disorder. Gottschalk A, et al. **Arch Gen Psychiatry** 1995 Nov; 52(11):947–59

Mood improvement in elderly women after in-hospital physical rehabilitation. Barbisoni P, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):346–9

Relations between problem orientation and optimism, pessimism, and trait affectivity: a construct validation study. Chang EC, et al. **Behav Res Ther** 1996 Feb; 34(2):185–94

Evaluative decision latencies mediated by induced affective states. Hermans D, et al. **Behav Res Ther** 1996 May–Jun; 34(5–6):483–8

Affective reactivity of language and the startle response in schizophrenia. Docherty NM, et al. **Biol Psychiatry** 1995 Jul 1;38(1):68–70

Properties of human affect induced by static color slides (IAPS): dimensional, categorical and electromyographic analysis. Davis WJ, et al. **Biol Psychol** 1995 Nov 16; 41(3):229–53

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group. Wardle J, et al. **BMJ** 1996 Jul 13; 313(7049):75–8

The relations between sociotropy and autonomy, positive and negative affect and two proposed depression subtypes. Jolly JB, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):91–101

The Symptom Questionnaire: British standardization data. Zeffert S, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):85–90

Emotional expression in upside-down faces: evidence for configurational and componential processing. McKelvie SJ. **Br J Soc Psychol** 1995 Sep;34 (Pt 3):325–34

Affective responses to social comparison: a study among disabled individuals. Ybema JF, et al. **Br J Soc Psychol** 1995 Sep;34 (Pt 3):279–92

A psychoeducational nursing intervention to enhance coping and affective state in newly diagnosed malignant melanoma patients. Fawzy NW. **Cancer Nurs** 1995 Dec;18(6):427–38

Empathic responsiveness and affective reactivity to infant stimuli in high- and low-risk for physical child abuse mothers [see comments] Milner JS, et al. **Child Abuse Negl** 1995 Jun;19(6):767–80. Comment in: Child Abuse Negl 1995 Jun;19(6):765–6.

Affective influences on startle in five-month-old infants: reactions to facial expressions of emotions. Balaban MT. **Child Dev** 1995 Feb;66(1):28–36

Children's judgements about psychological harm in social context. Helwig CC, et al. **Child Dev** 1995 Dec; 66(6):1680–93

Infant affective reactions to the resumption of maternal interaction after the still-face. Weinberg MK, et al. **Child Dev** 1996 Jun;67(3):905–14

Mood and hormonal changes during late pregnancy and puerperium. Asher I, et al. **Clin Exp Obstet Gynecol** 1995; 22(4):321–5

Affective discrimination and the implicit learning process. Manza L, et al. **Conscious Cogn** 1995 Dec;4(4):399–409

Ginseng therapy in non-insulin-dependent diabetic patients. Sotaniemi EA, et al. **Diabetes Care** 1995 Oct;18(10):1373–5

Symptoms and well-being in relation to glycemic control in type II diabetes. Van der Does FE, et al. **Diabetes Care** 1996 Mar;19(3):204–10

Affective modulation of the startle reflex in schizophrenic patients. Schlenker R, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(6):309–18

The impact of mood on time perception, memorization, and acceptance of waiting. Chebat JC, et al. **Genet Soc Gen Psychol Monogr** 1995 Nov;121(4):411–24

Effects of baseline responses, in-task feelings, and duration of activity on exercise-induced feeling states in women. Rejeski WJ, et al. **Health Psychol** 1995 Jul;14(4):350–9

Association between daily coping and end-of-day mood. Stone AA, et al. **Health Psychol** 1995 Jul;14(4):341–9

Reversal theory's mastery and sympathy states in smoking cessation. O'Connell KA, et al. **Image J Nurs Sch** 1995 Winter;27(4):311–6

Affective responses to acute exercise in elderly impaired males: the moderating effects of self-efficacy and age. McAuley E, et al. **Int J Aging Hum Dev** 1995;41(1):13–27

Variability in daily events and mood of family caregivers to cognitively impaired elders. MaloneBeach EE, et al. **Int J Aging Hum Dev** 1995;41(2):151–67

Mood recognition across the ages. Brosgole L, et al. **Int J Neurosci** 1995 Jun;82(3–4):169–89

The problem with weighing: effects on mood, self-esteem and body image. Ogden J, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):272–7

Interpretation and affect: aliquis. Sirois F. **Int J Psychoanal** 1995 Dec;76 (Pt 6):1095–107

The role of affects in the process of change in psychotherapy. Stein R. **Isr J Psychiatry Relat Sci** 1995;32(3):174–83 (26 ref.)

The effect of child negative affect on maternal discipline behavior. Arnold EH, et al. **J Abnorm Child Psychol** 1995 Oct;23(5):585–95

Facial expressions of emotion and psychopathology in adolescent boys. Keltner D, et al. **J Abnorm Psychol** 1995 Nov;104(4):644–52

Do schizophrenic patients show a disjunctive relationship among expressive, experiential, and psychophysiological components of emotion? Kring AM, et al. **J Abnorm Psychol** 1996 May;105(2):249–57

Anxiety, depression, and the anticipation of future positive and negative experiences. MacLeod AK, et al. **J Abnorm Psychol** 1996 May;105(2):286–9

Emotion recognition and social competence in chronic schizophrenia. Mueser KT, et al. **J Abnorm Psychol** 1996 May;105(2):271–5

Disgust and spider phobia. Mulkens SA, et al. **J Abnorm Psychol** 1996 Aug;105(3):464–8

Genital and psychoaffective response to erotic stimulation in sexually functional and dysfunctional men. Rowland DL, et al. **J Abnorm Psychol** 1996 May;105(2):194–203

Unconscious mood-congruent memory bias in depression. Watkins PC, et al. **J Abnorm Psychol** 1996 Feb;105(1):34–41

Prevailing mood, mood changes and dreams in bipolar disorder. Beauchemin KM, et al. **J Affect Disord** 1995 Oct 9;35(1-2):41–9

Affective valence of words, explicit and implicit memory in clinical depression. Danion JM, et al. **J Affect Disord** 1995 Jun 8;34(3):227–34

Changes in daily mood and self-restraint among undercontrolled preadolescents: a time-series analysis of "acting out". Weinberger DA, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1473–82

The experience of work and turnover intentions: interactive effects of value attainment, job satisfaction, and positive mood. George JM, et al. **J Appl Psychol** 1996 Jun; 81(3):318–25

Retrospective and prospective psychological and physical health as a function of negative affect and attributional style. Dua JK. **J Clin Psychol** 1995 Jul;51(4):507–18

Age and gender differences in the nature, meaning, and function of cherished possessions for children and adolescents. Dyl J, et al. **J Exp Child Psychol** 1996 Aug; 62(3):340–77

The relationship of HIV status, type of coagulation disorder, and school absenteeism to cognition, educational performance, mood, and behavior of boys with hemophilia. Mayes SD, et al. **J Genet Psychol** 1996 Jun;157(2):137–51

Observed affect in nursing home residents with Alzheimer's disease. Lawton MP, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):P3–14

Malignant distress on eye contact after severe head injury [letter] Fleminger S, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):114–5

Personality and parenting: exploring the mediating role of transient mood and daily hassles. Belsky J, et al. **J Pers** 1995 Dec;63(4):905–29

Repressive coping style and the experience and recall of emotion: a naturalistic study of daily affect. Cutler SE, et al. **J Pers** 1996 Jun;64(2):379–405

The relations of dispositional regulation and emotionally to elder's empathy-related responding and affect while volunteering. Eisenberg N, et al. **J Pers** 1996 Mar; 64(1):157–83

Affect intensity and individual differences in informational style. Larsen RJ, et al. **J Pers** 1996 Mar;64(1):185–207

Social-emotional adjustment and patterns of alcohol use among young adults. Weinberger DA, et al. **J Pers** 1996 Jun;64(2):495–527

Beliefs in realistic and unrealistic control: assessment and implications. Zuckerman M, et al. **J Pers** 1996 Jun; 64(2):435–64

Sensitivity to varying gains and losses: the role of self-discrepancies and event framing. Brendl CM, et al. **J Pers Soc Psychol** 1995 Dec;69(6):1028–51

On being cool and collected: mood regulation in anticipation of social interaction. Erber R, et al. **J Pers Soc Psychol** 1996 Apr;70(4):757–66

Processing goals, task interest, and the mood-performance relationship: a mediational analysis. Hirt ER, et al. **J Pers Soc Psychol** 1996 Aug;71(2):245–61

Reliability shifts in measurement reactivity: driven by content engagement or self-engagement? Knowles ES, et al. **J Pers Soc Psychol** 1996 May;70(5):1080–90

When less is more: counterfactual thinking and satisfaction among Olympic medalists. Medvec VH, et al. **J Pers Soc Psychol** 1995 Oct;69(4):603–10

Additivity of nonconscious affect: combined effects of priming and exposure. Murphy ST, et al. **J Pers Soc Psychol** 1995 Oct;69(4):589–602

Effects of mood during exposure to target information on subsequently reported judgments: an on-line model of misattribution and correction. Ottati VC, et al. **J Pers Soc Psychol** 1996 Jul;71(1):39–53

Central and peripheral self-conceptions are differentially influenced by mood: tests of the differential sensitivity hypothesis. Sedikides C. **J Pers Soc Psychol** 1995 Oct; 69(4):759–77

"I want to tell the whole world..." [editorial] Edelman M. **J Psychosoc Nurs Ment Health Serv** 1996 Apr;34(4):37–9

Distribution of positive moods in women with the premenstrual syndrome and in normal women. Metcalf MG, et al. **J Psychosom Res** 1995 Jul;39(5):609–18

Mood, learned resourcefulness and perceptions of control in type 1 diabetes mellitus. White R, et al. **J Psychosom Res** 1996 Feb;40(2):205–12

The acute effects of exercise on mood state. Yeung RR. **J Psychosom Res** 1996 Feb;40(2):123–41 (108 ref.)

Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. Westhoff C. **J Reprod Med** 1996 May;41(5 Suppl):401–6 (28 ref.)

Affect and memory in advertising: an empirical study of the compensatory processes. Chebat JC, et al. **J Soc Psychol** 1995 Aug;135(4):425–37

Orolaryngeal reflex responses to changes in affective state. Larson KK, et al. **J Speech Hear Res** 1995 Oct; 38(5):990–1000

Are rape memories different? A comparison of rape, other unpleasant, and pleasant memories among employed women. Tromp S, et al. **J Trauma Stress** 1995 Oct; 8(4):607–27

Expression of emotion in voice and music. Scherer KR. **J Voice** 1995 Sep;9(3):235–48 (89 ref.)

Acoustic concomitants of emotional expression in operatic singing: the case of Lucia in Ardi gli incensi. Siegwart H, et al. **J Voice** 1995 Sep;9(3):249–60

Well-being, symptoms and the menopausal transition. Dennerstein L. **Maturitas** 1996 Mar;23(2):147–57 (51 ref.)

Effects of the weather conditions on mood and behaviour: the role of acupuncture points. Sher L. **Med Hypotheses** 1996 Jan;46(1):19–20

Recollecting naturally-occurring intentions: a study of cognitive and affective factors. Ellis JA, et al. **Memory** 1993 Jun;1(2):107–26

Attachment security, affect regulation, and defensive responses to mood induction. Lay KL, et al. **Monogr Soc Res Child Dev** 1995;60(2-3):179–96

Nutrition and behavior. Beyth IJ, et al. **N J Med** 1996 Apr; 93(4):45–7

Hemisphere asymmetry and the processing of emotional words in anxiety. Richards A, et al. **Neuropsychologia** 1995 Jul;33(7):835–41

Akrasia, health behavior, relapse, and reversal theory. O'Connell KA. **Nurs Outlook** 1996 Mar–Apr;44(2):94–8

Comparison of original and revised scoring systems for the Multiple Affect Adjective Check List. Jacobsen BS, et al. **Nurs Res** 1996 Jan–Feb;45(1):57–60

Affect in diabetic women during pregnancy and postpartum. York R, et al. **Nurs Res** 1996 Jan–Feb;45(1):54–6

Comparison of two multidimensional coordinate systems for facial expressions. Bimler D, et al. **Percept Mot Skills** 1996 Feb;82(1):289–90

Cohesion correlates with affect in structured exercise classes. Courneya KS. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):1021–2

Hemispheric asymmetry as a function of handedness: perception of facial affect stimuli. Everhart DE, et al. **Percept Mot Skills** 1996 Feb;82(1):264–6

Motivation to participate, exercise affect, and outcome behaviors toward physical activity. Frederick CM, et al. **Percept Mot Skills** 1996 Apr;82(2):691–701

Blue questionnaires and blue mood. Herbst A, et al. **Percept Mot Skills** 1995 Oct;81(2):514

Alexithymia, affect recognition, and five factors of personality in substance abusers. Mann LS, et al. **Percept Mot Skills** 1995 Aug;81(1):35–40

From behavioral chronobiology to chronopsychology with special reference to circadian fluctuations of emotionality. Poirel C. **Percept Mot Skills** 1995 Oct;81(2):380–2

Head position and spinal position as determinants of

perceived emotional state. Schouwstra SJ, et al. **Percept Mot Skills** 1995 Oct;81(2):673–4

The false recognition of mood–matched and mood–opposite words in a memory task: introduction of a delayed testing condition. Whissell C, et al. **Percept Mot Skills** 1995 Oct; 81(2):659–64

Schizophrenic patients' perceptions of their relatives' attitudes. Tompson MC, et al. **Psychiatry Res** 1995 Jul 28; 57(2):155–67

Relationship of events and affect in the daily life of an elderly population. Lawton MP, et al. **Psychol Aging** 1995 Sep; 10(3):469–77

A new laboratory method for altering positive affect. Wiseman D, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1103–6

Application of a Rasch analysis to the examination of the perception of facial affect among persons with mental retardation. Gumpel T, et al. **Res Dev Disabil** 1996 Mar–Apr;17(2):161–71

Influence of symptoms, lung function, mood, and social support on level of functioning of patients with COPD. Graydon JE, et al. **Res Nurs Health** 1995 Dec;18(6):525–33

Patterns of depressed mood in midlife women; observations from the Seattle Midlife Women's Health Study. Woods NF, et al. **Res Nurs Health** 1996 Apr;19(2):111–23

[An unbiased study of the perception of smile and sadness by analysing the integration of emotions] Granato P, et al. **Ann Med Psychol (Paris)** 1996 Jan;154(1):1–9 (Eng. Abstr.) **(Fre)**

[DSM IV : An improved approach to mood disorders? Symposium proceedings. Paris, France, May 13, 1995] **Encephale** 1995 Dec;21 Spec No 5:1–67 **(Fre)**

[Development of the affect system] Moser U, et al. **Psyche (Stuttg)** 1996 Jan;50(1):32–84 (110 ref.) (Eng. Abstr.) **(Ger)**

[Effect of mood and analytic and intuitive judgement tendencies in the "false–fame" effect] Hänze M. **Z Psychol Z Angew Psychol** 1996;204(2):149–66 (Eng. Abstr.) **(Ger)**

[Two decades of the concept of alexithymia] Brzeziński R. **Psychiatr Pol** 1995 Jul–Aug;29(4):443–54 (Eng. Abstr.) **(Pol)**

[Tools for a clinical assessment of patients' attitude toward their schizophrenic illness: 3. Examples of clinical experiments] Wciórka J. **Psychiatr Pol** 1996 May–Jun; 30(3):415–27 (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

Measuring cocaine effect expectancies among therapeutic community inpatients. Schafer J, et al. **Addict Behav** 1996 Mar–Apr;21(2):205–10

Liability to alprazolam abuse in daughters of alcoholics. Ciraulo DA, et al. **Am J Psychiatry** 1996 Jul;153(7):956–8

Assessment of recovery following day–case arthroscopy. A comparison between propofol and isoflurane–based anaesthesia. Gupta A, et al. **Anaesthesia** 1995 Nov; 50(11):937–42

The effects of transnasal butorphanol on mood and psychomotor functioning in healthy volunteers. Zacny JP, et al. **Anesth Analg** 1996 May;82(5):931–5

Effect of propofol on affective state as assessed by place conditioning paradigm in rats. Pain L, et al. **Anesthesiology** 1996 Jul;85(1):121–8

Effects of dietary selenium on mood in healthy men living in a metabolic research unit. Hawkes WC, et al. **Biol Psychiatry** 1996 Jan 15;39(2):121–8

Influences of dietary and intraduodenal lipid on alertness, mood, and sustained concentration. Wells AS, et al. **Br J Nutr** 1995 Jul;74(1):115–23

Effect of valine on 5–HT–mediated prolactin release in healthy volunteers, and on mood in remitted depressed patients. Williamson DJ, et al. **Br J Psychiatry** 1995 Aug; 167(2):238–42

Melatonin–induced temperature suppression and its acute phase–shifting effects correlate in a dose–dependent manner in humans. Deacon S, et al. **Brain Res** 1995 Aug 7; 688(1–2):77–85

Acute subjective responses to paroxetine in normal volunteers. Brauer LH, et al. **Drug Alcohol Depend** 1995 Oct;39(3):223–30

Is aspirin, as used for antithrombosis, an emotion–modulating agent? Ketterer MW, et al. **J Psychosom Res** 1996 Jan; 40(1):53–8

Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double–blind, placebo–controlled EEG mapping and psychometric studies under normoxia. Saletu B, et al. **Methods Find Exp Clin Pharmacol** 1996 Jan–Feb; 18(1):55–66

Vitamin supplementation for 1 year improves mood. Benton D, et al. **Neuropsychobiology** 1995;32(2):98–105

The effects of L–dihydroxyphenylalanine on alertness and mood in alpha–methyl–para–tyrosine–treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety. McCann UD, et al. **Neuropsychopharmacology** 1995 Aug;13(1):41–52

Mood and performance effects of caffeine in relation to acute and chronic caffeine deprivation. Richardson NJ, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):313–20

Effect of initial treatment with antidepressants as a predictor of outcome after 8 weeks. Volz HP, et al. **Psychiatry Res** 1995 Sep 29;58(2):107–15

Preferences for ethanol and diazepam in anxious individuals: an evaluation of the self–medication hypothesis. Chutuape MA, et al. **Psychopharmacology (Berl)** 1995 Sep; 121(1):91–103

Overnight caffeine abstinence and negative reinforcement of preference for caffeine–containing drinks. Rogers PJ, et al. **Psychopharmacology (Berl)** 1995 Aug;120(4):457–62

Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients. Salín–Pascual RJ, et al. **Psychopharmacology (Berl)** 1995 Oct;121(4):476–9

Neuropsychologic and cardiovascular effects of clemastine fumarate under pressure. Sipinen SA, et al. **Undersea Hyperb Med** 1995 Dec;22(4):401–6

[Delay in the effect of antidepressive agents: pharmacologic approach] Allain H, et al. **Encephale** 1995 Mar;21 Spec No 2:9–15 (39 ref.) (Eng. Abstr.) **(Fre)**

[Delay of the antidepressant effect: clinical studies] Escande M, et al. **Encephale** 1995 Mar;21 Spec No 2:3–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Multidimensional psychometric assessment of preoperative mood. Effects of zolpidem compared to phenobarbital combined with promethazine as premedication] Uhlig T, et al. **Anaesthesist** 1995 Sep;44(9):634–42 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

To sleep—perchance to dream ... of affective disorders [letter] Stoline AM. **Am J Psychiatry** 1996 Jan;153(1):134–5

The neuroendocrinology of menstrual cycle mood disorders. Rubinow DR, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:648–59 (51 ref.)

Frontal brain asymmetry predicts affective style in men. Jacobs GD, et al. **Behav Neurosci** 1996 Feb;110(1):3–6

Intra–individual patterns of hormonal and affective adaptation to work demands: an n = 2 study of junior doctors. Robert G, et al. **Biol Psychol** 1996 Feb 5; 42(3):393–411

The comforting substrate and the right brain. Horton PC. **Bull Menninger Clin** 1995 Fall;59(4):480–6

Pleasant odors and congruency: effects on approach behavior. Knasko SC. **Chem Senses** 1995 Oct;20(5):479–87

Frontal activation asymmetry and social competence at four years of age. Fox NA, et al. **Child Dev** 1995 Dec; 66(6):1770–84

Negative affect and self–report of physical symptoms: two longitudinal studies of older adults. Leventhal EA, et al. **Health Psychol** 1996 May;15(3):193–9

Is diurnal variation of mood associated with parasympathetic activity? Rechlin T, et al. **J Affect Disord** 1995 Jun 8; 34(3):249–55

Do somatic complaints mask negative affect in youth? Terre L, et al. **J Am Coll Health** 1995 Nov;44(3):91–6

Cardiovascular reactivity and positive/negative affect during conversations. Warner RM, et al. **J Behav Med** 1995 Apr; 18(2):141–59

Behavioral effects and body activity level in female hospital staff nurses during work hour. Mathur K, et al. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):1–11

Cerebral laterality in affect and affective illness: a review. Mandal MK, et al. **J Psychol** 1996 Jul;130(4):447–59 (80 ref.)

Labor experience, maternal mood and cortisol and catecholamine levels in low–risk primiparous women. Mahomed K, et al. **J Psychosom Obstet Gynaecol** 1995 Dec; 16(4):181–6

Cholesterol and psychological well–being. Wardle J. **J Psychosom Res** 1995 Jul;39(5):549–62 (72 ref.)

Exercise, wellbeing, and endogenous molecules of mood [letter] Sher L. **Lancet** 1996 Aug 17;348(9025):477

Dissociation in prefrontal cortex of affective and attentional shifts. Dias R, et al. **Nature** 1996 Mar 7;380(6569):69–72

Lateralized effect of rapid–rate transcranial magnetic stimulation of the prefrontal cortex on mood. Pascual–Leone A, et al. **Neurology** 1996 Feb;46(2):499–502

Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. George MS, et al. **Neuroreport** 1995 Oct 2;6(14):1853–6

Asymmetrical involvement of mesolimbic dopaminergic neurons in affective perception. Besson C, et al. **Neuroscience** 1995 Oct;68(4):963–8

Hormones, mood, and cognitive functioning in postmenopausal women. Sherwin BB. **Obstet Gynecol** 1996 Feb;87(2 Suppl):20S–26S

Investigation of the effects and aftereffects of naturally occurring upper respiratory tract illnesses on mood and performance. Hall S, et al. **Physiol Behav** 1996 Mar; 59(3):569–77

Effects of carbohydrate intake on subsequent food intake and mood state. Reid M, et al. **Physiol Behav** 1995 Sep; 58(3):421–7

Biological and clinical validation of atypical depression. McGinn LK, et al. **Psychiatry Res** 1996 Mar 29; 60(2–3):191–8

Mood effects on limbic blood flow correlate with emotional self–rating: a PET study with oxygen–15 labeled water. Schneider F, et al. **Psychiatry Res** 1995 Nov 10; 61(4):265–83

High self–esteem, hardiness and affective stability are associated with higher basal pituitary–adrenal hormone levels. Zorrilla EP, et al. **Psychoneuroendocrinology** 1995; 20(6):591–601

Psychophysiological responses as indices of affective dimensions. Witvliet CV, et al. **Psychophysiology** 1995 Sep; 32(5):436–43

[The influence of suicide risk and despondency on the amplitude of P300 in major depression] Urcelay–Zaldua I, et al. **Neurophysiol Clin** 1995;25(5):291–6 (Eng. Abstr.) **(Fre)**

[Ontogenesis of affect regulation] Beckmann D, et al. **Psychother Psychosom Med Psychol** 1995 Dec; 45(12):427–35 (60 ref.) (Eng. Abstr.) **(Ger)**

RADIATION EFFECTS

Detrimental influence of bright light exposure on alertness, performance, and mood in the early morning. Daurat A, et al. **Neurophysiol Clin** 1996;26(1):8–14

AFFECTIVE DISORDERS

BLOOD

Biological markers in affective disturbances. Roglev M. **Folia Med (Plovdiv)** 1995;37(4A Suppl):83

CEREBROSPINAL FLUID

Increased neural cell adhesion molecule in the CSF of patients with mood disorder. Poltorak M, et al. **J Neurochem** 1996 Apr;66(4):1532–8

CHEMICALLY INDUCED

Vulnerability to fluoxetine–induced indifference syndrome among opiate addicts: a case report. Bertschy G, et al. **Biol Psychiatry** 1995 Sep 15;38(6):404–6

Cocaine blamed for infants' emotional problems [news] Roberts J. **BMJ** 1996 Jun 1;312(7043):1379

Organic solvent exposure, mood disorders, and cancer risk. An hypothesis. Frentzel–Beyme R. **Med Lav** 1995 May–Jun;86(3):284–6

CLASSIFICATION

Summary of the DSM–IV mood disorders field trial and issue overview. Keller MB, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):1–28

[Classification of mood disorders in adults] Guelfi JD. **Encephale** 1995 Dec;21 Spec No 5:21–9 (4 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Psychiatric comorbidity: prevalence in methadone maintenance treatment. Milby JB, et al. **Am J Drug Alcohol Abuse** 1996 Feb;22(1):95–107

Affective comorbidity in children and adolescents with attention deficit hyperactivity disorder. Butler SF, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):51–5

Organic solvent exposure, mood disorders, and cancer risk. An hypothesis. Frentzel–Beyme R. **Med Lav** 1995 May–Jun;86(3):284–6

A cross–sectional analysis of WAIS–R aging patterns with psychiatric inpatients: support for Horn's hypothesis that fluid cognitive abilities decline. Boone DE. **Percept Mot Skills** 1995 Oct;81(2):371–9

Rates of first hospitalizations for affective psychoses in Costa Rica. Handal N, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Nov;30(6):245–55

[Alexithymia and psychopathology in a clinical sample of obese subjects] Molinari E, et al. **Minerva Psichiatr** 1995 Sep;36(3):133–8 (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Accuracies and inaccuracies of the family history method: a multivariate approach. Roy MA, et al. **Acta Psychiatr Scand** 1996 Apr;93(4):224–34

Can mood disorder in women with breast cancer be identified preoperatively? Ramirez AJ, et al. **Br J Cancer** 1995 Dec; 72(6):1509–12

Demography of DSM–III borderline personality disorder (PD): a comparison with Axis II PDs, affective illness and schizophrenia convergent and discriminant validation. Taub JM. **Int J Neurosci** 1995 Jun;82(3–4):191–214 (96 ref.)

Patterns of diagnoses, comorbidities, and treatment in late–middle–aged and older affective disorder patients: comparison of mental health and medical sectors. Moos RH, et al. **J Am Geriatr Soc** 1996 Jun;44(6):682–8

The validity of mixed disorders of conduct and emotions in children and adolescents: a research note. Steinhausen HC, et al. **J Child Psychol Psychiatry** 1996 Mar; 37(3):339–43

Examining comorbidity and posttraumatic stress disorder in a Vietnam veteran population using the MMPI–2. Weyermann AG, et al. **J Trauma Stress** 1996 Apr; 9(2):353–60

A grade–six reading level key for the multiple affect adjective check list–revised. Lubin B, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):883–9

Chronic mood disorder and depressive personality. Shea MT, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):103–20 (42 ref.)

Persistence of chronic mood disorders: a 2 year follow–up. Furukawa T, et al. **Psychiatry Clin Neurosci** 1995 Mar; 49(1):19–24

Cues to the assessment of affects and moods: speech fluency and pausing. Alpert M, et al. **Psychopharmacol Bull** 1995; 31(2):421–4

Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). Dingemans PM, et al. **Psychopharmacology (Berl)** 1995 Dec;122(3):263-7

[Alexithymia and psychopathology in a clinical sample of obese subjects] Molinari E, et al. **Minerva Psichiatr** 1995 Sep;36(3):133-8 (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Relationship between the provision of counselling and the prescribing of antidepressants, hypnotics and anxiolytics in general practice. Fletcher J, et al. **Br J Gen Pract** 1995 Sep;45(398):467-9

A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. Ghadirian AM, et al. **J Clin Psychiatry** 1996 Jan;57(1):22-8

Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Bendz H, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):457-60

Nimodipine increases CSF somatostatin in affectively ill patients. Pazzaglia PJ, et al. **Neuropsychopharmacology** 1995 Aug;13(1):75-83

[The effect of amitriptyline on the pathological crying and other pseudobulbar signs] Szczudlik A, et al. **Neurol Neurochir Pol** 1995 Sep-Oct;29(5):663-74 (Eng. Abstr.) **(Pol)**

[Effect of pharmacotherapy of affective disorders on the psycho-semantics of alcoholic patients] Krupitskii EM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(6):67-71 (Eng. Abstr.) **(Rus)**

ECONOMICS

Managed mental health care and patterns of inpatient utilization for treatment of affective disorders. Frank RG, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Aug; 30(5):220-3

Crisis intervention and affective disorders: a comparative cost-effectiveness study. Rosset N, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Aug;30(5):231-5

EPIDEMIOLOGY

Affective disorders in Holland after prenatal exposure to the 1957 A2 influenza epidemic. Brown AS, et al. **Biol Psychiatry** 1995 Aug 15;38(4):270-3

Aggressive behaviour as a cause of psychiatric admission: a comparison between schizophrenic and affective disorder patients. Fux M, et al. **Med Law** 1995;14(3-4):293-300

[Obsessive disorders and syndromes and affective disorders. Apropos of a French epidemiologic obsessive compulsive disorders and obsessive compulsive syndromes DRT survey] Bourgeois M. **Encephale** 1996 May;22 Spec No 1:23-31 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Lowered serum cholesterol and low mood [editorial; comment] Brown SL. **BMJ** 1996 Sep 14;313(7058):637-8 . Comment on: BMJ 1996 Sep 14;313(7058):649-51. Comment on: BMJ 1996 Sep 14;313(7058):664.

Eating and emotional disorders in adolescent obese girls with insulin-dependent diabetes mellitus. Vila G, et al. **Eur Child Adolesc Psychiatry** 1995 Oct;4(4):270-9

GABA and mood disorders: a brief review and hypothesis. Petty F. **J Affect Disord** 1995 Aug 18;34(4):275-81 (60 ref.)

Anatomic correlates of psychological events related to temporolimbic epilepsy. Tackenberg JN, et al. **J Neurosci Nurs** 1996 Apr;28(2):73-81 (51 ref.)

Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Coplan JD, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20; 93(4):1619-23

[Hemiballismus with logorrhea and thymo-affective disinhibition caused by hematoma of the left subthalamic nucleus] Trillet M, et al. **Rev Neurol (Paris)** 1995 Jun-Jul; 151(6-7):416-9 (Eng. Abstr.) **(Fre)**

[Porphyria and psychiatric manifestations] Pérez Bravo A, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov-Dec;23(6):319-21 (Eng. Abstr.) **(Spa)**

GENETICS

Detection of linkage to affective disorders in the catalogued Amish pedigrees: a reply to Pauls et al [letter] Gershon ES, et al. **Am J Hum Genet** 1996 Jun;58(6):1381-5

Further association study on dopamine D2 receptor variant S311C in schizophrenia and affective disorders. Arinami T, et al. **Am J Med Genet** 1996 Apr 9;67(2):133-8

Evidence of a locus for schizophrenia and related disorders on the short arm of chromosome 5 in a large pedigree. Silverman JM, et al. **Am J Med Genet** 1996 Apr 9; 67(2):162-71

Autism, affective disorders, and social phobia. Smalley SL, et al. **Am J Med Genet** 1995 Feb 27;60(1):19-26

A family study on outpatients with mood and personality disorders [letter; comment] Burkart M, et al. **Compr Psychiatry** 1996 Mar-Apr;37(2):148-9. Comment on: Compr Psychiatry 1995 May-Jun;36(3):199-206.

Serotonin transporter gene polymorphism and affective disorder [letter; comment] Kunugi H, et al. **Lancet** 1996 May 11;347(9011):1340. Comment on: Lancet 1996 Mar 16;347(9003):731-3.

Status report on molecular genetic studies of affective disorders. **Psychiatr Genet** 1995 Spring;5(1):9-21

[Severe mood disorders and heredity] Bredbacka PE. **Duodecim** 1994;110(3):252-9 (44 ref.) **(Fin)**

HISTORY

Neurosurgery for affective disorders at Atkinson Morley's Hospital 1948-1994. Kitchen N. **Acta Neurochir Suppl (Wien)** 1995;64:64-8

The catecholamine hypothesis of affective disorders: a review of supporting evidence. 1965 [classical article] Schildkraut JJ. **J Neuropsychiatry Clin Neurosci** 1995 Fall;7(4):524-33; discussion 523-4

Pathological grief: two Victorian case studies. Ramchandani D. **Psychiatr Q** 1996 Spring;67(1):75-84

METABOLISM

Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Holsboer F, et al. **Neuroendocrinology** 1995 Oct;62(4):340-7

Recent advances in the GABA-A-benzodiazepine receptor pharmacology. Kostowski W. **Pol J Pharmacol** 1995 May-Jun;47(3):237-46 (57 ref.)

MICROBIOLOGY

Does Borna disease virus infect humans? [comment] Pyper JM. **Nat Med** 1995 Mar;1(3):209-10. Comment on: Nat Med 1995 Mar;1(3):232-6.

MORTALITY

Extended survival of patients on long-term lithium treatment. Ahrens B, et al. **Can J Psychiatry** 1995 Jun;40(5):241-6

PHYSIOPATHOLOGY

To sleep--perchance to dream ... of affective disorders [letter] Stoline AM. **Am J Psychiatry** 1996 Jan;153(1):134-5

Stress, conditioning, and the temporal aspects of affective disorders. Post RM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:677-96 (42 ref.)

The 18th annual meeting of the Canadian College of Neuropsychopharmacology in Association with the Japanese Society of Neuropsychopharmacology. Vancouver, Canada, June 4-7, 1995. Boksa P, et al. **J Psychiatry Neurosci** 1995 Nov;20(5):340-4

Cerebral laterality in affect and affective illness: a review. Mandal MK, et al. **J Psychol** 1996 Jul;130(4):447-59 (80 ref.)

Face and voice expression identification in patients with emotional and behavioural changes following ventral frontal lobe damage. Hornak J, et al. **Neuropsychologia** 1996 Apr;34(4):247-61

Regional cerebral blood flow in mood disorders: IV. Comparison of mania and depression. Rubin E, et al. **Psychiatry Res** 1995 May 31;61(1):1-10

PSYCHOLOGY

Pathways linking affective disturbances and physical disorders. Cohen S, et al. **Health Psychol** 1995 Sep; 14(5):374-80 (50 ref.)

Opiate dependence, comorbidity and seasonality of birth. Kell MJ. **J Addict Dis** 1995;14(3):19-34

Preschoolers of dysphoric mothers. Lang C, et al. **J Child Psychol Psychiatry** 1996 Feb;37(2):221-4

Size, detail, and line heaviness in children's drawings as correlates of emotional distress: (more) negative evidence. Joiner TE Jr, et al. **J Pers Assess** 1996 Aug;67(1):127-41

Alexithymia in primary health care patients. Joukamaa M, et al. **J Psychosom Res** 1995 Oct;39(7):833-42

Two decades of alexithymia [editorial] Salminen JK, et al. **J Psychosom Res** 1995 Oct;39(7):803-7

The General Health Questionnaire: how many items are really necessary in population surveys? Jacobsen BK, et al. **Psychol Med** 1995 Sep;25(5):957-61

The prevalence of symptoms of irritable bowel syndrome among acute psychiatric inpatients with an affective diagnosis. Dewsnap P, et al. **Psychosomatics** 1996 Jul-Aug; 37(4):385-9

Mood changes in homesick persons during a holiday trip. A multiple case study. Van Tilburg MA, et al. **Psychother Psychosom** 1996 Mar-Apr;65(2):91-6

Influence of locus of control on mood state disturbance after short-term sleep deprivation. Hill DW, et al. **Sleep** 1996 Jan;19(1):41-6

[Madness(es). Social psychiatric-affective-chaos theory observations] Ciompi L. **Schweiz Arch Neurol Psychiatr** 1996;147(1):32-7 **(Ger)**

[Effect of pharmacotherapy of affective disorders on the psycho-semantics of alcoholic patients] Krupitskii EM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(6):67-71 (Eng. Abstr.) **(Rus)**

REHABILITATION

Race and gender differences in the treatment of psychiatric disorders in young adolescents. Cuffe SP, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1536-43

A cross-sectional analysis of WAIS-R aging patterns with psychiatric inpatients: support for Horn's hypothesis that fluid cognitive abilities decline. Boone DE. **Percept Mot Skills** 1995 Oct;81(2):371-9

THERAPY

Practical management of treatment-resistant affective disorders. Bridges PK, et al. **Br J Hosp Med** 1995 Nov 15-Dec 12;54(10):501-6 (58 ref.)

Electrical dose titration for electroconvulsive therapy: a comparison with dose prediction methods. Enns M, et al. **Convuls Ther** 1995 Jun;11(2):86-93

Patterns of diagnoses, comorbidities, and treatment in late-middle-aged and older affective disorder patients: comparison of mental health and medical sectors. Moos RH, et al. **J Am Geriatr Soc** 1996 Jun;44(6):682-8

The clinical research of affective disorders. A personal perspective. Angst J. **Pharmacopsychiatry** 1995 Sep;28 Suppl 1:38-44 (0 ref.) **(Eng, Ger)**

AFFECTIVE DISORDERS, PSYCHOTIC

CHEMICALLY INDUCED

[Multiple sclerosis and major depression resistant to treatment. Case of a patient with antidepressive therapy-induced mood disorder, associated with manic features] Pariante CM, et al. **Clin Ter** 1995 Jun-Jul; 146(6-7):449-52 (Eng. Abstr.) **(Ita)**

CLASSIFICATION

Improved classification of psychiatric mood disorders using a feedforward neural network. Dumitra A, et al. **Medinfo** 1995;8 Pt 1:818-22

DIAGNOSIS

Somatic delusions in schizophrenia and the affective psychoses. McGilchrist I, et al. **Br J Psychiatry** 1995 Sep; 167(3):350-61

Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. Sax KW, et al. **Br J Psychiatry** 1996 Jan;168(1):68-71

Delineation of acute and transient psychotic disorders in a developing country setting. Susser E, et al. **Br J Psychiatry** 1995 Aug;167(2):216-9

Sexual disorders in nonacute psychiatric outpatients. Kockott G, et al. **Compr Psychiatry** 1996 Jan-Feb;37(1):56-61

Schizophrenia and affective disorder--distinct entities or continuum?: an analysis based on a prospective 6-year follow-up. Winokur G, et al. **Compr Psychiatry** 1996 Mar-Apr;37(2):77-87

Mood-congruent versus mood-incongruent psychotic symptoms in first-admission patients with affective disorder. Fennig S, et al. **J Affect Disord** 1996 Feb 12; 37(1):23-9

Clinical symptoms and platelet monoamine oxidase in subgroups and different states of affective disorders. Wahlund B, et al. **J Affect Disord** 1995 Oct 9;35(1-2):75-87

The nature of 'transient' and 'partial' psychoses: findings from the Northwick Park 'Functional' Psychosis Study. Johnstone EC, et al. **Psychol Med** 1996 Mar;26(2):361-9

Cues to the assessment of affects and moods: speech fluency and pausing. Alpert M, et al. **Psychopharmacol Bull** 1995; 31(2):421-4

DRUG THERAPY

New classes of antidepressants that may be lethal in combination [letter] Low G. **Can J Psychiatry** 1995 Jun; 40(5):277-8

The use of valproate in an elderly population with affective symptoms. Kando JC, et al. **J Clin Psychiatry** 1996 Jun; 57(6):238-40

Management of psychotic, treatment-resistant depression. Rothschild AJ. **Psychiatr Clin North Am** 1996 Jun; 19(2):237-52 (119 ref.)

Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Keller MB, et al. **Psychopharmacol Bull** 1995;31(2):205-12

ETIOLOGY

Blues and depression during early puerperium: home versus hospital deliveries. Pop VJ, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):701-6

Factors associated with mood and mood disorders in SLE. Shortall E, et al. **Lupus** 1995 Aug;4(4):272-9

GENETICS

[Severe mood disorders and heredity] Bredbacka PE. **Duodecim** 1994;110(3):252-9 (44 ref.) **(Fin)**

PHYSIOPATHOLOGY

There's no such thing as the amygdala [editorial] Kirkpatrick B. **Biol Psychiatry** 1996 Mar 1;39(5):309-10

[Autonomic regulation of the cardiovascular system in patients with schizoaffective psychosis] Mel'nikova TS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(6):81-3 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

[A trial of the use of nifedipine for preventing relapses in

affective and schizoaffective psychoses] Snedkova LV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):61–6 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Bizarre delusions and first-rank symptoms in a first-admission sample: a preliminary analysis of prevalence and correlates. Tanenberg-Karant M, et al. **Compr Psychiatry** 1995 Nov-Dec;36(6):428–34

Delusion of pregnancy in psychotic depression and ECT response [letter] Bernardo M, et al. **Convuls Ther** 1996 Mar; 12(1):39–40

Affective state dependence of the Tridimensional Personality Questionnaire. Strakowski SM, et al. **Psychiatry Res** 1995 Aug 28;57(3):209–14

[Expressed emotion and six-month treatment of outcome of depressive outpatients with mood disorder] Uehara T. **Seishin Shinkeigaku Zasshi** 1995;97(9):744–56 (Eng. Abstr.) **(Jpn)**

REHABILITATION

The Maine and Vermont three-decade studies of serious mental illness. II. Longitudinal course comparisons. DeSisto M, et al. **Br J Psychiatry** 1995 Sep;167(3):338–42

The Maine and Vermont three-decade studies of serious mental illness. I. Matched comparison of cross-sectional outcome. DeSisto MJ, et al. **Br J Psychiatry** 1995 Sep; 167(3):331–8

Preliminary results from a psychoeducational program to rehabilitate chronic patients. Halford WK, et al. **Psychiatr Serv** 1995 Nov;46(11):1189–91

THERAPY

Delusion of pregnancy in psychotic depression and ECT response [letter] Bernardo M, et al. **Convuls Ther** 1996 Mar; 12(1):39–40

AFFECTIVE PSYCHOSIS, BIPOLAR see **BIPOLAR DISORDER**

AFFECTIVE SYMPTOMS

COMPLICATIONS

Gender, paid work, and symptoms of emotional distress in rheumatoid arthritis patients. Fifield J, et al. **Arthritis Rheum** 1996 Mar;39(3):427–35

DIAGNOSIS

Childhood antecedents of adolescent personality disorders. Bernstein DP, et al. **Am J Psychiatry** 1996 Jul;153(7):907–13

Alexithymia: past and present. Sifneos PE. **Am J Psychiatry** 1996 Jul;153(7 Suppl):137–42 (72 ref.)

The Symptom Questionnaire: British standardization data. Zeffert S, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):85–90

A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Snaith RP, et al. **Br J Psychiatry** 1995 Jul;167(1):99–103

Negative symptoms and affective disturbance in schizophrenia and related disorders. Malla AK. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S55–9 (49 ref.)

The reliability of distinguishing primary versus secondary negative symptoms. Flaum M, et al. **Compr Psychiatry** 1995 Nov-Dec;36(6):421–7

Anhedonia and negative symptomatology in chronic schizophrenia. Loas G, et al. **Compr Psychiatry** 1996 Jan-Feb;37(1):5–11

A new approach to affective symptoms in relapsing-remitting multiple sclerosis. Noy S, et al. **Compr Psychiatry** 1995 Sep-Oct;36(5):390–5

Long-term consistency in speech/language profiles: II. Behavioral, emotional, and social outcomes. Beitchman JH, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun; 35(6):815–25

The Developmental Behavior Checklist: the development and validation of an instrument to assess behavioral and emotional disturbance in children and adolescents with mental retardation. Einfeld SL, et al. **J Autism Dev Disord** 1995 Apr;25(2):81–104

Brief report: communication, language, social, and emotional development. Prizant BM. **J Autism Dev Disord** 1996 Apr; 26(2):173–8

Inter-rater reliability of global assessment of functioning in a clinical setting. Rey JM, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):787–92

Differential diagnosis of chronic fatigue in children: behavioral and emotional dimensions. Carter BD, et al. **J Dev Behav Pediatr** 1996 Feb;17(1):16–21

Admission to a neonatal intensive care unit as a predictor of long-term health: a 12-year follow-up. Speechley KN, et al. **J Dev Behav Pediatr** 1995 Dec;16(6):397–405

Dependency and alexithymia in psychiatric inpatients. O'Neill RM, et al. **J Nerv Ment Dis** 1996 May;184(5):302–6

Structure of the twenty-item Toronto Alexithymia Scale. Haviland MG, et al. **J Pers Assess** 1996 Feb;66(1):116–25

Distorted self-perceptions: divergent self-reports as statistical outliers in the multimethod assessment of children's social-emotional adjustment. Weinberger DA. **J Pers Assess** 1996 Feb;66(1):126–43

Severity of alexithymia is related to psychosocial factors in patients with peritoneal dialysis. Fukunishi I, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):763–70

Criterion-related validity of diagnostic criteria for alexithymia in a general hospital psychiatric setting. Fukunishi I, et al. **Psychother Psychosom** 1996 Mar-Apr; 65(2):82–5

The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Aman MG, et al. **Res Dev Disabil** 1996 Jan-Feb;17(1):41–57

The Nisonger Child Behavior Rating Form: age and gender effects and norms. Tassé MJ, et al. **Res Dev Disabil** 1996 Jan-Feb;17(1):59–75

[French translation of the Chapman Social and Physical Anhedonia Questionnaire: validation of the French translation in controls and schizophrenic patients (see comments)] Assouly-Besse F, et al. **Encephale** 1995 Jul-Aug;21(4):273–84 (Eng. Abstr.). Comment in: Encephale 1996 Jan-Feb;22(1):71–2. **(Fre)**

[Translation and validation of the Revised Social Anhedonia Scale (SAS Social Anhedonia Scale, M.L. Eckblad, L.J. Chapman et al., 1982). Study of the internal and concurrent validity in 126 normal subjects] Kosmadakis CS, et al. **Encephale** 1995 Nov-Dec;21(6):437–43 (Eng. Abstr.) **(Fre)**

[Anhedonia in schizophrenia] Loas G, et al. **Encephale** 1995 Nov-Dec;21(6):453–7 (Eng. Abstr.) **(Fre)**

[French translation of the Social and Physical Anhedonia Scale of Chapman (letter)] Loas G. **Encephale** 1995 Nov-Dec;21(6):484 **(Fre)**

[Anhedonia in major depression. Comparison of 55 depressed patients with 54 healthy probands] Loas G. **Encephale** 1995 Sep-Oct;21(5):559–62 (Eng. Abstr.) **(Fre)**

[External validity, reliability and basic score determination of the Toronto Alexithymia Scales (TAS and TAS-20) in a group of alcoholic patients] Loas G, et al. **Encephale** 1996 Jan-Feb;22(1):35–40 (Eng. Abstr.) **(Fre)**

[Apropos of: evaluation scales of anhedonia. Methodological problems in the article by F. Assouly-Besse et al.: French translation of the Chapman Social and Physical Anhedonia Questionnaire (letter; comment)] Pierson A. **Encephale** 1996 Jan-Feb;22(1):71–2. Comment on: Encephale 1995 Jul-Aug;21(4):273–84. **(Fre)**

[What is concealed behind nonspecific emotional disorders (F93.8/9)—a diagnostic comparison with reference to 4 diagnostic codes of ICD-10] Lenz K, et al. **Prax Kinderpsychol Kinderpsychiatr** 1995 Jul-Aug; 44(6):203–8 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Managing agitation in critically ill patients. Harvey MA. **Am J Crit Care** 1996 Jan;5(1):7–16; quiz 17–8 (72 ref.)

The combined pharmacotherapy controversy [letter; comment] Wakefield TP. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):1–2. Comment on: J Am Acad Child Adolesc Psychiatry 1995 May;34(5):540.

[The efficacy of treatment with the tranquilizer tranxene in elderly persons with psychoemotional disorders against a background of initial and moderately pronounced atherosclerotic circulatory encephalopathy] Grebel'nik VI. **Lik Sprava** 1995 Jul-Aug;(7-8):29–32 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Developmental epidemiology. Angold A, et al. **Epidemiol Rev** 1995;17(1):74–82 (126 ref.)

The relationship between normal variation in IQ and common childhood psychopathology: a clinical study. Goodman R. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):187–96

Children's mental health service use across service sectors [see comments] Burns BJ, et al. **Health Aff (Millwood)** 1995 Fall;14(3):147–59. Comment in: Health Aff (Millwood) 1995 Winter;14(4):315.

Behavioral and emotional problems among Chinese and American children: parent and teacher reports for ages 6 to 13. Weine AM, et al. **J Abnorm Child Psychol** 1995 Oct; 23(5):619–39

The structure of psychological distress. Préville M, et al. **Psychol Rep** 1995 Aug;77(1):275–93

Job strain and psychological distress in white-collar workers. Bourbonnais R, et al. **Scand J Work Environ Health** 1996 Apr;22(2):139–45

[Gender and emotional disorders: the importance of the difference] Ferrara M, et al. **Epidemiol Prev** 1996 Apr-Sep; 20(2-3):246–50 (19 ref.) **(Ita)**

ETHNOLOGY

Sociocultural differences on hostility in alexithymic persons. Fukunishi I, et al. **Psychol Rep** 1995 Aug;77(1):253–4

ETIOLOGY

Disturbed mother-infant interaction in association with congenital heart disease [see comments] Gardner FV, et al. **Heart** 1996 Jul;76(1):56–9. Comment in: Heart 1996 Jul;76(1):8–9.

Personality in patients with long-term patellofemoral pain syndrome. Carlsson AM, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3-4):178–83

Modifiers of non-specific symptoms in occupational and environmental syndromes. Spurgeon A, et al. **Occup Environ Med** 1996 Jun;53(6):361–6 (61 ref.)

Physical comorbidity and medical care use in children with emotional problems [see comments] Angel RJ, et al. **Public Health Rep** 1996 Mar-Apr;111(2):140–5. Comment in: Public Health Rep 1996 Mar-Apr;111(2):138–9.

Finding the causal chain [comment] Hauser ST. **Public Health Rep** 1996 Mar-Apr;111(2):138–9. Comment on: Public Health Rep 1996 Mar-Apr;111(2):140–5.

-Psychosomatic aspects around the period of menopause- Czubalski K. **Ginekol Pol** 1995 Dec;66(12):692–6 (22 ref.) **(Pol)**

GENETICS

Affective reactivity of cognitive functioning and family history in schizophrenia. Docherty NM, et al. **Biol Psychiatry** 1996 Jan 1;39(1):59–64

Genetic heterogeneity may in part explain sex differences in the familial risk for schizophrenia. Goldstein JM, et al. **Biol Psychiatry** 1995 Dec 15;38(12):808–13

HISTORY

[Historical review of the concept of anhedonia] Olivares Diez JM. **Acta Psiquiatr Psicol Am Lat** 1995 May;41(2):148–61 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Visceral perception, anhedonia, and emotion. Ferguson ML, et al. **Biol Psychol** 1996 Jan 5;42(1-2):131–45

[Parallel visual processing characteristics in healthy alexithymic subjects. Administration of the Toronto Alexithymia Scale and the parallel visual information test (see comments)] Montreuil M, et al. **Encephale** 1995 Sep-Oct;21(5):589–95 (Eng. Abstr.). Comment in: Encephale 1996 Jan-Feb;22(1):69–70. **(Fre)**

PREVENTION & CONTROL

Developmental and behavioral issues in childhood injury prevention. Rivara FP. **J Dev Behav Pediatr** 1995 Oct; 16(5):362–70 (79 ref.)

PSYCHOLOGY

Traumatic brain injury, cognitive and emotional dysfunction. Impact of clinical neuropsychology research. Emilien G, et al. **Acta Neurol Belg** 1996 Jun;96(2):89–101 (73 ref.)

Are all suicidal ideas closely linked to hopelessness? Mendonca JD, et al. **Acta Psychiatr Scand** 1996 Apr; 93(4):246–51

Negligent infliction of emotional distress: a focus on relationships. Appleberry JM. **Am J Law Med** 1995; 21(2-3):301–22 (190 ref.)

Adoption and mental health: a theoretical critique of the psychopathological model. Wegar K. **Am J Orthopsychiatry** 1995 Oct;65(4):540–8 (55 ref.)

The effect of a self-management training package on the transfer of aggression control procedures in the absence of supervision. Ninness HA, et al. **Behav Modif** 1995 Oct; 19(4):464–90

Life-events and psychiatric symptoms in a general psychiatry clinic: the role of intrusion and avoidance. Spurrell MT, et al. **Br J Med Psychol** 1995 Dec;68 (Pt 4):333–40

Children: ethnic and political violence. Ladd GW, et al. **Child Dev** 1996 Feb;67(1):14–8

Violent political contexts and the emotional concerns of township youth. Straker G, et al. **Child Dev** 1996 Feb; 67(1):46–54

Alexithymia in a normal elderly population. Joukamaa M, et al. **Compr Psychiatry** 1996 Mar-Apr;37(2):144–7

The attribution of somatic symptoms in psychiatric outpatients. Wise TN, et al. **Compr Psychiatry** 1995 Nov-Dec;36(6):407–10

The relationship between dissociative symptoms, alexithymia, impulsivity, sexual abuse, and self-mutilation. Zlotnick C, et al. **Compr Psychiatry** 1996 Jan-Feb;37(1):12–6

The expression of emotional distress in old English prose and verse. Nicholson S. **Cult Med Psychiatry** 1995 Sep; 19(3):327–38

Arthritis and perceptions of quality of life: an examination of positive and negative affect in rheumatoid arthritis patients. Zautra AJ, et al. **Health Psychol** 1995 Sep; 14(5):399–408

Feelings and fantasy in eating disorders: a factor analysis of the Toronto Alexithymia Scale. Troop NA, et al. **Int J Eat Disord** 1995 Sep;18(2):151–7

Sensation-seeking and emotional disturbances in depression: relationships and evolution. Carton S, et al. **J Affect Disord** 1995 Jun 8;34(3):219–25

Nine-month changes of maternal expressed emotion in conduct and emotional disorders of childhood: a follow-up study. Vostanis P, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):833–46

IQ loss and emotional dysfunctions after mild head injury incurred in a motor vehicle accident. Parker RS, et al. **J Clin Psychol** 1996 Jan;52(1):32–43

Are maternal health behaviors related to preschool children's adjustment? A preliminary report. Walker LO, et al. **J Dev Behav Pediatr** 1995 Oct;16(5):345–9

Evidence for a verbal deficit in alexithymia. Lamberty GJ, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer; 7(3):320–4

Maternal responsiveness of socially high-risk mothers to the

elicitation cues of their 7-month-old infants. Karl D. **J Pediatr Nurs** 1995 Aug;10(4):254–63

Suggestions for studies of substance abusers' responses to nonverbal facial cues. Giannini AJ. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):881–2

Alexithymia and locus of control. Loas G, et al. **Percept Mot Skills** 1996 Feb;82(1):14

Anhedonia, depression, and suicidal ideation. Loas G, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):978

Alexithymia, affect recognition, and five factors of personality in substance abusers. Mann LS, et al. **Percept Mot Skills** 1995 Aug;81(1):35–40

Weight loss and psychopathology: a three-cluster MMPI typology. Valtolina G. **Percept Mot Skills** 1996 Feb; 82(1):275–81

Alexithymia and coping with stress in healthy persons: alexithymia as a personality trait is associated with low social support and poor responses to stress. Fukunishi I, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1299–304

College maladjustment may be related to alexithymia constructs with weakness of ego strength. Fukunishi I. **Psychol Rep** 1996 Jun;78(3 Pt 1):735–8

Self-esteem and alexithymia. Yelsma P. **Psychol Rep** 1995 Dec;77(3 Pt 1):735–8

Alexithymia and schizophrenias. Stanghellini G, et al. **Psychopathology** 1995;28(5):263–72

The stability of alexithymia in depressed patients. Wise TN, et al. **Psychopathology** 1995;28(4):173–6

Predictive value of alexithymia: a prospective study in somatizing patients. Bach M, et al. **Psychother Psychosom** 1995;64(1):43–8

Alexithymia in inflammatory bowel disease. A case-control study. Porcelli P, et al. **Psychother Psychosom** 1995; 64(1):49–53

Alexithymia: a further exploration of its nomological network. Vingerhoets AJ, et al. **Psychother Psychosom** 1995;64(1):32–42

[Relationship between anhedonia, affective dependency and autonomy in health subjects] Loas G, et al. **Acta Psychiatr Belg** 1995 May-Jun;95(3):152–8 (Eng. Abstr.) **(Fre)**

[Apropos of: characteristics of parallel visual process in alexithymic healthy subjects. Application of the Toronto Alexithymia Scle and the parallel visual information processing list (letter; comment)] Fremaux D, et al. **Encephale** 1996 Jan-Feb;22(1):69–70. Comment on: Encephale 1995 Sep-Oct;21(5):589–95. **(Fre)**

[First grade students in former East and West Berlin: socio-emotional adjustment and relation to attachment patterns of the children] Doerfel-Baasen D, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar-Apr; 45(3–4):111–23 (Eng. Abstr.) **(Ger)**

REHABILITATION

Enhancing family advocacy networks: an analysis of the roles of sponsoring organizations. Briggs HE, et al. **Community Ment Health J** 1995 Aug;31(4):317–33

Evaluation status, educational setting, and behavior ratings of students with serious emotional disturbance. Hutton JB. **Psychol Rep** 1995 Dec;77(3 Pt 1):1049–50

[Theory and practice in rehabilitation of emotionally handicapped young patients] Fegert JM. **Prax Kinderpsychol Kinderpsychiatr** 1995 Nov;44(9):350–9 (Eng. Abstr.) **(Ger)**

[Rehabilitation access for emotionally handicapped children and adolescents: qualification of standard institutions--construction of special institutions] Günter M. **Prax Kinderpsychol Kinderpsychiatr** 1995 Nov;44(9):366–9 (Eng. Abstr.) **(Ger)**

THERAPY

Children and mental health: how can the system be improved? England MJ, et al. **Health Aff (Millwood)** 1995 Fall;14(3):131–8

What do Dublin GPs expect from a psychiatric referral? Maguire N, et al. **Ir Med J** 1995 Nov-Dec;88(6):215–6

Results of treatment one year later: child and adolescent partial hospitalization. Kiser LJ, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):81–90

[Therapy of emotional disturbance by manipulation of the biological clocks] Nagayama H. **Seishin Shinkeigaku Zasshi** 1995;97(8):575–85 (61 ref.) **(Jpn)**

AFFERENT LOOP SYNDROME

DIAGNOSIS

[Afferent loop obstruction after total gastrectomy presenting as acute pancreatitis (clinical contribution to the etiopathogenesis)] Crescimanno R, et al. **Ann Ital Chir** 1995 Nov-Dec;66(6):893–8; Discussion 899 (Eng. Abstr.) **(Ita)**

[Afferent loop syndrome. Differential diagnosis problems in a case of unusual clinical presentation] Scaglione M, et al. **Radiol Med (Torino)** 1996 Jun;91(6):825–6 **(Ita)**

ETIOLOGY

Afferent loop syndrome due to scarring of a stomal ulcer following a Billroth II gastrectomy. Tsutsui S, et al. **Endoscopy** 1995 Jun;27(5):410

AFFERENT PATHWAYS

The effects of high urinary potassium concentration on pelvic nerve mechanoreceptors and 'silent' afferents from the rat bladder. Wen J, et al. **Adv Exp Med Biol** 1995;385:237–9

Special issue: Interoception and behavior. **Biol Psychol** 1996 Jan 5;42(1–2):1–244

Multiple origins of cerebellar cholinergic afferents from the lower brainstem in the gerbil. Lan CT, et al. **J Anat** 1995 Jun;186 (Pt 3):549–61

Central reorganization of sensory pathways following peripheral nerve regeneration in fetal monkeys. Florence SL, et al. **Nature** 1996 May 2;381(6577):69–71

ANATOMY & HISTOLOGY

Afferent projections to the Bötzinger complex from the upper cervical cord and other respiratory related structures in the brainstem in cats: retrograde WGA-HRP tracing. Gang S, et al. **J Auton Nerv Syst** 1995 Dec 5;56(1–2):1–7

Distribution and synaptology of glossopharyngeal afferent nerve terminals in the nucleus of the solitary tract of the hamster. Brining SK, et al. **J Comp Neurol** 1996 Feb 19; 365(4):556–74

Projections of ankle joint afferents to the spinal cord and brainstem of the chicken (Gallus g. domesticus). Gentle MJ, et al. **J Comp Neurol** 1995 Oct 30;361(4):669–80

Prenatal development of cerebrorubral and cerebellorubral projections in cats. Song WJ, et al. **Neurosci Lett** 1995 Nov 10;200(1):41–4

CYTOLOGY

The sensory innervation of the shoulder joint of the mouse. Backenköhler U, et al. **Anat Anz** 1996 Apr;178(2):173–81

Retinotopic organization of the superior colliculus in relation to the retinal distribution of afferent ganglion cells. Berson DM, et al. **Vis Neurosci** 1995 Jul-Aug;12(4):671–86

DRUG EFFECTS

Effect of diterpenoid alkaloids on cardiac sympathetic efferent and vagal afferent nerve activity. Chiao H, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):103–6

Effect of neonatal capsaicin on peptide-containing primary afferent fibres, eosinophil distribution and hyperresponsiveness in rat lung tissue following experimentally induced eosinophilia. Davies D, et al. **Neuroimmunomodulation** 1994 Sep-Oct;1(5):308–14

Effect of 6-OHDA lesions on striatal mRNA levels encoding for glutamate receptor subunits. Tremblay M, et al. **Neuroreport** 1995 Nov 13;6(16):2225–9

Interleukin-1 beta facilitates afferent sensory transmission in the primary somatosensory cortex of anesthetized rats. Won C, et al. **Neurosci Lett** 1995 Dec 15;201(3):255–8

EMBRYOLOGY

Changes in the segmental pattern of sensory neuron projections in the chick hindlimb under conditions of altered cell adhesion molecule function. Honig MG, et al. **Dev Biol** 1996 May 1;175(2):325–37

Prenatal development of somatosensory primary afferent connections in the sheep. Rees S, et al. **Reprod Fertil Dev** 1995;7(3):427–30

INJURIES

The effect of age on peripheral motor nerve function after crush injury in the rat. Belin BM, et al. **J Trauma** 1996 May;40(5):775–7

METABOLISM

Patterns of convergence and segregation in the medial nucleus accumbens of the rat: relationships of prefrontal cortical, midline thalamic, and basal amygdaloid afferents. Wright CI, et al. **J Comp Neurol** 1995 Oct 23; 361(3):383–403

PATHOLOGY

Demonstration of retinal afferents in the RCS rat, with reference to the retinohypothalamic projection and suprachiasmatic nucleus. Decker K, et al. **Cell Tissue Res** 1995 Dec;282(3):473–80

PHYSIOLOGY

Role of muscle afferents in the inhibition of motoneurons during fatigue. Garland SJ, et al. **Adv Exp Med Biol** 1995; 384:271–8 (50 ref.)

Dose-dependent increases in the renal sympathetic nerve activity during rapid increase in isoflurane concentration in intact, lower airway-deafferented, and baroreceptor-deafferented rabbits. Okamoto H, et al. **Anesthesiology** 1996 May;84(5):1196–204

Movement-induced depression of soleus H reflexes is consistent in humans over the range of excitatory afferents involved. Misiaszek JE, et al. **Brain Res** 1995 Dec 8; 702(1–2):271–4

In vitro study of afferent synaptic transmission in the rostral gustatory zone of the rat nucleus of the solitary tract. Wang L, et al. **Brain Res** 1995 Dec 8;702(1–2):188–98

Central projections of primary afferents from the interosseous nerve in the pigeon. Ohmori Y, et al. **Brain Res Bull** 1995; 38(3):269–74

Convergence of laryngeal afferents with different natures upon cat NTS neurons. Takagi S, et al. **Brain Res Bull** 1995;38(3):261–8

Convergence of afferents from superior sagittal sinus and tooth pulp on cells in the thalamus of the cat. Angus-Leppan H, et al. **Cephalalgia** 1995 Jun;15(3):191–9

Task-dependent effects evoked by foot muscle afferents on leg muscle activity in humans. Abbruzzese M, et al. **Electroencephalogr Clin Neurophysiol** 1996 Aug; 101(4):339–48

Afferent excitation of human motor cortex as revealed by enhancement of direct cortico-spinal actions on motoneurones. Baldissera F, et al. **Electroencephalogr Clin Neurophysiol** 1995 Dec; 97(6):394–401

Synaptic input of horizontal interneurons in stratum oriens of the hippocampal CA1 subfield: structural basis of feed-back activation. Blasco-Ibáñez JM, et al. **Eur J Neurosci** 1995 Oct 1;7(10):2170–80

Depression of transmission from group II muscle afferents by electrical stimulation of the cuneiform nucleus in the cat. Noga BR, et al. **Exp Brain Res** 1995;105(1):25–38

Dopaminergic control of transmission from group II muscle afferents to spinal neurones in the cat and guinea-pig. Skoog B, et al. **Exp Brain Res** 1995;105(1):39–47

Differences in the brain stem terminations of large- and small-diameter vestibular primary afferents. Huwe JA, et al. **J Neurophysiol** 1995 Sep;74(3):1362–6

Development of spontaneous activity and mechanosensitivity in axotomized afferent nerve fibers during the first hours after nerve transection in rats. Michaelis M, et al. **J Neurophysiol** 1995 Sep;74(3):1020–7

Electrophysiological evidence for overlapping dominant and latent inputs to somatosensory cortex in squirrel monkeys. Schroeder CE, et al. **J Neurophysiol** 1995 Aug;74(2):722–32

Serial E-M and simulation study of presynaptic inhibition along a group Ia collateral in the spinal cord. Walmsley B, et al. **J Neurophysiol** 1995 Aug;74(2):616–23

Characterization of a descending system that enables crossed group II inhibitory reflex pathways in the cat spinal cord. Aggelopoulos NC, et al. **J Neurosci** 1996 Jan 15;16(2):723–9

Arrest of afferent axon extension by target neurons in vitro is regulated by the NMDA receptor. Baird DH, et al. **J Neurosci** 1996 Apr 15;16(8):2642–8

Functional organization of a neural map in the cricket cercal sensory system. Jacobs GA, et al. **J Neurosci** 1996 Jan 15; 16(2):769–84

Velocity sensitivity of human muscle spindle afferents and slowly adapting type II cutaneous mechanoreceptors. Grill SE, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):593–602

Effects of hindlimb cutaneous afferent inputs on spinal reflex recording from tail muscle motoneurons in the spinalized cat. Wada N, et al. **J Vet Med Sci** 1995 Jun;57(3):571–2

Protein masking of a ribosomal RNA epitope is an early event in afferent deprivation-induced neuronal death. Garden GA, et al. **Mol Cell Neurosci** 1995 Jun;6(3):293–310

Pain pathways [letter; comment] Huxley A. **Nature** 1995 Dec 14;378(6558):658. Comment on: Nature 1995 Oct 5;377(6548):428–31. Comment on: Nature 1995 Oct 5;377(6548):432–5.

Lesions of the afferent catecholaminergic pathways inhibit the temporal activation of the CRH and POMC gene expression and ACTH release induced by human interleukin-1beta in the male rat. Parsadaniantz SM, et al. **Neuroendocrinology** 1995 Dec;62(6):586–95

Effect of TENS-like stimulation on C afferent-induced c-fos expression in the rat spinal cord. Wei F, et al. **Neuroreport** 1995 Aug 21;6(12):1659–63

Sub-diaphragmatic vagal afferent integration of meal-related gastrointestinal signals. Schwartz GJ, et al. **Neurosci Biobehav Rev** 1996;20(1):47–56 (31 ref.)

Polysynaptic neural pathways from low threshold trunk cutaneous afferents to tail motoneurons in the spinalized cat. Wada N, et al. **Neurosci Lett** 1995 Nov 10;200(1):49–52

The role of the gamma-system for improving information transmission in populations of Ia afferents. Bergenheim M, et al. **Neurosci Res** 1995 Sep;23(2):207–15

The influence of afferent inputs from skin and viscera on the activity of the bladder and the skeletal muscle surrounding the urethra in the rat. Morrison JF, et al. **Neurosci Res** 1995 Sep;23(2):195–205

The primary afferent pathway of extraocular muscle proprioception in the pigeon. Hayman MR, et al. **Neuroscience** 1995 Nov;69(2):671–83

Cooperative interactions among afferents govern the induction of homosynaptic long-term depression in the hippocampus. Kerr DS, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11637–41

[Somatosensory evoked potentials: interference and perceptual masking of cutaneous afferents in man] el Kharroussi M, et al. **Neurophysiol Clin** 1996;26(2):85–101 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Variability of the relative afferent pupillary defect. Kawasaki A, et al. **Am J Ophthalmol** 1995 Nov;120(5):622–33

The relative afferent pupillary defect and a novel method of fusion recovery with the Worth 4-dot test. Johnson LN. **Arch Ophthalmol** 1996 Feb;114(2):171–5

Gastric distension modulates hypothalamic neurons via a sympathetic afferent path through the mesencephalic periaqueductal gray. Barone FC, et al. **Brain Res Bull** 1995;

38(3):239–51
Influence of spinal cord injury on the morphology of bladder afferent and efferent neurons. Kruse MN, et al. **J Auton Nerv Syst** 1995 Sep 5;54(3):215–24
Obtaining automated diagnostic information and pain relief. Collins HW. **Med Hypotheses** 1995 Oct;45(4):389–91
[An analysis of A-wave with slowed conduction in its afferent and efferent pathways below the branching point] Hasegawa O, et al. **Rinsho Shinkeigaku** 1996 Mar; 36(3):488–91 (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Fine structure of the afferent synapses in the paratympanic organ of the chicken, with special reference to the synaptic bodies. Giannessi F, et al. **Anat Anz** 1996 Apr;178(2):127–31
Central projections of Tömösváry's organ in Lithobius forficatus (Chilopoda, Lithobiidae). Petykó Z, et al. **Cell Tissue Res** 1996 Feb;283(2):331–4
Ultrastructural basis for synaptic transmission between jaw-muscle spindle afferents and trigeminothalamic neurons in the rostral trigeminal sensory nuclei of the rat. Luo P, et al. **J Comp Neurol** 1995 Dec 4;363(1):109–28
AMPA receptor subunits underlying terminals of fine-caliber primary afferent fibers. Popratiloff A, et al. **J Neurosci** 1996 May 15;16(10):3363–72

AFFINITY, ANTIBODY see **ANTIBODY AFFINITY**

AFFINITY LABELING REAGENTS see **AFFINITY LABELS**

AFFINITY LABELS

Autoradiographic evidence of steroid affinity sites in nasal tissue. Kai S, et al. **Acta Otolaryngol Suppl (Stockh)** 1996; 522:57–62
Purification of 11 beta-hydroxysteroid dehydrogenase type 2 from human placenta utilizing a novel affinity labelling technique. Brown RW, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):997–1005
The photoactivatable NAD+ analogue [32P]2-azido-NAD+ defines intra- and inter-molecular interactions of the C-terminal domain of the G-protein G alpha t. Vaillancourt RR, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):987–93
Bromopyruvate for the affinity labelling of a single cysteine residue near the carboxylate binding site of lamb liver 6-phosphogluconate dehydrogenase. Hanau S, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):785–93
Synthesis and characterization of an aryl-azidoparoxetine. A novel photo-affinity probe for serotonin-transporter. Chudzik J, et al. **Biochem Pharmacol** 1995 Oct 12; 50(8):1211–5
Identification of the active sites of human and schistosomal hypoxanthine-guanine phosphoribosyltransferases by GMP-2',3'-dialdehyde affinity labeling. Kanaani J, et al. **Biochemistry** 1995 Nov 21;34(46):14987–96
Highly selective affinity labeling of DNA polymerase alpha-primase from human placenta by reactive analogs of ATP. Zakharova OD, et al. **Biochimie** 1995; 77(9):699–702
Reporter enzyme-nitrilotriacetic acid-nickel conjugates: reagents for detecting histidine-tagged proteins. Botting CH, et al. **Biotechniques** 1995 Sep;19(3):362–3
Scintigraphic techniques for delineation of infection and inflammation. Oyen WJ, et al. **Br J Hosp Med** 1995 Jul 12–Aug 15;54(2–3):75–80
Affinity labeling of recombinant ricin A chain with Procion blue MX-R. Alderton WK, et al. **Eur J Biochem** 1995 Nov 1;233(3):880–5
Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesis. Cesura AM, et al. **Eur J Biochem** 1996 Mar 15;236(3):996–1002
Photoaffinity labelling of the mitochondrial uncoupling protein by [3H]azido fatty acid affects the anion channel. Ružička M, et al. **FEBS Lett** 1996 Mar 18;382(3):239–43
Exploring the nucleotide-binding site in proteins by affinity labeling and site-directed mutagenesis. Fukui T. **J Biochem (Tokyo)** 1995 Jun;117(6):1139–44 (45 ref.)
Photoaffinity labeling of the lutropin receptor with synthetic peptide for carboxyl terminus of the human choriogonadotropin alpha subunit. Kundu GC, et al. **J Biol Chem** 1996 May 10;271(19):11063–6
Photoaffinity labeling of human recombinant sulfotransferases with 2-azidoadenosine 3',5'-[5'-32P]bisphosphate. Radominska A, et al. **J Biol Chem** 1996 Feb 9;271(6):3195–9
Estrogen-specific target site identified by progesterone-11 alpha-hemisuccinate-(2-[125I]-iodohistamine) in mouse brain membranes. Büküşoğlu C, et al. **J Steroid Biochem Mol Biol** 1996 Apr;58(1):89–94
Epitope tagging of flagellar proteins. Diener DR. **Methods Cell Biol** 1995;47:545–50
Photoaffinity labeling and strategies for plasma membrane protein purification. Feldwisch J, et al. **Methods Cell Biol** 1995;50:51–60
Cloning and characterization of a glutathione S-transferase that can be photolabeled with 5-azido-indole-3-acetic acid. Bilang J, et al. **Plant Physiol** 1995 Sep;109(1):253–60
[Analysis of GTP-binding protein function with a photoaffinity GTP analog] Hatta S, et al. **Nippon Yakurigaku Zasshi** 1995 Jun;105(6):431–6 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Structural studies of phorbol ester-binding domain of protein kinase C by photoaffinity labeling] Irie K. **Seikagaku** 1996 Feb;68(2):129–32 (16 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Synthesis of a radioiodinated photoreactive MAGE-1 peptide derivative and photoaffinity labeling of cell-associated human leukocyte antigen-A1 molecules. Anjuère F, et al. **Anal Biochem** 1995 Jul 20;229(1):61–7
Synthesis of aryl azide derivatives of UDP-GlcNAc and UDP-GalNAc and their use for the affinity labeling of glycosyltransferases and the UDP-HexNAc pyrophosphorylase. Zeng Y, et al. **Anal Biochem** 1996 Jul 15;239(1):99–106
Synthesis and characterization of a novel spin-labeled affinity probe of human erythrocyte band 3: characteristics of the stilbenedisulfonate binding site. Scothorn DJ, et al. **Biochemistry** 1996 May 28;35(21):6931–43
Tethered benzophenone reagents for the synthesis of photoactivatable ligands. Olszewski JD, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):395–400
Affinity probes for the GABA-gated chloride channel: selection of 5e-tert-butyl-2e-[4-(substituted-ethynyl)phenyl]-1,3-dithianes and optimization of linker moiety. Li QX, et al. **Bioorg Med Chem** 1995 Dec;3(12):1667–74
Affinity probes for the GABA-gated chloride channel: 5e-tert-butyl-2e-[4-(substituted-ethynyl)phenyl]-1,3-dithianes with photoactivatable, fluorescent, biotin, agarose and protein substituents. Li QX, et al. **Bioorg Med Chem** 1995 Dec;3(12):1675–84
Mono-, di- and tri-antennary D-galactose ligands as competitive inhibitors and photoaffinity labels of the hexose transporting system in erythrocytes. A model for the irreversible blocking of receptors in cell membranes. Lehmann J, et al. **Carbohydr Res** 1995 Oct 16;276(1):57–74
Synthesis of uridine-5-propylamine derivatives and their use in affinity chromatography of N-acetylglucosaminyltransferases I and II. Reck F. **Carbohydr Res** 1995 Oct 23;276(2):321–35
New steroidal diazo ketones as potential photoaffinity labeling reagents for the mineralocorticoid receptor: synthesis and biological activities. Davioud E, et al. **J Med Chem** 1996 Jul 5;39(14):2860–4
New reactive coenzyme analogues for affinity labeling of NAD+ and NADP+ dependent dehydrogenases. Jeck R, et al. **Z Naturforsch [C]** 1995 Jul–Aug;50(7–8):476–86

CHEMISTRY

Photoaffinity labeling with UMP of lysine 992 of carbamyl phosphate synthetase from Escherichia coli allows identification of the binding site for the pyrimidine inhibitor. Cervera J, et al. **Biochemistry** 1996 Jun 4; 35(22):7247–55
Synthesis, azido-tetrazole equilibrium studies and biological activity of 1-(2-azido-6-chloropyrid-4-yl)-3-phenylurea, a photoaffinity labeling reagent for cytokinin-binding proteins. Dias M, et al. **Bioorg Med Chem** 1995 Apr; 3(4):361–6
Photoaffinity labelling of a receptor structure for macrophage cytotoxicity inducing factor (MCF). Reyes CJ, et al. **Cytokine** 1996 Feb;8(2):141–6
2,8-Diazido-ATP--a short-length bifunctional photoaffinity label for photoaffinity cross-linking of a stable F1 in ATP synthase (from thermophilic bacteria PS3). Schäfer HJ, et al. **FEBS Lett** 1995 Dec 27;377(3):408–12
Photoaffinity labeling of a cell surface polyamine binding protein. Felschow DM, et al. **J Biol Chem** 1995 Dec 1; 270(48):28705–11
Photochemical reactions of azidocoumarins. Feng K, et al. **Photochem Photobiol** 1995 Nov;62(5):813–7

METABOLISM

6-Bromoflavone, a high affinity ligand for the central benzodiazepine receptors is a member of a family of active flavonoids. Marder M, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):384–9
Photoaffinity labeling of lysosomal membrane proteins with [125I]diiodotyrosine, a system h ligand. Andersson HC, et al. **Biochem Mol Med** 1995 Jun;55(1):71–3
Photoaffinity labeling with UMP of lysine 992 of carbamyl phosphate synthetase from Escherichia coli allows identification of the binding site for the pyrimidine inhibitor. Cervera J, et al. **Biochemistry** 1996 Jun 4; 35(22):7247–55
5'-(p-fluorosulfonylbenzoyl)-2'(or 3')-(methylanthraniloyl)adenosine, fluorescent affinity labels for adenine nucleotide binding sites: interaction with the kinase active site of the receptor for epidermal growth factor. Scoggins RM, et al. **Biochemistry** 1996 Jul 16; 35(28):9197–203
Catalytic role of the amino-terminal proline in 4-oxalocrotonate tautomerase: affinity labeling and heteronuclear NMR studies. Stivers JT, et al. **Biochemistry** 1996 Jan 23;35(3):803–13
Photoaffinity labelling of lactate dehydrogenase from pig heart with a bifunctional NAD(+)-analogue. Becker S, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):277–83
Stereo-selective affinity labelling of sheep liver sorbitol dehydrogenase by chloro-substituted analogues of 2-bromo-3-(5-imidazolyl)propionic acid. Lindstad RI, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):267–71
Photoaffinity labeling of elongation factor-2 with 8-azido derivatives of GTP and ATP. Guillot D, et al. **Eur J Biochem** 1996 Feb 15;236(1):149–54
Interaction of mitochondrial F1-ATPase with trinitrophenyl derivatives of ATP. Photoaffinity labeling of binding sites with 2-azido-2',3'-O-(4,6-trinitrophenyl)adenosine 5'-triphosphate. Muraliev MB. **Eur J Biochem** 1995 Sep 1;232(2):578–85
[3H]propyl-6-azido-beta-carboline-3-carboxylate: a new photoaffinity label for the GABAA-benzodiazepine receptor. Zezula J, et al. **Eur J Pharmacol** 1995 Jul 25; 281(1):93–6
Photolabeling acyl CoA binding proteins in microsome preparations. Hare JF. **FEBS Lett** 1995 Nov 20; 375(3):188–92
Peptide environment of the peptidyl transferase center from Escherichia coli 70 S ribosomes as determined by thermoaffinity labeling with dihydrospiramycin. Bischof O, et al. **J Biol Chem** 1995 Sep 29;270(39):23060–4
The major site of photoaffinity labeling of the gamma-aminobutyric acid type A receptor by [3H]flunitrazepam is histidine 102 of the alpha subunit. Duncalfe LL, et al. **J Biol Chem** 1996 Apr 19; 271(16):9209–14
dNTP binding to HIV-1 reverse transcriptase and mammalian DNA polymerase beta as revealed by affinity labeling with a photoreactive dNTP analog. Lavrik OI, et al. **J Biol Chem** 1996 Sep 6;271(36):21891–7
Synthesis and applicability of a photolabile 7,7-azi analogue of 3-sulfated taurine-conjugated bile salts. Dietrich A, et al. **J Lipid Res** 1995 Aug;36(8):1729–44
A new paclitaxel photoaffinity analog with a 3-(4-benzoylphenyl)propanoyl probe for characterization of drug-binding sites on tubulin and P-glycoprotein. Ojima I, et al. **J Med Chem** 1995 Sep 29;38(20):3891–4
125I-APE binding to adenosine receptors in coronary artery: photoaffinity labeling with 125I-azidoAPE. Hussain T, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):284–8
6-Coumarin diazonium salt: a specific affinity label of the Torpedo acetylcholinesterase peripheral site. Schalk I, et al. **Mol Pharmacol** 1995 Dec;48(6):1063–7

PHARMACOKINETICS

Identification of organic cation transporter in rat renal brush-border membrane by photoaffinity labeling. Kimura M, et al. **Biol Pharm Bull** 1995 Mar;18(3):388–95

PHARMACOLOGY

Determinants of substrate recognition in the protein-tyrosine phosphatase, PTP1. Zhang ZY, et al. **J Biol Chem** 1996 Mar 8;271(10):5386–92

RADIATION EFFECTS

Photochemical reactions of azidocoumarins. Feng K, et al. **Photochem Photobiol** 1995 Nov;62(5):813–7

AFIBRINOGENEMIA

BLOOD

Dysfibrinogenemia: a case with thrombosis (fibrinogen Richfield) and an overview of the clinical and laboratory spectrum. Schorer AE, et al. **Am J Hematol** 1995 Nov; 50(3):200–8

COMPLICATIONS

Splenic rupture in afibrinogenemia: conservative versus surgical management [letter; comment] Ehmann WC, et al. **Am J Med** 1995 Oct;99(4):444. Comment on: Am J Med 1994 Jan;96(1):92–4.
Severe hypofibrinogenemia associated with bilateral ischemic necrosis of toes and fingers. Chafa O, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):549–52
Cutaneous manifestations of congenital afibrinogenaemia. Rupec RA, et al. **Br J Dermatol** 1996 Mar;134(3):548–50
[Consumption coagulopathy during pregnancy: a case of afibrinogenemia during the second trimester] Debiéve F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):860–2 (9 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Effect of fibrinogen substitution in afibrinogenemia on hemorheology and platelet function. Reininger AJ, et al. **Thromb Haemost** 1995 Sep;74(3):853–8

GENETICS

A gamma Gly-268 to Glu substitution is responsible for impaired fibrin assembly in a homozygous dysfibrinogen Kurashiki I. Niwa K, et al. **Blood** 1996 Jun 1;87(11):4686–94
Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization. Lundberg UG, et al. **Thromb Res** 1995 Apr 15;78(2):95–106
Fibrinogen Claro--another dysfunctional fibrinogen variant with gamma 275 arginine-->histidine substitution. Steinmann C, et al. **Thromb Res** 1996 Jan 1;81(1):145–50
Heterozygous protein C deficiency and dysfibrinogenemia

acquired by liver transplantation. Cransac M, et al. **Transpl Int** 1995;8(4):307–11

AFLATOXIN B1

p53 proteins and aflatoxin b1: the good, the bad, and the ugly [editorial] Liang TJ. **Hepatology** 1995 Oct;22(4 Pt 1):1330–2 (21 ref.)

A viral genome containing an unstable aflatoxin B1–N7–guanine DNA adduct situated at a unique site. Bailey EA, et al. **Nucleic Acids Res** 1996 Jul 15; 24(14):2821–8

ANALOGS & DERIVATIVES

Refined solution structure of 8,9–dihydro–8–(N7–guanyl)–9–hydroxyaflatoxin B1 opposite CpA in the complementary strand of an oligodeoxynucleotide duplex as determined by 1H NMR. Johnston DS, et al. **Biochemistry** 1995 Oct 31; 34(43):14037–50

Human variability in hepatic glutathione S–transferase–mediated conjugation of aflatoxin B1–epoxide and other substrates. Slone DH, et al. **Pharmacogenetics** 1995 Aug;5(4):224–33

Mutational properties of the primary aflatoxin B1–DNA adduct. Bailey EA, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1535–9

ANALYSIS

Determination of aflatoxins in groundnut meal by high–performance liquid chromatography: a comparison of two methods of derivatisation of aflatoxin B1. Roch OG, et al. **Br J Biomed Sci** 1995 Dec;52(4):312–6

Aflatoxin B1 contamination in groundnut samples collected from different geographical regions of India: a multicentre study. Bhat RV, et al. **Food Addit Contam** 1996 Apr; 13(3):325–31

Natural co–occurrence of Fusarium toxins and aflatoxin B1 in corn for feed in north Vietnam. Wang DS, et al. **Nat Toxins** 1995;3(6):445–9

ANTAGONISTS & INHIBITORS

Inhibition of the hepatocarcinogenicity of aflatoxin B1 in rats by low levels of the phenolic antioxidants butylated hydroxyanisole and butylated hydroxytoluene. Williams GM, et al. **Cancer Lett** 1996 Jun 24;104(1):49–53

Mechanisms of chlorophyllin anticarcinogenesis against aflatoxin B1: complex formation with the carcinogen. Breinholt V, et al. **Chem Res Toxicol** 1995 Jun;8(4):506–14

Mechanisms of indole–3–carbinol (I3C) anticarcinogenesis: inhibition of aflatoxin B1–DNA adduction and mutagenesis by I3C acid condensation products. Takahashi N, et al. **Food Chem Toxicol** 1995 Oct;33(10):851–7

Cassia senna inhibits mutagenic activities of benzo[a]–pyrene, aflatoxin B1, shamma and methyl methanesulfonate. al–Dakan AA, et al. **Pharmacol Toxicol** 1995 Oct; 77(4):288–92

BIOSYNTHESIS

Structure and function of fas–1A, a gene encoding a putative fatty acid synthetase directly involved in aflatoxin biosynthesis in Aspergillus parasiticus. Mahanti N, et al. **Appl Environ Microbiol** 1996 Jan;62(1):191–5

Purification and characterization of versicolorin B synthase from Aspergillus parasiticus. Catalysis of the stereodifferentiating cyclization in aflatoxin biosynthesis essential to DNA interaction. McGuire SM, et al. **Biochemistry** 1996 Sep 3;35(35):11470–86

Effects of some insect growth regulators on growth of Aspergillus flavus and its productivity of aflatoxin B1 and lipids. el–Refai IM, et al. **Food Addit Contam** 1995 Jul–Aug; 12(4):585–90

Isolation and characterization of the versicolorin B synthase gene from Aspergillus parasiticus. Expansion of the aflatoxin b1 biosynthetic gene cluster. Silva JC, et al. **J Biol Chem** 1996 Jun 7;271(23):13600–8

The Aspergillus parasiticus polyketide synthase gene pksA, a homolog of Aspergillus nidulans wA, is required for aflatoxin B1 biosynthesis. Chang PK, et al. **Mol Gen Genet** 1995 Aug 21;248(3):270–7

CHEMISTRY

Refined solution structure of 8,9–dihydro–8–(N7–guanyl)–9–hydroxyaflatoxin B1 opposite CpA in the complementary strand of an oligodeoxynucleotide duplex as determined by 1H NMR. Johnston DS, et al. **Biochemistry** 1995 Oct 31; 34(43):14037–50

IMMUNOLOGY

Mucosal tolerance to aflatoxin B1. Oliver AR, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:422–4

[Production and characterization of monoclonal antibody against aflatoxin B1] Wang G, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Sep;26(3):275–8 (Eng. Abstr.) **(Chi)**

METABOLISM

Corn "nixtamalización" and the fate of radiolabelled aflatoxin B1 in the tortilla making process. Guzmán–de–Peña D, et al. **Bull Environ Contam Toxicol** 1995 Dec;55(6):858–64

Inhibition of CYP1A2 and CYP3A4 by oltipraz results in reduction of aflatoxin B1 metabolism in human hepatocytes in primary culture. Langouët S, et al. **Cancer Res** 1995 Dec 1;55(23):5574–9

The model Ah–receptor agonist beta–naphthoflavone inhibits aflatoxin B1–DNA binding in vivo in rainbow trout at dietary levels that do not induce CYP1A enzymes. Takahashi N, et al. **Carcinogenesis** 1996 Jan;17(1):79–87

Action of curcumin on the cytochrome P450–system catalyzing the activation of aflatoxin B1. Firozi PF, et al. **Chem Biol Interact** 1996 Mar 8;100(1):41–51

Induction of hepatic CYP1A by indole–3–carbinol in protection against aflatoxin B1 hepatocarcinogenesis in rainbow trout. Takahashi N, et al. **Food Chem Toxicol** 1995 Oct;33(10):841–50

Binding characteristics of bovine serum albumin–aflatoxin B1 to polystyrene microtiter plates: importance of hapten to carrier protein molar ratio. Vyjayanthi V, et al. **Indian J Exp Biol** 1995 May;33(5):329–32

Effects of maize weevils (Coleoptera: Curculionidae) on production of aflatoxin B1 by Aspergillus flavus in stored corn. Beti JA, et al. **J Econ Entomol** 1995 Dec; 88(6):1776–82

Determination of aflatoxin B1 biotransformation and binding to hepatic macromolecules in human precision liver slices. Heinonen JT, et al. **Toxicol Appl Pharmacol** 1996 Jan; 136(1):1–7

[In vitro study of the metabolic conversion of aflatoxin B1 into its epoxide] Mukendi N, et al. **C R Seances Soc Biol Fil** 1995;189(4):643–56 (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

Oltipraz–mediated changes in aflatoxin B(1) biotransformation in rat liver: implications for human chemointervention. Buetler TM, et al. **Cancer Res** 1996 May 15;56(10):2306–13

PHARMACOLOGY

The anticalmodulin effect of aflatoxin B1 on purified erythrocyte Ca(2+)–ATPase. Adebayo AO, et al. **Biosci Rep** 1995 Aug;15(4):209–20

Signal transduction mechanism in response to aflatoxin B1 exposure: protein kinase C activity. Mistry KJ, et al. **Chem Biol Interact** 1996 Mar 25;100(2):177–85

Characterization of a promoter for gamma–glutamyl transpeptidase activated in rat liver in response to aflatoxin B1 and ethoxyquin. Griffiths SA, et al. **Mol Carcinog** 1995 Dec;14(4):251–62

Antimutagenicity of ellagic acid against aflatoxin B1 in the Salmonella microsuspension assay. Loarca–Piña G, et al. **Mutat Res** 1996 May 17;360(1):15–21

Immunobiological activities of mould products: functional impairment of human monocytes exposed to aflatoxin B1. Cusumano V, et al. **Res Microbiol** 1996 Jun;147(5):385–91

TOXICITY

Chronic hepatitis B carriers with null genotypes of glutathione S–transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Chen CJ, et al. **Am J Hum Genet** 1996 Jul;59(1):128–34

Characterization of the rat glutathione S–transferase Yc2 subunit gene, GSTA5: identification of a putative antioxidant–responsive element in the 5'–flanking region of rat GSTA5 that may mediate chemoprotection against aflatoxin B1. Pulford DJ, et al. **Biochem J** 1996 Aug 15; 318 (Pt 1):75–84

Individual and combined effects of aflatoxin and gizzerosine in broiler chickens. Diaz GJ, et al. **Br Poult Sci** 1995 Dec; 36(5):729–36

Immunoperoxidase detection of 8–hydroxydeoxyguanosine in aflatoxin B1–treated rat liver and human oral mucosal cells. Yarborough A, et al. **Cancer Res** 1996 Feb 15; 56(4):683–8

Activation of K–ras in aflatoxin B1–induced lung tumors from AC3F1 (A/J x C3H/HeJ) mice. Donnelly PJ, et al. **Carcinogenesis** 1996 Aug;17(8):1735–40

An aflatoxin–associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Soini Y, et al. **Carcinogenesis** 1996 May;17(5):1007–12

Signal transduction mechanism in response to aflatoxin B1 exposure: phosphatidylinositol metabolism. Mistry KJ, et al. **Chem Biol Interact** 1995 Nov 17;98(2):145–52

Calorie restriction modulates chemically induced in vivo somatic mutation frequency. Casciano DA, et al. **Environ Mol Mutagen** 1996;27(2):162–4

Aflatoxin B1, 2–aminoanthracene, and 7,12–dimethylbenz[a]anthracene–induced frameshift mutations in human APRT. Zhu Y, et al. **Environ Mol Mutagen** 1995;26(3):234–9

Comparative methods of toxicity testing. Consensus document following an International Life Sciences Institute–ILSI Europe Workshop held in May 1995. Huggett AC, et al. **Food Chem Toxicol** 1996 Feb; 34(2):183–92 (34 ref.)

Biochemical and molecular aspects of mammalian susceptibility to aflatoxin B1 carcinogenicity. Neal GE. **Hum Exp Toxicol** 1995 Jul;14(7):619–20

Human hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1. Yan RQ, et al. **J Cancer Res Clin Oncol** 1996;122(5):289–95

Effect of herba artemisiae scopariae on cytogenetic damage induced by aflatoxin B1. Hong Z, et al. **J Tradit Chin Med** 1996 Mar;16(1):51–4

Aflatoxin B1 induced lacI mutation in liver and kidney of transgenic mice C57BL/6N: effect of phorone. Autrup H, et al. **Mutagenesis** 1996 Jan;11(1):69–73

Acute effect of aflatoxin B1 on different inbred mouse strains II. Almeida RM, et al. **Mycopathologia** 1996;133(1):23–9

Mutational properties of the primary aflatoxin B1–DNA adduct. Bailey EA, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1535–9

Malignant conversion of chemically transformed normal human cells. Milo GE, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5229–34

Activity of some respiratory enzymes and cytochrome contents in rat hepatic mitochondria following aflatoxin B1 administration. Sajan MP, et al. **Toxicol Lett** 1995 Oct; 80(1–3):55–60

Dose–related effect of aflatoxin B1 on liver drug metabolizing enzymes in rabbit. Guerre P, et al. **Toxicology** 1996 Apr 15;108(1–2):39–48

AFLATOXIN M1

TOXICITY

Aflatoxin M1 8,9–epoxide: preparation and mutagenic activity. Bujons J, et al. **Chem Res Toxicol** 1995 Apr–May; 8(3):328–32

URINE

Inhibition of aflatoxin Ml excretion in rat urine during dietary intervention with oltipraz. Chung FL, et al. **Carcinogenesis** 1996 Jun;17(6):1385–8

AFLATOXINS

Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Chen CJ, et al. **Hepatology** 1996 Jul;24(1):38–42

Aflatoxin destruction by microwave heating. Farag RS, et al. **Int J Food Sci Nutr** 1996 May;47(3):197–208

ADVERSE EFFECTS

Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Wang LY, et al. **Int J Cancer** 1996 Sep 4; 67(5):620–5

Aflatoxin exposure and cytogenetic alterations in individuals from the Gambia, West Africa. Miele M, et al. **Mutat Res** 1996 Feb 1;349(2):209–17

ANALYSIS

Aflatoxins and ochratoxin A in the weaning food of Nigerian children. Oyelami OA, et al. **Ann Trop Paediatr** 1996 Jun; 16(2):137–40

A UK retail survey of aflatoxins in herbs and spices and their fate during cooking. MacDonald S, et al. **Food Addit Contam** 1996 Jan;13(1):121–8

A survey of the natural occurrence of aflatoxins and zearalenone in Argentine field maize: 1983–1994. Resnik S, et al. **Food Addit Contam** 1996 Jan;13(1):115–20

Food surveillance in the Basque Country (Spain). II. Estimation of the dietary intake of organochlorine pesticides, heavy metals, arsenic, aflatoxin M1, iron and zinc through the Total Diet Study, 1990/91. Urieta I, et al. **Food Addit Contam** 1996 Jan;13(1):29–52

Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Chen CJ, et al. **Hepatology** 1996 Jul;24(1):38–42

Evaluation of sampling plans used in the United States, United Kingdom, and The Netherlands to test raw shelled peanuts for aflatoxin. Whitaker TB, et al. **J AOAC Int** 1995 Jul–Aug;78(4):1010–8

Postcolumn excitation of aflatoxins using cyclodextrins in liquid chromatography for food analysis. Cepeda A, et al. **J Chromatogr A** 1996 Jan 15;721(1):69–74

Aflatoxin contamination of corn used as bait for deer in the southeastern United States. Fischer JR, et al. **J Wildl Dis** 1995 Oct;31(4):570–2

A survey of aflatoxins and aflatoxigenic Aspergillus flavus in corn–based products from the Spanish market. Sanchis V, et al. **Microbiol Res** 1995 Nov;150(4):437–40

Comparison of the profiles of seedborne fungi and the occurrence of aflatoxins in mould–damaged beans and soybeans. Tseng TC, et al. **Microbios** 1995;84(339):105–16

Ochratoxin A and aflatoxins in breast milk samples from Sierra Leone. Jonsyn FE, et al. **Mycopathologia** 1995 Aug; 131(2):121–6

Determination of aflatoxins in dust and urine by liquid chromatography/electrospray ionization tandem mass spectrometry. Kussak A, et al. **Rapid Commun Mass Spectrom** 1995;9(13):1234–7

BIOSYNTHESIS

Effect of some spices as preservatives for storage of lentil (Lens esculenta L.) seeds. El–Maraghy SS.

Folia Microbiol (Praha) 1995;40(5):490-2

Comparison of the omtA genes encoding O-methyltransferases involved in aflatoxin biosynthesis from Aspergillus parasiticus and A. flavus. Yu J, et al. **Gene** 1995 Sep 22;163(1):121-5

Aflatoxin contamination of sorghum seeds during storage under controlled conditions. Mukherjee K, et al. **Int J Med Microbiol Virol Parasitol Infect Dis** 1995 Apr; 282(3):237-43

Characterization of the polyketide synthase gene (pksL1) required for aflatoxin biosynthesis in Aspergillus parasiticus. Feng GH, et al. **J Bacteriol** 1995 Nov; 177(21):6246-54

The plant growth regulator methyl jasmonate inhibits aflatoxin production by Aspergillus flavus. Goodrich-Tanrikulu M, et al. **Microbiology** 1995 Nov;141 (Pt 11):2831-7

Mycoflora and aflatoxin production in pigeon pea stored in jute sacks and iron bins. Bankole SA, et al. **Mycopathologia** 1995-96;132(3):155-60

Aflatoxin-producing potential of Aspergillus flavus and Aspergillus parasiticus isolated from samples of smoked-dried meat. Cvetnić Z, et al. **Nahrung** 1995; 39(4):302-7

Use of UV photography to identify aflatoxin-producing strains of Aspergillus flavus and A. parasiticus. Cvetnić Z, et al. **Z Lebensm Unters Forsch** 1995 Oct;201(4):399-401

[Relationship between aflatoxin and sclerotia production in aspergillus flavus] Wang Z, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1996 Jan;30(1):14-6 (Eng. Abstr.) **(Chi)**

BLOOD

[Immunological detection of aflatoxin-albumin adducts in children with chronic hepatitis B infection] Alvarez MT, et al. **G E N** 1995 Jan-Mar;49(1):36-41 (Eng. Abstr.) **(Spa)**

GENETICS

Molecular characterization of the afl-1 locus in Aspergillus flavus. Woloshuk CP, et al. **Appl Environ Microbiol** 1995 Aug;61(8):3019-23

Conservation of structure and function of the aflatoxin regulatory gene aflR from Aspergillus nidulans and A. flavus. Yu JH, et al. **Curr Genet** 1996 May;29(6):549-55

METABOLISM

Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People's Republic of China. Wang JS, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr;5(4):253-61

The Escherichia coli DNA repair protein UvrA can re-associate with the UvrB: aflatoxin B1-DNA complex in vitro. Allan JM, et al. **Mutat Res** 1996 Apr 2;362(3):261-8

Selective chemisorption and detoxification of aflatoxins by phyllosilicate clay. Phillips TD, et al. **Nat Toxins** 1995; 3(4):204-13; discussion 221 (59 ref.)

Degradation of aflatoxin by poultry litter. Jones FT, et al. **Poult Sci** 1996 Jan;75(1):52-8

PHARMACOKINETICS

Blood aflatoxin levels in patients with hepatocellular carcinoma in Singapore. Tan CK, et al. **Singapore Med J** 1995 Dec;36(6):612-4

PHARMACOLOGY

Influence of aflatoxin and fumonisin B1-containing culture material on growing barrows. Harvey RB, et al. **Am J Vet Res** 1995 Dec;56(12):1668-72

POISONING

Aflatoxin and outcome from acute lower respiratory infection in children in The Philippines. Denning DW, et al. **Ann Trop Paediatr** 1995 Sep;15(3):209-16

Reduced cytochrome P450 and increased heme oxygenase in liver during rabbit aflatoxicosis. Guerre P, et al. **Life Sci** 1996;58(21):1883-9

TOXICITY

Detection of aflatoxigenic molds in grains by PCR. Shapira R, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3270-3

Influence of the antibiotics lincomycin and tylosin on aflatoxicosis when added to aflatoxin-contaminated diets of growing swine. Harvey RB, et al. **J Vet Diagn Invest** 1995 Jul;7(3):374-9

Molecular biomarkers for aflatoxins and their application to human liver cancer. Scholl P, et al. **Pharmacogenetics** 1995; 5 Spec No:S171-6 (33 ref.)

Effects of feeding fumonisin B1 present in Fusarium moniliforme culture material and aflatoxin singly and in combination to turkey poults. Kubena LF, et al. **Poult Sci** 1995 Aug;74(8):1295-303

URINE

Immunoaffinity column clean-up for the high-performance liquid chromatographic determination of aflatoxins B1, B2, G1, G2, M1 and Q1 in urine. Kussak A, et al. **J Chromatogr B Biomed Appl** 1995 Oct 20;672(2):253-9

AFP see **ALPHA-FETOPROTEINS**

AFRICAN AMERICANS see **BLACKS**

AFRICAN GREEN MONKEY see **CERCOPITHECUS AETHIOPS**

AFRICAN HORSESICKNESS

DIAGNOSIS

A blocking ELISA for detection of antibody to a subgroup-reactive epitope of African horsesickness viral protein 7 (VP7) using a novel gamma-irradiated antigen. House JA, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:333-44

EPIDEMIOLOGY

Simulation studies of African horse sickness and Culicoides imicola (Diptera:Ceratopogonidae). Lord CC, et al. **J Med Entomol** 1996 May;33(3):328-38

Epidemiology of African horsesickness: antibodies in free-living elephants (Loxodonta africans) and their response to experimental infection. Barnard BJ, et al. **Onderstepoort J Vet Res** 1995 Dec;62(4):271-5

Epidemiology of African horsesickness: duration of viraemia in zebra (Equus burchelli). Barnard BJ, et al. **Onderstepoort J Vet Res** 1994 Dec;61(4):391-3

Continuing prevalence of African horse sickness in Nigeria. Adeyefa CA, et al. **Rev Elev Med Vet Pays Trop** 1995; 48(1):31-3

African horse sickness surveillance systems and regionalisation/zoning: the case of South Africa. Bosman P, et al. **Rev Sci Tech** 1995 Sep;14(3):645-53

African horse sickness and African carnivores. Alexander KA, et al. **Vet Microbiol** 1995 Nov;47(1-2):133-40

IMMUNOLOGY

Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7. Martínez-Torrecuadrada JL, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1211-21

The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses. Laviada MD, et al. **Virus Res** 1995 Oct;38(2-3):205-18

PREVENTION & CONTROL

Multiple gene expression in baculovirus system. Third generation vaccines for bluetongue disease and African horsesickness disease. Roy P. **Ann N Y Acad Sci** 1996 Jul 23;791:318-32

Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7. Martínez-Torrecuadrada JL, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1211-21

Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4. Stone-Marschat MA, et al. **Virology** 1996 Jun 1; 220(1):219-22

AFRICAN HORSESICKNESS VIRUS

CHEMISTRY

Crystal structure of the top domain of African horse sickness virus VP7: comparisons with bluetongue virus VP7. Basak AK, et al. **J Virol** 1996 Jun;70(6):3797-806

Subcellular localization of the nonstructural protein NS3 of African horsesickness virus. Stoltz MA, et al. **Onderstepoort J Vet Res** 1996 Mar;63(1):57-61

GENETICS

Characterization of the gene encoding core protein VP6 of two African horsesickness virus serotypes. Turnbull PJ, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1421-3

The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses. Laviada MD, et al. **Virus Res** 1995 Oct;38(2-3):205-18

IMMUNOLOGY

Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7. Martínez-Torrecuadrada JL, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1211-21

Influence of antigen presentation and exogenous cytokine activity during in vitro primary immunizations employed for the generation of monoclonal antibodies. Halabi G, et al. **J Immunol Methods** 1995 Oct 26;186(2):205-16

African horse sickness and African carnivores. Alexander KA, et al. **Vet Microbiol** 1995 Nov;47(1-2):133-40

Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4. Stone-Marschat MA, et al. **Virology** 1996 Jun 1; 220(1):219-22

The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses. Laviada MD, et al. **Virus Res** 1995 Oct;38(2-3):205-18

ISOLATION & PURIFICATION

Epidemiology of African horsesickness: antibodies in free-living elephants (Loxodonta africans) and their response to experimental infection. Barnard BJ, et al. **Onderstepoort J Vet Res** 1995 Dec;62(4):271-5

Detection of bluetongue virus and African horsesickness virus in co-infected cell cultures with NS1 gene probes. Venter EH, et al. **Onderstepoort J Vet Res** 1995 Dec; 62(4):217-22

PATHOGENICITY

Proteolytic cleavage of VP2, an outer capsid protein of African horse sickness virus, by species-specific serum proteases enhances infectivity in Culicoides. Marchi PR, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2607-11

AFRICAN LYMPHOMA see **BURKITT'S LYMPHOMA**

AFRICAN MEDICINE, TRADITIONAL see **MEDICINE, AFRICAN TRADITIONAL**

AFRICAN SLEEPING SICKNESS see **TRYPANOSOMIASIS, AFRICAN**

AFRICAN SWINE FEVER

DIAGNOSIS

Evaluation of the enzyme-linked immunosorbent assay for the rapid screening and detection of classical swine fever virus antigens in the blood of pigs. Depner K, et al. **Rev Sci Tech** 1995 Sep;14(3):677-89

EPIDEMIOLOGY

Serological study of pigs for antibody against African swine fever virus in two areas of southern Malawi. Allaway EC, et al. **Rev Sci Tech** 1995 Sep;14(3):667-76

An outbreak of African swine fever in the southern region of Malawi. Edelsten RM, et al. **Rev Sci Tech** 1995 Sep; 14(3):655-66

IMMUNOLOGY

Experimental African swine fever: apoptosis of lymphocytes and virus replication in other cells. Gómez-Villamandos JC, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2399-405

A study of the vaccinal value of various extracts of concealed antigens and salivary gland extracts against Ornithodoros erraticus and Ornithodoros moubata. Astigarraga A, et al. **Vet Parasitol** 1995 Nov;60(1-2):133-47

Virus association with lymphocytes in acute African swine fever. Carrasco L, et al. **Vet Res** 1996;27(3):305-12

PATHOLOGY

A pathological study of the perisinusoidal unit of the liver in acute African swine fever. Gómez-Villamandos JC, et al. **Res Vet Sci** 1995 Sep;59(2):146-51

In vivo replication of African swine fever virus (Malawi '83) in neutrophils. Carrasco L, et al. **Vet Res** 1996;27(1):55-62

The lesional changes and pathogenesis in the kidney in African swine fever. Hervás J, et al. **Vet Res Commun** 1996; 20(3):285-99 (44 ref.)

PREVENTION & CONTROL

A study of the vaccinal value of various extracts of concealed antigens and salivary gland extracts against Ornithodoros erraticus and Ornithodoros moubata. Astigarraga A, et al. **Vet Parasitol** 1995 Nov;60(1-2):133-47

VIROLOGY

Application of a monoclonal antibody recognizing protein p30 to detect African swine fever virus-infected cells in peripheral blood. Ramiro-Ibáñez F, et al. **J Virol Methods** 1995 Nov;55(3):339-45

AFRICAN SWINE FEVER VIRUS

CHEMISTRY

Characterization of the African swine fever virion protein j18L. Sun H, et al. **J Gen Virol** 1996 May;77 (Pt 5):941-6

The African swine fever virus IAP homolog is a late structural polypeptide. Chacón MR, et al. **Virology** 1995 Dec 20;214(2):670-4

DRUG EFFECTS

Functional and molecular characterization of African swine fever virus mutants resistant to phosphonoacetic acid. Marques MI, et al. **Virology** 1995 Dec 1;214(1):72-81

GENETICS

Amino acid tandem repeats within a late viral gene define the central variable region of African swine fever virus. Irusta PM, et al. **Virology** 1996 Jun 1;220(1):20-7

Functional and molecular characterization of African swine fever virus mutants resistant to phosphonoacetic acid. Marques MI, et al. **Virology** 1995 Dec 1;214(1):72-81

AFRICAN SWINE FEVER VIRUS

IMMUNOLOGY

Improvement of African swine fever virus neutralization assay using recombinant viruses expressing chromogenic marker genes. Gómez-Puertas P, et al. **J Virol Methods** 1995 Oct;55(2):271-9

Serological study of pigs for antibody against African swine fever virus in two areas of southern Malawi. Allaway EC, et al. **Rev Sci Tech** 1995 Sep;14(3):667-76

Evaluation of the enzyme-linked immunosorbent assay for the rapid screening and detection of classical swine fever virus antigens in the blood of pigs. Depner K, et al. **Rev Sci Tech** 1995 Sep;14(3):677-89

ISOLATION & PURIFICATION

Application of a monoclonal antibody recognizing protein p30 to detect African swine fever virus-infected cells in peripheral blood. Ramiro-Ibáñez F, et al. **J Virol Methods** 1995 Nov;55(3):339-45

Virus association with lymphocytes in acute African swine fever. Carrasco L, et al. **Vet Res** 1996;27(3):305-12

The lesional changes and pathogenesis in the kidney in African swine fever. Hervás J, et al. **Vet Res Commun** 1996; 20(3):285-99 (44 ref.)

METABOLISM

A structural DNA binding protein of African swine fever virus with similarity to bacterial histone-like proteins. Borca MV, et al. **Arch Virol** 1996;141(2):301-13

[Localizing the major peptides of African swine fever virus and virus-associated enzymes in the virion structure] Kolontsov AA. **Mol Gen Mikrobiol Virusol** 1995 Jul-Sep; (3):34-8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Fusion activity of African swine fever virus towards target membranes: lipid dependence and effect of dehydrating agents. Bernardes C, et al. **Biochem Mol Biol Int** 1995 Oct; 37(3):481-8

An African swine fever virus Bc1-2 homolog, 5-HL, suppresses apoptotic cell death. Afonso CL, et al. **J Virol** 1996 Jul;70(7):4858-63

Virus association with lymphocytes in acute African swine fever. Carrasco L, et al. **Vet Res** 1996;27(3):305-12

In vivo replication of African swine fever virus (Malawi '83) in neutrophils. Carrasco L, et al. **Vet Res** 1996;27(1):55-62

Functional and immunological properties of the baculovirus-expressed hemagglutinin of African swine fever virus. Ruiz-Gonzalvo F, et al. **Virology** 1996 Apr 1;218(1):285-9

The structural protein p54 is essential for African swine fever virus viability. Rodriguez F, et al. **Virus Res** 1996 Feb; 40(2):161-7

[Apoptosis in the African swine fever virus-swine mononuclear phagocyte system] Makarov VV. **Mol Gen Mikrobiol Virusol** 1995 Jul-Sep;(3):38-43 (Eng. Abstr.) **(Rus)**

AFTERCARE

see related

HALFWAY HOUSES

Going home [editorial] Bethell HJ. **BMJ** 1996 Jun 1; 312(7043):1372-3

Outpatient follow up [editorial; comment] [see comments] Emberton M. **BMJ** 1995 Nov 18;311(7016):1315-6. Comment on: BMJ 1995 Nov 18;311(7016):1344-5. Comment in: BMJ 1996 Mar 9;312(7031):640.

Continuing rise in emergency admissions. Visiting elderly patients at home immediately after discharge reduces emergency readmissions [letter] Townsend J, et al. **BMJ** 1996 Aug 3;313(7052):302

Plaster checks [letter; comment] Choyce MQ. **J Accid Emerg Med** 1995 Jun;12(2):160. Comment on: J Accid Emerg Med 1994 Dec;11(4):266-7.

Subjective perception of additional support requirements of elderly patients discharged from accident and emergency departments. Farnsworth TA, et al. **J Accid Emerg Med** 1995 Jun;12(2):107-10

Aftercare for participants in clinical research: ethical considerations in an asthma drug trial. Harth SC, et al. **J Med Ethics** 1995 Aug;21(4):225-8

Posttreatment services for chemically dependent adolescents. Spear SF, et al. **NIDA Res Monogr** 1995;156:341-64 (73 ref.)

Follow-up after therapy for prostate cancer. Treating the problems and caring for the man. Freedman A, et al. **Postgrad Med** 1996 Sep;100(3):125-9, 133-4, 136 (18 ref.)

Follow-up of colorectal cancer. Sugarbaker PH. **Tumori** 1995 May-Jun;81(3 Suppl):126-34 (64 ref.)

[Oncologic after-care and rehabilitation--physician-patient interaction in gynecologic oncology] Schünemann H, et al. **Arch Gynecol Obstet** 1995;257(1-4):277-83 (14 ref.) **(Ger)**

[Aftercare in patients with colorectal carcinomas] Mezger J, et al. **Dtsch Med Wochenschr** 1995 Nov 10; 120(45):1549-54 (44 ref.) **(Ger)**

-Exercise and sports as a therapeutic possibility in cancer after-care- Peters C, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):M19-23 **(Ger)**

[After-care of children and young adults surviving cancer. Initial recommendations by the late sequelae study group] Beck JD, et al. **Klin Padiatr** 1995 Jul-Aug;207(4):186-92 (Eng. Abstr.) **(Ger)**

[Oncologic after-care--a patient-oriented concept. Basic diagnostic plan for pediatric oncology patients] Duffner U, et al. **Klin Padiatr** 1995 Jul-Aug;207(4):193-203 (55 ref.) (Eng. Abstr.) **(Ger)**

[Short-bowel syndrome] Koblitz DK. **Z Gastroenterol** 1996 Jun;34 Suppl 2:41-6 (71 ref.) (Eng. Abstr.) **(Ger)**

[After-care rehabilitation after pancreas operations] Rosemeyer D. **Z Gastroenterol** 1996 Jun;34 Suppl 2:37-40 **(Ger)**

[Quality of life of tumor patients with colostomy] Schaube J, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 2:55-6 **(Ger)**

[Diagnosis of performance and function in after-care rehabilitation: principles for medical expert assessment] Tittor W. **Z Gastroenterol** 1996 Jun;34 Suppl 2:32-3 **(Ger)**

[What is the advantage of after-care rehabilitation in chronic inflammatory bowel diseases?] Zillessen E. **Z Gastroenterol** 1996 Jun;34 Suppl 2:47-50 **(Ger)**

[After-care rehabilitation after liver transplantation] Zilly W. **Z Gastroenterol** 1996 Jun;34 Suppl 2:34-6 **(Ger)**

[Smoking cessation and aftercare (letter; comment)] Korbøl G. **Tidsskr Nor Laegeforen** 1995 Sep 20;115(22):2824-5. Comment on: Tidsskr Nor Laegeforen 1995 Jun 30;115(17):2104-5. Comment on: Tidsskr Nor Laegeforen 1995 Jun 30;115(17):2106-9. Comment on: Tidsskr Nor Laegeforen 1995 Jun 30;115(17):2110-3. **(Nor)**

[Shorter sick listing after myocardial infarction. Substantial benefits of aftercare continuity] Nilsson G, et al. **Lakartidningen** 1996 Aug 28;93(34):2826-8 **(Swe)**

ECONOMICS

Sensitivity versus cost effectiveness in postoperative follow-up for colorectal cancer. Biggs CG, et al. **Curr Opin Gen Surg** 1994;:94-102

LEGISLATION & JURISPRUDENCE

Anti-therapeutic community mental health law [letter; comment] Eastman N. **BMJ** 1995 Sep 9;311(7006):689. Comment on: BMJ 1995 Jun 10;310(6993):1530.

METHODS

Patints prefer hospital follow up for cancer [letter; comment] Glynne-Jones R, et al. **BMJ** 1995 Dec 9;311(7019):1574-5 . Comment on: BMJ 1995 Mar 18;310(6981):685-6. Comment on: BMJ 1995 Jul 1;311(6996):54.

Emergency and long-term management of bleeding oesophageal varices. Parks RW, et al. **Br J Hosp Med** 1995 Aug 16-Sep 5;54(4):161-8 (10 ref.)

Colon surveillance after colorectal cancer surgery. Khoury DA, et al. **Dis Colon Rectum** 1996 Mar;39(3):252-6

Follow-up of pregnant teens at a hospital-based clinic. Forman SF, et al. **J Adolesc Health** 1995 Sep;17(3):193-7

[Diagnostic management and after care of cryptococcosis in 1995] Gangneux JP. **Sante** 1995 Sep-Oct;5(5):321-2 **(Fre)**

[Sense and nonsense in after-care of colorectal carcinoma] Schölmerich J. **Med Klin** 1996 Jun 15;91(6):420-7 (53 ref.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Coordinating a successful discharge plan. Hester LE. **Am J Nurs** 1996 Jun;96(6):35-7

A prison release program for HIV-positive women: linking them to health services and community follow-up [letter] Flanigan TP, et al. **Am J Public Health** 1996 Jun; 86(6):886-7

Clinic follow-up from the emergency department: do patients show up? Murray MJ, et al. **Ann Emerg Med** 1996 Jan; 27(1):56-8

Who provides follow-up care for patients with early breast cancer? Worster A, et al. **Can Fam Physician** 1995 Aug; 41:1314-20

Congestive heart failure: a continuum of care. Welsh C, et al. **J Nurs Care Qual** 1996 Jul;10(4):24-32

Infants with bronchopulmonary dysplasia: a developmental perspective. Mitchell SH. **J Pediatr Nurs** 1996 Jun; 11(3):145-51 (18 ref.)

PSYCHOLOGY

Effects of halfway house placement on retention of patients in substance abuse aftercare. Hitchcock HC, et al. **Am J Drug Alcohol Abuse** 1995 Aug;21(3):379-90

[Psychological stress on patients in tumor after-care after R0 resection of colorectal carcinomas] Graupe F, et al. **Chirurg** 1996 Jun;67(6):604-9; discussion 609-10 (Eng. Abstr.) **(Ger)**

[Psychological status of tumor patients. Observations and recommendations from the viewpoint of inpatient cancer after-care and oncologic rehabilitation] Delbrück H. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):M77-80 **(Ger)**

TRENDS

The long-term outcome of head injury: implications for service planning. Tennant A, et al. **Brain Inj** 1995 Aug-Sep; 9(6):595-605

[Preventive and after-care of elderly patients from the viewpoint of the established physician. Recommendations for new structures in ambulatory medical management of the elderly] Zeller W. **Fortschr Med** 1996 May 30; 114(15):191-2 **(Ger)**

[Gastrointestinal after-care rehabilitation at the Middle-Rhine Bad Salzig Clinic: a 10 year review] Herz R, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 2:15-9 **(Ger)**

[The status of after-care rehabilitation between acute clinic and ambulatory care] von Stetten D. **Z Gastroenterol** 1996 Jun;34 Suppl 2:6-13 **(Ger)**

UTILIZATION

The effects of travel barriers and age on the utilization of alcoholism treatment aftercare. Fortney JC, et al. **Am J Drug Alcohol Abuse** 1995 Aug;21(3):391-406

Use of post-hospital care by Medicare patients. Kane RL, et al. **J Am Geriatr Soc** 1996 Mar;44(3):242-50

AFTERIMAGE

Persistent palinopsia following ingestion of lysergic acid diethylamide (LSD). Kawasaki A, et al. **Arch Ophthalmol** 1996 Jan;114(1):47-50

Auditory sensitization during the perception of acoustical negative afterimages: analogies to visual processing? Wiegrebe L, et al. **Naturwissenschaften** 1995 Aug; 82(8):387-9

Disparity tuning of the stereoscopic (cyclopean) motion aftereffect. Patterson R, et al. **Vision Res** 1996 Apr; 36(7):975-83

PHYSIOLOGY

Visual scotoma and visual afterimages: some evidence that the perceived visual afterimage may not be a purely retinal phenomenon: a single case study. Davies P. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):849-50

Mechanisms of purely subjective contour tilt aftereffects. Van der Zwan R, et al. **Vision Res** 1995 Sep;35(18):2547-57

Visual motion aftereffects: critical adaptation and test conditions. Wade NJ, et al. **Vision Res** 1996 Jul; 36(14):2167-75

AGAMMAGLOBULINEMIA

Molecular and cellular aspects of X-linked agammaglobulinemia. Sideras P, et al. **Adv Immunol** 1995; 59:135-223 (445 ref.)

COMPLICATIONS

CD40 ligand deficiency presenting as unresponsive neutropenia. Andrews FJ, et al. **Arch Dis Child** 1996 May; 74(5):458-9

Encephalomyelitis in primary hypogammaglobulinaemia. Rudge P, et al. **Brain** 1996 Feb;119 (Pt 1):1-15

HCV infection in patients with primary defects of immunoglobulin production. Quinti I, et al. **Clin Exp Immunol** 1995 Oct;102(1):11-6

Pediatric AIDS with severe T-cell depression and hypogammaglobulinemia. Koutsonikolis A, et al. **Clin Pediatr (Phila)** 1995 Nov;34(11):605-7

Systemic amyloidosis in a patient with hypogammaglobulinaemia. Kotilainen P, et al. **J Intern Med** 1996 Aug;240(2):103-6

Fulminating systemic capillary leak syndrome with lymphocytosis and hypogammaglobulinemia. Kang PM, et al. **Ren Fail** 1995 Sep;17(5):615-7

Invasive thymoma with hypogammaglobulinemia spreading within the bronchial lumen. Honda T, et al. **Respiration** 1995;62(5):294-6

[Laboratory markers in hepatitis C virus infection in patients with antibody formation disorders treated with immunoglobulin preparations] Litzman J, et al. **Vnitr Lek** 1996 May;42(5):324-6 (Eng. Abstr.) **(Cze)**

[The safety of treatment with intravenous gamma-globulin in patients with primary hypogammaglobulinemias (letter; comment)] Sierra FJ, et al. **Med Clin (Barc)** 1995 Nov 11; 105(16):636. Comment on: Med Clin (Barc) 1995 Feb 18;104(6):201-6. **(Spa)**

DIAGNOSIS

Bruton's agammaglobulinaemia in a child presenting with cryptococcal empyema thoracis and periauricular pyogenic abscess. Wahab JA, et al. **Singapore Med J** 1995 Dec; 36(6):686-9

[An uncommon case of thrombopenic purpura] Michel M, et al. **Rev Med Interne** 1996;17 Suppl 2:251s-254s **(Fre)**

ENZYMOLOGY

Mutation analysis of the gene encoding Bruton's tyrosine kinase in a family with a sporadic case of X-linked agammaglobulinemia reveals three female carriers. Hagemann TL, et al. **Am J Med Genet** 1995 Nov 6; 59(2):188-92

The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function. Rawlings DJ, et al. **Semin Immunol** 1995 Aug;7(4):237-46 (81 ref.)

EPIDEMIOLOGY

Identification of Bruton's tyrosine kinase (Btk) gene

mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan. Hashimoto S, et al. **Blood** 1996 Jul 15;88(2):561–73

GENETICS

Discordant phenotype in siblings with X-linked agammaglobulinemia. Bykowsky MJ, et al. **Am J Hum Genet** 1996 Mar;58(3):477–83

Mutation analysis of the gene encoding Bruton's tyrosine kinase in a family with a sporadic case of X-linked agammaglobulinemia reveals three female carriers. Hagemann TL, et al. **Am J Med Genet** 1995 Nov 6; 59(2):188–92

Detection of a novel mutation in the SRC homology domain 2 (SH2) of Bruton's tyrosine kinase and direct female carrier evaluation in a family with X-linked agammaglobulinemia. Schuster V, et al. **Am J Med Genet** 1996 May 3;63(1):318–22

X linked agammaglobulinaemia with a 'leaky' phenotype. Jones A, et al. **Arch Dis Child** 1996 Jun;74(6):548–9

Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan. Hashimoto S, et al. **Blood** 1996 Jul 15;88(2):561–73

Structural basis for X-linked agammaglobulinemia (XLA): mutations at interacting Btk residues R562, W563, and A582. Maniar HS, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S198–202

Improved oligonucleotide primer set for molecular diagnosis of X-linked agammaglobulinaemia: predominance of amino acid substitutions in the catalytic domain of Bruton's tyrosine kinase. Vořechovský I, et al. **Hum Mol Genet** 1995 Dec;4(12):2403–5

BTKbase: a database of XLA-causing mutations. International Study Group. Vihinen M, et al. **Immunol Today** 1995 Oct;16(10):460–5 (39 ref.)

BTKbase, mutation database for X-linked agammaglobulinemia (XLA). Vihinen M, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):160–5

Genetic basis of the primary immunodeficiency syndromes. Adelman DC. **West J Med** 1995 Oct;163(4):373–4

THERAPY

Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973–93. Skull S, et al. **Arch Dis Child** 1996 Jun;74(6):527–30

Tolerability and kinetics of a solvent-detergent-treated intravenous immunoglobulin preparation in hypogammaglobulinaemia patients. Ebeling F, et al. **Vox Sang** 1995;69(2):91–4

[Personal experience with replacement therapy with intravenous gamma globulin] Litzman J, et al. **Vnitr Lek** 1995 Nov;41(11):759–63 (Eng. Abstr.) **(Cze)**

AGANGLIONOSIS, COLONIC see **HIRSCHSPRUNG DISEASE**

AGAR

[The study on the simplified agar media for mycobacteria] Kuang T, et al. **Wei Sheng Wu Hsueh Pao** 1995 Aug; 35(4):298–302 (Eng. Abstr.) **(Chi)**

AGAR DILUTION COUNT see **COLONY COUNT, MICROBIAL**

AGARICACEAE see **AGARICALES**

AGARICALES

Allergic contact dermatitis from Pleurotus mushroom. Rosina P, et al. **Contact Dermatitis** 1995 Oct;33(4):277–8

First electron spin resonance evidence for the production of semiquinone and oxygen free radicals from orellanine, a mushroom nephrotoxin. Richard JM, et al. **Free Radic Biol Med** 1995 Oct;19(4):417–29

[An outbreak of poisoning by mushrooms of the genus Omphalotus (letter)] Alguacil García GF, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):75 (8 ref.) **(Spa)**

CHEMISTRY

The structures of new lanostane triterpenes from the fruiting bodies of Hebeloma senescens. Garlaschelli L, et al. **J Nat Prod** 1995 Jul;58(7):992–1002

Levels of some trace elements in edible fungi. Jorhem L, et al. **Z Lebensm Unters Forsch** 1995 Oct;201(4):311–6

Characterisation of a fungus reference material, and a guide for use. Jorhem L, et al. **Z Lebensm Unters Forsch** 1995 Oct;201(4):317–21

[Mineral and amino acid contents of edible, cultivated shii-take mushrooms (Lentinus edodes)] Vetter J. **Z Lebensm Unters Forsch** 1995 Jul;201(1):17–9 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Cellulose degradation by Leucocoprinus gongylophorus, the fungus cultured by the leaf-cutting ant Atta sexdens rubropilosa. Bacci M Jr, et al. **Antonie Van Leeuwenhoek** 1995;67(4):385–6

Immobilization of manganese peroxidase from Lentinula edodes on alkylaminated Emphaze AB 1 polymer for generation of Mn3+ as an oxidizing agent. Grabski AC, et al. **Appl Biochem Biotechnol** 1996 Jul;60(1):1–17

A heme-containing ascorbate oxidase from Pleurotus ostreatus. Kim YR, et al. **J Biol Chem** 1996 Feb 9; 271(6):3105–11

GENETICS

Mechanisms for the development of genetically variable mycorrhizal mycelia in the ectomycorrhizal fungus Laccaria bicolor. de la Bastide PY, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3609–16

Inheritance of mitochondrial DNA in sexual crosses and protoplast cell fusions in Lentinula edodes. Fukuda M, et al. **Curr Genet** 1995 May;27(6):550–4

Genetic exchange and recombination in populations of the root-infecting fungus Armillaria gallica. Saville BJ, et al. **Mol Ecol** 1996 Aug;5(4):485–97

AGARICUS

[Disinfection of wood in mushroom growing cellars with Mycetox] Szymański J, et al. **Rocz Panstw Zakl Hig** 1995; 46(2):193–7 (Eng. Abstr.) **(Pol)**

CHEMISTRY

NMR lipids profiles of common mushrooms. Bonzom P, et al. **Biochem Soc Trans** 1995 Nov;23(4):613S

A multispecific saline-soluble lectin from the parasitic fungus Arthrobotrys oligospora. Similarities in the binding specificities compared with a lectin from the mushroom agaricus bisporus. Rosén S, et al. **Eur J Biochem** 1996 Jun 15;238(3):830–7

An abundant hydrophobin (ABH1) forms hydrophobic rodlet layers in Agaricus bisporus fruiting bodies. Lugones LG, et al. **Microbiology** 1996 May;142 (Pt 5):1321–9

ENZYMOLOGY

Correlation of exons with functional domains and folding regions in a cellulase from Agaricus bisporus. Yagüe E, et al. **Curr Genet** 1996 Jun;30(1):56–61

The dinuclear copper site structure of Agaricus bisporus tyrosinase in solution probed by X-ray absorption spectroscopy. Longa SD, et al. **J Biol Chem** 1996 Aug 30;271(35):21025–30

GENETICS

Plasmid RNA polymerase-like mitochondrial sequences in Agaricus bitorquis. Robison MM, et al. **Curr Genet** 1996 Mar;29(4):370–6

Correlation of exons with functional domains and folding regions in a cellulase from Agaricus bisporus. Yagüe E, et al. **Curr Genet** 1996 Jun;30(1):56–61

Analysis of inbreeding depression in Agaricus bisporus. Xu J. **Genetics** 1995 Sep;141(1):137–45

The Agaricus bisporus hypA gene encodes a hydrophobin and specifically accumulates in peel tissue of mushroom caps during fruit body development. De Groot PW, et al. **J Mol Biol** 1996 Apr 19;257(5):1008–18

Nucleotide sequence and expression of the gene encoding NADP+- dependent glutamate dehydrogenase (gdhA) from Agaricus bisporus. Schaap PJ, et al. **Mol Gen Genet** 1996 Feb 25;250(3):339–47

Transformation of the cultivated mushroom, Agaricus bisporus, to hygromycin B resistance. van de Rhee MD, et al. **Mol Gen Genet** 1996 Feb 25;250(3):252–8

VIROLOGY

Functional analysis of dsRNAs (L1, L3, L5, and M2) associated with isometric 34-nm virions of Agaricus bisporus (white button mushroom). Van der Lende TR, et al. **Virology** 1996 Mar 1;217(1):88–96

AGARIN see **MUSCIMOL**

AGAROSE see **SEPHAROSE**

AGE DETERMINATION BY SKELETON

Bone feature analysis using image processing techniques. Liu ZQ, et al. **Comput Biol Med** 1996 Jan;26(1):65–76

Final height and predicted height in boys with untreated constitutional growth delay. Sperlich M, et al. **Eur J Pediatr** 1995 Aug;154(8):627–32

A study on estimation of age from pubic symphysis. Sinha A, et al. **Forensic Sci Int** 1995 Aug 28;75(1):73–8

Advanced RUS and normal carpal bone age in childhood obesity. Polito C, et al. **Int J Obes Relat Metab Disord** 1995 Jul;19(7):506–7

Slipped capital femoral epiphysis. Prediction of contralateral involvement. Stasikelis PJ, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1149–55

The role of forensic anthropology in the recovery and analysis of Branch Davidian compound victims: assessing the accuracy of age estimations. Houck MM, et al. **J Forensic Sci** 1996 Sep;41(5):796–801

Perthes' disease after "irritable hip": delayed bone age shows the hip is a "marked man". Keenan WN, et al. **J Pediatr Orthop** 1996 Jan-Feb;16(1):20–3

METHODS

A regression method including chronological and bone age for predicting final height in Turner's syndrome, with a comparison of existing methods. van Teunenbroek A, et al. **Acta Paediatr** 1996 Apr;85(4):413–20

Automatic analysis of hand radiographs for the assessment of skeletal age: a subsymbolic approach. Rucci M, et al. **Comput Biomed Res** 1995 Jun;28(3):239–56

Accuracy of two dental and one skeletal age estimation method in Swedish adolescents. Kullman L. **Forensic Sci Int** 1995 Oct 30;75(2–3):225–36

Identification of osteocalcin as a permanent aging constituent of the bone matrix: basis for an accurate age at death determination. Ritz S, et al. **Forensic Sci Int** 1996 Jan 12; 77(1–2):13–26

The use of a computerized method of bone age assessment in clinical practice. Albanese A, et al. **Horm Res** 1995;44 Suppl 3:2–7

The wrong urn: commingling of cremains in mortuary practices. Kennedy KA. **J Forensic Sci** 1996 Jul; 41(4):689–92

Computer assisted bone age assessment. Dickhaus H, et al. **Medinfo** 1995;8 Pt 1:709–13

Estimation of age from soft X-ray findings of Japanese pubic symphysis based on a image processing. Sugiyama S, et al. **Nippon Hoigaku Zasshi** 1995 Oct;49(5):294–8

Estimation of age from image processing of soft X-ray findings in Japanese male thyroid cartilages. Sugiyama S, et al. **Nippon Hoigaku Zasshi** 1995 Aug;49(4):231–5

Estimation of age from soft X-ray findings of Japanese females thyroid cartilages. Sugiyama S, et al. **Nippon Hoigaku Zasshi** 1995 Aug;49(4):236–41

Computer-aided estimation of skeletal age and comparison with bone age evaluations by the method of Greulich-Pyle and Tanner-Whitehouse. Frisch H, et al. **Pediatr Radiol** 1996;26(3):226–31

Fetal bone age revisited: proposal of a new radiographic score. Stempflé N, et al. **Pediatr Radiol** 1995;25(7):551–5

Ultrasound and skeletal maturation [letter] Castriota-Scanderbeg A. **Skeletal Radiol** 1996 Feb; 25(2):142

Determination of skeletal maturity by ultrasound: a preliminary report. Wagner UA, et al. **Skeletal Radiol** 1995 Aug;24(6):417–20

[Development of a software for estimating skeletal age based on the TW2 method] Bechini M, et al. **Radiol Med (Torino)** 1996 May;91(5):637–9 **(Ita)**

[Short stature due to a partial idiopathic deficiency of the growth hormone. The role of the TW2 method in assessing treatment with r-hGH] Gibilisco G, et al. **Radiol Med (Torino)** 1996 Mar;91(3):181–6 (Eng. Abstr.) **(Ita)**

AGE DETERMINATION BY TEETH

Computerized measurements of the lower third molar related to chronologic age in young adults. Kullman L, et al. **Acta Odontol Scand** 1995 Aug;53(4):211–6

Estimation of age from dentin by using the racemization reaction of aspartic acid. Ohtani S. **Am J Forensic Med Pathol** 1995 Jun;16(2):158–61

Studies on age estimation using racemization of aspartic acid in cementum. Ohtani S. **J Forensic Sci** 1995 Sep;40(5):805–7

METHODS

Estimation of age from the teeth of unidentified corpses using the amino acid racemization method with reference to actual cases. Ohtani S. **Am J Forensic Med Pathol** 1995 Sep;16(3):238–42

Accuracy of two dental and one skeletal age estimation method in Swedish adolescents. Kullman L. **Forensic Sci Int** 1995 Oct 30;75(2–3):225–36

Age estimation of adults from dental radiographs. Kvaal SI, et al. **Forensic Sci Int** 1995 Jul 28;74(3):175–85

Age estimation from the permanent molar in northeast China by the method of average stage of attrition. Li C, et al. **Forensic Sci Int** 1995 Oct 30;75(2–3):189–96

Estimation of age from dentin by utilizing the racemization of aspartic acid: influence of pH. Ohtani S. **Forensic Sci Int** 1995 Oct 30;75(2–3):181–7

The validity of four methods for age determination by teeth in Swedish children: a multicentre study. Mörnstad H, et al. **Swed Dent J** 1995;19(4):121–30

VETERINARY

Ageing horses by an examination of their incisor teeth: an (im)possible task? Muylle S, et al. **Vet Rec** 1996 Mar 30; 138(13):295–301

An evaluation of the accuracy of ageing horses by their dentition: can a computer model be accurate? Richardson JD, et al. **Vet Rec** 1995 Aug 5;137(6):139–40

An evaluation of the accuracy of ageing horses by their dentition: changes of dental morphology with age. Richardson JD, et al. **Vet Rec** 1995 Jul 29;137(5):117–21

An evaluation of the accuracy of ageing horses by their dentition: a matter of experience? Richardson JD, et al. **Vet Rec** 1995 Jul 22;137(4):88–90

AGE DISTRIBUTION

Will aging of the population make Japan less productive? [letter] Sasaki H, et al. **J Am Geriatr Soc** 1996 Aug; 44(8):1013–4

Prognostic value of flow cytometry and correlation to some conventional prognostic factors: a retrospective study of archival specimens of 134 astrocytomas. Vavruch L, et al. **J Neurosurg** 1996 Jul;85(1):146–51

AGE FACTORS

The relationship between age and the use of DNR orders in critical care patients. Evidence for age discrimination. Boyd K, et al. **Arch Intern Med** 1996 Sep 9;156(16):1821–6

Age as a component of severity of illness scoring [letter] Barie PS, et al. **Crit Care Med** 1996 May;24(5):898–9

Donor age and outcome of liver transplantation. Hoofnagle JH, et al. **Hepatology** 1996 Jul;24(1):89–96

Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. Miller CB, et al. **J Clin Oncol** 1996 Apr;14(4):1327–32

Donor age greater than 50 years does not influence midterm results of heart transplantation. Livi U, et al. **Transplant Proc** 1996 Feb;28(1):91–2

Expanding the donor pool in cardiac transplantation by accepting donor hearts > 40 years. Zuckermann A, et al. **Transplant Proc** 1996 Feb;28(1):179–80

[Variability of drug effect--age factors] Guignard JP, et al. **Arch Pediatr** 1996;3 Suppl 1:229s–231s **(Fre)**

AGE OF ONSET

Re: "Association of education with reported age of onset and severity of Alzheimer's disease at presentation: implications for the use of clinical samples" [letter; comment] Peterson B. **Am J Epidemiol** 1996 Jun 1;143(11):1177. Comment on: Am J Epidemiol 1993 Feb 15;137(4):456–62.

Age at onset of puberty following high-dose central nervous system radiation therapy. Oberfield SE, et al. **Arch Pediatr Adolesc Med** 1996 Jun;150(6):589–92

Early onset of drinking and mortality among male alcoholics. A result of a 10-year prospective follow-up study in Hokkaido, Japan. Mori M, et al. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Dec;30(6):426–34

Childhood-onset schizophrenia: the severity of premorbid course. Alaghband-Rad J, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1273–83

Neuropsychophysiological study of children at risk for schizophrenia: a preliminary report. Hendren RL, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1284–91

Multimodal evoked potentials in multiple system and late onset cerebellar atrophies. Arpa J, et al. **Neurologia** 1995 Aug-Sep;10(7):288–96

Statistical pitfalls in detecting age-of-onset anticipation: the role of correlation in studying anticipation and detecting ascertainment bias. Hodge SE, et al. **Psychiatr Genet** 1995 Spring;5(1):43–7

[Adult onset mitochondrial myopathy without ophthalmoplegia. Four cases attributable to complex III and IV deficits in the respiratory chain] Bautista J, et al. **Neurologia** 1995 Oct;10(8):319–23 (Eng. Abstr.) **(Spa)**

[Etiological and prognostic factors in the late onset epilepsy] Martin R, et al. **Rev Neurol** 1995 Mar-Apr;23(120):285–9 (Eng. Abstr.) **(Spa)**

AGE-RELATED OSTEOPOROSIS see **OSTEOPOROSIS**

AGED

see related
HEALTH SERVICES FOR THE AGED
HOMES FOR THE AGED
HOUSING FOR THE ELDERLY
PENSIONS
RETIREMENT

Elder law and health care [letter] Kapp MB. **Acad Med** 1995 Dec;70(12):1059

Apolipoprotein E polymorphism, Alzheimer's disease and vascular dementia among elderly Finnish men. Stengård JH, et al. **Acta Neurol Scand** 1995 Oct;92(4):297–8

Appropriateness of therapy with angiotensin-converting-enzyme inhibitors in elderly outpatients. Scott MA, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):410–3

Alcohol consumption among the elderly in a general population, Erie County, New York. Mirand AL, et al. **Am J Public Health** 1996 Jul;86(7):978–84

Geriatric use of emergency medical services. Dickinson ET, et al. **Ann Emerg Med** 1996 Feb;27(2):199–203

Estimating treatment benefits for the elderly: the effect of competing risks. Welch HG, et al. **Ann Intern Med** 1996 Mar 15;124(6):577–84

Apolipoprotein E and cognitive change in an elderly population. Hyman BT, et al. **Ann Neurol** 1996 Jul; 40(1):55–66

Disability as a public health outcome in the aging population. Guralnik JM, et al. **Annu Rev Public Health** 1996;17:25–46 (98 ref.)

Working-out caregiving systems in African American families. Nkongho NO, et al. **Appl Nurs Res** 1996 Aug; 9(3):108–14

Hypermagnesemia: elderly over-the-counter drug users at risk [letter; comment] Blaine AM. **Arch Fam Med** 1996 Jun;5(6):323–4. Comment on: Arch Fam Med 1995 Aug;4(8):718–23.

Hypermagnesemia: elderly over-the-counter drug users at risk [letter; comment] Shechter M. **Arch Fam Med** 1996 Jun;5(6):323; discussion 324. Comment on: Arch Fam Med 1995 Aug;4(8):718–23.

Forming a therapeutic alliance with older adults. Hooper CR. **ASHA** 1996 Winter;38(1):43–5

Care of the aged [editorial] Game DA. **Aust Fam Physician** 1995 Oct;24(10):1793

Cobalamin and folate deficiency in the elderly. Matthews JH. **Baillieres Clin Haematol** 1995 Sep;8(3):679–97 (96 ref.)

Britain's over-60s are still getting around [news] Court C. **BMJ** 1996 Jun 29;312(7047):1632

Ethnic elders. Ebrahim S. **BMJ** 1996 Sep 7;313(7057):610–3

Environmental exposures in elderly Canadians with Parkinson's disease. Chaturvedi S, et al. **Can J Neurol Sci** 1995 Aug;22(3):232–4

Time to peak serum antibody response to influenza vaccine in the elderly. Gross PA, et al. **Clin Diagn Lab Immunol** 1996 May;3(3):361–2

When drug treatment in the elderly is not cost effective. An ethical dilemma in an environment of healthcare rationing. Chadwick R, et al. **Drugs Aging** 1995 Dec;7(6):416–9 (25 ref.)

Antiviral therapy of acute herpes zoster in older patients. Herne K, et al. **Drugs Aging** 1996 Feb;8(2):97–112 (89 ref.)

Fungal urinary tract infections in the elderly: treatment guidelines. Jacobs LG. **Drugs Aging** 1996 Feb;8(2):89–96 (32 ref.)

Bisphosphonates and the treatment of bone disease in the elderly. Johansen A, et al. **Drugs Aging** 1996 Feb; 8(2):113–26 (133 ref.)

ACE inhibitors in elderly patients with hypertension. Special considerations. Ravid M, et al. **Drugs Aging** 1996 Jan; 8(1):29–37 (89 ref.)

Use of misoprostol in the elderly: is the expense justified? Stucki G, et al. **Drugs Aging** 1996 Feb;8(2):84–8 (24 ref.)

Optimising thrombolytic therapy in elderly patients with acute myocardial infarction. Verstraete M, et al. **Drugs Aging** 1996 Jan;8(1):17–22 (32 ref.)

Quantitative aspects of swallowing in an elderly nondysphagic population [see comments] Nilsson H, et al. **Dysphagia** 1996 Summer;11(3):180–4. Comment in: Dysphagia 1996 Summer;11(3):185–6.

Dichotic listening, event-related potentials, and interhemispheric transfer in the elderly. Jerger J, et al. **Ear Hear** 1995 Oct;16(5):482–98

A 'revolutionary class' of scapegoats [editorial] Butler RN. **Geriatrics** 1996 Aug;51(8):13–4

The older driver: a handy tool to assess competence behind the wheel. Wiseman EJ, et al. **Geriatrics** 1996 Jul; 51(7):36–8, 41–2, 45

Minority perspectives from the Health and Retirement Study. Introduction: health and retirement among ethnic and racial minority groups. Jackson JS, et al. **Gerontologist** 1996 Jun; 36(3):282–4

Internet resources on aging: research. Post JA. **Gerontologist** 1996 Jun;36(3):277–81

Genotypes with the apolipoprotein epsilon4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men. Stengård JH, et al. **Hum Genet** 1996 May;97(5):677–84

Can activity monitors be used to assess compliance with walking programmes in the elderly? Robinson T, et al. **Int J Rehabil Res** 1995 Sep;18(3):263–5

The factor structure of the general health questionnaire (GHQ-30) in Japanese middle-aged and elderly residents. Ohta Y, et al. **Int J Soc Psychiatry** 1995 Winter; 41(4):268–75

Nutrition in the elderly [editorial] Keane EM. **Ir Med J** 1993 May;86(3):80–2

The prevalence of depression in a cohort of the very elderly. Girling DM, et al. **J Affect Disord** 1995 Aug 18; 34(4):319–29

Dichotic listening to speech: VA-CD data from elderly subjects. Noffsinger D, et al. **J Am Acad Audiol** 1996 Jan; 7(1):49–56

Making treatment decisions for incapacitated older adults without advance directives. AGS Ethics Committee. American Geriatrics Society [see comments] **J Am Geriatr Soc** 1996 Aug;44(8):986–7. Comment in: J Am Geriatr Soc 1996 Aug;44(8):994–6.

Seriously ill hospitalized adults: do we spend less on older patients? Support Investigators. Study to Understand Prognoses and Preference for Outcomes and Risks of Treatments. Hamel MB, et al. **J Am Geriatr Soc** 1996 Sep; 44(9):1043–8

Attitudes of beginning medical students toward older persons: a five-campus study. The University of California Academic Geriatric Resource Program Student Survey Research Group. Reuben DB, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1430–6

Driving vision [letter; comment] Rosenwasser HM. **J Am Optom Assoc** 1995 Oct;66(10):602. Comment on: J Am Optom Assoc 1995 Jun;66(6):343–51.

Right to pet ownership closer for seniors and disabled in federally assisted housing [news] Regula K. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1945, 1947

Mental status testing in the elderly nursing home population. Nadler JD, et al. **J Geriatr Psychiatry Neurol** 1995 Jul; 8(3):177–83

Functional and residential status transitions among nursing home residents. Gillen P, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):M29–36

Risk factors for falls in the Chinese elderly population. Ho SC, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep; 51(5):M195–8

Mixed trends in population health among older adults [editorial] Crimmins EM. **J Gerontol B Psychol Sci Soc Sci** 1996 Sep;51(5):S223–5

Motive and the geographic mobility of very old Americans. De Jong GF, et al. **J Gerontol B Psychol Sci Soc Sci** 1995 Nov;50(6):S395–404

The assessment of ADL among frail elderly in an interview survey: self-report versus performance-based tests and determinants of discrepancies. Kempen GI, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Sep;51(5):P254–60

A longitudinal study of change in domain-specific self-efficacy among older adults. McAvay GJ, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Sep;51(5):P243–53

Self-efficacy, physical decline, and change in functioning in community-living elders: a prospective study. Mendes de Leon CF, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul;51(4):S183–90

Aggregating poor and near-poor elderly under different resource definitions. Rendall MS. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul;51(4):S209–16

Opportunity wages and workforce adjustments: understanding the cost of in-home elder care. White-Means S, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Mar; 51(2):S82–90

Assessing health status in the elderly: the nutrition screening initiative. Barrocas A, et al. **J Health Care Poor Underserved** 1996 Aug;7(3):210–8

Nutrition in minority elders: current problems and future directions. Buchowski MS, et al. **J Health Care Poor Underserved** 1996 Aug;7(3):184–209 (158 ref.)

The aging of America. Satcher D. **J Health Care Poor Underserved** 1996 Aug;7(3):179–82

Health care access, health promotion, and older women of color. Yee DL, et al. **J Health Care Poor Underserved** 1996 Aug;7(3):252–72

Walking exercise and improved neuropsychological functioning in elderly patients with cardiac disease. Satoh T, et al. **J Intern Med** 1995 Nov;238(5):423–8

Effect of breast cancer screening after age 65. Chen HH, et al. **J Med Screen** 1995;2(1):10–4

Prevalence of dementia in an elderly rural population: effects of age, sex, and education. Prencipe M, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):628–33

Do clinical experiences affect nursing students' attitudes toward the elderly? Sheffler SJ. **J Nurs Educ** 1995 Oct; 34(7):312–6

Appropriateness of acute geriatric admissions [letter] Wilson PR. **J R Coll Physicians Lond** 1995 Sep-Oct;29(5):446–7

Inducing a 6-hour phase advance in the elderly: effects on sleep and temperature rhythms. Carrier J, et al. **J Sleep Res** 1996 Jun;5(2):99–105

From the Centers for Disease Control and Prevention. State-specific changes in physical activity among persons aged > or = 65 years--United States, 1987–1992. **JAMA** 1995 Nov 15;274(19):1500–1

Predicting hospital costs among older decedents over time. Culler SD, et al. **Med Care** 1995 Nov;33(11):1089–105

To smell a rose [letter] Finucane PM. **Med J Aust** 1996 Apr 15;164(8):512

Becoming an advocate for the elderly. Hoepfer M. **Pa Med** 1995 Nov;98(11):24–6

The older driver--a review. Morgan R, et al. **Postgrad Med J** 1995 Sep;71(839):525–8 (30 ref.)

Individual differences in stimulus intensity modulation and its relationship to two styles of depression in older adults. Allard C, et al. **Psychol Aging** 1995 Sep;10(3):395–403

Perceptions of life stress and chronic insomnia in older adults. Friedman L, et al. **Psychol Aging** 1995 Sep;10(3):352–7

Neuroleptic treatment of elderly patients. Woerner MG, et al. **Psychopharmacol Bull** 1995;31(2):333–7

What is old age? Robertson MC. **Public Health** 1996 Jul; 110(4):209–10

Physical performance, physical activity and quality of life in elderly people [editorial; comment] Grimby G. **Scand J Med Sci Sports** 1995 Jun;5(3):127–8. Comment on: Scand J Med Sci Sports 1995 Jun;5(3):129–42. Comment on: Scand J Med Sci Sports 1995 Jun;5(3):147–51.

Longitudinal studies of dependence in daily life activities among elderly persons. Sonn U. **Scand J Rehabil Med Suppl** 1996;34:1–35 (168 ref.)

New populations of old add to poor nations' burdens [news] Holden C. **Science** 1996 Jul 5;273(5271):46–8

Japan: feeling the strains of an aging population [news] Oshima S. **Science** 1996 Jul 5;273(5271):44–5

Live long and prosper? [news] Roush W. **Science** 1996 Jul 5;273(5271):42–6

The effect of temazepam on respiration in elderly insomniacs with mild sleep apnea. Camacho ME, et al. **Sleep** 1995 Oct; 18(8):644–5

Sleep and agitation in agitated nursing home residents: an observational study. Cohen-Mansfield J, et al. **Sleep** 1995

Oct;18(8):674–80
Melatonin replacement therapy of elderly insomniacs. Haimov I, et al. **Sleep** 1995 Sep;18(7):598–603
Is sleep apnea syndrome in the elderly a specific entity? Lévy P, et al. **Sleep** 1996 Apr;19(3 Suppl):S29–38 (78 ref.)
Verbal and physical aggression against demented elderly by informal caregivers in The Netherlands. Pot AM, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jun; 31(3–4):156–62
[Locomotive limitations in the elderly; something to consider] Coppelmans WH, et al. **Tijdschr Gerontol Geriatr** 1996 Jun; 27(3):115–9 (Eng. Abstr.) **(Dut)**
[Current incentives for geriatrics. Organizations for the aged confer with administrators of the VWS (editorial)] Sturkenboom A. **Tijdschr Gerontol Geriatr** 1996 Apr; 27(2):52–3 **(Dut)**
[Pharmacology in the elderly. Changes in the pharmacodynamic response to a given drug concentration and changes in mechanisms of regulation] Jolliet P, et al. **Ann Med Interne (Paris)** 1995;146(5):328–34 (71 ref.) **(Fre)**
[Aged couples and management of dependence. Study of 75 helping spouses] Bocquet H, et al. **Cah Sociol Demogr Med** 1995 Apr–Sep;35(2):125–48 (Eng. Abstr.) **(Fre)**
[Medical care of elderly patients (editorial)] Chagnon A. **Rev Med Interne** 1995;16(9):656–7 **(Fre)**
[[Wallonian general physicians. Which prescriptions should be given to elderly persons over 75 years?] Franck J, et al. **Rev Med Liege** 1996 Feb;51(2):163–74 (47 ref.) **(Fre)**
[Dental health and the state of oral hygiene in an elderly population in Rome] Marazzi MC, et al. **Ann Ig** 1995 Sep–Oct;7(5):391–8 (Eng. Abstr.) **(Ita)**
[Nisoldipine in the treatment of ischemic cardiopathy in the aged. Study of electric systole] Tamburrini LR. **Minerva Cardioangiol** 1995 Jun;43(6):263–71 (Eng. Abstr.) **(Ita)**
[Robotics serving the elderly and the handicapped (editorial)] Rovetta A, et al. **Minerva Med** 1995 Jun;86(6):239–43 (Eng. Abstr.) **(Ita)**
[Arrhythmias in the aged: prevalence and correlation with symptoms] Baratta L, et al. **Recenti Prog Med** 1996 Mar; 87(3):96–101 (Eng. Abstr.) **(Ita)**
[Falls among the elderly living in a rural community—prevalence and circumstances of falls by season] Niino N, et al. **Nippon Koshu Eisei Zasshi** 1995 Nov;42(11):975–81 (Eng. Abstr.) **(Jpn)**
[Social activities in the elderly] Tamakoshi A, et al. **Nippon Koshu Eisei Zasshi** 1995 Oct;42(10):888–96 (Eng. Abstr.) **(Jpn)**
[37th Annual meeting of the Japan Geriatrics Society. Osaka, Japan. October 18–20, 1995. Abstracts] **Nippon Ronen Igakkai Zasshi** 1995 Sep;32 Suppl:1–130 **(Jpn)**
[38th Annual meeting of the Japan Geriatrics Society, Chiba, Japan. June 11–13, 1996. Abstracts] **Nippon Ronen Igakkai Zasshi** 1996 May;33 Suppl:1–128 **(Jpn)**
[Retired people and causes of their death in relation to residence and former place of employment] Sharafutdinova NK. **Med Tr Prom Ekol** 1995;(12):11–3 (Eng. Abstr.) **(Rus)**
[Preoperative geriatric assessment in major surgery in the aged] Martín Graczyk AI, et al. **An Med Interna** 1995 Jun; 12(6):270–4 (Eng. Abstr.) **(Spa)**
[Efficacy and tolerance of the treatment of tuberculosis in the aged] Aguilar X, et al. **Arch Bronconeumol** 1996 Mar; 32(3):122–6 (Eng. Abstr.) **(Spa)**
[Hyponatremia in the aged (letter)] Camós P, et al. **Aten Primaria** 1996 Apr 15;17(6):427–8 **(Spa)**
[Consultation by third parties in primary care of the aged] García del Campo MM, et al. **Aten Primaria** 1995 Dec; 16(10):607–10, 612–4 (Eng. Abstr.) **(Spa)**
[Spanish version of the OARS Multidimensional Functional Assessment Questionnaire: cross-cultural adaptation and validity measurement] Grau Fibla G, et al. **Aten Primaria** 1996 May 15;17(8):486–95 (Eng. Abstr.) **(Spa)**
[Visual and auditory difficulties expressed by the aged] López-Torres Hidalgo J, et al. **Aten Primaria** 1995 Oct 31;16(7):437–40 (Eng. Abstr.) **(Spa)**
[Sexual activity in the elderly in a rural environment] Noguerol Alvarez M, et al. **Aten Primaria** 1996 Jul–Aug; 18(3):105–10 (Eng. Abstr.) **(Spa)**
[Drug consumption by people over 60 years of age in a rural area] Vega Quiroga S, et al. **Aten Primaria** 1996 May 15; 17(8):496–500 (Eng. Abstr.) **(Spa)**
[Changes in patterns of medication as function of age of the aging patient (review of the literature) (editorial)] Rosario Burgos EN. **Bol Asoc Med P R** 1995 Jul–Sep;87(7–9):121–3 (8 ref.) **(Spa)**
[The handicaps and the need for services among the aged detected in the health survey OARS-Vigo] Eiroa Patiño P, et al. **Med Clin (Barc)** 1996 May 4;106(17):641–8 (Eng. Abstr.) **(Spa)**
[Thrombolytic treatment in acute myocardial infarction in the aged: arguments in favor] Alonso-Orcajo N, et al. **Rev Esp Cardiol** 1995 Sep;48(9):589–93 (43 ref.) **(Spa)**
[Thrombolytic treatment in acute myocardial infarction in the aged: arguments against] Pabón Osuna P, et al. **Rev Esp Cardiol** 1995 Sep;48(9):581–8 (36 ref.) **(Spa)**
[Major surgery in geriatric age: are the risk factors quantifiable? (letter)] Uriarte Zaldúa C, et al. **Rev Esp Enferm Dig** 1996 Jan;88(1):57–9 **(Spa)**
[Automobile driving by the aged] Cortés Blanco M. **Rev Esp Salud Publica** 1995 Mar–Apr;69(2):189–93 (Eng. Abstr.) **(Spa)**
[Utilization of medication by the elderly in Argentine] Iñesta García A, et al. **Rev Esp Salud Publica** 1995 May–Aug; 69(3–4):315–27 (Eng. Abstr.) **(Spa)**
[Clinical aspects of vascular epilepsy in aging] Carod FJ, et al. **Rev Neurol** 1995 Nov–Dec;23(124):1314–7 (11 ref.) **(Spa)**
[Status epilepticus in the elderly] Cid MA. **Rev Neurol** 1995 Nov–Dec;23(124):1310–3 (27 ref.) **(Spa)**
[Characteristics of epilepsy in aged people] Oliveros A. **Rev Neurol** 1995 Nov–Dec;23(124):1292–6 **(Spa)**
[Epilepsy and cerebral aging. Pharmacokinetics of antiepileptic treatment in adult age] Oller Ferrer-Vidal L. **Rev Neurol** 1995 Nov–Dec;23(124):1318–9 **(Spa)**

PHYSIOLOGY

A randomized controlled trial of a home exercise programme for elderly people with poor mobility. McMurdo ME, et al. **Age Ageing** 1995 Sep;24(5):425–8
Impaired antibody responses to pneumococcal polysaccharide in elderly patients with low serum vitamin B12 levels [see comments] Fata FT, et al. **Ann Intern Med** 1996 Feb 1;124(3):299–304. Comment in: Circulation 1996 Feb 1;124(3):338–40.
Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Orwoll ES, et al. **Ann Intern Med** 1996 Jan 15;124(2):187–96
Apolipoprotein E genotype in elderly nondemented subjects without senile changes in the brain. Yamada M, et al. **Ann Neurol** 1996 Aug;40(2):243–5
Gait speed and activities of daily living function in geriatric patients. Potter JM, et al. **Arch Phys Med Rehabil** 1995 Nov;76(11):997–9
Protein requirements of elderly people. Campbell WW, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S180–3; discussion S183–5 (8 ref.)
Report on the working group on energy requirements of older individuals. Dupont JL, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S192
Energy requirements of older individuals. Roberts SB. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S112–7; discussion S117–8 (20 ref.)
Strengths and limitations of using the Revised Elderly Person's Disability Scale (REPDS) as a research tool in a Scottish context. Dallender J, et al. **Health Bull (Edinb)** 1996 May;54(3):229–31
Sleep in healthy elderly subjects: a 24-hour ambulatory polysomnographic study. Gigli GL, et al. **Int J Neurosci** 1996 Apr;85(3–4):263–71
Reaction of pituitary-adrenal and autonomic nervous systems to stress in trained and untrained elderly people. Korkushko OV, et al. **J Auton Nerv Syst** 1995 Jul 14;54(1):27–32
Bone density determinants in elderly women: a twin study. Flicker L, et al. **J Bone Miner Res** 1995 Nov;10(11):1607–13
Effects of a one-year high-intensity versus low-intensity resistance training program on bone mineral density in older women. Pruitt LA, et al. **J Bone Miner Res** 1995 Nov;10(11):1788–95
Effectiveness of water exercise on postural mobility in the well elderly: an experimental study on balance enhancement. Simmons V, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):M233–8
Dietary intakes of energy and water-soluble vitamins in different categories of aging. van der Wielen RP, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B100–7
Longitudinal study of basal cortisol levels in healthy elderly subjects: evidence for subgroups. Lupien S, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):95–105
Prevalence of movement disorders in institutionalized elderly. Moghal S, et al. **Neuroepidemiology** 1995; 14(6):297–300
Functional balance tests in 76-year-olds in relation to performance, activities of daily living and platform tests. Frändin K, et al. **Scand J Rehabil Med** 1995 Dec; 27(4):231–41
Renal reserve in the elderly. Fliser D, et al. **Semin Nephrol** 1995 Sep;15(5):463–7 (47 ref.)
Anesthetic considerations in the geriatric patient. Burney TL, et al. **Urol Clin North Am** 1996 Feb;23(1):19–26 (20 ref.)
Sexuality in the elderly. Kaiser FE. **Urol Clin North Am** 1996 Feb;23(1):99–109 (76 ref.)
[Cognitive and visual functions in a sample of the aged population: analysis of evoked potentials] Jech R, et al. **Cas Lek Cesk** 1995 Dec 13;134(24):791–7 (Eng. Abstr.) **(Cze)**
[Reduced endothelium-dependent peripheral vasodilation in the aged] Giordano G, et al. **Cardiologia** 1995 Jan; 40(1):47–50 (Eng. Abstr.) **(Ita)**
[A study of audiologic findings in the elderly] Shimoda K. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Sep;98(9):1426–39 (Eng. Abstr.) **(Jpn)**
[Hearing acuity in the elderly in Japan] Yagi M, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jun;99(6):869–74 (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Predictors of hospital contact by very elderly people: a pilot study from a cohort of people aged 75 years and over. Chi LY, et al. **Age Ageing** 1995 Sep;24(5):382–8
Activity levels and cognitive functioning in an elderly community sample. Christensen H, et al. **Age Ageing** 1996 Jan;25(1):72–80
Review: diogenes syndrome. Cooney C, et al. **Age Ageing** 1995 Sep;24(5):451–3 (14 ref.)
Diabetes and cognitive impairment: a community-based study of elderly subjects. Croxson SC, et al. **Age Ageing** 1995 Sep;24(5):421–4
The relationship between the mini-mental state examination and cognitive functioning in normal elderly adults: a componential analysis. Hill RD, et al. **Age Ageing** 1995 Sep; 24(5):440–6
Active euthanasia and physician-assisted suicide in Dutch nursing homes: patients' characteristics. Muller MT, et al. **Age Ageing** 1995 Sep;24(5):429–33
Older women and their images of health: a replication study. Perry J, et al. **ANS Adv Nurs Sci** 1995 Sep;18(1):51–61
Mood improvement in elderly women after in-hospital physical rehabilitation. Barbisoni P, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):346–9
Elders' perceptions of the role of group psychotherapy in fostering self-transcendence. Young CA, et al. **Arch Psychiatr Nurs** 1995 Dec;9(6):338–47
Dispositional optimism, dysphoria, health, and coping with hearing impairment in elderly adults. Andersson G, et al. **Audiology** 1995 Mar–Apr;34(2):76–84
Older women ignorant of breast screening [news] Dillner L. **BMJ** 1996 Jan 13;312(7023):75–6
Caring for older people. Loneliness. Forbes A. **BMJ** 1996 Aug 10;313(7053):352–4 (0 ref.)
Domestic violence against elderly women. Grunfeld AF, et al. **Can Fam Physician** 1996 Aug;42:1485–93
Short-term and long-term memory in elderly patients with NIDDM. Helkala EL, et al. **Diabetes Care** 1995 May; 18(5):681–5
Anorexia in older persons: epidemiology and optimal treatment. Morley JE. **Drugs Aging** 1996 Feb;8(2):134–55 (205 ref.)
The effects of poverty environments on elders' subjective well-being: a conceptual model. Brown V. **Gerontologist** 1995 Aug;35(4):541–8 (48 ref.)
Reminiscence: a continuity theory framework. Parker RG. **Gerontologist** 1995 Aug;35(4):515–25 (81 ref.)
Centenarians: their memories and future ambitions. Merriam SB, et al. **Int J Aging Hum Dev** 1995;41(2):117–32
Correlates of reminiscence activity among elderly individuals. Quackenbush SW, et al. **Int J Aging Hum Dev** 1995;41(2):169–81
Slowed reaction time performance on a divided attention task in elderly with environmental chemical odor intolerance. Bell IR, et al. **Int J Neurosci** 1996 Feb; 84(1–4):127–34
Suicide in the multiethnic elderly population of Australia, 1979–1990. Burvill PW. **Int Psychogeriatr** 1995 Summer; 7(2):319–33
Future directions for research on late-life suicide. Caine ED, et al. **Int Psychogeriatr** 1995 Summer;7(2):357–60
Suicide in the elderly: the United Kingdom perspective. Dennis MS, et al. **Int Psychogeriatr** 1995 Summer; 7(2):263–74
Six elderly suicides in a 1-year period in a rural midwestern community. Finkel SI, et al. **Int Psychogeriatr** 1995 Summer;7(2):221–30
Recent life events in elderly suicide: a nationwide study in Finland. Heikkinen ME, et al. **Int Psychogeriatr** 1995 Summer;7(2):287–300
Mental disorders in elderly suicide. Henriksson MM, et al. **Int Psychogeriatr** 1995 Summer;7(2):275–86
Ethnicity and elderly suicide in Singapore. Ko SM, et al. **Int Psychogeriatr** 1995 Summer;7(2):309–17
Epidemiology of suicide. Mościcki EK. **Int Psychogeriatr** 1995 Summer;7(2):137–48
Suicide in late life: challenges and opportunities for research. Introduction. Pearson JL, et al. **Int Psychogeriatr** 1995 Summer;7(2):131–6
Recent changes in suicide rates in selected eastern European and other European countries. Sartorius N. **Int Psychogeriatr** 1995 Summer;7(2):301–8
Suicide in later life in Japan: urban and rural differences. Watanabe N, et al. **Int Psychogeriatr** 1995 Summer; 7(2):253–61
Perceptions of physical fitness and exercise activity among older adults. Melillo KD, et al. **J Adv Nurs** 1996 Mar; 23(3):542–7
Just another elderly Medicare patient? [editorial] Parmley WW. **J Am Coll Cardiol** 1995 Nov 1;26(5):1374–5
Religious activity improves quality of life for ill older adults [letter] Reyes-Qrtiz CA, et al. **J Am Geriatr Soc** 1996 Sep; 44(9):1139
Estimating premorbid intelligence in African-American and white elderly veterans using the American version of the National Adult Reading Test. Boekamp JR, et al. **J Clin Exp Neuropsychol** 1995 Oct;17(5):645–53
Rural elders and the decision to stop driving. Johnson JE. **J Community Health Nurs** 1995;12(3):131–8
Psychological indicators of balance confidence: relationship to actual and perceived abilities. Myers AM, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):M37–43
The meaning of older adults' health appraisals: congruence with health status and determinant of mortality. Borawski

EA, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 May; 51(3):S157–70

The relations of dispositional regulation and emotionally to elder's empathy-related responding and affect while volunteering. Eisenberg N, et al. **J Pers** 1996 Mar; 64(1):157–83

Older adults and healthy lifestyle issues: results of a community study [letter; comment] Richmond DE, et al. **N Z Med J** 1996 Jul 12;109(1025):264. Comment on: N Z Med J 1996 May 24;109(1022):195.

Dementia in the elderly [letter; comment] Ritchie K. **Neurology** 1995 Nov;45(11):2112–3. Comment on: Neurology 1994 Aug;44(8):1427–32.

Cancer fatalism among elderly Caucasians and African Americans. Powe BD. **Oncol Nurs Forum** 1995 Oct; 22(9):1355–9

Assessing functional status of elderly adults via microcomputer. Yarnold PR, et al. **Percept Mot Skills** 1996 Apr;82(2):689–90

Chronic stress alters the immune response to influenza virus vaccine in older adults. Kiecolt-Glaser JK, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3043–7

Depressive symptoms in the elderly: association with total white blood cell count. Brown SL, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):849–60

Measuring social desirability among senior medical students. Merrill JM, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):859–64

Activists and delegators: elderly patients' preferences about control at the end of life. Kelner M. **Soc Sci Med** 1995 Aug;41(4):537–45

Psychosocial issues in geriatric urology: problems in treatment and treatment seeking. Umlauf MG, et al. **Urol Clin North Am** 1996 Feb;23(1):127–36 (35 ref.)

Elder care recipients' care-seeking process. Russell CK. **West J Nurs Res** 1996 Feb;18(1):43–62

[Pain, suffering and loneliness in the aged] Smitka V. **Cas Lek Cesk** 1995 Nov 1;134(21):699–700 **(Cze)**

[Placed in the wrong bed with a broken leg] Ligtenstein DA, et al. **Ned Tijdschr Geneeskd** 1996 Apr 20;140(16):865–7 **(Dut)**

[Application of the Behavioral Observation Scale Geriatrics in residents of nursing homes in Flanders] Habraken H, et al. **Tijdschr Gerontol Geriatr** 1995 Dec;26(6):253–8 (Eng. Abstr.) **(Dut)**

[Item series of the cognitive screening test compared to those of the mini-mental status examination] Schmand B, et al. **Tijdschr Gerontol Geriatr** 1996 Feb;27(1):29–33 (Eng. Abstr.) **(Dut)**

[Time factors and lack of motivation in the elderly] Hazif-Thomas C, et al. **Ann Med Psychol (Paris)** 1996 May; 154(2):140–4 (Eng. Abstr.) **(Fre)**

[Relationship of physical condition and functional capacity to depressive status in person aged 75 years] Osada H, et al. **Nippon Koshu Eisei Zasshi** 1995 Oct;42(10):897–909 (Eng. Abstr.) **(Jpn)**

[Global life satisfaction and its related factors in community elderly residents] Sugai K, et al. **Nippon Koshu Eisei Zasshi** 1996 May;43(5):374–89 (Eng. Abstr.) **(Jpn)**

[Factors related to impaired mental function of elderly in a rural community] Suzuki Y. **Nippon Koshu Eisei Zasshi** 1995 Jul;42(7):442–53 (Eng. Abstr.) **(Jpn)**

[Awareness and feelings of elderly patients and their families concerning disease during terminal hospitalization--malignancy versus non-malignancy] Nagura E, et al. **Nippon Ronen Igakkai Zasshi** 1995 Aug-Sep;32(8-9):571-80 (Eng. Abstr.) **(Jpn)**

STATISTICS & NUMERICAL DATA

The elderly who live alone in the United States: historical perspectives on household change. Kramarow EA. **Demography** 1995 Aug;32(3):335–52

African-American mortality at older ages: results of a matching study. Preston SH, et al. **Demography** 1996 May; 33(2):193–209

Differentials in active life expectancy in the older population of the United States. Crimmins EM, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 May;51(3):S111–20

Living arrangements of minority elders. Himes CL, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):S42–8

A measurement model of the Medical Outcomes Study 36-Item Short-Form Health Survey in a clinical sample of disadvantaged, older, black, and white men and women. Wolinsky FD, et al. **Med Care** 1996 Jun;34(6):537–48

Changing demographics and neurologic disease in the elderly. Riggs JE. **Neurol Clin** 1996 May;14(2):477–86 (41 ref.)

Underwriting the elderly life insurance applicant. Hankwitz PE. **Proc Annu Meet Med Sect Am Counc Life Insur** 1995; :79–93

Increasing lung cancer mortality rates in the elderly: a manifestation of differential survival. Riggs JE. **Regul Toxicol Pharmacol** 1995 Jun;21(3):370–4

Predictors for recurrent falls among the home-dwelling elderly. Luukinen H, et al. **Scand J Prim Health Care** 1995 Dec;13(4):294–9

Restructuring long-term care and the geography of ageing: a view from rural New Zealand. Joseph AE, et al. **Soc Sci Med** 1996 Mar;42(6):887–96

Incomes of the elderly and nonelderly, 1967–92. Radner DB. **Soc Secur Bull** 1995 Winter;58(4):82–97

AGED ABUSE see **ELDER ABUSE**

AGED, 80 AND OVER

Surgery in the very old patient: evaluation of factors linked to postoperative morbidity and mortality. Di Palo S, et al. **Aging (Milano)** 1995 Apr;7(2):110–6

CABG in octogenarians: early and late events and actuarial survival in comparison with a matched population [see comments] Cane ME, et al. **Ann Thorac Surg** 1995 Oct; 60(4):1033–7. Comment in: Ann Thorac Surg 1995 Oct;60(4):875–6.

Coronary operations in octogenarians: can we select the patients? [editorial; comment] Weintraub WS. **Ann Thorac Surg** 1995 Oct;60(4):875–6. Comment on: Ann Thorac Surg 1995 Oct;60(4):1033–7. Comment on: Ann Thorac Surg 1995 Oct;60(4):1038–43.

Determinants of operative mortality in octogenarians undergoing coronary bypass [see comments] Williams DB, et al. **Ann Thorac Surg** 1995 Oct;60(4):1038–43. Comment in: Ann Thorac Surg 1995 Oct;60(4):875–6.

Apolipoprotein E genotype determines survival in the oldest old (85 years or older) who have good cognition. Corder EH, et al. **Arch Neurol** 1996 May;53(5):418–22

Carotid artery surgery in the octogenarian. Thomas PC, et al. **Aust N Z J Surg** 1996 Apr;66(4):231–4

Quality of life in octogenarians after open heart surgery. Kumar P, et al. **Chest** 1995 Oct;108(4):919–26

Outcomes of coronary artery bypass graft surgery in 24,461 patients aged 80 years or older. Peterson ED, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II85–91

Immunology of centenarians [letter; comment] Steinmann G, et al. **Immunol Today** 1995 Nov;16(11):549–50. Comment on: Immunol Today 1995 Jan;16(1):12–6.

Colorectal surgery in octogenarians. Spivak H, et al. **J Am Coll Surg** 1996 Jul;183(1):46–50

Sex and Swedish 85-year olds [letter] Skoog I. **N Engl J Med** 1996 Apr 25;334(17):1140–1

Apolipoprotein E allele in centenarians. Asada T, et al. **Neurology** 1996 May;46(5):1484

Is it appropriate to offer dialysis to octogenarians? A modern conspiracy? [editorial] Oreopoulos DG. **Perit Dial Int** 1996 May-Jun;16(3):241–2

Octogenarian pearls [editorial] Alexander E Jr. **Surg Neurol** 1996 Jun;45(6):587–9

Open heart surgery in the octogenarians--a study on long-term survival and quality of life. Diegeler A, et al. **Thorac Cardiovasc Surg** 1995 Oct;43(5):265–70

[Influenza vaccine in 85-and-over aged: motivation of elderly and family physicians to vaccinate or not] van Haaren KM, et al. **Ned Tijdschr Geneeskd** 1995 Oct 21; 139(42):2144–8 (Eng. Abstr.) **(Dut)**

[Surgery of abdominal aortic aneurysms in octogenarians. Critical remarks on indications for surgical intervention in different age groups] Pizzetti F, et al. **Recenti Prog Med** 1995 Nov;86(11):437–41 (Eng. Abstr.) **(Ita)**

[Family history and the frequency of human leukocyte antigen (HLA-DR) in centenarians] Akisaka M, et al. **Nippon Ronen Igakkai Zasshi** 1996 Mar;33(3):180–5 (Eng. Abstr.) **(Jpn)**

[Sociomedical study of centenarians in Nagoya City] Inagaki T, et al. **Nippon Ronen Igakkai Zasshi** 1996 Feb;33(2):84–94 (Eng. Abstr.) **(Jpn)**

[Red blood cell parameters of healthy centenarians] Nozaki H, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jul;32(7):471–7 (Eng. Abstr.) **(Jpn)**

[Sexual activity in the elderly in a rural environment] Noguerol Alvarez M, et al. **Aten Primaria** 1996 Jul-Aug; 18(3):105–10 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Sleep in healthy elderly subjects: a 24-hour ambulatory polysomnographic study. Gigli GL, et al. **Int J Neurosci** 1996 Apr;85(3–4):263–71

Immunosenescence in humans: deterioration or remodelling? Franceschi C, et al. **Int Rev Immunol** 1995;12(1):57–74 (100 ref.)

Cognitive and functional status of the oldest old. Corey-Bloom J, et al. **J Am Geriatr Soc** 1996 Jun; 44(6):671–4

Blood reticulocyte count and plasma lactate dehydrogenase activity are positively related to the free fatty acid/albumin ratio in geriatric patients. Høstmark AT, et al. **Scand J Clin Lab Invest** 1995 Nov;55(7):649–53

[Cardiac output in patients in their 90's] Okazaki K, et al. **Masui** 1996 Mar;45(3):352–5 (Eng. Abstr.) **(Jpn)**

[Chronological study concerning ADL among Okinawan centenarians] Suzuki M, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jun;32(6):416–23 (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Factors associated with the wish to die in elderly people. Jorm AF, et al. **Age Ageing** 1995 Sep;24(5):389–92

Suicidal feelings in a population sample of nondemented 85-year-olds. Skoog I, et al. **Am J Psychiatry** 1996 Aug; 153(8):1015–20

Cognitive and functional status of the oldest old. Corey-Bloom J, et al. **J Am Geriatr Soc** 1996 Jun; 44(6):671–4

Perceptions of baby talk, frequency of receiving baby talk, and self-esteem among community and nursing home residents. O'Connor BP, et al. **Psychol Aging** 1996 Mar; 11(1):147–54

STATISTICS & NUMERICAL DATA

Prevalence and correlates of depression in a population of nonagenarians. Forsell Y, et al. **Br J Psychiatry** 1995 Jul; 167(1):61–4

Using a mailed survey to predict hospital admission among patients older than 80. Freedman JD, et al. **J Am Geriatr Soc** 1996 Jun;44(6):689–92

Survival after age 80 [letter; comment] Hughes-Davies TH. **N Engl J Med** 1996 Feb 22;334(8):537; discussion 538. Comment on: N Engl J Med 1995 Nov 2;333(18):1232–5.

Survival after the age of 80 in the United States, Sweden, France, England, and Japan [see comments] Manton KG, et al. **N Engl J Med** 1995 Nov 2;333(18):1232–5. Comment in: N Engl J Med 1996 Feb 22;334(8):537; discussion 538. Comment in: N Engl J Med 1996 Feb 22;334(8):537–8.

Survival after age 80 [letter; comment] Preston SH, et al. **N Engl J Med** 1996 Feb 22;334(8):537; discussion 538. Comment on: N Engl J Med 1995 Nov 2;333(18):1232–5.

Survival after age 80 [letter; comment] Sallar AM, et al. **N Engl J Med** 1996 Feb 22;334(8):537–8. Comment on: N Engl J Med 1995 Nov 2;333(18):1232–5.

Increasing lung cancer mortality rates in the elderly: a manifestation of differential survival. Riggs JE. **Regul Toxicol Pharmacol** 1995 Jun;21(3):370–4

Social security benefits and SSI payments for centenarians, December 1994. Lennox CB. **Soc Secur Bull** 1995 Fall; 58(3):55–6

[Geographical epidemiologic studies on factors associated with centenarians in Japan] Okamoto K, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jul;32(7):485–90 (Eng. Abstr.) **(Jpn)**

AGEISM see **PREJUDICE**

AGENCY FOR HEALTH CARE POLICY AND RESEARCH see **UNITED STATES AGENCY FOR HEALTH CARE POLICY AND RESEARCH**

AGEPC see **PLATELET ACTIVATING FACTOR**

AGEUSIA

CHEMICALLY INDUCED

Reversible ageusia associated with losartan [letter] Schlienger RG, et al. **Lancet** 1996 Feb 17;347(8999):471–2

[Ageusia caused by terbinafine (letter)] Martínez Yélamos S, et al. **Med Clin (Barc)** 1995 Sep 9;105(7):276 **(Spa)**

ETIOLOGY

Case of ageusia from a variety of causes. Deguchi K, et al. **J Laryngol Otol** 1996 Jun;110(6):598–601

[Expert evaluation of smell and taste disorders] Mrowinski D, et al. **HNO** 1996 Mar;44(3):157–63 **(Ger)**

AGGLUTINATION

Agglutination of Staphylococcus saprophyticus: a structural and cytochemical study. Morioka H, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1–2):101–5

AGGLUTINATION TESTS

Interpretation of the Widal test in the diagnosis of typhoid fever in Bangladeshi children. Saha SK, et al. **Ann Trop Paediatr** 1996 Mar;16(1):75–8

Agglutination of Streptococcus suis by sialic acid-binding lectins. Charland N, et al. **J Clin Microbiol** 1995 Aug; 33(8):2220–1

Specificity of Widal test in healthy blood donors and patients with meningitis. Harries AD, et al. **J Infect** 1995 Sep; 31(2):149–50

Performance evaluation of a particle agglutination test for antibody to human immunodeficiency virus 1: comparison with enzyme immunoassay. Elavia AJ, et al. **Vox Sang** 1995; 69(1):23–6

[Evaluation of direct agglutination tests in the detection of Leishmania (Viannia) braziliensis in possible reservoirs of cutaneous American leishmaniasis in the state of Ceará] Bezerra HS, et al. **Rev Soc Bras Med Trop** 1996 Mar-Apr; 29(2):181–4 (Eng. Abstr.) **(Por)**

[Direct agglutination tests in the serodiagnosis of visceral leishmaniasis in the state of Pará] Garcez LM, et al. **Rev Soc Bras Med Trop** 1996 Mar-Apr;29(2):165–80 (Eng. Abstr.) **(Por)**

[Use of a latex-agglutination test for determining anti-measles antibody titer] Aleksander SK, et al. **Vopr Virusol** 1995 Sep-Oct;40(5):231–4 (Eng. Abstr.) **(Rus)**

METHODS

Comparative evaluation of microagglutination test and serum agglutination test as supplementary diagnostic methods for brucellosis. Baum M, et al. **J Clin Microbiol** 1995 Aug; 33(8):2166–70

Coagglutination tes: for serotyping Pasteurella haemolytica. Fodor L, et al. **J Clin Microbiol** 1996 Feb;34(2):393–7
Evaluation of cleaving agents other than trypsin in direct agglutination test for further improving diagnosis of visceral leishmaniasis. el Harith A, et al. **J Clin Microbiol** 1995 Aug;33(8):1984–8
Development and testing of monoclonal antibody-based rapid immunodiagnostic test kits for direct detection of Vibrio cholerae O139 synonym Bengal. Hasan JA, et al. **J Clin Microbiol** 1995 Nov;33(11):2935–9
Automated reading and processing of quantitative IgG, IgM, IgA, and IgE isotypic agglutination results in microplates. Development and application in parasitology-mycology. Aubert D, et al. **J Immunol Methods** 1995 Oct 26; 186(2):323–8
A rapid test for endotoxin in whole blood. Rylatt D, et al. **Prog Clin Biol Res** 1995;392:273–84
Gelatin particle indirect agglutination test for serodiagnosis of schistosomiasis: comparative study with enzyme-linked immunosorbent assay. Kobayashi J, et al. **Rev Inst Med Trop Sao Paulo** 1994 Sep–Oct;36(5):389–94

STANDARDS

Agglutinins for brucellae antigens in blood sera of an urban and rural population in Kenya. Jumba MM, et al. **East Afr Med J** 1996 Mar;73(3):204–6
Serological cross reaction between legionella and campylobacter in the rapid microagglutination test. Boswell TC. **J Clin Pathol** 1996 Jul;49(7):584–6
Reducing the cost of HIV-testing through use of the IgG antibody captured particle adherence test (GACPAT) in district hospitals. Klokke AH, et al. **Trop Geogr Med** 1995; 47(6):296–9

VETERINARY

Comparative performance of the enzyme-linked immunosorbent assay (ELISA) and conventional assays in the diagnosis of bovine brucellosis in Argentina. Saravi MA, et al. **Vet Immunol Immunopathol** 1995 Jul; 47(1–2):93–9

AGGLUTININS

Anti-Pr cold agglutinins recognize immunodominant alpha 2,3- or alpha 2,6-sialyl groups on glycophorins. Kewitz S, et al. **Glycoconj J** 1995 Oct;12(5):714–20
Liver transplantation in a patient with high cold agglutinin titers. Emre S, et al. **Transplantation** 1995 Sep 27; 60(6):622–4

BLOOD

[125I]IgM (KAU) human monoclonal cold agglutinin: labelling and studies on its biological activity. Vigorito E, et al. **Appl Radiat Isot** 1995 Oct;46(10):975–9
Cold agglutinins: preoperative diagnosis leads to an uneventful perfusion. Innet LM, et al. **Perfusion** 1995 Sep; 10(5):343–5

IMMUNOLOGY

The frequent mutation Gly/Asp in CDR1H may determine a cross-reactive idiotope in anti-I cold agglutinins. Abatangelo C, et al. **Clin Exp Immunol** 1996 Apr; 104(1):185–90
Coexistence of anti-salmonella agglutinins in falciparum malaria [letter] Khubnani H, et al. **J Assoc Physicians India** 1995 Aug;43(8):585–6

METABOLISM

The I binding specificity of human VH 4-34 (VH 4-21) encoded antibodies is determined by both VH framework region 1 and complementarity determining region 3. Li Y, et al. **J Mol Biol** 1996 Mar 1;256(3):577–89

PHYSIOLOGY

Cardiac surgery and cold-reactive proteins. Agarwal SK, et al. **Ann Thorac Surg** 1995 Oct;60(4):1143–50 (47 ref.)

AGGLUTININS, PLANT see **LECTINS**

AGGLUTININS, WHEAT GERM see **WHEAT GERM AGGLUTININS**

AGGREGATION BIAS see **BIAS (EPIDEMIOLOGY)**

AGGREGATION, RECEPTOR see **RECEPTOR AGGREGATION**

AGGRESSION

Aggression and hostility in substance abusers: the relationship to abuse patterns, coping style, and relapse triggers. McCormick RA, et al. **Addict Behav** 1995 Sep–Oct; 20(5):555–62
Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease. Victoroff J, et al. **Arch Neurol** 1996 May;53(5):428–34
Congenic AB mice: a novel means for studying the (molecular) genetics of aggression. Schneider-Stock R, et al. **Behav Genet** 1995 Sep;25(5):475–82
Association of common health symptoms with bullying in primary school children. Williams K, et al. **BMJ** 1996 Jul 6;313(7048):17–9
Neuroanatomical and neurochemical mechanisms underlying amygdaloid control of defensive rage behavior in the cat. Shaikh MB, et al. **Braz J Med Biol Res** 1994 Dec; 27(12):2759–79 (43 ref.)
Residents' experiences of abuse, discrimination and sexual harassment during residency training. McMaster University Residency Training Programs [see comments] Cook DJ, et al. **Can Med Assoc J** 1996 Jun 1;154(11):1657–65. Comment in: Can Med Assoc J 1996 Jun 1;154(11):1705–8.
Abuse of residents: it's time to take action [editorial; comment] Myers MF. **Can Med Assoc J** 1996 Jun 1; 154(11):1705–8. Comment on: Can Med Assoc J 1996 Jun 1;154(11):1657–65.
Self-defense against verbal assault: shame, anger, and the social bond. Scheff TJ. **Fam Process** 1995 Sep;34(3):271–86
Cognitive and neuropsychological characteristics of physically aggressive boys. Séguin JR, et al. **J Abnorm Psychol** 1995 Nov;104(4):614–24
Animal behavior case of the month. Dogs were evaluated because of aggression. Dodman NH, et al. **J Am Vet Med Assoc** 1995 Nov 1;207(9):1168–71
Moderating role of trait aggressiveness in the effects of violent media on aggression. Bushman BJ. **J Pers Soc Psychol** 1995 Nov;69(5):950–60
Insult, aggression, and the southern culture of honor: an "experimental ethnography". Cohen D, et al. **J Pers Soc Psychol** 1996 May;70(5):945–59
Illegal drug use, alcohol and aggressive crime among Mexican-American and white male arrestees in San Antonio. Valdez A, et al. **J Psychoactive Drugs** 1995 Apr–Jun;27(2):135–43
Aggressive behavior on an inpatient geriatric unit. Ferguson JS, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Mar; 34(3):27–32
Least restrictive measures: alternatives to four-point restraints and seclusion. Morales E, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Oct;33(10):13–6
Aggression against doctors: a review. Hobbs FD, et al. **J R Soc Med** 1996 Feb;89(2):69–72 (38 ref.)
The motivation of Australian adolescent schoolchildren to engage in group discussions about bullying. Rigby K. **J Soc Psychol** 1995 Dec;135(6):773–4
Childhood aggression needs definition, therapy [news] Marwick C. **JAMA** 1996 Jan 10;275(2):90
Yelling attacks and wasted hands. Bosboom WM, et al. **Lancet** 1996 Jul 27;348(9022):238
High-fat diet induces aggressive behavior in male mice and rats. Hilakivi-Clarke L, et al. **Life Sci** 1996;58(19):1653–60
Neurobiology. Nitric oxide and bad behaviour [news; comment] Coles H. **Nature** 1995 Nov 23;378(6555):336. Comment on: Nature 1995 Nov 23;378(6555):383–6.
Frontal lobe injuries, violence, and aggression: a report of the Vietnam Head Injury Study. Grafman J, et al. **Neurology** 1996 May;46(5):1231–8
Nest defense and survival of offspring in highly aggressive wild Canadian female house mice. Vom Saal FS, et al. **Physiol Behav** 1995 Oct;58(4):669–78
Group selection for adaptation to multiple-hen cages: beak-related mortality, feathering, and body weight responses. Craig JV, et al. **Poult Sci** 1996 Mar;75(3):294–302
Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics. Miczek KA, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):38–56 (161 ref.)
Acute effect of altered tryptophan levels and alcohol on aggression in normal human males. Pihl RO, et al. **Psychopharmacology (Berl)** 1995 Jun;119(4):353–60
Cannabis—deceptive weed or decriminalised drug? [letter] Kaplan R. **S Afr Med J** 1996 May;86(5):565
Aggression in mice and men? [letter; comment] Rose SP. **Science** 1995 Oct 20;270(5235):362–4. Comment on: Science 1995 Jun 23;268(5218):1763–6.
Verbal and physical aggression against demented elderly by informal caregivers in The Netherlands. Pot AM, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jun; 31(3–4):156–62
Aggressive behavior in childhood and early adolescence: an ecological-developmental perspective on youth violence. Fraser MW. **Soc Work** 1996 Jul;41(4):347–61 (120 ref.)
Socialising puppies [letter] [see comments] Bower C. **Vet Rec** 1995 Jul 8;137(2):51. Comment in: Vet Rec 1995 Jul 22;137(4):103.
[Threats and physical violence at work] Laakkonen A, et al. **Duodecim** 1994;110(16):1510–6 (33 ref.) **(Fin)**
[Low concentration level of total serum cholesterol as a risk factor for suicidal and aggressive behavior] Ainiyet J, et al. **Psychiatr Pol** 1996 May–Jun;30(3):499–509 (31 ref.) (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Shankle WR, et al. **Alzheimer Dis Assoc Disord** 1995 Winter;9(4):233–7
Fluvoxamine treatment of compulsivity, impulsivity, and aggression [letter] Poyurovsky M, et al. **Am J Psychiatry** 1995 Nov;152(11):1688–9
Effect of subchronic and chronic exposure to 5-hydroxytryptophan (5-HTP) on the aggressive behavior induced by food competition in undernourished dominant and submissive pigeons (Columba livia). Fachinelli C, et al. **Behav Brain Res** 1996 Feb;75(1–2):113–8
Violence and schizophrenia: clozapine as a specific antiaggressive agent. Buckley P, et al. **Bull Am Acad Psychiatry Law** 1995;23(4):607–11
Leuprolide treatment of sexual aggression in a patient with Dementia and the Klüver-Bucy syndrome. Ott BR. **Clin Neuropharmacol** 1995 Oct;18(5):443–7
Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Kouri EM, et al. **Drug Alcohol Depend** 1995 Nov;40(1):73–9
Gabapentin associated with aggressive behavior in pediatric patients with seizures. Tallian KB, et al. **Epilepsia** 1996 May;37(5):501–2
Arginine vasotocin injection increases probability of calling in cricket frogs, but causes call changes characteristic of less aggressive males. Marler CA, et al. **Horm Behav** 1995 Dec;29(4):554–70
Physiological responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. Coccaro EF, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):177–9
Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. Bond AJ, et al. **J Affect Disord** 1995 Dec 13;35(3):117–23
Carbamazepine for combativeness in acute traumatic brain injury. Chatham-Showalter PE. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):96–9
The effects of alcohol on the aggressive responding of women. Dougherty DM, et al. **J Stud Alcohol** 1996 Mar; 57(2):178–86
An investigation of gender differences in alcohol-related aggression. Giancola PR, et al. **J Stud Alcohol** 1995 Sep; 56(5):573–9
Anabolic steroids and the mind. Corrigan B. **Med J Aust** 1996 Aug 19;165(4):222–6 (51 ref.)
Stability of interindividual differences in serotonin function and its relationship to severe aggression and competent social behavior in rhesus macaque females. Higley JD, et al. **Neuropsychopharmacology** 1996 Jan;14(1):67–76
Prenatal cocaine exposure affects social behavior in Sprague-Dawley rats. Johns JM, et al. **Neurotoxicol Teratol** 1995 Sep–Oct;17(5):569–76
Effect of the i.c.v. injection of 5,7-di-hydroxytryptamine on the aggressive behavior of dominant and submissive pigeons (Columba livia). Ison M, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):951–5
Effects of chlordiazepoxide on maternal aggression in mice depend on experience of resident and sex of intruder. Palanza P, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):175–82
Decrease in circulating tryptophan availability to the brain after acute ethanol consumption by normal volunteers: implications for alcohol-induced aggressive behaviour and depression. Badawy AA, et al. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:93–7
Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. Troisi A, et al. **Pharmacopsychiatry** 1995 May;28(3):73–6
Serotonin blocks vasopressin-facilitated offensive aggression: interactions within the ventrolateral hypothalamus of golden hamsters. Delville Y, et al. **Physiol Behav** 1996 Apr–May;59(4–5):813–6
Decreases in aggression in tryptophan-supplemented broiler breeder males are not due to increases in blood niacin levels. Shea-Moore MM, et al. **Poult Sci** 1996 Mar; 75(3):370–4
Prednisolone blocks extreme intermale social aggression in seizure-induced, brain-damaged rats: implications for the amygdaloid central nucleus, corticotrophin-releasing factor, and electrical seizures. Bedard AW, et al. **Psychol Rep** 1995 Aug;77(1):3–9
Methylphenidate effects on a laboratory aggression measure in children with ADHD. Casat CD, et al. **Psychopharmacol Bull** 1995;31(2):353–6
The lithium test dose prediction method in aggressive children. Malone RP, et al. **Psychopharmacol Bull** 1995; 31(2):379–82
Do alpha-2 adrenoceptors modify coping strategies in rats? Haller J, et al. **Psychopharmacology (Berl)** 1995 Dec; 122(4):379–85
Cholinergic modulation of a decrement in social investigation following repeated contacts between mice. Winslow JT, et al. **Psychopharmacology (Berl)** 1995 Sep;121(2):164–72
[Alcohol and aggression—violence prone drivers preventing passing maneuvers] Zabel GE. **Blutalkohol** 1996 Mar; 33(2):84–93 (Eng. Abstr.) **(Ger)**
[Effect of an exogenous histone substance administered by different routes on intraspecies aggression in male mice] Gladysheva OS, et al. **Biull Eksp Biol Med** 1995 Sep; 120(9):271–2 **(Rus)**
[Dependence of the anti-aggression properties of buspirone on time of day] Zamoshchina TA, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):291–4 **(Rus)**

PHYSIOLOGY

Gonadal hormones and aggression-maintaining effect of alcohol in male transgenic transforming growth factor-alpha mice. Hilakivi-Clarke L, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):708–13
On a biological regulation of aggression [letter; comment] Schwartz V. **Am J Psychiatry** 1995 Nov;152(11):1698–9.

Comment on: Am J Psychiatry 1994 Oct;151(10):1485–91.
Social isolation increases aggressive behaviour and alters the effects of diazepam in the rat social interaction test. Wongwitdecha N, et al. **Behav Brain Res** 1996 Feb; 75(1–2):27–32
Intermale aggression tested in two procedures, using four inbred strains of mice and their reciprocal congenics: Y chromosomal implications. Guillot PV, et al. **Behav Genet** 1995 Jul;25(4):357–60
Predatory aggression in male mice selectively bred for isolation-induced intermale aggression. Sandnabba NK. **Behav Genet** 1995 Jul;25(4):361–6
Studies on wild house mice (VIII): Postnatal maternal influences on intermale aggression in reciprocal F1's. Sluyter F, et al. **Behav Genet** 1995 Jul;25(4):367–70
The physiology of social conflict in rats: what is particularly stressful? Haller J, et al. **Behav Neurosci** 1996 Apr; 110(2):353–9
Brief, high-frequency stimulation of the corticomedial amygdala induces a delayed and prolonged increase of aggressiveness in male Syrian golden hamsters. Potegal M, et al. **Behav Neurosci** 1996 Apr;110(2):401–12
Social stress increases the acquisition of cocaine self-administration in male and female rats. Haney M, et al. **Brain Res** 1995 Nov 6;698(1–2):46–52
Y chromosomal effects on hippocampal mossy fiber distributions in mice selected for aggression. Hensbroek RA, et al. **Brain Res** 1995 Jun 5;682(1–2):203–6
Sleep patterns in children and young adults with mental retardation and severe behavior disorders. Piazza CC, et al. **Dev Med Child Neurol** 1996 Apr;38(4):335–44
Testosterone and aggression in male red jungle fowl. Johnsen TS, et al. **Horm Behav** 1995 Dec;29(4):593–8
Maternal aggression in rats: effects of olfactory bulbectomy, ZnSO4-induced anosmia, and vomeronasal organ removal. Kolunie JM, et al. **Horm Behav** 1995 Dec;29(4):492–518
Electrical and chemical stimulation of the same hypothalamic loci in relation to agressive behaviour in cats: a comparison study. Bhatia SC, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):369–76
Effect of dietary protein content on behavior in dogs. Dodman NH, et al. **J Am Vet Med Assoc** 1996 Feb 1; 208(3):376–9
The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. Hamazaki T, et al. **J Clin Invest** 1996 Feb 15;97(4):1129–33
Computer analysis and quantification of periaqueductal grey-induced defence behaviour. Beckett S, et al. **J Neurosci Methods** 1995 May;58(1–2):157–61
Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase [see comments] Nelson RJ, et al. **Nature** 1995 Nov 23;378(6555):383–6. Comment in: Nature 1995 Nov 23;378(6555):336.
Predatory aggression induced by hypothalamic stimulation: modulation by midbrain periaqueductal gray (PAG). Manchanda SK, et al. **Neurobiology (Bp)** 1995; 3(3–4):405–17
Mean genes. Hen R. **Neuron** 1996 Jan;16(1):17–21 (50 ref.)
Neurotransmitter basis of mollusc behavior: control of choice between the orienting and the defense response to the presentation of an unfamiliar object. D'yakonova VE, et al. **Neurosci Behav Physiol** 1995 May–Jun;25(3):247–51
Long-term sensitization in the common snail: electrophysiological correlates in the defense behavior command neurons. Gainutdinov KhL, et al. **Neurosci Behav Physiol** 1995 May–Jun;25(3):207–14
Biochemical background for an analysis of cost-benefit interrelations in aggression. Haller J. **Neurosci Biobehav Rev** 1995 Winter;19(4):599–604 (52 ref.)
c-Fos expression in female hamster brain following sexual and aggressive behaviors. Joppa MA, et al. **Neuroscience** 1995 Oct;68(3):783–92
Behavioral stress response of genetically selected aggressive and nonaggressive wild house mice in the shock-probe/defensive burying test. Sluyter F, et al. **Pharmacol Biochem Behav** 1996 May;54(1):113–6
Serotonin receptors and animal models of aggressive behavior. Olivier B, et al. **Pharmacopsychiatry** 1995 Oct; 28 Suppl 2:80–90 (92 ref.)
Aggression in the lactating female rat: the normal decline is not dependent on the physical development of the pups. Albert DJ, et al. **Physiol Behav** 1995 Sep;58(3):477–81
Serum NGF levels increase during lactation and following maternal aggression in mice. Alleva E, et al. **Physiol Behav** 1996 Mar;59(3):461–6
Lesion of hypothalamic paraventricular nucleus and maternal aggressive behavior in female rats. Consiglio AR, et al. **Physiol Behav** 1996 Apr–May;59(4–5):591–6
Is there a relationship between rat latent aggressiveness and susceptibility to convulsive crises? Cutrufo C, et al. **Physiol Behav** 1996 Apr–May;59(4–5):783–6
Successful intermale aggression and conditioned place preference in mice. Martínez M, et al. **Physiol Behav** 1995 Aug;58(2):323–8
Urine marking and maternal aggression of wild female mice in relation to anogenital distance at birth. Palanza P, et al. **Physiol Behav** 1995 Nov;58(5):827–35
Uses of vision by rats in play fighting and other close-quarter social interactions. Pellis SM, et al. **Physiol Behav** 1996 Apr–May;59(4–5):905–13
Aggression and personality: association with amino acids and monoamine metabolites. Møller SE, et al. **Psychol Med** 1996 Mar;26(2):323–31
[The physiological characteristics of new agressotropic neuropeptides] Sherstnev VV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul–Aug; 45(4):723–31 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Working with noncompliant and abusive dialysis patients: practical strategies based on ethics and the law. Johnson CC, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):77–86 (40 ref.)
Aggressivity in adolescent alcohol abusers: relationship with conduct disorder. Moss HB, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):642–6
Social information processing by aggressive and nonaggressive men with mental retardation. Fuchs C, et al. **Am J Ment Retard** 1995 Nov;100(3):244–52
Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Aarsland D, et al. **Am J Psychiatry** 1996 Feb;153(2):243–7
Cerebral glucose metabolism, CSF 5-HIAA levels, and aggressive behavior in rhesus monkeys. Doudet D, et al. **Am J Psychiatry** 1995 Dec;152(12):1782–7
Genetic-environmental interaction in the genesis of aggressivity and conduct disorders. Cadoret RJ, et al. **Arch Gen Psychiatry** 1995 Nov;52(11):916–24
Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Coccaro EF, et al. **Arch Gen Psychiatry** 1996 Jun;53(6):531–6
The effect of a self-management training package on the transfer of aggression control procedures in the absence of supervision. Ninness HA, et al. **Behav Modif** 1995 Oct; 19(4):464–90
Confirmatory factor analysis of The Aggression Questionnaire. Harris JA. **Behav Res Ther** 1995 Nov; 33(8):991–3
Perceptions and experiences of bullying in younger pupils. Smith PK, et al. **Br J Educ Psychol** 1995 Dec;65 (Pt 4):489–500
Fear of aggression at work among general practitioners who have suffered a previous episode of aggression. Hobbs FD. **Br J Gen Pract** 1994 Sep;44(386):390–4
A quantitative analysis of agonistic behavior in juvenile American lobsters (Homarus americanus L.). Huber R, et al. **Brain Behav Evol** 1995;46(2):72–83
Interrelationships between crime, substance abuse, and aggressive behaviours among persons with traumatic brain injury. Kreutzer JS, et al. **Brain Inj** 1995 Nov–Dec; 9(8):757–68
The acute management of aggressive behaviour in hospitalized children and adolescents. Measham TJ. **Can J Psychiatry** 1995 Aug;40(6):330–6 (30 ref.)
Capgras and Fregoli's syndrome, aggression and mental retardation: a report of two cases [letter] Ulzen TP. **Can J Psychiatry** 1995 Dec;40(10):636–9
Threats of corporal punishment as verbal aggression: a naturalistic study. Davis PW. **Child Abuse Negl** 1996 Apr; 20(4):289–304
Behavior segmentation by boys as a function of aggressiveness and prior information. Courtney ML, et al. **Child Dev** 1996 Jun;67(3):1034–47
Gender differences in children's normative beliefs about aggression: how do I hurt thee? Let me count the ways. Crick NR, et al. **Child Dev** 1996 Jun;67(3):1003–14
Social information-processing mechanisms in reactive and proactive aggression. Crick NR, et al. **Child Dev** 1996 Jun; 67(3):993–1002
Aggressive boys' hostile perceptual and response biases: the role of attention and impulsivity. Waldman ID. **Child Dev** 1996 Jun;67(3):1015–33
A comparison of aggressive-rejected and nonaggressive-rejected children's interpretations of self-directed and other-directed rejection. Zakriski AL, et al. **Child Dev** 1996 Jun;67(3):1048–70
Patients' threats. Expanded definition of assault. Flannery RB Jr, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):451–3
Household family structure and children's aggressive behavior: a longitudinal study of urban elementary school children. Vaden-Kiernan N, et al. **J Abnorm Child Psychol** 1995 Oct;23(5):553–68
Prospective prediction of husband marital aggression within newlywed couples. Leonard KE, et al. **J Abnorm Psychol** 1996 Aug;105(3):369–80
On the reinforcing effects of the content of verbal attention. Fisher WW, et al. **J Appl Behav Anal** 1996 Summer; 29(2):235–8
Pyramidal staff training in the extension of treatment for severe behavior disorders. Shore BA, et al. **J Appl Behav Anal** 1995 Fall;28(3):323–32
Impulsivity and the initiation of fights in children with disruptive behavior disorders. Halperin JM, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1199–211
Prediction of adolescent aggression by childhood personality measures: a comparison of projective procedures, self-report tests, and behavior ratings. Graybill D, et al. **J Clin Psychol** 1996 Jan;52(1):61–6
Childhood aggression and unconventionality: impact on later academic achievement, drug use, and workforce involvement. Brook JS, et al. **J Genet Psychol** 1995 Dec; 156(4):393–410
Frustrated aggression in psychiatric casualties of Operation Uphold Democracy. Hall DP, et al. **J Nerv Ment Dis** 1996 Jun;184(6):377–8
Association between intermale social aggression and cellular density within the central amygdaloid nucleus in rats with lithium/pilocarpine-induced seizures. Desjardins D, et al. **Percept Mot Skills** 1995 Oct;81(2):635–41
Sources of variance affecting receipt of aggression. Hewitt J. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):751–4
Decrease in circulating tryptophan availability to the brain after acute ethanol consumption by normal volunteers: implications for alcohol-induced aggressive behaviour and depression. Badawy AA, et al. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:93–7
The significance of aggression and impulsivity for self-mutilative behavior. Herpertz S, et al. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:64–72
Experimental models for aggression and inventories for the assessment of aggressive and autoaggressive behavior. Netter P, et al. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:58–63 (21 ref.)
Outward and inward directed aggressiveness: the interaction between violence and suicidality. Plutchik R. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:47–57 (58 ref.)
In quest for a possible association between heightened social aggression and excessive alcohol drinking in the rat. Bergvall AH, et al. **Physiol Behav** 1996 Apr–May; 59(4–5):807–12
Clinical research in aggressive patients, pitfalls in study design and measurement of aggression. Mak M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Oct; 19(6):993–1017 (48 ref.)
Clinical and administrative consequences of a reduced census on a psychiatric intensive care unit. Citrome L, et al. **Psychiatr Q** 1995 Fall;66(3):209–17
A dinucleotide repeat polymorphism at the gene for monoamine oxidase A and measures of aggressiveness. Vanyukov MM, et al. **Psychiatry Res** 1995 Nov 29; 59(1–2):35–41
Gender differences in aggression as a function of provocation: a meta-analysis. Bettencourt BA, et al. **Psychol Bull** 1996 May;119(3):422–47
Alcohol and aggression: a meta-analysis on the moderating effects of inhibitory cues, triggering events, and self-focused attention. Ito TA, et al. **Psychol Bull** 1996 Jul; 120(1):60–82
Concerns about drawing causal inferences from meta-analyses: an example in the study of gender differences in aggression. Knight GP, et al. **Psychol Bull** 1996 May;119(3):410–21
Relation of threatened egotism to violence and aggression: the dark side of high self-esteem. Baumeister RF, et al. **Psychol Rev** 1996 Jan;103(1):5–33 (175 ref.)
Factors precluding patients' discharge to the community. A geropsychiatric hospital survey. Vieweg V, et al. **Va Med Q** 1995 Fall;122(4):275–8
Relationship between alcohol consumption and victim behaviors immediately preceding sexual aggression by an acquaintance. Harrington NT, et al. **Violence Vict** 1994 Winter;9(4):315–24
Effects of feedback on emotion in hypermasculine males. Vass JS, et al. **Violence Vict** 1995 Fall;10(3):217–26
[Predisposition for violence in adolescence] Streeck-Fischer A. **Prax Kinderpsychol Kinderpsychiatr** 1995 Jul–Aug; 44(6):209–15 (Eng. Abstr.) **(Ger)**
[To what extent do school and class-specific factors contribute to aggression in schools?] Klicpera C, et al. **Z Kinder Jugenpsychiatr** 1995 Dec;23(4):243–54 (Eng. Abstr.) **(Ger)**
[Serum cholesterol, triglycerides, HDL and LDL in aggressive elderly patients with dementia] Scheffel A. **Psychiatr Pol** 1996 Jan–Feb;30(1):159–70 (Eng. Abstr.) **(Pol)**
[Experimental psychological aspects of preventing aggressive behavior] Neznanov NG, et al. **Sud Med Ekspert** 1996 Jan–Mar;39(1):30–1 (Eng. Abstr.) **(Rus)**
[Psychodynamics of aggression in neurotic structures] Hašto J. **Ceska Slov Psychiatr** 1995 Aug;91(4):208–15 (Eng. Abstr.) **(Slo)**

AGING

Trends in highway safety: effects of an aging population on accident propensity. Stamatiadis N, et al. **Accid Anal Prev** 1995 Aug;27(4):443–59
Mivacurium in special patient groups. Jones RM. **Acta Anaesthesiol Scand Suppl** 1995;106:47–54 (57 ref.)
Abnormal spermatozoa in the cauda epididymidis of adult and aged hamsters (Mesocricetus auratus): a study by electron microscopy. Calvo A, et al. **Acta Anat (Basel)** 1995;154(3):186–95
Mild age-related changes in the dentate gyrus of adult rhesus monkeys. Tigges J, et al. **Acta Anat (Basel)** 1995; 153(1):39–48
Selenium concentrations in serum, lens and aqueous humour of patients with senile cataract. Karakücük S, et al. **Acta Ophthalmol Scand** 1995 Aug;73(4):329–32
Mitochondrial ATP production rate in 55 to 73-year-old men: effect of endurance training. Berthon P, et al. **Acta Physiol Scand** 1995 Jun;154(2):269–74
Aging of the upper lip: a new treatment technique. Hinderer UT. **Aesthetic Plast Surg** 1995 Nov–Dec;19(6):519–26
Complex SMAS-platysma and senility. Levy S, et al. **Aesthetic Plast Surg** 1996 Winter;20(1):37–41

British Geriatrics Society spring meeting. Torquay, 6–8 April 1995. Abstracts. **Age Ageing** 1995;24 Suppl 2:P1–27

Colonic investigations in the elderly: colonoscopy or barium enema? Burtin P, et al. **Aging (Milano)** 1995 Aug;7(4):190–4

Influences of intentionality at encoding and retrieval on memory in adulthood and old age. Olofsson M, et al. **Aging (Milano)** 1996 Feb;8(1):42–6

Effects of ethanol consumption by adolescent alcohol–preferring P rats on subsequent behavioral performance in the cross–maze and slip funnel tests. Salimov RM, et al. **Alcohol** 1996 May–Jun;13(3):297–300

Long–term results after successful percutaneous transluminal coronary angioplasty in patients over 75 years of age. ten Berg JM, et al. **Am J Cardiol** 1996 Apr 1;77(9):690–5

Associations of fat and muscle masses with bone mineral in elderly men and women. Baumgartner RN, et al. **Am J Clin Nutr** 1996 Mar;63(3):365–72

Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Calles–Escandon J, et al. **Am J Clin Nutr** 1996 Jul; 64(1):7–11

Vitamin E and vitamin C supplement use and risk of all–cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Losonczy KG, et al. **Am J Clin Nutr** 1996 Aug; 64(2):190–6

Cross–calibration of fat and lean measurements by dual–energy X–ray absorptiometry to pig carcass analysis in the pediatric body weight range. Pintauro SJ, et al. **Am J Clin Nutr** 1996 Mar;63(3):293–8

Evidence for protection against age–related macular degeneration by carotenoids and antioxidant vitamins. Snodderly DM. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1448S–1461S (153 ref.)

Analysis of change in self–reported physical function among older persons in four population studies. Beckett LA, et al. **Am J Epidemiol** 1996 Apr 15;143(8):766–78

Successful aging: predictors and associated activities. Strawbridge WJ, et al. **Am J Epidemiol** 1996 Jul 15; 144(2):135–41

Is presentation of bacteremia in the elderly the same as in younger patients? Chassagne P, et al. **Am J Med** 1996 Jan; 100(1):65–70

Infective endocarditis in the elderly in the era of transesophageal echocardiography: clinical features and prognosis compared with younger patients. Werner GS, et al. **Am J Med** 1996 Jan;100(1):90–7

Informative morphogenetic and phenogenetic variants in children with cleft lip/cleft palate. Pelz L, et al. **Am J Med Genet** 1996 May 3;63(1):305–9

Neurodevelopmental changes with age in Ullrich–Turner syndrome [letter] Swillen A, et al. **Am J Med Genet** 1996 Jan 11;61(2):198

Aging in adults with Down syndrome: report from a longitudinal study. Burt DB, et al. **Am J Ment Retard** 1995 Nov;100(3):262–70

A one–year multicenter study of efficacy and safety of a continuous, low–dose, estradiol–releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Henriksson L, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):85–92

Age and the ovarian follicle pool assessed with transvaginal ultrasonography. Ruess ML, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):624–7

Estrogen replacement therapy and postural stability in the elderly. Goebel JA, et al. **Am J Otol** 1995 Jul;16(4):470–4

Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques. Fukumoto H, et al. **Am J Pathol** 1996 Jan; 148(1):259–65

The loss of independence in activities of daily living: the role of low normal cognitive function in elderly nuns. Greiner PA, et al. **Am J Public Health** 1996 Jan;86(1):62–6

Bone histomorphometric changes in the femoral neck of aging and ovariectomized rats. Yamamoto N, et al. **Anat Rec** 1995 Oct;243(2):175–85

Hemodynamic effects of intravenous ephedrine in infants and children anesthetized with halothane and nitrous oxide. Taguchi N, et al. **Anesth Analg** 1996 Mar;82(3):568–73

Shivering threshold during spinal anesthesia is reduced in elderly patients. Vassilieff N, et al. **Anesthesiology** 1995 Dec;83(6):1162–6

DHEAS as an effective vaccine adjuvant in elderly humans. Proof–of–principle studies. Araneo B, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:232–48

Sympathoadrenal activity and psychosocial stress. The significance of aging, long–term smoking, and stress models. Christensen NJ, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:640–7

Aging is associated in the 344/N Fischer rat with decreased stress responsivity of central and peripheral catecholaminergic systems and impairment of the hypothalamic–pituitary–adrenal axis. Cizza G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:491–511 (68 ref.)

Biosynthesis of DHEAS by the human adrenal cortex and its age–related decline. Hornsby PJ. **Ann N Y Acad Sci** 1995 Dec 29;774:29–46 (64 ref.)

Effects of aging and long–term calorie restriction on DHEA and DHEA sulfate in rhesus monkeys. Lane MA, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:319–22

Stress, aging, and memory. Involvement of peripheral catecholamines. Mabry TR, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:512–22 (53 ref.)

Sympathetic nervous system—immune system interactions in young and old Fischer 344 rats. Madden KS, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:523–34 (36 ref.)

Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect. Majewska MD. **Ann N Y Acad Sci** 1995 Dec 29;774:111–20 (86 ref.)

The sodium–calcium exchanger and glutamate–induced calcium loads in aged hippocampal neurons in vitro. Mills LR. **Ann N Y Acad Sci** 1996 Apr 15;779:379–90 (39 ref.)

Aging women: issues of mental health and maltreatment. Nadien M. **Ann N Y Acad Sci** 1996 Jun 18;789:129–45

On the possible role of nootropica in geriatric prevention and therapy. Nagy IZ. **Ann N Y Acad Sci** 1996 Jun 15; 786:444–52 (45 ref.)

An antistress and antiaging neurometabolic therapy. Accelerated lipofuscinolysis and stimulated anabolic regeneration by the antagonic–stress synergistic formula. Riga S, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:535–50

Does DHEAS restore immune competence in aged animals through its capacity to function as a natural modulator of peroxisome activities? Spencer NF, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:200–16 (129 ref.)

Dehydroepiandrosterone sulfate and aging. Vermeulen A. **Ann N Y Acad Sci** 1995 Dec 29;774:121–7 (54 ref.)

Replacement of DHEA in aging men and women. Potential remedial effects. Yen SS, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:128–42

mtDNA contributes to neural loss in aging [letter] Byrne E. **Ann Neurol** 1996 Jun;39(6):824

Assessment of nutritional risk in the elderly. Nikolaus T, et al. **Ann Nutr Metab** 1995;39(6):340–5

Age– and gender–related trends in the expression of glutathione S–transferases in human nasal mucosa. Krishna NS, et al. **Ann Otol Rhinol Laryngol** 1995 Oct;104(10 Pt 1):812–22

Age–related decline of rat liver multicatalytic proteinase activity and protection from oxidative inactivation by heat–shock protein 90. Conconi M, et al. **Arch Biochem Biophys** 1996 Jul 15;331(2):232–40

Bowel habit in relation to age and gender. Findings from the National Health Interview Survey and clinical implications. Harari D, et al. **Arch Intern Med** 1996 Feb 12;156(3):315–20

Effect of felodipine on systemic hemodynamics of spontaneous mild–hypertensive aged rats. Rivas–Cabañero L, et al. **Arch Physiol Biochem** 1995 Apr;103(1):87–90

Toothbrushing ability is related to age in children. Unkel JH, et al. **ASDC J Dent Child** 1995 Sep–Oct;62(5):346–8

The requirement for vitamins in aging and age–associated degenerative conditions. Blumberg J. **Bibl Nutr Dieta** 1995; (52):108–15 (44 ref.)

Age–associated changes of mitochondrial translation and respiratory function in mouse brain. Takai D, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):668–74

Age–related changes in mRNA, protein and catalytic activity of hepatic neutral cholesterol ester hydrolase in male rats: evidence for transcriptional regulation. Natarajan R, et al. **Biochim Biophys Acta** 1996 Jul 26;1302(2):153–8

Mitochondrial damage as a source of diseases and aging: a strategy of how to fight these. Zorov DB. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):10–5 (48 ref.)

Intestinal secretory response to atrial natriuretic peptide during postnatal development in the rabbit. Brockway PD, et al. **Biol Neonate** 1996;69(1):60–6

Developmental changes in seminiferous tubule extracellular matrix components of the mouse testis: alpha 3(IV) collagen chain expressed at the initiation of spermatogenesis. Enders GC, et al. **Biol Reprod** 1995 Dec;53(6):1489–99

Effect of developmental age or time after transplantation on Sertoli cell number and testicular size in inbred Fischer rats. Johnson L, et al. **Biol Reprod** 1996 May;54(5):948–59

Slower aging in women: a proposed evolutionary explanation. Rossler R, et al. **Biosystems** 1995;36(3):179–85

Adaptation of antihypertensive drug treatment with increasing age: from the young to the elderly. Focus on urapidil. **Blood Press** 1995;Suppl 3:1–73

Arterial and cardiac changes in hypertension in the elderly. Asmar R, et al. **Blood Press Suppl** 1995;3:31–7 (48 ref.)

Hypertension in the elderly: benefits of treatment. Chalmers J. **Blood Press Suppl** 1995;3:6–10

Characteristics of an ideal antihypertensive therapy for elderly hypertensives. Hansson L, et al. **Blood Press Suppl** 1995;3:68–72

Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press Suppl** 1995;3:21–5 (21 ref.)

Cost–benefit aspects of treatment of hypertension in the elderly. Lindholm LH, et al. **Blood Press Suppl** 1995;3:11–4

Pharmacological backgrounds of the drug treatment of hypertension in the elderly. Van Zwieten PA. **Blood Press Suppl** 1995;3:15–20 (33 ref.)

Teeth for life [letter] Crowley R. **Br Dent J** 1996 May 11; 180(9):326

The effects of prefrontal intracortical microinjections of an alpha–2 agonist, alpha–2 antagonist and lidocaine on the delayed alternation performance of aged rats. Tanila H, et al. **Brain Res Bull** 1996;40(2):117–9

Neonatal caffeine exposure alters seizure susceptibility in rats in an age–related manner. Guillet R. **Brain Res Dev Brain Res** 1995 Oct 27;89(1):124–8

Age of rat influences isolation of jejunal enterocytes from along the villus. Keelan M, et al. **Can J Physiol Pharmacol** 1995 Oct;73(10):1437–50

Social class, health and aging: socioeconomic determinants of self–reported morbidity among the noninstitutionalized elderly in Canada. Cairney J, et al. **Can J Public Health** 1996 May–Jun;87(3):199–203

The estrogen debate: to be (old) or not to be (old) [editorial; comment] Goltzman D. **Can J Surg** 1995 Oct;38(5):396–7 . Comment on: Can J Surg 1995 Oct;38(5):409–14. Comment on: Can J Surg 1995 Oct;38(5):415–9.

Trisomy 10: age and leukemic lineage associations. Morgan R, et al. **Cancer Genet Cytogenet** 1996 Jul 15;89(2):173–4

The relationship between age and karyotypic abnormalities in myelodysplastic syndromes. Wong KF, et al. **Cancer Genet Cytogenet** 1996 May;88(1):80–2

Age and reversible lung disease. Let's grow old, but not be forgotten or ignored! [editorial] Berger R. **Chest** 1995 Oct; 108(4):897–8 (10 ref.)

Elastase in the prevention of arterial aging and the treatment of atherosclerosis. Ooyama T, et al. **Ciba Found Symp** 1995; 192:307–17; discussion 318–20 (36 ref.)

High serum IgA concentrations in patients with diabetes mellitus: agewise distribution and relation to chronic complications. Rodriguez–Segade S, et al. **Clin Chem** 1996 Jul;42(7):1064–7

Effect of aging on susceptibility of low–density lipoproteins to oxidation. Schmuck A, et al. **Clin Chem** 1995 Nov; 41(11):1628–32

Induction and regulation of NFkappaB during aging: role of protein kinases. Trebilcock GU, et al. **Clin Immunol Immunopathol** 1996 Apr;79(1):87–91

The immature athlete. Common injuries and overuse syndromes of the elbow and wrist. Gill TJ 4th, et al. **Clin Sports Med** 1996 Apr;15(2):401–23 (49 ref.)

Effect of age and sex on the induction and elicitation of allergic contact dermatitis. Kwangsukstith C, et al. **Contact Dermatitis** 1995 Nov;33(5):289–98 (85 ref.)

Diabetic neuropathy in elderly patients. What can be done? Belmin J, et al. **Drugs Aging** 1996 Jun;8(6):416–29 (97 ref.)

COAEs and SSOAEs in adults with increased age. Prieve BA, et al. **Ear Hear** 1995 Oct;16(5):521–8

Risk factors for age–related cataracts. Hodge WG, et al. **Epidemiol Rev** 1995;17(2):336–46 (62 ref.)

Depression in old age. Is there a real decrease in prevalence? A review. Ernst C, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(6):272–87 (199 ref.)

Fatigability during repetitive maximal knee extensions in 14–year–old boys. Kanehisa H, et al. **Eur J Appl Physiol** 1995;72(1–2):170–4

Dietary intake in five ageing cohorts of men in Finland, Italy and The Netherlands. Huijbregts PP, et al. **Eur J Clin Nutr** 1995 Nov;49(11):852–60

Characterization of the tissue regression process in the uterus of older mice as apoptotic by the presence of Tp30, an isoform of terminin. Miller MM, et al. **Eur J Histochem** 1995;39(2):91–100

Dopamine—glutamate—GABA interactions and ageing: studies in the striatum of the conscious rat. Porras A, et al. **Eur J Neurosci** 1995 Nov 1;7(11):2183–8

Age–dependency of surfactant phospholipids and surfactant protein A in bronchoalveolar lavage fluid of children without bronchopulmonary disease. Ratjen F, et al. **Eur Respir J** 1996 Feb;9(2):328–33 (34 ref.)

Changes in movement capabilities with aging. Grabiner MD, et al. **Exerc Sport Sci Rev** 1995;23:65–104 (230 ref.)

Effects of age at first–pairing on the reproductive performance of Mongolian gerbils (Meriones unguiculatus). Kai O, et al. **Exp Anim** 1995 Oct;44(4):307–13

Age–related changes in visual function and visual organs of rats. Kiyosawa I. **Exp Anim** 1996 Apr;45(2):103–14 (34 ref.)

Globule leukocytes in transitional cell hyperplasia and carcinomas of aged mice. Kobayashi K, et al. **Exp Anim** 1995 Oct;44(4):329–31

Development and ageing of the RPE in a marsupial, the quokka. Fleming PA, et al. **Exp Eye Res** 1996 May; 62(5):457–69

Hydrodynamics of ageing Bruch's membrane: implications for macular disease. Starita C, et al. **Exp Eye Res** 1996 May;62(5):565–72

Differential phosphorylation of alpha–A crystallin in human lens of different age. Takemoto LJ. **Exp Eye Res** 1996 May; 62(5):499–504

Sex–specific life table aging rates in large medfly cohorts. Carey JR, et al. **Exp Gerontol** 1995 May–Aug; 30(3–4):315–25

Nutrition and its relationship to aging. Casper RC. **Exp Gerontol** 1995 May–Aug;30(3–4):299–314 (93 ref.)

Dietary restriction. Masoro EJ. **Exp Gerontol** 1995 May–Aug; 30(3–4):291–8 (27 ref.)

The evolutionary tangle of aging, sex, and reproduction and an experimental approach to its molecular dissection. Roy AK, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):83–94 (36 ref.)

Chronic overcrowding decreases cytoplasmic free calcium levels in T lymphocytes of aged CBA/CA mice. Csermely P, et al. **Experientia** 1995 Sep 29;51(9–10):976–9

The gerontogenes age–1 and daf–2 determine metabolic rate potential in aging Caenorhabditis elegans. Vanfleteren JR, et al. **FASEB J** 1995 Oct;9(13):1355–61

Increased susceptibility of low–density lipoprotein (LDL) to oxidation by gamma–radiolysis with age. Khalil A, et al.

FEBS Lett 1996 Aug 19;392(1):45–8

Redox perturbations in cysteamine-stressed astroglia: implications for inclusion formation and gliosis in the aging brain. Manganaro F, et al. **Free Radic Biol Med** 1995 Dec; 19(6):823–35

Role of calcium in brain aging. Gareri P, et al. **Gen Pharmacol** 1995 Dec;26(8):1651–7 (64 ref.)

Probing the evolution of senescence in Drosophila melanogaster with P-element tagging. Clark AG, et al. **Genetica** 1995;96(3):225–34

Gerontologic Challenges: Biological through Societal Perspectives. 48th Annual scientific meeting of the Gerontological Society of America. Los Angeles, California, November 15–19, 1995. Abstracts. **Gerontologist** 1995 Oct;35 Spec No 1:1–478

The aging semantic differential: a confirmatory factor analysis. Intrieri RC, et al. **Gerontologist** 1995 Oct; 35(5):616–21

Health-related quality of life and dizziness in old age [see comments]. Grimby A, et al. **Gerontology** 1995;41(5):286–98 . Comment in: Gerontology 1996;42(1):59.

Bibliography: growth and embryonic development and aging. National Library of Medicine MEDLINE search. **Growth Dev Aging** 1995 Winter;59(4):215–34

Effects of ageism on individual and health care providers' responses to healthy aging. Grant LD. **Health Soc Work** 1996 Feb;21(1):9–15 (46 ref.)

Effect of donor age and sex on the outcome of liver transplantation. Marino IR, et al. **Hepatology** 1995 Dec; 22(6):1754–62

Heteroplasmy levels of a mitochondrial gene mutation associated with diabetes mellitus decrease in leucocyte DNA upon aging. \ Hart LM, et al. **Hum Mutat** 1996; 7(3):193–7

Female age does not affect the capacity of human zona pellucida to bind spermatozoa. Yavetz H, et al. **Hum Reprod** 1995 Sep;10(9):2368–70

The murine thymic microenvironment: changes with age. Takeoka Y, et al. **Int Arch Allergy Immunol** 1996 Sep; 111(1):5–12

Physical workload and the aging worker: a review of the literature. de Zwart BC, et al. **Int Arch Occup Environ Health** 1995;68(1):1–12 (123 ref.)

Evaluation of presence and functional activity of potentially self-reactive T cells in aged mice. Crisi GM, et al. **Int Immunol** 1996 Mar;8(3):387–95

Aging and performance on implicit memory tasks: a brief review. Jelicic M. **Int J Neurosci** 1995 Jun;82(3–4):155–61 (46 ref.)

Sex and age specific assessment of genetic and environmental influences on body mass index in twins. Herskind AM, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20(2):106–13

Effects of jump training on bone hypertrophy in young and old rats. Umemura Y, et al. **Int J Sports Med** 1995 Aug; 16(6):364–7

Micronutrient status in elderly people. Geriatrie/Min. Vit. Aux Network. Monget AL, et al. **Int J Vitam Nutr Res** 1996;66(1):71–6

The contribution of dietary iron to iron status in a group of elderly subjects. Roebothan BV, et al. **Int J Vitam Nutr Res** 1996;66(1):66–70

Glutathione S-transferase M1 genotype and age-related cataracts. Lack of association in an Italian population. Alberti G, et al. **Invest Ophthalmol Vis Sci** 1996 May; 37(6):1167–73

Rhodopsin in immature rod outer segments. Dodge J, et al. **Invest Ophthalmol Vis Sci** 1996 Sep;37(10):1951–6

Location and severity of cortical opacities in different regions of the lens in age-related cataract. Graziosi P, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1698–703

Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Kvanta A, et al. **Invest Ophthalmol Vis Sci** 1996 Aug; 37(9):1929–34

Age, seasonality and health. Hermoni D, et al. **Isr J Med Sci** 1996 Jan;32(1):66–9

Age effects on duration discrimination with simple and complex stimuli. Fitzgibbons PJ, et al. **J Acoust Soc Am** 1995 Dec;98(6):3140–5

Effects of aging on the fine structure of the 2f1–f2 acoustic distortion product. He NJ, et al. **J Acoust Soc Am** 1996 Feb;99(2):1002–15

The role of progressive resistance training and nutrition in the preservation of lean body mass in the elderly. Fielding RA. **J Am Coll Nutr** 1995 Dec;14(6):587–94 (51 ref.)

Physical activity and older people: a walk a day keeps the doctor away [editorial; comment] Ettinger WH Jr. **J Am Geriatr Soc** 1996 Feb;44(2):207–8. Comment on: J Am Geriatr Soc 1996 Feb;44(2):113–20.

The National Institute on Aging at its twentieth anniversary: achievements and promise of research on aging. Hodes RJ, et al. **J Am Geriatr Soc** 1996 Feb;44(2):204–6

Left ventricular hypertrophy on electrocardiogram: prognostic implications from a 10-year cohort study of older subjects: a report from the Bronx Longitudinal Aging Study. Kahn S, et al. **J Am Geriatr Soc** 1996 May; 44(5):524–9

The defeat of aging versus the importance of death. Kane RS. **J Am Geriatr Soc** 1996 Mar;44(3):321–5

Research recommendations for cardiovascular aging research. NIA Cardiovascular Aging Advisory Panel [see comments] Premen AJ. **J Am Geriatr Soc** 1996 Sep; 44(9):1114–7. Comment in: J Am Geriatr Soc 1996 Sep;44(9):1123–4.

Geriatric oral health and its impact on eating. Ship JA, et al. **J Am Geriatr Soc** 1996 Apr;44(4):456–64 (105 ref.)

Postural hypotension and dizziness in a general aged population: a four-year follow-up of the Helsinki Aging Study. Tilvis RS, et al. **J Am Geriatr Soc** 1996 Jul; 44(7):809–14

Morphological and morphometric study of early changes in the ageing golden hamster testis. Horn R, et al. **J Anat** 1996 Feb;188 (Pt 1):109–17

Perivascular nerves of the human basal cerebral arteries: II. Changes in aging and Alzheimer's disease. Bleys RL, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):1048–57

Effects of hypothermia on traumatic brain injury in immature rats. Mansfield RT, et al. **J Cereb Blood Flow Metab** 1996 Mar;16(2):244–52

Age dependence of total cerebral blood flow volume from childhood to adulthood. Schöning M, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):827–33

Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. Bongarzone I, et al. **J Clin Endocrinol Metab** 1996 May;81(5):2006–9

Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. Welle S, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3239–43

The human lumbar intervertebral disc: evidence for changes in the biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, and degeneration. Antoniou J, et al. **J Clin Invest** 1996 Aug 15;98(4):996–1003

Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. Tschudi MR, et al. **J Clin Invest** 1996 Aug 15;98(4):899–905

Factors which influence levels of selected organisms in saliva of older individuals. Loesche WJ, et al. **J Clin Microbiol** 1995 Oct;33(10):2550–7

Age and sex do not affect the volume, cell numbers, or cell size of the suprachiasmatic nucleus of the rat: an unbiased stereological study. Madeira MD, et al. **J Comp Neurol** 1995 Oct 30;361(4):585–601

Age and seasonal effects on Holstein yield for four regions of the United States over time. Norman HD, et al. **J Dairy Sci** 1995 Aug;78(8):1855–61

Contributions of facial morphology, age, and gender to EMG activity under biting and resting conditions: a canonical correlation analysis. Fogle LL, et al. **J Dent Res** 1995 Aug; 74(8):1496–500

The site-specificity of supragingival calculus deposition on the lingual surfaces of the six permanent lower anterior teeth in humans and the effects of age, sex, gum-chewing habits, and the time since the last prophylaxis on calculus scores. Macpherson LM, et al. **J Dent Res** 1995 Oct; 74(10):1715–20

Fluoride reduces bone strength in older rats. Turner CH, et al. **J Dent Res** 1995 Aug;74(8):1475–81

Neurologic features of chronic minamata disease (organic mercury poisoning) and incidence of complications with aging. Uchino M, et al. **J Environ Sci Health B** 1995 Sep; 30(5):699–715

Studies of directed forgetting in older adults. Zacks RT, et al. **J Exp Psychol Learn Mem Cogn** 1996 Jan;22(1):143–56

Anatomy, histology, and development of the cardiac valvular system in elasmobranchs. Hamlett WC, et al. **J Exp Zool** 1996 Jun 1–15;275(2–3):83–94

Growth hormone supplementation increases skeletal muscle mass of old male Fischer 344/brown Norway rats. Cartee GD, et al. **J Gerontol A Biol Sci Med Sci** 1996 May; 51(3):B214–9

Aging increases the cardiotoxicity of daunorubicin and daunorubicinol in the rat. Cusack BJ, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):B376–84

A study of low-nutrient diets used for aging studies in the rat. Norido F, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):B270–5

Effects of benzodiazepine receptor inverse agonists and nicotine on behavioral vigilance in senescent rats. Turchi J, et al. **J Gerontol A Biol Sci Med Sci** 1996 May; 51(3):B225–31

Psychological obstacles to job or career change in late life. Bailey LL 3rd, et al. **J Gerontol B Psychol Sci Soc Sci** 1995 Nov;50(6):P280–8

Cardiovascular response of young and older males to mental challenge. Boutcher SH, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Sep;51(5):P261–7

What have we "made" of aging? Cole TR. **J Gerontol B Psychol Sci Soc Sci** 1995 Nov;50(6):S341–3

Self-ratings of health: do they also predict change in functional ability? Idler EL, et al. **J Gerontol B Psychol Sci Soc Sci** 1995 Nov;50(6):S344–53 (49 ref.)

Transitions in functional status and active life expectancy among older people in Japan. Liu X, et al. **J Gerontol B Psychol Sci Soc Sci** 1995 Nov;50(6):S383–94

Age changes in the distribution of visual attention. McCalley LT, et al. **J Gerontol B Psychol Sci Soc Sci** 1995 Nov; 50(6):P316–31

Aging, inhibition, working memory, and speed. Salthouse TA, et al. **J Gerontol B Psychol Sci Soc Sci** 1995 Nov; 50(6):P297–306

Social network characteristics and onset of ADL disability: MacArthur studies of successful aging. Seeman TE, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul;51(4):S191–200

Age and the sense of control among older adults. Wolinsky FD, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul; 51(4):S217–20

Experimental basis for autograft growth and viability. Kreitmann B, et al. **J Heart Valve Dis** 1995 Jul;4(4):379–83

Light microscopic autoradiographic study of DNA synthesis in cecal epithelial cells of aging mice. Jin C, et al. **J Histochem Cytochem** 1995 Dec;43(12):1223–8

Age-associated differences in TNF-alpha and nitric oxide production in endotoxic mice. Chorinchath BB, et al. **J Immunol** 1996 Feb 15;156(4):1525–30

Mitochondrial medicine. Luft R, et al. **J Intern Med** 1995 Nov;238(5):405–21 (119 ref.)

The relationships of motor function, education, age and cognitive function to the physical activities of daily living. Park JH, et al. **J Korean Med Sci** 1995 Jun;10(3):195–9

Acute labyrinthitis associated with systemic Candida albicans infection in ageing mice. Ashman RB, et al. **J Laryngol Otol** 1996 Jan;110(1):13–8

The effects of health histories on stochastic process models of aging and mortality. Yashin AI, et al. **J Math Biol** 1995; 34(1):1–16

Improvement of techniques for age grading hematophagous insects: ovarian oil-injection and ovariolar separation techniques. Hoc TQ, et al. **J Med Entomol** 1996 May; 33(3):286–9

Application of the ovarian oil injection and ovariolar separation techniques for age grading hematophagous Diptera. Hoc TQ. **J Med Entomol** 1996 May;33(3):290–6

Herpes encephalitis is a disease of middle aged and elderly people: polymerase chain reaction for detection of herpes simplex virus in the CSF of 516 patients with encephalitis. The Study Group. Koskiniemi M, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb;60(2):174–8

Study will track health of women in midlife. **J Nurs Adm** 1996 Feb;26(2):3

Evaluation of the Facts on Aging Quizzes I & II. Lusk SL, et al. **J Nurs Educ** 1995 Oct;34(7):317–24

Benign aging or Alzheimer disease? Gorman WF. **J Okla State Med Assoc** 1995 Sep;88(9):383–91 (51 ref.)

Age-related changes of the retrodiscal tissues in the temporomandibular joint [see comments] Pereira Júnior FJ, et al. **J Oral Maxillofac Surg** 1996 Jan;54(1):55–61; discussion 61–2. Comment in: J Oral Maxillofac Surg 1996 Jul;54(7):927.

Effect of age and training schedules on balance improvement exercises using visual biofeedback. Hamman R, et al. **J Otolaryngol** 1995 Aug;24(4):221–9

Age-related changes in colon motility. Di Lorenzo C, et al. **J Pediatr** 1995 Oct;127(4):593–6

Value of parents' estimates of children's developmental ages. Glascoe FP, et al. **J Pediatr** 1995 Nov;127(5):831–5

Effects of (-)-S-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4,5]decane L-tartrate monohydrate (YM796), a novel muscarinic agonist, on disturbance of passive avoidance learning behavior in drug-treated and senescence-accelerated mice. Suzuki M, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):728–36

Age-related changes of neuronal responsiveness to melatonin in the striatum of sham-operated and pinealectomized rats. Castillo-Romero JL, et al. **J Pineal Res** 1995 Sep; 19(2):79–86

Electron probe X-ray microanalysis of the elemental composition of the pineal gland of young adults and aged rats. Humbert W, et al. **J Pineal Res** 1996 Jan;20(1):39–44

Effects of age, education, and living environment on Boston Naming Test performance. Neils J, et al. **J Speech Hear Res** 1995 Oct;38(5):1143–9

The circadian rhythm in activity of the periodic acid Schiff reaction and of the Mg and Ca content in rat liver in relation to age and season of the year. Pawlicki K, et al. **J Trace Elem Med Biol** 1995 Mar;9(1):28–33

Different effects of ageing on elastic and muscular arterial bifurcations in men. Van Merode T, et al. **J Vasc Res** 1996 Jan-Feb;33(1):47–52

Long-term follow-up of patients with early atherosclerosis. Harris LM, et al. **J Vasc Surg** 1996 Apr;23(4):576–80; discussion 581

The sound of senescence. Linville SE. **J Voice** 1996 Jun; 10(2):190–200

Geriatric ethics: responsibilities and conspiracies, Part I. Ainslie N, et al. **Kans Med** 1996 Spring;97(1):13, 15

Mutant factor V (Arg506Gln) in healthy centenarians [letter] Mari D, et al. **Lancet** 1996 Apr 13;347(9007):1044

Age versus ageing as a cause of dementia [letter; comment] Winker MA. **Lancet** 1995 Dec 2;346(8988):1486. Comment on: Lancet 1995 Oct 7;346(8980):931–4.

Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. Wang GJ, et al. **Life Sci** 1995;56(14):PL249–53

Effects of peroxidative stress and age on the concentration of a deoxyguanosine-malondialdehyde adduct in rat DNA. Draper HH, et al. **Lipids** 1995 Oct;30(10):959–61

A morphologist's approach to the vagina—age-related changes and estrogen sensitivity. Forsberg JG. **Maturitas** 1995 Dec;22 Suppl:S7–S15 (82 ref.)

Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration. Notelovitz M. **Maturitas** 1995 Dec;22 Suppl:S31–3

Assessing oral heal.h-related quality of life: findings from the normative aging study. Kressin N, et al. **Med Care** 1996 May;34(5):416–27

"Grown-ups" with congenital heart disease [editorial] Celermajer DS, et al. **Med J Aust** 1996 Jun 17; 164(12):708–9

Geriatric medicine, a holistic specialty [editorial] Gray L. **Med J Aust** 1995 Oct 2;163(7):341–2

Understanding the causes of aging and cancer. Ames BN. **Microbiologia** 1995 Sep;11(3):305–8

Ageing—a biological perspective. Rattan SI. **Mol Aspects Med** 1995;16(5):439–508 (217 ref.)

An investigation of antioxidant status, DNA repair capacity and mutation as a function of age in humans. Barnett YA, et al. **Mutat Res** 1995 Oct;338(1–6):115–28

DNA adducts induced by lipids and lipid peroxidation products: possible relationships to I-compounds. Li D, et al. **Mutat Res** 1995 Oct;344(3–4):117–26

Genotoxicity of tacrine in primary hepatocytes isolated from B6C3F1 mice and aged ad libitum and calorie restricted Fischer 344 rats. Shaddock JG, et al. **Mutat Res** 1995 Aug; 344(1–2):79–88

Food for thought. Coyle JT. **Nat Med** 1995 Oct;1(10):1006–7

Rising health-care costs inevitable [editorial] [see comments] Culliton BJ. **Nat Med** 1995 Oct;1(10):975. Comment in: Nat Med 1996 Jan;2(1):5.

Seizure induced C-Fos mRNA in the rat brain: comparison between young and aging animals. Retchkiman I, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):41–4

Repeated assessment of spatial discrimination performance of aged rats in the Morris water escape task. van der Staay FJ, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):99–102

Stress-induced inhibition of the hypothalamic-pituitary-thyroid axis is attenuated in the aged Fischer 344/N male rat. Cizza G, et al. **Neuroendocrinology** 1995 Nov;62(5):506–13

Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese. Mak YT, et al. **Neurology** 1996 Jan; 46(1):146–9

Regeneration of olfactory sensory neurons and reconnection in the aging hamster central nervous system. Morrison EE, et al. **Neurosci Lett** 1995 Oct 6;198(3):213–7

Impaired release of cholecystokinin (CCK) from synaptosomes in old rats. Ohta M, et al. **Neurosci Lett** 1995 Oct 6;198(3):161–4

Heat-shock cognate 70 messenger RNA expression in postmortem human hippocampus: regional differences and age-related changes. Tohgi H, et al. **Neurosci Lett** 1995 Aug 18;196(1–2):89–92

Dopamine D1 receptor ligands modulate cognitive performance and hippocampal acetylcholine release in memory-impaired aged rats. Hersi AI, et al. **Neuroscience** 1995 Dec;69(4):1067–74

Regulation of phosphatidylinositide transduction system in the rat spinal cord during aging. Igwe OJ, et al. **Neuroscience** 1995 Dec;69(4):1239–51

Do children lose and maintain weight easier than adults: a comparison of child and parent weight changes from six months to ten years. Epstein LH, et al. **Obes Res** 1995 Sep;3(5):411–7

Body habitus changes among adult males from the normative aging study: relations to aging, smoking history and alcohol intake. Grinker JA, et al. **Obes Res** 1995 Sep;3(5):435–46

Body position, age and mass effect of adiposity on adipose tissue red cell flux in morbid obesity. Klassen GA, et al. **Obes Res** 1996 Mar;4(2):145–51

The ageing labour force. Nicholson PJ. **Occup Med (Oxf)** 1995 Oct;45(5):229–30

Effect of age on the interaction between the AC/A and CA/C ratios. Rosenfield M, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):451–5

Retinal vascular changes during aging in Wistar Kyoto rats. Application of corrosion cast and scanning electron microscopy. Bhutto IA, et al. **Ophthalmic Res** 1995; 27(5):249–61

Aging affects the conformation of cholesterol in the human eye lens. Duindam JJ, et al. **Ophthalmic Res** 1996;28 Suppl 1:86–91

Changes in the aging rat retina. Weisse I. **Ophthalmic Res** 1995;27 Suppl 1:154–63

Ten-year longitudinal study of periodontal attachment loss in healthy adults. Ship JA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Mar;81(3):281–90

MRI "road-map" of normal age-related bone marrow. I. Cranial bone and spine. Taccone A, et al. **Pediatr Radiol** 1995;25(8):588–95

MRI "road-map" of normal age-related bone marrow. II. Thorax, pelvis and extremities. Taccone A, et al. **Pediatr Radiol** 1995;25(8):596–606

A cross-sectional analysis of WAIS-R aging patterns with psychiatric inpatients: support for Horn's hypothesis that fluid cognitive abilities decline. Boone DE. **Percept Mot Skills** 1995 Oct;81(2):371–9

Thymus transplantation, a critical factor for correction of autoimmune disease in aging MRL/+mice. Hosaka N, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8558–62

Longevity and the genetic determination of collagen glycoxidation kinetics in mammalian senescence. Sell DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):485–90

Diagnosing senescence: inferring evolutionary causes from phenotypic patterns can be misleading. Blarer A, et al. **Proc R Soc Lond B Biol Sci** 1995 Dec 22;262(1365):305–12

Characterization of prostatic basal cell hyperplasia and neoplasia in aged macaques: comparative pathology in human and nonhuman primates. McEntee MF, et al. **Prostate** 1996 Jul;29(1):51–9

Aging, distraction, and the benefits of predictable location. Carlson MC, et al. **Psychol Aging** 1995 Sep;10(3):427–36

Everyday problem solving in older adults: observational assessment and cognitive correlates. Diehl M, et al. **Psychol Aging** 1995 Sep;10(3):478–91

Aging and experience in the recognition of musical transpositions. Halpern AR, et al. **Psychol Aging** 1995 Sep; 10(3):325–42

Relationship of events and affect in the daily life of an elderly population. Lawton MP, et al. **Psychol Aging** 1995 Sep; 10(3):469–77

Age effects in cued recall: sources from implicit and explicit memory. McEvoy CL, et al. **Psychol Aging** 1995 Sep; 10(3):314–24

Aging, source, and decision criteria: when false fame errors do and do not occur. Multhaup KS. **Psychol Aging** 1995 Sep;10(3):492–7

Unique and interactive effects of depression, age, socioeconomic advantage, and gender on cognitive performance of normal healthy older people. Rabbitt P, et al. **Psychol Aging** 1995 Sep;10(3):307–13

Larger nondeclarative than declarative deficits in learning and memory in human aging. Woodruff-Pak DS, et al. **Psychol Aging** 1995 Sep;10(3):416–26

Education, gender and cognitive performance in a 62-year-old normal population: results from the Turva Project. Portin R, et al. **Psychol Med** 1995 Nov; 25(6):1295–8

Complex effects of age and gender on hypothermic, adrenocorticotrophic hormone and cortisol responses to ipsapirone challenge in normal subjects. Gelfin Y, et al. **Psychopharmacology (Berl)** 1995 Aug;120(3):356–64

Depressive symptomatology and hypertension-associated morbidity and mortality in older adults. Simonsick EM, et al. **Psychosom Med** 1995 Sep–Oct;57(5):427–35

Acromial morphology: relation to sex, age, symmetry, and subacromial enthesophytes. Getz JD, et al. **Radiology** 1996 Jun;199(3):737–42

Absence of coronary calcification on double-helical CT scans: predictor of angiographically normal coronary arteries in elderly women? Shemesh J, et al. **Radiology** 1996 Jun;199(3):665–8

Cholinergic modulation of growth hormone, prolactin and thyroid stimulating hormone responses to thyrotropin-releasing hormone in normal aging. Giusti M, et al. **Recenti Prog Med** 1995 Sep;86(9):341–4

Effect of neonatal allylestrenol treatment (hormonal imprinting) on the serum testosterone and progesterone concentration in adult rat. Pap E, et al. **Reprod Fertil Dev** 1995;7(5):1249–51

In vitro study of the age-dependent caecal fermentation pattern and methanogenesis in young rabbits. Piattoni F, et al. **Reprod Nutr Dev** 1996;36(3):253–61

Medical and anthropological study of a world and Olympic champion, long-distance runner, 35 years after the end his racing career. Novotný V, et al. **Sb Lek** 1994;95(2):139–55

Electrophysiological, morphological, and morphometric effects of aging on nerve regeneration in rats. Choi SJ, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Jun; 29(2):133–40

Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein [see comments] Ball JM, et al. **Science** 1996 Apr 5;272(5258):101–4. Comment in: Science 1996 Apr 5;272(5258):46–8.

Hippocampal cell death [letter; comment] Cahill L, et al. **Science** 1996 May 31;272(5266):1251. Comment on: Science 1996 Mar 1;271(5253):1229–30.

Hippocampal cell death [letter; comment] Landfield PW, et al. **Science** 1996 May 31;272(5266):1249–51. Comment on: Science 1996 Mar 1;271(5253):1229–30.

Replicative senescence: implications for in vivo aging and tumor suppression. Smith JR, et al. **Science** 1996 Jul 5; 273(5271):63–7 (52 ref.)

Oxidative stress, caloric restriction, and aging. Sohal RS, et al. **Science** 1996 Jul 5;273(5271):59–63 (59 ref.)

For the cortex, neuron loss may be less than thought [news] Wickelgren I. **Science** 1996 Jul 5;273(5271):48–50

Is hippocampal cell death a myth? [news] [see comments] Wickelgren I. **Science** 1996 Mar 1;271(5253):1229–30. Comment in: Science 1996 May 31;272(5266):1249. Comment in: Science 1996 May 31;272(5266):1249–51. Comment in: Science 1996 May 31;272(5266):1251.

Hippocampal cell death [letter; comment] Zaidel DW, et al. **Science** 1996 May 31;272(5266):1249. Comment on: Science 1996 Mar 1;271(5253):1229–30.

Age and gender affect different characteristics of slow waves in the sleep EEG. Mourtazaev MS, et al. **Sleep** 1995 Sep; 18(7):557–64

Self report on sleep symptoms in older adults: correlates of daytime sleepiness and health. Schmitt FA, et al. **Sleep** 1996 Jan;19(1):59–64

Dysphonia in the elderly: diagnosis and management of age-related voice changes. Hagen P, et al. **South Med J** 1996 Feb;89(2):204–7

Growth and development of young athletes. Should competition levels be age related? [editorial] Baxter-Jones AD. **Sports Med** 1995 Aug;20(2):59–64

Aging, physical activity and sports injuries. An overview of common sports injuries in the elderly. Kallinen M, et al. **Sports Med** 1995 Jul;20(1):41–52 (76 ref.)

Visual problems of the aging musician. Kadrmas EF, et al. **Surv Ophthalmol** 1996 Jan–Feb;40(4):338–41

Spontaneous vascular neoplasms in aged Sprague-Dawley rats. Zwicker GM, et al. **Toxicol Pathol** 1995 Jul–Aug; 23(4):518–26

[Progresses in geriatrics in China, 1995] Wang S, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):768–70 (0 ref.) **(Chi)**

[Changes of intestinal flora in senile mouse models and the antagonistic activity of the root of Astragalus membraceus (Fisch) Bge] Yan M, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Oct;20(10):624–6, inside backcover (Eng. Abstr.) **(Chi)**

[Aging as a cause of hip fractures; a theoretic mathematical model] Reichgelt B, et al. **Ned Tijdschr Geneeskd** 1996 Jun 22;140(25):1312–7 (Eng. Abstr.) **(Dut)**

[Gerontology and an aging population. Reduction in fundamental research] [editorial] Goedhard WJ. **Tijdschr Gerontol Geriatr** 1995 Oct;26(5):195–6 **(Dut)**

[Urinary calculi in a geriatric setting] Mhiri MN, et al. **Ann Urol (Paris)** 1995;29(6–7):382–8 (Eng. Abstr.) **(Fre)**

[Physical and sports activities and aging: how to delay the state of dependence] Ginet J. **Bull Acad Natl Med** 1995 Oct;179(7):1493–502; discussion 1502–3 (Eng. Abstr.) **(Fre)**

[Cytotoxic chemotherapy in elderly patients: present and future] Freyer G, et al. **Bull Cancer (Paris)** 1995 Jul; 82(7):531–40 (66 ref.) (Eng. Abstr.) **(Fre)**

[Aging and sexuality in the male] Tordjman G. **Contracept Fertil Sex** 1996 Jun;24(6):501–4 (14 ref.) (Eng. Abstr.) **(Fre)**

[Changes in adrenergic innervation of the choroid during aging] Nuzzi R, et al. **J Fr Ophtalmol** 1996;19(2):89–96 (Eng. Abstr.) **(Fre)**

[Research using communication networks: ageing as an example (editorial)] Henrard JC. **Rev Epidemiol Sante Publique** 1996 Apr;44(2):99–100 **(Fre)**

[Development of the gastric glands of cats (Felis silvestris catus)] Knospe C. **Anat Histol Embryol** 1996 Jun; 25(2):75–94 (Eng. Abstr.) **(Ger)**

[Age, health status and the utilization of general practitioners and specialists] Geling O, et al. **Soz Praventivmed** 1996; 41(1):36–46 (Eng. Abstr.) **(Ger)**

[Most frequent causes for hand tremor in clinical practice] Málly J. **Orv Hetil** 1995 Oct 8;136(41):2211–6 (53 ref.) (Eng. Abstr.) **(Hun)**

[Referential value of auditory threshold depending on age] Giordano G. **Acta Otorhinolaryngol Ital** 1995 Jun; 15(3):198–204 (Eng. Abstr.) **(Ita)**

[RS3PE syndrome. A new rheumatic inflammatory syndrome in advanced age] Pittau E, et al. **Clin Ter** 1995 Nov; 146(11):663–73 (35 ref.) (Eng. Abstr.) **(Ita)**

[Effects of feed and mating age on reproductive performance in Syrian hamsters] Satoh M, et al. **Exp Anim** 1995 Oct; 43(5):731–5 (Eng. Abstr.) **(Jpn)**

[ENT practice for the aged] Shitara T. **Nippon Ronen Igakkai Zasshi** 1996 Feb;33(2):72–7 **(Jpn)**

[Cancer medicine and aged people] Suemasu K. **Nippon Ronen Igakkai Zasshi** 1996 Feb;33(2):67–71 **(Jpn)**

[Sleep problems among the elderly—what is done and what should be done?] Fossan GO. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):831 **(Nor)**

[Treatment of chronic insomnia. A recommendation with special emphasis on problems of the elderly] Neckelmann D. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):854–9 (40 ref.) (Eng. Abstr.) **(Nor)**

[Growing old at the end of the 20th century. The challenge to gerontology and geriatrics] Helena-Saldanha M. **Acta Med Port** 1995 Oct;8(10):573–8 (Eng. Abstr.) **(Por)**

[The maximum heart rate in the exercise test: the 220-age formula or Sheffield's table?] Mesquita A, et al. **Rev Port Cardiol** 1996 Feb;15(2):139–44, 101 (Eng. Abstr.) **(Por)**

[Changes in the number of alpha 2- and beta-adrenoreceptors in the brain stem and cerebral cortex of rats in ontogeny] Iushkova AA, et al. **Fiziol Zh Im I M Sechenova** 1995 Feb; 81(2):7–11 (Eng. Abstr.) **(Rus)**

[The age-related characteristics of the clinical picture of duodenal ulcer in women] Redchits IV, et al. **Lik Sprava** 1995 May–Jun;(5–6):149–52 (Eng. Abstr.) **(Rus)**

[Changes in the adrenergic innervation of the large intestine in the postnatal ontogeny of the white rat] Amvros'ev AP, et al. **Morfologiia** 1995;108(1):17–21 (Eng. Abstr.) **(Rus)**

[The age-related characteristics of the muscular layer of the common bile duct in man] Kialian GP, et al. **Morfologiia** 1995;108(1):10–2 (Eng. Abstr.) **(Rus)**

[Individual and age-related variability of the arteries to the atrioventricular node in the human heart] Spirina GA. **Morfologiia** 1994 Apr–Jun;106(4–6):129–39 (Eng. Abstr.) **(Rus)**

[The mechanisms of onto- and gerontogenesis] Arshavskiĭ IA. **Ontogenez** 1995 Nov–Dec;26(6):481–8 (Eng. Abstr.) **(Rus)**

[Medicine and the aging process at the end of the 20th century] Schüller Pérez A. **An R Acad Nac Med (Madr)** 1996;Spec No:31–49 (73 ref.)

(Spa)
[Status epilepticus in the elderly] Cid MA. **Rev Neurol** 1995 Nov-Dec;23(124):1310-3 (27 ref.) (Spa)
[Epileptogenesis. Epilepsy and aging] Olaskoaga J, et al. **Rev Neurol** 1995 Nov-Dec;23(124):1297-306 (87 ref.) (Spa)
[Characteristics of epilepsy in aged people] Oliveros A. **Rev Neurol** 1995 Nov-Dec;23(124):1292-6 (Spa)
[Epileptogenesis in the elderly. Part II. Spike-wave confusional states. Myoclonic seizure in Alzheimer's disease] Urcola J, et al. **Rev Neurol** 1995 Nov-Dec; 23(124):1307-9 (18 ref.) (Spa)
[Future drugs against aging? New research on molecular background of aging] Nordstedt C, et al. **Lakartidningen** 1995 Oct 18;92(42):3881-4 (20 ref.) (Swe)
[Age-related changes in the cervical spine studied based on the results of a quantitative analysis of its structural-functional characteristics] Kobzar IV, et al. **Fiziol Zh** 1995 Jan-Apr;41(1-2):19-25 (Eng. Abstr.) (Ukr)

BLOOD

Aspartame pharmacokinetics - the effect of ageing. Puthrasingam S, et al. **Age Ageing** 1996 May;25(3):217-20
Seasonal changes in haemostatic factors in young and elderly subjects. Stout RW, et al. **Age Ageing** 1996 May;25(3):256-8
The effect of age on hemopoiesis. Quaglino D, et al. **Aging (Milano)** 1996 Feb;8(1):1-12 (83 ref.)
Influence of combined antioxidant nutrient intakes on their plasma concentrations in an elderly population. Jacques PF, et al. **Am J Clin Nutr** 1995 Dec;62(6):1228-33
Impact of apolipoprotein E genotype variation on means, variances, and correlations of plasma lipid, lipoprotein, and apolipoprotein traits in octogenarians. Haviland MB, et al. **Am J Med Genet** 1995 Sep 25;58(4):315-31 (64 ref.)
Effects of aging on glucose regulation during wakefulness and sleep. Frank SA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):E1006-16
Age-related changes in total and high-density-lipoprotein cholesterol in elderly Dutch men. Weijenberg MP, et al. **Am J Public Health** 1996 Jun;86(6):798-803
Development of IgG subclasses in healthy Polish children. Gregorek H, et al. **Arch Immunol Ther Exp (Warsz)** 1994; 42(5-6):377-82
Aging and heparin-related bleeding. Campbell NR, et al. **Arch Intern Med** 1996 Apr 22;156(8):857-60
Gender differences of disturbed hemostasis related to fasting insulin level in healthy very elderly Japanese aged > or = 75 years. Kario K, et al. **Atherosclerosis** 1995 Aug; 116(2):211-9
Do elevated levels of abdominal visceral adipose tissue contribute to age-related differences in plasma lipoprotein concentrations in men? Lemieux S, et al. **Atherosclerosis** 1995 Nov;118(1):155-64
Somatostatin in preterm infants: postnatal changes and response to stress. Jain L, et al. **Biol Neonate** 1995; 68(2):81-6
The increase with age of the components of the tissue factor coagulation pathway is gender-dependent. Ariëns RA, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):433-7
Blood pressure and serum lipids in hypertensive men and women aged 60-97 years. Nguyen PC, et al. **Blood Press** 1995;Suppl 3:26-30
Age-related changes in factor VII proteolysis in vivo. Ofosu FA, et al. **Br J Haematol** 1996 Aug;94(2):407-12
Child-adult differences in whole blood lactate responses to incremental treadmill exercise. Tolfrey K, et al. **Br J Sports Med** 1995 Sep;29(3):196-9
Serum concentrations of apolipoprotein A-I, apolipoprotein B, and lipoprotein(a) in a population sample. Leino A, et al. **Clin Chem** 1995 Nov;41(11):1633-6
Serum prostate-specific antigen measured in children from birth to age 18 years. Randell EW, et al. **Clin Chem** 1996 Mar;42(3):420-3
Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation [see comments] Rasmussen K, et al. **Clin Chem** 1996 Apr;42(4):630-6. Comment in: Clin Chem 1996 Apr;42(4):492-3.
Endotoxin levels in sera of elderly individuals. Goto T, et al. **Clin Diagn Lab Immunol** 1994 Nov;1(6):684-8
Circulating levels of growth hormone, insulin-like growth factor-I and growth hormone binding protein in normal women of advanced reproductive age. Klein NA, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):285-92
Basal and exercise-induced changes in plasma catecholamines: relationship to age, smoking habits and sampling times. Jensen EW, et al. **Clin Physiol** 1995 Jul; 15(4):299-305
Number of platelet dense granules varies with age, schizophrenia and dementia. Kessler A, et al. **Dementia** 1995 Nov-Dec;6(6):330-3
Effect of aging on HbA1c in a working male Japanese population. Hashimoto Y, et al. **Diabetes Care** 1995 Oct; 18(10):1337-40
Melatonin enhances cortisol levels in aged but not young women. Cagnacci A, et al. **Eur J Endocrinol** 1995 Dec; 133(6):691-5
Age modulates effects of thyroid dysfunction on sex hormone binding globulin (SHBG) levels. Lecomte P, et al. **Exp Clin Endocrinol Diabetes** 1995;103(5):339-42
Hormonal modulation of antioxidant enzyme activities in young and old rats. Bolzán AD, et al. **Exp Gerontol** 1995 Mar-Apr;30(2):169-75
Genotype-environment interaction: apolipoprotein E (ApoE) gene effects and age as an index of time and spatial context in the human. Zerba KE, et al. **Genetics** 1996 May; 143(1):463-78
Age-related decreases in plasma adrenocorticotropic hormone, corticosterone, and aldosterone responses to exogenous corticotropin-releasing hormone in the rat. Brudieux R, et al. **Gerontology** 1995;41(6):308-14
Cell adhesion molecules CD11a and CD18 in blood monocytes in old age and the consequences for immunological dysfunction. Preliminary results. Chiricolo M, et al. **Gerontology** 1995;41(4):227-34
A simple procedure for calculating biological age [letter] Galzigna L, et al. **Gerontology** 1995;41(6):325
Aspirin-induced conformational changes in platelet membrane in subjects with stroke. Hasan M, et al. **Gerontology** 1995;41(4):212-9
Dehydroepiandrosterone sulfate in a long-term care aged population. Legrain S, et al. **Gerontology** 1995;41(6):343-51
Influence of age and health on immune functions and trace elements. Licastro F, et al. **Gerontology** 1995;41(4):235-41
Persistent grossly elevated erythrocyte sedimentation rate in elderly people: one year follow-up of morbidity and mortality. Stevens D, et al. **Gerontology** 1995;41(4):220-6
Free and total dopamine in human plasma: effects of posture, age and some pathophysiological conditions. Hashizume K, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S205-7
Lipoprotein levels in elderly patients with asthma. Cardiovascular Health Study Research Group. Enright PL, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):467-9
A clinical approach to "idiopathic" normocytic-normochromic anemia. Elis A, et al. **J Am Geriatr Soc** 1996 Jul;44(7):832-4
Decline of hemoglobin is accelerated in older subjects with a high lipoprotein (a) concentration [letter] Kario K, et al. **J Am Geriatr Soc** 1996 Jul;44(7):883-4
Close relationship between hemostatic factors and acute-phase reaction as normal aging process [letter] Kario K, et al. **J Am Geriatr Soc** 1996 May;44(5):614-5
Systemic oxidative stress and its relationship with age and illness. Associazione Medica "Sabin" [see comments] Mezzetti A, et al. **J Am Geriatr Soc** 1996 Jul;44(7):823-7 . Comment in: J Am Geriatr Soc 1996 Jul;44(7):873-5.
Insulin-like growth factor 1 and functional status in healthy older men. Papadakis MA, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1350-5
The change in serum protein concentration in response to the stress of total joint surgery: a comparison of older versus younger patients. Puskarich-May CL, et al. **J Am Geriatr Soc** 1996 May;44(5):555-8
Aldosterone responses to hyperkalemia in healthy elderly humans. Mulkerrin E, et al. **J Am Soc Nephrol** 1995 Nov; 6(5):1459-62
Divergent selection for blood serum insulin-like growth factor I concentration in beef cattle: I. Nongenetic effects. Davis ME, et al. **J Anim Sci** 1995 Jul;73(7):1927-32
Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. Van Cauter E, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2468-73
Hormonal responses in elders experiencing pre-syncopal symptoms during head-up tilt before and after exercise training. Carroll JF, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):M324-9
Atrial natriuretic peptide levels in the elderly: differentiating normal aging changes from disease. Davis KM, et al. **J Gerontol A Biol Sci Med Sci** 1996 May;51(3):M95-101
Plasma levels of vitamin E in Parkinson's disease. Federico A, et al. **J Neural Transm Suppl** 1995;45:267-70
Vitamin B-6 status during childhood: tracking from 2 months to 11 years of age. Heiskanen K, et al. **J Nutr** 1995 Dec; 125(12):2985-92
Seasonal changes in the levels of antidiuretic hormone and melatonin in the elderly. Asplund R, et al. **J Pineal Res** 1995 Apr;18(3):154-8
Hemostatic indices in healthy foals from birth to one month of age. Barton MH, et al. **J Vet Diagn Invest** 1995 Jul; 7(3):380-5
Effects of vitamin B2 on neutrophil functions in cattle. Osame S, et al. **J Vet Med Sci** 1995 Jun;57(3):493-5
Dietary fatty acids, membrane transport, and oxidative sensitivity in human erythrocytes. Mills DE, et al. **Lipids** 1995 Jul;30(7):657-63
Cytokine production and lymphocyte subpopulations in aged humans. An assessment during nocturnal sleep. Born J, et al. **Mech Ageing Dev** 1995 Oct 13;84(2):113-26
Influence of aging and neurodegenerative disease on changes in band 3-like proteins in white blood cells. Bosman GJ, et al. **Mech Ageing Dev** 1995 Apr 21;80(1):43-51
Rapid tyrosine phosphorylation of Grb2 and Shc in T cells exposed to anti-CD3, anti-CD4, and anti-CD45 stimuli: differential effects of aging. Ghosh J, et al. **Mech Ageing Dev** 1995 Jun 9;80(3):171-87
Superoxide generation by alveolar macrophages from aged rats: improvement by in vitro treatment with IFN-gamma. Hayakawa H, et al. **Mech Ageing Dev** 1995 Jun 9; 80(3):199-211
Both T- and K-kininogens increase in the serum of old rats but by different mechanisms. Sierra F. **Mech Ageing Dev** 1995 Oct 13;84(2):127-37
Age-related changes in mitogen-induced beta-endorphin release from human peripheral blood mononuclear cells. Manfredi B, et al. **Peptides** 1995;16(4):699-706
The effect of age and everyday exercise on steady-state plasma digoxin concentrations. Teague AC, et al. **Pharmacotherapy** 1995 Jul-Aug;15(4):502-8
Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism. Bosch JL, et al. **Prostate** 1995 Nov;27(5):241-9
Oxidative stress and antioxidant protection in degenerative psychoorganic syndrome in old agers. Negru T, et al. **Rom J Intern Med** 1995 Jan-Jun;33(1-2):55-60
The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Leinonen E, et al. **Ther Drug Monit** 1996 Apr;18(2):111-7
Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Andrew M. **Thromb Haemost** 1995 Jul;74(1):415-25 (141 ref.)
Changes in haemostatic factors and activation products after exercise in healthy subjects with different ages. van den Burg PJ, et al. **Thromb Haemost** 1995 Dec;74(6):1457-64
Hyperammonaemia in Irish wolfhounds [letter; comment] [see comments] Kerr MG. **Vet Rec** 1996 Feb 17; 138(7):167-8. Comment on: Vet Rec 1996 Feb 3;138(5):105-7. Comment in: Vet Rec 1996 Mar 23;138(12):288.
Total blood volume in the normally performing Standardbred trotter: age and sex variations. Persson SG, et al. **Zentralbl Veterinarmed A** 1996 Mar;43(1):57-64
[Improving effect of rhizoma Gastrodiae on learning and memory of senile rats] Gao N, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep;20(9):562-3, 568, inside backcover (Eng. Abstr.) (Chi)
[The content of pepsinogen in the blood plasma of growing fallow deer (Dama dama L.) raised helminth free and under natural conditions in captivity] Rehbein S, et al. **Berl Munch Tierarztl Wochenschr** 1995 Sep;108(9):321-5 (Eng. Abstr.) (Ger)
[Age dependency of laboratory values in dogs and cats. II. Electrolytes in serum] Kraft W, et al. **Tierarztl Prax** 1996 Apr;24(2):169-73 (Eng. Abstr.) (Ger)
[Dependency on age of laboratory values in dogs and cats. 1. Enzyme activities in blood serum] Kraft W, et al. **Tierarztl Prax** 1995 Oct;23(5):502-8 (Eng. Abstr.) (Ger)
[Intestinal absorption of homologous and heterologous immunoglobulin G in newborn calves] Erhard MH, et al. **Z Ernahrungswiss** 1995 Jun;34(2):160-3 (Eng. Abstr.) (Ger)
[Variation in the plasma endothelin levels in relation to age] Battistelli S, et al. **Minerva Cardioangiol** 1996 Mar; 44(3):111-4 (Eng. Abstr.) (Ita)
[Age-related changes and sex differences on the serum chemistry values in Sprague-Dawley rats—I. 6-30 weeks of age] Tsuchiya N, et al. **Exp Anim** 1995 Oct;43(5):671-8 (Eng. Abstr.) (Jpn)
[Changes in the level of endothelin-1 with aging] Komatsumoto S, et al. **Nippon Ronen Igakkai Zasshi** 1995 Oct;32(10):664-9 (Eng. Abstr.) (Jpn)
[The measurement of blood lactate concentration and its age change in days on healthy infant] Kinoshita K, et al. **Rinsho Byori** 1995 Oct;43(10):1071-6 (Eng. Abstr.) (Jpn)
[Homocysteinemia as a risk factor for myocardial infarct—the importance of age and of the homocysteinemia levels] Reis RP, et al. **Rev Port Cardiol** 1995 Oct;14(10):713-6 (Por)
[The retardation of DNA synthesis in adjacent replicon clusters in the lymphocytes of patients with Down's syndrome as a model of premature aging] Barenfel'd LS, et al. **Tsitologiia** 1995;37(9-10):900-4 (Eng. Abstr.) (Rus)
[The index of PSA age vs PSA density. 2 new instruments in the detection of prostatic carcinoma] Fernández Arjona M, et al. **Actas Urol Esp** 1995 Mar;19(3):187-91 (Eng. Abstr.) (Spa)
[The relationship of PSA to age and prostatic volume in patients with benign prostatic hypertrophy] Sánchez Sánchez E, et al. **Actas Urol Esp** 1995 Mar;19(3):181-6 (Eng. Abstr.) (Spa)
[Pineal functioning (melatonin levels) in healthy children of different ages. An update and the value of pineal gland study in pediatrics] Molina Carballo A, et al. **An Esp Pediatr** 1996 Jul;45(1):33-44 (124 ref.) (Eng. Abstr.) (Spa)

DRUG EFFECTS

Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. van den Brande P, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1705-8
Effect of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone on protein oxidation and life span. Dubey A, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):249-54
Chronic antioxidant treatment improves the cognitive performance of aged rats. Socci DJ, et al. **Brain Res** 1995 Sep 25;693(1-2):88-94
Effects of ginsenoside Rb1 and Rg1 on synaptosomal free calcium level, ATPase and calmodulin in rat hippocampus. Liu M, et al. **Chin Med J (Engl)** 1995 Jul;108(7):544-7
The changing face of hypertension and antihypertensive agents. Kitler ME. **Drugs Aging** 1996 Jan;8(1):5-11 (43 ref.)
Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Hassan AH, et al. **Exp Neurol** 1996 Jul;

140(1):43–52

Intraparenchymal NGF injections in adult and aged rats induce long-lasting Trk tyrosine phosphorylation. Knusel B, et al. **Exp Neurol** 1996 May;139(1):121–30

Effects of growth hormone and estrogen on T lymphocytes in older women. Bonello RS, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1038–42

No increased risk of Taxol toxicity in older patients [letter] Lichtman SM, et al. **J Am Geriatr Soc** 1996 Apr;44(4):472–4

Increased baseline sway contributes to increased losses of balance in older people following triazolam. Robin DW, et al. **J Am Geriatr Soc** 1996 Mar;44(3):300–4

Trophic factor supplementation: effect on the age-associated changes in body composition. Schwartz RS. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:151–6 (53 ref.)

Selective effects of nerve growth factor on spatial recent memory as assessed by a delayed nonmatching-to-position task in the water maze. Markowska AL, et al. **J Neurosci** 1996 May 15;16(10):3541–8

The effects of ascorbic acid and oxiracetam on scopolamine-induced amnesia in a habituation test in aged mice. de Angelis L, et al. **Neurobiol Learn Mem** 1995 Sep; 64(2):119–24

Acidic fibroblast growth factor protects memory and immunoreactivity impairment in senescence accelerated mice. Oomura Y, et al. **Neurobiology (Bp)** 1995; 3(3–4):371–80

Reduced glucocorticoid response to corticotropin secretagogues in the aged Sprague-Dawley rat. Scaccianoce S, et al. **Neuroendocrinology** 1995 Jul; 62(1):32–8

Aged rats are still responsive to the antidepressant and memory-improving effects of oxytocin. Arletti R, et al. **Neuropeptides** 1995 Sep;29(3):177–82

The suppression of age-related accumulation of lipid peroxides in rat brain by administration of Rooibos tea (Aspalathus linearis). Inanami O, et al. **Neurosci Lett** 1995 Aug 18;196(1–2):85–8

Ontogenetic development of the locomotor response to levodopa in the rat. Grigoriadis N, et al. **Pediatr Neurol** 1996 Jan;14(1):41–5

Comparative study of the presence of oxidative stress in sportsmen in competition and aged people, as well as the preventive effect of selenium administration. Olinescu R, et al. **Rom J Intern Med** 1995 Jan–Jun;33(1–2):47–54

[Clinical study of effect of zhengda zhenhua 851-R oral liquor on delayed aging process] Chen WZ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):468–71 (Eng. Abstr.) **(Chi)**

[Mechanism of tonifying kidney and removing blood stasis recipe in modulation of immune senescence] Jiang WY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun;15(6):353–5 (Eng. Abstr.) **(Chi)**

[Effect of zhuchun pill on immunity and endocrine function of elderly with kidney-yang deficiency] Yin GY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):601–3 (Eng. Abstr.) **(Chi)**

[Active antisenile constituents in Cistanche deserticola Y. C. Ma] Xue D, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov;20(11):687–9, 704 (Eng. Abstr.) **(Chi)**

[Effect of ethanolic extract from root tuber of Polygonum multiflorum Thunb. on liver and brain monoamine oxidase in senescence-accelerated mice in vivo] Yang X. **Chung Kuo Chung Yao Tsa Chih** 1996 Jan;21(1):48–9, inside back cover (Eng. Abstr.) **(Chi)**

[Pharmacodynamic changes in the elderly subject] Beltrami G, et al. **Clin Ter** 1996 Apr;147(4):181–91 (98 ref.) (Eng. Abstr.) **(Ita)**

[Genotypic, sex and age differences in appearance of the mutagenic effect of cyclophosphamide in mice] Durnev AD, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):387–90 **(Rus)**

[The effect of pyrimidines, levamisole and prodigiozan on the antigen-specific regulation of delayed hypersensitivity in relation to the age and strain of the mice] Gainutdinova DT, et al. **Eksp Klin Farmakol** 1995 Jul–Aug;58(4):45–7 (Eng. Abstr.) **(Rus)**

[The influence of naloxone on the antinociceptive effects of the brain system of negative reinforcement in the developing rabbit] Butkevich IP, et al. **Fiziol Zh Im I M Sechenova** 1995 Dec;81(12):31–5 (Eng. Abstr.) **(Rus)**

[The reflex and direct actions of novocaine on the rhythm of the heart beats in rats in early postnatal ontogeny] Kulaev BS, et al. **Zh Evol Biokhim Fiziol** 1995 Jan–Feb; 31(1):38–43 (Eng. Abstr.) **(Rus)**

GENETICS

Sex chromosome loss and aging: in situ hybridization studies on human interphase nuclei. Guttenbach M, et al. **Am J Hum Genet** 1995 Nov;57(5):1143–50

Evidence that specific mtDNA point mutations may not accumulate in skeletal muscle during normal human aging. Pallotti F, et al. **Am J Hum Genet** 1996 Sep;59(3):591–602

Accumulation of deletions and point mutations in mitochondrial genome in degenerative diseases. Tanaka M, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:102–11

Tandem duplications and large-scale deletions of mitochondrial DNA are early molecular events of human aging process. Wei YH, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:82–101

Identification of several isoforms of T-kininogen expressed in the liver of aging rats. Sierra F, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):333–8

Age-related changes in learning and memory and cholinergic neuronal function in senescence accelerated mice (SAM). Nitta A, et al. **Behav Brain Res** 1995 Dec 14;72(1–2):49–55

c-fos/c-jun expression and AP-1 activation in skin fibroblasts from centenarians. Grassilli E, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):517–23

Age-related extensive fragmentation of mitochondrial DNA into minicircles. Hayakawa M, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):369–77

Accumulation of deletions in MtDNA during tissue aging: analysis by long PCR. Reynier P, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):59–67

Age-related changes in the ovalbumin gene of the Japanese quail. Upadhyay R, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):356–61

IAP retrotransposons in the mouse liver as reporters of ageing. Dupressoir A, et al. **Biochim Biophys Acta** 1995 Dec 27;1264(3):397–402

Isolation and characterization of genomic and cDNA clones encoding mouse senescence marker protein-30 (SMP30). Fujita T, et al. **Biochim Biophys Acta** 1996 Jul 31; 1308(1):49–57

Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Busque L, et al. **Blood** 1996 Jul 1;88(1):59–65

Coloboma hyperactive mutant exhibits delayed neurobehavioral developmental milestones. Heyser CJ, et al. **Brain Res Dev Brain Res** 1995 Nov 21;89(2):264–9

Cytogenetic analyses of patients with skin tumors [letter] Severi-Aguiar GD, et al. **Cancer Genet Cytogenet** 1995 Nov;85(1):88

Do changes in chromosomes cause aging? Guarente L. **Cell** 1996 Jul 12;86(1):9–12 (21 ref.)

Ponce d'elegans: genetic quest for the fountain of youth. Kenyon C. **Cell** 1996 Feb 23;84(4):501–4 (17 ref.)

Radioautographic studies on aging change of DNA synthesis and the ultrastructural development of mouse adrenal gland. Ito M. **Cell Mol Biol (Noisy-le-grand)** 1996 Mar; 42(2):279–92

Study on DNA synthesis of aging mouse colon by light and electron microscopic radioautography. Jin C. **Cell Mol Biol (Noisy-le-grand)** 1996 Mar;42(2):255–68

Enhanced expression of myogenic regulatory genes in aging skeletal muscle. Musarò A, et al. **Exp Cell Res** 1995 Nov; 221(1):241–8

Stress experiments as a means of investigating age-specific mortality in Drosophila melanogaster. Khazaeli AA, et al. **Exp Gerontol** 1995 Mar–Apr;30(2):177–84

Genetic modulation of the senescent phenotype of Homo sapiens. Martin GM. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):49–59 (57 ref.)

Life span prediction from the rate of age-related DNA demethylation in normal and cancer cell lines. Mazin AL. **Exp Gerontol** 1995 Sep–Oct;30(5):475–84

Mitochondrial DNA mutations associated with aging and degenerative diseases. Ozawa T. **Exp Gerontol** 1995 May–Aug;30(3–4):269–90 (55 ref.)

Genetics of aging: current animal models. Shmookler Reis RJ, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):69–81 (67 ref.)

Regulation of gene expression is linked to life span in adult Drosophila. Rogina B, et al. **Genetics** 1995 Nov; 141(3):1043–8

Inherited stress resistance and longevity: a stress theory of ageing. Parsons PA. **Heredity** 1995 Aug;75 (Pt 2):216–21

Pregnancy and lifestyle study: the long-term use of the contraceptive pill and the risk of age-related miscarriage. Ford JH, et al. **Hum Reprod** 1995 Jun;10(6):1397–402

Aetiology of age-associated aneuploidy: a mechanism based on the 'free radical theory of ageing'. Tarin JJ. **Hum Reprod** 1995 Jun;10(6):1563–5 (25 ref.)

Cellular and molecular determinants of ageing. Rattan SI. **Indian J Exp Biol** 1996 Jan;34(1):1–6 (30 ref.)

T cell repertoire usage in humans, from newborns to centenarians. Cossarizza A, et al. **Int Rev Immunol** 1995; 12(1):41–55 (71 ref.)

V beta gene repertoire in the aging mouse: a developmental perspective. González-Quintial R, et al. **Int Rev Immunol** 1995;12(1):27–40 (81 ref.)

Accumulation of mitochondrial DNA deletions in human retina during aging. Barreau E, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):384–91

Genetic relationships of lamb weight, maternal ability, and mature ewe weight in Swedish finewool sheep. Näsholm A, et al. **J Anim Sci** 1996 Feb;74(2):329–39

Multiple deletions are detectable in mitochondrial DNA of aging mice. Tanhauser SM, et al. **J Biol Chem** 1995 Oct 20;270(42):24769–75

Accelerated senile amyloidosis induced by amyloidogenic Apoa-II gene shortens the life span of mice but does not accelerate the rate of senescence. Higuchi K, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):B295–302

Differential expression of reg-I and reg-II genes during aging in the normal mouse. Perfetti R, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):B308–15

The location of MZF-1 at the telomere of human chromosome 19q makes it vulnerable to degeneration in aging cells. Hoffman SM, et al. **Leuk Res** 1996 Mar; 20(3):281–3

Detection of the ageing-associated 5-Kb common deletion of mitochondrial DNA in blood and bone marrow of hematologically normal adults. Absence of the deletion in clonal bone marrow disorders. Gattermann N, et al. **Leukemia** 1995 Oct;9(10):1704–10

High levels of mitochondrial DNA deletions in skeletal muscle of old rhesus monkeys. Schwarze SR, et al. **Mech Ageing Dev** 1995 Sep 7;83(2):91–101

Embryo brain kinase: a novel gene of the eph/elk receptor tyrosine kinase family. Ellis J, et al. **Mech Dev** 1995 Aug; 52(2–3):319–41

Spermatid micronucleus analysis of aging effects in hamsters. Allen JW, et al. **Mutat Res** 1996 May;316(5–6):261–6

DNA damage, mutation and fine structure DNA repair in aging. Bohr VA, et al. **Mutat Res** 1995 Oct;338(1–6):25–34 (100 ref.)

Correlation between age and DNA damage detected by FADU in human peripheral blood lymphocytes. Chicca MC, et al. **Mutat Res** 1996 May;316(5–6):201–8

Alterations of c-fos gene methylation in the processes of aging and tumorigenesis in human liver. Choi EK, et al. **Mutat Res** 1996 Jul 5;354(1):123–8

Genotypic selection of mitochondrial and oncogenic mutations in human tissue suggests mechanisms of age-related pathophysiology. Cortopassi G, et al. **Mutat Res** 1995 Oct;338(1–6):151–9 (43 ref.)

Somatic mutations in the brain: relationship to aging? Evans DA, et al. **Mutat Res** 1995 Oct;338(1–6):173–82 (47 ref.)

Dietary supplements of antioxidants reduce hprt mutant frequency in splenocytes of aging mice. Gaziev AI, et al. **Mutat Res** 1995 Oct;338(1–6):77–86

Impact of age and environment on somatic mutation at the hprt gene of T lymphocytes in humans. Jones IM, et al. **Mutat Res** 1995 Oct;338(1–6):129–39

Human aging is associated with stochastic somatic mutations of mitochondrial DNA. Kadenbach B, et al. **Mutat Res** 1995 Oct;338(1–6):161–72 (112 ref.)

Aneuploidies and micronuclei in the germ cells of male mice of advanced age. Lowe X, et al. **Mutat Res** 1995 Oct; 338(1–6):59–76

Somatic mutagenesis and antimutagenesis in aging research. Martin GM. **Mutat Res** 1996 Feb 19;350(1):35–41 (55 ref.)

Use of transgenic mouse models for studying somatic mutations in aging. Martus HJ, et al. **Mutat Res** 1995 Oct; 338(1–6):203–13 (46 ref.)

The somatic mutation theory of ageing. Morley AA. **Mutat Res** 1995 Oct;338(1–6):19–23 (49 ref.)

Somatic movement of the mariner transposable element and lifespan of Drosophila species. Nikitin AG, et al. **Mutat Res** 1995 Oct;338(1–6):43–9

Spontaneous mutant frequency of lacZ gene in spleen of transgenic mouse increases with age. Ono T, et al. **Mutat Res** 1995 Oct;338(1–6):183–8

The effects of age and lifestyle factors on the accumulation of cytogenetic damage as measured by chromosome painting. Ramsey MJ, et al. **Mutat Res** 1995 Oct; 338(1–6):95–106

Effect of aging on spontaneous micronucleus frequencies in peripheral blood of nine mouse strains: the results of the 7th collaborative study organized by CSGMT/JEMS.MMS. Collaborative Study Group for the Micronucleus Test. Environmental Mutagen Society of Japan. Mammalian Mutagenesis Study Group. Sato S, et al. **Mutat Res** 1995 Oct;338(1–6):51–7

Sex chromosome aneuploidy and aging. Stone JF, et al. **Mutat Res** 1995 Oct;338(1–6):107–13 (51 ref.)

Deletional mutations are the basic cause of aging: historical perspectives. Strehler BL. **Mutat Res** 1995 Oct; 338(1–6):3–17

A cytogenetic study of radiological workers: effect of age, smoking and radiation burden on the micronucleus frequency. Thierens H, et al. **Mutat Res** 1996 Jun 10; 360(2):75–82

Nucleic acid fingerprinting by PCR-based methods: applications to problems in aging and mutagenesis. Welsh J, et al. **Mutat Res** 1995 Oct;338(1–6):215–29 (72 ref.)

P DNA element movement in somatic cells reduces lifespan in Drosophila melanogaster: evidence in support of the somatic mutation theory of aging. Woodruff RC, et al. **Mutat Res** 1995 Oct;338(1–6):35–42

Factors affecting somatic mutation frequencies in vivo. Zhang XB, et al. **Mutat Res** 1995 Oct;338(1–6):189–201

Genetic analysis of ageing: role of oxidative damage and environmental stresses. Martin GM, et al. **Nat Genet** 1996 May;13(1):25–34 (151 ref.)

Genetic and aging epidemiology. The merging of two disciplines. Cauley JA, et al. **Neurol Clin** 1996 May; 14(2):467–75 (53 ref.)

Marked increase in the number and variety of mitochondrial DNA rearrangements in aging human skeletal muscle [published erratum appears in Nucleic Acids Res 1995 Dec 11;23(23):4938] Melov S, et al. **Nucleic Acids Res** 1995 Oct 25;23(20):4122–6

Age-dependent silencing of globin transgenes in the mouse. Robertson G, et al. **Nucleic Acids Res** 1996 Apr 15; 24(8):1465–71

Age-related changes in learning, memory, and lipofuscin as a function of the percentage of SAMP8 genes. Flood JF, et al. **Physiol Behav** 1995 Oct;58(4):819–22

Senescence-induced expression of a homologue of delta 9 desaturase in rose petals. Fukuchi-Mizutani M, et al. **Plant Mol Biol** 1995 Nov;29(4):627–35

Age-specific inbreeding depression and components of genetic variance in relation to the evolution of senescence. Charlesworth B, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6140–5

The origin of trisomy in humans. Hassold T, et al. **Prog Clin Biol Res** 1995;393:1–12

Longevity, genes, and aging. Jazwinski SM. **Science** 1996 Jul 5;273(5271):54–9 (73 ref.)

Determination of life-span in Caenorhabditis elegans by four clock genes. Lakowski B, et al. **Science** 1996 May 17; 272(5264):1010–3

Mechanisms and evolution of aging. Lithgow GJ, et al. **Science** 1996 Jul 5;273(5271):80 (14 ref.)

Premature aging gene discovered [news; comment] Pennisi E. **Science** 1996 Apr 12;272(5259):193–4. Comment on: Science 1996 Apr 12;272(5259):258–62.

Worm genes imply a master clock [news] Pennisi E. **Science** 1996 May 17;272(5264):949–50

[Decreased performance in the elderly. Etiology: stochastic mutations of mitochondrial DNA?] Kadenbach B. **Fortschr Med** 1995 Dec 20;113(35–36):510 **(Ger)**

[The effect of age on the genetic correlates of visual evoked potentials in man] Martiutina TM, et al. **Fiziol Zh Im I M Sechenova** 1995 Apr;81(4):109–12 **(Rus)**

IMMUNOLOGY

Age-related decrease of nerve growth factor-like immunoreactivity in the basal forebrain of senescence-accelerated mice. Ohnishi K, et al. **Acta Neuropathol (Berl)** 1995;90(1):11–6

Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons. Ballou SP, et al. **Age Ageing** 1996 May;25(3):224–30

Aging, zinc and cell-mediated immune response [editorial] Fortes C. **Aging (Milano)** 1995 Apr;7(2):75–6

Prevalence of autoantibodies in the very elderly: association with symptoms of ischemic heart disease. Potocka-Plazak K, et al. **Aging (Milano)** 1995 Aug;7(4):218–20

Antioxidants and immune response in aged persons: overview of present evidence. Meydani SN, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1462S–1476S (146 ref.)

Immune dysregulation in the aging human lung. Meyer KC, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1072–9

Passive immune status at postpartum hour 24 and long-term health and performance of calves. Wittum TE, et al. **Am J Vet Res** 1995 Sep;56(9):1149–54

Senescence-accelerated mouse. Neurochemical studies on aging. Nomura Y, et al. **Ann N Y Acad Sci** 1996 Jun 15; 786:410–8

Protection against impairment of memory and immunoreactivity in senescence-accelerated mice by acidic fibroblast growth factor. Oomura Y, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:337–47

Fibroblast responses to cytokines are maintained during aging. Freedland M, et al. **Ann Plast Surg** 1995 Sep; 35(3):290–6

Humoral immune response to pneumococcal vaccination. Prevention of infections with Streptococcus pneumoniae by immunization. Konradsen HB. **APMIS Suppl** 1996; 60:1–28

Cytotoxicity towards neonatal versus adult BB rat pancreatic islet cells. Ekblond A, et al. **Autoimmunity** 1995;20(2):93–8

Extremely low birth weight infants have lower Fc gamma RIII (CD 16) plasma levels and their PMN produce less Fc gamma RIII compared to adults. Payne NR, et al. **Biol Neonate** 1996;69(4):235–42

Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Price TH, et al. **Blood** 1996 Jul 1;88(1):335–40

An age-related decrease in rescue from T cell death following costimulation mediated by CD28. Engwerda CR, et al. **Cell Immunol** 1996 May 25;170(1):141–8

Age-related reductions in the activation of mitogen-activated protein kinases p44mapk/ERK1 and p42mapk/ERK2 in human T cells stimulated via ligation of the T cell receptor complex. Whisler RL, et al. **Cell Immunol** 1996 Mar 15;168(2):201–10

Age-related decreases in IL-2 production by human T cells are associated with impaired activation of nuclear transcriptional factors AP-1 and NF-AT. Whisler RL, et al. **Cell Immunol** 1996 May 1;169(2):185–95

Age-dependent humoral responses of children to mycobacterial antigens. Fairchok MP, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):443–7

Comparison of cytotoxic properties of neonatal and adult neutrophils and monocytes and enhancement by cytokines. Stiehm ER, et al. **Clin Diagn Lab Immunol** 1994 May; 1(3):342–7

The association of age, gender and smoking with total IgE and specific IgE. Jarvis D, et al. **Clin Exp Allergy** 1995 Nov;25(11):1083–91

Normal levels of soluble E-selectin, soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease with age. Nash MC, et al. **Clin Exp Immunol** 1996 Jan;103(1):167–70

Vitamin E and aging immune response. Meydani SN, et al. **Clin Geriatr Med** 1995 Nov;11(4):567–76 (52 ref.)

Immune dysfunction in Down's syndrome: primary immune deficiency or early senescence of the immune system? Cuadrado E, et al. **Clin Immunol Immunopathol** 1996 Mar; 78(3):209–14 (61 ref.)

Tenfold increased incidence of spontaneous multiple myeloma in long-term immunosuppressed aging C57BL/KaLwRij mice. Radl J, et al. **Clin Immunol Immunopathol** 1996 May;79(2):155–62

Prenatal stress alters immune function in the offspring of rats. Klein SL, et al. **Dev Psychobiol** 1995 Sep;28(6):321–36

Age-dependent association of HLA-A24 in Japanese IDDM patients [letter] Mizota M, et al. **Diabetologia** 1996 Mar; 39(3):371–3

Impact of aging on gastrointestinal mucosal immunity. Schmucker DL, et al. **Dig Dis Sci** 1996 Jun;41(6):1183–93 (76 ref.)

Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Barrios C, et al. **Eur J Immunol** 1996 Jul;26(7):1489–96

Antibody protection in aging: influence of idiotypic repertoire and antibody binding activity to a bacterial antigen. Nicoletti C. **Exp Mol Pathol** 1995 Apr;62(2):99–108

Neurodegeneration in the central nervous system of apoE-deficient mice. Masliah E, et al. **Exp Neurol** 1995 Dec;136(2):107–22

Immunoreactivity of ageing C57BL female mice rendered tolerant to the H-Y antigen. Skowron-Cendrzak A, et al. **Folia Biol (Praha)** 1994;40(6):477–82

Effects of caloric restriction on age-related oxidative modifications of macromolecules and lymphocyte proliferation in rats. Tian L, et al. **Free Radic Biol Med** 1995 Dec;19(6):859–65

Cell adhesion molecules CD11a and CD18 in blood monocytes in old age and the consequences for immunological dysfunction. Preliminary results. Chiricolo M, et al. **Gerontology** 1995;41(4):227–34

Effectiveness of immunotherapy in aged leukemic mice. Dussault I, et al. **Gerontology** 1995;41(4):195–204

Influence of age and health on immune functions and trace elements. Licastro F, et al. **Gerontology** 1995;41(4):235–41

Aging and immune function: a possible role for growth hormone. Gelato MC. **Horm Res** 1996;45(1–2):46–9 (25 ref.)

CD8+ T cell subsets in aging. Ruiz M, et al. **Immunol Invest** 1995 Nov;24(6):891–5

T cell receptor V-segment frequencies in aged individuals. Ruiz M, et al. **Immunol Invest** 1996 Jan-Mar;25(1–2):111–4

Age-related changes in ConA-induced cytokine production by splenocytes from senescence accelerated mice SAMP8. Aoki K, et al. **Immunol Lett** 1995 May;46(1–2):169–75

Age-related changes in T gamma delta cells of NOD mice. Funda D, et al. **Immunol Lett** 1995 Mar;45(3):179–84

Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. Iakoubov L, et al. **Immunol Lett** 1995 Jul-Aug;47(1–2):147–9

Effect of dehydroepiandrosterone on mitogen-induced lymphocyte proliferation and cytokine production in young and old F344 rats. Pahlavani MA, et al. **Immunol Lett** 1995 Jul-Aug;47(1–2):9–14

Cytokine production pathway in the elderly. Caruso C, et al. **Immunol Res** 1996;15(1):84–90 (52 ref.)

Immunosenescence: ageing of the immune system. Pawelec G, et al. **Immunol Today** 1995 Sep;16(9):420–2

Immunology of centenarians [letter; comment] Steinmann G, et al. **Immunol Today** 1995 Nov;16(11):549–50. Comment on: Immunol Today 1995 Jan;16(1):12–6.

Age-related defects in CD2 receptor-induced activation in human T-cell subsets. Beckman I, et al. **Immunology** 1995 Dec;86(4):533–6

Reduced expression of the interleukin-2-receptor gamma chain on cord blood lymphocytes: relationship to functional immaturity of the neonatal immune response. Zola H, et al. **Immunology** 1996 Jan;87(1):86–91

Lipopolysaccharide-induced lethality and cytokine production in aged mice. Tateda K, et al. **Infect Immun** 1996 Mar;64(3):769–74

Regulation of CD95 (APO-1) expression and the induction of apoptosis in human T cells: changes in old age. Lechner H, et al. **Int Arch Allergy Immunol** 1996 Jul;110(3):238–43

Functional CD4+ T cell subsets defined by expression of CD45RC and NTA260 antigens and age-associated polarization in murine lupus. Nishimura H, et al. **Int Immunol** 1995 Jul;7(7):1115–23

Dysregulation of the humoral immune response in old mice. Zhao KS, et al. **Int Immunol** 1995 Jun;7(6):929–34

In vivo and in vitro study of the primary and secondary antibody response to a bacterial antigen in aged mice. Borghesi C, et al. **Int J Exp Pathol** 1995 Dec;76(6):419–24

Reversibility of the thymic involution and of age-related peripheral immune dysfunctions by zinc supplementation in old mice. Mocchegiani E, et al. **Int J Immunopharmacol** 1995 Sep;17(9):703–18

Effect of vitamin and trace element supplementation on immune indices in healthy elderly. Pike J, et al. **Int J Vitam Nutr Res** 1995;65(2):117–21

T cell repertoire usage in humans, from newborns to centenarians. Cossarizza A, et al. **Int Rev Immunol** 1995; 12(1):41–55 (71 ref.)

Immunosenescence in humans: deterioration or remodelling? Franceschi C, et al. **Int Rev Immunol** 1995;12(1):57–74 (100 ref.)

Introduction: the reshaping of the immune system with age. Franceschi C, et al. **Int Rev Immunol** 1995;12(1):1–4 (19 ref.)

V beta gene repertoire in the aging mouse: a developmental perspective. González-Quintial R, et al. **Int Rev Immunol** 1995;12(1):27–40 (81 ref.)

Aging associated changes in the generation and development of B cell memory. Klinman NR, et al. **Int Rev Immunol** 1995;12(1):5–12 (60 ref.)

Immunoendocrine reshaping with age. Panerai AE, et al. **Int Rev Immunol** 1995;12(1):75–84 (73 ref.)

Changes in the intestinal lymphoid compartment throughout life: implications for the local generation of intestinal T cells. Rozing J, et al. **Int Rev Immunol** 1995;12(1):13–25 (45 ref.)

Effects of growth hormone and estrogen on T lymphocytes in older women. Bonelio RS, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1038–42

Testes function and feedlot performance of bulls actively immunized against gonadotropin-releasing hormone: effect of age at immunization. Adams TE, et al. **J Anim Sci** 1996 May;74(5):950–4

Antibody responses to suspected periodontal pathogens in elderly subjects with periodontal disease. McArthur WP, et al. **J Clin Periodontol** 1995 Nov;22(11):842–9

Evidence for limited B-lymphopoiesis in adult rabbits. Crane MA, et al. **J Exp Med** 1996 May 1;183(5):2119–21

Primary allergic sensitization to environmental antigens: perinatal T cell priming as a determinant of responder phenotype in adulthood [comment] Holt PG. **J Exp Med** 1996 Apr 1;183(4):1297–301. Comment on: J Exp Med 1996 Apr 1;183(4):1613–21.

Constitutive expression of bcl-2 in B cells causes a lethal form of lupuslike autoimmune disease after induction of neonatal tolerance to H-2b alloantigens. López-Hoyos M, et al. **J Exp Med** 1996 Jun 1;183(6):2523–31

Relative contribution of T and B cells to hypermutation and selection of the antibody repertoire in germinal centers of aged mice. Yang X, et al. **J Exp Med** 1996 Mar 1; 183(3):959–70

Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors. Ferguson FG, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):B378–82

Diminished cell-cell binding by lymphocytes from healthy, elderly humans: evidence for altered activation of LFA-1 function with age. Jackola DR, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):B368–77

Altered switch in lipid composition during T-cell blast transformation in the healthy elderly. Stulnig TM, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):B383–90

Cytokine production by T lymphocytes from young and aged mice. Engwerda CR, et al. **J Immunol** 1996 May 15; 156(10):3621–30

Escherichia coli and Pseudomonas aeruginosa induce expansion of V delta 2 cells in adult peripheral blood, but of V delta 1 cells in cord blood. Kersten CM, et al. **J Immunol** 1996 Aug 15;157(4):1613–9

B cells are generated throughout life in humans. Nuñez C, et al. **J Immunol** 1996 Jan 15;156(2):866–72

Cytokine gene expression in islets and thyroids of BB rats. IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated nondiabetic BB rats. Zipris D, et al. **J Immunol** 1996 Feb 1;156(3):1315–21

Development of cellular immune functions in neonatal to weanling mice: relationship to Cryptosporidium parvum infection. Harp JA, et al. **J Parasitol** 1996 Apr;82(2):245–9

Preimmune resistance to Toxoplasma gondii in aged and young adult mice. Johnson LL, et al. **J Parasitol** 1995 Dec; 81(6):894–9

Age-related development of human anti-pig xenoantibody. Xu H, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1023–9

Immunological responses to polyvalent canine vaccines in dogs. Miyamoto T, et al. **J Vet Med Sci** 1995 Apr; 57(2):347–9

Immunoblot analysis for serum antibodies to Pneumocystis carinii by age and intensity of infection in rats. Hong ST, et al. **Korean J Parasitol** 1995 Sep;33(3):187–94

Age dependency of the composition of immunocompetent cells and the expression of adhesion molecules in rat laryngeal mucosa. Jecker P, et al. **Laryngoscope** 1996 Jun; 106(6):733–8

Anticardiolipin antibodies in two elderly subpopulations. Juby A, et al. **Lupus** 1995 Dec;4(6):482–5

Long-term culture of monoclonal human T lymphocytes: models for immunosenescence? Adibzadeh M, et al. **Mech Ageing Dev** 1995 Sep 15;83(3):171–83

Differential effects of interleukin-12 treatment on gene expression by allostimulated T cells from young and aged mice. Bloom ET, et al. **Mech Ageing Dev** 1995 Nov 24; 85(2–3):109–24

Role of immune response as determinant of tumor progression in function of host age in the B16 melanoma. Donin N, et al. **Mech Ageing Dev** 1995 May 12;80(2):121–37

Stimulatory effect of saponin from Panax ginseng on immune function of lymphocytes in the elderly. Liu J, et al. **Mech Ageing Dev** 1995 Aug 31;83(1):43–53

Interrelationship of fever, immune response and aging in mice. Norman DC, et al. **Mech Ageing Dev** 1995 Apr 21; 80(1):53–67

The role of circulating immune complexes; antinuclear and rheumatoid factor autoantibodies in aging in Nigerians. Oyeyinka GO, et al. **Mech Ageing Dev** 1995 Nov 24; 85(2–3):73–81

Lipopolysaccharide-, granulocyte-monocyte colony stimulating factor and pentoxifylline-mediated effects on formyl-methionyl-leucine-phenylalanine-stimulated neutrophil respiratory burst in the elderly. Tortorella C, et al. **Microbios** 1996;85(344):189-98

Immunological effect of a synthetic growth hormone peptide on the growth performance in swine. Wang BS, et al. **Mol Immunol** 1996 May-Jun;33(7-8):609-14

The aging of hematopoietic stem cells. Morrison SJ, et al. **Nat Med** 1996 Sep;2(9):1011-6

Quantitative and qualitative changes in CD44 and MEL-14 expression by T cells in C57BL/6 mice during aging. Barrat F, et al. **Res Immunol** 1995 Jan;146(1):23-34

The effect of leucotrofina and BSA (bovine serum albumin) antigen on the ontogenetical capacity of antibody generation in chicken. Roman J, et al. **Rom J Physiol** 1993 Jul-Dec;30(3-4):193-7

Signals leading to the activation of NF-kappa B transcription factor are stronger in neonatal than adult T lymphocytes. Kilpinen S, et al. **Scand J Immunol** 1996 Jul;44(1):85-8

Oral tolerization leads to active suppression and bystander tolerance in adult rats while anergy dominates in young rats. Lundin BS, et al. **Scand J Immunol** 1996 Jan; 43(1):56-63

The self-reactive antibody repertoire of normal human serum IgM is acquired in early childhood and remains conserved throughout life. Mouthon L, et al. **Scand J Immunol** 1996 Sep;44(3):243-51

The aging immune system: primer and prospectus. Miller RA. **Science** 1996 Jul 5;273(5271):70-4 (77 ref.)

Intrathymic tolerance and age. Qian T, et al. **Transplant Proc** 1995 Dec;27(6):3391

Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Danenberg HD, et al. **Vaccine** 1995;13(15):1445-8

In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant. Powers DC, et al. **Vaccine** 1995 Oct;13(14):1330-5

[mmunity to diphtheria in the 4-70 year age group in Italy. Wirz M, et al. **Vaccine** 1995;13(8):771-3

Immunoregulatory effects of ginsenoside Rg1 in aged rats] Liu M, et al. **Yao Hsueh Hsueh Pao** 1995 Nov;30(11):818-23 (Eng. Abstr.) **(Chi)**

Levels of interleukin-2)IL-2 and tumor necrosis factor alpha (TNF-alpha) mRNA in aged rat spleen under physiological conditions and in septic shock: possible role of pidotimod in gene expression modulation] Arosio B, et al. **Drugs Exp Clin Res** 1993;19 Suppl:9-14 **(Ita)**

Immunologic correlates of morphine tolerance and diluted effect of naloxone in rats of various ages] Kaliuzhnyi LV, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):67-70 **(Rus)**

Age-related features of inflammatory and immune responses of the gastric mucosa in women with chronic gastritis] Gazizova RR, et al. **Patol Fiziol Eksp Ter** 1995 Oct-Dec; (4):32-4 (Eng. Abstr.) **(Rus)**

[The immune system characteristics during normal aging and in Alzheimer's disease] Koliaskina GI, et al. **Vestn Ross Akad Med Nauk** 1996;(4):19-23 (32 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Monoamine oxidase-B-positive granular structures in the hippocampus of aged senescence-accelerated mouse (SAMP8). Nakamura S, et al. **Acta Neuropathol (Berl)** 1995; 90(6):626-32

Serum lipids and apolipoproteins from 1 to 15 years: changes with age and puberty, and relationships with diet, parental cholesterol and family history of ischaemic heart disease. Boulton TJ, et al. **Acta Paediatr** 1995 Oct;84(10):1113-8

Band 3 and its peptides during aging, radiation exposure, and Alzheimer's disease: alterations and self-recognition. Kay MM, et al. **Adv Exp Med Biol** 1995;383:167-93

Increased expression and specific localization of cathepsins E and D in vulnerable brain regions of aged and postischemic rats. Nakanishi H, et al. **Adv Exp Med Biol** 1995;362:335-9

The production of TNF, IL-1 and IL-6 in cutaneous tissues during maturation and aging. Stosic-Grujicic SS, et al. **Adv Exp Med Biol** 1995;371A:411-4

Effects of different types of anti-aging dietary restrictions on age-related atrial natriuretic factor changes: an immunochemical and ultrastructural study. Cavallini G, et al. **Aging (Milano)** 1995 Apr;7(2):117-22

Zinc, human diseases and aging. Fabris N, et al. **Aging (Milano)** 1995 Apr;7(2):77-93 (172 ref.)

The effect of aging on oro-cecal transit time in normal subjects and patients with gallstone disease. Pilotto A, et al. **Aging (Milano)** 1995 Aug;7(4):234-7

Effect of age on cardiac norepinephrine release in the female rat. Snyder DL, et al. **Aging (Milano)** 1995 Aug;7(4):210-7

Water fraction of lumbar vertebral bone marrow estimated from chemical shift misregistration on MR imaging: normal variations with age and sex. Ishijima H, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):355-8

Energy requirements from infancy to adulthood. Butte NF, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1047S-1052S

Body composition, body fat distribution, and resting metabolic rate in healthy centenarians. Paolisso G, et al. **Am J Clin Nutr** 1995 Oct;62(4):746-50

Influence of age on energy requirements. Roberts SB, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1053S-1058S

Evaluation of four methods for determining energy intake in young and older women: comparison with doubly labeled water measurements of total energy expenditure. Sawaya AL, et al. **Am J Clin Nutr** 1996 Apr;63(4):491-9

Relations among aging, antioxidant status, and cataract. Taylor A, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1439S-1447S (80 ref.)

Activation of nitric oxide synthesis in vascular smooth muscle cells and macrophages during development in spontaneously hypertensive rats. Xiao J, et al. **Am J Hypertens** 1996 Apr;9(4 Pt 1):377-84

Concerns with chronic analgesic therapy in elderly patients. Gloth FM 3rd. **Am J Med** 1996 Jul 31;101(1A):19S-24S (39 ref.)

Age-related changes in perimicrovascular protein distribution. Barber BJ, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1213-20

Expression of protein kinase C isoforms during cardiac ventricular development. Clerk A, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H1087-97

Expression of aquaporins-1 and -2 during nephrogenesis and in autosomal dominant polycystic kidney disease. Devuyst O, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F169-83

No effect of aging on skeletal muscle insulin-like growth factor mRNAs. Hamilton MT, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1183-8

Reduced threshold for myocardial cell calcium intolerance in the rat heart with aging. Hano O, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1607-12

Renal expression of osteopontin and alkaline phosphatase correlates with BUN levels in aged rats. Liang CT, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):F398-404

Retinoids, retinoic acid receptors, and cytoplasmic retinoid binding proteins in perinatal rat lung fibroblasts. McGowan SE, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):L463-72

Reciprocal regulation of cardiac Na-K-ATPase and Na/Ca exchanger: hypertension, thyroid hormone, development. Magyar CE, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C675-82

Age-dependent reduction in insulin secretion and insulin mRNA in isolated islets from rats. Perfetti R, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):E983-90

Effect of aging on the metabolism of phosphorus and 1,25-dihydroxyvitamin D in healthy men. Portale AA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E483-90

Characterization of Ca(2+)-release channels in fetal and adult rat hearts. Ramesh V, et al. **Am J Physiol** 1995 Sep; 269(3 Pt 2):H778-82

Myocardial adenosine A1 and A2 receptor activities during juvenile and adult stages of development. Sawmiller DR, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H235-43

Lung epithelial Na channel subunits are differentially regulated during development and by steroids. Tchepichev S, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C805-12

Persistence of metabolic consequences in the progeny of rats fed a HC formula in their early postnatal life. Vadlamudi S, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):E731-8

Differences in calcium kinetics between adolescent girls and young women. Wastney ME, et al. **Am J Physiol** 1996 Jul; 271(1 Pt 2):R208-16

Rat intestinal and hepatic ferritin subunit expression during development and after dietary iron feeding. Yeh KY, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G498-505

Tenascin in rat lung development: in situ localization and cellular sources. Zhao Y, et al. **Am J Physiol** 1995 Oct; 269(4 Pt 1):L482-91

Expression of transforming growth factor-beta type II receptor in rat lung is regulated during development. Zhao Y, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):L419-26

Quinine pharmacokinetics in young children with severe malaria. van Hensbroek MB, et al. **Am J Trop Med Hyg** 1996 Mar;54(3):237-42

Complete primary sequence of equine cartilage link protein deduced from complementary DNA. Dudhia J, et al. **Am J Vet Res** 1995 Jul;56(7):959-65

Postnatal maturation of tissue kallikrein-producing cells (connecting tubule cells) in the rat kidney: a morphometric and immunohistochemical study. Velarde V, et al. **Anat Embryol (Berl)** 1995 Nov;192(5):407-14

Aging alters the pharmacokinetics of pyridostigmine. Stone JG, et al. **Anesth Analg** 1995 Oct;81(4):773-6

Apoptosis and oxidative stress in the aging brain. Adams JD, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:135-51

Effects of aging on prejunctional control of neurotransmission in the rat. Docherty JR. **Ann N Y Acad Sci** 1996 Jun 15;786:264-73

Alteration of mitochondrial F0F1 ATP synthase during aging. Possible involvement of oxygen free radicals. Guerrieri F, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:62-71

Role of free radicals in and around vascular endothelial cells in the mechanism of aging. Inoue M, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:224-32

Leupeptin causes an accumulation of lipofuscin-like substances and other signs of aging in kidneys of young rats: further evidence for the protease inhibitor model of aging. Ivy GO, et al. **Ann N Y Acad Sci** 1996 Jun 15; 786:12-23

Increased sensitivity to oxidative stress and the loss of muscarinic receptor responsiveness in senescence. Joseph JA, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:112-9 (47 ref.)

The ATPase module and the process of cellular immortalization. Krgoll J. **Ann N Y Acad Sci** 1996 Jun 15;786:57-61 (36 ref.)

Free intracellular calcium in aging and Alzheimer's disease. Müller WE, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:305-20 (55 ref.)

Age-dependent impairment of mitochondrial function in rat heart tissue. Effect of pharmacological agents. Paradies G, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:252-63

Melatonin in the context of the free radical theory of aging. Reiter RJ, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:362-78 (73 ref.)

Simultaneous increase of mitochondrial DNA deletions and lipid peroxidation in human aging. Wei YH, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:24-43

Critical evaluation of the free radical theory of aging. A proposal for the oxidative stress hypothesis. Yu BP, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:1-11 (44 ref.)

Mitochondrial aging and lipoperoxidative products. Yu BP, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:44-56

Pharmacokinetics and pharmacodynamics of glyburide in young and elderly patients with non-insulin-dependent diabetes mellitus. Jaber LA, et al. **Ann Pharmacother** 1996 May;30(5):472-5

Pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in the neonatal macaque (Macaca nemestrina). Keller RD, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2829-31

Pyrraline ether crosslinks as a basis for protein crosslinking by the advanced Maillard reaction in aging and diabetes. Nagaraj RH, et al. **Arch Biochem Biophys** 1996 Jan 15; 325(2):152-8

An amino acid derived from aldol crosslink of elastin and collagen: structure, distribution, aging, and two models of hyperglycemia. Nakamura F, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):167-73

Age-related shortening of poly(A) tail of albumin mRNA. Shah GN, et al. **Arch Biochem Biophys** 1995 Dec 1; 324(1):105-10

Sex differences in human brain morphometry and metabolism: an in vivo quantitative magnetic resonance imaging and positron emission tomography study on the effect of aging. Murphy DG, et al. **Arch Gen Psychiatry** 1996 Jul;53(7):585-94

Effect of age on the pattern of short-term albumin uptake by the rabbit aortic wall near intercostal branch ostia. Sebkhi A, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb; 16(2):317-27

Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. Sakata N, et al. **Atherosclerosis** 1995 Jul;116(1):63-75

Atherogenic change in the thoracic aorta of the senescence-accelerated mouse. Yagi K, et al. **Atherosclerosis** 1995 Dec;118(2):233-6

Expression of multiple c-kit receptor messenger ribonucleic acid transcripts during postnatal development of the rat testis. Ali S, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):104-12

Age-related changes in the activities of antioxidant enzymes and lipid peroxidation status in ventral and dorsolateral prostate lobes of noble rats. Ghatak S, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):362-7

Progressive hyperphosphorylation of neurofilament heavy subunits with aging: possible involvement in the mechanism of neurofilament accumulation. Gou JP, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):368-76

Effect of aging on regulation of sdi-1 in rat hepatocytes. Kitano S, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):122-7

Age-dependent changes of NO synthase activity in the rat brain. Mollace V, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):822-7

Glycated Cu,Zn-superoxide dismutase in rat lenses: evidence for the presence of fragmentation in vivo. Takata I, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):243-8

Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage. Dudhia J, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):933-40

Major changes in complex I activity in mitochondria from aged rats may not be detected by direct assay of NADH:coenzyme Q reductase. Genova ML, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):105-9

Effects of aging on the synthesis of antithrombin-binding sites on heparin chains and heparan sulphate chains in the rat. Horner AA. **Biochem J** 1995 Nov 15;312 (Pt 1):245-9

Transient activation of mitochondrial translation regulates the expression of the mitochondrial genome during mammalian mitochondrial differentiation. Ostronoff LK, et al. **Biochem J** 1996 May 15;316 (Pt 1):183-91

Apolipoprotein E is increased in aged rat kidney. Chou SC, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):847-54

Cu/Zn-superoxide dismutase and glutathione peroxidase during aging. de Haan JB, et al. **Biochem Mol Biol Int** 1995 May;35(6):1281-97

Liver peroxisomal fatty acid oxidizing system during aging in control and clofibrate-treated mice. Périchon R, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):475-80

Regulation of rat olfactory glutathione S-transferase expression. Investigation of sex differences, induction, and ontogenesis. Banger KK, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):801-8

Expression of 12-imidazoline sites in rat prostate. Effect of

castration and aging. Regunathan S, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):455–9

Ageing is associated in females with a decline in the content and activity on the b–c1 complex in skeletal muscle mitochondria. Boffoli D, et al. **Biochim Biophys Acta** 1996 Jan 17;1315(1):66–72

Age–related changes in apolipoprotein A–I expression. Shah GN, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):277–82

Effect of glycation of albumin on its binding to renal brush–border membrane vesicles: influence of aging in rats. Verbeke P, et al. **Biochim Biophys Acta** 1996 Jun 13; 1282(1):93–100

Differential patterns of antioxidant enzyme mRNA expression in guinea pig lung and liver during development. Yuan HT, et al. **Biochim Biophys Acta** 1996 Mar 1; 1305(3):163–71

Ontogeny of rat myocardial A1 adenosine receptors. Cothran DL, et al. **Biol Neonate** 1995;68(2):111–8

Molecular forms of atrial natriuretic peptide in atria and plasma from fetal and adult female rats. Deloof S, et al. **Biol Neonate** 1995;68(4):292–300

Biochemical and morphological changes in the developing kidney. Kahane VL, et al. **Biol Neonate** 1995;68(2):141–52

Lipoprotein lipase activity in developing rat brain areas. Nuñez M, et al. **Biol Neonate** 1995;68(2):119–27

Variation in the glycosidase activity of human lens during aging and with advance of senile cataract. Kamei A. **Biol Pharm Bull** 1995 Oct;18(10):1450–3

Difference of mineral contents in human intervertebral disks and its age–related change. Tohno S, et al. **Biol Trace Elem Res** 1996 May;52(2):117–24

Mineral evolution of bone. Ravaglioli A, et al. **Biomaterials** 1996 Mar;17(6):617–22

Protein binding of sotalol enantiomers in young and elderly human and rat serum using ultrafiltration. Carr RA, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):705–12

The effect of aging on the pharmacokinetics of nalbuphine in rabbits. Ho ST, et al. **Biopharm Drug Dispos** 1995 Nov; 16(8):695–703

Effect of age on MAC in humans: a meta–analysis. Mapleson WW. **Br J Anaesth** 1996 Feb;76(2):179–85

The effects of age and gender on the pharmacokinetics of tenidap sodium in patients with rheumatoid arthritis and osteoarthritis. Caldwell JR, et al. **Br J Clin Pharmacol** 1995; 39 Suppl 1:3S–9S

Recovery of human skin collagen synthesis after short–term topical corticosteroid treatment and comparison between young and old subjects. Haapasaari KM, et al. **Br J Dermatol** 1996 Jul;135(1):65–9

Age–related decrease in the inductability of heat shock protein 72 in normal human skin. Muramatsu T, et al. **Br J Dermatol** 1996 Jun;134(6):1035–8

Differential effect of age on metabolisable energy content of high protein–low energy and low protein–high energy diets in young broiler chicks. Bartov I. **Br Poult Sci** 1995 Sep;36(4):631–43

Reduced binding of oxytocin in the rat brain during aging. Arsenijevic Y, et al. **Brain Res** 1995 Nov 6;698(1–2):275–9

Decrease in cytosolic Aspartyl–aminopeptidase but not in Alanyl–aminopeptidase activity in the frontal cortex of the aged rat. Iribar C, et al. **Brain Res** 1995 Jul 31; 687(1–2):211–3

Fast axonal transport rates are unchanged in 6– and 24–month F344 rats. Jacob JM. **Brain Res** 1995 Nov 13;699(1):154–6

Distribution of glial fibrillary acidic protein (GFAP) in the cochlear nucleus of adult and aged rats. Jalenques I, et al. **Brain Res** 1995 Jul 24;686(2):223–32

Testosterone effects on vasotocinergic innervation of sexually dimorphic medial preoptic nucleus and lateral septum during aging in male quail. Panzica GC, et al. **Brain Res** 1996 Mar 18;712(2):190–8

Regulation of extracellular adenosine levels in the striatum of aging rats. Pazzagli M, et al. **Brain Res** 1995 Jun 26; 684(1):103–6

Influence of age on the clearance of K+ from the extracellular space of rat hippocampal slices. Roberts EL Jr, et al. **Brain Res** 1996 Feb 5;708(1–2):16–20

Age–dependent and region–specific differences in the distribution of trace elements in 7 brain regions of Long–Evans Cinnamon (LEC) rats with hereditary abnormal copper metabolism. Saito T, et al. **Brain Res** 1995 Oct 16;695(2):240–4

Distribution of myelin lipid antigens in adult and developing rat spinal cord. Schiff R, et al. **Brain Res** 1995 Jul 24; 686(2):143–9

Cyclic changes in the release of norepinephrine and dopamine in the medial basal hypothalamus: effects of aging. ThyagaRajan S, et al. **Brain Res** 1995 Aug 14;689(1):122–8

Effects of age on messenger RNA expression of glucocorticoid, thyroid hormone, androgen, and estrogen receptors in postmortem human hippocampus. Tohgi H, et al. **Brain Res** 1995 Nov 27;700(1–2):245–53

Chronic elevation of S100 beta protein does not alter APP mRNA expression or promote beta–amyloid deposition in the brains of aging transgenic mice. Yao J, et al. **Brain Res** 1995 Dec 8;702(1–2):32–6

Developmental changes of apolipoprotein E immunoreactivity in Down syndrome brains. Arai Y, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):228–32

Calmodulin, calbindin–D28k, calretinin and neurocalcin in rat olfactory bulb during postnatal development. Bastianelli E, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):224–7

Effect of kainic acid–induced status epilepticus on inositol–trisphosphate and seizure–induced brain damage in mature and immature animals. Carmant L, et al. **Brain Res Dev Brain Res** 1995 Oct 27;89(1):67–72

Regulation by nerve growth factor of neuropeptide phenotypes in primary cultured sensory neurons prepared from aged as well as adult mice. Jiang ZG, et al. **Brain Res Dev Brain Res** 1995 Dec 21;90(1–2):190–3

Developmental profile of non–heme iron distribution in the rat brain during ontogenesis. Moos T. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):203–13

Glycogenolytic response of primary chick and mouse cultures of astrocytes to noradrenaline across development. O'Dowd BS, et al. **Brain Res Dev Brain Res** 1995 Sep 29; 88(2):220–3

Regional cerebral metabolic consequences of bilirubin in rat depend upon post–gestational age at the time of hyperbilirubinemia. Roger C, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):194–202

Ontogenetic development of histamine receptor subtypes in rat brain demonstrated by quantitative autoradiography. Ryu JH, et al. **Brain Res Dev Brain Res** 1995 Jul 14; 87(2):101–10

Evidence for dopamine receptor pruning between adolescence and adulthood in striatum but not nucleus accumbens. Teicher MH, et al. **Brain Res Dev Brain Res** 1995 Nov 21;89(2):167–72

Functional expression of voltage dependent sodium channels in Xenopus oocytes injected with mRNA from neonatal or adult rat brain. Virginio C, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):153–9

Age–related mu–, delta–and kappa–opioid ligands in respiratory–related brain regions of piglets: effect of prenatal cocaine. Zhang C, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):188–93

Changes in expression of lymphocyte amyloid precursor protein mRNA isoforms in normal aging and Alzheimer's disease. Ebstein RP, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):260–8

Altered expression of gamma 2L and gamma 2S GABAA receptor subunits in the aging rat brain. Gutiérrez A, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):91–102

Elevated AP–1 transcription factor DNA binding activity at the onset of functional plasticity during development of rat sensory cortical areas. Kaminska B, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):295–304

Developmental expression in the mouse nervous system of the p493F12 SAP kinase. Martin JH, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):47–57

Increased expression of serotonin transporter messenger RNA in raphe neurons of the aged rat. Meister B, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):87–96

Regulation of actin and tubulin gene expression by thyroid hormone during rat brain development. Poddar R, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):111–8

Synchronous patchy pattern of gene expression for adenylyl cyclase and phosphodiesterase but discrete expression for G–protein in developing rat striatum. Sakagami H, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):185–91

Variation of brain and serum cholinesterase activity with age in wild small mammals. Fishwick SK, et al. **Bull Environ Contam Toxicol** 1996 Apr;56(4):604–11

Bioaccumulation of HCH isomers in different tissues of young and old rats: a comparison. Siddiqui MK, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):896–902

An age–related decrease in the concentration of insulin–like growth factor binding protein–5 in human cortical bone. Nicolas V, et al. **Calcif Tissue Int** 1995 Sep;57(3):206–12

Gender–specific and developmental differences in protein kinase C isozyme expression in rat liver. Zangar RC, et al. **Carcinogenesis** 1995 Oct;16(10):2593–7

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Pitt B, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):693–700 (80 ref.)

Nitric oxide and superoxide anion production decrease with age in resident and activated rat peritoneal macrophages. Alvarez E, et al. **Cell Immunol** 1996 Apr 10;169(1):152–5

Aging does not affect steady–state expression of the Na+/Ca2+ exchanger in rat brain. Colvin RA, et al. **Cell Mol Neurobiol** 1996 Feb;16(1):11–9

Alterations of subtypes of cardiac adrenoceptors in old rat. Yu GS, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep; 16(5):452–4

Magnesium cardioplegia enhances mRNA levels and the maximal velocity of cytochrome oxidase I in the senescent myocardium during global ischemia. Faulk EA, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II405–12

Age–related changes in amounts and concentrations of collagen and elastin in normotensive human thoracic aorta. Cattell MA, et al. **Clin Chim Acta** 1996 Feb 9;245(1):73–84

N–methyladrenaline: age–dependent urinary excretion, perinatal organ content and relation with 'classical' catecholamines. Kema IP, et al. **Clin Chim Acta** 1995 Jul 14;238(2):137–50

Age–related changes in cerebral and peripheral monoamine contents in stroke–prone spontaneously hypertensive rats. Uchida T, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S80–2

The pharmacokinetics of zileuton in healthy young and elderly volunteers. Braeckman RA, et al. **Clin Pharmacokinet** 1995;29 Suppl 2:42–8

Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes. Fruncillo R, et al. **Clin Pharmacol Ther** 1996 Jun;59(6):603–12

Carbachol–regulation of the expression of alpha i1–subunit of Gi and inositol–[1,4,5]–trisphosphate receptor in brain samples obtained from neonatal and adult rats. Singh AK. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):205–13

Age–related changes of glycosidases in human retinal pigment epithelium. Cingle KA, et al. **Curr Eye Res** 1996 Apr;15(4):433–8

Further studies on the dynamic changes of glutathione and protein–thiol mixed disulfides in H2O2 induced cataract in rat lenses: distributions and effect of aging. Lou MF, et al. **Curr Eye Res** 1995 Oct;14(10):951–8

Menadione–dependent alpha glycerophosphate and succinate dehydrogenases in the developing canine retina. McLeod DS, et al. **Curr Eye Res** 1995 Sep;14(9):819–26

Regulation of insulin receptor mRNA splicing in rat tissues. Effect of fasting, aging, and diabetes. Vidal H, et al. **Diabetes** 1995 Oct;44(10):1196–201

Effect of 10% ethanol and sofalcone on prostaglandin E2 content, mucus gel thickness, and experimental ulcers in the stomach of developing rats. Tabata M, et al. **Digestion** 1996;57(1):47–53

Drug therapy of non–insulin–dependent diabetes mellitus in the elderly. Mooradian AD. **Drugs** 1996 Jun;51(6):931–41 (57 ref.)

P–glycoprotein expression and regulation. Age–related changes and potential effects on drug therapy. Gupta S. **Drugs Aging** 1995 Jul;7(1):19–29 (81 ref.)

ACE inhibitors. Differential use in elderly patients with hypertension. Israili ZH, et al. **Drugs Aging** 1995 Nov; 7(5):355–71 (225 ref.)

Recent advances in geriatric psychopharmacology. Naranjo CA, et al. **Drugs Aging** 1995 Sep;7(3):184–202 (85 ref.)

Pharmacokinetic optimisation of drug therapy in elderly patients. Parker BM, et al. **Drugs Aging** 1995 Jul;7(1):10–8 (38 ref.)

Effect of aging on insulin receptor, insulin receptor substrate–1, and phosphatidylinositol 3–kinase in liver and muscle of rats. Carvalho CR, et al. **Endocrinology** 1996 Jan;137(1):151–9

Characterization and identification of an adrenal age–related nonpolar fluorescent substance. Cheng B, et al. **Endocrinology** 1996 Jun;137(6):2447–56

Molecular cloning and expression of the relaxin–like factor from the mouse testis. Pusch W, et al. **Endocrinology** 1996 Jul;137(7):3009–13

Developmental expression of a candidate müllerian inhibiting substance type II receptor. Teixeira J, et al. **Endocrinology** 1996 Jan;137(1):160–5

Age related changes in biochemical markers of bone metabolism in horses. Price JS, et al. **Equine Vet J** 1995 May;27(3):201–7

Relationships between muscle carnitine, age and oxidative status. Starling RD, et al. **Eur J Appl Physiol** 1995; 71(2–3):143–6

Protein requirements of elderly people. Campbell WW, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S180–3; discussion S183–5 (8 ref.)

The pharmacokinetics of granisetron, a 5–HT3 antagonist in healthy young and elderly volunteers [letter] Allen A, et al. **Eur J Clin Pharmacol** 1995;48(6):519–20

Age–related changes in the density of muscarinic cholinergic M1 and M2 receptor subtypes in pyramidal neurons of the rat hippocampus. Amenta F, et al. **Eur J Histochem** 1995; 39(2):107–16

Differential expression patterns of five acetylcholine receptor subunit genes in rat muscle during development. Kues WA, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1376–85

Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Zafra F, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1342–52

Aging of the human endometrium: peri–implantation phase endometrium does not show any age–dependent variation in lectin binding. Noci I, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):11–21

Effects of ageing and adrenergic stimulation on alpha 1– and beta–adrenoceptors and phospholipid fatty acids in rat heart. Benediktsdóttir VE, et al. **Eur J Pharmacol** 1995 May 26;289(3):419–27

Oxygen supply and ion homeostasis of the respiratory network in the in vitro perfused brainstem of adult rats. Morawietz G, et al. **Exp Brain Res** 1995;106(2):265–74

IGF–I and insulin receptors in bovine skeletal muscle: comparisons of different developmental ages, two different genotypes and various individual muscles. Boge A, et al. **Exp Clin Endocrinol Diabetes** 1995;103(2):99–104

The role of "invertors" (intracellular activators) in age–related changes in cell response to hormones. Frolkis VV. **Exp Gerontol** 1995 May–Aug;30(3–4):401–14

Semiconduction of proteins as an attribute of the living state: the ideas of Albert Szent–Györgyi revisited in light of the recent knowledge regarding oxygen free radicals. Nagy IZ. **Exp Gerontol** 1995 May–Aug;30(3–4):327–35

Oxygen free radicals, melatonin, and aging. Pierrefiche G, et al. **Exp Gerontol** 1995 May–Aug;30(3–4):213–27 (75 ref.)

Effect of age on the fatty acid composition of phospholipids in human lymphocytes. Ponnappan U, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):125–33

Synthesis, modifications, and turnover of proteins during aging. Rattan SI. **Exp Gerontol** 1996 Jan-Apr;31(1-2):33-47 (88 ref.)

Increased expression of cathepsins E and D in reactive microglial cells associated with spongiform degeneration in the brain stem of senescence-accelerated mouse. Amano T, et al. **Exp Neurol** 1995 Dec;136(2):171-82

Mitochondrial glutathione oxidation correlates with age-associated oxidative damage to mitochondrial DNA. de la Asuncion JG, et al. **FASEB J** 1996 Feb;10(2):333-8

Down-regulation of mitochondrial mRNAs in the mdx mouse model for Duchenne muscular dystrophy. Gannoun-Zaki L, et al. **FEBS Lett** 1995 Nov 20; 375(3):268-72

Changes in the histidine residues of Cu/Zn superoxide dismutase during aging. Maria CS, et al. **FEBS Lett** 1995 Oct 23;374(1):85-8

Accumulation of nitrotyrosine on the SERCA2a isoform of SR Ca-ATPase of rat skeletal muscle during aging: a peroxynitrite-mediated process? Viner RI, et al. **FEBS Lett** 1996 Feb 5;379(3):286-90

Evidence for diminished midcycle ovarian androgen production in older reproductive aged women. Mushayandebvu T, et al. **Fertil Steril** 1996 Apr;65(4):721-3

Effect of liver cirrhosis and age on the glutathione concentration in the plasma, erythrocytes, and gastric mucosa of man. Loguercio C, et al. **Free Radic Biol Med** 1996;20(3):483-8

Restoration of brain protein synthesis in mature and aged rats by a DA agonist, piribedil. Bustany P, et al. **Fundam Clin Pharmacol** 1995;9(5):458-68

Comparison of the ontogenesis of thyroid hormones, growth hormone, and insulin-like growth factor-I in ad libitum and food-restricted (altricial) European starlings and (precocial) Japanese quail. Schew WA, et al. **Gen Comp Endocrinol** 1996 Mar;101(3):304-16

Immunohistochemical identification and morphometric study of ACTH cells of mink (Mustela vison) during growth and different stages of sexual activity in the adult. Vidal S, et al. **Gen Comp Endocrinol** 1995 Oct;100(1):18-26

Renal aging change of alpha 1-adrenoceptor in Wistar rats. Moriyama N, et al. **Gen Pharmacol** 1995 Mar;26(2):347-51

Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Cavelier L, et al. **Genomics** 1995 Sep 1;29(1):217-24

Principles to optimize drug treatment in the depressed elderly: practical pharmacokinetics and drug interactions. Cohen LJ. **Geriatrics** 1995 Oct;50 Suppl 1:S32-40 (33 ref.)

Reduced aerobic metabolic efficiency in postischemic myocardium dysfunction in rats: role of aging. Abete P, et al. **Gerontology** 1995;41(4):187-94

Diet, not aging, causes skeletal muscle insulin resistance. Barnard RJ, et al. **Gerontology** 1995;41(4):205-11

Effects of aging and antioxidants on glucose transport in rat adipocytes. Moustafa SA, et al. **Gerontology** 1995; 41(6):301-7

Expression of neolactoglycolipids: sialosyl-, disialosyl-, O-acetyldisialosyl- and fucosyl- derivatives of neolactotetraosyl ceramide and neolactohexaosyl ceramide in the developing cerebral cortex and cerebellum. Chou DK, et al. **Glycoconj J** 1996 Apr;13(2):295-305

Modulation of cholinergic synaptic functions by sialylcholesterol. Tanaka Y, et al. **Glycoconj J** 1996 Apr; 13(2):321-6

Immunocytochemical evaluation of the blood-brain barrier to endogenous albumin in the olfactory bulb and pons of senescence-accelerated mice (SAM). Ueno M, et al. **Histochem Cell Biol** 1996 Mar;105(3):203-12

Activation of angiotensin-generating systems in the developing rat kidney. Yosipiv IV, et al. **Hypertension** 1996 Feb;27(2):281-6

Centrophenoxine activates acetylcholinesterase activity in hippocampus of aged rats. Sharma D, et al. **Indian J Exp Biol** 1995 May;33(5):365-8

Age-related alterations in collagen and total protein metabolism determined in cultured rat dermal fibroblasts: age-related trends parallel those observed in rat skin in vivo. Mays PK, et al. **Int J Biochem Cell Biol** 1995 Sep; 27(9):937-45

Influence of aging on the oxidative and conjugative metabolism of propranolol. Tateishi T, et al. **Int J Clin Pharmacol Res** 1995;15(3):95-101

Calretinin immunoreactivity in adrenal glands of developing, adult and ageing Sprague-Dawley rats. Afework M, et al. **Int J Dev Neurosci** 1995 Oct;13(6):515-21

Permeability function related to cerebral microvessel enzymes during ageing in rats. Agrawal A, et al. **Int J Dev Neurosci** 1996 Apr;14(2):87-91

Polysialylated neural cell adhesion molecule expression by neurons and astroglial processes in the rat dentate gyrus declines dramatically with increasing age. Fox GB, et al. **Int J Dev Neurosci** 1995 Nov;13(7):663-72

Age-related changes in antioxidant enzymes, superoxide dismutase, catalase, glutathione peroxidase and glutathione in different regions of mouse brain. Hussain S, et al. **Int J Dev Neurosci** 1995 Dec;13(8):811-7

Protein quality and urea kinetics in prepubertal Chilean schoolboys. Bickerton AS, et al. **Int J Food Sci Nutr** 1996 Jan;47(1):61-70

Mechanical loading affects the synthesis of decorin and biglycan in intact immature articular cartilage in vitro. Visser Na, et al. **Int J Tissue React** 1994;16(5-6):195-203

Effect of age on superoxide dismutase activity of human trabecular meshwork. De La Paz MA, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1849-53

Growth hormone and aging change rat liver fatty acid binding protein levels. Singer SS, et al. **J Am Coll Nutr** 1996 Apr;15(2):169-74

Accuracy of equations to predict basal metabolic rate in older women. Taaffe DR, et al. **J Am Diet Assoc** 1995 Dec; 95(12):1387-92

Sequential changes in renal function tests in the old, old: results from the Bronx Longitudinal Aging Study [letter; comment] Drinka P. **J Am Geriatr Soc** 1995 Nov; 43(11):1321-2; discussion 1322-3. Comment on: J Am Geriatr Soc 1995 Apr;43(4):412-4.

Oxidative stress and aging: still a hypothesis [editorial; comment] Kritchevsky SB, et al. **J Am Geriatr Soc** 1996 Jul;44(7):873-5 (25 ref.). Comment on: J Am Geriatr Soc 1996 Jul;44(7):823-7.

Sequential changes in renal function tests in the old-old: results from the Bronx Longitudinal Aging Study [letter; comment] Marcus EL, et al. **J Am Geriatr Soc** 1995 Nov; 43(11):1322; discussion 1322-3. Comment on: J Am Geriatr Soc 1995 Apr;43(4):412-4.

Screening the older population for cobalamin (vitamin B12) deficiency. Stabler SP. **J Am Geriatr Soc** 1995 Nov; 43(11):1290-7 (47 ref.)

Free and protein-bound cobalamin absorption in healthy middle-aged and older subjects. van Asselt DZ, et al. **J Am Geriatr Soc** 1996 Aug;44(8):949-53

Peritoneal equilibration test results are different in infants, children, and adults. Mendley SR, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1309-12

The effects of aging on basement membrane in the testis. Richardson LL, et al. **J Androl** 1995 Mar-Apr;16(2):118-26

Gene expression in the aging brown Norway rat epididymis. Viger RS, et al. **J Androl** 1995 Mar-Apr;16(2):108-17

Effect of arginine and ornithine infusions on luteinizing hormone secretion in prepubertal ewes. Recabarren SE, et al. **J Anim Sci** 1996 Jan;74(1):162-6

Elucidation of factors associated with the maturity-related decline in degradability of big bluestem cell wall. Titgemeyer EC, et al. **J Anim Sci** 1996 Mar;74(3):648-57

HSP70 accumulation in tissues of heat-stressed rats is blunted with advancing age. Kregel KC, et al. **J Appl Physiol** 1995 Nov;79(5):1673-8

Estimation of arterial PCO2 in the elderly. St Croix CM, et al. **J Appl Physiol** 1995 Dec;79(6):2086-93

Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. Blackburn MR, et al. **J Biol Chem** 1996 Jun 21;271(25):15203-10

Molecular cloning and developmental expression of mouse p130, a member of the retinoblastoma gene family. Chen G, et al. **J Biol Chem** 1996 Apr 19;271(16):9567-72

Aging-dependent functional alterations of mitochondrial DNA (mtDNA) from human fibroblasts transferred into mtDNA-less cells. Laderman KA, et al. **J Biol Chem** 1996 Jul 5;271(27):15891-7

The spatio-temporal control of the expression of glutamine synthetase in the liver is mediated by its 5'-enhancer. Lie-Venema H, et al. **J Biol Chem** 1995 Nov 24; 270(47):28251-6

Age-related decline in mitogen-activated protein kinase activity in epidermal growth factor-stimulated rat hepatocytes. Liu Y, et al. **J Biol Chem** 1996 Feb 16; 271(7):3604-7

Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandins in the newborn. Peri KG, et al. **J Biol Chem** 1995 Oct 13;270(41):24615-20

Molecular cloning and characterization of a newly identified member of the cadherin family, PB-cadherin. Sugimoto K, et al. **J Biol Chem** 1996 May 10;271(19):11548-56

Regulation of hexokinase II gene expression by glucose flux in skeletal muscle. Tsao TS, et al. **J Biol Chem** 1996 Jun 21;271(25):14959-63

Age-dependent changes in the beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in human right atrium. Brodde OE, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):20-6

Responses to calcium and binding of 3H-nimodipine in the atrioventricular node, atria, and ventricles of mature and old male Fischer 344 rats. Kusumoto FM, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):348-53

Expression of hydrogen peroxide and glutathione metabolizing enzymes in human skin fibroblasts derived from donors of different ages. Keogh BP, et al. **J Cell Physiol** 1996 Jun;167(3):512-22

Metabolic response to tacrine (THA) and physostigmine in the aged rat brain. Bassant MH, et al. **J Cereb Blood Flow Metab** 1995 Nov;15(6):1093-102

Age dependency of changes in cerebral hemoglobin oxygenation during brain activation: a near-infrared spectroscopy study. Hock C, et al. **J Cereb Blood Flow Metab** 1995 Nov;15(6):1103-8

Cerebral metabolism following neonatal or adult hemineodecortication in cats: I. Effects on glucose metabolism using [14C]2-deoxy-D-glucose autoradiography. Hovda DA, et al. **J Cereb Blood Flow Metab** 1996 Jan;16(1):134-46

In vivo quantification of cerebral muscarinic receptors in normal human aging using positron emission tomography and [11C]tropanyl benzilate. Lee KS, et al. **J Cereb Blood Flow Metab** 1996 Mar;16(2):303-10

The metabolic topography of normal aging. Moeller JR, et al. **J Cereb Blood Flow Metab** 1996 May;16(3):385-98

Decreased bone formation and increased mineral dissolution during acute fasting in young women. Grinspoon SK, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3628-33

Effect of age on the intestinal absorption of vitamin D3-palmitate and nonesterified vitamin D2 in the term human infant. Hollis BW, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1385-8

Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. Vermeulen A, et al. **J Clin Endocrinol Metab** 1996 May; 81(5):1821-6

Activation of heat shock protein (hsp)70 and proto-oncogene expression by alpha1 adrenergic agonist in rat aorta with age. Chin JH, et al. **J Clin Invest** 1996 May 15; 97(10):2316-23

Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. Jilka RL, et al. **J Clin Invest** 1996 Apr 1; 97(7):1732-40

Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? Boos J, et al. **J Clin Oncol** 1995 Dec;13(12):2954-60

The age related amyloids: a growing family of unique biochemical substances. Cornwell GG 3rd, et al. **J Clin Pathol** 1995 Nov;48(11):984-9 (41 ref.)

Effects of aging on antipyrine clearance: predictive factors of metabolizing capacity. Jorquera F, et al. **J Clin Pharmacol** 1995 Sep;35(9):895-901

The lack of effect of aerobic exercise training on propranolol pharmacokinetics in young and elderly adults. Panton LB, et al. **J Clin Pharmacol** 1995 Sep;35(9):885-94

Effect of aging on atenolol pharmacokinetics and pharmacodynamics. Sowinski KM, et al. **J Clin Pharmacol** 1995 Aug;35(8):807-14

AMPA-selective glutamate receptor subtype immunoreactivity in the aged human hippocampal formation. Ikonomovic MD, et al. **J Comp Neurol** 1995 Aug 21;359(2):239-52

NADPH-diaphorase in the developing rat: lower brainstem and cervical spinal cord, with special reference to the trigemino-solitary complex. Takemura M, et al. **J Comp Neurol** 1996 Feb 19;365(4):511-25

Effects of physical exercise and aging on ascorbic acid and superoxide anion levels in peritoneal macrophages from mice and guinea pigs. De la Fuente M, et al. **J Comp Physiol [B]** 1995;165(4):315-9

Age and segmental differences in 5-hydroxytryptamine-induced hypersecretion in the pig small intestine. Grøndahl ML, et al. **J Comp Physiol [B]** 1996;166(1):21-9

Age-related endocrine deficiencies and fractures of the proximal femur. II implications of vitamin D deficiency in the elderly. Boonen S, et al. **J Endocrinol** 1996 Apr; 149(1):13-7 (57 ref.)

Age-related endocrine deficiencies and fractures of the proximal femur. I implications of growth hormone deficiency in the elderly. Boonen S, et al. **J Endocrinol** 1996 Apr;149(1):7-12 (72 ref.)

Differential regulation of plasma levels of insulin-like growth factors-I and -II by nutrition, age and growth hormone treatment in sheep. Hua KM, et al. **J Endocrinol** 1995 Dec; 147(3):507-16

Regulation of type 1 insulin-like growth factor (IGF) receptors and IGF-I mRNA by age and nutrition in ovine skeletal muscles. Oldham JM, et al. **J Endocrinol** 1996 Feb; 148(2):337-46

Altered polyamine biosynthesis with aging after massive proximal small bowel resection in rat. Sakamoto K, et al. **J Gastroenterol** 1996 Jun;31(3):338-46

Caloric restriction decreases age-dependent accumulation of the glycoxidation products, N epsilon-(carboxymethyl)lysine and pentosidine, in rat skin collagen. Cefalu WT, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):B337-41

The relationship of aging to endotoxin shock and to production of TNF-alpha. Chang HN, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):M220-2

Prolactin receptor gene expression in specific hypothalamic nuclei increases with age. Chiu S, et al. **J Gerontol A Biol Sci Med Sci** 1996 May;51(3):B220-4

Metabolic and hormonal changes induced by hypodermoclysis of glucose-saline solution in elderly patients. Dardaine V, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):M334-6

Brief dietary restriction increases skeletal muscle glucose transport in old Fischer 344 rats. Dean DJ, et al. **J Gerontol A Biol Sci Med Sci** 1996 May;51(3):B208-13

Training-induced enhancement of insulin action in human skeletal muscle: the influence of aging. Dela F, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):B247-52

Insulin stimulation of protein synthesis in rat skeletal muscle following resistance exercise is maintained with advancing age. Fluckey JD, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):B323-30

8-hydroxyguanine levels in nuclear DNA and its repair activity in rat organs associated with age. Hirano T, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):B303-7

Effects of aging on the regulation of intracellular pH in the

rat jejunum. Ikuma M, et al.
J Gerontol A Biol Sci Med Sci 1996 Sep;51(5):B346–53

Increased activation of EGF–receptor tyrosine kinase by EGF and TGF–alpha in the colonic mucosa of aged rats. Malecka–Panas E, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B60–5

Muscle protein turnover: methodological issues and the effect of aging. Nair KS. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:107–12 (26 ref.)

Oxidative status in senescence–accelerated mice. Park JW, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):B337–45

GnRH receptor site increase on the surface of cultured gonadotropes of senescent C57BL/6NNia mice. Parkening TA, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov; 50(6):B342–50

Molecular investigation of age–related changes in mouse endocrine pancreas. Perfetti R, et al.
J Gerontol A Biol Sci Med Sci 1996 Sep;51(5):B331–6

Effects of aging on energy requirements and the control of food intake in men. Roberts SB.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:101–6 (29 ref.)

Effects of age on energy expenditure and substrate oxidation during experimental overfeeding in healthy men. Roberts SB, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar; 51(2):B148–57

Effects of age on energy expenditure and substrate oxidation during experimental underfeeding in healthy men. Roberts SB, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar; 51(2):B158–66

Lipofuscin as a record of "rate of living" in an aquatic poikilotherm. Sheehy MR, et al.
J Gerontol A Biol Sci Med Sci 1995 Nov;50(6):B327–36

Effect of age and food restriction on alkaline protease activity in rat liver. Shibatani T, et al.
J Gerontol A Biol Sci Med Sci 1996 Mar;51(2):B175–8

Alteration of rat liver 20S proteasome activities by age and food restriction. Shibatani T, et al.
J Gerontol A Biol Sci Med Sci 1996 Sep;51(5):B316–22

Age–related changes in cardiac norepinephrine release: role of calcium movement. Snyder DL, et al.
J Gerontol A Biol Sci Med Sci 1995 Nov;50(6):B358–67

A measurement model of cortisol reactivity of healthy older adults. Préville M, et al.
J Gerontol B Psychol Sci Soc Sci 1996 Mar;51(2):P64–9

Postnatal development of NADPH–diaphorase/nitric oxide synthase positive nerve cells in the visual cortex of the rat. Lüth HJ, et al. **J Hirnforsch** 1995;36(3):313–28

Co–expression of vimentin and 19S–thyroglobulin in follicular cells located in the C–cell complex of dog thyroid gland. Kameda Y. **J Histochem Cytochem** 1995 Nov; 43(11):1097–106

Decreased epidermal lipid synthesis accounts for altered barrier function in aged mice. Ghadially R, et al.
J Invest Dermatol 1996 May;106(5):1064–9

Glycoproteins of the carcinoembryonic antigen (CEA) family are expressed in sweat and sebaceous glands of human fetal and adult skin. Metze D, et al. **J Invest Dermatol** 1996 Jan;106(1):64–9

Reciprocal changes in the postnatal expression of the sarcolemmal Na+–Ca(2+)–exchanger and SERCA2 in rat heart. Vetter R, et al. **J Mol Cell Cardiol** 1995 Aug; 27(8):1689–701

Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex. Galva MD, et al. **J Neural Transm Gen Sect** 1995; 101(1–3):83–94

Chronic treatment with the uncompetitive NMDA receptor antagonist memantine influences the polyamine and glycine binding sites of the NMDA receptor complex in aged rats. Bresink I, et al.
J Neural Transm Park Dis Dement Sect 1995;10(1):11–26

Astroglial cells express large amounts of GABAA receptor proteins in mature brain. Bureau M, et al. **J Neurochem** 1995 Nov;65(5):2006–15

alpha–Linolenic acid dietary deficiency alters age–related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. Delion S, et al. **J Neurochem** 1996 Apr;66(4):1582–91

Cloning of the alpha component of the chick ciliary neurotrophic factor receptor: developmental expression and down–regulation in denervated skeletal muscle. Ip FC, et al. **J Neurochem** 1995 Dec;65(6):2393–400

Detection and quantitation of perlecan mRNA levels in Alzheimer's disease and normal aged hippocampus by competitive reverse transcription–polymerase chain reaction. Maresh GA, et al. **J Neurochem** 1996 Sep; 67(3):1132–44

Chondroitin sulfate and chondroitin/keratan sulfate proteoglycans of nervous tissue: developmental changes of neurocan and phosphacan. Meyer–Puttlitz B, et al.
J Neurochem 1995 Nov;65(5):2327–37

The expression of two splice variants of metabotropic glutamate receptor subtype 5 in the rat brain and neuronal cells during development. Minakami R, et al.
J Neurochem 1995 Oct;65(4):1536–42

Differential regulation of hippocampal neurotrophins during aging in rats. Narisawa–Saito M, et al. **J Neurochem** 1996 Sep;67(3):1124–31

N–methyl–D–aspartate receptor proteins NR2A and NR2B are differentially distributed in the developing rat central nervous system as revealed by subunit–specific antibodies. Portera–Cailliau C, et al. **J Neurochem** 1996 Feb; 66(2):692–700

Diagnosis of fatal infantile defects of the mitochondrial respiratory chain: age dependence and postmortem analysis of enzyme activities. Majander A, et al. **J Neurol Sci** 1995 Dec;134(1–2):95–102

Transiently selective activation of phosphoinositide turnover in layer V pyramidal neurons after specific mGluRs stimulation in rat somatosensory cortex during early postnatal development. Bevilacqua JA, et al. **J Neurosci** 1995 Dec;15(12):7916–28

Developmental and regional expression of multifunctional Ca2+/calmodulin–dependent protein kinase isoforms in rat brain. Brocke L, et al. **J Neurosci** 1995 Oct;15(10):6797–808

Cloning and characterization of chi–1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family. Ciabarra AM, et al.
J Neurosci 1995 Oct;15(10):6498–508

Developmental and regional expression pattern of a novel NMDA receptor–like subunit (NMDAR–L) in the rodent brain. Sucher NJ, et al. **J Neurosci** 1995 Oct;15(10):6509–20

Co–localization of NG2 proteoglycan and PDGF alpha–receptor on O2A progenitor cells in the developing rat brain. Nishiyama A, et al. **J Neurosci Res** 1996 Feb 1;43(3):299–314

Neurons express ciliary neurotrophic factor mRNA in the early postnatal and adult rat brain. Seniuk–Tatton NA, et al. **J Neurosci Res** 1995 Aug 1;41(5):663–76

Dopamine transporters decrease with age. Volkow ND, et al. **J Nucl Med** 1996 Apr;37(4):554–9

Dietary polyunsaturated fatty acids and aging modulate glutathione–related antioxidants in rat liver. Christon R, et al. **J Nutr** 1995 Dec;125(12):3062–70

Hemicellulose does not affect iron bioavailability in chicks. Fly AD, et al. **J Nutr** 1996 Jan;126(1):308–16

Chronic protein deficiency differentially affects the kinetics of plasma proteins in young pigs. Jahoor F, et al.
J Nutr 1996 May;126(5):1489–95

Diet–induced nephrocalcinosis in female rats is irreversible and is induced primarily before the completion of adolescence. Peterson CA, et al. **J Nutr** 1996 Jan; 126(1):259–65

The duration of medium–chain triglyceride feeding determines brush border membrane lipid composition and hydrolase activity in newly weaned rats. Wang H, et al. **J Nutr** 1996 May;126(5):1455–62

Age–related changes of alpha–tocopherol transfer protein expression in rat liver. Kim HS, et al.
J Nutr Sci Vitaminol (Tokyo) 1996 Feb;42(1):11–8

Interleukin–1 (IL–1) bioactivity and inhibition of IL–1 bioactivity in supernatant fluid from cultured microphthalmic (mi) mice teeth of different ages. Symons AL, et al. **J Oral Pathol Med** 1995 Sep;24(8):365–73

Weanling and adult rats differ in fatty acid and carnitine metabolism during sepsis. Linz DN, et al.
J Pediatr Surg 1995 Jul;30(7):959–65; discussion 966

Assessment of antipyrine kinetics from saliva or plasma: influence of age. Jorquera F, et al.
J Pharm Biomed Anal 1995 Aug;13(9):1141–5

Effects of ageing on the oral absorption of D–xylose in rats. Yuasa H, et al. **J Pharm Pharmacol** 1995 May;47(5):373–8

Effects of ageing on the oral absorption of D–xylose in rats: analysis of gastrointestinal disposition. Yuasa H, et al.
J Pharm Pharmacol 1995 Jul;47(7):576–80

The expression of alpha 1 adrenoceptor subtypes changes with age in the rat aorta. Gurdal H, et al.
J Pharmacol Exp Ther 1995 Dec;275(3):1656–62

An antisense oligodeoxynucleotide to glyceraldehyde–3–phosphate dehydrogenase blocks age–induced apoptosis of mature cerebrocortical neurons in culture. Ishitani R, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):447–54

Alterations in calcium antagonist receptors and calcium content in senescent brain and attenuation by nimodipine and nicardipine. Yamada S, et al.
J Pharmacol Exp Ther 1996 May;277(2):721–7

The effects of age on the release of adenine nucleosides and nucleotides from rat caudal artery. Hashimoto M, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):841–8

Lipid and antioxidant changes in semen of broiler fowl from 25 to 60 weeks of age. Kelso KA, et al.
J Reprod Fertil 1996 Mar;106(2):201–6

Hepatic expression of sex hormone–binding globulin associated with the postnatal surge of serum androgen–binding activity in the Djungarian hamster. Cates JM, et al. **J Steroid Biochem Mol Biol** 1995 Nov; 55(2):147–58

Effects of medroxyprogesterone acetate and beta–estradiol on interleukin–6 production from osteoblasts and bone marrow macrophages of Wistar rats of different ages. Futamura Y. **J Toxicol Sci** 1995 May;20(2):155–60

Age–related lectin histochemical changes in the porcine small intestine. Chae C, et al. **J Vet Med Sci** 1995 Oct;57(5):883–9

Effect of a novel prolyl endopeptidase inhibitor, JTP–4819, on thyrotropin–releasing hormone–like immunoreactivity in the cerebral cortex and hippocampus of aged rats. Shinoda M, et al. **Jpn J Pharmacol** 1995 Nov;69(3):273–6

Differential expression of complement components in human fetal and adult kidneys. Timmerman JJ, et al.
Kidney Int 1996 Mar;49(3):730–40

Induction of EGF–receptor tyrosine kinase during early reparative phase of gastric mucosa and effects of aging. Relan NK, et al. **Lab Invest** 1995 Nov;73(5):717–26

The calcium hypothesis of brain aging and neurodegenerative disorders: significance in diabetic neuropathy. Biessels G, et al. **Life Sci** 1996;59(5–6):379–87 (67 ref.)

Long term treatment with (–)deprenyl reduces the optimal dose as well as the effective dose range for increasing antioxidant enzyme activities in old mouse brain. Carrillo MC, et al. **Life Sci** 1996;59(13):1047–57

In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Chang L, et al. **Life Sci** 1996; 58(22):2049–56

Cytosolic Ca2+ buffering, a cell property that in some neurons markedly decreases during aging, has a protective effect against NMDA/nitric oxide–induced excitotoxicity. Clementi E, et al. **Life Sci** 1996;59(5–6):389–97

Posttranslational changes in band 3 in adult and aging brain following treatment with ergoloid mesylates, comparison to changes observed in Alzheimer's disease. Cover CC, et al. **Life Sci** 1996;58(8):655–64

Evidence for decline in intracellular calcium buffering in adrenergic nerves of aged rats. Duckles SP, et al.
Life Sci 1996;58(22):2029–35

Down–regulation of free intracellular calcium in dissociated brain cells of aged mice and rats. Hartmann H, et al.
Life Sci 1996;59(5–6):435–49

The influence of aging on whole body choline release and clearance. Jenden DJ, et al. **Life Sci** 1996;58(22):2003–9

Calcium homeostasis in aged neurones. Kirischuk S, et al.
Life Sci 1996;59(5–6):451–9

Aging–related increase in hippocampal calcium channels. Landfield PW. **Life Sci** 1996;59(5–6):399–404 (17 ref.)

Decreased plasma membrane calcium transport activity in aging brain. Michaelis ML, et al. **Life Sci** 1996; 59(5–6):405–12 (16 ref.)

Calcium signals in T lymphocytes from old mice. Miller RA.
Life Sci 1996;59(5–6):469–75 (22 ref.)

Adenosine attenuation of isoproterenol–stimulated adenylyl cyclase activity is enhanced with aging in the adult heart. Romano FD, et al. **Life Sci** 1996;58(6):493–502

Regulation of pituitary beta–endorphin secretion in aging rats: in vitro responsiveness to dopamine. Saland LC, et al. **Life Sci** 1995 Mar 17;56(17):1415–25

Cytosolic and mitochondrial calcium in synaptosomes during aging. Satrústegui J, et al. **Life Sci** 1996;59(5–6):429–34 (33 ref.)

Differential oxidative damage to mitochondrial proteins during aging. Agarwal S, et al. **Mech Ageing Dev** 1995 Nov 3;85(1):55–63

Age–related increase in peptidylarginine deiminase in the male rat pituitary. Akiyama K, et al. **Mech Ageing Dev** 1995 Jul 14;81(2–3):119–29

Age–related changes in cellular localization and enzymatic activities of cathepsins B, L and D in the rat trigeminal ganglion neuron. Amano T, et al. **Mech Ageing Dev** 1995 Sep 15;83(3):133–41

Age–dependent modifications in the metabolism of mevalonate pathway lipids in rat brain. Andersson M, et al. **Mech Ageing Dev** 1995 Nov 3;85(1):1–14

Suppression of age–related changes in mouse hippocampal CA3 nerve cells by a free radical scavenger. Asanuma A, et al. **Mech Ageing Dev** 1995 Aug 31;83(1):55–64

Lack of major changes in ATPase activity in mitochondria from liver, heart, and skeletal muscle of rats upon ageing. Barogi S, et al. **Mech Ageing Dev** 1995 Oct 13;84(2):139–50

Renin gene expression in the aging kidney: effect of sodium restriction. Corman B, et al. **Mech Ageing Dev** 1995 Sep 29;84(1):1–13

Changes in the levels of enzymes which modulate the antioxidant balance occur during aging and correlate with cellular damage. Cristiano F, et al. **Mech Ageing Dev** 1995 May 12;80(2):93–105

Restriction and functional changes of dopamine release in rat striatum from young adult and old rats. Dobrev D, et al. **Mech Ageing Dev** 1995 May 12;80(2):107–19

Total RNA, rRNA and poly(A)+RNA abundances during aging in Caenorhabditis elegans. Fabian TJ, et al.
Mech Ageing Dev 1995 Sep 15;83(3):155–70

Decreased capacity of aged mice to produce interferon–gamma in Legionella pneumophila infection. Fujio H, et al. **Mech Ageing Dev** 1995 Jul 14;81(2–3):97–106

Age–associated changes in mitogen–induced lymphoproliferation and lymphokine production in the long–lived brown–Norway rat: effect of caloric restriction. Goonewardene IM, et al. **Mech Ageing Dev** 1995 Sep 7; 83(2):103–16

Reduced ability of hypothalamic and pituitary extracts from old mice to stimulate thymulin secretion in vitro. Goya RG, et al. **Mech Ageing Dev** 1995 Sep 15;83(3):143–54

Age–related enhancement of tumor necrosis factor (TNF) production in mice. Han D, et al. **Mech Ageing Dev** 1995 Sep 29;84(1):39–54

Alterations with age of the T3–stimulated release of atrial natriuretic peptide and its effect on water and sodium metabolism in rats. Hwu CM, et al. **Mech Ageing Dev** 1995 Nov 24;85(2–3):161–70

Post–transcriptional regulation of the Na+/Ca2+ exchanger in aging rat heart. Janapati V, et al. **Mech Ageing Dev** 1995 Oct 27;84(3):195–208

Neurochemical changes related to ageing in the senescence–accelerated mouse brain and the effect of chronic administration of nimodipine. Kabuto H, et al.
Mech Ageing Dev 1995 Apr 21;80(1):1–9

Contents of D-lactate and its related metabolites as well as enzyme activities in the liver, muscle and blood plasma of aging rats. Kawase M, et al. **Mech Ageing Dev** 1995 Sep 29;84(1):55–63

Age-related changes in basic fibroblast growth factor-immunoreactive cells of rat substantia nigra. Lolova IS, et al. **Mech Ageing Dev** 1995 Aug 8;82(2–3):73–89

Differential effects of aging on binding sites of the activated NMDA receptor complex in mice. Magnusson KR. **Mech Ageing Dev** 1995 Oct 27;84(3):227–43

Depletion of cytosolic GSH decreases the ATP levels and viability of synaptosomes from aged mice but not from young mice. Martínez M, et al. **Mech Ageing Dev** 1995 Sep 29;84(1):77–81

On the role of the peroxisome in ontogeny, ageing and degenerative disease. Masters CJ, et al. **Mech Ageing Dev** 1995 May 12;80(2):69–83 (31 ref.)

Decreases in protective enzymes correlates with increased oxidative damage in the aging mouse brain. Mo JQ, et al. **Mech Ageing Dev** 1995 Jul 14;81(2–3):73–82

Changes in the respiratory chain complexes activities and in the mitochondrial DNA content during ageing in D. subobscura. Morel F, et al. **Mech Ageing Dev** 1995 Oct 27;84(3):171–81

Alterations of superoxide dismutase iso-enzyme activity, content, and mRNA expression with aging in rat skeletal muscle. Oh-Ishi S, et al. **Mech Ageing Dev** 1995 Sep 29; 84(1):65–76

Carnitine-acylcarnitine translocase activity in cardiac mitochondria from aged rats: the effect of acetyl-L-carnitine. Paradies G, et al. **Mech Ageing Dev** 1995 Oct 13;84(2):103–12

Age-dependent stimulation or inhibition of calcium release from bone cultures by interleukin-1 beta. Rabadjija L, et al. **Mech Ageing Dev** 1995 Jul 14;81(2–3):83–95

Age-related changes in the uptake and release of glutamate and aspartate in the mouse brain. Saransaari P, et al. **Mech Ageing Dev** 1995 Jul 14;81(2–3):61–71

Age related decline in cytokine induced nitric oxide synthase activation and apoptosis in cultured endothelial cells: minimal involvement of nitric oxide in the apoptosis. Sato I, et al. **Mech Ageing Dev** 1995 Jun 30;81(1):27–36

Human lymphocytes incubated in vitro share multiple characteristics with geriatric-derived lymphocytes: a potential in vitro model for aging? Tu KY, et al. **Mech Ageing Dev** 1995 Aug 8;82(2–3):105–28

The influence of aging on dimethylnitrosamine-demethylase enzyme kinetics in rat liver microsomes. Van Asten JG, et al. **Mech Ageing Dev** 1995 Aug 8;82(2–3):63–72

Defects in liver and muscle glycogen metabolism in neonatal and adult New Zealand obese mice. Thorburn A, et al. **Metabolism** 1995 Oct;44(10):1298–302

Levels of superoxide dismutase mRNA in rat lens: effect of aging. Devamanoharan PS, et al. **Mol Cell Biochem** 1995 Nov 22;152(2):175–8

Partial restoration of impaired alpha 1-adrenergic responsiveness in parotid cells of aged rats by S-adenosylmethionine treatment. Kowatch MA, et al. **Mol Cell Biochem** 1995 Jul 5;148(1):73–7

Overexpression of myogenin in muscles of transgenic mice: interaction with Id-1, negative crossregulation of myogenic factors, and induction of extrasynaptic acetylcholine receptor expression. Gundersen K, et al. **Mol Cell Biol** 1995 Dec;15(12):7127–34

cAMP-dependent protein kinase in cerebral microvessels in aging and Alzheimer disease. Cashman RE, et al. **Mol Chem Neuropathol** 1995 Dec;26(3):247–58

Age-dependent effects of t-BuOOH on glutathione disulfide reductase, glutathione peroxidase, and malondialdehyde in the brain. Chang ML, et al. **Mol Chem Neuropathol** 1995 Oct;26(2):95–106

Prenatal cocaine exposure revealed minimal postnatal changes in rat striatal dopamine D2 receptor sites and mRNA levels in the offspring. Stadlin A, et al. **Mol Neurobiol** 1995 Aug-Dec;11(1–3):67–76

Heat-shock protein 90 and ubiquitin: developmental regulation during myogenesis. Bornman L, et al. **Muscle Nerve** 1996 May;19(5):574–80

Non-linear accumulation of 8-hydroxy-2'-deoxyguanosine, a marker of oxidized DNA damage, during aging. Kaneko T, et al. **Mutat Res** 1996 May;316(5–6):277–85

A network theory of ageing: the interactions of defective mitochondria, aberrant proteins, free radicals and scavengers in the ageing process. Kowald A, et al. **Mutat Res** 1996 May;316(5–6):209–36

Altered in vivo catecholamine release in the hypothalamic paraventricular nucleus of the aged rat. Hastings JA, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):161–7

GDNF mRNA expression in normal postnatal development, aging, and in Weaver mutant mice. Blum M, et al. **Neurobiol Aging** 1995 Nov-Dec;16(6):925–9

Levels of NGF, p75NGFR and ChAT immunoreactivity in brain of adult and aged microencephalic rats. Cimino M, et al. **Neurobiol Aging** 1996 Jan-Feb;17(1):137–42

Alterations in alpha-adrenoceptors in aging intraocular hippocampal grafts. Eriksdotter Jönhagen M, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):633–8

Age-related changes in tetrahydrobiopterin and GTP-cyclohydrolase activity in the brain and adrenal gland of rats. Hossain MA, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):627–32

A reduced calorie-high fiber diet retards age-associated decreases in muscarinic receptor sensitivity. Joseph JA, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):607–12

In vivo assessment of striatal dopamine release in the aged male Fischer 344 rat. Kametani H, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):639–46

Age-related changes in brain and pituitary 5 alpha-reductase with finasteride (Proscar) treatment. Lephart ED. **Neurobiol Aging** 1995 Jul-Aug;16(4):647–50

Estrogen induction of glial heat shock proteins: implications for hypothalamic aging. Mydlarski MB, et al. **Neurobiol Aging** 1995 Nov-Dec;16(6):977–81

Monoamine oxidase isoenzymes in rat brain: differential changes during postnatal development but not aging. Rao K, et al. **Neurobiol Aging** 1995 Sep-Oct;16(5):833–6

Morphometric analysis of somatotrophs: effects of age and dietary restriction. Shimokawa I, et al. **Neurobiol Aging** 1996 Jan-Feb;17(1):79–86

Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains. Tekirian TL, et al. **Neurobiol Aging** 1996 Mar-Apr;17(2):249–57

Rat tail artery norepinephrine release: age and effect of mitochondrial blockade. Tsai H, et al. **Neurobiol Aging** 1995 Sep-Oct;16(5):773–7

Altered cell calcium regulation in synaptosomes and brain cells of the 30-month-old rat: prominent effects in hippocampus. Villalba M, et al. **Neurobiol Aging** 1995 Sep-Oct;16(5):809–16

VIP neurons in the human SCN in relation to sex, age, and Alzheimer's disease. Zhou JN, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):571–6

Limited proteolytic processing of the mature form of cathepsin D in human and mouse brain: postmortem stability of enzyme structure and activity. Compaine A, et al. **Neurochem Int** 1995 Oct-Nov;27(4–5):385–96

Diminution of preprosomatostatin-mRNA in cerebral cortex of the aged rat. Nilsson L, et al. **Neurochem Int** 1995 Dec; 27(6):481–7

Chloride ions, potassium stimulation and release of endogenous taurine from cerebral cortical slices from 3 day old and 3 month old mice. Oja SS, et al. **Neurochem Int** 1995 Oct-Nov;27(4–5):313–8

Effects of aging on regional rates of cerebral protein synthesis in the Sprague-Dawley rat: examination of the influence of recycling of amino acids derived from protein degradation into the precursor pool. Smith CB, et al. **Neurochem Int** 1995 Oct-Nov;27(4–5):407–16

Treatment with NMDA receptor antagonists does not affect developmental changes in NMDA receptor properties in vivo. Van Lookeren Campagne M, et al. **Neurochem Int** 1995 Oct-Nov;27(4–5):355–66

Effect of a ubiquinone-like molecule on oxidative energy metabolism in rat cortical synaptosomes at different ages. Curti D, et al. **Neurochem Res** 1995 Sep;20(9):1001–6

Endogenous excitatory amino acid release from brain slices and astrocyte cultures evoked by trimethyltin and other neurotoxic agents. Dawson R Jr, et al. **Neurochem Res** 1995 Jul;20(7):847–58

Expression of low-molecular-weight neurofilament (NF-L) mRNA during postnatal development of the mouse brain. Kure R, et al. **Neurochem Res** 1995 Jul;20(7):833–46

Changes of mitochondrial cytochrome c oxidase and FoF1 ATP synthase subunits in rat cerebral cortex during aging. Nicoletti VG, et al. **Neurochem Res** 1995 Dec; 20(12):1465–70

A comparison of beta-amyloid deposition in the medial temporal lobe in sporadic Alzheimer's disease, Down's syndrome and normal elderly brains. Armstrong RA, et al. **Neurodegeneration** 1996 Mar;5(1):35–41

Influence of age, gender, hormonal status and smoking habits on colonic transit time. Meier R, et al. **Neurogastroenterol Motil** 1995 Dec;7(4):235–8

Modification of A1 and A2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. Cunha RA, et al. **Neuroreport** 1995 Jul 31;6(11):1583–8

Age-related production of new granule cells in the adult dentate gyrus. Seki T, et al. **Neuroreport** 1995 Dec 15; 6(18):2479–82

Age-related changes in composition of transcription factor, AP-1 complex in the rat brain. Asanuma M, et al. **Neurosci Lett** 1995 Dec 8;201(2):127–30

N-Acetyltransferase mechanism for alpha-melanocyte stimulating hormone regulation in rat ageing. Cangemi L, et al. **Neurosci Lett** 1995 Dec 1;201(1):65–8

Modulation of hippocampal ACh release by chronic nicergoline treatment in freely moving young and aged rats. Carfagna N, et al. **Neurosci Lett** 1995 Sep 15; 197(3):195–8

Age related change in the vasoactive intestinal polypeptide-immunoreactive neurons in the cerebral cortex of aged rats. Cha CI, et al. **Neurosci Lett** 1995 Sep 1; 197(1):45–8

Fibroblast growth factor (FGF)-2 sense and antisense mRNA and FGF receptor type 1 mRNA are present in the embryonic and adult rat nervous system: specific detection by nuclease protection assay. Grothe C, et al. **Neurosci Lett** 1995 Sep 15;197(3):175–8

Sub-chronic cold stress reduces 5-HT1A receptor responsiveness in the old but not in the young rat. Manhães de Castro R, et al. **Neurosci Lett** 1996 Jan 12;203(1):21–4

Peripherally injected scopolamine differentially modulates acetylcholine release in vivo in the young and aged rats. Scali C, et al. **Neurosci Lett** 1995 Sep 15;197(3):171–4

Decrease in synapsin I staining in the hypogastric ganglion of aged rats. Warburton AL, et al. **Neurosci Lett** 1995 Jul 21;194(3):157–60

Distribution of metabotropic glutamate receptor 7 messenger RNA in the developing and adult rat brain. Kinzie JM, et al. **Neuroscience** 1995 Nov;69(1):167–76

Relation between age-related changes in hyper-emotionality and serotonergic neuronal activities in the rat limbic system. Li JW, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun;15(3):231–8

Free radicals and aging of anterior segment tissues of the eye: a hypothesis. Green K. **Ophthalmic Res** 1995;27 Suppl 1:143–9 (41 ref.)

Ontogeny of copper-zinc and manganese superoxide dismutase in the developing rat retina: immunohistochemical and immunochemical study. Oguni M, et al. **Ophthalmic Res** 1995;27(4):227–33

Expression of extracellular matrix in human mandibular condyle. Ishibashi H, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):402–14

Developmental changes of tachykinins in the hypothalamus and anterior pituitary of female Siberian hamsters from prepuberty to adulthood. Debeljuk L, et al. **Peptides** 1995; 16(5):827–31

Age-related changes in pharmacokinetic parameters of phenytoin after liver resection in rats. Nakashima E, et al. **Pharm Res** 1995 Oct;12(10):1530–4

Effect of aging on the kinetics of blood-brain barrier uptake of tryptophan in rats. Tang JP, et al. **Pharm Res** 1995 Jul; 12(7):1085–91

Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. McLeod HL, et al. **Pharmacogenetics** 1995 Oct;5(5):281–6

Developmental changes in skin collagen biosynthesis pathway in posthatch male and female chickens. Pines M, et al. **Poult Sci** 1996 Apr;75(4):484–90

[Leu5]enkephalin-encoding sequences are targets for a specific DNA-binding factor. Bakalkin G, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9024–8

Circuit-specific alterations of N-methyl-D-aspartate receptor subunit 1 in the dentate gyrus of aged monkeys. Gazzaley AH, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3121–5

Synaptic activation of NF-kappa B by glutamate in cerebellar granule neurons in vitro. Guerrini L, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9077–81

Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Lütiohann D, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9799–804

Vitamin E prevents oxidative modification of brain and lymphocyte band 3 proteins during aging. Poulin JE, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5600–3

Lack of the DNA repair protein O6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors. Silber JR, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6941–6

Antioxidant capacity in different tissues of young and old rats. Cao G, et al. **Proc Soc Exp Biol Med** 1996 Apr; 211(4):359–65

Effects of long-term treatment with a monoamine oxidase B inhibitor, selegeline (L-deprenyl), on amino acid transmitter systems in the ageing rat brain. Saransaari P, et al. **Proc West Pharmacol Soc** 1995;38:13–7

The effects of ageing on glycation and the interpretation of glycaemic control in Type 2 diabetes. Kilpatrick ES, et al. **QJM** 1996 Apr;89(4):307–12

Ionizing radiation-induced phosphorylation of RPA p34 is deficient in ataxia telangiectasia and reduced in aged normal fibroblasts. Cheng X, et al. **Radiother Oncol** 1996 Apr;39(1):43–52

Opposite changes in the content of oxytocin- and vasopressin-like immunoreactive peptides in the rat thymus during aging. Melis MR, et al. **Regul Pept** 1995 Nov 10; 59(3):335–40

Age-related increased 14C-arachidonic acid uptake by platelets in normal subjects. Canal J, et al. **Rev Esp Fisiol** 1995 Mar;51(1):37–41

Comparative study of the presence of oxidative stress in sportsmen in competition and aged people, as well as the preventive effect of selenium administration. Olinescu R, et al. **Rom J Intern Med** 1995 Jan-Jun;33(1–2):47–54

Lipofuscin and ceroid pigments in aging and brain pathology. A review. I. Biochemical and morphological properties. Riga D, et al. **Rom J Neurol Psychiatry** 1995 Apr-Jun; 33(2):121–36 (107 ref.)

Folic acid age correlation established on folates determinations in cell homogenates. Atanasiu V, et al. **Rom J Physiol** 1994 Jan-Dec;31(1–4):69–73

Increase in single L-type calcium channels in hippocampal neurons during aging. Thibault O, et al. **Science** 1996 May 17;272(5264):1017–20

Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Togashi H, et al. **Stroke** 1996 Mar;27(3):520–5; discussion 525–6

The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. Banfield CR, et al. **Ther Drug Monit** 1996 Feb; 18(1):19–29

Tissue distribution and developmental expression of type XVI collagen in the mouse. Lai CH, et al. **Tissue Cell** 1996 Apr; 28(2):155–64

Changes in nitric oxide synthase activities in the cerebellum during development and aging of C57BL/6 mice. Tsukada M, et al. **Tohoku J Exp Med** 1995 Jun;176(2):69–74

Renal amino acid transport in immature and adult rats during thallium–induced nephrotoxicity. Fleck C, et al. **Toxicology** 1996 Jan 8;106(1–3):229–36

Membrane alterations in Alzheimer's disease and aging [letter; comment] Cowburn RF, et al. **Trends Neurosci** 1995 Nov;18(11):483–4. Comment on: Trends Neurosci 1995 May;18(5):203–6.

The influence of ageing on muscarinic receptors, beta–adrenoceptors and adenylate cyclase activity in the bovine lung. Roets E, et al. **Vet Res Commun** 1995; 19(3):221–30

Determination of age–related changes of cytochrome P–450 sensitive to mepyramine in rat hepatic microsomes. Wang NP, et al. **Yao Hsueh Hsueh Pao** 1995;30(10):726–30

[Changes of proteoglycans in lumbar intervertebral disc of bipedal rats with aging] Dong F, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jun;75(6):352–4, 383 (Eng. Abstr.) **(Chi)**

[Changes of proto–oncogene expression and cytosolic free calcium in activited T–lymphocytes of aged mice] Ran Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Aug;75(8):466–9, 509–510 (Eng. Abstr.) **(Chi)**

[Camptocormia or reducible lumbar kyphosis in elderly subjects. Apropos of 2 cases of lipoid degeneration of the paravertebral muscles] Legaye J, et al. **Acta Orthop Belg** 1995;61(4):278–81 (Eng. Abstr.) **(Fre)**

[Age–dependent changes in metabolites of the normal brain in childhood : observation by proton MR spectroscopy] Tanouchi M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 May; 56(6):405–10 (Eng. Abstr.) **(Jpn)**

[Stereoselective N–demethylation of chlorpheniramine in rat liver microsomes: studies on age and sex differences] Nomura A, et al. **Yakugaku Zasshi** 1995 Aug;115(8):633–40 (Eng. Abstr.) **(Jpn)**

[Human ovarian ceramides and gangliosides in aging] Diatlovitskaia EV, et al. **Biokhimiia** 1995 Aug;60(8):1302–6 (Eng. Abstr.) **(Rus)**

[Level of 2,3–diphosphoglycerate and adenosine triphosphate in erythrocytes and acid–base status in adult and newborn rats in acute hypoxia] Alatyrtsev VV, et al. **Biull Eksp Biol Med** 1995 Jun;119(6):631–3 **(Rus)**

[An invertor mechanism of the effect of insulin on the myocardiocyte cell membrane in animals of different ages] Frol'kis VV, et al. **Biull Eksp Biol Med** 1995 Aug; 120(8):122–5 **(Rus)**

[Ultrastructural–cytochemical analysis of cardiomyocytes from young and old rats during generalized overheating] Klinnikova MG, et al. **Biull Eksp Biol Med** 1995 Nov; 120(11):540–4 **(Rus)**

[Enzymatic composition of lymph from animals of different age groups during fever] Minnebaev MM, et al. **Biull Eksp Biol Med** 1995 Aug;120(8):139–41 **(Rus)**

[Activity of NO–synthase and generation of active forms of oxygen in sections of the aged rat brain: relationship with individual behavior] Onufriev MV, et al. **Biull Eksp Biol Med** 1995 Aug;120(8):145–7 **(Rus)**

[Activity of NO–synthase and radical formation in rat brain sections: age dependence] Onufriev MV, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):54–6 **(Rus)**

[Age changes in alpha–1–adrenoreceptors in sections of brains from hypertensive NISAG rats: their possible role in development of arterial hypertension] Shishkina GT, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):78–80 **(Rus)**

[Antioxidant system of mammalian liver and heart membranes during the postnatal ontogenesis period] Romanenko EB, et al. **Mol Biol (Mosk)** 1995 Nov–Dec;29(6):1391–7 **(Rus)**

[Changes in the succinate dehydrogenase activity in the muscle fibers of the m. quadriceps femoris of boys 7 to 17] Tambovtseva RV. **Morfologiia** 1996;109(1):68–70 (Eng. Abstr.) **(Rus)**

[The tissue antioxidant system in the early postnatal development of rats] L'vova SP, et al. **Ontogenez** 1996 May–Jun;27(3):204–7 (Eng. Abstr.) **(Rus)**

[Radionuclide biokinetics as a function of the age of experimental animals] Kalistratova VS, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):421–6 (Eng. Abstr.) **(Rus)**

[Status of enzymatic lipid peroxidation in the heart of young and old rats under stress] Svets VN, et al. **Vopr Med Khim** 1995 May–Jun;41(3):23–6 (Eng. Abstr.) **(Rus)**

[A comparative ontogenic analysis of the correlative characteristics between oxygen consumption and the catecholamine level of the blood and its cholinesterase activity at different age periods] Arshavskiĭ IA, et al. **Zh Evol Biokhim Fiziol** 1996 Jan–Feb;32(1):82–93 (Eng. Abstr.) **(Rus)**

[The neurochemical characteristics of rats differing by their behavior in the emotional resonance test. Free–radical processes and lipids of the cerebral cortex in older rats] Stepanichev MIu, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Sep–Oct; 45(5):990–8 (Eng. Abstr.) **(Rus)**

[The content of macro– and trace elements in the cardiac muscle of adult and old rats after stressor influence] Markova OO, et al. **Fiziol Zh** 1995 Jan–Apr;41(1–2):100–4 (Eng. Abstr.) **(Ukr)**

[The antioxidative activity of the tissues and lipids in rats of different ages] Paranich AV, et al. **Fiziol Zh** 1995 Jan–Apr;41(1–2):29–36 (Eng. Abstr.) **(Ukr)**

[Content of prostaglandins E2 and F1alpha in small intestine epithelium in cattle as a function of age and pathology in non–infectious diarrhea] Usatiuk PV, et al. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):106–8 (Eng. Abstr.) **(Ukr)**

PATHOLOGY

Senile plaques in an aged two–humped (Bactrian) camel (Camelus bactrianus). Nakamura S, et al. **Acta Neuropathol (Berl)** 1995;90(4):415–8

Cerebral beta amyloid deposition in patients with malignant neoplasms: its prevalence with aging and effects of radiation therapy on vascular amyloid. Sugihara S, et al. **Acta Neuropathol (Berl)** 1995;90(2):135–41

Medication–related adverse reactions and the elderly: a literature review. Atkin PA, et al. **Adverse Drug React Toxicol Rev** 1995 Autumn;14(3):175–91 (125 ref.)

Normal age–related conversion of bone marrow in the mandible: MR imaging findings. Yamada M, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1223–8

Molecular and cellular biology of the senescent hypertrophied and failing heart. Swynghedauw B, et al. **Am J Cardiol** 1995 Nov 2;76(13):2D–7D (21 ref.)

Apolipoprotein AI–derived pulmonary vascular amyloid in aged dogs. Roertgen KE, et al. **Am J Pathol** 1995 Nov; 147(5):1311–7

Study of ACTH–immunoreactive cells after transplantation of neonatal adrenal glands into adult adrenalectomized rats. Sarria R, et al. **Anat Histol Embryol** 1995 Sep;24(3):185–90

Age–related differences in mandibular ramus growth: a histologic study. Hans MG, et al. **Angle Orthod** 1995; 65(5):335–40

Texture analysis of protein distribution images to find differences due to aging and superfusion. Dutta S, et al. **Ann Biomed Eng** 1995 Nov–Dec;23(6):772–86

Growth hormone (GH) retardation of muscle damage due to immobilization in old rats. Possible intervention with a new long–acting recombinant GH. Fares FA, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:430–43

Clinical stage, age and treatment in tropical pyomyositis: a retrospective study including forty cases. Martínez–de Jesus FR, et al. **Arch Med Res** 1996 Summer;27(2):165–70

Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of very old patients. Giannakopoulos P, et al. **Arch Neurol** 1995 Dec; 52(12):1150–9

Nutritional aspects of hip fractures. Bonjour JP, et al. **Bone** 1996 Mar;18(3 Suppl):139S–144S (87 ref.)

Epidemiology of hip fractures: implications of the exponential increase with age. Melton LJ 3rd. **Bone** 1996 Mar;18(3 Suppl):121S–125S (53 ref.)

Clinicopathological characteristics of gastric cancer in the elderly. Kitamura K, et al. **Br J Cancer** 1996 Mar; 73(6):798–802

Late–onset focal dermal elastosis: clinical and histological features. Tajima S, et al. **Br J Dermatol** 1995 Aug; 133(2):303–5

Brain atrophy in normal ageing and Alzheimer's disease. Volumetric discrimination and clinical correlations. Förstl H, et al. **Br J Psychiatry** 1995 Dec;167(6):739–46

Short communication: breast parenchymal patterns and their changes with age. van Gils CH, et al. **Br J Radiol** 1995 Oct;68(814):1133–5

Müller cell changes precede photoreceptor cell degeneration in the age–related retinal degeneration of the Fischer 344 rat. DiLoreto DA Jr, et al. **Brain Res** 1995 Nov 6; 698(1–2):1–14

A stereological study of substantia nigra in young and old rhesus monkeys. Pakkenberg H, et al. **Brain Res** 1995 Sep 25;693(1–2):201–6

Selective sparing of human nucleus accumbens in aging and anoxia. Huang KW, et al. **Can J Neurol Sci** 1995 Nov; 22(4):290–3

Age–related characteristics of gastric carcinoma in young and elderly patients. Maehara Y, et al. **Cancer** 1996 May 1;77(9):1774–80

Rhinoplasty with advancing age. Characteristics and management. Rohrich RJ, et al. **Clin Plast Surg** 1996 Apr; 23(2):281–96

Management of cancer in the aged. Balducci L, et al. **Compr Ther** 1996 Feb;22(2):88–93 (28 ref.)

The effects of aging upon the connective tissues of the periodontal ligament. Moxham BJ, et al. **Connect Tissue Res** 1995;33(1–3):31–5

Is metformin safe enough for ageing type 2 diabetic patients? Gregorio F, et al. **Diabetes Metab** 1996 Feb;22(1):43–50

Drug–induced seizures in the elderly. Causative agents and optimal management. Franson KL, et al. **Drugs Aging** 1995 Jul;7(1):38–48 (78 ref.)

Rheumatoid arthritis in the elderly. Prevalence and optimal management. van Schaardenburg D. **Drugs Aging** 1995 Jul; 7(1):30–7 (57 ref.)

Age–dependent phenotypic expression of a pattern dystrophy of the retina. Thomann U, et al. **Eur J Ophthalmol** 1995 Apr–Jun;5(2):107–12

Incremental lines in human dental cementum in relation to age. Kvaal SI, et al. **Eur J Oral Sci** 1995 Aug;103(4):225–30

Changes in mandibular tooth alignment during adulthood from 18 to 50 years [letter; comment] Peck S, et al. **Eur J Orthod** 1996 Apr;18(2):213–4. Comment on: Eur J Orthod 1995 Jun;17(3):251–7.

Vascular pathology in the elderly. Hsu CY, et al. **Eur Neurol** 1995;35 Suppl 1:2–4 (20 ref.)

Incidence of prostate cancer will double by the year 2030: the argument against. George NJ. **Eur Urol** 1996;29 Suppl 2:10–2 (7 ref.)

Changes in nasal cavity volume and target area of exposure to nasal drops with age in rats. Kuboyama Y, et al. **Exp Anim** 1996 Jan;45(1):15–22

Degeneration of human oncogenes and mitochondrial genes occurs in cells that exhibit age–related pathology. Cortopassi G, et al. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):253–65 (43 ref.)

Abnormal cell proliferation and p52/p35–CSK expression in the colons of aging rats. Holt PR, et al. **Exp Gerontol** 1995 Sep–Oct;30(5):495–503

Greater severity of clinical features in older patients with Duane's retraction syndrome. Noonan CP, et al. **Eye** 1995; 9 (Pt 4):472–5

Anatomy of the Achilles tendon and plantar fascia in relation to the calcaneus in various age groups. Snow SW, et al. **Foot Ankle Int** 1995 Jul;16(7):418–21

Computerized microimage analysis of age–related changes of the human sinoatrial node. Luo B, et al. **Forensic Sci Int** 1995 Oct 30;75(2–3):149–55

Estradiol modulation of neuron loss in the medial division of medial preoptic nucleus in rats during aging. Hsieh YL, et al. **Gerontology** 1996;42(1):18–24

Age and experimental obstructive emphysema. A morphometrical study on the rat. Escolar JD, et al. **Histol Histopathol** 1995 Oct;10(4):875–87

Tobacco smoke and age as risk factors in emphysema. Morphometrical study on the rat. Escolar JD, et al. **Histol Histopathol** 1996 Jan;11(1):7–16

Age–related changes of aorta in Syrian hamsters of APA strain. Yamanouchi J, et al. **Histol Histopathol** 1995 Jul; 10(3):703–8

Gentamicin nephrotoxicity in the rat: influence of age and diabetes mellitus. Ali BH, et al. **Hum Exp Toxicol** 1996 Jan;15(1):51–55

Cellular and molecular determinants of ageing. Rattan SI. **Indian J Exp Biol** 1996 Jan;34(1):1–6 (30 ref.)

Gender differences and aging: effects on the human heart. Olivetti G, et al. **J Am Coll Cardiol** 1995 Oct;26(4):1068–79

Age–associated memory impairment and Alzheimer's disease [editorial; comment] Blass JP. **J Am Geriatr Soc** 1996 Feb; 44(2):209–11. Comment on: J Am Geriatr Soc 1996 Feb;44(2):133–8.

Hippocampal and neocortical involvement in normal brain aging and dementia: morphological and neurochemical profile of the vulnerable circuits. Hof PR, et al. **J Am Geriatr Soc** 1996 Jul;44(7):857–64 (83 ref.)

Effects of age, Helicobacter pylori, and NSAID usage on the upper gastrointestinal tract [letter] Hui E, et al. **J Am Geriatr Soc** 1996 Aug;44(8):1010–2

Atrophy of the corpus callosum in Alzheimer's disease versus healthy aging. Janowsky JS, et al. **J Am Geriatr Soc** 1996 Jul;44(7):798–803

1H–MRS, MRI–based hippocampal volumetry, and 99mTc–HMPAO–SPECT in normal aging, age–associated memory impairment, and probable Alzheimer's disease [see comments] Parnetti L, et al. **J Am Geriatr Soc** 1996 Feb; 44(2):133–8. Comment in: J Am Geriatr Soc 1996 Feb;44(2):209–11.

Age–related bone resorption in the normal incus: a case of maladaptive remodelling? Lannigan FJ, et al. **J Anat** 1995 Jun;186 (Pt 3):651–5

Pulmonary responses to heparin–protamine complexes: the effects of age and species. Horiguchi T, et al. **J Appl Physiol** 1996 Jan;80(1):56–61

Cell proliferation of human fibroblasts and osteoblasts in osteogenesis imperfecta: influence of age. Fedarko NS, et al. **J Bone Miner Res** 1995 Nov;10(11):1705–12

Age and temperature related changes to the ultrastructure and composition of human bone mineral. Holden JL, et al. **J Bone Miner Res** 1995 Sep;10(9):1400–9

Bone fragility in transgenic mice expressing a mutated gene for type I procollagen (COL1A1) parallels the age–dependent phenotype of human osteogenesis imperfecta. Pereira RF, et al. **J Bone Miner Res** 1995 Dec; 10(12):1837–43

Predictors of hip fractures in elderly men. Poór G, et al. **J Bone Miner Res** 1995 Dec;10(12):1900–7

Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. Jilka RL, et al. **J Clin Invest** 1996 Apr 1; 97(7):1732–40

Eosinophilic neuronal inclusions in the thalamus of ageing B6C3F1 mice. Yanai T, et al. **J Comp Pathol** 1995 Oct; 113(3):287–90

Cervical and lumbar MRI in asymptomatic older male lifelong athletes: frequency of degenerative findings. Healy JF, et al. **J Comput Assist Tomogr** 1996 Jan–Feb; 20(1):107–12

Photoaging versus intrinsic aging: a morphologic assessment of facial skin. Bhawan J, et al. **J Cutan Pathol** 1995 Apr; 22(2):154–9

Microscopic age changes in the human occipital bone. Cool SM, et al. **J Forensic Sci** 1995 Sep;40(5):789–96

Factors influencing the repair and adaptation of muscles in aged individuals: satellite cells and innervation. Carlson BM. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:96–100 (34 ref.)

Muscle biopsy as a tool in the study of aging. Coggan AR. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:30–4 (38 ref.)

From muscle properties to human performance, using magnetic resonance. Conley KE, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:35–40 (30 ref.)

Muscle performance and structure in the elderly as studied cross-sectionally and longitudinally. Grimby G. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:17–22 (22 ref.)

Loss of skeletal muscle mass with aging: effect on glucose tolerance. Kohrt WM, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:68–72 (43 ref.)

Human aging, muscle mass, and fiber type composition. Lexell J. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:11–6 (55 ref.)

Pathologic characterization of brown Norway, brown Norway x Fischer 344, and Fischer 344 x brown Norway rats with relation to age. Lipman RD, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B54–9

The application of blood flow measurements to the study of aging muscle. McCully KK, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:130–6 (80 ref.)

Relationship of age-related decreases in muscle mass and strength to skeletal status. Marcus R. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:86–7 (12 ref.)

Cell culture systems as tools for studying age-related changes in skeletal muscle. Peterson CA. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:142–4

Surface complexity of human neocortical astrocytic cells: changes with development, aging, and dementia. Senitz D, et al. **J Hirnforsch** 1995;36(4):531–7

Age-related reduction of the satellite cell sheath around spinal ganglion neurons in the rabbit. Pannese E, et al. **J Neurocytol** 1996 Feb;25(2):137–46

Quantitative computed tomography and magnetic resonance imaging in aging and Alzheimer's disease. A review. Smith CD. **J Neuroimaging** 1996 Jan;6(1):44–53 (122 ref.)

Differential expression of TGF-beta 1, 2 and 3 isotypes in Alzheimer's disease: a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. Peress NS, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):802–11

Changes in the electrophysiological properties of cat spinal motoneurons following the intramuscular injection of adriamycin compared with changes in the properties of motoneurons in aged cats. Liu RH, et al. **J Neurophysiol** 1995 Nov;74(5):1972–81

In vitro comparison of aged and young osteogenic and hemopoietic bone marrow stem cells and their derivative colonies. Dodson SA, et al. **J Periodontol** 1996 Mar; 67(3):184–96

Degenerative leukoencephalopathy and myelopathy in dasyurids. Holz PH, et al. **J Wildl Dis** 1995 Oct; 31(4):509–13

Pathologic findings in an aging Mongolian gerbil (Meriones unguiculatus) colony. Bingel SA. **Lab Anim Sci** 1995 Oct; 45(5):597–600

Urogenital ageing: an old problem newly recognized. Bachmann G. **Maturitas** 1995 Dec;22 Suppl:S1–S5

Analysis of mortality rate from carcinoma of prostate. Clive JM, et al. **Mech Ageing Dev** 1995 Aug 31;83(1):31–41

Structural changes induced by cytidine-5'-diphosphate choline (CDP-choline) chronic treatment in neurosecretory neurons of the supraoptic nucleus of aged CFW-mice. Crespo D, et al. **Mech Ageing Dev** 1995 Oct 27;84(3):183–93

Age- and trauma-dependent modifications of neuromuscular junction and skeletal muscle structure in the rat. Effects of long-term treatment with Acetyl-L-Carnitine. De Angelis C, et al. **Mech Ageing Dev** 1995 Nov 3;85(1):37–53

Age-related alterations in the morphology of femoral artery vasa vasorum in the rat. Phillips GD, et al. **Mech Ageing Dev** 1995 Aug 8;82(2-3):149–54

Differential effects of gonadectomy on thymic stromal cells in promoting T cell differentiation in mice. Utsuyama M, et al. **Mech Ageing Dev** 1995 Jul 14;81(2-3):107–17

Organ/body weight loss with aging: evidence for co-ordinated involution. Spencer RP. **Med Hypotheses** 1996 Feb;46(2):59–62

Age-dependent susceptibility of CNS glial populations in situ to the antimetabolite 6-aminonicotinamide. Krum JM. **Mol Chem Neuropathol** 1995 Oct;26(2):79–94

The canine as an animal model of human aging and dementia. Cummings BJ, et al. **Neurobiol Aging** 1996 Mar-Apr; 17(2):259–68 (106 ref.)

Correlations of synaptic and pathological markers with cognition of the elderly. Dickson DW, et al. **Neurobiol Aging** 1995 May-Jun;16(3):285–98; discussion 298–304

Age-related decline in MRI volumes of temporal lobe gray matter but not hippocampus. Sullivan EV, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):591–606

Cerebral amyloid angiopathy and plaques, and visceral amyloidosis in aged macaques. Uno H, et al. **Neurobiol Aging** 1996 Mar-Apr;17(2):275–81

A functional role for corpora amylacea based on evidence from complement studies. Singhrao SK, et al. **Neurodegeneration** 1995 Sep;4(3):335–45

Serum zinc, senile plaques, and neurofibrillary tangles: findings from the Nun Study. Tully CL, et al. **Neuroreport** 1995 Nov 13;6(16):2105–8

Synaptic loss in cognitively impaired aged rats is ameliorated by chronic human nerve growth factor infusion. Chen KS, et al. **Neuroscience** 1995 Sep;68(1):19–27

Comparison of pulmonary neutrophils in the adult and neonatal rat after hyperoxia. Keeney SE, et al. **Pediatr Res** 1995 Dec;38(6):857–63

Secretion of transforming growth factor-alpha (TGF alpha) by postnatal rabbit alveolar macrophages. Wagner CL, et al. **Pediatr Res** 1995 Jul;38(1):49–54

Magnetic resonance imaging of the aging brain in Down syndrome. Emerson JF, et al. **Prog Clin Biol Res** 1995; 393:123–38 (28 ref.)

Quantitative analysis of neuropathologic changes in the cerebral cortex of centenarians. Giannakopoulos P, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):577–92

Age-related changes in brain: I. Magnetic resonance imaging measures of temporal lobe volumes in normal subjects. Convit A, et al. **Psychiatr Q** 1995 Winter;66(4):343–55

T2 shortening in the motor cortex: effect of aging and cerebrovascular diseases. Hirai T, et al. **Radiology** 1996 Jun; 199(3):799–803

The morphologic and neurochemical basis of dementia: aging, hierarchical patterns of lesion distribution and vulnerable neuronal phenotype. Hof PR, et al. **Rev Neurosci** 1995 Apr-Jun;6(2):97–124

GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil. Marczynski TJ. **Rev Neurosci** 1995 Jul-Sep;6(3):221–58 (164 ref.)

Vitamin E deficiency as a model of precocious brain aging: assessment by X-ray microanalysis and morphometry. Bertoni-Freddari C, et al. **Scanning Microsc** 1995 Mar; 9(1):289–301; discussion 301–2

Pruritus in the elderly. Gilchrest BA. **Semin Dermatol** 1995 Dec;14(4):317–9 (22 ref.)

Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study [see comments] Longstreth WT Jr, et al. **Stroke** 1996 Aug;27(8):1274–82. Comment in: Stroke 1996 Aug;27(8):1269–73.

Signs of aging are apparent in the testis interstitium of Sprague Dawley rats at 6 months of age. Mendis-Handagama SM, et al. **Tissue Cell** 1995 Dec; 27(6):689–99

Age dependence of the cardiac lesions induced by minoxidil in the rat. Herman EH, et al. **Toxicology** 1996 Jun 17; 110(1-3):71–83

Osteochondrosis of the articular-epiphyseal cartilage complex in young horses: evidence for a defect in cartilage canal blood supply. Carlson CS, et al. **Vet Pathol** 1995 Nov; 32(6):641–7

Senile plaques and other senile changes in the brain of an aged American black bear. Uchida K, et al. **Vet Pathol** 1995 Jul;32(4):412–4

The lesions of rotavirus infection in 1- and 10-day-old gnotobiotic calves. Varshney KC, et al. **Vet Pathol** 1995 Nov;32(6):619–27

Declining density of intimal smooth muscle cells and age as preconditions for atheronecrosis in the basilar artery. Tracy RE. **Virchows Arch** 1995;427(2):131–8

Round cell sarcomas of possible myelomonocytic origin localized at the lip of aged dogs. Kipar A, et al. **Zentralbl Veterinarmed A** 1995 May;42(3):185–200

Age-related morphometrical changes of arteries of uterine wall in mares. Nambo Y, et al. **Zentralbl Veterinarmed A** 1995 Aug;42(6):383–7

[Transmission electron microscopic observation on the liver and cerebral cortex in aging mice treated with sijunzi decoction] Gong YX, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun; 15(6):359–61 (Eng. Abstr.) **(Chi)**

[Aging, disease and nerve cell death] Agid Y. **Bull Acad Natl Med** 1995 Jun;179(6):1193–203; discussion 1203–7 (Eng. Abstr.) **(Fre)**

[Age-related changes in the retina of WBN/Kob rats--a pathological study] Kiyosawa I, et al. **Exp Anim** 1995 Oct; 43(5):651–61 (Eng. Abstr.) **(Jpn)**

[Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys] Nakamura S, et al. **Exp Anim** 1995 Oct;43(5):711–8 (Eng. Abstr.) **(Jpn)**

[Aging changes in conjunctiva visualized by fluorescein angiography and histopathology] Takahashi A, et al. **Nippon Ganka Gakkai Zasshi** 1996 Apr;100(4):296–301 (Eng. Abstr.) **(Jpn)**

[Cerebral atrophy and ventricular enlargement in physiological ageing--a morphometrical study in 28 autopsy brain of normal old people] Yamada S, et al. **No To Shinkei** 1996 May;48(5):459–65 (Eng. Abstr.) **(Jpn)**

[Heart conduction system in the human in light of personal research] Grzybiak M, et al. **Pol Tyg Lek** 1995 Sep; 50(36-39):66–9 (Eng. Abstr.) **(Pol)**

[Morphofunctional features of fibroblasts in wound healing in old age] Grabovo i AN. **Arkh Patol** 1995 Nov-Dec; 57(6):35–8 (Eng. Abstr.) **(Rus)**

[The topographic anatomical validation of variants in the surgical treatment of acute mediastinitis in children from the age aspect] Zhvavyl NF, et al. **Vestn Khir Im I I Grek** 1992 Mar;148(3):308–12 (Eng. Abstr.) **(Rus)**

[Acetylcholinesterase-positive innervation of the thymus in old rats after ovariectomy] Dorko F, et al. **Bratisl Lek Listy** 1996 May;97(5):298–300 (Eng. Abstr.) **(Slo)**

[The relationship of PSA to age and prostatic volume in patients with benign prostatic hypertrophy] Sánchez Sánchez E, et al. **Actas Urol Esp** 1995 Mar;19(3):181–6 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Influence of age on circulation and arterial blood gases in man. Gunnarsson L, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):237–43

The influence of aging on skin temperature and hemodynamic changes during spinal anesthesia. Hirose M, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):891–5

The influence of ageing on the pharmacodynamics of mivacurium chloride. D'Honneur G, et al. **Acta Anaesthesiol Scand Suppl** 1995;106:45–6

Age-related regional variations of human skin blood flow response to histamine. Tur E. **Acta Derm Venereol** 1995 Nov;75(6):451–4

Evolutionary ancient roles of serotonin: long-lasting regulation of activity and development. Turlejski K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):619–36 (138 ref.)

Molecular biology of brain aging and neurodegenerative disorders. Wisniewski T, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):267–79 (93 ref.)

Age, weight, body mass index and endometrial thickness in postmenopausal women. Van den Bosch T, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):181–2

The influence of age on the flash visual evoked potentials. Contestabile MT, et al. **Acta Ophthalmol Scand** 1995 Aug; 73(4):308–12

Chondroitin sulphation in human joint tissues varies with age, zone and topography. Bayliss MT, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:22–5

Kinetics of release of aggrecan from explant cultures of bovine cartilage from different sources and from animals of different ages. Ilic MZ, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:33–7

Post-natal development of tonic activity and membrane excitability in mouse medial vestibular nucleus neurones. Dutia MB, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:101–4

Aging effects upon pursuit eye movements. Kato I, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:293–4

Hearing in hospitalised geriatric patients. A descriptive study. Jacobs RL, et al. **Acta Otorhinolaryngol Belg** 1996; 50(2):121–4

Effects of immobilization on the rat soleus muscle in relation to age. Ansved T. **Acta Physiol Scand** 1995 Jul; 154(3):291–302

Effects of age on sarcoplasmic reticulum properties and histochemical composition of fast- and slow-twitch rat muscles. Danieli-Betto D, et al. **Acta Physiol Scand** 1995 May;154(1):59–64

Myosin heavy chains in skeletal muscles of the common shrew (Sorex araneus): absence of a slow isoform and transitions of fast isoforms with ageing. Savolainen J, et al. **Acta Physiol Scand** 1995 Oct;155(2):233–9

Changes in the anal sphincter with age. An endosonographic study. Nielsen MB, et al. **Acta Radiol** 1996 May;37(3 Pt 1):357–61

Effects of age on VO2 kinetics during calf and cycling exercise. Chilibeck PD, et al. **Adv Exp Med Biol** 1995; 393:195–200

Muscle fatigue in old animals. Unique aspects of fatigue in elderly humans. Faulkner JA, et al. **Adv Exp Med Biol** 1995;384:471–80 (35 ref.)

Effects of omeprazole, a proton pump inhibitor, on pepsinogen-producing cells, with special reference to neonatal development. Kakei N, et al. **Adv Exp Med Biol** 1995;362:115–23

Matrix changes in the bladder associated with normal aging. Shapiro E, et al. **Adv Exp Med Biol** 1995;385:187–90; discussion 223–8 (23 ref.)

Ventilatory responses to isocapnic hypoxia in the eighth decade. Smith WD, et al. **Adv Exp Med Biol** 1995; 393:267–70

Changes in sensory organization test scores with age. Cohen H, et al. **Age Ageing** 1996 Jan;25(1):39–44

Circadian body temperatures and the effects of a cold stress in elderly and young subjects. Collins KJ, et al. **Age Ageing** 1995 Nov;24(6):485–9

Primitive reflexes and dementia: results from the Canadian Study of Health and Aging. Hogan DB, et al. **Age Ageing** 1995 Sep;24(5):375–81

Retardation by restricted feeding of age-related changes in steroidogenic activity of rat pre- and post-ovulatory follicles. Merry BJ, et al. **Age Ageing** 1996 May;25(3):250–5

Ageing is riskier than it looks. Sundström G. **Age Ageing**

1995 Sep;24(5):373–4
The need for a new biological model in geratology. Thompson MK. **Age Ageing** 1996 Mar;25(2):168–71
The Adelaide Activities Profile: a measure of the life-style activities of elderly people. Clark MS, et al. **Aging (Milano)** 1995 Aug;7(4):174–84
Outcome of elderly patients requiring ventilatory support in intensive care. Dardaine V, et al. **Aging (Milano)** 1995 Aug; 7(4):221–7
Psychomotor speed and physical activity in 75–year–old residents in three Nordic localities. Era P, et al. **Aging (Milano)** 1995 Aug;7(4):195–204
Aging effects on the perception of noxious and non–noxious thermal stimuli applied to the face. Heft MW, et al. **Aging (Milano)** 1996 Feb;8(1):35–41
Is late–life caloric restriction beneficial? Lipman RD, et al. **Aging (Milano)** 1995 Apr;7(2):136–9
Repeated testing of normal elderly with the Boston Naming Test. Mitrushina M, et al. **Aging (Milano)** 1995 Apr; 7(2):123–7
Insulin response during the oral glucose tolerance test: the role of age, sex, body fat and the pattern of fat distribution. Muller DC, et al. **Aging (Milano)** 1996 Feb;8(1):13–21
Quantifying functional ability to predict health–care use of elderly persons. Nikolaus T, et al. **Aging (Milano)** 1995 Jun; 7(3):258–60
Age and laxative use in hospitalized patients. A report of the "Gruppo Italiano di Farmacovigilanza nell'Anziano—GIFA". Pahor M, et al. **Aging (Milano)** 1995 Apr;7(2):128–35
Pupillometric evaluation and analysis of light reflex in healthy subjects as a tool to study autonomic nervous system changes with aging. Pozzessere G, et al. **Aging (Milano)** 1996 Feb;8(1):55–60
Apolipoprotein E allele frequencies in an Italian population: relation to age and lipid profile. Ruiu G, et al. **Aging (Milano)** 1995 Aug;7(4):185–9
Reduced left ventricular mechanical efficiency in elderly patients with coronary artery disease. Vigorito C, et al. **Aging (Milano)** 1995 Aug;7(4):205–9
Magnetization transfer MR of the normal adult brain. Mehta RC, et al. **AJNR Am J Neuroradiol** 1995 Nov–Dec; 16(10):2085–91
Functional abnormalities of the pharynx: a prospective analysis of radiographic abnormalities relative to age and symptoms. Frederick MG, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):353–7
Distribution of nicotinic subtypes in human brain. Court J, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:6–14
Biologic differences between early– and late–onset Alzheimer disease. Terry RD. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S26–7 (7 ref.)
Effects of aging per se on arterial stiffness: systemic and regional compliance in beagles. Haidet GC, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):319–27
Effect of aging and chronic angiotensin I converting enzyme inhibition on the endothelial function of the mesenteric arterial bed of the rat. Atkinson J. **Am J Cardiol** 1995 Nov 24;76(15):19E–23E
Similar orthostatic defense in active, healthy young adult and late middle–aged men. Bootsma M, et al. **Am J Cardiol** 1995 Nov 1;76(12):922–7
Effects of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic dysfunction. Dutka DP, et al. **Am J Cardiol** 1996 Jun 1;77(14):1197–201
Effect of aging from infancy to childhood on flow velocity patterns of pulmonary vein by Doppler echocardiography. Harada K, et al. **Am J Cardiol** 1996 Jan 15;77(2):221–4
Risk factors for wasting and stunti"g among children in Metro Cebu, Philippines. Ricci JA, et al. **Am J Clin Nutr** 1996 Jun;63(6):966–75
Relations of vitamin B–12, vitamin B–6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Riggs KM, et al. **Am J Clin Nutr** 1996 Mar; 63(3):306–14
Age–related impairments in the regulation of food intake. Rolls BJ, et al. **Am J Clin Nutr** 1995 Nov;62(5):923–31
Pulmonary function measures as predictors and correlates of cognitive functioning in later life. Chyou PH, et al. **Am J Epidemiol** 1996 Apr 15;143(8):750–6
Effect of active and passive smoking on ventilatory function in elderly men and women. Frette C, et al. **Am J Epidemiol** 1996 Apr 15;143(8):757–65
Type A behavior pattern and change in blood pressure from childhood to adolescence. The Minneapolis Children's Blood Pressure Study. Lee DJ, et al. **Am J Epidemiol** 1996 Jan 1;143(1):63–72
Influence of age, gender, and menstrual cycle on the normal electrogastrogram. Parkman HP, et al. **Am J Gastroenterol** 1996 Jan;91(1):127–33
Age–related and vasomotor stimuli–induced changes in renal vascular resistance detected by Doppler ultrasound. Boddi M, et al. **Am J Hypertens** 1996 May;9(5):461–6
24–h ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Wiinberg N, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 1):978–86
A twin study of age–related macular degeneration. Meyers SM, et al. **Am J Ophthalmol** 1995 Dec;120(6):757–66
Magnesium supplementation reduces development of diabetes in a rat model of spontaneous NIDDM. Balon TW, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):E745–52
Relationship between changes in body composition and insulin responsiveness in models of the aging rat. Barzilai N, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E591–7
Age–related changes in body composition are associated with hepatic insulin resistance in conscious rats. Barzilai N, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E930–6
Mechanisms for the generation of gas–exchange surface area in rat lung. Blanco LN. **Am J Physiol** 1995 Nov;269(5 Pt 1):L698–708
Transcription factors and pattern formation in the developing lung. Cardoso WV. **Am J Physiol** 1995 Oct;269(4 Pt 1):L429–42 (185 ref.)
Trehalase gene expression during postnatal development of rabbit intestine and kidney: effects of glucocorticoids. Galand G, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G833–41
Endocrine consequences of prenatal sodium depletion prepare rats for high need–free NaCl intake in adulthood. Galaverna O, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R578–83
Role of gastric blood flow in impaired defense and repair of aged rat stomachs. Grønbech JE, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G737–44
Ontogenic regulation of spatial differentiation in the crypt–villus axis of normal and isografted small intestine. Gutierrez ED, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):G500–11
Impact of early growth retardation on glucoregulatory control and insulin action in mature rats. Holness MJ. **Am J Physiol** 1996 Jun;270(6 Pt 1):E946–54
Circadian locomotor rhythms in aged hamsters following suprachiasmatic transplant. Hurd MW, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R958–68
Differential expression of alpha– and beta–enolase genes during rat heart development and hypertrophy. Keller A, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):H1843–51
Effect of aging and hypertension on contractility of resistance arteries: modulation by endothelial factors. Lang MG, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H837–44
Neonatal rat dietary carbohydrate affects pancreatic islet insulin secretion in adults and progeny. Laychock SG, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):E739–44
Adrenergic responsiveness is reduced, while baseline cardiac function is preserved in old adult conscious monkeys. Sato N, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1664–71
Role of muscarinic M2 receptors in regulating beta–adrenergic responsiveness in maturing rabbit airway smooth muscle. Schramm CM, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):L783–90
Noninvasive indexes of cardiac systolic and diastolic function in hyperthyroid and senescent mouse. Taffet GE, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2204–9
SERCA2a and mitochondrial cytochrome oxidase expression are increased in hearts of exercise–trained old rats. Tate CA, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H68–72
Diurnal heart rate variability in healthy subjects: effects of aging and sex difference. Yamasaki Y, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H303–10
Age–associated increase in rat ventricular ANP gene expression correlates with cardiac hypertrophy. Younes A, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H1003–8
Cognitive function and assessment of lung function in the elderly. Carvalhaes–Neto N, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1611–5
Skin test reactivity to common aeroallergens and decline of lung function. The Normative Aging Study. Gottlieb DJ, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):561–6
Alveolar and tissue surfactant pool sizes in humans. Rebello CM, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):625–8
Comparative analyses of peritoneal fluid from calves and adult cattle. Anderson DE, et al. **Am J Vet Res** 1995 Aug; 56(8):973–6
Event–time analysis of the effect of 60–day milk production on the parturition–to–conception interval in dairy cows. Harman JL, et al. **Am J Vet Res** 1996 May;57(5):634–9
Necropsy survey of metacarpal fusion in the horse. Les CM, et al. **Am J Vet Res** 1995 Nov;56(11):1421–32
Effects of rate of gain on scrotal circumference and histopathologic features of the testes of half–sibling yearling beef bulls. Ohl MW, et al. **Am J Vet Res** 1996 Jun; 57(6):844–7
Effect of sodium hexametaphosphate on dental calculus formation in dogs. Stookey GK, et al. **Am J Vet Res** 1995 Jul;56(7):913–8
C–cells of marmosets (Callithrix jacchus). Maile S, et al. **Anat Anz** 1996 Apr;178(2):159–67
Alveolar bone turnover in male rats: site– and age–specific changes. King GJ, et al. **Anat Rec** 1995 Jul;242(3):321–8
Ultrastructural quantitative analysis of the innervation of axillary lymph nodes in juvenile and old rats. Novotny GE, et al. **Anat Rec** 1995 Oct;243(2):223–33
Does age or pseudocholinesterase activity predict mivacurium infusion rate in children? Markakis DA, et al. **Anesth Analg** 1996 Jan;82(1):39–43
Age–related differences in mandibular ramus growth: a histologic study. Hans MG, et al. **Angle Orthod** 1995; 65(5):335–40
Prediction of adult skinfolds and body mass from infancy through adolescence. Gasser T, et al. **Ann Hum Biol** 1995 May–Jun;22(3):217–33
Growth hormone replacement in healthy older men improves body composition but not functional ability. Papadakis MA, et al. **Ann Intern Med** 1996 Apr 15;124(8):708–16
Stalking sarcopenia [editorial] Rosenberg IH, et al. **Ann Intern Med** 1995 Nov 1;123(9):727–8
Dehydroepiandrosterone (DHEA) and Aging. Proceedings of a conference. Washington, D.C., June 17–19, 1995. **Ann N Y Acad Sci** 1995 Dec 29;774:ix–xiv, 1–350
The role of hyperthermia in amphetamine's interactions with NMDA receptors, nitric oxide, and age to produce neurotoxicity. Bowyer JF. **Ann N Y Acad Sci** 1995 Sep 15;765:309–10
In vivo structural studies of the hippocampus in normal aging and in incipient Alzheimer's disease. de Leon MJ, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:1–13
Age–related changes in cortical blood flow activation during perception and memory. Grady CL. **Ann N Y Acad Sci** 1996 Jan 17;777:14–21
Aging and disease: extending functional life span. Harman D. **Ann N Y Acad Sci** 1996 Jun 15;786:321–36 (87 ref.)
Oxidative brain damage in aged mice. Protection by caloric reduction. Lal H, et al. **Ann N Y Acad Sci** 1995 Sep 15; 765:308
Apolipoprotein E polymorphism is associated with both senile plaque load and Alzheimer–type neurofibrillary tangle formation. März W, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:276–80
Structural–functional correlates of neuroprotection in the aging rabbit by a calcium channel blocker. Nimodipine reverses neocortical dendritic atrophy and improves memory retention. Mervis RF, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:312–3
Cellular and molecular mechanisms of cardiovascular aging. Molecular pharmacological implications. Miyamoto A, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:283–93 (58 ref.)
Frontal lobes, memory, and aging. Moscovitch M, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:119–50 (228 ref.)
Beta–amyloidosis in normal aging and transmitter signaling in human temporal lobe. Perry EK, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:388–92
The mismatch negativity to novel stimuli reflects cognitive decline. Schroeder MM, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:399–401
Somatostatin as a trophic factor. Analysis of transgenic mice overexpressing somatostatin in astrocytes. Schwartz JP, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:29–35
Impaired plasticity of neurons in aging. Biochemical, biophysical, and behavioral studies. Sugawa M, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:274–82
Is the preconditioning response conserved in senescent myocardium? Burns PG, et al. **Ann Thorac Surg** 1996 Mar; 61(3):925–9
Age differences in effects of hypothermic ischemia on endothelial and ventricular function. Hiramatsu T, et al. **Ann Thorac Surg** 1995 Dec;60(6 Suppl):S501–4
The relative utility of health–related fitness tests and skilled motor performance tests as measures of biological age in Japanese men. Lee MS, et al. **Appl Human Sci** 1996 May; 15(3):97–104
Age–associated problems in nutrition. Sone Y. **Appl Human Sci** 1995 Sep;14(5):201–10 (85 ref.)
A one–year follow–up study of body composition in a young woman. Takasaki Y. **Appl Human Sci** 1995 Jul;14(4):195–6
Semen characteristics, endocrine profiles, and testicular biopsies of infertile men of different ages. Merino G, et al. **Arch Androl** 1995 Nov–Dec;35(3):219–24
Decreased m3–muscarinic and alpha 1–adrenergic receptor stimulation of PIP2 hydrolysis in parotid gland membranes from aged rats: defect in activation of G alpha q/11. Sawaki K, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):319–26
Effects of age, socioeconomic status, and menstrual cycle on pulmonary response to ozone. Seal E Jr, et al. **Arch Environ Health** 1996 Mar–Apr;51(2):132–7
Sex differences in human brain morphometry and metabolism: an in vivo quantitative magnetic resonance imaging and positron emission tomography study on the effect of aging. Murphy DG, et al. **Arch Gen Psychiatry** 1996 Jul;53(7):585–94
Physiological predictors of increasing total and central adiposity in aging men and women. Poehlman ET, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2443–8
Changes in endothelium–dependent vascular responses associated with spontaneous hypertension and age in rats. Ibarra M, et al. **Arch Med Res** 1995;26 Spec No:S177–83
Aging effects on accommodation and outflow facility responses to pilocarpine in humans. Croft MA, et al. **Arch Ophthalmol** 1996 May;114(5):586–92
Ultrastructural age–related changes on the posterior iris surface. A possible relationship to the pathogenesis of exfoliation. Khalil AK, et al. **Arch Ophthalmol** 1996 Jun; 114(6):721–5
Measurements of human minor salivary gland secretions from different oral sites. Sivarajasingam V, et al. **Arch Oral Biol** 1995 Aug;40(8):723–9
The pattern of nutrient and energy utilization, retention and the chemical composition of the body in broilers from hatching to maturity. Burlacu G, et al. **Arch Tierernahr** 1996;49(2):125–49
A standard experimental diet for the study of fatty acid requirements of weaning and first ongrowing stages of the European sea bass Dicentrarchus labrax L.: comparison of extruded and extruded/coated diets. Coutteau P, et al. **Arch Tierernahr** 1996;49(1):49–59

Investigations on the influence of Clenbuterol and recombinant porcine somatotropin on nitrogen and energy metabolism in growing pigs. Jentsch W, et al. **Arch Tierernahr** 1993;45(1):1–11

Thermoregulatory activity of motor units during human development. Meigal A, et al. **Arctic Med Res** 1995 Oct; 54(4):192–200

Relation of intima–media thickness to atherosclerotic plaques in carotid arteries. The Vascular Aging (EVA) Study. Bonithon–Kopp C, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):310–6

Electrocardiographic values in Spanish–bred horses of different ages. Ayala I, et al. **Aust Vet J** 1995 Jun; 72(6):225–6

Early cerebellar lesions impair eyeblink conditioning in developing rats: differential effects of unilateral lesions on postnatal day 10 or 20. Freeman JH Jr, et al. **Behav Neurosci** 1995 Oct;109(5):893–902

Spatial learning and memory as a function of age in the dog. Head E, et al. **Behav Neurosci** 1995 Oct;109(5):851–8

Maze learning and morphology of frontal cortex in adult and aged basal forebrain–lesioned rats. Wellman CL, et al. **Behav Neurosci** 1995 Oct;109(5):837–50

Tissue–specific regulation of malic enzyme by thyroid hormone in the neonatal rat. Sood A, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):287–91

Cross–linking and the molecular packing of corneal collagen. Yamauchi M, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):311–5

Properties of circulating leukocytes in spontaneously hypertensive rats. Shen K, et al. **Biochem Cell Biol** 1995 Jul–Aug;73(7–8):491–500

Decrease in free–radical production with age in rat peritoneal macrophages. Alvarez E, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):555–60

A role of asialoglycoproteins for plasma–membrane–induced inhibition of the switching from alpha 1 to beta subtypes in adrenergic response during primary culture of rat hepatocytes. Kajiyama Y, et al. **Biochem J** 1996 Jun 15; 316 (Pt 3):743–9

Preservation of mitochondrial respiratory function by coenzyme Q10 in aged rat skeletal muscle. Sugiyama S, et al. **Biochem Mol Biol Int** 1995 Dec;37(6):1111–20

Failure to withstand oxidative stress induced by phospholipid hydroperoxides as a possible cause of the lens opacities in systemic diseases and ageing. Babizhayev MA. **Biochim Biophys Acta** 1996 Mar 1;1315(2):87–99

Effects of aging on the microclimate pH of the rat jejunum. Ikuma M, et al. **Biochim Biophys Acta** 1996 Apr 3; 1280(1):19–26

Variations of hepatic antioxidant systems and DNA ploidy in rats aged 2 to 8 months. Sanz N, et al. **Biochim Biophys Acta** 1996 Mar 1;1315(2):123–30

Neurochemical effects of a 20 kHz magnetic field on the central nervous system in prenatally exposed mice. Dimberg Y. **Bioelectromagnetics** 1995;16(4):263–7

Relationship between age and nephrotoxicity following single low–dose cisplatin (CDDP) injection in rats. Namikawa K, et al. **Biol Pharm Bull** 1995 Jul;18(7):957–62

Restoration of normal adult penile erectile response in aged rats by long–term treatment with androgens. Garban H, et al. **Biol Reprod** 1995 Dec;53(6):1365–72

Ageing, oscillations and efficiency. Gilbert DA. **Biosystems** 1995;36(1):1–5 (30 ref.)

Leukocyte rolling increases with age [letter] Yamada S, et al. **Blood** 1995 Dec 15;86(12):4707–8

Arterial and cardiac changes in hypertension in the elderly. Asmar R, et al. **Blood Press** 1995;Suppl 3:31–7 (48 ref.)

Hypertension in the elderly: benefits of treatment. Chalmers J. **Blood Press** 1995;Suppl 3:6–10 (24 ref.)

Characteristics of an ideal antihypertensive therapy for elderly hypertensives. Hansson L, et al. **Blood Press** 1995; Suppl 3:68–72 (25 ref.)

Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press** 1995;Suppl 3:21–5 (21 ref.)

Cost–benefit aspects of treatment of hypertension in the elderly. Lindholm LH, et al. **Blood Press** 1995;Suppl 3:11–4

Blood pressure and serum lipids in hypertensive men and women aged 60–97 years. Nguyen PC, et al. **Blood Press** 1995;Suppl 3:26–30

Pharmacological backgrounds of the drug treatment of hypertension in the elderly. van Zwieten PA. **Blood Press** 1995;Suppl 3:15–20 (33 ref.)

Nocturia may be due to growing old [letter] Blandy J. **BMJ** 1996 May 11;312(7040):1228–9

Fertility continues after age 40 [letter; comment] Cooper C. **BMJ** 1996 Apr 13;312(7036):975. Comment on: BMJ 1995 Dec 16;311(7020):1585–6.

Delayed childbearing [editorial] [see comments] Gosden R, et al. **BMJ** 1995 Dec 16;311(7020):1585–6. Comment in: BMJ 1996 Apr 13;312(7036):975.

Intersalt: hypertension rise with age revisited [see comments] Hanneman RL. **BMJ** 1996 May 18;312(7041):1283–4; discussion 1284–7. Comment in: BMJ 1996 May 18;312(7041):1239–40. Comment in: BMJ 1996 May 18;312(7041):1240–1. Comment in: BMJ 1996 May 18;312(7041):1241–2. Comment in: BMJ 1996 Jun 29;312(7047):1659–61.

Why do old men have big ears? [see comments] Heathcote JA. **BMJ** 1995 Dec 23–30;311(7021):1668. Comment in: BMJ 1996 Mar 2;312(7030):582.

Diet and overall survival in elderly people. Trichopoulou A, et al. **BMJ** 1995 Dec 2;311(7018):1457–60

Hormone replacement for men [editorial] Weksler ME. **BMJ** 1996 Apr 6;312(7035):859–60

Hormonal changes in male subjects over–ninety. Ravaglia G, et al. **Boll Soc Ital Biol Sper** 1995 May–Jun; 71(5–6):133–9

Etiology and prevention of age–related hip fractures. Hayes WC, et al. **Bone** 1996 Jan;18(1 Suppl):77S–86S (110 ref.)

Adaptation of non–growing former epiphysis and metaphyseal trabecular bones to aging and immobilization in rat. Ijiri K, et al. **Bone** 1995 Oct;17(4 Suppl):207S–212S

Epidemiology of hip fractures. Kannus P, et al. **Bone** 1996 Jan;18(1 Suppl):57S–63S (59 ref.)

Changes in the male to female ratio at different stages of life [see comments] Clarke CA, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):677–9. Comment in: Br J Obstet Gynaecol 1996 Apr;103(4):391–2.

Beta–adrenoceptor subtypes in young and old rat ventricular myocytes: a combined patch–clamp and binding study. Cerbai E, et al. **Br J Pharmacol** 1995 Sep;116(2):1835–42

Effect of restricted feeding during the rearing period and a "forced moult" at 40 weeks of production on the productivity of Pekin breeder ducks. Olver MD. **Br Poult Sci** 1995 Dec;36(5):737–46

Incremental changes in and distribution of chick weight with hen age in four poultry species. Shalev BA, et al. **Br Poult Sci** 1995 Jul;36(3):415–24

MPTP– and MPP(+)–induced effects on body temperature exhibit age– and strain–dependence in mice. Freyaldenhoven TE, et al. **Brain Res** 1995 Aug 7; 688(1–2):161–70

Effects of dietary restriction on motor learning and cerebellar noradrenergic dysfunction in aged F344 rats. Gould TJ, et al. **Brain Res** 1995 Jul 3;684(2):150–8

Developmental and activity–dependent changes in K+ currents in satellite glial cells in mouse superior cervical ganglion. Konishi T. **Brain Res** 1996 Feb 5;708(1–2):7–15

Increased light intensity prevents the age related loss of vasopressin–expressing neurons in the rat suprachiasmatic nucleus. Lucassen PJ, et al. **Brain Res** 1995 Sep 25; 693(1–2):261–6

Age–related loss of cholinergic–muscarinic coupling to PLC: comparison with changes in brain regional PLC subtypes mRNA distribution. Narang N, et al. **Brain Res** 1996 Feb 5;708(1–2):143–52

The effect of aging on efferent nerve fibers regeneration in mice. Verdú E, et al. **Brain Res** 1995 Oct 23;696(1–2):76–82

Suprachiasmatic nucleus grafts restore circadian function in aged hamsters. Viswanathan N, et al. **Brain Res** 1995 Jul 17;686(1):10–6

Circadian rhythm of spontaneous neuronal activity in the suprachiasmatic nucleus of old hamster in vitro. Watanabe A, et al. **Brain Res** 1995 Oct 16;695(2):237–9

Electrophysiologic correlates of age effects on visuospatial attention shift. Yamaguchi S, et al. **Brain Res Cogn Brain Res** 1995 Dec;3(1):41–9

Transient functional connections between the developing corticospinal tract and cervical spinal interneurons as demonstrated by c–fos immunohistochemistry. Curfs MH, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):214–9

Properties of low Mg2+ induced epileptiform activity in rat hippocampal and entorhinal cortex slices during adolescence. Gloveli T, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):145–52

NMDA antagonism during development extends sparing of hindlimb function to older spinally transected rats. Maier DL, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):135–44

Changes in blood pressure control in aged rats. Werner A, et al. **Braz J Med Biol Res** 1995 May;28(5):603–7

Aging changes in vertebral morphometry. Diacinti D, et al. **Calcif Tissue Int** 1995 Dec;57(6):426–9

Trabecular bone cell proliferation ex vivo increases with donor age in the rat: it is correlated with the extent of bone loss and not with histomorphometric indices of bone formation. Egrise D, et al. **Calcif Tissue Int** 1996 Jul; 59(1):45–50

Is bone mineral density advantage maintained long–term in previous weight lifters? Karlsson MK, et al. **Calcif Tissue Int** 1995 Nov;57(5):325–8

Age–related changes of whole skeleton and body composition in healthy men. Nuti R, et al. **Calcif Tissue Int** 1995 Nov;57(5):336–9

Concentric and eccentric knee extension strength in older and younger men and women. Porter MM, et al. **Can J Appl Physiol** 1995 Dec;20(4):429–39 (38 ref.)

Age–related changes in electrophysiological responses to muscarinic receptor stimulation in rat myocardium. Su N, et al. **Can J Physiol Pharmacol** 1995 Oct;73(10):1430–6

Stress triggers different pathophysiological mechanisms in younger and older cardiomyopathic hamsters. Chang Q, et al. **Cardiovasc Res** 1995 Dec;30(6):985–91

Age–related abnormalities in regulation of the ryanodine receptor in rat fast–twitch muscle. Damiani E, et al. **Cell Calcium** 1996 Jan;19(1):15–27

Band 3, the anion transporter, is conserved during evolution: implications for aging and vertebrate evolution. Kay MM, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Sep;41(6):833–42

Study on the DNA synthesis of pulmonary cells in aging mice by light microscopic radioautography. Sun L, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Sep;41(6):851–9

Effects of aging and castration on plasminogen activator and metalloprotease activities in the rat prostate complex. Wilson MJ, et al. **Cell Mol Biol Res** 1995;41(6):603–12

The spatio–temporal pattern of photoreceptor degeneration in the aged rd/rd mouse retina. Jiménez AJ, et al. **Cell Tissue Res** 1996 May;284(2):193–202

Ultrastructural localization of nitric oxide synthase and endothelin in rat pulmonary artery and vein during postnatal development and ageing. Loesch A, et al. **Cell Tissue Res** 1996 Mar;283(3):355–65

Effects of intraventricular encapsulated hNGF–secreting fibroblasts in aged rats. Lindner MD, et al. **Cell Transplant** 1996 Mar–Apr;5(2):205–23

Prefrontal alterations during memory processing in aging. Nielsen–Bohlman L, et al. **Cereb Cortex** 1995 Nov–Dec; 5(6):541–9

New oral dosage form for elderly patients. II. Release behavior of benfotiamine from silk fibroin gel. Hanawa T, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):872–6

Regional taste sensitivity to NaCl: relationship to subject age, tongue locus and area of stimulation. Matsuda T, et al. **Chem Senses** 1995 Jun;20(3):283–90

Reliability and validity of electrogustometry and its application to young and elderly persons. Murphy C, et al. **Chem Senses** 1995 Oct;20(5):499–503

Taste sensitivity and aging: high incidence of decline revealed by repeated threshold measures. Stevens JC, et al. **Chem Senses** 1995 Aug;20(4):451–9

Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort [see comments] Nicotra MB, et al. **Chest** 1995 Oct;108(4):955–61 . Comment in: Chest 1996 Aug;110(2):579.

Evaluating the bronchodilator response in elderly who have asthma [letter; comment] Teramoto S. **Chest** 1996 Feb; 109(2):589–90. Comment on: Chest 1995 Aug;108(2):401–6.

Dissociation of the restoration of copulatory behavior and the testicular morphology in old male rats with fetal brain grafting. Peng YI, et al. **Chin J Physiol** 1995;38(1):13–7

Effects of age and time of day on preferred work rates during prolonged exercise. Atkinson G, et al. **Chronobiol Int** 1995 Apr;12(2):121–34

Oestrogens and the structural and functional plasticity of neurons: implications for memory, ageing and neurodegenerative processes. McEwen BS, et al. **Ciba Found Symp** 1995;191:52–66; discussion 66–73 (43 ref.)

Aging does not affect the activation of the myocyte insulin–like growth factor–1 autocrine system after infarction and ventricular failure in Fischer 344 rats. Cheng W, et al. **Circ Res** 1996 Apr;78(4):536–46

Aging and cardiovascular disease: a summary of the Eighth Münster International Arteriosclerosis Symposium [news] Wissler RW, et al. **Circulation** 1996 May 1;93(9):1608–12

Changes in the sweatspot test with ageing and relation to cardiovascular autonomic function. Robinson T, et al. **Clin Auton Res** 1995 Jun;5(3):135–8

Serum testosterone and its relation to bone mineral density and body composition in normal males. Ongphiphadhanakul B, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):727–33

Blood pressure–related changes of endothelium–dependent relaxation in the aorta from SHRSP at developmental ages of hypertension. Tomita T, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S139–41

Effects of age on nutrient requirements. Chernoff R. **Clin Geriatr Med** 1995 Nov;11(4):641–51 (81 ref.)

Exercise, nutrition, and aging. Evans WJ. **Clin Geriatr Med** 1995 Nov;11(4):725–34 (49 ref.)

Age–related difference in tamoxifen disposition. Peyrade F, et al. **Clin Pharmacol Ther** 1996 Apr;59(4):401–10

Variability in the arterial pressure of newborns as compared to that of adults and old men. Menghetti E, et al. **Clin Ter** 1995 Oct;146(10):617–21

Syndromes of language dissolution in aging and dementia. Kirshner HS, et al. **Compr Ther** 1995 Sep;21(9):519–23 (30 ref.)

Interaction of oral contraceptive use with the effects of age, exercise habits and other cardiovascular risk modifiers on metabolic risk markers. Godsland IF. **Contraception** 1996 Jan;53(1):9–16

Topographic analysis of the changes in corneal shape due to aging. Hayashi K, et al. **Cornea** 1995 Sep;14(5):527–32

Calpain activity in the retinas of normal and RCS rats. Azarian SM, et al. **Curr Eye Res** 1995 Aug;14(8):731–5

Antioxidant enzymes of the human retina: effect of age on enzyme activity of macula and periphery. De La Paz MA, et al. **Curr Eye Res** 1996 Mar;15(3):273–8

A comparison of binocular summation in young and older patients. Pardhan S. **Curr Eye Res** 1996 Mar;15(3):315–9

Clinical evaluation of voiding symptoms and uroflowmetry in elderly men. A prospective study. Jørgensen JB. **Dan Med Bull** 1995 Jun;42(3):244–56 (113 ref.)

Leukocyte hexokinase activity in aging and Alzheimer disease. Antuono PG, et al. **Dementia** 1995 Jul–Aug; 6(4):200–4

Transient enhancement of cholinergic neurochemical markers induced by NGF in aged F344 rats. Santucci AC, et al. **Dementia** 1995 Jul–Aug;6(4):179–84

Synapse–associated expression of an acetylcholine receptor–inducing protein, ARIA/heregulin, and its putative receptors, ErbB2 and ErbB3, in developing mammalian muscle. Moscoso LM, et al. **Dev Biol** 1995 Nov; 172(1):158–69

Ontogeny of eyeblink conditioning in the rat: auditory frequency and discrimination learning effects. Andrews SJ,

et al. **Dev Psychobiol** 1995 Sep;28(6):307-20

A developmental and component analysis of active sleep. Blumberg MS, et al. **Dev Psychobiol** 1996 Jan;29(1):1-22

Salicylate-induced changes in auditory thresholds of adolescent and adult rats. Brennan JF, et al. **Dev Psychobiol** 1996 Jan;29(1):69-86

Auditory brainstem response in sheep. Part II: Postnatal development. Griffiths SK, et al. **Dev Psychobiol** 1996 Jan; 29(1):53-68

The surface evoked potential and parvalbumin-immunoreactivity in the somatosensory cortex of the developing rat. Seo-Hiraiwa ML, et al. **Dev Psychobiol** 1995 Sep;28(6):337-51

Age-dependent differences in insulin secretion and intracellular handling of insulin in isolated pancreatic islets of the rat. Borg LA, et al. **Diabete Metab** 1995 Dec; 21(6):408-14

Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Ferrannini E, et al. **Diabetes** 1996 Jul;45(7):947-53

Pancreatic polypeptide responses to hypoglycemia in aging and diabetes [letter] Meneilly GS. **Diabetes Care** 1996 May; 19(5):544-6

Age-related alteration of pancreatic beta-cell function. Increased proinsulin and proinsulin-to-insulin molar ratio in elderly, but not in obese, subjects without glucose intolerance. Shimizu M, et al. **Diabetes Care** 1996 Jan; 19(1):8-11

Insulin resistance in skeletal muscle of the male Otsuka Long-Evans Tokushima Fatty rat, a new model of NIDDM. Sato T, et al. **Diabetologia** 1995 Sep;38(9):1033-41

Alterations in the ultradian oscillations of insulin secretion and plasma glucose in aging. Scheen AJ, et al. **Diabetologia** 1996 May;39(5):564-72

Beta-cell growth in adolescent and adult rats treated with streptozotocin during the neonatal period. Wang RN, et al. **Diabetologia** 1996 May;39(5):548-57

Increased susceptibility of rat gastric mucosa to ulcerogenic stimulation with aging. Role of capsaicin-sensitive sensory neurons. Miyake H, et al. **Dig Dis Sci** 1996 Feb;41(2):339-45

Influence of age on natural and delayed healing of experimentally-induced gastric ulcers in rats. Penney AG, et al. **Dig Dis Sci** 1996 Sep;41(9):1838-44

Aging impairs afferent nerve function in rat intestine. Reduction of mesenteric hyperemia induced by intraduodenal capsaicin and acid. Seno K, et al. **Dig Dis Sci** 1996 Feb;41(2):346-51

Age-related changes of water and fat content in muscles estimated by magnetic resonance (MR) imaging. Tsubahara A, et al. **Disabil Rehabil** 1995 Aug-Sep;17(6):298-304

The optics of the eye-lens and lenticular senescence. A review. Pierscionek BK, et al. **Doc Ophthalmol** 1995; 89(4):321-35 (96 ref.)

The ontogeny of serum insulin-like growth factor-I concentration in foals: effects of dam parity, diet, and age at weaning. Cymbaluk NF, et al. **Domest Anim Endocrinol** 1996 May;13(3):197-209

Osteoarthritis in older patients. Optimum treatment. Bagge E, et al. **Drugs Aging** 1995 Sep;7(3):176-83 (47 ref.)

Switching drug availability from prescription only to over-the-counter status. Are elderly patients at increased risk? Benrimoj SI, et al. **Drugs Aging** 1995 Oct;7(4):255-65 (152 ref.)

Potential of antineoplastons in diseases of old age. Burzynski SR. **Drugs Aging** 1995 Sep;7(3):157-67 (175 ref.)

Age-related changes in vascular smooth muscle and endothelium. Dohi Y, et al. **Drugs Aging** 1995 Oct; 7(4):278-91 (141 ref.)

Drug poisoning in older patients. Preventative and management strategies. Haselberger MB, et al. **Drugs Aging** 1995 Oct;7(4):292-7 (32 ref.)

Anti-amyloid drugs: potential in the treatment of diseases associated with aging. Kisilevsky R. **Drugs Aging** 1996 Feb; 8(2):75-83 (70 ref.)

Sinusitis in the aged. Optimal management strategies. Knutson JW, et al. **Drugs Aging** 1995 Oct;7(4):310-6 (24 ref.)

Physiological aspects of aging. Implications for the treatment of cancer. Lichtman SM. **Drugs Aging** 1995 Sep;7(3):212-25 (173 ref.)

Should all older people be treated with growth hormone? Marcus R. **Drugs Aging** 1996 Jan;8(1):1-4

Epidemiology of adverse drug events in the nursing home setting. Monette J, et al. **Drugs Aging** 1995 Sep;7(3):203-11 (57 ref.)

Optimum treatment of rhinitis in the elderly. Tan R, et al. **Drugs Aging** 1995 Sep;7(3):168-75 (21 ref.)

A perspective on age-related changes of the swallowing mechanism and their clinical significance [editorial; comment] Feinberg MJ. **Dysphagia** 1996 Summer; 11(3):185-6. Comment on: Dysphagia 1996 Summer;11(3):180-4.

Age increases brain complexity. Anokhin AP, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jul;99(1):63-8

Postural modulation of the soleus H reflex in young and old subjects. Koceja DM, et al. **Electroencephalogr Clin Neurophysiol** 1995 Dec; 97(6):387-93

Aging, caffeine, and information processing: an event-related potential analysis. Lorist MM, et al. **Electroencephalogr Clin Neurophysiol** 1995 Sep; 96(5):453-67

Age-related changes in the electrophysiological response to visual stimulus novelty: a topographical approach. Thomas KM, et al. **Electroencephalogr Clin Neurophysiol** 1996 Apr; 98(4):294-308

Aging effects on auditory middle latency responses. Azumi T, et al. **Electromyogr Clin Neurophysiol** 1995 Nov; 35(7):397-401

Neuromuscular fatigue and recovery in women at different ages during heavy resistance loading. Häkkinen K. **Electromyogr Clin Neurophysiol** 1995 Nov;35(7):403-13

Proteolytic activity of IGFBP-3 in various clinical conditions during childhood studied by means of western immunoblotting. Hasegawa Y, et al. **Endocr J** 1995 Aug; 42(4):569-76

Secretion of insulin and glucagon by the perfused pancreas of genetically obese (fa/fa) Zucker rats and its alteration with aging. Hiramatsu S, et al. **Endocr J** 1995 Aug; 42(4):563-7

The aging thyroid. Mariotti S, et al. **Endocr Rev** 1995 Dec; 16(6):686-715 (403 ref.)

Developmental regulation of pituitary growth hormone-releasing hormone receptor gene expression in the rat. Korytko AI, et al. **Endocrinology** 1996 Apr; 137(4):1326-31

Decreased gonadotropin-releasing hormone neurosecretory response to glutamate agonists in middle-aged female rats on proestrus afternoon: a possible role in reproductive aging? Zuo Z, et al. **Endocrinology** 1996 Jun;137(6):2334-8

Ventilatory and timing parameters in normal horses at rest up to age one year. Koterba AM, et al. **Equine Vet J** 1995 Jul;27(4):257-64

Changes in breathing pattern in the normal horse at rest up to age one year. Koterba AM, et al. **Equine Vet J** 1995 Jul;27(4):265-74

Autoregulation of cochlear blood flow in young and aged mice. Nakashima T, et al. **Eur Arch Otorhinolaryngol** 1995; 252(5):308-11

Anaerobic and aerobic peak power output and the force-velocity relationship in endurance-trained athletes: effects of aging. Chamari K, et al. **Eur J Appl Physiol** 1995; 71(2-3):230-4

Maximal oxygen uptake in 153 elderly Dutch people (69-87 years) who participated in the 1993 Nijmegen 4-day march. de Wild GM, et al. **Eur J Appl Physiol** 1995;72(1-2):134-43

Neuromuscular performance in voluntary bilateral and unilateral contraction and during electrical stimulation in men at different ages. Häkkinen K, et al. **Eur J Appl Physiol** 1995;70(6):518-27

Effectiveness of lower-level voluntary exercise in disease prevention of mature rats. I. Cardiovascular risk factor modification. Suzuki K, et al. **Eur J Appl Physiol** 1995; 71(2-3):240-4

Stretch-shortening cycle during plantar flexion in young and elderly women and men. Svantesson U, et al. **Eur J Appl Physiol** 1995;71(5):381-5

Thermoregulation during heat exposure of young children compared to their mothers. Tsuzuki-Hayakawa K, et al. **Eur J Appl Physiol** 1995;72(1-2):12-7

Effect of regular physical training on age-associated alteration of body composition in men. Horber FF, et al. **Eur J Clin Invest** 1996 Apr;26(4):279-85

The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Andros E, et al. **Eur J Clin Pharmacol** 1996;50(1-2):41-6

Influence of age on venodilator effect of isoproterenol and amrinone. Harada K, et al. **Eur J Clin Pharmacol** 1996; 50(1-2):37-40

Involvement of serotonin in developmental plasticity of kitten visual cortex. Gu Q, et al. **Eur J Neurosci** 1995 Jun 1; 7(6):1146-53

The unique characteristics of inflammatory responses in mouse brain are acquired during postnatal development. Lawson LJ, et al. **Eur J Neurosci** 1995 Jul 1;7(7):1584-95

Failure of axon regeneration in postnatal rat entorhinohippocampal slice coculture is due to maturation of the axon, not that of the pathway or target. Li D, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1164-71

Glycine- and GABA-activated currents in identified glial cells of the developing rat spinal cord slice. Pastor A, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1188-98

Quantitative myocardial thallium single-photon emission computed tomography in normal women: demonstration of age-related differences. Cohen M, et al. **Eur J Nucl Med** 1996 Jan;23(1):25-30

Quantitative electroencephalography in aging brain and cerebrovascular disease: the effects of almitrine-raubasine. Sebban C. **Eur Neurol** 1995;35 Suppl 1:37-42 (16 ref.)

Physiological aging and penile erectile function: a study in the rat. Calabrò A, et al. **Eur Urol** 1996;29(2):240-4

Aging and body composition: biological changes and methodological issues. Going S, et al. **Exerc Sport Sci Rev** 1995;23:411-58 (173 ref.)

The evolution of research on motor development: new approaches bringing new insights. Whitall J. **Exerc Sport Sci Rev** 1995;23:243-73 (116 ref.)

Food identification, taste complaints, and depression in younger and older adults. Bischmann DA, et al. **Exp Aging Res** 1996 Jan-Mar;22(1):23-32

Modifications with aging in the role played by vision and proprioception for movement control. Chaput S, et al. **Exp Aging Res** 1996 Jan-Mar;22(1):1-21

Neuropsychological test performance, cognitive functioning, blood pressure, and age: the Framingham Heart Study. Elias MF, et al. **Exp Aging Res** 1995 Oct-Dec;21(4):369-91

Blood pressure, hypertension, and age as risk factors for poor cognitive performance. Elias PK, et al. **Exp Aging Res** 1995 Oct-Dec;21(4):393-417

Memory performance in relation to age, verbal ability, and activity. Erber JT, et al. **Exp Aging Res** 1996 Jan-Mar; 22(1):59-72

The effects of age on guided conjunction search. Folk CL, et al. **Exp Aging Res** 1996 Jan-Mar;22(1):99-118

Factors that influence metaphor comprehension skills in adulthood. Gregory ME, et al. **Exp Aging Res** 1996 Jan-Mar;22(1):83-98

Age-related impairment in instrumental conditioning is restricted to initial acquisition. Port RL, et al. **Exp Aging Res** 1996 Jan-Mar;22(1):73-81

Introduction of retired breeder F344/DuCrj rats for aging research. Takeshita M, et al. **Exp Anim** 1996 Apr; 45(2):205-8

Age-related changes in open-loop and closed-loop postural control mechanisms. Collins JJ, et al. **Exp Brain Res** 1995; 104(3):480-92

Validation of a mechanical method for measuring skin thickness: relation to age, body mass index, skin thickness determined by ultrasound, and bone mineral density. Kann P, et al. **Exp Clin Endocrinol Diabetes** 1995;103(2):113-8

The long-term effect of low protein diet on the somatostatin hypothalamic neuronal system and the pituitary growth hormone cells in growing ewe. Polkowska J, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):59-66

Proceedings of the 2nd International Symposium on the Neurobiology and Neuroendocrinology of Aging. Bregenz, Austria, July 24-28, 1994. **Exp Gerontol** 1995 May-Aug; 30(3-4):189-442

Impaired expression of hematopoietic growth factors: a candidate mechanism for the hematopoietic defect of aging. Buchanan JP, et al. **Exp Gerontol** 1996 Jan-Apr; 31(1-2):135-44

Central auditory aging: GABA changes in the inferior colliculus. Caspary DM, et al. **Exp Gerontol** 1995 May-Aug;30(3-4):349-60 (85 ref.)

Estrogen-induced hypothalamic beta-endorphin neuron loss: a possible model of hypothalamic aging. Desjardins GC, et al. **Exp Gerontol** 1995 May-Aug;30(3-4):253-67 (143 ref.)

The role of aging in the clinical expression of essential tremor. Elble RJ. **Exp Gerontol** 1995 May-Aug;30(3-4):337-47 (43 ref.)

Aging of neurons in the mollusc Lymnaea stagnalis small parietal ganglion: a morpho-functional comparison in the same neuron. Frolkis VV, et al. **Exp Gerontol** 1995 Sep-Oct;30(5):533-44

Prohibitin: potential role in senescence, development, and tumor suppression. McClung JK, et al. **Exp Gerontol** 1995 Mar-Apr;30(2):99-124 (90 ref.)

Individual differences in hypothalamic-pituitary-adrenal activity in later life and hippocampal aging. Meaney MJ, et al. **Exp Gerontol** 1995 May-Aug;30(3-4):229-51 (125 ref.)

Circadian temperature rhythms of older people. Monk TH, et al. **Exp Gerontol** 1995 Sep-Oct;30(5):455-74

The pineal gland and melatonin in relation to aging: a summary of the theories and of the data. Reiter RJ. **Exp Gerontol** 1995 May-Aug;30(3-4):199-212 (73 ref.)

Gonadotropin secretion during aging in women: review article. Rossmanith WG. **Exp Gerontol** 1995 May-Aug; 30(3-4):369-81 (38 ref.)

Changes in tissue responsiveness to hormones and neurotransmitters during aging. Roth GS. **Exp Gerontol** 1995 May-Aug;30(3-4):361-8 (30 ref.)

Effects of age on the pharmacodynamics of naproxen in the rat. Satterwhite JH, et al. **Exp Gerontol** 1995 Sep-Oct; 30(5):505-15

Limbic control of endocrine glands in aged rats. Verkhratsky NS. **Exp Gerontol** 1995 May-Aug;30(3-4):415-21

Intraperikaryal neurofilamentous accumulations in a subset of retinal ganglion cells in aged mice that express a human neurofilament gene. Vickers JC, et al. **Exp Neurol** 1995 Dec;136(2):266-9

Rapid development and a long life: an association expected under a stress theory of aging. Parsons PA. **Experientia** 1996 Jul 15;52(7):643-6 (54 ref.)

Longitudinal change of refractive error in infants during the first year of life. Wood IC, et al. **Eye** 1995;9 (Pt 5):551-7

Lymphatic absorption of retinol in young, mature, and old rats: influence of dietary restriction. Chevalier S, et al. **FASEB J** 1996 Jul;10(9):1085-90

Relationship between muscle myosin isoforms and contractile features in rabbit fast-twitch denervated muscle. d'Albis A, et al. **FEBS Lett** 1995 Nov 13;375(1-2):67-8

Cellular distribution of protein kinase C isozymes in CD3-mediated stimulation of human T lymphocytes with aging. Fulop T Jr, et al. **FEBS Lett** 1995 Nov 13; 375(1-2):69-74

Inhibitor sensitivity of respiratory complex I in human platelets: a possible biomarker of ageing. Merlo Pich M, et al. **FEBS Lett** 1996 Feb 12;380(1-2):176-8

Fetal myosin heavy chain increases in human masseter muscle during aging. Monemi M, et al. **FEBS Lett** 1996 May 13; 386(1):87-90

Age-dependent decrease in the growth hormone response to growth hormone-releasing hormone in normally cycling women. Coiro V, et al. **Fertil Steril** 1996 Aug;66(2):230-4

Effect of age on sperm fertility potential: oocyte donation

as a model. Gallardo E, et al. **Fertil Steril** 1996 Aug; 66(2):260–4

Age does not affect uterine resistance to vascular flow in patients undergoing oocyte donation. Guanes PP, et al. **Fertil Steril** 1996 Aug;66(2):265–70

The age-related decline in female fecundity: a quantitative controlled study of implanting capacity and survival of individual embryos after in vitro fertilization. Hull MG, et al. **Fertil Steril** 1996 Apr;65(4):783–90

Intracytoplasmic sperm injection: achievement of high pregnancy rates in couples with severe male factor infertility is dependent primarily upon female and not male factors. Oehninger S, et al. **Fertil Steril** 1995 Nov; 64(5):977–81

Transformation of sterols pattern in course of late development of rat brain. Wender M, et al. **Folia Neuropathol** 1995;33(1):31–4

Morphological study of microglia in human mesencephalon during the development and aging. Wierzba-Bobrowicz T, et al. **Folia Neuropathol** 1995;33(2):77–83 (46 ref.)

Age estimation from the permanent molar in northeast China by the method of average stage of attrition. Li C, et al. **Forensic Sci Int** 1995 Oct 30;75(2–3):189–96

Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study. Feldman M, et al. **Gastroenterology** 1996 Apr;110(4):1043–52

Age-related changes in [3H]baclofen binding in mouse cerebellum. Ishige K. **Gen Pharmacol** 1995 Oct; 26(6):1229–35

Density and age-specific mortality [comment] Curtsinger JW. **Genetica** 1995;96(3):179–82; discussion 183–6, 187–9. Comment on: Genetica 1993;91(1–3):99–109.

Reversing sarcopenia: how weight training can build strength and vitality. Evans WJ. **Geriatrics** 1996 May;51(5):46–7, 51–3; quiz 54 (18 ref.)

"The Alzheimerization of aging": a response [letter; comment] Blumenthal HT. **Gerontologist** 1995 Dec;35(6):721–3. Comment on: Gerontologist 1995 Aug;35(4):526–32.

Sex differences in human mortality and aging at late ages: the effect of mortality selection and state dynamics. Manton KG, et al. **Gerontologist** 1995 Oct;35(5):597–608

A note on viewing functional change in later life as migration. Uhlenberg P. **Gerontologist** 1995 Aug;35(4):549–52

Assessing biological age: reality? Bellamy D. **Gerontology** 1995;41(6):322–4 (2 ref.)

Assessing biological age: practicality? Bulpitt CJ. **Gerontology** 1995;41(6):315–21 (20 ref.)

Training influence on age-dependent changes in the gait of rats. Dorner H, et al. **Gerontology** 1996;42(1):7–13

Influence of age, treadmill running, and food restriction on plasma fibrinogen concentration and expression of gamma chain mRNA in female Sprague-Dawley rats. Dorner H, et al. **Gerontology** 1995;41(5):252–9

Influence of aging on the relaxant responses to omega-3 fatty acids in Fischer 344 rat aorta. Engler MB, et al. **Gerontology** 1996;42(1):25–35

Poor vision and dizziness in the elderly [letter; comment] Jack C, et al. **Gerontology** 1996;42(1):59. Comment on: Gerontology 1995;41(5):280–5. Comment on: Gerontology 1995;41(5):286–98.

Decreased mitogenic and osteogenic responsiveness of calvarial osteoblasts isolated from aged rats to basic fibroblast growth factor. Kato H, et al. **Gerontology** 1995; 41 Suppl 1:20–7

Developmental regulation of Xenopus beta-amyloid precursor protein gene expression. Okado H, et al. **Gerontology** 1995;41 Suppl 1:7–12

Are anthropometric changes in healthy adults caused by modifications in dietary habits or by aging? Ruiz-Torres A, et al. **Gerontology** 1995;41(5):243–51

Two-point discrimination test of the skin as an index of sensory aging. Shimokata H, et al. **Gerontology** 1995; 41(5):267–72

Does the supine position worsen respiratory function in elderly subjects? Vitacca M, et al. **Gerontology** 1996; 42(1):46–53

Changes in D-aspartic acid in human deciduous teeth with age from 1–20 years. Ohtani S, et al. **Growth Dev Aging** 1996 Spring;60(1):1–6

Peripheral nerve and muscle function in the aging Fischer 344/brown-Norway rat. Wineinger MA, et al. **Growth Dev Aging** 1995 Fall;59(3):107–19

Immunohistochemical localization of insulin-like growth factor-II in the perinatal rat gonad. Koike S, et al. **Growth Regul** 1995 Dec;5(4):185–89

Age related changes in gut physiology and nutritional status. Lovat LB. **Gut** 1996 Mar;38(3):306–9

Appraisal support predicts age-related differences in cardiovascular function in women. Uchino BN, et al. **Health Psychol** 1995 Nov;14(6):556–62

Age-related changes in auditory evoked potentials of gerbils. III. Low-frequency responses and repetition rate effects. Boettcher FA, et al. **Hear Res** 1995 Jul;87(1–2):208–19

Masking of auditory brainstem responses in young and aged gerbils. Boettcher FA, et al. **Hear Res** 1995 Sep; 89(1–2):1–13

Age-related changes in cochlear vascular conductance in mice. Brown JN, et al. **Hear Res** 1995 Jun;86(1–2):189–94

Decreased inhibition to lateral superior olive neurons in young and aged Sprague-Dawley rats. Finlayson PG. **Hear Res** 1995 Jul;87(1–2):84–95

Estimating the contribution of non-sensory factors to infant-adult differences in behavioral thresholds. Nozza RJ. **Hear Res** 1995 Nov;91(1–2):72–8

Postnatal development of CA3 pyramidal neurons and their afferents in the Ammon's horn of rhesus monkeys. Seress L, et al. **Hippocampus** 1995;5(3):217–31

Ageing and sperm function. Haidl G, et al. **Hum Reprod** 1996 Mar;11(3):558–60

Effects of aging on the female reproductive system. Pellicer A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:77–83 (37 ref.)

Influence of aging on insulin sensitivity in essential hypertensives and normotensives. Hirata A, et al. **Hypertens Res** 1995 Dec;18(4):307–11

The fibrinolytic system is not impaired in older men with hypertension. DeSouza CA, et al. **Hypertension** 1996 May; 27(5):1053–8

G protein alterations in hypertension and aging. Feldman RD, et al. **Hypertension** 1995 Nov;26(5):725–32

Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Gerhard M, et al. **Hypertension** 1996 Apr;27(4):849–53

Comparison of early and late start of antihypertensive agents and baroreceptor reflexes. Kumagai K, et al. **Hypertension** 1996 Feb;27(2):209–18

Preweanling administration of terazosin decreases blood pressure of hypertensive rats in adulthood. McCarty R, et al. **Hypertension** 1996 May;27(5):1115–20

Objective method to determine the contribution of the great toe to standing balance and preliminary observations of age-related effects. Tanaka T, et al. **IEEE Trans Rehabil Eng** 1996 Jun;4(2):84–90

Donor site, age, and health affect fibroblast growth in culture [letter] Ulrich-Merzenich G, et al. **In Vitro Cell Dev Biol Anim** 1995 Jul-Aug;31(7):494–6

Age-adjusted normal confidence intervals for heart rate variability in healthy subjects during head-up tilt. Piccirillo G, et al. **Int J Cardiol** 1995 Jun 30;50(2):117–24

Differential expression of the full-length and secreted truncated forms of EGF receptor during formation of dental tissues. Davideau JL, et al. **Int J Dev Biol** 1995 Aug; 39(4):605–15

Structure and function of basement membranes. Engvall E. **Int J Dev Biol** 1995 Oct;39(5):781–7 (71 ref.)

Studies on the physiological role of brain-derived neurotrophic factor and neurotrophin-3 in knockout mice. Ernfors P, et al. **Int J Dev Biol** 1995 Oct;39(5):799–807

Normal development and neoplasia: the imprinting connection. Ohlsson R, et al. **Int J Dev Biol** 1995 Oct; 39(5):869–76 (54 ref.)

Effect of early cortical lesion on the acute model of epilepsy. Culić M, et al. **Int J Dev Neurosci** 1995 Oct;13(6):655–8

Reinnervation of denervated iris by transplanted sympathetic ganglia: effect of neuronal age. Hiebert J, et al. **Int J Dev Neurosci** 1995 Oct;13(6):627–34

The relationship of blood lead and dietary calcium to blood pressure in the normative aging study. Proctor SP, et al. **Int J Epidemiol** 1996 Jun;25(3):528–36

British Connective Tissue Society Meeting. Bristol, 10–11 April 1996. Abstracts. **Int J Exp Pathol** 1996 Jun; 77(3):A1–25

Age-related thymus involution: zinc reverses in vitro the thymulin secretion defect. Mocchegiani E, et al. **Int J Immunopharmacol** 1995 Sep;17(9):745–9

Age estimation in biopsy specimens of dentin. Ritz S, et al. **Int J Legal Med** 1995;108(3):135–9

Effects of aging on P3 components of somatosensory event-related potentials elicited by different stimulus conditions. Conventional averages and single-trial analysis. Ito J, et al. **Int J Neurosci** 1996 Apr;85(3–4):165–72

Transcranial Doppler assessment of cerebral flow velocity at rest and during voluntary movements in young and elderly healthy subjects. Orlandi G, et al. **Int J Neurosci** 1996 Feb;84(1–4):45–53

Age-related changes in the noradrenergic pattern and receptor responses of the rat cardiovascular system after repeated microwave exposure. Soldani P, et al. **Int J Neurosci** 1995 May;82(1–2):61–9

Evoked brain rhythms are altered markedly in middle-aged subjects: single-sweep analysis. Yordanova J, et al. **Int J Neurosci** 1996 Mar;85(1–2):155–63

Age-related association between body mass index and blood pressure: the Humboldt Study. Chen Y, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19(11):825–31

Body fatness and waist circumference are independent predictors of the age-associated increase in fasting insulin levels in healthy men and women. Colman E, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19(11):798–803

Predictors of waist circumference change in healthy young adults. Eck LH, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19(11):765–9

Overweight and leanness in adulthood: prospective study of male participants in the Normative Aging Study. Grinker JA, et al. **Int J Obes Relat Metab Disord** 1996 Jun; 20(6):561–9

Influence of macronutrients on adiposity development: a follow up study of nutrition and growth from 10 months to 8 years of age. Rolland-Cachera MF, et al. **Int J Obes Relat Metab Disord** 1995 Aug;19(8):573–8

Effects of pancreatic duct ligation and aging on acute taurocholate-induced pancreatitis. Experiments in the perfused pancreas in rats. Kimura W, et al. **Int J Pancreatol** 1996 Apr;19(2):117–27

The influence of older age on breast cancer treatment decisions and outcome [see comments] Merchant TE, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):565–70 . Comment in: Int J Radiat Oncol Biol Phys 1996 Feb 1;34(3):753–4.

Ageism or acumen -- the treatment of older women with breast cancer [editorial; comment] Shank B. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):753–5. Comment on: Int J Radiat Oncol Biol Phys 1996 Feb 1;34(3):565–70.

An assessment of carbohydrate intake in collegiate distance runners. Tanaka JA, et al. **Int J Sport Nutr** 1995 Sep; 5(3):206–14

Force development of dynamic and static contractions in children and adults. Asai H, et al. **Int J Sports Med** 1996 Apr;17(3):170–4

Vernier acuity and aging. Lakshminarayanan V, et al. **Int Ophthalmol** 1995;19(2):109–15 (61 ref.)

Changes in renal function with aging among Japanese. Hosoya T, et al. **Intern Med** 1995 Jun;34(6):520–7

Tissue transglutaminase in apoptosis of photoreceptor cells in rat retina. Zhang SR, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1793–9

Age, sex and mental retardation related changes of brainstem auditory evoked potentials in Down's syndrome. Ferri R, et al. **Ital J Neurol Sci** 1995 Sep;16(6):377–83

Preconditioning does not prevent postischemic dysfunction in aging heart. Abete P, et al. **J Am Coll Cardiol** 1996 Jun; 27(7):1777–86

Bone composition and histological analysis of young and aged rats fed diets of varied calcium bioavailability. Peterson CA, et al. **J Am Coll Nutr** 1995 Jun;14(3):278–85

Salt taste perceptions and preferences are unrelated to sodium consumption in healthy older adults. Drewnowski A, et al. **J Am Diet Assoc** 1996 May;96(5):471–4

Predictors of change in walking velocity in older adults. Gibbs J, et al. **J Am Geriatr Soc** 1996 Feb;44(2):126–32

Doppler assessment of diastolic function comes of age [comment] Kitzman DW. **J Am Geriatr Soc** 1996 Jun; 44(6):729–32. Comment on: J Am Geriatr Soc 1996 Jun;44(6):634–7.

Shoe characteristics and balance in older women. Lord SR, et al. **J Am Geriatr Soc** 1996 Apr;44(4):429–33

Age-dependent influence on heart rate variability in salt-sensitive hypertensive subjects. Piccirillo G, et al. **J Am Geriatr Soc** 1996 May;44(5):530–8

Do neural factors underlie age differences in rapid ankle torque development? Thelen DG, et al. **J Am Geriatr Soc** 1996 Jul;44(7):804–8

Differences in the signs and symptoms of hyperthyroidism in older and younger patients. Trivalle C, et al. **J Am Geriatr Soc** 1996 Jan;44(1):50–3

The effects of ageing on cutaneous wound healing in mammals. Ashcroft GS, et al. **J Anat** 1995 Aug;187 (Pt 1):1–26 (287 ref.)

The composition of trigeminal nerve branches in normal adult chickens and after debeaking at different ages. Dubbeldam JL, et al. **J Anat** 1995 Jun;186 (Pt 3):619–27

Localisation of alkaline phosphatase in equine growth cartilage. Henson FM, et al. **J Anat** 1995 Aug;187 (Pt 1):151–9

Influence of age on the late retrograde effects of sciatic nerve section in the rat. Kerezoudi E, et al. **J Anat** 1995 Aug; 187 (Pt 1):27–35

Expression and upregulation of transferrin receptors and iron uptake in the epiplexus cells of different aged rats injected with lipopolysaccharide and interferon-gamma. Lu J, et al. **J Anat** 1995 Dec;187 (Pt 3):603–11

Arterial tortuosity in the femoropopliteal region during knee flexion: a magnetic resonance angiographic study. Wensing PJ, et al. **J Anat** 1995 Aug;187 (Pt 1):133–9

Effects of two non-steroidal antiandrogens on testicular function in prepubertal rats. Rulli SB, et al. **J Androl** 1995 May-Jun;16(3):225–32

Beta-adrenergic receptors in porcine adipocyte membranes: modification by animal age, depot site, and dietary protein deficiency. Akanbi KA, et al. **J Anim Sci** 1996 Mar; 74(3):551–61

Evaluation of copper sulfate and a copper lysine complex as growth promoters for weanling swine. Apgar GA, et al. **J Anim Sci** 1995 Sep;73(9):2640–6

Preweaning growth of Angus- (Bos taurus), Brahman- (Bos indicus), and Tuli- (Sanga) sired calves and reproductive performance of their Brahman dams. Browning R Jr, et al. **J Anim Sci** 1995 Sep;73(9):2558–63

The impact of environment and antimicrobial agents on the growth response of early-weaned pigs to spray-dried porcine plasma. Coffey RD, et al. **J Anim Sci** 1995 Sep; 73(9):2532–9

Interactive effects of feed intake and stage of growth on the lysine requirement of pigs. Coma J, et al. **J Anim Sci** 1995 Nov;73(11):3369–75

Injection-site lesions in carcasses of cattle receiving injections at branding and at weaning. George MH, et al. **J Anim Sci** 1995 Nov;73(11):3235–40

Growth and tissue accretion of lambs fed concentrate in drylot, grazed on alfalfa or ryegrass at weaning, or after backgrounding on ryegrass. McClure KE, et al. **J Anim Sci** 1995 Nov;73(11):3437–44

The effect of dietary methionine and its relationship to lysine on growth performance of the segregated early-weaned pig. Owen KQ, et al. **J Anim Sci** 1995 Dec;73(12):3666–72

Influence of gilt age and body composition at first breeding

on sow reproductive performance and longevity. Rozeboom DW, et al. **J Anim Sci** 1996 Jan;74(1):138–50

Alteration of heat production in young calves in relation to posture. Schrama JW, et al. **J Anim Sci** 1995 Aug; 73(8):2254–62

Effects of slaughter age on meat tenderness and USDA carcass maturity scores of beef females. Shackelford SD, et al. **J Anim Sci** 1995 Nov;73(11):3304–9

Effect of maturity on digestion kinetics of water–soluble and water–insoluble fractions of alfalfa and brome hay. Stefanon B, et al. **J Anim Sci** 1996 May;74(5):1104–15

Skeletal growth rates of weanling and yearling thoroughbred horses. Thompson KN. **J Anim Sci** 1995 Sep;73(9):2513–7

Evaluation of response to hormonal therapy in prepubertal gilts of different genetic lines. Tilton SL, et al. **J Anim Sci** 1995 Oct;73(10):3062–8

Effect of adding fat and(or) milk products to the weanling pig diet on performance in the nursery and subsequent grow–finish stages. Tokach MD, et al. **J Anim Sci** 1995 Nov;73(11):3358–68

Effect of prepubertal retinyl palmitate treatment on uterine development and subsequent uterine capacity in swine. Vallet JL, et al. **J Anim Sci** 1996 Mar;74(3):603–9

Calving intervals in beef cows at 2, 3, and 4 years of age when breeding is not restricted after calving. Werth LA, et al. **J Anim Sci** 1996 Mar;74(3):593–6

Effects of animal age, marbling score, calpastatin activity, subprimal cut, calcium injection, and degree of doneness on the palatability of steaks from limousin steers. Wulf DM, et al. **J Anim Sci** 1996 Mar;74(3):569–76

Age–dependent vulnerability to carotid chemodenervation in piglets. Côté A, et al. **J Appl Physiol** 1996 Jan; 80(1):323–31

Motor unit discharge behavior in older adults during maximal–effort contractions. Kamen G, et al. **J Appl Physiol** 1995 Dec;79(6):1908–13

Age alters regional distribution of blood flow during moderate–intensity exercise. Kenney WL, et al. **J Appl Physiol** 1995 Oct;79(4):1112–9

Augmented mesenteric and renal vasoconstriction during exercise in senescent Fischer 344 rats. Kregel KC. **J Appl Physiol** 1995 Sep;79(3):706–12

Maximal skin vascular conductance in subjects aged 5–85 yr. Martin HL, et al. **J Appl Physiol** 1995 Jul;79(1):297–301

Lesser vagal withdrawal during isometric exercise with age. Taylor JA, et al. **J Appl Physiol** 1995 Sep;79(3):805–11

Maximal airway response in mature and immature rabbits during tidal ventilation. Tepper RS, et al. **J Appl Physiol** 1995 Oct;79(4):1190–8

Aging among elite distance runners: a 22–yr longitudinal study. Trappe SW, et al. **J Appl Physiol** 1996 Jan; 80(1):285–90

In vitro maturation and fertilization of oocytes isolated from aged mice: a strategy to rescue valuable genetic resources. Eppig JJ, et al. **J Assist Reprod Genet** 1995 Apr; 12(4):269–73

In vitro fertilization in women age 40 and older: the impact of assisted hatching. Schoolcraft WB, et al. **J Assist Reprod Genet** 1995 Oct;12(9):581–4

Successful delivery at age 61: report of a case as a result of oocyte donation. Sposetti R. **J Assist Reprod Genet** 1995 Oct;12(9):658–60

Can the neurotrophic hypothesis explain degeneration and loss of plasticity in mature and ageing autonomic nerves? Gavazzi I, et al. **J Auton Nerv Syst** 1996 Apr 20; 58(1–2):1–10 (79 ref.)

Tyrosine hydroxylase– and nitric oxide synthase–immunoreactive nerve fibers in mitral valve of young adult and aged Fischer 344 rats. Jew JY, et al. **J Auton Nerv Syst** 1996 Apr 20;58(1–2):35–43

Age–related changes in contractile responses to noradrenaline in isolated blood vessels from rat and rabbit. Carvajal A, et al. **J Auton Pharmacol** 1995 Oct;15(5):321–6

Influence of age on the relaxation induced by nifedipine in aorta from spontaneously hypertensive and Wistar Kyoto rats. Hernández MC, et al. **J Auton Pharmacol** 1995 Oct; 15(5):379–92

Effect of age on noradrenaline responses in rat tail artery and aorta: role of endothelium. Tabernero A, et al. **J Auton Pharmacol** 1995 Oct;15(5):327–33

Identification of an element crucial for the sub–synaptic expression of the acetylcholine receptor epsilon–subunit gene. Duclert A, et al. **J Biol Chem** 1996 Jul 19; 271(29):17433–8

Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures. Ensrud KE, et al. **J Bone Miner Res** 1995 Nov; 10(11):1778–87

Determinants of bone mineral density in older men. Glynn NW, et al. **J Bone Miner Res** 1995 Nov;10(11):1769–77

Vitamin D receptor alleles and rates of bone loss: influences of years since menopause and calcium intake. Krall EA, et al. **J Bone Miner Res** 1995 Jun;10(6):978–84

The effects of menopause and age on calcitropic hormones: a cross–sectional study of 655 healthy women aged 35 to 90. Prince RL, et al. **J Bone Miner Res** 1995 Jun; 10(6):835–42

Effects of metrifonate, a cholinesterase inhibitor, on local cerebral glucose utilization in young and aged rats. Bassant MH, et al. **J Cereb Blood Flow Metab** 1996 Sep; 16(5):1014–25

Doxacurium block is not influenced by age. De Mey JC, et al. **J Clin Anesth** 1995 Sep;7(6):453–6

Dehydroepiandrosterone (DHEA): a fountain of youth? [editorial] Baulieu EE. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3147–51 (14 ref.)

Age and family relationship accentuate the risk of insulin–dependent diabetes mellitus (IDDM) in relatives of patients with IDDM. Cantor AB, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3739–43

Pulsatile growth hormone secretion in older persons is enhanced by fasting without relationship to sleep stages. Hartman ML, et al. **J Clin Endocrinol Metab** 1996 Jul; 81(7):2694–701

Calcium, parathyroid function, bone and aging [editorial; comment] Heaney RP. **J Clin Endocrinol Metab** 1996 May; 81(5):1697–8. Comment on: J Clin Endocrinol Metab 1996 May;81(5):1699–703.

The short term effects of tamoxifen on bone turnover in older women. Kenny AM, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3287–91

Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age. Klein NA, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1946–51

Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. Klein NA, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2742–5

Transient congenital hypothyroidism and hyperthyrotropinemia: normal thyroid function and physical development at the ages of 6–14 years. Köhler B, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1563–7

Role of parathyroid hormone in mediating nocturnal and age–related increases in bone resorption. Ledger GA, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3304–10

Volumetric bone mineral density in normal subjects, aged 5–27 years. Lu PW, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1586–90

Role of calcium intake in modulating age–related increases in parathyroid function and bone resorption [see comments] McKane WR, et al. **J Clin Endocrinol Metab** 1996 May; 81(5):1699–703. Comment in: J Clin Endocrinol Metab 1996 May;81(5):1697–8.

Amplified nocturnal luteinizing hormone (LH) secretory burst frequency with selective attenuation of pulsatile (but not basal) testosterone secretion in healthy aged men: possible Leydig cell desensitization to endogenous LH signaling—a clinical research center study. Mulligan T, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3025–31

Age effects of follicle–stimulating hormone and pulsatile luteinizing hormone secretion across the menstrual cycle of premenopausal women. Reame NE, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1512–8

Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. Toogood AA, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):460–5

Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. Veldhuis JD, et al. **J Clin Endocrinol Metab** 1995 Nov; 80(11):3209–22

Concept generation: validation of a test of executive functioning in a normal aging population. Levine B, et al. **J Clin Exp Neuropsychol** 1995 Oct;17(5):740–58

Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. Hollander AP, et al. **J Clin Invest** 1995 Dec; 96(6):2859–69

Target–specific differences in the dendritic morphology and neuropeptide content of neurons in the rat SCG during development and aging. Andrews TJ, et al. **J Comp Neurol** 1996 Apr 22;368(1):33–44

Postnatal development and aging of the rat ventral root L5: electron microscopic and immunohistochemical studies. Karlsson M, et al. **J Comp Neurol** 1996 Jan 8;364(2):211–8

Expression of the axonal cell adhesion molecules axonin–1 and Ng–CAM during the development of the chick retinotectal system. Rager G, et al. **J Comp Neurol** 1996 Feb 19;365(4):594–609

Long–term sensory hyperinnervation following neonatal skin wounds. Reynolds ML, et al. **J Comp Neurol** 1995 Aug 7;358(4):487–98

Differential maturation of cholinergic interneurons in the striatal patch versus matrix compartments. Van Vulpen EH, et al. **J Comp Neurol** 1996 Feb 19;365(4):683–91

Regulation of mucous acinar exocrine secretion with age. Culp DJ, et al. **J Dent Res** 1996 Jan;75(1):575–80

Measurement of skin elastic properties with a new suction device (I): Relationship to age, sex and the degree of obesity in normal individuals. Ishikawa T, et al. **J Dermatol** 1995 Oct;22(10):713–7

Involvement of epidermal growth factor in inducing adiposity of age female mice. Adachi H, et al. **J Endocrinol** 1995 Sep;146(3):381–93

Serum concentrations of follicle stimulating hormone and luteinizing hormone in normal girls and boys during prepuberty and at early puberty. Belgorosky A, et al. **J Endocrinol Invest** 1996 Feb;19(2):88–91

Age–dependent changes in thymuses in the European common frog, Rana temporaria. Plytycz B, et al. **J Exp Zool** 1995 Dec 15;273(6):451–60

Workshop on sarcopenia: muscle atrophy in old age. Airlie, Virginia, September 19–21, 1994. Proceedings. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:1–161

The role of aging on the control of contractile force by Na(+)–Ca2+ exchange in rat papillary muscle. Abete P, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):M251–9

YY1 and Sp1 transcription factors bind the human transferrin gene in an age–related manner. Adrian GS, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B66–75

Muscle torque in young and older untrained and endurance–trained men. Alway SE, et al. **J Gerontol A Biol Sci Med Sci** 1996 May;51(3):B195–201

Cross–sectional age differences in body composition in persons 60+ years of age. Baumgartner RN, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):M307–16

How fast do we age? Exercise performance over time as a biomarker. Bortz WM 4th, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):M223–5

The relationship of strength to function in the older adult. Brown M, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov; 50 Spec No:55–9

Complexity of age–related change in skeletal muscle. Brown M, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar; 51(2):B117–23

Changes in spinal reflexes preceding a voluntary movement in young and old adults. Burke JR, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):M17–22

Cytokines in aging and muscle homeostasis. Cannon JG. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:120–3 (39 ref.)

Factors influencing the repair and adaptation of muscles in aged individuals: satellite cells and innervation. Carlson BM. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:96–100 (34 ref.)

The regeneration of noninnervated muscle grafts and marcaine–treated muscles in young and old rats. Carlson BM, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan; 51(1):B43–9

Time course of hypertrophic adaptations of the anterior latissimus dorsi muscle to stretch overload in aged Japanese quail. Carson JA, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):B391–8

What insights into age–related changes in skeletal muscle are provided by animal models? Cartee GD. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:137–41 (43 ref.)

Stepping over obstacles: dividing attention impairs performance of old more than young adults. Chen HC, et al. **J Gerontol A Biol Sci Med Sci** 1996 May; 51(3):M116–22

From muscle properties to human performance, using magnetic resonance. Conley KE, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:35–40 (30 ref.)

Interrelationships of peak expiratory flow rate with physical and cognitive function in the elderly: MacArthur Foundation studies of aging. Cook NR, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):M317–23

Tongue strength and endurance in different aged individuals. Crow HC, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep; 51(5):M247–50

The significance of sarcopenia in old age. Dutta C, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:1–4

What is sarcopenia? Evans WJ. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:5–8 (36 ref.)

Muscle atrophy and weakness with aging: contraction–induced injury as an underlying mechanism. Faulkner JA, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:124–9 (36 ref.)

Progressive versus catastrophic disability: a longitudinal view of the disablement process. Ferrucci L, et al. **J Gerontol A Biol Sci Med Sci** 1996 May;51(3):M123–30

Age and systemic acid–base equilibrium: analysis of published data. Frassetto L, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B91–9

Effect of age on body water and resting metabolic rate. Fukagawa NK, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):M71–3

Food odor thresholds in relation to age, nutritional, and health status. Griep MI, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):B407–14

Muscle performance and structure in the elderly as studied cross–sectionally and longitudinally. Grimby G. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:17–22 (22 ref.)

Bilateral and unilateral neuromuscular function and muscle cross–sectional area in middle–aged and elderly men and women. Häkkinen K, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B21–9

Suppression of first pain and slow temporal summation of second pain in relation to age. Harkins SW, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):M260–5

The influence of aging on muscle strength and muscle fiber characteristics with special reference to eccentric strength. Hortobágyi T, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):B399–406

Age, gender, and muscular strength. Hurley BF. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:41–4 (50 ref.)

Functional consequences of sarcopenia: effects on thermoregulation. Kenney WL, et al.

J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:78–85 (73 ref.)

Changes in cortisol and growth hormone secretion during nocturnal sleep in the course of aging. Kern W, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):M3–9

Sensory peptides as neuromodulators of wound healing in aged rats. Khalil Z, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):B354–61

Age-related dynamics of cognitive brain functions in humans: an electrophysiological approach. Kügler CF, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B3–16

Motor units: remodeling in aged animals. Larsson L. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:91–5 (15 ref.)

Aged murine T-lymphocytes are more resistant to oxidative damage due to the predominance of the cells possessing the memory phenotype. Lohmiller JJ, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):B132–40

Glomerular dysfunction in the aging Fischer 344 rat is associated with excessive growth and normal mesangial cell function. McDermott GF, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):M80–5

Age-related changes in G proteins in rat aorta. Mader SL, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):B111–6

Glycine enhances binding to the NMDA receptor complex in aged mice, but does not correct the aging change. Magnusson KR. **J Gerontol A Biol Sci Med Sci** 1996 Mar; 51(2):B141–7

Why do exercise-induced ventricular arrhythmias increase with age? Role of M-mode echocardiographic aging changes. Mayuga R, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):M23–8

Subjective sleep characteristics of 1,485 males and females aged 50–93: effects of sex and age, and factors related to self-evaluated quality of sleep. Middelkoop HA, et al. **J Gerontol A Biol Sci Med Sci** 1996 May;51(3):M108–15

Age-related characterization of atrial adenosine A1 receptor activation: direct effects on chronotropic and inotropic function in the Fischer 344 rat. Montamat SC, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):B239–46

Age-related effects in rabbit hearts of N6-R-phenylisopropyladenosine, an adenosine A1 receptor agonist. Mudumbi RV, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):B351–7

Sarcopenia in aging humans: the impact of menopause and disease. Poehlman ET, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:73–7 (25 ref.)

Prior instrumental conditioning improves spatial cognition and attenuates changes in hippocampal function in aged rats. Port RL, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B17–20

Effect of aging on the click-rate induced facilitation of acoustic reflex thresholds. Rawool VW. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):B124–31

Short intertrial intervals impair water maze performance in old Fischer 344 rats. Rick JT, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):B253–60

The effect of exercise training on cold tolerance in adult and old C57BL/6J mice. Schaefer VI, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B38–42

Muscle function and mobility biomechanics in the elderly: an overview of some recent research. Schultz AB. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:60–3 (29 ref.)

Trophic factor supplementation: effect on the age-associated changes in body composition. Schwartz RS. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:151–6 (53 ref.)

Longitudinal changes in smell identification. Ship JA, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):M86–91

Gender-related differences in left ventricular filling dynamics in older subjects after endurance exercise training. Spina RJ, et al. **J Gerontol A Biol Sci Med Sci** 1996 May; 51(3):B232–7

Postural sensitivity to visual flow in aging adults with and without balance problems. Sundermier L, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):M45–52

Effects of age on rapid ankle torque development. Thelen DG, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep; 51(5):M226–32

Growth hormone-releasing hormone depletion in the female rat: similarities to aging. Thompson MC, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B83–90

Strength and aerobic training attenuate muscle wasting and improve resistance to the development of disability with aging. Tseng BS, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:113–9 (49 ref.)

Treatment of hepatitis C virus in elderly persons with interferon alpha. Van Thiel DH, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):M330–3

Interventions based on the possibility that oxidative stress contributes to sarcopenia. Weindruch R. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:157–61 (54 ref.)

Sexuality and aging—usual and successful. Wiley D, et al. **J Gerontol A Biol Sci Med Sci** 1996 May;51(3):M142–6

A 12-year follow-up study of ankle muscle function in older adults. Winegard KJ, et al. **J Gerontol A Biol Sci Med Sci** 1996 May;51(3):B202–7

Reciprocal expression of P-glycoprotein and TAP1 accompanied by higher expression of MHC class I antigens in T cells of old mice. Witkowski JM, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B76–82

Moderate caloric restriction prevents the age-related decline in growth hormone receptor signal transduction. Xu X, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar; 51(2):B167–74

Aging and the segregation of auditory stimulus sequences. Alain C, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Mar; 51(2):P91–3

Age differences in recall and predicting recall of action events and words. McDonald-Miszczak L, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Mar;51(2):P81–90

Age differences in postural stability are increased by additional cognitive demands. Maylor EA, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 May;51(3):P143–54

Judging event covariation: effects of age and memory demand. Mutter SA, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Mar;51(2):P70–80

The locus of age-related movement slowing: sensory processing in continuous goal-directed aiming. Pohl PS, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Mar; 51(2):P94–102

General and specific speed mediation of adult age differences in memory. Salthouse TA. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):P30–42 (32 ref.)

Circulating progenitor cells in human ontogenesis: response to growth factors and replating potential. Migliaccio G, et al. **J Hematother** 1996 Apr;5(2):161–70

Elastic lamina growth in the developing mouse aorta. Davis EC. **J Histochem Cytochem** 1995 Nov;43(11):1115–23

Relation between age, left ventricular mass and ventricular arrhythmias in patients with hypertension. Ferrara N, et al. **J Hum Hypertens** 1995 Jul;9(7):581–7

Fetal influences on adult hypertension. Law C. **J Hum Hypertens** 1995 Aug;9(8):649–51 (30 ref.)

Lisinopril administration improves insulin action in aged patients with hypertension. Paolisso G, et al. **J Hum Hypertens** 1995 Jul;9(7):541–6

Diurnal blood pressure profile in older patients with isolated systolic hypertension. The SYST-EUR Investigators. Thijs L, et al. **J Hum Hypertens** 1995 Nov;9(11):917–24

Neuroendocrine ageing. Björntorp P. **J Intern Med** 1995 Nov;238(5):401–4 (19 ref.)

Effects of age, sex, and heredity on measures of bone mass in baboons (Papio hamadryas). Kammerer CM, et al. **J Med Primatol** 1995 Dec;24(4):236–42

Decreased contractile responses to isoproterenol in isolated cardiac myocytes from aging guinea-pigs. Ferrara N, et al. **J Mol Cell Cardiol** 1995 May;27(5):1141–50

Modification of gap junction conductance by divalent cations and protons in neonatal rat heart cells. Firek L, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1633–43

Depressed transient outward current density in ventricular myocytes from cardiomyopathic Syrian hamsters of different ages. Thuringer D, et al. **J Mol Cell Cardiol** 1996 Feb;28(2):387–401

Gout, uric acid, albumin, and aging [letter] Seaton K. **J Natl Med Assoc** 1996 Aug;88(8):473, 486

Influence of age on the GH response to sumatriptan administration in man. Coiro V, et al. **J Neural Transm Gen Sect** 1995;101(1–3):195–200

Differential regulation of motor neuron survival and choline acetyltransferase expression following axotomy. Kou SY, et al. **J Neurobiol** 1995 Aug;27(4):561–72

In situ analysis of Na, K-ATPase alpha1- and alpha3-isoform mRNAs in aging rat hippocampus. Chauhan NB, et al. **J Neurochem** 1996 Apr;66(4):1742–51

Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. Igbavboa U, et al. **J Neurochem** 1996 Apr;66(4):1717–25

Role of proteoglycans in neural development, regeneration, and the aging brain. Small DH, et al. **J Neurochem** 1996 Sep;67(3):889–99 (140 ref.)

Spongy degeneration in the zitter rat: ultrastructural and immunohistochemical studies. Kondo A, et al. **J Neurocytol** 1995 Jul;24(7):533–44

Brain aging in normal Egyptians: neuropsychological, electrophysiological and cranial tomographic assessment. Elwan O, et al. **J Neurol Sci** 1996 Mar;136(1–2):73–80

Decreased monosynaptic GABAB-mediated inhibitory postsynaptic potentials in hippocampal CA1 pyramidal cells in the aged rat: pharmacological characterization and possible mechanisms. Billard JM, et al. **J Neurophysiol** 1995 Aug;74(2):539–46

Low-voltage activated calcium currents increase in basal forebrain neurons from aged rats. Murchison D, et al. **J Neurophysiol** 1995 Aug;74(2):876–87

Age-associated impairments in a test of attention: evidence for involvement of cholinergic systems. Jones DN, et al. **J Neurosci** 1995 Nov;15(11):7282–92

Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. Kuhn HG, et al. **J Neurosci** 1996 Mar 15;16(6):2027–33

Molecular indices of neuronal and glial plasticity in the hippocampal formation in a rodent model of age-induced spatial learning impairment. Sugaya K, et al. **J Neurosci** 1996 May 15;16(10):3427–43

Single-channel and whole-cell studies of calcium currents in young and aged rat hippocampal slice neurons. Thibault O, et al. **J Neurosci Methods** 1995 Jun;59(1):77–83

Gravitational artefact in frequency spectra of movement acceleration: implications for actigraphy in young and elderly subjects. Van Someren EJ, et al. **J Neurosci Methods** 1996 Mar;65(1):55–62

Axonal atrophy in aging is associated with a decline in neurofilament gene expression. Parhad IM, et al. **J Neurosci Res** 1995 Jun 15;41(3):355–66

Age and outcome after aneurysmal subarachnoid hemorrhage: why do older patients fare worse? Lanzino G, et al. **J Neurosurg** 1996 Sep;85(3):410–8

Age-related changes in intracranial compartment volumes in normal adults assessed by magnetic resonance imaging. Matsumae M, et al. **J Neurosurg** 1996 Jun;84(6):982–91

Effect of aging on myocardial perfusion reserve. Uren NG, et al. **J Nucl Med** 1995 Nov;36(11):2032–6

Growth failure and altered body composition are established by one month of age in infants with bronchopulmonary dysplasia. deRegnier RA, et al. **J Nutr** 1996 Jan; 126(1):168–75

Obese pigs fed a high cholesterol diet from birth to 2 months are less susceptible than lean pigs to atherosclerosis. Hackman AM, et al. **J Nutr** 1996 Feb;126(2):564–73

Moderate copper deprivation during gestation and lactation affects dentate gyrus and hippocampal maturation in immature male rats. Hunt CD, et al. **J Nutr** 1995 Oct; 125(10):2700–10

Pattern of amino acid requirements in humans: an interspecies comparison using published amino acid requirement recommendations. McLarney MJ, et al. **J Nutr** 1996 Jul; 126(7):1871–82 (55 ref.)

Functional and psychic deterioration in elderly people may be aggravated by folate deficiency. Ortega RM, et al. **J Nutr** 1996 Aug;126(8):1992–9

A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males. Welten DC, et al. **J Nutr** 1995 Nov;125(11):2802–13

Female aging and superovulation induction for IVF. Kim SH. **J Obstet Gynaecol** 1995 Feb;21(1):75–82

Performance on three-point vernier acuity targets as a function of age. Yebra-Pimentel Vilar E, et al. **J Opt Soc Am A** 1995 Oct;12(10):2293–304

Effect of aging on the rat condylar fracture model evaluated by bromodeoxyuridine immunohistochemistry. Sekine J, et al. **J Oral Maxillofac Surg** 1995 Nov;53(11):1317–21; discussion 1322–3

At odds about ratios and other statistics [letter; comment] Velly AM. **J Oral Maxillofac Surg** 1996 Jul;54(7):927. Comment on: J Oral Maxillofac Surg 1996 Jan;54(1):55–61; discussion 61–2.

Dental state and functional capacity in 75-year-olds in three Nordic localities. Osterberg T, et al. **J Oral Rehabil** 1995 Aug;22(8):653–60

Age trends in remodeling of the femoral midshaft differ between the sexes. Feik SA, et al. **J Orthop Res** 1996 Jul; 14(4):590–7

Patterns of haemogregarine load, aggregation and prevalence as a function of host age in the lizard Lacerta vivipara. Sorci G. **J Parasitol** 1996 Aug;82(4):676–8

Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/–)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. Broening HW, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):325–33

Cocaine sensitization in periadolescent and adult rats. Laviola G, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):345–57

Effects of age on aneural regeneration of soleus muscle in rat. Lewis DM, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):483–92

Possible acceleration of age effects on cognition following menopause. Halbreich U, et al. **J Psychiatr Res** 1995 May-Jun;29(3):153–63

Teaching old dogs [editorial] Schein JD. **J Rehabil Res Dev** 1995 Nov;32(4):vii–viii

Ageing, infecundity and reproductive senescence in free-ranging female rhesus monkeys. Johnson RL, et al. **J Reprod Fertil** 1995 Nov;105(2):271–8

Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. Saag KG, et al. **J Rheumatol** 1995 Nov; 22(11):2142–7

Gastric myoelectrical activities in elderly human subjects—surface electrogastrographic observations. Nishimura N, et al. **J Smooth Muscle Res** 1995 Apr; 31(2):43–9

Effect of aging on the esophageal motor functions. Nishimura N, et al. **J Smooth Muscle Res** 1996 Apr;32(2):43–50

The gonadotropin secretion pattern in normal women of advanced reproductive age in relation to the monotropic FSH rise. Klein NA, et al. **J Soc Gynecol Investig** 1996 Jan-Feb;3(1):27–32

Glottal airflow characteristics of women's voice production along an aging continuum. Sapienza CM, et al. **J Speech Hear Res** 1996 Apr;39(2):322–8

The influence of strength training, swim training and ageing on the Achilles tendon and m. soleus of the rat. Simonsen EB, et al. **J Sports Sci** 1995 Aug;13(4):291–5

The role of luminal nutrients in intestinal injury from mesenteric reperfusion and platelet-activating factor in the developing rat. Bhatia AM, et al. **J Surg Res** 1996 Jun; 63(1):152–6

Separate sexes and the mitochondrial theory of ageing. Allen JF. **J Theor Biol** 1996 May 21;180(2):135–40

Aging reduces postischemic recovery of coronary endothelial

function. Amrani M, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):238–45

Developmental differences in cytosolic calcium accumulation associated with surgically induced global ischemia: optimization of cardioplegic protection and mechanism of action. Tsukube T, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):175–84

A train of thought for delay of senility. Shen Z. **J Tradit Chin Med** 1995 Sep;15(3):220–3

The effect of age on peripheral motor nerve function after crush injury in the rat. Belin BM, et al. **J Trauma** 1996 May;40(5):775–7

Effect of age and sex on residual stress in the aorta. Saini A, et al. **J Vasc Res** 1995 Nov–Dec;32(6):398–405

Effects of enriched and impoverished housing environments on the electrocorticograms (ECoGs) of middle-aged rats. Chida Y, et al. **J Vet Med Sci** 1995 Aug;57(4):687–91

Cell counts in peripheral blood and bone marrow of male CBA/N mice. Matsumoto K, et al. **J Vet Med Sci** 1995 Aug;57(4):755–6

Fine structure of podocytes in the bovine renal corpuscle. Miyata H, et al. **J Vet Med Sci** 1995 Apr;57(2):359–61

Histological observation of the endometrium in repeat breeder cows. Ohtani S, et al. **J Vet Med Sci** 1995 Apr; 57(2):283–6

The relationship between plasma insulin-like growth factor-I (IGF-I) level and body weight in the horse. Ozawa A, et al. **J Vet Med Sci** 1995 Dec;57(6):1105–7

Production of term offspring by in vitro fertilization using old mouse spermatozoa. Wakayama T, et al. **J Vet Med Sci** 1995 Jun;57(3):545–7

Weight control and exercise. Cardinal features of successful preventive gerontology [editorial; comment] Hazzard WR. **JAMA** 1995 Dec 27;274(24):1964–5. Comment on: JAMA 1995 Dec 27;274(24):1915–21.

The naturalness of dying [letter; comment] Honig LS, et al. **JAMA** 1995 Oct 4;274(13):1016. Comment on: JAMA 1995 Apr 5;273(13):1039–43.

Effects of weight loss vs aerobic exercise training on risk factors for coronary disease in healthy, obese, middle-aged and older men. A randomized controlled trial [see comments] Katzel LI, et al. **JAMA** 1995 Dec 27; 274(24):1915–21. Comment in: JAMA 1995 Dec 27;274(24):1964–5. Comment in: JAMA 1996 May 22–29;275(20):1546–7.

Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study [see comments] Snowdon DA, et al. **JAMA** 1996 Feb 21;275(7):528–32. Comment in: JAMA 1996 Jun 26;275(24):1879.

A role for mitochondria in age-related disorders? [news] Stephenson J. **JAMA** 1996 May 22–29;275(20):1531–2

Age and intraocular pressure: how are they correlated? Qureshi IA. **JPMA J Pak Med Assoc** 1995 Jun;45(6):150–2

The mechanism of the physiologic disappearance of the third heart sound with aging. Longhini C, et al. **Jpn Heart J** 1996 Mar;37(2):215–26

Morphological study of age-related changes in Fischer rat lens. Uga S, et al. **Jpn J Ophthalmol** 1996;40(1):33–41

Changes in gastric function and healing of chronic gastric ulcers in aged rats. Tsukimi Y, et al. **Jpn J Pharmacol** 1995 May;68(1):103–10

The effects of aging on the rat bladder and its innervation. Hotta H, et al. **Jpn J Physiol** 1995;45(5):823–36

Decline in maximal oxygen uptake on work performance in rats during the developmental phase. Yano H, et al. **Jpn J Physiol** 1995;45(5):889–93

Glial fibrillary acidic protein expression in the developing human retina. Karim MM, et al. **Kobe J Med Sci** 1996 Apr; 42(2):111–7

Is senile dementia "age-related" or "ageing-related"?—evidence from meta-analysis of dementia prevalence in the oldest old [see comments] Ritchie K, et al. **Lancet** 1995 Oct 7;346(8980):931–4. Comment in: Lancet 1995 Dec 2;346(8988):1486. Comment in: Lancet 1995 Dec 2;346(8988):1486–7.

Age-related alterations in the auditory brainstem responses and the compound action potentials in guinea pigs. Nozawa I, et al. **Laryngoscope** 1996 Aug;106(8):1034–9

The current status of the calcium hypothesis of brain aging and Alzheimer's disease. Heidelberg, Germany, October 23–25, 1995. Proceedings of a conference. **Life Sci** 1996; 59(5–6):vii, 357–510

Cholinergic and Related Mechanisms in Aging and Disease: a Tribute to Donald J. Jenden, M.D. Los Angeles, California, November 17–18, 1995. **Life Sci** 1996; 58(22):1909–2064

Calcium-dependent afterhyperpolarization and learning in young and aging hippocampus. Disterhoft JF, et al. **Life Sci** 1996;59(5–6):413–20 (54 ref.)

Age-related effects of aluminum ingestion on brain aluminum accumulation and behavior in rats. Domingo JL, et al. **Life Sci** 1996;58(17):1387–95

Effect of intratesticular administration of somatostatin on testicular function in immature and adult rats. Gerendai I, et al. **Life Sci** 1996;59(10):859–66

Age-related changes before and after imposition of hemodynamic stress in the mammalian heart. Isoyama S. **Life Sci** 1996;58(19):1601–14 (112 ref.)

Lymphocyte norepinephrine and epinephrine, but not plasma catecholamines predict lymphocyte cAMP production. Knudsen JH, et al. **Life Sci** 1996;59(8):639–47

Cholinergic control of cerebral blood flow in stroke, trauma and aging. Scremin OU, et al. **Life Sci** 1996;58(22):2011–8

The effects of tropicamide on mydriasis in young rats exhibiting a natural deficit in passive-avoidance responding. Smith RD, et al. **Life Sci** 1996;59(9):753–60

Age dependency of the regional cerebral blood volume (rCBV) measured with dynamic susceptibility contrast MR imaging (DSC). Wenz F, et al. **Magn Reson Imaging** 1996; 14(2):157–62

Induction and repair of benzo[a]pyrene-DNA adducts in C57BL/6 and BALB/c mice: association with aging and longevity. Boerrigter ME, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):31–50 (50 ref.)

Effect of dietary high doses of vitamin E on the cell size of T and B lymphocyte subsets in young and old CBA mice. Brohée D, et al. **Mech Ageing Dev** 1995 Nov 24; 85(2–3):147–59

Age-dependent enzymuria, proteinuria and changes in renal blood flow and glomerular filtration rate in rats. Casadevall G, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):51–60

Age-dependent changes in response of rat prostatic tissues to isoproterenol and forskolin: changes with sexual maturation in function of G proteins. Chen C, et al. **Mech Ageing Dev** 1995 Jun 30;81(1):1–13

Postnatal development of methionine-enkephalin modulation of cholinergic transmission in cat ileum. Chernaeva L, et al. **Mech Ageing Dev** 1995 Sep 7;83(2):117–24

Changes in the plasmatic membrane characteristics during microsomal monooxygenase induction in the liver of adult and old rats. Frolkis VV, et al. **Mech Ageing Dev** 1995 May 12;80(2):139–45

Growth hormone does not enhance the anabolic effect of human parathyroid hormone (1–34) on bone in aging multiparous and virgin rats. Hock JM, et al. **Mech Ageing Dev** 1995 Nov 24;85(2–3):183–97

Altered regulation of pituitary luteinizing hormone secretion by GnRH and inhibin in the aged persistent-estrous female rat. Jih MH, et al. **Mech Ageing Dev** 1995 Sep 29; 84(1):15–27

Age-related changes in basal dendrite and dendritic spine of hippocampal pyramidal neurons (CA1) among SAMP1TA/Ngs—quantitative analysis by the rapid Golgi method. Kawaguchi S, et al. **Mech Ageing Dev** 1995 Aug 31;83(1):11–20

Prolonged recovery and reduced adaptation in aged rat muscle following eccentric exercise. McBride TA, et al. **Mech Ageing Dev** 1995 Sep 15;83(3):185–200

The last mitoses of the human fibroblast proliferative life span, physiopathologic implications. Macieira-Coelho A. **Mech Ageing Dev** 1995 Aug 8;82(2–3):91–104 (22 ref.)

Effects of age and endurance training on beta-adrenergic receptor characteristics in Fischer 344 rats. Mazzeo RS, et al. **Mech Ageing Dev** 1995 Oct 13;84(2):157–69

The effect of aging on bone composition of female Fischer 344 rats. Nnakwe NE. **Mech Ageing Dev** 1995 Nov 24; 85(2–3):125–31

Leukocyte migration inhibition studies and neutrophil cell function during aging in Nigerians. Oyeyinka GO, et al. **Mech Ageing Dev** 1995 Nov 24;85(2–3):83–93

Evolution of neuronal density in the ageing thalamic reticular nucleus. Ramos R, et al. **Mech Ageing Dev** 1995 Aug 31; 83(1):21–9

Increasing multiple myeloma mortality rates in the elderly: demonstration of increasing dependency with increasing age upon age group population size. Riggs JE. **Mech Ageing Dev** 1995 Jul 14;81(2–3):131–8

Ageing and prostate: age-related changes in androgen receptors of epithelial cells from benign hypertrophic glands compared with cancer. Sánchez-Visconti G, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):19–29

Dizocilpine binding to cerebral cortical membranes from developing and ageing mice. Saransaari P, et al. **Mech Ageing Dev** 1995 Nov 24;85(2–3):171–81

On age-related changes of cell membrane permeability in human buccal epithelium cells. Shckorbatov YG, et al. **Mech Ageing Dev** 1995 Sep 7;83(2):87–90

Age-related changes in the numbers of mammotrophs, somatotrophs and mammosomatotrophs in the anterior pituitary gland of female rats: a flow cytometric study. Shinkai T, et al. **Mech Ageing Dev** 1995 Sep 15;83(3):125–31

Oxidative stress and aging in the Mongolian gerbil (Meriones unguiculatus). Sohal RS, et al. **Mech Ageing Dev** 1995 Jun 30;81(1):15–25

The pattern of T lymphocyte differentiation is altered during thymic involution. Thoman ML. **Mech Ageing Dev** 1995 Aug 8;82(2–3):155–70

Neurotrophin receptor proteins immunoreactivity in the rat cerebellar cortex as a function of age. Torres JM, et al. **Mech Ageing Dev** 1995 Aug 31;83(1):1–9

Physical activity and immune senescence in men. Shinkai S, et al. **Med Sci Sports Exerc** 1995 Nov;27(11):1516–26

Aging in women—the four-compartment model of body composition. Aloia JF, et al. **Metabolism** 1996 Jan; 45(1):43–8

31P magnetic resonance spectroscopy of human liver in elderly patients: changes according to nutritional status and inflammatory state. Bourdel-Marchasson I, et al. **Metabolism** 1996 Sep;45(9):1059–61

Age-related changes in albumin-excluded volume fraction. Parameswaran S, et al. **Microvasc Res** 1995 Nov; 50(3):373–80

Alpha-tocopherol pretreatment improves endothelium-dependent vasodilation in aortic strips of young and aging rats exposed to oxidative stress. Guarnieri C, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):223–8

Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Chiu AY, et al. **Mol Cell Neurosci** 1995 Aug;6(4):349–62

Neurotrophin-3 as an essential signal for the developing nervous system. Chalazonitis A. **Mol Neurobiol** 1996 Feb; 12(1):39–53 (90 ref.)

Comparison of contractile properties between developing and regenerating soleus muscle: influence of external calcium concentration upon the contractility. Louboutin JP, et al. **Muscle Nerve** 1995 Nov;18(11):1292–9

The effects of ageing [letter; comment] [see comments] Pennington H. **N Z Med J** 1996 May 24;109(1022):195. Comment on: N Z Med J 1996 Apr 12;109(1019):122–5. Comment in: N Z Med J 1996 Jul 12;109(1025):264.

Assessment of the effects of aging and medication on salivary gland function in patients with xerostomia using 99mTC-scintigraphy. Kagami H, et al. **Nagoya J Med Sci** 1995 Dec;58(3–4):149–55

Slowing ageing by caloric restriction. Roth GS, et al. **Nat Med** 1995 May;1(5):414–5

Photobiology. Wrinkles waiting for GoDoT [news] Brash DE, et al. **Nature** 1996 Jan 25;379(6563):301–2

Autoradiographic localization and age-related changes in vasopressin receptors in spontaneously hypertensive rats. Hosoya M, et al. **Nephron** 1996;72(2):281–7

Aging and caloric restriction: human effects and mode of action. Austad SN. **Neurobiol Aging** 1995 Sep–Oct; 16(5):851–2; discussion 855–6 (19 ref.)

Neurotoxic effects of neonatal triethyltin (TET) exposure are exacerbated with aging. Barone S Jr, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):723–35

Scopolamine differentially affects memory of 8- and 16-month-old rats in the double Y-maze. Biggan SL, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):25–30

Aging impairs heart rate reflexes earlier in female than in male Sprague-Dawley rats. Buñag RD, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):87–93

CGRP innervation and receptors during aging of male and female hepatic rat portal veins. Carrier N, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):53–60

Hippocampal muscarinic receptor function in spatial learning-impaired aged rats. Chouinard ML, et al. **Neurobiol Aging** 1995 Nov–Dec;16(6):955–63

Age-related changes in hippocampal drug facilitation of memory processing in SAMP8 mice. Flood JF, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):15–24

Influence of aging on the seasonal rhythm of the vasopressin-expressing neurons in the human suprachiasmatic nucleus. Hofman MA, et al. **Neurobiol Aging** 1995 Nov–Dec;16(6):965–71

Target influence on aging of myelinated sensory nerve fibres. Johansson CS, et al. **Neurobiol Agirg** 1996 Jan–Feb; 17(1):61–6

Executive system dysfunction in the aged monkey: spatial and object reversal learning. Lai ZC, et al. **Neurobiol Aging** 1995 Nov–Dec;16(6):947–54

Delay in manifestations of aging by grafting NGF cultured chromaffin cells in adulthood. Mendoza-Ramirez JL, et al. **Neurobiol Aging** 1995 Nov–Dec;16(6):907–16

Neuroendocrine involvement in aging: evidence from studies of reproductive aging and caloric restriction. Nelson JF, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):837–43; discussion 855–6 (50 ref.)

Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Ovadia A, et al. **Neurobiol Aging** 1995 Nov–Dec;16(6):931–7

Memory impaired aged rats: no loss of principal hippocampal and subicular neurons. Rasmussen T, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):143–7

Density and pattern of dopamine D2-like receptors in the cerebellar cortex of aged rats. Ricci A, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):45–52

Age-related learning and memory deficits in odor-reward association in rats. Roman FS, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):31–40

Nimodipine facilitates retention of the classically conditioned nictitating membrane response in aged rabbits over long retention intervals. Solomon PR, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):791–6

Chronic RU486 treatment reduces age-related alterations of mouse hippocampal function. Talmi M, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):9–14

Functional changes of the peripheral nervous system with aging in the mouse. Verdú E, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):73–7

Use of caloric restriction to investigate neuroendocrine involvement in aging. Weindruch R, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):845–7; discussion 855–6 (30 ref.)

Age-related decrease in vulnerability to excitatory amino acids in the nucleus basalis. Wenk GL, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):1–7

Neuroendocrine involvement in the aging: evidence from studies of reproductive aging and caloric restriction. Wise PM. **Neurobiol Aging** 1995 Sep–Oct;16(5):853; discussion 855–6

Age-related changes in plasma catecholamine and glucose responses of F-344 rats to a single footshock as used in inhibitory avoidance training. Mabry TR, et al.

Neurobiol Learn Mem 1995 Sep;64(2):146–55

A simple and rapid test of sensorimotor function in the aged rat. Murphy MP, et al. **Neurobiol Learn Mem** 1995 Sep; 64(2):181–6

The involvement of Ca2+/calmodulin-dependent protein kinase in memory formation in day-old chicks. Zhao WQ, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):24–35

Neuroprotection against NMDA induced cell death in rat nucleus basalis by Ca2+ antagonist nimodipine, influence of aging and developmental drug treatment. Luiten PG, et al. **Neurodegeneration** 1995 Sep;4(3):307–14

A relative depletion of luteinizing hormone-releasing hormone was observed in the median eminence of young but not middle-aged rats on the evening of proestrus. Rubin BS, et al. **Neuroendocrinology** 1995 Sep;62(3):259–69

Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Bondi MW, et al. **Neurology** 1995 Dec;45(12):2203–6

Cortical projections to spinal motoneurons: changes with aging and amyotrophic lateral sclerosis. Eisen A, et al. **Neurology** 1996 May;46(5):1396–404

AAMI [letter; comment] Franceschi M, et al. **Neurology** 1996 May;46(5):1490–1. Comment on: Neurology 1995 Apr;45(4):741–7.

Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Morris JC, et al. **Neurology** 1996 Mar; 46(3):707–19

Healthy aging, memory subsystems and regional cerebral oxygen consumption. Eustache F, et al. **Neuropsychologia** 1995 Jul;33(7):867–87

The modulatory effect of melatonin on the dopamine-glutamate interaction in the anterior hypothalamus during ageing. Exposito I, et al. **Neuroreport** 1995 Nov 27;6(17):2399–403

Effects of aging on the expression of neurotrophins and their receptors in the rat pituitary gland. Kononen J, et al. **Neuroreport** 1995 Nov 27;6(17):2429–34

Age-related decrease of serotonergic fibres and S-100 beta immunoreactivity in the rat dentate gyrus. Nishimura A, et al. **Neuroreport** 1995 Jul 10;6(10):1445–8

Age-related functional differences between auditory cortices: a whole-head MEG study. Pekkonen E, et al. **Neuroreport** 1995 Sep 11;6(13):1803–6

Changes in circadian rhythms and sleep quality with aging: mechanisms and interventions. Myers BL, et al. **Neurosci Biobehav Rev** 1995 Winter;19(4):553–71 (318 ref.)

Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer's disease. Fukutani Y, et al. **Neurosci Lett** 1995 Nov 10;200(1):57–60

Age-dependent reduction of hippocampal LTP in mice lacking N-methyl-D-aspartate receptor epsilon 1 subunit. Ito I, et al. **Neurosci Lett** 1996 Jan 12;203(1):69–71

Mechanical allodynia is more strongly manifested in older rats in an experimental model of peripheral neuropathy. Kim YI, et al. **Neurosci Lett** 1995 Oct 20;199(2):158–60

Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. Kimura T, et al. **Neurosci Lett** 1996 Apr 12;208(1):53–6

Dynamic and static sensitivities of muscle spindle primary endings in aged rats to ramp stretch. Miwa T, et al. **Neurosci Lett** 1995 Dec 8;201(2):179–82

Decline and preservation of reversal learning abilities and acquisition in the course of senescence. Rahner-Welsch S, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):121–3

Maturation of static sensitivity is related to expansion of the capsular space in rat buccal stretch receptors. Yamamoto T, et al. **Neurosci Lett** 1995 Oct 13;199(1):61–4

Differential effects of aging on motoneurons and peripheral nerves innervating the hindlimb and forelimb muscles of rats. Hashizume K, et al. **Neurosci Res** 1995 May; 22(2):189–96

Temperature change-induced potentiation: a comparative study of facilitatory mechanisms in aged and young rat hippocampal slices. Buldakova S, et al. **Neuroscience** 1995 Sep;68(2):395–7

Age-related changes in diurnal acetylcholine release in the prefrontal cortex of male rats as measured by microdialysis. Mitsushima D, et al. **Neuroscience** 1996 May;72(2):429–34

Increased expression of type 1 insulin-like growth factor receptor messenger RNA in rat hippocampal formation is associated with aging and behavioral impairment. Stenvers KL, et al. **Neuroscience** 1996 May;72(2):505–18

Effects of aging on light-induced phase-shifting of circadian behavioral rhythms, fos expression and CREB phosphorylation in the hamster suprachiasmatic nucleus. Zhang Y, et al. **Neuroscience** 1996 Feb;70(4):951–61

Expanding cava septi pellucidi and cava vergae in children: report of three cases. Wester K, et al. **Neurosurgery** 1995 Jul;37(1):134–7

Habitual physical activity, psychomotor performance, and older workers. Ilmarinen J, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S44–52 (39 ref.)

Do dairy products improve bone density in adolescent girls? Kerstetter JE. **Nutr Rev** 1995 Nov;53(11):328–32 (26 ref.)

Micronutrient status and aging. Tucker K. **Nutr Rev** 1995 Sep;53(9 Pt 2):S9–15 (47 ref.)

Mild-to-moderate malnutrition and small intestine of young rhesus monkeys. Rana S, et al. **Nutrition** 1995 May-Jun; 11(3):292–5

Antiaging action of caloric restriction: endocrine and metabolic aspects. Masoro EJ. **Obes Res** 1995 Sep;3 Suppl 2:241s–247s (30 ref.)

Resistance to aging-associated obesity in capsaicin-desensitized rats one year after treatment. Melnyk A, et al. **Obes Res** 1995 Jul;3(4):337–44

Effects of noise and age on the auditory system. Boettcher FA, et al. **Occup Med** 1995 Jul-Aug;10(3):577–91 (41 ref.)

Presbycusis and occupational hearing loss. Rosenhall U, et al. **Occup Med** 1995 Jul-Aug;10(3):593–607 (73 ref.)

Effect on leukemia cell numbers of in vivo administration of immunotherapeutic agents is age-dependent. Dussault I, et al. **Oncology** 1996 May-Jun;53(3):241–6

The fluctuations of accommodation and ageing. Heron G, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):445–9

The role of membranes in lens ageing and cataract. Proceedings of a meeting. Naples, March 13–14, 1995. **Ophthalmic Res** 1996;28 Suppl 1:i–xi, 1–106

Changes in light scattering intensity of the transparent lenses of subjects selected from population-based surveys depending on age: analysis through Scheimpflug images. Fujisawa K, et al. **Ophthalmic Res** 1995 Mar-Apr; 27(2):89–101

Relationship between intraocular pressure and age in the exfoliation syndrome. Fukisawa K, et al. **Ophthalmologica** 1995;209(4):199–202

Influence of age on retinal and optic nerve head blood circulation. Groh MJ, et al. **Ophthalmology** 1996 Mar; 103(3):529–34

Effect of age on tear osmolality. Craig JP, et al. **Optom Vis Sci** 1995 Oct;72(10):713–7

Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females 10–24 years of age. Sabatier JP, et al. **Osteoporos Int** 1996;6(2):141–8

Comparison of sinus node response to exercise with responses from two different activity-based rate adaptive pacemakers in healthy subjects of different age groups. Roberts DH, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1882–8

Age is the best predictor of postoperative morphine requirements. Macintyre PE, et al. **Pain** 1996 Feb; 64(2):357–64

The effect of aging and duration of disability on long term health outcomes following spinal cord injury. Pentland W, et al. **Paraplegia** 1995 Jul;33(7):367–73

Developmental renal hemodynamics. Yao LP, et al. **Pediatr Nephrol** 1995 Oct;9(5):632–7 (59 ref.)

Nitric oxide and beta-adrenergic mechanisms modify contractile responses to norepinephrine in ovine fetal and newborn cerebral arteries. Wagerle LC, et al. **Pediatr Res** 1995 Aug;38(2):237–42

An auditory event related potential evaluation of sonar task experience and age. Merrill LL, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1363–76

Thermogenesis in brown adipose tissue with age: post-receptor activation by forskolin. Scarpace PJ, et al. **Pflugers Arch** 1996 Jan;431(3):388–94

Potassium currents in rat colonic smooth muscle cells and changes during development and aging. Xiong Z, et al. **Pflugers Arch** 1995 Aug;430(4):563–72

Age-dependent anticonvulsant action of clonazepam in the N-methyl-D-aspartate model of seizures. Velišek L, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):291–6

Age-related changes in the human lens as monitored by detection of porphyrin excited states. Roberts JE, et al. **Photochem Photobiol** 1995 Aug;62(2):339–41

Elastic properties of human aortas in relation to age and atherosclerosis: a structural model. Wuyts FL, et al. **Phys Med Biol** 1995 Oct;40(10):1577–97

Anaerobic metabolism during electrical stimulation of aged rat skeletal muscle. Hopp JF. **Phys Ther** 1996 Mar; 76(3):260–7

Aging and the hypothalamus: research perspectives. Bernardis LL, et al. **Physiol Behav** 1996 Mar;59(3):523–36 (220 ref.)

Performance on a smell screening test (the MODSIT): a study of 510 predominantly illiterate Chinese subjects. Liu HC, et al. **Physiol Behav** 1995 Dec;58(6):1251–5

An analysis of factors that induce hibernation in Syrian hamsters. Ueda S, et al. **Physiol Behav** 1995 Oct;58(4):653–7

A dynamic analysis of changes in the nasolabial fold using magnetic resonance imaging: implications for facial rejuvenation and facial animation surgery. Gosain AK, et al. **Plast Reconstr Surg** 1996 Sep;98(4):622–36

The aging process. Physiologic changes and pharmacologic implications. Troncale JA. **Postgrad Med** 1996 May; 99(5):111–4, 120–2

The older driver—a review. Morgan R, et al. **Postgrad Med J** 1995 Sep;71(839):525–8 (30 ref.)

Effect of dietary iron concentration, age, and length of iron feeding on feed intake and tissue iron concentration of broiler chicks for use as a bioassay of supplemental iron sources. Cao J, et al. **Poult Sci** 1996 Apr;75(4):495–504

Age-related changes of protein turnover in specific tissues of the chick. Tesseraud S, et al. **Poult Sci** 1996 May; 75(5):627–31

Selective vulnerability of late-generated dopaminergic neurons of the substantia nigra in weaver mutant mice. Bayer SA, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9137–40

Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. Forster MJ, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4765–9

Calorie restriction lowers body temperature in rhesus monkeys, consistent with a postulated anti-aging mechanism in rodents. Lane MA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4159–64

Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Li YM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30; 93(9):3902–7

Long-term functional recovery from age-induced spatial memory impairments by nerve growth factor gene transfer to the rat basal forebrain. Martínez-Serrano A, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6355–60

Preserved neuron number in the hippocampus of aged rats with spatial learning deficits. Rapp PR, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9 [illegible]26–30

Vitronectin is not essential for normal mammalian development and fertility. Zheng X, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12426–30

Effects of exercise training in the elderly: impact of progressive- resistance training on skeletal muscle and whole-body protein metabolism. Fielding RA. **Proc Nutr Soc** 1996 Nov;54(3):665–75 (58 ref.)

Functional ability and nutritional status of free-living elderly people. Manandhar MC. **Proc Nutr Soc** 1996 Nov; 54(3):677–91 (99 ref.)

Some nutritional aspects of ageing in dogs and cats. Taylor EJ, et al. **Proc Nutr Soc** 1996 Nov;54(3):645–56

Energy balance and health in SENECA participants. Survey in Europe on Nutrition and the Elderly, a Concerted Action. van Staveren WA, et al. **Proc Nutr Soc** 1996 Nov; 54(3):617–29

Assessment of the primary adrenal cortical and pancreatic hormone basal levels in relation to plasma glucose and age in the unstressed Ames dwarf mouse. Borg KE, et al. **Proc Soc Exp Biol Med** 1995 Nov;210(2):126–33

Thermoregulation with age: restoration of beta(3)-adrenergic responsiveness in brown adipose tissue by cold exposure. Scarpace PJ, et al. **Proc Soc Exp Biol Med** 1996 Apr; 211(4):374–80

Aging of the brain-testicular axis: reproductive systems of healthy old male rats with or without endocrine stimulation. Taylor G, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):69–75

Intracellular calcium buffering in adrenergic nerves: evidence for decline in the aged rat. Duckles SP, et al. **Proc West Pharmacol Soc** 1995;38:99–100

Age-related changes in brain: II. Positron emission tomography of frontal and temporal lobe glucose metabolism in normal subjects. De Santi S, et al. **Psychiatr Q** 1995 Winter;66(4):357–70

The effects of normal aging on cortisol and adrenocorticotropin responses to hypertonic saline infusion. Raskind MA, et al. **Psychoneuroendocrinology** 1995; 20(6):637–44

Gender differences in patterns of HPA axis response to challenge: Macarthur studies of successful aging. Seeman TE, et al. **Psychoneuroendocrinology** 1995;20(7):711–25

Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans. Little JT, et al. **Psychopharmacology (Berl)** 1995 Aug;120(3):280–8

Changes in brain activity patterns in aging: the novelty oddball. Fabiani M, et al. **Psychophysiology** 1995 Nov; 32(6):579–94

Developmental and pharmacological analysis of the cardiac response to an acoustic startle stimulus. Richardson R, et al. **Psychophysiology** 1996 Jan;33(1):31–41

Effects of physical activity and age on mitochondrial function. Brierley EJ, et al. **QJM** 1996 Apr;89(4):251–8

Doppler spectral analysis of blood flow velocities in common femoral artery: age-related changes in healthy subjects and characteristics of abnormal hemodynamics in obstructive arterial disease. Nomura K, et al. **Radiat Med** 1996 Jan-Feb; 14(1):13–7

Aging reduces the reliability of epidural epinephrine test doses. Guinard JP, et al. **Reg Anesth** 1995 May-Jun; 20(3):193–8

Hypertrophic cardiomyopathy in old agers. Definitions and general considerations. Stănescu C. **Rom J Intern Med** 1995 Jul-Dec;33(3–4):133–9 (16 ref.)

Effects of night work on the cognitive function in young and elderly subjects with specific reference to the auditory P300. Yasukouchi H, et al. **Sangyo Ika Daigaku Zasshi** 1995 Dec 1;17(4):229–46

Age, physical fitness and health. Astrand PO. **Sb Lek** 1994; 95(2):59–63

Sound localization. The interaction of aging, hearing loss and hearing protection. Abel SM, et al. **Scand Audiol** 1996; 25(1):3–12

Developmental, nutritional, and hormonal regulation of the pancreatitis-associated protein I and III gene expression in the rat small intestine. Sansonetti A, et al. **Scand J Gastroenterol** 1995 Jul;30(7):664–9

Cardiovascular changes with age and exercise. A 28-year longitudinal study [see comments] Kasch FW, et al. **Scand J Med Sci Sports** 1995 Jun;5(3):147–51. Comment in: Scand J Med Sci Sports 1995 Jun;5(3):127–8.

Aging of human muscle: structure, function and adaptability [see comments] Porter MM, et al. **Scand J Med Sci Sports** 1995 Jun;5(3):129–42 (122 ref.). Comment in: Scand J Med Sci Sports 1995 Jun;5(3):127–8.

Age and spinal mobility in ankylosing spondylitis. Viitanen JV, et al. **Scand J Rheumatol** 1995;24(5):314–5

Age-related changes in the circadian control of urine output. Rittig S, et al. **Scand J Urol Nephrol Suppl** 1995;173:71–4; discussion 74–5

General medicine and geriatrics, where is the difference? The example of infective disease. Evans JG. **Schweiz Med Wochenschr** 1995 Oct 7;125(40):1847–54 (34 ref.)

Caloric restriction and aging. Weindruch R. **Sci Am** 1996 Jan;274(1):46–52

Age-related mortality and adherent splenic cell mediator production to endotoxin in the rat. Cochran JB, et al. **Shock** 1995 Dec;4(6):450–4

Dimensions of spatial acuity in the touch sense: changes over the life span. Stevens JC, et al. **Somatosens Mot Res** 1995; 12(1):29–47

Degeneration and aging affect the tensile behavior of human lumbar anulus fibrosus. Acaroglu ER, et al. **Spine** 1995 Dec 15;20(24):2690–701

Ultrasonographic assessment of carotid wall characteristics and cognitive functions in a community sample of 59- to 71-year-olds. The EVA Study Group. Auperin A, et al. **Stroke** 1996 Aug;27(8):1290–5

Factors of carotid arterial enlargement in a population aged 59 to 71 years: the EVA study. Bonithon-Kopp C, et al. **Stroke** 1996 Apr;27(4):654–60

Kinetics of neurotensin gene expression in the developing gut. Evers BM, et al. **Surgery** 1996 Feb;119(2):186–90

Late outcome of amputees with premature atherosclerosis. Valentine RJ, et al. **Surgery** 1996 May;119(5):487–93

Identification of age-related changes of dopamine D1-like receptors in the rat cerebellar cortex. Ricci A, et al. **Synapse** 1995 Sep;21(1):37–44

Age, altitude, and arrhythmia. Alexander JK. **Tex Heart Inst J** 1995;22(4):308–16 (69 ref.)

Relationship of serum IgE concentration to level and rate of decline of pulmonary function: the Normative Aging Study. Shadick NA, et al. **Thorax** 1996 Aug;51(8):787–92

Enhanced vascular plasminogen activator (t-PA) release by epinephrine in aged rats. Iacoviello L, et al. **Thromb Haemost** 1995 May;73(5):841–4

Effects of dietary fiber on gastrointestinal transit time, fecal properties and fat absorption in rats. Munakata A, et al. **Tohoku J Exp Med** 1995 Aug;176(4):227–38

Age-related neoplasia in a lifetime study of ad libitum-fed and food-restricted B6C3F1 mice. Sheldon WG, et al. **Toxicol Pathol** 1995 Jul-Aug;23(4):458–76

Sexuality and aging. Schiavi RC, et al. **Urol Clin North Am** 1995 Nov;22(4):711–26 (126 ref.)

Nutrition and ageing at the population level. Kesteloot H. **Verh K Acad Geneeskd Belg** 1996;58(2):117–38; discussion 138–9 (24 ref.)

Gastro-oesophageal reflux during anaesthesia in the dog: the effect of age, positioning and type of surgical procedure. Galatos AD, et al. **Vet Rec** 1995 Nov 11;137(20):513–6

An evaluation of the accuracy of ageing horses by their dentition: changes of dental morphology with age. Richardson JD, et al. **Vet Rec** 1995 Jul 29;137(5):117–21

An evaluation of the accuracy of ageing horses by their dentition: a matter of experience? Richardson JD, et al. **Vet Rec** 1995 Jul 22;137(4):88–90

A comparison of sampling efficiency and internal noise level in young and old subjects. Pardhan S, et al. **Vision Res** 1996 Jun;36(11):1641–8

Age-related functional field losses are not eccentricity dependent. Seiple W, et al. **Vision Res** 1996 Jun; 36(12):1859–66

Age-related changes in the color-match-area effect. Swanson WH, et al. **Vision Res** 1996 Jul;36(14):2079–85

Age, time, entropy, and biological optimality—some remarks on the general problem of biological optimization. Kenner T. **Wien Med Wochenschr** 1996;146(5):104–7

Healthy aging and the quality of life. Darnton-Hill I. **World Health Forum** 1995;16(4):335–43; discussion 344–72 (13 ref.)

[Age-related transfer coefficients of the basic indices of cardiac variance] Nikolova R, et al. **Probl Khig** 1995; 20:59–68 (Eng. Abstr.) **(Bul)**

[The neural basis of learning and memory declines in aged rats] Hong A. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul; 26(3):240–2 (Eng. Abstr.) **(Chi)**

[Current viewpoints in the pathophysiology and treatment of muscle weakness in elderly men] Lamberts SW. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):68–72 (51 ref.) **(Dut)**

[Dying out or neglect? (editorial)] van Houten P. **Tijdschr Gerontol Geriatr** 1996 Apr;27(2):50–1 **(Dut)**

[Pharmacology in the elderly. Changes in the pharmacodynamic response to a given drug concentration and changes in mechanisms of regulation] Jolliet P, et al. **Ann Med Interne (Paris)** 1995;146(5):328–34 (71 ref.) **(Fre)**

[Degeneration of catecholaminergic neurons (editorial)] Chatellard-Causse C, et al. **Pathol Biol (Paris)** 1995 Sep; 43(7):577–80 (13 ref.) **(Fre)**

[Study of oxidative stress in the elderly] Congy F, et al. **Presse Med** 1995 Jul 1–8;24(24):1115–8 (Eng. Abstr.) **(Fre)**

[Which problems arise in the hydration of elderly persons?] Mutsers A. **Rev Med Liege** 1996 Mar;51(3):249–53 (25 ref.) **(Fre)**

[Orthostatic hypotension in the elderly] Büla C. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):145–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[The calcium hypothesis of brain aging] Müller WE, et al. **Nervenarzt** 1996 Jan;67(1):15–24 (59 ref.) (Eng. Abstr.) **(Ger)**

[Heart failure in elderly patients] Hunziker P, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1272–6 (34 ref.) (Eng. Abstr.) **(Ger)**

[Sports and rehabilitation in old age] Niederhauser HU. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1259–64 (30 ref.) (Eng. Abstr.) **(Ger)**

[Isokinetic training in the elderly] Hopf T, et al. **Sportverletz Sportschaden** 1995 Dec;9(4):129–30 **(Ger)**

[Breed and age dependent structure of the eye chamber angle in cats] Köbnick M, et al. **Tierarztl Prax** 1995 Dec; 23(6):603–8 (Eng. Abstr.) **(Ger)**

[Development of the iron supply in suckling pigs under variable iron supplementation with regard to environmental conditions] Lemacher S, et al. **Tierarztl Prax** 1995 Oct; 23(5):457–64 (Eng. Abstr.) **(Ger)**

[Longitudinal analysis of change in sports performance of women between ages 30 and 75: a comparison between peak and leisure sports participation] Okonek CC. **Z Gerontol Geriatr** 1996 Mar-Apr;29(2):127–35 (Eng. Abstr.) **(Ger)**

[Biological age in patients with progressive scleroderma] Sauer I, et al. **Z Gerontol Geriatr** 1996 May-Jun; 29(3):223–32 (Eng. Abstr.) **(Ger)**

[Andropause: myth or reality?] Tomer Y, et al. **Harefuah** 1995 Jun 15;128(12):785–8 (51 ref.) **(Heb)**

[Influence of aging on the unilateral and the contralateral amygdaloid kindling in rats] Kamata S. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):95–104 (Eng. Abstr.) **(Jpn)**

[Age-related functional changes of cancellous and cortical bone: histomorphometric study of bone in senescent rats fed with a low calcium diet] Tanaka K. **Kokubyo Gakkai Zasshi** 1996 Jun;63(2):387–407 (Eng. Abstr.) **(Jpn)**

[Intraoperative changes in blood lactate level and body temperature in younger and elderly adults] Yamada T, et al. **Masui** 1995 Aug;44(8):1102–6 (Eng. Abstr.) **(Jpn)**

[Detection of prostate cancer in urological practice: clinical establishment of serum PSA reference values by age] Yamazaki H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):702–9 (Eng. Abstr.) **(Jpn)**

[Influence of aging on electrogustometric threshold] Nakazato M, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Jul;98(7):1140–53 (Eng. Abstr.) **(Jpn)**

[A longitudinal study of hearing level aggravation due to aging] Ono Y. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Apr; 99(4):558–66 (Eng. Abstr.) **(Jpn)**

[Changes with aging in ECochG] Ota Y. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jun;99(6):944–53 (Eng. Abstr.) **(Jpn)**

[A study of audiologic findings in the elderly] Shimoda K. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Sep;98(9):1426–39 (Eng. Abstr.) **(Jpn)**

[Whole mouth gustatory test (Part 2)—Effect of aging, gender and smoking on the taste threshold] Yamauchi Y, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Jul; 98(7):1125–34 (Eng. Abstr.) **(Jpn)**

[Changes in the amounts of elastic and collagenous elements of normal aged and emphysematous lung: use of a model of static pressure-volume relationships] Min KY. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1161–7 (Eng. Abstr.) **(Jpn)**

[Characteristic and therapy of hypertension in the aged] Ogihara T. **Nippon Naika Gakkai Zasshi** 1996 Mar 10; 85(3):423–7 (8 ref.) **(Jpn)**

[Age-related changes in amplitude ratio, duration ratio and area ratio in nerve conduction studies] Kurokawa K, et al. **Nippon Ronen Igakkai Zasshi** 1995 Aug-Sep; 32(8–9):547–52 (Eng. Abstr.) **(Jpn)**

[Influence of aging upon changes in symptoms and cardiac size associated with surgical repair of atrial septal defect in adults] Shigematsu Y, et al. **Nippon Ronen Igakkai Zasshi** 1995 Nov;32(11):736–40 (Eng. Abstr.) **(Jpn)**

[Analytic study on EEG features of aging with/without psychiatric disorders: focussing at the alterations in the EEGs of the healthy, depressive and demented elderlies] Saito N. **Seishin Shinkeigaku Zasshi** 1995;97(10):801–24 (Eng. Abstr.) **(Jpn)**

[Calcium metabolism in bone] Lorenc RS. **Pol Tyg Lek** 1995 Nov;50(44–47):48–52 (28 ref.) **(Pol)**

[Concentration of serum sulphydryl groups in patients with rheumatoid arthritis dependent on age and duration of disease] Janiszewski M, et al. **Wiad Lek** 1994 Sep; 47(17–18):654–8 (Eng. Abstr.) **(Pol)**

[Esophageal motility in the patient over 70 years old] Dantas RO. **Arq Gastroenterol** 1995 Jan-Mar;32(1):3–7 (Eng. Abstr.) **(Por)**

[Presbyesophagus—the maturity of a concept (editorial)] Michelsohn NH. **Arq Gastroenterol** 1995 Jan-Mar;32(1):1–2 **(Por)**

[Classification, analysis and use of indicators of biological age for prediction of life expectancy] Krut'ko VN, et al. **Fiziol Cheloveka** 1995 Nov-Dec;21(6):42–6 **(Rus)**

[Enterosorption as a method for prolonging life] Mamaĭ AV, et al. **Fiziol Cheloveka** 1996 May-Jun;22(3):131–5 (32 ref.) **(Rus)**

[Modern concepts on the mechanisms of aging] Titov SA, et al. **Fiziol Cheloveka** 1996 Mar-Apr;22(2):118–23 (47 ref.) **(Rus)**

[The characteristics of the development of neurodynamic functions in young schoolchildren] Makarenko NV, et al. **Fiziol Zh** 1994 Sep-Dec;40(5–6):23–31 (Eng. Abstr.) **(Rus)**

[The blood supply to the skeletal muscles of chickens in ontogeny] Belichenko VM, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):130–41 (Eng. Abstr.) **(Rus)**

[The role of interoceptive afferentation in regulating motor activity in the early postnatal ontogeny of rats] Kulaev BS, et al. **Fiziol Zh Im I M Sechenova** 1995 Apr; 81(4):99–102 **(Rus)**

[The characteristics of the neuronal response of the motor cortex in older rabbits to specific stimulation] Mednikova IuS, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug; 81(8):173–5 **(Rus)**

[The role of parathyroid hormone in regulating the contractile activity of the portal vein in normo- and hypertensive rats of different ages] Petrova NB, et al. **Fiziol Zh Im I M Sechenova** 1995 Sep;81(9):134–42 (Eng. Abstr.) **(Rus)**

[The development of a thermoregulatory reaction to heat emission in ontogeny in rats] Petrova OP. **Fiziol Zh Im I M Sechenova** 1995 Sep;81(9):88–94 (Eng. Abstr.) **(Rus)**

[The function of the hypophyseal-adrenocortical system and the orienting-exploratory behavior of rat pups] Vataeva LA, et al. **Fiziol Zh Im I M Sechenova** 1995 Apr;81(4):83–7 **(Rus)**

[Age-related changes in the activity of the peptidergic endings in the skin of rats] Zhukova EM, et al. **Fiziol Zh Im I M Sechenova** 1995 Jul;81(7):145–7 (Eng. Abstr.) **(Rus)**

[The compensatory-adaptive reactions of the thyroid and adrenal adrenergic structures in the postnatal ontogeny of sympathectomized rats] Markov VN, et al. **Morfologiia** 1994 Jul-Dec;107(7–12):89–96 (Eng. Abstr.) **(Rus)**

[Aging as the final stage of differentiation: an approach to an aperiodic state?] Gilbert DA. **Ontogenez** 1996 Jan-Feb; 27(1):3–16 (75 ref.) **(Rus)**

[Audiogenic epilepsy in 101/HY mice at different periods of postnatal development] Poletaeva II, et al. **Ontogenez** 1996 May-Jun;27(3):222–31 (Eng. Abstr.) **(Rus)**

[The neuroimmune relationships during normal aging and in Alzheimer-type dementias] Fokin VF, et al. **Vestn Ross Akad Med Nauk** 1996;(4):32–9 (Eng. Abstr.) **(Rus)**

[Neuroimmune interactions in normal aging and in Alzheimer disease] Ponomareva NV, et al. **Vestn Ross Akad Med Nauk** 1995;(12):27–32 (Eng. Abstr.) **(Rus)**

[The development of the active sleep phase in phylogeny and ontogeny] Aristakesian EA, et al. **Zh Evol Biokhim Fiziol** 1995 May-Jun;31(3):346–65 (85 ref.) **(Rus)**

[Aging and the morphofunctional changes in the hypothalamo-hypophyseal-adrenal cortical system] Bazhanova ED. **Zh Evol Biokhim Fiziol** 1995 Jan-Feb; 31(1):92–102 (74 ref.) **(Rus)**

[The age-related inhibition of motor excitation of the spinal cord in the early postnatal ontogeny of rats] Bursian AV, et al. **Zh Evol Biokhim Fiziol** 1995 Jul-Aug;31(4):423–9 (Eng. Abstr.) **(Rus)**

[The participation of opioids in the antinociceptive effect induced by the stimulation of hypothalamic "pleasure zones" in 20- to 30-day-old rabbits] Butkevich IP, et al. **Zh Evol Biokhim Fiziol** 1995 Mar-Apr;31(2):200–7 (Eng. Abstr.) **(Rus)**

[The N-cholinergic activation of the periodic activity of excitable structures in early postnatal ontogeny] Kuznetsov SV. **Zh Evol Biokhim Fiziol** 1995 Mar-Apr;31(2):190–9 (Eng. Abstr.) **(Rus)**

[The characteristics of training 1.5- to 4.5-month-old puppies to spatial-temporal alternation] Vataeva LA, et al. **Zh Evol Biokhim Fiziol** 1995 Jul-Aug;31(4):449–57 (Eng. Abstr.) **(Rus)**

[Lateralization characteristics in the perception of speech in noise by children of different age groups] Zaĭtseva KA, et al. **Zh Evol Biokhim Fiziol** 1995 Mar-Apr;31(2):230–4 (Eng. Abstr.) **(Rus)**

[The dependence of the parasympathetic reaction of the mesencephalic section of the brain stem to age-, sex- and pigment-reagent-related factors] Vel'khover ES, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):36–9 (Eng. Abstr.) **(Rus)**

[The formation in adult rats of an instrumental food-acquisition skill by using the forelimb partially denervated in early postnatal ontogeny] Stashkevich IS, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Nov-Dec; 45(6):1206–10 **(Rus)**

[Changes in thermoregulation and age. Hypothermia and hyperthermia] Kolesár J. **Bratisl Lek Listy** 1996 Mar; 97(3):165–74 (Eng. Abstr.) **(Slo)**

[The aging process] Ayala AR, et al. **Gac Med Mex** 1995 Mar-Apr;131(2):157–72 **(Spa)**

[Degeneration and regeneration of the peripheral nervous system with aging] Verdú E, et al. **Rev Neurol** 1995 May-Jun;23(121):648–55 (98 ref.) (Eng. Abstr.) **(Spa)**

[The characteristics of energy substrate utilization during long-term physical loading in elderly men] Korkushko OV,

et al. **Fiziol Zh** 1995 Jan-Apr;41(1-2):92-9 (Eng. Abstr.) **(Ukr)**

PSYCHOLOGY

The effects of a mobile telephone task on driver behaviour in a car following situation. Alm H, et al. **Accid Anal Prev** 1995 Oct;27(5):707-15

Quality of care from the elderly person's perspective: subjective importance and perceived reality. Wilde B, et al. **Aging (Milano)** 1995 Apr;7(2):140-9

Variables associated with cognitive function in elderly California Seventh-day Adventists. Fraser GE, et al. **Am J Epidemiol** 1996 Jun 15;143(12):1181-90

Antecedents and consequences of negative life events in adulthood: a longitudinal study. Cui XJ, et al. **Am J Psychiatry** 1996 Jan;153(1):21-6

Age-related changes in the tip-of-the-tongue experience. Brown AS, et al. **Am J Psychol** 1996 Spring;109(1):79-91

A life span model of successful aging. Schulz R, et al. **Am Psychol** 1996 Jul;51(7):702-14

High apolipoprotein E epsilon 4 allele frequency in age-related memory decline. Blesa R, et al. **Ann Neurol** 1996 Apr;39(4):548-51

Associations of status and change measures of neuropsychological function with pathologic changes in elderly, originally nondemented subjects. Crystal HA, et al. **Arch Neurol** 1996 Jan;53(1):82-7

Separation of activation and pattern in grooming development of weaver mice. Bolivar VJ, et al. **Behav Brain Res** 1996 Feb;75(1-2):49-58

Motor behavior of heterozygous staggerer mutant (+/sg) versus normal (+/+) mice during aging. Caston J, et al. **Behav Brain Res** 1995 Dec 14;72(1-2):97-102

Spatial learning impairment in aged rats: comparing between aged basal forebrain lesioned and normal aged rats. Nakamura S, et al. **Behav Brain Res** 1995 Sep;70(1):69-76

Age-related changes in learning and memory and cholinergic neuronal function in senescence accelerated mice (SAM). Nitta A, et al. **Behav Brain Res** 1995 Dec 14;72(1-2):49-55

Lateralization of rotational behavior in developing and adult hamsters. Uziel D, et al. **Behav Brain Res** 1996 Feb; 75(1-2):169-77

Elderly in US have rising suicide risk [news] Charatan FB. **BMJ** 1996 Jan 20;312(7024):144

A quantitative analysis of agonistic behavior in juvenile American lobsters (Homarus americanus L.). Huber R, et al. **Brain Behav Evol** 1995;46(2):72-83

Reduced hippocampal CA1 Ca(2+)-induced long-term potentiation is associated with age-dependent impairment of spatial learning. Diana G, et al. **Brain Res** 1995 Jul 17; 686(1):107-10

The effects of a single neonatally induced convulsion on spatial navigation, locomotor activity and convulsion susceptibility in the adult rat. Kornelsen RA, et al. **Brain Res** 1996 Jan 8;706(1):155-9

Effect of capsaicin on learning, retention and extinction of spatial and active avoidance tasks in adult rats neonatally treated. Carobi C, et al. **Brain Res Cogn Brain Res** 1995 Oct;2(4):221-7

The effect of imagery on explicit and implicit tests of memory in young and old people: a double dissociation. McCauley ME, et al. **Can J Exp Psychol** 1996 Mar;50(1):34-41

Stability of Dental Anxiety Scale scores: a longitudinal study of older adults. Locker D, et al. **Community Dent Oral Epidemiol** 1995 Oct;23(5):259-61

Alexithymia in a normal elderly population. Joukamaa M, et al. **Compr Psychiatry** 1996 Mar-Apr;37(2):144-7

Cross-form priming in normal aging and in mild dementia of the Alzheimer type. Ergis AM, et al. **Cortex** 1995 Dec; 31(4):699-710

Ontogeny of orientation and spatial learning on the radial maze in mice. Chapillon P, et al. **Dev Psychobiol** 1995 Dec; 28(8):429-42

On the importance of evolution to developmental psychobiology. Hill WL. **Dev Psychobiol** 1995 Mar; 28(2):117-29 (70 ref.)

Cognitive impairment in elderly people. Predisposing factors and implications for experimental drug studies. Jolles J, et al. **Drugs Aging** 1995 Dec;7(6):459-79 (176 ref.)

Memory disorders in 8,037 elderly patients with age-associated memory impairment: multicenter trial with a 6-month follow-up under almitrine-raubasine. Poitrenaud J, et al. **Eur Neurol** 1995;35 Suppl 1:43-6

Neuropsychological test performance, cognitive functioning, blood pressure, and age: the Framingham Heart Study. Elias MF, et al. **Exp Aging Res** 1995 Oct-Dec;21(4):369-91

Blood pressure, hypertension, and age as risk factors for poor cognitive performance. Elias PK, et al. **Exp Aging Res** 1995 Oct-Dec;21(4):393-417

Working memory resource allocation by young, middle-aged, and old adults. Foos PW. **Exp Aging Res** 1995 Jul-Sep;21(3):239-50

Inter- and intra-individual differences in semantic priming among young and older adults. Lyons KE, et al. **Exp Aging Res** 1995 Jul-Sep;21(3):221-37

Free recall and recognition of slowly and rapidly presented words in very old age: a community-based study. Wahlin A, et al. **Exp Aging Res** 1995 Jul-Sep;21(3):251-71

The neuropsychology of aging. Zec RF. **Exp Gerontol** 1995 May-Aug;30(3-4):431-42 (79 ref.)

Coping with stress: a physician's guide to mental health in aging. Solomon R. **Geriatrics** 1996 Jul;51(7):46-8, 50-1; quiz 52

A note on viewing functional change in later life as migration. Uhlenberg P. **Gerontologist** 1995 Aug;35(4):549-52

Establishing the study of development as a dynamic force in health psychology [editorial; comment] Peterson L. **Health Psychol** 1996 May;15(3):155-7. Comment on: Health Psychol 1996 May;15(3):158-66. Comment on: Health Psychol 1996 May;15(3):167-75.

Relations among age, exercise, and psychological variables in a community sample of women. Wilcox S, et al. **Health Psychol** 1996 Mar;15(2):110-3

Perceptions of senior residents about a community-based nursing center. Scott CB, et al. **Image J Nurs Sch** 1995 Fall;27(3):181-6

Age and responses to the Love Attitudes Scale: consistency in structure, differences in scores. Butler R, et al. **Int J Aging Hum Dev** 1995;40(4):281-96

Successful aging, life satisfaction, and generativity in later life. Fisher BJ. **Int J Aging Hum Dev** 1995;41(3):239-50

Aging and encoding in memory: false alarms and decision criteria in a word-pair recognition task. Isingrini M, et al. **Int J Aging Hum Dev** 1995;41(1):79-88

Embodiment and emplacement: identities, representation and landscape in Sun City retirement communities. Laws G. **Int J Aging Hum Dev** 1995;40(4):253-80 (60 ref.)

Age and skilled psychomotor performance: a comparison of younger and older golfers. Over R, et al. **Int J Aging Hum Dev** 1995;41(1):1-12

Motivation in later life: theory and assessment. Vallerand RJ, et al. **Int J Aging Hum Dev** 1995;41(3):221-38

Human development in the context of aging and chronic illness: the role of attachment in Alzheimer's disease and stroke. Wright LK, et al. **Int J Aging Hum Dev** 1995; 41(2):133-50 (82 ref.)

The experience of being at home throughout the life span. Investigation of persons aged from 2 to 102. Zingmark K, et al. **Int J Aging Hum Dev** 1995;41(1):47-62

Age and gender differences in the impact of psoriasis on quality of life. Gupta MA, et al. **Int J Dermatol** 1995 Oct; 34(10):700-3

Concerns about aging and a drive for thinness: a factor in the biopsychosocial model of eating disorders? Gupta MA. **Int J Eat Disord** 1995 Dec;18(4):351-7

Slowed reaction time performance on a divided attention task in elderly with environmental chemical odor intolerance. Bell IR, et al. **Int J Neurosci** 1996 Feb; 84(1-4):127-34

Social variation in attitudes to obesity in children. Wardle J, et al. **Int J Obes Relat Metab Disord** 1995 Aug; 19(8):562-9

Creativity and the third age. Limentani A. **Int J Psychoanal** 1995 Aug;76 (Pt 4):825-33

Suicide, life course, and life story. Cohler BJ, et al. **Int Psychogeriatr** 1995 Summer;7(2):199-219

Suicide and aging. I: Patterns of psychiatric diagnosis. Conwell Y, et al. **Int Psychogeriatr** 1995 Summer; 7(2):149-64

Suicide and aging. II: The psychobiological interface. Conwell Y, et al. **Int Psychogeriatr** 1995 Summer; 7(2):165-81

From a cultural stance: suicide and aging in a changing world. Corin E. **Int Psychogeriatr** 1995 Summer; 7(2):335-55

Openness to experience and completed suicide across the second half of life. Duberstein PR. **Int Psychogeriatr** 1995 Summer;7(2):183-98

Reflections on cultural influences on aging and old-age suicide in Germany. Schmitz-Scherzer R. **Int Psychogeriatr** 1995 Summer;7(2):231-8

Suicide and aging in Japan: an examination of treated elderly suicide attempters. Takahashi Y, et al. **Int Psychogeriatr** 1995 Summer;7(2):239-51

Aging and memory: corrections for age, sex and education for three widely used memory tests. Zappalà G, et al. **Ital J Neurol Sci** 1995 Apr;16(3):177-84

The influence of depressive symptomatology on episodic memory functioning among clinically nondepressed older adults. Bäckman L, et al. **J Abnorm Psychol** 1996 Feb; 105(1):97-105

The biomedical construction of ageing: implications for nursing care of older people. Koch T, et al. **J Adv Nurs** 1996 May;23(5):954-9

Relationship between elderly carers and the older adult with learning disabilities: an overview of the literature. Maggs C, et al. **J Adv Nurs** 1996 Feb;23(2):243-51 (56 ref.)

Age, education, and changes in the Mini-Mental State Exam scores of older women: findings from the Nun Study. Butler SM, et al. **J Am Geriatr Soc** 1996 Jun;44(6):675-81

Predictors of change in walking velocity in older adults. Gibbs J, et al. **J Am Geriatr Soc** 1996 Feb;44(2):126-32

Alzheimer's disease as a metaphor for contemporary fears of aging [letter] O'Rourke N. **J Am Geriatr Soc** 1996 Feb; 44(2):220-1

Socioeconomic status and exercise self-efficacy in late life. Clark DO, et al. **J Behav Med** 1995 Aug;18(4):355-76

Aging as death rehearsal: the oppressiveness of reason. Gadow S. **J Clin Ethics** 1996 Spring;7(1):35-40

Effect of age on the line bisection test. Fujii T, et al. **J Clin Exp Neuropsychol** 1995 Dec;17(6):941-4

Neuropsychological test performance of specific diagnostic groups in the Canadian Study of Health and Aging (CSHA). Steenhuis RE, et al. **J Clin Exp Neuropsychol** 1995 Oct;17(5):773-85

Stability of the WAIS-R and WISC-III factor structure using cross-validation of covariance structures. Allen SR, et al. **J Clin Psychol** 1995 Sep;51(5):648-57

Topographic organization of a forebrain pathway involved with vocal learning in zebra finches. Johnson F, et al. **J Comp Neurol** 1995 Jul 24;358(2):260-78

Manual laterality in chimpanzees (Pan troglodytes) in complex tasks. Colell M, et al. **J Comp Psychol** 1995 Sep; 109(3):298-307

Prenatal auditory experience directs species-typical perceptual responsiveness in bobwhite quail chicks (Colinus virginianus). McBride T, et al. **J Comp Psychol** 1995 Sep; 109(3):321-9

Early auditory experience and the ontogeny of alarm-call discrimination in Belding's ground squirrels (Spermophilus beldingi). Mateo JM. **J Comp Psychol** 1996 Jun; 110(2):115-24

Social learning in the golden hamster (Mesocricetus auratus). Prato Previde E, et al. **J Comp Psychol** 1996 Jun; 110(2):203-8

Convergence of untutored song in group-reared zebra finches (Taeniopygia guttata). Volman SF, et al. **J Comp Psychol** 1995 Sep;109(3):211-21

Reasoning from memory: a lifespan inquiry into the necessity of remembering when reasoning about class inclusion. Howe ML, et al. **J Exp Child Psychol** 1996 Feb;61(1):1-42

Facial asymmetry and attractiveness judgment in developmental perspective. Kowner R. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):662-75

Age differences in stress, coping, and appraisal: findings from the Normative Aging Study. Aldwin CM, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul;51(4):P179-88

The effects of list-making on recall in young and elderly adults. Burack OR, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul;51(4):P226-33

Predicting age-related differences in visual information processing using a two-stage queuing model. Ellis RD, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 May; 51(3):P155-65

Aging and filtering by movement in visual search. Kramer AF, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul; 51(4):P201-16

Age differences in episodic memory, semantic memory, and priming: relationships to demographic, intellectual, and biological factors. Nyberg L, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul;51(4):P234-40

Where in an ordered sequence of variables do independent age-related effects occur? Salthouse TA. **J Gerontol B Psychol Sci Soc Sci** 1996 May;51(3):P166-78

Health and social precursors of later life retirement-community migration. Silverstein M, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 May;51(3):S150-6

The effects of preclinical dementia on estimates of normal cognitive functioning in aging. Sliwinski M, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul;51(4):P217-25

Behavioral slowing with age: boundary conditions of the generalized slowing model. Swearer JM, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jul;51(4):P189-200

Effect of age and disease duration on parkinsonian motor scores under levodopa therapy. Ransmayr G, et al. **J Neural Transm Park Dis Dement Sect** 1995;9(2-3):177-88

Influence of age, temperature, sex, height and diazepam on vibration perception. Meh D, et al. **J Neurol Sci** 1995 Dec; 134(1-2):136-42

Functional and psychic deterioration in elderly people may be aggravated by folate deficiency. Ortega RM, et al. **J Nutr** 1996 Aug;126(8):1992-9

Transition from the early 40s to the early 50s in self-directed women. Wink P. **J Pers** 1996 Mar;64(1):49-69

Graying of the critical items: effects of aging on responding to MMPI-2 critical items. Aaronson AL, et al. **J Pers Assess** 1996 Feb;66(1):169-76

The intersection of life stage and social events: personality and life outcomes. Duncan LE, et al. **J Pers Soc Psychol** 1995 Sep;69(3):558-68

Identity in three cohorts of midlife women. Helson R, et al. **J Pers Soc Psychol** 1995 Sep;69(3):544-57

Relation of shame and guilt to constructive versus destructive responses to anger across the lifespan. Tangney JP, et al. **J Pers Soc Psychol** 1996 Apr;70(4):797-809

Assessing individual differences in constructive versus destructive responses to anger across the lifespan. Tangney JP, et al. **J Pers Soc Psychol** 1996 Apr;70(4):780-96

The relationship of death anxiety with age and psychosocial maturity. Rasmussen CA, et al. **J Psychol** 1996 Mar; 130(2):141-4

Suicidal thought and self-transcendence in older adults. Buchanan D, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Oct;33(10):31-4

The underestimated role of temporal comparison: a test of the life-span model. Brown R, et al. **J Soc Psychol** 1996 Jun;136(3):325-31

Evaluation of persons of varying ages. Stolte JF. **J Soc Psychol** 1996 Jun;136(3):305-9

Demographic differences in coping with uncertainty about the future. van der Sijde PC, et al. **J Soc Psychol** 1996 Apr;136(2):159-64

Conservation of energy, uncertainty reduction, and swift utilization of medical care among the elderly: study II. Leventhal EA, et al. **Med Care** 1995 Oct;33(10):988-1000

In my era: evidence for the perception of a special period

of the past. Sehulster JR. **Memory** 1996 Mar;4(2):145–58
Nicotine enhances Morris water maze performance of young and aged rats. Socci DJ, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):857–60
Age and stress history effects on spatial performance in a swim task in Fischer–344 rats. Mabry TR, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):1–10
Age and education correction of Mini–Mental State Examination for English and Spanish–speaking elderly. Mungas D, et al. **Neurology** 1996 Mar;46(3):700–6
Are there any differences in the safety and efficacy of brofaromine and imipramine between non–elderly and elderly patients with major depression? Volz HP, et al. **Neuropsychobiology** 1995;32(1):23–30
Psychomotor functions in developing rats: ontogenetic approach to structure–function relationships. Bâ A, et al. **Neurosci Biobehav Rev** 1995 Fall;19(3):413–25
Adult reactivity in rats exposed to cocaine during two early postnatal periods. Dow–Edwards DL, et al. **Neurotoxicol Teratol** 1995 Sep–Oct;17(5):553–7
Relation between age–related changes in hyper–emotionality and serotonergic neuronal activities in the rat limbic system. Li JW, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun;15(3):231–8
Effects of age and level of work experience on occurrence of accidents. Cellier JM, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):931–40
Mental activity, health, and life–satisfaction. Delin CR, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):944–6
Male nurturing: older men don't want to share their views; young women do. Draper TW. **Percept Mot Skills** 1996 Feb;82(1):313–4
Language production in younger and older adults. Drummond S, et al. **Percept Mot Skills** 1996 Apr;82(2):578
Visual recognition training of older adults with speech spectrograms. Drummond SS, et al. **Percept Mot Skills** 1996 Apr;82(2):379–82
Collaborative referencing in elderly women. Filer L, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):995–1000
Handedness trends across age groups in a Japanese sample of 2316. Iwasaki S, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):979–94
Influences of aging, gender, and handedness on motor performance of upper and lower extremities. Kauranen K, et al. **Percept Mot Skills** 1996 Apr;82(2):515–25
Walking patterns and finger rhythm of older adults. Nagasaki H, et al. **Percept Mot Skills** 1996 Apr;82(2):435–47
Age–related changes in postural control and locomotion. Okuzumi H, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):991–4
Sex differences in color preferences among an elderly sample. Silver NC, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):920–2
Nicotine enhances the learning and memory of aged rats. Arendash GW, et al. **Pharmacol Biochem Behav** 1995 Nov; 52(3):517–23
Effects of varying temporal exposure to lead on behavioral development in herring gull (Larus argentatus) chicks. Burger J, et al. **Pharmacol Biochem Behav** 1995 Nov; 52(3):601–8
Relationship between memory and fear: developmental and pharmacological studies. Pletnikov MV, et al. **Pharmacol Biochem Behav** 1996 May;54(1):93–8
Effect of chronic piracetam on age–related changes of cross–maze exploration in mice. Salimov R, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):637–40
Cognitive psychophysiology in nootropic drug research: effects of Ginkgo biloba on event–related potentials (P300) in age–associated memory impairment. Semlitsch HV, et al. **Pharmacopsychiatry** 1995 Jul;28(4):134–42
Spatial navigation of staggerer and normal mice during juvenile and adult stages. Bensoula AN, et al. **Physiol Behav** 1995 Nov;58(5):823–5
Age–related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. Forster MJ, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4765–9
Age–related differences in the detection of three–dimensional surfaces from optic flow. Andersen GJ, et al. **Psychol Aging** 1995 Dec;10(4):650–8
Speed of information processing as a mediator between age and free–recall performance. Bryan J, et al. **Psychol Aging** 1996 Mar;11(1):3–9
Age and sex differences in strategies of coping and defense across the life span. Diehl M, et al. **Psychol Aging** 1996 Mar;11(1):127–39
Forgetting in the workplace: attributions and recommendations for young and older employees. Erber JT, et al. **Psychol Aging** 1995 Dec;10(4):565–9
Age differences in retrieval: further support for the resource–reduction hypothesis. Fastenau PS, et al. **Psychol Aging** 1996 Mar;11(1):140–6
Aging mothers' and their adult daughters' perceptions of conflict behaviors. Fingerman KL. **Psychol Aging** 1995 Dec;10(4):639–49
Temporal discounting in choice between delayed rewards: the role of age and income. Green L, et al. **Psychol Aging** 1996 Mar;11(1):79–84
Attentional flexibility and aging: you don't need to be 20 years of age to split the beam. Hahn S, et al. **Psychol Aging** 1995 Dec;10(4):597–609
Adult age differences in the inhibition of return of visual attention. Hartley AA, et al. **Psychol Aging** 1995 Dec; 10(4):670–83
Aging and interference: evidence from indirect memory tests. Hartman M. **Psychol Aging** 1995 Dec;10(4):659–69
Acquisition of prototype–based information about social groups in adulthood. Hess TM, et al. **Psychol Aging** 1996 Mar;11(1):179–90
Age and health bias in practicing clinical psychologists. James JW, et al. **Psychol Aging** 1995 Dec;10(4):610–6
Things that go bump in your life: explaining the reminiscence bump in autobiographical memory. Jansari A, et al. **Psychol Aging** 1996 Mar;11(1):85–91
Effects of age on state of awareness following implicit and explicit word–association tasks. Java RI. **Psychol Aging** 1996 Mar;11(1):108–11
Aging and single versus multiple cues in source monitoring. Johnson MK, et al. **Psychol Aging** 1995 Dec;10(4):507–17
Patterns of personality change across the life span. Jones CJ, et al. **Psychol Aging** 1996 Mar;11(1):57–65
Assessing stress–buffering effects: a cautionary note. Krause N. **Psychol Aging** 1995 Dec;10(4):518–26
Does job–related training performance decline with age? Kubeck JE, et al. **Psychol Aging** 1996 Mar;11(1):92–107 (100 ref.)
Stability and accuracy of metamemory in adulthood and aging: a longitudinal analysis. McDonald–Miszczak L, et al. **Psychol Aging** 1995 Dec;10(4):553–64
Age–related impairment in an event–based prospective–memory task. Maylor EA. **Psychol Aging** 1996 Mar;11(1):74–8
Social support as a mediator in the relation between functional status and quality of life in older adults. Newsom JT, et al. **Psychol Aging** 1996 Mar;11(1):34–44
Search for semantic inhibition failure during sentence comprehension by younger and older adults. Paul ST. **Psychol Aging** 1996 Mar;11(1):10–20
Antecedents and contexts of generativity motivation at midlife. Peterson BE, et al. **Psychol Aging** 1996 Mar; 11(1):21–33
Moral and social reasoning and perspective taking in later life: a longitudinal study. Pratt MW, et al. **Psychol Aging** 1996 Mar;11(1):66–73
Differential effects of aging on memory for content and context: a meta–analysis. Spencer WD, et al. **Psychol Aging** 1995 Dec;10(4):527–39
Depressive symptoms across older spouses and the moderating effect of marital closeness. Tower RB, et al. **Psychol Aging** 1995 Dec;10(4):625–38
On the mechanisms of plasticity in young and older adults after instruction in the method of loci: evidence for an amplification model. Verhaeghen P, et al. **Psychol Aging** 1996 Mar;11(1):164–78
Predictors of adherence to a structured exercise program for older women. Williams P, et al. **Psychol Aging** 1995 Dec; 10(4):617–24
Factors related to loneliness. Barretta D, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):827–30
Cross–sectional age differences in the self–conceptions of adults. Byrd M, et al. **Psychol Rep** 1995 Oct;77(2):540–2
Relationship of eight basic emotions with age, sex, education, satisfaction of life needs, and religion. Catipović–Veselica K, et al. **Psychol Rep** 1995 Aug;77(1):115–21
Association of scores for Type A behavior with age, sex, occupation, education, life needs satisfaction, smoking, and religion in 1084 employees. Catipović–Veselica K, et al. **Psychol Rep** 1995 Aug;77(1):131–8
Suicide notes at symbolic ages. Leenaars AA. **Psychol Rep** 1996 Jun;78(3 Pt 1):1034
Memory for parking location in large lots. Means LW, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):775–9
Aging and sense of control. Shapiro DH JR, et al. **Psychol Rep** 1995 Oct;77(2):616–8
An exploratory study of differences in developmental concerns of middle–aged men and women in India. Tikoo M. **Psychol Rep** 1996 Jun;78(3 Pt 1):883–7
Barriers and aids in conducting research with older homeless individuals. Vance D. **Psychol Rep** 1995 Jun;76(3 Pt 1):783–6
Women ages 30–60 and their crisis events. Waskel SA, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1211–7
Comparison of undergraduates with older adults on love styles and life satisfaction. Yancey GB, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1211–8
Sense of humor and longevity: older adults' self–ratings compared with ratings for deceased siblings. Yoder MA, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):945–6
Working memory in older subjects: dealing with ongoing and stored information in language comprehension. Brébion G, et al. **Psychol Res** 1995;58(3):225–32
The processing–speed theory of adult age differences in cognition. Salthouse TA. **Psychol Rev** 1996 Jul; 103(3):403–28 (110 ref.)
Naming norms for brief environmental sounds: effects of age and dementia. Fabiani M, et al. **Psychophysiology** 1996 Jul; 33(4):462–75
Meta–analysis of P300 normative aging studies. Polich J. **Psychophysiology** 1996 Jul;33(4):334–53
Flows of social support and health status among older persons in China. Liu X, et al. **Soc Sci Med** 1995 Oct;41(8):1175–84
Healthy aging and the quality of life. Darnton–Hill I. **World Health Forum** 1995;16(4):335–43; discussion 344–72 (13 ref.)
Analyses of adult age differences in associative learning. Salthouse TA, et al. **Z Psychol Z Angew Psychol** 1995; 203(4):351–60
[Personal meaning in the elderly: sources of meaning, welfare, coping and attitude to death] Ranst NV, et al. **Tijdschr Gerontol Geriatr** 1996 Feb;27(1):5–13 (Eng. Abstr.) **(Dut)**
[Modification of performance by activation in the elderly] Hüppe M, et al. **Z Exp Psychol** 1996;43(1):69–84 (Eng. Abstr.) **(Ger)**
[Experimental analysis of processing stressful information: differential and age–related psychological aspects] Wentura D, et al. **Z Exp Psychol** 1995;42(1):152–75 (Eng. Abstr.) **(Ger)**
[Aspects of physical capacity and quality of life in old age (editorial)] Kruse A. **Z Gerontol Geriatr** 1996 Mar–Apr; 29(2):93–4 **(Ger)**
[Interdisciplinary team––responsibilities and problems in the assessment of aging processes] Lehr U. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):382–7 **(Ger)**
[Life review: promoting the developmental potentials in aging] Lohmann R, et al. **Z Gerontol Geriatr** 1995 Jul–Aug; 28(4):236–41 (35 ref.) (Eng. Abstr.) **(Ger)**
[Aging and performance in various tasks of prospective memory] Martin M, et al. **Z Gerontol Geriatr** 1996 Mar–Apr;29(2):119–26 (Eng. Abstr.) **(Ger)**
[Wellbeing, health and autonomy in old age: the Basal IDA Study (Interdisciplinary Aging Study)] Perrig–Chiello P, et al. **Z Gerontol Geriatr** 1996 Mar–Apr;29(2):95–109 (Eng. Abstr.) **(Ger)**
[Quality of attachment representation, social integration and use of social network resources in advanced age] Wensauer M, et al. **Z Gerontol Geriatr** 1995 Nov–Dec;28(6):444–56 (89 ref.) (Eng. Abstr.) **(Ger)**
[Integration of prior knowledge in speech comprehension in relation to age] Beyer R, et al. **Z Psychol Z Angew Psychol** 1995;203(4):361–78 (Eng. Abstr.) **(Ger)**
[Recall of personal performance in the elderly] Knopf M. **Z Psychol Z Angew Psychol** 1995;203(4):335–49 (Eng. Abstr.) **(Ger)**
[Cognitive capacity in advanced age: initial results of the Berlin Aging Study] Lindenberger U, et al. **Z Psychol Z Angew Psychol** 1995;203(4):283–317 (Eng. Abstr.) **(Ger)**
[Age–related memory impairment and hippocampal damage in ddY male mice] Tanaka M, et al. **Exp Anim** 1995 Oct; 43(5):697–702 (Eng. Abstr.) **(Jpn)**
[Biological, psychological and social aspects of aging––prevention and therapeutic methods] Preradović M, et al. **Vojnosanit Pregl** 1994 Jul–Aug;51(4):321–8 **(Scr)**

URINE

Utility of creatinine excretion in body–composition studies of healthy men and women older than 60 y. Welle S, et al. **Am J Clin Nutr** 1996 Feb;63(2):151–6

AGING, CELL see **CELL AGING**

AGITATION, PSYCHOMOTOR see **PSYCHOMOTOR AGITATION**

AGKISTRODON

cDNA cloning and sequence analysis of a lysine–49 phospholipase A2 myotoxin from Agkistrodon contortrix laticinctus snake venom. Selistre de Araujo HS, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):21–30
Copperhead snakebite of the foot [letter] Reid H, et al. **J Am Podiatr Med Assoc** 1996 Jul;86(7):347–9
Conservative treatment of copperhead snakebites without antivenin. Whitley RE. **J Trauma** 1996 Aug;41(2):219–21
Snake–strike––induced ischemic colitis with colonic stricture complicated by disseminated intravascular coagulation. Iwakiri R, et al. **South Med J** 1995 Oct;88(10):1084–5

METABOLISM

Glycosylation of recombinant ancrod from Agkistrodon rhodostoma after expression in mouse epithelial cells. Geyer H, et al. **Eur J Biochem** 1996 Apr 1;237(1):113–27

AGKISTRODON RHODOSTOMA VENOM PROTEASE see **ANCROD**

AGKISTRODON SERINE PROTEINASE see **ANCROD**

AGMATINE

ANALYSIS

Quantitation of the putative neurotransmitter agmatine as the hexafluoroacetylacetonate derivative by stable isotope dilution gas chromatography and negative–ion chemical ionization mass spectrometry. Stickle D, et al. **Anal Biochem** 1996 Jul 1;238(2):129–36

METABOLISM

Comparison of the interaction of agmatine and crude methanolic extracts of bovine lung and brain with alpha 2–adrenoceptor binding sites. Pinthong D, et al. **Br J Pharmacol** 1995 Jun;115(4):689–95

Agmatine, a bioactive metabolite of arginine. Production, degradation, and functional effects in the kidney of the rat. Lortie MJ, et al. **J Clin Invest** 1996 Jan 15;97(2):413–20

Agmatine (decarboxylated arginine) is synthesized and stored in astrocytes. Regunathan S, et al. **Neuroreport** 1995 Oct 2;6(14):1897–900

Metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors. Holt A, et al. **Prog Brain Res** 1995;106:187–97

PHARMACOLOGY

Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Galea E, et al. **Biochem J** 1996 May 15;316 (Pt 1):247–9

Renal I1-imidazoline receptor-selective compounds mediate natriuresis in the rat. Smyth DD, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S63–7

Selective inhibition of inducible nitric oxide synthase by agmatine. Auguet M, et al. **Jpn J Pharmacol** 1995 Nov; 69(3):285–7

Effects of agmatine, an active metabolite of arginine metabolism, on the kidney [editorial] Morrissey JJ, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1217–9 (25 ref.)

Agmatine, a novel hypothalamic amine, stimulates pituitary luteinizing hormone release in vivo and hypothalamic luteinizing hormone-releasing hormone release in vitro. Kalra SP, et al. **Neurosci Lett** 1995 Jul 21;194(3):165–8

THERAPEUTIC USE

Agmatine treatment is neuroprotective in rodent brain injury models. Gilad GM, et al. **Life Sci** 1996;58(2):PL 41–6

AGNOGENIC MYELOID METAPLASIA see **MYELOID METAPLASIA**

AGNOSIA

[Amusia] Tichý J. **Sb Lek** 1995;96(1):53–5 **(Cze)**

[Perceptions and Agnosia. Proceedings of an international meeting of the French Society of Neurology. Paris, 9–10 June 1994] **Rev Neurol (Paris)** 1995 Aug–Sep; 151(8–9):440–526 **(Fre)**

COMPLICATIONS

Anosognosia in Alzheimer's disease [letter; comment] Auchus AP, et al. **Arch Neurol** 1996 Jan;53(1):10. Comment on: Arch Neurol 1995 Apr;52(4):415–20.

DIAGNOSIS

Anosognosia for depressive signs [letter; comment] Black KJ. **Am J Psychiatry** 1996 Feb;153(2):298. Comment on: Am J Psychiatry 1995 Jan;152(1):37–44.

Tactile agnosia. Underlying impairment and implications for normal tactile object recognition. Reed CL, et al. **Brain** 1996 Jun;119 (Pt 3):875–88

Prosopagnosia: a clinical and anatomical study of four patients. Takahashi N, et al. **Cortex** 1995 Jun;31(2):317–29

Acquired epileptiform opercular syndrome: a second case report, review of the literature, and comparison to the Landau-Kleffner syndrome. Shafrir Y, et al. **Epilepsia** 1995 Oct;36(10):1050–7 (32 ref.)

Topographic amnesia: spatial memory disorder, perceptual dysfunction, or category specific semantic memory impairment? McCarthy RA, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):318–25

[Anosognosia, 2)anosodiaphoria] Matsumine H, et al. **No To Shinkei** 1995 Dec;47(12):1196–7 **(Jpn)**

ETIOLOGY

Weak electromagnetic fields improve body image perception in patients with multiple sclerosis. Sandyk R. **Int J Neurosci** 1995 Jun;82(3–4):285–302

Improvement of body image perception in Parkinson's disease by treatment with weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Jun;82(3–4):269–83

Kluver-Bucy syndrome following heat stroke in a 12-year-old girl. Pitt DC, et al. **Pediatr Neurol** 1995 Jul; 13(1):73–6

[The relationship between visual agnosia and visual pathway for perception] Kojima J, et al. **No To Shinkei** 1996 Jan; 48(1):31–7 (Eng. Abstr.) **(Jpn)**

[Familial posterior cortical atrophy with visual agnosia and Bálint's syndrome] Otsuki M, et al. **No To Shinkei** 1995 Dec;47(12):1185–90 (Eng. Abstr.) **(Jpn)**

[Verbal auditory agnosia: SPECT study of the brain] Carmona C, et al. **Rev Neurol** 1995 Sep–Oct; 23(123):1047–50 (Eng. Abstr.) **(Spa)**

HISTORY

The black hole in Charley Toorop's "The three generations": a neuro-iconographic analysis and reconstruction. Lakke JP. **Clin Neurol Neurosurg** 1995 Aug;97(3):269–76

PHYSIOPATHOLOGY

A neurological dissociation between shape from shading and shape from edges. Humphrey GK, et al. **Behav Brain Res** 1996 Apr;76(1-2):117–25

The functional anatomy of recovery from auditory agnosia. A PET study of sound categorization in a neurological patient and normal controls. Engelien A, et al. **Brain** 1995 Dec;118 (Pt 6):1395–409

A comment on apperceptive agnosia. Warrington EK, et al. **Brain Cogn** 1995 Jul;28(2):173–7; discussion 178–9

Anosognosia in parietal lobe syndrome. Ramachandran VS. **Conscious Cogn** 1995 Mar;4(1):22–51

The role of visual discrimination disorders and neglect in perceptual categorization deficits in right and left hemisphere damaged patients. Mulder JL, et al. **Cortex** 1995 Sep;31(3):487–501

Covert face recognition in prosopagnosia: a dissociable function? Schweinberger SR, et al. **Cortex** 1995 Sep; 31(3):517–29

[Tactile agnosia and dysfunction of the primary somatosensory area. Data of the study by somatosensory evoked potentials in patients with deficits of tactile object recognition] Mauguière F, et al. **Rev Neurol (Paris)** 1995 Aug–Sep;151(8–9):518–27 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Anosognosia in Alzheimer's disease [letter; comment] Auchus AP, et al. **Arch Neurol** 1996 Jan;53(1):10. Comment on: Arch Neurol 1995 Apr;52(4):415–20.

Is face recognition 'special'? Evidence from neuropsychology. Farah MJ. **Behav Brain Res** 1996 Apr; 76(1–2):181–9 (18 ref.)

Anosognosia in Alzheimer's disease: a study of associated factors. Migliorelli R, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):338–44

Denial of disabilities in anosognosia [letter] Ramachandran VS, et al. **Nature** 1996 Aug 8;382(6591):501

Anosognosia for hemiplegia: test of the personal neglect hypothesis. Adair JC, et al. **Neurology** 1995 Dec; 45(12):2195–9

Preserved visual imagery in visual form agnosia. Servos P, et al. **Neuropsychologia** 1995 Nov;33(11):1383–94

Dissociation between two modes of spatial processing by a visual form agnosic. Servos P, et al. **Neuroreport** 1995 Oct 2;6(14):1893–6

[A case of integrative visual agnosia] Hirayama K, et al. **Rinsho Shinkeigaku** 1995 Jul;35(7):781–7 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

The functional anatomy of recovery from auditory agnosia. A PET study of sound categorization in a neurological patient and normal controls. Engelien A, et al. **Brain** 1995 Dec;118 (Pt 6):1395–409

THERAPY

Improvement of body image perception in Parkinson's disease by treatment with weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Jun;82(3–4):269–83

Weak electromagnetic fields improve body image perception in patients with multiple sclerosis. Sandyk R. **Int J Neurosci** 1995 Jun;82(3–4):285–302

AGONISTIC BEHAVIOR

A quantitative analysis of agonistic behavior in juvenile American lobsters (Homarus americanus L.). Huber R, et al. **Brain Behav Evol** 1995;46(2):72–83

Learning and male-male sexual competition in Japanese quail (Coturnix japonica). Gutiérrez G, et al. **J Comp Psychol** 1996 Jun;110(2):170–5

DRUG EFFECTS

Differential effects of CGS 12066B and CP-94,253 on murine social and agonistic behaviour. Bell R, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):7–16

Effects of the 5-HT1A antagonist (+)-WAY-100135 on murine social and agonistic behavior. Bell R, et al. **Pharmacol Biochem Behav** 1996 May;54(1):159–67

PHYSIOLOGY

The physiology of social conflict in rats: what is particularly stressful? Haller J, et al. **Behav Neurosci** 1996 Apr; 110(2):353–9

Involvement of the 5-HT1A subtype receptor in the neonatal organization of agonistic behaviour in the rat. Albonetti E, et al. **Pharmacol Biochem Behav** 1996 May;54(1):189–93

Interactive effect of food deprivation and agonistic behavior on blood parameters and muscle glycogen in pigs. Fernandez X, et al. **Physiol Behav** 1995 Aug;58(2):337–45

[The role of steroid hormones in the sexual and agonistic behaviors of male silver foxes] Osadchuk LV. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):78–83 (Eng. Abstr.) **(Rus)**

AGORAPHOBIA

Cognitive mediators of situational fear in agoraphobia. Hoffart A. **J Behav Ther Exp Psychiatry** 1995 Dec; 26(4):313–20

DIAGNOSIS

The symptom structure of panic disorder: a trial using factor and cluster analysis. Shioiri T, et al. **Acta Psychiatr Scand** 1996 Feb;93(2):80–6

DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis. Goisman RM, et al. **Am J Psychiatry** 1995 Oct; 152(10):1438–43

The panic-agoraphobic syndrome: a paradigm of the anxiety group of disorders and its implications for psychiatric practice and theory. Roth M. **Am J Psychiatry** 1996 Jul; 153(7 Suppl):111–24 (90 ref.)

Confirmatory factor analysis of the Fear Questionnaire with social phobia patients. Cox BJ, et al. **Br J Psychiatry** 1996 Apr;168(4):497–9

Agoraphobia without panic: case illustrations of an overlooked syndrome. Pollard CA, et al. **J Nerv Ment Dis** 1996 Jan;184(1):61–2

Effects of intravenous diazepam pretreatment on lactate-induced panic. Liebowitz MR, et al. **Psychiatry Res** 1995 Sep 29;58(2):127–38

Hypersensitivity to inhalation of carbon dioxide and panic attacks. Perna G, et al. **Psychiatry Res** 1995 Aug 28; 57(3):267–73

DRUG THERAPY

Anxiety sensitivity [letter; comment] Fava GA. **Am J Psychiatry** 1996 Aug;153(8):1109–10. Comment on: Am J Psychiatry 1995 Aug;152(8):1156–60.

Treatment of late-onset agoraphobia secondary to depression [letter] Flint AJ. **Can J Psychiatry** 1995 Nov;40(9):568

Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. Bond AJ, et al. **J Affect Disord** 1995 Dec 13;35(3):117–23

Algorithm for the treatment of panic disorder with agoraphobia. Jobson KO, et al. **Psychopharmacol Bull** 1995; 31(3):483–5

[Panic disorder and agoraphobia: what is effective?] Bandelow B, et al. **Fortschr Neurol Psychiatr** 1995 Nov; 63(11):451–64 (120 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Panic, agoraphobia, and vestibular dysfunction. Jacob RG, et al. **Am J Psychiatry** 1996 Apr;153(4):503–12

Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Magee WJ, et al. **Arch Gen Psychiatry** 1996 Feb;53(2):159–68

ETIOLOGY

Panic disorder and agoraphobia: hypothesis hothouse. Klein DF. **J Clin Psychiatry** 1996;57 Suppl 6:21–7 (38 ref.)

PHYSIOPATHOLOGY

Psychosensorial and related phenomena in panic disorder and in temporal lobe epilepsy. Toni C, et al. **Compr Psychiatry** 1996 Mar–Apr;37(2):125–33

PSYCHOLOGY

Cognition-behaviour links in the persistence of panic. Salkovskis PM, et al. **Behav Res Ther** 1996 May–Jun; 34(5–6):453–8

Minnesota Multiphasic Personality Inventory correlates of panic disorder with agoraphobia: changes with treatment. Ito LM, et al. **Braz J Med Biol Res** 1995 Sep;28(9):961–5

The impact of stress, fear of fatness, and panic disorder with agoraphobia on eating disorder symptomatology: a case study. Chesler BE. **Int J Eat Disord** 1995 Sep;18(2):195–8

Suicidal behavior in patients with panic disorder: retrospective and prospective data. Warshaw MG, et al. **J Affect Disord** 1995 Jun 8;34(3):235–47

Childhood trauma and personality disorder in 43 women with panic disorder. Moisan D, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1133–4

THERAPY

Patient-therapist interaction in the behavioral treatment of panic disorder with agoraphobia. Keijsers GP, et al. **Behav Modif** 1995 Oct;19(4):491–517

Change in danger cognitions in agoraphobia and social phobia during treatment. Poulton RG, et al. **Behav Res Ther** 1996 May–Jun;34(5–6):413–21

A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Cottraux J, et al. **Br J Psychiatry** 1995 Nov;167(5):635–41

Five group comparisons of treatments for anxiety disorders [letter] Sharp DM, et al. **Br J Psychiatry** 1995 Dec; 167(6):820–1

Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia. van Balkom AJ, et al. **J Nerv Ment Dis** 1996 Feb;184(2):133–5

AGRAMMATISM see **APHASIA, BROCA**

AGRANULOCYTOSIS

BLOOD

Procainamide-induced agranulocytosis differs serologically and clinically from procainamide-induced lupus. Starkebaum G, et al. **Clin Immunol Immunopathol** 1996 Feb; 78(2):112–9

AGRANULOCYTOSIS

CHEMICALLY INDUCED

Agranulocytosis in rheumatoid arthritis associated with long-term flucloxacillin for staphylococcal osteomyelitis. Burton IE, et al. **Acta Haematol** 1995;94(4):196–8

Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity. Casato M, et al. **Am J Med** 1995 Oct;99(4):386–91

Granulocytopenia after combined therapy with interferon and angiotensin- converting enzyme inhibitors: evidence for a synergistic hematologic toxicity [letter] Jacquot C, et al. **Am J Med** 1996 Aug;101(2):235–6

Agranulocytosis after addition of risperidone to clozapine treatment [letter] Godleski LS, et al. **Am J Psychiatry** 1996 May;153(5):735–6

Successful treatment of carbimazole-induced agranulocytosis and severe sepsis with granulocyte macrophage colony stimulating factor. Freebairn RC, et al. **Anaesth Intensive Care** 1995 Aug;23(4):510–2

Carbimazole-induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor—a case report. Ng SC. **Ann Acad Med Singapore** 1995 May; 24(3):465–6

Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease. Tamai H, et al. **Ann Intern Med** 1996 Mar 1;124(5):490–4

Agranulocytosis associated with yohimbine use [letter] Siddiqui MA, et al. **Arch Intern Med** 1996 Jun 10; 156(11):1235–6, 1238

Sulphasalazine-induced agranulocytosis successfully treated with filgrastim [letter] Crawford GP, et al. **Aust N Z J Med** 1996 Apr;26(2):240

The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Corzo D, et al. **Blood** 1995 Nov 15;86(10):3835–40

Effective treatment of drug-induced agranulocytosis using recombinant human granulocyte colony stimulating factor in pregnancy. Fujiwaki R, et al. **Gynecol Obstet Invest** 1995; 40(4):276–7

Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety. Furusawa S, et al. **J Clin Pharmacol** 1996 May;36(5):477–81 (13 ref.)

Free radical scavenging enzyme activity and related trace metals in clozapine-induced agranulocytosis: a pilot study. Linday LA, et al. **J Clin Psychopharmacol** 1995 Oct; 15(5):353–60

Biphasic granulocytopenia after administration of the first dose of OKT3. Bemelman FJ, et al. **J Lab Clin Med** 1995 Dec;126(6):571–9

Hypogammaglobulinaemia with absent B lymphocytes and agranulocytosis after carbamazepine treatment [letter] Spickett GP, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):459

The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. Maggs JL, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1463–75

Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction. Abe H, et al. **Jpn Heart J** 1995 Jul;36(4):483–7

Agranulocytosis in a drug addict with recurrent Staphylococcus aureus septicaemia. Leung WK, et al. **Postgrad Med J** 1995 Dec;71(842):757–8

Do white-cell count spikes predict agranulocytosis in clozapine recipients? Alvir JM, et al. **Psychopharmacol Bull** 1995;31(2):311–4

Agranulocytosis and near fatal sepsis due to 'Mexican aspirin' (dipyrone). Dorr VJ, et al. **South Med J** 1996 Jun; 89(6):612–4

[Agranulocytosis caused by clozapine: the importance of leukocyte monitoring and efficacy of hematopoietic growth factors] van Melick EJ, et al. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2437–40 (18 ref.) (Eng. Abstr.) **(Dut)**

[Agranulocytosis induced by dapsone prescribed for dermatitis herpetiformis] Machet L, et al. **Ann Dermatol Venereol** 1996;123(5):328–30 (Eng. Abstr.) **(Fre)**

[Acute drug-induced agranulocytosis. Clinical study apropos of 30 patients and evolution of etiologies over 2 decades] Paitel JF, et al. **Rev Med Interne** 1995;16(7):495–9 (Eng. Abstr.) **(Fre)**

[Adverse hematologic effects of ticlopidine (letter)] Lesesve JF, et al. **Therapie** 1995 Sep–Oct;50(5):468–70 (11 ref.) **(Fre)**

[Ticlopidine-induced pancytopenia: therapy of agranulocytosis with granulocyte colony stimulating factor] Schneider AW, et al. **Med Klin** 1996 Jun 15; 91(6):417–9 **(Ger)**

[Suppression of granulopoiesis by vesnarinone] Chen G. **Kokuhyo Gakkai Zasshi** 1996 Mar;63(1):8–17 (Eng. Abstr.) **(Jpn)**

[Successful treatment of agranulocytosis caused by carbimazole using recombinant granulocyte-macrophage colony stimulating factor] Kreze A Jr, et al. **Vnitr Lek** 1995 Jul;41(7):470–2 (Eng. Abstr.) **(Slo)**

[Agranulocytosis induced by calcium dobesilate (letter)] Cladera Serra A, et al. **Med Clin (Barc)** 1995 Oct 28; 105(14):558–9 **(Spa)**

CLASSIFICATION

Dapsone toxicity: some current perspectives. Coleman MD. **Gen Pharmacol** 1995 Nov;26(7):1461–7 (51 ref.)

COMPLICATIONS

Neutrophilic dermal infiltrates in granulocytopenic patients with acute leukemia. Heer-Sonderhoff AH, et al. **Ann Hematol** 1995 Nov;71(5):257–61

Neutrophilic dermatoses during granulocytopenia [see comments] Aractingi S, et al. **Arch Dermatol** 1995 Oct; 131(10):1141–5. Comment in: Arch Dermatol 1996 Jul;132(7):832–3.

Are neutrophilic dermatoses during granulocytopenia really neutrophilic? [letter; comment] Misery L, et al. **Arch Dermatol** 1996 Jul;132(7):832–3. Comment on: Arch Dermatol 1995 Oct;131(10):1141–5.

A papular eruption secondary to infection with Corynebacterium jeikeium, with histopathological features mimicking botryomycosis. Jucglà A, et al. **Br J Dermatol** 1995 Nov;133(5):801–4

The use of quinolones as therapy in granulocytopenic cancer patients. Comparison with other antimicrobials. Krcméry V Jr. **Drugs** 1995;49 Suppl 2:139–43 (30 ref.)

Effect of granulocyte colony-stimulating factor on the course of infection with gram-positive bacteria in mice during granulocytopenia induced by sublethal irradiation or cyclophosphamide. Buisman AM, et al. **J Infect Dis** 1996 Aug;174(2):417–21

Staphylococcus aureus bacteremia: a 14-year nationwide study in hematological patients with malignant disease or agranulocytosis. Skov R, et al. **Scand J Infect Dis** 1995; 27(6):563–8

[The course and prognosis of septic shock in patients with hemoblastoses and aplastic anemia in a state of agranulocytosis] Galstian GM, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):18–23 (Eng. Abstr.) **(Rus)**

CONGENITAL

Kostmann's disease, recombinant HuG-CSF, monosomy 7 and MDS/AML. Smith OP, et al. **Br J Haematol** 1995 Sep;91(1):150–3

An abnormal clone with monosomy 7 and trisomy 21 in the bone marrow of a child with congenital agranulocytosis (Kostmann disease) treated with granulocyte colony-stimulating factor. Evolution towards myelodysplastic syndrome and acute basophilic leukemia. Shekhter-Levin S, et al. **Cancer Genet Cytogenet** 1995 Oct 15;84(2):99–104

DIAGNOSIS

Do white-cell count spikes predict agranulocytosis in clozapine recipients? Alvir JM, et al. **Psychopharmacol Bull** 1995;31(2):311–4

[Acute agranulocytosis--pathogenesis, diagnosis and treatment] Kuratowska Z. **Pol Arch Med Wewn** 1995 May; 93(5):384–9 (15 ref.) **(Pol)**

DRUG THERAPY

Successful treatment of sorivudine-related agranulocytosis with granulocyte-colony stimulating factor [letter] Sato H, et al. **Am J Hematol** 1995 Nov;50(3):227

Sulphasalazine-induced agranulocytosis successfully treated with filgrastim [letter] Crawford GP, et al. **Aust N Z J Med** 1996 Apr;26(2):240

Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity? Locker GJ, et al. **Breast Cancer Res Treat** 1995 Jun;34(3):213–9

Rheumatoid arthritis exacerbation by G-CSF treatment for bucillamine-induced agranulocytosis [letter] Nakashima H, et al. **Clin Exp Rheumatol** 1995 Sep–Oct;13(5):677–9

Effective treatment of drug-induced agranulocytosis using recombinant human granulocyte colony stimulating factor in pregnancy. Fujiwaki R, et al. **Gynecol Obstet Invest** 1995; 40(4):276–7

ETHNOLOGY

The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Corzo D, et al. **Blood** 1995 Nov 15;86(10):3835–40

ETIOLOGY

Patterns of recovery phase infection after autologous blood progenitor cell transplantation in patients with malignancies. The Gruppo Italiano di Studio per la Manipolazione Cellulare in Ematologia. D'Antonio D, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):552–6

Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy. Wilder RB, et al. **Eur J Nucl Med** 1996 Aug;23(8):953–7

Bone marrow involvement, in intensively treated patients with intermediate grade non-Hodgkin's lymphoma, is a risk factor for granulocytopenia and fever. Kitay-Cohen Y, et al. **Leuk Lymphoma** 1996 Jan;20(3–4):333–6

GENETICS

Infantile genetic agranulocytosis (Kostmann type). A case report. Sağlam F, et al. **J Periodontol** 1995 Sep;66(9):808–10

Genetic factors and risk of agranulocytosis from metamizol. Vlahov V, et al. **Pharmacogenetics** 1996 Feb;6(1):67–72

IMMUNOLOGY

Tumor necrosis factor alpha plus interleukin 1 beta treatment protects granulocytopenic mice from Pseudomonas aeruginosa lung infection: role of an unusual inflammatory response. Amura CR, et al. **APMIS** 1995 Jun;103(6):447–59

Procainamide-induced agranulocytosis differs serologically and clinically from procainamide-induced lupus. Starkebaum G, et al. **Clin Immunol Immunopathol** 1996 Feb; 78(2):112–9

METABOLISM

Production of tumor necrosis factor-alpha in granulocytopenic mice with pulmonary candidiasis and its modification with granulocyte colony-stimulating factor. Futenma M, et al. **Microbiol Immunol** 1995;39(6):411–7

MICROBIOLOGY

Infections in febrile granulocytopenic patients: clinical features and pathogens. Wang FD, et al. **J Formos Med Assoc** 1996 May;95(5):410–3

Direct cultivation of the causative agent of human granulocytic ehrlichiosis [see comments] Goodman JL, et al. **N Engl J Med** 1996 Jan 25;334(4):209–15. Comment in: N Engl J Med 1996 Jan 25;334(4):262–3.

PATHOLOGY

[Metastatic aspergillus panniculitis in blast transformation of a myelodysplastic syndrome and agranulocytosis] Skaria AM, et al. **Hautarzt** 1995 Aug;46(8):579–81 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma. Niitsu N, et al. **Eur J Haematol** 1996 Mar; 56(3):163–7

Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. Wexler LH, et al. **J Clin Oncol** 1996 Mar; 14(3):901–10

GM-CSF instead of hematological support during high-dose chemotherapy for refractory malignant lymphoma. Avilés A, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):327–30

[Agranulocytosis caused by clozapine: the importance of leukocyte monitoring and efficacy of hematopoietic growth factors] van Melick EJ, et al. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2437–40 (18 ref.) (Eng. Abstr.) **(Dut)**

SURGERY

The effect of thymectomy on myasthenia gravis, thrombocytopenia, and granulocytopenia associated with thymoma: report of a case. Kobayashi M, et al. **Surg Today** 1995;25(12):1061–5 (14 ref.)

THERAPY

Successful treatment of carbimazole-induced agranulocytosis and severe sepsis with granulocyte macrophage colony stimulating factor. Freebairn RC, et al. **Anaesth Intensive Care** 1995 Aug;23(4):510–2

Carbimazole-induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor—a case report. Ng SC. **Ann Acad Med Singapore** 1995 May; 24(3):465–6

Methimazole-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF): a case report. Chien MN, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Nov;56(5):351–5

Successful treatment of agranulocytosis and sepsis with granulocyte colony stimulating factor in a case of Felty's syndrome [letter; comment] Marfeuille M, et al. **J Rheumatol** 1995 Sep;22(9):1803–4. Comment on: J Rheumatol 1993 Aug;20(8):1447–8.

[Use of hematopoietic growth factors] Elonen E. **Duodecim** 1995;111(8):733–40 (38 ref.) **(Fin)**

[Emergency drug therapy of thyroid disease] Tsushima T. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1848–51 (0 ref.) **(Jpn)**

[Acute agranulocytosis--pathogenesis, diagnosis and treatment] Kuratowska Z. **Pol Arch Med Wewn** 1995 May; 93(5):384–9 (15 ref.) **(Pol)**

[Experience in using plasmapheresis in comprehensive therapy of myelotoxic agranulocytosis in cancer patients] Legeza VI, et al. **Gematol Transfuziol** 1995 Jul-Aug; 40(4):21–3 (Eng. Abstr.) **(Rus)**

[Successful treatment of agranulocytosis caused by carbimazole using recombinant granulocyte-macrophage colony stimulating factor] Kreze A Jr, et al. **Vnitr Lek** 1995 Jul;41(7):470–2 (Eng. Abstr.) **(Slo)**

AGRANULOCYTOSIS, FELINE see **FELINE INFECTIOUS ENTERITIS**

AGRAPHIA

DIAGNOSIS

Objects and properties: a study of the breakdown of semantic memory. Funnell E. **Memory** 1995 Sep–Dec;3(3–4):497–518

PSYCHOLOGY

[A specific disorder of Kanji writing observed in a learning-disabled child—cognitive-psychological and neuropsychological analysis] Uno A, et al. **No To Hattatsu** 1995 Sep;27(5):395–400 (Eng. Abstr.) **(Jpn)**

AGRICULTURAL CHEMICALS see **AGROCHEMICALS**

AGRICULTURAL CROPS see **CROPS, AGRICULTURAL**

AGRICULTURAL WORKERS' DISEASES

Bullous pemphigoid complicating human orf. Murphy JK, et al. **Br J Dermatol** 1996 May;134(5):929–30

Pesticide appliers with mixed pesticide exposure: G-banded analysis and possible relationship to non-Hodgkin's lymphoma. Garry VF, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jan;5(1):11–6

Childhood brucellosis in north-western Greece: a retrospective analysis. Galanakis E, et al. **Eur J Pediatr** 1996 Jan;155(1):1–6

[Effects of students' work activities in autumn agricultural teams on their morbidity] Chernykh AM, et al. **Med Tr Prom Ekol** 1995;(8):16–8 (Eng. Abstr.) **(Rus)**

[Lipid peroxidation and antioxidant system in neurovascular disorders among poultry farm workers] Dobzhanskiĭ IS, et al. **Med Tr Prom Ekol** 1995;(10):37–9 (Eng. Abstr.) **(Rus)**

[Evaluation of health status of agricultural machine operators and agriculture students] Galuzova VG, et al. **Med Tr Prom Ekol** 1995;(8):7–10 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Determinants of disability in illnesses related to agricultural use of organophosphates (OPs) in California. Weinbaum Z, et al. **Am J Ind Med** 1995 Aug;28(2):257–74

Risk factors for occupational illnesses associated with the use of paraquat (1,1'-dimethyl-4,4'-bipyridylium dichloride) in California. Weinbaum Z, et al. **Arch Environ Health** 1995 Sep–Oct;50(5):341–8

Exposure evaluation is a crucial step for quantitative risk assessment of methomyl. Sinhaseni P, et al. **Arh Hig Rada Toksikol** 1995 Sep;46(3):301–6

Increased risk of suicide with exposure to pesticides in an intensive agricultural area. A 12-year retrospective study. Parrón T, et al. **Forensic Sci Int** 1996 May 17;79(1):53–63

A new mask filter cartridge used to determine applicator inhalation exposure to an alachlor herbicide (Lasso) during normal spraying operations. Flaherty DK, et al. **J Occup Environ Med** 1995 Sep;37(9):1116–21

Neurotoxicity among pesticide applicators exposed to organophosphates. Stokes L, et al. **Occup Environ Med** 1995 Oct;52(10):648–53

Bladder cancer among French farmers: does exposure to pesticides in vineyards play a part? Viel JF, et al. **Occup Environ Med** 1995 Sep;52(9):587–92

[Formaldehyde in the occupational environment. A possible cause of chemically induced reactive arthritis] Tilsted D, et al. **Ugeskr Laeger** 1996 Aug 5;158(32):4525–7 (Eng. Abstr.) **(Dan)**

[Evaluation of urinary excretion of ethylenethiourea in subjects occupationally and non-occupationally exposed to ethylenebis(dithiocarbamates)] Sciarra G, et al. **G Ital Med Lav** 1994 Jan–Nov;16(1–6):49–52 (Eng. Abstr.) **(Ita)**

[Prognostication in chronic pesticide poisoning in agricultural workers: state of lipid metabolism] Dobzhanskiĭ IS, et al. **Med Tr Prom Ekol** 1996;(1):20–2 (Eng. Abstr.) **(Rus)**

[Symptoms related to the use of agricultural pesticides. The perspective from the primary care service] Subías Lorén PJ, et al. **Aten Primaria** 1995 Dec;16(10):615–7 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

A case of Trichuris trichiura infection diagnosed by colonoscopy. Yoshida M, et al. **Am J Gastroenterol** 1996 Jan;91(1):161–2 (7 ref.)

Persistent wheeze in grain elevator workers should not be ignored. Senthilselvan A, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):701–5

Detection of hepatitis E virus infections among domestic swine in the Kathmandu Valley of Nepal. Clayson ET, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):228–32

Cumulative trauma disorders of the upper limbs in workers on an agricultural farm. Raffi GB, et al. **Arh Hig Rada Toksikol** 1996 Mar;47(1):19–23

An analysis of 190 cases of suspected pesticide illness. Lessenger JE, et al. **J Am Board Fam Pract** 1995 Jul–Aug;8(4):278–82

[An immunoenzyme method for detecting Brucella antibodies and antigen in the blood serum of animal breeders from farms with an unfavorable brucellosis situation] Podoliako MP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec;(6):53–4 **(Rus)**

[Respiratory function in poultry workers] Zuškin E, et al. **Lijec Vjesn** 1995 May–Jun;117(5–6):121–5 (Eng. Abstr.) **(Scr)**

EPIDEMIOLOGY

Intestinal parasitic infections among rural farming communities in eastern Sierra Leone. Gbakima AA, et al. **Afr J Med Med Sci** 1995 Jun;24(2):195–200

Epidemiology of allergic reactions in beekeepers: a lower prevalence in subjects with more than 5 years exposure. de la Torre-Morin F, et al. **Allergol Immunopathol (Madr)** 1995 May–Jun;23(3):127–32

Respiratory health of Hispanic migrant farm workers in Indiana. Garcia JG, et al. **Am J Ind Med** 1996 Jan;29(1):23–32

Back pain and risk of suicide among Finnish farmers [letter] Penttinen J. **Am J Public Health** 1995 Oct;85(10):1452–3

Characteristics of orf in a farming community in mid-Wales. Buchan J. **BMJ** 1996 Jul 27;313(7051):203–4

Rate of Creutzfeldt-Jakob disease in farmers is not significant [letter] Morrison DR. **BMJ** 1996 Aug 31;313(7056):562

Human and bovine tuberculosis in the Monze District of Zambia—a cross-sectional study [see comments] Cook AJ, et al. **Br Vet J** 1996 Jan;152(1):37–46. Comment in: Br Vet J 1996 Jan;152(1):3–5.

Agricultural exposures and cancer. Blair A, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:205–8 (39 ref.)

An epidemiological study of influenza viruses among Chinese farm families with household ducks and pigs. Shu LL, et al. **Epidemiol Infect** 1996 Aug;117(1):179–88

Some aspects of occupational safety and health in green tea workers. Mirbod SM, et al. **Ind Health** 1995;33(3):101–17

Prevalence of latex allergy among greenhouse workers. Carrillo T, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):699–701

Creutzfeldt-Jakob disease in Europe [letter] Delasnerie-Laupretre N, et al. **Lancet** 1995 Sep 30;346(8979):898

Prevalence of dermatoses and skin sensitisation associated with use of pesticides in fruit farmers of southern Taiwan. Guo YL, et al. **Occup Environ Med** 1996 Jun;53(6):427–31

Lung function and chronic respiratory symptoms of pig farmers: focus on exposure to endotoxins and ammonia and use of disinfectants. Preller L, et al. **Occup Environ Med** 1995 Oct;52(10):654–60

The risk of acquiring Q fever on farms: a seroepidemiological study. Thomas DR, et al. **Occup Environ Med** 1995 Oct;52(10):644–7

Work related distal airway obstruction in an agricultural population. Vergnenegre A, et al. **Occup Environ Med** 1995 Sep;52(9):581–6

[Seroepidemiological studies on zoonoses in farm workers in Apulia] Baldelli R, et al. **Ann Ig** 1995 Nov–Dec;7(6):445–50 (Eng. Abstr.) **(Ita)**

[Occupational allergic respiratory disorders in farmers] Mainarowa J, et al. **Pneumonol Pol** 1990 Sep–Oct;58(9–10):527–30 (Eng. Abstr.) **(Pol)**

[Occupational brucellosis: epidemiology and clinico-immunological correlations] Dobzhanskiĭ IS. **Med Tr Prom Ekol** 1996;(2):30–2 **(Rus)**

[Prevalence of occupational diseases among agricultural workers] Dumkina GZ, et al. **Med Tr Prom Ekol** 1995;(12):45–7 **(Rus)**

[Prevalence of allergic diseases in workers of industrial swine breeding] Fedotova EV, et al. **Med Tr Prom Ekol** 1995;(8):32–3 (Eng. Abstr.) **(Rus)**

[A water-borne outbreak of hepatitis A among students employed in agricultural operations on a vegetable-growing farm] Drankin DI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec;(6):33–4 **(Rus)**

ETIOLOGY

Intraoperative latex anaphylaxis observed in a farmer [letter] Baykara N, et al. **Anesthesiology** 1996 Feb;84(2):476–7

Green tobacco sickness: occupational nicotine poisoning in tobacco workers. Ballard T, et al. **Arch Environ Health** 1995 Sep–Oct;50(5):384–9

Socio-economic, environmental and health aspects of farm workers engaged in mango plantations. Gupta BN, et al. **Biomed Environ Sci** 1995 Dec;8(4):301–9

Creutzfeldt-Jakob disease and bovine spongiform encephalopathy: any connection? [see comments] Almond JW, et al. **BMJ** 1995 Nov 25;311(7017):1415–21 (14 ref.) . Comment in: BMJ 1996 Jan 20;312(7024):180. Comment in: BMJ 1996 Jan 20;312(7024):181. Comment in: BMJ 1996 Jul 20;313(7050):171–2.

Ovine Chlamydiosis in pregnancy. Flanagan PG, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):382–5

Severe urological complication of leech bite in the tropics. Hamid MS, et al. **Br J Urol** 1996 Jan;77(1):164–5

Farmers at risk for prostate cancer. Van Der Gulden JW, et al. **Br J Urol** 1996 Jan;77(1):6–14 (98 ref.)

Outbreak of Campylobacter infection among farm workers: an occupational hazard. Ellis A, et al. **Can Commun Dis Rep** 1995 Sep 15;21(17):153–6 **(Eng, Fre)**

Contact allergy to tylosin and cobalt in a pig-farmer. Tuomi ML, et al. **Contact Dermatitis** 1995 Oct;33(4):285

Seasonal variations in energy balance among agriculturalists in central Mali: compromise or adaptation? Adams AM. **Eur J Clin Nutr** 1995 Nov;49(11):809–23

Streptococcus suis as threat to pig-farmers and abattoir workers [letter; comment] Bartelink AK, et al. **Lancet** 1995 Dec 23–30;346(8991–8992):1707. Comment on: Lancet 1995 Nov 11;346(8985):1305–6.

BSE and farmworkers [letter] Shaw IC. **Lancet** 1995 Nov 18;346(8986):1365

Creutzfeldt-Jakob disease in a dairy farmer [letter] Smith PE, et al. **Lancet** 1995 Sep 30;346(8979):898

Creutzfeldt-Jakob disease in a beef farmer [letter] Young GR, et al. **Lancet** 1996 Aug 31;348(9027):610–1

[The diagnosis of asthma caused by cow hair epithelium] Taivainen A, et al. **Duodecim** 1994;110(21):1999–2003 **(Fin)**

[Prevalence of immediate allergy to respiratory allergens in fodder farmers in Doubs] Dubiez A, et al. **Rev Epidemiol Sante Publique** 1995;43(5):470–6 (Eng. Abstr.) **(Fre)**

[Sugar beet pollen allergy as a rare occupational disease] Hohenleutner S, et al. **Hautarzt** 1996 Jun;47(6):462–4 (Eng. Abstr.) **(Ger)**

[Allergies in agriculture] Gassner M. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):950–60 (37 ref.) (Eng. Abstr.) **(Ger)**

[Storage mite allergy in Western Norway] Finsnes KA. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3274–5 (Eng. Abstr.) **(Nor)**

[Pulmonary function in Norwegian farmers keeping domestic animals] Varslot M, et al. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1077–80 (Eng. Abstr.) **(Nor)**

[Results of bronchoprovocation tests with the allergen Erwinia herbicola in persons with occupational exposure to organic dust] Durda M, et al. **Pneumonol Pol** 1990 Sep–Oct;58(9–10):522–6 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

The role of atopy in grain dust-induced airway disease. Blaski CA, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):334–40

MICROBIOLOGY

Occurrence and clinical significance of thermophilic actinomycetes in cane-sugar mills. Gangwar M, et al. **Arch Environ Health** 1995 Sep–Oct;50(5):393–4

Panic in the potting shed. The association between Legionella longbeachae serogroup 1 and potting soils in Australia. Ruehlemann SA, et al. **Med J Aust** 1996 Jan 1;164(1):36–8

PREVENTION & CONTROL

Assessment of worker exposure to airborne molds in honeybee overwintering facilities. Sigler L, et al. **Am Ind Hyg Assoc J** 1996 May;57(5):484–90

Use of skin-cancer prevention strategies among farmers and their spouses. Rosenman KD, et al. **Am J Prev Med** 1995 Sep–Oct;11(5):342–7

Assessment of human exposure to pesticides in greenhouses and effectiveness of personal protective devices. Iorizzo L, et al. **Arh Hig Rada Toksikol** 1996 Mar;47(1):25–33

An ethicist's commentary on the veterinarian receiving complaints from swine barn workers concerning respiratory problems. Rollin BE. **Can Vet J** 1996 May;37(5):262–3

[Significance of the helmet respirator in the treatment of farmer's occupational asthma] Taivainen A, et al. **Duodecim** 1994;110(4):423–8 **(Fin)**

[Specific problems of occupational diseases in various branches of agricultural production] Dovzhanskiĭ IS. **Med Tr Prom Ekol** 1995;(8):29–31 (Eng. Abstr.) **(Rus)**

AGRICULTURE

Nonfatal farm injuries in Ontario: a population-based survey. Pickett W, et al. **Accid Anal Prev** 1995 Aug;27(4):425–33

IgG1 and IgG4 antibody responses to the dust mite Lepidoglyphus destructor in a naturally exposed farming population. Johansson E, et al. **Allergy** 1995 Jun;50(6):473–7

Farm-work hazard prevention efforts by school-based agricultural education instructors. Chapman LJ, et al. **Am J Ind Med** 1995 Oct;28(4):565–77

Urinary excretion of tetrahydrophtalimide in fruit growers with dermal exposure to captan. de Cock J, et al. **Am J Ind Med** 1995 Aug;28(2):245–56

An occupational health and safety intervention research agenda for production agriculture: does safety education work? Murphy DJ, et al. **Am J Ind Med** 1996 Apr;29(4):392–6

Fall-related occupational injuries on farms. Nordstrom DL, et al. **Am J Ind Med** 1996 May;29(5):509–15

Incidence of farm-work-related acute injury in a defined population. Nordstrom DL, et al. **Am J Ind Med** 1995 Oct;28(4):551–64

Longitudinal evaluation of dose-response relationships for environmental exposures and pulmonary function in swine production workers. Reynolds SJ, et al. **Am J Ind Med** 1996 Jan;29(1):33–40

Respiratory health of California rice farmers. McCurdy SA, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1553–9

Environmental impact of sewage sludge: possibility and limits

for agricultural use. Divizia M, et al. **Ann Ig** 1994 Jul-Dec; 6(4-6):941-4

Prospects and problems of intermittent irrigation for control of vector breeding in rice fields in southern India. Rajendran R, et al. **Ann Trop Med Parasitol** 1995 Oct; 89(5):541-9

Bovine spongiform encephalopathy. Disease is due to pressure on farming industry [letter; comment] Dealler S. **BMJ** 1996 Jul 20;313(7050):171. Comment on: BMJ 1996 May 25;312(7042):1313-4.

Seasonal atrazine contamination of drinking water in pig-breeding farm surroundings in agricultural and industrial areas of Croatia. Gojmerac T, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):225-30

Farm-related injuries taken seriously [letter] Goertzen J. **Can Fam Physician** 1995 Oct;41:1670

Causes of horse-related injuries in a rural western community. Thompson JM, et al. **Can Fam Physician** 1996 Jun;42:1103-9

Fatal farm injuries in Ontario, 1984 through 1992. Brison RJ, et al. **Can J Public Health** 1995 Jul-Aug;86(4):246-8

Tractor-related injuries in Ontario. Pickett W, et al. **Can J Public Health** 1995 Jul-Aug;86(4):243-6

Contact dermatitis due to a new fungicide used in the tulip bulb industry. Bruynzeel DP, et al. **Contact Dermatitis** 1995 Jul;33(1):8-11

Allergic contact dermatitis from Hedera helix L. García M, et al. **Contact Dermatitis** 1995 Aug;33(2):133-4

Butenylbithiophene, alpha-terthienyl and hydroxytremetone as contact allergens in cultivars of marigold (Tagetes sp.). Hausen BM, et al. **Contact Dermatitis** 1995 Jul;33(1):33-7

Flood control projects in Bangladesh: reasons for failure and recommendations for improvement. Hoque MM, et al. **Disasters** 1995 Sep;19(3):260-3

Agrochemicals exposure and health implications in Githunguri location, Kenya. Kimani VN, et al. **East Afr Med J** 1995 Aug;72(8):531-5

Organic farming goes big time [news] **Environ Health Perspect** 1994 May;102(5):429

The Agricultural Health Study. Alavanja MC, et al. **Environ Health Perspect** 1996 Apr;104(4):362-9

Predicting the discomfort caused by tractor vibration. Fairley TE. **Ergonomics** 1995 Oct;38(10):2091-106

Mortality due to poisoning in a developing agricultural country: trends over 20 years. Senanayake N, et al. **Hum Exp Toxicol** 1995 Oct;14(10):808-11

Mosquito breeding in relation to aquatic vegetation and some physico-chemical parameters in rice fields of central Gujarat. Kant R, et al. **Indian J Malariol** 1996 Mar; 33(1):30-40

Cancer in offspring of parents engaged in agricultural activities in Norway: incidence and risk factors in the farm environment. Kristensen P, et al. **Int J Cancer** 1996 Jan 3;65(1):39-50

Contact pemphigus. Vozza A, et al. **Int J Dermatol** 1996 Mar;35(3):199-201

Endectocidal drugs: ecological risks and counter-measures. Herd R. **Int J Parasitol** 1995 Aug;25(8):875-85 (82 ref.)

Case control study of agricultural injuries to older farmers in central Wisconsin [letter] Stueland DT, et al. **J Am Geriatr Soc** 1996 Apr;44(4):475-6

Urges reconsideration of AVMA's withdrawal from CAST [letter] Fogleman RW. **J Am Vet Med Assoc** 1996 Jun 15; 208(12):1960-1

What do food animal practitioners want to read? Herrick JB. **J Am Vet Med Assoc** 1996 Jan 15;208(2):196-7

Lessons on leadership for food animal practitioners. Humble JA. **J Am Vet Med Assoc** 1995 Nov 15;207(10):1279-80

Determination of DDT and related compounds in blood samples from agricultural workers. Guardino X, et al. **J Chromatogr A** 1996 Jan 5;719(1):141-7

Adaptation of the resettled Kenyah Dayak villagers to riverine environment in east Kalimantan: a preliminary report. Abe T, et al. **J Hum Ergol (Tokyo)** 1995 Jun; 24(1):33-6

Introducing ergonomics through "subak" organization among the farmers in Bali. Adiputra N, et al. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):101-5

The need for ergonomics considerations for the design and development of agricultural machinery in Thailand. Mamansari DU, et al. **J Hum Ergol (Tokyo)** 1995 Jun; 24(1):61-72 (11 ref.)

Ergonomics productivity enhancement at government-owned sugar cane factories in east Java, Indonesia. Manuaba A. **J Hum Ergol (Tokyo)** 1995 Jun; 24(1):115-8

A government agency's responsibility to the consumer. Young AL, et al. **J Nutr** 1996 Apr;126(4 Suppl):1010S-2S

From the Centers for Disease Control and Prevention. Agricultural auger-related injuries and fatalities--Minnesota, 1992-1994. **JAMA** 1995 Dec 13; 274(22):1754-5

The Netherlands. The Wageningen approach to human nutrition. Hautvast JG. **Lancet** 1996 May 4; 347(9010):1235-6

Vero cytotoxin-producing E coli O157 infection associated with farms [letter; comment] Trevena WB, et al. **Lancet** 1996 Jan 6;347(8993):60-1. Comment on: Lancet 1995 Aug 26;346(8974):572.

Down on the farm: health and safety in Australian agriculture [editorial] Fragar LJ. **Med J Aust** 1996 Jul 15;165(2):69-70

Fatalities associated with improper hitching to farm tractors--New York, 1991-1995. **MMWR Morb Mortal Wkly Rep** 1996 Apr 19; 45(15):307-11

The commercial and agricultural applications of animal transgenesis. Ward KA, et al. **Mol Biotechnol** 1995 Oct; 4(2):167-78 (63 ref.)

Temporary variations in chromosomal aberrations in a group of agricultural workers exposed to pesticides. Carbonell E, et al. **Mutat Res** 1995 Oct;344(3-4):127-34

Lung (agricultural/rural). do Pico GA. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):212-6

Factors influencing involvement in farm accidents. Harrell WA. **Percept Mot Skills** 1995 Oct;81(2):592-4

A European farmers' view of free trade and risk assessment for veterinary biologicals. Vaarkamp H. **Rev Sci Tech** 1995 Dec;14(4):1217-20

Testicular cancer in pesticide applicators in Swedish agriculture [letter] Dich J, et al. **Scand J Work Environ Health** 1996 Feb;22(1):66

Frequency of sister chromatid exchange and hematological effects in pesticide-exposed greenhouse sprayers. Lander F, et al. **Scand J Work Environ Health** 1995 Aug; 21(4):283-8

The form and bioavailability of non-ionic organic chemicals in sewage sludge-amended agricultural soils. Beck AJ, et al. **Sci Total Environ** 1996 Jun 21;185(1-3):125-49

Hazard to man and the environment posed by the use of urban waste compost: a review. Déportes I, et al. **Sci Total Environ** 1995 Nov 30;172(2-3):197-22 (182 ref.)

Screening the environmental fate of organic contaminants in sewage sludges applied to agricultural soils: II. The potential for transfers to plants and grazing animals. Duarte-Davidson R, et al. **Sci Total Environ** 1996 Jun 21; 185(1-3):59-70

Transfer of radionuclides to vegetable and other crops grown on land reclaimed from the sea. Green N, et al. **Sci Total Environ** 1995 Dec 1;173-174:385-92

Screening the environmental fate of organic contaminants in sewage sludges applied to agricultural soils: I. The potential for downward movement to groundwaters. Wilson SC, et al. **Sci Total Environ** 1996 Jun 21; 185(1-3):45-57

Agriculture finds a niche; drug researchers seek help [news] Kinoshita J. **Science** 1995 Nov 17;270(5239):1147-9

NFU sets out its position on farm animal welfare [news] **Vet Rec** 1995 Jul 8;137(2):30-1

[Malaria and rice growing in the Senegal River delta (Senegal)] Faye O, et al. **Ann Soc Belg Med Trop** 1995 Sep;75(3):179-89 (Eng. Abstr.) **(Fre)**

[Occupational asthma in an agricultural setting] Bessot JC, et al. **Rev Mal Respir** 1996 Jul;13(3):205-15 (103 ref.) (Eng. Abstr.) **(Fre)**

[Impact on the quality of life of respiratory symptoms and airway obstruction in an agricultural population (see comments)] Vergnenègre A, et al. **Rev Mal Respir** 1995; 12(6):615-21 (Eng. Abstr.). Comment in: Rev Mal Respir 1995;12(6):517-9. **(Fre)**

[Anopheles funestus and rice agriculture in the Madagascar highlands] Marrama L, et al. **Sante** 1995 Nov-Dec; 5(6):415-9 (Eng. Abstr.) **(Fre)**

[Microbiological public health aspects in the use of rain water as water reservoirs for toilet flushing, garden irrigation and laundry] Holländer R, et al. **Gesundheitswesen** 1996 May; 58(5):288-93 (Eng. Abstr.) **(Ger)**

[The indices of central and peripheral hemodynamics and of autonomic nervous system function in subjects with arterial hypertension working under different manufacturing conditions] Shelygin SI, et al. **Lik Sprava** 1995 May-Jun;(5-6):80-3 (Eng. Abstr.) **(Rus)**

[The effect of economic activities altering water resources on the parasitological situation] Artamoshin AS, et al. **Med Parazitol (Mosk)** 1995 Apr-Jun;(2):51-7 (50 ref.) (Eng. Abstr.) **(Rus)**

[Grounds of the duration of work shift for female vegetable growers working in the field in the summer] Afanas'eva RF, et al. **Med Tr Prom Ekol** 1995;(8):13-6 (Eng. Abstr.) **(Rus)**

[Assessment of factors determining the dynamics of pollution by Cs-137 of agricultural production after the Chernobyl AES accident] Sanzharova NI, et al. **Radiats Biol Radioecol** 1995 May-Jun;35(3):307-15 (Eng. Abstr.) **(Rus)**

[The health of women engaged in agricultural production in Ukraine (the experience and perspectives of epidemiological research)] Kundiev IuI, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):98-102 **(Rus)**

[Ecology or convention? No big differences between the different means in agriculture] **Lakartidningen** 1996 Feb 21;93(8):699 **(Swe)**

ECONOMICS

Measuring financial performance: an overview of financial statements. Dalsted NL. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):293-311 (2 ref.)

SPA: marketing and financial performance measures for the cow-calf enterprise. Gutierrez PH. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):313-60 (3 ref.)

Farm Financial Standards. McGrann JM. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):279-91 (3 ref.)

Stocker/feeder cattle standardized performance analysis. McGrann JM, et al. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):361-73 (3 ref.)

EDUCATION

Farm-work hazard prevention efforts by school-based agricultural education instructors. Chapman LJ, et al. **Am J Ind Med** 1995 Oct;28(4):565-77

Consumer concerns about modern technology in agriculture: considerations for undergraduate and graduate teaching. Weber GM, et al. **J Anim Sci** 1995 Sep;73(9):2727-32 (16 ref.)

[Evaluation of health status of agricultural machine operators and agriculture students] Galuzova VG, et al. **Med Tr Prom Ekol** 1995;(8):7-10 (Eng. Abstr.) **(Rus)**

HISTORY

[Rice: source of life and death on the plateaux of Madagascar] Laventure S, et al. **Sante** 1996 Mar-Apr;6(2):79-86 (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Auger injuries in the Wimmera region 1987-95. Read KO, et al. **Aust N Z J Surg** 1996 Apr;66(4):229-30

LEGISLATION & JURISPRUDENCE

Farm programs and food animal practitioners. Herrick JB. **J Am Vet Med Assoc** 1996 May 15;208(10):1641-2

Policy considerations for a realistic approach to hunger in Nigeria. Igbedioh SO. **Nutr Health** 1996;10(4):341-58

Minister outlines slaughter plans for older cattle [news] **Vet Rec** 1996 Apr 13;138(15):342

METHODS

Runoff losses of surface-applied metribuzin as influenced by yard waste compost amendments, no-tillage, and conventional-tillage. Malone RW, et al. **Bull Environ Contam Toxicol** 1996 Oct;57(4):536-43

Aflatoxin-producing strains of Aspergillus flavus in the mould flora of the different greenhouse substrates for the cultivation of cucumber (Cucumis sativus, L.). Ruiz JA, et al. **Int J Food Microbiol** 1996 Apr;29(2-3):193-9

Transgenic oilseed rape. How to assess the risk of outcrossing to wild relatives. Baranger A, et al. **Methods Mol Biol** 1995; 44:393-403

Transformation of soybean (Glycine max) via Agrobacterium tumefaciens and analysis of transformed plants. Chee PP, et al. **Methods Mol Biol** 1995;44:101-19

Leaf disk transformation. Curtis IS, et al. **Methods Mol Biol** 1995;44:59-70

Agrobacterium-mediated antibiotic resistance for selection of somatic hybrids. The genus Lycopersicon as a model system. Davey MR, et al. **Methods Mol Biol** 1995;44:167-83

Regulation of Agrobacterium gene manipulation. Dewhurst F. **Methods Mol Biol** 1995;44:369-91 (33 ref.)

Transformation protocols for broadleaved trees. Fenning TM, et al. **Methods Mol Biol** 1995;44:149-65

Agrobacterium-mediated transformation of soft fruit Rubus, Ribes, and Fragaria. Graham J, et al. **Methods Mol Biol** 1995;44:129-33

Agroinfection. Grimsley N. **Methods Mol Biol** 1995; 44:325-42

Agrobacterium-mediated transformation of potato genotypes. Kumar A. **Methods Mol Biol** 1995;44:121-8

Peanut transformation. Mansur E, et al. **Methods Mol Biol** 1995;44:87-100

Agrobacterium-mediated transformation of stem disks from oilseed rape (Brassica napus L.). Thomzik JE. **Methods Mol Biol** 1995;44:79-85

Agrobacterium-mediated transformation of protoplasts from oilseed rape (Brassica napus L.). Thomzik JE. **Methods Mol Biol** 1995;44:71-8

[Comparative investigations of mycotoxological status of alternatively and conventionally grown crops] Marx H, et al. **Z Lebensm Unters Forsch** 1995 Jul;201(1):83-6 (Eng. Abstr.) **(Ger)**

STANDARDS

Environmental considerations of disinfectants used in agriculture. Bruins G, et al. **Rev Sci Tech** 1995 Mar; 14(1):81-94 (15 ref.)

Stocker/feeder cattle standardized performance analysis. McGrann JM, et al. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):361-73 (3 ref.)

STATISTICS & NUMERICAL DATA

Machine-related occupational injuries in farm residents. Layde PM, et al. **Ann Epidemiol** 1995 Nov;5(6):419-26

Linking stress and injury in the farming environment: a secondary analysis of qualitative data. Kidd P, et al. **Health Educ Q** 1996 May;23(2):224-37

Incidence and risk factors of cancer among men and women in Norwegian agriculture. Kristensen P, et al. **Scand J Work Environ Health** 1996 Feb;22(1):14-26

[Accidents at work among women: an example from the INAIL data. Istituto Nazionale per l'Assicurazione contro gli Infortuni sul Lavoro] Nesti M, et al. **Epidemiol Prev**

1996 Apr-Sep;20(2-3):208-10 **(Ita)**

AGRIN

BIOSYNTHESIS

Expression of agrin mRNA is altered following seizures in adult rat brain. O'Connor LT, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):277-87

GENETICS

Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Gautam M, et al. **Cell** 1996 May 17; 85(4):525-35

Agrin acts via a MuSK receptor complex. Glass DJ, et al. **Cell** 1996 May 17;85(4):513-23

Alternative RNA splicing that determines agrin activity regulates binding to heparin and alpha-dystroglycan. Campanelli JT, et al. **Development** 1996 May; 122(5):1663-72

Tissue- and age-specific expression patterns of alternatively spliced agrin mRNA transcripts in embryonic rat suggest novel developmental roles. Stone DM, et al. **J Neurosci** 1995 Oct;15(10):6767-78

Alternative splicing of agrin alters its binding to heparin, dystroglycan, and the putative agrin receptor. Gesemann M, et al. **Neuron** 1996 Apr;16(4):755-67

METABOLISM

Alternative RNA splicing that determines agrin activity regulates binding to heparin and alpha-dystroglycan. Campanelli JT, et al. **Development** 1996 May; 122(5):1663-72

AChR phosphorylation and aggregation induced by an agrin fragment that lacks the binding domain for alpha-dystroglycan. Meier T, et al. **EMBO J** 1996 Jun 3; 15(11):2625-31

Cerebellar granule cells express a specific isoform of agrin that lacks the acetylcholine receptor aggregating activity. So KL, et al. **FEBS Lett** 1996 Jan 22;379(1):63-8

Agrin binding to alpha-dystroglycan. Domains of agrin necessary to induce acetylcholine receptor clustering are overlapping but not identical to the alpha-dystroglycan-binding region. Hopf C, et al. **J Biol Chem** 1996 Mar 1;271(9):5231-6

Alternative splicing of agrin alters its binding to heparin, dystroglycan, and the putative agrin receptor. Gesemann M, et al. **Neuron** 1996 Apr;16(4):755-67

Substrate-bound agrin induces expression of acetylcholine receptor epsilon-subunit gene in cultured mammalian muscle cells. Jones G, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5985-90

Alternative splicing of agrin regulates its binding to heparin alpha-dystroglycan, and the cell surface. O'Toole JJ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7369-74

Synapse-making molecules revealed [news] Wickelgren I. **Science** 1996 May 24;272(5265):1100

PHARMACOLOGY

Acetylcholine receptors and the cytoskeletal connection. Phillips WD. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):961-5 (40 ref.)

Immobilization of nicotinic acetylcholine receptors in mouse C2 myotubes by agrin-induced protein tyrosine phosphorylation. Meier T, et al. **J Cell Biol** 1995 Oct; 131(2):441-51

Neural agrin activates a high-affinity receptor in C2 muscle cells that is unresponsive to muscle agrin. Bowen DC, et al. **J Neurosci** 1996 Jun 15;16(12):3791-7

PHYSIOLOGY

Testing the agrin hypothesis. Kleiman RJ, et al. **Cell** 1996 May 17;85(4):461-4 (16 ref.)

Agrin-induced acetylcholine receptor clustering in mammalian muscle requires tyrosine phosphorylation. Ferns M, et al. **J Cell Biol** 1996 Mar;132(5):937-44

Agrin signals at the junction [news] Slater CR. **Nature** 1996 Jun 6;381(6582):478-9

Agrin is a differentiation-inducing "stop signal" for motoneurons in vitro. Campagna JA, et al. **Neuron** 1995 Dec;15(6):1365-74

Agrin: toward a molecular understanding of synapse regeneration. Deyst KA, et al. **Neurosurgery** 1995 Jul; 37(1):71-7 (81 ref.)

ULTRASTRUCTURE

An amino-terminal extension is required for the secretion of chick agrin and its binding to extracellular matrix. Denzer AJ, et al. **J Cell Biol** 1995 Dec;131(6 Pt 1):1547-60

AGROBACTERIUM

Transport of DNA into the nuclei of xenopus oocytes by a modified VirE2 protein of Agrobacterium. Guralnick B, et al. **Plant Cell** 1996 Mar;8(3):363-73

CHEMISTRY

NMR studies of succinoglycan repeating-unit octasaccharides from Rhizobium meliloti and Agrobacterium radiobacter. Chouly C, et al. **Int J Biol Macromol** 1995 Dec;17(6):357-63

Quantifying polyamines in Agrobacterium rhizogenes strains and in Ri plasmid transformed cells. Bagni N, et al. **Methods Mol Biol** 1995;44:223-36

CLASSIFICATION

Simple cultural tests for identification of Agrobacterium biovars. Bouzar H, et al. **Methods Mol Biol** 1995;44:9-13

ENZYMOLOGY

Substrate-induced inactivation of a crippled beta-glucosidase mutant: identification of the labeled amino acid and mutagenic analysis of its role. Gebler JC, et al. **Biochemistry** 1995 Nov 7;34(44):14547-53

Mechanism of Agrobacterium beta-glucosidase: kinetic analysis of the role of noncovalent enzyme/substrate interactions. Namchuk MN, et al. **Biochemistry** 1995 Dec 12;34(49):16194-202

Identification of the acid/base catalyst in Agrobacterium faecalis beta-glucosidase by kinetic analysis of mutants. Wang Q, et al. **Biochemistry** 1995 Nov 7;34(44):14554-62

Purification and properties of L(-)-carnitine dehydrogenase from Agrobacterium sp. Hanschmann H, et al. **Biochim Biophys Acta** 1996 Jun 4;1290(2):177-83

Topological mapping of the cysteine residues of N-carbamyl-D-amino-acid amidohydrolase and their role in enzymatic activity. Grifantini R, et al. **J Biol Chem** 1996 Apr 19;271(16):9326-31

The expressed protein in glyphosate-tolerant soybean, 5-enolpyruvylshikimate-3-phosphate synthase from Agrobacterium sp. strain CP4, is rapidly digested in vitro and is not toxic to acutely gavaged mice. Harrison LA, et al. **J Nutr** 1996 Mar;126(3):728-40

GENETICS

Universal PCR primers for detection of phytopathogenic Agrobacterium strains. Haas JH, et al. **Appl Environ Microbiol** 1995 Aug;61(8):2879-84

PCR detection of Ti and Ri plasmids from phytopathogenic Agrobacterium strains. Sawada H, et al. **Appl Environ Microbiol** 1995 Feb;61(2):828-31

Major differences between the rrnA operons of two strains of Agrobacterium vitis. Otten L, et al. **Arch Microbiol** 1996 Jul;166(1):68-70

Sequence and mutational analysis of a tartrate utilization operon from Agrobacterium vitis. Crouzet P, et al. **J Bacteriol** 1995 Nov;177(22):6518-26

Structure and functional analysis of a marine bacterial carotenoid biosynthesis gene cluster and astaxanthin biosynthetic pathway proposed at the gene level. Misawa N, et al. **J Bacteriol** 1995 Nov;177(22):6575-84

Agrobacterium-mediated transfer of geminiviruses to plant tissues. Boulton MI. **Methods Mol Biol** 1995;49:77-93 (47 ref.)

Electrotransformation of Agrobacterium. Lin JJ. **Methods Mol Biol** 1995;47:171-8

The plant oncogenes rolA, B, and C from Agrobacterium rhizogenes. Effects on morphology, development, and hormone metabolism. Michael T, et al. **Methods Mol Biol** 1995;44:207-22

Agrobacterium rhizogenes as a vector for transforming higher plants. Application in Lotus corniculatus transformation. Stougaard J. **Methods Mol Biol** 1995; 49:49-61 (18 ref.)

Agrobacterium-mediated transformation of Arabidopsis thaliana. Application in T-DNA tagging. Topping JF, et al. **Methods Mol Biol** 1995;49:63-76 (26 ref.)

Ti plasmid-encoded octopine and nopaline catabolism in Agrobacterium: specificities of the LysR-type regulators OccR and NocR, and protein-induced DNA bending. Kreusch D, et al. **Mol Gen Genet** 1995 Nov 1;249(1):102-10

Horizontal gene transfer: regulated expression of a tobacco homologue of the Agrobacterium rhizogenes rolC gene. Meyer AD, et al. **Mol Gen Genet** 1995 Nov 27; 249(3):265-73

Sequence and characterisation of a ribosomal RNA operon from Agrobacterium vitis. Otten L, et al. **Mol Gen Genet** 1996 Apr 24;251(1):99-107

Pleiotropic effects of regulatory ros mutants of Agrobacterium radiobacter and their interaction with Fe and glucose. Brightwell G, et al. **Mol Plant Microbe Interact** 1995 Sep-Oct;8(5):747-54

Characterization and distribution of tartrate utilization genes in the grapevine pathogen Agrobacterium vitis. Salomone JY, et al. **Mol Plant Microbe Interact** 1996 Jul;9(5):401-8

A plant oncogene as a phosphatase [letter] Filippini F, et al. **Nature** 1996 Feb 8;379(6565):499-500

The regulatory functions of the rolB and rolC genes of Agrobacterium rhizogenes are conserved in the homologous genes (Ngrol) of Nicotiana glauca in tobacco genetic tumors. Nagata N, et al. **Plant Cell Physiol** 1995 Sep;36(6):1003-12

Tissue-specific expression of the rolA gene mediates morphological changes in transgenic tobacco. Guivarc'h A, et al. **Plant Mol Biol** 1996 Jan;30(1):125-34

METABOLISM

Agrocins. Clare BG. **Biotechnology** 1995;28:619-32 (53 ref.)

Agrobacterium radiobacter and related organisms take up fructose via a binding-protein-dependent active-transport system. Williams SG, et al. **Microbiology** 1995 Oct;141 (Pt 10):2601-10

Ti plasmid-encoded octopine and nopaline catabolism in Agrobacterium: specificities of the LysR-type regulators OccR and NocR, and protein-induced DNA bending. Kreusch D, et al. **Mol Gen Genet** 1995 Nov 1;249(1):102-10

Characterization and distribution of tartrate utilization genes in the grapevine pathogen Agrobacterium vitis. Salomone JY, et al. **Mol Plant Microbe Interact** 1996 Jul;9(5):401-8

Early transcription of Agrobacterium T-DNA genes in tobacco and maize. Narasimhulu SB, et al. **Plant Cell** 1996 May;8(5):873-86

PATHOGENICITY

Universal PCR primers for detection of phytopathogenic Agrobacterium strains. Haas JH, et al. **Appl Environ Microbiol** 1995 Aug;61(8):2879-84

Agrobacterium virulence. Gartland JS. **Methods Mol Biol** 1995;44:15-28

Translocation and exudation of tumor metabolites in crown galled plants. Savka MA, et al. **Mol Plant Microbe Interact** 1996 May;9(4):310-3

AGROBACTERIUM TUMEFACIENS

Is Hodgkin's disease a human counterpart of bacterially induced crown-gall tumours? [letter] [see comments] Sauter C. **Lancet** 1995 Nov 25;346(8987):1433. Comment in: Lancet 1996 Mar 30;347(9005):901-2.

CHEMISTRY

The Agrobacterium tumefaciens virB7 gene product, a proposed component of the T-complex transport apparatus, is a membrane-associated lipoprotein exposed at the periplasmic surface. Fernandez D, et al. **J Bacteriol** 1996 Jun;178(11):3156-67

The Agrobacterium tumefaciens VirB7 lipoprotein is required for stabilization of VirB proteins during assembly of the T-complex transport apparatus. Fernandez D, et al. **J Bacteriol** 1996 Jun;178(11):3168-76

DRUG EFFECTS

Sensitivity of ribosomes from Agrobacterium tumefaciens to the ribosome-inactivating protein crotin 2 depending on the translocational state. Alegre C, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Mar;42(2):151-8

Effect of acetosyringone on growth and oncogenic potential of Agrobacterium tumefaciens. Dion P, et al. **Methods Mol Biol** 1995;44:37-45

[Comparative susceptibility of Ochrobactrum anthropi, Agrobacterium tumefaciens, Alcaligenes faecalis, Alcaligenes denitrificans subsp. denitrificans, Alcaligenes denitrificans subsp. xylosidans and Bordetella bronchiseptica against 35 antibiotics including 17 beta-lactams] Bizet C, et al. **Pathol Biol (Paris)** 1995 Apr; 43(4):258-63 (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Properties of D-hydantoinase from Agrobacterium tumefaciens and its use for the preparation of N-carbamyl D-amino acids. Durham DR, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):1095-100

Purification and characterization of catabolic mannopine cyclase encoded by the Agrobacterium tumefaciens Ti plasmid pTi15955. Hong SB, et al. **J Bacteriol** 1996 Apr; 178(8):2427-30

Mutational analysis of a conserved motif of Agrobacterium tumefaciens VirD2. Vogel AM, et al. **Nucleic Acids Res** 1995 Oct 25;23(20):4087-91

GENETICS

Highly insect-resistant transgenic tobacco plants containing both B.t. and CpTI genes. Zhao R, et al. **Chin J Biotechnol** 1995;11(1):1-7

The conjugal transfer system of Agrobacterium tumefaciens octopine-type Ti plasmids is closely related to the transfer system of an IncP plasmid and distantly related to Ti plasmid vir genes. Alt-Mörbe J, et al. **J Bacteriol** 1996 Jul;178(14):4248-57

Pleiotropic phenotypes caused by genetic ablation of the receiver module of the Agrobacterium tumefaciens VirA protein. Chang CH, et al. **J Bacteriol** 1996 Aug; 178(15):4710-6

Resection and mutagenesis of the acid pH-inducible P2 promoter of the Agrobacterium tumefaciens virG gene. Chang CH, et al. **J Bacteriol** 1996 Aug;178(15):4717-20

Identification of Agrobacterium tumefaciens genes that direct the complete catabolism of octopine. Cho K, et al. **J Bacteriol** 1996 Apr;178(7):1872-80

Mutational analysis of the input domain of the VirA protein of Agrobacterium tumefaciens. Doty SL, et al. **J Bacteriol** 1996 Feb;178(4):961-70

The tra region of the nopaline-type Ti plasmid is a chimera with elements related to the transfer systems of RSF1010, RP4, and F. Farrand SK, et al. **J Bacteriol** 1996 Jul; 178(14):4233-47

Temperature affects the T-DNA transfer machinery of Agrobacterium tumefaciens. Fullner KJ, et al. **J Bacteriol** 1996 Mar;178(6):1498-504

Conserved cis-acting promoter elements are required for density-dependent transcription of Agrobacterium tumefaciens conjugal transfer genes. Fuqua C, et al. **J Bacteriol** 1996 Jan;178(2):435-40

Ti plasmid-encoded genes responsible for catabolism of the crown gall opine mannopine by Agrobacterium tumefaciens are homologs of the T-region genes responsible for synthesis of this opine by the plant tumor. Kim KS, et al. **J Bacteriol** 1996 Jun;178(11):3275-84

A Ti plasmid-encoded enzyme required for degradation of mannopine is functionally homologous to the T-region-encoded enzyme required for synthesis of this opine in crown gall tumors. Kim KS, et al. **J Bacteriol** 1996 Jun;178(11):3285-92

Conservation of PcaQ, a transcriptional activator of pca genes for catabolism of phenolic compounds, in Agrobacterium tumefaciens and Rhizobium species. Parke D. **J Bacteriol** 1996 Jun;178(12):3671-5

Characterization of PcaQ, a LysR-type transcriptional activator required for catabolism of phenolic compounds, from Agrobacterium tumefaciens. Parke D. **J Bacteriol** 1996 Jan;178(1):266-72

Heat shock activation of the groESL operon of Agrobacterium tumefaciens and the regulatory roles of the inverted repeat. Segal G, et al. **J Bacteriol** 1996 Jun; 178(12):3634-40

The dnaKJ operon of Agrobacterium tumefaciens: transcriptional analysis and evidence for a new heat shock promoter. Segal G, et al. **J Bacteriol** 1995 Oct; 177(20):5952-8

Overexpression of chloroplastic Cu/Zn superoxide dismutase in plants. Allen RD. **Methods Mol Biol** 1995;44:309-23

Binary Ti plasmid vectors. An G. **Methods Mol Biol** 1995; 44:47-58

High-frequency and efficient Agrobacterium-mediated transformation of Arabidopsis thaliana ecotypes "C24" and "Landsberg erecta" using Agrobacterium tumefaciens. Barghchi M. **Methods Mol Biol** 1995;44:135-47

Transformation of soybean (Glycine max) via Agrobacterium tumefaciens and analysis of transformed plants. Chee PP, et al. **Methods Mol Biol** 1995;44:101-19

Leaf disk transformation. Curtis IS, et al. **Methods Mol Biol** 1995;44:59-70

Agrobacterium-mediated antibiotic resistance for selection of somatic hybrids. The genus Lycopersicon as a model system. Davey MR, et al. **Methods Mol Biol** 1995;44:167-83

Electroporation of Agrobacterium tumefaciens. den Dulk-Ras A, et al. **Methods Mol Biol** 1995;55:63-72

Regulation of Agrobacterium gene manipulation. Dewhurst F. **Methods Mol Biol** 1995;44:369-91 (33 ref.)

Transformation protocols for broadleaved trees. Fenning TM, et al. **Methods Mol Biol** 1995;44:149-65

Gene activation by T-DNA tagging. Fritze K, et al. **Methods Mol Biol** 1995;44:281-94

Leaf disk transformation using Agrobacterium tumefaciens-expression of heterologous genes in tobacco. Gallois P, et al. **Methods Mol Biol** 1995;49:39-48 (32 ref.)

Fluorometric GUS analysis for transformed plant material. Gartland KM, et al. **Methods Mol Biol** 1995;44:195-9

Agrobacterium-mediated transformation of soft fruit Rubus, Ribes, and Fragaria. Graham J, et al. **Methods Mol Biol** 1995;44:129-33

Agroinfection. Grimsley N. **Methods Mol Biol** 1995; 44:325-42

Manipulating photosynthesis in transgenic plants. Knight JS, et al. **Methods Mol Biol** 1995;44:263-80

Agrobacterium-mediated transformation of potato genotypes. Kumar A. **Methods Mol Biol** 1995;44:121-8

Use of cosmid libraries in plant transformations. Ma H. **Methods Mol Biol** 1995;44:351-67

Electroporation protocols for Agrobacterium. Main GD, et al. **Methods Mol Biol** 1995;44:405-12

Peanut transformation. Mansur E, et al. **Methods Mol Biol** 1995;44:87-100

The detection of neomycin phosphotransferase activity in plant extracts. Scheid OM, et al. **Methods Mol Biol** 1995; 44:201-6

Introduction of cloning plasmids into Agrobacterium tumefaciens. Shaw CH. **Methods Mol Biol** 1995;49:33-7 (14 ref.)

T-DNA transfer to maize plants. Shen WH, et al. **Methods Mol Biol** 1995;44:343-50

Agrobacterium-mediated transformation of stem disks from oilseed rape (Brassica napus L.). Thomzik JE. **Methods Mol Biol** 1995;44:79-85

Agrobacterium-mediated transformation of protoplasts from oilseed rape (Brassica napus L.). Thomzik JE. **Methods Mol Biol** 1995;44:71-8

Histochemical GUS analysis. Vitha S, et al. **Methods Mol Biol** 1995;44:185-93

Assessing cadmium partitioning in transgenic plants. Wagner GJ. **Methods Mol Biol** 1995;44:295-308

Study of the organization of the genomes of Escherichia coli, Brucella melitensis and Agrobacterium tumefaciens by insertion of a unique restriction site. Jumas-Bilak E, et al. **Microbiology** 1995 Oct;141 (Pt 10):2425-32

T-DNA genes responsible for inducing a necrotic response on grape vines. Deng W, et al. **Mol Plant Microbe Interact** 1995 Jul-Aug;8(4):538-48

Regulation of Agrobacterium tumefaciens virulence gene expression: isolation of a mutation that restores virGD52E function. Gubba S, et al. **Mol Plant Microbe Interact** 1995 Sep-Oct;8(5):788-91

Trans-kingdom conjugation between Agrobacterium tumefaciens and Saccharomyces cerevisiae, a bacterium and a yeast. Sawasaki Y, et al. **Plant Cell Physiol** 1996 Jan; 37(1):103-6

Vectors carrying two separate T-DNAs for co-transformation of higher plants mediated by Agrobacterium tumefaciens and segregation of transformants free from selection markers. Komari T, et al. **Plant J** 1996 Jul;10(1):165-74

5'-regulatory region of Agrobacterium tumefaciens T-DNA gene 6b directs organ-specific, wound-inducible and auxin-inducible expression in transgenic tobacco. Bagyan IL, et al. **Plant Mol Biol** 1995 Dec;29(6):1299-304

Sequence-specific interactions of wound-inducible nuclear factors with mannopine synthase 2' promoter wound-responsive elements. Ni M, et al. **Plant Mol Biol** 1996 Jan;30(1):77-96

Transfer of non-T-DNA portions of the Agrobacterium tumefaciens Ti plasmid pTiA6 from the left terminus of TL-DNA. Ramanathan V, et al. **Plant Mol Biol** 1995 Sep; 28(6):1149-54

Deviating T-DNA transfer from Agrobacterium tumefaciens to plants. van der Graaff E, et al. **Plant Mol Biol** 1996 Jun;31(3):677-81

Rice scutellum induces Agrobacterium tumefaciens vir genes and T-strand generation. Vijayachandra K, et al. **Plant Mol Biol** 1995 Oct;29(1):125-33

Agrobacterium tumefaciens-mediated transformation of yeast. Piers KL, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1613-8

Integration of complete transferred DNA units is dependent on the activity of virulence E2 protein of Agrobacterium tumefaciens. Rossi L, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):126-30

Pilus assembly by Agrobacterium T-DNA transfer genes. Fullner KJ, et al. **Science** 1996 Aug 23;273(5278):1107-9

Enzymatic synthesis of a quorum-sensing autoinducer through use of defined substrates [see comments] Moré MI, et al. **Science** 1996 Jun 14;272(5268):1655-8. Comment in: Science 1996 Jun 14;272(5268):1598-9.

GROWTH & DEVELOPMENT

Growth and storage of Agrobacterium. van Asma FM. **Methods Mol Biol** 1995;44:1-7

METABOLISM

Osa protein encoded by plasmid pSa is located at the inner membrane but does not inhibit membrane association of VirB and VirD virulence proteins in Agrobacterium tumefaciens. Chen CY, et al. **FEMS Microbiol Lett** 1996 Jan 1;135(1):85-92

Ti plasmid-encoded genes responsible for catabolism of the crown gall opine mannopine by Agrobacterium tumefaciens are homologs of the T-region genes responsible for synthesis of this opine by the plant tumor. Kim KS, et al. **J Bacteriol** 1996 Jun;178(11):3275-84

VirE1 protein mediates export of the single-stranded DNA-binding protein VirE2 from Agrobacterium tumefaciens into plant cells. Sundberg C, et al. **J Bacteriol** 1996 Feb;178(4):1207-12

Utilization of cellobiose and other beta-D-glucosides in Agrobacterium tumefaciens. Marasco R, et al. **Res Microbiol** 1995 Jul-Aug;146(6):485-92

PATHOGENICITY

An Agrobacterium virulence factor encoded by a Ti plasmid gene or a chromosomal gene is required for T-DNA transfer into plants. Pan SQ, et al. **Mol Microbiol** 1995 Jul; 17(2):259-69

T-DNA genes responsible for inducing a necrotic response on grape vines. Deng W, et al. **Mol Plant Microbe Interact** 1995 Jul-Aug;8(4):538-48

PHYSIOLOGY

Agrobacterium tumefaciens chemotaxis protocols. Shaw CH. **Methods Mol Biol** 1995;44:29-36

Genetic evidence for direct sensing of phenolic compounds by the VirA protein of Agrobacterium tumefaciens. Lee YW, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19; 92(26):12245-9

ULTRASTRUCTURE

Pilus assembly by Agrobacterium T-DNA transfer genes. Fullner KJ, et al. **Science** 1996 Aug 23;273(5278):1107-9

AGROCHEMICALS

see related **PESTICIDES**

ADVERSE EFFECTS

Cancer risk and residential proximity to cranberry cultivation in Massachusetts. Aschengrau A, et al. **Am J Public Health** 1996 Sep;86(9):1289-96

Agricultural exposures and cancer. Blair A, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:205-8 (39 ref.)

Semen quality among members of organic food associations in Zealand, Denmark [letter] Jensen TK, et al. **Lancet** 1996 Jun 29;347(9018):1844

Suspected hypersensitivity pneumonitis after exposure to a biologic forage inoculant. Mannino D, et al. **South Med J** 1996 Sep;89(9):898-901

[Occupational asthma in an agricultural setting] Bessot JC, et al. **Rev Mal Respir** 1996 Jul;13(3):205-15 (103 ref.) (Eng. Abstr.) **(Fre)**

[Human poisoning caused by chemicals for plant protection in 1994] Przybylska A. **Przegl Epidemiol** 1996;50(1-2):151-8 **(Pol)**

ANALYSIS

Use of computer models to assess exposure to agricultural chemicals via drinking water. Gustafson DI. **Sci Total Environ** 1995 Oct 27;171(1-3):35-42

STANDARDS

Uniform System for the Evaluation of Substances. V. ESPE, risk assessment for pesticides. Linders JB, et al. **Chemosphere** 1995 Sep;31(5):3237-48

Japanese authority GLP inspections for pharmaceuticals and agrochemicals. Preparing for and handling agency inspections. Iwaoka T. **Qual Assur** 1995 Jun;4(2):139-42

TOXICITY

Effects of agrochemicals on the immune systems of earthworms. Bunn KE, et al. **Bull Environ Contam Toxicol** 1996 Oct;57(4):632-9

The role of toxicology in the evaluation of new agrochemicals. Kuiper HA. **J Environ Sci Health B** 1996 May;31(3):353-63

AH RECEPTORS see **RECEPTORS, ARYL HYDROCARBON**

AH-5158 see **LABETALOL**

AHG-CDC TESTS see **CYTOTOXICITY TESTS, IMMUNOLOGIC**

AHR-1911 see **ISOTHIURONIUM**

AID TO FAMILIES WITH DEPENDENT CHILDREN

Help available for parents of disabled children. Smith C, et al. **Br J Hosp Med** 1995 Aug 16-Sep 5;54(4):154

Single mothers and welfare. Bassuk EL, et al. **Sci Am** 1996 Oct;275(4):60-3, 66-7

Social insurance provisions for children with disabilities in selected industrialized countries. Zeitzer IR. **Soc Secur Bull** 1995 Fall;58(3):32-48

ECONOMICS

The 'family cap': a popular but unproven method of welfare reform. Donovan P. **Fam Plann Perspect** 1995 Jul-Aug; 27(4):166-71 (41 ref.)

Potential cost savings for Medi-Cal, AFDC, food stamps, and WIC programs associated with increasing breast-feeding among low-income Hmong women in California. Tuttle CR, et al. **J Am Diet Assoc** 1996 Sep; 96(9):885-90

The influence of OASDI and SSI payments on the poverty status of families with children. Kearney JR, et al. **Soc Secur Bull** 1995 Fall;58(3):3-14

LEGISLATION & JURISPRUDENCE

Legislating away reality [editorial] Bassuk EL. **Am J Orthopsychiatry** 1995 Oct;65(4):460-1

The 'family cap': a popular but unproven method of welfare reform. Donovan P. **Fam Plann Perspect** 1995 Jul-Aug; 27(4):166-71 (41 ref.)

Fashioning a work-based strategy for welfare reform based on international human rights doctrine. Harvey P. **J Public Health Policy** 1995;16(3):269-85 (22 ref.)

Supplemental security income to children and adolescents [letter; comment] Copeland D. **Pediatrics** 1996 Mar; 97(3):440-1. Comment on: Pediatrics 1995 Apr;95(4):603-8.

STATISTICS & NUMERICAL DATA

Aid to families with dependent children: who receives more than $22 billion and why? Waldman HB. **ASDC J Dent Child** 1996 Mar-Apr;63(2):143-8

AID TO THE BLIND see **SOCIAL SECURITY**

AID TO THE TOTALLY DISABLED see **SOCIAL SECURITY**

AIDS see **ACQUIRED IMMUNODEFICIENCY SYNDROME**

AIDS ANTIBODIES see **HIV ANTIBODIES**

AIDS ANTIGENS see **HIV ANTIGENS**

AIDS-ASSOCIATED ENTEROPATHY see **HIV ENTEROPATHY**

AIDS-ASSOCIATED LYMPHOMA see LYMPHOMA, AIDS-RELATED

AIDS-ASSOCIATED NEPHROPATHY

Childhood AIDS nephropathy: a 10-year experience. Rajpoot D, et al. **J Natl Med Assoc** 1996 Aug;88(8):493-8

Human immunodeficiency virus-associated glomerulosclerosis. Humphreys MH. **Kidney Int** 1995 Aug; 48(2):311-20 (96 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.10 HIV and renal disease. Frankum BS, et al. **Med J Aust** 1996 Apr 15;164(8):483

DIAGNOSIS

HIV nephropathy in children. Zilleruelo G, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1469-85 (52 ref.)

DRUG THERAPY

Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Kimmel PL, et al. **Am J Kidney Dis** 1996 Aug;28(2):202-8

MORTALITY

Predictors of survival in HIV-infected patients on hemodialysis. Perinbasekar S, et al. **Am J Nephrol** 1996; 16(4):280-6

End-stage renal disease in patients infected with human immunodeficiency virus: a retrospective review of 38 cases. Obayomi OO, et al. **J Natl Med Assoc** 1995 Oct; 87(10):762-5

PATHOLOGY

Unexpected nephropathy. Gamouras G, et al. **Hosp Pract (Off Ed)** 1996 May 15;31(5):43-4

HIV-associated renal disease in London hospitals. Connolly JO, et al. **QJM** 1995 Sep;88(9):627-34

PHYSIOPATHOLOGY

HIV nephropathy in children. Zilleruelo G, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1469-85 (52 ref.)

ULTRASONOGRAPHY

Pelvocalyceal thickening in HIV-associated nephropathy. Wachsberg RH, et al. **Abdom Imaging** 1995 Jul-Aug; 20(4):371-5

[HIV-associated nephropathy] de Menezes MR, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul-Aug; 50(4):189-90 (Eng. Abstr.) **(Por)**

VIROLOGY

HBsAg in the kidneys of patients with HIV-associated nephropathy (HIVAN) [letter] Lopes GS, et al. **Clin Nephrol** 1996 Feb;45(2):133-4

AIDS DEMENTIA COMPLEX

Animal models recapitulate aspects of HIV/CNS disease. Vitković L, et al. **AIDS Res Hum Retroviruses** 1995 Jun; 11(6):753-9

Anaesthetic management of caesarean section in a patient with active recurrent genital herpes and AIDS-related dementia. Birnbach DJ, et al. **Br J Anaesth** 1995 Nov; 75(5):639-41

Feline immunodeficiency virus as a model for study of lentivirus infection of the central nervous system. Henriksen SJ, et al. **Curr Top Microbiol Immunol** 1995; 202:167-86 (88 ref.)

Transgenic models to assess the neuropathogenic potential of HIV-1 proteins and cytokines. Mucke L, et al. **Curr Top Microbiol Immunol** 1995;202:187-205 (98 ref.)

Selected models of HIV-induced neurological disease. Narayan O, et al. **Curr Top Microbiol Immunol** 1995; 202:151-66 (61 ref.)

Quinolinic acid levels in a murine retrovirus-induced immunodeficiency syndrome. Sei Y, et al. **J Neurochem** 1996 Jan;66(1):296-302

Neurological complications of HIV infection. Price RW. **Lancet** 1996 Aug 17;348(9025):445-52 (50 ref.)

[Maniac episode associated with stage C3 HIV infection (letter)] Bertolín JM, et al. **Med Clin (Barc)** 1995 Sep 30; 105(10):399 **(Spa)**

CEREBROSPINAL FLUID

Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in AIDS dementia complex [letter] Candito M, et al. **AIDS** 1995 Sep;9(9):1100-1

Increased cerebrospinal fluid levels of soluble receptors for tumour necrosis factor in HIV-infected patients with neurological diseases [letter] Vullo V, et al. **AIDS** 1995 Sep;9(9):1099-100

High levels of anti-HIV-1 envelope antibodies in cerebrospinal fluid as compared to serum from patients with AIDS dementia complex. Trujillo JR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):19-25

Increased neuropeptide Y-like immunoreactivity in cerebrospinal fluid and plasma of human immunodeficiency virus-infected patients: relationship to HIV encephalopathy. Malessa R, et al. **J Neurol Sci** 1996 Mar; 136(1-2):154-8

[Alpha tumor necrosis factor in central nervous system disease associated with HIV infection] Calvo Manuel E, et al. **An Med Interna** 1995 Jun;12(6):263-6 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Cytotoxic T lymphocytes and HIV-1 related neurologic disorders. Kalams SA, et al. **Curr Top Microbiol Immunol** 1995;202:79-88 (51 ref.)

DIAGNOSIS

Relation between stage of disease and neurobehavioral measures in children with symptomatic HIV disease. Brouwers P, et al. **AIDS** 1995 Jul;9(7):713-20

Early central nervous system response to HIV infection: sleep distortion and cognitive-motor decrements. White JL, et al. **AIDS** 1995 Sep;9(9):1043-50

The overlooked epidemic: HIV in older adults [see comments] Whipple B, et al. **Am J Nurs** 1996 Feb; 96(2):22-8; quiz 29 (9 ref.). Comment in: Am J Nurs 1996 May;96(5):18.

Imaging methods as a diagnostic tool in neuro-AIDS. A review. Arendt G. **Bildgebung** 1995 Dec;62(4):310-9 (51 ref.)

Development of subtle neurological signs after systemic illness in HIV-infected individuals. Lopez OL, et al. **Eur Neurol** 1996;36(2):71-5

Normative data for a brief neuropsychologic test battery in a cohort of injecting drug users. Concha M, et al. **Int J Addict** 1995 May;30(7):823-41

A hemophiliac with human immunodeficiency virus (HIV)-1-associated dementia complex [see comments] Arimura H, et al. **Intern Med** 1995 Oct;34(10):995-9 (12 ref.). Comment in: Intern Med 1995 Oct;34(10):935.

More acquired immunodeficiency syndrome (AIDS) dementia complex in Japan? [editorial; comment] Kanazawa I. **Intern Med** 1995 Oct;34(10):935. Comment on: Intern Med 1995 Oct;34(10):995-9.

Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurologic abnormalities. Conrad AJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):425-35

Dementia as a symptom of HIV disease [letter; comment] Rabins PV. **Lancet** 1996 Mar 16;347(9003):769-70. Comment on: Lancet 1996 Jan 27;347(8996):236.

Spatial data analysis in the quantitative assessment of cerebral white matter pathology on MRI in HIV infection. Corrigall RJ, et al. **Neuroradiology** 1995 Aug;37(6):429-33

Ophthalmologic manifestations of acquired immune deficiency syndrome-associated progressive multifocal leukoencephalopathy. Ormerod LD, et al. **Ophthalmology** 1996 Jun;103(6):899-906

Magnetic resonance spectroscopy in childhood AIDS encephalopathy. Pavlakis SG, et al. **Pediatr Neurol** 1995 May;12(4):277-82

Brain lesions in patients with AIDS: H-1 MR spectroscopy. Chang L, et al. **Radiology** 1995 Nov;197(2):525-31

Proton MR spectroscopy of the basal ganglia in healthy children and children with AIDS. Lu D, et al. **Radiology** 1996 May;199(2):423-8

Neurology of human immunodeficiency virus infection--past, present, and future. Jay C. **West J Med** 1995 Nov;163(5):470-1

[A contribution of brain imaging techniques to the diagnosis of psychiatric emergencies] Assouly-Besse F, et al. **Ann Med Psychol (Paris)** 1996 Jan;154(1):60-3 (Eng. Abstr.) **(Fre)**

[Non-infectious neurological involvement in HIV-1 infection in children (letter)] Tardieu M. **Arch Pediatr** 1996;3 Suppl 1:360s-361s **(Fre)**

[Cognition disorders in HIV infection. Validation of a brief neuropsychological evaluation battery] Desi M, et al. **Encephale** 1995 Jul-Aug;21(4):289-94 (Eng. Abstr.) **(Fre)**

[Clinical and paraclinical diagnosis of AIDS neurologic lesions] Bossi P, et al. **J Neuroradiol** 1995 Sep;22(3):142-7 (62 ref.) (Eng. Abstr.) **(Fre)**

[Imagery of human immunodeficiency virus (HIV) encephalitis] Brugières P, et al. **J Neuroradiol** 1995 Sep; 22(3):163-8 (Eng. Abstr.) **(Fre)**

[Introduction: the status and perspective of human immunodeficiency virus infection and its neurologic consequences] Cordoliani YS. **J Neuroradiol** 1995 Sep; 22(3):133-5 **(Fre)**

[Early cerebral lesions in HIV infection. Postmortem radio-pathologic correlations in non-AIDS asymptomatic seropositive patients] Hassine D, et al. **J Neuroradiol** 1995 Sep;22(3):148-60 (Eng. Abstr.) **(Fre)**

[Neuropsychiatric performance of HIV-infected patients] Thomas W, et al. **Med Klin** 1995 Aug 15;90(8):443-9 (Eng. Abstr.) **(Ger)**

[Dementia-paranoid syndrome as the initial manifestation of AIDS. Case report and diagnostic overview] Sobanski T, et al. **Nervenarzt** 1996 Jan;67(1):68-71 (Eng. Abstr.) **(Ger)**

[Magnetic resonance in AIDS-related encephalopathy] Gualdi GF, et al. **Clin Ter** 1995 Dec;146(12):843-56 (42 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Diffuse infiltrative CD8 lymphocytosis syndrome with predominant neurologic manifestations in two HIV-infected patients responding to zidovudine [letter] Bachmeyer C, et al. **AIDS** 1995 Sep;9(9):1101-2

A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Breitbart W, et al. **Am J Psychiatry** 1996 Feb;153(2):231-7

Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex. Burger DM, et al. **Pharm World Sci** 1995 Nov 24;17(6):218-21

[New strategies in anti-HIV therapy--consequences for the neurologist?] Enzensberger W, et al. **Nervenarzt** 1996 Jun; 67(6):506-8 (2 ref.) **(Ger)**

EPIDEMIOLOGY

Neuropsychiatric HIV-1 infection study: in Kenya and Zaire cross-sectional phase I and II. Sebit MB. **Cent Afr J Med** 1995 Oct;41(10):315-22

Psychiatric disorders and HIV infection: impact on one another. Lyketsos CG, et al. **Epidemiol Rev** 1995; 17(1):152-64 (82 ref.)

Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. Chiesi A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):39-44

Incidence proportion of and risk factors for AIDS patients diagnosed with HIV dementia, central nervous system toxoplasmosis, and cryptococcal meningitis. Wang F, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Jan 1;8(1):75-82

ETIOLOGY

Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. Bell JE, et al. **AIDS** 1996 May; 10(5):493-9

A case of fulminant human immunodeficiency virus dementia. Bassiri A, et al. **Clin Infect Dis** 1995 Nov;21(5):1313-4

Bartonella (Rochalimaea) antibodies, dementia, and cat ownership among men infected with human immunodeficiency virus. Schwartzman WA, et al. **Clin Infect Dis** 1995 Oct;21(4):954-9

HIV and dementia. Proceedings of the NIMH-sponsored conference "Pathogenesis of HIV Infection of the Brain: Impact on Function and Behavior". April 4-7, 1994, Chantilly, Virginia. **Curr Top Microbiol Immunol** 1995; 202:1-273

The pathogenesis of HIV infections of the brain. Johnson RT. **Curr Top Microbiol Immunol** 1995;202:3-10 (38 ref.)

AIDS dementia complex and HIV-1 brain infection: a pathogenetic framework for treatment and evaluation. Price RW. **Curr Top Microbiol Immunol** 1995;202:33-54 (68 ref.)

Transgenic models in the study of AIDS dementia complex. Toggas SM, et al. **Curr Top Microbiol Immunol** 1996; 206:223-41 (89 ref.)

Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. Fine SM, et al. **J Biol Chem** 1996 Jun 28;271(26):15303-6

Dysregulation of signal transduction pathways as a potential mechanism of nervous system alterations in HIV-1 gp120 transgenic mice and humans with HIV-1 encephalitis. Wyss-Coray T, et al. **J Clin Invest** 1996 Feb 1;97(3):789-98

Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. Brew BJ, et al. **J Infect Dis** 1996 Aug;174(2):294-8

[Biochemical studies on AIDS dementia complex--possible contribution of quinolinic acid during brain damage] Saito K. **Rinsho Byori** 1995 Sep;43(9):891-901 (36 ref.) (Eng. Abstr.) **(Jpn)**

[Organic mental disorders and AIDS] Kasparas GG. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):330-4 (14 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Role of immune activation and cytokine expression in HIV-1-associated neurologic diseases. Yoshioka M, et al. **Adv Neuroimmunol** 1995;5(3):335-58 (190 ref.)

Dementia at 700? [letter; comment] Kosmyna J. **Am J Nurs** 1996 May;96(5):18. Comment on: Am J Nurs 1996 Feb;96(2):22-8; quiz 29.

Intrathecal synthesis of antibodies to human herpesvirus 6 early antigen in patients with meningitis/encephalitis [letter] Patnaik M, et al. **Clin Infect Dis** 1995 Sep; 21(3):715-6

Distribution of transforming growth factor-beta isoforms in human immunodeficiency virus-1 encephalitis. Johnson MD, et al. **Hum Pathol** 1996 Jul;27(7):643-9

Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Nottet HS, et al. **Immunol Today** 1995 Sep;16(9):441-8 (85 ref.)

Managing HIV. Part 3: Mechanisms of diseases. 3.7 How HIV leads to neurological disease. Brew BJ, et al. **Med J Aust** 1996 Feb 19;164(4):233-4 (19 ref.)

AIDS DEMENTIA COMPLEX

METABOLISM

Deep gray matter structures in HIV infection: a proton MR spectroscopic study. Meyerhoff DJ, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):973–8

Increased brain levels of platelet-activating factor in a murine acquired immune deficiency syndrome are NMDA receptor-mediated. Nishida K, et al. **J Neurochem** 1996 Jan;66(1):433–5

Short echo time proton spectroscopy of the brain in HIV infection/AIDS. Paley M, et al. **Magn Reson Imaging** 1995; 13(6):871–5

Decreased expression of AMPA receptor messenger RNA and protein in AIDS: a model for HIV-associated neurotoxicity. Everall IP, et al. **Nat Med** 1995 Nov; 1(11):1174–8

Deoxyglucose uptake by mouse astrocytes: effects of temperature and retrovirus infection. Vann JM, et al. **Neurochem Res** 1995 Sep;20(9):1013–20

Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: A proton magnetic resonance spectroscopic study. Tracey I, et al. **Neurology** 1996 Mar;46(3):783–8

NURSING

The overlooked epidemic: HIV in older adults [see comments] Whipple B, et al. **Am J Nurs** 1996 Feb; 96(2):22–8; quiz 29 (9 ref.). Comment in: Am J Nurs 1996 May;96(5):18.

The role of the consultation-liaison nurse. Caring for patients with AIDS dementia complex. Price N. **J Psychosoc Nurs Ment Health Serv** 1995 Dec;33(12):31–4 (14 ref.)

PATHOLOGY

Neuronal pattern correlates with the severity of human immunodeficiency virus-associated dementia complex. Usefulness of spatial pattern analysis in clinicopathological studies. Asare E, et al. **Am J Pathol** 1996 Jan;148(1):31–8

Human immunodeficiency virus encephalitis in SCID mice [see comments] Persidsky Y, et al. **Am J Pathol** 1996 Sep; 149(3):1027–53. Comment in: Am J Pathol 1996 Sep;149(3):745–50.

Sub-cortical white-grey matter contrast on MRI as a quantitative marker of diffuse HIV-related parenchymal abnormality. Wilkinson ID, et al. **Clin Radiol** 1996 Jul; 51(7):475–9

Role for astrocytosis in HIV-1-associated dementia. Vitkovic L, et al. **Curr Top Microbiol Immunol** 1995;202:105–16 (49 ref.)

Quantitative neuropathologic assessment of HIV-1 encephalitis. Wiley CA. **Curr Top Microbiol Immunol** 1995; 202:55–61 (32 ref.)

Neuropathology of human immunodeficiency virus: questions and answers [editorial] Petito CK. **Hum Pathol** 1996 Jul; 27(7):623–4 (24 ref.)

Infection of Macaca nemestrina brain with human immunodeficiency virus type 1. Frumkin LR, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2467–76

The correlation between neuropsychological and neuroanatomic changes over time in asymptomatic and symptomatic HIV-1-infected individuals. Hall M, et al. **Neurology** 1996 Jun;46(6):1697–702

Activation of nuclear factor kappa B in brains from children with HIV-1 encephalitis. Dollard SC, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):518–28

The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases. Martinez AJ, et al. **Pathol Res Pract** 1995 Jun;191(5):427–43

In vivo magnetic resonance spectroscopy in HIV and HIV-related brain diseases. Chang L. **Rev Neurosci** 1995 Oct–Dec;6(4):365–78 (63 ref.)

[Early cerebral lesions in HIV infection. Postmortem radio-pathologic correlations in non-AIDS asymptomatic seropositive patients] Hassine D, et al. **J Neuroradiol** 1995 Sep;22(3):148–60 (Eng. Abstr.) **(Fre)**

[HIV and dementia: neuropathology] Seilhean D, et al. **J Neuroradiol** 1995 Sep;22(3):161–2 (Eng. Abstr.) **(Fre)**

[Morphologic diagnosis of a seronegative case of HIV-infection] Nedz'ved' MK, et al. **Arkh Patol** 1995 Jul–Aug;57(4):80–3 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

The Edinburgh cohort of HIV-positive injecting drug users at 10 years after infection: a case-control study of the evolution of dementia. Goodwin GM, et al. **AIDS** 1996 Apr;10(4):431–40

Effects of chronic alcohol abuse and HIV infection on brain phosphorus metabolites. Meyerhoff DJ, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):685–92

In vivo modeling of HIV-1 mediated neurodegeneration [comment] Masliah E. **Am J Pathol** 1996 Sep;149(3):745–50 (68 ref.). Comment on: Am J Pathol 1996 Sep;149(3):1027–53.

Human immunodeficiency virus encephalitis and dementia [editorial; comment] Wiley CA, et al. **Ann Neurol** 1995 Oct;38(4):559–60. Comment on: Ann Neurol 1995 Oct;38(4):563–70.

Alcohol abuse and HIV [letter; comment] Mendelson JH. **Biol Psychiatry** 1995 Sep 1;38(5):343–4. Comment on: Biol Psychiatry 1995 Feb 1;37(3):183–95.

Subacute measles encephalitis in a boy with perinatal HIV-1 infection [letter] Vigliano P, et al. **Dev Med Child Neurol** 1995 Dec;37(12):1117–9

Apoptosis and HIV neuropathogenesis. Espey MG. **Med Hypotheses** 1995 Jun;44(6):536–8

Trypsin inhibition: a potential cause of cobalamin deficiency common to the pathogenesis of Alzheimer-type dementia and AIDS dementia complex? McCaddon A, et al. **Med Hypotheses** 1995 Aug;45(2):200–4 (49 ref.)

Brain-emitted event-related potentials recorded during rapid decision-making may be useful in monitoring the neuropathogenesis of the human immunodeficiency virus (HIV). Linnville SE. **Percept Mot Skills** 1995 Aug; 81(1):209–10

[A contribution of brain imaging techniques to the diagnosis of psychiatric emergencies] Assouly-Besse F, et al. **Ann Med Psychol (Paris)** 1996 Jan;154(1):60–3 (Eng. Abstr.) **(Fre)**

[Neurological manifestations in HIV-infected child] Bossi G, et al. **Minerva Pediatr** 1995 Jul–Aug;47(7–8):285–95 (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

HIV-1, the brain, and combination therapy. Portegies P. **Lancet** 1995 Nov 11;346(8985):1244–5

Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex. Burger DM, et al. **Pharm World Sci** 1995 Nov 24;17(6):218–21

PSYCHOLOGY

Neurocognitive disorders in HIV-1 infection. HNRC Group. HIV Neurobehavioral Research Center. Grant I, et al. **Curr Top Microbiol Immunol** 1995;202:11–32 (77 ref.)

Abnormalities of visual spatial attention in HIV infection and the HIV-associated dementia complex. Maruff P, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):325–33

The correlation between neuropsychological and neuroanatomic changes over time in asymptomatic and symptomatic HIV-1-infected individuals. Hall M, et al. **Neurology** 1996 Jun;46(6):1697–702

Odor sensitivity is impaired in HIV-positive cognitively impaired patients. Razani J, et al. **Physiol Behav** 1996 Apr–May;59(4–5):877–81

[Anxious-depressive state and cognitive deficit in HIV infection] Silvestre D, et al. **Encephale** 1995 Jul–Aug; 21(4):285–8 (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

HIV neurology grey case. Greene L, et al. **Int J STD AIDS** 1995 Sep–Oct;6(5):329–30

RADIONUCLIDE IMAGING

Differentiating cerebral lymphoma from nonmalignant central nervous system lesions in patients with AIDS [letter] Hoffman JM, et al. **AJNR Am J Neuroradiol** 1995 Aug;16(7):1562–3

Functional brain imaging in HIV-1-infected children born to seropositive mothers. Depas G, et al. **J Nucl Med** 1995 Dec;36(12):2169–74

THERAPY

[AIDS dementia. Prognosis and therapeutic perspectives] Lubetzki C. **J Neuroradiol** 1995 Sep;22(3):169–71 (15 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. Ranki A, et al. **AIDS** 1995 Sep;9(9):1001–8

HIV type 1 V3 sequences and the development of dementia during AIDS. Di Stefano M, et al. **AIDS Res Hum Retroviruses** 1996 Apr 10;12(6):471–6

Human immunodeficiency virus in brain and correlation with dementia [letter] Brew BJ. **Ann Neurol** 1996 Jun; 39(6):828–9

AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations [see comments] Brew BJ, et al. **Ann Neurol** 1995 Oct;38(4):563–70. Comment in: Ann Neurol 1995 Oct;38(4):559–60.

Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Glass JD, et al. **Ann Neurol** 1995 Nov; 38(5):755–62

Quantitation of human immunodeficiency virus in brains of demented and nondemented patients with acquired immunodeficiency syndrome. Johnson RT, et al. **Ann Neurol** 1996 Mar;39(3):392–5

Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Power C, et al. **Curr Top Microbiol Immunol** 1995;202:89–104

Infection of Macaca nemestrina brain with human immunodeficiency virus type 1. Frumkin LR, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2467–76

AIDS ENCEPHALOPATHY see **AIDS DEMENTIA COMPLEX**

AIDS ENTEROPATHY see **HIV ENTEROPATHY**

AIDS, FELINE see **FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME**

AIDS, MURINE see **MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME**

AIDS-RELATED COMPLEX

BLOOD

Impairment of circulating lactoferrin in HIV-1 infection. Defer MC, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May; 41(3):417–21

COMPLICATIONS

Use of murine subinoculation for the diagnosis and isolation of toxoplasmosis in HIV-infected patients with persistent lymphadenopathy. Diego JA, et al. **Ann Trop Med Parasitol** 1993 Apr;87(2):179–84

Importance of human immunodeficiency virus-associated lymphadenopathy and tuberculous lymphadenitis in patients undergoing lymph node biopsy in Zambia [letter] Sarela A. **Br J Surg** 1996 Jun;83(6):869

Pericardial effusion in AIDS. Incidence and survival. Heidenreich PA, et al. **Circulation** 1995 Dec 1; 92(11):3229–34

Isolated lymphadenopathy on chest radiographs of HIV-infected patients. Haramati LB, et al. **Clin Radiol** 1996 May;51(5):345–9

14-year follow-up of HIV-infected homosexual men with lymphadenopathy syndrome [letter] Kaplan JE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):206–8

Hyponatremia in pediatric patients with HIV-1 infection. Tolaymat A, et al. **South Med J** 1995 Oct;88(10):1039–42

DRUG THERAPY

The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. Jacobson MA, et al. **AIDS** 1995 Jul;9(7):727–34

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Horton CM, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2309–15

A report on 8 seronegative converted HIV/AIDS patients with traditional Chinese medicine. Lu W, et al. **Chin Med J (Engl)** 1995 Aug;108(8):634–7

Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group. Gatell JM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jul; 12(3):249–58

EPIDEMIOLOGY

Importance of human immunodeficiency virus-associated lymphadenopathy and tuberculous lymphadenitis in patients undergoing lymph node biopsy in Zambia. Bem C, et al. **Br J Surg** 1996 Jan;83(1):75–8

IMMUNOLOGY

Persistent generalized lymphadenopathy and non-Hodgkin's lymphoma in AIDS: association with Rochalimaea henselae infection. Peter JB, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):115–6

HIV lymphadenopathy—a histopathological and immunomorphological study of 65 cases. Walewska-Zielecka B, et al. **Pol J Pathol** 1995;46(4):211–7

METABOLISM

The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients. Nazareno LA, et al. **Pharm Res** 1995 Oct;12(10):1462–5

PATHOLOGY

HIV lymphadenopathy—a histopathological and immunomorphological study of 65 cases. Walewska-Zielecka B, et al. **Pol J Pathol** 1995;46(4):211–7

THERAPY

Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. Collier AC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):150–6

VIROLOGY

Characterization of Epstein-Barr virus-infected cells in benign lymphadenopathy of patients seropositive for human immunodeficiency virus. Brousset P, et al. **Hum Pathol** 1996 Mar;27(3):263–8

Characteristics of EBV-infected cells in HIV-related lymphadenopathy: implications for the pathogenesis of EBV-associated and EBV-unrelated lymphomas of HIV-seropositive individuals. Dolcetti R, et al. **Int J Cancer** 1995 Nov 27;63(5):652–9

Human herpesvirus 6 in human immunodeficiency virus-infected individuals: association with early histologic phases of lymphadenopathy syndrome but not with

malignant lymphoproliferative disorders. Dolcetti R, et al. **J Med Virol** 1996 Apr;48(4):344–53

AIDS-RELATED LYMPHOMA see **LYMPHOMA, AIDS-RELATED**

AIDS-RELATED OPPORTUNISTIC INFECTIONS

Mucocutaneous fungal colonization in HIV-infected children. Don PC, et al. **Acta Derm Venereol** 1995 Jul; 75(4):310–11

Comprehensive guidelines on HIV-related opportunistic infections released [news] **Am J Health Syst Pharm** 1995 Oct 15;52(20):2166, 2170

Advances in the management of AIDS-related cytomegalovirus retinitis [see comments] Masur H, et al. **Ann Intern Med** 1996 Jul 15;125(2):126–36 (69 ref.). Comment in: Ann Intern Med 1996 Jul 15;125(2):144–5.

Clinical correlates of secondary meningitis in HIV-infected adults. Friedmann PD, et al. **Arch Intern Med** 1995 Nov 13;155(20):2231–7

Special issue: AIDS and the eye. **Arch Ophthalmol** 1996 Jul; 114(7):791–892

Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Saillour F, et al. **BMJ** 1996 Aug 24;313(7055):461–4

Cryptococcal meningitis. Jones GA, et al. **Br J Hosp Med** 1995 Nov 1–14;54(9):439–45 (38 ref.)

Mycocutaneous atypical mycobacterial infections in acquired immunodeficiency syndrome. Zanelli G, et al. **Clin Dermatol** 1995 May–Jun;13(3):281–8 (68 ref.)

Oral candidiasis in HIV-infected patients. Brawner DL, et al. **Curr Top Med Mycol** 1995;6:113–25 (68 ref.)

Kaposi's sarcoma with an intense parasitization by Leishmania. Gallego MA, et al. **Cutis** 1996 Feb;57(2):103–5

HIV-associated lesions. Greenberg MS. **Dermatol Clin** 1996 Apr;14(2):319–26 (39 ref.)

Primary localized cutaneous histoplasmosis in a patient with acquired immunodeficiency syndrome. Krunic A, et al. **Int J Dermatol** 1995 Aug;34(8):558–62

Management of protozoan infections in AIDS. The Jefferiss Wing Therapeutics and Protocols Group. Tomlinson DR, et al. **Int J STD AIDS** 1995 Jul–Aug;6(4):237–40 (7 ref.)

Special patient populations: onychomycosis in the HIV-positive patient. Gregory N. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 2):S13–6

Cutaneous cryptococcosis and histoplasmosis coinfection in a patient with AIDS. Myers SA, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):898–900

Mycobacterium haemophilum cellulitis and osteomyelitis in a man with AIDS. Holladay KL, et al. **J Am Board Fam Pract** 1996 Mar–Apr;9(2):122–4

Mycobacterium avium complex infection in AIDS: clinical features, treatment, and prevention. Eccles E, et al. **J Assoc Nurses AIDS Care** 1995 Sep–Oct;6(5):37–47; quiz 48–9 (23 ref.)

Extensive esophageal candidiasis in the absence of oral lesions in pediatric AIDS. Braegger CP, et al. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):104–6

Opportunistic infections in HIV seropositive individuals. Gazzard BG. **J R Coll Physicians Lond** 1995 Jul–Aug; 29(4):335–9 (21 ref.)

Ocular manifestations of AIDS [clinical conference] [see comments] Whitcup SM. **JAMA** 1996 Jan 10;275(2):142–4 . Comment in: JAMA 1996 Jan 10;275(2):149–50. Comment in: JAMA 1996 May 22–29;275(20):1545.

HIV-associated respiratory diseases. Miller R. **Lancet** 1996 Aug 3;348(9023):307–12 (50 ref.)

Neurological complications of HIV infection. Price RW. **Lancet** 1996 Aug 17;348(9025):445–52 (50 ref.)

AIDS and the eyes. Sarraf D, et al. **Lancet** 1996 Aug 24; 348(9026):525–8 (30 ref.)

Gastrointestinal manifestations of HIV infection. Sharpstone D, et al. **Lancet** 1996 Aug 10;348(9024):379–83 (50 ref.)

Cytomegalovirus retinitis in patients with AIDS: current status. Luckie AP. **Med J Aust** 1995 Nov 6;163(9):489–92 (24 ref.)

Cytomegalovirus retinitis in patients with AIDS: current status [letter] Nichols TT. **Med J Aust** 1996 Apr 1; 164(7):446

Pediatric HIV infection and its oral manifestations: a review. Chigurupati R, et al. **Pediatr Dent** 1996 Mar–Apr; 18(2):106–13 (68 ref.)

Cytomegalovirus sinus disease in a human immunodeficiency virus-infected child. Olivero MT, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):629–31

Mycobacterium avium intracellulare infection in children with AIDS. Gershon AA. **Pediatr Pulmonol Suppl** 1995; 11:7–9 (14 ref.)

Opportunistic fungal infections in patients with HIV disease: combating cryptococcosis and histoplasmosis. Kirchner JT. **Postgrad Med** 1996 Jun;99(6):209–16 (34 ref.)

Breast abscess with lethal septicemia due to Pseudomonas aeruginosa in a patient with AIDS. Roca B, et al. **Presse Med** 1996 May 18;25(17):803–4

Tuberculous pericarditis in an HIV-infected patient. Antony SJ, et al. **Scand J Infect Dis** 1995;27(4):411–3 (26 ref.)

Severe pulmonary infections in AIDS patients. Gatell JM, et al. **Semin Respir Infect** 1996 Jun;11(2):119–28 (57 ref.)

Renal abscess due to Aspergillus fumigatus in a patient with the acquired immunodeficiency syndrome. Segarra J, et al. **Urol Int** 1995;55(1):60–2

[Disseminated histoplasmosis disclosed by febrile miliaria in a patient with immunodeficiency virus infection (letter)] Briens E, et al. **Ann Med Interne (Paris)** 1995;146(7):524–6 (Fre)

[Bacillus cereus meningitis in a patient with human immunodeficiency virus infection (letter)] Chemlal K, et al. **Ann Med Interne (Paris)** 1995;146(7):522–4 (Fre)

[Escherichia coli bacteremia and cellulitis in AIDS. Apropos of 2 cases (letter)] Longuet P, et al. **Ann Med Interne (Paris)** 1995;146(7):521 (Fre)

[Severe leptospirosis in a patient with human immunodeficiency virus infection (letter)] Zylberberg H, et al. **Ann Med Interne (Paris)** 1995;146(7):522 (Fre)

[Upper genital tract infections in women infected with HIV: epidemiologic, diagnostic and therapeutic aspects] Panel P, et al. **Contracept Fertil Sex** 1996 Jun;24(6):488–94 (22 ref.) (Eng. Abstr.) (Fre)

[Chorioretinal manifestations in AIDS] Snyers B, et al. **J Fr Ophtalmol** 1995;18(10):634–44 (76 ref.) (Fre)

[Reactivation of hepatitis B in AIDS (letter)] Berthelot P, et al. **Presse Med** 1996 Jan 27;25(3):128 (Fre)

[Bacterial esophagitis in AIDS (letter)] Blanche P, et al. **Presse Med** 1995 Nov 11;24(34):1624 (Fre)

[Mycobacterium gordonae infections in human immunodeficiency virus infection] Maslo C, et al. **Presse Med** 1995 Sep 2–9;24(25):1157–60 (15 ref.) (Eng. Abstr.) (Fre)

[Pulmonary toxoplasmosis in patients with human immunodeficiency virus infection. 21 cases] Mortier E, et al. **Presse Med** 1996 Mar 23;25(10):485–90 (Eng. Abstr.) (Fre)

[Salmonella typhimurium cerebral abscess: rare complication of HIV infection (letter)] Smail A, et al. **Presse Med** 1996 Mar 30;25(11):556 (Fre)

[Rhodococcus equi pulmonary abscess in HIV infection] About I, et al. **Rev Med Interne** 1996;17(5):410–4 (25 ref.) (Eng. Abstr.) (Fre)

[Mycobacterium kansasii infection in patients with human immunodeficiency virus infection] Boudon P, et al. **Rev Med Interne** 1995;16(10):747–51 (Eng. Abstr.) (Fre)

[Kaposi disease (editorial)] Dupin N. **Rev Med Interne** 1995; 16(7):484–6 (Fre)

[Disseminated histoplasmosis: 2 cases in patients with human immunodeficiency virus infection in French Guiana] Gérard Y, et al. **Rev Med Interne** 1995;16(10):767–70 (Eng. Abstr.) (Fre)

[Varicella zoster virus retinitis in AIDS] Herrmann B, et al. **Rev Med Interne** 1996;17(2):169–70 (Fre)

[Strongyloides stercoralis in T-cell leukemia/lymphoma in adults and acquired immunodeficiency syndrome] Plumelle Y, et al. **Rev Med Interne** 1996;17(2):125–9 (Eng. Abstr.) (Fre)

[HIV infection and AIDS in dentistry. A report on the scientific meeting of 29 September 1995: continuing education at the Institut de Médecine Dentaire in Geneva] Perrier M. **Schweiz Monatsschr Zahnmed** 1995; 105(12):1602–3 (Fre)

[Cytomegalovirus infection in HIV] Ferone U, et al. **Riv Eur Sci Med Farmacol** 1994 May–Aug;16(3–4):55–60 (Eng. Abstr.) (Ita)

[Respiratory system changes in persons infected with the HIV virus] Niemirowska H. **Pneumonol Pol** 1990 Sep–Oct; 58(9–10):549–58 (42 ref.) (Pol)

[Opportunistic viral infections] Pannutti C. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:32–9 (Por)

[Update on microsporidiosis in humans] Atías A. **Rev Med Chil** 1995 Jun;123(6):762–72 (40 ref.) (Eng. Abstr.) (Spa)

BLOOD

Leishmaniasis in AIDS patients: results of leukocytoconcentration, a fast biological method of diagnosis. Izri MA, et al. **Bull World Health Organ** 1996; 74(1):91–3

Serum ferritin levels correlate with disease activity in patients with AIDS and disseminated histoplasmosis. Kirn DH, et al. **Clin Infect Dis** 1995 Oct;21(4):1048–9

Clinical features and serum beta 2-microglobulin levels in HIV-1 positive and negative Tanzanian patients with tuberculosis. Kennedy N, et al. **Int J STD AIDS** 1995 Jul–Aug;6(4):278–83

Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS. Piketty C, et al. **J Infect Dis** 1996 Jul;174(1):188–90

[Visceral Leishmaniasis and human immunodeficiency virus: role of serology. A case report (letter)] Brisou P, et al. **Med Trop (Mars)** 1995;55(4):393 (Fre)

CEREBROSPINAL FLUID

Predominance of neutrophils in the cerebrospinal fluid of AIDS patients with cytomegalovirus radiculopathy. Granter SR, et al. **Am J Clin Pathol** 1996 Mar;105(3):364–6

D-mannitol in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis. Megson GM, et al. **J Clin Microbiol** 1996 Jan;34(1):218–21

Quantitation of human cytomegalovirus (HCMV) DNA in cerebrospinal fluid by competitive PCR in AIDS patients with different HCMV central nervous system diseases. Shinkai M, et al. **Scand J Infect Dis** 1995;27(6):559–61

Diagnosis of cytomegalovirus infection of the nervous system in AIDS by polymerase chain reaction analysis of cerebrospinal fluid. Cinque P, et al. **Scand J Infect Dis Suppl** 1995;99:92–4

[AIDS-related cryptococcal meningitis at the Bobo-Dioulasso Hospital Center: five case reports] Ki-Zerbo GA, et al. **Med Trop (Mars)** 1996;56(1):63–5 (Eng. Abstr.) (Fre)

COMPLICATIONS

Retrobulbar neuritis in a patient with acquired immune deficiency syndrome. Cacciatori M, et al. **Acta Ophthalmol Scand** 1996 Apr;74(2):194–6

Ocular complication in HIV infected individuals. Harrison TJ. **Alaska Med** 1995 Jul–Sep;37(3):91–100 (78 ref.)

Fifth disease after immunoglobulin administration in an AIDS patient with parvovirus-induced red cell aplasia. French AL, et al. **Am J Med** 1996 Jul;101(1):108–9

Corneal endothelial deposits in patients with cytomegalovirus retinitis. Walter KA, et al. **Am J Ophthalmol** 1996 Apr; 121(4):391–6

Unilateral optic neuritis caused by Histoplasma capsulatum in a patient with the acquired immunodeficiency syndrome. Yau TH, et al. **Am J Ophthalmol** 1996 Mar;121(3):324–6

Spontaneous pneumothorax in the AIDS population. Spivak H, et al. **Am Surg** 1996 Sep;62(9):753–6

Neutropenia and iatrogenic neutrophil dysfunction in human immunodeficiency virus infection and acquired immunodeficiency syndrome [letter; comment] Arnott MA, et al. **Arch Intern Med** 1996 Jul 8;156(13):1475–6. Comment on: Arch Intern Med 1995 Oct 9;155(18):1965–70.

Neutropenia and bacterial infection in acquired immunodeficiency syndrome [see comments] Moore RD, et al. **Arch Intern Med** 1995 Oct 9;155(18):1965–70. Comment in: Arch Intern Med 1996 Jul 8;156(13):1475–6.

Mycobacterium kansasii septic arthritis in a patient with acquired immunodeficiency syndrome. García Vivar ML, et al. **Arthritis Rheum** 1996 May;39(5):881–2

Disease in children with HIV infection in Abidjan. Authors should have emphasised lack of tuberculosis in HIV positive children [letter; comment] Gilks C. **BMJ** 1996 May 18;312(7041):1302–3. Comment on: BMJ 1996 Feb 10;312(7027):335–8.

C. albicans septic arthritis in a patient with AIDS. Smith NA, et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):270–1

Disseminated varioliform pustular eruption due to Mycobacterium avium intracellulare in an HIV-infected patient. Bachelez H, et al. **Br J Dermatol** 1996 Apr; 134(4):801–3

Leishmania infection occurring in herpes zoster lesions in an HIV-positive patient. Barrio J, et al. **Br J Dermatol** 1996 Jan;134(1):164–6

Staphylococcal scalded skin syndrome in an HIV-1 seropositive man. Farrell AM, et al. **Br J Dermatol** 1996 May;134(5):962–5

Cutaneous Pneumocystis carinii and Cryptococcus neoformans in AIDS. Sandler B, et al. **Br J Dermatol** 1996 Jan;134(1):159–63

Mucocutaneous histoplasmosis in AIDS. Souza Filho FJ, et al. **Br J Dermatol** 1995 Sep;133(3):472–4 (26 ref.)

Cytomegalovirus retinitis in an AIDS patient without severe depletion in CD4 cell count [letter] Bagiivo E, et al. **Br J Ophthalmol** 1995 Oct;79(10):962–3

The challenge of HIV/AIDS related eye disease [editorial; comment] Courtright P. **Br J Ophthalmol** 1996 Jun; 80(6):496–7. Comment on: Br J Ophthalmol 1996 Jun;80(6):503–8.

Carcinoma of the conjunctiva and HIV infection in Uganda and Malawi [see comments] Waddell KM, et al. **Br J Ophthalmol** 1996 Jun;80(6):503–8. Comment in: Br J Ophthalmol 1996 Jun;80(6):496–7.

Severe complications of perianal sepsis in patients with human immunodeficiency virus. Consten EC, et al. **Br J Surg** 1996 Jun;83(6):778–80

Human immunodeficiency virus-related bacillary angiomatosis of the penis. Eden CG, et al. **Br J Urol** 1996 Feb;77(2):323–4

Sudden onset of large pericardial effusion in a 27-year-old man with AIDS. Muthuswamy P, et al. **Chest** 1995 Dec; 108(6):1739–41

Common superficial fungal infections in patients with AIDS. Aly R, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S128–32 (24 ref.)

Update on the status of Lyme borreliosis in British Columbia, Canada [letter] Banerjee S. **Clin Infect Dis** 1995 Sep; 21(3):704

Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses over a relatively short period [letter; comment] Churchill D, et al. **Clin Infect Dis** 1995 Nov;21(5):1352–3. Comment on: Clin Infect Dis 1995 Feb;20(2):263–6.

Cholera in a patient infected with human immunodeficiency virus [letter] Dahdouh MA, et al. **Clin Infect Dis** 1995 Sep; 21(3):689–90

Foscarnet-resistant multidermatomal zoster in a patient with AIDS. Fillet AM, et al. **Clin Infect Dis** 1995 Nov; 21(5):1348–9

Paracoccidioidomycosis and AIDS: an overview. Goldani LZ, et al. **Clin Infect Dis** 1995 Nov;21(5):1275–81 (41 ref.)

Bacteremic group A streptococcal pharyngitis presenting as acute airway obstruction [letter] Gradon JD, et al.

Clin Infect Dis 1995 Sep;21(3):704–5

Esophageal leishmaniasis in a patient infected with the human immunodeficiency virus [letter; comment] Gutiérrez-Macías A, et al. **Clin Infect Dis** 1995 Jul; 21(1):229–30. Comment on: Clin Infect Dis 1994 Jul;19(1):48–53.

Legionnaires' disease in patients infected with human immunodeficiency virus [letter; comment] Gutiérrez Rodero F, et al. **Clin Infect Dis** 1995 Sep;21(3):712–3. Comment on: Clin Infect Dis 1994 Feb;18(2):227–32.

Staphylococcal toxic shock syndrome associated with human immunodeficiency virus infection: report of a case with bacteremia. Gutiérrez Rodero F, et al. **Clin Infect Dis** 1996 May;22(5):875–6

Visceral leishmaniasis due to a Leishmania variant that shares kinetoplast DNA sequences with Leishmania braziliensis and Leishmania mexicana in a patient infected with human immunodeficiency virus: identification of the Leishmania species with use of the polymerase chain reaction [letter] Hernández DE, et al. **Clin Infect Dis** 1995 Sep;21(3):701–2

Invasive colitis and hepatitis due to previously uncharacterized spirochetes in patients with advanced human immunodeficiency virus infection. Kostman JR, et al. **Clin Infect Dis** 1995 Nov;21(5):1159–65

Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus [letter] Laguna F, et al. **Clin Infect Dis** 1995 Sep;21(3):711–2

Failure of the radiometric Bactec method to detect Mycobacterium avium complex in the blood of patients infected with human immunodeficiency virus who were treated with antibiotics. Lebrun L, et al. **Clin Infect Dis** 1995 Nov;21(5):1343–4

Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate [letter; comment] McBride MO, et al. **Clin Infect Dis** 1995 Sep;21(3):710. Comment on: Clin Infect Dis 1994 Jan;18(1):83–90.

Sinusitis in children infected with human immunodeficiency virus: clinical characteristics, risk factors, and prophylaxis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Mofenson LM, et al. **Clin Infect Dis** 1995 Nov;21(5):1175–81

Use of an Itraconazole/allopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS. Raffi F, et al. **Clin Infect Dis** 1995 Nov;21(5):1338–9

Pneumonia and respiratory distress syndrome during primary infection with Toxoplasma gondii [letter] Renold C, et al. **Clin Infect Dis** 1995 Sep;21(3):690–1

Predictors and outcome of multidrug-resistant tuberculosis. Salomon N, et al. **Clin Infect Dis** 1995 Nov;21(5):1245–52

Bartonella (Rochalimaea) antibodies, dementia, and cat ownership among men infected with human immunodeficiency virus. Schwartzman WA, et al. **Clin Infect Dis** 1995 Oct;21(4):954–9

Cyclospora cayetanensis infection in patients with and without AIDS: biliary disease as another clinical manifestation. Sifuentes-Osornio J, et al. **Clin Infect Dis** 1995 Nov;21(5):1092–7

Aspergillus sinusitis in patients with AIDS: report of three cases and review. Teh W, et al. **Clin Infect Dis** 1995 Sep; 21(3):529–35 (46 ref.)

Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Witzig RS, et al. **Clin Infect Dis** 1995 Jul; 21(1):77–85 (69 ref.)

Prolonged isolated fever due to attenuated extracerebral toxoplasmosis in patients infected with human immunodeficiency virus who are receiving trimethoprim-sulfamethoxazole as prophylaxis. Zylberberg H, et al. **Clin Infect Dis** 1995 Sep;21(3):680–1

Cryptococcosis in the era of AIDS—100 years after the discovery of Cryptococcus neoformans. Mitchell TG, et al. **Clin Microbiol Rev** 1995 Oct;8(4):515–48 (529 ref.)

Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Tappero JW, et al. **Clin Microbiol Rev** 1995 Jul;8(3):440–50 (68 ref.)

Pleural leak localization with Tc-99m pentetate aerosol in an AIDS patient with Pneumocystis carinii pneumonia. Cartland JP, et al. **Clin Nucl Med** 1996 May;21(5):408–9

Isolated lymphadenopathy on chest radiographs of HIV-infected patients. Haramati LB, et al. **Clin Radiol** 1996 May;51(5):345–9

Myopathy and HIV infection. Chariot P, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):497–502 (72 ref.)

Progressive outer retinal necrosis (PORN) in AIDS patients: a different appearance of varicella-zoster retinitis. Pavesio CE, et al. **Eye** 1995;9 (Pt 3):271–6

Retinal detachment in AIDS-related cytomegalovirus retinitis. Sandy CJ, et al. **Eye** 1995;9 (Pt 3):277–81

Perforation of the small intestine in a patient with disseminated Pneumocystis carinii infection in AIDS. Bierhoff E, et al. **Gen Diagn Pathol** 1996 Mar; 141(3–4):255–60

Community-based respiratory viral infections in HIV positive patients with lower respiratory tract disease: a prospective bronchoscopic study. Miller RF, et al. **Genitourin Med** 1996 Feb;72(1):9–11

Unusual association of American cutaneous leishmaniasis and acquired immunodeficiency syndrome. Nogueira-Castañon MC, et al. **Int J Dermatol** 1996 Apr;35(4):295–7

Post-kala-azar dermal Leishmaniasis in an HIV-patient [letter] Rios-Buceta L, et al. **Int J Dermatol** 1996 Apr; 35(4):303–4

Proximal white subungual onychomycosis in AIDS. Silva-Lizama E, et al. **Int J Dermatol** 1996 Apr;35(4):290–1

Autopsy findings of Addison's disease caused by systemic cytomegalovirus infection in a patient with acquired immunodeficiency syndrome. Takasawa A, et al. **Intern Med** 1995 Jun;34(6):533–6

Zygomycosis (mucormycosis) and HIV infection: report of three cases and review. Nagy-Agren SE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):441–9 (27 ref.)

Long survival in AIDS-related cytomegalovirus retinitis [letter] Sandy CJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):209–10

Acute hepatic and renal failure caused by Pneumocystis carinii in patients with AIDS. Boldorini R, et al. **J Clin Pathol** 1995 Oct;48(10):975–8

Cytomegalovirus viraemia in HIV infection: association with intercurrent infection. Evans MR, et al. **J Infect** 1995 Jul; 31(1):21–6

Toxoplasma pneumonia in a patient with AIDS [letter] Halme M, et al. **J Infect** 1995 Nov;31(3):252–3

Human herpesvirus 8 is present in the lymphoid system of healthy persons and can reactivate in the course of AIDS. Bigoni B, et al. **J Infect Dis** 1996 Mar;173(3):542–9

Identification by random amplification of polymorphic DNA of a common molecular type of Cryptococcus neoformans var. neoformans in patients with AIDS or other immunosuppressive conditions. Chen SC, et al. **J Infect Dis** 1996 Mar;173(3):754–8

Acute Sjögren-like syndrome as the first manifestation of a generalized CMV infection in a patient with AIDS. Van Vooren JP, et al. **J Laryngol Otol** 1995 Nov;109(11):1113–4

Red fingers syndrome in patients with HIV and hepatitis C infection [letter] Pechère M, et al. **Lancet** 1996 Jul 20; 348(9021):196–7

Anergy, AIDS and tuberculosis. Hegde HR. **Med Hypotheses** 1995 Nov;45(5):433–40 (48 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.11 HIV and eye disease. McCluskey PJ, et al. **Med J Aust** 1996 Apr 15;164(8):484–6

Managing HIV. Part 5: Treating secondary outcomes. 5.12 HIV and haematological disease. Street AM, et al. **Med J Aust** 1996 Apr 15;164(8):487–8

Acquired immunodeficiency syndrome (AIDS) and the eye. Armstrong RA. **Ophthalmic Physiol Opt** 1995 Sep;15 Suppl 2:S42–8 (25 ref.)

Tuberculous and nontuberculous mycobacterial infection of the pancreas in a patient with AIDS [letter] Albu E, et al. **Pancreas** 1996 May;12(4):412–3

Massive reversible pulmonary cysts in a patient with AIDS. Collazos J, et al. **Postgrad Med J** 1995 Dec;71(842):753–4

Breast abscess with lethal septicemia due to Pseudomonas aeruginosa in a patient with AIDS. Roca B, et al. **Presse Med** 1996 May 18;25(17):803–4

Disseminated disease due to Mycobacterium avium complex in AIDS. Flegg PJ, et al. **QJM** 1995 Sep;88(9):617–26

Gastrointestinal manifestations of acquired immunodeficiency syndrome: radiologic-pathologic correlation. Pantongrag-Brown L, et al. **Radiographics** 1995 Sep; 15(5):1155–78 (105 ref.)

Probability and characteristics of human immunodeficiency virus infection in male Greek military personnel with tuberculosis. Bouros D, et al. **Respiration** 1995;62(5):280–5

Disseminated Mycobacterium avium complex presenting with osteomyelitis of the distal femur and proximal tibia. Weingardt JP, et al. **Skeletal Radiol** 1996 Feb;25(2):193–6

Human immunodeficiency virus and recurrence of cutaneous leishmaniasis long after healed localized cutaneous leishmaniasis due to Leishmania aethiopica. Berhe N, et al. **Trans R Soc Trop Med Hyg** 1995 Jul-Aug;89(4):400–1

Diffuse cutaneous infection caused by a presumed monoxenous trypanosomatid in a patient infected with HIV. Dedet JP, et al. **Trans R Soc Trop Med Hyg** 1995 Nov-Dec;89(6):644–6

Recruitment to a trial of tuberculosis preventive therapy from a voluntary HIV testing centre in Lusaka: relevance to implementation. Godfrey-Faussett P, et al. **Trans R Soc Trop Med Hyg** 1995 Jul-Aug;89(4):354–8

Parkinsonism in an HIV-infected patient with hypodense cerebral lesion. de la Fuente-Aguado J, et al. **Tuber Lung Dis** 1996 Apr;77(2):191–2

Mycobacteria in HIV-infected patients in Buenos Aires. Di Lonardo M, et al. **Tuber Lung Dis** 1995 Jun;76(3):185–9

Factors associated with extrapulmonary tuberculosis as an AIDS-defining disease in Europe. The Coordinators of AIDS surveillance in Austria, Belgium, France, Germany, Italy, Portugal, Switzerland, United Kingdom and the city of Amsterdam. Schwoebel V, et al. **Tuber Lung Dis** 1995 Aug;76(4):281–5

Pott's disease of the cervico-occipital junction in an AIDS patient. Ventura G, et al. **Tuber Lung Dis** 1996 Apr; 77(2):188–90

[Extra-pulmonary pneumocystosis in the course of AIDS. Report of a case] Terris B, et al. **Ann Pathol** 1996;16(1):41–4 (Eng. Abstr.) **(Fre)**

[Colonic Histoplasma capsulatum pseudotumor in AIDS. Morphological and immunohistochemical diagnosis of an isolated lesion] Hofman P, et al. **Arch Anat Cytol Pathol** 1995;43(3):140–6 (Eng. Abstr.) **(Fre)**

[Ileal perforation with CMV enteritis in a newborn infant with acquired immunodeficiency syndrome (letter)] Maguer D, et al. **Arch Pediatr** 1995 Sep;2(9):900 **(Fre)**

[Hepatic peliosis, a still current disease (editorial)] Scoazec JY. **Gastroenterol Clin Biol** 1995 May;19(5):505–7 **(Fre)**

[Prognosis of retinal detachment in cytomegalovirus retinitis] Cochereau I, et al. **J Fr Ophtalmol** 1995;18(10):603–7 (Eng. Abstr.) **(Fre)**

[Isolation of an acid-alcohol resistant bacillus (BAAR) in the febrile HIV infected patients: Mycobacterium tuberculosis (MT) or Mycobacterium avium complex (MAC)?] Brel F, et al. **Pathol Biol (Paris)** 1995 Apr; 43(4):380–4 (Eng. Abstr.) **(Fre)**

[Left vocal cord paralysis in cytomegalovirus multifocal neuropathy in a patient with HIV infection] de La Blanchardiere A, et al. **Presse Med** 1996 Jan 27;25(3):106–7 (7 ref.) (Eng. Abstr.) **(Fre)**

[Prostatic tuberculous abscess in AIDS. 2 cases (letter)] Greder-Belan A, et al. **Presse Med** 1995 Sep 30;24(28):1315 **(Fre)**

[Acid-alcohol-resistant bacilli detected by microscopic analysis of exhaled air from HIV-infected patients: tuberculosis or mycobacteriosis?] Meynard JL, et al. **Presse Med** 1996 Feb 10;25(5):193–6 (Eng. Abstr.) **(Fre)**

[Cyclospora infection in a HIV infected patient (letter)] Raguin G, et al. **Presse Med** 1995 Jul 1–8;24(24):1134 **(Fre)**

[Visceral leishmaniasis and human immunodeficiency virus (HIV) infection in the south of France (letter; comment)] Rosenthal E, et al. **Presse Med** 1995 Nov 18;24(35):1666 . Comment on: Presse Med 1995 Jun 17;24(22):1036–40. **(Fre)**

[A case report of the atypical tuberculosis associated with AIDS] Arai Y, et al. **Kekkaku** 1995 Jul;70(7):431–7 (Eng. Abstr.) **(Jpn)**

[Massive and progressive hepatosplenomegaly caused by disseminated nontuberculous mycobacteriosis in a patient with acquired immunodeficiency syndrome] Hagiwara T, et al. **Kekkaku** 1995 Jul;70(7):423–9 (Eng. Abstr.) **(Jpn)**

[Cytomegalovirus retinitis and Pneumocystis carinii choroidopathy in a patient with AIDS] Usui N, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jan;100(1):84–92 (Eng. Abstr.) **(Jpn)**

[The clinical picture of mycotic complications in HIV-infected patients] Rakhmanova AG, et al. **Klin Med (Mosk)** 1995;73(3):44–7 (Eng. Abstr.) **(Rus)**

[Pneumocystis carinii infection in AIDS patients. Current prognosis of the respiratory insufficiency (editorial)] Rello J, et al. **Enferm Infecc Microbiol Clin** 1995 Oct;13(8):447–9 **(Spa)**

[Acalculous cholecystitis and intestinal cryptosporidiosis: frequent association in HIV patients] Salvador Grande F, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):593–6 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Diagnosis of Pneumocystis carinii pneumonia by bronchoalveolar lavage in AIDS patients. Comparison of Diff-Quik, fungifluor stain, direct immunofluorescence test and polymerase chain reaction. Armbruster C, et al. **Acta Cytol** 1995 Nov-Dec;39(6):1089–93

Pneumocystis carinii thyroiditis diagnosis by fine needle aspiration cytology: a case report. Keyhani-Rofagha S, et al. **Acta Cytol** 1996 Mar-Apr;40(2):307–10

Comparison of histologic stains in the diagnosis of Pneumocystis carinii. Naimey GL, et al. **Acta Cytol** 1995 Nov-Dec;39(6):1124–7

Detection of Isospora in the stools of AIDS patients using a new rapid autofluorescence technique [letter] Berlin OG, et al. **AIDS** 1996 Apr;10(4):442–3

Endobronchial tuberculosis in HIV-infected patients. Calpe JL, et al. **AIDS** 1995 Oct;9(10):1159–64

Rhodococcus equi infection in HIV-infected patients. Donisi A, et al. **AIDS** 1996 Apr;10(4):359–62

Marked elevation of the serum ferritin is highly specific for disseminated histoplasmosis in AIDS [letter] Kirn DH, et al. **AIDS** 1995 Oct;9(10):1204–5

Campylobacter infections in HIV-infected patients: clinical and bacteriological features. Molina J, et al. **AIDS** 1995 Aug;9(8):881–5

The endoscopic brush cytology specimen in the diagnosis of intestinal microsporidiosis [letter] Orenstein JM, et al. **AIDS** 1995 Oct;9(10):1199–201

Nested polymerase chain reaction for diagnosis and monitoring treatment response in AIDS patients with tuberculous meningitis. Scarpellini P, et al. **AIDS** 1995 Aug; 9(8):895–900

Radiologic-pathologic correlation. Cerebral toxoplasmosis and lymphoma in AIDS. Chang L, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1653–63

A rapid and inexpensive method for processing induced sputum for detection of Pneumocystis carinii. Rocha P, et al. **Am J Clin Pathol** 1996 Jan;105(1):52–7

Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration [see comments] Wilcox CM, et al. **Am J Gastroenterol** 1995 Nov;90(11):1938–41. Comment in: Am J Gastroenterol 1995 Nov;90(11):1914–5.

Isolated despite negative sputum TB tests. Petrec CA. **Am J Nurs** 1996 Jun;96(6):20

Diagnosis of microsporidial keratitis by confocal microscopy and the chromatrope stain. Shah GK, et al. **Am J Ophthalmol** 1996 Jan;121(1):89–91

Empiric diagnosis of Pneumocystis carinii pneumonia. Questions of accuracy and equity [editorial; comment] Glassroth J. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1433–4. Comment on: Am J Respir Crit Care Med 1995 Nov;152(5 Pt 1):1435–42.

Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia [see comments] Horner RD, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1435–42 . Comment in: Am J Respir Crit Care Med 1995 Nov;152(t Pt 1):1433–4.

Clinical and chest radiographic features of tuberculosis associated with human immunodeficiency virus in Zimbabwe. Pozniak AL, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1558–61

Microsporidia in humans [letter] Berg J, et al. **Ann Intern Med** 1996 Sep 15;125(6):522–3

Colonic bacillary angiomatosis. Huh YB, et al. **Ann Intern Med** 1996 Apr 15;124(8):735–7

Pulmonary complications of HIV infection. Murray JF. **Annu Rev Med** 1996;47:117–26 (30 ref.)

Acquired immunodeficiency syndrome--associated herpes simplex virus retinitis. Clinical description and use of a polymerase chain reaction--based assay as a diagnostic tool. Cunningham ET Jr, et al. **Arch Ophthalmol** 1996 Jul; 114(7):834–40

Effectiveness of entoptic perimetry for locating peripheral scotomas caused by cytomegalovirus retinitis. Plummer DJ, et al. **Arch Ophthalmol** 1996 Jul;114(7):828–31

Cytomegalovirus sinusitis. A new manifestation of AIDS. Marks SC, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):789–91 (11 ref.)

Effect of leukocyte concentration and inoculum volume on the laboratory identification of cytomegalovirus in peripheral blood by the centrifugation culture-antigen detection methodology. Lipson SM, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):53–6

Imaging methods as a diagnostic tool in neuro-AIDS. A review. Arendt G. **Bildgebung** 1995 Dec;62(4):310–9 (51 ref.)

HIV antibody test should be a routine investigation for undiagnosed pneumonia [letter] Scott GM. **BMJ** 1996 May 25;312(7042):1363

Herpes simplex virus infection masquerading as condyloma acuminata in a patient with HIV disease. Tong P, et al. **Br J Dermatol** 1996 Apr;134(4):797–800

Diagnostic assays in cytomegalovirus retinitis: detection of herpesvirus by simultaneous application of the polymerase chain reaction and local antibody analysis on ocular fluid [see comments] Doornenbal P, et al. **Br J Ophthalmol** 1996 Mar;80(3):235–40. Comment in: Br J Ophthalmol 1996 Mar;80(3):195–6.

Pulmonary botryomycosis in a patient with AIDS. Katapadi K, et al. **Chest** 1996 Jan;109(1):276–8

Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin. Falagas ME, et al. **Clin Infect Dis** 1996 May;22(5):809–12

Unusual presentation of cryptococcosis in a patient with AIDS. Finazzi R, et al. **Clin Infect Dis** 1996 Apr;22(4):709

Failure of the radiometric Bactec method to detect Mycobacterium avium complex in the blood of patients infected with human immunodeficiency virus who were treated with antibiotics. Lebrun L, et al. **Clin Infect Dis** 1995 Nov;21(5):1343–4

Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Meyohas MC, et al. **Clin Infect Dis** 1995 Sep;21(3):628–33

Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus: clinical characteristics in a case-control study. Mohle-Boetani JC, et al. **Clin Infect Dis** 1996 May;22(5):794–800

Atypical leishmaniasis in a patient infected with human immunodeficiency virus. Mondain-Miton V, et al. **Clin Infect Dis** 1995 Sep;21(3):663–5

AIDS-associated cytomegalovirus infection mimicking central nervous system tumors: a diagnostic challenge. Moulignier A, et al. **Clin Infect Dis** 1996 Apr;22(4):626–31

Bacillary angiomatosis and parenchymal peliosis: frequent absence of mucocutaneous lesions [editorial] Schwartzman WA. **Clin Infect Dis** 1996 May;22(5):801–2 (14 ref.)

Pulsatile chest wall swelling due to tubercular mediastinal lymphadenopathy in a patient with human immunodeficiency virus infection and syphilis. Sharma SK, et al. **Clin Infect Dis** 1996 May;22(5):871–2

Cyclospora cayetanensis infection in patients with and without AIDS: biliary disease as another clinical manifestation. Sifuentes-Osornio J, et al. **Clin Infect Dis** 1995 Nov;21(5):1092–7

Herpes zoster as the initial presentation of human immunodeficiency virus type 1 infection in Kenya. Tyndall MW, et al. **Clin Infect Dis** 1995 Oct;21(4):1035–7

Radiologic and laboratory evaluation of enhancing brain lesions in patients with AIDS. Johnson MD, et al. **Compr Ther** 1995 Nov;21(11):645–52 (45 ref.)

Neurologic opportunistic infections. Clifford DB. **Curr Opin Neurol** 1995 Jun;8(3):175–8 (32 ref.)

Progressive multifocal leukoencephalopathy: clinical and laboratory observations on a viral induced demyelinating disease in the immunodeficient patient. Major EO, et al. **Curr Opin Neurol** 1995 Jun;8(3):184–90 (58 ref.)

Botryomycosis in a patient with acquired immunodeficiency syndrome. Salvemini JN, et al. **Cutis** 1995 Sep;56(3):158–60

Bronchoalveolar lavage for the diagnosis of disseminated toxoplasmosis in AIDS patients. Gadea I, et al. **Diagn Microbiol Infect Dis** 1995 Aug;22(4):339–41

Unusual cause of fever and diarrhea in a patient with AIDS. Penicillium marneffei infection. Leung R, et al. **Dig Dis Sci** 1996 Jun;41(6):1212–5

Presumptive clinical criteria versus endoscopy in the diagnosis of Candida esophagitis at various HIV-1 disease stages. Antinori A, et al. **Endoscopy** 1995 Jun;27(5):371–6

Diagnosis of Toxoplasma gondii infection in AIDS patients by a tissue-culture technique. Contini C, et al. **Eur J Clin Microbiol Infect Dis** 1995 May;14(5):434–40

Role of antigenemia assay in the early diagnosis and prediction of human cytomegalovirus organ involvement in AIDS patients. Francisci D, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):498–503

Toxoplasma gondii surface antigen-1 in sera of HIV-infected patients as an indicator of reactivated toxoplasmosis. Letillois MF, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):899–903

Cost-analysis of four diagnostic strategies for Pneumocystis carinii pneumonia in HIV-infected subjects. Chouaid C, et al. **Eur Respir J** 1995 Sep;8(9):1554–8

Serological diagnosis of tuberculosis. Bothamley GH. **Eur Respir J Suppl** 1995 Sep;20:676s–688s (114 ref.)

Molecular diagnosis of tuberculosis. Richeldi L, et al. **Eur Respir J Suppl** 1995 Sep;20:689s–700s (95 ref.)

Septata intestinalis and Encephalitozoon cuniculi: cross-reactivity between two microsporidian species. Schottelius J, et al. **Folia Parasitol (Praha)** 1995; 42(3):169–72

Natural history and prognosis of diarrhea of unknown cause in patients with acquired immunodeficiency syndrome (AIDS). Fennerty MB. **Gastrointest Endosc** 1995 Nov; 42(5):496

A technique to examine the underlying mucosa in patients with AIDS and severe Candida esophagitis. Wilcox CM. **Gastrointest Endosc** 1995 Oct;42(4):360–3

Faecal alpha 1 antitrypsin as a marker of gastrointestinal disease in HIV antibody positive individuals. Sharpstone D, et al. **Gut** 1996 Feb;38(2):206–10

A man with "shrub leg". DeMasi R, et al. **Hosp Pract (Off Ed)** 1996 Jan 15;31(1):58–9

Bone marrow involvement by disseminated toxoplasmosis in acquired immunodeficiency syndrome: the value of bone marrow trephine biopsy and immunohistochemistry for the diagnosis. Brouland JP, et al. **Hum Pathol** 1996 Mar; 27(3):302–6

Intra-abdominal tuberculosis in acquired immunodeficiency syndrome. Diagnosis and management. Schanaider A, et al. **Int Surg** 1995 Apr-Jun;80(2):147–51

Detection of Pneumocystis carinii, Mycobacterium tuberculosis, and cytomegalovirus in human immunodeficiency virus (HIV)-infected patients with hemophilia by polymerase chain reaction of induced sputum samples. Shimomoto H, et al. **Intern Med** 1995 Oct; 34(10):976–81

CMV-antigenemia in peripheral blood for the diagnosis of CMV disease in HIV-infected patients. Salzberger B, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 1;11(4):365–9

Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV + patients with and without CMV disease. Wetherill PE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):33–7

Leishmaniasis presenting as a dermatomyositis-like eruption in AIDS. Daudén E, et al. **J Am Acad Dermatol** 1996 Aug; 35(2 Pt 2):316–9

Bacillus piliformis infection (Tyzzer's disease) in a patient infected with HIV-1: confirmation with 16S ribosomal RNA sequence analysis. Smith KJ, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):343–8 (18 ref.)

Kaposi's sarcoma versus bacillary angiomatosis. Caldwell BD, et al. **J Am Podiatr Med Assoc** 1996 Jun;86(6):260–2

Clinical and laboratory features of cryptococcal meningitis in HIV-AIDS patients [letter] Deo S. **J Assoc Physicians India** 1995 Oct;43(10):724

Rapid and fatal neurologic deterioration due to central nervous system Candida infection in an HIV-1-infected child. McAbee G, et al. **J Child Neurol** 1995 Sep; 10(5):405–7

High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. Bek B, et al. **J Clin Microbiol** 1996 Feb;34(2):457–9

Use of a multiplex PCR to detect and identify Mycobacterium avium and M. intracellulare in blood culture fluids of AIDS patients [letter; comment] Cormican MG, et al. **J Clin Microbiol** 1995 Aug;33(8):2230. Comment on: J Clin Microbiol 1995 Mar;33(3):668–74.

Improved detection of JC virus DNA in cerebrospinal fluid for diagnosis of AIDS-related progressive multifocal leukoencephalopathy. de Luca A, et al. **J Clin Microbiol** 1996 May;34(5):1343–6

Diagnosis of disseminated microsporidian Encephalitozoon hellem infection by PCR-Southern analysis and successful treatment with albendazole and fumagillin. Didier ES, et al. **J Clin Microbiol** 1996 Apr;34(4):947–52

Tissue diagnosis of intestinal microsporidiosis using a fluorescent stain with Uvitex 2B. Franzen C, et al. **J Clin Pathol** 1995 Nov;48(11):1009–10

Detection by PCR of Toxoplasma gondii in blood in the diagnosis of cerebral toxoplasmosis in patients with AIDS. Lamoril J, et al. **J Clin Pathol** 1996 Jan;49(1):89–92

Problems in the diagnosis of AIDS related cryptococcal meningitis: a case report. Mani RK, et al. **J Commun Dis** 1995 Jun;27(2):112–7

Health insurance and utilization in Pneumocystis carinii pneumonia. Loue S, et al. **J Gen Intern Med** 1995 Aug; 10(8):461–3

Bacillary angiomatosis mimicking pyogenic granuloma in the hand: a case report. Bastug DF, et al. **J Hand Surg [Am]** 1996 Mar;21(2):307–8

Diagnosis of Pneumocystis carinii pneumonia in AIDS patients by using polymerase chain reactions on serum specimens. Atzori C, et al. **J Infect Dis** 1995 Dec; 172(6):1623–6

Microsporidium: modified technique for light microscopic diagnosis. Punpoowong B, et al. **J Med Assoc Thai** 1995 May;78(5):251–4

Salmonella lung abscess and bacteraemia in an AIDS patient. Riantawan P, et al. **J Med Assoc Thai** 1996 May;79(5):333–6

Limited value of cerebrospinal fluid for direct detection of Toxoplasma gondii in toxoplasmic encephalitis associated with AIDS. Eggers C, et al. **J Neurol** 1995 Oct; 242(10):644–9

Adenovirus masquerading as microsporidia. Visvesvara GS, et al. **J Parasitol** 1996 Apr;82(2):316–9

Presumed Pott's disease [letter] Jellis J, et al. **Lancet** 1996 Feb 17;347(8999):476–7

Pneumocystis carinii pneumonia in Zimbabwe [see comments] Malin AS, et al. **Lancet** 1995 Nov 11; 346(8985):1258–61. Comment in: Lancet 1995 Nov 11;346(8985):1242–3. Comment in: Lancet 1996 Jan 13;347(8994):126; discussion 126–7.

Pneumocystis carinii in Africa: an emerging pathogen? [comment] Russian DA, et al. **Lancet** 1995 Nov 11; 346(8985):1242–3. Comment on: Lancet 1995 Nov 11;346(8985):1258–61.

Dementia in a 58-year-old woman [see comments] Sellal F, et al. **Lancet** 1996 Jan 27;347(8996):236. Comment in: Lancet 1996 Mar 16;347(9003):769–70.

Correlation of Pneumocystis carinii PCR with clinical diagnosis in immunocompromised patients [letter] Weig M, et al. **Lancet** 1996 May 4;347(9010):1266

AIDS and the lung. Huang L, et al. **Med Clin North Am** 1996 Jul;80(4):775–801 (114 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.5 HIV and opportunistic neurological infections. Jones PD, et al. **Med J Aust** 1996 Apr 1;164(7):418–21 (22 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.7 HIV and respiratory disease. Smith AI, et al. **Med J Aust** 1996 Apr 1;164(7):425–8 (33 ref.)

Variable efficiency of three primer pairs for the diagnosis of Pneumocystis carinii pneumonia by the polymerase chain reaction. De Luca A, et al. **Mol Cell Probes** 1995 Oct; 9(5):333–40

The lung in HIV infection: can pulmonary function testing help? Mitchell DM, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):214–22 (30 ref.)

Ophthalmologic manifestations of acquired immune deficiency syndrome-associated progressive multifocal leukoencephalopathy. Ormerod LD, et al. **Ophthalmology** 1996 Jun;103(6):899–906

Oral Mycobacterium avium complex infection in a patient with HIV-related disease. A case report. Robinson P, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):177–9

HIV-related Pneumocystis carinii thyroiditis: a unique case and literature review. Danahey DG, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):158–61 (15 ref.)

Bacillary angiomatosis presenting as a nasal mass with epistaxis. Vickery CL, et al. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):443–6

Toxoplasmosis diagnosis in pregnant women infected with human immunodeficiency virus I [letter] Hassl A, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):1016–7

Polymerase chain reaction is more sensitive than standard cytologic stains in detecting Pneumocystis carinii in bronchoalveolar lavages from human immunodeficiency virus type 1-infected infants and children with pneumonia. Leibovitz E, et al. **Pediatr Infect Dis J** 1995 Aug; 14(8):714–6

Detection of IgM antibodies to human herpesvirus 6 in Romanian children with nonprogressive human immunodeficiency virus disease. Nigro G, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):891–4

Disseminated Penicillium marneffei infection in human immunodeficiency virus-infected children. Sirisanthana V, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):935–40

Sinusitis caused by Mycobacterium avium-intracellulare in a patient with human immunodeficiency virus [letter] Sussman SJ. **Pediatr Infect Dis J** 1995 Aug;14(8):726–7

Clinical and radiological approach of pulmonary diseases in HIV infection in children. Dollfus C, et al. **Pediatr Pulmonol Suppl** 1995;11:5–6

Assessment of fever in HIV-infected patients. Gleckman R, et al. **Postgrad Med** 1996 Mar;99(3):78–80, 87–9, 93–4 passim (37 ref.)

Use of polyclonal IgG in HIV infection and AIDS. Buscombe JR, et al. **Q J Nucl Med** 1995 Sep;39(3):212–20 (34 ref.)

Screening for cytomegalovirus retinitis in HIV-positive and AIDS patients. Sandy CJ, et al. **QJM** 1995 Dec; 88(12):899–903

Radiology's role in diagnosis of AIDS-related pathologies. Vedda RA. **Radiol Technol** 1995 Jul–Aug;66(6):365–9; quiz 370–2 (25 ref.)

Toxoplasmosis and primary central nervous system lymphoma in HIV infection: diagnosis with MR spectroscopy. Chinn RJ, et al. **Radiology** 1995 Dec; 197(3):649–54

Pneumocystic infections: the radiologist's perspective. Kuhlman JE. **Radiology** 1996 Mar;198(3):623–35 (96 ref.)

Usefulness of the detection of Toxoplasma gondii antigens in AIDS patients. Fachado A, et al. **Rev Inst Med Trop Sao Paulo** 1994 Nov–Dec;36(6):525–9

Bacillary angiomatosis—another South African case [letter] Burgin S, et al. **S Afr Med J** 1996 Jan;86(1):95–6

HIV-related tuberculosis in South Africa—clinical features and outcome. Wilkinson D, et al. **S Afr Med J** 1996 Jan; 86(1):64–7

An unusual gastrointestinal presentation of leishmaniasis. McBride MO, et al. **Scand J Infect Dis** 1995;27(3):297–8

Pneumocystis carinii in bronchoalveolar lavage and induced sputum: detection with a nested polymerase chain reaction. Skøt J, et al. **Scand J Infect Dis** 1995;27(4):363–7

CMV PCR in leucocytes as an early marker for the development of CMV disease in AIDS patients. Quarner H, et al. **Scand J Infect Dis Suppl** 1995;99:94–5

Seminal vesicle abscess: a case report and review of literature. Pandey P, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):521–4 (14 ref.)

Invasive strongyloidiasis [letter] Arya SC. **Trop Geogr Med** 1995;47(6):310

Preliminary evaluation of a Mycobacterium tuberculosis lipooligosaccharide (LOS) antigen in the serological diagnosis of tuberculosis in HIV seropositive and seronegative patients. Daleine G, et al. **Tuber Lung Dis** 1995 Jun;76(3):234–9

Polymerase chain reaction for non-invasive diagnosis of brain mass lesions caused by Mycobacterium tuberculosis: report of five cases in human immunodeficiency virus-positive subjects. Monno L, et al. **Tuber Lung Dis** 1996 Jun; 77(3):280–4

Pulmonary tuberculosis in Guinea-Bissau: clinical and bacteriological findings, human immunodeficiency virus status and short term survival of hospitalized patients. Nauclér A, et al. **Tuber Lung Dis** 1996 Jun;77(3):226–32

Pulmonary Nocardiosis in a patient with human immunodeficiency virus disease. Barrow KO, et al. **West Indian Med J** 1996 Jun;45(2):63–4

Neurology of human immunodeficiency virus infection—past, present, and future. Jay C. **West J Med** 1995 Nov;163(5):470–1

[Value of the stool bacteriological test in Mycobacterium avium complex infections in AIDS] Bevilacqua S, et al. **Ann Med Interne (Paris)** 1995;146(7):496–9 (Eng. Abstr.) **(Fre)**

[Aids and chorioretinal opportunistic infections] De Munck J, et al. **Bull Soc Belge Ophtalmol** 1995;255:115–22 (Eng. Abstr.) **(Fre)**

[CMV and VZV encephalitis in AIDS] Hassine D, et al. **J Neuroradiol** 1995 Sep;22(3):184–92 (Eng. Abstr.) **(Fre)**

[Cerebral toxoplasmosis. Neuroradiologic diagnosis and prognostic monitoring] Martin-Duverneuil N, et al. **J Neuroradiol** 1995 Sep;22(3):196–203 (28 ref.) (Eng. Abstr.) **(Fre)**

[Cerebral arteritis in AIDS. Demonstration with MRA in 2 patients] Brunereau L, et al. **J Radiol** 1996 May; 77(5):367–71 (Eng. Abstr.) **(Fre)**

[Induced expectoration: its role in the diagnosis of pneumocystis carinii pneumonia] Cabié A, et al. **Presse Med** 1995 Jul 1–8;24(24):1119–20 (Eng. Abstr.) **(Fre)**

[Absence of regular medical follow-up: main cause of pneumocystosis diagnosed in patients with HIV infection in France in 1992 (letter)] Pradier C, et al. **Presse Med** 1995 Nov 11;24(34):1623 **(Fre)**

[Retrospective evaluation of the detection of Toxoplasma gondii by polymerase chain reaction in AIDS patients] Robert F, et al. **Presse Med** 1996 Mar 30;25(11):541–5 (Eng. Abstr.) **(Fre)**

[Diagnostic strategies of pulmonary pneumocystis infection in patients with HIV infection. Decision analysis and medico-economic consequences] Chouaid C, et al. **Rev Mal Respir** 1996 Jul;13(3):265–72 (Eng. Abstr.) **(Fre)**

[Bacteriological diagnosis of tuberculosis: current hieratic classification of methods] Carbonnelle B, et al. **Rev Med Interne** 1995;16(7):518–23 (45 ref.) (Eng. Abstr.) **(Fre)**

[Leishmaniasis: new diagnostic approaches] Robert F. **Sante** 1995 Jul–Aug;5(4):262 **(Fre)**

[Endoscopy of the upper gastrointestinal tract in HIV disease] Caca K, et al. **Bildgebung** 1995 Dec;62(4):244–51 (56 ref.) (Eng. Abstr.) **(Ger)**

[HIV infections in Germany (editorial)] Goebel FD. **Bildgebung** 1995 Dec;62(4):242–3 **(Ger)**

[HIV infection: findings in liver and bile ducts] Jablonowski H. **Bildgebung** 1995 Dec;62(4):260–70 (89 ref.) (Eng. Abstr.) **(Ger)**

[HIV infection and the lower gastrointestinal tract—characteristics of endoscopic diagnosis] Mauss S, et al. **Bildgebung** 1995 Dec;62(4):252–8 (46 ref.) (Eng. Abstr.) **(Ger)**

[AIDS: infections of the retina and choroid] Schimkat M, et al. **Bildgebung** 1995 Dec;62(4):288–301 (100 ref.) (Eng. Abstr.) **(Ger)**

[Generalized molluscum contagiosum in an African child with AIDS] Harms G, et al. **Hautarzt** 1995 Nov; 46(11):799–803 (Eng. Abstr.) **(Ger)**

[Clinical aspects and therapy of ubiquitous mycobacterioses] Fätkenheuer G, et al. **Internist (Berl)** 1995 Oct; 36(10):987–94 (52 ref.) **(Ger)**

[Clinical aspects and therapy of tuberculosis] Höffken G, et al. **Internist (Berl)** 1995 Oct;36(10):961–9 (61 ref.) **(Ger)**

[Young man with swelling of the left side of the neck and right testis] Jakob AR, et al. **Internist (Berl)** 1995 Nov; 36(11):1080–4 **(Ger)**

[Information from the American Academy of Ophthalmology: how AIDS affects the eye (news)] **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):aA7 **(Ger)**

[Increased possibility for HIV-associated retinal microangiopathy syndrome in patients with concomitant hepatitis C infection] Thierfelder S, et al. **Klin Monatsbl Augenheilkd** 1996 Mar;208(3):157–60 (Eng. Abstr.) **(Ger)**

[Toxic shock syndrome in AIDS] Klinker H, et al. **Med Klin** 1995 Dec 15;90(12):725–9 **(Ger)**

[Diagnostic value of protected bronchoalveolar lavage in HIV-associated pneumonia] Ewig S, et al. **Pneumologie** 1995 Oct;49(10):546–55 (Eng. Abstr.) **(Ger)**

[Tuberculous anal fistula in acquired immunologic deficiency syndrome] Musch E, et al. **Z Gastroenterol** 1995 Aug; 33(8):440–4 (Eng. Abstr.) **(Ger)**

[Magnetic resonance in AIDS-related encephalopathy] Gualdi GF, et al. **Clin Ter** 1995 Dec;146(12):843–56 (42 ref.) (Eng. Abstr.) **(Ita)**

[The influence of HIV infection on development of tuberculosis] Kwiatkowska S. **Pol Arch Med Wewn** 1995 May;93(5):421–6 (39 ref.) **(Pol)**

[Cerebral toxoplasmosis in AIDS patients, CT and MRI images and differential diagnostic problems] Miguel J, et al. **Acta Med Port** 1996 Jan;9(1):29–36 (Eng. Abstr.) **(Por)**

[Facial and cervical manifestations of AIDS] Gebrim EM, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul–Aug; 50(4):222–6 (22 ref.) (Eng. Abstr.) **(Por)**

[Exudative uveitis, chronic labial herpes and interstitial pneumonia in an HIV-positive child] Popa GC. **Oftalmologia** 1996 Jan–Mar;40(1):35–8 (Eng. Abstr.) **(Rum)**

[The current problems of the laboratory diagnosis of AIDS-related infections and infestations] Lysenko AIa. **Klin Lab Diagn** 1995 Nov–Dec;(6):110–3 **(Rus)**

[Applications of the polymerase chain reaction (PCR) to the diagnosis of central nervous system infections] Querol JM, et al. **An Med Interna** 1996 May;13(5):235–8 (20 ref.) (Eng. Abstr.) **(Spa)**

[The clinical characteristics of pleural tuberculosis in patients with and without human immunodeficiency virus infection] Cordero PJ, et al. **Arch Bronconeumol** 1995 Dec; 31(10):512–8 (Eng. Abstr.) **(Spa)**

[Hospital pneumonia due to Xanthomonas maltophilia and AIDS (letter)] Sitges M, et al. **Arch Bronconeumol** 1996 May;32(5):259–60 (6 ref.) **(Spa)**

[Hepatosplenic cryptococcosis, an infrequent cause of fever of unknown origin in AIDS (letter)] Bascuñana A, et al. **Rev Clin Esp** 1995 Dec;195(12):885–6 **(Spa)**

DRUG THERAPY

Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections. Jacobson MA. **Adv Exp Med Biol** 1996;394:85–92 (28 ref.)

Metronidazole treatment in a patient with AIDS and visceral leishmaniasis [letter] Arranz-Caso JA, et al. **AIDS** 1995 Dec;9(12):1377–8

Sorivudine (BV-ara-U) for the treatment of complicated refractory varicella zoster virus infection in HIV-infected patients [letter] Burdge DR, et al. **AIDS** 1995 Jul;9(7):810–2

Endophthalmitis as a complication of intravitreal treatment for cytomegalovirus retinitis [letter] Collazos J, et al. **AIDS** 1995 Aug;9(8):980–1

Fluconazole-resistant oral candidosis in HIV-infected patients [letter; comment] Diz Dios P, et al. **AIDS** 1995 Jul;9(7):809–10. Comment on: AIDS 1994 Jun;8(6):787–92. Comment on: AIDS 1994 Jul;8(7):945–50.

Failure of atovaquone in the treatment of cerebral toxoplasmosis [letter] Durand JM, et al. **AIDS** 1995 Jul; 9(7):812–3

Progressive multifocal leucoencephalopathy in AIDS: treatment with cytosine arabinoside [letter] Guarino M, et al. **AIDS** 1995 Jul;9(7):819–20

Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. Kassim S, et al. **AIDS** 1995 Oct;9(10):1185–91

Clindamycin desensitization in an AIDS patient [letter] Marcos C, et al. **AIDS** 1995 Oct;9(10):1201–2

Steroids do not enhance the risk of developing tuberculosis or other AIDS-related diseases in HIV-infected patients treated for Pneumocystis carinii pneumonia. Martos A, et al. **AIDS** 1995 Sep;9(9):1037–41

Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma. Uthayakumar S, et al. **AIDS** 1996 May; 10(5):515–9

Cytomegalovirus retinitis in AIDS: natural history, diagnosis, and treatment. Dunn JP, et al. **AIDS Clin Rev** 1995–96; :99–129 (120 ref.)

Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS. Laine L, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):553–6

Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients [see comments] Ozick LA, et al. **Am J Gastroenterol** 1995 Nov;90(11):1978–80. Comment in: Am J Gastroenterol 1996 Jul;91(7):1471–2.

Home infusion of antimicrobials as an option for patients with AIDS [letter] Laing RB, et al. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2467–8

Prospective trial of paromomycin for cryptosporidiosis in AIDS. Flanigan TP, et al. **Am J Med** 1996 Mar; 100(3):370–2

Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. Desatnik HR, et al. **Am J Ophthalmol** 1996 Jul; 122(1):121–3

Directly observed therapy for tuberculosis: the Harlem Hospital experience, 1993. el-Sadr W, et al. **Am J Public Health** 1996 Aug;86(8 Pt 1):1146–9

Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Lutfey M, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):837–40

Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. The Makerere University-Case Western Reserve University Research Collaboration. Whalen C, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1977–81

Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection. Belchi-Hernandez J, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):355–8

Treatment of cytomegalovirus retinitis in patients with AIDS [editorial; comment] Jabs DA. **Ann Intern Med** 1996 Jul 15;125(2):144–5. Comment on: Ann Intern Med 1996 Jul 15;125(2):98–103. Comment on: Ann Intern Med 1996 Jul 15;125(2):126–36.

Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report [see comments] Rahhal FM, et al. **Ann Intern Med** 1996 Jul 15;125(2):98–103. Comment in: Ann Intern Med 1996 Jul 15;125(2):144–5.

Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Safrin S, et al. **Ann Intern Med** 1996 May 1;124(9):792–802

Therapeutic approaches for AIDS-related toxoplasmosis [see comments] Behbahani R, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):760–8 (52 ref.). Comment in: Ann Pharmacother 1995 Dec;29(12):1303–4.

Sulfadiazine-induced multiple uroiithiasis and acute renal failure in a patient with AIDS and Toxoplasma encephalitis. Diaz F, et al. **Ann Pharmacother** 1996 Jan; 30(1):41–2

Topical fumagillin in the treatment of microsporidial keratoconjunctivitis in AIDS. Garvey MJ, et al. **Ann Pharmacother** 1995 Sep;29(9):872–4

Acute pancreatitis associated with sodium stibogluconate treatment in a patient with human immunodeficiency virus [letter] Domingo P, et al. **Arch Intern Med** 1996 May 13; 156(9):1029, 1032

Clinical vs photographic assessment of treatment of cytomegalovirus retinitis. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial Report 8. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. **Arch Ophthalmol** 1996 Jul;114(7):848–55

Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. **Arch Ophthalmol** 1996 Jan; 114(1):23–33

Serous retinal detachments in a patient with clinically resistant cytomegalovirus retinitis. Dodds EM, et al. **Arch Ophthalmol** 1996 Jul;114(7):896–7

Long-term, successful maintenance of bilateral cytomegalovirus retinitis using exclusively local therapy [letter] Duker JS, et al. **Arch Ophthalmol** 1996 Jul; 114(7):881–2

Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Marx JL, et al. **Arch Ophthalmol** 1996 Jul;114(7):815–20

Endogenous bacterial endophthalmitis as a complication of intravenous therapy for cytomegalovirus retinopathy [letter] Tufail A, et al. **Arch Ophthalmol** 1996 Jul; 114(7):879–80

Sustained-release intravitreal ganciclovir pellets in the treatment of cytomegalovirus retinitis in the acquired immunodeficiency syndrome [letter] Luckie A, et al. **Aust N Z J Ophthalmol** 1995 May;23(2):157–8

Cimetidine for mucosal warts in an HIV positive adult. Wargon O. **Australas J Dermatol** 1996 Aug;37(3):149–50

The use of oral ganciclovir in the treatment of cytomegalovirus retinitis in patients with AIDS. Ward-Able C, et al. **Can Med Assoc J** 1996 Feb 1; 154(3):363–8

The safety of i.v. pentamidine administered in an ambulatory setting. Yeung KT, et al. **Chest** 1996 Jul;110(1):136–40

Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis. Caumes E, et al.
Clin Infect Dis 1995 Sep;21(3):656–8

Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses over a relatively short period [letter; comment] Churchill D, et al. **Clin Infect Dis** 1995 Nov;21(5):1352–3. Comment on: Clin Infect Dis 1995 Feb;20(2):263–6.

Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS. Dautzenberg B, et al.
Clin Infect Dis 1996 Apr;22(4):705–8

Foscarnet-resistant multidermatomal zoster in a patient with AIDS. Fillet AM, et al. **Clin Infect Dis** 1995 Nov; 21(5):1348–9

Clarithromycin-induced digoxin toxicity in a patient with AIDS. Ford A, et al. **Clin Infect Dis** 1995 Oct;21(4):1051–2

Use of rifabutin in the treatment of pulmonary tuberculosis. Grassi C, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S50–4 (21 ref.)

Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus [letter] Laguna F, et al. **Clin Infect Dis** 1995 Sep;21(3):711–2

Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate [letter; comment] McBride MO, et al. **Clin Infect Dis** 1995 Sep;21(3):710. Comment on: Clin Infect Dis 1994 Jan;18(1):83–90.

Mycobacterium genavense infection in a patient with AIDS who was successfully treated with clarithromycin [letter] Matsiota-Bernard P, et al. **Clin Infect Dis** 1995 Jun; 20(6):1565–6

High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Menichetti F, et al.
Clin Infect Dis 1996 May;22(5):838–40

Mycobacterium avium complex infection, rifabutin, and uveitis—is there a connection? Nichols CW.
Clin Infect Dis 1996 Apr;22 Suppl 1:S43–7; discussion S47–9 (21 ref.)

Clarithromycin-induced mania in two patients with AIDS. Nightingale SD, et al. **Clin Infect Dis** 1995 Jun;20(6):1563–4

Recent advances in the management of cryptococcal meningitis in patients with AIDS. Powderly WG.
Clin Infect Dis 1996 May;22 Suppl 2:S119–23 (32 ref.)

Use of an Itraconazole/allopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS. Raffi F, et al. **Clin Infect Dis** 1995 Nov;21(5):1338–9

Predictors and outcome of multidrug-resistant tuberculosis. Salomon N, et al. **Clin Infect Dis** 1995 Nov;21(5):1245–52

Pentamidine concentrations in a mother with AIDS and in her neonate [letter] Schwebke K, et al. **Clin Infect Dis** 1995 Jun;20(6):1569–70

Rifabutin prophylaxis for Mycobacterium avium complex infection in patients with AIDS. Siegal FP.
Clin Infect Dis 1996 Apr;22 Suppl 1:S23–30; discussion S30–2 (38 ref.)

Cryptococcosis in the era of AIDS—100 years after the discovery of Cryptococcus neoformans. Mitchell TG, et al. **Clin Microbiol Rev** 1995 Oct;8(4):515–48 (529 ref.)

Effects on pulmonary function of two regimens of chemotherapy for AIDS related Kaposi's sarcoma. Denton AS, et al. **Clin Oncol (R Coll Radiol)** 1996;8(1):48–50

Cutaneous Acanthamoeba infection in the acquired immunodeficiency syndrome: response to multidrug therapy. Hunt SJ, et al. **Cutis** 1995 Nov;56(5):285–7

Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Spencer CM, et al. **Drugs** 1995 Jul;50(1):176–96 (64 ref.)

Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study. Barbaro G, et al. **Endoscopy** 1995 Jun;27(5):377–83

Drug resistance in Mycobacterium tuberculosis. Cole ST, et al. **Eur Respir J Suppl** 1995 Sep;20:701s–713s (116 ref.)

Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir. Jabs DA.
Infect Agents Dis 1995 Sep;4(3):131–42 (63 ref.)

Chemotherapy for AIDS-related and endemic African Kaposi's sarcoma in southern Africa. Stein ME, et al.
Int J Dermatol 1995 Oct;34(10):729–32

Benefit of oral zinc supplementation as an adjunct to zidovudine (AZT) therapy against opportunistic infections in AIDS. Mocchegiani E, et al. **Int J Immunopharmacol** 1995 Sep;17(9):719–27

Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Birley HD, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):353–5

Management of cytomegalovirus infection. The Jefferiss Wing Therapeutics and Protocols Group. Fisher M, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):313–9 (28 ref.)

Azithromycin in the management of opportunistic infections. Young LS. **Int J STD AIDS** 1996;7 Suppl 1:17

Comparison of therapeutic activity of fluconazole and itraconazole in the treatment of oesophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Barbaro G, et al. **Ital J Gastroenterol** 1995 May;27(4):175–80

Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. Kessler HA, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jun 1;12(2):147–52

Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals. Sin DD, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Aug 15;12(5):477–81

Treatment of AIDS and HIV-related conditions--1996. Goldschmidt RH, et al. **J Am Board Fam Pract** 1996 Mar-Apr;9(2):125–48 (88 ref.)

Relative growth measurement of Candida species in a single concentration of fluconazole predicts the clinical response to fluconazole in HIV infected patients with oral candidosis. Cartledge JD, et al. **J Antimicrob Chemother** 1996 Feb;37(2):275–83

Azole drug resistance in yeasts. Johnson EM, et al.
J Antimicrob Chemother 1995 Nov;36(5):751–5

Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV. St-Germain G, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):109–18

Pneumatoceles in pneumocystic carinii pneumonia of AIDS and low dose trimethoprim-sulphamethoxazole therapy. Rosha D, et al. **J Assoc Physicians India** 1995 Sep; 43(9):635–7

Diagnosis of disseminated microsporidian Encephalitozoon hellem infection by PCR-Southern analysis and successful treatment with albendazole and fumagillin. Didier ES, et al. **J Clin Microbiol** 1996 Apr;34(4):947–52

Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). Russo R, et al. **J Infect** 1996 Mar;32(2):133–7

Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. Maenza JR, et al. **J Infect Dis** 1996 Jan;173(1):219–25

Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. Hicks P, et al. **J Pediatr** 1996 Aug;129(2):297–300

Therapy for cytomegalovirus retinitis: still no silver lining [editorial; comment] Young LH. **JAMA** 1996 Jan 10; 275(2):149–50. Comment on: JAMA 1996 Jan 10;275(2):142–4.

How to treat bacteraemic Mycobacterium avium complex disease. Chin DP, et al. **Lancet** 1995 Oct 7;346(8980):920–1

Intraocular device for cytomegalovirus infection. Ernest JT.
Lancet 1995 Oct 14;346(8981):983–4

An HIV-1-positive child with fever and a scalp nodule. Malane MS, et al. **Lancet** 1995 Dec 2;346(8988):1466

Managing HIV. Part 5: Treating secondary outcomes. 5.16 HIV and bacterial infections. Allworth AM, et al.
Med J Aust 1996 May 6;164(9):546–8 (5 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.15 HIV and non-tuberculous mycobacterial infection. Hoy JF, et al. **Med J Aust** 1996 May 6;164(9):543–5 (29 ref.)

Drugs for AIDS and associated infections.
Med Lett Drugs Ther 1995 Oct 13;37(959):87–94

Management of HIV infection. A 1995-96 overview for the clinician. Henry K. **Minn Med** 1995 Nov;78(11):17–24 (25 ref.)

Port-a-cath-related Fusarium oxysporum infection in an HIV-infected patient: treatment with liposomal amphotericin B. Eljaschewitsch J, et al. **Mycoses** 1996 Mar-Apr;39(3-4):115–9

Megaloblastic cytopenia in an AIDS patient treated with trimethoprim-sulfamethoxazole. Shami PJ, et al.
N C Med J 1995 Dec;56(12):602–4

Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. Bishai WR, et al.
N Engl J Med 1996 Jun 13;334(24):1573–6

Advances in the prevention and treatment of Mycobacterium avium disease [editorial; comment] Horsburgh CR Jr.
N Engl J Med 1996 Aug 8;335(6):428–30. Comment on: N Engl J Med 1996 Aug 8;335(6):377–83. Comment on: N Engl J Med 1996 Aug 8;335(6):384–91. Comment on: N Engl J Med 1996 Aug 8;335(6):392–8.

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group [see comments] Shafran SD, et al. **N Engl J Med** 1996 Aug 8;335(6):377–83 . Comment in: N Engl J Med 1996 Aug 8;335(6):428–30.

Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir [letter] Zingman BS. **N Engl J Med** 1996 Jun 20;334(25):1674–5

Considerable ferment over antifungal agents [news] Fox JL.
Nat Med 1995 May;1(5):398

Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol. Lowe SH, et al. **Neth J Med** 1996 Jun;48(6):211–5

Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS. Cohen BA.
Neurology 1996 Feb;46(2):444–50

Ganciclovir intraocular implant. A clinicopathologic study. Charles NC, et al. **Ophthalmology** 1996 Mar;103(3):416–21

New developments in the treatment of CMV retinitis [editorial; comment] Freeman WR. **Ophthalmology** 1996 Jul;103(7):999–1000. Comment on: Ophthalmology 1996 Jul;103(7):1078–83.

Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis [see comments] Rahhal FM, et al. **Ophthalmology** 1996 Jul;103(7):1078–83. Comment in: Ophthalmology 1996 Jul;103(7):999–1000.

Pentamidine-induced hyperglycemia and ketosis in acquired immunodeficiency syndrome [letter] Lu CP, et al.
Pancreas 1995 Oct;11(3):315–6

Drug treatment of toxoplasmic encephalitis in acquired immunodeficiency syndrome. Winstanley P.
Postgrad Med J 1995 Jul;71(837):404–8

Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective. Benson CA.
Res Microbiol 1996 Jan-Feb;147(1-2):16–24 (43 ref.)

Solving the dilemma of antimycobacterial chemotherapy. Rastogi N, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):7–10 (30 ref.)

Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: a case-control study. Ammassari A, et al.
Scand J Infect Dis 1995;27(3):235–7

Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Barbaro G, et al.
Scand J Infect Dis 1995;27(6):613–7

Chronic ulcerating acyclovir-resistant varicella zoster lesions in an AIDS patient. Bernhard P, et al.
Scand J Infect Dis 1995;27(6):623–5

Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients. Chryssanthou E, et al. **Scand J Infect Dis** 1995;27(4):391–5

Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. Baldanti F, et al. **Scand J Infect Dis Suppl** 1995;99:103–4

Update (1995) on clinical trials of antiviral therapy and prophylaxis for AIDS-related cytomegalovirus disease. Jacobson MA. **Scand J Infect Dis Suppl** 1995;99:96–9 (25 ref.)

Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. Korraa H, et al.
South Med J 1996 Mar;89(3):272–7 (38 ref.)

Acute severe autonomic insufficiency during pentamidine therapy [letter] Siddiqui MA, et al. **South Med J** 1995 Oct; 88(10):1087–8

The element of surprise [editorial; comment] Jones M.
Trop Doct 1996 Apr;26(2):49. Comment on: Trop Doct 1996 Apr;26(2):55–7.

DEC treatment of non-nematodal infections [see comments] Mejía CR, et al. **Trop Doct** 1996 Apr;26(2):55–7. Comment in: Trop Doct 1996 Apr;26(2):49.

Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection [see comments] Elliott AM, et al. **Tuber Lung Dis** 1996 Feb; 77(1):27–9. Comment in: Tuber Lung Dis 1996 Feb;77(1):30–6.

Clarithromycin against Mycobacterium avium complex infections. Heifets LB. **Tuber Lung Dis** 1996 Feb; 77(1):19–26 (105 ref.)

The application of empiric antituberculosis treatment [letter] Lawn SD, et al. **Tuber Lung Dis** 1996 Jun;77(3):292

A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Schwander S, et al.
Tuber Lung Dis 1995 Jun;76(3):210–8

Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya [see comments] van Gorkom J, et al. **Tuber Lung Dis** 1996 Feb;77(1):30–6. Comment in: Tuber Lung Dis 1996 Feb;77(1):27–9.

[Intolerance to trimethoprim-sulfamethoxazole in Pneumocystis carinii pneumonia in AIDS. Search for predictive factors] Pinzani V, et al.
Ann Med Interne (Paris) 1995;146(7):505–9 (25 ref.) (Eng. Abstr.) **(Fre)**

[Uveitis with hypopyon in patients with acquired immunodeficiency syndrome, treated with Rifabutin] Frau E, et al. **J Fr Ophtalmol** 1995;18(6-7):435–8 (Eng. Abstr.) **(Fre)**

[Azithromycin: new orientations] Coulaud JP.
Pathol Biol (Paris) 1995 Jun;43(6):547–50 **(Fre)**

[Maintenance treatment of cerebral toxoplasmosis in AIDS: role of clarithromycin-minocycline combination (letter)] Sellal A, et al. **Presse Med** 1996 Mar 23;25(10):509 **(Fre)**

[Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis] Caumes E. **Rev Mal Respir** 1996; 13(2):101–6 (45 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of non-tuberculous mycobacterial infections] Dautzenberg B. **Rev Mal Respir** 1996;13(1):81–3 (17 ref.) **(Fre)**

[Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole] Béchade D, et al. **Rev Med Interne** 1996; 17(3):234–7 (20 ref.) (Eng. Abstr.) **(Fre)**

[Cytomegalovirus disease in the AIDS patient. The current status of therapy and the outlook] Stoehr A, et al. **Dtsch Med Wochenschr** 1995 Dec 22;120(51–52):1785–8 (39 ref.) **(Ger)**

[Controversy over tuberculosis therapy in HIV infected patients. Isoniazide therapy—brief chemotherapy (news)] Arnheim K. **Fortschr Med** 1995 Dec 20;113(35–36):14–5 **(Ger)**

[Therapy and prevention of pneumocystis carinii pneumonia] Goebel FD, et al. **Internist (Berl)** 1995 Dec;36(12):1150–5 (31 ref.) **(Ger)**

[Renaissance of tuberculosis?] Meyer FJ, et al. **Internist (Berl)** 1995 Dec;36(12):1162–73 (80 ref.) **(Ger)**

[Selective inhibition of replication of human cytomegalovirus by desferrioxamine in vitro and in vivo (case report)] Gümbel H, et al. **Ophthalmologe** 1995 Dec;92(6):840–3 (Eng. Abstr.) **(Ger)**

[Therapeutic approaches in diseases caused by mycobacteria] Urbanczik R. **Pneumologie** 1995 Dec;49 Suppl 3:649–52 (32 ref.) (Eng. Abstr.) **(Ger)**

[The role of aminoglycosides in HIV-infected patients] Opravil M. **Schweiz Med Wochenschr Suppl** 1996; 76:49S–53S (27 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of fungal infections in patients with AIDS] Boulos M. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:28–31 **(Por)**

[Clarithromycin combined with pyrimethamine in cerebral toxoplasmosis—a a report of 2 cases] Dalston MO, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):409–13 (11 ref.) (Eng. Abstr.) **(Por)**

[Opportunistic protozoal infections] Levi G. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:39–43 **(Por)**

[The treatment of cryptosporidiosis in AIDS patients using paromomycin] Stefani HN, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):355–7 (Eng. Abstr.) **(Por)**

[Ulcer in the urethral meatus and HIV infection (letter)] Len O, et al. **Enferm Infecc Microbiol Clin** 1995 Oct;13(8):497–8 **(Spa)**

[Acute renal insufficiency caused by a sulfadiazine in a patient with cerebral toxoplasmosis and AIDS (letter)] Rodríguez-Carballeira M, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):125–7 **(Spa)**

[News about HIV. Combination therapy with new drugs gives hope] Sönnerborg A, et al. **Lakartidningen** 1996 Feb 7;93(6):451–2 **(Swe)**

ECONOMICS

In-patient care for symptomatic, HIV-infected persons: a longitudinal study of hospitalizations, in-patient drug use, and related costs. Dijkgraaf MG, et al. **AIDS Care** 1995; 7(3):321–36

Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia [see comments] Horner RD, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1435–42 . Comment in: Am J Respir Crit Care Med 1995 Nov;152(t Pt 1):1433–4.

Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. Gable CB, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 1;12(4):413–20

Predictors of resource utilization for hospitalized patients with Pneumocystis carinii pneumonia (PCP): a summary of effects from the multi-city study of quality of PCP care. Horner RD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 1;12(4):379–85

EPIDEMIOLOGY

Frequencies of opportunistic diseases prior to death among HIV-infected persons. Community Programs for Clinical Research on AIDS. Chan IS, et al. **AIDS** 1995 Oct; 9(10):1145–51

Bacterial vaginosis and HIV seroprevalence among female commercial sex workers in Chiang Mai, Thailand. Cohen CR, et al. **AIDS** 1995 Sep;9(9):1093–7

Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room. Couldwell DL, et al. **AIDS** 1996 May; 10(5):521–5

The occurrence of Blastocystis hominis in HIV-infected patients [letter] Storgaard M, et al. **AIDS** 1996 Apr; 10(4):444–5

Rapid increase in HIV-related tuberculosis, Chiang Rai, Thailand, 1990–1994. Yanai H, et al. **AIDS** 1996 May; 10(5):527–31

Re: "The spectrum of medical conditions and symptoms before acquired immunodeficiency syndrome in homosexual and bisexual men infected with the human immunodeficiency virus" [letter; comment] Salman MD, et al. **Am J Epidemiol** 1996 Jan 1;143(1):102–3. Comment on: Am J Epidemiol 1995 Mar 1;141(5):395–404; discussion 405–6.

Duodenal and hepatic toxoplasmosis in a patient with HIV infection: review of the literature. Bonacini M, et al. **Am J Gastroenterol** 1996 Sep;91(9):1838–40 (13 ref.)

Lower Helicobacter pylori infection and peptic ulcer disease prevalence in patients with AIDS and suppressed CD4 counts. Cacciarelli AG, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1783–4

Infectious esophagitis in AIDS: what have we learned in the last decade? [editorial; comment] Raufman JP. **Am J Gastroenterol** 1995 Nov;90(11):1914–5. Comment on: Am J Gastroenterol 1995 Nov;90(11):1938–41.

Epidemiology of isosporiasis among persons with acquired immunodeficiency syndrome in Los Angeles County. Sorvillo FJ, et al. **Am J Trop Med Hyg** 1995 Dec; 53(6):656–9

Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Moore RD, et al. **Ann Intern Med** 1996 Apr 1;124(7):633–42

Impact of immunodeficiency virus (HIV) on Fournier's gangrene: observations in Zambia. Elem B, et al. **Ann R Coll Surg Engl** 1995 Jul;77(4):283–6

Tuberculosis is important problem in children with HIV infection in sub-Saharan Africa [letter] Maher D. **BMJ** 1996 Aug 31;313(7056):562–3

Importance of human immunodeficiency virus-associated lymphadenopathy and tuberculous lymphadenitis in patients undergoing lymph node biopsy in Zambia. Bem C, et al. **Br J Surg** 1996 Jan;83(1):75–8

Tuberculosis and HIV infection. Uragoda CG. **Ceylon Med J** 1996 Mar;41(1):5–6

Tuberculosis as an opportunistic disease in persons infected with human immunodeficiency virus. Castro KG. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S66–71 (71 ref.)

Disseminated histoplasmosis in persons infected with human immunodeficiency virus. Hajjeh RA. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S108–10 (27 ref.)

Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. AIDS in Europe Study Group. Lundgren JD, et al. **Clin Infect Dis** 1995 Jul;21(1):106–13

Human immunodeficiency virus and AIDS in Uganda. Mugerwa RD, et al. **East Afr Med J** 1996 Jan;73(1):20–6 (56 ref.)

Intestinal and extraintestinal cryptosporidiosis in AIDS patients. López-Vélez R, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):677–81

Intestinal histoplasmosis in AIDS patients: report of three cases observed in France and review of the literature. Trylesinski A, et al. **Eur J Gastroenterol Hepatol** 1995 Jul; 7(7):679–83 (23 ref.)

Tuberculosis today. Chrétien J. **Eur Respir J Suppl** 1995 Sep; 20:617s–619s

Epidemiology of tuberculosis in Europe. Rieder HL. **Eur Respir J Suppl** 1995 Sep;20:620s–632s (157 ref.)

Epidemiology of cryptosporidiosis among European AIDS patients. Pedersen C, et al. **Genitourin Med** 1996 Apr; 72(2):128–31

Lessons from home based care for persons affecting with HIV and AIDS. Yaima N, et al. **Indian J Public Health** 1995 Jul–Sep;39(3):113–5

Undernotification of tuberculosis in patients with AIDS. Balogun MA, et al. **Int J STD AIDS** 1996 Jan–Feb; 7(1):58–60

Incidence of disseminated histoplasmosis in HIV-infected patients in Switzerland [letter] Bucher HC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 1;11(4):417–8

Recent trends in Pneumocystis carinii pneumonia as AIDS-defining disease in nine European countries [letter] Hoover DR. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):485–6

Tuberculosis among AIDS patients in the United States, 1993. Jones JL, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jul; 12(3):293–7

Hospitalization of patients infected with active TB in New York State, 1987–1992: the effect of the HIV epidemic. Kaufman G, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):508–13

Mycobacterial infection in Mexican AIDS patients. Molina-Gamboa JD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):53–8

Seroepidemiology of cytomegalovirus in patients with advanced HIV disease: influence on disease expression and survival. Shepp DH, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 15;11(5):460–8

Incidence proportion of and risk factors for AIDS patients diagnosed with HIV dementia, central nervous system toxoplasmosis, and cryptococcal meningitis. Wang F, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Jan 1;8(1):75–82

High-energy, high-protein, oral, liquid, nutrition supplementation in patients with HIV infection: effect on weight status in relation to incidence of secondary infection. Stack JA, et al. **J Am Diet Assoc** 1996 Apr; 96(4):337–41

Seasonal variation of disseminated Penicillium marneffei infections in northern Thailand: a clue to the reservoir? Chariyalertsak S, et al. **J Infect Dis** 1996 Jun;173(6):1490–3

Factors associated with cytomegalovirus infection among human immunodeficiency virus type 1-seronegative and -seropositive women from an urban minority community. Clarke LM, et al. **J Infect Dis** 1996 Jan;173(1):77–82

Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya [see comments] Gilks CF, et al. **Lancet** 1996 Mar 16; 347(9003):718–23. Comment in: Lancet 1996 May 18;347(9012):1414.

Fungaemia in hospitalized patients. Perduca M, et al. **Mycoses** 1995 Sep–Oct;38(9–10):385–7

Zygomycosis in HIV-positive patients: a review of the literature. Van den Saffele JK, et al. **Mycoses** 1996 Mar–Apr;39(3–4):77–84 (51 ref.)

Is AIDS a predisposing factor to urinary tract infection? [letter] Marques LP, et al. **Nephron** 1996;72(2):338

Tuberculosis: what nurses need to know to help control the epidemic [letter] Lancaster E. **Nurs Outlook** 1996 Mar–Apr; 44(2):103–4

Risk factors for HIV-related orofacial soft-tissue manifestations in children. Ramos-Gomez FJ, et al. **Pediatr Dent** 1996 Mar–Apr;18(2):121–6

Nontuberculous pulmonary infections in pediatric AIDS. Bye MR. **Pediatr Pulmonol Suppl** 1995;11:3–4

Tuberculosis and HIV infection worldwide. Murray JF. **Pneumologie** 1995 Dec;49 Suppl 3:653–6 (22 ref.)

Tuberculosis epidemic worldwide emergency [news] **Public Health Rep** 1996 Jan–Feb;111(1):8–9

Current problems with tuberculosis treatment. Grosset J. **Res Microbiol** 1996 Jan–Feb;147(1–2):10–6 (32 ref.)

HIV and tuberculosis [letter] Davies GR, et al. **S Afr Med J** 1996 Jan;86(1):91

Human immunodeficiency virus-associated atypical mycobacterial skeletal infections. Hirsch R, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):347–56 (46 ref.)

Cryptosporidiosis in HIV infected patients in Thailand. Moolasart P, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):335–8

Intestinal microsporidiosis: first reported case in Thailand. Pitisuttithum P, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):378–80

Opportunistic and non-opportunistic parasites in HIV-positive and negative patients with diarrhoea in Tanzania. Gomez Morales MA, et al. **Trop Med Parasitol** 1995 Jun;46(2):109–14

Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and National Tuberculosis Control Program quality. Cantwell MF, et al. **Tuber Lung Dis** 1996 Jun;77(3):220–5

The increase in tuberculosis notifications in England and Wales since 1987. Doherty MJ, et al. **Tuber Lung Dis** 1995 Jun;76(3):196–200

Seroprevalence of HIV infection among patients with pulmonary tuberculosis in Yaounde-Cameroun. Kuaban C, et al. **West Afr J Med** 1995 Apr–Jun;14(2):112–5

Endemic mycosis complicating human immunodeficiency virus infection. Sarosi GA, et al. **West J Med** 1996 Apr; 164(4):335–40 (43 ref.)

[AIDS and tuberculosis: the situation in Madagascar] Auregan G, et al. **Arch Inst Pasteur Madagascar** 1995; 62(1):24–5 (Eng. Abstr.) **(Fre)**

[HIV infection in tuberculosis patients in Madagascar. Situation in 1–93] Morvan JM, et al. **Arch Inst Pasteur Madagascar** 1994;61(2):73–5 (Eng. Abstr.) **(Fre)**

[Seroprevalence of cytomegalovirus infection in human immunodeficiency virus infected subjects (letter)] Rey D, et al. **Presse Med** 1995 Oct 21;24(31):1445 **(Fre)**

[Impact of AIDS on the resurgence of tuberculosis and reduced availability of hospital beds in Brazzaville (Congo)] Loemba H, et al. **Sante** 1995 Sep–Oct;5(5):278–82 (Eng. Abstr.) **(Fre)**

[Tuberculosis in patients infected with HIV in Ho Chi Minh city] Pham DL. **Sante** 1996 Mar–Apr;6(2):74 **(Fre)**

[Reappearance of tuberculosis, risks and consequences!] Exner-Freisfeld H. **Gesundheitswesen** 1995 Dec; 57(12):798–805 (Eng. Abstr.) **(Ger)**

[HIV infection and tuberculosis] Brodt HR. **Internist (Berl)** 1995 Oct;36(10):970–9 (63 ref.) **(Ger)**

[Epidemiology of tuberculosis] Schlegel J, et al. **Internist (Berl)** 1995 Oct;36(10):951–6 (9 ref.) **(Ger)**

[The worldwide status of tuberculosis today] Billo NE. **Pneumologie** 1995 Dec;49 Suppl 3:633–5 **(Ger)**

[Does AIDS influence the epidemiology of tuberculosis?] Ferlinz R, et al. **Pneumologie** 1995 Aug;49(8):449–54 (7 ref.) **(Ger)**

[Tuberculosis among AIDS patients in Ullev]l hospital] Berild D. **Tidsskr Nor Laegeforen** 1995 Nov 10; 115(27):3361–4 (Eng. Abstr.) **(Nor)**

[The absence of invasive amebiasis in male homosexual AIDS patients in Recife] de Alencar LC, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):319–22 (Eng. Abstr.) **(Por)**

[The pattern of AIDS-indicative diseases in adults and adolescents in Spain, 1988–1993] Castilla J, et al. **Med Clin (Barc)** 1996 Feb 24;106(7):246–50 (Eng. Abstr.) **(Spa)**

[Tuberculosis and AIDS in Mexico] García-García M de L, et al. **Salud Publica Mex** 1995 Nov–Dec;37(6):539–48 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

AIDS defining conditions in Africans resident in the United

Kingdom. Del Amo J, et al. **Int J STD AIDS** 1996 Jan–Feb; 7(1):44–7

ETIOLOGY

First case of osteomyelitis due to Phialophora richardsiae in a patient with HIV infection [letter] Uberti-Foppa C, et al. **AIDS** 1995 Aug;9(8):975–6

Mycobacterium avium complex infection in AIDS. Kemper CA, et al. **AIDS Clin Rev** 1995–96;:153–228 (271 ref.)

Microsporidial keratoconjunctivitis caused by Septata intestinalis in a patient with acquired immunodeficiency syndrome. Lowder CY, et al. **Am J Ophthalmol** 1996 Jun; 121(6):715–7

Squamous cell carcinoma of the eyelid and the acquired immunodeficiency syndrome. Maclean H, et al. **Am J Ophthalmol** 1996 Feb;121(2):219–21

Presumed ocular and central nervous system tuberculosis in a patient with the acquired immunodeficiency syndrome. Muccioli C, et al. **Am J Ophthalmol** 1996 Feb;121(2):217–9

Limbal and choroidal Cryptococcus infection in the acquired immunodeficiency syndrome. Muccioli C, et al. **Am J Ophthalmol** 1995 Oct;120(4):539–40

Bilateral endogenous Fusarium endophthalmitis associated with acquired immunodeficiency syndrome [clinical conference] Glasgow BJ, et al. **Arch Ophthalmol** 1996 Jul; 114(7):873–7

Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Hoover DR, et al. **Arch Ophthalmol** 1996 Jul;114(7):821–7

Acquired immunodeficiency syndrome and the eye—1996 [editorial] Jabs DA. **Arch Ophthalmol** 1996 Jul;114(7):863–6 (61 ref.)

Cholecystectomy in patients with AIDS: clinicopathologic correlations in 107 cases. French AL, et al. **Clin Infect Dis** 1995 Oct;21(4):852–8

Bartonella (Rochalimaea) antibodies, dementia, and cat ownership among men infected with human immunodeficiency virus. Schwartzman WA, et al. **Clin Infect Dis** 1995 Oct;21(4):954–9

Bacille Calmette-Guérin (BCG) meningitis in an AIDS patient 12 years after vaccination with BCG. van Deutekom H, et al. **Clin Infect Dis** 1996 May;22(5):870–1

Is vulvovaginal candidiasis an AIDS-related illness? White MH. **Clin Infect Dis** 1996 May;22 Suppl 2:S124–7 (29 ref.)

Community-acquired pneumonia due to Staphylococcus cohnii in an HIV-infected patient: case report and review. Mastroianni A, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):904–8

Nosocomial colonization and infection in persons infected with human immunodeficiency virus. Craven DE, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):304–18 (90 ref.)

Hickman catheter-associated primary cutaneous aspergillosis in a patient with the acquired immunodeficiency syndrome. Romero LS, et al. **Int J Dermatol** 1995 Aug;34(8):551–3

Hypercalcemia associated with cytomegalovirus infection in an AIDS patient [letter] Fallatah S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Jan 1;8(1):101–2

Patterns of opportunistic infections in patients with HIV infection. Finkelstein DM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):38–45

Catheter-associated fungemia due to Wangiella (Exophiala) dermatitidis. Nachman S, et al. **J Clin Microbiol** 1996 Apr; 34(4):1011–3 (10 ref.)

Red fingers syndrome in HIV patients [letter] Battegay M, et al. **Lancet** 1996 Sep 14;348(9029):763

HIV-related oral disease. Greenspan D, et al. **Lancet** 1996 Sep 14;348(9029):729–33 (38 ref.)

Cytomegalovirus optic neuritis: characteristics, therapy and survival. Mansor AM, et al. **Ophthalmologica** 1995; 209(5):260–6

[Somatic pathology in drug addicts infected with HIV] Coulaud JP. **Sante** 1996 Mar–Apr;6(2):75 **(Fre)**

[Clinical dermatologic and genital manifestations in drug addicts infected with HIV] Nguyen VU, et al. **Sante** 1996 Mar–Apr;6(2):71 **(Fre)**

GENETICS

Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. Suzuki Y, et al. **J Infect Dis** 1996 Jan;173(1):265–8

Genetic diversity at the internal transcribed spacer regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia. Tsolaki AG, et al. **J Infect Dis** 1996 Jul;174(1):141–56

IMMUNOLOGY

Evidence for an effect of human leukocyte antigens on susceptibility to Kaposi's sarcoma related to charge and peptide-binding properties of class I molecules [letter] Marmor M, et al. **AIDS** 1995 Oct;9(10):1194–5

Microsporidiosis in patients with relatively preserved CD4 counts [letter] Sowerby TM, et al. **AIDS** 1995 Aug;9(8):975

CD8+ T lymphocytes and cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome [letter; comment] Pakola SJ, et al. **Am J Ophthalmol** 1996 Apr;121(4):455–6. Comment on: Am J Ophthalmol 1995 Sep;120(3):283–90.

Community-acquired pneumonia: impact of immune status. Mundy LM, et al. **Am J Respir Crit Care Med** 1995 Oct; 152(4 Pt 1):1309–15

Peripheral gamma delta T-cell populations in HIV-infected individuals with mycobacterial infection. Ruiz P, et al. **Cytometry** 1995 Sep 15;22(3):211–6

Longitudinal study of cytomegalovirus antibodies in individuals infected with the human immunodeficiency virus. Flø RW, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):504–11

PPD skin reactivity and anergy in HIV-infected patients in Hawaii. Shikuma CM, et al. **Hawaii Med J** 1996 Jun; 55(6):100–3

Total lymphocyte count as a surrogate for CD4+ lymphocyte count in African patients coinfected with HIV and tuberculosis [letter; comment] Wood R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 1;11(4):411–3. Comment on: J Acquir Immune Defic Syndr Hum Retrovirol 1995 Apr 1;8(4):386–91.

Postoperative infection following orthopaedic surgery in human immunodeficiency virus-infected hemophiliacs with CD4 counts < or = 200/mm3. Ragni MV, et al. **J Arthroplasty** 1995 Dec;10(6):716–21

Genital ulcers associated with human immunodeficiency virus-related immunosuppression in female sex workers in Abidjan, Ivory Coast [see comments] Ghys PD, et al. **J Infect Dis** 1995 Nov;172(5):1371–4. Comment in: J Infect Dis 1996 Aug;174(2):445–7.

Disseminated Mycobacterium avium complex infection in AIDS: immunopathogenic significance of an activated tumor necrosis factor system and depressed serum levels of 1,25 dihydroxyvitamin D. Haug CJ, et al. **J Infect Dis** 1996 Jan;173(1):259–62

CD4 + T counts with a course of antituberculous therapy in healthy and HIV-infected patients. Saenghirunvattana S. **J Med Assoc Thai** 1996 Apr;79(4):246–8

Anergy, AIDS and tuberculosis. Hegde HR. **Med Hypotheses** 1995 Nov;45(5):433–40 (48 ref.)

Managing HIV. Part 3: Mechanisms of disease. 3.3 How HIV leads to opportunistic infections. Crowe SM, et al. **Med J Aust** 1996 Feb 5;164(3):171–3

Oral soft tissue manifestations and CD4 lymphocyte counts in HIV-infected children. Howell RB, et al. **Pediatr Dent** 1996 Mar–Apr;18(2):117–20

Tuberculosis without tubercles [editorial; comment] Horsburgh CR Jr. **Tuber Lung Dis** 1996 Jun;77(3):197–8. Comment on: Tuber Lung Dis 1996 Jun;77(3):244–9.

[Prognostic value of interleukin-8 in AIDS-related Pneumocystis carinii pneumonia] Benfield TL, et al. **Ugeskr Laeger** 1996 Mar 11;158(11):1513–7 (Eng. Abstr.) **(Dan)**

[The influence of HIV infection on development of tuberculosis] Kwiatkowska S. **Pol Arch Med Wewn** 1995 May;93(5):421–6 (39 ref.) **(Pol)**

METABOLISM

GRO alpha and interleukin-8 in Pneumocystis carinii or bacterial pneumonia and adult respiratory distress syndrome. Villard J, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1549–54

MICROBIOLOGY

Rhodococcus equi infection in 3 AIDS patients. Colebunders R, et al. **Acta Clin Belg** 1996;51(2):101–5

Lung abscess due to nontyphoid Salmonella in an immunocompromised host. Case report with review of the literature. Ridha AG, et al. **Acta Clin Belg** 1996; 51(3):175–83 (41 ref.)

Atypical cytomorphologic appearance of Cryptococcus neoformans: a report of five cases. Williamson JD, et al. **Acta Cytol** 1996 Mar–Apr;40(2):363–70

Invasive fungal sinusitis in immunosuppressed patients. Report of three cases. Zapater E, et al. **Acta Otorhinolaryngol Belg** 1996;50(2):137–42

Histoplasma prostatic abscess: rare cause in an immunocompromised patient [letter] Shah RD, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):471

Statement on fungal infection in HIV patients [news] **Am Fam Physician** 1995 Nov 1;52(6):1928

Enteroadherent eaeA-positive Escherichia coli associated with chronic AIDS-related diarrhea [letter] Hii JH, et al. **Ann Intern Med** 1996 Sep 15;125(6):523

Tuberculous abscess of the prostate in AIDS [letter] Wolf LE. **Ann Intern Med** 1996 Jul 15;125(2):156

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Sanglard D, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2378–86

Cutaneous Cryptococcus infection and AIDS. Report of 12 cases and review of the literature. Murakawa GJ, et al. **Arch Dermatol** 1996 May;132(5):545–8 (36 ref.)

Mycobacterium genavense infection and survival [letter; comment] Glesby MJ, et al. **Arch Intern Med** 1995 Oct 23;155(19):2128–9. Comment on: Arch Intern Med 1995 Feb 27;155(4):400–4.

Bronchoesophageal fistula due to multidrug-resistant tuberculosis in a patient infected with human immunodeficiency virus [letter; comment] Asnis DS, et al. **Clin Infect Dis** 1995 Oct;21(4):1061–2. Comment on: Clin Infect Dis 1994 Nov;19(5):954–7.

Incidence and clinical relevance of anaerobic bacterial infections in patients with AIDS at an infectious diseases institute. Coronado O, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S212–3

Delayed development of tuberculous bronchoesophageal fistulas in a patient with AIDS necessitates endoscopic surgery [letter; comment] Dronda F, et al. **Clin Infect Dis** 1995 Oct;21(4):1062–3. Comment on: Clin Infect Dis 1994 Nov;19(5):954–7.

Infectious endocarditis due to non-typhi Salmonella in patients infected with human immunodeficiency virus: report of two cases and review. Fernández Guerrero ML, et al. **Clin Infect Dis** 1996 May;22(5):853–5 (10 ref.)

Pulmonary infection due to Leuconostoc species in a patient with AIDS [letter] Ferrer S, et al. **Clin Infect Dis** 1995 Jul;21(1):225–6

Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Gallant JE, et al. **Clin Infect Dis** 1996 Apr;22(4):671–82 (208 ref.)

Rhodococcus equi mastoiditis in a patient with AIDS. Lopes Cardoso FL, et al. **Clin Infect Dis** 1996 Apr;22(4):713

Recurrent Helicobacter cinaedi bacteremia in a patient infected with human immunodeficiency virus: case report. Mammen MP Jr, et al. **Clin Infect Dis** 1995 Oct;21(4):1055

Mycobacterium kansasii bacteremia in patients infected with human immunodeficiency virus. Parenti DM, et al. **Clin Infect Dis** 1995 Oct;21(4):1001–3

Emergence of multidrug resistance in Campylobacter jejuni isolates from three patients infected with human immunodeficiency virus. Tee W, et al. **Clin Infect Dis** 1995 Sep;21(3):634–8

Oral manifestation of disseminated Mycobacterium kansasii infection in a patient with AIDS. Nüesch R, et al. **Dermatology** 1996;192(2):183–4 (10 ref.)

Laboratory and clinical evaluation of Mycobacterium xenopi isolates. Marx CE, et al. **Diagn Microbiol Infect Dis** 1995 Apr;21(4):195–202

Microbiology of HIV associated bacteraemia and diarrhoea in adults from Nairobi, Kenya. Batchelor BI, et al. **Epidemiol Infect** 1996 Aug;117(1):139–44

Multiple recurrent bacillary angiomatosis due to Bartonella quintana in an HIV-infected patient [letter] Colson P, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):178–80

Pathogenic Nocardia isolated from clinical specimens including those of AIDS patients in Thailand. Poonwan N, et al. **Eur J Epidemiol** 1995 Oct;11(5):507–12

Mycobacterium genavense invasive infection in two children with AIDS: long-term followup. Reymond D, et al. **Eur J Pediatr** 1995;154(9 Suppl 4):S74–6

Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. Venkateswarlu K, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):337–41

Infectious colitides in patients with acquired immunodeficiency syndrome. Mosenkis BN, et al. **Gastroenterologist** 1995 Sep;3(3):241–8 (72 ref.)

Bordetella bronchiseptica pneumonia in an AIDS patient: a new opportunistic infection [letter] Libanore M, et al. **Infection** 1995 Sep–Oct;23(5):312–3

Salmonella typhimurium empyema in an AIDS patient. Colebunders R, et al. **Int J STD AIDS** 1995 Jul–Aug; 6(4):287–8

Isolated renal mucormycosis: case report and review. Levy E, et al. **J Am Soc Nephrol** 1995 Jun;5(12):2014–9 (25 ref.)

Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of Mycobacterium avium complex. Piersimoni C, et al. **J Antimicrob Chemother** 1995 Sep;36(3):497–502

Bacterial pneumonia in adult patients with HIV infection. Moroni M, et al. **J Chemother** 1995 Aug;7(4):292–306

Typing Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting. Boerlin P, et al. **J Clin Microbiol** 1996 May;34(5):1235–48

Strategy to detect and identify Bartonella species in routine clinical laboratory yields Bartonella henselae from human immunodeficiency virus-positive patient and unique Bartonella strain from his cat. Clarridge JE 3rd, et al. **J Clin Microbiol** 1995 Aug;33(8):2107–13

Disseminated Penicillium marneffei infection in a patient with acquired immunodeficiency syndrome. Chang CC, et al. **J Formos Med Assoc** 1995 Sep;94(9):572–5

Penicillin-resistant pneumococci—an emerging threat to successful therapy. McGowan JE Jr, et al. **J Hosp Infect** 1995 Jun;30 Suppl:472–82

Mycobacterium kansasii scalp abscesses in an AIDS patient [letter] Nandwani R, et al. **J Infect** 1995 Jul;31(1):79–80

Identification by random amplification of polymorphic DNA of a common molecular type of Cryptococcus neoformans var. neoformans in patients with AIDS or other immunosuppressive conditions. Chen SC, et al. **J Infect Dis** 1996 Mar;173(3):754–8

Identification of virulence-associated antigens and plasmids in Rhodococcus equi from patients with AIDS. Takai S, et al. **J Infect Dis** 1995 Nov;172(5):1306–11

Bacillary angiomatosis and mycobacterium infection coexisting in a cutaneous lesion in a patient with AIDS. Chiewchanvit S, et al. **J Med Assoc Thai** 1996 May; 79(5):337–40

Imbalance between Pneumocystis carinii cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis. Tamburrini E, et al. **J Med Microbiol** 1996 Aug;45(2):146–8

In-vitro proteinase production by oral Candida albicans

isolates from individuals with and without HIV infection and its attenuation by antimycotic agents. Wu T, et al. **J Med Microbiol** 1996 Apr;44(4):311-6

Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole. Goldani LZ, et al. **J Med Vet Mycol** 1995 Jul-Aug;33(4):267-70 (22 ref.)

Penicillium marneffei part of Southeast Asian AIDS [news] Phillips P. **JAMA** 1996 Jul 10;276(2):86-7

Invasive pneumococcal disease in HIV-1 infected patients [letter; comment] Domingo P, et al. **Lancet** 1996 May 18; 347(9012):1414. Comment on: Lancet 1996 Mar 16;347(9003):718-23.

A painful rash with AIDS. Farrell AM, et al. **Lancet** 1996 Feb 10;347(8998):372

Think fungus in HIV-infection [news] Pini P. **Lancet** 1996 Jul 27;348(9022):257

Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Sullivan DJ, et al. **Microbiology** 1995 Jul;141 (Pt 7):1507-21

Pseudomonas aeruginosa pneumonia/sepsis as an initial opportunistic infection in an HIV patient. Amundson DE, et al. **Mil Med** 1996 Mar;161(3):179

Enteric pathogens associated with gastrointestinal dysfunction in children with HIV infection. Ramos-Soriano AG, et al. **Mol Cell Probes** 1996 Apr; 10(2):67-73

Revival of "median rhomboid glossitis"? [letter] Pindborg JJ. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):2-3

Mycoplasmas and oncogenesis: persistent infection and multistage malignant transformation. Tsai S, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10197-201

Acute gonococcal sepsis in an HIV-infected woman. Jacoby HM, et al. **Sex Transm Dis** 1995 Nov-Dec;22(6):380-2

Genetic and serovar typing of clinical isolates of the Mycobacterium avium-intracellulare complex. De Smet KA, et al. **Tuber Lung Dis** 1996 Feb;77(1):71-6

Acute community-acquired bacterial pneumonia in Human Immunodeficiency Virus (HIV) infected and non-HIV-infected adult patients in Cameroon: aetiology and outcome. Koulla-Shiro S, et al. **Tuber Lung Dis** 1996 Feb;77(1):47-51

A pilot study of antituberculous combination comparing rifabutin with rifampicin in the treatment of Human Immunodeficiency Virus-1 associated tuberculosis [letter] Sticht-Groh V. **Tuber Lung Dis** 1996 Feb;77(1):99

[Oropharyngeal candidiasis resistant to fluconazole in patients infected by HIV] Drobacheff C, et al. **Ann Dermatol Venereol** 1996;123(2):85-9 (Eng. Abstr.) **(Fre)**

[Esophago-gastroduodenal involvement in human immunodeficiency virus infection] Bouchaud O, et al. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B125-9 **(Fre)**

[Autopsy findings in 70 AIDS patients who died in a department of pneumology in Ivory Coast: impact of tuberculosis] Domoua K, et al. **Med Trop (Mars)** 1995; 55(3):252-4 (Eng. Abstr.) **(Fre)**

[Disseminated Histoplasma capsulatum histoplasmosis in African AIDS patients (3 cases)] Imbert P, et al. **Med Trop (Mars)** 1995;55(2):151-3 (12 ref.) (Eng. Abstr.) **(Fre)**

[Five cases of non-typhoid salmonellosis in patients infected with the human immunodeficiency virus in Senegal] Morel H, et al. **Med Trop (Mars)** 1995;55(2):135-8 (Eng. Abstr.) **(Fre)**

[New opportunistic pathogens in AIDS] Morillon M. **Med Trop (Mars)** 1996;56(1):17-20 (20 ref.) **(Fre)**

[African histoplasmosis due to Histoplasma capsulatum var. duboisii: relationship with AIDS in recent Congolese cases] Chandenier J, et al. **Sante** 1995 Jul-Aug;5(4):227-34 (Eng. Abstr.) **(Fre)**

[African histoplasmosis in a patient with HIV-2 infection] Eichmann A, et al. **Schweiz Med Wochenschr** 1996 May 4;126(18):765-9 (Eng. Abstr.) **(Ger)**

[Disseminated infection with Mycobacterium celatum] Emler S, et al. **Schweiz Med Wochenschr** 1996 Jun 15; 126(24):1062-5 (Eng. Abstr.) **(Ger)**

MORTALITY

Projecting disease when death is likely. Hoover DR, et al. **Am J Epidemiol** 1996 May 1;143(9):943-52

Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Selik RM, et al. **Ann Intern Med** 1995 Dec 15; 123(12):933-6

Tuberculosis as a predictor of survival in AIDS. Study had several flaws [letter; comment] Holmes WC, et al. **BMJ** 1996 Mar 23;312(7033):776. Comment on: BMJ 1995 Dec 2;311(7018):1468-71.

Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. AIDS in Europe Study Group [see comments] Perneger TV, et al. **BMJ** 1995 Dec 2; 311(7018):1468-71. Comment in: BMJ 1996 Mar 23;312(7033):776.

Acquired immunodeficiency syndrome, Pneumocystis carinii pneumonia, and futility [editorial; comment] Notterman DA. **Crit Care Med** 1996 Jun;24(6):907-9. Comment on: Crit Care Med 1996 Jun;24(6):963-7.

Predicting in-hospital outcome in HIV-associated Pneumocystis carinii pneumonia. Bauer T, et al. **Infection** 1995 Sep-Oct;23(5):272-7

Impact of the human immunodeficiency virus type-1 on common pediatric illnesses in Zambia. Chintu C, et al. **J Trop Pediatr** 1995 Dec;41(6):348-53

Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee. Vakil NB, et al. **N Engl J Med** 1996 Jan 4;334(1):19-23

Tuberculosis mortality associated with AIDS and drug or alcohol abuse: analysis of multiple cause-of-death data. White MC, et al. **Public Health** 1996 May;110(3):185-9

[Prognostic factors of Pneumocystis carinii pneumonia in AIDS] Hoen B, et al. **Presse Med** 1996 Mar 16;25(9):443-8 (Eng. Abstr.) **(Fre)**

PARASITOLOGY

Light and electron microscopic identification of Cyclospora species in the small intestine. Evidence of the presence of asexual life cycle in human host. Sun T, et al. **Am J Clin Pathol** 1996 Feb;105(2):216-20

Atypical cutaneous histological features of visceral leishmaniasis in acquired immunodeficiency syndrome. Perrin C, et al. **Am J Dermatopathol** 1995 Apr;17(2):145-50

Toxoplasmosis of the bladder in a patient with AIDS [letter] Besnier JM, et al. **Clin Infect Dis** 1995 Aug;21(2):452-4

Strongyloides stercoralis first-stage larvae in the lungs of a patient with AIDS: primary localization or a noninvasive form of dissemination? Cirioni O, et al. **Clin Infect Dis** 1996 Apr;22(4):737

Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with the human immunodeficiency virus: response to therapy with albendazole. Dore GJ, et al. **Clin Infect Dis** 1995 Jul;21(1):70-6

Multiorgan microsporidiosis: report of five cases and review. Gunnarsson G, et al. **Clin Infect Dis** 1995 Jul;21(1):37-44 (46 ref.)

Strongyloides stercoralis hyperinfection syndrome in a patient with AIDS: diagnosis by fluorescent microscopy. Nomura J, et al. **Clin Infect Dis** 1996 Apr;22(4):736

Rosacea-like demodicosis in an HIV-positive child. Barrio J, et al. **Dermatology** 1996;192(2):143-5 (23 ref.)

Microsporidium in AIDS patients: a perspective. Chukwuma C Sr. **East Afr Med J** 1996 Jan;73(1):72-5 (35 ref.)

Microbiological findings about pulmonary cryptosporidiosis in two AIDS patients. Dupont C, et al. **J Clin Microbiol** 1996 Jan;34(1):227-9

Small subunit ribosomal DNA phylogeny of various microsporidia with emphasis on AIDS related forms. Baker MD, et al. **J Eukaryot Microbiol** 1995 Sep-Oct; 42(5):564-70

Characterization of Encephalitozoon (Septata) intestinalis isolates cultured from nasal mucosa and bronchoalveolar lavage fluids of two AIDS patients. Didier ES, et al. **J Eukaryot Microbiol** 1996 Jan-Feb;43(1):34-43

Intestinal microsporidiosis with Septata intestinalis in a patient with AIDS--response to albendazole. Franzen C, et al. **J Infect** 1995 Nov;31(3):237-9

Chagasic granulomatous encephalitis in immunosuppressed patients. Computed tomography and magnetic resonance imaging findings. Di Lorenzo GA, et al. **J Neuroimaging** 1996 Apr;6(2):94-7

Parasitism of HIV-infected patients by insect flagellates [letter; comment] Dedet JP. **Lancet** 1996 May 18; 347(9012):1409. Comment on: Lancet 1996 Jan 27;347(8996):264-5.

HIV co-infection with a currently non-pathogenic flagellate [letter] [see comments] Jiménez MI, et al. **Lancet** 1996 Jan 27;347(8996):264-5. Comment in: Lancet 1996 May 18;347(9012):1409.

Lethal infection by a previously unrecognised metazoan parasite. Santamaría-Fríes M, et al. **Lancet** 1996 Jun 29; 347(9018):1797-801

Intestinal microsporidiosis in AIDS patients with diarrhoeal illness in Apulia (south Italy) Marangi A, et al. **New Microbiol** 1995 Oct;18(4):435-9

Microsporidial rhinosinusitis: is this the next pathogen to infect the sinuses of the immunocompromised host? Josephson GD, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):137-9

Human microsporidioses and AIDS: recent advances. Desportes-Livage I. **Parasite** 1996 Jun;3(2):107-13 (12 ref.)

Specific and rapid detection of Microsporidia in stool specimens from AIDS patients by PCR. Ombrouck C, et al. **Parasite** 1996 Mar;3(1):85-6

Development and ultrastructure of Trachipleistophora hominis n.g., n.sp. after in vitro isolation from an AIDS patient and inoculation into athymic mice. Hollister WS, et al. **Parasitology** 1996 Jan;112 (Pt 1):143-54

Blastocystis hominis in human immunodeficiency virus-related diarrhea. Albrecht H, et al. **Scand J Gastroenterol** 1995 Sep;30(9):909-14

Cyclospora infection in an HIV infected patient with ultrastructural study. Wanachiwanawin D, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):375-7

Opportunistic and non-opportunistic parasites in HIV-positive and negative patients with diarrhoea in Tanzania. Gomez Morales MA, et al. **Trop Med Parasitol** 1995 Jun;46(2):109-14

[Proctology and human immunodeficiency virus] Puy-Montbrun T. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B145-9 **(Fre)**

[Hepatobiliary and pancreatic diseases in human immunodeficiency virus infection] Roulot D. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B150-6 **(Fre)**

[Extracerebral toxoplasmosis in immunodepressed subjects. Case report of a case of pulmonary toxoplasmosis in an HIV-positive patient and literature review] Kamm W, et al. **Rev Med Suisse Romande** 1996 May;116(5):385-90 (23 ref.) **(Fre)**

PATHOLOGY

Pulmonary microsporidiosis in a patient with the acquired immunodeficiency syndrome. A case report. Remadi S, et al. **Acta Cytol** 1995 Nov-Dec;39(6):1112-6

Fine needle aspiration diagnosis of intramuscular bacillary angiomatosis. A case report. Sanchez MA, et al. **Acta Cytol** 1996 Jul-Aug;40(4):751-5

Morphologic features and clinical significance of skin involvement in patients with AIDS-related cryptococcosis. Manfredi R, et al. **Acta Derm Venereol** 1996 Jan;76(1):72-4

Giant ulcers in the ileum and colon caused by cytomegalovirus in patients with AIDS. Balthazar EJ, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1275-6

The ear in the acquired immunodeficiency syndrome: I. Temporal bone histopathologic study. Michaels L, et al. **Am J Otol** 1994 Jul;15(4):515-22

Pathologic quiz case 2. Bilateral herpes zoster oticus. Lee D, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb; 122(2):195, 197-8

A foveal-sparing pattern of cytomegalovirus retinitis in the acquired immunodeficiency syndrome. Luckie AP, et al. **Aust N Z J Ophthalmol** 1996 Feb;24(1):53-9 (23 ref.)

HIV-associated eosinophilic folliculitis: case report and review of the literature. Basarab T, et al. **Br J Dermatol** 1996 Mar;134(3):499-503 (16 ref.)

Opportunistic infections of the central nervous system in children with HIV infection: report of 9 autopsy cases and review of literature. Wrzolek MA, et al. **Clin Neuropathol** 1995 Jul-Aug;14(4):187-96 (41 ref.)

Norwegian scabies in a patient with AIDS: report of a case. Suarez Fernandez R, et al. **Cutis** 1995 Jul;56(1):57-60

Disseminated cutaneous Cryptococcus clinically mimicking basal cell carcinoma [letter] Murakawa GJ, et al. **Dermatol Surg** 1995 Nov;21(11):992-3 (8 ref.)

Endoscopic-pathologic correlates of Candida esophagitis in acquired immunodeficiency syndrome. Wilcox CM, et al. **Dig Dis Sci** 1996 Jul;41(7):1337-45

Colocalisation of human immunodeficiency virus and human cytomegalovirus infection in brain autopsy tissue from AIDS patients. Balluz IM, et al. **Ir J Med Sci** 1996 Apr-Jun;165(2):133-8

Scutular favus-like tinea cruris et pedis in a patient with AIDS. Bakos L, et al. **J Am Acad Dermatol** 1996 Jun; 34(6):1086-7

Recalcitrant giant molluscum contagiosum in a patient with AIDS. Cronin TA Jr, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):266-7

Widespread cutaneous bacillary angiomatosis and a large fungating mass in an HIV-positive man. Fagan WA, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):285-7

Deep dermatophytosis caused by Trichophyton rubrum in a patient with AIDS. Tsang P, et al. **J Am Acad Dermatol** 1996 Jun;34(6):1090-1

Identifying and treating HIV-related oral conditions: a clinical grand rounds approach [clinical conference] Truelove EL, et al. **J Am Dent Assoc** 1995 Oct; 126(10):1394-400

The endoscopic appearance of severe intestinal Mycobacterium avium complex infection as a coarsely granular mucosa due to massive infiltration and expansion of intestinal villi without mucosal exudation. Cappell MS, et al. **J Clin Gastroenterol** 1995 Dec;21(4):323-6

Pseudomembranous oral candidiasis in HIV infection: ultrastructural findings. Reichart PA, et al. **J Oral Pathol Med** 1995 Jul;24(6):276-81

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 17-1996. A 48-year-old man with the acquired immunodeficiency syndrome, abdominal pain, and bloody diarrhea [clinical conference] **N Engl J Med** 1996 May 30;334(22):1461-7

Images in clinical medicine. Histoplasmosis [see comments] Daoust P, et al. **N Engl J Med** 1996 Mar 14;334(11):700 . Comment in: N Engl J Med 1996 Jul 25;335(4):291.

Invasive aspergillosis of the larynx in AIDS. Kingdom TT, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):135-7

Cancer in the HIV-infected child. Berkowitz R, et al. **Pediatr Dent** 1996 Mar-Apr;18(2):127-8

Oral findings in asymptomatic (P-1) and symptomatic (P-2) HIV infected children. Del Toro A, et al. **Pediatr Dent** 1996 Mar-Apr;18(2):114-6

Infections in children with human immunodeficiency virus/acquired immunodeficiency syndrome: an autopsy study of 30 cases in south Florida, 1990-1993. Reik RA, et al. **Pediatr Pathol Lab Med** 1995 Mar-Apr;15(2):269-81

Comparative histopathological study of pulmonary tuberculosis in human immunodeficiency virus-infected and non-infected patients. Di Perri G, et al. **Tuber Lung Dis** 1996 Jun;77(3):244-9

Penile mass caused by the newly described organism Mycobacterium celatum. Dahl DM, et al. **Urology** 1996 Feb;47(2):266-8 (13 ref.)

[Pathologic anatomy of cytomegalovirus encephalomyelitis and varicella-zona virus encephalomyelitis] Henin D, et

al. **J Neuroradiol** 1995 Sep;22(3):180–3 (14 ref.) (Eng. Abstr.) **(Fre)**

[Crusted scabies, an important dermatological differential diagnosis in AIDS (letter)] Slevogt H, et al. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):778–9 **(Ger)**

[Vitreous involvement in cytomegalovirus retinitis] Richter R, et al. **Ophthalmologe** 1995 Oct;92(5):685–6 (Eng. Abstr.) **(Ger)**

[Morphologic diagnosis of a seronegative case of HIV-infection] Nedz'ved' MK, et al. **Arkh Patol** 1995 Jul–Aug;57(4):80–3 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Differential activation of the extracellular signal-regulated kinase, Jun kinase and Janus kinase-Stat pathways by oncostatin M and basic fibroblast growth factor in AIDS-derived Kaposi's sarcoma cells. Faris M, et al. **AIDS** 1996 Apr;10(4):369–78

Assessment of cytomegalovirus retinitis. Clinical evaluation vs centralized grading of fundus photographs. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. **Arch Ophthalmol** 1996 Jul; 114(7):791–805

Measuring visual function and quality of life in patients with cytomegalovirus retinitis. Development of a questionnaire. Studies of Ocular Complication of AIDS Research Group. Wu AW, et al. **Arch Ophthalmol** 1996 Jul;114(7):841–7

Determining the pathogenetic significance of cytomegalovirus in patients with AIDS [letter] Antoniou M, et al. **Chest** 1996 Sep;110(3):863

Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS. McCutchan JA. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S196–201 (42 ref.)

Clinical characteristics and outcome of Pneumocystis carinii pneumonia in HIV-infected and otherwise immunosuppressed patients. Ewig S, et al. **Eur Respir J** 1995 Sep;8(9):1548–53

Cytomegalovirus polyradiculopathy in HIV-infected patients. Meier PA, et al. **J Gen Intern Med** 1996 Jan; 11(1):47–9

Progressive intractable actinomycosis in patients with AIDS. Manfredi R, et al. **Scand J Infect Dis** 1995;27(4):405–7

Persistent reduction in lung function after Pneumocystis carinii pneumonia in AIDS patients. Nelsing S, et al. **Scand J Infect Dis** 1995;27(4):351–5

[Parvovirus B19 infection. New physiopathological approaches] Labau E, et al. **Presse Med** 1996 Feb 3; 25(4):162–6 (26 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Testing and management of Toxoplasma serology in HIV-seropositive patients [letter] Aarons E, et al. **AIDS** 1996 Apr;10(4):443–4

Preventive therapy for tuberculosis in HIV infection: the promise and the reality [editorial] O'Brien RJ, et al. **AIDS** 1995 Jul;9(7):665–73 (83 ref.)

Reasons for failure of prevention of Toxoplasma encephalitis. Swiss HIV Cohort Study. Van Delden C, et al. **AIDS** 1996 May;10(5):509–13

Multiple opportunistic pathogen prophylaxis for patients with advanced HIV disease: an overview. Jacobson MA. **AIDS Clin Rev** 1995–96;:47–63 (24 ref.)

Guidelines issued for prevention of opportunistic infections in persons with HIV.U.S. Public Health Service and Infectious Disease Society of America [see comments] **Am Fam Physician** 1995 Nov 1;52(6):1922, 1924–7. Comment in: Am Fam Physician 1995 Nov 1;52(6):1656, 1659–60.

Ganciclovir for cytomegalovirus infection [news] **Am Fam Physician** 1996 Mar;53(4):1441

AAP tuberculin testing recommendations [news] **Am Fam Physician** 1996 May 15;53(7):2378

Isolated despite negative sputum TB tests. Petrec CA. **Am J Nurs** 1996 Jun;96(6):20

Tuberculosis control in resource-poor settings with high rates of HIV infection [editorial; comment] De Cock KM. **Am J Public Health** 1996 Aug;86(8 Pt 1):1071–3. Comment on: Am J Public Health 1996 Aug;86(8 Pt 1):1094–7.

Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. Kaplan JE, et al. **Am J Trop Med Hyg** 1996 Jul;55(1):1–11 (113 ref.)

USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary [see comments] **Ann Intern Med** 1996 Feb 1;124(3):349–68. Comment in: Ann Intern Med 1996 Feb 1;124(3):342–4.

Prophylaxis for HIV-related infections: a work in progress [editorial; comment] Powderly WG. **Ann Intern Med** 1996 Feb 1;124(3):342–4. Comment on: Ann Intern Med 1996 Feb 1;124(3):348–68.

Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Trapnell CB, et al. **Ann Intern Med** 1996 Mar 15;124(6):573–6

Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Graham NM, et al. **Arch Intern Med** 1996 Apr 22;156(8):889–94

A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Ioannidis JP, et al. **Arch Intern Med** 1996 Jan 22;156(2):177–88

Lack of usefulness of radiographic screening for pulmonary disease in asymptomatic HIV-infected adults. Pulmonary Complications of HIV Infection Study Group. Schneider RF, et al. **Arch Intern Med** 1996 Jan 22;156(2):191–5

An effectiveness community-based clinical trial of Respirgard II and Fisoneb nebulizers for Pneumocystis carinii prophylaxis with aerosol pentamidine in HIV-infected individuals. Toronto Aerosol Pentamidine Study (TAPS) Group. McIvor RA, et al. **Chest** 1996 Jul; 110(1):141–6

USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. USPHS/IDSA Prevention of Opportunistic Infections Working Group. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S32–43

Microsporidiosis as an AIDS-related opportunistic infection. Bryan RT. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S62–5 (57 ref.)

Prophylaxis for tuberculosis in Europe--ongoing research. Carosi G, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S55–60 (31 ref.)

Potential role of rifabutin in prophylaxis for tuberculosis and infections due to multiple opportunistic pathogens. Chaisson RE. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S61–6; discussion S66–9 (51 ref.)

Indicators for assessment of compliance with quality standards for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Gross PA, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S138–41 (0 ref.)

Cryptosporidiosis: sources of infection and guidelines for prevention. Juranek DD. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S57–61 (52 ref.)

USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Kaplan JE, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S12–31

USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Kaplan JE, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S1–11

Opportunistic coccidioidomycosis in patients infected with human immunodeficiency virus: prevention issues and priorities. McNeil MM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S111–3 (19 ref.)

Preventing disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus. Ostroff SM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S72–6 (27 ref.)

Quality standards for preventing opportunistic infections related to human immunodeficiency virus and their implementation. Phair JP, et al. **Clin Infect Dis** 1995 Aug; 21 Suppl 1:S125

Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in adults and adolescents infected with human immunodeficiency virus. Phair JP, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S128–9 (8 ref.)

Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Reef SE, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S99–102 (24 ref.)

Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Richards FO Jr, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S49–56 (44 ref.)

Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. Simonds RJ, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S44–8 (41 ref.)

Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in infants and children born to women infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S132–3 (4 ref.)

The diagnosis and management of perinatal HIV infection. Nesheim SR. **Clin Obstet Gynecol** 1996 Jun;39(2):396–410 (84 ref.)

Azithromycin in the prophylaxis of opportunistic infections in AIDS. McCutchan JA. **Int J STD AIDS** 1996;7 Suppl 1:34–7

Treatment and prophylaxis of Mycobacterium avium complex. Young LS. **Int J STD AIDS** 1996;7 Suppl 1:23–7 (15 ref.)

Viral/bacterial vaccination rates in HIV-infected patients [letter] Bavry AA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):528–9

Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. MacPhail LA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):470–6

Long-term administration of aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia in infants and children with symptomatic human immunodeficiency virus infection. The Italian Pediatric Collaborative Study Group on Pentamidine. Principi N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):158–63

Need for action against tuberculosis [news] **J Adv Nurs** 1995 Nov;22(5):827

Infection prevention strategies for children with cancer and AIDS: contrasting dilemmas. Chanock SJ, et al. **J Hosp Infect** 1995 Jun;30 Suppl:197–208 (69 ref.)

Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial. The Italian PCP Study Group. Rizzardi GP, et al. **J Infect** 1996 Mar; 32(2):123–31

Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. Glesby MJ, et al. **J Infect Dis** 1996 Jun;173(6):1477–80

Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. Leport C, et al. **J Infect Dis** 1996 Jan;173(1):91–7

Iron overload as a mechanism for the lowered survival in AIDS patients receiving dapsone-iron protoxalate for secondary prophylaxis of Pneumocystis carinii pneumonia [letter; comment] Weinberg GA. **J Infect Dis** 1996 Jul; 174(1):241–2. Comment on: J Infect Dis 1995 Sep;172(3):656–64.

Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals. Saenghirunvattana S. **J Med Assoc Thai** 1996 May; 79(5):285–7

Clarithromycin prophylaxis against Cryptosporidium enteritis in patients with AIDS. Jordan WC. **J Natl Med Assoc** 1996 Jul;88(7):425–7

Oral ganciclovir fails to prevent CMV in HIV trial [news] McCarthy M. **Lancet** 1995 Sep 30;346(8979):895

TB. A global emergency, WHO, July 1994 [news] **Lepr Rev** 1995 Sep;66(3):270–1

Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. Freedberg KA, et al. **Med Decis Making** 1996 Jan–Mar;16(1):29–35

Managing HIV. Recommendations for antimicrobial prophylaxis in HIV. Mijch AM, et al. **Med J Aust** 1996 May 6;164(9):551

1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention. **MMWR Morb Mortal Wkly Rep** 1995 Apr 28;44(RR-4):1–11

USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. **MMWR Morb Mortal Wkly Rep** 1995 Jul 14; 44(RR-8):1–34

Bacterial pneumonia in HIV [letter; comment] Cohen JI. **N Engl J Med** 1996 Jan 18;334(3):195. Comment on: N Engl J Med 1995 Sep 28;333(13):845–51.

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group [see comments] Havlir DV, et al. **N Engl J Med** 1996 Aug 8;335(6):392–8 . Comment in: N Engl J Med 1996 Aug 8;335(6):428–30.

A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome [see comments] Pierce M, et al. **N Engl J Med** 1996 Aug 8;335(6):384–91. Comment in: N Engl J Med 1996 Aug 8;335(6):428–30.

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. Spector SA, et al. **N Engl J Med** 1996 Jun 6;334(23):1491–7

Rhabdomyolysis and the acquired immunodeficiency syndrome [letter; comment] Beversdorf D, et al. **Neurology** 1996 May;46(5):1498. Comment on: Neurology 1994 Sep;44(9):1692–6.

Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. Thea DM, et al. **Pediatrics** 1996 Jan;97(1):59–64

Tuberculosis and HIV-AIDS [news] **Public Health Rep** 1996 Jan–Feb;111(1):9

Evaluating the quality of life associated with rifabutin prophylaxis for Mycobacterium avium complex in persons with AIDS: combining Q-TWiST and multiattribute utility techniques. Revicki DA, et al. **Qual Life Res** 1995 Aug; 4(4):309–18

Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. Nielsen TL, et al. **Scand J Infect Dis** 1995;27(3):217–20

Tuberculosis and AIDS: the impact on the hospital social worker. Wade K, et al. **Soc Work Health Care** 1995; 21(3):29–41

Use of BCG in high prevalence areas for HIV. Felten MK, et al. **Trop Med Parasitol** 1995 Jun;46(2):69–71 (30 ref.)

Pattern of utilization of rifabutin for prophylaxis of Mycobacterium avium complex among patients with advanced human immunodeficiency virus disease in a community setting. Mandigo K, et al. **Tuber Lung Dis** 1996 Jun;77(3):233–8

[The impact of the prevention of cerebral toxoplasmosis]

Katlama C. **J Neuroradiol** 1995 Sep;22(3):193-5 (Eng. Abstr.) **(Fre)**

[Risk factors of the occurrence of cerebral toxoplasmosis in patients with HIV infection. Definition of indications of primary prevention. Proposals of the Toxoplasmosis and other protozoan infections Group. Coordinated action N.5 - 1996 February (news)] Leport C, et al. **Presse Med** 1996 Mar 30;25(11):519-20 **(Fre)**

[Effect of primary prevention of Pneumocystis carinii pneumonia on the inaugural clinical and biological presentation of AIDS: 624 cases (Aquitaine Cohort, 1985-1994)] Morlat P, et al. **Rev Med Interne** 1995; 16(11):815-7 (Eng. Abstr.) **(Fre)**

[Prevention of opportunistic infections in HIV infection] Pesce A. **Rev Med Interne** 1995;16 Suppl 3:315s-319s (20 ref.) **(Fre)**

[Prevention of opportunistic infections in HIV infected patients. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America] Bornkessel B. **Med Monatsschr Pharm** 1996 Jul; 19(7):206-14 **(Ger)**

RADIOGRAPHY

Detection and differential diagnosis of pulmonary infections and tumors in patients with AIDS: value of chest radiography versus CT. Kang EY, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):15-9

Toxoplasmosis of the corpus callosum: another butterfly. Lee HJ, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1280-1

Isolated renal mucormycosis in two patients with AIDS. Pastor-Pons E, et al. **AJR Am J Roentgenol** 1996 Jun; 166(6):1282-4

Radiographic presentation of pulmonary tuberculosis in severely immunosuppressed HIV-seropositive patients. Asimos AW, et al. **Am J Emerg Med** 1996 Jul;14(4):359-63

Lower lung field tuberculosis in Yaounde, Cameroon. Kuaban C, et al. **Cent Afr J Med** 1996 Mar;42(3):62-5

Cryptococcal pneumonia in patients with the acquired immunodeficiency syndrome. Friedman EP, et al. **Clin Radiol** 1995 Nov;50(11):756-60

The radiological manifestations of the acquired immune deficiency syndrome--Part 1. Banerjee AK. **Int J STD AIDS** 1996 Jan-Feb;7(1):27-31

Acute nephritis by Aspergillus in a patient with AIDS. Munõz-Bustillo E, et al. **Nephrol Dial Transplant** 1996 Jan; 11(1):194-6

Spectrum of chest radiographic abnormalities in children with AIDS and Pneumocystis carinii pneumonia. Sivit CJ, et al. **Pediatr Radiol** 1995;25(5):389-92

Pneumothorax as the presenting sign of Pneumocystis carinii infection in an HIV-positive child with prior lymphocytic interstitial pneumonitis. Solomon KS, et al. **Pediatr Radiol** 1996;26(8):559-62

Pulmonary tuberculosis: comparison of CT findings in HIV-seropositive and HIV-seronegative patients. Leung AN, et al. **Radiology** 1996 Mar;198(3):687-91

HIV infection: analysis in 259 consecutive patients with abnormal abdominal CT findings. Radin R. **Radiology** 1995 Dec;197(3):712-22

[Asymptomatic pulmonary pneumocytosis accidentally discovered in a patient with HIV infection (letter)] Schott R, et al. **Presse Med** 1996 Jan 20;25(2):81 **(Fre)**

[Standard radiological characteristics of thoracic sites of tuberculosis in patients with AIDS in a Tunisian population] Tiouiri H, et al. **Rev Pneumol Clin** 1995; 51(6):321-4 (12 ref.) (Eng. Abstr.) **(Fre)**

[Pneumococcal pneumonia in a patient with HIV infection. Development to excavation. Apropos of a case] Venot P, et al. **Rev Pneumol Clin** 1996;52(1):29-32 (11 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic results of abdominal computerized tomography in HIV-infected patients] Knollmann FD, et al. **Aktuelle Radiol** 1995 Nov;5(6):351-5 (Eng. Abstr.) **(Ger)**

[Radioisomorphisms of sclerosing cholangitis] Knollmann FD, et al. **Aktuelle Radiol** 1995 Jul;5(4):227-31 (Eng. Abstr.) **(Ger)**

[Differential radiologic diagnosis of HIV-associated lung diseases] Becker-Gaab C, et al. **Bildgebung** 1995 Dec; 62(4):302-9 (16 ref.) (Eng. Abstr.) **(Ger)**

[Paranasal sinus mycetoma with orbital involvement in a patient with AIDS] Busch M, et al. **Bildgebung** 1995 Sep; 62(3):199-201 (Eng. Abstr.) **(Ger)**

[Pulmonary complications in HIV-positive patients with advanced immune deficiency (less than 200 helper cells)] Jacobi V, et al. **Rontgenpraxis** 1995 Oct;48(10):283-8 **(Ger)**

[Pulmonary complications in HIV-positive patients with minimal immune deficiency] Jacobi V, et al. **Rontgenpraxis** 1995 Sep;48(9):254-8 **(Ger)**

[Pneumocystis carinii lung infections in AIDS patients: a study with high-resolution computed tomography (HRCT)] Bianco R, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):370-6 (Eng. Abstr.) **(Ita)**

[Rhodococcus equi lung infection in AIDS patients. A report of 4 cases] Carli Moretti C, et al. **Radiol Med (Torino)** 1996 Apr;91(4):477-80 (13 ref.) **(Ita)**

RADIONUCLIDE IMAGING

Identification of AIDS-related tuberculosis with concordant gallium-67 and three-hour delayed thallium-201 scintigraphy. Gómez MV, et al. **Eur J Nucl Med** 1996 Jul; 23(7):852-4

Abnormal gallium-67 skull uptake: a sign of peripheral marrow activation in HIV-positive patients with disseminated mycobacterioses. del Val Gomez M, et al. **J Nucl Med** 1995 Dec;36(12):2211-3

Immunoscintigraphy with a 99Tcm-labelled anti-granulocyte monoclonal antibody in patients with human immunodeficiency virus infection and AIDS. Prvulovich EM, et al. **Nucl Med Commun** 1995 Oct; 16(10):838-45

The role of gallium and labeled leukocyte scintigraphy in the AIDS patient. Palestro CJ, et al. **Q J Nucl Med** 1995 Sep;39(3):221-30

[Cerebral lesions in AIDS: what can be expected from scintigraphy? Cerebral tomographic scintigraphy using thallium-201: a contribution to the differential diagnosis of lymphomas and infectious lesions] Berry I, et al. **J Neuroradiol** 1995 Sep;22(3):218-28 (Eng. Abstr.) **(Fre)**

THERAPY

Empiric outpatient management of HIV-related pneumonia: economical or unwise? [editorial] Masur H, et al. **Ann Intern Med** 1996 Feb 15;124(4):451-3

Management of persistent B19 parvovirus infection in AIDS. Ramratnam B, et al. **Br J Haematol** 1995 Sep;91(1):90-2

The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis. Chang HR. **Int J STD AIDS** 1996;7 Suppl 1:18-22 (34 ref.)

Intralesional interferon for the treatment of recalcitrant molluscum contagiosum in HIV antibody positive individuals--a preliminary report. Nelson MR, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):351-2

Predictors of resource utilization for hospitalized patients with Pneumocystis carinii pneumonia (PCP): a summary of effects from the multi-city study of quality of PCP care. Horner RD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 1;12(4):379-85

CMV retinitis monoclonal antibody trial halted [news] McCarthy M. **Lancet** 1996 Aug 31;348(9027):603

Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine. Lustig V, et al. **Neth J Med** 1995 Aug; 47(2):66-9

[Pneumocystis carinii pneumonia in AIDS: retrospective analysis of 80 documented cases (1985-1993)] Morlat P, et al. **Rev Med Interne** 1996;17(1):25-33 (Eng. Abstr.) **(Fre)**

[The therapy of viral hepatitis in HIV-infected patients] Rockstroh JK, et al. **Dtsch Med Wochenschr** 1995 Dec 8; 120(49):1705-8 (29 ref.) **(Ger)**

[Retinitis due to cytomegalovirus in AIDS] Mackiewicz J, et al. **Klin Oczna** 1995 Mar-Apr;97(3-4):74-6 (Eng. Abstr.) **(Pol)**

TRANSMISSION

Transmission of Mycobacterium tuberculosis from tuberculosis patients with HIV infection or AIDS. Cauthen GM, et al. **Am J Epidemiol** 1996 Jul 1;144(1):69-77

Transmission of tuberculosis to contacts of sputum positive adults in Malawi. Topley JM, et al. **Arch Dis Child** 1996 Feb;74(2):140-3

Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. Barchiesi F, et al. **Clin Infect Dis** 1995 Sep;21(3):561-4

Sexually transmissible agent and African Kaposi's sarcoma [editorial] Matondo P, et al. **Int J STD AIDS** 1996 Jan-Feb; 7(1):4-6 (35 ref.)

ULTRASONOGRAPHY

Microabscesses of the liver and spleen in AIDS: detection with 5-MHz sonography. Murray JG, et al. **Radiology** 1995 Dec;197(3):723-7

[Ultrasound skin findings in HIV infection by imaging with 7.5 MHz linear transducers] Bogner JR, et al. **Bildgebung** 1995 Dec;62(4):281-6 (14 ref.) (Eng. Abstr.) **(Ger)**

[Ultrasound findings in HIV patients] Lüthen R, et al. **Bildgebung** 1995 Dec;62(4):271-80 (45 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Relationship between cytomegalovirus cells and survival in acquired immunodeficiency syndrome patients. Lemert CM, et al. **Acta Cytol** 1996 Mar-Apr;40(2):205-10

Subtle clues to the diagnosis of the herpesvirus by light microscopy. Herpetic syringitis. Sangueza OP, et al. **Am J Dermatopathol** 1995 Apr;17(2):163-8

Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease. Wolf DG, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2552-4

Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group. Jabs DA, et al. **Arch Ophthalmol** 1996 Jul;114(7):809-14

Clinico-pathological study of cytomegalovirus (CMV) in AIDS autopsies: under-recognition of CMV pneumonitis and CMV adrenalitis. Dore GJ, et al. **Aust N Z J Med** 1995 Oct;25(5):503-6

Cytomegalovirus-induced alveolar hemorrhage in patients with AIDS: a new clinical entity? Herry I, et al. **Clin Infect Dis** 1996 Apr;22(4):616-20

Kaposi's sarcoma herpesvirus in oral Kaposi's sarcoma [letter] DiAlberti L, et al. **Eur J Cancer B Oral Oncol** 1996 Jan;32B(1):68-9

Active HHV-6 infection in the lymph nodes of HIV-infected patients: in vitro evidence that HHV-6 can break HIV latency. Knox KK, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 1;11(4):370-8

Infection of human immunodeficiency virus 1 transgenic mice with Toxoplasma gondii stimulates proviral transcription in macrophages in vivo. Gazzinelli RT, et al. **J Exp Med** 1996 Apr 1;183(4):1645-55

Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. Donovan RM, et al. **J Infect Dis** 1996 Aug;174(2):401-3

Cytomegalovirus glycoprotein B groups associated with retinitis in AIDS. Shepp DH, et al. **J Infect Dis** 1996 Jul; 174(1):184-7

Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates. Smith IL, et al. **J Infect Dis** 1996 Jun;173(6):1481-4

Cytomegalovirus in bronchoalveolar lavage specimens from patients with AIDS: comparison with antigenaemia and viraemia. Angelici E, et al. **J Med Microbiol** 1996 Aug; 45(2):149-52

Detection of several types of human papilloma viruses in AIDS-associated Kaposi's sarcoma. Adams V, et al. **J Med Virol** 1995 Jul;46(3):189-93

Human herpesvirus 6 in human immunodeficiency virus-infected individuals: association with early histologic phases of lymphadenopathy syndrome but not with malignant lymphoproliferative disorders. Dolcetti R, et al. **J Med Virol** 1996 Apr;48(4):344-53

PCR detection of JC virus DNA in brain tissue from patients with and without progressive multifocal leukoencephalopathy. Ferrante P, et al. **J Med Virol** 1995 Nov;47(3):219-25

Detection of HCV RNA in serum and seminal fluid from HIV-1 co-infected intravenous drug addicts. Fiore RJ, et al. **J Med Virol** 1995 Aug;46(4):364-7

Quantitation of human cytomegalovirus genomes in the brain of AIDS patients. Kühn JE, et al. **J Med Virol** 1995 Sep; 47(1):70-82

Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. Sarasini A, et al. **J Med Virol** 1995 Nov;47(3):237-44

Adenovirus mixture isolated from the brain of an AIDS patient with encephalitis. Schnurr D, et al. **J Med Virol** 1995 Oct;47(2):168-71

Use of the polymerase chain reaction to detect genomes of human immunodeficiency virus and cytomegalovirus in post-mortem tissues. Webster A, et al. **J Med Virol** 1995 Sep;47(1):23-8

Frequent recurrence and persistence of varicella-zoster virus infections in children infected with human immunodeficiency virus type 1. von Seidlein L, et al. **J Pediatr** 1996 Jan;128(1):52-7

Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. Baldanti F, et al. **J Virol** 1996 Mar;70(3):1390-5

Kaposi's sarcoma and KSHV [letter; comment] Noel JC. **Lancet** 1995 Nov 18;346(8986):1359. Comment on: Lancet 1995 Sep 23;346(8978):799-802.

Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Boshoff C, et al. **Nat Med** 1995 Dec; 1(12):1274-8

KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma [see comments] Gao SJ, et al. **Nat Med** 1996 Aug;2(8):925-8. Comment in: Nat Med 1996 Aug;2(8):862-3.

Successful treatment of CMV-induced adrenal insufficiency by ganciclovir in a patient with the acquired immunodeficiency syndrome. Sanhes L, et al. **Nephrol Dial Transplant** 1995;10(5):704-5

Subacute measles virus encephalitis: a new and fatal opportunistic infection in a patient with AIDS. Budka H, et al. **Neurology** 1996 Feb;46(2):586-7

Herpesviridae-associated persistent mucocutaneous ulcers in acquired immunodeficiency syndrome. A clinicopathologic study. Flaitz CM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):433-41

Clinical viral infections and temporal bone histologic studies of patients with AIDS. Davis LE, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):695-701

[Parasitic and viral enteritis in human immunodeficiency virus infection] Cotte L, et al. **Gastroenterol Clin Biol** 1995; 19(5 Pt 2):B130-5 **(Fre)**

[Spontaneous corneal perforation and conjunctival molluscum contagiosum in a AIDS patient] Williamson W, et al. **J Fr Ophtalmol** 1995;18(11):703-7 (Eng. Abstr.) **(Fre)**

[Cytomegalovirus pneumopathies. What role should be given to cytomegaloviruses isolated from blood and bronchoalveolar lavage fluid in AIDS and from organ and bone marrow grafts?] Blot F, et al. **Rev Pneumol Clin** 1995; 51(6):309–20 (102 ref.) (Eng. Abstr.) **(Fre)**

[Kaposi sarcoma apparently induced by a new oncogenic herpesvirus (news)] Gürtler L. **Fortschr Med** 1995 Aug 20;113(22–23):7–8 **(Ger)**

[Clinical manifestations and course of cytomegalovirus colitis in AIDS patients] Giezendanner S, et al. **Schweiz Med Wochenschr** 1995 Dec 16;125(50):2417–22 (Eng. Abstr.) **(Ger)**

[Rotavirus studied in the feces of 10 patients with the acquired immunodeficiency syndrome (AIDS)] Machado AA, et al. **Rev Soc Bras Med Trop** 1996 May–Jun; 29(3):283–4 **(Por)**

[HIV is a threat even to eye-sight. Cooperation between clinics has improved diagnosis and treatment] Hedquist BG, et al. **Lakartidningen** 1996 Mar 20;93(12):1121–5 **(Swe)**

AIDS SEROCONVERSION see HIV SEROPOSITIVITY

AIDS SERODIAGNOSIS

see related
HIV SEROPREVALENCE

Detection of human immunodeficiency virus-1 DNA, RNA and antibody, and occult blood in inactivated saliva: availability of the filter paper disk method. Kakizawa J, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):218–23

Correlates of acceptance of HIV testing and post-test counseling in the obstetrical setting. Sorin MD, et al. **AIDS Educ Prev** 1996 Feb;8(1):72–85

Repeat negative human immunodeficiency virus (HIV) testing in San Francisco: magnitude and characteristics. McFarland W, et al. **Am J Epidemiol** 1995 Oct 1; 142(7):719–23

Testing for human immunodeficiency virus infection in patients with tuberculosis. Barnes PF, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1448–50

Feasibility of an emergency department-based, risk-targeted voluntary HIV screening program. Kelen GD, et al. **Ann Emerg Med** 1996 Jun;27(6):687–92

German company halts delivery of HIV test kits [news] Karcher HL. **BMJ** 1996 Apr 27;312(7038):1059–60

HIV pre-test discussion [editorial] Miller R, et al. **BMJ** 1996 Jul 20;313(7050):130

US approves HIV "home test" [news] Roberts J. **BMJ** 1996 May 25;312(7042):1317

HIV testing practices of primary care physicians: an Ontario survey. Skotniski EM, et al. **Can J Public Health** 1996 May–Jun;87(3):172–5

Qualitative evaluation of the Canadian Medical Association's counselling guidelines for HIV serologic testing. Rowan MS, et al. **Can Med Assoc J** 1996 Mar 1;154(5):665–71

AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1995 Dec 15; 5(50):289–90

The impact of HIV testing on blood utilization in the intensive care unit in patients with gastrointestinal bleeding. Ravry ME, et al. **Intensive Care Med** 1995 Nov; 21(11):933–6

Home screening test for HIV approved [news] **J Am Osteopath Assoc** 1996 Jun;96(6):334

Management of blood donors whose donations are repeatedly falsely positive by the HIV antibody screening test. Atrah HI, et al. **J Clin Pathol** 1995 Sep;48(9):865–7

HIV screening and treatment in pregnancy. Ross EL. **J Miss State Med Assoc** 1996 Aug;37(8):706–7

Prenatal and neonatal HIV testing [letter; comment] Fischer CT. **JAMA** 1996 Feb 7;275(5):357–8. Comment on: JAMA 1995 Oct 11;274(14):1165–8.

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Jul 3;276(1):14

HIV counseling and testing of pregnant women [letter] Phillips KA, et al. **JAMA** 1996 Jul 24–31;276(4):283–4

HIV testing over Easter. Banatvala JE. **Lancet** 1996 Apr 20;347(9008):1058–9

False-negative HIV test leads to widespread retesting [news] Choo V. **Lancet** 1996 Apr 13;347(9007):1031

Difficulties and strategies of HIV diagnosis. Gürtler L. **Lancet** 1996 Jul 20;348(9021):176–9 (30 ref.)

Training medical students in HIV/AIDS test counselling: results of a randomized trial. Campbell E, et al. **Med Educ** 1996 Mar;30(2):134–41

Prevalence of antibodies against an immunodominant region of the HIV-1 envelope glycoprotein gp41 in sera from HIV-1 infected individuals in Brazil. Bongertz V, et al. **Mem Inst Oswaldo Cruz** 1994 Jul–Sep;89(3):369–70

HIV testing among women aged 18–44 years—United States, 1991 and 1993. **MMWR Morb Mortal Wkly Rep** 1996 Aug 30;45(34):733–7

The HIV antibody test. **Nurse Pract** 1996 Mar;21(3):121–2

HIV and informed consent [letter] Fennell WM. **S Afr Med J** 1996 Apr;86(4):378

HIV testing in the workplace [editorial] London L, et al. **S Afr Med J** 1996 Apr;86(4):329–30

A review of research on the nature and quality of HIV testing services: a proposal for process-based studies. Beardsell S, et al. **Soc Sci Med** 1996 Mar;42(5):733–43 (112 ref.)

Antigen testing for human immunodeficiency virus (HIV) and the magnet effect: will the benefit of a new HIV test be offset by the numbers of higher risk, test-seeking donors attracted to blood centers? Retrovirus Epidemiology Donor Study. Korelitz JJ, et al. **Transfusion** 1996 Mar; 36(3):203–8

An audit of HIV testing and HIV serostatus in tuberculosis patients, Blantyre, Malawi. Harries AD, et al. **Tuber Lung Dis** 1995 Oct;76(5):413–7

[Retrospective evaluation of western blot for detection of early HIV infections] Neifer S, et al. **Gesundheitswesen** 1995 Aug–Sep;57(8–9):489–93 (Eng. Abstr.) **(Ger)**

[Epidemiology of HIV in Germany (status: 30 June 1995)--transmission among heterosexuals and value of HIV screening programs] Wittkowski KM. **Gesundheitswesen** 1996 Apr;58(4):229–33 (Eng. Abstr.) **(Ger)**

[Introduction and evaluation of HIV tests in the North-East part of Tanzania] Haukenes G, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3289–90 (Eng. Abstr.) **(Nor)**

[Counseling and HIV-testing among hospital patients in Arusha and Kilimanjaro] Lie GT, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3286–8 (Eng. Abstr.) **(Nor)**

LEGISLATION & JURISPRUDENCE

Home HIV testing and conflicts with state HIV testing regulations. Fabbri WO. **Am J Law Med** 1995;21(4):419–44 (230 ref.)

Rules on HIV testing of source patients [news] Pugliese G. **Infect Control Hosp Epidemiol** 1995 Sep;16(9):525

Pediatric HIV disease, zidovudine in pregnancy, and unblinding heelstick surveys. Reframing the debate on prenatal HIV testing [see comments] Minkoff H, et al. **JAMA** 1995 Oct 11;274(14):1165–8. Comment in: JAMA 1996 Feb 7;275(5):357–8.

HIV tests for babies to be mandatory in USA [news] Rovner J. **Lancet** 1996 May 11;347(9011):1325

CDC and Congress at odds over mandatory HIV testing [news] Touchette N. **Nat Med** 1995 Aug;1(8):723–4

METHODS

Home HIV test gets nod [news] **Am J Nurs** 1996 Jul;96(7):14

Characteristics and clinical significance of a stabilization assay to detect specific antibodies to reverse transcriptase of human immunodeficiency virus. Morita M, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):583–9

Chimeric synthetic peptides as antigens for detection of antibodies to HIV-1 and HIV-2. Shah K, et al. **East Afr Med J** 1996 Jan;73(1):63–6

Testing of saliva and serum for HIV in high-risk populations. Ad Hoc Group for the Comparative Saliva and Serum Study. Vall Mayans M, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):710–3

When to perform the final HIV antibody test following possible exposure. The British Co-operative Clinical Group. **Int J STD AIDS** 1995 Sep–Oct;6(5):332–5

Reactivity of Argentine serum samples against synthetic V3-based HIV-1 peptides [letter] Pampuro SE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):527–8

Evaluation of a dipstick method for the detection of human immunodeficiency virus infection. Beristain CN, et al. **J Clin Lab Anal** 1995;9(6):347–50

Performance of a rapid, on-site human immunodeficiency virus antibody assay in a public health setting. Kassler WJ, et al. **J Clin Microbiol** 1995 Nov;33(11):2899–902

Simplified testing for antibodies to human immunodeficiency virus. Pagcharoenpol P, et al. **J Clin Microbiol** 1996 Apr; 34(4):973–4

How much weight should viral load carry? [news] [see comments] Steele FR. **Nat Med** 1996 May;2(5):502. Comment in: Nat Med 1996 Aug;2(8):832–3.

Radio immune Western blotting: a possible solution to indeterminate conventional Western blotting results for the serodiagnosis of HIV infections. Portincasa P, et al. **New Microbiol** 1996 Jan;19(1):85–90

Application of laboratory diagnostics in HIV nursing. Barrick B, et al. **Nurs Clin North Am** 1996 Mar;31(1):41–56 (47 ref.)

Comparison of a rapid nonisotopic polymerase chain reaction assay with four commonly used methods for the early diagnosis of human immunodeficiency virus type 1 infection in neonates and children. Kovacs A, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):948–54

Counseling and testing for HIV prevention: costs, effects, and cost-effectiveness of more rapid screening tests. Farnham PG, et al. **Public Health Rep** 1996 Jan–Feb; 111(1):44–53; discussion 54

Reducing the cost of HIV-testing through use of the IgG antibody captured particle adherence test (GACPAT) in district hospitals. Klokke AH, et al. **Trop Geogr Med** 1995; 47(6):296–9

MORTALITY

Estimation of survival after AIDS diagnosis: CD4 T lymphocyte count versus clinical severity. Turner BJ, et al. **J Clin Epidemiol** 1996 Jan;49(1):59–65

NURSING

Application of laboratory diagnostics in HIV nursing. Barrick B, et al. **Nurs Clin North Am** 1996 Mar;31(1):41–56 (47 ref.)

PSYCHOLOGY

Trends and predictors of human immunodeficiency virus antibody testing by homosexual and bisexual adolescent males, 1989–1994. Povinelli M, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):33–8

Psychosocial differences between recently HIV tested and non-tested gay men who reside in smaller US cities. Heckman TG, et al. **Int J STD AIDS** 1995 Nov–Dec; 6(6):436–40

Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: implications for secondary prevention efforts. Stall R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):151–60

A controlled study of anxiety and morbid cognitions at initial screening for human immunodeficiency virus (HIV) in a cohort of people with haemophilia. Jones QJ, et al. **J Psychosom Res** 1995 Jul;39(5):597–608

Counselling and the HIV test [letter; comment] Mankazana M, et al. **S Afr Med J** 1996 Jan;86(1):98. Comment on: S Afr Med J 1995 Jun;85(6):512–4.

STANDARDS

Physician satisfaction with human immunodeficiency virus type 1 and hepatitis B virus testing in San Diego County. Rau J, et al. **Med Care** 1996 Jan;34(1):1–10

Pitfalls in HIV testing. Application and limitations of current tests. Cordes RJ, et al. **Postgrad Med** 1995 Nov; 98(5):177–80, 185–6, 189 (22 ref.)

STATISTICS & NUMERICAL DATA

A cross-sectional study on factors including HIV testing and counselling determining unsafe injecting practices among injecting drug users of Manipur. Sarkar S, et al. **Indian J Public Health** 1995 Jul–Sep;39(3):86–92

Opportunities for targeting publicly funded human immunodeficiency virus counseling and testing. Peterman TA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):69–74

Assessment of HIV testing rates among HIV infected individuals using incidence data on HIV and AIDS diagnoses. Marschner IC. **Stat Med** 1996 Mar 15; 15(5):497–511

[Demand and HIV testing prescription in primary care. Registry of the network of sentinel physicians from Castilla y León in 1991, 1992, and 1993] Vega Alonso AT, et al. **Gac Sanit** 1996 Jan–Feb;10(52):25–33 (Eng. Abstr.) **(Spa)**

TRENDS

Trends and predictors of human immunodeficiency virus antibody testing by homosexual and bisexual adolescent males, 1989–1994. Povinelli M, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):33–8

UTILIZATION

Changes in multiple sexual partnerships, HIV testing, and condom use among US heterosexuals 18 to 49 years of age, 1990 and 1992. Choi KH, et al. **Am J Public Health** 1996 Apr;86(4):554–6

Preoperative HIV testing [letter; comment] Pincus RL. **Ear Nose Throat J** 1995 Sep;74(9):657. Comment on: Ear Nose Throat J 1995 May;74(5):313.

Preoperative HIV antibody testing: the views of surgeons and patients. Meadows J, et al. **Int J STD AIDS** 1995 Nov–Dec;6(6):426–30

AIDS SEROLOGY see AIDS SERODIAGNOSIS

AIDS SEROPOSITIVITY see HIV SEROPOSITIVITY

AIDS, SIMIAN see SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME

AIDS VACCINES

Conference on Advances in AIDS Vaccine Development: 7th annual meeting of the National Cooperative Vaccine Development Groups for AIDS. November 6–10, 1994. **AIDS Res Hum Retroviruses** 1995 Oct;11(10):1273–319

New insights into the role of host cell proteins in antiviral vaccine protection [letter] Montefiori DC. **AIDS Res Hum Retroviruses** 1995 Dec;11(12):1429–31

Assessing HIV vaccine effects. Koopman JS, et al. **Am J Epidemiol** 1995 Nov 15;142(10):1113–20

The immune response to HIV gp120 induced by nucleic acid immunization (NAI). Peet N, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:257–60

Nucleic acid vaccination with HIV regulatory genes. Wahren B, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:278–81

HIV preventive vaccines. Progress to date. Esparza J, et al. **Drugs** 1995 Nov;50(5):792–804 (153 ref.)

Preventive and therapeutic AIDS peptide vaccines. Rubinstein A, et al. **Eur J Pediatr** 1995;154(9 Suppl 4):S28–9

Hepatitis B immunization: a potential incentive to HIV vaccine trial participation in Thailand? Beyrer C, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr

1;11(4):396–400
Interest among gay/bisexual men in greater Boston in participating in clinical trials of preventive HIV vaccines. Gross M, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Aug 1;12(4):406–12
Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. Harrison K, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Nov 1;10(3):386–90
Interest in HIV vaccines among Italian injection drug users. The Network Interregionale SERT [letter] Serpelloni G, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):206–7
Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector. Frankel FR, et al. **J Immunol** 1995 Nov 15;155(10):4775–82
Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. Berman PW, et al.
J Infect Dis 1996 Jan;173(1):52–9
Enumeration of lymphokine-secreting cells as a quantitative measure for cellular immune responses in rhesus macaques. van der Meide PH, et al. **J Med Primatol** 1995 Dec; 24(4):271–81
Fourth annual survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates. Warren JT, et al. **J Med Primatol** 1995 May;24(3):150–68
Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice. Lapham C, et al. **J Virol** 1996 May;70(5):3084–92
Reconsidering an attenuated vaccine for AIDS. Beale J. **Lancet** 1996 Feb 10;347(8998):344–5
Trial results thwart HIV-vaccine hopes [news] McCarthy M. **Lancet** 1996 Apr 27;347(9009):1173
Nef vaccination against HIV disease [letter] Montagnier L. **Lancet** 1995 Oct 28;346(8983):1170
Two candidates for a live AIDS vaccine emerge [news] Rowe PM. **Lancet** 1996 Sep 14;348(9029):742
HIV subtypes raise vaccine anxieties [news] Rowe PM. **Lancet** 1996 Mar 2;347(9001):603
Managing HIV. Part 8: Controlling an epidemic. 8.3 Prospects for a preventive HIV vaccine. Kent SJ, et al. **Med J Aust** 1996 Aug 19;165(4):212–5
Canarypox as a vector for HIV vaccine [news] Fricker J. **Mol Med Today** 1996 Jun;2(6):225
Candidate AIDS vaccines. Graham BS, et al.
N Engl J Med 1995 Nov 16;333(20):1331–9 (100 ref.)
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques [see comments] Abimiku AG, et al. **Nat Med** 1995 Apr;1(4):321–9. Comment in: Nat Med 1995 Apr;1(4):295–7.
A "complement-ary" AIDS vaccine. Dierich MP, et al.
Nat Med 1996 Feb;2(2):153–5 (26 ref.)
FDA panel reluctantly approves AIDS vaccine trial [news] Fox JL. **Nat Med** 1995 Mar;1(3):191–2
Genentech sheds gp120 vaccine [news] Gershon D.
Nat Med 1996 Apr;2(4):370–1
Whether and when an AIDS vaccine? Hilleman MR.
Nat Med 1995 Nov;1(11):1126–9
Progress towards a vaccine to prevent sexual transmission of HIV. Miller CJ, et al. **Nat Med** 1996 Jul;2(7):751–2
Scandal touches HIV vaccine development in Japan [news] Nathan R. **Nat Med** 1995 Aug;1(8):727
gp 120: good, bad or indifferent? [news] Steele FR.
Nat Med 1995 Nov;1(11):1105–6
Assessing animal models of AIDS [comment] Stott J, et al. **Nat Med** 1995 Apr;1(4):295–7. Comment on: Nat Med 1995 Apr;1(4):321–9.
HIV vaccine: sell-out or vote of confidence by Genentech? [news] Wadman M. **Nature** 1996 Feb 29;379(6568):757
HIV vaccine strategy seeks to woo industry [news] Wadman M. **Nature** 1996 Feb 22;379(6567):665
A candidate live inactivatable attenuated vaccine for AIDS. Chakrabarti BK, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9810–5
Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. McElrath MJ, et al.
Proc Natl Acad Sci U S A 1996 Apr 30;93(9):3972–7
Strategies of research for a vaccine against AIDS. Essex M. **Pubbl Stn Zool Napoli II** 1995;17(1):141–9
OTA swan song has many verses [news]
Public Health Rep 1995 Nov-Dec;110(6):651–2
Investors sought for AIDS vaccine trials [news] **Science** 1996 Mar 1;271(5253):1237
A perspective on AIDS vaccines. Bloom BR. **Science** 1996 Jun 28;272(5270):1888–90
Thailand weighs AIDS vaccine tests [news] Cohen J. **Science** 1995 Nov 10;270(5238):904–7
Vaccine drought spurs NIAID plan to improve industry ties... [news] Cohen J. **Science** 1996 Mar 1;271(5253):1227–8
Attenuated retrovirus vaccines and AIDS [letter; comment] Kestler HW, et al. **Science** 1995 Nov 17;270(5239):1219; discussion 1220–2. Comment on: Science 1995 Mar 24;267(5205):1820–5.
Attenuated retrovirus vaccines and AIDS [letter; comment] Marx PA. **Science** 1995 Nov 17;270(5239):1219–20; discussion 1220–2. Comment on: Science 1995 Mar 24;267(5205):1820–5.
Attenuated HIV vaccine: caveats [letter; comment] Ruprecht RM, et al. **Science** 1996 Mar 29;271(5257):1790–2. Comment on: Science 1995 Nov 10;270(5238):988–91.
Attenuated retrovirus vaccines and AIDS [letter; comment] Shearer GM, et al. **Science** 1995 Nov 17;270(5239):1219; discussion 1220–2. Comment on: Science 1995 Mar 24;267(5205):1820–5.
Attenuated retrovirus vaccines and AIDS [letter; comment] Van Rompay KK, et al. **Science** 1995 Nov 17; 270(5239):1218–9; discussion 1220–2. Comment on: Science 1995 Mar 24;267(5205):1820–5.
Introducing a first AIDS vaccine in Switzerland: a Policy Delphi analysis. Zuber PL, et al. **Soz Praventivmed** 1996; 41(2):126–7
The status of HIV/AIDS vaccines—1993. Weber J.
Ther Immunol 1994 Apr;1(2):95–100
Modelling HIV vaccination. McLean AR, et al.
Trends Microbiol 1995 Dec;3(12):458–62 (18 ref.)
[Progress in vaccination against AIDS] Burny A.
Bull Mem Acad R Med Belg 1995;150(3–4):145–53; discussion 153–5 (Eng. Abstr.) **(Fre)**
[Clinical experimentation with HIV vaccines: scientific and ethical dilemmas] Lallemant M, et al.
Pubbl Stn Zool Napoli II 1995;17(1):151–69 (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. Celentano DD, et al. **AIDS** 1995 Sep;9(9):1079–83
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. Keefer MC, et al. **AIDS Res Hum Retroviruses** 1996 May 20;12(8):683–93
Receptor-linked antigen delivery system. Importance of autologous alpha 2-macroglobulin in the development of peptide vaccine. Mitsuda S, et al.
Biochem Biophys Res Commun 1995 Nov 2;216(1):399–405
Can communities protect autonomy? Ethical dilemmas in HIV preventative drug trials. Zion D.
Camb Q Healthc Ethics 1995 Fall;4(4):516–23
Will preventive HIV vaccine efficacy trials be possible with female injection drug users? Meyers K, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Dec 15;10(5):577–85
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Gorse GJ, et al. **J Infect Dis** 1996 Feb;173(2):330–9
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Mascola JR, et al.
J Infect Dis 1996 Feb;173(2):340–8
Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network. Gorse GJ, et al. **Vaccine** 1995 Sep; 13(13):1170–9
[AIDS vaccine: who should be selected for the test?] Marcus U. **Fortschr Med** 1995 Nov 20;113(32):16–7 **(Ger)**
[Vaccines against AIDS finally in sight? Vaccination campaigns in China and Uganda in preliminary stages (news)] Wolf HJ. **Fortschr Med** 1995 Nov 10;113(31):20, 22 **(Ger)**

ADVERSE EFFECTS

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Graham BS, et al. **Ann Intern Med** 1996 Aug 15;125(4):270–9

CHEMISTRY

Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Weissburg RP, et al. **Pharm Res** 1995 Oct; 12(10):1439–46

ECONOMICS

AIDS vaccine 'needs focused effort' as drug firms back off research [news] Butler D. **Nature** 1995 Nov 23; 378(6555):323–4
The marketplace of HIV/AIDS [news] Cohen J. **Science** 1996 Jun 28;272(5270):1880–1

GENETICS

Is the Nef protein of HIV-1 required for pathogenesis? Miller MD, et al. **Trends Microbiol** 1996 May;4(5):171–2; discussion 173
Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120. Fouts TR, et al. **Vaccine** 1995 Dec;13(17):1697–705
Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine. Fouts TR, et al. **Vaccine** 1995 Apr;13(6):561–9

IMMUNOLOGY

Antiplatelet antibodies during the course of HIV-preventive vaccine trial [letter] Kaplan C, et al. **AIDS** 1996 Apr; 10(4):447–9
Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals? Rencher SD, et al. **AIDS Res Hum Retroviruses** 1995 Sep; 11(9):1131–3
Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins. Rovinski B, et al.
AIDS Res Hum Retroviruses 1995 Oct;11(10):1187–95
Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. Salmon-Céron D, et al.
AIDS Res Hum Retroviruses 1995 Dec;11(12):1479–86
Preparation and characterization of human HIV type 1 neutralizing reference sera. Vujcic LK, et al.
AIDS Res Hum Retroviruses 1995 Jul;11(7):783–7
Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Graham BS, et al. **Ann Intern Med** 1996 Aug 15;125(4):270–9
Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination. Shiver JW, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:198–208
DNA inoculation induces cross clade anti-HIV-1 responses. Wang B, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:186–97
HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice. Sarin PS, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):401–7
Peptide immunization in humans: a combined CD8+/CD4+ T cell-targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL). Brander C, et al. **Clin Exp Immunol** 1996 Jul; 105(1):18–25
A macromolecular multicomponent peptide vaccine prepared using the glutaraldehyde conjugation method with strong immunogenicity for HIV-1. Hamajima K, et al.
Clin Immunol Immunopathol 1995 Dec;77(3):374–9
Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates. Reeves JP, et al. **Hybridoma** 1995 Jun;14(3):235–42
Progress in AIDS vaccine development. Johnston MI.
Int Arch Allergy Immunol 1995 Dec;108(4):313–7 (29 ref.)
HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella. Berggren RE, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Dec 15;10(5):489–95
Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). Staats HF, et al.
J Immunol 1996 Jul 1;157(1):462–72
Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. Suzue K, et al. **J Immunol** 1996 Jan 15;156(2):873–9
Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. VanCott TC, et al.
J Immunol 1995 Oct 15;155(8):4100–10
Human studies in the development of human immunodeficiency virus vaccines. Dolin R. **J Infect Dis** 1995 Nov;172(5):1175–83 (91 ref.)
Human immunodeficiency virus type 1 candidate vaccine breakthrough infection [letter; comment] Mascola JR, et al. **J Infect Dis** 1995 Dec;172(6):1636–8. Comment on: J Infect Dis 1995 May;171(5):1343–7.
Immunologic mechanism for human immunodeficiency virus type 1 gp120 vaccine failure [letter; comment] O'Toole C, et al. **J Infect Dis** 1996 Feb;173(2):512–3. Comment on: J Infect Dis 1995 May;171(5):1343–7.
A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). Valentine FT, et al. **J Infect Dis** 1996 Jun;173(6):1336–46
Resistance of previously infected chimpanzees to successive challenges with a heterologous intra :lade B strain of human immunodeficiency virus type 1. Shibata R, et al.
J Virol 1996 Jul;70(7):4361–9
Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Bukawa H, et al. **Nat Med** 1995 Jul;1(7):681–5
HIV-1 Tat protein as a potential AIDS vaccine. Goldstein G. **Nat Med** 1996 Sep;2(9):960–4 (34 ref.)
Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Putkonen P, et al. **Nat Med** 1995 Sep;1(9):914–8
Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Honda M, et al.

Proc Natl Acad Sci U S A 1995 Nov 7;92(23):10693–7
Uganda may host AIDS vaccine trial [news] Holden C. **Science** 1996 May 3;272(5262):657
Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV–1 gp120. Fouts TR, et al. **Vaccine** 1995 Dec;13(17):1697–705
Overview: practical insights from comparative immunology and pathogenesis of AIDS, hepatitis B, and measles for developing an HIV vaccine. Hilleman MR. **Vaccine** 1995 Dec;13(18):1733–40 (41 ref.)
Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies. Jones DH, et al. **Vaccine** 1995 Aug;13(11):991–9
Immune responses induced by administration of encapsidated poliovirus replicons which express HIV–1 gag and envelope proteins. Moldoveanu Z, et al. **Vaccine** 1995 Aug; 13(11):1013–22
Immunogenicity of the yeast recombinant p17/p24:Ty virus–like particles (p24–VLP) in healthy volunteers. Weber J, et al. **Vaccine** 1995 Jun;13(9):831–4
[Nucleic acid vaccines for study in AIDS patients are approved. Vaccines of genetic molecules––humoral and cellular immune response (news)] Hobom B. **Fortschr Med** 1995 Dec 20;113(35–36):12 **(Ger)**

ISOLATION & PURIFICATION

[Bare DNA as a new vaccine against HIV––DNA as vaccine (news) (published erratum appears in Schweiz Rundsch Med Prax 1995 Dec 19;84(51–52):1545)] Mölling K. **Schweiz Rundsch Med Prax** 1995 Nov 21;84(47):1400–1 **(Ger)**

PHARMACOLOGY

Peptide immunization in humans: a combined CD8+/CD4+ T cell–targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL). Brander C, et al. **Clin Exp Immunol** 1996 Jul; 105(1):18–25
Utility of SHIV for testing HIV–1 vaccine candidates in macaques. Lu Y, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):99–106
Potential impact of low efficacy HIV–1 vaccines in populations with high rates of infection. Anderson RM, et al. **Proc R Soc Lond B Biol Sci** 1995 Aug 22; 261(1361):147–51
HIV–1 candidate vaccines can induce antibodies which share specificity with human monoclonal antibodies capable of neutralizing primary isolates [letter] Davis D. **Vaccine** 1996 Mar;14(4):353–4
A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine. Race E, et al. **Vaccine** 1995 Nov;13(16):1567–75

THERAPEUTIC USE

Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV–1SF2. el–Amad Z, et al. **AIDS** 1995 Dec;9(12):1313–22
Acceptability of HIV vaccine trials in high–risk heterosexual cohorts in Mombasa, Kenya. Jackson DJ, et al. **AIDS** 1995 Nov;9(11):1279–83
Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)
Initial studies on active immunization of HIV–infected subjects using a gp120–depleted HIV–1 Immunogen: long–term follow–up. Levine AM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 1;11(4):351–64
Safety and immunogenicity of a gp120–depleted, inactivated HIV–1 immunogen: results of a double–blind, adjuvant controlled trial. Trauger RJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S74–82
Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection. Wallace MR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 1;12(4):358–62
Candidate AIDS vaccine inspires hope [news] Rowe PM. **Lancet** 1996 Aug 31;348(9027):603
Controversial AIDS vaccine fails to delay disease [news] **Nature** 1996 Apr 25;380(6576):662
State of the science. HIV vaccine development. Grady C, et al. **Nurs Clin North Am** 1996 Mar;31(1):25–39 (44 ref.)
Clinical considerations in vaccine trials with special reference to candidate HIV vaccines. Fast PE, et al. **Pharm Biotechnol** 1995;6:97–134 (255 ref.)
AIDS vaccine trial disappointing [news] **Science** 1996 Apr 19;272(5260):341
AIDS vaccine therapy trial launched [news] Holden C. **Science** 1996 Mar 15;271(5255):1501
[Safer trials of vaccine and gene therapy against HIV] Ikuta K. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):21–6 (31 ref.) (Eng. Abstr.) **(Jpn)**

AIDS VIRUS see **HIV–1**

AIDS VIRUS RECEPTORS see **RECEPTORS, HIV**

AIKIDO see **MARTIAL ARTS**

AIR

Re: the role of carbon dioxide and atmospheric air in double–contrast barium enema [letter; comment] Pochaczevsky R. **Abdom Imaging** 1996 May–Jun; 21(3):282–3. Comment on: Abdom Imaging 1995 Sep–Oct;20(5):436–9.
High–resolution CT of mastoid sinus pneumocele with external auditory canal stenosis. Lichtenberg R, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1703–6
Utility of parameters measured during pneumatic dilation as predictors of successful dilation. Wong RC, et al. **Am J Gastroenterol** 1996 Jun;91(6):1126–9
A human respiratory–tissue organ culture incorporating an air interface. Jackson AD, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1130–5
Intraalveolar bubbles and bubble films. I. formation and development during the first 48 hours of extrauterine life in rabbits. Scarpelli EM, et al. **Anat Rec** 1996 Mar; 244(3):344–57
Forced air speeds rewarming in accidental hypothermia. Steele MT, et al. **Ann Emerg Med** 1996 Apr;27(4):479–84
Pneumolabyrinth as a computed tomographic finding in poststapedectomy vertigo. Isaacson JE, et al. **Ann Otol Rhinol Laryngol** 1995 Dec;104(12):974–6
Pupillary block, angle–closure glaucoma produced by an anterior chamber air bubble in a nanophthalmic eye [letter] Flowers CW Jr, et al. **Arch Ophthalmol** 1996 Sep; 114(9):1145–6
Self–induced pneumoparotitis. Goguen LA, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1426–9 (28 ref.)
Calorimetric studies on solid alpha–chymotrypsin preparations in air and in organic solvents. Oste–Triantafyllou A, et al. **Biochim Biophys Acta** 1996 Jun 7;1295(1):110–8
Preoxygenation––the importance of a good face mask seal [see comments] McGowan P, et al. **Br J Anaesth** 1995 Dec; 75(6):777–8. Comment in: Br J Anaesth 1996 May;76(5):748.
Case of the month: "air–in a view". England R, et al. **Br J Radiol** 1996 Jul;69(823):681–2
Air or CO2 as an insufflation agent for double contrast barium enema [letter; comment] Deignan R, et al. **Clin Radiol** 1996 May;51(5):382. Comment on: Clin Radiol 1995 Aug;50(8):558–61.
Air or CO2 as an insufflation agent for double contrast barium enema [letter; comment] Husien AM. **Clin Radiol** 1996 May;51(5):382. Comment on: Clin Radiol 1995 Aug;50(8):558–61.
Air or CO2 as an insufflation agent for double contrast barium enema [letter; comment] Rankine JJ. **Clin Radiol** 1996 May;51(5):382. Comment on: Clin Radiol 1995 Aug;50(8):558–61.
Haemodynamic and hormonal response to a stream of cooled air. Walsh JT, et al. **Eur J Appl Physiol** 1995;72(1–2):76–80
Use of warm air dryers in neonatal intensive care units [letter] Krishnan L, et al. **Indian Pediatr** 1995 Feb;32(2):247–9
Exposure to air during surgery inhibits cellular activity in flexor tendons. Abrahamsson SO. **J Hand Surg [Br]** 1996 Jun;21(3):299–302
Air friction and rolling resistance during cycling. de Groot G, et al. **Med Sci Sports Exerc** 1995 Jul;27(7):1090–5
Expired air temperature during steady–state running. Kolkhorst FW, et al. **Med Sci Sports Exerc** 1995 Dec; 27(12):1621–5
The clinical significance of spontaneous pneumobilia. Baz MA, et al. **N C Med J** 1995 Aug;56(8):398–400
The bubble test: an atraumatic method for canalicular laceration repair. Loff HJ, et al. **Ophthal Plast Reconstr Surg** 1996 Mar;12(1):61–4
Bubbles, bubbles, everywhere [letter] Stevenson GW, et al. **Paediatr Anaesth** 1995;5(3):205–6
Comparison of absorbed radiation doses in barium and air enema reduction of intussusception: a phantom study. Persliden J, et al. **Pediatr Radiol** 1996;26(5):329–32
Intussusception: ability of fluoroscopic images obtained during air enemas to depict lead points and other abnormalities. Miller SF, et al. **Radiology** 1995 Nov; 197(2):493–6
Air enema for reduction of intussusception in children: risk of bacteremia. Somekh E, et al. **Radiology** 1996 Jul; 200(1):217–8
Efficacy of fluid–air exchange during pars plana vitrectomy. Rubin JS, et al. **Retina** 1995;15(4):291–4
[Pneumolabyrinth. Radiologic sign of perilymph fistula] Schneider W, et al. **HNO** 1995 Nov;43(11):669–71 (Eng. Abstr.) **(Ger)**
[Comparison between the efficacy of oxygen and atmospheric air in sewage water purification installations] Tonelli E, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):945–52 (Eng. Abstr.) **(Ita)**
[A box for performing air–carbon dioxide–radon baths] Gusarev II, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun;(3):31–3 **(Rus)**

ANALYSIS

Occupant generated carbon dioxide as a measure of dilution ventilation efficiency. Jankovic JT, et al. **Am Ind Hyg Assoc J** 1996 Aug;57(8):756–9
A laboratory method for generation of replicate filter samples of asbestos fibers in air. Skogstad A, et al. **Am Ind Hyg Assoc J** 1996 Aug;57(8):741–5
A calibration program for Rotorod samplers. Frenz DA, et al. **Ann Allergy Asthma Immunol** 1996 Mar;76(3):245–6
Analysis of ethanol in expired air during low–flow isoflurane anaesthesia. Olsson J, et al. **Br J Anaesth** 1996 Jan; 76(1):85–9
Does abnormal single–breath nitrogen wash–out predict an accelerated decline in FEV1 in lung–healthy subjects? Dahlqvist M. **Clin Physiol** 1995 Sep;15(5):459–66
Monitoring of aromatic amine exposures in workers at a chemical plant with a known bladder cancer excess. Ward EM, et al. **J Natl Cancer Inst** 1996 Aug 7;88(15):1046–52
The novel selected–ion flow tube approach to trace gas analysis of air and breath. Smith D, et al. **Rapid Commun Mass Spectrom** 1996;10(10):1183–98 (37 ref.)
[My use of the Association Française d'Études des Ambroisies pollen calendar for Lyon–Bron (P. Cour collector)] Bouteloup F. **Allerg Immunol (Paris)** 1995 Nov; 27(9):326–31 (Eng. Abstr.) **(Fre)**
[Airborne Japanese cedar allergens studied by immunoblotting technique using anti–Cry j I monoclonal antibody––comparison with actual pollen counts and effect of wind speed and directions] Iwaya M, et al. **Arerugi** 1995 Jul;44(7):670–7 (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY see **AIR MICROBIOLOGY**

VIROLOGY see **AIR MICROBIOLOGY**

AIR AMBULANCES

Airborne and rescue point–of–care testing. Herr DM, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S54–8
U.S. Air Force aeromedical evacuation of obstetric patients in Europe. Connor SB, et al. **Aviat Space Environ Med** 1995 Nov;66(11):1090–3
Inadequacy of visual alarms in helicopter air medical transport. Fromm RE Jr, et al. **Aviat Space Environ Med** 1995 Aug;66(8):784–6
Increased flight surgeon role in military aeromedical evacuation. Lyons TJ, et al. **Aviat Space Environ Med** 1995 Oct;66(10):927–9 (16 ref.)
The USAF ambulance system [letter; comment] Sortman DC. **Aviat Space Environ Med** 1995 Jul;66(7):705–6. Comment on: Aviat Space Environ Med 1994 Mar;65(3):243–8.
Effects of helicopter service on survival after trauma. Dramatic management of trauma may be counter productive [letter; comment] Bache J. **BMJ** 1995 Oct 28; 311(7013):1165–6. Comment on: BMJ 1995 Jul 22;311(6999):217–22.
Health chiefs review London's helicopter ambulance service [news] Court C. **BMJ** 1995 Nov 4;311(7014):1185
Effects of helicopter service on survival after trauma. Service is part of a continuum of care [letter; comment] Greengross P. **BMJ** 1995 Oct 28;311(7013):1164–5. Comment on: BMJ 1995 Jul 22;311(6999):217–22.
Effects of helicopter service on survival after trauma. Design of study predisposed to type II error [letter; comment] Maclean AD, et al. **BMJ** 1995 Oct 28;311(7013):1165; discussion 1166. Comment on: BMJ 1995 Jul 22;311(6999):217–22.
Effects of helicopter service on survival after trauma. Helicopters do not care for patients [letter; comment] Wilden JN. **BMJ** 1995 Oct 28;311(7013):1165; discussion 1166. Comment on: BMJ 1995 Jul 22;311(6999):217–22.
Effects of helicopter service on survival after trauma. Miscalculation exaggerated benefits [letter; comment] Wilkes GJ. **BMJ** 1995 Oct 28;311(7013):1165; discussion 1166. Comment on: BMJ 1995 Jul 22;311(6999):217–22.
Prehospital monitoring of trauma patients: experience of a helicopter emergency medical service. Morley AP. **Br J Anaesth** 1996 May;76(5):726–30 (56 ref.)
Air transport of obstetric critical care patients to tertiary centers. Elliott JP, et al. **J Reprod Med** 1996 Mar; 41(3):171–4
Outcome assessments and air ambulance services [letter] Glaser A, et al. **Lancet** 1996 Jun 29;347(9018):1843
Which groups of patients benefit from helicopter evacuation? [see comments] Hotvedt R, et al. **Lancet** 1996 May 18; 347(9012):1362–6. Comment in: Lancet 1996 May 18;347(9012):1348–9.
Air ambulances: missions of mercy or flights of futility? [comment] Naylor CD, et al. **Lancet** 1996 May 18; 347(9012):1348–9. Comment on: Lancet 1996 May 18;347(9012):1362–6.
Helicopter emergency medical service [letter] Skogvoll E, et al. **Lancet** 1996 Aug 24;348(9026):543–4
A review of United States Air Force aeromedical evacuation of acute myocardial infarction patients in Europe. Connor SB, et al. **Mil Med** 1995 Oct;160(10):491–3
Air evacuation of critically burned patients. Santos FX, et al. **Mil Med** 1995 Nov;160(11):593–6
[Time for integrated emergency medicine air ambulance services in Scandinavia?] Lexow K. **Nord Med** 1995; 110(10):264 (Eng. Abstr.) **(Nor)**
[Helicopter landing sites on hospitals in Central Sweden. Only one of 27 approved] Gedeborg R, et al. **Lakartidningen** 1995 Sep 20;92(38):3477–9 **(Swe)**

ECONOMICS

Economizing. Copters grounded by cost cutting. MacPherson P. **Hosp Health Netw** 1996 Mar 20;70(6):77–8

AIR AMBULANCES

The costs and benefits of helicopter emergency ambulance services in England and Wales. Snooks HA, et al. **J Public Health Med** 1996 Mar;18(1):67–77

Does the potential for organ donation justify scene flights for gunshot wounds to the head? [see comments] Cocanour CS, et al. **J Trauma** 1995 Nov;39(5):968–70. Comment in: J Trauma 1996 Apr;40(4):675.

Does the potential for organ donation justify scene flights for gunshot wounds to the head? [letter; comment] Reilly PM, et al. **J Trauma** 1996 Apr;40(4):675. Comment on: J Trauma 1995 Nov;39(5):968–70.

Outcome assessments and air ambulance services [letter] Zafren K. **Lancet** 1996 Jun 29;347(9018):1843

Ill country patients [letter] Holmes MG. **N Z Med J** 1996 Jun 28;109(1024):242

STANDARDS

Air ambulance trauma transport: a quality review. van Wijngaarden M, et al. **J Trauma** 1996 Jul;41(1):26–31

AIR BAGS

see related
SEAT BELTS

Air bag alert. National Highway Traffic Safety Administration. **Ann Emerg Med** 1996 Aug;28(2):241–2

Air bags and the teachable moment. Todd KH. **Ann Emerg Med** 1996 Aug;28(2):242

Injury reduction by the airbag in accidents. Kuner EH, et al. **Injury** 1996 Apr;27(3):185–8

Airbag safety: deployment in an automobile crash with a fall from height. Barton ED. **J Emerg Med** 1995 Jul–Aug; 13(4):481–4

Automobile restraint systems and injury prevention. Hendey GW. **West J Med** 1996 Jan;164(1):63–4

[Air bags: benefits and risks] Haddad R, et al. **Harefuah** 1996 Jan 15;130(2):120–2 (25 ref.) **(Heb)**

[Air bags—do they help?] Solheim K. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):471 **(Nor)**

ADVERSE EFFECTS

Forearm fracture due to the release of an automobile air bag. Kirchhoff R, et al. **Acta Orthop Scand** 1995 Oct;66(5):483

Corneoscleral laceration caused by air–bag trauma. Baker RS, et al. **Am J Ophthalmol** 1996 Jun;121(6):709–11

Air bag–related corneal rupture after radial keratotomy. Goldberg MA, et al. **Am J Ophthalmol** 1995 Dec; 120(6):800–2

Occult ascending aortic rupture in the presence of an air bag. Dunn JA, et al. **Ann Thorac Surg** 1996 Aug;62(2):577–8

Anterior segment trauma and air bags [letter] McDermott ML, et al. **Arch Ophthalmol** 1995 Dec;113(12):1567–8

Bilateral corneal contusion and angle recession caused by an airbag [letter] Michaeli–Cohen A, et al. **Br J Ophthalmol** 1996 May;80(5):487

Airbag injury during low impact collision [letter] Molia LM, et al. **Br J Ophthalmol** 1996 May;80(5):487–8

Ocular alkali burn associated with automobile air–bag activation. White JE, et al. **Can Med Assoc J** 1995 Oct 1;153(7):933–4

Air bag dermatitis. Foley S, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):824–5

Air bag "tattoo," a lasting impression [letter] Beckerman B, et al. **J Emerg Med** 1995 Sep–Oct;13(5):680–2

A fatality associated with the deployment of an automobile airbag. Brown DK, et al. **J Trauma** 1995 Dec;39(6):1204–6

Airbag–induced eye injuries: a report of 25 cases. Duma SM, et al. **J Trauma** 1996 Jul;41(1):114–9

Bilateral Smith fracture of the radius caused by airbag deployment. Marco F, et al. **J Trauma** 1996 Apr;40(4):663–4

Traumatic blindness after airbag deployment: bilateral lenticular dislocation. Onwuzuruigbo CJ, et al. **J Trauma** 1996 Feb;40(2):314–6

From the Centers for Disease Control and Prevention. Air–bag–associated fatal injuries to infants and children riding in front passenger seats—United States. **JAMA** 1995 Dec 13;274(22):1752–3

Airbags and fatal injuries to children. Bourke GJ. **Lancet** 1996 Mar 2;347(9001):560

Air–bag–associated fatal injuries to infants and children riding in front passenger seats—United States. **MMWR Morb Mortal Wkly Rep** 1995 Nov 17;44(45):845–7

Ocular injuries related to air bag inflation. Vichnin MC, et al. **Ophthalmic Surg Lasers** 1995 Nov–Dec;26(6):542–8

Air bag–bruised face [letter] Rozner L. **Plast Reconstr Surg** 1996 Jun;97(7):1517–9

[Cervical avulsion fracture caused by an air bag] Schipper IB, et al. **Ned Tijdschr Geneeskd** 1995 Dec 23; 139(51):2661–4 (Eng. Abstr.) **(Dut)**

LEGISLATION & JURISPRUDENCE

[Severe perforating eye injury caused by an air bag in a traffic skid accident] Biechl–Lautenbach KS, et al. **Klin Monatsbl Augenheilkd** 1996 Mar;208(3):196–200 (Eng. Abstr.) **(Ger)**

AIR BLADDER see AIR SACS

AIR–BLOOD BARRIER see BLOOD–AIR BARRIER

AIR CONDITIONING

Evaporative cooling and other home factors and lower respiratory tract illness during the first year of life. Group Health Medical Associates. Aldous MB, et al. **Am J Epidemiol** 1996 Mar 1;143(5):423–30

Comparison of multiplex PCR and culture for detection of Legionellae in cooling tower water samples. Chang HR, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):258–62

Total and respirable dust in swine confinement buildings: the benefit of respiratory protective masks and effect of recirculated air. Pickrell JA, et al. **Vet Hum Toxicol** 1995 Oct;37(5):430–5

[Nitrous oxide exposure to personnel in a recovery room with modern climate control] Hoerauf K, et al. **Anaesthesist** 1995 Aug;44(8):590–4 (Eng. Abstr.) **(Ger)**

[The air–circulation system in buildings with precision and sterile–environment technologies] Krupkin GIa, et al. **Med Tr Prom Ekol** 1995;(11):43–4 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Air–conditioning in hospitals [letter] Antia NH. **Natl Med J India** 1995 Nov–Dec;8(6):295

METHODS

Continuous and intermittent personal microclimate cooling strategies. Bomalaski SH, et al. **Aviat Space Environ Med** 1995 Aug;66(8):745–50

[Plasma catalytic purification of the spacecraft air from hydrocarbons] Zlotopol'skiĭ VM, et al. **Aviakosm Ekolog Med** 1995;29(6):54–7 (Eng. Abstr.) **(Rus)**

[Plasmo–catalytic removal of oxygen–containing organic compounds from the spacecraft air] Zlotopol'skiĭ VM, et al. **Aviakosm Ekolog Med** 1995;29(5):56–9 (Eng. Abstr.) **(Rus)**

[Biocatalysis using immobilized cells or enzymes as a method of water and air purification in habitable enclosed environment] Lebedeva TE, et al. **Kosm Biol Aviakosm Med** 1991 Nov–Dec;25(6):42–5 (Eng. Abstr.) **(Rus)**

AIR EMBOLISM see EMBOLISM, AIR

AIR IONIZATION

[Ion generators and bronchial asthma (letter)] Jonassen N. **Ugeskr Laeger** 1996 Jul 15;158(29):4203–4 **(Dan)**

AIR MICROBIOLOGY

Factors affecting microbiological colony count accuracy for bioaerosol sampling and analysis. Chang CW, et al. **Am Ind Hyg Assoc J** 1995 Oct;56(10):979–86

Assessment of worker exposure to airborne molds in honeybee overwintering facilities. Sigler L, et al. **Am Ind Hyg Assoc J** 1996 May;57(5):484–90

Fungus spores, air pollutants, and other determinants of peak expiratory flow rate in children. Neas LM, et al. **Am J Epidemiol** 1996 Apr 15;143(8):797–807

Cross–sectional follow–up of a flu–like respiratory illness among fiberglass manufacturing employees: endotoxin exposure associated with two distinct sequelae. Milton DK, et al. **Am J Ind Med** 1995 Oct;28(4):469–88

Unusual cause of lethal pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Pittet D, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):541–4

A cloud adult: the Staphylococcus aureus–virus interaction revisited. Sheretz RJ, et al. **Ann Intern Med** 1996 Mar 15; 124(6):539–47

Thermophilic actinomycetes in cane sugar mills: an aeromicrobiologic and seroepidemiologic study. Khan ZU, et al. **Antonie Van Leeuwenhoek** 1995;67(4):339–44

PCR for bioaerosol monitoring: sensitivity and environmental interference. Alvarez AJ, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3639–44

Quantitative analysis of bacterial aerosols in two different dental clinic environments. Grenier D. **Appl Environ Microbiol** 1995 Aug;61(8):3165–8

Occurrence of airborne bacteria and pathogen indicators during land application of sewage sludge. Pillai SD, et al. **Appl Environ Microbiol** 1996 Jan;62(1):296–9

Comparison of methods for detection and enumeration of airborne microorganisms collected by liquid impingement. Terzieva S, et al. **Appl Environ Microbiol** 1996 Jul; 62(7):2264–72

Molecular techniques and their potential application in monitoring the microbiological quality of indoor air. MacNeil L, et al. **Can J Microbiol** 1995 Aug;41(8):657–65 (69 ref.)

Asthmatic symptoms and indoor levels of micro–organisms and house dust mites. Björnsson E, et al. **Clin Exp Allergy** 1995 May;25(5):423–31

Chemotaxis of alveolar macrophages and neutrophils in response to microbial products derived from organic dust. Milanowski J, et al. **Environ Res** 1995 Apr;69(1):59–66

Production of reactive oxygen metabolites by opsonized fungi and bacteria isolated from indoor air, and their interactions with soluble stimuli, fMLP or PMA. Ruotsalainen M, et al. **Environ Res** 1995 May;69(2):122–31

TB engineering controls: mobile high–efficiency–filter air cleaners. **Health Devices** 1995 Oct;24(10):368–418

Studies of ventilation efficiency in a protective isolation room by the use of a scale model [see comments] Marshall JW, et al. **Infect Control Hosp Epidemiol** 1996 Jan;17(1):5–10. Comment in: Infect Control Hosp Epidemiol 1996 Jan;17(1):3–4.

Microfungi in indoor air are able to trigger histamine release by non–IgE–mediated mechanisms. Larsen FO, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S23–4

Environmental microbial contamination. Pilot study in a dental surgery. Osorio R, et al. **Int Dent J** 1995 Dec; 45(6):352–7

A year–round study on functional relationships of airborne fungi with meteorological factors. Li DW, et al. **Int J Biometeorol** 1995 Nov;39(2):74–80

Aflatoxin–producing strains of Aspergillus flavus in the mould flora of the different greenhouse substrates for the cultivation of cucumber (Cucumis sativus, L.). Ruiz JA, et al. **Int J Food Microbiol** 1996 Apr;29(2–3):193–9

Reducing bacterial aerosol contamination with a chlorhexidine gluconate pre–rinse. Logothetis DD, et al. **J Am Dent Assoc** 1995 Dec;126(12):1634–9

Some factors affecting the airborne survival of bacteria outdoors. Handley BA, et al. **J Appl Bacteriol** 1995 Oct; 79(4):368–78

Fungal spore concentrations in the atmosphere at the Anatolia quarter of Istanbul, Turkey. Colakoğlu G. **J Basic Microbiol** 1996;36(3):155–62

Risk of airborne transmission in an operating theatre containing four ultraclean air units. Babb JR, et al. **J Hosp Infect** 1995 Nov;31(3):159–68

Theatre air sampling—once a year is not enough [letter] Fox C, et al. **J Hosp Infect** 1996 Apr;32(4):319–20

Fungal aerobiology: how, when and where? Hay RJ, et al. **J Hosp Infect** 1995 Jun;30 Suppl:352–7

The efficacy of filters used in respiratory function apparatus. Leeming JP, et al. **J Hosp Infect** 1995 Nov;31(3):205–10

Contamination of evacuated pneumoperitoneum air following laparoscopic cholecystectomy: preliminary results from a prospective study. Oshodi TO, et al. **J R Coll Surg Edinb** 1996 Apr;41(2):82–3

Detection of airborne cytomegalovirus in hospital rooms of immunocompromised patients. McCluskey R, et al. **J Virol Methods** 1996 Jan;56(1):115–8

Indoor aeromycota in relation to residential characteristics and allergic symptoms. Li DW, et al. **Mycopathologia** 1995 Sep;131(3):149–57

Environmental microbial challenges to an aseptic Blow–Fill–Seal process—a practical study. Jones DJ, et al. **PDA J Pharm Sci Technol** 1995 Sep–Oct;49(5):226–34

Hazard analyses of airborne contamination in clean rooms—application of a method for limitation of risks. Ljungqvist B, et al. **PDA J Pharm Sci Technol** 1995 Sep–Oct;49(5):239–43

Airborne micro–organisms in a health care environment [letter] Yousefi V. **S Afr Med J** 1996 Feb;86(2):181

Prevalence of microfungi in Finnish cow barns and some aspects of the occurrence of Wallemia sebi and Fusaria. Hanhela R, et al. **Scand J Work Environ Health** 1995 Jun; 21(3):223–8

Hazard to man and the environment posed by the use of urban waste compost: a review. Déportes I, et al. **Sci Total Environ** 1995 Nov 30;172(2–3):197–22 (182 ref.)

Microbiologic considerations. Disinfection and sterilization strategies and the potential for airborne transmission of bloodborne pathogens. Favero MS, et al. **Surg Clin North Am** 1995 Dec;75(6):1071–89 (40 ref.)

[Humidifiers] Daschner F. **Dtsch Med Wochenschr** 1995 Dec 1;120(48):1678 **(Ger)**

[Air microbial burden at garbage sorting facilities] Jager E, et al. **Zentralbl Hyg Umweltmed** 1995 Jun;197(5):398–407 (Eng. Abstr.) **(Ger)**

[Bacteriological study of air in dental offices] Bori Z, et al. **Fogorv Sz** 1996 Mar;89(3):89–95 (Eng. Abstr.) **(Hun)**

[Indoor pollution: the microbiological findings in some work environments] Sebastiani Annicchiarico L, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):813–9 (Eng. Abstr.) **(Ita)**

[Daily observations (1970–1992) of fluctuations in frequency of occurrence of a sector structure in bacterial colonies selected from open air and from S. aureus cultures] Faraone P. **Biofizika** 1995 Jul–Aug;40(4):786–92 (Eng. Abstr.) **(Rus)**

[Survival of Marburg virus infectivity on contaminated surfaces and in aerosols] Belanov EF, et al. **Vopr Virusol** 1996 Jan–Feb;41(1):32–4 (Eng. Abstr.) **(Rus)**

[Certain pathogenetic characteristics of a disease in monkeys in infected with the Marburg virus by an airborne route] Lub MIu, et al. **Vopr Virusol** 1995 Jul–Aug;40(4):158–61 (Eng. Abstr.) **(Rus)**

[Skin test with aeroallergens untested in Mexico] Pérez Tovar MP, et al. **Rev Alerg Mex** 1995 Sep–Oct;42(5):86–8 (Eng. Abstr.) **(Spa)**

AIR MOVEMENTS

Predicting the path of pollutants [news] Manuel J. **Environ Health Perspect** 1995 Jul–Aug;103(7–8):676–8

AIR POLLUTANTS

Predicting the path of pollutants [news] Manuel J.

Environ Health Perspect 1995 Jul-Aug;103(7-8):676-8
Dangerous atmospheres: IH concerns in confined spaces. Johnson LF. **Occup Health Saf** 1996 May;65(5):43-4, 47
Fibres, particles and the lung: new perspectives. 14th Summer meeting of the British Association for Lung Research, Edinburgh, United Kingdom, 11-12 September 1995. Abstracts. **Respir Med** 1995 Nov;89(10):717-50
Monitoring of exposure to air pollution. Williams ML. **Sci Total Environ** 1995 Jun 16;168(2):169-74 (6 ref.)
[Plasmo-catalytic removal of oxygen-containing organic compounds from the spacecraft air] Zlotopol'skiĭ VM, et al. **Aviakosm Ekolog Med** 1995;29(5):56-9 (Eng. Abstr.) **(Rus)**
[Regional and local problems of chemical environmental pollution and health of the population (review of the literature)] Revich BA, et al. **Med Tr Prom Ekol** 1995; (9):23-9 (12 ref.) **(Rus)**
[Impact of outdoor pollution on indoor air quality. The case of downtown Santiago (Chile)] Gil L, et al. **Rev Med Chil** 1995 Apr;123(4):411-25 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Ambient carbon monoxide and hospitalizations for heart failure: earlier findings [letter] Hexter AC. **Am J Public Health** 1996 Jul;86(7):1031-2
Ambient air pollution and hospitalization for congestive heart failure among elderly people in seven large US cities [see comments] Morris RD, et al. **Am J Public Health** 1995 Oct;85(10):1361-5. Comment in: Am J Public Health 1995 Oct;85(10):1343-5.
Health effects of outdoor air pollution. Part 2. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society. **Am J Respir Crit Care Med** 1996 Feb;153(2):477-98 (226 ref.)
Greater ozone-induced inflammatory responses in subjects with asthma. Scannell C, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):24-9
Persistent organic pollutants--the state of contamination of ambient air in central Europe. Possible sources and effects. Holoubek I. **Arch Toxicol Suppl** 1996;18:381-90 (10 ref.)
Association between air pollution and acute childhood wheezy episodes: prospective observational study [see comments] Buchdahl R, et al. **BMJ** 1996 Mar 16; 312(7032):661-5. Comment in: BMJ 1996 Mar 16;312(7032):649-50. Comment in: BMJ 1996 Jun 22;312(7046):1607; discussion 1607-8.
Relative sensitivity of the ocular trigeminal, nasal trigeminal and olfactory systems to airborne chemicals. Cometto-Muñiz JE, et al. **Chem Senses** 1995 Apr; 20(2):191-8
Long-term canine exposure studies with ambient air pollutants. Heyder J, et al. **Eur Respir J** 1996 Mar; 9(3):571-84 (101 ref.)
Respiratory effects of air pollution: the importance of a multidisciplinary approach to conduct research [editorial; comment] Paoletti P, et al. **Eur Respir J** 1995 Jun;8(6):883-4 . Comment on: Eur Respir J 1995 Jun;8(6):976-95.
Increased sister chromatid exchange (SCE) frequencies in lymphocytes from traffic policemen exposed to automobile exhaust pollution. Chandrasekaran R, et al. **Hum Exp Toxicol** 1996 Apr;15(4):301-4
Nasal lavage as tool for health effect assessment of photochemical air pollution. Steerenberg PA, et al. **Hum Exp Toxicol** 1996 Feb;15(2):111-9
Daily PM10/mortality associations: an investigations of at-risk subpopulations. Ito K, et al. **J Expo Anal Environ Epidemiol** 1996 Jan-Mar;6(1):79-95
Singapore's haze and acute asthma in children [letter] Chew FT, et al. **Lancet** 1995 Nov 25;346(8987):1427
Sick library syndrome. Hay RJ. **Lancet** 1995 Dec 16; 346(8990):1573-4
Risk factors for lung cancer among nonsmokers with emphasis on lifestyle factors. Gao YT. **Lung Cancer** 1996 Mar;14 Suppl 1:S39-45 (24 ref.)
Exposure assessment needs in studies of acute health effects. Lebowitz MD. **Sci Total Environ** 1995 Jun 16;168(2):109-17
Air pollution: brown skies research. Tattersfield AE. **Thorax** 1996 Jan;51(1):13-22 (43 ref.)
Hydrogen sulfide and reduced-sulfur gases adversely affect neurophysiological functions. Kilburn KH, et al. **Toxicol Ind Health** 1995 Mar-Apr;11(2):185-97
Air pollutants and respiratory hypersensitivity. Devalia JL, et al. **Toxicol Lett** 1996 Aug;86(2-3):169-76 (55 ref.)
Exposure to environmental chemicals relevant for respiratory hypersensitivity: global aspects. Schwela D. **Toxicol Lett** 1996 Aug;86(2-3):131-42 (13 ref.)
Interaction of environmental chemicals with respiratory sensitization. Van Loveren H, et al. **Toxicol Lett** 1996 Aug; 86(2-3):163-7 (12 ref.)
Adverse health effects of air pollutants in a nonsmoking population. Pope CA 3rd. **Toxicology** 1996 Jul 17; 111(1-3):149-55 (19 ref.)
Assessment of the impact of ambient air pollutants on health in Helsinki, Finland. Pönkä A. **World Health Stat Q** 1995; 48(2):126-31
[Comment on Wassermann, O., H. Kruse: Health risks of emissions from refuse incinerators (letter; comment)] Rüden H. **Gesundheitswesen** 1995 Aug-Sep;57(8-9):504. Comment on: Gesundheitswesen 1995 Jan;57(1):26-35. **(Ger)**
[Comment on Wassermann, O.,H. Kruse: health risks of emissions from refuse incinerators (letter; comment)] Schwenk M. **Gesundheitswesen** 1995 Aug-Sep; 57(8-9):503-4. Comment on: Gesundheitswesen 1995 Jan;57(1):26-35. **(Ger)**
[Statistical description of health complaints after pyrethroid exposure--a comparison of exposed groups] Weigelt E, et al. **Gesundheitswesen** 1995 Dec;57(12):792-7 (Eng. Abstr.) **(Ger)**

ANALYSIS

Field performance measurements of half-facepiece respirators--foundry operations. Myers WR, et al. **Am Ind Hyg Assoc J** 1996 Feb;57(2):166-74
Effect of dilution, temperature, and preservatives on the long-term stability of standardized inhalant allergen extracts. Niemeijer NR, et al. **Ann Allergy Asthma Immunol** 1996 Jun;76(6):535-40
Monitoring lead pollution near a storage battery recycling plant in Taiwan, Republic of China. Yeh CY, et al. **Arch Environ Contam Toxicol** 1996 Feb;30(2):227-34
Monitoring of personal exposure to air pollutants. Subjects' experience. Fugaš M. **Arh Hig Rada Toksikol** 1995 Jun; 46(2):237-41
Variations of volatile chlorinated hydrocarbons in ambient air at industrial areas in Niigata. Kawata K, et al. **Bull Environ Contam Toxicol** 1996 Jul;57(1):1-7
Airborne mutagens produced by frying beef, pork and a soy-based food. Thiébaud HP, et al. **Food Chem Toxicol** 1995 Oct;33(10):821-8
Comparison of direct alpha spectrometry and neutron activation analysis of aerosol filters for determination of workplace thorium air concentrations. Hotzl H, et al. **Health Phys** 1996 May;70(5):651-5
Indoor pollution from heating. Arashidani K, et al. **Ind Health** 1996;34(3):205-15
A simple, reliable method for the determination of chlorinated volatile organics in human breath and air using glass sampling tubes. Stein VB, et al. **J Anal Toxicol** 1996 May-Jun;20(3):145-50
Collection and analysis of butyltin compounds in air at nanogram-per-cubic-meter levels. Swami K, et al. **J AOAC Int** 1996 Jan-Feb;79(1):170-4
A recovery method for airborne gunshot residue retained in human nasal mucus. Schwartz RH, et al. **J Forensic Sci** 1995 Jul;40(4):659-61
Polycyclic aromatic hydrocarbons in central London air during 1991 and 1992. Brown JR, et al. **Sci Total Environ** 1996 Jan 5;177(1-3):73-84
Vascular plants as sensitive indicators of lead and PCB transport from local sources in the Canadian Arctic. Dushenko WT, et al. **Sci Total Environ** 1996 Sep 20; 188(1):29-38
A study of the distribution of urban environmental lead levels in Cape Town, South Africa. Von Schirnding YE, et al. **Sci Total Environ** 1996 Sep 20;188(1):1-8
Air pollution and COPD [letter] Ayres JG, et al. **Thorax** 1995 Aug;50(8):917-8
[The basic parameters affecting the taking of air samples by concentration methods--the absorption method] Mukhtarova M. **Probl Khig** 1995;20:171-6 (Eng. Abstr.) **(Bul)**
[The basic parameters affecting the taking of air samples by concentration methods--the adsorption method] Mukhtarova M. **Probl Khig** 1995;20:177-85 (Eng. Abstr.) **(Bul)**
[A spectrophotometric method for controlling the concentration of aromatic hydrocarbons in the calibration of indicator tubes] Panova N. **Probl Khig** 1995;20:191-8 (Eng. Abstr.) **(Bul)**
[Correlation between concentration of ammonia in the air of pigsties and the activity of fattening pigs in deep litter] Hoy S. **DTW Dtsch Tierarztl Wochenschr** 1995 Aug; 102(8):323-6 (Eng. Abstr.) **(Ger)**
[An attempt of applying the image processing for the automatic estimation of sampled airborne pollen] Kawashima S, et al. **Arerugi** 1995 Sep;44(9):1150-8 (Eng. Abstr.) **(Jpn)**
[Exposure to mineral fibers in selected ceramics plants] Woźniak H, et al. **Med Pr** 1995;46(4):327-36 (Eng. Abstr.) **(Pol)**
[Concentration of imidazolines in the air] Trubnikova LI, et al. **Med Tr Prom Ekol** 1996;(2):27-9 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Clothing--an important source of mite allergen exposure. Tovey ER, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):999-1001

METABOLISM

Positive effects of pollution [letter] Friebe A, et al. **Nature** 1996 Jul 11;382(6587):120

PHARMACOKINETICS

Variability of fine particle deposition in healthy adults: effect of age and gender. Bennett WD, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1641-7
Partition coefficients between human blood or adipose tissue and air for aromatic solvents. Pierce CH, et al. **Scand J Work Environ Health** 1996 Apr;22(2):112-8
[Pentachlorophenol--results of a Bavarian human monitoring program] Liebl B, et al. **Gesundheitswesen** 1996 Jun; 58(6):332-8 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Expression of Arabidopsis cytosolic ascorbate peroxidase gene in response to ozone or sulfur dioxide. Kubo A, et al. **Plant Mol Biol** 1995 Nov;29(3):479-89

POISONING

Vanadium air pollution: a cause of malabsorption and immunosuppression in cattle. Gummow B, et al. **Onderstepoort J Vet Res** 1994 Dec;61(4):303-16

TOXICITY

The effect of ethanol and coal dust on the tracheal mucosa--histochemical examinations of animals in experimental conditions. Czerny K, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:195-9
The decline of mink in Georgia, North Carolina, and South Carolina: the role of contaminants. Osowski SL, et al. **Arch Environ Contam Toxicol** 1995 Oct;29(3):418-23
Incidence of cancer among persons living near a municipal solid waste landfill site in Montreal, Québec. Goldberg MS, et al. **Arch Environ Health** 1995 Nov-Dec;50(6):416-24
Acute effects of total suspended particles and sulfur dioxides on preterm delivery: a community-based cohort study. Xu X, et al. **Arch Environ Health** 1995 Nov-Dec;50(6):407-15
Characterization of the effects of an airborne mixture of chemicals on the respiratory tract and smoothing polynomial spline analysis of the data. Boylstein LA, et al. **Arch Toxicol** 1995;69(9):579-89
Biological and biochemical effects of air pollutants: synergistic effects of sulphite. Hippeli S, et al. **Biochem Soc Symp** 1995;61:153-61 (43 ref.)
Coal fly ash exposure at agronomic levels does not induce triploidy in maize. Taets C, et al. **Bull Environ Contam Toxicol** 1996 May;56(5):690-5
32P-postlabelling of bulky human DNA adducts enriched by different methods including immunoaffinity chromatography. Widlak P, et al. **Chem Biol Interact** 1996 Jan 5;99(1-3):99-107
1,3 Butadiene, a vapor phase component of environmental tobacco smoke, accelerates arteriosclerotic plaque development. Penn A, et al. **Circulation** 1996 Feb 1; 93(3):552-7
Safety testing of tebufenozide, a new molt-inducing insecticide, for effects on nontarget forest soil invertebrates. Addison JA. **Ecotoxicol Environ Saf** 1996 Feb;33(1):55-61
Urban levels of air pollution increase lung responsiveness in rats. Pereira P, et al. **Environ Res** 1995 May;69(2):96-101
Changes in the nasal epithelium of rats exposed by inhalation to mixtures of formaldehyde, acetaldehyde, and acrolein. Cassee FR, et al. **Fundam Appl Toxicol** 1996 Feb; 29(2):208-18
Histopathological changes in the respiratory tract of mice exposed to ten families of airborne chemicals. Zissu D. **J Appl Toxicol** 1995 May-Jun;15(3):207-13
Preneoplastic lesions, DNA adduct formation and mutagenicity of 5-, 7- and 9-hydroxy-2-nitrofluorene, metabolites of the air pollutant 2-nitrofluorene. Cui XS, et al. **Mutat Res** 1996 Aug 12;369(3-4):147-55
Vicia faba root tip micronucleus test on the mutagenicity of water-soluble contents of cigarette smoke. Ji Q, et al. **Mutat Res** 1996 Jan 16;359(1):1-6
Correlation between cumulative labeling indices measured in the terminal bronchioles and in the centriacinar region in the lungs of rats exposed to oxidant air pollutants. Lee C, et al. **Toxicol Lett** 1995 Oct;80(1-3):25-8
Regional deposition of gases and particles in the lung: implications for mixtures. Gerrity TR. **Toxicology** 1995 Dec 28;105(2-3):327-34
Interaction of air pollutants and pulmonary allergic responses in experimental animals. Gilmour MI. **Toxicology** 1995 Dec 28;105(2-3):335-42 (48 ref.)

AIR POLLUTANTS, ENVIRONMENTAL

Ozone odours and phototherapy [letter] O'Brien TJ. **Australas J Dermatol** 1996 Aug;37(3):162
WHO sets new guidelines for air pollution [news] Carnall D. **BMJ** 1995 Nov 11;311(7015):1246
Sulfuric acid aerosol followed by ozone exposure in healthy and asthmatic subjects. Frampton MW, et al. **Environ Res** 1995 Apr;69(1):1-14
Particulate air pollution and mortality: more than the Philadelphia story [comment] Dockery DW, et al. **Epidemiology** 1995 Nov;6(6):629-32. Comment on: Epidemiology 1995 Sep;6(5):471-3. Comment on: Epidemiology 1995 Sep;6(5):476-84.
Respiratory effects of air pollutants: experimental studies in humans [see comments] Sandström T. **Eur Respir J** 1995 Jun;8(6):976-95 (221 ref.). Comment in: Eur Respir J 1995 Jun;8(6):883-4.
The increase in hay fever: pollen, particulate matter and SO2 in ambient air. Seaton A, et al. **QJM** 1996 Apr;89(4):279-84
[Role of atmospheric pollutants in asthma] Charpin D, et al. **Rev Pneumol Clin** 1996;52(2):70-8 (54 ref.) (Eng. Abstr.) **(Fre)**

[Disorders of clearance of pollutants from the lung] Mustajbegović J, et al. **Lijec Vjesn** 1996 Jan–Feb; 118(1–2):39–43 (88 ref.) (Eng. Abstr.) **(Scr)**

ADVERSE EFFECTS

Health effects of methyl tertiary butyl ether (MTBE) in gasoline in Alaska. Gordian ME, et al. **Alaska Med** 1995 Jul–Sep;37(3):101–3, 119

Reactions to airborne fish particles [letter] David TJ. **Allergy** 1995 Nov;50(11):931–2

Fungus spores, air pollutants, and other determinants of peak expiratory flow rate in children. Neas LM, et al. **Am J Epidemiol** 1996 Apr 15;143(8):797–807

Acute health effects of exposure to high levels of air pollution in eastern Europe. Peters A, et al. **Am J Epidemiol** 1996 Sep 15;144(6):570–81

Low-level air pollution and hospital admissions for cardiac and cerebrovascular diseases in Helsinki. Pönkä A, et al. **Am J Public Health** 1996 Sep;86(9):1273–80

Is carbon monoxide a risk factor for hospital admission for heart failure? [editorial; comment] Schwartz J. **Am J Public Health** 1995 Oct;85(10):1343–5. Comment on: Am J Public Health 1995 Oct;85(10):1361–5.

Acute effects of ozone on the pulmonary function of exercising schoolchildren from Mexico City. Castillejos M, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1501–7

Daily asthma severity in relation to personal ozone exposure and outdoor fungal spores. Delfino RJ, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):633–41

Associations of PM10 and airborne iron with respiratory health of adults living near a steel factory. Dusseldorp A, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1932–9

Possible involvement of an environmental agent in the development of acute eosinophilic pneumonia. Imokawa S, et al. **Ann Allergy Asthma Immunol** 1996 May; 76(5):419–22

Effect of sulfur dioxide on cytokine production of human alveolar macrophages in vitro. Knorst MM, et al. **Arch Environ Health** 1996 Mar–Apr;51(2):150–6

Urban ectopy in the mountains: carbon monoxide exposure at high altitude. Leaf DA, et al. **Arch Environ Health** 1996 Jul–Aug;51(4):283–90

Breast cancer risk and residence near industry or traffic in Nassau and Suffolk Counties, Long Island, New York. Lewis-Michl EL, et al. **Arch Environ Health** 1996 Jul–Aug; 51(4):255–65

The South Karelia Air Pollution Study: effects of low-level exposure to malodorous sulfur compounds on symptoms. Partti-Pellinen K, et al. **Arch Environ Health** 1996 Jul–Aug; 51(4):315–20

Possible effect of air pollutants (Mexico City) on superoxide dismutase activity and serum lipoperoxides in the human adult. Hicks JJ, et al. **Arch Med Res** 1996 Summer; 27(2):145–9

Abatement of tropospheric ozone: effects of strategies to improve air quality on public health and other sectors. Guest CS, et al. **Aust N Z J Public Health** 1996 Jun; 20(3):301–8 (55 ref.)

Effect of air pollution on asthma is "small" [news] Carnall D. **BMJ** 1995 Oct 28;311(7013):1120

Sydney's asthma witch hunt [news] Chapman S. **BMJ** 1995 Nov 25;311(7017):1390

Woodsmoke exposure and risk for obstructive airways disease among women. Dennis RJ, et al. **Chest** 1996 Jan; 109(1):115–9

Mast cell-associated basic fibroblast growth factor in the fibrotic response to environmental toxins. The Beryllium Model. Inoue Y, et al. **Chest** 1996 Mar;109(3 Suppl):43S–44S

Pulmonary responses to allergens and pollutants. Lebowitz MD, et al. **Chest** 1996 Mar;109(3 Suppl):54S–55S

Usefulness of animal models for predicting human responses to long-term inhalation of particles. Mauderly JL. **Chest** 1996 Mar;109(3 Suppl):65S–68S (24 ref.)

Ultrafine particles as a potential environmental health hazard. Studies with model particles. Oberdörster G, et al. **Chest** 1996 Mar;109(3 Suppl):68S–69S

Environmental toxins induce intracellular responses of airway epithelium through reactive species of oxygen and nitrogen. Roger S. Mitchell Lecture. Rochelle LG, et al. **Chest** 1996 Mar;109(3 Suppl):35S–39S

The effects of air pollution on children. Bates DV. **Environ Health Perspect** 1995 Sep;103 Suppl 6:49–53 (49 ref.)

Lung cancer and air pollution. Cohen AJ, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:219–24 (50 ref.)

Risk assessment of environmentally influenced airway diseases based on time-series analysis. Herbarth O. **Environ Health Perspect** 1995 Sep;103(9):852–6

Do waste incinerators induce adverse respiratory effects? An air quality and epidemiological study of six communities. Shy CM, et al. **Environ Health Perspect** 1995 Jul–Aug; 103(7–8):714–24

Fine particulate air pollution and mortality in two Southern California counties. Ostro B. **Environ Res** 1995 Aug; 70(2):98–104

Temperature, ambient ozone levels, and mortality during summer 1994, in Belgium. Sartor F, et al. **Environ Res** 1995 Aug;70(2):105–13

Acute respiratory effects of low level summer smog in primary school children. Cuijpers CE, et al. **Eur Respir J** 1995 Jun;8(6):967–75

Short-term effects of air pollution on health: a European approach using epidemiological time-series data. The APHEA project: background, objectives, design. Katsouyanni K, et al. **Eur Respir J** 1995 Jun;8(6):1030–8

Outdoor air pollution and asthma. **Food Chem Toxicol** 1996 Mar;34(3):318–9

Rubber latex in the air: an occupational and environmental cause of asthma? Hopkins J. **Food Chem Toxicol** 1995 Oct; 33(10):895–9 (23 ref.)

Two-year follow-up study of the effect of acid fog on adult asthma patients. Tanaka H, et al. **Intern Med** 1996 Feb; 35(2):100–4

Cat antigen in homes with and without cats may induce allergic symptoms. Bollinger ME, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):907–14

Exposure and sensitization to environmental allergen of predominantly Hispanic children with asthma in San Diego's inner city. Christiansen SC, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):288–94

Chronic respiratory symptoms associated with estimated long-term ambient concentrations of fine particulates less than 2.5 microns in aerodynamic diameter (PM2.5) and other air pollutants. Abbey DE, et al. **J Expo Anal Environ Epidemiol** 1995 Apr–Jun;5(2):137–59

Measurement error in air pollution exposure assessment. Navidi W, et al. **J Expo Anal Environ Epidemiol** 1995 Apr–Jun;5(2):111–24

Particulate pollution and health: a review of the Utah valley experience. Pope CA 3rd. **J Expo Anal Environ Epidemiol** 1996 Jan–Mar;6(1):23–34 (19 ref.)

A critical review of PM10–mortality time-series studies. Thurston GD. **J Expo Anal Environ Epidemiol** 1996 Jan–Mar;6(1):3–21 (33 ref.)

Mortality following cotton defoliation: San Joaquin Valley, California, 1970–1990. Ames RG, et al. **J Occup Environ Med** 1995 Jul;37(7):812–9

Little arrows [letter; comment] Freed DL. **Lancet** 1996 Jan 27;347(8996):267–8. Comment on: Lancet 1995 Dec 2;346(8988):1475.

Assessment of environmental and occupational exposures to butadiene as a model for risk estimation of petrochemical emissions. Sorsa M, et al. **Mutagenesis** 1996 Jan;11(1):9–17

In situ monitoring with the Tradescantia bioassays on the genotoxicity of gaseous emissions from a closed landfill site and an incinerator. Ma TH, et al. **Mutat Res** 1996 Jan 16;359(1):39–52

Respiratory symptoms and environmental factors in schoolchildren in the Bay of Plenty. Moyes CD, et al. **N Z Med J** 1995 Sep 8;108(1007):358–61

Cot death and cot mattresses [letter; comment] Richardson BA. **N Z Med J** 1995 Sep 8;108(1007):370. Comment on: N Z Med J 1995 Mar 8;108(995):69–70.

Airborne pollutants and the immune system. Albright JF, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):232–8 (35 ref.)

Legacy of lead exposure: consequences for the central nervous system. Cory-Slechta DA. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):224–6

Bone: target and source of environmental pollutant exposure. McGowan JA. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):220–3 (14 ref.)

The frequency of toxic methemoglobinemias in people living in the vicinity of refuse dumps in Barycz. Pach J, et al. **Przegl Lek** 1996;53(4):348–50

Exposure of children to pollutants in house dust and indoor air. Roberts JW, et al. **Rev Environ Contam Toxicol** 1995; 143:59–78 (74 ref.)

Ozone level effect on respiratory illness: an investigation of emergency department visits. Jones GN, et al. **South Med J** 1995 Oct;88(10):1049–56

Effect of ambient levels of smoke and sulphur dioxide on the health of a national sample of 23 year old subjects in 1981. Scarlett JF, et al. **Thorax** 1995 Jul;50(7):764–8

Hospital admission rates for asthma and respiratory disease in the West Midlands: their relationship to air pollution levels. Walters S, et al. **Thorax** 1995 Sep;50(9):948–54

Gasoline as an oncological problem [editorial] Maltoni C, et al. **Toxicol Ind Health** 1995 Mar–Apr;11(2):115–7

Review of the Wisconsin DHSS report on health concerns attributed to reformulated gasoline use in southeastern Wisconsin [editorial] Rudo K. **Toxicol Ind Health** 1995 Sep–Oct;11(5):463–6 (3 ref.)

Exposure to environmental chemicals relevant for respiratory hypersensitivity: European aspects. Sivertsen B, et al. **Toxicol Lett** 1996 Aug;86(2–3):143–53 (23 ref.)

Asthma and air pollution. Balmes JR. **West J Med** 1995 Oct; 163(4):372–3

[Epidemiological studies on risk for adverse pregnancy outcomes in women neighboring a petrochemical works] Chen Z, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul;29(4):209–12 (Eng. Abstr.) **(Chi)**

[Genetic epidemiological studies on male lung cancer] Jin Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Sep; 29(5):283–5 (Eng. Abstr.) **(Chi)**

[Advances in the study on biological effects of diesel exhaust] Lu Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Sep;29(5):305–6 (15 ref.) **(Chi)**

[Asthma to green coffee of environmental origin] Mairesse M, et al. **Rev Mal Respir** 1996 Jul;13(3):308–9 (Eng. Abstr.) **(Fre)**

[Multiple chemical sensitivity disorder in patients with neurotoxic illnesses] Lohmann K, et al. **Gesundheitswesen** 1996 Jun;58(6):322–31 (Eng. Abstr.) **(Ger)**

[Lung function and prevalence of irritation of eyes and respiratory airways on days with elevated ozone concentrations] Höppe P, et al. **Immun Infekt** 1995 Oct; 23(5):161–5 (Eng. Abstr.) **(Ger)**

ANALYSIS

Evaluation of the mass balance model used by the Environmental Protection Agency for estimating inhalation exposure to new chemical substances. Fehrenbacher MC, et al. **Am Ind Hyg Assoc J** 1996 Jun;57(6):526–36

Multi-element, multi-media method for the determination of airborne elemental emissions by inductively coupled plasma atomic emission spectrometry. Kimbrough DE, et al. **Analyst** 1996 Mar;121(3):309–15

Comparison between outdoor and indoor airborne allergenic activity. D'Amato G, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):147–52

Inorganic particles in bronchoalveolar lavage fluids from nonoccupationally exposed subjects. Falchi M, et al. **Arch Environ Health** 1996 Mar–Apr;51(2):157–61

Diurnal cycle of SO2 concentrations in Rijeka and its relation to maximum and average daily concentrations. Matković N, et al. **Arh Hig Rada Toksikol** 1995 Jun;46(2):207–16

Total suspended particulate matter concentrations in Zagreb during the 1975–1993 period. Sega K, et al. **Arh Hig Rada Toksikol** 1995 Jun;46(2):217–24

Exposure to pesticides in ambient air. Beard J, et al. **Aust J Public Health** 1995 Aug;19(4):357–62

Exposure to pesticides in ambient air [letter] Beard J, et al. **Aust N Z J Public Health** 1996 Jun;20(3):325–6

Peridomestic deposition of ultra-low volume malathion applied as a mosquito adulticide. Tietze NS, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):210–18

People on the garbage dumps of Cairo: a toxicological in vivo model? Marth E, et al. **Cent Eur J Public Health** 1995 Aug;3(3):154–7

Characterization of air contaminants formed by the interaction of lava and sea water. Kullman GJ, et al. **Environ Health Perspect** 1994 May;102(5):478–82

A breath of fresh technology. Medlin J. **Environ Health Perspect** 1995 Oct;103(10):918–9

Biological monitoring of polycyclic aromatic hydrocarbon exposure in a highly polluted area of Poland. Ovrebø S, et al. **Environ Health Perspect** 1995 Sep;103(9):838–43

Air toxics: sources and monitoring in Texas. Pendleton DR. **Environ Health Perspect** 1995 Sep;103 Suppl 6:223–8

Updating about reductions of air and blood lead concentrations in Turin, Italy, following reductions in the lead content of gasoline. Bono R, et al. **Environ Res** 1995 Jul;70(1):30–4

A small-volume constant-flow air sampling device for thermal desorption GC analysis. Kanno S, et al. **Ind Health** 1995;33(4):207–11

Direct determination of allergens in ambient aerosols: methodological aspects. Schäppi GF, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):364–70

The exposure of cyclists, car drivers and pedestrians to traffic-related air pollutants. van Wijnen JH, et al. **Int Arch Occup Environ Health** 1995;67(3):187–93

Vehicle occupants' exposure to aromatic volatile organic compounds while commuting on an urban-suburban route in Korea. Jo WK, et al. **J Air Waste Manag Assoc** 1996 Aug;46(8):749–54

Urban ozone plumes and population distribution by income and race: a case study of New York and Philadelphia. Liu F. **J Air Waste Manag Assoc** 1996 Mar;46(3):207–15

Measurement of organic acids, aldehydes, and ketones in residential environments and their relation to ozone. Reiss R, et al. **J Air Waste Manag Assoc** 1995 Oct;45(10):811–22

Environmental distribution of house dust mite allergen (Der p 5). Li CS, et al. **J Allergy Clin Immunol** 1996 Mar; 97(3):857–9

Measurement of airborne mite allergen exposure in individual subjects. Sakaguchi M, et al. **J Allergy Clin Immunol** 1996 May;97(5):1040–4

Simultaneous gas chromatographic determination of four toxic gases generally present in combustion atmospheres. Endecott BR, et al. **J Anal Toxicol** 1996 May–Jun; 20(3):189–94

Quantification of ventilation on distribution of gaseous pollutants emitted from stored swine manure. Liao CM, et al. **J Environ Sci Health B** 1995 Nov;30(6):859–93

Chronic respiratory symptoms associated with estimated long-term ambient concentrations of fine particulates less than 2.5 microns in aerodynamic diameter (PM2.5) and other air pollutants. Abbey DE, et al. **J Expo Anal Environ Epidemiol** 1995 Apr–Jun;5(2):137–59

Estimating fine particulates less than 2.5 microns in aerodynamic diameter (PM2.5) from airport visibility data in California. Abbey DE, et al. **J Expo Anal Environ Epidemiol** 1995 Apr–Jun;5(2):161–80

Measurement error in air pollution exposure assessment. Navidi W, et al. **J Expo Anal Environ Epidemiol** 1995 Apr–Jun;5(2):111–24

Intercommunity differences in acid aerosol (H+)/sulfate (SO4(2-) ratios. Ozkaynak H, et al.

J Expo Anal Environ Epidemiol 1996 Jan-Mar;6(1):35-55
The ozone hole. Lehmann P. **Med J Aust** 1995 Dec 4-18; 163(11-12):576-8 (7 ref.)
Measuring NO2 exposure in respiratory disease. Pilotto LS, et al. **Nat Med** 1995 Jun;1(6):517-8
Individual exposure to particulate air pollution and its relevance to thresholds for health effects: a study of traffic wardens. Watt M, et al. **Occup Environ Med** 1995 Dec; 52(12):790-2
The femur capitulum as a biomarker of contamination due to indicating lead content in the air by participation of the other metals. Kwapuliński J, et al. **Sci Total Environ** 1995 Dec 8;175(1):57-64
PM10 in Canada. Pryor SC, et al. **Sci Total Environ** 1996 Jan 5;177(1-3):57-71
Distribution of toxic and radiation components in air particulates. Rausch H, et al. **Sci Total Environ** 1995 Dec 1;173-174:283-91
[Concentrations and size distributions of aerosols in middle summer of Chengdu] Jiang J, et al.
Hua Hsi I Ko Ta Hsueh Hsueh Pao 1995 Dec;26(4):452-4 (Eng. Abstr.) **(Chi)**
[Metrology of airborne particles carrying the principal air allergens] De Blay F, et al. **Rev Mal Respir** 1995; 12(4):343-52 (Eng. Abstr.) **(Fre)**
[Mercury emission measurements in a crematorium. The dentistry aspects (see comments)] Matter-Grütter C, et al. **Schweiz Monatsschr Zahnmed** 1995;105(8):1023-8 (Eng. Abstr.). Comment in: Schweiz Monatsschr Zahnmed 1995;105(8):1011, 1013. **(Ger)**
[Pollutant dispersion models: their application to the case of dispersion in the vicinity of a building] Leuzzi G, et al. **Ann Ig** 1996 Jan-Feb;8(1):147-57 (Eng. Abstr.) **(Ita)**
[Atmospheric contamination by aromatic polycyclic hydrocarbons in an urban area] Poli A, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):783-92 (Eng. Abstr.) **(Ita)**
[Dust particles and metals in outdoor and indoor air of Upper Silesia] Górny RL, et al. **Rocz Panstw Zakl Hig** 1995; 46(2):151-61 (Eng. Abstr.) **(Pol)**
[Urban air pollution by carcinogenic N-nitrosamines] Khesina AIa, et al. **Vestn Ross Akad Med Nauk** 1996; (3):25-8 (Eng. Abstr.) **(Rus)**

BLOOD

Prenatal lead exposure and the pregnancy outcome. A case-control study in southern Poland. Pietrzyk JJ, et al. **Przegl Lek** 1996;53(4):342-7

IMMUNOLOGY

Possible involvement of an environmental agent in the development of acute eosinophilic pneumonia. Imokawa S, et al. **Ann Allergy Asthma Immunol** 1996 May; 76(5):419-22
Respirable tire fragments contain specific IgE-binding and bridging latex antigens. Williams PB, et al. **Chest** 1996 Mar; 109(3 Suppl):13S
Evaluation of the allergic/irritant potential of air pollutants: detection of proteins modified by volatile organic compounds from oilseed rape (Brassica napus ssp. oleifera) using electrospray ionization-mass spectrometry. Butcher RD, et al. **Clin Exp Allergy** 1995 Oct;25(10):985-92
Inhalant allergen-specific T-cell reactivity is detectable in close to 100% of atopic and normal individuals: covert responses are unmasked by serum-free medium. Upham JW, et al. **Clin Exp Allergy** 1995 Jul;25(7):634-42
Exposure and sensitization to environmental allergen of predominantly Hispanic children with asthma in San Diego's inner city. Christiansen SC, et al.
J Allergy Clin Immunol 1996 Aug;98(2):288-94
Environmental distribution of house dust mite allergen (Der p 5). Li CS, et al. **J Allergy Clin Immunol** 1996 Mar; 97(3):857-9
Measurement of airborne mite allergen exposure in individual subjects. Sakaguchi M, et al. **J Allergy Clin Immunol** 1996 May;97(5):1040-4
Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. Thepen T, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):828-37
Influence of air pollution on humoral immune response. Stiller-Winkler R, et al. **J Clin Epidemiol** 1996 May; 49(5):527-34
T-cell "priming" against environmental allergens in human neonates: sequential deletion of food antigen reactivity during infancy with concomitant expansion of responses to ubiquitous inhalant allergens. Holt PG, et al.
Pediatr Allergy Immunol 1995 May;6(2):85-90
Environmental factors and primary T-cell sensitisation to inhalant allergens in infancy: reappraisal of the role of infections and air pollution. Holt PG.
Pediatr Allergy Immunol 1995 Feb;6(1):1-10 (85 ref.)
[Circulating immune complexes in airborne allergy--a protective role?] Jarząb J, et al. **Przegl Lek** 1995; 52(8):375-81 (Eng. Abstr.) **(Pol)**

METABOLISM

Seasonal variation of DNA adduct pattern in human lymphocytes analyzed by 32P-HPLC. Möller L, et al. **Carcinogenesis** 1996 Jan;17(1):61-6
Environmental hazard assessment of chemicals and products. Part VI. Abiotic degradation in the troposphere. Klöpffer W. **Chemosphere** 1996 Sep;33(6):1083-99 (71 ref.)
Bromo-deoxyuridine (BRDU) uptake in the lungs of rats inhaling amosite asbestos or vitreous fibres at equal airborne fibre concentrations. Donaldson K, et al.
Exp Toxicol Pathol 1995 May;47(2-3):207-11
Disposition, metabolism, and toxicity of methyl tertiary butyl ether, an oxygenate for reformulated gasoline. Hutcheon DE, et al. **J Toxicol Environ Health** 1996 Apr 5; 47(5):453-64 (40 ref.)

PHARMACOKINETICS

Pharmacokinetic modeling approaches for describing the uptake, systemic distribution, and disposition of inhaled chemicals. Gargas ML, et al. **Crit Rev Toxicol** 1995; 25(3):237-54 (70 ref.)
Toxicokinetics and acute effects of MTBE and ETBE in male volunteers. Johanson G, et al. **Toxicol Lett** 1995 Dec; 82-83:713-8

POISONING

Intratracheally administered liposomal alpha-tocopherol protects the lung against long-term toxic effects of paraquat. Suntres ZE, et al. **Biomed Environ Sci** 1995 Dec; 8(4):289-300
Little arrows [see comments] Waldron HA. **Lancet** 1995 Dec 2;346(8988):1475. Comment in: Lancet 1996 Jan 27;347(8996):267-8.

STANDARDS

[Hygienic regulation of combined effects of a complex mixture of sulfurous anhydride, hydrogen fluoride and nitrogen dioxide in the environmental air] Iskandarova ShT. **Gig Sanit** 1996 Mar-Apr;(2):3-5 (Eng. Abstr.) **(Rus)**

TOXICITY

Biomarker alterations produced in rat lung by intratracheal instillations of air particulate extracts and chemoprevention with oral N-acetylcysteine. Izzotti A, et al. **Cancer Res** 1996 Apr 1;56(7):1533-8
Sulphur dioxide: a potent glutathione depleting agent. Langley-Evans SC, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1996 Jun;114(2):89-98
Pharmacokinetic modeling approaches for describing the uptake, systemic distribution, and disposition of inhaled chemicals. Gargas ML, et al. **Crit Rev Toxicol** 1995; 25(3):237-54 (70 ref.)
Red oak condensate: its apparent lack of cytotoxic and genotoxic effects as compared with three other wood-drying condensates. Mark HF, et al. **Cytobios** 1995; 84(338-339):133-40
Observations on asthma. Bates DV.
Environ Health Perspect 1995 Sep;103 Suppl 6:243-7 (49 ref.)
Air toxics and asthma: impacts and end points. Eschenbacher WL, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:209-11
Seasonal and spatial variation of the bacterial mutagenicity of fine organic aerosol in southern california. Hannigan MP, et al. **Environ Health Perspect** 1996 Apr;104(4):428-36
Associations between criteria air pollutants and asthma. Koren HS. **Environ Health Perspect** 1995 Sep;103 Suppl 6:235-42 (106 ref.)
Evaluation of a possible association of urban air toxics and asthma. Leikauf GD, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:253-71 (179 ref.)
Science and policy in regulatory decision making: getting the facts right about hazardous air pollutants. Sexton K. **Environ Health Perspect** 1995 Sep;103 Suppl 6:213-22
Disposition, metabolism, and toxicity of methyl tertiary butyl ether, an oxygenate for reformulated gasoline. Hutcheon DE, et al. **J Toxicol Environ Health** 1996 Apr 5; 47(5):453-64 (40 ref.)
Measurement of the urinary benzene metabolite trans,trans-muconic acid from benzene exposure in humans. Yu R, et al. **J Toxicol Environ Health** 1996 Aug 9; 48(5):453-77
Metabolic activation of the genotoxic environmental contaminants 2- and 3-nitrofluoranthene in variants of Salmonella typhimurium TA98. Ball LM, et al.
Mutagenesis 1995 Nov;10(6):497-504
Mutation spectra of chemical fractions of a complex mixture: role of nitroarenes in the mutagenic specificity of municipal waste incinerator emissions. DeMarini DM, et al.
Mutat Res 1996 Jan 17;349(1):1-20
Uncertainty and variation in indirect exposure assessments: an analysis of exposure to tetrachlorodibenzo-p-dioxin from a beef consumption pathway. Price PS, et al.
Risk Anal 1996 Apr;16(2):263-77
Acrolein-induced smooth muscle hyperresponsiveness and eicosanoid release in excised ferret tracheae. Ben-Jebria A, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):35-44
Ozone-induced alteration in beta-adrenergic pharmacological modulation of pulmonary macrophages. McGovern TJ, et al. **Toxicol Appl Pharmacol** 1996 Mar; 137(1):51-6
Evaluation of the subacute pulmonary and testicular inhalation toxicity of diborane in rats. Nomiyama T, et al. **Toxicol Appl Pharmacol** 1996 May;138(1):77-83
Methyl tertiary butyl ether (MTBE)--evaluation of MTBE carcinogenicity studies. Rudo KM. **Toxicol Ind Health** 1995 Mar-Apr;11(2):167-73 (14 ref.)
Health effects of inhaled tertiary amyl methyl ether and ethyl tertiary butyl ether. White RD, et al. **Toxicol Lett** 1995 Dec;82-83:719-24
Interaction of gaseous and particulate pollutants in the respiratory tract: mechanisms and modulators. Schlesinger RB. **Toxicology** 1995 Dec 28;105(2-3):315-25
Chronic inhalation exposure to ozone and nitric acid elevates stress-inducible heat shock protein 70 in the rat lung. Wong CG, et al. **Toxicology** 1996 Feb 22;107(2):111-9
[Mutagenicity and anti-mutagenicity assay of airborne suspended particles in Shijiazhuang city] Zhao Z, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul;29(4):213-5 (Eng. Abstr.) **(Chi)**
[The hygienic standardization of 3-phenoxybenzyl alcohol in the atmospheric air of populated places] Iskandarova ShT. **Gig Sanit** 1995 Nov-Dec;(6):6-8 (Eng. Abstr.) **(Rus)**
[The evaluation of the mutagenic activity of gaseous particles in the atmospheric air by using a microbiological test] Dugan AM, et al. **Mikrobiol Z** 1995 Jul-Aug;57(4):66-72 (Eng. Abstr.) **(Rus)**
[The mutagenic activity of suspended particles in the atmosphere in the industrial cities of Ukraine] Dugan AI, et al. **Tsitol Genet** 1995 Sep-Oct;29(5):28-34 (Eng. Abstr.) **(Rus)**

AIR POLLUTANTS, OCCUPATIONAL

see related

GAS SCAVENGERS

Experimental and numerical studies on the impact of work practices used to control exposures occurring in booth-type hoods. Flynn MR, et al. **Am Ind Hyg Assoc J** 1996 May; 57(5):469-75
Control of paint overspray in autobody repair shops. Heitbrink WA, et al. **Am Ind Hyg Assoc J** 1995 Oct; 56(10):1023-32
Upper airway symptoms and function in wood surface coating industry workers. Holmström M, et al.
Am J Ind Med 1995 Aug;28(2):207-20
A statistical analysis of data on exposure to xylene at selected workplaces in the U.K. Gardner R. **Ann Occup Hyg** 1996 Aug;40(4):411-22
A study of personal and area airborne asbestos concentrations during asbestos abatement: a statistical evaluation of fibre concentration data. Lange JH, et al. **Ann Occup Hyg** 1996 Aug;40(4):449-66
Chemical pollutants in X-ray film processing departments. Scobbie E, et al. **Ann Occup Hyg** 1996 Aug;40(4):423-35
Dustiness, silicosis & tuberculosis in small scale pottery workers. Saiyed HN, et al. **Indian J Med Res** 1995 Sep; 102:138-42
Reduction of aerosols produced by ultrasonic scalers. Harrel SK, et al. **J Periodontol** 1996 Jan;67(1):28-32
Dealing with spilt mercury [letter] Kulshrestha MK, et al. **Occup Med (Oxf)** 1996 Feb;46(1):91-2
[Indoor pollution: the microbiological findings in some work environments] Sebastiani Annicchiarico L, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):813-9 (Eng. Abstr.) **(Ita)**
[Hygienic assessment of dust and gas factors at the enterprises using phosphoric acid production wastes] Rumiantsev GI, et al. **Gig Sanit** 1996 Mar-Apr;(2):13-5 (Eng. Abstr.) **(Rus)**
[Evaluation of present-day production of propylene oxide and prognostication of health status of the workers] Gimranova GG, et al. **Med Tr Prom Ekol** 1996;(2):34-8 **(Rus)**
[Specific source of the entry of polluting substances into living accommodations] Ianin EP. **Med Tr Prom Ekol** 1995; (10):39-40 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Laser smoke evacuator: effective removal of mutagenic cautery smoke. Hunter JG. **Aesthetic Plast Surg** 1996 Mar-Apr;20(2):177-8
Occupational asthma in horticulture caused by Lathyrus odoratus. Jansen A, et al. **Allergy Proc** 1995 May-Jun; 16(3):135-9
Cancer of the lung, pleura, larynx and pharynx in an area with an asbestos-cement plant. Curin K, et al.
Arh Hig Rada Toksikol 1995 Sep;46(3):289-300
Controlling dental occupational exposure to nitrous oxide [letter] Girdler NM. **Br Dent J** 1996 Jun 8;180(11):409
An ethicist's commentary on the veterinarian receiving complaints from swine barn workers concerning respiratory problems. Rollin BE. **Can Vet J** 1996 May; 37(5):262-3
Lung function studies in some Nigerian bank workers. Osim EE, et al. **Cent Afr J Med** 1996 Feb;42(2):43-6
Uranium dust exposure and lung cancer risk in four uranium processing operations. Dupree EA, et al. **Epidemiology** 1995 Jul;6(4):370-5
Wood dust. **IARC Monogr Eval Carcinog Risks Hum** 1995; 62:35-215 (383 ref.)
The correlation of chest radiograph and pulmonary function tests in asbestos miners and millers. Dave SK, et al.
Indian J Chest Dis Allied Sci 1996 Apr-Jun;38(2):81-9
Chronic and acute respiratory effects among grain mill workers. Gimenez C, et al.

Int Arch Occup Environ Health 1995;67(5):311–5
A prospective, controlled study showing that rubber gloves are the major contributor to latex aeroallergen levels in the operating room. Heilman DK, et al.
J Allergy Clin Immunol 1996 Aug;98(2):325–30
Occupational asthma caused by imbuia wood dust [case report] Jeebhay MF, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):1025–7
Pulmonary responses to purified zinc oxide fume. Kuschner WG, et al. **J Investig Med** 1995 Aug;43(4):371–8
A new mask filter cartridge used to determine applicator inhalation exposure to an alachlor herbicide (Lasso) during normal spraying operations. Flaherty DK, et al.
J Occup Environ Med 1995 Sep;37(9):1116–21
Monitoring acrylic fiber workers for liver toxicity and exposure to dimethylacetamide. 2. Serum clinical chemistry results of dimethylacetamide-exposed workers. Spies GJ, et al. **J Occup Environ Med** 1995 Sep;37(9):1102–7
Monitoring acrylic fiber workers for liver toxicity and exposure to dimethylacetamide. 1. Assessing exposure to dimethylacetamide by air and biological monitoring. Spies GJ, et al. **J Occup Environ Med** 1995 Sep;37(9):1093–101
ETS exposure in the workplace. Perceptions and reactions by employees in 114 work sites. Thompson B, et al.
J Occup Environ Med 1995 Sep;37(9):1086–92
Benzene exposure in Royal Naval submarines. Dean MR.
J R Soc Med 1996 May;89(5):286P–8P
Assessment of environmental and occupational exposures to butadiene as a model for risk estimation of petrochemical emissions. Sorsa M, et al. **Mutagenesis** 1996 Jan;11(1):9–17
Effect of sulphur dioxide exposure on human chromosomes. Yadav JS, et al. **Mutat Res** 1996 Jan 16;359(1):25–9
Some altered concentrations of elements in semen of workers exposed to trinitrotoluene. Liu HX, et al.
Occup Environ Med 1995 Dec;52(12):842–5
Chronic effects of welding exposure on pulmonary function tests and respiratory symptoms. Ozdemir O, et al.
Occup Environ Med 1995 Dec;52(12):800–3
Avoid injury in confined spaces. Bove K, et al.
Occup Health Saf 1995 Sep;64(9):42–6
Lung (agricultural/rural). do Pico GA.
Otolaryngol Head Neck Surg 1996 Feb;114(2):212–6
Occupational asthma due to chloramine-T solution. Kujala VM, et al. **Respir Med** 1995 Nov;89(10):693–5
Cancer incidence and mortality of patients with suspected solvent-related disorders. Berlin K, et al.
Scand J Work Environ Health 1995 Oct;21(5):362–7
Visual dysfunction among styrene-exposed workers. Campagna D, et al. **Scand J Work Environ Health** 1995 Oct;21(5):382–90
Cancer incidence, mortality and exposure-response among Swedish man-made vitreous fiber production workers. Plato N, et al. **Scand J Work Environ Health** 1995 Oct; 21(5):353–61
Improved nasal clearance among pulp–mill workers after the reduction of lime dust. Torén K, et al.
Scand J Work Environ Health 1996 Apr;22(2):102–7
Respiratory irritants encountered at work. Taylor AJ.
Thorax 1996 May;51(5):541–5 (17 ref.)
Biomonitoring of diesel exhaust-exposed workers. DNA and hemoglobin adducts and urinary 1-hydroxypyrene as markers of exposure. Nielsen PS, et al. **Toxicol Lett** 1996 Jul;86(1):27–37
Exposure-response functions in Air Force toxic risk modeling. Philipson LL, et al. **Toxicology** 1996 Jul 17; 111(1–3):239–49 (22 ref.)
[The toxic hygiene problems of workers in the Dinamik automobile tire plant in Sofia] Ivanova-Chemishanska L, et al. **Probl Khig** 1995;20:138–45 (Eng. Abstr.) **(Bul)**
[Analysis of biochemical components of seminal plasma in male workers exposed to mercury vapor] Li H, et al.
Chung Hua Yu Fang I Hsueh Tsa Chih 1995 Nov; 29(6):351–3 (Eng. Abstr.) **(Chi)**
[Occupational exposure to formaldehyde and risk of cancer] Hansen J, et al. **Ugeskr Laeger** 1996 Jul 15;158(29):4191–4 (Eng. Abstr.) **(Dan)**
[Exposure of intensive care personnel to isoflurane in long-term sedation] Hoerauf K, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Dec; 30(8):483–7 (Eng. Abstr.) **(Ger)**
[Contamination by inhalational anesthetics on the intensive care unit—sequelae of an unnecessary sedation regimen? (editorial)] Schulte am Esch J, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Dec; 30(8):465–6 **(Ger)**
[Occupational asthma: definition—epidemiology—etiologic substances—prognosis—prevention—diagnosis—expert assessment aspects] Merget R, et al. **Pneumologie** 1996 May; 50(5):356–63 (83 ref.) **(Ger)**
[Ethylene oxide in hospitals—occupational medicine and hygienic aspects] Avni A, et al. **Harefuah** 1995 Nov 15; 129(10):431–5 **(Heb)**
[The mortality of female workers exposed to PCBs] Tironi A, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):200–2 **(Ita)**
[Nylon fiber and possible lung pathology (letter)] Calisti R, et al. **Med Lav** 1995 Jul–Aug;86(4):360–2 **(Ita)**
[Biological monitoring of exposure to solvents: a method for the gas-chromatographic determination of aromatic hydrocarbons in the blood and urine] Fustinoni S, et al. **Med Lav** 1996 Jan–Feb;87(1):63–75 (Eng. Abstr.) **(Ita)**
[The first case of severe pneumopathy due to hard metals successfully undergoing a lung transplant] Tomasini M, et al. **Med Lav** 1995 Jul–Aug;86(4):325–31 (6 ref.) (Eng. Abstr.) **(Ita)**
[Exposure to anesthetic gases] Aasmoe L, et al.
Tidsskr Nor Laegeforen 1995 Sep 10;115(21):2652–5 (Eng. Abstr.) **(Nor)**
[Expert statement and assessment of medical impairment in work-related pulmonary disease] Kongerud J, et al.
Tidsskr Nor Laegeforen 1996 Feb 28;116(6):759–63 (Eng. Abstr.) **(Nor)**
[When does the occupational environment cause lung disease?] Moen BE. **Tidsskr Nor Laegeforen** 1996 Feb 28; 116(6):713–4 **(Nor)**
[Concentration of dihydroepiandrosterone, dihydroepiandrosterone sulphate and testosterone during premature menopause in women chronically exposed to carbon disulfide] Stanosz S, et al. **Med Pr** 1995;46(4):337–40 (Eng. Abstr.) **(Pol)**
[Effects of antibiotics on the gastric mucosa and Helicobacter pylori in prolonged therapy] Aruin LI, et al.
Klin Med (Mosk) 1995;73(5):78 **(Rus)**
[Industrial hygiene problems in the manufacture of polymetal materials] Dubeikovskaia LS, et al. **Med Tr Prom Ekol** 1995;(11):8–10 (Eng. Abstr.) **(Rus)**
[Industrial hygiene of workers in diphenylolpropane production] Kogan OS, et al. **Med Tr Prom Ekol** 1995; (12):40–4 **(Rus)**
[Respiratory system reactions to organic aerosol exposure] Zuškin E, et al. **Arh Hig Rada Toksikol** 1996 Mar; 47(1):57–67 (Eng. Abstr.) **(Scr)**
[Comment on the article about teratogenesis due to industrial pollution caused by organic solvents (letter; comment)] Borja Aburto VH. **Salud Publica Mex** 1996 Mar–Apr; 38(2):83–4. Comment on: Salud Publica Mex 1996 Jan–Feb;38(1):3–12. **(Spa)**
[Industrial pollution due to organic solvents as a cause of teratogenesis (see comments)] Saavedra-Ontiveros D, et al. **Salud Publica Mex** 1996 Jan–Feb;38(1):3–12 (Eng. Abstr.). Comment in: Salud Publica Mex 1996 Mar–Apr;38(2):83–4. **(Spa)**

ANALYSIS

Low flow anaesthesia reduces occupational exposure to inhalation anaesthetics. Environmental and biological measurements in operating room personnel. Imberti R, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):586–91
Exposure to total and respirable minerals in an abrasive manufacturing facility. Granados-Correa F, et al.
Am Ind Hyg Assoc J 1996 Aug;57(8):753–5
Air quality in an animal facility: particulates, ammonia, and volatile organic compounds. Kacergis JB, et al.
Am Ind Hyg Assoc J 1996 Jul;57(7):634–40
A laboratory method for generation of replicate filter samples of asbestos fibers in air. Skogstad A, et al.
Am Ind Hyg Assoc J 1996 Aug;57(8):741–5
A transient model of mass transfer and kinetics in a passive vapor sampler. Williams CE, et al.
Am Ind Hyg Assoc J 1995 Nov;56(11):1074–82
The relationships between urinary elimination, airborne concentration, and radioactive hand contamination for workers exposed to uranium. Yu RC, et al.
Am Ind Hyg Assoc J 1996 Jul;57(7):615–20
Anesthetic gas-scavenging in the laboratory [letter] Perouansky M, et al. **Anesthesiology** 1996 Mar;84(3):751
The use of a new static device based on the collection of the thoracic fraction for the assessment of the airborne concentration of asbestos fibres by transmission electron microscopy. Kauffer E, et al. **Ann Occup Hyg** 1996 Jun; 40(3):311–9
On-site monitoring of personal exposure to tetrachloroethylene at dry cleaning establishments. Keen C, et al. **Ann Occup Hyg** 1996 Jun;40(3):281–92
Airborne exposure to polycyclic aromatic hydrocarbons (PAHs) and urinary excretion of 1-hydroxypyrene of carbon anode plant workers. Petry T, et al.
Ann Occup Hyg 1996 Jun;40(3):345–57
Lead, chromium, and cadmium exposure during abrasive blasting. Conroy LM, et al. **Arch Environ Health** 1996 Mar–Apr;51(2):95–9
Short communication: estimates of radiation dose to National Health Service workers in Northamptonshire from raised radon levels. Denman AR, et al. **Br J Radiol** 1996 Jan; 69(817):72–5
Thermal desorption-gas chromatography for the determination of emission of volatile organic compounds from furnishing materials. Igielska B, et al.
Bull Inst Marit Trop Med Gdynia 1995;46(1–4):43–51
Long-term monitoring and prevention of occupational lead exposure in a production plant. Jaremin B, et al.
Bull Inst Marit Trop Med Gdynia 1995;46(1–4):31–42
Survey of airborne antibiotics. Møller NE, et al.
Contact Dermatitis 1996 Apr;34(4):300–1
Environmental contamination by cobalt in the vicinity of a cemented tungsten carbide tool grinding plant. Abraham JL, et al. **Environ Res** 1995 Apr;69(1):67–74
Comparison of direct alpha spectrometry and neutron activation analysis of aerosol filters for determination of workplace thorium air concentrations. Hotzl H, et al.
Health Phys 1996 May;70(5):651–5
A total sample preparation method for the measurement of airborne asbestos and other fibers by optical and electron microscopy. Kohyama N, et al. **Ind Health** 1996; 34(3):185–203
Selection of desorbing solvents for organic compounds from active carbon tubes. Matsumura Y. **Ind Health** 1996; 34(3):167–76
Urinary 1-naphthol and 1-pyrenol as indicators of exposure to coal tar products. Heikkilä P, et al.
Int Arch Occup Environ Health 1995;67(3):211–7
Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air. II. 1,1,1-Trichloroethane and trichloroethylene. Laparé S, et al. **Int Arch Occup Environ Health** 1995;67(6):375–94
N,N-dimethylbenzylamine: occupational exposure, analysis and biological monitoring. Ståhlbom B, et al.
Int Arch Occup Environ Health 1995;67(3):159–64
Environmental microbial contamination. Pilot study in a dental surgery. Osorio R, et al. **Int Dent J** 1995 Dec; 45(6):352–7
Gas chromatography of 4,4'-diphenylmethane diisocyanate in the workplace atmosphere. Melzi D'Eril GM, et al.
J Chromatogr A 1995 Dec 1;718(1):141–6
Air contamination following aerosol ventilation in the gamma camera room. Greaves CD, et al. **Nucl Med Commun** 1995 Nov;16(11):901–4
Occupational exposure to inhalable and total aerosol in the primary nickel production industry. Tsai PJ, et al.
Occup Environ Med 1995 Dec;52(12):793–9
Health status and exposure of workers at a pilot brown coal liquefaction plant in Australia, 1985–1991. Driscoll T, et al. **Occup Med (Oxf)** 1995 Oct;45(5):239–46
Aerosolized silicone in a medical library [letter] Schneider AM, et al. **Plast Reconstr Surg** 1996 Jul;98(1):185–6
Fiber exposure assessment in the Swedish rock wool and slag wool production industry in 1938–1990. Plato N, et al. **Scand J Work Environ Health** 1995 Oct;21(5):345–52
Effect of lanthanides on the relaxation rates of 89Y and 29Si in yttrium silicon oxynitride phases. Meinhold RH, et al.
Solid State Nucl Magn Reson 1995 Nov;5(2):151–61
Sampling and analysis of airborne resin acids and solvent-soluble material derived from heated colophony (rosin) flux: a method to quantify exposure to sensitizing compounds liberated during electronics soldering. Smith PA, et al. **Toxicology** 1996 Jul 17;111(1–3):225–38
Total and respirable dust in swine confinement buildings: the benefit of respiratory protective masks and effect of recirculated air. Pickrell JA, et al. **Vet Hum Toxicol** 1995 Oct;37(5):430–5
[The personal exposure of workers in the manufacture of xylenes—in Burgas (the Neftokhim firm)] Panova N, et al. **Probl Khig** 1995;20:185–91 (Eng. Abstr.) **(Bul)**
[The assessment of arsenic exposure in copper smelting] Tsolova S, et al. **Probl Khig** 1995;20:128–38 (Eng. Abstr.) **(Bul)**
[Occupational exposure in the operating room by isoflurane when using the laryngeal mask] Hoerauf K, et al.
Gesundheitswesen 1996 Jun;58(6):341–5 (Eng. Abstr.) **(Ger)**
[Anesthetic gas pollution in operating rooms: the health and hygiene and management problems] D'Alessandro D, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):821–33 (Eng. Abstr.) **(Ita)**
[Occupational exposure to asbestos in removal and protective treatment of roof coverings] Maino A, et al. **Med Lav** 1995 Nov–Dec;86(6):546–554 (Eng. Abstr.) **(Ita)**
[MEDICHEM'95 Congress chemical industry as a global citizen—balancing risks and benefits, (19–22 September 1995) Cambridge, USA] Indulski JA. **Med Pr** 1996; 47(2):195–205 **(Pol)**
[Refractory ceramic fibers, kinds, health effects after exposure, TLVs] Woźniak H, et al. **Med Pr** 1996; 47(4):393–9 (17 ref.) (Eng. Abstr.) **(Pol)**
[A chromatographic method for determining diphenylolpropane in the air of a work area] Kogan OS, et al. **Gig Sanit** 1996 Jan–Feb;(1):48–9 **(Rus)**
[Detection of oxime-2-methyl-1-diethylamine butanone-3+ inhibitor in the workplace air by thin-layer chromatography] Ledovskikh NG. **Med Tr Prom Ekol** 1995;(6):24–5 (Eng. Abstr.) **(Rus)**
[Urban air pollution by carcinogenic N-nitrosamines] Khesina AIa, et al. **Vestn Ross Akad Med Nauk** 1996; (3):25–8 (Eng. Abstr.) **(Rus)**

BLOOD

[Blood interface in environmental and occupational exposure to industrial chemical pollutants] Brugnone F, et al.
G Ital Med Lav 1994 Jan–Nov;16(1–6):11–7 (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Immunologic responses to isocyanates in sensitized asthmatic subjects. Redlich CA, et al. **Chest** 1996 Mar;109(3 Suppl):6S–8S

METABOLISM

Reactions of arsine with hemoglobin. Hatlelid KM, et al.
J Toxicol Environ Health 1996 Feb 9;47(2):145–57

PHARMACOKINETICS

Breakthrough time of a respirator cartridge for carbon tetrachloride vapor flow of workers' respiratory patterns. Tanaka S, et al. **Ind Health** 1996;34(3):227–36

POISONING

Recommended diagnostic criteria for occupational chronic lead poisoning. Sun JB, et al. **Biomed Environ Sci** 1995 Dec;8(4):318–29

Arsine toxicity: chemical and mechanistic implications. Klimecki WT, et al. **J Toxicol Environ Health** 1995 Dec; 46(4):399–409 (49 ref.)

The usefulness of carboxyhemoglobin, methemoglobin and blood lactate concentration in evaluating the health condition of Kraków inhabitants exposed to primary pollutants. Groszek B, et al. **Przegl Lek** 1996;53(4):338–41

TOXICITY

Toxicity of combustion products of polymeric materials. Cempel M. **Bull Inst Marit Trop Med Gdynia** 1993–94; 44–45(1–4):75–81 (21 ref.)

Detection of surface free radical activity of respirable industrial fibres using supercoiled phi X174 RF1 plasmid DNA. Gilmour PS, et al. **Carcinogenesis** 1995 Dec; 16(12):2973–9

Red oak condensate: its apparent lack of cytotoxic and genotoxic effects as compared with three other wood-drying condensates. Mark HF, et al. **Cytobios** 1995; 84(338–339):133–40

Occupational asthma. Chan-Yeung M. **Environ Health Perspect** 1995 Sep;103 Suppl 6:249–52 (40 ref.)

Pharmacologic characterization of wool dust extract in isolated guinea pig trachea. Schachter EN, et al. **Environ Res** 1995 May;69(2):90–5

Respiratory health effects of man-made vitreous (mineral) fibres. De Vuyst P, et al. **Eur Respir J** 1995 Dec; 8(12):2149–73 (169 ref.)

Mutagenicity of airborne particulate organic material from urban and industrial areas of São Paulo, Brazil. Sato MI, et al. **Mutat Res** 1995 Dec;335(3):317–30

[Respiratory and cardiovascular effects of acetylcholine provocation after inhalation exposure to various occupational pollutants--studies in the rabbit] Marek W, et al. **Pneumologie** 1996 May;50(5):342–9 (Eng. Abstr.) **(Ger)**

[The forecasting of hygienic regulations for industrial substances possessing irritant action] Novikov SM, et al. **Gig Sanit** 1995 Nov-Dec;(6):16–20 (Eng. Abstr.) **(Rus)**

[The maximum permissible concentrations, the approximate safe exposure levels and diagnostic tests for poisoning by inhibitors of metal corrosion] Paustovskaia VV. **Lik Sprava** 1995 Jul-Aug;(7–8):40–3 (Eng. Abstr.) **(Rus)**

[Experimental data on bases of MAC of piroxicam in the air of workplace] Bogachuk GP, et al. **Med Tr Prom Ekol** 1996;(4):26–8 (Eng. Abstr.) **(Rus)**

[Hygienic evaluation of work conditions in the production of liladox (starter of vinyl chloride polymerization)] Lemeshevskaia EP, et al. **Med Tr Prom Ekol** 1996;(1):37–9 **(Rus)**

[Toxicity dynamics of anionic dyes in the air of a work place and long-term effects after absorption through the skin] Nikulina GL, et al. **Med Tr Prom Ekol** 1995;(6):25–8 (Eng. Abstr.) **(Rus)**

[Hygienic assessment of occupational hazards resulting form low-soluble lead compounds] Shevliakov VD, et al. **Med Tr Prom Ekol** 1995;(7):21–4 (Eng. Abstr.) **(Rus)**

[The characteristics of the biological action and regulation of submicroscopic aerosols in the industrial environment] Shevchenko AM, et al. **Vrach Delo** 1995 Jan-Feb; (1–2):91–4 (Eng. Abstr.) **(Rus)**

URINE

Evaluation of occupational exposure to benzene by urinalysis. Ghittori S, et al. **Int Arch Occup Environ Health** 1995; 67(3):195–200

Exposure to glycols and their renal effects in motor servicing workers. Laitinen J, et al. **Occup Med (Oxf)** 1995 Oct; 45(5):259–62

Biological monitoring of lead in workers exposed to tetraethyllead. Vural N, et al. **Sci Total Environ** 1995 Oct 27;171(1–3):183–7

AIR POLLUTANTS, RADIOACTIVE

Summary of the BIOMOVS A4 scenario: testing models of the air-pasture-cow milk pathway using Chernobyl fallout data. Peterson SR, et al. **Health Phys** 1996 Aug; 71(2):149–59

Estimated maximum thyroid doses from 129I releases from the Hanford site for the years 1944–1995. Robkin MA, et al. **Health Phys** 1995 Dec;69(6):917–22

ADVERSE EFFECTS

Re: "Case-control study of residential radon and lung cancer in Winnipeg, Manitoba, Canada" [letter; comment] Archer VE. **Am J Epidemiol** 1995 Oct 15;142(8):884–6. Comment on: Am J Epidemiol 1994 Aug 15;140(4):310–22.

Uranium dust exposure and lung cancer risk in four uranium processing operations. Dupree EA, et al. **Epidemiology** 1995 Jul;6(4):370–5

Radon and childhood cancers [editorial; comment] Parker L, et al. **Eur J Cancer** 1996 Feb;32A(2):201–4. Comment on: Eur J Cancer 1996 Feb;32A(2):282–5.

Radon in Devon and Cornwall and paediatric malignancies [see comments] Thorne R, et al. **Eur J Cancer** 1996 Feb; 32A(2):282–5. Comment in: Eur J Cancer 1996 Feb;32A(2):201–4.

Comments on "Breast cancer: evidence for a relation to fission products in the diet" [comment] Musolino SV. **Int J Health Serv** 1995;25(3):475–80; discussion 481–8. Comment on: Int J Health Serv 1993;23(4):783–804.

Importance of radon as a threat to public health. Donohoe K, et al. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):271–6 (23 ref.)

Exposure assessment needs in studies of delayed health effects. Stolwijk JA. **Sci Total Environ** 1995 Jun 16; 168(2):119–22

[Radon and cancer risk: epidemiological studies after occupational or domestic exposure] Tirmarche M. **Rev Epidemiol Sante Publique** 1995;43(5):451–60 (Eng. Abstr.) **(Fre)**

[The radon problem] Mancini C. **Ann Ig** 1996 Jan-Feb; 8(1):137–45 (Eng. Abstr.) **(Ita)**

ANALYSIS

Short communication: estimates of radiation dose to National Health Service workers in Northamptonshire from raised radon levels. Denman AR, et al. **Br J Radiol** 1996 Jan; 69(817):72–5

Survey of 222Rn concentrations in dwellings and soils in the Dutch Belgian border region. Albering HJ, et al. **Health Phys** 1996 Jan;70(1):64–9

Development of an atmospheric 222Rn concentration model using a hydrodynamic meteorological model: I. One-dimensional practical model. Chino M, et al. **Health Phys** 1996 Jan;70(1):47–54

Development of an atmospheric 222Rn concentration model using a hydrodynamic meteorological model: II. Three-dimensional research-purpose model. Chino M, et al. **Health Phys** 1996 Jan;70(1):55–63

On the reduction of error in alpha track detector measurements of indoor 222Rn. Dudney CS, et al. **Health Phys** 1995 Oct;69(4):501–7

Model testing using Chernobyl data: III. Atmospheric resuspension of radionuclides in Ukrainian regions impacted by Chernobyl fallout. Garger EK, et al. **Health Phys** 1996 Jan;70(1):18–24

Radon mitigation at Birch Cliff Public School. Moridi R, et al. **Health Phys** 1996 Jan;70(1):99–102

Indoor 222Rn concentrations in Central Asturias. Perez Iglesias JM, et al. **Health Phys** 1996 May;70(5):689–94

Single point aerosol sampling: evaluation of mixing and probe performance in a nuclear stack. Rodgers JC, et al. **Health Phys** 1996 Jan;70(1):25–35

Radon concentrations and exposure levels in Hungarian caves. Szerbin P. **Health Phys** 1996 Sep;71(3):362–9

Alpha self-absorption in monazite dusts. Terry KW. **Health Phys** 1995 Oct;69(4):553–5

Lung dose estimates from air sampling and bioassay data--a comparison. West CM, et al. **Health Phys** 1995 Oct; 69(4):481–6

Outdoor field evaluation of passive tritiated water vapor samplers at Canadian power reactor sites. Wood MJ. **Health Phys** 1996 Feb;70(2):258–67

Unexpectedly slow decrease of Chernobyl-derived radiocesium in air and deposition in Bavaria/Germany. Bunzl K, et al. **Naturwissenschaften** 1995 Sep;82(9):417–20

Air contamination following aerosol ventilation in the gamma camera room. Greaves CD, et al. **Nucl Med Commun** 1995 Nov;16(11):901–4

Burning radionuclide question: what happens to iodine, cesium and chlorine in biomass fires? Amiro BD, et al. **Sci Total Environ** 1996 Aug 30;187(2):93–103

Residual Chernobyl fallout and Sellafield pollutants found on the Isle of Man. McKenna P, et al. **Sci Total Environ** 1995 Dec 1;173–174:7–14

Atmospheric deposition of cosmogenic 7Be and 137Cs from fallout of the Chernobyl accident. Papastefanou C, et al. **Sci Total Environ** 1995 Aug 18;170(1–2):151–6

Distribution of toxic and radiation components in air particulates. Rausch H, et al. **Sci Total Environ** 1995 Dec 1;173–174:283–91

[Contamination levels to room air arising from the use of 99mTc-gas and prevention from the contamination] Komatani A, et al. **Kaku Igaku** 1996 Apr;33(4):443–5 (Eng. Abstr.) **(Jpn)**

[Comparative analysis of two diffusion methods for radon Rn-222 estimation in atmospheric air by means of gamma ray spectrometry and liquid scintillation counting] Gorzkowski B, et al. **Rocz Panstw Zakl Hig** 1995; 46(1):71–80 (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

[Change in biological availability of 137Cs in grassland ecosystems after the accident at Chernobyl Atomic Energy Station] Fesenko SV, et al. **Dokl Akad Nauk** 1996 Apr; 347(6):847–9 **(Rus)**

TOXICITY

Biokinetics of nuclear fuel compounds and biological effects of nonuniform radiation. Lang S, et al. **Environ Health Perspect** 1995 Oct;103(10):920–34 (191 ref.)

Evaluation of the NESHAP radiological risk assessment. Wahl LE. **Health Phys** 1996 Sep;71(3):279–83

AIR POLLUTION

Bronchial responsiveness, eosinophilia, and short term exposure to air pollution. Søyseth V, et al. **Arch Dis Child** 1995 Nov;73(5):418–22

UK government wants to improve air quality [news] Beecham L. **BMJ** 1996 Aug 31;313(7056):511

Air pollution related to transport. Diesel is the main problem [letter] Jones RR. **BMJ** 1996 Jun 22;312(7046):1605–6

Chromosome aberrations in humans in relation to site of residence. Milillo CP, et al. **Mutat Res** 1996 Aug 8; 360(3):173–9

More worries about pollution [editorial] **Nature** 1996 Jun 6; 381(6582):451

Occupational exposures estimated by means of job exposure matrices in relation to lung function in the PAARC survey. Le Moual N, et al. **Occup Environ Med** 1995 Oct; 52(10):634–43

Effects on the natural world: animals and plants. Bailey BJ. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):290–1

Air pollution in the United States. Nichols M. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):253–4

International medicine and air pollution. Scott JK. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):288–9

Air and water pollution are intertwined. Soderstrom RM. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):286–7

Direct and indirect exposure to air pollution. Thron RW. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):281–5 (24 ref.)

Air pollution and daily mortality in three Swiss urban areas. Wietlisbach V, et al. **Soz Praventivmed** 1996;41(2):107–15

Asthma, airways responsiveness and air pollution in two contrasting districts of northern England. Devereux G, et al. **Thorax** 1996 Feb;51(2):169–74

[POLAIR: software and methodological guide for the epidemiological investigation of a point source atmospheric pollution] Balducci F, et al. **Rev Epidemiol Sante Publique** 1995 Dec;43(6):594–603 (Eng. Abstr.) **(Fre)**

[Air pollution in Switzerland and respiratory diseases in adults.Results of a preliminary study of the cross-sectional part of the Sapaldia study] Leuenberger P. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1096–100 (Eng. Abstr.) **(Ger)**

[Environmental odor pollution--health significance in humans (editorial)] Shipira I, et al. **Harefuah** 1995 Nov 1;129(9):323–5 **(Heb)**

[Atmospheric pollution: acid depositions] De Luca D'Alessandro E. **Ann Ig** 1994 Jul-Dec;6(4–6):793–802 (27 ref.) (Eng. Abstr.) **(Ita)**

[Trends of air pollution versus those of consultation rate and mortality rate for bronchial asthma in individuals aged 40 years and above in the Yokkaichi region] Kitabatake M, et al. **Nippon Eiseigaku Zasshi** 1995 Aug;50(3):737–47 (Eng. Abstr.) **(Jpn)**

[Air pollution and health] Dybing E, et al. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2147–8 **(Nor)**

[Association of air pollution and mortality: a review of recent epidemiological studies] Ballester Diez F, et al. **Rev Esp Salud Publica** 1995 Mar-Apr;69(2):177–88 (38 ref.) (Eng. Abstr.) **(Spa)**

[Impact of outdoor pollution on indoor air quality. The case of downtown Santiago (Chile)] Gil L, et al. **Rev Med Chil** 1995 Apr;123(4):411–25 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Acute health effects of exposure to high levels of air pollution in eastern Europe. Peters A, et al. **Am J Epidemiol** 1996 Sep 15;144(6):570–81

Health effects of outdoor air pollution. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society. **Am J Respir Crit Care Med** 1996 Jan;153(1):3–50 (578 ref.)

SAPALDIA Study. Swiss study on Air Pollution and Respiratory Diseases in Adults [letter; comment] Atteslander P, et al. **Am J Respir Crit Care Med** 1996 Jan; 153(1):462–3. Comment on: Am J Respir Crit Care Med 1994 Nov;150(5 Pt 1):1221–8.

Effects of air pollution on the respiratory health of asthmatic children living in Mexico City. Romieu I, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):300–7

The effects of air pollution on ventilatory lung functions. Matković V, et al. **Arh Hig Rada Toksikol** 1995 Jun; 46(2):225–36

Asthma epidemics and air pollution. Epidemic of asthma was not associated with episode of air pollution [letter] Anderson HR, et al. **BMJ** 1996 Jun 22;312(7046):1606–7

Air pollution and daily mortality in London: 1987–92 [see comments] Anderson HR, et al. **BMJ** 1996 Mar 16; 312(7032):665–9. Comment in: BMJ 1996 Mar 16;312(7032):649–50.

Lung cancer, smoking, and environment: a cohort study of the Danish population. Engholm G, et al. **BMJ** 1996 May 18;312(7041):1259–63

Asthma epidemics and air pollution. Upper respiratory tract infection and fall in atmospheric temperature may lead to attacks of childhood asthma [letter; comment] Hawker J, et al. **BMJ** 1996 Jun 22;312(7046):1606. Comment on: BMJ 1996 Mar 9;312(7031):590–1.

What exacerbates asthma? [letter] Abelsohn A, et al.

Can Fam Physician 1996 Apr;42:620
Environmental air pollution and DNA adducts in Copenhagen bus drivers--effect of GSTM1 and NAT2 genotypes on adduct levels. Nielsen PS, et al. **Carcinogenesis** 1996 May;17(5):1021-7
Use of outpatient clinics as a health indicator for communities around a coal-fired power plant. Goren AI, et al. **Environ Health Perspect** 1995 Dec;103(12):1110-5
Synoptic weather modeling and estimates of the exposure-response relationship between daily mortality and particulate air pollution. Pope CA 3rd, et al. **Environ Health Perspect** 1996 Apr;104(4):414-20
Short-term effects of air pollution on hospital emergency outpatient visits and admissions in the greater Athens, Greece area. Pantazopoulou A, et al. **Environ Res** 1995 Apr;69(1):31-6
Air pollution and daily mortality in Philadelphia [see comments] Moolgavkar SH, et al. **Epidemiology** 1995 Sep; 6(5):476-84. Comment in: Epidemiology 1995 Sep;6(5):471-3. Comment in: Epidemiology 1995 Nov;6(6):629-32.
Particulate air pollution and mortality: the Philadelphia story [editorial; comment] [see comments] Samet JM. **Epidemiology** 1995 Sep;6(5):471-3 (14 ref.). Comment on: Epidemiology 1995 Sep;6(5):476-84. Comment in: Epidemiology 1995 Nov;6(6):629-32.
Air pollution and hospital admissions for respiratory disease. Schwartz J. **Epidemiology** 1996 Jan;7(1):20-8
Outdoor pollution and headache. Nattero G, et al. **Headache** 1996 Apr;36(4):243-5
Two-year follow-up study of the effect of acid fog on adult asthma patients. Tanaka H, et al. **Intern Med** 1996 Feb; 35(2):100-4
Air pollution and mortality: issues and uncertainties. Lipfert FW, et al. **J Air Waste Manag Assoc** 1995 Dec; 45(12):949-66 (54 ref.)
Short term respiratory health effects of ambient air pollution: results of the APHEA project in Paris. Dab W, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:s42-6
Short term effects of air pollution on health: a European approach using epidemiologic time series data: the APHEA protocol. Katsouyanni K, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:S12-8
Effects of air pollution on daily hospital admissions for respiratory disease in London between 1987-88 and 1991-92. Ponce de Leon A, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:s63-70
Asthma and ambient air pollution in Helsinki. Pönkä A, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:s59-62
Short term effects of air pollution on emergency hospital admissions for respiratory disease: results of the APHEA project in two major cities in The Netherlands, 1977-89. Schouten JP, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:s22-9
Daily mortality and air pollutants: findings from Köln, Germany. Spix C, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:s52-8
Air pollution and mortality in Barcelona. Sunyer J, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:s76-80
Daily mortality and "winter type" air pollution in Athens, Greece--a time series analysis within the APHEA project. Touloumi G, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:s47-51
Short term effects of urban air pollution on respiratory health in Milan, Italy, 1980-89. Vigotti MA, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:s71-5
Short term effect of air pollution on mortality in Polish urban populations--what is different? Wojtyniak B, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:S36-41
Short term effects of air pollution on mortality in the city of Lyon, France, 1985-90. Zmirou D, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:S30-5
Air pollution and mortality: results from a study of Santiago, Chile. Ostro B, et al. **J Expo Anal Environ Epidemiol** 1996 Jan-Mar;6(1):97-114
Time-activity patterns and diurnal variation of respiratory status in a panel of asthmatics: implications for short-term air pollution effects. Shamoo DA, et al. **J Expo Anal Environ Epidemiol** 1994 Apr-Jun;4(2):133-48
Hispanic environmental health: ambient and indoor air pollution. National Coalition of Hispanic Health and Human Services Organizations (COSSMHO). **Otolaryngol Head Neck Surg** 1996 Feb;114(2):256-64 (27 ref.)
Blood and air pollution: state of knowledge and research needs. Badman DG, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):205-8 (16 ref.)
Impact of air pollution on women's health. Society for the Advancement of Women's Health Research. Bryant K. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):267-70
Air pollution hazards to children. Etzel RA. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):265-6
Skin effects of air pollution. Goldsmith LA. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):217-9
Opening remarks at the conference on air pollution impacts on body organs and systems. Goldstein JC. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):198
Effects of air pollution on the upper aerodigestive tract. Holt GR. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):201-4
Psychiatric aspects of air pollution. Lundberg A. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):227-31 (39 ref.)
Effects of air pollution on African-American and other minority populations. Olden K. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):255
Aerospace air pollution issues. Patterson RE, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):277-80
Effect of air pollution in asthma and respiratory allergy. Peden DB. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):242-7 (33 ref.)
Air pollution and its effect on the upper respiratory tract and on allergic rhinosinusitis. Trevino RJ. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):239-41
Sudden infant death syndrome in relation to weather and optimetrically measured air pollution in Taiwan. Knöbel HH, et al. **Pediatrics** 1995 Dec;96(6):1106-10
Progressive hypomagnesemia in the industrialised part of southern Poland. Stępniewski M, et al. **Przegl Lek** 1996; 53(4):375-6
The free radical basis of air pollution: focus on ozone. Kelly FJ, et al. **Respir Med** 1995 Nov;89(10):647-56 (77 ref.)
'If this is what it's doing to our washing, what is it doing to our lungs?' Industrial pollution and public understanding in north-east England. Moffatt S, et al. **Soc Sci Med** 1995 Sep;41(6):883-91
Environmental risks: scientific concepts and social perception. Vineis P. **Theor Med** 1995 Jun;16(2):153-69
Health effects of an air pollution episode in London, December 1991. Anderson HR, et al. **Thorax** 1995 Nov; 50(11):1188-93
Short-term association between air pollution and emergency room visits for asthma in Barcelona. Castellsague J, et al. **Thorax** 1995 Oct;50(10):1051-6
Air pollution: brown skies research. Tattersfield AE. **Thorax** 1996 Jan;51(1):13-22 (43 ref.)
Hospital admission rates for asthma and respiratory disease in the West Midlands: their relationship to air pollution levels. Walters S, et al. **Thorax** 1995 Sep;50(9):948-54
Asthma and the environment: do environmental factors affect the incidence and prognosis of asthma? Samet JM. **Toxicol Lett** 1995 Dec;82-83:33-8 (15 ref.)
Environmentally induced asthma. Utell MJ, et al. **Toxicol Lett** 1995 Dec;82-83:47-53 (21 ref.)
Asthma and air pollution. Balmes JR. **West J Med** 1995 Oct; 163(4):372-3
[The functional characteristics of the cardiovascular system in children exposed to air pollution] Barkov LV, et al. **Gig Sanit** 1996 Jan-Feb;(1):8-10 (Eng. Abstr.) **(Rus)**
[Unusual attendance at Hospital Emergency Services for asthma and chronic obstructive pulmonary disease and SO2 air pollution in Cartagena (Spain)] Guillén Pérez JJ, et al. **Rev Esp Salud Publica** 1995 May-Aug;69(3-4):305-14 (Eng. Abstr.) **(Spa)**

ANALYSIS

Evaluation of a chemical spot-test kit for the detection of airborne particulate lead in the workplace. Ashley K, et al. **Am Ind Hyg Assoc J** 1996 Feb;57(2):161-5
Exposure to airborne metals in the manufacture and maintenance of hard metal and stellite blades. Linnainmaa M, et al. **Am Ind Hyg Assoc J** 1996 Feb;57(2):196-201
Urban air quality and human health: a Toronto perspective. Campbell ME, et al. **Can J Public Health** 1995 Sep-Oct; 86(5):351-7
The association between air pollution and the daily number of deaths: findings from the Slovak Republic contribution to the APHEA project. Bachárová L, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:s19-21
Methodological issues in studies of air pollution and daily counts of deaths or hospital admissions. Schwartz J, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:S3-11
Personal exposure to airborne particles and metals: results from the Particle TEAM study in Riverside, California. Ozkaynak H, et al. **J Expo Anal Environ Epidemiol** 1996 Jan-Mar;6(1):57-78
Distributions of nitropyrenes and mutagenicity in airborne particulates collected with an Andersen sampler. Hayakawa K, et al. **Mutat Res** 1995 Oct;348(2):57-61
Allergen levels causing sensitisation, bronchial hyperreactivity and asthma. Dreborg S. **Pediatr Allergy Immunol** 1995;6 Suppl 7:22-6 (44 ref.)
[Dust particles and metals in outdoor and indoor air of Upper Silesia] Górny RL, et al. **Rocz Panstw Zakl Hig** 1995; 46(2):151-61 (Eng. Abstr.) **(Pol)**
[Dioxins in the municipal waste incineration process--threats, norms, actual situation, counter-actions] Pająk T. **Rocz Panstw Zakl Hig** 1996;47(1):105-19 (Eng. Abstr.) **(Pol)**

LEGISLATION & JURISPRUDENCE

Air pollution: time for more clean air legislation? [editorial; comment] Bates DV. **BMJ** 1996 Mar 16;312(7032):649-50 . Comment on: BMJ 1996 Mar 16;312(7032):661-5. Comment on: BMJ 1996 Mar 16;312(7032):665-9. Comment on: BMJ 1996 Mar 16;312(7032):676-7.
Air pollution related to transport. Doctors should support parliamentary bill [letter] Hill S. **BMJ** 1996 Jun 22; 312(7046):1606
Regulators face questioning on particulate rules. Reichhardt T. **Nature** 1996 Mar 7;380(6569):11-2

PREVENTION & CONTROL

Abatement of tropospheric ozone: effects of strategies to improve air quality on public health and other sectors. Guest CS, et al. **Aust N Z J Public Health** 1996 Jun; 20(3):301-8 (55 ref.)
Science and policy in regulatory decision making: getting the facts right about hazardous air pollutants. Sexton K. **Environ Health Perspect** 1995 Sep;103 Suppl 6:213-22
A 10-point exhaust ventilation management standard. Burton DJ. **Occup Health Saf** 1996 Jan;65(1):22
Evaluation of chemical amendments to reduce ammonia volatilization from poultry litter. Moore PA Jr, et al. **Poult Sci** 1996 Mar;75(3):315-20
[Examination of feed and slurry additives for decrease of ammonia emissions in swine housing] Krieger R, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Aug;102(8):316-20 (Eng. Abstr.) **(Ger)**
[Animal housing climatic quality in various harmful conditions in broiler production to avoid heat stress in summer] Tegethoff V, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Mar;103(3):87-91 (Eng. Abstr.) **(Ger)**
[Plasma catalytic purification of the spacecraft air from hydrocarbons] Zlotopol'skiĭ VM, et al. **Aviakosm Ekolog Med** 1995;29(6):54-7 (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

A population-based exposure model for benzene. MacIntosh DL, et al. **J Expo Anal Environ Epidemiol** 1995 Jul-Sep; 5(3):375-403 (73 ref.)
Establishing links between air quality and health: searching for the impossible? Dunn C, et al. **Soc Sci Med** 1996 Mar; 42(6):831-41
The spatial analysis of covariates in a study of environmental epidemiology. Donnelly CA. **Stat Med** 1995 Nov 15-30; 14(21-22):2393-409
Assessment of the impact of ambient air pollutants on health in Helsinki, Finland. Pönkä A. **World Health Stat Q** 1995; 48(2):126-31
The effect of outdpor air pollution on mortality risk: an ecological study from Santiago, Chile. Salinas M, et al. **World Health Stat Q** 1995;48(2):118-25
[Prospective epidemiologic study on respiratory diseases in children in Cracow. Pilot study] Jedrychowski W, et al. **Przegl Epidemiol** 1995;49(3):331-9 (Eng. Abstr.) **(Pol)**

AIR POLLUTION, INDOOR

see related

ENVIRONMENTAL ILLNESS

Study on the ability of a new barrier to reduce airborne mite allergens. Rigamonti IE, et al. **Allerg Immunol (Paris)** 1996 Mar;28(3):70-3
Occupant generated carbon dioxide as a measure of dilution ventilation efficiency. Jankovic JT, et al. **Am Ind Hyg Assoc J** 1996 Aug;57(8):756-9
Air quality in an animal facility: particulates, ammonia, and volatile organic compounds. Kacergis JB, et al. **Am Ind Hyg Assoc J** 1996 Jul;57(7):634-40
Unrecognised environmental pollution by desflurane [letter] Radcliffe JJ, et al. **Anaesthesia** 1996 Jan;51(1):100
Anesthetic gas-scavenging in the laboratory [letter] Perouansky M, et al. **Anesthesiology** 1996 Mar;84(3):751
Knowledge about indoor radon in the United States: 1990 National Health Interview Survey. Eheman CR, et al. **Arch Environ Health** 1996 May-Jun;51(3):245-7
Home dampness and childhood respiratory symptoms in a subtropical climate. Li CS, et al. **Arch Environ Health** 1996 Jan-Feb;51(1):42-6
Photochemical smog and PUVA cabinets [letter] Walter J. **Australas J Dermatol** 1996 May;37(2):114
External ocular hyperemia: a quantifiable indicator of spacecraft air quality. Ogle JW, et al. **Aviat Space Environ Med** 1996 May;67(5):423-8
Molecular techniques and their potential application in monitoring the microbiological quality of indoor air. MacNeil L, et al. **Can J Microbiol** 1995 Aug;41(8):657-65 (69 ref.)
Cardiovascular effects of environmental tobacco smoke [editorial; comment] Weiss ST. **Circulation** 1996 Aug 15; 94(4):599. Comment on: Circulation 1996 Aug 15;94(4):622-8.
Asthmatic symptoms and indoor levels of micro-organisms and house dust mites. Björnsson E, et al. **Clin Exp Allergy** 1995 May;25(5):423-31
Survey of 222Rn concentrations in dwellings and soils in the Dutch Belgian border region. Albering HJ, et al. **Health Phys** 1996 Jan;70(1):64-9
How to screen for 222Rn in large buildings. Dudney CS, et al. **Health Phys** 1996 Feb;70(2):250-7
On the reduction of error in alpha track detector measurements of indoor 222Rn. Dudney CS, et al. **Health Phys** 1995 Oct;69(4):501-7
Indoor 222Rn concentrations in Central Asturias. Perez Iglesias JM, et al. **Health Phys** 1996 May;70(5):689-94
Elevated indoor exposure in Chinese carbon brick and cave dwellings. Wang Z, et al. **Health Phys** 1996 Sep;71(3):374-8
Radon measurements in underground dwellings from two prefectures in China. Wang ZY, et al. **Health Phys** 1996 Feb;70(2):192-8

Pollution and its control in asbestos milling processes in India. Mukherjee AK, et al. **Ind Health** 1996;34(1):35–43

Microfungi in indoor air are able to trigger histamine release by non–IgE–mediated mechanisms. Larsen FO, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S23–4

Indoor particles: a review. Wallace L. **J Air Waste Manag Assoc** 1996 Feb;46(2):98–126 (106 ref.)

Mite allergen (Der p 1) concentration in houses and its relation to the presence and severity of asthma in a population of Sydney schoolchildren. Marks GB, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):441–8

Is there a dose–response relationship between exposure to indoor allergens and symptoms of asthma? [editorial] Platts–Mills TA, et al. **J Allergy Clin Immunol** 1995 Oct; 96(4):435–40 (44 ref.)

Airborne insecticide residues after broadcast application for cat flea (Siphonaptera: Pulicidae) control. Koehler PG, et al. **J Econ Entomol** 1995 Dec;88(6):1684–9

Theatre air sampling—once a year is not enough [letter] Fox C, et al. **J Hosp Infect** 1996 Apr;32(4):319–20

Carbon monoxide poisoning at an indoor ice arena and bingo hall—Seattle, 1996. From the Centers for Disease Control and Prevention. **JAMA** 1996 May 15;275(19):1468–9

From the Centers for Disease Control and Prevention. Mercury exposure among residents of a building formerly used for industrial purposes—New Jersey, 1995. **JAMA** 1996 Jul 3;276(1):17–8

Carbon monoxide poisoning at an indoor ice arena and bingo hall—Seattle, 1996. **MMWR Morb Mortal Wkly Rep** 1996 Apr 5;45(13):265–7

Mercury exposure among residents of a building formerly used for industrial purposes—New Jersey, 1995. **MMWR Morb Mortal Wkly Rep** 1996 May 24;45(20):422–4

Effect of indoor air pollution on the respiratory system of women using different fuels for cooking in an urban slum of Pondicherry. Dutt D, et al. **Natl Med J India** 1996 May–Jun;9(3):113–7

Indoor air pollution in India [editorial] Smith KR. **Natl Med J India** 1996 May–Jun;9(3):103–4

Indoor air quality. Taking a second look at blueprints. Kerbel W. **Occup Health Saf** 1995 Jan;64(1):47–9, 72

Domestic magnetic field exposures in Avon. Preece AW, et al. **Phys Med Biol** 1996 Jan;41(1):71–81

[Allergic diseases in the indoor environment] Schata M. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):196–211 (8 ref.) (Eng. Abstr.) **(Ger)**

[Bacteriological study of air in dental offices] Bori Z, et al. **Fogorv Sz** 1996 Mar;89(3):89–95 (Eng. Abstr.) **(Hun)**

[Indoor air quality in buildings. Conference proceedings. Italy, 26 January 1995] **Ann Ig** 1996 Jan–Feb;8(1):1–188 **(Ita)**

[Comfort in operating rooms. The preliminary results of a study by questionnaire] D'Alessandro D, et al. **Ann Ig** 1996 Jan–Feb;8(1):113–20 (Eng. Abstr.) **(Ita)**

[Pollutant dispersion models: their application to the case of dispersion in the vicinity of a building] Leuzzi G, et al. **Ann Ig** 1996 Jan–Feb;8(1):147–57 (Eng. Abstr.) **(Ita)**

[The quality of the indoor air in Roman dwellings. A study by questionnaire] Micali O, et al. **Ann Ig** 1996 Jan–Feb; 8(1):3–11 (Eng. Abstr.) **(Ita)**

[The quality of the indoor air in dwellings in L'Aquila. A study by questionnaire] Onorato P, et al. **Ann Ig** 1996 Jan–Feb;8(1):13–9 (Eng. Abstr.) **(Ita)**

[Indoor pollution: the microbiological findings in some work environments] Sebastiani Annicchiarico L, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):813–9 (Eng. Abstr.) **(Ita)**

[A pilot study of the air quality in dental environments] Simonetti D'Arca A, et al. **Ann Ig** 1996 Jan–Feb;8(1):83–92 (Eng. Abstr.) **(Ita)**

[Environmental comfort in 2 Roman dental clinic complexes] Tarsitani G, et al. **Ann Ig** 1996 Jan–Feb;8(1):93–101 (Eng. Abstr.) **(Ita)**

[Specific source of the entry of polluting substances into living accommodations] Ianin EP. **Med Tr Prom Ekol** 1995; (10):39–40 (Eng. Abstr.) **(Rus)**

[Compare indoor air quality in Eastern Europe and here (letter)] Svensson G. **Lakartidningen** 1995 Dec 6; 92(49):4675 **(Swe)**

ADVERSE EFFECTS

Birch–pollen antigenic activity of settled dust in rural and urban homes. Yli–Panula E, et al. **Allergy** 1995 Apr; 50(4):303–7

Effects of indoor air pollution on lung function of primary school children in Jordan. Gharaibeh NS. **Ann Trop Paediatr** 1996 Jun;16(2):97–102

Air pollution in homes [editorial] Coggon D. **BMJ** 1996 May 25;312(7042):1316

More homes at risk from radon [news] Dillner L. **BMJ** 1996 May 25;312(7042):1320

Woodsmoke exposure and risk for obstructive airways disease among women. Dennis RJ, et al. **Chest** 1996 Jan; 109(1):115–9

Environmental tobacco smoke and coronary heart disease in the American Cancer Society CPS–II cohort [see comments] Steenland K, et al. **Circulation** 1996 Aug 15; 94(4):622–8. Comment in: Circulation 1996 Aug 15;94(4):596–8. Comment in: Circulation 1996 Aug 15;94(4):599.

Indoor air pollution and childhood asthma: effective environmental interventions. Etzel RA. **Environ Health Perspect** 1995 Sep;103 Suppl 6:55–8 (43 ref.)

Environmental risk factors of childhood asthma in urban centers. Malveaux FJ, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:59–62 (30 ref.)

Exposure to house dust mite allergens and the clinical activity of asthma. Custovic A, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):64–72

Cytogenetic evaluation of medical students exposed to formaldehyde vapor in the gross anatomy dissection laboratory. Vasudeva N, et al. **J Am Coll Health** 1996 Jan; 44(4):177–9

Indoor air pollution and asthma in hospitalized children in a tropical environment. Azizi BH, et al. **J Asthma** 1995; 32(6):413–8

Nitrogen dioxide pneumonitis in ice hockey players. Karlson–Stiber C, et al. **J Intern Med** 1996 May; 239(5):451–6

A complication of indoor pistol shooting. White SA, et al. **J Laryngol Otol** 1996 Jul;110(7):663–4

Indoor radon exposure and risk of lung cancer: a nested case–control study in Finland. Auvinen A, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):966–72

Monitoring of aromatic amine exposures in workers at a chemical plant with a known bladder cancer excess. Ward EM, et al. **J Natl Cancer Inst** 1996 Aug 7;88(15):1046–52

Gas stoves and respiratory health [comment] Brauer M, et al. **Lancet** 1996 Feb 17;347(8999):412. Comment on: Lancet 1996 Feb 17;347(8999):426–31.

Association of respiratory symptoms and lung function in young adults with use of domestic gas appliances [see comments] Jarvis D, et al. **Lancet** 1996 Feb 17; 347(8999):426–31. Comment in: Lancet 1996 Feb 17;347(8999):412. Comment in: Lancet 1996 Apr 13;347(9007):1052–3. Comment in: Lancet 1996 May 25;347(9013):1490–1.

Absence of association between respiratory symptoms in young adults with use of gas stoves in Belgium [letter; comment] Wieringa M, et al. **Lancet** 1996 May 25; 347(9013):1490–1. Comment on: Lancet 1996 Feb 17;347(8999):426–31.

Risk factors for lung cancer among nonsmokers with emphasis on lifestyle factors. Gao YT. **Lung Cancer** 1996 Mar;14 Suppl 1:S39–45 (24 ref.)

Diet as a confounder of the association between air pollution and female lung cancer: Hong Kong studies on exposures to environmental tobacco smoke, incense, and cooking fumes as examples. Koo LC, et al. **Lung Cancer** 1996 Mar; 14 Suppl 1:S47–61 (21 ref.)

Some lifestyle factors in human lung cancer: a case–control study of 792 lung cancer cases. Lei YX, et al. **Lung Cancer** 1996 Mar;14 Suppl 1:S121–36

Indoor burning coal air pollution and lung cancer—a case–control study in Fuzhou, China. Luo RX, et al. **Lung Cancer** 1996 Mar;14 Suppl 1:S113–9

Analysis and estimates of attributable risk factors for lung cancer in Nanjing, China. Shen XB, et al. **Lung Cancer** 1996 Mar;14 Suppl 1:S107–12

Lung cancer in nonsmoking Chinese women: a case–control study. Wang TJ, et al. **Lung Cancer** 1996 Mar;14 Suppl 1:S93–8

Summary of papers and research recommendations presented at the International Symposium on Lifestyle Factors and Human Lung Cancer, Guangzhou, China. Wu JM, et al. **Lung Cancer** 1996 Mar;14 Suppl 1:S223–34

Lifestyle, environmental pollution and lung cancer in cities of Liaoning in northeastern China. Xu ZY, et al. **Lung Cancer** 1996 Mar;14 Suppl 1:S149–60

Management of indoor air quality problems: "primum non nocere" [letter; comment] Magnavita N. **Occup Environ Med** 1995 Nov;52(11):782. Comment on: Occup Environ Med 1995 Mar;52(3):170–6.

Molds, fungi cause sick building syndrome [news] **Occup Health Saf** 1996 Jan;65(1):13–4

Hispanic environmental health: ambient and indoor air pollution. National Coalition of Hispanic Health and Human Services Organizations (COSSMHO). **Otolaryngol Head Neck Surg** 1996 Feb;114(2):256–64 (27 ref.)

Environmental factors influencing the levels of indoor allergens. Munir AK. **Pediatr Allergy Immunol** 1995;6 Suppl 7:13–21 (91 ref.)

Indoor air pollution. Etzel RA. **Pediatr Ann** 1995 Dec; 24(12):653–6

Possible mechanisms for the respiratory tract effects of noncarcinogenic indoor–climate pollutants and bases for their risk assessment. Damgård Nielsen G, et al. **Scand J Work Environ Health** 1995 Jun;21(3):165–78 (113 ref.)

Health effects of indoor–air microorganisms [see comments] Husman T. **Scand J Work Environ Health** 1996 Feb; 22(1):5–13 (95 ref.). Comment in: Scand J Work Environ Health 1996 Feb;22(1):1–3.

Environmental chemicals relevant for respiratory hypersensitivity: the indoor environment. Becher R, et al. **Toxicol Lett** 1996 Aug;86(2–3):155–62 (47 ref.)

[Solvent emissions in a school building after using a construction moisture protection substance] Bent S, et al. **Gesundheitswesen** 1996 Apr;58(4):234–6 (Eng. Abstr.) **(Ger)**

[Mercury burden in humans caused by housing in formerly mirrored rooms] Lederer P, et al. **Gesundheitswesen** 1995 Jul;57(7):391–6 (Eng. Abstr.) **(Ger)**

[In a 1970–built high school multiple increased PCB (polychlorinated biphenyl) readings in concentrations of around 3,800 micrograms /pro cubic meter were obtained] Rüdiger HW. **Internist (Berl)** 1995 Sep;36(9):931–2 **(Ger)**

[The radon problem] Mancini C. **Ann Ig** 1996 Jan–Feb; 8(1):137–45 (Eng. Abstr.) **(Ita)**

ANALYSIS

Dust mite allergens in the office environment [see comments] Janko M, et al. **Am Ind Hyg Assoc J** 1995 Nov; 56(11):1133–40. Comment in: Am Ind Hyg Assoc J 1996 Jun;57(6):573–4.

The sensitive individual and the indoor environment: case study. Martin JR. **Am Ind Hyg Assoc J** 1995 Nov; 56(11):1121–6

Estimating exposure intensity in an imperfectly mixed room. Nicas M. **Am Ind Hyg Assoc J** 1996 Jun;57(6):542–50

Assessment of worker exposure to airborne molds in honeybee overwintering facilities. Sigler L, et al. **Am Ind Hyg Assoc J** 1996 May;57(5):484–90

Evaporative cooling and other home factors and lower respiratory tract illness during the first year of life. Group Health Medical Associates. Aldous MB, et al. **Am J Epidemiol** 1996 Mar 1;143(5):423–30

Comparison between outdoor and indoor airborne allergenic activity. D'Amato G, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):147–52

Effect of environmental conditions on re–emission of formaldehyde from textile materials. Wiglusz R, et al. **Bull Inst Marit Trop Med Gdynia** 1995;46(1–4):53–8

Relation between residential radon concentrations and housing characteristics. The Cracow Study. Jedrychowski W, et al. **Cent Eur J Public Health** 1995 Aug;3(3):158–60

Indoor pollution from heating. Arashidani K, et al. **Ind Health** 1996;34(3):205–15

Direct quantitative analysis of respirable cristobalite on filter by infrared spectrophotometry. Shinohara Y. **Ind Health** 1996;34(1):25–34

Environmental microbial contamination. Pilot study in a dental surgery. Osorio R, et al. **Int Dent J** 1995 Dec; 45(6):352–7

Measurement of organic acids, aldehydes, and ketones in residential environments and their relation to ozone. Reiss R, et al. **J Air Waste Manag Assoc** 1995 Oct;45(10):811–22

Release of asbestos fibers during casting ring liner manipulation. Davis DR. **J Prosthet Dent** 1995 Sep; 74(3):294–8

Immunochemical and molecular methods for defining and measuring indoor allergens: in dust and air. Chapman MD, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 7:8–12 (32 ref.)

Lead levels, home dust, and proximity to lead smelters [letter; comment] Landrigan PJ. **Pediatrics** 1996 Apr;97(4):603–4 . Comment on: Pediatrics 1995 Apr;95(4):550–4.

Risk assessment methodologies for carcinogenic compounds in indoor air. Nexø BA. **Scand J Work Environ Health** 1995 Oct;21(5):376–81

The impact of heavy metals from environmental tobacco smoke on indoor air quality as determined by Compton suppression neutron activation analysis. Landsberger S, et al. **Sci Total Environ** 1995 Dec 1;173–174:323–37

[Pentachlorophenol—results of a Bavarian human monitoring program] Liebl B, et al. **Gesundheitswesen** 1996 Jun; 58(6):332–8 (Eng. Abstr.) **(Ger)**

[Evaluation of wood preservative pollutants of indoor air] Liebl B, et al. **Gesundheitswesen** 1995 Aug–Sep; 57(8–9):476–88 (Eng. Abstr.) **(Ger)**

[Air quality study in a university library of Rome] Bellante De Martiis G, et al. **Ann Ig** 1996 Jan–Feb;8(1):47–54 (Eng. Abstr.) **(Ita)**

[The air quality in operating rooms: an analysis of an environmental monitoring program] D'Alessandro D, et al. **Ann Ig** 1996 Jan–Feb;8(1):103–12 (Eng. Abstr.) **(Ita)**

[Anesthetic gas pollution in operating rooms: the health and hygiene and management problems] D'Alessandro D, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):821–33 (Eng. Abstr.) **(Ita)**

[Air quality study in school environments: an evaluation of microclimate parameters] Liberatore S, et al. **Ann Ig** 1996 Jan–Feb;8(1):21–34 (Eng. Abstr.) **(Ita)**

[The internal air quality in the reading rooms of a state library] Micali O, et al. **Ann Ig** 1996 Jan–Feb;8(1):55–64 (Eng. Abstr.) **(Ita)**

[The indoor air in dental environments] Simonetti D'Arca A, et al. **Ann Ig** 1996 Jan–Feb;8(1):71–81 (Eng. Abstr.) **(Ita)**

LEGISLATION & JURISPRUDENCE

Mobilizing a low–income African–American community around tobacco control: a force field analysis. Ellis GA, et al. **Health Educ Q** 1995 Nov;22(4):443–57

PREVENTION & CONTROL

Carbon monoxide detectors and emergency physicians [editorial] Leikin JB. **Am J Emerg Med** 1996 Jan;14(1):90–4

Reducing the levels of formaldehyde exposure in gross anatomy laboratories. Coleman R. **Anat Rec** 1995 Dec; 243(4):531–3

Clean–air video will interest MDs who treat patients with allergies, respiratory problems. Rafuse J. **Can Med Assoc J** 1996 Mar 15;154(6):912–3

Environmental tobacco smoke and policies for its control.

AIR POLLUTION, INDOOR

Yamato H, et al. **Ind Health** 1996;34(3):237–44

PCB and dioxin re-entry criteria for building surfaces and air. Michaud JM, et al. **J Expo Anal Environ Epidemiol** 1994 Apr–Jun;4(2):197–227

Theatre air and operating conditions [letter; comment] Humphreys H. **J Hosp Infect** 1995 Oct;31(2):154–5. Comment on: J Hosp Infect 1995 May;30(1):80–2.

Reduction of aerosols produced by ultrasonic scalers. Harrel SK, et al. **J Periodontol** 1996 Jan;67(1):28–32

Condensation and mould: the Canadian experience. Rayner KF. **J R Soc Health** 1996 Apr;116(2):83–6 (19 ref.)

What's that smell? Burton DJ. **Occup Health Saf** 1995 Sep; 64(9):39–40

Strategies for indoor allergen elimination. Wahn U, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 7:42–6 (41 ref.)

Air filtration units [letter; comment] Warbuton CJ, et al. **Respir Med** 1995 Nov;89(10):714. Comment on: Respir Med 1995 May;89(5):394.

[Prevention during building construction against electromagnetic fields caused by high voltage electric lines—principles and risk evaluation] Boikat U, et al. **Gesundheitswesen** 1996 Mar;58(3):147–53 (50 ref.) (Eng. Abstr.) **(Ger)**

[Contamination levels to room air arising from the use of 99mTc-gas and prevention from the contamination] Komatani A, et al. **Kaku Igaku** 1996 Apr;33(4):443–5 (Eng. Abstr.) **(Jpn)**

[Plasmo-catalytic removal of oxygen-containing organic compounds from the spacecraft air] Zlotopol'skii VM, et al. **Aviakosm Ekolog Med** 1995;29(5):56–9 (Eng. Abstr.) **(Rus)**

AIR POLLUTION, RADIOACTIVE

Unexpectedly slow decrease of Chernobyl-derived radiocesium in air and deposition in Bavaria/Germany. Bunzl K, et al. **Naturwissenschaften** 1995 Sep;82(9):417–20

Air contamination following aerosol ventilation in the gamma camera room. Greaves CD, et al. **Nucl Med Commun** 1995 Nov;16(11):901–4

ADVERSE EFFECTS

Adult leukemia and proximity-based surrogates for exposure to Pilgrim plant's nuclear emissions. Morris MS, et al. **Arch Environ Health** 1996 Jul–Aug;51(4):266–74

Residual radiation in Hiroshima and Nagasaki [letter] Roff SR. **Lancet** 1996 Aug 31;348(9027):620

[Tolerance for physical loading and its determinative factors in persons who took part in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Khomaziuk IN. **Lik Sprava** 1995 May–Jun; (5–6):31–5 **(Rus)**

[The clinical and biochemical characteristics of the status of stomach cancer patients who were exposed to ionizing radiation as a result of the accident at the Chernobyl Atomic Electric Power Station] Korobko VB, et al. **Lik Sprava** 1995 May–Jun;(5–6):19–22 (Eng. Abstr.) **(Rus)**

[The functional status of the hypophyseal-thyroid and hypophyseal-adrenal systems in breast cancer patients taking into account their exposure to the factors of the accident at the Chernobyl Atomic Electric Power Station] Maevskaia LP. **Lik Sprava** 1995 May–Jun;(5–6):29–31 (Eng. Abstr.) **(Rus)**

[The health status of children up to 14 years old living in an area of long-term post-accident exposure to low doses of ionizing radiation] Ponomarenko VM. **Lik Sprava** 1995 May–Jun;(5–6):12–5 (Eng. Abstr.) **(Rus)**

[Late changes in the body function of the inhabitants in the area of the eastern Urals radioactive trace] Privalova LI, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):323–31 (Eng. Abstr.) **(Rus)**

[The role of immunological changes in diseases in regions contaminated by radionuclides after the accident at the Chernobyl Atomic Electric Power Station] Shubik VM, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):332–7 (Eng. Abstr.) **(Rus)**

[The characteristics of disorders of general adaptation reactions in people who suffered as a consequence of the accident at the Chernobyl Atomic Electric Power Station and their correction by means of balneo- and phytotherapy] Sarancha SM, et al. **Lik Sprava** 1995 Jul–Aug;(7–8):47–51 (Eng. Abstr.) **(Ukr)**

[The metabolic aspects of the sequelae of the accident at the Chernobyl Atomic Electric Power Station in the course of kidney diseases] Vozianov OF, et al. **Lik Sprava** 1995 May–Jun;(5–6):15–9 (Eng. Abstr.) **(Ukr)**

ANALYSIS

Relation between residential radon concentrations and housing characteristics. The Cracow Study. Jedrychowski W, et al. **Cent Eur J Public Health** 1995 Aug;3(3):158–60

Potential for bias in epidemiologic studies that rely on glass-based retrospective assessment of radon. Weinberg CR. **Environ Health Perspect** 1995 Nov;103(11):1042–6

PREVENTION & CONTROL

Comments on Tengs et al., "Comparative study of the cost-effectiveness of life-saving interventions" [letter; comment] Puskin JS, et al. **Risk Anal** 1996 Apr;16(2):131 . Comment on: Risk Anal 1995 Jun;15(3):369–90.

[Contamination levels to room air arising from the use of 99mTc-gas and prevention from the contamination] Komatani A, et al. **Kaku Igaku** 1996 Apr;33(4):443–5 (Eng. Abstr.) **(Jpn)**

AIR POLLUTION, TOBACCO SMOKE see **TOBACCO SMOKE POLLUTION**

AIR PRESSURE

Influence of 12 weeks of hypobaric hypoxia on fibre type composition of the rat soleus muscle. Itoh K, et al. **Acta Physiol Scand** 1995 Jul;154(3):417–8

Mean airway pressure as an index of mean alveolar pressure. Valta P, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1825–30

Sodium citrate ingestion and muscle performance in acute hypobaric hypoxia. Hausswirth C, et al. **Eur J Appl Physiol** 1995;71(4):362–8

L-arginine-related responses to pressure and vasoactive agents in monocrotaline-treated rat pulmonary arteries. Madden JA, et al. **J Appl Physiol** 1995 Aug;79(2):589–93

Effects of hypobaric hypoxia on antioxidant enzymes in rats. Nakanishi K, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):869–76

Erythropoietin production during flights with pressurised aircrafts [letter] Gunga HC, et al. **Lancet** 1996 Aug 10; 348(9024):416

Analysis of evoked and spontaneous quantal release at high pressure in crustacean excitatory synapses. Golan H, et al. **Pflugers Arch** 1995 Sep;430(5):617–25

[Blood preservation and air transport: study of physical constraints (temperature and pressure)] Almanza L, et al. **Transfus Clin Biol** 1995;2(5):349–55 (Eng. Abstr.) **(Fre)**

[The effect of hyperbarism on the electrical stability and aggregation ability of liposomal membranes] Tiurin-Kuz'min AIu. **Aviakosm Ekolog Med** 1995; 29(2):25–7 (Eng. Abstr.) **(Rus)**

[The effect of the composition of an artificial gas environment under pressure up to 5.1 MPa on the oxidation-reduction reactions in the human body] Semko VV, et al. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):76–82 (Eng. Abstr.) **(Rus)**

AIR QUALITY, INDOOR see **AIR POLLUTION, INDOOR**

AIR RADIOGRAPHY see **PNEUMORADIOGRAPHY**

AIR REVITALIZATION see **AIR CONDITIONING**

AIR SACS

BLOOD SUPPLY

Linear gap and tight junctional assemblies between capillary endothelial cells in the eel rete mirabile. Wagner R, et al. **Anat Rec** 1995 Aug;242(4):545–52

METABOLISM

Mechanisms of acid release in isolated gas gland cells of the European eel Anguilla anguilla. Pelster B. **Am J Physiol** 1995 Oct;269(4 Pt 2):R793–9

AIRCRAFT

Aircraft noise, hearing ability, and annoyance. Wu TN, et al. **Arch Environ Health** 1995 Nov–Dec;50(6):452–6

Airline policy relating to passengers with epilepsy [letter; comment] Ko D. **Arch Neurol** 1996 May;53(5):405–6. Comment on: Arch Neurol 1994 May;51(5):519–20. Comment on: Arch Neurol 1995 Dec;52(12):1215–8.

U.S. Naval helicopter mishaps: cockpit egress problems. Barker CO, et al. **Aviat Space Environ Med** 1996 May; 67(5):480–5

Sustaining helicopter pilot performance with Dexedrine during periods of sleep deprivation. Caldwell JA, et al. **Aviat Space Environ Med** 1995 Oct;66(10):930–7

The feasibility of collecting in-flight EEG data from helicopter pilots. Caldwell JA Jr, et al. **Aviat Space Environ Med** 1995 Sep;66(9):883–9

Deaths and injuries as a result of lightning strikes to aircraft. Cherington M, et al. **Aviat Space Environ Med** 1995 Jul; 66(7):687–9

Cockpit-cabin crew interaction: satisfaction with communication and information exchange. Skogstad A, et al. **Aviat Space Environ Med** 1995 Sep;66(9):841–8

Airborne transmission of infectious diseases aboard aircraft [letter; comment] Ungs TJ. **Aviat Space Environ Med** 1995 Sep;66(9):913–4. Comment on: Aviat Space Environ Med 1995 Mar;66(3):220–4.

Virtual reality exposure therapy in the treatment of fear of flying: a case report. Rothbaum BO, et al. **Behav Res Ther** 1996 May–Jun;34(5–6):477–81

Psychophysiological responses to changes in workload during simulated air traffic control. Brookings JB, et al. **Biol Psychol** 1996 Feb 5;42(3):361–77

Electrooculographic and performance indices of fatigue during simulated flight. Morris TL, et al. **Biol Psychol** 1996 Feb 5;42(3):343–60

Physiological indices of workload in a simulated flight task. Veltman JA, et al. **Biol Psychol** 1996 Feb 5;42(3):323–42

Effects of work demands on immunoglobulin A and cortisol in air traffic controllers. Zeier H, et al. **Biol Psychol** 1996 Feb 5;42(3):413–23

Cancer among airline cabin attendants. Risk due to active and passive smoking should have been mentioned [letter; comment] Fogelholm R. **BMJ** 1996 Jan 6;312(7022):53; discussion 53–4. Comment on: BMJ 1995 Sep 9;311(7006):649–52.

Risk of breast cancer is also increased among Danish female airline cabin attendants [letter; comment] Lynge E. **BMJ** 1996 Jan 27;312(7025):253. Comment on: BMJ 1995 Sep 9;311(7006):649–52.

Incidence of cancer among Finnish airline cabin attendants, 1967–92 [see comments] Pukkala E, et al. **BMJ** 1995 Sep 9;311(7006):649–52. Comment in: BMJ 1996 Jan 6;312(7022):53; discussion 53–4. Comment in: BMJ 1996 Jan 6;312(7022):53–4. Comment in: BMJ 1996 Jan 27;312(7025):253.

Cancer among airline cabin attendants. Interpretation of study minimises occupational hazards [letter; comment] Roff SR. **BMJ** 1996 Jan 6;312(7022):53–4. Comment on: BMJ 1995 Sep 9;311(7006):649–52.

Government secrecy. Safety of air travellers is not protected [letter; comment] Swire H. **BMJ** 1996 Jun 8;312(7044):1475 . Comment on: BMJ 1996 Feb 24;312(7029):455–6.

Flying doctor service faces reforms [news] Zinn C. **BMJ** 1995 Oct 7;311(7010):894

Ambulance or helicopter [editorial] Steedman DJ. **Br J Hosp Med** 1996 Apr 17–30;55(8):460–3

High-performance aircraft—a possible cause of male infertility. Jequier AM. **Br J Urol** 1996 Jun;77(6):920–2

The safety of air transportation of patients with advanced lung disease. Experience with 21 patients requiring lung transplantation or pulmonary thromboendarterectomy. Kramer MR, et al. **Chest** 1995 Nov;108(5):1292–6

Advising patients about air travel. **Drug Ther Bull** 1996 Apr; 34(4):30–2

An outbreak of cholera from food served on an international aircraft. Eberhart-Phillips J, et al. **Epidemiol Infect** 1996 Feb;116(1):9–13

Technology. Mile-high medicine [news] **Hosp Health Netw** 1996 Jul 20;70(14):11

Facilities—a new hospital takes wing. Serb C. **Hosp Health Netw** 1995 Oct 5;69(19):88

The occurrence of thromboembolic events following airplane flights—'the economy class syndrome'. Levy Y, et al. **Isr J Med Sci** 1995 Oct;31(10):621–3

Analog neural network-based helicopter gearbox health monitoring system. Monsen PT, et al. **J Acoust Soc Am** 1995 Dec;98(6):3235–49

Legislative and regulatory front. A question of acclimation [news] Kahler SC. **J Am Vet Med Assoc** 1995 Dec 15; 207(12):1536, 1538–9

Eye scanning behavior as a discriminator of instrument- and scenery-centered flight task. Katoh Z, et al. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):80–4

Air travel induced meningitis following vestibular schwannoma (acoustic neuroma) surgery. Callanan V, et al. **J Laryngol Otol** 1996 Mar;110(3):258–60 (18 ref.)

Noise induced hearing loss in military helicopter aircrew—a review of the evidence. Owen JP. **J R Army Med Corps** 1995 Jun;141(2):98–101 (19 ref.)

Runway malaria in a British serviceman. Connor MP, et al. **J R Soc Med** 1995 Jul;88(7):415P–416P

Jet leg, pulmonary embolism, and hypoxia [letter] Bagshaw M. **Lancet** 1996 Aug 10;348(9024):415–6

Erythropoietin production during flights with pressurised aircrafts [letter] Gunga HC, et al. **Lancet** 1996 Aug 10; 348(9024):416

Jet "leg", pulmonary embolism, and hypoxia [letter] James PB. **Lancet** 1996 Jun 15;347(9016):1697

Too many haematologists on one aeroplane [letter] Rees DC. **Lancet** 1996 Jan 27;347(8996):274

Jet flight leg [letter] Shuster S. **Lancet** 1996 Mar 23; 347(9004):832–3

Jet leg, pulmonary embolism, and hypoxia [letter] Simons R, et al. **Lancet** 1996 Aug 10;348(9024):416

Breast cancer in female flight attendants. Stewart T, et al. **Lancet** 1995 Nov 25;346(8987):1379

Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight [see comments] Kenyon TA, et al. **N Engl J Med** 1996 Apr 11;334(15):933–8 . Comment in: N Engl J Med 1996 Apr 11;334(15):981–2. Comment in: N Engl J Med 1996 Aug 29;335(9):675; discussion 675–6.

Airline travel and infection [editorial; comment] Wenzel RP. **N Engl J Med** 1996 Apr 11;334(15):981–2. Comment on: N Engl J Med 1996 Apr 11;334(15):933–8.

Planes, kangaroos, and the CAPD manual. Carruthers DM, et al. **Perit Dial Int** 1996;16 Suppl 1:S452–4

Postdural puncture headache and air travel after spinal anesthesia with a 24-gauge Sprotte needle [letter] Panadero A, et al. **Reg Anesth** 1995 Sep–Oct;20(5):463–4

Predictors of short-term survival after helicopter rescue. Bonatti J, et al. **Resuscitation** 1995 Oct;30(2):133–40

Assessment of oxygen supplementation during air travel. Cramer D, et al. **Thorax** 1996 Feb;51(2):202–3

Gastrointestinal problems in airline crew members. Enck P, et al. **Z Gastroenterol** 1995 Sep;33(9):513–6

[Erythrocyte concentrated and air transport: evaluation of quality] Almanza L, et al. **Transfus Clin Biol** 1995; 2(5):343–7 (Eng. Abstr.) **(Fre)**

[Blood preservation and air transport: study of physical

constraints (temperature and pressure)] Almanza L, et al. **Transfus Clin Biol** 1995;2(5):349–55 (Eng. Abstr.) **(Fre)**

[Animal welfare laws concerning air transportation of lobsters and langostinos] Hildebrandt K. **Berl Munch Tierarztl Wochenschr** 1995 Apr;108(4):148–9 (Eng. Abstr.) **(Ger)**

[An automated support system for making decisions in medical evacuation measures using aircraft] Berezhnov ES, et al. **Voen Med Zh** 1995 Dec;(12):40–4 **(Rus)**

[The dynamic cytochemical indices of the blood in helicopter pilots who participated in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Smirnov NA, et al. **Voen Med Zh** 1995 Aug;(8):42–3 **(Rus)**

[Psychophysiologic stress in pilots during flight in modern supersonic, high performance planes with complex automation systems] Debijadi R. **Vojnosanit Pregl** 1994 Nov–Dec;51(6):518–26 **(Scr)**

STANDARDS

Aircraft and ship disinfection. Cancellotti FM. **Rev Sci Tech** 1995 Mar;14(1):177–89 (20 ref.)

AIRSICKNESS see **MOTION SICKNESS**

AIRWAY OBSTRUCTION

Comparison of sedation with midazolam and ketamine: effects on airway muscle activity. Drummond GB. **Br J Anaesth** 1996 May;76(5):663–7

Electrically-activated dilator muscles reduce pharyngeal resistance in anaesthetized dogs with upper airway obstruction. Bishara H, et al. **Eur Respir J** 1995 Sep;8(9):1537–42

Pediatric stridor and airway compromise. Zalzal GH. **J Med Liban** 1994;42(4):221–6 (15 ref.)

Reducing choking deaths in children [letter; comment] Flynn D. **JAMA** 1996 May 1;275(17):1313; discussion 1314. Comment on: JAMA 1995 Dec 13;274(22):1763–6.

Reducing choking deaths in children [letter; comment] Kerr HD. **JAMA** 1996 May 1;275(17):1313–4. Comment on: JAMA 1995 Dec 13;274(22):1763–6.

CHEMICALLY INDUCED

Upper airway compromise in acute chlorpromazine ingestion. Russell SA, et al. **Am J Emerg Med** 1996 Sep;14(5):467–8

Airway obstruction in boilermakers exposed to fuel oil ash. A prospective investigation. Hauser R, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1478–84

Upper airway closure: a primary source of difficult ventilation with sufentanil induction of anesthesia. Abrams JT, et al. **Anesth Analg** 1996 Sep;83(3):629–32

Magnetic resonance imaging of the upper airway. Effects of propofol anesthesia and nasal continuous positive airway pressure in humans [see comments] Mathru M, et al. **Anesthesiology** 1996 Feb;84(2):273–9. Comment in: Anesthesiology 1996 Feb;84(2):253–5.

Upper airway obstruction during midazolam sedation: modification by nasal CPAP. Nozaki-Taguchi N, et al. **Can J Anaesth** 1995 Aug;42(8):685–90

Topical upper airway anaesthesia with lidocaine increases airway resistance by impairing glottic function. Beydon L, et al. **Intensive Care Med** 1995 Nov;21(11):920–6

Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. O'Sullivan S, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):421–32

Aerosolized LTB4 produces delayed onset increases in pulmonary gas trapping. Silbaugh SA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Feb;54(2):115–21

COMPLICATIONS

Associations among upper airway structure, body position, and obesity in skeletal Class I male patients with obstructive sleep apnea. Ono T, et al. **Am J Orthod Dentofacial Orthop** 1996 Jun;109(6):625–34

Upper airway obstruction in children with Down syndrome. Jacobs IN, et al. **Arch Otolaryngol Head Neck Surg** 1996 Sep;122(9):945–50

Medic Alert UK should start new section for patients with a difficult airway [letter] Liban JB. **BMJ** 1996 Aug 17;313(7054):425

Update on the status of Lyme borreliosis in British Columbia, Canada [letter] Banerjee S. **Clin Infect Dis** 1995 Sep;21(3):704

Bacteremic group A streptococcal pharyngitis presenting as acute airway obstruction [letter] Gradon JD, et al. **Clin Infect Dis** 1995 Sep;21(3):704–5

Postobstructive pulmonary edema induced by endotracheal tube occlusion. Dicpinigaitis PV, et al. **Intensive Care Med** 1995 Dec;21(12):1048–50

Streptococcus pneumoniae in the nasal cavity of mice causes lower respiratory tract infection after airway obstruction. Iizawa Y, et al. **J Med Microbiol** 1996 Jun;44(6):490–5

Orthopnea due to an aneurysm of the thoracic aorta. Spiropoulos K, et al. **Respiration** 1995;62(3):174–6

Relationship of acute obstructive airway change to chronic (fixed) obstruction. Becklake MR. **Thorax** 1995 Sep;50 Suppl 1:S16–21 (57 ref.)

[Pulmonary edema after upper airway obstruction] Varpula T, et al. **Duodecim** 1995;111(7):633–7 **(Fin)**

CONGENITAL

Prenatal sonographic diagnosis of upper airway obstruction: a challenge that can be achieved. Golan-Porat N, et al. **J Laryngol Otol** 1996 Jun;110(6):583–5 (16 ref.)

DIAGNOSIS

Vocal cord dysfunction masquerading as exercise-induced asthma. a physiologic cause for "choking" during athletic activities. McFadden ER Jr, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):942–7

Laryngomalacia. The search for the second lesion. Mancuso RF, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):302–6

Obstructive sleep apnea in infants and young children. Ward SL, et al. **J Clin Neurophysiol** 1996 May;13(3):198–207 (40 ref.)

Proximal pH-metry for diagnosis of upper airway complications of gastroesophageal reflux. Conley SF, et al. **J Otolaryngol** 1995 Oct;24(5):295–8

Multiple oncocytic laryngeal cysts presenting as acute airway obstruction. Westerberg BD, et al. **J Otolaryngol** 1995 Oct;24(5):319–21

Upper airway obstruction caused by low-grade tracheal papillary adenocarcinoma: an usual flow-volume loop pattern. Clarke DE, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1286–8

Flow volume loops in the evaluation of upper airway obstruction. Lunn WW, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):721–9 (13 ref.)

Video laryngoscopy. Stone RE Jr. **Otolaryngol Clin North Am** 1995 Aug;28(4):731–5

The single breath test in neonates: does pressurization of the pneumotachograph make a difference? Coates AL, et al. **Pediatr Pulmonol** 1995 May;19(5):299–306

Airways and lung: CT versus bronchography through the fiberoptic bronchoscope. Naidich DP, et al. **Radiology** 1996 Sep;200(3):613–4

Bronchial airflow limitation and chest findings in adults with respiratory infection. Melbye H. **Scand J Prim Health Care** 1995 Dec;13(4):261–7

[Bronchoconstriction symptoms mimicking bronchial asthma--report of two cases] Rogala B, et al. **Przegl Lek** 1995;52(8):403–4 (Eng. Abstr.) **(Pol)**

[Functional laryngeal obstruction] Alonso Peces ME, et al. **Arch Bronconeumol** 1995 Dec;31(10):543–5 (12 ref.) (Eng. Abstr.) **(Spa)**

[The utility of the flow-volume curve in detecting fixed extrathoracic stenoses in patients with chronic obstructive pulmonary disease] Izquierdo Alonso JL, et al. **Arch Bronconeumol** 1996 May;32(5):216–21 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

The efficacy and safety of inhaled salmeterol 50 microg bd in older patients with reversible airflow obstruction. Starke ID, et al. **Age Ageing** 1996 Jan;25(1):67–71

[Bronchodilator drugs] Tschopp JM. **Rev Med Suisse Romande** 1996 May;116(5):325–7 (27 ref.) **(Fre)**

[Chronopharmacology of reversible airway obstruction] Haen E. **Wien Med Wochenschr** 1995;145(17–18):439–45 (38 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Steam inhalation causing delayed airway occlusion. Hathaway PB, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):322

Acquired airway obstruction caused by hypertrophic mucosa of the arytenoids and aryepiglottic folds. Nonomura N, et al. **Am J Otolaryngol** 1996 Jan–Feb;17(1):71–4

Exposure to biomass smoke and chronic airway disease in Mexican women. A case-control study. Pérez-Padilla R, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):701–6

Testing the laryngeal mask [letter] Boge E, et al. **Anaesth Intensive Care** 1995 Dec;23(6):751–2

Upper airway obstruction in Parkinson's disease [see comments] Fitzpatrick AJ. **Anaesth Intensive Care** 1995 Jun;23(3):367–9. Comment in: Anaesth Intensive Care 1996 Feb;24(1):122–3.

Upper airway obstruction in Parkinson's disease [letter; comment] Willson G, et al. **Anaesth Intensive Care** 1996 Feb;24(1):122–3. Comment on: Anaesth Intensive Care 1995 Jun;23(3):367–9.

Misplacement of a mini-tracheostomy [letter] Alexander R, et al. **Anaesthesia** 1995 Nov;50(11):1012

Cardiopulmonary complications during anaesthesia and surgery for severe thoracic lordoscoliosis. Bagshaw ON, et al. **Anaesthesia** 1995 Oct;50(10):890–2

Kinking of tracheal tubes [letter] Emmanuel ER. **Anaesthesia** 1996 Mar;51(3):287

Upper airway obstruction caused by acquired inhibitor to factor VIII. Joynt GM, et al. **Anaesthesia** 1996 Jul;51(7):689–91

Intra-operative tracheal obstruction by tumour fragments [letter; comment] Satur CM, et al. **Anaesthesia** 1995 Dec;50(12):1102–3. Comment on: Anaesthesia 1995 Mar;50(3):249–50.

Kinking of a tracheal tube in the nasal cavity [letter] Stacey M, et al. **Anaesthesia** 1995 Oct;50(10):917

Obstruction of tracheostomy tube by tracheal wall after percutaneous tracheostomy [letter] Sun KO. **Anaesthesia** 1996 Mar;51(3):288

Hot air warming devices--a potential hazard [letter] Thompson N. **Anaesthesia** 1996 Mar;51(3):287

Airway obstruction due to arytenoid prolapse in two children [letter] Turner GD, et al. **Anaesthesia** 1996 Aug;51(8):796

A potential choking hazard [letter] Gunter JB. **Anesthesiology** 1996 Jul;85(1):228

Effect of blood pressure changes on air flow dynamics in the upper airway of the decerebrate cat. Mayor AH, et al. **Anesthesiology** 1996 Jan;84(1):128–34

Questioning conventional wisdom. New technology applied to investigating an old problem [editorial; comment] Robotham JL. **Anesthesiology** 1996 Feb;84(2):253–5. Comment on: Anesthesiology 1996 Feb;84(2):273–9.

Pulmonary vascular sling responsible for esophageal and tracheal obstruction. A case report. Yurdakul Y, et al. **Angiology** 1996 May;47(5):511–5

Near-hanging caused by a toy necklace. Chin N, et al. **Ann Emerg Med** 1995 Oct;26(4):522–5

Apparent life threatening events and infant holding practices. Byard RW, et al. **Arch Dis Child** 1995 Dec;73(6):502–4

Assessment of pulmonary mechanics and breathing patterns during posturally induced glossoptosis in infants. Cozzi F, et al. **Arch Dis Child** 1996 Jun;74(6):512–6

Laryngomalacia. The search for the second lesion. Mancuso RF, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):302–6

Goitre causing acute respiratory arrest. Raftos JR, et al. **Aust N Z J Surg** 1996 May;66(5):331–2

Delayed diagnosis of Kawasaki disease presenting with massive lymphadenopathy and airway obstruction. Burgner D, et al. **BMJ** 1996 Jun 8;312(7044):1471–2

Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement. Gittoes NJ, et al. **BMJ** 1996 Feb 24;312(7029):484

Mouthguards [letter] Jagger RG. **Br Dent J** 1996 Jan 20;180(2):50

Cervical haematoma and airway obstruction [letter; comment] Calder I, et al. **Br J Anaesth** 1996 Jun;76(6):888–9. Comment on: Br J Anaesth 1996 Jan;76(1):156–9.

Comparison of sedation with midazolam and ketamine: effects on airway muscle activity. Drummond GB. **Br J Anaesth** 1996 May;76(5):663–7

Airway problems after carotid endarterectomy [see comments] Munro FJ, et al. **Br J Anaesth** 1996 Jan;76(1):156–9. Comment in: Br J Anaesth 1996 Jun;76(6):888–9.

Tracheal rupture following blunt chest trauma presenting as endotracheal tube obstruction. Henderson CL, et al. **Can J Anaesth** 1995 Sep;42(9):816–9

Upper airway obstruction in a woman with AIDS-related laryngeal Kaposi's sarcoma. Beitler AJ, et al. **Chest** 1996 Mar;109(3):836–7

Nasal lavage cellularity, grain dust, and airflow obstruction. Blaski CA, et al. **Chest** 1996 Apr;109(4):1086–92

Myasthenia gravis and upper airway obstruction. Putman MT, et al. **Chest** 1996 Feb;109(2):400–4

The impossible airway: a plan. Rosa P Jr, et al. **Chest** 1996 Jun;109(6):1649–50

Grain dust, endotoxin, and airflow obstruction. Schwartz DA. **Chest** 1996 Mar;109(3 Suppl):57S–63S (51 ref.)

Mechanisms of increased airway microvascular permeability: role in airway inflammation and obstruction. Goldie RG, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):387–96 (88 ref.)

Traumatic epiglottis following blind finger sweep to remove a pharyngeal foreign body. Kabbani M, et al. **Clin Pediatr (Phila)** 1995 Sep;34(9):495–7

Nontuberculous Mycobacteria subcarinal lymphadenitis and severe airway obstruction. Souid AK, et al. **Clin Pediatr (Phila)** 1995 Dec;34(12):657–9

Exhalation obstruction due to Laerdal valve misassembly. Ho AM, et al. **Crit Care Med** 1996 Feb;24(2):362–4

Airway obstruction secondary to rhinoscleroma during pregnancy. Armstrong WB, et al. **Ear Nose Throat J** 1995 Nov;74(11):768–73 (40 ref.)

Airway obstruction in children with infectious mononucleosis. Wohl DL, et al. **Ear Nose Throat J** 1995 Sep;74(9):630–8

Choking spells following septorhinoplasty secondary to displaced nasal packing. Yanagisawa E, et al. **Ear Nose Throat J** 1995 Nov;74(11):744–6

Bronchial obstruction secondary to aneurysm of a persistent ductus arteriosus. Roughneen PT, et al. **Eur J Cardiothorac Surg** 1996;10(2):146–7

Case of the month: a 20-month-old boy with fever, respiratory distress and necrotizing skin lesions. Alsaeid K, et al. **Eur J Pediatr** 1996 Apr;155(4):341–2

Bradykinin-induced release of thromboxane B2 into bronchoalveolar lavage fluid of guinea pigs: relationship to airflow obstruction. Kawikova I, et al. **Eur J Pharmacol** 1995 Jul 14;280(3):293–9

Stent flexibility: an essential feature in the treatment of dynamic airway collapse. Hautmann H, et al. **Eur Respir J** 1996 Mar;9(3):609–11

Esophageal achalasia and coexistent upper esophageal sphincter relaxation disorder presenting with airway

obstruction. Ali GN, et al. **Gastroenterology** 1995 Oct; 109(4):1328–32

Airway foreign bodies in children. Somanath BP, et al. **Indian Pediatr** 1995 Aug;32(8):890–7 (26 ref.)

Bilateral mandibular subcondylar fractures contributing to airway obstruction. Bavitz JB, et al. **Int J Oral Maxillofac Surg** 1995 Aug;24(4):273–5

Otolaryngologic manifestations of multiple pterygium syndrome. MacArthur CJ, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):135–40

Lingual pressures induced by mouthgags. Senders CW, et al. **Int J Pediatr Otorhinolaryngol** 1995 Aug;33(1):53–60

Hairy polyp of the oropharynx: an unusual cause of intermittent neonatal airway obstruction. Walsh RM, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):129–34

Importance of the inhaler mouthpiece cover [letter] O'Donnell JJ, et al. **Intensive Care Med** 1995 Aug;21(8):698

Pneumomediastinum presenting as acute airway obstruction. Caraballo V, et al. **J Emerg Med** 1996 Mar–Apr; 14(2):159–63

Improvement of upper airway obstruction after 131I-treatment of multinodular nontoxic goiter evaluated by flow volume loop curves. Nygaard B, et al. **J Endocrinol Invest** 1996 Feb;19(2):71–5

Mechanisms of unexpected death in infants and young children following foreign body ingestion. Byard RW. **J Forensic Sci** 1996 May;41(3):438–41

An unusual foreign body obstructing endotracheal tube connector. Roy B, et al. **J Indian Med Assoc** 1995 Sep; 93(9):358

Proximal pH-metry for diagnosis of upper airway complications of gastroesophageal reflux. Conley SF, et al. **J Otolaryngol** 1995 Oct;24(5):295–8

Endobronchial tumor embolism: a preventable cause of death. Pathi V, et al. **J Thorac Cardiovasc Surg** 1996 Sep; 112(3):844–5

'Chicane-like' airway as a complication of lingual tonsils [letter] Conacher ID, et al. **Lancet** 1996 Aug 17; 348(9025):475

Nasal inflammation in patients with obstructive sleep apnea. Rubinstein I. **Laryngoscope** 1995 Feb;105(2):175–7

Characterization of postoperative edema following laser-assisted uvulopalatoplasty using MRI and polysomnography: implications for the outpatient treatment of obstructive sleep apnea syndrome. Terris DJ, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):124–8

Airway obstruction in the Pierre Robin sequence. Tomaski SM, et al. **Laryngoscope** 1995 Feb;105(2):111–4

Radiotherapy for oral manifestations of Kaposi's sarcoma [letter; comment] Narasimhan P, et al. **Mayo Clin Proc** 1996 Feb;71(2):213. Comment on: Mayo Clin Proc 1995 Sep;70(9):869–79.

Endobronchial thrombolysis with streptokinase for airway obstruction due to blood clots. Vajo Z, et al. **Mayo Clin Proc** 1996 Jun;71(6):595–6

Accidental infant death and stroller-prams. Byard RW, et al. **Med J Aust** 1996 Aug 5;165(3):140–1

Airway obstruction. The problem and its causes. Courey MS. **Otolaryngol Clin North Am** 1995 Aug;28(4):673–84 (15 ref.)

Obstructing laryngeal granuloma after brief endotracheal intubation in neonates. Kelly SM, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):138–40

Tracheal tube occlusion affecting surgical management of gastroschisis [letter] Burden RJ, et al. **Paediatr Anaesth** 1995;5(2):143–4

Retropharyngeal air accumulation as a complication of pneumomediastinum and a cause of airway obstruction in asthma. Cohn RC, et al. **Pediatr Emerg Care** 1995 Oct; 11(5):298–9

Acute airway obstruction by laryngeal haematomas in acute immune thrombocytopenic purpura. Aiken TC, et al. **Postgrad Med J** 1996 Apr;72(846):233–4

Small parts aspiration, ingestion, and choking in small children: findings of the small parts research project. Rider G, et al. **Risk Anal** 1996 Jun;16(3):321–30

Obliterative airway disease after heterotopic tracheal xenotransplantation in a concordant rodent model: pathogenesis and treatment. Reichenspurner H, et al. **Transplant Proc** 1996 Apr;28(2):729–30

[Respiratory insufficiency caused by a vocal cord polyp. An accidental finding during respiratory function tests] Larsen KM, et al. **Ugeskr Laeger** 1995 Nov 6;157(45):6272–3 (Eng. Abstr.) **(Dan)**

[Choking due to 'flippos' (letter] Spierings P. **Ned Tijdschr Geneeskd** 1996 May 25;140(21):1133–4 **(Dut)**

[Referral necessary in suspected foreign body aspiration] van der Woude GF, et al. **Ned Tijdschr Geneeskd** 1996 May 11;140(19):1009–11 **(Dut)**

[Medical ENT diagnosis and therapy of sleep-associated respiratory disorders with obstruction of the upper airways] Riechelmann H, et al. **Pneumologie** 1995 Oct;49(10):523–7 (33 ref.) **(Ger)**

[Cephalad movement of the carina due to CD (Cotrel-Dubousset) instrumentation for idiopathic scoliosis] Furuno K, et al. **Masui** 1995 Dec;44(12):1614–7 (Eng. Abstr.) **(Jpn)**

[Long-term study of patients with pulmonary tuberculosis sequelae after bilateral thoracoplasty-airway obstruction and its causes] Zhou C, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1180–5 (Eng. Abstr.) **(Jpn)**

[Pulmonary function in patients with rheumatic mitral valve disease. Preoperative evaluation] Strzyżakowska M, et al. **Pol Arch Med Wewn** 1995 Jan;93(1):63–8 (Eng. Abstr.) **(Pol)**

[Milk microaspiration as a cause of recurrent bronchial obstruction in infants] Chiappero M, et al. **Allergol Immunopathol (Madr)** 1995 Sep–Oct;23(5):207–10 (Eng. Abstr.) **(Spa)**

[Upper airway obstruction by a foreign body (letter)] Doussinague JM, et al. **Rev Esp Anestesiol Reanim** 1995 Dec;42(10):439–40 **(Spa)**

[Upper airway obstruction. An unusual and life-threatening complication of Waran therapy] Engborg L, et al. **Lakartidningen** 1995 Oct 25;92(43):3997, 3999 **(Swe)**

METABOLISM

Disposition of inhaled 1,1,1,2-tetrafluoroethane (HFA134A) in healthy subjects and in patients with chronic airflow limitation. Measurement by 18F-labeling and whole-body gamma-counting. Pike VW, et al. **Drug Metab Dispos** 1995 Aug;23(8):832–9

Allergen-induced late-phase airways obstruction in the pig: the role of endogenous cortisol. Fornhem C, et al. **Eur Respir J** 1995 Jun;8(6):928–37

MORTALITY

Designing the death out of balloons [editorial; comment] Baker SP, et al. **JAMA** 1995 Dec 13;274(22):1805. Comment on: JAMA 1995 Dec 13;274(22):1763–6.

Characteristics of objects that cause choking in children [see comments] Rimell FL, et al. **JAMA** 1995 Dec 13; 274(22):1763–6. Comment in: JAMA 1995 Dec 13;274(22):1805. Comment in: JAMA 1996 May 1;275(17):1313; discussion 1314. Comment in: JAMA 1996 May 1;275(17):1313–4.

NURSING

Mastering emergency airway management. Somerson SJ, et al. **Am J Nurs** 1996 May;96(5):24–30; quiz 31 (11 ref.)

PHYSIOPATHOLOGY

Correlation between functional, radiological and anatomical abnormalities in upper airway obstruction (UAO) due to tracheal stenosis. Demedts M, et al. **Acta Otorhinolaryngol Belg** 1995;49(4):331–9

Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease [see comments] Emerman CL, et al. **Ann Emerg Med** 1996 Feb;27(2):159–63. Comment in: Ann Emerg Med 1996 Feb;27(2):236–8.

Acute airway obstruction in the hospitalized infant: four hard lessons in the distal trachea. Isaacson G. **Ann Otol Rhinol Laryngol** 1996 Jul;105(7):532–5

The promotion of patent airways and inhibition of antigen-induced bronchial obstruction by endogenous nitric oxide. Persson MG, et al. **Br J Pharmacol** 1995 Dec; 116(7):2957–62

Characteristics and diagnostic significance of wheezes during exercise-induced airway obstruction in children with asthma. Rietveld S, et al. **Chest** 1996 Sep;110(3):624–31

Leukotrienes as mediators of airway obstruction and inflammation in asthma. Dahlén B, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:50–4 (42 ref.)

Postnatal development of responses to airflow obstruction. Harding R, et al. **Clin Exp Pharmacol Physiol** 1995 Aug; 22(8):537–43 (33 ref.)

Esophago/pharyngo/laryngeal interrelationships: airway protection mechanisms. Kidder TM. **Dysphagia** 1995 Fall; 10(4):228–31 (21 ref.)

Separation of airway and tissue properties by transfer respiratory impedance and thoracic gas volume in reversible airway obstruction. Marchal F, et al. **Eur Respir J** 1996 Feb;9(2):253–61

Upper airway collapsibility, and contractile and metabolic characteristics of musculus uvulae. Sériès F, et al. **FASEB J** 1996 Jun;10(8):897–904

Acute systemic blood pressure elevation in obstructive and nonobstructive breath hold in primates. White SG, et al. **J Appl Physiol** 1995 Jul;79(1):324–30

Role of airway receptors in the reflex responses of human inspiratory muscles to airway occlusion. Butler JE, et al. **J Physiol (Lond)** 1995 Aug 15;487 (Pt 1):273–81

Video laryngoscopy. Stone RE Jr. **Otolaryngol Clin North Am** 1995 Aug;28(4):731–5

Respiratory inductive plethysmography in the evaluation of lower airway obstruction during methacholine challenge in infants. Rusconi F, et al. **Pediatr Pulmonol** 1995 Dec; 20(6):396–402

Assessment of tidal breathing patterns for monitoring of bronchial obstruction in infants. Banovcin P, et al. **Pediatr Res** 1995 Aug;38(2):218–20

Effect of bronchoconstrictive aerosols on pulmonary gas trapping in the A/J mouse. Yiamouyiannis CA, et al. **Respir Physiol** 1995 Oct;102(1):97–104

Bronchial airflow limitation and chest findings in adults with respiratory infection. Melbye H. **Scand J Prim Health Care** 1995 Dec;13(4):261–7

Impaired reflex responses to airway occlusion in the inspiratory muscles of asthmatic subjects. Butler JE, et al. **Thorax** 1996 May;51(5):490–5

[Impact on the quality of life of respiratory symptoms and airway obstruction in an agricultural population (see comments)] Vergnenègre A, et al. **Rev Mal Respir** 1995; 12(6):615–21 (Eng. Abstr.). Comment in: Rev Mal Respir 1995;12(6):517–9. **(Fre)**

PREVENTION & CONTROL

Surfactant nebulization does not alter airflow obstruction and bronchial responsiveness to histamine in asthmatic children. Oetomo SB, et al. **Am J Respir Crit Care Med** 1996 Mar; 153(3):1148–52

A practical evaluation of four human-powered portable airway aspirators. Arnstein FE. **Anaesthesia** 1996 Jan; 51(1):63–8

Controlled-release theophylline inhibits early morning airway obstruction and hyperresponsiveness in asthmatic subjects. Crescioli S, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):106–10

Impact of community educational programmes on foreign body aspiration in Israel. Sadan N, et al. **Eur J Pediatr** 1995 Oct;154(10):859–62

Protective effect of sodium cromoglycate on lipopolysaccharide-induced bronchial obstruction in asthmatics. Michel O, et al. **Int Arch Allergy Immunol** 1995 Nov;108(3):298–302

Assessment of the effect of head and neck position on upper airway anatomy in sedated paediatric patients using magnetic resonance imaging. Shorten GD, et al. **Paediatr Anaesth** 1995;5(4):243–8

Bedside fiberoptic bronchoscopy for tracheostomy decannulation. Lee TS, et al. **Respir Med** 1995 Sep; 89(8):571–5

[Indications of tracheotomy before uvulopalatopharyngoplasty in patients with severe obstructive sleep apnea syndrome] Zhang L, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995;30(3):138–9 (Eng. Abstr.) **(Chi)**

RADIOGRAPHY

Evidence of expiratory CT scans of small-airway obstruction in sarcoidosis. Gleeson FV, et al. **AJR Am J Roentgenol** 1996 May;166(5):1052–4 (12 ref.)

Cephalometric comparison of characteristics in chronically snoring patients with and without sleep apnea syndrome. Frohberg U, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):28–33

Radiology of the central airways. Worrell JA. **Otolaryngol Clin North Am** 1995 Aug;28(4):701–20 (23 ref.)

A case of bronchial cast. Murata R, et al. **Pediatr Radiol** 1996;26(5):359–61

Thin-section CT, emphysema, air trapping, and airway obstruction [editorial; comment] Müller NL, et al. **Radiology** 1996 Jun;199(3):621–2 (22 ref.). Comment on: Radiology 1996 Jun;199(3):825–9.

RADIONUCLIDE IMAGING

Pulmonary studies using positron emission tomography. Rhodes CG, et al. **Eur Respir J** 1995 Jun;8(6):1001–17 (80 ref.)

RADIOTHERAPY

Endobronchial radiation therapy for obstructing malignancies: ten years' experience with iridium-192 high-dose radiation brachytherapy afterloading technique in 365 patients. Macha HN, et al. **Lung** 1995;173(5):271–80

SURGERY

Management of upper airway obstruction using a Seldinger minitracheotomy kit. Ala-Kokko TI, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):385–8

Our technique of partial inferior turbinoplasty: long-term results evaluated by rhinomanometry. Katz S, et al. **Acta Otorhinolaryngol Belg** 1996;50(1):13–8

Airway management in Ludwig's angina. Young P, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):239

Cricopharyngeus myotomy for upper airway obstruction in achalasia. Campbell KL, et al. **Br J Surg** 1995 Dec; 82(12):1668–9

Tracheostomy in children. Shinkwin CA, et al. **J R Soc Med** 1996 Apr;89(4):188–92

Operative evaluation of airway obstruction. Gardner GM, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):737–50 (12 ref.)

Magill forceps: a vital forceps. Rubio Quiñones F, et al. **Pediatr Emerg Care** 1995 Oct;11(5):302–3

Free fibula flap mandible reconstruction for oral obstruction secondary to giant fibrous dysplasia. Feingold RS, et al. **Plast Reconstr Surg** 1996 Jan;97(1):196–201

THERAPY

Emergency intubation with the combitube in a case of severe facial burn [letter] Wagner A, et al. **Am J Emerg Med** 1995 Nov;13(6):681–3

Mastering emergency airway management. Somerson SJ, et al. **Am J Nurs** 1996 May;96(5):24–30; quiz 31 (11 ref.)

Yet another simple connector for transtracheal ventilation [letter] Williams DJ. **Anaesthesia** 1995 Sep;50(9):833

Rapid-sequence intubation of the pediatric patient. Pediatric

Emergency Medicine Committee of the American College of Emergency Physicians [see comments] Gerardi MJ, et al. **Ann Emerg Med** 1996 Jul;28(1):55–74 (200 ref.). Comment in: Ann Emerg Med 1996 Jul;28(1):79–81.

Bronchoscopic treatment modalities in lung cancer, indications and limitations [letter; comment] Sutedja G, et al. **Ann Oncol** 1995 Nov;6(9):951–2. Comment on: Ann Oncol 1995 Jul;6(6):523–31.

Endobronchial stents [letter; comment] Kohman LJ. **Ann Thorac Surg** 1996 Feb;61(2):777. Comment on: Ann Thorac Surg 1995 Jun;59(6):1417–22.

Emergency use of the laryngeal mask airway in severe upper airway obstruction caused by supraglottic oedema. King CJ, et al. **Br J Anaesth** 1995 Dec;75(6):785–6

Stridor in the small infant. Herbertson MJ, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):418

Upper airway obstruction during midazolam sedation: modification by nasal CPAP. Nozaki-Taguchi N, et al. **Can J Anaesth** 1995 Aug;42(8):685–90

Metallic endoprostheses for malignant tracheobronchial obstruction: initial experience. Tan BS, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):91–6

Fiberoptic bronchoscopic cryotherapy in the management of tracheobronchial obstruction. Mathur PN, et al. **Chest** 1996 Sep;110(3):718–23

Use of the laryngeal mask prior to definitive intubation in a difficult airway: a case report. Aye T, et al. **J Emerg Med** 1995 Sep–Oct;13(5):711–4

The grandson of the Heimlich maneuver. Eschelbach MM. **J Fam Pract** 1995 Nov;41(5):505–6

Management of upper airway obstruction: intubation vs tracheotomy. Bu Saba NY, et al. **J Med Liban** 1994; 42(4):235–9 (18 ref.)

The use of expandable metallic airway stents for tracheobronchial obstruction in children. Filler RM, et al. **J Pediatr Surg** 1995 Jul;30(7):1050–5; discussion 1055–6

Nasogastric intubation for nutrition and airway protection in infants with Robin sequence. Prodoehl DC, et al. **J Perinatol** 1995 Sep–Oct;15(5):395–7

Gastric rupture after the Heimlich maneuver. Bintz M, et al. **J Trauma** 1996 Jan;40(1):159–60

Management of airway obstruction in cicatricial pemphigoid. Lazor JB, et al. **Laryngoscope** 1996 Aug;106(8):1014–7

Airway obstruction in the Pierre Robin sequence. Tomaski SM, et al. **Laryngoscope** 1995 Feb;105(2):111–4

Current concepts in airway management for cardiopulmonary resuscitation. Reed AP. **Mayo Clin Proc** 1995 Dec;70(12):1172–84 (111 ref.)

Stent placement is justifiable in end-stage patients with malignant airway tumours. Sutedja G, et al. **Respiration** 1995;62(3):148–50

Endoscopic management of acute respiratory failure related to tracheobronchial malignancies. Ninane V. **Support Care Cancer** 1995 Nov;3(6):418–21 (40 ref.)

[First aid in asphyxia] Lichtveld RA, et al. **Ned Tijdschr Geneeskd** 1996 May 25;140(21):1115–8 **(Dut)**

[Consensus 'Basic Resuscitation' from the Nederlandse Reanimatie Raad (letter)] van Dongen AM. **Ned Tijdschr Geneeskd** 1996 May 18;140(20):1094 **(Dut)**

[Airway occlusion as an emergency. Recognition and treatment] Lipp M, et al. **Internist (Berl)** 1995 Aug; 36(8):765–8 (15 ref.) **(Ger)**

[Interdisciplinary therapeutic concept in severe bacterial infections of the central respiratory tract in childhood] Damm M, et al. **Laryngorhinootologie** 1996 May; 75(5):293–300 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Prenatal sonographic diagnosis of upper airway obstruction: a challenge that can be achieved. Golan-Porat N, et al. **J Laryngol Otol** 1996 Jun;110(6):583–5 (16 ref.)

VETERINARY

Investigation of heart rate variability in a dog with upper respiratory tract obstruction. Little CJ, et al. **J Small Anim Pract** 1995 Nov;36(11):502–6

Transendoscopic laser treatment of guttural pouch tympanites in eight foals. Tate LP Jr, et al. **Vet Surg** 1995 Sep–Oct;24(5):367–72

AIRWAY RESISTANCE

Volume history response of airway resistance. Ahmad HR, et al. **Adv Exp Med Biol** 1995;393:111–5

Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals. Kaminsky DA, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1784–90

Mouth leak with nasal continuous positive airway pressure increases nasal airway resistance. Richards GN, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):182–6

Effects of ventilator resistance and compliance on phrenic nerve activity in spontaneously breathing cats. Schulze A, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):671–6

Mean airway pressure as an index of mean alveolar pressure. Valta P, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1825–30

Failure of ventilation in an infant due to increased resistance of a disposable heat and moisture exchanger [letter] Barnes SD, et al. **Anesth Analg** 1996 Jul;83(1):193

The long-term effects of open cosmetic septorhinoplasty on nasal air flow. Constantinides MS, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jan;122(1):41–5

Upper airway resistance syndrome, nocturnal blood pressure monitoring, and borderline hypertension. Guilleminault C, et al. **Chest** 1996 Apr;109(4):901–8

Rhinomanometric study in China. Li X, et al. **Chin Med J (Engl)** 1995 Jul;108(7):557–60 (15 ref.)

Resistance, humidity and temperature of the tracheal airway. McRae RD, et al. **Clin Otolaryngol** 1995 Aug;20(4):355–6

Nasal resistance—a reliable assessment of nasal patency? Szucs E, et al. **Clin Otolaryngol** 1995 Oct;20(5):390–5

Closed-loop control of airway occlusion pressure at 0.1 second (P0.1) applied to pressure-support ventilation: algorithm and application in intubated patients. Iotti GA, et al. **Crit Care Med** 1996 May;24(5):771–9

Comparison of direct and indirect calculations of laryngeal airway resistance in various voicing conditions. McHenry M, et al. **Eur J Disord Commun** 1995;30(4):435–49

Electrically-activated dilator muscles reduce pharyngeal resistance in anaesthetized dogs with upper airway obstruction. Bishara H, et al. **Eur Respir J** 1995 Sep; 8(9):1537–42

Measurement of nitric oxide in human nasal airway. Imada M, et al. **Eur Respir J** 1996 Mar;9(3):556–9

A new method for P0.1 measurement using standard respiratory equipment [see comments] Kuhlen R, et al. **Intensive Care Med** 1995 Jul;21(7):554–60. Comment in: Intensive Care Med 1995 Jul;21(7):545–6.

Comparison of four methods of assessing airflow resistance before and after induced airway narrowing in normal subjects. Phagoo SB, et al. **J Appl Physiol** 1995 Aug; 79(2):518–25

Correlations between subjective sensation of nasal patency and rhinomanometry in both unilateral and total nasal assessment. Sipilä J, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Sep–Oct; 57(5):260–3

Effect of partial middle turbinectomy on nasal airflow and resistance. Cook PR, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):413–9 (32 ref.)

Upper airway resistance syndrome after uvulopalatopharyngoplasty for obstructive sleep apnea syndrome. Woodson BT. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):457–61

Interrelationship between postocclusional oscillatory pressure transients and standard lung function in healthy and asthmatic children. Frey U, et al. **Pediatr Pulmonol** 1995 Jun;19(6):379–88

Comparison of dynamic and passive measurements of respiratory mechanics in ventilated newborn infants. Kugelman A, et al. **Pediatr Pulmonol** 1995 Oct;20(4):258–64

Evaluation of the interrupter technique for measuring change in airway resistance in 5-year-old asthmatic children. Phagoo SB, et al. **Pediatr Pulmonol** 1995 Dec;20(6):387–95

Gender affects the detection of resistive loads. Harver A, et al. **Percept Mot Skills** 1996 Feb;82(1):301–2

Dependence of collateral and small airway resistances of CO2 and volume in dog lobes. Kikuchi R, et al. **Respir Physiol** 1995 Jun;100(3):245–52

The mask: style and volume do not influence rhinomanometry. Maranta CA, et al. **Rhinology** 1995 Jun; 33(2):84–5

Manometric rhinometry: a new method of measuring nasal volume. Porter M, et al. **Rhinology** 1995 Jun;33(2):86–8

[Primary headache and orthognathorhinodontia in childhood] Gianni E, et al. **Ital J Neurol Sci** 1995 Nov; 16(8 Suppl):57–68 (Eng. Abstr.) **(Ita)**

DRUG EFFECTS

Susceptibility to platelet-activating factor-induced airway hyperreactivity and hyperpermeability: interstrain variation and genetic control. Longphre M, et al. **Am J Respir Cell Mol Biol** 1995 Nov;13(5):586–94

Dissociation of bradykinin-induced plasma exudation and reactivity in the peripheral airways. Berman AR, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):418–23

Efficacy of topical tuaminoheptane combined with N-acetyl-cysteine in reducing nasal resistance. A double-blind rhinomanometric study versus xylometazoline and placebo. Cogo A, et al. **Arzneimittelforschung** 1996 Apr;46(4):385–8

Evaluation of airway hyperreactivity in interleukin-5 transgenic mice. Iwamoto T, et al. **Int Arch Allergy Immunol** 1995;108 Suppl 1:28–30

Topical upper airway anaesthesia with lidocaine increases airway resistance by impairing glottic function. Beydon L, et al. **Intensive Care Med** 1995 Nov;21(11):920–6

Differential responses of global airway, terminal airway, and tissue impedances to histamine. Hantos Z, et al. **J Appl Physiol** 1995 Nov;79(5):1440–8

Topical active H1-antihistamines and their effect on nasal airway resistance. van Houten RJ, et al. **J Laryngol Otol** 1995 Sep;109(9):841–3

Preparation of bovine tracheal smooth muscle for in vitro pharmacological studies. Hashjin GS, et al. **J Pharmacol Toxicol Methods** 1995 Oct;34(2):103–8

Acute and chronic treatment with glucocorticosteroids, modifying the beta 2-adrenergic response of the guinea pig trachea. Seco AJ, et al. **Lung** 1995;173(5):321–8

Nasal airway resistance after decongestion with a nasal spray or a bellows device. Jessen M, et al. **Rhinology** 1996 Mar; 34(1):28–31

[Experimental data on equivalent percent change in measured parameters of the dose-response relationship in inhaled methacholine provocation tests (letter; comment)] Evers H. **Pneumologie** 1995 Nov;49(11):605–6. Comment on: Pneumologie 1995 Jun;49(6):383–7. **(Ger)**

[Respiratory and cardiovascular effects of acetylcholine provocation after inhalation exposure to various occupational pollutants--studies in the rabbit] Marek W, et al. **Pneumologie** 1996 May;50(5):342–9 (Eng. Abstr.) **(Ger)**

[Responder and non-responder in the bronchodilator test?] Vollmer M, et al. **Pneumologie** 1995 Nov;49(11):584–9 (Eng. Abstr.) **(Ger)**

[Chronopharmacology of reversible airway obstruction] Haen E. **Wien Med Wochenschr** 1995;145(17–18):439–45 (38 ref.) (Eng. Abstr.) **(Ger)**

[Effect of BAY u3405-thromboxane A2 receptor antagonist, on biphasic airway responses induced by platelet-activating factor in actively sensitized guinea pigs] Arima M, et al. **Arerugi** 1995 Jul;44(7):701–7 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Positive nasal challenge responses to Blomia tropicalis. Stanaland BE, et al. **J Allergy Clin Immunol** 1996 May; 97(5):1045–9

PHYSIOLOGY

Comment on study of nasal respiratory resistance [letter; comment] Timms DJ. **Am J Orthod Dentofacial Orthop** 1995 Oct;108(4):19A. Comment on: Am J Orthod Dentofacial Orthop 1994 Jul;106(1):34–9.

Rigid external resistances cause effort dependent maximal expiratory and inspiratory flows. Melissant CF, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1709–12

Increased respiratory system resistance and bronchial smooth muscle hypertrophy in children with acute postoperative pulmonary hypertension. Schindler MB, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1347–52

Do tidal expiratory flow patterns reflect lung mechanics in infants? Seddon PC, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1248–52

Tidal breathing analysis as a measure of airway obstruction in children three years of age and older. van der Ent CK, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1253–8

Partitioning of total pulmonary resistance in horses. Lavoie JP, et al. **Am J Vet Res** 1995 Jul;56(7):924–9

Serial distribution of airway diameters from input impedance and computed tomography. Jackson AC, et al. **Ann Biomed Eng** 1995 Nov–Dec;23(6):740–9

Postural changes in respiratory airflow pressure and resistance in nasal, hypopharyngeal, and pharyngeal airway in normal subjects. Tvinnereim M, et al. **Ann Otol Rhinol Laryngol** 1996 Mar;105(3):218–21

Interoception of respiratory resistance in asthmatic patients. Dahme B, et al. **Biol Psychol** 1996 Jan 5;42(1–2):215–29

Symptom reporting in asthma patients and insulin-dependent diabetics. Schandry R, et al. **Biol Psychol** 1996 Jan 5; 42(1–2):231–44

Dyspnea following experimentally induced increased nasal airway resistance. Warren DW, et al. **Cleft Palate Craniofac J** 1996 May;33(3):231–5

Effect of psychological stress on airway impedance in individuals with asthma and panic disorder. Carr RE, et al. **J Abnorm Psychol** 1996 Feb;105(1):137–41

Superior laryngeal nerve blockade and inspiratory resistive load detection in normal subjects. Fitzpatrick MF, et al. **J Appl Physiol** 1995 Nov;79(5):1567–70

Individual differences in relationship between upper airway resistance and ventilation during sleep onset. Kay A, et al. **J Appl Physiol** 1995 Aug;79(2):411–9

Lung tissue resistance and hysteretic moduli of lung parenchyma. Kimmel E, et al. **J Appl Physiol** 1995 Aug; 79(2):461–6

Analysis of low-frequency lung impedance in rabbits with nonlinear models. Peslin R, et al. **J Appl Physiol** 1995 Sep; 79(3):771–80

Thermal artifacts in plethysmographic airway resistance measurements. Peslin R, et al. **J Appl Physiol** 1995 Dec; 79(6):1958–65

Effect of surface forces on oscillatory behavior of lungs. Stamenović D, et al. **J Appl Physiol** 1995 Nov; 79(5):1578–85

Enlargement of the lateral pharyngeal fat pad space in pigs increases upper airway resistance. Winter WC, et al. **J Appl Physiol** 1995 Sep;79(3):726–31

Mechanism of atrial natriuretic peptide release with increased inspiratory resistance. Yalkut D, et al. **J Lab Clin Med** 1996 Sep;128(3):322–8

Increasing background inspiratory resistance changes somatosensory sensations in healthy man. Balzamo E, et al. **Neurosci Lett** 1995 Sep 8;197(2):125–8

Submental stimulation and supraglottic resistance during mouth breathing. Hida W, et al. **Respir Physiol** 1995 Jul; 101(1):79–85

Nasal resistance in recumbency and sleep. Miljeteig H, et al. **Rhinology** 1995 Jun;33(2):82–3

[Forced oscillation technique in respiratory system studies. III. Compliance and airway resistance in children with lung fibrosis] Tomalak W, et al. **Pneumonol Alergol Pol** 1995;

63(11-12):690-4 (Eng. Abstr.) **(Pol)**

AIVR see ACCELERATED IDIOVENTRICULAR RHYTHM

AJMALINE

ANALOGS & DERIVATIVES

Rate-dependent effects of detajmium and propafenone on ventricular conduction and refractoriness in isolated guinea pig hearts. Stark U, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):125-31

PHARMACOLOGY

Effects of ajmaline on non-sodium ionic currents in guinea pig ventricular myocytes. Enomoto K, et al. **Jpn Heart J** 1995 Jul;36(4):465-76

AKATHISIA see PSYCHOMOTOR AGITATION

AKATHISIA, DRUG-INDUCED

see related
DYSKINESIA, DRUG-INDUCED

Drug-induced akathisia revisited. Chung WS, et al. **Br J Clin Pract** 1996 Jul-Aug;50(5):270-8 (101 ref.)

Terminal restlessness and nicotine withdrawal [letter] Krajnik M, et al. **Lancet** 1995 Oct 14;346(8981):1044

CLASSIFICATION

[Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms] Petit M, et al. **Encephale** 1996 Jun;22 Spec No 2:13-8 (20 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Complicating factors in the analysis of acute drug-induced akathisia [letter; comment] Rosebush PI, et al. **Arch Gen Psychiatry** 1995 Oct;52(10):878-80. Comment on: Arch Gen Psychiatry 1994 Dec;51(12):963-74.

[The serotonin syndrome: review of the literature and description of an original study] Lejoyeux M, et al. **Encephale** 1995 Sep-Oct;21(5):537-43 (45 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Reversal of a paradoxical reaction to midazolam with flumazenil. Thurston TA, et al. **Anesth Analg** 1996 Jul; 83(1):192

Cyproheptadine treatment in neuroleptic-induced akathisia. Weiss D, et al. **Br J Psychiatry** 1995 Oct;167(4):483-6

Akathisia-like behavior following ECT, and its successful treatment with low-dose mianserin. Poyurovsky M, et al. **Int Clin Psychopharmacol** 1995 Nov;10(4):257-60

Lithium-induced akathisia responds to low-dose mianserin: case report. Poyurovsky M, et al. **Int Clin Psychopharmacol** 1995 Nov;10(4):261-3

Is there a rationale for iron supplementation in the treatment of akathisia? A review of the evidence. Gold R, et al. **J Clin Psychiatry** 1995 Oct;56(10):476-83 (63 ref.)

EPIDEMIOLOGY

The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Sachdev P. **Schizophr Bull** 1995;21(3):431-49 (130 ref.)

The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Sachdev P. **Schizophr Bull** 1995;21(3):451-61 (70 ref.)

ETIOLOGY

Akathisia following low-dose droperidol for antiemesis in day-case patients. Foster PN, et al. **Anaesthesia** 1996 May; 51(5):491-4

Metoclopramide-induced impotence and akathisia: a case report. Tsai SJ. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jun;57(6):443-6

Akathisia: a review and case report following paroxetine treatment. Baldassano CF, et al. **Compr Psychiatry** 1996 Mar-Apr;37(2):122-4 (40 ref.)

Serotonin syndrome in the elderly after antidepressive monotherapy [letter] Fischer P. **J Clin Psychopharmacol** 1995 Dec;15(6):440-2

Prolonged neurological sequelae after combination treatment with lithium and antipsychotic drugs [letter] Mani J, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):350-1

Opioids and akathisia [letter; comment] Mercadante S. **J Pain Symptom Manage** 1995 Aug;10(6):415. Comment on: J Pain Symptom Manage 1994 Oct;9(7):454-61.

Flupentixol-induced aversion to crack cocaine [letter] Gawin FH, et al. **N Engl J Med** 1996 May 16;334(20):1340-1

[Alarming increase in deptropine poisonings] van Zoelen GA, et al. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):98-9 **(Dut)**

[The serotonin syndrome; a misdiagnosed complication of antidepressive agents] Verhoeven WM, et al. **Ned Tijdschr Geneeskd** 1995 Oct 14;139(41):2073-5 **(Dut)**

[Akathisia induced by low doses of neuroleptics after a pallidal infarction (letter)] Auzou P, et al. **Presse Med** 1996 Feb 17;25(6):260 **(Fre)**

[SSRI-induced akathesia] Hofmann M, et al. **Psychiatr Prax** 1996 May;23(3):143-4 **(Ger)**

THERAPY

Improvement of both tardive dystonia and akathisia after botulinum toxin injection. Shulman LM, et al. **Neurology** 1996 Mar;46(3):844-5

AKATHISIA, TARDIVE see AKATHISIA, DRUG-INDUCED

AKINETIC MUTISM

ETIOLOGY

[Akinetic mutism with right hemiplegia caused by infarction in the territory of the left anterior cerebral artery] Lechevalier B, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):181-9 (27 ref.) (Eng. Abstr.) **(Fre)**

AKINETIC PETIT MAL see EPILEPSY, ABSENCE

AKR VIRUS

IMMUNOLOGY

AKR.H-2b lymphocytes inhibit the secondary in vitro cytotoxic T-lymphocyte response of primed responder cells to AKR/Gross murine leukemia virus-induced tumor cell stimulation. Rich RF, et al. **J Virol** 1996 Jan; 70(1):402-14

D-ALA(2)-D-LEU(5)-ENKEPHALIN see ENKEPHALIN, LEUCINE-2-ALANINE

ALAGILLE SYNDROME

[Alagille syndrome] Hata K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):523-6 (15 ref.) **(Jpn)**

[Dysmorphogenesis of intrahepatic bile duct] Okanoue T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):553-4 (12 ref.) **(Jpn)**

BLOOD

Fatty acid content in lymphocytes from children with syndromic paucity of interlobular bile ducts, Alagille syndrome. Pina P, et al. **J Inherit Metab Dis** 1995; 18(6):727-36

COMPLICATIONS

Alagille syndrome (arteriohepatic dysplasia) [letter; comment] Santoro G, et al. **Am Heart J** 1995 Dec; 130(6):1317-8. Comment on: Am Heart J 1994 Mar;127(3):695-9.

Alagille's syndrome associated with cystic renal disease. Martin SR, et al. **Arch Dis Child** 1996 Mar;74(3):232-5 (14 ref.)

Aortic calcification and renal cysts demonstrated by CT in a teenager with Alagille syndrome. Pombo F, et al. **Pediatr Radiol** 1995;25(4):314-5

[Dermatological manifestations of Alagille syndrome] Doutre MS, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):207-8 (7 ref.) **(Fre)**

DRUG THERAPY

[Long-term ursodeoxycholic acid treatment of cholestatic liver diseases in childhood--clinical and biochemical effects] Kardorff R, et al. **Klin Padiatr** 1996 May-Jun; 208(3):118-22 (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Alagille syndrome in 1995. Clinical and genetic data] Deleuze JF, et al. **Gastroenterol Clin Biol** 1995 Jun-Jul; 19(6-7):587-96 (103 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Submicroscopic deletions are rare in Alagille syndrome [letter] Deleuze F, et al. **Am J Hum Genet** 1996 Aug; 59(2):477-8

Molecular analysis of 24 Alagille syndrome families identifies a single submicroscopic deletion and further localizes the Alagille region within 20p12. Rand EB, et al. **Am J Hum Genet** 1995 Nov;57(5):1068-73

Construction of a 3.7-Mb physical map within human chromosome 20p12 ordering 18 markers in the Alagille syndrome locus. Pollet N, et al. **Genomics** 1995 Jun 10; 27(3):467-74

[Liver cell carcinoma as a late complication of Alagille syndrome (arterio-hepatic dysplasia)] Wegmann W, et al. **Leber Magen Darm** 1996 May;26(3):157-8, 161-3 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Butterfly vertebra: look for Alagille's syndrome [letter] Maillefert JF, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep; 62(7-8):537-8

RADIONUCLIDE IMAGING

Alagille's syndrome. New manifestations. Balich S, et al. **Clin Nucl Med** 1996 Feb;21(2):98-101

Focal liver hyperplasia in Alagille syndrome: assessment with hepatoreceptor and hepatobiliary imaging. Torizuka T, et al. **J Nucl Med** 1996 Aug;37(8):1365-7

ALAMETHICIN

ANALOGS & DERIVATIVES

Membrane structure of voltage-gated channel forming peptides by site-directed spin-labeling. Barranger-Mathys M, et al. **Biochemistry** 1996 Jan 16;35(2):498-505

Ion channel stabilization of synthetic alamethicin analogs by rings of inter-helix H-bonds. Molle G, et al. **Biophys J** 1996 Apr;70(4):1669-75

Studies on metabolites of mycoparasitic fungi. IV. Minor peptaibols of Trichoderma koningii. Huang Q, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1663-7

CHEMISTRY

Membrane structure of voltage-gated channel forming peptides by site-directed spin-labeling. Barranger-Mathys M, et al. **Biochemistry** 1996 Jan 16;35(2):498-505

Antimicrobial peptide pores in membranes detected by neutron in-plane scattering. He K, et al. **Biochemistry** 1995 Dec 5;34(48):15614-8

Engineering stabilized ion channels: covalent dimers of alamethicin. You S, et al. **Biochemistry** 1996 May 21; 35(20):6225-32

Hydrogen bond stabilities in membrane-reconstituted alamethicin from amide-resolved hydrogen-exchange measurements. Dempsey CE, et al. **Biophys J** 1996 Apr; 70(4):1777-88

Two classes of alamethicin transmembrane channels: molecular models from single-channel properties. Mak DO, et al. **Biophys J** 1995 Dec;69(6):2323-36

Molecular dynamics of alamethicin transmembrane channels from open-channel current noise analysis. Mak DO, et al. **Biophys J** 1995 Dec;69(6):2337-49

Membrane orientation of the N-terminal segment of alamethicin determined by solid-state 15N NMR. North CL, et al. **Biophys J** 1995 Dec;69(6):2392-7

Influence of proline-14 substitution on the secondary structure in a synthetic analogue of alamethicin. Brachais L, et al. **Biopolymers** 1995 Oct;36(4):547-58

METABOLISM

Noise-induced enhancement of signal transduction across voltage-dependent ion channels. Bezrukov SM, et al. **Nature** 1995 Nov 23;378(6555):362-4

PHARMACOLOGY

Small concentrations of alamethicin induce a cubic phase in bulk phosphatidylethanolamine mixtures. Keller SL, et al. **Biochim Biophys Acta** 1996 Jan 31;1278(2):241-6

The effect of free radicals on the conductance induced by alamethicin in planar lipid membranes: activation and inactivation. Zeidler U, et al. **Biochim Biophys Acta** 1996 May 22;1281(1):73-9

ALANINE

Codon-based combinatorial alanine scanning site-directed mutagenesis: design, implementation, and polymerase chain reaction screening. Chatellier J, et al. **Anal Biochem** 1995 Aug 10;229(2):282-90

Investigation of applicability of alanine and radiochromic detectors to dosimetry of proton clinical beams. Nichiporov D, et al. **Appl Radiat Isot** 1995 Dec;46(12):1355-62

Site-directed mutagenesis of the conserved serine 138 of human placental NAD+-dependent 15-hydroxyprostaglandin dehydrogenase to an alanine results in an inactive enzyme. Ensor CM, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):330-3

Alanine-scanning mutagenesis of human transcript elongation factor TFIIS. Cipres-Palacin G, et al. **Biochemistry** 1995 Nov 21;34(46):15375-80

Membrane structure of protein kinase C and calmodulin binding domain of myristoylated alanine rich C kinase substrate determined by site-directed spin labeling. Qin Z, et al. **Biochemistry** 1996 Mar 5;35(9):2917-25

Conformation and dynamics of [3-13C]Ala- labeled bacteriorhodopsin and bacterioopsin, induced by interaction with retinal and its analogs, as studied by 13C nuclear magnetic resonance. Tuzi S, et al. **Biochemistry** 1996 Jun 11;35(23):7520-7

Germline mosaicism for an alanine to valine substitution at residue beta 140 in hemoglobin Puttelange, a new variant with high oxygen affinity. Wajcman H, et al. **Hum Genet** 1995 Dec;96(6):711-6

Correlation among secondary structure, amyloid precursor protein accumulation, and neurotoxicity of amyloid beta(25-35) peptide as analyzed by single alanine substitution. Sato K, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1108-11

Functional studies and polymerization of recombinant hemoglobin Glu-alpha2beta26(A3) --> Val/Glu-7(A4) --> Ala. Lesecq S, et al. **J Biol Chem** 1996 Jul 19; 271(29):17211-4

Formation of parallel and antiparallel coiled-coils controlled by the relative positions of alanine residues in the hydrophobic core. Monera OD, et al. **J Biol Chem** 1996 Feb 23;271(8):3995-4001

Site-directed mutagenesis of glycine 99 to alanine in L-lactate monooxygenase from Mycobacterium smegmatis. Sun W, et al. **J Biol Chem** 1996 Jul 19;271(29):17226-33

Arachnoid cyst and chronic subdural haematoma in a child with osteogenesis imperfecta type III resulting from the substitution of glycine 1006 by alanine in the pro alpha 2(I) chain of type I procollagen. Cole WG, et al. **J Med Genet** 1996 Mar;33(3):193-6

Alanine scanning mutagenesis of conserved arginine/lysine-arginine/lysine-X-X-arginine/lysine G protein-activating motifs on m1 muscarinic acetylcholine receptors. Lee NH, et al. **Mol Pharmacol** 1996 Jul; 50(1):140-8

Template-nucleated alanine-lysine helices are stabilized by position-dependent interactions between the lysine side chain and the helix barrel. Groebke K, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4025-9

The use of alanine/boron mixtures in neutron dosimetry [letter; comment] Desrosiers MF. **Radiat Res** 1996 May; 145(5):651. Comment on: Radiat Res 1995 Oct;144(1):59-63.

ANALOGS & DERIVATIVES

Synthesis of an N-methyldehydroalanine-containing fragment of microcystin by combination of solid phase peptide synthesis and beta-elimination in solution. Zetterström M, et al. **Acta Chem Scand** 1995 Sep; 49(9):696-700

A kinetic study of the hydrolysis of the N-tosylalanine ester of 3-hydroxy-5-phenylpyrrole and related compounds by human leukocyte elastase. Jackson DS, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):108-14

Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome. Sato F, et al. **Arch Toxicol** 1995;69(7):444-9

1H-NMb spectroscopy of beta-thiocyanatoalanine. Phelan P, et al. **Biochem Soc Trans** 1996 Feb;24(1):130S

Gain of D-alanyl-D-lactate or D-lactyl-D-alanine synthetase activities in three active-site mutants of the Escherichia coli D-alanyl-D-alanine ligase B. Park IS, et al. **Biochemistry** 1996 Aug 13;35(32):10464-71

Formation of the alpha-aminoacrylate immediate limits the overall reaction catalyzed by O-acetylserine sulfhydrylase. Woehl EU, et al. **Biochemistry** 1996 Apr 16;35(15):4776-83

Synthesis of azidoaniline derivatives of oligonucleotides and investigation of their photochemical behavior. Godovikova TS, et al. **Bioconjug Chem** 1996 May-Jun;7(3):343-8

The genetics of lantibiotic biosynthesis. Jack R, et al. **Bioessays** 1995 Sep;17(9):793-802 (69 ref.)

Inactivation of gamma-aminobutyric acid aminotransferase by L-3-chloroalanine hydroxamate. Silverman RB, et al. **Bioorg Med Chem** 1995 Jan;3(1):11-8

Lantibiotics. Gasson MJ. **Biotechnology** 1995;28:283-306 (78 ref.)

Characterization of the pharmacology and regional distribution of (S)-[3H]-5-fluorowillardiine binding in rat brain. Hawkins LM, et al. **Br J Pharmacol** 1995 Oct; 116(3):2033-9

Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Sekiyama N, et al. **Br J Pharmacol** 1996 Apr; 117(7):1493-503

Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome. Mayeno AN, et al. **Chem Res Toxicol** 1995 Oct-Nov;8(7):911-6

Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine. Arakawa T, et al. **Dig Dis Sci** 1995 Nov;40(11):2469-72

Rebamipide protects against activation of neutrophils by Helicobacter pylori. Yoshida N, et al. **Dig Dis Sci** 1996 Jun;41(6):1139-44

The effect of 2-amino-3-phosphonopropionic acid (AP-3) in the gerbil model of cerebral ischaemia. Maginn M, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):259-62

Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt. Willenbrock R, et al. **Hypertension** 1996 Jun;27(6):1259-66

Effect of the environment and role of the pi-pi stacking interactions in the stabilization of the 3(10)-helix conformation in dehydroalanine oligopeptides. Alemän C. **Int J Pept Protein Res** 1995 Nov;46(5):408-18

Synthesis, crystal structure and conformation in solution of four stereoisomeric cyclo-lanthionine derivatives. Osapay G, et al. **Int J Pept Protein Res** 1995 Sep-Oct; 46(3-4):290-301

Determination of combined residues of metalaxyl and 2,6-dimethylaniline metabolites in urine by gas chromatography/mass spectrometry. Headley JV, et al. **J AOAC Int** 1996 Jan-Feb;79(1):117-23

Calculations of the phi-psi conformational contour maps for N-acetyl alanine N'-methyl amide and of the characteristic ratios of poly-L-alanine using various molecular mechanics forcefields. Lee CH, et al. **J Biomol Struct Dyn** 1995 Oct; 13(2):201-18

Separation and quantification of D- and L-phosphoserine in rat brain using N alpha-(2,4-dinitro-5-fluorophenyl)-L-alaninamide (Marfey's reagent) by high-performance liquid chromatography with ultraviolet detection. Goodnough DB, et al. **J Chromatogr B Biomed Appl** 1995 Oct 20; 672(2):290-4

Computational analysis of binding affinity and neural response at the L-alanine receptor. Venanzi TJ, et al. **J Comput Aided Mol Des** 1995 Oct;9(5):439-47

The X-ray crystal structure of thrombin in complex with N alpha-2-naphthylsulfonyl-L-3-amidino-phenylalanyl-4-methylpiperidide: the beneficial effect of filling out an empty cavity. Bergner A, et al. **J Enzym Inhib** 1995; 9(1):101-10

In vitro bone biocompatibility of poly (anhydride-co-imides) containing pyromellitylimidoalanine. Attawia MA, et al. **J Orthop Res** 1996 May;14(3):445-54

Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction. Gonzalez W, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):573-81

Preventive effect of rebamipide on gastric lesions induced by ischemia-reperfusion in the rat. Kim CD, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):340-4

Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction. Marie C, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1324-31

Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors. Seymour AA, et al. **J Pharmacol Exp Ther** 1996 Feb; 276(2):708-13

Cytogenetic effects of Metalaxyl on human and animal chromosomes. Hrelia P, et al. **Mutat Res** 1996 Jul 10; 369(1-2):81-6

Binding of the new radioligand (S)-[3H]AMPA to rat brain synaptic membranes: effects of a series of structural analogues of the non-NMDA receptor agonist willardiine. Hawkins LM, et al. **Neuropharmacology** 1995 Apr; 34(4):405-10

2-amino-3-phosphonopropionic acid (AP3) and its N-methyl analog improve learning and memory in rats. Winnicka MM, et al. **Pol J Pharmacol** 1995 Jan-Feb; 47(1):1-7

Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Balzarini J, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7295-9

Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain. Strolin Benedetti M, et al. **Prog Brain Res** 1995; 106:123-34

Incorporation of an unnatural amino acid in the active site of porcine pancreatic phospholipase A2. Substitution of histidine by 1,2,4-triazole-3-alanine yields an enzyme with high activity at acidic pH. Beiboer SH, et al. **Protein Eng** 1996 Apr;9(4):345-52

Protective effect of N-benzoyl-beta-alanine against cisplatin nephrotoxicity in rats. Tokunaga J, et al. **Ren Fail** 1996 Mar;18(2):225-40

In vitro transforming effect of the fungicides metalaxyl and zineb. Perocco P, et al. **Teratog Carcinog Mutagen** 1995; 15(2):73-80

Progressive retinal toxicity in neonatal rats treated with D,L-2-amino-3-phosphonopropionate (D,L-AP3). Fix AS, et al. **Vet Pathol** 1995 Sep;32(5):521-31

Analysis of metalaxyl residues in wines by SPE in combination with HRCGC and GC/MS. Kakaliková L, et al. **Z Lebensm Unters Forsch** 1996 Jul;203(1):56-60

ANALYSIS

[Evaluation of different markers for the determination of microbial nitrogen flow into the duodenum of dairy cows] Schönhusen U, et al. **Arch Tierernahr** 1995;48(1-2):147-58 (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

L-alanine production from glucose fermentation by hyperthermophilic members of the domains bacteria and Archaea: a remnant of an ancestral metabolism? Ravot G, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2657-9

Properties of glutamate dehydrogenase and its involvement in alanine production in a hyperthermophilic archaeon, Thermococcus profundus. Kobayashi T, et al. **J Biochem (Tokyo)** 1995 Sep;118(3):587-92

CEREBROSPINAL FLUID

Inhibitory and excitatory amino acids in cerebrospinal fluid of neurolathyrism patients, a highly prevalent motorneurone disease. Khan JK, et al. **Acta Neurol Scand** 1995 Jun;91(6):506-10

CHEMISTRY

Substitution of alanine543 with a threonine residue at the carboxy terminal end of the beta-chain is associated with thermolabile hexosaminidase B in a Jewish family of Oriental ancestry. De Gasperi R, et al. **Biochem Mol Med** 1995 Oct;56(1):31-6

Three-dimensional solution structure of the cyanide adduct of a Met80Ala variant of Saccharomyces cerevisiae iso-1-cytochrome c. Identification of ligand-residue interactions in the distal heme cavity. Banci L, et al. **Biochemistry** 1995 Sep 12;34(36):11385-98

Alanine point-mutations in the reactive region of bovine pancreatic trypsin inhibitor: effects on the kinetics and thermodynamics of binding to beta-trypsin and alpha-chymotrypsin. Castro MJ, et al. **Biochemistry** 1996 Sep 3;35(35):11435-46

Truncation and alanine-scanning mutants of type I adenylyl cyclase. Tang WJ, et al. **Biochemistry** 1995 Nov 7; 34(44):14563-72

Polymethylene spacer linked bis(Ala) peptides form modified beta-sheet structures. Crystal structure and self-assembly pattern of adipoyl and suberoyl analogues. Karle IL, et al. **Int J Pept Protein Res** 1995 Jul;46(1):24-9

Modelling the optimal simulation path in the peptide chain folding--studies based on geometry of alanine heptapeptide. Roterman I. **J Theor Biol** 1995 Dec 7; 177(3):283-8

The relative positions of alanine residues in the hydrophobic core control the formation of two-stranded or four-stranded alpha-helical coiled-coils. Monera OD, et al. **Protein Eng** 1996 Apr;9(4):353-63

The Alacoil: a very tight, antiparallel coiled-coil of helices. Gernert KM, et al. **Protein Sci** 1995 Nov;4(11):2252-60

Empirical correlation for the replacement of Ala by Gly: importance of amino acid secondary intrinsic propensities. López-Hernández E, et al. **Proteins** 1995 Aug;22(4):340-9

[Alanine dehydrogenase from the cyanobacterium Plectonema boryanum] Perepelitsa SI, et al. **Ukr Biokhim Zh** 1995 Jan-Feb;67(1):38-45 (Eng. Abstr.) **(Rus)**

GENETICS

The role of leucine 116 in determining substrate specificity in human B1 alcohol dehydrogenase. Hurley TD, et al. **Adv Exp Med Biol** 1995;372:321-5

Human class 1 aldehyde dehydrogenase. Expression and site-directed mutagenesis. Jones KM, et al. **Adv Exp Med Biol** 1995;372:17-23

Comparison between thymidylate synthase B of Bacillus subtilis ATCC6633 and 168. Montorsi M, et al. **Biochem Mol Biol Int** 1995 May;35(6):1245-51

The Gly74-->Ser and Ser3-->Ala mutations in Rhodobacter sphaeroides Y thioredoxin: effects on active site reactivity and protein interaction. Pille S, et al. **Eur J Biochem** 1996 Feb 1;235(3):713-20

Role of the "helix clamp" in HIV-1 reverse transcriptase catalytic cycling as revealed by alanine-scanning mutagenesis. Beard WA, et al. **J Biol Chem** 1996 May 24; 271(21):12213-20

A mutation in which alanine 128 Is replaced by aspartic acid abolishes dimerization of the b-subunit of the F0F1-ATPase from Escherichia coli. Howitt SM, et al. **J Biol Chem** 1996 Mar 22;271(12):7038-42

Probing immunogenicity of a T cell epitope by L-alanine and D-amino acid scanning. Maillère B, et al. **Mol Immunol** 1995 Oct;32(14-15):1073-80

Modular design of components of the operational RNA code for alanine in evolution. Schimmel P, et al. **Trends Biochem Sci** 1995 Sep;20(9):333-4

IMMUNOLOGY

Probing immunogenicity of a T cell epitope by L-alanine and D-amino acid scanning. Maillère B, et al. **Mol Immunol** 1995 Oct;32(14-15):1073-80

METABOLISM

Estimation of glucose-alanine-lactate-glutamine cycles in postabsorptive humans: role of skeletal muscle. Perriello G, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E443-50

Except for alanine, muscle protein catabolism is not influenced by alterations in glucose metabolism during sepsis. Gore DC, et al. **Arch Surg** 1995 Nov;130(11):1171-6; discussion 1176-7

Glutamine and alanine metabolism in NIDDM. Stumvoll M, et al. **Diabetes** 1996 Jul;45(7):863-8

Alanine metabolism in isolated human kidney tubules--Use of a mathematical model. Fouque D, et al. **Eur J Biochem** 1996 Feb 15;236(1):128-37

The effect of starvation on leucine, alanine and glucose metabolism in obese subjects. Umpleby AM, et al. **Eur J Clin Invest** 1995 Aug;25(8):619-26

Neural control of intestinal amino acid absorption. Carey HV. **Gastroenterology** 1996 Jan;110(1):315-7

Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Marchesini G, et al. **Hepatology** 1996 May;23(5):1084-92

Decreased ureagenesis from alanine, but not from ammonia and glutamine, in the perfused rat liver after partial hepatectomy. Moriyama M, et al. **Hepatology** 1996 Jun; 23(6):1584-90

The D-Alanyl carrier protein in Lactobacillus casei: cloning, sequencing, and expression of dltC. Debabov DV, et al. **J Bacteriol** 1996 Jul;178(13):3869-76

Exchange of aspartate and alanine. Mechanism for development of a proton-motive force in bacteria. Abe K, et al. **J Biol Chem** 1996 Feb 9;271(6):3079-84

Oxidation of alanine, acetate, glutamate, and succinate by

digitonin-permeabilized Leishmania major promastigotes. Blum JJ. **J Eukaryot Microbiol** 1996 Mar-Apr;43(2):144-50

Alanine substitutions in calmodulin-binding peptides result in unexpected affinity enhancement. Montigiani S, et al. **J Mol Biol** 1996 Apr 26;258(1):6-13

Correlation of teichoic acid D-alanyl esterification with the expression of methicillin resistance in Staphylococcus aureus. O'Brien MJ, et al. **Microbios** 1995;83(335):119-37

Upregulation of Na(+)-dependent alanine transport in vascular endothelial cells by serum: role of intracellular Ca2+. Escobales N, et al. **Microcirculation** 1994 Apr; 1(1):49-58

Ontogeny of L-alanine uptake in plasma membrane vesicles from rat liver. Amat M, et al. **Pediatr Res** 1995 Jul; 38(1):81-5

Lack of effect of cocaine on lysine and alanine uptake in human placental villi or transfer in perfused human placenta. Krishna RB, et al. **Reprod Fertil Dev** 1995; 7(6):1495-7

Alanine transport across the human placental brush border membrane and the role of SH groups in carrier function. Scholl A, et al. **Z Ernahrungswiss** 1995 Dec;34(4):285-92

PHARMACOLOGY

T4 depresses olfactory responses to L-alanine and plasma T3 and T3 production in smoltifying Atlantic salmon. Morin PP, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1434-40

Effects of L-alanine and L-alanine peptides on the chemotaxis of tetrahymena: evolutionary conclusions. Csaba G, et al. **Biosci Rep** 1995 Aug;15(4):185-90

Alanine protects liver from injury caused by F-galactosamine and CCl4. Maezono K, et al. **Hepatology** 1996 Jul; 24(1):185-91

Endothelin-1 stimulates myristoylated alanine-rich C-kinase substrate (MARCKS) phosphorylation in rat cerebellar slices. Catalán RE, et al. **Neurosci Lett** 1995 Jul 14; 194(1-2):53-6

RADIATION EFFECTS

The effects of boron on the electron paramagnetic resonance spectra of alanine irradiated with thermal neutrons [see comments] Ciesielski B, et al. **Radiat Res** 1995 Oct; 144(1):59-63. Comment in: Radiat Res 1996 May;145(5):651.

ALANINE AMINOTRANSFERASE

ANTAGONISTS & INHIBITORS

Aminooxy acetic acid: a selective inhibitor of alanine:glyoxylate aminotransferase and its use in the diagnosis of primary hyperoxaluria type I. Andy V, et al. **Clin Chim Acta** 1995 Dec 29;243(2):105-14

BLOOD

Elevated serum liver enzyme concentrations during ritodrine therapy. Shen O, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):183-4

Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. McCormick SE, et al. **Am J Gastroenterol** 1996 Aug;91(8):1516-22

Hepatitis C virus RNA in patients with anti-HCV on hemodialysis. Relationship to transaminase levels. Garcia-Valdecasas J, et al. **ASAIO J** 1994 Jul-Sep; 40(3):M450-3

The pathogenesis of decreased aspartate aminotransferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency. Ono K, et al. **Clin Nephrol** 1995 Jun;43(6):405-8

Aminotransferase activities in mouse, Mus domesticus, erythrocytes separated according to age. Westrick JA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct-Nov;109(2-3):489-97

Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors. Kwan D, et al. **Dig Dis Sci** 1995 Sep;40(9):1951-5

Preferential virological response to interferon-alpha 2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low gamma-GT/ALT ratio. Mihm S, et al. **Dig Dis Sci** 1996 Jun;41(6):1256-64

Effect of oestrogen/gestagen replacement therapy on liver enzymes in patients with Ullrich-Turner syndrome. Wemme H, et al. **Eur J Pediatr** 1995 Oct;154(10):807-10

Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Serfaty L, et al. **Gastroenterology** 1996 Jan;110(1):291-5

Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Yasuda K, et al. **Gastroenterology** 1995 Oct;109(4):1295-300

Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial. Sánchez-Tapias JM, et al. **Gut** 1996 Apr;38(4):603-9

Virological patterns of hepatitis C virus in chronic hepatitis C with biochemical sustained response to interferon therapy [letter; comment] De Mitri MS, et al. **Hepatology** 1996 May;23(5):1287-9. Comment on: Hepatology 1994 Feb;19(2):280-5.

Age, sex and transaminase dependency of specific and nonspecific results from enzyme immunoassays for antibodies to hepatitis C virus and follow-up of blood donors. Caspari G, et al. **Infusionsther Transfusionsmed** 1995 Aug;22(4):208-19

Increased levels of alcohol markers (gamma GT, MCV, ASAT, ALAT) in older patients are not related to high alcohol intake [letter] Mowé M, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1136-7

A preliminary report on the prognostic value of selected diagnostic enzymes among certain malignant and schistosomal malignant patients. Ahmed SA. **J Egypt Soc Parasitol** 1995 Dec;25(3):659-76

Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy. Van Thiel DH, et al. **J Hepatol** 1995 Nov; 23(5):503-8

Elevation of ALT to AST ratio in patients with enteroviral myocarditis. Kanda T, et al. **J Med** 1995;26(3-4):153-62

Dietary wheat gluten alleviates the elevation of serum transaminase activities in D-galactosamine-injected rats. Manabe A, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Apr; 42(2):121-32

Effect of weight reduction on serum transaminase activities in children with simple obesity [letter; comment] Tazawa Y, et al. **J Pediatr** 1996 Apr;128(4):587-8. Comment on: J Pediatr 1994 Aug;125(2):239-41.

Depletion of glutathione and hepato-toxicity caused by vinyl ethers in mice. Isobe M, et al. **J Toxicol Sci** 1995 May; 20(2):161-4

The fluctuations of hepatitis C virus RNA and IgM anti-HCV (core) serum levels correlate with those of alanine aminotransferases during the hepatitis relapses of patients treated with interferon. Negro F, et al. **J Viral Hepat** 1995;2(4):171-4

Do serum ALAT values reflect the inflammatory activity in the liver of patients with chronic viral hepatitis? Cahen DL, et al. **Liver** 1996 Apr;16(2):105-9

Hepatitis B and C prevalences among blood donors in the south region of Brazil. Vasconcelos HC, et al. **Mem Inst Oswaldo Cruz** 1994 Oct-Dec;89(4):503-7

Recombinant human erythropoietin improves enzyme activity in erythrocytes of predialysis uremics. Pietrzak I, et al. **Miner Electrolyte Metab** 1996;22(1-3):102-5

Long term follow-up and patterns of response of ALT in patients with chronic hepatitis NANB/C treated with recombinant interferon-alpha. da Silva LC, et al. **Rev Inst Med Trop Sao Paulo** 1995 May-Jun;37(3):239-43

Effects of pyridoxal 5'-phosphate on plasma alanine aminotransferase determinations in toxicological studies. Evans GO, et al. **Toxicol Lett** 1995 Oct;80(1-3):34-7

Comparison of acute hepatocellular proliferating cell nuclear antigen labeling indices and growth fractions, p34cdc2 kinases, and serum enzymes in carbon tetrachloride-treated rats. Monticello TM, et al. **Toxicol Pathol** 1995 Jul-Aug; 23(4):439-46

Relationship of serum alanine aminotransferase (ALT) to body mass index (BMI) in blood donors: the need to correct ALT for BMI in blood donor screening. Ramesh V, et al. **Transfus Med** 1995 Dec;5(4):273-4

Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Busch MP, et al. **Transfusion** 1995 Nov-Dec; 35(11):903-10

[Liver-protecting and alanine aminotransferase lowering actions of hongning gantai] Chen Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):299-300, 312, 320, inside cover (Eng. Abstr.) **(Chi)**

[Viral hepatitis A with prolonged course in adults] Altman C, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):42-6 (Eng. Abstr.) **(Fre)**

[Interactions between chronic viral hepatitis C and pregnancy] Grangé JD, et al. **Gastroenterol Clin Biol** 1995 May;19(5):520-4 (29 ref.) (Eng. Abstr.) **(Fre)**

[Alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamate dehydrogenase (GLDH), alkaline phosphatase (AP) and gamma-glutamyltransferase (GGP) in intestinal diseases of dogs] Dodurka T, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jul;108(7):244-8 (Eng. Abstr.) **(Ger)**

[Expert consultation. Prolonged elevation of transaminase concentration] Ramadori G. **Leber Magen Darm** 1996 Mar; 26(2):114 **(Ger)**

[Histological features and HLA-DNA types in HCV carriers with persistently normal ALT levels] Kuzushita N, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:576-81 **(Jpn)**

[Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] Miura Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:266-71 (12 ref.) **(Jpn)**

[Plasma levels of alanine aminotransferase in experimental liver necrosis induced by overdosage of paracetamol in mice] Carrasco R, et al. **Rev Esp Enferm Dig** 1995 Dec; 87(12):865-8 (Eng. Abstr.) **(Spa)**

[Hepatitis C seroconversion in a blood donor: the value of ALT determination (letter)] Pérez Vaquero MA, et al. **Sangre (Barc)** 1996 Feb;41(1):74 **(Spa)**

GENETICS

A recombinant tyrosine aminotransferase from Trypanosoma cruzi has both tyrosine aminotransferase and alanine aminotransferase activities. Montemartini M, et al. **FEMS Microbiol Lett** 1995 Nov 1;133(1-2):17-20

Fidelity of translation initiation of mRNA for the precursor of rat mitochondrial serine:pyruvate/alanine:glyoxylate aminotransferase. Funai T, et al. **J Biochem (Tokyo)** 1995 May;117(5):1008-16

Molecular cloning and sequencing of a cDNA encoding alanine-glyoxylate aminotransferase 2 from rat kidney. Lee IS, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):856-62

Genetic analysis of serum alanine transaminase activity in normal and hepatitis C virus-infected chimpanzees: an application of research-oriented genetic management. Williams-Blangero S, et al. **Lab Anim Sci** 1996 Feb; 46(1):26-30

Polymorphisms in the alanine:glyoxylate aminotransferase gene and their application to the prenatal diagnosis of primary hyperoxaluria type 1. Rumsby G, et al. **Nephrol Dial Transplant** 1995;10 Suppl 8:30-2

METABOLISM

Enzymatic elimination of fluoride from alpha-fluoro-beta-alanine. Porter DJ, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1475-84

Effects of mebendazole, albendazole and praziquantel on alanine aminotransferase and aspartate aminotransferase of Echinococcus granulosus cyst wall harbored in mice. Xiao S, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):107-10

The effect of prostaglandin E1 on liver adenine nucleotides and cytoplasmic enzymes in a porcine model of normothermic hepatic ischemia. Helling TS, et al. **Hepatology** 1995 Nov;22(5):1554-9

Carotenoids protect cultured rat hepatocytes from injury caused by carbon tetrachloride. Kim H. **Int J Biochem Cell Biol** 1995 Dec;27(12):1303-9

Role of leucine 201 of thermostable D-amino acid aminotransferase from a thermophile, Bacillus sp. YM-1. Kishimoto K, et al. **J Biochem (Tokyo)** 1995 Apr; 117(4):691-6

Mammalian alanine/glyoxylate aminotransferase 1 is imported into peroxisomes via the PTS1 translocation pathway. Increased degeneracy and context specificity of the mammalian PTS1 motif and implications for the peroxisome-to-mitochondrion mistargeting of AGT in primary hyperoxaluria type 1. Motley A, et al. **J Cell Biol** 1995 Oct;131(1):95-109

SECRETION

The influence of antagonists of poly(ADP-ribose) metabolism on acetaminophen hepatotoxicity. Kröger H, et al. **Gen Pharmacol** 1996 Jan;27(1):167-70

URINE

Effect of proximal tubular glucose transport blockade on urinary enzyme excretions in hyperglycemic rats. Ishii N, et al. **Enzyme Protein** 1994-95;48(5-6):243-50

D-ALANINE CARBOXYPEPTIDASE see **CARBOXYPEPTIDASE TRANSPEPTIDASE**

ALANINE RACEMASE

METABOLISM

[Thermostable alanine racemase from Escherichia coli strain XL1-Blue with cloned pBLUESCRIPT ("Stratagene")] Rekoslavskaia NI, et al. **Dokl Akad Nauk** 1995 Jul; 343(1):115-8 **(Rus)**

ALANINE-SPECIFIC TRNA see **RNA, TRANSFER, ALA**

2-ALANYL-LEUCINE ENKEPHALIN see **ENKEPHALIN, LEUCINE-2-ALANINE**

ALANYL T RNA SYNTHETASE

CHEMISTRY

Further characterization of Escherichia coli alanyl-tRNA synthetase. Sood SM, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):295-301

GENETICS

Localization of two human autoantigen genes by PCR screening and in situ hybridization--glycyl-tRNA synthetase locates to 7p15 and alanyl-tRNA synthetase locates to 16q22. Nichols RC, et al. **Genomics** 1995 Nov 1;30(1):131-2

The same Arabidopsis gene encodes both cytosolic and mitochondrial alanyl-tRNA synthetases. Mireau H, et al. **Plant Cell** 1996 Jun;8(6):1027-39

METABOLISM

Further characterization of Escherichia coli alanyl-tRNA synthetase. Sood SM, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):295-301

Specific function of a G.U wobble pair from an adjacent helical site in tRNA(Ala) during recognition by alanyl-tRNA synthetase. McClain WH, et al. **RNA** 1996 Feb;2(2):105-9

Functional evidence for indirect recognition of G.U in tRNA(Ala) by alanyl-tRNA synthetase. Gabriel K, et al. **Science** 1996 Jan 12;271(5246):195-7

ALBENDAZOLE

ADMINISTRATION & DOSAGE

Development of an injectable formulation of albendazole and in vivo evaluation of its efficacy against Echinococcus multilocularis metacestode. Rodrigues JM Jr, et al. **Int J Parasitol** 1995 Dec;25(12):1437–41

Inoperable liver echinococcosis treated by oral antiparasitic drugs. Shalev I, et al. **J Clin Gastroenterol** 1996 Apr; 22(3):246–7

Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine. Wen H, et al. **Parasitology** 1996 Aug;113 (Pt 2):111–21

Control of gastrointestinal parasitism in calves with albendazole delivered via an intraruminal controlled-release device. Bell SL, et al. **Vet Parasitol** 1996 Apr;62(3–4):275–90

ADVERSE EFFECTS

Albendazole-induced pseudomembranous colitis. Shah V, et al. **Am J Gastroenterol** 1996 Jul;91(7):1453–4 (11 ref.)

ANALOGS & DERIVATIVES

Bioavailability comparison between albendazole and albendazole sulphoxide in rats and man. Dominguez L, et al. **Farmaco** 1995 Oct;50(10):697–702

The pharmacokinetics of albendazole metabolites following administration of albendazole, albendazole sulfoxide and netobimin to one-month- and eight-month-old sheep. McKellar QA, et al. **Int J Parasitol** 1995 Oct; 25(10):1207–12

Anti-tubulin immunohistochemistry study of Echinococcus granulosus protoscolices incubated with albendazole and albendazole sulphoxide in vitro. Pérez-Serrano J, et al. **Parasitol Res** 1995;81(5):438–40

Plasma disposition kinetics of albendazole metabolites in pigs fed different diets. Alvarez LI, et al. **Res Vet Sci** 1996 Mar; 60(2):152–6

Bioavailability of different benzimidazole volume-dose formulations in sheep. Benchaoui HA, et al. **Vet Rec** 1995 Aug 12;137(7):171–2

Small intestinal sulphoxidation of albendazole. Villaverde C, et al. **Xenobiotica** 1995 May;25(5):433–41

ANALYSIS

Dietary intake estimates as a means to the harmonization of maximum residue levels for veterinary drugs. I. Concept. Fitzpatrick SC, et al. **J Vet Pharmacol Ther** 1995 Oct; 18(5):325–7

DIAGNOSTIC USE

Cysticercosis mimicking brain tumor: the role of albendazole as a diagnostic tool. Del Brutto OH, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):256–8

PHARMACOKINETICS

The effect of a short-term reduction in feed on the pharmacokinetics and efficacy of albendazole in sheep. Hennessy DR, et al. **Aust Vet J** 1995 Jan;72(1):29–30

Bioavailability comparison between albendazole and albendazole sulphoxide in rats and man. Dominguez L, et al. **Farmaco** 1995 Oct;50(10):697–702

The pharmacokinetics of albendazole metabolites following administration of albendazole, albendazole sulfoxide and netobimin to one-month- and eight-month-old sheep. McKellar QA, et al. **Int J Parasitol** 1995 Oct; 25(10):1207–12

Plasma disposition kinetics of albendazole metabolites in pigs fed different diets. Alvarez LI, et al. **Res Vet Sci** 1996 Mar; 60(2):152–6

Bioavailability of different benzimidazole volume-dose formulations in sheep. Benchaoui HA, et al. **Vet Rec** 1995 Aug 12;137(7):171–2

Nutritional condition affects the disposition kinetics of albendazole in cattle. Sánchez SF, et al. **Xenobiotica** 1996 Mar;26(3):307–19

PHARMACOLOGY

A comparison of two methods for assessing drug sensitivity in Giardia duodenalis. Pearce DA, et al. **Appl Parasitol** 1996 Jun;37(2):111–6

Effect of antihydatid drugs on carbohydrate metabolism of metacestode of echinococcus granulosus. Xiao S, et al. **Chin Med J (Engl)** 1995 Sep;108(9):682–8

Ascaris suum: ultrastructural effect of in vitro albendazole therapy. Magambo JK. **East Afr Med J** 1996 Feb; 73(2):140–2

The effect of intraoperative mebendazole-albendazole applications on the hepatobiliary system. Erzurumlu K, et al. **Eur Surg Res** 1995;27(5):340–5

In vitro cultivation of the human microsporidium Vittaforma corneae: development and effect of albendazole. Silveira H, et al. **Folia Parasitol (Praha)** 1995;42(4):241–50

Anti-tubulin immunohistochemistry study of Echinococcus granulosus protoscolices incubated with albendazole and albendazole sulphoxide in vitro. Pérez-Serrano J, et al. **Parasitol Res** 1995;81(5):438–40

THERAPEUTIC USE

Treatment of porcine cysticercosis with albendazole. Gonzalez AE, et al. **Am J Trop Med Hyg** 1995 Nov; 53(5):571–4

Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Carpio A, et al. **Arch Intern Med** 1995 Oct 9;155(18):1982–8

Autopsy verification of Encephalitozoon intestinalis (microsporidiosis) eradication following albendazole therapy. Joste NE, et al. **Arch Pathol Lab Med** 1996 Feb; 120(2):199–203

Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial. Kelly P, et al. **BMJ** 1996 May 11; 312(7040):1187–91

The efficacy of three anthelmintic drugs given in a single dose. Sorensen E, et al. **Ceylon Med J** 1996 Jun;41(2):42–5

Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with the human immunodeficiency virus: response to therapy with albendazole. Dore GJ, et al. **Clin Infect Dis** 1995 Jul;21(1):70–6

A comparative clinical trial of albendazole versus metronidazole in children with giardiasis. Misra PK, et al. **Indian Pediatr** 1995 Jul;32(7):779–82

A comparative clinical trial of albendazole versus metronidazole in giardiasis. Misra PK, et al. **Indian Pediatr** 1995 Mar;32(3):291–4

Cerebral and subcutaneous cysticercosis treated with albendazole. Schmidt DK, et al. **Int J Dermatol** 1995 Aug; 34(8):574–9

Evaluation of the efficacy of albendazole against the larvae of Taenia solium in experimentally infected pigs, and kinetics of the immune response. Kaur M, et al. **Int J Parasitol** 1995 Dec;25(12):1443–50

Failure of albendazole therapy in two common types of parenchymal neurocysticercosis. Garg RK, et al. **J Assoc Physicians India** 1995 Oct;43(10):706–7

Pulmonary hydatidosis medical and surgical management. Maniar DR, et al. **J Assoc Physicians India** 1996 Jan; 44(1):63–4

Diagnosis of disseminated microsporidian Encephalitozoon hellem infection by PCR-Southern analysis and successful treatment with albendazole and fumagillin. Didier ES, et al. **J Clin Microbiol** 1996 Apr;34(4):947–52

Disseminated Encephalitozoon (Septata) intestinalis infection in a patient with AIDS: novel diagnostic approaches and autopsy-confirmed parasitological cure following treatment with albendazole. Sobottka I, et al. **J Clin Microbiol** 1995 Nov;33(11):2948–52

Intestinal microsporidiosis with Septata intestinalis in a patient with AIDS--response to albendazole. Franzen C, et al. **J Infect** 1995 Nov;31(3):237–9

Neurocysticercosis: optimal dose treatment with albendazole. Cruz I, et al. **J Neurol Sci** 1995 Nov;133(1–2):152–4

Vitamin A status of Indonesian children infected with Ascaris lumbricoides after dosing with vitamin A supplements and albendazole. Tanumihardjo SA, et al. **J Nutr** 1996 Feb; 126(2):451–7

Albendazole in neurocysticercosis. Padma MV, et al. **Natl Med J India** 1995 Nov-Dec;8(6):255–8

Two cases of giardiasis unsuccessfully treated by albendazole [letter] Brasseur P, et al. **Parasite** 1995 Dec;2(4):422

Effect of removing Ascaris on the growth of Guatemalan schoolchildren. Watkins WE, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):871–6

Targeted chemotherapy for parasite infestations in rural black preschool children. Taylor M, et al. **S Afr Med J** 1995 Sep;85(9):870–4

Rate of reinfection with intestinal nematodes after treatment of children with mebendazole or albendazole in a highly endemic area. Albonico M, et al. **Trans R Soc Trop Med Hyg** 1995 Sep-Oct;89(5):538–41

Reinfection patterns of Oesophagostomum bifurcum after anthelmintic treatment. Krepel HP, et al. **Trop Geogr Med** 1995;47(4):160–3

Efficacy of albendazole and fenbendazole against Giardia infection in cattle. Xiao L, et al. **Vet Parasitol** 1996 Jan; 61(1–2):165–70

[Observation on dynamics of circulating antigen from patients with cysticercosis before and after treatment] Zhang Y, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):222–4 (Eng. Abstr.) **(Chi)**

[Synergic effect of albendazole plus metronidazole association in the treatment of metronidazole-resistant giardiasis] Cacopardo B, et al. **Clin Ter** 1995 Dec; 146(12):761–7 (Eng. Abstr.) **(Ita)**

TOXICITY

Effects observed on gestational day 13 in rat embryos exposed to albendazole. Mantovani A, et al. **Reprod Toxicol** 1995 May-Jun;9(3):265–73

ALBERS-SCHOENBERG DISEASE see **OSTEOPETROSIS**

ALBINISM

see related
CHEDIAK-HIGASHI SYNDROME

EMBRYOLOGY

Retinal axon divergence in the optic chiasm: midline cells are unaffected by the albino mutation. Marcus RC, et al. **Development** 1996 Mar;122(3):859–68

GENETICS

Intellectual and educational attainment in albinism. Fulcher T, et al. **J Pediatr Ophthalmol Strabismus** 1995 Nov-Dec; 32(6):368–72

Insertion of a novel transposable element in the tyrosinase gene is responsible for an albino mutation in the medaka fish, Oryzias latipes. Koga A, et al. **Mol Gen Genet** 1995 Dec 10;249(4):400–5

METABOLISM

Pharmacokinetics of ofloxacin in serum and vitreous humor of albino and pigmented rabbits. Perkins RJ, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1493–8

PHYSIOPATHOLOGY

Ca2+ fluxes and channel regulation in rods of the albino rat. Knopp A, et al. **J Gen Physiol** 1996 May;107(5):577–95

Albino visual pathway [letter; comment] Kosmorsky GS. **Neurology** 1996 Jul;47(1):311. Comment on: Neurology 1994 Oct;44(10):1921–6.

VETERINARY

Ovarian morphology and follicular development in sex-linked imperfect albino (s(al)-s) and nonalbino hens before or after a forced moult. Su H, et al. **Br Poult Sci** 1995 Sep;36(4):645–53

A method for separating sex-linked imperfect albino (S*ALS) and nonalbino embryos before hatch. Santos GA, et al. **Poult Sci** 1996 May;75(5):585–8

Effects of sex-linked imperfect albinism (sal-s) in the chicken on the relationships of plasma concentrations of progesterone and 17 beta-estradiol with egg production. Su H, et al. **Poult Sci** 1996 Jan;75(1):13–9

ALBINISM, CUTANEOUS see **PIEBALDISM**

ALBINISM, OCULAR

COMPLICATIONS

Transillumination of iris and subnormal visual acuity--ocular albinism? Sjödell L, et al. **Br J Ophthalmol** 1996 Jul; 80(7):617–23

DIAGNOSIS

[Clinico-physiological characteristics of albinism] Eskina EN, et al. **Vestn Oftalmol** 1995 Oct-Dec;111(4):33–4 (Eng. Abstr.) **(Rus)**

GENETICS

A new region of conservation is defined between human and mouse X chromosomes. Dinulos MB, et al. **Genomics** 1996 Jul 1;35(1):244–7

Analysis of the OA1 gene reveals mutations in only one-third of patients with X-linked ocular albinism. Schiaffino MV, et al. **Hum Mol Genet** 1995 Dec;4(12):2319–25

METABOLISM

Differences between albino and pigmented rabbit eyes in the intraocular pharmacokinetics of sparfloxacin. Fukuda M, et al. **Drugs** 1995;49 Suppl 2:314–6

PATHOLOGY

Albinism and the associated ocular defects. Oetting WS, et al. **Metab Pediatr Syst Ophthalmol** 1994;17(1–4):5–9 (19 ref.)

PHYSIOPATHOLOGY

Effects of prolonged uniocular dark adaptation on the direct-current electroretinogram of pigmented and albino rabbits. Textorius O, et al. **Doc Ophthalmol** 1995; 90(3):305–17

Visual evoked potentials with crossed asymmetry in incomplete congenital stationary night blindness. Tremblay F, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1783–92

ALBINISM, OCULOCUTANEOUS

Generalized osteoporosis in a patient with oculocutaneous hypopigmentation syndrome (OOCHS), without cerebral defects. A new syndrome? Hernández A, et al. **Clin Genet** 1996 Jan;49(1):46–8

COMPLICATIONS

Ocular findings in the Hermansky-Pudlak syndrome. Izquierdo NJ, et al. **Trans Am Ophthalmol Soc** 1995; 93:191–200; discussion 200–2

DIAGNOSIS

Diagnosis of oculocutaneous albinism with molecular analysis. Summers CG, et al. **Am J Ophthalmol** 1996 Jun; 121(6):724–6

ALBINISM, OCULOCUTANEOUS

Histology of fetal eyes with oculocutaneous albinism. Akeo K, et al. **Arch Ophthalmol** 1996 May;114(5):613–6

Dyspnea in a 30–year–old Hispanic man with albinism. Horowitz ID. **Chest** 1995 Oct;108(4):1158–60

ENZYMOLOGY

Detection of point mutations in human tyrosinase gene by improved allele–specific amplification. Matsunaga J, et al. **Exp Dermatol** 1995 Dec;4(6):377–81

EPIDEMIOLOGY

Oculocutaneous albinism among schoolchildren in Harare, Zimbabwe. Kagore F, et al. **J Med Genet** 1995 Nov; 32(11):859–61

GENETICS

Mutation in and lack of expression of tyrosinase–related protein–1 (TRP–1) in melanocytes from an individual with brown oculocutaneous albinism: a new subtype of albinism classified as "OCA3". Boissy RE, et al. **Am J Hum Genet** 1996 Jun;58(6):1145–56

A gene causing Hermansky–Pudlak syndrome in a Puerto Rican population maps to chromosome 10q2 [see comments] Wildenberg SC, et al. **Am J Hum Genet** 1995 Oct;57(4):755–65. Comment in: Am J Hum Genet 1995 Oct;57(4):743–7.

X–linked albinism–deafness syndrome and Waardenburg syndrome type II: a hypothesis [letter] Zlotogora J. **Am J Med Genet** 1995 Nov 20;59(3):386–7

Diagnosis of oculocutaneous albinism with molecular analysis. Summers CG, et al. **Am J Ophthalmol** 1996 Jun; 121(6):724–6

Misrouting of tyrosinase with a truncated cytoplasmic tail as a result of the murine platinum (cp) mutation. Beermann F, et al. **Exp Eye Res** 1995 Nov;61(5):599–607

Linkage disequilibrium mapping of the gene for Hermansky–Pudlak syndrome to chromosome 10q23.1–q23.3. Fukai K, et al. **Hum Mol Genet** 1995 Sep; 4(9):1665–9

Estimation of carrier frequency of a 2.7 kb deletion allele of the P gene associated with OCA2 in African–Americans. Durham–Pierre D, et al. **Hum Mutat** 1996;7(4):370–3

Type I oculocutaneous albinism associated with a full–length deletion of the tyrosinase gene. Schnur RE, et al. **J Invest Dermatol** 1996 May;106(5):1137–40

PATHOLOGY

Epidermal melanocytes in normal and tyrosinase–negative oculocutaneous albinism fetuses. Kikuchi A, et al. **Arch Dermatol Res** 1995;287(6):529–33

Abnormality in the optic nerve of albino mutant quails. Takatsuji K, et al. **Invest Ophthalmol Vis Sci** 1987 Feb; 28(2):384–90

Albinism and the associated ocular defects. Oetting WS, et al. **Metab Pediatr Syst Ophthalmol** 1994;17(1–4):5–9 (19 ref.)

Ceroid pigment deposition in circulating blood monocytes and T lymphocytes in Hermansky–Pudlak syndrome: an ultrastructural study. Sakuma T, et al. **Pathol Int** 1995 Nov; 45(11):866–70

ALBINISM, PARTIAL see **PIEBALDISM**

ALBINISM, TYROSINASE–NEGATIVE see **ALBINISM, OCULOCUTANEOUS**

ALBINISM, TYROSINASE–POSITIVE see **ALBINISM, OCULOCUTANEOUS**

ALBINISM, YELLOW–MUTANT see **ALBINISM, OCULOCUTANEOUS**

ALBRIGHT'S SYNDROME see **FIBROUS DYSPLASIA, POLYOSTOTIC**

ALBUMIN RECEPTORS see **RECEPTORS, ALBUMIN**

ALBUMINS

see related
PREALBUMIN
RECEPTORS, ALBUMIN

Albumin–coated vascular prostheses: A five–year follow–up. al–Khaffaf H, et al. **J Vasc Surg** 1996 Apr;23(4):686–90

ADMINISTRATION & DOSAGE

Heat–stabilized albumin microspheres as a sustained drug delivery system for the antimetabolite, 5–fluorouracil. Truter EJ. **Artif Cells Blood Substit Immobil Biotechnol** 1995;23(5):579–86

Comparison of a new intravenous echo contrast agent (BY 963) with Albunex for opacification of left ventricular cavity. Leischik R, et al. **Basic Res Cardiol** 1996 Jan–Feb; 91(1):101–9

Properties of water–insoluble mitomycin C–albumin conjugate as a sustained release drug delivery system in mice inoculated with Sarcoma 180. Tanaka T, et al. **Biol Pharm Bull** 1995 Dec;18(12):1724–8

Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Shaker AG, et al. **Fertil Steril** 1996 May;65(5):992–6

Does it make sense to administer albumin to the patient with nephrotic oedema? [editorial] Dorhout Mees EJ. **Nephrol Dial Transplant** 1996 Jul;11(7):1224–6 (17 ref.)

Long–term high–colloid oncotic therapy for ischemic brain edema in gerbils. Hakamata Y, et al. **Stroke** 1995 Nov; 26(11):2149–53

[Changing the use of albumin at the Oslo hospital] Fosse E, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):54–7 (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Nephrotic syndrome in childhood complicated by life threatening pulmonary oedema. Reid CJ, et al. **BMJ** 1996 Jan 6;312(7022):36–8

[Overuse of albumin] Svennevig JL. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):15 **(Nor)**

ANALYSIS

IgG, albumin and total IgG index in the aqueous humour of eyes with pseudoexfoliation syndrome. Moreno–Montañés J, et al. **Acta Ophthalmol Scand** 1995 Jun;73(3):249–51

Association of increased bronchoalveolar lavage fluid albumin and serum beta 2–microglobulin with pulmonary complications after allogeneic bone marrow transplantation. Kreuzfelder E, et al. **Bone Marrow Transplant** 1995 Aug;16(2):249–52

Studies on the mechanism of early onset macular degeneration in cynomolgus (Macaca fascicularis) monkeys. I. Abnormal concentrations of two proteins in the retina. Nicolas MG, et al. **Exp Eye Res** 1996 Mar; 62(3):211–9

Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Chen CJ, et al. **Hepatology** 1996 Jul;24(1):38–42

Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. Agrawal B, et al. **J Hypertens** 1996 Feb;14(2):223–8

Age–related changes in albumin–excluded volume fraction. Parameswaran S, et al. **Microvasc Res** 1995 Nov; 50(3):373–80

[Evaluation of combined test of sequential fecal occult blood and albumin in the screening of colorectal neoplasms] Li S, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep; 17(5):381–3 (Eng. Abstr.) **(Chi)**

[Analysis of protein nutrient reserves of the clitellum and cocoon albumin in Eisenia fetida Sav (Annelida Oligochaeta). Demonstration of a glycolipoprotein comparable to vitellogenin] Rouabah–Sadaoui L, et al. **Reprod Nutr Dev** 1995;35(5):491–501 (Eng. Abstr.) **(Fre)**

[Sugars and lipids of the clitellum and cocoon albumin in Eisenia fetida Sav (Annelida Oligochaeta)] Rouabah–Sadaoui L, et al. **Reprod Nutr Dev** 1995; 35(5):537–48 (Eng. Abstr.) **(Fre)**

[Diagnosis of neoplastic ascites: combined use of albumin gradient between serum and ascites and cholesterol in ascitic fluid] Sartori M, et al. **Recenti Prog Med** 1996 Feb; 87(2):75–7 **(Ita)**

[Endoscopic and clinical parameters in assessing th degree of portal hypertension: the value of the serum–ascitic fluid albumin gradient] Torres E, et al. **Rev Gastroenterol Peru** 1996 Jan–Apr;16(1):20–6 (Eng. Abstr.) **(Spa)**

ANTAGONISTS & INHIBITORS

Retinoic acid–stimulated liver stellate cells suppress the production of albumin from parenchymal cells via TGF–beta. Koda H, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):565–9

BIOSYNTHESIS

Metformin induces an agonist–specific increase in albumin production by primary cultured rat hepatocytes. Zaïbi MS, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):775–80

[The study of the biological activation induced by the lymphocyte transfusion—the induction of the bio–reproducing protein (BRP)] Sato I. **Hum Cell** 1995 Sep; 8(3):77–84 (18 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD see SERUM ALBUMIN

CEREBROSPINAL FLUID

[Transthyretin and albumin in cerebrospinal fluid in patients with acute leukemias or lymphomas of high grade malignancy] Millo B, et al. **Acta Haematol Pol** 1996; 27(1):73–7 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Poly(ethylene glycol)–serum albumin hydrogel as matrix for enzyme immobilization: biomedical applications. D'Urso EM, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995;23(5):587–95

Characterization of chlorinated adducts of hemoglobin and albumin following administration of pentachlorophenol to rats. Waidyanatha S, et al. **Chem Res Toxicol** 1996 Apr–May;9(3):647–53

Modified 2S albumins with improved tryptophan content are correctly expressed in transgenic tobacco plants. Marcellino LH, et al. **FEBS Lett** 1996 May 6;385(3):154–8

Interaction of antithrombin III with surface–immobilized albumin–heparin conjugates. van Delden CJ, et al. **J Biomed Mater Res** 1995 Nov;29(11):1317–29

DIAGNOSTIC USE

Myocardial perfusion abnormalities during low–dose dobutamine after coronary reperfusion can be demonstrated with intravenous perfluorocarbon–exposed sonicated dextrose albumin ultrasound contrast. Porter TR, et al. **Am Heart J** 1996 Jun;131(6):1079–87

Improved visualization of pulmonary venous flow Doppler signal by intravenous injection of sonicated albumin. Izumi C, et al. **Am J Cardiol** 1996 Sep 1;78(5):598–600

Evaluation of left atrial appendage stasis in patients with atrial fibrillation using transesophageal echocardiography with an intravenous albumin–contrast agent. Kato H, et al. **Am J Cardiol** 1996 Aug 1;78(3):365–9

Evidence for a relation between inspired gas mixture and the left ventricular contrast achieved with Albunex in a canine model. Geiser EA, et al. **Clin Cardiol** 1996 Apr; 19(4):289–95

Visualization of protein losing enteropathy in infantile systemic hyalinosis with Tc–99m HSA after albumin challenge. Shields E, et al. **Clin Nucl Med** 1996 May; 21(5):415–6

Albunex and beyond. Ostensen J. **Clin Radiol** 1996 Feb;51 Suppl 1:8–10

Residual myocardial perfusion in reversibly damaged myocardium by dipyridamole contrast echocardiography. Rovai D, et al. **Eur Heart J** 1996 Feb;17(2):296–301

Improvement of transthoracic pulmonary venous flow Doppler signal with intravenous injection of sonicated albumin. Williams MJ, et al. **J Am Coll Cardiol** 1995 Dec; 26(7):1741–6

Intravenous Albunex during transesophageal echocardiography: quantitative assessment by videodensitometry and integrated backscatter analysis from unprocessed radiofrequency signals. Angermann CE, et al. **J Am Soc Echocardiogr** 1995 Nov–Dec;8(6):839–53

Left ventricular volume determination using Albunex. Zotz RJ, et al. **J Am Soc Echocardiogr** 1996 Jan–Feb;9(1):1–8

Technetium–99m–galactosyl–neoglycoalbumin combined with iodine–123–Tyr–(A14)–insulin visualizes human hepatocellular carcinomas. Kurtaran A, et al. **J Nucl Med** 1995 Oct;36(10):1875–81

Diagnostic performance of a receptor–binding radiopharmacokinetic model. Vera DR, et al. **J Nucl Med** 1996 Jan;37(1):160–4

In situ 19F MRS measurement of RIF–1 tumor blood volume: corroboration by radioisotope–labeled [125I]–albumin and correlation to tumor size. Baldwin NJ, et al. **Magn Reson Imaging** 1996;14(3):275–80

Regional comparison of tumor vascularity and permeability parameters measured by albumin–Gd–DTPA and Gd–DTPA. Su MY, et al. **Magn Reson Med** 1995 Sep; 34(3):402–11

Noninvasive evaluation of systolic pressures of pulmonary artery and right ventricle using contrast–enhanced doppler echocardiography: comparative study using sonicated albumin or glucose solution. Ishii M, et al. **Pediatr Cardiol** 1996 May–Jun;17(3):175–80

Contrast–enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. Schwickert HC, et al. **Radiology** 1996 Mar; 198(3):893–8

Mammary carcinoma model: correlation of macromolecular contrast–enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. van Dijke CF, et al. **Radiology** 1996 Mar;198(3):813–8

First clinical experience with sonicated human serum albumin (Albunex) as an intrafallopian ultrasound contrast medium. Holte J, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):62–5

[Evaluation of internal thoracic artery bypass grafting with perfusion contrast echocardiography] Utsunomiya H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):982–9 (Eng. Abstr.) **(Jpn)**

GENETICS

Direct solution hybridization of guanidine thiocyanate–solubilized cells for quantitation of mRNAs in hepatocytes. Kaabache T, et al. **Anal Biochem** 1995 Dec 10;232(2):225–30

Age–related shortening of poly(A) tail of albumin mRNA. Shah GN, et al. **Arch Biochem Biophys** 1995 Dec 1; 324(1):105–10

Identification and isolation of human epithelial cell colonies that express specific gene products. Gibson–D'Ambrosio RE, et al. **Biotechniques** 1995 Nov;19(5):784–6, 788–90

Detection of albumin messenger RNA in blood is not restricted to hepatocellular carcinoma [letter] Ijzermans JN, et al. **Hepatology** 1996 Jun;23(6):1708–9

Quantitation of alpha–fetoprotein and albumin messenger RNA in human hepatocellular carcinoma. Niwa Y, et al. **Hepatology** 1996 Jun;23(6):1384–92

C/EBP–beta/LAP controls down–regulation of albumin gene transcription during liver regeneration. Trautwein C, et al. **J Biol Chem** 1996 Sep 6;271(36):22262–70

Nucleosome positioning properties of the albumin

transcriptional enhancer. McPherson CE, et al. **Nucleic Acids Res** 1996 Feb 1;24(3):397–404

Differentiation of the normal and mutant rat albumin genes on hepatic tissue sections by in situ PCR. Tokusashi Y, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3790–1

Nucleoprotein architecture of the albumin transcriptional enhancer. Zaret KS. **Semin Cell Biol** 1995 Aug;6(4):209–18 (56 ref.)

Characterization of somatic cell hybrids exhibiting extinction of AFP, albumin and an AFP–HPRT transgene. Keherly MJ, et al. **Somat Cell Mol Genet** 1996 Mar;22(2):119–34

Accumulation of a sulphur–rich seed albumin from sunflower in the leaves of transgenic subterranean clover (Trifolium subterraneum L.). Khan MR, et al. **Transgenic Res** 1996 May;5(3):179–85

IMMUNOLOGY

IgE cross–reactivities against albumins in patients allergic to animals. Spitzauer S, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):951–9

Modulation of antigen–antibody complexations by immunoglobulins. Andersson K, et al. **Scand J Immunol** 1995 Oct;42(4):407–17

METABOLISM

Immunohistochemical demonstration of interleukin–1 beta induced changes in acute–phase proteins and albumin in rat liver. Ballmer PE, et al. **Acta Histochem** 1995 Jul; 97(3):281–9

Effect of dietary protein and enalapril on proximal tubular delivery and absorption of albumin in nephrotic rats. Fitzgibbon WR, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):F986–96

Mobilization of annexin V during the uptake of DNP–albumin by human dendritic cells. Larsson M, et al. **APMIS** 1995 Dec;103(12):855–61

Relationship between protein damage and ferrylmyoglobin. Miura T, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):587–94

Characterization of progesterone–3–[125I–BSA] binding sites in the medial preoptic area and anterior hypothalamus. Caldwell JD, et al. **Brain Res** 1995 Sep 25;693(1–2):225–32

Temporal patterns of aflatoxin–albumin adducts in hepatitis B surface antigen–positive and antigen–negative residents of Daxin, Qidong County, People's Republic of China. Wang JS, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr;5(4):253–61

Introduction of macromolecules into living Dictyostelium cells by electroporation. Yumura S, et al. **Cell Struct Funct** 1995 Jun;20(3):185–90

Diabetes exacerbates inflammatory responses to ischemia–reperfusion. Panés J, et al. **Circulation** 1996 Jan 1;93(1):161–7

The control of ingress of albumin into developing enamel from adjacent dentine of the rat incisor. Shore RC, et al. **Connect Tissue Res** 1995;33(1–3):151–5

The source of fluid and protein in serous retinal detachments. Takeuchi A, et al. **Curr Eye Res** 1996 Jul;15(7):764–7

Role of intraduodenal proteases in plasma cholecystokinin and pancreaticobiliary responses to protein and amino acids. Thimister PW, et al. **Gastroenterology** 1996 Feb; 110(2):567–75

Immunocytochemical evaluation of the blood–brain barrier to endogenous albumin in the olfactory bulb and pons of senescence–accelerated mice (SAM). Ueno M, et al. **Histochem Cell Biol** 1996 Mar;105(3):203–12

Effects of glucose and an aldose reductase inhibitor on albumin permeation through a layer of cultured bovine vascular endothelial cells. Mimura K, et al. **Horm Metab Res** 1995 Oct;27(10):442–6

Mechanism of anti–HIV activity of negatively charged albumins: biomolecular interaction with the HIV–1 envelope protein gp120. Kuipers ME, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 15;11(5):419–29

Effects of luminal antigen on intestinal albumin and hyaluronan permeability and ion transport in atopic patients. Knutson TW, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1225–32

Matrix metalloproteinase (stromelysin–1) increases the albumin permeability of isolated rat glomeruli. Sharma R, et al. **J Lab Clin Med** 1996 Sep;128(3):297–303

The role of nitric oxide in the regulation of macromolecular transport in rat jejunum. Kimm MH, et al. **J Physiol (Lond)** 1996 Jan 1;490 (Pt 1):243–8

Increased peritoneal permeability to albumin in streptozotocin diabetic rats. Shostak A, et al. **Kidney Int** 1996 Mar;49(3):705–14

Congenital enterocyte heparan sulphate deficiency with massive albumin loss, secretory diarrhoea, and malnutrition. Murch SH, et al. **Lancet** 1996 May 11;347(9011):1299–301

Bidirectional peritoneal transport of albumin in continuous ambulatory peritoneal dialysis. Joffe P, et al. **Nephrol Dial Transplant** 1995;10(9):1725–32

Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Heimbürger O, et al. **Nephron** 1996; 72(2):135–44

Kinetics of receptor–mediated endocytosis of albumin in cells derived from the proximal tubule of the kidney (opossum kidney cells): influence of Ca2+ and cAMP. Gekle M, et al. **Pflugers Arch** 1995 Jul;430(3):374–80

Targeting of drug to the hepatocytes by fatty acids. Influence of the carrier (albumin or galactosylated albumin) on the fate of the fatty acids and their analogs. Charbon V, et al. **Pharm Res** 1996 Jan;13(1):27–31

Prolonged circulation of recombinant human granulocyte–colony stimulating factor by covalent linkage to albumin through a heterobifunctional polyethylene glycol. Paige AG, et al. **Pharm Res** 1995 Dec;12(12):1883–8

Does albumin affect clotting of fibrinogen with thrombin? [letter; comment] Lipinski B. **Thromb Haemost** 1995 Oct; 74(4):1206. Comment on: Thromb Haemost 1995 Mar;73(3):349–55.

Further studies on immunoglobulin G– and albumin–binding properties of streptococci of serological group L. Sippel K, et al. **Zentralbl Veterinarmed [B]** 1995 Sep;42(7):421–6

[New functional properties of albumin] Pentiuk AA, et al. **Vopr Med Khim** 1995 May–Jun;41(3):11–3 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Drug release from new bioartificial hydrogel. Gayet JC, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(5):605–11

Comparison of saturable transport and extracellular pathways in the passage of interleukin–1 alpha across the blood–brain barrier. Plotkin SR, et al. **J Neuroimmunol** 1996 Jun; 67(1):41–7

Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis [see comments] Savin VJ, et al. **N Engl J Med** 1996 Apr 4;334(14):878–83. Comment in: N Engl J Med 1996 Apr 4;334(14):914–5.

Periventricular penetration and disappearance of ICV Tyr–MIF–1, DAMGO, tyrosine, and albumin. Maness LM, et al. **Peptides** 1996;17(2):247–50

Cytokine–induced increases in endothelial permeability occur after adhesion molecule expression. Marcus BC, et al. **Surgery** 1996 Aug;120(2):411–6; discussion 416–7

[Study of pharmacokinetics of liver targeting antimalarial agent neoglycoalbumin–primaquine conjugate (NGA–PQ) and primaquine phosphate in mouse] Li TL, et al. **Yao Hsueh Hsueh Pao** 1995;30(10):721–5 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Proximal tubular cell synthesis and secretion of endothelin–1 on challenge with albumin and other proteins. Zoja C, et al. **Am J Kidney Dis** 1995 Dec;26(6):934–41

Vasoreactivity of Fluosol perfluorocarbon emulsion vs. Earl's balanced salt/albumin perfusates in the isolated perfused rat lung. Mullett CJ, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):449–57

Protection by chlorpromazine, albumin and bivalent cations against haemolysis induced by melittin, [Ala–14]melittin and whole bee venom. Rudenko SV, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):747–54

The influence of Albunex on the pulmonary circulation in patients with pulmonary hypertension or left heart failure. Zotz RJ, et al. **Eur Heart J** 1996 Feb;17(2):302–7

Albumin binding and time action of acylated insulins in various species. Kurtzhals P, et al. **J Pharm Sci** 1996 Mar; 85(3):304–8

Effect of isovolemic hemodilution with dextran and albumin on thrombus formation in artificial vessel grafts inserted into the abdominal aorta of the rabbit. Frost–Arner L, et al. **Microsurgery** 1995;16(5):357–61

Human serum albumin enhances sodium currents in NH15–CA2 neuroblastoma x glioma hybrid cells. Rahn K, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):25–8

Hypertonic/hyperoncotic fluids reverse prostaglandin E2 (PGE2)–induced T–cell suppression. Coimbra R, et al. **Shock** 1995 Jul;4(1):45–9

THERAPEUTIC USE

The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patients [see comments] Boldt J, et al. **Anesth Analg** 1996 Aug;83(2):254–61. Comment in: Anesth Analg 1996 Aug;83(2):209–12.

Large–dose administration of 6% hydroxyethyl starch 200/0.5 total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin [see comments] Vogt NH, et al. **Anesth Analg** 1996 Aug;83(2):262–8. Comment in: Anesth Analg 1996 Aug;83(2):209–12.

Albumin prophylaxis of ovarian hyperstimulation syndrome. DiPiro CV, et al. **Ann Pharmacother** 1996 Apr;30(4):402–4

Albumin and nonprotein colloid solution use in US academic health centers. Yim JM, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2450–5

Therapeutic use of albumin. De Gaudio AR. **Int J Artif Organs** 1995 Apr;18(4):216–24 (60 ref.)

Comparison of hetastarch with albumin for postoperative volume expansion in children after cardiopulmonary bypass. Brutocao D, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):348–51

Is intravenous albumin a placebo? [letter] Rewald E, et al. **Lancet** 1995 Dec 2;346(8988):1497

Closantel intoxication in a dog. McEntee K, et al. **Vet Hum Toxicol** 1995 Jun;37(3):234–6

[Outcome of the use of albumin and colloid plasma substitutes from 1989 to 1993 in a French University Hospital Center] Audibert G, et al. **Ann Fr Anesth Reanim** 1995;14(6):517–22 (Eng. Abstr.) **(Fre)**

[The study of the biological activation induced by the lymphocyte transfusion—the induction of the bio–reproducing protein (BRP)] Sato I. **Hum Cell** 1995 Sep; 8(3):77–84 (18 ref.) (Eng. Abstr.) **(Jpn)**

TOXICITY

Renal toxicity of albumin and other lipoproteins. Schreiner GF. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):369–73 (33 ref.)

URINE see ALBUMINURIA

ALBUMINURIA

Anticoagulant protein C activity in non–insulin–dependent diabetic patients with normoalbuminuria and microalbuminuria. Veglio M, et al. **Acta Diabetol** 1995 Jun; 32(2):106–9

The changing course of diabetic nephropathy: low–density lipoprotein cholesterol and blood pressure correlate with regression of proteinuria. Ellis D, et al. **Am J Kidney Dis** 1996 Jun;27(6):809–18

Microalbuminuria: prognostic and therapeutic implications in diabetic and hypertensive pregnancy. Bar J, et al. **Diabet Med** 1995 Aug;12(8):649–56 (110 ref.)

Screening for microalbuminuria in type 2 diabetic patients: the evaluation of a dipstick test in general practice [see comments] de Grauw WJ, et al. **Diabet Med** 1995 Aug; 12(8):657–63. Comment in: Diabet Med 1995 Aug;12(8):647–8.

Microalbuminuria in non–insulin dependent diabetes mellitus [editorial; comment] Kumar S. **Diabet Med** 1995 Aug; 12(8):647–8 (11 ref.). Comment on: Diabet Med 1995 Aug;12(8):657–63.

Are frozen urine samples acceptable for estimating albumin excretion in research? Shield JP, et al. **Diabet Med** 1995 Aug;12(8):713–6

Lack of reproducibility of low–dose dopamine–induced microalbuminuria in type 1 diabetic patients [letter] Segers O, et al. **Diabete Metab** 1995 Jun;21(3):194–5

Albuminuria and poor glycemic control predict mortality in NIDDM. Gall MA, et al. **Diabetes** 1995 Nov; 44(11):1303–9

Microalbuminuria in NIDDM is caused by increased excretion of unmodified albumin. Ishibashi F. **Diabetes** 1996 Jun;45(6):731–5

Glycemic control and prognosis in type I diabetic patients with microalbuminuria. Bojestig M, et al. **Diabetes Care** 1996 Apr;19(4):313–7

Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Chan JC, et al. **Diabetes Care** 1995 Jul;18(7):1013–6

Impaired left ventricular diastolic function and vascular postischemic vasodilation associated with microalbuminuria in IDDM patients. Guglielmi MD, et al. **Diabetes Care** 1995 Mar;18(3):353–60

Effects of enalapril and nitrendipine on the excretion of epidermal growth factor and albumin in hypertensive NIDDM patients. Josefsberg Z, et al. **Diabetes Care** 1995 May;18(5):690–3

Elevated serum total renin is insensitive in detecting incipient diabetic nephropathy. Matinlauri IH, et al. **Diabetes Care** 1995 Oct;18(10):1357–61

Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Mogensen CE, et al. **Diabetes Care** 1995 Apr; 18(4):572–81 (85 ref.)

Albuminuria and 24–h ambulatory blood pressure in normoalbuminuric and microalbuminuric NIDDM patients. A longitudinal study. Nielsen S, et al. **Diabetes Care** 1995 Nov;18(11):1434–41

Similar insulin sensitivity in NIDDM patients with normo– and microalbuminuria. Nielsen S, et al. **Diabetes Care** 1995 Jun;18(6):834–42

Exercise testing as a long–term predictor of the development of microalbuminuria in normoalbuminuric IDDM patients. O'Brien SF, et al. **Diabetes Care** 1995 Dec;18(12):1602–5

Evaluation of a new semiquantitative stix for microalbuminuria [letter] Poulsen PL, et al. **Diabetes Care** 1995 May;18(5):732–3

Determinants of progression of microalbuminuria in adolescents with IDDM. Rudberg S, et al. **Diabetes Care** 1996 Apr;19(4):369–71

Association between lipoprotein(a) and insulin–like growth factor I during puberty and the relationship to microalbuminuria in children and adolescents with IDDM. Rudberg S, et al. **Diabetes Care** 1995 Jul;18(7):933–9

Five–year prospective study of glomerular filtration rate and albumin excretion rate in normofiltering and hyperfiltering normoalbuminuric NIDDM patients. Silveiro SP, et al. **Diabetes Care** 1996 Feb;19(2):171–4

Albuminuria is an independent predictor of carotid intima–media thickness and atherosclerosis in NIDDM patients [letter] Willey KA, et al. **Diabetes Care** 1995 Nov; 18(11):1502–3

Raised serum sialic acid concentration precedes onset of microalbuminuria in IDDM. A 10–year follow–up study. Yokoyama H, et al. **Diabetes Care** 1996 May;19(5):435–40

Noninvasive detection of functional alterations of the arterial wall in IDDM patients with and without microalbuminuria. Zenere BM, et al. **Diabetes Care** 1995 Jul;18(7):975–82

Renin–aldosterone axis in normoalbuminuric insulin–dependent diabetes mellitus patients with glomerular hyperfiltration. de Azevedo MJ, et al. **Diabetes Res Clin Pract** 1995 Mar;27(3):205–10

Exercise versus overnight albumin excretion rates in subjects with type 1 diabetes. Garg SK, et al. **Diabetes Res Clin Pract** 1995 Apr;28(1):51–5

Long–term effect of eicosapentaenoic acid ethyl (EPA–E) on albuminuria of non–insulin dependent diabetic patients. Shimizu H, et al. **Diabetes Res Clin Pract** 1995 Apr; 28(1):35–40

Albumin excretion rate levels in non–diabetic offspring of NIDDM patients with and without nephropathy. Gruden G, et al. **Diabetologia** 1995 Oct;38(10):1218–22

Albumin excretion and vascular deaths in NIDDM. MacLeod JM, et al. **Diabetologia** 1995 May;38(5):610–6

Urinary albumin excretion rate and 24–h ambulatory blood pressure in NIDDM with microalbuminuria: effects of a monounsaturated–enriched diet. Nielsen S, et al. **Diabetologia** 1995 Sep;38(9):1069–75

Blood pressure, retinopathy and urinary albumin excretion in IDDM: the EURODIAB IDDM Complications Study. Stephenson JM, et al. **Diabetologia** 1995 May;38(5):599–603

Increased prevalence of salt sensitivity of blood pressure in IDDM with and without microalbuminuria. Strojek K, et al. **Diabetologia** 1995 Dec;38(12):1443–8

Influence of bacteriuria on the determination of urinary albumin excretion rate [letter] Pedersen LM, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul;33(7):451–2

Alterations in cortisol metabolism in insulin–dependent diabetes mellitus: relationship with metabolic control and estimated blood volume and effect of angiotensin–converting enzyme inhibition. Dullaart RP, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3002–8

Microalbuminuria cannot predict cardiovascular death in Japanese subjects with non–insulin–dependent diabetes mellitus. Araki S, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):323–5

Possible effect of angiotensin–converting enzyme inhibition on glomerular charge selectivity. Hansen PM, et al. **J Diabetes Complications** 1995 Jul–Sep;9(3):158–62

Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin–dependent diabetes mellitus patients. Mogensen CE. **J Diabetes Complications** 1995 Oct–Dec;9(4):337–49 (99 ref.)

Insulin resistance in non–insulin–dependent diabetes mellitus is associated with microalbuminuria independently of ambulatory blood pressure. Pinkney JH, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):230–3

24–h ambulatory blood pressure, daytime and nighttime urinary albumin and retinol–binding protein excretion in type I diabetic patients. Pontuch P, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):234–6

Do the effects of blood pressure control on the progression of diabetic nephropathy depend on disease stage? Katagiri T, et al. **Tohoku J Exp Med** 1995 Aug;176(4):219–25

[Renal hemodynamics and albuminuria in patients with arterial hypertension] Stříbrná J, et al. **Cas Lek Cesk** 1995 Dec 6;134(23):749–51 (Eng. Abstr.) **(Cze)**

[Microalbuminuria in patients with glomerulonephritis in remission] Havrda M, et al. **Vnitr Lek** 1996 Apr; 42(4):229–33 (Eng. Abstr.) **(Cze)**

[Microalbuminuria and non–insulin–dependent diabetes: practical interpretation and therapeutic consequences] Bouhanick B, et al. **Diabete Metab** 1995 Oct;21(4):295–8 (20 ref.) **(Fre)**

[Microalbuminuria in clinical practice] Bar J, et al. **Harefuah** 1995 Jun 15;128(12):797–800 (40 ref.) **(Heb)**

[Diurnal changes in blood pressure, albuminuria and urinary excretion of retinol–binding protein in type I diabetics] Pontuch P, et al. **Vnitr Lek** 1996 Jan;42(1):3–6 (Eng. Abstr.) **(Slo)**

BLOOD

Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Kario K, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):455–61

Elevated plasma levels of vascular cell adhesion molecule–1 (VCAM–1) in diabetic patients with microalbuminuria: a marker of vascular dysfunction and progressive vascular disease. Schmidt AM, et al. **Br J Haematol** 1996 Mar; 92(3):747–50

COMPLICATIONS

Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the Hypertension and Ambulatory Recording Venetia Study (HARVEST Study). Palatini P, et al. **Am J Hypertens** 1996 Apr;9(4 Pt 1):334–41

Evidence of impaired glomerular charge selectivity in nondiabetic subjects with microalbuminuria: relevance to cardiovascular disease. Kofoed–Enevoldsen A, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):450–4

Albuminuria, insulin resistance and dyslipidaemia in Chinese patients with non–insulin–dependent diabetes (NIDDM). Chan JC, et al. **Diabet Med** 1996 Feb;13(2):150–5

Microalbuminuria and severity of diabetic retinopathy in type 1 diabetic patients: association and relationship with some risk factors. Crimi S, et al. **Diabete Metab** 1995 Dec; 21(6):440–5

Plasma and urine malondialdehyde levels in non–insulin–dependent diabetic patients with and without microalbuminuria. Ozben T, et al. **Int J Clin Lab Res** 1995; 25(3):162–4

Microalbuminuria in obese patients with or without hypertension. Valensi P, et al. **Int J Obes Relat Metab Disord** 1996 Jun;20(6):574–9

Prevalence of microalbuminuria, lipoprotein (a) and coronary artery disease in the lipid clinic. Cummings MH, et al. **J Clin Pathol** 1996 Jan;49(1):19–23

Comparison of ramipril and nitrendipine [letter; comment] Chan JC, et al. **J Hum Hypertens** 1995 Nov;9(11):931. Comment on: J Hum Hypertens 1995 Feb;9(2):131–5.

Apolipoprotein B independently predicts progression of very–low–level albuminuria in insulin–dependent diabetes mellitus. Watts GF, et al. **Metabolism** 1996 Sep; 45(9):1101–7

Microalbuminuria as a marker of cardiovascular and renal disease in essential hypertension. Bigazzi R, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:10–4 (58 ref.)

Prevalence of micro– and macroalbuminuria and their relationship with other cardiovascular risk factors in essential hypertension. Pontremoli R, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:6–9

[Arterial pressure and urinary excretion of albumin in adults with sickle cell disease] Foucan L, et al. **Presse Med** 1995 Oct 21;24(31):1428–32 (Eng. Abstr.) **(Fre)**

[Nephropathy and microalbuminuria in type II diabetes] Mur Martí T, et al. **Aten Primaria** 1995 Nov 30;16(9):516–24 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Microalbuminuria as an early predictor of hypertensive complications in pregnant women at high risk. Bar J, et al. **Am J Kidney Dis** 1996 Aug;28(2):220–5

Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation [see comments] Kiberd BA, et al. **BMJ** 1995 Dec 16;311(7020):1595–9. Comment in: BMJ 1996 Jun 1;312(7043):1420–1.

Microalbuminuria: a predictor of pregnancy–induced hypertension. Das V, et al. **Br J Obstet Gynaecol** 1996 Sep; 103(9):928–30

Microalbuminuria or micro–alpha–1–microglobulinuria: which one is better predictor of the development of the secondary nephropathy? [letter] Marczewski KT, et al. **Clin Nephrol** 1996 Feb;45(2):136–7

Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. Agrawal B, et al. **J Hypertens** 1996 Feb;14(2):223–8

The development and validation of a competitive, microtiter plate enzymeimmunoassay for human albumin in urine. Akman S, et al. **J Immunoassay** 1995 Aug;16(3):279–96

ACE inhibitors and diabetics with albuminuria [letter; comment] Wills CJ, et al. **Lancet** 1995 Dec 16; 346(8990):1638. Comment on: Lancet 1995 Oct 21;346(8982):1080–4.

Surveillance for complications of diabetes: don't wait for symptoms before intervening. Hirsch IB. **Postgrad Med** 1996 Mar;99(3):147–55, 159–62 (24 ref.)

[How to evaluate microalbuminuria? (editorial)] Mundet Tuduri X, et al. **Aten Primaria** 1996 Feb 29;17(3):175–6 **(Spa)**

DRUG THERAPY

Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Donnelly R, et al. **Am J Cardiol** 1996 Feb 22;77(6):26B–30B (33 ref.)

Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. Dominguez LJ, et al. **Am J Hypertens** 1995 Aug;8(8):808–14

Effect of low–dose ramipril on microalbuminuria in normotensive or mild hypertensive non–insulin–dependent diabetic patients. North–East Italy Microalbuminuria Study Group. Trevisan R, et al. **Am J Hypertens** 1995 Sep; 8(9):876–83

Decrease of exercise–induced microalbuminuria in patients with type I diabetes by means of an angiotensin–converting enzyme inhibitor. Inserra F, et al. **Am J Kidney Dis** 1996 Jan;27(1):26–33

Association of post–renal transplant erythrocytosis and microalbuminuria: response to angiotensin–converting enzyme inhibition. Mulhern JG, et al. **Am J Nephrol** 1995; 15(4):318–22

Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long–acting calcium antagonists. Bakris GL, et al. **Ann Intern Med** 1996 Aug 1;125(3):201–4

Effects of long–term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4–year, prospective, randomized study. Sano T, et al. **Diabet Med** 1996 Feb;13(2):120–4

Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. Abbott K, et al. **J Clin Pharmacol** 1996 Mar;36(3):274–9

Dr. Tian Naigeng's experience in treatment of albuminuria in chronic nephritis. Wu J. **J Tradit Chin Med** 1995 Sep; 15(3):170–3

ACE inhibitors and diabetics with albuminuria. The DIABHYCAR Study Group [letter; comment] Marre M, et al. **Lancet** 1995 Dec 16;346(8990):1638. Comment on: Lancet 1995 Oct 21;346(8982):1080–4.

Cyclosporin A reduces albuminuria in experimental anti–GBM nephritis independently from changes in GFR. Schrijver G, et al. **Nephrol Dial Transplant** 1995; 10(7):1149–54

Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Tamsma JT, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):182–5

Clinical effect of the anti–platelet drug, dilazep dihydrochloride, in patients at the microalbuminuric stage of diabetic nephropathy––a multi–center study. Koide H, et al. **Nippon Jinzo Gakkai Shi** 1995 Nov;37(11):644–8

Increased plasma thrombin–antithrombin III complex levels in non–insulin dependent diabetic patients with albuminuria are reduced by ethyl icosapentatenoate. Shimizu H, et al. **Thromb Haemost** 1995 Nov;74(5):1231–4

[Comparison of treatment effects with an angiotensin converting enzyme inhibitor––lisinopril and a calcium blocker––nifedipine retard on urinary albumin excretion in patients with non–complicated essential hypertension] Widecka K, et al. **Pol Arch Med Wewn** 1995 Feb; 93(2):135–42 (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Microalbuminuria, cardiovascular risk factors, and insulin resistance in two populations with a high risk of type 2 diabetes mellitus. Hodge AM, et al. **Diabet Med** 1996 May; 13(5):441–9

Microalbuminuria in patients with NIDDM: an overview. Alzaid AA. **Diabetes Care** 1996 Jan;19(1):79–89 (136 ref.)

Prevalence and risk factors for micro– and macroalbuminuria in an Italian population–based cohort of NIDDM subjects. Bruno G, et al. **Diabetes Care** 1996 Jan;19(1):43–7

Diabetes in urban African–Americans. II. High prevalence of microalbuminuria and nephropathy in African–Americans with diabetes. Goldschmid MG, et al. **Diabetes Care** 1995 Jul;18(7):955–61

Prevalence and associated features of albuminuria in Koreans with NIDDM. Lee KU, et al. **Diabetes Care** 1995 Jun; 18(6):793–9

A comparison of renal disease across two continents; the epidemiology of diabetes complications study and the EURODIAB IDDM Complications Study. Lloyd CE, et al. **Diabetes Care** 1996 Mar;19(3):219–25

Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Niskanen LK, et al. **Diabetes Care** 1996 May;19(5):486–93

24–h blood pressure recordings in type I diabetic patients. Hansen KW, et al. **J Diabetes Complications** 1995 Oct–Dec; 9(4):237–40

Prediabetic blood pressure and familial predisposition to renal disease in Pima Indians with non–insulin–dependent diabetes mellitus. Nelson RG, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):212–4

Albuminuria in normotensive and hypertensive individuals attending offices of general practitioners. Hörner D, et al. **J Hypertens** 1996 May;14(5):655–60

Microalbumin as a marker of premature delivery. Massé J, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):661–3

[Microalbuminuria and macrovascular risk factors in insulin–dependent diabetic children] Bravo Ríos EL, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):19–25 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Racial differences in the prevalence of microalbuminuria in hypertension. Summerson JH, et al. **Am J Kidney Dis** 1995 Oct;26(4):577–9

ETIOLOGY

Accumulation of glycated albumin in end–stage renal failure: evidence for the principle of "physiological microalbuminuria". Donnelly SM. **Am J Kidney Dis** 1996 Jul;28(1):62–6

Microalbuminuria: a sensitive indicator of non–renal disease? Gosling P. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):439–41

Is microalbuminuria progressive? Shield JP, et al. **Arch Dis Child** 1995 Dec;73(6):512–4

Long–term renoprotective effect of angiotensin–converting enzyme inhibition in non–insulin–dependent diabetes mellitus. A 7–year follow–up study [see comments] Ravid M, et al. **Arch Intern Med** 1996 Feb 12;156(3):286–9. Comment in: Arch Intern Med 1996 Feb 12;156(3):239–40.

Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. Microalbuminuria Collaborative Study Group, United Kingdom [see comments] **BMJ** 1995 Oct 14;311(7011):973–7. Comment in: BMJ 1996 Jan 27;312(7025):253; discussion 254. Comment in: BMJ 1996 Jan 27;312(7025):253–4. Comment in: BMJ 1996 Jan 27;312(7025):254.

Effect of intensive treatment in insulin dependent diabetes mellitus with microalbuminuria. Interpretation of study's results is open to criticism [letter; comment] Bender R, et al. **BMJ** 1996 Jan 27;312(7025):254. Comment on: BMJ 1995 Oct 14;311(7011):973–7.

Effect of intensive treatment in insulin dependent diabetes mellitus with microalbuminuria. Sample size was too small

[letter; comment] Chaturvedi N, et al. **BMJ** 1996 Jan 27; 312(7025):253; discussion 254. Comment on: BMJ 1995 Oct 14;311(7011):973–7.

Effect of intensive treatment in insulin dependent diabetes mellitus with microalbuminuria. Work in non-insulin diabetes corroborates study's findings [letter; comment] Davison R, et al. **BMJ** 1996 Jan 27;312(7025):253–4. Comment on: BMJ 1995 Oct 14;311(7011):973–7.

Microalbuminuria: a marker of systemic disease. Gosling P. **Br J Hosp Med** 1995 Sep 20–Oct 3;54(6):285–90 (20 ref.)

Urinary microalbumin as a marker for intermittent claudication. Matsushita M, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):421–4

Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. Mahmud N, et al. **Gut** 1996 Jan;38(1):99–103

Hypertension, hyperlipidemia, and abdominal obesity and the development of microalbuminuria in patients with non-insulin-dependent diabetes mellitus. Spangler JG, et al. **J Am Board Fam Pract** 1996 Jan–Feb;9(1):1–6

Estimated urinary albumin index: a predictor of microalbuminuria in type 2 diabetes. Okada S, et al. **J Int Med Res** 1996 Jan–Feb;24(1):47–58

U.K. Prospective Diabetes Study. XV: Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM. Dudley CR, et al. **Kidney Int** 1995 Dec;48(6):1907–11

Diabetes and hypertension. Australian Diabetes Society position statement [letter; comment] Mogyorosi A, et al. **Med J Aust** 1996 May 6;164(9):571–2. Comment on: Med J Aust 1995 Oct 2;163(7):372–5.

Effect of gonadectomy on the development of diabetes mellitus, hypertension, and albuminuria in the rat model. Iwase M, et al. **Metabolism** 1996 Feb;45(2):155–61

Different mediator systems in biphasic heterologous phase of anti-GBM nephritis in mice. Feith GW, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):599–607

Diabetic renal disease: microalbuminuria, implications and intervention. Savage MW, et al. **Nutrition** 1995 Nov–Dec; 11(6):761–4 (57 ref.)

[Microalbuminuria in rheumatoid arthritis] Nordin H, et al. **Ugeskr Laeger** 1996 May 27;158(22):3141–3 (Eng. Abstr.) **(Dan)**

[Microalbuminuria in diabetes mellitus] van Etten RW, et al. **Ned Tijdschr Geneeskd** 1995 Sep 9;139(36):1823–8 (72 ref.) **(Dut)**

[Microalbuminuria in diabetes mellitus—illness or symptom?] Müller WA. **Versicherungsmedizin** 1996 Jun 1;48(3):70–6 (84 ref.) (Eng. Abstr.) **(Ger)**

[Variations in microalbuminuria in essential hypertension treated with ACE inhibitors, calcium antagonists and their association] Abate D, et al. **Minerva Cardioangiol** 1995 Jul–Aug;43(7–8):303–7 (Eng. Abstr.) **(Ita)**

GENETICS

Association analyses of the polymorphisms of angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics. Ohno T, et al. **Metabolism** 1996 Feb;45(2):218–22

IMMUNOLOGY

Significance of anti-nuclear and anti-extracellular matrix autoantibodies for albuminuria in murine lupus nephritis; a longitudinal study on plasma and glomerular eluates in MRL/l mice. van Bruggen MC, et al. **Clin Exp Immunol** 1996 Jul;105(1):132–9

METABOLISM

Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. Deckert T, et al. **BMJ** 1996 Apr 6; 312(7035):871–4

Characteristics of the sodium/hydrogen exchange in non-insulin-dependent diabetic patients with microalbuminuria and hypertension. Zaidi KF, et al. **Clin Sci (Colch)** 1996 Jan;90(1):13–9

Reduction of leucocyte proteolytic enzyme activity in diabetic patients with microalbuminuria and proteinuria: its possible role in diabetic nephropathy. McLennan SV, et al. **Diabet Med** 1996 Feb;13(2):145–9

Indications of low sex hormone binding globulin (SHBG) in young females with type 1 diabetes, and an independent association to microalbuminuria. Rudberg S, et al. **Diabet Med** 1995 Sep;12(9):816–22

Reduced glomerular size- and charge-selectivity in clinically healthy individuals with microalbuminuria. Jensen JS, et al. **Eur J Clin Invest** 1995 Aug;25(8):608–14

Insulin resistance in microalbuminuric hypertension. Sites and mechanisms. Bianchi S, et al. **Hypertension** 1995 Nov; 26(5):789–95

Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat. Gin T, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):281–9

Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. Bigazzi R, et al. **J Hum Hypertens** 1995 Oct;9(10):827–33

Increased peritoneal permeability to albumin in streptozotocin diabetic rats. Shostak A, et al. **Kidney Int** 1996 Mar;49(3):705–14

Angiotensin-converting enzyme inhibition in experimental in-situ immune complex glomerulonephritis: influence on renal function, proteinuria, and morphology. Thaiss F, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):40–6

Is microalbuminuria in diabetes due to changes in glomerular heparan sulphate? [editorial] van den Born J, et al. **Nephrol Dial Transplant** 1995;10(8):1277–9

Effect of lipoid nephrosis cytokine on glomerular sulfated compounds and albuminuria. Garin EH. **Pediatr Nephrol** 1995 Oct;9(5):587–93

Equivalent effects of nicardipine and captopril on urinary albumin excretion of type 2, non-insulin-dependent diabetic subjects with mild to moderate hypertension. Bouhanick B. **Therapie** 1996 Jan–Feb;51(1):41–7

PATHOLOGY

A quantitative ultrastructural study of juxtaglomerular arterioles in IDDM patients with micro- and normoalbuminuria. Osterby R, et al. **Diabetologia** 1995 Nov;38(11):1320–7

PHYSIOPATHOLOGY

The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Laffel LM, et al. **Am J Med** 1995 Nov;99(5):497–504

Peri-operative assessment of glomerular permeability. De Gaudio AR, et al. **Anaesthesia** 1995 Sep;50(9):810–2

Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. **Diabetologia** 1996 May;39(5):587–93

Angiotensin-converting enzyme (ACE) gene polymorphism in type II diabetic patients with increased albumin excretion rate. Panagiotopoulos S, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):272–6

Lack of correlation between microalbuminuria and endothelial function in essential hypertensive patients. Taddei S, et al. **J Hypertens** 1995 Sep;13(9):1003–8

Prognostic significance of albuminuria for the development of nephropathy. Viberti GF. **J Hypertens Suppl** 1995 Aug; 13(2):S87–9 (15 ref.)

Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients. Wirta OR, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):449–56

PREVENTION & CONTROL

Differing effects of antihypertensive agents on urinary albumin excretion. Weir MR. **Am J Nephrol** 1996; 16(3):237–45 (69 ref.)

Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition. Allen TJ, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):318–22

Prevention of diabetic renal disease with special reference to microalbuminuria [see comments] Mogensen CE, et al. **Lancet** 1995 Oct 21;346(8982):1080–4 (49 ref.). Comment in: Lancet 1995 Dec 16;346(8990):1638.

Effect of gonadectomy on the development of diabetes mellitus, hypertension, and albuminuria in the rat model. Iwase M, et al. **Metabolism** 1996 Feb;45(2):155–61

Sodium depletion prevents albuminuria in hypertensive rats. Jyothirmayi GN, et al. **Res Commun Mol Pathol Pharmacol** 1995 Oct;90(1):115–24

URINE

Urinary excretions of high molecular weight beta-thromboglobulin and albumin are independently associated with coronary heart disease in women, a nested case-control study of middle-aged women in the Diagnostisch Onderzoek Mammacarcinoom (DOM) Cohort, Utrecht, Netherlands. Gorgels WJ, et al. **Am J Epidemiol** 1995 Dec 1;142(11):1157–64

An in-depth examination of the excretion of albumin and other sensitive markers of renal damage in mild hypertension. Mueller PW, et al. **Am J Hypertens** 1995 Nov;8(11):1072–82

Relationship of steady state and ambulatory blood pressure variability to left ventricular mass and urinary albumin excretion in essential hypertension. Veerman DP, et al. **Am J Hypertens** 1996 May;9(5):455–60

Renal function (microalbuminuria). Ward KM. **Anal Chem** 1995 Jun 15;67(12):383R–391R (144 ref.)

Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Bruno G, et al. **Ann Intern Med** 1996 Oct 15;125(8):653–7

Interference by calcium in the measurement of urinary "microalbumins". Taylor K, et al. **Clin Chem** 1996 Feb; 42(2):332–4

Intra-individual variation of overnight urinary albumin excretion in clinically healthy middle-aged individuals. Jensen JS. **Clin Chim Acta** 1995 Dec 15;243(1):95–9

Urinary albumin fragments as a new clinical parameter for the early detection of diabetic nephropathy. Yagame M, et al. **Intern Med** 1995 Jun;34(6):463–8

Microalbuminuria in non-insulin dependent diabetes and essential hypertension—a marker of severe disease [letter] Ahmed S. **J Assoc Physicians India** 1995 Jul;43(7):517–8

Urinary microalbumin measurement using a homogeneous liposomal immunoassay. Frost SJ, et al. **J Immunol Methods** 1996 Aug 14;194(2):105–11

Estimated urinary albumin index: a predictor of microalbuminuria in type 2 diabetes. Okada S, et al. **J Int Med Res** 1996 Jan–Feb;24(1):47–58

Lack of a relationship between urinary albumin excretion rate and insulin resistance in patients with non-insulin-dependent diabetes mellitus. Rizvi A, et al. **Metabolism** 1996 Sep;45(9):1062–4

Subclinical signs of kidney dysfunction following short exposure to silica in the absence of silicosis. Hotz P, et al. **Nephron** 1995;70(4):438–42

Effects of moderate changes in protein intake on urinary albumin excretion in type I diabetic patients. Percheron C, et al. **Nutrition** 1995 Jul–Aug;11(4):345–9

Urinary albumin excretion in Spanish children. Niño Jesus Group. Sanchez-Bayle M, et al. **Pediatr Nephrol** 1995 Aug; 9(4):428–30

Urinary excretion of albumin and transferrin in lithium maintenance treatment: daily versus alternate-day lithium dosing schedule. Jensen HV, et al. **Psychopharmacology (Berl)** 1995 Dec;122(3):317–20

[Screening for microalbuminuria in diabetic patients using a single voided urine specimen] Tulokas T. **Duodecim** 1994; 110(9):883–7 **(Fin)**

[Diabetic nephropathy: significance of microalbuminuria and proteinuria in Type I and Type II diabetes mellitus] Lehmann R, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1265–71 (53 ref.) (Eng. Abstr.) **(Ger)**

[Urinary albumin excretion increases during an acute myocardial infarct especially in patients who develop heart failure] Berton G, et al. **G Ital Cardiol** 1995 Aug; 25(8):999–1009 (Eng. Abstr.) **(Ita)**

[Microalbuminuria—laboratory methods and implications] Kumasaka K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:129–32 (12 ref.) **(Jpn)**

ALBUTEROL

ADMINISTRATION & DOSAGE

Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Steffensen I, et al. **Allergy** 1995 Aug; 50(8):657–63

Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Colice GL. **Am J Med** 1996 Jan 29;100(1A):11S–18S

Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Cockcroft DW, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1485–9

Dose–response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients. Dhand R, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):388–93

Albuterol delivery in a model of mechanical ventilation. Comparison of metered-dose inhaler and nebulizer efficiency. Diot P, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1391–4

Aerosol delivery from a metered-dose inhaler during mechanical ventilation. An in vitro model. Fink JB, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):382–7

The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Inman MD, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):65–9

Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children. Skoner DP, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):462–8

Treatment of acute bronchospasm with beta-adrenergic agonist aerosols delivered by a nasal bilevel positive airway pressure circuit. Pollack CV Jr, et al. **Ann Emerg Med** 1995 Nov;26(5):552–7

Effects of the beta-adrenergic agonist salbutamol and its withdrawal on protein metabolism of lambs. del Barrio AS, et al. **Ann Nutr Metab** 1995;39(5):317–24

Drug delivery in asthma: a comparison of spacers with a jet nebuliser. Gibson PG, et al. **Aust N Z J Med** 1995 Aug; 25(4):324–9

Determinants of aerosolized albuterol delivery to mechanically ventilated infants. Coleman DM, et al. **Chest** 1996 Jun;109(6):1607–13

Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand [see comments] Hess D, et al. **Chest** 1996 Aug;110(2):498–505. Comment in: Chest 1996 Aug;110(2):316–7.

Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Newhouse MT, et al. **Chest** 1996 Sep;110(3):595–603

Inhalation of single vs multiple metered-dose bronchodilator actuations from reservoir devices. An in vitro study. Rau JL, et al. **Chest** 1996 Apr;109(4):969–74

Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults. Shrestha M, et al. **Chest** 1996 Jul;110(1):42–7

A week-long course of inhaled beta-agonist or anticholinergic agent may reduce dyspnea during exercise in COPD [letter] Teramoto S, et al. **Chest** 1996 Jun; 109(6):1666–7

Intranasal salbutamol has no effect on mucociliary clearance in normal subjects. Roberts DN, et al. **Clin Otolaryngol** 1995 Jun;20(3):246–8

Albuterol delivery by metered-dose inhaler in a mechanically ventilated pediatric lung model. Garner SS, et al. **Crit Care Med** 1996 May;24(5):870–4

Reduced dose salbutamol in comparison with standard dosage for symptom relief in asthma. Yates DH, et al. **Eur Respir J** 1995 Nov;8(11):1847–51

Treatment of nocturnal asthma by addition of oral slow-release albuterol to standard treatment in stable asthma patients. Van Keimpema AR, et al. **J Asthma** 1996; 33(2):119–24

Oral albuterol for acute cough. Hickner JM. **J Fam Pract** 1996 Feb;42(2):111–2

A randomized controlled trial of oral albuterol in acute cough. Littenberg B, et al. **J Fam Pract** 1996 Jan; 42(1):49–53

MDI with spacer vs nebulizer in pediatric asthma. Shaughnessy AF, et al. **J Fam Pract** 1996 Jan;42(1):29–30

Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. Tal A, et al. **J Pediatr** 1996 Apr;128(4):479–84

Comparison of non-chlorofluorocarbon-containing salbutamol and conventional inhaler [letter] Desager KN, et al. **Lancet** 1996 Jul 20;348(9021):200–1

Probability of particle and salbutamol deposition in the respiratory tract: comparison between MDI and Autohaler. Terzano C, et al. **Monaldi Arch Chest Dis** 1996 Jun; 51(3):236–42

Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network [see comments] Drazen JM, et al. **N Engl J Med** 1996 Sep 19;335(12):841–7. Comment in: N Engl J Med 1996 Sep 19;335(12):886–8.

Inhaled beta 2-agonists in the treatment of asthma [editorial; comment] O'Byrne PM, et al. **N Engl J Med** 1996 Sep 19;335(12):886–8. Comment on: N Engl J Med 1996 Sep 19;335(12):841–7.

Particle size distribution of single and multiple sprays of salbutamol metered-dose inhalers (MDIs). Graham SJ, et al. **Pharm Res** 1995 Sep;12(9):1380–4

Loading effect on particle size measurements by inertial sampling of albuterol metered dose inhalers. Nasr MM, et al. **Pharm Res** 1995 Nov;12(11):1677–81

A comparison of the clinical efficacy and patient acceptability of terbutaline Turbuhaler and salbutamol Rotahaler, in adult patients with asthma. Gioulekas D, et al. **Respir Med** 1996 Apr;90(4):205–9

Emergency treatment of asthma [letter; comment] Barry PW, et al. **Thorax** 1995 Jul;50(7):814. Comment on: Thorax 1995 Jan;50(1):1–2. Comment on: Thorax 1995 Jan;50(1):79–80.

Factors affecting total and "respirable" dose delivered by a salbutamol metered dose inhaler. Everard ML, et al. **Thorax** 1995 Jul;50(7):746–9

Inhalation therapy with magnesium sulfate and salbutamol sulfate in bronchial asthma. Meral A, et al. **Turk J Pediatr** 1996 Apr–Jun;38(2):169–75

[Salmeterol improves the control of disease in patients with moderate asthma. A comparative study of inhaled salmeterol 50 mg and salbutamol depot tablets 8 mg, both administered twice daily] Ringbaek TJ, et al. **Ugeskr Laeger** 1996 Jul 1;158(27):3940–3 (Eng. Abstr.) **(Dan)**

[Effect duration and treatment effectiveness of salmeterol, fenoterol and salbutamol in severe forms of respiratory tract obstruction] Vollmer M, et al. **Pneumologie** 1995 Oct; 49(10):528–34 (Eng. Abstr.) **(Ger)**

[A comparison of two delivery methods on the bronchodilator effects of beta 2-stimulant] Kishida M, et al. **Arerugi** 1996 Jun;45(6):542–5 (Eng. Abstr.) **(Jpn)**

[The treatment of bronchial asthma with powdered salbutamol and powdered beclomethasone dipropionate] Basacopol A, et al. **Pneumoftiziologia** 1995 Jan–Jun; 44(1–2):25–8 (Eng. Abstr.) **(Rum)**

[Effect on FEV1 induced by the administration of salbutamol with aerochamber and metered dose inhaler] Vázquez Aceves ML, et al. **Rev Alerg Mex** 1995 May–Jun;42(3):41–4 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Treatment of proctalgia fugax with salbutamol inhalation. Eckardt VF, et al. **Am J Gastroenterol** 1996 Apr; 91(4):686–9

Arrhythmogenic effects of combined orally administered theophylline and albuterol in patients with chronic obstructive pulmonary disease. Cukier A, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2869–77

A case of life-threatening lactic acidosis after smoke inhalation – interference between beta-adrenergic agents and ethanol? Taboulet P, et al. **Intensive Care Med** 1995 Dec;21(12):1039–41

Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. Bhagat R, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):47–52

Exacerbation of psychosis associated with inhaled albuterol [letter] Martin W, et al. **J Clin Psychopharmacol** 1995 Dec; 15(6):446–7

Paradoxical bronchoconstriction with salbutamol [letter] Wheatley G, et al. **J R Army Med Corps** 1995 Jun; 141(2):113

Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus. Craig VL, et al. **Pediatr Emerg Care** 1996 Feb;12(1):1–5

[Acute myopathy in an asthmatic patient treated with corticoids and muscle relaxants in the intensive care unit] Sangla I, et al. **Presse Med** 1996 Feb 24;25(7):284–6 (Eng. Abstr.) **(Fre)**

[Cardiac monitoring in bronchial asthma patients taking salben] Kakhnovskii IM, et al. **Ter Arkh** 1996;68(3):50–2 **(Rus)**

ANALOGS & DERIVATIVES

The efficacy and safety of inhaled salmeterol 50 microg bd in older patients with reversible airflow obstruction. Starke ID, et al. **Age Ageing** 1996 Jan;25(1):67–71

The first 20 minutes after a single dose of inhaled salmeterol in asthmatic children. Barbato A, et al. **Allergy** 1995 Jun; 50(6):506–10

A 4-week comparison of salmeterol and terbutaline in adult asthma. Hermansson BA, et al. **Allergy** 1995 Jul;50(7):551–8

A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma. Leblanc P, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):324–8

Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. Meijer GG, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1887–92

Functional and binding characteristics of long-acting beta 2-agonists in lung and heart. Roux FJ, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1489–95

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Woolcock A, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1481–8

Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma. Bousquet J, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):189–94

Safety of salmeterol in the maintenance treatment of asthma [see comments] Nathan RA, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):243–8. Comment in: Ann Allergy Asthma Immunol 1995 Sep;75(3):209–11.

Salmeterol xinafoate in children on high dose inhaled steroids. Russell G, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):423–8

Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconstriction. Schaanning J, et al. **Ann Allergy Asthma Immunol** 1996 Jan;76(1):57–60

Salmeterol for the treatment of asthma [editorial; comment] Weinberger M. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):209–11 (26 ref.). Comment on: Ann Allergy Asthma Immunol 1995 Sep;75(3):243–8.

Salmeterol for emphysema? [letter] Healey D. **Aust Fam Physician** 1996 Aug;25(8):1340

Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro. Anderson R, et al. **Br J Pharmacol** 1996 Apr;117(7):1387–94

Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle. Ellis KE, et al. **Br J Pharmacol** 1995 Nov; 116(5):2510–6

Rapid onset of tolerance to the bronchoprotective effect of salmeterol [see comments] Bhagat R, et al. **Chest** 1995 Nov; 108(5):1235–9. Comment in: Chest 1996 Jul;110(1):305–6. Comment in: Chest 1996 Jul;110(1):306.

Loss of bronchoprotection with salmeterol [letter; comment] D'Urzo AD. **Chest** 1996 Jul;110(1):306. Comment on: Chest 1995 Nov;108(5):1235–9.

Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol [see comments] Kalra S, et al. **Chest** 1996 Apr;109(4):953–6. Comment in: Chest 1996 Apr;109(4):862–4.

Asthma mortality and beta-agonists [letter; comment] Skorodin MS. **Chest** 1995 Dec;108(6):1768. Comment on: Chest 1995 Apr;107(4):1116–24.

Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics. Di Lorenzo G, et al. **Clin Exp Allergy** 1995 Oct;25(10):951–6

Efficacy and safety of salmeterol in childhood asthma. Lenney W, et al. **Eur J Pediatr** 1995 Dec;154(12):983–90

Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group. Boyd G. **Eur Respir J** 1995 Sep; 8(9):1494–8

Overnight protection by inhaled salmeterol on exercise-induced asthma in children. Carlsen KH, et al. **Eur Respir J** 1995 Nov;8(11):1852–5

Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses. Pizzichini MM, et al. **Eur Respir J** 1996 Mar;9(3):449–55

Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life [see comments] Rutten-van Mölken MP, et al. **Eur Respir J** 1995 Jun;8(6):888–98. Comment in: Eur Respir J 1995 Jun;8(6):885–7.

Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. Verberne AA, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):938–46

Comparison of Diskus inhaler, a new multidose powder inhaler, with Diskhaler inhaler for the delivery of salmeterol to asthmatic patients. Canadian Study Group. Boulet LP, et al. **J Asthma** 1995;32(6):429–36

Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. Mann RD, et al. **J Clin Epidemiol** 1996 Feb;49(2):247–50

Determination of salmeterol in metered-dose and dry-powder inhalers by reversed-phase high performance liquid chromatography. Nayak VG, et al. **J Pharm Biomed Anal** 1996 Feb;14(4):511–3

Bronchodilation subsensitivity to salbutamol after salmeterol [letter; comment] Barnes N. **Lancet** 1995 Oct 7; 346(8980):968; discussion 968–9. Comment on: Lancet 1995 Jul 22;346(8969):201–6.

Bronchodilation subsensitivity to salbutamol after salmeterol [letter; comment] Ng HW. **Lancet** 1995 Oct 7; 346(8980):968; discussion 968–9. Comment on: Lancet 1995 Jul 22;346(8969):201–6.

Bronchodilation subsensitivity to salbutamol after salmeterol [letter] Weinberger M. **Lancet** 1995 Oct 7;346(8980):968–9

Relaxation kinetics of formoterol and salmeterol in the guinea pig trachea in vitro. Anderson P, et al. **Lung** 1996; 174(3):159–70

Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lindén A, et al. **Lung** 1996;174(1):1–22 (52 ref.)

Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. Clark RB, et al. **Mol Pharmacol** 1996 Jan;49(1):182–9

Comparison of duration of agonist action at beta 1- and beta 2- adrenoceptors in C6 glioma cells: evidence that the long duration of action of salmeterol is specific to the beta 2-adrenoceptor. McCrea KE, et al. **Mol Pharmacol** 1996 May;49(5):927–37

Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Grove A, et al. **Thorax** 1996 Jan;51(1):54–8

Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol. Grove A, et al. **Thorax** 1996 Jun;51(6):585–9

Salmeterol in smokers with COPD [letter; comment] Lipworth BJ. **Thorax** 1996 Jan;51(1):110. Comment on: Thorax 1995 Jul;50(7):750–4.

Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study [see comments] Ulrik CS. **Thorax** 1995 Jul; 50(7):750–4. Comment in: Thorax 1996 Jan;51(1):110.

Long-acting beta 2-agonists and their role in asthma management. Galant SP. **West J Med** 1995 Oct;163(4):372

[Salmeterol improves the control of disease in patients with moderate asthma. A comparative study of inhaled salmeterol 50 mg and salbutamol depot tablets 8 mg, both administered twice daily] Ringbaek TJ, et al. **Ugeskr Laeger** 1996 Jul 1;158(27):3940–3 (Eng. Abstr.) **(Dan)**

[The effect of salmeterol in the treatment of smokers with chronic obstructive lung disease] Ulrik CS. **Ugeskr Laeger** 1996 Jun 17;158(25):3604–7 (Eng. Abstr.) **(Dan)**

[Salmeterol no longer banned in Olympic Games (letter)] van Dam JG. **Ned Tijdschr Geneeskd** 1996 Aug 3; 140(31):1612 **(Dut)**

[Effect duration and treatment effectiveness of salmeterol, fenoterol and salbutamol in severe forms of respiratory tract obstruction] Vollmer M, et al. **Pneumologie** 1995 Oct; 49(10):528–34 (Eng. Abstr.) **(Ger)**

[Effect of 16-week use of salmeterol on ECP levels, pulmonary function tests and bronchial hyperreactivity in patients with chronic obstructive lung disease] Chazan R, et al. **Pol Tyg Lek** 1995 Oct;50(40–44):48–9, 63 (Eng. Abstr.) **(Pol)**

[Salmeterol-induced enuresis in children] **Lakartidningen** 1996 May 22;93(21):2083 **(Swe)**

BLOOD

Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis. Demnati R, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):319–24

Effect of hypoxia and beta 2-agonists on the activity of the renin-angiotensin system in normal subjects. Millar EA, et al. **Clin Sci (Colch)** 1995 Sep;89(3):273–6

Determination of salbutamol enantiomers in human plasma and urine by chiral high-performance liquid chromatography. Boulton DW, et al. **J Chromatogr B Biomed Appl** 1995 Oct 6;672(1):103–9

CHEMISTRY

Preparation and in vitro dissolution of salbutamol sulphate microcapsules and tabletted microcapsules. Yazan Y, et al. **J Microencapsul** 1995 Nov–Dec;12(6):601–7

A microcalorimetric investigation of the interaction of surfactants with crystalline and partially crystalline salbutamol sulphate in a model inhalation aerosol system. Blackett PM, et al. **Pharm Res** 1995 Nov;12(11):1689–93

The distribution of oleic acid between salbutamol base drug and different propellant blends. Eriksson PM, et al. **Pharm Res** 1995 May;12(5):715–9

Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Ward GH, et al. **Pharm Res** 1995 May;12(5):773–9

DIAGNOSTIC USE

[Responder and non-responder in the bronchodilator test?] Vollmer M, et al. **Pneumologie** 1995 Nov;49(11):584–9 (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

Analysis of beta-agonists in urine and tissues by capillary gas chromatography–mass spectrometry: in vivo study of salbutamol disposition in calves. Montrade MP, et al. **Food Addit Contam** 1995 Sep–Oct;12(5):625–36

Lung bioavailability of generic and innovator salbutamol MDIs [letter; comment] Chrystyn H, et al. **Thorax** 1996 Jun;51(6):658. Comment on: Thorax 1996 Mar;51(3):325–6.

Lung bioavailability of generic and innovator salbutamol metered dose inhalers [see comments] Clark DJ, et al. **Thorax** 1996 Mar;51(3):325–6. Comment in: Thorax 1996 Jun;51(6):658.

PHARMACOLOGY

Salbutamol reduces pulmonary neutrophil sequestration of platelet-activating factor in humans. Masclans JR, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):529–32

Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers. Kiely DG, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):313–8

Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle. Ellis KE, et al. **Br J Pharmacol** 1995 Nov; 116(5):2510–6

The lack of a role for potassium channel opening in the action of relaxin in the rat isolated uterus; a comparison with levcromakalim and salbutamol. Hughes SJ, et al. **Br J Pharmacol** 1996 Apr;117(7):1435–42

Calcium mobilization and isometric tension in bovine tracheal smooth muscle: effects of salbutamol and histamine. Hirsh AJ, et al. **Cell Calcium** 1996 Jan;19(1):73–81

Partial vs full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol. Bremner P, et al. **Chest** 1996 Apr;109(4):957–62

Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics. Di Lorenzo G, et al. **Clin Exp Allergy** 1995 Oct;25(10):951–6

Intranasal salbutamol has no effect on mucociliary clearance in normal subjects. Roberts DN, et al. **Clin Otolaryngol** 1995 Jun;20(3):246–8

Effect of oral digoxin, topical ouabain and salbutamol on transepithelial nasal potential difference in patients with cystic fibrosis. Peckham DG, et al. **Clin Sci (Colch)** 1995 Sep;89(3):277–84

Beta-adrenergic mechanisms in the nasal mucosa vascular bed. Lacroix JS, et al. **Eur Arch Otorhinolaryngol** 1995; 252(5):298–303

Salbutamol-induced airway hyperreactivity in guinea pigs is not due to a loss of its bronchodilator effect. Buchheit KH, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):85–8

Influence of salbutamol and isoproterenol on the production of TNF and reactive oxygen species by bovine alveolar macrophages and calcitriol differentiated HL-60 cells. Gu Y, et al. **Immunopharmacol Immunotoxicol** 1996 Feb; 18(1):115–28

Helium/oxygen flow volume curves in normal Indian males > 50 year, and the effect of bronchodilator aerosols on airflow variables in this subject group. Dikshit MB, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):330–8

Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists. Torphy TJ, et al. **J Biol Chem** 1995 Oct 6;270(40):23598–604

Interaction of salbutamol and galanin on both basal and growth hormone releasing hormone-stimulated growth hormone secretion in humans. Arvat E, et al. **J Endocrinol Invest** 1995 May;18(5):324–8

Effect of two beta 2-agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis. Giustina A, et al. **J Endocrinol Invest** 1995 Dec;18(11):847–52

Bronchodilation subsensitivity to salbutamol after salmeterol [letter; comment] Barnes N. **Lancet** 1995 Oct 7; 346(8980):968; discussion 968–9. Comment on: Lancet 1995 Jul 22;346(8969):201–6.

Bronchodilation subsensitivity to salbutamol after salmeterol [letter; comment] Ng HW. **Lancet** 1995 Oct 7; 346(8980):968; discussion 968–9. Comment on: Lancet 1995 Jul 22;346(8969):201–6.

Bronchodilation subsensitivity to salbutamol after salmeterol [letter] Weinberger M. **Lancet** 1995 Oct 7;346(8980):968–9

Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lindén A, et al. **Lung** 1996;174(1):1–22 (52 ref.)

The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Caruso JF, et al. **Med Sci Sports Exerc** 1995 Nov;27(11):1471–6

Effects of oral albuterol on serum lipids and carbohydrate metabolism in healthy men. Maki KC, et al. **Metabolism** 1996 Jun;45(6):712–7

Relaxant effects of pituitary adenylate cyclase activating polypeptide (PACAP) on epithelium-intact and -denuded guinea-pig trachea: a comparison with vasoactive intestinal peptide (VIP). Conroy DM, et al. **Neuropeptides** 1995 Sep; 29(3):121–7

Acute hyperoxic injury attenuates the relaxing effects of "loop" diuretics and salbutamol on large airways of newborn guinea pigs. Marinkovich GA, et al. **Pediatr Res** 1995 Sep;38(3):280–5

Salbutamol and high-intensity treadmill running in nonasthmatic highly conditioned athletes. Heir T, et al. **Scand J Med Sci Sports** 1995 Aug;5(4):231–6

Beta 2 agonist/antagonist activity of salbutamol [letter; comment] Jonkers RE, et al. **Thorax** 1995 Nov; 50(11):1227–8. Comment on: Thorax 1995 Feb;50(2):134–8.

THERAPEUTIC USE

Terbutaline vs albuterol for out-of-hospital respiratory distress: randomized, double-blind trial. Zehner WJ Jr, et al. **Acad Emerg Med** 1995 Aug;2(8):686–91

Effect of albuterol treatment on subsequent dialytic potassium removal. Allon M, et al. **Am J Kidney Dis** 1995 Oct; 26(4):607–13

Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. Levin DC, et al. **Am J Med** 1996 Jan 29;100(1A):40S–48S

Isoetharine versus albuterol for acute asthma: greater immediate effect, but more side effects. Shrestha M, et al. **Am J Med** 1996 Mar;100(3):323–7

Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Belman MJ, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):967–75

The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. Hordvik NL, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):156–60

A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma. Leblanc P, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):324–8

Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children. Skoner DP, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):462–8

The clinical relevance of tachyphylaxis to beta 2 agonists. Barnes NC. **Br J Clin Pract Symp Suppl** 1995 Sep;81:18–9

Eformoterol versus salbutamol in elderly patients with ROAD. Hendrick DJ. **Br J Clin Pract Symp Suppl** 1995 Sep;81:4–5

Eformoterol versus salbutamol in patients with ROAD. Maesen FP. **Br J Clin Pract Symp Suppl** 1995 Sep;81:8–10

Determination of post-salbutamol methacholine dose shift [letter] Cockcroft DW, et al. **Chest** 1996 Aug;110(2):579–80

Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD [letter] Ikeda A, et al. **Chest** 1996 Jan;109(1):294

Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD [letter; comment] Ingram RH Jr. **Chest** 1996 Jan; 109(1):293. Comment on: Chest 1995 Feb;107(2):401–5.

A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma. Karpel JP, et al. **Chest** 1996 Sep;110(3):611–6

Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Kleerup EC, et al. **Chest** 1996 Mar; 109(3):702–7

Sleep quality and nocturnal respiratory function with once-daily theophylline (Uniphyl) and inhaled salbutamol in patients with COPD. Man GC, et al. **Chest** 1996 Sep; 110(3):648–53

Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus. Groves AM, et al. **Circulation** 1995 Dec 15;92(12):3394–6

Skeletal muscle magnesium and potassium in asthmatics treated with oral beta 2-agonists. Gustafson T, et al. **Eur Respir J** 1996 Feb;9(2):237–40

Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life [see comments] Rutten-van Mölken MP, et al. **Eur Respir J** 1995 Jun;8(6):888–98. Comment in: Eur Respir J 1995 Jun;8(6):885–7.

Pediatric asthma--a correlation of clinical treatment and oxygen saturation. Cook T, et al. **Hawaii Med J** 1995 Jul; 54(7):665–8

A controlled trial of nebulized salbutamol and adrenaline in acute severe asthma. Abroug F, et al. **Intensive Care Med** 1995 Jan;21(1):18–23

The effect of inhaled albuterol in moderate to severe asthma. Apter AJ, et al. **J Allergy Clin Immunol** 1996 Aug; 98(2):295–301

Effect of salbutamol on oxygen saturation in COPD. Charoenratanakul S, et al. **J Med Assoc Thai** 1996 Apr; 79(4):218–21

Salbutamol in the treatment of asthma [letter] Perrin-Fayolle M. **Lancet** 1995 Oct 21;346(8982):1101

Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. König P, et al. **Pediatr Pulmonol** 1995 Oct;20(4):205–14

Plasma atrial natriuretic peptide during spontaneous bronchoconstriction in asthmatics. Robichaud A, et al. **Peptides** 1995;16(4):653–6

Effect of acute hyperoxia on the bronchodilator response to salbutamol in stable asthmatic patients. Dagg KD, et al. **Thorax** 1996 Aug;51(8):853–4

Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Moayyedi P, et al. **Thorax** 1995 Aug;50(8):834–7

[Salmeterol no longer banned in Olympic Games (letter)] van Dam JG. **Ned Tijdschr Geneeskd** 1996 Aug 3; 140(31):1612 **(Dut)**

[Effect of salbutamol inhalation on small airways function in patients with sarcoidosis] Krzywiecki A, et al. **Pneumonol Alergol Pol** 1995;63(5–6):264–7 (Eng. Abstr.) **(Pol)**

TOXICITY

Metered-dose inhaler salbutamol-induced tracheal epithelial lesions in intubated rabbits. Effects of the site of administration and time. Shorten GD, et al. **Chest** 1995 Dec;108(6):1668–72

URINE

Determination of salbutamol enantiomers in human plasma and urine by chiral high-performance liquid chromatography. Boulton DW, et al. **J Chromatogr B Biomed Appl** 1995 Oct 6;672(1):103–9

ALCALIGENES

Infection by Alcaligenes xylosoxidans subsp. xylosoxidans in neutropenic patients. Knippschild M, et al. **Oncology** 1996 May-Jun;53(3):258–62

Alcaligenes xylosoxidans subsp xylosoxidans in children with chronic otorrhea. Wintermeyer SM, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):332–4 (15 ref.)

Nosocomial infection by Alcaligenes xylosoxidans in neutropenic patients [letter] Hoffkes HG, et al. **Presse Med** 1995 Sep 2–9;24(25):1180

Unsuccessful treatment of CAPD peritonitis caused by Alcaligenes xylosoxidans subsp. denitrificans. Haqqie SS, et al. **Ren Fail** 1995 Sep;17(5):611–4

[Alcaligenes denitrificans subsp. xylosoxidans infection in a patient with corticodependent chronic respiratory insufficiency (letter)] Mofredj A, et al. **Presse Med** 1996 Feb 24;25(7):306 **(Fre)**

[Bacteremia caused by Achromobacter xylosidans (letter)] Mollà M, et al. **Med Clin (Barc)** 1996 Jan 13;106(1):38 **(Spa)**

CHEMISTRY

Crystal structure of the flavohemoglobin from Alcaligenes eutrophus at 1.75 A resolution. Ermler U, et al. **EMBO J** 1995 Dec 15;14(24):6067–77

Spectroscopic and electrochemical studies on active-site transitions of the type 1 copper protein pseudoazurin from Achromobacter cycloclastes. Kohzuma T, et al. **J Biol Chem** 1995 Oct 27;270(43):25733–8

CLASSIFICATION

Investigation of hospital-acquired infections due to Alcaligenes denitrificans subsp. xylosoxidans by DNA restriction fragment length polymorphism [letter; comment] Frederiksen W. **J Clin Microbiol** 1995 Nov;33(11):3081. Comment on: J Clin Microbiol 1994 Oct;32(10):2631.

Transfer of two Burkholderia and an Alcaligenes species to Ralstonia gen. Nov.: Proposal of Ralstonia pickettii (Ralston, Palleroni and Doudoroff 1973) comb. Nov., Ralstonia solanacearum (Smith 1896) comb. Nov. and Ralstonia eutropha (Davis 1969) comb. Nov. Yabuuchi E, et al. **Microbiol Immunol** 1995;39(11):897–904

DRUG EFFECTS

Effects of atrazine on Ochrobactrum anthropi membrane fatty acids. Laura D, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2644–6

[Comparative susceptibility of Ochrobactrum anthropi, Agrobacterium tumefaciens, Alcaligenes faecalis, Alcaligenes denitrificans subsp. denitrificans, Alcaligenes denitrificans subsp. xylosidans and Bordetella bronchiseptica against 35 antibiotics including 17 beta-lactams] Bizet C, et al. **Pathol Biol (Paris)** 1995 Apr; 43(4):258–63 (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Purification and characterization of dihydropyrimidine dehydrogenase from Alcaligenes eutrophus. Schmitt U, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):175–82

Characterisation of a chromosomally encoded catechol 1,2-dioxygenase (E.C. 1.13.11.1) from Alcaligenes eutrophus CH34. Sauret-Ignazi G, et al. **Arch Microbiol** 1996 Jul;166(1):42–50

Structure of Alcaligenes faecalis nitrite reductase and a copper site mutant, M150E, that contains zinc. Murphy ME, et al. **Biochemistry** 1995 Sep 26;34(38):12107–17

Hydroxylation of quinaldic acid: quinaldic acid 4-monooxygenase from Alcaligenes sp. F-2 versus quinaldic acid 4-oxidoreductases. Bubeck B, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):39–44

Structural and immunological studies on the soluble formate dehydrogenase from Alcaligenes eutrophus. Friedebold J, et al. **Biol Chem Hoppe Seyler** 1995 Sep;376(9):561–8

Characterization of the first enzyme in 2,4-dichlorophenoxyacetic acid metabolism. Hausinger RP, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:37–9

(8 ref.)
hyp gene products in Alcaligenes eutrophus are part of a hydrogenase–maturation system. Dernedde J, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):351–8
Alcaligenes eutrophus possesses a second pyruvate dehydrogenase (E1). Hein S, et al. **Eur J Biochem** 1996 May 1;237(3):674–84
Muconolactone isomerase of the 3–oxoadipate pathway catalyzes dechlorination of 5–chloro–substituted muconolactones. Prucha M, et al. **Eur J Biochem** 1996 Apr 15;237(2):350–6
An iron dioxygenase from Alcaligenes faecalis catalyzing the oxidation of pyruvic oxime to nitrite. Ono Y, et al. **FEMS Microbiol Lett** 1996 Jun 1;139(2–3):103–8
The Alcaligenes eutrophus membrane–bound hydrogenase gene locus encodes functions involved in maturation and electron transport coupling. Bernhard M, et al. **J Bacteriol** 1996 Aug;178(15):4522–9
Maleylacetate reductases in chloroaromatic–degrading bacteria using the modified ortho pathway: comparison of catalytic properties. Müller D, et al. **J Bacteriol** 1996 Jan; 178(1):298–300
NADPH–dependent reductive ortho dehalogenation of 2,4–dichlorobenzoic acid in Corynebacterium sepedonicum KZ–4 and Coryneform bacterium strainNTB–1 via 2,4–dichlorobenzoyl coenzyme A. Romanov V, et al. **J Bacteriol** 1996 May;178(9):2656–61
Primary structure of N–acyl–D–glutamate amidohydrolase from Alcaligenes xylosoxydans subsp. xylosoxydans A–6. Wakayama M, et al. **J Biochem (Tokyo)** 1995 Jul; 118(1):204–9
The structure of copper–nitrite reductase from Achromobacter cycloclastes at five pH values, with NO2– bound and with type II copper depleted. Adman ET, et al. **J Biol Chem** 1995 Nov 17;270(46):27458–74
Saccharomyces cerevisiae expressing bacterial polyhydroxybutyrate synthase produces poly–3–hydroxybutyrate. Leaf TA, et al. **Microbiology** 1996 May;142 (Pt 5):1169–80
A tectorial membrane fovea in the cochlea of the mustached bat. Kösal M, et al. **Naturwissenschaften** 1996 Feb; 83(2):89–91
[Use of polymerase chain reaction for detecting the RBPC gene in natural samples] Chernykh NA. **Mikrobiologiia** 1995 Nov–Dec;64(6):792–6 (Eng. Abstr.) **(Rus)**

GENETICS

Gene transfer of Alcaligenes eutrophus JMP134 plasmid pJP4 to indigenous soil recipients. DiGiovanni GD, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2521–6
Constitutive expression of the cloned phenol hydroxylase gene(s) from Alcaligenes eutrophus JMP134 and concomitant trichloroethylene oxidation. Kim Y, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3227–33
Recombination of a 3–chlorobenzoate catabolic plasmid from Alcaligenes eutrophus NH9 mediated by direct repeat elements. Ogawa N, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3788–95
Cloning, characterization, and expression of the nitric oxide–generating nitrite reductase and of the blue copper protein genes of Achromobacter cycloclastes. Chen JY, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):423–8
hyp gene products in Alcaligenes eutrophus are part of a hydrogenase–maturation system. Dernedde J, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):351–8
Alcaligenes eutrophus possesses a second pyruvate dehydrogenase (E1). Hein S, et al. **Eur J Biochem** 1996 May 1;237(3):674–84
The Legionella pneumophila hel locus encodes intracellularly induced homologs of heavy–metal ion transporters of Alcaligenes spp. McClain MS, et al. **Infect Immun** 1996 May;64(5):1532–40
The Alcaligenes eutrophus membrane–bound hydrogenase gene locus encodes functions involved in maturation and electron transport coupling. Bernhard M, et al. **J Bacteriol** 1996 Aug;178(15):4522–9
Operator binding of the CbbR protein, which activates the duplicate cbb CO2 assimilation operons of Alcaligenes eutrophus. Kusian B, et al. **J Bacteriol** 1995 Nov; 177(22):6568–74
Identification of a partition and replication region in the Alcaligenes eutrophus megaplasmid pMOL28. Taghavi S, et al. **Mol Gen Genet** 1996 Feb 5;250(2):169–79

ISOLATION & PURIFICATION

Ochrobactrum anthropi endophthalmitis after uncomplicated cataract surgery. Braun M, et al. **Am J Ophthalmol** 1996 Aug;122(2):272–3
Isolation of Alcaligenes sp. strain L6 at low oxygen concentrations and degradation of 3–chlorobenzoate via a pathway not involving (chloro)catechols. Krooneman J, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2427–34
Alcaligenes xylosoxidans neonatal meningitis: a case report. Pan CH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Apr;57(4):301–4
Evaluation of pulsed–field gel electrophoresis and rep–PCR for the epidemiological analysis of Ochrobactrum anthropi strains. van Dijck P, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec;14(12):1099–1102
Meningitis caused by Alcaligenes (Achromobacter) xylosoxidans associated with epidural catheter [letter] Ramos JM, et al. **Infection** 1995 Nov–Dec;23(6):395–6
From the Centers for Disease Control and Prevention. Ochrobactrum anthropi meningitis associated with cadaveric pericardial tissue processed with a contaminated solution—Utah, 1994. **JAMA** 1996 Aug 28;276(8):596
Ochrobactrum anthropi meningitis associated with cadaveric pericardial tissue processed with a contaminated solution—Utah, 1994. **MMWR Morb Mortal Wkly Rep** 1996 Aug 9;45(31):671–3
Extraction and purification of microbial DNA from petroleum–contaminated soils and detection of low numbers of toluene, octane and pesticide degraders by multiplex polymerase chain reaction and Southern analysis. Knaebel DB, et al. **Mol Ecol** 1995 Oct;4(5):579–91
Alcaligenes xylosoxidans–associated infection in an infant with cholesteatoma [letter] Bénaoudia F, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):637–8
[Infection in the dialysis unit as a contributing factor to the problem of hospital acquired infections] Sosnowska A, et al. **Pol Arch Med Wewn** 1995 Apr;93(4):322–8 (Eng. Abstr.) **(Pol)**

METABOLISM

Maintenance and induction of naphthalene degradation activity in Pseudomonas putida and an Alcaligenes sp. under different culture conditions. Guerin WF, et al. **Appl Environ Microbiol** 1995 Nov;61(11):4061–8
Isolation of Alcaligenes sp. strain L6 at low oxygen concentrations and degradation of 3–chlorobenzoate via a pathway not involving (chloro)catechols. Krooneman J, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2427–34
Effects of atrazine on Ochrobactrum anthropi membrane fatty acids. Laura D, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2644–6
Recombination of a 3–chlorobenzoate catabolic plasmid from Alcaligenes eutrophus NH9 mediated by direct repeat elements. Ogawa N, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3788–95
Nitrous oxide production by Alcaligenes faecalis under transient and dynamic aerobic and anaerobic conditions. Otte S, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2421–6
Hydrogen oxidation by membranes from autotrophically grown Alcaligenes eutrophus H16: role of the cyanide–resistant pathway in energy transduction. Komen R, et al. **Arch Microbiol** 1996 Jun;165(6):418–20
Degradation of homovanillate by a strain of Variovorax paradoxus via ring hydroxylation. Allison N, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2–3):213–9
Occurrence of polyhydroxyalkanoic acid granule–associated proteins related to the Alcaligenes eutrophus H16 GA24 protein in other bacteria. Wieczorek R, et al. **FEMS Microbiol Lett** 1996 Jan 1;135(1):23–30
Kalimantacins A, B and C, novel antibiotics from Alcaligenes sp. YL–02632S. I. Taxonomy, fermentation, isolation and biological properties. Kamigiri K, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):136–9
Kalimantacin A, B, and C, novel antibiotics produced by Alcaligenes sp. YL–02632S. II. Physico–chemical properties and structure elucidation. Tokunaga T, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):140–4
Acetate utilization is inhibited by benzoate in Alcaligenes eutrophus: evidence for transcriptional control of the expression of acoE coding for acetyl coenzyme A synthetase. Ampe F, et al. **J Bacteriol** 1995 Oct; 177(20):5826–33
Carboxyl–terminal processing of the cytoplasmic NAD–reducing hydrogenase of Alcaligenes eutrophus requires the hoxW gene product. Thiemermann S, et al. **J Bacteriol** 1996 Apr;178(8):2368–74
Studies on protein–protein interaction between copper–containing nitrite reductase and pseudoazurin from Alcaligenes faecalis S–6. Kukimoto M, et al. **J Biol Chem** 1996 Jun 7;271(23):13680–3
Flux limitations in the ortho pathway of benzoate degradation of Alcaligenes eutrophus: metabolite overflow and induction of the meta pathway at high substrate concentrations. Ampe F, et al. **Microbiology** 1996 Jul;142 (Pt 7):1807–17
Degradation of PCB in different soils by inoculated Alcaligenes xylosoxidans. Haluška L, et al. **Sci Total Environ** 1995 Dec 15;175(3):275–85

PATHOGENICITY

Ochrobactrum anthropi meningitis in pediatric pericardial allograft transplant recipients. Chang HJ, et al. **J Infect Dis** 1996 Mar;173(3):656–60

ULTRASTRUCTURE

Antigenic determinants of the membrane–bound hydrogenase in Alcaligenes eutrophus are exposed toward the periplasm. Eismann K, et al. **J Bacteriol** 1995 Nov;177(21):6309–12

VIROLOGY

Introduction of Pseudomonas aeruginosa mutator phage D3112 into Alcaligenes eutrophus strain CH34. Krylov V, et al. **Res Microbiol** 1995 Mar–Apr;146(3):245–50
[Introduction of mutator phage D3112 of Pseudomonas aeruginosa into Alcaligenes eutrophus var. metallotollerans (Strain CH34)] Krylov VN. **Genetika** 1996 Jan;32(1):146–9 (Eng. Abstr.) **(Rus)**

ALCHEMY

Alchemy, homeopathy and the treatment of borderline cases. Whitmont EC. **J Anal Psychol** 1996 Jul;41(3):369–86
The meaning of component analysis: decomposition of the free energy in terms of specific interactions. Boresch S, et al. **J Mol Biol** 1995 Dec 15;254(5):801–7

ALCIAN BLUE

Novel fixation of plant tissue, staining through paraffin with alcian blue and hematoxylin, and improved slide preparation. Graham ET, et al. **Biotech Histochem** 1995 Sep;70(5):263–6

CHEMISTRY

Alcian blue. Now you see it, now you don't. Scott JE. **Eur J Oral Sci** 1996 Feb;104(1):2–9 (17 ref.)

DIAGNOSTIC USE

Mucin secretion by gastric carcinoma cells: PAS alcian blue stain study. Wabinga HR. **East Afr Med J** 1996 May;73(5 Suppl):S19–20
[Alcian Blue and Leu 7 in the diagnosis of thyroid malignancy] Dušková J. **Cesk Patol** 1995 Dec;31(4):111–3 (Eng. Abstr.) **(Cze)**

ALCOHOL ABUSE see **ALCOHOLISM**

ALCOHOL AMNESTIC DISORDER

[Diagnosis and treatment of alcohol–induced somatic damage (editorial)] Hardt F. **Ugeskr Laeger** 1996 Aug 19; 158(34):4733 **(Dan)**

DIAGNOSIS

The effect of heavy social drinking on recall and event–related potentials. Nichols JM, et al. **J Stud Alcohol** 1996 Mar;57(2):125–35
The Autobiographical Memory Interview (AMI) in organic and psychogenic amnesia. Kopelman MD. **Memory** 1994 Jun;2(2):211–35 (66 ref.)
[Progressive supranuclear paralysis; a late diagnosis (letter; comment)] Drijver E. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2392–3. Comment on: Ned Tijdschr Geneeskd 1995 Jul 29;139(30):1521–4. **(Dut)**

EPIDEMIOLOGY

Wernicke–Korsakoff syndrome in Sydney hospitals: before and after thiamine enrichment of flour. Ma JJ, et al. **Med J Aust** 1995 Nov 20;163(10):531–4

ETIOLOGY

"Grievous bodily harm:" gamma hydroxybutyrate abuse leading to a Wernicke–Korsakoff syndrome. Friedman J, et al. **Neurology** 1996 Feb;46(2):469–71

GENETICS

No association between the c2 allele at the cytochrome P450IIE1 gene and alcohol induced liver disease, alcohol Korsakoff's syndrome or alcohol dependence syndrome. Ball DM, et al. **Drug Alcohol Depend** 1995 Oct;39(3):181–4

HISTORY

Cerebral bases of consciousness: a historical view. Markowitsch HJ. **Neuropsychologia** 1995 Sep;33(9):1181–92

PATHOLOGY

Chronic alcoholics without Wernicke–Korsakoff syndrome or cirrhosis do not lose serotonergic neurons in the dorsal raphe nucleus. Baker KG, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):61–6

PHYSIOPATHOLOGY

Memory functioning in social drinkers: a study of event–related potentials. Fox AM, et al. **Alcohol Alcohol** 1995 May;30(3):303–10
Impaired delay eyeblink conditioning in amnesic Korsakoff's patients and recovered alcoholics. McGlinchey–Berroth R, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1127–32
Neural basis of confabulation. Benson DF, et al. **Neurology** 1996 May;46(5):1239–43
Severe global amnesia presenting as Wernicke–Korsakoff syndrome but resulting from atypical lesions. Welch LW, et al. **Psychol Med** 1996 Mar;26(2):421–5

PSYCHOLOGY

No selective deficit in recall in amnesia. MacAndrew SB, et al. **Memory** 1994 Sep;2(3):241–54
[Cognitive dysfunction following anterior communicating artery aneurysm rupture. Comparison with alcoholic Korsakoff syndrome on neuropsychological performance] Mimura M, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):850–4 (Eng. Abstr.) **(Jpn)**

ALCOHOL CONSUMPTION see **ALCOHOL DRINKING**

ALCOHOL DEHYDROGENASE

ADMINISTRATION & DOSAGE

The influence of enzyme concentration on the encapsulation of glutamate dehydrogenase and alcohol dehydrogenase in red blood cells. Sanz S, et al. **Biotechnol Appl Biochem** 1995 Oct;22 (Pt 2):223–31

ANALYSIS

Analytical approaches to alcohol dehydrogenase structures. Gheorghe MT, et al. **Adv Exp Med Biol** 1995;372:417–26

Alcohol dehydrogenase (ADH) isozymes in the AdhN/AdhN strain of Peromyscus maniculatus (ADH–deermouse) and a possible role of class III ADH in alcohol metabolism. Haseba T, et al. **Biochem Genet** 1995 Oct;33(9–10):349–63

ANTAGONISTS & INHIBITORS

4–Methylpyrazole, an alcohol dehydrogenase inhibitor, exacerbates alcohol–induced microencephaly during the brain growth spurt. Chen WJ, et al. **Alcohol** 1995 Jul–Aug; 12(4):351–5

The effects of disulfiram on equine hepatic alcohol dehydrogenase and its efficiency against alcoholism: vinegar effect. Langeland BT, et al. **Alcohol Alcohol** 1996 Jan;31(1):75–80

Evidence that cytochrome P–4502E1 contributes to ethanol elimination at low doses: effects of diallyl sulfide and 4–methyl pyrazole on ethanol elimination in the perfused rat liver. Matsumoto H, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):12A–16A

Kinetics of irreversible inhibition of yeast alcohol dehydrogenase during modification by o–phthaldehyde. Le WP, et al. **Enzyme Protein** 1994–95;48(3):183–90

BIOSYNTHESIS

Upstream structure of human ADH7 gene and the organ distribution of its expression. Yokoyama H, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):216–22

A nuclear protein, synthesized in growth–arrested human hepatoblastoma cells, is a novel member of the short–chain alcohol dehydrogenase family. Gabrielli F, et al. **Eur J Biochem** 1995 Sep 1;232(2):473–7

Pre–mRNA topology is important for 3'–end formation in Saccharomyces cerevisiae and mammals. Stumpf G, et al. **Mol Cell Biol** 1996 May;16(5):2204–13

Chromatin remodeling during Saccharomyces cerevisiae ADH2 gene activation. Verdone L, et al. **Mol Cell Biol** 1996 May;16(5):1978–88

Two mitochondrial alcohol dehydrogenase activities of Kluyveromyces lactis are differently expressed during respiration and fermentation. Saliola M, et al. **Mol Gen Genet** 1995 Dec 20;249(6):665–72

Transcription factor veracity: is GBF3 responsible for ABA–regulated expression of Arabidopsis Adh? Lu G, et al. **Plant Cell** 1996 May;8(5):847–57

The Arabidopsis Adh gene exhibits diverse nucleosome arrangements within a small DNase I–sensitive domain. Vega–Palas MA, et al. **Plant Cell** 1995 Nov;7(11):1923–32

BLOOD

Serum class I and II alcohol dehydrogenase activity during the course of viral hepatitis. Chrostek L, et al. **Eur J Clin Chem Clin Biochem** 1995 Nov;33(11):825–9

The effect of endotoxin on alcohol dehydrogenase (ADH) activity in the serum of ethanol intoxicated rats. Chrostek L, et al. **Rocz Akad Med Bialymst** 1994;39:74–80

[Alcohol dehydrogenase (ADH)] Matsushima T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:419–22 (10 ref.) **(Jpn)**

CHEMISTRY

Crystallizations of novel forms of alcohol dehydrogenase. el–Ahmad M, et al. **Adv Exp Med Biol** 1995;372:365–71

Human and rat class IV alcohol dehydrogenases. Correlations of primary structures with enzymatic properties. Farrés J, et al. **Adv Exp Med Biol** 1995;372:331–9

Zinc binding of alcohol and sorbitol dehydrogenases. Karlsson C, et al. **Adv Exp Med Biol** 1995;372:397–406

Structural and sequence comparisons of quinone oxidoreductase, zeta–crystallin, and glucose and alcohol dehydrogenases. Edwards KJ, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):173–83

Magnetic and optical properties of copper–substituted alcohol dehydrogenase: a bisthiolate copper (II) complex. Farrar JA, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):447–56

Mechanism of aldehyde oxidation catalyzed by horse liver alcohol dehydrogenase. Olson LP, et al. **Biochemistry** 1996 Jul 30;35(30):9782–91

Activation of Sulfolobus solfataricus alcohol dehydrogenase by modification of cysteine residue 38 with iodoacetic acid. Raia CA, et al. **Biochemistry** 1996 Jan 16;35(2):638–47

Hydrostatic pressure induces conformational and catalytic changes on two alcohol dehydrogenases but no oligomeric dissociation. Dallet S, et al. **Biochim Biophys Acta** 1996 May 2;1294(1):15–24

Proteolytic activation of grass carp (Ctenopharygodon idellus) liver alcohol dehydrogenase. Tsui HT, et al. **Biochim Biophys Acta** 1996 Aug 15;1296(1):41–6

Involvement of the C–terminal tail in the activity of Drosophila alcohol dehydrogenase. Evaluation of truncated proteins constructed by site–directed mutagenesis. Albalat R, et al. **Eur J Biochem** 1995 Oct 15; 233(2):498–505

Interaction of a fluorescent analog of N–deacetyl–N–methyl–colchicine (colcemid) with liver alcohol dehydrogenase. Sengupta S, et al. **Eur J Biochem** 1995 Sep 15;232(3):844–8

Liver class–I alcohol dehydrogenase isozyme relationships and constant patterns in a variable basic structure. Distinctions from characterization of an ethanol dehydrogenase in cobra, Naja naja. Shafqat J, et al. **Eur J Biochem** 1996 Mar 1;236(2):571–8

Acid–induced folding of yeast alcohol dehydrogenase under low pH conditions. Le WP, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):674–9

X–ray structure of human beta3beta3 alcohol dehydrogenase. The contribution of ionic interactions to coenzyme binding. Davis GJ, et al. **J Biol Chem** 1996 Jul 19;271(29):17057–61

Function of multiple heme c moieties in intramolecular electron transport and ubiquinone reduction in the quinohemoprotein alcohol dehydrogenase–cytochrome c complex of Gluconobacter suboxydans. Matsushita K, et al. **J Biol Chem** 1996 Mar 1;271(9):4850–7

The coordination of the catalytic zinc in alcohol dehydrogenase studied by combined quantum–chemical and molecular mechanics calculations. Ryde U. **J Comput Aided Mol Des** 1996 Apr;10(2):153–64

Crystal structure of cod liver class I alcohol dehydrogenase: substrate pocket and structurally variable segments. Ramaswamy S, et al. **Protein Sci** 1996 Apr;5(4):663–71

On the role of Glu–68 in alcohol dehydrogenase. Ryde U. **Protein Sci** 1995 Jun;4(6):1124–32

CLASSIFICATION

Mammalian class VI alcohol dehydrogenase. Novel types of the rodent enzymes. Höög JO, et al. **Adv Exp Med Biol** 1995;372:355–64

GENETICS

Molecular evolution of class I alcohol dehydrogenases in primates. Models for gene evolution and comparison of 3' untranslated regions of cDNAS. Cheung B, et al. **Adv Exp Med Biol** 1995;372:315–20

Class I and class IV alcohol dehydrogenase (retinol dehydrogenase) gene expression in mouse embryos. Duester G, et al. **Adv Exp Med Biol** 1995;372:301–13 (42 ref.)

The role of leucine 116 in determining substrate specificity in human B1 alcohol dehydrogenase. Hurley TD, et al. **Adv Exp Med Biol** 1995;372:321–5

The alcohol dehydrogenase system. Jörnvall H, et al. **Adv Exp Med Biol** 1995;372:281–94 (51 ref.)

Cloning and expression of a human stomach alcohol dehydrogenase isozyme. Kedishvili NY, et al. **Adv Exp Med Biol** 1995;372:341–7

Useful mutants of Zymomonas mobilis alcohol dehydrogenase–2 obtained by the use of polymerase chain reaction random mutagenesis. Rellos P, et al. **Adv Exp Med Biol** 1995;372:435–40

Analysis of CA repeats in first intron of class I ADH gene in Long–Evans Cinnamon rats developing fatal intoxication after ethanol intake. Katsuki S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):33A–35A

Effects of cimetidine on blood ethanol levels after alcohol ingestion and genetic polymorphisms of sigma–alcohol dehydrogenase in Japanese. Kawashima O, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):36A–39A

Association of restriction fragment–length polymorphisms in the alcohol dehydrogenase 2 gene with alcoholic brain atrophy. Maezawa Y, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):29A–32A

Alcohol–metabolizing enzyme polymorphisms and alcoholism in Japan. Maezawa Y, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):951–4

The class I alcohol dehydrogenase gene is glucocorticoid–responsive in the rat hepatoma microcell hybrid cell line, 11–3. Majewski JL, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1430–4

Characteristics of Japanese alcoholics with the atypical aldehyde dehydrogenase 2*2. I. A comparison of the genotypes of ALDH2, ADH2, ADH3, and cytochrome P–4502E1 between alcoholics and nonalcoholics. Nakamura K, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):52–5

ADH2 gene polymorphisms are determinants of alcohol pharmacokinetics. Thomasson HR, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1494–9

Inactivation of an aldehyde/alcohol dehydrogenase gene from Clostridium acetobutylicum ATCC 824. Green EM, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:213–21

Genotypes of alcohol–metabolizing enzymes in Mexicans with alcoholic liver cirrhosis. Lisker–Yourkowitzky R, et al. **Arch Med Res** 1995;26 Spec No:S63–7

Upstream structure of human ADH7 gene and the organ distribution of its expression. Yokoyama H, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):216–22

The chromosomal organisation of the alcohol dehydrogenase region of the genome of Drosophila melanogaster. Davis T, et al. **Biochem Soc Trans** 1996 Feb;24(1):109S

Cloning and expression of a putative alcohol dehydrogenase gene of Entamoeba histolytica and its application to immunological examination. Kimura A, et al. **Clin Diagn Lab Immunol** 1996 May;3(3):270–4

Gene expression in a young multigene family: tissue–specific differences in the expression of the human alcohol dehydrogenase genes ADH1, ADH2, and ADH3. Brown CJ, et al. **DNA Cell Biol** 1996 Mar;15(3):187–96

Linking of isozyme and class variability patterns in the emergence of novel alcohol dehydrogenase functions. Characterization of isozymes in Uromastix hardwickii. Hjelmqvist L, et al. **Eur J Biochem** 1996 Mar 1; 236(2):563–70

Purification and cDNA cloning of the alcohol dehydrogenase of the flesh fly Sarcophaga peregrina. A structural relationship between alcohol dehydrogenase and a 25–kDa protein. Horio T, et al. **Eur J Biochem** 1996 May 1; 237(3):698–703

Generation of small fusion genes carrying phleomycin resistance and Drosophila alcohol dehydrogenase reporter properties: their application in retroviral vectors. Gautier R, et al. **Exp Cell Res** 1996 May 1;224(2):291–301

Alcohol dehydrogenase polymorphism in barrel cactus populations of Drosophila mojavensis. Cleland S, et al. **Genetics** 1996 Jul;98(1):115–7

Effects of a transposable element insertion on alcohol dehydrogenase expression in Drosophila melanogaster. Dunn RC, et al. **Genetics** 1995 Jun;140(2):667–77

High incidence of ADH2*1/ALDH2*1 genes among Japanese alcohol dependents and patients with alcoholic liver disease. Tanaka F, et al. **Hepatology** 1996 Feb; 23(2):234–9

Polymorphisms in alcohol metabolizing enzyme genes and alcoholic cirrhosis in Japanese patients: a multivariate analysis. Yamauchi M, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1136–42

Translation of the adhE transcript to produce ethanol dehydrogenase requires RNase III cleavage in Escherichia coli. Aristarkhov A, et al. **J Bacteriol** 1996 Jul; 178(14):4327–32

Cloning and overexpression in Escherichia coli of the genes encoding NAD–dependent alcohol dehydrogenase from two Sulfolobus species. Cannio R, et al. **J Bacteriol** 1996 Jan;178(1):301–5

Association of a restriction fragment length polymorphism in the alcohol dehydrogenase 2 gene with Japanese alcoholic liver cirrhosis. Yamauchi M, et al. **J Hepatol** 1995 Nov;23(5):519–23

Molecular characterization of a chromosomal region involved in the oxidation of acetyl–CoA to glyoxylate in the isocitrate–lyase–negative methylotroph Methylobacterium extorquens AM1. Chistoserdova LV, et al. **Microbiology** 1996 Jun;142 (Pt 6):1459–68

Intra– and interspecific variation of the alcohol dehydrogenase locus region in wild plants Arabis gemmifera and Arabidopsis thaliana [letter] Miyashita NT, et al. **Mol Biol Evol** 1996 Feb;13(2):433–6

Molecular phylogeny and genome evolution in the Drosophila virilis species group: duplications of the alcohol dehydrogenase gene. Nurminsky DI, et al. **Mol Biol Evol** 1996 Jan;13(1):132–49

Matrix attachment regions and transcribed sequences within a long chromosomal continuum containing maize Adh1. Avramova Z, et al. **Plant Cell** 1995 Oct;7(10):1667–80

Transcription factor veracity: is GBF3 responsible for ABA–regulated expression of Arabidopsis Adh? Lu G, et al. **Plant Cell** 1996 May;8(5):847–57

The Arabidopsis Adh gene exhibits diverse nucleosome arrangements within a small DNase I–sensitive domain. Vega–Palas MA, et al. **Plant Cell** 1995 Nov;7(11):1923–32

Isolation and characterization of the Adh2 5' region from Petunia hybrida. Atkinson EF, et al. **Plant Mol Biol** 1996 Jan;30(2):367–71

Intron length variation of the Adh gene in Brachyscome (Asteraceae). Denda T, et al. **Plant Mol Biol** 1995 Sep; 28(6):1067–73

Abscisic acid induces the alcohol dehydrogenase gene in Arabidopsis. de Bruxelles GL, et al. **Plant Physiol** 1996 Jun;111(2):381–91

The vertebrate alcohol dehydrogenase system: variable class II type form elucidates separate stages of enzymogenesis. Hjelmqvist L, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10904–8

Pea formaldehyde–active class III alcohol dehydrogenase: common derivation of the plant and animal forms but not of the corresponding ethanol–active forms (classes I and P). Shafqat J, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5595–9

Complementation of an Escherichia coli adhE mutant by the Entamoeba histolytica EhADH2 gene provides a method for the identification of new antiamebic drugs. Yong TS, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6464–9

Ethanol utilization regulatory protein: profile alignments give no evidence of origin through aldehyde and alcohol dehydrogenase gene fusion. Nicholas HB Jr, et al. **Protein Sci** 1995 Dec;4(12):2621–4

Structure and regulation of the Candida albicans ADH1 gene encoding an immunogenic alcohol dehydrogenase. Bertram G, et al. **Yeast** 1996 Feb;12(2):115–27

[Alcohol dehydrogenase polymorphism and the genotypic adaptation of D. melanogaster to the action of selective factors] Totskiĭ VN, et al. **Tsitol Genet** 1995 Nov–Dec;

29(6):54–9 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Purification and properties of murine corneal alcohol dehydrogenase. Evidence for class IV ADH properties. Downes JE, et al. **Adv Exp Med Biol** 1995;372:349–54

Isolation and characterization of three alcohol dehydrogenase isozymes from Syrian golden hamsters. Keung WM. **Alcohol Clin Exp Res** 1996 Apr;20(2):213–20

Inducible UDP-glucose dehydrogenase from French bean (Phaseolus vulgaris L.) locates to vascular tissue and has alcohol dehydrogenase activity. Robertson D, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):311–7

Affinity precipitation of dehydrogenases with bis-NADH derivatives. Irwin JA, et al. **Biochem Soc Trans** 1996 Feb; 24(1):11S

Purification and cDNA cloning of the alcohol dehydrogenase of the flesh fly Sarcophaga peregrina. A structural relationship between alcohol dehydrogenase and a 25-kDa protein. Horio T, et al. **Eur J Biochem** 1996 May 1; 237(3):698–703

Ethanol inhibition of retinoic acid synthesis as a potential mechanism for fetal alcohol syndrome. Deltour L, et al. **FASEB J** 1996 Jul;10(9):1050–7

Purification and characterization of the alcohol dehydrogenase from a novel strain of Bacillus stearothermophilus growing at 70 degrees C. Guagliardi A, et al. **Int J Biochem Cell Biol** 1996 Feb;28(2):239–46

Preparation and characterization of isozymes and isoforms of horse liver alcohol dehydrogenase. Hubatsch I, et al. **J Chromatogr A** 1995 Sep 8;711(1):105–12

METABOLISM

Expression and activities of class IV alcohol dehydrogenase and class III aldehyde dehydrogenase in human mouth. Dong YJ, et al. **Alcohol** 1996 May-Jun;13(3):257–62

Enzymatic pattern of aldehyde metabolism during HL-60 cell differentiation. Barrera G, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):73–9

Cloning and expression of the gene encoding the Thermoanaerobacter ethanolicus 39E secondary-alcohol dehydrogenase and biochemical characterization of the enzyme. Burdette DS, et al. **Biochem J** 1996 May 15;316 (Pt 1):115–22

Inducible UDP-glucose dehydrogenase from French bean (Phaseolus vulgaris L.) locates to vascular tissue and has alcohol dehydrogenase activity. Robertson D, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):311–7

Comparison of the metabolism of alcohols by rat hepatic and pulmonary alcohol dehydrogenase. Carlson GP, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):65–71

Temperature-nearly-independent binding constant in several biochemical systems. The underlying entropy-driven binding mechanism and its practical significance. Miklavc A. **Biochem Pharmacol** 1996 Mar 22;51(6):723–9

Aldehyde dehydrogenase activity of Drosophila melanogaster alcohol dehydrogenase: burst kinetics at high pH and aldehyde dismutase activity at physiological pH. Henehan GT, et al. **Biochemistry** 1995 Sep 26; 34(38):12294–301

Mechanism of aldehyde oxidation catalyzed by horse liver alcohol dehydrogenase. Olson LP, et al. **Biochemistry** 1996 Jul 30;35(30):9782–91

Activation of Sulfolobus solfataricus alcohol dehydrogenase by modification of cysteine residue 38 with iodoacetic acid. Raia CA, et al. **Biochemistry** 1996 Jan 16;35(2):638–47

Hydrostatic pressure induces conformational and catalytic changes on two alcohol dehydrogenases but no oligomeric dissociation. Dallet S, et al. **Biochim Biophys Acta** 1996 May 2;1294(1):15–24

Proteolytic activation of grass carp (Ctenopharygodon idellus) liver alcohol dehydrogenase. Tsui HT, et al. **Biochim Biophys Acta** 1996 Aug 15;1296(1):41–6

Kinetic and modelling studies of NAD+ and poly(ethylene glycol)-bound NAD+ in horse liver alcohol dehydrogenase. Vanhommerig SA, et al. **Biochim Biophys Acta** 1996 Jul 18;1295(2):125–38

Overexpression of ADH1 confers hyper-resistance to formaldehyde in Saccharomyces cerevisiae. Grey M, et al. **Curr Genet** 1996 Apr;29(5):437–40

Gastric metabolism of ethanol in Syrian golden hamster. Batra SC, et al. **Dig Dis Sci** 1995 Dec;40(12):2712–6

Alcohol dehydrogenase in the human colon and rectum. Seitz HK, et al. **Digestion** 1996;57(2):105–8

Si-face stereospecificity at C5 of coenzyme F420 for F420-dependent glucose-6-phosphate dehydrogenase from Mycobacterium smegmatis and F420-dependent alcohol dehydrogenase from Methanoculleus thermophilicus. Klein AR, et al. **Eur J Biochem** 1996 Jul 1;239(1):93–7

Interaction of a fluorescent analog of N-deacetyl-N-methyl-colchicine (colcemid) with liver alcohol dehydrogenase. Sengupta S, et al. **Eur J Biochem** 1995 Sep 15;232(3):844–8

Alcohol dehydrogenase: multiplicity and relatedness in the solvent-producing clostridia. Chen JS. **FEMS Microbiol Rev** 1995 Oct;17(3):263–73 (44 ref.)

Characterization of a glutathione-dependent formaldehyde dehydrogenase from Rhodobacter sphaeroides. Barber RD, et al. **J Bacteriol** 1996 Mar;178(5):1386–93

Mitochondrial alcohol dehydrogenase from ethanol-grown Euglena gracilis. Ono K, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1178–82

X-ray structure of human beta3beta3 alcohol dehydrogenase. The contribution of ionic interactions to coenzyme binding. Davis GJ, et al. **J Biol Chem** 1996 Jul 19;271(29):17057–61

Function of multiple heme c moieties in intramolecular electron transport and ubiquinone reduction in the quinohemoprotein alcohol dehydrogenase-cytochrome c complex of Gluconobacter suboxydans. Matsushita K, et al. **J Biol Chem** 1996 Mar 1;271(9):4850–7

The NADP-linked aldehyde reductase of Leishmania donovani. Keegan FP, et al. **J Eukaryot Microbiol** 1995 May-Jun;42(3):255–7

Surface localization, regulation, and biologic properties of the 96-kDa alcohol/aldehyde dehydrogenase (EhADH2) of pathogenic Entamoeba histolytica. Flores BM, et al. **J Infect Dis** 1996 Jan;173(1):226–31

Substrate specificity of nine NAD(+)-dependent alcohol dehydrogenases in Aspergillus nidulans. Sealy-Lewis HM, et al. **Microbiology** 1995 Sep;141 (Pt 9):2295–300

Liver alcohol dehydrogenase activity and ethanol levels during chronic ethanol intake in pregnant rats and their offspring. Través C, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):93–9

A general assay for antibody catalysis using acridone as a fluorescent tag. Reymond JL, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4251–6

Engineering yeast alcohol dehydrogenase. Replacing Trp54 by Leu broadens substrate specificity. Weinhold EG, et al. **Protein Eng** 1995 May;8(5):457–61

[Human alcohol dehydrogenase] Chrostek L, et al. **Postepy Hig Med Dosw** 1996;50(1):95–107 (65 ref.) (Eng. Abstr.) **(Pol)**

[Class I and II alcohol dehydrogenase isoenzymes as biochemical markers of alcoholism] Chrostek L, et al. **Psychiatr Pol** 1996 Mar-Apr;30(2):321–9 (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Computational modeling of a putative fetal alcohol syndrome mechanism. Whitmire D, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1587–93

Retinoic acid synthesis in mouse embryos during gastrulation and craniofacial development linked to class IV alcohol dehydrogenase gene expression. Ang HL, et al. **J Biol Chem** 1996 Apr 19;271(16):9526–34

ALCOHOL DETERRENTS

ADVERSE EFFECTS

Cyanamide-associated alcoholic liver disease: a sequential histological evaluation. Yokoyama A, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1307–11

[Retrobulbar optic neuritis caused by disulfiram (Espéral): a case (letter; comment)] Geffray L, et al. **Rev Med Interne** 1995;16(12):973. Comment on: Rev Med Interne 1995;16(1):67–72. **(Fre)**

[Peripheral neuropathies caused by disulfiram] Dano P, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):294–5 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Nitrosyl cyanide, a putative metabolic oxidation product of the alcohol-deterrent agent cyanamide. Shirota FN, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):141–7

PHARMACOKINETICS

Potentiation of the bioavailability of daidzin by an extract of Radix puerariae. Keung WM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4284–8

PHARMACOLOGY

The effects of disulfiram on equine hepatic alcohol dehydrogenase and its efficiency against alcoholism: vinegar effect. Langeland BT, et al. **Alcohol Alcohol** 1996 Jan;31(1):75–80

Suppression of alcohol intake after administration of the Chinese herbal medicine, NPI-028, and its derivatives. Overstreet DH, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):221–7

In vitro effect of dithiocarbamate pesticides and of CaNa2EDTA on human serum dopamine-beta-hydroxylase. de Paris P, et al. **Biomed Environ Sci** 1995 Jun;8(2):114–21

Ethanol intake-reducing effects of ipsapirone in rats are not due to simple stimulus substitution. De Beun R, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):891–8

Contribution of "diazepam-insensitive" GABAA receptors to the alcohol antagonist properties of Ro 15-4513 and related imidazobenzodiazepines. Harris BD, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):113–8

Suppression of ethanol intake in alcohol-preferring rats by prior voluntary saccharin consumption. Kampov-Polevoy AB, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):59–64

The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Krishnan-Sarin S, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):153–9

The 5-HT4 receptor antagonist, GR113808, reduces ethanol intake in alcohol-preferring rats. Panocka I, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):255–9

Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats. Rezvani AH, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):615–20

Changes in serotonin metabolism during treatment with the aldehyde dehydrogenase inhibitors disulfiram and cyanamide. Beck O, et al. **Pharmacol Toxicol** 1995 Nov; 77(5):323–6

Potentiation of the bioavailability of daidzin by an extract of Radix puerariae. Keung WM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4284–8

Daidzin suppresses ethanol consumption by Syrian golden hamsters without blocking acetaldehyde metabolism. Keung WM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8990–3

[Medichronal lowers blood ethanol and acetaldehyde and restores the concentration of catecholamines in rat tissues] Bozhko HKZh, et al. **Ukr Biokhim Zh** 1995 Mar-Apr; 67(2):108–12 (Eng. Abstr.) **(Ukr)**

POISONING

Acute encephalopathy and polyneuropathy after disulfiram intoxication. Zorzon M, et al. **Alcohol Alcohol** 1995 Sep; 30(5):629–31

[Acute and reversible myoclonic encephalopathy, extrapyramidal syndrome, polyneuropathy caused by chronic disulfiram poisoning] De Sèze J, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):667–9 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Acamprosate in alcohol dependence: how does it work? Littleton J. **Addiction** 1995 Sep;90(9):1179–88 (42 ref.)

How to get the best out of antabuse. Kristenson H. **Alcohol Alcohol** 1995 Nov;30(6):775–83 (47 ref.)

Conference summary: Consensus Conference on Alcohol Dependence and the Role of Pharmacotherapy in its Treatment. Chick J, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):391–402 (82 ref.)

Innovative perspectives on strategies to develop effective alcoholism treatment programs. **Drug Alcohol Depend** 1995 Sep;39 Suppl 1:S23–4

The treatment of alcoholism in France. Batel P. **Drug Alcohol Depend** 1995 Sep;39 Suppl 1:S15–21

Pharmacotherapy and psychotherapy for the treatment of alcoholism in Germany. Soyka M. **Drug Alcohol Depend** 1995 Sep;39 Suppl 1:S9–13 (40 ref.)

Compliance among heavy alcohol users in clinical drug trials. Sullivan JT, et al. **J Subst Abuse** 1988-89;1(2):183–94

Naltrexone in alcohol dependence [letter] Brewer C. **Lancet** 1995 Nov 18;346(8986):1374

Disulfiram (antabuse) contracts in treatment of alcoholism. O'Farrell TJ, et al. **NIDA Res Monogr** 1995;150:65–91

[What is used as a drug for problem drinking?] Heinälä P, et al. **Duodecim** 1995;111(8):761–8 (30 ref.) **(Fin)**

[Disulfiram therapy] Widenius T, et al. **Duodecim** 1994; 110(2):153–8 (10 ref.) **(Fin)**

[The action of medichronal (glucose-glycine-formate) on the serotonin blood level in alcoholism patients] Bozhko GKh, et al. **Lik Sprava** 1995 May-Jun;(5-6):130–2 (Eng. Abstr.) **(Rus)**

TOXICITY

Comparative effects of two dithiocarbamates disulfiram and thiram, on adrenal catecholamine content and on plasma dopamine-beta-hydroxylase activity. Caroldi S, et al. **Arch Toxicol** 1995;69(10):690–3

Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Vaccari A, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):102–8

ALCOHOL DRINKING

see related
ALCOHOLISM
TEMPERANCE

Barriers to help-seeking for change in drinking: a gender-focused review of the literature. Schober R, et al. **Addict Behav** 1996 Jan-Feb;21(1):81–92 (96 ref.)

Work-site variation in managerial drinking. Howland J, et al. **Addiction** 1996 Jul;91(7):1007–17

Psychopathology and alcohol consumption among treatment-seeking alcoholics: a prospective study. Tómasson K, et al. **Addiction** 1996 Jul;91(7):1019–30

A comment on science and the alcohol beverage industry [letter; comment] Tongue E. **Addiction** 1996 Jul; 91(7):1063–4. Comment on: Addiction 1995 Jan;90(1):3–8. Comment on: Addiction 1995 Oct;90(10):1309–11.

Sex under the influence of alcohol among Norwegian adolescents. Traeen B, et al. **Addiction** 1996 Jul; 91(7):995–1006

Evidence that the amygdala is involved in the inhibitory effects of 5-HT3 receptor antagonists on alcohol drinking in rats. Dyr W, et al. **Alcohol** 1995 Jul-Aug;12(4):387–91

Amphetamine-induced hyperactivity: differences between rats with high or low preference for alcohol. Fahlke C, et al. **Alcohol** 1995 Jul-Aug;12(4):363–7

Lack of effect of dopamine D2 blockade on ethanol intake in selected and unselected strains of rats. Goodwin FL, et al. **Alcohol** 1996 May-Jun;13(3):273–9

Adrenalectomy prevents the development of alcohol

preference in male rats. Lamblin F, et al. **Alcohol** 1996 May-Jun;13(3):233-8
Volitional consumption of ethanol by fawn-hooded rats: effects of alternative solutions and drug treatments. McMillen BA, et al. **Alcohol** 1995 Jul-Aug;12(4):345-50
Alcohol consumption as a cofactor in the progression of HIV infection and AIDS. Penkower L, et al. **Alcohol** 1995 Nov-Dec;12(6):547-52
Effects of aminotriazole on ethanol, water, and food intake and on brain catalase in UChA and UChB rats. Tampier L, et al. **Alcohol** 1995 Jul-Aug;12(4):341-4
A good man's fault: alcohol and Irish people at home and abroad. Greenslade L, et al. **Alcohol Alcohol** 1995 Jul; 30(4):407-17
The association between alcohol consumption and suicide and homicide rates: a study of 13 nations. Lester D. **Alcohol Alcohol** 1995 Jul;30(4):465-8
Changes of G-protein levels in platelet membranes from alcoholics during short-term and long-term abstinence. Lichtenberg-Kraag B, et al. **Alcohol Alcohol** 1995 Jul; 30(4):455-64
Energy value of moderate alcohol consumption by humans. Rumpler WV, et al. **Am J Clin Nutr** 1996 Jul;64(1):108-14
Earlobe crease in women: evaluation of reproductive factors, alcohol use, and Quetelet index and relation to atherosclerotic disease. Petrakis NL. **Am J Med** 1995 Oct; 99(4):356-61
Pitfalls of SPECT studies of acute ethanol-induced changes in cerebral blood flow [letter; comment] Schlaepfer TE, et al. **Am J Psychiatry** 1995 Nov;152(11):1695-6. Comment on: Am J Psychiatry 1994 Oct;151(10):1505-8.
Wine consumption and other dietary variables in males under 60 before and after acute myocardial infarction. Cleophas TJ, et al. **Angiology** 1996 Aug;47(8):789-96
Alcohol and injuries [letter; comment] Hamilton JT. **Arch Fam Med** 1996 Feb;5(2):67-8. Comment on: Arch Fam Med 1995 Jun;4(6):499-501.
The effects of alcohol consumption on laboratory-induced panic and state anxiety. Kushner MG, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):264-70
Early onset of drinking and mortality among male alcoholics. A result of a 10-year prospective follow-up study in Hokkaido, Japan. Mori M, et al. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Dec;30(6):426-34
Alcohol elimination and simulator performance of male and female aviators: a preliminary report. Taylor JL, et al. **Aviat Space Environ Med** 1996 May;67(5):407-13
Examination of a three-dimensional drinking motives questionnaire in a young adult university student sample. Stewart SH, et al. **Behav Res Ther** 1996 Jan;34(1):61-71
Sensible drinking ... or elsewhere [letter; comment] Bayliss L, et al. **BMJ** 1996 Feb 24;312(7029):507. Comment on: BMJ 1996 Jan 6;312(7022):1.
Depression in carers of elderly people living at home. Alcohol misuse could be a factor [letter; comment] Bird RH. **BMJ** 1996 May 11;312(7040):1224. Comment on: BMJ 1996 Jan 20;312(7024):153-6.
Don't rely on drinking wine to prevent traveller's diarrhoea [letter; comment] Cook KA, et al. **BMJ** 1996 Mar 9; 312(7031):642. Comment on: BMJ 1995 Dec 23-30;311(7021):1657-60.
Counting the cost of alcohol for young people [news] Court C. **BMJ** 1995 Nov 25;311(7017):1388
Alcohol--pushing the limits [news] [see comments] Dillner L, et al. **BMJ** 1996 Jan 6;312(7022):7-9. Comment in: BMJ 1996 Jan 6;312(7022):1.
Sensible drinking [editorial; comment] [see comments] Edwards G. **BMJ** 1996 Jan 6;312(7022):1. Comment on: BMJ 1996 Jan 6;312(7022):7-9. Comment in: BMJ 1996 Feb 24;312(7029):506. Comment in: BMJ 1996 Feb 24;312(7029):506-7. Comment in: BMJ 1996 Feb 24;312(7029):507.
Alcohol consumption and risk of coronary heart disease. Studies suggest that wine has additional effect to that of ethanol [letter] Grønbaek M, et al. **BMJ** 1996 Aug 10; 313(7053):365
Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: six year follow up in the Copenhagen male study. Hein HO, et al. **BMJ** 1996 Mar 23;312(7033):736-41
Advice on alcohol consumption has narrow perspective [letter; comment] Jayasinghe S. **BMJ** 1995 Oct 7; 311(7010):950. Comment on: BMJ 1995 Jul 1;311(6996):3-4.
Sensible drinking. Few people will change their drinking habits in London ... [letter; comment] Kessaris N, et al. **BMJ** 1996 Feb 24;312(7029):506-7. Comment on: BMJ 1996 Jan 6;312(7022):1.
Sensible drinking. Civil servants should be congratulated for rejecting "whole population theory" [letter; comment] Le Fanu J. **BMJ** 1996 Feb 24;312(7029):507. Comment on: BMJ 1996 Jan 6;312(7022):1.
Sensible drinking. Government's recommendations should be considered as a whole [letter; comment] Podger GJ. **BMJ** 1996 Feb 24;312(7029):506. Comment on: BMJ 1996 Jan 6;312(7022):1.
Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits. Rimm EB, et al. **BMJ** 1996 Mar 23; 312(7033):731-6 (57 ref.)
Government advice on sensible drinking does not conflict with the data [letter] Thorley A. **BMJ** 1996 Sep 7; 313(7057):624-5
Alcohol consumption and risk of coronary heart disease. Association cannot be assumed to be causal [letter] Whitaker L, et al. **BMJ** 1996 Aug 10;313(7053):365-6
The cardioprotective effects of moderate alcohol consumption [editorial; comment] White IR. **BMJ** 1996 May 11;312(7040):1179-80. Comment on: BMJ 1996 May 11;312(7040):1200.
Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors. Westerdahl J, et al. **Br J Cancer** 1996 May;73(9):1126-31
Alcohol and life expectancy [editorial] Grønbaek M. **Br J Hosp Med** 1995 Oct 4-17;54(7):306-7
Alcohol and the regulation of energy balance: overnight effects on diet-induced thermogenesis and fuel storage. Murgatroyd PR, et al. **Br J Nutr** 1996 Jan;75(1):33-45
The effects of alcoholic beverages on urate metabolism in gout sufferers. Eastmond CJ, et al. **Br J Rheumatol** 1995 Aug;34(8):756-9
A case-control study of reproductive variables, alcohol, and smoking in premenopausal bilateral breast cancer. Haile RW, et al. **Breast Cancer Res Treat** 1996;37(1):49-56
Perceived risks and benefits of alcohol, cigarette, and drug use among urban low-income African-American early adolescents. Feigelman S, et al. **Bull N Y Acad Med** 1995 Summer;72(1):57-75
Linking alcohol and health: irrelevant and dangerous. Jayasinghe S. **Ceylon Med J** 1996 Mar;41(1):22
Alcohol and the NIDDM patient. Bell DS. **Diabetes Care** 1996 May;19(5):509-13 (60 ref.)
Prevalence of chronic diseases in alcohol abstainers. La Vecchia C, et al. **Epidemiology** 1995 Jul;6(4):436-8
The association of moderate maternal and paternal alcohol consumption with birthweight and gestational age. Windham GC, et al. **Epidemiology** 1995 Nov;6(6):591-7
Reported alcohol intake, diet and body mass index in male smokers. Männistö S, et al. **Eur J Clin Nutr** 1996 Apr; 50(4):239-45
Alcohol and drugs (medical and illicit) in fatal road accidents in a city of 300,000 inhabitants. Hansen AC, et al. **Forensic Sci Int** 1996 May 17;79(1):49-52
The impact of alcohol consumption and marijuana use on high school graduation. Yamada T, et al. **Health Econ** 1996 Jan-Feb;5(1):77-92
Resistance-skills training and onset of alcohol use: evidence for beneficial and potentially harmful effects in public schools and in private Catholic schools. Donaldson SI, et al. **Health Psychol** 1995 Jul;14(4):291-300
Residual pressor effects of chronic alcohol in detoxified alcoholics. York JL, et al. **Hypertension** 1996 Jul; 28(1):133-8
The facilitating and enhancing roles Greek associations play in college drinking. Lo CC, et al. **Int J Addict** 1995 Aug; 30(10):1311-22
Alcohol purchase age laws and the serial beginning drinker in New York. Yu J. **Int J Addict** 1995 Aug;30(10):1289-301
Ethanol intake and body weight among smokers [letter; comment] Liu S. **Int J Epidemiol** 1996 Feb;25(1):225-6. Comment on: Int J Epidemiol 1995 Jun;24(3):543-6.
Moderate alcohol consumption and its relation to visceral fat and plasma androgens in healthy women. Cigolini M, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):206-12
Alcohol use among college students in Scotland compared with norms from the United States. Delk EW, et al. **J Am Coll Health** 1996 May;44(6):274-81
Factorial validity and equivalency of the Alcohol Expectancy Questionnaire Tension-Reduction Subscale across gender and drinking frequency. Hittner JB. **J Clin Psychol** 1995 Jul;51(4):563-76
Assessment of alcohol and tobacco use in dental schools' health history forms. Yellowitz JA, et al. **J Dent Educ** 1995 Dec;59(12):1091-6
Acetaminophen hepatotoxicity [letter] Langdon DE. **J Fam Pract** 1996 Jul;43(1):13
The associations between alcohol drinking and dietary habits and blood pressure in Japanese men. Choudhury SR, et al. **J Hypertens** 1995 Jun;13(6):587-93
Drinking to regulate positive and negative emotions: a motivational model of alcohol use. Cooper ML, et al. **J Pers Soc Psychol** 1995 Nov;69(5):990-1005
Tobacco and alcohol billboards in 50 Chicago neighborhoods: market segmentation to sell dangerous products to the poor. Hackbarth DP, et al. **J Public Health Policy** 1995;16(2):213-30
Alcohol and the heart in perspective. Sensible limits reaffirmed. A Working Group of the Royal Colleges of Physicians, Psychiatrists and General Practitioners. **J R Coll Physicians Lond** 1995 Jul-Aug;29(4):266-71
Alcohol and the young. Summary of a report of a joint working party of the Royal College of Physicians and the British Paediatric Association. **J R Coll Physicians Lond** 1995 Nov-Dec;29(6):470-4
Explaining the French paradox. Burr ML. **J R Soc Health** 1995 Aug;115(4):217-9
Ought low alcohol intake to be promoted for health reasons? Holman CD, et al. **J R Soc Med** 1996 Mar;89(3):123-9 (36 ref.)
Regional differences in alcohol and fatal injury: a comparison of data from two county coroners. Cherpitel CJ. **J Stud Alcohol** 1996 May;57(3):244-8
Alcoholic beverage consumption and associated factors in Porto Alegre, a southern Brazilian city: a population-based survey. Moreira LB, et al. **J Stud Alcohol** 1996 May; 57(3):253-9
Getting drunk and growing up: trajectories of frequent binge drinking during the transition to young adulthood. Schulenberg J, et al. **J Stud Alcohol** 1996 May; 57(3):289-304
Sources of alcohol for underage drinkers. Wagenaar AC, et al. **J Stud Alcohol** 1996 May;57(3):325-33
Investigator-observed alcohol-induced flushing but not self-report of flushing is a valid predictor of ALDH2 genotype. Wall TL, et al. **J Stud Alcohol** 1996 May; 57(3):267-72
Alcohol outcome expectancies and alcohol use and problems. Wood MD, et al. **J Stud Alcohol** 1996 May;57(3):283-8
What every mental health professional should know about alcohol. Miller WR, et al. **J Subst Abuse Treat** 1995 Sep-Oct;12(5):355-65
Treatment charges, payment sources, and disability from alcohol-related trauma. Waller JA, et al. **J Trauma** 1995 Nov;39(5):963-7
Alcohol and driving. Alvarez FJ, et al. **Lancet** 1996 Apr 13;347(9007):985-6
Alcohol consumption [letter; comment] Hawks D. **Lancet** 1995 Nov 11;346(8985):1306. Comment on: Lancet 1995 Sep 16;346(8977):716.
A not-so-sensible drinks policy [see comments] Marmot M. **Lancet** 1995 Dec 23-30;346(8991-8992):1643-4. Comment in: Lancet 1996 Feb 24;347(9000):545. Comment in: Lancet 1996 Feb 24;347(9000):545-6.
A not-so-sensible drinks policy [letter; comment] Mason JM. **Lancet** 1996 Feb 24;347(9000):545. Comment on: Lancet 1995 Dec 23-30;346(8991-8992):1643-4.
For creationists, a call to the bar [letter] Newton P. **Lancet** 1996 Mar 9;347(9002):702
A not-so-sensible drinks policy [letter; comment] Powles J, et al. **Lancet** 1996 Feb 24;347(9000):545-6. Comment on: Lancet 1995 Dec 23-30;346(8991-8992):1643-4.
Further reflections on the NHMRC recommendations for alcohol consumption [letter; comment] Gijsbers AJ, et al. **Med J Aust** 1996 Jul 15;165(2):117. Comment on: Med J Aust 1996 Feb 5;164(3):141-5.
Alcohol and pregnancy: doctors' attitudes, knowledge and clinical practice. Leversha AM, et al. **N Z Med J** 1995 Oct 27;108(1010):428-30
Elevated alcohol consumption in null mutant mice lacking 5-HT1B serotonin receptors. Crabbe JC, et al. **Nat Genet** 1996 Sep;14(1):98-101
Body habitus changes among adult males from the normative aging study: relations to aging, smoking history and alcohol intake. Grinker JA, et al. **Obes Res** 1995 Sep;3(5):435-46
Q.E.D. saliva testing isn't flawed [letter] Hinchey WM. **Occup Health Saf** 1996 May;65(5):10
The ecology of alcohol consumption. Lester D. **Percept Mot Skills** 1995 Oct;81(2):462
Occupational and nonoccupational correlates of alcohol consumption in urban transit operators. Ragland DR, et al. **Prev Med** 1995 Nov;24(6):634-45
Recognition and liking of tobacco and alcohol advertisements among adolescents: relationships with susceptibility to substance use. Unger JB, et al. **Prev Med** 1995 Sep; 24(5):461-6
Potentiation of the bioavailability of daidzin by an extract of Radix puerariae. Keung WM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4284-8
Daidzin suppresses ethanol consumption by Syrian golden hamsters without blocking acetaldehyde metabolism. Keung WM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8990-3
Significance of adrenal corticosteroid secretion for the food restriction-induced enhancement of alcohol drinking in the rat. Hansen S, et al. **Psychopharmacology (Berl)** 1995 Sep; 121(2):213-21
Effects of the dopamine D1 receptor antagonist SCH 39166 on the ingestive behaviour of alcohol-preferring rats. Panocka I, et al. **Psychopharmacology (Berl)** 1995 Jul; 120(2):227-35
Breath testing for alcohol [letter] Campbell GD. **S Afr Med J** 1996 Mar;86(3):278-9
Selection of women at high risk of breast cancer using two lifestyle markers: a case control study. Erichsen GG, et al. **Scand J Prim Health Care** 1995 Jun;13(2):157-60
Is moderate alcohol intake in pregnancy associated with the craniofacial features related to the fetal alcohol syndrome? Olsen J, et al. **Scand J Soc Med** 1995 Sep;23(3):156-61
Moderate alcohol consumption in pregnancy and subsequent left-handedness. Olsen J. **Scand J Soc Med** 1995 Sep; 23(3):162-6
Alcohol consumption in a rural area of Cantabria. Herrera Castanedo S, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jun;31(3-4):199-206
Factors associated with alcohol use in young adulthood. Pritchard ME, et al. **Subst Use Misuse** 1996 May; 31(6):679-89
Health aspects of pregnancy and childbirth: United States, 1982-88. Chandra A. **Vital Health Stat 23** 1995 Aug; (18):1-74
[Lies told by the alcohol and tobacco industries and their friends (letter)] Nelpor K, et al. **Cas Lek Cesk** 1995 Sep 20;134(18):596 **(Cze)**
[Mortality differences associated with moderate consumption of beer, wine and spirits] Grønbaek MN, et al. **Ugeskr Laeger** 1996 Apr 15;158(16):2258-61 (Eng. Abstr.) **(Dan)**

[In vino veritas? (editorial)] Grønbaek MN. **Ugeskr Laeger** 1995 Nov 13;157(46):6415 **(Dan)**

[How much does my patient drink?] Poikolainen K. **Duodecim** 1994;110(9):870–6 (34 ref.) **(Fin)**

[A wine pitcher, cause of lead poisoning] Jouglard J, et al. **Presse Med** 1996 Feb 17;25(6):243–6 (8 ref.) (Eng. Abstr.) **(Fre)**

[Alcohol and diabetes] Georgescu M, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):707–11 (17 ref.) **(Fre)**

[Breakfast habits in moderately obese adults and its effect on daily energy and nutrient intake, on alcohol consumption and on various clinical and anthropometric parameters] Spagnoli TD, et al. **Minerva Gastroenterol Dietol** 1995 Sep;41(3):237–45 (Eng. Abstr.) **(Ita)**

[Alcohol consumption and coronary disease in men] Targa L, et al. **Minerva Med** 1996 May;87(5):201–6 (Eng. Abstr.) **(Ita)**

[Present status and future of alcohol studies in the field of public health] Kamishima H. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Feb; 31(1):33–53 (28 ref.) **(Jpn)**

[The effect of work-related stress with change of working conditions for workers with alcohol drinking habit and liver disorder] Kaneko M, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Feb; 31(1):81–94 (Eng. Abstr.) **(Jpn)**

[Alcohol—more than wine with meals] Aasland OG. **Tidsskr Nor Laegeforen** 1995 Sep 20;115(22):2757–8 **(Nor)**

[Alcohol consumption among adolescents in 3 municipalities. A survey of local variations in alcohol consumption] Grimsmo A, et al. **Tidsskr Nor Laegeforen** 1995 Sep 20; 115(22):2759–63 (Eng. Abstr.) **(Nor)**

[Development of drinking habit among adolescents. Factors connected with alcohol consumption] Grimsmo A, et al. **Tidsskr Nor Laegeforen** 1995 Sep 20;115(22):2764–7 (Eng. Abstr.) **(Nor)**

[Alcohol consumption among adolescents in 3 municipalities (letter)] Thelle DS. **Tidsskr Nor Laegeforen** 1995 Oct 20; 115(25):3180 **(Nor)**

[Study of the efficiency of operators exposed to stress factors] Kovalev SV. **Gig Sanit** 1995 Sep–Oct;(5):28–30 (Eng. Abstr.) **(Rus)**

[Intensification of alcohol motivation in CBA mice by means of transferring syngeneic splenocytes or blood serum] Pletsityi KD, et al. **Vopr Med Khim** 1995 Nov–Dec; 41(6):48–9 (Eng. Abstr.) **(Rus)**

[Use of primary care services by adolescents and detection of health problems other than those for which they came] Colino Nevot R, et al. **Aten Primaria** 1995 Dec; 16(10):594–600 (Eng. Abstr.) **(Spa)**

[Test screening—a way to find heavy drinkers (letter)] Andréasson S. **Lakartidningen** 1995 Nov 1;92(44):4077 **(Swe)**

[Abuse of alcohol and central nervous system stimulants. A growing problem in developing countries] Eide AH, et al. **Lakartidningen** 1995 Nov 29;92(48):4569–71 (31 ref.) **(Swe)**

[Fight against increased abuse of alcohol among the elderly and women in the USA] Wirschubsky ZG. **Lakartidningen** 1996 Aug 28;93(34):2850–1 **(Swe)**

ADVERSE EFFECTS

Injury as a motivator to reduce drinking. Longabaugh R, et al. **Acad Emerg Med** 1995 Sep;2(9):817–25

Could bacterial acetaldehyde production explain the deleterious effect of alcohol on skin diseases? [letter] Höök-Nikanne J, et al. **Acta Derm Venereol** 1995 Jul; 75(4):330

A critique of chapter 3: "Individual drinking and degree of risk". Batel P. **Addiction** 1995 Nov;90(11):1450–1

Predictive capacity of the AUDIT questionnaire for alcohol-related harm. Conigrave KM, et al. **Addiction** 1995 Nov;90(11):1479–85

The effect of a moderate dose of alcohol on the traffic hazard perception profile of young drink-drivers. Deery HA, et al. **Addiction** 1996 Jun;91(6):815–27

The economic costs of alcohol-related absenteeism and reduced productivity among the working population of New Zealand. Jones S, et al. **Addiction** 1995 Nov; 90(11):1455–61

A major contribution to improve the science policy discussion. Mann K. **Addiction** 1995 Nov;90(11):1451–2

Population science, prejudice and policy on alcohol. Marmot MG. **Addiction** 1995 Nov;90(11):1441–3

Investigations into the toxic effects of alcohol on skeletal muscle. Reilly ME, et al. **Adverse Drug React Toxicol Rev** 1995 Summer;14(2):117–50 (141 ref.)

Do not change the numbers—clarify the message. The government review of the Sensible Drinking message: a Medical Council on Alcoholism view. **Alcohol Alcohol** 1995 Sep;30(5):571–5

'J-shaped' relationship between drinking during pregnancy and birth weight: reanalysis of prospective epidemiological data. Abel EL, et al. **Alcohol Alcohol** 1995 May; 30(3):345–55

Memory functioning in social drinkers: a study of event-related potentials. Fox AM, et al. **Alcohol Alcohol** 1995 May;30(3):303–10

Effect of acute alcohol ingestion on mineral metabolism and osteoblastic function. García-Sanchez A, et al. **Alcohol Alcohol** 1995 Jul;30(4):449–53

Alcohol and road traffic accidents. Mayou R, et al. **Alcohol Alcohol** 1995 Nov;30(6):709–11

Alcohol consumption and visual contrast sensitivity. Roquelaure Y, et al. **Alcohol Alcohol** 1995 Sep;30(5):681–5

Ethnic differences in the biological consequences of alcohol abuse: a comparison between south Asian and European males. Wickramasinghe SN, et al. **Alcohol Alcohol** 1995 Sep;30(5):675–80

Physical morbidity in patients admitted to a private hospital for detoxification from alcohol. Wylie AS, et al. **Alcohol Alcohol** 1995 Sep;30(5):641–3

Effect of prenatal ethanol and stress on levels of beta-endorphin in different brain regions of the rat. Baker RA, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):727–34

Lack of plasma complement activation in severe acute alcoholic hepatitis. Bird GL, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1537–40

Alcohol consumption and physical fitness among young adults. Braun BL, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):1048–54

Diabetic patients' alcohol use and quality of life: relationships with prescribed treatment compliance among older males. Cox WM, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):327–31

Alcohol ingestion impairs host defenses predisposing otherwise healthy mice to Pneumocystis carinii infection. D'Souza NB, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1219–25

Alcohol, hepatotropic viruses, and hepatocellular carcinoma [editorial] Nalpas B, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1089–95 (96 ref.)

Carbohydrate-deficient transferrin as a marker of alcohol abuse: relationship to alcohol consumption, severity of liver disease, and fibrogenesis. Niemelä O, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1203–8

Moderate alcohol consumption and disorders of human spermatogenesis. Pajarinen J, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):332–7

Dose-dependent effects of acute in vivo ethanol exposure on extracellular glutamate concentration in the cerebral cortex of the near-term fetal sheep. Reynolds JD, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1447–53

Is alcohol-related flushing a protective factor for alcoholism in Caucasians? Slutske WS, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):582–92

Alcohol hangover and managerial effectiveness. Streufert S, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1141–6

Role of plasma vasopressin in changes of water balance accompanying acute alcohol intoxication. Taivainen H, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):759–62

Effect of alcohol use on allograft rejection rates after liver transplantation for alcoholic liver disease. Van Thiel DH, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1151–5

Effect of chronic alcoholism on human muscle glycogen and glucose metabolism. Vernet M, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1295–9

The hyperphagic effect of a high-fat diet and alcohol intake persists after control for energy density. Tremblay A, et al. **Am J Clin Nutr** 1996 Apr;63(4):479–82

Alcohol, the elderly, and motor vehicle crashes. Higgins JP, et al. **Am J Emerg Med** 1996 May;14(3):265–7

Re: "Point/counterpoint: meta-analysis of observational studies" [letter; comment] Longnecker MP. **Am J Epidemiol** 1995 Oct 1;142(7):779–82. Comment on: Am J Epidemiol 1994 Nov 1;140(9):771–8. Comment on: Am J Epidemiol 1994 Nov 1;140(9):779–82. Comment on: Am J Epidemiol 1994 Nov 1;140(9):783–7. Comment on: Am J Epidemiol 1994 Nov 1;140(9):788–91.

Re: "Tobacco, alcohol, and colorectal tumors: a multistep process" [letter; comment] Neugut AI. **Am J Epidemiol** 1995 Dec 15;142(12):1346–7. Comment on: Am J Epidemiol 1995 Jun 1;141(11):1038–46.

Alcohol intake and subjective health. Poikolainen K, et al. **Am J Epidemiol** 1996 Aug 15;144(4):346–50

Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Ohnishi K, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1374–9

Polymorphism in ALDH2-genotype in Japanese men and the alcohol-blood pressure relationship. Tsuritani I, et al. **Am J Hypertens** 1995 Nov;8(11):1053–9

Effect measures for behavioral factors adversely affecting fetal growth. Spinillo A, et al. **Am J Perinatol** 1996 Feb; 13(2):119–23

Florida goes statewide with alcohol health warning signs. Cleary D. **Am J Public Health** 1996 Jun;86(6):882–3

Relationship of cigarette smoking, alcohol use, and dietary habits with sigmoid colon adenomas. Todoroki I, et al. **Ann Epidemiol** 1995 Nov;5(6):478–83

Lipid vs protein theories of alcohol action in the nervous system. Peoples RW, et al. **Annu Rev Pharmacol Toxicol** 1996;36:185–201 (112 ref.)

Smoking, alcohol, sexual behaviour and drug use in women with cervical human papillomavirus infection. Sikström B, et al. **Arch Gynecol Obstet** 1995;256(3):131–7

Alcohol-related problems in older persons. Determinants, consequences, and screening. Fink A, et al. **Arch Intern Med** 1996 Jun 10;156(11):1150–6 (76 ref.)

Coffee consumption, alcohol use, and cigarette smoking as determinants of serum total and HDL cholesterol in two Serbian cohorts of the Seven Countries Study. Jansen DF, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov; 15(11):1793–7

Alcohol & tobacco: some good news & some bad news. Dille JR. **Aviat Space Environ Med** 1995 Jul;66(7):704

Effect of alcohol on the threshold for detecting angular acceleration. Ross LE, et al. **Aviat Space Environ Med** 1995 Jul;66(7):635–40

The effect of social deprivation on birthweight, excluding physiological and pathological effects. Wilcox MA, et al. **Br J Obstet Gynaecol** 1995 Nov;102(11):918–24

The influence of cigarette smoking, alcohol, and green tea consumption on the risk of carcinoma of the cardia and distal stomach in Shanghai, China. Ji BT, et al. **Cancer** 1996 Jun 15;77(12):2449–57

Cigarette smoking and alcohol consumption and the risk of pancreatic cancer: a case-control study in Shanghai, China. Ji BT, et al. **Cancer Causes Control** 1995 Jul;6(4):369–76

Alcohol intake and breast cancer risk: effect of exposure from 15 years of age. Holmberg L, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Dec;4(8):843–7

Lifetime alcohol consumption and breast cancer risk among postmenopausal women in Los Angeles. Longnecker MP, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov; 4(7):721–5

"Moderate" drinking during pregnancy: cause for concern? Abel EL. **Clin Chim Acta** 1996 Mar 15;246(1–2):149–54 (15 ref.)

Health effects of moderate alcohol consumption: a paradigmatic risk factor. Goldberg DM, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):1–3

Alcohol and hypertension. Klatsky AL. **Clin Chim Acta** 1996 Mar 15;246(1–2):91–105 (28 ref.)

Mild maternal drinking and pregnancy outcome: perceived versus true risks. Koren G, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):155–62

The questionable link between alcohol intake and cancer. Rubin E. **Clin Chim Acta** 1996 Mar 15;246(1–2):143–8 (14 ref.)

Assessing moderate alcohol consumption as a personal risk factor. Werner M. **Clin Chim Acta** 1996 Mar 15; 246(1–2):5–20 (45 ref.)

Alcohol and hypertension. Beilin LJ. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):185–8 (35 ref.)

Alcohol, hypertension, coronary disease and stroke. Lip GY, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):189–94 (66 ref.)

The effects of cigarette smoking and alcohol consumption on blood haemoglobin, erythrocytes and leucocytes: a dose related study on male subjects. Whitehead TP, et al. **Clin Lab Haematol** 1995 Jun;17(2):131–8

Beer potomania: two cases and review of the literature. Fenves AZ, et al. **Clin Nephrol** 1996 Jan;45(1):61–4 (14 ref.)

Toxicological effects of ethanol on human health. Ahmed FE. **Crit Rev Toxicol** 1995;25(4):347–67 (113 ref.)

Unpleasant alcohol effect in diabetes associated with 3243 bp mitochondrial tRNALeu(UUR) mutation [letter] Suzuki Y, et al. **Diabetes Care** 1995 Jun;18(6):880–1

Decrease in alcohol tolerance: clinical significance in alcohol dependence. Ziółkowski M, et al. **Drug Alcohol Depend** 1995 Jul;39(1):33–6

Research and prevention priorities for alcohol carcinogenesis. Rothman KJ. **Environ Health Perspect** 1995 Nov;103 Suppl 8:161–3

Alcohol as a cause of cancer. Thomas DB. **Environ Health Perspect** 1995 Nov;103 Suppl 8:153–60 (65 ref.)

Maternal smoking, alcohol consumption, and fetal growth [letter; comment] Windham GC, et al. **Epidemiology** 1995 Sep;6(5):570–1. Comment on: Epidemiology 1995 Mar;6(2):115–20.

Case-control study of oral dysplasia and risk habits among patients of a dental hospital. Kulasegaram R, et al. **Eur J Cancer B Oral Oncol** 1995 Jul;31B(4):227–31

Alcohol, tobacco, diet and the risk of oral cancer: a pooled analysis of three case-control studies. Macfarlane GJ, et al. **Eur J Cancer B Oral Oncol** 1995 May;31B(3):181–7

Body fatness in active individuals reporting low lipid and alcohol intake. Tremblay A, et al. **Eur J Clin Nutr** 1995 Nov;49(11):824–31

Alcohol intake as a risk factor for peripheral arterial disease in the general population in the Edinburgh Artery Study. Jepson RG, et al. **Eur J Epidemiol** 1995 Feb;11(1):9–14

The association between oral leukoplakia and use of tobacco, alcohol and khat based on relative risks assessment in Kenya. Macigo FG, et al. **Eur J Oral Sci** 1995 Oct; 103(5):268–73

Acute heavy alcohol intake increases silent myocardial ischaemia in patients with stable angina pectoris. Rossinen J, et al. **Heart** 1996 Jun;75(6):563–7

A multiple-level, comprehensive approach to the prevention of fetal alcohol syndrome (FAS) and other alcohol-related birth defects (ARBD). May PA. **Int J Addict** 1995; 30(12):1549–602 (160 ref.)

The effectiveness of selected risk factors in mediating gender differences in drinking and it problems. Thomas BS. **J Adolesc Health** 1995 Aug;17(2):91–8

Investigation of the mechanism of alcohol-induced bronchial asthma. Shimoda T, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):74–84

Alcohol consumption and risk of deep venous thrombosis and pulmonary embolism in older persons. Pahor M, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1030–7

Psychoactive medication, alcohol use, and falls among older adults. Sheahan SL, et al. **J Behav Med** 1995 Apr; 18(2):127–40

Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. Imrey PB, et al. **J Clin Microbiol** 1995 Dec; 33(12):3133–7

A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. Castaneda R, et al. **J Clin Psychiatry** 1996 May;57(5):207–12 (82 ref.)

Alcohol, hypertension and cardiovascular disease [editorial] Beilin LJ. **J Hypertens** 1995 Sep;13(9):939–42

Alcohol intake and cardiovascular mortality in hypertensive patients: report from the Department of Health Hypertension Care Computing Project. Palmer AJ, et al. **J Hypertens** 1995 Sep;13(9):957–64

Ethanol ingestion reduces antipneumococcal activity of rat pulmonary surfactant. Rubins JB, et al. **J Infect Dis** 1996 Sep;174(3):507–12

Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a Childrens Cancer Group study. Shu XO, et al. **J Natl Cancer Inst** 1996 Jan 3;88(1):24–31

Tobacco, alcohol, and oral cancer: the patient's perspective. Fabian MC, et al. **J Otolaryngol** 1996 Apr;25(2):88–93

Harmful effects of drinking and the use and perceived effectiveness of treatment. Burton TL, et al. **J Stud Alcohol** 1995 Nov;56(6):611–5

The Driving Expectancy Questionnaire: development, psychometric assessment and predictive utility among young drink–drivers. Deery HA, et al. **J Stud Alcohol** 1996 Mar;57(2):193–202

The effects of alcohol on the aggressive responding of women. Dougherty DM, et al. **J Stud Alcohol** 1996 Mar; 57(2):178–86

Patterns of DSM–IV alcohol abuse and dependence symptoms in adolescent drinkers. Martin CS, et al. **J Stud Alcohol** 1995 Nov;56(6):672–80

The adverse impact of heavy episodic drinkers on other college students. Wechsler H, et al. **J Stud Alcohol** 1995 Nov;56(6):628–34

Low alcohol drinks and risk of high blood alcohol in children [letter] Jones AW. **J Toxicol Clin Toxicol** 1996;34(3):349–50

Alcohol as a risk factor for downhill skiing trauma. Salminen S, et al. **J Trauma** 1996 Feb;40(2):284–7

Tobacco, alcohol and dietary factors associated with the risk of oral cancer among Japanese. Takezaki T, et al. **Jpn J Cancer Res** 1996 Jun;87(6):555–62

Differential effects of cigarette smoking and alcohol consumption on the plasma levels of carotenoids in middle–aged Japanese men. Tsubono Y, et al. **Jpn J Cancer Res** 1996 Jun;87(6):563–9

Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver [see comments] Teli MR, et al. **Lancet** 1995 Oct 14;346(8981):987–90. Comment in: Lancet 1995 Dec 9;346(8989):1562–3.

The measure of life–time alcohol consumption in patients with cirrhosis: reproducibility and clinical relevance. Arico S, et al. **Liver** 1995 Aug;15(4):202–8

Prenatal alcohol, marijuana, and tobacco use: infant mental and motor development. Richardson GA, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):479–87

Alcohol and breast cancer: is there a conclusion? Hankinson SE, et al. **Nutrition** 1995 May–Jun;11(3):320–1

Self–reported effects of alcohol use on symptoms of schizophrenia. Pristach CA, et al. **Psychiatr Serv** 1996 Apr; 47(4):421–3

The association of alcohol consumption with self–reported illness in university students. Engs RC, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):727–36

Alcohol consumption and health: synergistic interaction with personality. Grossarth–Maticek R, et al. **Psychol Rep** 1995 Oct;77(2):675–87

Comments on "Alcohol use and risky sex among college students" [comment] Ridley DR, et al. **Psychol Rep** 1995 Oct;77(2):421–2. Comment on: Psychol Rep 1995 Jun;76(3 Pt 1):723–6.

Perceptions of risks of drinking and boating among Massachusetts boaters. Howland J, et al. **Public Health Rep** 1996 Jul–Aug;111(4):372–7

Youth beliefs and knowledge about the risks of drinking while pregnant. MacKinnon DP, et al. **Public Health Rep** 1995 Nov–Dec;110(6):754–63

Octreotide reduces alcohol–induced hypotension and orthostatic symptoms in primary autonomic failure. Chaudhuri KR, et al. **QJM** 1995 Oct;88(10):719–25

New experiments underscore warnings on maternal drinking [news] Braun S. **Science** 1996 Aug 9;273(5276):738–9

Measurement error models for ordinal exposure variables measured with error. Rosner BA. **Stat Med** 1996 Feb 15; 15(3):293–303

Tobacco, alcohol, diet and risk of prostate cancer. De Stefani E, et al. **Tumori** 1995 Sep–Oct;81(5):315–20

Alcohol intake in patients admitted acutely to a general medical unit. McKnight JA, et al. **Ulster Med J** 1995 Oct; 64(2):157–63

Long–term changes in bone mass after partial gastrectomy in a well–defined population and its relation to tobacco and alcohol consumption. Krogsgaard MR, et al. **World J Surg** 1995 Nov–Dec;19(6):867–71

[Electrocardiographic anomalies during stress–induced hypoglycemia (letter)] Garcin JM, et al. **Presse Med** 1996 Jan 6–13;25(1):40 **(Fre)**

[Alcohol and aggression—violence prone drivers preventing passing maneuvers] Zabel GE. **Blutalkohol** 1996 Mar; 33(2):84–93 (Eng. Abstr.) **(Ger)**

[Effect of exogenous toxins on fertility] Görnig VM, et al. **Fortschr Med** 1996 May 20;114(14):169–71 (Eng. Abstr.) **(Ger)**

[Increased incidence of dermatoses in nicotine and alcohol abuse] Becker J. **Hautarzt** 1995 Oct;46(10):735 **(Ger)**

[Bladder tumors and the consumption of coffee and alcohol: a hospital case–control study in the province of Brescia] Donato F, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):217–8 **(Ita)**

[Obesity due to alcohol intake] Nakamura H, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:430–5 (8 ref.) **(Jpn)**

[Alcohol consumption and glomerulonephritis caused by IgA mesangial deposits. (Berger's disease)] García R, et al. **Rev Med Chil** 1995 Jan;123(1):37–43 (Eng. Abstr.) **(Spa)**

BLOOD

Plasma concentrations of beta–endorphin, adrenocorticotropic hormone, and cortisol in drinking and abstinent chronic alcoholics. del Arbol JL, et al. **Alcohol** 1995 Nov–Dec;12(6):525–9

Significant increase of blood alcohol by cimetidine after repetitive drinking of small alcohol doses. Gupta AM, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1083–7

Effects of cimetidine on blood ethanol levels after alcohol ingestion and genetic polymorphisms of sigma–alcohol dehydrogenase in Japanese. Kawashima O, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):36A–39A

Methanol in human breath. Taucher J, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1147–50

Relation of smoking and alcohol consumption to serum fatty acids. Simon JA, et al. **Am J Epidemiol** 1996 Aug 15; 144(4):325–34

High–density–lipoprotein cholesterol and types of alcoholic beverages consumed among men and women. Parker DR, et al. **Am J Public Health** 1996 Jul;86(7):1022–7

The effects of cigarette smoking and alcohol consumption on blood lipids: a dose–related study on men. Whitehead TP, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):99–106

Consistent relationship between selenium and apolipoprotein A–II concentrations in the sera of fasting middle–aged male abstainers and regular consumers of alcohol. Koyama H, et al. **Biol Trace Elem Res** 1995 Oct;50(1):33–42

Circulating total and ionized magnesium after ethanol ingestion. Wu C, et al. **Clin Chem** 1996 Apr;42(4):625–9

Effects of alcohol on plasma lipoprotein metabolism. Frohlich JJ. **Clin Chim Acta** 1996 Mar 15;246(1–2):39–49 (30 ref.)

Wine: does the colour count? Goldberg DM, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):183–93

Endogenous methanol: variability in concentration and rate of production. Evidence of a deep compartment? Haffner HT, et al. **Forensic Sci Int** 1996 May 31;79(2):145–54

Female drivers suspected for drunken or drugged driving. Skurtveit S, et al. **Forensic Sci Int** 1995 Oct 30; 75(2–3):139–48

Activities of acetylcholinesterase and NA+, K+ –ATP–ase in human erythrocytes after ethanol consumption. Dudek IM, et al. **Int J Occup Med Environ Health** 1995;8(2):109–14

[Concentration dependent ethanol metabolism in steady–state] Wehner HD, et al. **Blutalkohol** 1996 Jan; 33(1):17–22 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[A new method for correcting alcoholic motivation] Batuev AS, et al. **Fiziol Zh Im I M Sechenova** 1995 Jan; 81(1):135–41 **(Rus)**

ECONOMICS

A grouped data regression approach to estimating economic and social influences on individual drinking behaviour. Sutton M, et al. **Health Econ** 1995 May–Jun;4(3):237–47

EPIDEMIOLOGY

Alcohol use among subcritically injured emergency department patients. Becker B, et al. **Acad Emerg Med** 1995 Sep;2(9):784–90

Alcohol and tobacco use in the Minnesota Heart Health Program. Nothwehr F, et al. **Addict Behav** 1995 Jul–Aug; 20(4):463–70

Combining methods to identify new measures of women's drinking problems. Part I: The ethnographic stage. Ames G, et al. **Addiction** 1996 Jun;91(6):829–44

Cultural orientation and adolescents' alcohol use in Zimbabwe. Eide AH, et al. **Addiction** 1996 Jun;91(6):807–14

Potential consequences from possible changes to Nordic retail alcohol monopolies resulting from European Union membership. Holder HD, et al. **Addiction** 1995 Dec; 90(12):1603–18

Heavy drinking in the restaurant business: the role of social modelling and structural factors of the work–place. Kjaerheim K, et al. **Addiction** 1995 Nov;90(11):1487–95

Prague women's drinking before and after the 'velvet revolution' of 1989: a longitudinal study. Kubička L, et al. **Addiction** 1995 Nov;90(11):1471–8

Are males actually heavier drinkers than females? [letter] Lo CC, et al. **Addiction** 1995 Nov;90(11):1547–50

Young teenagers and access to alcohol in a Swiss canton: evidence from observational testing and from a telephone survey. Vaucher S, et al. **Addiction** 1995 Dec; 90(12):1619–25

Teenage drinking: a 4–year comparative study. Foxcroft DR, et al. **Alcohol Alcohol** 1995 Nov;30(6):713–9

Increased female drinking in accordance with post–industrial urbanization in Japan. Takano T, et al. **Alcohol Alcohol** 1996 Jan;31(1):41–9

Retrospective self–report of alcohol consumption: test–retest reliability by telephone. Cohen BB, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1156–61

Beverage effects on patterns of alcohol consumption. Del Rio C, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1583–6

Alcohol and substance use among Japanese high school students. Matsushita S, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):379–83

Drinking patterns and health status in smoking and nonsmoking alcoholics. York JL, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):666–73

Style, consumption, and problem drinking: a measurement model. Yu J. **Alcohol Clin Exp Res** 1995 Oct;19(5):1192–7

Alcohol use and prostate cancer risk in US blacks and whites. Hayes RB, et al. **Am J Epidemiol** 1996 Apr 1;143(7):692–7

Reliability of alcohol intake as recalled from 10 years in the past. Liu S, et al. **Am J Epidemiol** 1996 Jan 15;143(2):177–86

Alcohol consumption and myocardial infarction: a case–control study in France and Northern Ireland [comment] Marques–Vidal P, et al. **Am J Epidemiol** 1996 Jun 1;143(11):1089–93. Comment on: Am J Epidemiol 1996 Jun 1;143(11):1094–8; discussion 1099.

Alcohol consumption and coronary heart disease: good habits may be more important than just good wine [see comments] Rimm EB. **Am J Epidemiol** 1996 Jun 1;143(11):1094–8; discussion 1099 (39 ref.). Comment in: Am J Epidemiol 1996 Jun 1;143(1):1089–93.

Greater alcohol use in women with PMS [letter; comment] Ragan PW. **Am J Psychiatry** 1995 Oct;152(10):1539–40. Comment on: Am J Psychiatry 1994 Oct;151(10):1503–4.

Drug use patterns at major rock concert events. Erickson TB, et al. **Ann Emerg Med** 1996 Jul;28(1):22–6

Is a history of alcohol problems or of psychiatric disorder associated with attrition at 11–year follow–up? Bucholz KK, et al. **Ann Epidemiol** 1996 May;6(3):228–34

Childhood cancer and parental use of alcohol and tobacco. Sorahan T, et al. **Ann Epidemiol** 1995 Sep;5(5):354–9

How much alcohol in Western Australia is consumed in a 'hazardous' or 'harmful' way? [letter] Oddy W, et al. **Aust J Public Health** 1995 Aug;19(4):434

Patterns of common drug use in teenagers. Patton GC, et al. **Aust J Public Health** 1995 Aug;19(4):393–9

Designer drinks and drunkenness amongst a sample of Scottish schoolchildren [see comments] McKeganey N, et al. **BMJ** 1996 Aug 17;313(7054):401. Comment in: BMJ 1996 Aug 17;313(7054):375.

Drinking, smoking, and illicit drug use among 15 and 16 year olds in the United Kingdom [see comments] Miller PM, et al. **BMJ** 1996 Aug 17;313(7054):394–7. Comment in: BMJ 1996 Aug 17;313(7054):375.

Drinking and driving among Ontario high school students, 1977–1995. Stoduto G, et al. **Can J Public Health** 1996 May–Jun;87(3):187–8

Alcohol consumption and risk of colorectal cancer in a cohort of Finnish men. Glynn SA, et al. **Cancer Causes Control** 1996 Mar;7(2):214–23

Case–control and cohort studies of moderate alcohol consumption and stroke. Camargo CA Jr. **Clin Chim Acta** 1996 Mar 15;246(1–2):107–19 (41 ref.)

Alcohol and coronary heart disease: consistent relationship and public health implications. Criqui MH. **Clin Chim Acta** 1996 Mar 15;246(1–2):51–7 (27 ref.)

Epidemiologic data on alcoholic beverage consumption and risk of cancer. Longnecker MP, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):121–41 (130 ref.)

Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Becker U, et al. **Hepatology** 1996 May;23(5):1025–9

A comparative study of two methods for the measurement of alcohol consumption in the general population. Romelsjö A, et al. **Int J Epidemiol** 1995 Oct;24(5):929–36

Psychiatric comorbidity with problematic alcohol use in high school students. Rohde P, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):101–9

Alcohol use in retirement communities. Adams WL. **J Am Geriatr Soc** 1996 Sep;44(9):1082–5

Smoking and alcohol intake in a rural Indian population and correlation with hypertension and coronary heart disease prevalence. Gupta R, et al. **J Assoc Physicians India** 1995 Apr;43(4):253–8

Drug and alcohol use in fatally injured drivers in Washington State. Logan BK, et al. **J Forensic Sci** 1996 May; 41(3):505–10

Alcohol consumption among HIV–infected patients. Lefevre F, et al. **J Gen Intern Med** 1995 Aug;10(8):458–60

Drug and alcohol use among lesbian and gay people in a southern U.S. sample: epidemiological, comparative, and methodological findings from the Trilogy Project. Skinner WF, et al. **J Homosex** 1996;30(3):59–92

Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. Ko YC,

et al. **J Oral Pathol Med** 1995 Nov;24(10):450–3

Alcohol consumption among older urban American Indians [see comments] Barker JC, et al. **J Stud Alcohol** 1996 Mar; 57(2):119–24. Comment in: J Stud Alcohol 1996 Mar;57(2):117–8.

Demographic characteristics, drinking patterns and drink–driving behavior of injured male drivers and motorcycle riders. Holubowycz OT, et al. **J Stud Alcohol** 1995 Sep;56(5):513–21

The growth of conduct problem behaviors from middle childhood to early adolescence: sex differences and the suspected influence of early alcohol use. Johnson EO, et al. **J Stud Alcohol** 1995 Nov;56(6):661–71

Drinking by police officers, general drivers and late–night drivers. Meyers AR, et al. **J Stud Alcohol** 1996 Mar; 57(2):187–92

Alcoholic beverage consumption and associated factors in Porto Alegre, a southern Brazilian city: a population–based survey. Moreira LB, et al. **J Stud Alcohol** 1996 May; 57(3):253–9

Cycles of alcohol dependence: frequency–domain analyses of daily drinking logs for matched alcohol–dependent and nondependent subjects. Mundt JC, et al. **J Stud Alcohol** 1995 Sep;56(5):491–9

Seasonal variation in alcohol use. Uitenbroek DG. **J Stud Alcohol** 1996 Jan;57(1):47–52

Changes in alcohol consumption resulting from the elimination of retail wine monopolies: results from five U.S. states. Wagenaar AC, et al. **J Stud Alcohol** 1995 Sep; 56(5):566–72

Alcohol and older American Indians [editorial; comment] Westermeyer J. **J Stud Alcohol** 1996 Mar;57(2):117–8. Comment on: J Stud Alcohol 1996 Mar;57(2):119–24.

Subgroup variation in U.S. drinking patterns: results of the 1992 national longitudinal alcohol epidemiologic study. Dawson DA, et al. **J Subst Abuse** 1995;7(3):331–44

Addiction among high school pupils in Holon (Israel) and their attitudes towards drugs: a pilot study (1993–1994). Brook U. **J Trop Pediatr** 1996 Jun;42(3):175–7

From the Centers for Disease Control and Prevention. Update: alcohol–related traffic crashes and fatalities among youth—United States, 1982–1994. **JAMA** 1995 Dec 27; 274(24):1904–5

The relation of smoking, alcohol use and obesity to risk of sigmoid colon and rectal adenomas. Honjo S, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1019–26

Roadside driver alcohol survey and hospital alcohol survey in Port Moresby, Papua New Guinea. Attah Johnson FY, et al. **Med Law** 1995;14(3–4):157–61

Update: alcohol–related traffic crashes and fatalities among youth and young adults—United States, 1982–1994. **MMWR Morb Mortal Wkly Rep** 1995 Dec 1;44(47):869–74

Alcohol involvement in fatal motor–vehicle crashes—United States, 1993–1994. **MMWR Morb Mortal Wkly Rep** 1995 Dec 1;44(47):886–7

Association between postpartum substance use and depressive symptoms, stress, and social support in adolescent mothers. Barnet B, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):659–66

Prevalence and consequences of smoking, alcohol use, and illicit drug use at five worksites. French MT, et al. **Public Health Rep** 1995 Sep–Oct;110(5):593–9

The prevalence of selected risk factors for chronic disease among American Indians in Washington State. Kimball EH, et al. **Public Health Rep** 1996 May–Jun;111(3):264–71

Smoking, consumption of alcohol and sedentary life style in population grouping and their relationships with lipemic disorders. Martins IS, et al. **Rev Saude Publica** 1995 Feb; 29(1):38–45

Alcohol consumption in a rural area of Cantabria. Herrera Castanedo S, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jun;31(3–4):199–206

Alcohol consumption and stroke mortality. 20–year follow–up of 15,077 men and women. Hansagi H, et al. **Stroke** 1995 Oct;26(10):1768–73

Patterns of alcohol intake and risk of stroke in middle–aged British men. Wannamethee SG, et al. **Stroke** 1996 Jun; 27(6):1033–9

Relationship between alcohol consumption and victim behaviors immediately preceding sexual aggression by an acquaintance. Harrington NT, et al. **Violence Vict** 1994 Winter;9(4):315–24

Evaluation and monitoring of action on alcohol. Targets, indicators and monitoring and reporting systems for action on alcohol. Anderson P, et al. **WHO Reg Publ Eur Ser** 1995;59:1–89

The relationship between college females' drinking and their sexual behaviors. Piombo M, et al. **Womens Health Issues** 1996 Jul–Aug;6(4):221–8

[Trends in alcohol consumption in Switzerland from 1975–1992] Schmid H, et al. **Schweiz Med Wochenschr** 1996 Jun 22;126(25):1099–106 (Eng. Abstr.) **(Ger)**

[Survey of alcohol drinking and results of studies of alcoholism biological markers within the scope of a neurologic occupational medicine study of industrial workers] Reinhardt F, et al. **Versicherungsmedizin** 1996 Jun 1;48(3):101–3 (Eng. Abstr.) **(Ger)**

[Alcohol and women: a study in high schools] Tumino E, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):265–6 **(Ita)**

[Prevalence of drinkers at risk and associated factors among men attending primary care clinics] Fernández MI, et al. **Aten Primaria** 1996 Feb 29;17(3):182–6 (Eng. Abstr.) **(Spa)**

[Alcohol consumption in schoolchildren] Ariza Cardenal C, et al. **Med Clin (Barc)** 1995 Oct 21;105(13):481–6 (Eng. Abstr.) **(Spa)**

[Toxic habits in adolescents (letter; comment)] Costa Zamora P, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):78. Comment on: Med Clin (Barc) 1995 May 27;104(20):784–8. **(Spa)**

[Tobacco and alcohol habits in a hospitalized population in a third level center. Region of Murcia] Botía Martínez F, et al. **Rev Esp Salud Publica** 1995 May–Aug;69(3–4):283–94 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Differences in Asian and white drinking: consumption level, drinking contexts, and expectancies. O'Hare T. **Addict Behav** 1995 Mar–Apr;20(2):261–6

Alcohol and pancreatic cancer in blacks and whites in the United States. Silverman DT, et al. **Cancer Res** 1995 Nov 1;55(21):4899–905

The role of gender and acculturation on determining the consumption of alcoholic beverages among Mexican–Americans and Central Americans in the United States. Marín G, et al. **Int J Addict** 1995 May;30(7):779–94

Alcohol, sexual practices, and risk of AIDS among blacks, Hispanics, and whites. Caetano R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 15;10(5):554–61

Dietary practices, alcohol consumption, and smoking behavior: ethnic, sex, and acculturation differences. Otero–Sabogal R, et al. **J Natl Cancer Inst Monogr** 1995; (18):73–82

Role of cigarette smoking as a gateway drug to alcohol use in Hispanic junior high school students. Parra–Medina DM, et al. **J Natl Cancer Inst Monogr** 1995;(18):83–6

Racial and ethnic correlates of tobacco, alcohol and illicit drug use in a pregnant population. Wiemann CM, et al. **J Reprod Med** 1995 Aug;40(8):571–8

Husband's level of drinking and egalitarianism in Mexican–American families. Alaniz ML. **Subst Use Misuse** 1996 May;31(6):647–61

GENETICS

MDMA (Ecstasy) substitutes for the ethanol discriminative cue in HAD but not LAD rats. Meehan SM, et al. **Alcohol** 1995 Nov–Dec;12(6):569–72

Genetic control of alcohol deprivation effect in congenic mice. Salimov R, et al. **Alcohol** 1995 Sep–Oct;12(5):469–74

Ethanol consumption and taste preferences in C57BL/6ByJ and 129/J mice. Bachmanov AA, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):201–6

Strategies for mapping and identifying quantitative trait loci specifying behavioral responses to alcohol. Buck KJ. **Alcohol Clin Exp Res** 1995 Aug;19(4):795–801 (57 ref.)

Voluntary alcohol consumption in BXD recombinant inbred mice: relationship to alcohol metabolism. Gill K, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):185–90

Gonadal hormones and aggression–maintaining effect of alcohol in male transgenic transforming growth factor–alpha mice. Hilakivi–Clarke L, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):708–13

Association between low contents of dopamine and serotonin in the nucleus accumbens and high alcohol preference. McBride WJ, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1420–2

Bidirectional selective breeding for ethanol effects on locomotor activity: characterization of FAST and SLOW mice through selection generation 35. Shen EH, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1234–45

Acute effects of alcohol on P300 in Asians with different ALDH2 genotypes. Wall TL, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):617–22

Enhanced sensitivity of pituitary beta–endorphin to ethanol in subjects at high risk of alcoholism. Gianoulakis C, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):250–7

Molecular genetic analysis of the role of GABAergic systems in the behavioral and cellular actions of alcohol. Buck KJ. **Behav Genet** 1996 May;26(3):313–23 (72 ref.)

Quantitative trait loci for ethanol sensitivity in the LS x SS recombinant inbred strains: interval mapping. Markel PD, et al. **Behav Genet** 1996 Jul;26(4):447–58

Genetic analysis of the corticosterone response to ethanol in BXD recombinant inbred mice. Roberts AJ, et al. **Behav Neurosci** 1995 Dec;109(6):1199–208

Effects of access to a running wheel on food, water and ethanol intake in rats bred to accept ethanol. McMillan DE, et al. **Drug Alcohol Depend** 1995 Nov;40(1):1–7

Identification of sex–specific quantitative trait loci controlling alcohol preference in C57BL/ 6 mice [see comments] Melo JA, et al. **Nat Genet** 1996 Jun;13(2):147–53. Comment in: Nat Genet 1996 Jun;13(2):137–8.

Effect of ethanol on extracellular dopamine in the nucleus accumbens of alcohol–preferring AA and alcohol–avoiding ANA rats. Kiianmaa K, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):29–34

IMMUNOLOGY

Immunoglobulin M synthesis after burn injury: the effects of chronic ethanol on postinjury synthesis. Tabata T, et al. **J Burn Care Rehabil** 1995 Jul–Aug;16(4):400–6

Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Ben–Eliyahu S, et al. **Nat Med** 1996 Apr;2(4):457–60

LEGISLATION & JURISPRUDENCE

A view of alcohol policy and the public good from Turkmenistan. Kerimi N. **Addiction** 1996 Jun;91(6):775–8

Enforcement of drunken driving laws in cases involving injured intoxicated drivers. Runge JW, et al. **Ann Emerg Med** 1996 Jan;27(1):66–72

Use of pseudo–patrons to assess compliance with laws regarding under–age drinking. Lang E, et al. **Aust N Z J Public Health** 1996 Jun;20(3):296–300

Pseudo–drunk–patron evaluation of bar–staff compliance with Western Australian liquor law. Rydon P, et al. **Aust N Z J Public Health** 1996 Jun;20(3):290–5

Interpretations of risk: the use of scientific information in the development of the alcohol warning label policy. Kaskutas LA. **Int J Addict** 1995;30(12):1519–48 (70 ref.)

Epidemiological perspectives on alcohol and the law [letter] Girard M. **Lancet** 1996 Jun 22;347(9017):1772

Self–interest and attitudes about legislation controlling alcohol. Crowe JW, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):995–1003

Effects of drinking by the victim or offender on verdicts in a simulated trial of an acquaintance rape. Fischer GJ. **Psychol Rep** 1995 Oct;77(2):579–86

[Lowering the promille limit?] Bialas B. **Blutalkohol** 1996 May;33(3):142–51 (Eng. Abstr.) **(Ger)**

[Revoked driving right—a blunt weapon? (comment) (see comments)] Bode HJ. **Blutalkohol** 1995 Nov;32(6):314–6 (Eng. Abstr.). Comment on: Blutalkohol 1995 Sep;32(5):254–67. Comment in: Blutalkohol 1996 Jan;33(1):44–6. **(Ger)**

[Initial experiences with the "0.8 promille regulation in Thüringen] Giebe W, et al. **Blutalkohol** 1995 Sep; 32(5):279–84 (Eng. Abstr.) **(Ger)**

[Dental prosthesis—residual alcohol content?] Katzgraber F, et al. **Blutalkohol** 1995 Sep;32(5):274–8 (Eng. Abstr.) **(Ger)**

[Use of the ADH/REA method (Abbott Tdx–REA) in forensic blood alcohol determination] Mebs D, et al. **Blutalkohol** 1996 Mar;33(2):71–7 (Eng. Abstr.) **(Ger)**

[Experiences after 2 years observation of a chronic alcoholic] Schmidt G, et al. **Blutalkohol** 1995 Sep;32(5):268–73 (Eng. Abstr.) **(Ger)**

[Reliability of back–calculation of blood alcohol concentration to the time of infraction] Schyma C, et al. **Blutalkohol** 1996 Mar;33(2):65–70 (Eng. Abstr.) **(Ger)**

[Determining the duration of suspended license for alcohol intoxicated drivers] Winkler W. **Blutalkohol** 1995 Nov; 32(6):305–13 (Eng. Abstr.) **(Ger)**

[Revoking the right to drive—a blunt weapon against alcohol intoxicated drivers, hit–and–run drivers and speed limit and red light offenders? (see comments)] Zabel GE. **Blutalkohol** 1995 Sep;32(5):254–67 (56 ref.) (Eng. Abstr.). Comment in: Blutalkohol 1995 Nov;32(6):314–6. **(Ger)**

METABOLISM

Prefrontal levels of 5–HIAA, but not dopamine, predict alcohol consumption in male Wistar rats following 6–OHDA lesions. Deckel AW, et al. **Alcohol** 1995 Nov–Dec;12(6):563–8

Acetaldehyde metabolism by brain mitochondria from UChA and UChB rats. Quintanilla ME, et al. **Alcohol** 1995 Nov–Dec;12(6):519–24

Serum proteinase activities in head and neck squamous cell carcinoma patients. Bongers V, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2763–6

Effect of chronic alcohol consumption by rats on tumor necrosis factor–alpha and interleukin–6 clearance in vivo and by the isolated, perfused liver. Deaciuc IV, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):891–9

Fundamental studies on alcohol dependence and disposition. Komura S, et al. **Forensic Sci Int** 1996 Jun 28; 80(1–2):99–107 (37 ref.)

The relationship between serum gamma–glutamyl transpeptidase levels and hypertension: common in drinkers and nondrinkers. Yamada Y, et al. **Hypertens Res** 1995 Dec; 18(4):295–301

Influence of ethanol ingestion on tetracycline kinetics. Seitz C, et al. **Int J Clin Pharmacol Ther** 1995 Aug;33(8):462–4

Capillary electrophoresis of hair proteins modified by alcohol intake in laboratory rats. Jelínková D, et al. **J Chromatogr A** 1995 Aug 11;709(1):111–9

Lean and heavy women may not use energy from alcohol with equal efficiency. Clevidence BA, et al. **J Nutr** 1995 Oct;125(10):2536–40

CETP and LCAT activities are unrelated to smoking and moderate alcohol consumption in healthy normolipidemic men. Ito T, et al. **Jpn Circ J** 1995 Aug;59(8):541–6

Effects of bezafibrate on erythrocyte membrane phospholipids in alcohol–treated rats. Fujioka S, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Feb; 31(1):67–80

Influences of housing conditions and ethanol intake on binding characteristics of D2, 5–HT1A, and benzodiazepine receptors of rats. Rilke O, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):23–8

MORTALITY

Suicide rates and alcohol consumption in the United States, 1970–89. Gruenewald PJ, et al. **Addiction** 1995 Aug; 90(8):1063–75

Alcohol and suicide: a comparative analysis of France and

Sweden. Norström T. **Addiction** 1995 Nov;90(11):1463–9
Alcohol consumption, life context, and coping predict mortality among late–middle–aged drinkers and former drinkers. Mertens JR, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):313–9
Mortality associated with wines, beers, and spirits. Australian data suggest that choice of beverage relates to lifestyle and personality [letter; comment] Burke V, et al. **BMJ** 1995 Oct 28;311(7013):1166. Comment on: BMJ 1995 May 6;310(6988):1165–9.
Mortality associated with wines, beers, and spirits. Risk function had peculiar properties [letter; comment] Duffy J, et al. **BMJ** 1995 Oct 28;311(7013):1167. Comment on: BMJ 1995 May 6;310(6988):1165–9.
Mortality associated with wines, beers, and spirits. Binge drinkers should have been identified separately [letter; comment] Jadhav PP, et al. **BMJ** 1995 Oct 28; 311(7013):1166–7. Comment on: BMJ 1995 May 6;310(6988):1165–9.
Serum high density lipoprotein cholesterol, alcohol, and coronary mortality in male smokers [see comments] Paunio M, et al. **BMJ** 1996 May 11;312(7040):1200–3. Comment in: BMJ 1996 May 11;312(7040):1179–80.
Mortality associated with wines, beers, and spirits. Study confounded by lack of correction for social class [letter; comment] Westin S. **BMJ** 1995 Oct 28;311(7013):1167. Comment on: BMJ 1995 May 6;310(6988):1165–9.
Mortality associated with wines, beers, and spirits. Inappropriate groups were used to calculate relative risk [letter; comment] Wilson V, et al. **BMJ** 1995 Oct 28; 311(7013):1166; discussion 1166–7. Comment on: BMJ 1995 May 6;310(6988):1165–9.
Alcohol and all–cause mortality [letter; comment] Rehm J. **Int J Epidemiol** 1996 Feb;25(1):215–6; discussion 218–20. Comment on: Int J Epidemiol 1995 Feb;24(1):100–5.
Alcohol and all–cause mortality [letter; comment] White I. **Int J Epidemiol** 1996 Feb;25(1):217–8; discussion 218–20. Comment on: Int J Epidemiol 1995 Feb;24(1):100–5.
Meta–analysis of alcohol and all–cause mortality: a validation of NHMRC recommendations [see comments] Holman CD, et al. **Med J Aust** 1996 Feb 5;164(3):141–5. Comment in: Med J Aust 1996 Feb 5;164(3):133–4. Comment in: Med J Aust 1996 Jul 15;165(2):117.
That's the limit: alcohol consumption and health. Meta–analyses validate the NHMRC recommendations on responsible drinking [editorial; comment] Saunders JB. **Med J Aust** 1996 Feb 5;164(3):133–4. Comment on: Med J Aust 1996 Feb 5;164(3):141–5.

PATHOLOGY

Early perivenular fibrogenesis—precirrhotic lesions among moderate alcohol consumers and chronic alcoholics. Savolainen V, et al. **J Hepatol** 1995 Nov;23(5):524–31
[The morphochemical characteristics of the neurons of the sensorimotor cortex and neostriatum in rats with differing degrees of alcohol preference] Gershtein LM, et al. **Fiziol Zh Im I M Sechenova** 1995 Mar;81(3):90–6 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Dose–related effects of alcohol on dynamic posturography and oculomotor measures. Goebel JA, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:212–5
Influence of low dose alcohol on fixation suppression. Harder T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:33–6
Diet composition, alcohol utilization, and dependence. Fisher H, et al. **Alcohol** 1996 Mar–Apr;13(2):195–200
Mesolimbic dopamine system in alcohol–preferring rats. Zhou FC, et al. **Alcohol** 1995 Sep–Oct;12(5):403–12
Cue–exposure to alcohol–associated stimuli reduces autonomic reactivity, but not craving and anxiety, in dependent drinkers. McCusker CG, et al. **Alcohol Alcohol** 1995 May;30(3):319–27
Variability of ethanol absorption and breath concentrations during a large–scale alcohol administration study. Friel PN, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1055–60
GABAergic transmission in the nucleus accumbens is involved in the termination of ethanol self–administration in rats. Hodge CW, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1486–93
Gender difference in alcohol–evoked hypothalamic–pituitary–adrenal activity in the rat: ontogeny and role of neonatal steroids. Ogilvie KM, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):255–61
Alcohol stimulates ACTH secretion in the rat: mechanisms of action and interactions with other stimuli. Rivier C. **Alcohol Clin Exp Res** 1996 Apr;20(2):240–54 (207 ref.)
Association of the waist–to–hip ratio is different with wine than with beer or hard liquor consumption. Atherosclerosis Risk in Communities Study Investigators. Duncan BB, et al. **Am J Epidemiol** 1995 Nov 15;142(10):1034–8
Smoking, drinking, and thinking. The Zutphen Elderly Study. Launer LJ, et al. **Am J Epidemiol** 1996 Feb 1; 143(3):219–27
Effects of alcohol moderation on blood pressure and intracellular cations in mild essential hypertension. Hsieh ST, et al. **Am J Hypertens** 1995 Jul;8(7):696–703
Alcohol, coronary disease, and hypertension. Klatsky AL. **Annu Rev Med** 1996;47:149–60 (95 ref.)
Effects of alcohol on the sleep–stage structure of a nap in the afternoon. Van F, et al. **Biol Psychol** 1995 Aug; 41(1):55–9
Alcohol and coronary heart disease. Shaper AG. **Eur Heart J** 1995 Dec;16(12):1760–4 (20 ref.)
Alcohol and obesity. Prentice AM. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S44–50 (31 ref.)
Role of estradiol in alcohol intake and alcohol–related behaviors. Hilakivi–Clarke L. **J Stud Alcohol** 1996 Mar; 57(2):162–70
[The effect of transcranial electrostimulation on initial alcoholic motivation in rats] Zav'ialov AV, et al. **Fiziol Zh Im I M Sechenova** 1995 Jan;81(1):114–8 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Health, society and alcohol [editorial] Anderson P. **Addiction** 1996 Jun;91(6):749–52
Harm reduction, not alcohol consumption reduction [letter] Pittman DJ. **Addiction** 1995 Nov;90(11):1550–1
Do cage scores predict readiness to reduce alcohol consumption in medical in–patients? Dent TH, et al. **Alcohol Alcohol** 1995 Sep;30(5):577–80
Treatment, health promotion and alcohol controls and the decrease of alcohol consumption and problems in Ontario: 1975–1993. Smart RG, et al. **Alcohol Alcohol** 1995 May; 30(3):337–43
Suppression of alcohol intake after administration of the Chinese herbal medicine, NPI–028, and its derivatives. Overstreet DH, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):221–7
Reducing alcohol–impaired driving in Massachusetts: the Saving Lives Program [see comments] Hingson R, et al. **Am J Public Health** 1996 Jun;86(6):791–7. Comment in: Am J Public Health 1996 Jun;86(6):784–5.
Reduce drunk driving for everyone's sake [letter; comment] Jacobsen P. **Am J Public Health** 1996 Jun;86(6):890–1. Comment on: Am J Public Health 1994 Nov;84(11):1732–7.
Project Northland: outcomes of a communitywide alcohol use prevention program during early adolescence [see comments] Perry CL, et al. **Am J Public Health** 1996 Jul; 86(7):956–65. Comment in: Am J Public Health 1996 Jul;86(7):923–4.
Reducing death on the road: the effects of minimum safety standards, publicized crash tests, seat belts, and alcohol. Robertson LS. **Am J Public Health** 1996 Jan;86(1):31–4
Community solutions to community problems—preventing adolescent alcohol use [editorial; comment] Wechsler H, et al. **Am J Public Health** 1996 Jul;86(7):923–4. Comment on: Am J Public Health 1996 Jul;86(7):956–65.
An intervention for preventing alcohol use among inner–city middle school students. Werch CE, et al. **Arch Fam Med** 1996 Mar;5(3):146–52
A systematic review of parent–oriented programs to prevent children's use of alcohol and other drugs. Elmquist DL. **J Drug Educ** 1995;25(3):251–79
Improving hypertension control among excessive alcohol drinkers: a randomised controlled trial in France. The WALPA Group. Lang T, et al. **J Epidemiol Community Health** 1995 Dec;49(6):610–6
MADD's position on alcohol advertising: a response to Marshall and Oleson [comment] DeJong W, et al. **J Public Health Policy** 1995;16(2):231–8. Comment on: J Public Health Policy 1994 Spring;15(1):54–70.
School health policies prohibiting tobacco use, alcohol and other drug use, and violence. Ross JG, et al. **J Sch Health** 1995 Oct;65(8):333–8
Heeding the alcoholic beverage warning label during pregnancy: multiparae versus nulliparae. Hankin JR, et al. **J Stud Alcohol** 1996 Mar;57(2):171–7
NHMRC recommendations on abstinence from alcohol in pregnancy. National Health and Medical Research Council [letter] Holman CD, et al. **Med J Aust** 1996 Jun 3; 164(11):699
Commercial availability of alcohol to young people: results of alcohol purchase attempts. Forster JL, et al. **Prev Med** 1995 Jul;24(4):342–7
Identification and care of problems associated with alcohol ingestion in pregnancy. Hankin JR, et al. **Semin Perinatol** 1995 Aug;19(4):286–92 (24 ref.)
Young people and alcohol, drugs and tobacco. Anderson K. **WHO Reg Publ Eur Ser** 1995;66:1–83 (59 ref.)
Community and municipal action on alcohol. Ritson B. **WHO Reg Publ Eur Ser** 1995;63:1–102
[The European Alcohol Action Plan. The Alcohol, Drug and Tobacco Unit. Department of Lifestyles and Health, Regional Office for Europe. World Health Organization. Copenhagen, 1993] Gil López E, et al. **Rev Esp Salud Publica** 1995 Sep–Oct;69(5):361–83 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Injury as a motivator to reduce drinking. Longabaugh R, et al. **Acad Emerg Med** 1995 Sep;2(9):817–25
Testing the global–slowing hypothesis: are alcohol's effects on human performance process–specific or task–general? Ryan C, et al. **Acta Psychol (Amst)** 1996 Jun;92(1):59–78
The effects of stress and coping on daily alcohol use in women. Breslin FC, et al. **Addict Behav** 1995 Mar–Apr; 20(2):141–7
Cognitive and situational factors predict alcoholic beverage selection. Corcoran KJ. **Addict Behav** 1995 Jul–Aug; 20(4):525–32
Two pathways out of drinking problems without professional treatment. Humphreys K, et al. **Addict Behav** 1995 Jul–Aug; 20(4):427–41
Alcohol expectancies and changes in beer consumption of first–year college students. Kidorf M, et al. **Addict Behav** 1995 Mar–Apr;20(2):225–31
The relationship between sexual insecurity, the alcohol expectation for enhanced sexual experience, and consumption patterns. Mooney DK. **Addict Behav** 1995 Mar–Apr;20(2):243–50
Social influences on young adults' alcohol consumption: norms, modeling, pressure, socializing, and conformity. Oostveen T, et al. **Addict Behav** 1996 Mar–Apr; 21(2):187–97
The consistency of family and peer influences on the development of substance use in adolescence. Duncan TE, et al. **Addiction** 1995 Dec;90(12):1647–60
Black identity and drinking in the US: a national study. Herd D, et al. **Addiction** 1996 Jun;91(6):845–57
Loss of control and inability to abstain: the measurement of and the relationship between two constructs in male alcoholics. Kahler CW, et al. **Addiction** 1995 Aug; 90(8):1025–36; discussion 1037–51
Culture, drugs and unsafe sex: confusion about causation [editorial] Rhodes T. **Addiction** 1996 Jun;91(6):753–8
Controlled drinking after 25 years: how important was the great debate? [editorial] Sobell MB, et al. **Addiction** 1995 Sep;90(9):1149–53; discussion 1157–77 (28 ref.)
Sex differences and the effects of tail pinch on ethanol drinking in Maudsley rats. Adams N. **Alcohol** 1995 Sep–Oct;12(5):463–8
Effects of ibotenic acid lesions of the ventral striatum and the medial prefrontal cortex on ethanol consumption in the rat. Hansen S, et al. **Alcohol** 1995 Sep–Oct; 12(5):397–402
Absence of tolerance to the aversive stimulus properties of ethanol following oral ethanol self–administration. Shoaib M, et al. **Alcohol** 1996 Mar–Apr;13(2):175–80
Encouraging drinking at safe limits on single occasions: the potential contribution of protection motivation theory. Ben–Ahron V, et al. **Alcohol Alcohol** 1995 Sep;30(5):633–9
Hon v. Stroh Brewery Company: what do we mean by "moderate" and "heavy" drinking? Abel EL, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1024–31
Development and initial validation of a measure of drinking urges in abstinent alcoholics. Bohn MJ, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):600–6
Occupational stress and the risk of alcohol abuse and dependence. Crum RM, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):647–55
Failure to find postshock increases in ethanol preference. Fidler TL, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):110–21
Sucrose, ethanol, and sucrose/ethanol reinforced responding under variable–interval schedules of reinforcement. Files FJ, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1271–8
Patterns of ethanol consumption in a continuous access situation: the effect of adding a sweetener to the ethanol solution. Samson H, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):101–9
Effects of chronic ethanol exposure on oral self–administration of ethanol or saccharin by Wistar rats. Schulteis G, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):164–71
Effects of hostility on alcohol stress–response–dampening. Zeichner A, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):977–83
Alcohol schema acquisition in preschoolers: differences between children of alcoholics and children of nonalcoholics. Zucker RA, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1011–7
Experience of a "slip" among alcoholics treated with naltrexone or placebo. O'Malley SS, et al. **Am J Psychiatry** 1996 Feb;153(2):281–3
The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Anton RF, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):225–31
Correlates of multigravida women's binge drinking during pregnancy. A longitudinal study. Pascoe JM, et al. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1325–9
The effects of work intensity on adolescent mental health, achievement, and behavioral adjustment: new evidence from a prospective study. Mortimer JT, et al. **Child Dev** 1996 Jun;67(3):1243–61
Financial stress, social support, and alcohol involvement: a longitudinal test of the buffering hypothesis in a general population survey. Peirce RS, et al. **Health Psychol** 1996 Jan;15(1):38–47
Social context and sensation seeking: gender differences in college student drinking motivations. Beck KH, et al. **Int J Addict** 1995 Jul;30(9):1101–15
Submission and rebellion: excessive drinking of women in problematic heterosexual partner relationships. Lammers SM, et al. **Int J Addict** 1995 May;30(7):901–17
Depression and drinking behavior among women and men: a three–wave longitudinal study of older adults. Schutte KK, et al. **J Consult Clin Psychol** 1995 Oct;63(5):810–22
Illegal drug use, alcohol and aggressive crime among Mexican–American and white male arrestees in San Antonio. Valdez A, et al. **J Psychoactive Drugs** 1995 Apr–Jun;27(2):135–43

Factors associated with the stages of alcohol use among inner city school youth. Werch CE, et al. **J Sch Health** 1995 Sep;65(7):255–9

An investigation of gender differences in alcohol-related aggression. Giancola PR, et al. **J Stud Alcohol** 1995 Sep; 56(5):573–9

Parent and sibling influences on adolescent alcohol use and misuse: evidence from a U.S. adoption cohort. McGue M, et al. **J Stud Alcohol** 1996 Jan;57(1):8–18

Validation of daily self-reported alcohol consumption using interactive voice response (IVR) technology. Perrine MW, et al. **J Stud Alcohol** 1995 Sep;56(5):487–90

Behavioral and social consequences related to the consumption of different beverage types. Smart RG. **J Stud Alcohol** 1996 Jan;57(1):77–84 (60 ref.)

The relationship between ethanol intake and DSM-III alcohol use disorders: a cross-perspective analysis. Grant BF, et al. **J Subst Abuse** 1988–89;1(2):231–52

Self-efficacy, standards, and abstinence violation: a comparison between newly sober and long-term sober alcoholics. Ross SM, et al. **J Subst Abuse** 1988–89; 1(2):221–9

Extraversion and alcohol: Eysenck's drug postulate revisited. Rammsayer T. **Neuropsychobiology** 1995;32(4):197–207

Ethanol intake-reducing effects of ipsapirone in rats are not due to simple stimulus substitution. De Beun R, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):891–8

The relationships among saccharin consumption, oral ethanol, and i.v. cocaine self-administration. Gahtan E, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):919–25

Effects of ventral tegmental microinjections of the GABAA agonist muscimol on self-administration of ethanol and sucrose. Hodge CW, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):971–7

Suppression of ethanol intake in alcohol-preferring rats by prior voluntary saccharin consumption. Kampov-Polevoy AB, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):59–64

Effect of ethanol on extracellular dopamine in the nucleus accumbens of alcohol-preferring AA and alcohol-avoiding ANA rats. Kiianmaa K, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):29–34

The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Krishnan-Sarin S, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):153–9

Alcohol intake in high alcohol drinking (HAD) rats is suppressed by FG5865, a novel 5-HT1A agonist/5-HT2 antagonist. Long TA, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):33–40

The 5-HT4 receptor antagonist, GR113808, reduces ethanol intake in alcohol-preferring rats. Panocka I, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):255–9

Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats. Rezvani AH, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):615–20

In quest for a possible association between heightened social aggression and excessive alcohol drinking in the rat. Bergvall AH, et al. **Physiol Behav** 1996 Apr–May; 59(4–5):807–12

Pain sensitivity and saccharin intake in alcohol-preferring and -nonpreferring rat strains. Kampov-Polevoy AB, et al. **Physiol Behav** 1996 Apr–May;59(4–5):683–8

Voluntary alcohol consumption in rats: relationships to defensive burying and stress gastric erosions. Sandbak T, et al. **Physiol Behav** 1996 Apr–May;59(4–5):983–9

Alcohol and aggression: a meta-analysis on the moderating effects of inhibitory cues, triggering events, and self-focused attention. Ito TA, et al. **Psychol Bull** 1996 Jul; 120(1):60–82

Factors related to loneliness. Barretta D, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):827–30

Alcohol use and risky sex among college students [see comments] Carroll JL, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):723–6. Comment in: Psychol Rep 1995 Oct;77(2):421–2.

Alcohol consumption, locus of control, and self-esteem of high school and college students. Jih CS, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):851–7

Personality, peer influence, and use of alcohol and drugs by first-year university students. Valliant PM. **Psychol Rep** 1995 Oct;77(2):401–2

Behavioral effects of alcohol in novice and experienced drinkers: alcohol expectancies and impairment. Fillmore MT, et al. **Psychopharmacology (Berl)** 1995 Nov; 122(2):175–81

Anxiety: a potential predictor of vulnerability to the initiation of ethanol self-administration in rats. Spanagel R, et al. **Psychopharmacology (Berl)** 1995 Dec;122(4):369–73

The effect of lorazepam on memory and event-related potentials in heavy and light social drinkers. Nichols JM, et al. **Psychophysiology** 1996 Jul;33(4):446–56

Predicting 13-year-olds' drinking using parents' self-reported alcohol use and restrictiveness compared with offspring's perception. Aas H, et al. **Scand J Psychol** 1996 Jun;37(2):113–20

Psychological factors in the relationship between alcohol and cardiovascular morbidity. Roberts R, et al. **Soc Sci Med** 1995 Dec;41(11):1513–6

Alcohol expectancies and the personal and parental drinking patterns of women. Bogart CJ, et al. **Women Health** 1995; 22(4):51–66

[The influence of job characteristics and workplace subculture on individuals' drinking behavior--an exploratory pilot study] Yang MJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Jun; 12(6):339–47 (Eng. Abstr.) **(Chi)**

[Risk factors related to alcohol use among adolescents of fathers with alcoholism] Yang MS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Dec; 11(12):686–96 (Eng. Abstr.) **(Chi)**

[Need for control in the workplace and motivation for alcohol consumption: a written survey in 3 public civil service agencies] Puls W. **Soz Praventivmed** 1995; 40(5):309–17 (Eng. Abstr.) **(Ger)**

[Alteration of drinking pattern after the entrance of university] Umezono T, et al. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Dec;30(6):435–46 (Eng. Abstr.) **(Jpn)**

THERAPY

Impact of prior and current alcohol use on use of services by patients with depression and chronic medical illnesses. Jackson CA, et al. **Health Serv Res** 1995 Dec;30(5):687–705

Advanced in studies on acupuncture abstinence. Cui M. **J Tradit Chin Med** 1996 Mar;16(1):65–9 concl (38 ref.)

Advances in studies on acupuncture abstinence. Cui M. **J Tradit Chin Med** 1995 Dec;15(4):301–7, contd (32 ref.)

Treatment of adolescent substance abusers: issues for practice and research. Jenson JM, et al. **Soc Work Health Care** 1995; 21(2):1–18 (58 ref.)

URINE

A urinary marker of alcohol intake. Yu MC, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Dec;4(8):849–55

Laboratory testing for recent alcohol consumption: comparison of ethanol, methanol, and 5-hydroxytryptophol. Helander A, et al. **Clin Chem** 1996 Apr;42(4):618–24

[Urinary beta-hexosaminidase activity as a marker for the monitoring of sobriety] Wehr H, et al. **Psychiatr Pol** 1995 Sep–Oct;29(5):689–96 (Eng. Abstr.) **(Pol)**

ALCOHOL, ETHYL

see related
ALCOHOLIC BEVERAGES

Expectancies relate to symptoms of alcohol dependence in young adults. Williams RJ, et al. **Addiction** 1996 Jul; 91(7):1031–9

4-Methylpyrazole, an alcohol dehydrogenase inhibitor, exacerbates alcohol-induced microencephaly during the brain growth spurt. Chen WJ, et al. **Alcohol** 1995 Jul–Aug; 12(4):351–5

Effects of nimodipine and other calcium channel antagonists in alcohol-preferring AA rats. De Beun R, et al. **Alcohol** 1996 May–Jun;13(3):263–71

GM1 ganglioside reduces ethanol intoxication and the development of ethanol dependence. Wallis CJ, et al. **Alcohol** 1995 Nov–Dec;12(6):573–80

Ambulatory medical detoxification for alcohol. Abbott PJ, et al. **Am J Drug Alcohol Abuse** 1995 Nov;21(4):549–63 (30 ref.)

A review of factors affecting treatment outcomes: Expected Treatment Outcome Scale. Alemi F, et al. **Am J Drug Alcohol Abuse** 1995 Nov;21(4):483–509

Gender differences in early life risk factors for substance use/abuse: a study of an African-American sample. Friedman AS, et al. **Am J Drug Alcohol Abuse** 1995 Nov; 21(4):511–31

The consequences of drug use/abuse for vocational career: a longitudinal study of a male urban African-American sample. Friedman AS, et al. **Am J Drug Alcohol Abuse** 1996 Feb;22(1):57–73

The diagnostic value of BAC for identifying alcohol-related problems among DWI offenders: another look. Lucker GW, et al. **Am J Drug Alcohol Abuse** 1995 Nov; 21(4):573–80

Lipofection reagents prepared by a simple ethanol injection technique. Campbell MJ. **Biotechniques** 1995 Jun; 18(6):1027–32

Long-term preservation of DNA in agarose gels using 70% ethanol. Jacobs D, et al. **Biotechniques** 1995 Dec; 19(6):892–4

Effects of ethanol concentration and incubation period at 65 degrees C on CAT activity in mammalian cell extracts. Leahy P, et al. **Biotechniques** 1995 Dec;19(6):894–8

A GOD electrode free from the influence of ethanol. Hu W, et al. **Chin J Biotechnol** 1995;11(1):61–7

Drugs acting at central benzodiazepine receptors attenuate ethanol-induced gastric lesions in rats. Khadour F, et al. **Eur J Pharmacol** 1996 Mar 18;298(3):271–7

Aggregated DNA in ethanol solution. Piškur J, et al. **FEBS Lett** 1995 Nov 20;375(3):174–8 (38 ref.)

Portal vein embolization with steel coils and absolute ethanol: a comparative experimental study with canine liver. Yamakado K, et al. **Hepatology** 1995 Dec;22(6):1812–8

The importance of tissue fixation for light microscopic immunohistochemical localization of peroxisomal proteins: the superiority of Carnoy's fixative over Baker's formalin and Bouin's solution. Lehmann T, et al. **Histochem Cell Biol** 1995 Mar;103(3):187–95

The effect of Kupffer cell elimination on ethanol-induced liver damage in mice. Goldin RD, et al. **Int J Exp Pathol** 1995 Oct;76(5):353–9

Alcohol and drug abuse in an urban trauma center: predictors of screening and detection. Buchfuhrer LA, et al. **J Addict Dis** 1996;15(1):65–74

A path analysis of gender differences in adolescent onset of alcohol, tobacco and other drug use (ATOD), reported ATOD use and adverse consequences of ATOD use. Thomas BS. **J Addict Dis** 1996;15(1):33–52

Comparison of DSM-III-R symptoms for alcohol dependence between patient self-report and clinician interview or the Structured Clinical Interview for DSM-III-R. Wiseman EJ, et al. **J Addict Dis** 1996; 15(2):43–54

Recent changes in the etiology of hearing disorders: perinatal drug exposure. Gerber SE, et al. **J Am Acad Audiol** 1995 Sep;6(5):371–7 (50 ref.)

Advertising health risk products: ethics vs. economics. Gupta S, et al. **J Am Pharm Assoc (Wash)** 1996 Jun;NS36(6):381–2

Ethanol-dependent oxygen consumption and acetaldehyde formation during vanadyl oxidation by H2O2. Ravishankar HN, et al. **Mol Cell Biochem** 1996 Jan 26;154(2):101–6

Can we judge the strength of a drink? Standing L, et al. **Percept Mot Skills** 1995 Oct;81(2):365–6

Resolution of hyperthyroidism in a pregnant woman with toxic thyroid nodule by percutaneous ethanol injection. Cortelazzi D, et al. **Thyroid** 1995 Dec;5(6):473–5

A pilot study of alcohol and drug-related traffic accidents and death in two Jamaican parishes, 1991. Francis M, et al. **West Indian Med J** 1995 Sep;44(3):99–101

Approaches to alcohol control policy. Lehto J. **WHO Reg Publ Eur Ser** 1995;60:1–61

[The present and the future of alcohol study in the field of Pharmacology] Suzuki T. **Arukoru Kenkyuto Yakubutsu Ison** 1996 Apr;31(2):135–45 (24 ref.) **(Jpn)**

[Efficacy of epidural neurolysis] Hongo T, et al. **Masui** 1995 Nov;44(11):1537–41 (Eng. Abstr.) **(Jpn)**

[Stability of phenyl salicylate in alcoholic-aqueous solution] Miyatake N, et al. **Yakugaku Zasshi** 1996 Jan;116(1):65–70 (Eng. Abstr.) **(Jpn)**

[The effect of nifedipine and chlordiazepoxide on alcohol withdrawal syndrome] Samochowiec J, et al. **Psychiatr Pol** 1996 Mar–Apr;30(2):307–20 (Eng. Abstr.) **(Pol)**

[Mediator systems in mechanisms of remission of experimental alcoholism and relapses of pathological craving for alcohol] Veretinskaia AG, et al. **Vopr Med Khim** 1995 Sep–Oct;41(5):13–5 (Eng. Abstr.) **(Rus)**

[Cannabis and alcohol use as prognosis factors in the short-term progress of schizophrenia] Martínez Arévalo MJ, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Jul–Aug;23(4):189–92 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Simulated intraperitoneal absorption of irrigating fluid. Olsson J, et al. **Acta Obstet Gynecol Scand** 1995 Oct; 74(9):707–13

Dose-related effects of alcohol on dynamic posturography and oculomotor measures. Goebel JA, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:212–5

Effects of moderate chronic alcoholism treatment on fertilization. Cebral E, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(3):147–53

Aspiration and sclerotherapy of symptomatic simple renal cysts: value of two injections of a sclerosing agent. Hanna RM, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):781–3

Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcohol. Brandão F, et al. **Alcohol** 1996 May–Jun;13(3):239–49

Serum lipoprotein(a) [Lp(a)] in alcoholic men: effect of withdrawal. Delarue J, et al. **Alcohol** 1996 May–Jun; 13(3):309–14

Effects of ethanol consumption by adolescent alcohol-preferring P rats on subsequent behavioral performance in the cross-maze and slip funnel tests. Salimov RM, et al. **Alcohol** 1996 May–Jun;13(3):297–300

How much alcohol should I use in my experiments? [editorial] Deitrich RA, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):1–2

Low dose of ethanol suppresses mismatch negativity of auditory event-related potentials. Jääskeläinen IP, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):607–10

Exposure of neonatal rats to alcohol by vapor inhalation demonstrates specificity of microcephaly and Purkinje cell loss but not astrogliosis. Ryabinin AE, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):784–91

Chronic alcohol feeding inhibits atherogenesis in C57BL/6 hyperlipidemic mice. Emeson EE, et al. **Am J Pathol** 1995 Dec;147(6):1749–58

Intravenous alcohol in 1945 and beyond [letter; comment] Moore DC. **Anesthesiology** 1995 Dec;83(6):1372. Comment on: Anesthesiology 1995 Feb;82(2):602.

Acute hepatotoxicity of acetaminophen in rats treated with ethanol plus isopentanol. Kostrubsky VE, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1743–8

Interaction of ethanol and the organophosphorus insecticide parathion. O'Shaughnessy JA, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1925–32

Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic

factors in 105 Western patients. Lencioni R, et al. **Cancer** 1995 Nov 15;76(10):1737–46

O6-methylguanine DNA adduct formation and modulation by ethanol in placenta and fetal tissues after exposure of pregnant patas monkeys to N-nitrosodimethylamine. Chhabra SK, et al. **Cancer Res** 1995 Dec 15;55(24):6017–20

One-shot percutaneous ethanol injection of liver tumors under general anesthesia: preliminary data on efficacy and complications. Giorgio A, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):27–31

How I do it. Arteriovenous malformation management. Yakes WF, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):65–71

Percutaneous ethanol injection for thyroid cysts: a word of caution [letter] Iacconi P, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):126

Effects of an acute dose of ethanol on dopaminergic and serotonergic systems from rat cerebral cortex and striatum. Gil-Martín E, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Mar;113(3):399–402

The TCA Masque. A new cream formulation used alone and in combination with Jessner's solution [see comments] Chiarello SE, et al. **Dermatol Surg** 1996 Aug;22(8):687–90 . Comment in: Dermatol Surg 1996 Aug;22(8):681.

Experimental liver fibrosis induced in rats receiving high doses of alcohol and alternating between regular and vitamin-depleted diets. Hirano H, et al. **Experientia** 1996 Jul 15;52(7):710–5

Endogenous methanol: variability in concentration and rate of production. Evidence of a deep compartment? Haffner HT, et al. **Forensic Sci Int** 1996 May 31;79(2):145–54

Prevention of recurrent bleeding from gastric ulcer with a nonbleeding visible vessel by endoscopic injection of absolute ethanol: a prospective, controlled trial. Koyama T, et al. **Gastrointest Endosc** 1995 Aug;42(2):128–31

The use of percutaneous ethanol injection therapy for recurrence of hepatocellular carcinoma. Kotoh K, et al. **Hepatogastroenterology** 1995 Jul;42(3):197–200

Treatment of large liver cyst evaluated with CA 19–9 in the cystic fluid. Ikeda Y, et al. **HPB Surg** 1996;9(3):179–82

Saccadic characteristics of monozygotic and dizygotic twins before and after alcohol administration. Gale BW, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):339–44

Retrocrural splanchnic nerve alcohol neurolysis with a CT-guided anterior transaortic approach. Fields S. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):157–60

Treatment of central venous catheter occlusions with ethanol and hydrochloric acid. Werlin SL, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep–Oct;19(5):416–8

Effect of heavy alcohol intake on long-term results after curative resection of hepatitis C virus-related hepatocellular carcinoma. Okada S, et al. **Jpn J Cancer Res** 1996 Aug;87(8):867–73

Alcohol sclerotherapy for benign solitary solid cold thyroid nodules [letter] Bennedbaek FN, et al. **Lancet** 1995 Nov 4;346(8984):1227

Histological changes in brain tissue and vasculature after intracarotid infusion of organic solvents in rats. Sampei K, et al. **Neuroradiology** 1996 Apr;38(3):291–4

Percutaneous ethanol injection therapy for hepatocellular carcinoma: validity of MR imaging in the evaluation of treatment effect. Usui H, et al. **Radiat Med** 1995 May–Jun; 13(3):103–8

Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Bartolozzi C, et al. **Radiology** 1995 Dec;197(3):812–8

Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Livraghi T, et al. **Radiology** 1995 Oct;197(1):101–8

The effect of ethanol upon early development in mice and rats. XXII. The effect of chronic consumption of nonalcoholic beer upon preimplantation development in rats. Fazakas-Todea I. **Rom J Morphol Embryol** 1995 Jan–Jun;41(1–2):19–22

Non-invasive loco-regional therapy for hepatocellular carcinoma. Tanikawa K. **Semin Surg Oncol** 1996 May–Jun; 12(3):189–92 (15 ref.)

[Percutaneous ethanol injection therapy for the treatment of postoperative recurrent primary liver cancer] Li B, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep;17(5):371–3 (Eng. Abstr.) **(Chi)**

[Clinical application of endoscopic injection of medication for stopping gastric bleeding] Liu B, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jul;34(7):446–8 (Eng. Abstr.) **(Chi)**

[Alcohol administration for prevention of withdrawal delirium in alcohol dependent surgical intensive care patients: pro] Engelhardt W. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):183–4 **(Ger)**

[Alcohol as therapeutic drug in alcohol dependent intensive care patients: contra] Krumholz W. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):181–2 **(Ger)**

[Is co-administration of ethanol to the distension medium in surgical hysteroscopy a screening method to prevent fluid overload? A prospective randomized comparative study of ablative versus non-ablative hysteroscopy and various ethanol concentrations] Aydeniz B, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:108–12 (Eng. Abstr.) **(Ger)**

[Treatment of hot thyroid nodule with percutaneous ethanol injection: indications, complications, and prognostic factors] Angelini F, et al. **Radiol Med (Torino)** 1996 Jun; 91(6):774–80 (Eng. Abstr.) **(Ita)**

[Percutaneous ethanol injection therapy for small hepatocellular carcinoma] Shiina S, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):835–9 (Eng. Abstr.) **(Jpn)**

[A preliminary study of percutaneous ethanol injection therapy for hepatocellular carcinoma: evaluation of the ethanol diffusion area by the ethanol mixed with gadolinium] Matsumura K, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jun;56(7):517–9 (Eng. Abstr.) **(Jpn)**

[Percutaneous ethanol injection therapy of hepatoma] Shiina S, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2008–11 (5 ref.) **(Jpn)**

[Percutaneous ethanol injection therapy for hepatocellular carcinoma in hepatic dome directly under right diaphragma—the trial of artificial ascites method] Hayashida K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct;92(10):1752–8 (Eng. Abstr.) **(Jpn)**

[Effect of ethanol concentration on the maximum specific growth rate and composition of biomass in a mutant strain of Yarrowia lipolytica No. 1] Kamzolova SV, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):71–3 **(Rus)**

[Treatment of autonomous thyroid gland nodules using percutaneous injections of ethanol under ultrasonography control—initial experience] Gonsorčíková V, et al. **Vnitr Lek** 1996 Mar;42(3):166–70 (Eng. Abstr.) **(Slo)**

ADVERSE EFFECTS

Testing the global-slowing hypothesis: are alcohol's effects on human performance process-specific or task-general? Ryan C, et al. **Acta Psychol (Amst)** 1996 Jun;92(1):59–78

The effect of a moderate dose of alcohol on the traffic hazard perception profile of young drink-drivers. Deery HA, et al. **Addiction** 1996 Jun;91(6):815–27

Clinical physiological study of the therapeutic effects of phenytoin in acute alcohol withdrawal and the asthenic-autonomic syndrome in patients with chronic alcoholism. Ilyuchina VA, et al. **Alcohol** 1995 Nov–Dec; 12(6):511–7

Time-dependent quantifiable withdrawal from ethanol in the rat: effect of method of dependence induction. Macey DJ, et al. **Alcohol** 1996 Mar–Apr;13(2):163–70

Sex hormones and alcohol withdrawal: does a good supply of testosterone prevent serious symptoms during detoxification? Ruusa J, et al. **Alcohol** 1996 Mar–Apr; 13(2):139–45

Genetic control of alcohol deprivation effect in congenic mice. Salimov R, et al. **Alcohol** 1995 Sep–Oct;12(5):469–74

Effects of alcohol and liver cirrhosis on the GH-IGF-I axis. Santolaria F, et al. **Alcohol Alcohol** 1995 Nov;30(6):703–8

Development and initial validation of a measure of drinking urges in abstinent alcoholics. Bohn MJ, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):600–6

Introduction to the symposium on alcohol and T-cell immunity [comment] Chiappelli F, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):535–8. Comment on: Alcohol Clin Exp Res 1995 Jun;19(3):539–44.

Brain atrophy and cognitive function in older abstinent alcoholic men. Di Sclafani V, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1121–6

Late-onset seizures in alcohol withdrawal. Mayo-Smith MF, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):656–9

Behavioral dysfunction and cognitive efficiency in male and female alcoholics. Nixon SJ, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):577–81

Alcohol hangover and managerial effectiveness. Streufert S, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1141–6

Alcohol reactions in subjects of European descent: effects on alcohol use and on physical and psychomotor responses to alcohol. Whitfield JB, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):81–6

Alcohol withdrawal syndrome. Yost DA. **Am Fam Physician** 1996 Aug;54(2):657–64, 669

Valproate treatment of alcohol withdrawal and mania [letter] Hammer BA, et al. **Am J Psychiatry** 1996 Sep;153(9):1232

Ethanol monitoring of fluid absorption: education is important [letter; comment] Olsson J, et al. **Anesth Analg** 1995 Oct;81(4):885–6. Comment on: Anesth Analg 1995 Jan;80(1):212.

CNS effects and abuse liability of anabolic-androgenic steroids. Lukas SE. **Annu Rev Pharmacol Toxicol** 1996; 36:333–57 (125 ref.)

Lipid vs protein theories of alcohol action in the nervous system. Peoples RW, et al. **Annu Rev Pharmacol Toxicol** 1996;36:185–201 (112 ref.)

Polygraphic sleep measures differentiate alcoholics and stimulant abusers during short-term abstinence. Thompson PM, et al. **Biol Psychiatry** 1995 Dec 15;38(12):831–6

Prophylaxis of alcohol withdrawal syndrome in alcohol-dependent patients admitted to the intensive care unit after tumour resection. Spies CD, et al. **Br J Anaesth** 1995 Dec;75(6):734–9

Intellectual impairment among recently abstinent alcoholic abusers. O'Mahony JF, et al. **Br J Clin Psychol** 1996 Feb; 35 (Pt 1):77–83

Traumatic brain injury, alcohol and quantitative neuroimaging: preliminary findings. Bigler ED, et al. **Brain Inj** 1996 Mar;10(3):197–206

Ethanol withdrawal does not induce a reduction in the number of spontaneously active dopaminergic neurons in the mesolimbic system. Diana M, et al. **Brain Res** 1995 Jun 5;682(1–2):29–34

Ethanol- and threonine-induced hypertension in rats: a common mechanism. Vasdev S, et al. **Can J Cardiol** 1995 Oct;11(9):807–15 (56 ref.)

Alcohol and hypertension. Beilin LJ. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):185–8 (35 ref.)

Alcohol, hypertension, coronary disease and stroke. Lip GY, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):189–94 (66 ref.)

Parkinsonism in alcohol withdrawal: case report and review of the literature. Luijckx GJ, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):336–9 (18 ref.)

Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. Spies CD, et al. **Crit Care Med** 1996 Mar; 24(3):414–22 (64 ref.)

Intragastric polyethylene glycol-400 protects against ethanol-induced gastric mucosal lesions despite pretreatment with indomethacin or iodoacetamide. Gutiérrez-Cabano CA. **Dig Dis Sci** 1995 Sep;40(9):2029–36

Ethanol-induced gastrointestinal damage. Influence of endogenous antioxidant components and gender. Moghadasian MH, et al. **Dig Dis Sci** 1996 Apr;41(4):791–7

Relationships between metal ions and oxygen free radicals in ethanol-induced damage to cultured rat gastric mucosal cells. Mutoh H, et al. **Dig Dis Sci** 1995 Dec;40(12):2704–11

Drugs and alcohol: harmful cocktails? **Drug Ther Bull** 1996 May;34(5):36–8 (22 ref.)

Influence of alcohol on the hydromineral hormone responses to exercise in a warm environment. Saini J, et al. **Eur J Appl Physiol** 1995;72(1–2):32–6

Role of alcohol and tobacco in the aetiology of head and neck cancer: a case-control study in the Doubs region of France. Andre K, et al. **Eur J Cancer B Oral Oncol** 1995 Sep;31B(5):301–9

Alcoholic chronic pancreatitis: its relation to alcoholic acute pancreatitis [letter] Ammann RW. **Gastroenterol Clin Biol** 1996;20(3):312–4

Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats [see comments] Babyatsky MW, et al. **Gastroenterology** 1996 Feb; 110(2):489–97. Comment in: Gastroenterology 1996 Feb;110(2):632–5.

Effects of prolonged ethanol intake and malnutrition on rat pancreas. López JM, et al. **Gut** 1996 Feb;38(2):285–92

Ethanol feeding of micropigs alters methionine metabolism and increases hepatocellular apoptosis and proliferation. Halsted CH, et al. **Hepatology** 1996 Mar;23(3):497–505

Barbiturates in alcohol withdrawal [letter; comment] Matz R. **Hosp Pract (Off Ed)** 1995 Sep 15;30(9):26, 28. Comment on: Hosp Pract (Off Ed) 1995 Jun 15;30(6):49–54, 56–8.

Different pathways of in vitro ethanol-induced apoptosis in thymocytes and splenic T and B lymphocytes. Slukvin II, et al. **Immunopharmacology** 1995 Nov;31(1):43–57

Effects of chronic treatment with ethanol and withdrawal on levels of monoamines in rat cerebral cortex and striatum. Influence of midazolam, thiopenthal and somatostatin. Gil-Martín E, et al. **Int J Biochem Cell Biol** 1995 Dec; 27(12):1267–76

A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. Castaneda R, et al. **J Clin Psychiatry** 1996 May;57(5):207–12 (82 ref.)

Increased human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells induced by ethanol: potential immunopathogenic mechanisms. Bagasra O, et al. **J Infect Dis** 1996 Mar;173(3):550–8

Relationship between oral pain and ethanol concentration in mouthrinses. Bolanowski SJ, et al. **J Periodontal Res** 1995 May;30(3):192–7

Increases in non-N-methyl-D-aspartate glutamatergic transmission, but no change in gamma-aminobutyric acidB transmission, in CA1 neurons during withdrawal from in vivo chronic ethanol treatment. Molleman A, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1035–41

Visuospatial perception, construction and memory in alcoholism. Beatty WW, et al. **J Stud Alcohol** 1996 Mar; 57(2):136–43

Heeding the alcoholic beverage warning label during pregnancy: multiparae versus nulliparae. Hankin JR, et al. **J Stud Alcohol** 1996 Mar;57(2):171–7

Perceptuomotor function of homeless males in alcohol rehabilitation. Zlotnick C, et al. **J Subst Abuse** 1995; 7(2):235–44

Carbohydrate-deficient transferrin for identification of drug overdose patients at risk of an alcohol withdrawal syndrome. Köppel C, et al. **J Toxicol Clin Toxicol** 1996; 34(3):297–300

Acetaminophen, NSAIDs and alcohol. **Med Lett Drugs Ther** 1996 Jun 21;38(977):55–6

Comparative studies of Ca N-acetylhomotaurinate and Ca N-acetyltaurinate. II. Preventive and opposing actions of the acute ethanol depletive effect on the ionic transfer through the isolated human amnion. Guiet-Bara A, et al. **Methods Find Exp Clin Pharmacol** 1995 Jul-Aug; 17(6):361–8

Treatment of vertebral hemangioma by intralesional injection of absolute ethanol [letter; comment] Heiss JD, et al.

N Engl J Med 1996 May 16;334(20):1340. Comment on: N Engl J Med 1994 Aug 25;331(8):508–11.

The effect of the ingestion of ethanol on obstruction of the left ventricular outflow tract in hypertrophic cardiomyopathy. **Paz R, et al. N Engl J Med** 1996 Sep 26;335(13):938–41

Amoxapine overdose in a young man: a transient mitochondrial abnormality? **Mancias P, et al. Pharmacotherapy** 1995 Jul–Aug;15(4):528–32

Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. **Peppers MP. Pharmacotherapy** 1996 Jan–Feb;16(1):49–57 (49 ref.)

Prenatal ethanol diminishes reactivity of presumed dopamine D3 receptors in rats. **Brus R, et al. Pol J Pharmacol** 1995 Mar–Apr;47(2):109–14

Effects of ethanol on the processing of low probability stimuli: an ERP study. **Grillon C, et al. Psychopharmacology (Berl)** 1995 Jun;119(4):455–65

[Effect of the duration of chronic alcoholic pancreatitis on the severity of outbreaks of acute pancreatitis] **Chemtob A, et al. Gastroenterol Clin Biol** 1995 Aug–Sep; 19(8–9):664–7 (Eng. Abstr.) **(Fre)**

[Controversy over the possible existence of an autonomous acute alcoholic pancreatitis (letter)] **Moreau J. Gastroenterol Clin Biol** 1996;20(3):314–5 **(Fre)**

[Does chronic alcohol drinking modify digestive gastrobiliary motility?] **Wedmann B, et al. Leber Magen Darm** 1996 Mar; 26(2):98–102 (Eng. Abstr.) **(Ger)**

[Do alcohol or drug abuse induce schizophrenia?] **Hambrecht M, et al. Nervenarzt** 1996 Jan;67(1):36–45 (Eng. Abstr.) **(Ger)**

[Survey of alcohol drinking and results of studies of alcoholism biological markers within the scope of a neurologic occupational medicine study of industrial workers] **Reinhardt F, et al. Versicherungsmedizin** 1996 Jun 1;48(3):101–3 (Eng. Abstr.) **(Ger)**

[Comparison of nerve damage with alcohol and that with phenol in guinea pigs] **Matsuda T, et al. Masui** 1995 Nov; 44(11):1464–6 (Eng. Abstr.) **(Jpn)**

[Acute alcoholism after ethanol fixation for ovarian chocolate cyst] **Tei A, et al. Masui** 1996 Apr;45(4):496–9 (Eng. Abstr.) **(Jpn)**

[Serum lipid peroxides in alcoholic patients] **Rosnowska M, et al. Psychiatr Pol** 1995 Jul–Aug;29(4):539–46 (Eng. Abstr.) **(Pol)**

[Neurological and neurophysiological aspects of the alcohol abstinence syndrome] **Solovov AV. Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):57–9 (Eng. Abstr.) **(Rus)**

[The cardiovascular effects of alcohol] **Estruch R. Med Clin (Barc)** 1995 Nov 11;105(16):628–35 (80 ref.) **(Spa)**

ANALOGS & DERIVATIVES

Adaptation of Pseudomonas sp. GJ1 to 2-bromoethanol caused by overexpression of an NAD-dependent aldehyde dehydrogenase with low affinity for halogenated aldehydes. **Van der Ploeg JR, et al. Arch Microbiol** 1996 Apr;165(4):258–64

Asymmetric synthesis and enantiospecificity of binding of 2-(1,2,3,4-tetrahydro-1-isoquinolyl)-ethanol derivatives to mu and kappa receptors. **Wanner KT, et al. Arch Pharm (Weinheim)** 1996 Jan;329(1):11–22

Mechanism for antigen detection on deplasticized epoxy sections. **Brorson SH, et al. Micron** 1995;26(4):301–10

ANALYSIS

Identification of hazardous/harmful drinking among subcritically injured patients. **Clifford PR, et al. Acad Emerg Med** 1996 Mar;3(3):239–45

Screening for L-arabinose fermenting yeasts. **Dien BS, et al. Appl Biochem Biotechnol** 1996 Spring;57–58:233–42

Analysis of ethanol in expired air during low-flow isoflurane anaesthesia. **Olsson J, et al. Br J Anaesth** 1996 Jan; 76(1):85–9

Analysis of breath alcohol via infrared spectrophotometry: predicting false ethanol results by application of the base-line method to vapor phase infrared spectra. **Labianca DA. Eur J Clin Chem Clin Biochem** 1996 Jan;34(1):59–61

Medicolegal alcohol determination: variability of the blood-to breath-alcohol ratio and its effect on reported breath-alcohol concentrations. **Labianca DA, et al. Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):919–25 (17 ref.)

Postmortem degradation of administered ethanol-d6 and production of endogenous ethanol: experimental studies using rats and rabbits. **Takayasu T, et al. Forensic Sci Int** 1995 Dec 18;76(2):129–40

Experimental studies on postmortem diffusion of ethanol-d6 using rats. **Takayasu T, et al. Forensic Sci Int** 1995 Dec 29;76(3):179–88

Ethanol in biological fluids: headspace GC measurement. **Macchia T, et al. J Anal Toxicol** 1995 Jul–Aug;19(4):241–6

Distribution of ethanol in postmortem liver. **Jenkins AJ, et al. J Forensic Sci** 1995 Jul;40(4):611–3

Brain alcohol detectability increase with repeated administration in humans: a proton spectroscopy study. **Kaufman MJ, et al. Magn Reson Med** 1996 Mar; 35(3):435–40

Carbohydrate and alcohol content of 200 oral liquid medications for use in patients receiving ketogenic diets. **Feldstein TJ. Pediatrics** 1996 Apr;97(4):506–11

[Measurement of expired alcohol concentrations with a new electrochemical sensor. A model investigation to determine interference with volatile anesthetics and clinical application] **Gehring H, et al. Anaesthesist** 1996 Feb; 45(2):154–62 (Eng. Abstr.) **(Ger)**

[The development of the conditions for the direct gas chromatographic determination of ethyl alcohol in cadaveric material] **Iablochkin VD. Sud Med Ekspert** 1995 Oct–Dec;38(4):17–20 (Eng. Abstr.) **(Rus)**

[The Q.E.D. test--possibility for rapid determination of ethanol levels in saliva] **Bošan-Kilibarda I, et al. Lijec Vjesn** 1995 Jun;117 Suppl 2:109–11 (Eng. Abstr.) **(Scr)**

ANTAGONISTS & INHIBITORS

Influence of CGS 8216 on some acute effects of ethanol. **Kotlińska J, et al. Alcohol Alcohol** 1995 Sep;30(5):601–5

Glucocorticoid interactions with ethanol effects on synaptic plasma membranes: influence on [125I]calmodulin binding. **Sze PY. J Pharmacol Exp Ther** 1996 Feb;276(2):578–84

BLOOD

Blood ethanol estimation: a comparison of three methods [letter] **Keim ME, et al. Acad Emerg Med** 1996 Jan; 3(1):85–7

Ethanol-associated hypoglycemia is uncommon. **Sucov A, et al. Acad Emerg Med** 1995 Mar;2(3):185–9

Alcohol and road traffic accidents. **Mayou R, et al. Alcohol Alcohol** 1995 Nov;30(6):709–11

Estimating blood alcohol from urinary alcohol at autopsy. **Kuroda N, et al. Am J Forensic Med Pathol** 1995 Sep; 16(3):219–22

Postmortem diffusion of alcohol from the stomach. **Pounder DJ, et al. Am J Forensic Med Pathol** 1995 Jun;16(2):89–96

Lowering state legal blood alcohol limits to 0.08%: the effect on fatal motor vehicle crashes. **Hingson R, et al. Am J Public Health** 1996 Sep;86(9):1297–9

External quality assessment of techniques for assay of serum ethanol. **Wilson JF, et al. Ann Clin Biochem** 1995 Nov;32 (Pt 6):540–4

Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. **Gianoulakis C, et al. Arch Gen Psychiatry** 1996 Mar;53(3):250–7

GP autopsies [letter; comment] **Colebatch T. Aust Fam Physician** 1995 Nov;24(11):2146. Comment on: Aust Fam Physician 1995 Sep;24(9):1765.

Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. **Ma J, et al. Cancer Chemother Pharmacol** 1996;38(4):391–4

Plasma alcohol concentrations in patients following paclitaxel infusion. **Webster LK, et al. Cancer Chemother Pharmacol** 1996;37(5):499–501

Simultaneous measurement of ethanol and ethyl-d5 alcohol by stable isotope gas chromatography-mass spectrometry. **Dean RA, et al. Clin Chem** 1996 Mar;42(3):367–72

Salivary reagent stick measures serum ethanol concentrations [letter] **de Keijzer MH, et al. Clin Chem** 1996 Jun;42(6 Pt 1):985–6

Pathoanatomic findings and blood alcohol analysis at autopsy (BAC) in forensic diagnoses of undetermined suicide. A cross-cultural study. **Ferrada-Noli M, et al. Forensic Sci Int** 1996 Apr 2;78(2):157–63

Drugs usage of drivers suspected of driving under the influence of alcohol and/or drugs. A study of one week's samples in 1979 and 1993 in Finland. **Lillsunde P, et al. Forensic Sci Int** 1996 Jan 12;77(1-2):119–29

Concerning the article by Charles L. Winek, Jr. et al., entitled: 'The role of trauma in postmortem blood alcohol determination' (Forensic Sci. Int., 71 (1995) 1–8) [letter; comment] **Rabl W, et al. Forensic Sci Int** 1995 Jul 28; 74(3):213–4. Comment on: Forensic Sci Int 1995 Jan 21;71(1):1–8.

The effect of storage at various temperatures on blood alcohol concentration. **Winek T, et al. Forensic Sci Int** 1996 Apr 23;78(3):179–85

Historical anecdote related to chemical tests for intoxication [letter] **Andréasson R, et al. J Anal Toxicol** 1996 May-Jun; 20(3):207–8

Comparison of ethanol concentrations in blood, serum, and blood cells for forensic application. **Charlebois RC, et al. J Anal Toxicol** 1996 May-Jun;20(3):171–8

Measuring ethanol in saliva with the QED enzymatic test device: comparison of results with blood- and breath-alcohol concentrations. **Jones AW. J Anal Toxicol** 1995 May-Jun;19(3):169–74

Serum-ethanol determination: comparison of lactate and lactate dehydrogenase interference in three enzymatic assays. **Nine JS, et al. J Anal Toxicol** 1995 May-Jun; 19(3):192–6

A response to "Serum-ethanol determination: comparison of lactate and lactate dehydrogenase interference in three enzymatic assays" [letter] **Winek CL, et al. J Anal Toxicol** 1996 May-Jun;20(3):211–2

The role of ethanol in heroin deaths. **Levine B, et al. J Forensic Sci** 1995 Sep;40(5):808–10

Effects of blood alcohol concentrations on negative punishment: implications for decision making. **Meier SE, et al. J Stud Alcohol** 1996 Jan;57(1):85–96

Low alcohol drinks and risk of high blood alcohol in children [letter] **Jones AW. J Toxicol Clin Toxicol** 1996;34(3):349–50

Analysis of 12 months of blood alcohol levels in patients in an urban emergency department [letter] **Jelinek GA, et al. Med J Aust** 1996 Jun 3;164(11):699–700

Ethanol and acetaldehyde metabolism in chinese with different aldehyde dehydrogenase-2 genotypes. **Luu SU, et al. Proc Natl Sci Counc Repub China B** 1995 Jul; 19(3):129–36

Reliability of blood alcohol determinations at clinical chemistry laboratories in Sweden. **Jones AW, et al. Scand J Clin Lab Invest** 1995 Oct;55(6):463–8

[Validation of blood ethanol determination method by gas chromatography (letter)] **Clerc Y, et al. Ann Biol Clin (Paris)** 1995;53(4):233–8 **(Fre)**

[Blood ethanol and isopropanol (letter)] **Malandain H, et al. Ann Biol Clin (Paris)** 1996;54(2):97 **(Fre)**

[Ethyl alcohol levels in the expiratory air vs blood alcohol levels. 204 cases in an emergency unit] **Derogis V, et al. Presse Med** 1995 Jun 24;24(23):1067–70 (Eng. Abstr.) **(Fre)**

[Lowering the promille limit?] **Bialas B. Blutalkohol** 1996 May;33(3):142–51 (Eng. Abstr.) **(Ger)**

[Gas-mass spectrometry in the identification and determination of ethanol in blood] **Cušić S, et al. Vojnosanit Pregl** 1995 May-Jun;52(3):241–5 (Eng. Abstr.) **(Scr)**

[Alcohol level and injury risks in traffic accidents in Tudela (Navarre)] **Cia Lecumberi MT, et al. Gac Sanit** 1996 Mar-Apr;10(53):55–61 (Eng. Abstr.) **(Spa)**

[Alcohol measurement in traffic accidents: how long will the ostrich strategy last? (editorial)] **Plasència A. Gac Sanit** 1996 Mar-Apr;10(53):51–4 **(Spa)**

[Medichronal lowers blood ethanol and acetaldehyde and restores the concentration of catecholamines in rat tissues] **Bozhko HKZh, et al. Ukr Biokhim Zh** 1995 Mar-Apr; 67(2):108–12 (Eng. Abstr.) **(Ukr)**

CHEMICAL SYNTHESIS

Studies on cognitive enhancing agents. II. Antiamnestic and antihypoxic activities of 1-aryl-2-(2-aminoethoxy)ethanols. **Ono S, et al. Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1488–91

Studies on cognitive enhancing agents. III. Antiamnestic and antihypoxic activities of a series of 1-bicycloaryl-2-(omega-aminoalkoxy)ethanols. **Ono S, et al. Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1492–6

CHEMISTRY

Amphiphilic binding site of ethanol in reversed lipid micelles. **Klemm WR, et al. Alcohol** 1996 Mar-Apr;13(2):133–8

Interaction of melanin with carbon- and oxygen-centered radicals from methanol and ethanol. **Dunford R, et al. Free Radic Biol Med** 1995 Dec;19(6):735–40

DIAGNOSTIC USE

Can ethanol be omitted from the lactose absorption test? **Buttery JE, et al. Clin Biochem** 1995 Dec;28(6):599–601

Ethanol monitoring of irrigating fluid absorption. **Hahn RG. Eur J Anaesthesiol** 1996 Mar;13(2):102–15 (60 ref.)

Life-threatening transurethral resection syndrome despite monitoring of fluid absorption with ethanol. **Hahn RG. Eur J Anaesthesiol** 1995 Jul;12(4):431–3

Evaluation of the microdialysis ethanol technique for monitoring of subcutaneous adipose tissue blood flow in humans. **Fellländer G, et al. Int J Obes Relat Metab Disord** 1996 Mar;20(3):220–6

Muscle blood flow in cats: comparison of microdialysis ethanol technique with direct measurement. **Hickner RC, et al. J Appl Physiol** 1995 Aug;79(2):638–47

A mathematical model for measuring blood flow in skeletal muscle with the microdialysis ethanol technique. **Wallgren F, et al. J Appl Physiol** 1995 Aug;79(2):648–59

ECONOMICS

The economics of alcohol policy. **Lehto J. WHO Reg Publ Eur Ser** 1995;61:1–53

ISOLATION & PURIFICATION

Membrane based ethanol separation process. **Choudhury JP, et al. Hindustan Antibiot Bull** 1994 Aug-Nov; 36(3-4):135–40 (32 ref.)

METABOLISM

Additional proof of reduction of ethanol absorption from rat intestine in vivo by high acetaldehyde concentrations. **Kinoshita H, et al. Alcohol Alcohol** 1995 Jul;30(4):419–21

Alcohol and energy intake. **Lands WE. Am J Clin Nutr** 1995 Nov;62(5 Suppl):1101S–1106S (55 ref.)

Is "alcohol-free" beer a placebo? [letter; comment] **Roeggla M, et al. Ann Emerg Med** 1995 Dec;26(6):762–3. Comment on: Ann Emerg Med 1995 May;25(5):636–41.

Alcohol metabolism in Helicobacter pylori-infected stomach. **Roine RP, et al. Ann Med** 1995 Oct;27(5):583–8

Cellulose degradation and ethanol production by thermophilic bacteria using mineral growth medium. **Ahn HJ, et al. Appl Biochem Biotechnol** 1996 Spring; 57–58:599–604

Increased xylose reductase activity in the xylose-fermenting

yeast Pichia stipitis by overexpression of XYL1. Dahn KM, et al. **Appl Biochem Biotechnol** 1996 Spring;57-58:267-76
Fermentation of orange peel hydrolysates by ethanologenic Escherichia coli. Effects of nutritional supplements. Grohmann K, et al. **Appl Biochem Biotechnol** 1996 Spring; 57-58:383-8
Performance of a magnetically stabilized bed reactor with immobilized yeast cells. Ivanova V, et al. **Appl Biochem Biotechnol** 1996 May;59(2):187-98
The construction of a stable starch-fermenting yeast strain using genetic engineering and rare-mating. Kim TG, et al. **Appl Biochem Biotechnol** 1996 Apr;59(1):39-51
Factors contributing to the loss of ethanologenicity of Escherichia coli B recombinants pLOI297 and KO11. Lawford HG, et al. **Appl Biochem Biotechnol** 1996 Spring; 57-58:293-305
Studies on nutrient requirements and cost-effective supplements for ethanol production by recombinant E. coli. Lawford HG, et al. **Appl Biochem Biotechnol** 1996 Spring; 57-58:307-26
Continuous alcoholic fermentation process in a tower reactor with recycling of flocculating yeast. Paiva TC, et al. **Appl Biochem Biotechnol** 1996 Spring;57-58:535-41
Continuous ethanol production from nonsterilized carob pod extract by immobilized Saccharomyces cerevisiae on mineral kissiris using a two-reactor system. Roukas T. **Appl Biochem Biotechnol** 1996 Jun;59(3):299-307
Genotypes of alcohol-metabolizing enzymes in Mexicans with alcoholic liver cirrhosis. Lisker-Yourkowitzky R, et al. **Arch Med Res** 1995;26 Spec No:S63-7
Alcohol dehydrogenase (ADH) isozymes in the AdhN/AdhN strain of Peromyscus maniculatus (ADH-deermouse) and a possible role of class III ADH in alcohol metabolism. Haseba T, et al. **Biochem Genet** 1995 Oct;33(9-10):349-63
Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals. Comoglio A, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1313-6
Effect of aniline on ethanol oxidation and carbohydrate metabolism in isolated hepatocytes. Efthivoulou MA, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):863-7
Direct binding of ethanol to bovine serum albumin: a fluorescent and 13C NMR multiplet relaxation study. Avdulov NA, et al. **Biochemistry** 1996 Jan 9;35(1):340-7
Expression of acylphosphatase in Saccharomyces cerevisiae enhances ethanol fermentation rate. Raugei G, et al. **Biotechnol Appl Biochem** 1996 Jun;23 (Pt 3):273-8
Alcohol flushing, patch test, and ADH and ALDH genotypes in Brazilian ethnic groups. Santos BR, et al. **Braz J Med Biol Res** 1995 May;28(5):513-8
A reevaluation of the thermodynamics of growth of Saccharomyces cerevisiae on glucose, ethanol, and acetic acid. Battley EH. **Can J Microbiol** 1995 Apr-May; 41(4-5):388-98
Effects of ethanol metabolism on PKC activity in isolated rat hepatocytes. Domenicotti C, et al. **Chem Biol Interact** 1996 Mar 25;100(2):155-63
Bioactive saponins and glycosides. II. Senegae Radix. (2): Chemical structures, hypoglycemic activity, and ethanol absorption-inhibitory effect of E-senegasaponin c, Z-senegasaponin c, and Z-senegins II, III, and IV. Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul; 44(7):1305-13
High-concentration ethanol production from cooked corn starch by using medium-temperature cooking process. Chi Z, et al. **Chin J Biotechnol** 1995;11(3):171-6
Fatty acid ethyl ester synthase, an enzyme for nonoxidative ethanol metabolism, is present in serum after liver and pancreatic injury. Aleryani S, et al. **Clin Chem** 1996 Jan; 42(1):24-7
Fundamental studies on alcohol dependence and disposition. Komura S, et al. **Forensic Sci Int** 1996 Jun 28; 80(1-2):99-107 (37 ref.)
Postmortem degradation of administered ethanol-d6 and production of endogenous ethanol: experimental studies using rats and rabbits. Takayasu T, et al. **Forensic Sci Int** 1995 Dec 18;76(2):129-40
Glycine prevents alcohol-induced liver injury by decreasing alcohol in the rat stomach. Iimuro Y, et al. **Gastroenterology** 1996 May;110(5):1536-42
Ethanol transport in Zymomonas mobilis measured by using in vivo nuclear magnetic resonance spin transfer. Schoberth SM, et al. **J Bacteriol** 1996 Mar;178(6):1756-61
Process optimization for continuous ethanol fermentation by alginate-immobilized cells of Saccharomyces cerevisiae HAU-1. Yadav BS, et al. **J Basic Microbiol** 1996; 36(3):205-10
Mitochondrial alcohol dehydrogenase from ethanol-grown Euglena gracilis. Ono K, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1178-82
Saturable ethanol binding in rat liver microsomes. Channareddy S, et al. **J Biol Chem** 1996 Jul 26; 271(30):17625-8
Interaction of ethanol with inducers of glucose-regulated stress proteins. Ethanol potentiates inducers of grp78 transcription. Hsieh KP, et al. **J Biol Chem** 1996 Feb 2; 271(5):2709-16
In-vitro production of ethanol in urine by fermentation. Sulkowski HA, et al. **J Forensic Sci** 1995 Nov;40(6):990-3
Lean and heavy women may not use energy from alcohol with equal efficiency. Clevidence BA, et al. **J Nutr** 1995 Oct;125(10):2536-40
Changes in hepatic enzyme activities related to ethanol metabolism in mice following chronic ethanol administration. Kishimoto R, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Oct;41(5):527-43
Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s. Asai H, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1004-9
Investigator-observed alcohol-induced flushing but not self-report of flushing is a valid predictor of ALDH2 genotype. Wall TL, et al. **J Stud Alcohol** 1996 May; 57(3):267-72
Antioxidant defense system in lung of male and female rats: interactions with alcohol, copper, and type of dietary carbohydrate. Fields M, et al. **Metabolism** 1996 Jan; 45(1):49-56
1-Hydroxyethyl radical formation during NADPH- and NADH-dependent oxidation of ethanol by human liver microsomes. Rao DN, et al. **Mol Pharmacol** 1996 May; 49(5):814-21
Mutagenicity of soy sauce treated with nitrite in the presence of ethanol or alcoholic beverages. Higashimoto M, et al. **Mutat Res** 1995 Dec;345(3-4):155-66
Liver alcohol dehydrogenase activity and ethanol levels during chronic ethanol intake in pregnant rats and their offspring. Través C, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):93-9
[Changes in ethanol metabolism in chronic alcoholics and genetic and ethnic factors affecting its metabolism] Hirt M. **Soud Lek** 1995 Feb;40(1):2-3 (Eng. Abstr.) (Cze)
[Serum lipid peroxides in alcoholic patients] Rosnowska M, et al. **Psychiatr Pol** 1995 Jul-Aug;29(4):539-46 (Eng. Abstr.) (Pol)
[The effect of autolysis on characteristics of amino acid mixtures, obtained using ethanol-assimilating yeasts] Belousova NI, et al. **Prikl Biokhim Mikrobiol** 1995 Jul-Aug;31(4):458-62 (Eng. Abstr.) (Rus)

PHARMACOKINETICS

A major contribution to improve the science policy discussion. Mann K. **Addiction** 1995 Nov;90(11):1451-2
Application of bioelectric impedance methodology and prediction equations to determine the volume of distribution for ethanol. York JL, et al. **Alcohol** 1995 Nov-Dec;12(6):553-8
Simple versus sophisticated models of breath alcohol exhalation profiles. Lubkin SR, et al. **Alcohol Alcohol** 1996 Jan;31(1):61-7
Analysis of ethanol and acetaldehyde recovery from perchloric acid-treated blood. Whitmire D, et al. **Alcohol Alcohol** 1995 Sep;30(5):623-8
Low-density lipoprotein reconstituted with fatty acid ethyl esters as a physiological vehicle for ethyl ester delivery to intact cells. Bird DA, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1265-70
Variability of ethanol absorption and breath concentrations during a large-scale alcohol administration study. Friel PN, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1055-60
Problems in pharmacokinetic analysis of alcohol disposition: a trial of the Bayesian least-squares method. Fujimiya T, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):2A-6A
Voluntary alcohol consumption in BXD recombinant inbred mice: relationship to alcohol metabolism. Gill K, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):185-90
Significant increase of blood alcohol by cimetidine after repetitive drinking of small alcohol doses. Gupta AM, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1083-7
Effects of cimetidine on blood ethanol levels after alcohol ingestion and genetic polymorphisms of sigma-alcohol dehydrogenase in Japanese. Kawashima O, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):36A-39A
Cellular signals in alcohol-induced liver injury: a review. Lands WE. **Alcohol Clin Exp Res** 1995 Aug;19(4):928-38 (112 ref.)
Changes in blood alcohol levels as a function of alcohol concentration and repeated alcohol exposure in adult female rats: potential risk factors for alcohol-induced fetal brain injury. Maier SE, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):923-7
The class I alcohol dehydrogenase gene is glucocorticoid-responsive in the rat hepatoma microcell hybrid cell line, 11-3. Majewski JL, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1430-4
Hepatic saturation mechanism of ethanol: application of mathematical models to ethanol outflow profiles in the perfused rat liver. Matsumoto H, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):7A-11A
Evidence that cytochrome P-4502E1 contributes to ethanol elimination at low doses: effects of diallyl sulfide and 4-methyl pyrazole on ethanol elimination in the perfused rat liver. Matsumoto H, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):12A-16A
Evaluation of the Alcopatch, a transdermal dosimeter for monitoring alcohol consumption. Phillips M, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1547-9
Use of lymphocytes for assessing ethanol-mediated alterations in the expression of hepatic cytochrome P4502E1. Raucy JL, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1369-75
Alcohol and endotoxin: another path to alcoholic liver injury? Schenker S, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1364-6 (40 ref.)
ADH2 gene polymorphisms are determinants of alcohol pharmacokinetics. Thomasson HR, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1494-9
Changes in GABAA receptor function and cross-tolerance to ethanol in diazepam-dependent rats. Toki S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):40A-44A
Use of ICD-9-CM codes in the estimation of alcohol-involved injury: search for a surrogate II. Treno AJ, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):320-6
Effect of the cytochrome P-4501IE1 genotype on ethanol elimination rate in alcoholics and control subjects. Ueno Y, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):17A-21A
Ethanol diffusion miscalculation [letter; comment] McGregor B. **Am J Surg** 1995 Oct;170(4):406. Comment on: Am J Surg 1990 Dec;160(6):567-70.
Quantitative trait loci for ethanol sensitivity in the LS x SS recombinant inbred strains: interval mapping. Markel PD, et al. **Behav Genet** 1996 Jul;26(4):447-58
Inhibitory effect of glycine on ethanol absorption from gastrointestinal tract. Akao T, et al. **Biol Pharm Bull** 1995 Dec;18(12):1653-6
Inter-individual and intra-individual variability of ethanol concentration-time profiles: comparison of ethanol ingestion before or after an evening meal. Fraser AG, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):387-92
Expired breath ethanol measurement to calculate irrigating fluid absorption during transurethral resection of the prostate: experience in a district general hospital. Checketts MR, et al. **Br J Urol** 1996 Feb;77(2):198-202
Bioactive saponins and glycosides. I. Senegae radix. (1): E-senegasaponins a and b and Z-senegasaponins a and b, their inhibitory effect on alcohol absorption and hypoglycemic activity. Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2115-22
Disposition and first-pass metabolism of ethanol in humans: is it gastric or hepatic and does it depend on gender? Ammon E, et al. **Clin Pharmacol Ther** 1996 May; 59(5):503-13
Gastric metabolism of ethanol in Syrian golden hamster. Batra SC, et al. **Dig Dis Sci** 1995 Dec;40(12):2712-6
First-pass metabolism of alcohol. Absence of diurnal variation and its inhibition by cimetidine after evening meal. Sharma R, et al. **Dig Dis Sci** 1995 Oct;40(10):2091-7
Medicolegal alcohol determination: variability of the blood-to breath-alcohol ratio and its effect on reported breath-alcohol concentrations. Labianca DA, et al. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):919-25 (17 ref.)
Pharmacokinetic interactions of alcohol and acetylsalicylic acid. Melander O, et al. **Eur J Clin Pharmacol** 1995; 48(2):151-3
Experimental studies on postmortem diffusion of ethanol-d6 using rats. Takayasu T, et al. **Forensic Sci Int** 1995 Dec 29;76(3):179-88
Ranitidine increases the bioavailability of postprandial ethanol by the reduction of first pass metabolism. Brown AS, et al. **Gut** 1995 Sep;37(3):413-7
Omeprazole therapy does not affect pharmacokinetics of orally administered ethanol in healthy male subjects. Minocha A, et al. **J Clin Gastroenterol** 1995 Sep;21(2):107-9
Evaluation of fluid absorption during laser prostatectomy by breath ethanol techniques [see comments] Cummings JM, et al. **J Urol** 1995 Dec;154(6):2080-2. Comment in: J Urol 1995 Dec;154(6):2093-5.
Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. Amir I, et al. **Life Sci** 1996;58(6):511-8
[Breath alcohol analyzers with electrochemical sensory--accuracy of measurements in lung model ventilation] Gehring H, et al. **Biomed Tech (Berl)** 1996 Mar; 41(3):54-9 (Eng. Abstr.) (Ger)
[Traffic accidents in alcoholic intoxication] Erath D, et al. **Blutalkohol** 1996 Mar;33(2):57-64 (Eng. Abstr.) (Ger)
[Initial experiences with the "0.8 promille regulation in Thüringen] Giebe W, et al. **Blutalkohol** 1995 Sep; 32(5):279-84 (Eng. Abstr.) (Ger)
[Changes in the spectrum of alcohol-induced traffic accidents in relation to blood alcohol level] Haffner HT, et al. **Blutalkohol** 1996 Mar;33(2):78-83 (Eng. Abstr.) (Ger)
[Use of the ADH/REA method (Abbott Tdx-REA) in forensic blood alcohol determination] Mebs D, et al. **Blutalkohol** 1996 Mar;33(2):71-7 (Eng. Abstr.) (Ger)
[Ethanol-independent methanol elimination in chronic alcoholics] Musshoff F, et al. **Blutalkohol** 1995 Nov; 32(6):317-36 (Eng. Abstr.) (Ger)
[Old wine in new bottles: the "promille-killer" Party Plus] Schmidt V, et al. **Blutalkohol** 1995 Sep;32(5):241-53 (Eng. Abstr.) (Ger)
[Congener analysis in a drinking trial with unusually high alcohol content] Schmitt G, et al. **Blutalkohol** 1995 Nov; 32(6):337-43 (Eng. Abstr.) (Ger)
[Drinking trials for back calculation in long elapsed time intervals] Schröter A, et al. **Blutalkohol** 1995 Nov; 32(6):344-52 (Eng. Abstr.) (Ger)
[Reliability of back-calculation of blood alcohol concentration to the time of infraction] Schyma C, et al. **Blutalkohol** 1996 Mar;33(2):65-70 (Eng. Abstr.) (Ger)
[Self-assessment of blood alcohol content in acute alcoholic intoxication] Seidl S, et al. **Blutalkohol** 1996 Jan;33(1):23-30 (Eng. Abstr.) (Ger)
[Formation of so-called byproducts (propanols, butanols et al.) from ethanol by microorganisms] Stöhlmacher P.

Blutalkohol 1996 May;33(3):113–41 (200 ref.) (Eng. Abstr.) **(Ger)**

[Concentration dependent ethanol metabolism in steady-state] Wehner HD, et al. **Blutalkohol** 1996 Jan; 33(1):17–22 (Eng. Abstr.) **(Ger)**

[Driving ban—a blunt weapon? Response to the comment by Bode (letter; comment)] Zabel RG. **Blutalkohol** 1996 Jan;33(1):44–6. Comment on: Blutalkohol 1995 Nov;32(6):314–6. **(Ger)**

PHARMACOLOGY

Alcohol effects on paraventricular hypothalamic nucleus morphometry. Pérez-Delgado M, et al. **Acta Anat (Basel)** 1995;153(4):282–9

Influence of low dose alcohol on fixation suppression. Harder T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:33–6

Inhibitory action of in vitro ethanol and acetaldehyde exposure on LHRH-and phorbol ester-stimulated testosterone secretion by rat testicular interstitial cells. Wanderley MI, et al. **Acta Physiol Pharmacol Ther Latinoam** 1994;44(4):135–41

Ethanol inhibits NMDA-induced toxicity and trophism in cultured cerebellar granule cells. Wegelius K, et al. **Acta Physiol Scand** 1995 May;154(1):25–34

Addictive drugs as reinforcers: multiple partial actions on memory systems. White NM. **Addiction** 1996 Jul; 91(7):921–49; discussion 951–65 (304 ref.)

Effect of ethanol on amino acids and related compounds in rat plasma, heart, aorta, bronchus, and pancreas. Abdel-Nabi R, et al. **Alcohol** 1996 Mar-Apr;13(2):171–4

Glutamate and N-methyl-D-aspartate binding sites in the guinea pig hippocampus: ontogeny and effect of acute in vitro ethanol exposure. Abdollah S, et al. **Alcohol** 1995 Jul-Aug;12(4):369–75

Effect of chronic maternal ethanol administration on glutamate and N-methyl-D-aspartate binding sites in the hippocampus of the near-term fetal guinea pig. Abdollah S, et al. **Alcohol** 1995 Jul-Aug;12(4):377–82

Alcohol-induced changes in blood gases, glucose, and lactate in pregnant and nonpregnant rats. Abel EL. **Alcohol** 1996 May-Jun;13(3):281–5

Alcohol inhibits cell mitosis in G2-M phase in cell cycle in a human lymphocytes in vitro study. Ahluwalia BS, et al. **Alcohol** 1995 Nov-Dec;12(6):589–92

Neuronal differentiation modifies the effect of ethanol exposure on voltage-dependent calcium channels in NG 108-15 cells. Bergamaschi S, et al. **Alcohol** 1995 Nov-Dec; 12(6):497–503

Lysosomal and nonlysosomal protease activities of the brain in response to ethanol feeding. Bonner AB, et al. **Alcohol** 1995 Nov-Dec;12(6):505–9

Nitric oxide synthase activity in the hippocampus, frontal cerebral cortex, and cerebellum of the guinea pig: ontogeny and in vitro ethanol exposure. Brien JF, et al. **Alcohol** 1995 Jul-Aug;12(4):329–33

Prolonged treatment with carbamazepine increases the stimulatory effects of ethanol in mice. Camarini R, et al. **Alcohol** 1995 Jul-Aug;12(4):305–8

Liver antioxidant defenses in mice fed ethanol and the AIN-76A diet. Chen LH, et al. **Alcohol** 1995 Sep-Oct; 12(5):453–7

The effect of ethanol and calcium channel antagonists on rabbit EEG. Czarnecka E, et al. **Alcohol** 1996 May-Jun; 13(3):221–6

Single-dose ritanserin and alcohol in healthy volunteers: a placebo-controlled trial. Estevez F, et al. **Alcohol** 1995 Nov-Dec;12(6):541–5

Development of neurochemical and behavioral sensitivity to ethanol in long-sleep and short-sleep mice. French TA, et al. **Alcohol** 1995 Sep-Oct;12(5):423–31

Influence of ethanol on the salsolinol excretion in healthy subjects. Haber H, et al. **Alcohol** 1995 Jul-Aug; 12(4):299–303

Role of acetaldehyde in the actions of ethanol on the brain--a review. Hunt WA. **Alcohol** 1996 Mar-Apr;13(2):147–51 (66 ref.)

Effects of ethanol and auditory distraction on forced choice reaction time. Jääskeläinen IP, et al. **Alcohol** 1996 Mar-Apr; 13(2):153–6

Dose-related effect of alcohol on mismatch negativity and reaction time performance. Jääskeläinen IP, et al. **Alcohol** 1995 Nov-Dec;12(6):491–5

D, L-(tetrazol-5-yl)glycine stimulation of NMDA receptors in neonatal dissociated neurons: inhibition by ethanol. Jones TW, et al. **Alcohol** 1996 Mar-Apr;13(2):181–5

Dietary protein regimens and chronic ethanol administration effects on sodium- and proton-dependent solute uptake in rat intestine. Kaur J, et al. **Alcohol** 1995 Sep-Oct; 12(5):459–62

Influence of ethanol on circulation in surface-induced hypothermia and subsequent rewarming. Lauri T, et al. **Alcohol** 1996 Mar-Apr;13(2):117–23

Effects of ethanol feeding and malnutrition on collagen synthesizing and degrading enzymes in rat pancreas. López JM, et al. **Alcohol** 1996 May-Jun;13(3):227–31

The suppressant effect of ethanol, delivered via intrahippocampal microdialysis, on the firing of local pyramidal cells in freely behaving rats. Ludvig N, et al. **Alcohol** 1995 Sep-Oct;12(5):417–21

Acute ethanol and selected growth suppressor transcripts in regenerating rat liver. Lumpkin CK Jr, et al. **Alcohol** 1995 Jul-Aug;12(4):357–62

Cocaethylene-induced lethality in mice is potentiated by alcohol. Meehan SM, et al. **Alcohol** 1995 Jul-Aug; 12(4):383–5

MDMA (Ecstasy) substitutes for the ethanol discriminative cue in HAD but not LAD rats. Meehan SM, et al. **Alcohol** 1995 Nov-Dec;12(6):569–72

Glutamate and cysteinylglycine effects on NMDA receptors: inhibition by ethanol. Morris J, et al. **Alcohol** 1996 Mar-Apr;13(2):157–62

[3H]MK-801 binding in various brain regions of rat lines selected for differential alcohol sensitivity. Näkki R, et al. **Alcohol** 1995 Jul-Aug;12(4):335–40

Ganglioside long-chain base composition of rat brain subcellular fractions after chronic ethanol administration. Omodeo-Salé F, et al. **Alcohol** 1996 May-Jun;13(3):291–5

Effects of oral ethanol on serum lipoprotein cholesterol in juvenile meat-type chickens. Peebles ED, et al. **Alcohol** 1996 Mar-Apr;13(2):111–5

Ethanol increases uterine blood flow and fetal arterial blood oxygen tension in the near-term pregnant ewe. Reynolds JD, et al. **Alcohol** 1996 May-Jun;13(3):251–6

Genetic differences in ethanol-induced conditioned taste aversion after ethanol preexposure. Risinger FO, et al. **Alcohol** 1995 Nov-Dec;12(6):535–9

Explorative and drinking behavior after prolonged access to alcohol and following chronic piracetam administration in mice. Salimov R, et al. **Alcohol** 1995 Nov-Dec; 12(6):485–9

Alcohol inhibits neurite extension and increases N-myc and c-myc proteins. Saunders DE, et al. **Alcohol** 1995 Sep-Oct; 12(5):475–83

Absence of tolerance to the aversive stimulus properties of ethanol following oral ethanol self-administration. Shoaib M, et al. **Alcohol** 1996 Mar-Apr;13(2):175–80

Delayed generalization testing produces enhanced alcohol aversions in rats. Thiele TE, et al. **Alcohol** 1996 Mar-Apr; 13(2):201–7

Angiotensin II antagonists block ethanol effects on the aerial righting reflex. Tracy HA Jr, et al. **Alcohol** 1996 May-Jun; 13(3):287–9

Heterogeneity of tolerance developed to effects of ethanol on rotarod and accelerod performances in rats. Uzbay IT, et al. **Alcohol** 1995 Nov-Dec;12(6):593–5

Early handling can attenuate adverse effects of fetal ethanol exposure. Weinberg J, et al. **Alcohol** 1995 Jul-Aug; 12(4):317–27

Different levels of [3H]MK-801 binding in long-sleep and short-sleep lines of mice. Wilson WR, et al. **Alcohol** 1996 May-Jun;13(3):315–20

Effect of acute alcohol ingestion on mineral metabolism and osteoblastic function. García-Sanchez A, et al. **Alcohol Alcohol** 1995 Jul;30(4):449–53

ESBRA 1994 Award Lecture. Phosphatidylethanol formation: specific effects of ethanol mediated via phospholipase D. Gustavsson L. **Alcohol Alcohol** 1995 Jul; 30(4):391–406 (84 ref.)

Changes of G-protein levels in platelet membranes from alcoholics during short-term and long-term abstinence. Lichtenberg-Kraag B, et al. **Alcohol Alcohol** 1995 Jul; 30(4):455–64

Influence of ethanol administration on the activity and compartmentation of rat liver monoamine oxidases. Medvedev AE, et al. **Alcohol Alcohol** 1995 Nov; 30(6):729–35

Role of alcoholic beverages in essential hypertensive patients. Rabbia F, et al. **Alcohol Alcohol** 1995 Jul;30(4):433–9

Hormonal and chemical influences on the expression of class 2 aldehyde dehydrogenases in rat H4IIEC3 and human HuH7 hepatoma cells. Crabb DW, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1414–9

8-Bromo-cAMP mimics beta-adrenergic sensitization of GABA responses to ethanol in cerebellar Purkinje neurons in vivo. Freund RK, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):408–12

Effects of ethanol on glucose transporter expression in cultured hippocampal neurons. Hu IC, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1398–402

Ethanol at pharmacologically relevant concentrations inhibits contractility of isolated smooth muscle cells of cat esophagus. Keshavarzian A, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):180–4

Induction of cytochrome P-4502E1 by ethanol in rat Kupffer cells. Koivisto T, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):207–12

Alcohol inhibits epidermal growth factor-stimulated progesterone secretion from human granulosa cells. McKenzie PP, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1382–8

Ethanol inhibition of AMPA and kainate receptor-mediated depolarizations of hippocampal area CA1. Martin D, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1312–6

Acute ethanol impairs spatial memory but not stimulus/response memory in the rat. Matthews DB, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):902–9

Possible role of striatal adenosine in the modulation of acute ethanol-induced motor incoordination in rats. Meng ZH, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):892–901

Low-dose effect of ethanol on locomotor activity induced by activation of the mesolimbic system. Milton GV, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):768–76

Mutations affecting sensitivity to ethanol in the nematode, Caenorhabditis elegans. Morgan PG, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1423–9

Role of protein synthesis on ethanol regulation of adenylyl cyclase activity in wild-type S49 murine lymphoma cells. Nakamura J. **Alcohol Clin Exp Res** 1996 Apr;20(2):302–6

Gender difference in alcohol-evoked hypothalamic-pituitary-adrenal activity in the rat: ontogeny and role of neonatal steroids. Ogilvie KM, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):255–61

Combined inhibitory effects of ethanol and adenosine on the responses of rabbit platelets to thrombin. Rand ML, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1279–85

N-methyl-D-aspartate-stimulated increases in intracellular calcium exhibit brain regional differences in sensitivity to inhibition by ethanol. Randoll LA, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):197–200

Alcohol stimulates ACTH secretion in the rat: mechanisms of action and interactions with other stimuli. Rivier C. **Alcohol Clin Exp Res** 1996 Apr;20(2):240–54 (207 ref.)

Ethanol's action on the GABAA receptor: is there a requirement for parsimony? Tabakoff B. **Alcohol Clin Exp Res** 1995 Dec;19(6):1597–8

Selective effects of ethanol on the generation of cAMP by particular members of the adenylyl cyclase family. Yoshimura M, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1435–40

Continuous exposure of cultured rat cerebellar macroneurons to ethanol-depressed NMDA and KCl-stimulated elevations of intracellular calcium. Zou JY, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):840–5

Effect of ethanol on airway caliber and nonspecific bronchial responsiveness in patients with alcohol-induced asthma. Myou S, et al. **Allergy** 1996 Jan;51(1):52–5

Acute effects of ethanol ingestion on signal-averaged electrocardiograms. Cardy MA, et al. **Am J Cardiol** 1996 Jun 15;77(15):1356–7

Selective responses of hormones involved in carbohydrate and lipid metabolism and properties of erythrocyte membranes during the menstrual cycle in premenopausal women consuming moderate amounts of alcohol. Bhathena SJ, et al. **Am J Clin Nutr** 1995 Oct;62(4):751–6

Alcohol and energy intake. Lands WE. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1101S–1106S (55 ref.)

Effects of ethanol, xylose, and glucose on canine jejunal motility. Charles F, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):G363–9

Rat hepatocytes and Kupffer cells interact to produce interleukin-8 (CINC) in the setting of ethanol. Maher JJ. **Am J Physiol** 1995 Oct;269(4 Pt 1):G518–23

Propofol and ethanol produce additive hypnotic and anesthetic effects in the mouse. Garfield JM, et al. **Anesth Analg** 1996 Jul;83(1):156–61

Effect of chronic ethanol administration and dietary protein regimens on intestinal absorption of macromolecules in rats. Kaur J, et al. **Ann Nutr Metab** 1995;39(3):152–8

Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Kostrubsky VE, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):516–20

Differential regulation of manganese superoxide dismutase activity by alcohol and TNF in human hepatoma cells. Perera CS, et al. **Arch Biochem Biophys** 1995 Nov 10; 323(2):471–6

The effects of alcohol consumption on laboratory-induced panic and state anxiety. Kushner MG, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):264–70

The electroencephalogram after alcohol administration in high-risk men and the development of alcohol use disorders 10 years later. Volavka J, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):258–63

Asymmetric synthesis and enantiospecificity of binding of 2-(1,2,3,4-tetrahydro-1-isoquinolyl)-ethanol derivatives to mu and kappa receptors. Wanner KT, et al. **Arch Pharm (Weinheim)** 1996 Jan;329(1):11–22

Ethanol-induced redistribution of cholesteryl ester transfer protein (CETP) between lipoproteins. Hannuksela ML, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):213–21

Effect of chronic ethanol on phospholipase A2- and C-activity in chick embryo brain, heart and liver. Natsuki R. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Oct; 30(5):348–57

Stress controllability influences the ataxic properties of both ethanol and midazolam in the rat. Drugan RC, et al. **Behav Neurosci** 1996 Apr;110(2):360–7

Secretion of prostaglandins elicited by lipopolysaccharide and ethanol in cultured rat Kupffer cells. Victorov AV, et al. **Biochem Biophys Res Commun** 1995 Oct 13; 215(2):691–7

Inhibition of the cerebellar inositol 1,4,5-trisphosphate-sensitive Ca2+ channel by ethanol and other aliphatic alcohols. Mezna M, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):175–9

Ethanol has different effects on Ca(2+)-transport ATPases of muscle, brain and blood platelets. Mitidieri F, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):733–7

Ethanol decreases the levels of GLUT2 glucose transporter mRNA in hepatocytes. Nagamatsu S, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):675–80

Biochemical characterization of ethanol actions on dihydropyridine-sensitive calcium channels in brain synaptosomes. Canda A, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1711–8

Effect of chronic alcohol consumption by rats on tumor necrosis factor-alpha and interleukin-6 clearance in vivo

and by the isolated, perfused liver. Deaciuc IV, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):891–9

Effects of diet and ethanol on the expression and localization of cytochromes P450 2E1 and P450 2C7 in the colon of male rats. Hakkak R, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):61–9

In vitro effects of ethanol on polymorphonuclear leukocyte membrane receptor expression and mobility. Nilsson E, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):225–31

Regulation of the stress-like protein adenotin in PC 12 cells by ethanol exposure. Rabin RA. **Biochem Pharmacol** 1996 Jan 26;51(2):183–6

Potentiation of mitogen-activated protein kinase by ethanol in embryonic liver cells. Reddy MA, et al. **Biochem Pharmacol** 1996 Mar 8;51(5):661–8

Probing the ligand binding sites of fatty acid and sterol carrier proteins: effects of ethanol. Schroeder F, et al. **Biochemistry** 1995 Sep 19;34(37):11919–27

Effects of ethanol on lateral and rotational mobility of plasma membrane vesicles isolated from cultured mouse myeloma cell line Sp2/0–Ag14. Kang JS, et al. **Biochim Biophys Acta** 1996 Jun 11;1281(2):157–63

Ethanol consumption alters trafficking of lysosomal enzymes and affects the processing of procathepsin L in rat liver. Kharbanda KK, et al. **Biochim Biophys Acta** 1996 Aug 29; 1291(1):45–52

Ethanol-enhanced permeation of phosphatidylcholine/phosphatidylethanolamine mixed liposomal membranes due to ethanol-induced lateral phase separation. Komatsu H, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):73–9

Ethanol, morphine and barbiturate alter the hemodynamic and cerebral response to cocaine in newborn pigs. Albuquerque ML, et al. **Biol Neonate** 1995;67(6):432–40

Inhibitory effect of ethanol and colchicine on the intracellular processing of beta-glucuronidase which occurs in the Golgi complex. Nishimura Y, et al. **Biol Pharm Bull** 1995 Jul; 18(7):938–44

The effect of ethanol and diazepam on the fatty acid composition of plasma and liver phospholipids in the rat. Ristić V, et al. **Biol Pharm Bull** 1995 Jun;18(6):842–5

Effects of alcohol on the sleep-stage structure of a nap in the afternoon. Van F, et al. **Biol Psychol** 1995 Aug; 41(1):55–9

Effects of moderate doses of ethyl alcohol on cerebral lateralization of language and on hand movements. I: A dual-task paradigm study. Clarici A, et al. **Boll Soc Ital Biol Sper** 1995 Jul–Aug;71(7–8):213–20

Evaluation of the central effects of alcohol and caffeine interaction. Azcona O, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):393–400

Effect of alcohol on body core temperature during cold-water immersion. Roeggla G, et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):239–40

Alcohol and the regulation of energy balance: overnight effects on diet-induced thermogenesis and fuel storage. Murgatroyd PR, et al. **Br J Nutr** 1996 Jan;75(1):33–45

Haemodynamic effects of irrigating fluids studied by Doppler ultrasonography in volunteers. Nilsson A, et al. **Br J Urol** 1996 Apr;77(4):541–6

Inhibition of human motor cortex by ethanol. A transcranial magnetic stimulation study. Ziemann U, et al. **Brain** 1995 Dec;118 (Pt 6):1437–46

Selective destruction of midbrain raphe nuclei by 5,7-DHT: is brain 5-HT involved in alcohol drinking in Sprague-Dawley rats? Adell A, et al. **Brain Res** 1995 Sep 25;693(1–2):70–9

Effects of ethanol on respiratory activity in the neonatal rat brainstem-spinal cord preparation. Di Pasquale E, et al. **Brain Res** 1995 Oct 16;695(2):271–4

Ethanol suppresses the induction of long-term potentiation in vivo. Givens B, et al. **Brain Res** 1995 Aug 7; 688(1–2):27–33

Calcitonin gene-related peptide (CGRP) content and CGRP receptor binding sites in discrete forebrain regions of alcohol-preferring vs. -nonpreferring rats, and high alcohol-drinking vs. low alcohol-drinking rats. Hwang BH, et al. **Brain Res** 1995 Sep 4;690(2):249–53

Effects of systemic and local ethanol on responses of rat cerebellar Purkinje neurons to iontophoretically applied gamma-aminobutyric acid. Lee RS, et al. **Brain Res** 1995 Jul 31;687(1–2):1–11

Effects of systemic and local ethanol on responses of rat cerebellar Purkinje neurons to iontophoretically applied norepinephrine and gamma-aminobutyric acid. Lee RS, et al. **Brain Res** 1995 Jul 31;687(1–2):12–21

Dynamic analysis of ethanol effects on NMDA-evoked dopamine overflow in rat striatum. Lin AM, et al. **Brain Res** 1995 Oct 23;696(1–2):15–20

Ethanol enhances muscarinic cholinergic neurotransmission in rat hippocampus in vitro. Madamba SG, et al. **Brain Res** 1995 Jul 10;685(1–2):21–32

Involvement of benzodiazepine/GABA-A receptor complex in ethanol-induced state-dependent learning in rats. Nakagawa Y, et al. **Brain Res** 1995 Jul 17;686(1):70–6

Modulatory effects of acute ethanol on metabotropic glutamate responses in cultured Purkinje neurons. Netzeband JG, et al. **Brain Res** 1995 Aug 7;688(1–2):105–13

Ethanol withdrawal hyperexcitability in vitro is selectively decreased by a competitive NMDA receptor antagonist. Ripley TL, et al. **Brain Res** 1995 Nov 13;699(1):1–11

Alterations of the thalamo-cortical system in rats prenatally exposed to ethanol are prevented by concurrent administration of acetyl-L-carnitine. Santarelli M, et al. **Brain Res** 1995 Nov 6;698(1–2):241–7

Perturbation of target-directed neurite outgrowth in embryonic CNS co-cultures grown in the presence of ethanol. Heaton MB, et al. **Brain Res Dev Brain Res** 1995 Nov 21;89(2):270–80

Ethanol stimulates diazepam binding inhibitor (DBI) mRNA expression in primary cultured neurons. Katsura M, et al. **Brain Res Mol Brain Res** 1995 Dec 28;34(2):355–9

Influence of acetaldehyde and ethanol on rat hepatic lipocyte characteristics in primary culture. Sato T, et al. **Cell Biol Int** 1995 Oct;19(10):879–81

Double effect of ethanol on intracellular Ca2+ levels in undifferentiated PC12 cells. Belia S, et al. **Cell Signal** 1995 May;7(4):389–95

In vivo potentiation of 1,2-dibromoethane hepatotoxicity by ethanol through inactivation of glutathione-s-transferase. Aragno M, et al. **Chem Biol Interact** 1996 Jan 5; 99(1–3):277–88

Systemic and regional haemodynamic effects of caffeine and alcohol in fasting subjects [corrected] [published erratum appears in Clin Auton Res 1995 Sep;5(4):235] Stubbs TA, et al. **Clin Auton Res** 1995 Jun;5(3):123–7

Effects of alcohol on plasma lipoprotein metabolism. Frohlich JJ. **Clin Chim Acta** 1996 Mar 15;246(1–2):39–49 (30 ref.)

Effects of alcohol on platelet functions. Renaud SC, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):77–89 (50 ref.)

Acute effect of ethanol on renal electrolyte transport in the rat. Carney SL, et al. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):629–34

Molecular and cellular adaptations in signal transduction pathways following ethanol exposure. Fitzgerald LW, et al. **Clin Neurosci** 1995;3(3):165–73 (98 ref.)

Cellular and behavioral neurobiology of alcohol: receptor-mediated neuronal processes. Grant KA, et al. **Clin Neurosci** 1995;3(3):155–64 (98 ref.)

Effects of an acute dose of ethanol on dopaminergic and serotonergic systems from rat cerebral cortex and striatum. Gil-Martín E, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Mar;113(3):399–402

Effect of beer, yeast-fermented glucose, and ethanol on pancreatic enzyme secretion in healthy human subjects. Chari ST, et al. **Dig Dis Sci** 1996 Jun;41(6):1216–24

Effect of 10% ethanol and sofalcone on prostaglandin E2 content, mucus gel thickness, and experimental ulcers in the stomach of developing rats. Tabata M, et al. **Digestion** 1996;57(1):47–53

Increased blood and brain cocaine concentrations with ethanol cotreatment in mice. Roberts SM, et al. **Drug Metab Dispos** 1995 Jun;23(6):664–6

Effects of ethanol treatment on Leydig cellular NADPH-generating enzymes and lipid profiles. Srikanth V, et al. **Endocr J** 1995 Oct;42(5):705–12

Failure of ethanol metabolites to alter gonadotropin secretion or luteinizing hormone synthesis in vitro. Uddin S, et al. **Endocr Res** 1995 Aug;21(3):653–70

Effect of ethanol on the protein secondary structure of the human gastric mucosa, in vitro. Lin SY, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):255–61

Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects. Patat A, et al. **Eur J Clin Pharmacol** 1995;48(2):143–50

Nitric oxide and sensory afferent neurones modulate the protective effects of low-dose endotoxin on rat gastric mucosal damage. Barrachina D, et al. **Eur J Pharmacol** 1995 Jul 14;280(3):339–42

GABAA receptor antagonism in the extended amygdala decreases ethanol self-administration in rats. Hyytiä P, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):151–9

Modification of behavioral effects of 8-hydroxy-2-(di-n-propylamino)tetralin following chronic ethanol consumption in the rat: evidence for the involvement of 5-HT1A receptors in ethanol dependence. Kleven M, et al. **Eur J Pharmacol** 1995 Aug 15; 281(3):219–28

Chronic alcoholization alters the expression of 5-HT1A and 5-HT1B receptor subtypes in rat brain. Nevo I, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):229–39

Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. Rossetti ZL, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):177–83

Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 maintain functional tolerance to ethanol. Szabò G, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):35–41

Ethanol exposure stimulates cartilage differentiation by embryonic limb mesenchyme cells. Kulyk WM, et al. **Exp Cell Res** 1996 Mar 15;223(2):290–300

Ethanol inhibition of retinoic acid synthesis as a potential mechanism for fetal alcohol syndrome. Deltour L, et al. **FASEB J** 1996 Jul;10(9):1050–7

Identification of the nuclear transcription factor NFkappaB in rat after in vivo ethanol administration. Ward RJ, et al. **FEBS Lett** 1996 Jul 1;389(2):119–22

Intracellular acidification does not account for inhibition of Saccharomyces cerevisiae growth in the presence of ethanol. Rosa MF, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2–3):271–4

Influence of ethanol on the lipid content and fatty acid composition of Saccharomyces cerevisiae. Sajbidor J, et al. **Folia Microbiol (Praha)** 1995;40(5):508–10

Effect of ethanol on nitrite oxidation in the perfused rat liver. Watanabe M, et al. **Food Chem Toxicol** 1995 Nov; 33(11):935–40

Stress proteins and SH-groups in oxidant-induced cell damage after acute ethanol administration in rat. Calabrese V, et al. **Free Radic Biol Med** 1996;20(3):391–7

Alterations in fluorinated ether anesthetics effects on heme metabolism following chronic ethanol consumption. Buzaleh AM, et al. **Gen Pharmacol** 1995 Oct;26(6):1425–9

Regulation of mRNA export in response to stress in Saccharomyces cerevisiae. Saavedra C, et al. **Genes Dev** 1996 Jul 1;10(13):1608–20

Ciprofloxacin prevents the inhibitory effects of acute ethanol exposure on hepatic regeneration in the rat. Minuk GY, et al. **Hepatology** 1995 Dec;22(6):1797–800

Selective portal vein embolization with absolute ethanol induces hepatic hypertrophy and makes more extensive hepatectomy possible. Ogasawara K, et al. **Hepatology** 1996 Feb;23(2):338–45

A collagen enhancer-promoter construct in transgenic mice is markedly stimulated by ethanol administration. Walton CM, et al. **Hepatology** 1996 Feb;23(2):310–5

Synergistic effect of alcohol and nicotine on glycosaminoglycan metabolism in rats. Ashakumary L, et al. **Indian J Exp Biol** 1995 Dec;33(12):940–2

Studies on psychomotor performance in healthy volunteers after diazepam, propranolol and alcohol given alone or in combination. Khajuria V, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):242–6

Maturation of cerebellar granule cells is delayed in cultures derived from ethanol-treated chick embryos: survival and proliferation studies. Srivastava N, et al. **Int J Dev Neurosci** 1995 Oct;13(6):529–37

Effect of ethanol on human erythrocyte superoxide dismutase activity and malonyl dialdehyde concentration. Dudek IM, et al. **Int J Occup Med Environ Health** 1995;8(3):239–43

Gastric eicosanoid synthesis in normal subjects and alcoholics after ethanol stimulation. Franco L, et al. **Ital J Gastroenterol** 1995 Jun;27(5):244–7

Effect of oral ethanol intake on muscle sympathetic nerve activity and cardiovascular functions in humans. Iwase S, et al. **J Auton Nerv Syst** 1995 Sep 5;54(3):206–14

Induction of the synthesis of hsp27 and alpha B crystallin in tissues of heat-stressed rats and its suppression by ethanol or an alpha 1-adrenergic antagonist. Inaguma Y, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1238–43

Chronic ethanol-mediated up-regulation of the N-methyl-D-aspartate receptor polypeptide subunits in mouse cortical neurons in culture. Follesa P, et al. **J Biol Chem** 1996 Jun 7;271(23):13297–9

Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. Roberts BJ, et al. **J Biol Chem** 1995 Dec 15;270(50):29632–5

Decreased binding of asialoglycoproteins to hepatocytes from ethanol-fed rats. Consequence of both impaired synthesis and inactivation of the asialoglycoprotein receptor. Tworek BL, et al. **J Biol Chem** 1996 Feb 2;271(5):2531–8

Immunoglobulin M synthesis after burn injury: the effects of chronic ethanol on postinjury synthesis. Tabata T, et al. **J Burn Care Rehabil** 1995 Jul–Aug;16(4):400–6

Alcohol inhibits cell-cell adhesion mediated by human L1. Ramanathan R, et al. **J Cell Biol** 1996 Apr;133(2):381–90

Ethanol decreases nocturnal plasma levels of thyrotropin and growth hormone but not those of thyroid hormones or prolactin in man. Ekman AC, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2627–32

Influence of prenatal ethanol exposure on cholinergic development in the rat striatum. Heaton MB, et al. **J Comp Neurol** 1996 Jan 1;364(1):113–20

Acute exposure to alcohol during early postnatal life causes a deficit in the total number of cerebellar Purkinje cells in the rat. Pauli J, et al. **J Comp Neurol** 1995 Sep 25; 360(3):506–12

Influence of chronic prenatal ethanol on cholinergic neurons of the septohippocampal system. Swanson DJ, et al. **J Comp Neurol** 1996 Jan 1;364(1):104–12

Fracture toughness of experimental dental composites aged in ethanol. Ferracane JL, et al. **J Dent Res** 1995 Jul; 74(7):1418–23

Behavioral economics of concurrent ethanol-sucrose and sucrose reinforcement in the rat: effects of altering variable-ratio requirements. Petry NM, et al. **J Exp Anal Behav** 1995 Nov;64(3):331–59

Factors affecting the role of the spindle during early response of mouse oocytes to ethanol stimulation. Rybouchkin A, et al. **J Exp Zool** 1996 Aug 15;275(6):469–75

Interaction of Kupffer cells to splenic macrophages and hepatocytes in endotoxin clearance: effect of alcohol. Fukui H, et al. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S31–4

Inhibition of gap junction intercellular communications of cultured rat hepatocytes by ethanol: role of ethanol metabolism. Abou Hashieh I, et al. **J Hepatol** 1996 Mar; 24(3):360–7

Effects of ethanol on hepatitis B virus Pre-S/S gene expression in the human hepatocellular carcinoma derived HEP G2 hepatitis B DNA positive cell line. Ganne-Carrié N, et al. **J Hepatol** 1995 Aug;23(2):153–9

Regulation of ferritin expression by alcohol in a human hepatoblastoma cell line and in rat hepatocyte cultures. Moirand R, et al. **J Hepatol** 1995 Oct;23(4):431–9

Hepatic mitochondrial oxidative metabolism and lipid

peroxidation in iron-loaded rats fed ethanol. Tector AJ, et al. **J Lab Clin Med** 1995 Dec;126(6):597–602

Ethanol modulates apolipoprotein B mRNA editing in the rat. Lau PP, et al. **J Lipid Res** 1995 Oct;36(10):2069–78

EPR linewidth (T2) method to measure oxygen permeability of phospholipid bilayers and its use to study the effect of low ethanol concentrations. Smirnov AI, et al. **J Magn Reson B** 1996 May;111(2):149–57

Alcohol inhibits the depolarization-induced stimulation of oxidative phosphorylation in synaptosomes. Li HL, et al. **J Neurochem** 1996 Apr;66(4):1691–7

Ethanol-induced inhibition of [3H]thienylcyclohexylpiperidine (TCP) binding to NMDA receptors in brain synaptic membranes and to a purified protein complex. Michaelis EK, et al. **J Neurochem** 1996 Jul;67(1):201–11

Ethanol increases cytochrome P4502E1 and induces oxidative stress in astrocytes. Montoliu C, et al. **J Neurochem** 1995 Dec;65(6):2561–70

Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. Weiss F, et al. **J Neurosci** 1996 May 15;16(10):3474–85

Effects of ethanol on neuroblastoma cells in culture: role of gangliosides in neuritogenesis and substrate adhesion. Leskawa KC, et al. **J Neurosci Res** 1995 Oct 15; 42(3):377–84

Anesthetic-dependent pial arteriolar response to ethanol. Gordon EL, et al. **J Neurosurg** 1995 Nov;83(5):875–7

CYP-2E1 inhibitors partially ameliorate the changes in hepatic fatty acid composition induced in rats by chronic administration of ethanol and a high fat diet. Morimoto M, et al. **J Nutr** 1995 Dec;125(12):2953–64

Changes in hepatic enzyme activities related to ethanol metabolism in mice following chronic ethanol administration. Kishimoto R, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Oct;41(5):527–43

Activation of cyclic AMP-dependent protein kinase reverses tolerance of a nucleoside transporter to ethanol. Coe IR, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):365–9

Common genetic determinants of the ataxic and hypothermic effects of ethanol in BXD/Ty recombinant inbred mice: genetic correlations and quantitative trait loci. Crabbe JC, et al. **J Pharmacol Exp Ther** 1996 May;277(2):624–32

Sensitization of gamma-aminobutyric acidA receptors to neuroactive steroids in rats during ethanol withdrawal. Devaud LL, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):510–7

Interactions between ethanol, endogenous adenosine and adenosine uptake in hippocampal brain slices. Diao L, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):542–6

The role of specific eicosanoids in mediating the acute narcotic effects of ethanol. Elmer GI, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):308–15

Identification of genetic markers for initial sensitivity and rapid tolerance to ethanol-induced ataxia using quantitative trait locus analysis in BXD recombinant inbred mice. Gallaher EJ, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):604–12

Mechanisms of ethanol-induced suppression of a primary antibody response in a mouse model for binge drinking. Han YC, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):950–7

Effects of the benzodiazepine inverse agonist RO19-4603 on the maintenance of tolerance to a single dose of ethanol. June HL, et al. **J Pharmacol Exp Ther** 1995 Sep; 274(3):1105–12

Long-term exposure to ethanol increases the number and function of muscarinic M1 receptors in human neuroblastoma cells. Larsson C, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):313–9

Striatal dopamine receptors and adenylyl cyclase activity in a rat model of alcohol addiction: effects of ethanol and lisuride treatment. May T, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1195–203

Evaluation of potential genetic associations between ethanol tolerance and sensitization in BXD/Ty recombinant inbred mice. Phillips TJ, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):613–23

Critical role for glucocorticoid receptors in stress- and ethanol-induced locomotor sensitization. Roberts AJ, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):790–7

The effects of chronic amphetamine treatment on prenatal ethanol-induced changes in dopamine receptor function: electrophysiological findings. Shen RY, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1054–60

Effect of ethanol on the excitability of the inferior olive in decerebrate ferret. Svensson P, et al. **J Pharmacol Exp Ther** 1996 May;277(2):761–7

The effects of clomipramine on the excitatory action of ethanol on dopaminergic neurons of the ventral tegmental area in vitro. Trifunović RD, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):34–40

Development of alcohol tolerance in the rat after a single exposure to combined treatment with arginine8-vasopressin and ethanol. Wu PH, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1283–91

Evidence for a selective effect of ethanol on N-methyl-d-aspartate responses: ethanol affects a subtype of the ifenprodil-sensitive N-methyl-d-aspartate receptors. Yang X, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):114–24

Ethanol exposure alters the phosphorylation of cyclic AMP responsive element binding protein and cyclic AMP responsive element binding activity in rat cerebellum. Yang X, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):338–46

Role of Kupffer cells in reperfusion injury in fat-loaded livers from ethanol-treated rats. Zhong Z, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1512–7

Pharmacologic characteristics of potentiation of 5-HT3 receptors by alcohols and diethyl ether in NCB-20 neuroblastoma cells. Zhou Q, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):732–40

Ethanol and benzodiazepines. The influence of CGS 8216 on the ethanol-induced hypothermia and motor incoordination in mice and rats. Fidecka S, et al. **J Physiol Pharmacol** 1995 Dec;46(4):429–37

An effect of alcohol on the distribution of spatial attention. Post RB, et al. **J Stud Alcohol** 1996 May;57(3):260–6

Cardiac contractile and sarcoplasmic reticulum function after acute ethanol consumption. Horton JW, et al. **J Surg Res** 1996 Aug;64(2):132–8

Inhibitory effect of ethanol on voltage-dependent potassium currents in single aortic smooth muscle cells. Wu SN, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Sep; 11(9):514–20

Interaction of ethanol and anoxia with muscarinic receptor--stimulated phosphoinositide metabolism during brain development. Balduini W, et al. **Life Sci** 1995; 57(18):1667–73

Formation of tetrahydroharman (1-methyl-1,2,3,4-tetrahydro-beta-carboline) by Helicobacter pylori in the presence of ethanol and tryptamine. Callaway JC, et al. **Life Sci** 1996; 58(21):1817–21

Immunomodulation by pycnogenol in retrovirus-infected or ethanol-fed mice. Cheshier JE, et al. **Life Sci** 1996;58(5):PL 87–96

The influence of ethanol exposure on insulin-like growth factor (IGF) type II receptors in fetal rat tissues. Mauceri HJ, et al. **Life Sci** 1996;59(1):51–60

Ethanol enhances the in situ phosphorylation of MARCKS and protein kinase C activity in primary cultures of astrocytes. Smith TL, et al. **Life Sci** 1996;58(10):855–60

Ethanol induces a paradoxical simultaneous increase in circulating concentrations of insulin-like growth factor binding protein-1 and insulin. Knip M, et al. **Metabolism** 1995 Oct;44(10):1356–9

Metabolic fluxes in chemostat cultures of Schizosaccharomyces pombe grown on mixtures of glucose and ethanol. de Jong-Gubbels P, et al. **Microbiology** 1996 Jun;142 (Pt 6):1399–407

Effects of chronic ethanol exposure on cultured cerebellar granule cells. Omodeo-Salé F, et al. **Mol Chem Neuropathol** 1995 Oct;26(2):159–69

Region distribution of the gangliosides in rat brain after chronic ethanol treatment. Vrbaški SR. **Mol Chem Neuropathol** 1995 Jun-Aug;25(2-3):273–81

Glycine modulates ethanol inhibition of heteromeric N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Buller AL, et al. **Mol Pharmacol** 1995 Oct; 48(4):717–23

Expression, induction, and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes. Carpenter SP, et al. **Mol Pharmacol** 1996 Feb;49(2):260–8

Ethanol increases the activity of large conductance, Ca(2+)-activated K+ channels in isolated neurohypophysial terminals. Dopico AM, et al. **Mol Pharmacol** 1996 Jan;49(1):40–8

A single amino acid determines differences in ethanol actions on strychnine-sensitive glycine receptors. Mascia MP, et al. **Mol Pharmacol** 1996 Aug;50(2):402–6

Co-administration of ethanol transiently inhibits urethane genotoxicity as detected by a kinetic study of micronuclei induction in mice. Choy WN, et al. **Mutat Res** 1996 Apr 6;367(4):237–44

Increasing effect of ethanol on 5-HT3 receptor-mediated 14C-guanidinium influx in N1E-115 neuroblastoma cells. Barann M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug;352(2):149–56

Retrograde enhancement of human kinesthetic memory by alcohol: consolidation or protection against interference? Hewitt GP, et al. **Neurobiol Learn Mem** 1996 May; 65(3):269–77

The effect of ethanol on HSP70 in cultured rat glial cells and in brain areas of rat pups exposed to ethanol in utero. Holownia A, et al. **Neurochem Res** 1995 Jul;20(7):875–8

Ethanol inhibits muscarinic receptor-stimulated phosphoinositide metabolism and calcium mobilization in rat primary cortical cultures. Kovacs KA, et al. **Neurochem Res** 1995 Aug;20(8):939–49

Astrocyte differentiation is enhanced in chick embryos treated with ethanol during early neuroembryogenesis. Srivastava N, et al. **Neurochem Res** 1995 Sep;20(9):985–9

Alcohol addiction: an enigma among us. Tabakoff B, et al. **Neuron** 1996 May;16(5):909–12 (25 ref.)

Autoradiographical study of types 1 and 2 of benzodiazepine receptors in rat brain after chronic ethanol treatment and its withdrawal. Negro M, et al. **Neuropharmacology** 1995 Sep;34(9):1177–82

Extraversion and alcohol: Eysenck's drug postulate revisited. Rammsayer T. **Neuropsychobiology** 1995;32(4):197–207

Benzodiazepine receptor ligands with different intrinsic efficacies alter ethanol intake in alcohol-nonpreferring (NP) rats. June HL, et al. **Neuropsychopharmacology** 1996 Jan;14(1):55–66

Chronic alcohol exposure decreases brain intracellular free magnesium concentration in rats. Mullins PG, et al. **Neuroreport** 1995 Aug 21;6(12):1633–6

Chronic ethanol administration decreases brain-derived neurotrophic factor gene expression in the rat hippocampus. MacLennan AJ, et al. **Neurosci Lett** 1995 Sep 8;197(2):105–8

Problem solving following neonatal exposure to cocaine, ethanol, or cocaine/ethanol in combination in rats. Barron S, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):197–203

Antagonism by intracerebellar Ro15-4513 of acute ethanol-induced motor incoordination in mice. Dar MS. **Pharmacol Biochem Behav** 1995 Sep;52(1):217–23

D-cycloserine enhances rapid tolerance to ethanol motor incoordination. Khanna JM, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):609–14

Effect of ethanol on extracellular dopamine in the nucleus accumbens of alcohol-preferring AA and alcohol-avoiding ANA rats. Kiianmaa K, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):29–34

Contingent drug tolerance: differential tolerance to the anticonvulsant, hypothermic, and ataxic effects of ethanol. Kim CK, et al. **Pharmacol Biochem Behav** 1995 Nov; 52(3):531–9

Neurosteroids block the memory-impairing effects of ethanol in mice. Melchior CL, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):51–6

Cognitive function in rats with alcohol ingestion. Sasaki H, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):845–8

Ethanol effect on activation and maintenance of cold stress response in immature rats. Spiers DE, et al. **Pharmacol Biochem Behav** 1996 Jul;54(3):555–64

Hepatic glutathione after ethanol administration in rat: effects of cimetidine and omeprazole. Battiston L, et al. **Pharmacol Res** 1995 May;31(5):305–11

Effects of ethanol on peripheral benzodiazepine binding sites in the mouse cerebellum and brain stem. Wong PT, et al. **Pharmacology** 1995 Jun;51(1):66–72

Decrease in circulating tryptophan availability to the brain after acute ethanol consumption by normal volunteers: implications for alcohol-induced aggressive behaviour and depression. Badawy AA, et al. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:93–7

Does consumption of beer, alcohol, and bitter substances affect bitterness perception? Guinard JX, et al. **Physiol Behav** 1996 Apr-May;59(4-5):625–31

Dietary compensation by humans for supplemental energy provided as ethanol or carbohydrate in fluids. Mattes RD. **Physiol Behav** 1996 Jan;59(1):179–87

Spatial learning ability of rats following acute exposure to alcohol during early postnatal life. Pauli J, et al. **Physiol Behav** 1995 Nov;58(5):1013–20

Conditioned place preference after prolonged pre-exposure to ethanol. Bienkowski P, et al. **Pol J Pharmacol** 1995 Mar-Apr;47(2):189–91

Effects of 5-HT3 receptor antagonists on ethanol-induced hyperlocomotion in mice. Kostowski W, et al. **Pol J Pharmacol** 1995 Jul-Aug;47(4):293–7

Analeptic effect of TRH in rats selectively bred for differential CNS sensitivity to ethanol. French TA, et al. **Proc West Pharmacol Soc** 1995;38:5–7

Haloperidol prevents ethanol-stimulated locomotor activity but fails to block sensitization. Broadbent J, et al. **Psychopharmacology (Berl)** 1995 Aug;120(4):475–82

Concurrent self-administration of ethanol and an alternative nondrug reinforcer in monkeys: effects of income (session length) on demand for drug. Carroll ME, et al. **Psychopharmacology (Berl)** 1995 Jul;120(1):1–9

Preferences for ethanol and diazepam in anxious individuals: an evaluation of the self-medication hypothesis. Chutuape MA, et al. **Psychopharmacology (Berl)** 1995 Sep; 121(1):91–103

Empirical evidence that the state dependence and drug discrimination paradigms can generate different outcomes. Colpaert FC, et al. **Psychopharmacology (Berl)** 1995 Aug; 120(3):272–9

Localization of genes influencing ethanol-induced conditioned place preference and locomotor activity in BXD recombinant inbred mice. Cunningham CL. **Psychopharmacology (Berl)** 1995 Jul;120(1):28–41

Significance of adrenal corticosteroid secretion for the food restriction-induced enhancement of alcohol drinking in the rat. Hansen S, et al. **Psychopharmacology (Berl)** 1995 Sep; 121(2):213–21

Defective habituation to nociceptive stimulation in alcohol-avoiding ANA rats. Honkanen A, et al. **Psychopharmacology (Berl)** 1995 Jul;120(1):21–7

Effects of post-ethanol administration of NMDA and non-NMDA receptor antagonists on the development of ethanol tolerance in C57Bl mice. Karcz-Kubicha M, et al. **Psychopharmacology (Berl)** 1995 Jul;120(1):49–56

Ro 15-4513 selectively attenuates ethanol, but not sucrose, reinforced responding in a concurrent access procedure; comparison to other drugs. Petry NM. **Psychopharmacology (Berl)** 1995 Sep;121(2):192–203

Acute effect of altered tryptophan levels and alcohol on aggression in normal human males. Pihl RO, et al. **Psychopharmacology (Berl)** 1995 Jun;119(4):353–60

Anxiety: a potential predictor of vulnerability to the initiation of ethanol self-administration in rats. Spanagel R, et al.

Psychopharmacology (Berl) 1995 Dec;122(4):369–73

Alcohol, anxiolytics and social stress in rats. Tornatzky W, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):135–44

Alcohol pharmacodynamics in young–elderly adults contrasted with young and middle–aged subjects. Tupler LA, et al. **Psychopharmacology (Berl)** 1995 Apr; 118(4):460–70

Diazepam prevents progression of kindled alcohol withdrawal behaviour. Ulrichsen J, et al. **Psychopharmacology (Berl)** 1995 Oct;121(4):451–60

Methamphetamine facilitates ethanol–induced depressions in cerebellar Purkinje neurons of prazocin– or DSP4–treated rats. Wang Y, et al. **Psychopharmacology (Berl)** 1995 Oct; 121(4):433–41

Effect of exposure in vitro to ethanol and hypoxia on gamma–aminobutyric acid efflux in the hippocampus of the fetal and adult guinea–pig. Catlin MC, et al. **Reprod Fertil Dev** 1995;7(5):1339–44

Intravenous injection of acetaldehyde but not ethanol induces histamine–mediated bronchoconstriction in guinea pigs. Myou S, et al. **Respiration** 1995;62(3):143–7

The effect of ethanol upon early development in mice and rats. XX. The effect of chronic biparental beer intake in mice upon early implantation events. Fazakas–Todea I. **Rom J Morphol Embryol** 1995 Jan–Jun;41(1–2):7–12

The influence of beer, cognac and ethanol upon the follicular state of mouse ovaries on day 4 of pregnancy. Sandor S, et al. **Rom J Morphol Embryol** 1995 Jan–Jun;41(1–2):3–6

Ethanol affects leukotriene generation and leukotriene–induced functional responses in human polymorphonuclear granulocytes. Nilsson E, et al. **Scand J Clin Lab Invest** 1995 Nov;55(7):589–96

Water and solute dynamics after intravenous infusion of new irrigating fluids in the rabbit. Zhang W, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):241–7

New experiments underscore warnings on maternal drinking [news] Braun S. **Science** 1996 Aug 9;273(5276):738–9

Acute effects of ethanol on responses of cerebral arterioles. Mayhan WG, et al. **Stroke** 1995 Nov;26(11):2097–101; discussion 2102

Regulation of neuronal nitric oxide synthase by chronic ethanol ingestion. Fitzgerald LW, et al. **Synapse** 1995 Sep; 21(1):93–5

Inhibitory effect of alcohol on cyclic GMP accumulation in human platelets. Dong QS, et al. **Thromb Res** 1995 Oct 15;80(2):143–51

Inhibition of platelet aggregation in whole blood by alcohol. Torres Duarte AP, et al. **Thromb Res** 1995 Apr 15; 78(2):107–15

Ethanol consumption suppresses the IL2–induced proliferation of NK cells. Gallucci RM, et al. **Toxicol Appl Pharmacol** 1996 May;138(1):90–7

Influence of Aroclor 1254, phenobarbital, beta–naphthoflavone, and ethanol pretreatment on the biotransformation of cyclophosphamide in male and female rats. Sessink PJ, et al. **Toxicology** 1996 Aug 16; 112(2):141–50

Variations in peroxisomal catalase of neonatal rat hepatocyte subpopulations. Effect of pre– and postnatal exposure to alcohol. Tolosa D, et al. **Virchows Arch** 1995;427(3):309–15

The effect of ethanol and specific growth rate on the lipid content and composition of Saccharomyces cerevisiae grown anaerobically in a chemostat. Arneborg N, et al. **Yeast** 1995 Aug;11(10):953–9

[Elimination effect of ethyl alcohol on the DCCD–induced inhibition of hydrolytic activity of H+–ATPase complex] Li SG, et al. **Shih Yen Sheng Wu Hsueh Pao** 1995 Dec; 28(4):389–96 (Eng. Abstr.) **(Chi)**

[Alcohol and free radicals: from basic research to clinical prospects] Nordmann R, et al. **Bull Acad Natl Med** 1995 Dec;179(9):1839–50; discussion 1850–3 (41 ref.) (Eng. Abstr.) **(Fre)**

[Effects of an hydrosoluble fraction from bovine bone (Ossopan) on murine osteoblasts in culture] Cuq P, et al. **C R Seances Soc Biol Fil** 1995;189(2):303–12 (Eng. Abstr.) **(Fre)**

[Alcohol and diabetes] Georgescu M, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):707–11 (17 ref.) **(Fre)**

[Immune status studies after one–time alcohol consumption in healthy subjects] Mohadjer C, et al. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1577–81 (Eng. Abstr.) **(Ger)**

[Is alcohol healthy? (editorial)] Sieber C. **Schweiz Rundsch Med Prax** 1996 May 7;85(19):615–6 (21 ref.) **(Ger)**

[Effect of ethanol on head injury] Shapira Y, et al. **Harefuah** 1995 Aug;129(3–4):145–7 **(Heb)**

[Effect of ethanol on expression of nitric oxide synthases in the cerebral culture cells from chick embryo] Mori C, et al. **Nippon Yakurigaku Zasshi** 1996 Apr;107(4):197–203 (Eng. Abstr.) **(Jpn)**

[The role of dopamine neurotransmission on the development of ethanol dependence and course of abstinence syndrome] Samochowiec J. **Ann Acad Med Stetin** 1994;40:195–217 (Eng. Abstr.) **(Pol)**

[Ultrastructural reorganization of synaptic contacts in organotypic culture of the cerebral cortex in the presence of ethanol] Mel'nikova TN, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):99–102 **(Rus)**

[Effect of super low doses of ethanol on the activity of Purkinje cells in the rat cerebellum] Grigor'ian RA, et al. **Dokl Akad Nauk SSSR** 1992;325(4):865–8 **(Rus)**

[Ethanol mechanism(s) of action on LHRH secretion] Canteros MG, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(1):55–63 (18 ref.) **(Spa)**

[The effect of parenterally administered alcohol on the riboflavin balance in the tissues of white mice] Sokolovs'ka VV, et al. **Fiziol Zh** 1995 May–Aug;41(3–4):76–80 (Eng. Abstr.) **(Ukr)**

POISONING

Ethanol ingestion and related hypoglycemia in a pediatric and adolescent emergency department population. Ernst AA, et al. **Acad Emerg Med** 1996 Jan;3(1):46–9

Biochemical markers of cerebral injury in patients with minor head trauma and ethanol intoxication. Levitt MA, et al. **Acad Emerg Med** 1995 Aug;2(8):675–80

Combined ethanol and glycol poisoning [letter] Fox AW. **Am J Kidney Dis** 1996 Aug;28(2):307

Serum methanol in the absence of methanol ingestion [letter; comment] Malandain H, et al. **Ann Emerg Med** 1996 Jul; 28(1):102–3. Comment on: Ann Emerg Med 1995 Sep;26(3):393.

Ingestion of an unknown alcohol. Trummel J, et al. **Ann Emerg Med** 1996 Mar;27(3):368–74

Correlates of multigravida women's binge drinking during pregnancy. A longitudinal study. Pascoe JM, et al. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1325–9

Laryngeal dystonia [letter] Murray V. **Br J Psychiatry** 1995 Nov;167(5):698–9

Alcoholic rhabdomyolysis: a review. Bessa O Jr. **Conn Med** 1995 Sep;59(9):519–21 (19 ref.)

Rhabdomyolysis following acute alcohol intoxication. Hewitt SM, et al. **J Accid Emerg Med** 1995 Jun;12(2):143–4

Unsuspected self–poisoning with flecainide and alcohol. Sadler DW, et al. **J Forensic Sci** 1995 Sep;40(5):903–5

Gabapentin, valproic acid, and ethanol intoxication: elevated blood levels with mild clinical effects. Fernández MC, et al. **J Toxicol Clin Toxicol** 1996;34(4):437–9

Acute ethanol intoxication and endotoxemia after trauma. Woodman GE, et al. **J Trauma** 1996 Jul;41(1):61–71; discussion 71–2

Acute ethanol poisonings during the New Year's Eve party '95/'96 in Kraków. Pach J, et al. **Przegl Lek** 1996; 53(4):324–8

The effect of reduced glutathione (TAD–600) on the behavior of rats neonatally intoxicated with ethanol. Lupu V, et al. **Rom J Physiol** 1994 Jan–Dec;31(1–4):59–67

Actions of acute ethanol intoxication on cardiopulmonary function after an endotoxin challenge. Woodman GE, et al. **Surgery** 1996 Jul;120(1):80–92

[Biochemical characteristics of various adaptation mechanisms in acute alcoholic intoxication] Sinitskiĭ VN, et al. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):90–5 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

The effect of ethanol on alcohol–responsive essential tremor: a positron emission tomography study. Boecker H, et al. **Ann Neurol** 1996 May;39(5):650–8

Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Ishii H, et al. **Cancer** 1996 May 1;77(9):1792–6

Alcohol and coronary heart disease: the evidence for a protective effect. Kannel WB, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):59–76 (44 ref.)

A modified technique for ethanol injection of liver tumors: preliminary results. Elgindy NM, et al. **Eur Radiol** 1996; 6(4):494–501

Experimental selective segmental ablation of rat liver by transportal ethanol injection. Kaminou T, et al. **Eur Radiol** 1996;6(4):502–9

Treatment of solitary autonomous thyroid nodules by percutaneous ethanol injection: results of an Italian multicenter study. The Multicenter Study Group. Lippi F, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3261–4

Value of ethanol injection in the treatment of the autonomous thyroid nodule [editorial] Ferrari C. **J Endocrinol Invest** 1995 Jun;18(6):465–7

Ethanol sclerotherapy for symptomatic simple renal cysts. el–Diasty TA, et al. **J Endourol** 1995 Jun;9(3):273–6

Management of symptomatic polycystic liver disease: laparoscopy adjuvant with alcohol sclerotherapy. Jeng KS, et al. **J Gastroenterol Hepatol** 1995 May–Jun;10(3):359–62

Percutaneous intravascular ethanol injection of the supplying tumor vessel in the treatment of hepatocellular carcinoma larger than 3 cm. Lin ZY, et al. **J Ultrasound Med** 1996 Feb;15(2):155–60

Percutaneous ethanol injection therapy (PEIT) for hepatocellular carcinoma (HCC). Mueller PR. **Jpn J Cancer Res** 1995 Nov;86(11):inside front cover

Effects of ethanol in a putative rodent model of tardive dyskinesia. Stoessl AJ. **Pharmacol Biochem Behav** 1996 Jul; 54(3):541–6

Intralesional ethanol in the treatment of unresectable liver cancer. Livraghi T, et al. **World J Surg** 1995 Nov–Dec; 19(6):801–6

[Percutaneous alcoholization of simple serous cysts of the kidney] Aboutaieb R, et al. **Ann Urol (Paris)** 1995; 29(5):280–3 (Eng. Abstr.) **(Fre)**

[A new treatment of osteoid osteoma: percutaneous sclerosis with ethanol under scanner guidance] Sanhaji L, et al. **J Radiol** 1996 Jan;77(1):37–40 (Eng. Abstr.) **(Fre)**

TOXICITY

Alcohol intake effects on the dorsal vagal complex of the rat: a cellular morphometric study. Bañuelos–Pineda J, et al. **Acta Anat (Basel)** 1995;153(2):145–50

Influence of ethanol on the activity of glycosidases in rats exposed to cadmium (Cd2+). Arciuch LP, et al. **Acta Biochim Pol** 1995;42(3):297–9

Influence of chronic alcohol treatment on the GFAP–immunoreactivity in astrocytes of the hippocampus in rats. Franke H. **Acta Histochem** 1995 Jul;97(3):263–71

Endothelial–cell injury of the basilar artery caused by ethanol infusion in dogs. Kobayashi H, et al. **Acta Neurochir (Wien)** 1996;138(1):84–9

Investigations into the toxic effects of alcohol on skeletal muscle. Reilly ME, et al. **Adverse Drug React Toxicol Rev** 1995 Summer;14(2):117–50 (141 ref.)

Prenatal alcohol exposure and the effects of environmental enrichment on hippocampal dendritic spine density. Berman RF, et al. **Alcohol** 1996 Mar–Apr;13(2):209–16

Prevention of ethanol–induced sympathetic overactivity and degeneration by dexmedetomidine. Jaatinen P, et al. **Alcohol** 1995 Sep–Oct;12(5):439–46

Cortical cell plasma membrane alterations after in vitro alcohol exposure: prevention by GM1 ganglioside. Laev H, et al. **Alcohol** 1996 Mar–Apr;13(2):187–94

Acetaldehyde involvement in ethanol–induced potentiation of rat hepatocyte damage due to the carcinogen 1,2–dibromoethane. Chiarpotto E, et al. **Alcohol Alcohol** 1995 Nov;30(6):721–8

Ethanol decreases basal cytosolic–free calcium concentration in cultured skeletal muscle cells. Cofán M, et al. **Alcohol Alcohol** 1995 Sep;30(5):617–21

Effect of chronic ethanol consumption on glycosylation processes in rat liver microsomes and Golgi apparatus. Cottalasso D, et al. **Alcohol Alcohol** 1996 Jan;31(1):51–9

Intermittent ethanol exposure of adult rats: hippocampal cell loss after one month of treatment. Lundqvist C, et al. **Alcohol Alcohol** 1995 Nov;30(6):737–48

Effects of alcohol on blastocyst implantation site blood flow in the rat. Mitchell JA, et al. **Alcohol Alcohol** 1996 Jan; 31(1):81–7

Changes in the ileal disaccharidase activities in rats after long–term ethanol feeding. Rodriguez–Castilla J, et al. **Alcohol Alcohol** 1996 Jan;31(1):69–74

Low–level hyperbaric exposure antagonizes locomotor effects of ethanol and n–propanol but not morphine in C57BL mice. Alkana RL, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):693–700

Chronic ethanol consumption alters effects of ethanol in vitro on brain membrane structure of high alcohol sensitivity and low alcohol sensitivity rats. Avdulov NA, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):886–91

In vitro comparison of the effects of ethanol and acetaldehyde on dorsal root ganglion neurons. Bradley DM, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1345–50

Development and characterization of a binge drinking model in mice for evaluation of the immunological effects of ethanol. Carson EJ, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):132–8

Stage–dependent effects of ethanol on cranial neural crest cell development: partial basis for the phenotypic variations observed in fetal alcohol syndrome. Cartwright MM, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1454–62

Alcohol modulation of human normal T–cell activation, maturation, and migration [see comments] Chiappelli F, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):539–44. Comment in: Alcohol Clin Exp Res 1995 Jun;19(3):535–8.

Effects of prenatal alcohol exposure and aging on auditory function in the rat: preliminary results. Church MW, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):172–9

Neuronal degeneration in rat cerebrocortical and olfactory regions during subchronic "binge" intoxication with ethanol: possible explanation for olfactory deficits in alcoholics. Collins MA, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):284–92

Effects of prenatal ethanol exposure and stress in adulthood on lymphocyte populations in rats. Giberson PK, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1286–94

Low doses of ethanol impair spatial working memory and reduce hippocampal theta activity. Givens B. **Alcohol Clin Exp Res** 1995 Jun;19(3):763–7

To be or not to be: how ethanol can affect neuronal death during development. Hoffman PL, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):193–5

Analysis of CA repeats in first intron of class I ADH gene in Long–Evans Cinnamon rats developing fatal intoxication after ethanol intake. Katsuki S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):33A–35A

Effect of chronic ethanol feeding on nitric oxide synthesis by rat Kupffer cells. Kimura H, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):69A–72A

GABAA receptor function and binding in stably transfected cells: chronic ethanol treatment. Klein RL, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1338–44

Conditioned taste aversions induced by alcohol and lithium in rats selectively bred for ethanol neurosensitivity. Kulkosky PJ, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):945–50

Ethanol-induced oxidative stress in the liver. Kurose I, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):77A-85A (88 ref.)

1-week withdrawal from 8 weeks alcohol consumption protects the heart from sepsis-induced dysfunction. McDonough KH. **Alcohol Clin Exp Res** 1995 Aug; 19(4):834-9

Heart mitochondria response to alcohol is different than brain and liver. Marin-Garcia J, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1463-6

Effect of ethanol consumption on adult rat liver mitochondrial populations analyzed by flow cytometry. Mateos A, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1327-30

Ethanol alters spatial processing of hippocampal place cells: a mechanism for impaired navigation when intoxicated. Matthews DB, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):404-7

Perinatal maternal ethanol effects on pregnant mice and on offspring viability and growth: influences of exposure time and weaning diet. Middaugh LD, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1351-8

Effect of pre- or postnatal exposure to ethanol on the total number of neurons in the principal sensory nucleus of the trigeminal nerve: cell proliferation and neuronal death. Miller MW. **Alcohol Clin Exp Res** 1995 Oct;19(5):1359-63

Limited ethanol exposure selectively alters the proliferation of precursor cells in the cerebral cortex. Miller MW. **Alcohol Clin Exp Res** 1996 Feb;20(1):139-43

Evaluation of ethanol on gastric epithelial restoration in vitro. Murai T, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):45A-46A

Effect of ethanol on function of the rat heart and skeletal muscles. Pagala M, et al. **Alcohol Clin Exp Res** 1995 Jun; 19(3):676-84

Human neutrophil functions are inhibited in vitro by clinically relevant ethanol concentrations. Patel M, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):275-83

Structural reorganization in the supraoptic nucleus of withdrawn rats following long-term alcohol consumption. Sousa N, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):879-85

Effect of ethanol on the synthesis of insulin-like growth factor 1 (IGF-1) and the IGF-1 receptor in late prepubertal female rats: a correlation with serum IGF-1. Srivastava V, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1467-73

Age-dependent inhibition of long-term potentiation by ethanol in immature versus mature hippocampus. Swartzwelder HS, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1480-5

Effects of chronic alcohol consumption and aging on dopamine D2 receptors in Fischer 344 rats. Tajuddin NF, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):144-51

Effect of vitamin E deficiency on inhibition of liver regeneration by long-term administration of alcohol. Tanaka T, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):47A-50A

Repeated ethanol withdrawal produces site-dependent increases in EEG spiking. Veatch LM, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):262-7

Gene expression of A- and B-type natriuretic peptides in response to acute ethanol ingestion. Wigle DA, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1317-20

Effects of chronic alcohol consumption and aging on dopamine D1 receptors in Fischer 344 rats. Woods JM, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1331-7

Ethanol suppresses growth hormone-mediated cellular responses in liver slices. Xu X, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1246-51

Effect of chronic ethanol consumption on the activities of residual small bowel brush-border enzymes after proximal jejunum resection in the rat. Zucoloto S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):152-5

Giant mitochondria induced in rat pancreatic exocrine cells by ethanol and iron. Tandler B, et al. **Anat Rec** 1996 May; 245(1):65-75

The effect of ethanol and coal dust on the tracheal mucosa--histochemical examinations of animals in experimental conditions. Czerny K, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:195-9

The effect of ethyl alcohol on fetal fibroblasts in vitro. Kifer-Wysocka E, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:169-72

Ferritin stimulation of lipid peroxidation by microsomes after chronic ethanol treatment: role of cytochrome P4502E1. Kukielka E, et al. **Arch Biochem Biophys** 1996 Aug 1; 332(1):121-7

Influence of acute and chronic ethanol treatment on interferon production in mice. Daniluk J, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(3):239-46

Effect of carbon tetrachloride intoxication and ethanol ingestion on interferon production in mice. Daniluk J, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):325-30

Teratogenic effects of alcohol: current status of animal research and in vitro models. Guerri C. **Arch Toxicol Suppl** 1996;18:71-80 (55 ref.)

Inhibition of the Kupffer cell inflammatory response by acute ethanol: NF-kappa B activation and subsequent cytokine production. Fox ES, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):134-40

Studies on urea synthesis in the liver of rats treated chronically with ethanol using perfused livers, isolated hepatocytes, and mitochondria. Adachi K, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1391-9

Antioxidant status in the jejunum: effect of acute ethanol dosage. Marway JS, et al. **Biochem Soc Trans** 1995 Aug; 23(3):463S

Compartmentation of total RNA in catabolism: a comparative analysis of skin, bone, skeletal muscle and liver in response to endotoxin and alcohol. Paice AG, et al. **Biochem Soc Trans** 1995 Aug;23(3):465S

Chronic effects of alcohol upon protein profiling in ventricular tissue. Patel VB, et al. **Biochem Soc Trans** 1995 Aug;23(3):461S

The effect of supplementation on alpha-tocopherol levels in liver, heart and skeletal muscle. Reilly ME, et al. **Biochem Soc Trans** 1995 Aug;23(3):466S

Time-course changes in skeletal muscle protein synthesis in vivo in response to ethanol. Reilly ME, et al. **Biochem Soc Trans** 1995 Aug;23(3):467S

Transglutaminase activity in rat liver after acute ethanol administration. Sessa A, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):371-5

Ethanol neurobehavioural teratogenesis and the role of L-glutamate in the fetal hippocampus. Reynolds JD, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1209-23 (175 ref.)

Formation of etheno and oxoethyl adducts in liver DNA from rats exposed subchronically to urethane in drinking water and ethanol. Sotomayor RE, et al. **Cancer Lett** 1996 Feb 27;100(1-2):155-61

Chronic and acute ethanol treatment modifies fluidity and composition in plasma membranes of a human hepatic cell line (WRL-68). Gutiérrez-Ruiz MC, et al. **Cell Biol Toxicol** 1995 Apr;11(2):69-78

Rabbit polymorphonuclear granulocyte function during ethanol administration--migration and oxidative responses in a joint with immune complex synovitis. Nilsson E, et al. **Clin Exp Immunol** 1995 Oct;102(1):137-43

Increased blood pressure and changes in membrane lipids associated with chronic ethanol treatment of rats. Puddey IB, et al. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):655-7

Effects of traditional herbal medicine on gastric mucin against ethanol-induced gastric injury in rats. Goso Y, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jan;113(1):17-21

Toxicological effects of ethanol on human health. Ahmed FE. **Crit Rev Toxicol** 1995;25(4):347-67 (113 ref.)

Role of dorsal motor nucleus of vagus in gastric function and mucosal damage induced by ethanol in rats. Chan YS, et al. **Dig Dis Sci** 1995 Nov;40(11):2312-6

Hepatic mitochondrial and lysosomal alterations in acute experimental pancreatitis with ethanolic coetiology in rats. Poplawski C, et al. **Dig Dis Sci** 1996 Jan;41(1):139

Gastric injury induced by ethanol and ischemia-reperfusion in the rat. Differing roles for lipid peroxidation and oxygen radicals. Smith GS, et al. **Dig Dis Sci** 1996 Jun; 41(6):1157-64

Mechanisms for cytoprotection by vitamin U from ethanol-induced gastric mucosal damage in rats. Watanabe T, et al. **Dig Dis Sci** 1996 Jan;41(1):49-54

Prostaglandin-induced protection of cultured rat gastric cells against ethanol is inhibited by a microtubule inhibitor. Arakawa T, et al. **Digestion** 1996;57(1):41-6

Effect of enprostil and cimetidine on ethanol-induced damage to intestinal epithelial cell lines IRD 98 and IEC 17. Giannarelli S, et al. **Digestion** 1995;56(6):509-15

Effects of chronic nitric oxide synthase inhibition in cold-restraint and ethanol-induced gastric mucosal damage in rats. Qiu BS, et al. **Digestion** 1996;57(1):60-6

The first observation of O2- generation at real time in vivo from non-Kupffer sinusoidal cells in perfused rat liver during acute ethanol intoxication. Nakano M, et al. **FEBS Lett** 1995 Sep 25;372(2-3):140-3

Nuclear DNA strand breaks during ethanol-induced oxidative stress in rat brain. Renis M, et al. **FEBS Lett** 1996 Jul 22;390(2):153-6

The heat shock and ethanol stress responses of yeast exhibit extensive similarity and functional overlap. Piper PW. **FEMS Microbiol Lett** 1995 Dec 15;134(2-3):121-7 (38 ref.)

Induction of hepatic and renal P4502E1 of neonatal rats exposed translactationally to ethanol. Chhabra SK, et al. **Food Chem Toxicol** 1996 May;34(5):469-76

Acute ethanol administration induces oxidative changes in rat pancreatic tissue. Altomare E, et al. **Gut** 1996 May; 38(5):742-6

Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol. Albano E, et al. **Hepatology** 1996 Jan;23(1):155-63

Effects of ethanol administration on components of the ubiquitin proteolytic pathway in rat liver. Born LJ, et al. **Hepatology** 1996 Jun;23(6):1556-63

Alcohol and iron: a radical combination? Houglum K. **Hepatology** 1996 Jun;23(6):1700-3

Appearance of oval cells in the liver of rats after long-term exposure to ethanol. Smith PG, et al. **Hepatology** 1996 Jan; 23(1):145-54

Acetaldehyde and malondialdehyde react together to generate distinct protein adducts in the liver during long-term ethanol administration. Tuma DJ, et al. **Hepatology** 1996 Apr;23(4):872-80

The role of non-protein sulfhydryl compounds in gastric adaptive cytoprotection against ethanol-induced mucosal damage in rats. Ko JK, et al. **Inflamm Res** 1995 Jun; 44(6):242-4

Stimulation of gastric acid secretion by (R)-alpha-methylhistamine in the rat: influence of the increased gastric juice volume on ethanol-induced lesions. Morini G, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S106-7

Ethanol neuronotoxicity in the embryonic chick brain in ovo and in culture: interaction of the neural cell adhesion molecule (NCAM). Kentroti S, et al. **Int J Dev Neurosci** 1995 Dec;13(8):859-70

Ethanol neurotoxicity on neuroblast-enriched cultures from three-day-old chick embryo is attenuated by the neuronotrophic action of GABA. Spoerri PE, et al. **Int J Dev Neurosci** 1995 Oct;13(6):539-44

Prenatal alcohol exposure selectively suppresses cell-mediated but not humoral immune responsiveness. Gottesfeld Z, et al. **Int J Immunopharmacol** 1995 Mar; 17(3):247-54

An investigation of the interaction between alcohol and fibroblasts in wound healing. Stephens P, et al. **Int J Oral Maxillofac Surg** 1996 Apr;25(2):161-4

The effect of chronic alcohol administration on cerulein-induced pancreatitis. Korsten MA, et al. **Int J Pancreatol** 1995 Aug;18(1):25-31

Acute ethanol hepatotoxicity is modulated by bile salt hydrophilic-hydrophobic properties. Alvaro D, et al. **Ital J Gastroenterol** 1995 Jul-Aug;27(6):335-9

Role of cysteine proteases and protease inhibitors in gastric mucosal damage induced by ethanol or ammonia in the rat. Nagy L, et al. **J Clin Invest** 1996 Aug 15;98(4):1047-54

Permanent neuronal cell loss in the cerebellum of rats exposed to continuous low blood alcohol levels during the brain growth spurt: a stereological investigation. Napper RM, et al. **J Comp Neurol** 1995 Nov 13;362(2):283-92

Ethanol intake, plasma catecholamine levels, and ST-segment changes without myocardial injury in rats with short-term ethanol consumption. Fantidis P, et al. **J Electrocardiol** 1995 Oct;28(4):307-12

Role of endogenous substance P in ethanol-induced mucosal damage in the rat stomach. Hayashi H, et al. **J Gastroenterol** 1996 Jun;31(3):314-22

Ethanol-related liver injury in the rat: a model of steatosis, inflammation and pericentral fibrosis. Keegan A, et al. **J Hepatol** 1995 Nov;23(5):591-600

Three-day exposure to low-dose ethanol alters guanine nucleotide binding protein expression in the developing rat hippocampus. Davis-Cox MI, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):758-64

Gastric injury and protection against alcohol and acid: influence of perturbations in glutathione metabolism. Smith GS, et al. **J Surg Res** 1996 Mar;61(2):395-403

Comparison of thermally oxidized lipids and acetaminophen with concurrent consumption of ethanol as inducers of liver cirrhosis. Fouad FM, et al. **J Toxicol Environ Health** 1995 Oct;46(2):217-32

Both ethanol and protein deficiency increase messenger RNA levels for pancreatic lithostathine. Apte MV, et al. **Life Sci** 1996;58(6):485-92

Differential effects of chronic calcium channel blocker treatment on the inotropic response of diabetic rat myocardium to acute ethanol exposure. Brown RA, et al. **Life Sci** 1996;59(10):835-47

Cocaethylene is as cardiotoxic as cocaine but is less toxic than cocaine plus ethanol. Henning RJ, et al. **Life Sci** 1996; 59(8):615-27

Alcohol exposure during brain development reduces 3H-MK-801 binding and enhances metabotropic-glutamate receptor-stimulated phosphoinositide hydrolysis in rat hippocampus. Vallés S, et al. **Life Sci** 1995 Mar 17;56(17):1373-83

Chronic ethanol intake reduces the flux through liver branched-chain keto-acid dehydrogenase. Bernal CA, et al. **Metabolism** 1995 Oct;44(10):1243-6

Frequency-dependent effect of ethanol on action potentials of frog skeletal muscle fibers. Oz M, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun;17(5):295-8

Chronic ethanol consumption differentially alters the expression of gamma-aminobutyric acidA receptor subunit mRNAs in rat cerebral cortex: competitive, quantitative reverse transcriptase-polymerase chain reaction analysis. Devaud LL, et al. **Mol Pharmacol** 1995 Nov;48(5):861-8

Mutagenicity of 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid treated with nitrite in the presence of alcohols. Higashimoto M, et al. **Mutat Res** 1996 Jan;367(1):43-9

Ethanol-induced single-strand DNA breaks in rat brain cells. Singh NP, et al. **Mutat Res** 1995 Dec;345(3-4):191-6

Effects of prenatal ethanol exposure on dopamine systems in C57BL/6J mice. Boggan WO, et al. **Neurotoxicol Teratol** 1996 Jan-Feb;18(1):41-8

Comparative effects of prenatal cocaine, alcohol, and undernutrition on maternal/fetal toxicity and fetal body composition in the Sprague-Dawley rat with observations on strain-dependent differences. Church MW, et al. **Neurotoxicol Teratol** 1995 Sep-Oct;17(5):559-67

Prenatal ethanol exposure in rats: long-lasting effects on learning. Clausing P, et al. **Neurotoxicol Teratol** 1995 Sep-Oct;17(5):545-52

Effects of prenatal maternal ethanol on male offspring progressive-ratio performance and response to amphetamine. Gentry GD, et al. **Neurotoxicol Teratol** 1995 Nov-Dec;17(6):673-7

Effects of prenatal ethanol exposure and early experience

on home-cage and open-field activity in mice. Mothes HK, et al. **Neurotoxicol Teratol** 1996 Jan-Feb;18(1):59-65

Acute gestational cocaine exposure alone or in combination with low-dose ethanol does not influence prenatal mortality or fetal weight in mice. Salo AL, et al. **Neurotoxicol Teratol** 1995 Sep-Oct;17(5):577-81

Alterations of mouse embryonic branchial nerves and ganglia induced by ethanol. Van Maele-Fabry G, et al. **Neurotoxicol Teratol** 1995 Jul-Aug;17(4):497-506

Role of brain cocaethylene levels in combined cocaine-ethanol lethality in mice. Hayase T, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Feb; 31(1):95-109

Oxygen radical generation and acute pancreatitis: effects of dibutyltin dichloride/ethanol and ethanol on rat pancreas. Weber H, et al. **Pancreas** 1995 Nov;11(4):382-8

The lethal effects of ethanol and cocaine and their combination in mice: implications for cocaethylene formation. Schechter MD, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):245-8

Effects of dietary gamma-linolenic acid and prenatal ethanol on mouse brain and behavior. Wainwright PE, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):843-52

Effects of ethanol on recombinant rat GABAA receptors: [35S]t-butylbicyclophosphorothionate ([35S]TBPS) binding study. Korpi ER, et al. **Pharmacol Toxicol** 1995 Aug;77(2):87-90

Low ethanol concentrations enhance GABAergic inhibitory postsynaptic potentials in hippocampal pyramidal neurons only after block of GABAB receptors. Wan FJ, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5049-54

Ethanol-induced changes in insulin-like growth factors and IGF gene expression in the fetal brain. Singh SP, et al. **Proc Soc Exp Biol Med** 1996 Sep;212(4):349-54

Ultrastructural study of the coagulating gland of Wistar rats submitted to experimental chronic alcohol ingestion. Cagnon VH, et al. **Prostate** 1996 Jun;28(6):341-6

Ethanol potentiates valproic acid-induced neural tube defects (NTDs) in mice due to toxicokinetic interactions. Elmazar MM, et al. **Reprod Toxicol** 1995 Sep-Oct;9(5):427-33

In vitro effects of ethanol on human gastric and pancreatic lipolytic activities/enzymes. Sternby B, et al. **Scand J Gastroenterol** 1996 Feb;31(2):146-53

Chronic ethanol consumption exacerbates liver injury following hemorrhagic shock: role of sinusoidal perfusion failure. Bauer I, et al. **Shock** 1995 Nov;4(5):324-31

Interactive effects of alcohol and diabetes during pregnancy on the rat fetus. Lin Y, et al. **Teratog Carcinog Mutagen** 1995;15(3):147-53

Effects of prenatal alcohol exposure on the postnatal morphology of the rat oculomotor nucleus. Burrows RC, et al. **Teratology** 1995 May;51(5):318-28

Ethanol-induced teratogenesis: free radical damage as a possible mechanism. Kotch LE, et al. **Teratology** 1995 Sep; 52(3):128-36

Aspirin-alcohol interaction in the production of cleft palate and limb malformations in the TO mouse. Padmanabhan R, et al. **Teratology** 1995 Jun;51(6):404-17

Effects of acute acetaldehyde, chronic ethanol, and pargyline treatment on agonist responses of the rat aorta. Brown RA, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):170-8

Alterations in nuclear ploidy and cell phase distribution of rat liver cells in experimental alcoholic liver disease: relationship to antioxidant enzyme gene expression. Fogt F, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):87-93

Role of glucocorticoids in ethanol-induced decreases in expression of MHC class II molecules on B cells and selective decreases in spleen cell number. Weiss PA, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):153-62

Effects of ethanol administration on cerebral non-protein sulfhydryl content in rats exposed to styrene vapour. Coccini T, et al. **Toxicology** 1996 Jan 8;106(1-3):115-22

Effect of irrigating fluids and prostate tissue extracts on isolated cardiomyocytes. Zhang W, et al. **Urology** 1995 Dec;46(6):821-4

[Alcohol and mortality] Blanc MH. **Rev Med Suisse Romande** 1995 Nov;115(11):905-14 (65 ref.) **(Fre)**

[Inhalation effect of low doses of ethanol during pregnancy on development of rat offspring] Liopo AV, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):265-7 **(Rus)**

[Piracetam as a corrector of long-term learning disorders caused by prenatal alcohol exposure: the significance of the length of therapy] Trofimov SS, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):435-7 **(Rus)**

[The effect of tetrachloromethane and ethanol on the release by rat splenocytes of immunomodulating factors] Smakhtin MIu, et al. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):48-50 (Eng. Abstr.) **(Rus)**

[Interrelationship between splenocyte immunomodulating factors in animals undergoing combined exposure to ethanol and tetrachloromethane] Konoplia AI, et al. **Patol Fiziol Eksp Ter** 1995 Oct-Dec;(4):22-4 (Eng. Abstr.) **(Rus)**

[Effects of ethanol on thyroid gland development] Matavulj M, et al. **Med Pregl** 1994;47(9-10):314-9 (Eng. Abstr.) **(Scr)**

[Experimental induction of abnormalities by the instillation of ethanol in embryonated eggs of chickens (Gallus gallus)] Illanes J, et al. **Anat Histol Embryol** 1995 Dec;24(4):217-21 (Eng. Abstr.) **(Spa)**

URINE

Estimating blood alcohol from urinary alcohol at autopsy. Kuroda N, et al. **Am J Forensic Med Pathol** 1995 Sep; 16(3):219-22

A urinary marker of alcohol intake. Yu MC, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Dec;4(8):849-55

Laboratory testing for recent alcohol consumption: comparison of ethanol, methanol, and 5-hydroxytryptophol. Helander A, et al. **Clin Chem** 1996 Apr;42(4):618-24

ALCOHOL, METHYL

Electrotransfer of Long Ranger sequencing gels using a methanol-TBE buffer. Musich PR, et al. **Biotechniques** 1995 Sep;19(3):382-6

Organotellurium compounds as efficient retarders of lipid peroxidation in methanol. Engman L, et al. **Free Radic Biol Med** 1995 Oct;19(4):441-52

Protein extraction and western blotting from methacarn-fixed tissue. Lalani EN, et al. **J Pathol** 1995 Nov;177(3):323-8

ADVERSE EFFECTS

Short-term inhalation toxicity of methanol, gasoline, and methanol/gasoline in the rat. Poon R, et al. **Toxicol Ind Health** 1995 May-Jun;11(3):343-61

ANALYSIS

On the 3.35 ppm singlet resonance in proton NMR spectra of brain tissue: scyllo-inositol or methanol contamination? [letter; comment] Malandain H, et al. **Ann Emerg Med** 1996 Jul; 28(1):102-3. Comment on: Ann Emerg Med 1995 Sep;26(3):393.

Endogenous methanol: variability in concentration and rate of production. Evidence of a deep compartment? Haffner HT, et al. **Forensic Sci Int** 1996 May 31;79(2):145-54

BLOOD

Serum methanol in the absence of methanol ingestion [letter; comment] Malandain H, et al. **Ann Emerg Med** 1996 Jul; 28(1):102-3. Comment on: Ann Emerg Med 1995 Sep;26(3):393.

Endogenous methanol: variability in concentration and rate of production. Evidence of a deep compartment? Haffner HT, et al. **Forensic Sci Int** 1996 May 31;79(2):145-54

CHEMISTRY

Interaction of melanin with carbon- and oxygen-centered radicals from methanol and ethanol. Dunford R, et al. **Free Radic Biol Med** 1995 Dec;19(6):735-40

The methanol-induced globular and expanded denatured states of cytochrome c: a study by CD fluorescence, NMR and small-angle X-ray scattering. Kamatari YO, et al. **J Mol Biol** 1996 Jun 14;259(3):512-23

METABOLISM

Selectivity of methyl-fructoside synthesis with beta-fructofuranosidase. Rodríguez M, et al. **Appl Biochem Biotechnol** 1996 May;59(2):167-75

Chloroform degradation in methanogenic methanol enrichment cultures and by Methanosarcina barkeri 227. Bagley DM, et al. **Appl Environ Microbiol** 1995 Sep; 61(9):3195-201

In vivo metabolites of N omega-nitro-L-arginine methyl ester: methanol and N omega-nitro-L-arginine. Brouillet E, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):487-90

Isolation, sequence and overexpression of the gene encoding NAD-dependent formate dehydrogenase from the methylotrophic yeast Candida methylica. Allen SJ, et al. **Gene** 1995 Aug 30;162(1):99-104

Identification and nucleotide sequences of mxaA, mxaC, mxaK, mxaL, and mxaD genes from Methylobacterium extorquens AM1. Morris CJ, et al. **J Bacteriol** 1995 Dec; 177(23):6825-31

Specific roles of methylcobamide:coenzyme M methyltransferase isozymes in metabolism of methanol and methylamines in Methanosarcina barkeri. Ferguson DJ Jr, et al. **J Biol Chem** 1996 Mar 1;271(9):5189-94

Methanol oxidation mutants in Methylobacterium extorquens AM1: identification of new genetic complementation groups. Springer AL, et al. **Microbiology** 1995 Nov;141 (Pt 11):2985-93

Review: methylotrophic yeasts as factories for the production of foreign proteins. Faber KN, et al. **Yeast** 1995 Nov; 11(14):1331-44 (111 ref.)

PHARMACOKINETICS

Methanol in human breath. Taucher J, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1147-50

A pharmacokinetic model of inhaled methanol in humans and comparison to methanol disposition in mice and rats. Perkins RA, et al. **Environ Health Perspect** 1995 Jul-Aug; 103(7-8):726-33

Comparative toxicokinetics of methanol in the female mouse and rat. Ward KW, et al. **Fundam Appl Toxicol** 1995 Jul; 26(2):258-64

[Ethanol-independent methanol elimination in chronic alcoholics] Musshoff F, et al. **Blutalkohol** 1995 Nov; 32(6):317-36 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Effect of organic modifier concentrations on electrokinetic migrations in micellar electrokinetic chromatography. Chen N, et al. **Electrophoresis** 1995 Aug;16(8):1457-62

Methanol-mediated, modular self-assembly of antiparallel beta-dimers. Crystal structure of C alpha backbone-modified tripeptide Bz-Aib-NHCOCO-Aib-OMe. Karle IK, et al. **Int J Pept Protein Res** 1995 Jul;46(1):65-8

Methanol traps the troponin-tropomyosin-actin complex in an "off-state". Matsuura Y, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1293-8

POISONING

MR findings in methanol intoxication. Gaul HP, et al. **AJNR Am J Neuroradiol** 1995 Oct;16(9):1783-6

Methanol intoxication with putaminal and white matter necrosis: MR and CT findings. Rubinstein D, et al. **AJNR Am J Neuroradiol** 1995 Aug;16(7):1492-4

"There's death in the cup, so beware!" Young DB, et al. **Am J Forensic Med Pathol** 1995 Sep;16(3):223-8

Utility of the serum osmol gap in the diagnosis of methanol or ethylene glycol ingestion [see comments] Glaser DS. **Ann Emerg Med** 1996 Mar;27(3):343-6. Comment in: Ann Emerg Med 1996 Mar;27(3):363-4.

Bilateral putaminal hemorrhage related to methanol poisoning: a complication of hemodialysis? Case report. Giudicissi Filho M, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3-A):485-7

Activated charcoal--an antidote to methyl alcohol poisoning. Mathangi DC, et al. **J Indian Med Assoc** 1995 Apr; 93(4):136-7

Methanol ingestion. 'Guaranteed to make you feel good'. d'Autremont S, et al. **J La State Med Soc** 1995 Sep; 147(9):417-20

4-Methylpyrazole--present status [editorial; comment] Jacobsen D, et al. **J Toxicol Clin Toxicol** 1996;34(4):379-81 . Comment on: J Toxicol Clin Toxicol 1996;34(4):373-7.

Successful renal transplantation from two donors with methanol intoxication. Freidlaender MM, et al. **Transplantation** 1996 May 27;61(10):1549-52

Bittering agents: their potential application in reducing ingestions of engine coolants and windshield wash. Jackson MH, et al. **Vet Hum Toxicol** 1995 Aug;37(4):323-6

Hyperammonemia with severe methanol intoxication. Foster WA, et al. **West J Med** 1995 Oct;163(4):377-9

TOXICITY

Embryotoxicity of methanol in well-nourished and malnourished rats. De-Carvalho RR, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2915-23

Acute toxicity of methanol to Mytilus edulis. Helmstetter A, et al. **Bull Environ Contam Toxicol** 1996 Oct; 57(4):675-81

Lipidemic effect of methanol. Gaafar KM, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):661-6

Assessment of offspring development and behavior following gestational exposure to inhaled methanol in the rat. Stanton ME, et al. **Fundam Appl Toxicol** 1995 Nov;28(1):100-10

Comparative toxicokinetics of methanol in the female mouse and rat. Ward KW, et al. **Fundam Appl Toxicol** 1995 Jul; 26(2):258-64

Potentiation of carbon tetrachloride hepatotoxicity by inhaled methanol: time course of injury and recovery. Simmons JE, et al. **J Toxicol Environ Health** 1995 Oct; 46(2):203-16

Role of formate in methanol-induced exencephaly in CD-1 mice. Dorman DC, et al. **Teratology** 1995 Jul;52(1):30-40

Recent developments in methanol toxicity. Medinsky MA, et al. **Toxicol Lett** 1995 Dec;82-83:707-11 (17 ref.)

Methanol potentiation of carbon tetrachloride hepatotoxicity: the central role of cytochrome P450. Allis JW, et al. **Toxicology** 1996 Aug 16;112(2):131-40

URINE

Laboratory testing for recent alcohol consumption: comparison of ethanol, methanol, and 5-hydroxytryptophol. Helander A, et al. **Clin Chem** 1996 Apr;42(4):618-24

ALCOHOL OXIDOREDUCTASES

Mediated amperometric determination of ammonia with a methanol dehydrogenase from Pseudomonas sp. AM-1 immobilized carbon paste electrode. Suye S, et al. **Biosens Bioelectron** 1996;11(5):529-34

ANTAGONISTS & INHIBITORS

Woodward's reagent K inactivation of Escherichia coli L-threonine dehydrogenase: increased absorbance at 340-350 nm is due to modification of cysteine and histidine residues, not aspartate or glutamate carboxyl groups. Johnson AR, et al. **Protein Sci** 1996 Feb;5(2):382-90

BIOSYNTHESIS

Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Soldan M, et al. **Biochem Pharmacol** 1996 Jan 26; 51(2):117-23

Over-expression of pig lung carbonyl reductase in

Escherichia coli. Nakanishi M, et al. **Biol Pharm Bull** 1995 Sep;18(9):1248–50

Cloning of a cDNA for a second retinol dehydrogenase type II. Expression of its mRNA relative to type I. Chai X, et al. **J Biol Chem** 1995 Nov 24;270(47):28408–12

Nucleotide sequence of the mxcQ and mxcE genes, required for methanol dehydrogenase synthesis in Methylobacterium organophilum XX: a two-component regulatory system. Xu HH, et al. **Microbiology** 1995 Oct;141 (Pt 10):2543–51

BLOOD

Glucose–6–phosphate dehydrogenase deficiency severely restricts the biotransformation of daunorubicin in human erythrocytes. Amitai Y, et al. **J Lab Clin Med** 1996 Jun; 127(6):588–98

CHEMISTRY

Lysine residues in the coenzyme–binding region of mouse lung carbonyl reductase. Deyashiki Y, et al. **Adv Exp Med Biol** 1995;372:241–8

Sequence analysis of frog rho–crystallin by cDNA cloning and sequencing: a member of the aldo–keto reductase family. Lu SF, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1079–88

Structure of the quinoprotein glucose dehydrogenase of Escherichia coli modelled on that of methanol dehydrogenase from Methylobacterium extorquens. Cozier GE, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):679–85

Comparative analysis of the QUTR transcription repressor protein and the three C–terminal domains of the pentafunctional AROM enzyme. Lamb HK, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):941–50

113Cd nuclear magnetic resonance studies of cabbage histidinol dehydrogenase. Kanaori K, et al. **Biochemistry** 1996 May 14;35(19):5949–54

1.7 A structure of FR–1, a fibroblast growth factor–induced member of the aldo–keto reductase family, complexed with coenzyme and inhibitor. Wilson DK, et al. **Biochemistry** 1995 Nov 7;34(44):14323–30

The role of a beta barrel loop 4 extension in modulating the physical and functional properties of long–chain 2–hydroxy–acid oxidase isozymes. Belmouden A, et al. **Eur J Biochem** 1996 Jun 15;238(3):790–8

Structural and mechanistic similarities of 6–phosphogluconate and 3–hydroxyisobutyrate dehydrogenases reveal a new enzyme family, the 3–hydroxyacid dehydrogenases. Hawes JW, et al. **FEBS Lett** 1996 Jul 8;389(3):263–7

Revision of the amino–acid sequence of 3–isopropylmalate dehydrogenase from Salmonella typhimurium by means of X–ray crystallography. Kryger G, et al. **Gene** 1995 Oct 16;164(1):85–7

Further stabilization of 3–isopropylmalate dehydrogenase of an extreme thermophile, Thermus thermophilus, by a suppressor mutation method. Kotsuka T, et al. **J Bacteriol** 1996 Feb;178(3):723–7

Structural and functional consequences of mutations in 6–pyruvoyltetrahydropterin synthase causing hyperphenylalaninemia in humans. Phosphorylation is a requirement for in vivo activity. Oppliger T, et al. **J Biol Chem** 1995 Dec 8;270(49):29498–506

6–Pyruvoyl tetrahydropterin synthase, an enzyme with a novel type of active site involving both zinc binding and an intersubunit catalytic triad motif; site–directed mutagenesis of the proposed active center, characterization of the metal binding site and modelling of substrate binding. Bürgisser DM, et al. **J Mol Biol** 1995 Oct 20;253(2):358–69

Determination of the gene sequence and the three–dimensional structure at 2.4 angstroms resolution of methanol dehydrogenase from Methylophilus W3A1. Xia Z, et al. **J Mol Biol** 1996 Jun 14;259(3):480–501

X–ray studies of quinoproteins. Mathews FS. **Methods Enzymol** 1995;258:191–216

The crystal structure of thermostable mutants of chimeric 3–isopropylmalate dehydrogenase, 2T2M6T. Sakurai M, et al. **Protein Eng** 1995 Aug;8(8):763–7

The role of glutamate 87 in the kinetic mechanism of Thermus thermophilus isopropylmalate dehydrogenase. Dean AM, et al. **Protein Sci** 1995 Oct;4(10):2156–67

[Structure–activity relationships in multienzyme complexes] Gol'dshtein BN, et al. **Mol Biol (Mosk)** 1995 May–Jun; 29(3):603–11 (35 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Characterization of the promoter of the gene for a mouse vas deferens protein related to the aldo–keto reductase superfamily: effect of steroid hormones and phorbol esters. Fabre S, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(3–4):315–25

DEFICIENCY

Strain– and sex–related differences of acetohexamide reductase activities in liver microsomes and cytosol of rats: the Wistar–Imamichi strain lacks the male–specific microsomal enzyme activity. Imamura Y, et al. **Life Sci** 1995;57(19):1811–7

GENETICS

Molecular cloning and sequencing of mouse hepatic 11 beta–hydroxysteroid dehydrogenase/carbonyl reductase. A member of the short chain dehydrogenase superfamily. Maser E, et al. **Adv Exp Med Biol** 1995;372:211–21

Expression of human and rat carbonyl reductase in E. coli. Comparison of the recombinant enzymes. Wermuth B. **Adv Exp Med Biol** 1995;372:203–9

Molecular characterization of an Aspergillus parasiticus dehydrogenase gene, norA, located on the aflatoxin biosynthesis gene cluster. Cary JW, et al. **Appl Environ Microbiol** 1996 Feb;62(2):360–6

Characterization of the Rhodococcus sp. NI86/21 gene encoding alcohol: N,N'–dimethyl–4–nitrosoaniline oxidoreductase inducible by atrazine and thiocarbamate herbicides. Nagy I, et al. **Arch Microbiol** 1995 Jun; 163(6):439–46

Sequence analysis of frog rho–crystallin by cDNA cloning and sequencing: a member of the aldo–keto reductase family. Lu SF, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1079–88

Cloning and expression of an Entamoeba histolytica NAPD+(–)dependent alcohol dehydrogenase gene. Rodríguez MA, et al. **Biochim Biophys Acta** 1996 Apr 10; 1306(1):23–6

Unusual evolution of 11beta– and 17beta–hydroxysteroid and retinol dehydrogenases. Baker ME. **Bioessays** 1996 Jan; 18(1):63–70 (47 ref.)

Suppression of flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense and sense genes. de Lange P, et al. **Curr Top Microbiol Immunol** 1995; 197:57–75 (88 ref.)

Conserved regulation of the Hansenula polymorpha MOX promoter in Saccharomyces cerevisiae reveals insights in the transcriptional activation by Adr1p. Pereira GG, et al. **Eur J Biochem** 1996 May 15;238(1):181–91

Characterization of the gene encoding quinohaemoprotein ethanol dehydrogenase of Comamonas testosteroni. Stoorvogel J, et al. **Eur J Biochem** 1996 Feb 1;235(3):690–8

Analysis of beta–ketothiolase and acetoacetyl–CoA reductase genes of a methylotrophic bacterium, Paracoccus denitrificans, and their expression in Escherichia coli. Yabutani T, et al. **FEMS Microbiol Lett** 1995 Nov 1; 133(1–2):85–90

Cloning of a rat cDNA encoding retinol dehydrogenase isozyme type III. Chai X, et al. **Gene** 1996 Mar 9; 169(2):219–22

Cloning, sequencing and expression of the ilvBNC gene cluster from Streptomyces avermitilis. De Rossi E, et al. **Gene** 1995 Dec 1;166(1):127–32

Revision of the amino–acid sequence of 3–isopropylmalate dehydrogenase from Salmonella typhimurium by means of X–ray crystallography. Kryger G, et al. **Gene** 1995 Oct 16;164(1):85–7

High–level production of spinach glycolate oxidase in the methylotrophic yeast Pichia pastoris: engineering a biocatalyst. Payne MS, et al. **Gene** 1995 Dec 29; 167(1–2):215–9

Enzyme polymorphism in Drosophila melanogaster populations collected in two different habitats in Hungary. Pecsenye K, et al. **Genetica** 1995;96(3):257–68

Structure and expression of wild–type and suppressible alleles of the Drosophila purple gene. Kim N, et al. **Genetics** 1996 Apr;142(4):1157–68

Identification of a common 6–pyruvoyl–tetrahydropterin synthase mutation at codon 87 in Chinese phenylketonuria caused by tetrahydrobiopterin synthesis deficiency. Liu TT, et al. **Hum Genet** 1996 Sep;98(3):313–6

Phanerochaete chrysosporium glyoxal oxidase is encoded by two allelic variants: structure, genomic organization, and heterologous expression of glx1 and glx2. Kersten PJ, et al. **J Bacteriol** 1995 Nov;177(21):6106–10

glc locus of Escherichia coli: characterization of genes encoding the subunits of glycolate oxidase and the glc regulator protein. Pellicer MT, et al. **J Bacteriol** 1996 Apr; 178(7):2051–9

cDNA cloning, expression, and mutagenesis study of leukotriene B4 12–hydroxydehydrogenase. Yokomizo T, et al. **J Biol Chem** 1996 Feb 2;271(5):2844–50

Determination of the gene sequence and the three–dimensional structure at 2.4 angstroms resolution of methanol dehydrogenase from Methylophilus W3A1. Xia Z, et al. **J Mol Biol** 1996 Jun 14;259(3):480–501

Nucleotide sequence of the gene encoding beta–isopropylmalate dehydrogenase (leuB) from Bacteroides fragilis. Sarker MR, et al. **Microbiol Immunol** 1995;39(7):525–9

Molecular characterization of a chromosomal region involved in the oxidation of acetyl–CoA to glyoxylate in the isocitrate–lyase–negative methylotroph Methylobacterium extorquens AM1. Chistoserdova LV, et al. **Microbiology** 1996 Jun;142 (Pt 6):1459–68

Screening of stable proteins in an extreme thermophile, Thermus thermophilus. Tamakoshi M, et al. **Mol Microbiol** 1995 Jun;16(5):1031–6

Molecular cloning and characterization of Rosa hybrida dihydroflavonol 4–reductase gene. Tanaka Y, et al. **Plant Cell Physiol** 1995 Sep;36(6):1023–31

Molecular characterization and expression of alfalfa (Medicago sativa L.) flavanone–3–hydroxylase and dihydroflavonol–4–reductase encoding genes. Charrier B, et al. **Plant Mol Biol** 1995 Nov;29(4):773–86

Pumpkin hydroxypyruvate reductases with and without a putative C–terminal signal for targeting to microbodies may be produced by alternative splicing. Hayashi M, et al. **Plant Mol Biol** 1996 Jan;30(1):183–9

A disruption–replacement approach for the targeted integration of foreign genes in Hansenula polymorpha. Agaphonov MO, et al. **Yeast** 1995 Oct;11(13):1241–7

An 8.2 kb DNA segment from chromosome XIV carries the RPD3 and PAS8 genes as well as the Saccharomyces cerevisiae homologue of the thiamine–repressed nmt1 gene and a chromosome III–duplicated gene for a putative aryl–alcohol dehydrogenase. Van Dyck L, et al. **Yeast** 1995 Aug;11(10):987–91

IMMUNOLOGY

Immunological characterization of serine–glyoxylate aminotransferase and hydroxypyruvate reductase from a methylotrophic bacterium, Hyphomicrobium methylovorum GM2. Hagishita T, et al. **FEMS Microbiol Lett** 1996 Aug 15;142(1):49–52

ISOLATION & PURIFICATION

Purification and properties of benzyl alcohol dehydrogenase from a denitrifying Thauera sp. Biegert T, et al. **Arch Microbiol** 1995 Jun;163(6):418–23

Adult–male–specific S–warfarin (11S–OH) and progesterone (20 beta–OH) keto–reductases in rat hepatic microsomes are not identical. Apanovitch D, et al. **Biochim Biophys Acta** 1996 Aug 29;1291(1):16–26

The 30 kDa protein co–purified with chick liver glutathione S–transferases is a carbonyl reductase. Tsai SP, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):289–92

3–Deoxyglucosone reductase in dog adrenal glands. Identification as aldose reductase. Matsuura K, et al. **Biol Pharm Bull** 1995 Dec;18(12):1765–7

Purification and properties of codeinone reductase (NADPH) from Papaver somniferum cell cultures and differentiated plants. Lenz R, et al. **Eur J Biochem** 1995 Oct 1; 233(1):132–9

Purification and characterization of 3–isopropylmalate dehydrogenase from a thermoacidophilic archaebacterium Sulfolobus sp. strain 7. Yoda E, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):243–7

Generation mechanism and purification of an inactive form convertible in vivo to the active form of quinoprotein alcohol dehydrogenase in Gluconobacter suboxydans. Matsushita K, et al. **J Bacteriol** 1995 Nov;177(22):6552–9

Purification and catalytic properties of a novel acetohexamide–reducing enzyme from rabbit heart. Imamura Y, et al. **J Biochem (Tokyo)** 1996 Apr; 119(4):648–52

D–2–hydroxyglutaric acidaemia: identification of a new enzyme, D–2–hydroxyglutarate dehydrogenase, localized in mitochondria. Wanders RJ, et al. **J Inherit Metab Dis** 1995;18(2):194–6

METABOLISM

Purification and properties of benzyl alcohol dehydrogenase from a denitrifying Thauera sp. Biegert T, et al. **Arch Microbiol** 1995 Jun;163(6):418–23

Structures important in NAD(P)(H) specificity for mammalian retinol and 11–Cis–retinol dehydrogenases. Tsigelny I, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):118–27

The interaction of methanol dehydrogenase and its cytochrome electron acceptor. Dales SL, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):261–5

Site–directed mutagenesis of a serine residue in cinnamyl alcohol dehydrogenase, a plant NADPH–dependent dehydrogenase, affects the specificity for the coenzyme. Lauvergeat V, et al. **Biochemistry** 1995 Sep 26; 34(38):12426–34

Transient–state kinetic analysis of the oxidative decarboxylation of D–malate catalyzed by tartrate dehydrogenase. Tipton PA. **Biochemistry** 1996 Mar 5; 35(9):3108–14

1.7 A structure of FR–1, a fibroblast growth factor–induced member of the aldo–keto reductase family, complexed with coenzyme and inhibitor. Wilson DK, et al. **Biochemistry** 1995 Nov 7;34(44):14323–30

Functional analysis of E. coli threonine dehydrogenase by means of mutant isolation and characterization. Chen YW, et al. **Biochim Biophys Acta** 1995 Dec 6;1253(2):208–14

Purification and properties of L(–)–carnitine dehydrogenase from Agrobacterium sp. Hanschmann H, et al. **Biochim Biophys Acta** 1996 Jun 4;1290(2):177–83

The 30 kDa protein co–purified with chick liver glutathione S–transferases is a carbonyl reductase. Tsai SP, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):289–92

In vitro oxidative decarboxylation of L–2–hydroxy–4–methylthiobutanoic acid by L–2–hydroxy acid oxidase A from chicken liver. Ferjancic–Biagini A, et al. **Biochimie** 1995;77(4):249–55

Localization and activity of adrenal carbonyl reductase during the estrous cycle. Inazu N, et al. **Biol Pharm Bull** 1995 May;18(5):671–6

Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Gonzalez B, et al. **Cancer Res** 1995 Oct 15;55(20):4646–50

Prostaglandin–metabolizing enzymes during pregnancy: characterization of NAD(+)–dependent prostaglandin dehydrogenase, carbonyl reductase, and cytochrome P450–dependent prostaglandin omega–hydroxylase. Okita

RT, et al. **Crit Rev Biochem Mol Biol** 1996 Apr; 31(2):101–26 (100 ref.)

Substrate specificity of flavin–dependent vanillyl–alcohol oxidase from Penicillium simplicissimum. Evidence for the production of 4–hydroxycinnamyl alcohols from 4–allylphenols. Fraaije MW, et al. **Eur J Biochem** 1995 Nov 15;234(1):271–7

Prostaglandin–E2 9–reductase from corpus luteum of pseudopregnant rabbit is a member of the aldo–keto reductase superfamily featuring 20 alpha–hydroxysteroid dehydrogenase activity. Wintergalen N, et al. **Eur J Biochem** 1995 Nov 15;234(1):264–70

Immunocytochemical localization of L–alpha–hydroxyacid oxidase in dense bar of dumb–bell–shaped peroxisomes of monkey kidney. Yokota S, et al. **Histochem Cell Biol** 1995 Jul;104(1):55–61

Generation mechanism and purification of an inactive form convertible in vivo to the active form of quinoprotein alcohol dehydrogenase in Gluconobacter suboxydans. Matsushita K, et al. **J Bacteriol** 1995 Nov;177(22):6552–9

Synthesis of sn–glycerol 3–phosphate, a key precursor of membrane lipids, in Bacillus subtilis. Morbidoni HR, et al. **J Bacteriol** 1995 Oct;177(20):5899–905

Purification and catalytic properties of a novel acetohexamide–reducing enzyme from rabbit heart. Imamura Y, et al. **J Biochem (Tokyo)** 1996 Apr; 119(4):648–52

Ligand–induced changes in the conformation of 3–isopropylmalate dehydrogenase from Thermus thermophilus. Kadono S, et al. **J Biochem (Tokyo)** 1995 Oct;118(4):745–52

Cellular retinol–binding protein–supported retinoic acid synthesis. Relative roles of microsomes and cytosol. Boerman MH, et al. **J Biol Chem** 1996 Mar 8;271(10):5610–6

Glyoxal oxidase from Phanerochaete chrysosporium is a new radical–copper oxidase. Whittaker MM, et al. **J Biol Chem** 1996 Jan 12;271(2):681–7

The absence of Pmp47, a putative yeast peroxisomal transporter, causes a defect in transport and folding of a specific matrix enzyme. Sakai Y, et al. **J Cell Biol** 1996 Jul;134(1):37–51

6–Pyruvoyl tetrahydropterin synthase, an enzyme with a novel type of active site involving both zinc binding and an intersubunit catalytic triad motif; site–directed mutagenesis of the proposed active center, characterization of the metal binding site and modelling of substrate binding. Bürgisser DM, et al. **J Mol Biol** 1995 Oct 20;253(2):358–69

Strain– and sex–related differences of acetohexamide reductase activities in liver microsomes and cytosol of rats: the Wistar–Imamichi strain lacks the male–specific microsomal enzyme activity. Imamura Y, et al. **Life Sci** 1995;57(19):1811–7

Relationship between perinatal appearance of cellular retinol–binding protein, type II and retinal reductase activity in chick liver. Takase S, et al. **Life Sci** 1996; 58(2):135–44

The QUTA activator and QUTR repressor proteins of Aspergillus nidulans interact to regulate transcription of the quinate utilization pathway genes. Lamb HK, et al. **Microbiology** 1996 Jun;142 (Pt 6):1477–90

The role of glutamate 87 in the kinetic mechanism of Thermus thermophilus isopropylmalate dehydrogenase. Dean AM, et al. **Protein Sci** 1995 Oct;4(10):2156–67

PHYSIOLOGY

The role of a beta barrel loop 4 extension in modulating the physical and functional properties of long–chain 2–hydroxy–acid oxidase isozymes. Belmouden A, et al. **Eur J Biochem** 1996 Jun 15;238(3):790–8

ALCOHOL, PROPYL

Short technical reports. Modification of the TRI reagent procedure for isolation of RNA from polysaccharide– and proteoglycan–rich sources. Chomczynski P, et al. **Biotechniques** 1995 Dec;19(6):942–5

ANALOGS & DERIVATIVES

Synthesis and antiplatelet activity of 1–tert–butylamino–3–(3–thienyloxy)–2–propanols. Abdallah S, et al. **Arch Pharm (Weinheim)** 1996 Apr; 329(4):216–22

Nonideality of water–hexafluoropropanol mixtures as studied by X–ray small angle scattering. Kuprin S, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1151–6

Stereo–selective affinity labelling of sheep liver sorbitol dehydrogenase by chloro–substituted analogues of 2–bromo–3–(5–imidazolyl)propionic acid. Lindstad RI, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):267–71

Actions of selected hepatotoxicants on freshly isolated and cryopreserved rat hepatocytes. Pang JM, et al. **Cryobiology** 1996 Apr;33(2):226–35

Substrate specificity of flavin–dependent vanillyl–alcohol oxidase from Penicillium simplicissimum. Evidence for the production of 4–hydroxycinnamyl alcohols from 4–allylphenols. Fraaije MW, et al. **Eur J Biochem** 1995 Nov 15;234(1):271–7

Loss of mitochondrial membrane potential is not essential to hepatocyte killing by allyl alcohol. Rikans LE, et al. **Toxicol Lett** 1995 Nov 15;81(2–3):159–65

Oxidation of pyridine nucleotides is an early event in the lethality of allyl alcohol. Rikans LE, et al. **Toxicology** 1996 Jan 8;106(1–3):85–92

ANALYSIS

Postmortem degradation of administered ethanol–d6 and production of endogenous ethanol: experimental studies using rats and rabbits. Takayasu T, et al. **Forensic Sci Int** 1995 Dec 18;76(2):129–40

DIAGNOSTIC USE

[Blood ethanol and isopropanol (letter)] Malandain H, et al. **Ann Biol Clin (Paris)** 1996;54(2):97 (Fre)

METABOLISM

Biotransformation of acetone to isopropanol observed in a motorist involved in a sobriety check. Jones AW, et al. **J Forensic Sci** 1995 Jul;40(4):686–7

PHARMACOKINETICS

[Formation of so–called byproducts (propanols, butanols et al.) from ethanol by microorganisms] Stöhlmacher P. **Blutalkohol** 1996 May;33(3):113–41 (200 ref.) (Eng. Abstr.) (Ger)

PHARMACOLOGY

Synthesis and antiplatelet activity of 1–tert–butylamino–3–(3–thienyloxy)–2–propanols. Abdallah S, et al. **Arch Pharm (Weinheim)** 1996 Apr; 329(4):216–22

Quantitative evaluation of aqueous isopropyl alcohol enhancement on skin flux of terbutaline (sulfate). 2. Permeability contributions of equilibrated drug species across human skin in vitro. Liu P, et al. **J Pharm Sci** 1996 Mar;85(3):320–5

POISONING

Ingestion of an unknown alcohol. Trummel J, et al. **Ann Emerg Med** 1996 Mar;27(3):368–74

Acute isopropyl alcohol intoxication in a horse. Somerville BA, et al. **Can Vet J** 1996 Jun;37(6):359–60

THERAPEUTIC USE

A comparison of two skin preps used in cardiac surgical procedures. Hagen KS, et al. **AORN J** 1995 Sep; 62(3):393–402

TOXICITY

Low–level hyperbaric exposure antagonizes locomotor effects of ethanol and n–propanol but not morphine in C57BL mice. Alkana RL, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):693–700

Isopropyl alcohol. Dhillon S, et al. **J Appl Toxicol** 1995 Nov–Dec;15(6):501–6

Dose–dependent suppression of toluene metabolism by isopropyl alcohol and methyl ethyl ketone after experimental exposure of rats. Uaki H, et al. **Toxicol Lett** 1995 Nov 15;81(2–3):229–34

ALCOHOL WITHDRAWAL DELIRIUM

BLOOD

D–fenfluramine–induced prolactin responses in postwithdrawal alcoholics and controls. Farren CK, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1578–82

CEREBROSPINAL FLUID

Levels of gamma–aminobutyric acid in cerebrospinal fluid and plasma during alcohol withdrawal. Adinoff B, et al. **Psychiatry Res** 1995 Nov 29;59(1–2):137–44

COMPLICATIONS

Airway control in a patient with an unstable cervical fracture and delirium tremens. Harding D, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):59

DIAGNOSIS

The histories of withdrawal convulsions and delirium tremens in 1648 alcohol dependent subjects. Schuckit MA, et al. **Addiction** 1995 Oct;90(10):1335–47

The Windsor Clinic Alcohol Withdrawal Assessment Scale (WCAWAS): investigation of factors associated with complicated withdrawals. Metcalfe P, et al. **Alcohol Alcohol** 1995 May;30(3):367–72

Relationship between alcohol withdrawal seizures and temporal lobe white matter volume deficits. Sullivan EV, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):348–54

Postoperative confusion in a 42–year–old man. Isaacson JH. **Cleve Clin J Med** 1995 Nov–Dec;62(6):370–1

DRUG THERAPY

The management of alcohol withdrawal using chlormethiazole. Morgan MY. **Alcohol Alcohol** 1995 Nov; 30(6):771–4 (21 ref.)

The irreversible gamma–aminobutyrate transaminase inhibitor vigabatrin in the treatment of the alcohol withdrawal syndrome [letter] Stuppaeck CH, et al. **Alcohol Alcohol** 1996 Jan;31(1):109–11

Late–onset seizures in alcohol withdrawal. Mayo–Smith MF, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):656–9

Alcohol withdrawal syndrome. Yost DA. **Am Fam Physician** 1996 Aug;54(2):657–64, 669

Management of delirium tremens on the head and neck service. Alvi A, et al. **Am J Otolaryngol** 1995 Jul–Aug; 16(4):224–31 (25 ref.)

Opiates in ethanol withdrawal. Tsueda K, et al. **Anesth Analg** 1995 Oct;81(4):874–7

[Alcohol as therapeutic drug in alcohol dependent intensive care patients: contra] Krumholz W. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):181–2 (Ger)

[Treatment of delirium tremens with quick administration of diazepam] Wasilewski D, et al. **Psychiatr Pol** 1995 Sep–Oct;29(5):675–86 (Eng. Abstr.) (Pol)

ETIOLOGY

Physical morbidity in patients admitted to a private hospital for detoxification from alcohol. Wylie AS, et al. **Alcohol Alcohol** 1995 Sep;30(5):641–3

GENETICS

Time course and genetic variation in the regulation of calcium channel antagonist binding sites in rodent tissues during the induction of ethanol physical dependence and withdrawal. Guppy LJ, et al. **Alcohol Alcohol** 1995 Sep; 30(5):607–15

HISTORY

[Historical study of seven cases of delirium tremens in Spain in the first half of the XIX century] Conde López VJ, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Jul–Aug;23(4):200–16 (Eng. Abstr.) (Spa)

PHYSIOPATHOLOGY

Evidence for reduced dopamine D2 receptor sensitivity in postwithdrawal alcoholics. Farren CK, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1520–4

Repeated ethanol withdrawal produces site–dependent increases in EEG spiking. Veatch LM, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):262–7

Alcohol withdrawal tremor. Milanov I, et al. **Electromyogr Clin Neurophysiol** 1996 Jan–Feb;36(1):15–20

[Study of psychopathologic–biorhythm aspects of alcoholic patients in the withdrawal phase—initial results of a pilot study] Peter K, et al. **Wien Med Wochenschr** 1995; 145(17–18):454–5 (Eng. Abstr.) (Ger)

PREVENTION & CONTROL

Clinical pathway effects on treatment of the alcohol withdrawal syndrome. Morgan T, et al. **S D J Med** 1996 Jun;49(6):195–200

[Alcohol administration for prevention of withdrawal delirium in alcohol dependent surgical intensive care patients: pro] Engelhardt W. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):183–4 (Ger)

PSYCHOLOGY

The phenomenology of perceptual hallucinations in alcohol–induced delirium tremens. Platz WE, et al. **Psychopathology** 1995;28(5):247–55

THERAPY

Second–line and 'alternative' treatments for alcohol withdrawal: alpha–agonists, beta–blockers, anticonvulsants, acupuncture and neuro–electric therapy. Brewer C. **Alcohol Alcohol** 1995 Nov;30(6):799–803 (25 ref.)

ALCOHOLIC BEVERAGES

Cognitive and situational factors predict alcoholic beverage selection. Corcoran KJ. **Addict Behav** 1995 Jul–Aug; 20(4):525–32

Role of alcoholic beverages in essential hypertensive patients. Rabbia F, et al. **Alcohol Alcohol** 1995 Jul;30(4):433–9

Hon v. Stroh Brewery Company: what do we mean by "moderate" and "heavy" drinking? Abel EL, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1024–31

Methanol in human breath. Taucher J, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1147–50

Association of the waist–to–hip ratio is different with wine than with beer or hard liquor consumption. Atherosclerosis Risk in Communities Study Investigators. Duncan BB, et al. **Am J Epidemiol** 1995 Nov 15;142(10):1034–8

Designer drinks and drunkenness amongst a sample of Scottish schoolchildren [see comments] McKeganey N, et al. **BMJ** 1996 Aug 17;313(7054):401. Comment in: BMJ 1996 Aug 17;313(7054):375.

Behavioral and social consequences related to the consumption of different beverage types. Smart RG. **J Stud Alcohol** 1996 Jan;57(1):77–84 (60 ref.)

What every mental health professional should know about alcohol. Miller WR, et al. **J Subst Abuse Treat** 1995 Sep–Oct;12(5):355–65

Mutagenicity of soy sauce treated with nitrite in the presence of ethanol or alcoholic beverages. Higashimoto M, et al.

Mutat Res 1995 Dec;345(3–4):155–66

[Is alcohol healthy? (editorial)] Sieber C.
Schweiz Rundsch Med Prax 1996 May 7;85(19):615–6 (21 ref.) **(Ger)**

ADVERSE EFFECTS

Alcohol intake, cigarette smoking, and sleep disturbance [letter; comment] Aubin HJ, et al. **Arch Intern Med** 1996 May 13;156(9):1028. Comment on: Arch Intern Med 1995 Apr 10;155(7):734–7.

Potentiation of occupational carbon tetrachloride toxicity by ethanol abuse. Manno M, et al. **Hum Exp Toxicol** 1996 Apr;15(4):294–300

Interpretations of risk: the use of scientific information in the development of the alcohol warning label policy. Kaskutas LA. **Int J Addict** 1995;30(12):1519–48 (70 ref.)

Low alcohol drinks and risk of high blood alcohol in children [letter] Jones AW. **J Toxicol Clin Toxicol** 1996;34(3):349–50

Lichen planus after consumption of a gold-containing liquor [letter] Russell MA, et al. **N Engl J Med** 1996 Feb 29; 334(9):603

The influence of beer, cognac and ethanol upon the follicular state of mouse ovaries on day 4 of pregnancy. Sandor S, et al. **Rom J Morphol Embryol** 1995 Jan–Jun;41(1–2):3–6

A case of phenytoin–alcohol interaction [letter] Bellibas SE, et al. **Therapie** 1995 Sep–Oct;50(5):487–8

ANALYSIS

High-performance liquid chromatographic determination of the biologically active principle hypericin in phytotherapeutic vegetable extracts and alcoholic beverages. Micali G, et al. **J Chromatogr A** 1996 Apr 19; 731(1–2):336–9

[Ethanol-independent methanol elimination in chronic alcoholics] Musshoff F, et al. **Blutalkohol** 1995 Nov; 32(6):317–36 (Eng. Abstr.) **(Ger)**

CLASSIFICATION

High-density-lipoprotein cholesterol and types of alcoholic beverages consumed among men and women. Parker DR, et al. **Am J Public Health** 1996 Jul;86(7):1022–7

HISTORY

Ginger Jake and the blues: a tragic song of poisoning. Woolf AD. **Vet Hum Toxicol** 1995 Jun;37(3):252–4

MICROBIOLOGY

Yeast communities in a natural tequila fermentation. Lachance MA. **Antonie Van Leeuwenhoek** 1995 Aug; 68(2):151–60

STANDARDS

High-performance liquid chromatographic profiles of aloe constituents and determination of aloin in beverages, with reference to the EEC regulation for flavouring substances. Zonta F, et al. **J Chromatogr A** 1995 Dec 1;718(1):99–106

STATISTICS & NUMERICAL DATA

Do not change the numbers—clarify the message. The government review of the Sensible Drinking message: a Medical Council on Alcoholism view. **Alcohol Alcohol** 1995 Sep;30(5):571–5

Beverage effects on patterns of alcohol consumption. Del Rio C, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1583–6

Style, consumption, and problem drinking: a measurement model. Yu J. **Alcohol Clin Exp Res** 1995 Oct;19(5):1192–7

Reliability of alcohol intake as recalled from 10 years in the past. Liu S, et al. **Am J Epidemiol** 1996 Jan 15;143(2):177–86

Using panel data to determine the effect of advertising on brand-level distilled spirits sales. Gius MP.
J Stud Alcohol 1996 Jan;57(1):73–6

SUPPLY & DISTRIBUTION

Potential consequences from possible changes to Nordic retail alcohol monopolies resulting from European Union membership. Holder HD, et al. **Addiction** 1995 Dec; 90(12):1603–18

Do role-model societies exist? Negrete JC. **Addiction** 1995 Nov;90(11):1443–5

Young teenagers and access to alcohol in a Swiss canton: evidence from observational testing and from a telephone survey. Vaucher S, et al. **Addiction** 1995 Dec; 90(12):1619–25

Treatment, health promotion and alcohol controls and the decrease of alcohol consumption and problems in Ontario: 1975–1993. Smart RG, et al. **Alcohol Alcohol** 1995 May; 30(3):337–43

Alcohol availability and alcohol-related crashes: does distance make a difference? Giacopassi D, et al.
Am J Drug Alcohol Abuse 1995 Aug;21(3):407–16

The relationship of alcohol sales to cirrhosis mortality. Gruenewald PJ, et al. **J Stud Alcohol** 1995 Nov; 56(6):635–41

Alcohol availability and alcoholism. Bondy S. **JAMA** 1995 Dec 20;274(23):1832

Commercial availability of alcohol to young people: results of alcohol purchase attempts. Forster JL, et al.
Prev Med 1995 Jul;24(4):342–7

TOXICITY

Absence of evidence for mutagenicity of alcoholic beverages: an analysis of hprt mutant frequencies in 153 normal humans. Cole J, et al. **Mutagenesis** 1995 Sep;10(5):449–52

[The effect of combined toxicity on the development of alcoholic pancreatic lesions. A long-term experimental trial] Peneda J, et al. **Acta Med Port** 1995 Mar;8(3):137–43 (Eng. Abstr.) **(Por)**

ALCOHOLIC CARDIOMYOPATHY see **CARDIOMYOPATHY, ALCOHOLIC**

ALCOHOLIC CIRRHOSIS see **LIVER CIRRHOSIS, ALCOHOLIC**

ALCOHOLIC FATTY LIVER see **FATTY LIVER, ALCOHOLIC**

ALCOHOLIC HEPATITIS see **HEPATITIS, ALCOHOLIC**

ALCOHOLIC INTOXICATION

Speaking sober in the emergency department [editorial] Bernstein E. **Acad Emerg Med** 1995 Sep;2(9):762–4

Judgment of intoxication by untrained social drinkers across drinking settings. Williams JG, et al. **Addict Behav** 1995 Sep–Oct;20(5):679–83

The geography of availability and driving after drinking. Gruenewald PJ, et al. **Addiction** 1996 Jul;91(7):967–83

Sex under the influence of alcohol among Norwegian adolescents. Traeen B, et al. **Addiction** 1996 Jul; 91(7):995–1006

Pseudo-drunk-patron evaluation of bar-staff compliance with Western Australian liquor law. Rydon P, et al.
Aust N Z J Public Health 1996 Jun;20(3):290–5

Drugs, alcohol and liability [editorial] Harty-Golder B.
J Fla Med Assoc 1996 Jun–Jul;83(6):425–8

Methanol ingestion. 'Guaranteed to make you feel good'. d'Autremont S, et al. **J La State Med Soc** 1995 Sep; 147(9):417–20

Alcohol and driving. Alvarez FJ, et al. **Lancet** 1996 Apr 13;347(9007):985–6

Alcohol misuse and adolescent sexual behaviors and risk taking. Fergusson DM, et al. **Pediatrics** 1996 Jul;98(1):91–6

Can we judge the strength of a drink? Standing L, et al.
Percept Mot Skills 1995 Oct;81(2):365–6

Breath testing for alcohol [letter] Hedden FG, et al.
S Afr Med J 1995 Dec;85(12):1302

[Non-hospitalization orders for subjects with presumed alcoholic intoxication] Dequin PF, et al. **Presse Med** 1996 May 25;25(18):833–6 (Eng. Abstr.) **(Fre)**

[Drunkenness in traffic in Geneva: distribution and detection] Michiels W, et al. **Soz Praventivmed** 1996;41(1):19–27 (Eng. Abstr.) **(Fre)**

BLOOD

Effect of acute alcohol intoxication on the opioid system in humans. Aguirre JC, et al. **Alcohol** 1995 Nov–Dec; 12(6):559–62

Role of albumin and high-density lipoprotein as endotoxin-binding proteins in rats with acute and chronic alcohol loading. Kitano H, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):73A–76A

Unknown alcohol [letter] Linden CH. **Ann Emerg Med** 1996 Sep;28(3):371

The activity of cathepsin A and cathepsin D in the serum of persons acutely intoxicated with ethanol and chronic alcoholics. Kamiński J, et al. **Rocz Akad Med Bialymst** 1995;40(1):209–12

[Ethyl alcohol levels in the expiratory air vs blood alcohol levels. 204 cases in an emergency unit] Derogis V, et al.
Presse Med 1995 Jun 24;24(23):1067–70 (Eng. Abstr.) **(Fre)**

[Congener analysis in a drinking trial with unusually high alcohol content] Schmitt G, et al. **Blutalkohol** 1995 Nov; 32(6):337–43 (Eng. Abstr.) **(Ger)**

[Reliability of back-calculation of blood alcohol concentration to the time of infraction] Schyma C, et al.
Blutalkohol 1996 Mar;33(2):65–70 (Eng. Abstr.) **(Ger)**

[Self-assessment of blood alcohol content in acute alcoholic intoxication] Seidl S, et al. **Blutalkohol** 1996 Jan;33(1):23–30 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Identification of hazardous/harmful drinking among subcritically injured patients. Clifford PR, et al.
Acad Emerg Med 1996 Mar;3(3):239–45

Biochemical markers of cerebral injury in patients with minor head trauma and ethanol intoxication. Levitt MA, et al.
Acad Emerg Med 1995 Aug;2(8):675–80

Ethanol-associated hypoglycemia is uncommon. Sucov A, et al. **Acad Emerg Med** 1995 Mar;2(3):185–9

Guidelines focus on common substance-use disorders [news]
Am J Health Syst Pharm 1996 Feb 1;53(3):228, 229, 230

Ethylene glycol poisoning with a normal anion gap caused by concurrent ethanol ingestion: importance of the osmolal gap. Ammar KA, et al. **Am J Kidney Dis** 1996 Jan; 27(1):130–3

The study of the relationship between lifestyle characteristic self-reported drinking patterns and trauma. Brotman S, et al. **Am Surg** 1995 Nov;61(11):975–9

Enforcement of drunken driving laws in cases involving injured intoxicated drivers. Runge JW, et al.
Ann Emerg Med 1996 Jan;27(1):66–72

Traumatic brain injury, alcohol and quantitative neuroimaging: preliminary findings. Bigler ED, et al.
Brain Inj 1996 Mar;10(3):197–206

Alcoholic rhabdomyolysis: a review. Bessa O Jr.
Conn Med 1995 Sep;59(9):519–21 (19 ref.)

A case of life-threatening lactic acidosis after smoke inhalation – interference between beta-adrenergic agents and ethanol? Taboulet P, et al. **Intensive Care Med** 1995 Dec;21(12):1039–41

The role of ethanol in heroin deaths. Levine B, et al.
J Forensic Sci 1995 Sep;40(5):808–10

The effect of ethanol upon early development in mice and rats. XXI. The effect of acute maternal ethanol intoxication upon in vitro hatching of mouse embryos. Checiu M.
Rom J Morphol Embryol 1995 Jan–Jun;41(1–2):13–8

[A cause for error in automatic detection of halogenated agents: alcoholic intoxication (letter)] Bouyssou H, et al.
Ann Fr Anesth Reanim 1995;14(3):313–4 **(Fre)**

[Complete arrhythmia, caused by atrial fibrillation, causing ischemic cerebral vascular accident following acute alcoholic intoxication in a young subject (letter)] Rosolacci T, et al. **Presse Med** 1995 Dec 16–23;24(39):1911 **(Fre)**

[Holiday heart syndrome] Rau T, et al.
Dtsch Med Wochenschr 1996 Sep 6;121(36):1108 **(Ger)**

DIAGNOSIS

Blood ethanol estimation: a comparison of three methods [letter] Keim ME, et al. **Acad Emerg Med** 1996 Jan; 3(1):85–7

Judgment of intoxication by untrained social drinkers across drinking settings. Williams JG, et al. **Addict Behav** 1995 Sep–Oct;20(5):679–83

Measuring and reporting the concentration of acetaldehyde in human breath. Jones AW. **Alcohol Alcohol** 1995 May; 30(3):271–85 (45 ref.)

Simple versus sophisticated models of breath alcohol exhalation profiles. Lubkin SR, et al. **Alcohol Alcohol** 1996 Jan;31(1):61–7

The diagnostic value of BAC for identifying alcohol-related problems among DWI offenders: another look. Lucker GW, et al. **Am J Drug Alcohol Abuse** 1995 Nov; 21(4):573–80

Confusion and nausea in a man who appeared to be drunk. Breckenridge MB, et al. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):47–8

[Test performance with minimal alcoholic intoxication] Bartl G, et al. **Blutalkohol** 1996 Jan;33(1):1–16 (Eng. Abstr.) **(Ger)**

[Changes in the spectrum of alcohol-induced traffic accidents in relation to blood alcohol level] Haffner HT, et al.
Blutalkohol 1996 Mar;33(2):78–83 (Eng. Abstr.) **(Ger)**

[Use of the ADH/REA method (Abbott Tdx-REA) in forensic blood alcohol determination] Mebs D, et al.
Blutalkohol 1996 Mar;33(2):71–7 (Eng. Abstr.) **(Ger)**

[Drinking trials for back calculation in long elapsed time intervals] Schröter A, et al. **Blutalkohol** 1995 Nov; 32(6):344–52 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

GM1 ganglioside reduces ethanol intoxication and the development of ethanol dependence. Wallis CJ, et al.
Alcohol 1995 Nov–Dec;12(6):573–80

Detoxification: the use of benzodiazepines. Shaw GK.
Alcohol Alcohol 1995 Nov;30(6):765–70 (20 ref.)

[The corrective properties of glycine in alcoholic intoxication in the fetal period of pregnancy] Sheveleva GA, et al.
Eksp Klin Farmakol 1996 Jan–Feb;59(1):27–9 (Eng. Abstr.) **(Rus)**

[Effect of zinc-metallothionein on lipid peroxidation in blood plasma and in mouse liver in acute alcoholic intoxication] Koterov AN, et al. **Ukr Biokhim Zh** 1995 Jul–Aug; 67(4):80–7 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

The effect of endotoxin on alcohol dehydrogenase (ADH) activity in the serum of ethanol intoxicated rats. Chrostek L, et al. **Rocz Akad Med Bialymst** 1994;39:74–80

[Glutathione reductase activation in acute alcoholic intoxication] Sokolovs'ka VV, et al. **Fiziol Zh** 1995 Jan–Apr;41(1–2):112–6 (Eng. Abstr.) **(Ukr)**

EPIDEMIOLOGY

Alcohol and non-fatal injury in the U.S. general population: a risk function analysis. Cherpitel CJ, et al.
Accid Anal Prev 1995 Oct;27(5):651–61

A filter model to describe bias in official statistics on alcohol-related injuries. Webb GR. **Accid Anal Prev** 1995 Oct;27(5):687–97

Prevalence of female alcohol dependence and abuse in Sweden. Spak F, et al. **Addiction** 1995 Aug;90(8):1077–88

Alcohol availability and alcohol-related crashes: does distance make a difference? Giacopassi D, et al.
Am J Drug Alcohol Abuse 1995 Aug;21(3):407–16

Drinking on campus. Undergraduate intoxication requiring emergency care. Wright SW, et al.
Arch Pediatr Adolesc Med 1996 Jul;150(7):699–702

Drug use, binge drinking and attempted suicide among

homeless and potentially homeless youth. Sibthorpe B, et al. **Aust N Z J Psychiatry** 1995 Jun;29(2):248–56

Designer drinks and drunkenness amongst a sample of Scottish schoolchildren [see comments] McKeganey N, et al. **BMJ** 1996 Aug 17;313(7054):401. Comment in: BMJ 1996 Aug 17;313(7054):375.

Is there a relationship between "heavy drinking" and HIV high risk sexual behaviors among general population subjects? Shillington AM, et al. **Int J Addict** 1995 Sep; 30(11):1453–78

Demographic characteristics, drinking patterns and drink–driving behavior of injured male drivers and motorcycle riders. Holubowycz OT, et al. **J Stud Alcohol** 1995 Sep;56(5):513–21

Drinking by police officers, general drivers and late–night drivers. Meyers AR, et al. **J Stud Alcohol** 1996 Mar; 57(2):187–92

Relationship between alcohol consumption and victim behaviors immediately preceding sexual aggression by an acquaintance. Harrington NT, et al. **Violence Vict** 1994 Winter;9(4):315–24

[Automobile driving with alcohol impaired abilities in young people from rural areas in Quebec: a comparison of the years 1983 and 1992] Audet T, et al. **Can J Public Health** 1995 Sep–Oct;86(5):333–4 **(Fre)**

[Drunkenness in traffic in Geneva: occasional abuse or alcoholism?] Michiels W, et al. **Soz Praventivmed** 1996; 41(1):28–35 (Eng. Abstr.) **(Fre)**

[Traffic accidents in alcoholic intoxication] Erath D, et al. **Blutalkohol** 1996 Mar;33(2):57–64 (Eng. Abstr.) **(Ger)**

ETHNOLOGY

Changes in drinking patterns among whites, blacks and Hispanics, 1984–1992. Caetano R, et al. **J Stud Alcohol** 1995 Sep;56(5):558–65

ETIOLOGY

[Acute alcoholism after ethanol fixation for ovarian chocolate cyst] Tei A, et al. **Masui** 1996 Apr;45(4):496–9 (Eng. Abstr.) **(Jpn)**

[Alcoholic intoxication caused by intravenous nitroglycerin: an underestimated risk? (letter)] Barrachina F, et al. **Med Clin (Barc)** 1996 Apr 13;106(14):555–6 **(Spa)**

GENETICS

Task persistence after alcohol consumption among children of alcoholics. Baer JS, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):955–60

Analysis of CA repeats in first intron of class I ADH gene in Long–Evans Cinnamon rats developing fatal intoxication after ethanol intake. Katsuki S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):33A–35A

Gene expression of A– and B–type natriuretic peptides in response to acute ethanol ingestion. Wigle DA, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1317–20

Aldehyde dehydrogenase activities in the brains of rats and mice genetically selected for different sensitivity to alcohol. Zimatkin SM, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1300–6

Analeptic effect of TRH in rats selectively bred for differential CNS sensitivity to ethanol. French TA, et al. **Proc West Pharmacol Soc** 1995;38:5–7

HISTORY

Historical anecdote related to chemical tests for intoxication [letter] Andréasson R, et al. **J Anal Toxicol** 1996 May–Jun; 20(3):207–8

IMMUNOLOGY

Development and characterization of a binge drinking model in mice for evaluation of the immunological effects of ethanol. Carson EJ, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):132–8

Alcohol modulation of human normal T–cell activation, maturation, and migration [see comments] Chiappelli F, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):539–44. Comment in: Alcohol Clin Exp Res 1995 Jun;19(3):535–8.

Introduction to the symposium on alcohol and T–cell immunity [comment] Chiappelli F, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):535–8. Comment on: Alcohol Clin Exp Res 1995 Jun;19(3):539–44.

Interleukin–6 tumor necrosis factor–alpha clearance and metabolism in vivo and by the isolated, perfused liver in the rat: effect of acute alcohol administration. Deaciuc IV, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):293–301

Alcohol modulates alveolar macrophage tumor necrosis factor–alpha, superoxide anion, and nitric oxide secretion in the rat. D'Souza NB, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):156–63

Anticardiolipin antibodies and acute alcoholic intoxication. Biron C, et al. **Lupus** 1995 Dec;4(6):486–90

METABOLISM

Alcohol–associated acute head trauma in human subjects is associated with early deficits in serum ionized Mg and Ca. Altura BM, et al. **Alcohol** 1995 Sep–Oct;12(5):433–7

Plasma and urine salsolinol in humans: effect of acute ethanol intake on the enantiomeric composition of salsolinol. Haber H, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):87–92

Alterations in CNS gene expression in a rodent model of moderate traumatic brain injury complicated by acute alcohol intoxication. Sall JM, et al. **Exp Neurol** 1996 Jun; 139(2):257–68

Effects of cocaine administration route on the formation of cocaethylene in drinkers: an experiment using rats. Moriya F, et al. **Forensic Sci Int** 1995 Dec 29;76(3):189–97

Drink driving legislation: medicine and the law. Marks P. **Med Leg J** 1995;63 (Pt 3):119–27 (17 ref.)

[Brain and liver amino acids in rats with portacaval anastomosis in acute alcoholic intoxication] Ostrovskiĭ Slu, et al. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):93–9 (Eng. Abstr.) **(Rus)**

MORTALITY

Alcohol in fatal and nonfatal injuries: a comparison of coroner and emergency room data from the same county. Cherpitel CJ. **Alcohol Clin Exp Res** 1996 Apr;20(2):338–42

Role of alcohol in traffic crashes involving women: passenger car fatalities in northern Sweden. Öström M, et al. **J Stud Alcohol** 1995 Sep;56(5):506–12

PATHOLOGY

Effects of ethanol administration on brain neurotensin–like immunoreactivity in rats. Wachi M, et al. **Acta Neurol Scand** 1996 Feb–Mar;93(2–3):211–4

Neuronal degeneration in rat cerebrocortical and olfactory regions during subchronic "binge" intoxication with ethanol: possible explanation for olfactory deficits in alcoholics. Collins MA, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):284–92

Homicidal blunt head trauma, diffuse axonal injury, alcoholic intoxication, and cardiorespiratory arrest: a case report of a forensic syndrome of acute brainstem dysfunction. Ramsay DA, et al. **Am J Forensic Med Pathol** 1995 Jun; 16(2):107–14

[Toxic alcohol–induced, acute intrahepatic cholestasis with reversible increase of the CA 19–9 tumor marker in chronic alcoholic hepatitis] Griga T, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:62–3 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Anterior brain dysfunctioning as a risk factor in alcoholic behaviors. Deckel AW, et al. **Addiction** 1995 Oct; 90(10):1323–34

Possible central adenosinergic modulation of ethanol–induced alterations in [14C]glucose utilization in mice. Anwer J, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):777–83

How much alcohol should I use in my experiments? [editorial] Deitrich RA, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):1–2

Low dose of ethanol suppresses mismatch negativity of auditory event–related potentials. Jääskeläinen IP, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):607–10

Ethanol alters spatial processing of hippocampal place cells: a mechanism for impaired navigation when intoxicated. Matthews DB, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):404–7

Role of plasma vasopressin in changes of water balance accompanying acute alcohol intoxication. Taivainen H, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):759–62

Changes in GABAA receptor function and cross–tolerance to ethanol in diazepam–dependent rats. Toki S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):40A–44A

Alcohol and head injury: an issue revisited. Kelly DF. **J Neurotrauma** 1995 Oct;12(5):883–90 (62 ref.)

PREVENTION & CONTROL

After the party's over: evaluation of a drinking and driving prevention program. Kuthy S, et al. **J Neurosci Nurs** 1995 Oct;27(5):273–7

Community and municipal action on alcohol. Ritson B. **WHO Reg Publ Eur Ser** 1995;63:1–102

[Lowering the promille limit?] Bialas B. **Blutalkohol** 1996 May;33(3):142–51 (Eng. Abstr.) **(Ger)**

[The European Alcohol Action Plan. The Alcohol, Drug and Tobacco Unit. Department of Lifestyles and Health, Regional Office for Europe. World Health Organization. Copenhagen, 1993] Gil López E, et al. **Rev Esp Salud Publica** 1995 Sep–Oct;69(5):361–83 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Enhanced tiredness among young impaired male nighttime drivers. Corfitsen MT. **Accid Anal Prev** 1996 Mar; 28(2):155–62

The organizational implications of smokeless tobacco use in the lumber mill industry. Donaldson SI, et al. **Addict Behav** 1996 Mar–Apr;21(2):259–67

Alcohol expectancies and changes in beer consumption of first–year college students. Kidorf M, et al. **Addict Behav** 1995 Mar–Apr;20(2):225–31

Social influences on young adults' alcohol consumption: norms, modeling, pressure, socializing, and conformity. Oostveen T, et al. **Addict Behav** 1996 Mar–Apr; 21(2):187–97

The effect of a moderate dose of alcohol on the traffic hazard perception profile of young drink–drivers. Deery HA, et al. **Addiction** 1996 Jun;91(6):815–27

Aggressivity in adolescent alcohol abusers: relationship with conduct disorder. Moss HB, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):642–6

Alcohol hangover and managerial effectiveness. Streufert S, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1141–6

Alcohol reactions in subjects of European descent: effects on alcohol use and on physical and psychomotor responses to alcohol. Whitfield JB, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):81–6

Alcohol's effects on requisites for sexual risk reduction in men: an initial experimental investigation. Gordon CM, et al. **Health Psychol** 1996 Jan;15(1):56–60

Early modeling of drinking behavior by Native American elementary school children playing drunk. Mail PD. **Int J Addict** 1995 Jul;30(9):1187–97

Stress and alcohol: the moderating effect of chronic stress on the acute stress–intoxication relationship. Breslin FC, et al. **J Stud Alcohol** 1995 Sep;56(5):546–52

The Driving Expectancy Questionnaire: development, psychometric assessment and predictive utility among young drink–drivers. Deery HA, et al. **J Stud Alcohol** 1996 Mar;57(2):193–202

The effects of alcohol on the aggressive responding of women. Dougherty DM, et al. **J Stud Alcohol** 1996 Mar; 57(2):178–86

Effects of blood alcohol concentrations on negative punishment: implications for decision making. Meier SE, et al. **J Stud Alcohol** 1996 Jan;57(1):85–96

The effect of heavy social drinking on recall and event–related potentials. Nichols JM, et al. **J Stud Alcohol** 1996 Mar;57(2):125–35

College students' decisions to intervene in alcohol–related situations. Thomas RW, et al. **J Stud Alcohol** 1995 Sep; 56(5):580–8

The adverse impact of heavy episodic drinkers on other college students. Wechsler H, et al. **J Stud Alcohol** 1995 Nov;56(6):628–34

Alcohol and aggression: a meta–analysis on the moderating effects of inhibitory cues, triggering events, and self–focused attention. Ito TA, et al. **Psychol Bull** 1996 Jul; 120(1):60–82

[Joy riding: multiple criminal car rides in an intoxicated state in relation to dyssocial personality with addictive tendencies] Knecht T. **Arch Kriminol** 1995 Jul–Aug; 196(1–2):1–5 (Eng. Abstr.) **(Ger)**

REHABILITATION

[Old wine in new bottles: the "promille–killer" Party Plus] Schmidt V, et al. **Blutalkohol** 1995 Sep;32(5):241–53 (Eng. Abstr.) **(Ger)**

THERAPY

Treatment approaches to alcohol problems. Heather N. **WHO Reg Publ Eur Ser** 1995;65:1–201 (262 ref.)

ALCOHOLIC LIVER DISEASES see **LIVER DISEASES, ALCOHOLIC**

ALCOHOLICS ANONYMOUS

Two pathways out of drinking problems without professional treatment. Humphreys K, et al. **Addict Behav** 1995 Jul–Aug; 20(4):427–41

Life domains, alcoholics anonymous, and role incumbency in the 3–year course of problem drinking. Humphreys K, et al. **J Nerv Ment Dis** 1996 Aug;184(8):475–81

AA group dynamics and 12–step activity. Tonigan JS, et al. **J Stud Alcohol** 1995 Nov;56(6):616–21

Meta–analysis of the literature on Alcoholics Anonymous: sample and study characteristics moderate findings. Tonigan JS, et al. **J Stud Alcohol** 1996 Jan;57(1):65–72

AA and other helpseeking for alcohol problems: former drinkers in the U.S. general population. Hasin DS, et al. **J Subst Abuse** 1995;7(3):281–92

The 1994 distinguished lecturer in substance abuse. Khantzian EJ. **J Subst Abuse Treat** 1995 May–Jun;12(3):157–65

A retrospective study of the concept of spirituality as understood by recovering individuals. Mathew RJ, et al. **J Subst Abuse Treat** 1996 Jan–Feb;13(1):67–73

Does Alcoholics Anonymous involvement predict treatment outcome? Montgomery HA, et al. **J Subst Abuse Treat** 1995 Jul–Aug;12(4):241–6

Alcoholics anonymous and rational recovery: readability of the "big book" vs the small book. Rather BC, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1313–4

ALCOHOLISM

see related
ALCOHOL DETERRENTS
ALCOHOLICS ANONYMOUS
FETAL ALCOHOL SYNDROME
PSYCHOSES, ALCOHOLIC
TEMPERANCE

Ethics in alcohol research and publishing [editorial] Badaway AA. **Alcohol Alcohol** 1996 Jan;31(1):7–9

Some thoughts and reflections on authorship. Jones AW. **Alcohol Alcohol** 1996 Jan;31(1):11–5

Medical education about alcohol: review of its role and effectiveness. Walsh RA. **Alcohol Alcohol** 1995 Nov; 30(6):689–702 (126 ref.)

Perioperative management of the alcohol–dependent patient.

Chiang PP. **Am Fam Physician** 1995 Dec;52(8):2267–73

Alcohol research: at the cutting edge. Gordis E. **Arch Gen Psychiatry** 1996 Mar;53(3):199–201

Fetal homicide charge for drinking while pregnant [news] Macready N. **BMJ** 1996 Sep 14;313(7058):645

Prevalence of alcohol histories in medical and nursing notes of patients admitted with self poisoning. Shepherd RM, et al. **BMJ** 1995 Sep 30;311(7009):847

The problems of alcohol abuse [editorial] Kaye S. **Bol Asoc Med P R** 1995 Mar–Apr;87(3–4):39–41

Drink, drugs and dentistry—are you at risk? **Br Dent J** 1996 May 25;180(10):392–3

Neurobehavioral aspects of the pharmacotherapy of alcohol dependence. Anton RF, et al. **Clin Neurosci** 1995; 3(3):145–54 (105 ref.)

Cohabiting relationships and sexual interest of male alcoholics. Bergman B, et al. **J Addict Dis** 1996;15(1):53–63

An exploratory study of African American collegiate adult children of alcoholics. Rodney HE, et al. **J Am Coll Health** 1996 May;44(6):267–72

Inconsistencies in the literature on collegiate adult children of alcoholics: factors to consider for African Americans. Rodney HE. **J Am Coll Health** 1996 Jul;45(1):19–25 (58 ref.)

Health services use and mortality among older primary care patients with alcoholism. Callahan CM, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1378–83

Benzodiazepines in alcoholics [letter] Hershberg PI. **J Fam Pract** 1996 Apr;42(4):342

Social–emotional adjustment and patterns of alcohol use among young adults. Weinberger DA, et al. **J Pers** 1996 Jun;64(2):495–527

Alcohol liaison in action. The Canterbury experience. Rake MO, et al. **J R Coll Physicians Lond** 1995 Jul–Aug; 29(4):275–9

A longitudinal study of parenting as a protective factor for children of alcoholics. Curran PJ, et al. **J Stud Alcohol** 1996 May;57(3):305–13

Multiple authorship: trends over 50 years in the Journal of Studies on Alcohol [letter] Howard MO, et al. **J Stud Alcohol** 1996 Jan;57(1):105–6

What every mental health professional should know about alcohol. Miller WR, et al. **J Subst Abuse Treat** 1995 Sep–Oct;12(5):355–65

Alcoholism in the elderly. Council on Scientific Affairs, American Medical Association [see comments] **JAMA** 1996 Mar 13;275(10):797–801. Comment in: JAMA 1996 Mar 13;275(10):803–4.

Patients who drink alcohol: pain, pleasure, and paradox [editorial; comment] Delbanco TL. **JAMA** 1996 Mar 13; 275(10):803–4. Comment on: JAMA 1996 Mar 13;275(10):761–7. Comment on: JAMA 1996 Mar 13;797–801.

The disease called addiction: emerging evidence in a 200–year debate. Meyer RE. **Lancet** 1996 Jan 20; 347(8995):162–6 (62 ref.)

Natural law, human dignity and alcohol. Rougé D, et al. **Med Law** 1995;14(7–8):543–6

The riddle of the chemically dependent physician. Heartbreak or joy? **N C Med J** 1996 Jul–Aug;57(4):204–6

Physician assistant impairment. A peer review program for North Carolina. Mattingly DE, et al. **N C Med J** 1996 Jul–Aug;57(4):233–5

The contrast between physicians seen by the medical board and those seen in private practice. Stratas NE. **N C Med J** 1996 Jul–Aug;57(4):218–22

A Hungarian physician's views on alcoholism [letter] Hargitai Z. **Postgrad Med** 1996 Jun;99(6):46–7

[Risk factors related to alcohol use among adolescents of fathers with alcoholism] Yang MS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Dec; 11(12):686–96 (Eng. Abstr.) **(Chi)**

[Parental alcoholism, fetal alcohol syndrome. Conference of the Institute of Scientific Research on Beverages] **Rev Fr Gynecol Obstet** 1995 Dec;90(12):558–9 **(Fre)**

[Psychiatric studies on alcoholism in Japan] Saito T. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Dec;30(6):411–25 (137 ref.) **(Jpn)**

[The present and the future of alcohol study in the field of Pharmacology] Suzuki T. **Arukoru Kenkyuto Yakubutsu Ison** 1996 Apr;31(2):135–45 (24 ref.) **(Jpn)**

[Alcohol—more than wine with meals] Aasland OG. **Tidsskr Nor Laegeforen** 1995 Sep 20;115(22):2757–8 **(Nor)**

[Pathologic states related to alcoholism] Manso CF. **Acta Med Port** 1995 Dec;8(12):711–7 (107 ref.) (Eng. Abstr.) **(Por)**

[A health system that does not live up to expectations. A primary health care team attempt at an integrated approach to a case (letter)] Cárdenas Rodríguez M, et al. **Aten Primaria** 1996 Feb 29;17(3):232–3 **(Spa)**

[Use of alcoholism psychiatric services during an 18–month follow–up of alcoholic men] Aldama E, et al. **Med Clin (Barc)** 1996 May 25;106(20):768–75 (Eng. Abstr.) **(Spa)**

BLOOD

Plasma concentrations of beta–endorphin, adrenocorticotropic hormone, and cortisol in drinking and abstinent chronic alcoholics. del Arbol JL, et al. **Alcohol** 1995 Nov–Dec;12(6):525–9

Serum lipoprotein(a) [Lp(a)] in alcoholic men: effect of withdrawal. Delarue J, et al. **Alcohol** 1996 May–Jun; 13(3):309–14

Determination of (R)– and (S)–salsolinol sulfate and dopamine sulfate levels in plasma of nonalcoholics and alcoholics. Rommelspacher H, et al. **Alcohol** 1995 Jul–Aug; 12(4):309–15

Changes of G–protein levels in platelet membranes from alcoholics during short–term and long–term abstinence. Lichtenberg–Kraag B, et al. **Alcohol Alcohol** 1995 Jul; 30(4):455–64

Identification of cholesta–3,5–dien–7–one by gas chromatography–mass spectrometry in the erythrocyte membrane of alcoholic patients. Adachi J, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):51A–55A

Changes in the fatty acid profile of plasma and adipose tissue in rats after long–term ethanol feeding. Gómez–Tubío A, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):747–52

Role of albumin and high–density lipoprotein as endotoxin–binding proteins in rats with acute and chronic alcohol loading. Kitano H, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):73A–76A

Harman and norharman in alcoholism: correlations with psychopathology and long–term changes. Rommelspacher H, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):3–8

Abnormality in membrane fatty acid compositions of cells measured on erythrocyte in alcoholic liver disease. Shiraishi K, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):56A–59A

Effect of ethanol on the synthesis of insulin–like growth factor 1 (IGF–1) and the IGF–1 receptor in late prepubertal female rats: a correlation with serum IGF–1. Srivastava V, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1467–73

Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B–12, and vitamin B–6 status. Cravo ML, et al. **Am J Clin Nutr** 1996 Feb;63(2):220–4

Exclusion of linkage between alcoholism and the MNS blood group region on chromosome 4q in multiplex families. Neiswanger K, et al. **Am J Med Genet** 1995 Feb 27; 60(1):72–9

Low plasma homovanillic acid levels in recently abstinent alcoholic men. Fulton MK, et al. **Am J Psychiatry** 1995 Dec;152(12):1819–20

Assessment of iron status in association with excess alcohol consumption. Ford C, et al. **Ann Clin Biochem** 1995 Nov; 32 (Pt 6):527–31

New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution two–dimensional gel electrophoresis. Gravel P, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):78–85

Increased serum gamma–aminobutyric acid (GABA) levels in young men at high–risk for alcoholism. Garbutt JC, et al. **Biol Psychiatry** 1995 Nov 15;38(10):704–6

Circulating total and ionized magnesium after ethanol ingestion. Wu C, et al. **Clin Chem** 1996 Apr;42(4):625–9

Transferrin microheterogeneity as a probe in normal and disease states. De Jong G, et al. **Glycoconj J** 1995 Jun; 12(3):219–26

Increased levels of alcohol markers (gamma GT, MCV, ASAT, ALAT) in older patients are not related to high alcohol intake [letter] Mowé M, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1136–7

Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients. Lagrost L, et al. **J Biol Chem** 1996 Aug 9;271(32):19058–65

Effects of abstinence on sex hormone profile in alcoholic patients without liver failure. Iturriaga H, et al. **J Endocrinol Invest** 1995 Sep;18(8):638–44

Elevated levels of serum carbohydrate deficient transferrin are not specific for alcohol abuse in patients with liver disease. Radosavljevic M, et al. **J Hepatol** 1995 Dec; 23(6):706–11

Relevance of carbohydrate–deficient transferrin as a predictor of alcoholism in intensive care patients following trauma. Spies CD, et al. **J Trauma** 1995 Oct;39(4):742–8

Elevated norharman plasma levels in alcoholic patients and controls resulting from tobacco smoking. Breyer–Pfaff U, et al. **Life Sci** 1996;58(17):1425–32

Changes of carbohydrate–deficient transferrin in chronic alcoholism. König P, et al. **Neuropsychobiology** 1995; 32(4):192–6

The activity of cathepsin A and cathepsin D in the serum of persons acutely intoxicated with ethanol and chronic alcoholics. Kamiński J, et al. **Rocz Akad Med Bialymst** 1995;40(1):209–12

[Carbohydrate deficient transferrin—reliability of the test? (letter; comment)] Grønbaek MN. **Ugeskr Laeger** 1995 Sep 18;157(38):5261. Comment on: Ugeskr Laeger 1995 Jun 19;157(25):3610–3. **(Dan)**

[Is there a relationship between alcoholism and the chance of traffic accidents? (letter; comment)] van Pelt J. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2758. Comment on: Ned Tijdschr Geneeskd 1995 Oct 7;139(40):2020–3. **(Dut)**

[Can the L/A ratio identify acute alcoholic pancreatitis?] Deltenre P, et al. **Acta Gastroenterol Belg** 1995 Mar–Apr; 58(2):222–9 (Eng. Abstr.) **(Fre)**

[Ethanol–independent methanol elimination in chronic alcoholics] Musshoff F, et al. **Blutalkohol** 1995 Nov; 32(6):317–36 (Eng. Abstr.) **(Ger)**

[Congener analysis in a drinking trial with unusually high alcohol content] Schmitt G, et al. **Blutalkohol** 1995 Nov; 32(6):337–43 (Eng. Abstr.) **(Ger)**

[Formation of so–called byproducts (propanols, butanols et al.) from ethanol by microorganisms] Stöhlmacher P. **Blutalkohol** 1996 May;33(3):113–41 (200 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation of selected immunological and biochemical parameters of blood in alcohol dependency] Leksowski W, et al. **Psychiatr Pol** 1996 Mar–Apr;30(2):297–305 (Eng. Abstr.) **(Pol)**

[Serum lipid peroxides in alcoholic patients] Rosnowska M, et al. **Psychiatr Pol** 1995 Jul–Aug;29(4):539–46 (Eng. Abstr.) **(Pol)**

[The effect of electrotranquilization on the hormonal indices of alcoholic patients] Darenskiĭ ID, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):67–9 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Early–onset alcoholics have lower cerebrospinal fluid 5–hydroxyindoleacetic acid levels than late–onset alcoholics. Fils–Aime ML, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):211–6

CLASSIFICATION

Classification of alcoholics on the basis of plasma beta–endorphin concentration. Aguirre JC, et al. **Alcohol** 1995 Nov–Dec;12(6):531–4

Hon v. Stroh Brewery Company: what do we mean by "moderate" and "heavy" drinking? Abel EL, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1024–31

Prediction of 3–year outcome of treated alcoholics by an empirically derived multivariate typology. Yoshino A, et al. **Am J Psychiatry** 1996 Jun;153(6):829–30

Miscoding of mental health diagnoses and stigmatization [letter; comment] Devitt N. **Arch Fam Med** 1995 Nov; 4(11):917. Comment on: Arch Fam Med 1994 Apr;3(4):319–20.

Essential and reactive alcoholism: a review. Walker RD, et al. **J Clin Psychol** 1996 Jan;52(1):80–95 (39 ref.)

Problems in the application of the Addiction Severity Index (ASI) in rural substance abuse services. Wertz JS, et al. **J Subst Abuse** 1995;7(2):175–88

COMPLICATIONS

Alcoholic dyshaematopoiesis: morphological features of alcohol–induced bone marrow damage in biopsy sections compared with aspiration smears. Budde R, et al. **Acta Haematol** 1995;94(2):74–7

Malleolar fractures in alcoholics treated with biodegradable internal fixation. 6/16 reoperations in a randomized study. Kankare J, et al. **Acta Orthop Scand** 1995 Dec;66(6):524–8

Shoulder injuries common in alcoholics. An analysis of 413 injuries. Nordqvist A, et al. **Acta Orthop Scand** 1996 Aug; 67(4):364–6

Effects of moderate chronic alcoholism treatment on fertilization. Cebral E, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(3):147–53

Predictors of neuropsychological impairment in alcoholics: antisocial versus nonantisocial subtypes. Waldstein SR, et al. **Addict Behav** 1996 Jan–Feb;21(1):21–7

Alcoholic hypogonadism: hormonal response to clomiphene. Martínez–Riera A, et al. **Alcohol** 1995 Nov–Dec; 12(6):581–7

An unusual case of central pontine myelinolysis. Joseph AP, et al. **Alcohol Alcohol** 1995 Jul;30(4):423–5

Alcohol and road traffic accidents. Mayou R, et al. **Alcohol Alcohol** 1995 Nov;30(6):709–11

Parental history of alcoholism: a risk factor for alcohol–related peripheral neuropathies. Pessione F, et al. **Alcohol Alcohol** 1995 Nov;30(6):749–54

Assessment of zinc nutritional status of pellagra patients. Vannucchi H, et al. **Alcohol Alcohol** 1995 May; 30(3):297–302

Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease. Coelho–Little ME, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1173–6

Brain atrophy and cognitive function in older abstinent alcoholic men. Di Sclafani V, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1121–6

High diastolic blood pressure: common among women who are heavy drinkers. Seppä K, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):47–51

Interleukin 1 and tumor necrosis factor in obese alcoholics compared with normal–weight patients. Bunout D, et al. **Am J Clin Nutr** 1996 Mar;63(3):373–6

Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Ohnishi K, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1374–9

Evaluation of hypotheses on pathogenesis of alcoholic pancreatitis. Pitchumoni CS, et al. **Am J Gastroenterol** 1996 Apr;91(4):637–47 (121 ref.)

Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Rosman AS, et al. **Am J Gastroenterol** 1996 Mar;91(3):498–505 (67 ref.)

Occult GI bleeding in the alcoholic. Zwas FR, et al. **Am J Gastroenterol** 1996 Mar;91(3):551–3

Familial alcoholism in manic–depressive (bipolar) disease. Winokur G, et al. **Am J Med Genet** 1996 Apr 9;

67(2):197–201
Moderate prenatal alcohol exposure and psychomotor development at preschool age [see comments] Larroque B, et al. **Am J Public Health** 1995 Dec;85(12):1654–61. Comment in: Am J Public Health 1995 Dec;85(12):1614–5.
Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial. McGrath PJ, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):232–40
Alcohol-related problems in older persons. Determinants, consequences, and screening. Fink A, et al. **Arch Intern Med** 1996 Jun 10;156(11):1150–6 (76 ref.)
Alcohol and the nervous system. Lovell J. **Aust Fam Physician** 1995 Sep;24(9):1680–4
Attention-related brain potential and cognition in alcoholism-associated organic brain disorders. Eckardt MJ, et al. **Biol Psychiatry** 1996 Jan 15;39(2):143–6
Frequency of cholelithiasis in alcoholics. Oliveira LC, et al. **Braz J Med Biol Res** 1995 Jan;28(1):58–60
Vertebral fractures and osteopenia in chronic alcoholic patients. Peris P, et al. **Calcif Tissue Int** 1995 Aug; 57(2):111–4
Successful screening for early esophageal cancer in alcoholics using endoscopy and mucosa iodine staining [see comments] Yokoyama A, et al. **Cancer** 1995 Sep 15; 76(6):928–34. Comment in: Cancer 1996 Sep;76(6):919–21.
Multiple primary esophageal and concurrent upper aerodigestive tract cancer and the aldehyde dehydrogenase-2 genotype of Japanese alcoholics [published erratum appears in Cancer 1996 Aug 1;78(3):578] Yokoyama A, et al. **Cancer** 1996 May 15;77(10):1986–90
Severe alkalemia, hyponatremia, and diabetic ketoacidosis in an alcoholic man. Bustamante EA, et al. **Chest** 1996 Jul; 110(1):273–5
Recurrent left pleural effusion in a 44-year-old woman with a history of alcohol abuse. Iglesias JI, et al. **Chest** 1996 Aug;110(2):547–9
Alcohol, hypertension, coronary disease and stroke. Lip GY, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):189–94 (66 ref.)
Hypocalcaemia and chronic alcohol intoxication: transient hypoparathyroidism secondary to magnesium deficiency. Hermans C, et al. **Clin Rheumatol** 1996 Mar;15(2):193–6 (31 ref.)
Gender effects on the clinical presentation of alcoholics at a psychiatric hospital. Cornelius JR, et al. **Compr Psychiatry** 1995 Nov–Dec;36(6):435–40
Coexistence of subacute cutaneous lupus erythematosus and porphyria cutanea tarda: a case report. Camisa C, et al. **Cutis** 1995 Aug;56(2):101–3
Serum lipase and amylase ratio in acute alcoholic and nonalcoholic pancreatitis by using Dupont ACA discrete clinical analyzer. Ansari E, et al. **Dig Dis Sci** 1996 Sep; 41(9):1823–7
Role of salivary and seric epidermal growth factor in pathogenesis of reflux esophagitis in chronic alcoholics and nondrinkers. Benamouzig R, et al. **Dig Dis Sci** 1996 Aug; 41(8):1595–9
Comparison of post-ERCP biological pancreatitis in chronic alcoholic and control nonalcoholic group [letter] Hastier P, et al. **Dig Dis Sci** 1996 Mar;41(3):549
Deficiency in antioxidant factors in patients with alcohol-related chronic pancreatitis. Van Gossum A, et al. **Dig Dis Sci** 1996 Jun;41(6):1225–31
Drink and diet [news] **Environ Health Perspect** 1995 Jun; 103(6):542–3
Myoclonic alcoholic epilepsy. Bartolomei F, et al. **Epilepsia** 1996 Apr;37(4):406–9
Neurologic complications in patients with chronic alcohol dependance. Dosheva V. **Folia Med (Plovdiv)** 1995;37(4A Suppl):78
Various mechanisms of death and their possible association with alcoholism. Thomsen JL. **Forensic Sci Int** 1996 Jun 14;79(3):199–204
Atherosclerosis in alcoholics. Thomsen JL. **Forensic Sci Int** 1995 Oct 30;75(2–3):121–31
Course of alcoholic chronic pancreatitis: a prospective clinicomorphological long-term study [see comments] Ammann RW, et al. **Gastroenterology** 1996 Jul; 111(1):224–31. Comment in: Gastroenterology 1996 Jul;111(1):258–9.
Role of the necrosis-fibrosis sequence in the pathogenesis of alcoholic chronic pancreatitis [editorial; comment] Longnecker DS. **Gastroenterology** 1996 Jul;111(1):258–9. Comment on: Gastroenterology 1996 Jul;111(1):224–31.
High amplitude contractions in the middle third of the oesophagus: a manometric marker of chronic alcoholism? Grande L, et al. **Gut** 1996 May;38(5):655–62
Influence of alcohol abuse on recurrence after curative resection of hepatocellular carcinoma. Okada S, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):944–9
Prevalence of blood-borne viruses among intravenous drug users and alcoholics in Hiroshima, Japan. Ichimura H, et al. **Int J STD AIDS** 1995 Nov–Dec;6(6):441–3
Intercurrent complications in chronic alcoholic men admitted to the intensive care unit following trauma. Spies CD, et al. **Intensive Care Med** 1996 Apr;22(4):286–93
Mexiletine for painful alcoholic neuropathy. Nishiyama K, et al. **Intern Med** 1995 Jun;34(6):577–9
Alcoholic liver disease in alcoholic chronic pancreatitis: a prospective study. Gullo L, et al. **Ital J Gastroenterol** 1995 Mar;27(2):69–72
Enteral nutritional support in acute alcoholic pancreatitis. Simpson WG, et al. **J Am Coll Nutr** 1995 Dec;14(6):662–5
Alcohol consumption and risk of deep venous thrombosis and pulmonary embolism in older persons. Pahor M, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1030–7
Chronic alcoholism: an important condition in the dentist-patient relationship. Robb ND, et al. **J Dent** 1996 Jan–Mar;24(1–2):17–24 (45 ref.)
A long-term study of the interaction between iron and alcohol in an animal model of iron overload. Olynyk J, et al. **J Hepatol** 1995 Jun;22(6):671–6
Alcoholism: independent predictor of survival in patients with head and neck cancer. Deleyiannis FW, et al. **J Natl Cancer Inst** 1996 Apr 17;88(8):542–9
Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia. Hamera E, et al. **J Nerv Ment Dis** 1995 Sep;183(9):559–65
The frequency of alcoholism among patients with pain due to terminal cancer. Bruera E, et al. **J Pain Symptom Manage** 1995 Nov;10(8):599–603
Characterisation of the effects of alcohol use and abuse on the brain [letter] Lingford-Hughes A. **J R Soc Health** 1996 Apr;116(2):122–3
Alcohol abuse and stage of HIV disease in intravenous drug abusers. Lake-Bakaar G, et al. **J R Soc Med** 1996 Jul; 89(7):389–92
Development of a 'Charcot-like joint' in tophaceous gout. Laversuch CJ, et al. **J R Soc Med** 1995 Dec;88(12):713p–5p
Evaluation of macrocytosis by general practitioners. Seppä K, et al. **J Stud Alcohol** 1996 Jan;57(1):97–100
A man with alcoholism and HIV infection, 1 year later [comment] Delbanco TL, et al. **JAMA** 1996 Apr 3; 275(13):1029. Comment on: JAMA 1995 Sep 13;274(10):837–43.
Alcohol interventions in trauma centers. Current practice and future directions [see comments] Gentilello LM, et al. **JAMA** 1995 Oct 4;274(13):1043–8. Comment in: JAMA 1996 Feb 7;275(5):358. Comment in: JAMA 1996 Feb 7;275(5):358; discussion 358–9.
A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression [see comments] Mason BJ, et al. **JAMA** 1996 Mar 13;275(10):761–7. Comment in: JAMA 1996 Mar 13;275(10):803–4.
The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults. Moss M, et al. **JAMA** 1996 Jan 3;275(1):50–4
Treatment of alcoholism and nicotine dependence [letter] Zucker RS. **JAMA** 1996 Sep 11;276(10):783–4
Management of alcohol withdrawal [letter; comment] Gorelick DA. **Mayo Clin Proc** 1995 Dec;70(12):1224. Comment on: Mayo Clin Proc 1995 Aug;70(8):777–82.
Management of alcohol withdrawal [letter; comment] Strickland RA, et al. **Mayo Clin Proc** 1995 Dec;70(12):1224 . Comment on: Mayo Clin Proc 1995 Aug;70(8):777–82.
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-1995. A 72-year-old man with exertional dyspnea, fatigue, and extensive ecchymoses and purpuric lesions [clinical conference] [see comments] **N Engl J Med** 1995 Dec 21;333(25):1695–702 . Comment in: N Engl J Med 1996 Apr 18;334(16):1065.
Case 39-1995: scurvy [letter; comment] Bistrian BR. **N Engl J Med** 1996 Apr 18;334(16):1065. Comment on: N Engl J Med 1995 Dec 21;333(25):1695–702.
Images in clinical medicine. Osmotic myelinolysis. Hart BL, et al. **N Engl J Med** 1995 Nov 9;333(19):1259
Medical disorders of alcoholism [letter; comment] Meropol SB. **N Engl J Med** 1996 Feb 8;334(6):406. Comment on: N Engl J Med 1995 Oct 19;333(16):1058–65.
Case 39-1995: scurvy [letter; comment] O'Conner ME. **N Engl J Med** 1996 Apr 18;334(16):1065. Comment on: N Engl J Med 1995 Dec 21;333(25):1695–702.
An update on incidence of FAS: FAS is not an equal opportunity birth defect. Abel EL. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):437–43 (80 ref.)
Pain profile in alcoholic and nonalcoholic chronic pancreatitis (CP) [letter] Ammann RW. **Pancreas** 1996 Apr; 12(3):315–8
Natural histories of alcoholic and idiopathic chronic pancreatitis [letter] Layer PH, et al. **Pancreas** 1996 Apr; 12(3):318–20
Histopathologic study of coexistent pathologic states in pancreatic fibrosis in patients with chronic alcohol abuse: two distinct pathologic fibrosis entities with different mechanisms. Suda K, et al. **Pancreas** 1996 May;12(4):369–72
Cigarette smoking: an independent risk factor in alcoholic pancreatitis. Talamini G, et al. **Pancreas** 1996 Mar; 12(2):131–7
Multiple hepatic abscesses due to Yersinia enterocolitica. Strungs I, et al. **Pathology** 1995 Oct;27(4):374–7 (14 ref.)
Tuberculosis mortality associated with AIDS and drug or alcohol abuse: analysis of multiple cause-of-death data. White MC, et al. **Public Health** 1996 May;110(3):185–9
Chronic alcoholic myopathy: diagnostic clues and relationship with other ethanol-related diseases. Sacanella E, et al. **QJM** 1995 Nov;88(11):811–7
Alcohol dependence, smoking status, reproductive characteristics, and bone mineral density in premenopausal women. Clark K, et al. **Res Nurs Health** 1996 Oct; 19(5):399–408
Neuromyotonia in alcoholic patients with gastrectomy. Voiculescu V, et al. **Rom J Neurol Psychiatry** 1995 Jan–Mar;33(1):3–6
Chronic hepatitis C in alcoholic patients: prevalence, genotypes, and correlation to liver disease. Befrits R, et al. **Scand J Gastroenterol** 1995 Nov;30(11):1113–8
Mental disease in a forensic autopsy population of alcoholics. Thomsen JL. **Sci Justice** 1996 Apr–Jun;36(2):89–92
Alcohol intake in patients admitted acutely to a general medical unit. McKnight JA, et al. **Ulster Med J** 1995 Oct; 64(2):157–63
[Diagnosis and treatment of alcohol-induced somatic damage (editorial)] Hardt F. **Ugeskr Laeger** 1996 Aug 19; 158(34):4733 **(Dan)**
[Alcoholic ketoacidosis (see comments)] Holm EA, et al. **Ugeskr Laeger** 1995 Oct 23;157(43):5982–5 (Eng. Abstr.). Comment in: Ugeskr Laeger 1995 Dec 18;157(51):7156–7. **(Dan)**
[Alcoholic ketoacidosis (letter; comment)] Thomsen JL, et al. **Ugeskr Laeger** 1995 Dec 18;157(51):7156–7. Comment on: Ugeskr Laeger 1995 Oct 23;157(43):5982–5. **(Dan)**
[Is there a connection between alcoholism and the chance of traffic accidents? (see comments)] Korzec A, et al. **Ned Tijdschr Geneeskd** 1995 Oct 7;139(40):2020–3. Comment in: Ned Tijdschr Geneeskd 1995 Dec 30;139(52):2758. **(Dut)**
[Effect of the duration of chronic alcoholic pancreatitis on the severity of outbreaks of acute pancreatitis] Chemtob A, et al. **Gastroenterol Clin Biol** 1995 Aug–Sep; 19(8–9):664–7 (Eng. Abstr.) **(Fre)**
[Ileal malabsorption of vitamin B12 in the chronic alcoholics (letter)] Kaltenbach G, et al. **Gastroenterol Clin Biol** 1995 May;19(5):544–5 **(Fre)**
[Clinical, biological and developmental aspects of alcoholic ketoacidosis] Gaches F, et al. **Presse Med** 1996 Jun 8; 25(20):924–8 (Eng. Abstr.) **(Fre)**
[Clinical case of the month. Physiopathology, symptoms, complications and treatment of alcoholic ketoacidosis: apropos of a fatal case] Lambermont B, et al. **Rev Med Liege** 1996 Apr;51(4):266–9 **(Fre)**
[Epigastric symptoms and alcohol drinking in a mechanic] Swarovsky B, et al. **Internist (Berl)** 1995 Aug;36(8):828–32 **(Ger)**
[Vitamin B in human metabolism. Diabetic polyneuropathies. 3rd Hohenheimer symposium. November 11, 1992. Alcoholic neuropathies. Stuttgart, 3 June 1992] **Nervenarzt** 1993 Feb;64(2 Suppl):1–4 **(Ger)**
[Electrolyte disturbances and unconsciousness in a 63-year-old alcoholic patient (clinical conference)] Horber FF, et al. **Schweiz Rundsch Med Prax** 1996 Apr 23; 85(17):559–66 **(Ger)**
[Treatment of chronic alcoholic pancreatitis with a new acid-resistant pancreatin product] Kempelen I, et al. **Orv Hetil** 1995 Sep 17;136(38):2051–5 (Eng. Abstr.) **(Hun)**
[Influence of heavy drinking for the development of hepatocellular carcinoma in type C cirrhosis] Chiba T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:731–5 (23 ref.) **(Jpn)**
[Pancreatic ascites] Jasiński A, et al. **Pol Arch Med Wewn** 1995 Mar;93(3):253–5 (Eng. Abstr.) **(Pol)**
[Alcohol-smoking interaction in hepatic lesions] Borini P. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep–Oct; 50(5):259–63 (Eng. Abstr.) **(Por)**
[Cardiovascular impact of alcoholism] Faintuch JJ. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jan–Feb;50(1):76–9 (47 ref.) (Eng. Abstr.) **(Por)**
[Clinico-pathogenetic variants of chronic alcoholic gastritis] Kochegurov VN, et al. **Klin Med (Mosk)** 1995;73(6):65 **(Rus)**
[Acute intestinal infections and chronic alcoholism] Brodov LE, et al. **Ter Arkh** 1995;67(11):27–30 (Eng. Abstr.) **(Rus)**
[Toxic lesions of the optic nerve] Mozherenkov VP, et al. **Vestn Oftalmol** 1996 Jan–Mar;112(1):54–5 (32 ref.) **(Rus)**
[The dynamics of developmental disorders of the brain in fetuses obtained from mothers consuming alcohol during pregnancy (14- to 15-week-old fetuses)] Kovetskiĭ NS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(3):58–62 (Eng. Abstr.) **(Rus)**
[Cognitive deficits in alcoholics--significance of cognitive evoked potentials (P-300)] Mišić-Pavkov G, et al. **Med Pregl** 1995;48(11–12):388–90 (Eng. Abstr.) **(Scr)**
[Comorbidity of panic disorder and alcoholism in a sample of 100 alcoholic patients] Segui J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1994 May–Jun;22(3):137–42 (Eng. Abstr.) **(Spa)**
[Alcoholic patient with dyspnea and dental phlegmon] Capdevila E, et al. **Enferm Infecc Microbiol Clin** 1996 Mar; 14(3):195–7 **(Spa)**
[Alcoholic osteopenia: observations (letter)] García Sánchez A, et al. **Gastroenterol Hepatol** 1995 Oct;18(8):444–5 **(Spa)**
[Acute alcohol proximal (femoral) neuropathy] Uterga JM, et al. **Rev Neurol** 1995 Mar–Apr;23(120):454 **(Spa)**

CONGENITAL see FETAL ALCOHOL SYNDROME

DIAGNOSIS

Standardized patients as a measure of change in the ability of family physicians to detect and manage alcohol abuse. Lockyer J, et al. **Acad Med** 1996 Jan;71(1 Suppl):S1–3
Validity of the SCID in substance abuse patients. Kranzler HR, et al. **Addiction** 1996 Jun;91(6):859–68

ALCOHOLISM

The medical profile of unidentified problem drinkers in general practice: test of an hypothesis. Cornel M, et al. **Alcohol Alcohol** 1995 Sep;30(5):651–9

Longitudinal comparison of carbohydrate-deficient transferrin and gamma-glutamyl transferase: complementary markers of excessive alcohol consumption. Helander A, et al. **Alcohol Alcohol** 1996 Jan;31(1):101–7

Measuring and reporting the concentration of acetaldehyde in human breath. Jones AW. **Alcohol Alcohol** 1995 May; 30(3):271–85 (45 ref.)

The thyrotropin releasing hormone stimulation test in alcoholism. Pienaar WP, et al. **Alcohol Alcohol** 1995 Sep; 30(5):661–7

Carbohydrate-deficient transferrin evaluation in dry blood spots. Bean P, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):56–60

Gamma-glutamyltranspeptidase and carbohydrate deficient transferrin: alternative measures of excessive alcohol consumption. Litten RZ, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1541–6 (37 ref.)

Carbohydrate-deficient transferrin in alcohol and nonalcohol abusers with liver disease. Meregalli M, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1525–7

Preadolescent conduct disorder behaviors predict relapse and progression of addiction for adolescent alcohol and drug abusers. Myers MG, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1528–36

Carbohydrate-deficient transferrin as a marker of alcohol abuse: relationship to alcohol consumption, severity of liver disease, and fibrogenesis. Niemelä O, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1203–8

Beta-carbolines in chronic alcoholics undergoing elective tumor resection. Spies CD, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):969–76

Relationship between alcohol withdrawal seizures and temporal lobe white matter volume deficits. Sullivan EV, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):348–54

Use of ICD-9-CM codes in the estimation of alcohol-involved injury: search for a surrogate II. Treno AJ, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):320–6

Validity of the diagnostic interview schedule for detecting alcoholism in psychiatric inpatients. Goethe JW, et al. **Am J Drug Alcohol Abuse** 1995 Nov;21(4):565–71

A prospective endoscopic evaluation of the causes of upper GI hemorrhage in alcoholics: a focus on alcoholic gastropathy. Wilcox CM, et al. **Am J Gastroenterol** 1996 Jul;91(7):1343–7

Performance of alcoholism screening questionnaires in elderly veterans. Morton JL, et al. **Am J Med** 1996 Aug; 101(2):153–9

Diagnosis and treatment of drug and alcohol abuse in women. Kaufman E. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):21–7 (27 ref.)

A long-term follow-up of male alcohol abuse. Vaillant GE. **Arch Gen Psychiatry** 1996 Mar;53(3):243–9

A prospective follow-up study of alcoholic violent offenders and fire setters. Virkkunen M, et al. **Arch Gen Psychiatry** 1996 Jun;53(6):523–9

The electroencephalogram after alcohol administration in high-risk men and the development of alcohol use disorders 10 years later. Volavka J, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):258–63

Alcohol-related problems in older persons. Determinants, consequences, and screening. Fink A, et al. **Arch Intern Med** 1996 Jun 10;156(11):1150–6 (76 ref.)

Early identification, screening, and brief intervention for adolescent alcohol use. Werner MJ, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1241–8 (73 ref.)

Traumatic brain injury, alcohol and quantitative neuroimaging: preliminary findings. Bigler ED, et al. **Brain Inj** 1996 Mar;10(3):197–206

Identifying and managing problem drinkers. Kahan M. **Can Fam Physician** 1996 Apr;42:661–71 (59 ref.)

Alcohol risk assessment and intervention for family physicians. Project of the College of Family Physicians of Canada. Peters C, et al. **Can Fam Physician** 1996 Apr; 42:681–9 (31 ref.)

Validity of psychiatric diagnoses in patients with substance use disorders: is the interview more important than the interviewer? Kranzler HR, et al. **Compr Psychiatry** 1995 Jul–Aug;36(4):278–88

Clinical profile of comorbid major depression and alcohol use disorders in an initial psychiatric evaluation. Salloum IM, et al. **Compr Psychiatry** 1995 Jul–Aug;36(4):260–6

Features of cocaine dependence with concurrent alcohol abuse. Brady KT, et al. **Drug Alcohol Depend** 1995 Jul; 39(1):69–71

Decrease in alcohol tolerance: clinical significance in alcohol dependence. Ziółkowski M, et al. **Drug Alcohol Depend** 1995 Jul;39(1):33–6

Gender differences in medical presentation and detection of patients with a history of alcohol abuse or dependence. Amodei N, et al. **J Addict Dis** 1996;15(1):19–31

Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler HR. **J Clin Psychiatry** 1996;57 Suppl 7:15–21; discussion 22–4 (60 ref.)

Comparative concurrent validities of five alcoholism measures in a psychiatric hospital. Watson CG, et al. **J Clin Psychol** 1995 Sep;51(5):676–84

Do primary care physicians screen patients about alcohol intake using the CAGE questions? Wenrich MD, et al. **J Gen Intern Med** 1995 Nov;10(11):631–4

Anterior brain deficits in chronic alcoholism. Cause or effect? Ciesielski KT, et al. **J Nerv Ment Dis** 1995 Dec; 183(12):756–61

Life domains, alcoholics anonymous, and role incumbency in the 3-year course of problem drinking. Humphreys K, et al. **J Nerv Ment Dis** 1996 Aug;184(8):475–81

Reliability of individual diagnostic criterion items for psychoactive substance dependence and the impact on diagnosis. Bucholz KK, et al. **J Stud Alcohol** 1995 Sep; 56(5):500–5

Patterns of DSM-IV alcohol abuse and dependence symptoms in adolescent drinkers. Martin CS, et al. **J Stud Alcohol** 1995 Nov;56(6):672–80

A study examining the psychometric properties of the SMAST-13. Short Michigan Alcoholism Screening Test. Fleming MF, et al. **J Subst Abuse** 1988–89;1(2):173–82

The relationship between ethanol intake and DSM-III alcohol use disorders: a cross-perspective analysis. Grant BF, et al. **J Subst Abuse** 1988–89;1(2):231–52

Evaluating students' substance abuse assessment skills. Murphy SA, et al. **J Subst Abuse** 1995;7(3):357–64

DSM-III-R alcohol dependence criteria in Russian and American men. Zanis DA, et al. **J Subst Abuse** 1995; 7(2):253–61

Carbohydrate-deficient transferrin for identification of drug overdose patients at risk of an alcohol withdrawal syndrome. Köppel C, et al. **J Toxicol Clin Toxicol** 1996; 34(3):297–300

Unusual cause of hypotension associated with penetrating trauma. Ma OJ, et al. **J Trauma** 1996 Jan;40(1):161–4

Recognising drug and alcohol problems in patients referred to consultation-liaison psychiatry. Smith GC, et al. **Med J Aust** 1995 Sep 18;163(6):307, 310–2

Psychiatric diagnoses in North Carolina Physicians Health Program participants. Betts WC. **N C Med J** 1996 Jul–Aug; 57(4):214–5

Self-reported effects of alcohol use on symptoms of schizophrenia. Pristach CA, et al. **Psychiatr Serv** 1996 Apr; 47(4):421–3

Patterns of DSM-III-R alcohol dependence symptom progression in a general population survey. Nelson CB, et al. **Psychol Med** 1996 May;26(3):449–60

Improving identification of and intervention for alcoholism. Mehler PS, et al. **West J Med** 1995 Oct;163(4):335–40

[How much does my patient drink?] Poikolainen K. **Duodecim** 1994;110(9):870–6 (34 ref.) **(Fin)**

[Who has alcoholic liver disease?] Salaspuro M. **Duodecim** 1994;110(20):1895–900 (22 ref.) **(Fin)**

[Carbohydrate-deficient transferrin and liver diseases. Study of 94 patients] Ouyahya F, et al. **Gastroenterol Clin Biol** 1995 Aug–Sep;19(8–9):698–702 (Eng. Abstr.) **(Fre)**

[Detection of alcoholism in the medical office: applicability of the CAGE questionnaire by the practicing physician. Group of Medical Practitioners PMU] Perdrix A, et al. **Schweiz Med Wochenschr** 1995 Sep 23;125(38):1772–8 (Eng. Abstr.) **(Fre)**

[Experiences after 2 years observation of a chronic alcoholic] Schmidt G, et al. **Blutalkohol** 1995 Sep;32(5):268–73 (Eng. Abstr.) **(Ger)**

[Changes in platelet adenylyl cyclase system in alcoholics] Katamura Y, et al. **Arukoru Kenkyuto Yakubutsu Ison** 1996 Apr;31(2):164–76 (Eng. Abstr.) **(Jpn)**

[Diagnostic importance of analyzing the expired air in alcoholism] Iakovchenko VA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):60–2 (Eng. Abstr.) **(Rus)**

[Evaluation of the efficacy of naltrexone in alcoholism by the determination of serum carbohydrate-deficient transferrin] Martinez Ruiz M, et al. **An Med Interna** 1995 Dec;12(12):589–92 (Eng. Abstr.) **(Spa)**

[Detection and intervention in excessive alcohol consumption (letter)] Delgado MT, et al. **Med Clin (Barc)** 1996 Mar 30;106(12):477–8 **(Spa)**

DIET THERAPY

Influence of an n-6 polyunsaturated fatty acid-enriched diet on the development of tolerance during chronic ethanol administration in rats. Meehan E, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1441–6

DRUG THERAPY

Clinical physiological study of the therapeutic effects of phenytoin in acute alcohol withdrawal and the asthenic-autonomic syndrome in patients with chronic alcoholism. Ilyuchina VA, et al. **Alcohol** 1995 Nov–Dec; 12(6):511–7

Acamprosate as an aid in the treatment of alcoholism. Chick J. **Alcohol Alcohol** 1995 Nov;30(6):785–7 (17 ref.)

How to get the best out of antabuse. Kristenson H. **Alcohol Alcohol** 1995 Nov;30(6):775–83 (47 ref.)

The pharmacological treatment of alcoholism: from basic science to clinical medicine. Verbanck PM. **Alcohol Alcohol** 1995 Nov;30(6):757–64 (81 ref.)

Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Volpicelli JR, et al. **Alcohol Alcohol** 1995 Nov;30(6):789–98 (42 ref.)

Experience of a "slip" among alcoholics treated with naltrexone or placebo. O'Malley SS, et al. **Am J Psychiatry** 1996 Feb;153(2):281–3

Long-term antidepressant treatments alter 5-HT2A and 5-HT2C receptor-mediated hyperthermia in Fawn-Hooded rats. Aulakh CS, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):65–70

Effect of pyrrolidone carboxylate (PCA) and pyridoxine on liver metabolism during chronic ethanol intake in rats. Calabrese V, et al. **Int J Tissue React** 1995;17(1):15–20

Effect of L-propionyl carnitine on some properties of erythrocytes and leukocytes of alcohol abusers. Conte A, et al. **Int J Tissue React** 1995;17(1):21–31

The use of sodium valproate in the treatment of alcoholism. Minuk GY, et al. **J Addict Dis** 1995;14(2):67–74

Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. Brady KT, et al. **J Clin Psychiatry** 1995 Nov;56(11):502–5

Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler HR. **J Clin Psychiatry** 1996;57 Suppl 7:15–21; discussion 22–4 (60 ref.)

Treating depression in alcoholics. Douglas MB, et al. **J Fam Pract** 1996 Jun;42(6):565–6

Current treatment for alcohol withdrawal [editorial] Hyman SE. **J Gen Intern Med** 1995 Sep;10(9):523–4

Alcohol withdrawal: a nationwide survey of inpatient treatment practices. Saitz R, et al. **J Gen Intern Med** 1995 Sep;10(9):479–87

Evidence for prolonged recovery of dopaminergic transmission after detoxification in alcoholics with poor treatment outcome. Heinz A, et al. **J Neural Transm Gen Sect** 1995;102(2):149–57

A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression [see comments] Mason BJ, et al. **JAMA** 1996 Mar 13;275(10):761–7. Comment in: JAMA 1996 Mar 13;275(10):803–4.

Naltrexone in alcohol dependence [letter] Brewer C. **Lancet** 1995 Nov 18;346(8986):1374

Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Whitworth AB, et al. **Lancet** 1996 May 25;347(9013):1438–42

Bromocriptine in the treatment of alcoholics [letter; comment] Goldman D. **Nat Med** 1995 Aug;1(8):720–1. Comment on: Nat Med 1995 Apr;1(4):337–41.

Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele [see comments] Lawford BR, et al. **Nat Med** 1995 Apr;1(4):337–41. Comment in: Nat Med 1995 Aug;1(8):720–1.

Strategies to maximize the efficacy of naltrexone for alcohol dependence. O'Malley SS. **NIDA Res Monogr** 1995; 150:53–64

Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. Cornelius JR, et al. **Psychopharmacol Bull** 1995;31(2):297–303

The utility of diazepam loading in the treatment of alcohol withdrawal among psychiatric inpatients. Salloum IM, et al. **Psychopharmacol Bull** 1995;31(2):305–10

[What is used as a drug for problem drinking?] Heinälä P, et al. **Duodecim** 1995;111(8):761–8 (30 ref.) **(Fin)**

[Disulfiram therapy] Widenius T, et al. **Duodecim** 1994; 110(2):153–8 (10 ref.) **(Fin)**

[Does acamprosate deminish the appetite for alcohol in weaned alcoholics?] Roussaux JP, et al. **J Pharm Belg** 1996 Mar–Apr;51(2):65–8 (Eng. Abstr.) **(Fre)**

[The action of medichronal (glucose-glycine-formate) on the serotonin blood level in alcoholism patients] Bozhko GKh, et al. **Lik Sprava** 1995 May–Jun;(5–6):130–2 (Eng. Abstr.) **(Rus)**

[The use of a decoction of the rhizome of Leuzea carthamoides for the treatment of alcoholics with depressive states] Ibatov AN. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):78–9 (Eng. Abstr.) **(Rus)**

[Effect of pharmacotherapy of affective disorders on the psycho-semantics of alcoholic patients] Krupitskiĭ EM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(6):67–71 (Eng. Abstr.) **(Rus)**

[Evaluation of the efficacy of naltrexone in alcoholism by the determination of serum carbohydrate-deficient transferrin] Martinez Ruiz M, et al. **An Med Interna** 1995 Dec;12(12):589–92 (Eng. Abstr.) **(Spa)**

ECONOMICS

The economic costs of alcohol-related absenteeism and reduced productivity among the working population of New Zealand. Jones S, et al. **Addiction** 1995 Nov; 90(11):1455–61

Ethics, funding and alcohol research. Plant M, et al. **Alcohol Alcohol** 1996 Jan;31(1):17–25

[Alcohol drinking--problems in assessing the public economic impact] Neumann M, et al. **Fortschr Med** 1995 Nov 30;113(33):476–9 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Effects of various cytochrome P-450 inducers on testosterone metabolism and several monooxygenase activities in Sprague-Dawley (SpD), high alcohol sensitivity (HAS) and low alcohol sensitivity (LAS) rats. Duffy O, et al. **Alcohol Alcohol** 1995 May;30(3):329–35

Changes in the ileal disaccharidase activities in rats after long-term ethanol feeding. Rodriguez-Castilla J, et al. **Alcohol Alcohol** 1996 Jan;31(1):69–74

Cytochrome P-450 2E1 in rat liver, kidney and lung

microsomes after chronic administration of ethanol either orally or by inhalation. Zerilli A, et al. **Alcohol Alcohol** 1995 May;30(3):357–65

Reduced fatty acid ethyl ester synthase activity in the white blood cells of alcoholics. Gorski NP, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):268–74

Effects of long-term alcohol intake on ADP ribosylation in rat liver plasma membranes. Nomura F, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):60A–62A

Effect of chronic ethanol consumption on the activities of residual small bowel brush-border enzymes after proximal jejunum resection in the rat. Zucoloto S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):152–5

Monoamine oxidases and alcoholism. I. Studies in unrelated alcoholics and normal controls. Parsian A, et al. **Am J Med Genet** 1995 Oct 9;60(5):409–16

Platelet monoamine oxidase activity levels in subgroups of alcoholics: diagnostic, temporal, and clinical correlates. Anthenelli RM, et al. **Biol Psychiatry** 1995 Sep 15; 38(6):361–8

Increased levels of alcohol markers (gamma GT, MCV, ASAT, ALAT) in older patients are not related to high alcohol intake [letter] Mowé M, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1136–7

Personality disorders according to DSM-III-R and thrombocyte monoamine oxidase activity in type 1 and type 2 alcoholics. Hallman J, et al. **J Stud Alcohol** 1996 Mar; 57(2):155–61

Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Lucas D, et al. **Pharmacogenetics** 1995 Oct;5(5):298–304

[Class I and II alcohol dehydrogenase isoenzymes as biochemical markers of alcoholism] Chrostek L, et al. **Psychiatr Pol** 1996 Mar–Apr;30(2):321–9 (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Alcohol-related problems in primary care patients in Nigeria. Abiodun OA. **Acta Psychiatr Scand** 1996 Apr;93(4):235–9

Manic depressive (bipolar) disorder [letter; comment] Petri ML. **Acta Psychiatr Scand** 1995 Nov;92(5):398. Comment on: Acta Psychiatr Scand 1994 Feb;89(2):102–10.

To what extent is female alcohol dependence and abuse known in the health care system? The use of multi-source information in a Swedish population survey. Spak F. **Acta Psychiatr Scand** 1996 Feb;93(2):87–91

A nationwide representative sample of treatment-seeking alcoholics: a study of psychiatric comorbidity. Tómasson K, et al. **Acta Psychiatr Scand** 1995 Nov;92(5):378–85

Condom use among gay/bisexual male substance abusers using the timeline follow-back method. Crosby GM, et al. **Addict Behav** 1996 Mar–Apr;21(2):249–57

Combining methods to identify new measures of women's drinking problems. Part I: The ethnographic stage. Ames G, et al. **Addiction** 1996 Jun;91(6):829–44

The AUDIT questionnaire: choosing a cut-off score. Alcohol Use Disorder Identification Test. Conigrave KM, et al. **Addiction** 1995 Oct;90(10):1349–56

Potential consequences from possible changes to Nordic retail alcohol monopolies resulting from European Union membership. Holder HD, et al. **Addiction** 1995 Dec; 90(12):1603–18

Heavy drinking in the restaurant business: the role of social modelling and structural factors of the work-place. Kjaerheim K, et al. **Addiction** 1995 Nov;90(11):1487–95

Are males actually heavier drinkers than females? [letter] Lo CC, et al. **Addiction** 1995 Nov;90(11):1547–50

Combining methods to identify new measures of women's drinking problems. Part II: The survey stage. Saltz R, et al. **Addiction** 1996 Jul;91(7):1041–51

Prevalence of female alcohol dependence and abuse in Sweden. Spak F, et al. **Addiction** 1995 Aug;90(8):1077–88

A profile of alcohol and drug misusers in an Arab community [letter] Younis YO, et al. **Addiction** 1995 Dec;90(12):1683–4

Female prostitutes in south London: use of heroin, cocaine and alcohol, and their relationship to health risk behaviours. Gossop M, et al. **AIDS Care** 1995;7(3):253–60

Prevalence of alcohol and illicit drug use by expectant mothers. Jacob J, et al. **Alaska Med** 1995 Jul–Sep;37(3):83–7

A good man's fault: alcohol and Irish people at home and abroad. Greenslade L, et al. **Alcohol Alcohol** 1995 Jul; 30(4):407–17

Women alcoholics—social, demographic and clinical characteristics in a Brazilian sample. Hochgraf PB, et al. **Alcohol Alcohol** 1995 Jul;30(4):427–32

The association between alcohol consumption and suicide and homicide rates: a study of 13 nations. Lester D. **Alcohol Alcohol** 1995 Jul;30(4):465–8

Prevalence of alcohol problems among adult somatic in-patients in Naples. Rambaldi A, et al. **Alcohol Alcohol** 1995 Jul;30(4):441–8

Retrospective self-report of alcohol consumption: test-retest reliability by telephone. Cohen BB, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1156–61

Beverage effects on patterns of alcohol consumption. Del Rio C, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1583–6

Alcohol and substance use among Japanese high school students. Matsushita S, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):379–83

Human immunodeficiency virus-type 1 infection in an inner-city alcohol treatment program. Schleifer SJ, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):75–80

Alcohol and other drug use among Hispanics in New York State. Welte JW, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):1061–6

Drinking patterns and health status in smoking and nonsmoking alcoholics. York JL, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):666–73

Style, consumption, and problem drinking: a measurement model. Yu J. **Alcohol Clin Exp Res** 1995 Oct;19(5):1192–7

Alcohol abuse in urban Indian adolescents and women: a longitudinal study for assessment and risk evaluation. Walker RD, et al. **Am Indian Alsk Native Ment Health Res** 1996;7(1):1–47; discussion 48–97

Liability to alprazolam abuse in daughters of alcoholics. Ciraulo DA, et al. **Am J Psychiatry** 1996 Jul;153(7):956–8

Relationship between alcohol problems and anxiety disorders [letter; comment] Kushner MG. **Am J Psychiatry** 1996 Jan; 153(1):139–40. Comment on: Am J Psychiatry 1994 Dec;151(12):1723–34.

Disproportionate lethality in psychiatric patients with concurrent alcohol and cocaine abuse. Salloum IM, et al. **Am J Psychiatry** 1996 Jul;153(7):953–5

Anorexia nervosa and bulimia nervosa in alcohol-dependent men and women and their relatives. Schuckit MA, et al. **Am J Psychiatry** 1996 Jan;153(1):74–82

Alcohol consumption among the elderly in a general population, Erie County, New York. Mirand AL, et al. **Am J Public Health** 1996 Jul;86(7):978–84

Substance use among schizophrenic outpatients: prevalence, course, and relation to functional status. Chouljian TL, et al. **Ann Clin Psychiatry** 1995 Mar;7(1):19–24

How much alcohol in Western Australia is consumed in a 'hazardous' or 'harmful' way? [letter] Oddy W, et al. **Aust J Public Health** 1995 Aug;19(4):434

Drug and alcohol problems among individuals with severe mental illness in south London. Menezes PR, et al. **Br J Psychiatry** 1996 May;168(5):612–9

Verbal creativity, depression and alcoholism. An investigation of one hundred American and British writers. Post F. **Br J Psychiatry** 1996 May;168(5):545–55

Interrelationships between crime, substance abuse, and aggressive behaviours among persons with traumatic brain injury. Kreutzer JS, et al. **Brain Inj** 1995 Nov–Dec; 9(8):757–68

Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey. Grant BF, et al. **Drug Alcohol Depend** 1995 Oct;39(3):197–206

The Alcohol Use Disorder and Associated Disabilities Interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. Grant BF, et al. **Drug Alcohol Depend** 1995 Jul;39(1):37–44

Socio-demographic correlates and pattern of drug abuse in eastern Saudi Arabia. Hafeiz HB. **Drug Alcohol Depend** 1995 Jun;38(3):255–9

Cannabis use in a drug and alcohol clinic population. McBride AJ. **Drug Alcohol Depend** 1995 Jul;39(1):29–32

DSM-III-R alcohol abuse and dependence and psychiatric comorbidity in Ontario: results from the Mental Health Supplement to the Ontario Health Survey. Ross HE. **Drug Alcohol Depend** 1995 Aug;39(2):111–28

Personality antecedents of alcoholism in a national area probability sample. Cloninger CR, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(4–5):239–44

Mental health problems and alcohol abuse: co-occurrence and gender differences. O'Hare T. **Health Soc Work** 1995 Aug;20(3):207–14

Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Adams PC, et al. **Hepatology** 1996 Apr;23(4):724–7

Public health. Alcoholism in the elderly [news] **Hosp Health Netw** 1995 Oct 20;69(20):12

Substance involvement among juvenile murderers: comparisons with older offenders based on interviews with prison inmates. Fendrich M, et al. **Int J Addict** 1995 Sep; 30(11):1363–82

Adolescent drug misuse treatment and use of medical care services. Freeborn DK, et al. **Int J Addict** 1995 May; 30(7):795–822

Prevalence of abuse and dependency in chronic pain patients. Hoffmann NG, et al. **Int J Addict** 1995 Jun;30(8):919–27

Substance misuse in individuals with spinal cord injury. Radnitz CL, et al. **Int J Addict** 1995 Jul;30(9):1117–40 (50 ref.)

The effect of alcohol and substance abuse on the course of bipolar affective disorder. Feinman JA, et al. **J Affect Disord** 1996 Feb 12;37(1):43–9

Predictors of comorbid alcohol and substance abuse in depressed adolescents. King CA, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):743–51

Psychiatric comorbidity with problematic alcohol use in high school students. Rohde P, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):101–9

A brief screening instrument for assessing parental alcoholism in college student populations. Vail-Smith K, et al. **J Am Coll Health** 1996 Jan;44(4):151–6

Alcohol use in retirement communities. Adams WL. **J Am Geriatr Soc** 1996 Sep;44(9):1082–5

Benzodiazepine use in anxiety disordered patients with and without a history of alcoholism. Mueller TI, et al. **J Clin Psychiatry** 1996 Feb;57(2):83–9

Prevalence estimates of alcohol problems in a Veterans Administration outpatient population: AUDIT vs. MAST. Luckie LF, et al. **J Clin Psychol** 1995 May;51(3):422–5

Prevalence of drugs and alcohol in autopsied homicide cases in St. John Parish, Louisiana. Clark TA. **J La State Med Soc** 1996 Jun;148(6):257–9

Alcohol consumption among older urban American Indians [see comments] Barker JC, et al. **J Stud Alcohol** 1996 Mar; 57(2):119–24. Comment in: J Stud Alcohol 1996 Mar;57(2):117–8.

Analysis of cut points for screening instruments for alcohol problems in the emergency room. Cherpitel CJ. **J Stud Alcohol** 1995 Nov;56(6):695–700

Influence of alcoholism on the prognosis of schizophrenic patients. Kozarić-Kovačić D, et al. **J Stud Alcohol** 1995 Nov;56(6):622–7

Cycles of alcohol dependence: frequency-domain analyses of daily drinking logs for matched alcohol-dependent and nondependent subjects. Mundt JC, et al. **J Stud Alcohol** 1995 Sep;56(5):491–9

Intraclass correlation among measures related to alcohol use by young adults: estimates, correlates and applications in intervention studies. Murray DM, et al. **J Stud Alcohol** 1995 Nov;56(6):681–94

Seasonal variation in alcohol use. Uitenbroek DG. **J Stud Alcohol** 1996 Jan;57(1):47–52

Alcohol and older American Indians [editorial; comment] Westermeyer J. **J Stud Alcohol** 1996 Mar;57(2):117–8. Comment on: J Stud Alcohol 1996 Mar;57(2):119–24.

Subgroup variation in U.S. drinking patterns: results of the 1992 national longitudinal alcohol epidemiologic study. Dawson DA, et al. **J Subst Abuse** 1995;7(3):331–44

AA and other helpseeking for alcohol problems: former drinkers in the U.S. general population. Hasin DS, et al. **J Subst Abuse** 1995;7(3):281–92

Alcohol availability and alcoholism. Bondy S. **JAMA** 1995 Dec 20;274(23):1832

P300 amplitudes vary inversely with continuum of risk in first degree male relatives of alcoholics. Benegal V, et al. **Psychiatr Genet** 1995 Winter;5(4):149–56

Substance abuse and lifestyle among an urban schizophrenic population: some observations. Cohen E, et al. **Psychiatry** 1995 May;58(2):113–20

The role of drug and alcohol abuse in recent increases in depression in the US. Klerman GL, et al. **Psychol Med** 1996 Mar;26(2):343–51

Alcohol use among American Indian adolescents: the role of culture in pathological drinking. O'Nell TD, et al. **Soc Sci Med** 1996 Feb;42(4):565–78

Regional analyses of alcohol and suicide in Norway: some empirical considerations. Rossow I. **Suicide Life Threat Behav** 1995 Fall;25(3):401–9

The relationship between college females' drinking and their sexual behaviors. Piombo M, et al. **Womens Health Issues** 1996 Jul–Aug;6(4):221–8

[Drunkenness in traffic in Geneva: occasional abuse or alcoholism?] Michiels W, et al. **Soz Praventivmed** 1996; 41(1):28–35 (Eng. Abstr.) **(Fre)**

[Alcoholism as a social problem. The alcoholic patient in a permissive societies—possibilities for prevention] Stosberg K. **Fortschr Med** 1995 Dec 10;113(34):490–4 (Eng. Abstr.) **(Ger)**

[Psychiatric disorders in hospitalized internal medicine and surgical patients. Prevalence and need for treatment] Arolt V, et al. **Nervenarzt** 1995 Sep;66(9):670–7 (Eng. Abstr.) **(Ger)**

[Construction and validation of an indicator for alcohol problems in the Swiss Health Survey] Frick U, et al. **Soz Praventivmed** 1996;41(3):133–42 (Eng. Abstr.) **(Ger)**

[Survey of alcohol drinking and results of studies of alcoholism biological markers within the scope of a neurologic occupational medicine study of industrial workers] Reinhardt F, et al. **Versicherungsmedizin** 1996 Jun 1;48(3):101–3 (Eng. Abstr.) **(Ger)**

[Sociodemographic and epidemiologic characteristics of hospitalized alcoholics in Vojvodina] Saponja N, et al. **Med Pregl** 1996;49(3–4):119–24 (Eng. Abstr.) **(Scr)**

[Comorbidity in panic disorders and alcoholism (II). Alcoholism in a sample of 148 patients with panic disorders] Segui J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov–Dec;23(6):288–92 (Eng. Abstr.) **(Spa)**

[The age of onset of alcohol-related problems as a prognostic factor in abstinence in patients admitted to a general hospital] Rubio Valladolid G, et al. **Rev Clin Esp** 1995 Dec; 195(12):820–4 (Eng. Abstr.) **(Spa)**

[Abuse of alcohol and central nervous system stimulants. A growing problem in developing countries] Eide AH, et al. **Lakartidningen** 1995 Nov 29;92(48):4569–71 (31 ref.) **(Swe)**

ETHNOLOGY

Ethnic differences in the biological consequences of alcohol abuse: a comparison between south Asian and European males. Wickramasinghe SN, et al. **Alcohol Alcohol** 1995 Sep;30(5):675–80

Ethnic differences in performance of screening instruments for identifying harmful drinking and alcohol dependence in the emergency room. Cherpitel CJ, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):628–34

Relationships between socioeconomic status and drinking problems among black and white men. Jones-Webb RJ, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):623–7

Alcoholism, hepatitis B and C viral infections, and impaired

liver function among Taiwanese aboriginal groups. Shen CY, et al. **Am J Epidemiol** 1996 May 1;143(9):936–42

Association of monoamine oxidase A alleles with alcoholism among male Chinese in Taiwan. Hsu YP, et al. **Am J Psychiatry** 1996 Sep;153(9):1209–11

Racial effects on the clinical presentation of alcoholics at a psychiatric hospital. Cornelius JR, et al. **Compr Psychiatry** 1996 Mar–Apr;37(2):102–8

Alcoholism in Ghana--a socio-cultural exploration. Akyeampong E. **Cult Med Psychiatry** 1995 Jun; 19(2):261–80

The role of gender and acculturation on determining the consumption of alcoholic beverages among Mexican-Americans and Central Americans in the United States. Marín G, et al. **Int J Addict** 1995 May;30(7):779–94

Changes in drinking patterns among whites, blacks and Hispanics, 1984–1992. Caetano R, et al. **J Stud Alcohol** 1995 Sep;56(5):558–65

Causes of alcoholism: a qualitative study of traditional Muscogee (Creek) Indians. Wing DM, et al. **Public Health Nurs** 1995 Dec;12(6):417–23

Alcoholism in the United States. Racial and ethnic considerations. **Rep Group Adv Psychiatry** 1996;(141):vii–x, 1–111

ETIOLOGY

Alcoholism: the role of different motivational systems. Pihl RO, et al. **J Psychiatry Neurosci** 1995 Nov;20(5):372–96 (205 ref.)

Causes of alcoholism: a qualitative study of traditional Muscogee (Creek) Indians. Wing DM, et al. **Public Health Nurs** 1995 Dec;12(6):417–23

[Functional significance of diazepam binding inhibitor (DBI) in establishment of alcohol dependence] Katsura M, et al. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):217–27 (50 ref.) (Eng. Abstr.) **(Jpn)**

[The effect of combined toxicity on the development of alcoholic pancreatic lesions. A long-term experimental trial] Peneda J, et al. **Acta Med Port** 1995 Mar;8(3):137–43 (Eng. Abstr.) **(Por)**

[Interdepartmental division of functional biochemistry] Synyts'kyi VM. **Ukr Biokhim Zh** 1995 May–Jun; 67(3):129–32 (Eng. Abstr.) **(Ukr)**

GENETICS

Family history of alcoholism and psychiatric co-morbidity in Brazilian male alcoholics and controls. Araujo NP, et al. **Addiction** 1995 Sep;90(9):1205–11

Alcohol and drug problems: a multivariate behavioural genetic analysis of co-morbidity. Jang KL, et al. **Addiction** 1995 Sep;90(9):1213–21

Time course and genetic variation in the regulation of calcium channel antagonist binding sites in rodent tissues during the induction of ethanol physical dependence and withdrawal. Guppy LJ, et al. **Alcohol Alcohol** 1995 Sep; 30(5):607–15

Chronic ethanol consumption alters effects of ethanol in vitro on brain membrane structure of high alcohol sensitivity and low alcohol sensitivity rats. Avdulov NA, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):886–91

Task persistence after alcohol consumption among children of alcoholics. Baer JS, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):955–60

A strategy for the identification of candidate genes for alcohol-related phenotypes and other human disorders using rapid polymerase chain reaction mapping of gene-based sequence-tagged sites. Berry R, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):821–3

Strategies for mapping and identifying quantitative trait loci specifying behavioral responses to alcohol. Buck KJ. **Alcohol Clin Exp Res** 1995 Aug;19(4):795–801 (57 ref.)

Cytochrome P4502E1 genotypes, alcoholism, and alcoholic cirrhosis in Han Chinese and Atayal Natives of Taiwan. Carr LG, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):43–6

Effect of diazepam on plasma gamma-aminobutyric acid in sons of alcoholic fathers. Cowley DS, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):343–7

Classical and neoclassical approaches to the genetic analysis of alcohol-related phenotypes. Dudek BC, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):802–10

EEG dimension in sons of alcoholics. Ehlers CL, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):992–8

Thyrotropin and prolactin responses to thyrotropin-releasing hormone in young men at high or low risk for alcoholism. Garbutt JC, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1133–40

Identifying alcoholism vulnerability alleles. Goldman D. **Alcohol Clin Exp Res** 1995 Aug;19(4):824–31 (71 ref.)

Event-related potentials in alcoholic men, their high-risk male relatives, and low-risk male controls. Hill SY, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):567–76

CYP2E1 and ALDH2 genotypes and alcohol dependence in Japanese. Iwahashi K, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):564–6

Indicators of genetic and environmental influence in alcohol-dependent individuals. Johnson EO, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):67–74

GABAA receptor function and binding in stably transfected cells: chronic ethanol treatment. Klein RL, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1338–44

Family history of alcoholism and the mediation of alcohol intake by catalase: further evidence for catalase as a marker of the propensity to ingest alcohol. Koechling UM, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1096–104

Behavioral effects and pharmacokinetics of propofol in rats selected for differential ethanol sensitivity. Liu Y, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):874–8

Association between low contents of dopamine and serotonin in the nucleus accumbens and high alcohol preference. McBride WJ, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1420–2

Alcohol sensitivity and smoking history in men and women. Madden PA, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1111–20

Alcohol-metabolizing enzyme polymorphisms and alcoholism in Japan. Maezawa Y, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):951–4

Association of restriction fragment-length polymorphisms in the alcohol dehydrogenase 2 gene with alcoholic brain atrophy. Maezawa Y, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):29A–32A

Characteristics of Japanese alcoholics with the atypical aldehyde dehydrogenase 2*2. I. A comparison of the genotypes of ALDH2, ADH2, ADH3, and cytochrome P-4502E1 between alcoholics and nonalcoholics. Nakamura K, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):52–5

Mitochondrial aldehyde dehydrogenase polymorphism in Asian and American Indian populations: detection of new ALDH2 alleles. Novoradovsky A, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1105–10

Association of alcoholism with the N-glycosylation polymorphism of pseudodeficient human arylsulfatase A. Park DS, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):228–33

Structural characterization of variant forms of arylsulfatase A that associate with alcoholism. Park DS, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):234–9

A simple auditory oddball task in young adult males at high risk for alcoholism. Ramachandran G, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):9–15

Use of lymphocytes for assessing ethanol-mediated alterations in the expression of hepatic cytochrome P4502E1. Raucy JL, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1369–75

Comparison of direct interview and family history diagnoses of alcohol dependence. Rice JP, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1018–23

Bidirectional selective breeding for ethanol effects on locomotor activity: characterization of FAST and SLOW mice through selection generation 35. Shen EH, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1234–45

Is alcohol-related flushing a protective factor for alcoholism in Caucasians? Slutske WS, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):582–92

Ethanol's action on the GABAA receptor: is there a requirement for parsimony? Tabakoff B. **Alcohol Clin Exp Res** 1995 Dec;19(6):1597–8

Effect of the cytochrome P-450IIE1 genotype on ethanol elimination rate in alcoholics and control subjects. Ueno Y, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):17A–21A

Use of transgenics, null mutants, and antisense approaches to study ethanol's actions. Wehner JM, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):811–20 (79 ref.)

Aldehyde dehydrogenase activities in the brains of rats and mice genetically selected for different sensitivity to alcohol. Zimatkin SM, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1300–6

Relationship of genetically transmitted alpha EEG traits to anxiety disorders and alcoholism. Enoch MA, et al. **Am J Med Genet** 1995 Oct 9;60(5):400–8

Screening the dopamine D1 receptor gene in 131 schizophrenics and eight alcoholics: identification of polymorphisms but lack of functionally significant sequence changes. Liu Q, et al. **Am J Med Genet** 1995 Apr 24; 60(2):165–71

Association and linkage studies of the TAQI A1 allele at the dopamine D2 receptor gene in samples of female and male alcoholics [see comments] Neiswanger K, et al. **Am J Med Genet** 1995 Aug 14;60(4):267–71. Comment in: Am J Med Genet 1995 Aug 14;60(4):272–5.

What can the DRD2/alcoholism story teach us about association studies in psychiatric genetics? [editorial; comment] Neiswanger K, et al. **Am J Med Genet** 1995 Aug 14;60(4):272–5. Comment on: Am J Med Genet 1995 Aug 14;60(4):267–71.

Exclusion of linkage between alcoholism and the MNS blood group region on chromosome 4q in multiplex families. Neiswanger K, et al. **Am J Med Genet** 1995 Feb 27; 60(1):72–9

Monoamine oxidases and alcoholism. II. Studies in alcoholic families. Suarez BK, et al. **Am J Med Genet** 1995 Oct 9; 60(5):417–23

Preliminary evidence for an association of a dinucleotide repeat polymorphism at the MAOA gene with early onset alcoholism/substance abuse. Vanyukov MM, et al. **Am J Med Genet** 1995 Apr 24;60(2):122–6

Segregation analysis of alcoholism in high density families: a replication. Yuan H, et al. **Am J Med Genet** 1996 Feb 16;67(1):71–6

Depression spectrum disease, I: The role of gene-environment interaction. Cadoret RJ, et al. **Am J Psychiatry** 1996 Jul;153(7):892–9

Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Gianoulakis C, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):250–7

An 8-year follow-up of 450 sons of alcoholic and control subjects. Schuckit MA, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):202–10

Replication of the Stockholm Adoption Study of alcoholism. Confirmatory cross-fostering analysis. Sigvardsson S, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):681–7

The dopamine D2 receptor gene TaqI A1 polymorphism and alcoholism in a Mexican population. Cruz C, et al. **Arch Med Res** 1995 Winter;26(4):421–6

Molecular genetic analysis of the role of GABAergic systems in the behavioral and cellular actions of alcohol. Buck KJ. **Behav Genet** 1996 May;26(3):313–23 (72 ref.)

P300 amplitude decrements in children from families of alcoholic female probands. Hill SY, et al. **Biol Psychiatry** 1995 Nov 1;38(9):622–32

No association between alcoholism and multiple polymorphisms at the dopamine D2 receptor gene (DRD2) in three distinct Taiwanese populations. Lu RB, et al. **Biol Psychiatry** 1996 Mar 15;39(6):419–29

Personality disorder in alcohol dependents [letter] Iwahashi K, et al. **Can J Psychiatry** 1995 Aug;40(6):362–3

Candidate genes in alcoholism. Goldman D. **Clin Neurosci** 1995;3(3):174–81 (76 ref.)

No association between the c2 allele at the cytochrome P450IIE1 gene and alcohol induced liver disease, alcohol Korsakoff's syndrome or alcohol dependence syndrome. Ball DM, et al. **Drug Alcohol Depend** 1995 Oct;39(3):181–4

Common genetic mechanisms in alcohol, drug, and mental disorder comorbidity. Pickens RW, et al. **Drug Alcohol Depend** 1995 Aug;39(2):129–38

Alcohol dependence, family history, and D2 dopamine receptor function as neuroendocrinologically assessed with apomorphine. Wiesbeck GA, et al. **Drug Alcohol Depend** 1995 Nov;40(1):49–53

High incidence of ADH2*1/ALDH2*1 genes among Japanese alcohol dependents and patients with alcoholic liver disease. Tanaka F, et al. **Hepatology** 1996 Feb; 23(2):234–9

Genetics and primary prevention of drug and alcohol abuse. Tarter RE. **Int J Addict** 1995 Sep;30(11):1479–84 (14 ref.)

Assessment of family history of alcoholism in sons of alcoholic fathers. Cowley DS, et al. **J Addict Dis** 1995; 14(2):75–81

Childhood psychopathology in children from families of alcoholic female probands. Hill SY, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):725–33

Increased prevalence of alcoholism in relatives of depressed and bipolar children. Todd RD, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):716–24

Problem solving and coping strategies in persons with spinal cord injury who have and do not have a family history of alcoholism. Schandler SL, et al. **J Spinal Cord Med** 1996 Apr;19(2):78–86

Assessing and tracking family histories of alcoholism. Johnson V, et al. **J Stud Alcohol** 1995 Nov;56(6):654–60

Familial resemblances in alcohol use: genetic or cultural transmission? Koopmans JR, et al. **J Stud Alcohol** 1996 Jan;57(1):19–28

Incidence and characteristics of spinal cord injured patients with a family history of alcoholism. Schandler SL, et al. **J Stud Alcohol** 1995 Sep;56(5):522–7

Why mice drink [news; comment] Goldman D. **Nat Genet** 1996 Jun;13(2):137–8. Comment on: Nat Genet 1996 Jun;13(2):147–53.

P300 amplitudes vary inversely with continuum of risk in first degree male relatives of alcoholics. Benegal V, et al. **Psychiatr Genet** 1995 Winter;5(4):149–56

Dopamine D1, D2 and D3 receptor genes in alcohol dependence. Sander T, et al. **Psychiatr Genet** 1995 Winter; 5(4):171–6

Childhood parental loss and alcoholism in women: a causal analysis using a twin-family design. Kendler KS, et al. **Psychol Med** 1996 Jan;26(1):79–95

The relationship between bipolar disorder and alcoholism: a controlled family study. Maier W, et al. **Psychol Med** 1995 Jul;25(4):787–96

[Depression and alcoholism: a potential familial-genetic relationship] Kasperowicz-Dąbrowiecka A, et al. **Psychiatr Pol** 1996 Mar–Apr;30(2):281–96 (45 ref.) (Eng. Abstr.) **(Pol)**

[Genetic aspects of heart lesions in patients with chronic alcoholism] Mamontova NS, et al. **Klin Med (Mosk)** 1995; 73(4):52–4 (Eng. Abstr.) **(Rus)**

[Major histocompatibility system as a risk factor for alcoholic liver disease] Llop E, et al. **Rev Med Chil** 1995 Jun; 123(6):687–93 (Eng. Abstr.) **(Spa)**

HISTORY

Temporarily detained: tuberculous alcoholics in Seattle, 1949 through 1960. Lerner BH. **Am J Public Health** 1996 Feb; 86(2):257–65

Rev Harold Nelson Burden and Katherine Mary Burden: pioneers of inebriate reformatories and mental deficiency institutions. Carpenter PK. **J R Soc Med** 1996 Apr; 89(4):205–9

[Verlaine: long sobs on Normandy] Henry R. **Union Med Can** 1995 Mar;124(1):23–5 **(Fre)**

[Vilmos Lippich, forgotten pioneer of medical statistics and fight against alcoholism. Addition to footnotes] Kiss L.

Orv Hetil 1996 Jan 28;137(4):191-3 **(Hun)**

IMMUNOLOGY

The effect of ethanol ingestion on killing of Streptococcus pneumoniae, Staphylococcus aureus and Staphylococcus epidermidis by rat neutrophils. Jareo PW, et al. **Alcohol Alcohol** 1995 May;30(3):311-8

Antibodies made against a formaldehyde-protein adduct cross react with an acetaldehyde-protein adduct. Implications for the origin of antibodies in human serum which recognize acetaldehyde-protein adducts. Pietrzak ER, et al. **Alcohol Alcohol** 1995 May;30(3):373-8

Alcohol modulation of human normal T-cell activation, maturation, and migration [see comments] Chiappelli F, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):539-44. Comment in: Alcohol Clin Exp Res 1995 Jun;19(3):535-8.

Introduction to the symposium on alcohol and T-cell immunity [comment] Chiappelli F, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):535-8. Comment on: Alcohol Clin Exp Res 1995 Jun;19(3):539-44.

Modulation of T-cell adhesion markers, and the CD45R and CD57 antigens in human alcoholics. Cook RT, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):555-63

Alcohol use and T-lymphocyte subsets among injection drug users with HIV-1 infection: a prospective analysis. Crum RM, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):364-71

Alcohol ingestion impairs host defenses predisposing otherwise healthy mice to Pneumocystis carinii infection. D'Souza NB, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1219-25

Alcohol modulates alveolar macrophage tumor necrosis factor-alpha, superoxide anion, and nitric oxide secretion in the rat. D'Souza NB, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):156-63

Ethanol as a possible cofactor in the development of murine AIDS. Fitzpatrick EA, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):915-22

Increased serum IgE in alcohol abusers. González-Quintela A, et al. **Clin Exp Allergy** 1995 Aug;25(8):756-64

Loss of the CD5+ and CD45RAhi B cell subsets in alcoholics. Cook RT, et al. **Clin Exp Immunol** 1996 Feb; 103(2):304-10

Phosphatidylinositol metabolism in lymphocytes of chronic alcoholic patients after anti-CD3 stimulation. Hrelia S, et al. **Immunol Lett** 1995 May;46(1-2):63-6

[Evaluation of selected immunological and biochemical parameters of blood in alcohol dependency] Leksowski W, et al. **Psychiatr Pol** 1996 Mar-Apr;30(2):297-305 (Eng. Abstr.) **(Pol)**

METABOLISM

DRD4 dopamine receptor genotype and CSF monoamine metabolites in Finnish alcoholics and controls. Adamson MD, et al. **Am J Med Genet** 1995 Jun 19;60(3):199-205

Screening the dopamine D1 receptor gene in 131 schizophrenics and eight alcoholics: identification of polymorphisms but lack of functionally significant sequence changes. Liu Q, et al. **Am J Med Genet** 1995 Apr 24; 60(2):165-71

Alcohol, corticosteroids, energy utilization, and hippocampal endangerment. Eskay RL, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:105-14

Positron emission tomographic studies of cerebral benzodiazepine-receptor binding in chronic alcoholics. Gilman S, et al. **Ann Neurol** 1996 Aug;40(2):163-71

Effect of chronic ethanol consumption on the energy state and structural stability of periportal and perivenous hepatocytes. Ivester P, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):14-21

Studies on urea synthesis in the liver of rats treated chronically with ethanol using perfused livers, isolated hepatocytes, and mitochondria. Adachi K, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1391-9

Ethanol consumption reduces the proteolytic capacity and protease activities of hepatic lysosomes. Kharbanda KK, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):421-9

Oxidative modification of proteins in chronic alcoholics. Grattagliano I, et al. **Boll Soc Ital Biol Sper** 1995 Jul-Aug; 71(7-8):189-95

Medicolegal alcohol determination: variability of the blood-to breath-alcohol ratio and its effect on reported breath-alcohol concentrations. Labianca DA, et al. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):919-25 (17 ref.)

Fundamental studies on alcohol dependence and disposition. Komura S, et al. **Forensic Sci Int** 1996 Jun 28; 80(1-2):99-107 (37 ref.)

Serum carbohydrate-deficient transferrin: mechanism of increase after chronic alcohol intake. Xin Y, et al. **Hepatology** 1995 Nov;22(5):1462-8

Gastric eicosanoid synthesis in normal subjects and alcoholics after ethanol stimulation. Franco L, et al. **Ital J Gastroenterol** 1995 Jun;27(5):244-7

Influence of glutathione on the oxidation of 1-methyl-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline: chemistry of potential relevance to the addictive and neurodegenerative consequences of ethanol use. Han QP, et al. **J Med Chem** 1996 Mar 29;39(7):1494-508

Effects of chronic ethanol consumption on sterol transfer proteins in mouse brain. Myers-Payne SC, et al. **J Neurochem** 1996 Jan;66(1):313-20

Distribution of the mu and delta opioid binding sites in the brain of the alcohol-preferring AA and alcohol-avoiding ANA lines of rats. de Waele JP, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):518-27

Striatal dopamine receptors and adenylyl cyclase activity in a rat model of alcohol addiction: effects of ethanol and lisuride treatment. May T, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1195-203

Both ethanol and protein deficiency increase messenger RNA levels for pancreatic lithostathine. Apte MV, et al. **Life Sci** 1996;58(6):485-92

Losses of arachidonic acid in rat liver after alcohol inhalation. Salem N Jr, et al. **Lipids** 1996 Mar;31 Suppl:S153-6

Ritanserin pharmacokinetics in abstinent chronic alcoholics. Estévez F, et al. **Medicina (B Aires)** 1995;55(1):39-44

Dopamine transporter, alcoholism and other diseases [comment] Goldman D. **Nat Med** 1995 Jul;1(7):624-5. Comment on: Nat Med 1995 Jul;1(7):654-7.

Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics [see comments] Tiihonen J, et al. **Nat Med** 1995 Jul;1(7):654-7 . Comment in: Nat Med 1995 Jul;1(7):623-5. Comment in: Nat Med 1995 Jul;1(7):623-5.

Chronic ethanol consumption increases the amount of mRNA for retinoic acid and triiodothyronine receptors in mouse brain. Alfos S, et al. **Neurosci Lett** 1996 Mar 15; 206(2-3):73-6

Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic pancreatitis, and alcoholic chronic pancreatitis. Imamura T, et al. **Pancreas** 1995 Nov;11(4):357-64

Effects of ethanol on peripheral benzodiazepine binding sites in the mouse cerebellum and brain stem. Wong PT, et al. **Pharmacology** 1995 Jun;51(1):66-72

[Changes in ethanol metabolism in chronic alcoholics and genetic and ethnic factors affecting its metabolism] Hirt M. **Soud Lek** 1995 Feb;40(1):2-3 (Eng. Abstr.) **(Cze)**

[Functional significance of diazepam binding inhibitor (DBI) in establishment of alcohol dependence] Katsura M, et al. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):217-27 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Neuromediator systems in the mechanisms of remission and recurrence in alcoholism] Vekshina NL, et al. **Eksp Klin Farmakol** 1995 Sep-Oct;58(5):62-4 (Eng. Abstr.) **(Rus)**

[Lipid peroxidation and status of the antioxidant system in opiate addiction, chronic alcoholism, or substance abuse caused by inhaling solvent vapors] Seledtsov AM. **Vopr Med Khim** 1995 May-Jun;41(3):50-3 (Eng. Abstr.) **(Rus)**

[Mediator systems in mechanisms of remission of experimental alcoholism and relapses of pathological craving for alcohol] Veretinskaia AG, et al. **Vopr Med Khim** 1995 Sep-Oct;41(5):13-5 (Eng. Abstr.) **(Rus)**

MORTALITY

Predictive capacity of the AUDIT questionnaire for alcohol-related harm. Conigrave KM, et al. **Addiction** 1995 Nov;90(11):1479-85

Suicide rates and alcohol consumption in the United States, 1970-89. Gruenewald PJ, et al. **Addiction** 1995 Aug; 90(8):1063-75

Alcohol and suicide: a comparative analysis of France and Sweden. Norström T. **Addiction** 1995 Nov;90(11):1463-9

Alcohol and suicide--the Portuguese experience. Skog OJ, et al. **Addiction** 1995 Aug;90(8):1053-61

Drug abuse and intoxication in alcoholics. Thomsen JL, et al. **Alcohol Alcohol** 1995 May;30(3):379-83

Trends in alcohol-related mortality among New Mexico's American Indians, Hispanics, and non-Hispanic whites. Gilliland FD, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1572-7

Assessing gender interactions in the prediction of mortality in alcoholic men and women: a 20-year follow-up study. Lewis CE, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1162-72

Predictors of mortality in alcoholic men: a 20-year follow-up study. Lewis CE, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):984-91

Alcohol consumption, life context, and coping predict mortality among late-middle-aged drinkers and former drinkers. Mertens JR, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):313-9

How does IHS relate administratively to the high alcoholism mortality rate? Burns TR. **Am Indian Alsk Native Ment Health Res** 1995;6(3):31-45

Early onset of drinking and mortality among male alcoholics. A result of a 10-year prospective follow-up study in Hokkaido, Japan. Mori M, et al. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Dec;30(6):426-34

Alcoholic ketoacidosis as a cause of death in forensic cases. Thomsen JL, et al. **Forensic Sci Int** 1995 Oct 30; 75(2-3):163-71

Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. Hurt RD, et al. **JAMA** 1996 Apr 10;275(14):1097-103

Tuberculosis, AIDS, and death among substance abusers on welfare in New York City [see comments] Friedman LN, et al. **N Engl J Med** 1996 Mar 28;334(13):828-33. Comment in: N Engl J Med 1996 Mar 28;334(13):859-60.

NURSING

Alcoholic patients: keeping hope alive. Gorman M. **Am J Nurs** 1996 Jan;96(1):20

PATHOLOGY

Effects of ethanol administration on brain neurotensin-like immunoreactivity in rats. Wachi M, et al. **Acta Neurol Scand** 1996 Feb-Mar;93(2-3):211-4

Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcohol. Brandão F, et al. **Alcohol** 1996 May-Jun;13(3):239-49

Influence of selenium supplementation in non-toxic doses on testis lipid peroxide and antioxidant levels in chronic alcohol-fed rats. Bekpinar S, et al. **Alcohol Alcohol** 1995 Sep;30(5):645-50

Effect of chronic ethanol consumption on glycosylation processes in rat liver microsomes and Golgi apparatus. Cottalasso D, et al. **Alcohol Alcohol** 1996 Jan;31(1):51-9

Chronic alcoholics without Wernicke-Korsakoff syndrome or cirrhosis do not lose serotonergic neurons in the dorsal raphe nucleus. Baker KG, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):61-6

Neuronal degeneration in rat cerebrocortical and olfactory regions during subchronic "binge" intoxication with ethanol: possible explanation for olfactory deficits in alcoholics. Collins MA, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):284-92

Regional differences in the effects of chronic ethanol administration on [3H]zolpidem binding in rat brain. Devaud LL, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):910-4

Noradrenergic locus coeruleus neurons [letter] Halliday G, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):191-2 (15 ref.)

Attenuation of glutamate-induced neurotoxicity in chronically ethanol-exposed cerebellar granule cells by NMDA receptor antagonists and ganglioside GM1. Hoffman PL, et al. **Alcohol Clin Exp Res** 1995 Jun; 19(3):721-6

Synapse-to-neuron ratio in the lateral geniculate nucleus of rats exposed chronically to ethanol. Kjellström C, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1261-4

Reduced activities of thiamine-dependent enzymes in brains of alcoholics in the absence of Wernicke's encephalopathy. Lavoie J, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1073-7

Effect of ethanol consumption on adult rat liver mitochondrial populations analyzed by flow cytometry. Mateos A, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1327-30

Roles of alcohol, hepatitis virus infection, and gender in the development of hepatocellular carcinoma in patients with liver cirrhosis. Miyakawa H, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):91A-94A

Structural reorganization in the supraoptic nucleus of withdrawn rats following long-term alcohol consumption. Sousa N, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):879-85

Effects of chronic alcohol consumption and aging on dopamine D2 receptors in Fischer 344 rats. Tajuddin NF, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):144-51

Effect of chronic alcoholism on human muscle glycogen and glucose metabolism. Vernet M, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1295-9

Effects of chronic alcohol consumption and aging on dopamine D1 receptors in Fischer 344 rats. Woods JM, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1331-7

Organomegaly in chronic alcoholics. Sadler DW, et al. **Am J Forensic Med Pathol** 1995 Sep;16(3):249-52

Morphological changes in the corpus callosum in chronic alcoholism. Tarnowska-Dziduszko E, et al. **Folia Neuropathol** 1995;33(1):25-9

Effect of chronic alcoholism on neuronal nuclear size and neuronal population in the mammillary body and the anterior thalamic complex of man. Belzunegui T, et al. **Histol Histopathol** 1995 Jul;10(3):633-8

Early perivenular fibrogenesis--precirrhotic lesions among moderate alcohol consumers and chronic alcoholics. Savolainen V, et al. **J Hepatol** 1995 Nov;23(5):524-31

Neuroimaging in alcoholism: CT and MRI results and clinical correlates. Mann K, et al. **J Neural Transm Gen Sect** 1995; 99(1-3):145-55 (76 ref.)

Neurofibrillary tangles in chronic alcoholics. Cullen KM, et al. **Neuropathol Appl Neurobiol** 1995 Aug;21(4):312-8

PHYSIOPATHOLOGY

Cerebral blood flow in just detoxified alcohol dependent patients. A 99 m Tc-HMPAO-SPECT study. Mampunza S, et al. **Acta Neurol Belg** 1995;95(3):164-9

Anterior brain dysfunctioning as a risk factor in alcoholic behaviors. Deckel AW, et al. **Addiction** 1995 Oct; 90(10):1323-34

Diet composition, alcohol utilization, and dependence. Fisher H, et al. **Alcohol** 1996 Mar-Apr;13(2):195-200

Cue-exposure to alcohol-associated stimuli reduces autonomic reactivity, but not craving and anxiety, in dependent drinkers. McCusker CG, et al. **Alcohol Alcohol** 1995 May;30(3):319-27

Chronic ethanol consumption ameliorates the maturity-onset diabetes-obesity syndrome in CBA mice. al Qatari M, et al. **Alcohol Alcohol** 1996 Jan;31(1):89-99

Possible central adenosinergic modulation of ethanol-induced alterations in [14C]glucose utilization in mice. Anwer J, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):777-83

Delayed P3A in abstinent elderly male chronic alcoholics. Biggins CA, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):1032–42

Voice of the victims. Erickson CK. **Alcohol Clin Exp Res** 1995 Jun;19(3):674–5

GABAergic transmission in the nucleus accumbens is involved in the termination of ethanol self-administration in rats. Hodge CW, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1486–93

Impaired delay eyeblink concitioning in amnesic Korsakoff's patients and recovered alcoholics. McGlinchey-Berroth R, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1127–32

Effects of chronic alcohol abuse and HIV infection on brain phosphorus metabolites. Meyerhoff DJ, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):685–92

Adult male rats exposed to an alcohol diet exhibit a blunted adrenocorticotropic hormone response to immune or physical stress: possible role of nitric oxide. Rivier C. **Alcohol Clin Exp Res** 1995 Dec;19(6):1474–9

Equilibrative adenosine transport in rat hepatocytes after chronic ethanol feeding. Wannamaker VL, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):735–40

Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. Krystal JH, et al. **Am J Psychiatry** 1996 Jan; 153(1):83–92

Pathophysiology of alcoholism [letter; comment] Pagliaro LA, et al. **Am J Psychiatry** 1996 May;153(5):739; discussion 740. Comment on: Am J Psychiatry 1995 Mar;152(3):332–40.

Pathophysiology of alcoholism [letter; comment] Rosenstein DL, et al. **Am J Psychiatry** 1996 May;153(5):740. Comment on: Am J Psychiatry 1995 Mar;152(3):332–40.

Pathophysiology of alcoholism [letter; comment] Wiseman EJ. **Am J Psychiatry** 1996 May;153(5):739–40. Comment on: Am J Psychiatry 1995 Mar;152(3):332–40.

Electrophysiological findings during the menstrual cycle in women with and without late luteal phase dysphoric disorder: relationship to risk for alcoholism? Ehlers CL, et al. **Biol Psychiatry** 1996 Apr 15;39(8):720–32

Alcohol abuse and HIV [letter; comment] Mendelson JH. **Biol Psychiatry** 1995 Sep 1;38(5):343–4. Comment on: Biol Psychiatry 1995 Feb 1;37(3):183–95.

The neurology of alcoholic denial: implications for assessment and treatment. Duffy JD. **Can J Psychiatry** 1995 Jun;40(5):257–63 (30 ref.)

The effects of alcoholism on the hypothalamic-pituitary-adrenal axis: interaction with endogenous opioid peptides. Inder WJ, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):283–90

Alcoholism: the clinical/basic science interface. Meyer RE. **Clin Neurosci** 1995;3(3):141–4 (24 ref.)

Resting energy expenditure in patients with alcoholic chronic pancreatitis. Hébuterne X, et al. **Dig Dis Sci** 1996 Mar; 41(3):533–9

Autonomic neuropathy in chronic alcoholism: evaluation of cardiovascular, pupillary and sympathetic skin responses. Miralles R, et al. **Eur Neurol** 1995;35(5):287–92

Chronic ethanol consumption increases hepatic sinusoidal contractile response to endothelin-1 in the rat. Bauer M, et al. **Hepatology** 1995 Nov;22(5):1565–76

A proposed sequence of reactions leading to collagen biosynthesis, fibrosis, and hypertension in alcoholics. Brecher AS, et al. **J Investig Med** 1996 Feb;44(2):36–41 (107 ref.)

Pathogenetic mechanisms of hypomagnesemia in alcoholic patients. Elisaf M, et al. **J Trace Elem Med Biol** 1995 Dec; 9(4):210–4

Alcoholism abolishes the growth hormone response to sumatriptan administration in man. Coiro V, et al. **Metabolism** 1995 Dec;44(12):1577–80

The psychobiological regulation of social cooperation [comment] Cloninger CR. **Nat Med** 1995 Jul;1(7):623–5 (21 ref.). Comment on: Nat Med 1995 Jul;1(7):654–7.

Alcohol addiction: an enigma among us. Tabakoff B, et al. **Neuron** 1996 May;16(5):909–12 (25 ref.)

The role of dopamine neurotransmission in ethanol dependence development and ethanol withdrawal in rats. Samochowiec J, et al. **Pharmazie** 1995 Dec;50(12):815–8

Partial left ventricular ischemia in isolated hearts obtained from ethanol-dependent rats. Guppy LJ, et al. **Proc West Pharmacol Soc** 1995;38:73–5

Serotonin-stimulated intracellular calcium mobilization in platelets from alcoholic men. Reist C, et al. **Psychiatry Res** 1995 Aug 28;57(3):275–8

Neuroendocrine support for a relationship between "novelty seeking" and dopaminergic function in alcohol-dependent men. Wiesbeck GA, et al. **Psychoneuroendocrinology** 1995; 20(7):755–61

Information processing during eye tracking as revealed by event-related potentials in schizophrenics, alcoholics, and healthy controls. Kathmann N, et al. **Schizophr Res** 1995 Aug 1;16(2):145–56

Remission of severe alcoholic polyneuropathy after liver transplantation. Spahn TW, et al. **Z Gastroenterol** 1995 Dec; 33(12):711–4

[Does chronic alcohol drinking modify digestive gastrobiliary motility?] Wedmann B, et al. **Leber Magen Darm** 1996 Mar; 26(2):98–102 (Eng. Abstr.) **(Ger)**

[Study of psychopathologic-biorhythm aspects of alcoholic patients in the withdrawal phase—initial results of a pilot study] Peter K, et al. **Wien Med Wochenschr** 1995; 145(17–18):454–5 (Eng. Abstr.) **(Ger)**

[The role of dopamine neurotransmission on the development of ethanol dependence and course of abstinence syndrome] Samochowiec J. **Ann Acad Med Stetin** 1994;40:195–217 (Eng. Abstr.) **(Pol)**

[Bile-secreting function of the liver in patients with chronic alcoholism and ways of correcting it] Mikhallovskaia AIu, et al. **Vopr Pitan** 1995;(5):34–6 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Prospective screening of substance dependence: the advantages of directness. Svanum S, et al. **Addict Behav** 1995 Mar-Apr;20(2):205–13

A critique of chapter 3: "Individual drinking and degree of risk". Batel P. **Addiction** 1995 Nov;90(11):1450–1

Zambia: the need for a national 'Policy Options Working Group'. Haworth A. **Addiction** 1995 Nov;90(11):1447–8

Alcohol policy and the dilemma of Africa. Ikuesan BA. **Addiction** 1995 Nov;90(11):1445–7

A major contribution to improve the science policy discussion. Mann K. **Addiction** 1995 Nov;90(11):1451–2

Population science, prejudice and policy on alcohol. Marmot MG. **Addiction** 1995 Nov;90(11):1441–3

The World Health Organization's Expert Committee on drug dependence: comments on the 28th report (1994) [editorial] Negrete JC. **Addiction** 1995 Nov;90(11):1437–9

Do role-model societies exist? Negrete JC. **Addiction** 1995 Nov;90(11):1443–5

The value of independence. Raistrick D. **Addiction** 1995 Nov; 90(11):1452–3

Alcohol policy and the public good: a Chinese view. Wei H. **Addiction** 1995 Nov;90(11):1448–50

Do not change the numbers—clarify the message. The government review of the Sensible Drinking message: a Medical Council on Alcoholism view. **Alcohol Alcohol** 1995 Sep;30(5):571–5

Contrasting self-report screens for alcohol problems: a review. Maisto SA, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1510–6 (24 ref.)

Effectiveness of the Alcohol Use Disorders Identification Test in occupational health screenings. Seppä K, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):999–1003

An ecological assessment of community-based interventions for prevention and health promotion: approaches to measuring community coalitions. Goodman RM, et al. **Am J Community Psychol** 1996 Feb;24(1):33–61

A cross-national trial of brief interventions with heavy drinkers. WHO Brief Intervention Study Group. **Am J Public Health** 1996 Jul;86(7):948–55

Community-based approaches for the prevention of alcohol, tobacco, and other drug use. Aguirre-Molina M, et al. **Annu Rev Public Health** 1996;17:337–58 (121 ref.)

I treated; now I want to prevent. Waltman RE. **Arch Fam Med** 1995 Oct;4(10):831

Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Sass H, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):673–80

Early identification, screening, and brief intervention for adolescent alcohol use. Werner MJ, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1241–8 (73 ref.)

Residents' assessment of a community-based alcohol initiative in the Canadian Arctic. Callaway M, et al. **Arctic Med Res** 1995 Oct;54(4):184–91

Alcohol withdrawal at home. Pilot project for frail elderly people. Evans DJ, et al. **Can Fam Physician** 1996 May; 42:937–45

Secondary prevention of excessive alcohol use: assessing the prospects of implementation. Botelho RJ, et al. **Fam Pract** 1996 Apr;13(2):182–93 (139 ref.)

Concept abuse in the drug field. Agar M. **Int J Addict** 1995 Jul;30(9):1165–8

The use of a structured assessment interview as an intervention to reduce dropout rates in outpatient relapse prevention groups for "problem" drinkers. Keaney F, et al. **Int J Addict** 1995 Aug;30(10):1355–62

Early intervention in the path to alcohol problems through conduct problems: treatment involvement and child behavior change. Nye CL, et al. **J Consult Clin Psychol** 1995 Oct;63(5):831–40

A systematic review of parent-oriented programs to prevent children's use of alcohol and other drugs. Elmquist DL. **J Drug Educ** 1995;25(3):251–79

Sources of alcohol and drug information among Israeli urban adolescents. Weiss S, et al. **J Drug Educ** 1995;25(3):211–22

Drinking problems of nursing students. Marion LN, et al. **J Nurs Educ** 1996 May;35(5):196–203

Alcohol-problem prevention research policy: the need for a phases research model. Holder H, et al. **J Public Health Policy** 1995;16(3):324–46 (43 ref.)

Alcohol and the young. Summary of a report of a joint working party of the Royal College of Physicians and the British Paediatric Association. **J R Coll Physicians Lond** 1995 Nov-Dec;29(6):470–4

Cues to parent involvement in drug prevention and school activities. Hahn EJ, et al. **J Sch Health** 1996 May; 66(5):165–70

Patient factors influencing variation in the use of preventive interventions for alcohol abuse by primary care physicians. Volk RJ, et al. **J Stud Alcohol** 1996 Mar;57(2):203–9

Alcohol interventions in trauma centers. Current practice and future directions [see comments] Gentilello LM, et al. **JAMA** 1995 Oct 4;274(13):1043–8. Comment in: JAMA 1996 Feb 7;275(5):358. Comment in: JAMA 1996 Feb 7;275(5):358; discussion 358–9.

Alcohol interventions in trauma centers [letter; comment] Gitlitz GF. **JAMA** 1996 Feb 7;275(5):358. Comment on: JAMA 1995 Oct 4;274(13):1043–8.

Alcohol interventions in trauma centers [letter; comment] Miller JS. **JAMA** 1996 Feb 7;275(5):358; discussion 358–9 . Comment on: JAMA 1995 Oct 4;274(13):1043–8.

Alcohol interventions in trauma centers [letter; comment] Rostenberg PO. **JAMA** 1996 Feb 7;275(5):358; discussion 358–9. Comment on: JAMA 1995 Oct 4;274(13):1043–8.

Disulfiram (antabuse) contracts in treatment of alcoholism. O'Farrell TJ, et al. **NIDA Res Monogr** 1995;150:65–91

Alcoholism. Taking a preventive, public health approach. Blondell RD, et al. **Postgrad Med** 1996 Jul;100(1):69–72, 78–80 (16 ref.)

The effect among older persons of a general preventive visit on three health behaviors: smoking, excessive alcohol drinking, and sedentary lifestyle. The Medicare Preventive Services Research Team. Burton LC, et al. **Prev Med** 1995 Sep;24(5):492–7

Recruitment to a university alcohol program: evaluation of social marketing theory and stepped approach model. Gries JA, et al. **Prev Med** 1995 Jul;24(4):348–56

Evaluation and monitoring of action on alcohol. Targets, indicators and monitoring and reporting systems for action on alcohol. Anderson P, et al. **WHO Reg Publ Eur Ser** 1995;59:1–89

Community and municipal action on alcohol. Ritson B. **WHO Reg Publ Eur Ser** 1995;63:1–102

[Screening for risk factors for alcohol consumption in the Quebec Health Survey] Tempier RP. **Can J Public Health** 1996 May-Jun;87(3):183–6 (Eng. Abstr.) **(Fre)**

[The European plan of action concerning alcohol consumption: a look to the future (editorial)] Robledo de Dios T, et al. **Med Clin (Barc)** 1996 Apr 20;106(15):581–2 **(Spa)**

[The European Alcohol Action Plan. The Alcohol, Drug and Tobacco Unit. Department of Lifestyles and Health, Regional Office for Europe. World Health Organization. Copenhagen, 1993] Gil López E, et al. **Rev Esp Salud Publica** 1995 Sep-Oct;69(5):361–83 (Eng. Abstr.) **(Spa)**

[Test screening—a way to find heavy drinkers (letter)] Andréasson S. **Lakartidningen** 1995 Nov 1;92(44):4077 **(Swe)**

[Fight against increased abuse of alcohol among the elderly and women in the USA] Wirschubsky ZG. **Lakartidningen** 1996 Aug 28;93(34):2850–1 **(Swe)**

PSYCHOLOGY

Parental alcohol abuse and gender as predictors of psychopathology in adult children of alcoholics. Belliveau JM, et al. **Addict Behav** 1995 Sep-Oct;20(5):619–25

The effects of stress and coping on daily alcohol use in women. Breslin FC, et al. **Addict Behav** 1995 Mar-Apr; 20(2):141–7

Relationship of depression with measures of social functioning in adult drug abusers. Donohue B, et al. **Addict Behav** 1996 Mar-Apr;21(2):211–6

Classifying COAs with three variations of the CAST: classification rates, stability, and gender differences. Havey JM, et al. **Addict Behav** 1995 Jul-Aug;20(4):501–7

Alternative cut-point scores for the CAST-6. Hodgins DC, et al. **Addict Behav** 1995 Mar-Apr;20(2):267–70

Autonomic cued reactivity in alcoholics: the effect of olfactory stimuli. Stormark KM, et al. **Addict Behav** 1995 Sep-Oct;20(5):571–84

Loss of control and inability to abstain: the measurement of and the relationship between two constructs in male alcoholics. Kahler CW, et al. **Addiction** 1995 Aug; 90(8):1025–36; discussion 1037–51

An evaluation of type A and B alcoholics. Schuckit MA, et al. **Addiction** 1995 Sep;90(9):1189–203

Psychopathology and alcohol consumption among treatment-seeking alcoholics: a prospective study. Tómasson K, et al. **Addiction** 1996 Jul;91(7):1019–30

Experimental alcoholism: world wide need to standardize animal models [editorial] Myers RD. **Alcohol** 1996 Mar-Apr;13(2):109–10

A test of Tiffany's cognitive model of drug urges and drug-use behavior. Bradizza CM, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1043–7

Occupational stress and the risk of alcohol abuse and dependence. Crum RM, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):647–55

Voice of the victims. Erickson CK. **Alcohol Clin Exp Res** 1995 Oct;19(5):1209–10

Aggressivity in adolescent alcohol abusers: relationship with conduct disorder. Moss HB, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):642–6

Behavioral dysfunction and cognitive efficiency in male and female alcoholics. Nixon SJ, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):577–81

Evidence of alcohol-related efficiency deficits in an episodic learning task. Nixon SJ, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):21–4

Group similarities in beliefs concerning the causes of alcohol problems and the effectiveness of means of overcoming

problem alcohol use. Peralta CD, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):964–8

Effects of chronic ethanol exposure on oral self-administration of ethanol or saccharin by Wistar rats. Schulteis G, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):164–71

Effects of disease-related cues in alcoholic inpatients: results of a controlled "Alcohol Stroop" study. Stetter F, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):593–9

Automatic activation of alcohol concepts in response to positive outcomes of alcohol use. Weingardt KR, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):25–30

Alcohol schema acquisition in preschoolers: differences between children of alcoholics and children of nonalcoholics. Zucker RA, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1011–7

Effects of parental alcoholism and life stress on Hispanic and Non-Hispanic Caucasian adolescents: a prospective study. Barrera M Jr, et al. **Am J Community Psychol** 1995 Aug; 23(4):479–507

Adolescent suicidal behaviors as a function of depression, hopelessness, alcohol use, and social support: a longitudinal investigation. Reifman A, et al. **Am J Community Psychol** 1995 Jun;23(3):329–54

Evaluation of a preventive intervention for a self-selected subpopulation of children. Short JL, et al. **Am J Community Psychol** 1995 Apr;23(2):223–47

What can the DRD2/alcoholism story teach us about association studies in psychiatric genetics? [editorial; comment] Neiswanger K, et al. **Am J Med Genet** 1995 Aug 14;60(4):272–5. Comment on: Am J Med Genet 1995 Aug 14;60(4):267–71.

The resurrection and the life. Green VL. **Am J Orthopsychiatry** 1996 Jan;66(1):12–16

Predicting alcohol and drug use in early adulthood: the role of internalizing and externalizing behavior problems in early adolescence. Steele RG, et al. **Am J Orthopsychiatry** 1995 Jul;65(3):380–8

Disproportionate lethality in psychiatric patients with concurrent alcohol and cocaine abuse. Salloum IM, et al. **Am J Psychiatry** 1996 Jul;153(7):953–5

Are smokers with alcohol disorders less likely to quit? Breslau N, et al. **Am J Public Health** 1996 Jul;86(7):985–90

Morbid jealousy in alcoholism. Michael A, et al. **Br J Psychiatry** 1995 Nov;167(5):668–72

Pharmacogenetic models of alcoholism. Li TK, et al. **Clin Neurosci** 1995;3(3):182–8 (62 ref.)

Specificity of substance use in anxiety-disordered subjects. Goldenberg IM, et al. **Compr Psychiatry** 1995 Sep–Oct; 36(5):319–28

The association between childhood irritability and liability to substance use in early adolescence: a 2-year follow-up study of boys at risk for substance abuse. Tarter RE, et al. **Drug Alcohol Depend** 1995 Oct;39(3):253–61

Children of alcoholic parents. A review. Steinhausen HC. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):143–52 (55 ref.)

Treating the patient who is disfigured by head and neck cancer. Kunkel EJ, et al. **Gen Hosp Psychiatry** 1995 Nov; 17(6):444–50

Financial stress, social support, and alcohol involvement: a longitudinal test of the buffering hypothesis in a general population survey. Peirce RS, et al. **Health Psychol** 1996 Jan;15(1):38–47

Individual and situational markers of condom use and sex with nonprimary partners among alcoholic inpatients: findings from the ATRISK Study. Scheidt DM, et al. **Health Psychol** 1996 May;15(3):185–92

The Drinker's Partner Distress Scale: an instrument for measuring the distress caused by drinkers to their partners. Crisp BR, et al. **Int J Addict** 1995 Jun;30(8):1009–17

Psychological symptomatology in spouses and adult children of alcoholics: an examination of the hypothesized personality characteristics of codependency. Hinkin CH, et al. **Int J Addict** 1995 May;30(7):843–61

Submission and rebellion: excessive drinking of women in problematic heterosexual partner relationships. Lammers SM, et al. **Int J Addict** 1995 May;30(7):901–17

Early modeling of drinking behavior by Native American elementary school children playing drunk. Mail PD. **Int J Addict** 1995 Jul;30(9):1187–97

Psychopathy, schizophrenia, alcohol abuse, and violent recidivism. Rice ME, et al. **Int J Law Psychiatry** 1995 Summer;18(3):333–42

The relation of parent alcoholism to adolescent substance use: a longitudinal follow-up study. Chassin L, et al. **J Abnorm Psychol** 1996 Feb;105(1):70–80

A longitudinal study of drug and alcohol use by psychosis-prone and impulsive-nonconforming individuals. Kwapil TR. **J Abnorm Psychol** 1996 Feb;105(1):114–23

A pilot study of factors associated with resilience to substance abuse in adolescent sons of alcoholic fathers. Springer SA, et al. **J Addict Dis** 1995;14(2):53–66

Marital status, alcohol abuse and attempted suicide: a logit model. Stack S, et al. **J Addict Dis** 1995;14(2):43–51

Drug-taking behaviours of pregnant substance abusers in treatment. Higgins PG, et al. **J Adv Nurs** 1995 Sep; 22(3):425–32

Personality characteristics of adult children of alcoholics. Baker DE, et al. **J Clin Psychol** 1995 Sep;51(5):694–702

Dimensional characteristics of the SCL-90-R: evaluation of gender differences in dually diagnosed inpatients. Carpenter KM, et al. **J Clin Psychol** 1995 May;51(3):383–90

Codependence, narcissism, and childhood trauma. Irwin HJ. **J Clin Psychol** 1995 Sep;51(5):658–65

Mental disorder and criminality. Male alcoholism. Modestin J, et al. **J Nerv Ment Dis** 1996 Jul;184(7):393–402

Internal structure of the MMPI-2 Addiction Potential Scale in alcoholic and psychiatric inpatients. Sawrie SM, et al. **J Pers Assess** 1996 Feb;66(1):177–93

Alcoholism: the role of different motivational systems. Pihl RO, et al. **J Psychiatry Neurosci** 1995 Nov;20(5):372–96 (205 ref.)

Reply to Maltzman's "Why alcoholism is a disease" [comment] Lilienfeld SO. **J Psychoactive Drugs** 1995 Jul–Sep;27(3):287–91. Comment on: J Psychoactive Drugs 1994 Jan–Mar;26(1):13–31.

Lesbian alcohol and marijuana use: correlates of HIV risk behaviors and abusive relationships. Perry SM. **J Psychoactive Drugs** 1995 Oct–Dec;27(4):413–9

Visuospatial perception, construction and memory in alcoholism. Beatty WW, et al. **J Stud Alcohol** 1996 Mar; 57(2):136–43

The role of stress and family relationships in mediating problem drinking and fathers' personal adjustment. Dumka LE, et al. **J Stud Alcohol** 1995 Sep;56(5):528–37

Do codependent traits involve more than basic dimensions of personality and psychopathology? Gotham HJ, et al. **J Stud Alcohol** 1996 Jan;57(1):34–9

Visual laterality patterns for the perception of emotional words in alcoholic and aging individuals. Hutner N, et al. **J Stud Alcohol** 1996 Mar;57(2):144–54

Parent and sibling influences on adolescent alcohol use and misuse: evidence from a U.S. adoption cohort. McGue M, et al. **J Stud Alcohol** 1996 Jan;57(1):8–18

The impact of coping styles and family communication on the social skills of children of alcoholics. Segrin C, et al. **J Stud Alcohol** 1996 Jan;57(1):29–33

Assessing life stressors and social resources: applications to alcoholic patients. Moos RH, et al. **J Subst Abuse** 1988–89; 1(2):135–52

Eating disorders and substance abuse in women: a comparative study of MMPI patterns. Minnesota Multiphasic Personality Inventory. Shisslak CM, et al. **J Subst Abuse** 1988–89;1(2):209–19

Imperial pathologies: medical discourse and drink in Dubliners' "Grace". Kane J. **Lit Med** 1995 Fall; 14(2):191–209

Health behavior correlates of hazardous drinking by Army personnel. Fertig JB, et al. **Mil Med** 1996 Jun;161(6):352–5

Cultural aspects of substance abuse and alcoholism. Assessment and management. Westermeyer J. **Psychiatr Clin North Am** 1995 Sep;18(3):589–605 (68 ref.)

Alcohol abuse in individuals exposed to trauma: a critical review. Stewart SH. **Psychol Bull** 1996 Jul;120(1):83–112 (280 ref.)

Interpersonal dependency in alcoholic and obese men. Mills JK. **Psychol Rep** 1995 Jun;76(3 Pt 1):737–8

Personality, peer influence, and use of alcohol and drugs by first-year university students. Valliant PM. **Psychol Rep** 1995 Oct;77(2):401–2

Neuroendocrine support for a relationship between "novelty seeking" and dopaminergic function in alcohol-dependent men. Wiesbeck GA, et al. **Psychoneuroendocrinology** 1995; 20(7):755–61

Family climate and parent-child relationships: recollections from a nonclinical sample of adult children of alcoholic fathers. Tweed SH, et al. **Res Nurs Health** 1996 Aug; 19(4):311–21

Expectations and motives for substance use in schizophrenia. Mueser KT, et al. **Schizophr Bull** 1995;21(3):367–78

Domestic abuse by male alcohol and drug addicts. Bennett LW, et al. **Violence Vict** 1994 Winter;9(4):359–68

A grounded theory of balancing alcohol recovery and pregnancy. Brudenell I. **West J Nurs Res** 1996 Aug; 18(4):429–40

[External validity, reliability and basic score determination of the Toronto Alexithymia Scales (TAS and TAS-20) in a group of alcoholic patients] Loas G, et al. **Encephale** 1996 Jan–Feb;22(1):35–40 (Eng. Abstr.) **(Fre)**

[Alcoholism from the psychiatric viewpoint. Diagnosis, neurobiology, pathophysiology and clinical manifestations] Wiesbeck GA, et al. **Internist (Berl)** 1996 Jul;37(7):761–72 (10 ref.) **(Ger)**

[Effect of verbal reinforcement on visual-spatial function] Tsagareli MG. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):73–6 **(Rus)**

[Effect of pharmacotherapy of affective disorders on the psycho-semantics of alcoholic patients] Krupitskii EM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(6):67–71 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Neuroimaging in alcoholism: CT and MRI results and clinical correlates. Mann K, et al. **J Neural Transm Gen Sect** 1995; 99(1–3):145–55 (76 ref.)

[A solitary pulmonary nodule in an alcoholic patient] Arjona A, et al. **Rev Clin Esp** 1995 Sep;195(9):661–2 **(Spa)**

REHABILITATION

Randomized perturbed posturography in abstinent chronic alcoholics. Ledin T. **Acta Otolaryngol Suppl (Stockh)** 1995; 520 Pt 2:447–9

Significant reversibility of alcoholic brain shrinkage within 3 weeks of abstinence. Trabert W, et al. **Acta Psychiatr Scand** 1995 Aug;92(2):87–90

Relationship of depression with measures of social functioning in adult drug abusers. Donohue B, et al. **Addict Behav** 1996 Mar–Apr;21(2):211–6

Two pathways out of drinking problems without professional treatment. Humphreys K, et al. **Addict Behav** 1995 Jul–Aug; 20(4):427–41

Remediation can only give what it has, so do not ask too much. Assailly JP. **Addiction** 1995 Dec;90(12):1594–5; discussion 1595–601

Alcohol, other drugs, and what we gain from our patients [editorial] Edwards G. **Addiction** 1995 Aug;90(8):1021–3

Entering treatment for alcohol abuse: a stress and coping model. Finney JW, et al. **Addiction** 1995 Sep;90(9):1223–40

Meta-analysis helps to define the policy-relevance of drink driving research. Hedlund J. **Addiction** 1995 Dec; 90(12):1593–4; discussion 1595–601

Nicotine patch therapy for smoking cessation in recovering alcoholics. Hurt RD, et al. **Addiction** 1995 Nov; 90(11):1541–6

Comments on brief intervention of alcohol problems: a review of a review [letter; comment] Jönson H, et al. **Addiction** 1995 Aug;90(8):1118–21. Comment on: Addiction 1993 Mar;88(3):315–35.

Acamprosate in alcohol dependence: how does it work? Littleton J. **Addiction** 1995 Sep;90(9):1179–88 (42 ref.)

Meta-analysis of remedial interventions with drink/drive offenders: a useful clarification of what is and is not known. McKnight AJ. **Addiction** 1995 Dec;90(12):1591–2; discussion 1595–601

Settling old questions, stimulating new ones [comment] Mann RE. **Addiction** 1995 Dec;90(12):1587–9; discussion 1595–601 . Comment on: Addiction 1995 Jul;90(7):907–26.

How to have a high success rate in treatment: advice for evaluators of alcoholism programs. Miller WR, et al. **Addiction** 1996 Jun;91(6):779–85

Explaining abstinence rates following treatment for alcohol abuse: a quantitative synthesis of patient, research design and treatment effects. Monahan SC, et al. **Addiction** 1996 Jun;91(6):787–805

The need to standardize methodology. Nickel WR. **Addiction** 1995 Dec;90(12):1595; discussion 1595–601

Inherent problems with meta-analysis [comment] Peck RC. **Addiction** 1995 Dec;90(12):1589–91; discussion 1595–601. Comment on: Addiction 1995 Jul;90(7):907–26.

Management and treatment efficacy of drug and alcohol problems: what do doctors believe? Roche AM, et al. **Addiction** 1995 Oct;90(10):1357–66

The histories of withdrawal convulsions and delirium tremens in 1648 alcohol dependent subjects. Schuckit MA, et al. **Addiction** 1995 Oct;90(10):1335–47

Controlled drinking after 25 years: how important was the great debate? [editorial] Sobell MB, et al. **Addiction** 1995 Sep;90(9):1149–53; discussion 1157–77 (28 ref.)

Do cage scores predict readiness to reduce alcohol consumption in medical in-patients? Dent TH, et al. **Alcohol Alcohol** 1995 Sep;30(5):577–80

Interpreting the evidence on brief interventions for excessive drinkers: the need for caution. Heather N. **Alcohol Alcohol** 1995 May;30(3):287–96 (35 ref.)

Out-patient alcohol detoxification—outcome after 2 months. Klijnsma MP, et al. **Alcohol Alcohol** 1995 Sep;30(5):669–73

The Windsor Clinic Alcohol Withdrawal Assessment Scale (WCAWAS): investigation of factors associated with complicated withdrawals. Metcalfe P, et al. **Alcohol Alcohol** 1995 May;30(3):367–72

Prevalence of alcohol problems among adult somatic in-patients in Naples. Rambaldi A, et al. **Alcohol Alcohol** 1995 Jul;30(4):441–8

Alcohol consumption and visual contrast sensitivity. Roquelaure Y, et al. **Alcohol Alcohol** 1995 Sep;30(5):681–5

Treatment, health promotion and alcohol controls and the decrease of alcohol consumption and problems in Ontario: 1975–1993. Smart RG, et al. **Alcohol Alcohol** 1995 May; 30(3):337–43

The irreversible gamma-aminobutyrate transaminase inhibitor vigabatrin in the treatment of the alcohol withdrawal syndrome [letter] Stuppaeck CH, et al. **Alcohol Alcohol** 1996 Jan;31(1):109–11

Physical morbidity in patients admitted to a private hospital for detoxification from alcohol. Wylie AS, et al. **Alcohol Alcohol** 1995 Sep;30(5):641–3

Acute encephalopathy and polyneuropathy after disulfiram intoxication. Zorzon M, et al. **Alcohol Alcohol** 1995 Sep; 30(5):629–31

Development and initial validation of a measure of drinking urges in abstinent alcoholics. Bohn MJ, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):600–6

Detection of relapses in alcohol-dependent patients using carbohydrate-deficient transferrin: improvement with individualized reference levels during long-term monitoring. Borg S, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):961–3

DSM-IV alcohol dependence in a treatment sample of white, black, and Mexican-American men. Caetano R, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):384–90

Conference summary: Consensus Conference on Alcohol Dependence and the Role of Pharmacotherapy in its Treatment. Chick J, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):391–402 (82 ref.)

Voice of the Victims. Erickson CK.

Alcohol Clin Exp Res 1996 Apr;20(2):403
Voice of the victims. Erickson CK.
Alcohol Clin Exp Res 1995 Dec;19(6):1594–5
Voice of the victims. Erickson CK.
Alcohol Clin Exp Res 1996 Feb;20(1):93
Evidence for reduced dopamine D2 receptor sensitivity in postwithdrawal alcoholics. Farren CK, et al.
Alcohol Clin Exp Res 1995 Dec;19(6):1520–4
D-fenfluramine-induced prolactin responses in postwithdrawal alcoholics and controls. Farren CK, et al.
Alcohol Clin Exp Res 1995 Dec;19(6):1578–82
Toward an alcohol treatment model: a comparison of treated and untreated respondents with DSM-IV alcohol use disorders in the general population. Grant BF.
Alcohol Clin Exp Res 1996 Apr;20(2):372–8
Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers. Kranzler HR, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):16–20 (20 ref.)
Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Malec E, et al.
Alcohol Clin Exp Res 1996 Apr;20(2):307–12
Brain proton magnetic resonance spectroscopy studies in recently abstinent alcoholics. Martin PR, et al.
Alcohol Clin Exp Res 1995 Aug;19(4):1078–82
Late-onset seizures in alcohol withdrawal. Mayo-Smith MF, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):656–9
Effects of cerebral electrical stimulation on alcoholism: a pilot study. Padjen AL, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1004–10
Longitudinal changes in magnetic resonance imaging brain volumes in abstinent and relapsed alcoholics. Pfefferbaum A, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1177–91
Evaluation of the Alcopatch, a transdermal dosimeter for monitoring alcohol consumption. Phillips M, et al.
Alcohol Clin Exp Res 1995 Dec;19(6):1547–9
Utility of carbohydrate-deficient transferrin as a marker of relapse in alcoholic patients. Rosman AS, et al.
Alcohol Clin Exp Res 1995 Jun;19(3):611–6
Cyanamide-associated alcoholic liver disease: a sequential histological evaluation. Yokoyama A, et al.
Alcohol Clin Exp Res 1995 Oct;19(5):1307–11
Influence of social desirability response set on self-report for assessing the outcome of treated alcoholics. Yoshino A, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1517–9
The effects of travel barriers and age on the utilization of alcoholism treatment aftercare. Fortney JC, et al.
Am J Drug Alcohol Abuse 1995 Aug;21(3):391–406
Effects of halfway house placement on retention of patients in substance abuse aftercare. Hitchcock HC, et al.
Am J Drug Alcohol Abuse 1995 Aug;21(3):379–90
Prediction of 3-year outcome of treated alcoholics by an empirically derived multivariate typology. Yoshino A, et al. **Am. J Psychiatry** 1996 Jun;153(6):829–30
Polygraphic sleep measures differentiate alcoholics and stimulant abusers during short-term abstinence. Thompson PM, et al. **Biol Psychiatry** 1995 Dec 15;38(12):831–6
Intellectual impairment among recently abstinent alcohol abusers. O'Mahony JF, et al. **Br J Clin Psychol** 1996 Feb; 35 (Pt 1):77–83
The role of self-help programs in the rehabilitation of persons with severe mental illness and substance use disorders. Noordsy DL, et al. **Community Ment Health J** 1996 Feb; 32(1):71–81; discussion 83–6
The tridimensional personality model: influencing variables in a sample of detoxified alcohol dependents. European Fluvoxamine in Alcoholism Study Group. Meszaros K, et al. **Compr Psychiatry** 1996 Mar-Apr;37(2):109–14
Innovative perspectives on strategies to develop effective alcoholism treatment programs. **Drug Alcohol Depend** 1995 Sep;39 Suppl 1:S23–4
The treatment of alcoholism in France. Batel P.
Drug Alcohol Depend 1995 Sep;39 Suppl 1:S15–21
The treatment mapping survey; a descriptive study of drug and alcohol treatment responses in 23 countries. Gossop M. **Drug Alcohol Depend** 1995 Jul;39(1):7–14
Factors associated with coping in persons undergoing alcohol and drug detoxification. Madden C, et al.
Drug Alcohol Depend 1995 Jun;38(3):229–35
Current strategies for the treatment of alcohol dependence in the United States. O'Malley SS.
Drug Alcohol Depend 1995 Sep;39 Suppl 1:S3–7
Pharmacotherapy and psychotherapy for the treatment of alcoholism in Germany. Soyka M.
Drug Alcohol Depend 1995 Sep;39 Suppl 1:S9–13 (40 ref.)
Residual pressor effects of chronic alcohol in detoxified alcoholics. York JL, et al. **Hypertension** 1996 Jul; 28(1):133–8
The efficacy of treatments in reducing alcohol consumption: a meta-analysis. Agosti V. **Int J Addict** 1995 Jun; 30(8):1067–77
Quality of alcohol use histories collected at intake to substance user treatment. Turner CF, et al.
Int J Addict 1995 Jun;30(8):963–89
A treatment model for women substance users. Wald R, et al. **Int J Addict** 1995 May;30(7):881–8
Factors associated with the receipt of alcohol treatment services among American Indian adolescents. Novins DK, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan; 35(1):110–7
Alpha-theta brainwave neurofeedback training: an effective treatment for male and female alcoholics with depressive symptoms. Saxby E, et al. **J Clin Psychol** 1995 Sep; 51(5):685–93
Determinants of research follow-up participation in an alcohol treatment outcome trial. Stout RL, et al.
J Consult Clin Psychol 1996 Jun;64(3):614–8
Levels of dissociation in detoxified substance abusers and their relationship to chronicity of alcohol and drug use. Wenzel K, et al. **J Nerv Ment Dis** 1996 Apr;184(4):220–7
Alcohol-related risk factors associated with HIV infection among patients entering alcoholism treatment: implications for prevention. Boscarino JA, et al. **J Stud Alcohol** 1995 Nov;56(6):642–53
Stress, vulnerability and adult alcohol relapse. Brown SA, et al. **J Stud Alcohol** 1995 Sep;56(5):538–45
Reality monitoring in recovering alcoholics. Burnett LJ, et al. **J Stud Alcohol** 1996 Mar;57(2):210–6
Harmful effects of drinking and the use and perceived effectiveness of treatment. Burton TL, et al.
J Stud Alcohol 1995 Nov;56(6):611–5
Alcoholism and typology: findings in an Irish private hospital population. Farren CK, et al. **J Stud Alcohol** 1996 May; 57(3):249–52
The cost-effectiveness of treatment for alcoholism: a second approximation. Finney JW, et al. **J Stud Alcohol** 1996 May; 57(3):229–43
Examining mediators of change in traditional chemical dependency treatment. Morgenstern J, et al.
J Stud Alcohol 1996 Jan;57(1):53–64
The Adolescent Relapse Coping Questionnaire: psychometric validation. Myers MG, et al. **J Stud Alcohol** 1996 Jan; 57(1):40–6
Validation of daily self-reported alcohol consumption using interactive voice response (IVR) technology. Perrine MW, et al. **J Stud Alcohol** 1995 Sep;56(5):487–90
Short-term treatment careers and outcomes of previously untreated alcoholics. Timko C, et al. **J Stud Alcohol** 1995 Nov;56(6):597–610
AA group dynamics and 12-step activity. Tonigan JS, et al. **J Stud Alcohol** 1995 Nov;56(6):616–21
Meta-analysis of the literature on Alcoholics Anonymous: sample and study characteristics moderate findings. Tonigan JS, et al. **J Stud Alcohol** 1996 Jan;57(1):65–72
Combined behavioral and pharmacological treatment of alcoholic methadone patients. Bickel WK, et al.
J Subst Abuse 1988-89;1(2):161–71
Resolution from alcohol problems with and without treatment: reasons for change. Cunningham JA, et al.
J Subst Abuse 1995;7(3):365–72
Family and client characteristics as predictors of outpatient treatment outcome for adolescent drug abusers. Friedman AS, et al. **J Subst Abuse** 1995;7(3):345–56
Twelve-step program use among Oxford House residents: spirituality or social support in sobriety? Nealon-Woods MA, et al. **J Subst Abuse** 1995;7(3):311–8
Self-efficacy, standards, and abstinence violation: a comparison between newly sober and long-term sober alcoholics. Ross SM, et al. **J Subst Abuse** 1988–89; 1(2):221–9
Situational analysis of coping in substance-abusing patients. Schmitz JM, et al. **J Subst Abuse** 1995;7(2):189–204
Compliance among heavy alcohol users in clinical drug trials. Sullivan JT, et al. **J Subst Abuse** 1988–89;1(2):183–94
Effect of cigarette smoking on alcohol treatment outcome. Toneatto A, et al. **J Subst Abuse** 1995;7(2):245–52
Social settings and addiction relapse. Walton MA, et al.
J Subst Abuse 1995;7(2):223–33
Perceptuomotor function of homeless males in alcohol rehabilitation. Zlotnick C, et al. **J Subst Abuse** 1995; 7(2):235–44
The effect of anxiety and depression on completion/withdrawal status in patients admitted to substance abuse detoxification program. Araujo L, et al. **J Subst Abuse Treat** 1996 Jan-Feb;13(1):61–6
Trazodone for the treatment of depression in alcoholics [letter] Hershberg PI. **J Subst Abuse Treat** 1995 Jul-Aug; 12(4):297
Recovering substance abuse staff members' beliefs about addiction. Humphreys K, et al. **J Subst Abuse Treat** 1996 Jan-Feb;13(1):75–8
The 1994 distinguished lecturer in substance abuse. Khantzian EJ. **J Subst Abuse Treat** 1995 May-Jun;12(3):157–65
Group intervention with pre-recovery patients. Martin K, et al. **J Subst Abuse Treat** 1996 Jan-Feb;13(1):33–41
A retrospective study of the concept of spirituality as understood by recovering individuals. Mathew RJ, et al. **J Subst Abuse Treat** 1996 Jan-Feb;13(1):67–73
Does Alcoholics Anonymous involvement predict treatment outcome? Montgomery HA, et al. **J Subst Abuse Treat** 1995 Jul-Aug;12(4):241–6
Treatment of alcohol and cocaine addiction by the combination of pemoline and fenfluramine: a preliminary case series [letter] Rothman RB. **J Subst Abuse Treat** 1995 Nov-Dec;12(6):449–53
Community mobile treatment. What it is and how it works. Wiebe J, et al. **J Subst Abuse Treat** 1996 Jan-Feb; 13(1):23–31
Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. Hurt RD, et al. **JAMA** 1996 Apr 10;275(14):1097–103
Treatment of alcoholism and nicotine dependence [letter] Zucker RS. **JAMA** 1996 Sep 11;276(10):783–4
CQI action team: responding to the detoxification patient. Gunn SR, et al. **Jt Comm J Qual Improv** 1995 Oct; 21(10):531–40
Alcoholics anonymous and rational recovery: readability of the "big book" vs the small book. Rather BC, et al.
Percept Mot Skills 1995 Dec;81(3 Pt 2):1313–4
The Supreme Court's ruling in Edmonds v. Oxford house: implications for group homes. Petrila J. **Psychiatr Serv** 1995 Oct;46(10):1011–2
New developments in employee assistance programs. White RK, et al. **Psychiatr Serv** 1996 Apr;47(4):387–91
Assessing effects of treatment for substance abuse: a further contribution to the validation of the Employee Reliability Inventory. Borofsky GL, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):1043–9
Childhood abuse as a factor in attrition from drug rehabilitation. Palmer JA, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):879–82
Clinical pathway effects on treatment of the alcohol withdrawal syndrome. Morgan T, et al. **S D J Med** 1996 Jun;49(6):195–200
The road to recovery. New law removes one barrier to rehabilitation for impaired physicians. Jones TL.
Tex Med 1995 Aug;91(8):22–4
Psychiatric prognostic factors in patients with alcohol-related end-stage liver disease before liver transplantation. Röggla H, et al. **Wien Klin Wochenschr** 1996;108(9):272–5
[Drug addiction. The social medical approach to the addiction epidemic] van Santen G.
Ned Tijdschr Geneeskd 1995 Dec 16;139(50):2601–3 **(Dut)**
[Opinion and attitude of physicians regarding organization and participation on a multidisciplinary alcoholism unit] Boitel S, et al. **Schweiz Arch Neurol Psychiatr** 1996; 147(1):19–24 (Eng. Abstr.) **(Fre)**
[Alcohol administration for prevention of withdrawal delirium in alcohol dependent surgical intensive care patients: pro] Engelhardt W.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Apr; 31(3):183–4 **(Ger)**
[Alcohol as therapeutic drug in alcohol dependent intensive care patients: contra] Krumholz W.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Apr; 31(3):181–2 **(Ger)**
[Change in automobile driving capacity assessment--a contribution to the correlation between diagnosis and therapy] Pund B, et al. **Blutalkohol** 1996 Jan;33(1):31–43 (Eng. Abstr.) **(Ger)**
[Driving ban--a blunt weapon? Response to the comment by Bode (letter; comment)] Zabel RG. **Blutalkohol** 1996 Jan;33(1):44–6. Comment on: Blutalkohol 1995 Nov;32(6):314–6. **(Ger)**
[Role of the family physician in treatment of alcoholic patients] Kuth N, et al. **Fortschr Med** 1995 Nov 30; 113(33):473–5 (Eng. Abstr.) **(Ger)**
[The alcoholic patient in general practice. From initial contact to implementing therapy] Luderer HJ.
Fortschr Med 1995 Nov 30;113(33):469–72 (17 ref.) (Eng. Abstr.) **(Ger)**
[Craving--an adequately defined concept?] Wetterling T, et al. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):142–52 (136 ref.) (Eng. Abstr.) **(Ger)**
[The hospital, a site for prevention? From prevention of drug dependence to general drug promotion] Fleischmann H, et al. **Gesundheitswesen** 1996 Jun;58(6):315–8 (Eng. Abstr.) **(Ger)**
[Criteria for admission of drug dependent criminals for withdrawal treatment according to section 64 StGB with reference to the newest legal guidelines] Möller A, et al.
Gesundheitswesen 1996 May;58(5):283–7 (Eng. Abstr.) **(Ger)**
[Treatment of drug dependent patients in a psychiatric department] Grischke-Silber J, et al. **Psychiatr Prax** 1995 Sep;22(5):193–6 (Eng. Abstr.) **(Ger)**
[Motivational work with alcohol dependent patients] John U, et al. **Psychiatr Prax** 1995 Sep;22(5):186–8 (Eng. Abstr.) **(Ger)**
[Drug dependence in psychiatric practice--new trends in therapy of dependence (editorial)] Krausz M.
Psychiatr Prax 1995 Sep;22(5):177–8 **(Ger)**
[Results of integrated inpatient detoxification and motivation treatment of alcohol dependent patients] Stetter F, et al.
Psychiatr Prax 1995 Sep;22(5):189–92 (Eng. Abstr.) **(Ger)**
[Alcohol abusers after treatment at a clinic--a follow-up study] Sexton H. **Tidsskr Nor Laegeforen** 1995 Sep 20; 115(22):2768–72 (Eng. Abstr.) **(Nor)**
[Urinary beta-hexosaminidase activity as a marker for the monitoring of sobriety] Wehr H, et al. **Psychiatr Pol** 1995 Sep-Oct;29(5):689–96 (Eng. Abstr.) **(Pol)**

THERAPY

Diagnosis and treatment of drug and alcohol abuse in women. Kaufman E. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):21–7 (27 ref.)
Practice guideline for the treatment of patients with substance use disorders: alcohol, cocaine, opioids. American Psychiatric Association. **Am J Psychiatry** 1995 Nov;152(11 Suppl):1–80
Recovery from alcohol problems with and without treatment: prevalence in two population surveys. Sobell LC, et al. **Am J Public Health** 1996 Jul;86(7):966–72

Differential treatment: considerations for the female alcoholic. Cirillo JM. **Ann N Y Acad Sci** 1996 Jun 18; 789:83–99

The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Anton RF, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):225–31

Alcohol treatment and health care system reform. McCrady BS, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):737–46 (109 ref.)

Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. O'Malley SS, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):217–24

Identifying and managing problem drinkers. Kahan M. **Can Fam Physician** 1996 Apr;42:661–71 (59 ref.)

Treating alcoholism through a narrative approach. Case study and rationale. Kaminsky D, et al. **Can Fam Physician** 1996 Apr;42:673–6

Alcohol risk assessment and intervention for family physicians. Project of the College of Family Physicians of Canada. Peters C, et al. **Can Fam Physician** 1996 Apr; 42:681–9 (31 ref.)

Concurrent cocaine withdrawal is associated with reduced severity of alcohol withdrawal. Castaneda R, et al. **Compr Psychiatry** 1995 Nov–Dec;36(6):441–7

Impact of prior and current alcohol use on use of services by patients with depression and chronic medical illnesses. Jackson CA, et al. **Health Serv Res** 1995 Dec;30(5):687–705

Themes and variations among seven comprehensive perinatal drug and alcohol abuse treatment models. Clayson Z, et al. **Health Soc Work** 1995 Aug;20(3):234–8

Alcoholism: the role of different motivational systems. Pihl RO, et al. **J Psychiatry Neurosci** 1995 Nov;20(5):372–96 (205 ref.)

Outcome of domiciliary care after inpatient alcoholism treatment in male veterans. Ross R, et al. **J Subst Abuse Treat** 1995 Sep–Oct;12(5):319–26

Does this treatment work? Validation of an outcomes module for alcohol dependence. Rost KM, et al. **Med Care** 1996 Apr;34(4):283–94

Alcoholics anonymous and rational recovery: readability of the "big book" vs the small book. Rather BC, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1313–4

Prevention and treatment of alcoholism [letter] Wartenberg AA. **Postgrad Med** 1996 Sep;100(3):48, 50

Treatment approaches to alcohol problems. Heather N. **WHO Reg Publ Eur Ser** 1995;65:1–201 (262 ref.)

[Ambulatory treatment of alcoholics. A prospective study] Nielsen B, et al. **Ugeskr Laeger** 1996 May 27;158(22):3160–3 (Eng. Abstr.) **(Dan)**

[Alcohol abusers after treatment at clinics—a follow-up study (letter)] Vollset P. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3180 **(Nor)**

[The effect of electrotranquilization on the hormonal indices of alcoholic patients] Darenskiĭ ID, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):67–9 (Eng. Abstr.) **(Rus)**

[The follow-up of therapeutic remission in alcoholics] Iakovchenko VA. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(2):57–60 (Eng. Abstr.) **(Rus)**

[Detection and intervention in excessive alcohol consumption (letter)] Delgado MT, et al. **Med Clin (Barc)** 1996 Mar 30;106(12):477–8 **(Spa)**

URINE

Laboratory testing for recent alcohol consumption: comparison of ethanol, methanol, and 5-hydroxytryptophol. Helander A, et al. **Clin Chem** 1996 Apr;42(4):618–24

VIROLOGY

Infection with hepatitis B or C virus of peripheral blood mononuclear cells in serologically negative chronic alcoholic patients [letter] Baischer W, et al. **J Hepatol** 1995 Oct;23(4):481

ALCOHOLS

Interim and archival preservation of plant specimens in alcohols for DNA studies. Flournoy LE, et al. **Biotechniques** 1996 Apr;20(4):657–60

ADVERSE EFFECTS

Relative sensitivity of the ocular trigeminal, nasal trigeminal and olfactory systems to airborne chemicals. Cometto-Muñiz JE, et al. **Chem Senses** 1995 Apr; 20(2):191–8

ANALYSIS

A full evaporation headspace technique with capillary GC and ITD: a means for quantitating volatile organic compounds in biological samples. Schuberth J. **J Chromatogr Sci** 1996 Jul;34(7):314–9

CHEMICAL SYNTHESIS

Facile syntheses of C2-symmetrical HIV-1 protease inhibitors. König S, et al. **Arch Pharm (Weinheim)** 1995 Oct;328(10):699–704

CHEMISTRY

In vitro influences of alcohols on mouse synaptosomes, and structure–activity relationships. Tanii H, et al. **Arch Toxicol** 1995;69(9):617–23

Structural functions of antimicrobial long-chain alcohols and phenols. Kubo I, et al. **Bioorg Med Chem** 1995 Jul; 3(7):873–80

Detection of substances with alcoholic or phenolic hydroxyl groups by generation of hydrogen peroxide with imidazole and peroxyoxalate chemiluminescence. Nozaki O, et al. **J Biolumin Chemilumin** 1995 Nov–Dec;10(6):339–44

Structure–odor relationships: using neural networks in the estimation of camphoraceous or fruity odors and olfactory thresholds of aliphatic alcohols. Chastrette M, et al. **J Chem Inf Comput Sci** 1996 Jan–Feb;36(1):108–13

Quantitative relationships of structure-activity and volume fraction for selected nonpolar and polar narcotic chemicals. Jaworska JS, et al. **SAR QSAR Environ Res** 1993;1(1):3–19

Competing pathway involved in allylic acetoxylation of androst-5-en-17-one, and oxidation of allylic alcohols with chromium oxides. Numazawa M, et al. **Steroids** 1995 Aug; 60(8):499–505

Aminopropylation of vitamin D hormone (1 alpha,25-dihydroxyvitamin D3), its biological precursors, and other steroidal alcohols: an anchoring moiety for affinity studies of sterols. Roy A, et al. **Steroids** 1995 Aug; 60(8):530–3

METABOLISM

Peroxidase-mediated bromination of unsaturated fatty acids to form bromohydrins. Carr AC, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):227–33

Cloning and expression of a rat liver phenobarbital-inducible UDP-glucuronosyltransferase (2B12) with specificity for monoterpenoid alcohols. Green MD, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):460–8

Comparison of the metabolism of alcohols by rat hepatic and pulmonary alcohol dehydrogenase. Carlson GP, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):65–71

Reactivity of alcohols toward the phosphoenzyme intermediate in the protein-tyrosine phosphatase-catalyzed reaction: probing the transition state of the dephosphorylation step. Zhao Y, et al. **Biochemistry** 1996 Sep 10;35(36):11797–804

In vitro cell injury by oxidized low density lipoprotein involves lipid hydroperoxide-induced formation of alkoxyl, lipid, and peroxyl radicals. Coffey MD, et al. **J Clin Invest** 1995 Oct;96(4):1866–73

Substrate specificity of nine NAD(+)-dependent alcohol dehydrogenases in Aspergillus nidulans. Sealy-Lewis HM, et al. **Microbiology** 1995 Sep;141 (Pt 9):2295–300

Quantitative structure-biodegradability relationships (QSBRs) using modified autocorrelation method (MAM). Zakarya D, et al. **SAR QSAR Environ Res** 1993;1(1):21–7

Species- and gender-related differences in amine, alcohol and phenol sulphoconjugations. Shiraga T, et al. **Xenobiotica** 1995 Nov;25(10):1063–71

PHARMACOKINETICS

[Congener analysis in a drinking trial with unusually high alcohol content] Schmitt G, et al. **Blutalkohol** 1995 Nov; 32(6):337–43 (Eng. Abstr.) **(Ger)**

[Formation of so-called byproducts (propanols, butanols et al.) from ethanol by microorganisms] Stöhlmacher P. **Blutalkohol** 1996 May;33(3):113–41 (200 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Inhibition of the cerebellar inositol 1,4,5-trisphosphate-sensitive Ca2+ channel by ethanol and other aliphatic alcohols. Mezna M, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):175–9

Effects of alkanols, alkanediols and glycerol on red blood cell shape and hemolysis. Bakaltcheva IB, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):73–80

Actions of long chain alcohols on GABAA and glutamate receptors: relation to in vivo effects. Dildy-Mayfield JE, et al. **Br J Pharmacol** 1996 May;118(2):378–84

Micelle-like conformation of humic substances as revealed by size exclusion chromatography. Piccolo A, et al. **Chemosphere** 1996 Aug;33(4):595–602

Reversible inhibition of gap junctional intercellular communication, synchronous contraction, and synchronism of intracellular Ca2+ fluctuation in cultured neonatal rat cardiac myocytes by heptanol. Kimura H, et al. **Exp Cell Res** 1995 Oct;220(2):348–56

Correlation between the n-alkanols-induced sensitization of erythrocytes to hyperthermia and the fluidization of their membrane. Ivanov IT, et al. **Int J Hyperthermia** 1995 Sep–Oct;11(5):673–83

Primary alcohols modulate the activation of the G protein-coupled receptor rhodopsin by a lipid-mediated mechanism. Mitchell DC, et al. **J Biol Chem** 1996 Aug 9;271(32):19033–6

Relationship of alcohol-induced changes in Mg(2+)-ATPase activity of rabbit intestinal brush border membrane with changes in fluidity of its lipid bilayer. Kitagawa S, et al. **J Membr Biol** 1995 Jul;146(2):193–9

Inhibition of rho1 receptor GABAergic currents by alcohols and volatile anesthetics. Mihic SJ, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):411–6

'Fusel' alcohols induce hyphal-like extensions and pseudohyphal formation in yeasts. Dickinson JR. **Microbiology** 1996 Jun;142 (Pt 6):1391–7

A structural basis for enantioselective inhibition of Candida rugosa lipase by long-chain aliphatic alcohols. Holmquist M, et al. **Protein Sci** 1996 Jan;5(1):83–8

A phenomenological model describing pharyngeal pulsing in the nematode Caenorhabditis elegans anesthetized by alcohol. Biswas SN, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):233–44

POISONING

Unknown alcohol [letter] Linden CH. **Ann Emerg Med** 1996 Sep;28(3):371

THERAPEUTIC USE

The treatment of the splitting nail with phenol alcohol partial nail matricectomy. Miller MA, et al. **Dermatol Surg** 1996 Apr;22(4):388–90

Anti-ulcer activity of higher primary alcohols of beeswax. Carbajal D, et al. **J Pharm Pharmacol** 1995 Sep;47(9):731–3

TOXICITY

Spheroid cultures of human hepatoblastoma cells (HuH-6 line) and their application for cytotoxicity assay of alcohols. Kosaka T, et al. **Acta Med Okayama** 1996 Apr;50(2):61–6

In vitro influences of alcohols on mouse synaptosomes, and structure–activity relationships. Tanii H, et al. **Arch Toxicol** 1995;69(9):617–23

[The hygienic standardization of 3-phenoxybenzyl alcohol in the atmospheric air of populated places] Iskandarova ShT. **Gig Sanit** 1995 Nov–Dec;(6):6–8 (Eng. Abstr.) **(Rus)**

[Effects of ethanol on thyroid gland development] Matavulj M, et al. **Med Pregl** 1994;47(9–10):314–9 (Eng. Abstr.) **(Scr)**

ALCOHOLS, AMYL

ADMINISTRATION & DOSAGE

Acute hepatotoxicity of acetaminophen in rats treated with ethanol plus isopentanol. Kostrubsky VE, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1743–8

Studies on the prenatal toxicity of 3-methyl-1-butanol and 2-methyl-1-propanol in rats and rabbits following inhalation exposure. Klimisch HJ, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):77–89

CHEMISTRY

Karalicin, a new biologically active compound from Pseudomonas fluorescens/putida. I. Production, isolation, physico-chemical properties and structure elucidation. Lampis G, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):260–2

METABOLISM

Karalicin, a new biologically active compound from Pseudomonas fluorescens/putida. I. Production, isolation, physico-chemical properties and structure elucidation. Lampis G, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):260–2

PHARMACOLOGY

Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Kostrubsky VE, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):516–20

Karalicin, a new biologically active compound from Pseudomonas fluorescens/putida. II. Biological properties. Lampis G, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):263–6

'Fusel' alcohols induce hyphal-like extensions and pseudohyphal formation in yeasts. Dickinson JR. **Microbiology** 1996 Jun;142 (Pt 6):1391–7

TOXICITY

Studies on the prenatal toxicity of 3-methyl-1-butanol and 2-methyl-1-propanol in rats and rabbits following inhalation exposure. Klimisch HJ, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):77–89

ALCOHOLS, BUTYL

ADMINISTRATION & DOSAGE

Studies on the prenatal toxicity of 3-methyl-1-butanol and 2-methyl-1-propanol in rats and rabbits following inhalation exposure. Klimisch HJ, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):77–89

BLOOD

Measurement of methyl tert-butyl ether and tert-butyl alcohol in human blood by purge-and-trap gas chromatography-mass spectrometry using an isotope-dilution method. Bonin MA, et al. **J Anal Toxicol** 1995 May–Jun;19(3):187–91

METABOLISM

Single-strand breaks in double-stranded DNA irradiated in anoxic solution: contribution of tert-butanol radicals.

ALCOHOLS, BUTYL

Udovičić L, et al. **Radiat Res** 1996 Aug;146(2):198–205

PHARMACOKINETICS

Biotransformation of lifibrol (U–83860) to mixed glyceride metabolites by rat and human hepatocytes in primary culture. Sun EL, et al. **Drug Metab Dispos** 1996 Feb; 24(2):221–31

Postmortem diffusion of ingested and aspirated paint thinner. Fuke C, et al. **Forensic Sci Int** 1996 Apr 23;78(3):199–207

Development of physiologically based pharmacokinetic model for methyl tertiary-butyl ether and tertiary-butanol in male Fisher-344 rats. Borghoff SJ, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):264–75

[Formation of so-called byproducts (propanols, butanols et al.) from ethanol by microorganisms] Stöhlmacher P. **Blutalkohol** 1996 May;33(3):113–41 (200 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Interaction of alkanols and local anesthetics with spin-labeled Ca(2+)-ATPase of sarcoplasmic reticulum vesicles. Anteneodo C, et al. **Biochim Biophys Acta** 1996 Jun 11; 1281(2):150–6

Altered in vivo and in vitro behavior of butanol-modified bone marrow cells. Joshi SS, et al. **Exp Hematol** 1995 Nov; 23(12):1284–8

Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series. Reich SH, et al. **J Med Chem** 1996 Jul 5;39(14):2781–94

TOXICITY

Studies on the prenatal toxicity of 3-methyl-1-butanol and 2-methyl-1-propanol in rats and rabbits following inhalation exposure. Klimisch HJ, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):77–89

Toxicity and carcinogenicity of t-butyl alcohol in rats and mice following chronic exposure in drinking water. Cirvello JD, et al. **Toxicol Ind Health** 1995 Mar–Apr; 11(2):151–65

Administration of subtoxic doses of t-butyl alcohol and trichloroacetic acid to male Wistar rats to study the interactive toxicity. Acharya S, et al. **Toxicol Lett** 1995 Oct;80(1–3):97–104

ALCOHOLS, HEXYL

PHARMACOLOGY

The nature of uncoupling by n-hexane, 1-hexanethiol and 1-hexanol in rat liver mitochondria. Canton M, et al. **Biochim Biophys Acta** 1996 May 20;1274(1–2):39–47

ALCOHOLS, OCTYL

Evaluation of light traps combined with carbon dioxide and 1-octen-3-ol to collect anophelines in Venezuela. Rubio-Palis Y. **J Am Mosq Control Assoc** 1996 Mar; 12(1):91–6

Comparison of carbon dioxide, octenol and a host-odour as mosquito attractants in the Upper Rhine Valley, Germany. Becker N, et al. **Med Vet Entomol** 1995 Oct;9(4):377–80

CHEMISTRY

Determination of octanol/water partition coefficients for long-chain homologs of orcinol from cereal grains. Kozubek A. **Acta Biochim Pol** 1995;42(2):247–51

Applicability of a continuum solvation model to the octanol water transfer: CFF91 based model for amino acids. Schmidt AB, et al. **Biopolymers** 1995 Nov;36(5):599–605

Rapid determination of logarithmic partition coefficients between n-octanol and water using micellar electrokinetic capillary chromatography. Smith JT, et al. **J Chromatogr B Biomed Appl** 1995 Jul 7;669(1):59–66

Comparison of structure-activity relationships derived from two methods for estimating octanol-water partition coefficients. Cash GG, et al. **SAR QSAR Environ Res** 1996; 5(2):113–24

METABOLISM

Growth on octane alters the membrane lipid fatty acids of Pseudomonas oleovorans due to the induction of alkB and synthesis of octanol. Chen Q, et al. **J Bacteriol** 1995 Dec; 177(23):6894–901

A distinctive effect of CCCP on the transfer of erythromycin to 1-octanol: a possible model in promoting the intracellular antibiotic-accumulation through lipid in a staphylococcal cytoplasmic membrane. Matsuoka M, et al. **Res Commun Mol Pathol Pharmacol** 1996 Apr;92(1):85–93

PHARMACOLOGY

Halothane and octanol block Ca2+ oscillations in pancreatic acini by multiple mechanisms. Deutsch DE, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G779–88

Octanol, a gap junction uncoupling agent, changes intracellular [H+] in rat astrocytes. Pappas CA, et al. **Glia** 1996 Jan;16(1):7–15

ALCOHOLS, SUGAR see **SUGAR ALCOHOLS**

ALCURONIUM

[Neuromuscular blockade after atracurium and alcuronium with propofol and thiopental] Ginz HF, et al. **Anaesthesist** 1996 Jan;45(1):47–51 (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

The pharmacodynamics and pharmacokinetics of alcuronium [letter; comment] Parker CJ, et al. **Anesth Analg** 1995 Dec; 81(6):1315–6. Comment on: Anesth Analg 1995 Feb;80(2):373–7.

Pharmacokinetics of alcuronium in children with acyanotic and cyanotic cardiac disease undergoing cardiopulmonary bypass surgery. Weekes LM, et al. **Paediatr Anaesth** 1995; 5(6):369–74

PHARMACOLOGY

The pharmacodynamics and pharmacokinetics of alcuronium [letter; comment] Parker CJ, et al. **Anesth Analg** 1995 Dec; 81(6):1315–6. Comment on: Anesth Analg 1995 Feb;80(2):373–7.

Positive and negative allosteric interactions on muscarinic receptors. Hejnová L, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):427–30

Subtype selectivity of the positive allosteric action of alcuronium at cloned M1–M5 muscarinic acetylcholine receptors. Jakubík J, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1077–83

Competition between positive and negative allosteric effectors on muscarinic receptors. Proška J, et al. **Mol Pharmacol** 1995 Oct;48(4):696–702

Positive allosteric action of alcuronium on solubilized cardiac muscarinic receptors. Musílková J, et al. **Neurochem Int** 1995 Oct–Nov;27(4–5):337–43

[Clinical research of muscular relaxation induced by alcuronium and pancuronium] Gong Z, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Aug; 17(4):301–4 (Eng. Abstr.) **(Chi)**

ALCURONIUM CHLORIDE see **ALCURONIUM**

ALDEHYDE DEHYDROGENASE

ANALYSIS

Microtiter plate-based determination of multiple concentration-inhibition relationships. Nelson AN, et al. **Anal Biochem** 1995 Nov 1;231(2):437–9

ANTAGONISTS & INHIBITORS

Nitrate esters as inhibitors and substrates of aldehyde dehydrogenase. Pietruszko R, et al. **Adv Exp Med Biol** 1995;372:25–34

Characterization of the in vivo inhibition of rat hepatic microsomal aldehyde dehydrogenase activity by metyrapone. Martini R, et al. **Biochem Pharmacol** 1996 May 3;51(9):1187–93

S-methylation as a bioactivation mechanism for mono- and dithiocarbamate pesticides as aldehyde dehydrogenase inhibitors. Staub RE, et al. **Chem Res Toxicol** 1995 Dec; 8(8):1063–9

Phenethyl isothiocyanate, a new dietary liver aldehyde dehydrogenase inhibitor. Lindros KO, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):79–83

Changes in serotonin metabolism during treatment with the aldehyde dehydrogenase inhibitors disulfiram and cyanamide. Beck O, et al. **Pharmacol Toxicol** 1995 Nov; 77(5):323–6

Daidzin suppresses ethanol consumption by Syrian golden hamsters without blocking acetaldehyde metabolism. Keung WM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8990–3

BIOSYNTHESIS

Studies on the induction of rat class 3 aldehyde dehydrogenase. Pappas P, et al. **Adv Exp Med Biol** 1995; 372:143–9 (37 ref.)

Constitutive and overexpressed human cytosolic class-3 aldehyde dehydrogenases in normal and neoplastic cells/secretions. Sladek NE, et al. **Adv Exp Med Biol** 1995; 372:103–14 (41 ref.)

Comparative assessment of metabolic enzyme levels in macrophage populations of the F344 rat. Germolec DR, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1495–504

Ligands of four receptors in the nuclear steroid/thyroid hormone superfamily inhibit induction of rat cytosolic aldehyde dehydrogenase-3 (ALDH3c) by 3-methylcholanthrene. Karageorgou M, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2113–7

Constitutive expression of class 3 aldehyde dehydrogenase in cultured rat corneal epithelium. Boesch JS, et al. **J Biol Chem** 1996 Mar 1;271(9):5150–7

Inhibition of gene expression by triple helix formation in hepatoma cells. Tu GC, et al. **J Biol Chem** 1995 Nov 24; 270(47):28402–7

Interleukin-1 and tumor necrosis factor alpha induce class 1 aldehyde dehydrogenase mRNA and protein in bone marrow cells. Moreb JS, et al. **Leuk Lymphoma** 1995 Dec; 20(1–2):77–84

Induction of CYP1A1 and ALDH-3 in lymphoid tissues from Fisher 344 rats exposed to 2,3,7,8-tetrachlorodibenzodioxin (TCDD). Germolec DR, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):57–66

CHEMISTRY

Crystallization of sheep liver cytosolic aldehyde dehydrogenase in a form suitable for high resolution X-ray structural analysis. Baker HM, et al. **Adv Exp Med Biol** 1995;372:67–70

Covalent modification of class 2 and class 3 aldehyde dehydrogenase by 4-hydroxynonenal. Hartley DP, et al. **Adv Exp Med Biol** 1995;372:93–101

Use of a chromophoric reporter group to probe the active site of cytosolic aldehyde dehydrogenase. Kitson TM, et al. **Adv Exp Med Biol** 1995;372:35–43

The reduction of propionic anhydride by aldehyde dehydrogenase-NADH mixtures AT pH 7. Motion RL, et al. **Adv Exp Med Biol** 1995;372:53–60

Progress toward the tertiary structure of (class 3) aldehyde dehydrogenase. Sun J, et al. **Adv Exp Med Biol** 1995; 372:71–7

DRUG EFFECTS

Repeated oral benzene exposure alters enzymes involved in benzene metabolism. Daiker DH, et al. **J Toxicol Environ Health** 1996 Aug 9;48(5):439–51

GENETICS

Transgenesis of the aldehyde dehydrogenase-2 (ALDH2) locus in a mouse model and in cultured human cells. Chang C, et al. **Adv Exp Med Biol** 1995;372:131–6

Tissue-specific expression and preliminary functional analysis of the 5' flanking regions of the human mitochondrial aldehyde dehydrogenase (ALDH2) gene. Dipple KM, et al. **Adv Exp Med Biol** 1995;372:123–30

Class 3 aldehyde dehydrogenase. A northern perspective in the land down under. Feimer J, et al. **Adv Exp Med Biol** 1995;372:137–41 (12 ref.)

Cloning and characterization of genes encoding four additional human aldehyde dehydrogenase isozymes. Hsu LC, et al. **Adv Exp Med Biol** 1995;372:159–68

Human class 1 aldehyde dehydrogenase. Expression and site-directed mutagenesis. Jones KM, et al. **Adv Exp Med Biol** 1995;372:17–23

Cloning and characterisation of the cDNA for sheep liver cytosolic aldehyde dehydrogenase. Stayner CK, et al. **Adv Exp Med Biol** 1995;372:61–6

Mouse class 3 aldehyde dehydrogenases. Vasiliou V, et al. **Adv Exp Med Biol** 1995;372:151–8

Site directed mutagenesis to probe for active site components of liver mitochondrial aldehyde dehydrogenase. Weiner H, et al. **Adv Exp Med Biol** 1995;372:1–7 (17 ref.)

Hormonal and chemical influences on the expression of class 2 aldehyde dehydrogenases in rat H4IIEC3 and human HuH7 hepatoma cells. Crabb DW, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1414–9

Voluntary alcohol consumption in BXD recombinant inbred mice: relationship to alcohol metabolism. Gill K, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):185–90

CYP2E1 and ALDH2 genotypes and alcohol dependence in Japanese. Iwahashi K, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):564–6

Alcohol-metabolizing enzyme polymorphisms and alcoholism in Japan. Maezawa Y, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):951–4

Association of restriction fragment-length polymorphisms in the alcohol dehydrogenase 2 gene with alcoholic brain atrophy. Maezawa Y, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):29A–32A

Characteristics of Japanese alcoholics with the atypical aldehyde dehydrogenase 2*2. I. A comparison of the genotypes of ALDH2, ADH2, ADH3, and cytochrome P-4502E1 between alcoholics and nonalcoholics. Nakamura K, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):52–5

Mitochondrial aldehyde dehydrogenase polymorphism in Asian and American Indian populations: detection of new ALDH2 alleles. Novoradovsky A, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1105–10

Acute effects of alcohol on P300 in Asians with different ALDH2 genotypes. Wall TL, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):617–22

Aldehyde dehydrogenase activities in the brains of rats and mice genetically selected for different sensitivity to alcohol. Zimatkin SM, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1300–6

Polymorphism in ALDH2-genotype in Japanese men and the alcohol-blood pressure relationship. Tsuritani I, et al. **Am J Hypertens** 1995 Nov;8(11):1053–9

Inactivation of an aldehyde/alcohol dehydrogenase gene from Clostridium acetobutylicum ATCC 824. Green EM, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:213–21

Genotypes of alcohol-metabolizing enzymes in Mexicans with alcoholic liver cirrhosis. Lisker-Yourkowitzky R, et al. **Arch Med Res** 1995;26 Spec No:S63–7

Molecular mechanism of null expression of aldehyde dehydrogenase-1 in rat liver. Chen J, et al. **Biochem Genet** 1996 Apr;34(3–4):109–16

Genetic analysis of the phenobarbital regulation of the cytochrome P-450 2b-9 and aldehyde dehydrogenase type 2 mRNAs in mouse liver. Damon M, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):481–6

Response of [Ah] battery genes to compounds that protect against menadione toxicity. Vasiliou V, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1885–91

Induction of cyclophosphamide–resistance by aldehyde–dehydrogenase gene transfer. Magni M, et al. **Blood** 1996 Feb 1;87(3):1097–103

Multiple primary esophageal and concurrent upper aerodigestive tract cancer and the aldehyde dehydrogenase–2 genotype of Japanese alcoholics [published erratum appears in Cancer 1996 Aug 1;78(3):578] Yokoyama A, et al. **Cancer** 1996 May 15;77(10):1986–90

Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4–hydroperoxycyclophosphamide. Moreb J, et al. **Cancer Gene Ther** 1996 Jan–Feb;3(1):24–30

Description of a novel fusion transcript between HMGI–C, a gene encoding for a member of the high mobility group proteins, and the mitochondrial aldehyde dehydrogenase gene. Kazmierczak B, et al. **Cancer Res** 1995 Dec 15; 55(24):6038–9

Mouse microsomal Class 3 aldehyde dehydrogenase: AHD3 cDNA sequence, inducibility by dioxin and clofibrate, and genetic mapping. Vasiliou V, et al. **DNA Cell Biol** 1996 Mar;15(3):235–45

Cloning of a cDNA encoding rat aldehyde dehydrogenase with high activity for retinal oxidation. Bhat PV, et al. **Gene** 1995 Dec 12;166(2):303–6

High incidence of ADH2*1/ALDH2*1 genes among Japanese alcohol dependents and patients with alcoholic liver disease. Tanaka F, et al. **Hepatology** 1996 Feb; 23(2):234–9

Polymorphisms in alcohol metabolizing enzyme genes and alcoholic cirrhosis in Japanese patients: a multivariate analysis. Yamauchi M, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1136–42

The aldehyde dehydrogenase ALDH2*2 allele exhibits dominance over ALDH2*1 in transduced HeLa cells. Xiao Q, et al. **J Clin Invest** 1995 Nov;96(5):2180–6

Distribution of messenger RNAs for aldehyde dehydrogenase 1, aldehyde dehydrogenase 2, and aldehyde dehydrogenase 5 in human tissues. Stewart MJ, et al. **J Investig Med** 1996 Feb;44(2):42–6

The frequency of the mitochondrial aldehyde dehydrogenase I2 (atypical) allele in Caucasian, Oriental and African black populations determined by the restriction profile of PCR–amplified DNA. Dandré F, et al. **Mol Cell Probes** 1995 Jun;9(3):189–93

Ethanol and acetaldehyde metabolism in chinese with different aldehyde dehydrogenase–2 genotypes. Luu SU, et al. **Proc Natl Sci Counc Repub China B** 1995 Jul; 19(3):129–36

Ethanol utilization regulatory protein: profile alignments give no evidence of origin through aldehyde and alcohol dehydrogenase gene fusion. Nicholas HB Jr, et al. **Protein Sci** 1995 Dec;4(12):2621–4

CarRS of Azospirillum brasilense is homologous to a large family of aldehyde dehydrogenases rather than to two–component regulators [letter] Ramseier TM, et al. **Res Microbiol** 1995 Jun;146(5):425–9

The rf2 nuclear restorer gene of male–sterile T–cytoplasm maize [see comments] Cui X, et al. **Science** 1996 May 31; 272(5266):1334–6. Comment in: Science 1996 May 31;272(5266):1279–80.

Infertility treatment: a nuclear restorer gene in maize [comment] Levings CS 3rd. **Science** 1996 May 31; 272(5266):1279–80 (16 ref.). Comment on: Science 1996 May 31;272(5266):1334–6.

ISOLATION & PURIFICATION

New human aldehyde dehydrogenases. Pietruszko R, et al. **Adv Exp Med Biol** 1995;372:169–72

A second molybdoprotein aldehyde dehydrogenase from Amycolatopsis methanolica NCIB 11946. Kim SW, et al. **Arch Biochem Biophys** 1996 Jan 1;325(1):1–7

The purification and some properties of the Mg(2+)–activated cytosolic aldehyde dehydrogenase of Saccharomyces cerevisiae. Dickinson FM. **Biochem J** 1996 Apr 15;315 (Pt 2):393–9

METABOLISM

Metabolism of cyclophosphamide by aldehyde dehydrogenases. Agarwal DP, et al. **Adv Exp Med Biol** 1995;372:115–22

Studies of the esterase activity of cytosolic aldehyde dehydrogenase using sterically hindered and cyclic substrates. Kitson KE, et al. **Adv Exp Med Biol** 1995; 372:45–52

Kinetic studies on class 3 aldehyde dehydrogenase from bovine cornea. Riley IK, et al. **Adv Exp Med Biol** 1995; 372:85–92

Substrate binding pocket structure of human aldehyde dehydrogenases. A substrate specificity approach. Yin SJ, et al. **Adv Exp Med Biol** 1995;372:9–16 (48 ref.)

Expression and activities of class IV alcohol dehydrogenase and class III aldehyde dehydrogenase in human mouth. Dong YJ, et al. **Alcohol** 1996 May–Jun;13(3):257–62

Effects of benzodiazepines on aldehyde dehydrogenase activity. Helander A, et al. **Alcohol** 1995 Sep–Oct; 12(5):413–5

Identification of protein–receptor components required for the import of prealdehyde dehydrogenase into rat liver mitochondria. Pchelintseva O, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):54–62

Adaptation of Pseudomonas sp. GJ1 to 2–bromoethanol caused by overexpression of an NAD–dependent aldehyde dehydrogenase with low affinity for halogenated aldehydes. Van der Ploeg JR, et al. **Arch Microbiol** 1996 Apr;165(4):258–64

Enzymatic pattern of aldehyde metabolism during HL–60 cell differentiation. Barrera G, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):73–9

The purification and some properties of the Mg(2+)–activated cytosolic aldehyde dehydrogenase of Saccharomyces cerevisiae. Dickinson FM. **Biochem J** 1996 Apr 15;315 (Pt 2):393–9

Aldehyde dehydrogenase from adult human brain that dehydrogenates gamma–aminobutyraldehyde: purification, characterization, cloning and distribution. Kikonyogo A, et al. **Biochem J** 1996 May 15;316 (Pt 1):317–24

A comparison of nitrophenyl esters and lactones as substrates of cytosolic aldehyde dehydrogenase. Kitson TM, et al. **Biochem J** 1996 May 15;316 (Pt 1):225–32

Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism. Klyosov AA, et al. **Biochemistry** 1996 Apr 9;35(14):4445–56

Kinetics and specificity of human liver aldehyde dehydrogenases toward aliphatic, aromatic, and fused polycyclic aldehydes. Klyosov AA. **Biochemistry** 1996 Apr 9;35(14):4457–67

Hepatocyte expression of tumor associated aldehyde dehydrogenase (ALDH–3) and p21 Ras following diethylnitrosamine (DEN) initiation and chronic exposure to di(2–ethylhexyl)phthalate (DHEP). Richmond RE, et al. **Carcinogenesis** 1996 Aug;17(8):1647–55

Human breast adenocarcinoma MCF–7/0 cells electroporated with cytosolic class 3 aldehyde dehydrogenases obtained from tumor cells and a normal tissue exhibit differential sensitivity to mafosfamide. Sreerama L, et al. **Drug Metab Dispos** 1995 Oct; 23(10):1080–4

The role of positive charges and structural segments in the presequence of rat liver aldehyde dehydrogenase in import into mitochondria. Hammen PK, et al. **J Biol Chem** 1996 Aug 30;271(35):21041–8

Membrane topology and retention of microsomal aldehyde dehydrogenase in the endoplasmic reticulum. Masaki R, et al. **J Biol Chem** 1996 Jul 12;271(28):16939–44

Cloning of a cDNA encoding an aldehyde dehydrogenase and its expression in Escherichia coli. Recognition of retinal as substrate. Wang X, et al. **J Biol Chem** 1996 Jul 5; 271(27):16288–93

Surface localization, regulation, and biologic properties of the 96–kDa alcohol/aldehyde dehydrogenase (EhADH2) of pathogenic Entamoeba histolytica. Flores BM, et al. **J Infect Dis** 1996 Jan;173(1):226–31

Investigator–observed alcohol–induced flushing but not self–report of flushing is a valid predictor of ALDH2 genotype. Wall TL, et al. **J Stud Alcohol** 1996 May; 57(3):267–72

Downexpression of aldehyde dehydrogenase 1 in murine lung tumors. Dragani TA, et al. **Mol Carcinog** 1996 Jul; 16(3):123–5

[Regional and cellular distribution of mitochondrial high–affinity aldehyde dehydrogenase in the rat brain (an immunocytochemical study)] Zimatkin SM, et al. **Morfologiia** 1994 Apr–Jun;106(4–6):83–91 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti–cancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross–linking and lethality. Bunting KD, et al. **J Biol Chem** 1996 May 17;271(20):11884–90

Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. Bunting KD, et al. **J Biol Chem** 1996 May 17;271(20):11891–6

RADIATION EFFECTS

Effect of UVB radiation on corneal aldehyde dehydrogenase. Uma L, et al. **Curr Eye Res** 1996 Jun;15(6):685–90

ALDEHYDE-LYASES

ANALYSIS

Localisation of 15–hydroxy prostaglandin dehydrogenase (PGDH) and steroidogenic enzymes in the equine placenta [see comments] Han X, et al. **Equine Vet J** 1995 Sep; 27(5):334–9. Comment in: Equine Vet J 1995 Sep;27(5):324–5.

ANTAGONISTS & INHIBITORS

Molecular modelling of known non–steroidal inhibitors of 17 alpha–hydroxylase/17,20–lyase using antimycotic compounds. Ahmed S. **Drug Des Discov** 1994 Jul; 12(1):77–88

Transforming growth factor–beta inhibits ovarian 17 alpha–hydroxylase activity by a direct noncompetitive mechanism. Fournet N, et al. **Endocrinology** 1996 Jan; 137(1):166–74

BIOSYNTHESIS

Expression of the gene for cytochrome P–450 17 alpha–hydroxylase/C17–20 lyase (CYP17) in porcine Leydig cells: identification of a DNA sequence that mediates cAMP response. Zhang P, et al. **Biochim Biophys Acta** 1996 Jun 3;1307(1):73–82

Expression of cytochrome P450 17alpha–hydroxylase/C17–20 lyase in the fetal rat testis is reduced by maternal exposure to exogenous estrogens. Majdic G, et al. **Endocrinology** 1996 Mar;137(3):1063–70

CHEMISTRY

Molecular cloning of the full–length cDNA of (S)–hydroxynitrile lyase from Hevea brasiliensis. Functional expression in Escherichia coli and Saccharomyces cerevisiae and identification of an active site residue. Hasslacher M, et al. **J Biol Chem** 1996 Mar 8;271(10):5884–91

Catalytic mechanism of the metal–dependent fuculose aldolase from Escherichia coli as derived from the structure. Dreyer MK, et al. **J Mol Biol** 1996 Jun 14; 259(3):458–66

DEFICIENCY

Case report: 17 alpha–hydroxylase/17,20–lyase deficiency: a rare cause of endocrine hypertension. Hermans C, et al. **Am J Med Sci** 1996 Sep;312(3):126–9

Prismatic cases: 17,20–desmolase (17,20–lyase) deficiency. Zachmann M. **J Clin Endocrinol Metab** 1996 Feb; 81(2):457–9

GENETICS

Cloning and expression of hamster adrenal cytochrome P450C17 cDNA. Cloutier M, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:294–6

Functional expression of recombinant spiny dogfish shark (Squalus acanthias) cytochrome P450c17 (17 alpha–hydroxylase/C17,20–lyase) in yeast (Pichia pastoris). Trant JM. **Arch Biochem Biophys** 1996 Feb 1;326(1):8–14

Expression of the gene for cytochrome P–450 17 alpha–hydroxylase/C17–20 lyase (CYP17) in porcine Leydig cells: identification of a DNA sequence that mediates cAMP response. Zhang P, et al. **Biochim Biophys Acta** 1996 Jun 3;1307(1):73–82

A new strategy for the cloning, overexpression and one step purification of three DHAP–dependent aldolases: rhamnulose–1–phosphate aldolase, fuculose–1–phosphate aldolase and tagatose–1,6–diphosphate aldolase. Garcia–Junceda E, et al. **Bioorg Med Chem** 1995 Jul; 3(7):945–53

Cloning and sequence analysis of the gene encoding 3–hexulose–6–phosphate synthase from the methylotrophic bacterium, Methylomonas aminofaciens 77a, and its expression in Escherichia coli. Yanase H, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2–3):201–5

Aberrant splicing of rat steroid 17 alpha–hydroxylase transcripts. Sanne JL, et al. **Gene** 1995 Nov 20;165(2):327–8

Sequence of the Escherichia coli C homoprotocatechuic acid degradative operon completed with that of the 2,4–dihydroxyhept–2–ene–1,7–dioic acid aldolase–encoding gene (hpcH). Stringfellow JM, et al. **Gene** 1995 Dec 1;166(1):73–6

Analysis of the distal 5' region of the human CYP17 gene. Maghsoudlou SS, et al. **Genome** 1995 Oct;38(5):845–9

Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha–hydroxylase/17–20–lyase deficiency in two French Canadian patients. Laflamme N, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):264–8

Temporal and spatial expression of amygdalin hydrolase and (R)–(+)–mandelonitrile lyase in black cherry seeds. Zheng L, et al. **Plant Physiol** 1995 Sep;109(1):31–9

ISOLATION & PURIFICATION

Crystallization and preliminary crystallographic studies of 3–deoxy–D–manno–octulosonate–8–phosphate synthase from Escherichia coli. Tolbert WD, et al. **Proteins** 1996 Mar;24(3):407–8

METABOLISM

The relation between two molecular species of P–450 in adult testis and 17 alpha–hydroxylase and 17,20–lyase activities. Kuwada M, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):524–9

Mechanistic kinship between hydroxylation and desaturation reactions: acyl–carbon bond cleavage promoted by pig and human CYP17 (P–450(17)alpha; 17 alpha–hydroxylase–17,20–lyase). Lee–Robichaud P, et al. **Biochemistry** 1995 Oct 31;34(43):14104–13

Essential cysteines in 3–deoxy–D–manno–octulosonic acid 8–phosphate synthase from Escherichia coli: analysis by chemical modification and site–directed mutagenesis. Salleh HM, et al. **Biochemistry** 1996 Jul 9;35(27):8942–7

Quo vadis photorespiration: a tale of two aldolases. Hixon M, et al. **FEBS Lett** 1996 Sep 2;392(3):281–4

ALDEHYDE-LYASES

Ligand dependence of cytochrome P450c17 protection against proteolytic inactivation: structural, methodological and functional implications. Kühn-Velten WN, et al. **FEBS Lett** 1996 Jun 10;388(1):21-5

Molecular cloning of the full-length cDNA of (S)-hydroxynitrile lyase from Hevea brasiliensis. Functional expression in Escherichia coli and Saccharomyces cerevisiae and identification of an active site residue. Hasslacher M, et al. **J Biol Chem** 1996 Mar 8;271(10):5884-91

Catalytic mechanism of the metal-dependent fuculose aldolase from Escherichia coli as derived from the structure. Dreyer MK, et al. **J Mol Biol** 1996 Jun 14; 259(3):458-66

Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Zhang LH, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10619-23

ALDEHYDE OXIDOREDUCTASES

ANALYSIS

Retinoic acid synthesis in the developing spinal cord. Dräger UC, et al. **Adv Exp Med Biol** 1995;372:185-92 (26 ref.)

BIOSYNTHESIS

Control of hemA expression in Rhodobacter sphaeroides 2.4.1: regulation through alterations in the cellular redox state. Zeilstra-Ryalls JH, et al. **J Bacteriol** 1996 Feb; 178(4):985-93

Members of a low-copy number gene family encoding glutamyl-tRNA reductase are differentially expressed in barley. Bougri O, et al. **Plant J** 1996 Jun;9(6):867-78

CHEMISTRY

Carbon monoxide dehydrogenase from Clostridium thermoaceticum: quaternary structure, stoichiometry of its SDS-induced dissociation, and characterization of the faster-migrating form. Xia J, et al. **Biochemistry** 1996 Feb 13;35(6):1965-71

Resonance Raman study on the iron-sulfur centers of Desulfovibrio gigas aldehyde oxidoreductase. Zhelyaskov V, et al. **Biochim Biophys Acta** 1995 Oct 25;1252(2):300-4

The tungsten formylmethanofuran dehydrogenase from Methanobacterium thermoautotrophicum contains sequence motifs characteristic for enzymes containing molybdopterin dinucleotide. Hochheimer A, et al. **Eur J Biochem** 1995 Dec 15;234(3):910-20

Properties of rabbit liver aldehyde oxidase and the relationship of the enzyme to xanthine oxidase and dehydrogenase. Turner NA, et al. **Eur J Biochem** 1995 Sep 1;232(2):646-57

A polyferredoxin with eight [4Fe-4S] clusters as a subunit of molybdenum formylmethanofuran dehydrogenase from Methanosarcina barkeri. Vorholt JA, et al. **Eur J Biochem** 1996 Feb 15;236(1):309-17

Alcohol dehydrogenase of class III: consistent patterns of structural and functional conservation in relation to class I and other proteins. Hjelmqvist L, et al. **FEBS Lett** 1995 Oct 16;373(3):212-6

Spectroelectrochemical characterization of the metal centers in carbon monoxide dehydrogenase (CODH) and nickel-deficient CODH from Rhodospirillum rubrum. Spangler NJ, et al. **J Biol Chem** 1996 Apr 5;271(14):7973-7

Metal-carbon bonds in nature [comment] Kovacs JA, et al. **Science** 1995 Oct 27;270(5236):587-8 (22 ref.). Comment on: Science 1995 Oct 27;270(5236):628-30.

Crystal structure of the xanthine oxidase-related aldehyde oxido-reductase from D. gigas. Romão MJ, et al. **Science** 1995 Nov 17;270(5239):1170-6

DEFICIENCY

Personality disorder in alcohol dependents [letter] Iwahashi K, et al. **Can J Psychiatry** 1995 Aug;40(6):362-3

Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency. Gibson KM, et al. **J Inherit Metab Dis** 1995;18(2):143-6

Sjögren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. De Laurenzi V, et al. **Nat Genet** 1996 Jan;12(1):52-7

GENETICS

Promoters of the mammalian class III alcohol dehydrogenase genes. Edenberg HJ, et al. **Adv Exp Med Biol** 1995; 372:295-300

Mutations of human class III alcohol dehydrogenase. Estonius M, et al. **Adv Exp Med Biol** 1995;372:327-30

Cloning and nucleotide sequencing of the membrane-bound L-sorbosone dehydrogenase gene of Acetobacter liquefaciens IFO 12258 and its expression in Gluconobacter oxydans. Shinjoh M, et al. **Appl Environ Microbiol** 1995 Feb;61(2):413-20

Increase in osmotolerance of Rhizobium fredii soybean isolate BD32 by the proB proA operon of Escherichia coli. Neumivakin LV, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):796-801

Alcohol flushing, patch test, and ADH and ALDH genotypes in Brazilian ethnic groups. Santos BR, et al. **Braz J Med Biol Res** 1995 May;28(5):513-8

Molecular properties of the lys1+ gene and the regulation of alpha-aminoadipate reductase in Schizosaccharomyces pombe. Ford RA, et al. **Curr Genet** 1995 Jul;28(2):131-7

Characterization of the functional gene encoding mouse class III alcohol dehydrogenase (glutathione-dependent formaldehyde dehydrogenase) and an unexpressed processed pseudogene with an intact open reading frame. Foglio MH, et al. **Eur J Biochem** 1996 Apr 15; 237(2):496-504

The LYS5 gene of Saccharomyces cerevisiae. Miller KG, et al. **Gene** 1996 Jun 12;172(1):167-8

Enzyme polymorphism in Drosophila melanogaster populations collected in two different habitats in Hungary. Pecsenye K, et al. **Genetica** 1995;96(3):257-68

Human gamma-aminobutyraldehyde dehydrogenase (ALDH9): cDNA sequence, genomic organization, polymorphism, chromosomal localization, and tissue expression. Lin SW, et al. **Genomics** 1996 Jun 15; 34(3):376-80

Mutations in the Corynebacterium glutamicum proline biosynthetic pathway: a natural bypass of th proA step. Ankri S, et al. **J Bacteriol** 1996 Aug;178(15):4412-9

Translation of the adhE transcript to produce ethanol dehydrogenase requires RNase III cleavage in Escherichia coli. Aristarkhov A, et al. **J Bacteriol** 1996 Jul; 178(14):4327-32

Transcription of the glutamyl-tRNA reductase (hemA) gene in Salmonella typhimurium and Escherichia coli: role of the hemA P1 promoter and the arcA gene product. Choi P, et al. **J Bacteriol** 1996 Feb;178(3):638-46

Characterization of the cdhD and cdhE genes encoding subunits of the corrinoid/iron-sulfur enzyme of the CO dehydrogenase complex from Methanosarcina thermophila. Maupin-Furlow J, et al. **J Bacteriol** 1996 Jan;178(2):340-6

Molecular analysis of the anaerobic succinate degradation pathway in Clostridium kluyveri. Söhling B, et al. **J Bacteriol** 1996 Feb;178(3):871-80

Cloning and characterization of a gene (msdA) encoding methylmalonic acid semialdehyde dehydrogenase from Streptomyces coelicolor. Zhang YX, et al. **J Bacteriol** 1996 Jan;178(2):490-5

Purification, cDNA cloning, and tissue distribution of bovine liver aldehyde oxidase. Calzi ML, et al. **J Biol Chem** 1995 Dec 29;270(52):31037-45

Carbon monoxide dehydrogenase from Methanosarcina frisia Göl. Characterization of the enzyme and the regulated expression of two operon-like cdh gene clusters. Eggen RIL, et al. **J Biol Chem** 1996 Jun 14;271(24):14256-63

A retinaldehyde dehydrogenase as a structural protein in a mammalian eye lens. Gene recruitment of eta-crystallin. Graham C, et al. **J Biol Chem** 1996 Jun 28;271(26):15623-8

The 4-hydroxy-2-oxovalerate aldolase and acetaldehyde dehydrogenase (acylating) encoded by the nahM and nahO genes of the naphthalene catabolic plasmid pWW60-22 provide further evidence of conservation of meta-cleavage pathway gene sequences. Platt A, et al. **Microbiology** 1995 Sep;141 (Pt 9):2223-33

Partial inhibition of protein synthesis accelerates the synthesis of porphyrin in heme-deficient mutants of Escherichia coli. Nakayashiki T, et al. **Mol Gen Genet** 1995 Nov 15; 249(2):139-46

A second and differentially expressed glutamyl-tRNA reductase gene from Arabidopsis thaliana. Kumar AM, et al. **Plant Mol Biol** 1996 Feb;30(3):419-26

Pea formaldehyde-active class III alcohol dehydrogenase: common derivation of the plant and animal forms but not of the corresponding ethanol-active forms (classes I and P). Shafqat J, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5595-9

Complementation of an Escherichia coli adhE mutant by the Entamoeba histolytica EhADH2 gene provides a method for the identification of new antiamebic drugs. Yong TS, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6464-9

Analysis of aldehyde oxidase and xanthine dehydrogenase/oxidase as possible candidate genes for autosomal recessive familial amyotrophic lateral sclerosis. Berger R, et al. **Somat Cell Mol Genet** 1995 Mar; 21(2):121-31

ISOLATION & PURIFICATION

Purification and kinetic characterization of gamma-aminobutyraldehyde dehydrogenase from rat liver. Testore G, et al. **Int J Biochem Cell Biol** 1995 Nov; 27(11):1201-10

METABOLISM

Retinoic acid synthesizing enzymes in the embryonic and adult vertebrate. McCaffery P, et al. **Adv Exp Med Biol** 1995;372:173-83 (45 ref.)

CO dehydrogenase. Ferry JG. **Annu Rev Microbiol** 1995; 49:305-33 (132 ref.)

Strain differences of liver aldehyde oxidase activity in rats. Sugihara K, et al. **Biochem Mol Biol Int** 1995 Nov; 37(5):861-9

The role of aldehyde oxidase in the in vivo metabolism of benzothiazole. Fowler AM, et al. **Biochem Soc Trans** 1995 Nov;23(4):604S

Spectroscopic states of the CO oxidation/CO2 reduction active site of carbon monoxide dehydrogenase and mechanistic implications. Anderson ME, et al. **Biochemistry** 1996 Jun 25;35(25):8371-80

Aldehyde dehydrogenase activity of Drosophila melanogaster alcohol dehydrogenase: burst kinetics at high pH and aldehyde dismutase activity at physiological pH. Henehan GT, et al. **Biochemistry** 1995 Sep 26; 34(38):12294-301

Involvement of cysteine 289 in the catalytic activity of an NADP(+)-specific fatty aldehyde dehydrogenase from Vibrio harveyi. Vedadi M, et al. **Biochemistry** 1995 Dec 26;34(51):16725-32

Nucleotides of tRNA (Glu) involved in recognition by barley chloroplast glutamyl-tRNA synthetase and glutamyl-tRNA reductase. Willows RD, et al. **Biochim Biophys Acta** 1995 Sep 19;1263(3):228-34

Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Sugihara K, et al. **Drug Metab Dispos** 1996 Feb;24(2):199-202

Alcohol dehydrogenase of class III: consistent patterns of structural and functional conservation in relation to class I and other proteins. Hjelmqvist L, et al. **FEBS Lett** 1995 Oct 16;373(3):212-6

Stabilization of a HemA-LacZ hybrid protein against proteolysis during carbon starvation in atp mutants of Salmonella typhimurium. Archer CD, et al. **J Bacteriol** 1996 Apr;178(8):2462-4

Characterization of a glutathione-dependent formaldehyde dehydrogenase from Rhodobacter sphaeroides. Barber RD, et al. **J Bacteriol** 1996 Mar;178(5):1386-93

Purification and characterization of a benzylviologen-linked, tungsten-containing aldehyde oxidoreductase from Desulfovibrio gigas. Hensgens CM, et al. **J Bacteriol** 1995 Nov;177(21):6195-200

Molybdenum and vanadium do not replace tungsten in the catalytically active forms of the three tungstoenzymes in the hyperthermophilic archaeon Pyrococcus furiosus. Mukund S, et al. **J Bacteriol** 1996 Jan;178(1):163-7

Cellular retinol-binding protein-supported retinoic acid synthesis. Relative roles of microsomes and cytosol. Boerman MH, et al. **J Biol Chem** 1996 Mar 8;271(10):5610-6

Carbon monoxide dehydrogenase from Methanosarcina frisia Göl. Characterization of the enzyme and the regulated expression of two operon-like cdh gene clusters. Eggen RIL, et al. **J Biol Chem** 1996 Jun 14;271(24):14256-63

Partial reactions catalyzed by protein components of the acetyl-CoA decarbonylase synthase enzyme complex from Methanosarcina barkeri. Grahame DA, et al. **J Biol Chem** 1996 Apr 5;271(14):8352-8

Partial inhibition of protein synthesis accelerates the synthesis of porphyrin in heme-deficient mutants of Escherichia coli. Nakayashiki T, et al. **Mol Gen Genet** 1995 Nov 15; 249(2):139-46

Pea formaldehyde-active class III alcohol dehydrogenase: common derivation of the plant and animal forms but not of the corresponding ethanol-active forms (classes I and P). Shafqat J, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5595-9

Role of aldehyde oxidase in biogenic amine metabolism. Beedham C, et al. **Prog Brain Res** 1995;106:345-53 (52 ref.)

A methylnickel intermediate in a bimetallic mechanism of acetyl-coenzyme A synthesis by anaerobic bacteria [see comments] Kumar M, et al. **Science** 1995 Oct 27; 270(5236):628-30. Comment in: Science 1995 Oct 27;270(5236):587-8.

PHYSIOLOGY

Rabbit liver class III alcohol dehydrogenase: a cathodic isoform with formaldehyde dehydrogenase activity. Keung WM, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):860-6

Metabolism of acetaldehyde to acetate by rat hepatic P-450s: presence of different metabolic pathway from acetaldehyde dehydrogenase system. Kunitoh S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):22A-24A

ALDEHYDE REDUCTASE

ANTAGONISTS & INHIBITORS

Aldose reductase inhibitor prevents hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucose. Yasunari K, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2207-12

Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase. Nakano T, et al. **Biochemistry** 1996 Aug 27;35(34):11196-202

Study on anti-cataract drugs from natural sources. II. Effects of buddlejae flos on in vitro aldose reductase activity. Matsuda H, et al. **Biol Pharm Bull** 1995 Mar;18(3):463-6

Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Goto Y, et al. **Biomed Pharmacother** 1995;49(6):269-77

New approaches for treatment in diabetes: aldose reductase inhibitors. Hotta N. **Biomed Pharmacother** 1995; 49(5):232-43 (168 ref.)

Inhibition of aldose reductase by maesanin and related p-benzoquinone derivatives and effects on other enzymes. Haraguchi H, et al. **Bioorg Med Chem** 1996 Jan;4(1):49-53

Identification of an aldose reductase inhibitor site by affinity labeling. Kador PF, et al. **Bioorg Med Chem** 1995 Oct; 3(10):1313-24

Topical aldose reductase inhibitor [editorial; comment] Coster D. **Br J Ophthalmol** 1995 Dec;79(12):1064-5.

Comment on: Br J Ophthalmol 1995 Dec;79(12):1074–7.
Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients [see comments] Ohguro N, et al. **Br J Ophthalmol** 1995 Dec;79(12):1074–7 . Comment in: Br J Ophthalmol 1995 Dec;79(12):1064–5.
Five new C-methyl flavonoids, the potent aldose reductase inhibitors from Matteuccia orientalis Trev. **Basnet P, et al. Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1558–64
Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes. Fruncillo R, et al. **Clin Pharmacol Ther** 1996 Jun;59(6):603–12
Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. Uchida K, et al. **Clin Ther** 1995 May–Jun;17(3):460–6
Inhibition of naphthalene cataract in rats by aldose reductase inhibitors. Lou MF, et al. **Curr Eye Res** 1996 Apr; 15(4):423–32
Effect of treatment with an aldose-reductase inhibitor on symptomatic carpal tunnel syndrome in type 2 diabetes. Monge L, et al. **Diabet Med** 1995 Dec;12(12):1097–101
Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy. Fabiani F, et al. **Diabete Metab** 1995 Dec;21(5):360–4
Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Cameron NE, et al. **Diabetologia** 1996 Feb;39(2):172–82
Minimal effects of two aldose reductase inhibitors, AL–1576 and AL–4114, after subacute topical–ocular dosing on xenobiotic biotransformation in rabbits. Sastry SG, et al. **Drug Metab Dispos** 1995 Oct;23(10):1094–8
An aldose reductase inhibitor, TAT, prevents electroretinographic abnormalities and ADP-induced hyperaggregability in streptozotocin-induced diabetic rats. Hotta N, et al. **Eur J Clin Invest** 1995 Dec;25(12):948–54
Different effects of two aldose reductase inhibitors on nociception and prostaglandin E. Calcutt NA, et al. **Eur J Pharmacol** 1995 Oct 16;285(2):189–97
Inhibition of aldose reductase by dihydroflavonols in Engelhardtia chrysolepis and effects on other enzymes. Haraguchi H, et al. **Experientia** 1996 Jun 15;52(6):564–7
Acid derivatives of benzisothiazole–1,1–dioxide as inhibitors of rat lens aldose reductase. Da Settimo A, et al. **Farmaco** 1996 Apr;51(4):261–7
Effects of glucose and an aldose reductase inhibitor on albumin permeation through a layer of cultured bovine vascular endothelial cells. Mimura K, et al. **Horm Metab Res** 1995 Oct;27(10):442–6
The influence of a peptide sequence from PF-4 (CT–112) on type II collagen–induced arthritis in mice. Wooley PH, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S125–6
Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY–121,509. Robinson WG Jr, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1149–56
Sorbinil prevention of diabetic-like retinopathy in the galactose-fed rat model. Robison WG Jr, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2368–80
Thermorubin and 2-hydroxyphenyl acetic acid, aldose reductase inhibitors. Hayashi K, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1345–6
Reversal of defective peripheral nerve conduction velocity, nutritive endoneurial blood flow, and oxygenation by a novel aldose reductase inhibitor, WAY–121,509, in streptozotocin–induced diabetic rats. Cameron NE, et al. **J Diabetes Complications** 1996 Jan–Feb;10(1):43–53
An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy. Hara T, et al. **J Lab Clin Med** 1995 Dec;126(6):541–7
Highly selective aldose reductase inhibitors. 1. 3–(Arylalkyl)–2,4,5–trioxoimidazolidine–1–acetic acids. Ishii A, et al. **J Med Chem** 1996 Apr 26;39(9):1924–7
Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. Haraguchi H, et al. **J Nat Prod** 1996 Apr;59(4):443–5
Effect of propionyl–L–carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin–induced diabetes: comparison with an aldose reductase inhibitor. Hotta N, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):49–55
An aldose reductase inhibitor but not myo–inositol blocks enhanced polyphosphoinositide turnover in peripheral nerve from diabetic rats. Berti–Mattera L, et al. **Metabolism** 1996 Mar;45(3):320–7
The effects of acetyl–L–carnitine and sorbinil on peripheral nerve structure, chemistry, and function in experimental diabetes. Malone JI, et al. **Metabolism** 1996 Jul;45(7):902–7
[Pharmacological prevention of late complications of diabetes] Jensen TJ, et al. **Ugeskr Laeger** 1996 Apr 22; 158(17):2402–3 **(Dan)**
[Biochemical changes in lens, aqueous humor and vitreous body and effects of aldose reductase inhibitor (TAT) on rats with experimental diabetes] Saito H. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):339–50 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Redox balances in recombinant Saccharomyces cerevisiae. Hahn–Hägerdal B, et al. **Ann N Y Acad Sci** 1996 May 15; 782:286–96
Tissue-specific expression of two aldose reductase-like genes in mice: abundant expression of mouse vas deferens protein and fibroblast growth factor–regulated protein in the adrenal gland. Lau ET, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):609–15
Long-term induction of an aldose reductase protein by basic fibroblast growth factor in rat astrocytes in vitro. Laeng P, et al. **Electrophoresis** 1995 Jul;16(7):1240–50

BLOOD

Increased levels of methylglyoxal–metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin–dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study. Ratliff DM, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):488–92

CHEMISTRY

Structure and mechanism of aldehyde reductase. Flynn TG, et al. **Adv Exp Med Biol** 1995;372:193–201
Stopped–flow studies of human aldose reductase reveal which enzyme form predominates during steady–state turnover in either reaction direction. Grimshaw CE, et al. **Adv Exp Med Biol** 1995;372:229–40
Rho B–crystallin, an aldose reductase–like lens protein in the gecko Lepidodactylus lugubris. Röll B, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):452–8
Human aldose reductase: subtle effects revealed by rapid kinetic studies of the C298A mutant enzyme. Grimshaw CE, et al. **Biochemistry** 1995 Nov 7;34(44):14366–73
Human aldose reductase: pK of tyrosine 48 reveals the preferred ionization state for catalysis and inhibition. Grimshaw CE, et al. **Biochemistry** 1995 Nov 7; 34(44):14374–84
Human aldose reductase: rate constants for a mechanism including interconversion of ternary complexes by recombinant wild–type enzyme. Grimshaw CE, et al. **Biochemistry** 1995 Nov 7;34(44):14356–65
Purification, kinetic characterization and involvement of tryptophan residue at the NADPH binding site of xylose reductase from Neurospora crassa. Rawat UB, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):222–30
All in the family [news] Harrison DH. **Nat Struct Biol** 1995 Sep;2(9):719–20
Structure of porcine aldehyde reductase holoenzyme. el–Kabbani O, et al. **Nat Struct Biol** 1995 Aug;2(8):687–92

DRUG EFFECTS

Nerve microvessel changes in diabetes are prevented by aldose reductase inhibition. Benstead TJ, et al. **Can J Neurol Sci** 1995 Aug;22(3):192–7
Aminoguanidine does not inhibit aldose reductase activity in galactose-fed rats. Dvornik D, et al. **J Diabetes Complications** 1996 Jan–Feb;10(1):23–30

GENETICS

Purification and characterization of recombinant human placental and rat lens aldose reductases expressed in Escherichia coli. Sato S, et al. **Adv Exp Med Biol** 1995; 372:259–68
Cloning of the aldehyde reductase gene from a red yeast, Sporobolomyces salmonicolor, and characterization of the gene and its product. Kita K, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2303–10
4–hydroxy–2,3–trans–nonenal induces transcription and expression of aldose reductase. Spycher S, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):512–6
Tissue-specific expression of two aldose reductase-like genes in mice: abundant expression of mouse vas deferens protein and fibroblast growth factor–regulated protein in the adrenal gland. Lau ET, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):609–15
Isolation and characterization of the gene encoding xylose reductase from Kluyveromyces lactis. Billard P, et al. **Gene** 1995 Aug 30;162(1):93–7
Aldose reductase and myo–inositol transporter mRNA are independently regulated in rat renal medulla. Nakanishi T, et al. **J Am Soc Nephrol** 1996 Feb;7(2):283–9
ORE, a eukaryotic minimal essential osmotic response element. The aldose reductase gene in hyperosmotic stress. Ferraris JD, et al. **J Biol Chem** 1996 Aug 2; 271(31):18318–21
Chromosome 7q35 and susceptibility to diabetic microvascular complications [see comments] Patel A, et al. **J Diabetes Complications** 1996 Mar–Apr;10(2):62–7. Comment in: J Diabetes Complications 1996 Mar–Apr;10(2):61.
Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma. Takahashi M, et al. **Jpn J Cancer Res** 1996 Apr; 87(4):337–41
Characterization of the osmotic response element of the human aldose reductase gene promoter. Ruepp B, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8624–9

ISOLATION & PURIFICATION

Purification and characterization of recombinant human placental and rat lens aldose reductases expressed in Escherichia coli. Sato S, et al. **Adv Exp Med Biol** 1995; 372:259–68
3–Deoxyglucosone reductase in dog adrenal glands. Identification as aldose reductase. Matsuura K, et al. **Biol Pharm Bull** 1995 Dec;18(12):1765–7

METABOLISM

Molecular modelling calculations on the binding of D– and L–xylose to wild–type aldose reductase and its H110Q and H110A mutants. De Winter HL, et al. **Adv Exp Med Biol** 1995;372:223–7
Increased xylose reductase activity in the xylose–fermenting yeast Pichia stipitis by overexpression of XYL1. Dahn KM, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:267–76
Oxidized aldose reductase: in vivo factor not in vitro artifact. Grimshaw CE, et al. **Arch Biochem Biophys** 1996 Mar 1; 327(1):89–97
Aldose reductase is a major reductase for isocaproaldehyde, a product of side-chain cleavage of cholesterol, in human and animal adrenal glands. Matsuura K, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):265–71
Enzymatic pattern of aldehyde metabolism during HL–60 cell differentiation. Barrera G, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):73–9
Lipid peroxidation product, 4–hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Srivastava S, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):741–6
Substrate specificity of an aflatoxin–metabolizing aldehyde reductase. Ellis EM, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):535–41
Human aldose reductase: pK of tyrosine 48 reveals the preferred ionization state for catalysis and inhibition. Grimshaw CE, et al. **Biochemistry** 1995 Nov 7; 34(44):14374–84
Purification, kinetic characterization and involvement of tryptophan residue at the NADPH binding site of xylose reductase from Neurospora crassa. Rawat UB, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):222–30
Study on anti–cataract drugs from natural sources. II. Effects of buddlejae flos on in vitro aldose reductase activity. Matsuda H, et al. **Biol Pharm Bull** 1995 Mar;18(3):463–6
Aldose reductase (EC 1.1.1.21) activity and reduced–glutathione content in lenses of diabetic sand rats (Psammomys obesus) fed with acarbose. Cohen–Melamed E, et al. **Br J Nutr** 1995 Nov;74(5):607–15
Regulation of carbonyl–reducing enzymes in rat liver by chemoprotectors. Ellis EM, et al. **Cancer Res** 1996 Jun 15; 56(12):2758–66
Galactosemic neuropathy in transgenic mice for human aldose reductase. Yagihashi S, et al. **Diabetes** 1996 Jan; 45(1):56–9
The effect of non–enzymatic glycation on recombinant human aldose reductase. Yamaoka T, et al. **Diabetes Res Clin Pract** 1995 Mar;27(3):165–9
Hormonal regulation of aldose reductase in rat ovary during the estrous cycle. Iwata N, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):444–8
Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes. Takahashi M, et al. **Int J Cancer** 1995 Sep 15;62(6):749–54
Protein patterns, osmolytes, and aldose reductase of L–929 cells exposed to hyperosmotic media. Libioulle C, et al. **J Cell Physiol** 1996 Jul;168(1):147–54
The NADP–linked aldehyde reductase of Leishmania donovani. Keegan FP, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):255–7
A heterologous reductase affects the redox balance of recombinant Saccharomyces cerevisiae. Meinander N, et al. **Microbiology** 1996 Jan;142 (Pt 1):165–72
Aldose reductase: black sheep or skeleton in the cupboard? Crabbe MJ, et al. **Nat Struct Biol** 1996 Aug;3(8):659–61
All in the family [news] Harrison DH. **Nat Struct Biol** 1995 Sep;2(9):719–20
Inhibition of aldose reductase: 13C NMR studies in isolated peripheral nerve. Waterton JC, et al. **NMR Biomed** 1995 May;8(3):133–8
Semi–quantitation of mRNA by polymerase chain reaction. Levels of oxidative defense enzymes and aldose reductase in rat lenses cultured in hyperglycemic or oxidative medium. Khanna P, et al. **Res Commun Mol Pathol Pharmacol** 1996 Apr;92(1):3–18

PHARMACOLOGY

Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo–controlled double–blind study. Goto Y, et al. **Biomed Pharmacother** 1995;49(6):269–77
Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation. Okada Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug;43(8):1385–7
Anti–inflammatory activity of an orally active peptide sequence from PF–4 on acute inflammation and DTH. Talmadge JE, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S199–200

THERAPEUTIC USE

Drug trials in neuropathy. Hughes RA, et al.

ALDEHYDE REDUCTASE

Baillieres Clin Neurol 1995 Nov;4(3):607-27 (87 ref.)
New approaches for treatment in diabetes: aldose reductase inhibitors. Hotta N. **Biomed Pharmacother** 1995; 49(5):232-43 (168 ref.)

ALDEHYDES

Factors affecting DNA damage caused by lipid hydroperoxides and aldehydes. Yang MH, et al. **Free Radic Biol Med** 1996;20(2):225-36

ANALYSIS

Simultaneous measurement of enzyme activity, protein, mRNA, and metabolites in small samples. Burke WJ, et al. **Anal Biochem** 1995 Sep 20;230(2):345-8
Determination of aldehydes and other lipid peroxidation products in biological samples by gas chromatography-mass spectrometry. Luo XP, et al. **Anal Biochem** 1995 Jul 1;228(2):294-8
Detection of short-chain alpha-hydroxyaldehydic compounds as pentafluorbenzyloxime derivatives in bovine liver. Loidl-Stahlhofen A, et al. **Chem Phys Lipids** 1995 Aug 1;77(1):113-9
Determination of lipid ester ozonides and core aldehydes by high-performance liquid chromatography with on-line mass spectrometry. Ravandi A, et al. **J Biochem Biophys Methods** 1995 Nov;30(4):271-85
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Yoritaka A, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2696-701
Dependence of the 12-methyltridecanal concentration in beef on the age of the animal. Guth H, et al. **Z Lebensm Unters Forsch** 1995 Jul;201(1):25-6
Evaluation of the stable reaction products of histidine with formaldehyde or with other carbonyl compounds in dairy products. Pellegrino L, et al. **Z Lebensm Unters Forsch** 1996 Jan;202(1):66-71
[Detection of treatment of chicken breast with ionized rays and gradation of radiation dosage with the help of headspace gas chromatography and discriminant analysis evaluation] Elsner T, et al. **Z Lebensm Unters Forsch** 1996 Jan;202(1):63-5 (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

Attenuation of 4-hydroxynonenal-induced cataractogenesis in rat lens by butylated hydroxytoluene. Srivastata SK, et al. **Curr Eye Res** 1996 Jul;15(7):749-54

BLOOD

Plasma fatty acid changes and increased lipid peroxidation in patients with adult respiratory distress syndrome. Quinlan GJ, et al. **Crit Care Med** 1996 Feb;24(2):241-6

CHEMICAL SYNTHESIS

Bisaldehyde allosteric effectors as molecular ratchets and probes. Boyiri T, et al. **Biochemistry** 1995 Nov 21; 34(46):15021-36
Preparations of psi-peptide bond and peptide-aldehyde inhibitors of atrial granule serine proteinase, a candidate processing enzyme of pro-atrial natriuretic factor. Damodaran A, et al. **J Protein Chem** 1995 Aug;14(6):431-40

CHEMISTRY

Covalent modification of class 2 and class 3 aldehyde dehydrogenase by 4-hydroxynonenal. Hartley DP, et al. **Adv Exp Med Biol** 1995;372:93-101
Identification and quantitation of choline glycerophospholipids that contain aldehyde residues by fluorometric high-performance liquid chromatography. Ou Z, et al. **Anal Biochem** 1995 May 20;227(2):289-94
Chemical characterization of a protein-4-hydroxy-2-nonenal cross-link: immunochemical detection in mitochondria exposed to oxidative stress. Cohn JA, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):158-64
Mechanism of aldehyde oxidation catalyzed by horse liver alcohol dehydrogenase. Olson LP, et al. **Biochemistry** 1996 Jul 30;35(30):9782-91
Chemical ecology of astigmatid mites--XLV. (2R, 3R)-epoxyneral: sex pheromone of the acarid mite Caloglyphus sp. (Acarina: Acaridae). Mori N, et al. **Bioorg Med Chem** 1996 Mar;4(3):289-95
Changes induced in bovine serum albumin following interactions with the lipid peroxidation product E-2-octenal. Alaiz M, et al. **Chem Phys Lipids** 1995 Aug 25;77(2):217-23

IMMUNOLOGY

Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Uchida K, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):241-8
Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Soltysik S, et al. **Vaccine** 1995;13(15):1403-10
[The relationship between 4-hydroxynonenal-derived epitopes on apolipoprotein B and coronary heart disease] Chen Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Oct; 75(10):581-3, 637 (Eng. Abstr.) **(Chi)**

METABOLISM

Horse liver alcohol dehydrogenase-catalyzed aldehyde oxidation. The sequential oxidation of alcohols to carboxylic acids under NADH recycling conditions. Oppenheimer NJ, et al. **Adv Exp Med Biol** 1995;372:407-15
Oxidation of omega-oxo fatty acids by cytochrome P450BM-3 (CYP102). Davis SC, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):35-42
Enzymatic pattern of aldehyde metabolism during HL-60 cell differentiation. Barrera G, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):73-9
Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Srivastava S, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):741-6
Aldehyde dehydrogenase from adult human brain that dehydrogenates gamma-aminobutyraldehyde: purification, characterization, cloning and distribution. Kikonyogo A, et al. **Biochem J** 1996 May 15;316 (Pt 1):317-24
How allosteric effectors can bind to the same protein residue and produce opposite shifts in the allosteric equilibrium. Abraham DJ, et al. **Biochemistry** 1995 Nov 21; 34(46):15006-20
Bisaldehyde allosteric effectors as molecular ratchets and probes. Boyiri T, et al. **Biochemistry** 1995 Nov 21; 34(46):15021-36
Aldehyde dehydrogenase activity of Drosophila melanogaster alcohol dehydrogenase: burst kinetics at high pH and aldehyde dismutase activity at physiological pH. Henehan GT, et al. **Biochemistry** 1995 Sep 26; 34(38):12294-301
Kinetics and specificity of human liver aldehyde dehydrogenases toward aliphatic, aromatic, and fused polycyclic aldehydes. Klyosov AA. **Biochemistry** 1996 Apr 9;35(14):4457-67
Tryptophan 250 on the alpha subunit plays an important role in flavin and aldehyde binding to bacterial luciferase. Effects of W-->Y mutations on catalytic function. Li Z, et al. **Biochemistry** 1995 Nov 21;34(46):15084-90
Mechanism of aldehyde oxidation catalyzed by horse liver alcohol dehydrogenase. Olson LP, et al. **Biochemistry** 1996 Jul 30;35(30):9782-91
Proposed mechanism for the cytochrome P450-catalyzed conversion of aldehydes to hydrocarbons in the house fly, Musca domestica. Reed JR, et al. **Biochemistry** 1995 Dec 12;34(49):16221-7
Linoleic acid oxidation in the presence of amino compounds produces pyrroles by carbonyl amine reactions. Zamora R, et al. **Biochim Biophys Acta** 1995 Oct 5;1258(3):319-27
The integral role of triacyl glycerols in the biosynthesis of the aldehydic sex pheromones of Manduca sexta (L). Tumlinson JH, et al. **Bioorg Med Chem** 1996 Mar; 4(3):451-60
Direct characterization of protein adducts of the lipid peroxidation product 4-hydroxy-2-nonenal using electrospray mass spectrometry. Bruenner BA, et al. **Chem Res Toxicol** 1995 Jun;8(4):552-9
Identification of cis-2-butene-1,4-dial as a microsomal metabolite of furan. Chen LJ, et al. **Chem Res Toxicol** 1995 Oct-Nov;8(7):903-6
Oxidation of aldehydes catalyzed by pig liver flavin-containing monooxygenase. Chen GP, et al. **Drug Metab Dispos** 1995 Dec;23(12):1390-3
Increased levels of 4-hydroxynonenal in human monocytes fed with malarial pigment hemozoin. A possible clue for hemozoin toxicity. Schwarzer E, et al. **FEBS Lett** 1996 Jun 17;388(2-3):119-22
4-hydroxynonenal is degraded to mercapturic acid conjugate in rat kidney. Petras T, et al. **Free Radic Biol Med** 1995 Nov;19(5):685-8
Purification and kinetic characterization of gamma-aminobutyraldehyde dehydrogenase from rat liver. Testore G, et al. **Int J Biochem Cell Biol** 1995 Nov; 27(11):1201-10
Human pancreatic islet beta-cell destruction by cytokines involves oxygen free radicals and aldehyde production. Rabinovitch A, et al. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3197-202
Lipid ester-bound aldehydes among copper-catalyzed peroxidation products of human plasma lipoproteins. Kamido H, et al. **J Lipid Res** 1995 Sep;36(9):1876-86
The impact of alteration of polyunsaturated fatty acid levels on C6-aldehyde formation of Arabidopsis thaliana leaves. Zhuang H, et al. **Plant Physiol** 1996 Jul;111(3):805-12

PHARMACOKINETICS

Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes. Takahashi M, et al. **Int J Cancer** 1995 Sep 15;62(6):749-54

PHARMACOLOGY

E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. Montine TJ, et al. **Am J Pathol** 1996 Jan;148(1):89-93
4-Hydroxynonenal mimics ozone-induced modulation of macrophage function ex vivo. Hamilton RF Jr, et al. **Am J Respir Cell Mol Biol** 1996 Aug;15(2):275-82
Inhibition of lecithin-cholesterol acyltransferase and modification of HDL apolipoproteins by aldehydes. McCall MR, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct; 15(10):1599-606
4-Hydroxynonenal triggers Ca2+ influx in isolated rat hepatocytes. Carini R, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):772-6
Induction of procollagen type I gene expression and synthesis in human hepatic stellate cells by 4-hydroxy-2,3-nonenal and other 4-hydroxy-2,3-alkenals is related to their molecular structure. Parola M, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):261-4
4-hydroxy-2,3-trans-nonenal induces transcription and expression of aldose reductase. Spycher S, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):512-6
Altered methional homoeostasis is associated with decreased apoptosis in BAF3 bcl2 murine lymphoid cells. Roch AM, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):973-81
Inhibition of poly(ADP-ribose) formation by 4-hydroxynonenal in primary cultures of rabbit synovial fibroblasts. Ullrich O, et al. **Biochem J** 1996 May 1;315 (Pt 3):705-8
trans,trans-2,4-decadienal: cytotoxicity and effect on glutathione level in human erythroleukemia (HEL) cells. Nappez C, et al. **Cancer Lett** 1996 Jan 19;99(1):115-9
Cytotoxic and chemotactic potencies of several aldehydic components of oxidised low density lipoprotein for human monocyte-macrophages. Müller K, et al. **FEBS Lett** 1996 Jun 17;388(2-3):165-8
Effect of 4-Hydroxynonenal on cell cycle progression and expression of differentiation-associated antigens in HL-60 cells. Barrera G, et al. **Free Radic Biol Med** 1996; 20(3):455-62
Inhibition of adenine nucleotide translocator by lipid peroxidation products. Chen JJ, et al. **Free Radic Biol Med** 1995 Nov;19(5):583-90
Monohydroperoxidized fatty acids but not 4-hydroxynonenal induced acute cardiac cell damage. Iliou JP, et al. **Free Radic Biol Med** 1995 Dec;19(6):773-83
4-hydroxynonenal inhibits Na(+)-K(+)-ATPase. Siems WG, et al. **Free Radic Biol Med** 1996;20(2):215-23
Single-cell investigation by laser scanning confocal microscopy of cytochemical alterations resulting from extracellular oxidant challenge. Pompella A, et al. **Histochem Cell Biol** 1996 Mar;105(3):173-8
Evidences of 4-hydroxynonenal involvement in modulation of phagocyte activities. Di Mauro C, et al. **Int J Tissue React** 1995;17(2):61-72
Inhibition of lecithin: cholesterol acyltransferase activity in human blood plasma by cigarette smoke extract and reactive aldehydes. Chen C, et al. **J Biochem Toxicol** 1995 Jun;10(3):121-8
4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. Kristal BS, et al. **J Biol Chem** 1996 Mar 15;271(11):6033-8
Preparations of psi-peptide bond and peptide-aldehyde inhibitors of atrial granule serine proteinase, a candidate processing enzyme of pro-atrial natriuretic factor. Damodaran A, et al. **J Protein Chem** 1995 Aug;14(6):431-40

TOXICITY

Attenuation of 4-hydroxynonenal-induced cataractogenesis in rat lens by butylated hydroxytoluene. Srivastata SK, et al. **Curr Eye Res** 1996 Jul;15(7):749-54
Genotoxic effects of the alpha, beta-unsaturated aldehydes 2-trans-butenal, 2-trans-hexenal and 2-trans, 6-cis-nonadienal. Dittberner U, et al. **Mutat Res** 1995 Dec; 335(3):259-65
Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Wieslander AP, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):348-52
4-Hydroxynonenal-induced cell death in murine alveolar macrophages. Li L, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):135-43

ALDICARB

METABOLISM

Use of aquatic organisms as models to determine the in vivo contribution of flavin-containing monooxygenases in xenobiotic biotransformation. Schlenk D. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):323-30
In vitro comparison of aldicarb oxidation in various food-producing animal species. Montesissa C, et al. **Vet Hum Toxicol** 1995 Aug;37(4):333-6

ALDOLASE see **FRUCTOSEDIPHOSPHATE ALDOLASE**

ALDOSE REDUCTASE see **ALDEHYDE REDUCTASE**

ALDOSTERONE

see related
HYPERALDOSTERONISM
HYPOALDOSTERONISM
PSEUDOHYPOALDOSTERONISM
RECEPTORS, ALDOSTERONE
RENIN-ANGIOTENSIN SYSTEM

Biological determinants of aldosterone-induced cardiac fibrosis in rats. Robert V, et al. **Hypertension** 1995 Dec; 26(6 Pt 1):971-8

ANALOGS & DERIVATIVES

Urinary excretion of 19-noraldosterone in the spontaneously hypertensive rat and stroke-prone spontaneously hypertensive rat. Takeda Y, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S20-2

Increased aldosterone-18-glucuronide/tetrahydroaldosterone ratios in pregnancy. Wacker J, et al. **Endocr Res** 1995 Feb-May; 21(1-2):197-202

Biotin-labelled and photoactivatable aldosterone and progesterone derivatives as ligands for affinity chromatography, fluorescence immunoassays and photoaffinity labelling. Eisen C, et al. **Eur J Biochem** 1996 Apr 15;237(2):514-8

Effect of adrenocorticotropin stimulation on the synthesis of 19-noraldosterone in man. Takeda Y, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1852-5

21-Deoxyaldosteronism is not a new syndrome [letter; comment] Ulick S. **J Clin Endocrinol Metab** 1995 Nov; 80(11):3388-9. Comment on: J Clin Endocrinol Metab 1995 Mar;80(3):737-44.

ANALYSIS

[Aldosterone] Tanaka K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:483-6 (8 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS see ALDOSTERONE ANTAGONISTS

BIOSYNTHESIS

Long-PCR of the ANP gene and PCR-SSCP analysis of the proximal promoter region of the ANP gene in patients with aldosterone producing adenoma. Tunny TJ, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):172-8

Reconstitution of the steroidogenic pathway from cholesterol to aldosterone in liposome membranes. Kominami S, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):199-206

Analysis of the renin gene in patients with aldosterone-producing adenomas by polymerase chain reaction-single stranded conformational polymorphisms and long polymerase chain reaction. Ballantine DM, et al. **Clin Exp Pharmacol Physiol** 1995 Jun-Jul;22(6-7):484-6

PCR-SSCP analysis of the angiotensin II type 1 receptor gene in patients with aldosterone-producing adenomas. Klemm SA, et al. **Clin Exp Pharmacol Physiol** 1995 Jun-Jul; 22(6-7):457-9

The effects of KN62, a Ca2+/calmodulin-dependent protein kinase II inhibitor, on adrenocortical cell aldosterone production. Clyne CD, et al. **Endocr Res** 1995 Feb-May; 21(1-2):259-65

Cortisol: a tool to study aldosterone biosynthesis in rats. Matković L, et al. **Endocr Res** 1995 Feb-May;21(1-2):471-5

Neuropeptides in the adrenal gland: distribution, localization of receptors, and effects on steroid hormone synthesis. Tóth IE, et al. **Endocr Res** 1995 Feb-May;21(1-2):39-51 (135 ref.)

Selective increases in adrenal steroidogenic capacity during acute respiratory disease in infants. Hanukoglu A, et al. **Eur J Endocrinol** 1995 Nov;133(5):552-6

Atrial natriuretic peptide stimulates aldosterone production by turkey (Meleagris gallopavo) adrenal steroidogenic cells. Kocsis JF, et al. **Gen Comp Endocrinol** 1995 Sep; 99(3):364-72

Inhibition of aldosterone production by adrenomedullin, a hypotensive peptide, in the rat. Yamaguchi T, et al. **Hypertension** 1996 Aug;28(2):308-14

Role of Ca2+ in the action of adrenocorticotropin in cultured human adrenal glomerulosa cells. Gallo-Payet N, et al. **J Clin Invest** 1996 Jul 15;98(2):460-6

Ectopic aldosteronoma associated to another adrenocortical adenoma in the adrenal gland of the same side. Mazza E, et al. **J Endocrinol Invest** 1995 Nov;18(10):809-12

The adrenal renin-angiotensin system: a local hormonal regulator of aldosterone production. Mulrow PJ, et al. **J Hypertens** 1996 Feb;14(2):173-6 (41 ref.)

Specific inhibition of the last steps of aldosterone biosynthesis by 18-vinylprogesterone in bovine adrenocortical cells. Defaye G, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1-2):141-7

Quantitative analysis of messenger ribonucleic acid encoding natriuretic peptide receptors in aldosterone-producing adenoma. Chen YM, et al. **Mol Cell Endocrinol** 1995 Jun; 111(2):139-46

Novel natriuretic peptide receptor/guanylyl cyclase A-selective agonist inhibits angiotensin II- and forskolin-evoked aldosterone synthesis in a human zona glomerulosa cell line. Olson LJ, et al. **Mol Pharmacol** 1996 Aug;50(2):430-5

[Dysfunction of the aldosterone synthesis pathway as a marker of malignity in symptomatic and asymptomatic adrenal masses] Aupetit-Faisant B, et al. **Bull Acad Natl Med** 1995 Oct;179(7):1355-65; discussion 1365-7 (Eng. Abstr.) **(Fre)**

BLOOD

Aldosterone and blood pressure in obese subjects during short-term starvation. Ljutić D, et al. **Acta Med Croatica** 1995;49(4-5):165-8

Influence of humoral and neurohormonal factors on cardiovascular hypertrophy in untreated essential hypertensives. Schroeder AP, et al. **Am J Hypertens** 1996 Mar;9(3):207-15

Effect of felodipine on blood pressure, body sodium, plasma renin activity and plasma aldosterone in hypertensive and normotensive rats. Ledingham JM, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S323-5

Plasma aldosterone response to ACTH in subtypes of primary aldosteronism. Stowasser M, et al. **Clin Exp Pharmacol Physiol** 1995 Jun-Jul;22(6-7):460-2

Reduced plasma aldosterone concentrations in randomly selected patients with insulin-dependent diabetes mellitus. Cronin CC, et al. **Diabet Med** 1995 Sep;12(9):809-15

Renin-aldosterone axis in normoalbuminuric insulin-dependent diabetes mellitus patients with glomerular hyperfiltration. de Azevedo MJ, et al. **Diabetes Res Clin Pract** 1995 Mar;27(3):205-10

Characteristics of aldosterone-producing adenoma responsive to upright posture. Toraya S, et al. **Endocr J** 1995 Aug;42(4):481-7

ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Pitt D. **Eur Heart J** 1995 Dec;16 Suppl N:107-10

Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Struthers AD. **Eur Heart J** 1995 Dec;16 Suppl N:103-6 (26 ref.)

Influence of alcohol on the hydromineral hormone responses to exercise in a warm environment. Saini J, et al. **Eur J Appl Physiol** 1995;72(1-2):32-6

Relative value of computed tomography scanning and venous sampling in establishing the cause of primary hyperaldosteronism. Sheaves R, et al. **Eur J Endocrinol** 1996 Mar;134(3):308-13

Age-related decreases in plasma adrenocorticotropic hormone, corticosterone, and aldosterone responses to exogenous corticotropin-releasing hormone in the rat. Brudieux R, et al. **Gerontology** 1995;41(6):308-14

Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Davidson NC, et al. **Heart** 1996 Jun;75(6):576-81

Aldosterone levels and cardiac hypertrophy in professional cyclists. Iglesias Cubero G, et al. **Int J Sports Med** 1995 Oct;16(7):475-7

Response of serum angiotensin converting enzyme, plasma renin activity and plasma aldosterone to conventional dialysis in patients on chronic haemodialysis. Letizia C, et al. **Int Urol Nephrol** 1995;27(4):465-70

Aldosterone responses to hyperkalemia in healthy elderly humans. Mulkerrin E, et al. **J Am Soc Nephrol** 1995 Nov; 6(5):1459-62

Hormonal changes in normal and polycythemic high-altitude natives. Antezana AM, et al. **J Appl Physiol** 1995 Sep; 79(3):795-800

The effects of hexachlorobenzene on circulating levels of adrenal steroids in the ovariectomized rat. Foster WG, et al. **J Biochem Toxicol** 1995 Jun;10(3):129-35

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. Struthers AD. **J Card Fail** 1996 Mar;2(1):47-54 (56 ref.)

Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects. Ogihara T, et al. **J Cardiovasc Pharmacol** 1995 Sep; 26(3):490-4

Effect of losartan, an angiotensin II receptor antagonist, on response of cortisol and aldosterone to adrenocorticotrophic hormone. Sasaki M, et al. **J Clin Pharmacol** 1995 Aug;35(8):776-9

Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. Rossi G, et al. **J Hypertens** 1995 Oct;13(10):1181-91

Role of epinephrine-induced hypokalemia in the regulation of renin and aldosterone in humans. Kolloch RE, et al. **J Lab Clin Med** 1996 Jan;127(1):50-6

Role of ouabain-like compound in the regulation of plasma aldosterone concentration in rats. Yamada K, et al. **Life Sci** 1996;58(21):1833-7

Regulation of amiloride-sensitive Na+ transport in immature rat distal colon by aldosterone. Pácha J, et al. **Pediatr Res** 1995 Sep;38(3):356-60

Does industrial environment influence the prevalence of arterial hypertension, plasma cholesterol and uric acid concentration and activity of the renin-aldosterone system? Więcek A, et al. **Przegl Lek** 1996;53(4):356-9

Hyperaldosteronism: sampling the adrenal veins. Doppman JL, et al. **Radiology** 1996 Feb;198(2):309-12

Breed differences in the plasma renin activity and plasma aldosterone concentration of dogs. Pedersen HD, et al. **Zentralbl Veterinarmed A** 1995 Sep;42(7):435-41

[Are atrial natriuretic factor, renin, aldosterone and catecholamines modified during general anesthesia for total hip arthroplasty?] Hachimi A, et al. **Cah Anesthesiol** 1995; 43(5):449-53 **(Fre)**

[Conn's adenoma. Diagnostic and prognostic value of the measurement of potassium, renin, aldosterone levels and the aldosterone/renin ratio] Massien-Simon C, et al. **Presse Med** 1995 Sep 23;24(27):1238-42 (Eng. Abstr.) **(Fre)**

[Relationship between vasoactive substances and changes in blood pressure during hemodialysis] Takahashi M. **Nippon Jinzo Gakkai Shi** 1995 Oct;37(10):549-57 (Eng. Abstr.) **(Jpn)**

[Effects of changes in central hemodynamics and hormonal systems of its regulation on the etiology of portal hypertension complications in patients with liver cirrhosis] Tsykin DB, et al. **Klin Med (Mosk)** 1995;73(4):99 **(Rus)**

METABOLISM

Corticosteroid metabolism in isolated perfused rat liver and kidney. Experimental studies with emphasis on aldosterone. Egfjord M. **Acta Physiol Scand Suppl** 1995;627:1-42 (226 ref.)

Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Trapp T, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):286-91

The promiscuous receptor: a case for the guardian enzyme. Weber KT, et al. **Cardiovasc Res** 1995 Aug;30(2):176-80 (34 ref.)

Effects of neurokinin-A on the rat hypothalamo-pituitary-adrenal axis. Malendowicz LK, et al. **Endocr Res** 1995 Nov;21(4):757-67

Ascorbate depletion prevents aldosterone stimulation by sodium deficiency in the guinea pig. Redmann A, et al. **Eur J Endocrinol** 1995 Oct;133(4):499-506

Dopaminergic regulation of aldosterone secretion: its pathophysiologic significance in subsets of primary aldosteronism. Naruse M, et al. **Hypertens Res** 1995 Jun; 18 Suppl 1:S59-64

Regulation of Na+,K+-ATPase in submandibular glands of hypophysectomized male mice by steroid and thyroid hormones. Kurihara K, et al. **J Histochem Cytochem** 1996 Jul;44(7):703-11

Putative steroid binding domain of the human mineralocorticoid receptor, expressed in E. coli in the presence of heat shock proteins shows typical native receptor characteristics. Jaglaguier S, et al. **J Steroid Biochem Mol Biol** 1996 Jan;57(1-2):43-50

Sulfhydryl groups are involved in the binding of agonists and antagonists to the human mineralocorticoid receptor. Souque A, et al. **J Steroid Biochem Mol Biol** 1996 Mar; 57(5-6):315-21

[Role of afferent renal nerves in 2K2C Goldblatt hypertension] Wang Q, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):366-72 (Eng. Abstr.) **(Chi)**

[Binding of aldosterone with rat brain corticosteroid receptors: effect of typological features of behavior and stress] Akimov IuA, et al. **Biull Eksp Biol Med** 1995 Jul; 120(7):49-51 **(Rus)**

[The binding of [3H]aldosterone by brain corticosteroid receptors in rats with different individual-typological behavioral characteristics] Onufriev MV, et al. **Izv Akad Nauk Ser Biol** 1996 May-Jun;(3):344-50 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Differential regulation of Na+-K+-ATPase gene expression by corticosteriods in vascular smooth muscle cells. Muto S, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C731-9

Effect of aldosterone on renal potassium conservation in the rat. Ornt DB, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E1003-8

Nongenomic effects of aldosterone on intracellular pH in vascular smooth muscle cells. Wehling M, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):181-6

Regulation of angiotensinogen gene expression in the rat forebrain by adrenal steroids and relation to salt appetite. Riftina F, et al. **Brain Res Mol Brain Res** 1995 Nov; 33(2):201-8

Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Ikeda U, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):69-73

Modulation of cytosolic protein kinase C and calcium ion activity by steroid hormones in rat distal colon. Doolan CM, et al. **J Biol Chem** 1996 Apr 12;271(15):8763-7

Regulation of a sodium channel-associated G-protein by aldosterone. Rokaw MD, et al. **J Biol Chem** 1996 Feb 23; 271(8):4491-6

Stress-induced changes in blood leukocyte distribution. Role of adrenal steroid hormones. Dhabhar FS, et al. **J Immunol** 1996 Aug 15;157(4):1638-44

Effects of vasopressin and aldosterone on the lateral mobility of epithelial Na+ channels in A6 renal epithelial cells. Smith PR, et al. **J Membr Biol** 1995 Sep;147(2):195-205

Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. Campbell SE, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1545-60

Aldosterone modulates both the Na/H antiport and Cl/HCO3 exchanger in cultured neonatal rat cardiac cells. Korichneva I, et al. **J Mol Cell Cardiol** 1995 Nov; 27(11):2521-8

Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts? Köhler E, et al. **J Vasc Res** 1996 Jul-Aug;33(4):315-26

Guanine nucleotide-dependent carboxymethylation: a pathway for aldosterone modulation of apical Na+ permeability in epithelia. Sariban-Sohraby S, et al. **Kidney Int** 1995 Oct;48(4):965-9 (66 ref.)

Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Zhou

G, et al. **Mol Cell Biochem** 1996 Jan 26;154(2):171–8

Aldosterone activates the nuclear pore transporter in cultured kidney cells imaged with atomic force microscopy. Folprecht G, et al. **Pflugers Arch** 1996 Sep;432(5):831–8

PHYSIOLOGY

Renin–angiotensin–aldosterone system, RR interval, and blood pressure variability during postural changes in borderline arterial hypertension. Duprez DA, et al. **Am J Hypertens** 1995 Jul;8(7):683–8

Aldosterone–dependent regulation of Na–K–ATPase subunit mRNA in the rat CCD: competitive PCR analysis. Tsuchiya K, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F7–15

Aldosterone and its mechanism of action: more questions than answers. Fuller PJ. **Aust N Z J Med** 1995 Dec;25(6):800–7 (57 ref.)

The possible roles of hormones and enzymes in the production of the acute attack in Menière's disease [letter; comment] Naftalin L. **Eur Arch Otorhinolaryngol** 1995; 252(6):383–4. Comment on: Eur Arch Otorhinolaryngol 1994;251(3):173–7.

The renin–angiotensin–aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Brilla CG, et al. **Eur Heart J** 1995 Dec;16 Suppl O:107–9 (24 ref.)

Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Weber KT, et al. **Eur Heart J** 1995 Dec;16 Suppl N:12–8 (83 ref.)

Aldosterone and heart failure. Zannad F. **Eur Heart J** 1995 Dec;16 Suppl N:98–102 (33 ref.)

Role of aldosterone in the remnant kidney model in the rat. Greene EL, et al. **J Clin Invest** 1996 Aug 15;98(4):1063–8

Aldosterone action, sodium channels and inherited disease. Fuller PJ, et al. **J Endocrinol** 1996 Mar;148(3):387–90

Renin–angiotensin–aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). Laragh JH. **J Hum Hypertens** 1995 Jun;9(6):385–90 (47 ref.)

Two new culprits in cardiovascular disease: QT dispersion and aldosterone. Struthers AD. **J Hum Hypertens** 1995 Aug;9(8):659–61 (19 ref.)

[New data on mineralocorticoid hormones. Physiopathological implications (editorial)] Corvol P, et al. **Presse Med** 1995 Sep 23;24(27):1235–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Role of vasopressin and aldosterone in the mechanism of osmoregulating reaction] Nesterov VV, et al. **Patol Fiziol Eksp Ter** 1995 Jul–Sep;(3):44–6 (Eng. Abstr.) **(Rus)**

SECRETION

Masked hyperprolactinemia in a case of aldosterone–producing adrenal adenoma [letter] Oki Y, et al. **Ann Intern Med** 1995 Dec 1;123(11):893–4

Calcified aldosterone–producing adrenocortical adenoma. Jelic TM, et al. **Clin Imaging** 1996 Jan–Mar;20(1):50–4

Expression of type 1 angiotensin II receptors in human aldosteronomas. Sarzani R, et al. **Endocr Res** 1995 Feb–May;21(1–2):189–95

Zonation, paracrine function and aldosterone secretion in the rat adrenal cortex. Vinson GP, et al. **Endocr Res** 1995 Feb–May;21(1–2):1–12

C–type natriuretic peptide as a possible local modulator of aldosterone secretion in bovine adrenal zona glomerulosa. Kawai M, et al. **Endocrinology** 1996 Jan;137(1):42–6

Inhibition of aldosterone turn–off phenomenon following chronic adrenocorticotropin treatment with in vivo administration of antiglucocorticoid and antioxidants in rats. Ni H, et al. **Eur J Endocrinol** 1995 Nov;133(5):578–84

Increase of aldosterone secretion following acute haloperidol administration: possible clinical implications. Liberini P, et al. **Int Clin Psychopharmacol** 1996 Mar;11(1):67–70

Adrenal tumor producing 11–deoxycorticosterone, 18–hydroxy–11–deoxycorticosterone and aldosterone. Toyoda Y, et al. **Intern Med** 1996 Feb;35(2):123–8

Pituitary adenylate–cyclase activating peptide enhances aldosterone secretion of human adrenal gland: evidence for an indirect mechanism, probably involving the local release of catecholamines. Neri G, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):169–73

Effects of sodium depletion on the response of rat adrenal zona glomerulosa cells to stimulation by neuropeptides: actions of vasoactive intestinal peptide, enkephalin, substance P, neuropeptide Y and corticotrophin–releasing hormone. Hinson JP, et al. **J Endocrinol** 1995 Aug; 146(2):209–14

Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion. Vesely DL, et al. **J Endocrinol** 1995 Sep;146(3):373–80

Adrenomedullin and calcitonin gene–related peptide inhibit aldosterone secretion in rats, acting via a common receptor. Mazzocchi G, et al. **Life Sci** 1996;58(10):839–44

Increase of aldosterone secretion in adrenal cortex suspensions derived from pregnant rats. Brochu M, et al. **Proc Soc Exp Biol Med** 1996 Jun;212(2):147–52

[Mechanism of inhibition of aldosterone secretion by a Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism] Yokoyama T, et al. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1059–74 (Eng. Abstr.) **(Jpn)**

ALDOSTERONE ANTAGONISTS

ADMINISTRATION & DOSAGE

ACE inhibitor co–therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Pitt D. **Eur Heart J** 1995 Dec;16 Suppl N:107–10

[Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization] Grunwald K, et al. **Geburtshilfe Frauenheilkd** 1994 Nov;54(11):634–45 (Eng. Abstr.) **(Ger)**

METABOLISM

Sulfhydryl groups are involved in the binding of agonists and antagonists to the human mineralocorticoid receptor. Souque A, et al. **J Steroid Biochem Mol Biol** 1996 Mar; 57(5–6):315–21

PHARMACOLOGY

Effects of adding spironolactone to an angiotensin–converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Barr CS, et al. **Am J Cardiol** 1995 Dec 15; 76(17):1259–65

Cell membrane cation transport systems during aldosterone antagonism. Lijnen P, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):462–8

Anxiolytic–like effects of selective mineralocorticoid and glucocorticoid antagonists on fear–enhanced behavior in the elevated plus–maze. Korte SM, et al. **Psychoneuroendocrinology** 1995;20(4):385–94

THERAPEUTIC USE

Effects of adding spironolactone to an angiotensin–converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Barr CS, et al. **Am J Cardiol** 1995 Dec 15; 76(17):1259–65

Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone–producing adenomas. Rossi E, et al. **Am J Hypertens** 1995 Sep;8(9):884–93

Comparison of spironolactone–oral contraceptive versus cyproterone acetate–estrogen regimens in the treatment of hirsutism. Erenus M, et al. **Fertil Steril** 1996 Aug; 66(2):216–9

The effect of long–term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Nevens F, et al. **Hepatology** 1996 May; 23(5):1047–52

ALDOSTERONE RECEPTORS see **RECEPTORS, ALDOSTERONE**

ALDOSTERONISM see **HYPERALDOSTERONISM**

ALDRICH SYNDROME see **WISKOTT–ALDRICH SYNDROME**

ALDRIN

PHARMACOLOGY

Effect of aldrin on carbohydrate, protein, and ionic metabolism of a freshwater catfish, Heteropneustes fossilis. Singh NN, et al. **Bull Environ Contam Toxicol** 1996 Aug; 57(2):204–10

Cyclodiene insecticides–induced changes in the central depressive effect of chlorpromazine in rats. Balasubramaniam E, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):231–6

ALEUTIAN DISEASE VIRUS see **ALEUTIAN MINK DISEASE PARVOVIRUS**

ALEUTIAN MINK DISEASE

see related
CHEDIAK–HIGASHI SYNDROME

DIAGNOSIS

Diagnostic exercise: ataxia and incoordination in ferrets. Rozengurt N, et al. **Lab Anim Sci** 1995 Aug;45(4):432–4

TRANSMISSION

Investigation of the pathogenesis of transplacental transmission of Aleutian mink disease parvovirus in experimentally infected mink. Broll S, et al. **J Virol** 1996 Mar;70(3):1455–66

The relationship between capsid protein (VP2) sequence and pathogenicity of Aleutian mink disease parvovirus (ADV): a possible role for raccoons in the transmission of ADV infections. Oie KL, et al. **J Virol** 1996 Feb;70(2):852–61

ALEUTIAN MINK DISEASE PARVOVIRUS

GENETICS

Identification of a DNA segment in ferret Aleutian disease virus similar to a hypervariable capsid region of mink Aleutian disease parvovirus. Saifuddin M, et al. **Arch Virol** 1996;141(7):1329–36

PATHOGENICITY

The relationship between capsid protein (VP2) sequence and pathogenicity of Aleutian mink disease parvovirus (ADV): a possible role for raccoons in the transmission of ADV infections. Oie KL, et al. **J Virol** 1996 Feb;70(2):852–61

PHYSIOLOGY

Subcellular localization of Aleutian mink disease parvovirus proteins and DNA during permissive infection of Crandell feline kidney cells. Oleksiewicz MB, et al. **J Virol** 1996 May;70(5):3242–7

ALEUTS see **ESKIMOS**

ALEXIA see **DYSLEXIA, ACQUIRED**

ALEXITHYMIA see **AFFECTIVE SYMPTOMS**

ALFALFA

Digestion characteristics by beef cattle consuming bermudagrass or bromegrass hay alone or with alfalfa and(or) corn. Sun W, et al. **Arch Tierernahr** 1993; 45(3):263–79

Enhanced intake and production of cows offered ensiled alfalfa with higher neutral detergent fiber digestibility. Dado RG, et al. **J Dairy Sci** 1996 Mar;79(3):418–28

In vitro ruminal degradation and synthesis of protein on fractions extracted from alfalfa hay and silage. Peltekova VD, et al. **J Dairy Sci** 1996 Apr;79(4):612–9

[Effect of growth rate of lucerne on the degradability of crude protein in the rumen and on in vitro digestibility of non–degraded crude protein] Chrenková M, et al. **Arch Tierernahr** 1993;45(3):281–91 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Alfalfa pills and autoimmune diseases [letter; comment] Farnsworth NR. **Am J Clin Nutr** 1995 Nov;62(5):1026–8 . Comment on: Am J Clin Nutr 1994 Oct;60(4):639–40.

Alfalfa, vitamin E, and autoimmune disorders [letter; comment] Whittam J, et al. **Am J Clin Nutr** 1995 Nov; 62(5):1025–6. Comment on: Am J Clin Nutr 1994 Oct;60(4):639–40.

CHEMISTRY

Effects of alfalfa root saponins on digestive function in sheep. Klita PT, et al. **J Anim Sci** 1996 May;74(5):1144–56

A biotechnological approach to improving the nutritive value of alfalfa. Tabe LM, et al. **J Anim Sci** 1995 Sep;73(9):2752–9

Effects of sodium sulfite on recovery and composition of detergent fiber and lignin. Hintz RW, et al. **J AOAC Int** 1996 Jan–Feb;79(1):16–22

ENZYMOLOGY

Nucleotide sequences of four pathogen–induced alfalfa peroxidase–encoding cDNAs. el–Turk J, et al. **Gene** 1996 May 8;170(2):213–6

MMK2, a novel alfalfa MAP kinase, specifically complements the yeast MPK1 function. Jonak C, et al. **Mol Gen Genet** 1995 Oct 25;248(6):686–94

Alfalfa NADH–dependent glutamate synthase: structure of the gene and importance in symbiotic N2 fixation. Vance CP, et al. **Plant J** 1995 Sep;8(3):345–58

GENETICS

Cloning novel alfalfa cyclin sequences—a RACE–PCR approach. Russinova E, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):703–14

Identification of three highly expressed replacement histone H3 genes of alfalfa. Robertson AJ, et al. **DNA Seq** 1996; 6(3):137–46

Use of a subtractive hybridization approach to identify new Medicago truncatula genes induced during root nodule development. Gamas P, et al. **Mol Plant Microbe Interact** 1996 May;9(4):233–42

The D–type alfalfa cyclin gene cycMs4 complements G1 cyclin–deficient yeast and is induced in the G1 phase of the cell cycle. Dahl M, et al. **Plant Cell** 1995 Nov; 7(11):1847–57

A sugar transporter from Medicago truncatula: altered expression pattern in roots during vesicular–arbuscular (VA) mycorrhizal associations. Harrison MJ. **Plant J** 1996 Apr;9(4):491–503

Molecular characterization and expression of alfalfa (Medicago sativa L.) flavanone–3–hydroxylase and dihydroflavonol–4–reductase encoding genes. Charrier B, et al. **Plant Mol Biol** 1995 Nov;29(4):773–86

The expression pattern of alfalfa flavanone 3–hydroxylase promoter–gus fusion in Nicotiana benthamiana correlates

with the presence of flavonoids detected in situ. Charrier B, et al. **Plant Mol Biol** 1996 Mar;30(6):1153–68
Stress responses in alfalfa (Medicago sativa L.). XX. Transcriptional activation of phenlpropanoid pathway genes in elicitor-induced cell suspension cultures. Ni W, et al. **Plant Mol Biol** 1996 Feb;30(3):427–38

METABOLISM

Calcium spiking in plant root hairs responding to Rhizobium nodulation signals. Ehrhardt DW, et al. **Cell** 1996 May 31; 85(5):673–81
Effect of maturity on digestion kinetics of water-soluble and water-insoluble fractions of alfalfa and brome hay. Stefanon B, et al. **J Anim Sci** 1996 May;74(5):1104–15

MICROBIOLOGY

Efficacy of chlorine and heat treatment in killing Salmonella stanley inoculated onto alfalfa seeds and growth and survival of the pathogen during sprouting and storage. Jaquette CB, et al. **Appl Environ Microbiol** 1996 Jul; 62(7):2212–5
Genetic diversity of an Italian Rhizobium meliloti population from different Medicago sativa varieties. Paffetti D, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2279–85
Evidence that two genomic species of Rhizobium are associated with Medicago truncatula. Rome S, et al. **Arch Microbiol** 1996 Apr;165(4):285–8
Detection of Rhizobium meliloti cells in field soil and nodules by polymerase chain reaction. Watson RJ, et al. **Can J Microbiol** 1995 Sep;41(9):816–25
Calcium spiking in plant root hairs responding to Rhizobium nodulation signals. Ehrhardt DW, et al. **Cell** 1996 May 31; 85(5):673–81
In Rhizobium meliloti, the operon associated with the nod box n5 comprises nodL, noeA and noeB, three host-range genes specifically required for the nodulation of particular Medicago species. Ardourel M, et al. **Mol Microbiol** 1995 Aug;17(4):687–99
Characterization of a Rhizobium meliloti proline dehydrogenase mutant altered in nodulation efficiency and competitiveness on alfalfa roots. Jiménez-Zurdo JI, et al. **Mol Plant Microbe Interact** 1995 Jul–Aug;8(4):492–8
Biotin and other water-soluble vitamins are key growth factors for alfalfa root colonization by Rhizobium meliloti 1021. Streit WR, et al. **Mol Plant Microbe Interact** 1996 Jul;9(5):330–8
A sugar transporter from Medicago truncatula: altered expression pattern in roots during vesicular-arbuscular (VA) mycorrhizal associations. Harrison MJ. **Plant J** 1996 Apr;9(4):491–503
Low molecular weight EPS II of Rhizobium meliloti allows nodule invasion in Medicago sativa. González JE, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8636–41

PHYSIOLOGY

Developmental and cell cycle regulation of alfalfa nucMs1, a plant homolog of the yeast Nsr1 and mammalian nucleolin. Bögre L, et al. **Plant Cell** 1996 Mar;8(3):417–28

STANDARDS

Serum alpha-tocopherol, vitamin A, and blood selenium concentrations, and glutathione peroxidase activity in llamas fed alfalfa hay. Dart AJ, et al. **Am J Vet Res** 1996 May;57(5):689–92
Growth and tissue accretion of lambs fed concentrate in drylot, grazed on alfalfa or ryegrass at weaning, or after backgrounding on ryegrass. McClure KE, et al. **J Anim Sci** 1995 Nov;73(11):3437–44

VIROLOGY

Characterization of the alfalfa mosaic virus strain T6. Kúdela O, et al. **Acta Virol** 1995 Jun;39(3):131–5

ALFALFA MOSAIC VIRUS

DRUG EFFECTS

Effect of hydrocarbons and crude oil contamination on the sensitivity of French bean to alfalfa mosaic virus. Jurík M, et al. **Acta Virol** 1995 Dec;39(5–6):275–77

ENZYMOLOGY

RNA duplex unwinding activity of alfalfa mosaic virus RNA-dependent RNA polymerase. de Graaff M, et al. **FEBS Lett** 1995 Sep 11;371(3):219–22

GENETICS

Purification, characterization, assembly and crystallization of assembled alfalfa mosaic virus coat protein expressed in Escherichia coli. Yusibov V, et al. **J Gen Virol** 1996 Apr; 77 (Pt 4):567–73
The 5' terminal sequence of alfalfa mosaic virus RNA 3 is dispensable for replication and contains a determinant for symptom formation. van der Vossen EA, et al. **Virology** 1996 Jul 15;221(2):271–80
Analysis of cis-acting elements in the 5' leader sequence of alfalfa mosaic virus RNA 3. van der Vossen EA, et al. **Virology** 1996 Jun 15;220(2):539–43
Characterization of sequences controlling the synthesis of alfalfa mosaic virus subgenomic RNA in vivo. van der Vossen EA, et al. **Virology** 1995 Oct 1;212(2):663–72

GROWTH & DEVELOPMENT

High-affinity RNA-binding domains of alfalfa mosaic virus coat protein are not required for coat protein-mediated resistance. Yusibov V, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8980–4

METABOLISM

Structural elements of the 3'-terminal coat protein binding site in alfalfa mosaic virus RNAs. Reusken CB, et al. **Nucleic Acids Res** 1996 Jul 15;24(14):2660–5
Interaction between RNA-dependent RNA polymerase of alfalfa mosaic virus and its template: oxidation of vicinal hydroxyl groups blocks in vitro RNA synthesis. De Graaff M, et al. **Virology** 1995 Nov 10;213(2):650–4
cis-preferential stimulation of alfalfa mosaic virus RNA 3 accumulation by the viral coat protein. van der Vossen EA, et al. **Virology** 1996 Jun 1;220(1):163–70

PATHOGENICITY

The 5' terminal sequence of alfalfa mosaic virus RNA 3 is dispensable for replication and contains a determinant for symptom formation. van der Vossen EA, et al. **Virology** 1996 Jul 15;221(2):271–80

PHYSIOLOGY

Characterization of the alfalfa mosaic virus strain T6. Kúdela O, et al. **Acta Virol** 1995 Jun;39(3):131–5

ALFENTANIL

Effect of the addition of alfentanil to lignocaine during axillary brachial plexus anaesthesia. Gormley WP, et al. **Br J Anaesth** 1996 Jun;76(6):802–5
Combined alfentanil-methohexital anesthesia in electroconvulsive therapy. Dinwiddie SH, et al. **Convuls Ther** 1995 Sep;11(3):170–6
Propofol and alfentanil mixture for outpatient surgery [letter; comment] Isert P. **J Clin Anesth** 1995 Jun;7(4):357. Comment on: J Clin Anesth 1994 Mar–Apr;6(2):166–7.
Use of alfentanil for in vitro fertilization oocyte retrieval. Shapira SC, et al. **J Clin Anesth** 1996 Jun;8(4):282–5
Potency of doxacurium in infants, children, and adolescents during N2O-O2-alfentanil anesthesia. Taivainen TR, et al. **J Clin Anesth** 1996 May;8(3):225–8
Patient controlled analgesia for shock wave lithotripsy: the effect of self-administered alfentanil on pain intensity and drug requirement [see comments] Schelling G, et al. **J Urol** 1996 Jan;155(1):43–7. Comment in: J Urol 1996 Jan;155(1):56–7.
Retrobulbar versus peribulbar block: alfentanil in eye blocks [letter] de Córdoba JL, et al. **Reg Anesth** 1996 Mar–Apr; 21(2):171
Alfentanil for conscious sedation during colonoscopy [letter; comment] Balaklaw LA. **South Med J** 1996 Mar; 89(3):357–8. Comment on: South Med J 1995 Jun;88(6):630–4.
Alfentanil for sedation during colonoscopy [letter; comment] Hill TR. **South Med J** 1996 Mar;89(3):356–7; discussion 357–8. Comment on: South Med J 1995 Jun;88(6):630–4.
[EEG changes during propofol-alfentanil-nitrous oxide anesthesia] Arndt VM, et al. **Anaesthesiol Reanim** 1995; 20(5):126–33 (Eng. Abstr.) **(Ger)**
[Total intravenous anesthesia (TIVA) in geriatric surgery. S-(+)-ketamine versus alfentanil] Adams HA, et al. **Anaesthesist** 1995 Dec;44 Suppl 3:S540–8 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Intubating conditions and neuromuscular effects of mivacurium during propofol-alfentanil anaesthesia. Van Aken H, et al. **Acta Anaesthesiol Scand Suppl** 1995;106:26–9
Propofol-opioid mixtures during prolonged infusions [letter] Ghouri AF, et al. **Anesth Analg** 1996 Apr;82(4):888–9
Time course characteristics of acute tolerance development to continuously infused alfentanil in rats. Kissin I, et al. **Anesth Analg** 1996 Sep;83(3):600–5
Prevention of pain on injection of propofol: a comparison of lidocaine with alfentanil. Nathanson MH, et al. **Anesth Analg** 1996 Mar;82(3):469–71
Computer-controlled infusion of alfentanil versus patient-controlled administration of morphine for postoperative analgesia: a double-blind randomized trial [see comments] van den Nieuwenhuyzen MC, et al. **Anesth Analg** 1995 Oct;81(4):671–9. Comment in: Anesth Analg 1995 Oct;81(4):665–7.
Continuous intrathecal administration of shortlasting mu opioids remifentanil and alfentanil in the rat. Buerkle H, et al. **Anesthesiology** 1996 Apr;84(4):926–35
A comparison between total intravenous anaesthesia using a propofol/alfentanil mixture and an inhalational technique for laparoscopic gynaecological sterilization. Collins SJ, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):33–7
Continuous infusions of alfentanil and propofol for coronary artery surgery. Roekaerts PM, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):362–7
A pharmacokinetic approach to resolving spinal and systemic contributions to epidural alfentanil analgesia and side-effects. Coda BA, et al. **Pain** 1995 Sep;62(3):329–37
Antinociception and side effects of L- and D-dipalmitoylphosphatidyl choline liposome-encapsulated alfentanil after spinal delivery in rats. Isackson J, et al. **Pharmacol Toxicol** 1995 Nov;77(5):333–40

BLOOD

A pharmacokinetic approach to resolving spinal and systemic contributions to epidural alfentanil analgesia and side-effects. Coda BA, et al. **Pain** 1995 Sep;62(3):329–37

ECONOMICS

Normalized demand for drugs and other reinforcers. Hursh SR, et al. **J Exp Anal Behav** 1995 Nov;64(3):373–84

PHARMACOKINETICS

Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Egan TD, et al. **Anesthesiology** 1996 Apr;84(4):821–33
Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. Fiset P, et al. **Anesthesiology** 1995 Nov;83(5):944–55
Measured context-sensitive half-times of remifentanil and alfentanil. Kapila A, et al. **Anesthesiology** 1995 Nov; 83(5):968–75
Follicular fluid levels of midazolam, fentanyl, and alfentanil during transvaginal oocyte retrieval. Soussis I, et al. **Fertil Steril** 1995 Nov;64(5):1003–7
Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. Frenkel C, et al. **Intensive Care Med** 1995 Dec;21(12):981–8
[Effect of duration of infusion on elimination rate of alfentanil] Castor G, et al. **Anaesthesiol Reanim** 1995; 20(4):97–100 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

A cost-benefit evaluation of using propofol and alfentanil for a short gynecological procedure. Enlund M, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):416–20
QT interval of the ECG, heart rate and arterial pressure during anaesthetic induction: comparative effects of alfentanil and esmolol. Korpinen R, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):809–13
The effects of midazolam, droperidol, fentanyl, and alfentanil on phagocytosis and killing of bacteria by polymorphonuclear leukocytes in vitro. Krumholz W, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):624–7
The influence of alfentanil pre-treatment on ventilatory effects of doxapram following induction of anaesthesia with propofol. O'Connor B, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):156–9
Alfentanil modifies the neurocirculatory responses to desflurane. Yonker-Sell AE, et al. **Anesth Analg** 1996 Jan; 82(1):162–6
Validation of the alfentanil canonical univariate parameter as a measure of opioid effect on the electroencephalogram. Gambús PL, et al. **Anesthesiology** 1995 Oct;83(4):747–56
Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. Pavlin DJ, et al. **Anesthesiology** 1996 Jan;84(1):23–37
Pharmacodynamic interaction between propofol and alfentanil when given for induction of anesthesia. Vuyk J, et al. **Anesthesiology** 1996 Feb;84(2):288–99
Normalized demand for drugs and other reinforcers. Hursh SR, et al. **J Exp Anal Behav** 1995 Nov;64(3):373–84
Comparative clinical pharmacology of short-acting mu opioids in drug abusers. Greenwald MK, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1228–36
Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. Mandema JW, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1185–94
Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Park KM, et al. **Pain** 1995 Nov;63(2):163–72

THERAPEUTIC USE

The treatment of postanaesthetic shivering: a double blind comparison between alfentanil and pethidine. Lyons B, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):979–82
Patient-controlled alfentanil. Target-controlled infusion for postoperative analgesia. Irwin MG, et al. **Anaesthesia** 1996 May;51(5):427–30
Alfentanil dose-response relationships for relief of postoperative pain. Tverskoy M, et al. **Anesth Analg** 1996 Aug;83(2):387–93
Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. Warner DS, et al. **Anesth Analg** 1996 Aug;83(2):348–53
Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Max MB, et al. **Clin Neuropharmacol** 1995 Aug;18(4):360–8
[A comparative study of intravenous opioid analgesia. Sufentanil and alfentanil for extracorporeal shock-wave lithotripsy in urologic patients] Weninger E, et al. **Anaesthesist** 1996 Apr;45(4):330–6 (Eng. Abstr.) **(Ger)**

ALFENTANYL

ALFENTANYL see ALFENTANIL

ALGAE

Toxin of the marine alga Prymnesium patelliferum enhances voltage dependent Ca(2+)-currents, elevates the cytosolic Ca(2+)-concentration and facilitates hormone release in clonal rat pituitary cells. Kolderup J, et al. **Acta Physiol Scand** 1995 Jul;154(3):321–7

Promoting activity of microcystins extracted from waterblooms in SHE cell transformation assay. Wangth HB, et al. **Biomed Environ Sci** 1996 Mar;9(1):46–51

Global climate controversy [letter; comment] Gray JS, et al. **JAMA** 1996 Aug 7;276(5):372–3; discussion 373–4. Comment on: JAMA 1996 Jan 17;275(3):217–23.

CHEMISTRY

Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults. Innis SM, et al. **Am J Clin Nutr** 1996 Aug;64(2):159–67

Cell growth inhibitory effects of caulerpenyne, a sesquiterpenoid from the marine algae Caulerpa taxifolia. Fischel JL, et al. **Anticancer Res** 1995 Sep–Oct; 15(5B):2155–60

In vitro antiviral activities of sulfated polysaccharides from a marine microalga (Cochlodinium polykrikoides) against human immunodeficiency virus and other enveloped viruses. Hasui M, et al. **Int J Biol Macromol** 1995 Oct; 17(5):293–7

Primary structure of cyanelle peptidoglycan of Cyanophora paradoxa: a prokaryotic cell wall as part of an organelle envelope. Pfanzagl B, et al. **J Bacteriol** 1996 Jan; 178(2):332–9

Antibiotic activity of marine algae against multi-antibiotic resistant bacteria. Mahasneh I, et al. **Microbios** 1995; 83(334):23–6

The effects of a purified toxic extract of Prymnesium patelliferum on transport of ions through the plasma membrane of synaptosomes. Meldahl AS, et al. **Toxicon** 1995 Aug;33(8):1071–86

CLASSIFICATION

Intraspecific variation in small-subunit rRNA sequences in GenBank: why single sequences may not adequately represent prokaryotic taxa. Clayton RA, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):595–9

DRUG EFFECTS

Assessment of the toxicity to algae of colored substances. Comber MH, et al. **Bull Environ Contam Toxicol** 1995 Dec; 55(6):922–8

Acute toxicity of fire control chemicals to Daphnia magna (Straus) and Selenastrum capricornutum (Printz). McDonald SF, et al. **Ecotoxicol Environ Saf** 1996 Feb; 33(1):62–72

Antioxidant survey to assess antagonism to redox stress using a prokaryotic and an eukaryotic system. Baker H, et al. **Experientia** 1996 Jun 15;52(6):597–9

[Effect of carbaryl and lead on phenols, chlorophyll and proteins of the microalga Ankistrodesmus falcatus] Martínez-Tabche L, et al. **Rev Latinoam Microbiol** 1995 Apr–Jun;37(2):93–9 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Inactivation of vanadium bromoperoxidase: formation of 2-oxohistidine. Meister Winter GE, et al. **Biochemistry** 1996 Sep 10;35(36):11805–11

The deduced primary structure of subunit I from cytochrome c oxidase suggests that the genus Polytomella shares a common mitochondrial origin with Chlamydomonas. Antaramian A, et al. **Biochim Biophys Acta** 1996 Mar 28; 1273(3):198–202

In vitro import of pre-ferredoxin-NADP+-oxidoreductase from Cyanophora paradoxa into cyanelles and into pea chloroplasts. Jakowitsch J, et al. **FEBS Lett** 1996 Feb 26; 381(1–2):153–5

Vanadium-dependent haloperoxidases. Vilter H. **Met Ions Biol Syst** 1995;31:325–62 (192 ref.)

GENETICS

The chlorarachniophyte: a cell with two different nuclei and two different telomeres. Gilson P, et al. **Chromosoma** 1995 May;103(9):635–41

Phylogenetic position of the Chromista plastids based on small subunit rRNA coding regions. Medlin LK, et al. **Curr Genet** 1995 Nov;28(6):560–5

Rampant horizontal transfer and duplication of rubisco genes in eubacteria and plastids. Delwiche CF, et al. **Mol Biol Evol** 1996 Jul;13(6):873–82

Molecular study of a light-harvesting apoprotein of Giraudyopsis stellifer (Chrysophyceae). Passaquet C, et al. **Plant Mol Biol** 1995 Oct;29(1):135–48

ISOLATION & PURIFICATION

Identification of algae which interfere with the detection of Giardia cysts and Cryptosporidium oocysts and a method for alleviating this interference. Rodgers MR, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3759–63

METABOLISM

Ataxonomic assessment of phytoplankton integrity by means of flow cytometry. Steinberg CE, et al. **Arch Toxicol Suppl** 1996;18:417–34

A soluble motor from the alga Nitella supports fast movement of actin filaments in vitro. Rivolta MN, et al. **Biochim Biophys Acta** 1995 Nov 21;1232(1–2):1–4

Copper transfer and influence on a marine food chain. Edding M, et al. **Bull Environ Contam Toxicol** 1996 Oct; 57(4):617–24

Determination of bioconcentration potential of tetrachloroethylene in marine algae by 13C. Wang X, et al. **Chemosphere** 1996 Sep;33(5):865–77

Polarography as a tool in peptide and protein analysis: studies on metal–chelating substances induced by cadmium in the algae Pheodactylum tricornutum and the graminae Agrostis capillaris. Nyberg S, et al. **Ecotoxicol Environ Saf** 1995 Nov;32(2):147–53

Metabolism of phenols by Ochromonas danica. Semple KT, et al. **FEMS Microbiol Lett** 1995 Nov 15;133(3):253–7

Spatial organization of transport domains and subdomain formation in the plasma membrane of Chara corallina. Fisahn J, et al. **J Membr Biol** 1995 Oct;147(3):275–81

PHYSIOLOGY

Phosphoinositide signalling in plant and algal responses to physiological stimuli. Crain RC, et al. **Biochem Soc Trans** 1995 Nov;23(4):853–6 (28 ref.)

VIROLOGY

Genetic diversity in marine algal virus communities as revealed by sequence analysis of DNA polymerase genes. Chen F, et al. **Appl Environ Microbiol** 1996 Aug; 62(8):2869–74

ALGAE, BLUE-GREEN see CYANOBACTERIA

ALGAE, BROWN

CHEMISTRY

Antitumor and antiproliferative effects of a fucan extracted from ascophyllum nodosum against a non-small-cell bronchopulmonary carcinoma line. Riou D, et al. **Anticancer Res** 1996 May–Jun;16(3A):1213–8

Measurement and manipulation of cytosolic pH in polarizing zygotes. Kropf DL, et al. **Eur J Cell Biol** 1995 Nov; 68(3):297–305

DRUG EFFECTS

Effects of tributyltin and formaldehyde on the germination and growth of Phyllospora comosa (Labillardiere) C. Agardh (Phaeophyta: Fucales). Burridge TR, et al. **Bull Environ Contam Toxicol** 1995 Oct;55(4):525–32

Acute toxicity tests using Phyllospora comosa (Labillardiere) C. Agardh (Phaeophyta: Fucales) and Allorchestes compressa Dana (Crustacea: Amphipoda). Burridge TR, et al. **Bull Environ Contam Toxicol** 1995 Oct;55(4):621–8

GENETICS

Spatial redistribution of poly(A)+ RNA during polarization of the Fucus zygote is dependent upon microfilaments. Bouget FY, et al. **Dev Biol** 1995 Sep;171(1):258–61

METABOLISM

Poor fermentability of "mekabu" (sporophyll of Undaria pinnatifida) alginic acid in batch culture using pig cecal bacteria. Togari N, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Apr;41(2):179–85

VIROLOGY

A Feldmannia algal virus has two genome size-classes. Ivey RG, et al. **Virology** 1996 Jun 15;220(2):267–73

A brown algal virus genome contains a "RING" zinc finger motif. Krueger SK, et al. **Virology** 1996 May 1;219(1):301–3

Characterization of a repetitive DNA element in a brown algal virus. Lee AM, et al. **Virology** 1995 Oct 1; 212(2):474–80

ALGAE, GREEN

Lectin from Codium fragile ssp. tomentosoides conjugated to colloidal gold: a new histochemical reagent. Griffin RL, et al. **Br J Biomed Sci** 1995 Sep;52(3):225–7

Evaluation of the toxicological risk to humans of caulerpenyne using human hematopoietic progenitors, melanocytes, and keratinocytes in culture. Parent-Massin D, et al. **J Toxicol Environ Health** 1996 Jan;47(1):47–59

Programmed cell death [letter] Fulton AB. **Science** 1996 Oct 4;274(5284):20–1

CHEMISTRY

Bioavailability of a natural isomer mixture compared with synthetic all-trans beta-carotene in human serum. Ben-Amotz A, et al. **Am J Clin Nutr** 1996 May; 63(5):729–34

Fluctuation analysis of myosin-coated bead movement along actin bundles of Nitella. Yamasaki H, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):831–6

Partial characterization of a putative 110 kDa myosin from the green alga Chara corallina by in vitro binding of fluorescent F-actin. Grolig F, et al. **Cell Biol Int** 1996 May; 20(5):365–73

X-ray and enzymic studies on amorphous cellulose of the Macroalga ulva. Pizzoferrato L. **Eur J Clin Nutr** 1995 Oct; 49 Suppl 3:S229–32

Effect of ethylene bis isobutyl xanthate isolated from a marine green alga Dictyosphaeria favulosa on mosquito Aedes aegypti. Rao JV, et al. **Indian J Exp Biol** 1995 May; 33(5):399–40

Myosin from alga Chara: unique structure revealed by electron microscopy. Yamamoto K, et al. **J Mol Biol** 1995 Nov 24;254(2):109–12

Structure and biosynthesis of novel conjugated polyene fatty acids from the marine green alga Anadyomene stellata. Mikhailova MV, et al. **Lipids** 1995 Jul;30(7):583–9

Purification of SF-assemblin. Bremerich A, et al. **Methods Cell Biol** 1995;47:315–21

Localization and characterization of a novel 20 kDa polypeptide in the chloroplast of the green alga Dunaliella salina. Andreasson E, et al. **Plant Cell Physiol** 1995 Dec; 36(8):1483–92

CLASSIFICATION

Ribosomal RNA-based oligonucleotide probes to identify marine green ultraphytoplankton. Knauber DC, et al. **J Eukaryot Microbiol** 1996 Mar–Apr;43(2):89–94

Phylogeny of the Chlamydomonadales (Chlorophyceae): a comparison of ribosomal RNA gene sequences from the nucleus and the chloroplast. Buchheim MA, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):391–402

DRUG EFFECTS

Respirometric toxicity test: freshwater alga Scenedesmus quadricauda sensitivity to organotin compounds. Fargasová A, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):993–9

Inhibitive effect of organotin compounds on the chlorophyll content of the green freshwater alga Scenedesmus quadricauda. Fargasová A. **Bull Environ Contam Toxicol** 1996 Jul;57(1):99–106

Toxic effects of organic solvents on the growth of Chlorella vulgaris and Selenastrum capricornutum. El Jay A. **Bull Environ Contam Toxicol** 1996 Aug;57(2):191–8

Effect of aluminum and zinc on enzyme activities in the green alga Selenastrum capricornutum. Kong FX, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):759–65

New algal enzyme bioassay for the rapid assessment of aquatic toxicity. Peterson SM, et al. **Bull Environ Contam Toxicol** 1996 May;56(5):750–7

Chromium-induced sexual reproduction gives rise to a Cr-tolerant progeny in Scenedesmus acutus. Corradi MG, et al. **Ecotoxicol Environ Saf** 1995 Oct;32(1):12–8

ENZYMOLOGY

Purification and properties of four phosphoenolpyruvate carboxylase isoforms from the green alga Selenastrum minutum: evidence that association of the 102-kDa catalytic subunit with unrelated polypeptides may modify the physical and kinetic properties of the enzyme. Rivoal J, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):47–57

The evolutionary conservation of a novel protein modification, the conversion of cysteine to serinesemialdehyde in arylsulfatase from Volvox carteri. Selmer T, et al. **Eur J Biochem** 1996 Jun 1;238(2):341–5

Purification, metal cofactor, N-terminal sequence and subunit composition of a 5-aminolevulinic acid dehydratase from the unicellular green alga Scenedesmus obliquus, mutant C-2A'. Stolz M, et al. **Eur J Biochem** 1996 Mar 1; 236(2):600–8

Expression in Escherichia coli and properties of the carotene ketolase from Haematococcus pluvialis. Breitenbach J, et al. **FEMS Microbiol Lett** 1996 Jul 1;140(2–3):241–6

GENETICS

Primary and secondary structure analyses of the rDNA group-I introns of the Zygnematales (Charophyta). Bhattacharya D, et al. **Curr Genet** 1996 Feb;29(3):282–6

UAG is a sense codon in several chlorophycean mitochondria. Hayashi-Ishimaru Y, et al. **Curr Genet** 1996 Jun;30(1):29–33

Expression in Escherichia coli and properties of the carotene ketolase from Haematococcus pluvialis. Breitenbach J, et al. **FEMS Microbiol Lett** 1996 Jul 1;140(2–3):241–6

A salt-resistant plasma membrane carbonic anhydrase is induced by salt in Dunaliella salina. Fisher M, et al. **J Biol Chem** 1996 Jul 26;271(30):17718–23

Ribosomal RNA-based oligonucleotide probes to identify marine green ultraphytoplankton. Knauber DC, et al. **J Eukaryot Microbiol** 1996 Mar–Apr;43(2):89–94

Phylogeny of the Chlamydomonadales (Chlorophyceae): a comparison of ribosomal RNA gene sequences from the nucleus and the chloroplast. Buchheim MA, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):391–402

Expression of the Volvox gene encoding nitrate reductase: mutation-dependent activation of cryptic splice sites and intron-enhanced gene expression from a cDNA. Gruber H, et al. **Plant Mol Biol** 1996 Apr;31(1):1–12

Isolation and functional identification of a novel cDNA for astaxanthin biosynthesis from Haematococcus pluvialis, and

astaxanthin synthesis in Escherichia coli. Kajiwara S, et al. **Plant Mol Biol** 1995 Oct;29(2):343–52
Physical map and gene organization of the mitochondrial genome from the unicellular green alga Platymonas (Tetraselmis) subcordiformis (Prasinophyceae). Kessler U, et al. **Plant Mol Biol** 1995 Dec;29(5):1081–6
Atypical phytochrome gene structure in the green alga Mesotaenium caldariorum. Lagarias DM, et al. **Plant Mol Biol** 1995 Dec;29(6):1127–42

ISOLATION & PURIFICATION

Two cases of prototothecosis in Nagoya, Japan. Matsumoto Y, et al. **Australas J Dermatol** 1996 May;37 Suppl 1:S42–3
Detection of green algae (Chlorophyceae) for the diagnosis of drowning. Yoshimura S, et al. **Int J Legal Med** 1995; 108(1):39–42

METABOLISM

Biosynthesis of isoprenoids (carotenoids, sterols, prenyl side-chains of chlorophylls and plastoquinone) via a novel pyruvate/glyceraldehyde 3-phosphate non-mevalonate pathway in the green alga Scenedesmus obliquus. Schwender J, et al. **Biochem J** 1996 May 15;316 (Pt 1):73–80
Accumulation of tetradifon in an algae (Nannochloris oculata) and the cladoceran, Daphnia magna. Ferrando MD, et al. **Bull Environ Contam Toxicol** 1996 Jul; 57(1):139–45
Effects of algae frozen at different temperatures on chronic assessment endpoints observed with Daphnia magna. Cotelle S, et al. **Ecotoxicol Environ Saf** 1996 Mar; 33(2):137–42
Microalgae and wastewater treatment. Hammouda O, et al. **Ecotoxicol Environ Saf** 1995 Aug;31(3):205–10
Binding studies on the combining site of a GalNAc alpha 1-->-specific lectin with Thomsen-Friedenreich activity prepared from green marine algae Codium fragile subspecies tomentosoides. Wu AM, et al. **Eur J Biochem** 1995 Oct 1;233(1):145–51
Free calcium in Micrasterias: local gradients are not detected in growing lobes. Holzinger A, et al. **Eur J Cell Biol** 1995 Aug;67(4):363–71
Patch clamp study of the voltage-dependent anion channel in the thylakoid membrane. Pottosin II, et al. **J Membr Biol** 1995 Nov;148(2):143–56
Light intensity regulation of cab gene transcription is signaled by the redox state of the plastoquinone pool. Escoubas JM, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24; 92(22):10237–41

PHYSIOLOGY

Lack of an endogenous circadian rhythm in oxygen evolution by an ancient alga (Acicularia schenckii, Acetabulariaceae). Berger S, et al. **Eur J Cell Biol** 1995 Nov;68(3):339–44
The fastest actin-based motor protein from the green algae, Chara, and its distinct mode of interaction with actin. Higashi-Fujime S, et al. **FEBS Lett** 1995 Nov 13; 375(1–2):151–4
Changes in ultrastructure of cytoplasm and nucleus during spermiogenesis in Chara vulgaris. Kwiatkowska M. **Folia Histochem Cytobiol** 1996;34(1):41–56
Effect of symplasmic isolation and antigibberellin treatment on morphogenesis in Chara. Kwiatkowska M. **Folia Histochem Cytobiol** 1995;33(2):133–7
Small G proteins of two green algae are localized to exocytic compartments and to flagella. Huber H, et al. **Plant Mol Biol** 1996 May;31(2):279–93

ULTRASTRUCTURE

Lipids and membrane function in green algae. Thompson GA Jr. **Biochim Biophys Acta** 1996 Jul 12;1302(1):17–45 (183 ref.)
Changes in ultrastructure of cytoplasm and nucleus during spermiogenesis in Chara vulgaris. Kwiatkowska M. **Folia Histochem Cytobiol** 1996;34(1):41–56
Preparation and reactivation of Spermatozopsis cytoskeletons. Lechtreck KF, et al. **Methods Cell Biol** 1995; 47:335–40

VIROLOGY

Large deletions in antigenic variants of the chlorella virus PBCV-1. Landstein D, et al. **Virology** 1995 Dec 20; 214(2):413–20
Large deletions in the genome of Chlorella virus CVK1. Songsri P, et al. **Virology** 1995 Dec 20;214(2):405–12

ALGAE, RED

From the Centers for Disease Control and Prevention. Outbreak of gastrointestinal illness associated with consumption of seaweed--Hawaii, 1994. **JAMA** 1995 Dec 13;274(22):1753–4
Outbreak of gastrointestinal illness associated with consumption of seaweed--Hawaii, 1994. **MMWR Morb Mortal Wkly Rep** 1995 Oct 6;44(39):724–7

CHEMISTRY

Isolation and characterization of a Photosystem II complex from the red alga Cyanidium caldarium: association of cytochrome c-550 and a 12 kDa protein with the complex. Enami I, et al. **Biochim Biophys Acta** 1995 Dec 12; 1232(3):208–16
Identification of antimutagenic substances in an extract of edible red alga, Porphyra tenera (asakusa-nori). Okai Y, et al. **Cancer Lett** 1996 Feb 27;100(1–2):235–40
Studies on the post-coital contraceptive mechanisms of crude extract of Sri Lankan marine red algae, Gelidiella acerosa. Premakumara GA, et al. **Contraception** 1995 Sep; 52(3):203–7
The discovery of a novel R-phycoerythrin from an antarctic red alga. MacColl R, et al. **J Biol Chem** 1996 Jul 19; 271(29):17157–60
Majapolene A, a cytotoxic peroxide, and related sesquiterpenes from the red alga Laurencia majuscula. Erickson KL, et al. **J Nat Prod** 1995 Dec;58(12):1848–60

ENZYMOLOGY

Purification and characterization of a galactose-1-phosphate: UDP-glucose uridyltransferase from the red alga Galdieria sulphuraria. Gross W, et al. **Eur J Biochem** 1995 Nov 15; 234(1):258–63

GENETICS

Structural features and phylogeny of the actin gene of Chondrus crispus (Gigartinales, Rhodophyta). Bouget FY, et al. **Curr Genet** 1995 Jul;28(2):164–72
Isolation, characterization and chromosomal mapping of an actin gene from the primitive red alga Cyanidioschyzon merolae. Takahashi H, et al. **Curr Genet** 1995 Oct; 28(5):484–90
Cloning and characterization of the nuclear gene and cDNAs for triosephosphate isomerase of the marine red alga Gracilaria verrucosa. Zhou YH, et al. **Curr Genet** 1995 Sep;28(4):317–23
The nuclear gene and cDNAs encoding cytosolic glyceraldehyde-3-phosphate dehydrogenase from the marine red alga Gracilaria verrucosa: cloning, characterization and phylogenetic analysis. Zhou YH, et al. **Curr Genet** 1995 Sep;28(4):324–32
Elongation factor 1 alpha genes of the red alga Porphyra purpurea include a novel, developmentally specialized variant. Liu QY, et al. **Plant Mol Biol** 1996 Apr;31(1):77–85
Genes encoding the same three subunits of respiratory complex II are present in the mitochondrial DNA of two phylogenetically distant eukaryotes. Burger G, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2328–32
Molecular characterization of a positively photoregulated nuclear gene for a chloroplast RNA polymerase sigma factor in Cyanidium caldarium. Liu B, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3313–8
Nuclear encoding of a chloroplast RNA polymerase sigma subunit in a red alga. Tanaka K, et al. **Science** 1996 Jun 28;272(5270):1932–5

METABOLISM

State transitions or delta pH-dependent quenching of photosystem II fluorescence in red algae. Delphin E, et al. **Biochemistry** 1996 Jul 23;35(29):9435–45

ALGAL VIRUSES see PHYCODNAVIRIDAE

ALGINATES

Culture of chondrocytes in alginate and collagen carrier gels. van Susante JL, et al. **Acta Orthop Scand** 1995 Dec; 66(6):549–56
Glycol methacrylate embedding of alginate-polylysine microencapsulated pancreatic islets. Fritschy WM, et al. **Biotech Histochem** 1995 Jul;70(4):188–93
Four alginate dressings in the treatment of partial thickness wounds: a comparative experimental study. Agren MS. **Br J Plast Surg** 1996 Mar;49(2):129–34
De novo cartilage generation using calcium alginate-chondrocyte constructs. Paige KT, et al. **Plast Reconstr Surg** 1996 Jan;97(1):168–78; discussion 179–80
Membrane compactness affects the integrity and immunoprotection of alginate-poly-L-lysine-alginate microcapsules. Hsu BR, et al. **Transplant Proc** 1995 Dec; 27(6):3227–31
[Immobilization in alginate gels] Jankovský M, et al. **Vet Med (Praha)** 1996 May;41(5):159–64 (60 ref.) (Eng. Abstr.) **(Cze)**

CHEMISTRY

Electron-transfer function of NAD+-immobilized alginic acid. Nakamura Y, et al. **Biochim Biophys Acta** 1996 Mar 15;1289(2):221–5
Encapsulation of urease enzyme in xanthan-alginate spheres. Elçin YM. **Biomaterials** 1995 Oct;16(15):1157–61
Non-decay type fast-setting calcium phosphate cement: composite with sodium alginate. Ishikawa K, et al. **Biomaterials** 1995 May;16(7):527–32
Surface modifications of alginate/poly(L-lysine) microcapsular membranes with poly(ethylene glycol) and poly(vinyl alcohol). Kung IM, et al. **Biomaterials** 1995 May; 16(8):649–55
Alginate polycation microcapsules. II. Some functional properties. Thu B, et al. **Biomaterials** 1996 Jun; 17(11):1069–79
Alginate polycation microcapsules. I. Interaction between alginate and polycation. Thu B, et al. **Biomaterials** 1996 May;17(10):1031–40
Kojic acid production from cocoa juice by Aspergillus flavus entrapped in calcium alginate. el-Sharkawy SH. **Boll Chim Farm** 1995 Jun;134(6):316–9
Rheological studies of the interaction of mucins with alginate and polyacrylate. Fuongfuchat A, et al. **Carbohydr Res** 1996 Apr 18;284(1):85–99
A comparison of three methods for preparing reversible hydrocolloid duplicating material. Wilhelm MW, et al. **J Prosthet Dent** 1995 Dec;74(6):557–62
A family of modular type mannuronan C-5-epimerase genes controls alginate structure in Azotobacter vinelandii. Ertesvåg H, et al. **Mol Microbiol** 1995 May;16(4):719–31
Addition of a bacterial alginate lyase to purulent CF sputum in vitro can result in the disruption of alginate and modification of sputum viscoelasticity. Mrsny RJ, et al. **Pulm Pharmacol** 1994 Dec;7(6):357–66

METABOLISM

Exopolysaccharide alginate synthesis in Pseudomonas aeruginosa: enzymology and regulation of gene expression. Shankar S, et al. **Adv Enzymol Relat Areas Mol Biol** 1995; 70:221–55 (84 ref.)
Alginate, the slime exopolysaccharide of Pseudomonas aeruginosa, binds human leukocyte elastase, retards inhibition by alpha 1-proteinase inhibitor, and accelerates inhibition by secretory leukoprotease inhibitor. Ying QL, et al. **Am J Respir Cell Mol Biol** 1996 Aug;15(2):283–91
High-alkaline protease from Bacillus PB92 entrapped in calcium alginate gel. Physicochemical and microscopic studies. Roig MG, et al. **Appl Biochem Biotechnol** 1995 Nov;55(2):95–121
Carbohydrate fluxes into alginate biosynthesis in Azotobacter vinelandii NCIB 8789: NMR investigations of the triose pools. Beale JM Jr, et al. **Biochemistry** 1996 Apr 9; 35(14):4492–501
The use of chitosan to increase the stability of calcium alginate beads with entrapped yeast cells. Li X. **Biotechnol Appl Biochem** 1996 Jun;23 (Pt 3):269–72
Evaluation of new small barium alginate microcapsules. Cappai A, et al. **Int J Artif Organs** 1995 Feb;18(2):96–102
Effect on Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum on to pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampicin. Dupont MJ, et al. **J Antimicrob Chemother** 1995 Jul;36(1):231–6
Ofloxacin, norfloxacin and ceftazidime increase the production of alginate and promote the formation of biofilm of Pseudomonas aeruginosa in vitro [letter] Takahashi A, et al. **J Antimicrob Chemother** 1995 Oct;36(4):743–5
Use of ultrasound to facilitate antibiotic diffusion through Pseudomonas aeruginosa alginate. Williams KA, et al. **J Antimicrob Chemother** 1995 Sep;36(3):463–73
Identification of algI and algJ in the Pseudomonas aeruginosa alginate biosynthetic gene cluster which are required for alginate O acetylation. Franklin MJ, et al. **J Bacteriol** 1996 Apr;178(8):2186–95
Characterization of the genes coding for the putative sigma factor AlgU and its regulators MucA, MucB, MucC, and MucD in Azotobacter vinelandii and evaluation of their roles in alginate biosynthesis. Martínez-Salazar JM, et al. **J Bacteriol** 1996 Apr;178(7):1800–8
Alginate synthesis in Pseudomonas aeruginosa: the role of AlgL (alginate lyase) and AlgX. Monday SR, et al. **J Bacteriol** 1996 Feb;178(3):625–32
Poor fermentability of "mekabu" (sporophyll of Undaria pinnatifida) alginic acid in batch culture using pig cecal bacteria. Togari N, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Apr;41(2):179–85
The Escherichia coli genes sspA and rnk can functionally replace the Pseudomonas aeruginosa alginate regulatory gene algR2. Schlictman D, et al. **Mol Microbiol** 1995 Apr; 16(2):309–20
[Alginates of Pseudomonas aeruginosa: a complex regulation of the pathway of biosynthesis] Schmitt-Andrieu L, et al. **C R Acad Sci III** 1996 Mar;319(3):153–60 (62 ref.) (Eng. Abstr.) **(Fre)**
[Mucoid clones of Pseudomonas aeruginosa PAO1, surviving after induction of prophage transposons] Krylov VN, et al. **Genetika** 1995 Oct;31(10):1375–9 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

TNF production from peripheral blood mononuclear cells in diabetic patients after stimulation with alginate and lipopolysaccharide. Kulseng B, et al. **Scand J Immunol** 1996 Mar;43(3):335–40
[The effect of algisorb on the level of the accumulation of zirconium, ruthenium, iodine and cesium radioactive isotopes in the body of rats] Ivannikov AT, et al. **Radiats Biol Radioecol** 1996 May-Jun;36(3):427–33 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

[Radiation-induced changes of alginic acid and sodium alginate] Revina AA, et al. **Radiats Biol Radioecol** 1996 May-Jun;36(3):380–6 **(Rus)**

ALGINATES

THERAPEUTIC USE

Effect of alginate and alginate-cimetidine combination therapy on stimulated postprandial gastro-oesophageal reflux. Washington N, et al. **J Pharm Pharmacol** 1995 Nov; 47(11):879–82

ALGODYSTROPHIC SYNDROME see REFLEX SYMPATHETIC DYSTROPHY

ALGOR MORTIS see POSTMORTEM CHANGES

ALGORITHMS

Examining the NRMP algorithm. National Resident Matching Program [letter; comment] Colenbrander A. **Acad Med** 1996 Apr;71(4):309–12. Comment on: Acad Med 1995 Jun;70(6):470–6; discussion 490–4. Comment on: Acad Med 1995 Jun;70(6):477–84; discussion 485–9.

Oxygen availability in critical illness--an investigation using the oxygen status algorithm. Morgan J, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:185–7

Oxygen status algorithm, version 3, with some applications. Siggaard-Andersen M, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:13–20

Apnoea detection: human performance and reliability of a computer algorithm. Macey PM, et al. **Acta Paediatr** 1995 Oct;84(10):1103–7

Prediction of HIV peptide epitopes by a novel algorithm. Roberts CG, et al. **AIDS Res Hum Retroviruses** 1996 May 1;12(7):593–610

Three-dimensional CT: real-time interactive volume rendering. Johnson PT, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):581–3

Image-guided percutaneous biopsy of musculoskeletal tumors: an algorithm for selection of specific biopsy techniques [see comments] Logan PM, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):137–41. Comment in: AJR Am J Roentgenol 1996 Aug;167(2):532–3.

An imaging algorithm for the differential diagnosis of adrenal adenomas and metastases. McNicholas MM, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1453–9

Compression sonography in patients with indeterminate or low-probability lung scans: lack of usefulness in the absence of both symptoms of deep-vein thrombosis and thromboembolic risk factors. Rosen MP, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):285–9

An approach to diagnostic imaging of suspected pulmonary embolism. Bergus GR, et al. **Am Fam Physician** 1996 Mar; 53(4):1259–66

Utility of the 12-lead electrocardiogram in localizing the origin of right ventricular outflow tract tachycardia. Jadonath RL, et al. **Am Heart J** 1995 Nov;130(5):1107–13

Assessment of heart rate variability by using different commercially available systems. Jung J, et al. **Am J Cardiol** 1996 Jul 1;78(1):118–20

Automatic backscatter analysis of regional left ventricular systolic function using color kinesis. Schwartz SL, et al. **Am J Cardiol** 1996 Jun 15;77(15):1345–50

An algorithmic approach to thyroid function testing in a managed care setting. 3-year experience. Feldkamp CS, et al. **Am J Clin Pathol** 1996 Jan;105(1):11–6

Exponentially adjusted moving mean procedure for quality control. An optimized patient sample control procedure. Smith FA, et al. **Am J Clin Pathol** 1996 Jan;105(1):44–51

Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting. Berard CM, et al. **Am J Health Syst Pharm** 1995 Sep 1;52(17):1879–85

Algorithms for estimating personal exposures to chemical agents in the Semiconductor Health Study. Woskie SR, et al. **Am J Ind Med** 1995 Dec;28(6):699–711

Tuberculosis control in health care workers: an algorithmic approach [see comments] Grimes RM, et al. **Am J Infect Control** 1996 Apr;24(2):70–8; discussion 79–82 . Comment in: Am J Infect Control 1996 Apr;24(2):79–82.

Assessment of radial aspheres by the Arc-step algorithm as implemented by the Keratron keratoscope. Tripoli NK, et al. **Am J Ophthalmol** 1995 Nov;120(5):658–64

Determination of the position of nucleus cochlear implant electrodes in the inner ear. Skinner MW, et al. **Am J Otol** 1994 Sep;15(5):644–51

Mortality prediction algorithm and intensive care [letter; comment] Read MS, et al. **Anaesthesia** 1995 Sep;50(9):823–4 . Comment on: Anaesthesia 1995 Feb;50(2):103–7.

Determination of optimally resolving gel concentration and migration time (path) in gel electrophoresis. Aldroubi A, et al. **Anal Biochem** 1995 Nov 1;231(2):432–6

Deconvolution of gel filtration chromatographs of human plasma lipoproteins. Barbee KA, et al. **Anal Biochem** 1995 Nov 1;231(2):301–8

Analysis of EEG transients by means of matching pursuit. Durka PJ, et al. **Ann Biomed Eng** 1995 Sep-Oct; 23(5):608–11

Two applications of wavelets and related techniques in medical imaging. Healy DM Jr, et al. **Ann Biomed Eng** 1995 Sep-Oct;23(5):637–65

Multiscale analysis for singularity detection in pulmonary microvascular pressure transients. Karrakchou M, et al. **Ann Biomed Eng** 1995 Sep-Oct;23(5):562–73

Optimal time-frequency projections for localized tomography. Olson T. **Ann Biomed Eng** 1995 Sep-Oct; 23(5):622–36

Failure to agree on the electrocardiographic diagnosis of ventricular tachycardia. Herbert ME, et al. **Ann Emerg Med** 1996 Jan;27(1):35–8

A novel tree-structured analysis for non-invasive diagnosis of gastric adenocarcinoma. Wu MS, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2739–43

An algorithm for complete enumeration of the mechanisms of supraventricular tachycardias that use multiple atrioventricular, AV nodal, and/or Mahaim pathways. Widman LE, et al. **Artif Intell Med** 1995 Aug;7(4):361–86

Evolution of biological regulation networks under complex environmental constraints. Chiva E, et al. **Biol Cybern** 1995 Sep;73(4):323–33

Informational properties of neural nets performing algorithmic and logical tasks. Ritz BM, et al. **Biol Cybern** 1996 Jun;74(6):549–55

Discriminant analysis algorithm based on a distance function and on a Bayesian decision. Villarroya A, et al. **Biometrics** 1995 Sep;51(3):908–19

Genetic-algorithm selection of a regulatory structure that directs flux in a simple metabolic model. Gilman A, et al. **Biophys J** 1995 Oct;69(4):1321–33

Monte Carlo modeling of small-angle scattering data from non-interacting homogeneous and heterogeneous particles in solution. Henderson SJ. **Biophys J** 1996 Apr; 70(4):1618–27

A cellular automaton model for the proliferation of migrating contact-inhibited cells. Lee Y, et al. **Biophys J** 1995 Oct; 69(4):1284–98

A genetic algorithm that seeks native states of peptides and proteins. Sun S. **Biophys J** 1995 Aug;69(2):340–55

A new algorithm for idealizing single ion channel data containing multiple unknown conductance levels. VanDongen AM. **Biophys J** 1996 Mar;70(3):1303–15

RNA loop structure prediction via bond scaling and relaxation. Frederic T, et al. **Biopolymers** 1996 Jun; 38(6):769–79

Exploration of compact protein conformations using the guided replication Monte Carlo method. Solomon JE, et al. **Biopolymers** 1995 Nov;36(5):579–97

The evolution of understanding: a genetic algorithm model of the evolution of communication. Levin M. **Biosystems** 1995;36(3):167–78

A comparison of methods for self-adaptation in evolutionary algorithms. Saravanan N, et al. **Biosystems** 1995; 36(2):157–66

A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. Brennan P, et al. **BMJ** 1996 Aug 24;313(7055):471–6

Algorithm to detect left ventricular dysfunction after myocardial infarction. Low specificity of algorithm would lead to extensive overtreatment [letter; comment] Darbar D, et al. **BMJ** 1996 Mar 2;312(7030):579–80. Comment on: BMJ 1994 Nov 19;309(6965):1343–50.

Prospective evaluation of pharmacokinetic model-controlled infusion of propofol in adult patients. Short TG, et al. **Br J Anaesth** 1996 Feb;76(2):313–5

Investigation and staging of lung cancer. Plant P, et al. **Br J Hosp Med** 1996 May 15-Jun 4;55(10):627–30

The optimization and inherent limitations of 3D conformal radiotherapy treatment plans of the prostate. Oldham M, et al. **Br J Radiol** 1995 Aug;68(812):882–93

Characterizing the local oscillatory content of spontaneous cortical activity during mental imagery. Tesche CD, et al. **Brain Res Cogn Brain Res** 1995 Oct;2(4):243–9

Algorithms for verbal autopsies: a validation study in Kenyan children. Quigley MA, et al. **Bull World Health Organ** 1996; 74(2):147–54

Ottawa ankle rules. Stiell I. **Can Fam Physician** 1996 Mar; 42:478–80

Variability of molecular biomarker measurements from nonlinear calibration curves. Gang SJ, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jan;5(1):57–61

Two-dimensional echocardiographic evaluation of left ventricular ejection fraction by the ellipsoid single-plane algorithm: a reliable method for assessing low or very low ejection fraction values? Corrao S, et al. **Cardiology** 1995; 86(6):503–7

In vivo validation of an experimental adaptive quantitative coronary angiography algorithm to circumvent overestimation of small luminal diameters. Keane D, et al. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):17–24; discussion 25–6

Clinical evaluation of algorithms for ST measurement during exercise test. Petrucci E, et al. **Clin Cardiol** 1996 Mar; 19(3):248–52

Validation of an algorithm for oral anticoagulant dosing and appointment scheduling. Vadher BD, et al. **Clin Lab Haematol** 1995 Dec;17(4):339–45

Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Lanctôt KL, et al. **Clin Pharmacol Ther** 1995 Dec;58(6):692–8

A rapid access motif database (RAMdb) with a search algorithm for the retrieval patterns in nucleic acids or protein databanks. Fondrat C, et al. **Comput Appl Biosci** 1995 Jun;11(3):273–9

A weighting system and algorithm for aligning many phylogenetically related sequences. Gotoh O. **Comput Appl Biosci** 1995 Oct;11(5):543–51

Alignments of DNA and protein sequences containing frameshift errors. Guan X, et al. **Comput Appl Biosci** 1996 Feb;12(1):31–40

Positional sequencing by hybridization. Hannenhalli S, et al. **Comput Appl Biosci** 1996 Feb;12(1):19–24

An algorithm for analysing probed partial digestion experiments. Karp RM, et al. **Comput Appl Biosci** 1995 Jun;11(3):229–35

A new algorithm for predicting splice site sequence based on an improvement of categorical discriminant analysis. Sirajuddin K, et al. **Comput Appl Biosci** 1995 Aug; 11(4):349–59

LGANN: a parallel system combining a local genetic algorithm and neural networks for the prediction of secondary structure of proteins. Vivarelli F, et al. **Comput Appl Biosci** 1995 Jun;11(3):253–60

Identification of functional elements in unaligned nucleic acid sequences by a novel tuple search algorithm. Wolfertstetter F, et al. **Comput Appl Biosci** 1996 Feb;12(1):71–80

New algorithmic-based digital filter processing system for real-time continuous blood pressure measurement and analysis in conscious rats. Nagai R, et al. **Comput Biol Med** 1995 Nov;25(6):483–94

Ray casting and the enclosing-net algorithm for extracting shapes from volume data. Semwal SK, et al. **Comput Biol Med** 1995 Mar;25(2):261–76

Automated grading of venous beading. Gregson PH, et al. **Comput Biomed Res** 1995 Aug;28(4):291–304

A computer algorithm to impute interrupted heart rate data for the spectral analysis of heart rate variability--the ARIC study. Liao D, et al. **Comput Biomed Res** 1996 Apr; 29(2):140–51

Detection of motion during tomographic acquisition by an optical flow algorithm. Noumeir R, et al. **Comput Biomed Res** 1996 Feb;29(1):1–15

Fuzzy sets for feature identification in biomedical signals with self-assessment of reliability: an adaptable algorithm modeling human procedure in BAEP analysis. Piater J, et al. **Comput Biomed Res** 1995 Oct;28(5):335–53

Classification of arrhythmic events in ambulatory electrocardiogram, using artificial neural networks. Silipo R, et al. **Comput Biomed Res** 1995 Aug;28(4):305–18

Parallel processing of chemical information in a local area network--III. Using genetic algorithms for conformational analysis of biomacromolecules. Beckers ML, et al. **Comput Chem** 1996 Aug;20(4):449–57

Algorithms for finding the axis of a helix: fast rotational and parametric least-squares methods. Christopher JA, et al. **Comput Chem** 1996 Sep;20(3):339–45

Calculation of patient's complexity: paramedical and nursing facets. Delacrétaz AC, et al. **Comput Methods Programs Biomed** 1995 Sep-Oct; 48(1-2):97–102

User-requirements driven learning. Karthaus V, et al. **Comput Methods Programs Biomed** 1995 Sep-Oct; 48(1-2):39–44

Hinge estimators of location: robust to asymmetry. Reed JF 3rd, et al. **Comput Methods Programs Biomed** 1996 Jan; 49(1):11–7

Automated laboratory protocols. Winkel P, et al. **Comput Methods Programs Biomed** 1996 Jan;49(1):69–83

An inductive algorithm approach to knowledge acquisition for expert system development. A pilot study. Henry SB. **Comput Nurs** 1995 Sep-Oct;13(5):226–32

Homeostatic control of plasma calcium concentration. Hurwitz S. **Crit Rev Biochem Mol Biol** 1996 Feb; 31(1):41–100 (500 ref.)

Current computational tools for de novo ligand design. Böhm HJ. **Curr Opin Biotechnol** 1996 Aug;7(4):433–6 (61 ref.)

Genetic algorithms for protein structure prediction. Pedersen JT, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):227–31 (40 ref.)

A force feedback joystick and control algorithm for wheelchair obstacle avoidance. Brienza DM, et al. **Disabil Rehabil** 1996 Mar;18(3):123–9

Neuromagnetic source imaging with FOCUSS: a recursive weighted minimum norm algorithm. Gorodnitsky IF, et al. **Electroencephalogr Clin Neurophysiol** 1995 Oct; 95(4):231–51

Amino acid compositions of proteins and their identities. Galat A, et al. **Electrophoresis** 1995 Jul;16(7):1095–103

Exact estimates for a rate ratio. Martin DO, et al. **Epidemiology** 1996 Jan;7(1):29–33

Validation of automated brain contour determination in normal and abnormal cerebral single-photon emission tomography. van Elmbt LR, et al. **Eur J Nucl Med** 1995 Jun;22(6):537–42

On the generation of short-axis and radial long-axis slices in thallium-201 myocardial perfusion single-photon emission tomography. van Hastenberg RP, et al. **Eur J Nucl Med** 1996 Aug;23(8):924–31

Programming the duration of a motor sequence: role of the primary and supplementary motor areas in man. Vidal F, et al. **Exp Brain Res** 1995;106(2):339–50

Motor performance score: a new algorithm for accurate behavioral testing of spinal cord injury in rats. von Euler M, et al. **Exp Neurol** 1996 Feb;137(2):242–54

Evaluating a new algorithm for linking maternal and newborn medical records. Grace KR, et al. **Genet Epidemiol** 1995;12(4):361–9

A chromosome-based method to infer IBD scores for missing and ambiguous markers. Gu C, et al. **Genet Epidemiol** 1995; 12(6):871–6

Maximum-likelihood estimation in linkage heterogeneity models including additional information via the EM

algorithm. Houwing-Duistermaat JJ, et al. **Genet Epidemiol** 1995;12(5):515-27

Identification and mapping of Mendelian subtypes of disease. Vieland VJ, et al. **Genet Epidemiol** 1995;12(6):819-24

Clinical algorithms for the screening of Chlamydia trachomatis in Turkish women. Ronsmans C, et al. **Genitourin Med** 1996 Jun;72(3):182-6

Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm. Slatkin M, et al. **Heredity** 1996 Apr;76 (Pt 4):377-83

Caring for the terminally Ill. Bascom PB, et al. **Hosp Pract (Off Ed)** 1996 May 15;31(5):75-8, 82-4, 89; discussion 89-90

Management after a first myocardial infarction. Flapan AD. **Hosp Pract (Off Ed)** 1996 May 15;31(5):133-7, 141-6 (11 ref.)

An incremental algorithm for efficient multipoint linkage analysis. Kramer RW, et al. **Hum Hered** 1995 Nov-Dec; 45(6):323-36

Three-dimensional anatomical model-based segmentation of MR brain images through Principal Axes Registration. Arata LK, et al. **IEEE Trans Biomed Eng** 1995 Nov; 42(11):1069-78

Iterative Principal Axes Registration method for analysis of MR-PET brain images. Dhawan AP, et al. **IEEE Trans Biomed Eng** 1995 Nov;42(11):1079-87

Experimental investigation of an adaptive feedback algorithm for hot spot reduction in radio-frequency phased-array hyperthermia. Fenn AJ, et al. **IEEE Trans Biomed Eng** 1996 Mar;43(3):273-80

Improved method for computation of potentials in a realistic head shape model. Fletcher DJ, et al. **IEEE Trans Biomed Eng** 1995 Nov;42(11):1094-104

Direct speech feature estimation using an iterative EM algorithm for vocal fold pathology detection. Gavidia-Ceballos L, et al. **IEEE Trans Biomed Eng** 1996 Apr;43(4):373-83

Self-organizing map in recognition of topographic patterns of EEG spectra. Joutsiniemi SL, et al. **IEEE Trans Biomed Eng** 1995 Nov;42(11):1062-8

Adaptive estimation of latency changes in evoked potentials. Kong X, et al. **IEEE Trans Biomed Eng** 1996 Feb; 43(2):189-97

Genetic design of optimum linear and nonlinear QRS detectors. Poli R, et al. **IEEE Trans Biomed Eng** 1995 Nov; 42(11):1137-41

A pedigree-based algorithm for finding efficient peeling sequences. Harbron C. **IMA J Math Appl Med Biol** 1995; 12(1):13-27

Algorithms for early management of pelvic fractures. Nerlich M, et al. **Injury** 1996;27 Suppl 1:S-A29-37

A new automatic cardiac output control algorithm for moving actuator total artificial heart by motor current waveform analysis. Choi WW, et al. **Int J Artif Organs** 1996 Mar;19(3):189-96

A polygon matching algorithm and its applications to verification of radiation field placement in radiotherapy. Leszczynski K, et al. **Int J Biomed Comput** 1995 Sep; 40(1):59-67

Mathematical representation of organ growth in the human embryo/fetus. Luecke RH, et al. **Int J Biomed Comput** 1995 Jun;39(3):337-47

An expectation maximization reconstruction algorithm for emission tomography with non-uniform entropy prior. Noumeir R, et al. **Int J Biomed Comput** 1995 Jun; 39(3):299-310

Comparison of different neural network algorithms in the diagnosis of acute appendicitis. Pesonen E, et al. **Int J Biomed Comput** 1996 Jan;40(3):227-33

Object-free adaptive meshing in highly heterogeneous 3-D domains. Schimpf PH, et al. **Int J Biomed Comput** 1996 Jan;40(3):209-25

Automated determination of left ventricular volume curves from bi-plane digital angiography without explicit use of edge detection algorithms. Raff U, et al. **Int J Card Imaging** 1996 Mar;12(1):31-45

Using the Potts glass for solving the clustering problem. Bengtsson M, et al. **Int J Neural Syst** 1995 Jun;6(2):119-32

Ensemble competitive learning neural networks with reduced input dimension. Kim J, et al. **Int J Neural Syst** 1995 Jun; 6(2):133-42

Training neural networks by means of genetic algorithms working on very long chromosomes. Korning PG. **Int J Neural Syst** 1995 Sep;6(3):299-316

Learning in recurrent finite difference networks. Tsung FS, et al. **Int J Neural Syst** 1995 Sep;6(3):249-56

The evaluation of screening methods to identify medically unnecessary hospital stay for patients with pneumonia. Hartz AJ, et al. **Int J Qual Health Care** 1996 Feb;8(1):3-11

Quantitative vs. subjective portal verification using digital portal images. Bissett R, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):489-95

Shape recovery and volume calculation from biplane angiography in the stereotactic radiosurgical treatment of arteriovenous malformations. Foroni R, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):565-77

Computer-aided design and fabrication of an electron bolus for treatment of the paraspinal muscles. Low DA, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1127-38

Evaluation of a pencil-beam dose calculation technique for charged particle radiotherapy. Petti PL. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):1049-57

Comparison of simulated annealing algorithms for conformal therapy treatment planning. Rosen II, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1091-9

Probabilistic structure calculations: a three-dimensional tRNA structure from sequence correlation data. Altman RB. **Ismb** 1993;1:12-20

The value of prior knowledge in discovering motifs with MEME. Bailey TL, et al. **Ismb** 1995;3:21-9

FLASH: a fast look-up algorithm for string homology. Califano A, et al. **Ismb** 1993;1:56-64

Protein structure prediction: selecting salient features from large candidate pools. Cherkauer KJ, et al. **Ismb** 1993; 1:74-82

A divide and conquer approach to multiple alignment. Dress A, et al. **Ismb** 1995;3:107-13

Parallel sequence alignment in limited space. Grice JA, et al. **Ismb** 1995;3:145-53

Evaluating regularizers for estimating distributions of amino acids. Karplus K. **Ismb** 1995;3:188-96

An optimized parsing algorithm well suited to RNA folding. Lefebvre F. **Ismb** 1995;3:222-30

A small automaton for word recognition in DNA sequences and its application to consensus analysis of regulatory elements in DNA regions controlling gene expression. Lefèvre C, et al. **Ismb** 1993;1:243-50

Identification of localized and distributed bottlenecks in metabolic pathways. Mavrovouniotis ML. **Ismb** 1993; 1:275-83

Discovering sequence similarity by the algorithmic significance method. Milosavljević A. **Ismb** 1993;1:284-91

Genetic algorithms for DNA sequence assembly. Parsons R, et al. **Ismb** 1993;1:310-8

DNA sequence assembly and genetic algorithms new results and puzzling insights. Parsons R, et al. **Ismb** 1995;3:277-84

A new approach to primer selection in polymerase chain reaction experiments. Pearson WR, et al. **Ismb** 1995; 3:285-91

Time-efficient docking of flexible ligands into active sites of proteins. Rarey M, et al. **Ismb** 1995;3:300-8

A distance-based block searching algorithm. Sagot MF, et al. **Ismb** 1995;3:322-31

Using temporal reasoning for genome map assembly. Schmeltzer O. **Ismb** 1995;3:332-40

Automata-theoretic models of mutation and alignment. Searls DB, et al. **Ismb** 1995;3:341-9

BONSAI Garden: parallel knowledge discovery system for amino acid sequences. Shoudai T, et al. **Ismb** 1995;3:359-66

A partial digest approach to restriction site mapping. Skiena SS, et al. **Ismb** 1993;1:362-70

Identification of human gene structure using linear discriminant functions and dynamic programming. Solovyev VV, et al. **Ismb** 1995;3:367-75

Computationally efficient cluster representation in molecular sequence megaclassification. States DJ, et al. **Ismb** 1993; 1:387-94

Towards an intelligent system for the automatic assignment of domains in globular proteins. Sternberg MJ, et al. **Ismb** 1995;3:376-83

Neweyes: a system for comparing biological sequences using the running Karp-Rabin Greedy String-Tiling algorithm. Wise MJ. **Ismb** 1995;3:393-401

Identification of protein motifs using conserved amino acid properties and partitioning techniques. Wu TD, et al. **Ismb** 1995;3:402-10

New method for accurate calculation of regurgitant flow rate based on analysis of Doppler color flow maps of the proximal flow field. Validation in a canine model of mitral regurgitation with initial application in patients. Schwammenthal E, et al. **J Am Coll Cardiol** 1996 Jan; 27(1):161-72

On-line echocardiographic assessment of hemodynamic indexes by an adaptive Doppler analysis algorithm and signal/noise ratio calculation. Tardif JC, et al. **J Am Soc Echocardiogr** 1996 Jan-Feb;9(1):9-17

Optimisation of metric matrix embedding by genetic algorithms. van Kampen AH, et al. **J Biomol NMR** 1996 May;7(3):214-24

Toward an exhaustive sampling of the configurational spaces of the two forms of the peptide hormone guanylin. de Groot BL, et al. **J Biomol Struct Dyn** 1996 Apr; 13(5):741-51

A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. Mentré F, et al. **J Biopharm Stat** 1995 Jul;5(2):141-58

Algorithm for determining equivalent A-constants and surgeon factors. McEwan JR. **J Cataract Refract Surg** 1996 Jan-Feb;22(1):123-34

Statistical techniques for diagnosing CIN using fluorescence spectroscopy: SVD and CART. Atkinson EN, et al. **J Cell Biochem Suppl** 1995;23:125-30

Identification of common functional configurations among molecules. Barnum D, et al. **J Chem Inf Comput Sci** 1996 May-Jun;36(3):563-71

Stigmata: an algorithm to determine structural commonalities in diverse datasets. Shemetulskis NE, et al. **J Chem Inf Comput Sci** 1996 Jul-Aug;36(4):862-71

Intravenous drug delivery systems: toward an intravenous "vaporizer". Egan TD. **J Clin Anesth** 1996 May;8(3 Suppl):8S-14S (38 ref.)

A mathematical model that improves the validity of osteoarthritis diagnoses obtained from a computerized diagnostic database. Gabriel SE, et al. **J Clin Epidemiol** 1996 Sep;49(9):1025-9

Microbiological investigation of polyarthralgia. Jones JW, et al. **J Clin Pathol** 1995 Aug;48(8):777-9

The atom assignment problem in automated de novo drug design. 4. Tests for site-directed fragment placement based on molecular complementarity. Barakat MT, et al. **J Comput Aided Mol Des** 1995 Oct;9(5):448-56

The atom assignment problem in automated de novo drug design. 3. Algorithms for optimization of fragment placement onto 3D molecular graphs. Barakat MT, et al. **J Comput Aided Mol Des** 1995 Aug;9(4):359-72

A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. Jones G, et al. **J Comput Aided Mol Des** 1995 Dec;9(6):532-49

Placement of medium-sized molecular fragments into active sites of proteins. Rarey M, et al. **J Comput Aided Mol Des** 1996 Feb;10(1):41-54

Comparison of projection algorithms used for the construction of maximum intensity projection images. Schreiner S, et al. **J Comput Assist Tomogr** 1996 Jan-Feb; 20(1):56-67

Fast algorithms for inferring evolutionary trees. Agarwala R, et al. **J Comput Biol** 1995 Fall;2(3):397-407

Physical mapping of chromosomes using unique probes. Alizadeh F, et al. **J Comput Biol** 1995 Summer;2(2):159-84

Short superstrings and the structure of overlapping strings. Armen C, et al. **J Comput Biol** 1995 Summer;2(2):307-32

Algorithms for protein structural motif recognition. Berger B. **J Comput Biol** 1995 Spring;2(1):125-38

Fragment collapsing and splitting while assembling high-resolution restriction maps. Gillett W, et al. **J Comput Biol** 1995 Summer;2(2):185-205

Physical mapping by STS hybridization: algorithmic strategies and the challenge of software evaluation. Greenberg DS, et al. **J Comput Biol** 1995 Summer; 2(2):219-73

Fast protein folding in the hydrophobic-hydrophilic model within three-eighths of optimal. Hart WE, et al. **J Comput Biol** 1996 Spring;3(1):53-96

Biological evaluation of d2, an algorithm for high-performance sequence comparison. Hide W, et al. **J Comput Biol** 1994 Fall;1(3):199-215

A new algorithm for DNA sequence assembly. Idury RM, et al. **J Comput Biol** 1995 Summer;2(2):291-306

A note on scoring clones given a probe ordering. Jain M, et al. **J Comput Biol** 1995 Spring;2(1):33-7

Constructing aligned sequence blocks. Miller W, et al. **J Comput Biol** 1994 Spring;1(1):51-64

Approximate matching of network expressions with spacers. Myers EW. **J Comput Biol** 1996 Spring;3(1):33-51

Constructing lattice models of protein chains with side groups. Reva BA, et al. **J Comput Biol** 1995 Winter; 2(4):527-35

Reconstruction of a string from substring precedence data. Rubinov AR, et al. **J Comput Biol** 1995 Summer; 2(2):371-81

Locating protein coding regions in human DNA using a decision tree algorithm. Salzberg S. **J Comput Biol** 1995 Fall;2(3):473-85

Method for calculation of probability of matching a bounded regular expression in a random data string. Sewell RF, et al. **J Comput Biol** 1995 Spring;2(1):25-31

A subgraph problem from restriction maps of DNA. Wang C. **J Comput Biol** 1994 Fall;1(3):227-34

An exponential example for a partial digest mapping algorithm. Zhang Z. **J Comput Biol** 1994 Fall;1(3):235-9

Chaining multiple-alignment blocks. Zhang Z, et al. **J Comput Biol** 1994 Fall;1(3):217-26

Subjective quality assessment of computed radiography hand images. Britton CA, et al. **J Digit Imaging** 1996 Feb; 9(1):21-4

Lossless medical image compression by multilevel decomposition. Kang KS, et al. **J Digit Imaging** 1996 Feb; 9(1):11-20

HAPLO: a program using the EM algorithm to estimate the frequencies of multi-site haplotypes. Hawley ME, et al. **J Hered** 1995 Sep-Oct;86(5):409-11

Siggaard-Andersen algorithm-derived p50 parameters: perturbation by abnormal hemoglobin-oxygen affinity and acid-base disturbances. Morgan TJ, et al. **J Lab Clin Med** 1995 Oct;126(4):365-72

Evolutionary optimization in quantitative structure-activity relationship: an application of genetic neural networks. So SS, et al. **J Med Chem** 1996 Mar 29;39(7):1521-30

Automatic analysis of protein conformational changes by multiple linkage clustering. Boutonnet NS, et al. **J Mol Biol** 1995 Nov 3;253(4):633-47

Identifying the tertiary fold of small proteins with different topologies from sequence and secondary structure using the genetic algorithm and extended criteria specific for strand regions. Dandekar T, et al. **J Mol Biol** 1996 Mar 1;256(3):645-60

A surface of minimum area metric for the structural comparison of proteins. Falicov A, et al. **J Mol Biol** 1996 May 24;258(5):871-92

From structure to sequence and back again. Hinds DA, et al. **J Mol Biol** 1996 Apr 26;258(1):201-9

FASTA-SWAP and FASTA-PAT: pattern database searches using combinations of aligned amino acids, and a novel scoring theory. Ladunga I, et al. **J Mol Biol** 1996 Jun 21;259(4):840-54

ALGORITHMS

Global optimum protein threading with gapped alignment and empirical pair score functions. Lathrop RH, et al. **J Mol Biol** 1996 Feb 2;255(4):641–65

Thermodynamic prediction of conserved secondary structure: application to the RRE element of HIV, the tRNA-like element of CMV and the mRNA of prion protein. Lück R, et al. **J Mol Biol** 1996 May 24; 258(5):813–26

Complex salt bridges in proteins: statistical analysis of structure and function. Musafia B, et al. **J Mol Biol** 1995 Dec 8;254(4):761–70

A fast flexible docking method using an incremental construction algorithm. Rarey M, et al. **J Mol Biol** 1996 Aug 23;261(3):470–89

Description of RNA folding by "simulated annealing". Schmitz M, et al. **J Mol Biol** 1996 Jan 12;255(1):254–66

Statistical potentials extracted from protein structures: how accurate are they? Thomas PD, et al. **J Mol Biol** 1996 Mar 29;257(2):457–69

An algorithm for high-resolution detection of postsynaptic quantal events in extracellular records. Bykhovskaia M, et al. **J Neurosci Methods** 1996 Apr;65(2):173–82

A computer-controlled apparatus for measuring and analysing myoclonic jerk activity in guinea pigs. Lloyd PS, et al. **J Neurosci Methods** 1996 Feb;64(2):253–62

Multiple source localization using genetic algorithms. McNay D, et al. **J Neurosci Methods** 1996 Feb;64(2):163–72

Automated interstudy image registration technique for SPECT and PET. Eberl S, et al. **J Nucl Med** 1996 Jan; 37(1):137–45

Operator-less processing of myocardial perfusion SPECT studies. Germano G, et al. **J Nucl Med** 1995 Nov; 36(11):2127–32

Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. Germano G, et al. **J Nucl Med** 1995 Nov;36(11):2138–47

Three-dimensional demarcation of perfusion zones corresponding to specific coronary arteries: application for automated interpretation of myocardial SPECT. Slomka PJ, et al. **J Nucl Med** 1995 Nov;36(11):2120–6

Motion correction in exercise first-pass radionuclide ventriculography without an external point source. Yano S, et al. **J Nucl Med** 1995 Nov;36(11):1941–4

Intermodality, retrospective image registration in the thorax. Yu JN, et al. **J Nucl Med** 1995 Dec;36(12):2333–8

An approach to the diagnosis of chronic wrist pain. Hodgson SP, et al. **J R Coll Surg Edinb** 1995 Dec;40(6):407–10

The contour-buildup algorithm to calculate the analytical molecular surface. Totrov M, et al. **J Struct Biol** 1996 Jan–Feb;116(1):138–43

Emergent abdominal sonography as a screening test in a new diagnostic algorithm for blunt trauma. Boulanger BR, et al. **J Trauma** 1996 Jun;40(6):867–74

Algorithm for managing a baby with dusky soles. Daga SR, et al. **J Trop Pediatr** 1995 Aug;41(4):241–3

Evolving concepts in the diagnosis and treatment of arterial high flow priapism. Hakim LS, et al. **J Urol** 1996 Feb; 155(2):541–8

Prediction of outcome in critically ill patients using artificial neural network synthesised by genetic algorithm. Dybowski R, et al. **Lancet** 1996 Apr 27;347(9009):1146–50

Clinical algorithm for treatment of Plasmodium falciparum malaria in children [see comments] Redd SC, et al. **Lancet** 1996 Jan 27;347(8996):223–7. Comment in: Lancet 1996 May 11;347(9011):1327; discussion 1328–9. Comment in: Lancet 1996 May 11;347(9011):1327–8; discussion 1328–9. Comment in: Lancet 1996 May 11;347(9011):1328; discussion 1328–9.

Locally focused MRI. Cao Y, et al. **Magn Reson Med** 1995 Dec;34(6):858–67

Removal of lipid artifacts in 1H spectroscopic imaging by data extrapolation. Haupt CI, et al. **Magn Reson Med** 1996 May;35(5):678–87

An in vivo automated shimming method taking into account shim current constraints. Wen H, et al. **Magn Reson Med** 1995 Dec;34(6):898–904

Approach for the smoothing of three-dimensional reconstructions of the human spine using dual Kriging interpolation. André B, et al. **Med Biol Eng Comput** 1996 May;34(3):185–91

Multiple scattering effect in transmission pulse oximetry. Fine I, et al. **Med Biol Eng Comput** 1995 Sep;33(5):709–12

Construction and application of hierarchical decision tree for classification of ultrasonographic prostate images. Giesen RJ, et al. **Med Biol Eng Comput** 1996 Mar;34(2):105–9

Dynamic cross-spectral analysis of biological signals by means of bivariate ARMA processes with time-dependent coefficients. Schack B, et al. **Med Biol Eng Comput** 1995 Jul;33(4):605–10

Continuous trees and NEVADA simulation: a quadrature approach to modeling continuous random variables in decision analysis. Bryg DJ. **Med Decis Making** 1995 Oct–Dec;15(4):318–32

Using cluster analysis for medical resource decision making. Dilts D, et al. **Med Decis Making** 1995 Oct–Dec; 15(4):333–47 (72 ref.)

Bayesian decision making based on measurements containing errors. Philosophov LV. **Med Decis Making** 1995 Jul–Sep; 15(3):264–75

Separation of fetal and maternal ECG complexes from a mixed signal using an algorithm based on linear regression. Genevier ES, et al. **Med Eng Phys** 1995 Oct;17(7):514–22

Running discrete Fourier transform for time--frequency analysis of biomedical signals. Olkkonen H. **Med Eng Phys** 1995 Sep;17(6):455–8

Metrological opportunities of the dynamic mode of operating an enzyme amperometric biosensor. Sokolov S, et al. **Med Eng Phys** 1995 Sep;17(6):471–6

Thyroid function testing based on assay of thyroid-stimulating hormone: assessing an algorithm's reliability [see comments] Davey RX, et al. **Med J Aust** 1996 Mar 18;164(6):329–32. Comment in: Med J Aust 1996 Mar 18;164(6):324–5.

Robust three-dimensional object definition in CT and MRI. Bland PH, et al. **Med Phys** 1996 Jan;23(1):99–107

The relaxation of supercoiled DNA molecules as a biophysical dosimeter for ionizing radiations: a feasibility study. Chen W, et al. **Med Phys** 1995 Sep;22(9):1369–75

Systematic verification of a three-dimensional electron beam dose calculation algorithm. Cheng A, et al. **Med Phys** 1996 May;23(5):685–93

A fully automated algorithm for the segmentation of lung fields on digital chest radiographic images. Duryea J, et al. **Med Phys** 1995 Feb;22(2):183–91

Simultaneous optimization of dynamic multileaf collimation and scanning patterns or compensation filters using a generalized pencil beam algorithm. Gustafsson A, et al. **Med Phys** 1995 Jul;22(7):1141–56

An algorithm for improving the accuracy of discrete ROI integrals. Hauser DL, et al. **Med Phys** 1995 Jun; 22(6):723–32

A grey-level image alignment algorithm for registration of portal images and digitally reconstructed radiographs. Hristov DH, et al. **Med Phys** 1996 Jan;23(1):75–84

A fast and stable maximum a posteriori conjugate gradient reconstruction algorithm. Lalush DS, et al. **Med Phys** 1995 Aug;22(8):1273–84

Measurement of a photon penumbra-generating kernel for a convolution-adapted ratio-TAR algorithm for 3D treatment planning. Low DA, et al. **Med Phys** 1995 Sep; 22(9):1395–403

The evaluation of optimized implants for idealized implant geometries. Low DA, et al. **Med Phys** 1995 Sep; 22(9):1477–85

A convolution-adapted ratio-TAR algorithm for 3D photon beam treatment planning. Zhu XR, et al. **Med Phys** 1995 Aug;22(8):1315–27

Structure optimization of neural networks with A* -algorithm application in EEG pattern analysis. Doering A, et al. **Medinfo** 1995;8 Pt 1:814–7

Evaluation of partial classification algorithms using ROC curves. Tusch G. **Medinfo** 1995;8 Pt 2:904–8

Linguistic analysis of nucleotide sequences: algorithms for pattern recognition and analysis of codon strategy. Pesole G, et al. **Methods Enzymol** 1996;266:281–94

Reconstruction of gene trees from sequence data. Saitou N. **Methods Enzymol** 1996;266:427–49

Multiple protein sequence alignment: algorithms and gap insertion. Taylor WR. **Methods Enzymol** 1996;266:343–67

Relative apparent synapomorphy analysis (RASA). I: The statistical measurement of phylogenetic signal. Lyons-Weiler J, et al. **Mol Biol Evol** 1996 Jul;13(6):749–57

The VITESSE algorithm for rapid exact multilocus linkage analysis via genotype set-recoding and fuzzy inheritance [see comments] O'Connell JR, et al. **Nat Genet** 1995 Dec; 11(4):402–8. Comment in: Nat Genet 1995 Dec;11(4):354–5.

Hints. Abu-Mostafa YS. **Neural Comput** 1995 Jul;7(4):639–71 (34 ref.)

A simple spike train decoder inspired by the sampling theorem. August DA, et al. **Neural Comput** 1996 Jan; 8(1):67–84

An information-maximization approach to blind separation and blind deconvolution. Bell AJ, et al. **Neural Comput** 1995 Nov;7(6):1129–59

LeRec: a NN/HMM hybrid for on-line handwriting recognition. Bengio Y, et al. **Neural Comput** 1995 Nov; 7(6):1289–303

Sorting with self-organizing maps. Budinich M. **Neural Comput** 1995 Nov;7(6):1188–90

The target switch algorithm: a constructive learning procedure for feed-forward neural networks. Campbell C, et al. **Neural Comput** 1995 Nov;7(6):1245–64

On the practical applicability of VC dimension bounds. Holden SB, et al. **Neural Comput** 1995 Nov;7(6):1265–88

Self-organization as an iterative kernel smoothing process. Mulier F, et al. **Neural Comput** 1995 Nov;7(6):1165–77

Stable encoding of large finite-state automata in recurrent neural networks with sigmoid discriminants. Omlin CW, et al. **Neural Comput** 1996 May 15;8(4):675–96

Learning and generalization with Minimerror, a temperature-dependent learning algorithm. Raffin B, et al. **Neural Comput** 1995 Nov;7(6):1206–24

On the distribution and convergence of feature space in self-organizing maps. Yin H, et al. **Neural Comput** 1995 Nov;7(6):1178–87

Supplement: treatment for Parkinson's disease [letter] Muilenburg ND. **Neurology** 1995 Dec;45(12):2301–2

Medical management of severe head injury: present and future. Chesnut RM. **New Horiz** 1995 Aug;3(3):581–93 (45 ref.)

PairWise and SearchWise: finding the optimal alignment in a simultaneous comparison of a protein profile against all DNA translation frames. Birney E, et al. **Nucleic Acids Res** 1996 Jul 15;24(14):2730–9

SAGA: sequence alignment by genetic algorithm. Notredame C, et al. **Nucleic Acids Res** 1996 Apr 15;24(8):1515–24

An algorithmic approach to cancer pain management. Hudzinski DM. **Nurs Clin North Am** 1995 Dec;30(4):711–23 (11 ref.)

An ethically justified algorithm for offering, recommending, and performing cesarean delivery and its application in managed care practice [see comments] Chervenak FA, et al. **Obstet Gynecol** 1996 Feb;87(2):302–5. Comment in: Obstet Gynecol 1996 Jul;88(1):157–8.

An ethically justified algorithm for offering, recommending, and performing cesarean delivery and its application in managed care practice [letter; comment] Saad A. **Obstet Gynecol** 1996 Jul;88(1):157–8. Comment on: Obstet Gynecol 1996 Feb;87(2):302–5.

Algorithm helps healthcare practitioners manage opioid-induced sedation. Skalla K. **Oncol Nurs Forum** 1996 Apr;23(3):542–3

A spline surface algorithm for reconstruction of corneal topography from a videokeratographic reflection pattern. Halstead MA, et al. **Optom Vis Sci** 1995 Nov;72(11):821–7

Inhibition of bradycardia pacing caused by far-field atrial sensing in a third-generation cardioverter defibrillator with an automatic gain feature. Curwin JH, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):124–6

A fast and reliable algorithm to localize accessory pathways based on the polarity of the QRS complex on the surface ECG during sinus rhythm. d'Avila A, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1615–27

A computer algorithm for differentiating valid from distorted pulse oximeter waveforms in neonates. Adams JA, et al. **Pediatr Pulmonol** 1995 May;19(5):307–11

On the possibility of directly accessing every human brain by electromagnetic induction of fundamental algorithms. Persinger MA. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):791–9

A predictive algorithm for skin permeability: the effects of molecular size and hydrogen bond activity. Potts RO, et al. **Pharm Res** 1995 Nov;12(11):1628–33

Filtered backprojection reconstruction of combined parallel beam and cone beam SPECT data. Defrise M, et al. **Phys Med Biol** 1995 Sep;40(9):1517–37

A filtered backprojection algorithm for axial head motion correction in fan-beam SPECT. Li J, et al. **Phys Med Biol** 1995 Dec;40(12):2053–63

A simple and novel algorithm for time-resolved multiwavelength oximetry. Oda M, et al. **Phys Med Biol** 1996 Mar;41(3):551–62

Model-based scatter correction for fully 3D PET. Ollinger JM. **Phys Med Biol** 1996 Jan;41(1):153–76

Radiotherapy treatment planning with dynamic wedges--an algorithm for generating wedge factors and beam data. Thomas SJ, et al. **Phys Med Biol** 1995 Sep;40(9):1421–33

A comparative study of three fast algorithms to estimate cerebral blood flow and distribution volume using N-isopropyl-p-[123I]iodoamphetamine and two SPECT scans. Yokoi T, et al. **Phys Med Biol** 1995 Sep; 40(9):1499–515

Incorporating a priori information into the Sheffield filtered backprojection algorithm. Avis NJ, et al. **Physiol Meas** 1995 Aug;16(3 Suppl A):A111–22

Experimental validation of a novel reconstruction algorithm for electrical impedance tomography based on backprojection of Lagrange multipliers. Bayford R, et al. **Physiol Meas** 1995 Aug;16(3 Suppl A):A237–47

A method for comparative evaluation of EIT algorithms using a standard data set. Ider YZ, et al. **Physiol Meas** 1995 Aug;16(3 Suppl A):A227–36

A fast parametric modelling algorithm with the Powell method. Lu L, et al. **Physiol Meas** 1995 Aug;16(3 Suppl A):A39–47

3D reconstruction in electrical impedance imaging using a direct sensitivity matrix approach. Morucci JP, et al. **Physiol Meas** 1995 Aug;16(3 Suppl A):A123–8

The SAPHIRE server: a new algorithm and implementation. Hersh W, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:858–62

Categorization by reference: a novel approach to MeSH term assignment. Kouramajian V, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:878–82

How the first biopolymers could have evolved. Abkevich VI, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23; 93(2):839–44

On constructing folding heteropolymers. Ebeling M, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8798–802

Enhanced conformational sampling in Monte Carlo simulations of proteins: application to a constrained peptide. Kidera A. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9886–9

Calculating the probability of multitaxon evolutionary trees: bootstrappers Gambit. Lake JA. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9662–6

An O(N log N) algorithm for shape modeling. Malladi R, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9389–92

Neighboring base composition and transversion/transition bias in a comparison of rice and maize chloroplast noncoding regions. Morton BR. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9717–21

A maximum likelihood algorithm for genome mapping of cytogenetic loci from meiotic configuration data. Reyes-Valdés MH, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9824–8

A simple algorithm for the calculation of multiple site titration curves. Karshikoff A. **Protein Eng** 1995 Mar; 8(3):243–8

Finding the global minimum: a fuzzy end elimination implementation. Keller DA, et al. **Protein Eng** 1995 Sep; 8(9):893–904

The application of hydrogen bonding analysis in X-ray crystallography to help orientate asparagine, glutamine and histidine side chains. McDonald IK, et al. **Protein Eng** 1995 Mar;8(3):217–24

Improved genetic algorithm–based protein structure comparisons: pairwise and multiple superpositions. May AC, et al. **Protein Eng** 1995 Sep;8(9):873–82

A simple protein folding algorithm using a binary code and secondary structure constraints. Sun S, et al. **Protein Eng** 1995 Aug;8(8):769–78

Fuzzy cluster analysis of simple physicochemical properties of amino acids for recognizing secondary structure in proteins. Mocz G. **Protein Sci** 1995 Jun;4(6):1178–87

Gibbs motif sampling: detection of bacterial outer membrane protein repeats. Neuwald AF, et al. **Protein Sci** 1995 Aug; 4(8):1618–32

Comparison of methods for searching protein sequence databases. Pearson WR. **Protein Sci** 1995 Jun;4(6):1145–60

Topology prediction of membrane proteins. Persson B, et al. **Protein Sci** 1996 Feb;5(2):363–71

Contact interactions method: a new algorithm for protein folding simulations. Toma L, et al. **Protein Sci** 1996 Jan; 5(1):147–53

Folding proteins with a simple energy function and extensive conformational searching. Yue K, et al. **Protein Sci** 1996 Feb;5(2):254–61

Automatic recognition of hydrophobic clusters and their correlation with protein folding units. Zehfus MH. **Protein Sci** 1995 Jun;4(6):1188–202

Computational method for relative binding energies of enzyme–substrate complexes. Zhang T, et al. **Protein Sci** 1996 Feb;5(2):348–56

Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method. Chou KC, et al. **Proteins** 1996 Jan;24(1):51–72

Structural superposition of proteins with unknown alignment and detection of topological similarity using a six-dimensional search algorithm. Diederichs K. **Proteins** 1995 Oct;23(2):187–95

Local moves: an efficient algorithm for simulation of protein folding. Elofsson A, et al. **Proteins** 1995 Sep;23(1):73–82

Knowledge-based protein secondary structure assignment. Frishman D, et al. **Proteins** 1995 Dec;23(4):566–79

Rigid domains in proteins: an algorithmic approach to their identification. Nichols WL, et al. **Proteins** 1995 Sep; 23(1):38–48

Ab initio structure prediction for small polypeptides and protein fragments using genetic algorithms. Pedersen JT, et al. **Proteins** 1995 Nov;23(3):454–60

Accurate general method for lattice approximation of three-dimensional structure of a chain molecule. Rykunov DS, et al. **Proteins** 1995 Jun;22(2):100–9

LINUS: a hierarchic procedure to predict the fold of a protein. Srinivasan R, et al. **Proteins** 1995 Jun;22(2):81–99

Treatment algorithms in treatment-resistant depression. Amsterdam JD, et al. **Psychiatr Clin North Am** 1996 Jun; 19(2):371–86 (72 ref.)

Sub-typing depression, III. Development of a clinical algorithm for melancholia and comparison with other diagnostic measures. Parker G, et al. **Psychol Med** 1995 Jul;25(4):833–40

Composite probability modelling of increasing resolution where diagnostic covariates are unmeasurable for some subjects. Szalai JP, et al. **Psychol Rep** 1995 Aug;77(1):67–78

Algorithm for the treatment of obsessive-compulsive disorder (OCD). Jefferson JW, et al. **Psychopharmacol Bull** 1995;31(3):487–90

Algorithm for the treatment of panic disorder with agoraphobia. Jobson KO, et al. **Psychopharmacol Bull** 1995; 31(3):483–5

International Psychopharmacology Algorithm Project Report. Jobson KO, et al. **Psychopharmacol Bull** 1995; 31(3):457–9, 491–500

Algorithms for the treatment of subtypes of unipolar major depression. Nelson JC, et al. **Psychopharmacol Bull** 1995; 31(3):475–82

Algorithm for schizophrenia in Japan. Sato M. **Psychopharmacol Bull** 1995;31(3):501–4

Algorithms for the treatment of bipolar manic-depressive illness. Suppes T, et al. **Psychopharmacol Bull** 1995; 31(3):469–74

Algorithms for the treatment of schizophrenia. Zarate CA Jr, et al. **Psychopharmacol Bull** 1995;31(3):461–7

Three-dimensional spiral CT during arterial portography: comparison of three rendering techniques. Heath DG, et al. **Radiographics** 1995 Jul;15(4):1001–11

Stress fractures. Anderson MW, et al. **Radiology** 1996 Apr; 199(1):1–12 (105 ref.)

Diagnosis of acute pulmonary embolism: time for a new approach [editorial; comment] Goodman LR, et al. **Radiology** 1996 Apr;199(1):25–7. Comment on: Radiology 1996 Apr;199(1):31–5.

Registration and alignment of three-dimensional images: an interactive visual approach. Habboush IH, et al. **Radiology** 1996 May;199(2):573–8

A comparison of conventional 'forward planning' with inverse planning for 3D conformal radiotherapy of the prostate. Oldham M, et al. **Radiother Oncol** 1995 Jun; 35(3):248–62

The optimisation of wedge filters in radiotherapy of the prostate. Oldham M, et al. **Radiother Oncol** 1995 Dec; 37(3):209–20

A comparison of thermodynamic foldings with comparatively derived structures of 16S and 16S-like rRNAs. Konings DA, et al. **RNA** 1995 Aug;1(6):559–74

Averaging evoked potentials with an improved weighting algorithm. Gerull G, et al. **Scand Audiol** 1996;25(1):21–7

Making DNA add. Guarnieri F, et al. **Science** 1996 Jul 12; 273(5272):220–3

Indeterminate organization of the visual system [see comments] Hilgetag CC, et al. **Science** 1996 Feb 9; 271(5250):776–7. Comment in: Science 1996 Feb 9;271(5250):777.

Mapping the protein universe. Holm L, et al. **Science** 1996 Aug 2;273(5275):595–603 (36 ref.)

Criticality and parallelism in combinatorial optimization. Macready WG, et al. **Science** 1996 Jan 5;271(5245):56–9

Computational molecular biology. Software matchmakers help make sense of sequences [news] Taubes G. **Science** 1996 Aug 2;273(5275):588–90

On hierarchies: response to Hilgetag et al [comment] Van Essen DC, et al. **Science** 1996 Feb 9;271(5250):777. Comment on: Science 1996 Feb 9;271(5250):776–7.

Deconvolution of 29Si magic-angle spinning nuclear magnetic resonance spectra of silicate glasses revisited--some critical comments. Mahler J, et al. **Solid State Nucl Magn Reson** 1995 Oct;5(1):63–78

An empirical comparison of expert-derived and data-derived classification trees. Chiogna M, et al. **Stat Med** 1996 Jan 30;15(2):157–69

Planning and revising the sample size for a trial. Gould AL. **Stat Med** 1995 May 15–30;14(9–10):1039–51; discussion 1053–5 (15 ref.)

MCMC methods for putative pollution source problems in environmental epidemiology. Lawson AB. **Stat Med** 1995 Nov 15–30;14(21–22):2473–85

Analysis of pseudo-profiles in organ pharmacokinetics and toxicokinetics. Mager H, et al. **Stat Med** 1995 May 15–30; 14(9–10):1009–24

Exact logistic regression: theory and examples. Mehta CR, et al. **Stat Med** 1995 Oct 15;14(19):2143–60

Exact power computation for dose-response studies. Tang ML, et al. **Stat Med** 1995 Oct 30;14(20):2261–72

A hybrid paired and unpaired analysis for the comparison of proportions. Thomson PC. **Stat Med** 1995 Jul 15; 14(13):1463–70

An introduction to multivariate adaptive regression splines. Friedman JH, et al. **Stat Methods Med Res** 1995 Sep; 4(3):197–217

Trees and splines in survival analysis. Intrator O, et al. **Stat Methods Med Res** 1995 Sep;4(3):237–61

Extending the elements of tree-structured regression. Segal MR. **Stat Methods Med Res** 1995 Sep;4(3):219–36

A euristic approach to the volume reconstruction of arteriovenous malformations from biplane angiography. Foroni R, et al. **Stereotact Funct Neurosurg** 1995;64 Suppl 1:134–46

Development of a fast optimization preview in radiation treatment planning. Höffner J, et al. **Strahlenther Onkol** 1996 Jul;172(7):384–94

Prospective evaluation of a dose prediction algorithm for intravenous tobramycin in adolescent and adult patients with cystic fibrosis. Touw DJ, et al. **Ther Drug Monit** 1996 Apr;18(2):118–23

A tissue composition-based algorithm for predicting tissue:air partition coefficients of organic chemicals. Poulin P, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):126–30

A mechanistic algorithm for predicting blood:air partition coefficients of organic chemicals with the consideration of reversible binding in hemoglobin. Poulin P, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):131–7

Improved methods for determination of rotational symmetries in macromolecules. Kocsis E, et al. **Ultramicroscopy** 1995 Sep;60(2):219–28

Automatic particle picking from electron micrographs. Lata KR, et al. **Ultramicroscopy** 1995 Jun;58(3–4):381–91

Multiple resolution Bayesian segmentation of ultrasound images. Ashton EA, et al. **Ultrason Imaging** 1995 Oct; 17(4):291–304

A simulation algorithm for ultrasound liver backscattered signals. Zatari D, et al. **Ultrasonics** 1995 Nov;33(6):469–74

Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Meister GE, et al. **Vaccine** 1995 Apr;13(6):581–91

[Consensus inflammatory intestinal diseases in children: ulcerative colitis and Crohn disease. Work Group Academic Medical Center, Amsterdam] Büller HA, et al. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):544–50 (6 ref.) (Eng. Abstr.) **(Dut)**

[What to do in a 60-year-old HIV-positive woman with a cerebral arteriovenous malformation? Decision analysis (see comments)] Dippel DW, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2362–9 (52 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1996 Feb 17;140(7):386–7. **(Dut)**

[How I examine... global dilatation of the cerebral ventricles in an elderly patient] Pirotte B, et al. **Rev Med Liege** 1995 Aug;50(8):350–1 **(Fre)**

[Development and evaluation of screening algorithms for sexually transmitted diseases in pregnant women at Libreville, Gabon] Bourgeois A, et al. **Sante** 1996 Mar–Apr; 6(2):115–21 (Eng. Abstr.) **(Fre)**

[Adaptive algorithm for automatic measurement of retinal vascular diameter] Münch K, et al. **Biomed Tech (Berl)** 1995 Nov;40(11):322–5 (Eng. Abstr.) **(Ger)**

[Detection of rapid eye movement with rapidly adapting neuronal fuzzy systems in imprecise REM syntax] Wallner F. **Biomed Tech (Berl)** 1996 Apr;41(4):84–90 (Eng. Abstr.) **(Ger)**

[High resolution computerized tomography of the petrous bones in a bone algorithm and 2D reconstruction for evaluation of the facial nerve canal] Marangos N, et al. **HNO** 1995 Dec;43(12):732–6 (Eng. Abstr.) **(Ger)**

[Treatment strategies in mechanical and electrical cardiovascular failure] Oechslin E. **Ther Umsch** 1996 Aug; 53(8):646–57 (21 ref.) (Eng. Abstr.) **(Ger)**

[The ABCD of resuscitation] Osterwalder JJ. **Ther Umsch** 1996 Aug;53(8):611–4 (Eng. Abstr.) **(Ger)**

[Diagnostic procedures in obscure cervical nodes in adults] Wolfensberger M. **Ther Umsch** 1995 Nov;52(11):763–7 (Eng. Abstr.) **(Ger)**

[Blunt and penetrating abdominal trauma. Patient assessment algorithm and principles for management] Ertel W, et al. **Unfallchirurg** 1996 Apr;99(4):288–303 (28 ref.) **(Ger)**

[Suggested clinical algorithm for the management of mild head injuries in the emergency department] Levi L, et al. **Harefuah** 1996 Jan 1;130(1):45–8 **(Heb)**

[Global optimization of the conformational energy of oligopeptides using a tunnel algorithm] Petukhov MG, et al. **Biofizika** 1992 Mar–Apr;37(2):226–30 (Eng. Abstr.) **(Rus)**

[A computer model of "sense of humor". I. General algorithm] Suslov IM. **Biofizika** 1992 Mar–Apr;37(2):318–24 (Eng. Abstr.) **(Rus)**

[Model of the perception of perturbed angular motion of the cockpit as part of pilot's information model] Azarskov VN, et al. **Kosm Biol Aviakosm Med** 1991 Nov–Dec;25(6):14–7 (Eng. Abstr.) **(Rus)**

[Neural network algorithms for recognition of complex binary images without their previous segmentation] Tret'iakov VP, et al. **Med Tekh** 1995 Jul–Aug;(4):5–9 (Eng. Abstr.) **(Rus)**

[Technological algorithms--a universal means for intensifying the functioning of a regional forensic medical service] Dontsov VG. **Sud Med Ekspert** 1995 Oct–Dec; 38(4):31–3 (Eng. Abstr.) **(Rus)**

[An algorithm for the ultrasonic monitoring of patients who have undergone cystectomy] Sitdykov EN, et al. **Urol Nefrol (Mosk)** 1995 Sep–Oct;(5):41–4 **(Rus)**

[Potential of ultrasonography in urologic diagnostic algorithms] Mayayo Dehesa T, et al. **Arch Esp Urol** 1995 Sep;48(7):665–77; discussion 678 (35 ref.) (Eng. Abstr.) **(Spa)**

ALIENATION, SOCIAL see **SOCIAL ALIENATION**

ALIMEMAZINE see **TRIMEPRAZINE**

ALKADIENES

CHEMICAL SYNTHESIS

Phosphodiester amidates of allenic nucleoside analogues: anti-HIV activity and possible mechanism of action. Winter H, et al. **J Med Chem** 1996 Aug 16;39(17):3300–6

PHARMACOLOGY

Depudecin, a microbial metabolite containing two epoxide groups, exhibits anti-angiogenic activity in vivo. Oikawa T, et al. **Biol Pharm Bull** 1995 Sep;18(9):1305–7

ALKALI see **ALKALIES**

ALKALI METALS see **METALS, ALKALI**

ALKALIES

see related

HYPERCALCEMIA

A prospective randomized study to assess the efficacy of post-operative nasal medication after endonasal surgery. Spraggs PD, et al. **J Laryngol Otol** 1995 Jul;109(7):618–21

Preparation of plasmid DNA using alkaline lysis. Joly E. **Methods Mol Biol** 1996;58:257–63

ADVERSE EFFECTS

Should we add an acid to an alkali injury? For now, let's remain neutral! [editorial] Smilkstein MJ. **Acad Emerg Med** 1995 Nov;2(11):945–6

Treatment of a severe alkali burn. Erdmann D, et al. **Burns** 1996 Mar;22(2):141–6

Burns caused by domestic alkalis. Rider MA, et al. **J Accid Emerg Med** 1995 Jun;12(2):130–1

METABOLISM

Regulation of luminal alkalinization and acidification in the cortical collecting duct by angiotensin II. Weiner ID, et

ALKALIES

al. **Am J Physiol** 1995 Nov;269(5 Pt 2):F730–8

K(+)- and HCO3(-)-dependent acid-base transport in squid giant axons. I. Base efflux. Hogan EM, et al. **J Gen Physiol** 1995 Nov;106(5):821–44

K(+)- and HCO3(-)-dependent acid-base transport in squid giant axons II. Base influx. Hogan EM, et al. **J Gen Physiol** 1995 Nov;106(5):845–62

Studies on the mechanism of swelling-induced lysosomal alkalinization in vascular smooth muscle cells. Busch GL, et al. **Pflugers Arch** 1996 Mar;431(5):690–6

PHARMACOLOGY

Relative contributions of excitatory and inhibitory neuronal activity to alkaline transients evoked by stimulation of Schaffer collaterals in the rat hippocampal slice. Taira T, et al. **J Neurophysiol** 1995 Aug;74(2):643–9

Effect of alkaline ionized water on reproduction in gestational and lactational rats. Watanabe T. **J Toxicol Sci** 1995 May; 20(2):135–42

POISONING

Corrosive injuries of the oesophagus and stomach: experience in management at a regional paediatric centre. Stiff G, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2):119–23 (68 ref.)

THERAPEUTIC USE

Alkali therapy, hyperphosphatemia, and acute tumor lysis syndrome [letter] Koduri PR. **Med Pediatr Oncol** 1996 Jan; 26(1):73

ALKALINE EARTH METALS see **METALS, ALKALINE EARTH**

ALKALINE PHOSPHATASE

see related

HYPOPHOSPHATASIA

The preparation of fluorescein-labeled nucleic acid probes and their detection using alkaline phosphatase-catalyzed dioxetane chemiluminescence. Cunningham M, et al. **Methods Mol Biol** 1996;58:53–63

[Properties of enzymes for enzyme immunoassay] Maekawa M. **Nippon Rinsho** 1995 Sep;53(9):2154–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Zeptomole-detecting biosensor for alkaline phosphatase in an electrochemical immunoassay for 2,4-dichlorophenoxyacetic acid. Bauer CG, et al. **Anal Chem** 1996 Aug 1;68(15):2453–8

Bispecific multivalent antibody studied by real-time interaction analysis for the development of an antigen-inhibition enzyme-linked immunosorbent assay. Reinartz HW, et al. **Analyst** 1996 Jun;121(6):767–71

Bone alkaline phosphatase in rheumatic diseases. Beyeler C, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):379–84

Measurement of bone-specific alkaline phosphatase by an immunoselective enzyme assay method. Hata K, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):127–31

A biotinylated undecylthiophene copolymer bioconjugate for surface immobilization: creating an alkaline phosphatase chemiluminescence-based biosensor. Pande R, et al. **Bioconjug Chem** 1996 Jan-Feb;7(1):159–64

Amperometric detection of alkaline phosphatase activity at a horseradish peroxidase enzyme electrode based on activated carbon: potential application to electrochemical immunoassay. Ho WO, et al. **Biosens Bioelectron** 1995 Fall; 10(8):683–91

Ultrastructural cytochemistry of human gastric cancer: electron microscopic observations of five organellae marker enzymes. Yang G, et al. **Chin Med J (Engl)** 1995 Nov;108(11):859–63

Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children. Crofton PM, et al. **Clin Endocrinol (Oxf)** 1996 Apr; 44(4):385–94

Echinococcus granulosus, E. multilocularis and mammalian liver-type alkaline phosphatases: a comparative study. Lawton P, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):295–301

Separation of the two most closely related isoenzymes of alkaline phosphatase by two-dimensional electrophoresis. Otto VI, et al. **Electrophoresis** 1995 Jul;16(7):1284–8

Usefulness of reference materials in calibration of enzyme activities. Lessinger JM, et al. **Eur J Clin Chem Clin Biochem** 1995 Nov;33(11):859–64

Determination of alkaline phosphatase isozymes in amniotic fluid. Sembaj A, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):281–4

Ultrastructural localization of alkaline phosphatase activity in the proximal convoluted tubule cells of the gerbil Meriones crassus using a cerium-based method. Safer AM. **Eur J Histochem** 1995;39(2):149–56

Simultaneous demonstration of CD15 and alkaline phosphatase activity in cryostat sections of rat fetuses: a detailed technical description for the developing brain. Marani E, et al. **Eur J Morphol** 1995 Apr;33(2):137–47

Qualitative and quantitative detection of alkaline phosphatase coupled to an oligonucleotide probe for somatostatin mRNA after in situ hybridization using unfixed rat brain tissue. Asan E, et al. **Histochem Cell Biol** 1995 Jun; 103(6):463–71

Alkaline phosphatase reactivity in rabbit airway epithelium: a potentially useful marker for airway basal cells. Inayama Y, et al. **Histochem Cell Biol** 1995 Sep;104(3):191–8

Localisation of alkaline phosphatase in equine growth cartilage. Henson FM, et al. **J Anat** 1995 Aug;187 (Pt 1):151–9

A new luminometer for sensitive quantification by chemiluminescence of specific proteins in microtitre plates and on blot membranes. Vesterberg O. **J Biochem Biophys Methods** 1995 Nov;30(4):301–14

Alkaline phosphatase activity in Penicillium roqueforti and in blue-veined cheeses. Rosenthal I, et al. **J Dairy Sci** 1996 Jan;79(1):16–9

Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. Lorente JA, et al. **J Urol** 1996 Apr; 155(4):1348–51

Stimulation of human prostate cancer cell lines by factors present in human osteoblast-like cells but not in bone marrow. Lang SH, et al. **Prostate** 1995 Nov;27(5):287–93

[Isoenzyme] Ohta H, et al. **Nippon Rinsho** 1996 Jun; 54(6):1505–9 (16 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Okadaic acid inhibits alkaline phosphatase activity in MC3T3-E1 cells. Choi JY, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):943–7

Effects of deferoximine on chondrocyte alkaline phosphatase activity: proxidant role of deferoximine in thalassemia. Hatori M, et al. **Calcif Tissue Int** 1995 Sep;57(3):229–36

BIOSYNTHESIS

Differential expression and butyrate response of human alkaline phosphatase genes are mediated by upstream DNA elements. Park C, et al. **Biochemistry** 1996 Jul 30; 35(30):9807–14

Design of a novel bicistronic expression vector with demonstration of a p16INK4-induced G(1)-S block(1). Poulos NE, et al. **Cancer Res** 1996 Apr 15;56(8):1719–23

Increased efficiency of alkaline phosphatase production levels in Escherichia coli using a degenerate PelB signal sequence. Le Calvez H, et al. **Gene** 1996 Apr 17;170(1):51–5

Osteosarcoma hybrids can preferentially target alkaline phosphatase activity to matrix vesicles: evidence for independent membrane biogenesis. Leach RJ, et al. **J Bone Miner Res** 1995 Nov;10(11):1614–24

Induction of heat labile alkaline phosphatase by butyrate in differentiating endometrial cells. Fleming H, et al. **J Cell Biochem** 1995 Aug;58(4):509–16

Bovine enamel organ cells express tissue non-specific alkaline phosphatase mRNA. Yuan ZA, et al. **J Dent Res** 1995 Dec; 74(12):1886–90

ALP induction by beta-glycerophosphate during the non-mineralization phase in vitro. Chen L, et al. **J Tongji Med Univ** 1996;16(1):20–4

BLOOD

The "pseudo-cholangiocarcinoma sign" in patients with cavernous transformation of the portal vein and its effect on the serum alkaline phosphatase and bilirubin levels. Bayraktar Y, et al. **Am J Gastroenterol** 1995 Nov; 90(11):2015–9

Benign familial hyperphosphatasemia in Siberian huskies. Lawler DF, et al. **Am J Vet Res** 1996 May;57(5):612–7

Serum 5'-nucleotidase and alkaline phosphatase activities after high dose chemotherapy and bone marrow transplantation in cases of malignancy in children. Clerc-Renaud P, et al. **Ann Biol Clin (Paris)** 1995; 53(3):125–30

Mass versus activity: validation of an immunometric assay for bone alkaline phosphatase in serum. Price CP, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):405–12

Serum ostase in the follow-up of breast cancer patients. Marchei P, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):2217–22

Serum bone alkaline phosphatase in the follow-up of skeletal metastases. Zaninotto M, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2223–8

Serum alkaline phosphatase, calcium, and phosphate levels following clinical use of natural coral. Case reports. Alpaslan G, et al. **Aust Dent J** 1995 Oct;40(5):327–9

Leukocyte alkaline phosphatase and serum gamma-glutamil transferase activities in horses used for production of hyper immune sera. Kampl B, et al. **Berl Munch Tierarztl Wochenschr** 1995 Aug;108(8):290–3

Is erythrocyte alkaline phosphatase activity a marker of zinc status in humans? Samman S, et al. **Biol Trace Elem Res** 1996 Mar;51(3):285–91

Some blood plasma constituents correlate with human cataract. Donnelly CA, et al. **Br J Ophthalmol** 1995 Nov; 79(11):1036–41

Significance of placental alkaline phosphatase (PLAP) in the monitoring of patients with seminoma. Koshida K, et al. **Br J Urol** 1996 Jan;77(1):138–42

Changes in serum carboxyterminal telopeptide of type I collagen in an experimental model of canine osteomyelitis. Philipov JP, et al. **Calcif Tissue Int** 1995 Aug;57(2):152–4

A comparison of pooled, fresh-frozen, and lyophilized sera as a matrix for enzyme proficiency testing: the experience of the Ontario Laboratory Proficiency Testing Program. Henderson AR, et al. **Clin Biochem** 1996 Apr;29(2):183–5

Efficacy of simultaneous determination of bone alkaline phosphatase mass concentration in serum and urinary excretion of pyridinium cross-links for detection of bone metastases. Withold W, et al. **Clin Biochem** 1995 Oct; 28(5):511–9

Skeletal alkaline phosphatase activity in serum [editorial; comment] Farley J, et al. **Clin Chem** 1995 Nov; 41(11):1551–3. Comment on: Clin Chem 1995 Nov;41(11):1560–6.

Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum [see comments] Gomez B Jr, et al. **Clin Chem** 1995 Nov;41(11):1560–6. Comment in: Clin Chem 1995 Nov;41(11):1551–3.

Standards required for quantification of skeletal alkaline phosphatase [letter; comment] Klein G, et al. **Clin Chem** 1996 Mar;42(3):480–2. Comment on: Clin Chem 1994 Sep;40(9):1749–56.

Evaluation of a new commercial IRMA for bone-specific alkaline phosphatase during treatment with hormone replacement therapy and calcitonin. Overgaard K, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):973–4

Method for determination of bone alkaline phosphatase activity: analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases. Withold W, et al. **Clin Chem** 1996 Feb;42(2):210–7

Low serum alkaline phosphatase activity associated with severe Wilson's disease. Is the breakdown of alkaline phosphatase molecules caused by reactive oxygen species? Hoshino T, et al. **Clin Chim Acta** 1995 Jun 30;238(1):91–100

Pedigree of a family with hyper-alkaline-phosphatasemia apparently inherited as an autosomal recessive trait [letter] Kawasaki S, et al. **Clin Chim Acta** 1995 Jun 30; 238(1):109–11

Comparison between serum levels of bone alkaline phosphatase and the carboxy-terminal propeptide of type I procollagen as markers of bone formation in patients following renal transplantation. Withold W, et al. **Clin Chim Acta** 1995 Aug 14;239(2):143–51

Serum calcium, inorganic phosphate and alkaline phosphatase activity in lactating females. Onwuameze IC. **East Afr Med J** 1995 Jun;72(6):379–80

Clinical utility of a wheat-germ precipitation assay for determination of bone alkaline phosphatase concentrations in patients with different metabolic bone diseases. Braga V, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul;33(7):433–9

Monitoring of bone metabolism after bone marrow transplantation by measuring two different markers of bone turnover. Withold W, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):193–7

Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. Ureña P, et al. **J Am Soc Nephrol** 1996 Mar;7(3):506–12

The flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression-free survival in prostatic carcinoma. Pelger RC, et al. **J Urol** 1996 Jul;156(1):122–6

Leukocyte alkaline phosphatase score in plasma cell dyscrasias: correlation with disease severity and circulating levels of granulocyte-colony stimulating factor. Stasi R, et al. **Leuk Lymphoma** 1995 May;17(5–6):479–83

Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma. Liu PP, et al. **Oncology** 1996 Jul-Aug;53(4):275–80

Utilization of the bone/liver alkaline phosphatase activity ratio in blood plasma as an indicator of ascorbate deficiency in salmonid fish. Matusiewicz M, et al. **Proc Soc Exp Biol Med** 1996 May;212(1):44–51

Biological variation in bone-derived biochemical markers in serum. Panteghini M, et al. **Scand J Clin Lab Invest** 1995 Nov;55(7):609–16

Acid phosphatase: defining a role in androgen-independent prostate cancer. Steineck G, et al. **Urology** 1996 May; 47(5):719–26

[Alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamate dehydrogenase (GLDH), alkaline phosphatase (AP) and gamma-glutamyltransferase (GGP) in intestinal diseases of dogs] Dodurka T, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jul;108(7):244–8 (Eng. Abstr.) **(Ger)**

[Osteopenia in childhood. Hereditary hyperphosphatasia] Bajaj SK, et al. **Radiologe** 1995 Nov;35(11):871–2 (Eng. Abstr.) **(Ger)**

[Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report] Casetta G, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):9–12 (Eng. Abstr.) **(Ita)**

[Alkaline phosphatase isoenzymes in a case of transient hyperphosphatasemia] Botti C, et al. **Pediatr Med Chir** 1995 Nov-Dec;17(6):587–9 (Eng. Abstr.) **(Ita)**

[A case of left atrial myxoma with remarkable elevation of serum alkaline phosphatase level] Goko C, et al. **Kyobu Geka** 1995 Sep;48(10):877–9 (Eng. Abstr.) **(Jpn)**

[Neutrophil alkaline phosphatase (NAP) score] Aoyagi M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:221–4 (17 ref.) **(Jpn)**

[Alkaline phosphatase and its isozyme] Iino S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:276–9 (6 ref.) **(Jpn)**

[A predictive and prognostic study on two cases of transient

hyperphosphatasemia of infancy] Ohba N, et al. **Rinsho Byori** 1996 Jan;44(1):76–80 (Eng. Abstr.) **(Jpn)**

[Benign familial hypophosphatasemia (letter)] Ponce A, et al. **Rev Clin Esp** 1996 May;196(5):342 **(Spa)**

CHEMISTRY

Homogeneous assays for riboflavin mediated by the interaction between enzyme–biotin and avidin–riboflavin conjugates. Kim MJ, et al. **Anal Biochem** 1995 Nov 1; 231(2):400–6

Reversible unfolding of Escherichia coli alkaline phosphatase: active site can be reconstituted by a number of pathways. Sarkar SN, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):174–80

A stable phage–display system using a phagemid vector: phage display of hen egg–white lysozyme (HEL), Escherichia coli alkaline, phosphatase, and anti–HEL monoclonal antibody, HyHEL10. Maenaka K, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):682–7

Long time–scale probing of the protein globular core using hydrogen–exchange and room temperature phosphorescence. Schlyer BD, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):670–4

A novel Bacillus intermedius extracellular alkaline phosphatase: isolation, physico–chemical and catalytic characteristics. Sharipova MR, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):753–61

Kinetic and X–ray structural studies of a mutant Escherichia coli alkaline phosphatase (His–412–>Gln) at one of the zinc binding sites. Ma L, et al. **Biochemistry** 1996 Feb 20; 35(7):2394–402

Membrane topology of helices VII and XI in the lactose permease of Escherichia coli studied by lacY–phoA fusion analysis and site–directed spectroscopy. Ujwal ML, et al. **Biochemistry** 1995 Nov 14;34(45):14909–17

Microheterogeneity of the hydrophobic and hydrophilic part of the glycosylphosphatidylinositol anchor of alkaline phosphatase from calf intestine. Armesto J, et al. **Eur J Biochem** 1996 May 15;238(1):259–69

Comparative study of the sugar chains of alkaline phosphatases purified from rat liver and rat AH–130 hepatoma cells. Occurrence of fucosylated high–mannose–type and hybrid–type sugar chains. Endo T, et al. **Eur J Biochem** 1996 Mar 1;236(2):579–90

Direct kinetic evidence for triplet state energy transfer from Escherichia coli alkaline phosphatase tryptophan 109 to bound terbium. Schlyer BD, et al. **J Biol Chem** 1995 Sep 29;270(39):22890–4

3–D structure of the D153G mutant of Escherichia coli alkaline phosphatase: an enzyme with weaker magnesium binding and increased catalytic activity. Dealwis CG, et al. **Protein Eng** 1995 Sep;8(9):865–71

Escherichia coli alkaline phosphatase: X–ray structural studies of a mutant enzyme (His–412–>Asn) at one of the catalytically important zinc binding sites. Ma L, et al. **Protein Sci** 1995 Aug;4(8):1498–506

DEFICIENCY

Mice lacking tissue non–specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B–6. Waymire KG, et al. **Nat Genet** 1995 Sep;11(1):45–51

DIAGNOSTIC USE

Spectrophotometric assay using streptavidin–alkaline phosphatase conjugate for studies on the proteolysis of polymer bead–bound peptides. Shin JS, et al. **Anal Biochem** 1996 Apr 5;236(1):9–13

DRUG EFFECTS

A possible mechanism of increase in serum alkaline phosphatase activity in rats given granulocyte colony–stimulating factor. Kato Y, et al. **Exp Anim** 1996 Jan;45(1):23–32

The effect of menopause and hormone replacement therapy on bone alkaline phosphatase. Alexandersen P, et al. **Scand J Clin Lab Invest** 1995 Nov;55(7):571–6

GENETICS

cDNA encoding a functional feline liver/bone/kidney–type alkaline phosphatase. Ghosh AK, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):240–9

Differential expression and butyrate response of human alkaline phosphatase genes are mediated by upstream DNA elements. Park C, et al. **Biochemistry** 1996 Jul 30; 35(30):9807–14

Tissue–nonspecific alkaline phosphatase participates in the establishment and growth of feather germs in embryonic chick skin cultures. Crawford K, et al. **Dev Dyn** 1995 Sep; 204(1):48–56

1,25–Dihydroxyvitamin D3 and transforming growth factor–beta act synergistically to override extinction of liver/bone/kidney alkaline phosphatase in osteosarcoma hybrid cells. Johnson–Pais TL, et al. **Exp Cell Res** 1996 Jul 10;226(1):67–74

Regulation of osteoblast gene expression in intratypic osteosarcoma hybrid cells. Johnson–Pais TL, et al. **Exp Cell Res** 1995 Dec;221(2):370–6

Construction of an alkaline phosphatase fusion–generating transposon, mTn10phoA. McClain MS, et al. **Gene** 1996 Apr 17;170(1):147–8

Distribution of placental alkaline phosphatase gene (PLAP) frequencies in two groups of Muslim populations of Andhra Pradesh. Chitra KY, et al. **Gene Geogr** 1995 Apr;9(1):5–6

Placental and germ cell alkaline phosphatase RFLPs and haplotypes associated with spontaneous abortion. Wennberg C, et al. **Hum Hered** 1995 Sep–Oct;45(5):272–7

Shedding of the lymphocyte L–selectin adhesion molecule is inhibited by a hydroxamic acid–based protease inhibitor. Identification with an L–selectin–alkaline phosphatase reporter. Feehan C, et al. **J Biol Chem** 1996 Mar 22; 271(12):7019–24

Bovine enamel organ cells express tissue non–specific alkaline phosphatase mRNA. Yuan ZA, et al. **J Dent Res** 1995 Dec; 74(12):1886–90

Mutations at positions 153 and 328 in Escherichia coli alkaline phosphatase provide insight towards the structure and function of mammalian and yeast alkaline phosphatases. Murphy JE, et al. **J Mol Biol** 1995 Nov 3;253(4):604–17

A Bacillus subtilis secreted phosphodiesterase/alkaline phosphatase is the product of a Pho regulon gene, phoD. Eder S, et al. **Microbiology** 1996 Aug;142 (Pt 8):2041–7

The cyanobacterium Synechococcus sp. strain PCC 7942 contains a second alkaline phosphatase encoded by phoV. Wagner KU, et al. **Microbiology** 1995 Dec;141 (Pt 12):3049–58

Infantile hypophosphatasia: successful prenatal assessment by testing for tissue–non–specific alkaline phosphatase isoenzyme gene mutations. Henthorn PS, et al. **Prenat Diagn** 1995 Nov;15(11):1001–6

Restriction fragment length polymorphism of genes of the alpha 2(XI) collagen, bone morphogenetic protein–2, alkaline phosphatase, and tumor necrosis factor–alpha among patients with ossification of posterior longitudinal ligament and controls from the Japanese population. Koga H, et al. **Spine** 1996 Feb 15;21(4):469–73

[Polymorphism of placental alkaline phosphatase on the level of DNA and protein in the Mordovian population] Bekman G, et al. **Genetika** 1996 Mar;32(3):420–4 (Eng. Abstr.) **(Rus)**

[Genetic analysis of differences in alkaline phosphatase activity in two Drosophila virilis strains differing in heat stress response] Sukhanova MZh, et al. **Genetika** 1996 Jan; 32(1):68–72 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Azure B–eosin APAAP staining: a method for simultaneous hematological and immunological cell analysis. Koch B, et al. **Biotech Histochem** 1995 Sep;70(5):267–70

Definition of a discontinuous immunodominant epitope of intestinal alkaline phosphatase, an autoantigen in acute bacterial infections. Kolbus N, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):298–306

A potential use of a monoclonal antibody to placental alkaline phosphatase (PLAP) to detect lymph node metastases of seminoma. Koshida K, et al. **J Urol** 1996 Jan;155(1):337–41

Fetal alkaline phosphatase/maternal IgG immune complexes in trisomy 21 pregnancies [letter] Grozdea J, et al. **Prenat Diagn** 1995 Nov;15(11):1084–5

ISOLATION & PURIFICATION

[Isolation and certain properties of mutant alkaline phosphatase of Escherichia coli] Nesmeianova MA, et al. **Biokhimiia** 1996 Jan;61(1):89–99 (Eng. Abstr.) **(Rus)**

METABOLISM

Effect of chronic ethanol consumption on the activities of residual small bowel brush–border enzymes after proximal jejunum resection in the rat. Zucoloto S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):152–5

The measurement of acid and alkaline phosphatase in gingival crevicular fluid during orthodontic tooth movement. Insoft M, et al. **Am J Orthod Dentofacial Orthop** 1996 Mar; 109(3):287–96

Renal expression of osteopontin and alkaline phosphatase correlates with BUN levels in aged rats. Liang CT, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):F398–404

Glycosylphosphatidylinositol–alkaline phosphatase from calf intestine as substrate for glycosylphosphatidylinositol–specific phospholipases—microassay using hydrophobic chromatography in pipet tips. Rhode H, et al. **Anal Biochem** 1995 Oct 10;231(1):99–108

Expression of tissue non–specific alkaline phosphatase stimulates differentiated behaviour in specific transformed cell populations. Hui MZ, et al. **Anat Rec** 1996 Apr; 244(4):423–36

Enzymatic properties of adult human Sertoli cells in vitro. Carreau S, et al. **Andrologia** 1996 Mar–Apr;28(2):89–95

Construction, expression and characterisation of a single chain anti–tumour antibody (scFv)–IL–2 fusion protein. Boleti E, et al. **Ann Oncol** 1995 Nov;6(9):945–7

Reversible unfolding of Escherichia coli alkaline phosphatase: active site can be reconstituted by a number of pathways. Sarkar SN, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):174–80

Intestinal alkaline phosphatase can transphosphorylate thiamin to thiamin monophosphate during intestinal transport in the rat. Rindi G, et al. **Arch Physiol Biochem** 1995 Apr;103(1):33–8

C–type natriuretic peptide as an autocrine/paracrine regulator of osteoblast. Evidence for possible presence of bone natriuretic peptide system. Suda M, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):1–6

Bip/GRP78 but not calnexin associates with a precursor of glycosylphosphatidylinositol–anchored protein. Oda K, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):623–30

A novel Bacillus intermedius extracellular alkaline phosphatase: isolation, physico–chemical and catalytic characteristics. Sharipova MR, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):753–61

Crystallographic analysis of reversible metal binding observed in a mutant (Asp153—>Gly) of Escherichia coli alkaline phosphatase. Dealwis CG, et al. **Biochemistry** 1995 Oct 31;34(43):13967–73

The nature of the transition state for enzyme–catalyzed phosphoryl transfer. Hydrolysis of O–aryl phosphorothioates by alkaline phosphatase. Hollfelder F, et al. **Biochemistry** 1995 Sep 26;34(38):12255–64

Accurate kinetic modeling of alkaline phosphatase in the Escherichia coli periplasm: implications for enzyme properties and substrate diffusion. Martinez MB, et al. **Biochemistry** 1996 Jan 30;35(4):1179–86

Participation of a proton–translocating plasma membrane ATPase, acid phosphatase and alkaline phosphatase in ATP degradation by Aspergillus niger extracts. Elzainy TA, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):91–7

Evidence for a glycosylinositolphospholipid–anchored alkaline phosphatase in the aquatic plant Spirodela oligorrhiza. Morita N, et al. **Biochim Biophys Acta** 1996 May 21;1290(1):53–62

Detection of alkaline and acid phosphatases around titanium implants: a light microscopical and histochemical study in rabbits. Piattelli A, et al. **Biomaterials** 1995 Nov; 16(17):1333–8

Reporter enzyme–nitrilotriacetic acid–nickel conjugates: reagents for detecting histidine–tagged proteins. Botting CH, et al. **Biotechniques** 1995 Sep;19(3):362–3

Immunohistochemical localization of the estrogen receptor in human osteoblastic SaOS–2 cells: association of receptor levels with alkaline phosphatase activity. Sutherland MK, et al. **Bone** 1996 Apr;18(4):361–9

Changes in bone mineral density and bone–specific alkaline phosphatase in ovariectomized ewes. Turner AS, et al. **Bone** 1995 Oct;17(4 Suppl):395S–402S

Diurnal rhythm of prostanoid secretion from bone/marrow organ in the rat. Yosipovitch G, et al. **Bone** 1995 Jul; 17(1):79–83

Kinetic studies on the membrane form of intestinal alkaline phosphatase. Costa MH, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2859–62

Phosphate regulates the stability of skeletal alkaline phosphatase activity in human osteosarcoma (SaOS–2) cells without equivalent effects on the level of skeletal alkaline phosphatase immunoreactive protein. Farley JR. **Calcif Tissue Int** 1995 Nov;57(5):371–8

Regulation of human Caco–2 intestinal epithelial brush border enzyme activity by cyclic nucleotides. Basson MD, et al. **Cancer Lett** 1996 Feb 6;99(2):155–60

Alkaline phosphatase distribution in the plasma membrane of uterine epithelial cells is markedly altered during early pregnancy in the rat. Bucci M, et al. **Cell Biol Int** 1995 Nov;19(11):921–8

Is bone alkaline phosphatase an adequate marker of bone metabolism during acute corticosteroid treatment? Peretz A, et al. **Clin Chem** 1996 Jan;42(1):102–3

Elevated liver isoenzymes of alkaline phosphatase and disease activity in patients with Crohn's disease. Vogelsang H, et al. **Digestion** 1996;57(1):11–5

Soluble constituents of the ER lumen are required for GPI anchoring of a model protein. Vidugiriene J, et al. **EMBO J** 1995 Oct 2;14(19):4686–94

Age related changes in biochemical markers of bone metabolism in horses. Price JS, et al. **Equine Vet J** 1995 May;27(3):201–7

Effect of sodium valproate on renal cell brush–border enzymes in rats. Cepelak I, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):673–7

Effect of retinoic acid on the proliferation and alkaline phosphatase activity of osteoblastic MC3T3–E1 cells by modulating the release of local regulators from monocytes. Kaji H, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(5):297–302

Enzymatic and immunological activity of 4000 years aged bone alkaline phosphatase. Weser U, et al. **FEBS Lett** 1995 Nov 20;375(3):280–2

Nonspecific alkaline phosphatase activity can be responsible for staining of NADPH–diaphorase activity in certain non–neural cells. Grozdanovic Z, et al. **Folia Histochem Cytobiol** 1995;33(1):3–10

Immunolocalization of alkaline phosphatase and surfactant–like particle proteins in rat duodenum during fat absorption. Zhang Y, et al. **Gastroenterology** 1996 Feb; 110(2):478–88

Redistribution and fate of colchicine–induced alkaline phosphatase in rat hepatocytes: possible formation of autophagosomes whose membrane is derived from excess plasma membrane. Araki N, et al. **Histochem Cell Biol** 1995 Oct;104(4):257–65

Localization of collagens and alkaline phosphatase activity during mineralization and ossification of human first rib cartilage. Claassen H, et al. **Histochem Cell Biol** 1996 Mar; 105(3):213–9

Dynamic reorganization of the alkaline

phosphatase-containing compartment during chemotactic peptide stimulation of human neutrophils imaged by backscattered electrons. Fernández-Segura E, et al. **Histochem Cell Biol** 1995 Aug;104(2):175-81

Effects of parathyroid hormone related peptide (1-34) and 1,25-dihydroxyvitamin D on bone alkaline phosphatase activity in fetal rat calvaria cultures. Municio MJ, et al. **Horm Metab Res** 1995 Jun;27(6):296-9

Alteration in alkaline phosphatase activity of duodenal tissue following vestibulo-cerebellar modulation. Guha D, et al. **Indian J Exp Biol** 1995 Oct;33(10):788-90

N(omega)-phosphoarginine phosphatase (17 kDa) and alkaline phosphatase as protein arginine phosphatases. Kumon A, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):719-24

Sorting and intracellular trafficking of a glycosylphosphatidylinositol-anchored protein and two hybrid transmembrane proteins with the same ectodomain in Madin-Darby canine kidney epithelial cells. Arreaza G, et al. **J Biol Chem** 1995 Oct 6;270(40):23641-7

Direct kinetic evidence for triplet state energy transfer from Escherichia coli alkaline phosphatase tryptophan 109 to bound terbium. Schlyer BD, et al. **J Biol Chem** 1995 Sep 29;270(39):22890-4

Extracellular matrix synthesized by clonal osteogenic cells is osteoinductive in vivo and in vitro: role of transforming growth factor-beta 1 in osteoblast cell-matrix interaction. Kirk MD, et al. **J Bone Miner Res** 1995 Aug;10(8):1203-8

Ecto-alkaline phosphatase considered as levamisole-sensitive phosphohydrolase at physiological pH range during mineralization in cultured fetal calvaria cells. Anagnostou F, et al. **J Cell Biochem** 1996 Mar 15;60(4):484-94

Synergistic stimulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities by retinoic acid and astroglial factors in immortalized rat brain microvessel endothelial cells. el Hafny B, et al. **J Cell Physiol** 1996 Jun;167(3):451-60

Aberrant properties of alkaline phosphatase in patient fibroblasts correlate with clinical expressivity in severe forms of hypophosphatasia. Fedde KN, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2587-94

Alkaline phosphatase activity in the periodontal ligament and gingiva of the rat molar: its relation to cementum formation. Groeneveld MC, et al. **J Dent Res** 1995 Jul;74(7):1374-81

Effects of different magnitudes of tension-force on alkaline phosphatase activity in periodontal ligament cells. Yamaguchi M, et al. **J Dent Res** 1996 Mar;75(3):889-94

17 beta-oestradiol enhances the stimulatory effect of 1,25-dihydroxyvitamin D3 on alkaline phosphatase activity in human osteosarcoma SaOS-2 cells in a differentiation-dependent manner. Rao LG, et al. **J Endocrinol** 1996 Jan;148(1):181-7

Mechanism of action of cobalt ions on rat osseous plate alkaline phosphatase. Ciancaglini P, et al. **J Inorg Biochem** 1995 Nov 15;60(3):155-62

Kinetic and structural consequences of replacing the aspartate bridge by asparagine in the catalytic metal triad of Escherichia coli alkaline phosphatase. Tibbitts TT, et al. **J Mol Biol** 1996 Apr 5;257(3):700-15

Loss of attachment in the marginal periodontium of the rat incisor under non-inflammatory conditions. Expression of alkaline phosphatase activity. Experimental Oral Biology Group. Groeneveld MC, et al. **J Periodontal Res** 1996 Jan; 31(1):66-72

Cell-bound and extracellular matrix-associated alkaline phosphatase activity in rat periodontal ligament. Experimental Oral Biology Group. Groeneveld MC, et al. **J Periodontal Res** 1996 Jan;31(1):73-9

Regulation of alkaline phosphatase: implications for calcium pyrophosphate dihydrate crystal dissolution and other alkaline phosphatase functions. Shinozaki T, et al. **J Rheumatol** 1996 Apr;23(4):677-83

Variation in 1,25-dihydroxyvitamin D3 regulation of proliferation and alkaline phosphatase activity in late-passage rat osteoblastic cell lines. Murray S, et al. **J Steroid Biochem Mol Biol** 1993 Aug;46(2):227-33

Glial-conditioned medium elevates alkaline phosphatase activity in cultured bovine aortic endothelial cells. Mizuguchi H, et al. **Microvasc Res** 1995 Jul;50(1):129-32

Characterization of the phosphatidylinositol-specific phospholipase C-released form of rat osseous plate alkaline phosphatase and its possible significance on endochondral ossification. Pizauro JM, et al. **Mol Cell Biochem** 1995 Nov 22;152(2):121-9

Congenital muscular dystrophy syndromes distinguished by alkaline and acid phosphatase, merosin, and dystrophin staining. Connolly AM, et al. **Neurology** 1996 Mar; 46(3):810-14

Age-dependent expression of osteoblastic phenotypic markers in normal human osteoblasts cultured long-term in the presence of dexamethasone. Sutherland MS, et al. **Osteoporos Int** 1995;5(5):335-43

Serum osteocalcin and bone and liver alkaline phosphatase isoforms in healthy children and adolescents. Magnusson P, et al. **Pediatr Res** 1995 Dec;38(6):955-61

Reconversion of fosphenytoin in the presence of intestinal alkaline phosphatase. TenHoor CN, et al. **Pharm Res** 1995 Nov;12(11):1806-9

Biochemical characterization of the extracellular phosphatases produced by phosphorus-deprived Chlamydomonas reinhardtii. Quisel JD, et al. **Plant Physiol** 1996 Jul;111(3):839-48

Spinal motor neuron neuroaxonal spheroids in chronic aluminum neurotoxicity contain phosphatase-resistant high molecular weight neurofilament (NFH). Gaytan-Garcia S, et al. **Toxicology** 1996 Apr 15;108(1-2):17-24

A fetal intestinal-type alkaline phosphatase produced in Caco-2 cells. Fukui K, et al. **Tumour Biol** 1996;17(5):320-4

[Improvement of result coherence in clinical enzymology: multicenter study of gamma-glutamyltransferase, alkaline phosphatase and amylase activities] Lessinger JM, et al. **Ann Biol Clin (Paris)** 1995;53(3):147-54 (Eng. Abstr.) **(Fre)**

[Functional analysis of transforming growth factor-beta type II dominant negative receptor] Takarada M. **Kokubyo Gakkai Zasshi** 1996 Jun;63(2):375-86 (Eng. Abstr.) **(Jpn)**

[Disruption of processing of alkaline phosphatase as a result of single amino acid changes affects the composition and metabolism of phospholipids from Escherichia coli, secreting mutant proteins] Kalinin AE, et al. **Biokhimiia** 1996 Jan;61(1):100-9 (Eng. Abstr.) **(Rus)**

[Permeability of the Escherichia coli outer membrane for ethidium ions and periplasmic alkaline phosphatase during increased synthesis of it] Mikhaleva NI, et al. **Biokhimiia** 1995 Jul;60(7):1161-70 (Eng. Abstr.) **(Rus)**

[Alkaline phosphatase isoforms in murine organs after bilateral adrenalectomy] Tsirel'nikov NI, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):262-4 **(Rus)**

[Cellular interactions in the intracellular parasitism of cryptosporidia. I. The effect of Cryptosporidium parvum on the phosphatase activity in the small intestine enterocytes of experimentally infected newborn rat pups] Beier TV, et al. **Tsitologiia** 1995;37(8):829-37 (Eng. Abstr.) **(Rus)**

SECRETION

Enhanced biliary excretion of canalicular membrane enzymes in estrogen-induced and obstructive cholestasis, and effects of different bile acids in the isolated perfused rat liver. Accatino L, et al. **J Hepatol** 1995 Jun;22(6):658-70

URINE

Urinary excretion of renal brush border membrane enzymes in leprosy patients--effect of multidrug therapy. Kohli MM, et al. **Experientia** 1996 Feb 15;52(2):127-30

Significance of elevated urinary human intestinal alkaline phosphatase in Japanese people exposed to environmental cadmium. Kido T, et al. **Toxicol Lett** 1995 Oct; 80(1-3):49-54

[Urinary alkaline phosphatases] Komoda T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:454-9 (20 ref.) **(Jpn)**

[Urinary proteins (focusing on alkaline phosphatases)] Sato T, et al. **Rinsho Byori** 1996 Jul;44(7):622-6 (Eng. Abstr.) **(Jpn)**

ALKALOIDS

Benzo[c]phenanthridine alkaloids sanguinarine and chelerythrine: biological activities and dental care applications. Walterová D, et al. **Acta Univ Palacki Olomuc Fac Med** 1995;139:7-16 (110 ref.)

ANALYSIS

Formation of tetrahydro-beta-carbolines in human saliva. Tsuchiya H, et al. **Biochem Pharmacol** 1995 Dec 22; 50(12):2109-12

Gramine and free amino acids as indicators of fluoride-induced stress in barley and its consequences to insect herbivory. Hautala EL, et al. **Ecotoxicol Environ Saf** 1995 Aug;31(3):238-45

Reversed-phase high-performance liquid chromatography--photodiode-array analysis of alkaloid drugs of forensic interest. Theodoridis G, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23;668(2):253-63

Taxane-specific monoclonal antibodies: measurement of taxol, baccatin III, and "total taxanes" in Taxus brevifolia extracts by enzyme immunoassay. Grothaus PG, et al. **J Nat Prod** 1995 Jul;58(7):1003-14

Determination of datura alkaloids by using chromatographic techniques: a review. Papadoyannis IN. **Nat Toxins** 1995; 3(4):310-6; discussion 317 (17 ref.)

[Effect of ginger-processing on beta-sitosterol and total alkaloid contents in Rhizoma Pinelliae] Wu H, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Nov;20(11):662-4, 702-3 (Eng. Abstr.) **(Chi)**

[A simultaneous determination of evodiamine and rutaecarpine in oriental pharmaceutical decoctions containing Evodia fruit by ion-pair high-performance liquid chromatography] Ueda J, et al. **Yakugaku Zasshi** 1996 Jan;116(1):59-64 (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Cholera toxin accentuates the antagonism by acetylcholine of higenamine-induced positive chronotropy is isolated right atria of mice. Kimura I, et al. **Biol Pharm Bull** 1995 Nov;18(11):1509-12

BIOSYNTHESIS

Uncoupled defense gene expression and antimicrobial alkaloid accumulation in elicited opium poppy cell cultures. Facchini PJ, et al. **Plant Physiol** 1996 Jul;111(3):687-97

[Cell cultured of Macleaya cordata--a producer of antimicrobial benzo[c]phenanthridine alkaloids] Fonin VS, et al. **Antibiot Khimioter** 1995 Aug;40(8):17-22 (Eng. Abstr.) **(Rus)**

BLOOD

Development of a high-performance liquid chromatographic method for the analysis of staurosporine. Gurley LR, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):125-38

CHEMICAL SYNTHESIS

Strategies for the synthesis of some complex antitumor alkaloids. Pandit UK. **Farmaco** 1995 Nov;50(11):749-54 (32 ref.)

Asymmetric syntheses, opioid receptor affinities, and antinociceptive effects of 8-amino-5,9-methanobenzocyclooctenes, a new class of structural analogues of the morphine alkaloids. Schultz AG, et al. **J Med Chem** 1996 May 10;39(10):1956-66

Solution- and solid-state structures of the (-)-n-heptylcarbamate of geneseroline and its hydrochloride salt. Redenti E, et al. **J Pharm Sci** 1995 Sep; 84(9):1126-33

CHEMISTRY

Characterization of tubulin-alkaloid interactions by enzyme-linked immunosorbent assay. Liliom K, et al. **Anal Biochem** 1995 Jun 10;228(1):18-26

Interactions of aristololactam beta-D-glucoside with right-handed and left-handed forms of synthetic deoxyribonucleic acid: spectroscopic and thermodynamic study. Ray A, et al. **Biochemistry** 1996 Jun 11; 35(23):7394-402

Further minor metabolites of staurosporine produced by a Streptomyces longisporoflavus strain. Cai Y, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):519-26

Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. Furet P, et al. **J Comput Aided Mol Des** 1995 Dec; 9(6):465-72

Alkaloids of Datura ferox from Argentina. Vitale AA, et al. **J Ethnopharmacol** 1995 Dec 1;49(2):81-9

NMR and molecular modeling study of the conformations of taxol 2'-acetate in chloroform and aqueous dimethyl sulfoxide solutions. Williams HJ, et al. **J Med Chem** 1996 Mar 29;39(7):1555-9

Diterpenoid alkaloids from Delphinium davisii. Ulubelen A, et al. **J Nat Prod** 1996 Apr;59(4):360-6

Drug-protein conjugates: haptenation of 1-methyl-10 alpha-methoxydihydrolysergol and 5-bromonicotinic acid to albumin for the production of epitope-specific monoclonal antibodies against nicergoline. Gabor F, et al. **J Pharm Sci** 1995 Sep;84(9):1120-5

Biological activities of pyrrolidinoindoline alkaloids from Calycodendron milnei. Saad HE, et al. **Planta Med** 1995 Aug;61(4):313-6

Rearranged taxoids from Taxus yunnanensis [letter] Yue Q, et al. **Planta Med** 1995 Aug;61(4):375-7

[Cytotoxicity of aspidospermane indole alkaloids with a modified tryptamine chain] Lewin G. **J Nat Prod** 1995 Jul; 58(7):1089-91 **(Fre)**

HISTORY

Psychoactive constituents of the genus Sceletium N.E.Br. and other Mesembryanthemaceae: a review. Smith MT, et al. **J Ethnopharmacol** 1996 Mar;50(3):119-30 (67 ref.)

ISOLATION & PURIFICATION

Herquline B, a new platelet aggregation inhibitor produced by Penicillium herquei Fg-372. Enomoto Y, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):50-3

Further brominated bis- and tris-indole alkaloids from the deep-water New Caledonian marine sponge Orina Sp. Bifulco G, et al. **J Nat Prod** 1995 Aug;58(8):1254-60

Antiplatelet of vasorelaxing actions of some benzylisoquinoline and phenanthrene alkaloids. Chen KS, et al. **J Nat Prod** 1996 May;59(5):531-4

Idiospermuline, a trimeric pyrrolidinoindoline alkaloid from the seed of Idiospermum australiense. Kuke RK, et al. **J Nat Prod** 1995 Aug;58(8):1200-8

HIV inhibitory natural products. 26. Quinoline alkaloids from Euodia roxburghiana. McCormick JL, et al. **J Nat Prod** 1996 May;59(5):469-71

13-O-acetylvakhmatine, a new diterpenoid alkaloid from the seeds of Consolida ambigua. Venkateswarlu V, et al. **J Nat Prod** 1995 Oct;58(10):1527-32

Indolopyridoquinazoline alkaloids with antiplatelet aggregation activity from Zanthoxylum integrifoliolum. Sheen WS, et al. **Planta Med** 1996 Apr;62(2):175-6

Bioactive alkaloids from the tropical marine sponge Axinella carteri. Supriyono A, et al. **Z Naturforsch [C]** 1995 Sep-Oct;50(9-10):669-74

[Alkaloids from Penicillium species fungi isolated from food products] Solov'eva TF, et al. **Prikl Biokhim Mikrobiol** 1995 Sep-Oct;31(5):545-50 (Eng. Abstr.) **(Rus)**

METABOLISM

Occurrence of the opiate alkaloid-selective mu3 receptor in

mammalian microglia, astrocytes and Kupffer cells. Dobrenis K, et al. **Brain Res** 1995 Jul 24;686(2):239–48

Alkaloids from frog skins: selective probes for ion channels and nicotinic receptors. Daly JW. **Braz J Med Biol Res** 1995 Oct;28(10):1033–42 (28 ref.)

Ganoine formation in the scales of primitive actinopterygian fishes, lepisosteids and polypterids. Sire JY. **Connect Tissue Res** 1995;33(1–3):213–22

UV–B– and oxidative stress–induced increase in nicotinamide and trigonelline and inhibition of defensive metabolism induction by poly(ADP–ribose)polymerase inhibitor in plant tissue. Berglund T, et al. **FEBS Lett** 1996 Feb 12; 380(1–2):188–93

Further minor metabolites of staurosporine produced by a Streptomyces longisporoflavus strain. Cai Y, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):519–26

Characterization and mechanism of the berberine bridge enzyme, a covalently flavinylated oxidase of benzophenanthridine alkaloid biosynthesis in plants. Kutchan TM, et al. **J Biol Chem** 1995 Oct 13; 270(41):24475–81

Some ethnopharmacological notes on African hallucinogens. De Smet PA. **J Ethnopharmacol** 1996 Mar;50(3):141–6 (50 ref.)

Effects of various isoquinoline alkaloids on in vitro 3H–dopamine uptake by rat striatal synaptosomes. Protais P, et al. **J Nat Prod** 1995 Oct;58(10):1475–84

Chelidonium majus L.: components with in vitro affinity for the GABAA receptor. Positive cooperation of alkaloids. Häberlein H, et al. **Planta Med** 1996 Jun;62(3):227–31

Overexpression of a tryptophan decarboxylase cDNA in Catharanthus roseus crown gall calluses results in increased tryptamine levels but not in increased terpenoid indole alkaloid production. Goddijn OJ, et al. **Transgenic Res** 1995 Sep;4(5):315–23

PHARMACOKINETICS

Horseradish peroxidase permeability across rat nasal mucosa in selective stimulation of substance P innervation with capsaicin. Jeon S, et al. **Ann Otol Rhinol Laryngol** 1995 Nov;104(11):895–8

[Pharmacological effects of hordenine] Hapke HJ, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Jun;102(6):228–32 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Morphological studies on rat's liver after a ten–day treatment with Chelidonium majus L. alkaloid thiophosphoric acid derivative (Ukraine). Jodłowska–Jędrych B. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:119–24

In vitro cytotoxic activity of two potential anticancer drugs isolated from Strychnos: strychnopentamine and usambarensine. Bonjean KA, et al. **Anticancer Res** 1996 May–Jun;16(3A):1129–37

Effect of cepharanthin and hyperthermia on the intracellular accumulation of adriamycin in the NIH3T3 cell lines transfected with oncogenes accompanied with pSV2neo vector. Gaoi XS, et al. **Anticancer Res** 1995 Sep–Oct; 15(5B):1991–6

Antifungal activity of new compounds from Nepeta leucophylla and Nepeta clarkei. Saxena J, et al. **Appl Environ Microbiol** 1996 Feb;62(2):702–4

Endoplasmic reticulum kifunensine–resistant alpha–mannosidase is enzymatically and immunologically related to the cytosolic alpha–mannosidase. Weng S, et al. **Arch Biochem Biophys** 1996 Jan 1;325(1):113–23

Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction. Mann K, et al. **Arch Sex Behav** 1996 Feb;25(1):1–16

UCN–01, 7–hydroxyl–staurosporine, inhibits kinase activity of cyclin–dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Kawakami K, et al. **Biochem Biophys Res Commun** 1996 Feb 27; 219(3):778–83

Staurosporine potentiates cAMP–mediated promoter activity of the vasoactive intestinal polypeptide gene in rat pheochromocytoma PC12 cells. Sasaki K, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1114–20

Decreased accumulation and dephosphorylation of the mitosis–specific form of nucleophosmin/B23 in staurosporine–induced chromosome decondensation. Lu YY, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):321–7

Natural–product inhibitors of human DNA ligase I. Tan GT, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):993–1000

Staurosporine–induced thymocyte apoptosis is inhibited by herbimycin A, a specific inhibitor of protein tyrosine kinase. Azuma Y, et al. **Biochem Mol Biol Int** 1995 Nov; 37(4):635–43

Biphasic effect of staurosporine on thymocyte apoptosis. Suzuki K, et al. **Biochem Mol Biol Int** 1995 Apr; 35(5):1085–92

Effects of benzophenanthridine alkaloids on the phosphorylation of an approximately 44 kDa protein present in a mitochondrial fraction of the rat heart. Lombardini JB, et al. **Biochem Pharmacol** 1996 Jan 26; 51(2):151–7

Inhibitory effect of alkaloids extracted from the stem bark of Hunteria zeylanica on 5–lipoxygenase activity in vitro. Reanmongkol W, et al. **Biol Pharm Bull** 1995 Jun; 18(6):910–2

The biological activity of cyclic bis(bibenzyls): a rational approach. Keseru GM, et al. **Bioorg Med Chem** 1995 Nov; 3(11):1511–7

Enhancing effect of staurosporine on NO production in rat peritoneal macrophages via a protein kinase C–independent mechanism. Sowa G, et al. **Br J Pharmacol** 1995 Sep; 116(2):1711–2

Neonatal capsaicin treatment (NCT) alters the metabolic activity of the rat somatosensory cortex in response to mechanical deflection of the mystacial vibrissae. Wu CC, et al. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):62–8

Interphase and M–phase oral KB carcinoma cells are targetted in staurosporine–induced apoptosis. Swe M, et al. **Cancer Lett** 1996 Jul 12;104(2):145–52

A brief staurosporine treatment of mitotic cells triggers premature exit from mitosis and polyploid cell formation. Hall LL, et al. **Cancer Res** 1996 Aug 1;56(15):3551–9

Staurosporine induces a complete program of terminal differentiation in neoplastic mouse keratinocytes via activation of protein kinase C. Stanwell C, et al. **Carcinogenesis** 1996 Jun;17(6):1259–65

Staurosporine enhances Ca2+ entry induced by depletion of intracellular Ca2+ stores in rat parotid acinar cells. Tojyo Y, et al. **Cell Calcium** 1995 Jan;17(1):32–40

Apoptosis in 7–hydroxystaurosporine–treated T lymphoblasts correlates with activation of cyclin–dependent kinases 1 and 2. Wang Q, et al. **Cell Growth Differ** 1995 Aug; 6(8):927–36

Effects of tetrandrine and chlorpromazine on synthesis of collagen and hyaluronic acid in cultured human lung fibroblasts. Liu HL, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):412–4

No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. Vahlhaus C, et al. **Circ Res** 1996 Sep;79(3):407–14

Antihypertensive effects, determined by a telemetry method, of trichloromethiazide and 7–O–ethylfangchinoline, a derivative of tetrandrine, in spontaneously hypertensive rats. Kawashima K, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S300–1

Control of 1,25–dihydroxyvitamin D3 receptor–mediated enhancement of osteocalcin gene transcription: effects of perturbing phosphorylation pathways by okadaic acid and staurosporine. Desai RK, et al. **Endocrinology** 1995 Dec; 136(12):5685–93

Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Meggio F, et al. **Eur J Biochem** 1995 Nov 15;234(1):317–22

Effect of berbamine on cytosolic phospholipase A2 activation in rabbit platelets. Akiba S, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):343–50

Selectivity of action of staurosporine on Ca2+ movements and contractions in vascular smooth muscles. Asano M, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):693–701

Staurosporine inhibits inositol phosphate formation in bovine adrenal medullary cells. Bunn SJ, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):227–36

Cryptolepine–induced vasodilation in the isolated perfused kidney of the rat: role of G–proteins, K+ and Ca2+ channels. Oyekan AO. **Eur J Pharmacol** 1995 Oct 4; 285(1):1–9

Psycholeine, a natural alkaloid extracted from Psychotria oleoides, acts as a weak antagonist of somatostatin. Rasolonjanahary R, et al. **Eur J Pharmacol** 1995 Oct 4; 285(1):19–23

BCL–2 and MCL–1 expression in Chinese hamster ovary cells inhibits intracellular acidification and apoptosis induced by staurosporine. Reynolds JE, et al. **Exp Cell Res** 1996 Jun 15;225(2):430–6

Staurosporine–induced neuronal apoptosis. Koh JY, et al. **Exp Neurol** 1995 Oct;135(2):153–9

Modulation of drug–induced apoptosis in a human B–lymphoma cell line (HT58). Mihalik R, et al. **Immunol Lett** 1995 Nov;48(1):17–21

The modulatory effect of tetrandrine on the CD23, CD25 and HLA–DR expression and cytokine production in different groups of asthmatic patients. Tsai JJ, et al. **Int Arch Allergy Immunol** 1995 Oct;108(2):183–8

Endocrine and metabolic response to muscarinic stimulation and inhibition in the ruminant: effects of slaframine. Chapa AM, et al. **J Anim Sci** 1995 Dec;73(12):3673–80

Influence of duodenal slaframine infusion on site of nutrient disappearance from the digestive tract of steers fed a high–concentrate diet. Streeter MN, et al. **J Anim Sci** 1995 Oct;73(10):3103–10

Further minor metabolites of staurosporine produced by a Streptomyces longisporoflavus strain. Cai Y, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):519–26

The effect of cryptolepine on the morphology and survival of Escherichia coli, Candida albicans and Saccharomyces cerevisiae. Sawer IK, et al. **J Appl Bacteriol** 1995 Sep; 79(3):314–21

Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO–1– and staurosporine–induced cell death. Mehlen P, et al. **J Biol Chem** 1996 Jul 12;271(28):16510–4

D4–GDI, a substrate of CPP32, is proteolyzed during Fas–induced apoptosis. Na S, et al. **J Biol Chem** 1996 May 10;271(19):11209–13

Staurosporine inhibits interferon alpha–induced gene expression in Friend erythroleukemia cells through a PKC independent pathway. Percario ZA, et al. **J Biol Regul Homeost Agents** 1995 Jan–Mar;9(1):7–14

Role of Ced–3/ICE–family proteases in staurosporine–induced programmed cell death. Jacobsen MD, et al. **J Cell Biol** 1996 Jun;133(5):1041–51

Comparative study of the cytostatic effects of Oliphen and Ukrain. Voltchek I, et al. **J Chemother** 1996 Apr;8(2):144–6

Anti–lipase activity of Kampo formulations, coptidis rhizoma and its alkaloids against Propionibacterium acnes. Higaki S, et al. **J Dermatol** 1996 May;23(5):310–4

Inhibition of copper/quinoprotein amine oxidases from Aspergillus niger by benzophenanthridine alkaloids. Luhová L, et al. **J Enzym Inhib** 1995;9(4):295–302

Analgesic activity of Psychotria colorata (Willd ex R. & S.) Muell. Arg. alkaloids. Elisabetsky E, et al. **J Ethnopharmacol** 1995 Oct;48(2):77–83

Staurosporine induces a sequential program of mouse keratinocyte terminal differentiation through activation of PKC isozymes. Stanwell C, et al. **J Invest Dermatol** 1996 Mar;106(3):482–9

Comparative study of the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa. Chiou WF, et al. **J Nat Prod** 1996 Apr;59(4):374–8

HIV inhibitory natural products. 26. Quinoline alkaloids from Euodia roxburghiana. McCormick JL, et al. **J Nat Prod** 1996 May;59(5):469–71

UCN–01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. Wang Q, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):956–65

Staurosporine induces astrocytic phenotypes and differential expression of specific PKC isoforms in C6 glial cells. Kronfeld I, et al. **J Neurochem** 1995 Oct;65(4):1505–14

Staurosporine induces programmed cell death in embryonic neurons and activation of the ceramide pathway. Wiesner DA, et al. **J Neurochem** 1996 Apr;66(4):1418–25

Staurosporine blocks evoked release of FM1–43 but not acetylcholine from frog motor nerve terminals. Henkel AW, et al. **J Neurosci** 1995 Dec;15(12):8246–58

Feeding of potato, tomato and eggplant alkaloids affects food consumption and body and liver weights in mice. Friedman M, et al. **J Nutr** 1996 Apr;126(4):989–99

Whole mouth microbiota effects following subgingival delivery of sanguinarium. Godowski KC, et al. **J Periodontol** 1995 Oct;66(10):870–7

Cepharanthin, a multidrug resistant modifier, is a substrate for P–glycoprotein. Hirai M, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):73–8

Antioxidant activity of tetrandrine and its inhibition of quartz–induced lipid peroxidation. Shi X, et al. **J Toxicol Environ Health** 1995 Oct;46(2):233–48

Effects of yew alkaloids and related compounds on guinea–pig isolated perfused heart and papillary muscle. Alloatti G, et al. **Life Sci** 1996;58(10):845–54

Plant alkaloids, tetrandrine and hernandezine, inhibit calcium–depletion stimulated calcium entry in human and bovine endothelial cells. Low AM, et al. **Life Sci** 1996; 58(25):2327–35

Staurosporine inhibits the effects of leukotrienes C4 and D4 in isolated guinea pig heart and trachea. Schäfer S, et al. **Methods Find Exp Clin Pharmacol** 1995 Sep;17(7):469–76

Stimulation of nuclear import by simian virus 40–transformed cell extracts is dependent on protein kinase activity. Feldherr C, et al. **Mol Cell Biol** 1995 Dec;15(12):7043–9

Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance. Zhang X, et al. **Mol Pharmacol** 1996 Feb;49(2):288–94

Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug–resistant cells. Kisara S, et al. **Oncol Res** 1995; 7(3–4):191–200

Hypothermic effect of harmala alkaloid in rats: involvement of serotonergic mechanism. Abdel–Fattah AF, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):421–6

Effect of (–)–cathinone, a psychoactive alkaloid from khat (Catha edulis Forsk.) and caffeine on sexual behaviour in rats. Taha SA, et al. **Pharmacol Res** 1995 May; 31(5):299–303

In vitro biological activities of alkaloids from Cryptolepis sanguinolenta. Cimanga K, et al. **Planta Med** 1996 Feb; 62(1):22–7

Chelidonium majus L.: components with in vitro affinity for the GABAA receptor. Positive cooperation of alkaloids. Häberlein H, et al. **Planta Med** 1996 Jun;62(3):227–31

Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. Kobayashi Y, et al. **Planta Med** 1995 Oct; 61(5):414–8

Inhibitory effects of protoberberine alkaloids from the roots of Coptis japonica on catecholamine biosynthesis in PC12 cells. Lee MK, et al. **Planta Med** 1996 Feb;62(1):31–4

Lipoxygenase inhibition and antioxidant properties of protoberberine and aporphine alkaloids isolated from Mahonia aquifolium [letter] Mišík V, et al. **Planta Med** 1995 Aug;61(4):372–3

Anti–herpes virus activity of aporphine alkaloids. Montanha JA, et al. **Planta Med** 1995 Oct;61(5):419–24

Screening for in vitro antifungal activities of some indole alkaloids [letter] Quetin–Leclercq J, et al. **Planta Med** 1995 Oct;61(5):475–7

Studies on the inhibitory effects of some acridone alkaloids on Epstein–Barr virus activation [letter] Takemura Y, et al. **Planta Med** 1995 Aug;61(4):366–8

Naturally occurring somatostatin and vasoactive intestinal

peptide inhibitors. Isolation of alkaloids from two marine sponges. Vassas A, et al. **Planta Med** 1996 Feb;62(1):28–30

Lack of calcium–antagonizing activity of dehydroevodiamine on the chronotropic and inotropic activities of mouse isolated atria. Wong KK. **Planta Med** 1996 Jun;62(3):246–9

G1 arrest and down–regulation of cyclin E/cyclin–dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Schnier JB, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5941–6

Induction of apoptosis in prostatic tumor cell line DU145 by staurosporine, a potent inhibitor of protein kinases. Zhang H, et al. **Prostate** 1996 Aug;29(2):69–76

Inhibition of chemomigration of a human prostatic carcinoma cell (TSU–pr1) line by inhibition of epidermal growth factor receptor function. Zolfaghari A, et al. **Prostate** 1996 Apr;28(4):232–8

Dorsal periaqueductal gray–induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Jenck F, et al. **Psychiatry Res** 1995 Jul 28;57(2):181–91

Calcium antagonistic actions of tetrandrine depend on cell types. Takemura H, et al. **Res Commun Mol Pathol Pharmacol** 1995 Oct;90(1):59–68

[A dynamic study on inhibitory effect of palustrine on mg2(+)–ATpase and Ca2(+)–ATPase of brain synaptic vesicle membrane in rats] Ji Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Jan;21(1):42–5, 64 (Eng. Abstr.) **(Chi)**

[Effects of neferine on the 45Ca–influx and efflux induced by activation of alpha–1 adrenoceptor of vascular smooth muscle] Wang Y. **Chung Kuo Chung Yao Tsa Chih** 1996 Feb;21(2):117–8, inside back cover (Eng. Abstr.) **(Chi)**

[Effect of tetrandrine on pulmonary hypertension induced by monocrotaline in rats] Zhang S, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):378–80 (Eng. Abstr.) **(Chi)**

[Effects of neferine and its combination with taurine on platelet aggregation and experimental thrombosis in rats] Huang HL, et al. **Yao Hsueh Hsueh Pao** 1995;30(7):486–90 (Eng. Abstr.) **(Chi)**

[Pharmacological effects of hordenine] Hapke HJ, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Jun;102(6):228–32 (Eng. Abstr.) **(Ger)**

[Modification to the functional status of the hemostatic system with the use of berberine sulfate] Ziablitskiĭ VM, et al. **Eksp Klin Farmakol** 1996 Jan–Feb;59(1):37–9 (Eng. Abstr.) **(Rus)**

[A disorder in the energy–conversion processes in the liver mitochondria of rats under the action of sanguinarin and AFMA] Beliaeva TN, et al. **Tsitologiia** 1995;37(3):237–48 (Eng. Abstr.) **(Rus)**

POISONING

Ingestion of poison hemlock (Conium maculatum). Frank BS, et al. **West J Med** 1995 Dec;163(6):573–4

THERAPEUTIC USE

Treatment for potency problems with Afrodor 2000. Baumbusch F, et al. **Acta Chir Hung** 1995–96;35(1–2):87–92

High–dose biscoclaurine alkaloids together with prednisolone raise platelet counts in chronic idiopathic thrombocytopenic purpura [letter] Saito N, et al. **Am J Hematol** 1996 Feb;51(2):173–4

Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction. Mann K, et al. **Arch Sex Behav** 1996 Feb;25(1):1–16

A biochemical study on combined treatment of experimental silicosis with tetradrine–PVNO and tetradrine–QOHP in rats. Yu L, et al. **Biomed Environ Sci** 1995 Sep;8(3):265–8

Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P–glycoprotein. Quesada AR, et al. **Br J Cancer** 1996 Sep;74(5):677–82

Calcium channel blockers in cirrhotic patients with portal hypertension. Li D, et al. **Chin Med J (Engl)** 1995 Nov; 108(11):803–8

Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN–01, a selective protein kinase C inhibitor. Pollack IF, et al. **J Neurosurg** 1996 Jun;84(6):1024–32

Plasmodium berghei mouse model: antimalarial activity of new alkaloid salts and of thiosemicarbazone and acridine derivatives. Loiseau PM, et al. **Trop Med Int Health** 1996 Jun;1(3):379–84

[Effects of guan–fu base a on experimental cardiac arrhythmias and myocardial contractility] Dong YL, et al. **Yao Hsueh Hsueh Pao** 1995;30(8):577–82 (Eng. Abstr.) **(Chi)**

[Protective effects of tetrandrine on ischemic myocardia in anesthetized dogs] Yao WX, et al. **Yao Hsueh Hsueh Pao** 1995;30(9):651–4 (Eng. Abstr.) **(Chi)**

[Use of antimicrobial materials containing sangviritrin in the prevention of nosocomial infections] Sedov AV, et al. **Gig Sanit** 1996 Mar–Apr;(2):36–8 **(Rus)**

[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525–9 (29 ref.) **(Spa)**

TOXICITY

Effect of quaternary benzo[c]phenanthridine alkaloids sanguinarine, chelerythrine and fagaronine on some mammalian cells. Vavrečková C, et al. **Acta Univ Palacki Olomuc Fac Med** 1994;138:7–10

Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P–glycoprotein in multidrug–resistant MCF–7/Adr cells. Budworth J, et al. **Br J Cancer** 1996 May;73(9):1063–8

Evaluation of the cytotoxic mechanism mediated by baccatin III, the synthetic precursor of taxol. Pengsuparp T, et al. **Chem Biol Interact** 1996 Aug 14;101(2):103–14

Physiological responses of rats fed loline and ergot alkaloids from endophyte–infected tall fescue. Jackson JA, et al. **Drug Chem Toxicol** 1996;19(1–2):85–96

A 90–day feeding study of lupin (Lupinus angustifolius) flour spiked with lupin alkaloids in the rat. Butler WH, et al. **Food Chem Toxicol** 1996 Jun;34(6):531–6

The mutagenicities of alkaloids and N–nitrosoguvacoline from betel quid. Wang CK, et al. **Mutat Res** 1996 Aug 8;360(3):165–71

Anti–nutritional factors of Datura in feedstuffs. Piva G, et al. **Nat Toxins** 1995;3(4):238–41; discussion 242 (24 ref.)

Directly toxic effects of plant chemicals which may occur in human and animal foods. Seawright AA. **Nat Toxins** 1995;3(4):227–32; discussion 242 (54 ref.)

Effect of alkaloid toxins from tropical marine sponges on membrane sodium currents. Rentas AL, et al. **Toxicon** 1995 Apr;33(4):491–7

The effect of feeding dried tomato vines to beef cattle. Shlosberg A, et al. **Vet Hum Toxicol** 1996 Apr;38(2):135–6

Bioactive alkaloids from the tropical marine sponge Axinella carteri. Supriyono A, et al. **Z Naturforsch [C]** 1995 Sep–Oct;50(9–10):669–74

ALKALOSIS

COMPLICATIONS

Severe alkalemia, hyponatremia, and diabetic ketoacidosis in an alcoholic man. Bustamante EA, et al. **Chest** 1996 Jul; 110(1):273–5

Apparent mineralocorticoid excess due to 11 beta–hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation. Kitanaka S, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):353–9 (33 ref.)

[Severe metabolic alkalosis with a consciousness disorder] Niederstadt C, et al. **Dtsch Med Wochenschr** 1996 Aug 2; 121(31–32):978–82 (19 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Metabolic alkalosis with hypo–electrolytaemia or pseudo–Bartter syndrome as a presentation of cystic fibrosis in infancy. Discription of three cases [letter] Escobar Castro H, et al. **Eur J Pediatr** 1995 Oct;154(10):868–9

[Bouveret syndrome—a rare gallstone complication] Hürlimann R, et al. **Z Gastroenterol** 1995 Aug;33(8):445–8 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Hydrochloric acid infusion for treatment of severe metabolic alkalosis in a neonate. Nasimi A, et al. **Clin Pediatr (Phila)** 1996 May;35(5):271–2

ETIOLOGY

Urinary chloride excretion distinguishes between renal and extrarenal metabolic alkalosis. Mersin SS, et al. **Eur J Pediatr** 1995 Dec;154(12):979–82

Severe metabolic alkalosis due to choledochoduodenal fistula [letter] Altun B, et al. **Nephron** 1995;71(1):116–7

METABOLISM

Metabolic alkalosis decreases bone calcium efflux by suppressing osteoclasts and stimulating osteoblasts. Bushinsky DA. **Am J Physiol** 1996 Jul;271(1 Pt 2):F216–22

Effects of chronic Cl depletion alkalosis on proximal tubule transport and renal production of ammonium. DuBose TD Jr, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):F508–14

Intracellular alkalosis during hypoxia in newborn mouse brain in the presence of systemic acidosis: a phosphorus magnetic resonance spectroscopic study. Mitsufuji N, et al. **Brain Dev** 1995 Jul–Aug;17(4):256–60

Bicarbonate transport in collecting duct segments during chloride–depletion alkalosis. Galla JH, et al. **Kidney Int** 1995 Jul;48(1):52–5

The cellular basis of metabolic alkalosis. Sabatini S. **Kidney Int** 1996 Mar;49(3):906–17 (88 ref.)

PATHOLOGY

Metabolic alkalosis decreases bone calcium efflux by suppressing osteoclasts and stimulating osteoblasts. Bushinsky DA. **Am J Physiol** 1996 Jul;271(1 Pt 2):F216–22

Rapid induction of hyperplasia in vitro in rat bladder explants by elevated sodium ion concentrations and alkaline pH. Storer RD, et al. **Toxicol Appl Pharmacol** 1996 Jun; 138(2):219–30

PHYSIOPATHOLOGY

[Metabolic alkalosis after heart surgery interventions in childhood] Schranz D, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S65–8 **(Ger)**

ULTRASONOGRAPHY

[Renovascular hypertension due to unilateral renal artery stenosis with hypokalemic alkalosis, the salt–losing syndrome and reversible hyperechogenicity of the contralateral kidney. A study of 2 infants] Castelló Girona F, et al. **An Esp Pediatr** 1996 Jul;45(1):49–52 (14 ref.) (Eng. Abstr.) **(Spa)**

URINE

Urinary chloride excretion distinguishes between renal and extrarenal metabolic alkalosis. Mersin SS, et al. **Eur J Pediatr** 1995 Dec;154(12):979–82

ALKALOSIS, RESPIRATORY

ETIOLOGY

Urea cycle disorders: diagnosis, pathophysiology, and therapy. Brusilow SW, et al. **Adv Pediatr** 1996;43:127–70 (59 ref.)

Severe hyperventilation and respiratory alkalosis during pressure–support ventilation: report of a hazard. Chui PT, et al. **Anaesthesia** 1995 Nov;50(11):978–80

Respiratory alkalosis caused by assist control mechanical ventilation in a patient with a bronchopleural fistula. Pruitt RF, et al. **J Trauma** 1996 Mar;40(3):481–2

PHYSIOPATHOLOGY

Decrease in oxygen cost of contractility during hypocapnic alkalosis in canine hearts. Onishi K, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H1905–13

ALKANES

A multipurpose MRI phantom based on a reverse micelle solution. Roe JE, et al. **Magn Reson Med** 1996 Jan; 35(1):136–41

ANALYSIS

n–Alkanes and polynuclear aromatic hydrocarbons in fresh–frozen and precooked–frozen mussels. Hernández JE, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):461–8

A whiff of new interest in alkane evolution. Lison D. **Hum Exp Toxicol** 1995 Oct;14(10):854–5

Plant wax components: a new approach to estimating intake and diet composition in herbivores. Dove H, et al. **J Nutr** 1996 Jan;126(1):13–26 (62 ref.)

CHEMICAL SYNTHESIS

New 5–HT3 (serotonin–3) receptor antagonists. IV. Synthesis and structure–activity relationships of azabicycloalkaneacetamide derivatives. Kato M, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug;43(8):1351–7

Synthesis and structure–activity studies of a series of 1–oxa–8–azaspiro[4.5]decanes as M1 muscarinic agonists. Tsukamoto S, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):842–52

CHEMISTRY

Platelet aggregation inhibiting and anticoagulant effects of oligoamines, Part 33. From tetradecane– to octacosanediamines. Rehse K, et al. **Arch Pharm (Weinheim)** 1996 Apr;329(4):191–6

Two–photon induced fluorescence of linear alkanes; a possible intrinsic lipid probe. Gryczynski I, et al. **Biophys Chem** 1996 Jan;57(2–3):291–5

ISOLATION & PURIFICATION

[Chemical constituents of Astragalus chinensis L.] Xu Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):296–7, 320 (Eng. Abstr.) **(Chi)**

METABOLISM

Characterization of the n–alkane and fatty acid hydroxylating cytochrome P450 forms 52A3 and 52A4. Scheller U, et al. **Arch Biochem Biophys** 1996 Apr 15;328(2):245–54

Isolation and characterization of a novel oxygenase that catalyzes the first step of n–alkane oxidation in Acinetobacter sp. strain M–1. Maeng JH, et al. **J Bacteriol** 1996 Jul;178(13):3695–700

Rhamnolipid biosurfactant enhancement of hexadecane biodegradation by Pseudomonas aeruginosa. Shreve GS, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):331–7

PHARMACOKINETICS

Inhalation experiments with mixtures of hydrocarbons. Experimental design, statistics and interpretation of kinetics and possible interactions. Eide I, et al. **Arch Toxicol** 1996; 70(7):397–404

Oil–induced arthritis in DA rats: tissue distribution of arthritogenic 14C–labelled hexadecane. Kleinau S, et al. **Int J Immunopharmacol** 1995 May;17(5):393–401

PHARMACOLOGY

Induction of toluene oxidation activity in Pseudomonas mendocina KR1 and Pseudomonas sp. strain ENVPC5 by chlorinated solvents and alkanes. McClay K, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3479–81

The CYP52 multigene family of Candida maltosa encodes functionally diverse n-alkane-inducible cytochromes P450. Zimmer T, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):784-9

Synthesis and structure-activity studies of a series of 1-oxa-8-azaspiro[4.5]decanes as M1 muscarinic agonists. Tsukamoto S, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):842-52

A study of the structural basis of the ability of chlorinated alkanes and alkenes to induce aneuploidy and toxicity in the mold Aspergillus nidulans. Rosenkranz HS, et al. **Mutat Res** 1996 Jul 22;354(2):183-93

TOXICITY

Light catalytically cracked naphtha: subchronic toxicity of vapors in rats and mice and developmental toxicity screen in rats. Dalbey WE, et al. **J Toxicol Environ Health** 1996 Jan;47(1):77-91

[The effect of benzine and formaldehyde on the prenatal development of rats with induced iron trace-element disorder] Senichenkova IN, et al. **Ontogenez** 1996 Mar-Apr;27(2):108-13 (Eng. Abstr.) **(Rus)**

ALKANESULFONATES

METABOLISM

Active microtubule-dependent secretion of a fluorescent bile salt derivative in skate hepatocyte clusters. Miller DS, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):G887-96

The in vitro methylation of DNA by a minor groove binding methyl sulfonate ester. Encell L, et al. **Chem Res Toxicol** 1996 Apr-May;9(3):563-7

PHARMACOLOGY

Detoxification of paraquat poisoning: effects of carbohydrate sulfate, alkylsulfate and alkylsulfonate on active oxygen. Tsuchiya T, et al. **Biol Pharm Bull** 1995 Dec;18(12):1700-4

THERAPEUTIC USE

Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease [see comments] Kisilevsky R, et al. **Nat Med** 1995 Feb;1(2):143-8. Comment in: Nat Med 1995 Feb;1(2):120-2.

ALKANESULFONIC ACIDS

CHEMISTRY

Polyethylene sulfonate: a tight-binding inhibitor of 6-phosphogluconate dehydrogenase of Cryptococcus neoformans. Niehaus WG, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):325-30

In situ polymerization of pyrrole in animal tissue in the formation of hybrid biomaterials. Khor E, et al. **Biomaterials** 1995 May;16(8):657-61

Sulfobacins A and B, novel von Willebrand factor receptor antagonists. II. Structural elucidation. Kamiyama T, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):929-36

ISOLATION & PURIFICATION

Sulfobacins A and B, novel von Willebrand factor receptor antagonists. I. Production, isolation, characterization and biological activities. Kamiyama T, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):924-8

ALKAPTONURIA

COMPLICATIONS

Ochronotic arthropathy: rapid destructive hip osteoarthritis associated with metabolic disease. Corrà T, et al. **Clin Rheumatol** 1995 Jul;14(4):474-7

Ochronosis and alkaptonuria. Case report and literature review. Kneebone TS, et al. **J Am Podiatr Med Assoc** 1995 Oct;85(10):554-5 (7 ref.)

DRUG THERAPY

Symptomatic response to ascorbic acid. Pradeep JK, et al. **Br J Urol** 1996 Feb;77(2):319-20

ENZYMOLOGY

Purification of the homogentisic acid oxidase from mammalian liver. Hudecová S, et al. **Int J Biochem Cell Biol** 1995 Dec;27(12):1357-63

GENETICS

The molecular basis of alkaptonuria [see comments] Fernández-Cañón JM, et al. **Nat Genet** 1996 Sep; 14(1):19-24. Comment in: Nat Genet 1996 Sep;14(1):5-6.

Alkaptonuria: such a long journey [news; comment] Scriver CR. **Nat Genet** 1996 Sep;14(1):5-6. Comment on: Nat Genet 1996 Sep;14(1):19-24.

RADIOGRAPHY

Imaging in alkaptonuria. Misson N, et al. **J Belge Radiol** 1996 Apr;79(2):72-3

ALKENES

BLOOD

Marked enrichment of the alkenylacyl subclass of plasma ethanolamine glycerophospholipid with eicosapentaenoic acid in human subjects consuming a fish oil concentrate. Wilkinson T, et al. **Lipids** 1996 Mar;31 Suppl:S211-5

CHEMICAL SYNTHESIS

A versatile and convenient protocol for the stereocontrolled synthesis of olefinic insect pheromones. Vasil'ev AA, et al. **Bioorg Med Chem** 1996 Mar;4(3):389-400

CHEMISTRY

Conformational disorder in unsaturated phospholipids by FTIR spectroscopy. Chia NC, et al. **Biochim Biophys Acta** 1996 Sep 4;1283(2):141-50

Conformational aspects of glutathione conjugates of chlorinated alkenes: a computational study. Shim JY, et al. **Chem Res Toxicol** 1996 Apr-May;9(3):667-75

Kinetics and mechanism of photocycloaddition of deoxyuridines to 2,3-dimethyl-2-butene. Haga N, et al. **Photochem Photobiol** 1995 Jun;61(6):557-62

METABOLISM

Purification and characterization of taxa-4(5),11(12)-diene synthase from Pacific yew (Taxus brevifolia) that catalyzes the first committed step of taxol biosynthesis. Hezari M, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):437-44

Species-dependent differences in biotransformation pathways of 2-methylpropene (isobutene). Cornet M, et al. **Chem Res Toxicol** 1995 Oct-Nov;8(7):987-92

Genetic control of male cuticular hydrocarbons in Drosophila melanogaster. Ferveur JF, et al. **Genet Res** 1996 Jun;67(3):211-8

Carbon dioxide fixation in the metabolism of propylene and propylene oxide by Xanthobacter strain Py2. Small FJ, et al. **J Bacteriol** 1995 Nov;177(21):6170-5

The high activity of rat glutathione transferase 8-8 with alkene substrates is dependent on a glycine residue in the active site. Björnestedt R, et al. **J Biol Chem** 1995 Dec 15;270(50):29705-9

Effect of the hepatocarcinogenic peroxisome proliferator Wy-14,643 in vivo: no increase in ethane exhalation or hepatic conjugated dienes. Conway JG, et al. **Toxicol Appl Pharmacol** 1995 Dec;135(2):229-36

PHARMACOKINETICS

In vitro biotransformation of 2-methylpropene (isobutene) in rat lung tissue in comparison with liver tissue. Cornet M, et al. **Arch Toxicol** 1995;70(1):64-7

PHARMACOLOGY

Effects of novel 3,4-bisphenylhex(3)enes on cell proliferation in malignant and normal cells. Pechan R, et al. **Cancer Lett** 1996 Jan 2;98(2):163-8

A study of the structural basis of the ability of chlorinated alkanes and alkenes to induce aneuploidy and toxicity in the mold Aspergillus nidulans. Rosenkranz HS, et al. **Mutat Res** 1996 Jul 22;354(2):183-93

TOXICITY

Ovarian toxicity of 4-vinylcyclohexene and related olefins in B6C3F1 mice: role of diepoxides. Doerr JK, et al. **Chem Res Toxicol** 1995 Oct-Nov;8(7):963-9

7-ALKOXYCOUMARIN O-DEALKYLASE

ANALYSIS

A microfluorometric method for measuring ethoxycoumarin-O-deethylase activity on individual Drosophila melanogaster abdomens: interest for screening resistance in insect populations. de Sousa G, et al. **Anal Biochem** 1995 Jul 20;229(1):86-91

ANTAGONISTS & INHIBITORS

Mechanism-based inactivation of cytochrome P450 2B1 by 9-ethynylphenanthrene. Roberts ES, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):295-302

Mechanistic studies of 9-ethynylphenanthrene-inactivated cytochrome P450 2B1. Roberts ES, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):303-12

Inhibition of P-450 by aucubin: is the biological activity of aucubin due to its glutaraldehyde-like aglycone? Bartholomaeus A, et al. **Toxicol Lett** 1995 Oct; 80(1-3):75-83

BIOSYNTHESIS

Induction of cytochrome P450-dependent monooxygenase in serum-free cultured Hep G2 cells. Nakama A, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1407-12

GENETICS

Establishment of immortal hepatocytes from a CYP3A7-transgenic/p53-knockout mouse. Shimoji M, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):1001-5

METABOLISM

7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Yamazaki H, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):313-9

ALKYL GLYCERYL ETHERS see **GLYCERYL ETHERS**

ALKYL SULFONATES see **ALKANESULFONATES**

ALKYLATING AGENTS

ADMINISTRATION & DOSAGE

Participation of TNF-alpha and IL-1 in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. Gomes TN, et al. **Braz J Med Biol Res** 1995 Oct; 28(10):1103-8

Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Slagle BL, et al. **Mol Carcinog** 1996 Apr; 15(4):261-9

ADVERSE EFFECTS

Mutagenic damage to mammalian cells by therapeutic alkylating agents. Sanderson BJ, et al. **Mutat Res** 1996 Aug 17;355(1-2):41-57 (118 ref.)

ANALYSIS

Tobacco smoke-associated N7-alkylguanine in DNA of larynx tissue and leucocytes. Szyfter K, et al. **Carcinogenesis** 1996 Mar;17(3):501-6

CHEMISTRY

Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Trissel LA, et al. **Am J Health Syst Pharm** 1996 May 1;53(9):1041-5

A 32P-postlabeling method for the detection of adducts in the DNA of human fibroblasts exposed to sulfur mustard. Niu T, et al. **Chem Biol Interact** 1996 Mar 8;100(1):77-84

Amino acids and peptides. XL. Synthesis of Ac-Tyr-Val-Ala-Asp-MCA using newly developed acetylating reagent. Taguchi H, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug;43(8):1336-9

Alkylation of Escherichia coli thioredoxin by S-(2-chloroethyl)glutathione and identification of the adduct on the active site cysteine-32 by mass spectrometry. Erve JC, et al. **Chem Res Toxicol** 1995 Oct-Nov; 8(7):934-41

Evidence for DNA phosphate backbone alkylation and cleavage by pyrrolo[1,2-a]benzimidazoles: small molecules capable of causing base-pair-specific phosphodiester bond hydrolysis. Schulz WG, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11854-8

[Biological monitoring of exposure to alkylating xenobiotics by determining them using a new analytical approach in complexes with hemoglobin, plasma proteins and mercapturic acids in urine. II. Acrylamide] Hashimoto K, et al. **Vopr Med Khim** 1995 Jul-Aug;41(4):22-5 (Eng. Abstr.) **(Rus)**

[Biological monitoring of exposure to alkylating xenobiotics by determining them in complexes with plasma proteins, hemoglobin, mercapturic acids from urine of rats and industrial workers. I. Acrylonitrile] Ivanov VV, et al. **Vopr Med Khim** 1995 Jul-Aug;41(4):18-22 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Comparison of inhibition of glucose-stimulated insulin secretion in rat islets of Langerhans by streptozotocin and methyl and ethyl nitrosoureas and methanesulphonates. Lack of correlation with nitric oxide-releasing or O6-alkylating ability. Delaney CA, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2015-20

Evaluation by polymerase chain reaction on the effect of beta-propiolactone and binary ethyleneimine on DNA. Groseil C, et al. **Biologicals** 1995 Sep;23(3):213-20

Inactivation of DNA by beta-propiolactone. Perrin P, et al. **Biologicals** 1995 Sep;23(3):207-11

3-methyladenine-DNA-glycosylase and O6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines. Damia G, et al. **Br J Cancer** 1996 Apr;73(7):861-5

Differential sensitivity of [3H]7-OH-DPAT-labeled binding sites in rat brain to inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Levant B. **Brain Res** 1995 Nov 6;698(1-2):146-54

In vitro effect of cyclophosphamide on the binding of radiopharmaceuticals (99mTcO4- and 99mTc-MDP) to blood elements. Ripoll-Hamer E, et al. **Braz J Med Biol Res** 1995 Feb;28(2):256-60

Effect of cyclophosphamide on the binding of 99mTcO-4 and 99mTc-MDP to blood cells and plasma proteins. Santos JS, et al. **Braz J Med Biol Res** 1995 Jan;28(1):131-5

Alkylation of oxytocin by S-(2-chloroethyl)glutathione and characterization of adducts by tandem mass spectrometry and Edman degradation. Erve JC, et al.

Chem Res Toxicol 1995 Apr-May;8(3):414-21

Alkylating agents induce UVM, a recA-independent inducible mutagenic phenomenon in Escherichia coli. Wang G, et al. **Genetics** 1995 Nov;141(3):813-23

Forced evolution of glutathione S-transferase to create a more efficient drug detoxication enzyme. Mulder GJ. **Hum Exp Toxicol** 1996 Feb;15(2):181-2

Activation of heat shock factor by alkylating agents is triggered by glutathione depletion and oxidation of protein thiols. Liu H, et al. **J Biol Chem** 1996 Mar 1;271(9):4805-12

Activation of the human DNA polymerase beta promoter by a DNA-alkylating agent through induced phosphorylation of cAMP response element-binding protein-1. Narayan S, et al. **J Biol Chem** 1996 Aug 2; 271(31):18508-13

Alteration of gene expression in rat mammary tumors induced by N-methyl-N-nitrosourea. Young LH, et al. **Mol Carcinog** 1996 Apr;15(4):251-60

p53 accumulates in micronuclei after treatment with a DNA breaking chemical, methylnitrosourea, and with the spindle poison, vinblastine. Granetto C, et al. **Mutat Res** 1996 Jun 10;352(1-2):61-4

Analysis of mitotic recombination induced by several mono- and bifunctional alkylating agents in the Drosophila wing-spot test. Rodriquez-Arnaiz R, et al. **Mutat Res** 1996 Apr 13;351(2):133-45

Sulphur mustards inhibit binding of transcription factor AP2 in vitro. Gray PJ. **Nucleic Acids Res** 1995 Nov 11; 23(21):4378-82

Nitrogen mustard inhibits transcription and translation in a cell free system. Masta A, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3508-15

Segregation of DNA polynucleotide strands into sister chromatids and the use of endoreduplicated cells to track sister chromatid exchanges induced by crosslinks, alkylations, or x-ray damage. Wolff S, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5765-9

Effects of levamisole, DTC and low-dose mechlorethamine on humoral response of SRBC-immunized rabbits exposed to cold stress. Obminska-Domoradzka B, et al. **Zentralbl Veterinarmed [B]** 1995 Mar;42(1):12-8

[The effect of armin on neuromuscular transmission in the frog against a background of hexadecamethonium action] Grigor'ev VM. **Fiziol Zh Im I M Sechenova** 1995 Jul; 81(7):27-32 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. Furst DE. **Baillieres Clin Rheumatol** 1995 Nov;9(4):711-29 (41 ref.)

Nitrogen mustard therapy and nephrotic syndrome [letter] Arumugam R, et al. **Pediatr Nephrol** 1996 Feb;10(1):130-1

Nitrogen mustard therapy of pediatric nephrotic syndrome [editorial] Tune BM, et al. **Pediatr Nephrol** 1996 Feb; 10(1):131

Cyclosporin-induced remission in an infant with alkylating agents-resistant nephrotic syndrome. A case report. Yilmaz GG, et al. **Turk J Pediatr** 1995 Oct-Dec;37(4):411-4

TOXICITY

Alkylation of DNA and its aftermath. Lawley PD. **Bioessays** 1995 Jun;17(6):561-8 (54 ref.)

Targeted disruption of the DNA repair methyltransferase gene renders mice hypersensitive to alkylating agent. Tsuzuki T, et al. **Carcinogenesis** 1996 Jun;17(6):1215-20

Enhancement of bacterial mutagenicity of bifunctional alkylating agents by expression of mammalian glutathione S-transferase. Thier R, et al. **Chem Res Toxicol** 1995 Apr-May;8(3):465-72

Detection of point mutations in T lymphocytes. van Zeeland AA, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1841-3

Unexpected genetic toxicity to rodents of the N',N'-dimethyl analogues of MNU and ENU. Tinwell H, et al. **Environ Mol Mutagen** 1996;27(3):202-10

Karyotype abnormalities in a variant Chinese hamster cell line resistant to methyl methanesulphonate. Sciandrello G, et al. **Hereditas** 1996;124(1):39-46

Activity of iPMS and nPMS in mouse bone marrow micronucleus assays: comparison with mouse dominant lethal assay data. Adler ID, et al. **Mutat Res** 1996 Feb 1;349(2):241-7

Series: current issues in mutagenesis and carcinogenesis, No. 66. Lijinsky's observation that the spontaneous tumour incidence in F334 rats is unaffected by prior damage to DNA. Ashby J. **Mutat Res** 1996 Feb 1;349(2):289-90

Molecular analysis of mutations induced by ethylating N-nitroso compounds in the lacI gene of Escherichia coli. Jiao J, et al. **Mutat Res** 1996 Jun 10;352(1-2):39-45

Fate of lesions that elicit sister chromatid exchanges (FLE-SCE) produced in DNA by alkylating agents in vivo. Morales-Ramírez P, et al. **Mutat Res** 1995 Aug; 344(1-2):13-26

Role of induced genetic instability in the mutagenic effects of chemicals and radiation. Murnane JP. **Mutat Res** 1996 Jan;367(1):11-23 (160 ref.)

Mutational spectra induced under distinct excision repair conditions by the 3 methylating agents N-methyl-N-nitrosourea, N-methyl-N'-nitro-N-nitrosoguanidine and N-nitrosodimethylamine in postmeiotic male germ cells of Drosophila. Nivard MJ, et al. **Mutat Res** 1996 Jun 10; 352(1-2):97-115

Embryotoxicity induced by alkylating agents: 9. Low dose prenatal-toxic risk estimation of ethylmethanesulfonate based on no-observed-adverse-effect-level risk factor approach, dose-response relationships, and molecular dosimetry. Platzek T, et al. **Teratog Carcinog Mutagen** 1995; 15(2):81-92

ALKYLATING AGENTS, ANTINEOPLASTIC see **ANTINEOPLASTIC AGENTS, ALKYLATING**

ALKYLATION

N-[18F]-fluoroalkylation of noraporphines: microwave versus thermal treatment. Zijlstra S, et al. **Eur J Morphol** 1995 Apr;33(2):154-7

ALKYNES

ADVERSE EFFECTS

A phase I trial of hypoxoside as an oral prodrug for cancer therapy--absence of toxicity. Smit BJ, et al. **S Afr Med J** 1995 Sep;85(9):865-70

CHEMICAL SYNTHESIS

Aryl 1-but-3-ynyl-4-phenyl-1,2,3,6-tetrahydropyridines as potential antipsychotic agents: synthesis and structure-activity relationships. Glase SA, et al. **J Med Chem** 1996 Aug 2;39(16):3179-87

CHEMISTRY

Mechanism of lipoxygenase inactivation by the linoleic acid analogue octadeca-9,12-diynoic acid. Schilstra MJ, et al. **Biochemistry** 1996 Mar 19;35(11):3396-401

Antitumor activity and stereochemistry of acetylenic alcohols from the sponge Cribrochalina vasculum. Hallock YF, et al. **J Nat Prod** 1995 Dec;58(12):1801-7

Photochemistry of acetylenic ketones in micellar solutions as studied by product-yield-detected ESR and transient absorption techniques. Polyakov NE, et al. **Photochem Photobiol** 1995 Jun;61(6):545-51

ISOLATION & PURIFICATION

Santolindiacetylene, a polyacetylene derivative isolated from the essential oil of Santolina canescens. Utrilla MP, et al. **J Nat Prod** 1995 Nov;58(11):1749-52

PHARMACOKINETICS

The pharmacokinetic behaviour of hypoxoside taken orally by patients with lung cancer in a phase I trial. Albrecht CF, et al. **S Afr Med J** 1995 Sep;85(9):861-5

Morphological characterisation of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy. Albrecht CF, et al. **S Afr Med J** 1995 Sep;85(9):853-60

PHARMACOLOGY

Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine. Peck R, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):22-31

Differential vasodilatory action of 2-octynyladenosine (YT-146), an adenosine A2 receptor agonist, in the isolated rat femoral artery and vein. Abiru T, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):9-15

Early administration of YT-146, an adenosine A2 receptor agonist, inhibits neointimal thickening after rat femoral artery endothelium injury. Takiguchi Y, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):205-7

Chemistry and antimicrobial activity of caryoynencins analogs. Yamaguchi M, et al. **J Med Chem** 1995 Dec 22; 38(26):5015-22

A cytotoxic diacetylene from Dendropanax arboreus [letter] Setzer WN, et al. **Planta Med** 1995 Oct;61(5):470-1

ALL, ADULT see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

ALL, CHILDHOOD see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

ALL-TERRAIN VEHICLES see **OFF-ROAD MOTOR VEHICLES**

ALLANTOIN

ANALYSIS

Determination of allantoin in biological, cosmetic, and pharmaceutical samples. Chen XB, et al. **J AOAC Int** 1996 May-Jun;79(3):628-35 (56 ref.)

BLOOD

[Plasma allantoin in patients undergoing maintenance hemodialysis] Sasaki K, et al. **Nippon Jinzo Gakkai Shi** 1996 Apr;38(4):164-70 (Eng. Abstr.) **(Jpn)**

METABOLISM

Purification and characterization of allantoate amidohydrolase from Bacillus fastidiosus. Xu Z, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):99-104

Degradation of purines: only ureidoglycollate lyase out of four allantoin-degrading enzymes is present in mammals. Fujiwara S, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):315-8

Labelling of uric acid and allantoin in different purine organs and urine of the rat. Pizzichini M, et al. **Life Sci** 1996; 59(11):893-9

THERAPEUTIC USE

Possibilities of scar treatment after thoracic surgery. Maragakis M, et al. **Drugs Exp Clin Res** 1995;21(5):199-206

URINE

Urinary excretion of purine derivatives and tissue xanthine oxidase (EC 1.2.3.2) activity in buffaloes (Bubalis bubalis) with special reference to differences between buffaloes and Bos taurus cattle. Chen XB, et al. **Br J Nutr** 1996 Mar; 75(3):397-407

ALLANTOIS

BLOOD SUPPLY

VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane. Wilting J, et al. **Dev Biol** 1996 May 25;176(1):76-85

A novel radiological approach for the experimental study of angiogenesis: angiography of the chick embryo and its chorioallantoic membrane. Siamblis D, et al. **Eur J Radiol** 1996 Feb;21(3):220-4

Vascular pattern in the chorioallantoic membrane (CAM) after laser/photosensitive compound treatment. II. Microscopic findings. Klepáček I, et al. **Folia Biol (Praha)** 1995;41(3-4):190-6

Trapidil inhibits endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane and in the rat cornea. Benelli U, et al. **J Ocul Pharmacol Ther** 1995 Summer;11(2):157-66

CHEMISTRY

Developmental changes of free amino acid concentrations in fetal fluids of pigs. Wu G, et al. **J Nutr** 1995 Nov; 125(11):2859-68

DRUG EFFECTS

Exogenous heparin induces an increase in glycosaminoglycans of the chick embryo chorioallantoic membrane: its possible role in the regulation of angiogenic processes. Ribatti D, et al. **Int J Microcirc Clin Exp** 1995 Jul-Aug;15(4):181-5

In vivo damage to chorioallantoic membrane blood vessels by porphycene-induced photodynamic therapy. Gottfried V, et al. **J Photochem Photobiol B** 1995 Oct;30(2-3):115-21

EMBRYOLOGY

Defective chorioallantoic fusion in mid-gestation lethality of parthenogenone<-->tetraploid chimeras. Spindle A, et al. **Dev Biol** 1996 Feb 1;173(2):447-58

METABOLISM

Purification and properties of porcine allantoic fluid retinol-binding protein. Vallet JL. **Domest Anim Endocrinol** 1996 Mar;13(2):127-38

Amniotic and allantoic fluid concentrations of thyroxine, 3,3',5'-tri-iodothyronine, 3,3'-di-iodothyronine and 3',5'-di-iodothyronine in the pig during the period of gestation. Brzezińska-Slebodzińska E, et al. **J Endocrinol** 1995 Nov;147(2):245-51

MICROBIOLOGY

Egg dipping in hydrogen peroxide solution to eliminate Salmonella typhimurium from eggshell membranes. Padron M. **Avian Dis** 1995 Jul-Sep;39(3):627-30

ALLELES

Apolipoprotein E allele frequencies in an Italian population: relation to age and lipid profile. Ruiu G, et al. **Aging (Milano)** 1995 Aug;7(4):185-9

Identifying alcoholism vulnerability alleles. Goldman D. **Alcohol Clin Exp Res** 1995 Aug;19(4):824-31 (71 ref.)

Search for rearrangements and/or allelic loss of the fas/APO-1 gene in 101 human lymphomas. Xerri L, et al. **Am J Clin Pathol** 1995 Oct;104(4):424-30

Allelic variation in the cagA gene of Helicobacter pylori obtained from Korea compared to the United States. Miehlke S, et al. **Am J Gastroenterol** 1996 Jul;91(7):1322-5

Haplotype analysis of the Mexican frameshift Cd 11 (-T) and -28 A->C beta-thalassemia alleles. Perea FJ, et al. **Am J Hematol** 1996 Mar;51(3):240-2

Non-Mendelian transmission in dentatorubral-pallidoluysian atrophy and Machado-Joseph disease: the mutant allele is preferentially transmitted in male meiosis. Ikeuchi T, et al. **Am J Hum Genet** 1996 Apr;58(4):730-3

Are moment bounds on the recombination fraction between

a marker and a disease locus too good to be true? Allelic association mapping revisited for simple genetic diseases in the Finnish population. Kaplan NL, et al. **Am J Hum Genet** 1995 Dec;57(6):1486–98

Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene. Primo–Parmo SL, et al. **Am J Hum Genet** 1996 Jan;58(1):52–64

Lysosomal free sialic acid storage disorders with different phenotypic presentations—infantile–form sialic acid storage disease and Salla disease—represent allelic disorders on 6q14–15. Schleutker J, et al. **Am J Hum Genet** 1995 Oct; 57(4):893–901

A pseudodeficiency allele (D152N) of the human beta–glucuronidase gene. Vervoort R, et al. **Am J Hum Genet** 1995 Oct;57(4):798–804

FH Tulsa–1 and –2: two unique alleles for familial hypercholesterolemia presenting in an affected two–year–old African–American male. Blackett PR, et al. **Am J Med Genet** 1995 Nov 20;59(3):300–3

Allelic association at the D14S43 locus in early onset Alzheimer's disease. French Alzheimer's Disease Collaborative Study Group. Brice A, et al. **Am J Med Genet** 1995 Apr 24;60(2):91–3

No evidence for allelic association between bipolar disorder and monoamine oxidase A gene polymorphisms. Craddock N, et al. **Am J Med Genet** 1995 Aug 14;60(4):322–4

A combined analysis of D22S278 marker alleles in affected sib–pairs: support for a susceptibility locus for schizophrenia at chromosome 22q12. Schizophrenia Collaborative Linkage Group (Chromosome 22). Gill M, et al. **Am J Med Genet** 1996 Feb 16;67(1):40–5

Constitutive heterochromatin of chromosome 1 and Duffy blood group alleles in schizophrenia. Kosower NS, et al. **Am J Med Genet** 1995 Apr 24;60(2):133–8

Evidence for a genetic association between alleles of monoamine oxidase A gene and bipolar affective disorder. Lim LC, et al. **Am J Med Genet** 1995 Aug 14;60(4):325–31

Mutation analysis of Australasian Gaucher disease patients [letter] Nelson PV, et al. **Am J Med Genet** 1995 Sep 25; 58(4):382

Apolipoprotein E–epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Premkumar DR, et al. **Am J Pathol** 1996 Jun;148(6):2083–95

Monoallelic expression of the insulin–like growth factor–2 gene in ovarian cancer. Yun K, et al. **Am J Pathol** 1996 Apr;148(4):1081–7

Cystic fibrosis 3849+10kb C > T mutation associated with severe pulmonary disease and male fertility. Dreyfus DH, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):858–60

Allele frequencies of the major milk proteins in the Finnish Ayrshire and detection of a new kappa–casein variant. Ikonen T, et al. **Anim Genet** 1996 Jun;27(3):179–81

Identification and characterization of new BoLA–DRB3 alleles by heteroduplex analysis and direct sequencing. Sitte K, et al. **Anim Genet** 1995 Dec;26(6):413–7

Apolipoprotein E alleles and brain vascular pathology in Alzheimer's disease. Kalaria RN, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:266–70

ApoE2 allele, Down's syndrome, and dementia. Royston MC, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:255–9

Apolipoprotein E alleles in sporadic inclusion–body myositis and hereditary inclusion–body myopathy [letter] Askanas V, et al. **Ann Neurol** 1996 Aug;40(2):264–5

High apolipoprotein E epsilon 4 allele frequency in age–related memory decline. Blesa R, et al. **Ann Neurol** 1996 Apr;39(4):548–51

The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. Chen X, et al. **Ann Neurol** 1995 Oct;38(4):653–8

Alzheimer's disease and apolipoprotein E–4 allele in an Amish population. Pericak–Vance MA, et al. **Ann Neurol** 1996 Jun;39(6):700–4

Apolipoprotein E alleles as risk factors in Alzheimer's disease. Roses AD. **Annu Rev Med** 1996;47:387–400 (66 ref.)

VNTR locus D1S80: allele frequencies and genotype distribution in the region of Düsseldorf. Huckenbeck W, et al. **Anthropol Anz** 1996 Mar;54(1):7–17

Microdissection as a means to verify allelic imbalance in tumour biology samples. Speiser P, et al. **Anticancer Res** 1996 Jan–Feb;16(1):461–4

Altered protein synthesis in p53 null and hemizygous transgenic mouse embryonic fibroblasts. He C, et al. **Appl Theor Electrophor** 1995;5(1):15–24

cDNA–directed expression of two allelic variants of cytochrome P450 2C11 using COS1 and SF21 insect cells. Biagini C, et al. **Arch Biochem Biophys** 1996 Feb 15; 326(2):298–305

Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. Seshadri S, et al. **Arch Neurol** 1995 Nov; 52(11):1074–9

Association of tumor necrosis factor microsatellite polymorphisms with HLA–DRB1*04–bearing haplotypes in rheumatoid arthritis patients. Hajeer AH, et al. **Arthritis Rheum** 1996 Jul;39(7):1109–14

Common variation in the gene for apolipoprotein B modulates postprandial lipoprotein metabolism: a hypothesis generating study. Peacock RE, et al. **Atherosclerosis** 1995 Jul;116(1):135–45

Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Jounaïdi Y, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):466–70

The Gly–54–>Asp allelic form of human mannose–binding protein (MBP) fails to bind MBP–associated serine protease. Matsushita M, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):1021–3

Selective damage to the active X chromosome by camptothecin and amsacrine as determined by an allele–specific alkaline unwinding assay. Austin MJ, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1317–9

Allele–specific HLA–DRB1 amplification of forensic evidence samples with mixed genotypes. Allen M, et al. **Biotechniques** 1995 Sep;19(3):454–63

Hereditary spherocytosis with band 3 deficiency. Association with a nonsense mutation of the band 3 gene (allele Lyon), and aggravation by a low–expression allele occurring in trans (allele Genas). Alloisio N, et al. **Blood** 1996 Aug 1; 88(3):1062–9

Decreased stability of the O allele mRNA transcript of the ABO gene [letter] O'Keefe DS, et al. **Blood** 1996 Apr 1; 87(7):3061–2

Relation of common allelic variation at vitamin D receptor locus to bone mineral density and postmenopausal bone loss: cross sectional and longitudinal population study. Jørgensen HL, et al. **BMJ** 1996 Sep 7;313(7057):586–90

Molecular analysis of HLA–DQB1 alleles in childhood common acute lymphoblastic leukaemia. Dearden SP, et al. **Br J Cancer** 1996 Mar;73(5):603–9

Allelotype of squamous cell carcinoma of the head and neck: fractional allele loss correlates with survival. Field JK, et al. **Br J Cancer** 1995 Nov;72(5):1180–8

Differential allele loss on chromosome 9q22.3 in human non–melanoma skin cancer. Holmberg E, et al. **Br J Cancer** 1996 Jul;74(2):246–50

Allelic imbalance in the region of the BRCA1 gene in ductal carcinoma in situ of the breast. Munn KE, et al. **Br J Cancer** 1996 Mar;73(5):636–9

Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. Kihana T, et al. **Cancer** 1995 Jul 1;76(1):72–8

Allelic loss of chromosome 17p, mutation of the p53 gene, and microsatellite instability in right– and left–sided colorectal cancer. Watatani M, et al. **Cancer** 1996 Apr 15; 77(8 Suppl):1688–93

Allelic status of chromosome 1 in neoplasms of the nervous system. Bello MJ, et al. **Cancer Genet Cytogenet** 1995 Sep; 83(2):160–4

p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles. Rand A, et al. **Cancer Lett** 1996 Jan 2;98(2):183–91

Genetic alterations in untreated metastases and androgen–independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cher ML, et al. **Cancer Res** 1996 Jul 1;56(13):3091–102

Ubiquitous somatic alterations at microsatellite alleles occur infrequently in Barrett's–associated esophageal adenocarcinoma. Gleeson CM, et al. **Cancer Res** 1996 Jan 15;56(2):259–63

Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Healy E, et al. **Cancer Res** 1996 Feb 1;56(3):589–93

Allelic loss on chromosome 10 in prostate adenocarcinoma. Ittmann M. **Cancer Res** 1996 May 1;56(9):2143–7

Biallelic inactivation of the APC gene in hepatoblastoma. Kurahashi H, et al. **Cancer Res** 1995 Nov 1;55(21):5007–11

Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Phillips NJ, et al. **Cancer Res** 1996 Feb 1; 56(3):606–11

Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. Roz L, et al. **Cancer Res** 1996 Mar 15;56(6):1228–31

Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma. Schwerdtle RF, et al. **Cancer Res** 1996 Jul 1;56(13):2927–30

Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Tahara H, et al. **Cancer Res** 1996 Feb 1;56(3):599–605

High–density marker analysis of 11p15.5 in non–small cell lung carcinomas reveals allelic deletion of one shared and one distinct region when compared to breast carcinomas. Tran YK, et al. **Cancer Res** 1996 Jul 1;56(13):2916–21

Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Trybus TM, et al. **Cancer Res** 1996 May 15;56(10):2263–7

Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12–21. Vocke CD, et al. **Cancer Res** 1996 May 15;56(10):2411–6

Characterization of purified human recombinant cytochrome P4501A1–Ile462 and –Val462: assessment of a role for the rare allele in carcinogenesis. Zhang ZY, et al. **Cancer Res** 1996 Sep 1;56(17):3926–33

Transferrin C3 offers protection against smoking–associated lung cancer? Sikström C, et al. **Carcinogenesis** 1996 Jul; 17(7):1447–9

The genetic basis of preference for sweet substances among inbred strains of mice: preference ratio phenotypes and the alleles of the Sac and dpa loci. Capeless CG, et al. **Chem Senses** 1995 Jun;20(3):291–8

Three different point mutations in the butyrylcholinesterase gene of three Japanese subjects with a silent phenotype: possible Japanese type alleles. Sudo K, et al. **Clin Biochem** 1996 Apr;29(2):165–9

A TaqI RFLP in the type IV collagen alpha 5 chain gene (COL4A5) with the rare allele more frequently found in seven Chinese Alport syndrome patients. Chan SY, et al. **Clin Genet** 1995 May;47(5):278–9

Comprehensive typing of HLA–DPB1 alleles by polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP). Sengar DP, et al. **Clin Invest Med** 1995 Dec; 18(6):465–72

Determination and allelic allocation of seven nucleotide transitions within the arylamine N–acetyltransferase gene in the Polish population. Mrozikiewicz PM, et al. **Clin Pharmacol Ther** 1996 Apr;59(4):376–82

Quantitative genetics. Loci with large effects. Keightley PD. **Curr Biol** 1995 May 1;5(5):485–7 (7 ref.)

New alleles of mgm1: a gene encoding a protein with a GTP–binding domain related to dynamin. Backer JS. **Curr Genet** 1995 Oct;28(5):499–501

Evidence for sltA1 as a salt–sensitive allele of the arginase gene (agaA) in the ascomycete Aspergillus nidulans. Clement DJ, et al. **Curr Genet** 1996 Apr;29(5):462–7

Allele–specific suppression of temperature–sensitive mutations of the Saccharomyces cerevisiae RAD52 gene. Kaytor MD, et al. **Curr Genet** 1996 Feb;29(3):203–10

Paramutation in maize and related allelic interactions. Patterson GI, et al. **Curr Top Microbiol Immunol** 1995; 197:121–41 (94 ref.)

Gain–of–function alleles of Bearded interfere with alternative cell fate decisions in Drosophila adult sensory organ development. Leviten MW, et al. **Dev Biol** 1996 Jun 15; 176(2):264–83

Distribution of HLA–DPB1, –DQB1 –DQA1 alleles among Sardinian celiac patients. Boy MF, et al. **Dis Markers** 1995 Aug;12(3):199–204

Frequency of the new HLA–B*2709 allele in ankylosing spondylitis patients and healthy individuals. D'Amato M, et al. **Dis Markers** 1995 Aug;12(3):215–7

No association between the c2 allele at the cytochrome P450IIE1 gene and alcohol induced liver disease, alcohol Korsakoff's syndrome or alcohol dependence syndrome. Ball DM, et al. **Drug Alcohol Depend** 1995 Oct;39(3):181–4

Negative signalling via the P58/NKR for HLA.C alleles. Vitale M, et al. **Eur J Histochem** 1994;38 Suppl 1:69–76

Maternal HLA class II allogenotypes are markers for the predisposition to fetal losses in families of women with unexplained recurrent fetal loss. Christiansen OB, et al. **Eur J Immunogenet** 1995 Aug;22(4):323–34

DNA typing of DQ and DR alleles in IgA–deficient subjects. Fiore M, et al. **Eur J Immunogenet** 1995 Oct;22(5):403–11

Rapid characterization of HLA class I alleles by gene mapping using ARMS PCR. Krausa P, et al. **Eur J Immunogenet** 1995 Jun;22(3):283–7

Determination of DQB1 alleles using PCR amplification and allele–specific primers. Lepage V, et al. **Eur J Immunogenet** 1995 Oct;22(5):413–22

HLA–DRB1*0401 is associated with susceptibility to insulin–dependent diabetes mellitus independently of the DQB1 locus. Tait BD, et al. **Eur J Immunogenet** 1995 Aug; 22(4):289–97

Altered Th1/Th2 balance associated with the immunosuppressive/protective effect of the H–2Ab allele on the response to allo–4–hydroxyphenylpyruvate dioxygenase. Brunner M, et al. **Eur J Immunol** 1995 Dec; 25(12):3285–9

Glutamine and tetrapeptide repeat variations affect the biological activity of different mouse interleukin–2 alleles. Matesanz F, et al. **Eur J Immunol** 1996 Aug;26(8):1675–82

A functionally significant allelic polymorphism in a T cell receptor V beta gene segment. Vessey SJ, et al. **Eur J Immunol** 1996 Jul;26(7):1660–3

A new spontaneous allele at the pink–eyed dilution (p) locus discovered in Mus musculus castaneus. Tsuji A, et al. **Exp Anim** 1995 Oct;44(4):347–51

Complement C7 M/N allotyping in infectious diseases. Würzner R, et al. **Exp Clin Immunogenet** 1995;12(2):61–5

Allele epsilon 4 of apolipoprotein E shows a dose effect on age at onset of Pick disease. Farrer LA, et al. **Exp Neurol** 1995 Dec;136(2):162–70

Allelic forms of the knob associated histidine–rich protein gene of Plasmodium falciparum. Kant R, et al. **FEBS Lett** 1996 Feb 12;380(1–2):147–51

Production and crystallization of MHC class I B allele single peptide complexes. Reid SW, et al. **FEBS Lett** 1996 Mar 25;383(1–2):119–23

Sequence determination of an allele ladder for the STR polymorphism at the CD4 locus and application of the ladder in testing an Austrian Caucasian population sample. Glock B, et al. **Forensic Sci Int** 1996 Apr 2;78(2):125–30

Allele frequencies of four VNTR loci in the Chinese population in Hong Kong. Tsui P, et al. **Forensic Sci Int** 1996 Jun 14;79(3):175–85

D1S80 VNTR locus genotypes in population of south Poland; meta–analysis pointer to genetic disequilibrium of human populations. Turowska B, et al. **Forensic Sci Int** 1995 Oct 30;75(2–3):207–16

Allelic loss on chromosomes 4q and 16q in hepatocellular carcinoma: association with elevated alpha–fetoprotein production. Yeh SH, et al. **Gastroenterology** 1996 Jan; 110(1):184–92

Schizosaccharomyces pombe rad23 is allelic with swi10, a mating–type switching/radioresistance gene that shares sequence homology with human and mouse ERCC1. Hang H, et al. **Gene** 1996 Apr 17;170(1):113–7

ALLELES

Isolation of an HSP12-homologous gene of Schizosaccharomyces pombe suppressing a temperature-sensitive mutant allele of cdc4. Jang YJ, et al. **Gene** 1996 Jun 12;172(1):125–9

Molecular analysis of genetic changes in ependymomas. Bijlsma EK, et al. **Genes Chromosomes Cancer** 1995 Aug; 13(4):272–7

Loss of chromosome 17 loci in prostate cancer detected by polymerase chain reaction quantitation of allelic markers. Brothman AR, et al. **Genes Chromosomes Cancer** 1995 Aug; 13(4):278–84

Allelic imbalance study of 16q in human primary breast carcinomas using microsatellite markers. Dorion-Bonnet F, et al. **Genes Chromosomes Cancer** 1995 Nov;14(3):171–81

Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Henske EP, et al. **Genes Chromosomes Cancer** 1995 Aug;13(4):295–8

Loss of heterozygosity on chromosome arms 5q, 11p, 11q, 13q, and 16p in human testicular germ cell tumors. al-Jehani RM, et al. **Genes Chromosomes Cancer** 1995 Aug; 13(4):249–56

Patterns of loss of heterozygosity at loci from chromosome arm 13q suggests a possible involvement of BRCA2 in sporadic breast tumors. Kerangueven F, et al. **Genes Chromosomes Cancer** 1995 Aug;13(4):291–4

Loss of heterozygosity on the X chromosome in human breast cancer. Loupart ML, et al. **Genes Chromosomes Cancer** 1995 Aug;13(4):229–38

Allelic imbalance in gastric cancer: an affected site on chromosome arm 3p. Schneider BG, et al. **Genes Chromosomes Cancer** 1995 Aug;13(4):263–71

Soybean resistance genes specific for different Pseudomonas syringae avirulence genes are allelic, or closely linked, at the RPG1 locus. Ashfield T, et al. **Genetics** 1995 Dec; 141(4):1597–604

The diversity of alleles at the hsd locus in natural populations of Escherichia coli. Barcus VA, et al. **Genetics** 1995 Aug; 140(4):1187–97

Sequences required for paramutation of the maize b gene map to a region containing the promoter and upstream sequences. Patterson GI, et al. **Genetics** 1995 Aug; 140(4):1389–406

Two distinct temperature-sensitive alleles at the elav locus of Drosophila are suppressed nonsense mutations of the same tryptophan codon. Samson ML, et al. **Genetics** 1995 Nov;141(3):1101–11

Gene genealogies within mutant allelic classes. Slatkin M. **Genetics** 1996 May;143(1):579–87

Two-dimensional DNA typing of human pedigrees: spot pattern characterization and segregation. Mullaart E, et al. **Genomics** 1995 Oct 10;29(3):641–6

Allelotyping in Wilms tumors identifies a putative third tumor suppressor gene on chromosome 11. Radice P, et al. **Genomics** 1995 Jun 10;27(3):497–501

Inactive allele-specific methylation and chromatin structure of the imprinted gene U2af1-rs1 on mouse chromosome 11. Shibata H, et al. **Genomics** 1996 Jul 1;35(1):248–52

Allele-dependent recombination frequency: homology requirement in meiotic recombination at the hot spot in the mouse major histocompatibility complex. Yoshino M, et al. **Genomics** 1995 May 20;27(2):298–305

Allele capture by selection for flanking markers: a new method for analyzing multigenic traits [editorial] Harrison DE, et al. **Growth Dev Aging** 1995 Fall;59(3):73–6

HLA class II gene frequencies in Crohn's disease: a population based analysis in Germany. Reinshagen M, et al. **Gut** 1996 Apr;38(4):538–42

p53 allelotypes and enhanced detection of allelic loss in ovarian cancer: lack of correlation with familial and clinical factors. Skilling JS, et al. **Gynecol Oncol** 1996 May; 61(2):180–8

Constraints and normalized measures for cytonuclear disequilibria. Asmussen MA, et al. **Heredity** 1996 Mar;76 (Pt 3):207–14

S-allele sequence diversity in natural populations of Solanum carolinense (Horsenettle). Richman AD, et al. **Heredity** 1995 Oct;75 (Pt 4):405–15

Allele-specific quantification of TNFA transcripts in rheumatoid arthritis. Brinkman BM, et al. **Hum Genet** 1996 Jun;97(6):813–8

Complex mutational events at the HumD21S11 locus. Brinkmann B, et al. **Hum Genet** 1996 Jul;98(1):60–4

Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus. Caron H, et al. **Hum Genet** 1996 Jun;97(6):834–7

Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. Clay FE, et al. **Hum Genet** 1996 Jun;97(6):723–6

Identification of a Ser857-Asn857 substitution in DRK1 (KCNB1), population frequencies and lack of association to the low voltage alpha EEG trait. Mazzanti CM, et al. **Hum Genet** 1996 Aug;98(2):134–7

Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Shaikh S, et al. **Hum Genet** 1996 Jun;97(6):714–9

Suballeles of the ABO blood group system in a Japanese population. Fukumori Y, et al. **Hum Hered** 1996 Mar-Apr; 46(2):85–91

Nucleotide sequence analysis of HLA-B*1523 and B*8101. Dominant alpha-helical motifs produce complex serologic recognition patterns for the HLA-B"DT" and HLA-B"NM5" antigens. Ellexson ME, et al. **Hum Immunol** 1995 Oct;44(2):103–10

Sequence-based typing of HLA-A2 alleles using a primer with an extra base mismatch. Ishikawa Y, et al. **Hum Immunol** 1995 Apr;42(4):315–8

The 8.5-kb PstI allele of the stress protein gene, Hsp70-2: an independent risk factor for systemic lupus erythematosus in African Americans? Jarjour W, et al. **Hum Immunol** 1996 Jan;45(1):59–63

Defining the allelic variants of HLA-A30 in the Sardinian population using amplification refractory mutation system—polymerase chain reaction. Krausa P, et al. **Hum Immunol** 1995 Sep;44(1):35–42

Ultrastructural allelic variation in HLA-DQB1 promoter elements. Leech N, et al. **Hum Immunol** 1995 Aug; 43(4):251–8

Both HLA-B*1301 and B*1302 exist in Asian populations and are associated with different haplotypes. Lin L, et al. **Hum Immunol** 1995 May;43(1):51–6

Genetic polymorphism of the human tumor necrosis factor region in insulin-dependent diabetes mellitus. Linkage disequilibrium of TNFab microsatellite alleles with HLA haplotypes. Monos DS, et al. **Hum Immunol** 1995 Oct; 44(2):70–9

Association of the HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis. Reed AM, et al. **Hum Immunol** 1995 Nov;44(3):131–5

A new HLA-C allele, Cw*1403, associated with HLA-B44 in Japanese. Wang H, et al. **Hum Immunol** 1995 Aug; 43(4):295–300

Identification and DNA typing of two Cw7 alleles (Cw*0702 and Cw*0704) in Japanese, with the corrected sequence of Cw*0702. Wang H, et al. **Hum Immunol** 1996 Jan; 45(1):52–8

Structural analysis of the minisatellite present at the 3' end of the human apolipoprotein B gene: new definition of the alleles and evolutionary implications. Buresi C, et al. **Hum Mol Genet** 1996 Jan;5(1):61–8

Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. Goldberg YP, et al. **Hum Mol Genet** 1995 Oct;4(10):1911–8

On unequal allelic expression of the neurofibromin gene in neurofibromatosis type 1. Hoffmeyer S, et al. **Hum Mol Genet** 1995 Aug;4(8):1267–72

Allele-specific replication timing in imprinted domains: absence of asynchrony at several loci. Kawame H, et al. **Hum Mol Genet** 1995 Dec;4(12):2287–93

Recombination and allelic association in the Xq/Yq homology region. Li L, et al. **Hum Mol Genet** 1995 Nov; 4(11):2013–6

Double mutant alleles: are they rare? Savov A, et al. **Hum Mol Genet** 1995 Jul;4(7):1169–71

Allelic association and deletions in autosomal recessive proximal spinal muscular atrophy: association of marker genotype with disease severity and candidate cDNAs. Wirth B, et al. **Hum Mol Genet** 1995 Aug;4(8):1273–84

Mass allele detection (MAD) of rare 5-HT1A structural variants with allele-specific amplification and electrochemiluminescent detection. Bergen A, et al. **Hum Mutat** 1996;7(2):135–43

Characterization of large CTG repeat expansions in myotonic dystrophy alleles using PCR. Cheng S, et al. **Hum Mutat** 1996;7(4):304–10

Allele-specific competitive blocker PCR: a one-step method with applicability to pool screening. Orou A, et al. **Hum Mutat** 1995;6(2):163–9

Surrogate light chain expression is required to establish immunoglobulin heavy chain allelic exclusion during early B cell development. Löffert D, et al. **Immunity** 1996 Feb; 4(2):133–44

The rat cim effect: TAP allele-dependent changes in a class I MHC anchor motif and evidence against C-terminal trimming of peptides in the ER. Powis SJ, et al. **Immunity** 1996 Feb;4(2):159–65

An altered position of the alpha 2 helix of MHC class I is revealed by the crystal structure of HLA-B*3501. Smith KJ, et al. **Immunity** 1996 Mar;4(3):203–13

Sequencing of a new HLA-DR14 allele (DRB1(*)1422). Adami N, et al. **Immunogenetics** 1996;43(4):248–9

New alleles of IGKV genes A2 and A18 suggest significant human IGKV locus polymorphism. Atkinson MJ, et al. **Immunogenetics** 1996;44(2):115–20

Characterization of the expressed CIITA allele in the class II MHC transcriptional mutant RJ2.2.5. Brown JA, et al. **Immunogenetics** 1996;43(1-2):88–91

A new HLA-DRB1(*)13 allele (DRB1(*)1318) with a short DRB1(*)08 sequence. Dormoy A, et al. **Immunogenetics** 1996;43(4):240–1

Allelic repertoire of the human MHC class I MICA gene. Fodil N, et al. **Immunogenetics** 1996;44(5):351–7

HLA-A null allele with a stop codon, HLA-A*0215N, identified in a homozygous state in a healthy adult. Ishikawa Y, et al. **Immunogenetics** 1996;43(1-2):1–5

Identification of new TAP2 alleles in gorilla: evolution of the locus within hominoids. Loflin PT, et al. **Immunogenetics** 1996;44(3):161–9

DPB1*BR: an Mhc class II DPB1 allele (DPB1*6601) of negroid origin. Schnittger L, et al. **Immunogenetics** 1996; 44(5):405–6

Nucleotide sequence of a new HLA-DPB1 allele, DPB1*02013. Schranz P, et al. **Immunogenetics** 1996; 44(2):159–60

Nucleotide sequence of a new HLA-DRB1(*)11 allele (DRB1(*)1124). Schranz P, et al. **Immunogenetics** 1996; 43(4):242–3

A new HLA-B35 (B*3516) allele found in a Mexican of Nahua (Aztec) descent. Vargas-Alarcón G, et al. **Immunogenetics** 1996;43(4):244–5

Search for linkage disequilibrium between alleles in the T cell receptor alpha and beta chain loci and susceptibility to rheumatic fever. Abbott WG, et al. **Immunol Cell Biol** 1995 Aug;73(4):369–71

Abrogation of the allelic exclusion in a T cell receptor beta chain gene transgenic mouse strain. Mazda O, et al. **Immunol Invest** 1995 Nov;24(6):927–46

Evolution of MHC class II allelic diversity. McDevitt H. **Immunol Rev** 1995 Feb;143:113–22 (25 ref.)

Quantifying the degree of convergence in primate Mhc-DRB genes. O hUigin C. **Immunol Rev** 1995 Feb;143:123–40 (24 ref.)

Molecular analysis of HLA-DPB1 alleles in idiopathic systemic sclerosis patients and uranium miners with systemic sclerosis. Rihs HP, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):216–22

Identification of an Mhc-DPB1 allele involved in susceptibility to experimental autoimmune encephalomyelitis in rhesus macaques. Slierendregt BL, et al. **Int Immunol** 1995 Oct;7(10):1671–9

HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1. Stuber G, et al. **Int Immunol** 1995 Apr; 7(4):653–63

Dominant-negative p53 can restore tumorigenicity of L-929 cells in immunocompetent mice. Appleman LJ, et al. **Int J Cancer** 1995 Nov 15;63(4):576–83

Allelic loss on chromosomes 8p, 22q and 18q (DCC) in human prostate cancer. Crundwell MC, et al. **Int J Cancer** 1996 Aug 22;69(4):295–300

Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Ohta M, et al. **Int J Cancer** 1996 Mar 15;65(6):762–7

Decreased frequency of HLA-DRB1 13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. Sastre-Garau X, et al. **Int J Cancer** 1996 Jun 21; 69(3):159–64

Association of allelic losses on human chromosomal arms 11Q and 16Q in sporadic breast cancer. Schmutzler RK, et al. **Int J Cancer** 1996 Aug 22;69(4):307–11

Structural variation of novel alleles at the Hum vWA and Hum FES/FPS short tandem repeat loci. Barber MD, et al. **Int J Legal Med** 1995;108(1):31–5

Hungarian population data for the STR systems TH01 and VWA. Furedi S, et al. **Int J Legal Med** 1995;108(1):48–9

Dutch Caucasian population data on the loci LDLR, GYPA, HBGG, D7S8, and GC. Kloosterman AD, et al. **Int J Legal Med** 1995;108(1):36–8

Evaluation of an ACTBP2 ladder composed of 26 sequenced alleles. Möller A, et al. **Int J Legal Med** 1995;108(2):75–8

Observation of null alleles apparently due to deletions. Möller A, et al. **Int J Legal Med** 1995;108(2):90–2

D1S80 (pMCT118): analysis of 3 ethnic subpopulations living in Brussels. Sepulchre MA, et al. **Int J Legal Med** 1995; 108(1):45–7

Distribution of HLA DQA.1 alleles in New Zealand Caucasian, Maori and Pacific Islander populations. Comparison with other population studies. Stringer P, et al. **Int J Legal Med** 1995;108(1):2–7

Mitochondrial alleles of Simulium damnosum sensu lato infected with Onchocerca volvulus. Tang J, et al. **Int J Parasitol** 1995 Oct;25(10):1251–4

Nonallelism of erd and prcd and exclusion of the canine RDS/peripherin gene as a candidate for both retinal degeneration loci. Ray K, et al. **Invest Ophthalmol Vis Sci** 1996 Apr;37(5):783–94

Prevalence of dementia and distribution of ApoE alleles in Japanese centenarians: an almost-complete survey in Yamanashi Prefecture, Japan. Asada T, et al. **J Am Geriatr Soc** 1996 Feb;44(2):151–5

Allelic dropout caused by allele-specific amplification failure in single-cell PCR of the cystic fibrosis delta F508 deletion. Dreesen JC, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):112–4

Polymerase chain reaction amplification specificity: incidence of allele dropout using different DNA preparation methods for heterozygous single cells. Gitlin SA, et al. **J Assist Reprod Genet** 1996 Feb;13(2):107–11

Reduced allele dropout in single-cell analysis for preimplantation genetic diagnosis of cystic fibrosis. Ray PF, et al. **J Assist Reprod Genet** 1996 Feb;13(2):104–6

Allele dropout in sequential PCR and FISH analysis of single cells (cell recycling). Rechitsky S, et al. **J Assist Reprod Genet** 1996 Feb;13(2):115–24

HLA-DP and susceptibility to insulin-dependent diabetes mellitus in an ethnically mixed population. Associations with other HLA-alleles. Balducci-Silano PL, et al. **J Autoimmun** 1995 Jun;8(3):425–37

Specific destruction of islet transplants in NOD<—>C57BL/6 and NOD<—>C3H/Tif embryo aggregation chimeras irrespective of allelic differences in beta-cell antigens. Leijon K, et al. **J Autoimmun** 1995 Jun; 8(3):347–56

Allelic exchange in Mycobacterium tuberculosis with long linear recombination substrates. Balasubramanian V, et al. **J Bacteriol** 1996 Jan;178(1):273–9

Novel alleles of the Escherichia coli dnaA gene are defective in replication of pSC101 but not of oriC. Sutton MD, et al. **J Bacteriol** 1995 Nov;177(22):6657–65

Bcl-2 expression and allelic loss of the p53 gene in gastric carcinomas. Saegusa M, et al. **J Cancer Res Clin Oncol** 1996;122(7):427–32

Are allelic losses at 11q13 universal in MEN 1 tumors? [editorial; comment] Brandi ML, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3162–3. Comment on: J Clin Endocrinol Metab 1996 Sep;81(9):3164–7.

Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? Dotzenrath C, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3194–6

The aldehyde dehydrogenase ALDH2*2 allele exhibits dominance over ALDH2*1 in transduced HeLa cells. Xiao Q, et al. **J Clin Invest** 1995 Nov;96(5):2180–6

A mouse model for the delta F508 allele of cystic fibrosis. Zeiher BG, et al. **J Clin Invest** 1995 Oct;96(4):2051–64

The absence of a B allele in acquired B blood group phenotype confirmed by a DNA based genotyping method. Yip SP, et al. **J Clin Pathol** 1996 Feb;49(2):180–1

The cytoplasmic domains of immunoglobulin (Ig) alpha and Ig beta can independently induce the precursor B cell transition and allelic exclusion. Papavasiliou F, et al. **J Exp Med** 1995 Nov 1;182(5):1389–94

D1S80 typing of DNA from simulated forensic specimens. Baechtel FS, et al. **J Forensic Sci** 1995 Jul;40(4):536–45

D1S80 locus typing by micro thermal cycler. Application to genetic identity testing. Castro A, et al. **J Forensic Sci** 1995 Jul;40(4):546–50

A new extremely large allele at the D1S80 (MCT118) locus. Kádasi L, et al. **J Forensic Sci** 1995 Sep;40(5):906–7

Genotyping of the DQA1*4 alleles by restriction enzyme digestion of the PCR product from the AmpliType PM kit. Lee JC, et al. **J Forensic Sci** 1995 Nov;40(6):1065–7

Typing of DNA HLA-DQ alpha alleles extracted from human nail material using polymerase chain reaction. Tahir MA, et al. **J Forensic Sci** 1995 Jul;40(4):634–6

Prevention of false results from preferential PCR amplification or VNTR alleles. Pai CY, et al. **J Formos Med Assoc** 1996 Jan;95(1):69–72

A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. de Haas M, et al. **J Immunol** 1996 Apr 15; 156(8):3948–55

Mutations in human CD4 impair the functional interaction with different human and mouse class II isotypes and alleles. Fleury S, et al. **J Immunol** 1996 Mar 1; 156(5):1848–55

Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles. Kirschmann DA, et al. **J Immunol** 1995 Dec 15; 155(12):5655–62

Allele-specific motifs characterize HLA-DQ interactions with a diabetes-associated peptide derived from glutamic acid decarboxylase. Kwok WW, et al. **J Immunol** 1996 Mar 15;156(6):2171–7

Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. Neisig A, et al. **J Immunol** 1996 May 1; 156(9):3196–206

Study of HLA-DQA1 alleles in celiac children. Nieto A, et al. **J Investig Allergol Clin Immunol** 1995 Jul–Aug; 5(4):209–15

The influence of the HLA-DRB1*13 allele on measles vaccine response. Hayney MS, et al. **J Investig Med** 1996 Jun;44(5):261–3

Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers [see comments] Kishimoto Y, et al. **J Natl Cancer Inst** 1995 Aug 16;87(16):1224–9. Comment in: J Natl Cancer Inst 1995 Aug 16;87(16):1201–2.

SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. Lehtovirta M, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):644–9

Allelic deletion mapping of putative tumor suppressor genes on 17q in sporadic ovarian cancer. Chen KC, et al. **J Obstet Gynaecol** 1995 Dec;21(6):619–24

The effect of mating structure and progeny distribution on heterozygosity versus the number of alleles as measures of variation. Campbell RB. **J Theor Biol** 1995 Aug 21; 175(4):503–9

Conditions for soft selection favoring the evolution of hybrid inviability. Johnson NA, et al. **J Theor Biol** 1995 Oct 21; 176(4):493–9

Allelic loss at the tuberous sclerosis (Tsc2) gene locus in spontaneous uterine leiomyosarcomas and pituitary adenomas in the Eker rat model. Kubo Y, et al. **Jpn J Cancer Res** 1995 Sep;86(9):828–32

Equivalent parental distribution of frequently lost alleles and biallelic expression of the H19 gene in human testicular germ cell tumors. Mishina M, et al. **Jpn J Cancer Res** 1996 Aug;87(8):816–23

Deletion mapping of chromosome 10 in human glioma. Sonoda Y, et al. **Jpn J Cancer Res** 1996 Apr;87(4):363–7

Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Wu WJ, et al. **Jpn J Cancer Res** 1995 Aug;86(8):730–6

Germ cell tumors: unraveling a biological paradox [editorial; comment] Chaganti RS, et al. **Lab Invest** 1995 Nov; 73(5):593–5. Comment on: Lab Invest 1995 Nov;73(5):606–14.

Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lakhani SR, et al. **Lab Invest** 1996 Jan; 74(1):129–35

Apolipoprotein E allele distribution in parents of Down's syndrome children. Avramopoulos D, et al. **Lancet** 1996 Mar 30;347(9005):862–5

Apolipoprotein E-epsilon 4 gene dose [letter] Corder E, et al. **Lancet** 1995 Oct 7;346(8980):967–8

Attenuation of apolipoprotein E Epsilon4 allele gene dose in late age [letter; comment] Corder EH, et al. **Lancet** 1996 Feb 24;347(9000):542. Comment on: Lancet 1995 Nov 25;346(8987):1387–90.

Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample [see comments] Henderson AS, et al. **Lancet** 1995 Nov 25;346(8987):1387–90. Comment in: Lancet 1996 Feb 24;347(9000):542.

Sequence characterization of alleles Gpi1-Sa and Gpi1-Sb at the glucose phosphate isomerase structural locus. Pearce SR, et al. **Mamm Genome** 1995 Aug;6(8):537–9

Loss of heterozygosity on chromosomes 1, 11, 12, and 14 in hybrid mouse lung adenocarcinomas. Herzog CR, et al. **Mol Carcinog** 1996 Jun;16(2):83–90

Allele and genotype frequencies of eight DNA polymorphisms in the Italian population. Trabetti E, et al. **Mol Cell Probes** 1995 Jun;9(3):183–8

Null microsatellite alleles due to nucleotide sequence variation in the grey-sided vole Clethrionomys rufocanus. Ishibashi Y, et al. **Mol Ecol** 1996 Aug;5(4):589–90

The molecular basis and evolutionary history of a microsatellite null allele in bears. Paetkau D, et al. **Mol Ecol** 1995 Aug;4(4):519–20

An effective method for allele-specific sequencing using restriction enzyme and biotinylation (ASSURE B). Zhang DX, et al. **Mol Ecol** 1996 Aug;5(4):591–4

Novel alleles of cdc13 and cdc2 isolated as suppressors of mitotic catastrophe in Schizosaccharomyces pombe. Berry LD, et al. **Mol Gen Genet** 1996 Jul 26;251(6):635–46

Characterisation of a new allele of pale cress and its role in greening in Arabidopsis thaliana. Grevelding C, et al. **Mol Gen Genet** 1996 Jul 19;251(5):532–41

The biallelic a mating type locus of Ustilago maydis: remnants of an additional pheromone gene indicate evolution from a multiallelic ancestor. Urban M, et al. **Mol Gen Genet** 1996 Mar 7;250(4):414–20

Molecular population genetic analysis of the streptokinase gene of Streptococcus pyogenes: mosaic alleles generated by recombination. Kapur V, et al. **Mol Microbiol** 1995 May; 16(3):509–19

Quantitation of the allelic imbalance provides evidence on tumour heterogeneity: a hypothesis. Kiaris H, et al. **Mutat Res** 1996 Jul 5;354(1):35–9

A C3H strain-specific allele (alpha va126) of the murine alpha-globin gene newly detected by UT-PAGE and RT-PCR-SSCP analysis. Sato H, et al. **Mutat Res** 1996 Apr 13;351(2):125–32

Efficient modification of human chromosomal alleles using recombination-proficient chicken/human microcell hybrids. Dieken ES, et al. **Nat Genet** 1996 Feb;12(2):174–82

Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele [see comments] Lawford BR, et al. **Nat Med** 1995 Apr;1(4):337–41. Comment in: Nat Med 1995 Aug;1(8):720–1.

Head injury, amyloid beta and Alzheimer's disease [letter; comment] Roses AD, et al. **Nat Med** 1995 Jul;1(7):603–4 . Comment on: Nat Med 1995 Feb;1(2):135–7.

ApoE as a prognostic factor for post-traumatic coma [letter; comment] Sorbi S, et al. **Nat Med** 1995 Sep;1(9):852. Comment on: Nat Med 1995 Feb;1(2):135–7.

C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Griffith ME, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):438–43

Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Bondi MW, et al. **Neurology** 1995 Dec;45(12):2203–6

Apolipoprotein-epsilon4 and head trauma: Synergistic or additive risks? [letter; comment] Katzman R, et al. **Neurology** 1996 Mar;46(3):889–91. Comment on: Neurology 1995 Mar;45(3 Pt 1):555–7.

PCR amplification of D2S44 (YNH24) alleles. Kishida T, et al. **Nippon Hoigaku Zasshi** 1995 Oct;49(5):299–303

PAH Mutation Analysis Consortium Database: a database for disease-producing and other allelic variation at the human PAH locus. Hoang L, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):127–31

Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. Kondo M, et al. **Oncogene** 1996 Mar 21;12(6):1365–8

Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinoma and underlying disease. Takeda S, et al. **Oncogene** 1996 Apr 4;12(7):1589–92

Rapid method for separation of microsatellite alleles by the PhastSystem. Buzás Z, et al. **PCR Methods Appl** 1995 Jun; 4(6):380–1

Batched analysis of genotypes. LeDuc C, et al. **PCR Methods Appl** 1995 Jun;4(6):331–6

Identification of a new non-functional CYP2C18 allele in Japanese: substitution of T204 to A in exon2 generates a premature stop codon. Komai K, et al. **Pharmacogenetics** 1996 Feb;6(1):117–9

Selfish genetic elements and their role in evolution: the evolution of sex and some of what that entails. Hurst LD. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):321–32

Molecular analysis of two functional homologues of the S3 allele of the Papaver rhoeas self-incompatibility gene isolated from different populations. Walker EA, et al. **Plant Mol Biol** 1996 Mar;30(5):983–94

Apparent segregation of null alleles ascribed to deletions of the ornithine transcarbamylase gene in congenital hyperammonaemia. Segues B, et al. **Prenat Diagn** 1995 Aug; 15(8):757–61

Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Schmidt JV, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6731–6

Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Bouma G, et al. **Scand J Immunol** 1996 Apr; 43(4):456–63

Allelic diversity and gene genealogy at the self-incompatibility locus in the Solanaceae. Richman AD, et al. **Science** 1996 Aug 30;273(5279):1212–6

Testing independence when the form of the bivariate distribution is unspecified. Geisser S, et al. **Stat Med** 1995 Aug 15;14(15):1621–39

Genotypic variations of type III collagen in patients with cerebral aneurysms. Brega KE, et al. **Surg Neurol** 1996 Sep; 46(3):253–6; discussion 256–7

Identification of a novel HLA-B40 allele (B*4008) in a patient with leukemia. Adams EJ, et al. **Tissue Antigens** 1995 Sep;46(3 (Pt 1)):204–5

Predictability of alloreactivity among unrelated individuals: role for HLA-DPB1. Awdeh ZL, et al. **Tissue Antigens** 1995 Sep;46(3 (Pt 1)):180–6

A novel HLA-A24 allele (A*2405) identified by single-strand conformation polymorphism analysis and confirmed by solid-phase sequencing and isoelectric focusing. Blasczyk R, et al. **Tissue Antigens** 1995 Jul; 46(1):54–8

Determination of HLA class II alleles by genotyping in a Manchu population in the northern part of China and its relationship with Han and Japanese populations. Geng L, et al. **Tissue Antigens** 1995 Aug;46(2):111–6

Two novel DRB1 alleles, DRB1*1118 and DRB1*1119, detected by PCR-SSOP and confirmed by DNA sequencing. Heine U, et al. **Tissue Antigens** 1995 Jul; 46(1):68–70

Definition of HLA-C alleles using sequence-specific oligonucleotide probes (PCR-SSOP). Kennedy LJ, et al. **Tissue Antigens** 1995 Sep;46(3 (Pt 1)):187–95

Characterization of a new DPB1 allele (DPB1*5701) isolated from a Caucasian individual. Mersch G, et al. **Tissue Antigens** 1995 Sep;46(3 (Pt 1)):208–12

On the nucleotide sequences of B*2702 and B*2705. Moses JH, et al. **Tissue Antigens** 1995 Jul;46(1):50–3

A comprehensive approach for typing the alleles of the HLA-B locus by automated sequencing. Petersdorf EW, et al. **Tissue Antigens** 1995 Aug;46(2):73–85

The relative distribution of B35 alleles and their IEF isotypes in a HLA-B35-positive population. Ragupathi G, et al. **Tissue Antigens** 1995 Jul;46(1):24–31

Allelic heterogeneity of HLA-B35 subtypes in different populations as assessed by DNA typing. Satz ML, et al. **Tissue Antigens** 1995 Sep;46(3 (Pt 1)):196–203

A new HLA-DRB1*1116 allele sharing DR13 and DR11 sequence motifs. Thonnard J, et al. **Tissue Antigens** 1995 Aug;46(2):124–7

A complete exon 2 sequence of the HLA-DPA1*02012 allele. Versluis LF, et al. **Tissue Antigens** 1995 Sep;46(3 (Pt 1)):206–7

Tracking H-2 alleles in transgenic mice by RFLP and heteroduplex analysis. Shanmugam V, et al. **Transgenic Res** 1996 May;5(3):203–8

The INS B allele (1,428 Fok I) is associated with reduced IDDM incidence in autoantibody-positive first degree relatives despite the presence of autoantibodies and high-risk HLA alleles. Pugliese A, et al. **Transplant Proc** 1995 Dec;27(6):3392

The frequencies of HLA alleles and haplotypes and their distribution among donors and renal patients in the UNOS registry. Zachary AA, et al. **Transplantation** 1996 Jul 27; 62(2):272–83

Rapid identification of ApoE alleles by multiple-single-strand conformation polymorphism (SSCP) analysis. Wilton S, et al. **Trends Genet** 1995 Sep; 11(9):341

Immunoregulatory role of H-2 and intra-H-2 alleles on antibody responses to recombinant preparations of B-subunits of Escherichia coli heat-labile enterotoxin (rEtxB) and cholera toxin (rCtxB). Nashar TO, et al. **Vaccine** 1995 Jun;13(9):803–10

Genomic cloning and characterization of the nonoccupied allele corresponding to the integration site of human papillomavirus type 16 DNA in the cervical cancer cell line SiHa. Bauer-Hofmann R, et al. **Virology** 1996 Mar 1;217(1):33–41

[Correlation study of allelic gene deletion of nm23-H1 and

human colorectal carcinoma metastasis] Xu W, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):263–5 (Eng. Abstr.) **(Chi)**

[Distribution of ABO allele frequencies in the Cologne registration district (Nordrhein-Westfalen)] Scheil HG, et al. **Anthropol Anz** 1995 Sep;53(3):199–208 (Eng. Abstr.) **(Ger)**

[Genetic determination of bone density] Baltzer A, et al. **Z Orthop Ihre Grenzgeb** 1996 May–Jun;134(3):198, 199–200 (Eng. Abstr.) **(Ger)**

[Allelic variations of DPB1, DQA1, DQB1 and DRB1 and rheumatoid arthritis: further genetic and statistical considerations] Morozzi G, et al. **Ann Ital Med Int** 1995 Jul–Sep;10(3):171–4 (Eng. Abstr.) **(Ita)**

[Atheroma plaque and Apo E alleles] Venarucci D, et al. **Minerva Cardioangiol** 1996 Jan–Feb;44(1–2):15–8 (Eng. Abstr.) **(Ita)**

[Analysis of the allele specific Ag-binding site on murine class II MHC] Kajino K. **Hokkaido Igaku Zasshi** 1996 Mar; 71(2):187–203 (Eng. Abstr.) **(Jpn)**

[HLA-DR2 alleles and uveitis in leprosy] Joko S, et al. **Nippon Rai Gakkai Zasshi** 1995 Jul;64(2):112–8 (Eng. Abstr.) **(Jpn)**

[The relationship between genotypes of HLA-DRB1 alleles and progression of bony destruction changes of rheumatoid arthritis] Toda Y, et al. **Ryumachi** 1995 Jun;35(3):514–20 (Eng. Abstr.) **(Jpn)**

[Mutant allele specific amplification (MASA)] Sugai S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):546–8 (11 ref.) **(Jpn)**

[Allele-specific sequencing] Kalinin VN, et al. **Doki Akad Nauk** 1995 Aug;343(5):692–4 **(Rus)**

[Analysis of allelic variants of the hypervariable locus of apolipoprotein B in Bashkir and Komi populations] Khusnutdinova EK, et al. **Genetika** 1995 Jul;31(7):995–1000 (Eng. Abstr.) **(Rus)**

[Allelic variants of apolipoproteins B and CII genes in patients with ischemic heart disease and in healthy persons from the Moscow population] Pogoda TV, et al. **Genetika** 1995 Jul;31(7):1001–9 (Eng. Abstr.) **(Rus)**

[Distribution of the kappa-casein gene alleles in the bison (Bison bonasus) population] Udina IG, et al. **Genetika** 1995 Dec;31(12):1704–6 (Eng. Abstr.) **(Rus)**

[Genetic instability in the Drosophila melanogaster lozenge locus: characteristics of the lz75V locus] Voloshina MA, et al. **Genetika** 1995 Dec;31(12):1637–44 (Eng. Abstr.) **(Rus)**

[Genetics of unstable alleles of X-chromosome genes isolated during the outburst of the yellow mutation in 1982–1991 in the natural population of Drosophila melanogaster in Umani] Zakharov IK, et al. **Genetika** 1995 Aug; 31(8):1079–84 (Eng. Abstr.) **(Rus)**

[Segregation and genetic dispersion analysis of the pedigrees of breast cancer patients in the Kiev region] Naleskina LA, et al. **Tsitol Genet** 1995 Sep–Oct;29(5):60–4 (Eng. Abstr.) **(Rus)**

[Allelic loss on chromosome 11q13 in male breast cancer] Sanz Ortega J. **An R Acad Nac Med (Madr)** 1995; 112(4):669–77 **(Spa)**

ALLELISM TEST see **GENETIC COMPLEMENTATION TEST**

ALLERGEN BRONCHIAL PROVOCATION TESTS see **BRONCHIAL PROVOCATION TESTS**

ALLERGEN IMMUNOTHERAPY see **DESENSITIZATION, IMMUNOLOGIC**

ALLERGENS

see related
BITES AND STINGS
DUST
FEATHERS
FUNGI

Allergen-induced late airways reactions in the pig. Influence of endogenous and exogenous glucocorticoids. Fornhem C. **Acta Physiol Scand Suppl** 1995;631:1–48

Study on the ability of a new barrier to reduce airborne mite allergens. Rigamonti IE, et al. **Allerg Immunol (Paris)** 1996 Mar;28(3):70–3

Immunotherapy with the storage mite lepidoglyphus destructor. Armentia-Medina A, et al. **Allergol Immunopathol (Madr)** 1995 Sep–Oct;23(5):211–23

Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Feliziani V, et al. **Allergol Immunopathol (Madr)** 1995 Sep–Oct; 23(5):224–30

Diagnostic value of the nasal provocation test with Dermatophagoides pteronyssinus in childhood asthma. Baki A, et al. **Allergy** 1995 Sep;50(9):751–4

Allergen nomenclature. King TP, et al. **Allergy** 1995 Sep; 50(9):765–74

Atopy and skin reactivity at school age in children followed up from birth, with special reference to atopy prevention in infancy and atopic findings at preschool age. Kuikka L, et al. **Allergy Proc** 1995 Nov–Dec;16(6):313–7

Inflammatory and T-cell profile of asthmatic airways 6 hours after local allergen provocation. Gratziou C, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):515–20

Exposure-sensitization relationship for alpha-amylase allergens in the baking industry. Houba R, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):130–6

The effect of ozone exposure on allergen responsiveness in subjects with asthma or rhinitis. Jörres R, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):56–64

Effect of diuretics on allergen-induced contractions of passively sensitized human bronchi in vitro. Pavord I, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1164–9

House dust mite allergens. A major risk factor for childhood asthma in Australia. Peat JK, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):141–6

Seasonal characteristics of ragweed pollen dispersal in the United States. Frenz DA, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):417–22

Prevalence of sensitization to Dermatophagoides pteronyssinus in several industrial populations. Macan J, et al. **Arh Hig Rada Toksikol** 1995 Dec;46(4):399–404

Basement shower hypersensitivity pneumonitis secondary to Epicoccum nigrum. Hogan MB, et al. **Chest** 1996 Sep; 110(3):854–6

What the pulmonologist needs to know about allergy. Hoover GE, et al. **Clin Chest Med** 1995 Dec;16(4):603–20 (129 ref.)

The use of domestic steam cleaning for the control of house dust mites. Colloff MJ, et al. **Clin Exp Allergy** 1995 Nov; 25(11):1061–6

Glycidyl methacrylate and ethoxyethyl acrylate: new allergens in emulsions used to impregnate paper and textile materials. Matura M, et al. **Contact Dermatitis** 1995 Aug; 33(2):123–4

Esoteric contact dermatitis. Part III: Ragweed dermatitis [news] Fisher AA. **Cutis** 1996 Apr;57(4):199–200

Contact allergy testing alternatives: 1996. Scheman A. **Cutis** 1996 Apr;57(4):235–40 (22 ref.)

Latex allergen allergic reactions [letter] Bastyr EJ 3rd. **Diabetes Care** 1996 May;19(5):546

Interactions of sulfates of divalent metals in nickel-sulfate-sensitive patients. Santucci B, et al. **Exp Dermatol** 1996 Apr;5(2):79–83

Expression of Zm13, a pollen specific maize protein, in Escherichia coli reveals IgE-binding capacity and allergenic potential. Heiss S, et al. **FEBS Lett** 1996 Mar 4;381(3):217–21

Significance of rubber elongation factor as a latex allergen. Alenius H, et al. **Int Arch Allergy Immunol** 1996 Apr; 109(4):362–8

Establishment and characterization of ovalbumin-specific T cell lines from patients with egg allergy. Katsuki T, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):344–51

Fel d 1-specific IgG antibodies induced by natural exposure have blocking activity in skin tests. Witteman AM, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):369–75

Allergen nomenclature [editorial] Larsen JN, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):577–8

Socioeconomic status and race as risk factors for cockroach allergen exposure and sensitization in children with asthma. Sarpong SB, et al. **J Allergy Clin Immunol** 1996 Jun; 97(6):1393–401

Chemical treatment of carpets to reduce allergen: comparison of the effects of tannic acid and other treatments on proteins derived from dust mites and cats. Woodfolk JA, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):325–33

Enhancement of Antigen-specific functional responses by neutrophils from allergic patients. Monteseirín J, et al. **J Exp Med** 1996 Jun 1;183(6):2571–9

Low zone tolerance to contact allergens in mice: a functional role for CD8+ T helper type 2 cells. Steinbrink K, et al. **J Exp Med** 1996 Mar 1;183(3):759–68

The Florida environment. Important outdoor aeroallergens. Jelks ML. **J Fla Med Assoc** 1996 Jun–Jul;83(6):406–10

House dust mite allergy in Florida. Ledford DK. **J Fla Med Assoc** 1996 Jun–Jul;83(6):411–4

Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Tan BB, et al. **Lancet** 1996 Jan 6;347(8993):15–8

Environmental control in childhood asthma. Naspitz CK, et al. **Pediatr Pulmonol Suppl** 1995;11:47–8

Conditioning allergic skin responses in humans: a controlled trial. Booth RJ, et al. **Psychosom Med** 1995 Sep–Oct; 57(5):492–5

Identification of soyabean allergens and immune mechanisms of dietary sensitivities in preruminant calves. Lallès JP, et al. **Res Vet Sci** 1996 Mar;60(2):111–6

Air filtration units [letter; comment] Warbuton CJ, et al. **Respir Med** 1995 Nov;89(10):714. Comment on: Respir Med 1995 May;89(5):394.

Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma. van Velzen E, et al. **Thorax** 1996 Jun;51(6):582–4

Environmental factors and respiratory hypersensitivity: experiences from studies in Eastern and Western Europe. Björkstén B. **Toxicol Lett** 1996 Aug;86(2–3):93–8 (17 ref.)

Stimulation by oxazolone of increased IL-6, but not IL-10, in the skin of mice. Holliday MR, et al. **Toxicology** 1996 Jan 8;106(1–3):237–42

[Natural substances causing allergies and dermatitis] Tumová L, et al. **Ceska Slov Farm** 1995 Dec;44(6):293–300 (Eng. Abstr.) **(Cze)**

[Replacement of preservation agent Kathon CG in cosmetics by Euxyl K 400; indeed out of the frying pan into the fire] de Groot AC. **Ned Tijdschr Geneeskd** 1995 Sep 9; 139(36):1850 **(Dut)**

[Feather allergy--rarer than formerly thought] Kilpiö K, et al. **Duodecim** 1995;111(4):331–6 **(Fin)**

[My use of the Association Française d'Études des Ambroisies pollen calendar for Lyon-Bron (P. Cour collector)] Bouteloup F. **Allerg Immunol (Paris)** 1995 Nov; 27(9):326–31 (Eng. Abstr.) **(Fre)**

[Prevalence of ragweed hayfever in the south and east of the greater Lyon region in 1993] Déchamp C, et al. **Allerg Immunol (Paris)** 1995 Nov;27(9):320, 323–5 (Eng. Abstr.) **(Fre)**

[Natural allergens and recombinant allergens] Deviller P. **Allerg Immunol (Paris)** 1995 Nov;27(9):316–9 (6 ref.) (Eng. Abstr.) **(Fre)**

[Allergologic survey in 251 patients with moderate or severe dermatitis. Incidence and value of the detection of contact eczema, food allergy or sensitization to air-borne allergens] Guillet MH, et al. **Ann Dermatol Venereol** 1996; 123(3):157–64 (Eng. Abstr.) **(Fre)**

[New aero-allergens] De Blay F, et al. **Rev Pneumol Clin** 1996;52(2):79–87 (84 ref.) (Eng. Abstr.) **(Fre)**

[Latex allergy: from contact urticaria to asthma] Helbling A. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):978–82 (22 ref.) (Eng. Abstr.) **(Ger)**

[Allergic diseases in the indoor environment] Schata M. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):196–211 (8 ref.) (Eng. Abstr.) **(Ger)**

[Correlation between exposure to allergenic pollens and allergic manifestations] Rachmiel M, et al. **Harefuah** 1996 Apr 15;130(8):505–11, 584 (Eng. Abstr.) **(Heb)**

[Comparison of intradermal and prick tests based on samples of the most common allergens in the Zadar region] Mazzi A. **Lijec Vjesn** 1995 Mar–Apr;117(3–4):76–9 (Eng. Abstr.) **(Scr)**

[Frequency of allergens in immediate, late, and dual allergic skin response at the National Institute of Pediatrics] Wakida G, et al. **Rev Alerg Mex** 1995 Jul–Aug;42(4):69–73 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

The guinea pig maximization test--with a multiple dose design. Andersen KE, et al. **Acta Derm Venereol** 1995 Nov; 75(6):463–9

Immediate nasal response to allergen challenge cytologic changes in the nasal secretions and histologic changes in the nasal mucosa. Pelikan Z, et al. **Adv Exp Med Biol** 1995; 371B:847–53

Late nasal response to allergen challenge cytologic changes in the nasal secretions and histologic changes in the nasal mucosa. Pelikan Z, et al. **Adv Exp Med Biol** 1995; 371B:855–60

Effect of terfenadine and budesonide on nasal symptoms, olfaction, and nasal airway patency following allergen challenge. Hilberg O. **Allergy** 1995 Aug;50(8):683–8

Ragweed antigen causes interleukin-8 production in sensitized dog trachea. Kaneko T, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):136–40

Pretreatment with allergen prevents immediate hypersensitivity and airway hyperresponsiveness. Oshiba A, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):102–9

Allergy injection at home [letter] Anand SC. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):82

Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Donovan JP, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):74–80

Safety questions for skin test devices [letter] Engler DB. **Ann Allergy Asthma Immunol** 1996 May;76(5):478

Biologic potency and immunoblotting studies of extracts of three cockroach species. Smith DL, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):317–23

An in vivo model of allergic inflammation: pulmonary human cell infiltrate in allergen-challenged allergic Hu-SCID mice. Duez C, et al. **Eur J Immunol** 1996 May; 26(5):1088–93

Comparative influence of a single allergen exposure on the different components of airway response to methacholine. Boulet LP, et al. **Int Arch Allergy Immunol** 1996 Aug; 110(4):388–96

Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study. Andri L, et al. **J Allergy Clin Immunol** 1996 Jan; 97(1 Pt 1):34–41

Inhaled beta 2-agonists and allergen-induced airway responses [letter; comment] Cockcroft DW, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):1013–4. Comment on: J Allergy Clin Immunol 1995 Mar;95(3):641–51.

A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis. Day JH, et al. **J Allergy Clin Immunol** 1996 May;97(5):1050–7

Dynamics of nasal eosinophils in response to a nonnatural allergen challenge in patients with allergic rhinitis and control subjects: a biopsy and brush study. Godthelp T, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):800–11

Effects of luminal antigen on intestinal albumin and hyaluronan permeability and ion transport in atopic patients. Knutson TW, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1225–32

Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies. Pauli G, et al.

J Allergy Clin Immunol 1996 May;97(5):1100-9

Positive nasal challenge responses to Blomia tropicalis. Stanaland BE, et al. **J Allergy Clin Immunol** 1996 May; 97(5):1045-9

Induction of atopic dermatitis by inhalation of house dust mite. Tupker RA, et al. **J Allergy Clin Immunol** 1996 May; 97(5):1064-70

Local intranasal immunotherapy with allergen in powder in atopic patients sensitive to Parietaria officinalis pollen. Ariano R, et al. **J Investig Allergol Clin Immunol** 1995 May-Jun;5(3):126-32

Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. Troise C, et al. **J Investig Allergol Clin Immunol** 1995 Jan-Feb;5(1):25-30

T-cell "priming" against environmental allergens in human neonates: sequential deletion of food antigen reactivity during infancy with concomitant expansion of responses to ubiquitous inhalant allergens. Holt PG, et al. **Pediatr Allergy Immunol** 1995 May;6(2):85-90

Specific down-regulation of anti-allergen IgE and IgG antibodies in humans associated with injections of allergen-specific antibody complexes. Jacquemin MG, et al. **Ther Immunol** 1995 Feb;2(1):41-52

ADVERSE EFFECTS

Inhalant allergens: as a cause of respiratory allergy in east Mediterranean area, Turkey. Güneser S, et al. **Allergol Immunopathol (Madr)** 1996 May-Jun;24(3):116-9

Aerobiologic and clinical aspects of mould allergy in Europe. D'Amato G, et al. **Allergy** 1995 Nov;50(11):870-7 (62 ref.)

Reactions to airborne fish particles [letter] David TJ. **Allergy** 1995 Nov;50(11):931-2

Latex allergens in glove-powdering slurries. Lundberg M, et al. **Allergy** 1995 Apr;50(4):378-80

Allergen challenge in asthma: association of eosinophils and lymphocytes with interleukin-5. Sur S, et al. **Allergy** 1995 Nov;50(11):891-8

Parietaria pollinosis: clinical and epidemiological aspects. Liccardi G, et al. **Allergy Asthma Proc** 1996 Jan-Feb; 17(1):23-9

Novel predictive assay for contact allergens using human skin explant cultures. Pistoor FH, et al. **Am J Pathol** 1996 Jul;149(1):337-43

Daily asthma severity in relation to personal ozone exposure and outdoor fungal spores. Delfino RJ, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):633-41

Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Diamant Z, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1790-5

Exogenous stimuli and circadian peak expiratory flow variation in allergic asthmatic children. Meijer GG, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):237-42

Serum house-dust-mite antibodies and reduced FEV1 in adults of a Norwegian community. Omenaas E, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1158-63

Multifactorial immunologic lung disease: a case report. Krasnick J, et al. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):239-41

Skin prick tests and in vitro immunoassays with native spices and spice extracts. Niinimäki A, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):280-6

Extensive subcutaneous fibrosis in a patient treated with alum precipitated allergenic extract. Orfan NA, et ai. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):453-6

Rush immunotherapy: experience with a one-day schedule. Sharkey P, et al. **Ann Allergy Asthma Immunol** 1996 Feb; 76(2):175-80

Allergic conjunctivitis caused by sugi (Cryptomeria japonica D. Don) pollen out of season. Fujishima H, et al. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):113-7

Pulmonary responses to allergens and pollutants. Lebowitz MD, et al. **Chest** 1996 Mar;109(3 Suppl):54S-55S

Sensitivity to two major allergens (Cry j I and Cry j II) in patients with Japanese cedar (Cryptomeria japonica) pollinosis. Hashimoto M, et al. **Clin Exp Allergy** 1995 Sep; 25(9):848-52

Influence of the menstrual cycle on skin-prick test reactions to histamine, morphine and allergen. Kalogeromitros D, et al. **Clin Exp Allergy** 1995 May;25(5):461-6

Specific immunotherapy in house dust mite allergy. Bousquet J, et al. **Clin Rev Allergy Immunol** 1995 Summer;13(2):151-9 (57 ref.)

Atopic dermatitis and delayed hypersensitivity to dust mites. Castelain M. **Clin Rev Allergy Immunol** 1995 Summer; 13(2):161-72 (53 ref.)

Introduction. House dust mite allergy. Guérin B. **Clin Rev Allergy Immunol** 1995 Summer;13(2):107-13 (57 ref.)

Patch testing with fragrances: results of a multicenter study of the European Environmental and Contact Dermatitis Research Group with 48 frequently used constituents of perfumes. Frosch PJ, et al. **Contact Dermatitis** 1995 Nov; 33(5):333-42

Contact urticaria from chironomids. Galindo PA, et al. **Contact Dermatitis** 1996 Apr;34(4):297

Butenylbithiophene, alpha-terthienyl and hydroxytremetone as contact allergens in cultivars of marigold (Tagetes sp.). Hausen BM, et al. **Contact Dermatitis** 1995 Jul;33(1):33-7

In vivo cytokine profiles in allergic and irritant contact dermatitis. Hoefakker S, et al. **Contact Dermatitis** 1995 Oct; 33(4):258-66

Methyl acrylate: a new sensitizer in nail lacquer. Kanerva L, et al. **Contact Dermatitis** 1995 Sep;33(3):203-4

Oral lichenoid lesions, mercury hypersensitivity and combined hypersensitivity to mercury and other metals: histologically-proven reproduction of the reaction by patch testing with metal salts. Koch P, et al. **Contact Dermatitis** 1995 Nov;33(5):323-8

Persistent allergic contact dermatitis at the site of primary sensitization with squaric acid dibutyl ester. Nasca MR, et al. **Contact Dermatitis** 1995 Dec;33(6):438

Photocontact dermatitis from rue (Ruta montana L.). Ortiz-Frutos FJ, et al. **Contact Dermatitis** 1995 Oct; 33(4):284

Allergic contact dermatitis from Pleurotus mushroom. Rosina P, et al. **Contact Dermatitis** 1995 Oct;33(4):277-8

Contact allergens in toothpastes and a review of their hypersensitivity. Sainio EL, et al. **Contact Dermatitis** 1995 Aug;33(2):100-5 (74 ref.)

Occupational hand dermatitis in hospital environments. Stingeni L, et al. **Contact Dermatitis** 1995 Sep;33(3):172-6

Allergic contact dermatitis from cow hair and dander. Timmer C, et al. **Contact Dermatitis** 1996 Apr;34(4):292-3

Textile dye contact allergens. Hatch KL. **Curr Probl Dermatol** 1995;22:8-16

Paint dermatitis: the role of "routine" patch test series in detecting contact allergens in paint [news] Fisher AA. **Cutis** 1995 Jul;56(1):16

Tolerance to different toilet paper preparations: toxicological and allergological aspects. Blecher P, et al. **Dermatology** 1995;191(4):299-304

Atopic dermatitis: new knowledge and new approaches. Kolmer HL, et al. **Hosp Pract (Off Ed)** 1995 Oct 15; 30(10):63-72 (9 ref.)

Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis. Bernstein DI, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):749-55

Cat antigen in homes with and without cats may induce allergic symptoms. Bollinger ME, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):907-14

Exposure and sensitization to environmental allergen of predominantly Hispanic children with asthma in San Diego's inner city. Christiansen SC, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):288-94

Mite allergens did not cause asthma epidemics in Barcelona, Spain. Codina R, et al. **J Allergy Clin Immunol** 1996 Jul; 98(1):236-8

Exposure to house dust mite allergens and the clinical activity of asthma. Custovic A, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):64-72

A prospective, controlled study showing that rubber gloves are the major contributor to latex aeroallergen levels in the operating room. Heilman DK, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):325-30

A low allergen diet is a significant intervention in infantile colic: results of a community-based study. Hill DJ, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):886-92

The accuracy of features in the clinical history for predicting atopic sensitization to airborne allergens in children. Murray AB, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):588-96

Allium cepa seeds: a new occupational allergen. Navarro JA, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):690-3

Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing patients with symptomatic from patients with asymptomatic allergy to common aeroallergens. Pastorello EA, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):580-7

Influence of allergen avoidance on the eosinophil phase of airway inflammation in children with allergic asthma. Piacentini GL, et al. **J Allergy Clin Immunol** 1996 May; 97(5):1079-84

"Hidden" allergens in foods. Steinman HA. **J Allergy Clin Immunol** 1996 Aug;98(2):241-50 (93 ref.)

Occupational asthma caused by grass juice. Subiza J, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):693-5

Systemic reactions to immunotherapy: comparisons between two large allergy practices. Wells JH. **J Allergy Clin Immunol** 1996 Apr;97(4):1030-2

Hypoallergenicity and the dermatologist's perception. Draelos ZD, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):248-51

Multiple cutaneous B-cell pseudolymphomas after allergen injections. Goerdt S, et al. **J Am Acad Dermatol** 1996 Jun; 34(6):1072-4

Anaphylactic reaction to aprotinin [letter] Ceriana P, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):477-8

Triclosan reduces the clinical symptoms of the allergic patch test reaction (APR) elicited with 1% nickel sulphate in sensitised patients. Barkvoll P, et al. **J Clin Periodontol** 1995 Jun;22(6):485-7

Work-related asthma in a population exposed to grain, flour and other ingredient dusts. Smith TA, et al. **Occup Med (Oxf)** 1996 Feb;46(1):37-40

Major basic protein and topical administration of ketotifen in pollinosis under natural allergen provocation. Kato M, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Sep-Oct; 57(5):269-72

Environmental factors influencing the levels of indoor allergens. Munir AK. **Pediatr Allergy Immunol** 1995;6 Suppl 7:13-21 (91 ref.)

Allergen exposure and development of atopic diseases: progress and challenges [editorial] Neijens HJ, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 7:5-7

The Schultz-Dale response of sensitized canine bronchial smooth muscle. Sigurdsson SB, et al. **Respir Physiol** 1995 Oct;102(1):79-87

[Contact dermatoses: new antigens and current events] Castelain M. **Allerg Immunol (Paris)** 1995 Dec;27(10):363-9 (37 ref.) (Eng. Abstr.) **(Fre)**

[Importance of the leukotriene C4 liberation test for the diagnosis of drug allergy (preliminary results)] Sainte-Laudy J, et al. **Allerg Immunol (Paris)** 1996 Feb; 28(2):44-7 (Eng. Abstr.) **(Fre)**

[Asthma to green coffee of environmental origin] Mairesse M, et al. **Rev Mal Respir** 1996 Jul;13(3):308-9 (Eng. Abstr.) **(Fre)**

[Beta-2 agonists, exposure to allergens and bronchial hyperreactivity in children with allergic asthma] Piacentini GL, et al. **Pediatr Med Chir** 1995 Nov-Dec;17(6):515-7 (Eng. Abstr.) **(Ita)**

[Phytotherapy of the sensitization state caused by metal allergens] Martinson TG. **Med Tr Prom Ekol** 1995; (11):37-40 (Eng. Abstr.) **(Rus)**

[Colitis induced by a food allergen. A report of 20 cases] Armisén Pedrejón A, et al. **An Esp Pediatr** 1996 Jan; 44(1):21-4 (Eng. Abstr.) **(Spa)**

[The allergen-asthma relationship in the home microenvironment] Vázquez Nava F, et al. **Rev Alerg Mex** 1996 Mar-Apr;43(2):29-33 (Eng. Abstr.) **(Spa)**

ANALYSIS

Basic isoforms of Par o 1, the major allergen of Parietaria officinalis pollen. Coscia MR, et al. **Allergy** 1995 Nov; 50(11):899-904

Allergen avoidance in a day-care center. Munir AK, et al. **Allergy** 1996 Jan;51(1):36-41

Prevention of latex allergy. Wrangsjö K, et al. **Allergy** 1996 Jan;51(1):65-7

House dust mite allergen [letter; comment] Chew GL. **Am Ind Hyg Assoc J** 1996 Jun;57(6):573-4. Comment on: Am Ind Hyg Assoc J 1995 Nov;56(11):1133-40.

Air quality in an animal facility: particulates, ammonia, and volatile organic compounds. Kacergis JB, et al. **Am Ind Hyg Assoc J** 1996 Jul;57(7):634-40

Mite and cat allergen levels in homes and severity of asthma. Chan-Yeung M, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1805-11

Effect of application of benzyl benzoate on house dust mite allergen levels. Chang JH, et al. **Ann Allergy Asthma Immunol** 1996 Sep;77(3):187-90

Mountain cedar allergens found in nonpollen tree parts. Goetz DW, et al. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):256-60

Seasonal changes in mite allergen (Der I and Der II) concentrations in Japanese homes. Miyazawa H, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):170-4

Prevalence of house dust mites in the Rocky Mountain states. Nelson HS, et al. **Ann Allergy Asthma Immunol** 1995 Oct; 75(4):337-9

Major cat allergen (Fel d I) levels in the homes of patients with asthma and their relationship to sensitization to cat dander. Quirce S, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):325-30

Short-term effects of extermination and cleaning on cockroach allergen Bla g 2 in settled dust. Sarpong SB, et al. **Ann Allergy Asthma Immunol** 1996 Mar;76(3):257-60

Identification of low molecular weight allergens of American cockroach and production of monoclonal antibodies. Wu CH, et al. **Ann Allergy Asthma Immunol** 1996 Feb; 76(2):195-203

Identification of contact allergens in unmodified rosin using a combination of patch testing and analytical chemistry techniques. Sadhra S, et al. **Br J Dermatol** 1996 Apr; 134(4):662-8

Evaluation of the allergic/irritant potential of air pollutants: detection of proteins modified by volatile organic compounds from oilseed rape (Brassica napus ssp. oleifera) using electrospray ionization-mass spectrometry. Butcher RD, et al. **Clin Exp Allergy** 1995 Oct;25(10):985-92

Absence of continuous epitopes in the house dust mite major allergens Der p I from Dermatophagoides pteronyssinus and Der f I from Dermatophagoides farinae. Collins SP, et al. **Clin Exp Allergy** 1996 Jan;26(1):36-42

Characterization of the house dust mite allergen Der p 7 by monoclonal antibodies. Shen HD, et al. **Clin Exp Allergy** 1995 May;25(5):416-22

Separation of jumper ant (Myrmecia pilosula) venom allergens: a novel group of highly basic proteins. Donovan GR, et al. **Electrophoresis** 1995 May;16(5):804-10

Glutathione S-transferase a major allergen of the house dust mite, Dermatophagoides pteronyssinus. O'Neill GM, et al. **Immunol Lett** 1995 Dec;48(2):103-7

Identification of IgE-binding egg white proteins: comparison of results obtained by different methods. Aabin B, et al. **Int Arch Allergy Immunol** 1996 Jan;109(1):50-7

Direct determination of allergens in ambient aerosols: methodological aspects. Schäppi GF, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):364-70

Identification of T-cell epitopes of Lol p 9, a major allergen of ryegrass (Lolium perenne) pollen. Blaher B, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):124-32

Assessment of the endogenous allergens in glyphosate-tolerant and commercial soybean varieties. Burks AW, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):1008-10

Allergens of horse dander: comparison among breeds and individual animals by immunoblotting. Felix K, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):169-71

Environmental distribution of house dust mite allergen (Der p 5). Li CS, et al. **J Allergy Clin Immunol** 1996 Mar; 97(3):857-9

Improved diagnosis of allergic bronchopulmonary aspergillosis with gp66 (formerly antigen 7) of Aspergillus fumigatus for specific IgE detection. Little SA, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):55-63

Sequential determinations of Blomia tropicalis allergens in mattress and floor dust samples in a tropical city. Puerta L, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):689-91

Measurement of airborne mite allergen exposure in individual subjects. Sakaguchi M, et al. **J Allergy Clin Immunol** 1996 May;97(5):1040-4

Characterization of the allergen(s) in latex protein extracts. Tomazic VJ, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):635-42

Clothing--an important source of mite allergen exposure. Tovey ER, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):999-1001

Removal of mite allergens from blankets: comparison of dry cleaning and hot water washing. Watanabe M, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):1010-2

Immunogold probes for light and electron microscopic localization of Ole e I in several Oleaceae pollens. Fernandez MC, et al. **J Histochem Cytochem** 1996 Feb; 44(2):151-8

Scanning electron microscopy of immunogold labeled cat allergens (Fel d 1) on the surface of airborne house dust particles. Ormstad H, et al. **J Immunol Methods** 1995 Dec 1;187(2):245-51

Analysis of the IgE-epitope of Der f 2, a major mite allergen, by in vitro mutagenesis. Nishiyama C, et al. **Mol Immunol** 1995 Oct;32(14-15):1021-9

Identification of a Brazil-nut allergen in transgenic soybeans [see comments] Nordlee JA, et al. **N Engl J Med** 1996 Mar 14;334(11):688-92. Comment in: N Engl J Med 1996 Mar 14;334(11):726-8.

Immunochemical and molecular methods for defining and measuring indoor allergens: in dust and air. Chapman MD, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 7:8-12 (32 ref.)

Allergen levels causing sensitisation, bronchial hyperreactivity and asthma. Dreborg S. **Pediatr Allergy Immunol** 1995;6 Suppl 7:22-6 (44 ref.)

trategies for indoor allergen elimination. Wahn U, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 7:42-6 (41 ref.)

Latex allergen levels of injectable collagen stored in syringes with rubber plungers. Jones JM, et al. **Urology** 1996 Jun; 47(6):898-902

[Metrology of airborne particles carrying the principal air allergens] De Blay F, et al. **Rev Mal Respir** 1995; 12(4):343-52 (Eng. Abstr.) **(Fre)**

[Airborne Japanese cedar allergens studied by immunoblotting technique using anti-Cry j I monoclonal antibody--comparison with actual pollen counts and effect of wind speed and directions] Iwaya M, et al. **Arerugi** 1995 Jul;44(7):670-7 (Eng. Abstr.) **(Jpn)**

[The pollen count of Cryptomeria japonica and nasal symptom of Cryptomeria japonica pollinosis patients in recent three years in Mie Prefecture] Masuda S, et al. **Arerugi** 1996 Jun;45(6):570-6 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

The biology of allergenic domestic mites. An update. Hart BJ. **Clin Rev Allergy Immunol** 1995 Summer;13(2):115-33 (134 ref.)

Sex difference in Fel d 1 allergen production. Jalil-Colome J, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):165-8

Production of a recombinant imported fire ant venom allergen, Sol i 2, in native and immunoreactive form. Schmidt M, et al. **J Allergy Clin Immunol** 1996 Jul; 98(1):82-8

CHEMISTRY

Monomeric chemically modified allergens: immunologic and physicochemical characterization. Mistrello G, et al. **Allergy** 1996 Jan;51(1):8-15

Investigation of the stability of apple allergen extracts. Rudeschko O, et al. **Allergy** 1995 Jul;50(7):575-80

Isolation and characterization of the 18-kDa major apple allergen and comparison with the major birch pollen allergen (Bet v I). Vieths S, et al. **Allergy** 1995 May; 50(5):421-30

Allergenic cross-reactivity of foods and characterization of food allergens and extracts. Bernhisel-Broadbent J. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):295-303; quiz 304-7 (80 ref.)

Effect of dilution, temperature, and preservatives on the long-term stability of standardized inhalant allergen extracts. Niemeijer NR, et al. **Ann Allergy Asthma Immunol** 1996 Jun;76(6):535-40

A local lymph-node assay validation study of a structure-activity relationship model for contact allergens. Hostýnek JJ, et al. **Arch Dermatol Res** 1995;287(6):567-71

A major wheat allergen has a Gln-Gln-Gln-Pro-Pro motif identified as an IgE-binding epitope. Tanabe S, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):290-3

Characterization of allergenic components from house dust mite Dermatophagoides siboney. Purification of Der s 1 and Der s 2 allergens. Ferrándiz R, et al. **Clin Exp Allergy** 1995 Oct;25(10):922-8

The allergenic properties of fresh and preserved Hevea brasiliensis latex protein preparations. Kekwick R, et al. **Clin Exp Immunol** 1996 May;104(2):337-42

Studies on the carbohydrate moieties of the timothy grass pollen allergen Phl p I. Petersen A, et al. **Electrophoresis** 1995 May;16(5):869-75

Sequence analysis of wheat grain allergens separated by two-dimensional electrophoresis with immobilized pH gradients. Posch A, et al. **Electrophoresis** 1995 Jul; 16(7):1115-9

Molecular characterization of Api g 1, the major allergen of celery (Apium graveolens), and its immunological and structural relationships to a group of 17-kDa tree pollen allergens. Breiteneder H, et al. **Eur J Biochem** 1995 Oct 15;233(2):484-9

IgE-binding trypsin inhibitors in plant pollen extracts. Berrens L, et al. **Experientia** 1995 Sep 29;51(9-10):953-5

Characterization of Phl p 4, a major timothy grass (Phleum pratense) pollen allergen. Fischer S, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):189-98

Allergy to the heat-labile proteins alpha-lactalbumin and beta-lactoglobulin in mare's milk. Gall H, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1304-7

Studies of allergen extract stability: the effects of dilution and mixing. Nelson HS, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):382-8

In vitro investigation of cross-reactivity between birch and ash pollen allergen extracts. Wahl R, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):99-106

Secondary structure and tertiary fold of the birch pollen allergen Bet v 1 in solution. Faber C, et al. **J Biol Chem** 1996 Aug 9;271(32):19243-50

cDNA cloning and protein analysis of a bovine dermal allergen with homology to psoriasin. Rautiainen J, et al. **J Invest Dermatol** 1995 Nov;105(5):660-3

Structure-activity relationships and computer-assisted analysis of respiratory sensitization potential. Karol MH, et al. **Toxicol Lett** 1996 Aug;86(2-3):187-91 (10 ref.)

CLASSIFICATION

Allergenic relationship between taxonomically diverse pollens. Pham NH, et al. **Clin Exp Allergy** 1995 Jul; 25(7):599-606

DIAGNOSTIC USE

Basic and practical aspects of recombinant allergens. Scheiner O, et al. **Allergy** 1995 May;50(5):384-91 (94 ref.)

Type III allergy skin testing. Position statement for EAACI Subcommittee on Skin Tests and Allergen Standardization. Terho E, et al. **Allergy** 1995 May;50(5):392-6

Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Cockcroft DW, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1485-9

Lung sounds during allergen-induced asthmatic responses in patients with asthma [see comments] Schreur HJ, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1474-80. Comment in: Am J Respir Crit Care Med 1996 May;153(5):1469-71.

Pulmonary inflammation after segmental ragweed challenge in allergic asthmatic and nonasthmatic subjects. Shaver JR, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1189-97

The European standard series. European Environmental and Contact Dermatitis Research Group (EECDRG). Bruynzeel DP, et al. **Contact Dermatitis** 1995 Sep; 33(3):145-8 (16 ref.)

The development and course of test reactions to gold sodium thiosulfate. Bruze M, et al. **Contact Dermatitis** 1995 Dec; 33(6):386-91

Contact allergy to Dermatophagoides in atopic dermatitis patients and healthy subjects. Manzini BM, et al. **Contact Dermatitis** 1995 Oct;33(4):243-6

The allergen bank: the idea behind it and the preliminary results with it. Andersen KE. **Curr Probl Dermatol** 1995; 22:1-7

Comparison between incremental and single-dose allergen administration in bronchial provocation tests. Wasserfallen JB, et al. **J Asthma** 1996;33(3):169-78

Correlation of modified radioallergosorbent test scores and skin test results. Tandy JR, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):42-5

Study of nasal cytology in atopic patients after nasal allergen challenge. Wang D, et al. **Rhinology** 1995 Jun;33(2):78-81

A comparison of the potency of several Brucella allergens used to detect brucellosis in cattle. Bercovich Z, et al. **Vet Res Commun** 1996;20(2):141-51

Production of Brucella allergens and evaluation of their biological activity in a guinea-pig bio-assay. Bercovich Z, et al. **Zentralbl Veterinarmed [B]** 1995 Mar;42(1):19-27

[Do nasal and conjunctival provocation tests represent a trustworthy parameter for the follow-up of childhood IgE-dependent bronchial asthma?] Botey J, et al. **Allerg Immunol (Paris)** 1996 Feb;28(2):52-4 (Eng. Abstr.) **(Fre)**

[An in-vitro leukocytolysis method for the diagnosis of a drug allergy] Vavilov MP, et al. **Klin Lab Diagn** 1996 Jan-Feb;(1):44-7 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Tannic acid's effect on bird antigen. Craig TJ, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):348-50

Specific depletion of the house dust mite allergen Der p 1 cereal flour prolamins. Barber D, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):963-5

GENETICS

High level expression of birch pollen profilin (Bet v 2) in Escherichia coli: purification and characterization of the recombinant allergen. Susani M, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):250-63

High-level expression in Escherichia coli and purification of recombinant plant profilins: comparison of IgE-binding capacity and allergenic activity. Vrtala S, et al. **Biochim Biophys Res Commun** 1996 Sep 4;226(1):42-50

Molecular cloning and characterization of the major allergen Myr p II from the venom of the jumper ant Myrmecia pilosula: Myr p I and Myr p II share a common protein leader sequence. Street MD, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1-2):87-97

Cloning, sequencing and expression in Escherichia coli of Pha a 1 and four isoforms of Pha a 5, the major allergens of canary grass pollen. Suphioglu C, et al. **Clin Exp Allergy** 1995 Sep;25(9):853-65

An allergenic polypeptide representing a variable region of hsp 70 cloned from a cDNA library of Cladosporium herbarum. Zhang L, et al. **Clin Exp Allergy** 1996 Jan; 26(1):88-95

Recombinant allergens for diagnosis and therapy of allergic diseases. Valenta R, et al. **Curr Opin Immunol** 1995 Dec; 7(6):751-6 (68 ref.)

Expression in Escherichia coli of Sin a 1, the major allergen from mustard. González De La Peña MA, et al. **Eur J Biochem** 1996 May 1;237(3):827-32

Cloning, expression and immunological characterization of Ory s 1, the major allergen of rice pollen. Xu H, et al. **Gene** 1995 Oct 27;164(2):255-9

Cloning Aspergillus fumigatus allergens by the pJuFo filamentous phage display system. Crameri R, et al. **Int Arch Allergy Immunol** 1996 May;110(1):41-5

Direct expression of Der f2, a major house dust mite allergen, in Escherichia coli. Iwamoto N, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):356-61

High-level expression of tree pollen isoallergens in Escherichia coli. Weiss C, et al. **Int Arch Allergy Immunol** 1996 Jul;110(3):282-7

Complementary DNA cloning of the predominant allergen of bovine dander: a new member in the lipocalin family. Mäntyjärvi R, et al. **J Allergy Clin Immunol** 1996 Jun; 97(6):1297-303

Isolation and preliminary characterization of cDNA encoding American cockroach allergens. Wu CH, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):352-9

Cloning of cockroach allergen, Bla g 4, identifies ligand binding proteins (or calycins) as a cause of IgE antibody responses. Arruda LK, et al. **J Biol Chem** 1995 Dec 29; 270(52):31196-201

A cDNA from pea petals with sequence similarity to pollen allergen, cytokinin-induced and genetic tumour-specific genes: identification of a new family of related sequences. Michael AJ. **Plant Mol Biol** 1996 Jan;30(1):219-24

IMMUNOLOGY

Occurrence and clinical features of sensitization to Pityrosporum orbiculare and other allergens in children with atopic dermatitis. Lindgren L, et al. **Acta Derm Venereol** 1995 Jul;75(4):300-4

Bronchial inhalation challenge procedures with allergens and other bronchoconstrictor substances. Spector S. **Allerg Immunol (Paris)** 1996 Apr;28(4):112, 115-8 (38 ref.)

Costimulation of CD3/TcR complex with either integrin or nonintegrin ligands protects CD4+ allergen-specific T-cell clones from programmed cell death. Agea E, et al. **Allergy** 1995 Aug;50(8):677-82

Effect of allergen provocation on inflammatory cell profile and endothelin-like immunoreactivity in guinea-pig airways. Andersson SE, et al. **Allergy** 1995 Apr; 50(4):349-58

Skin prick test reactivity to common aeroallergens in relation to total IgE, respiratory symptoms, and smoking in a general population sample of northern Italy. Baldacci S, et al. **Allergy** 1996 Mar;51(3):149-56

Cross-reacting IgE antibodies recognizing latex allergens, including Hev b 1, as well as papain. Baur X, et al. **Allergy** 1995 Jul;50(7):604-9

Cross-reactivity of IgE-binding components between boiled Atlantic shrimp and German cockroach. Crespo JF, et al. **Allergy** 1995 Nov;50(11):918-24

Allergen cross-reactivity between Pityrosporum orbiculare and Candida albicans. Huang X, et al. **Allergy** 1995 Aug; 50(8):648-56

Nedocromil sodium reduces allergen-induced plasma extravasation in the guinea pig nasal mucosa by inhibition of tachykinin release. Javdan P, et al. **Allergy** 1995 Oct; 50(10):825-9

Monoclonal antibody against a major latex allergen reacts

with latex products and ammoniated natural latex. Lu LJ, et al. **Allergy** 1995 Jul;50(7):545–50

Monomeric chemically modified allergens: immunologic and physicochemical characterization. Mistrello G, et al. **Allergy** 1996 Jan;51(1):8–15

Effects of "systemic" budesonide concentrations on in vitro allergen-induced activation of blood mononuclear cells isolated from asthmatic patients. Oddera S, et al. **Allergy** 1995 May;50(5):397–404

Epitope analysis of HLA-DR-restricted helper T-cell responses to Der p II, a major allergen molecule of Dermatophagoides pteronyssinus. Okano M, et al. **Allergy** 1996 Jan;51(1):29–35

Interaction of allergens from house-dust mite and from cereal flours: Dermatophagoides pteronyssinus alpha-amylase (Der p 4) and wheat and rye alpha-amylase inhibitors. Sánchez-Monge R, et al. **Allergy** 1996 Mar;51(3):176–80

Studies on shared antigenic/allergenic components among fungi. Verma J, et al. **Allergy** 1995 Oct;50(10):811–6

Characterization of Chenopodiales (Amaranthus retroflexus, Chenopodium album, Kochia scoparia, Salsola pestifer) pollen allergens. Würtzen PA, et al. **Allergy** 1995 Jun; 50(6):489–97

Birch-pollen antigenic activity of settled dust in rural and urban homes. Yli-Panula E, et al. **Allergy** 1995 Apr; 50(4):303–7

Immunological properties of allergen chemically modified with synthetic copolymer of N-vinylpyrrolidone and maleic anhydride. Babakhin AA, et al. **Allergy Proc** 1995 Sep–Oct;16(5):261–8

Relative allergenicity of cow's milk and cow's milk-based formulas in an animal model. Kitagawa S, et al. **Am J Med Sci** 1995 Nov;310(5):183–7

Production of interleukin-4 and interferon-gamma by TCR-V beta-expressing T-cell subsets in allergen-sensitized mice. Renz H, et al. **Am J Respir Cell Mol Biol** 1996 Jan;14(1):36–43

Cellular infiltration and eicosanoid synthesis in brown Norway rat lungs after allergen challenge. Yu W, et al. **Am J Respir Cell Mol Biol** 1995 Oct;13(4):477–86

Skin test reactivity to common aeroallergens and decline of lung function. The Normative Aging Study. Gottlieb DJ, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):561–6

The role of endogenous corticosterone in the late-phase response to allergen challenge in the brown Norway rat. Turner DJ, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):545–50

Role of airway eosinophils in the development of allergen-induced airway hyperresponsiveness in dogs. Woolley MJ, et al. **Am J Respir Crit Care Med** 1995 Nov; 152(5 Pt 1):1508–12

Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge. Ciprandi G, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):446–52

Comparison between outdoor and indoor airborne allergenic activity. D'Amato G, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):147–52

Hypersensitivity to banana in latex-allergic patients. Identification of two major banana allergens of 33 and 37 kD. Delbourg MF, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):321–6

Hypersensitivity to latex and Ficus benjamina allergens. Delbourg MF, et al. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):496–500

Efficacy of acrivastine with pseudoephedrine in treatment of allergic rhinitis due to ragweed. Dockhorn RJ, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):204–8

Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy. Litwin A, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):132–8

English plantain and psyllium: lack of cross-allergenicity by crossed immunoelectrophoresis. Morgan MS, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):351–9

Occupational asthma due to deer dander. Nahm DH, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):423–6

Sensitization to airborne allergens in children with respiratory symptoms. Silvestri M, et al. **Ann Allergy Asthma Immunol** 1996 Mar;76(3):239–44

Successful replacement of allergen-specific immunotherapy by allergen-mixture therapy. Song CH, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):402–8

Comparison between allergen-induced and exercise-induced asthma with respect to the late asthmatic response, airway responsiveness, and Creola bodies in sputum. Tateishi K, et al. **Ann Allergy Asthma Immunol** 1996 Sep;77(3):229–37

Parenteral and oral administration of tolerogens: protein-IgG conjugates. Borel Y, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:80–7

High serum levels of allergen specific IgG-4 (asIgG-4) for common food allergens in healthy blood donors. Kruszewski J, et al. **Arch Immunol Ther Exp (Warsz)** 1994; 42(4):259–61

Specific pollen allergen activates eosinophils of the patient with chronic allergic contact urticaria. Panaszek B, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):253–8

Specific IgE in the identification of allergens in allergic rhinitis Malaysian patients. Choon-Kook S, et al. **Asian Pac J Allergy Immunol** 1995 Jun;13(1):23–7

Prevalence of allergy to some inhalants among rhinitis patients in Malaysia. Ho TM, et al. **Asian Pac J Allergy Immunol** 1995 Jun;13(1):11–6

Seasonal prevalence of air-borne pollen and spores in Kuala Lumpur, Malaysia. Ho TM, et al. **Asian Pac J Allergy Immunol** 1995 Jun;13(1):17–22

Allergens of Bipolaris species. Lim SH, et al. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):101–5

A major wheat allergen has a Gln-Gln-Gln-Pro-Pro motif identified as an IgE-binding epitope. Tanabe S, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):290–3

Modulation of immune responses to allergens of house dust mite. Hawrylowicz C, et al. **Biochem Soc Trans** 1995 Aug; 23(3):660–4 (29 ref.)

Use of monoclonal antibodies in the standardization of Parietaria judaica allergenic extracts. Afferni C, et al. **Biologicals** 1995 Sep;23(3):239–47

CD34-deficient mice have reduced eosinophil accumulation after allergen exposure and show a novel crossreactive 90-kD protein. Suzuki A, et al. **Blood** 1996 May 1; 87(9):3550–62

Histamine release in skin monitored with the microdialysis technique does not correlate with the weal size induced by cow allergen. Horsmanheimo L, et al. **Br J Dermatol** 1996 Jan;134(1):94–100

Eosinophil infiltration into human skin is antigen-dependent in the late-phase reaction. Litchfield TM, et al. **Br J Dermatol** 1996 Jun;134(6):997–1004

Quantitation of the major allergen of several Parietaria pollens by an anti-Par 1 monoclonal antibody-based ELISA. Analysis of crossreactivity among purified Par j 1, Par o 1 and Par m 1 allergens. Ayuso R, et al. **Clin Exp Allergy** 1995 Oct;25(10):993–9

Podocarpus gracilior and Callitris verrucosa—newly identified allergens that crossreact with Cupressus sempervirens. Bar Dayan Y, et al. **Clin Exp Allergy** 1995 May;25(5):456–60

The decay of house dust mite allergens, Der p I and Der p II, under natural conditions. de Boer R, et al. **Clin Exp Allergy** 1995 Aug;25(8):765–70

Effects of IL-4 and IL-13 on total and allergen specific IgE production by cultured PBMC from allergic patients determined with recombinant pollen allergens. Dolecek C, et al. **Clin Exp Allergy** 1995 Sep;25(9):879–89

Detection of allergen-specific IgE in tears of grass pollen-allergic patients with allergic rhinoconjunctivitis. Hoffmann-Sommergruber K, et al. **Clin Exp Allergy** 1996 Jan;26(1):79–87

The association of age, gender and smoking with total IgE and specific IgE. Jarvis D, et al. **Clin Exp Allergy** 1995 Nov;25(11):1083–91

Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen. Menz G, et al. **Clin Exp Allergy** 1996 Jan;26(1):50–60

Factors related to the development of sensitization to green coffee and castor bean allergens among coffee workers. Romano C, et al. **Clin Exp Allergy** 1995 Jul;25(7):643–50

Differences in titres of IgE, IgG4 and other IgG subclass anti-Der p 2 antibodies in allergic and non-allergic patients measured with recombinant allergen. Tame A, et al. **Clin Exp Allergy** 1996 Jan;26(1):43–9

Inhalant allergen-specific T-cell reactivity is detectable in close to 100% of atopic and normal individuals: covert responses are unmasked by serum-free medium. Upham JW, et al. **Clin Exp Allergy** 1995 Jul;25(7):634–42

Skin-prick test and RAST responses to cereals in children with atopic dermatitis. Characterization of IgE-binding components in wheat and oats by an immunoblotting method. Varjonen E, et al. **Clin Exp Allergy** 1995 Nov; 25(11):1100–7

Dust mite allergens. Stewart GA. **Clin Rev Allergy Immunol** 1995 Summer;13(2):135–50 (65 ref.)

Allergen testing in patients with type I hypersensitivity. **Drug Ther Bull** 1995 Jun;33(6):45–7 (17 ref.)

Multicentre evaluation of Capture Assay Radim Liquid Allergen for measurement of specific IgE antibodies. Banfi G, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct; 33(10):755–9

Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Parronchi P, et al. **Eur J Immunol** 1996 Mar;26(3):697–703

Distribution of Dermatophagoides mite (Acari: Pyroglyphidae) antigens in homes of allergic patients in Japan. Konishi E, et al. **Exp Appl Acarol** 1995 May; 19(5):275–86

Differential cytokine production following chronic exposure of mice to chemical respiratory and contact allergens. Dearman RJ, et al. **Immunology** 1995 Dec;86(4):545–50

Cross-antigenicity of horse serum albumin with dog and cat albumins: study of three short peptides with significant inhibitory activity towards specific human IgE and IgG antibodies. Goubran Botros H, et al. **Immunology** 1996 Jul; 88(3):340–7

T-cells subsets and activation in bronchial mucosa of sensitized Brown-Norway rats after single allergen exposure. Haczku A, et al. **Immunology** 1995 Aug; 85(4):591–7

Airway hyperresponsiveness, elevation of serum-specific IgE and activation of T cells following allergen exposure in sensitized Brown-Norway rats. Haczku A, et al. **Immunology** 1995 Aug;85(4):598–603

Allergen-stimulated interleukin-4 and interferon-gamma production in primary culture: responses of subjects with allergic rhinitis and normal controls. Imada M, et al. **Immunology** 1995 Jul;85(3):373–80

Multiple B- and T-cell epitopes on a major allergen of Kentucky Bluegrass pollen. Zhang L, et al. **Immunology** 1996 Feb;87(2):283–90

Cocos nucifera pollen inducing allergy: sensitivity test and immunological study. Karmakar PR, et al. **Indian J Exp Biol** 1995 Jul;33(7):489–96

Multiple dust allergy in a semiurban environs. Kumar S, et al. **Indian J Med Sci** 1995 Jan;49(1):1–4

Shared IgE-binding sites among separated components of natural rubber latex. Aamir R, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):48–54

A guinea pig model of hypersensitivity to allergenic fractions of natural rubber latex. Aamir R, et al. **Int Arch Allergy Immunol** 1996 Jun;110(2):187–94

Airway responses following intradermal sensitization to different types of allergens: ovalbumin, trimellitic anhydride and Dermatophagoides farinae. Arakawa H, et al. **Int Arch Allergy Immunol** 1995 Nov;108(3):274–80

Heterogeneity of pollen proteins within individual Betula pendula trees. Hjelmroos M, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):368–76

Purification and characterization of an allergenic monomeric hemoglobin from a chironomid distributed worldwide, Polypedium nubifer. Kawai K, et al. **Int Arch Allergy Immunol** 1996 Jul;110(3):288–97

Cloning and expression of a murine Fab fragment recognizing a defined linear epitope of Chironomus thummi thummi major allergen Chi t 1-9. Kipp B, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):348–53

Group 5 allergens of timothy grass (Phl p 5) bear cross-reacting T cell epitopes with group 1 allergens of rye grass (Lol p 1). Müller WD, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):352–5

IgE responsiveness to Dermatophagoides farinae in young asthmatic children: IgE binding study using recombinant allergens of Der f1, Der f2 and mutant proteins of Der f2. Noguchi E, et al. **Int Arch Allergy Immunol** 1996 Aug; 110(4):380–7

Mechanism of allergic cross-reactions. V. High incidence of unanticipated cross-stimulation by natural allergens of rat basophilic leukemia cells sensitized with monoclonal IgE antibodies. Varga JM, et al. **Int Arch Allergy Immunol** 1995 Oct;108(2):196–9

N-terminus of a major allergen, Alt a 1, of Alternaria alternata defined to be an epitope. Zhang L, et al. **Int Arch Allergy Immunol** 1995 Nov;108(3):254–9

Sensitization to para-tertiary-butylphenolformaldehyde resin. Massone L, et al. **Int J Dermatol** 1996 Mar; 35(3):177–80

Supplemental tests in the evaluation of occupational hand dermatitis in soldiers. Wolf R, et al. **Int J Dermatol** 1996 Mar;35(3):173–6

Cross-reactivity between the major allergen from olive pollen and unrelated glycoproteins: evidence of an epitope in the glycan moiety of the allergen. Batanero E, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1264–71

Food allergy to honey: pollen or bee products? Characterization of allergenic proteins in honey by means of immunoblotting. Bauer L, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):65–73

Baker's asthma caused by Saccharomyces cerevisiae in dry powder form. Belchi-Hernandez J, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):131–4

Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. Bhagat R, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):47–52

Cockroaches and mites share the same beds. Birnbaum J, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):561–2

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. Durham SR, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1356–65

Cockroach and Dermatophagoides pteronyssinus cross-react [letter] Eriksson NE, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):471–3

Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. Ferreira FD, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):95–103

Cellular and mediator responses twenty-four hours after local endobronchial allergen challenge of asthmatic airways. Frew AJ, et al. **J Allergy Clin Immunol** 1996 Jul; 98(1):133–43

T-cell receptor peptides that inhibit the T-cell response to allergen induce transforming growth factor-beta 1 production. Hawrylowicz CM, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):707–9

Isolation and characterization of a clone encoding a major allergen (Bla g Bd90K) involved in IgE-mediated cockroach hypersensitivity. Helm R, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):172–80

Quantitative assessment of exposure to dog (Can f 1) and cat (Fel d 1) allergens: relation to sensitization and asthma among children living in Los Alamos, New Mexico. Ingram JM, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):449–56

Allergen-specific IgE levels and mite allergen exposure in children with acute asthma first seen in an emergency department and in nonasthmatic control subjects. Nelson RP Jr, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):258–63

Is there a dose-response relationship between exposure to indoor allergens and symptoms of asthma? [editorial] Platts-Mills TA, et al. **J Allergy Clin Immunol** 1995 Oct; 96(4):435-40 (44 ref.)

Parietaria judaica-specific T-cell clones from atopic patients: heterogeneity in restriction, V beta usage, and cytokine profile. Sallusto F, et al. **J Allergy Clin Immunol** 1996 Feb; 97(2):627-37

Eosinophil recruitment is associated with IL-5, but not with RANTES, twenty-four hours after allergen challenge. Sur S, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1272-8

Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. Thepen T, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):828-37

Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure. Tomassini M, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1350-5

Type 1 allergic reactions to plant-derived food: a consequence of primary sensitization to pollen allergens. Valenta R, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):893-5 (29 ref.)

No relationship between skin-infiltrating TH2-like cells and allergen-specific IgE response in atopic dermatitis. Virtanen T, et al. **J Allergy Clin Immunol** 1995 Sep; 96(3):411-20

Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). Vrtala S, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):781-7

In vitro investigation of cross-reactivity between birch and ash pollen allergen extracts. Wahl R, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):99-106

The relationship between RAST and skin test results in patients with asthma or rhinitis: a quantitative study with purified major allergens. Witteman AM, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):16-25

Chronologic analysis of in situ cytokine expression in mite allergen-induced dermatitis in atopic subjects. Yamada N, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1069-75

Construction of a combinatorial IgE library from an allergic patient. Isolation and characterization of human IgE Fabs with specificity for the major timothy grass pollen allergen, Phl p 5. Steinberger P, et al. **J Biol Chem** 1996 May 3; 271(18):10967-72

Recombinant peanut allergen Ara h I expression and IgE binding in patients with peanut hypersensitivity. Burks AW, et al. **J Clin Invest** 1995 Oct;96(4):1715-21

Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. Ferreira F, et al. **J Exp Med** 1996 Feb 1;183(2):599-609

Immunotherapy in adult asthma. Squillace SP. **J Fam Pract** 1996 May;42(5):455

The main IgE-binding epitope of a major latex allergen, prohevein, is present in its N-terminal 43-amino acid fragment, hevein. Alenius H, et al. **J Immunol** 1996 Feb 15;156(4):1618-25

Oligoclonality of lung T lymphocytes following exposure to allergen in asthma. Burastero SE, et al. **J Immunol** 1995 Dec 15;155(12):5836-46

HLA-DQ8 transgenic mice lacking endogenous class II molecules respond to house dust allergens: identification of antigenic epitopes. Neeno T, et al. **J Immunol** 1996 May 1;156(9):3191-5

Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. Teran LM, et al. **J Immunol** 1996 Aug 15;157(4):1806-12

Lepidoglyphus destructor acarus in the urban house environment. Juliá JC, et al. **J Investig Allergol Clin Immunol** 1995 Nov-Dec; 5(6):318-21

Platelet aggregation in IgE-mediated allergy with elevated soluble Fc epsilon RII/CD23 level. Rogala B, et al. **J Investig Allergol Clin Immunol** 1995 May-Jun;5(3):161-5

Bronchial provocation with cat allergen: long-term outcome of the late allergic reaction and the individual IgE CRIE pattern. Wasserfallen JB, et al. **J Investig Allergol Clin Immunol** 1995 May-Jun;5(3):134-41

Early detection of specific IgE antibody against house dust mite in children at risk of allergic disease. Sasai K, et al. **J Pediatr** 1996 Jun;128(6):834-40

Imaging allergen-invoked airway inflammation in atopic asthma with [18F]-fluorodeoxyglucose and positron emission tomography. Taylor IK, et al. **Lancet** 1996 Apr 6;347(9006):937-40

Common IgE-epitopes of recombinant Phl p I, the major timothy grass pollen allergen and natural group I grass pollen isoallergens. Laffer S, et al. **Mol Immunol** 1996 Mar-Apr;33(4-5):417-26

Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Smith AM, et al. **Mol Immunol** 1996 Mar-Apr;33(4-5):399-405

Local expansion of allergen-specific CD30+Th2-type gamma delta T cells in bronchial asthma. Spinozzi F, et al. **Mol Med** 1995 Nov;1(7):821-6

Biochemical, antigenic and allergenic characterization of crude extracts of Drechslera (Helminthosporium) monoceras. Menezes EA, et al. **Mycopathologia** 1995 Aug; 131(2):75-81

Allergies to transgenic foods--questions of policy [editorial; comment] Nestle M. **N Engl J Med** 1996 Mar 14; 334(11):726-8. Comment on: N Engl J Med 1996 Mar 14;334(11):688-92.

Biochemical features of grain legume allergens in humans and animals. Lallès JP, et al. **Nutr Rev** 1996 Apr;54(4 Pt 1):101-7 (65 ref.)

Enzyme immunoassays for total and allergen specific IgE in population studies. Doekes G, et al. **Occup Environ Med** 1996 Jan;53(1):63-70

Oilseed rape and bronchial reactivity. Soutar A, et al. **Occup Environ Med** 1995 Sep;52(9):575-80

Environmental factors and primary T-cell sensitisation to inhalant allergens in infancy: reappraisal of the role of infections and air pollution. Holt PG. **Pediatr Allergy Immunol** 1995 Feb;6(1):1-10 (85 ref.)

Early acquisition of sensitization in childhood asthma. Holt PG. **Pediatr Pulmonol Suppl** 1995;11:44-6

The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways. Banner KH, et al. **Pulm Pharmacol** 1995 Feb;8(1):37-42

Allergen-induced glycoconjugate secretion in guinea-pig trachea in vivo: modulation by indomethacin, BW B70C and ZD-2138. Yeadon M, et al. **Pulm Pharmacol** 1995 Feb; 8(1):53-63

Role of eosinophils and cell adhesion molecules in the allergen-induced asthmatic response of rats. Uyama O, et al. **Res Commun Mol Pathol Pharmacol** 1995 Oct;90(1):3-15

Methacholine-induced histamine liberation during airway challenge tests in Ascaris skin-sensitive sheep. Marek W, et al. **Respiration** 1995;62(6):322-30

Co-stimulation-induced release of pro-inflammatory cytokine interleukin-8 by allergen-specific T cells. Spinozzi F, et al. **Scand J Immunol** 1996 Jul;44(1):80-4

Specific down-regulation of anti-allergen IgE and IgG antibodies in humans associated with injections of allergen-specific antibody complexes. Jacquemin MG, et al. **Ther Immunol** 1995 Feb;2(1):41-52

Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. Djukanović R, et al. **Thorax** 1996 Jun; 51(6):575-81

Identification of a dog IgD-like molecule by a monoclonal antibody. Yang M, et al. **Vet Immunol Immunopathol** 1995 Aug;47(3-4):215-24

Serological response of cattle to Brucella allergen after repeated intradermal applications of this allergen. Muskens JA, et al. **Vet Microbiol** 1996 Jan;48(1-2):174-8

[Assay of IgE specific to dog epithelia by the Pharmacia CAP RAST technique: comparison of the two CAP RAST e2 and e5] Drouet M, et al. **Allerg Immunol (Paris)** 1996 Apr;28(4):106, 109-11 (Eng. Abstr.) **(Fre)**

[Overview on RAST inhibition] Sabbah A, et al. **Allerg Immunol (Paris)** 1996 Mar;28(3):86-7 (Eng. Abstr.) **(Fre)**

[A new allergen dibromodicyanobutane. Report of a study in 310 patients January-December 1994] Vigan M, et al. **Ann Dermatol Venereol** 1996;123(5):322-4 (Eng. Abstr.) **(Fre)**

[Risk indicators of reaginic allergy: relations between atopic dermatitis and serum specific IgE of various pneumallergens] De Montis G. **Ann Med Interne (Paris)** 1995;146(8):551-4 (Eng. Abstr.) **(Fre)**

[Oral immunotherapy in oculorhinitis from Gramineae] Pacor ML, et al. **Recenti Prog Med** 1996 Jan;87(1):4-6 (Eng. Abstr.) **(Ita)**

[Effectiveness of oral immunotherapy in bronchial asthma caused by Dermatophagoides pternyssinus] Pacor ML, et al. **Recenti Prog Med** 1995 Dec;86(12):489-91 (Eng. Abstr.) **(Ita)**

[Desensitization immunotherapy on patients with mite-positive bronchial asthma using purified mite feces antigen fractions] Asaoku Y, et al. **Arerugi** 1995 Jul; 44(7):692-700 (Eng. Abstr.) **(Jpn)**

[Endothelin-1 levels in sputum and plasma of asthmatic patient after allergen provocation] Kurokawa M, et al. **Arerugi** 1996 Apr;45(4):386-92 (Eng. Abstr.) **(Jpn)**

[Comparative study on the assay for IgE antibodies specific for Chamaecyparis obtusa pollen between AlaSTAT and CAP-RAST] Nohara O, et al. **Arerugi** 1996 Jun;45(6):562-9 (Eng. Abstr.) **(Jpn)**

[Study of cockroach allergy in asthmatic children. The positive rates and antigenicity of cockroach allergen] Onoue Y, et al. **Arerugi** 1995 Oct;44(10):1207-15 (Eng. Abstr.) **(Jpn)**

[Chronological analysis of eosinophil infiltration in mite-allergen induced dermatitis in atopic patients] Wakugawa M, et al. **Arerugi** 1995 Oct;44(10):1199-206 (Eng. Abstr.) **(Jpn)**

[Guidelines for standardization of allergens and cedar pollen allergen extract in Japan] Yasue H, et al. **Arerugi** 1996 Apr; 45(4):416-21 **(Jpn)**

[Role of adhesion molecules (VLA-4) in the asthmatic response to allergens] Tanimukai T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1240-9 (Eng. Abstr.) **(Jpn)**

[Cockroach allergy: a study of its prevalence using skin tests with commercial extracts] Cuesta C, et al. **Allergol Immunopathol (Madr)** 1995 Nov-Dec; 23(6):295-300 (34 ref.) (Eng. Abstr.) **(Spa)**

[Clinico-immunologic course during immunotherapy for ++pneumoallergens] López de Armentia SL. **Allergol Immunopathol (Madr)** 1996;24 Suppl 1:80-4 **(Spa)**

[Prevalence of sensitization to Blomia in Gran Canaria] Sánchez Palacios A, et al. **Allergol Immunopathol (Madr)** 1995 May-Jun;23(3):105-10 (Eng. Abstr.) **(Spa)**

[Skin test with aeroallergens untested in Mexico] Pérez Tovar MP, et al. **Rev Alerg Mex** 1995 Sep-Oct;42(5):86-8 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Two-dimensional analysis of cow's milk allergens with the IPG-DALT technique. Brodard V, et al. **Adv Exp Med Biol** 1995;371B:875-8

Cow's milk allergy: the humoral immune response to eight purified allergens. Wal JM, et al. **Adv Exp Med Biol** 1995; 371B:879-81

Identification of important allergenic proteins in extracts of the granary weevil (Sitophilus granarius). Herling C, et al. **Allergy** 1995 May;50(5):441-6

Isolation and characterization of the 18-kDa major apple allergen and comparison with the major birch pollen allergen (Bet v I). Vieths S, et al. **Allergy** 1995 May; 50(5):421-30

Hypersensitivity to banana in latex-allergic patients. Identification of two major banana allergens of 33 and 37 kD. Delbourg MF, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):321-6

Purification and identification of allergenic alpha(2u)-globulin species of rat urine. Bayard C, et al. **Biochim Biophys Acta** 1996 Jun 4;1290(2):129-34

Prohevein from the rubber tree (Hevea brasiliensis) is a major latex allergen. Alenius H, et al. **Clin Exp Allergy** 1995 Jul; 25(7):659-65

Characterization of allergenic components from house dust mite Dermatophagoides siboney. Purification of Der s 1 and Der s 2 allergens. Ferrándiz R, et al. **Clin Exp Allergy** 1995 Oct;25(10):922-8

Molecular cloning and immunological characterization of the house dust mite allergen Der f 7. Shen HD, et al. **Clin Exp Allergy** 1995 Oct;25(10):1000-6

Isolation and quantification of a new tuliposide (tuliposide D) by HPLC in Alstroemeria. Christensen LP, et al. **Contact Dermatitis** 1995 Sep;33(3):188-92

2-methoxy-6-pentyl-1,4-dihydroxybenzene (miconidin) from Primula obconica: a possible allergen? Krebs M, et al. **Contact Dermatitis** 1995 Aug;33(2):90-3

Shared IgE-binding sites among separated components of natural rubber latex. Aamir R, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):48-54

Purification and characterization of the major allergen from apple and its allergenic cross-reactivity with Bet v 1. Fahlbusch B, et al. **Int Arch Allergy Immunol** 1995 Oct; 108(2):119-26

Purification and characterization of an allergenic monomeric hemoglobin from a chironomid distributed worldwide, Polypedium nubifer. Kawai K, et al. **Int Arch Allergy Immunol** 1996 Jul;110(3):288-97

Identification and characterization of the major allergens of velvet grass (Holcus lanatus), Hol l 1 and Hol l 5. Schramm G, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):354-63

Isolation and characterization of a clone encoding a major allergen (Bla g Bd90K) involved in IgE-mediated cockroach hypersensitivity. Helm R, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):172-80

Allergens in Hymenoptera venom. XXVII: bumblebee venom allergy and allergens. Hoffman DR, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):812-21

Characterization of apple 18 and 31 kd allergens by microsequencing and evaluation of their content during storage and ripening. Hsieh LS, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):960-70

One of the rubber latex allergens is a lysozyme. Yagami T, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):677-86

Application of reversed-phase high-performance liquid chromatography in the purification of major allergens from grass pollen. Fahlbusch B, et al. **J Immunol Methods** 1996 Jul 17;194(1):27-34

Purification, characterization and molecular cloning of Cha o 1, a major allergen of Chamaecyparis obtusa (Japanese cypress) pollen. Suzuki M, et al. **Mol Immunol** 1996 Mar-Apr;33(4-5):451-60

METABOLISM

Investigation of acid phosphatase as a possible IgE-binding marker for pollen allergens and their polymerized derivatives. Berrens L, et al. **Allergol Immunopathol (Madr)** 1995 Mar-Apr;23(2):79-84

Cry j 2, a major allergen of Japanese cedar pollen, shows polymethylgalacturonase activity. Ohtsuki T, et al. **Allergy** 1995 Jun;50(6):483-8

Bronchial epithelial cells of atopic patients with asthma lack the ability to inactivate allergens. Mori L, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):817-24

Albumin adducts, hemoglobin adducts and urinary metabolites in workers exposed to 4,4'-methylenediphenyl diisocyanate. Sepai O, et al. **Carcinogenesis** 1995 Oct; 16(10):2583-7

Fate and biological effects of polymeric MDI (4,4'-diphenylmethane diisocyanate and homologs) in small artificial ponds. Heimbach F, et al. **Ecotoxicol Environ Saf** 1996 Mar;33(2):143–53

Reduction of 14–16 kDa allergenic proteins in transgenic rice plants by antisense gene. Tada Y, et al. **FEBS Lett** 1996 Aug 12;391(3):341–5

Evaluation of the gut mucosal barrier: evidence for increased antigen transfer in children with atopic eczema. Majamaa H, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):985–90

PHARMACOLOGY

The kinetics of the cytologic and rhinomanometric changes in the nose after challenge with allergen. Bernheim N, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):229–33 (20 ref.)

In vitro keratinocytes responses to chemical allergens. Corsini E, et al. **Boll Chim Farm** 1995 Nov;134(10):569–73

Paraphenylene diamine, a contact allergen, induces oxidative stress in normal human keratinocytes in culture. Picardo M, et al. **Br J Dermatol** 1996 Apr;134(4):681–5

Induction of calcium-independent nitric oxide synthase by allergen challenge in sensitized rat lung in vivo. Yeadon M, et al. **Br J Pharmacol** 1995 Nov;116(6):2545–6

Regulation of cytokine production by sugi allergen–pullulan conjugate. Kohno K, et al. **Cell Immunol** 1996 Mar 15; 168(2):211–9

Selective restimulation of antigen or allergen preactivated T cells using OKT3 F(ab)2 results in the secretion of TH–1 or TH–2–like cytokine patterns. Jutel M, et al. **Clin Exp Allergy** 1995 Nov;25(11):1108–17

Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen–induced late cutaneous responses. Taborda–Barata L, et al. **Clin Exp Allergy** 1996 Jan;26(1):68–78

Allergenic epitopes of ovalbumin (OVA) in patients with hen's egg allergy: inhibition of basophil histamine release by haptenic ovalbumin peptide. Honma K, et al. **Clin Exp Immunol** 1996 Mar;103(3):446–53

Der p I, a major allergen of the house dust mite, proteolytically cleaves the low–affinity receptor for human IgE (CD23). Schulz O, et al. **Eur J Immunol** 1995 Nov; 25(11):3191–4

The effects of an inhaled corticosteroid on oxygen radical production by bronchoalveolar cells after allergen or ozone in dogs. Stevens WH, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):251–7

Increased maximal airway response to methacholine during seasonal allergic rhinitis in nonasthmatic subjects: relationships with airway wall thickness and inflammation. Boulet LP, et al. **Eur Respir J** 1995 Jun;8(6):913–21

Allergen–induced late–phase airways obstruction in the pig: the role of endogenous cortisol. Fornhem C, et al. **Eur Respir J** 1995 Jun;8(6):928–37

Allergen–induced late–phase airways obstruction in the pig: mediator release and eosinophil recruitment. Fornhem C, et al. **Eur Respir J** 1995 Jul;8(7):1100–9

Prevention and reversal of superantigen–induced anergy by contact allergen exposure. Saloga J, et al. **Exp Dermatol** 1995 Oct;4(5):308–12

Possible involvement of mononuclear cells stimulated with specific allergen from asthmatic patients in ICAM–1 expression on the eosinophilic cell line. Chihara J, et al. **Immunol Lett** 1995 Jun;46(3):241–4

Differential modulation by betamethasone of allergen–induced cell influx and cell peroxidase in guinea–pig lungs. Yeadon M, et al. **Inflamm Res** 1995 Aug; 44 Suppl 2:S177–8

Concentrations of myeloperoxidase in nasal secretions of atopic patients after nasal allergen challenge and during natural allergen exposure. Wang D, et al. **Int Arch Allergy Immunol** 1996 May;110(1):85–90

Effect of nedocromil sodium on allergen–induced airway responses and changes in the quantity of airway smooth muscle in rats. Du T, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):400–7

Detection of allergen–induced genes in peripheral blood mononuclear cells of patients with allergic asthma using subtractive hybridization. Fukuda T, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1076–82

Allergen–induced histamine release in intact human skin in vivo assessed by skin microdialysis technique: characterization of factors influencing histamine releasability. Petersen LJ, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):672–9

Effect of six–hour exposure to nitrogen dioxide on early–phase nasal response to allergen challenge in patients with a history of seasonal allergic rhinitis. Wang JH, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):669–76

Affinity–purified Dermatophagoides farinae antigen induces CD23 on T and B lymphocytes and monocytes specifically in patients with atopic dermatitis. Zhang HM, et al. **J Dermatol Sci** 1996 Mar;11(3):202–8

Contact allergens and epidermal proinflammatory cytokines modulate Langerhans cell E–cadherin expression in situ. Schwarzenberger K, et al. **J Invest Dermatol** 1996 Mar; 106(3):553–8

Reliability of histamine release test in dust mite allergy: influence of the degree of sensitization. Resano A, et al. **J Investig Allergol Clin Immunol** 1995 Sep–Oct;5(5):289–93

Characterization of chemical allergens as a function of divergent cytokine secretion profiles induced in mice. Dearman RJ, et al. **Toxicol Appl Pharmacol** 1996 Jun; 138(2):308–16

Chemicals and proteins as allergens and adjuvants. Kapsenberg ML. **Toxicol Lett** 1996 Aug;86(2–3):79–83 (30 ref.)

THERAPEUTIC USE

A double–blind, placebo controlled study of Alpare mite D. pteronyssinus immunotherapy in asthmatic patients. Franco C, et al. **Allergol Immunopathol (Madr)** 1995 Mar–Apr; 23(2):58–66

Basic and practical aspects of recombinant allergens. Scheiner O, et al. **Allergy** 1995 May;50(5):384–91 (94 ref.)

Modified allergen immunotherapy: effect on immunoglobulin E production. Babakhin AA, et al. **Allergy Proc** 1995 Jul–Aug;16(4):195–202 (46 ref.)

Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Donovan JP, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):74–80

Persistent subcutaneous nodules in patients hyposensitized with aluminum–containing allergen extracts. García–Patos V, et al. **Arch Dermatol** 1995 Dec;131(12):1421–4

Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Andri L, et al. **Clin Exp Allergy** 1995 Nov;25(11):1092–9

Allergen immunotherapy in young children [letter; comment] Wolf SI. **J Allergy Clin Immunol** 1995 Oct;96(4):568–70. Comment on: J Allergy Clin Immunol 1994 Oct;94(4):662–5.

Long–term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. Tosti A, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):199–201

Local intranasal immunotherapy with allergen in powder in atopic patients sensitive to Parietaria officinalis pollen. Ariano R, et al. **J Investig Allergol Clin Immunol** 1995 May–Jun;5(3):126–32

Nonspecific changes in immunotherapy with house dust extract. García NM, et al. **J Investig Allergol Clin Immunol** 1995 Jan–Feb;5(1):18–24

Intranasal immunotherapy with Dermatophagoides extract: in vivo and in vitro results of a double–blind placebo–controlled trial. Fanales–Belasio E, et al. **Rhinology** 1995 Sep;33(3):126–31

Effectiveness of allergy immunotherapy for asthma. Sokol W. **West J Med** 1995 Oct;163(4):368

[Oral immunotherapy in oculorhinitis from Gramineae] Pacor ML, et al. **Recenti Prog Med** 1996 Jan;87(1):4–6 (Eng. Abstr.) **(Ita)**

[Specific immunotherapy in patients with bronchial asthma hypersensitive to housedust mites] Złotnik I, et al. **Pneumonol Alergol Pol** 1995;63 Suppl 2:42–51 (Eng. Abstr.) **(Pol)**

[Multicenter drug surveillance of sublingual immunotherapy in allergic patients] Almagro E, et al. **Allergol Immunopathol (Madr)** 1995 Jul–Aug;23(4):153–9 (Eng. Abstr.) **(Spa)**

TOXICITY

Local lymph node activation in rats after dermal application of the sensitizers 2,4–dinitrochlorobenzene and trimellitic anhydride. Arts JH, et al. **Food Chem Toxicol** 1996 Jan; 34(1):55–62

Validation of skin sensitization assays. Basketter DA, et al. **Food Chem Toxicol** 1995 Dec;33(12):1057–9

Experimental assessment of the sensitizing properties of formaldehyde. Hilton J, et al. **Food Chem Toxicol** 1996 Jun; 34(6):571–8

Cytometric profile of molybdenum–induced contact sensitization versus a strong allergen reaction to oxazolone in murine auricular lymph node (ALN) test. Abdouh M, et al. **Int J Immunopharmacol** 1995 Jul;17(7):545–54

Predictive testing for respiratory sensitization in the mouse. Kimber I, et al. **Toxicol Lett** 1996 Aug;86(2–3):193–8 (31 ref.)

Structure activity relationships in skin sensitization using the murine local lymph node assay. Ashby J, et al. **Toxicology** 1995 Dec 10;103(3):177–94

URINE

Variation in rat urinary aeroallergen levels explained by differences in site, task and exposure group. Nieuwenhuijsen MJ, et al. **Ann Occup Hyg** 1995 Dec; 39(6):819–25

ALLERGIC ALVEOLITIS, EXTRINSIC see **ALVEOLITIS, EXTRINSIC ALLERGIC**

ALLERGIC ANGIITIS see **CHURG–STRAUSS SYNDROME**

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS see **ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY**

ALLERGIC CONJUNCTIVITIS see **CONJUNCTIVITIS, ALLERGIC**

ALLERGIC CONTACT DERMATITIS see **DERMATITIS, ALLERGIC CONTACT**

ALLERGIC CUTANEOUS ANGIITIS see **VASCULITIS, ALLERGIC CUTANEOUS**

ALLERGIC CUTANEOUS VASCULITIS see **VASCULITIS, ALLERGIC CUTANEOUS**

ALLERGIC GRANULOMATOUS ANGIITIS see **CHURG–STRAUSS SYNDROME**

ALLERGIC PURPURA see **PURPURA, SCHOENLEIN–HENOCH**

ALLERGY see **HYPERSENSITIVITY**

ALLERGY (SPECIALTY) see **ALLERGY AND IMMUNOLOGY**

ALLERGY AND IMMUNOLOGY

Type III allergy skin testing. Position statement for EAACI Subcommittee on Skin Tests and Allergen Standardization. Terho E, et al. **Allergy** 1995 May;50(5):392–6

Allergists as directors of medical departments: a demonstration of leadership. Settipane GA. **Allergy Proc** 1995 May–Jun;16(3):143–6

Implications of practice parameters (guidelines). Spector SL. **Allergy Proc** 1995 Nov–Dec;16(6):303–4

Effect of allergy specialist care on the quality of life in patients with asthma. Storms B, et al. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):491–4

The impact of managed care formularies on the practice of allergy–immunology [editorial] Storms WW. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):4–5

Bela Schick Lecture, 1995. The three Ps: unabridged [editorial] Wray BB. **Ann Allergy Asthma Immunol** 1996 May;76(5):412–5 (18 ref.)

Avery–Landsteiner Prize awarded to Tim R. Mosmann, professor and chairman of the Department of Immunology of the University of Alberta in Edmonton/Alberta, Canada. Melchers F. **Behring Inst Mitt** 1995 Jun;(96):3 p preceding table of contents **(Eng, Ger)**

Clinical immunology. Mollnes TE, et al. **BMJ** 1996 Jun 8; 312(7044):1465–9 (35 ref.)

Immunology research. De Landázuri MO. **Clin Sci (Colch)** 1996 Mar;90(3):148–53

15th Scientific Congress of the European Society for Pediatric Hematology and Immunology (ESPHI). Bingen, Germany, 23–26 August 1995. Abstracts. **Eur J Pediatr** 1995 Sep;154(9):757–93

Integrated care for asthma: matching care to the patient. Osman LM, et al. **Eur Respir J** 1996 Mar;9(3):444–8

Meetings of the American Society for Biochemistry and Molecular Biology, American Society for Investigative Pathology, the American Association of Immunologists. New Orleans, Louisiana, June 2–6, 1996. Abstracts. **FASEB J** 1996 Apr 30;10(6):A959–1617

Joint annual meeting of the Austrian Society for Allergy and Immunology and the Society for Immunology. Vienna, September 27–30, 1995. Abstracts. **Immunobiology** 1995 Sep;194(1–3):1–361

Joint Congress of the British and Netherlands Societies for Immunology. Brighton, United Kingdom, 6–8 December 1995. Abstracts. **Immunol Suppl** 1995;1:1–169

52nd Annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI). New Orleans, Louisiana, March 15–20, 1996. Abstracts. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 3):183–576

Internet for the allergist. Bell T. **J Asthma** 1996;33(3):143–8 (6 ref.)

Automatic recognition of medical terminology (immunology). Ananiadou S. **Medinfo** 1995;8 Pt 1:3–7

Synopsis book. Best articles relevant to pediatric allergy and immunology. 1994–1995. **Pediatrics** 1996 Aug;98(2 Pt 2):319–54

Can microbial pathogenesis team up with immunology? Tuomanen E. **Trends Microbiol** 1995 Dec;3(12):456–7

[Progresses in microbiology and immunology in China, 1995] Wen Y. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):781 (0 ref.) **(Chi)**

[Meeting report on the "2nd Dermatologic Alps Seminar" Allergology, Occupational and Environmental Dermatology 25 to 28 May 1995 in Berchtesgaden] Aberer W. **Hautarzt** 1996 Mar;47(3):227–8 **(Ger)**

[45th general meeting of the Japanese Society of Allergology. Tokyo, Japan. October 25–27, 1995. Abstracts] **Arerugi** 1995 Aug;44(8):725–1066 **(Jpn)**

[The work experience of the allergology office of a garrison hospital] Karnaukhov IuN, et al. **Voen Med Zh** 1996 Jan; 317(1):27–8 **(Rus)**

ECONOMICS

Some questions concerning science funding in Brazil: immunology as an example. dos–Reis GA. **Braz J Med Biol Res** 1994 Dec;27(12):2705–8

EDUCATION

Allergy and immunology. American Academy of Family Physicians. **Am Fam Physician** 1996 Jan;53(1):389–91

Physicians' metered dose inhaler technique after a single teaching session. Resnick DJ, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):145–8

Integrating a primary care role with allergy and immunology training. Schuller D, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):878–81

Board requirements versus National Institutes of Health requirements. Wasserman SI, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):871–5

Allergy and immunology training in Florida. Current and future. Lockey RF. **J Fla Med Assoc** 1996 Jun–Jul; 83(6):376–8

HISTORY

Overview of immunology in Mexico. Kumate J. **Arch Med Res** 1995;26 Spec No:S85–6

Creation of first malaria vaccine raises troubling questions about "intellectual racism" [interview by Kirsteen MacLeod] Patarroyo M. **Can Med Assoc J** 1995 Nov 1; 153(9):1319–21

Mucosal solutions in Australia. Clancy R. **Immunol Cell Biol** 1995 Oct;73(5):387–8

Elie Metchnikoff (1845–1916) [editorial] **Indian J Physiol Pharmacol** 1995 Jul;39(3):175–6

History of training programs in allergy and immunology in Florida. Bukantz SC. **J Fla Med Assoc** 1996 Jun–Jul; 83(6):373–5

[Eulogy of Professor Jules Bordet, Nobel Prize in Medicine and Physiology in 1919] Govaerts A. **Bull Mem Acad R Med Belg** 1994;149(12):452–5 **(Fre)**

[Twenty–five years at the Allergy Clinic AM in Bialymstok] Chyrek–Borowska S, et al. **Pneumonol Alergol Pol** 1995; 63 Suppl 2:9–11 **(Pol)**

[Biography and contributions to the development of Polish Allergy by Prof. zw hab. med. Sabina Chyrek–Borowska] Romański B. **Pneumonol Alergol Pol** 1995;63 Suppl 2:12–6 **(Pol)**

History of the Sociedad Latinoamericana de Alergia e Inmunologia. Pérez Mart ín J. **Rev Alerg Mex** 1996 Mar–Apr;43(2):26–8 **(Spa)**

INSTRUMENTATION

Exposure chamber for allergen challenge. The development and validation of a new concept. Rønborg SM, et al. **Allergy** 1996 Feb;51(2):82–8

A calibration program for Rotorod samplers. Frenz DA, et al. **Ann Allergy Asthma Immunol** 1996 Mar;76(3):245–6

METHODS see IMMUNOLOGIC TECHNIQUES

ORGANIZATION & ADMINISTRATION

Allergists, antitrust, and managed care. Miles JJ. **Allergy Proc** 1995 Nov–Dec;16(6):305–9

Current practice and future directions in clinical immunology. Barnes RM, et al. **J R Soc Med** 1995 Jul; 88(7):395–7

[Laboratory support for the immunological and allergological services in a general medical center] Reznikov IuP, et al. **Klin Lab Diagn** 1995 Nov–Dec;(6):80–1 **(Rus)**

STANDARDS

The peer review system—still no alternative in sight [editorial] Wick G. **Int Arch Allergy Immunol** 1996 Jan; 109(1):1–2

TRENDS

IRINE symposium; immunologic advances in the Commonwealth of Independent States(Part 1). DuBuske LM. **Allergy Proc** 1995 Jul–Aug;16(4):171–5

Medical care in Russia in 1995: a state of transition [editorial] Reilly SW. **Ann Allergy Asthma Immunol** 1996 Jun; 76(6):479–83

Special issue: The 9th International Congress of Immunology. San Francisco, California, 23–29 July 1995. **Immunol Today** 1995 Jul;16(7):305–62

Exponential growth in apoptosis. Cohen JJ. **Immunol Today** 1995 Jul;16(7):346–8

Allergy: who, why and what to do about it? HayGlass KT. **Immunol Today** 1995 Nov;16(11):505–7

Immunology research in the UK: a scientific audit. O'Driscoll M, et al. **Immunol Today** 1995 Sep;16(9):413–7

Dendritic cells: a major story unfolds. Stingl G, et al. **Immunol Today** 1995 Jul;16(7):330–3 (32 ref.)

Antigen presentation—recent developments. Rammensee HG. **Int Arch Allergy Immunol** 1996 Aug;110(4):299–307 (63 ref.)

Justifying a mechanism–based specialty. Adkinson NF Jr, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):868–71

Update on cytokines. Borish L, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):719–33; quiz 734

Allergy versus asthma as the focus of the subspecialty. Platts–Mills TA, et al. **J Allergy Clin Immunol** 1996 Mar; 97(3):865–8

Referring for knowledge base: what is the case for referral? Schatz M, et al. **J Allergy Clin Immunol** 1996 Mar; 97(3):876–8

Integrating a primary care role with allergy and immunology training. Schuller D, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):878–81

Conjoint versus separate boards. Shearer WT, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):881–4

Whither clinical immunology? Rich RR. **J Immunol** 1995 Nov 15;155(10):4992–5

The impact of recent advances in microbiology and immunology on perinatal and women's health care. Munro CL. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug; 24(6):525–31 (32 ref.)

Allergy and immunology. Baker JR Jr, et al. **JAMA** 1996 Jun 19;275(23):1794–5

[Immunological novelties for clinicians] Meri S, et al. **Duodecim** 1994;110(2):175–7 (8 ref.) **(Fin)**

[Importance of progress achieved in fundamental biomedical sciences, especially in immunology, for the design of new vaccines] Louis J. **Schweiz Med Wochenschr** 1996 Jul 9; 126(27–28):1208–9 (Eng. Abstr.) **(Fre)**

[The outlook for the development of a laboratory immunological service] Cheredeev AN. **Klin Lab Diagn** 1995 Nov–Dec;(6):76–8 **(Rus)**

ALLERTON VIRUS see HERPESVIRUS 2, BOVINE

ALLESCHERIA see PSEUDALLESCHERIA

ALLETHRIN

CHEMISTRY

Effect of the pyrethroid insecticide allethrin on membrane fluidity. Moya–Quiles MR, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1299–308

PHARMACOLOGY

Effect of the pyrethroid insecticide allethrin on membrane fluidity. Moya–Quiles MR, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1299–308

TOXICITY

Bioallethrin causes permanent changes in behavioural and muscarinic acetylcholine receptor variables in adult mice exposed neonatally to DDT. Johansson U, et al. **Eur J Pharmacol** 1995 Jul 1;293(2):159–66

ALLIED HEALTH OCCUPATIONS

MANPOWER see ALLIED HEALTH PERSONNEL

STATISTICS & NUMERICAL DATA

Report of the National Commission on Allied Health. **J Allied Health** 1996 Winter;25(1):1–137

ALLIED HEALTH PERSONNEL

Apparent versus real exposures of nuclear medicine technologists during aerosol lung ventilation scanning [comment] Pityn PJ, et al. **Am Ind Hyg Assoc J** 1996 Feb; 57(2):202–4. Comment on: Am Ind Hyg Assoc J 1994 Dec;55(12):1144–8.

Sharing care between allied health professionals and general practitioners [editorial] Moorhead R. **Aust Fam Physician** 1995 Nov;24(11):1985

A matter of choice? [letter; comment] Lee TS, et al. **Chest** 1996 Feb;109(2):583. Comment on: Chest 1995 Jun;107(6):1655–61.

Physician–ordered respiratory care vs physician–ordered use of a respiratory therapy consult service. Results of a prospective observational study [see comments] Stoller JK, et al. **Chest** 1996 Aug;110(2):422–9. Comment in: Chest 1996 Aug;110(2):313–4.

Respiratory care education includes intubations [letter; comment] Watson TJ. **Chest** 1996 Feb;109(2):583–4. Comment on: Chest 1995 Jun;107(6):1655–61.

Calculation of patient's complexity: paramedical and nursing facets. Delacrétaz AC, et al. **Comput Methods Programs Biomed** 1995 Sep–Oct; 48(1–2):97–102

Application of American College of Surgeons' field triage guidelines by pre–hospital personnel. Norcross ED, et al. **J Am Coll Surg** 1995 Dec;181(6):539–44

Prevalence of antibodies to hepatitis B and C among fire department personnel prior to implementation of a hepatitis B vaccination program [letter; comment] Pardoe KL. **J Occup Environ Med** 1996 Feb;38(2):124–5; discussion 127–8. Comment on: J Occup Environ Med 1995 Jun;37(6):663–4.

Prevalence of antibodies to hepatitis B and C among fire department personnel prior to implementation of a hepatitis B vaccination program [letter; comment] Porter ES, et al. **J Occup Environ Med** 1996 Feb;38(2):125–7; discussion 127–8. Comment on: J Occup Environ Med 1995 Jun;37(6):663–4.

Needlestick malaria [letter] Haworth FL, et al. **Lancet** 1995 Nov 18;346(8986):1361

[Significance of initial defibrillation by paramedics] Mauer D, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):303–6 (30 ref.) **(Ger)**

EDUCATION

Multiskilling: who, how, when, and why? Foto M. **Am J Occup Ther** 1996 Jan;50(1):7–9

Benefits of the collaborative model [letter; comment] Miller T, et al. **Phys Ther** 1995 Dec;75(12):1137–9. Comment on: Phys Ther 1995 Jun;75(6):503–10.

Proposal for the development of an audiological assistant training program. Muller A. **Scand Audiol Suppl** 1996; 42:47–8

[Education of paramedics in resuscitation: after 6 months some procedures forgotten. Knowledge and capability of medical lay personnel after education in cardiovascular resuscitation] Töpperwein HH. **Fortschr Med** 1996 Jan 20; 114(1–2):30 **(Ger)**

HISTORY

[Technicians in the area of radiology] Cardinale AE. **Radiol Med (Torino)** 1995 Nov;90(5):564–70 **(Ita)**

LEGISLATION & JURISPRUDENCE

Defining the PTA's roles. Amborse–Walsh L. **Phys Ther** 1996 Apr;76(4):410–3

PSYCHOLOGY

Physical therapist assistants' perceptions of the documented roles of the physical therapist assistant. Robinson AJ, et al. **Phys Ther** 1995 Dec;75(12):1054–64; discussion 1064–6

STANDARDS

Cerebrovascular accident patients: an interdisciplinary/multidisciplinary audit. Penman GM, et al. **Aust Clin Rev** 1991;11:106–10

Unusual ECG tracing, unusual cause [letter] Tibrewala L. **Indian Heart J** 1996 Jan–Feb;48(1):81

SUPPLY & DISTRIBUTION

Report of the National Commission on Allied Health. **J Allied Health** 1996 Winter;25(1):1–137

TRENDS

Project on role of allied health care professions needs online input [letter] Houghton S. **Can Med Assoc J** 1996 May 15;154(10):1468

UTILIZATION

Position paper: use of occupational therapy aides in occupational therapy practice. American Occupational Therapy Association. Ramsay DL. **Am J Occup Ther** 1995 Nov–Dec;49(10):1023–5

Social conscience [letter; comment] O'Donnell EM. **Hosp Health Netw** 1995 Dec 5;69(23):8. Comment on: Hosp Health Netw 1995 Sep 20;69(18):28–30, 32, 34.

Project management. Lessons learned from introducing a multitask environmental worker program. Pischke–Winn K, et al. **J Nurs Adm** 1996 Jun;26(6):31–8

ALLIGATORS AND CROCODILES

Alligator rhodopsin: sequence and biochemical properties. Smith WC, et al. **Exp Eye Res** 1995 Nov;61(5):569–78

A wonderful dog–master story [letter] Hakansson BO. **Trop Doct** 1996 Apr;26(2):88

Sustainable use of wildlife [letter] Cooper JE. **Vet Rec** 1995 Jun 10;136(23):596

ANATOMY & HISTOLOGY

Spinally projecting neurons of the dorsal column nucleus in a reptile: locus of origin and trajectory of termination. Pritz MB. **Brain Behav Evol** 1996;47(3):138–48

[Histology and histochemistry of the kidney and ureters of the Caiman crocodilus yacare (Daudin, 1802)—Crocodilia Reptilia)] Jin SM, et al. **Rev Bras Biol** 1995 Feb; 55(1):97–103 (Eng. Abstr.) **(Por)**

EMBRYOLOGY

Mathematical models for growth in alligator (Alligator mississippiensis) embryos developing at different incubation temperatures. Bardsley WG, et al. **J Anat** 1995 Aug;187 (Pt 1):181–90

Responses to chronic hypoxia in embryonic alligators. Warburton SJ, et al. **J Exp Zool** 1995 Sep 1;273(1):44–50

The molecular biology of temperature–dependent sex determination. Johnston CM, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29; 350(1333):297–303; discussion 303–4

GENETICS

Variations in mitochondrial tRNA gene organization of reptiles as phylogenetic markers. Kumazawa Y, et al. **Mol Biol Evol** 1995 Sep;12(5):759–72

Dynamics of Mhc evolution in birds and crocodilians: amplification of class II genes with degenerate primers. Edwards SV, et al. **Mol Ecol** 1995 Dec;4(6):719–29

Mitochondrial gene order adjacent to the control region in crocodile, turtle, and tuatara. Quinn TW, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):344–51

The molecular biology of temperature–dependent sex determination. Johnston CM, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29; 350(1333):297–303; discussion 303–4

IMMUNOLOGY

Dynamics of Mhc evolution in birds and crocodilians: amplification of class II genes with degenerate primers. Edwards SV, et al. **Mol Ecol** 1995 Dec;4(6):719–29

METABOLISM

Gonadal steroidogenesis in vitro from juvenile alligators obtained from contaminated or control lakes. Guillette LJ Jr, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:31–6

Reduction in penis size and plasma testosterone concentrations in juvenile alligators living in a contaminated environment. Guillette LJ Jr, et al. **Gen Comp Endocrinol** 1996 Jan;101(1):32–42

MICROBIOLOGY

Mycoplasma-associated polyarthritis in farmed crocodiles (Crocodylus niloticus) in Zimbabwe. Mohan K, et al. **Onderstepoort J Vet Res** 1995 Mar;62(1):45–9

PARASITOLOGY

Pentastomid parasites of the family Sebekidae Fain, 1961 in west African dwarf crocodiles Osteolaemus tetraspis Cope, 1851 from the Congo, with a description of Alofia parva n. sp. Riley J, et al. **Onderstepoort J Vet Res** 1995 Sep; 62(3):151–62

PHYSIOLOGY

Central vascular flow patterns in the alligator Alligator mississipiensis. Malvin GM, et al. **Am J Physiol** 1995 Nov; 269(5 Pt 2):R1133–9

Neuropeptide immunoreactivity and co-existence in cardiovascular nerves and autonomic ganglia of the estuarine crocodile, Crocodylus porosus, and cardiovascular effects of neuropeptides. Karila P, et al. **Regul Pept** 1995 Jul 21;58(1–2):25–39

Breathing pattern and cost of ventilation in the American alligator. Wang T, et al. **Respir Physiol** 1995 Oct; 102(1):29–37

ALLIUM

A prospective cohort study on the relationship between onion and leek consumption, garlic supplement use and the risk of colorectal carcinoma in The Netherlands. Dorant E, et al. **Carcinogenesis** 1996 Mar;17(3):477–84

Consumption of onions and a reduced risk of stomach carcinoma. Dorant E, et al. **Gastroenterology** 1996 Jan; 110(1):12–20

Allium cepa seeds: a new occupational allergen. Navarro JA, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):690–3

Onion powder in baby food may induce anemia in cats [letter] Kaplan AJ. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1405

Allium test. Fiskesjö G. **Methods Mol Biol** 1995;43:119–27

CHEMISTRY

In situ localization of nucleolin in the plant nucleolar matrix. Minguez A, et al. **Exp Cell Res** 1996 Jan 10;222(1):171–8

Antiperoxide effects of S-allyl cysteine sulphoxide isolated from Allium sativum Linn and gugulipid in cholesterol diet fed rats. Sheela CG, et al. **Indian J Exp Biol** 1995 May; 33(5):337–41

CYTOLOGY

Meiosis in the leek (Allium porrum L.) revisited. I. Prophase I pairing. Khazanehdari KA, et al. **Chromosome Res** 1995 Nov;3(7):433–9

DRUG EFFECTS

Effects of Mg2+, Co2+, and Hg2+ on the nucleus and nucleolus in root tip cells of Allium cepa. Liu D, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):779–87

Brassinolide is a selective ribosomal cistron regulator in onion leaf base tissue. Karagiannis CS, et al. **Mech Ageing Dev** 1995 Apr 21;80(1):35–42

The evaluation of waste, surface and ground water quality using the Allium test procedure. Smaka-Kincl V, et al. **Mutat Res** 1996 Jul 5;368(3–4):171–9

ENZYMOLOGY

Occurrence and characterization of a dehydratase enzyme in the leek icosanoyl-CoA synthase complex. Lessire R, et al. **Biochim Biophys Acta** 1993 Sep 8;1169(3):243–9

GENETICS

The inheritance of B chromosomes in Allium schoenoprasum L. Bougourd SM, et al. **Chromosome Res** 1996 Feb; 4(2):151–8

IMMUNOLOGY

Bronchial asthma caused by onion [letter; comment] Kawane H. **J Allergy Clin Immunol** 1995 Oct;96(4):568. Comment on: J Allergy Clin Immunol 1994 Nov;94(5):928–30.

METABOLISM

Subnucleolar location of fibrillarin and variation in its levels during the cell cycle and during differentiation of plant cells. Cerdido A, et al. **Chromosoma** 1995 May; 103(9):625–34

Post-mitotic assembly of the nucleolus. I. The internal matrix network is a recruitment site for processing nucleolar components in prenucleolar bodies. Moreno Díaz de la Espina S, et al. **Chromosome Res** 1996 Feb;4(2):103–10

PHYSIOLOGY

A potent antimicrobial protein from onion seeds showing sequence homology to plant lipid transfer proteins. Cammue BP, et al. **Plant Physiol** 1995 Oct;109(2):445–55

ALLIUM SATIVUM see **GARLIC**

ALLNORTOXIFERINE see **ALCURONIUM**

ALLOANTIBODIES see **ISOANTIBODIES**

ALLOANTIGENS see **ISOANTIGENS**

ALLOCEBUS see **CHEIROGALEIDAE**

ALLOGRAFT see **TRANSPLANTATION, HOMOLOGOUS**

ALLOGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

ALLOLEVIVIRUS

CHEMISTRY

Secondary structure model for the first three domains of Q beta RNA. Control of A-protein synthesis. Beekwilder J, et al. **J Mol Biol** 1996 Feb 16;256(1):8–19

ALLOMYCES see **MASTIGOMYCOTINA**

ALLOPURINOL

ADMINISTRATION & DOSAGE

Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Graham S, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):299–304

Use of an Itraconazole/allopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS. Raffi F, et al. **Clin Infect Dis** 1995 Nov;21(5):1338–9

Successful treatment of herpangina with allopurinol mouthwashes [letter] Waldfahrer F, et al. **Laryngoscope** 1995 Dec;105(12 Pt 1):1405

A survey of allopurinol dosage prescribing. McClintock AD, et al. **N Z Med J** 1995 Aug 25;108(1006):346–7

ADVERSE EFFECTS

Allopurinol, erythema multiforme, and renal insufficiency. Kumar A, et al. **BMJ** 1996 Jan 20;312(7024):173–4

Fever, rash, and angioedema after a course of allopurinol. Yale SH, et al. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):92–4

Successful desensitization for treatment of a fixed drug eruption to allopurinol. Kelso JM, et al. **J Allergy Clin Immunol** 1996 May;97(5):1171–2

Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Cummins D, et al. **Transplantation** 1996 Jun 15;61(11):1661–2

[Fatal hepatitis due to allopurinol in Dakar (letter)] Wade B, et al. **Med Trop (Mars)** 1995;55(2):186–7 **(Fre)**

[Hypersensitivity syndrome caused by allopurinol. A case of massive hepatic necrosis] González U, et al. **Rev Invest Clin** 1995 Sep-Oct;47(5):409–13 (Eng. Abstr.) **(Spa)**

ANALOGS & DERIVATIVES

Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Coste H, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1577–85

IMMUNOLOGY

Successful desensitization for treatment of a fixed drug eruption to allopurinol. Kelso JM, et al. **J Allergy Clin Immunol** 1996 May;97(5):1171–2

PHARMACOKINETICS

Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals. Walter-Sack I, et al. **Eur J Clin Pharmacol** 1995;49(3):215–20

The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse. Mills PC, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):451–6

PHARMACOLOGY

Allopurinol effects in rat liver transplantation on recovery of energy metabolism and free radical-induced damage. Kusumoto K, et al. **Eur Surg Res** 1995;27(5):285–91

Podocyte architecture in puromycin aminonucleoside-treated rats administered tungsten or allopurinol. Ricardo SD, et al. **Exp Nephrol** 1995 Sep-Oct;3(5):270–9

Beneficial effects of allopurinol on glutathione levels and glutathione peroxidase activity in rat ischaemic acute renal failure. Alataş O, et al. **J Int Med Res** 1996 Jan-Feb; 24(1):33–9

Effect of high lipid diet and allopurinol on the development of experimentally induced arthritis in rats. Yossif AM, et al. **Pharmacology** 1995 Sep;51(3):160–4

Allopurinol inhibits endothelin release after mesenteric ischemia-reperfusion injury. Buyukgebiz O, et al. **Transplant Proc** 1995 Oct;27(5):2699–700

Allopurinol improves postischemic skeletal muscle performance and endurance but not high-energy phosphate levels. Gürke L, et al. **Transplant Proc** 1995 Oct; 27(5):2840–1

[Effects of allopurinol on damage caused by ischemia and reperfusion of skeletal muscles: an in vivo spectroscopic analysis (31P-MR) in rats] Gürke L, et al. **Ann Ital Chir** 1996 Jan-Feb;67(1):73–5 (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

The anti-inflammatory and anti-hyperuricemic effects of Chinese herbal formula danggui-nian-tong-tang on acute gouty arthritis: a comparative study with indomethacin and allopurinol. Chou CT, et al. **Am J Chin Med** 1995; 23(3–4):261–71

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Ribera E, et al. **Am J Med** 1996 May;100(5):496–501

Randomised controlled trial of allopurinol prophylaxis in very preterm infants. Russell GA, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F27–31

Effects of allopurinol and steroids on inflammation and oxidative tissue damage in experimental lens induced uveitis: a biochemical and morphological study. Augustin AJ, et al. **Br J Ophthalmol** 1996 May;80(5):451–7

Free radical generation and the role of allopurinol as a cardioprotective agent during coronary artery bypass grafting surgery. Movahed A, et al. **Can J Cardiol** 1996 Feb;12(2):138–44

Use of allopurinol to treat visceral leishmaniosis in a dog. Lester SJ, et al. **J Am Vet Med Assoc** 1996 Aug 1; 209(3):615–7

The effect of allopurinol on interstitial purine metabolism and tissue damage in skeletal muscle I-R injury. Asami A, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):209–16

Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-hodgkin lymphoma. Keuzenkamp-Jansen CW, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):145–50

Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double-blind controlled study. Persson BE, et al. **J Urol** 1996 Mar;155(3):961–4

Allopurinol for prostatitis: where is the evidence? Nickel JC, et al. **Lancet** 1996 Jun 22;347(9017):1711–2

Non-bacterial prostatitis [letter] Persson BE, et al. **Lancet** 1996 Sep 14;348(9029):761

Allopurinol for Old World cutaneous leishmaniasis [letter] Halbert AR, et al. **Pediatr Dermatol** 1995 Sep;12(3):287–8

Treatment with allopurinol and itraconazole changes lytic activity in patients with chronic, low grade Trypanosoma cruzi infection. Sánchez G, et al. **Trans R Soc Trop Med Hyg** 1995 Jul-Aug;89(4):438–9

Allopurinol in the treatment of canine visceral leishmaniasis [see comments] Liste F, et al. **Vet Rec** 1995 Jul 1; 137(1):23–4. Comment in: Vet Rec 1995 Sep 2;137(10):252.

Treatment of canine visceral leishmaniasis with allopurinol [letter; comment] Vercammen F, et al. **Vet Rec** 1995 Sep 2;137(10):252. Comment on: Vet Rec 1995 Jul 1;137(1):23–4.

[Diagnosis and treatment of gout: not always simple] van Vugt RM, et al. **Ned Tijdschr Geneeskd** 1996 Jan 27; 140(4):177–9 **(Dut)**

ALLOSTERIC REGULATION

Positive and negative cooperativities at subsequent steps of oxygenation regulate the allosteric behavior of multistate sebacylhemoglobin. Bucci E, et al. **Biochemistry** 1996 Mar 19;35(11):3418–25

Tetramer-dimer equilibrium of phosphofructokinase and formation of hybrid tetramers. Le Bras G, et al. **Biochemistry** 1995 Oct 10;34(40):13203–10

Identification of residues linked to the slow-->fast transition of thrombin. Guinto ER, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11185–9

ALLOSTERIC SITE

Regulatory changes in the control of carbamoyl phosphate synthetase induced by truncation and mutagenesis of the allosteric binding domain. Czerwinski RM, et al. **Biochemistry** 1995 Oct 24;34(42):13920–7

Effect of substrates and pH on the intestinal Na+/phosphate cotransporter: evidence for an intervesicular divalent phosphate allosteric regulatory site. Peerce BE. **Biochim Biophys Acta** 1995 Oct 4;1239(1):1–10

Loss of allosteric behaviour in recombinant hemoglobin alpha 2 beta 2(92)(F8) His-->Ala: restoration upon addition of strong effectors. Dumoulin A, et al. **FEBS Lett** 1995 Oct 23;374(1):39–42

ALLOTYPES, IMMUNOGLOBULIN see **IMMUNOGLOBULIN ALLOTYPES**

ALLOTYPES, IMMUNOGLOBULIN GM see **IMMUNOGLOBULIN GM ALLOTYPES**

ALLOTYPES, IMMUNOGLOBULIN INV see **IMMUNOGLOBULIN INV ALLOTYPES**

ALLOTYPIC ANTIBODIES see **IMMUNOGLOBULIN ALLOTYPES**

ALLOWING TO DIE see **EUTHANASIA, PASSIVE**

ALLOXAN

Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse. Ahrén B, et al. **Diabetologia** 1996 Apr;39(4):383-90

PHARMACOLOGY

Defective repair of oxidative damage in the mitochondrial DNA of a xeroderma pigmentosum group A cell line. Driggers WJ, et al. **Cancer Res** 1996 Mar 15;56(6):1262-6

TOXICITY

Real time microfiberoptic redox fluorometry: modulation of the pyridine nucleotide status of the organogenesis-stage rat visceral yolk sac with cyanide and alloxan. Thorsrud BA, et al. **Toxicol Appl Pharmacol** 1995 Dec;135(2):237-45

ALLOXAN DIABETES see **DIABETES MELLITUS, EXPERIMENTAL**

ALLOXANTHINE see **OXYPURINOL**

ALLOYS

Palliative treatment of obstructing esophageal cancer with nitinol stents: value, safety, and long-term results. Winkelbauer FW, et al. **AJR Am J Roentgenol** 1996 Jan; 166(1):79-84

Successful exclusion of a large femoropopliteal aneurysm with a covered nitinol stent. Dorffner R, et al. **Cardiovasc Intervent Radiol** 1996 Mar-Apr;19(2):117-9

Percutaneous transcatheter coil occlusion of the patent ductus arteriosus aided by the nitinol snare: further observations. Ing FF, et al. **Cardiovasc Intervent Radiol** 1995 Jul-Aug;18(4):222-6

Nitinol esophageal stents: new designs and clinical indications. Strecker EP, et al. **Cardiovasc Intervent Radiol** 1996 Jan-Feb;19(1):15-20

Metal on metal total hip replacement workshop consensus document. Amstutz HC, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S297-303

Tissue reaction to metal on metal total hip prostheses. Doorn PF, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S187-205

Human macrophage response to retrieved titanium alloy particles in vitro. Maloney WJ, et al. **Clin Orthop** 1996 Jan;(322):268-78

Comparison of alloys and designs in a hip simulator study of metal on metal implants. Medley JB, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S148-59

Metallic implants used in foot surgery. Chang TJ, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):457-74 (57 ref.)

Highly flexible self-expanding meshed metal stents for palliation of malignant esophagogastric obstruction. Grund KE, et al. **Endoscopy** 1995 Sep;27(7):486-94

Results of the new nitinol self-expandable stents for distal biliary structures. Smits M, et al. **Endoscopy** 1995 Sep; 27(7):505-8

Palliative treatment of neoplastic strictures by self-expanding nitinol Strecker stent. Pocek M, et al. **Eur Radiol** 1996; 6(2):230-5

Memory metal stents for palliation of malignant obstruction of the oesophagus and cardia. May A, et al. **Gut** 1995 Sep; 37(3):309-13

Evaluation of inductively heated ferromagnetic alloy implants for therapeutic interstitial hyperthermia. Paulus JA, et al. **IEEE Trans Biomed Eng** 1996 Apr;43(4):406-13

Experimental arterial stent placement. Comparison of a new Nitinol stent and Wallstent. Schürmann K, et al. **Invest Radiol** 1995 Jul;30(7):412-20

Gallium alloy restorations in primary teeth: a 12-month study. Kaga M, et al. **J Am Dent Assoc** 1996 Aug; 127(8):1195-200

Effect of corrosion products (neodymium iron boron) on oral fibroblast proliferation. Evans RD, et al. **J Appl Biomater** 1995 Fall;6(3):199-202

Mixed mode fracture characterization of hydroxylapatite-titanium alloy interface. Mann KA, et al. **J Appl Biomater** 1994 Winter;5(4):285-91

Corrosion at the interface. A possible solution to cobalt-chrome heads on titanium alloy stems. Yerby SA, et al. **J Arthroplasty** 1996 Feb;11(2):157-62

Mixed-metal fretting corrosion of Ti6Al4V and wrought cobalt alloy. Kawalec JS, et al. **J Biomed Mater Res** 1995 Jul;29(7):867-73

Mechanical properties of the binary titanium-zirconium alloys and their potential for biomedical materials. Kobayashi E, et al. **J Biomed Mater Res** 1995 Aug; 29(8):943-50

Degradation potential of plasma-sprayed hydroxyapatite-coated titanium implants. Paschalis EP, et al. **J Biomed Mater Res** 1995 Dec;29(12):1499-505

Ultramicrotomy of nanocrystalline materials. McMahon G, et al. **Microsc Res Tech** 1995 Jul 1;31(4):267-74

Electrochemical and microstructural study of oxide films formed electrochemically at microcrystalline Al-Fe-V-Si alloys. Thomas SC, et al. **Microsc Res Tech** 1995 Jul 1; 31(4):285-92

Palliation of malignant esophageal strictures with self-expanding nitinol stents: drawbacks and complications. Acunaş B, et al. **Radiology** 1996 Jun;199(3):648-52

[Animal experiment study of titanium with surface coatings of (Ti,Nb)ON and (Ti,Zr)O] Thull R, et al. **Biomed Tech (Berl)** 1995 Oct;40(10):289-95 (Eng. Abstr.) **(Ger)**

[Self-expanding nitinol stent--use in esophageal carcinoma] Decker P, et al. **Chirurg** 1995 Dec;66(12):1258-62 (Eng. Abstr.) **(Ger)**

[Abscess development caused by ingrown nitinol spiral as a fatal complication of a partially deteriorated MEMOSOND-PEG] Gossner L, et al. **Z Gastroenterol** 1996 Jun;34(6):378-81 (Eng. Abstr.) **(Ger)**

[Highly flexible self-expanding metal mesh stents: a new kind of palliative therapy of malignant dysphagia] Grund KE, et al. **Z Gastroenterol** 1995 Jul;33(7):392-8 (Eng. Abstr.) **(Ger)**

[Management of an iliac artery aneurysm with percutaneous placement of a Dacron-nitinol vascular endoprosthesis] Sievert H, et al. **Z Kardiol** 1995 Oct;84(10):860-2 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Nickel-containing alloys and platings and their ability to cause dermatitis. Lidén C, et al. **Br J Dermatol** 1996 Feb; 134(2):193-8

Mortality of copper cadmium alloy workers with special reference to lung cancer and non-malignant diseases of the respiratory system, 1946-92. Sorahan T, et al. **Occup Environ Med** 1995 Dec;52(12):804-12

[The morphological characteristics of the lung lesions in straighteners working with brass-bronze alloys] Voznesenskiĭ NK, et al. **Gig Sanit** 1995 Nov-Dec;(6):20-2 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Effect of nickel addition on microstructure and properties of Ti-Co-Ni alloys. Chern Lin JH, et al. **Biomaterials** 1995 Dec;16(18):1401-7

Biochemical surface modification of Co-Cr-Mo. Puleo DA. **Biomaterials** 1996 Jan;17(2):217-22

Wear behavior and histopathology of classic cemented metal on metal hip endoprostheses. Willert HG, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S160-86

Effects of precoating surface treatments on fatigue of Ti-6Al-4V. Eberhardt AW, et al. **J Appl Biomater** 1995 Fall;6(3):171-4

Characterization of electrolytically prepared brushite and hydroxyapatite coatings on orthopedic alloys. Redepenning J, et al. **J Biomed Mater Res** 1996 Mar;30(3):287-94

DIAGNOSTIC USE

Mechanical impactor employing Nitinol probes to fragment human calculi: fragmentation efficiency with flexible endoscope deflection. Loisides P, et al. **J Endourol** 1995 Oct;9(5):371-4

STANDARDS

Corrosion and other electrochemical aspects of biomaterials. Bundy KJ. **Crit Rev Biomed Eng** 1994;22(3-4):139-251 (1712 ref.)

TOXICITY

Metal carcinogenesis in total joint arthroplasty. Animal models. Lewis CG, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S264-8 (37 ref.)

In vitro biocompatibility, mechanical properties, and corrosion resistance of Ti-Zr-Nb-Ta-Pd and Ti-Sn-Nb-Ta-Pd alloys. Ito A, et al. **J Biomed Mater Res** 1995 Jul;29(7):893-9

[Morphological transformation of BHK-21 cells by nickel titanium shape memory alloy particles encapsulated by titanium oxide] Qin R, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Nov;75(11):663-5, 708-9 (Eng. Abstr.) **(Chi)**

ALLYL COMPOUNDS

CHEMISTRY

Louisianins A, B, C and D: non-steroidal growth inhibitors of testosterone-responsive SC 115 cells. II. Physico-chemical properties and structural elucidation. Takamatsu S, et al. **J Antibiot (Tokyo)** 1995 Oct; 48(10):1090-4

A new universal linker for solid phase DNA synthesis. Lyttle MH, et al. **Nucleic Acids Res** 1996 Jul 15;24(14):2793-8

Competing pathway involved in allylic acetoxylation of androst-5-en-17-one, and oxidation of allylic alcohols with chromium oxides. Numazawa M, et al. **Steroids** 1995 Aug; 60(8):499-505

ISOLATION & PURIFICATION

Louisianins A, B, C and D: non-steroidal growth inhibitors of testosterone-responsive SC 115 cells. I. Taxonomy, fermentation, isolation and biological characteristics. Komiyama K, et al. **J Antibiot (Tokyo)** 1995 Oct; 48(10):1086-9

PHARMACOLOGY

Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial. Stoltz M, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):342-53

Louisianins A, B, C and D: non-steroidal growth inhibitors of testosterone-responsive SC 115 cells. I. Taxonomy, fermentation, isolation and biological characteristics. Komiyama K, et al. **J Antibiot (Tokyo)** 1995 Oct; 48(10):1086-9

Protection from 1,1-dichloroethylene-induced Clara cell injury by diallyl sulfone, a derivative of garlic. Forkert PG, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1665-71

Selectivity of MDL 72,974A for MAO-B inhibition based on substrate and metabolite concentrations in plasma. Huebert ND, et al. **Prog Brain Res** 1995;106:135-42

[Effect of Allitridi on deforming of peripheral leucocytes in patients with acute cerebral infarction] Mao JS, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jul; 15(7):395-7 (Eng. Abstr.) **(Chi)**

[Effect of allitridum on macrophage-medicated cytotoxicity] Zhang G, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Jan; 21(1):45-7, inside back cover (Eng. Abstr.) **(Chi)**

[Antiradical activity of a diallyl series ternary copolymer in realizing an antimutagenic effect] Odin AP, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):265-7 **(Rus)**

TOXICITY

Modifications of neurofilament proteins by possible metabolites of allyl chloride in vitro. He Y, et al. **Drug Chem Toxicol** 1995 Nov;18(4):315-31

ALLYLAMINE

ANALOGS & DERIVATIVES

Antifungal agents, Part 11. Biphenyl analogues of naftifine: synthesis and antifungal activities. Porretta GC, et al. **Arch Pharm (Weinheim)** 1995 Sep;328(9):667-72

Allergic contact dermatitis from naftifine. Willa-Craps C, et al. **Contact Dermatitis** 1995 Jun;32(6):369-70

Antimycotic susceptibility testing of mould-fungi with allylamines by disk diffusion. Venugopal PV, et al. **Indian J Med Sci** 1995 May;49(5):109-13

ALLYLESTRENOL

PHARMACOLOGY

Effect of prenatal allylestrenol treatment (hormonal imprinting) on the serum testosterone and progesterone level in adult rats. Pap E, et al. **Gen Pharmacol** 1995 Mar; 26(2):365-7

Effect of neonatal allylestrenol treatment (hormonal imprinting) on the serum testosterone and progesterone concentration in adult rat. Pap E, et al. **Reprod Fertil Dev** 1995;7(5):1249-51

ALLYLGLYCINE

ANALOGS & DERIVATIVES

Growth-suppressive activities of serine protease inhibitors, ONO-3403 and ONO-5046, toward normal and transformed murine fibroblasts. Hiwasa T, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1823-6

Unique binding of a novel synthetic inhibitor, N-[3-[4-[4-(amidinophenoxy)carbonyl]phenyl]-2-methyl-2-propenoyl]- N-allylglycine methanesulfonate, to bovine trypsin, revealed by the crystal structure of the complex. Odagaki Y, et al. **Biochemistry** 1995 Oct 3;34(39):12849-53

ALLYLNORMORPHINE see **NALORPHINE**

ALMITRINE

ADMINISTRATION & DOSAGE

Dose-response curves of inhaled nitric oxide with and without intravenous almitrine in nitric oxide-responding patients with acute respiratory distress syndrome. Lu Q, et al. **Anesthesiology** 1995 Nov;83(5):929-43

PHARMACOLOGY

Effects of almitrine on the ventilatory control, breathing pattern and maximal exercise tolerance in hypoxemic patients with chronic obstructive pulmonary disease. Ribeiro SA, et al. **Braz J Med Biol Res** 1995 Aug; 28(8):859-67

Beneficial effects of a novel anti-hypoxemic agent, TEI-7322, on bleomycin-induced experimental hypoxemia in rats. Horiuchi H, et al. **Eur J Pharmacol** 1995 Dec 4; 287(1):27-34

THERAPEUTIC USE

Cerebral ischemia: from pharmacology to modern techniques and clinical implications. Value of almitrine-raubasin

(Duxil Duxaril). International symposium, Hangzhou, People's Republic of China, May 14, 1994. **Eur Neurol** 1995; 35 Suppl 1:1–46

Pathophysiology of postischemic hypoxia and cerebral protection: implications of the almitrine and raubasine combination. Chan P. **Eur Neurol** 1995;35 Suppl 1:23–7 (41 ref.)

Memory disorders in 8,037 elderly patients with age-associated memory impairment: multicenter trial with a 6-month follow-up under almitrine-raubasine. Poitrenaud J, et al. **Eur Neurol** 1995;35 Suppl 1:43–6

Glial fibrillary acidic protein expression after transient brain ischemia: evidence for a pharmacological modulation by almitrine-raubasine. Pujol JF, et al. **Eur Neurol** 1995;35 Suppl 1:12–6

Quantitative electroencephalography in aging brain and cerebrovascular disease: the effects of almitrine-raubasine. Sebban C. **Eur Neurol** 1995;35 Suppl 1:37–42 (16 ref.)

TOXICITY

Lipidosis of the dorsal root ganglia in rats treated with an almitrine metabolite. Yamanaka Y, et al. **Arch Toxicol** 1995; 69(6):391–6

ALMITRINE BISMESYLATE see **ALMITRINE**

ALOE

The preventive and therapeutic potential of the squalene-containing compound, Roidex, on tumor promotion and regression. Desai KN, et al. **Cancer Lett** 1996 Mar 19;101(1):93–6

Zinc acetate and lyophilized aloe barbadensis as vaginal contraceptive. Fahim MS, et al. **Contraception** 1996 Apr; 53(4):231–6

A 35 kDa mannose-binding lectin with hemagglutinating and mitogenic activities from "Kidachi Aloe" (Aloe arborescens Miller var. natalensis Berger). Koike T, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1205–10

Effect of aloe vera gel to healing of burn wound a clinical and histologic study. Visuthikosol V, et al. **J Med Assoc Thai** 1995 Aug;78(8):403–9

Decreased levels of 2-amino-3-methylimidazo[4,5-f]quinoline-DNA adducts in rats treated with beta-carotene, alpha-tocopherol and freeze-dried aloe. Uehara N, et al. **Jpn J Cancer Res** 1996 Apr;87(4):342–8

Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo-controlled, double-blind study. Syed TA, et al. **Trop Med Int Health** 1996 Aug; 1(4):505–9

CHEMISTRY

High-performance liquid chromatographic profiles of aloe constituents and determination of aloin in beverages, with reference to the EEC regulation for flavouring substances. Zonta F, et al. **J Chromatogr A** 1995 Dec 1;718(1):99–106

Antiinflammatory C-glucosyl chromone from Aloe barbadensis. Hutter JA, et al. **J Nat Prod** 1996 May; 59(5):541–3

ALOE EMODIN see **EMODIN**

ALOPECIA

Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study. Schnohr P, et al. **Am Heart J** 1995 Nov;130(5):1003–10

Progressive extrapyramidal disorder with primary hypogonadism and alopecia in sibs: a new syndrome? Devriendt K, et al. **Am J Med Genet** 1996 Mar 1;62(1):54–7

GAPO syndrome: report on the first case in Japan. Moriya N, et al. **Am J Med Genet** 1995 Sep 11;58(3):257–61

Does fortune favour the bald? Psychological correlates of hair loss in males. Wells PA, et al. **Br J Psychol** 1995 Aug; 86 (Pt 3):337–44

A redefinition of male pattern baldness [letter; comment] Stough D, et al. **Dermatol Surg** 1996 May;22(5):484–5. Comment on: Dermatol Surg 1995 Feb;21(2):123–35.

The symptom experience of alopecia. Pickard-Holley S. **Semin Oncol Nurs** 1995 Nov;11(4):235–8 (16 ref.)

BLOOD

Transcutaneous PO2 of the scalp in male pattern baldness: a new piece to the puzzle. Goldman BE, et al. **Plast Reconstr Surg** 1996 May;97(6):1109–16; discussion 1117

CHEMICALLY INDUCED

Alopecia associated with fluconazole therapy [letter; comment] Goldsmith LA. **Ann Intern Med** 1996 Jul 15; 125(2):153; discussion 153–4. Comment on: Ann Intern Med 1995 Sep 1;123(5):354–7.

Treatment of valproate-induced alopecia [letter] Fatemi SH, et al. **Ann Pharmacother** 1995 Dec;29(12):1302

Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Ljungman P, et al. **Bone Marrow Transplant** 1995 Jun;15(6):869–71

Hair loss associated with fluoxetine but not with citalopram [letter] Seifritz E, et al. **Can J Psychiatry** 1995 Aug; 40(6):362

The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models. Sredni B, et al. **Int J Cancer** 1996 Jan 3; 65(1):97–103

Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. Hussein AM. **Int J Dermatol** 1995 Jul;34(7):470–3

A randomized trial of minoxidil in chemotherapy-induced alopecia. Duvic M, et al. **J Am Acad Dermatol** 1996 Jul; 35(1):74–8

Fluoxetine associated paresthesias and alopecia in a woman who tolerated sertraline [letter; comment] Bhatara VS, et al. **J Clin Psychiatry** 1996 May;57(5):227. Comment on: J Clin Psychiatry 1995;56 Suppl 2:49–55.

Alopecia side-effect of antituberculosis drugs [letter] FitzGerald JM, et al. **Lancet** 1996 Feb 17;347(8999):472

Treatment of warfarin-induced hair loss with ubidecarenone [letter] Nagao T, et al. **Lancet** 1995 Oct 21;346(8982):1104–5

Generalized hair loss and selenium exposure. Srivastava AK, et al. **Vet Hum Toxicol** 1995 Oct;37(5):468–9

[Alopecia caused by nimodipine (letter)] Daghfous R, et al. **Therapie** 1995 Nov-Dec;50(6):590–1 (Fre)

[Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease] Netzer P. **Schweiz Med Wochenschr** 1995 Dec 16;125(50):2438–42 (Eng. Abstr.) (Ger)

COMPLICATIONS

Baldness and coronary heart disease rates in men from the Framingham Study. Herrera CR, et al. **Am J Epidemiol** 1995 Oct 15;142(8):828–33

Lipid profiles, alopecia, and coronary disease: any relationship? [letter] Guzzo CA, et al. **Dermatol Surg** 1996 May;22(5):481

Twenty-nail dystrophy (trachyonychia) caused by lichen planus in a patient with alopecia universalis and ichthyosis vulgaris. Taniguchi S, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):903–5

CONGENITAL

Presuturing--a technique for closing congenital vertex aplasia [letter] Fernandez-Gutierrez L, et al. **Int J Dermatol** 1995 Aug;34(8):590

X-linked recessive inheritance in a family with isolated congenital alopecia [letter] Anzai H, et al. **Lancet** 1996 Feb 3;347(8997):337–8

Congenital triangular alopecia (Brauer nevus). García-Hernández MJ, et al. **Pediatr Dermatol** 1995 Dec; 12(4):301–3

DIAGNOSIS

[Meralgia paresthetica. A rare differential diagnosis of circumscribed alopecia] Nabavi DG, et al. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):834–8 (25 ref.) (Eng. Abstr.) (Ger)

DRUG THERAPY

Hair growth therapy(ies) for androgenetic alopecia [letter; comment] Rand S. **Arch Dermatol** 1996 Jun;132(6):714–5. Comment on: Arch Dermatol 1995 Dec;131(12):1373–5.

Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride [see comments] Walsh DS, et al. **Arch Dermatol** 1995 Dec; 131(12):1373–5. Comment in: Arch Dermatol 1996 Jun;132(6):714–5.

Minoxidil induced hair growth after leukaemia treatment? [letter] Vickers MA, et al. **Arch Dis Child** 1995 Aug; 73(2):184

A randomized trial of minoxidil in chemotherapy-induced alopecia. Duvic M, et al. **J Am Acad Dermatol** 1996 Jul; 35(1):74–8

The penetration enhancer SEPA augments stimulation of scalp hair growth by topical minoxidil in the balding stumptail macaque. Diani AR, et al. **Skin Pharmacol** 1995; 8(5):221–8

[Acne, hirsutism and androgenic alopecia] Dobrić I, et al. **Lijec Vjesn** 1996 Mar;118 Suppl 1:48–51 (Eng. Abstr.) (Scr)

EPIDEMIOLOGY

Baldness and ischemic heart disease in a national sample of men. Ford ES, et al. **Am J Epidemiol** 1996 Apr 1; 143(7):651–7

Actinic keratoses: the bald facts [letter] Long CC, et al. **Arch Dermatol** 1996 Sep;132(9):1132–3

ETIOLOGY

The moth-eaten alopecia of secondary syphilis. A histopathological study of 12 patients. Jordaan HF, et al. **Am J Dermatopathol** 1995 Apr;17(2):158–62 (16 ref.)

Alopecia associated with fluconazole therapy [letter; comment] Shear NH. **Ann Intern Med** 1996 Jul 15; 125(2):153; discussion 153–4. Comment on: Ann Intern Med 1995 Sep 1;123(5):354–7.

Alopecia universalis in liver transplant patients treated with cyclosporin [letter] Monti M, et al. **Br J Dermatol** 1995 Oct;133(4):663–4

Diffuse female hair thinning. Levine N. **Geriatrics** 1996 Aug; 51(8):27

Basaloid folliculolymphoid hyperplasia with alopecia as an expression of mycosis fungoides (CTCL). Kossard S, et al. **J Cutan Pathol** 1995 Oct;22(5):466–71

Headband alopecia [letter] Marino RV. **Pediatrics** 1995 Dec; 96(6):1174

Alopecia and sure-closure [letter; comment] Har-Shai Y, et al. **Plast Reconstr Surg** 1996 Jun;97(7):1520. Comment on: Plast Reconstr Surg 1995 Sep;96(3):747–8.

Relationship between cataracts and epilation in atomic bomb survivors. Neriishi K, et al. **Radiat Res** 1995 Oct; 144(1):107–13

GENETICS

Alopecia/mental retardation syndrome. Hannig VL, et al. **Am J Med Genet** 1995 Aug 28;58(2):123–4 (13 ref.)

GAPO syndrome: a new case. Sandgren G. **Am J Med Genet** 1995 Jul 31;58(1):87–90 (16 ref.)

Characterization of psoriasiform and alopecic skin lesions in HLA-B27 transgenic rats. Yanagisawa H, et al. **Am J Pathol** 1995 Oct;147(4):955–64

Keratosis follicularis spinulosa decalvans: report of a new pedigree. Herd RM, et al. **Br J Dermatol** 1996 Jan; 134(1):138–42

Alopecia-mental retardation syndrome associated with convulsions and hypergonadotropic hypogonadism. Devriendt K, et al. **Clin Genet** 1996 Jan;49(1):6–9

X-linked recessive inheritance in a family with isolated congenital alopecia [letter] Anzai H, et al. **Lancet** 1996 Feb 3;347(8997):337–8

PATHOLOGY

The moth-eaten alopecia of secondary syphilis. A histopathological study of 12 patients. Jordaan HF, et al. **Am J Dermatopathol** 1995 Apr;17(2):158–62 (16 ref.)

Satoyoshi syndrome: an unusual postnatal multisystemic disorder. Ehlayel MS, et al. **Am J Med Genet** 1995 Jul 17;57(4):620–5

Characterization of psoriasiform and alopecic skin lesions in HLA-B27 transgenic rats. Yanagisawa H, et al. **Am J Pathol** 1995 Oct;147(4):955–64

Quantification of hair follicle parameters using computer image analysis: a comparison of androgenetic alopecia with normal scalp biopsies. Lee MS, et al. **Australas J Dermatol** 1995 Aug;36(3):143–7

A comparison of the culture and growth of dermal papilla cells from hair follicles from non-balding and balding (androgenetic alopecia) scalp. Randall VA, et al. **Br J Dermatol** 1996 Mar;134(3):437–44

Clinical and histopathologic features of hair loss in patients with HIV-1 infection. Smith KJ, et al. **J Am Acad Dermatol** 1996 Jan;34(1):63–8

Histopathology of non-scarring alopecia. Sperling LC, et al. **J Cutan Pathol** 1995 Apr;22(2):97–114 (47 ref.)

Dry skin lesions with marked hair loss in a case of BL leprosy. A case report. Edward VK, et al. **Lepr Rev** 1996 Jun; 67(2):141–4

PHYSIOPATHOLOGY

Hair growth and the fluid factor. Foote SI. **Med Hypotheses** 1995 Jun;44(6):475–8 (18 ref.)

PREVENTION & CONTROL

Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. Hussein AM. **Int J Dermatol** 1995 Jul;34(7):470–3

PSYCHOLOGY

Fictional character helps children cope with alopecia. Quinn G, et al. **Oncol Nurs Forum** 1995 Nov-Dec;22(10):1573

SURGERY

The occipito-parietal flap method in the treatment of male baldness. Ezaki T, et al. **Aesthetic Plast Surg** 1995 Sep-Oct; 19(5):469–72

Re: Minimal expansion for correction of male pattern baldness [letter; comment] Hubbard TJ. **Ann Plast Surg** 1995 Oct;35(4):441. Comment on: Ann Plast Surg 1995 Apr;34(4):379–84.

Hair restoration: answered questions [letter; comment] Bernstein RM. **Dermatol Surg** 1996 Jan;22(1):97–8. Comment on: Dermatol Surg 1995 Apr;21(4):306–11.

Consecutive wide and long single hair-bearing transposition flaps in combination with hair transplantation for the management of slot formation after alopecia reducing surgery. Brandy DA. **Dermatol Surg** 1996 Apr; 22(4):355–62; discussion 363

Circumferential scalp reduction with a suture-in-place Silastic-Dacron extender. Brandy DA. **Dermatol Surg** 1996 Feb;22(2):137–47

A concentric method for mini-micrografting extensively bald patients. Brandy DA. **Dermatol Surg** 1995 Nov; 21(11):963–9

Scalp flaps in the treatment of baldness. Long-term results. Epstein JS, et al. **Dermatol Surg** 1996 Jan;22(1):45–50

A redefinition of male pattern baldness and its treatment implications [letter; comment] Shiell RC. **Dermatol Surg** 1995 Oct;21(10):909. Comment on: Dermatol Surg 1995 Feb;21(2):123–35.

Planning for maximum coverage in surgical hair restoration. Unger WP. **Dermatol Surg** 1996 Feb;22(2):161–73;

discussion 173–4
How "safe" is safe enough? [letter; comment] Unger WP. **Dermatol Surg** 1996 Feb;22(2):191. Comment on: Dermatol Surg 1995 Jun;21(6):523–38.
Presuturing—a technique for closing congenital vertex aplasia [letter] Fernandez-Gutierrez L, et al. **Int J Dermatol** 1995 Aug;34(8):590
Linear transverse forehead incision for patients with alopecia praematura—technical note. Anegawa S, et al. **Neurol Med Chir (Tokyo)** 1995 Aug;35(8):604–6

THERAPY

Guidelines of care for androgenetic alopecia. American Academy of Dermatology. Drake LA, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):465–9
The feasibility of targeted selective gene therapy of the hair follicle. Li L, et al. **Nat Med** 1995 Jul;1(7):705–6

VETERINARY

Focal and generalized alopecia. O'Dair HA, et al. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):851–70 (87 ref.)
Black hair follicular dysplasia in a tricolour Jack Russell terrier. Knottenbelt CM, et al. **Vet Rec** 1996 May 11; 138(19):475–6
[Alopecia above the tail base in cats] Sinke JD. **Tijdschr Diergeneeskd** 1996 Apr 1;121(7):205–7 **(Dut)**

ALOPECIA, ANDROGENETIC see **ALOPECIA**

ALOPECIA AREATA

CHEMICALLY INDUCED

Hair loss associated with fluvoxamine use [letter] Parameshwar E. **Am J Psychiatry** 1996 Apr;153(4):581–2
Alopecia associated with zidovudine therapy. Geletko SM, et al. **Pharmacotherapy** 1996 Jan–Feb;16(1):79–81

COMPLICATIONS

Alopecia areata in a patient with candidiasis–endocrinopathy syndrome: unsuccessful treatment trial with diphenylcyclopropenone. Böni R, et al. **Dermatology** 1995; 191(1):68–71
Celiac disease and alopecia areata: report of a new association. Corazza GR, et al. **Gastroenterology** 1995 Oct; 109(4):1333–7
Alopecia universalis in a patient with psoriasis vulgaris [letter] Yamamoto T, et al. **J Dermatol** 1995 Aug; 22(8):623–4

DRUG THERAPY

Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months' follow-up. Gordon PM, et al. **Br J Dermatol** 1996 May;134(5):869–71
PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years' experience at St John's Institute of Dermatology. Taylor CR, et al. **Br J Dermatol** 1995 Dec;133(6):914–8
Oral cyclosporin A restores hair growth in the DEBR rat model for alopecia areata. Oliver RF, et al. **Clin Exp Dermatol** 1995 Mar;20(2):127–31
Alopecia areata in a patient with candidiasis–endocrinopathy syndrome: unsuccessful treatment trial with diphenylcyclopropenone. Böni R, et al. **Dermatology** 1995; 191(1):68–71
Topical immunotherapy in alopecia areata: anamnestic and clinical criteria of prognostic significance. Weise K, et al. **Dermatology** 1996;192(2):129–33
[How far should treatment of severe alopecia areata be managed?] Delaporte E. **Ann Dermatol Venereol** 1996; 123(2):139–42 **(Fre)**

ETIOLOGY

Occurrence of alopecia areata in a patient receiving systemic cyclosporine A [letter] Misciali C, et al. **Arch Dermatol** 1996 Jul;132(7):843–4
Does interleukin-1 induce hair loss? Hoffmann R, et al. **Dermatology** 1995;191(4):273–5 (17 ref.)
Clinical-epidemiologic study of alopecia areata. Roselino AM, et al. **Int J Dermatol** 1996 Mar;35(3):181–4 (8 ref.)
[Monthly question: what should be done in diffuse alopecia in women?] **Ann Dermatol Venereol** 1995;122(3):139–41 **(Fre)**
[Therapy of alopecia areata in atopy] Schwanitz HJ, et al. **Dtsch Med Wochenschr** 1996 Mar 8;121(10):321–2 **(Ger)**

GENETICS

Tumor necrosis factor alpha (TNF-alpha) gene polymorphism in alopecia areata. Galbraith GM, et al. **Hum Genet** 1995 Oct;96(4):433–6
Significance of cytokine patterns in alopecia areata before and after therapeutic allergic contact dermatitis [letter; comment] Stricker RB, et al. **J Invest Dermatol** 1996 Feb; 106(2):379–80. Comment on: J Invest Dermatol 1994 Oct;103(4):530–3.
Concurrent appearance of alopecia areata in siblings [letter] Alsaleh QA, et al. **Pediatr Dermatol** 1995 Sep;12(3):285–6

IMMUNOLOGY

The DEBR rat, alopecia areata and autoantibodies to the hair follicle. McElwee KJ, et al. **Br J Dermatol** 1996 Jan; 134(1):55–63
Loss of contact sensitization evaluated by laser Doppler blood flowmetry and transepidermal water loss measurement. Seo KI, et al. **Contact Dermatitis** 1996 Apr; 34(4):233–6
Antismooth muscle and antiparietal cell antibodies in Indians with alopecia areata. Kumar B, et al. **Int J Dermatol** 1995 Aug;34(8):542–5
HLA class II antigen associations help to define two types of alopecia areata. Colombe BW, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):757–64

METABOLISM

Growth factor mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. Hoffmann R, et al. **Acta Derm Venereol** 1996 Jan;76(1):17–20

PATHOLOGY

Histopathology of non-scarring alopecia. Sperling LC, et al. **J Cutan Pathol** 1995 Apr;22(2):97–114 (47 ref.)

PSYCHOLOGY

[Examination of the significance of psychological factors in the etiology of alopecia areata. I. Examining Type A behavior] Wyględowska-Kania M, et al. **Przegl Lek** 1995; 52(6):311–4 (Eng. Abstr.) **(Pol)**

THERAPY

Dapsone versus topical immunotherapy in alopecia areata. van Baar HM, et al. **Br J Dermatol** 1995 Aug;133(2):270–4
Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. Tosti A, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):199–201
Alopecia areata in Korea (1982–1994). Ro BI. **J Dermatol** 1995 Nov;22(11):858–64
[Therapy of alopecia areata in atopy] Schwanitz HJ, et al. **Dtsch Med Wochenschr** 1996 Mar 8;121(10):321–2 **(Ger)**

ALOPECIA, MALE PATTERN see **ALOPECIA**

ALOPECIA MUCINOSA see **MUCINOSIS, FOLLICULAR**

ALOUATTA

Population status and conservation of red howling monkeys and white-fronted capuchin monkeys in Trinidad. Agoramoorthy G, et al. **Folia Primatol (Basel)** 1995; 64(3):158–62
Feeding on a marsh-living herbaceous plant by black howler monkeys (Alouatta caraya) in central Brazil. Rodrigues FH, et al. **Folia Primatol (Basel)** 1995;65(2):115–7

PHYSIOLOGY

Trichromatic colour vision in New World monkeys. Jacobs GH, et al. **Nature** 1996 Jul 11;382(6587):156–8

ALPACAS see **CAMELIDS, NEW WORLD**

ALPERS SYNDROME see **CEREBRAL SCLEROSIS, DIFFUSE**

ALPHA 1-ACID GLYCOPROTEIN see **OROSOMUCOID**

ALPHA 1-ACID SEROMUCOID see **OROSOMUCOID**

ALPHA-ACTININ see **ACTININ**

ALPHA 2-ACUTE PHASE GLOBULINS see **ALPHA-MACROGLOBULINS**

ALPHA-ADRENERGIC BLOCKING AGENTS see **ADRENERGIC ALPHA-ANTAGONISTS**

ALPHA-ADRENERGIC RECEPTOR AGONISTS see **ADRENERGIC ALPHA-AGONISTS**

ALPHA-ADRENERGIC RECEPTOR BLOCKADERS see **ADRENERGIC ALPHA-ANTAGONISTS**

ALPHA-ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA**

ALPHA-1 ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA-1**

ALPHA-2 ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA-2**

ALPHA,ALPHA-DIPYRIDYL see **2,2'-DIPYRIDYL**

ALPHA-AMINOADIPIC ACID see **2-AMINOADIPIC ACID**

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID

see related
RECEPTORS, AMPA

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID

ANALOGS & DERIVATIVES

A new highly selective metabotropic excitatory amino acid agonist: 2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid. Bräuner-Osborne H, et al. **J Med Chem** 1996 Aug 2;39(16):3188–94

ANTAGONISTS & INHIBITORS

The AMPA antagonist LY293558 improves functional neurological outcome following reversible spinal cord ischemia in rabbits. Bowes MP, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):967–72
Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties. Desos P, et al. **J Med Chem** 1996 Jan 5;39(1):197–206
Schedule-controlled behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid antagonist LY293558 in pigeons. Benvenga MJ, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):164–70
AMPA antagonist LY293558 does not affect the severity of hypoxic-ischemic injury in newborn pigs. LeBlanc MH, et al. **Stroke** 1995 Oct;26(10):1908–14; discussion 1914–5

METABOLISM

Reversible changes in hippocampal 3H-AMPA binding following inhibitory avoidance training in the rat. Cammarota M, et al. **Neurobiol Learn Mem** 1996 Jul; 66(1):85–8
Binding of the new radioligand (S)-[3H]AMPA to rat brain synaptic membranes: effects of a series of structural analogues of the non-NMDA receptor agonist willardiine. Hawkins LM, et al. **Neuropharmacology** 1995 Apr; 34(4):405–10
[Possible role of the AMPA/KA receptors in cultured Müller cells] Kawasaki I, et al. **Nippon Ganka Gakkai Zasshi** 1995 Nov;99(11):1214–21 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

The non-competitive AMPA/kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics. Borowicz KK, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):319–26
Effects of nerve growth factor treatment on rats with lesions of the nucleus basalis magnocellularis produced by ibotenic acid, quisqualic acid, and AMPA. Winkler J, et al. **Exp Neurol** 1995 Dec;136(2):234–50
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, but not N-methyl-D-aspartate, activates mitogen-activated protein kinase through G-protein beta gamma subunits in rat cortical neurons. Wang Y, et al. **J Biol Chem** 1995 Sep 29;270(39):22783–7
Basic fibroblast growth factor selectively increases AMPA-receptor subunit GluR1 protein level and differentially modulates Ca2+ responses to AMPA and NMDA in hippocampal neurons. Cheng B, et al. **J Neurochem** 1995 Dec;65(6):2525–36
Glutamate release evoked by glutamate receptor agonists in cultured chick retina cells: modulation by arachidonic acid. Duarte CB, et al. **J Neurosci Res** 1996 May 15;44(4):363–73
Age-related decrease in vulnerability to excitatory amino acids in the nucleus basalis. Wenk GL, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):1–7
In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid. Schoepp DD, et al. **Neuropharmacology** 1995 Sep;34(9):1159–68
Neurite outgrowth of murine cerebellar granule cells can be enhanced by aniracetam with or without alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA). Fushiki S, et al. **Neurosci Lett** 1995 Oct 27;199(3):171–4
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors modulate dopamine release in rat hippocampus and striatum. Maione S, et al. **Neurosci Lett** 1995 Jul 7; 193(3):181–4
The effects of N-methyl-D-aspartate (NMDA) and non-NMDA receptor agonists and antagonists on hypothalamic neurones in the anaesthetized rat which respond to changes in scrotal skin temperature. Taylor DC, et al. **Neurosci Lett** 1995 Dec 15;201(3):259–61
Glutamatergic and GABAergic postsynaptic responses of striatal spiny neurons to intrastriatal and cortical stimulation recorded in slice preparations. Kita H.

Neuroscience 1996 Feb;70(4):925–40

TOXICITY

Differential cellular response after glutamate analog hippocampal damage. Araujo M, et al. **J Neurosci Res** 1996 May 15;44(4):397–409

ALPHA-AMINOTOLUENE see **BENZYLAMINES**

ALPHA-AMYLASE

ADVERSE EFFECTS

Exposure-sensitization relationship for alpha-amylase allergens in the baking industry. Houba R, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):130–6

ANALYSIS

Usefulness of reference materials in calibration of enzyme activities. Lessinger JM, et al. **Eur J Clin Chem Clin Biochem** 1995 Nov;33(11):859–64

Technical note: a simple, rapid assay for alpha-amylase in bovine pancreatic juice. Walker JA, et al. **J Anim Sci** 1996 Mar;74(3):658–62

Amylase activity in tracheobronchial secretions of laryngectomized patients. Nandapalan V, et al. **J Laryngol Otol** 1995 Jul;109(7):637–9

A study of alpha-amylase activity in tracheobronchial secretions of seriously ill patients with tracheostomies. Nandapalan V, et al. **J Laryngol Otol** 1995 Jul;109(7):640–3

ANTAGONISTS & INHIBITORS

Spacer-modified oligosaccharides with basic anchoring groups are inhibitors for endo-glycanases: porcine pancreatic alpha-amylase as model enzyme. Lehmann J, et al. **Carbohydr Res** 1995 Oct 16;276(1):43–55

Mechanism-based inhibition of yeast alpha-glucosidase and human pancreatic alpha-amylase by a new class of inhibitors. 2-Deoxy-2,2-difluoro-alpha-glycosides. Braun C, et al. **J Biol Chem** 1995 Nov 10;270(45):26778–81

The inhibition of human salivary alpha-amylase by type II alpha-amylase inhibitor from Triticum aestivum is competitive, slow and tight-binding. Goff DJ, et al. **J Enzym Inhib** 1995;9(2):163–70

Carbohydrate and protein-based inhibitors of porcine pancreatic alpha-amylase: structure analysis and comparison of their binding characteristics. Machius M, et al. **J Mol Biol** 1996 Jul 19;260(3):409–21

Mechanism of protein stabilization by disulfide bridges: calorimetric unfolding studies on disulfide-deficient mutants of the alpha-amylase inhibitor tendamistat. Vogl T, et al. **J Mol Biol** 1995 Dec 1;254(3):481–96

Protective mechanism of the Mexican bean weevil against high levels of alpha-amylase inhibitor in the common bean. Ishimoto M, et al. **Plant Physiol** 1996 Jun;111(2):393–401

[Alpha-amylase inhibitors and soluble dietary fiber in rye: partial purification and effect on postprandial glycemia] Täufel A, et al. **Z Ernahrungswiss** 1996 Jun;35(2):199–205 (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

The glucose effect and regulation of alpha-amylase synthesis in the hyperthermophilic archaeon Sulfolobus solfataricus. Haseltine C, et al. **J Bacteriol** 1996 Feb;178(4):945–50

Induction and repression of alpha-amylase production in batch and continuous cultures of Aspergillus oryzae. Mørkeberg R, et al. **Microbiology** 1995 Oct;141 (Pt 10):2449–54

Gibberellin-regulated expression of a myb gene in barley aleurone cells: evidence for Myb transactivation of a high-pI alpha-amylase gene promoter. Gubler F, et al. **Plant Cell** 1995 Nov;7(11):1879–91

Okadaic acid, a protein phosphatase inhibitor, blocks calcium changes, gene expression, and cell death induced by gibberellin in wheat aleurone cells. Kuo A, et al. **Plant Cell** 1996 Feb;8(2):259–69

A gibberellin-stimulated ubiquitin-conjugating enzyme gene is involved in alpha-amylase gene expression in rice aleurone. Chen X, et al. **Plant Mol Biol** 1995 Nov; 29(4):787–95

BLOOD

The activity of granulocyte alpha-amylase in acute appendicitis. Zakrzewska I, et al. **Rocz Akad Med Bialymst** 1994;39:81–5

CHEMISTRY

Comparison of stored and secreted rat pancreatic digestive enzymes by mass spectrometry: alpha-amylase. Young MK, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):63–71

Spacer-modified oligosaccharides with basic anchoring groups are inhibitors for endo-glycanases: porcine pancreatic alpha-amylase as model enzyme. Lehmann J, et al. **Carbohydr Res** 1995 Oct 16;276(1):43–55

Elucidation of the subsite structure of bacterial saccharifying alpha-amylase and its mode of degradation of maltose. Suganuma T, et al. **Carbohydr Res** 1996 Feb 28; 282(1):171–80

Characterization of a novel alpha-amylase from Lipomyces kononenkoae and expression of its gene (LKA1) in Saccharomyces cerevisiae. Steyn AJ, et al. **Curr Genet** 1995 Nov;28(6):526–33

Crystal structure of pig pancreatic alpha-amylase isoenzyme II, in complex with the carbohydrate inhibitor acarbose. Gilles C, et al. **Eur J Biochem** 1996 Jun 1;238(2):561–9

A circularly permuted alpha-amylase-type alpha/beta-barrel structure in glucan-synthesizing glucosyltransferases. MacGregor EA, et al. **FEBS Lett** 1996 Jan 15;378(3):263–6

Variability in heat-induced fragmentation of a protein in the presence of dodecyl sulfate: the role of an intramolecular sulfhydryl/disulfide exchange. Kubo K. **J Biochem (Tokyo)** 1995 Dec;118(6):1112–7

The structure of human pancreatic alpha-amylase at 1.8 A resolution and comparisons with related enzymes. Brayer GD, et al. **Protein Sci** 1995 Sep;4(9):1730–42

GENETICS

Concanavalin A- and wheat germ agglutinin-conjugated lectins as a tool for the identification of multiple N-glycosylation sites in heterologous protein expressed in yeast. García R, et al. **Anal Biochem** 1995 Nov 1; 231(2):342–8

Cloning and characterization of an alpha-amylase gene from Streptomyces sp WL6. Chen I, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):1059–67

Comparison of primary structures and substrate specificities of two pullulan-hydrolyzing alpha-amylases, TVA I and TVA II, from Thermoactinomyces vulgaris R-47. Tonozuka T, et al. **Biochim Biophys Acta** 1995 Sep 27; 1252(1):35–42

Characterization of a novel alpha-amylase from Lipomyces kononenkoae and expression of its gene (LKA1) in Saccharomyces cerevisiae. Steyn AJ, et al. **Curr Genet** 1995 Nov;28(6):526–33

Cloning, sequence analysis and expression in yeasts of a cDNA containing a Lipomyces kononenkoae alpha-amylase-encoding gene. Steyn AJ, et al. **Gene** 1995 Dec 1;166(1):65–71

Enzyme polymorphism in Drosophila melanogaster populations collected in two different habitats in Hungary. Pecsenye K, et al. **Genetica** 1995;96(3):257–68

Evolutionary relationships and sequence variation of alpha-amylase variants encoded by duplicated genes in the Amy locus of Drosophila melanogaster. Inomata N, et al. **Genetics** 1995 Sep;141(1):237–44

Evolution of the response patterns to dietary carbohydrates and the developmental differentiation of gene expression of alpha-amylase in Drosophila. Inomata N, et al. **J Mol Evol** 1995 Dec;41(6):1076–84

Expression of periplasmic alpha-amylase of Xanthomonas campestris K-11151 in Escherichia coli and its action on maltose. Abe J, et al. **Microbiology** 1996 Jun;142 (Pt 6):1505–12

The evolutionary history of the amylase multigene family in Drosophila pseudoobscura. Popadić A, et al. **Mol Biol Evol** 1996 Jul;13(6):883–8

Amylase gene structures in primates: retroposon insertions and promoter evolution. Samuelson LC, et al. **Mol Biol Evol** 1996 Jul;13(6):767–79

The -16 region, a vital sequence for the utilization of a promoter in Bacillus subtilis and Escherichia coli. Voskuil MI, et al. **Mol Microbiol** 1995 Jul;17(2):271–9

Gibberellin-regulated expression of a myb gene in barley aleurone cells: evidence for Myb transactivation of a high-pI alpha-amylase gene promoter. Gubler F, et al. **Plant Cell** 1995 Nov;7(11):1879–91

Post-transcriptional regulation of bifunctional alpha-amylase/subtilisin inhibitor expression in barley embryos by abscisic acid. Liu JH, et al. **Plant Mol Biol** 1995 Dec;29(5):1087–91

Members of a new family of DNA-binding proteins bind to a conserved cis-element in the promoters of alpha-Amy2 genes. Rushton PJ, et al. **Plant Mol Biol** 1995 Nov; 29(4):691–702

Functional analysis of linker insertions and point mutations in the alpha-Amy2/54 GA-regulated promoter. Tregear JW, et al. **Plant Mol Biol** 1995 Nov;29(4):749–58

Sugars act as signal molecules and osmotica to regulate the expression of alpha-amylase genes and metabolic activities in germinating cereal grains. Yu SM, et al. **Plant Mol Biol** 1996 Mar;30(6):1277–89

IMMUNOLOGY

[Complement-binding antibodies to alpha-amylase in the diagnosis of chronic pancreatitis] Amosova EN, et al. **Lik Sprava** 1995 May-Jun;(5-6):91–3 (Eng. Abstr.) **(Rus)**

METABOLISM

Detection of binding of denatured salivary alpha-amylase to Streptococcus sanguis. Bergmann JE, et al. **Arch Oral Biol** 1995 Oct;40(10):973–4

The alpha-amylase of Bacillus coagulans. Keating LA, et al. **Biochem Soc Trans** 1996 Feb;24(1):44S

Covalent immobilization of alpha-amylase onto pHEMA microspheres: preparation and application to fixed bed reactor. Arica MY, et al. **Biomaterials** 1995 Jul;16(10):761–8

Effects of metals on alpha-amylase activity in the digestive gland of the green mussel, Perna viridis L. Yan T, et al. **Bull Environ Contam Toxicol** 1996 Apr;56(4):677–82

Elucidation of the subsite structure of bacterial saccharifying alpha-amylase and its mode of degradation of maltose. Suganuma T, et al. **Carbohydr Res** 1996 Feb 28; 282(1):171–80

Molecular modelling of the interaction between the catalytic site of pig pancreatic alpha-amylase and amylose fragments. Casset F, et al. **Eur J Biochem** 1995 Aug 15; 232(1):284–93

alpha-Amylase and isoamylase levels in renal transplant recipients compared to uremic patients. Dardamanis MA, et al. **Ren Fail** 1995 Nov;17(6):715–9

PHARMACOLOGY

The effect of alpha-amylase on the acrosomal membrane of human sperm. Esterhuizen AD, et al. **J Assist Reprod Genet** 1995 Apr;12(4):283–7

ALPHA 1-ANTICHYMOTRYPSIN

ANALYSIS

Immunohistochemical detection of alpha 1-antitrypsin, alpha 1-antichymotrypsin, transferrin and ferritin in ameloblastoma. Takahashi H, et al. **Anal Cell Pathol** 1995 Sep;9(2):135–50

Alpha-1-antichymotrypsin expression in lung adenocarcinoma and its possible association with tumor progression. Higashiyama M, et al. **Cancer** 1995 Oct 15; 76(8):1368–76

Microheterogeneity of acute phase proteins in patients with clinically active and clinically nonactive osteoarthritis. Hrycaj P, et al. **Clin Rheumatol** 1995 Jul;14(4):434–40

Kupffer cells in multiple organ failure—their activation as revealed by immunohistochemistry for lysozyme, alpha 1-antichymotrypsin, and lectins. Niki T, et al. **Gen Diagn Pathol** 1995 May;141(1):21–7

PSA immunoreactivity detected in LNCaP cell medium, breast tumor cytosol, and female serum. Wu JT, et al. **J Clin Lab Anal** 1995;9(4):243–51

BIOSYNTHESIS

Serine proteinase inhibitors in human skeletal muscle: expression of beta-amyloid protein precursor and alpha 1-antichymotrypsin in vivo and during myogenesis in vitro. Akaaboune M, et al. **J Cell Physiol** 1995 Dec;165(3):503–11

IL-1 beta and TNF alpha, but not IL-6, induce alpha 1-antichymotrypsin expression in the human astrocytoma cell line U373 MG. Machein U, et al. **Neuroreport** 1995 Nov 27;6(17):2283–6

BLOOD

Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex [see comments] Pettersson K, et al. **Clin Chem** 1995 Oct;41(10):1480–8. Comment in: Clin Chem 1996 Aug;42(8 Pt 1):1297–8.

Microheterogeneity of acute-phase glycoproteins in patients with pulmonary sarcoidosis. Hrycaj P, et al. **Eur Respir J** 1996 Feb;9(2):313–8

Development of a microplate ELISA for free PSA and PSA-ACT complex in serum. Wu JT, et al. **J Clin Lab Anal** 1995;9(4):252–60

Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. Lieberman J, et al. **Neurobiol Aging** 1995 Sep-Oct;16(5):747–53

Acute-phase plasma proteins in gastric cancer: association with metastatic potential and prognosis. Ogoshi K, et al. **Tumour Biol** 1996;17(5):281–9

[Alpha 1-antichymotrypsin (ACT)] Mashige F, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:198–202 (20 ref.) **(Jpn)**

[Specific quantification of gamma-seminoprotein-alpha 1 antichymotrypsin complex in serum by monoclonal antibody-based enzyme immunoassay] Chichibu K, et al. **Rinsho Byori** 1995 Nov;43(11):1153–8 (Eng. Abstr.) **(Jpn)**

CEREBROSPINAL FLUID

Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease. Harigaya Y, et al. **Intern Med** 1995 Jun;34(6):481–4

CHEMISTRY

Structural change in alpha-chymotrypsin induced by complexation with alpha 1-antichymotrypsin as seen by enhanced sensitivity to proteolysis. Stavridi ES, et al. **Biochemistry** 1996 Aug 20;35(33):10608–15

GENETICS

The defective secretion of a naturally occurring alpha-1-antichymotrypsin variant with a frameshift mutation. Tsuda M, et al. **Eur J Biochem** 1996 Feb 1; 235(3):821–7

No genetic effect of alpha1-antichymotrypsin in Alzheimer disease. Haines JL, et al. **Genomics** 1996 Apr 1;33(1):53–6

IMMUNOLOGY

Suppressive effect of anti-alpha 1-antichymotrypsin serum on pulmonary fibrosis induced by phorbol myristate acetate

in vivo. Nagareda T, et al. **Lab Invest** 1995 Oct;73(4):541–6

METABOLISM

Role of the P2 residue in determining the specificity of serpins. Djie MZ, et al. **Biochemistry** 1996 Sep 3; 35(35):11461–9

Immunohistochemical evaluation of proliferating cell nuclear antigen, prostate-specific antigen and alpha 1-antichymotrypsin in human prostate cancer. Igawa M, et al. **Br J Urol** 1996 Jan;77(1):107–12

Lyophilized PSA-ACT complex is stable [letter; comment] Chen Z, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1297–8. Comment on: Clin Chem 1995 Oct;41(10):1480–8.

Technicon Immuno 1 PSA assay measures both free and alpha-1-antichymotrypsin-complexed prostate-specific antigen on an equimolar basis. Zhou Z, et al. **J Clin Lab Anal** 1996;10(3):155–9

A specific structural interaction of Alzheimer's peptide A beta 1–42 with alpha 1-antichymotrypsin [letter] Janciauskiene S, et al. **Nat Struct Biol** 1996 Aug;3(8):668–71

In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin [see comments] Huber PR, et al. **Prostate** 1995 Sep;27(3):166–75. Comment in: Prostate 1996 Jul;29(1):65–6.

[Glycoforms of alpha-1 antichymotrypsin in infectious process. Diagnostic value and follow-up] Hachulla E, et al. **Presse Med** 1996 Apr 20;25(14):661–4 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Complex formation between PSA isoenzymes and protease inhibitors. Leinonen J, et al. **J Urol** 1996 Mar; 155(3):1099–103

SECRETION

The defective secretion of a naturally occurring alpha-1-antichymotrypsin variant with a frameshift mutation. Tsuda M, et al. **Eur J Biochem** 1996 Feb 1; 235(3):821–7

THERAPEUTIC USE

Alpha-1-antichymotrypsin is an effective inhibitor of pancreatitis-induced lung injury. O'Donovan DA, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):847–52

ALPHA 1-ANTITRYPSIN

Is nephrocalcin related to the urinary derivative (bikunin) of inter-alpha-trypsin inhibitor? Tang Y, et al. **Br J Urol** 1995 Oct;76(4):425–30

ADMINISTRATION & DOSAGE

[An alpha 1-antitrypsin aerosol in the treatment of cystic fibrosis] Ferrer Calvete J, et al. **An Esp Pediatr** 1996 Feb; 44(2):109–11 (Eng. Abstr.) **(Spa)**

ANALYSIS

Immunohistochemical detection of alpha 1-antitrypsin, alpha 1-antichymotrypsin, transferrin and ferritin in ameloblastoma. Takahashi H, et al. **Anal Cell Pathol** 1995 Sep;9(2):135–50

Serum complex of trypsin 2 and alpha 1 antitrypsin as diagnostic and prognostic marker of acute pancreatitis: clinical study in consecutive patients. Hedström J, et al. **BMJ** 1996 Aug 10;313(7053):333–7

A DNA probe study on the origin of the cancer recognition, immunedefense suppression and serine protease protection peptide. Cercek L, et al. **Cancer Detect Prev** 1995; 19(4):325–30

Neutrophil elastase-alpha 1-antitrypsin in middle ear fluid in chronic otitis media with effusion. Tierney P, et al. **Clin Otolaryngol** 1995 Jun;20(3):230–3

Does methotrexate affect serum level of IgA-alpha-1 antitrypsin complex in early rheumatoid arthritis? Lacki JK, et al. **Clin Rheumatol** 1995 Sep;14(5):566–9

Fecal alpha 1-antitrypsin detection of colorectal neoplasia. An evaluation using HemoQuant. Moran A, et al. **Dig Dis Sci** 1995 Dec;40(12):2522–5

Faecal alpha 1 antitrypsin as a marker of gastrointestinal disease in HIV antibody positive individuals. Sharpstone D, et al. **Gut** 1996 Feb;38(2):206–10

Serum trypsinogen-2 and trypsin-2-alpha(1)-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas. Hedström J, et al. **Int J Cancer** 1996 May 3;66(3):326–31

Efficacy of systemically administered acetylsalicylic acid plus scaling on periodontal health and elastase-alpha 1-proteinase inhibitor in gingival crevicular fluid. Flemmig TF, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):153–9

Serum elastase and alpha-1-antitrypsin levels in patients with ruptured and unruptured cerebral aneurysms. Baker CJ, et al. **Neurosurgery** 1995 Jul;37(1):56–61; discussion 61–2

[Initial personal experiences with alpha-1-antitrypsin determination in feces] Schwery S, et al. **Schweiz Med Wochenschr** 1995 Sep 23;125(38):1783–7 (Eng. Abstr.) **(Ger)**

[alpha 1-Antitrypsin (alpha 1-AT)] Miyake K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:193–7 (18 ref.) **(Jpn)**

[Alpha-1-antitrypsin, albumin and whole protein in meconium and stools during the first days of life in the neonate] Lisowska-Myjak B, et al. **Pediatr Pol** 1995 Oct; 70(10):819–26 (Eng. Abstr.) **(Pol)**

BIOSYNTHESIS

Alpha 1-antitrypsin expression in human thyroid papillary carcinoma. Poblete MT, et al. **Am J Surg Pathol** 1996 Aug; 20(8):956–63

The expression and characterization of five recombinant murine alpha 1-protease inhibitor proteins. Paterson T, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):64–9

Differences in distribution and synthesis of the functional opponents alpha 1-proteinase inhibitor and neutrophil elastase in eukaryotic cells. Davids E, et al. **Histochem Cell Biol** 1995 Sep;104(3):245–53

CHEMISTRY

Isolation and characterization of alpha 1-protease inhibitor from canine plasma. Melgarejo T, et al. **Am J Vet Res** 1996 Mar;57(3):258–63

In vitro fibril formation from alpha 1-antitrypsin-derived C-terminal peptides. Janciauskiene S, et al. **Biol Chem Hoppe Seyler** 1995 Jul;376(7):415–23

Decreased branching, increased fucosylation and changed sialylation of alpha-1-proteinase inhibitor in breast and ovarian cancer. Goodarzi MT, et al. **Clin Chim Acta** 1995 May 15;236(2):161–71

Crystal structure of an uncleaved alpha 1-antitrypsin reveals the conformation of its inhibitory reactive loop. Song HK, et al. **FEBS Lett** 1995 Dec 18;377(2):150–4

Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms. Turner GA, et al. **Glycoconj J** 1995 Jun; 12(3):211–8 (62 ref.)

Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. Elliott PR, et al. **Nat Struct Biol** 1996 Aug; 3(8):676–81

Probing the native strain iin alpha1-antitrypsin [letter] Lee KN, et al. **Nat Struct Biol** 1996 Jun;3(6):497–500

CLASSIFICATION

Subtyping of group-specific component and protease inhibitor by rapid isoelectric focusing on PhastSystem. Guo Y, et al. **Electrophoresis** 1996 Mar;17(3):537–9

DEFICIENCY

Histopathological features of liver disease [letter; comment] Miale TD. **Acta Paediatr** 1995 Aug;84(8):964. Comment on: Acta Paediatr Suppl 1994 Feb;393:8–12.

Clinical features and lung function in 18-year-old adolescents with alpha 1-antitrypsin deficiency. Sveger T, et al. **Acta Paediatr** 1995 Jul;84(7):815–6

Is having alpha-1-antitrypsin deficiency necessarily bad for your liver? Rosenthal P. **Am J Gastroenterol** 1996 May; 91(5):1053–4

Alpha 1-antitrypsin deficiency and pregnancy. Kuller JA, et al. **Am J Perinatol** 1995 Sep;12(5):303–5

Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ. Seersholm N, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1922–5

[Alpha 1-antitrypsin-deficient variant Siiyama (Ser53[TCC] to Phe53[TTC]) is prevalent in Japan. Status of alpha 1-antitrypsin deficiency in Japan. Seyama K, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2119–26

Relationship between a mild alpha 1 proteinase inhibitor deficiency and respiratory symptoms in a family. Huet-Duvillier G, et al. **Ann Clin Biochem** 1995 Nov;32 (Pt 6):545–9

Treatment of alpha-1-antitrypsin deficiency, massive edema, and panniculitis with alpha-1 protease inhibitor [letter] Furey NL, et al. **Ann Intern Med** 1996 Oct 15;125(8):699

Sweet's syndrome leading to acquired cutis laxa (Marshall's syndrome) in an infant with alpha 1-antitrypsin deficiency. Hwang ST, et al. **Arch Dermatol** 1995 Oct;131(10):1175–7

Alpha-1-antitrypsin PLowell: a normally functioning variant present in low concentration. Cook L, et al. **Aust N Z J Med** 1995 Dec;25(6):695–7

Alpha 1-antitrypsin deficiency deaths in the United States from 1979–1991. An analysis using multiple-cause mortality data. Browne RJ, et al. **Chest** 1996 Jul;110(1):78–83

Recent pulmonary observations in alpha 1-antitrypsin deficiency, primary biliary cirrhosis, chronic hepatitis C, and other hepatic problems. Krowka MJ. **Clin Chest Med** 1996 Mar;17(1):67–82 (90 ref.)

Pseudotumours of hepatic imaging. Kane PA, et al. **Clin Radiol** 1996 May;51(5):362–5

Chronic pancreatitis with alpha 1-antitrypsin deficiency: from uncontrolled trypsin activation? [letter; comment] Blackstone MO. **Dig Dis Sci** 1996 Mar;41(3):549–51. Comment on: Dig Dis Sci 1995 Sep;40(9):1997–2001.

Alpha 1-antitrypsin deficiency and chronic pancreatitis [see comments] Rabassa AA, et al. **Dig Dis Sci** 1995 Sep; 40(9):1997–2001. Comment in: Dig Dis Sci 1996 Mar;41(3):549–51.

Liver function in patients with pulmonary emphysema due to severe alpha-1-antitrypsin deficiency (Pi ZZ). von Schönfeld J, et al. **Digestion** 1996;57(3):165–9

Copper associated childhood cirrhosis [letter; comment] Knisely AS. **Gut** 1995 Oct;37(4):590–1. Comment on: Gut 1994 Oct;35(10):1497–500.

Alpha-1-antitrypsin deficiency in aneurysmal disease. St Jean P, et al. **Hum Hered** 1996 Mar-Apr;46(2):92–7

Effective treatment with alpha 1-protease inhibitor of chronic cutaneous vasculitis associated with alpha 1-antitrypsin deficiency. Dowd SK, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):913–6

Giant intracranial aneurysm and fibromuscular dysplasia in an adolescent with alpha 1-antitrypsin deficiency. Schievink WI, et al. **J Neurosurg** 1996 Sep;85(3):503–6

Alpha 1 antitrypsin defective Lewis rats injected with heparin: comparison of the glomerular changes with those of Lewis rats produced anti BSA antibody. Nakatsuji T. **Keio J Med** 1996 Jun;45(2):109–13

Neutrophil recruitment into the lungs is associated with increased lung elastase burden, decreased lung elastin, and emphysema in alpha 1 proteinase inhibitor-deficient mice. Cavarra E, et al. **Lab Invest** 1996 Aug;75(2):273–80

Gene therapy for alpha 1-antitrypsin deficiency. Geddes DM, et al. **Monaldi Arch Chest Dis** 1995 Oct;50(5):388–93

Henoch-Schönlein purpura and alpha 1-antitrypsin deficiency. Elzouki AN, et al. **Nephrol Dial Transplant** 1995;10(8):1454–7

Alpha 1-antitrypsin deficiency: evaluation of bronchiectasis with CT. King MA, et al. **Radiology** 1996 Apr; 199(1):137–41

Patient-administered sequential spirometry in healthy volunteers and patients with alpha 1-antitrypsin deficiency. Madsen F, et al. **Respir Med** 1996 Mar;90(3):131–8

Ulcerative colitis responsive to smoking and to nicotine chewing gum in a patient with alpha 1 anti-trypsin deficiency. Watson JP, et al. **Respir Med** 1995 Oct; 89(9):635–6

Prognosis and life expectancy on alpha-1-antitrypsin deficiency and chronic liver disease. Propst A, et al. **Scand J Gastroenterol** 1995 Nov;30(11):1108–12

A 49-year-old man with alpha 1-antitrypsin deficiency and abnormal iron study results. Brunt EM, et al. **Semin Liver Dis** 1996 Feb;16(1):97–101

alpha 1-antitrypsin phenotype PiMZ, a risk factor for liver cirrhosis but not for liver cancers in Thailand. Smanadhikorn P, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):240–2

Bronchiectasis and homozygous (P1ZZ) alpha 1-antitrypsin deficiency [letter] Al-Kassimi F. **Thorax** 1996 Feb;51(2):228

Transplantation for end stage liver disease related to alpha 1 antitrypsin. Vennarecci G, et al. **Transplantation** 1996 May 27;61(10):1488–95

Inherited liver diseases in adults. Kumar A, et al. **West J Med** 1995 Oct;163(4):382–6 (20 ref.)

[Gene therapy for alpha 1-antitrypsin deficiency. Hopes, realities and perspectives] LeMarchand P. **Rev Mal Respir** 1996;13(1):7–12 (24 ref.) (Eng. Abstr.) **(Fre)**

[Genetic disposition to chronic polypoid sinusitis and alpha 1-proteinase inhibitor deficiency types] Maune S, et al. **HNO** 1995 Sep;43(9):537–9 (Eng. Abstr.) **(Ger)**

[Bronchiectasis and infection incidence in alpha 1-antitrypsin deficiency. The value of high-resolution computed tomography] Kauczor HU, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):378–82 (Eng. Abstr.) **(Ger)**

[Liver cirrhosis associated with metabolic disorders] Ono M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):191–6 (26 ref.) **(Jpn)**

[The evolution of the replacement treatment of emphysema due to alpha 1-antitrypsin deficiency (letter)] Manresa F. **Arch Bronconeumol** 1995 Aug-Sep;31(7):371–2 **(Spa)**

[Bronchiectasis and alpha 1-antitrypsin deficiency (letter; comment)] Roig Figueroa V, et al. **Arch Bronconeumol** 1995 Oct;31(8):429. Comment on: Arch Bronconeumol 1994 Nov;30(9):473. **(Spa)**

[Heterozygotic alpha-1 antitrypsin deficiency. A case report] Bataller Sifre R, et al. **Gastroenterol Hepatol** 1996 Jun-Jul; 19(6):313–6 (Eng. Abstr.) **(Spa)**

GENETICS

Plasmid-liposome transfer of the alpha 1 antitrypsin gene to cystic fibrosis bronchial epithelial cells prevents elastase-induced cell detachment and cytokine release. Canonico AE, et al. **Am J Respir Cell Mol Biol** 1996 Apr; 14(4):348–55

[Alpha 1-antitrypsin-deficient variant Siiyama (Ser53[TCC] to Phe53[TTC]) is prevalent in Japan. Status of alpha 1-antitrypsin deficiency in Japan. Seyama K, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2119–26

Genetic control of PI and GC variants in the American mink. Borodin GP, et al. **Anim Genet** 1995 Dec;26(6):435–7

Alpha-1-antitrypsin PLowell: a normally functioning variant present in low concentration. Cook L, et al. **Aust N Z J Med** 1995 Dec;25(6):695–7

Long-term expression of the human alpha1-antitrypsin gene in mice employing anionic and cationic liposome vectors. Crepso J, et al. **Biochem Pharmacol** 1996 May 17; 51(10):1309–14

Molecular cloning and sequence analysis of cDNA encoding plasma alpha-1-antiproteinase from Syrian hamster: implications for the evolution of Rodentia. Nakatani T, et al. **Biochim Biophys Acta** 1995 Sep 19;1263(3):245–8

Investigation of association between alpha-1 proteinase inhibitor haplotype and endometritis in the thoroughbred

mare [see comments] Pemberton AD, et al. **Equine Vet J** 1994 Mar;26(2):122–4. Comment in: Equine Vet J 1994 Mar;26(2):89–90.

Temporal and tissue-specific expression of the MET ORF driven by the complete transcriptional unit of human A1AT gene in transgenic mice. Amicone L, et al. **Gene** 1995 Sep 11;162(2):323–8

alpha-1-Antitrypsin (Pi) polymorphism in Serbia: deviation of Pi M subtype distribution from the Hardy-Weinberg equilibrium. Jelić-Ivanović Z, et al. **Gene Geogr** 1994 Aug; 8(2):129–35

Human alpha 1-antitrypsin gene transfer to in vivo mouse hepatocytes. Aliño SF, et al. **Hum Gene Ther** 1996 Mar 1;7(4):531–6

Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of human alpha 1-antitrypsin in vivo. Okuyama T, et al. **Hum Gene Ther** 1996 Mar 20;7(5):637–45

Low frequency of PIM3 gene in patients with monoclonal gammopathies. Jelić-Ivanović Z, et al. **Hum Hered** 1996 Mar-Apr;46(2):115–7

Alpha-1-antitrypsin subtypes in Polish newborns. Kowalska A, et al. **Hum Hered** 1995 Nov-Dec;45(6):351–4

Role of a distal enhancer containing a functional NF-kappa B-binding site in lipopolysaccharide-induced expression of a novel alpha 1-antitrypsin gene. Ray A, et al. **J Biol Chem** 1995 Dec 8;270(49):29201–8

Alpha-1-antitrypsin phenotypes among patients with intracranial aneurysms. Schievink WI, et al. **J Neurosurg** 1996 May;84(5):781–4

Genetic variants of serum alpha 1 antitrypsin. Shahid A, et al. **JPMA J Pak Med Assoc** 1995 Sep;45(9):245–6

The PiZ gene of alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Segelmark M, et al. **Kidney Int** 1995 Sep;48(3):844–50

Patterns of divergence during evolution of alpha 1-proteinase inhibitors in mammals. Goodwin RL, et al. **Mol Biol Evol** 1996 Feb;13(2):346–58

C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Griffith ME, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):438–43

The Malaysian experience in the typing of genetic variants of alpha-1-antitrypsin. Desa NM, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:311–4

Regulation of the acute phase response genes alpha 1-acid glycoprotein and alpha 1-antitrypsin correlates with sensitivity to thermal injury. Gilpin DA, et al. **Surgery** 1996 Jun;119(6):664–73

[Expression of the human alpha-1-antitrypsin gene in transgenic rats] Tsymbalenko NV, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):81–3 **(Rus)**

IMMUNOLOGY

Macrophage presentation of endogenous self-protein: the MHC class II presentation pathway is not accessible to intracellular C5 or alpha 1-antitrypsin. Grant CF, et al. **Cell Immunol** 1996 Feb 1;167(2):230–40

ISOLATION & PURIFICATION

Isolation and characterization of alpha 1-protease inhibitor from canine plasma. Melgarejo T, et al. **Am J Vet Res** 1996 Mar;57(3):258–63

METABOLISM

Interleukin 8 and granulocyte elastase alpha 1 proteinase inhibitor complex in the tracheobronchial aspirate of infants with chronic lung disease following inter-uterine infection. Takasaki J, et al. **Acta Paediatr Jpn** 1996 Apr;38(2):132–6

The house dust mite allergen Der p1 catalytically inactivates alpha 1-antitrypsin by specific reactive centre loop cleavage: a mechanism that promotes airway inflammation and asthma. Kalsheker NA, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):59–61

Folding pathway of human alpha 1-antitrypsin: characterization of an intermediate that is active but prone to aggregation. Kim D, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):378–84

The contribution of the conserved hinge region residues of alpha1-antitrypsin to its reaction with elastase. Hopkins PC, et al. **Biochemistry** 1995 Dec 5;34(48):15872–9

Identification of thrombin residues that modulate its interactions with antithrombin III and alpha 1-antitrypsin. Le Bonniec BF, et al. **Biochemistry** 1995 Sep 26; 34(38):12241–8

Prognostic value of serum alpha-1-antitrypsin in hepatocellular carcinoma. Pirisi M, et al. **Eur J Cancer** 1996 Feb;32A(2):221–5

Protection against peroxynitrite-dependent tyrosine nitration and alpha 1-antiproteinase inactivation by oxidized and reduced lipoic acid. Whiteman M, et al. **FEBS Lett** 1996 Jan 22;379(1):74–6

Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Levy MY, et al. **Gene Ther** 1996 Mar;3(3):201–11

Cellular internalization and degradtion of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein. Kounnas MZ, et al. **J Biol Chem** 1996 Mar 15;271(11):6523–9

The endoplasmic reticulum degradation pathway for mutant secretory proteins alpha1-antitrypsin Z and S is distinct from that for an unassembled membrane protein. Teckman JH, et al. **J Biol Chem** 1996 May 31;271(22):13215–20

Alpha 1-antitrypsin is degraded and non-functional in chronic wounds but intact and functional in acute wounds: the inhibitor protects fibronectin from degradation by chronic wound fluid enzymes. Rao CN, et al. **J Invest Dermatol** 1995 Oct;105(4):572–8

Alpha 1-antitrypsin activity in subarachnoid hemorrhage. Tartara F, et al. **Life Sci** 1996;59(1):15–20

[The change of serum alpha 1-antitrypsin level in patients with spontaneous pneumothorax] Chen Y. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Aug; 18(4):228–9, 256 (Eng. Abstr.) **(Chi)**

[Activity of alpha 1-antitrypsin in blood of patients operated on for tumor and benign hyperplasia of the prostate] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):77–8 (Eng. Abstr.) **(Pol)**

[Activity of alpha 1-antitrypsin in blood of patients with prostatic tumor] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb; 51(6–9):89–90 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Increased elastin-degrading activity and neointimal formation in porcine aortic organ culture. Reduction of both features with a serine proteinase inhibitor. Oho S, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2200–6

The expression and characterization of five recombinant murine alpha 1-protease inhibitor proteins. Paterson T, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):64–9

Clearance of human factor XIa-inhibitor complexes in rats. Wuillemin WA, et al. **Br J Haematol** 1996 Jun 2;93(4):950–4

Inhibition of neutrophil elastase by the alpha1-proteinase inhibitor-immunoglobulin A complex. Adam C, et al. **FEBS Lett** 1996 May 6;385(3):201–4

Interaction of the human serine protease inhibitor alpha-1-antitrypsin with Cryptosporidium parvum. Forney JR, et al. **J Parasitol** 1996 Jun;82(3):496–502

Alpha 1-proteinase inhibitor abrogates proteolytic and secretagogue activity of cystic fibrosis sputum. Hansen G, et al. **Respiration** 1995;62(3):117–24

PHYSIOLOGY

The interaction of alpha 1-proteinase inhibitor and tissue kallikrein in controlling allergic ovine airway hyperresponsiveness. Forteza R, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):36–42

[Serpins, a functionally important class of proteins: the paradigm of alpha-1-antitrypsin] Emmerich J. **Rev Med Interne** 1996;17(2):176–9 (27 ref.) **(Fre)**

SECRETION

Assessment of bystander effect potency produced by intratumoral implantation of HSVtk-expressing cells using surrogate marker secretion to monitor tumor growth kinetics. Marini FC 3rd, et al. **Gene Ther** 1995 Nov; 2(9):655–9

THERAPEUTIC USE

Treatment of alpha-1-antitrypsin deficiency, massive edema, and panniculitis with alpha-1 protease inhibitor [letter] Furey NL, et al. **Ann Intern Med** 1996 Oct 15;125(8):699

Effective treatment with alpha 1-protease inhibitor of chronic cutaneous vasculitis associated with alpha 1-antitrypsin deficiency. Dowd SK, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):913–6

[The evolution of the replacement treatment of emphysema due to alpha 1-antitrypsin deficiency (letter)] Manresa F. **Arch Bronconeumol** 1995 Aug-Sep;31(7):371–2 **(Spa)**

ALPHA-BLOCKERS, ADRENERGIC see **ADRENERGIC ALPHA-ANTAGONISTS**

ALPHA-CARBOXYLASE see **PYRUVATE DECARBOXYLASE**

ALPHA-CELL TUMOR see **GLUCAGONOMA**

ALPHA-CHAIN DISEASE see **IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE**

ALPHA-CHLORHYDRIN see **ALPHA-CHLOROHYDRIN**

ALPHA-CHLOROHYDRIN

ADMINISTRATION & DOSAGE

Effects of short-term administration of alpha-chlorohydrin on reproductive toxicity parameters in male Sprague-Dawley rats. Yamada T, et al. **J Toxicol Sci** 1995 Aug;20(3):195–205

ANALOGS & DERIVATIVES

Inhibition of glycolysis in boar spermatozoa by alpha-chlorohydrin phosphate appears to be mediated by phosphatase activity. Jones AR, et al. **Reprod Fertil Dev** 1995;7(5):1089–94

TOXICITY

Effects of short-term administration of alpha-chlorohydrin on reproductive toxicity parameters in male Sprague-Dawley rats. Yamada T, et al. **J Toxicol Sci** 1995 Aug;20(3):195–205

An in vivo and in vitro investigation into the effects of alpha-chlorohydrin on sperm motility and correlation with fertility in the Han Wistar rat. Woods J, et al. **Reprod Toxicol** 1996 May-Jun;10(3):199–207

ALPHA-1,24-CORTICOTROPIN see **COSYNTROPIN**

ALPHA-DIFLUOROMETHYLORNITHINE see **EFLORNITHINE**

5 ALPHA-DIHYDROTESTOSTERONE see **STANOLONE**

ALPHA-ENDOTHELIAL GROWTH FACTOR see **ENDOTHELIAL GROWTH FACTORS**

ALPHA-FETOPROTEINS

ADMINISTRATION & DOSAGE

Alpha-fetoprotein-mediated targeting of anti-cancer drugs to tumor cells in vitro. Severin SE, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):385–92

ANALYSIS

Term delivery after hepatocellular carcinoma resection in previous pregnancy. Hsieh TT, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):77–8

Immunoelectrophoretic differentiation of alpha-fetoprotein in disorders with elevated serum alpha-fetoprotein levels or during pregnancy. Chen RJ, et al. **Acta Oncol** 1995; 34(7):931–5

Neural tube defects: prenatal screening [letter; comment] Sickler GK, et al. **AJR Am J Roentgenol** 1996 Feb; 166(2):466–7. Comment on: AJR Am J Roentgenol 1995 Feb;164(2):421–8.

Maternal serum markers levels in consecutive pregnancies: a possible genetic predisposition to abnormal levels. Dar H, et al. **Am J Med Genet** 1996 Jan 11;61(2):154–7

Normal nuchal thickness in the midtrimester indicates reduced risk of Down syndrome in pregnancies with abnormal triple-screen results. Bahado-Singh RO, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1106–10

The origin of alpha-fetoprotein in first-trimester anembryonic pregnancies. Jauniaux E, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1749–53

Prenatal maternal dried blood screening with alpha-fetoprotein and free beta-human chorionic gonadotropin for open neural tube defect and Down syndrome. Macri JN, et al. **Am J Obstet Gynecol** 1996 Feb; 174(2):566–72

Associations between adverse perinatal outcome and serially obtained second- and third-trimester maternal serum alpha-fetoprotein measurements. Simpson JL, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1742–8

The effects of gestation dating on the calculation of patient specific risks in Down's syndrome screening. Bishop J, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):464–77

Lectin-affinity electrophoresis for the detection of AFP microheterogeneities in patients with hepatocellular carcinoma. Zaninotto M, et al. **Anticancer Res** 1996 Jan-Feb;16(1):305–9

Hepatitis B- and hepatitis C-associated hepatocellular carcinoma: evaluation of alpha-fetoprotein as a diagnostic marker. Songsivilai S, et al. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):167–71

Isoelectric focusing of alphafetoprotein in patients with hepatocellular carcinoma--frequency of specific banding patterns at non-diagnostic serum levels. Ho S, et al. **Br J Cancer** 1996 Apr;73(8):985–8

Alpha fetoprotein as marker for a case of orbital yolk sac tumour [letter] Yih JP, et al. **Br J Ophthalmol** 1995 Aug; 79(8):787–8

Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Aoyagi Y, et al. **Cancer** 1996 May 1; 77(9):1781–6

Diagnosis of hepatocellular carcinoma by concanavalin A affinity electrophoresis of serum alpha-fetoprotein. Saitoh S, et al. **Cancer** 1995 Oct 1;76(7):1139–44

Diagnosis of premature rupture of membranes with an improved alpha-fetoprotein monoclonal antibody kit. Kishida T, et al. **Clin Chem** 1995 Oct;41(10):1500–3

Maternal serum screening for birth defects: results of a Connecticut regional program. Benn PA, et al. **Conn Med** 1996 Jun;60(6):323–7

Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Raedle J, et al. **Dig Dis Sci** 1995 Dec; 40(12):2587–94

Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization. Yamashita F, et al.

Eur J Gastroenterol Hepatol 1995 Jul;7(7):627-33

Biochemical and Doppler predictors of poor perinatal outcome in a fetus with four umbilical vessels. Martinez JM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep; 62(1):145-7

Haemangioendothelioma in a preterm infant associated with highly elevated alpha-fetoprotein [letter] Lehrnbecher T, et al. **Eur J Pediatr** 1996 May;155(5):423-4

Impact of abnormal second-trimester maternal serum single, double, and triple screening on patient choices about prenatal diagnosis. Lowry DL, et al. **Fetal Diagn Ther** 1995 Sep-Oct;10(5):286-9

Carbohydrate-based measurements on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. Aoyagi Y. **Glycoconj J** 1995 Jun;12(3):194-9 (66 ref.)

Picogram detection levels of asialofetuin via the carbohydrate moieties using the light addressable potentiometric sensor. Dill K, et al. **Glycoconj J** 1995 Oct;12(5):660-3

Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Izuno K, et al. **Hepatogastroenterology** 1995 Jul-Aug; 42(4):387-93

Unexplained elevated maternal serum alpha-fetoprotein in singleton pregnancies as a predictor of fetal risk. Akinbiyi AA. **Int J Gynaecol Obstet** 1996 Apr;53(1):17-21

Study of serum prealbumin and serum alpha fetoprotein in cases of fulminant hepatic failure. Jain SK, et al. **J Assoc Physicians India** 1995 Jul;43(7):462-3

Circulating intercellular adhesion molecule 1 predicts non-specific elevation of alpha 1-fetoprotein. Falleti E, et al. **J Cancer Res Clin Oncol** 1996;122(6):366-9

Elevated serum alpha-fetoprotein in a patient with undifferentiated carcinoma of the gall bladder. Ng WK, et al. **J Clin Pathol** 1995 Nov;48(11):1061-3

Highly sensitive amperometric enzyme immunoassay for alpha-fetoprotein in human serum. Della Ciana L, et al. **J Immunol Methods** 1996 Jun 14;193(1):51-62

Logistic regression generated probability estimates for trisomy 21 outcomes from serum alpha fetoprotein and beta human chorionic gonadotrophin: simplification with increased specificity. Evans MI, et al. **J Matern Fetal Med** 1996 Jan-Feb;5(1):1-6

Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization. McDuffie RS Jr, et al. **J Matern Fetal Med** 1996 Mar-Apr; 5(2):70-3

Amniotic fluid alpha fetoprotein (AFAFP) and maternal serum alpha fetoprotein (MSAFP) in abdominal pregnancies: correlation with extent and site of placental implantation and clinical implications. Shumway JB, et al. **J Matern Fetal Med** 1996 May-Jun;5(3):120-3

Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland. Crossley JA, et al. **J Med Screen** 1994 Jul;1(3):180-3

Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group. Piggott M, et al. **J Med Screen** 1994 Jan;1(1):45-9

Family care related to alpha-fetoprotein screening. Covington C, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):125-30 (28 ref.)

Similarity of insulin-dependent diabetics' and non-insulin-dependent diabetics' levels of beta-hCG and unconjugated estriol with controls: no need to adjust as with alpha-fetoprotein. Evans MI, et al. **J Soc Gynecol Investig** 1996 Jan-Feb;3(1):20-2

The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers [see comments] Saxman SB, et al. **J Urol** 1996 Feb;155(2):587-9. Comment in: J Urol 1996 Feb;155(2):593-4.

Highly-sensitive identification of alpha-fetoprotein mRNA in circulating peripheral blood of hepatocellular carcinoma patients. Funaki N, et al. **Life Sci** 1995;57(17):1621-31

Determination of alpha-fetoprotein by radioimmunoassay. Improvement of the quality of a locally produced kit. Nikolić JA. **Med Pregl** 1993;46 Suppl 1:64-5

Determination of alpha-fetoprotein by radioimmunoassay. Ten year experience in applying a locally produced kit. Nikolić JA, et al. **Med Pregl** 1993;46 Suppl 1:66-8

Expression of serum albumin and of alphafetoprotein in murine normal and neoplastic primitive embryonic structures. Trojan J, et al. **Mol Reprod Dev** 1995 Dec; 42(4):369-78

Hyperechogenic fetal bowel and elevated serum alpha-fetoprotein: a poor fetal prognosis. Achiron R, et al. **Obstet Gynecol** 1996 Sep;88(3):368-71

Elevated second-trimester maternal serum hCG alone or in combination with elevated alpha-fetoprotein. Benn PA, et al. **Obstet Gynecol** 1996 Feb;87(2):217-22

Unexplained elevated maternal serum alpha-fetoprotein levels and pregnancy outcome in twins. Hong S, et al. **Obstet Gynecol** 1996 Sep;88(3):337-42

Down syndrome screening in an Asian population using alpha-fetoprotein and free beta-hCG: a report of the Taiwan Down Syndrome Screening Group. Hsu JJ, et al. **Obstet Gynecol** 1996 Jun;87(6):943-7

Prognostic significance of unexplained elevated amniotic fluid alpha-fetoprotein. Wenstrom KD, et al. **Obstet Gynecol** 1996 Feb;87(2):213-6

Enhanced twin pregnancy detection within an open neural tube defect and Down syndrome screening protocol using free-beta hCG and AFP. Barnabei VM, et al. **Prenat Diagn** 1995 Dec;15(12):1131-4

Fetal ductus venosus flow velocity waveforms and maternal serum AFP before and after first-trimester transabdominal chorionic villus sampling. Brezinka C, et al. **Prenat Diagn** 1995 Aug;15(8):699-703

Alpha-fetoprotein elevation in maternal serum after percutaneous umbilical blood sampling (PUBS) [letter] Buscaglia M, et al. **Prenat Diagn** 1996 Apr;16(4):375-6

Two-analyte assay for Down syndrome screening [letter] Cavalli P. **Prenat Diagn** 1995 Jul;15(7):680-1

Alpha-fetoprotein and acetylcholinesterase activity in first- and early second-trimester amniotic fluid. Jørgensen FS, et al. **Prenat Diagn** 1995 Jul;15(7):621-5

Abnormal levels of maternal serum human chorionic gonadotropin and alpha-fetoprotein in the second trimester: relation to fetal weight and preterm delivery. Morssink LP, et al. **Prenat Diagn** 1995 Nov;15(11):1041-6

Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. Palomaki GE, et al. **Prenat Diagn** 1995 Aug;15(8):713-23

Effect of gravidity and parity on the parameters used in serum screening for trisomy 21 [letter] Zimmermann R, et al. **Prenat Diagn** 1995 Aug;15(8):781-2

Recurrent hepatocellular carcinoma after liver transplantation: spectrum of CT findings and recurrence patterns. Ferris JV, et al. **Radiology** 1996 Jan;198(1):233-8

Immunohistochemical evaluation of canine primary liver carcinomas: distribution of alpha-fetoprotein, carcinoembryonic antigen, keratins and vimentin. Martín de las Mulas J, et al. **Res Vet Sci** 1995 Sep;59(2):124-7

Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma. Nakao A, et al. **Semin Surg Oncol** 1996 May-Jun;12(3):160-3

Impact of prenatal mid-trimester screening on the prevalence of fetal structural anomalies: a prospective epidemiological study. Papp Z, et al. **Ultrasound Obstet Gynecol** 1995 Nov; 6(5):320-6

Purification of canine alpha-fetoprotein and alpha-fetoprotein values in dogs. Yamada T, et al. **Vet Immunol Immunopathol** 1995 Jul;47(1-2):25-33

[Screening for Down's syndrome--results of a 3-year study] Kimlová I, et al. **Ceska Gynekol** 1996 Apr;61(2):75-8 (Eng. Abstr.) **(Cze)**

[Increase of alpha-fetoprotein in pancreatic endocrine tumors with hepatic metastases. Apropos of 2 cases] Lesur G, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):204-6 (Eng. Abstr.) **(Fre)**

-Increased AFP values- Zimmermann R. **Arch Gynecol Obstet** 1995;256 Suppl:S173-7 **(Ger)**

[Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis] Aoyagi Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2003-7 (5 ref.) **(Jpn)**

[Carcino-fetal antigens] Endo Y. **Nippon Rinsho** 1996 Jun; 54(6):1499-504 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The alpha-fetoprotein level analysis in open neural tube defects and chromosomal aberrations in the fetus] Ilnicka A, et al. **Neurol Neurochir Pol** 1996 Jan-Feb;30(1):65-75 (Eng. Abstr.) **(Pol)**

[Alphafetoprotein in hepatic tumours and benign liver diseases] Forones NM, et al. **Rev Assoc Med Bras** 1995 Mar-Apr;41(2):91-3 (Eng. Abstr.) **(Por)**

[Contents of alpha-fetoprotein in the blood of pregnant women as a criterion of the presence of congenital heart defects in the fetus] Vakharlovskiĭ VG, et al. **Akush Ginekol (Mosk)** 1995;(4):22-4 (Eng. Abstr.) **(Rus)**

[Use of a mathematical model to establish normal serum parameters characterizing the function of the fetoplacental complex] Shmagel' KV. **Klin Lab Diagn** 1995 May-Jun; (3):28-32 (Eng. Abstr.) **(Rus)**

[The use of the screening of maternal serum factors for the prenatal diagnosis of fetal developmental defects and chromosomal diseases] Arbuzova SB, et al. **Tsitol Genet** 1995 Jul-Aug;29(4):44-7 (Eng. Abstr.) **(Rus)**

[Prognostic value of AFP in chronic carriers of HBsAg with Down's syndrome (letter)] Carrascosa D, et al. **Aten Primaria** 1995 Sep 30;16(5):296-7 **(Spa)**

[The prognostic value of alpha-fetoprotein (AFP) in hepatocellular cancer in chronic carriers of HBsAg and positive HBeAg (letter)] Carrascosa D, et al. **Aten Primaria** 1996 Jul-Aug;18(3):147-8 **(Spa)**

ANTAGONISTS & INHIBITORS

Inhibition of alpha-fetoprotein production in a hepatoma cell line by antisense oligonucleotide analogues. Lin SB, et al. **J Biochem (Tokyo)** 1995 May;117(5):1100-4

BIOSYNTHESIS

Expression of alpha-fetoprotein by ovarian Sertoli-Leydig cell tumors. Case report and review of the literature. Hammad A, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1075-9 (29 ref.)

Modulation of the expression of liver-specific functions in novel human hepatocyte lines cultured in a collagen gel sandwich configuration. Kono Y, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):628-32

Lectin affinity electrophoretic demonstration of tissue specificity and malignant alteration of human alpha-fetoprotein isoforms produced in transgenic mice. Koyama Y, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):757-61

Allelic loss on chromosomes 4q and 16q in hepatocellular carcinoma: association with elevated alpha-fetoprotein production. Yeh SH, et al. **Gastroenterology** 1996 Jan; 110(1):184-92

Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Kanai F, et al. **Hepatology** 1996 Jun;23(6):1359-68

Inhibition of alpha-fetoprotein production in a hepatoma cell line by antisense oligonucleotide analogues. Lin SB, et al. **J Biochem (Tokyo)** 1995 May;117(5):1100-4

Alpha-fetoprotein production by a malignant mixed müllerian tumour of the uterus. Phillips KA, et al. **J Clin Pathol** 1996 Apr;49(4):349-51

Alpha-fetoprotein-producing gastric carcinoma: biological properties of a cultured cell line. Sekiguchi M, et al. **J Gastroenterol** 1995 Oct;30(5):589-98

AFP-producing squamous cell carcinoma of the lung in an adolescent. Asamura H, et al. **Jpn J Clin Oncol** 1996 Apr; 26(2):103-6 (12 ref.)

The alpha1-fetoprotein locus is activated by a nuclear receptor of the Drosophila FTZ-F1 family. Galarneau L, et al. **Mol Cell Biol** 1996 Jul;16(7):3853-65

Alpha-fetoprotein-producing adenocarcinoma of the sigmoid colon with possible hepatoid differentiation. Hocking GR, et al. **Pathology** 1995 Jul;27(3):277-9

[A case of alpha-fetoprotein producing mediastinal germ cell tumor treated with preoperative chemotherapy] Arai K, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1213-5 (Eng. Abstr.) **(Jpn)**

[A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with FEP (5-FU, Epirubicin, cisplatin) therapy by continuous venous daily infusion of 5-FU and low-dose CDDP] Hoshino K, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1197-200 (Eng. Abstr.) **(Jpn)**

[Alpha-fetoprotein producing hepatocellular carcinoma, AT-III producing hepatocellular carcinoma] Nakamura K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):265-8 (11 ref.) **(Jpn)**

CHEMISTRY

Picogram detection levels of asialofetuin via the carbohydrate moieties using the light addressable potentiometric sensor. Dill K, et al. **Glycoconj J** 1995 Oct;12(5):660-3

Biochemical characterization of alpha-fetoprotein and other serum proteins produced by a uterine endometrial adenocarcinoma. Koyama Y, et al. **Jpn J Cancer Res** 1996 Jun;87(6):612-7

DIAGNOSTIC USE

An organotypical in vitro model of the liver parenchyma for uptake studies of diagnostic MR receptor agents. Bader A, et al. **Magn Reson Imaging** 1995;13(7):991-1002

GENETICS

Application of mRNA differential display to liver cirrhosis: reduced fetuin expression in biliary cirrhosis in the rat. Forestier M, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):377-83

Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Kaneko S, et al. **Cancer Res** 1995 Nov 15;55(22):5283-7

Fetal hepatic alpha-fetoprotein mRNA expression in fetuses with trisomy 21 and 18 at 12-15 weeks gestation. Brizot ML, et al. **Early Hum Dev** 1996 Mar 22;44(3):155-9

The chimpanzee alpha-fetoprotein-encoding gene shows structural similarity to that of gorilla but distinct differences from that of human. Nishio H, et al. **Gene** 1995 Sep 11; 162(2):213-20

Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences. Arbuthnot P, et al. **Hepatology** 1995 Dec;22(6):1788-96

Quantitation of alpha-fetoprotein and albumin messenger RNA in human hepatocellular carcinoma. Niwa Y, et al. **Hepatology** 1996 Jun;23(6):1384-92

The alpha1-fetoprotein locus is activated by a nuclear receptor of the Drosophila FTZ-F1 family. Galarneau L, et al. **Mol Cell Biol** 1996 Jul;16(7):3853-65

Developmental control of transcription of the CAT reporter gene by a truncated mouse alphafetoprotein gene regulatory region in transgenic mice. Ghebranious N, et al. **Mol Reprod Dev** 1995 Sep;42(1):1-6

Characterization of somatic cell hybrids exhibiting extinction of AFP, albumin and an AFP-HPRT transgene. Keherly MJ, et al. **Somat Cell Mol Genet** 1996 Mar;22(2):119-34

Expression of the alpha-fetoprotein gene in human breast cancer. Esteban C, et al. **Tumour Biol** 1996;17(5):299-305

[Cell-specific expression of AFP gene is dependent on some nuclear proteins] Liu HH, et al. **Shih Yen Sheng Wu Hsueh Pao** 1995 Jun;28(2):157-62 (Eng. Abstr.) **(Chi)**

[Several transcription factors participate in the functioning of the alpha-fetoprotein gene promoter] Bois-Joyeux B, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):541-50 (51 ref.) (Eng. Abstr.) **(Fre)**

[Human alpha-fetoprotein transcriptional regulatory regions: application to gene therapy] Tamaoki T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2613-7 (25 ref.) **(Jpn)**

IMMUNOLOGY

Evidence that immunosuppression is an intrinsic property of the alpha-fetoprotein molecule. Semeniuk DJ, et al. **Adv Exp Med Biol** 1995;383:255-69

ISOLATION & PURIFICATION

Purification of canine alpha-fetoprotein and alpha-fetoprotein values in dogs. Yamada T, et al. **Vet Immunol Immunopathol** 1995 Jul;47(1-2):25-33

METABOLISM

Primary mediastinal malignant germ cell tumour. Single institution experience in Chinese patients and correlation with specific alpha-fetoprotein bends. Chan AT, et al. **Acta Oncol** 1996;35(2):221-7 (29 ref.)

Issues associated with prenatal testing for fetal abnormalities [letter; comment] Reid JR IV. **Am Fam Physician** 1996 Jun;53(8):2435, 2439-40. Comment on: Am Fam Physician 1995 Dec;52(8):2173-4, 2177. Comment on: Am Fam Physician 1995 Dec;52(8):2277-83, 2285-6.

Colon cancer with a high serum alpha-fetoprotein level. Kato K, et al. **Am J Gastroenterol** 1996 May;91(5):1045-6

Elevated MSAFP levels and congenital heart defects: are there associations? [letter; comment] Hajdú J, et al. **Am J Med Genet** 1995 Sep 11;58(3):292. Comment on: Am J Med Genet 1994 Feb 1;49(3):337-40.

Uterine artery Doppler velocimetry in the detection of adverse obstetric outcomes in women with unexplained elevated maternal serum alpha-fetoprotein levels. Konchak PS, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1115-9

Maternal serum analyte levels after first-trimester multifetal pregnancy reduction. Shulman LP, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1072-4

Interactions of gelatinases with soluble and immobilized fetuin and asialofetuin. Ochieng J, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):250-5

Velamentous umbilical cord insertion may be suspected from maternal serum alpha-fetoprotein and hCG. Heinonen S, et al. **Br J Obstet Gynaecol** 1996 Mar;103(3):209-13

The relation between serum markers in the second trimester and placental pathology. A study on extremely small for gestational age fetuses. Morssink LP, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):779-83

Interaction of lectins with their ligand carbohydrate of alpha-fetoprotein: analysis by mixed-lectin affinity electrophoresis. Taketa K, et al. **Electrophoresis** 1996 Mar; 17(3):483-8

Alpha-fetoprotein-concanavalin A binding as a marker to discriminate between germ cell tumours and liver diseases. Mora J, et al. **Eur J Cancer** 1995 Dec;31A(13-14):2239-42

Persisting elevation of alpha-fetoprotein after chemotherapy for germ cell tumour--not always due to viable malignancy? [letter] Shannon JA, et al. **Eur J Cancer** 1995 Sep;31A(10):1722

Maternal age-dependent and sex-related changes of gestational serum alpha-fetoprotein. Szabó M, et al. **Fetal Diagn Ther** 1995 Nov-Dec;10(6):368-72

A case of alpha-fetoprotein-producing gastric cancer showing an exogastric growth pattern. Nakashima H, et al. **J Clin Gastroenterol** 1996 Mar;22(2):150-3

Mechanisms of alphafetoprotein transfer in the perfused human placental cotyledon from uncomplicated pregnancy. Brownbill P, et al. **J Clin Invest** 1995 Nov;96(5):2220-6

Modernized version of Todaro and De Larco's 1978 hypothesis on the autocrine nature of tumor growth [letter] Laderoute MP. **J Natl Cancer Inst** 1996 Sep 4; 88(17):1239-40

Elevation of maternal alpha-fetoprotein in systemic lupus erythematosus: a controlled study. Petri M, et al. **J Rheumatol** 1995 Jul;22(7):1365-8

The arterial ketone body ratio and serum alpha-fetoprotein level in patients with acute hepatic failure. Yamasaki H, et al. **Liver** 1995 Aug;15(4):219-23

Elevated alpha-fetoprotein and human chorionic gonadotropin as a marker for placental trisomy 16 in the second trimester? Zimmermann R, et al. **Prenat Diagn** 1995 Dec;15(12):1121-4

Alpha-fetoprotein binding and uptake by primary cultures of human skeletal muscle. Lorenzo HC, et al. **Tumour Biol** 1996;17(4):251-60

[Maternal serum screening for detection of fetal chromosome abnormalities] Holzgreve W, et al. **Gynakologe** 1995 Oct; 28(5):280-8 (44 ref.) **(Ger)**

[Triple test: problem or enhancement of prenatal diagnosis (editorial)] Rauskolb R, et al. **Z Geburtshilfe Neonatol** 1995 May-Jun;199(3):91 **(Ger)**

[Comment on the contribution by Benz et al.: Serum screening for Down syndrome in women under 35 years of age with an age independent index (letter)] Reynolds T, et al. **Z Geburtshilfe Neonatol** 1995 May-Jun; 199(3):128-9 **(Ger)**

[Estrogen binding activities of recombinant alpha-fetoproteins expressed in yeast] Shahbazzadeh D. **Hokkaido Igaku Zasshi** 1995 May;70(3):473-83 (Eng. Abstr.) **(Jpn)**

[A case study of nonfunctioning islet cell tumor in patient with splenic tumor and increased AFP] Zeki S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May;93(5):382-7 (20 ref.) **(Jpn)**

PHARMACOLOGY

[Alpha-fetoprotein suppresses keratinocyte proliferation in vitro] Voroteliak EA, et al. **Izv Akad Nauk Ser Biol** 1996 Jan-Feb;(1):117-20 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. Demetriou M, et al. **J Biol Chem** 1996 May 31; 271(22):12755-61

The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. Schinke T, et al. **J Biol Chem** 1996 Aug 23; 271(34):20789-96

Alpha-fetoprotein signal sequences: a proposed mechanism for subcellular localization and organelle targeting. Mizejewski GJ. **J Theor Biol** 1995 Sep 7;176(1):103-13

[Experience in use of biologically active substances from human fetal tissue in treating oncological diseases] Rodionov SIu, et al. **Biull Eksp Biol Med** 1995 Nov; 120(11):522-4 **(Rus)**

SECRETION

Acinar cell carcinoma of the pancreas: a rare case of an alpha-fetoprotein-producing cystic tumor. Ishizaki A, et al. **Eur J Radiol** 1995 Nov;21(1):58-60

A case of ovarian serous adenocarcinoma suggestive of transformation to an AFP-producing tumor during chemotherapy. Kataoka A, et al. **J Obstet Gynaecol** 1995 Oct;21(5):451-9

ALPHA-GALACTOSIDASE

BIOSYNTHESIS

High-level expression and purification of coffee bean alpha-galactosidase produced in the yeast Pichia pastoris. Zhu A, et al. **Arch Biochem Biophys** 1995 Dec 1; 324(1):65-70

CHEMISTRY

The DAG family of glycosyl hydrolases combines two previously identified protein families [letter] Dagnall BH, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):349-50

DEFICIENCY

[Fabry disease (alpha-galactosidase deficiency)] Okumiya T, et al. **Nippon Rinsho** 1995 Dec;53(12):2952-9 (21 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. Okumiya T, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1219-24

Expression and characterization of recombinant alpha-galactosidase in baculovirus-infected insect cells. Zhu A, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):332-7

Structural organization and expression of the mouse gene encoding alpha-galactosidase A. Ohshima T, et al. **Gene** 1995 Dec 12;166(2):277-80

Identification of the alpha-galactosidase MEL genes in some populations of Saccharomyces cerevisiae: a new gene MEL11. Naumov GI, et al. **Genet Res** 1996 Apr;67(2):101-8

Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease. Sugimoto Y, et al. **Hum Gene Ther** 1995 Jul;6(7):905-15

New point mutation (R301X) of the alpha-galactosidase A gene causing Fabry disease. Kawanishi C, et al. **Hum Mutat** 1995;6(2):186-7

METABOLISM

Characterization of recombinant alpha-galactosidase for use in seroconversion from blood group B to O of human erythrocytes. Zhu A, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):324-9

Aggregation of the inactive form of human alpha-galactosidase in the endoplasmic reticulum. Ishii S, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):812-5

Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. Okumiya T, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1219-24

Enzymic hydrolysis of raffinose and stachyose in soymilk by alpha-galactosidase from Gibberella fujikuroi. Mulimani VH, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):897-905

Isolation and characterization of novel heterogeneous branched cyclomalto-oligosaccharides (cyclodextrins) produced by transgalactosylation with alpha-galactosidase from coffee bean. Koizumi K, et al. **Carbohydr Res** 1995 Nov 30;278(1):129-42

Use of beta-maltosides (p-nitrophenyl-beta-D-maltoside, 2-chloro-4- nitrophenyl-beta-D-maltoside and 4-methylumbelliferyl-beta-D-maltoside) as substrates for the assay of neutral alpha-glucosidase from human kidney and urine. Lukomskaya IS, et al. **Clin Chim Acta** 1996 Jan 31;244(2):145-54

PHARMACOLOGY

Deantigenation of human type B erythrocytes with Glycine max alpha-D-galactosidase. Hobbs L, et al. **Biomed Pharmacother** 1995;49(5):244-50

Multiple-unit and second transfusions of red cells enzymatically converted from group B to group O: report on the end of phase 1 trials. Lenny LL, et al. **Transfusion** 1995 Nov-Dec;35(11):899-902

ALPHA-GLOBIN see **GLOBIN**

ALPHA-GLOBULINS

ADMINISTRATION & DOSAGE

TNF/IL-1-inducible protein TSG-6 potentiates plasmin inhibition by inter-alpha-inhibitor and exerts a strong anti-inflammatory effect in vivo. Wisniewski HG, et al. **J Immunol** 1996 Feb 15;156(4):1609-15

ANALYSIS

Gene expression and protein distribution of inter-alpha-trypsin inhibitor in three human hepatoma cell lines. Héron A, et al. **Cell Biol Int** 1995 Jul;19(7):593-602

A specific immunoradiometric assay of cationic trypsin(ogen) that does not recognize trypsin-alpha-1-proteinase inhibitor complex. Lafont P, et al. **Clin Chim Acta** 1995 Mar 31;235(2):197-206

Spectroscopic characterization by photodiode array detection of human urinary and amniotic protein HC subpopulations fractionated by anion-exchange and size-exclusion high-performance liquid chromatography. Calero M, et al. **J Chromatogr A** 1996 Jan 5;719(1):149-57

Assessment of serum levels of alpha-1-microglobulin, beta-2-microglobulin, and retinol binding protein in the fetal blood. A method for prenatal evaluation of renal function. Cobet G, et al. **Prenat Diagn** 1996 Apr; 16(4):299-305

[alpha 1-Microglobulin (protein HC)] Itoh Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:189-92 (18 ref.) **(Jpn)**

BIOSYNTHESIS

Ciprofibrate represses alpha 2u-globulin expression in liver and inhibits d-limonene nephrotoxicity. Alvares K, et al. **Carcinogenesis** 1996 Feb;17(2):311-6

Gene expression and protein distribution of inter-alpha-trypsin inhibitor in three human hepatoma cell lines. Héron A, et al. **Cell Biol Int** 1995 Jul;19(7):593-602

CHEMISTRY

An IgE-binding TAME esterase in the urine of the mouse, Mus musculus domesticus. Berrens L. **Immunol Lett** 1995 Jul-Aug;47(1-2):29-32

GENETICS

Hepatic heat shock and acute-phase gene expression are induced simultaneously after celiotomy in the anesthetized pig. Pannen BH, et al. **Anesthesiology** 1995 Oct;83(4):850-9

Bovine alpha 1-microglobulin/bikunin. Isolation and characterization of liver cDNA and urinary alpha 1-microglobulin. Lindqvist A, et al. **Biochim Biophys Acta** 1996 Apr 10;1306(1):98-106

Cloning of the rice seed alpha-globulin-encoding gene: sequence similarity of the 5'-flanking region to those of the genes encoding wheat high-molecular-weight glutenin and barley D hordein. Nakase M, et al. **Gene** 1996 May 8;170(2):223-6

Genetic polymorphism of the H1 subunit of inter-alpha-trypsin inhibitor. Harada A, et al. **Int J Legal Med** 1995;108(2):113-5

Genetic polymorphism of the inter-alpha-trypsin inhibitor (ITI) in Cádiz Province, southern Spain. Romero Palanco JL, et al. **J Forensic Sci** 1996 Jul;41(4):664-6

Expression of rat alpha 1-microglobulin-bikunin in baculovirus-transformed insect cells. Bratt T, et al. **Protein Expr Purif** 1995 Aug;6(4):431-8

IMMUNOLOGY

Involvement of the three inter-alpha-trypsin inhibitor (ITI) heavy chains in each member of the serum ITI family. Héron A, et al. **FEBS Lett** 1995 Oct 30;374(2):195-8

Development of an enzyme-linked immunosorbent assay for human plasma inter-alpha-trypsin inhibitor (ITI) using specific antibodies against each of the H1 and H2 heavy chains. Mizon C, et al. **J Immunol Methods** 1996 Mar 28; 190(1):61-70

Effects of passive immunization against alpha-2u-globulin and supplementation with alpha-2u-globulin on serum gonadotrophins and testicular activity. Biswas R, et al. **Life Sci** 1996;58(17):1469-74

ALPHA-GLOBULINS

ISOLATION & PURIFICATION

Isolation of a pentraxin-like protein from rainbow trout serum. Jensen LE, et al. **Dev Comp Immunol** 1995 Jul-Aug; 19(4):305-14

METABOLISM

Bip/GRP78 but not calnexin associates with a precursor of glycosylphosphatidylinositol-anchored protein. Oda K, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):623-30

Factor IX Zutphen: a Cys18-->Arg mutation results in formation of a heterodimer with alpha 1-microglobulin and the inability to form a calcium-induced conformation. Wojcik EG, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):753-9

Covalent linkage between proteins of the inter-alpha-inhibitor family and hyaluronic acid is mediated by a factor produced by granulosa cells. Chen L, et al. **J Biol Chem** 1996 Aug 9;271(32):19409-14

Inter-alpha-trypsin inhibitor bound to tumor cells is cleaved into the heavy chains and the light chain on the cell surface. Kobayashi H, et al. **J Biol Chem** 1996 May 10; 271(19):11362-7

Evidence for the covalent binding of SHAP, heavy chains of inter-alpha-trypsin inhibitor, to hyaluronan. Zhao M, et al. **J Biol Chem** 1995 Nov 3;270(44):26657-63

Induction of protein droplet (alpha 2 mu-globulin) nephropathy in male rats after short-term dosage with 1,8-cineole and l-limonene. Kristiansen E, et al. **Toxicol Lett** 1995 Oct;80(1-3):147-52

Alpha 2u-globulins in the urine of male rats: a reliable indicator for alpha 2u-globulin accumulation in the kidney. Saito K, et al. **Toxicology** 1996 Jan 8;106(1-3):149-57

PHYSIOLOGY

The inter-alpha-inhibitor family: from structure to regulation. Salier JP, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):1-9 (68 ref.)

URINE

Purification and identification of allergenic alpha(2u)-globulin species of rat urine. Bayard C, et al. **Biochim Biophys Acta** 1996 Jun 4;1290(2):129-34

A mathematical equation to differentiate overload proteinuria from tubulo-interstitial involvement in glomerular diseases. Hofmann W, et al. **Clin Nephrol** 1995 Jul;44(1):28-31

Urinary alpha 1- and beta 2-microglobulin in light chain proteinuria. Honkanen E, et al. **Clin Nephrol** 1995 Jul; 44(1):22-7

Microalbuminuria or micro-alpha-1-microglobulinuria: which one is better predictor of the development of the secondary nephropathy? [letter] Marczewski KT, et al. **Clin Nephrol** 1996 Feb;45(2):136-7

Urinary excretion of type IV collagen and laminin in the evaluation of nephropathy in NIDDM: comparison with urinary albumin and markers of tubular dysfunction and/or damage. Banu N, et al. **Diabetes Res Clin Pract** 1995 Jul; 29(1):57-67

Urinary alpha1-microglobulin, beta2-microglobulin, and retinol-binding protein levels in general populations in Japan with references to cadmium in urine, blood, and 24-hour food duplicates. Ikeda M, et al. **Environ Res** 1995 Jul;70(1):35-46

Identification of uronic-acid-rich protein as urinary bikunin, the light chain of inter-alpha-inhibitor. Atmani F, et al. **Eur J Biochem** 1996 Mar 15;236(3):984-90

The determination of alpha 1-microglobulin by means of an automated latex immunoassay. Straub JP, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul;33(7):425-31

Spectroscopic characterization by photodiode array detection of human urinary and amniotic protein HC subpopulations fractionated by anion-exchange and size-exclusion high-performance liquid chromatography. Calero M, et al. **J Chromatogr A** 1996 Jan 5;719(1):149-57

Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Carraro M, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):444-8

Alpha 2u-globulins in the urine of male rats: a reliable indicator for alpha 2u-globulin accumulation in the kidney. Saito K, et al. **Toxicology** 1996 Jan 8;106(1-3):149-57

1,4-ALPHA-GLUCAN BRANCHING ENZYME

ANALYSIS

Physical association of starch biosynthetic enzymes with starch granules of maize endosperm. Granule-associated forms of starch synthase I and starch branching enzyme II. Mu-Forster C, et al. **Plant Physiol** 1996 Jul;111(3):821-9

CHEMISTRY

Evidence for essential arginine residues at the active sites of maize branching enzymes. Cao H, et al. **J Protein Chem** 1996 Apr;15(3):291-304

Analysis of the active center of branching enzyme II from maize endosperm. Kuriki T, et al. **J Protein Chem** 1996 Apr;15(3):305-13

GENETICS

Exclusion of primary congenital glaucoma (buphthalmos) from two candidate regions of chromosome arm 6p and chromosome 11 [letter] Akarsu AN, et al. **Am J Med Genet** 1996 Jan 22;61(3):290-2

Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene. Bao Y, et al. **J Clin Invest** 1996 Feb 15;97(4):941-8

Tissue-specific glycogen branching isoenzymes in a multicellular prokaryote, Streptomyces coelicolor A3(2). Bruton CJ, et al. **Mol Microbiol** 1995 Oct;18(1):89-99

Expression of Escherichia coli branching enzyme in tubers of amylose-free transgenic potato leads to an increased branching degree of the amylopectin. Kortstee AJ, et al. **Plant J** 1996 Jul;10(1):83-90

Two closely related cDNAs encoding starch branching enzyme from Arabidopsis thaliana. Fisher DK, et al. **Plant Mol Biol** 1996 Jan;30(1):97-108

Evolutionary conservation and expression patterns of maize starch branching enzyme I and IIb genes suggests isoform specialization. Gao M, et al. **Plant Mol Biol** 1996 Mar; 30(6):1223-32

METABOLISM

Cyclization reaction catalyzed by branching enzyme. Takata H, et al. **J Bacteriol** 1996 Mar;178(6):1600-6

ALPHA 2-GLUCOPROTEINS see **ALPHA-MACROGLOBULINS**

1,4-ALPHA-GLUCOSIDASE, EXO see **GLUCAN 1,4-ALPHA-GLUCOSIDASE**

ALPHA-GLUCOSIDASES

ANALYSIS

Alpha-1,4-glucosidase activity and the presence of germinal epithelium cells in the semen for differential diagnosis of obstructive and nonobstructive azoospermia. Sandoval L, et al. **Arch Androl** 1995 Sep-Oct;35(2):155-8

ANTAGONISTS & INHIBITORS

Nectrisine is a potent inhibitor of alpha-glucosidases, demonstrating activities similarly at enzyme and cellular levels. Tsujii E, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):459-66

The mechanism of alpha-glucosidase inhibition in the management of diabetes. Bischoff H. **Clin Invest Med** 1995 Aug;18(4):303-11 (31 ref.)

Reversal of abnormal retinal hemodynamics in diabetic rats by acarbose, an alpha-glucosidase inhibitor. Takagi C, et al. **Curr Eye Res** 1995 Sep;14(9):741-9

Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Pagano G, et al. **Diabete Metab** 1995 Jun;21(3):162-7

An alpha-glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans. Goto Y, et al. **Diabetes Res Clin Pract** 1995 May;28(2):81-7

Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Göke B, et al. **Digestion** 1995;56(6):493-501

Effect of miglitol and acarbose on starch digestion, daily plasma glucose profiles and cataract formation. Madar Z, et al. **J Basic Clin Physiol Pharmacol** 1993 Apr-Jun; 4(1-2):69-81

Mechanism-based inhibition of yeast alpha-glucosidase and human pancreatic alpha-amylase by a new class of inhibitors. 2-Deoxy-2,2-difluoro-alpha-glycosides. Braun C, et al. **J Biol Chem** 1995 Nov 10;270(45):26778-81

Use of an alpha-glucosidase inhibitor to synchronize sugar absorption with delayed insulin secretion in a patient with non-insulin-dependent diabetes mellitus. Okada S, et al. **J Int Med Res** 1996 Jan-Feb;24(1):164-8

Effect of an alpha-glucosidase inhibitor combined with sulphonylurea treatment on glucose metabolism in patients with non-insulin-dependent diabetes mellitus. Okada S, et al. **J Int Med Res** 1995 Jul-Aug;23(4):279-83

No effect of an alpha-glucosidase inhibitor on glucose metabolism in patients with non-insulin-dependent diabetes mellitus and low function of pancreatic beta cells. Okada S, et al. **J Int Med Res** 1995 Jul-Aug;23(4):294-8

Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus. Vannasaeng S, et al. **J Med Assoc Thai** 1995 Nov; 78(11):578-85

Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Shinozaki K, et al. **Metabolism** 1996 Jun;45(6):731-7

AO-128, alpha-glucosidase inhibitor: antiobesity and antidiabetic actions in genetically obese-diabetic rats, Wistar fatty. Ikeda H, et al. **Obes Res** 1995 Nov;3 Suppl 4:617S-621S

Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Qualmann C, et al. **Scand J Gastroenterol** 1995 Sep;30(9):892-6

Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. Lu X, et al. **Virology** 1995 Nov 10;213(2):660-5

[alpha-Glucosidase inhibitors in the therapy of diabetes mellitus] Giorgino R, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:61S-65S (45 ref.) (Eng. Abstr.) **(Ita)**

BIOSYNTHESIS

MIG1-dependent and MIG1-independent glucose regulation of MAL gene expression in Saccharomyces cerevisiae. Hu Z, et al. **Curr Genet** 1995 Aug;28(3):258-66

GENETICS

Molecular cloning of cDNA and analysis of expression of the gene for alpha-glucosidase from the hypopharyngeal gland of the honeybee Apis mellifera L. Ohashi K, et al. **Biochem Biophys Res Commun** 1996 Apr 16;221(2):380-5

Identification of a small deletion in one allele of patients with infantile form of glycogen storage disease type II. Shieh JJ, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):322-6

AGI, a previously unreported D. melanogaster alpha-glucosidase: partial purification, characterization, and cytogenetic mapping. Parker GF, et al. **Biochem Genet** 1996 Apr;34(3-4):117-31

Two genes encoding midgut-specific maltase-like polypeptides from Anopheles gambiae. Zheng L, et al. **Exp Parasitol** 1995 Nov;81(3):272-83

Localization of the human glucosidase I gene to chromosome 2p12-p13 by fluorescence in situ hybridization and PCR analysis of somatic cell hybrids. Kalz-Füller B, et al. **Genomics** 1996 Jun 15;34(3):442-3

Molecular cloning, sequencing, and expression of a cDNA encoding alpha-glucosidase from Mucor javanicus. Sugimoto M, et al. **J Biochem (Tokyo)** 1996 Mar; 119(3):500-5

Prenatal diagnosis of glycogen storage disease type II: enzyme assay or mutation analysis? Kleijer WJ, et al. **Pediatr Res** 1995 Jul;38(1):103-6

Molecular cloning and characterization of a gibberellin-inducible, putative alpha-glucosidase gene from barley. Tibbot BK, et al. **Plant Mol Biol** 1996 Jan; 30(2):229-41

ISOLATION & PURIFICATION

AGI, a previously unreported D. melanogaster alpha-glucosidase: partial purification, characterization, and cytogenetic mapping. Parker GF, et al. **Biochem Genet** 1996 Apr;34(3-4):117-31

Purification and characterization of alpha-glucosidase complex from the intestine of the frog, Rana japonica. Takesue Y, et al. **Biochim Biophys Acta** 1996 Sep 5; 1296(2):152-8

METABOLISM

Effect of chronic ethanol consumption on the activities of residual small bowel brush-border enzymes after proximal jejunum resection in the rat. Zucoloto S, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):152-5

The presence of alpha-glucosidase, glycerophosphocholine and carnitine in the epididymis and ejaculate of the vervet monkey (Cercopithecus aethiops) and the Chacma baboon (Papio ursinus). Fourie MH, et al. **Andrologia** 1995 Jul-Aug;27(4):239-43

New discriminatory level for glucosidase activity to diagnose epididymal obstruction or dysfunction. Kret B, et al. **Arch Androl** 1995 Jul-Aug;35(1):29-33

Maltitol and maltobionate act differently on maltose- and maltooligosaccharide hydrolysis by human small intestinal glucoamylase-maltase indicating two different enzyme binding modes. Günther S, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):295-302

Lysosomal alpha-glucosidase: cell-specific processing and altered maturation in HT-29 colon cancer cells. Francí C, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):33-40

Properties and stabilization of an extracellular alpha-glucosidase from the extremely thermophilic archaebacteria Thermococcus strain AN1: enzyme activity at 130 degrees C. Piller K, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):197-205

Characterization of partially purified alpha-glucosidase in the insoluble fraction of bovine crystalline lens. Kamei A, et al. **Biol Pharm Bull** 1995 Aug;18(8):1133-7

Unequivocal identification of Asp-214 as the catalytic nucleophile of Saccharomyces cerevisiae alpha-glucosidase using 5-fluoro glycosyl fluorides. McCarter JD, et al. **J Biol Chem** 1996 Mar 22;271(12):6889-94

Effect of a detergent Triton X-100 on growth and alpha-glucosidase production by the thermophilic fungus Malbranchea sulfurea. Gupta AK, et al. **Microbios** 1995; 84(339):127-30

A carbohydrate-degrading enzyme from Candida albicans: correlation between alpha-glucosidase activity and fungal growth. Bramono K, et al. **Mycoses** 1995 Sep-Oct; 38(9-10):349-53

High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Van Hove JL, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):65-70

ALPHA-HELICAL CONFORMATION, PROTEIN see **PROTEIN STRUCTURE, SECONDARY**

ALPHA-HEPARIN see **HEPARIN**

20 ALPHA-HYDROXYPROGESTERONE see **DIHYDROPROGESTERONE**

ALPHA-INTERFERON see **INTERFERON-ALPHA**

ALPHA-KETOACID CARBOXYLASE see **PYRUVATE DECARBOXYLASE**

ALPHA-LINOLENIC ACID

ADMINISTRATION & DOSAGE

Effects of dietary alpha-linolenic acid and strain of hen on the fatty acid composition, storage stability, and flavor characteristics of chicken eggs. Ahn DU, et al. **Poult Sci** 1995 Sep;74(9):1540-7

ANALYSIS

Separation of gamma- and alpha-linolenic acid containing triacylglycerols by capillary supercritical fluid chromatography. Manninen P, et al. **Lipids** 1995 Jul; 30(7):665-71

BIOSYNTHESIS

Synthesis of linoleate and alpha-linolenate by chain elongation in the rat. Cunnane SC, et al. **Lipids** 1995 Aug; 30(8):781-3

BLOOD

Biochemical effects of dietary linoleic/alpha-linolenic acid ratio in term infants. Jensen CL, et al. **Lipids** 1996 Jan; 31(1):107-13

DEFICIENCY

Influence of a dietary alpha-linolenic acid deficiency on learning in the Morris water maze and on the effects of morphine. Francès H, et al. **Eur J Pharmacol** 1996 Mar 18;298(3):217-25

alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. Delion S, et al. **J Neurochem** 1996 Apr;66(4):1582-91

Effect of dietary alpha-linolenic acid deficiency on habituation. Frances H, et al. **Life Sci** 1996;58(21):1805-16

Effects of dietary alpha-linolenic acid deficiency on neuromuscular and cognitive functions in mice. Francès H, et al. **Life Sci** 1995;57(21):1935-47

METABOLISM

Nutritional attributes of dietary flaxseed oil [letter; comment] Mantzioris E, et al. **Am J Clin Nutr** 1995 Oct;62(4):841-2 . Comment on: Am J Clin Nutr 1995 Jan;61(1):62-8.

The desaturation and elongation of linolenic acid and eicosapentaenoic acid by hepatocytes and liver microsomes from rainbow trout (Oncorhynchus mykiss) fed diets containing fish oil or olive oil. Buzzi M, et al. **Biochim Biophys Acta** 1996 Jan 19;1299(2):235-44

Immobilization of lipases on polyethylene and application to perilla oil hydrolysis for production of alpha-linolenic acid. Watanabe T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun;41(3):307-12

Essential fatty acid uptake and metabolism in the developing rodent brain. Pawlosky RJ, et al. **Lipids** 1996 Mar;31 Suppl:S103-7

Metabolism of linoleic and alpha-linolenic acids in cultured cardiomyocytes: effect of different N-6 and N-3 fatty acid supplementation. Bordoni A, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):217-22

[The utilization of [9,10-(3)H] stearic and [1-(14)C] linolenic acids in the in-vitro synthesis of lipids in ruminant tissues] Zakhariv OIa, et al. **Zh Evol Biokhim Fiziol** 1995 Jul-Aug; 31(4):404-9 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Effect of a high alpha-linolenate and high linoleate diet on membrane-associated enzyme activities in rat brain--modulation of Na+, K+- ATPase activity at suboptimal concentrations of ATP. Tsutsumi T, et al. **Biol Pharm Bull** 1995 May;18(5):664-70

Alpha-linolenic acid in rapeseed oil partly compensates for the effect of fish restriction on plasma long chain n-3 fatty acids. Valsta LM, et al. **Eur J Clin Nutr** 1996 Apr; 50(4):229-35

Effect of dietary alpha-linolenic acid intake on incorporation of docosahexaenoic and arachidonic acids into plasma phospholipids of term infants. Sauerwald TU, et al. **Lipids** 1996 Mar;31 Suppl:S131-5

Effects of dietary alpha- and gamma-linolenic acids on liver fatty acids, lipid metabolism, and survival in sepsis. Larsson-Backström C, et al. **Shock** 1995 Jul;4(1):11-20

STANDARDS

alpha-Linolenic acid: a preventive in secondary coronary events? Hartman IS. **Nutr Rev** 1995 Jul;53(7):194-7 (13 ref.)

THERAPEUTIC USE

Effects of intravenous perilla oil emulsion on nutritional status, polyunsaturated fatty acid composition of tissue phospholipids, and thromboxane A2 production in streptozotocin-induced diabetic rats. Ikeda A, et al. **Nutrition** 1995 Sep-Oct;11(5):450-5

Protective capability of dietary Zizyphus mistol seed oil, rich in 18:3, n-3, on the development of two murine mammary gland adenocarcinomas with high or low metastatic potential. Muñoz SF, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Aug; 53(2):135-8

TOXICITY

Suppressing effect of perilla oil on azoxymethane-induced foci of colonic aberrant crypts in rats. Onogi N, et al. **Carcinogenesis** 1996 Jun;17(6):1291-6

Effects of metal ions on lipid peroxidation in cultured rat hepatocytes loaded with alpha-linolenic acid. Furono K, et al. **J Toxicol Environ Health** 1996 Jun 7;48(2):121-9

ALPHA-LIPOPROTEIN DEFICIENCY, FAMILIAL see **TANGIER DISEASE**

ALPHA-LIPOPROTEINS see **LIPOPROTEINS, HDL**

ALPHA-MACROFETOPROTEINS see **ALPHA-MACROGLOBULINS**

ALPHA-MACROGLOBULINS

Inhibition and entrapment of aspartic proteinases by alpha 2-macroglobulin. Athauda SB, et al. **Adv Exp Med Biol** 1995;362:305-13

[From the Smart alpha 2-macroglobulin to single molecule biochemistry] Ikai A. **Seikagaku** 1996 Mar;68(3):179-95 (47 ref.) **(Jpn)**

[Direct analysis of the peptide bond cleavage by rapid quenching method] Shibuya N, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1959-62 (3 ref.) **(Jpn)**

ANALYSIS

Acute-phase proteins and serologic profiles of chagasic children from an endemic area in Bolivia. Medrano-Mercado N, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):154-61

Development and clinical application of a new ELISA assay to determine plasmin-alpha2-antiplasmin complexes in plasma. Montes R, et al. **Br J Haematol** 1996 Mar; 92(4):979-85

Subcellular localization of the low density lipoprotein receptor-related protein (alpha 2-macroglobulin receptor) in human brain. Tooyama I, et al. **Brain Res** 1995 Sep 11; 691(1-2):235-8

Quantitative immunoassay for complexes of prostate-specific antigen with alpha2-macroglobulin. España F, et al. **Clin Chem** 1996 Apr;42(4):545-50

Mediators of fibrinolysis in orthotopic liver transplantation. Cheema SP, et al. **Clin Transplant** 1996 Feb;10(1 Pt 1):24-7

Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1-proteinase inhibitor, and alpha2-macroglobulin. Grinnell F, et al. **J Invest Dermatol** 1996 Feb;106(2):335-41

[alpha 2-Macroglobulin] Ohtani H. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:210-2 (10 ref.) **(Jpn)**

BIOSYNTHESIS

alpha2-Macroglobulin is mainly produced by cancer cells and not by hepatocytes in rats with colon carcinoma metastases in liver. Smorenburg SM, et al. **Hepatology** 1996 Mar;23(3):560-70

Transcription factors Stat3 and Stat5b are present in rat liver nuclei late in an acute phase response and bind interleukin-6 response elements. Ripperger JA, et al. **J Biol Chem** 1995 Dec 15;270(50):29998-30006

The kidney is a major site of alpha(2)-antiplasmin production. Menoud PA, et al. **J Clin Invest** 1996 Jun 1;97(11):2478-84

Expression of mouse alpha-macroglobulins, lipoprotein receptor-related protein, LDL receptor, apolipoprotein E, and lipoprotein lipase in pregnancy. Overbergh L, et al. **J Lipid Res** 1995 Aug;36(8):1774-86

Heterogeneity in the synthesis of alpha-macroglobulins in outbred Swiss albino mice acutely infected with Trypanosoma cruzi. Luz MR, et al. **Parasitol Res** 1995; 81(8):662-7

Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Schaefer TS, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9097-101

CHEMISTRY

Purification and characterization of a tetrameric alpha-macroglobulin proteinase inhibitor from the gastropod mollusc Biomphalaria glabrata. Bender RC, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):893-900

Design of a new protease inhibitor by the manipulation of the bait region of alpha 2-macroglobulin: inhibition of the tobacco etch virus protease by mutant alpha 2-macroglobulin. Van Rompaey L, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):191-5

Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera. Heeb MJ, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):917-23

Thiol ester cleavage-dependent conformational change in human alpha 2-macroglobulin. Influence of attacking nucleophile and of Cys949 modification. Gettins PG. **Biochemistry** 1995 Sep 26;34(38):12233-40

Preparation and characterization of a C-terminal fragment of pregnancy zone protein corresponding to the receptor-binding peptide from human alpha 2-macroglobulin. Jensen PE, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):254-8

Shared amino acid sequences between glutamic acid decarboxylase 65 and 67 and alpha-2-macroglobulin. A focus for cross-reactive autoantibodies? [letter] [see comments] Norazmi MN, et al. **Diabetologia** 1995 Jul; 38(7):874-5. Comment in: Diabetologia 1996 Feb;39(2):246-7.

Alpha 2-macroglobulin conformation determines binding affinity for activin A and plasma clearance of activin A/alpha 2-macroglobulin complex. Niemuller CA, et al. **Endocrinology** 1995 Dec;136(12):5343-9

Crystallisation and preliminary X-ray analysis of the receptor-binding domain of human and bovine alpha 2-macroglobulin. Dolmer K, et al. **FEBS Lett** 1995 Sep 18;372(1):93-5

Mechanical unfolding of alpha2-macroglobulin molecules with atomic force microscope. Mitsui K, et al. **FEBS Lett** 1996 Apr 29;385(1-2):29-33

Expression and refolding of a high-affinity receptor binding domain from rat alpha 1-macroglobulin. Nielsen KL, et al. **FEBS Lett** 1995 Oct 16;373(3):296-8

Low resolution X-ray structure of human methylamine-treated alpha 2-macroglobulin. Andersen GR, et al. **J Biol Chem** 1995 Oct 20;270(42):25133-41

Studies of complexes between proteases, substrates and the protease inhibitor alpha 2-macroglobulin using capillary electrophoresis with laser-induced fluorescence detection. Reif OW, et al. **J Chromatogr A** 1995 Nov 17; 716(1-2):363-9

DRUG EFFECTS

Purification and characterization of three alpha 2-antiplasmin and alpha 2-macroglobulin inactivating enzymes from the venom of the Mexican west coast rattlesnake (Crotalus basiliscus). Svoboda P, et al. **Toxicon** 1995 Oct; 33(10):1331-46

GENETICS

Synthesis of a Cys949Tyr alpha 2-macroglobulin thiol ester mutant: co-transfection with wild-type alpha 2-macroglobulin in an episomal expression system. Van Rompaey L, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):183-90

Expression and distribution of low density lipoprotein receptor-related protein mRNA in the rat central nervous system. Ishiguro M, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):37-46

The LIF response element of the alpha 2 macroglobulin gene confers LIF-induced transcriptional activation in embryonal stem cells. Hocke GM, et al. **Cytokine** 1995 Aug; 7(6):491-502

Expression and refolding of a high-affinity receptor binding domain from rat alpha 1-macroglobulin. Nielsen KL, et al. **FEBS Lett** 1995 Oct 16;373(3):296-8

Transcription factors Stat3 and Stat5b are present in rat liver nuclei late in an acute phase response and bind interleukin-6 response elements. Ripperger JA, et al. **J Biol Chem** 1995 Dec 15;270(50):29998-30006

IMMUNOLOGY

Receptor-linked antigen delivery system. Importance of autologous alpha 2-macroglobulin in the development of peptide vaccine. Mitsuda S, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):399-405

Molecular mimicry and the T-cell repertoire [letter; comment] Baum H, et al. **Diabetologia** 1996 Feb;39(2):246-7 . Comment on: Diabetologia 1995 Jul;38(7):874-5.

Shared amino acid sequences between glutamic acid decarboxylase 65 and 67 and alpha-2-macroglobulin. A focus for cross-reactive autoantibodies? [letter] [see comments] Norazmi MN, et al. **Diabetologia** 1995 Jul; 38(7):874-5. Comment in: Diabetologia 1996 Feb;39(2):246-7.

METABOLISM

Interleukin 1 beta (IL-1 beta) and the IL-1 beta-alpha 2-macroglobulin complex upregulate the platelet-derived growth factor alpha-receptor on rat pulmonary fibroblasts. Lindroos PM, et al. **Am J Respir Cell Mol Biol** 1995 Oct; 13(4):455-65

Synthesis of a Cys949Tyr alpha 2-macroglobulin thiol ester mutant: co-transfection with wild-type alpha 2-macroglobulin in an episomal expression system. Van Rompaey L, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):183-90

Differences in the binding of transforming growth factor beta 1 to the acute-phase reactant and constitutively synthesized alpha-macroglobulins of rat. Webb DJ, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):579-86

ALPHA-MACROGLOBULINS

Thiol ester cleavage-dependent conformational change in human alpha 2-macroglobulin. Influence of attacking nucleophile and of Cys949 modification. Gettins PG. **Biochemistry** 1995 Sep 26;34(38):12233-40

Nickel is a specific inhibitor for the binding of activated alpha 2-macroglobulin to the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Hussain MM, et al. **Biochemistry** 1995 Dec 12; 34(49):16074-81

Evaluation of plasma alpha-2-macroglobulin and interactions with tumour necrosis factor-alpha in horses with endotoxemic signs. Coté N, et al. **Can J Vet Res** 1996 Apr; 60(2):150-7

Elastase binding capacity of alpha 2-macroglobulin and its association with glucocorticoid concentration in southern African black patients with hepatocellular carcinoma. Gaillard MC, et al. **Clin Chim Acta** 1995 Sep 15; 240(2):179-85

Reaction of human alpha2-antiplasmin and plasmin stopped-flow fluorescence kinetics. Christensen U, et al. **FEBS Lett** 1996 May 27;387(1):58-62

Localization of alpha 2-macroglobulin protein and messenger RNA in rat liver fibrosis: evidence for the synthesis of alpha 2-macroglobulin within Schistosoma mansoni egg granulomas. Tiggelman AM, et al. **Hepatology** 1996 May; 23(5):1260-7

Urinary excretion rate and clearance of IgG4 and alpha 2-macroglobulin in type 2 diabetic patients. Ito S, et al. **Horm Metab Res** 1995 Jun;27(6):303-4

Identification of the serum factor required for liposome-primed activation of mouse peritoneal macrophages. Modified alpha 2-macroglobulin enhances Fc gamma receptor-mediated phagocytosis of opsonized sheep red blood cells. Murai M, et al. **Immunology** 1995 Sep;86(1):64-70

Modification of alpha 2-macroglobulin into a macrophage-activating factor through the action of liposome-stimulated B-cell membranous glycosidases. Murai M, et al. **Immunology** 1995 Sep;86(1):58-63

alpha 2-Macroglobulin binds to and inhibits mannose-binding protein-associated serine protease. Terai I, et al. **Int Immunol** 1995 Oct;7(10):1579-84

Selective mutations in cloned and expressed alpha-macroglobulin receptor binding fragment alter binding to either the alpha2-macroglobulin signaling receptor or the low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor. Howard GC, et al. **J Biol Chem** 1996 Jun 14;271(24):14105-11

Identification of residues in alpha-macroglobulins important for binding to the alpha2-macroglobulin receptor/Low density lipoprotein receptor-related protein. Nielsen KL, et al. **J Biol Chem** 1996 May 31;271(22):12909-12

Analysis of ligand binding to the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that lipoprotein lipase and the carboxyl-terminal domain of the receptor-associated protein bind to the same site. Nielsen MS, et al. **J Biol Chem** 1995 Oct 6; 270(40):23713-9

Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. Qiu WQ, et al. **J Biol Chem** 1996 Apr 5;271(14):8443-51

Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha2-macroglobulin and pregnancy zone protein. Valnickova Z, et al. **J Biol Chem** 1996 May 31;271(22):12937-43

Ligand-toxin hybrids directed to the alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein exhibit lower toxicity than native Pseudomonas exotoxin. Zdanovsky AG, et al. **J Biol Chem** 1996 Mar 15; 271(11):6122-8

alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. Conese M, et al. **J Cell Biol** 1995 Dec;131(6 Pt 1):1609-22

Altered interaction of Cis-dichlorodiammineplatinum(II)--modified alpha 2-macroglobulin (alpha 2M) with the low density lipoprotein receptor-related protein/alpha 2M receptor but not the alpha 2M signaling receptor. Howard GC, et al. **J Clin Invest** 1996 Mar 1;97(5):1193-203

Elevated conversion of alpha-2-macroglobulin to the complexed form in gingival crevicular fluid from adult periodontitis patients. Rosin M, et al. **J Periodontal Res** 1995 Nov;30(6):436-44

Study on proteinase-inhibiting capacity of plasma alpha 2-macroglobulin in idiopathic nephrotic syndrome. Asami T, et al. **Nephron** 1996;72(4):512-7

In situ hybridization studies of alpha 2-macroglobulin receptor and receptor-associated protein in human prostate carcinoma. McGarvey T, et al. **Prostate** 1996 May; 28(5):311-7

TAT and PAP in hemodialysis patients: two cats in a bag? [letter] Haznedaroğlu IC, et al. **Thromb Res** 1995 Dec 1; 80(5):447-9

[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6-9):86-8 (Eng. Abstr.) **(Pol)**

[Antithrombin III and alpha 2-antiplasmin in blood of patients operated on for benign prostatic hyperplasia] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6-9):75-6 (Eng. Abstr.) **(Pol)**

[The effect of plasmin and its complexes with alpha 2-antiplasmin and alpha 2-macroglobulin on secretion of proteinase and plasminogen inhibitors from peripheral mononuclear cells] Zhabin SG, et al. **Vopr Med Khim** 1995 May-Jun;41(3):34-7 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2 Perides G, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):690-5

Clearance of human factor XIa-inhibitor complexes in rats. Wuillemin WA, et al. **Br J Haematol** 1996 Jun 2;93(4):950-4

Activated alpha 2-macroglobulin promotes mitogenesis in rat vascular smooth muscle cells by a mechanism that is independent of growth-factor-carrier activity. Webb DJ, et al. **Eur J Biochem** 1995 Dec 15;234(3):714-22

Inhibition of transforming growth factor-beta-induced cataractous changes in lens explants by ocular media and alpha 2-macroglobulin. Schulz MW, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1509-19

Native and activated forms of alpha 2-macroglobulin increase expression of platelet-derived growth factor alpha-receptor in vascular smooth muscle cells. Evidence for autocrine transforming growth factor-beta activity. Weaver AM, et al. **J Biol Chem** 1995 Dec 22; 270(51):30741-8

Inhibition of long-term potentiation development in rat hippocampal slice by alpha 2-macroglobulin, an acute-phase protein in the brain. Cavuş I, et al. **J Neurosci Res** 1996 Feb 1;43(3):282-8

Inhibition of cysteine proteinase from Schistosoma mansoni larvae by alpha-macroglobulin from the plasma of Biomphalaria glabrata. Fryer SE, et al. **J Parasitol** 1996 Apr;82(2):343-7

PHYSIOLOGY

Complex formation between PSA isoenzymes and protease inhibitors. Leinonen J, et al. **J Urol** 1996 Mar; 155(3):1099-103

URINE

A radioimmunometric assay for urinary alpha 2-macroglobulin. Ito S, et al. **Tohoku J Exp Med** 1995 Jul;176(3):137-47

[Differential diagnosis of rejection after kidney transplantation. Noninvasive rapid diagnosis by determining special urinary proteins] Steinhoff J. **Fortschr Med** 1995 Dec 20;113(35-36):507-9 (Eng. Abstr.) **(Ger)**

ALPHA-METHYLDOPA see **METHYLDOPA**

ALPHA-MSH

ADMINISTRATION & DOSAGE

Alpha-melanocyte-stimulating hormone reduces endotoxin-induced liver inflammation. Chiao H, et al. **J Clin Invest** 1996 May 1;97(9):2038-44

ANALOGS & DERIVATIVES

Identification of ligand binding residues in extracellular loops of the melanocortin 1 receptor. Chhajlani V, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):521-5

Spin label and 2H-NMR studies on the interaction of melanotropic peptides with lipid bilayers. Biaggi MH, et al. **Eur Biophys J** 1996;24(4):251-9

High-performance liquid chromatographic assay for Melanotan-1 ([Nle4-DPhe7]alpha-melanocyte-stimulating hormone) in biological matrices. Surendran N, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):235-42

Topographical modification of melanotropin peptide analogues with beta-methyltryptophan isomers at position 9 leads to differential potencies and prolonged biological activities. Haskell-Luevano C, et al. **J Med Chem** 1995 Nov 10;38(23):4720-9

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Dorr RT, et al. **Life Sci** 1996;58(20):1777-84

Changes in dopaminergic control of circulating melanocyte-stimulating hormone-related peptides at puberty. Facchinetti F, et al. **Pediatr Res** 1995 Jul; 38(1):91-4

The melanotropic peptide, [Nle4,D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation. Jiang J, et al. **Pigment Cell Res** 1995 Dec; 8(6):314-23

ANTAGONISTS & INHIBITORS

Melatonin antagonizes alpha-melanocyte-stimulating hormone enhancement of melanogenesis in mouse melanoma cells by blocking the hormone-induced accumulation of the c locus tyrosinase. Valverde P, et al. **Eur J Biochem** 1995 Aug 15;232(1):257-63

Inhibition of alpha-MSH secretion is associated with increased cyclic-AMP egress from the neurointermediate lobe of Xenopus laevis. Leenders HJ, et al. **Life Sci** 1995 Nov 17;57(26):2447-53

Characterization of a putative alpha-MSH antagonist 153N-6 at melanocortin receptor subtypes by radioligand binding. Chhajlani V. **Peptides** 1996;17(2):349-51

BIOSYNTHESIS

alpha-MSH production, receptors, and influence on neopterin in a human monocyte/macrophage cell line. Rajora N, et al. **J Leukoc Biol** 1996 Feb;59(2):248-53

N-Acetyltransferase mechanism for alpha-melanocyte stimulating hormone regulation in rat ageing. Cangemi L, et al. **Neurosci Lett** 1995 Dec 1;201(1):65-8

BLOOD

Domestic cats show episodic variation in plasma concentrations of adrenocorticotropin, alpha-melanocyte-stimulating hormone (alpha-MSH), cortisol and thyroxine with circadian variation in plasma alpha-MSH concentrations. Kemppainen RJ, et al. **Eur J Endocrinol** 1996 May;134(5):602-9

Plasma concentration of cytokine antagonists in patients with HIV infection. Catania A, et al. **Neuroimmunomodulation** 1994 Jan;1(1):42-9

Serum levels of prolactin and alpha-melanotrophin and structure of the ovary during the reproductive cycle of Columba livia (domestic pigeon). Castagnino RA, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1994;52(2):5-10

[Serum and hypophyseal profiles of alpha-melanotropin and prolactin during the reproductive cycle of Leptodactylus ocellatus] Vivas AB, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(1):15-8 (Eng. Abstr.) **(Spa)**

METABOLISM

Agouti structure and function: characterization of a potent alpha-melanocyte stimulating hormone receptor antagonist. Willard DH, et al. **Biochemistry** 1995 Sep 26; 34(38):12341-6

Immunohistochemical evidence of alpha-, beta- and gamma 3-melanocyte stimulating hormone expression in cutaneous malignant melanoma of nodular type. Liu PY, et al. **J Dermatol Sci** 1995 Nov;10(3):203-12

The anticytokine neuropeptide alpha-melanocyte-stimulating hormone in synovial fluid of patients with rheumatic diseases: comparisons with other anticytokine molecules. Catania A, et al. **Neuroimmunomodulation** 1994 Sep-Oct;1(5):321-8

Binding of anti-inflammatory alpha-melanocyte-stimulating-hormone peptides and proinflammatory cytokines to receptors on melanoma cells. Lyson K, et al. **Neuroimmunomodulation** 1994 Mar-Apr; 1(2):121-6

Interaction of alpha-MSH and substance P with interfaces containing gangliosides. González M, et al. **Peptides** 1996; 17(2):269-74

PHARMACOLOGY

Alpha-melanocyte stimulating hormone induces collagenase/matrix metalloproteinase-1 in human dermal fibroblasts. Kiss M, et al. **Biol Chem Hoppe Seyler** 1995 Jul;376(7):425-30

The presence and effects of mammalian signal molecules in immunocytes of the insect Leucophaea maderae. Scharrer B, et al. **Cell Tissue Res** 1996 Jan;283(1):93-7

Alpha-melanocyte stimulating hormone-induced pigmentation is blocked by depletion of protein kinase C. Park HY, et al. **Exp Cell Res** 1996 Aug 25;227(1):70-9

Agouti protein can act independently of melanocyte-stimulating hormone to inhibit melanogenesis. Hunt G, et al. **J Endocrinol** 1995 Nov;147(2):R1-4

Pro-opiomelanocortin-derived peptides induce IL-10 production in human monocytes. Bhardwaj RS, et al. **J Immunol** 1996 Apr 1;156(7):2517-21

alpha-Melanocyte-stimulating hormone induces hapten-specific tolerance in mice. Grabbe S, et al. **J Immunol** 1996 Jan 15;156(2):473-8

The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats. Ceriani G, et al. **Neuroimmunomodulation** 1994 Jan;1(1):28-32

Effects of luteinizing-hormone-releasing hormone, alpha-melanocyte-stimulating hormone, naloxone, dexamethasone and indomethacin on interleukin-2-induced corticotropin-releasing factor release. Karanth S, et al. **Neuroimmunomodulation** 1995 May-Jun;2(3):166-73

Alpha-melanocyte-stimulating hormone inhibits corticotropin-releasing factor release by blocking protein kinase C. Lyson K, et al. **Neuroimmunomodulation** 1994 May-Jun;1(3):153-8

Alpha-melanocyte-stimulating hormone suppresses antigen-stimulated T cell production of gamma-interferon. Taylor AW, et al. **Neuroimmunomodulation** 1994 May-Jun; 1(3):188-94

alpha-MSH-induced behavior: changes after diazepam and baclofen administration related with cyclic AMP levels. Cremer C, et al. **Peptides** 1995;16(5):821-5

Synergic action of gangliosides on alpha-MSH-induced cyclic AMP levels in rat brain slices. Lezcano NE, et al. **Peptides** 1996;17(2):345-7

Alpha-melanocyte-stimulating hormone (MSH) inhibits insulin secretion in HIT-T 15 cells. Shimizu H, et al. **Peptides** 1995;16(4):605-8

PHYSIOLOGY

Elevations of somatolactin in plasma and pituitaries and increased alpha-MSH cell activity in red drum exposed

to black background and decreased illumination. Zhu Y, et al. **Gen Comp Endocrinol** 1996 Jan;101(1):21-31

The neuropeptide alpha-melanocyte-stimulating hormone: a key component of neuroimmunomodulation. Catania A, et al. **Neuroimmunomodulation** 1994 Mar-Apr;1(2):93-9 (65 ref.)

SECRETION

Electrochemical detection of exocytosis at single rat melanotrophs. Paras CD, et al. **Anal Chem** 1995 Oct 15; 67(20):3633-7

Biphasic effect of MCH on alpha-MSH release from the tilapia (Oreochromis mossambicus) pituitary. Gröneveld D, et al. **Peptides** 1995;16(5):945-9

Neuropeptide Y inhibits Ca2+ oscillations, cyclic AMP, and secretion in melanotrope cells of Xenopus laevis via a Y1 receptor. Scheenen WJ, et al. **Peptides** 1995;16(5):889-95

THERAPEUTIC USE

Effect of beta-endorphin and alpha-melanotropin on muscle wasting in mice. Smith ME, et al. **J Neurol Sci** 1995 May; 129 Suppl:127-30

ALPHA-NAPHTHYL ACETATE ESTERASE see **NAPHTHOL AS D ESTERASE**

ALPHA-NAPHTHYLAMINE see **1-NAPHTHYLAMINE**

ALPHA-NAPHTHYLISOTHIOCYANATE see **1-NAPHTHYLISOTHIOCYANATE**

ALPHA PARTICLES

Gross alpha-particle activities in the ground waters in Western Anatolia. Akyil S, et al. **Appl Radiat Isot** 1996 Jul;47(7):709-11

Induction of genomic instability in normal human bronchial epithelial cells by 238Pu alpha-particles. Kennedy CH, et al. **Carcinogenesis** 1996 Aug;17(8):1671-6

A comparison of four aqueous-miscible liquid scintillation cocktails with an alpha/beta discriminating Wallac 1415 liquid scintillation counter. DeVol TA, et al. **Health Phys** 1996 Jan;70(1):41-6

On the reduction of error in alpha track detector measurements of indoor 222Rn. Dudney CS, et al. **Health Phys** 1995 Oct;69(4):501-7

Alpha self-absorption in monazite dusts. Terry KW. **Health Phys** 1995 Oct;69(4):553-5

Estimation of single-strand breaks induced in the dried film of DNA by high energy alpha particle from a cyclotron. Basak J. **Indian J Biochem Biophys** 1996 Feb;33(1):35-8

Alpha particle mutagenesis of human lymphoblastoid cell lines. Amundson SA, et al. **Int J Radiat Biol** 1996 Aug; 70(2):219-26

Microdosimetry of haemopoietic stem cells irradiated by alpha particles from the short-lived products of 222Rn decays in fat cells and haemopoietic tissue. Charlton DE, et al. **Int J Radiat Biol** 1996 May;69(5):585-92

Evidence for an effect of exposure to low levels of alpha particle irradiation in larval cells of Drosophila as measured in the wing-spot test. Pimentel E, et al. **Mutat Res** 1996 Jul 5;354(1):139-42

Effects of alpha-particles on survival and chromosomal aberrations in human mammary epithelial cells. Durante M, et al. **Radiat Environ Biophys** 1995 Aug;34(3):195-204

The quality of DNA double-strand breaks: a Monte Carlo simulation of the end-structure of strand breaks produced by protons and alpha particles. Ottolenghi A, et al. **Radiat Environ Biophys** 1995 Nov;34(4):239-44

The effect of dimethyl sulfoxide on the induction of DNA double-strand breaks in V79-4 mammalian cells by alpha particles. deLara CM, et al. **Radiat Res** 1995 Oct; 144(1):43-9

Micronucleus induction in human lymphocytes: comparative effects of X rays, alpha particles, beta particles and neutrons and implications for biological dosimetry. Mill AJ, et al. **Radiat Res** 1996 May;145(5):575-85

The biological effectiveness of radon-progeny alpha particles. V. Comparison of oncogenic transformation by accelerator-produced monoenergetic alpha particles and by polyenergetic alpha particles from radon progeny. Miller RC, et al. **Radiat Res** 1996 Jul;146(1):75-80

Clastogenic effects of defined numbers of 3.2 MeV alpha particles on individual CHO-K1 cells. Nelson JM, et al. **Radiat Res** 1996 May;145(5):568-74

Influence of cell position relative to planar alpha-particle sources on survival and preneoplastic transformation of primary rat tracheal epithelial cells. Terzaghi-Howe M, et al. **Radiat Res** 1996 Apr;145(4):432-41

THERAPEUTIC USE

Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Zalutsky MR, et al. **Acta Oncol** 1996;35(3):373-9 (36 ref.)

Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Zalutsky MR, et al. **Recent Results Cancer Res** 1996;141:101-22 (41 ref.)

ALPHA 2-PLASMIN INHIBITOR see **ANTIPLASMIN**

ALPHA 1-PROTEASE INHIBITOR see **ALPHA 1-ANTITRYPSIN**

ALPHA 1-PROTEINASE INHIBITOR see **ALPHA 1-ANTITRYPSIN**

ALPHA RAYS see **ALPHA PARTICLES**

5-ALPHA-REDUCTASE, TESTOSTERONE see **TESTOSTERONE 5-ALPHA-REDUCTASE**

ALPHA RHYTHM

Relationship of genetically transmitted alpha EEG traits to anxiety disorders and alcoholism. Enoch MA, et al. **Am J Med Genet** 1995 Oct 9;60(5):400-8

Operant (biofeedback) control of left-right frontal alpha power differences: potential neurotherapy for affective disorders. Rosenfeld JP, et al. **Biofeedback Self Regul** 1995 Sep;20(3):241-58

Effects of sleep deprivation on spontaneous eye blink rate and alpha EEG power. Barbato G, et al. **Biol Psychiatry** 1995 Sep 1;38(5):340-1

Differentiation of alpha coma from awake alpha by nonlinear dynamics of electroencephalography. Kim YW, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jan;98(1):35-41

Reactivity of magnetic parieto-occipital alpha rhythm during visual imagery. Salenius S, et al. **Electroencephalogr Clin Neurophysiol** 1995 Dec; 95(6):453-62

Parental generalized EEG alpha activity predisposes to spike wave discharges in offspring. Doose H, et al. **Hum Genet** 1995 Dec;96(6):695-704

Alpha-theta brainwave neurofeedback training: an effective treatment for male and female alcoholics with depressive symptoms. Saxby E, et al. **J Clin Psychol** 1995 Sep; 51(5):685-93

Transient alpha coma following minor head trauma in a patient with primitive trigeminal artery. Morioka M, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):224-8

Aberrant interhemispheric alpha coherence on electroencephalography in schizophrenic patients during activation tasks. Morrison-Stewart SL, et al. **Psychol Med** 1996 May;26(3):605-12

The therapy by ischemic stress induces a durable EEG synchronization in alpha frequency band. Stoica E, et al. **Rom J Neurol Psychiatry** 1995 Jul-Dec;33(3-4):169-81

Determination of observer-rated alpha activity during sleep. Flanigan MJ, et al. **Sleep** 1995 Oct;18(8):702-6

The reliability of visual scoring of alpha EEG activity during sleep. MacLean AW, et al. **Sleep** 1995 Sep;18(7):565-9

[Perception and reproduction of time intervals in people with varying alpha- and beta-rhythm characteristics] Dzhebrailova TD. **Fiziol Cheloveka** 1995 Jul-Aug; 21(4):86-91 **(Rus)**

[Dynamics of rhythmic components of the EEG alpha-band under conditions of relaxation] Gorev AS. **Fiziol Cheloveka** 1995 Sep-Oct;21(5):51-7 **(Rus)**

[Correlation between the parameters of local and distant synchronization of brain potentials in a state of quiet wakefulness] Kiroĭ VN, et al. **Fiziol Cheloveka** 1996 May-Jun;22(3):18-21 **(Rus)**

[Parameters of alpha-rhythm and productivity of memorization] Mal'tseva IV, et al. **Fiziol Cheloveka** 1996 May-Jun;22(3):11-7 **(Rus)**

[Visual illusions and the alpha-rhythm EEG] Shevelev IA, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan-Feb; 46(1):34-9 (Eng. Abstr.) **(Rus)**

[A version of alpha coma] Ramírez Pérez A, et al. **Rev Neurol** 1995 Jan-Feb;23(119):134-5 (Eng. Abstr.) **(Spa)**

ALPHA-THALASSEMIA

BLOOD

Composition of the intra-erythroblastic precipitates in thalassaemia and congenital dyserythropoietic anaemia (CDA): identification of a new type of CDA with intra-erythroblastic precipitates not reacting with monoclonal antibodies to alpha- and beta-globin chains. Wickramasinghe SN, et al. **Br J Haematol** 1996 Jun 1; 93(3):576-85

Serum interleukin-8 levels in thalassemia intermedia. Dore F, et al. **Haematologica** 1995 Sep-Oct;80(5):431-3

Alterations and pathology of thalassemic red cells: comparison between alpha- and beta-thalassemia. Bunyaratvej A, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:257-60

COMPLICATIONS

Cardiovascular function during rest and exercise in patients with sickle-cell anemia and coexisting alpha thalassemia-2. Braden DS, et al. **Am J Hematol** 1996 Jun;52(2):96-102

Paradoxical increase of painful crises in sickle cell patients with alpha-thalassemia [letter; comment] Billett HH, et al. **Blood** 1995 Dec 1;86(11):4382. Comment on: Blood 1995 Jul 15;86(2):776-83.

DIAGNOSIS

Comparison of the HbH inclusion test and a PCR test in routine screening for alpha thalassaemia in Hong Kong. Chan AY, et al. **J Clin Pathol** 1996 May;49(5):411-3

Comparison of haemoglobin H inclusion bodies with embryonic zeta globin in screening for alpha thalassaemia. Chan LC, et al. **J Clin Pathol** 1995 Sep;48(9):861-4

Clinical problem-solving: if at first you don't succeed [letter; comment] Gambino R, et al. **N Engl J Med** 1996 Apr 4; 334(14):918-9; discussion 920. Comment on: N Engl J Med 1995 Dec 7;333(23):1557-60.

[Direct genotyping and antenatal diagnosis of deletional alpha-thalassemia of the southeast Asian type by polymerase chain reaction technique] Zhong M, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Oct;30(10):597-9 (Eng. Abstr.) **(Chi)**

[Thalassemia] Hattori Y. **Rinsho Byori** 1995 Aug;43(8):776-80 (8 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Prevalence of alpha-thalassemias in northern Thailand. Lemmens-Zygulska M, et al. **Hum Genet** 1996 Sep; 98(3):345-7

Hematologic disorders in children from southeast Asia. Glader BE, et al. **Pediatr Clin North Am** 1996 Jun; 43(3):665-81 (48 ref.)

Genetic problems and genetic services in Malaysia: a country report. Hassan K. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:11-5

Prevalence of hemoglobin E, alpha-thalassemia and glucose-6-phosphate dehydrogenase deficiency in 1,000 cord bloods studied in Bangkok. Tanphaichitr VS, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:271-4

GENETICS

A novel mutation in the putative DNA helicase XH2 is responsible for male-to-female sex reversal associated with an atypical form of the ATR-X syndrome. Ion A, et al. **Am J Hum Genet** 1996 Jun;58(6):1185-91

The alpha / beta and alpha 2 / alpha 1-globin mRNA ratios in different forms of alpha-thalassemia. Smetanina NS, et al. **Biochim Biophys Acta** 1996 Apr 12;1315(3):188-92

The relative levels of alpha 2-, alpha 1-, and zeta-mRNA in HB H patients with different deletional and nondeletional alpha-thalassemia determinants. Smetanina NS, et al. **Biochim Biophys Acta** 1996 Aug 23;1316(3):176-82

Inactivation of mouse alpha-globin gene by homologous recombination: mouse model of hemoglobin H disease. Chang J, et al. **Blood** 1996 Sep 1;88(5):1846-51

Age dependence of the gene frequency of alpha-thalassemia in sickle cell anemia in Cuba [letter] Martinez G, et al. **Blood** 1996 Sep 1;88(5):1898-9

Detection of alpha-thalassemia-1 (Southeast Asian type) and its application for prenatal diagnosis. Winichagoon P, et al. **Clin Genet** 1995 Jun;47(6):318-20

Developmental analysis of the Hba(th-J) mouse mutation: effects on mouse peri-implantation development and identification of two candidate genes. Hendrey J, et al. **Dev Biol** 1995 Nov;172(1):253-63

Molecular basis of alpha-thalassemia in Portugal. Peres MJ, et al. **Hemoglobin** 1995;19(6):343-52

Syndromal mental retardation due to mutations in a regulator of gene expression. Gibbons RJ, et al. **Hum Mol Genet** 1995;4 Spec No:1705-9 (24 ref.)

Rapid detection of point mutations and polymorphisms of the alpha-globin genes by DGGE and SSCA. Harteveld KL, et al. **Hum Mutat** 1996;7(2):114-22

The alpha-thalassemia/mental retardation syndromes. Gibbons RJ, et al. **Medicine (Baltimore)** 1996 Mar; 75(2):45-52 (32 ref.)

Molecular basis of alpha zero-thalassemia in northeast of Thailand. Fucharoen G, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:249-51

Molecular mechanisms of thalassemia in southeast Asia. Winichagoon P, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:235-40

The thalassemia syndromes lessons from molecular medicines index case. Benz EJ Jr. **Trans Am Clin Climatol Assoc** 1995; 107:20-36; discussion 35-6 (15 ref.)

[Genetic abnormality of unrecognized hemoglobin: alpha-thalassemia (editorial)] Orsini A, et al. **Arch Pediatr** 1996 Mar;3(3):210-2 **(Fre)**

METABOLISM

The interaction of alpha zero thalassaemia with Hb Icaria: three unusual cases of haemoglobinopathy H. Kanavakis E, et al. **Br J Haematol** 1996 Feb;92(2):332-5

Isolated beta-globin chains reproduce, in normal red cell membranes, the defective binding of spectrin to alpha-thalassaemic membranes. Shalev O, et al. **Br J Haematol** 1996 Aug;94(2):273-8

THERAPY

Haemolytic transfusion reactions due to Mi-antibodies; need to include MiltenbergerIII positive cells in pre-transfusion antibody screening in Hong Kong. Cheng G, et al. **Clin Lab Haematol** 1995 Jun;17(2):183-4

Lack of evidence of permanent engraftment after in utero

ALPHA-THALASSEMIA

fetal stem cell transplantation in congenital hemoglobinopathies. Westgren M, et al. **Transplantation** 1996 Apr 27;61(8):1176-9

ALPHA-TOXIN see **PHOSPHOLIPASE C**

ALPHA-TRANSDUCIN see **TRANSDUCIN**

ALPHA-TRICHOSANTHIN see **TRICHOSANTHIN**

ALPHA-VINCULIN see **VINCULIN**

ALPHACETYLMETHADOL see **METHADYL ACETATE**

ALPHAHERPESVIRINAE

CLASSIFICATION

Characterization of phocid herpesvirus-1 and -2 as putative alpha- and gammaherpesviruses of North American and European pinnipeds. Harder TC, et al. **J Gen Virol** 1996 Jan;77 (Pt 1):27-35

GENETICS

Molecular evolution of infectious laryngotracheitis virus (ILTV; gallid herpesvirus 1): an ancient example of the Alphaherpesviridae? Johnson MA, et al. **Vet Microbiol** 1995 Sep;46(1-3):221-31

A feline herpesvirus-1 recombinant with a deletion in the genes for glycoproteins gI and gE is effective as a vaccine for feline rhinotracheitis. Sussman MD, et al. **Virology** 1995 Dec 1;214(1):12-20

IMMUNOLOGY

Pathogenicity and vaccine efficacy of a thymidine kinase-deficient mutant of feline herpesvirus type 1 in cats. Yokoyama N, et al. **Arch Virol** 1996;141(3-4):481-94

Molecular basis of antigenic variation between the glycoproteins C of respiratory bovine herpesvirus 1 (BHV-1) and neurovirulent BHV-5. Chowdhury SI. **Virology** 1995 Nov 10;213(2):558-68

Glycoproteins gI and gE of feline herpesvirus-1 are virulence genes: safety and efficacy of a gI-gE deletion mutant in the natural host. Kruger JM, et al. **Virology** 1996 Jun 15; 220(2):299-308

ISOLATION & PURIFICATION

Inhibition of PCR by aqueous and vitreous fluids. Wiedbrauk DL, et al. **J Clin Microbiol** 1995 Oct;33(10):2643-6

ALPHAVIRUS

Mosquito-borne viruses and epidemic polyarthritis. Mackenzie JS, et al. **Med J Aust** 1996 Jan 15;164(2):90-3 (21 ref.)

GENETICS

Genetic conservation of Highlands J viruses. Cilnis MJ, et al. **Virology** 1996 Apr 15;218(2):343-51

[Analysis of the primary structure of segments of the Karelian fever virus genome] Uryvaev LV, et al. **Vopr Virusol** 1995 Sep-Oct;40(5):198-202 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Budding of alphaviruses. Strauss JH, et al. **Trends Microbiol** 1995 Sep;3(9):346-50 (34 ref.)

IMMUNOLOGY

Ockelbo virus (Togaviridae: Alphavirus) neutralizing antibodies in experimentally infected Swedish birds. Lundström JO, et al. **J Wildl Dis** 1996 Jan;32(1):87-93

PHYSIOLOGY

Prostaglandin A1 inhibits replication of Mayaro virus in Aedes albopictus cells. Barbosa JA, et al. **Braz J Med Biol Res** 1995 Jan;28(1):27-30

Serum concentration and increased temperature alter Mayaro virus RNA and protein synthesis in Aedes albopictus (mosquito)-infected cells. Motta MC, et al. **Braz J Med Biol Res** 1995 Jan;28(1):18-26

Studies on the replication of Mayaro virus grown in interferon treated cells. Rebello MC, et al. **Mem Inst Oswaldo Cruz** 1994 Oct-Dec;89(4):619-23

ALPHAVIRUS INFECTIONS

Mosquito-borne viruses and epidemic polyarthritis. Mackenzie JS, et al. **Med J Aust** 1996 Jan 15;164(2):90-3 (21 ref.)

DIAGNOSIS

IgG avidity in the diagnosis of acute Ross River virus infection. Kapeleris J, et al. **Dis Markers** 1996 Mar; 12(4):279-82

Detection of immunoglobulin G to a Sindbis-related virus by a membrane antigen enzyme immunoassay. Scalia G, et al. **New Microbiol** 1996 Jan;19(1):91-6

EPIDEMIOLOGY

What is the potential for future outbreaks of chikungunya, dengue and yellow fever in southern Africa? [editorial] Jupp PG, et al. **S Afr Med J** 1996 Jan;86(1):35-7 (20 ref.)

ETIOLOGY

Transfusions: how many cases of Ross River virus infection do we cause? [letter] Weinstein P, et al. **Med J Aust** 1995 Sep 4;163(5):276

IMMUNOLOGY

IgG avidity in the diagnosis of acute Ross River virus infection. Kapeleris J, et al. **Dis Markers** 1996 Mar; 12(4):279-82

Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis. Amor S, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):281-91

Regulation of lymphocyte homing into the brain during viral encephalitis at various stages of infection. Irani DN, et al. **J Immunol** 1996 May 15;156(10):3850-7

METABOLISM

Patterns of lymphokine production by Semliki Forest virus-specific T-cell hybridomas stimulated with different antigen-presenting cells. Watari E, et al. **Jpn J Med Sci Biol** 1995 Jun;48(3):131-43

MORTALITY

Inhibition of nitric oxide synthesis increases mortality in Sindbis virus encephalitis. Tucker PC, et al. **J Virol** 1996 Jun;70(6):3972-7

PATHOLOGY

Alphavirus-induced apoptosis in mouse brains correlates with neurovirulence. Lewis J, et al. **J Virol** 1996 Mar; 70(3):1828-35

PREVENTION & CONTROL

Bcl-2 protects mice against fatal alphavirus encephalitis. Levine B, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):4810-5

TRANSMISSION

Travel-related vector-borne virus infections in Germany. Schwarz TF, et al. **Arch Virol Suppl** 1996;11:57-65

Laboratory transmission of Sindbis virus by Aedes albopictus, Ae. aegypti, and Culex pipiens (Diptera: Culicidae). Dohm DJ, et al. **J Med Entomol** 1995 Nov;32(6):818-21

VETERINARY

Ockelbo virus (Togaviridae: Alphavirus) neutralizing antibodies in experimentally infected Swedish birds. Lundström JO, et al. **J Wildl Dis** 1996 Jan;32(1):87-93

Prevalence of hemagglutination-inhibition and neutralizing antibodies to arboviruses in horses of java. Widjaja S, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):109-13

VIROLOGY

Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis. Linn ML, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):407-11

Effect of E2 envelope glycoprotein cytoplasmic domain mutations on Sindbis virus pathogenesis. Levine B, et al. **J Virol** 1996 Feb;70(2):1255-60

ALPORT'S SYNDROME see **NEPHRITIS, HEREDITARY**

ALPRAZOLAM

ADMINISTRATION & DOSAGE

Long-term follow-up after a drug trial for panic disorder. Katschnig H, et al. **Br J Psychiatry** 1995 Oct;167(4):487-94

ADVERSE EFFECTS

Withdrawal of routine psychiatric medications in a general medical ward [letter] Sloan D. **Ir Med J** 1996 May-Jun; 89(3):116

Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. Bond AJ, et al. **J Affect Disord** 1995 Dec 13;35(3):117-23

Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition [letter] Ketter TA, et al. **J Clin Psychiatry** 1996 Jul;57(7):307

Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. Greene DS, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):399-408

CHEMISTRY

Structure and thermal stability of alprazolam and selected solvates. Caira MR, et al. **J Pharm Sci** 1995 Nov; 84(11):1379-84

DIAGNOSTIC USE

Studies with [11C]alprazolam: an agonist for the benzodiazepine receptor. Dobbs FR, et al. **Nucl Med Biol** 1995 May;22(4):459-66

PHARMACOKINETICS

Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk. Oo CY, et al. **Br J Clin Pharmacol** 1995 Sep;40(3):231-6

A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Yasui N, et al. **Clin Pharmacol Ther** 1996 May;59(5):514-9

PHARMACOLOGY

Liability to alprazolam abuse in daughters of alcoholics. Ciraulo DA, et al. **Am J Psychiatry** 1996 Jul;153(7):956-8

Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects. Semlitsch HV, et al. **Eur J Clin Pharmacol** 1995; 49(3):183-91

Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines. Benschop RJ, et al. **FASEB J** 1996 Mar;10(4):517-24

Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. Griebel G, et al. **Neuropharmacology** 1995 Dec;34(12):1625-33

Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Jenck F, et al. **Psychiatry Res** 1995 Jul 28;57(2):181-91

Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects. Fleishaker JC, et al. **Psychopharmacology (Berl)** 1995 Jul;120(2):169-76

A comparative study of the psychological effects of DN-2327, a partial benzodiazepine agonist, and alprazolam. Suzuki M, et al. **Psychopharmacology (Berl)** 1995 Oct; 121(4):442-50

POISONING

Allergic and toxic reaction to alprazolam [letter] Mur P, et al. **Postgrad Med J** 1995 Jul;71(837):444

THERAPEUTIC USE

Effects of alprazolam on the development of Moloney sarcoma virus-induced tumors in stressed mice. Freire-Garabal M, et al. **Cancer Detect Prev** 1996; 20(2):160-5

Effects of alprazolam on glucose regulation in diabetes. Results of double-blind, placebo-controlled trial. Lustman PJ, et al. **Diabetes Care** 1995 Aug;18(8):1133-9

Diazepam versus alprazolam for the treatment of panic disorder. Noyes R Jr, et al. **J Clin Psychiatry** 1996 Aug; 57(8):349-55

Premenstrual syndrome no progesterone; premenstrual dysphoric disorder no serotonin deficiency [see comments] van Leusden HA. **Lancet** 1995 Dec 2;346(8988):1443-4. Comment in: Lancet 1996 Jan 13;347(8994):122. Comment in: Lancet 1996 Feb 17;347(8999):470-1.

Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo. Laakman G, et al. **Psychopharmacology (Berl)** 1995 Jul;120(1):109-15

A multiple imputation strategy for clinical trials with truncation of patient data. Lavori PW, et al. **Stat Med** 1995 Sep 15;14(17):1913-25

[The efficacy of alprazolam in the therapy of panic disorders] Diukova GM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):9-13 (Eng. Abstr.) **(Rus)**

ALPRENOLOL

ANALOGS & DERIVATIVES

Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular beta-blocker, in dogs. Polgar P, et al. **Life Sci** 1995;56(14):1207-13

ANALYSIS

Enantioselective quantitation of (R)- and (S)-alprenolol by gas chromatography-mass spectrometry in human saliva an plasma. Höld KM, et al. **J Chromatogr Sci** 1996 Jan; 34(1):13-9

CHEMISTRY

Enantioselective quantitation of (R)- and (S)-alprenolol by gas chromatography-mass spectrometry in human saliva an plasma. Höld KM, et al. **J Chromatogr Sci** 1996 Jan; 34(1):13-9

METABOLISM

Cytochrome P450 isozymes involved in aromatic hydroxylation and side-chain N-desisopropylation of alprenolol in rat liver microsomes. Narimatsu S, et al. **Biol Pharm Bull** 1995 Aug;18(8):1060-5

ALPROSTADIL

ADMINISTRATION & DOSAGE

Papaverine and prostaglandin E1 gel applications for impotence. Chiang HS, et al. **Ann Acad Med Singapore** 1995 Sep;24(5):767–9

Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo–controlled, randomized, double–blind, multicenter clinical trial [see comments] Abraham E, et al. **Crit Care Med** 1996 Jan;24(1):10–5. Comment in: Crit Care Med 1996 Jan;24(1):3.

Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease. Kramer HH, et al. **Eur J Pediatr** 1995 Sep;154(9):700–7

Atypical Kawasaki disease with peripheral gangrene and myocardial infarction: therapeutic implications. von Planta M, et al. **Eur J Pediatr** 1995 Oct;154(10):830–4

An attempt to standardize the pharmacological diagnostic screening of vasculogenic impotence with prostaglandin E1. McMahon CG. **Int J Impot Res** 1995 Jun;7(2):83–90

Effect of prostaglandin E1 infusion on kidney function in patients with severe heart failure [letter] Wutte M, et al. **J Heart Lung Transplant** 1996 Mar;15(3):317–8

Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses [see comments] Bechara A, et al. **J Urol** 1996 Mar;155(3):913–4. Comment in: J Urol 1996 Mar;155(3):924–5.

Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis [see comments] Chen RN, et al. **J Urol** 1996 Jan;155(1):138–40. Comment in: J Urol 1996 Jan;155(1):147.

Quality of life in patients using self–administered intracavernous injections of prostaglandin E1 for erectile dysfunction. Gheorghiu S, et al. **J Urol** 1996 Jul;156(1):80–1

Re: The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction [letter; comment] Kim YC. **J Urol** 1995 Nov;154(5):1870–1. Comment on: J Urol 1995 Jan;153(1):80–1.

Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group [see comments] Linet OI, et al. **N Engl J Med** 1996 Apr 4; 334(14):873–7. Comment in: N Engl J Med 1996 Apr 4;334(14):913–4.

Injection therapy for erectile dysfunction [editorial; comment] Lipshultz LI. **N Engl J Med** 1996 Apr 4; 334(14):913–4. Comment on: N Engl J Med 1996 Apr 4;334(14):873–7.

Slow injection of prostaglandin E1 decreases associated penile pain. Gheorghiu D, et al. **Urology** 1996 Jun; 47(6):903–4

[Effects of prostaglandin E1 on plasma cytokine levels during pneumonectomy] Matsumoto Y, et al. **Masui** 1996 Mar; 45(3):304–8 (Eng. Abstr.) **(Jpn)**

[Effect of prostaglandin E1 on arterial ketone body ratio during and after hepatectomy] Nakayama M, et al. **Masui** 1995 Sep;44(9):1224–7 (Eng. Abstr.) **(Jpn)**

[Effects of amrinon and prostaglandin E1 on intraoperative central and peripheral temperatures during peripheral arterial surgery] Nonaka A, et al. **Masui** 1996 May; 45(5):576–81 (Eng. Abstr.) **(Jpn)**

[Plasma concentration of lidocaine in patients undergoing hepatectomy with continuous epidural anesthesia–influence of extent of hepatectomy and prostaglandin E1 infusion] Satoh O, et al. **Masui** 1996 May; 45(5):624–8 (Eng. Abstr.) **(Jpn)**

[Results of intra–arterial administration of PGE1 prostaglandin] Ciostek P, et al. **Wiad Lek** 1994 Oct; 47(19–20):750–2 (Eng. Abstr.) **(Pol)**

[The therapeutic and diagnostic potentials of the intra–corpora cavernosa use of alprostadil, Edex, in patients with erectile dysfunction] M.zo EB, et al. **Ter Arkh** 1995; 67(10):45–8 (Eng. Abstr.) **(Rus)**

[Prostaglandin E1 in the diagnosis and therapy of erectile disorders] Loran OB, et al. **Urol Nefrol (Mosk)** 1995 Jul–Aug;(4):35–8 (Eng. Abstr.) **(Rus)**

[Long–term results of the treatment with intracavernous injection of vasoactive drugs] Rodríguez Vela L, et al. **Arch Esp Urol** 1996 Apr;49(3):257–69 (25 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Alkalization does not alleviate penile pain induced by intracavernous injection of prostaglandin E1. Godschalk M, et al. **J Urol** 1996 Sep;156(3):999–1000

[Priapism after intracavernous injection of PgE1 in two cases of impotence following total cysto–prostatectomy] Llopis J, et al. **J Urol (Paris)** 1995;101(2):104–6 (Eng. Abstr.) **(Fre)**

[Stasis priapism secondary to PGE1: transformation into high–flow priapism] Negrín Díaz A, et al. **Actas Urol Esp** 1996 Mar;20(3):289–91 (Eng. Abstr.) **(Spa)**

ANALOGS & DERIVATIVES

Is misoprostol the drug of choice for induced cervical ripening in early pregnancy termination? Platz–Christensen JJ, et al. **Acta Obstet Gynecol Scand** 1995 Nov; 74(10):809–12

Blood loss in termination of early pregnancy with mifepristone and gemeprost. Prasad RN, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):329–31

Medical pregnancy termination in the presence of a massive uterine fibroid. Fenwick DK, et al. **Br J Clin Pract** 1995 Nov–Dec;49(6):332–3

The effects of gemeprost on the second trimester fetus. Lazda EJ, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):731–4

Uterine rupture during therapeutic abortion in the second trimester using mifepristone and prostaglandin [letter; comment] Thong KJ, et al. **Br J Obstet Gynaecol** 1995 Oct;102(10):844–5. Comment on: Br J Obstet Gynaecol 1995 Apr;102(4):332–3.

Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP–sensitive potassium channels. Hide EJ, et al. **Br J Pharmacol** 1995 Nov;116(5):2435–40

The effect of a synthetic 7–thiaprostaglandin E1 derivative, TEI–6122, on monocyte chemoattractant protein–1 induced chemotaxis in THP–1 cells. Tanaka H, et al. **Br J Pharmacol** 1995 Oct;116(4):2298–302

Oral misoprostol versus vaginal gemeprost for cervical dilatation prior to vacuum aspiration in women in the sixth to twelfth week of gestation. Ngai SW, et al. **Contraception** 1995 Jun;51(6):347–50

Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Baird DT, et al. **Hum Reprod** 1995 Jun;10(6):1521–7

Toxic epidermal necrolysis after mifepristone/gemeprost–induced abortion. Lecorvaisier–Pieto C, et al. **J Am Acad Dermatol** 1996 Jul; 35(1):112

Preferential binding of the novel prostaglandin SC–46275 to canine gastric versus intestinal receptors. Tsai BS, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):368–73

PGE0 inhibits collagen and glycosaminoglycan–synthesis in the rabbit arterial wall. Rodrigues M, et al. **Vasa** 1995; 24(4):333–6

[Termination of pregnancy in the 2nd trimester by serial administration of gemeprost vaginal suppositories. A retrospective study] Krauss T, et al. **Geburtshilfe Frauenheilkd** 1994 Nov;54(11):623–6 (Eng. Abstr.) **(Ger)**

[Premature termination of pregnancy in the 2nd and 3rd trimester. Serial administration of 1 mg gemeprost vaginal suppositories versus intravenous sulproston] Müller T, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):234–8 (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Prostaglandin synthesis by cumulus–oocyte complexes: effects on in vitro fertilization in mice. Viggiano JM, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):261–5

BLOOD

Plasma prostaglandin E1 concentrations and hemodynamics during intravenous infusions of prostaglandin E1 in humans and swine. Awas JA, et al. **Transplantation** 1996 Jun 15; 61(11):1624–9

[Prostaglandin E1 and its metabolites] Shio H, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:702–5 (9 ref.) **(Jpn)**

DIAGNOSTIC USE

The clinical assessment of erectile dysfunction: a comparison of nocturnal penile tumescence monitoring and intracavernosal injections. Bancroft J, et al. **Int J Impot Res** 1995 Jun;7(2):123–30

An attempt to standardize the pharmacological diagnostic screening of vasculogenic impotence with prostaglandin E1. McMahon CG. **Int J Impot Res** 1995 Jun;7(2):83–90

The effects of stress and coping upon the diagnostic intracavernous injection in men with erectile dysfunction. van der Borght W, et al. **J Psychosom Res** 1995 Oct; 39(7):865–73

The application of prostaglandin E1 indirect portal vein angiography and color Doppler ultrasound in patients with post–devascularization portal hypertension. Peng ZH, et al. **J Tongji Med Univ** 1995;15(3):154–7

Stress and the erectile response to intracavernosal prostaglandin E1 in men with erectile dysfunction. Granata A, et al. **Psychosom Med** 1995 Jul–Aug;57(4):336–44

[The therapeutic and diagnostic potentials of the intra–corpora cavernosa use of alprostadil, Edex, in patients with erectile dysfunction] M.zo EB, et al. **Ter Arkh** 1995; 67(10):45–8 (Eng. Abstr.) **(Rus)**

[Symposium on Edex (alprostadil) in the diagnosis and treatment of erectile dysfunction] Borisov VV. **Urol Nefrol (Mosk)** 1995 Nov–Dec;(6):53 **(Rus)**

[Prostaglandin E1 in the diagnosis and therapy of erectile disorders] Loran OB, et al. **Urol Nefrol (Mosk)** 1995 Jul–Aug;(4):35–8 (Eng. Abstr.) **(Rus)**

METABOLISM

Endothelin–1 and prostaglandin E2 levels increase in patients with burns [letter; comment] Aktan AO, et al. **J Am Coll Surg** 1995 Dec;181(6):583–4. Comment on: J Am Coll Surg 1995 Mar;180(3):318–22.

[Prostaglandin E1 and its metabolites] Shio H, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:702–5 (9 ref.) **(Jpn)**

PHARMACOKINETICS

Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. Cawello W, et al. **Br J Clin Pharmacol** 1995 Sep;40(3):273–6

Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Lea AP, et al. **Drugs Aging** 1996 Jan;8(1):56–74 (123 ref.)

A study in patients with erectile dysfunction comparing different formulations of prostaglandin E1. Alprostadil Study Group. Vanderschueren D, et al. **J Urol** 1995 Nov; 154(5):1744–7

PHARMACOLOGY

The effects of prostaglandin E1 on hepatic allograft vascular inflow: a prospective randomized double–blind study. Chavin KC, et al. **Am Surg** 1996 Mar;62(3):184–7

Endothelin–1 concentrations and optimisation of arterial oxygenation and venous admixture by selective pulmonary artery infusion of prostaglandin E1 during thoracotomy. Chen TL, et al. **Anaesthesia** 1996 May;51(5):422–6

The effects of lipo–prostaglandin E1 on axial pattern flaps in rabbits. Kuwahara H, et al. **Ann Plast Surg** 1995 Dec; 35(6):620–6

Prostaglandin E1 or prostacyclin in Euro–Collins solution fails to improve lung preservation. Kukkonen S, et al. **Ann Thorac Surg** 1995 Dec;60(6):1617–22

Prostaglandin I1 analogues, SM–10902 and SM–10906, affect human keratinocytes and fibroblasts in vitro in a manner similar to PGE1: therapeutic potential for wound healing. Kaneko F, et al. **Arch Dermatol Res** 1995;287(6):539–45

Platelet sensitivity to prostaglandin E1 inhibition is reduced in pre–eclampsia but not in nonproteinuric gestational hypertension. Torres PJ, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):19–24

Nitric oxide reduces body temperature and sympathetic input to brown adipose tissue during PGE1–hyperthermia. Monda M, et al. **Brain Res Bull** 1995;38(5):489–93

1,25–Dihydroxyvitamin D3 promotes prostaglandin E1–induced differentiation of HL–60 cells. Kawase T, et al. **Calcif Tissue Int** 1995 Nov;57(5):359–66

Differential microcirculation dynamics during deliberate hypotension induced by nicardipine, PGE1 and trimethaphan in rat mesentery. Takakura K, et al. **Can J Anaesth** 1995 Nov;42(11):1035–9

Properties of prostaglandin E1 [letter; comment] Sinzinger H, et al. **Circulation** 1996 Apr 1;93(7):1476–7. Comment on: Circulation 1994 Apr;89(4):1786–91.

Effect of prostaglandin E1 on hepatic function after hepatectomy in patients with chronic liver disease. Une Y, et al. **Clin Ther** 1995 Nov–Dec;17(6):1118–25

Effect of prostaglandin E1 on ammonia concentration in blood of patients with hepatic resection. Aono T, et al. **Dig Dis Sci** 1996 Jan;41(1):126–30

Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Lea AP, et al. **Drugs Aging** 1996 Jan;8(1):56–74 (123 ref.)

Prostaglandin E1 increases binding of 123I–low–density lipoprotein to the human liver in vivo. Sinzinger H, et al. **Eur J Clin Pharmacol** 1996;49(6):515–20

Role of cyclic adenosine monophosphate in prostaglandin E1–induced penile erection in rabbits. Lin JS, et al. **Eur Urol** 1995;28(3):259–65

Prostaglandin E1 inhibits TNF alpha–induced T–cell adhesion to endothelial cells by selective down–modulation of ICAM–1 expression on endothelial cells. Weiss JM, et al. **Exp Dermatol** 1995 Oct;4(5):302–7

Concomitant use of prostaglandin E1 and prednisolone; inhibition of superoxide anion production by polymorphonuclear leucocytes. Miyata M, et al. **Fukushima J Med Sci** 1995 Jun;41(1):15–28

GM1 ganglioside modulates prostaglandin E1 stimulated adenylyl cyclase in neuro–2A cells. Wu G, et al. **Glycoconj J** 1996 Apr;13(2):235–9

The effect of prostaglandin E1 on liver adenine nucleotides and cytoplasmic enzymes in a porcine model of normothermic hepatic ischemia. Helling TS, et al. **Hepatology** 1995 Nov;22(5):1554–9

Postoperative intravenous infusion of alprostadil (PGE1) does not improve renal function in hepatic transplant recipients. Manasia AR, et al. **J Am Coll Surg** 1996 Apr; 182(4):347–52

Evaluation of protective effects of prostaglandin E1 on ischemic liver damage with in vivo 31P–MR spectroscopy. Nabeshima M, et al. **Magn Reson Med** 1995 Sep; 34(3):457–61

Differential effects of prostaglandin E1 and prostaglandin E2 on growth and differentiation of murine myeloid leukemic cell line, M1. Sawamura H, et al. **Microbiol Immunol** 1995;39(10):809–15

Intrathecal prostaglandin E1 produces a long–lasting allodynic state. Saito Y, et al. **Pain** 1995 Dec;63(3):303–11

Effects of prostaglandin E1, and papaverine on non–neurogenic and neurogenic contraction of the isolated rabbit erectile tissue. Italiano G, et al. **Pharmacol Res** 1995 May;31(5):313–7

Cell cycle related inhibition of mouse vascular smooth muscle cell proliferation by prostaglandin E1: relationship between prostaglandin E1 and intracellular cAMP levels. Fan YY,

et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Feb; 54(2):101–7

Effects of lipo–prostaglandin E1 on random pattern flaps in rabbits. Kuwahara H, et al.
Scand J Plast Reconstr Surg Hand Surg 1996 Mar; 30(1):23–8

Effects of lipo–prostaglandin E1 on chemokine release in ischemia and reperfusion of the liver. Kawano K, et al. **Transplant Proc** 1996 Jun;28(3):1924–5

Effect of lipoprostaglandin E1 in concordant xenografts. Yoshida Y, et al. **Transplant Proc** 1996 Jun;28(3):1410–1

Plasma prostaglandin E1 concentrations and hemodynamics during intravenous infusions of prostaglandin E1 in humans and swine. Awas JA, et al. **Transplantation** 1996 Jun 15; 61(11):1624–9

[Anesthesia in experimental single–lung transplantation: hemodynamic and respiratory changes during prostaglandin E1 and nitroglycerin infusion] Della Rocca G, et al. **Minerva Anestesiol** 1995 May;61(5):207–18 (Eng. Abstr.) **(Ita)**

[Intravenous infusion of prostagrandin E1 during and after gastrectomy on postoperative hepato–renal functions in senile patients] Murakawa T, et al. **Masui** 1996 Mar; 45(3):356–61 (Eng. Abstr.) **(Jpn)**

[The effects of prostaglandin E1 and epidural anesthesia on peripheral blood flow] Sakuma K, et al. **Masui** 1995 Oct; 44(10):1350–5 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Role of prostaglandins E1, E2 and F2 alpha in the brain in interleukin 1 beta–induced adrenocorticotropin secretion in the rat. Watanobe H, et al. **Cytokine** 1995 Oct;7(7):710–2

SECRETION

[Dynamics of biliary prostaglandin secretion in patients with dyskinesia of the biliary tracts] Vorob'ev LP, et al.
Patol Fiziol Eksp Ter 1995 Oct–Dec;(4):37–8 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Prostaglandin E1 improves necrobiosis lipoidica [letter] Kuwert C, et al. **Acta Derm Venereol** 1995 Jul;75(4):319–20

Treatment for impotence gains FDA approval [news] **Am J Health Syst Pharm** 1995 Oct 1;52(19):2078–9

Prostaglandin E1 treatment [letter; comment] Yegen C, et al. **Ann Surg** 1995 Dec;222(6):767–8. Comment on: Ann Surg 1994 Jul;220(1):53–8.

Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP–sensitive potassium channels. Hide EJ, et al.
Br J Pharmacol 1995 Nov;116(5):2435–40

Ketanserin plus prostaglandin E1 (PGE–1) as intracavernosal therapy for patients with erectile dysfunction unresponsive to PGE–1 alone. Mirone V, et al. **Br J Urol** 1996 May; 77(5):736–9

Bilateral ptosis with ophthalmoplegia in a 72–year–old woman with diabetes. Nakai A, et al. **Diabetes Res** 1994; 26(2):89–92

Alprostadil for erectile impotence. **Drug Ther Bull** 1995 Aug; 33(8):61–2 (13 ref.)

Effects of prostaglandin E1 on intra–operative central and peripheral temperatures during upper abdominal surgery. Matsukawa T, et al. **Eur J Anaesthesiol** 1995 Jul; 12(4):417–22

Intraurethral prostaglandin improves quality of vacuum erection therapy. John H, et al. **Eur Urol** 1996;29(2):224–6

Long–term intracavernous self–injection with prostaglandin E1 for the treatment of erectile dysfunction. Canale D, et al. **Int J Androl** 1996 Feb;19(1):28–32

Recount of prostaglandin E1 therapy in a patient with Raynaud's phenomenon [letter] DiGiovanni RL, et al.
J Am Osteopath Assoc 1995 Oct;95(10):572

Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP–elevating effects of prostaglandin E1. Chirkov YY, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):961–6

Prostaglandin E1 increases indocyanine green disappearance rate in patients with chronic liver disease. Aono T, et al. **J Int Med Res** 1995 Jul–Aug;23(4):299–307

Long–term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure [see comments] Godschalk M, et al. **J Urol** 1996 Mar;155(3):915–7. Comment in: J Urol 1996 Mar;155(3):924–5.

The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. Porst H. **J Urol** 1996 Mar; 155(3):802–15 (219 ref.)

Alprostadil for the treatment of erectile dysfunction. Kupecz D. **Nurse Pract** 1996 May;21(5):143–5

A randomized trial of two preparations of vaginal prostaglandin for pre–induction cervical ripening. Murray HG, et al. **Obstet Gynecol** 1995 Dec;86(6):880–5

Biphasic effect of prostaglandin E1 on the severity of acute pancreatitis induced by a closed duodenal loop in rats. Pozsar J, et al. **Pancreas** 1996 Mar;12(2):159–64

A comparative study of the effects of iloprost and PGE1 on pulmonary arterial pressure and edema formation in the isolated perfused rat lung model. Misselwitz B, et al.
Prostaglandins 1996 Mar;51(3):179–90

Prostaglandin E1 in the medical management of erectile dysfunction in a genito–urinary medicine clinic. Armstrong DK, et al. **Ulster Med J** 1994 Apr;63(1):18–22

[Treatment of erectile insufficiency] Bondil P.
Presse Med 1995 Oct 28;24(32):1531–6 (Eng. Abstr.) **(Fre)**

[Use of PGE1 in severe ischemia of the lower extremities. Clinical study] Occhionorelli S, et al.
Minerva Cardioangiol 1995 Jun;43(6):247–56 (73 ref.) (Eng. Abstr.) **(Ita)**

[Effects of prostaglandin E1 (PGE1) on pulmonary hypertension and lung vascular remodeling in a rat monocrotaline model of human pulmonary hypertension] Ono S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Aug;33(8):862–7 (Eng. Abstr.) **(Jpn)**

[Prostaglandin E1 bladder instillations for late–onset hemorrhagic cystitis following allogeneic bone marrow transplantation] Nakaseko C, et al. **Rinsho Ketsueki** 1995 Aug;36(8):728–34 (Eng. Abstr.) **(Jpn)**

[Symposium on Edex (alprostadil) in the diagnosis and treatment of erectile dysfunction] Borisov VV.
Urol Nefrol (Mosk) 1995 Nov–Dec;(6):53 **(Rus)**

[Treatment of patients with subfulminant forms of viral hepatitis B using prostaglandin E1] Bojić I, et al.
Vojnosanit Pregl 1995 Sep–Oct;52(5):471–5 (Eng. Abstr.) **(Scr)**

[Erectile dysfunction: clinical course with intracavernous PGE1] Ruiz Rubio JL, et al. **Arch Esp Urol** 1996 Apr; 49(3):253–6 (Eng. Abstr.) **(Spa)**

ALTEPLASE

ADMINISTRATION & DOSAGE

Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. Tomsick T, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):79–85

Clinical experience with intracoronary tissue plasminogen activator: results of a multicenter registry. Intracoronary t–PA Registry Investigators. **Cathet Cardiovasc Diagn** 1995 Mar;34(3):196–201

Lesion–directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. Gurbel PA, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):382–91

Optimizing coronary thrombolysis with i.v. administration of recombinant tissue plasminogen activator. Single bolus vs double bolus vs front–loading. Prewitt RM, et al.
Chest 1996 Feb;109(2):510–5

Enhanced intracoronary thrombosis using a novel local drug delivery system [letter; comment] Tønnesen KH.
Circulation 1996 Feb 1;93(3):615–6. Comment on: Circulation 1995 Feb 1;91(3):785–93.

Pre–hospital thrombolytic therapy with either alteplase or streptokinase. Practical applications, complications and long–term results in 529 patients. Grijseels EW, et al.
Eur Heart J 1995 Dec;16(12):1833–8

Local release of fibrinolytic agents for adhesion prevention. Hill–West JL, et al. **J Surg Res** 1995 Dec;59(6):759–63

Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis. Ouriel K, et al. **J Vasc Surg** 1995 Nov; 22(5):593–7

Effect of the initial bolus volume of recombinant tissue–type plasminogen activator on coronary recanalization and infarct size in Japanese acute myocardial infarction patients. Kumamoto University Myocardial Infarction Study (KUMIS) Group. Ogawa H, et al. **Jpn Circ J** 1995 Oct; 59(10):663–72

Tissue plasminogen activator for acute ischemic stroke [letter; comment] Qureshi N. **N Engl J Med** 1996 May 23; 334(21):1406. Comment on: N Engl J Med 1995 Dec 14;333(24):1581–7. Comment on: N Engl J Med 1995 Dec 14;333(24):1632–3.

A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm [letter] Findlay JM. **Neurosurgery** 1995 Nov;37(5):1026–7

Prevention of microvascular thrombosis with short–term infusion of human tissue–type plasminogen activator. Rohrich RJ, et al. **Plast Reconstr Surg** 1996 Jul;98(1):118–28

Intraoperative thrombolytic treatment of microarterial occlusion by selective rt–PA infusion. Stassen JM, et al.
Plast Reconstr Surg 1995 Oct;96(5):1215–7

Intermittent regional therapy with rt–PA is not superior to systemic thrombolysis in deep vein thrombosis (DVT)—a German multicenter trial. Schwieder G, et al.
Thromb Haemost 1995 Nov;74(5):1240–3

Acadesine reduces the frequency of coronary artery reocclusion following rt–PA induced thrombolysis in the dog. Young MA, et al. **Thromb Haemost** 1995 Nov; 74(5):1348–52

Repetitive, low–dose tissue plasminogen activator for clearance of experimental vitreous hemorrhage. Zhao P, et al. **Yen Ko Hsueh Pao** 1995 Mar;11(1):29–31, 40

[Tissue plasminogen activator after resuscitation in fulminant pulmonary embolism (letter)] Böttiger BW.
Dtsch Med Wochenschr 1995 Nov 3;120(44):1528–9 **(Ger)**

[High–dosage systemic lysis of a fulminant pulmonary embolism in an echocardiographically recognized mobile thrombus of the right heart (letter)] Müller C, et al.
Dtsch Med Wochenschr 1995 Dec 15;120(50):1758 **(Ger)**

[Thrombolytic therapy of renal artery embolism. An expanded case report with review of the literature] Gulba DC, et al. **Internist (Berl)** 1996 Jun;37(6):623–7 (51 ref.) **(Ger)**

[Risk factors, prevention and therapy of fibrin reactions after IOL implantation] Müller–Jensen K, et al.
Klin Monatsbl Augenheilkd 1995 Nov;207(5):287–91 (Eng. Abstr.) **(Ger)**

[Local thrombolytic treatment of spontaneous intracerebral hemorrhage with plasminogen activator (rt–PA). Indications and limits (letter)] Schaller C, et al.
Nervenarzt 1995 Oct;66(10):792 **(Ger)**

[Selective percutaneous transluminal thrombolytic therapy with rt–PA in central retinal artery occlusion] Vulpius K, et al. **Ophthalmologe** 1996 Apr;93(2):149–53 (Eng. Abstr.) **(Ger)**

[A modified technic for local rt–PA catheter–mediated lysis] Müller–Hülsbeck S, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995 Nov;163(5):424–9 (Eng. Abstr.) **(Ger)**

[Local fibrinolysis in massive pulmonary thromboembolism (letter)] Garro P, et al. **Med Clin (Barc)** 1996 Mar 9; 106(9):354 **(Spa)**

ADVERSE EFFECTS

Choroidal hemorrhage associated with systemic tissue plasminogen activator. Khawly JA, et al.
Am J Ophthalmol 1996 May;121(5):577–8

A canine coronary artery thrombosis model: application of photochemically induced thrombosis. Umemura K, et al.
Arch Int Pharmacodyn Ther 1995 Jul–Aug;330(1):13–24

Lingual haematoma after treatment with alteplase (recombinant tissue plasminogen activator) for acute myocardial infarction. McMechan SR, et al. **Br Heart J** 1995 Aug;74(2):205

Lingual haematoma after treatment with alteplase (recombinant tissue plasminogen activator) for acute myocardial infarction [letter] Kounis NG, et al. **Heart** 1996 Apr;75(4):427

Tissue plasminogen activator for acute ischemic stroke [letter; comment] Koroshetz WJ. **N Engl J Med** 1996 May 23; 334(21):1405–6. Comment on: N Engl J Med 1995 Dec 14;333(24):1581–7.

No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno–occlusive disease after allogeneic bone marrow transplantation. Hägglund H, et al.
Transplant Proc 1995 Dec;27(6):3535

[A rare case of coronary artery perforation by a PTCA guide wire complicating with postinfarction cardiac rupture after thrombolytic therapy] Ogino H, et al.
Nippon Kyobu Geka Gakkai Zasshi 1995 Aug;43(8):1151–4 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Growth factors, tissue and urokinase–type plasminogen activators in venous ulcers. Lagattolla NR, et al.
Ann Cardiol Angeiol (Paris) 1995 Jun–Aug;44(6):299–303

Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. de Maat MP, et al. **Arterioscler Thromb Vasc Biol** 1996 Sep; 16(9):1156–62

Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Robbie LA, et al.
Arterioscler Thromb Vasc Biol 1996 Apr;16(4):539–45

Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Ganesh S, et al. **Cancer** 1996 Mar 15;77(6):1035–43

Relation of hormone–replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Shahar E, et al.
Circulation 1996 Jun 1;93(11):1970–5

Cytosolic tissue–type plasminogen activator (t–PA) levels in ductal infiltrating carcinomas of the breast classified according to different clinical and biological parameters [letter] Garcia Muñiz JL, et al. **Int J Biol Markers** 1995 Apr–Jun;10(2):119–21

Immunocytochemical localization of plasminogen activators in carcinomas in the cervix and vulva. Parolini S, et al.
Int J Tissue React 1994;16(5–6):251–8

Relationship between tissue plasminogen activator, plasminogen activator inhibitor and CT image in chronic subdural hematoma. Lim DJ, et al. **J Korean Med Sci** 1995 Oct;10(5):373–8

Vascular tissue plasminogen activator and the development of coronary artery disease in heart–transplant recipients. Labarrere CA, et al. **N Engl J Med** 1995 Oct 26; 333(17):1111–6

Fibrinolysis in human peritoneum during operation. Holmdahl L, et al. **Surgery** 1996 Jun;119(6):701–5

von Willebrand factor, soluble P–selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Blann AD, et al. **Thromb Haemost** 1995 Aug;74(2):626–30

Endothelial haemostatic factors may be associated with mortality in patients on long–term anticoagulant treatment. Brännström M, et al. **Thromb Haemost** 1995 Aug; 74(2):612–5

Immunoassay of murine t–PA, u–PA and PAI–1 using monoclonal antibodies raised in gene–inactivated mice. Declerck PJ, et al. **Thromb Haemost** 1995 Nov;74(5):1305–9

Does low protein concentration of tissue–type plasminogen

activator predict a low risk of spontaneous deep vein thrombosis? Gram J, et al. **Thromb Haemost** 1995 Aug; 74(2):718–21

Fibrin D–dimer, haemostatic factors and peripheral arterial disease. Lee AJ, et al. **Thromb Haemost** 1995 Sep; 74(3):828–32

[Tissue–plasminogen activator (t–PA)] Sakuragawa N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:59–63 (20 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Complexation of the tissue plasminogen activator protease with benzamidine–type inhibitors: interference by the kringle 2 module. Hu CK, et al. **Biochemistry** 1996 Mar 12;35(10):3270–6

Reversible modification of tissue–type plasminogen activator by methylphosphonate esters. Zhao O, et al. **Bioorg Med Chem** 1996 Apr;4(4):523–9

BIOSYNTHESIS

Stimulation of tissue–type plasminogen activator expression by retinoic acid in human endothelial cells requires retinoic acid receptor beta 2 induction. Lansink M, et al. **Blood** 1996 Jul 15;88(2):531–41

T–cell lymphokines, interleukin–4 and gamma interferon, modulate the induction of vascular smooth muscle cell tissue plasminogen activator and migration by serum and platelet–derived growth factor. Wang W, et al. **Circ Res** 1995 Dec;77(6):1095–106

Effect of transforming growth factor–beta on plasminogen activator production of cultured human uveal melanoma cells. Park SS, et al. **Curr Eye Res** 1996 Jul;15(7):755–63

Fibrin deposition in tissues from endotoxin–treated mice correlates with decreases in the expression of urokinase–type but not tissue–type plasminogen activator. Yamamoto K, et al. **J Clin Invest** 1996 Jun 1;97(11):2440–51

Tissue plasminogen activator production by monocytes in venous thrombolysis. Soo KS, et al. **J Pathol** 1996 Feb; 178(2):190–4

Heparin–binding epidermal growth factor–like growth factor: p91 activation induction of plasminogen activator/inhibitor, and tubular morphogenesis in human microvascular endothelial cells. Ushiro S, et al. **Jpn J Cancer Res** 1996 Jan;87(1):68–77

Complex intracellular signal transduction regulates tissue plasminogen activator (t–PA) and plasminogen activator inhibitor type–1 (PAI–1) synthesis in cultured human umbilical vein endothelium. Rydholm H, et al. **Scand J Clin Lab Invest** 1995 Jul;55(4):323–30

Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Seeds NW, et al. **Science** 1995 Dec 22;270(5244):1992–4

Cyclosporine A inhibits tPA mRNA transcription in A431 cell line. Teofoli P, et al. **Skin Pharmacol** 1996;9(2):137–40

Brain capillary tissue plasminogen activator in a diabetes stroke model. Kittaka M, et al. **Stroke** 1996 Apr;27(4):712–9

Retinoids induced t–PA synthesis by C6 glioma cells—role in tumoral haemorrhagic necrosis. Pernod G, et al. **Thromb Haemost** 1996 Feb;75(2):332–8

Regulation of plasminogen activator inhibitor activity by plasmin in endothelial cells. Shi GY, et al. **Thromb Res** 1996 Jan 1;81(1):75–84

BLOOD

Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions. Terres W, et al. **Am Heart J** 1995 Oct;130(4):711–6

Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor–1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Tomura S, et al. **Am J Kidney Dis** 1996 Jun;27(6):848–54

Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Beer NA, et al. **Am J Med Sci** 1996 May; 311(5):205–10

Plasminogen activator inhibitor–1, tissue–type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women. Svendsen OL, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar; 16(3):381–5

An enzyme immunoassay for the simultaneous determination of active type–1 plasminogen activator inhibitor (PAI–1), and t–PA/PAI–1 complexes. Nieuwenhuizen W, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):520–6

Plasma plasminogen activator inhibitor–1, tissue plasminogen activator and serum lipoprotein(a) after reperfusion therapy in acute myocardial infarction: comparison between sequential and direct percutaneous transluminal coronary angioplasty. Hara M, et al. **Cardiology** 1995;86(5):407–10

Comparison of von Willebrand factor and tissue plasminogen activator concentrations in plasma and serum. Nilsson TK, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):976–7

Mediators of fibrinolysis in orthotopic liver transplantation. Cheema SP, et al. **Clin Transplant** 1996 Feb;10(1 Pt 1):24–7

The association of fibrinolysis and hyperlipidaemia with quantitative sensory tests in an epidemiological study of Swedish type 1 diabetic patients. Lithner F, et al. **Diabet Med** 1995 Jul;12(7):590–4

Fibrinolysis and diabetic retinopathy in NIDDM. Mansfield MW, et al. **Diabetes Care** 1995 Dec;18(12):1577–81

Enhanced levels of tissue–type plasminogen activator in borderline hypertension. Wall U, et al. **Hypertension** 1995 Nov;26(5):796–800

Evaluation of tissue plasminogen activator and plasminogen activator inhibitor–I levels in acute myocardial infarction. Yamada S, et al. **J Cardiol** 1996 Apr;27(4):171–8

The effect of PGI2 analogue on vascular endothelial function and platelet aggregation in patients with NIDDM. Nishimura M, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):330–3

No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids. Petersen KR, et al. **Metabolism** 1996 Jul;45(7):833–7

Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease. Ozoran K, et al. **Scand J Rheumatol** 1995;24(6):376–82

Tissue plasminogen activator and plasminogen activator inhibitor–1 in stroke patients. Lindgren A, et al. **Stroke** 1996 Jun;27(6):1066–71

Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Dahl OE, et al. **Thromb Res** 1995 Nov 15;80(4):299–306

Reductions in tissue plasminogen activator and thrombomodulin in blood draining veins damaged by venous access devices. Horne MK 3rd, et al. **Thromb Res** 1995 Aug 15;79(4):369–76

[Clinical significance of fibrinolytic system defectiveness in exercise induced myocardial ischemia and its mechanism] Deng H, et al. **Chung Hua Nei Ko Tsa Chih** 1995 May; 34(5):305–8 (Eng. Abstr.) **(Chi)**

[An analysis on the activity status of fibrinolytic system in Chinese patients with acute cerebral infarction] Zhang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Aug;34(8):518–21 (Eng. Abstr.) **(Chi)**

[Levels of tissue–type plasminogen activator (T–PA), its inhibitor (PAI–1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus] Kvasnička J, et al. **Cas Lek Cesk** 1996 Mar 20;135(6):174–7 (Eng. Abstr.) **(Cze)**

[Changes of the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor–1 in cerebral infarction induced by the venous occlusion] Wakamatsu S, et al. **Nippon Ronen Igakkai Zasshi** 1995 Aug–Sep; 32(8–9):566–70 (Eng. Abstr.) **(Jpn)**

[Changes in plasma tissue plasminogen activator (t–PA) and plasminogen activator inhibitor 1 (PAI–1) by the interferon treatment for chronic hepatitis C] Hayashi T, et al. **Rinsho Byori** 1995 Sep;43(9):948–52 (Eng. Abstr.) **(Jpn)**

[Studies on the mechanism of hyperfibrinolysis in liver cirrhosis—changes of plasma t–PA, PAI–1 and active PAI–1 levels in liver cirrhosis] Matsuura R, et al. **Rinsho Byori** 1995 Dec;43(12):1256–60 (Eng. Abstr.) **(Jpn)**

[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma] Iwan–Ziętek I, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):91–3 (Eng. Abstr.) **(Pol)**

CEREBROSPINAL FLUID

Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. Akenami FO, et al. **J Clin Pathol** 1996 Jul;49(7):577–80

CHEMISTRY

Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Lam XM, et al. **Am J Health Syst Pharm** 1995 Sep 1;52(17):1904–9

The use of high–performance anion–exchange chromatography and matrix–assisted laser desorption/ionization time–of–flight mass spectrometry to monitor and identify oligosaccharide degradation. Field M, et al. **Anal Biochem** 1996 Jul 15;239(1):92–8

The glycosylation of Bowes melanoma tissue plasminogen activator: lectin mapping, reaction with anti–L2/HNK–1 antibodies and the presence of sulphated/glucuronic acid containing glycans. Jaques AJ, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):427–37

Characterisation of the complex of plasminogen activator inhibitor type 1 with tissue–type plasminogen activator by mass spectrometry and size–exclusion chromatography. Strömqvist M, et al. **Biochim Biophys Acta** 1996 Jun 7; 1295(1):103–9

Protein loop grafting to construct a variant of tissue–type plasminogen activator that binds platelet integrin alpha IIb beta 3. Smith JW, et al. **J Biol Chem** 1995 Dec 22; 270(51):30486–90

Non–native capillary isoelectric focusing for the analysis of the microheterogeneity of glycoproteins. Kubach J, et al. **J Chromatogr A** 1996 Jun 21;737(2):281–9

Rapid one–step capillary isoelectric focusing method to monitor charged glycoforms of recombinant human tissue–type plasminogen activator. Moorhouse KG, et al. **J Chromatogr A** 1995 Nov 24;717(1–2):61–9

The 2.3 A crystal structure of the catalytic domain of recombinant two–chain human tissue–type plasminogen activator. Lamba D, et al. **J Mol Biol** 1996 Apr 26; 258(1):117–35

The solution structure and backbone dynamics of the fibronectin type I and epidermal growth factor–like pair of modules of tissue–type plasminogen activator. Smith BO, et al. **Structure** 1995 Aug 15;3(8):823–33

ECONOMICS

Study assigns dollar value to alteplase–streptokinase debate [news] **Am J Health Syst Pharm** 1995 Aug 1;52(15):1600

Thrombolytic treatment. Streptokinase is more economical than alteplase [letter; comment] Mucklow JC. **BMJ** 1995 Dec 2;311(7018):1506. Comment on: BMJ 1995 Sep 2;311(7005):582–3.

A cost–effectiveness model of thrombolytic therapy for acute myocardial infarction [see comments] Kalish SC, et al. **J Gen Intern Med** 1995 Jun;10(6):321–30. Comment in: J Gen Intern Med 1995 Jun;10(6):351–2.

GENETICS

Interaction of mutants of tissue–type plasminogen activator with liver cells: effect of domain deletions. Kuiper J, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):775–80

Construction, expression and the characterization of t–PA mutants with increased plasma half–life and resistance to inhibition by PAI–1. Liu S, et al. **Chin J Biotechnol** 1995; 11(1):17–25

Coordinated expression of tissue–type plasminogen activator and plasminogen activator inhibitor type 1 during corpus luteum formation and luteolysis in the adult pseudopregnant rat. Liu K, et al. **Endocrinology** 1996 May; 137(5):2126–32

Differential binding of cAMP–responsive–element (CRE)–binding protein–1 and activating transcription factor–2 to a CRE–like element in the human tissue–type plasminogen activator (t–PA) gene promoter correlates with opposite regulation of t–PA by phorbol ester in HT–1080 and HeLa cells. Costa M, et al. **Eur J Biochem** 1996 May 1;237(3):532–8

Involvement of retinoic acid receptor alpha in the stimulation of tissue–type plasminogen–activator gene expression in human endothelial cells. Kooistra T, et al. **Eur J Biochem** 1995 Sep 1;232(2):425–32

Isolation of tissue–type plasminogen activator, cathepsin H, and non–specific cross–reacting antigen from SK–PC–1 pancreas cancer cells using subtractive hybridization. Paciucci R, et al. **FEBS Lett** 1996 Apr 29;385(1–2):72–6

Distribution and frequency of a polymorphic Alu insertion at the plasminogen activator locus in humans. Tishkoff SA, et al. **Hum Genet** 1996 Jun;97(6):759–64

Variants of tissue–type plasminogen activator with substantially enhanced response and selectivity toward fibrin co–factors. Strandberg L, et al. **J Biol Chem** 1995 Oct 6;270(40):23444–9

Localization of tissue plasminogen activator mRNA in the developing rat cerebellum and effects of inhibiting tissue plasminogen activator on granule cell migration. Ware JH, et al. **J Neurobiol** 1995 Sep;28(1):9–22

A different form of long–lasting potentiation revealed in tissue plasminogen activator mutant mice. Frey U, et al. **J Neurosci** 1996 Mar 15;16(6):2057–63

The promise of new genetically engineered plasminogen activators. Cutler D, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):3S–7S (16 ref.)

Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Leonardsson G, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12446–50

Inhibitory effect of 3'–untranslated region (3'–UTR) of human tissue–plasminogen activator (ht–PA) mRNA on its expression. Ouyang Y, et al. **Sci China B** 1995 Oct; 38(10):1253–60

Transcriptional regulation of tissue– and urokinase–type plasminogen activator genes by thrombin in human fetal lung fibroblasts. Hayakawa Y, et al. **Thromb Haemost** 1995 Aug;74(2):704–10

Alu–repeat polymorphism in the tissue–type plasminogen activator (tPA) gene does not affect basal endothelial tPA synthesis [letter] van den Eijnden–Schrauwen Y, et al. **Thromb Haemost** 1995 Oct;74(4):1202

IMMUNOLOGY

Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor–1 after cleavage of the reactive center loop or after complex formation with various serine proteinases. Debrock S, et al. **FEBS Lett** 1995 Dec 4;376(3):243–6

Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. Fritzler MJ, et al. **J Rheumatol** 1995 Sep;22(9):1688–93

ISOLATION & PURIFICATION

Extraction of plasminogen activator in the rat's submaxillary gland. Lucas ON, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(2):115–22

METABOLISM

Active site labeling with dansyl–glutamyl–glycyl–arginyl chloromethyl ketone demonstrates the full activity of the refolded and purified tissue–type plasminogen activator variant BM 06.022. Kohnert U, et al.

Appl Biochem Biotechnol 1995 Nov;55(2):157–66
Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Hembrough TA, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):763–9
Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions. Kuiper J, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):775–80
Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Gils A, et al. **Biochemistry** 1996 Jun 11;35(23):7474–81
Hormonal regulation of plasminogen activator in rat and mouse seminiferous epithelium. Liu YX, et al.
Biol Signals 1995 Jul–Aug;4(4):232–40
Reversible modification of tissue-type plasminogen activator by methylphosphonate esters. Zhao O, et al.
Bioorg Med Chem 1996 Apr;4(4):523–9
Degradation of tissue-type plasminogen activator by human monocyte-derived macrophages is mediated by the mannose receptor and by the low-density lipoprotein receptor-related protein. Noorman F, et al. **Blood** 1995 Nov 1;86(9):3421–7
Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro. Hauptmann J, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):579–83
Azelaic acid decreases the fibrinolytic potential of cultured human melanoma cells in vitro. Addo-Boadu K, et al.
Cancer Lett 1996 Jun 5;103(2):125–9
Plasmin-catalyzed proteolysis in colorectal neoplasia. Delbaldo C, et al. **Cancer Res** 1995 Oct 15;55(20):4688–95
Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice. de Vries TJ, et al.
Cancer Res 1995 Oct 15;55(20):4681–7
Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor. Mars WM, et al. **Cancer Res** 1996 Jun 15;56(12):2837–43
In vitro oxidative damage to tissue-type plasminogen activator: a selective modification of the biological functions. Feng YH, et al. **Cardiovasc Res** 1995 Aug; 30(2):255–61
Novel markers for constitutive secretion used to show that tissue plasminogen activator is sorted to the regulated pathway in transfected PC12 cells. Harrison TM, et al.
Cell Biol Int 1996 Apr;20(4):293–9
The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Chandler WL, et al. **Circulation** 1995 Nov 15;92(10):2984–94
Gastric mucosal plasminogen activators in Helicobacter pylori infection. Götz JM, et al. **Dig Dis Sci** 1996 Aug; 41(8):1577–82
tPA of human keratinocytes: contribution to cell surface-associated plasminogen activation and upregulation by retinoic acid. Buessecker F, et al. **Exp Dermatol** 1995 Dec;4(6):357–64
The role of the finger and growth factor domains in the clearance of tissue-type plasminogen activator by hepatocytes. Camani C, et al. **J Biol Chem** 1995 Nov 3; 270(44):26053–6
Distinct mechanisms contribute to stringent substrate specificity of tissue-type plasminogen activator. Coombs GS, et al. **J Biol Chem** 1996 Feb 23;271(8):4461–7
Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells. Higazi AAR, et al. **J Biol Chem** 1996 Jul 26;271(30):17650–5
Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy. Sakharov DV, et al.
J Biol Chem 1996 Jan 26;271(4):2133–8
Protein loop grafting to construct a variant of tissue-type plasminogen activator that binds platelet integrin alpha IIb beta 3. Smith JW, et al. **J Biol Chem** 1995 Dec 22; 270(51):30486–90
Variants of tissue-type plasminogen activator with substantially enhanced response and selectivity toward fibrin co-factors. Strandberg L, et al. **J Biol Chem** 1995 Oct 6;270(40):23444–9
Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator. van Meijer M, et al. **J Biol Chem** 1996 Mar 29;271(13):7423–8
Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts. Allan EH, et al. **J Cell Physiol** 1995 Dec; 165(3):521–9
Serum is a potent stimulator of keratinocyte tissue plasminogen activator expression. Chen CS, et al.
J Invest Dermatol 1996 Feb;106(2):238–42
The imbalance of plasminogen activators and inhibitor in preeclampsia. Gao M, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):9–16
The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus. Northeast AD, et al. **J Vasc Surg** 1995 Nov;22(5):573–9
In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Kingston IB, et al. **Nat Med** 1995 Feb;1(2):138–42
Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis [published erratum appears in Nat Med 1995 Jun;1(6):598] Palabrica TM, et al. **Nat Med** 1995 Mar;1(3):256–9
Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Tsirka SE, et al. **Nature** 1995 Sep 28;377(6547):340–4
Expression of tissue plasminogen activator in cerebral capillaries: possible fibrinolytic function of the blood-brain barrier. Zlokovic BV, et al. **Neurosurgery** 1995 Nov; 37(5):955–61
Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Bugge TH, et al.
Proc Natl Acad Sci U S A 1996 Jun 11;93(12):5899–904
The position of the structurally autonomous kringle 2 domain influences the functional features of tissue-type plasminogen activator. Bakker AH, et al. **Protein Eng** 1995 Mar;8(3):293–300
Aggregated, conformationally changed fibrinogen exposes the stimulating sites for t-PA-catalysed plasminogen activation. Haddeland U, et al. **Thromb Haemost** 1996 Feb; 75(2):326–31
Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells. Grimsley PG, et al. **Thromb Res** 1995 Aug 15; 79(4):353–61
Effects of cadmium on the release of tissue plasminogen activator and plasminogen activator inhibitor type 1 from cultured human vascular smooth muscle cells and fibroblasts. Yamamoto C, et al. **Toxicology** 1996 Jan 8; 106(1-3):179–85
[Formation of adhesions and change in activity of tissue plasminogen activator in the parietal peritoneum of the anterior stomach wall in rats depending on the method of restoring it] Mynbaev OA, et al.
Biull Eksp Biol Med 1996 Mar;121(3):328–31 **(Rus)**

PHARMACOLOGY

Mechanism of potentiation of tissue-type plasminogen activator. Lazos SA, et al. **Biochem Mol Biol Int** 1995 Dec; 37(6):1071–77
Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Ragni M, et al. **Circulation** 1996 May 15;93(10):1913–8
Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding. Shatos MA, et al. **Circulation** 1996 Aug 15;94(4):636–42
Effects of ionic and nonionic contrast media on clot structure, platelet function and thrombolysis mediated by tissue plasminogen activator in plasma clots. Carr ME Jr, et al.
Haemostasis 1995 Jul–Aug;25(4):172–81
Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. Modi NB, et al.
J Cardiovasc Pharmacol 1996 Jan;27(1):105–12
Effect of intraperitoneal chemotherapy and fibrinolytic therapy on tumor implantation in wound sites. Jacquet P, et al. **J Surg Oncol** 1996 Jun;62(2):128–34
Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. Weitz JI.
J Vasc Interv Radiol 1995 Nov–Dec;6(6 Pt 2 Su):19S–23S
Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator. Pekelharing HL, et al. **Thromb Haemost** 1996 Mar; 75(3):497–502
Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions. Wu JH, et al. **Thromb Haemost** 1995 Aug;74(2):711–7
Altered lysis resistance of platelet-rich clots in patients with insulin-dependent diabetes mellitus. Udvardy M, et al.
Thromb Res 1995 Jul 1;79(1):57–63

PHYSIOLOGY

Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. Schnaper HW, et al.
J Cell Physiol 1995 Oct;165(1):107–18
Interleukin-1 beta up-regulates the plasminogen activator/plasmin system in human mesangial cells. Wilson HM, et al. **Kidney Int** 1996 Apr;49(4):1097–104
Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Huang YY, et al.
Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8699–704
Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells. Kuiper J, et al. **Thromb Haemost** 1995 Nov;74(5):1298–304

SECRETION

Hemodynamic forces modulate the effects of cytokines on fibrinolytic activity of endothelial cells. Kawai Y, et al.
Blood 1996 Mar 15;87(6):2314–21
Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo [see comments] Dunn PF, et al. **Circulation** 1996 Apr 1; 93(7):1439–46. Comment in: Circulation 1996 Apr 1;93(7):1319–20.
Secretion of prostacyclin, tissue plasminogen activator and its inhibitor by cultured adult human endothelial cells grown on different matrices. Gillis C, et al.
Eur J Vasc Endovasc Surg 1996 Feb;11(2):127–33
Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator. Gualandris A, et al. **J Neurosci** 1996 Apr 1;16(7):2220–5
Regulation of tissue-type plasminogen activator and plasminogen activator inhibitor type-1 in cultured rat Sertoli and Leydig cells. Liu Y, et al.
Sci China C Life Sci 1996 Feb;39(1):37–44
Amiloride inhibits tissue-type plasminogen activator (t-PA) release from vascular endothelium [letter] Iacoviello L, et al. **Thromb Haemost** 1995 Aug;74(2):808–9
Enhanced vascular plasminogen activator (t-PA) release by epinephrine in aged rats. Iacoviello L, et al.
Thromb Haemost 1995 May;73(5):841–4

THERAPEUTIC USE

Tissue plasminogen activator (tPA) to facilitate removal of post-traumatic submacular haemorrhage. Laatikainen L, et al. **Acta Ophthalmol Scand** 1995 Aug;73(4):361–2
Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation [see comments] Jansen O, et al. **AJNR Am J Neuroradiol** 1995 Nov-Dec; 16(10):1977–86. Comment in: AJNR Am J Neuroradiol 1995 Nov-Dec;16(10):1994–2000.
Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator. Peuhkurinen K, et al.
Am Heart J 1996 Jan;131(1):7–13
Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction. Romeo F, et al. **Am Heart J** 1995 Oct;130(4):692–7
Effect of reperfusion modality on outcome in nonsmokers and smokers with acute myocardial infarction (a Primary Angioplasty in Myocardial Infarction [PAMI] substudy). PAMI Investigators. Bowers TR, et al. **Am J Cardiol** 1996 Sep 1;78(5):511–5
A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. O'Connor CM, et al.
Am J Cardiol 1996 Apr 15;77(10):791–7
Management of stroke complicating cardiac catheterization with recombinant tissue-type plasminogen activator. Oezbek C, et al. **Am J Cardiol** 1995 Oct 1;76(10):733–5
Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy. Stone GW, et al.
Am J Cardiol 1996 Jul 1;78(1):19–25
Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction. Zahger D, et al.
Am J Cardiol 1995 Oct 15;76(11):749–52
Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group. Zeymer U, et al. **Am J Cardiol** 1995 Nov 15;76(14):997–1001
Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage [letter; comment] Hawkins WR. **Am J Ophthalmol** 1995 Oct; 120(4):550–2. Comment on: Am J Ophthalmol 1994 Nov 15;118(5):559–68.
Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid. Kamei M, et al. **Am J Ophthalmol** 1996 Mar;121(3):267–75
Fluorescein labeling of tissue plasminogen activator for subretinal thrombolysis. Schneiderman TE, et al.
Am J Ophthalmol 1995 Dec;120(6):797–8
Use of tissue type plasminogen activator in neonates: case reports and review of the literature. Smets K, et al.
Am J Perinatol 1996 May;13(4):217–22 (21 ref.)
Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts. Comerota AJ, et al. **Am J Surg** 1996 Aug;172(2):105–12
Thrombolytic treatment of acute on chronic leg ischaemia. von Knorring S, et al. **Ann Chir Gynaecol** 1995;84(4):369–71
Acute myocardial infarction treatments in 58 Italian hospitals: a drug utilization survey. Venturini F, et al.
Ann Pharmacother 1995 Nov;29(11):1100–5
Phase I study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus. Whitelaw A, et al.
Arch Dis Child Fetal Neonatal Ed 1996 Jul;75(1):F20–6
Dramatic response of livedoid vasculitis to tissue plasminogen activator (tPA) [letter] Johnson DW, et al.
Aust N Z J Med 1995 Aug;25(4):370–1
PAI-1-resistant t-PA: low doses prevent fibrin deposition in rabbits with increased PAI-1 activity. Krishnamurti C, et al. **Blood** 1996 Jan 1;87(1):14–9

Reversal of severe hepatic veno-occlusive disease by combined plasma exchange and rt-PA treatment. Espigado I, et al. **Bone Marrow Transplant** 1995 Aug;16(2):313-6

Recombinant tissue plasminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient [letter; comment] Feldman L, et al. **Bone Marrow Transplant** 1995 Nov;16(5):727. Comment on: Bone Marrow Transplant 1994 Jul;14(1):176-7.

Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate. Patton DF, et al. **Bone Marrow Transplant** 1996 Mar;17(3):443-7

Rescue thrombolysis: alteplase as adjuvant treatment after streptokinase in acute myocardial infarction. Mounsey JP, et al. **Br Heart J** 1995 Oct;74(4):348-53

Fibrinolysis of experimental subretinal haemorrhage without removal using tissue plasminogen activator. Morse LS, et al. **Br J Ophthalmol** 1996 Jul;80(7):658-62

Aspirin improves the outcome of intra-arterial thrombolysis with tissue plasminogen activator. Thrombolysis Study Group. Braithwaite BD, et al. **Br J Surg** 1995 Oct; 82(10):1357-8

Interpreting results from thrombolytic megatrials: distinguishing fact from fiction. Brophy JM. **Can J Cardiol** 1996 Jan;12(1):89-92 (22 ref.)

Extended infusion of rtPA lysis of pulmonary emboli: influence of time after onset of symptoms on outcome. Aschauer M, et al. **Cardiovasc Intervent Radiol** 1995 Sep-Oct;18(5):288-90

New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Benedict CR, et al. **Circulation** 1995 Nov 15;92(10):3032-40

Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Bode C, et al. **Circulation** 1996 Sep 1;94(5):891-8

Fibrin-selective thrombolytic therapy for acute myocardial infarction. Collen D. **Circulation** 1996 Mar 1;93(5):857-65 (90 ref.)

New treatments for acute ischemic stroke [news] Ferguson JJ. **Circulation** 1996 May 1;93(9):1604

A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. Vanderschueren S, et al. **Circulation** 1995 Oct 15;92(8):2044-9

Thrombolysis in ischemic stroke: double or quits? [editorial] van Gijn J. **Circulation** 1996 May 1;93(9):1616-7 (21 ref.)

Accelerated thrombolysis with high dose bolus t-PA extends the role of peripheral thrombolysis but may increase the risks. Braithwaite BD, et al. **Clin Radiol** 1995 Nov; 50(11):747-50

Topically applied recombinant tissue plasminogen activator for the treatment of venous ulcers. Preliminary report. Falanga V, et al. **Dermatol Surg** 1996 Jul;22(7):643-4

Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Gillis JC, et al. **Drugs** 1995 Jul;50(1):102-36 (154 ref.)

Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction. Wagstaff AJ, et al. **Drugs** 1995 Aug; 50(2):289-316 (185 ref.)

Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy [see comments] Baardman T, et al. **Eur Heart J** 1996 Feb;17(2):237-46. Comment in: Eur Heart J 1996 Feb;17(2):167-8.

Successful thrombolysis treatment of a spontaneous left main coronary artery dissection without subsequent surgery [letter] Leclercq F, et al. **Eur Heart J** 1996 Feb;17(2):320-1

Thrombolytic therapy reduces the incidence of left ventricular thrombus after anterior myocardial infarction. Relationship to vessel patency and infarct size. Pizzetti G, et al. **Eur Heart J** 1996 Mar;17(3):421-8

Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT-I (hirudin for the improvement of thrombolysis). Zeymer U, et al. **Eur Heart J** 1995 Jul;16 Suppl D:22-7

Peripheral arterial occlusions: local low-dose thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA). Hess H, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):97-104

Initial clinical experience with tissue plasminogen activator (tPA) assisted removal of submacular haemorrhage. Moriarty AP, et al. **Eye** 1995;9 (Pt 5):582-8

Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic vitreoretinopathy. Hesse L, et al. **Ger J Ophthalmol** 1995 Nov;4(6):323-7

The use of tissue plasminogen activator in post-traumatic total hyphaema. Laatikainen L, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jan;234(1):67-8

Thrombolysis utilisation in acute myocardial infarction in Bahrain. Chawla AK, et al. **Indian Heart J** 1996 Mar-Apr; 48(2):155-8

Corneal endothelial permeability in protection glaucoma filter bleb with tissue plasminogen activator. Szymanski A, et al. **Int Ophthalmol** 1995;19(1):13-7

One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. Anderson HV, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1643-50

Influence of cigarette smoking on rate of reopening of the infarct-related coronary artery after myocardial infarction: a multivariate analysis. de Chillou C, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1662-8

Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. Karnash SL, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1651-6

Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators). Langer A, et al. **J Am Coll Cardiol** 1996 May;27(6):1327-32

Clinical presentation and results of thrombolytic therapy in older patients with massive pulmonary embolism: a comparison with non-elderly patients. Gisselbrecht M, et al. **J Am Geriatr Soc** 1996 Feb;44(2):189-93

The safety and efficacy of low-dose tissue plasminogen activator in the treatment of systemic sclerosis. Wilson D, et al. **J Dermatol** 1995 Sep;22(9):637-42

t-PA for treating acute ischemic stroke. Shaughnessy AS, et al. **J Fam Pract** 1996 May;42(5):458-9

Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t-PA for the prevention of vasospasm. Bell TE, et al. **J Neurosci Nurs** 1996 Apr;28(2):107-13 (37 ref.)

Treatment of failing glaucoma filtering cystic blebs with tissue plasminogen activator (tPA). Lee PF, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):227-32

Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. Chen L, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1276-83

Streptokinase versus alteplase in acute myocardial infarction. Friedman HS. **J R Soc Med** 1996 Aug;89(8):427-30

Recombinant tissue plasminogen activator for the treatment of lower extremity peripheral vascular occlusive disease. Bero CJ, et al. **J Vasc Interv Radiol** 1995 Jul-Aug; 6(4):571-7

Thrombolysis for acute stroke [letter; comment] Ciccone A, et al. **JAMA** 1996 Apr 3;275(13):983-4; discussion 984-5. Comment on: JAMA 1995 Oct 4;274(13):1017-25.

ECASS: lessons for future thrombolytic stroke trials. European Cooperative Acute Stroke Study [editorial; comment] [see comments] Fisher M, et al. **JAMA** 1995 Oct 4;274(13):1058-9. Comment on: JAMA 1995 Oct 4;274(13):1017-25. Comment in: JAMA 1996 Apr 3;275(13):984-5.

Thrombolysis in stroke: Between the promise and the peril [editorial; comment] Hachinski V. **JAMA** 1996 Sep 25; 276(12):995-6. Comment on: JAMA 1996 Sep 25;276(12):961-6.

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) [see comments] Hacke W, et al. **JAMA** 1995 Oct 4; 274(13):1017-25. Comment in: JAMA 1995 Oct 4;274(13):1058-9. Comment in: JAMA 1996 Apr 3;275(13):983; discussion 984-5. Comment in: JAMA 1996 Apr 3;275(13):983-4; discussion 984-5. Comment in: JAMA 1996 Apr 3;275(13):984-5.

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Aug 14;276(6):443

Thrombolysis for acute stroke [letter; comment] von Kummer R, et al. **JAMA** 1996 Apr 3;275(13):984-5. Comment on: JAMA 1995 Oct 4;274(13):1017-25. Comment on: JAMA 1995 Oct 4;274(13):1058-9.

Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. Weaver WD, et al. **JAMA** 1996 Mar 13;275(10):777-82

Thrombolysis for acute stroke [letter; comment] Wood L. **JAMA** 1996 Apr 3;275(13):983; discussion 984-5. Comment on: JAMA 1995 Oct 4;274(13):1017-25.

A novel modified tissue-type plasminogen activator (t-PA), E6010, reduces reperfusion arrhythmias induced after coronary thrombolysis--comparison of native t-PA and urokinase. Saito M, et al. **Jpn Circ J** 1995 Aug;59(8):556-64

Accelerated ST-segment reduction after thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) compared to urokinase. Derad I, et al. **Jpn Heart J** 1996 Jan;37(1):33-41

Intravenous thrombolysis in refractory unstable angina pectoris. Anderson HV. **Lancet** 1995 Oct 28; 346(8983):1113-4

Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction [see comments] Kellett J, et al. **Med Decis Making** 1995 Oct-Dec;15(4):297-310 (145 ref.) . Comment in: Med Decis Making 1995 Oct-Dec;15(4):395-6.

Accelerated tPA versus streptokinase for suspected myocardial infarction: waiting for our Mountain Dew [editorial; comment] McNutt R, et al. **Med Decis Making** 1995 Oct-Dec;15(4):395-6. Comment on: Med Decis Making 1995 Oct-Dec;15(5):297-310.

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group [see comments] **N Engl J Med** 1995 Dec 14;333(24):1581-7. Comment in: N Engl J Med 1995 Dec 14;333(24):1632-3. Comment in: N Engl J Med 1996 May 23;334(21):1405; discussion 1406. Comment in: N Engl J Med 1996 May 23;334(21):1405-6. Comment in: N Engl J Med 1996 May 23;334(21):1406.

Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction [see comments] Andreotti F, et al. **N Engl J Med** 1996 Jan 4;334(1):7-12. Comment in: N Engl J Med 1996 Jan 4;334(1):51-2. Comment in: N Engl J Med 1996 Jul 4;335(1):59; discussion 60-1. Comment in: N Engl J Med 1996 Jul 4;335(1):59-60; discussion 60-1.

Acute stroke--on the threshold of a therapy? [editorial; comment] [see comments] del Zoppo GJ. **N Engl J Med** 1995 Dec 14;333(24):1632-3. Comment on: N Engl J Med 1995 Dec 14;333(24):1581-7. Comment in: N Engl J Med 1996 May 23;334(21):1406.

Tissue plasminogen activator for acute ischemic stroke [letter; comment] Friedman HS. **N Engl J Med** 1996 May 23; 334(21):1405; discussion 1406. Comment on: N Engl J Med 1995 Dec 14;333(24):1581-7.

Preinfarction angina [letter; comment] Kloner RA, et al. **N Engl J Med** 1996 Jul 4;335(1):59-60; discussion 60-1. Comment on: N Engl J Med 1996 Jan 4;334(1):7-12.

Preinfarction angina [letter; comment] Migrino RQ, et al. **N Engl J Med** 1996 Jul 4;335(1):59; discussion 60-1. Comment on: N Engl J Med 1996 Jan 4;334(1):7-12.

Recombinant tissue plasminogen activator (rt-PA) as first-line therapy for declotting of haemodialysis access. Andriani M, et al. **Nephrol Dial Transplant** 1995; 10(9):1714-9

Acute cerebellar edema following intra-arterial tissue plasminogen activator thrombolysis for basilar artery occlusion--case report. Matsumoto K, et al. **Neurol Med Chir (Tokyo)** 1996 Jul;36(7):455-7

Combination tissue plasminogen activator and ticlopidine therapy in a rabbit model of acute thromboembolic stroke. Bednar MM, et al. **Neurol Res** 1996 Feb;18(1):45-8

Influence of a 'brain protector' drug 21-amino steroid on the effects of experimental embolic stroke treated by thrombolysis. Orozco J, et al. **Neurol Res** 1995 Dec; 17(6):423-5

A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Findlay JM, et al. **Neurosurgery** 1995 Jul;37(1):168-76; discussion 177-8

Tissue plasminogen activator in the surgical excision of subfoveal choroidal neovascular membranes. Thomas JW, et al. **Ophthalmic Surg** 1995 Jul-Aug;26(4):374-6

Intracameral tissue plasminogen activator after glaucoma surgery. Indications, effectiveness, and complications. Lundy DC, et al. **Ophthalmology** 1996 Feb;103(2):274-82

Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil. MacCumber MW, et al. **Ophthalmology** 1996 Feb; 103(2):269-73

Catheter-directed thrombolysis with recombinant tissue plasminogen activator for acute pulmonary embolism after fontan operation. Beitzke A, et al. **Pediatr Cardiol** 1996 Nov-Dec;17(6):410-2

Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease. Tsubata S, et al. **Pediatr Cardiol** 1995 Jul-Aug;16(4):186-9

Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Coll GE, et al. **Retina** 1995;15(4):319-26

Finding new drugs to treat stroke [news] Barinaga M. **Science** 1996 May 3;272(5262):664-6

Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Brandt T, et al. **Stroke** 1996 May;27(5):875-81

Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke. Correlations of outcome with clinical and radiological data. Trouillas P, et al. **Stroke** 1996 May;27(5):882-90

Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality. Paloma MJ, et al. **Thromb Haemost** 1995 Dec;74(6):1578-82

Treatment of fulminant meningococcemia with recombinant tissue plasminogen activator [letter] Zenz W, et al. **Thromb Haemost** 1995 Aug;74(2):802-3

[Thrombolytic therapy in acute cerebral ischemia] Boysen G, et al. **Ugeskr Laeger** 1996 Feb 5;158(6):786-9 **(Dan)**

[Thrombolytic therapy with rt-PA for thrombosis of tricuspid valve prosthesis during pregnancy] Azzano O, et al. **Arch Mal Coeur Vaiss** 1995 Feb;88(2):267-70 (Eng. Abstr.) **(Fre)**

[Pulmonary embolism: which thrombolytic should be chosen?] Pacouret G, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1763-7 (Eng. Abstr.) **(Fre)**

[Thrombolytic therapy for myocardial infarction in oral anticoagulation] Pizzulli L, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):424 **(Ger)**

[Thrombolysis in acute stroke with tissue plasminogen activator (news)] Willig V, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):A8-A10 **(Ger)**

[GUSTO (Global Utilization of Streptokinase & t-PA for Occluded Coronary Arteries): comparison of four therapeutic strategies in acute myocardial infarction.

Washington, 30 April 1993] **Internist (Berl)** 1993 Jul;34(7 Suppl):1–12 **(Ger)**

[Application of alteplase in prevention of cerebral vasospasm and its sequelae in patients after aneurysmal subarachnoid hemorrhage from ruptured cerebral aneuryam] Majchrzak H, et al. **Neurol Neurochir Pol** 1995 May–Jun;29(3):379–87 (Eng. Abstr.) **(Pol)**

[One center's experience with fibrinolytic treatment in children] Jarmoliński T, et al. **Pediatr Pol** 1996 May; 71(5):443–52 (Eng. Abstr.) **(Pol)**

[Recombinant tissue plasminogen activator for thrombolytic therapy of right atrial thrombus in a neonate and infant] Karolczak MA, et al. **Pediatr Pol** 1996 May;71(5):465–9 (Eng. Abstr.) **(Pol)**

[Brazilian study with alteplase in acute myocardial infarction--EBRALT] Batlouni M, et al. **Arq Bras Cardiol** 1995 Aug;65(2):175–9 (Eng. Abstr.) **(Por)**

[Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen] Maksimenko AV, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):48–51 **(Rus)**

ALTERNARIA

Cutaneous alternariosis occurring in a patient treated with local intrarectal corticosteroids [letter] Machet L, et al. **Acta Derm Venereol** 1995 Jul;75(4):328–9

Cutaneous alternariosis in a nonimmunocompromised patient. Saenz–Santamaria MC, et al. **Int J Dermatol** 1995 Aug; 34(8):556–7 (10 ref.)

[Alternaria tenuissima plurifocal cutaneous infection] Castanet J, et al. **Ann Dermatol Venereol** 1995;122(3):115–8 (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Effect of dichlorvos on growth and mycotoxin production by Alternaria alternata. Dalcero A, et al. **Food Addit Contam** 1996 Apr;13(3):315–20

GENETICS

Phylogeny of Alternaria fungi known to produce host–specific toxins on the basis of variation in internal transcribed spacers of ribosomal DNA. Kusaba M, et al. **Curr Genet** 1995 Oct;28(5):491–8

IMMUNOLOGY

N–terminus of a major allergen, Alt a I, of Alternaria alternata defined to be an epitope. Zhang L, et al. **Int Arch Allergy Immunol** 1995 Nov;108(3):254–9

[Human basophil degranulation test (HBDT) in fungal allergic asthmatic patients] Gu M, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Jun; 18(3):158–60, 190 (Eng. Abstr.) **(Chi)**

ISOLATION & PURIFICATION

Phaeohyphomycosis in a cat. Outerbridge CA, et al. **Can Vet J** 1995 Oct;36(10):629–30

Phaeohyphomycosis caused by Alternaria species and Phaeosclera dematioides Sigler, Tsuneda and Carmichael. Palencarova E, et al. **Clin Exp Dermatol** 1995 Sep; 20(5):419–22

Cutaneous alternariosis in an immunocompromised patient. Chaidemenos GC, et al. **Cutis** 1995 Sep;56(3):145–50 (40 ref.)

Cutaneous phaeohyphomycosis caused by Alternaria longipes in an immunosuppressed patient. Gené J, et al. **J Clin Microbiol** 1995 Oct;33(10):2774–6

[Determination of Alternaria mycotoxins in selected raw and processed fruit and vegetable products] Giryn H, et al. **Rocz Panstw Zakl Hig** 1995;46(2):129–33 (Eng. Abstr.) **(Pol)**

METABOLISM

Antioxidant function of melanin in black fungi. Jacobson ES, et al. **Infect Immun** 1995 Dec;63(12):4944–5

ALTERNATIVE COMPLEMENT PATHWAY see **COMPLEMENT PATHWAY, ALTERNATIVE**

ALTERNATIVE MEDICINE

Students' attitudes toward alternative health care [letter] Gracely EJ, et al. **Acad Med** 1996 Feb;71(2):109–10

Alternative Therapies chosen by Index Medicus [news] **Altern Ther Health Med** 1996 Jul;2(4):28

FDA shortens approval periods for new cancer treatments [news] **Altern Ther Health Med** 1996 Jul;2(4):28

Informed consent and alternative medicine. Clouser KD, et al. **Altern Ther Health Med** 1996 Mar;2(2):76–8

The trickster: medicine's forgotten character [editorial] Dossey L. **Altern Ther Health Med** 1996 Mar;2(2):6–14

Alternative therapies and multiple sclerosis: two case reports. Fawcett J, et al. **Altern Ther Health Med** 1996 Sep;2(5):67–9

The voices of experience and the process of change in medicine. Gordon JS. **Altern Ther Health Med** 1996 May; 2(3):96, 95

Michael Harner, PhD. Shamanic healing: we are not alone [interview by Bonnie Horrigan] Harner M. **Altern Ther Health Med** 1996 May;2(3):68–75

In support of clinical research in alternative medicine. Hatfield M. **Altern Ther Health Med** 1996 Mar;2(2):80

Culturally grounded review of research assumptions. Hufford DJ. **Altern Ther Health Med** 1996 Jul;2(4):47–53

Wants to see belief systems included with research data [letter] Jaber R. **Altern Ther Health Med** 1996 Jul;2(4):18–9

Wayne Jonas, MD: at the helm of the OAM [interview by Bonnie Horrigan] Jonas W. **Altern Ther Health Med** 1996 Jan;2(1):82–91

Alternative medicine's relevance to public health practice and research [news] Justice B. **Altern Ther Health Med** 1996 May;2(3):24–5

Complementary therapies in HIV disease. Kaiser JD, et al. **Altern Ther Health Med** 1996 Jul;2(4):42–6

The effect of maitake mushrooms on liver and serum lipids. Kubo K, et al. **Altern Ther Health Med** 1996 Sep;2(5):62–6

Alternative medicine in the workplace. Lippin RA. **Altern Ther Health Med** 1996 Jan;2(1):47–51 (28 ref.)

The Healing Web: nursing borrows from Native American tradition to create a better approach to healing. Moore NG. **Altern Ther Health Med** 1996 Mar;2(2):30–1

Pew Commission report: focusing care on the community for the 21st century [news] Moore NG. **Altern Ther Health Med** 1996 Sep;2(5):28–34

The American Holistic Centers: a model in integrative care. Moore NG. **Altern Ther Health Med** 1996 Sep;2(5):38–9

Body, mind, heart, and spirit: a new paradigm of cancer care [news] Moore NG. **Altern Ther Health Med** 1996 Jul; 2(4):30, 32–3

Viewing persons as stories: a perspective for holistic care. Nagai–Jacobson MG, et al. **Altern Ther Health Med** 1996 Jul;2(4):54–8

New MeSH terms add accessibility to alternative medicine literature. Pavek RR. **Altern Ther Health Med** 1996 Mar; 2(2):25–8

Janet Quinn, RN, PhD. Therapeutic touch and a healing way [interview by Bonnie Horrigan] Quinn J. **Altern Ther Health Med** 1996 Jul;2(4):69–75

Wants to see public health departments incorporate alternative therapies [letter] Schneider J. **Altern Ther Health Med** 1996 Jan;2(1):14

Leanna Standish, ND, PhD. From neuroscience to naturopathy [interview by Bonnie Horrigan] Standish L. **Altern Ther Health Med** 1996 Sep;2(5):80–9

Report from June 13–14 AMPAC meeting. Alternative Medicine Program Advisory Council. Villaire M. **Altern Ther Health Med** 1996 Sep;2(5):22–5

Update on Minneapolis, Seattle alternative medicine research centers. Villaire M. **Altern Ther Health Med** 1996 Jul; 2(4):25

Disputes conclusions in Hildenbrand study [letter] Zollman C, et al. **Altern Ther Health Med** 1996 Jul;2(4):14–5, 17–8

Alternative therapies [editorial] Bryan–Brown CW, et al. **Am J Crit Care** 1995 Nov;4(6):416–8

Rainforest holds many lessons for pharmacy. Stover KA. **Am Pharm** 1995 Sep;NS35(9):13

Kombucha "mushroom" hepatotoxicity [letter] Perron AD, et al. **Ann Emerg Med** 1995 Nov;26(5):660–1

Antiscience trends in the rise of the "alternative medicine" movement. Sampson W. **Ann N Y Acad Sci** 1996 Jun 24; 775:188–97 (34 ref.)

"Sucking with vampires". The medicine of unreason. Weissmann G. **Ann N Y Acad Sci** 1996 Jun 24;775:179–87 (26 ref.)

The relativity of alternative medicine [editorial; comment] Alpert JS. **Arch Intern Med** 1995 Dec 11–25;155(22):2385 . Comment on: Arch Intern Med 1995 Dec 11–25;155(22):2405–8.

Complementary medicine. What physicians think of it: a meta–analysis [see comments] Ernst E, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2405–8. Comment in: Arch Intern Med 1995 Dec 11–25;155(22):2385.

Determinants of nontraditional therapy use in patients with HIV infection. A prospective study. Singh N, et al. **Arch Intern Med** 1996 Jan 22;156(2):197–201

Commissioning complementary medicine. Evaluations of efficacy of treatments should be consistent [letter; comment] Brewin T, et al. **BMJ** 1995 Sep 23;311(7008):809 . Comment on: BMJ 1995 May 6;310(6988):1151–2.

Research priorities in complementary medicine [letter] Ernst E, et al. **BMJ** 1996 Jun 8;312(7044):1481–2

"Probiotic" remedies are not what they seem [letter] Hamilton–Miller JM, et al. **BMJ** 1996 Jan 6;312(7022):55–6

Safety of complementary medicines should be monitored [letter; comment] Saw HM. **BMJ** 1996 Jan 13;312(7023):122 . Comment on: BMJ 1995 Sep 2;311(7005):633.

The health beliefs and behaviours of orthodox and complementary medicine clients. Furnham A, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):49–61

Anecdotes and empiricism [letter] May P. **Br J Gen Pract** 1996 Mar;46(404):201

Science and antiscience in complementary medicine [editorial] Ernst E. **Br J Hosp Med** 1995 Oct 4–17; 54(7):304–5

Opening Pandora's box. Family physicians and alternative medicine. Blair L. **Can Fam Physician** 1995 Oct;41:1807–10

Herbal products begin to attract the attention of brand–name drug companies. Cottrell K. **Can Med Assoc J** 1996 Jul 15;155(2):216–9

Physicians should keep an open mind on complementary health care, Congress says. Spencer MH. **Can Med Assoc J** 1995 Dec 15;153(12):1796–7

Alternative therapies in veterinary medicine [letter] Physick–Sheard PW. **Can Vet J** 1995 Sep;36(9):529–30

Alternative and complementary cancer therapies. Cassileth BR, et al. **Cancer** 1996 Mar 15;77(6):1026–34 (61 ref.)

Alternative cancer medicine: a ten–year update. Cassileth BR, et al. **Cancer Invest** 1996;14(4):396–404 (46 ref.)

Shark cartilage: the Laetrile of the 1990s [editorial] Markman M. **Cleve Clin J Med** 1996 May–Jun;63(3):179–80

Speleotherapy in asthma and allergic diseases [letter; comment] Karakoca Y, et al. **Clin Exp Allergy** 1995 Jul; 25(7):666–7. Comment on: Clin Exp Allergy 1994 Sep;24(9):813–25.

Complementary cancer treatments: hope or hazard? Ernst E. **Clin Oncol (R Coll Radiol)** 1995;7(4):259–63 (34 ref.)

Complementary therapies [editorial] Vernon CC. **Clin Oncol (R Coll Radiol)** 1996;8(1):1–2

Mind over maladies. Can yoga, prayer and meditation be adapted for managed care? [interview by Jim Montague] Benson H. **Hosp Health Netw** 1996 Apr 20;70(8):26–7

Alternative medicine. Seattle goes au naturel. Hagland M. **Hosp Health Netw** 1996 Mar 20;70(6):82

Alternative therapies as control behaviours used by cancer patients. Montbriand MJ. **J Adv Nurs** 1995 Oct; 22(4):646–54

Complementary or alternative medicine [letter] Barrett S. **J Am Board Fam Pract** 1996 Jan–Feb;9(1):71

Physicians' attitudes toward complementary or alternative medicine: a regional survey. Berman BM, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):361–6

Complementary or alternative medicine [letter] Davis EH. **J Am Board Fam Pract** 1996 Jan–Feb;9(1):70

Brief report: alternative approaches to the development of effective treatments for autism. Rimland B, et al. **J Autism Dev Disord** 1996 Apr;26(2):237–41 (7 ref.)

Has medicine lost its heart? [editorial] Hedge BM. **J Indian Med Assoc** 1995 Jul;93(7):253–4

Alternative medicine: does it play a role in the management of voice disorders? D'Antoni ML, et al. **J Voice** 1995 Sep; 9(3):308–11

Defining and assessing alternative medicine practices [letter] Gorski T. **JAMA** 1996 Jul 17;276(3):195–6

Uptake of alternative medicine [letter; comment] Ernst E. **Lancet** 1996 Apr 6;347(9006):972. Comment on: Lancet 1996 Mar 2;347(9001):569–73.

Uptake of alternative medicine [letter; comment] Kaptchuk TJ. **Lancet** 1996 Apr 6;347(9006):972. Comment on: Lancet 1996 Mar 2;347(9001):569–73.

"Natural" therapy for infectious diseases. Golledge CL, et al. **Med J Aust** 1996 Jan 15;164(2):94–5

Managing HIV. Part 7: Professional issues. 7.4 HIV and complementary medicine. McKnight I, et al. **Med J Aust** 1996 Aug 5;165(3):143–5

Keep an open mind [letter] Klaus R. **N Y State Dent J** 1995 Nov;61(9):17–8

Alternative voices [letter; comment] Sherman JA. **N Y State Dent J** 1995 Nov;61(9):16. Comment on: N Y State Dent J 1995 Aug–Sep;61(7):16–7.

Maharishi Vedic Health Science [letter] Lovell–Smith HD. **N Z Med J** 1996 Apr 26;109(1020):151

Complementary medicine [letter] Abbot NC, et al. **Nature** 1996 May 30;381(6581):361

Effects of citrus fragrance on immune function and depressive states. Komori T, et al. **Neuroimmunomodulation** 1995 May–Jun;2(3):174–80

The metaphysics of holism: laughter in carnival with alternative medicine. Elgee NJ. **Pharos** 1995 Fall; 58(4):18–20

Renal failure associated with alternative medical therapies. Farrell J, et al. **Ren Fail** 1995 Nov;17(6):759–64

Alternative medicine--a doctor's perspective [letter] Heusser P. **S Afr Med J** 1995 Aug;85(8):795–6

Alternative medicine--a doctor's perspective [letter] Levin S. **S Afr Med J** 1996 Feb;86(2):183–4

Alternative medicine--a doctor's perspective [letter] Pantanowitz D. **S Afr Med J** 1996 Feb;86(2):184

Alternative medicine--a doctor's perspective [letter] Pantanowitz D. **S Afr Med J** 1995 Aug;85(8):794–5

Alternative medicine--a doctor's perspective [letter] Richards A. **S Afr Med J** 1996 Feb;86(2):184

Alternative cancer treatments. Aulas JJ. **Sci Am** 1996 Sep; 275(3):162–3 (0 ref.)

General practitioners' assessment of and interest in alternative medicine in Canada. Verhoef MJ, et al. **Soc Sci Med** 1995 Aug;41(4):511–5

Proven and unproven therapies in cancer treatment: a controversy among German oncologists [news] Stiefel F. **Support Care Cancer** 1995 Jul;3(4):219–20

Unproven (questionable) cancer therapies. Brigden ML. **West J Med** 1995 Nov;163(5):463–9 (39 ref.)

[Alternative fragments?] Damkier A, et al. **Ugeskr Laeger** 1996 Aug 5;158(32):4527–9 **(Dan)**

[It should be obvious to everyone (editorial)] Hartling OJ. **Ugeskr Laeger** 1996 Aug 12;158(33):4621 **(Dan)**

[Does the National Board of Health adn Welfare support worthless research on alternative therapy? (letter)] Olesen J. **Ugeskr Laeger** 1995 Dec 4;157(49):6889–90 **(Dan)**

[Is 'Cuba–therapy'useful in retinitis pigmentosa?] **Ned Tijdschr Geneeskd** 1996 Jan 27;140(4):217 **(Dut)**

[Alternative medicine] Saano V. **Duodecim** 1995;111(1):78–84 (41 ref.) **(Fin)**

[The cancer patient between academic medicine and

alternative medicine--therapeutic concepts] Nagel GA. **Arch Gynecol Obstet** 1995;257(1-4):283-94 (13 ref.) **(Ger)**

[Comment on the interview with R. F. Schmidt and G. Thews. Clinical principles and medical decision making (letter)] Scheler F. **Internist (Berl)** 1995 Oct;36(10):1018 **(Ger)**

[Talking medicine contra alternative medicine? (letter; comment)] Heimpel H. **Med Klin** 1995 Sep 15;90(9):554. Comment on: Med Klin 1995 Jun 15;90(6):372-3. **(Ger)**

[Alternative treatment methods in cancer] Jungi WF, et al. **Med Monatsschr Pharm** 1996 Jan;19(1):6-16 (8 ref.) **(Ger)**

[Is there a scientific alternative to alternative medicine?] Adler RH. **Schweiz Rundsch Med Prax** 1995 Dec 19; 84(51-52):1517-21 (Eng. Abstr.) **(Ger)**

[The mistletoe myth--claims, reality and provable perspectives] Gabius HJ, et al. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):103-10 (Eng. Abstr.) **(Ger)**

[Smoking cessation with alternative methods] Stumpfe KD. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):511-4 (27 ref.) (Eng. Abstr.) **(Ger)**

[Consultations with practitioners of alternative medicine] Bernstein JH, et al. **Harefuah** 1996 Jan 15;130(2):83-5, 144, 143 (Eng. Abstr.) **(Heb)**

[The challenge of alternative medicine] Leibovici L. **Harefuah** 1996 Jan 15;130(2):109-13 (20 ref.) **(Heb)**

[The "kangaroo mother" method (editorial)] Mosseri R, et al. **Harefuah** 1996 Jan 15;130(2):95-7 (15 ref.) **(Heb)**

[Theory and practice of alternative practice] de Avila-Pires FD. **Rev Saude Publica** 1995 Apr;29(2):147-51 (Eng. Abstr.) **(Por)**

[Knowledge and use of alternative medicine among elementary school students and teachers] dos Santos MG, et al. **Rev Saude Publica** 1995 Jun;29(3):221-7 (Eng. Abstr.) **(Por)**

[References to the article by Prof. V. Zikmund: Problems with the limitations of medicine (letter)] Solár G. **Bratisl Lek Listy** 1995 Dec;96(12):677-9 **(Slo)**

[Respected research institutes in the USA receive support for alternative medicine. Self-hypnosis and laying-on-of-hands in heart surgery] Bergström L. **Lakartidningen** 1996 Feb 28;93(9):753-5 **(Swe)**

[Unconventional medicine a topic for European cooperation (letter)] Eklöf M. **Lakartidningen** 1996 Feb 7;93(6):446 **(Swe)**

[Considering alternative therapeutic forms is worthwhile (letter)] Lindholm E. **Lakartidningen** 1996 Feb 28;93(9):765 **(Swe)**

ECONOMICS

The development and dissemination of non-patentable therapies (NPTs). Root-Bernstein RS. **Perspect Biol Med** 1995 Autumn;39(1):110-7 (26 ref.)

[Alternative medicine--a true alternative or only another market?] Ziegenhagen DJ. **Versicherungsmedizin** 1996 Apr 1;48(2):33-5 **(Ger)**

HISTORY

The efficacy, history, and politics of medicinal plants. Lipp FJ. **Altern Ther Health Med** 1996 Jul;2(4):36-41 (40 ref.)

Alienation and the production of strangers: Western medical epistemology and the architectonics of the body. An historical perspective [see comments] Martensen RL. **Cult Med Psychiatry** 1995 Jun;19(2):141-82. Comment in: Cult Med Psychiatry 1995 Jun;19(2):207-15. Comment in: Cult Med Psychiatry 1995 Jun;19(2):217-23.

Profile: Wayne B. Jonas. Probing medicine's outer reaches [news] Stix G. **Sci Am** 1996 Oct;275(4):52, 56

LEGISLATION & JURISPRUDENCE

Access to Medical Treatment Act stalled in senate and house subcommittees [news] **Altern Ther Health Med** 1996 Jul; 2(4):34

An overview of state alternative healing practices law [news] Beck RL. **Altern Ther Health Med** 1996 Jan;2(1):31-3

Integrating conventional medicine and alternative therapies. Green JA. **Altern Ther Health Med** 1996 Jul;2(4):77-81

Regulating complementary medicine [editorial] Stone J. **BMJ** 1996 Jun 15;312(7045):1492-3

[Consequences of the public health structure law for naturopathic methods in gynecology] Böddeker E. **Arch Gynecol Obstet** 1995;257(1-4):121-5 **(Ger)**

[Expert assessment of unconventional treatment methods within the scope of legal health insurance--problems based on current court decisions] Nüchtern E. **Gesundheitswesen** 1995 Aug-Sep;57(8-9):437-42 (Eng. Abstr.) **(Ger)**

[Alternative medicine in private personal insurance] Ostendorf GM. **Versicherungsmedizin** 1995 Dec 1; 47(6):224-31 (Eng. Abstr.) **(Ger)**

[Special treatment methods in general practice--legal medicine viewpoint] Wagner HJ. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):123-5 (Eng. Abstr.) **(Ger)**

METHODS

[Cupping as evaluated by the client] Vaskilampi T, et al. **Duodecim** 1994;110(16):1505-9 **(Fin)**

[General interpretation of so-called alternative practices] Lecomte J. **Rev Med Liege** 1996 Apr;51(4):307-12 **(Fre)**

STANDARDS

Complementary medicine and the scientific method [letter; comment] McGoey JS. **Can Med Assoc J** 1996 Jan 1; 154(1):14-5; discussion 15-6. Comment on: Can Med Assoc J 1995 Jul 1;153(1):45-9.

Complementary medicine and the scientific method [letter; comment] Sutter MC. **Can Med Assoc J** 1996 Jan 1; 154(1):14; discussion 15-6. Comment on: Can Med Assoc J 1995 Jul 1;153(1):45-9.

[Beliefs and knowledge of medicine, or how to become a "successful" practitioner of naturopathy] Personne M. **Lakartidningen** 1996 Jan 3;93(1-2):10-1 **(Swe)**

TRENDS

Medical pluralism in the United States: a review. Baer HA. **Med Anthropol Q** 1995 Dec;9(4):493-502

UTILIZATION

Use of non-proven therapies. Differences in attitudes between Norwegian patients with non-malignant disease and patients suffering from cancer. Risberg T, et al. **Acta Oncol** 1995;34(7):893-8

Unconventional cancer therapy--survey of patients with gynaecological malignancy. Münstedt K, et al. **Arch Gynecol Obstet** 1996;258(2):81-8

Complementary medicine is booming worldwide [news] **BMJ** 1996 Jul 20;313(7050):131-3

Alternative medicine: should it be used by children? Spigelblatt LS. **Curr Probl Pediatr** 1995 Jul;25(6):180-8 (67 ref.)

The use of non-proven therapy among patients treated in Norwegian oncological departments. A cross-sectional national multicentre study. Risberg T, et al. **Eur J Cancer** 1995 Oct;31A(11):1785-9

Alternative/complementary therapies used by persons with HIV disease. Nokes KM, et al. **J Assoc Nurses AIDS Care** 1995 Jul-Aug;6(4):19-24

Uptake of alternative medicine [letter; comment] Baldwin of Bewdley. **Lancet** 1996 Apr 6;347(9006):972-3. Comment on: Lancet 1996 Mar 2;347(9001):569-73.

Uptake of alternative medicine [letter; comment] Kristoffersen SS, et al. **Lancet** 1996 Apr 6;347(9006):972. Comment on: Lancet 1996 Mar 2;347(9001):569-73.

Prevalence and cost of alternative medicine in Australia [see comments] MacLennan AH, et al. **Lancet** 1996 Mar 2; 347(9001):569-73. Comment in: Lancet 1996 Apr 6;347(9006):972. Comment in: Lancet 1996 Apr 6;347(9006):972-3.

[Use of complimentary medical therapies in HIV/AIDS in Switzerland] Brauchli P, et al. **Schweiz Med Wochenschr** 1996 Jul 27;126(30):1297-305 (Eng. Abstr.) **(Ger)**

ALTERNATIVE SPLICING

A novel mutation in the putative DNA helicase XH2 is responsible for male-to-female sex reversal associated with an atypical form of the ATR-X syndrome. Ion A, et al. **Am J Hum Genet** 1996 Jun;58(6):1185-91

FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Meyers GA, et al. **Am J Hum Genet** 1996 Mar;58(3):491-8

Expression of alternatively spliced fibronectin variants during remodeling in proliferative glomerulonephritis. Barnes JL, et al. **Am J Pathol** 1995 Nov;147(5):1361-71

Cloning, embryonic expression, and alternative splicing of a murine kidney-specific Na-K-Cl cotransporter. Igarashi P, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):F405-18

Recurrent transition at a CG dinucleotide in exon 12 of COL2A1 produces kniest dysplasia with abnormal RNA splicing by chondrocytes and lymphoblasts and interruption of the triple helix of type II collagen. Chen L, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:234-7

Identification of a novel alternatively spliced isoform of the Na(+)-Ca2+ exchanger (NACA8) in heart. Reilly RF, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:129-31

Alternative splicing of a chondrocyte-specific gene. Reynolds PR, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:321-4

APP gene family. Alternative splicing generates functionally related isoforms. Sandbrink R, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:281-7

Alternative splicing of the Na(+)-Ca2+ exchanger gene, NCX1. Schulze DH, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:46-57 (32 ref.)

A splice variant of CD44 expressed in the rat apical ectodermal ridge contributes to limb outgrowth. Wainwright D, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:345-9

Differentially spliced exon 5 of the Wilms' tumor gene WT1 modifies gene function. Hewitt SM, et al. **Anticancer Res** 1996 Mar-Apr;16(2):621-6

Expression of alternatively spliced lck transcripts from the proximal promoter in colorectal cancer derived cell lines. Mayer K, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1733-7

Retarded and aberrant splicings caused by single exon mutation in a phosphoglycerate kinase variant. Ookawara T, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):35-40

Alternative splicing and cDNA sequence of myelin basic protein gene of the Lewis rat [letter] Malotka J, et al. **Autoimmunity** 1995;20(1):67-8

Mutation screening and identification of a sequence variation in the human ob gene coding region. Considine RV, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):735-9

Biochemical properties of a novel U2AF65 protein isoform generated by alternative RNA splicing. Ding F, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):675-83

Complete nucleotide sequence, structural organization, and an alternatively spliced exon of mouse h1-calponin gene. Gao J, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):292-7

Different expression of the myotonin protein kinase gene in discrete areas of human brain. Gennarelli M, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):489-94

Alternative RNA splicing-generated cardiac troponin T isoform switching: a non-heart-restricted genetic programming synchronized in developing cardiac and skeletal muscles. Jin JP. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):883-9

An embryonic alternative transcription initiation site and the 5'-upstream structure of mouse cardiac troponin T gene. Jin JP, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):1168-74

Identification of novel alternatively spliced pyruvate carboxylase mRNAs with divergent 5'-untranslated regions which are expressed in a tissue-specific manner. Jitrapakdee S, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):695-700

Type I inositol-triphosphate receptor gene is alternatively spliced in human cerebral arteries. Katušić ZS, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):803-9

An alternatively spliced form of the human lysosome-associated membrane protein-2 gene is expressed in a tissue-specific manner. Konecki DS, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):757-67

Apo-dystrophins (Dp140 and Dp71) and dystrophin splicing isoforms in developing brain. Morris GE, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):361-7

A novel donor splice site mutation in the glycogen debranching enzyme gene is associated with glycogen storage disease type III. Okubo M, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):493-9

Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Pramono ZA, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):445-9

An alternatively spliced isoform of the Spi-B transcription factor. Ray-Gallet D, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):257-63

An alternately spliced mRNA encoding functional domains of murine MAdCAM-1. Schiffer SG, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):170-6

A human protective protein gene partially overlaps the gene encoding phospholipid transfer protein on the complementary strand of DNA. Shimmoto M, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):802-6

Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor. Birkenhäger R, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):703-7

Alternative processing of the sarco/endoplasmic reticulum Ca(2+)-ATPase transcripts during muscle differentiation is a specifically regulated process. Bosch LV, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):647-51

The human leukotriene A4 hydrolase gene is expressed in two alternatively spliced mRNA forms. Jendraschak E, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):733-7

The properties of a subtype of the inositol 1,4,5-trisphosphate receptor resulting from alternative splicing of the mRNA in the ligand-binding domain. Lièvremont JP, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):755-62

Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. McPhee I, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):965-74

Alternative RNA splicing of the human endothelin-A receptor generates multiple transcripts. Miyamoto Y, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):795-801

Characterization of human AMP deaminase 2 (AMPD2) gene expression reveals alternative transcripts encoding variable N-terminal extensions of isoform L. Van den Bergh F, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):401-10

Complete structure of the murine p36 (annexin II) gene. Identification of mRNAs for both the murine and the human gene with alternatively spliced 5' noncoding exons. Fey MF, et al. **Biochim Biophys Acta** 1996 May 2; 1306(2-3):160-70

The alternative exons 1 of the mouse aromatase cytochrome P-450 gene. Honda S, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):145-50

Modification of the alternative splicing process of testosterone-repressed prostate message-2 (TRPM-2) gene by protein synthesis inhibitors and heat shock treatment. Kimura K, et al. **Biochim Biophys Acta** 1996 Jun 3; 1307(1):83-8

Naturally occurring splicing variants of the hMSH2 gene containing nonsense codons identify possible mRNA instability motifs within the gene coding region. Marshall

B, et al. **Biochim Biophys Acta** 1996 Jul 31;1308(1):88–92

The choice between alternative IIIb and IIIc exons of the FGFR–3 gene is not strictly tissue–specific. Scotet E, et al. **Biochim Biophys Acta** 1995 Nov 7;1264(2):238–42

Asynchronous regulation of splicing events within protein 4.1 pre–mRNA during erythroid differentiation. Baklouti F, et al. **Blood** 1996 May 1;87(9):3934–41

Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. Gotley DC, et al. **Br J Cancer** 1996 Aug;74(3):342–51

Neuronatin mRNA: alternatively spliced forms of a novel brain–specific mammalian developmental gene. Joseph R, et al. **Brain Res** 1995 Aug 28;690(1):92–8

Characterization of two fish glutamate receptor cDNA molecules: absence of RNA editing at the Q/R site. Kung SS, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):119–30

The distribution of splice variants of the NMDAR1 subunit mRNA in adult rat brain. Laurie DJ, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):94–108

Expression of agrin mRNA is altered following seizures in adult rat brain. O'Connor LT, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):277–87

Effect of adrenal steroids on preproneurokinin–A gene expression in discrete regions of the rat brain. Pompei P, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):209–16

Identification of two alternatively spliced transcripts of STEP: a subfamily of brain–enriched protein tyrosine phosphatases. Sharma E, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):87–93

The RNA binding protein HuD: rat cDNA and analysis of the alternative spliced mRNA in neuronal differentiating cell lines P19 and PC12. Steller U, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):285–96

p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Liggett WH Jr, et al. **Cancer Res** 1996 Sep 15;56(18):4119–23

Relief of ornithine decarboxylase messenger RNA translational repression induced by alternative splicing of its 5' untranslated region. Pyronnet S, et al. **Cancer Res** 1996 Apr 15;56(8):1742–5

An alternatively spliced exon in the extracellular domain of the human alpha 6 integrin subunit--functional analysis of the alpha 6 integrin variants. Delwel GO, et al. **Cell Adhes Commun** 1995 May;3(2):143–61

Cloning, developmental expression, and evidence for alternative splicing of the murine tuberous sclerosis (TSC2) gene product. Kim KK, et al. **Cell Mol Biol Res** 1995; 41(6):515–26

Developmental role of transcription factor isoforms generated by alternative splicing. López AJ. **Dev Biol** 1995 Dec;172(2):396–411 (118 ref.)

The developmental consequences of alternate splicing in sex determination and differentiation in Drosophila. MacDougall C, et al. **Dev Biol** 1995 Dec;172(2):353–76 (144 ref.)

Chicken perinatal troponin Ts are generated by a combination of novel and phylogenetically conserved alternative splicing pathways. Schachat F, et al. **Dev Biol** 1995 Sep;171(1):233–9

Alternative RNA splicing that determines agrin activity regulates binding to heparin and alpha–dystroglycan. Campanelli JT, et al. **Development** 1996 May; 122(5):1663–72

The mec–8 gene of C. elegans encodes a protein with two RNA recognition motifs and regulates alternative splicing of unc–52 transcripts. Lundquist EA, et al. **Development** 1996 May;122(5):1601–10

FGF–8 isoforms activate receptor splice forms that are expressed in mesenchymal regions of mouse development. MacArthur CA, et al. **Development** 1995 Nov; 121(11):3603–13

Alternatively spliced forms of the Drosophila alphaPS2 subunit of integrin are sufficient for viability and can replace the function of the alphaPS1 subunit of integrin in the retina. Roote CE, et al. **Development** 1996 Jun; 122(6):1985–94

Regulation of insulin receptor mRNA splicing in rat tissues. Effect of fasting, aging, and diabetes. Vidal H, et al. **Diabetes** 1995 Oct;44(10):1196–201

Binding of human, porcine and bovine insulin to insulin receptors from human brain, muscle and adipocytes and to expressed recombinant alternatively spliced insulin receptor isoforms [see comments] Kotzke G, et al. **Diabetologia** 1995 Jul;38(7):757–63. Comment in: Diabetologia 1996 Feb;39(2):248–9.

Chronic primary hyperinsulinaemia is associated with altered insulin receptor mRNA splicing in muscle of patients with insulinoma. Sbraccia P, et al. **Diabetologia** 1996 Feb; 39(2):220–5

Alternative splicing gives rise to two isoforms of Zfhep, a zinc finger/homeodomain protein that binds T3–response elements. Cabanillas AM, et al. **DNA Cell Biol** 1996 Aug; 15(8):643–51

Identification of novel mRNA isoforms for human DNA polymerase beta. Chyan YJ, et al. **DNA Cell Biol** 1996 Aug; 15(8):653–9

Alternative splicing generates four different forms of a non–transmembrane protein tyrosine phosphatase mRNA. Reddy RS, et al. **DNA Cell Biol** 1995 Dec;14(12):1007–15

Cloning and sequence of the feline max, and max 9 transcripts. Gallagher RC, et al. **DNA Seq** 1995;5(5):269–71

Nucleotide sequence and molecular variants of rat receptor–type protein tyrosine phosphatase–zeta/beta. Maurel P, et al. **DNA Seq** 1995;5(5):323–8

The two isoforms of mouse terminal deoxynucleotidyl transferase differ in both the ability to add N regions and subcellular localization. Bentolila LA, et al. **EMBO J** 1995 Sep 1;14(17):4221–9

In vivo membrane assembly of split variants of the E.coli outer membrane protein OmpA. Koebnik R. **EMBO J** 1996 Jul 15;15(14):3529–37

Trans–acting factors regulate the expression of CD44 splice variants. Konig H, et al. **EMBO J** 1996 Aug 1; 15(15):4030–9

Mutant U5A cells are complemented by an interferon–alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. Lutfalla G, et al. **EMBO J** 1995 Oct 16;14(20):5100–8

Identification and characterization of three members of the human SR family of pre–mRNA splicing factors. Screaton GR, et al. **EMBO J** 1995 Sep 1;14(17):4336–49

A splice variant of the neurotrophin receptor trkB with increased specificity for brain–derived neurotrophic factor. Strohmaier C, et al. **EMBO J** 1996 Jul 1;15(13):3332–7

Expression of an active Na+/Ca2+ exchanger isoform lacking the six C–terminal transmembrane segments. Gabellini N, et al. **Eur J Biochem** 1996 Aug 1; 239(3):897–904

A single point mutation in the splice donor site of the low–density–lipoprotein–receptor gene produces intron read–through, exon–skipped and cryptic–site–utilized transcripts. Maruyama T, et al. **Eur J Biochem** 1995 Sep 15;232(3):700–5

Purification and characterization of the soluble interleukin–6 receptor from human plasma and identification of an isoform generated through alternative splicing. Müller–Newen G, et al. **Eur J Biochem** 1996 Mar 15; 236(3):837–42

Gene structure of the murine calcium channel beta3 subunit, cDNA and characterization of alternative splicing and transcription products. Murakami M, et al. **Eur J Biochem** 1996 Feb 15;236(1):138–43

Conserved alternative splicing in the 5'–untranslated region of the muscle–specific enolase gene. Primary structure of mRNAs, expression and influence of secondary structure on the translation efficiency. Oliva D, et al. **Eur J Biochem** 1995 Aug 15;232(1):141–9

Alternative splicing of the pyruvate kinase M gene in a minigene system. Takenaka M, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):366–71

Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. Heider KH, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2385–91

Splicing of exon 5 in the WT1 gene is disrupted in Wilms' tumour [see comments] Simms LA, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2270–6. Comment in: Eur J Cancer 1995 Dec;31A(13–14):2138–40.

Adhesion mediated by fibronectin's alternatively spliced EDb (EIIIB) and its neighboring type III repeats. Chen W, et al. **Exp Cell Res** 1996 Feb 25;223(1):9–19

Alternative splicing of fibronectin--many different proteins but few different functions. french–Constant C. **Exp Cell Res** 1995 Dec;221(2):261–71 (111 ref.)

The fibronectin gene as a model for splicing and transcription studies. Kornblihtt AR, et al. **FASEB J** 1996 Feb; 10(2):248–57 (76 ref.)

Alternative splicing of AMPA receptor subunits: regulation in clonal cell lines. Christnacher A, et al. **FEBS Lett** 1995 Oct 2;373(1):93–6

Genomic structure and alternative splicing of the murine bhk/ctk/ntk gene. Ershler MA, et al. **FEBS Lett** 1995 Nov 13;375(1–2):50–2

Localization of leptin receptor mRNA and the long form splice variant (Ob–Rb) in mouse hypothalamus and adjacent brain regions by in situ hybridization. Mercer JG, et al. **FEBS Lett** 1996 Jun 3;387(2–3):113–6

cDNA cloning and characterization of A3i, an alternatively spliced rat A3 adenosine receptor variant. Sajjadi FG, et al. **FEBS Lett** 1996 Mar 11;382(1–2):125–9

Identification of alternative splicing form of Stat2. Sugiyama T, et al. **FEBS Lett** 1996 Mar 4;381(3):191–4

Alternative splicing of the Drosophila melanogaster rotundRacGAP gene. Hoemann CD, et al. **Gene** 1996 Feb 12;168(2):135–41

An intron enhancer recognized by splicing factors activates polyadenylation. Lou H, et al. **Genes Dev** 1996 Jan 15; 10(2):208–19

Assembly of specific SR protein complexes on distinct regulatory elements of the Drosophila doublesex splicing enhancer. Lynch KW, et al. **Genes Dev** 1996 Aug 15; 10(16):2089–101

A negative feedback mechanism revealed by functional analysis of the alternative isoforms of the Drosophila splicing regulator transformer–2. Mattox W, et al. **Genetics** 1996 May;143(1):303–14

Conserved alternative splicing patterns and splicing signals in the Drosophila sodium channel gene para. Thackeray JR, et al. **Genetics** 1995 Sep;141(1):203–14

Structure of the human laminin gamma 2 chain gene (LAMC2): alternative splicing with different tissue distribution of two transcripts. Airenne T, et al. **Genomics** 1996 Feb 15;32(1):54–64

Developmental expression of p107 mRNA and evidence for alternative splicing of the p107 (RBL1) gene product. Kim KK, et al. **Genomics** 1995 Aug 10;28(3):520–9

Identification of an alternative transcript from the human iduronate–2–sulfatase (IDS) gene. Malmgren H, et al. **Genomics** 1995 Sep 1;29(1):291–3

Structure of the human myelin/oligodendrocyte glycoprotein gene and multiple alternative spliced isoforms. Pham–Dinh D, et al. **Genomics** 1995 Sep 20;29(2):345–52

Alternative splicing of the tuberous sclerosis 2 (TSC2) gene in human and mouse tissues. Xu L, et al. **Genomics** 1995 Jun 10;27(3):475–80

Expression of aberrantly spliced growth hormone receptor mRNA in the sex–linked dwarf chicken, Gifu 20. Tanaka M, et al. **Growth Regul** 1995 Dec;5(4):218–23

Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype–phenotype relationship. Ploos van Amstel JK, et al. **Hum Genet** 1996 Jan;97(1):51–9

Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Tokino T, et al. **Hum Genet** 1996 May;97(5):625–31

APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis. van der Luijt RB, et al. **Hum Genet** 1995 Dec;96(6):705–10

Evidence for the presence of the alternatively spliced HLA–G mRNA forms in human mononuclear cells from peripheral blood and umbilical cord blood. Kirszenbaum M, et al. **Hum Immunol** 1995 Jul;43(3):237–41

Soluble HLA–G molecule. An alternatively spliced HLA–G mRNA form candidate to encode it in peripheral blood mononuclear cells and human trophoblasts. Moreau P, et al. **Hum Immunol** 1995 Jul;43(3):231–6

Cloning and characterization of alternatively spliced isoforms of Dp71. Austin RC, et al. **Hum Mol Genet** 1995 Sep; 4(9):1475–83

Two novel splicing mutations in the XPA gene in patients with group A xeroderma pigmentosum. Satokata I, et al. **Hum Mol Genet** 1995 Oct;4(10):1993–4

The pre–mRNA of nuclear respiratory factor 1, a regulator of mitochondrial biogenesis, is alternatively spliced in human tissues and cell lines. Spelbrink JN, et al. **Hum Mol Genet** 1995 Sep;4(9):1591–6

Distinct transcription start sites generate two forms of BRCA1 mRNA. Xu CF, et al. **Hum Mol Genet** 1995 Dec; 4(12):2259–64

Alternatively spliced forms of human killer inhibitory receptors. Döhring C, et al. **Immunogenetics** 1996; 44(3):227–30

Alternatively spliced forms of the human myeloid Fc alpha receptor (CD89) in neutrophils. Morton HC, et al. **Immunogenetics** 1996;43(4):246–7

Genomic structure, chromosome location, and alternative splicing of the human NKG2A gene. Plougastel B, et al. **Immunogenetics** 1996;44(4):286–91

Extracellular pH controls pre–mRNA alternative splicing of tenascin–C in normal, but not in malignantly transformed, cells. Borsi L, et al. **Int J Cancer** 1996 May 29;66(5):632–5

Immunohistochemical detection of adhesion molecule CD44 splice variants in lymph node metastases of cervical cancer. Kainz C, et al. **Int J Cancer** 1996 Jun 21;69(3):170–3

CD44 expression patterns in breast and colon tumors: a PCR–based study of splice variants. Rodriguez C, et al. **Int J Cancer** 1995 Oct 20;64(5):347–54

Temporally distinctive changes of alternative splicing patterns during myogenic differentiation of C2C12 cells. Harada Y, et al. **J Biochem (Tokyo)** 1995 Oct;118(4):780–90

Lymphocyte isoforms of mouse p50 LSP1, which are phosphorylated in mitogen–activated T cells, are formed through alternative splicing and phosphorylation. Matsumoto N, et al. **J Biochem (Tokyo)** 1995 Jul; 118(1):237–43

Tissue–specific isoforms of chicken myomesin are generated by alternative splicing. Bantle S, et al. **J Biol Chem** 1996 Aug 9;271(32):19042–52

A novel K+ channel beta–subunit (hKv beta 1.3) is produced via alternative mRNA splicing. England SK, et al. **J Biol Chem** 1995 Dec 1;270(48):28531–4

Isolation of MEK5 and differential expression of alternatively spliced forms. English JM, et al. **J Biol Chem** 1995 Dec 1;270(48):28897–902

Cloning of a fibroblast growth factor receptor 1 splice variant from Xenopus embryos that lacks a protein kinase C site important for the regulation of receptor activity. Gillespie LL, et al. **J Biol Chem** 1995 Sep 29;270(39):22758–63

The transcription factor Spi–1/PU.1 binds RNA and interferes with the RNA–binding protein p54nrb. Hallier M, et al. **J Biol Chem** 1996 May 10;271(19):11177–81

Mapping the functional domains within the carboxyl terminus of alpha–tropomyosin encoded by the alternatively spliced ninth exon. Hammell RL, et al. **J Biol Chem** 1996 Feb 23;271(8):4236–42

Alzheimer's disease betaA4 protein release and amyloid precursor protein sorting are regulated by alternative splicing. Hartmann T, et al. **J Biol Chem** 1996 May 31; 271(22):13208–14

Structures, alternative splicing, and neurexin binding of multiple neuroligins. Ichtchenko K, et al. **J Biol Chem** 1996 Feb 2;271(5):2676–82

A novel 55–kDa regulatory subunit for phosphatidylinositol 3–kinase structurally similar to p55PIK Is generated by

alternative splicing of the p85alpha gene. Inukai K, et al. **J Biol Chem** 1996 Mar 8;271(10):5317–20

Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR–3 localizes to the nucleus. Johnston CL, et al. **J Biol Chem** 1995 Dec 22;270(51):30643–50

Neuron–specific alternative splicing of nonmuscle myosin II heavy chain–B pre–mRNA requires a cis–acting intron sequence. Kawamoto S. **J Biol Chem** 1996 Jul 26; 271(30):17613–6

Mutation detection in the med and medJ alleles of the sodium channel Scn8a. Unusual splicing due to a minor class AT–AC intron. Kohrman DC, et al. **J Biol Chem** 1996 Jul 19;271(29):17576–81

Alternatively spliced transcripts from the Drosophila eIF4E gene produce two different Cap–binding proteins. Lavoie CA, et al. **J Biol Chem** 1996 Jul 5;271(27):16393–8

Molecular cloning, splice variants, expression, and purification of phospholipase C–delta 4. Lee SB, et al. **J Biol Chem** 1996 Jan 5;271(1):25–31

Extensive alternative splicing within the amino–propeptide coding domain of alpha2(XI) procollagen mRNAs. Expression of transcripts encoding truncated pro–alpha chains. Lui VCH, et al. **J Biol Chem** 1996 Jul 12; 271(28):16945–51

Expression of novel secreted isoforms of human immunoglobulin E proteins. Lyczak JB, et al. **J Biol Chem** 1996 Feb 16;271(7):3428–36

An alternative splicing product of the lamin A/C gene lacks exon 10. Machiels BM, et al. **J Biol Chem** 1996 Apr 19; 271(16):9249–53

The Pem homeobox gene. Androgen–dependent and –independent promoters and tissue–specific alternative RNA splicing. Maiti S, et al. **J Biol Chem** 1996 Jul 19; 271(29):17536–46

Identification of two isoforms of mouse neuropeptide Y–Y1 receptor generated by alternative splicing. Isolation, genomic structure, and functional expression of the receptors. Nakamura M, et al. **J Biol Chem** 1995 Dec 15; 270(50):30102–10

The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. Oakley RH, et al. **J Biol Chem** 1996 Apr 19;271(16):9550–9

Alternative splicing in the N–terminal extracellular domain of the pituitary adenylate cyclase–activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP–27 and PACAP–38 in phospholipase C activation. Pantaloni C, et al. **J Biol Chem** 1996 Sep 6;271(36):22146–51

Baculovirus expression of chicken nonmuscle heavy meromyosin II–B. Characterization of alternatively spliced isoforms. Pato MD, et al. **J Biol Chem** 1996 Feb 2; 271(5):2689–95

Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. Pisegna JR, et al. **J Biol Chem** 1996 Jul 19;271(29):17267–74

Sequence divergence associated with species–specific splicing of the nonmuscle beta–tropomyosin alternative exon. Pret AM, et al. **J Biol Chem** 1996 May 10;271(19):11511–7

The nuclear trafficking of extracellular fibroblast growth factor (FGF)–1 correlates with the perinuclear association of the FGF receptor–1alpha isoforms but not the FGF receptor–1beta isoforms. Prudovsky IA, et al. **J Biol Chem** 1996 Jun 14;271(24):14198–205

Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. Rockenstein EM, et al. **J Biol Chem** 1995 Nov 24;270(47):28257–67

Immunochemical characterization and developmental expression of Shaker potassium channels from the nervous system of Drosophila. Rogero O, et al. **J Biol Chem** 1995 Oct 27;270(43):25746–51

Neuronal nitric–oxide synthase–mu, an alternatively spliced isoform expressed in differentiated skeletal muscle. Silvagno F, et al. **J Biol Chem** 1996 May 10;271(19):11204–8

A splice variant of the ITF–2 transcript encodes a transcription factor that inhibits MyoD activity. Skerjanc IS, et al. **J Biol Chem** 1996 Feb 16;271(7):3555–61

Pancreatic beta–cell–specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. Terauchi Y, et al. **J Biol Chem** 1995 Dec 22;270(51):30253–6

Membrane–bound versus secreted forms of human asialoglycoprotein receptor subunits. Role of a juxtamembrane pentapeptide. Tolchinsky S, et al. **J Biol Chem** 1996 Jun 14;271(24):14496–503

Mutually exclusive neuronal expression of peptides encoded by the FMRFa gene underlies a differential control of copulation in Lymnaea. van Golen FA, et al. **J Biol Chem** 1995 Nov 24;270(47):28487–93

Three N–terminal variants of the AE2 Cl–/HCO3– exchanger are encoded by mRNAs transcribed from alternative promoters. Wang Z, et al. **J Biol Chem** 1996 Mar 29;271(13):7835–43

Characterization of an alternatively spliced GM2 activator protein, GM2A protein. An activator protein which stimulates the enzymatic hydrolysis of N–acetylneuraminic acid, but not N–acetylgalactosamine, from GM2. Wu YY, et al. **J Biol Chem** 1996 May 3;271(18):10611–5

Alternative splicing of a specific cytoplasmic exon alters the binding characteristics of murine platelet/endothelial cell adhesion molecule–1 (PECAM–1). Yan HC, et al. **J Biol Chem** 1995 Oct 6;270(40):23672–80

Alternative splicing of the human cholesteryl ester transfer protein gene in transgenic mice. Exon exclusion modulates gene expression in response to dietary or developmental change. Yang TP, et al. **J Biol Chem** 1996 May 24; 271(21):12603–9

A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44. Yu Q, et al. **J Biol Chem** 1996 Aug 23;271(34):20603–7

Alternative splicing of smooth muscle myosin heavy chains and its functional consequences. Haase H, et al. **J Cell Biochem** 1996 Mar 15;60(4):521–8

Multiple mRNA species are generated by alternate polyadenylation from the human calmodulin–I gene. Senterre–Lesenfants S, et al. **J Cell Biochem** 1995 Aug; 58(4):445–54

Tumor–specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor–beta receptors in human pituitary adenomas. Alexander JM, et al. **J Clin Endocrinol Metab** 1996 Feb; 81(2):783–90

Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone–releasing hormone receptor in human pituitary adenomas. Hashimoto K, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2933–9

Altered insulin receptor messenger ribonucleic acid splicing in liver is associated with deterioration of glucose tolerance in the spontaneously obese and diabetic rhesus monkey: analysis of controversy between monkey and human studies. Huang Z, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1552–6

Alternative splicing of amelogenin mRNA from rat incisor ameloblasts. Li R, et al. **J Dent Res** 1995 Dec;74(12):1880–5

52–kD SS–A/Ro: genomic structure and identification of an alternatively spliced transcript encoding a novel leucine zipper–minus autoantigen expressed in fetal and adult heart. Chan EK, et al. **J Exp Med** 1995 Oct 1;182(4):983–92

Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. Wang RF, et al. **J Exp Med** 1996 Mar 1;183(3):1131–40

Higher expression levels of alternatively spliced pX mRNA in human T lymphotropic virus type I asymptomatic carriers positive for antibodies to p40tax protein. Hirata M, et al. **J Infect Dis** 1995 Oct;172(4):1098–102

Evidence for alternative splicing of the chicken vasoactive intestinal polypeptide gene transcript. Talbot RT, et al. **J Mol Endocrinol** 1995 Aug;15(1):81–91

Differentiation alters the expression of the two splice variants of the serotonin 5–HT3 receptor–A mRNA in NG108–15 cells. Emerit MB, et al. **J Neurochem** 1995 Nov; 65(5):1917–25

The expression of two splice variants of metabotropic glutamate receptor subtype 5 in the rat brain and neuronal cells during development. Minakami R, et al. **J Neurochem** 1995 Oct;65(4):1536–42

The human aromatic L–amino acid decarboxylase gene can be alternatively spliced to generate unique protein isoforms. O'Malley KL, et al. **J Neurochem** 1995 Dec;65(6):2409–16

Gene therapeutic approach to primary and metastatic brain tumors: I. CD44 variant pre–RNA alternative splicing as a CEPT control element. Asman DC, et al. **J Neurooncol** 1995 Dec;26(3):243–50

Expression of CD44 splice variants in human primary brain tumors. Kaaijk P, et al. **J Neurooncol** 1995 Dec; 26(3):185–90

Schwann cell tumors express characteristic patterns of CD44 splice variants. Sherman L, et al. **J Neurooncol** 1995 Dec; 26(3):171–84 (57 ref.)

Tissue– and age–specific expression patterns of alternatively spliced agrin mRNA transcripts in embryonic rat suggest novel developmental roles. Stone DM, et al. **J Neurosci** 1995 Oct;15(10):6767–78

Cloning of the mouse fibronectin V–region and variation of its splicing pattern in experimental immune complex glomerulonephritis. Bergijk EC, et al. **J Pathol** 1996 Apr; 178(4):462–8

Retention of CD44 introns in bladder cancer: understanding the alternative splicing of pre–mRNA opens new insights into the pathogenesis of human cancers [editorial] Cooper DL. **J Pathol** 1995 Sep;177(1):1–3 (28 ref.)

Identification of a splice variant of the rat and human mineralocorticoid receptor genes. Bloem LJ, et al. **J Steroid Biochem Mol Biol** 1995 Nov;55(2):159–62

Tissue–dependent expression of a novel splice variant of the human oestrogen receptor. Daffada AA, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3–4):413–21

Identification and tissue distribution of a novel variant of 11 beta–hydroxysteroid dehydrogenase 1 transcript. Yang K, et al. **J Steroid Biochem Mol Biol** 1995 Nov;55(2):247–53

Enhanced splicing of nonconsensus 3' splice sites late during adenovirus infection. Mühlemann O, et al. **J Virol** 1995 Nov;69(11):7324–7

Alternative splicing of T cell receptor (TCR) alpha chain transcripts containing V alpha 1 or V alpha 14 elements. Mahotka C, et al. **Leukemia** 1995 Oct;9(10):1700–3

Acute myelogenous leukemia: a disorder of gene splicing? van der Reijden BA, et al. **Leukemia** 1996 Feb;10(2):204–6

A new alternative splice variant of the mouse Fas antigen with a deletion in the N–terminal portion of the extracellular domain. Nakajima T, et al. **Life Sci** 1996; 58(9):761–8

Possible alternative splicing of the rat SA gene. Gu L, et al. **Mamm Genome** 1995 Sep;6(9):683–4

Expression of CD44 and the pattern of CD44 alternative splicing in uveal melanoma. Danen EH, et al. **Melanoma Res** 1996 Feb;6(1):31–5

Presence of exon splicing silencers within human immunodeficiency virus type 1 tat exon 2 and tat–rev exon 3: evidence for inhibition mediated by cellular factors. Amendt BA, et al. **Mol Cell Biol** 1995 Nov;15(11):6480

Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3–kinase in muscle and brain. Antonetti DA, et al. **Mol Cell Biol** 1996 May;16(5):2195–203

Variant Max protein, derived by alternative splicing, associates with c–Myc in vivo and inhibits transactivation. Arsura M, et al. **Mol Cell Biol** 1995 Dec;15(12):6702–9

Conserved intron elements repress splicing of a neuron–specific c–src exon in vitro. Chan RC, et al. **Mol Cell Biol** 1995 Nov;15(11):6377–85

Intron retention generates a novel isoform of the murine vitamin D receptor that acts in a dominant negative way on the vitamin D signaling pathway. Ebihara K, et al. **Mol Cell Biol** 1996 Jul;16(7):3393–400

Interactions among SR proteins, an exonic splicing enhancer, and a lentivirus Rev protein regulate alternative splicing. Gontarek RR, et al. **Mol Cell Biol** 1996 May;16(5):2325–31

An intron enhancer containing a 5' splice site sequence in the human calcitonin/calcitonin gene–related peptide gene. Lou H, et al. **Mol Cell Biol** 1995 Dec;15(12):7135–42

Muscle–specific splicing enhancers regulate inclusion of the cardiac troponin T alternative exon in embryonic skeletal muscle. Ryan KJ, et al. **Mol Cell Biol** 1996 Aug; 16(8):4014–23

Complex alternative RNA processing generates an unexpected diversity of poly(A) polymerase isoforms. Zhao W, et al. **Mol Cell Biol** 1996 May;16(5):2378–86

Splicing variants of the human growth hormone mRNA: detection in pituitary, mononuclear cells and dermal fibroblasts. Palmetshofer A, et al. **Mol Cell Endocrinol** 1995 Sep 22;113(2):225–34

Differential alternative splicing of PACAP receptor in pituitary cell subpopulations. Vertongen P, et al. **Mol Cell Endocrinol** 1995 Sep 22;113(2):131–5

Alternatively spliced human type 1 angiotensin II receptor mRNAs are translated at different efficiencies and encode two receptor isoforms. Curnow KM, et al. **Mol Endocrinol** 1995 Sep;9(9):1250–62

Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. Moore EE, et al. **Mol Endocrinol** 1995 Aug; 9(8):959–68

Generation of a variant of human interleukin–4 by alternative splicing. Alms WJ, et al. **Mol Immunol** 1996 Mar–Apr; 33(4–5):361–70

Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue–specific distributions. Kotani M, et al. **Mol Pharmacol** 1995 Nov;48(5):869–79

Changes in the carboxyl–terminal domain of metabotropic glutamate receptor 1 by alternative splicing generate receptors with differing agonist–independent activity. Prézeau L, et al. **Mol Pharmacol** 1996 Mar;49(3):422–9

Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Sigalas I, et al. **Nat Med** 1996 Aug;2(8):912–7

The tetrodotoxin–insensitive sodium current in rat dorsal root ganglia is unlikely to involve the expression of the tetrodotoxin–resistant sodium channel, SkM2. Donahue LM. **Neurochem Res** 1995 Jun;20(6):713–7

Alternative splicing of agrin alters its binding to heparin, dystroglycan, and the putative agrin receptor. Gesemann M, et al. **Neuron** 1996 Apr;16(4):755–67

Relative exon affinities and suboptimal splice site signals lead to non–equivalence of two cassette exons. Andreadis A, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3585–93

Exon skipping induced by cold stress in a potato invertase gene transcript. Bournay AS, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2347–51

An intronic (A/U)GGG repeat enhances the splicing of an alternative intron of the chicken beta–tropomyosin pre–mRNA. Sirand–Pugnet P, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3501–7

Splicing of two weak 3' splice sites from the adenovirus major late region is enhanced in nuclear extracts from adenovirus infected cells. Mühlemann O, et al. **Nucleic Acids Symp Ser** 1995;(33):220–3

Genomic organization and alternatively processed forms of Cek5, a receptor protein–tyrosine kinase of the Eph subfamily. Connor RJ, et al. **Oncogene** 1995 Dec 7; 11(11):2429–38

The human tumour suppressor gene p53 is alternatively spliced in normal cells. Flaman JM, et al. **Oncogene** 1996 Feb 15;12(4):813–8

Expression of CD44 splice variants in normal respiratory epithelium and bronchial carcinomas: no evidence for altered CD44 splicing in metastasis. Givehchian M, et al. **Oncogene** 1996 Mar 7;12(5):1137–44

Alternatively spliced cyclin C mRNA is widely expressed, cell cycle regulated, and encodes a truncated cyclin box.

Li H, et al. **Oncogene** 1996 Aug 15;13(4):705–12
Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines. Meazza R, et al. **Oncogene** 1996 May 16;12(10):2187–92
Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells. Menke AL, et al. **Oncogene** 1996 Feb 1;12(3):537–46
Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET. Myers SM, et al. **Oncogene** 1995 Nov 16;11(10):2039–45
A new member of the DP family, DP-3, with distinct protein products suggests a regulatory role for alternative splicing in the cell cycle transcription factor DRTF1/E2F. Ormondroyd E, et al. **Oncogene** 1995 Oct 19;11(8):1437–46
Alternative splicing of PSP94 (prostatic secretory protein of 94 amino acids) mRNA in prostate tissue. Xuan JW, et al. **Oncogene** 1995 Sep 21;11(6):1041–7
An anther-specific gene encoded by an S locus haplotype of Brassica produces complementary and differentially regulated transcripts. Boyes DC, et al. **Plant Cell** 1995 Aug; 7(8):1283–94
Organ-specific differences in the ratio of alternatively spliced chorismate synthase (LeCS2) transcripts in tomato. Görlach J, et al. **Plant J** 1995 Sep;8(3):451–6
Alternative splicing results in two different transcripts for H-protein of the glycine cleavage system in the C4 species Flaveria trinervia. Kopriva S, et al. **Plant J** 1995 Sep; 8(3):435–41
The use of an alternative promoter in the Arabidopsis thaliana HMG1 gene generates an mRNA that encodes a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase isoform with an extended N-terminal region. Lumbreras V, et al. **Plant J** 1995 Oct;8(4):541–9
Proteolysis of major histocompatibility complex class II-associated invariant chain is regulated by the alternatively spliced gene product, p41. Fineschi B, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10257–61
Specificity of dimer formation in tropomyosins: influence of alternatively spliced exons on homodimer and heterodimer assembly. Gimona M, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9776–80
Mouse Col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Muragaki Y, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8763–7
Alternative splicing of agrin regulates its binding to heparin alpha-dystroglycan, and the cell surface. O'Toole JJ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7369–74
An alternatively spliced form of the transcription factor Sp1 containing only a single glutamine-rich transactivation domain. Persengiev SP, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9107–11
Titration of serine/arginine (SR) splicing factors during adenoviral infection modulates E1A pre-mRNA alternative splicing. Himmelspach M, et al. **RNA** 1995 Oct; 1(8):794–806
Alternative splicing of the Euglena gracilis chloroplast roaA transcript. Jenkins KP, et al. **RNA** 1995 Aug;1(6):624–33
Overexpression of the SR proteins ASF/SF2 and SC35 influences alternative splicing in vivo in diverse ways. Wang J, et al. **RNA** 1995 May;1(3):335–46
High expression of membrane cofactor protein of complement (CD46) in human leukaemia cell lines: implication of an alternatively spliced form containing the STA domain in CD46 up-regulation. Hara T, et al. **Scand J Immunol** 1995 Dec;42(6):581–90
Role of alternatively spliced beta E-globin mRNA on clinical severity of beta-thalassemia/hemoglobin E disease. Winichagoon P, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:241–5
Variability of alpha 1,3-galactosyltransferase splicing isoforms in pig tissues. Vanhove B, et al. **Transplant Proc** 1996 Apr;28(2):622–3
Two strong 5' splice sites and competing, suboptimal 3' splice sites involved in alternative splicing of human immunodeficiency virus type 1 RNA. O'Reilly MM, et al. **Virology** 1995 Nov 10;213(2):373–85
[Expression of CD44 isoforms in normal human liver and also in regenerative and neoplastic liver changes] Seelentag WK, et al. **Verh Dtsch Ges Pathol** 1995;79:144–7 (Eng. Abstr.) **(Ger)**
[Expression of a splice-variant of the mts1 gene in normal and tumorous human tissue] Ambartsumian NS, et al. **Genetika** 1995 Sep;31(9):1194–200 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Alternative splicing and differential expression of DT-diaphorase transcripts in human colon tumors and in peripheral mononuclear cells in response to mitomycin C treatment. Yao KS, et al. **Cancer Res** 1996 Apr 15; 56(8):1731–6

GENETICS

Evolutionarily conserved alternative pre-mRNA splicing regulates structure and function of the spectrin-actin binding domain of erythroid protein 4.1. Winardi R, et al. **Blood** 1995 Dec 1;86(11):4315–22
Molecular cloning of a cDNA for the human inositol 1,4,5-trisphosphate receptor type 1, and the identification of a third alternatively spliced variant. Nucifora FC Jr, et al. **Brain Res Mol Brain Res** 1995 Sep;32(2):291–6
Alternative splicing of amelogenins. Simmer JP. **Connect Tissue Res** 1995;32(1–4):131–6
Developmental regulation of acetylcholinesterase transcripts in the mouse diaphragm: alternative splicing and focalization. Legay C, et al. **Eur J Neurosci** 1995 Aug 1; 7(8):1803–9
Alternative splicing at the C-terminal but not at the N-terminal domain of the NMDA receptor NR1 is altered in the kindled hippocampus. Vezzani A, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2513–7
Alternative splicing gives rise to two novel long isoforms of Zn-alpha 2-glycoprotein, a member of the immunoglobulin superfamily. Uría JA, et al. **Gene** 1996 Mar 9;169(2):233–6
Splice site mutation causing deletion of exon 21 sequences from the pro alpha 2(I) chain of type I collagen in a patient with severe dentinogenesis imperfecta but very mild osteogenesis imperfecta. Nicholls AC, et al. **Hum Mutat** 1996;7(3):219–27
Differential expression of alternate mB7-2 transcripts. Borriello F, et al. **J Immunol** 1995 Dec 15;155(12):5490–7
Molecular organization and alternative splicing in zipper, the gene that encodes the Drosophila non-muscle myosin II heavy chain. Mansfield SG, et al. **J Mol Biol** 1996 Jan 12;255(1):98–109
Molecular analysis of the presenilin 1 (S182) gene in "sporadic" cases of Alzheimer's disease: identification and characterisation of unusual splice variants. Anwar R, et al. **J Neurochem** 1996 Apr;66(4):1774–7
Promoter region and alternatively spliced exons of the rat mu-opioid receptor gene. Mayer P, et al. **J Neurochem** 1996 Jun;66(6):2272–8
Abnormal splicing of the leptin receptor in diabetic mice. Lee GH, et al. **Nature** 1996 Feb 15;379(6566):632–5
Identification of the alternative spliced form of the alpha 2/delta subunit of voltage sensitive Ca2+ channels expressed in PC12 cells. Gilad B, et al. **Neurosci Lett** 1995 Jul 7;193(3):157–60
Trans-splicing and alternative-tandem-cis-splicing: two ways by which mammalian cells generate a truncated SV40 T-antigen. Eul J, et al. **Nucleic Acids Res** 1996 May 1; 24(9):1653–61
Species- and tissue-specific expression of the C-terminal alternatively spliced form of the tumor suppressor p53. Will K, et al. **Nucleic Acids Res** 1995 Oct 25;23(20):4023–8
Splicing patterns of fibronectin mRNA from normal and osteoarthritic human articular cartilage. Rencic A, et al. **Osteoarthritis Cartilage** 1995 Sep;3(3):187–96

IMMUNOLOGY

The autoantigen La/SS-B: analysis of the expression of alternatively spliced La mRNA isoforms. Hilker M, et al. **Cell Tissue Res** 1996 Jun;284(3):383–9

PHYSIOLOGY

Alternative splicing of natriuretic peptide A and B receptor transcripts in the rat brain. Francoeur F, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S172–4
Primary structure of the long and short splice variants of mouse collagen XII and their tissue-specific expression during embryonic development. Böhme K, et al. **Dev Dyn** 1995 Dec;204(4):432–45
Expression patterns of laminin receptor splice variants alpha 6A beta 1 and alpha 6B beta 1 suggest different roles in mouse development. Thorsteinsdóttir S, et al. **Dev Dyn** 1995 Nov;204(3):240–58
Alternative splicing of exon 14 determines nuclear or cytoplasmic localisation of fmr1 protein isoforms. Sittler A, et al. **Hum Mol Genet** 1996 Jan;5(1):95–102
In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). Reinhold MI, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3419–25
Regional and laminar differences in synaptic localization of NMDA receptor subunit NR1 splice variants in rat visual cortex and hippocampus. Johnson RR, et al. **J Comp Neurol** 1996 May 6;368(3):335–55

ALTERNATIVES TO ANIMAL TESTING see ANIMAL TESTING ALTERNATIVES

ALTITUDE

see related
MOUNTAINEERING

Body weight loss during acute hypoxia: effects of increased convective oxygen transport or previous acclimation. Leal TL, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995; 45(1):9–14
Cardiovascular response to exercise in humans following acclimatization to extreme altitude. Savard GK, et al. **Acta Physiol Scand** 1995 Aug;154(4):499–509
Double-blind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude. Peroni DG, et al. **Allergy** 1995 Nov;50(11):925–30
High altitude-related neurocardiogenic syncope. Freitas J, et al. **Am J Cardiol** 1996 May 1;77(11):1021
Increased incidence of placental chorioangioma in high-altitude pregnancies: hypobaric hypoxia as a possible etiologic factor. Reshetnikova OS, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):557–61
Socioeconomic change and patterns of growth in the Andes. Leatherman TL, et al. **Am J Phys Anthropol** 1995 Jul; 97(3):307–21
Growth differences between children of highland and coastal Ecuador. Leonard WR, et al. **Am J Phys Anthropol** 1995 Sep;98(1):47–57
Effect of zolpidem on sleep and ventilatory patterns at simulated altitude of 4,000 meters. Beaumont M, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1864–9
Is normobaric simulation of hypobaric hypoxia accurate in chronic airflow limitation? Naughton MT, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1956–60
Mechanical ventilation at moderate altitude [letter] Roeggla M. **Anaesth Intensive Care** 1995 Aug;23(4):515–6
Anthropometric comparison between high- and low-altitude Saudi Arabians. Khalid M. **Ann Hum Biol** 1995 Sep–Oct; 22(5):459–65
Ice-based altitude distribution of natural radiation annual exposure rate in the Antarctica zone over the latitude range 69 degrees S–77 degrees S using a pair-filter thermoluminescence method. Nakajima T, et al. **Appl Radiat Isot** 1995 Dec;46(12):1363–8
Urban ectopy in the mountains: carbon monoxide exposure at high altitude. Leaf DA, et al. **Arch Environ Health** 1996 Jul–Aug;51(4):283–90
Altitude-dependent decrease in plasma fibronectin [letter] Wenisch C, et al. **Arch Intern Med** 1995 Oct 9; 155(18):2012–3
Effect of low altitude on glycolytic key enzymes in red blood cells. Bashir NA. **Aviat Space Environ Med** 1996 May; 67(5):478–9
Speech production and cognitive deficits on Mt. Everest. Lieberman P, et al. **Aviat Space Environ Med** 1995 Sep; 66(9):857–64
The effect of altitude pre-acclimatization on acute mountain sickness during reexposure. Lyons TP, et al. **Aviat Space Environ Med** 1995 Oct;66(10):957–62
Salt excretory capacity in natives adapted to moderate high altitude living after acute mobilization to sea level. Ramirez G, et al. **Aviat Space Environ Med** 1995 Nov;66(11):1063–70
Variations in the presentation of altitude-induced chokes. Rudge FW. **Aviat Space Environ Med** 1995 Dec; 66(12):1185–7
Asymptomatic retinal haemorrhage is common at altitude [letter; comment] MacLaren RE. **BMJ** 1995 Sep 23; 311(7008):812–3. Comment on: BMJ 1995 May 13;310(6989):1248–52.
Heart rate and respiratory rhythm dynamics on ascent to high altitude. Lipsitz LA, et al. **Br Heart J** 1995 Oct; 74(4):390–6
Poor ventilatory response to mild hypoxia may inhibit acclimatization at moderate altitude in elderly patients after carotid surgery. Roeggla G, et al. **Br J Sports Med** 1995 Jun;29(2):110–2
Exposure to moderate altitude and cardiorespiratory diseases. Gong H Jr. **Cardiologia** 1995 Jul;40(7):477–88 (98 ref.)
Preflight evaluation. Patients and methods [letter; comment] Bhattacharyya P, et al. **Chest** 1996 Apr;109(4):1129. Comment on: Chest 1995 Feb;107(2):352–7.
CPAP machine performance and altitude. Fromm RE Jr, et al. **Chest** 1995 Dec;108(6):1577–80
Effect of altitude on hand-held peak flowmeters. Jensen RL, et al. **Chest** 1996 Feb;109(2):475–9
Effect of moderate altitude on the effect of mouth-to-mouth ventilation on blood gas analysis [letter; comment] Roeggla G, et al. **Chest** 1995 Oct;108(4):1183–4. Comment on: Chest 1994 Dec;106(6):1806–10.
Precision and accuracy of the Accu-Chek Advantage blood glucose monitoring system at high altitude [letter] Chmielewski SA, et al. **Clin Chem** 1996 Jan;42(1):115–7
Autonomic regulation of heart rate and peripheral circulation: comparison of high altitude and sea level residents. Passino C, et al. **Clin Sci (Colch)** 1996;91 Suppl:81–3
Intracranial pressure at high altitude and acute mountain sickness. Wright AD, et al. **Clin Sci (Colch)** 1995 Aug; 89(2):201–4
Hemoglobin affinity and structure in high-altitude and sea-level carnivores from Peru. León-Velarde F, et al. **Comp Biochem Physiol A Physiol** 1996 Apr;113(4):407–11
The effect of inositol hexaphosphate in the high-affinity hemoglobin of the Andean chicken (Gallus gallus). Mejía O, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov;109(2–3):437–41
Effects of mild hypoxia on perceptual-motor performance: a signal-detection approach. McCarthy D, et al. **Ergonomics** 1995 Oct;38(10):1979–92
Effects of altitude on top speeds during 1 h unaccompanied cycling. Capelli C, et al. **Eur J Appl Physiol** 1995; 71(5):469–71
Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. Kamimori GH, et al. **Eur J Clin Pharmacol** 1995;48(2):167–70
High altitude exposure reduces bronchial responsiveness to hypo-osmolar aerosol in lowland asthmatics. Allegra L, et al. **Eur Respir J** 1995 Nov;8(11):1842–6
Pathogenesis of high-altitude pulmonary oedema [comment] Fiorenzano G, et al. **Eur Respir J** 1995 Nov;8(11):1987. Comment on: Eur Respir J 1995 Apr;8(4):523–9.
Ventilatory and pulmonary vascular response to hypoxia and susceptibility to high altitude pulmonary oedema.

Hohenhaus E, et al. **Eur Respir J** 1995 Nov;8(11):1825–33

High altitude pulmonary oedema: who gets it and why? [editorial] Peacock AJ. **Eur Respir J** 1995 Nov; 8(11):1819–21

Estimation of the degree of acclimatization to high altitude by a rapid and simple physiological examination. Saito S, et al. **Int Arch Occup Environ Health** 1995;67(5):347–51

Free and total thyroid hormones in humans at extreme altitude. Basu M, et al. **Int J Biometeorol** 1995 Aug; 39(1):17–21

The association between strenuous physical activity and obesity in a high and low altitude populations in southern Saudi Arabia. Khalid ME.
Int J Obes Relat Metab Disord 1995 Nov;19(11):776–80

Dead Sea: natural oxygen enrichment at low altitude. Kramer MR, et al. **Isr J Med Sci** 1996 Jul;32 Suppl:S20–3

Dust mites at high altitude in a tropical climate. Sánchez-Medina M, et al. **J Allergy Clin Immunol** 1996 May;97(5):1167–8

Pulmonary arterial hypertension in nonagenarians [letter] Crausman RS, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1177

Hormonal changes in normal and polycythemic high-altitude natives. Antezana AM, et al. **J Appl Physiol** 1995 Sep; 79(3):795–800

Invited editorial on "effect of altitude on uterine artery blood flow during normal pregnancy" and "alterations in uteroplacental blood flow precede hypertension in preeclampsia at high altitude" [editorial; comment] Clark KE. **J Appl Physiol** 1995 Jul;79(1):5–6. Comment on: J Appl Physiol 1995 Jul;79(1):7–14. Comment on: J Appl Physiol 1995 Jul;79(1):15–22.

Maximal rate of blood lactate accumulation during exercise at altitude in humans. Grassi B, et al. **J Appl Physiol** 1995 Jul;79(1):331–9

Enhanced cardiac metabolism of plasma glucose in high-altitude natives: adaptation against chronic hypoxia. Holden JE, et al. **J Appl Physiol** 1995 Jul;79(1):222–8

Cardiac enzyme activities in fetal and adult pregnant and nonpregnant sheep exposed to high-altitude hypoxemia. Ohtsuka T, et al. **J Appl Physiol** 1995 Oct;79(4):1286–9

Acclimatization at high altitude in gradual and acute induction. Purkayastha SS, et al. **J Appl Physiol** 1995 Aug; 79(2):487–92

Effect of altitude on uterine artery blood flow during normal pregnancy [see comments] Zamudio S, et al.
J Appl Physiol 1995 Jul;79(1):7–14. Comment in: J Appl Physiol 1995 Jul;79(1):5–6.

Alterations in uteroplacental blood flow precede hypertension in preeclampsia at high altitude [see comments] Zamudio S, et al. **J Appl Physiol** 1995 Jul; 79(1):15–22. Comment in: J Appl Physiol 1995 Jul;79(1):5–6.

Effects of exposure to high altitude on plasma endothelin-1 levels in normal subjects. Morganti A, et al.
J Hypertens 1995 Aug;13(8):859–65

Selenium levels and glutathione peroxidase activities in blood in an andean high-altitude population. Imai H, et al.
J Nutr Sci Vitaminol (Tokyo) 1995 Jun;41(3):349–61

The arterial oxygen status of clinically healthy dogs at an altitude of 1250 metres. Leisewitz AL, et al.
J S Afr Vet Assoc 1995 Dec;66(4):213–8

Measurement of maximal oxygen consumption of thoroughbred horses at an altitude of 1250m using open-circuit flow-through calorimetry. Lund RJ, et al.
J S Afr Vet Assoc 1995 Dec;66(4):239–43

Association of pulmonary artery size on chest radiograph with residence at elevated altitudes. Ghio AJ, et al.
J Thorac Imaging 1996 Winter;11(1):53–7

Evaluation of the Cosmed K2 telemetry system during exercise at moderate altitude. Bigard AX, et al.
Med Sci Sports Exerc 1995 Sep;27(9):1333–8

Urinary excretion of meperidine and normeperidine in man upon acute and chronic exposure to high altitude. Ritschel WA, et al. **Methods Find Exp Clin Pharmacol** 1996 Jan–Feb; 18(1):49–53

Arterial oxygen saturation in Tibetan and Han infants born in Lhasa, Tibet. Niermeyer S, et al. **N Engl J Med** 1995 Nov 9;333(19):1248–52

Third-trimester arterial blood gas and acid base values in normal pregnancy at moderate altitude. Hankins GD, et al. **Obstet Gynecol** 1996 Sep;88(3):347–50

Refractive changes during 72-hour exposure to high altitude after refractive surgery. Mader TH, et al.
Ophthalmology 1996 Aug;103(8):1188–95

Effects of simulated high altitude on patients who have had radial keratotomy. Ng JD, et al. **Ophthalmology** 1996 Mar; 103(3):452–7

Factors associated with stroke following the Fontan procedure. Day RW, et al. **Pediatr Cardiol** 1995 Nov–Dec; 16(6):270–5

Chorangiosis and chorangioma in three cohorts of placentas from Nepal, Tibet, and Japan. Soma H, et al.
Reprod Fertil Dev 1995;7(6):1533–8

Hypoxic ventilatory responses in Tibetan residents of 4400 m compared with 3658 m. Curran LS, et al.
Respir Physiol 1995 Jun;100(3):223–30

Aerobic exercise capacity at sea level and at altitude in Kenyan boys, junior and senior runners compared with Scandinavian runners. Saltin B, et al.
Scand J Med Sci Sports 1995 Aug;5(4):209–21

Effects of small-volume infusion of 7.5% hypertonic saline/6% dextran-70 on the cardiovascular function of traumatic-hemorrhagic shock rats at high altitude. Mei JM, et al. **Shock** 1995 Dec;4(6):421–4

Age, altitude, and arrhythmia. Alexander JK.
Tex Heart Inst J 1995;22(4):308–16 (69 ref.)

Effect of altitude on spirometric parameters and the performance of peak flow meters. Pollard AJ, et al.
Thorax 1996 Feb;51(2):175–8

Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma. van Velzen E, et al. **Thorax** 1996 Jun;51(6):582–4

Haematological parameters in brown Swiss and Holstein cattle at high altitude. Claxton JR, et al.
Trop Anim Health Prod 1996 Feb;28(1):112–6

Diving at altitude: a review of decompression strategies. Egi SM, et al. **Undersea Hyperb Med** 1995 Sep;22(3):281–300

Ascites syndrome in a turkey reared above 2000 metres [letter] Duff JP, et al. **Vet Rec** 1995 Sep 16;137(12):300

Sea-level physical activity and acute mountain sickness at moderate altitude. Honigman B, et al. **West J Med** 1995 Aug;163(2):117–21

[Changes in the status of the adaptation of workers at the television relay station on top of Botev Peak] Nikolova R, et al. **Probl Khig** 1995;20:68–73 (Eng. Abstr.) **(Bul)**

[Anopheles funestus and rice agriculture in the Madagascar highlands] Marrama L, et al. **Sante** 1995 Nov–Dec; 5(6):415–9 (Eng. Abstr.) **(Fre)**

[Vector control in the epidemics of the Madagascar highlands] Randriantsimaniry D. **Sante** 1995 Nov–Dec; 5(6):392–6 (Eng. Abstr.) **(Fre)**

[Lung problems in acute to subacute exposure to medium altitudes] Marugg D. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1101–7 (41 ref.) (Eng. Abstr.) **(Ger)**

[Periodic breathing during sleep at high altitudes in patients with bronchial asthma] Koziej M, et al.
Pneumonol Alergol Pol 1996;64(3-4):141–9 (Eng. Abstr.) **(Pol)**

[Cardiorespiratory evaluation of athletes for competitions at high altitudes] Costa RV. **Arq Bras Cardiol** 1995 Feb; 64(2):183–6 **(Por)**

[Changes in the structures of the kidney medullary layer in rats during adaptation to high altitude] Iangalycheva EA, et al. **Aviakosm Ekolog Med** 1995;29(3):55–7 **(Rus)**

[Chronobiologic study of cardiac activity regulation in the course of urgent adaptation of healthy persons to high altitude conditions] Fedorova OI. **Fiziol Cheloveka** 1995 Jul–Aug;21(4):100–10 **(Rus)**

[A genetic and demographic study of Dagestan highland populations and migrants to the lowlands. The relationship between levels of consanguinity, homozygosity and physiologic sensitivity] Bulaeva KB, et al. **Genetika** 1996 Jan;32(1):93–102 (Eng. Abstr.) **(Rus)**

[Characteristics of the progression of silicosis under alpine conditions] Voznesenskii NK. **Gig Sanit** 1996 Jan–Feb; (1):16–8 (Eng. Abstr.) **(Rus)**

[The rehabilitation under alpine conditions of the participants in the cleanup of the accident at the Chernobyl Atomic Electric Power Station who are ill with chronic bronchitis] Brimkulov NN, et al. **Ter Arkh** 1996;68(3):34–7 (Eng. Abstr.) **(Rus)**

[The use of EHF therapy in the rehabilitation of patients with chronic bronchitis at a moderate altitude] Shamenova ShI, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan–Feb;(1):12–4 (Eng. Abstr.) **(Rus)**

[Upper digestive hemorrhage in the inhabitants of high altitudes in Peru] Berrios J, et al.
Rev Gastroenterol Peru 1996 Jan–Apr;16(1):13–8 (Eng. Abstr.) **(Spa)**

[Acute altitude sickness and ventilatory function in subjects intermittently exposed to hypobaric hypoxia] Saldías F, et al. **Rev Med Chil** 1995 Jan;123(1):44–50 (Eng. Abstr.) **(Spa)**

ALTITUDE SICKNESS

Selections from current literature: the traveller to high altitude. Fahrenwald R. **Fam Pract** 1995 Jun;12(2):237–41 (0 ref.)

A trek to the top: a review of acute mountain sickness. Porcelli MJ, et al. **J Am Osteopath Assoc** 1995 Dec; 95(12):718–20 (15 ref.)

Medicine and mechanisms in altitude sickness.
Recommendations. Coote JH. **Sports Med** 1995 Sep; 20(3):148–59 (67 ref.)

Sea-level physical activity and acute mountain sickness at moderate altitude. Honigman B, et al. **West J Med** 1995 Aug;163(2):117–21

[Altitude medicine] Wu T. **Chung Hua I Hsueh Tsa Chih** 1996 Jan;76(1):71–2 (0 ref.) **(Chi)**

[A study on the clinical classification of high altitude heart disease] Li Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 May;34(5):309–11 (Eng. Abstr.) **(Chi)**

COMPLICATIONS

High-altitude pulmonary edema with primary pulmonary hypertension. Naeije R, et al. **Chest** 1996 Jul;110(1):286–9

High-altitude pulmonary edema [letter; comment] de Clari F, et al. **N Engl J Med** 1996 Jul 18;335(3):207. Comment on: N Engl J Med 1996 Mar 7;334(10):662–3.

High-altitude pulmonary edema [letter; comment] Goetz AE, et al. **N Engl J Med** 1996 Jul 18;335(3):206–7. Comment on: N Engl J Med 1996 Mar 7;334(10):662–3.

High altitude pulmonary oedema: still a place for controversy? [editorial] Richalet JP. **Thorax** 1995 Sep; 50(9):923–9 (133 ref.)

[Structural changes of extra pulmonary artery and pulmonary arterioles of rats during chronic hypoxia and their significance] Song W, et al.
Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1995 Jun; 17(3):197–203 (Eng. Abstr.) **(Chi)**

[Changes of collagen distribution in extrapulmonary arteries of hypoxia-induced pulmonary hypertensive rat] Xu Z, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Jun;17(3):167–71 (Eng. Abstr.) **(Chi)**

DIAGNOSIS

Evaluation of the Lake Louise acute mountain sickness scoring system in a hypobaric chamber. Savourey G, et al. **Aviat Space Environ Med** 1995 Oct;66(10):963–7

Prediction of acute mountain sickness. Austin D, et al.
BMJ 1995 Oct 14;311(7011):989–90

How can acute mountain sickness be quantified at moderate altitude? Roeggla G, et al. **J R Soc Med** 1996 Mar; 89(3):141–3

DRUG THERAPY

EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Roncin JP, et al.
Aviat Space Environ Med 1996 May;67(5):445–52

ETHNOLOGY

Are Himalayan Sherpas better protected against brain damage associated with extreme altitude climbs? Garrido E, et al. **Clin Sci (Colch)** 1996 Jan;90(1):81–5

HISTORY

BLB oxygen mask and aviation [letter] Miller JM.
Mayo Clin Proc 1995 Oct;70(10):1020

IMMUNOLOGY

Hypothesis: angiogenesis cytokines in high altitude cerebral oedema. Severinghaus JW.
Acta Anaesthesiol Scand Suppl 1995;107:177–8

PATHOLOGY

New evidence from magnetic resonance imaging of brain changes after climbs at extreme altitude. Garrido E, et al.
Eur J Appl Physiol 1995;70(6):477–81

[The ultrastructure of the cerebral cortex in the muskrat Ondatra zibethica in high-altitude hypoxia] Dem'ianenko GP, et al. **Zh Evol Biokhim Fiziol** 1995 Jul–Aug;31(4):500–2 **(Rus)**

PHYSIOPATHOLOGY

High-altitude pulmonary edema: current concepts. Hultgren HN. **Annu Rev Med** 1996;47:267–84 (71 ref.)

Intracranial pressure at high altitude and acute mountain sickness. Wright AD, et al. **Clin Sci (Colch)** 1995 Aug; 89(2):201–4

Acute mountain sickness relates to sea-level partial pressure of oxygen. Savourey G, et al. **Eur J Appl Physiol** 1995; 70(6):469–76

Morphological alterations in the hippocampus following hypobaric hypoxia. Shukitt-Hale B, et al.
Hum Exp Toxicol 1996 Apr;15(4):312–9

Hypothetical roles of angiogenesis, osmotic swelling, and ischemia in high-altitude cerebral edema. Severinghaus JW. **J Appl Physiol** 1995 Aug;79(2):375–9 (68 ref.)

Acute mountain sickness [letter] McNeil EL.
J R Soc Med 1996 Jun;89(6):359–60

Diving at altitude: a review of decompression strategies. Egi SM, et al. **Undersea Hyperb Med** 1995 Sep;22(3):281–300

[The adaptation of the microcirculatory bed of the major veins to the intermittent action of high-altitude hypoxia] Kramar NI, et al. **Morfologiia** 1995;108(2):39–40 (Eng. Abstr.) **(Rus)**

[Role of the hemostatic system in the mechanisms of development of high-altitude cerebral edema] Tukhvatshin RR. **Patol Fiziol Eksp Ter** 1996 Jan–Mar;(1):7–9 **(Rus)**

PREVENTION & CONTROL

The effect of altitude pre-acclimatization on acute mountain sickness during reexposure. Lyons TP, et al.
Aviat Space Environ Med 1995 Oct;66(10):957–62

31P magnetic resonance spectroscopy of the Sherpa heart: a phosphocreatine/adenosine triphosphate signature of metabolic defense against hypobaric hypoxia. Hochachka PW, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):1215–20

The use of low-dose acetazolamide to prevent mountain sickness [letter] Meyer BH. **S Afr Med J** 1995 Aug; 85(8):792–3

[Altitude illness] Bosch FH. **Ned Tijdschr Geneeskd** 1995 Dec 2;139(48):2465–7 **(Dut)**

ALTRETAMINE

ADMINISTRATION & DOSAGE

Oral therapy for small cell lung cancer. Postmus PE, et al.
Lung Cancer 1995 Jun;12 Suppl 3:S63–70 (29 ref.)

ALTRETAMINE

PHARMACOLOGY

In vivo antitumor activity of hexamethylmelamine against human breast, stomach and colon carcinoma xenografts. Tanino H, et al. **Jpn J Cancer Res** 1995 Aug;86(8):770–5

THERAPEUTIC USE

Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Lee CR, et al. **Eur J Gynaecol Oncol** 1996;17(2):99–103

Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Rose PG, et al. **Gynecol Oncol** 1996 Jul;62(1):100–2

TOXICITY

Hexamethylmelamine is a potent inducer of deletions in male germ cells of Drosophila melanogaster. Aguirrezabalaga I, et al. **Carcinogenesis** 1995 Nov;16(11):2679–83

ALTRUISM

In search of altruistic community: patterns of social support mobilization following Hurricane Hugo. Kaniasty K, et al. **Am J Community Psychol** 1995 Aug;23(4):447–77

Colleges and trusts are blocking humanitarian service [letter] Beale P. **BMJ** 1995 Oct 14;311(7011):1027

Humanitarian responses to mass violence perpetrated against vulnerable populations [see comments] Gellert GA. **BMJ** 1995 Oct 14;311(7011):995–1001. Comment in: BMJ 1995 Oct 14;311(7011):1001–2.

A comparison of the writings of Sir William Osler and his exemplar, Sir Thomas Browne. Hookman P. **Bull N Y Acad Med** 1995 Summer;72(1):136–50

Self-interest and altruism in intergenerational relations. Logan JR, et al. **Demography** 1995 Aug;32(3):353–64

The proper focus of nursing: a critique of the "caring" ideology. Barker PJ, et al. **Int J Nurs Stud** 1995 Aug; 32(4):386–97 (44 ref.)

The parable of the Good Samaritan: implications for the euthanasia debate. House HW. **Issues Law Med** 1995 Fall; 11(2):159–84

An analysis of altruism: a concept of caring. Smith A. **J Adv Nurs** 1995 Oct;22(4):785–90 (22 ref.)

Professionalism--where are all the heroes? DeRosa GP. **J Bone Joint Surg Am** 1996 Sep;78(9):1295–9

Sexual preference and altruism. Salais D, et al. **J Homosex** 1995;28(1–2):185–96

Is humanity too costly a place to keep open? [editorial] Roy DJ. **J Palliat Care** 1995 Autumn;11(3):3–4

Evolution of altruism in optional and compulsory games. Batali J, et al. **J Theor Biol** 1995 Jul 12;175(2):161–71

Priorities in humanitarian relief [letter; comment] Diskett P, et al. **Lancet** 1995 Oct 7;346(8980):970. Comment on: Lancet 1995 Jul 29;346(8970):312–3.

Reflections on a humanitarian mission 20 years later: Operation Babylift. Aune RC. **Mil Med** 1995 Nov; 160(11):584–7

Antecedents and contexts of generativity motivation at midlife. Peterson BE, et al. **Psychol Aging** 1996 Mar; 11(1):21–33

Time pressure, type A syndrome, and organizational citizenship behavior: a field study replication of Hui, Organ, and Crooker (1994) [comment] Organ DW, et al. **Psychol Rep** 1995 Aug;77(1):179–85. Comment on: Psychol Rep 1994 Aug;75(1 Pt 1):199–208.

The humanitarian and scientific interests of Thomas Hodgkin (1798–1866), discoverer of a disease. Dubovsky H. **S Afr Med J** 1996 May;86(5):556–8

Medical humanitarianism and human rights: reflections on doctors without borders and doctors of the world. Fox RC. **Soc Sci Med** 1995 Dec;41(12):1607–16; discussion 1617–26

Beneficence re-examined: protective intervention in mental health. Murdach AD. **Soc Work** 1996 Jan;41(1):26–32 (43 ref.)

[Humanitarianism: the gardener, the truck driver and the "shrink"] Maqueda F. **Psychiatr Enfant** 1995;38(1):311–43 (4 ref.) (Eng. Abstr.) **(Fre)**

ALU REPETITIVE SEQUENCE see **REPETITIVE SEQUENCES, NUCLEIC ACID**

ALUM COMPOUNDS

Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Weissburg RP, et al. **Pharm Res** 1995 Oct; 12(10):1439–46

ADMINISTRATION & DOSAGE

Aluminum toxicity following intravesical alum irrigation for hemorrhagic cystitis. Kanwar VS, et al. **Med Pediatr Oncol** 1996 Jul;27(1):64–7

ADVERSE EFFECTS

A review of hospital discharge rates in a population around Camelford in North Cornwall up to the fifth anniversary of an episode of aluminium sulphate absorption. Owen PJ, et al. **J Public Health Med** 1995 Jun;17(2):200–4

Aluminum toxicity following intravesical alum irrigation for hemorrhagic cystitis. Kanwar VS, et al. **Med Pediatr Oncol** 1996 Jul;27(1):64–7

ANALYSIS

Interference of alum on analysis of methamphetamine in urine specimens [letter] Liu CY, et al. **Clin Chem** 1996 Feb; 42(2):338–40

PHARMACOKINETICS

Renal filtration and excretion of aluminium in the rat: dose–response relationships and effects of aluminium speciation. Lote CJ, et al. **Hum Exp Toxicol** 1995 Jun; 14(6):494–9

PHARMACOLOGY

In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Brewer JM, et al. **Eur J Immunol** 1996 Sep; 26(9):2062–6

In vitro antimicrobial activity of potash alum. Dutta S, et al. **Indian J Med Res** 1996 Jul;104:157–9

Interferon-gamma inductive effect of liposomes as an immunoadjuvant. Aramaki Y, et al. **Vaccine** 1995 Dec; 13(18):1809–14

THERAPEUTIC USE

Evaluation of an alum-containing mouthrinse in children for plaque and gingivitis inhibition during 4 weeks of supervised use. Putt MS, et al. **Pediatr Dent** 1996 Mar–Apr; 18(2):139–44

ALUMINA see **ALUMINUM OXIDE**

ALUMINUM

Prevalence and predictors of asthma in working groups in British Columbia. Siracusa A, et al. **Am J Ind Med** 1995 Sep;28(3):411–23

The bioavailability of 26Al-labelled aluminium citrate and aluminium hydroxide in volunteers. Priest ND, et al. **Biometals** 1996 Jul;9(3):221–8

Accidents in the aluminium smelting industry. Das BC, et al. **Ind Health** 1995;33(4):191–8

Killing of Streptococcus sanguis in biofilms using a light-activated antimicrobial agent. Wilson M, et al. **J Antimicrob Chemother** 1996 Feb;37(2):377–81

Laser welding with albumin-based solder: experimental full-tubed skin graft urethroplasty. Kirsch AJ, et al. **Lasers Surg Med** 1996;18(3):225–30

Nuclear spin–lattice relaxation mechanisms in kaolinite confirmed by magic-angle spinning. Hayashi S, et al. **Solid State Nucl Magn Reson** 1995 Aug;4(6):331–40

[Covering dental defects with aluminum cast dowel construction and technology of their manufacture] Khudonogov GI. **Med Tekh** 1995 Sep–Oct;(5):41–2 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Biological indicators of exposure to total and respirable aluminium dust fractions in a primary aluminium smelter. Röllin HB, et al. **Occup Environ Med** 1996 Jun;53(6):417–21

ADVERSE EFFECTS

Subcutaneous nodules in a patient hyposensitized with aluminium-containing allergen extracts: a microanalytical study. Morroni M, et al. **Anal Cell Pathol** 1995 Oct; 9(3):235–41

Persistent subcutaneous nodules in patients hyposensitized with aluminum-containing allergen extracts. García-Patos V, et al. **Arch Dermatol** 1995 Dec;131(12):1421–4

Frequencies of sister chromatid exchanges in lymphocytes of Portland cement factory workers. Fatima SK, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):704–8

Occupational asthma in aluminium potroom workers related to pre-employment eosinophil count. Sorgdrager B, et al. **Eur Respir J** 1995 Sep;8(9):1520–4

Status and future concerns of clinical and environmental aluminum toxicology. Flaten TP, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):527–41 (97 ref.)

What we know and what we need to know about developmental aluminum toxicity. Golub MS, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):585–97 (74 ref.)

Speciation of aluminum in biological systems. Harris WR, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):543–68 (132 ref.)

Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney. Jeffery EH, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):649–65 (80 ref.)

Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered? Savory J, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):615–35 (96 ref.)

Can the mechanisms of aluminum neurotoxicity be integrated into a unified scheme? Strong MJ, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):599–613

Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs. Yokel RA, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):667–83 (90 ref.)

Myoclonic encephalopathy after exposure to aluminum [letter] Hoang-Xuan K, et al. **Lancet** 1996 Mar 30; 347(9005):910–1

Amyloid, aluminum and the aetiology of Alzheimer's disease [letter; comment] Exley C. **Med J Aust** 1996 Feb 19; 164(4):252–3. Comment on: Med J Aust 1995 Sep 4;163(5):256–9.

Amyloid, aluminium and the aetiology of Alzheimer's disease [see comments] Storey E, et al. **Med J Aust** 1995 Sep 4; 163(5):256–9 (49 ref.). Comment in: Med J Aust 1996 Feb 19;164(4):252–3. Comment in: Med J Aust 1996 Mar 18;164(6):382–3.

Amyloid, aluminium and the aetiology of Alzheimer's disease [letter; comment] Walton JR. **Med J Aust** 1996 Mar 18; 164(6):382–3. Comment on: Med J Aust 1995 Sep 4;163(5):256–9.

Aluminum toxicity following intravesical alum irrigation for hemorrhagic cystitis. Kanwar VS, et al. **Med Pediatr Oncol** 1996 Jul;27(1):64–7

Is there a problem with dietary aluminum? [letter] Molony RH. **N Z Med J** 1996 Feb 23;109(1016):61

Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. D'Haese PC, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1874–84

Effects on the nervous system among welders exposed to aluminium and manganese. Sjögren B, et al. **Occup Environ Med** 1996 Jan;53(1):32–40

[The neurological screening of workers in the manufacture of copper and aluminum rolled wire] Kostova V. **Probl Khig** 1995;20:198–209 (Eng. Abstr.) **(Bul)**

[Urinary excretion of fluorides in children living around an aluminum smelter] Declercq C, et al. **Rev Epidemiol Sante Publique** 1995;43(5):504–9 (Eng. Abstr.) **(Fre)**

[Aluminum osteopathy in a patient hemodialysed for chronic renal insufficiency and treated by long term administration of sucralfate (letter)] Level C, et al. **Rev Med Interne** 1996; 17(4):348–9 **(Fre)**

[Aluminum in deodorants] Potokar M. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):777 **(Ger)**

[Spirometric investigation and spiro-ergometric test in evaluation of exercise tolerance in patients suffering from aluminosis and silicosis] Serwatowski P, et al. **Pneumonol Alergol Pol** 1995;63(9–10):498–501 (Eng. Abstr.) **(Pol)**

ANALYSIS

Lack of topographical relationship between sites of aluminum deposition and senile plaques in the Alzheimer's disease brain. Kasa P, et al. **Acta Neuropathol (Berl)** 1995; 90(5):526–31

Rapid and reliable method for the determination of aluminium in bone by electrothermal atomic absorption spectrometry. Tang S, et al. **Analyst** 1996 Feb; 121(2):195–200

Aluminum content of infant formulas used in Turkey. Sahin G, et al. **Biol Trace Elem Res** 1995 Oct;50(1):87–96

Determination of serum and urinary aluminum by HPLC with fluorometric detection of Al-lumogallion complex. Lee BL, et al. **Clin Chem** 1996 Sep;42(9):1405–11

Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. Kasarskis EJ, et al. **J Neurol Sci** 1995 Jun;130(2):203–8

Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. McLachlan DR, et al. **Neurology** 1996 Feb;46(2):401–5

Aluminum levels in human milk. Mandić ML, et al. **Sci Total Environ** 1995 Sep 29;170(3):165–70

In vitro and in vivo evaluation of potential aluminum chelators. Graff L, et al. **Vet Hum Toxicol** 1995 Oct; 37(5):455–61

Aluminium and fluoride in hospital daily diets and in teas. Nabrzyski M, et al. **Z Lebensm Unters Forsch** 1995 Oct; 201(4):307–10

[Duplicate study on the dietary intake of some metals/metalloids by children in Germany. part II. Aluminum, cadmium and lead] Wilhelm M, et al. **Zentralbl Hyg Umweltmed** 1995 Jun;197(5):357–69 (Eng. Abstr.) **(Ger)**

[Aluminium] Manabe S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:823–5 (13 ref.) **(Jpn)**

BLOOD

Lipofuscin products, lipid peroxides and aluminum accumulation in red blood cells of hemodialyzed patients. Jain SK, et al. **Am J Nephrol** 1995;15(4):306–11

Abnormal trace elements in a patient on total parenteral nutrition with normal renal function. Leung FY, et al. **Clin Biochem** 1995 Jun;28(3):297–302

Hyperaluminemia associated with liver transplantation and acute renal failure. Erasmus RT, et al. **Clin Transplant** 1995 Aug;9(4):307–11

Aluminum concentrations in critically ill children with renal impairment [letter; comment] Baines PB, et al.

Crit Care Med 1995 Nov;23(11):1931. Comment on: Crit Care Med 1994 Nov;22(11):1769–73.

Sucralfate effervescent tablet: treatment of peptic ulcer disease and change in serum aluminium concentration. Schütze K, et al. **Hepatogastroenterology** 1995 Jul; 42(3):240–5

Effectiveness of deferiprone (L1) releasing the aluminum bound to plasma proteins in chronic renal failure [letter] Canteros-Piccotto MA, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1488–9

Trend evaluation of aluminium in uraemic patients on chronic hemodialysis [letter] Di Iorio BR, et al. **Nephron** 1995; 71(4):471–2

[Reversed-phase high-performance liquid chromatograph—application to serum aluminium monitoring] Hoshino H, et al. **Nippon Rinsho** 1996 Jan; 54(1):215–20 (9 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Electrochemical impedance spectroscopy of preoxidized MA 956 superalloy during in vitro experiments. Escudero ML, et al. **Biomaterials** 1995 Jun;16(9):735–40

An FTIR spectroscopic study of calf-thymus DNA complexation with Al(III) and Ga(III) cations. Ahmad R, et al. **J Biomol Struct Dyn** 1996 Apr;13(5):795–802

Standardization in biological analyses of aluminum: what are the needs? Lovell MA, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):637–48 (45 ref.)

In vitro and in vivo comparative studies on chelation of aluminum by some polyaminocarboxylic acids. Graff L, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jun; 88(3):271–92

Corrosion of aluminium in soft drinks. Seruga M, et al. **Z Lebensm Unters Forsch** 1996 Apr;202(4):308–12

IMMUNOLOGY

Vaccine adjuvants based on gamma inulin. Cooper PD. **Pharm Biotechnol** 1995;6:559–80 (73 ref.)

METABOLISM

Zeolitic ammonium ion exchange for portable hemodialysis dialysate regeneration [letter; comment] Roberts M. **ASAIO J** 1995 Oct–Dec;41(4):899. Comment on: ASAIO J 1995 Apr–Jun;41(2):221–6.

Kinetics of aluminum-induced inhibition of delta-aminolevulinic acid dehydratase in vitro. Schroeder TM, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):927–31

Usage of gallium as a model for aluminium localisation in human neuroblastoma cells. Dobson CB, et al. **Biochem Soc Trans** 1995 Nov;23(4):598S

Metal binding and ferritin immunoreactivity in a high molecular weight fraction from rat brain. San-Marina S, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):277–83

An in vitro study on the binding of Al(III) to human serum transferrin with the isoelectric focusing technique. de Jong G, et al. **Biometals** 1995 Oct;8(4):352–6

Aluminum tolerance of Pseudomonas fluorescens in a phosphate-deficient medium. Appanna VD, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):404–11

Silent and progressing accumulation of aluminum in bone without definite histological osteomalacic aspects in chronic hemodialysis patients. Suzuki M, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S51–5

Neurofibrillary pathology and aluminum in Alzheimer's disease. Shin RW, et al. **Histol Histopathol** 1995 Oct; 10(4):969–78 (168 ref.)

Aluminium deposition in liver and kidney following acute intravenous administration of aluminium chloride or citrate in conscious rats. Spencer AJ, et al. **Hum Exp Toxicol** 1995 Oct;14(10):787–94

Spectroscopic study of the interaction of aluminum ions with human transferrin. Tang S, et al. **J Inorg Biochem** 1995 Nov 15;60(3):175–85

Interaction of synthetic Alzheimer beta-protein-derived analogs with aqueous aluminum: a low-field 27Al NMR investigation. Vyas SB, et al. **J Protein Chem** 1995 Nov; 14(8):633–44

Age-related effects of aluminum ingestion on brain aluminum accumulation and behavior in rats. Domingo JL, et al. **Life Sci** 1996;58(17):1387–95

Frequency of adynamic bone disease and aluminum storage in Italian uraemic patients—retrospective analysis of 1429 iliac crest biopsies. Ballanti P, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):663–7

[D-Pen2,D-Pen5]enkephalin, a delta opioid agonist reduces endogenous aluminum content in the rat central nervous system. Gulya K, et al. **Neuroscience** 1995 May; 66(2):499–506

Quantitative evaluation of Al maltolate-induced neurodegeneration with subsequent Al removal by desferrioxamine treatment. Huang Y, et al. **Neurotoxicology** 1995 Summer;16(2):291–6

Effects of sucralfate and ranitidine on aluminum concentrations in elderly volunteers. Moore JG, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):742–6

In vitro and in vivo comparative studies on chelation of aluminum by some polyaminocarboxylic acids. Graff L, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jun; 88(3):271–92

A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption. Graff L, et al. **Res Commun Mol Pathol Pharmacol** 1995 Sep; 89(3):373–88

PHARMACOKINETICS

Distribution of aluminum in different brain regions and body organs of rat. Julka D, et al. **Biol Trace Elem Res** 1996 May;52(2):181–92

Influence of organic acids on aluminium absorption and storage in rat tissues. Testolin G, et al. **Food Addit Contam** 1996 Jan;13(1):21–7

Tissue aluminium distribution in growing, mature and ageing rats: relationship to changes in gut, kidney and bone metabolism. Greger JL, et al. **Food Chem Toxicol** 1995 Oct; 33(10):867–75

Inter-subject variability in the metabolism of aluminium following intravenous injection as citrate. Talbot RJ, et al. **Hum Exp Toxicol** 1995 Jul;14(7):595–9

The lack of influence of long-term potassium citrate and calcium citrate treatment in total body aluminum burden in patients with functioning kidneys. Sakhaee K, et al. **J Am Coll Nutr** 1996 Feb;15(1):102–6

Aluminum toxicokinetics. Exley C, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):569–84 (64 ref.)

Can aluminium-containing antacid produce dementia? [letter] Jobst K, et al. **Nephron** 1995;71(4):473

Bile is an important route of elimination of ingested aluminum by conscious male Sprague-Dawley rats. Sutherland JE, et al. **Toxicology** 1996 May 17;109(2-3):101–9

PHARMACOLOGY

Aluminum facilitation of iron-mediated lipid peroxidation is dependent on substrate, pH and aluminum and iron concentrations. Xie CX, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):222–6

Effect of Ti, Al, and V ions on the relative growth rate of fibroblasts (L929) and osteoblasts (MC3T3-E1) cells. Rao S, et al. **Biomed Mater Eng** 1996;6(2):79–86

Impact of aluminium, fluoride and fluoroaluminate complex on ATPase activity of Nostoc linckia and Chlorella vulgaris. Husaini Y, et al. **Biometals** 1996 Jul;9(3):277–83

Inhibition of bovine brain acetylcholinesterase by aluminum. Moraes MS, et al. **Braz J Med Biol Res** 1994 Nov; 27(11):2635–8

Effect of various surfactants and aluminum solutions on in vitro acid dissolution of dental enamel. Putt MS, et al. **Caries Res** 1995;29(6):490–7

Dual effects of fluoroaluminate on activation of calcium influx and inhibition of agonist-induced calcium mobilization in rat glomerulosa cells. Grazzini E, et al. **Cell Calcium** 1996 Jan;19(1):29–41

Effect of the aluminium ion on hepatic elimination of quinine and quinidine. Jakovljević V, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul–Sep; 20(3):185–90

Effects of aluminum on neuronal signal transduction: mechanisms underlying disruption of phosphoinositide hydrolysis. Shafer TJ, et al. **Gen Pharmacol** 1995 Sep; 26(5):889–95 (46 ref.)

Altered cholinergic metabolism in rat CNS following aluminum exposure: implications on learning performance. Julka D, et al. **J Neurochem** 1995 Nov;65(5):2157–64

Characterization of a novel protein in chick intestine that exhibits calcium-binding activity and regulation by dietary calcium, aluminum and vitamin D. Dunn MA, et al. **J Nutr** 1995 Dec;125(12):2916–24

Inhibition of proteolysis enhances aluminum-induced perikaryal neurofilament accumulation but does not enhance tau accumulation. Shea TB, et al. **Mol Chem Neuropathol** 1995 Dec;26(3):195–212

Different effects of aluminum upon carbonic anhydrases and Na+/K+-ATPase activities in rat. Zatta P, et al. **Neurosci Lett** 1995 Sep 1;197(1):65–8

Hydroxyl radical generation in rat brain is initiated by iron but not aluminum, as determined by microdialysis with salicylate trapping and GC-MS analysis. Xie CX, et al. **Neurotoxicology** 1995 Fall;16(3):489–96

POISONING

Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Wang M, et al. **Am J Kidney Dis** 1995 Nov;26(5):836–44

Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators. Kontoghiorghes GJ. **Arch Toxicol Suppl** 1996; 18:202–14 (56 ref.)

Application of long-term cultured neurons in aging and neurological research: aluminum neurotoxicity, synaptic degeneration and Alzheimer's disease. Kuroda Y, et al. **Gerontology** 1995;41 Suppl 1:2–6

Treatment of aluminum overload using a cartridge with immobilized desferrioxamine. Anthone S, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1271–7

Aluminium and possible alarming health hazards [letter] Bhandari U, et al. **J R Soc Health** 1995 Dec;115(6):394

Fatal encephalopathy after otoneurosurgery procedure with an aluminum-containing biomaterial. Hantson P, et al. **J Toxicol Clin Toxicol** 1995;33(6):645–8

Epidemic aluminum intoxication in hemodialysis patients traced to use of an aluminum pump. Burwen DR, et al. **Kidney Int** 1995 Aug;48(2):469–74

Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Barata JD, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):125–32

Influence of hydroxypyridones and desferrioxamine on the mobilization of aluminium from tissues of aluminium-loaded rats. Florence AL, et al. **Neurodegeneration** 1995 Dec;4(4):449–55

Aluminum toxicity in infants and children. American Academy of Pediatrics, Committee on Nutrition. **Pediatrics** 1996 Mar;97(3):413–6

STANDARDS

Analytical validation of a general protocol for the preparation of dose-controlled solutions in aluminum toxicology. Tapparo A, et al. **Analyst** 1995 Sep; 120(9):2425–9

TOXICITY

Analytical validation of a general protocol for the preparation of dose-controlled solutions in aluminum toxicology. Tapparo A, et al. **Analyst** 1995 Sep; 120(9):2425–9

Effects of aluminum(III) on catechol-stimulated nerve growth factor biosynthesis by cultured mouse brain astroglial cells. Kobayashi D, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):675–84

Altered calcium homeostasis: a possible mechanisms of aluminium-induced neurotoxicity. Julka D, et al. **Biochim Biophys Acta** 1996 Jan 17;1315(1):47–54

Impairment of motor coordination in mice after ingestion of aluminum chloride. Sahin G, et al. **Biol Trace Elem Res** 1995 Oct;50(1):79–85

Microbial interactions with aluminium. Piña RG, et al. **Biometals** 1996 Jul;9(3):311–6 (63 ref.)

Effect of chronic aluminum exposure on the levels of conjugated dienes and enzymatic antioxidants in hippocampus and whole brain of rat. Gupta A, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):716–22

Effect of aluminum and zinc on enzyme activities in the green alga Selenastrum capricornutum. Kong FX, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):759–65

Evaluation of the developmental neuroendocrine and reproductive toxicology of aluminium. Agarwal SK, et al. **Food Chem Toxicol** 1996 Jan;34(1):49–53

Plasma prolactin, cortisol, and thyroid responses of the brown trout (Salmo trutta) exposed to lethal and sublethal aluminium in acidic soft waters. Waring CP, et al. **Gen Comp Endocrinol** 1996 Jun;102(3):377–85

Neurofibrillary pathology and aluminum in Alzheimer's disease. Shin RW, et al. **Histol Histopathol** 1995 Oct; 10(4):969–78 (168 ref.)

Aluminum inhibits both initiation and progression of mineralization of osteoid nodules formed in differentiating rat calvaria cell cultures. Bellows CG, et al. **J Bone Miner Res** 1995 Dec;10(12):2011–6

Effects of aluminum on bone surface ion composition. Bushinsky DA, et al. **J Bone Miner Res** 1995 Dec; 10(12):1988–97

Kinetic constraints in acute aluminium toxicity in the rainbow trout (Oncorhynchus mykiss). Exley C, et al. **J Theor Biol** 1996 Mar 7;179(1):25–31

Developing a workshop to address unresolved research issues. Brandt BF. **J Toxicol Environ Health** 1996 Aug 30; 48(6):ix–xii (6 ref.)

The role of experimental chronic renal failure and aluminium intoxication in cellular immune response. Tzanno-Martins C, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):474–80

Reproductive and developmental toxicity of aluminum: a review. Domingo JL. **Neurotoxicol Teratol** 1995 Jul–Aug; 17(4):515–21 (59 ref.)

In vitro exposure to aluminum does not alter long-term potentiation or glutamate release in rat hippocampal slices. Gilbert ME, et al. **Neurotoxicol Teratol** 1996 Mar–Apr; 18(2):175–80

Quantitative evaluation of Al maltolate-induced neurodegeneration with subsequent Al removal by desferrioxamine treatment. Huang Y, et al. **Neurotoxicology** 1995 Summer;16(2):291–6

Aluminum-induced model of motor neuron degeneration: subperineurial injection of aluminum in rabbits. Kihira T, et al. **Neurotoxicology** 1995 Fall;16(3):413–24

Nephrotoxicities of aluminium and/or cadmium-metallothionein in rats: creatinine excretion and metabolism of selected essential metals. Liu JX, et al. **Pharmacol Toxicol** 1995 Aug;77(2):155–60

Environmental hazards of aluminum to plants, invertebrates, fish, and wildlife. Sparling DW, et al. **Rev Environ Contam Toxicol** 1996;145:1–127 (242 ref.)

Toxicological investigations in the semiconductor industry: IV. Studies on the subchronic oral toxicity and genotoxicity of vacuum pump oils contaminated by waste products from aluminum plasma etching processes. Bauer S, et al. **Toxicol Ind Health** 1995 Sep–Oct;11(5):523–41

Sex-related differences in the effect of aluminum on calcium transport in the small intestine of the rat. Orihuela D, et al. **Toxicol Lett** 1996 Jun;85(3):165–71

Spinal motor neuron neuroaxonal spheroids in chronic aluminum neurotoxicity contain phosphatase-resistant high molecular weight neurofilament (NFH). Gaytan-Garcia S,

et al. **Toxicology** 1996 Apr 15;108(1-2):17-24

Iron and manganese uptake by offspring of lactating mice fed a high aluminum diet. Golub MS, et al. **Toxicology** 1996 May 17;109(2-3):111-8

The role of experimental aluminum intoxication in allogeneic immunoresponse. Tzanno-Martins C, et al. **Transpl Int** 1995;8(5):396-8

Comparison on reactivity of Fe(III) and Al(III) compounds in the presence of hydrogen peroxide: its relevance to possible origin for central nervous system toxicity by aluminum ion. Nishida Y, et al. **Z Naturforsch [C]** 1995 Jul-Aug;50(7-8):571-7

[The long-term action of low concentrations of aluminum on the central nervous system of white rats and the determination of the potential danger of the action of these concentrations on man] Oganesian GA, et al. **Zh Evol Biokhim Fiziol** 1995 Jul-Aug;31(4):483-8 (Eng. Abstr.) **(Rus)**

URINE

The role of silicic acid in the renal excretion of aluminium. Bellia JP, et al. **Ann Clin Lab Sci** 1996 May-Jun; 26(3):227-33

Renal filtration and excretion of aluminium in the rat: dose-response relationships and effects of aluminium speciation. Lote CJ, et al. **Hum Exp Toxicol** 1995 Jun; 14(6):494-9

Aluminum urinary excretion in patients with chronic renal failure in treatment with conservative conventional therapy and with ketoanalogs: research on fasting patients and after a pharmacological load [letter] Di Iorio B, et al. **Nephron** 1995;71(3):371-2

ALUMINUM COMPOUNDS

PbF2 compared to Al2O3 and AlF3 to produce an epithermal neutron beam for radiotherapy. Liu HB. **Med Phys** 1996 Feb;23(2):279-80

ADMINISTRATION & DOSAGE

Aluminium deposition in liver and kidney following acute intravenous administration of aluminium chloride or citrate in conscious rats. Spencer AJ, et al. **Hum Exp Toxicol** 1995 Oct;14(10):787-94

CHEMISTRY

The difference between ADP-beryllium fluoride and ADP-aluminium fluoride complexes of the spin-labeled myosin subfragment 1. Ponomarev MA, et al. **FEBS Lett** 1995 Sep 11;371(3):261-3

Chloride effects on Gs subunit dissociation. Fluoroaluminate binding to Gs does not cause subunit dissociation in the absence of chloride ion. Toyoshige M, et al. **J Biol Chem** 1996 Apr 12;271(15):8791-5

Structure and properties of aluminum-containing adjuvants. Hem SL, et al. **Pharm Biotechnol** 1995;6:249-76 (36 ref.)

Nuclear magnetic resonance study of a high-surface-area aluminum phosphate glass and its thermally reversible sol-gel precursor. Harmer MA, et al. **Solid State Nucl Magn Reson** 1995 Oct;5(1):35-49

Double rotation and magic-angle spinning nuclear magnetic resonance study of 27Al: reexamination of the aluminium borate 9Al2O3.2B2O3. Massiot D, et al. **Solid State Nucl Magn Reson** 1995 Nov;5(2):175-80

High fraction of penta-coordinated aluminium in amorphous and crystalline aluminium borates. Simon S, et al. **Solid State Nucl Magn Reson** 1995 Nov;5(2):163-73

Comparison on reactivity of Fe(III) and Al(III) compounds in the presence of hydrogen peroxide: its relevance to possible origin for central nervous system toxicity by aluminum ion. Nishida Y, et al. **Z Naturforsch [C]** 1995 Jul-Aug;50(7-8):571-7

METABOLISM

Formation and characterization of a transition state complex of Azotobacter vinelandii nitrogenase. Duyvis MG, et al. **FEBS Lett** 1996 Feb 19;380(3):233-6

Manipulation of B cell antigen receptor tyrosine phosphorylation using aluminum fluoride and sodium orthovanadate. Campbell KS, et al. **Mol Immunol** 1995 Nov;32(16):1283-94

Formation of a transition-state analog of the Ras GTPase reaction by Ras-GDP, tetrafluoroaluminate, and GTPase-activating proteins. Mittal R, et al. **Science** 1996 Jul 5;273(5271):115-7

PHARMACOKINETICS

Bioaccumulation of water soluble aluminium chloride in the hippocampus after transdermal uptake in mice. Anane R, et al. **Arch Toxicol** 1995;69(8):568-71

PHARMACOLOGY

Reversibility of neurofilamentous inclusion formation following repeated sublethal intracisternal inoculums of AlCl3 in New Zealand white rabbits. Strong MJ, et al. **Acta Neuropathol (Berl)** 1995;90(1):57-67

Aluminum fluoride inhibition of nitrogenase: stabilization of a nucleotide.Fe-protein.MoFe-protein complex. Renner KA, et al. **Biochemistry** 1996 Apr 30;35(17):5353-8

Endocytosis inhibitors abolish the active transport of polypeptides in the mucosa of the nasal upper concha of the rabbit. Cremaschi D, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):27-33

Mg2+-dependent phosphatase as an inhibitory mediator of the nonselective cation current induced by aluminum fluoride in guinea-pig chromaffin cells. Inoue M, et al. **Brain Res** 1995 Jul 31;687(1-2):199-204

The effect of GTP on the aluminum fluoride- and forskolin-activated adenylyl cyclase from human embryonic kidney 293 cells. Sanchez-Yagüe J, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct-Nov; 109(2-3):359-69

Interactions of N-ethylmaleimide and aluminium fluoride with GABAB receptor function in rat neocortical slices. Ong J, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):197-200

Binding of phosphate, aluminum fluoride, or beryllium fluoride to F-actin inhibits severing by gelsolin. Allen PG, et al. **J Biol Chem** 1996 Mar 1;271(9):4665-70

A comparative study of ATP and GTP complexation with trivalent Al, Ga and Fe cations. Determination of cation binding site and nucleotide conformation by FTIR difference spectroscopy. el-Mahdaoui L, et al. **J Biomol Struct Dyn** 1995 Aug;13(1):69-86

Aluminum fluoride stimulates surface protrusions in cells overexpressing the ARF6 GTPase. Radhakrishna H, et al. **J Cell Biol** 1996 Aug;134(4):935-47

Proximal sciatic axotomy does not inhibit the induction of neurofilamentous inclusions following intracisternal aluminum chloride exposure. Strong MJ, et al. **J Neuropathol Exp Neurol** 1996 Apr;55(4):419-23

Adjuvant properties of aluminum and calcium compounds. Gupta RK, et al. **Pharm Biotechnol** 1995;6:229-48 (126 ref.)

Stearyl tyrosine. An organic equivalent of aluminum-based immunoadjuvants. Penney C. **Pharm Biotechnol** 1995; 6:611-24 (26 ref.)

[Comparison of toxic effects of brucite and aluminium-treated chrysotile on macrophage] Guo C, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul; 29(4):219-21 (Eng. Abstr.) **(Chi)**

[The chronic action of large doses of aluminum on nervous and cardiac activities in rats administered it intramuscularly] Titkov ES, et al. **Zh Evol Biokhim Fiziol** 1995 Jan-Feb;31(1):52-8 (Eng. Abstr.) **(Rus)**

POISONING

Oral aluminium phosphide poisoning. Sharma A. **Indian Pediatr** 1995 Mar;32(3):339-42 (17 ref.)

Lipid peroxidation in acute aluminium phosphide poisoning. Chugh SN, et al. **J Assoc Physicians India** 1995 Apr; 43(4):265-6

Cardiovascular manifestations in aluminium phosphide poisoning with special reference to echocardiographic changes. Gupta MS, et al. **J Assoc Physicians India** 1995 Nov;43(11):773-4, 779-80

Tissue magnesium content and histopathological changes in non-survivors of aluminium phosphide poisoning. Siwach SB, et al. **J Assoc Physicians India** 1995 Oct;43(10):676-8

THERAPEUTIC USE

[Frey's syndrome: physiopathology and medical therapy] Celoria G, et al. **Minerva Chir** 1995 Nov;50(11):1025-7 (Eng. Abstr.) **(Ita)**

TOXICITY

Reversibility of neurofilamentous inclusion formation following repeated sublethal intracisternal inoculums of AlCl3 in New Zealand white rabbits. Strong MJ, et al. **Acta Neuropathol (Berl)** 1995;90(1):57-67

Effects of aluminum chloride on the nucleus and nucleolus in root tip cells of Hordeum vulgare. Zhang Y. **Mutat Res** 1995 Oct;335(2):137-42

Inhibition of rat brain phosphatidylinositol-specific phospholipase C by aluminum: regional differences, interactions with aluminum salts, and mechanisms. Nostrandt AC, et al. **Toxicol Appl Pharmacol** 1996 Jan; 136(1):118-25

[The functional and morphological changes in the liver and kidneys of white rats treated with aluminum] Nikolova P, et al. **Eksp Med Morfol** 1994;32(1-2):52-61 (Eng. Abstr.) **(Bul)**

ALUMINUM L-GLUTAMATE see **GLUTAMATES**

ALUMINUM HYDROXIDE

CHEMISTRY

Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins. Rinella JV Jr, et al. **Vaccine** 1996 Mar;14(4):298-300

DIAGNOSTIC USE

Gastric emptying of two radiolabelled antacids with simultaneous monitoring of gastric pH. Monés J, et al. **Eur J Nucl Med** 1995 Oct;22(10):1123-8

HISTORY

[Scientific raisins from 125 years SMW (Swiss Medical Weekly). Modification of phosphate metabolism by administration of aluminum hydroxide. 1956 (classical article)] Baur H, et al. **Schweiz Med Wochenschr** 1995 Nov 25;125(47):2305-7 **(Ger)**

PHARMACOKINETICS

The bioavailability of 26Al-labelled aluminium citrate and aluminium hydroxide in volunteers. Priest ND, et al. **Biometals** 1996 Jul;9(3):221-8

Are calcitriol boli worth the return to aluminum hydroxide as a phosphate binder in severe secondary hyperparathyroidism? [letter] Calabrese G, et al. **Nephron** 1995;71(1):113-4

Can aluminium-containing antacid produce dementia? [letter] Jobst K, et al. **Nephron** 1995;71(4):473

PHARMACOLOGY

Effect of Rennie Liquid versus Maalox Liquid on intragastric pH in a double-blind, randomized, placebo-controlled, triple cross-over study in healthy volunteers. Hürlimann S, et al. **Am J Gastroenterol** 1996 Jun;91(6):1173-80

Comparison of the effects of ranitidine effervescent tablets and magnesium hydroxide-aluminium oxide on intragastric acidity. A single-centre, randomised, open cross-over study. Propst A, et al. **Arzneimittelforschung** 1996 Jun; 46(6):621-4

Pharmacokinetics of tenidap sodium administered with food or antacid in healthy volunteers. Coates PE, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:17S-19S

Effect of aluminum hydroxide/magnesium hydroxide antacid and bismuth subsalicylate on gastric pH in horses. Clark CK, et al. **J Am Vet Med Assoc** 1996 May 15; 208(10):1687-91

Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid. de Bony F, et al. **J Antimicrob Chemother** 1996 Feb;37(2):383-7

Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. Mizuki Y, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:41-55 (46 ref.)

Adjuvanticity of aluminium hydroxide and calcium phosphate in diphtheria-tetanus vaccines--I. Aggerbeck H, et al. **Vaccine** 1995 Oct;13(14):1360-5

Effects of aluminum adjuvant on systemic reactions of lipopolysaccharides in swine. Norimatsu M, et al. **Vaccine** 1995 Oct;13(14):1325-9

THERAPEUTIC USE

Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Janssen MJ, et al. **Clin Nephrol** 1996 Feb;45(2):111-9

Booster vaccination against diphtheria and tetanus in man. Comparison of calcium phosphate and aluminium hydroxide as adjuvants--II. Aggerbeck H, et al. **Vaccine** 1995 Oct;13(14):1366-74

[Comparison of the effects of Rocgel and anti-H2 on the symptomatology of gastroesophageal reflux without esophagitis] Houcke P, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Sep;31(4):264-7 (Eng. Abstr.) **(Fre)**

[Antibacterial treatment of gastric ulcers associated with Helicobacter pylori without acid suppression] Folwaczny C. **Z Gastroenterol** 1995 Jul;33(7):416-7 **(Ger)**

ALUMINUM HYDROXIDE GEL see **ALUMINUM HYDROXIDE**

ALUMINUM OXIDE

Histological evaluation of bone reactions to aluminium oxide dental implants in man: a case report. Piattelli A, et al. **Biomaterials** 1996 Apr;17(7):711-4

Fracture of an alumina ceramic head in total hip arthroplasty. Higuchi F, et al. **J Arthroplasty** 1995 Dec;10(6):851-4

Four year clinical study of glass-infiltrated, sintered alumina crowns. Pröbster L. **J Oral Rehabil** 1996 Mar;23(3):147-51

PbF2 compared to Al2O3 and AlF3 to produce an epithermal neutron beam for radiotherapy. Liu HB. **Med Phys** 1996 Feb;23(2):279-80

Ultramicrotomy of industrial alumina. Antonovsky A. **Microsc Res Tech** 1995 Jul 1;31(4):300-7

CHEMISTRY

Composite biomaterials based on ceramic polymers. I. Reinforced systems based on Al2O3/PMMA/PLLA. Rodríguez-Lorenzo LM, et al. **J Biomed Mater Res** 1996 Apr;30(4):515-22

Contamination of titanium castings by aluminium oxide blasting. Darvell BW, et al. **J Dent** 1995 Oct;23(5):319-22

Dimensional and formation analysis of a restorative ceramic and how it works. Campbell SD, et al. **J Prosthet Dent** 1995 Oct;74(4):332-40

Magic-angle spinning nuclear magnetic resonance study of the structure of some PbO-Al2O3-P2O5 glasses. Lockyer MW, et al. **Solid State Nucl Magn Reson** 1995 Oct; 5(1):23-34

27Al magic-angle spinning nuclear magnetic resonance satellite transition spectroscopy of glasses in the system K2O-Al2O3-SiO2. Mundus C, et al. **Solid State Nucl Magn Reson** 1995 Oct;5(1):79-88

METABOLISM

The interaction of blood proteins with alpha-alumina. de-Queiroz AA, et al. **Braz J Med Biol Res** 1994 Nov; 27(11):2569-71

PHARMACOLOGY

The effect of HA, TCP and ALCAP bioceramic capsules on the viability of human monocyte and monocyte derived macrophages. Ross L, et al. **Biomed Sci Instrum** 1996; 32:71-9

Effects of gamma-alumina and hydroxyapatite coatings on the growth and metabolism of human osteoblasts. Labat B, et al. **J Biomed Mater Res** 1995 Nov;29(11):1397-401

[An experimental study of the tissue compatibility of titanium implants coated with hydroxyapatite and aluminum oxide by plasma spraying] Frolov AG, et al. **Stomatologiia (Mosk)** 1995;74(3):9-11 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Use of Proplast II as a subperiosteal implant for the correction of anophthalmic enophthalmos. Shah S, et al. **Br J Ophthalmol** 1995 Sep;79(9):830-3

[Comparison of the effects of Rocgel and anti-H2 on the symptomatology of gastroesophageal reflux without esophagitis] Houcke P, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Sep;31(4):264-7 (Eng. Abstr.) **(Fre)**

[A new sorbent for hemosorption] Kizner TA, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):60-2 (Eng. Abstr.) **(Rus)**

ALUMINUM SILICATES

Bone replacement in head and neck surgery: a biocompatible alternative. Cole I, et al. **Aust N Z J Surg** 1996 Jul; 66(7):469-72

DNA binding to mica correlates with cationic radius: assay by atomic force microscopy. Hansma HG, et al. **Biophys J** 1996 Apr;70(4):1933-9

Tell-tale teeth: abrasion from the traditional clay pipe. Kvaal SI, et al. **Endeavour** 1996;20(1):28-30

In-vivo evaluation of a feldspathic ceramic system: 2-year results. Friedl KH, et al. **J Dent** 1996 Jan-Mar; 24(1-2):25-31

Accelerated progressive massive fibrosis and mica dust. Baban NK, et al. **J Tenn Med Assoc** 1995 Nov;88(11):430-2

Ossiculoplasty with polymaleinate ionomeric prosthesis. McElveen JT Jr, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):420-6

ADVERSE EFFECTS

In vitro biological effects of clay minerals advised as substitutes for asbestos. Governa M, et al. **Cell Biol Toxicol** 1995 Oct;11(5):237-49

Vermiculite: a review of the mineralogy and health effects of vermiculite exploitation. Addison J. **Regul Toxicol Pharmacol** 1995 Jun;21(3):397-405 (74 ref.)

ANALYSIS

Off-resonance nutation nuclear magnetic resonance study of framework aluminosilicate glasses with Li, Na, K, Rb or Cs as charge-balancing cation. Dirken PJ, et al. **Solid State Nucl Magn Reson** 1995 Nov;5(2):189-200

CHEMISTRY

Solubility of hydroxyapatite/mica composites. Nordström EG, et al. **Biomed Mater Eng** 1996;6(2):73-8

Laboratory evaluation of three visible light-cured resinous liners. Kakaboura AI, et al. **J Dent** 1996 May;24(3):223-31

Vermiculite: a review of the mineralogy and health effects of vermiculite exploitation. Addison J. **Regul Toxicol Pharmacol** 1995 Jun;21(3):397-405 (74 ref.)

PHARMACOLOGY

Selective chemisorption and detoxification of aflatoxins by phyllosilicate clay. Phillips TD, et al. **Nat Toxins** 1995; 3(4):204-13; discussion 221 (59 ref.)

THERAPEUTIC USE

Light and transmission electron microscopic studies following frontal sinus obliteration with ionomer cement in cats. Dazert S, et al. **Eur Arch Otorhinolaryngol** 1995; 252(6):332-5

Treatment of exposed implant threads using a synthetic bone graft. Hürzeler MB, et al. **J Oral Rehabil** 1995 Jul; 22(7):481-9

[Decontamination with clay or alcoholate of pigs percutaneously poisoned with VX and soman] Knežević DL, et al. **Vojnosanit Pregl** 1994 Nov-Dec;51(6):488-91 (Eng. Abstr.) **(Scr)**

TOXICITY

Cytotoxic and transforming effects of some iron-containing minerals in Syrian hamster embryo cells. Elias Z, et al. **Cancer Detect Prev** 1995;19(5):405-14

ALUMINUM SUCROSE SULFATE see **SUCRALFATE**

ALVEOLALGIA see **DRY SOCKET**

ALVEOLAR ABSCESS, APICAL see **PERIAPICAL ABSCESS**

ALVEOLAR BONE LOSS

COMPLICATIONS

Results of treatment of fractures of the atrophic edentulous mandible by compression plating: a retrospective evaluation of 84 consecutive cases. Luhr HG, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):250-4; discussion 254-5

Changes in the position of the mental foramen as a result of alveolar atrophy. Soikkonen K, et al. **J Oral Rehabil** 1995 Nov;22(11):831-3

Massive gingival enlargement and alveolar bone loss: report of two cases. Schmidt BL, et al. **J Periodontol** 1995 Sep; 66(9):811-6

EPIDEMIOLOGY

Prevalence of marginal alveolar bone loss in children referred for treatment to the Paediatric Clinic at the School of Dentistry, University of Otago. Drummond BK, et al. **N Z Dent J** 1995 Dec;91(406):138-40

ETIOLOGY

Prevalence and severity of apical root resorption and alveolar bone loss in orthodontically treated adults. Lupi JE, et al. **Am J Orthod Dentofacial Orthop** 1996 Jan;109(1):28-37

Mandibular incisors, alveolar bone, and symphysis after orthodontic treatment. A retrospective study. Wehrbein H, et al. **Am J Orthod Dentofacial Orthop** 1996 Sep; 110(3):239-46

Factors affecting crestal bone loss with dental implants partially covered with a porous coating: a finite element analysis. Vaillancourt H, et al. **Int J Oral Maxillofac Implants** 1996 May-Jun;11(3):351-9

Treating the oral sequelae of an acoustic neuroma. Whitaker EJ, et al. **J Am Dent Assoc** 1996 Feb;127(2):231-3

The influence of endodontic infection on progression of marginal bone loss in periodontitis. Jansson L, et al. **J Clin Periodontol** 1995 Oct;22(10):729-34

Resolution of ligature-induced peri-implantitis lesions in the dog. Marinello CP, et al. **J Clin Periodontol** 1995 Jun; 22(6):475-9

In vivo administration of IL-1 beta accelerates silk ligature-induced alveolar bone resorption in rats. Koide M, et al. **J Oral Pathol Med** 1995 Oct;24(9):420-34

Delayed implants in the anterior maxilla with the IMZ-implant system: a radiographical evaluation. de Wijs FL, et al. **J Oral Rehabil** 1995 Nov;22(11):797-802

Re: Post-rhizotomy periodontal atrophy (J Periodontol 1995; 66:301-302) [letter; comment] Sheridan PJ. **J Periodontol** 1995 Nov;66(11):1016. Comment on: J Periodontol 1995 Apr;66(4):301-2.

Failure of a hydroxyapatite-coated endosteal dental implant: a clinical report. Taylor JC, et al. **J Prosthet Dent** 1996 Apr;75(4):353-5

Oral signs as indicators of possible osteoporosis in elderly women. Taguchi A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):612-6

HISTORY

Alveolar bone loss on neolithic man remains on 38 skulls of Khirokitia's (Cyprus) inhabitants. Mitsis FJ, et al. **J Clin Periodontol** 1995 Oct;22(10):788-93

Dental conditions and temporomandibular joints in an early mesolithic bog man. Borrman H, et al. **Swed Dent J** 1996; 20(1-2):1-14

METABOLISM

Alveolar bone turnover in male rats: site- and age-specific changes. King GJ, et al. **Anat Rec** 1995 Jul;242(3):321-8

MICROBIOLOGY

The composition of subgingival microflora in two groups of children with and without primary dentition alveolar bone loss. Bimstein E, et al. **Pediatr Dent** 1996 Jan-Feb; 18(1):42-7

PATHOLOGY

Three-dimensional interpretation of alveolar bone dehiscences. An anatomical-radiological study--Part I. Fuhrmann R. **Fortschr Kieferorthop** 1996 Apr;57(2):62-74 **(Eng, Ger)**

Resolution of ligature-induced peri-implantitis lesions in the dog. Marinello CP, et al. **J Clin Periodontol** 1995 Jun; 22(6):475-9

Biometric design of complete dentures related to residual ridge resorption. Klemetti E, et al. **J Prosthet Dent** 1996 Mar;75(3):281-4

Overdentures with roots or implants for elderly patients: a comparison [letter; comment] Tarlow JL. **J Prosthet Dent** 1996 Mar;75(3):346. Comment on: J Prosthet Dent 1994 Nov;72(5):543-50.

[Histological study on experimental tooth movement in alveolar bone defects implanted with decalcified bone powder] Uji M. **Kokubyo Gakkai Zasshi** 1996 Mar; 63(1):208-21 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Dentoalveolar stress from bodily tooth movement at different levels of bone loss. Cobo J, et al. **Am J Orthod Dentofacial Orthop** 1996 Sep;110(3):256-62

A review of residual ridge resorption and bone density. Klemetti E. **J Prosthet Dent** 1996 May;75(5):512-4 (32 ref.)

Radiographic study of bone loss of mandibular lingual cortical plate accompanied by third molar development. Yamaoka M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):650-4

PREVENTION & CONTROL

Not all bone loss created equal [letter] Eisenberger YS. **Angle Orthod** 1996;66(2):85

The benefits of estrogen replacement therapy on oral health. The Leisure World cohort. Paganini-Hill A. **Arch Intern Med** 1995 Nov 27;155(21):2325-9

Long-term bone mass evaluation of mandible and lumbar spine in a group of women receiving hormone replacement therapy. Jacobs R, et al. **Eur J Oral Sci** 1996 Feb; 104(1):10-16

Ridge preservation: why not? Christensen GJ. **J Am Dent Assoc** 1996 May;127(5):669-70

Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. Shoji K, et al. **J Periodontal Res** 1995 Jul;30(4):277-84

Alveolar ridge preservation following extraction of maxillary anterior teeth. Report on 23 consecutive cases. Nemcovsky CE, et al. **J Periodontol** 1996 Apr;67(4):390-5

The effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats. Yaffe A, et al. **J Periodontol** 1995 Nov;66(11):999-1003

Treatment results with immediate overdentures: an evaluation of 4.5 years. van Waas MA, et al. **J Prosthet Dent** 1996 Aug;76(2):153-7

RADIOGRAPHY

Three-dimensional interpretation of periodontal lesions and remodeling during orthodontic treatment. Part III. Fuhrmann R. **Fortschr Kieferorthop** 1996 Aug;57(4):224-37 **(Eng, Ger)**

Three-dimensional interpretation of alveolar bone dehiscences. An anatomical-radiological study--Part I. Fuhrmann R. **Fortschr Kieferorthop** 1996 Apr;57(2):62-74 **(Eng, Ger)**

Diagnosis of infra-alveolar bony lesions in the dentate alveolar process with high-resolution computed tomography. Experimental results. Langen HJ, et al. **Invest Radiol** 1995 Jul;30(7):421-6

Radiographic alveolar bone loss from posterior teeth in young adults over a 4-year period. Bishop K, et al. **J Clin Periodontol** 1995 Nov;22(11):835-41

Periodontal bone loss of teeth with metal posts. A radiographic study. Eliasson S, et al. **J Clin Periodontol** 1995 Nov;22(11):850-3

Assessment of alveolar bone loss with high resolution computed tomography. Fuhrmann RA, et al. **J Periodontal Res** 1995 Jul;30(4):258-63

Radiographic evaluation of bone regeneration following periodontal surgery with or without expanded polytetrafluoroethylene barriers. Eickholz P, et al. **J Periodontol** 1996 Apr;67(4):379-85

Comparison of film, direct digital, and tuned-aperture computed tomography images to identify the location of crestal defects around endosseous titanium implants. Webber RL, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):480-90

SURGERY

Prosthetic management of the atrophic mandible using endosseous implants and overdentures: a six year review [see comments] Chan MF, et al. **Br Dent J** 1995 Nov 11; 179(9):329-37. Comment in: Br Dent J 1996 May 11;180(9):324.

Prosthetic rehabilitation of the atrophic maxilla using pre-implant surgery and endosseous implants. Chan MF, et al. **Br Dent J** 1996 Jul 20;181(2):51-8

Mandibular rehabilitation: a case study using inferior cadaver graft. Balshi TJ, et al. **Int J Oral Maxillofac Implants** 1995 Sep-Oct;10(5):589-94

Interpositional bone grafting technique to widen narrow maxillary ridge. Lustmann J, et al. **Int J Oral Maxillofac Implants** 1995 Sep-Oct;10(5):568-77

A new approach to regeneration of surgically reduced alveolar ridges in dogs: a clinical and histologic study. Smukler H, et al. **Int J Oral Maxillofac Implants** 1995 Sep-Oct;10(5):537-51

One-step reconstruction of the severely resorbed mandible with onlay bone grafts and endosteal implants. A 5-year follow-up. Vermeeren JI, et al. **Int J Oral Maxillofac Surg** 1996 Apr;25(2):112-5

Clinical evaluation of natural coral and porous hydroxyapatite implants in periodontal bone lesions: results of a 1-year follow-up. Mora F, et al. **J Clin Periodontol** 1995 Nov;22(11):877-84

Collagen gel and membrane in guided tissue regeneration in periodontal fenestration defects in dogs. Tal H, et al. **J Clin Periodontol** 1996 Jan;23(1):1–6

Long-term effects of gingival fibroblast-coated hydroxylapatite graft on periodontal osseous defects. Feng F, et al. **J Formos Med Assoc** 1995 Aug;94(8):494–8

Autologous bone grafts and endosseous implants: complementary techniques. Triplett RG, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):486–94

Evaluation of a collagen membrane with and without bone grafts in treating periodontal intrabony defects. Chen CC, et al. **J Periodontol** 1995 Oct;66(10):838–47

Healing response to anorganic bone implantation in periodontal intrabony defects in dogs. Part I. Bone regeneration. A microradiographic study. Clergeau LP, et al. **J Periodontol** 1996 Feb;67(2):140–9

Periodontal regeneration of human intrabony defects with titanium reinforced membranes. A controlled clinical trial. Cortellini P, et al. **J Periodontol** 1995 Sep;66(9):797–803

Periodontal regeneration of human intrabony defects with bioresorbable membranes. A controlled clinical trial. Cortellini P, et al. **J Periodontol** 1996 Mar;67(3):217–23

Repair following treatment of circumferential periodontal defects in dogs with collagen and expanded polytetrafluoroethylene barrier membranes. Crigger M, et al. **J Periodontol** 1996 Apr;67(4):403–13

Radiographic evaluation of bone regeneration following periodontal surgery with or without expanded polytetrafluoroethylene barriers. Eickholz P, et al. **J Periodontol** 1996 Apr;67(4):379–85

Clinical and microbiological observations of early polytetrafluoroethylene membrane exposure in guided bone regeneration. Case reports in primates. Fritz ME, et al. **J Periodontol** 1996 Mar;67(3):245–9

A Comparative study of ePTFE periodontal membranes with and without decalcified freeze-dried bone allografts for the regeneration of interproximal intraosseous defects. Mellado JR, et al. **J Periodontol** 1995 Sep;66(9):751–5

Re: Demineralized freeze-dried and autologous bone as aids to healing (J Periodontol 1994; 64; 1128–1133) [letter; comment] Mellonig JT, et al. **J Periodontol** 1995 Nov; 66(11):1013–6. Comment on: J Periodontol 1994 Dec;65(12):1128–33.

Fate of demineralized freeze-dried bone allografts in human intrabony defects. Reynolds MA, et al. **J Periodontol** 1996 Feb;67(2):150–7

[Fractures of the atrophic mandible—a challenge for therapy] Luhr HG, et al. **Fortschr Kiefer Gesichtschir** 1996;41:151–4 (Eng. Abstr.) **(Ger)**

[Value of dental CT for the implant specialty in mouth, jaw and facial surgery] Widlitzek H, et al. **Radiologe** 1996 Mar; 36(3):229–35 (Eng. Abstr.) **(Ger)**

ALVEOLAR ECHINOCOCCIS, HEPATIC see **ECHINOCOCCOSIS, HEPATIC**

ALVEOLAR LAVAGE FLUID see **BRONCHOALVEOLAR LAVAGE FLUID**

ALVEOLAR MACROPHAGES see **MACROPHAGES, ALVEOLAR**

ALVEOLAR NERVE, INFERIOR see **MANDIBULAR NERVE**

ALVEOLAR NERVE, SUPERIOR see **MAXILLARY NERVE**

ALVEOLAR PROCESS

see related
ALVEOLECTOMY
ALVEOLOPLASTY
DENTAL ARCH

The pathophysiology of alveolar osteonecrosis of the jaw: anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. Gruppo R, et al. **J Lab Clin Med** 1996 May;127(5):481–8

ABNORMALITIES

Congenital unilateral fusion of the mandibular and maxillary alveolar ridges, temporomandibular joint, and coronoid process: a case report. Behnia H, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):773–6

[The role of autologous parietal bone graft in alveolar cleft] Siciliano S, et al. **Minerva Stomatol** 1995 Sep;44(9):389–95 (Eng. Abstr.) **(Ita)**

ANATOMY & HISTOLOGY

Effects of buccal shields on the maxillary dentoalveolar structures and the midpalatal suture—histologic and biometric studies in rabbits. Kalogirou K, et al. **Am J Orthod Dentofacial Orthop** 1996 May;109(5):521–30

Three-dimensional interpretation of labiolingual bone width of the lower incisors. Part II. Fuhrmann R. **Fortschr Kieferorthop** 1996 Jun;57(3):168–85 **(Eng, Ger)**

Three-dimensional interpretation of alveolar bone dehiscences. An anatomical-radiological study—Part I. Fuhrmann R. **Fortschr Kieferorthop** 1996 Apr;57(2):62–74 **(Eng, Ger)**

Clinical comparison of desired versus actual amount of surgical crown lengthening. Herrero F, et al. **J Periodontol** 1995 Jul;66(7):568–71

[Variants in the arrangement of the tooth roots in the alveolar arches of the human jaws based on computed tomographic data] Galvoronskii IV, et al. **Morfologiia** 1994 Apr–Jun; 106(4–6):17–26 (Eng. Abstr.) **(Rus)**

CYTOLOGY

The effect of cobalt-60 irradiation on bone marrow cellularity and alveolar osteoclasts. Tsay TP, et al. **Proc Natl Sci Counc Repub China B** 1995 Jul;19(3):185–95

GROWTH & DEVELOPMENT

Palatal surgery without denudation of bone favours dentoalveolar development in dogs. Leenstra TS, et al. **Int J Oral Maxillofac Surg** 1995 Dec;24(6):440–4

INJURIES

CO2 lasers and temperature changes of titanium implants. Oyster DK, et al. **J Periodontol** 1995 Dec;66(12):1017–24

INNERVATION

Identification of axons in the peri-implant region by immunohistochemistry. Weiner S, et al. **Int J Oral Maxillofac Implants** 1995 Nov–Dec;10(6):689–95

METABOLISM

Crevicular fluid osteocalcin and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis. A pilot study in beagle dogs. Giannobile WV, et al. **J Clin Periodontol** 1995 Dec;22(12):903–10

PATHOLOGY

The anterior alveolus: its importance in limiting orthodontic treatment and its influence on the occurrence of iatrogenic sequelae. Handelman CS. **Angle Orthod** 1996;66(2):95–109; discussion 109–10

Microradiography and fluorescence microscopy of bone remodeling on the basal crypt of permanent mandibular premolars in dogs during eruption. Pilipili CM, et al. **Connect Tissue Res** 1995;32(1–4):171–81

The edentulous maxillary alveolar process in the region of the maxillary sinus—a study of physical dimension. Ulm CW, et al. **Int J Oral Maxillofac Surg** 1995 Aug; 24(4):279–82

Lack of furcal bone loss following the tunneling procedure. Little LA, et al. **J Clin Periodontol** 1995 Aug;22(8):637–41

An unusual intraosseous melanoma in the maxillary alveolus. Lombardi T, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):677–82

PHYSIOLOGY

Devices for dentoalveolar regeneration: an up-to-date literature review. Hardwick R, et al. **J Periodontol** 1995 Jun;66(6):495–505 (58 ref.)

RADIATION EFFECTS

The effect of cobalt-60 irradiation on bone marrow cellularity and alveolar osteoclasts. Tsay TP, et al. **Proc Natl Sci Counc Repub China B** 1995 Jul;19(3):185–95

RADIOGRAPHY

Three-dimensional interpretation of alveolar bone dehiscences. An anatomical-radiological study—Part I. Fuhrmann R. **Fortschr Kieferorthop** 1996 Apr;57(2):62–74 **(Eng, Ger)**

Diagnosis of infra-alveolar bony lesions in the dentate alveolar process with high-resolution computed tomography. Experimental results. Langen HJ, et al. **Invest Radiol** 1995 Jul;30(7):421–6

Radiographic amelocemental junction and alveolar crest: effect of X-ray beam angulation. Jenkins SM, et al. **J Oral Rehabil** 1995 Sep;22(9):679–84

Spatial resolution and angular alignment tolerance in radiometric analysis of alveolar bone change. Shrout MK, et al. **J Periodontol** 1996 Jan;67(1):41–5

Room for improvement? The accuracy of dental practitioners who diagnose bony pathoses with radiographs. Stheeman SE, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):251–4

Alveolar cleft bone grafts: results and imprecisions of the dental radiograph. Lee C, et al. **Plast Reconstr Surg** 1995 Dec;96(7):1534–8

[Computerized tomography of the alveolar process] Schüller H. **Radiologe** 1996 Mar;36(3):221–5 (Eng. Abstr.) **(Ger)**

SURGERY

Cleft width and secondary alveolar bone graft success. Long RE Jr, et al. **Cleft Palate Craniofac J** 1995 Sep;32(5):420–7

Comparison of facial form in primary alveolar bone-grafted and nongrafted unilateral cleft lip and palate patients: intercenter retrospective study. Trotman CA, et al. **Cleft Palate Craniofac J** 1996 Mar;33(2):91–5

Application of the interseptal alveolotomy for closing the oroantral fistula. Hori M, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1392–6

Alveolar cleft bone grafting (Part II): Secondary bone grafting. Ochs MW. **J Oral Maxillofac Surg** 1996 Jan; 54(1):83–8 (37 ref.)

Alveolar cleft bone grafts: results and imprecisions of the dental radiograph. Lee C, et al. **Plast Reconstr Surg** 1995 Dec;96(7):1534–8

Maxillary alveolar cleft repair in dogs using recombinant human bone morphogenetic protein-2 and a polymer carrier. Mayer M, et al. **Plast Reconstr Surg** 1996 Aug; 98(2):247–59

Lymphangioma treatment with Nd-YAG laser. Taşar F, et al. **Turk J Pediatr** 1995 Jul–Sep;37(3):253–6

ULTRASTRUCTURE

Confocal laser scanning microscopic studies on alveolar bone remodeling with orthodontic tooth movement and retention. Yagishita H, et al. **Scanning Microsc** 1995 Sep; 9(3):781–8

ALVEOLAR RESORPTION see **ALVEOLAR BONE LOSS**

ALVEOLAR RIDGE AUGMENTATION

Evaluation of the incorporation of bone grafts used in maxillofacial surgery with [18F]fluoride ion and dynamic positron emission tomography. Berding G, et al. **Eur J Nucl Med** 1995 Oct;22(10):1133–40

[Influence of various impression procedures for mandibular distal extension removable partial denture on displacement of residual ridge] Sato M. **Kokubyo Gakkai Zasshi** 1996 Mar;63(1):88–107 (Eng. Abstr.) **(Jpn)**

METHODS

Cleft width and secondary alveolar bone graft success. Long RE Jr, et al. **Cleft Palate Craniofac J** 1995 Sep;32(5):420–7

Mandibular rehabilitation: a case study using inferior cadaver graft. Balshi TJ, et al. **Int J Oral Maxillofac Implants** 1995 Sep–Oct;10(5):589–94

The use of demineralized laminar bone sheets in guided bone regeneration procedures: report of three cases. Fugazzotto PA. **Int J Oral Maxillofac Implants** 1996 Mar–Apr; 11(2):239–44

Interpositional bone grafting technique to widen narrow maxillary ridge. Lustmann J, et al. **Int J Oral Maxillofac Implants** 1995 Sep–Oct;10(5):568–77

A new approach to regeneration of surgically reduced alveolar ridges in dogs: a clinical and histologic study. Smukler H, et al. **Int J Oral Maxillofac Implants** 1995 Sep–Oct;10(5):537–51

The TIME technique: a new method for localized alveolar ridge augmentation prior to placement of dental implants. von Arx T, et al. **Int J Oral Maxillofac Implants** 1996 May–Jun;11(3):387–94

One-step reconstruction of the severely resorbed mandible with onlay bone grafts and endosteal implants. A 5-year follow-up. Vermeeren JI, et al. **Int J Oral Maxillofac Surg** 1996 Apr;25(2):112–5

Mandibular alveolar ridge augmentation in the dog using distraction osteogenesis. Block MS, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):309–14

Lateral ridge augmentation using autografts and barrier membranes: a clinical study with 40 partially edentulous patients. Buser D, et al. **J Oral Maxillofac Surg** 1996 Apr; 54(4):420–32; discussion 432–3

Long-term stability of atrophic ridges reconstructed with hydroxylapatite: a prospective study. Mercier P, et al. **J Oral Maxillofac Surg** 1996 Aug;54(8):960–8; discussion 968–9

Alveolar ridge preservation following extraction of maxillary anterior teeth. Report on 23 consecutive cases. Nemcovsky CE, et al. **J Periodontol** 1996 Apr;67(4):390–5

Vertical ridge augmentation using a resorbable membrane: a case report. Piattelli M, et al. **J Periodontol** 1996 Feb; 67(2):158–61

Failures in ridge reconstruction with hydroxyapatite. Analysis of cases and methods for surgical revision. Mercier P. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Oct;80(4):389–93

Ridge reconstruction with hydroxyapatite [letter] Schaffer AB. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):376

ALVEOLECTOMY

Comparative evaluation of function after surgery for cancer of the alveolobuccal complex. Patel SG, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):698–703; discussion 703–4

ALVEOLITIS, EXTRINSIC ALLERGIC

Potentially fatal hypersensitivity pneumonitis in a child. Krasnick J, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):388–91

Summer-type hypersensitivity pneumonitis. Ando M, et al. **Intern Med** 1995 Aug;34(8):707–12 (37 ref.)

BLOOD

[The characteristics of the protein and lipid metabolic indices of poultry farmers with extrinsic allergic alveolitis] Reheda

MS. **Fiziol Zh** 1994 Sep-Dec;40(5-6):118-20 (Eng. Abstr.) **(Ukr)**

CHEMICALLY INDUCED

A clinical study of minocycline-induced pneumonitis. Toyoshima M, et al. **Intern Med** 1996 Mar;35(3):176-9
Suspected hypersensitivity pneumonitis after exposure to a biologic forage inoculant. Mannino D, et al. **South Med J** 1996 Sep;89(9):898-901
[Lung disease induced by isotretinoin] Oliviero G, et al. **Rev Mal Respir** 1995;12(6):631-3 (Eng. Abstr.) **(Fre)**
[Toxic pneumosclerosis and alveolitis in workers of hydrometallurgic production of nickel] Artiunina GP. **Med Tr Prom Ekol** 1996;(3):22-5 (Eng. Abstr.) **(Rus)**
[Extrinsic allergic alveolitis caused by isocyanates (letter)] Pedrouzo Bardelas J, et al. **Med Clin (Barc)** 1996 May 18; 106(19):756-7 **(Spa)**

COMPLICATIONS

[Alveolitis and Pneumocystis carinii infection in a worker exposed to plaster (letter)] Sánchez Varilla JM, et al. **Rev Clin Esp** 1995 Aug;195(8):591 **(Spa)**

DIAGNOSIS

Paper mill workers and chronic extrinsic allergic alveolitis [letter] Festa JL. **Am Fam Physician** 1996 Apr;53(5):1522-4
Multifactorial immunologic lung disease: a case report. Krasnick J, et al. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):239-41
Hypersensitivity pneumonitis: problems in diagnosis. Krasnick J, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):1027-30
Occupational hypersensitivity pneumonitis in Japan: data on a nationwide epidemiological study. Yoshida K, et al. **Occup Environ Med** 1995 Sep;52(9):570-4
Hypersensitivity pneumonitis: a noninfectious granulomatosis. Sharma OP, et al. **Semin Respir Infect** 1995 Jun;10(2):96-106 (32 ref.)
[Espartosis or plasterer's lung? (letter)] Pérez Arellano JL, et al. **Med Clin (Barc)** 1996 Mar 2;106(8):318 **(Spa)**

DRUG THERAPY

[Evaluation of the usefulness of bronchoalveolar lavage for prognosing and monitoring the treatment of patients with chronic allergic alveolitis] Jastrzębski D, et al. **Pneumonol Alergol Pol** 1996;64(3-4):157-64 (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

[Extrinsic allergic alveolitis of occupational origin] Toubas D, et al. **Presse Med** 1995 Oct 14;24(30):1391-6 (42 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Paper mill workers and chronic extrinsic allergic alveolitis [letter] Festa JL. **Am Fam Physician** 1996 Apr;53(5):1522-4
Experimental hypersensitivity pneumonitis: cellular requirements. Schuyler M, et al. **Clin Exp Immunol** 1996 Jul;105(1):169-75
Biopsy-confirmed hypersensitivity pneumonitis in automobile production workers exposed to metalworking fluids--Michigan, 1994-1995. **MMWR Morb Mortal Wkly Rep** 1996 Jul 19;45(28):606-10
Sump bay fever: inhalational fever associated with a biologically contaminated water aerosol. Anderson K, et al. **Occup Environ Med** 1996 Feb;53(2):106-11
[Hypersensitivity pneumonitis caused by a home humidifier] Hagiwara S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep; 33(9):1024-9 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Results of bronchoprovocation tests with the allergen Erwinia herbicola in persons with occupational exposure to organic dust] Durda M, et al. **Pneumonol Pol** 1990 Sep-Oct;58(9-10):522-6 (Eng. Abstr.) **(Pol)**

GENETICS

Major histocompatibility complex class II genes control susceptibility to hypersensitivity pneumonitis in the mouse. Donnelly KB, et al. **Chest** 1996 Mar;109(3 Suppl):73S

IMMUNOLOGY

Tannic acid's effect on bird antigen. Craig TJ, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):348-50
Experimental hypersensitivity pneumonitis: cellular requirements. Schuyler M, et al. **Clin Exp Immunol** 1996 Jul;105(1):169-75
Soluble intercellular adhesion molecule-1 (ICAM-1) in sera and bronchoalveolar lavage (BAL) fluids of extrinsic allergic alveolitis. Shijubo N, et al. **Clin Exp Immunol** 1995 Oct;102(1):91-7
Chemokines in bronchoalveolar lavage fluid in summer-type hypersensitivity pneumonitis. Sugiyama Y, et al. **Eur Respir J** 1995 Jul;8(7):1084-90
Experimental hypersensitivity pneumonitis: in vitro effects of interleukin-2 and interferon-gamma. Fei R, et al. **J Lab Clin Med** 1995 Nov;126(5):485-94
Hypersensitivity pneumonitis induced by a smut fungus Ustilago esculenta. Yoshida K, et al. **Thorax** 1996 Jun; 51(6):650-1; discussion 656-7

METABOLISM

Elevated levels of IL-6, INF-gamma, and TNF-alpha in mice in response to cotton dust are modulated by anti-TNF-alpha antiserum. Shvedova AA, et al. **Exp Lung Res** 1996 Mar-Apr;22(2):149-61

MICROBIOLOGY

Basement shower hypersensitivity pneumonitis secondary to Epicoccum nigrum. Hogan MB, et al. **Chest** 1996 Sep; 110(3):854-6

PHYSIOPATHOLOGY

Regulatory effects of endogenous interleukin-1 receptor antagonist protein in immunoglobulin G immune complex-induced lung injury. Shanley TP, et al. **J Clin Invest** 1996 Feb 15;97(4):963-70

RADIOGRAPHY

Hypersensitivity pneumonitis: correlation of individual CT patterns with functional abnormalities. Hansell DM, et al. **Radiology** 1996 Apr;199(1):123-8
[Hypersensitivity pneumopathies: x-ray computed tomographic aspects] Moysan P, et al. **J Radiol** 1995 Jul; 76(7):435-40 (27 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[The course of allergic alveolitis based on personal experience] Korzeniewska-Kosela M, et al. **Pneumonol Pol** 1990 Nov-Dec;58(11-12):620-3 (Eng. Abstr.) **(Pol)**

ALVEOLITIS, FIBROSING see **PULMONARY FIBROSIS**

ALVEOLOCAPILLARY MEMBRANE see **BLOOD-AIR BARRIER**

ALVEOLOPLASTY

see related
DENTURE, COMPLETE, IMMEDIATE

Long-term results of segmental repositioning of the maxilla in cleft palate patients without previously grafted alveolo-palatal clefts. Erbe M, et al. **J Craniomaxillofac Surg** 1996 Apr;24(2):109-17

METHODS

Alternative donor site for alveolar bone grafting in adults with cleft lip and palate. So LL, et al. **Angle Orthod** 1996; 66(1):9-16 (64 ref.)

ALZHEIMER BETA-PROTEIN see **AMYLOID BETA-PROTEIN**

ALZHEIMER'S DISEASE

see related
AMYLOID BETA-PROTEIN
AMYLOID BETA-PROTEIN PRECURSOR
APHASIA, PRIMARY PROGRESSIVE
NEUROFIBRILLARY TANGLES
NEUROFILAMENT PROTEINS
TAU PROTEINS

Symposium on Alzheimer's disease. Antwerp, May 11-13, 1995. Abstracts. **Acta Neurol Belg** 1996 Mar;96(1):69-78
International commentaries on "guidelines for addressing ethical and legal issues in Alzheimer disease research". Post S. **Alzheimer Dis Assoc Disord** 1995 Winter;9(4):188-92
Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques. Fukumoto H, et al. **Am J Pathol** 1996 Jan; 148(1):259-65
beta PP and Tau interaction. A possible link between amyloid and neurofibrillary tangles in Alzheimer's disease. Giaccone G, et al. **Am J Pathol** 1996 Jan;148(1):79-87
Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Masliah E, et al. **Am J Pathol** 1996 Jan;148(1):201-10
Crashes and violations among drivers with Alzheimer disease. Trobe JD, et al. **Arch Neurol** 1996 May;53(5):411-6
Test-retest reliability of a dichotic digits test for assessing central auditory function in Alzheimer's disease. Strouse AL, et al. **Audiology** 1995 Mar-Apr;34(2):85-90
The secreted form of the Alzheimer's beta-amyloid precursor protein stimulates a membrane-associated guanylate cyclase. Barger SW, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):45-7
Euthanasia and related ethical issues in dementias of later life with special reference to Alzheimer's disease. Roth M. **Br Med Bull** 1996 Apr;52(2):263-79
Clinical neurosciences and Alzheimer's disease. Cacabelos R. **Clin Sci (Colch)** 1996 Mar;90(3):153-6
Degenerative diseases. **Curr Opin Neurol** 1995 Aug; 8(4):B97-124
The Alzheimerization of aging [see comments] Adelman RC. **Gerontologist** 1995 Aug;35(4):526-32. Comment in: Gerontologist 1995 Dec;35(6):721-3.
Impact of dementia special care units: resource use and outcomes [letter; comment] Volicer L, et al. **Gerontologist** 1995 Oct;35(5):581-2. Comment on: Gerontologist 1995 Apr;35(2):179-84.
Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? [see comments] Birge SJ. **J Am Geriatr Soc** 1996 Jul;44(7):865-70 (79 ref.) . Comment in: J Am Geriatr Soc 1996 Jul;44(7):878-80.
Should Alzheimer's disease patients be allowed to drive? A medical, legal, and ethical dilemna [editorial; comment] Freedman ML, et al. **J Am Geriatr Soc** 1996 Jul;44(7):876-7 . Comment on: J Am Geriatr Soc 1996 Jul;44(7):815-7.
Fairhill guidelines on ethics of the care of people with Alzheimer's disease: a clinical summary. Center for Biomedical Ethics, Case Western Reserve University and the Alzheimer's Association [see comments] Post SG, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1423-9. Comment in: J Am Geriatr Soc 1995 Dec;43(12):1437-8.
The "co-pilot" driver syndrome [see comments] Shua-Haim JR, et al. **J Am Geriatr Soc** 1996 Jul;44(7):815-7. Comment in: J Am Geriatr Soc 1996 Jul;44(7):876-7.
Alzheimer's syndrome, not Alzheimer's disease. Shua-Haim JR, et al. **J Am Geriatr Soc** 1996 Jan;44(1):96-7
Linguistic ability in early life and Alzheimer disease in late life [letter; comment] Massie HN. **JAMA** 1996 Jun 26; 275(24):1879. Comment on: JAMA 1996 Feb 21;275(7):528-32.
Driving and Alzheimer disease [letter; comment] Mattes JA. **JAMA** 1996 Jan 17;275(3):182; discussion 182-3. Comment on: JAMA 1995 May 3;273(17):1360-5.
Linguistic ability in early life and Alzheimer disease in late life [letter] Miranda G. **JAMA** 1996 Jun 26;275(24):1879
Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study [see comments] Snowdon DA, et al. **JAMA** 1996 Feb 21;275(7):528-32. Comment in: JAMA 1996 Jun 26;275(24):1879.
Driving and Alzheimer disease [letter; comment] Weintraub MI. **JAMA** 1996 Jan 17;275(3):182; discussion 182-3. Comment on: JAMA 1995 May 3;273(17):1360-5.
Legal implications of Alzheimer's disease. Stratton WT. **Kans Med** 1995 Summer;96(2):44-5
The Schmitt Symposium: The Cytoskeleton and Alzheimer's Disease. Proceedings. Rochester, New York, May 21-23, 1994. **Neurobiol Aging** 1995 May-Jun;16(3):227-499
Alzheimer's disease death certificates [letter] Frecker MF, et al. **Neurology** 1995 Dec;45(12):2298-9
The consortium to establish a registry for Alzheimer's disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer's disease. Heyman A, et al. **Neurology** 1996 Mar;46(3):656-60
Indomethacin and Alzheimer's disease. Smalheiser NR, et al. **Neurology** 1996 Feb;46(2):583
Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Hsiao KK, et al. **Neuron** 1995 Nov;15(5):1203-18
Distribution and expression of the alpha-tubulin mRNA in the hippocampus and the temporal cortex in Alzheimer's disease. Brion JP, et al. **Pathol Res Pract** 1995 Jul; 191(6):490-8
Senile words [news] Wallich P. **Sci Am** 1996 Jun;274(6):26, 28
[Trial to produce animal model of Alzheimer's disease by continuous infusion of beta-amyloid protein into the rat cerebral ventricle] Nabeshima T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Oct; 15(5):411-8 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Methodological aspects and discrepancies in the clinical trials in Alzheimer's disease] Borja J, et al. **Rev Neurol** 1995 Jan-Feb;23(119):125-8 (30 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Apolipoprotein E in patients with dementia of the Alzheimer type and vascular dementia. Isoe K, et al. **Acta Neurol Scand** 1996 Feb-Mar;93(2-3):133-7
Prospective study of increased platelet membrane fluidity as a risk factor for Alzheimer's disease: results at 5 years. Zubenko GS, et al. **Am J Psychiatry** 1996 Mar;153(3):420-3
Plasma and red blood cell thiamine deficiency in patients with dementia of the Alzheimer's type. Gold M, et al. **Arch Neurol** 1995 Nov;52(11):1081-6
Peripheral blood lymphocyte subset distribution and function in patients with Alzheimer's disease and other dementias. Hu GR, et al. **Aust N Z J Med** 1995 Jun;25(3):212-7
Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease. Shetty HU, et al. **Clin Chem** 1996 Feb;42(2):298-302
Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease [letter] Kawano M, et al. **Clin Chim Acta** 1995 Aug 14;239(2):209-11
Serum cytokine levels in patients with Alzheimer's disease. Chao CC, et al. **Clin Diagn Lab Immunol** 1994 Jul; 1(4):433-6
Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. Hampel H, et al. **Dementia** 1995 Nov-Dec;6(6):348-54
Erythrocyte sedimentation rate in Alzheimer's dementia [letter] Robinson D, et al. **J Am Geriatr Soc** 1995 Oct; 43(10):1177-8
High-performance liquid chromatographic assay for xanomeline, a specific M-1 agonist, and its metabolite in

human plasma. Kasper SC, et al.
J Chromatogr B Biomed Appl 1995 Jul 21;669(2):397–403
Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases. Ahlskog JE, et al. **J Neurol Sci** 1996 Mar;136(1–2):162–8
Advanced glycation endproducts–associated parameters in the peripheral blood of patients with Alzheimer's disease. Thome J, et al. **Life Sci** 1996;59(8):679–85
Changes in platelet phospholipase C protein level and activity in Alzheimer's disease. Matsushima H, et al.
Neurobiol Aging 1995 Nov–Dec;16(6):895–900
Cerebrospinal fluid 'neuronal thread protein' comes from serum by passage over the blood–brain barrier. Blennow K, et al. **Neurodegeneration** 1995 Jun;4(2):187–93
Erythrocyte thiolmethyltransferase: another failed marker for Alzheimer's and Parkinson's diseases. Hurwitz A, et al.
Neurology 1995 Oct;45(10):1903–6
Peripheral serotonin in Alzheimer's disease. Kumar AM, et al. **Neuropsychobiology** 1995;32(1):9–12
Plasma neuropeptide Y is reduced in patients with Alzheimer's disease. Koide S, et al. **Neurosci Lett** 1995 Sep 29;198(2):149–51
Blood–brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs. Martel CL, et al. **Neurosci Lett** 1996 Mar 15; 206(2–3):157–60
Serotonin uptake and its kinetics in platelets of women with Alzheimer's disease. Kumar AM, et al. **Psychiatry Res** 1995 Nov 29;59(1–2):145–50
Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease. Mari D, et al.
Thromb Haemost 1996 Feb;75(2):216–8
[Lipid metabolism parameters in patients with multi-infarct dementia and Alzheimer's type dementia] Sygitowicz G, et al. **Neurol Neurochir Pol** 1996 Mar–Apr;30(2):213–9; quiz 220 (Eng. Abstr.) **(Pol)**

CEREBROSPINAL FLUID

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Arai H, et al. **Ann Neurol** 1995 Oct; 38(4):649–52
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Motter R, et al. **Ann Neurol** 1995 Oct;38(4):643–8
Cerebrospinal fluid concentrations of soluble amyloid beta–protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain. Pirttilä T, et al. **Arch Neurol** 1996 Feb;53(2):189–93
Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia. Heilig M, et al. **Biol Psychiatry** 1995 Aug 15;38(4):210–6
Cerebrospinal fluid and plasma distribution of myo–inositol and other polyols in Alzheimer disease. Shetty HU, et al. **Clin Chem** 1996 Feb;42(2):298–302
Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer's disease? Blennow K, et al. **Dementia** 1995 Nov–Dec;6(6):306–11
Changes in a CSF antigen associated with dementia. Carretero MT, et al. **Dementia** 1995 Sep–Oct;6(5):281–5
Evidence of blood–cerebrospinal fluid–barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. Hampel H, et al. **Dementia** 1995 Nov–Dec;6(6):348–54
Alpha 1–antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease. Harigaya Y, et al. **Intern Med** 1995 Jun;34(6):481–4
Elevated cerebrospinal fluid tau levels: implications for the early diagnosis of Alzheimer's disease [letter] Terajima M, et al. **J Am Geriatr Soc** 1996 Aug;44(8):1012–3
Indoleamine concentrations in cerebrospinal fluid from patients with Alzheimer type and Binswanger type dementias before and after administration of citalopram, a synthetic serotonin uptake inhibitor. Tohgi H, et al.
J Neural Transm Park Dis Dement Sect 1995;9(2–3):121–31
Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease [letter] Rösler N, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb; 60(2):237–8
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Blennow K, et al. **Mol Chem Neuropathol** 1995 Dec;26(3):231–45
A population–based study of tau protein and ubiquitin in cerebrospinal fluid in 85–year–olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Skoog I, et al.
Neurodegeneration 1995 Dec;4(4):433–42
CSF excitatory amino acids and severity of illness in Alzheimer's disease. Csernansky JG, et al. **Neurology** 1996 Jun;46(6):1715–20
Interleukin–1 beta and interleukin–6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Blum–Degen D, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):17–20
Amyloid beta–peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. Lannfelt L, et al. **Neurosci Lett** 1995 Oct 27; 199(3):203–6
Increased cerebrospinal fluid pyruvate levels in Alzheimer's disease. Parnetti L, et al. **Neurosci Lett** 1995 Oct 27; 199(3):231–3
[Effect of apolipoprotein E phenotype on cerebrospinal fluid levels of tau in patients with dementia of Alzheimer type] Kanemaru K, et al. **Nippon Ronen Igakkai Zasshi** 1996 Feb; 33(2):120–1 **(Jpn)**

CLASSIFICATION

Classification of psychotic symptoms in dementia sufferers. Ballard CG, et al. **Acta Psychiatr Scand** 1995 Jul;92(1):63–8
A comment on age at onset as a subtype of Alzheimer disease. Brooks JO 3rd. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S28–9 (9 ref.)
Is early–onset Alzheimer disease a distinct subgroup within the Alzheimer disease population? Raskind MA, et al.
Alzheimer Dis Assoc Disord 1995;9 Suppl 1:S2–6 (41 ref.)
Should we differentiate subtypes of Alzheimer disease? [editorial] Whitehouse PJ. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S1

COMPLICATIONS

Adverse effects of potential agents for the treatment of Alzheimer's disease: a review. Domingo JL.
Adverse Drug React Toxicol Rev 1995 Summer;14(2):101–15 (91 ref.)
Symptoms of depression in Alzheimer's disease, frontal lobe–type dementia, and subcortical dementia. Lopez OL, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:389–92
Anosognosia in Alzheimer's disease [letter; comment] Auchus AP, et al. **Arch Neurol** 1996 Jan;53(1):10. Comment on: Arch Neurol 1995 Apr;52(4):415–20.
Making the diagnosis of mixed and non–Alzheimer's dementias. Hansen LA, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1023–31 (34 ref.)
Lexical and nonlexical spelling deficits in dementia of the Alzheimer type. Aarsland D, et al. **Brain Lang** 1996 Mar; 52(3):551–63
Effect of seizures on progression of dementia of the Alzheimer type. Volicer L, et al. **Dementia** 1995 Sep–Oct; 6(5):258–63
Affective disturbances in Alzheimer's disease. Bungener C, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1066–71
Alzheimer's disease and non–insulin–dependent diabetes mellitus: common features do not make common bedfellows [editorial; comment] Halter JB. **J Am Geriatr Soc** 1996 Aug; 44(8):992–3. Comment on: J Am Geriatr Soc 1996 Aug;44(8):897–904.
The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. Jost BC, et al.
J Am Geriatr Soc 1996 Sep;44(9):1078–81
Apolipoprotein–E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer's disease? [see comments] Nielson KA, et al. **J Am Geriatr Soc** 1996 Aug; 44(8):897–904. Comment in: J Am Geriatr Soc 1996 Aug;44(8):992–3.
Higher respiratory infection rates on an Alzheimer's special care unit and successful intervention. Perls TT, et al.
J Am Geriatr Soc 1995 Dec;43(12):1341–4
Dementia and Down syndrome. Tyler CV Jr, et al.
J Fam Pract 1996 Jun;42(6):619–21
Study of Alzheimer's dementia patients with parkinsonian features. Snowden MB, et al.
J Geriatr Psychiatry Neurol 1995 Jul;8(3):154–8
Executive dysfunction in early Alzheimer's disease. Binetti G, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):91–3
Alzheimer's disease in a case of cortical basal ganglionic degeneration with severe dementia [letter] Eberhard DA, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):109–10
Spastic tetraplegia as an initial manifestation of familial Alzheimer's disease. Sodeyama N, et al.
J Neurol Neurosurg Psychiatry 1995 Oct;59(4):395–9
Treatment of depression in Parkinson's disease: a meta–analysis. Klaassen T, et al.
J Neuropsychiatry Clin Neurosci 1995 Summer;7(3):281–6
Mania in Alzheimer's disease. Lyketsos CG, et al.
J Neuropsychiatry Clin Neurosci 1995 Summer;7(3):350–2
Discourse topic management in senile dementia of the Alzheimer's type. Mentis M, et al. **J Speech Hear Res** 1995 Oct;38(5):1054–66
Phonologic processing deficits in Alzheimer's disease. Biassou N, et al. **Neurology** 1995 Dec;45(12):2165–9
Temporal pattern of cognitive decline and incontinence is different in Alzheimer's disease and diffuse Lewy body disease. Del–Ser T, et al. **Neurology** 1996 Mar;46(3):682–6
Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Ellis RJ, et al. **Neurology** 1996 Jun;46(6):1592–6
Alzheimer's disease with and without coexisting Parkinson's disease changes: apolipoprotein E genotype and neuropathologic correlates. Gearing M, et al. **Neurology** 1995 Nov;45(11):1985–90
Apolipoprotein–epsilon4 and head trauma: Synergistic or additive risks? [letter; comment] Katzman R, et al.
Neurology 1996 Mar;46(3):889–91. Comment on: Neurology 1995 Mar;45(3 Pt 1):555–7.
Prediction of probable Alzheimer's disease in memory–impaired patients: A prospective longitudinal study. Tierney MC, et al. **Neurology** 1996 Mar;46(3):661–5
Alzheimer's disease and the eye. Armstrong RA, et al.
Ophthalmic Physiol Opt 1996 Mar;16 Suppl 1:S2–8 (32 ref.)
Relationship between autoimmune thyroid disease Rand Alzheimer's disease. Genovesi G, et al.
Panminerva Med 1996 Mar;38(1):61–3
Alzheimer's disease in the NAS–NRC Registry of aging twin veterans, IV. Performance characteristics of a two–stage telephone screening procedure for Alzheimer's dementia. Gallo JJ, et al. **Psychol Med** 1995 Nov;25(6):1211–9
[Progressive severity of left unilateral apraxia in 2 cases of Alzheimer disease] Ceccaldi M, et al.
Rev Neurol (Paris) 1995 Apr;151(4):240–6 (36 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Improving the diagnostic accuracy of the Mini–Mental State Examination. Monsch AU, et al. **Acta Neurol Scand** 1995 Aug;92(2):145–50
Paired helical filaments and straight tubules in astrocytes: an electron microscopic study in dementia of the Alzheimer type. Yamazaki M, et al. **Acta Neuropathol (Berl)** 1995; 90(1):31–6
Cognitive decline in patients with Alzheimer's disease, vascular dementia and senile dementia of Lewy body type. Ballard C, et al. **Age Ageing** 1996 May;25(3):209–13
Review: Binswanger's disease, leukoaraiosis and dementia [letter; comment] Hasan M, et al. **Age Ageing** 1995 Sep; 24(5):454 (4 ref.). Comment on: Age Ageing 1994 Jan;23(1):75–81.
Primitive reflexes and dementia: results from the Canadian Study of Health and Aging. Hogan DB, et al.
Age Ageing 1995 Sep;24(5):375–81
A flexible system of detection for Alzheimer's disease and related dementias. Gurland BJ, et al. **Aging (Milano)** 1995 Jun;7(3):165–72 (18 ref.)
Linear measures of atrophy in mild Alzheimer disease. Frisoni GB, et al. **AJNR Am J Neuroradiol** 1996 May; 17(5):913–23
Where's the chicken? [comment] Huckman MS.
AJNR Am J Neuroradiol 1995 Nov–Dec;16(10):2008–9. Comment on: AJNR Am J Neuroradiol 1995 Nov–Dec;16(10):2001–7.
Evaluation of automated MR spectroscopy: application in Alzheimer disease. Moats RA, et al.
AJNR Am J Neuroradiol 1995 Oct;16(9):1779–82
MR anatomy of the substantia innominata and findings in Alzheimer disease: a preliminary report [see comments] Sasaki M, et al. **AJNR Am J Neuroradiol** 1995 Nov–Dec; 16(10):2001–7. Comment in: AJNR Am J Neuroradiol 1995 Nov–Dec;16(10):2008–9.
Validation of the NINCDS–ADRDA criteria regarding gait in the clinical diagnosis of Alzheimer disease. A clinicopathologic study. Ala TA, et al.
Alzheimer Dis Assoc Disord 1995 Fall;9(3):152–9
Consensus statement on predictive testing for Alzheimer disease. Brodaty H, et al. **Alzheimer Dis Assoc Disord** 1995 Winter;9(4):182–7
Identification of fast and slow decliners in Alzheimer disease: a different approach. Brooks JO 3rd, et al.
Alzheimer Dis Assoc Disord 1995;9 Suppl 1:S19–25 (23 ref.)
A comment on age at onset as a subtype of Alzheimer disease. Brooks JO 3rd. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S28–9 (9 ref.)
Is early–onset Alzheimer disease a distinct subgroup within the Alzheimer disease population? Raskind MA, et al.
Alzheimer Dis Assoc Disord 1995;9 Suppl 1:S2–6 (41 ref.)
Preliminary findings from the predictors study: utility of clinical signs for predicting disease course. Stern Y, et al.
Alzheimer Dis Assoc Disord 1995;9 Suppl 1:S14–8 (30 ref.)
Biologic differences between early– and late–onset Alzheimer disease. Terry RD. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S26–7 (7 ref.)
Early symptoms and neurological findings in demented subjects from a community survey. Torres HA, et al.
Alzheimer Dis Assoc Disord 1995 Fall;9(3):170–5
Should we differentiate subtypes of Alzheimer disease? [editorial] Whitehouse PJ. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S1
Predicting the onset of Alzheimer's disease using Bayes' theorem. Prince MJ. **Am J Epidemiol** 1996 Feb 1; 143(3):301–8
Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Aarsland D, et al. **Am J Psychiatry** 1996 Feb;153(2):243–7
Dynamic susceptibility contrast MRI of regional cerebral blood volume in Alzheimer's disease. Harris GJ, et al.
Am J Psychiatry 1996 May;153(5):721–4
SPECT findings on psychosis in Alzheimer's disease. Kotrla KJ, et al. **Am J Psychiatry** 1995 Oct;152(10):1470–5
Negative symptoms in Alzheimer's disease. Reichman WE, et al. **Am J Psychiatry** 1996 Mar;153(3):424–6
In vivo structural studies of the hippocampus in normal aging and in incipient Alzheimer's disease. de Leon MJ, et al.
Ann N Y Acad Sci 1996 Jan 17;777:1–13
Near infrared spectroscopy in the diagnosis of Alzheimer's disease. Hock C, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:22–9 (20 ref.)
Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Arai H, et al. **Ann Neurol** 1995 Oct; 38(4):649–52
Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Feany MB, et al.
Ann Neurol 1996 Aug;40(2):139–48 (93 ref.)
Alzheimer's disease or Alzheimer's diseases? Clues from molecular epidemiology [editorial] Hyman BT.
Ann Neurol 1996 Aug;40(2):135–6
Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view [letter; comment] Kakulas BA,

et al. **Ann Neurol** 1995 Dec;38(6):966–7. Comment on: Ann Neurol 1995 Jul;38(1):2–4. Comment on: Ann Neurol 1995 Jul;38(1):6–14.

Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease [letter] Kamboh MI, et al. **Ann Neurol** 1995 Dec; 38(6):967–70

Clinicopathological studies of Alzheimer disease [letter] Claus JJ. **Arch Neurol** 1996 Sep;53(9):837

A standardized technique for establishing onset and duration of symptoms of Alzheimer's disease. Sano M, et al. **Arch Neurol** 1995 Oct;52(10):961–6

The prediction of Alzheimer disease. The role of patient and informant perceptions of cognitive deficits. Tierney MC, et al. **Arch Neurol** 1996 May;53(5):423–7

Blunted adrenocorticotropin and increased adrenal steroid response to human corticotropin-releasing hormone in Alzheimer's disease. Näsman B, et al. **Biol Psychiatry** 1996 Mar 1;39(5):311–8

Quantified electroencephalographic changes in depressed patients with and without dementia. Pozzi D, et al. **Biol Psychiatry** 1995 Nov 15;38(10):677–83

Extrapyramidal signs should be sought more often in Alzheimer's disease [letter; comment] Lowenthal MN. **BMJ** 1996 Jul 6;313(7048):45. Comment on: BMJ 1996 Mar 23;312(7033):724.

Referral patterns and diagnosis in presenile Alzheimer's disease: implications for general practice. Newens AJ, et al. **Br J Gen Pract** 1994 Sep;44(386):405–7

A magnetic resonance imaging study of white matter lesions in depression and Alzheimer's disease. O'Brien J, et al. **Br J Psychiatry** 1996 Apr;168(4):477–85

Further evidence that reading ability is not preserved in Alzheimer's disease. O'Carroll RE, et al. **Br J Psychiatry** 1995 Nov;167(5):659–62

Lewy body diseases with dementia: pathophysiology and treatment. Cummings JL. **Brain Cogn** 1995 Aug; 28(3):266–80 (64 ref.)

Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Katzman R, et al. **Brain Cogn** 1995 Aug;28(3):259–65 (43 ref.)

Specific patterns of cortical dysfunction in dementia and Parkinson's disease demonstrated by the acceleration spectrum entropy of the EEG. Jelles B, et al. **Clin Electroencephalogr** 1995 Oct;26(4):188–92

Diagnostic usefulness of linear and nonlinear quantitative EEG analysis in Alzheimer's disease. Stam CJ, et al. **Clin Electroencephalogr** 1996 Apr;27(2):69–77

Quantitative EEG in frontotemporal dementia. Yener GG, et al. **Clin Electroencephalogr** 1996 Apr;27(2):61–8

Alzheimer's disease: an update. Sandson TA, et al. **Compr Ther** 1995 Sep;21(9):480–5 (41 ref.)

Non-Alzheimer's disease amyloidoses of the nervous system. Castaño EM, et al. **Curr Opin Neurol** 1995 Aug;8(4):279–85 (57 ref.)

Temporal quantification of Alzheimer's disease severity: 'time index' model. Ashford JW, et al. **Dementia** 1995 Sep–Oct; 6(5):269–80

Atrophy of hippocampal formation subdivisions correlates with stage and duration of Alzheimer disease. Bobinski M, et al. **Dementia** 1995 Jul–Aug;6(4):205–10

Tetraethylammonium-induced calcium concentration changes in skin fibroblasts from patients with Alzheimer disease. Matsuyama SS, et al. **Dementia** 1995 Sep–Oct; 6(5):241–4

Dietary changes, compulsions and sexual behavior in frontotemporal degeneration. Miller BL, et al. **Dementia** 1995 Jul–Aug;6(4):195–9

Use of the Arizona Battery for Communication Disorders of Dementia in the UK. Armstrong L, et al. **Eur J Disord Commun** 1996;31(2):171–80

Clinical features and mortality in patients with early-onset Alzheimer's disease. Samson WN, et al. **Eur Neurol** 1996; 36(2):103–6

Parkinson's and Alzheimer's: new tools, new attitudes in patient care. Jenkyn LR, et al. **Geriatrics** 1996 Jan; 51(1):65–70, 72

Brain electrical activity (quantitative EEG and bit-mapping neurocognitive CNV components), psychometrics and clinical findings in presenile subjects with initial mild cognitive decline or probable Alzheimer-type dementia. Zappoli R, et al. **Ital J Neurol Sci** 1995 Sep;16(6):341–76 (177 ref.)

Clinical trials in cognitively impaired older adults: home versus clinic assessments. Bédard M, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1127–30

Age-associated memory impairment and Alzheimer's disease [editorial; comment] Blass JP. **J Am Geriatr Soc** 1996 Feb; 44(2):209–11. Comment on: J Am Geriatr Soc 1996 Feb;44(2):133–8.

The natural history of Alzheimer's disease [letter; comment] Boersma F, et al. **J Am Geriatr Soc** 1996 Jun;44(6):734. Comment on: J Am Geriatr Soc 1995 Nov;43(11):1248–55.

The neuropsychological differentiation of patients with very mild Alzheimer's disease and/or major depression. desRosiers G, et al. **J Am Geriatr Soc** 1995 Nov; 43(11):1256–63

1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease [see comments] Parnetti L, et al. **J Am Geriatr Soc** 1996 Feb; 44(2):133–8. Comment in: J Am Geriatr Soc 1996 Feb;44(2):209–11.

A simple scoring system for clock drawing in patients with Alzheimer's disease [letter] Shua-Haim J, et al. **J Am Geriatr Soc** 1996 Mar;44(3):335

Improved reliability of the Standardized Alzheimer's Disease Assessment Scale (SADAS) compared with the Alzheimer's Disease Assessment Scale (ADAS). Standish TI, et al. **J Am Geriatr Soc** 1996 Jun;44(6):712–6

The use of performance-based assessment instruments in cognitively impaired older patients [letter] Zanetti O, et al. **J Am Geriatr Soc** 1996 Aug;44(8):1014–5

ERP indices and neuropsychological performance as predictors of functional outcome in dementia. Cohen RA, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8(4):217–25

Longitudinal changes in cognitive functioning in adult day care participants. Cohen-Mansfield J, et al. **J Geriatr Psychiatry Neurol** 1996 Jan;9(1):30–8

Differentiation of the dementias of Alzheimer's and Parkinson's disease with the dementia rating scale. Paolo AM, et al. **J Geriatr Psychiatry Neurol** 1995 Jul;8(3):184–8

Study of Alzheimer's dementia patients with parkinsonian features. Snowden MB, et al. **J Geriatr Psychiatry Neurol** 1995 Jul;8(3):154–8

Multimodal evoked potentials in Alzheimer's disease and Binswanger's disease. Tachibana H, et al. **J Geriatr Psychiatry Neurol** 1996 Jan;9(1):7–12

Cardinal features of cognitive dysfunction in Alzheimer's disease: a factor-analytic study of the Alzheimer's Disease Assessment Scale. Talwalker S, et al. **J Geriatr Psychiatry Neurol** 1996 Jan;9(1):39–46

Behavioural disturbance in people with Down's syndrome and dementia. Prasher VP, et al. **J Intellect Disabil Res** 1995 Oct;39 (Pt 5):432–6

99mTc-HMPAO-SPECT in the diagnosis of senile dementia of Alzheimer's type—a study under clinical routine conditions. Stoppe G, et al. **J Neural Transm Gen Sect** 1995; 99(1–3):195–211

Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Southwick PC, et al. **J Neurochem** 1996 Jan;66(1):259–65

Quantitative computed tomography and magnetic resonance imaging in aging and Alzheimer's disease. A review. Smith CD. **J Neuroimaging** 1996 Jan;6(1):44–53 (122 ref.)

Neuropsychological tests and [99mTc]-HM PAO SPECT in the diagnosis of Alzheimer's dementia. Villa G, et al. **J Neurol** 1995 Jun;242(6):359–66

Brain atrophy in frontotemporal dementia. Frisoni GB, et al. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):157–65

Diagnostic usefulness of apolipoprotein E epsilon 4 in the diagnosis of the dementias [letter] Frisoni GB, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):699–700

SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. Lehtovirta M, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):644–9

Clinical application of electrophysiological markers in the differential diagnosis of depression and very mild Alzheimer's disease. Swanwick GR, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):82–6

Regional variation in the distribution of apolipoprotein E and A beta in Alzheimer's disease. Gearing M, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):833–41

Benign aging or Alzheimer disease? Gorman WF. **J Okla State Med Assoc** 1995 Sep;88(9):383–91 (51 ref.)

The Neurobehavioral Rating Scale: reliability in patients with dementia. Sultzer DL, et al. **J Psychiatr Res** 1995 May–Jun; 29(3):185–91

Vascular risk factors and atherosclerosis as risk factors for cognitive decline and dementia [editorial] Prince MJ. **J Psychosom Res** 1995 Jul;39(5):525–30 (31 ref.)

Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group [see comments] **Lancet** 1996 Apr 20; 347(9008):1091–5 (77 ref.). Comment in: Lancet 1996 Apr 27;347(9009):1184–5. Comment in: Lancet 1996 Aug 3;348(9023):334.

APOE genotyping and Alzheimer's disease [letter; comment] Breitner JC. **Lancet** 1996 Apr 27;347(9009):1184–5. Comment on: Lancet 1996 Apr 20;347(9008):1091–5.

Clock-face drawing to differentiate Lewy body and Alzheimer type dementia syndromes [letter; comment] Gnanalingham KK, et al. **Lancet** 1996 Mar 9; 347(9002):696–7. Comment on: Lancet 1996 Apr 20;347(9008):1115.

Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease [letter; comment] Kakulas BA, et al. **Lancet** 1996 Aug 17;348(9025):483. Comment on: Lancet 1996 Jul 13;348(9020):90–3.

Apolipoprotein E genotyping in Alzheimer's disease [letter] McKeith IG, et al. **Lancet** 1996 Jun 22;347(9017):1775

Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease [see comments] Saunders AM, et al. **Lancet** 1996 Jul 13;348(9020):90–3. Comment in: Lancet 1996 Aug 17;348(9025):483. Comment in: Lancet 1996 Aug 17;348(9025):483–4.

APOE genotyping in differential diagnosis of Alzheimer's disease [letter; comment] Slooter AJ, et al. **Lancet** 1996 Aug 3;348(9023):334. Comment on: Lancet 1996 Apr 20;347(9008):1091–5.

Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease [letter; comment] Smith AD, et al. **Lancet** 1996 Aug 17;348(9025):483–4. Comment on: Lancet 1996 Jul 13;348(9020):90–3.

Clock-face drawing to differentiate dementia syndrome [letter; comment] Swanwick GR, et al. **Lancet** 1996 Apr 20;347(9008):1115. Comment on: Lancet 1996 Mar 9;347(9002):696–7.

The Autobiographical Memory Interview (AMI) in organic and psychogenic amnesia. Kopelman MD. **Memory** 1994 Jun;2(2):211–35 (66 ref.)

Preservation of categorical knowledge in Alzheimer's disease: a computational account. Tippett LJ, et al. **Memory** 1995 Sep–Dec;3(3–4):519–33

Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Lannfelt L, et al. **Nat Med** 1995 Aug;1(8):829–32

Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. Lieberman J, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):747–53

Scopolamine-induced impairment as a potential predictor of Alzheimer's disease in individuals with Apolipoprotein E type 4 alleles. Pomara N, et al. **Neurochem Res** 1995 Dec; 20(12):1519–20

Comparison of seven sets of criteria used for the diagnosis of vascular dementia. Verhey FR, et al. **Neuroepidemiology** 1996;15(3):166–72

Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. Massman PJ, et al. **Neurology** 1996 Mar;46(3):720–6

Subtle extrapyramidal signs and incident dementia: a follow-up analysis. Richards M, et al. **Neurology** 1995 Oct; 45(10):1942

Consistency of clinical diagnosis in a community-based longitudinal study of dementia and Alzheimer's disease. Schofield PW, et al. **Neurology** 1995 Dec;45(12):2159–64

X-ray microprobe analysis of corpora amylacea. Tokutake S, et al. **Neuropathol Appl Neurobiol** 1995 Jun;21(3):269–73

MRI of amygdala fails to diagnose early Alzheimer's disease. Laakso MP, et al. **Neuroreport** 1995 Nov 27;6(17):2414–8

Pupillary response to tropicamide in patients with Alzheimer disease. Loupe DN, et al. **Ophthalmology** 1996 Mar; 103(3):495–503

Gait disturbance of patients with vascular and Alzheimer-type dementias. Tanaka A, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):735–8

Fluorescent light-induced chromatid breaks distinguish Alzheimer disease cells from normal cells in tissue culture. Parshad RP, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5146–50

Discriminant analysis of MRI measures as a method to determine the presence of dementia of the Alzheimer type. DeCarli C, et al. **Psychiatry Res** 1995 Jul 28;57(2):119–30

Neuropsychiatric and neuropsychological correlates of delusions in Alzheimer's disease. Migliorelli R, et al. **Psychol Med** 1995 May;25(3):505–13

Recency effect in Alzheimer's disease: a reappraisal. Carlesimo GA, et al. **Q J Exp Psychol A** 1996 May; 49(2):315–25

Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. MacKay S, et al. **Radiology** 1996 Feb;198(2):537–45

Assessing cognitive function in schizophrenics and patients with Alzheimer's disease. Mohs RC. **Schizophr Res** 1995 Sep;17(1):115–21 (65 ref.)

Dementia--an update. Jagust W. **West J Med** 1995 Nov; 163(5):473–4

[Presentation by the GRECO group of the French adaptation of a cognitive assessment scale used in Alzheimer type dementia] Puel M, et al. **Presse Med** 1996 Jun 22; 25(22):1028–32 (14 ref.) (Eng. Abstr.) **(Fre)**

[Patchy changes in white matter in cranial computerized and magnetic resonance tomography--significance for (differential) diagnosis of dementia of the Alzheimer type and vascular dementia] Stoppe G, et al. **Fortschr Neurol Psychiatr** 1995 Nov;63(11):425–40 (150 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis of Alzheimer disease is probably made too frequently, ultimately from uncertainty of examination results] Krieg JC. **Internist (Berl)** 1995 Nov;36(11):1097–8 **(Ger)**

[The Alzheimer test (editorial)] Wilhelm H, et al. **Klin Monatsbl Augenheilkd** 1995 Jul;207(1):1–2 **(Ger)**

[Volumetric brain changes and quantitative EEG in normal aging and Alzheimer's dementia] Förstl H, et al. **Nervenarzt** 1996 Jan;67(1):53–61 (Eng. Abstr.) **(Ger)**

[Premorbid intelligence diagnosis with the MWT-B(Multiple Choice Word Test-B) in patients with Alzheimer disease] Kessler J, et al. **Nervenarzt** 1995 Sep;66(9):696–702 (Eng. Abstr.) **(Ger)**

[Quantitative magnetic resonance tomography and the severity of deficits in dementia of the Alzheimer type] Pantel J, et al. **Nervenarzt** 1996 Jan;67(1):46–52 (Eng. Abstr.) **(Ger)**

[Quantification of dementia-related disabilities in daily behavior with the DAFS (Direct Assessment of Functional Status): reliability and validity of a German test version] Hochrein A, et al. **Z Gerontol Geriatr** 1996 May–Jun; 29(3):216–22 (Eng. Abstr.) **(Ger)**

[Cerebrospinal fluid tau in senile dementia of Alzheimer type] Kanemaru K, et al. **Nippon Ronen Igakkai Zasshi** 1995 Aug–Sep;32(8–9):597–8 **(Jpn)**

[Some problems in giving notice of the name of a disease: with special reference to Alzheimer's disease and vascular dementia] Hirai S. **No To Shinkei** 1996 May;48(5):431–5

(3 ref.) **(Jpn)**

[Differential diagnosis and diagnostic markers of Alzheimer's disease] **Takeda M. Seishin Shinkeigaku Zasshi** 1995; 97(8):557–66 (4 ref.) **(Jpn)**

[Clinical picture of dementia] **Parnowski T. Psychiatr Pol** 1995 Sep–Oct;29(5):593–605 (50 ref.) (Eng. Abstr.) **(Pol)**

[Time in neuropsychological examination of dementias: Alzheimer's disease versus Parkinson disease] **Gil–Saladié D, et al. Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov–Dec;23(6):299–304 (Eng. Abstr.) **(Spa)**

[Alzheimer's disease. Considerations for its clinical diagnosis] **Vasconcelos D. Gac Med Mex** 1995 Jan–Feb;131(1):64–71 (20 ref.) (Eng. Abstr.) **(Spa)**

[Prion–type pathologies: from scrapie to prion–related dementias. On the borderline between veterinary and human pathology] **Domich L. Rev Neurol** 1996 Jul; 24(131):785–802 (250 ref.) **(Spa)**

[Dementias: current situation and future perspectives] **Espert R, et al. Rev Neurol** 1995 Jan–Feb;23(119):70–6 (90 ref.) (Eng. Abstr.) **(Spa)**

[Clinical trials in the Alzheimer's disease: evaluation of the therapeutic response] **Frank A, et al. Rev Neurol** 1995 Jan–Feb;23(119):111–7 (41 ref.) (Eng. Abstr.) **(Spa)**

[Alzheimer's disease] **Giménez–Roldán S. Rev Neurol** 1995 Jan–Feb;23(119):96–102 (62 ref.) **(Spa)**

[Design of clinical trials for patients with Alzheimer's disease] **Matías–Guiu J, et al. Rev Neurol** 1995 Jan–Feb; 23(119):108–10 **(Spa)**

[The evaluation of the temporal lobe size by magnetic resonance in Alzheimer's disease] **Rodríguez RM, et al. Rev Neurol** 1995 Jan–Feb;23(119):59–61 (Eng. Abstr.) **(Spa)**

[A model system in cell culture shows pathogenic processes. Biochemical diagnosis in Alzheimer dementia] **Lannfelt L, et al. Lakartidningen** 1996 Jun 12;93(24):2326–31 (46 ref.) **(Swe)**

DRUG THERAPY

Posatirelin for the treatment of late–onset Alzheimer's disease: a double–blind multicentre study vs citicoline and ascorbic acid. **Parnetti L, et al. Acta Neurol Scand** 1995 Aug;92(2):135–40

Adverse effects of potential agents for the treatment of Alzheimer's disease: a review. **Domingo JL. Adverse Drug React Toxicol Rev** 1995 Summer;14(2):101–15 (91 ref.)

Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic–like, and cytoprotective properties. **Arneric SP, et al. Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:50–61

Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine. **Asthana S, et al. Alzheimer Dis Assoc Disord** 1995 Winter;9(4):223–32

Acetyl–L–carnitine in Alzheimer disease: a short–term study on CSF neurotransmitters and neuropeptides. **Bruno G, et al. Alzheimer Dis Assoc Disord** 1995 Fall;9(3):128–31

The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study". **Cutler NR, et al. Alzheimer Dis Assoc Disord** 1995 Fall;9(3):139–45

Clinical heterogeneity: responders to cholinergic therapy. **Eagger SA, et al. Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:37–42 (72 ref.)

Cholinergic signaling in Alzheimer disease: therapeutic strategies [editorial] **Perry E. Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:1–2

Low–dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. **Shankle WR, et al. Alzheimer Dis Assoc Disord** 1995 Winter;9(4):233–7

Nicotinic receptors and neurodegenerative dementing diseases: basic research and clinical implications. **Whitehouse PJ, et al. Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:3–5

Maximizing function in Alzheimer's disease: what role for tacrine? **Smucker WD. Am Fam Physician** 1996 Aug; 54(2):645–52

Therapeutic effects of CDP–choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. **Cacabelos R, et al. Ann N Y Acad Sci** 1996 Jan 17;777:399–403

M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. **Fisher A, et al. Ann N Y Acad Sci** 1996 Jan 17;777:189–96 (21 ref.)

Preliminary evaluation of besipirdine for the treatment of Alzheimer's disease. Besipirdine Study Group. **Huff FJ. Ann N Y Acad Sci** 1996 Jan 17;777:410–4

Anti–inflammatory drugs in the fight against Alzheimer's disease. **McGeer PL, et al. Ann N Y Acad Sci** 1996 Jan 17;777:213–20 (16 ref.)

HWA 285 (propentofylline)—a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type. **Rother M, et al. Ann N Y Acad Sci** 1996 Jan 17;777:404–9 (23 ref.)

The role of anti–inflammatory drugs in the prevention and treatment of Alzheimer's disease. **Breitner JC. Annu Rev Med** 1996;47:401–11 (81 ref.)

Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma. **Peskind ER, et al. Biol Psychiatry** 1995 Oct 15; 38(8):532–8

Randomization model methods for evaluating treatment efficacy in multicenter clinical trials. **Davis CS, et al. Biometrics** 1995 Sep;51(3):1163–74

Neuroleptic prescribing in residents of nursing homes. Use may be justified if other factors have been considered [letter; comment] **Tobiansky R, et al. BMJ** 1996 Jun 29; 312(7047):1668–9. Comment on: **BMJ** 1996 Mar 9;312(7031):611–2.

Psychopharmacology of Alzheimer's disease. **Procter AW. Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):191–4 (20 ref.)

Efficacy of tablet huperzine–A on memory, cognition, and behavior in Alzheimer's disease. **Xu SS, et al. Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):391–5

Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. **Mohr E, et al. Clin Neuropharmacol** 1995 Feb;18(1):28–38

Clinical pharmacokinetics of drugs for Alzheimer's disease. **Parnetti L. Clin Pharmacokinet** 1995 Aug;29(2):110–29 (111 ref.)

Therapeutic trials in Alzheimer's disease. **Whitehouse PJ, et al. Curr Opin Neurol** 1995 Aug;8(4):275–8 (25 ref.)

Long–term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease. **Minthon L, et al. Dementia** 1995 Sep–Oct;6(5):245–51

THA—historical aspects, review of pharmacological properties and therapeutic effects. **Soares JC, et al. Dementia** 1995 Jul–Aug;6(4):225–34 (73 ref.)

Adjunctive therapy in patients with Alzheimer's disease. A practical approach. **Corey–Bloom J, et al. Drugs Aging** 1995 Aug;7(2):79–87 (46 ref.)

Drug treatment of Alzheimer's disease. Effects on caregiver burden and patient quality of life. **Hollister L, et al. Drugs Aging** 1996 Jan;8(1):47–55 (58 ref.)

Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. **Ohkura T, et al. Endocr J** 1994 Aug;41(4):361–71

Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. **Cutler NR, et al. Eur J Clin Pharmacol** 1995;48(6):421–8

Variability in the plasma protein binding of velnacrine (1–hydroxy tacrine hydrochloride). A potential agent for Alzheimer's disease. **Wood DM, et al. Eur J Clin Pharmacol** 1996;50(1–2):115–9

Response to tacrine in patients with dementia of the Alzheimer's type: cerebral perfusion change is related to change in mental status. **Harkins SW, et al. Int J Neurosci** 1996 Feb;84(1–4):149–56

One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type. **Ahlin A, et al. Int Psychogeriatr** 1995 Spring;7(1):75–83

Alzheimer's disease: the role of tacrine therapy. **Jogerst G. Iowa Med** 1995 Oct;85(10):409–11 (0 ref.)

Zolpidem for the treatment of agitation in elderly demented patients [letter] **Jackson CW, et al. J Clin Psychiatry** 1996 Aug;57(8):372–3

Treating the agitated Alzheimer patient. **Zayas EM, et al. J Clin Psychiatry** 1996;57 Suppl 7:46–51; discussion 52–4

Neuroleptic treatment of agitation and psychosis in dementia. **Devanand DP, et al. J Geriatr Psychiatry Neurol** 1995 Oct; 8 Suppl 1:S18–27 (141 ref.)

Evaluation of cycloserine in the treatment of Alzheimer's disease. **Fakouhi TD, et al. J Geriatr Psychiatry Neurol** 1995 Oct;8(4):226–30

Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open–label study. **Kaufer DI, et al. J Geriatr Psychiatry Neurol** 1996 Jan;9(1):1–6

Substituted (pyrroloamino)pyridines: potential agents for the treatment of Alzheimer's disease. **Davis L, et al. J Med Chem** 1996 Jan 19;39(2):582–7

Synthesis and structure–activity relationships of N–propyl–N–(4–pyridinyl)–1H–indol–1–amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease. **Klein JT, et al. J Med Chem** 1996 Jan 19;39(2):570–81

Therapeutic approaches related to amyloid–beta peptide and Alzheimer's disease. **Schenk DB, et al. J Med Chem** 1995 Oct 13;38(21):4141–54 (181 ref.)

Alzheimer's disease: a treatment in sight? [editorial] **Lovestone S, et al. J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):566–7

Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia research Clinic. **Lyketsos CG, et al. J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):67–73

Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. **Bores GM, et al. J Pharmacol Exp Ther** 1996 May;277(2):728–38

Antiinflammatory drugs in the treatment of Alzheimer's disease [editorial] **MacKenzie IR. J Rheumatol** 1996 May; 23(5):806–8

Ethics committees [letter] [see comments] **Kellett JM. Lancet** 1996 Feb 3;347(8997):331. Comment in: Lancet 1996 Mar 23;347(9004):833–4.

Long–term tacrine treatment in patients with Alzheimer's disease [letter] **Solomon PR, et al. Lancet** 1996 Jul 27; 348(9022):275–6

Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. **Sramek JJ, et al. Life Sci** 1996;58(15):1201–7

Double–blind placebo–controlled study of velnacrine in Alzheimer's disease. **Zemlan FP, et al. Life Sci** 1996; 58(21):1823–32

Thiamine therapy in Alzheimer's disease. **Mimori Y, et al. Metab Brain Dis** 1996 Mar;11(1):89–94

Possible pharmacological approaches to slowing down Alzheimer's disease progression. **Coleman PD. Neurobiol Aging** 1995 Nov–Dec;16(6):873–5; discussion 875–6, 879–82

A neurochemical approach for studying response to acetylcholine in Alzheimer's disease. **Alder JT, et al. Neurochem Res** 1995 Jul;20(7):769–71

The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. **Weinstock M. Neurodegeneration** 1995 Dec;4(4):349–56 (82 ref.)

Nonsteroidal anti–inflammatory drugs in Alzheimer's disease [letter; comment] **Haruda FD. Neurology** 1995 Nov; 45(11):2116. Comment on: Neurology 1995 Jan;45(1):51–5.

Long–term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. **Knopman D, et al. Neurology** 1996 Jul;47(1):166–77

d–Cycloserine enhances implicit memory in Alzheimer patients. **Schwartz BL, et al. Neurology** 1996 Feb; 46(2):420–4

Triazolam in Alzheimer's disease: pilot study on sleep and memory effects. **McCarten JR, et al. Pharmacol Biochem Behav** 1995 Oct;52(2):447–52

Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi–infarct dementia. **Kanowski S, et al. Pharmacopsychiatry** 1996 Mar;29(2):47–56

Noncompetitive NMDA receptor antagonists with fast open–channel blocking kinetics and strong voltage–dependency as potential therapeutic agents for Alzheimer's dementia. **Müller WE, et al. Pharmacopsychiatry** 1995 Jul;28(4):113–24 (90 ref.)

L–deprenyl and physostigmine for the treatment of Alzheimer's disease. **Marin DB, et al. Psychiatry Res** 1995 Oct 16;58(3):181–9

Neuroendocrine responses to intravenous infusion of arecoline in patients with Alzheimer's disease. **Asthana S, et al. Psychoneuroendocrinology** 1995;20(6):623–36

Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. **Pollock BG, et al. Psychopharmacol Bull** 1995;31(2):327–31

Treating Alzheimer's disease. **Wilcock GK, et al. QJM** 1995 Sep;88(9):673–6 (16 ref.)

Searching for drugs that combat Alzheimer's [news] **Marx J. Science** 1996 Jul 5;273(5271):50–3

[Selegiline in the treatment of Alzheimer's disease] **Obenberger J, et al. Cas Lek Cesk** 1995 Jun 14; 134(12):388–90 (Eng. Abstr.) **(Cze)**

[Alzheimer disease: anti–inflammatory agents could be of therapeutic value (interview by Elisabeth B. Moosmann)] **Bauer J. Fortschr Med** 1996 Apr 10;114(10):16–8 **(Ger)**

[New therapeutic possibilities with low–affinity NMDA receptor antagonists] **Kornhuber J, et al. Nervenarzt** 1996 Jan;67(1):77–82 (22 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities and limits of therapy of cognition disorders in the elderly] **Hoyer S. Z Gerontol Geriatr** 1995 Nov–Dec; 28(6):457–62 (56 ref.) (Eng. Abstr.) **(Ger)**

[New strategies in the acute and chronic treatment of the patient with Alzheimer's dementia] **Rocco PL. Minerva Med** 1996 Apr;87(4):171–7 (14 ref.) **(Ita)**

[Nerve growth factor strategy and preparation of animal model for Alzheimer–type senile dementia] **Nabeshima T. Yakugaku Zasshi** 1995 Jul;115(7):499–512 (59 ref.) (Eng. Abstr.) **(Jpn)**

[The use of nimodipine in elderly dementia patients] **Damulin IV, et al. Ter Arkh** 1995;67(10):77–9 (Eng. Abstr.) **(Rus)**

[Pharmacological treatment of Alzheimer's disease: present situation and perspectives] **Jané F. Rev Neurol** 1995 Jan–Feb;23(119):103–7 (43 ref.) (Eng. Abstr.) **(Spa)**

[More accurate diagnosis could identify patients suitable for tacrine therapy (letter; comment) (see comments)] **Andreasen N, et al. Lakartidningen** 1996 Mar 27;93(13):1200 . Comment on: Lakartidningen 1996 Jan 3;93(1–2):22–4. Comment in: Lakartidningen 1996 Mar 27;93(13):1200, 1203. **(Swe)**

[Patients must have right to test available therapy (letter)] **Lindahl C. Lakartidningen** 1996 Mar 27;93(13):1203–4 **(Swe)**

[A balanced debate on tacrine is necessary (letter; comment)] **Marcusson J. Lakartidningen** 1996 Mar 27;93(13):1200, 1203 . Comment on: Lakartidningen 1996 Mar 27;93(13):1200. **(Swe)**

[Alzheimer disease cannot be treated with Cognex (letter)] **Shafazand M. Lakartidningen** 1996 Apr 10;93(15):1406 **(Swe)**

ECONOMICS

Economic analysis of Alzheimer's disease in outpatients: impact of symptom severity. **Souêtre EJ, et al. Int Psychogeriatr** 1995 Spring;7(1):115–22

Alzheimer's disease and managed care: challenges and strategies [editorial] **Mintzer JE, et al. J S C Med Assoc** 1996 Jun;92(6):255–60

Cost justification of a commmunity health information network: the ComputerLink for AD caregivers. **Payton FC, et al. Proc Annu Symp Comput Appl Med Care** 1995; :566–70

ENZYMOLOGY

White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues. Yamada T, et al. **Acta Neuropathol (Berl)** 1995; 90(5):421–4

Cholinesterases and the pathology of Alzheimer disease. Geula C, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:23–8

Nonclassical roles of cholinesterases in the embryonic brain and possible links to Alzheimer disease. Layer PG. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:29–36

Reduction of platelet phospholipase C activity in patients with Alzheimer disease. Matsushima H, et al. **Alzheimer Dis Assoc Disord** 1995 Winter;9(4):213–7

A novel brain cysteine protease forms an SDS stable complex with the beta-amyloid precursor protein. Chang T, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:183–8

The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. Chen X, et al. **Ann Neurol** 1995 Oct;38(4):653–8

Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer's disease. Mastrogiacoma F, et al. **Ann Neurol** 1996 May;39(5):585–91

Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. Mastrogiacoma F, et al. **Ann Neurol** 1996 May;39(5):592–8

Substrate specificity of human platelet monoamine oxidase B activity Parkinson's and Alzheimer's disease. Fitzgerald DH, et al. **Biochem Soc Trans** 1996 Feb;24(1):63S

No evidence for abnormalities in kinetics of platelet monoamine oxidase in Alzheimer's disease [letter] Konings CH, et al. **Clin Chim Acta** 1995 Aug 31;240(1):99–102

Transient elevations in pancreatic enzymes in response to a cholinesterase inhibitor [letter] Pomara N, et al. **Clin Neuropharmacol** 1995 Oct;18(5):464–5

Leukocyte hexokinase activity in aging and Alzheimer disease. Antuono PG, et al. **Dementia** 1995 Jul–Aug; 6(4):200–4

A decrease in neural sialyltransferase activity in Alzheimer's disease. Maguire TM, et al. **Dementia** 1995 Jul–Aug; 6(4):185–90

Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease. Gattaz WF, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(3):129–31

Changes of activity and isozyme pattern of phosphofructokinase in the brains of patients with Alzheimer's disease. Bigl M, et al. **J Neurochem** 1996 Sep; 67(3):1164–71

Ca2+-dependent and Ca2+-independent protein kinase C changes in the brain of patients with Alzheimer's disease. Matsushima H, et al. **J Neurochem** 1996 Jul;67(1):317–23

Colocalization of lysosomal hydrolase and beta-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimer's disease and Down's syndrome. Cataldo AM, et al. **J Neuropathol Exp Neurol** 1996 Jun;55(6):704–15

alpha-calcium-calmodulin-dependent kinase II is associated with paired helical filaments of Alzheimer's disease. Xiao J, et al. **J Neuropathol Exp Neurol** 1996 Sep;55(9):954–63

cAMP-dependent protein kinase in cerebral microvessels in aging and Alzheimer disease. Cashman RE, et al. **Mol Chem Neuropathol** 1995 Dec;26(3):247–58

Decreases in protease nexins in Alzheimer's disease brain. Choi BH, et al. **Neurobiol Aging** 1995 Jul–Aug;16(4):557–62

Cerebral microvessels in Alzheimer's have reduced protein kinase C activity. Grammas P, et al. **Neurobiol Aging** 1995 Jul–Aug;16(4):563–9

Glutamine synthetase (GS) expression is reduced in senile dementia of the Alzheimer type. Le Prince G, et al. **Neurochem Res** 1995 Jul;20(7):859–62

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Inestrosa NC, et al. **Neuron** 1996 Apr;16(4):881–91

Increased acetylcholinesterase activity in the CSF of Alzheimer patients carrying apolipoprotein epsilon4 allele. Soininen H, et al. **Neuroreport** 1995 Dec 15;6(18):2518–20

A serine protease in Alzheimer's disease cells cleaves a 16K-peptide with flanking residues upstream to beta-amyloid-N-terminus as natural substrate. Matsumoto A, et al. **Neurosci Lett** 1995 Aug 11;195(3):171–4

Increased expression and subcellular translocation of the mitogen activated protein kinase kinase and mitogen-activated protein kinase in Alzheimer's disease. Arendt T, et al. **Neuroscience** 1995 Sep;68(1):5–18

[Effects of AF64A on neurons containing both nitric oxide synthase and choline acetyltransferase in the rat septal complex] Yu FL, et al. **Sheng Li Hsueh Pao** 1996 Feb; 48(1):15–22 (Eng. Abstr.) **(Chi)**

EPIDEMIOLOGY

Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Jarvik G, et al. **Am J Hum Genet** 1996 Jan;58(1):191–200

Characteristics of familial aggregation in early-onset Alzheimer's disease: evidence of subgroups. Campion D, et al. **Am J Med Genet** 1995 Jun 19;60(3):221–7

Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Hendrie HC, et al. **Am J Psychiatry** 1995 Oct; 152(10):1485–92

Schizophrenia: a 100-year retrospective [letter; comment] Oken RJ, et al. **Am J Psychiatry** 1995 Nov;152(11):1692–3; discussion 1694–5. Comment on: Am J Psychiatry 1994 Oct;151(10):1409–16.

Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Devanand DP, et al. **Arch Gen Psychiatry** 1996 Feb;53(2):175–82

Validation of a French version of an informant-based questionnaire as a screening test for Alzheimer's disease. Law S, et al. **Br J Psychiatry** 1995 Oct;167(4):541–4

Epidemiology of presenile Alzheimer's disease in Scotland (1974–88) I. non-random geographical variation. Whalley LJ, et al. **Br J Psychiatry** 1995 Dec;167(6):728–31

Epidemiology of presenile Alzheimer's disease in Scotland (1974–88) II. Exposures to possible risk factors. Whalley LJ, et al. **Br J Psychiatry** 1995 Dec;167(6):732–8

Prior intra-operative hypotension is not a risk factor for development of Alzheimer's disease. Bohnen NI, et al. **Can J Neurol Sci** 1996 Feb;23(1):57–8

Alzheimer's disease survey in Guangdong of China. Wang Z, et al. **Chin Med J (Engl)** 1995 Oct;108(10):789–90

History of depression as a risk factor for Alzheimer's disease. Speck CE, et al. **Epidemiology** 1995 Jul;6(4):366–9

Sources of variability in prevalence rates of Alzheimer's disease. Corrada M, et al. **Int J Epidemiol** 1995 Oct; 24(5):1000–5 (37 ref.)

Usefulness of the Clinical Dementia Rating scale in screening for dementia. Juva K, et al. **Int Psychogeriatr** 1995 Spring; 7(1):17–24

Impact of sample selection on APOE epsilon 4 allele frequency: a comparison of two Alzheimer's disease samples. Tsuang D, et al. **J Am Geriatr Soc** 1996 Jun; 44(6):704–7

Impact of referral bias on clinical and epidemiological studies of Alzheimer's disease. Kokmen E, et al. **J Clin Epidemiol** 1996 Jan;49(1):79–83

South Florida Program on Aging and Health. Assessing the prevalence of Alzheimer's disease in three ethnic groups. Prineas RJ, et al. **J Fla Med Assoc** 1995 Dec;82(12):805–10

Geographically overlapping Alzheimer's disease registries: comparisons and implications. Barnhart RL, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8(4):203–8

Apolipoprotein E epsilon 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers. St Clair D, et al. **J Med Genet** 1995 Aug;32(8):642–4

Neuroepidemiology of vascular and Alzheimer's dementia among African-American women. Harris Y, et al. **J Natl Med Assoc** 1995 Oct;87(10):741–5

Are depressive mood disturbances in adults with Down's syndrome an early sign of dementia? Meins W. **J Nerv Ment Dis** 1995 Oct;183(10):663–4

A comparison of multiplex and simplex families with Alzheimer's disease/senile dementia of Alzheimer type within a well defined population. Alafuzoff I, et al. **J Neural Transm Park Dis Dement Sect** 1994;7(1):61–72

Prevalence of dementia in an elderly rural population: effects of age, sex, and education. Prencipe M, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):628–33

Natural history of Alzheimer's disease: prognostic value of plateaux. Piccini C, et al. **J Neurol Sci** 1995 Aug; 131(2):177–82

Do cultural differences affect Alzheimer disease? [editorial; comment] Martin GM, et al. **JAMA** 1996 Sep 25; 276(12):993–5. Comment on: JAMA 1996 Sep 25;276(12):955–60.

More evidence links NSAID, estrogen use with reduced Alzheimer risk [news] Stephenson J. **JAMA** 1996 May 8; 275(18):1389–90

Risk factors for dementia in Parkinson's disease: effect of education. Glatt SL, et al. **Neuroepidemiology** 1996 Jan–Feb;15(1):20–5

The clinical epidemiology of Alzheimer's disease. Keefover RW. **Neurol Clin** 1996 May;14(2):337–51 (194 ref.)

The "protective" influence of cigarette smoking on Alzheimer's and Parkinson's diseases. Quagmire or opportunity for neuroepidemiology? Riggs JE. **Neurol Clin** 1996 May;14(2):353–8 (24 ref.)

Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. Duara R, et al. **Neurology** 1996 Jun;46(6):1575–9

Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Edland SD, et al. **Neurology** 1996 Jul;47(1):254–6

Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. McLachlan DR, et al. **Neurology** 1996 Feb;46(2):401–5

Increased risk of familial late-onset Alzheimer's disease in women. Payami H, et al. **Neurology** 1996 Jan;46(1):126–9

Season of birth and Alzheimer's disease: a population-based study in Saguenay-Lac-St-Jean/Québec (IMAGE Project). Vézina H, et al. **Psychol Med** 1996 Jan;26(1):143–9

Determining the prevalence of Alzheimer's disease in elderly South Africans [editorial] de Villiers C, et al. **S Afr Med J** 1996 Feb;86(2):135–6

Alzheimer's disease: preliminary study of spatial distribution at birth place. Jean H, et al. **Soc Sci Med** 1996 Mar; 42(6):871–8

Influence of apolipoprotein E genotype on cerebral amyloid angiopathy in the elderly. Itoh Y, et al. **Stroke** 1996 Feb; 27(2):216–8

[Epidemiologic autopsy in Alzheimer's disease] Koukolík F. **Cas Lek Cesk** 1996 Jun 12;135(12):378–81 (Eng. Abstr.) **(Cze)**

[Dementias: current situation and future perspectives] Espert R, et al. **Rev Neurol** 1995 Jan–Feb;23(119):70–6 (90 ref.) (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Alzheimer's disease and Alzheimer-type of cerebral degenerations in Chinese. Ng HK. **Clin Exp Neurol** 1994; 31:85–98

Neuropsychological test performance in African-American and white patients with Alzheimer's disease. Welsh KA, et al. **Neurology** 1995 Dec;45(12):2207–11

ETIOLOGY

Neurologic manifestations of intravascular lymphomatosis. Chapin JE, et al. **Acta Neurol Scand** 1995 Jun;91(6):494–9

Re: "Association of education with reported age of onset and severity of Alzheimer's disease at presentation: implications for the use of clinical samples" [letter; comment] Peterson B. **Am J Epidemiol** 1996 Jun 1;143(11):1177. Comment on: Am J Epidemiol 1993 Feb 15;137(4):456–62.

Characteristics of familial aggregation in early-onset Alzheimer's disease: evidence of subgroups. Campion D, et al. **Am J Med Genet** 1995 Jun 19;60(3):221–7

The Golgi apparatus and the pathogenesis of Alzheimer's disease [comment] Dal Canto MC. **Am J Pathol** 1996 Feb; 148(2):355–60 (40 ref.). Comment on: Am J Pathol 1996 Feb;148(2):415–26.

The role of heparan sulfate proteoglycans in the pathogenesis of Alzheimer's disease. Small DH, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:316–21 (18 ref.)

Molecular physiology, biochemistry, and pharmacology of Alzheimer's amyloid precursor protein (APP). Suh YH, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:169–83 (59 ref.)

Alzheimer's disease, herpes simplex virus type 1, cold sores and apolipoprotein E4. Lin WR, et al. **Biochem Soc Trans** 1995 Nov;23(4):594S

Parkinson's, Alzheimer's, and motor neurone disease [editorial] [see comments] Ben-Shlomo Y, et al. **BMJ** 1996 Mar 23;312(7033):724. Comment in: BMJ 1996 Jul 6;313(7048):45.

Epidemiology of presenile Alzheimer's disease in Scotland (1974–88) II. Exposures to possible risk factors. Whalley LJ, et al. **Br J Psychiatry** 1995 Dec;167(6):732–8

Cognitive problems in the elderly. Dal Forno G, et al. **Curr Opin Neurol** 1995 Aug;8(4):256–61 (44 ref.)

The cortical neuritic dystrophy of Alzheimer's disease: nature, significance, and possible pathogenesis. Larner AJ. **Dementia** 1995 Jul–Aug;6(4):218–24 (84 ref.)

"The Alzheimerization of aging": a response [letter; comment] Blumenthal HT. **Gerontologist** 1995 Dec;35(6):721–3. Comment on: Gerontologist 1995 Aug;35(4):526–32.

Application of long-term cultured neurons in aging and neurological research: aluminum neurotoxicity, synaptic degeneration and Alzheimer's disease. Kuroda Y, et al. **Gerontology** 1995;41 Suppl 1:2–6

Excessive glutamine sensitivity in Alzheimer's disease and Down syndrome lymphocytes. Peeters MA, et al. **J Neurol Sci** 1995 Nov;133(1–2):31–41

Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered? Savory J, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):615–35 (96 ref.)

High blood pressure and dementia [letter; comment] Korczyn AD. **Lancet** 1996 Jul 6;348(9019):65; discussion 65–6. Comment on: Lancet 1996 Apr 27;347(9009):1141–5.

High blood pressure and dementia [letter; comment] Rockwood K, et al. **Lancet** 1996 Jul 6;348(9019):65; discussion 65–6. Comment on: Lancet 1996 Apr 27;347(9009):1141–5.

The mystery of Alzheimer's disease and its prevention by melatonin. Maurizi CP. **Med Hypotheses** 1995 Oct; 45(4):339–40

Deleterious network hypothesis of Alzheimer's disease. Ying W. **Med Hypotheses** 1996 May;46(5):421–8

Amyloid, aluminum and the aetiology of Alzheimer's disease [letter; comment] Exley C. **Med J Aust** 1996 Feb 19; 164(4):252–3. Comment on: Med J Aust 1995 Sep 4;163(5):256–9.

Amyloid, aluminium and the aetiology of Alzheimer's disease [see comments] Storey E, et al. **Med J Aust** 1995 Sep 4; 163(5):256–9 (49 ref.). Comment in: Med J Aust 1996 Feb 19;164(4):252–3. Comment in: Med J Aust 1996 Mar 18;164(6):382–3.

Amyloid, aluminium and the aetiology of Alzheimer's disease [letter; comment] Walton JR. **Med J Aust** 1996 Mar 18; 164(6):382–3. Comment on: Med J Aust 1995 Sep 4;163(5):256–9.

The effects of repetitive mild brain injury on cytoskeletal protein and behavior. Kanayama G, et al. **Methods Find Exp Clin Pharmacol** 1996 Mar;18(2):105–15

New clues to Alzheimer's disease: unraveling the roles of amyloid and tau [comment] Yankner BA. **Nat Med** 1996 Aug;2(8):850–2 (22 ref.). Comment on: Nat Med 1996 Aug;2(8):864–70.

Untangling the pathophysiochemistry of beta-amyloid [news; comment] Mattson MP. **Nat Struct Biol** 1995 Nov; 2(11):926–8. Comment on: Nat Struct Biol 1995

Nov;2(11):990–8.

Apolipoprotein–epsilon4 and head trauma: Synergistic or additive risks? [letter; comment] Katzman R, et al. **Neurology** 1996 Mar;46(3):889–91. Comment on: Neurology 1995 Mar;45(3 Pt 1):555–7.

Genetic dissection of Alzheimer disease, a heterogeneous disorder. Schellenberg GD. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8552–9 (144 ref.)

[Alzheimer's disease and trace elements] Yoshida H, et al. **Nippon Rinsho** 1996 Jan;54(1):111–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Apolipoprotein E polymorphism in Alzheimer's disease] Shimohama S. **Nippon Ronen Igakkai Zasshi** 1996 Mar; 33(3):173–7 **(Jpn)**

[Problems of the amyloid beta precursor protein in pathogenesis of the Alzheimer type dementia] Shoji M, et al. **Nippon Ronen Igakkai Zasshi** 1996 Mar;33(3):164–8 **(Jpn)**

[Neurofibrillary changes and phosphorylated tau of Alzheimer's disease] Takeda M, et al. **Nippon Ronen Igakkai Zasshi** 1996 Mar;33(3):169–72 **(Jpn)**

GENETICS

The amyloid peptide precursor in Alzheimer's disease. Octave JN. **Acta Neurol Belg** 1995 Dec;95(4):197–209 (70 ref.)

Lack of point mutation of the APP gene in sporadic Alzheimer's disease in Japanese. Nonomura Y, et al. **Acta Neurol Scand** 1996 Feb–Mar;93(2–3):138–41

Apolipoprotein E polymorphism, Alzheimer's disease and vascular dementia among elderly Finnish men. Stengård JH, et al. **Acta Neurol Scand** 1995 Oct;92(4):297–8

Apolipoprotein E genotype and neuropathological phenotype in two members of a German family with chromosome 14–linked early onset Alzheimer's disease. Egensperger R, et al. **Acta Neuropathol (Berl)** 1995;90(3):257–65

Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia. Martinoli MG, et al. **Acta Neuropathol (Berl)** 1995; 90(3):239–43

Does early-onset Alzheimer disease constitute a distinct subtype? The contribution of molecular genetics. Harvey RJ, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S7–13 (70 ref.)

Apolipoprotein epsilon 4 allele in Swedish twins and siblings with Alzheimer disease. Lannfelt L, et al. **Alzheimer Dis Assoc Disord** 1995 Fall;9(3):166–9

Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Jarvik G, et al. **Am J Hum Genet** 1996 Jan;58(1):191–200

Gender difference in apolipoprotein E–associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Payami H, et al. **Am J Hum Genet** 1996 Apr;58(4):803–11

Evidence for major gene inheritance of Alzheimer disease in families of patients with and without apolipoprotein E epsilon 4. Rao VS, et al. **Am J Hum Genet** 1996 Sep; 59(3):664–75

Relative risk of Alzheimer disease and age–at–onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Tang MX, et al. **Am J Hum Genet** 1996 Mar; 58(3):574–84

Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's Disease but is not causative. Bennett C, et al. **Am J Med Genet** 1995 Feb 27;60(1):1–6

Allelic association at the D14S43 locus in early onset Alzheimer's disease. French Alzheimer's Disease Collaborative Study Group. Brice A, et al. **Am J Med Genet** 1995 Apr 24;60(2):91–3

Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients. Brown MD, et al. **Am J Med Genet** 1996 Jan 22;61(3):283–9

Segregation analysis of Alzheimer pedigrees: rare Mendelian dominant mutation(s) explain a minority of early-onset cases. French Alzheimer Collaborative Group. Martinez M, et al. **Am J Med Genet** 1996 Feb 16;67(1):9–12

Clinical features of early onset, familial Alzheimer's disease linked to chromosome 14. Mullan M, et al. **Am J Med Genet** 1995 Feb 27;60(1):44–52

SSCP analysis and sequencing of the human prion protein gene (PRNP) detects two different 24 bp deletions in an atypical Alzheimer's disease family. Perry RT, et al. **Am J Med Genet** 1995 Feb 27;60(1):12–8

Widespread neuronal expression of the presenilin–1 early-onset Alzheimer's disease gene in the murine brain. Cribbs DH, et al. **Am J Pathol** 1996 Jun;148(6):1797–806

Aberrant GAP–43 gene expression in Alzheimer's disease. de la Monte SM, et al. **Am J Pathol** 1995 Oct;147(4):934–46

Apolipoprotein E–epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Premkumar DR, et al. **Am J Pathol** 1996 Jun;148(6):2083–95

Atrophy of the hippocampal formation in early familial Alzheimer's disease. A longitudinal MRI study of at–risk members of a family with an amyloid precursor protein 717Val–Gly mutation. Fox NC, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:226–32

Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease. Window on molecular epidemiology. Hyman BT, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:158–65 (27 ref.)

Apolipoprotein E alleles and brain vascular pathology in Alzheimer's disease. Kalaria RN, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:266–70

Clinical and neuroimaging features of familial Alzheimer's disease. Rossor MN, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:49–56 (18 ref.)

Alzheimer's disease and apolipoprotein E in Italy. Sorbi S, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:260–5

Lack of association of trinucleotide repeat polymorphisms in very–low–density lipoprotein receptor gene with Alzheimer's disease. Chung H, et al. **Ann Neurol** 1996 Jun; 39(6):800–3

No increased risk of the apolipoprotein E epsilon2 allele with early–onset Alzheimer's disease [letter] Corder EH, et al. **Ann Neurol** 1996 Mar;39(3):414–6

Apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives. Farrer LA, et al. **Ann Neurol** 1995 Nov; 38(5):797–808

Abeta–peptide length and apolipoprotein E genotype in Alzheimer's disease. Gearing M, et al. **Ann Neurol** 1996 Mar;39(3):395–9

Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Gomez–Isla T, et al. **Ann Neurol** 1996 Jan;39(1):62–70

Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view [letter; comment] Kakulas BA, et al. **Ann Neurol** 1995 Dec;38(6):966–7. Comment on: Ann Neurol 1995 Jul;38(1):2–4. Comment on: Ann Neurol 1995 Jul;38(1):6–14.

Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease [letter] Kamboh MI, et al. **Ann Neurol** 1995 Dec; 38(6):967–70

Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. Levy–Lahad E, et al. **Ann Neurol** 1995 Oct;38(4):678–80

Understanding Alzheimer's disease: expect more genes and other things [editorial] Mayeux R. **Ann Neurol** 1996 Jun; 39(6):689–90

Lack of association of very low density lipoprotein receptor gene polymorphism with Caucasian Alzheimer's disease. Okuizumi K, et al. **Ann Neurol** 1996 Aug;40(2):251–4

Alzheimer's disease and apolipoprotein E–4 allele in an Amish population. Pericak–Vance MA, et al. **Ann Neurol** 1996 Jun;39(6):700–4

Missense mutations of the PS–1/S182 gene in German early–onset Alzheimer's disease patients [letter] Sandbrink R, et al. **Ann Neurol** 1996 Aug;40(2):265–6

Genetic studies in Alzheimer's disease with an NACP/alpha–synuclein polymorphism. Xia Y, et al. **Ann Neurol** 1996 Aug;40(2):207–15

Apolipoprotein E alleles as risk factors in Alzheimer's disease. Roses AD. **Annu Rev Med** 1996;47:387–400 (66 ref.)

Medical education [letter] Menken M. **Arch Neurol** 1996 Mar; 53(3):215

Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. Seshadri S, et al. **Arch Neurol** 1995 Nov; 52(11):1074–9

The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions. Egensperger R, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):484–6

Missense mutations associated with familial Alzheimer's disease in Sweden lead to the production of the amyloid peptide without internalization of its precursor. Essalmani R, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):89–96

Regional and cellular presenilin 1 gene expression in human and rat tissues. Suzuki T, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):708–13

Olfactory identification deficits in relatives of Alzheimer's disease patients. Serby M, et al. **Biol Psychiatry** 1996 Mar 1;39(5):375–7

Alzheimer's disease: genetics or environment? Mera SL. **Br J Biomed Sci** 1996 Jun;53(2):91–2 (8 ref.)

Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease. Norrman J, et al. **Br J Psychiatry** 1995 Oct;167(4):533–6

Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Katzman R, et al. **Brain Cogn** 1995 Aug;28(3):259–65 (43 ref.)

Reported sequence homology between Alzheimer amyloid770 and the MRC OX–2 antigen does not predict function [letter] Richards SJ, et al. **Brain Res Bull** 1995; 38(3):305–6

Canadian patient played key role in uncovering secrets about early–onset Alzheimer's disease. Lyttle J. **Can Med Assoc J** 1996 Mar 15;154(6):905–7

Amyloid beta amyloidosis in Alzheimer's disease. Price DL, et al. **Curr Opin Neurol** 1995 Aug;8(4):268–74 (71 ref.)

Progress in Alzheimer's disease genetics. Schellenberg GD. **Curr Opin Neurol** 1995 Aug;8(4):262–7 (68 ref.)

Cumulative risk of Alzheimer–like dementia in relatives of autopsy–confirmed cases of Alzheimer's disease. Hocking LB, et al. **Dementia** 1995 Nov–Dec;6(6):355–6

Familial Alzheimer's disease and cortical Lewy bodies: is there a genetic susceptibility factor? Lippa CF, et al. **Dementia** 1995 Jul–Aug;6(4):191–4

Production of intracellular amyloid–containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. De Strooper B, et al. **EMBO J** 1995 Oct 16;14(20):4932–8

Negative transactivation of cAMP response element by familial Alzheimer's mutants of APP. Ikezu T, et al. **EMBO J** 1996 May 15;15(10):2468–75

Intrinsic signaling function of APP as a novel target of three V642 mutations linked to familial Alzheimer's disease. Okamoto T, et al. **EMBO J** 1996 Aug 1;15(15):3769–77

Expression of V642 APP mutant causes cellular apoptosis as Alzheimer trait–linked phenotype. Yamatsuji T, et al. **EMBO J** 1996 Feb 1;15(3):498–509

Genes and recent developments in the epidemiology of Alzheimer's disease and related dementia. Breitner JC, et al. **Epidemiol Rev** 1995;17(1):39–47 (99 ref.)

A mechanism for beta–amyloid overproduction in Alzheimer's disease: precursor–independent generation of beta–amyloid via antisense RNA–primed mRNA synthesis. Volloch V. **FEBS Lett** 1996 Jul 22;390(2):124–8 (31 ref.)

Decreased cytochrome–c oxidase activity and lack of age–related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Cavelier L, et al. **Genomics** 1995 Sep 1;29(1):217–24

No genetic effect of alpha1–antichymotrypsin in Alzheimer disease. Haines JL, et al. **Genomics** 1996 Apr 1;33(1):53–6

Association of apolipoprotein E but not B with Alzheimer's disease. Poduslo SE, et al. **Hum Genet** 1995 Nov; 96(5):597–600

Polymorphisms in the human apolipoprotein–J/clusterin gene: ethnic variation and distribution in Alzheimer's disease. Tycko B, et al. **Hum Genet** 1996 Oct;98(4):430–6

Mutations of the presenilin I gene in families with early–onset Alzheimer's disease. Campion D, et al. **Hum Mol Genet** 1995 Dec;4(12):2373–7

A yeast artificial chromosome contig from human chromosome 14q24 spanning the Alzheimer's disease locus AD3. Clark RF, et al. **Hum Mol Genet** 1995 Aug; 4(8):1347–54

Genetic and physical characterization of the early–onset Alzheimer's disease AD3 locus on chromosome 14q24.3. Cruts M, et al. **Hum Mol Genet** 1995 Aug;4(8):1355–64

Molecular genetic analysis of familial early–onset Alzheimer's disease linked to chromosome 14q24.3. Cruts M, et al. **Hum Mol Genet** 1995 Dec;4(12):2363–71

The upstream stimulatory factor functionally interacts with the Alzheimer amyloid beta–protein precursor gene. Kovacs DM, et al. **Hum Mol Genet** 1995 Sep;4(9):1527–33

Impact of sample selection on APOE epsilon 4 allele frequency: a comparison of two Alzheimer's disease samples. Tsuang D, et al. **J Am Geriatr Soc** 1996 Jun; 44(6):704–7

Temporal progression of hippocampal atrophy and apolipoprotein E gene in Alzheimer's disease [letter] Yamaguchi S, et al. **J Am Geriatr Soc** 1996 Feb;44(2):216–7

Intracellular accumulation of beta–amyloid in cells expressing the Swedish mutant amyloid precursor protein. Martin BL, et al. **J Biol Chem** 1995 Nov 10;270(45):26727–30

Enhanced release of amyloid beta–protein from codon 670/671 "Swedish" mutant beta–amyloid precursor protein occurs in both secretory and endocytic pathways. Perez RG, et al. **J Biol Chem** 1996 Apr 12;271(15):9100–7

Amyloid beta–protein and the genetics of Alzheimer's disease. Selkoe DJ. **J Biol Chem** 1996 Aug 2; 271(31):18295–8 (93 ref.)

Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta–secretase" site occurs in the golgi apparatus. Thinakaran G, et al. **J Biol Chem** 1996 Apr 19; 271(16):9390–7

Rate of progression in familial Alzheimer's disease. Swearer JM, et al. **J Geriatr Psychiatry Neurol** 1996 Jan;9(1):22–5

Apolipoprotein E epsilon 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers. St Clair D, et al. **J Med Genet** 1995 Aug;32(8):642–4

Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. West RL, et al. **J Mol Neurosci** 1995;6(2):141–6

Characterization of muscarinic acetylcholine receptors in cultured adult skin fibroblasts: effects of the Swedish Alzheimer's disease APP 670/671 mutation on binding levels. Vestling M, et al. **J Neural Transm Park Dis Dement Sect** 1995;10(1):1–10

Molecular analysis of the presenilin 1 (S182) gene in "sporadic" cases of Alzheimer's disease: identification and characterisation of unusual splice variants. Anwar R, et al. **J Neurochem** 1996 Apr;66(4):1774–7

Magnetic resonance and single–photon emission tomography findings in a pair of twins discordant for Alzheimer's disease. Geroldi C, et al. **J Neuroimaging** 1996 Apr; 6(2):76–80

Diagnostic usefulness of apolipoprotein E epsilon 4 in the diagnosis of the dementias [letter] Frisoni GB, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):699–700

Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease. Ibarreta D, et al. **J Neurol Sci** 1995 Dec;134(1–2):146–9

Selection biases during recruitment of patients and relatives for a family study in the elderly. Heun R, et al. **J Psychiatr Res** 1995 Nov–Dec;29(6):491–504

Catastrophe, chaos and Alzheimer's disease. The F E Williams Lecture. Rossor MN.

J R Coll Physicians Lond 1995 Sep–Oct;29(5):412–8 (60 ref.)

Apolipoprotein E and Alzheimer's disease. Stephens D. J R Soc Health 1996 Feb;116(1):41–3 (7 ref.)

Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. JAMA 1995 Nov 22–29;274(20):1627–9 (55 ref.)

Linkage and haplotype analysis of familial early-onset Alzheimer disease in Japanese population. Kamino K, et al. Jpn J Hum Genet 1995 Sep;40(3):229–41

Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group [see comments] Lancet 1996 Apr 20; 347(9008):1091–5 (77 ref.). Comment in: Lancet 1996 Apr 27;347(9009):1184–5. Comment in: Lancet 1996 Aug 3;348(9023):334.

Apolipoprotein E allele distribution in parents of Down's syndrome children. Avramopoulos D, et al. Lancet 1996 Mar 30;347(9005):862–5

Mutation analysis of presenillin 1 gene in Alzheimer's disease [letter] Boteva K, et al. Lancet 1996 Jan 13;347(8994):130–1

Presenilin–1 polymorphism and Alzheimer's disease [letter; comment] Bouras C, et al. Lancet 1996 Apr 27; 347(9009):1185–6. Comment on: Lancet 1996 Feb 24;347(9000):509–12.

Familial Alzheimer's disease associated with S182 codon 286 mutation [letter] [retracted by Chapman J, Korczyn AD, Goldfarb LG. In: Lancet 1996 Jul 20;348(9021):206] Chapman J, et al. Lancet 1995 Oct 14;346(8981):1040

Alzheimer's disease in twins [letter; comment] Christensen K, et al. Lancet 1996 Apr 6;347(9006):976. Comment on: Lancet 1996 Mar 2;347(9001):573–8.

Apolipoprotein E–epsilon 4 gene dose [letter] Corder E, et al. Lancet 1995 Oct 7;346(8980):967–8

Presenilin–1 polymorphism and Alzheimer's disease [letter; comment] [see comments] Higuchi S, et al. Lancet 1996 Apr 27;347(9009):1186. Comment on: Lancet 1996 Feb 24;347(9000):509–12. Comment in: Lancet 1996 Jun 1;347(9014):1560.

Apolipoprotein E genotyping in Alzheimer's disease [letter] Humphries S, et al. Lancet 1996 Jun 22;347(9017):1776

Alzheimer's disease in twins [letter; comment] Jongbloet PH. Lancet 1996 Apr 6;347(9006):975–6. Comment on: Lancet 1996 Mar 2;347(9001):573–8.

Presenilin–1 polymorphism and Alzheimer's disease. The UK Alzheimer's Disease Collaborative Group [letter; comment] [see comments] Kehoe P, et al. Lancet 1996 Apr 27; 347(9009):1185. Comment on: Lancet 1996 Feb 24;347(9000):509–12. Comment in: Lancet 1996 Jun 1;347(9014):1560.

Apolipoprotein E genotyping in Alzheimer's disease. The UK Alzheimer's Disease Genetic consortium [letter] Lovestone S, et al. Lancet 1996 Jun 22;347(9017):1775–6

Presenilin–1 polymorphism and Alzheimer's disease [letter] Owen MJ, et al. Lancet 1996 Aug 10;348(9024):414

Presenilin–1 polymorphism and Alzheimer's disease. The Alzheimer's Study Group [letter; comment] Pérez–Tur J, et al. Lancet 1996 Jun 1;347(9014):1560–1. Comment on: Lancet 1996 Feb 24;347(9000):509–12.

Alzheimer's disease, Down's syndrome, and chromosome segregation [letter] Potter H, et al. Lancet 1996 Jul 6; 348(9019):66

Alzheimer's disease in Finnish twins [see comments] Raiha I, et al. Lancet 1996 Mar 2;347(9001):573–8. Comment in: Lancet 1996 Apr 6;347(9006):975–6. Comment in: Lancet 1996 Apr 6;347(9006):976.

Incomplete penetrance of familial Alzheimer's disease in a pedigree with a novel presenilin–1 gene mutation [letter] Rossor MN, et al. Lancet 1996 Jun 1;347(9014):1560

Specificity, sensitivity, and predictive value of apolipoprotein–E genotyping for sporadic Alzheimer's disease [see comments] Saunders AM, et al. Lancet 1996 Jul 13;348(9020):90–3. Comment in: Lancet 1996 Aug 17;348(9025):483. Comment in: Lancet 1996 Aug 17;348(9025):483–4.

Presenilin–1 polymorphism and Alzheimer's disease [letter; comment] Scott WK, et al. Lancet 1996 Jun 1; 347(9014):1560. Comment on: Lancet 1996 Feb 24;347(9000):509–12. Comment on: Lancet 1996 Apr 27;347(9009):1185. Comment on: Lancet 1996 Apr 27;347(9009):1186.

Presenilin–1 polymorphism and Alzheimer's disease [letter; comment] Scott WK, et al. Lancet 1996 Apr 27; 347(9009):1186–7. Comment on: Lancet 1996 Feb 24;347(9000):509–12.

Genetic association between intronic polymorphism in presenilin–1 gene and late–onset Alzheimer's disease. Alzheimer's Disease Collaborative Group [see comments] Wragg M, et al. Lancet 1996 Feb 24;347(9000):509–12. Comment in: Lancet 1996 Apr 27;347(9009):1185. Comment in: Lancet 1996 Apr 27;347(9009):1185–6. Comment in: Lancet 1996 Apr 27;347(9009):1186. Comment in: Lancet 1996 Apr 27;347(9009):1186–7. Comment in: Lancet 1996 Jun 1;347(9014):1560. Comment in: Lancet 1996 Jun 1;347(9014):1560–1.

A human ubiquitin conjugating enzyme, L–UBC, maps in the Alzheimer's disease locus on chromosome 14q24.3. Robinson PA, et al. Mamm Genome 1995 Oct;6(10):725–31

Alzheimer's disease and apolipoprotein E genotype in Western Australia: an autopsy–verified series. Fabian VA, et al. Med J Aust 1996 Jul 15;165(2):77–80

When a mind dies [editorial; comment] Campion EW. N Engl J Med 1996 Mar 21;334(12):791–2. Comment on: N Engl J Med 1996 Mar 21;334(12):745–51.

Molecular epidemiology of Alzheimer's disease [editorial; comment] Hyman BT, et al. N Engl J Med 1995 Nov 9; 333(19):1283–4. Comment on: N Engl J Med 1995 Nov 9;333(19):1242–7.

Apolipoprotein E and the neuropathology of dementia [letter; comment] Itoh Y, et al. N Engl J Med 1996 Feb 29; 334(9):599–600. Comment on: N Engl J Med 1995 Nov 9;333(19):1242–7.

Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E [see comments] Reiman EM, et al. N Engl J Med 1996 Mar 21;334(12):752–8. Comment in: N Engl J Med 1996 Mar 21;334(12):792–4. Comment in: N Engl J Med 1996 Jul 18;335(3):207–8.

The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Alzheimer's Disease Collaborative Group. Nat Genet 1995 Oct;11(2):219–22

Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Okuizumi K, et al. Nat Genet 1995 Oct;11(2):207–9

Presenilins and Alzheimer disease [news] Van Broeckhoven C. Nat Genet 1995 Nov;11(3):230–2

The Swedish mutation causes early–onset Alzheimer's disease by beta–secretase cleavage within the secretory pathway. Haass C, et al. Nat Med 1995 Dec;1(12):1291–6

Secreted amyloid beta–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease [see comments] Scheuner D, et al. Nat Med 1996 Aug;2(8):864–70. Comment in: Nat Med 1996 Aug;2(8):850–2.

Familial Alzheimer's chromosome 14 mutations [letter] Wasco W, et al. Nat Med 1995 Sep;1(9):848

Facilitation of lin–12–mediated signalling by sel–12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Levitan D, et al. Nature 1995 Sep 28;377(6547):351–4

Expression of APP in transgenic mice: a comparison of neuron–specific promoters. Andrä K, et al. Neurobiol Aging 1996 Mar–Apr;17(2):183–90

Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele. Heinonen O, et al. Neurobiol Aging 1995 Jul–Aug;16(4):505–13

New hopes arise with the transgenic model for Alzheimer's disease [comment] Kotula L, et al. Neurobiol Aging 1995 Jul–Aug;16(4):701–3. Comment on: Neurobiol Aging 1995 Jul–Aug;16(4):685–99.

Rational design of an animal model for Alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent. Loring JF, et al. Neurobiol Aging 1996 Mar–Apr;17(2):173–82

Lack of beta–amyloidosis in transgenic mice expressing low levels of familial Alzheimer's disease missense mutations. Malherbe P, et al. Neurobiol Aging 1996 Mar–Apr; 17(2):205–14

Scopolamine–induced impairment as a potential predictor of Alzheimer's disease in individuals with Apolipoprotein E type 4 alleles. Pomara N, et al. Neurochem Res 1995 Dec; 20(12):1519–20

Apolipoprotein E genotype and Alzheimer's disease in an elderly Norwegian cohort. Benjamin R, et al. Neurodegeneration 1996 Mar;5(1):43–7

Alzheimer's disease with and without coexisting Parkinson's disease changes: apolipoprotein E genotype and neuropathologic correlates. Gearing M, et al. Neurology 1995 Nov;45(11):1985–90

Epsilon 4 allele of apolipoprotein E increases risk of Alzheimer's disease in a Chinese population. Hong CJ, et al. Neurology 1996 Jun;46(6):1749–51

Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? Lautenschlager NT, et al. Neurology 1996 Mar; 46(3):641–50

Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Lehtovirta M, et al. Neurology 1996 Feb; 46(2):413–9

Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Lippa CF, et al. Neurology 1996 Feb;46(2):406–12

Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese. Mak YT, et al. Neurology 1996 Jan; 46(1):146–9

Japanese siblings with missense mutation (717Val –> Ile) in amyloid precursor protein of early–onset Alzheimer's disease. Matsumura Y, et al. Neurology 1996 Jun; 46(6):1721–3

A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele. Mui S, et al. Neurology 1996 Jul;47(1):196–201

The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Olichney JM, et al. Neurology 1996 Jul;47(1):190–6

ApoE genotypes in Australia: roles in early and late onset Alzheimer's disease and Down's syndrome. Martins RN, et al. Neuroreport 1995 Jul 31;6(11):1513–6

High levels of amyloid–beta protein from S182 (Glu246) familial Alzheimer's cells. Martins RN, et al. Neuroreport 1995 Dec 29;7(1):217–20

A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin–1 gene. Perez–Tur J, et al. Neuroreport 1995 Dec 29;7(1):297–301

A mutation in codon 717 of the amyloid precursor protein gene in an Australian family with Alzheimer's disease. Brooks WS, et al. Neurosci Lett 1995 Oct 27;199(3):183–6

Mutation analysis of the chromosome 14q24.3 dihydrolipoyl succinyltransferase (DLST) gene in patients with early–onset Alzheimer disease. Cruts M, et al. Neurosci Lett 1995 Oct 13;199(1):73–7

Amyloid beta–peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. Lannfelt L, et al. Neurosci Lett 1995 Oct 27; 199(3):203–6

Polymerase chain reaction quantification of lymphoid amyloid precursor protein mRNAs in Alzheimer's disease and Down's syndrome. Ledoux S, et al. Neurosci Lett 1995 Jun 30;193(2):137–9

Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians. Morris CM, et al. Neurosci Lett 1995 Dec 1;201(1):45–7

Apolipoprotein E polymorphism and susceptibility to early– and late–onset sporadic Alzheimer's disease in Hokkaido, the northern part of Japan. Nunomura A, et al. Neurosci Lett 1996 Mar 8;206(1):17–20

A closely linked gene to apolipoprotein E may serve as an additional risk factor for Alzheimer's disease. Poduslo SE, et al. Neurosci Lett 1995 Dec 1;201(1):81–3

Apolipoprotein E (APOE) allele frequencies in late–onset sporadic Alzheimer's disease (AD), mixed dementia and vascular dementia: lack of association of epsilon 4 allele with AD in Italian octogenarian patients. Scacchi R, et al. Neurosci Lett 1995 Dec 15;201(3):231–4

Molecular cloning and expression of the rat homologue of presenilin–1. Takahashi H, et al. Neurosci Lett 1996 Mar 15;206(2–3):113–6

Failure to detect missense mutations in the S182 gene in a series of late–onset Alzheimer's disease cases. Tsuda T, et al. Neurosci Lett 1995 Dec 8;201(2):188–90

No association found between Alzheimer's disease and a mitochondrial tRNA glutamine gene variant. Wragg MA, et al. Neurosci Lett 1995 Dec 8;201(2):107–10

Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Lehtovirta M, et al. Neuroscience 1995 Jul; 67(1):65–72

Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Nagy Z, et al. Neuroscience 1995 Dec; 69(3):757–61

Searching for a marker for Alzheimer's disease–Apo–E. Venarucci D, et al. Panminerva Med 1995 Jun;37(2):68–70

Identification and expression analysis of a potential familial Alzheimer disease gene on chromosome 1 related to AD3. Li J, et al. Proc Natl Acad Sci U S A 1995 Dec 19; 92(26):12180–4

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Poirier J, et al. Proc Natl Acad Sci U S A 1995 Dec 19;92(26):12260–4

Genetic dissection of Alzheimer disease, a heterogeneous disorder. Schellenberg GD. Proc Natl Acad Sci U S A 1995 Sep 12;92(19):8552–9 (144 ref.)

Conservation of synteny between the genome of the pufferfish (Fugu rubripes) and the region on human chromosome 14 (14q24.3) associated with familial Alzheimer disease (AD3 locus) [see comments] Trower MK, et al. Proc Natl Acad Sci U S A 1996 Feb 20; 93(4):1366–9. Comment in: Proc Natl Acad Sci U S A 1996 Feb 20;93(4):1363–5.

Genetic determinants of Alzheimer disease. St George–Hyslop P. Prog Clin Biol Res 1995;393:139–45 (23 ref.)

Screening for mutations at codon 717 of the amyloid precursor protein gene in Alzheimer's disease. Dai XY, et al. Psychiatry Clin Neurosci 1995 Jun;49(3):175–8

Evoked potentials in subjects at risk for Alzheimer's disease. Boutros N, et al. Psychiatry Res 1995 Jun 29;57(1):57–63

Major depression in Alzheimer's disease. An interaction between gender and family history. Lyketsos CG, et al. Psychosomatics 1996 Jul–Aug;37(4):380–4

Genetic clues to Alzheimer's disease. Dewji NN, et al. Science 1996 Jan 12;271(5246):159–60

Interfering with apoptosis: Ca(2+)–binding protein ALG–2 and Alzheimer's disease gene ALG–3. Vito P, et al. Science 1996 Jan 26;271(5248):521–5

G protein–mediated neuronal DNA fragmentation induced by familial Alzheimer's disease–associated mutants of APP. Yamatsuji T, et al. Science 1996 May 31;272(5266):1349–52

Estimation of the proportion of genetic cases in late–onset diseases: an application to Alzheimer's disease. Tzourio C, et al. Stat Med 1995 Jun 30;14(12):1353–63

Genetic susceptibility to Alzheimer disease. Pericak–Vance MA, et al. Trends Genet 1995 Dec;11(12):504–8 (66 ref.)

Two new genes for Alzheimer's disease [news] Hardy J, et al. Trends Neurosci 1995 Oct;18(10):436

[Apolipoprotein E polymorphism and Alzheimer disease] van der Weide J, et al. Tijdschr Gerontol Geriatr 1996 Apr; 27(2):73–7 (Eng. Abstr.) (Dut)

[Current genetic linkages of Alzheimer's disease (editorial)]

Haltia M. **Duodecim** 1995;111(5):389–92 **(Fin)**
[Alzheimer's disease and the association of genetic polymorphism of apolipoprotein E and liquor beta protein in Finns] Lehtimäki T, et al. **Duodecim** 1995;111(5):401–7 **(Fin)**
[Phenotype of familial forms of early-onset Alzheimer's disease linked to chromosome 14. Clinical and neuropsychological characteristics of a large group] Hannequin D, et al. **Rev Neurol (Paris)** 1995 Dec; 151(12):682–90 (74 ref.) (Eng. Abstr.) **(Fre)**
[Molecular mechanisms in Alzheimer disease] Simons VM. **Fortschr Med** 1995 Nov 10;113(31):441–2 (Eng. Abstr.) **(Ger)**
[Genetic predisposition for Alzheimer's disease] Staufenbiel M, et al. **Ther Umsch** 1995 Dec;52(12):821–5 (28 ref.) (Eng. Abstr.) **(Ger)**
[Positional cloning of the genes for progeroid syndromes] Miki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Mar; 41(3):245–54 (41 ref.) **(Jpn)**
[The search for a mutation in the gene coding the beta-amyloid protein precursor gene in patients with Alzheimer-type dementias] Golimbet VE, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):75–8 (Eng. Abstr.) **(Rus)**

HISTORY

An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde" [classical article] Alzheimer A, et al. **Clin Anat** 1995;8(6):429–31
Auguste D. and Alzheimer's disease [news] O'Brien C. **Science** 1996 Jul 5;273(5271):28

IMMUNOLOGY

Early complement components in Alzheimer's disease brains. Veerhuis R, et al. **Acta Neuropathol (Berl)** 1996;91(1):53–60
Differential vasopressin and oxytocin innervation of the human parabrachial nucleus: no changes in Alzheimer's disease. van Zwieten EJ, et al. **Brain Res** 1996 Mar 4; 711(1–2):146–52
Bovine and human tau, highly homologous but less crossreactive: implications for Alzheimer disease. Alonso A del C, et al. **Brain Res Mol Brain Res** 1995 Jul; 31(1–2):194–200
Transforming growth factor beta in Alzheimer's disease. Chao CC, et al. **Clin Diagn Lab Immunol** 1994 Jan; 1(1):109–10
Synaptophysin immunoreactivity is stable 36 h postmortem. Liu X, et al. **Dementia** 1995 Jul–Aug;6(4):211–7
Manganese and copper–zinc superoxide dismutases in the human olfactory mucosa: increased immunoreactivity in Alzheimer's disease. Kulkarni–Narla A, et al. **Exp Neurol** 1996 Aug;140(2):115–25
Antibodies to human brain spectrin in Alzheimer's disease. Vázquez J, et al. **J Neuroimmunol** 1996 Aug;68(1–2):39–44
Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease. Rösler N, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):452–4
Anticardiolipin antibodies in two elderly subpopulations. Juby A, et al. **Lupus** 1995 Dec;4(6):482–5
Constitutive Alzheimer's-type tau epitopes in a neuritogenic rat CNS cell line. Lambert MP, et al. **Neurobiol Aging** 1995 Jul–Aug;16(4):583–9
Early amyloid-beta deposits show different immunoreactivity to the amino- and carboxy-terminal regions of beta-peptide in Alzheimer's disease and Down's syndrome brain. Kida E, et al. **Neurosci Lett** 1995 Jun 30;193(2):105–8
Relationship between autoimmune thyroid disease Rand Alzheimer's disease. Genovesi G, et al. **Panminerva Med** 1996 Mar;38(1):61–3
[The immune system characteristics during normal aging and in Alzheimer's disease] Koliaskina GI, et al. **Vestn Ross Akad Med Nauk** 1996;(4):19–23 (32 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Paired helical filament tau (PHFtau) in Niemann–Pick type C disease is similar to PHFtau in Alzheimer's disease. Auer IA, et al. **Acta Neuropathol (Berl)** 1995;90(6):547–51
Plasma membrane fragility in dystrophic neurites in senile plaques of Alzheimer's disease: an index of oxidative stress. Praprotnik D, et al. **Acta Neuropathol (Berl)** 1996;91(1):1–5
Immunogold labelling of paired helical filaments and amyloid fibrils by specific monoclonal and polyclonal antibodies. Reig S, et al. **Acta Neuropathol (Berl)** 1995;90(5):441–7
A lysosomal marker for activated microglial cells involved in Alzheimer classic senile plaques. Verbeek MM, et al. **Acta Neuropathol (Berl)** 1995;90(5):493–503
Astroglial localization of cholesteryl ester transfer protein in normal and Alzheimer's disease brain tissues. Yamada T, et al. **Acta Neuropathol (Berl)** 1995;90(6):633–6
Band 3 and its peptides during aging, radiation exposure, and Alzheimer's disease: alterations and self-recognition. Kay MM, et al. **Adv Exp Med Biol** 1995;383:167–93
Plasma arginine vasopressin response to hypertonic saline infusion in Alzheimer disease. Peskind ER, et al. **Alzheimer Dis Assoc Disord** 1995 Winter;9(4):238–42
Signal transduction mechanisms in Alzheimer disease. Shimohama S, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:15–22
Abnormally phosphorylated tau protein in senile dementia of Lewy body type and Alzheimer disease: evidence that the disorders are distinct. Strong C, et al. **Alzheimer Dis Assoc Disord** 1995 Winter;9(4):218–22
Apolipoprotein E in the genetics and epidemiology of Alzheimer's disease. Hardy J. **Am J Med Genet** 1995 Oct 9;60(5):456–60
Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. Christie RH, et al. **Am J Pathol** 1996 Feb;148(2):399–403
Selective binding of soluble Abeta1–40 and Abeta1–42 to a subset of senile plaques. Prior R, et al. **Am J Pathol** 1996 Jun;148(6):1749–56
Amino acid concentration in dementia of the Alzheimer type and multi-infarct dementia. Mochizuki Y, et al. **Ann Clin Lab Sci** 1996 May–Jun;26(3):275–8
High affinity choline transporter status in Alzheimer's disease tissue from rapid autopsy. Bissette G, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:197–204 (12 ref.)
Defective protein kinase C alpha leads to impaired secretion of soluble beta-amyloid precursor protein from Alzheimer's disease fibroblasts. Govoni S, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:332–7
Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer's disease-associated amyloid beta peptide. Hensley K, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:120–34 (49 ref.)
Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques. Hüll M, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:205–12
Regulation of tau phosphorylation in Alzheimer's disease. Lee VM. **Ann N Y Acad Sci** 1996 Jan 17;777:107–13 (37 ref.)
Free intracellular calcium in aging and Alzheimer's disease. Müller WE, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:305–20 (55 ref.)
Altered expression of amyloid beta precursor mRNAs in cerebral vessels, meninges, and choroid plexus in Alzheimer's disease. Premkumar DR, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:288–92
Clinical and neuroimaging features of familial Alzheimer's disease. Rossor MN, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:49–56 (18 ref.)
Molecular physiology, biochemistry, and pharmacology of Alzheimer's amyloid precursor protein (APP). Suh YH, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:169–83 (59 ref.)
Fractionation of amyloid beta-protein (A beta) in Alzheimer's disease and Down's syndrome brains. Presence of membrane-bound A beta. Yanagisawa K, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:184–94
Ontogenetic expression of spot 35 protein (calbindin-D28k) in human olfactory receptor neurons and its decrease in Alzheimer's disease patients. Yamagishi M, et al. **Ann Otol Rhinol Laryngol** 1996 Feb;105(2):132–9
Plasma and red blood cell thiamine deficiency in patients with dementia of the Alzheimer's type. Gold M, et al. **Arch Neurol** 1995 Nov;52(11):1081–6
Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. MacKay S, et al. **Arch Neurol** 1996 Feb;53(2):167–74
Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Messier C, et al. **Behav Brain Res** 1996 Feb;75(1–2):1–11 (127 ref.)
Apolipoprotein J and Alzheimer's amyloid beta solubility. Matsubara E, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):671–9
The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis. Soto C, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):701–7
In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics. Esler WP, et al. **Biochemistry** 1996 Jan 23;35(3):749–57
Candidate gamma-secretases in the generation of the carboxyl terminus of the Alzheimer's disease beta A4 amyloid: possible involvement of cathepsin D. Evin G, et al. **Biochemistry** 1995 Oct 31;34(43):14185–92
Calcium stores in cultured fibroblasts and their changes with Alzheimer's disease. Gibson GE, et al. **Biochim Biophys Acta** 1996 Jun 7;1316(2):71–7
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex [see comments] Gabriel SM, et al. **Biol Psychiatry** 1996 Jan 15;39(2):82–91. Comment in: Biol Psychiatry 1996 Jan 15;39(2):79–81.
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex [editorial; comment] Hirsch SR, et al. **Biol Psychiatry** 1996 Jan 15;39(2):79–81. Comment on: Biol Psychiatry 1996 Jan 15;39(2):82–91.
Lack of association between clinical symptoms and postmortem indices of brain serotonin function in Alzheimer's disease [letter] Lawlor BA, et al. **Biol Psychiatry** 1995 Jun 15;37(12):895–6
Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia. Akbarian S, et al. **Brain Res** 1995 Nov 20;699(2):297–304
Calretinin-immunoreactive neurons in the normal human temporal cortex and in Alzheimer's disease. Fonseca M, et al. **Brain Res** 1995 Sep 11;691(1–2):83–91
Diminished [3H]inositol(1,4,5)P3 but not [3H]inositol(1,3,4,5)P4 binding in Alzheimer's disease brain. Garlind A, et al. **Brain Res** 1995 May 29;681(1–2):160–6
Activation of c-Fos contributes to amyloid beta-peptide-induced neurotoxicity. Gillardon F, et al. **Brain Res** 1996 Jan 8;706(1):169–72
Changes of growth inhibitory factor after stab wounds in rat brain. Hozumi I, et al. **Brain Res** 1995 Aug 7; 688(1–2):143–8
Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Jefferies WA, et al. **Brain Res** 1996 Mar 11;712(1):122–6
Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain. Kida E, et al. **Brain Res** 1995 Jul 10;685(1–2):211–6
Increase in vasopressin binding sites in the human choroid plexus in Alzheimer's disease. Korting C, et al. **Brain Res** 1996 Jan 8;706(1):151–4
Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's beta-amyloid peptide in cultured vascular smooth muscle cells. Mazur-Kolecka B, et al. **Brain Res** 1995 Nov 6; 698(1–2):217–22
Fas antigen expression in brains of patients with Alzheimer-type dementia. Nishimura T, et al. **Brain Res** 1995 Oct 16;695(2):137–45
Immunoreactivity for Bcl-2 protein within neurons in the Alzheimer's disease brain increases with disease severity. Satou T, et al. **Brain Res** 1995 Oct 30;697(1–2):35–43
Alterations of low molecular weight acid phosphatase protein level in Alzheimer's disease. Shimohama S, et al. **Brain Res** 1995 Nov 13;699(1):125–9
Co-localization of amyloid-associated proteins with amyloid beta in rat soleus muscle in chloroquine-induced myopathy: a possible model for amyloid beta formation in Alzheimer's disease. Tsuzuki K, et al. **Brain Res** 1995 Nov 20; 699(2):260–5
beta-Amyloid-induced toxicity in rat hippocampal cells: in vitro evidence for the involvement of free radicals. Manelli AM, et al. **Brain Res Bull** 1995;38(6):569–76
Free D-serine concentration in normal and Alzheimer human brain. Nagata Y, et al. **Brain Res Bull** 1995;38(2):181–3
Expression of the amyloid protein precursor of Alzheimer's disease in the developing rat olfactory system. Clarris HJ, et al. **Brain Res Dev Brain Res** 1995 Aug 28;88(1):87–95
Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Bertrand P, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):174–8
Changes in expression of lymphocyte amyloid precursor protein mRNA isoforms in normal aging and Alzheimer's disease. Ebstein RP, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):260–8
Expression and distribution of low density lipoprotein receptor-related protein mRNA in the rat central nervous system. Ishiguro M, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):37–46
Production and increased detection of amyloid beta protein and amyloidogenic fragments in brain microvessels, meningeal vessels and choroid plexus in Alzheimer's disease. Kalaria RN, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):58–68
Clinical pharmacokinetics of drugs for Alzheimer's disease. Parnetti L. **Clin Pharmacokinet** 1995 Aug;29(2):110–29 (111 ref.)
Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Asthana S, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):299–309
Disruption of the cytoskeleton in Alzheimer's disease. Lee VM. **Curr Opin Neurobiol** 1995 Oct;5(5):663–8 (43 ref.)
Cytokines in Alzheimer's disease and multiple sclerosis. Patterson PH. **Curr Opin Neurobiol** 1995 Oct;5(5):642–6 (44 ref.)
Alzheimer's disease: distribution of changes in intraneuronal lipopigment in the frontal cortex. Dowson JH, et al. **Dementia** 1995 Nov–Dec;6(6):334–42
Heat shock protein 70 mRNA levels in mononuclear blood cells from patients with dementia of the Alzheimer type. Wakutani Y, et al. **Dementia** 1995 Nov–Dec;6(6):301–5
Diabetes mellitus and Alzheimer's disease: glycation as a biochemical link [letter] Smith MA, et al. **Diabetologia** 1996 Feb;39(2):247
The role of beta-amyloid in the development of Alzheimer's disease. Ii K. **Drugs Aging** 1995 Aug;7(2):97–109 (154 ref.)
The molecular significance of amyloid beta-peptide for Alzheimer's disease. Haass C. **Eur Arch Psychiatry Clin Neurosci** 1996;246(3):118–23 (54 ref.)
A beta A4 amyloid precursor protein gene and Alzheimer's disease. Hendriks L, et al. **Eur J Biochem** 1996 Apr 1; 237(1):6–15 (123 ref.)
Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Sticht H, et al. **Eur J Biochem** 1995 Oct 1; 233(1):293–8
Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Ge J, et al. **Eur J Pharmacol** 1996 Feb 22;297(3):299–306
Expression of the amyloid precursor protein of Alzheimer's disease on the surface of transfected HeLa cells. Culvenor JG, et al. **Exp Cell Res** 1995 Oct;220(2):474–81

(3H)hemicholinium-3 binding sites in postmortem brains of human patients with Alzheimer's disease and multi-infarct dementia. Krištofiková Z, et al. **Exp Gerontol** 1995 Mar-Apr;30(2):125-36

Localization and cell association of C1q in Alzheimer's disease brain. Afagh A, et al. **Exp Neurol** 1996 Mar; 138(1):22-32

Identification in immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's disease. Snow AD, et al. **Exp Neurol** 1996 Apr; 138(2):305-17

Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. Trojanowski JQ, et al. **FASEB J** 1995 Dec;9(15):1570-6 (77 ref.)

Characterization of human presenilin 1 using N-terminal specific monoclonal antibodies: Evidence that Alzheimer mutations affect proteolytic processing. Mercken M, et al. **FEBS Lett** 1996 Jul 8;389(3):297-303

A mechanism for beta-amyloid overproduction in Alzheimer's disease: precursor-independent generation of beta-amyloid via antisense RNA-primed mRNA synthesis. Volloch V. **FEBS Lett** 1996 Jul 22;390(2):124-8 (31 ref.)

AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal formation of patients with Alzheimer's disease. Ikonomovic MD, et al. **Hippocampus** 1995;5(5):469-86

Neurofibrillary pathology and aluminum in Alzheimer's disease. Shin RW, et al. **Histol Histopathol** 1995 Oct; 10(4):969-78 (168 ref.)

Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Mahley RW. **Isr J Med Sci** 1996 Jun;32(6):414-29 (72 ref.)

The regions of the Fe65 protein homologous to the phosphotyrosine interaction/phosphotyrosine binding domain of Shc bind the intracellular domain of the Alzheimer's amyloid precursor protein. Fiore F, et al. **J Biol Chem** 1995 Dec 29;270(52):30853-6

The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. Golabek AA, et al. **J Biol Chem** 1996 May 3;271(18):10602-6

Alzheimer's disease betaA4 protein release and amyloid precursor protein sorting are regulated by alternative splicing. Hartmann T, et al. **J Biol Chem** 1996 May 31; 271(22):13208-14

Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. Kuo YM, et al. **J Biol Chem** 1996 Feb 23;271(8):4077-81

Selective loss of cerebral keratan sulfate in Alzheimer's disease. Lindahl B, et al. **J Biol Chem** 1996 Jul 19; 271(29):16991-4

Intracellular accumulation of beta-amyloid in cells expressing the Swedish mutant amyloid precursor protein. Martin BL, et al. **J Biol Chem** 1995 Nov 10;270(45):26727-30

Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. Rockenstein EM, et al. **J Biol Chem** 1995 Nov 24;270(47):28257-67

Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein. Xu H, et al. **J Biol Chem** 1995 Oct 6;270(40):23243-5

Endothelin receptors in ischemic rat brain and Alzheimer brain. Kohzuki M, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S329-31

Combined study of cerebral glucose metabolism and [11C]methionine accumulation in probable Alzheimer's disease using positron emission tomography. Salmon E, et al. **J Cereb Blood Flow Metab** 1996 May;16(3):399-408

The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. Sramek JJ, et al. **J Clin Pharmacol** 1995 Aug;35(8):800-6

Complement C1q and C3 mRNA expression in the frontal cortex of Alzheimer's patients. Fischer B, et al. **J Mol Med** 1995 Sep;73(9):465-71

Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. West RL, et al. **J Mol Neurosci** 1995;6(2):141-6

Characterization of the high affinity heparin binding site of the Alzheimer's disease beta A4 amyloid precursor protein (APP) and its enhancement by zinc(II). Multhaup G, et al. **J Mol Recognit** 1995 Jul-Aug;8(4):247-57

kappa-1 Opioid receptors of the temporal cortex are preserved in Alzheimer's disease. Mackay KB, et al. **J Neural Transm Park Dis Dement Sect** 1994;7(1):73-9

Characterization of muscarinic acetylcholine receptors in cultured adult skin fibroblasts: effects of the Swedish Alzheimer's disease APP 670/671 mutation on binding levels. Vestling M, et al. **J Neural Transm Park Dis Dement Sect** 1995;10(1):1-10

Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. Checler F. **J Neurochem** 1995 Oct;65(4):1431-44 (101 ref.)

Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. Chen CP, et al. **J Neurochem** 1996 Apr;66(4):1592-8

Characterization of the glycolipid associated with Alzheimer paired helical filaments. Goux WJ, et al. **J Neurochem** 1996 Aug;67(2):723-33

Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. Harr SD, et al. **J Neurochem** 1996 Jun;66(6):2429-35

Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. Hensley K, et al. **J Neurochem** 1995 Nov;65(5):2146-56

Surface phosphorylation by ecto-protein kinase C in brain neurons: a target for Alzheimer's beta-amyloid peptides. Hogan MV, et al. **J Neurochem** 1995 Nov;65(5):2022-30

Neurotoxicity of a carboxyl-terminal fragment of the Alzheimer's amyloid precursor protein. Kim SH, et al. **J Neurochem** 1996 Sep;67(3):1172-82

Tau protein from Alzheimer's disease patients is glycated at its tubulin-binding domain. Ledesma MD, et al. **J Neurochem** 1995 Oct;65(4):1658-64

Detection and quantitation of perlecan mRNA levels in Alzheimer's disease and normal aged hippocampus by competitive reverse transcription-polymerase chain reaction. Maresh GA, et al. **J Neurochem** 1996 Sep; 67(3):1132-44

Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. Morrison LD, et al. **J Neurochem** 1996 Sep;67(3):1328-31

High-resolution separation of amyloid beta-peptides: structural variants present in Alzheimer's disease amyloid. Näslund J, et al. **J Neurochem** 1996 Jul;67(1):294-301

Affinity purification of proteoglycans that bind to the amyloid protein precursor of Alzheimer's disease. Williamson TG, et al. **J Neurochem** 1995 Nov;65(5):2201-8

The distribution and biochemical properties of a Cdc2-related kinase, KKIALRE, in normal and Alzheimer brains. Yen SH, et al. **J Neurochem** 1995 Dec;65(6):2577-84

Elemental imbalances in the olfactory pathway in Alzheimer's disease. Samudralwar DL, et al. **J Neurol Sci** 1995 Jun;130(2):139-45

Expression of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, in the central nervous system and in Alzheimer's disease. Christie RH, et al. **J Neuropathol Exp Neurol** 1996 Apr;55(4):491-8

Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. Hempen B, et al. **J Neuropathol Exp Neurol** 1996 Sep;55(9):964-72

Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease. Ladner CJ, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):783-9

Crosslinking of apolipoprotein E by products of lipid peroxidation. Montine TJ, et al. **J Neuropathol Exp Neurol** 1996 Feb;55(2):202-10

Neurofibrillary tangles in progressive supranuclear palsy contain the same tau epitopes identified in Alzheimer's disease PHFtau. Schmidt ML, et al. **J Neuropathol Exp Neurol** 1996 May;55(5):534-9

Immunolocalization and redistribution of the FAC1 protein in Alzheimer's disease. Schoonover S, et al. **J Neuropathol Exp Neurol** 1996 Apr;55(4):444-55

Catastrophe and Alzheimer's disease [letter] Larner AJ. **J R Coll Physicians Lond** 1995 Nov-Dec;29(6):549

Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Cummings BJ, et al. **Lancet** 1995 Dec 9;346(8989):1524-8

beta-Amyloid vasoactivity in Alzheimer's disease [letter] Gurwitz D. **Lancet** 1996 May 25;347(9013):1492

beta-Amyloid vasoactivity in Alzheimer's disease [letter] Kalaria RN, et al. **Lancet** 1996 May 25;347(9013):1492-3

Amyloidogenic processing of Alzheimer's amyloid precursor protein in vitro and its modulation by metal ions and tacrine. Chong YH, et al. **Life Sci** 1996;59(7):545-57

Posttranslational changes in band 3 in adult and aging brain following treatment with ergoloid mesylates, comparison to changes observed in Alzheimer's disease. Cover CC, et al. **Life Sci** 1996;58(8):655-64

Minireview. Galanin-acetylcholine interactions: relevance to memory and Alzheimer's disease. Crawley JN. **Life Sci** 1996;58(24):2185-99 (112 ref.)

Lymphocytes and neutrophils as peripheral models to study the effect of beta-amyloid on cellular calcium signalling in Alzheimer's disease. Eckert A, et al. **Life Sci** 1996; 59(5-6):499-510 (47 ref.)

Soluble beta-amyloid induces Alzheimer's disease features in human fibroblasts and in neuronal tissues. Etcheberrigaray R, et al. **Life Sci** 1996;59(5-6):491-8 (42 ref.)

Altered oxidation and signal transduction systems in fibroblasts from Alzheimer patients. Gibson G, et al. **Life Sci** 1996;59(5-6):477-89 (81 ref.)

Peripheral cells as an investigational tool for Alzheimer's disease. Govoni S, et al. **Life Sci** 1996;59(5-6):461-8 (68 ref.)

Neurotrophins and Alzheimer's disease: beyond the cholinergic neurons. Knusel B, et al. **Life Sci** 1996; 58(22):2019-27 (38 ref.)

Deleterious network hypothesis of Alzheimer's disease. Ying W. **Med Hypotheses** 1996 May;46(5):421-8

Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer's disease. Héroux M, et al. **Metab Brain Dis** 1996 Mar;11(1):81-8 (35 ref.)

Non-proline-dependent protein kinases phosphorylate several sites found in tau from Alzheimer disease brain. Singh TJ, et al. **Mol Cell Biochem** 1996 Jan 26; 154(2):143-51

Breakdown of membrane phospholipids in Alzheimer disease. Involvement of excitatory amino acid receptors. Farooqui AA, et al. **Mol Chem Neuropathol** 1995 Jun-Aug; 25(2-3):155-73 (94 ref.)

Inhibition of protein phosphatase 1 stimulates secretion of Alzheimer amyloid precursor protein. da Cruz e Silva EF, et al. **Mol Med** 1995 Jul;1(5):535-41

No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Ahlskog JE, et al. **Mov Disord** 1995 Sep;10(5):566-73

Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Alonso AC, et al. **Nat Med** 1996 Jul; 2(7):783-7

Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Kovacs DM, et al. **Nat Med** 1996 Feb; 2(2):224-9

Alzheimer's amyloid of another flavour [comment] Selkoe DJ. **Nat Med** 1995 Oct;1(10):998-9. Comment on: Nat Med 1995 Oct;1(10):1062-6.

Tau protein directly interacts with the amyloid beta-protein precursor: implications for Alzheimer's disease. Smith MA, et al. **Nat Med** 1995 Apr;1(4):365-9

Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease [see comments] Wang JZ, et al. **Nat Med** 1996 Aug; 2(8):871-5. Comment in: Nat Med 1996 Aug;2(8):850-2.

Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Yan SD, et al. **Nat Med** 1995 Jul;1(7):693-9

GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease [see comments] Yanagisawa K, et al. **Nat Med** 1995 Oct; 1(10):1062-6. Comment in: Nat Med 1995 Oct;1(10):998-9.

A specific structural interaction of Alzheimer's peptide A beta 1-42 with alpha 1-antichymotrypsin [letter] Janciauskiene S, et al. **Nat Struct Biol** 1996 Aug;3(8):668-71

Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease [see comments] Behan DP, et al. **Nature** 1995 Nov 16;378(6554):284-7. Comment in: Nature 1995 Nov 16;378(6554):233-4.

Alzheimer's disease. Amyloid ox-tox transducers [news; comment] Mattson MP, et al. **Nature** 1996 Aug 22; 382(6593):674-5. Comment on: Nature 1996 Aug 22;382(6593):685-91. Comment on: Nature 1996 Aug 22;382(6593):716-9.

Alzheimer's disease. A radical vascular connection [news; comment] Stamler JS. **Nature** 1996 Mar 14; 380(6570):108-11. Comment on: Nature 1996 Mar 14;380(6570):168-71.

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease [see comments] Yan SD, et al. **Nature** 1996 Aug 22;382(6593):685-91. Comment in: Nature 1996 Aug 22;382(6593):674.

Expression of APP in transgenic mice: a comparison of neuron-specific promoters. Andrä K, et al. **Neurobiol Aging** 1996 Mar-Apr;17(2):183-90

Are reactive oxygen species involved in Alzheimer's disease? [see comments] Benzi G, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):661-74 (201 ref.). Comment in: Neurobiol Aging 1995 Jul-Aug;16(4):675-8. Comment in: Neurobiol Aging 1995 Jul-Aug;16(4):667-82; discussion 683. Comment in: Neurobiol Aging 1995 Jul-Aug;16(4):679-82; discussion 683.

Presence of tau in isolated nuclei from human brain. Brady RM, et al. **Neurobiol Aging** 1995 May-Jun;16(3):479-86

Oxidative stress and Alzheimer's disease [comment] Choi BH. **Neurobiol Aging** 1995 Jul-Aug;16(4):675-8 (49 ref.). Comment on: Neurobiol Aging 1995 Jul-Aug;16(4):661-74.

Increased proteolytic activity in lymphocytes from patients with early onset Alzheimer's disease. Karlsson JO, et al. **Neurobiol Aging** 1995 Nov-Dec;16(6):901-6

Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Klunk WE, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):541-8

Examination of phosphorylated tau protein as a PHF-precursor at early stage Alzheimer's disease. Lai RY, et al. **Neurobiol Aging** 1995 May-Jun;16(3):433-45

Isolation of a phosphorylated soluble tau fraction from Alzheimer's disease brain. Ledesma MD, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):515-22

Effects of postmortem interval, age, and Alzheimer's disease on G-proteins in human brain. Li X, et al. **Neurobiol Aging** 1996 Jan-Feb;17(1):115-22

Rational design of an animal model for Alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent. Loring JF, et al. **Neurobiol Aging** 1996 Mar-Apr;17(2):173-82

PDGF is associated with neuronal and glial alterations of Alzheimer's disease. Masliah E, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):549-56

Membrane interactions of a phosphomonoester elevated early in Alzheimer's disease. Mason RP, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):531-9

Free radicals and disruption of neuronal ion homeostasis in AD: a role for amyloid beta-peptide? [comment] Mattson MP. **Neurobiol Aging** 1995 Jul-Aug;16(4):679-82; discussion 683 (40 ref.). Comment on: Neurobiol Aging 1995 Jul-Aug;16(4):661-74.

Hyperphosphorylation of tau in PHF.

Morishima-Kawashima M, et al. **Neurobiol Aging** 1995 May-Jun;16(3):365-71; discussion 371-80 (56 ref.)

Expression of the protooncogene bcl-2 in Alzheimer's disease brain. O'Barr S, et al. **Neurobiol Aging** 1996 Jan-Feb; 17(1):131-6

SCG10, a neuron-specific growth-associated protein in Alzheimer's disease. Okazaki T, et al. **Neurobiol Aging** 1995 Nov-Dec;16(6):883-94

Quantitative analysis of tau protein in paired helical filament preparations: implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease. Wischik CM, et al. **Neurobiol Aging** 1995 May-Jun; 16(3):409-17; discussion 418-31

VIP neurons in the human SCN in relation to sex, age, and Alzheimer's disease. Zhou JN, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):571-6

Carnitine, carnitine acetyltransferase, and glutathione in Alzheimer brain. Makar TK, et al. **Neurochem Res** 1995 Jun;20(6):705-11

Neural membrane phospholipids in Alzheimer disease. Wells K, et al. **Neurochem Res** 1995 Nov;20(11):1329-33

A comparison of beta-amyloid deposition in the medial temporal lobe in sporadic Alzheimer's disease, Down's syndrome and normal elderly brains. Armstrong RA, et al. **Neurodegeneration** 1996 Mar;5(1):35-41

Acetylcholine muscarinic M2 receptor stimulated [35S]GTP gamma S binding shows regional selective changes in Alzheimer's disease postmortem brain. Cowburn RF, et al. **Neurodegeneration** 1996 Mar;5(1):19-26

Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly. Zhan SS, et al. **Neurodegeneration** 1995 Sep;4(3):291-7

Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Morris JC, et al. **Neurology** 1996 Mar; 46(3):707-19

Microglial interleukin-1 alpha expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution. Sheng JG, et al.
Neuropathol Appl Neurobiol 1995 Aug;21(4):290-301

Induction of p21ras in Alzheimer pathology. Gärtner U, et al. **Neuroreport** 1995 Jul 10;6(10):1441-4

beta-Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for Alzheimer's disease. Harris ME, et al. **Neuroreport** 1995 Oct 2;6(14):1875-9

Two actin binding proteins, actin depolymerizing factor and cofilin, are associated with Hirano bodies. Maciver SK, et al. **Neuroreport** 1995 Oct 23;6(15):1985-8

Experimental deposition of Alzheimer amyloid beta-protein in canine leptomeningeal vessels. Prior R, et al.
Neuroreport 1995 Sep 11;6(13):1747-51

Amyloidosis, advanced glycation end products and Alzheimer disease [letter; comment] Smith MA, et al. **Neuroreport** 1995 Aug 21;6(12):1595-6. Comment on: Neuroreport 1995 Apr 19;6(6):866-8.

Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Warpman U, et al. **Neuroreport** 1995 Nov 27;6(17):2419-23

Granules in glial cells of patients with Alzheimer's disease are immunopositive for C-terminal sequences of beta-amyloid protein. Akiyama H, et al. **Neurosci Lett** 1996 Mar 15;206(2-3):169-72

Defective phorbol ester-stimulated secretion of beta-amyloid precursor protein from Alzheimer's disease fibroblasts. Bergamaschi S, et al. **Neurosci Lett** 1995 Dec 1;201(1):1-5

K+ currents of human T-lymphocytes are unaffected by Alzheimer's disease and amyloid beta protein. Cohen CD, et al. **Neurosci Lett** 1996 Jan 5;202(3):177-80

Assembly of Alzheimer-like, insoluble filaments from brain cerebrosides. Goux WJ, et al. **Neurosci Lett** 1995 Jun 16; 192(3):149-52

Brain polyamine levels are altered in Alzheimer's disease. Morrison LD, et al. **Neurosci Lett** 1995 Sep 1;197(1):5-8

Decreased protein synthetic activity of the hypothalamic tuberomamillary nucleus in Alzheimer's disease as suggested by smaller Golgi apparatus. Salehi A, et al.
Neurosci Lett 1995 Jun 23;193(1):29-32

Apolipoprotein E (APOE) allele frequencies in late-onset sporadic Alzheimer's disease (AD), mixed dementia and vascular dementia: lack of association of epsilon 4 allele with AD in Italian octogenarian patients. Scacchi R, et al. **Neurosci Lett** 1995 Dec 15;201(3):231-4

Polyamines in frontal cortex of patients with Down syndrome and Alzheimer disease. Seidl R, et al. **Neurosci Lett** 1996 Mar 15;206(2-3):193-5

Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Storga D, et al. **Neurosci Lett** 1996 Jan 12;203(1):29-32

ApoE immunoreactivity and microglial cells in Alzheimer's disease brain. Uchihara T, et al. **Neurosci Lett** 1995 Jul 28;195(1):5-8

Free radical formation in autopsy samples of Alzheimer and control cortex. Zhou Y, et al. **Neurosci Lett** 1995 Aug 4; 195(2):89-92

Site-specific regulation of Alzheimer-like tau phosphorylation in living neurons. Burack MA, et al. **Neuroscience** 1996 May;72(1):167-84

Reduced beta-amyloid response in lymphocytes of patients with Alzheimer's disease. Bondy B, et al.
Pharmacopsychiatry 1995 Jul;28(4):143-6

A model for beta-amyloid aggregation and neurotoxicity based on the free radical generating capacity of the peptide: implications of "molecular shrapnel" for Alzheimer's disease. Hensley K, et al. **Proc West Pharmacol Soc** 1995; 38:113-20

Screening for mutations at codon 717 of the amyloid precursor protein gene in Alzheimer's disease. Dai XY, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):175-8

Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Pollock BG, et al.
Psychopharmacol Bull 1995;31(2):327-31

Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study. Sunderland T, et al.
Psychopharmacology (Berl) 1995 Sep;121(2):231-41

H-1 MR spectroscopic imaging of white matter signal hyperintensities: Alzheimer disease and ischemic vascular dementia. Constans JM, et al. **Radiology** 1995 Nov; 197(2):517-23

The amyloid peptide and its precursor in Alzheimer's disease. Octave JN. **Rev Neurosci** 1995 Oct-Dec;6(4):287-316 (289 ref.)

Neuropeptide changes in cortical and deep gray structures in Alzheimer's disease. Roeske LC, et al. **Rev Neurosci** 1995 Oct-Dec;6(4):317-28 (156 ref.)

The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Multhaup G, et al. **Science** 1996 Mar 8;271(5254):1406-9

Misfolding the way to disease [news] Taubes G. **Science** 1996 Mar 15;271(5255):1493-5

Membrane alterations in Alzheimer's disease and aging [letter; comment] Cowburn RF, et al. **Trends Neurosci** 1995 Nov;18(11):483-4. Comment on: Trends Neurosci 1995 May;18(5):203-6.

[Alzheimer disease: hypotheses implicating apolipoproteins E] Blain H, et al. **Presse Med** 1996 May 4-11;25(16):763-8 (35 ref.) (Eng. Abstr.) **(Fre)**

[1H-MR spectroscopic imaging in patients with clinically diagnosed Alzheimer's disease] Block W, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995 Sep;163(3):230-7 (Eng. Abstr.) **(Ger)**

[Abnormality of cytoskeletons and their phosphorylation in Alzheimer's disease] Nakamura Y, et al. **Seikagaku** 1996 Feb;68(2):133-6 (25 ref.) **(Jpn)**

[Lipid metabolism parameters in patients with multi-infarct dementia and Alzheimer's type dementia] Sygitowicz G, et al. **Neurol Neurochir Pol** 1996 Mar-Apr;30(2):213-9; quiz 220 (Eng. Abstr.) **(Pol)**

[The neurochemical aspects of Alzheimer's disease] Almeida R, et al. **Acta Med Port** 1995 Oct;8(10):567-72 (46 ref.) (Eng. Abstr.) **(Por)**

[Protein phosphorylation in the normal nervous system and in Alzheimer's disease] Burbaeva GSh, et al.
Vestn Ross Akad Med Nauk 1996;(4):13-8 (43 ref.) (Eng. Abstr.) **(Rus)**

MORTALITY

Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991. Schulte PA, et al. **Am J Public Health** 1996 Sep;86(9):1281-8

Cause of death in Alzheimer's disease. Beard CM, et al.
Ann Epidemiol 1996 May;6(3):195-200

NURSING

Reaching consensus: the process of recommending treatment decisions for Alzheimer's patients. Hurley AC, et al.
ANS Adv Nurs Sci 1995 Dec;18(2):33-43

Kitwood's approach to dementia and dementia care: a critical but appreciative review. Adams T. **J Adv Nurs** 1996 May; 23(5):948-53 (32 ref.)

Caring for a parent with Alzheimer's disease: process of daughter caregiver stress. McCarty EF. **J Adv Nurs** 1996 Apr;23(4):792-803

Reminiscence. A supportive intervention for the person with Alzheimer's disease. Rentz CA.
J Psychosoc Nurs Ment Health Serv 1995 Nov;33(11):15-20

ComputerLink: the impact of a computer network on Alzheimer's caregivers' decision-making confidence and skill. Casper GR, et al. **Medinfo** 1995;8 Pt 2:1546

PATHOLOGY

The neurobiology of Alzheimer's disease. Brion JP.
Acta Clin Belg 1996;51(2):80-90 (76 ref.)

Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Claudio L.
Acta Neuropathol (Berl) 1996;91(1):6-14

Diagnostic accuracy of Alzheimer's disease: a clinicopathological study. Jellinger KA.
Acta Neuropathol (Berl) 1996;91(2):219-20

Lack of topographical relationship between sites of aluminum deposition and senile plaques in the Alzheimer's disease brain. Kasa P, et al. **Acta Neuropathol (Berl)** 1995; 90(5):526-31

Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Kosunen O, et al.
Acta Neuropathol (Berl) 1996;91(2):185-93

Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Mielke R, et al.
Acta Neuropathol (Berl) 1996;91(2):174-9

Alzheimer's disease-type neurofibrillary degeneration in verrucose dysplasias of the cerebral cortex. Morán MA, et al. **Acta Neuropathol (Berl)** 1995;90(4):356-65

Alzheimer paired helical filaments: a comparison with the twisted ribbon model. Pollanen MS, et al.
Acta Neuropathol (Berl) 1995;90(2):194-7

Plasma membrane fragility in dystrophic neurites in senile plaques of Alzheimer's disease: an index of oxidative stress. Praprotnik D, et al. **Acta Neuropathol (Berl)** 1996;91(1):1-5

White matter amyloid in Alzheimer's disease brain. Uchihara T, et al. **Acta Neuropathol (Berl)** 1995;90(1):51-6

Autopsy survey for Alzheimer's disease in Nigerian Africans: a preliminary report. Osuntokun BO, et al.
Afr J Med Med Sci 1995 Mar;24(1):75-9

Autopsy practices at CERAD and Alzheimer disease center sites: a survey of neuropathologists. Cochran EJ, et al.
Alzheimer Dis Assoc Disord 1995 Winter;9(4):203-7

Cholinesterases and the pathology of Alzheimer disease. Geula C, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:23-8

Clinicopathologic study of probable Alzheimer disease: assessment of criteria for excluding cerebrovascular disease. Sevush S, et al. **Alzheimer Dis Assoc Disord** 1995 Winter; 9(4):208-12

Evidence of neuronal oxidative damage in Alzheimer's disease. Good PF, et al. **Am J Pathol** 1996 Jul;149(1):21-8

P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Higgins LS, et al. **Am J Pathol** 1996 Aug; 149(2):585-96

Ultrastructural instability of paired helical filaments from corticobasal degeneration as examined by scanning transmission electron microscopy. Ksiezak-Reding H, et al. **Am J Pathol** 1996 Aug;149(2):639-51

Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Mann DM, et al. **Am J Pathol** 1996 Apr;148(4):1257-66

In Alzheimer's disease the Golgi apparatus of a population of neurons without neurofibrillary tangles is fragmented and atrophic [see comments] Stieber A, et al.
Am J Pathol 1996 Feb;148(2):415-26. Comment in: Am J Pathol 1996 Feb;148(2):355-60.

Multicenter clinicopathological correlation in dementia. Victoroff J, et al. **Am J Psychiatry** 1995 Oct; 152(10):1476-84

Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Beffert U, et al.
Ann N Y Acad Sci 1996 Jan 17;777:166-74

Atrophy of the hippocampal formation in early familial Alzheimer's disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. Fox NC, et al.
Ann N Y Acad Sci 1996 Jan 17;777:226-32

Immortalized neural cells from trisomy 16 mice as models for Alzheimer's disease. Frederiksen K, et al.
Ann N Y Acad Sci 1996 Jan 17;777:415-20

Tau protein and the neurofibrillary pathology of Alzheimer's disease. Goedert M. **Ann N Y Acad Sci** 1996 Jan 17; 777:121-31 (26 ref.)

A hypothesis on the pathogenesis of Alzheimer's disease. Harman D. **Ann N Y Acad Sci** 1996 Jun 15;786:152-68 (100 ref.)

Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques. Hüll M, et al.
Ann N Y Acad Sci 1996 Jan 17;777:205-12

Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention. Iqbal K, et al.
Ann N Y Acad Sci 1996 Jan 17;777:132-8 (22 ref.)

Apolipoprotein E polymorphism is associated with both senile plaque load and Alzheimer-type neurofibrillary tangle formation. März W, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:276-80

Amyloid beta-protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Van Nostrand WE, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:297-302 (19 ref.)

Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Gomez-Isla T, et al.
Ann Neurol 1996 Jan;39(1):62-70

Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). Mann DM, et al. **Ann Neurol** 1996 Aug; 40(2):149-56

Incorrect diagnosis of Alzheimer's disease. A clinicopathologic study. Klatka LA, et al. **Arch Neurol** 1996 Jan;53(1):35-42 (57 ref.)

Association of dementia severity with cortical gray matter and abnormal white matter volumes in dementia of the Alzheimer type. Stout JC, et al. **Arch Neurol** 1996 Aug; 53(8):742-9

Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease. Victoroff J, et al. **Arch Neurol** 1996 May;53(5):428-34

Making the diagnosis of mixed and non-Alzheimer's dementias. Hansen LA, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1023-31 (34 ref.)

Amyloid beta 1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs. Wisniewski T, et al.
Biochem J 1996 Jan 15;313 (Pt 2):575-80

Brain atrophy in normal ageing and Alzheimer's disease. Volumetric discrimination and clinical correlations. Förstl H, et al. **Br J Psychiatry** 1995 Dec;167(6):739-46

Amyloid beta-protein ending at Thr43 is a minor component of some diffuse plaques in the Alzheimer's disease brain, but is not found in cerebrovascular amyloid. Iizuka T, et al. **Brain Res** 1995 Dec 8;702(1-2):275-8

Microdensitometric measures of cytoplasmic RNA and total protein in pyramidal neurons of the insular cortex and midfrontal gyrus in patients with Alzheimer's disease. Colurso GJ, et al. **Cell Biochem Funct** 1995 Dec; 13(4):287-92

Severe cardiovascular disease and Alzheimer's disease: senile plaque formation in cortical areas. Soneira CF, et al. **Clin Anat** 1996;9(2):118-27

Alzheimer's disease and Alzheimer-type of cerebral degenerations in Chinese. Ng HK. **Clin Exp Neurol** 1994; 31:85-98

The cortical neuritic dystrophy of Alzheimer's disease: nature, significance, and possible pathogenesis. Larner AJ. **Dementia** 1995 Jul-Aug;6(4):218-24 (84 ref.)

Electroencephalographic correlates of periventricular white matter lesions in probable Alzheimer's disease. Lopez OL, et al. **Dementia** 1995 Nov-Dec;6(6):343-7

Inflammatory mechanisms in Alzheimer's disease. Hüll M, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(3):124-8 (36 ref.)

Neurofibrillary pathology and aluminum in Alzheimer's disease. Shin RW, et al. **Histol Histopathol** 1995 Oct; 10(4):969-78 (168 ref.)

Autoimmune alterations in choroid plexus basement membrane of some patients with Alzheimer's disease [letter; comment] Cserni G. **Hum Pathol** 1995 Oct;26(10):1168-9 . Comment on: Hum Pathol 1994 Nov;25(11):1185-90.

Multiscale detection and analysis of the senile plaques of Alzheimer's disease. Hibbard LS, et al. **IEEE Trans Biomed Eng** 1995 Dec;42(12):1218-25

Hippocampal and neocortical involvement in normal brain aging and dementia: morphological and neurochemical profile of the vulnerable circuits. Hof PR, et al. **J Am Geriatr Soc** 1996 Jul;44(7):857-64 (83 ref.)

Atrophy of the corpus callosum in Alzheimer's disease versus healthy aging. Janowsky JS, et al. **J Am Geriatr Soc** 1996 Jul;44(7):798-803

Temporal progression of hippocampal atrophy and apolipoprotein E gene in Alzheimer's disease [letter] Yamaguchi S, et al. **J Am Geriatr Soc** 1996 Feb;44(2):216-7

Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. Roher AE, et al. **J Biol Chem** 1996 Aug 23; 271(34):20631-5

Mitotic mechanisms in Alzheimer's disease? Vincent I, et al. **J Cell Biol** 1996 Feb;132(3):413-25

Perivascular nerves of the human basal cerebral arteries: II. Changes in aging and Alzheimer's disease. Bleys RL, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):1048-57

Entorhinal cortex modules of the human brain. Solodkin A, et al. **J Comp Neurol** 1996 Feb 19;365(4):610-7

Methodological problems and clinical relevance of structural neuroimaging in dementia research. Lang CJ. **J Neural Transm Gen Sect** 1995;99(1-3):131-43 (45 ref.)

Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. Hensley K, et al. **J Neurochem** 1995 Nov;65(5):2146-56

Alzheimer-type pathology in melanin-bleached sections of substantia nigra. Uchihara T, et al. **J Neurol** 1995 Aug; 242(8):485-9

Alzheimer's disease in a case of cortical basal ganglionic degeneration with severe dementia [letter] Eberhard DA, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):109-10

Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease. Hely MA, et al. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):531-8

Some unusual responses of astrocytes to ghost tangles in a long duration case of juvenile Alzheimer's disease: an electron microscopic study. Nakano I, et al. **J Neurol Sci** 1996 Mar;136(1-2):41-6

Free radical damage, iron, and Alzheimer's disease. Smith MA, et al. **J Neurol Sci** 1995 Dec;134 Suppl:92-4 (21 ref.)

Regional variation in the distribution of apolipoprotein E and A beta in Alzheimer's disease. Gearing M, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):833-41

Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: implications for Alzheimer's disease. Metzger RE, et al. **J Neuropathol Exp Neurol** 1996 Mar; 55(3):372-80

Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. Mrak RE, et al. **J Neuropathol Exp Neurol** 1996 Mar;55(3):273-9

Differential expression of TGF-beta 1, 2 and 3 isotypes in Alzheimer's disease: a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. Peress NS, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):802-11

Microglia are not exclusively associated with plaque-rich regions of the dentate gyrus in Alzheimer's disease. Roe MT, et al. **J Neuropathol Exp Neurol** 1996 Mar;55(3):366-71

Two types of senile plaque [letter; comment] Rosenblum WI. **J Neuropathol Exp Neurol** 1996 Jan;55(1):131-2. Comment on: J Neuropathol Exp Neurol 1995 Jul;54(4):548-56.

Neocortical lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. Samuel W, et al. **J Neuropathol Exp Neurol** 1996 Jan;55(1):44-52

Immunolocalization and redistribution of the FAC1 protein in Alzheimer's disease. Schoonover S, et al. **J Neuropathol Exp Neurol** 1996 Apr;55(4):444-55

Cerebral magnetic resonance imaging compared in Alzheimer's and multi-infarct dementia. Reed KM, et al. **J Neuropsychiatry Clin Neurosci** 1991 Winter;3(1):51-7

Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. Gómez-Isla T, et al. **J Neurosci** 1996 Jul 15;16(14):4491-500

Contingent vulnerability of entorhinal parvalbumin-containing neurons in Alzheimer's disease. Solodkin A, et al. **J Neurosci** 1996 May 15;16(10):3311-21

Lewy body pathology and heterogeneity of Alzheimer's disease [letter] Liberini P, et al. **JAMA** 1995 Oct 18; 274(15):1199

Hair abnormalities in Alzheimer's disease [letter] Bruno G, et al. **Lancet** 1996 Mar 30;347(9005):901

Visualisation and quantification of rates of atrophy in Alzheimer's disease. Fox NC, et al. **Lancet** 1996 Jul 13; 348(9020):94-7

S182 protein in Alzheimer's disease neuritic plaques [letter] Wisniewski T, et al. **Lancet** 1995 Nov 18;346(8986):1366

Temporal bone findings in Alzheimer's disease. Sinha UK, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):1-5

Peripheral cells as an investigational tool for Alzheimer's disease. Govoni S, et al. **Life Sci** 1996;59(5-6):461-8 (68 ref.)

Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer's disease. Hayn M, et al. **Life Sci** 1996; 59(7):537-44

Localisation and association of pathomorphological changes at the brainstem in Alzheimer's disease. Giess R, et al. **Mech Ageing Dev** 1995 Oct 27;84(3):209-26

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Blennow K, et al. **Mol Chem Neuropathol** 1995 Dec;26(3):231-45

Oxidative damage in Alzheimer's [letter] Smith MA, et al. **Nature** 1996 Jul 11;382(6587):120-1

Staging of Alzheimer's disease-related neurofibrillary changes. Braak H, et al. **Neurobiol Aging** 1995 May-Jun; 16(3):271-8; discussion 278-84 (45 ref.)

Neurons bearing neurofibrillary tangles are responsible for selected synaptic deficits in Alzheimer's disease. Callahan LM, et al. **Neurobiol Aging** 1995 May-Jun;16(3):311-4

Correlations of synaptic and pathological markers with cognition of the elderly. Dickson DW, et al. **Neurobiol Aging** 1995 May-Jun;16(3):285-98; discussion 298-304

Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer's disease. Dournaud P, et al. **Neurobiol Aging** 1995 Sep-Oct; 16(5):817-23

Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits. Frautschy SA, et al. **Neurobiol Aging** 1996 Mar-Apr;17(2):311-21

APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Greenberg BD, et al. **Neurobiol Aging** 1996 Mar-Apr; 17(2):153-71 (323 ref.)

Role of microglia in senile plaque formation. Mackenzie IR, et al. **Neurobiol Aging** 1995 Sep-Oct;16(5):797-804

Relationship between plaques, tangles, and dystrophic processes in Alzheimer's disease. Trojanowski JQ, et al. **Neurobiol Aging** 1995 May-Jun;16(3):335-40; discussion 341-5 (47 ref.)

The older rabbit as an animal model: implications for Alzheimer's disease. Woodruff-Pak DS, et al. **Neurobiol Aging** 1996 Mar-Apr;17(2):283-90 (87 ref.)

Deposits of A beta fibrils are not toxic to cortical and hippocampal neurons in vitro. Wujek JR, et al. **Neurobiol Aging** 1996 Jan-Feb;17(1):107-13

Alzheimer neurofibrillary lesions: molecular nature and potential roles of different components. Yen SH, et al. **Neurobiol Aging** 1995 May-Jun;16(3):381-7 (92 ref.)

Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Cummings BJ, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):11-23

Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. Benjamin R, et al. **Neurodegeneration** 1995 Dec;4(4):443-8

Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer's disease and in frontal lobe degeneration. Brun A, et al. **Neurodegeneration** 1995 Jun; 4(2):171-7

Association of A beta 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. Fukumoto H, et al. **Neurodegeneration** 1996 Mar;5(1):13-7

Microwave treatment enhances the immunostaining of amyloid deposits in both the transmissible and non-transmissible brain amyloidoses. Liberski PP, et al. **Neurodegeneration** 1996 Mar;5(1):95-9

Dystrophic neurites define diffuse as well as core-containing senile plaques in Alzheimer's disease [letter] Rifenburg RP, et al. **Neurodegeneration** 1995 Jun;4(2):235-7

A functional role for corpora amylacea based on evidence from complement studies. Singhrao SK, et al. **Neurodegeneration** 1995 Sep;4(3):335-45

The consortium to establish a registry for Alzheimer's Disease (CERAD). Part XIII. Obtaining autopsy in Alzheimer's disease. Fillenbaum GG, et al. **Neurology** 1996 Jan;46(1):142-5

Low body weight in Alzheimer's disease is associated with mesial temporal cortex atrophy. Grundman M, et al. **Neurology** 1996 Jun;46(6):1585-91

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IX. A prospective cliniconeuropathologic study of Parkinson's features in Alzheimer's disease. Hulette C, et al. **Neurology** 1995 Nov; 45(11):1991-5

Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study. Laakso MP, et al. **Neurology** 1996 Mar;46(3):678-81

Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Lippa CF, et al. **Neurology** 1996 Feb;46(2):406-12

Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. McLachlan DR, et al. **Neurology** 1996 Feb;46(2):401-5

Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Morris JC, et al. **Neurology** 1996 Mar; 46(3):707-19

Severity of hippocampal atrophy correlates with the prolongation of MRI T2 relaxation time in temporal lobe epilepsy but not in Alzheimer's disease. Pitkänen A, et al. **Neurology** 1996 Jun;46(6):1724-30

Mechanisms of neuronal degeneration in Alzheimer's disease. Yankner BA. **Neuron** 1996 May;16(5):921-32 (172 ref.)

Pathology of subcortical visual centres in relation to cortical degeneration in Alzheimer's disease. Leuba G, et al. **Neuropathol Appl Neurobiol** 1995 Oct;21(5):410-22

Microglial interleukin-1 alpha expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution. Sheng JG, et al. **Neuropathol Appl Neurobiol** 1995 Aug;21(4):290-301

Serum zinc, senile plaques, and neurofibrillary tangles: findings from the Nun Study. Tully CL, et al. **Neuroreport** 1995 Nov 13;6(16):2105-8

Hippocampal mossy fibers in Alzheimer's disease. Kiktenko AI, et al. **Neurosci Behav Physiol** 1996 Jan-Feb;26(1):1-5

Is the clustering of beta-amyloid (A beta) deposits in the frontal cortex of Alzheimer patients determined by blood vessels? Armstrong RA. **Neurosci Lett** 1995 Aug 4; 195(2):121-4

Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer's disease. Fukutani Y, et al. **Neurosci Lett** 1995 Nov 10;200(1):57-60

Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Layfield R, et al. **Neurosci Lett** 1996 May 3;209(1):57-60

Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Lehtovirta M, et al. **Neuroscience** 1995 Jul; 67(1):65-72

Histopathology of the substantia nigra in Alzheimer's disease. Reyes MG, et al. **Panminerva Med** 1996 Mar;38(1):8-14

Cortical mapping of Alzheimer pathology in brains of aged non-demented subjects. Vermersch P, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Oct; 19(6):1035-47

Transgenic mice and modeling Alzheimer's disease. Higgins LS, et al. **Rev Neurosci** 1995 Apr-Jun;6(2):87-96 (91 ref.)

The morphologic and neurochemical basis of dementia: aging, hierarchical patterns of lesion distribution and vulnerable neuronal phenotype. Hof PR, et al. **Rev Neurosci** 1995 Apr-Jun;6(2):97-124

GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil. Marczynski TJ. **Rev Neurosci** 1995 Jul-Sep;6(3):221-58 (164 ref.)

PHYSIOPATHOLOGY

Improved detection of auditory P3 abnormality in dementia using a variety of stimuli. Attias J, et al. **Acta Neurol Scand** 1995 Jul;92(1):96-101

Unilateral spatial neglect in Alzheimer's disease. A line bisection study. Ishiai S, et al. **Acta Neurol Scand** 1996 Feb-Mar;93(2-3):219-24

Primitive reflexes and dementia: results from the Canadian Study of Health and Aging. Hogan DB, et al. **Age Ageing** 1995 Sep;24(5):375-81

Orthostasis in Alzheimer disease: a retrospective analysis. Jhee SS, et al. **Alzheimer Dis Assoc Disord** 1995 Winter; 9(4):243-6

Alzheimer disease, attention, and the cholinergic system. Lawrence AD, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:43-9

Visual-spatial deficits expalin visual symptoms in Alzheimer's disease. Butter CM, et al. **Am J Ophthalmol** 1996 Jul; 122(1):97-105

Visual cortical dysfunction in Alzheimer's disease evaluated with a temporally graded "stress test" during PET. Mentis MJ, et al. **Am J Psychiatry** 1996 Jan;153(1):32-40

Apolipoprotein E, synaptic plasticity and Alzheimer's disease. Poirier J, et al. **Ann Med** 1995 Dec;27(6):663-70 (89 ref.)

The Neurobiology of Alzheimer's Disease. Proceedings of a meeting. Zurich, Switzerland, February 17-19, 1995. **Ann N Y Acad Sci** 1996 Jan 17;777:1-439

Alterations in functional neuroanatomical connectivity in Alzheimer's disease. Positron emission tomography of auditory verbal short-term memory. Becker JT, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:239–42

Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Beffert U, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:166–74

Dual-task paradigm: a means to examine the central executive. Della Sala S, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:161–71

Receptor-effector coupling dysfunctions in Alzheimer's disease. Fowler CJ, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:294–304 (72 ref.)

Tau protein and the neurofibrillary pathology of Alzheimer's disease. Goedert M. **Ann N Y Acad Sci** 1996 Jan 17; 777:121–31 (26 ref.)

Amyloid fibril toxicity in Alzheimer's disease and diabetes. Lorenzo A, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:89–95 (12 ref.)

Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease. Mahley RW, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:139–45 (24 ref.)

Molecular membrane interactions of a phospholipid metabolite. Implications for Alzheimer's disease pathophysiology. Mason RP, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:368–73

Topography of the maximum of the amplitude of EEG frequency bands in dementia of the Alzheimer type. Ihl R, et al. **Biol Psychiatry** 1996 Mar 1;39(5):319–25

Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease. Lawlor BA, et al. **Biol Psychiatry** 1995 Aug 1;38(3):185–8

Longitudinal visual evoked potentials in Alzheimer's disease: a preliminary report. Swanwick GR, et al. **Biol Psychiatry** 1996 Mar 15;39(6):455–7

Category and attribute knowledge deterioration in Alzheimer's disease. Cox DM, et al. **Brain Lang** 1996 Mar; 52(3):536–50

Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Ginsberg L, et al. **Brain Res** 1995 Nov 6;698(1–2):223–6

Neurodegeneration mediated by glutamate and beta-amyloid peptide: a comparison and possible interaction. Gray CW, et al. **Brain Res** 1995 Sep 11;691(1–2):169–79

Lesion with the neurotoxin AF64A alters hippocampal cholinergic receptor function. Thorne B, et al. **Brain Res Bull** 1995;38(2):121–7

Scalp topography of SEP late components in patients with supra-tentorial lesions. Yuya H, et al. **Brain Topogr** 1996 Spring;8(3):333–6

Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Pollard HB, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):513–26 (67 ref.)

The semantic memory impairment of Alzheimer's disease: category-specific? Tippett LJ, et al. **Cortex** 1996 Mar; 32(1):143–53

Electroencephalographic correlates of periventricular white matter lesions in probable Alzheimer's disease. Lopez OL, et al. **Dementia** 1995 Nov–Dec;6(6):343–7

Eye movement dysfunction in dementia of the Alzheimer type. Moser A, et al. **Dementia** 1995 Sep–Oct;6(5):264–8

Effect of seizures on progression of dementia of the Alzheimer type. Volicer L, et al. **Dementia** 1995 Sep–Oct; 6(5):258–63

Prognostic significance of quantitative electroencephalography in Alzheimer patients: preliminary observations. Rodriguez G, et al. **Electroencephalogr Clin Neurophysiol** 1996 Aug;99(2):123–8

Distribution of event-related potentials in patients with dementia. Yokoyama Y, et al. **Electromyogr Clin Neurophysiol** 1995 Nov;35(7):431–7

Of mind and matter—or what really matters in Alzheimer's disease? Neurobiological substrates of clinical deficits in Alzheimer's disease. Förstl H. **Eur Arch Psychiatry Clin Neurosci** 1996;246(3):116–7

Overexpression of amyloid precursor protein of Alzheimer's type in brains of intoxicated children. Maślińska D, et al. **Folia Neuropathol** 1995;33(3):129–33

Differential involvement of phospholipase C isozymes in Alzheimer's disease. Shimohama S, et al. **Gerontology** 1995; 41 Suppl 1:13–9

Dysfunction of visual cortex contributes to disturbed processing of visual information in Alzheimer's disease. Mielke R, et al. **Int J Neurosci** 1995 May;82(1–2):1–9

Oral temperature change and cognitive decline in Alzheimer's patients [letter] Collins KJ. **J Am Geriatr Soc** 1996 Sep;44(9):1135–6

Reply to Whitehouse and Deal editorial [letter; comment] Dick EG. **J Am Geriatr Soc** 1996 Jun;44(6):734–7. Comment on: J Am Geriatr Soc 1995 Nov;43(11):1314–5.

The natural history of Alzheimer's disease: a brain bank study [see comments] Jost BC, et al. **J Am Geriatr Soc** 1995 Nov; 43(11):1248–55. Comment in: J Am Geriatr Soc 1995 Nov;43(11):1314–5. Comment in: J Am Geriatr Soc 1996 Jun;44(6):734.

Weight change in Alzheimer's disease. White H, et al. **J Am Geriatr Soc** 1996 Mar;44(3):265–72

Situated beyond modernity: lessons for Alzheimer's disease research [editorial; comment] [see comments] Whitehouse PJ, et al. **J Am Geriatr Soc** 1995 Nov;43(11):1314–5. Comment on: J Am Geriatr Soc 1995 Nov;43(11):1248–55. Comment in: J Am Geriatr Soc 1996 Jun;44(6):734–7.

Visual attention and perception in patients with Huntington's disease: comparisons with other subcortical and cortical dementias. Filoteo JV, et al. **J Clin Exp Neuropsychol** 1995 Oct;17(5):654–67

Biologic markers and neurochemical correlates of agitation and psychosis in dementia. Kirby M, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S2–7 (63 ref.)

Observed sleep/wakefulness and severity of dementia in an Alzheimer's disease special care unit. Bliwise DL, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50(6):M303–6

Event-related potential prolongation in Alzheimer's disease signifies frontal lobe impairment: evidence from SPECT imaging. O'Mahony D, et al. **J Gerontol A Biol Sci Med Sci** 1996 May;51(3):M102–7

Application of a growth curve approach to modeling the progression of Alzheimer's disease. Stern Y, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):M179–84

Correlation between cognitive brain function and electrical brain activity in dementia of Alzheimer type. Dierks T, et al. **J Neural Transm Gen Sect** 1995;99(1–3):55–62

Regional cerebral blood flow measured by 99mTc-HMPAO SPECT differs in subgroups of Alzheimer's disease. Soininen H, et al. **J Neural Transm Park Dis Dement Sect** 1995;9(2–3):95–109

Functional imaging predicts cognitive decline in Alzheimer's disease. Jagust WJ, et al. **J Neuroimaging** 1996 Jul; 6(3):156–60

Executive dysfunction in early Alzheimer's disease. Binetti G, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):91–3

Limbic system dysfunction in Alzheimer's disease [letter] Blesa R, et al. **J Neurol Neurosurg Psychiatry** 1995 Oct; 59(4):450–1

Comparison of positron emission tomography, cognition, and brain volume in Alzheimer's disease with and without severe abnormalities of white matter. DeCarli C, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb;60(2):158–67

The basis for behavioural disturbances in dementia [editorial] Esiri MM. **J Neurol Neurosurg Psychiatry** 1996 Aug; 61(2):127–30 (57 ref.)

Deficiency of a neuronal growth-sustaining factor in fibroblasts of patients with Alzheimer's disease. Plioplys AV. **J Neurol Sci** 1995 Nov;133(1–2):24–30

Apathy and loss of insight in Alzheimer's disease: a SPECT imaging study. Ott BR, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):41–6

Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. Cataldo AM, et al. **J Neurosci** 1996 Jan;16(1):186–99

The 18th annual meeting of the Canadian College of Neuropsychopharmacology in Association with the Japanese Society of Neuropsychopharmacology. Vancouver, Canada, June 4–7, 1995. Boksa P, et al. **J Psychiatry Neurosci** 1995 Nov;20(5):340–4

The current status of the calcium hypothesis of brain aging and Alzheimer's disease. Heidelberg, Germany, October 23–25, 1995. Proceedings of a conference. **Life Sci** 1996; 59(5–6):vii, 357–510

Trypsin inhibition: a potential cause of cobalamin deficiency common to the pathogenesis of Alzheimer-type dementia and AIDS dementia complex? McCaddon A, et al. **Med Hypotheses** 1995 Aug;45(2):200–4 (49 ref.)

Disturbances in signal transduction mechanisms in Alzheimer's disease. Fowler CJ, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:287–92 (34 ref.)

Neuropathology in the Down's syndrome brain [comment] Tanzi RE. **Nat Med** 1996 Jan;2(1):31–2. Comment on: Nat Med 1996 Jan;2(1):93–5.

Skin vessel reactivity is impaired in Alzheimer's disease. Algotsson A, et al. **Neurobiol Aging** 1995 Jul–Aug; 16(4):577–82

Neurons bearing neurofibrillary tangles are responsible for selected synaptic deficits in Alzheimer's disease. Callahan LM, et al. **Neurobiol Aging** 1995 May–Jun;16(3):311–4

Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Craft S, et al. **Neurobiol Aging** 1996 Jan–Feb;17(1):123–30

Degenerative and protective signaling mechanisms in the neurofibrillary pathology of AD. Mattson MP. **Neurobiol Aging** 1995 May–Jun;16(3):447–57; discussion 458–63 (99 ref.)

Methodological aspects of evaluating effects of AD progression. Mohs RC. **Neurobiol Aging** 1995 Nov–Dec; 16(6):867–9; discussion 869–70, 879–82

Clinically meaningful interference in AD progression. Phelps CH. **Neurobiol Aging** 1995 Nov–Dec;16(6):877–8; discussion 879–82

Influence of the patient's environment on the progression of Alzheimer's disease. Sandman PO. **Neurobiol Aging** 1995 Nov–Dec;16(6):871; discussion 879–82

Circadian locomotor activity and core-body temperature rhythms in Alzheimer's disease. Satlin A, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):765–71

AD progression as a function of disease stage. Sclan SG. **Neurobiol Aging** 1995 Nov–Dec;16(6):865–6; discussion 879–82

Functional alterations in neural circuits in Alzheimer's disease. Simonian NA, et al. **Neurobiol Aging** 1995 May–Jun;16(3):305–9 (38 ref.)

Alzheimer's disease: maladaptive synaptoplasticity hypothesis. Neill D. **Neurodegeneration** 1995 Jun; 4(2):217–32 (250 ref.)

Vision in dementia: contrast effects. Lakshminarayanan V, et al. **Neurol Res** 1996 Feb;18(1):9–15

Focal temporal lobe dysfunction in probable Alzheimer's disease predicts a slow rate of cognitive decline. Butters MA, et al. **Neurology** 1996 Mar;46(3):687–92

Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Lehtovirta M, et al. **Neurology** 1996 Feb; 46(2):413–9

Mechanisms of neuronal degeneration in Alzheimer's disease. Yankner BA. **Neuron** 1996 May;16(5):921–32 (172 ref.)

Network analysis of PET-mapped visual pathways in Alzheimer type dementia. Horwitz B, et al. **Neuroreport** 1995 Nov 27;6(17):2287–92

Selective impairment of spatial attention during visual search in Alzheimer's disease. Parasuraman R, et al. **Neuroreport** 1995 Oct 2;6(14):1861–4

Derangement in stress response of apolipoprotein E-deficient mice. Gordon I, et al. **Neurosci Lett** 1996 Mar 15; 206(2–3):212–4

Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Nagy Z, et al. **Neuroscience** 1995 Dec; 69(3):757–61

Energy requirements in Alzheimer's disease patients. Wolf-Klein GP, et al. **Nutrition** 1995 May–Jun;11(3):264–8

Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy. Ruehl WW, et al. **Prog Brain Res** 1995;106:217–25 (32 ref.)

Dissociation of galaninergic and neurotrophic plasticity in Down syndrome and Alzheimer disease. Mufson EJ, et al. **Prog Clin Biol Res** 1995;393:105–22

Enhanced adrenal sensitivity to adrenocorticotrophic hormone (ACTH) is evidence of HPA axis hyperactivity in Alzheimer's disease. O'Brien JT, et al. **Psychol Med** 1996 Jan;26(1):7–14

Electroencephalography and single photon emission computed tomography in dementia: a comparative study. Sloan EP, et al. **Psychol Med** 1995 May;25(3):631–8

Neuropsychological, psychiatric, and cerebral blood flow findings in vascular dementia and Alzheimer's disease. Starkstein SE, et al. **Stroke** 1996 Mar;27(3):408–14

[Alzheimer's disease in 1995] Mavroudakis N. **Rev Med Brux** 1996 Apr;17(2):57–60 (17 ref.) (Eng. Abstr.) **(Fre)**

[Isoform 4 of apolipoprotein E and Alzheimer disease. Specificity and clinical study] Mahieux F, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):231–9 (71 ref.) (Eng. Abstr.) **(Fre)**

[Cerebral hemodynamics in patients with dementia] Abe S, et al. **Nippon Ronen Igakkai Zasshi** 1996 Feb;33(2):95–104 (Eng. Abstr.) **(Jpn)**

[Longitudinal study of neuropsychological and cerebral blood flow changes in Alzheimer-type dementia] Hanyu H, et al. **Nippon Ronen Igakkai Zasshi** 1995 Nov; 32(11):728–35 (Eng. Abstr.) **(Jpn)**

[The relationship between visual agnosia and visual pathway for perception] Kojima J, et al. **No To Shinkei** 1996 Jan; 48(1):31–7 (Eng. Abstr.) **(Jpn)**

[Closing-in phenomena observed in patients with Alzheimer's disease—analysis of drawing behavior and eye movements] Midorikawa Y, et al. **Seishin Shinkeigaku Zasshi** 1996; 98(3):151–69 (Eng. Abstr.) **(Jpn)**

[Analytic study on EEG features of aging with/without psychiatric disorders: focussing at the alterations in the EEGs of the healthy, depressive and demented elderlies] Saito N. **Seishin Shinkeigaku Zasshi** 1995;97(10):801–24 (Eng. Abstr.) **(Jpn)**

[The effect of amitriptyline on the pathological crying and other pseudobulbar signs] Szczudlik A, et al. **Neurol Neurochir Pol** 1995 Sep–Oct;29(5):663–74 (Eng. Abstr.) **(Pol)**

[Cognitive heterogeneity in Alzheimer's disease] De Brito-Marques PR, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3-A):451–4 (Eng. Abstr.) **(Por)**

[The neuroimmune relationships during normal aging and in Alzheimer-type dementias] Fokin VF, et al. **Vestn Ross Akad Med Nauk** 1996;(4):32–9 (Eng. Abstr.) **(Rus)**

[Neuroimmune interactions in normal aging and in Alzheimer disease] Ponomareva NV, et al. **Vestn Ross Akad Med Nauk** 1995;(12):27–32 (Eng. Abstr.) **(Rus)**

[Dementias: present situation and future perspectives (II). Biological markers] Espert R, et al. **Rev Neurol** 1995 Jan–Feb;23(119):77–85 (107 ref.) (Eng. Abstr.) **(Spa)**

[The evaluation of the temporal lobe size by magnetic resonance in Alzheimer's disease] Rodríguez RM, et al. **Rev Neurol** 1995 Jan–Feb;23(119):59–61 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Oestrogen replacement therapy and Alzheimer's disease. Paganini-Hill A. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:80–6 (49 ref.)

Protection against Alzheimer's disease? [comment] Burns A, et al. **Lancet** 1996 Aug 17;348(9025):420–1. Comment on: Lancet 1996 Aug 17;348(9025):429–32.

Effect of oestrogen during menopause on risk and age at

onset of Alzheimer's disease [see comments] Tang MX, et al. **Lancet** 1996 Aug 17;348(9025):429–32. Comment in: Lancet 1996 Aug 17;348(9025):420–1.

The diseases of Alzheimer and Pick from the viewpoint of prevention. Marcinkowski T. **Med Hypotheses** 1996 Mar; 46(3):180–2

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Breitner JC, et al. **Neurobiol Aging** 1995 Jul–Aug; 16(4):523–30

Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Gozes I, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):427–32

Schizophrenia, Alzheimer's disease, and anti-inflammatory agents. Oken RJ, et al. **Schizophr Bull** 1996;22(1):1–4 (24 ref.)

Searching for drugs that combat Alzheimer's [news] Marx J. **Science** 1996 Jul 5;273(5271):50–3

Estrogen replacement therapy in the elderly. Paganini-Hill A. **Zentralbl Gynakol** 1996;118(5):255–61 (41 ref.)

[Tacrine against Alzheimer disease? Still uncertain for which patients may the treatment be beneficial (see comments)] Wallin A. **Lakartidningen** 1996 Jan 3;93(1–2):22–4. Comment in: Lakartidningen 1996 Mar 27;93(13):1200. **(Swe)**

PSYCHOLOGY

The relationship between Piaget and cognitive levels in persons with Alzheimer's disease and related disorders. Matteson MA, et al. **Aging (Milano)** 1996 Feb;8(1):61–9

Disorders of visual and spatial perception in the early stage of Alzheimer's disease. Binetti G, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:221–5

Visual versus auditory memory stimulation in patients with probable Alzheimer's disease. A PET study with 18 FDG. Kessler J, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:233–8

Gender comparisons of cognitive performances among vascular dementia, Alzheimer disease, and older adults without dementia. Buckwalter JG, et al. **Arch Neurol** 1996 May;53(5):436–9

Associations of status and change measures of neuropsychological function with pathologic changes in elderly, originally nondemented subjects. Crystal HA, et al. **Arch Neurol** 1996 Jan;53(1):82–7

Cognitive test performance in detecting, staging, and tracking Alzheimer's disease. Locascio JJ, et al. **Arch Neurol** 1995 Nov;52(11):1087–99

Assessing the competency of patients with Alzheimer's disease under different legal standards. A prototype instrument [see comments] Marson DC, et al. **Arch Neurol** 1995 Oct;52(10):949–54. Comment in: Arch Neurol 1995 Oct;52(10):955–9.

Neuropsychologic predictors of competency in Alzheimer's disease using a rational reasons legal standard [comment] Marson DC, et al. **Arch Neurol** 1995 Oct;52(10):955–9. Comment on: Arch Neurol 1995 Oct;52(10):949–54.

Association of dementia severity with cortical gray matter and abnormal white matter volumes in dementia of the Alzheimer type. Stout JC, et al. **Arch Neurol** 1996 Aug; 53(8):742–9

The prediction of Alzheimer disease. The role of patient and informant perceptions of cognitive deficits. Tierney MC, et al. **Arch Neurol** 1996 May;53(5):423–7

Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease. Victoroff J, et al. **Arch Neurol** 1996 May;53(5):428–34

Communicating with persons with Alzheimer's disease: experiences of family and formal caregivers. Richter JM, et al. **Arch Psychiatr Nurs** 1995 Oct;9(5):279–85

Training to criterion in eyeblink classical conditioning in Alzheimer's disease, Down's syndrome with Alzheimer's disease, and healthy elderly. Woodruff-Pak DS, et al. **Behav Neurosci** 1996 Feb;110(1):22–9

Lack of association between clinical symptoms and postmortem indices of brain serotonin function in Alzheimer's disease [letter] Lawlor BA, et al. **Biol Psychiatry** 1995 Jun 15;37(12):895–6

Family members' attitudes toward telling the patient with Alzheimer's disease their diagnosis. Maguire CP, et al. **BMJ** 1996 Aug 31;313(7056):529–30

Community care in presenile Alzheimer's disease [letter; comment] Evans M. **Br J Psychiatry** 1995 Sep;167(3):408 . Comment on: Br J Psychiatry 1995 Jun;166(6):777–82.

Identification of famous faces and famous names in early Alzheimer's disease. Relationship to anterograde episodic and general semantic memory. Greene JD, et al. **Brain** 1996 Feb;119 (Pt 1):111–28

The fractionation of remote memory. Evidence from a longitudinal study of dementia of Alzheimer type. Greene JD, et al. **Brain** 1996 Feb;119 (Pt 1):129–42

Asymmetries in the covert orienting of visual spatial attention to spatial and non-spatial cues in Alzheimer's disease. Maruff P, et al. **Brain** 1995 Dec;118 (Pt 6):1421–35

Different components in word-list forgetting of pure amnesics, degenerative demented and healthy subjects. Carlesimo GA, et al. **Cortex** 1995 Dec;31(4):735–45

Forgetting from long-term memory in dementia and pure amnesia: role of task, delay of assessment and aetiology of cerebral damage. Carlesimo GA, et al. **Cortex** 1995 Jun; 31(2):285–300

Cross-form priming in normal aging and in mild dementia of the Alzheimer type. Ergis AM, et al. **Cortex** 1995 Dec; 31(4):699–710

Changes of the relative severity of naming, fluency and recall impairment in the course of dementia of the Alzheimer type. Pollman S, et al. **Dementia** 1995 Sep–Oct;6(5):252–7

Of mind and matter—or what really matters in Alzheimer's disease? Neurobiological substrates of clinical deficits in Alzheimer's disease. Förstl H. **Eur Arch Psychiatry Clin Neurosci** 1996;246(3):116–7

Life events as correlates of burden in spouse caregivers of persons with Alzheimer's disease. Russo J, et al. **Exp Aging Res** 1995 Jul–Sep;21(3):273–94

Personality change in dementia of the Alzheimer's type: relations to caregiver personality and burden. Welleford EA, et al. **Exp Aging Res** 1995 Jul–Sep;21(3):295–314

The effects of a life review program on disorientation, social interaction and self-esteem of nursing home residents. Tabourne CE. **Int J Aging Hum Dev** 1995;41(3):251–66

Human development in the context of aging and chronic illness: the role of attachment in Alzheimer's disease and stroke. Wright LK, et al. **Int J Aging Hum Dev** 1995; 41(2):133–50 (82 ref.)

Dysfunction of visual cortex contributes to disturbed processing of visual information in Alzheimer's disease. Mielke R, et al. **Int J Neurosci** 1995 May;82(1–2):1–9

Dimensions of social support and social conflict as predictors of caregiver depression. MaloneBeach EE, et al. **Int Psychogeriatr** 1995 Spring;7(1):25–38

Kitwood's approach to dementia and dementia care: a critical but appreciative review. Adams T. **J Adv Nurs** 1996 May; 23(5):948–53 (32 ref.)

Attitudes of older adults' on being told the diagnosis of Alzheimer's disease. Holroyd S, et al. **J Am Geriatr Soc** 1996 Apr;44(4):400–3

Dementia and guns [see comments] Mendez MF. **J Am Geriatr Soc** 1996 Apr;44(4):409–10 (10 ref.). Comment in: J Am Geriatr Soc 1996 Apr;44(4):467–9.

Alzheimer's disease as a metaphor for contemporary fears of aging [letter] O'Rourke N. **J Am Geriatr Soc** 1996 Feb; 44(2):220–1

Gender differences in the behavioral manifestations of Alzheimer's disease. Ott BR, et al. **J Am Geriatr Soc** 1996 May;44(5):583–7

Effects of aging and of Alzheimer's disease on verbal memory. Antonelli Incalzi R, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):580–9

Calculation and number processing in mild Alzheimer's disease. Deloche G, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):634–9

Odor identification as an early marker for Alzheimer's disease: impact of lexical functioning and detection sensitivity. Morgan CD, et al. **J Clin Exp Neuropsychol** 1995 Oct;17(5):793–803

Wayfinding in dementia of the Alzheimer type: planning abilities. Passini R, et al. **J Clin Exp Neuropsychol** 1995 Dec;17(6):820–32

Dissociation between declarative and procedural learning in dementia and depression. Sabe L, et al. **J Clin Exp Neuropsychol** 1995 Dec;17(6):841–8

Retrieval from semantic memory and its implications for Alzheimer's disease. Rohrer D, et al. **J Exp Psychol Learn Mem Cogn** 1995 Sep;21(5):1127–39

Neuroleptic treatment of agitation and psychosis in dementia. Devanand DP, et al. **J Geriatr Psychiatry Neurol** 1995 Oct; 8 Suppl 1:S18–27 (141 ref.)

The depressions of Alzheimer's disease: sorting, pharmacotherapy, and clinical advice. Knesper DJ. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S40–51 (147 ref.)

Behavioral disturbance in dementia. Lloyd C, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8(4):213–6

Graphomotor perseveration and wandering in Alzheimer's disease. Ryan JP, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8(4):209–12

Acquisition and long-term retention of a gross motor skill in Alzheimer's disease patients under constant and varied practice conditions. Dick MB, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Mar;51(2):P103–11

Observed affect in nursing home residents with Alzheimer's disease. Lawton MP, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):P3–14

Correlation between cognitive brain function and electrical brain activity in dementia of Alzheimer type. Dierks T, et al. **J Neural Transm Gen Sect** 1995;99(1–3):55–62

Anosognosia in Alzheimer's disease: a study of associated factors. Migliorelli R, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):338–44

Apathy and loss of insight in Alzheimer's disease: a SPECT imaging study. Ott BR, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):41–6

Observations on the physostigmine syndrome in patients with Alzheimer's disease. Wirkowski E, et al. **J Neuropsychiatry Clin Neurosci** 1991 Winter;3(1):73–5

Toward an anthropology of senility: anger, weakness, and Alzheimer's in Banaras, India. Cohen L. **Med Anthropol Q** 1995 Sep;9(3):314–34

Correlations of synaptic and pathological markers with cognition of the elderly. Dickson DW, et al. **Neurobiol Aging** 1995 May–Jun;16(3):285–98; discussion 298–304

Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease. Becker JT, et al. **Neurology** 1996 Mar;46(3):692–700

Focal temporal lobe dysfunction in probable Alzheimer's disease predicts a slow rate of cognitive decline. Butters MA, et al. **Neurology** 1996 Mar;46(3):687–92

Cognitive performance on the Alzheimer's Disease Assessment Scale: effect of education. Doraiswamy PM, et al. **Neurology** 1995 Nov;45(11):1980–4

Language comprehension profiles in Alzheimer's disease, multi-infarct dementia, and frontotemporal degeneration. Grossman M, et al. **Neurology** 1996 Jul;47(1):183–9

Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease: A CERAD analysis, Part XII. Koss E, et al. **Neurology** 1996 Jan;46(1):136–41

Toward a neurologic model of competency: Cognitive predictors of capacity to consent in Alzheimer's disease using three different legal standards. Marson DC, et al. **Neurology** 1996 Mar;46(3):666–72

The spectrum of behavioral changes in Alzheimer's disease. Mega MS, et al. **Neurology** 1996 Jan;46(1):130–5

Language, Alzheimer's disease, and gender [letter] Padovani A, et al. **Neurology** 1996 Feb;46(2):592

A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease. Ramachandran G, et al. **Neurology** 1996 Jul;47(1):256–9

Category-specific difficulty naming with verbs in Alzheimer's disease. Robinson KM, et al. **Neurology** 1996 Jul;47(1):178–82

Neuropsychological test performance in African-American and white patients with Alzheimer's disease. Welsh KA, et al. **Neurology** 1995 Dec;45(12):2207–11

Triazolam in Alzheimer's disease: pilot study on sleep and memory effects. McCarten JR, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):447–52

Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease. Semla TP, et al. **Pharmacotherapy** 1995 Jul–Aug; 15(4):495–501

Psychological, social, and health impact of caregiving: a comparison of black and white dementia family caregivers and noncaregivers. Haley WE, et al. **Psychol Aging** 1995 Dec;10(4):540–52

Contextual constraint facilitates semantic decisions about object pictures by Alzheimer patients. Nebes RD, et al. **Psychol Aging** 1995 Dec;10(4):590–6

Weight changes in caregivers of Alzheimer's care recipients: psychobehavioral predictors. Vitaliano PP, et al. **Psychol Aging** 1996 Mar;11(1):155–63

Awareness of time in dementia of the Alzheimer type. Grewal RP. **Psychol Rep** 1995 Jun;76(3 Pt 1):717–8

Major depression in Alzheimer's disease. An interaction between gender and family history. Lyketsos CG, et al. **Psychosomatics** 1996 Jul–Aug;37(4):380–4

Cognitive decline due to aging among persons with Down syndrome. Das JP, et al. **Res Dev Disabil** 1995 Nov–Dec; 16(6):461–78

Neuropsychological, psychiatric, and cerebral blood flow findings in vascular dementia and Alzheimer's disease. Starkstein SE, et al. **Stroke** 1996 Mar;27(3):408–14

A family's coming to terms with Alzheimer's disease. Perry JA, et al. **West J Nurs Res** 1996 Feb;18(1):12–28

Discovering life quality in coping with dementia. Quayhagen MP, et al. **West J Nurs Res** 1996 Apr;18(2):120–35

[Behavior assessment in Alzheimer type dementia using the disruptive behavior questionnaire] Lebert F, et al. **Presse Med** 1996 Apr 20;25(14):665–7 (Eng. Abstr.) **(Fre)**

[Willingness to participate in dementia research by relatives of Alzheimer patients and family members of cognitively normal persons] Haupt M, et al. **Nervenarzt** 1995 Sep; 66(9):708–11 (Eng. Abstr.) **(Ger)**

[Perception of stress by caregiving relatives of dementia patients] Adler C, et al. **Z Gerontol Geriatr** 1996 Mar–Apr; 29(2):143–9 (Eng. Abstr.) **(Ger)**

[Frontal lobe dementia and Alzheimer type dementia] Miyoshi K. **Nippon Ronen Igakkai Zasshi** 1996 Mar; 33(3):154–7 **(Jpn)**

[Neuropsychological comparison between dementia of Alzheimer type and multiple subcortical infarction by easily applicable test battery] Tei H, et al. **Rinsho Shinkeigaku** 1995 Nov;35(11):1205–9 (Eng. Abstr.) **(Jpn)**

[Closing-in phenomena observed in patients with Alzheimer's disease—analysis of drawing behavior and eye movements] Midorikawa Y, et al. **Seishin Shinkeigaku Zasshi** 1996; 98(3):151–69 (Eng. Abstr.) **(Jpn)**

[Concomitant therapies in the clinical trial in Alzheimer's disease] Bermejo F, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):118–24 (81 ref.) (Eng. Abstr.) **(Spa)**

[Dementias: present situation and future perspectives (III). Neurological, therapeutic, psychosocial aspects and patient care] Espert R, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):86–95 (138 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

A case of Alzheimer's disease with extensive focal white matter changes. Zahner B, et al. **Dementia** 1995 Sep–Oct; 6(5):294–300

Methodological problems and clinical relevance of structural neuroimaging in dementia research. Lang CJ. **J Neural Transm Gen Sect** 1995;99(1–3):131–43 (45 ref.)

[Correlative study of the brain CT and clinical features of patients with Down's syndrome in three clinical stages of Alzheimer type dementia] Maruyama K, et al.

Rinsho Shinkeigaku 1995 Jul;35(7):775–80 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Alterations in functional neuroanatomical connectivity in Alzheimer's disease. Positron emission tomography of auditory verbal short-term memory. Becker JT, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:239–42

Functional imaging patterns in Alzheimer's disease. Relationships to neurobiology. Jagust WJ. **Ann N Y Acad Sci** 1996 Jan 17;777:30–6 (20 ref.)

Visual versus auditory memory stimulation in patients with probable Alzheimer's disease. A PET study with 18 FDG. Kessler J, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:233–8

Abnormal brain glucose metabolism in the delusional misidentification syndromes: a positron emission tomography study in Alzheimer disease. Mentis MJ, et al. **Biol Psychiatry** 1995 Oct 1;38(7):438–49

The clinical utility of visual evaluation of scintigraphic perfusion patterns for Alzheimer's disease using I-123 IMP SPECT. Ishii K, et al. **Clin Nucl Med** 1996 Feb; 21(2):106–10

Changes in local cerebral blood flow by neuroactivation and vasoactivation in patients with impaired cognitive function. Knapp WH, et al. **Eur J Nucl Med** 1996 Aug;23(8):878–88

SPECT in dementia: clinical and pathological correlation. Read SL, et al. **J Am Geriatr Soc** 1995 Nov;43(11):1243–7

The contribution of single photon emission tomography to the clinical differentiation of degenerative cortical brain disorders. Talbot PR, et al. **J Neurol** 1995 Sep; 242(9):579–86

Diagnosing Alzheimer's disease in elderly, mildly demented patients: the impact of routine single photon emission computed tomography. Van Gool WA, et al. **J Neurol** 1995 Jun;242(6):401–5

A SPECT study of parkinsonism in Alzheimer's disease. Starkstein SE, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):308–13

The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. Sultzer DL, et al. **J Neuropsychiatry Clin Neurosci** 1995 Fall;7(4):476–84

PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. Groom GN, et al. **J Nucl Med** 1995 Dec;36(12):2207–10

Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. Irie T, et al. **J Nucl Med** 1996 Apr;37(4):649–55

Use of neural networks in brain SPECT to diagnose Alzheimer's disease. Page MP, et al. **J Nucl Med** 1996 Feb; 37(2):195–200

Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. Piert M, et al. **J Nucl Med** 1996 Feb;37(2):201–8

Discriminant value of semiquantitative SPECT data in mild Alzheimer's disease [letter; comment] Prohovnik I. **J Nucl Med** 1996 Feb;37(2):404. Comment on: J Nucl Med 1994 Sep;35(9):1450–5. Comment on: J Nucl Med 1994 Sep;35(9):1455–6.

Positron-emission tomography and Alzheimer's disease [letter; comment] Pedro-Botet J, et al. **N Engl J Med** 1996 Jul 18;335(3):207–8. Comment on: N Engl J Med 1996 Mar 21;334(12):752–8.

Tetrahydroaminoacridine modulates technetium-99m labelled ethylene dicysteinate retention in Alzheimer's disease measured with single photon emission computed tomography imaging. Riekkinen P Jr, et al. **Neurosci Lett** 1995 Jul 28;195(1):53–6

Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Burdette JH, et al. **Radiology** 1996 Mar; 198(3):837–43

[Comments on the article, Alzheimer's disease (letter)] Aguilar Rebolledo F. **Gac Med Mex** 1995 Sep-Dec; 131(5–6):625–7 **(Spa)**

REHABILITATION

Structuring the acquisition and retrieval environment to facilitate learning in individuals with dementia of the Alzheimer type. Hutton S, et al. **Memory** 1996 Mar; 4(2):113–30

[Computer-assisted individualized memory training in Alzheimer patients] Hofmann M, et al. **Nervenarzt** 1995 Sep;66(9):703–7 (Eng. Abstr.) **(Ger)**

THERAPY

Reality orientation therapy in Alzheimer disease: useful or not? A controlled study. Zanetti O, et al. **Alzheimer Dis Assoc Disord** 1995 Fall;9(3):132–8

Computer-based cognitive training in Alzheimer's disease patients. Hofmann M, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:249–54

Assessing the competency of patients with Alzheimer's disease under different legal standards. A prototype instrument [see comments] Marson DC, et al. **Arch Neurol** 1995 Oct;52(10):949–54. Comment in: Arch Neurol 1995 Oct;52(10):955–9.

A moving experience: reconfiguring a special care unit for Alzheimer's patients. Hepburn K, et al. **Gerontologist** 1995 Dec;35(6):831–5

Alzheimer's disease: long-term care issues. Kovach CR. **Issues Law Med** 1996 Summer;12(1):47–56

Life-sustaining treatment decisions by spouses of patients with Alzheimer's disease. Mezey M, et al. **J Am Geriatr Soc** 1996 Feb;44(2):144–50

Improving long-term care for persons with Alzheimer's disease [editorial; comment] Sloane PD, et al. **J Am Geriatr Soc** 1996 Jan;44(1):91–2. Comment on: J Am Geriatr Soc 1996 Jan;44(1):7–13.

Physician visit frequency in Alzheimer's disease [letter; comment] Murden RA. **J Gen Intern Med** 1995 Sep; 10(9):533. Comment on: J Gen Intern Med 1995 Apr;10(4):187–93.

Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Schneider LS, et al. **Neurology** 1996 Jun;46(6):1580–4

Alzheimer's disease patients and their caregivers: medical care issues for the primary care physician. Barrett JJ, et al. **South Med J** 1996 Jan;89(1):1–9

A reason to hope: linking dementia research, care and services in the 21st century. Antuono P, et al. **Wis Med J** 1995 Oct;94(10):546–7

[New therapeutic prospects in Alzheimer disease] Rouhart F. **Rev Med Interne** 1995;16(11):860–3 (28 ref.) (Eng. Abstr.) **(Fre)**

[Toward a treatment for dementia] Ghika J. **Schweiz Rundsch Med Prax** 1995 Sep 19;84(38):1050–3 (47 ref.) (Eng. Abstr.) **(Fre)**

[Guidelines for integrated management of demented patients in nursing homes for the elderly] Höft B, et al. **Z Gerontol Geriatr** 1996 Mar-Apr;29(2):150–8 (Eng. Abstr.) **(Ger)**

[Dementias: present situation and future perspectives (III). Neurological, therapeutic, psychosocial aspects and patient care] Espert R, et al. **Rev Neurol** 1995 Jan-Feb; 23(119):86–95 (138 ref.) (Eng. Abstr.) **(Spa)**

AMANITA

Soma siddhas and alchemical enlightenment: psychedelic mushrooms in Buddhist tradition. Hajicek-Dobberstein S. **J Ethnopharmacol** 1995 Oct;48(2):99–118

Haemoperfusion in Amanita phalloides poisoning. Aji DY, et al. **J Trop Pediatr** 1995 Dec;41(6):371–4

CHEMISTRY

Purification and characterization of a lectin from the toxic mushroom Amanita pantherina. Zhuang C, et al. **Biochim Biophys Acta** 1996 Aug 29;1291(1):40–4

AMANITINS

GENETICS

Mutations in the alpha-amanitin conserved domain of the largest subunit of yeast RNA polymerase III affect pausing, RNA cleavage and transcriptional transitions. Thuillier V, et al. **EMBO J** 1996 Feb 1;15(3):618–29

PHARMACOLOGY

Amanitin greatly reduces the rate of transcription by RNA polymerase II ternary complexes but fails to inhibit some transcript cleavage modes. Rudd MD, et al. **J Biol Chem** 1996 Aug 30;271(35):21549–58

Transcription of protein-coding genes in Entamoeba histolytica is insensitive to high concentrations of alpha-amanitin. Lioutas C, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):259–61

A promotor directing alpha-amanitin-sensitive transcription of GARP, the major surface antigen of insect stage Trypanosoma congolense. Graham SV, et al. **Nucleic Acids Res** 1996 Jan 15;24(2):272–81

In vivo degradation of RNA polymerase II largest subunit triggered by alpha-amanitin. Nguyen VT, et al. **Nucleic Acids Res** 1996 Aug 1;24(15):2924–9

[Phallotoxins as modifiers in the study of muscles] Bukatina AE. **Biofizika** 1996 Jan-Feb;41(1):95–102 (38 ref.) (Eng. Abstr.) **(Rus)**

AMANTADINE

ADMINISTRATION & DOSAGE

Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients. Handelsman L, et al. **Drug Alcohol Depend** 1995 Oct; 39(3):173–80

[Amantadine in the prevention of nosocomial influenza] Bíró L, et al. **Orv Hetil** 1996 Jan 28;137(4):171–4 (Eng. Abstr.) **(Hun)**

ADVERSE EFFECTS

Unexpected amantadine intoxication in the death of a trauma patient. Hartshorne NJ, et al. **Am J Forensic Med Pathol** 1995 Dec;16(4):340–3

No difference in the effect of biperiden and amantadine on negative symptoms in medicated chronic schizophrenic patients. Silver H, et al. **Biol Psychiatry** 1995 Sep 15; 38(6):413–5

Amantadine, livedo reticularis, and antiphospholipid antibodies [letter] Paulson GW, et al. **Clin Neuropharmacol** 1995 Oct;18(5):466–7

Psychotic episode related to phenylpropanolamine and amantadine in a healthy female [letter] Stroe AE, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):457–8

Breakthrough panic after amantadine treatment in a Parkinson's disease patient [letter] Noveske FG. **J Clin Psychiatry** 1996 Aug;57(8):374

Amantadine-induced "vocal" myoclonus [letter] Pfeiffer RF. **Mov Disord** 1996 Jan;11(1):104–6

ANALOGS & DERIVATIVES

Blockade of glutamate- and cholinergic ion channels by amantadane derivatives. Magazanik LG, et al. **Neurosci Behav Physiol** 1996 Jan-Feb;26(1):13–22

[The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain] Kudrin VS, et al. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):8–11 (Eng. Abstr.) **(Rus)**

METABOLISM

Use of digitalis glycosides to identify the mechanisms of amantadine transport by renal tubules. Escobar MR, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1189–94

Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Kornhuber J, et al. **Neuropharmacology** 1995 Jul;34(7):713–21

PHARMACOKINETICS

L(+)- and D(-)-lactate modulate rat renal tubular accumulation of amantadine in the presence and absence of bicarbonate. Escobar MR, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1317–23

PHARMACOLOGY

Effect of pH on in vitro potency of amantadine against Plasmodium falciparum. Evans SG, et al. **Am J Trop Med Hyg** 1996 Mar;54(3):232–6

Amantadine induces c-fos in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists. Tomitaka S, et al. **Eur J Pharmacol** 1995 Oct 16;285(2):207–11

MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Wenk GL, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):267–70

Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. Klimov AI, et al. **J Infect Dis** 1995 Nov;172(5):1352–5

Blockade of glutamate- and cholinergic ion channels by amantadane derivatives. Magazanik LG, et al. **Neurosci Behav Physiol** 1996 Jan-Feb;26(1):13–22

Understanding the mechanism of action of the anti-influenza virus drug amantadine [letter] Pinto LH, et al. **Trends Microbiol** 1995 Jul;3(7):271

THERAPEUTIC USE

The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Geisler MW, et al. **Arch Neurol** 1996 Feb;53(2):185–8

In vitro and in vivo sensitivity of a non-mouse-adapted influenza A (Beijing) virus infection to amantadine and ribavirin. Sidwell RW, et al. **Chemotherapy** 1995 Nov-Dec; 41(6):455–61

Amantadine treatment of a patient with anoxic brain injury. Edby K, et al. **Childs Nerv Syst** 1995 Oct;11(10):607–9

Color vision in Parkinson's disease: missing influence of amantadine sulphate. Büttner T, et al. **Clin Neuropharmacol** 1995 Oct;18(5):458–63

Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study. Botez MI, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep;61(3):259–64

Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. Oliveto A, et al. **J Subst Abuse Treat** 1995 Nov-Dec;12(6):423–8

Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Krupp LB, et al. **Neurology** 1995 Nov;45(11):1956–61

Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Uitti RJ, et al. **Neurology** 1996 Jun;46(6):1551–6

[New therapeutic possibilities with low-affinity NMDA receptor antagonists] Kornhuber J, et al. **Nervenarzt** 1996 Jan;67(1):77–82 (22 ref.) (Eng. Abstr.) **(Ger)**

AMAPARI VIRUS see **TACARIBE COMPLEX VIRUSES**

AMARANTH

CHEMISTRY

Effect of home processing on total and extractable calcium and zinc content of spinach (Spinach oleracia) and amaranth (Amaranthus tricolor) leaves. Yadav SK, et al. **Plant Foods Hum Nutr** 1995 Jul;48(1):65–72

TOXICITY

Genotoxicity testing of two red dyes in the somatic and germ line cells of Drosophila. Tripathy NK, et al. **Food Chem Toxicol** 1995 Nov;33(11):923–7

AMAUROSIS see **BLINDNESS**

AMAUROTIC FAMILIAL IDIOCY see LIPOIDOSIS

AMBATHIZON see THIOACETAZONE

AMBER

Age of bacteria from amber [letter; comment] Beckenbach AT. **Science** 1995 Dec 22;270(5244):2015–6; discussion 2016–7. Comment on: Science 1995 May 19;268(5213):1060–4.

Amino acid racemization and the preservation of ancient DNA [see comments] Poinar HN, et al. **Science** 1996 May 10;272(5263):864–6. Comment in: Science 1996 May 10;272(5263):810.

Age of bacteria from amber [letter; comment] Priest FG. **Science** 1995 Dec 22;270(5244):2015; discussion 2016–7. Comment on: Science 1995 May 19;268(5213):1060–4.

Just how old is that DNA, anyway? [news; comment] Service RF. **Science** 1996 May 10;272(5263):810. Comment on: Science 1996 May 10;272(5263):864–6.

AMBIDEXTERITY see LATERALITY

AMBLYOPIA

Update on strabismus and amblyopia. Campos EC. **Acta Ophthalmol Scand** 1995;73 Suppl 214:17–24; discussion 24–5 (88 ref.)

Update on strabismus and amblyopia. Campos EC. **Acta Ophthalmol Scand Suppl** 1995;(214):17–24; discussion 24–5 (90 ref.)

DIAGNOSIS

Results of treatment of amblyopia with a screening program for early detection. Lennerstrand G, et al. **Acta Ophthalmol Scand Suppl** 1996;(219):42–5

Visual screening programme for preschool children [letter] Spowart KM. **Br J Ophthalmol** 1996 Jul;80(7):678

Field trial of the Otago photoscreener. Kennedy R, et al. **Can J Ophthalmol** 1995 Jun;30(4):193–7

Amblyopia in unilateral congenital ptosis: early detection by sweep visual evoked potential. Cibis GW, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Oct;233(10):605–9

The reliability of interpretation of photoscreening results with the off PS–100 in Headstart preschool children. Lewis RC, et al. **J Am Optom Assoc** 1995 Jul;66(7):429–34

Photoscreening for amblyogenic factors. Ottar WL, et al. **J Pediatr Ophthalmol Strabismus** 1995 Sep–Oct; 32(5):289–95

Recognition of TNO stereotest figures in the absence of true stereopsis [letter] Charman WN, et al. **Optom Vis Sci** 1995 Jul;72(7):535–6

[Sensitivity of refraction measurement with the infrared videorefractometer VRB 200] Gusek GC, et al. **Klin Monatsbl Augenheilkd** 1995 Oct;207(4):232–8 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Visual acuities and scotomas after 3 weeks' levodopa administration in adult amblyopia. Gottlob I, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Jul;233(7):407–13

EPIDEMIOLOGY

Vision screening of preschool children in Italy. Ingrosso A, et al. **Ophthalmic Epidemiol** 1995 Mar;2(1):41–4

Baltimore Vision Screening Project. Preslan MW, et al. **Ophthalmology** 1996 Jan;103(1):105–9

[Detection of visual acuity disorders and amblyopia in preschool children (see comments)] Fernández Menéndez MJ, et al. **Aten Primaria** 1995 Sep 15;16(4):192–6 (Eng. Abstr.). Comment in: Aten Primaria 1996 May 15;17(8):543. **(Spa)**

ETIOLOGY

Amblyopia in congenital ptosis. Hornblass A, et al. **Ophthalmic Surg** 1995 Jul–Aug;26(4):334–7

Amblyopia. Campos E. **Surv Ophthalmol** 1995 Jul–Aug; 40(1):23–39 (177 ref.)

GENETICS

Blepharophimosis, ptosis, epicanthus inversus, telecanthus, amblyopia, and menstrual abnormality in sisters. Amano T, et al. **Jpn J Ophthalmol** 1995;39(2):172–6

HISTORY

Cuban epidemic neuropathy, 1991 to 1994: history repeats itself a century after the "amblyopia of the blockade". Ordúñez–Garcia PO, et al. **Am J Public Health** 1996 May; 86(5):738–43

PHYSIOPATHOLOGY

Physiology of suppression in strabismic amblyopia. Harrad R, et al. **Br J Ophthalmol** 1996 Apr;80(4):373–7 (63 ref.)

Conjugacy of saccades in deep amblyopia. Maxwell GF, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2514–22

Binocular luminance summation in humans with defective binocular vision. Sireteanu R. **Invest Ophthalmol Vis Sci** 1987 Feb;28(2):349–55

Amblyopia: a tale of two approaches. Hess RF. **Ophthalmic Physiol Opt** 1995 Sep;15(5):395–7

Flash visual evoked potential (VEP) in amblyopia and optic nerve disease. Davis ET, et al. **Optom Vis Sci** 1995 Sep; 72(9):612–8

Neural plasticity in adults with amblyopia. Levi DM, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6830–4

Better performance through amblyopic than through normal eyes. Fahle M, et al. **Vision Res** 1996 Jul;36(13):1939–44

Uncalibrated distortions vs undersampling. Field DJ, et al. **Vision Res** 1996 Jul;36(14):2121–4

Is the motion system relatively spared in amblyopia? Evidence from cortical evoked responses. Kubová Z, et al. **Vision Res** 1996 Jan;36(1):181–90

Color and luminance vision in human amblyopia: shifts in isoluminance, contrast sensitivity losses, and positional deficits. Mullen KT, et al. **Vision Res** 1996 Mar; 36(5):645–53

Amblyopic quasi–blindness for image structure. Treutwein B, et al. **Vision Res** 1996 Jul;36(14):2211–28

PREVENTION & CONTROL

Is community screening for amblyopia possible, or appropriate? Wright MC, et al. **Arch Dis Child** 1995 Sep; 73(3):192–5

Preschool visual screening [editorial; comment] Elston J. **Br J Ophthalmol** 1995 Dec;79(12):1063–4. Comment on: Br J Ophthalmol 1995 Dec;79(12):1068–73.

Assessment of an inner city visual screening programme for preschool children [see comments] Williamson TH, et al. **Br J Ophthalmol** 1995 Dec;79(12):1068–73. Comment in: Br J Ophthalmol 1995 Dec;79(12):1063–4.

[Measurement of the visual acuity to networks with the Teller's cards: efficient detection of amblyopia in infants and young children?] Speeg–Schatz C, et al. **J Fr Ophtalmol** 1995;18(8–9):510–5 (Eng. Abstr.) **(Fre)**

SURGERY

[Lamellar keratoplasty with the excimer laser. Initial clinical results] Eckhardt HB, et al. **Ophthalmologe** 1996 Jun; 93(3):242–6 (Eng. Abstr.) **(Ger)**

THERAPY

Results of treatment of amblyopia with a screening program for early detection. Lennerstrand G, et al. **Acta Ophthalmol Scand Suppl** 1996;(219):42–5

Modulation of amblyopia therapy [letter; comment] Benezra D. **Br J Ophthalmol** 1996 May;80(5):492. Comment on: Br J Ophthalmol 1995 Sep;79(9):802–6.

Modulation of amblyopia therapy following early surgery for unilateral congenital cataracts [editorial; comment] Harrad R. **Br J Ophthalmol** 1995 Sep;79(9):793. Comment on: Br J Ophthalmol 1995 Sep;79(9):802–6.

Modulation of amblyopia therapy following early surgery for unilateral congenital cataracts [see comments] Lloyd IC, et al. **Br J Ophthalmol** 1995 Sep;79(9):802–6. Comment in: Br J Ophthalmol 1995 Sep;79(9):793. Comment in: Br J Ophthalmol 1996 May;80(5):492.

Factors affecting the outcome of children treated for amblyopia [letter; comment] Flanagan DW, et al. **Eye** 1995; 9 (Pt 5):664. Comment on: Eye 1994;8 (Pt 6):627–31.

Measurement of compliances with occlusion therapy [letter; comment] Moseley MJ, et al. **J Pediatr Ophthalmol Strabismus** 1995 Nov–Dec; 32(6):399–400. Comment on: J Pediatr Ophthalmol Strabismus 1995 Mar–Apr;32(2):98–101.

Factors affecting the outcome of children treated for amblyopia. Good WV. **Surv Ophthalmol** 1996 Mar–Apr; 40(5):422–3

[Diagnosis and treatment of amblyopia] Lang J. **Ther Umsch** 1996 Jan;53(1):20–4 (Eng. Abstr.) **(Ger)**

AMBLYSTOMA see AMBYSTOMA

AMBROXOL

ADMINISTRATION & DOSAGE

[Evaluation of ambroxol given prenatally and postnatally on gas exchange in the newborn with respiratory distress syndrome] Sackey S, et al. **Ginekol Pol** 1995 Jul; 66(7):409–12 (Eng. Abstr.) **(Pol)**

ANALOGS & DERIVATIVES

Neltenexine: morphological investigation of protection against elastase–induced emphysema in rats. Braga PC, et al. **Drugs Exp Clin Res** 1995;21(2):51–7

PHARMACOLOGY

The effect of Ambroxol on bleomycin–induced changes in phospholipid composition of rat lung surfactant. Stettner S, et al. **Acta Physiol Hung** 1995;83(2):181–7

Evaluation of the effects of ambroxol on the ofloxacin concentrations in bronchial tissues in COPD patients with infectious exacerbation. Paganin F, et al. **Biopharm Drug Dispos** 1995 Jul;16(5):393–401

Use of ambroxol and bromhexine as mucolytics for enhanced diffusion of furaltadone into tracheobronchial secretions in broilers. Sumano H, et al. **Br Poult Sci** 1995 Jul; 36(3):503–7

Ambroxol inhibits doxorubicin–induced lipid peroxidation in heart of mice. Nowak D, et al. **Free Radic Biol Med** 1995 Nov;19(5):659–63

THERAPEUTIC USE

Antenatal ambroxol usage in the prevention of infant respiratory distress syndrome. Beneficial and adverse effects. Kimya Y, et al. **Clin Exp Obstet Gynecol** 1995; 22(3):204–11 (39 ref.)

The management of cystic fibrosis with carbocysteine lysine salt: single–blind comparative study with ambroxol hydrochloride. Caramia G, et al. **J Int Med Res** 1995 Jul–Aug;23(4):284–93

Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol. Lusuardi M, et al. **Monaldi Arch Chest Dis** 1995 Oct; 50(5):346–51

[Comparison of mortality and morbidity in newborns treated with ambroxol prenatally and postnatally] Sackey S, et al. **Ginekol Pol** 1995 Aug;66(8):439–43 (Eng. Abstr.) **(Pol)**

AMBULANCES

Precision, accuracy, and managed care implications of a hand–held whole blood analyzer in the prehospital setting. Tortella BJ, et al. **Am J Clin Pathol** 1996 Jul;106(1):124–7

Outcomes in severely ill patients transported without prehospital ALS. Hu SC, et al. **Am J Emerg Med** 1996 Jan;14(1):86–8

The revolution and evolution of prehospital cardiac care. Eisenberg MS, et al. **Arch Intern Med** 1996 Aug 12–26; 156(15):1611–9 (43 ref.)

Paramedic vs private transportation of trauma patients. Effect on outcome. Demetriades D, et al. **Arch Surg** 1996 Feb; 131(2):133–8

Prioritised ambulance call out may be necessary [letter; comment] Hall DJ. **BMJ** 1996 Jan 13;312(7023):124–5. Comment on: BMJ 1995 Jul 29;311(7000):281.

Ambulance or helicopter [editorial] Steedman DJ. **Br J Hosp Med** 1996 Apr 17–30;55(8):460–3

Beware of pain or even absence of pain in emergency calls [editorial; comment] Cokkinos DV. **Eur Heart J** 1995 Dec; 16(12):1747–8. Comment on: Eur Heart J 1995 Dec;16(12):1789–94.

Ambulance despatchers' estimation of intensity of pain and presence of associated symptoms in relation to outcome in patients who call for an ambulance because of acute chest pain [see comments] Herlitz J, et al. **Eur Heart J** 1995 Dec;16(12):1789–94. Comment in: Eur Heart J 1995 Dec;16(12):1747–8.

Out–of–hospital cardiac arrest due to coronary heart disease: a comparison of survival before and after the introduction of defribrillators in ambulances. Leslie WS, et al. **Heart** 1996 Feb;75(2):195–9

[The Norwegian Medical Company in Bosnia––humanitarian tasks] Dommerud SA. **Tidsskr Nor Laegeforen** 1996 Aug 20;116(19):2337–8 **(Nor)**

[Cost savings increase the pressure on ambulance care (letter)] Gårdelöf B. **Lakartidningen** 1995 Nov 15; 92(46):4316 **(Swe)**

ECONOMICS

An analysis of the appropriate use of the Caledon ambulance service in the Overberg. A short report. Frank SA, et al. **S Afr Med J** 1995 Nov;85(11):1185–6

HISTORY

St. John and first aid for the weak leg. Donald JC. **Am J Surg** 1996 May;171(5):450–2

STANDARDS

Comparison of ambulance dispatch protocols for nontraumatic abdominal pain. Lammers RL, et al. **Ann Emerg Med** 1995 Nov;26(5):579–89

[Emergency ambulances manned by physicians] Hansen TB, et al. **Ugeskr Laeger** 1996 Jan 22;158(4):425–7 **(Dan)**

STATISTICS & NUMERICAL DATA

Pattern of basic life support ambulance use in an urban pediatric population. Brady WJ Jr, et al. **Am J Emerg Med** 1996 May;14(3):250–3

Utstein style format for cardiac arrest analysis [letter; comment] Low SW. **N Z Med J** 1995 Sep 22;108(1008):392 . Comment on: N Z Med J 1995 Jul 28;108(1004):297–9.

AMBULANCES, AIR see AIR AMBULANCES

AMBULATION, EARLY see EARLY AMBULATION

AMBULATORY BLOOD PRESSURE MONITORING see BLOOD PRESSURE MONITORING, AMBULATORY

AMBULATORY CARE

New models for emergency and ambulatory care at academic health centers––Part III: Boston and Alberta, Canada. Ling LJ, et al. **Acad Emerg Med** 1995 Nov;2(11):1001–6

Teaching and learning in ambulatory care settings: a thematic review of the literature. Irby DM. **Acad Med** 1995 Oct; 70(10):898–931 (152 ref.)

Non–urgent emergency department visits by patients from

a resident ambulatory care clinic. McLeod PJ, et al. **Acad Med** 1995 Oct;70(10):932

Confronting the costs of ambulatory-care training [letter] Sostok MA, et al. **Acad Med** 1995 Nov;70(11):949–50

Evaluation of the effectiveness of an ambulatory teaching/treatment programme for non-insulin dependent (type 2) diabetic patients. Domenech MI, et al. **Acta Diabetol** 1995 Oct;32(3):143–7

Results of out-patient cataract surgery in patients who live far from the surgeon. Rebolleda Fernández G, et al. **Acta Ophthalmol Scand** 1995 Aug;73(4):350–2

Reduction mammaplasty: a comparison of outpatient and inpatient procedures. Davies BW, et al. **Aesthetic Plast Surg** 1996 Winter;20(1):77–80

Two methods of anesthesia for rhinoplasty in outpatient setting. Niechajev I, et al. **Aesthetic Plast Surg** 1996 Mar–Apr;20(2):159–63

Out-patient alcohol detoxification--outcome after 2 months. Klijnsma MP, et al. **Alcohol Alcohol** 1995 Sep;30(5):669–73

Outpatient management of tuberculosis [see comments] McColloster P, et al. **Am Fam Physician** 1996 Apr; 53(5):1579–94 (12 ref.). Comment in: Am Fam Physician 1996 Apr;53(5):1511–2.

Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Aliot E, et al. **Am J Cardiol** 1996 Jan 25;77(3):66A–71A

Ambulatory medical detoxification for alcohol. Abbott PJ, et al. **Am J Drug Alcohol Abuse** 1995 Nov;21(4):549–63 (30 ref.)

Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. Gillis S, et al. **Am J Hematol** 1996 Jan;51(1):26–31

Yield of laboratory tests for case-finding in the ambulatory general medical examination. Boland BJ, et al. **Am J Med** 1996 Aug;101(2):142–52

Preventing hospitalizations for asthma by improving ambulatory management [editorial; comment] Greenberger PA. **Am J Med** 1996 Apr;100(4):381–2. Comment on: Am J Med 1996 Apr;100(4):386–94.

A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Hanlon JT, et al. **Am J Med** 1996 Apr;100(4):428–37

Inadequate outpatient medical therapy for patients with asthma admitted to two urban hospitals [see comments] Hartert TV, et al. **Am J Med** 1996 Apr;100(4):386–94. Comment in: Am J Med 1996 Apr;100(4):381–2.

Experience with community academic practice: strategies for the ambulatory education of residents. Hershey CO, et al. **Am J Med** 1995 Nov;99(5):530–6

Screening for common problems in ambulatory elderly: clinical confirmation of a screening instrument [see comments] Moore AA, et al. **Am J Med** 1996 Apr; 100(4):438–43. Comment in: Am J Med 1996 Apr;100(4):383–5.

Breast cancer surveillance: ambulatory care focus in residency may influence practice patterns. Borum ML. **Am J Med Sci** 1996 Sep;312(3):123–5

Efficacy of outpatient induction with low-dose intravaginal prostaglandin E2: a randomized, double-blind, placebo-controlled trial. O'Brien JM, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1855–9

Effectiveness of an intensive outpatient rehabilitation program for postacute stroke patients. Werner RA, et al. **Am J Phys Med Rehabil** 1996 Mar–Apr;75(2):114–20

Interest in physician-assisted suicide among ambulatory HIV-infected patients. Breitbart W, et al. **Am J Psychiatry** 1996 Feb;153(2):238–42

Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Daniel DG, et al. **Am J Psychiatry** 1996 Mar;153(3):417–9

Psychiatric disorders and functional disability in outpatients with traumatic brain injuries. Fann JR, et al. **Am J Psychiatry** 1995 Oct;152(10):1493–9

'Walking' epidurals in labour [editorial] Morgan BM. **Anaesthesia** 1995 Oct;50(10):839–40

Acute treatment response in outpatients with panic disorder: high versus low depressive symptoms. Black DW, et al. **Ann Clin Psychiatry** 1995 Dec;7(4):181–8

Benign breast surgery: is there a need for outpatient follow-up? [letter] Harries SA, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):233

Outpatient left ventricular assist device support: a destination rather than a bridge. Catanese KA, et al. **Ann Thorac Surg** 1996 Sep;62(3):646–52; discussion 653

Current management of acute bronchitis in ambulatory care [letter] Hahn DL. **Arch Fam Med** 1996 Sep;5(9):439; discussion 440

Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Coley CM, et al. **Arch Intern Med** 1996 Jul 22;156(14):1565–71

Improving participation and interrater agreement in scoring Ambulatory Pediatric Association abstracts. How well have we succeeded? Kemper KJ, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):380–3

Outpatient liver biopsy using ultrasound guidance and the Biopty gun is safe and cost effective. Smith BC, et al. **Aust N Z J Med** 1995 Jun;25(3):209–11

Outpatient waiting times scrutinised [news] Court C. **BMJ** 1995 Dec 2;311(7018):1456

Outpatient follow up [editorial; comment] [see comments] Emberton M. **BMJ** 1995 Nov 18;311(7016):1315–6. Comment on: BMJ 1995 Nov 18;311(7016):1344–5. Comment in: BMJ 1996 Mar 9;312(7031):640.

Prospective study of trends in referral patterns in fundholding and non-fundholding practices in the Oxford region, 1990–4 [see comments] Surender R, et al. **BMJ** 1995 Nov 4;311(7014):1205–8. Comment in: BMJ 1996 Feb 17;312(7028):444–5. Comment in: BMJ 1996 Feb 17;312(7028):445.

Evaluation of the Pneupac Ventipac portable ventilator: comparison of performance in a mechanical lung and anaesthetized patients. McCluskey A, et al. **Br J Anaesth** 1995 Nov;75(5):645–50

A comprehensive one-stop menstrual problem clinic for the diagnosis and management of abnormal uterine bleeding [see comments] Baskett TF, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):76–7. Comment in: Br J Obstet Gynaecol 1996 Jun;103(6):596.

A comprehensive one-stop menstrual problem clinic for the diagnosis and management of abnormal uterine bleeding [letter; comment] Walker D, et al. **Br J Obstet Gynaecol** 1996 Jun;103(6):596. Comment on: Br J Obstet Gynaecol 1996 Jan;103(1):76–7.

A randomized clinical trial of in-patient multidisciplinary treatment versus routine out-patient care in active rheumatoid arthritis. Vliet Vlieland TP, et al. **Br J Rheumatol** 1996 May;35(5):475–82

Outpatient interstitial thermoradiotherapy. Lee DJ, et al. **Cancer** 1996 Jun 1;77(11):2363–70

Guidelines for the use of nebulizers in the home and at domiciliary sites. Report of a consensus conference. National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. O'Donohue WJ Jr. **Chest** 1996 Mar;109(3):814–20 (32 ref.)

The safety of i.v. pentamidine administered in an ambulatory setting. Yeung KT, et al. **Chest** 1996 Jul;110(1):136–40

Outpatient cervical ripening. Sawai SK, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):301–9 (23 ref.)

Office management of common neurologic problems. Moe PG. **Compr Ther** 1995 Sep;21(9):513–8 (16 ref.)

Data capture for quality management nursing opportunity. Denwood R. **Comput Nurs** 1996 Jan–Feb;14(1):39–44

A second quiet revolution: ambulatory ECT [editorial] Fink M, et al. **Convuls Ther** 1996 Mar;12(1):1–2

Ambulatory electroconvulsive therapy: report of a task force of the association for convulsive therapy. Association for Convulsive Therapy . Fink M, et al. **Convuls Ther** 1996 Mar;12(1):42–55

Developing an outpatient electroconvulsive therapy program: a nursing perspective. Gunderson-Falcone G. **Convuls Ther** 1995 Sep;11(3):202–4

Outpatient management of HIV infection in the adult: an update. Boswell SL. **Curr Clin Top Infect Dis** 1995; 15:301–43 (189 ref.)

Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in a pediatric neurology office practice. Linder SL. **Headache** 1996 Jul–Aug;36(7):419–22

Open-access paediatric echocardiography: changing role and referral patterns to a consultant-led service in a tertiary referral centre. Tybulewicz AT, et al. **Heart** 1996 Jun; 75(6):632–4

The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Lindor KD, et al. **Hepatology** 1996 May;23(5):1079–83

Gynaecoradiological uterine resection. Gleicher N, et al. **Hum Reprod** 1995 Jul;10(7):1801–3

The use of a structured assessment interview as an intervention to reduce dropout rates in outpatient relapse prevention groups for "problem" drinkers. Keaney F, et al. **Int J Addict** 1995 Aug;30(10):1355–62

Rapid responders to intensive treatment of bulimia nervosa. Olmsted MP, et al. **Int J Eat Disord** 1996 Apr;19(3):279–85

Outpatients in neurological rehabilitation. Barnes MP, et al. **Int J Rehabil Res** 1996 Mar;19(1):39–45

Continuum of care controversy [letter] Rubes RH, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug;35(8):973–4

The name of the game is change. Fred Hutchinson Cancer Research Center's clinical nutrition department is ahead of the game [interview by Deborah Shattuck] Aker S, et al. **J Am Diet Assoc** 1995 Nov;95(11):1255–6

The effectiveness and efficiency of outpatient geriatric evaluation and management. Engelhardt JB, et al. **J Am Geriatr Soc** 1996 Jul;44(7):847–56

Provision of nonacute, ambulatory geriatric services in a sparsely populated region of Norway [letter; comment] Ranhoff AH, et al. **J Am Geriatr Soc** 1996 Apr;44(4):478–9 . Comment on: J Am Geriatr Soc 1995 Jul;43(7):733–40.

The accuracy of medication data in an outpatient electronic medical record. Wagner MM, et al. **J Am Med Inform Assoc** 1996 May–Jun;3(3):234–44

A comparison of outpatient cardiac and pulmonary rehabilitation patients. Reardon JZ, et al. **J Cardpulm Rehabil** 1995 Jul–Aug;15(4):277–82

Proceedings of the 10th SAMBA (Society for Ambulatory Anesthesia) annual meeting. Indian Wells, California, April 27–30, 1995. **J Clin Anesth** 1995 Nov;7(7):555–633

A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. Baldwin DS, et al. **J Clin Psychiatry** 1996;57 Suppl 2:46–52

Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. Feiger A, et al. **J Clin Psychiatry** 1996;57 Suppl 2:53–62

The effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic. Tsuang D, et al. **J Clin Psychiatry** 1995 Dec;56(12):549–55

Command hallucinations in outpatients with schizophrenia. Zisook S, et al. **J Clin Psychiatry** 1995 Oct;56(10):462–5

Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. Grad RM. **J Fam Pract** 1995 Nov;41(5):473–81 (41 ref.)

Family medicine research in the community setting: what can we learn from successful researchers? Hueston WJ, et al. **J Fam Pract** 1996 Aug;43(2):171–6

Treating croup with dexamethasone. Spaulding C. **J Fam Pract** 1996 Feb;42(2):111

Ambulatory chronotherapy with 5-fluorouracil, folinic acid, and carboplatin for advanced non-small cell lung cancer. A phase II feasibility trial. Focan C, et al. **J Infus Chemother** 1995;5(3 Suppl 1):148–52

Home-based inpatient treatment vs. outpatient day clinic treatment: a preliminary report in opiate-dependent patients. Lerner AG, et al. **J Nerv Ment Dis** 1995 Nov; 183(11):715

Validating specific psychopathology scales in older outpatients with schizophrenia. McAdams LA, et al. **J Nerv Ment Dis** 1996 Apr;184(4):246–51

Impact of DSM-III axis III on the diagnosis of physical disorders in ambulatory psychiatric patients. Saavedra JE, et al. **J Nerv Ment Dis** 1995 Nov;183(11):711–4

Prediction of positive placebo response among chronic schizophrenic outpatients. Taiminen T, et al. **J Nerv Ment Dis** 1996 Feb;184(2):109–13

A series of 1000 consecutive out-patient diagnostic hysteroscopies. Cooper MJ, et al. **J Obstet Gynaecol** 1995 Oct;21(5):503–7

Family and client characteristics as predictors of outpatient treatment outcome for adolescent drug abusers. Friedman AS, et al. **J Subst Abuse** 1995;7(3):345–56

Healing of venous ulcers in an ambulatory care program: the roles of chronic venous insufficiency and patient compliance. Erickson CA, et al. **J Vasc Surg** 1995 Nov; 22(5):629–36

Triage of ambulatory patients [editorial; comment] Adams SL, et al. **JAMA** 1996 Aug 14;276(6):493–4. Comment on: JAMA 1996 Aug 15;276(6):460–5.

Quality of outpatient care: diabetes [letter; comment] Clemenson N. **JAMA** 1995 Nov 22–29;274(20):1584; discussion 1585. Comment on: JAMA 1995 May 17;273(19):1503–8. Comment on: JAMA 1995 May 17;273(19):1534–7.

Outpatients care of HIV-1-infected destitute people: a study in Paris, France [letter] Chauvin P, et al. **Lancet** 1996 Aug 17;348(9025):480

Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage. National Audit of Acute Upper Gastrointestinal Haemorrhage [see comments] Rockall TA, et al. **Lancet** 1996 Apr 27; 347(9009):1138–40. Comment in: Lancet 1996 Apr 27;347(9009):1130. Comment in: Lancet 1996 Jul 20;348(9021):201. Comment in: Lancet 1996 Jul 20;348(9021):201–2.

Outpatient cautery-assisted uvulopalatoplasty. Zinder DJ, et al. **Laryngoscope** 1995 Nov;105(11):1256–7

Diagnosis and outpatient management of congestive heart failure. Karon BL. **Mayo Clin Proc** 1995 Nov;70(11):1080–5 (00 ref.)

Management of depression in the outpatient office. Salazar WH. **Med Clin North Am** 1996 Mar;80(2):431–55 (95 ref.)

A server architecture for ambulatory patient record systems. Dargahi R, et al. **Medinfo** 1995;8 Pt 1:219–22

After hours medical services [letter] Gray B. **N Z Med J** 1996 Aug 23;109(1028):325

'Knowingly and willingly in the support and comfort of a patient' [editorial; comment] Harding LK, et al. **Nucl Med Commun** 1995 Nov;16(11):877–8. Comment on: Nucl Med Commun 1995 Nov;16(11):879–92.

Radiation protection issues associated with nuclear medicine out-patients [see comments] Thomson WH, et al. **Nucl Med Commun** 1995 Nov;16(11):879–92 (43 ref.). Comment in: Nucl Med Commun 1995 Nov;16(11):877–8.

The cost of teaching residents outpatient obstetrics and gynecology in a university medical center. Flanagan T, et al. **Obstet Gynecol** 1995 Dec;86(6):1014–7

2500 Outpatient diagnostic hysteroscopies. Nagele F, et al. **Obstet Gynecol** 1996 Jul;88(1):87–92

Office hysteroscopy. Siegler AM. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):457–71 (34 ref.)

Deep vein thrombosis prophylaxis in the outpatient setting: preventing complications following hospital discharge. Turpie AG. **Orthopedics** 1995 Jul;18 Suppl:15–7

Pediatric residents' continuity clinics: how are we really doing? Dumont-Driscoll MC, et al. **Pediatrics** 1995 Oct; 96(4 Pt 1):616–21

Positioning post-outpatient cardiac catheterization. Rein A, et al. **Prog Cardiovasc Nurs** 1995 Fall;10(4):4–10

The management of non-compliance with referral to out-patient after-care among attempted suicide patients:

a controlled intervention study. Van Heeringen C, et al. **Psychol Med** 1995 Sep;25(5):963–70

Utilization of radiologic services in different payment systems and patient populations. Burkhardt JH, et al. **Radiology** 1996 Jul;200(1):201–7

Added value of radiologist consultation to family practitioners in the outpatient setting. Franken EA Jr, et al. **Radiology** 1995 Dec;197(3):759–62

Extensive stage small cell lung cancer: determining suitability for outpatient management of febrile neutropenia. Rapp JS, et al. **Semin Oncol** 1996 Apr;23(2):xv–xxii; discussion xxii

Outpatient treatment of bulimia nervosa: an illustrative case study. Low BL. **Singapore Med J** 1995 Feb;36(1):92–5

Impact of the change from an injectable to a fully oral regimen on patient adherence to ambulatory tuberculosis treatment in Dar es Salaam, Tanzania. Chum HJ, et al. **Tuber Lung Dis** 1995 Aug;76(4):286–9

[Ambulatory treatment of psychiatric diseases among the deaf in Denmark] Alberdi F. **Ugeskr Laeger** 1996 Aug 19; 158(34):4763–6 (Eng. Abstr.) **(Dan)**

[Emergency care during ambulatory vasectomy] Lamberg A, et al. **Ugeskr Laeger** 1996 Aug 12;158(33):4649–50 (Eng. Abstr.) **(Dan)**

[Outpatient treatment of deep venous thromboses] Potron G, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):448–53 (Eng. Abstr.) **(Fre)**

[Ambulatory care of depressed patients. Retrospective study of 60 patients hospitalized for an episode of major depression] Oreve-Mauratille MJ, et al. **Ann Med Psychol (Paris)** 1995 Aug–Sep;153(7):461–6 **(Fre)**

[Effects of ambulatory respiratory rehabilitation on exercise tolerance and quality of life in chronic obstructive lung disease patients (see comments] Grosbois JM, et al. **Rev Mal Respir** 1996;13(1):61–7 (Eng. Abstr.). Comment in: Rev Mal Respir 1996;13(1):5–6. **(Fre)**

[Management of the insulin-dependent diabetic in ambulatory practice: the first year] de Kalbermatten N. **Rev Med Suisse Romande** 1995 Sep;115(9):681–6 **(Fre)**

[Nosocomial infections: a problem in ambulatory practice] Francioli P. **Rev Med Suisse Romande** 1996 May; 116(5):371–7 (5 ref.) **(Fre)**

[Management of type II diabetics in ambulatory practice] Jacot E. **Rev Med Suisse Romande** 1995 Sep;115(9):687–91 **(Fre)**

[Etomidate versus propofol for anesthesia in ambulatory cardioversion] Kick O, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):288–92 (Eng. Abstr.) **(Ger)**

[Ambulatory-access echocardiography—"service" for practitioners. Its importance for the diagnosis and therapy planning of heart failure] **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1340–1 **(Ger)**

[Fetal version as ambulatory intervention] Nohe G, et al. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):328–30 (Eng. Abstr.) **(Ger)**

[Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma] Atzpodien J, et al. **Med Klin** 1996 Apr 12;91 Suppl 3:38–43 (Eng. Abstr.) **(Ger)**

[Indications for family therapy in university ambulatory psychotherapy] Cierpka M, et al. **Prax Kinderpsychol Kinderpsychiatr** 1995 Sep;44(7):250–60 (Eng. Abstr.) **(Ger)**

[Treatment of a borderline patient in a community psychiatry team center] Porath A. **Psychiatr Prax** 1996 Mar;23(2):98 **(Ger)**

[Scope recommendations for ambulatory medical rehabilitation of 2 November 1995. Federal Study Group for Rehabilitation] **Rehabilitation (Stuttg)** 1996 May; 35(2):86–92 **(Ger)**

[Ambulatory therapy in varicose veins] Eichlisberger R, et al. **Ther Umsch** 1996 Apr;53(4):295–303 (24 ref.) (Eng. Abstr.) **(Ger)**

[Family practice diagnosis of patients with venous diseases in relation to severity, diagnosis and practice facilities. Results of the ASAM study "Physician status and factor evaluation study of ambulatory patient management"] Hoopmann M, et al. **Vasa** 1996;25(2):134–41 (Eng. Abstr.) **(Ger)**

[Ambulatory rehabilitation after myocardial infarct in Austria] Benzer W, et al. **Wien Klin Wochenschr** 1995; 107(24):766–70 (Eng. Abstr.) **(Ger)**

[Ambulatory rehabilitation of cardiac patients in Switzerland] Saner H, et al. **Wien Klin Wochenschr** 1995;107(24):771–3 (Eng. Abstr.) **(Ger)**

[Impact of DRG on the American hospital system. Development of day hospital] Salvo I, et al. **Minerva Anestesiol** 1995 May;61(5):229–31 **(Ita)**

[Hypertension in pregnancy: management protocols and pregnancy outcome followed at our ambulatory service] Frusca T, et al. **Minerva Ginecol** 1995 May;47(5):215–22 (Eng. Abstr.) **(Ita)**

[Usefulness of a second-level centralized ambulatory service for the staging of diseases of the endometrium and the lower genital tract in a provincial hospital] Vigada G, et al. **Minerva Ginecol** 1995 May;47(5):211–4 (Eng. Abstr.) **(Ita)**

[Reservoir system for bronchial arterial injection against lung cancer patients in an outpatient clinic] Masuda H, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:454–6 (Eng. Abstr.) **(Jpn)**

[Combined chemotherapy with 5-FU and low dose CDDP for advanced or recurrent cancer of the digestive system and home anti-cancer chemotherapy] Ogura T, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:433–8 (Eng. Abstr.) **(Jpn)**

[Clinical study of ambulatory cancer chemotherapy for advanced colorectal cancer] Takahashi N, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:447–52 (Eng. Abstr.) **(Jpn)**

[Outpatient chemotherapy with continuous infusion of 5-fluorouracil (CI 5-FU) and intravenous bolus leucovorin (IVB LV) in advanced gastrointestinal cancer: the second report] Tsuji Y, et al. **Gan To Kagaku Ryoho** 1995 Dec; 22 Suppl 4:439–46 (Eng. Abstr.) **(Jpn)**

[Ambulatory follow-up of patients with myelomeningocele in a pediatric hospital] Salomão JF, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3-A):444–50 (Eng. Abstr.) **(Por)**

[Outpatient treatment and follow-up of adolescents and adults with mucoviscidosis in a specialized center] Kuprina EA, et al. **Klin Med (Mosk)** 1996;74(1):23–5 (Eng. Abstr.) **(Rus)**

[The effect of the dietary correction of nutrition on rehabilitative efficacy in IHD patients after having had a myocardial infarct during dispensary observation] Shanavazova SA, et al. **Ter Arkh** 1996;68(1):33–5 (Eng. Abstr.) **(Rus)**

[The efficacy of fiber bronchoscopy under outpatient polyclinic conditions] Katkov VI, et al. **Voen Med Zh** 1996 May;317(5):35–7, 80 (Eng. Abstr.) **(Rus)**

[The early diagnosis of systemic connective tissue lesions at the polyclinic stage] Moskovko VM, et al. **Voen Med Zh** 1995 Jun;(6):39–41 **(Rus)**

[The efficacy of the dispensary observation of patients with ischemic heart disease who live in a rural locality] Todosienko LA, et al. **Vrach Delo** 1995 Jan–Feb; (1–2):153–5 (Eng. Abstr.) **(Rus)**

[An outpatient study in ENT (otorhinolaryngology) emergencies at a general hospital] Pérez Obón J, et al. **Acta Otorrinolaringol Esp** 1995 Jul–Aug;46(4):298–304 (Eng. Abstr.) **(Spa)**

[Classification systems in case-mix groups in ambulatory care. Perspectives for our primary health care] Juncosa S, et al. **Aten Primaria** 1996 Jan;17(1):76–82 (34 ref.) **(Spa)**

[Hospital admissions of children for conditions treatable by ambulatory care in the community of Valencia] Lerga Ramos I, et al. **Aten Primaria** 1995 Sep 15;16(4):197–202 (Eng. Abstr.) **(Spa)**

[National Task Force on Home and Ambulatory Artificial Nutrition. NADYA. The NADYA Group] Gómez Candela C, et al. **Nutr Hosp** 1995 Sep–Oct;10(5):258–63 (Eng. Abstr.) **(Spa)**

ECONOMICS

Is treatment in groups a useful alternative for psychiatry in low-income countries? An evaluation of a psychiatric outpatient unit in Nicaragua. Caldera T, et al. **Acta Psychiatr Scand** 1995 Nov;92(5):386–91

Empiric outpatient management of HIV-related pneumonia: economical or unwise? [editorial] Masur H, et al. **Ann Intern Med** 1996 Feb 15;124(4):451–3

Charges for outpatient rehabilitation: growth and differences in provider types. Buchanan JL, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):320–8

Evaluation of two interventions to reduce the ancillary costs of outpatient care for rheumatoid arthritis. Katz JN, et al. **Arthritis Rheum** 1996 Jan;39(1):177–8

Evaluation of medical cost lost due to smoking in Chinese cities. Chen J, et al. **Biomed Environ Sci** 1995 Dec; 8(4):335–41

Measuring of impact of patient counseling in the outpatient pharmacy setting: development and implementation of the counseling models for the Kaiser Permanente/USC Patient Consultation Study. Johnson KA, et al. **Clin Ther** 1995 Sep–Oct;17(5):988–1002

Multivariate cost-effectiveness analysis: an application to optimizing ambulatory care for hypertension. Shepard DS, et al. **Inquiry** 1995 Fall;32(3):320–31

Pediatric hospitalization due to ambulatory care-sensitive conditions in Valencia (Spain). Casanova C, et al. **Int J Qual Health Care** 1996 Feb;8(1):51–9

Economic analysis of Alzheimer's disease in outpatients: impact of symptom severity. Souêtre EJ, et al. **Int Psychogeriatr** 1995 Spring;7(1):115–22

The effect of first-contact care with primary care clinicians on ambulatory health care expenditures [see comments] Forrest CB, et al. **J Fam Pract** 1996 Jul;43(1):40–8. Comment in: J Fam Pract 1996 Jul;43(1):30–32.

Physician response to patient insurance status in ambulatory care clinical decision-making. Implications for quality of care. Mort EA, et al. **Med Care** 1996 Aug;34(8):783–97

Systemwide provider performance in a Medicaid program. Profiling the care of patients with chronic illnesses. Powe NR, et al. **Med Care** 1996 Aug;34(8):798–810

Effectiveness, patient matching, and insurance coverage for depression. McGuire TG. **Soc Psychiatry Psychiatr Epidemiol** 1995 Aug;30(5):240–3

An economic evaluation of schizophrenia—1991. Wyatt RJ, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Aug; 30(5):196–205 (49 ref.)

An economic evaluation of manic-depressive illness—1991. Wyatt RJ, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Aug;30(5):213–9

[Comment on W. Brand: Ambulatory rehabilitation—effectiveness and cost savings (letter; comment)] Emde, et al. **Versicherungsmedizin** 1995 Dec 1;47(6):234–5. Comment on: Versicherungsmedizin 1995 Jun 1;47(3):95–6. **(Ger)**

LEGISLATION & JURISPRUDENCE

Involuntary outpatient civil commitment: what can Britain learn from the U.S. experience? A civil liberties perspective. Fulop NJ. **Int J Law Psychiatry** 1995 Summer; 18(3):291–303

Forensic psychiatry in Israel: involuntary out-patient treatment [editorial] Silfen P, et al. **Isr J Psychiatry Relat Sci** 1995;32(2):79

Outpatient commitment [letter; comment] Ryan JM. **Psychiatr Serv** 1995 Dec;46(12):1291. Comment on: Psychiatr Serv 1995 Aug;46(8):778–84.

A national survey of the use of outpatient commitment [see comments] Torrey EF, et al. **Psychiatr Serv** 1995 Aug; 46(8):778–84. Comment in: Psychiatr Serv 1995 Dec;46(12):1291.

Treatment of sexual offenders in an outpatient community-based program. Bingham JE, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1195–200

["Ambulatory rehabilitation" in orthopedic/traumatologic diseases of the musculoskeletal system] Blandfort R. **Chirurg** 1996 Jun;67(6):Suppl 139–40 **(Ger)**

[Social legislative and structural deficits of ambulatory management of chronic psychiatric and handicapped patients] Rössler W, et al. **Nervenarzt** 1995 Nov; 66(11):802–10 (34 ref.) (Eng. Abstr.) **(Ger)**

[Structural prerequisites for ambulatory geriatric rehabilitation—the ambulatory rehabilitation team] Finger C. **Z Gastroenterol** 1996 Jun;34 Suppl 2:106–8 **(Ger)**

METHODS

Outpatient endometrial assessment. Read MD. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):150–3 (45 ref.)

Radial artery approach for outpatient peripheral arteriography [letter] Bishop NL. **Clin Radiol** 1996 Aug; 51(8):598–9

Enhancement of proxy appointment for older persons: physician counselling in the ambulatory setting. Meier DE, et al. **J Am Geriatr Soc** 1996 Jan;44(1):37–43

Office laparoscopy as a screening tool for early detection of ovarian cancer. Runowicz CD. **J Cell Biochem Suppl** 1995;23:238–42 (12 ref.)

How far can the paediatric patient with a serious infection be managed as an outpatient? Dagan R. **J Hosp Infect** 1995 Jun;30 Suppl:172–8

A quasi-experimental comparison of the effectiveness of 6- versus 12-hour per week outpatient treatments for cocaine dependence. Alterman AI, et al. **J Nerv Ment Dis** 1996 Jan;184(1):54–6

Reduction of nausea and vomiting from epidural opioids by adding droperidol to the infusate in home-bound patients. Aldrete JA. **J Pain Symptom Manage** 1995 Oct;10(7):544–7

Implementation of a formal treatment agreement for outpatient management of chronic nonmalignant pain with opioid analgesics. Burchman SL, et al. **J Pain Symptom Manage** 1995 Oct;10(7):556–63 (19 ref.)

Microprocessor-based physiological signal monitoring and recording system for ambulatory subjects. Kao SD, et al. **Med Biol Eng Comput** 1995 Nov;33(6):830–4

Outpatient asthma management. Cockcroft DW, et al. **Med Clin North Am** 1996 Jul;80(4):701–18 (60 ref.)

A trial of increased access to primary care [letter] Snider GL, et al. **N Engl J Med** 1996 Sep 19;335(12):896; discussion 897–8

The outpatient management of febrile neutropenia in cancer patients. Freifeld AG, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):599–606, 611–2; discussion 615–6 (31 ref.)

Comparison of the accuracy of impedance plethysmography and compression ultrasonography in outpatients with clinically suspected deep vein thrombosis. A two centre paired-design prospective trial. Wells PS, et al. **Thromb Haemost** 1995 Dec;74(6):1423–7

[Effective preoperative studies in outpatient anesthesiology] Langemeijer JJ, et al. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1723–6 (Eng. Abstr.) **(Dut)**

[Total and prolonged parenteral nutrition at the hospital and at the patient's home: its socio-economic importance] Joyeux H, et al. **Bull Acad Natl Med** 1995 Nov; 179(8):1625–36 (Eng. Abstr.) **(Fre)**

[The ambulatory rehabilitation of patients with the sequelae of a stroke: a differential approach] Belova AN. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):88–91 **(Rus)**

[Ambulatory oxygen therapy via a transtracheal catheter] Díaz Lobato S, et al. **Arch Bronconeumol** 1996 May; 32(5):225–9 (Eng. Abstr.) **(Spa)**

[Lateral photo-color therapy in the combined ambulatory treatment of mental disorders] Marstenkovs'kyĭ IA. **Lik Sprava** 1995 Jul–Aug;(7–8):111–3, 193 (Eng. Abstr.) **(Ukr)**

ORGANIZATION & ADMINISTRATION

Developing collaborative partnerships between inpatient nephrology and outpatient dialysis units. Lewandowski L. **Adv Ren Replace Ther** 1995 Oct;2(4):371–2

Developing pharmacy's role in ambulatory care: Parkland Health and Hospital System. Hatwig CA.
Am J Health Syst Pharm 1996 Feb 15;53(4 Suppl 1):S27–32

Developing pharmacy's role in ambulatory care: Cedars–Sinai Medical Center. Shane R.
Am J Health Syst Pharm 1996 Feb 15;53(4 Suppl 1):S32–6

The outpatient setting as a teaching environment. Tunbridge M. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):344–6

Concerns about increasing use of ambulatory care raised at QMA annual meeting. Wharry S. **Can Med Assoc J** 1996 Jun 1;154(11):1755

A network approach to outpatient service delivery systems: resources flow and system influence. Oliver AL, et al.
Health Serv Res 1996 Feb;30(6):771–89

Issues of variability and bias affecting multisite measurement of quality of care. Orav EJ, et al. **Med Care** 1996 Sep;34(9 Suppl):SS87–101

What makes quality assurance effective? Results from a randomized, controlled trial in 16 primary care group practices. Palmer RH, et al. **Med Care** 1996 Sep;34(9 Suppl):SS29–39

Consistency in performance among primary care practitioners. Palmer RH, et al. **Med Care** 1996 Sep;34(9 Suppl):SS52–66

Quality improvement among primary care practitioners: an overall appraisal of results of the Ambulatory Care Medical Audit Demonstration Project. Palmer RH, et al.
Med Care 1996 Sep;34(9 Suppl):SS102–13

The Ambulatory Care Medical Audit Demonstration Project. Research design. Palmer RH, et al. **Med Care** 1996 Sep; 34(9 Suppl):SS12–28

Ambulatory care of the HIV–infected child. O'Hara MJ, et al. **Nurs Clin North Am** 1996 Mar;31(1):179–205 (46 ref.)

Putting guidelines to work in an ambulatory care setting. Dolan CS. **Oncol Nurs Forum** 1995 Oct;22(9):1436

The computerization of ambulatory pediatric practice. Zurhellen WM. **Pediatrics** 1995 Oct;96(4 Pt 2):835–42; discussion 842–4

Medical audit used for estimation of optimum level of outpatient care. Lindström K, et al.
Scand J Prim Health Care 1995 Sep;13(3):175–81

[Comments on organization and activity of ENT day hospital department: three years of experience] Marcotullio D, et al. **Acta Otorhinolaryngol Ital** 1995 Oct;15(5):395–9 (Eng. Abstr.) **(Ita)**

[The organizational forms for the early detection and prevention of acute pyelonephritis and dispensary care for pregnant women] Dovlatian AA, et al.
Akush Ginekol (Mosk) 1995;(6):49–53 **(Rus)**

[The organization of medical care for patients with neurostomatological diseases under outpatient conditions] Borisova EG. **Stomatologiia (Mosk)** 1995;74(5):68 **(Rus)**

[The dispensary care of servicemen utilizing the territorial principle in providing dental care] Silaenkov VM.
Voen Med Zh 1995 Mar;(3):29–31 **(Rus)**

PSYCHOLOGY

The life situation of a long–term psychiatric patient: some restrictions in, and possibilities of, open care. Nikkonen M. **J Adv Nurs** 1995 Jul;22(1):101–9

STANDARDS

Ambulatory care certificate program for pharmacists. Jannsen RK, et al. **Am J Health Syst Pharm** 1996 May 1;53(9):1018–23

Outpatient management of diabetes mellitus in five Arizona Medicare managed care plans. Marshall CL, et al.
Am J Med Qual 1996 Summer;11(2):87–93

Client–centered approach to develop a seating clinic satisfaction questionnaire: a qualitative study. McComas J, et al. **Am J Occup Ther** 1995 Nov–Dec;49(10):980–5

Important elements of outpatient care: a comparison of patients' and physicians' opinions. Laine C, et al.
Ann Intern Med 1996 Oct 15;125(8):640–5

Routine nasal surgery: an audit of outpatient follow–up. Murthy P, et al. **Postgrad Med J** 1996 Jan;72(843):37–40

Developing outcome measures for ambulatory care—an application to asthma and diabetes. McColl E, et al.
Soc Sci Med 1995 Nov;41(10):1339–48

[Patient satisfaction in the ambulatory setting: validation of a scale and identification of associated factors] Perneger TV, et al. **Schweiz Med Wochenschr** 1996 May 18; 126(20):864–71 (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Patient's choice of hospital or office for Medicaid ambulatory care in Alabama. Bronstein JM, et al. **Med Care** 1996 Apr; 34(4):348–60

Record linkage strategies, outpatient procedures, and administrative data. Roos LL, et al. **Med Care** 1996 Jun; 34(6):570–82

Laboratory services utilization: a survey of repeat investigations in ambulatory care. Branger PJ, et al.
Neth J Med 1995 Nov;47(5):208–13

Evaluation of 2–week doctor visit reporting in the national health interview survey. Edwards WS, et al.
Vital Health Stat 2 1996 Aug;(122):1–46 (17 ref.)

[Clinical statistics on outpatients during a ten–year period (1983, 10–1993, 12) at Department of Urology, Fukui Medical School] Kanamaru H, et al. **Hinyokika Kiyo** 1995 Nov;41(11):953–6 (Eng. Abstr.) **(Jpn)**

TRENDS

Recent advances: ambulatory care and family medicine. Gums JG. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):716–8 (10 ref.)

The changing nature of ambulatory rehabilitation programs and services in a managed care environment. Gill HS.
Arch Phys Med Rehabil 1995 Dec;76(12 Suppl):SC10–5

Continuity of care and delivery of ambulatory services to children in community health clinics. O'Malley AS, et al.
J Community Health 1996 Jun;21(3):159–73

Acute and chronic psychiatric care: establishing boundaries. Sederer LI, et al. **Psychiatr Q** 1995 Fall;66(3):263–74

[Preventive and after–care of elderly patients from the viewpoint of the established physician. Recommendations for new structures in ambulatory medical management of the elderly] Zeller W. **Fortschr Med** 1996 May 30; 114(15):191–2 **(Ger)**

[The status of after–care rehabilitation between acute clinic and ambulatory care] von Stetten D. **Z Gastroenterol** 1996 Jun;34 Suppl 2:6–13 **(Ger)**

UTILIZATION

Utilization of inpatient and outpatient resources for the management of hemodialysis access complications. Rocco MV, et al. **Am J Kidney Dis** 1996 Aug;28(2):250–6

Impact of visit copayments on outpatient mental health utilization by members of a health maintenance organization. Simon GE, et al. **Am J Psychiatry** 1996 Mar; 153(3):331–8

Impact of prior and current alcohol use on use of services by patients with depression and chronic medical illnesses. Jackson CA, et al. **Health Serv Res** 1995 Dec;30(5):687–705

Ambulatory care practice variation within a Medicaid program. Weiner JP, et al. **Health Serv Res** 1996 Feb; 30(6):751–70

Health insurance and use of medical services by men infected with HIV. Katz MH, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Jan 1;8(1):58–63

Utilization of ambulatory health services by urban adolescents [see comments] Ryan SA, et al.
J Adolesc Health 1996 Mar;18(3):192–202. Comment in: Nippon Koshu Eisei Zasshi 1996 Mar;18(3):165.

Stress, gender, cognitive impairment, and outpatient physician use in later life. Krause N.
J Gerontol B Psychol Sci Soc Sci 1996 Jan;51(1):P15–23

Ambulatory visits to hospital emergency departments. Patterns and reasons for use. 24 Hours in the ED Study Group [see comments] Young GP, et al. **JAMA** 1996 Aug 14;276(6):460–5. Comment in: JAMA 1996 Aug 14;276(6):493–4.

Utilization of physician resources for ambulatory care. Tataryn DJ, et al. **Med Care** 1995 Dec;33(12 Suppl):DS84–99

[The work load of family physicians in deprived neighborhoods in Amsterdam: do their patients com more often?] Reijneveld SA. **Ned Tijdschr Geneeskd** 1995 Oct 7;139(40):2043–7 (Eng. Abstr.) **(Dut)**

[The clinico–epidemiological characteristics of a contingent of older patients being cared for by the psychoneurological office of a regional polyclinic] Zozulia TV.
Zh Nevropatol Psikhiatr Im S S Korsakova 1995;95(2):65–8 (Eng. Abstr.) **(Rus)**

AMBULATORY CARE FACILITIES

Results of out–patient cataract surgery in patients who live far from the surgeon. Rebolleda Fernández G, et al.
Acta Ophthalmol Scand 1995 Aug;73(4):350–2

Calculating a clinic's childhood immunization rate: costs and returns [letter; comment] Stevens C, et al.
Arch Fam Med 1996 Jun;5(6):325–6. Comment on: Arch Fam Med 1995 Jul;4(7):625–7.

Reactive arthritis in patients attending an urban sexually transmitted diseases clinic. Rich E, et al.
Arthritis Rheum 1996 Jul;39(7):1172–7

Evaluation of a primary care anticoagulant clinic. Reporting of results should be standardised [letter; comment] Fitzmaurice DA, et al. **BMJ** 1996 Jun 22; 312(7046):1609–10; discussion 1610. Comment on: BMJ 1996 Mar 2;312(7030):560.

Evaluation of a primary care anticoagulant clinic. Authors did not present enough data [letter; comment] Fowlie PW. **BMJ** 1996 Jun 22;312(7046):1609. Comment on: BMJ 1996 Mar 2;312(7030):560.

The role of an anaesthetist in a field hospital during the cholera epidemic among Rwandan refugees in Goma. Ginosar Y, et al. **Br J Anaesth** 1995 Dec;75(6):810–6

A comprehensive one–stop menstrual problem clinic for the diagnosis and management of abnormal uterine bleeding [letter] Liston WA. **Br J Obstet Gynaecol** 1996 Aug; 103(8):851–2

Private medical clinic for travellers fills a niche in Vancouver. Tempelman–Kluit A. **Can Med Assoc J** 1996 Mar 1;154(5):697–8

Prevalence of dry eye in Japanese eye centers. Hikichi T, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Sep; 233(9):555–8

Effectiveness of a specialized asthma clinic in reducing asthma morbidity in an inner–city minority population. Sperber K, et al. **J Asthma** 1995;32(5):335–43

Health and safety in Medical Centres; finding the hazards and reducing the risks. Buchanan JD.
J R Nav Med Serv 1995 Summer;81(2):134–7

Do we need pigmented lesion clinics? [letter] Ibbotson SH, et al. **Lancet** 1995 Nov 18;346(8986):1373

Integrated development of a knowledge–based CPR system for quality assurance in diabetes outpatient clinics. Moser W, et al. **Medinfo** 1995;8 Pt 1:236–9

Nurse–managed cancer–screening clinic [letter] Granneman S, et al. **Nurse Pract** 1996 May;21(5):6, 8, 13–4

"A tuberculosis control plan for ambulatory care centers" [letter; comment] Scott K. **Nurse Pract** 1995 Oct;20(10):7 . Comment on: Nurse Pract 1995 Jun;20(6):34–6, 39–40.

Condom use among patients attending six sexually transmitted disease clinics in Switzerland. Paget WJ, et al.
Sex Transm Dis 1995 Sep–Oct;22(5):303–9

Outpatient coronary angiography using 7 French catheters in Singapore. Mak KH, et al. **Singapore Med J** 1995 Feb; 36(1):49–51

[The prehospital anesthesia consultation in French speaking Switzerland (Letter)] Klopfenstein CE, et al.
Can J Anaesth 1996 Mar;43(3):317–8 **(Fre)**

[Functions of a health center to support health services of a municipality--a questionnaire to municipalities in Shikoku] Toyota M, et al. **Nippon Koshu Eisei Zasshi** 1996 Apr;43(4):325–35 **(Jpn)**

[Health centers and school health services (letter)] Andersen JF, et al. **Tidsskr Nor Laegeforen** 1996 Aug 20; 116(19):2355–6 **(Nor)**

[Health service for physicians--what do physicians want? (letter)] Flottorp S, et al. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):893 **(Nor)**

[Health service for physicians. What do physicians want—form and substance?] Thorsen O, et al.
Tidsskr Nor Laegeforen 1995 Dec 10;115(30):3788–90 (Eng. Abstr.) **(Nor)**

[Analysis of mortality in outpatient departments] Karmilov VA. **Arkh Patol** 1996 Mar–Apr;58(2):71–3 (Eng. Abstr.) **(Rus)**

[Experience in using a diagnostic magnetometer in emergency care] Gurfinkel' IuI, et al. **Biofizika** 1995 Sep–Oct;40(5):1042–9 (Eng. Abstr.) **(Rus)**

[Drug prescriptions in general medicine clinics or drugs prescribed by primary care physicians? (letter; comment)] Costa Alcaraz AM, et al. **Aten Primaria** 1995 Oct 31; 16(7):454–5. Comment on: Aten Primaria 1995 Mar 31;15(5):286–8. **(Spa)**

[Suitability of a tobacco dependence clinic in primary care] Granollers Mercader S, et al. **Aten Primaria** 1995 Oct 15; 16(6):331–6 (Eng. Abstr.) **(Spa)**

[Valuable methods for lung function measurements. Spirometry at ambulatory centers is excellent for early diagnosis] Larsson M. **Lakartidningen** 1995 Nov 22; 92(47):4427–30, 4435–7 (27 ref.) **(Swe)**

ECONOMICS

Financial effect of clinical decisions: case study of a dialysis center. Balas EA, et al. **J Med Syst** 1995 Dec;19(6):465–74

Using a voucher system to extend health services to migrant farmworkers. Slesinger DP, et al. **Public Health Rep** 1996 Jan–Feb;111(1):57–62

HISTORY

McMahon Medical Clinic, 1972–1992. Bitonte R.
Bull N Y Acad Med 1995 Summer;72(1):118–35

Evolution of undergraduate education in ambulatory settings: historical models. Greenberg LW. **Pharos** 1995 Fall; 58(4):13–7 (20 ref.)

ORGANIZATION & ADMINISTRATION

Pharmacist–managed ticlopidine clinic [letter] Pecini M.
Am J Health Syst Pharm 1995 Sep 15;52(18):2030–1

Review of efficiencies and patient satisfaction in Australian and New Zealand day surgery units: a pilot study. Rudkin GE, et al. **Anaesth Intensive Care** 1996 Feb;24(1):74–8

Managing the increased workload in anticoagulant clinics. Computerised decision support is valuable [letter; comment] Fitzmaurice DA, et al. **BMJ** 1996 May 11; 312(7040):1226. Comment on: BMJ 1996 Feb 3;312(7026):286.

Evaluation of a primary care anticoagulant clinic managed by a pharmacist [see comments] Macgregor SH, et al.
BMJ 1996 Mar 2;312(7030):560. Comment in: BMJ 1996 Jun 22;312(7046):1609. Comment in: BMJ 1996 Jun 22;312(7046):1609; discussion 1610. Comment in: BMJ 1996 Jun 22;312(7046):1609–10; discussion 1610.

Methods for managing the increased workload in anticoagulant clinics [see comments] Taylor FC, et al.
BMJ 1996 Feb 3;312(7026):286. Comment in: BMJ 1996 May 11;312(7040):1226. Comment in: BMJ 1996 May 11;312(7040):1226–7.

Managing the increased workload in anticoagulant clinics. Clinics led by nurse practitioners can work well [letter; comment] Van de Pette J, et al. **BMJ** 1996 May 11; 312(7040):1226–7. Comment on: BMJ 1996 Feb 3;312(7026):286.

Investigation of benefits and costs of an ophthalmic outreach clinic in general practice. Gillam SJ, et al.
Br J Gen Pract 1995 Dec;45(401):649–52

Reducing patient waiting times through quality assurance methods in La Troncal, Ecuador. Hermida J, et al.

Bull Pan Am Health Organ 1996 Jun;30(2):118–24
When to perform the final HIV antibody test following possible exposure. The British Co-operative Clinical Group. **Int J STD AIDS** 1995 Sep–Oct;6(5):332–5
A school-based clinic for elementary schools in Phoenix, Arizona. Wenzel M. **J Sch Health** 1996 Apr;66(4):125–7
QED: quick and early diagnosis. Kendall MJ, et al. **Lancet** 1996 Aug 24;348(9026):528–9
Caring and sharing [comment] Orton P. **Lancet** 1995 Oct 14;346(8981):984. Comment on: Lancet 1995 Oct 14;990–4.
Herodotus and the multidisciplinary clinic. Schipper H, et al. **Lancet** 1995 Nov 18;346(8986):1312–3
Initiating an ophthalmic laser program for VA outpatients. Newcomb RD. **Mil Med** 1995 Aug;160(8):381–4
Nurse practitioner in a rural setting. Thornton CL. **Nurs Clin North Am** 1996 Sep;31(3):495–505
The computerization of ambulatory pediatric practice. Zurhellen WM. **Pediatrics** 1995 Oct;96(4 Pt 2):835–42; discussion 842–4
[Problems, organization and methods of a regional diabetic out-patient clinic based on analysis of personal experience (letter)] Nawrotna-Walcowa R. **Pol Tyg Lek** 1996 Jan; 51(1–5):61–2 **(Pol)**

STANDARDS

Evaluation of a primary care anticoagulant clinic. Issue of quality control was not addressed [letter; comment] Adlakha S, et al. **BMJ** 1996 Jun 22;312(7046):1609; discussion 1610. Comment on: BMJ 1996 Mar 2;312(7030):560.
Assessment of a direct referral hearing aid clinic. Zeitoun H, et al. **Br J Audiol** 1995 Feb;29(1):13–21
Diabetes care: a guideline to the facilities needed to support internationally endorsed standards. Busch-Sørensen M, et al. **Diabet Med** 1995 Sep;12(9):833–8
[Patient satisfaction in the ambulatory setting: validation of a scale and identification of associated factors] Perneger TV, et al. **Schweiz Med Wochenschr** 1996 May 18; 126(20):864–71 (Eng. Abstr.) **(Fre)**
[Cooperation for quality development in primary health care: the new laboratory committee will become "a long arm" of SEQLA] Hellsing K, et al. **Lakartidningen** 1996 Feb 14;93(7):547–9 **(Swe)**
[A new clinical audit model for primary health care. Health centers are inspected for quality control] Lennholm B. **Lakartidningen** 1996 Mar 20;93(12):1093–4, 1099 **(Swe)**

STATISTICS & NUMERICAL DATA

Prevalence of enteric parasitic infection among HIV-infected attendees of an inner city AIDS clinic. Esfandiari A, et al. **Cell Mol Biol (Noisy-le-grand)** 1995;41 Suppl 1:S19–23
[Questionnaire survey of AIDS examination recipients at government-run public health center regarding AIDS awareness promotion and HIV examinations] Hasegawa S, et al. **Nippon Koshu Eisei Zasshi** 1996 Apr;43(4):276–85 (Eng. Abstr.) **(Jpn)**

TRENDS

Follow-up of comprehensive geriatric assessment in a family medicine residency clinic [see comments] Cefalu CA, et al. **J Am Board Fam Pract** 1995 Jul–Aug;8(4):263–9. Comment in: J Am Board Fam Pract 1995 Jul–Aug;8(4):337–40.

UTILIZATION

Use of outpatient clinics as a health indicator for communities around a coal-fired power plant. Goren AI, et al. **Environ Health Perspect** 1995 Dec;103(12):1110–5
Accessibility of genitourinary medicine clinics. Hope VD, et al. **Genitourin Med** 1996 Feb;72(1):52–5
[Outpatient sports clinic, first impressions] Keizer SB, et al. **Ned Tijdschr Geneeskd** 1996 Jul 27;140(30):1548–51 (Eng. Abstr.) **(Dut)**

AMBULATORY CARE FACILITIES, HOSPITAL see **OUTPATIENT CLINICS, HOSPITAL**

AMBULATORY CARE INFORMATION SYSTEMS

Reporting adverse drug reactions in an ambulatory care setting. Finn B, et al. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2704–6
The value of computers in the clinic. Nalin P, et al. **J Fam Pract** 1996 Aug;43(2):124–5
A managed care workstation for support of ambulatory care in Veterans Health Administration medical centers. Levy C, et al. **J Med Syst** 1995 Oct;19(5):387–96
The computer will see you now [editorial] **Lancet** 1996 Apr 27;347(9009):1127
A proposed architecture for ambulatory systems development. Buffone GJ, et al. **Medinfo** 1995;8 Pt 1:363–6
An experimental study on home health care support information system construction. Ishikawa K, et al. **Medinfo** 1995;8 Pt 1:581–5
A shared computer-based problem-oriented patient record for the primary care team. Linnarsson R, et al. **Medinfo** 1995;8 Pt 2:1663
An information system for emergency and out-patient departments. Maxwell DM. **Medinfo** 1995;8 Pt 1:60
Collaborative social and medical service application. Petermann CA, et al. **Medinfo** 1995;8 Pt 2:1671
Beyond computer-based clinical reminders: improvement of the total service quality by small-group based organizational learning in primary care. Timpka T, et al. **Medinfo** 1995;8 Pt 1:559–63
A data model that captures clinical reasoning about patient problems. Barrows RC Jr, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:402–5
Evaluating a comprehensive outpatient clinical information system: a case study and model for system evaluation. Chin HL, et al. **Proc Annu Symp Comput Appl Med Care** 1995; :717–21
Acceptance and performance by clinicians using an ambulatory electronic medical record in an HMO. Krall MA. **Proc Annu Symp Comput Appl Med Care** 1995;:708–11
A randomized evaluation of a computer-based physician's workstation: design considerations and baseline results. Rotman BL, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:693–7
A findings model for an ambulatory pediatric record: essential data, relational modeling, and vocabulary considerations. Shiffman RN. **Proc Annu Symp Comput Appl Med Care** 1995;:411–5
Methods for assessing information needs of clinicians in ambulatory care. Tang PC, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:630–4

ORGANIZATION & ADMINISTRATION

Computerized medical information systems [letter; comment] Keulen DJ. **J Fam Pract** 1996 Jul;43(1):13–4. Comment on: J Fam Pract 1996 Mar;42(3):233–6.
Computerized medical information systems [letter; comment] Salkowe J. **J Fam Pract** 1996 Jul;43(1):14. Comment on: J Fam Pract 1996 Mar;42(3):233–6.

STANDARDS

Case study: practical tools for improving needs-based health management and technology assessment. The PHC MAP series. Wilson RG. **Int J Technol Assess Health Care** 1995 Fall;11(4):709–15
The SAPPHIRE toolkit: an interactive system for the evaluation of primary healthcare computing. Pitt M, et al. **Medinfo** 1995;8 Pt 2:1672
Policy on the development of immunization of tracking systems. American Academy of Pediatrics Committee on Practice and Ambulatory Medicine. **Pediatrics** 1996 Jun; 97(6 Pt 1):927

UTILIZATION

Has general practitioner computing made a difference to patient care? A systematic review of published reports. Sullivan F, et al. **BMJ** 1995 Sep 30;311(7009):848–52 (56 ref.)

AMBULATORY ELECTROCARDIOGRAPHY see **ELECTROCARDIOGRAPHY, AMBULATORY**

AMBULATORY MONITORING see **MONITORING, AMBULATORY**

AMBULATORY SURGERY

see related
SURGICENTERS

Patient-controlled premedication by i.v. midazolam for ambulatory surgery. Bernard JM, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):331–7
Effect of intravenous ketoprofen on pain after outpatient laparoscopic sterilisation. Eriksson H. **Acta Anaesthesiol Scand** 1995 Oct;39(7):975–8
Balanced analgesia improves recovery and outcome after outpatient tubal ligation. Eriksson H, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):151–5
Mivacurium in short to intermediate surgical procedures. Platt MW. **Acta Anaesthesiol Scand Suppl** 1995;106:30–4
Day-case trabeculectomies: safety and efficacy. Beatty S, et al. **Acta Ophthalmol Scand** 1996 Apr;74(2):132–4
Postural control after propofol anaesthesia in minor surgery. Ledin T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:313–6
Ambulatory phlebectomy compared to sclerotherapy for varicose and telangiectatic veins: indications and complications. Weiss RA, et al. **Adv Dermatol** 1996;11:3–16; discussion 17 (37 ref.)
Outpatient therapeutic ERCP: cutting sphincters and cutting costs [editorial; comment] Bjorkman DJ, et al. **Am J Gastroenterol** 1996 Aug;91(8):1485–6. Comment on: Am J Gastroenterol 1996 Aug;91(8):1499–502.
A prospective study of the safety of endoscopic therapy for choledocholithiasis in an outpatient population [see comments] Elfant AB, et al. **Am J Gastroenterol** 1996 Aug; 91(8):1499–502. Comment in: Am J Gastroenterol 1996 Aug;91(8):1485–6.
Minilaparotomy for the ambulatory management of ovarian cysts. Flynn M, et al. **Am J Obstet Gynecol** 1995 Dec; 173(6):1727–9; discussion 1729–30
Anterior cruciate ligament reconstruction as an outpatient procedure. Tierney GS, et al. **Am J Sports Med** 1995 Nov–Dec;23(6):755–6
Hospital admission following ambulatory surgery. Greenburg AG, et al. **Am J Surg** 1996 Jul;172(1):21–3
Physical, psychological, and economic advantages of accelerated discharge after surgical treatment for breast cancer. Kambouris A. **Am Surg** 1996 Feb;62(2):123–7
Rocuronium bromide in dental day case anaesthesia--a comparison with atracurium and vecuronium. Chetty MS, et al. **Anaesth Intensive Care** 1996 Feb;24(1):37–41
Review of efficiencies and patient satisfaction in Australian and New Zealand day surgery units: a pilot study. Rudkin GE, et al. **Anaesth Intensive Care** 1996 Feb;24(1):74–8
Analgesia for day surgery. Evaluation of the effect of diclofenac given before or after surgery with or without bupivacaine infiltration. Chan A, et al. **Anaesthesia** 1996 Jun;51(6):592–5
Anaesthesia for day-care arthroscopy. A comparison between desflurane and isoflurane. Gupta A, et al. **Anaesthesia** 1996 Jan;51(1):56–62
Assessment of recovery following day-case arthroscopy. A comparison between propofol and isoflurane-based anaesthesia. Gupta A, et al. **Anaesthesia** 1995 Nov; 50(11):937–42
Recovery from outpatient anaesthesia. Factors affecting outcome. Korttila K. **Anaesthesia** 1995 Oct;50 Suppl:22–8 (63 ref.)
A comparison of the recovery characteristics of sevoflurane and halothane in children. Sury MR, et al. **Anaesthesia** 1996 Jun;51(6):543–6
Laparoscopic and open inguinal hernia repair [letter] Taylor RS, et al. **Anaesthesia** 1996 Feb;51(2):204–5
Recovery profile after desflurane with or without ondansetron compared with propofol in patients undergoing outpatient gynecological laparoscopy. Eriksson H, et al. **Anesth Analg** 1996 Mar;82(3):533–8
Sevoflurane for outpatient anesthesia: a comparison with propofol. Fredman B, et al. **Anesth Analg** 1995 Oct; 81(4):823–8
Preoperative fasting time: is the traditional policy changing? Results of a national survey. Green CR, et al. **Anesth Analg** 1996 Jul;83(1):123–8
Continuous hypopharyngeal pH measurements in spontaneously breathing anesthetized outpatients: laryngeal mask airway versus tracheal intubation [see comments] Joshi GP, et al. **Anesth Analg** 1996 Feb;82(2):254–7. Comment in: Anesth Analg 1996 Aug;83(2):441–2.
Preoperative multimodal analgesia facilitates recovery after ambulatory laparoscopic cholecystectomy. Michaloliakou C, et al. **Anesth Analg** 1996 Jan;82(1):44–51
Surgical patients' attitudes regarding participation in clinical anesthesia research [see comments] Mingus ML, et al. **Anesth Analg** 1996 Feb;82(2):332–7. Comment in: Anesth Analg 1996 Aug;83(2):438.
Sevoflurane versus desflurane for outpatient anesthesia: a comparison of maintenance and recovery profiles. Nathanson MH, et al. **Anesth Analg** 1995 Dec;81(6):1186–90
A multicenter comparison of maintenance and recovery with sevoflurane or isoflurane for adult ambulatory anesthesia. The Sevoflurane Multicenter Ambulatory Group. Philip BK, et al. **Anesth Analg** 1996 Aug;83(2):314–9
Intravenous therapy and outpatient surgery outcomes [letter; comment] Rosenberg MK. **Anesth Analg** 1995 Dec; 81(6):1314. Comment on: Anesth Analg 1995 Apr;80(4):682–6.
The role of sevoflurane in outpatient anesthesia. Smith I, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S67–72 (24 ref.)
Comparison of rocuronium and mivacurium to succinylcholine during outpatient laparoscopic surgery. Tang J, et al. **Anesth Analg** 1996 May;82(5):994–8
A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures. Tang J, et al. **Anesth Analg** 1996 Aug;83(2):304–13
Combined spinal/epidural anesthesia for outpatient surgery [letter; comment] Joshi GP. **Anesthesiology** 1996 Feb; 84(2):481–2. Comment on: Anesthesiology 1995 Sep;83(3):528–34.
Preoperative pregnancy testing in ambulatory surgery [letter; comment] Lewis I, et al. **Anesthesiology** 1996 May; 84(5):1259–60; discussion 1261. Comment on: Anesthesiology 1995 Oct;83(4):690–3.
Preoperative pregnancy testing in ambulatory surgery. Incidence and impact of positive results [see comments] Manley S, et al. **Anesthesiology** 1995 Oct;83(4):690–3. Comment in: Anesthesiology 1996 May;84(5):1259–60; discussion 1261. Comment in: Anesthesiology 1996 May;84(5):1260; discussion 1261. Comment in: Anesthesiology 1996 May;84(5):1260–1.
Preoperative pregnancy testing in ambulatory surgery [letter; comment] Rosenberg MK. **Anesthesiology** 1996 May; 84(5):1260; discussion 1261. Comment on: Anesthesiology 1995 Oct;83(4):690–3.
Preoperative pregnancy testing in ambulatory surgery [letter; comment] Zeig NJ, et al. **Anesthesiology** 1996 May; 84(5):1260–1. Comment on: Anesthesiology 1995 Oct;83(4):690–3.
Day surgery--the future. Jarrett PE. **Ann Chir Gynaecol** 1995;84(4):379–83 (37 ref.)
A day ward in the life of a district urologist: planning the urology day ward list. Cetti NE. **Ann R Coll Surg Engl** 1995 Nov;77(6 Suppl):302–3
Tension-free mesh hernia repair: review of 1098 cases using local anaesthesia in a day unit [see comments] Kark AE, et al. **Ann R Coll Surg Engl** 1995 Jul;77(4):299–304.

Comment in: Ann R Coll Surg Engl 1995 Nov;77(6):466–7. Comment in: Ann R Coll Surg Engl 1995 Nov;77(6):467.
Comparison of diclofenac sodium and morphine sulphate for postoperative analgesia after day case inguinal hernia surgery. McEvoy A, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):363–6
Safety and cost–efficiency of 24–hour hospitalization for carotid endarterectomy. Musser DJ, et al. **Ann Vasc Surg** 1996 Mar;10(2):143–6
The use of diazepam and ketamine for i.v. conscious sedation in outpatient surgery settings. Ringler JD. **AORN J** 1995 Oct;62(4):638–45
Short–stay outpatient tonsillectomy [letter] Berry YJ. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):897; discussion 897–8
Short–stay outpatient tonsillectomy [letter] Goodman RS. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):897; discussion 897–8
Day–case cataract surgery [letter] Goold JE. **Br J Anaesth** 1996 Feb;76(2):333
Day–case cataract surgery [letter] Maltby JR, et al. **Br J Anaesth** 1996 Feb;76(2):333
Regional anaesthesia for outpatient nasal surgery. Molliex S, et al. **Br J Anaesth** 1996 Jan;76(1):151–3
Cognitive failures after general anaesthesia for day–case surgery. Tzabar Y, et al. **Br J Anaesth** 1996 Feb;76(2):194–7
General anaesthesia for day–case cataract surgery [letter; comment] Whitehead PN. **Br J Anaesth** 1995 Aug; 75(2):252–3. Comment on: Br J Anaesth 1995 Feb;74(2):145–8.
Anaesthesia for day–case surgery. Hitchcock M, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):202–6 (20 ref.)
Perianal and anorectal conditions [see comments] Kumar D. **Br J Hosp Med** 1996 Apr 17–30;55(8):464–7. Comment in: Br J Hosp Med 1996 Apr 17–30;55(8):463.
Day–case procedures [editorial; comment] Russell RC. **Br J Hosp Med** 1996 Apr 17–30;55(8):463. Comment on: Br J Hosp Med 1996 Apr 17–30;55(8):464–7. Comment on: Br J Hosp Med 1996 Apr 17–30;55(8):468–71. Comment on: Br J Hosp Med 1996 Apr 17–30;55(8):472–5.
The training implications of day–case surgery [see comments] Sharp RJ, et al. **Br J Hosp Med** 1996 Apr 17–30;55(8):472–5 Comment in: Br J Hosp Med 1996 Apr 17–30;55(8):463.
Is day–case prostatectomy feasible? Keoghane SR, et al. **Br J Urol** 1995 Nov;76(5):600–3
Urological day case surgery [letter; comment] Willis RG. **Br J Urol** 1995 Nov;76(5):671–2. Comment on: Br J Urol 1995 Jun;75(6):708–11.
Practical infection control. Berry AJ. **Can J Anaesth** 1995 Nov;42(11):1051–3
Discharge criteria––a new trend. Chung F. **Can J Anaesth** 1995 Nov;42(11):1056–8
Management of postoperative pain and emesis. White PF. **Can J Anaesth** 1995 Nov;42(11):1053–5
Quebec hopes to overcome province's surgical–delay problem. Martin M. **Can Med Assoc J** 1995 Oct 1; 153(7):1001–2
Comparison of intranasal midazolam and sufentanil premedication in pediatric outpatients. Zedie N, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):341–8
Maneuver to facilitate ambulatory phlebectomy. Olivencia JA. **Dermatol Surg** 1996 Jul;22(7):654–5
Ambulatory phlebectomy. A rare complication of local anesthetic: case report and literature review. Olivencia JA. **Dermatol Surg** 1996 Jan;22(1):53–5 (15 ref.)
Intraoperative radiation therapy and Mohs micrographic surgery on an outpatient basis. Siegle RJ, et al. **Dermatol Surg** 1995 Nov;21(11):975–8 (16 ref.)
Ambulatory hemorrhoidectomy with CO2 laser. Hodgson WJ, et al. **Dis Colon Rectum** 1995 Dec;38(12):1265–9
Uvulectomy in the office setting. Ariyasu L, et al. **Ear Nose Throat J** 1995 Oct;74(10):721–2
Co–induction of anaesthesia: day–case surgery. Whitwam JG. **Eur J Anaesthesiol Suppl** 1995 Nov;12:25–34 (50 ref.)
Propranolol reduces the anxiety associated with day case surgery. Mealy K, et al. **Eur J Surg** 1996 Jan;162(1):11–4
Outpatient surgical treatment of anal fissure. Neufeld DM, et al. **Eur J Surg** 1995 Jun;161(6):435–8
Day case laparoscopic cholecystectomy: a safe and cost effective procedure. Prasad A, et al. **Eur J Surg** 1996 Jan; 162(1):43–6
Is day case liver biopsy underutilised? Douds AC, et al. **Gut** 1995 Oct;37(4):574–5
Outpatient surgery of varices of the lower limbs: experience of 2,568 cases at four universities. Baccaglini U, et al. **Int Angiol** 1995 Dec;14(4):397–9
The integration of diagnostic tests and the role of outpatient surgery in the management of breast disease. Ranieri E, et al. **Int Surg** 1995 Apr–Jun;80(2):181–4
Proceedings of the 10th SAMBA (Society for Ambulatory Anesthesia) annual meeting. Indian Wells, California, April 27–30, 1995. **J Clin Anesth** 1995 Nov;7(7):555–633
Incidence of nausea and vomiting in outpatients undergoing general anesthesia in relation to selection of intraoperative opioid. Cepeda MS, et al. **J Clin Anesth** 1996 Jun;8(4):324–8
A post–anesthetic discharge scoring system for home readiness after ambulatory surgery. Chung F, et al. **J Clin Anesth** 1995 Sep;7(6):500–6
Comparison of sevoflurane and halothane anesthesia in children undergoing outpatient ear, nose, and throat surgery. Greenspun JC, et al. **J Clin Anesth** 1995 Aug; 7(5):398–402
Pediatric ambulatory anesthesia: role of parents. Hannallah RS. **J Clin Anesth** 1995 Nov;7(7):597–9
Propofol and alfentanil mixture for outpatient surgery [letter; comment] Isert P. **J Clin Anesth** 1995 Jun;7(4):357. Comment on: J Clin Anesth 1994 Mar–Apr;6(2):166–7.
Propofol permits tracheal intubation but does not affect postoperative myalgias. Mingus ML, et al. **J Clin Anesth** 1996 May;8(3):220–4
Cost–effectiveness analysis of antiemetic therapy for ambulatory surgery [letter; comment] Parasuraman TV, et al. **J Clin Anesth** 1995 Aug;7(5):440–3. Comment on: J Clin Anesth 1994 Sep–Oct;6(5):370–7.
Desflurane is not associated with faster operating room exit times in outpatients. Patel N, et al. **J Clin Anesth** 1996 Mar; 8(2):130–5
Pediatric ambulatory anesthesia: NPO––before or after surgery? Schreiner MS, et al. **J Clin Anesth** 1995 Nov; 7(7):589–96 (41 ref.)
Oxygen administration during transport and recovery after outpatient surgery does not prevent episodic arterial desaturation. Scuderi PE, et al. **J Clin Anesth** 1996 Jun; 8(4):294–300
The use of Bier's block for day case surgery. Dunlop DJ, et al. **J Hand Surg [Br]** 1995 Oct;20(5):679–80
Outpatient laparoscopic cholecystectomy feasibility. Taylor E, et al. **J Laparoendosc Surg** 1996 Apr;6(2):73–7
Outpatient cholecystectomy. Voitk AJ. **J Laparoendosc Surg** 1996 Apr;6(2):79–81
Day–stay myringoplasty. Benson–Mitchell R, et al. **J Laryngol Otol** 1996 May;110(5):421–4
KTP–532 laser tonsillectomy––a potential day–case procedure? [letter] Kaluskar SK. **J Laryngol Otol** 1996 Feb; 110(2):205–7
Would day–case adult tonsillectomy be safe? Moralee SJ, et al. **J Laryngol Otol** 1995 Dec;109(12):1166–7
Day–case septal surgery under general anaesthesia and local anaesthesia with sedation. Srinivasan V, et al. **J Laryngol Otol** 1995 Jul;109(7):614–7
Blood glucose concentration in pediatric outpatient surgery. Somboonviboon W, et al. **J Med Assoc Thai** 1996 Apr; 79(4):236–9
Propofol: an alternative general anesthetic for outpatient oral surgery. Pastuovic MN, et al. **J Oral Maxillofac Surg** 1996 Aug;54(8):943–8
Continuous quality improvement in a day ward. Senior S, et al. **J Qual Clin Pract** 1995 Sep;15(3):177–81
Complications of office based arthroscopy of the knee. Szachnowski P, et al. **J Rheumatol** 1995 Sep;22(9):1722–5
Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. Smack DP, et al. **JAMA** 1996 Sep 25;276(12):972–7
Evaluation of oral midazolam as pre–medication in day care surgery in adult Pakistani patients. Ahmed N, et al. **JPMA J Pak Med Assoc** 1995 Sep;45(9):239–41
Ambulatory tonsillectomy and adenoidectomy. Gabalski EC, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):77–80
An overview of consumer–driven ambulatory surgery: operative laparoscopy. Geier WS. **Nurse Pract** 1995 Nov; 20(11 Pt 1):36, 46–51 (61 ref.)
Ambulatory vs. in–patient stapedectomy: a randomized twenty–patient pilot study. Corvera G, et al. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):355–9
Comparison of 25 G and 29 G Quincke spinal needles in paediatric day case surgery. A prospective randomized study of the puncture characteristics, success rate and postoperative complaints. Kokki H, et al. **Paediatr Anaesth** 1996;6(2):115–9
Day case survey of postoperative nausea and vomiting [letter] Mawer RJ, et al. **Paediatr Anaesth** 1995;5(3):203–5
Computer–assisted continuous infusion for the delivery of target–controlled infusions of propofol during outpatient surgery. Arndt GA, et al. **Pharmacotherapy** 1995 Jul–Aug; 15(4):512–6
The effects of sevoflurane and isoflurane on recovery from outpatient surgery. O'Hara DA, et al. **Pharmacotherapy** 1996 May–Jun;16(3):446–52
How to handle rigid endoscopes in office surgical facilities [letter] Hamas RS. **Plast Reconstr Surg** 1996 Sep; 98(3):574–5
A comparison of sedation techniques for outpatient rhinoplasty: midazolam versus midazolam plus ketamine. Moscona RA, et al. **Plast Reconstr Surg** 1995 Oct; 96(5):1066–74
Arguments for day case surgery [see comments] Alexander–Williams J. **Practitioner** 1996 Mar; 240(1560):152–60 (10 ref.). Comment in: Practitioner 1996 Mar;240(1560):131.
Outpatient percutaneous nephrostomy. Gray RR, et al. **Radiology** 1996 Jan;198(1):85–8
A randomized controlled trial of laparoscopic extraperitoneal hernia repair as a day surgical procedure. Bessell JR, et al. **Surg Endosc** 1996 May;10(5):495–500
149 ambulatory laparoscopic cholecystectomies. Fiorillo MA, et al. **Surg Endosc** 1996 Jan;10(1):52–6
Is outpatient laparoscopic cholecystectomy wise? Saunders CJ, et al. **Surg Endosc** 1995 Dec;9(12):1263–8
Patients' perception of day case surgery. Kelly MC. **Ulster Med J** 1994 Apr;63(1):27–31
Peripheral nerve blocks for paediatric day–stay surgery: one year's experience in a district general hospital. Keohane M, et al. **Ulster Med J** 1995 Apr;64(1):39–41
Same day surgery for radical retropubic prostatectomy: is it an attainable goal? Palmer JS, et al. **Urology** 1996 Jan; 47(1):23–8
[Ambulatory laparoscopic varicocelectomy. The first experiences] Gehr NR. **Ugeskr Laeger** 1996 Apr 8; 158(15):2123–5 (Eng. Abstr.) **(Dan)**
[Patient assessment in ambulatory surgery. A questionnaire study] Nielsen TR, et al. **Ugeskr Laeger** 1996 Mar 25; 158(13):1823–6 (Eng. Abstr.) **(Dan)**
[Effective preoperative studies in outpatient anesthesiology] Langemeijer JJ, et al. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1723–6 (Eng. Abstr.) **(Dut)**
[Patient discharge criteria following surgery in day care] Zuurmond WW, et al. **Ned Tijdschr Geneeskd** 1996 Feb 24;140(8):422–4 **(Dut)**
[Does outpatient general anesthesia fulfill all expectations? (editorial)] Lindgren L, et al. **Duodecim** 1995;111(9):815–7 **(Fin)**
[Ambulatory surgery: where are we? Elements for answering. . . (editorial)] Parmentier G, et al. **Ann Fr Anesth Reanim** 1995;14(5):383–6 **(Fre)**
[Tonsillectomy in a day care hospital. A socioeconomic study at the Robert Debré Hospital in Paris] Contencin P, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(4):174–82 (Eng. Abstr.) **(Fre)**
[Ambulatory laser and turbinectomy in the treatment of nasal obstruction. Apropos of 68 cases] Lachiver X, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(6):285–92 (Eng. Abstr.) **(Fre)**
[Anesthesia for ambulatory surgery in children] Flubacher P. **Rev Med Suisse Romande** 1996 Apr;116(4):251–3 **(Fre)**
[General ambulatory anesthesia in oral medicine and maxillofacial surgery] Boufflers E, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):247–58 (22 ref.) **(Fre)**
[A comparative study of the use of sevoflurane and propofol in ambulatory surgery] Motsch J, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S57–62 (Eng. Abstr.) **(Ger)**
[Comparison of sevoflurane and isoflurane in ambulatory surgery. Results of a multicenter study] Scholz J, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S63–70 (Eng. Abstr.) **(Ger)**
–Indications and complications of ambulatory surgery in a general practice operating room– Baertschi U. **Arch Gynecol Obstet** 1995;256 Suppl:S1–5 **(Ger)**
[Contribution to the discussion of quality assurance measures in ambulatory surgery] Doench K. **Arch Gynecol Obstet** 1995;257(1–4):202–5 **(Ger)**
[Ambulatory endoscopic surgery––ovary and leiomyoma] Gallinat A. **Arch Gynecol Obstet** 1995;257(1–4):17–21 **(Ger)**
[Prevention of thrombosis with fraxiparin 0.3 after ambulatory surgery] Schain FH. **Fortschr Med** 1996 Apr 30;114(12):149–52 (Eng. Abstr.) **(Ger)**
[Integration, organization and results of ambulatory surgery in a central hospital] Rotzer A, et al. **Swiss Surg** 1995; (6):307–10; discussion 310 (Eng. Abstr.) **(Ger)**
[Liability in ambulatory surgery from the legal viewpoint] Jansen C. **Z Arztl Fortbild (Jena)** 1995 Nov;89(6):663–6 (Eng. Abstr.) **(Ger)**
[Medical malpractice in ambulatory surgery] Kienzle HF. **Z Arztl Fortbild (Jena)** 1995 Nov;89(6):666–72; discussion 673–5 (Eng. Abstr.) **(Ger)**
[Ambulatory surgery: current status and prospects] Sias F, et al. **Ann Ital Chir** 1996 Jan–Feb;67(1):111–5; discussion 116–7 (Eng. Abstr.) **(Ita)**
[Ambulatory hemorrhoidectomy: results of 500 surgical operations] Carditello A. **Chir Ital** 1994;46(6):68–70 (Eng. Abstr.) **(Ita)**
[Ambulatory phlebectomy: our experience] Stio F, et al. **G Chir** 1995 Oct;16(10):459–60 (Eng. Abstr.) **(Ita)**
[Ambulatory phlebectomy with Müller procedure in the treatment of lower limb varices. Indications, technique and long–term results] Ferrara G, et al. **Minerva Chir** 1995 Jul–Aug;50(7–8):681–5 (Eng. Abstr.) **(Ita)**
[Ambulatory surgery. Patients and patient education] Bredland T, et al. **Tidsskr Nor Laegeforen** 1996 Feb 20; 116(5):610–4 (Eng. Abstr.) **(Nor)**
[Admissions and readmissions from a unit of ambulatory surgery. Experiences after 2 411 surgical interventions] Grøgaard B, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28; 116(6):742–5 (Eng. Abstr.) **(Nor)**
[Ambulatory surgery and incentives] Høsteng T, et al. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):872–3 (Eng. Abstr.) **(Nor)**
[Postoperative treatment and follow–up] Kvalsvik O. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):849–53 (Eng. Abstr.) **(Nor)**
[Selection of patients for ambulatory surgery] Kvalsvik O. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):500–3 (Eng. Abstr.) **(Nor)**
[Ambulatory surgery, preoperative anamnesis and clinical examination (letter)] Noess PA. **Tidsskr Nor Laegeforen** 1996 Apr 20;116(10):1258 **(Nor)**
[Ambulatory surgery––preoperative examinations] Raeder JC. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):497–9 (Eng. Abstr.) **(Nor)**
[Day surgery] Solheim K. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):355 **(Nor)**
[Outpatient surgery in pediatric ENT] Miró JL, et al. **Acta Otorrinolaringol Esp** 1995 Sep–Oct;46(5):345–8 (Eng.

Abstr.) (Spa)
[Ondansetron in the prevention of postoperative nausea and vomiting in ambulatory surgery] Bustos-Molina F, et al. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):138-41 (Eng. Abstr.) (Spa)
[Ambulatory surgery must follow the rules of the game! Strict patient selection is important] Enlund M. **Lakartidningen** 1995 Sep 27;92(39):3598-9 (Swe)

ADVERSE EFFECTS

Postoperative thromboembolism after day-case herniorrhaphy. Riber C, et al. **Br J Surg** 1996 Mar; 83(3):420-21
Outpatient thyroid and parathyroid surgery: a prospective study of feasibility, safety, and costs. Mowschenson PM, et al. **Surgery** 1995 Dec;118(6):1051-3; discussion 1053-4
[Thromboembolic complications in ambulatory surgery. A retrospective study of 1691 patients] Wessel N, et al. **Tidsskr Nor Laegeforen** 1996 Feb 20;116(5):615-6 (Eng. Abstr.) (Nor)

ECONOMICS

Economic benefits attributed to opening a preoperative evaluation clinic for outpatients. Pollard JB, et al. **Anesth Analg** 1996 Aug;83(2):407-10
Cost containment: a charge comparison of anterior cruciate ligament reconstruction. Novak PJ, et al. **Arthroscopy** 1996 Apr;12(2):160-4
Cost effectiveness of day stay versus inpatient radiofrequency (RF) ablation for the treatment of supraventricular tachyarrhythmias. Weerasooriya HR, et al. **Aust N Z J Med** 1996 Apr;26(2):206-9
Cost analysis of propofol versus thiopental induction anesthesia in outpatient laparoscopic gynecologic surgery. Wagner BK, et al. **Clin Ther** 1995 Jul-Aug;17(4):770-6
Application of cost-utility and quality-adjusted life years analyses to monitored anesthesia care for sedation only. Dexter F. **J Clin Anesth** 1996 Jun;8(4):286-8
Practical, cost-effective regional anesthesia for ambulatory surgery. Greenberg CP. **J Clin Anesth** 1995 Nov; 7(7):614-21 (32 ref.)
Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery [letter; comment] Lake AP, et al. **J Clin Anesth** 1995 Sep;7(6):551-3. Comment on: J Clin Anesth 1994 Sep-Oct;6(5):370-7.
Practical cost-effective choices: ambulatory general anesthesia. Philip BK. **J Clin Anesth** 1995 Nov;7(7):606-13 (31 ref.)
Global fees for managed care in ambulatory surgery. Wilson TD. **J Clin Anesth** 1995 Nov;7(7):578-80
Outpatient circumcisions [letter] Moreno CA, et al. **J Fam Pract** 1996 Mar;42(3):306; discussion 307
Septoplasty as a day-case procedure--a two centre study. Benson-Mitchell R, et al. **J Laryngol Otol** 1996 Feb; 110(2):129-31
The hidden costs of keyhole care [editorial; comment] Kerrigan P. **Practitioner** 1996 Mar;240(1560):131. Comment on: Practitioner 1996 Mar;240(1560):152-60.
Outpatient thyroid and parathyroid surgery: a prospective study of feasibility, safety, and costs. Mowschenson PM, et al. **Surgery** 1995 Dec;118(6):1051-3; discussion 1053-4

INSTRUMENTATION

KTP/532 laser tonsillectomy--a potential day-case procedure [letter; comment] Llewellyn R. **J Laryngol Otol** 1995 Dec;109(12):1234-5. Comment on: J Laryngol Otol 1995 Jun;109(6):515-9.
[The role of outpatient conization with a diathermy loop in the diagnosis and treatment of CIN] Mele GA. **Minerva Ginecol** 1996 Apr;48(4):155-7 (Eng. Abstr.) (Ita)

METHODS

A step towards day case prostatectomy. Suvakovic N, et al. **Br J Urol** 1996 Feb;77(2):212-4
Outpatient ACL surgery: a review of safety, practicality, and economy. Malek MM, et al. **Instr Course Lect** 1996; 45:281-6
Snare uvulopalatoplasty [see comments] Weingarten C. **Laryngoscope** 1995 Oct;105(10):1033-6. Comment in: Laryngoscope 1996 Mar;106(3 Pt 1):370.
[Treatment of strabismus in ambulatory surgery] Cordonnier M, et al. **Bull Soc Belge Ophtalmol** 1994;254:79-84 (Eng. Abstr.) (Fre)
[Breast reconstruction with the use of tissue expanders in outpatient treatment] Martinazzoli A, et al. **G Chir** 1996 Apr;17(4):195-6 (Eng. Abstr.) (Ita)

NURSING

Outpatient vaginal hysterectomy as a new trend in gynecology. Bran DF, et al. **AORN J** 1995 Nov;62(5):810-4

PSYCHOLOGY

Effect of music on ambulatory surgery patients' preoperative anxiety. Augustin P, et al. **AORN J** 1996 Apr;63(4):750, 753-8
The effect of humorous and musical distraction on preoperative anxiety. Gaberson KB. **AORN J** 1995 Nov; 62(5):784-8, 790-1

STANDARDS

A survey of post-operative care after day case surgery. Wedderburn AW, et al. **Ann R Coll Surg Engl** 1996 Mar; 78(2 Suppl):70-1
Canadian Association of General Surgeons' position statement on ambulatory care. Pollett WG. **Can J Surg** 1996 Jun;39(3):183-4 (Eng, Fre)
Creating greater efficiency in ambulatory surgery. Hecht AD. **J Clin Anesth** 1995 Nov;7(7):581-4
Accountability through accreditation [editorial] Laskin DM. **J Oral Maxillofac Surg** 1996 Mar;54(3):249
Discrediting accreditation [letter] Ronald JB. **J Oral Maxillofac Surg** 1996 Sep;54(9):1142
Ambulatory paediatric surgery. The development of a day-care surgical centre. Rode H, et al. **S Afr Med J** 1994 Dec;84(12):829-33
[Check-ups via telephone after day surgery. An effective part of quality assurance work] Persson BM, et al. **Lakartidningen** 1996 Jun 12;93(24):2331-2 (Swe)

STATISTICS & NUMERICAL DATA

The changing pattern of day-care treatment for children in a London dental teaching hospital. Mason C, et al. **Br Dent J** 1995 Aug 19;179(4):136-40
Day case oral surgery: a review of 25 years experience at the Dublin Dental Hospital. Sleeman D, et al. **Br Dent J** 1995 Sep 23;179(6):221-4
[The extent of ambulatory surgery (letter)] Kindseth O. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):783-4 (Nor)
[The extent of ambulatory surgery. A questionnaire study among hospital directors and senior physicians] Raeder JC. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):372-6 (Eng. Abstr.) (Nor)

TRENDS

The scope of day-case surgery [editorial] Devlin HB. **Br J Hosp Med** 1995 Sep 20-Oct 3;54(6):244-5
[Ambulatory surgery in orthopedics--nothing new! (comment] Hipp E, et al. **Fortschr Med** 1995 Jul 20; 113(20-21):310. Comment on: Fortschr Med 1995 Jul 20;113(20-21):307-9. (Ger)
[Ambulatory operations in orthopedics (see comments)] Roth P. **Fortschr Med** 1995 Jul 20;113(20-21):307-9 (Eng. Abstr.) Comment in: Fortschr Med 1995 Jul 20;113(20-21):310. (Ger)

UTILIZATION

Is the number of surgical day cases a good indicator of rising drug costs? Sturgess R, et al. **J Clin Pharm Ther** 1995 Aug; 20(4):225-8
Patterns of decline among inpatient procedures [see comments] Duffy SQ, et al. **Public Health Rep** 1995 Nov-Dec;110(6):674-81. Comment in: Public Health Rep 1995 Nov-Dec;110(6):682-3.
[Ambulatory surgery in the hospital--analysis of a 1978-1994 patient sample] Klug W. **Zentralbl Chir** 1995;120(8):598-603 (Eng. Abstr.) (Ger)
[Utilization of a unit of ambulatory surgery] Hoel TM, et al. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):376-8 (Eng. Abstr.) (Nor)
[Use and causes of discontinuation of eye surgical interventions at a university ambulatory surgery center] Arieta CE, et al. **Rev Assoc Med Bras** 1995 May-Jun; 41(3):233-5 (Eng. Abstr.) (Por)

AMBYSTOMA

EMBRYOLOGY

The cardiac mutant gene c in axolotls: cellular, developmental, and molecular studies. Lemanski LF, et al. **Cell Mol Biol Res** 1995;41(4):293-305 (28 ref.)
Activin A and transforming growth factor-beta stimulate heart formation in axolotls but not rescue cardiac lethal mutants. Mangiacapra FJ, et al. **Cell Tissue Res** 1995 Nov; 282(2):227-36
Tissue boundaries and cell behavior during neurulation. Jacobson AG, et al. **Dev Biol** 1995 Sep;171(1):98-110
Uncoupling histogenesis from morphogenesis in the vertebrate embryo by collapse of the transneural tube potential. Borgens RB, et al. **Dev Dyn** 1995 Aug; 203(4):456-67
Identification and expression of a homologue of the murine HoxA5 gene in the Mexican axolotl (Ambystoma mexicanum). Gaur A, et al. **Gene** 1995 Sep 11;162(2):249-53
Effects of extracellular matrix molecules on subepidermal neural crest cell migration in wild type and white mutant (dd) axolotl embryos. Olsson L, et al. **Pigment Cell Res** 1996 Feb;9(1):18-27

GENETICS

In vivo protein synthesis in developing hearts of normal and cardiac mutant axolotls (Ambystoma mexicanum). Erginel-Unaltuna N, et al. **Cell Mol Biol Res** 1995; 41(3):181-7
The cardiac mutant gene c in axolotls: cellular, developmental, and molecular studies. Lemanski LF, et al. **Cell Mol Biol Res** 1995;41(4):293-305 (28 ref.)
Identification and expression of a homologue of the murine HoxA5 gene in the Mexican axolotl (Ambystoma mexicanum). Gaur A, et al. **Gene** 1995 Sep 11;162(2):249-53
Separating population structure from population history: a cladistic analysis of the geographical distribution of mitochondrial DNA haplotypes in the tiger salamander, Ambystoma tigrinum. Templeton AR, et al. **Genetics** 1995 Jun;140(2):767-82

GROWTH & DEVELOPMENT

When neural crest and placodes collide: interactions between melanophores and the lateral lines that generate stripes in the salamander Ambystoma tigrinum tigrinum (Ambystomatidae). Parichy DM. **Dev Biol** 1996 May 1; 175(2):283-300

METABOLISM

Diffusion coefficient of the cyclic GMP analog 8-(fluoresceinyl)thioguanosine 3',5' cyclic monophosphate in the salamander rod outer segment. Koutalos Y, et al. **Biophys J** 1995 Nov;69(5):2163-7
Distribution of keratan sulphate and chondroitin sulphate in wild type and white mutant axolotl embryos during neural crest cell migration. Olsson L, et al. **Pigment Cell Res** 1996 Feb;9(1):5-17

AMBYSTOMA MEXICANUM

ANATOMY & HISTOLOGY

Hard tissue of teeth and their calcium and phosphate content in Ambystoma mexicanum (Urodela: Ambystomatidae). Bolte M, et al. **Anat Anz** 1996 Jan;178(1):71-80

EMBRYOLOGY

Nucleotide sequence and expression of ribosomal protein S3 mRNA during embryogenesis in the Mexican axolotl (Ambystoma mexicanum). Bhatia R, et al. **Biochem Mol Biol Int** 1996 May;38(6):1079-85
The epidermis is a source of directional information for the migrating pronephric duct in Ambystoma mexicanum embryos. Drawbridge J, et al. **Dev Biol** 1995 Dec; 172(2):440-51
The role of vertical and planar signals during the early steps of neural induction. Grunz H, et al. **Int J Dev Biol** 1995 Jun;39(3):539-43

GROWTH & DEVELOPMENT

Confocal microscopy of a newly identified protein associated with heart development in the Mexican axolotl. Erginel-Unaltuna N, et al. **Cell Mol Biol Res** 1995; 41(2):117-30

METABOLISM

Nucleotide sequence and expression of ribosomal protein S3 mRNA during embryogenesis in the Mexican axolotl (Ambystoma mexicanum). Bhatia R, et al. **Biochem Mol Biol Int** 1996 May;38(6):1079-85
Identification of cDNA clones encoding HMG 2, a major protein of the mexican axolotl hydrocortisone-sensitive thymocytes. de Guerra A, et al. **Dev Comp Immunol** 1995 Sep-Oct;19(5):417-23

PHYSIOLOGY

Characterization of an ultraviolet photoreception mechanism in the retina of an amphibian, the axolotl (Ambystoma mexicanum). Deutschlander ME, et al. **Neurosci Lett** 1995 Sep 8;197(2):93-6

AMBYSTOMATIDAE

GROWTH & DEVELOPMENT

Pigment patterns of larval salamanders (Ambystomatidae, Salamandridae): the role of the lateral line sensory system and the evolution of pattern-forming mechanisms. Parichy DM. **Dev Biol** 1996 May 1;175(2):265-82

AMCHA see TRANEXAMIC ACID

AMDINOCILLIN

PHARMACOLOGY

Mecillinam resistance in Escherichia coli is conferred by loss of a second activity of the AroK protein. Vinella D, et al. **J Bacteriol** 1996 Jul;178(13):3818-28
Resistance to mecillinam produced by the co-operative action of mutations affecting lipopolysaccharide, spoT, and cya or crp genes of Salmonella typhimurium. Antón DN. **Mol Microbiol** 1995 May;16(3):587-95

AMDINOCILLIN PIVOXIL

ADVERSE EFFECTS

Effect of short-term treatment with pivalic acid containing antibiotics on serum carnitine concentration--a risk irrespective of age. Abrahamsson K, et al. **Biochem Mol Med** 1995 Jun;55(1):77-9
Transient reduction of human left ventricular mass in carnitine depletion induced by antibiotics containing pivalic

acid. Abrahamsson K, et al. **Br Heart J** 1995 Dec; 74(6):656–9

AMEBA see **AMOEBA**

AMEBIASIS

see related
AMEBICIDES

COMPLICATIONS

Disseminated acanthamebiasis in patients with AIDS. A report of five cases and a review of the literature. Murakawa GJ, et al. **Arch Dermatol** 1995 Nov; 131(11):1291–6

DIAGNOSIS

Acanthamoeba: ecology, pathogenicity and laboratory detection. Walker CW. **Br J Biomed Sci** 1996 Jun; 53(2):146–51 (30 ref.)

Balamuthia mandrillaris: a newly recognized agent for amebic meningoencephalitis. Rowen JL, et al.
Pediatr Infect Dis J 1995 Aug;14(8):705–10 (30 ref.)

Evaluation of three serological tests for the detection of antiamebic antibodies applied to sera of patients from an area endemic for amebiasis. Lotter H, et al.
Trop Med Parasitol 1995 Sep;46(3):180–2

Amebiasis of the penis. Hejase MJ, et al. **Urology** 1996 Jul; 48(1):151–4

DRUG THERAPY

Cutaneous Acanthamoeba infection in the acquired immunodeficiency syndrome: response to multidrug therapy. Hunt SJ, et al. **Cutis** 1995 Nov;56(5):285–7

Antiamoebic activity of Piper longum fruits against Entamoeba histolytica in vitro and in vivo. Ghoshal S, et al. **J Ethnopharmacol** 1996 Mar;50(3):167–70

In vivo study of artemisinin and its derivatives against primary amebic meningoencephalitis caused by Naegleria fowleri. Gupta S, et al. **J Parasitol** 1995 Dec;81(6):1012–3

Metronidazole to clear intestinal parasites [letter] Cohen J. **Lancet** 1996 Jul 27;348(9022):273

ETIOLOGY

Amebic keratitis in a wearer of disposable contact lenses due to a mixed Vahlkampfia and Hartmannella infection. Aitken D, et al. **Ophthalmology** 1996 Mar;103(3):485–94

PARASITOLOGY

Axenic growth and drug sensitivity studies of Balamuthia mandrillaris, an agent of amebic meningoencephalitis in humans and other animals. Schuster FL, et al.
J Clin Microbiol 1996 Feb;34(2):385–8

PHYSIOPATHOLOGY

The duration of the cyst stage and the viability and virulence of Acanthamoeba isolates. Mazur T, et al.
Trop Med Parasitol 1995 Jun;46(2):106–8

SURGERY

[Amebic abscess of the brain. First successfully operated case in the world] Quijano-Pitman F. **Gac Med Mex** 1995 Sep–Dec;131(5–6):586 **(Spa)**

VETERINARY

Amoebic gill infection of turbot, Scophthalmus maximus. Dyková I, et al. **Folia Parasitol (Praha)** 1995;42(2):91–6

The occurrence of antibodies to Naegleria species in wild mammals. Kollars TM Jr, et al. **J Parasitol** 1996 Feb; 82(1):73–7

AMEBIASIS, HEPATIC see **LIVER ABSCESS, AMEBIC**

AMEBIASIS, INTESTINAL see **DYSENTERY, AMEBIC**

AMEBIC DYSENTERY see **DYSENTERY, AMEBIC**

AMEBICIDES

ISOLATION & PURIFICATION

Amoebicidal compounds from medicinal plants. Di Stasi LC. **Parassitologia** 1995 Apr;37(1):29–39 (56 ref.)

PHARMACOLOGY

Increase in mRNA of multiple Eh pgp genes encoding P-glycoprotein homologues in emetine-resistant Entamoeba histolytica parasites. Descoteaux S, et al.
Gene 1995 Oct 16;164(1):179–84

The lethal effects of biguanides on cysts and trophozoites of Acanthamoeba castellanii. Khunkitti W, et al.
J Appl Bacteriol 1996 Jul;81(1):73–7

Anticryptosporidial activity of paromomycin [letter; comment] Cirioni O, et al. **J Infect Dis** 1995 Oct; 172(4):1169–70. Comment on: J Infect Dis 1994 Aug;170(2):419–24.

Evaluation of a two-phase scid mouse model preconditioned with anti-interferon-gamma monoclonal antibody for drug testing against Cryptosporidium parvum. Tzipori S, et al.
J Infect Dis 1995 Oct;172(4):1160–4

Effects of chaparrin, nordihydroguaiaretic acid and their structural analogues on Entamoeba histolytica cultures. Calzado-Flores C, et al. **Proc West Pharmacol Soc** 1995; 38:105–6

In vitro cytotoxicity of chaparrin from Castela texana. Calzado-Flores C, et al. **Proc West Pharmacol Soc** 1995; 38:49–50

Rapid in vitro test for determination of anti-amoebic activity. Mukhopadhyay RM, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr;90(2):189–91

POISONING

The effect of hypertonic sodium bicarbonate on QRS duration in rats poisoned with chloroquine. Curry SC, et al. **J Toxicol Clin Toxicol** 1996;34(1):73–6

SUPPLY & DISTRIBUTION

Drug prescribing practices of general practitioners and paediatricians for childhood diarrhoea in Karachi, Pakistan. Nizami SQ, et al. **Soc Sci Med** 1996 Apr;42(8):1133–9

THERAPEUTIC USE

Activity of a new oxadiazole compound, against experimental infections with Entamoeba histolytica and Giardia lamblia in animal models. Bhopale KK, et al.
Ann Trop Med Parasitol 1993 Apr;87(2):169–78

Is there any reason to continue treating Blastocystis infections? [editorial; comment] Markell EK.
Clin Infect Dis 1995 Jul;21(1):104–5 (11 ref.). Comment on: Clin Infect Dis 1995 Jul;21(1):97–101.

Cutaneous Acanthamoeba infection in the acquired immunodeficiency syndrome: response to multidrug therapy. Hunt SJ, et al. **Cutis** 1995 Nov;56(5):285–7

In vivo study of artemisinin and its derivatives against primary amebic meningoencephalitis caused by Naegleria fowleri. Gupta S, et al. **J Parasitol** 1995 Dec;81(6):1012–3

Effect of single dose of secnidazole in treatment of intestinal amoebiasis. Omrani G, et al. **JPMA J Pak Med Assoc** 1995 Jun;45(6):159

[Amebic abscess of the liver: ultrasound guided puncture] Pham Van L, et al. **Ann Chir** 1996;50(4):340–3 (Eng. Abstr.) **(Fre)**

AMEBOMA see **AMEBIASIS**

AMEIURUS see **ICTALURIDAE**

AMELIA see **ECTROMELIA**

AMELOBLASTOMA

COMPLICATIONS

[Adamantinoma and osteofibrous dysplasia of the tibia] Gaubert J, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(4):333–7 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Cystic lesions of the maxillomandibular region: MR imaging distinction of odontogenic keratocysts and ameloblastomas from other cysts. Minami M, et al.
AJR Am J Roentgenol 1996 Apr;166(4):943–9

EPIDEMIOLOGY

Ameloblastoma in children. The Zimbabwean experience. Chidzonga MM.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Feb;81(2):168–70

PATHOLOGY

Immunohistochemical detection of alpha 1-antitrypsin, alpha 1-antichymotrypsin, transferrin and ferritin in ameloblastoma. Takahashi H, et al. **Anal Cell Pathol** 1995 Sep;9(2):135–50

Fine-needle aspiration cytology of ameloblastic carcinoma of the maxilla: a rare tumor. Ingram EA, et al.
Diagn Cytopathol 1996 May;14(3):249–52

Granular cell ameloblastoma: a case report with histochemical findings. Lo Muzio L, et al.
Eur J Cancer B Oral Oncol 1996 May;32B(3):210–2

Immunohistochemical localization of fibroblast growth factor-1 (FGF-1) and FGF-2 in cultured human ameloblastoma epithelial cells and ameloblastoma tissues. Myoken Y, et al. **J Oral Pathol Med** 1995 Oct;24(9):387–92

Peripheral ameloblastoma. Gurol M, et al. **J Periodontol** 1995 Dec;66(12):1065–8

Rhabdomyosarcoma arising in the course of long-standing ameloblastoma. Taniguchi K, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Aug;80(2):202–6

[Calcifying odontogenic epithelial tumor (Pindborg's tumor). Review of a case with maxillary localization] Caubet Biayna J, et al. **An Otorrinolaringol Ibero Am** 1995; 22(4):405–12 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Three-dimensional computed tomography reconstruction in treatment planning for large ameloblastoma. Altini M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):619–22

SURGERY

Le Fort 1 downfracture approach for the treatment of a posterior maxillary ameloblastoma. Symington OG, et al.
J Can Dent Assoc 1995 Dec;61(12):1048–52 (24 ref.)

Surgical management of ameloblastoma. Current status of the literature. Feinberg SE, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Apr;81(4):383–8 (31 ref.)

AMELOBLASTS

CHEMISTRY

Immunolocalization of the cation-independent mannose 6-phosphate receptor and cathepsin B in the enamel organ and alveolar bone of the rat incisor. Al Kawas S, et al.
Calcif Tissue Int 1996 Sep;59(3):192–9

CYTOLOGY

A histochemical study of apoptosis in the reduced ameloblasts of erupting mouse molars. Shibata S, et al.
Arch Oral Biol 1995 Jul;40(7):677–80

ENZYMOLOGY

Localization of plasma membrane Ca2+ pump mRNA and protein in human ameloblasts by in situ hybridization and immunohistochemistry. Borke JL, et al.
Connect Tissue Res 1995;33(1–3):139–44

METABOLISM

Enamel mineralization and the role of ameloblasts in calcium transport. Takano Y. **Connect Tissue Res** 1995; 33(1–3):127–37 (74 ref.)

PHYSIOLOGY

Endocytotic functions of ameloblasts and odontoblasts: immunocytochemical and tracer studies on the uptake of plasma proteins. Nanci A, et al. **Anat Rec** 1996 Jun; 245(2):219–34

Enamel matrix proteins and ameloblast biology. Deutsch D, et al. **Connect Tissue Res** 1995;32(1–4):97–107 (123 ref.)

DNA localization in nuclear fragments of apoptotic ameloblasts using anti-DNA immunoelectron microscopy: programmed cell death of ameloblasts. Nishikawa S, et al.
Histochem Cell Biol 1995 Aug;104(2):151–9

SECRETION

Influence of fluoride on secretory pathway of the secretory ameloblast in rat incisor tooth germs exposed to sodium fluoride. Matsuo S, et al. **Arch Toxicol** 1996;70(7):420–9

AMELOGENESIS

Enamel matrix proteins and ameloblast biology. Deutsch D, et al. **Connect Tissue Res** 1995;32(1–4):97–107 (123 ref.)

The control of ingress of albumin into developing enamel from adjacent dentine of the rat incisor. Shore RC, et al.
Connect Tissue Res 1995;33(1–3):151–5

Molecular mechanisms of dental enamel formation. Simmer JP, et al. **Crit Rev Oral Biol Med** 1995;6(2):84–108 (194 ref.)

Evidence for amelogenin "nanospheres" as functional components of secretory-stage enamel matrix. Fincham AG, et al. **J Struct Biol** 1995 Jul–Aug;115(1):50–9

GENETICS

Understanding enamel formation from mutations causing X-linked amelogenesis imperfecta. Lagerström-Fermér M, et al. **Connect Tissue Res** 1995;32(1–4):241–6 (40 ref.)

PHYSIOLOGY

Recent observations on enamel crystal formation during mammalian amelogenesis. Aoba T. **Anat Rec** 1996 Jun; 245(2):208–18 (74 ref.)

Protein dynamics of amelogenesis. Smith CE, et al.
Anat Rec 1996 Jun;245(2):186–207

Enamel matrix protein turnover during amelogenesis: basic biochemical properties of short-lived sulfated enamel proteins. Smith CE, et al. **Calcif Tissue Int** 1995 Aug; 57(2):133–44

Morphological study of amelogenesis in the rat lower incisor after thyro-parathyroidectomy, parathyroidectomy and thyroidectomy. Acevedo AC, et al. **Cell Tissue Res** 1996 Jan;283(1):151–7

Immunohistochemical localization of carbonic anhydrase isozyme II in rat incisor epithelial cells at various stages of amelogenesis. Toyosawa S, et al. **Cell Tissue Res** 1996 Aug;285(2):217–25

AMELOGENESIS IMPERFECTA

GENETICS

Understanding enamel formation from mutations causing X-linked amelogenesis imperfecta. Lagerström-Fermér M, et al. **Connect Tissue Res** 1995;32(1-4):241-6 (40 ref.)

[Incidence of structural disorders of teeth in hereditary epidermolysis bullosa] Gábris K, et al. **Fogorv Sz** 1996 Jan; 89(1):7-10 (25 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

The mineral and protein content of enamel in amelogenesis imperfecta. Wright JT, et al. **Connect Tissue Res** 1995; 32(1-4):247-52

PATHOLOGY

Ultrastructural study of tooth enamel with amelogenesis imperfecta in AI-nephrocalcinosis syndrome. Phakey P, et al. **Connect Tissue Res** 1995;32(1-4):253-9

PHYSIOPATHOLOGY

A new form of skeletal dysplasia with amelogenesis imperfecta and platyspondyly. Verloes A, et al. **Clin Genet** 1996 Jan;49(1):2-5

AMENORRHEA

Frequency variation of spontaneous otoacoustic emissions during a naturally occurring menstrual cycle, amenorrhea, and oral contraception: a brief report. Penner MJ. **Ear Hear** 1995 Aug;16(4):428-32

A study of the lactational amenorrhoea method of family planning in New Zealand women. France MM. **N Z Med J** 1996 May 24;109(1022):189-91

[Lactational amenorrhea as a method of family planning] Canto-de Cetina T, et al. **Salud Publica Mex** 1996 Jan-Feb; 38(1):58-63 (38 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Serum immunoreactive inhibin levels in polycystic ovarian disease (PCOD) and hypogonadotropic amenorrhea. Mizunuma H, et al. **Endocr J** 1994 Aug;41(4):409-14

Prolactin response to suckling and maintenance of postpartum amenorrhea among intensively breastfeeding Nepali women. Stallings JF, et al. **Endocr Res** 1996 Feb; 22(1):1-28

Hormone testing in women with adult-onset amenorrhea. Laufer MR, et al. **Gynecol Obstet Invest** 1995;40(3):200-3

Circulating ovarian autoantibodies and FSH and LH levels in adolescent girls with primary menstrual cycle disorders. Hořejší J, et al. **J Pediatr Adolesc Gynecol** 1996 Apr; 9(2):74-8

CHEMICALLY INDUCED

Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Gonzalez-Crespo MR, et al. **Br J Rheumatol** 1995 Aug; 34(8):737-41

Amenorrhea associated with intraspinal morphine [letter] Paice JA, et al. **J Pain Symptom Manage** 1995 Nov; 10(8):582-3

COMPLICATIONS

Osteoporosis in Turner's syndrome and other forms of primary amenorrhoea. Davies MC, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):741-6

A patient with a progesterone-producing adrenal adenoma who presented with primary amenorrhea. van Zonneveld P, et al. **Gynecol Endocrinol** 1995 Sep;9(3):189-94

Osteopenia in primary and secondary amenorrhea. Ulrich U, et al. **Horm Metab Res** 1995 Sep;27(9):432-5

Circulatory collapse in a 30-year-old amenorrheic woman. Goswami R, et al. **Postgrad Med J** 1996 Aug;72(850):501-4

[Sports, bones and hormones. Multiple interactions (editorial)] Maugars Y, et al. **Presse Med** 1995 Sep 30; 24(28):1284-6 (15 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Evaluation of amenorrhea. Kiningham RB, et al. **Am Fam Physician** 1996 Mar;53(4):1185-94 (44 ref.)

DIET THERAPY

Treatment of athletic amenorrhea with a diet and training intervention program. Dueck CA, et al. **Int J Sport Nutr** 1996 Mar;6(1):24-40

DRUG THERAPY

Resumption of menstruation in three women with secondary amenorrhoea after treatment with ivermectin. Anosike JC, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):693-4

Long-term follow-up of women with amenorrhea-galactorrhea treated with bromocriptine. Tartagni M, et al. **Clin Exp Obstet Gynecol** 1995; 22(4):301-6

Naltrexone treatment restores menstrual cycles in patients with weight loss-related amenorrhea. Genazzani AD, et al. **Fertil Steril** 1995 Nov;64(5):951-6

Naltrexone administration modulates the neuroendocrine control of luteinizing hormone secretion in hypothalamic amenorrhoea. Genazzani AD, et al. **Hum Reprod** 1995 Nov; 10(11):2868-71

Termination of early pregnancy (up to and after 63 days of amenorrhea) with mifepristone (RU 486) and increasing doses of misoprostol. Aubény E, et al. **Int J Fertil Menopausal Stud** 1995;40 Suppl 2:85-91

Reversal of amenorrhoea after Mectizan treatment. Anosike JC, et al. **Trop Geogr Med** 1995;47(5):222-4

ETIOLOGY

Distress amenorrhea. Tolis G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:660-4 (35 ref.)

Growth hormone deficiency and hypogonadism in a patient with multiple sclerosis. Davies JS, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):117-9

Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Holmes-Walker DJ, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):291-6

A physician survey of therapy for exercise-associated amenorrhea: a brief report. Haberland CA, et al. **Clin J Sport Med** 1995 Oct;5(4):246-50

Evaluation of amenorrhea. Aloi JA. **Compr Ther** 1995 Oct; 21(10):575-8 (7 ref.)

Longitudinal analysis of the effects of infant-feeding practices on postpartum amenorrhea. Zohoori N, et al. **Demography** 1996 May;33(2):167-80

Clinical review 77: evaluation of secondary amenorrhea. Warren MP. **J Clin Endocrinol Metab** 1996 Feb; 81(2):437-42 (20 ref.)

Isolated adrenocorticotropin deficiency presenting as primary infertility. Atkin SL, et al. **J Endocrinol Invest** 1995 Jun; 18(6):456-9

Prolonged amenorrhea associated with total nodal irradiation for Hodgkin's disease. Halyard MY, et al. **J Natl Med Assoc** 1996 Jun;88(6):391-3

Nocturnal melatonin and luteinizing hormone rhythms in women with hyperprolactinemic amenorrhea. Luboshitzky R, et al. **J Pineal Res** 1996 Mar;20(2):72-8

Secondary amenorrhoea after total body irradiation in pre-puberty. Albanese A, et al. **J R Soc Med** 1996 Feb; 89(2):113P-4P

Secondary amenorrhoea. Bulusu S. **J R Soc Med** 1996 Apr; 89(4):220P-1P

Delayed puberty and reversible pituitary enlargement in a girl. Holt RI, et al. **J R Soc Med** 1996 Aug;89(8):464-6

Transverse vaginal septum associated with tubal atresia. Polasek PM, et al. **Mayo Clin Proc** 1995 Oct;70(10):965-8

GENETICS

Unique unbalanced X;X translocation (Xq22;p11.2) in a woman with primary amenorrhea but without Ullrich-Turner syndrome. Letterie GS. **Am J Med Genet** 1995 Dec 4;59(4):414-6

Trisomy 18 mosaicism associated with secondary amenorrhea: ratios of mosaicism in different samples and complications. Uehara S, et al. **Clin Genet** 1996 Feb; 49(2):91-4

Gonadal dysfunction in mitochondrial encephalomyopathies. Chen CM, et al. **Eur Neurol** 1995;35(5):281-6

Cytogenetic study of primary amenorrhoea. Roy AK, et al. **J Indian Med Assoc** 1995 Aug;93(8):291-2

METABOLISM

The relation of the gonadotrophin response to chlormadinone according to body weight in patients with amenorrhea due to polycystic ovarian syndrome. Carranza-Lira S, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):161-4

Effects of a dopamine antagonist (metoclopramide) on the release of beta-endorphin, ACTH and cortisol in hyperprolactinemic-amenorrheic women. Seki K, et al. **Gynecol Obstet Invest** 1995;40(1):42-5

PATHOLOGY

[Vaginal cytology in eating disorders in young girls] Nicoli JM, et al. **Rev Fr Gynecol Obstet** 1995 May-Jun; 90(5-6):291-6 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Case history. Breast asymmetry: unusual presentation. Rodriguez MA. **Alaska Med** 1995 Jul-Sep;37(3):112

Naltrexone treatment restores menstrual cycles in patients with weight loss-related amenorrhea. Genazzani AD, et al. **Fertil Steril** 1995 Nov;64(5):951-6

Growth hormone (GH)-releasing hormone-induced GH response in hypothalamic amenorrhea: evidence of altered central neuromodulation. Genazzani AD, et al. **Fertil Steril** 1996 May;65(5):935-8

Spontaneous episodic release of adenohypophyseal hormones in hypothalamic amenorrhea. Genazzani AD, et al. **Gynecol Endocrinol** 1995 Dec;9(4):325-34 (63 ref.)

Luteinizing hormone pulsatile release and the length of lactational amenorrhoea. Díaz S, et al. **Hum Reprod** 1995 Aug;10(8):1957-61

Naltrexone administration modulates the neuroendocrine control of luteinizing hormone secretion in hypothalamic amenorrhoea. Genazzani AD, et al. **Hum Reprod** 1995 Nov; 10(11):2868-71

Nutrient intake and psychological and physiological assessment in eumenorrheic and amenorrheic female athletes: a preliminary study. Perry AC, et al. **Int J Sport Nutr** 1996 Mar;6(1):3-13

Bone mineral density in premenopausal anovulatory women. Park KH, et al. **J Obstet Gynaecol** 1995 Feb;21(1):89-97

Gymnasts, distance runners, anorexics body composition and menstrual status. Bale P, et al. **J Sports Med Phys Fitness** 1996 Mar;36(1):49-53

Bone density at multiple skeletal sites in amenorrheic athletes. Rencken ML, et al. **JAMA** 1996 Jul 17;276(3):238-40

[The adolescent and secondary amenorrhea] Eiholzer U. **Rev Med Suisse Romande** 1995 Aug;115(8):609-12 **(Fre)**

-Effect of endogenous opioids on adrenal cortex activity in women with hypothalamic amenorrhea- Krause BT, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35(4):194-8 (Eng. Abstr.) **(Ger)**

[Evaluation of beta-endorphin levels and gonadotropin, prolactin, cortisol and estradiol in serum of girls with secondary amenorrhea associated with weight loss] Męczekalski B, et al. **Ginekol Pol** 1995 Oct;66(10):596-9 (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Should amenorrhoea be necessary for the diagnosis of anorexia nervosa? Evidence from a Canadian community sample. Garfinkel PE, et al. **Br J Psychiatry** 1996 Apr; 168(4):500-6

THERAPY

A physician survey of therapy for exercise-associated amenorrhea: a brief report. Haberland CA, et al. **Clin J Sport Med** 1995 Oct;5(4):246-50

From physiology to clinics--20 years of experience with pulsatile GnRH. Leyendecker G, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65 Suppl:S3-12 (107 ref.)

ULTRASONOGRAPHY

Relationship between sonographic endometrial thickness and progestin-induced withdrawal bleeding. Nakamura S, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):722-5

AMERICAN DENTAL ASSOCIATION

1995: A year of achievement for the ADA [news] **J Am Dent Assoc** 1996 Jan;127(1):26, 28, 30 passim

ADA advertising++ standards. **J Am Dent Assoc** 1996 Apr; 127(4):491-2

Promoting the profession [letter] Durick RJ. **J Am Dent Assoc** 1996 May;127(5):558, 560

Gold Hill revisited [editorial] Meskin LH. **J Am Dent Assoc** 1996 Jan;127(1):12, 14

AGD/ADA [letter] Nelson RT. **J Am Dent Assoc** 1995 Nov; 126(11):1472, 1474

A letter to Dr. Ten Pas [letter] Simon JW. **J Am Dent Assoc** 1996 Jan;127(1):16-7

Dental specialties [letter] [published erratum appears in J Am Dent Assoc 1995 Dec;126(12):1600] Stanley HR. **J Am Dent Assoc** 1995 Oct;126(10):1340, 1342

The American Dental Association's commitment to electronic data interchange. Narcisi JP. **J Dent Educ** 1996 Jan;60(1):28-32

ECONOMICS

Invest now for the future [editorial] [see comments] Meskin LH. **J Am Dent Assoc** 1995 Sep;126(9):1200, 1202. Comment in: J Am Dent Assoc 1996 Feb;127(2):158.

AMERICAN HEART ASSOCIATION

ACC/AHA collaborate on guidelines for the evaluation and management of heart failure. **Am Fam Physician** 1996 May 1;53(6):2196-8

Using public policy to fight heart disease and stroke. A 21st century approach [news] Gilpin B, et al. **Circulation** 1995 Nov 15;92(10):2785

AHA's new research initiative [news] Louis C, et al. **Circulation** 1995 Dec 15;92(12):3369-70

Roster maker [letter] Sea C. **MD Comput** 1996 Mar-Apr; 13(2):127

AMERICAN HOSPITAL ASSOCIATION

ORGANIZATION & ADMINISTRATION

Been there. Done that. Now what? Lumsdon K. **Hosp Health Netw** 1996 Aug 20;70(16):18-20, 22, 24 passim

AMERICAN MEDICAL ASSOCIATION

AMA house scrutinizes managed care prescription policies, decries payments to pharmacists for switches [news] **Am J Health Syst Pharm** 1995 Sep 15;52(18):1967, 1970

US doctors reaffirm opposition to euthanasia [news] McDaniel CG. **BMJ** 1996 Jul 6;313(7048):11

(K)noteworthy role: serving as AMA vice speaker [interview by Bob Carlson] Knote JA. **Indiana Med** 1995 Sep-Oct; 88(5):320-4

AMERICAN MEDICAL ASSOCIATION

Medicare under a microscope at AMA [news] **Iowa Med** 1995 Aug;85(8):315

AMA's role in the Medicare reform bill [editorial] Hall J. **Iowa Med** 1995 Dec;85(12):471

Comments on the AMA report "Ethical issues in managed care [see comments] Miles SH, et al. **J Clin Ethics** 1995 Winter;6(4):306–11. Comment in: J Clin Ethics 1995 Winter;6(4):312–7. Comment in: J Clin Ethics 1995 Winter;6(4):318–9.

Interests, obligations, and justice: some notes toward an ethic of managed care [comment] Pellegrino ED. **J Clin Ethics** 1995 Winter;6(4):312–7. Comment on: J Clin Ethics 1995 Winter;6(4):306–11.

A response to "Comments on the AMA report 'ethical issues in managed care'" [comment] Plows CW. **J Clin Ethics** 1995 Winter;6(4):318–9. Comment on: J Clin Ethics 1995 Winter;6(4):306–11.

Delegate's AMA report 1995 annual meeting of the House of Delegates. **J Miss State Med Assoc** 1995 Sep;36(9):281–7

AMA and USP seek physician assistance in preventing medication errors. **J Miss State Med Assoc** 1995 Dec; 36(11):383–5

AMA applauds President's call for curbs on teen use of tobacco. Bristrow LR. **J Miss State Med Assoc** 1995 Sep; 36(9):277

You've come a long way, baby! [editorial] Hartness DS Jr. **J Miss State Med Assoc** 1995 Sep;36(9):276, 278

AMA statement to the House Ways and Means Committee Subcommittee on Health. Bristow LR. **J Okla State Med Assoc** 1995 Sep;88(9):398–401

Ramblings from an AMA ex-delegate [editorial] Thomison JB. **J Tenn Med Assoc** 1996 Feb;89(2):60–2

Index to volume 274. **JAMA** 1995 Dec 27;274(24):1972–2023

Remarks of the AMA executive vice president. Todd JS. **JAMA** 1996 Mar 13;275(10):802

US specialists object to AMA's call for mandatory HIV testing [news] Rovner J. **Lancet** 1996 Aug 3;348(9023):330

Bridging the worlds of organized medicine and public health. A conversation with Michigan's chief medical officer Ronald M. Davis, MD [interview by M. Susan Raef] Davis RM. **Mich Med** 1995 Aug;94(8):46–8

Analysis of AMA Medicare proposal shows savings of $162 billion [news] **Minn Med** 1995 Oct;78(10):36

The ethical challenge of managed care. A critique of the AMA's stance. Wolf SM. **Minn Med** 1996 Jun;79(6):29–32

Reinventing the house of medicine: the study of the federation. Bohigian GM. **Mo Med** 1995 Sep;92(9):566–7

Is the AMA losing perspective? [letter] Manning GC. **Pa Med** 1995 Jun;98(6):10

Back at the table. Medicare debate is reminiscent of health-system reform battle. Ortolon K. **Tex Med** 1995 Aug;91(8):18–21

EVP report: the view from here. Restructuring Medicare or resurrecting the lost covenant. Adams TL. **Wis Med J** 1995;94(8):439–40

HISTORY

The evolution of American Medical Association policies concerning health care of veterans. Kendall JW. **Mil Med** 1995 Oct;160(10):518–21 (10 ref.)

ORGANIZATION & ADMINISTRATION

AMA officer: put patient in driver's seat [interview by Bob Carlson] Johnson D Jr. **Indiana Med** 1995 Nov–Dec; 88(6):418–24

American Medical Association's new "EVP". People and patients—his "foremost priority" [news] Collins A. **J Ky Med Assoc** 1996 Jun;94(6):251–2

Organized medicine needs a tune-up. Blight CO. **Mich Med** 1996 May;95(5):16–7

Hold harmless, due process resolutions supported by AMA House of Delegates [news] **Pa Med** 1995 Sep;98(9):40–1

AMERICAN NURSES' ASSOCIATION

More than rearranging the deck chairs [editorial] Joel LA. **Am J Nurs** 1996 Aug;96(8):7

AMERICAN SPEECH-LANGUAGE-HEARING ASSOCIATION

PPOs: are they good for ASHA members? Task Force on Treatment Outcome and Cost Effectiveness. Kreb RA, et al. **ASHA** 1995 Nov–Dec;37(11–12):39–41

AMERICIUM

ADMINISTRATION & DOSAGE

[The effect of the intratracheal administration of americium-241 on rat alveolar macrophages] Shopova V, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):434–9 (Eng. Abstr.) **(Rus)**

ANALYSIS

Comparative distribution of 241 Am and 239,240 Pu in soils around the Rocky Flats Environmental Technology Site. Ibrahim SA, et al. **Health Phys** 1996 Apr;70(4):520–6

A comprehensive appraisal of 241Am in soils around Rocky Flats, Colorado. Litaor MI, et al. **Health Phys** 1996 Sep; 71(3):347–57

The gender-specific chest wall thickness prediction equations for routine measurements of 239Pu and 241Am within the lungs using HPGe detectors. Vickers LR. **Health Phys** 1996 Mar;70(3):346–57

DIAGNOSTIC USE

Binding of 241Am to carp cytosolic fractions in vitro. Nafissi T, et al. **Biochem Mol Biol Int** 1995 May;35(6):1269–79

METABOLISM

Optimising the removal of inhaled plutonium and americium from the rat by administration of ZnDTPA in drinking water. Gray SA, et al. **Hum Exp Toxicol** 1995 Nov; 14(11):902–8

PHARMACOKINETICS

Changes in soft tissue concentrations of plutonium and americium with time after human occupational exposure. Filipy RE, et al. **Health Phys** 1996 Feb;70(2):153–9

Treatment with 3,4,3-LIHOPO of simulated wounds contaminated with plutonium and americium in rat. Volf V, et al. **Int J Radiat Biol** 1996 Jul;70(1):109–14

TOXICITY

Long-term effects on tumour incidence and survival from 241Am exposure of the BALB/c mouse in utero and during adulthood. van den Heuvel R, et al. **Int J Radiat Biol** 1995 Dec;68(6):679–86

AMERINDS, CENTRAL AMERICAN see **INDIANS, CENTRAL AMERICAN**

AMERINDS, NORTH AMERICAN see **INDIANS, NORTH AMERICAN**

AMERINDS, SOUTH AMERICAN see **INDIANS, SOUTH AMERICAN**

AMETHOCAINE see **TETRACAINE**

AMETHOPTERIN see **METHOTREXATE**

AMETROPIA see **REFRACTIVE ERRORS**

AMFEPRAMON see **DIETHYLPROPION**

AMIDASES see **AMIDOHYDROLASES**

AMIDES

Synthesis of novel phosphoramidite reagents for the attachment of antisense oligonucleotides to various regions of the benzophenanthridine ring system. Chen JK, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):473–82

Comparison of ropivacaine and bupivacaine for extradural analgesia [letter; comment] al-Kaisy AA. **Br J Anaesth** 1995 Aug;75(2):246. Comment on: Br J Anaesth 1995 Mar;74(3):261–5.

Comparison of ropivacaine and bupivacaine for extradural analgesia [letter; comment] Lyons G, et al. **Br J Anaesth** 1995 Sep;75(3):373–4. Comment on: Br J Anaesth 1995 Mar;74(3):261–5.

Ropivacaine. McClure JH. **Br J Anaesth** 1996 Feb; 76(2):300–7 (88 ref.)

Continuous extradural infusion of ropivacaine for prevention of postoperative pain after major orthopaedic surgery. Turner G, et al. **Br J Anaesth** 1996 May;76(5):606–10

Synthesis and physicochemical, biological, and pharmacological properties of new bile acids amidated with cyclic amino acids. Roda A, et al. **J Med Chem** 1996 May 24;39(11):2270–6

The synthesis of blocked triplet-phosphoramidites and their use in mutagenesis. Ono A, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4677–82

A double-blind comparison of the abdominal wall relaxation produced by epidural 0.75% ropivacaine and 0.75% bupivacaine in gynecologic surgery. Tuttle AA, et al. **Reg Anesth** 1995 Nov–Dec;20(6):515–20

ADMINISTRATION & DOSAGE

Epidural ropivacaine infusion for postoperative analgesia after major lower abdominal surgery—a dose finding study. Scott DA, et al. **Anesth Analg** 1995 Nov;81(5):982–6

A double-blind comparison of 0.25% ropivacaine and 0.25% bupivacaine for extradural analgesia in labour. Eddleston JM, et al. **Br J Anaesth** 1996 Jan;76(1):66–71

Postoperative analgesia by continuous extradural infusion of ropivacaine after upper abdominal surgery. Schug SA, et al. **Br J Anaesth** 1996 Apr;76(4):487–91

Continuous epidural infusion of ropivacaine for the prevention of postoperative pain after major orthopaedic surgery: a dose-finding study. Badner NH, et al. **Can J Anaesth** 1996 Jan;43(1):17–22

A double-blind comparison of ropivacaine 0.5%, 0.75%, 1.0% and bupivacaine 0.5%, injected epidurally, in patients undergoing abdominal hysterectomy. Finucane BT, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):442–9

ADVERSE EFFECTS

1995 Gaston Labat Lecture. Ropivacaine. White knight or dark horse? de Jong RH. **Reg Anesth** 1995 Nov–Dec; 20(6):474–81 (37 ref.)

ANALYSIS

Separation of NOEs from degenerate amide protons in 13C/15N-labeled proteins using a 3D 13C'-edited NOESY-H(N)CO experiment. Zhang W, et al. **J Magn Reson B** 1996 Jun;111(3):305–9

[Fluorometric determination of amide protein groups] Shepotinovskaia IV, et al. **Klin Lab Diagn** 1995 May–Jun; (3):18–20 (Eng. Abstr.) **(Rus)**

BLOOD

Prothrombin cleavage by human vascular smooth muscle cells: a potential alternative pathway to the coagulation cascade. Benzakour O, et al. **J Cell Biochem** 1995 Dec; 59(4):514–28

Determination of free concentration of ropivacaine and bupivacaine in blood plasma by ultrafiltration and coupled-column liquid chromatography. Arvidsson T, et al. **J Chromatogr B Biomed Appl** 1995 Jun 9;668(1):91–8

CHEMICAL SYNTHESIS

Sensitizing properties of new N-(2-arylalkyl) propionamides in drug-sensitive and multidrug-resistant tumor cells. Ros F, et al. **Arch Pharm (Weinheim)** 1995 Dec; 328(11–12):755–9

Galactose-containing amphiphiles prepared with a lipophilic radical initiator: association processes between liposomes triggered by enzymatic reaction. Ohno K, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):361–6

Carboxamides and hydrazide of glycopeptide antibiotic eremomycin. Synthesis and antibacterial activity. Pavlov AY, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):194–8

Potent inhibitors of acyl-CoA:cholesterol acyltransferase. 2. Structure-activity relationships of novel N-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)amides. Kataoka K, et al. **J Med Chem** 1996 Mar 15;39(6):1262–70

Synthesis of 2-amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors. Mathé-Allainmat M, et al. **J Med Chem** 1996 Aug 2;39(16):3089–95

Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design. Melnick M, et al. **J Med Chem** 1996 Jul 5;39(14):2795–811

[Synthesis of an ethylamide of the cyclic undecapeptide sequence 593-603 of transmembrane glycoprotein gp41 of the human immunodeficiency virus type 2] Sidorova MV, et al. **Bioorg Khim** 1995 Sep;21(9):675–83 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Mass spectrometric determination of isotopic exchange rates of amide hydrogens located on the surfaces of proteins. Dharmasiri K, et al. **Anal Chem** 1996 Jul 15;68(14):2340–4

A 1H NMR analysis of the interaction between terephthalamide derivatives and the oligonucleotide duplex d(GGTAATTACC)2. Pavlopoulos S, et al. **Anticancer Drug Des** 1995 Dec;10(8):623–39

Salt effects on the amide hydrogen exchange of bovine pancreatic trypsin inhibitor. Christoffersen M, et al. **Biochemistry** 1996 Feb 20;35(7):2309–15

Synthesis and evaluation of deglycobleomycin A2 analogues containing a tertiary N-methyl amide and simple ester replacement for the L-histidine secondary amide: direct functional characterization of the requirement for secondary amide metal complexation. Boger DL, et al. **Bioorg Med Chem** 1996 Feb;4(2):179–93

The synthesis of peptidomimetic combinatorial libraries through successive amide alkylations. Dörner B, et al. **Bioorg Med Chem** 1996 May;4(5):709–15

Nonenzymatic deamidation of food proteins. Riha WE 3rd, et al. **Crit Rev Food Sci Nutr** 1996 Feb;36(3):225–55 (102 ref.)

The liquid amide transfer model and the unfolding thermodynamics of small globular proteins. Barone G, et al. **Int J Biol Macromol** 1995 Oct;17(5):251–7

Overexpression of myoglobin and assignment of its amide, C alpha and C beta resonances. Jennings PA, et al. **J Biomol NMR** 1995 Nov;6(3):271–6

Measurement of intrinsic exchange rates of amide protons in a 15N-labeled peptide. Koide S, et al. **J Biomol NMR** 1995 Nov;6(3):306–12

Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series. Reich SH, et al. **J Med Chem** 1996 Jul 5;39(14):2781–94

Quantitation of the area of overlap between second-derivative amide I infrared spectra to determine the structural similarity of a protein in different states. Kendrick BS, et al. **J Pharm Sci** 1996 Feb;85(2):155–8

Cyclic polyamides for recognition in the minor groove of DNA. Cho J, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10389–92

Binding of a hairpin polyamide in the minor groove of DNA: sequence-specific enthalpic discrimination. Pilch DS, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8306–11

The pH dependence of hydrogen-deuterium exchange in trp

repressor: the exchange rate of amide protons in proteins reflects tertiary interactions, not only secondary structure. Finucane MD, et al. **Protein Sci** 1996 Apr;5(4):653–62

METABOLISM

Effect of amino acid residues at the cleavable site of substrates on the remarkable activation of thermolysin by salts. Inouye K, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):133–8

Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. Maurelli S, et al. **FEBS Lett** 1995 Dec 11;377(1):82–6

Study of H2O2 interaction with copper(II) complexes with diamino–diamide type ligands, diastereoisomeric dipeptides, and tripeptides. Bonomo RP, et al. **J Inorg Biochem** 1995 Nov 15;60(3):205–18

Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides. Garratt PJ, et al. **J Med Chem** 1996 Apr 26; 39(9):1797–805

Identification of yeasts by hydrolysis of amides. Mira–Gutiérrez J, et al. **Mycoses** 1995 Mar–Apr; 38(3–4):101–6

Recognition of DNA by designed ligands at subnanomolar concentrations. Trauger KW, et al. **Nature** 1996 Aug 8; 382(6591):559–61

Amide cleavage by a ribozyme: correction [letter] Joyce GF, et al. **Science** 1996 Apr 5;272(5258):18–9

PHARMACOKINETICS

Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers. Emanuelsson BM, et al. **Anesth Analg** 1995 Dec; 81(6):1163–8

Pharmacokinetics and analgesic effect of ropivacaine during continuous epidural infusion for postoperative pain relief. Erichsen CJ, et al. **Anesthesiology** 1996 Apr;84(4):834–42

PHARMACOLOGY

Comparison of vascular effects of ropivacaine and lidocaine on isolated rings of human arteries. Gherardini G, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):765–8

The effect of continuous epidural infusion of ropivacaine (0.1%, 0.2% and 0.3%) on nerve conduction velocity and postural control in volunteers. Zaric D, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):342–9

Comparative electrophysiologic and hemodynamic effects of several amide local anesthetic drugs in anesthetized dogs. Bruelle P, et al. **Anesth Analg** 1996 Mar;82(3):648–56

Spinal cord blood flow after intrathecal injection of ropivacaine: a screening for neurotoxic effects. Kristensen JD, et al. **Anesth Analg** 1996 Mar;82(3):636–40

(2E,4E)-N-(4-(1H-indol-3-yl)piperidin-1-yl)alkyl-5-(substituted phenyl)-2,4-pentadienamides as antiallergic agents with antihistaminic and anti slow-reacting substance (SRS) activities. Shigenaga S, et al. **Arch Pharm (Weinheim)** 1996 Jan;329(1):3–10

Involvement of leukotriene B4 in zymosan-induced rat pleurisy: inhibition of leukocyte infiltration by the 5-lipoxygenase inhibitor T-0757. Kikuchi M, et al. **Biol Pharm Bull** 1995 Sep;18(9):1302–4

Enhancement of NMDA-induced increases in levels of endogenous adenosine by adenosine deaminase and adenosine transport inhibition in rat striatum. Delaney SM, et al. **Brain Res** 1995 Dec 8;702(1–2):72–6

Suppression of human immunoglobulin E antibody production by a new naphthalene derivative. Uejima Y, et al. **Immunopharmacology** 1995 Aug;30(2):167–76

Involvement of leukotrienes in allergic pleurisy in actively sensitized rats: inhibition by the lipoxygenase inhibitor T-0757 of the increase in vascular permeability and leukotriene E4 production. Kikuchi M, et al. **Inflamm Res** 1996 Apr;45(4):192–7

Carboxamides and hydrazide of glycopeptide antibiotic eremomycin. Synthesis and antibacterial activity. Pavlov AY, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):194–8

Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors. Baraldi PG, et al. **J Med Chem** 1996 Feb 2;39(3):802–6

Inhibition of E-selectin-, ICAM-1-, and VCAM-1-mediated cell adhesion by benzo[b]thiophene-, benzofuran-, indole-, and naphthalene-2-carboxamides: identification of PD 144795 as an antiinflammatory agent. Boschelli DH, et al. **J Med Chem** 1995 Oct 27;38(22):4597–614

3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists. Hipskind PA, et al. **J Med Chem** 1996 Feb 2;39(3):736–48

Effect of insect-growth-disrupting amines and amides on Schistosoma mansoni in vitro. Foster JM, et al. **J Parasitol** 1996 Apr;82(2):340–3

Zeneca ZD6169 and its analogs from a novel series of anilide tertiary carbinols: in vitro KATP channel opening activity in bladder detrusor. Li JH, et al. **Pharmacology** 1995 Jun; 51(1):33–42

K-channel opening activity of ZD6169 and its analogs: effect on 86Rb efflux and 3H-P1075 binding in bladder smooth muscle. Trivedi S, et al. **Pharmacology** 1995 Jun; 50(6):388–97

POISONING

Intracardiac injection of T-61, a veterinary euthanasia drug. Hantson P, et al. **J Toxicol Clin Toxicol** 1996;34(2):235–9

THERAPEUTIC USE

Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Anderson IC, et al. **Cancer Res** 1996 Feb 15;56(4):715–8

Synthesis and antipancreatitis activities of novel N-(2-sulfonylamino-5-trifluoromethyl-3-pyridyl) carboxamide derivatives as phospholipase A2 inhibitors. Kimura H, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct; 43(10):1696–700

Anthelmintic properties of alpha-sanshool from Zanthoxylum liebmannianum. Navarrete A, et al. **Planta Med** 1996 Jun;62(3):250–1

1995 Gaston Labat Lecture. Ropivacaine. White knight or dark horse? de Jong RH. **Reg Anesth** 1995 Nov–Dec; 20(6):474–81 (37 ref.)

TOXICITY

Quantification of the hemolysis associated with use of T-61 as a euthanasia agent in rabbits—a comparison with Euthanyl (pentobarbital sodium) and the impact on serum hexosaminidase measurements. Doughty MJ, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1274–80

AMIDINES

Double long-chain amidine liposome-mediated self replicating RNA transfection. El Ouahabi A, et al. **FEBS Lett** 1996 Feb 12;380(1–2):108–12

ANTAGONISTS & INHIBITORS

Morin hydrate inhibits azo-initiator induced oxidation of human low density lipoprotein. Wu TW, et al. **Life Sci** 1996;58(2):PL 17–22

CHEMISTRY

Inhibition of Df-protease--induced kinin release by synthetic inhibitors. Noguchi Y, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):935–41

A crystallographic and spectroscopic study of the complex between d(CGCGAATTCGCG)2 and 2,5-bis(4-guanylphenyl)furan, an analogue of berenil. Structural origins of enhanced DNA-binding affinity. Laughton CA, et al. **Biochemistry** 1996 May 7; 35(18):5655–61

Small changes in cationic substituents of diphenylfuran derivatives have major effects on the binding affinity and the binding mode with RNA helical duplexes. Zhao M, et al. **Bioorg Med Chem** 1995 Jun;3(6):785–94

Structure-activity relationships of inhibitors derived from 3-amidinophenylalanine. Stürzebecher J, et al. **J Enzym Inhib** 1995;9(1):87–99

PHARMACOLOGY

Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose tolerance, and NIDDM. Haffner SM, et al. **Diabetes Care** 1995 May;18(5):646–53

Amidines are potent inhibitors of nitric oxide synthases: preferential inhibition of the inducible isoform. Southan GJ, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):311–8

Plant defense metabolism is increased by the free radical-generating compound AAPH. Ohlsson AB, et al. **Free Radic Biol Med** 1995 Sep;19(3):319–27

Inhibitory effects of H2-receptor antagonists on cytochrome P450 in male ICR mice. Kim DH, et al. **Hum Exp Toxicol** 1995 Aug;14(8):623–9

In vivo effects of 4-amidinoindan-1-one 2'-amidinohydrazone (CGP 48664A) and alpha-difluoromethylornithine (DFMO) on L1210 growth, cell-cycle phase distribution and polyamine contents. Dorhout B, et al. **Int J Cancer** 1995 Sep 15;62(6):738–42

Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. Weller T, et al. **J Med Chem** 1996 Aug 2;39(16):3139–47

AQ-0145, a newly developed histamine H3 antagonist, decreased seizure susceptibility of electrically induced convulsions in mice. Murakami K, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:70–3

THERAPEUTIC USE

Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Rabbani SA, et al. **Int J Cancer** 1995 Dec 11; 63(6):840–5

TOXICITY

Histamine release from rat peritoneal mast cells and human basophils induced by the free radical generator 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH). Burrows MS, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S9–10

AMIDOHYDROLASES

ANALYSIS

High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes. Lang W, et al. **Anal Biochem** 1996 Jun 15;238(1):40–5

A new approach to assay endo-type carbohydrases: bifluorescent-labeled substrates for glycoamidases and ceramide glycanases. Lee KB, et al. **Anal Biochem** 1995 Sep 1;230(1):31–6

ANTAGONISTS & INHIBITORS

(1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. Bielawska A, et al. **J Biol Chem** 1996 May 24;271(21):12646–54

Similarity of effects of N8-acetylspermidine and its deacetylase inhibitor on stimulating the growth of L1210 cells. Wang Z, et al. **Proc West Pharmacol Soc** 1995;38:41–3

BIOSYNTHESIS

Biosynthesis of Azorhizobium caulinodans Nod factors. Study of the activity of the NodABCS proteins by expression of the genes in Escherichia coli. Mergaer P, et al. **J Biol Chem** 1995 Dec 8;270(49):29217–23

Male sterility in transgenic tobacco plants induced by tapetum-specific deacetylation of the externally applied non-toxic compound N-acetyl-L-phosphinothricin. Kriete G, et al. **Plant J** 1996 Jun;9(6):809–18

BLOOD

Biotinylation of histones by human serum biotinidase: assessment of biotinyl-transferase activity in sera from normal individuals and children with biotinidase deficiency. Hymes J, et al. **Biochem Mol Med** 1995 Oct;56(1):76–83

Increased plasma biotinidase activity in patients with glycogen storage disease type Ia: effect of biotin supplementation. Burlina AB, et al. **J Inherit Metab Dis** 1996;19(2):209–12

[Activity of choline esterases in blood cells and serum and cobalt activated acylase in toxic and non-toxic liver damage] Borowiak K. **Ann Acad Med Stetin** 1995;41:145–54 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Novel cellulose-binding domains, NodB homologues and conserved modular architecture in xylanases from the aerobic soil bacteria Pseudomonas fluorescens subsp. cellulosa and Cellvibrio mixtus. Millward-Sadler SJ, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):39–48

Secondary structure of holo- and apo-aminoacylase from prediction, circular dichroism, and FT-Raman spectroscopy. Tang ZY, et al. **J Biochem (Tokyo)** 1995 Oct; 118(4):706–9

Primary structure of N-acyl-D-glutamate amidohydrolase from Alcaligenes xylosoxydans subsp. xylosoxydans A-6. Wakayama M, et al. **J Biochem (Tokyo)** 1995 Jul; 118(1):204–9

Active site and oligosaccharide recognition residues of peptide-N4-(N-acetyl-beta-D-glucosaminyl)asparagine amidase F. Kuhn P, et al. **J Biol Chem** 1995 Dec 8; 270(49):29493–7

Inactivation and unfolding of aminoacylase during denaturation in sodium dodecyl sulfate solutions. He B, et al. **J Protein Chem** 1995 Jul;14(5):349–57

Conformational changes in pantetheine hydrolase as a function of guanidinium chloride concentration. Maurizi G, et al. **J Protein Chem** 1995 Jul;14(5):373–9

DEFICIENCY

Biotinylation of histones by human serum biotinidase: assessment of biotinyl-transferase activity in sera from normal individuals and children with biotinidase deficiency. Hymes J, et al. **Biochem Mol Med** 1995 Oct;56(1):76–83

First-trimester enzyme exclusion of Farber disease using a micromethod with [3H]ceramide. Akhunov VS, et al. **J Inherit Metab Dis** 1995;18(5):616–9

Reversible metabolic myopathy in biotinidase deficiency: its possible role in causing hypotonia. Bay CA, et al. **J Inherit Metab Dis** 1995;18(6):701–4

Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells. Levade T, et al. **J Neurol Sci** 1995 Dec;134(1–2):108–14

Biotinidase mutational "hotspot" [letter; comment] Gordon A. **Nat Genet** 1996 Jun;13(2):144–5. Comment on: Nat Genet 1995 Sep;11(1):96–8.

[Farber's lipogranulomatosis] Koga M. **Nippon Rinsho** 1995 Dec;53(12):3009–13 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Biotinidase deficiency. Its form of presentation and response to treatment] Campistol J, et al. **An Esp Pediatr** 1996 Apr; 44(4):389–92 (22 ref.) **(Spa)**

GENETICS

Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. Kaul R, et al. **Am J Hum Genet** 1996 Jul;59(1):95–102

Sizing of the Rhodococcus sp. R312 genome by pulsed-field gel electrophoresis. Localization of genes involved in nitrile degradation. Bigey F, et al. **Antonie Van Leeuwenhoek** 1995

Aug;68(2):173–9
Oxidative modification of a cephalosporin C acylase from Pseudomonas strain N176 and site-directed mutagenesis of the gene. Saito Y, et al. **Appl Environ Microbiol** 1996 Aug; 62(8):2919–25
Molecular cloning and sequencing of a cDNA encoding dihydropyrimidinase from the rat liver. Matsuda K, et al. **Biochim Biophys Acta** 1996 Jun 7;1307(2):140–4
Isolation of NAD cycle mutants defective in nicotinamide mononucleotide deamidase in Salmonella typhimurium. Cheng W, et al. **J Bacteriol** 1995 Dec;177(23):6711–7
A plasmid encoding enzymes for nylon oligomer degradation: nucleotide sequence and analysis of pOAD2. Kato K, et al. **Microbiology** 1995 Oct;141 (Pt 10):2585–90
Biotinidase mutational "hotspot" [letter; comment] Gordon A. **Nat Genet** 1996 Jun;13(2):144–5. Comment on: Nat Genet 1995 Sep;11(1):96–8.
Mutational hotspot in the human biotinidase gene causes profound biotinidase deficiency [see comments] Pomponio RJ, et al. **Nat Genet** 1995 Sep;11(1):96–8. Comment in: Nat Genet 1996 Jun;13(2):144–5.
Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus [see comments] Scorpio A, et al. **Nat Med** 1996 Jun;2(6):662–7 . Comment in: Nat Med 1996 Jun;2(6):635–6.
New Zealand's leap into gene therapy [news] [see comments] Marshall E. **Science** 1996 Mar 15;271(5255):1489–90. Comment in: Science 1996 Apr 26;272(5261):467. Comment in: Science 1996 Apr 26;272(5261):469–70. Comment in: Science 1996 May 24;272(5265):1085.

ISOLATION & PURIFICATION

Purification and properties of an amidase from Rhodococcus erythropolis MP50 which enantioselectively hydrolyzes 2-arylpropionamides. Hirrlinger B, et al. **J Bacteriol** 1996 Jun;178(12):3501–7
Physical, biochemical, and immunological characterization of a thermostable amidase from Klebsiella pneumoniae NCTR 1. Nawaz MS, et al. **J Bacteriol** 1996 Apr; 178(8):2397–401
Purification and characterization of chitin deacetylase from Colletotrichum lindemuthianum. Tsigos I, et al. **J Biol Chem** 1995 Nov 3;270(44):26286–91
Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. Ueda N, et al. **J Biol Chem** 1995 Oct 6;270(40):23823–7

METABOLISM

Properties of D-hydantoinase from Agrobacterium tumefaciens and its use for the preparation of N-carbamyl D-amino acids. Durham DR, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):1095–100
Determination of N-myristoyl peptide sequence both by MALDI TOF MASS and with an N-myristoyl cleaving enzyme (polymyxin acylase). Misumi S, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):632–9
Expression of the mouse mastocytoma glucosaminyl N-deacetylase/ N-sulfotransferase in human kidney 293 cells results in increased N-sulfation of heparan sulfate. Cheung WF, et al. **Biochemistry** 1996 Apr 23;35(16):5250–6
Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. Maurelli S, et al. **FEBS Lett** 1995 Dec 11;377(1):82–6
Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. Implications for cellular proliferation and differentiation. Coroneos E, et al. **J Biol Chem** 1995 Oct 6;270(40):23305–9
Topological mapping of the cysteine residues of N-carbamyl-D-amino-acid amidohydrolase and their role in enzymatic activity. Grifantini R, et al. **J Biol Chem** 1996 Apr 19;271(16):9326–31
A novel enzyme that cleaves the N-acyl linkage of ceramides in various glycosphingolipids as well as sphingomyelin to produce their lyso forms. Ito M, et al. **J Biol Chem** 1995 Oct 13;270(41):24370–4
Purification and characterization of chitin deacetylase from Colletotrichum lindemuthianum. Tsigos I, et al. **J Biol Chem** 1995 Nov 3;270(44):26286–91
Enzymatic release of oligosaccharides from glycoproteins for chromatographic and electrophoretic analysis. O'Neill RA. **J Chromatogr A** 1996 Jan 12;720(1-2):201–15 (101 ref.)
Biotinidase activity in patients with phenylketonuria. Schulpis KH, et al. **J Inherit Metab Dis** 1995;18(6):750–1
Biotinidase Km-variants: detection and detailed biochemical investigations. Suormala T, et al. **J Inherit Metab Dis** 1995; 18(6):689–700
Inactivation and unfolding of aminoacylase during denaturation in sodium dodecyl sulfate solutions. He B, et al. **J Protein Chem** 1995 Jul;14(5):349–57
Conformational changes in pantetheine hydrolase as a function of guanidinium chloride concentration. Maurizi G, et al. **J Protein Chem** 1995 Jul;14(5):373–9
Kinetics of the course of reactivation of aminoacylase reconstituted using Mn2+ ions. Zhang YX, et al. **J Protein Chem** 1995 Nov;14(8):695–701
Continuous spectrophotometric assay of conjugated bile acid hydrolase. Kirby LC, et al. **Lipids** 1995 Sep;30(9):863–7
Male sterility in transgenic tobacco plants induced by tapetum-specific deacetylation of the externally applied non-toxic compound N-acetyl-L-phosphinothricin. Kriete G, et al. **Plant J** 1996 Jun;9(6):809–18

PHARMACOLOGY

Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus [see comments] Scorpio A, et al. **Nat Med** 1996 Jun;2(6):662–7 . Comment in: Nat Med 1996 Jun;2(6):635–6.

PHYSIOLOGY

Do de-N-glycosylation enzymes have an important role in plant cells? Berger S, et al. **Biochimie** 1995;77(9):751–60 (98 ref.)

AMIDOLACETATE see **METHADYL ACETATE**

AMIDONE see **METHADONE**

AMIDOPHENAZON see **AMINOPYRINE**

AMIDOPHOSPHORIBOSYLTRANSFERASE

ANTAGONISTS & INHIBITORS

Inhibitors of dihydro-orotase, amidophosphoribosyltransferase and IMP cyclohydrolase as potential drugs. Christopherson RI, et al. **Biochem Soc Trans** 1995 Nov;23(4):888–93

CHEMISTRY

Structure and function of the glutamine phosphoribosylpyrophosphate amidotransferase glutamine site and communication with the phosphoribosylpyrophosphate site. Kim JH, et al. **J Biol Chem** 1996 Jun 28;271(26):15549–57
A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Brannigan JA, et al. **Nature** 1995 Nov 23;378(6555):416–9

AMIDOTREZOATE see **DIATRIZOATE**

AMIFOSTINE

ADMINISTRATION & DOSAGE

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. Kemp G, et al. **J Clin Oncol** 1996 Jul;14(7):2101–12
Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. Rubin JS, et al. **J Laryngol Otol** 1995 Aug; 109(8):744–7

ANALOGS & DERIVATIVES

Delay or inhibition of rat lens opacification using pantethine and WR-77913. Clark JI, et al. **Exp Eye Res** 1996 Jan; 62(1):75–84

CHEMISTRY

Compatibility of amifostine with selected drugs during simulated Y-site administration. Trissel LA, et al. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2208–12
HPLC and 31P NMR characterization of the reaction between antitumor platinum agents and the phosphorothioate chemoprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). Thompson DC, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1413–9

PHARMACOKINETICS

Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Spencer CM, et al. **Drugs** 1995 Dec;50(6):1001–31 (176 ref.)
Pharmacokinetic profile of amifostine. Shaw LM, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):18–22 (19 ref.)

PHARMACOLOGY

Protective effect of the thiol agent WR-2721 against cyclophosphamide-induced cytotoxicity in the mouse erythropoietic system. Mazur L, et al. **Acta Physiol Hung** 1995;83(2):189–94
Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Spencer CM, et al. **Drugs** 1995 Dec;50(6):1001–31 (176 ref.)
Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. Douay L, et al. **Eur J Cancer** 1995;31A Suppl 1:S14–6
Hypotensive mechanisms of amifostine. Ryan SV, et al. **J Clin Pharmacol** 1996 Apr;36(4):365–73
Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Capizzi R. **Semin Oncol** 1996 Aug;23(4 Suppl 8):2–17 (99 ref.)
Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. List AF, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):58–63
Suppressing effect of WR-2721 on micronuclei induced by cyclophosphamide in mice. Czyżewska A, et al. **Teratog Carcinog Mutagen** 1995;15(3):109–14
[Experience in the search of new prolonged-action radiation-protective agents] Grachev SA, et al. **Radiats Biol Radioecol** 1996 Mar-Apr;36(2):190–4 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. Betticher DC, et al. **Br J Cancer** 1995 Dec;72(6):1551–5
Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Capizzi RL, et al. **Eur J Cancer** 1995;31A Suppl 1:S8–13 (11 ref.)
Amifostine plus granulocyte colony-stimulating factor therapy enhances recovery from supralethal radiation exposures: preclinical experience in animals models. Patchen ML. **Eur J Cancer** 1995;31A Suppl 1:S17–21
Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Peters GJ, et al. **Eur J Cancer** 1995;31A Suppl 1:S1–7 (45 ref.)
Future development of amifostine in cancer treatment. Alberts DS, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):90–9 (61 ref.)
Introduction: applications of amifostine in cancer treatment. Alberts DS. **Semin Oncol** 1996 Aug;23(4 Suppl 8):1
Amifostine and chemotherapy-related thrombocytopenia. Budd GT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):49–52 (31 ref.)
Use of amifostine in bone marrow purging. Cagnoni PJ, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):44–8
Cytoprotective agents for anthracyclines. Dorr RT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):23–34 (122 ref.)
Antimutagenic effects of amifostine: clinical implications. Kataoka Y, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):53–7
Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Paine GD, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):35–9
Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Rose PG. **Semin Oncol** 1996 Aug;23(4 Suppl 8):83–9
High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer. Schiller JH. **Semin Oncol** 1996 Aug;23(4 Suppl 8):78–82
Guidelines for the administration of amifostine. Schuchter LM. **Semin Oncol** 1996 Aug;23(4 Suppl 8):40–3
Amifostine and radiation therapy: past, present, and future. Tannehill SP, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):69–77 (40 ref.)
The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix. Wadler S, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):64–8 (33 ref.)
[The effect of gammaphos on the course and outcome of surgical treatment in combined radiation injuries in pigs] Cakić J, et al. **Vojnosanit Pregl** 1994 May-Jun;51(3):179–91 (Eng. Abstr.) **(Scr)**

TOXICITY

Frequency of micronuclei in mouse peripheral blood erythrocytes following WR-2721 application and X-irradiation. Mazur L. **Folia Biol (Krakow)** 1995; 43(3-4):111–4

AMIKACIN

ADMINISTRATION & DOSAGE

Lipid-based slow-release formulation of amikacin sulfate reduces foreign body-associated infections in mice. Roehrborn AA, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1752–5
Mycobacterium chelonae keratitis: resolution after debridement and presoaked collagen shields. Lois N, et al. **Cornea** 1995 Sep;14(5):536–9
Use of antibiotic-impregnated polymethyl methacrylate for treatment of an open radial fracture in a horse. Schneider RK, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1454–7
Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Schuler D. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:99–108
Amikacin administration in open heart surgery. Oto O, et al. **Panminerva Med** 1995 Jun;37(2):65–7

ADVERSE EFFECTS

Hypermagnesiuria and hypercalciuria in childhood leukemia: an effect of amikacin therapy. Wu B, et al. **J Pediatr Hematol Oncol** 1996 Feb;18(1):86–9

[Toxic retinopathy caused by intravitreal injection of amikacin and vancomycin] Piguet B, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):358–9 (Eng. Abstr.) **(Fre)**

ANALOGS & DERIVATIVES

Synthesis of 5-deoxy-5-epifluoro derivatives of arbekacin, amikacin, and 1-N-[(S)-4-amino-2-hydroxybutanoyl]tobramycin (study on structure--toxicity relationships). Shitara T, et al. **Carbohydr Res** 1995 Oct 16;276(1):75–89

ANALYSIS

[Determination of amikacin by single oscillopolarography in the presence of formaldehyde] Sun CL, et al. **Yao Hsueh Hsueh Pao** 1996;31(2):126–31 (Eng. Abstr.) **(Chi)**

ECONOMICS

[New modalities of administration of amikacin: economic point of view of a hospital pharmacist] Charpiat B, et al. **Pathol Biol (Paris)** 1996 Feb;44(2):141–4 (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

Pharmacokinetics of amikacin in children with kwashiorkor. Hendricks MK, et al. **Ann Trop Paediatr** 1995 Dec; 15(4):295–8

Tissue and serum concentrations of amikacin after intramuscular and intrauterine administration to mares in estrus. Orsini JA, et al. **Can Vet J** 1996 Mar;37(3):157–60

[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis] Cotera A, et al. **Rev Med Chil** 1995 Jun;123(6):742–8 (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Morphological indications of hair cell neodifferentiation in the organ of Corti of amikacin treated rat pups. Lenoir M, et al. **C R Acad Sci III** 1996 Apr;319(4):269–76

Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa. Gerçeker AA, et al. **Chemotherapy** 1995 Nov-Dec;41(6):433–6

Mechanism of amikacin resistance in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Hurley JC, et al. **Diagn Microbiol Infect Dis** 1995 Aug; 22(4):331–6

In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. Gerçeker AA, et al. **J Antimicrob Chemother** 1995 Oct;36(4):707–11

Treatment of experimental rabbit infective endocarditis due to a multidrug-resistant Pseudomonas aeruginosa with high-dose ceftazidime alone and combined with amikacin or sulbactam or both. Xiong YQ, et al. **J Antimicrob Chemother** 1995 May;35(5):697–706

Antibacterial activity of liposomal amikacin against Pseudomonas aeruginosa in vitro. Antos M, et al. **Pharmacol Res** 1995 Jul-Aug;32(1-2):85–7

[Kinetics of bactericidal activity of cefepime and cefpirome alone or combined with gentamicin, amikacin or ciprofloxacin against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae hyperproductive in cephalosporinase] Elkhaïli H, et al. **Pathol Biol (Paris)** 1996 May;44(5):367–73 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. Velasco E, et al. **Am J Clin Oncol** 1995 Oct;18(5):429–35

Lipid-based slow-release formulation of amikacin sulfate reduces foreign body-associated infections in mice. Roehrborn AA, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1752–5

Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group [see comments] **Arch Ophthalmol** 1995 Dec; 113(12):1479–96. Comment in: Arch Ophthalmol 1995 Dec;113(12):1555–7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1025; discussion 1026–7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1025–6; discussion 1026–7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1027–8; discussion 1028–9. Comment in: Arch Ophthalmol 1996 Aug;114(8):1029; discussion 1028–9, 1030. Comment in: Arch Ophthalmol 1996 Aug;114(8):1029–30; discussion 1028–9.

Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin. Solberg CO, et al. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:157–66

The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections. Leal del Rosal P. **J Chemother** 1995 Jun;7 Suppl 2:143–8

Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections. Rodriguez-Noriega E, et al. **J Chemother** 1995 Jun;7 Suppl 2:155–60

Isepamicin versus amikacin in the treatment of urinary tract infection. Sturm W. **J Chemother** 1995 Jun;7 Suppl 2:149–54

A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients. Viganò A, et al. **J Chemother** 1995 Jun;7 Suppl 2:95–101

[Bacteriological monitoring of the treatment of Pseudomonas aeruginosa infections with amikacin administrated at once-daily dosis in patients with cystic fibrosis] Canis F, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):343–51 (Eng. Abstr.) **(Fre)**

[Amikacin in single daily doses in children with fever] Solórzano-Santos F, et al. **Rev Invest Clin** 1996 Jan-Feb; 48(1):13–8 (Eng. Abstr.) **(Spa)**

AMILORIDE

ADMINISTRATION & DOSAGE

Immunohistochemical correlates of peripheral gustatory sensitivity to sodium and amiloride. Stewart RE, et al. **Acta Anat (Basel)** 1995;153(4):310–9

Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. Bowler IM, et al. **Arch Dis Child** 1995 Nov;73(5):427–30

Concentration of inhaled amiloride in cystic fibrosis [letter] Viaca A, et al. **Lancet** 1996 Apr 20;347(9008):1126

ADVERSE EFFECTS

Severe hyponatraemia in elderly patients: cause for concern [letter] Hornick P. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):230

ANALOGS & DERIVATIVES

Effect of central infusion of benzamil on Dahl S rat hypertension. Gomez-Sanchez EP, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H1044–7

The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. Yamagata M, et al. **Br J Cancer** 1996 Jun; 73(11):1328–34

Photolabile amiloride derivatives as cation site probes of the Na,K-ATPase. Ellis-Davies GC, et al. **J Biol Chem** 1996 Apr 26;271(17):10353–8

Angiotensin II stimulation of the basolateral located Na+/H+ antiporter in eel (Anguilla anguilla) enterocytes. Vilella S, et al. **J Mol Endocrinol** 1996 Feb;16(1):57–62

Mechanism of cardiac inotropy by phenamil, and epithelial sodium channel blocker. Guia A, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):163–73

Protective effects of dimethyl amiloride against postischemic myocardial dysfunction in rabbit hearts: phosphorus 31-nuclear magnetic resonance measurements of intracellular pH and cellular energy [see comments] Koike A, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):765–75 . Comment in: J Thorac Cardiovasc Surg 1996 Sep;112(3):776–7.

Transient prolongation of ventricular action potential duration after metabolic inhibition. Kasama M, et al. **Jpn Heart J** 1995 Nov;36(6):775–87

Non-selective effects of amiloride and its analogues on ion transport systems and their cytotoxicities in cardiac myocytes. Murata Y, et al. **Jpn J Pharmacol** 1995 Jul; 68(3):279–85

Benzamil-induced conductive state of insulin-stimulated, amiloride-blockable cation channel in fetal lung epithelium. Marunaka Y, et al. **Jpn J Physiol** 1995;45(5):895–904

Effect of dexamethasone on sodium channel block and densities in A6 cells. Granitzer M, et al. **Pflugers Arch** 1995 Aug;430(4):493–500

[Benzamil and mucoviscidosis. Primary culture of nasal mucosa as an electrophysiologic in vitro model] Blank U, et al. **HNO** 1996 Apr;44(4):172–7 (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

[Assessment of the role of enterocyte ion exchange in the intestinal absorption of amoxicillin, based on a study of the interaction with amiloride] Westphal JF, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):590–5 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Effect of amiloride and emopamil on intracranial pressure. Plangger C, et al. **Acta Neurol Scand** 1995 Nov; 92(5):416–22

Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate +/- amiloride in normal human adults. Olivier KN, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):217–23

Mechanisms of increased myocardial contractility with hypertonic saline solutions in isolated blood-perfused rabbit hearts. Mouren S, et al. **Anesth Analg** 1995 Oct;81(4):777–82

Amiloride-sensitive Na+ conductance in native Xenopus oocytes. Weber WM, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):201–6

Inhibition of trichocyst exocytosis and calcium influx in Paramecium by amiloride and divalent cations. Kerboeuf D, et al. **Biol Cell** 1996;86(1):39–43

Amiloride inhibition of chorda tympani responses to NaCl and its temperature dependency in mice. Ninomiya Y, et al. **Brain Res** 1996 Feb 5;708(1-2):153–8

Amiloride is an ineffective conditioned stimulus in taste aversion learning. Markison S, et al. **Chem Senses** 1995 Oct; 20(5):559–63

Amiloride toxicity in the fission yeast Schizosaccharomyces pombe is released by thiamine and mutations in the thiamine-repressible gene car1. Niederberger C, et al. **Gene** 1996 May 24;171(1):119–22

Amiloride-sensitive Na+ channel-like immunoreactivity in the luminal membrane of some non-sensory epithelia of the inner ear. Mizuta K, et al. **Hear Res** 1995 Aug; 88(1-2):199–205

Myocardial recovery during post-ischemic reperfusion: optimal concentrations of Na+ and Ca2+ in the reperfusate and protective effects of amiloride added to cardioplegic solution. Yamada T, et al. **Heart Vessels** 1995; 10(6):310–7

Suppression by amiloride of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Iishi H, et al. **Int J Cancer** 1995 Nov 27; 63(5):716–9

Modification of intracellular pH and thermotolerance development by amiloride. Liu JC, et al. **Int J Hyperthermia** 1995 Jul-Aug;11(4):511–22

Intracoronary amiloride prevents contractile dysfunction of postischemic "stunned" myocardium: role of hemodynamic alterations and inhibition of Na+/H+ exchange and L-type Ca2+ channels. Smart SC, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1365–73

The mammalian degenerin MDEG, an amiloride-sensitive cation channel activated by mutations causing neurodegeneration in Caenorhabditis elegans. Waldmann R, et al. **J Biol Chem** 1996 May 3;271(18):10433–6

Molecular cloning and functional expression of a novel amiloride-sensitive Na+ channel. Waldmann R, et al. **J Biol Chem** 1995 Nov 17;270(46):27411–4

Protective effect of amiloride during hypothermic hyperkalemic preservation: a 31P NMR study in isolated pig hearts. Kupriyanov VV, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2237–48

Control of the amiloride-sensitive Na+ current in mouse salivary ducts by intracellular anions is mediated by a G protein. Dinudom A, et al. **J Physiol (Lond)** 1995 Sep 15; 487 (Pt 3):549–55

Mechanisms of intracellular Mg2+ regulation affected by amiloride and ouabain in the guinea-pig taenia caeci. Nakayama S, et al. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):1–12

Amiloride inhibits meal-stimulated colonic absorption. Whang EE, et al. **J Surg Res** 1996 Feb 1;60(2):303–6

Non-selective effects of amiloride and its analogues on ion transport systems and their cytotoxicities in cardiac myocytes. Murata Y, et al. **Jpn J Pharmacol** 1995 Jul; 68(3):279–85

Benzamil-induced conductive state of insulin-stimulated, amiloride-blockable cation channel in fetal lung epithelium. Marunaka Y, et al. **Jpn J Physiol** 1995;45(5):895–904

Stimulation of calcium transport by amiloride in mouse distal convoluted tubule cells. Friedman PA, et al. **Kidney Int** 1995 Nov;48(5):1427–34

Regulation of amiloride-sensitive Na+ transport in immature rat distal colon by aldosterone. Pácha J, et al. **Pediatr Res** 1995 Sep;38(3):356–60

Amiloride-blockable Ca2+-activated Na+-permeant channels in the fetal distal lung epithelium. Marunaka Y. **Pflugers Arch** 1996 Mar;431(5):748–56

Localization and regulation by steroids of the alpha, beta and gamma subunits of the amiloride-sensitive Na+ channel in colon, lung and kidney. Renard S, et al. **Pflugers Arch** 1995 Jul;430(3):299–307

Beneficial effect of amiloride, A Na(+)-H+ exchange blocker, in a murine model of dilated cardiomyopathy. Taniguchi Y, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):201–10

Amiloride inhibits tissue-type plasminogen activator (t-PA) release from vascular endothelium [letter] Iacoviello L, et al. **Thromb Haemost** 1995 Aug;74(2):808–9

[Distribution of amiloride-sensitive sodium channel in epithelial tissue] Bonvalet JP, et al. **C R Seances Soc Biol Fil** 1995;189(2):169–77 (14 ref.) (Eng. Abstr.) **(Fre)**

[The effect of amiloride and furosemide on synaptic potentials in spinal motor neurons and difference in potentials in frog dermal epithelium] Gapanovich SO, et al. **Dokl Akad Nauk** 1995 Jun;342(6):827–9 **(Rus)**

THERAPEUTIC USE

Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Bennett WD, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1796–801

Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Robinson M, et al. **Am J Respir Crit Care Med** 1996 May; 153(5):1503–9

Diuretics and sudden cardiac death [letter; comment] Horowitz MS. **Ann Intern Med** 1996 Aug 15;125(4):347; discussion 348–9. Comment on: Ann Intern Med 1995 Oct 1;123(7):481–7.

Combined therapy with dimethylthiourea, diltiazem and amiloride/dimethylamiloride in the ischemic/reperfused heart. Karwatowska-Prokopczuk E, et al.

AMILORIDE

Cardiovasc Res 1995 Jul;30(1):70–8

Effects of diuretic therapy on the development of tolerance to nitroglycerin and exercise capacity in patients with chronic stable angina. Parker JD, et al. **Circulation** 1996 Feb 15;93(4):691–6

The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. Kool MJ, et al. **J Hypertens** 1995 Aug;13(8):839–48

Influence of a high salt diet on glomerular injury and the preventive effects of amiloride in adriamycin nephropathy. Nagashima A, et al. **Nephron** 1995;71(1):87–94

[Pharmacological approach in pulmonary involvement of cystic fibrosis] Chinet T. **Arch Pediatr** 1996;3 Suppl 1:117s–118s **(Fre)**

TOXICITY

Influence of dietary amiloride supplement on the zinc status of growing rats with marginal zinc supply. Kirchgessner M, et al. **Res Exp Med (Berl)** 1995;195(4):237–42

AMINACRINE

ANALOGS & DERIVATIVES

QSAR of acridines, III. Structure–activity relationship for antitumour imidazoacridinones and intercorrelations between in vivo and in vitro tests. Mazerska Z, et al. **Anticancer Drug Des** 1996 Jan;11(1):73–88

METABOLISM

Interactions of intercalative and minor groove binding ligands with triplex poly(dA).[poly(dT)]2 and with duplex poly(dA).poly(dT) and poly[d(A–T)]2 studied by CD, LD, and normal absorption. Kim HK, et al. **Biochemistry** 1996 Jan 30;35(4):1187–94

PHARMACOLOGY

The effect of aminophylline on the contraction threshold of rat diaphragm fibers and its modification by 9-aminoacridine. Losavio AS, et al. **Life Sci** 1996; 58(13):1031–7

TOXICITY

Frameshift mutagenesis by 9-aminoacridine: antimutagenic effects of adenosine compounds. Kopsidas G, et al. **Mutat Res** 1996 Jun 10;352(1–2):135–42

AMINE OXIDASE (COPPER-CONTAINING)

ANALYSIS

In situ detection of diamine oxidase activity using enhanced chemiluminescence. Bruun L, et al. **Anal Biochem** 1996 Jan 1;233(1):130–6

Determination of the activity of diamine oxidase in extremely small tissue samples. Schwelberger HG, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S94–5

Detection of reaction intermediates in topa quinone enzymes. Hartmann C, et al. **Methods Enzymol** 1995;258:69–90

ANTAGONISTS & INHIBITORS

Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Lizcano JM, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):187–95

Inhibition of pig kidney diamine oxidase by nazlinin and nazlinin derivatives. Cheng E, et al. **Biochim Biophys Acta** 1995 Dec 6;1253(2):189–92

Mechanism-based inactivation of porcine kidney diamine oxidase by 1,4-diamino-2-butene. He Z, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):117–27

Inhibition of copper/quinoprotein amine oxidases from Aspergillus niger by benzophenanthridine alkaloids. Luhová L, et al. **J Enzym Inhib** 1995;9(4):295–302

Further studies on the ex-vivo effects of procarbazine and monomethylhydrazine on rat semicarbazide-sensitive amine oxidase and monoamine oxidase activities. Holt A, et al. **J Pharm Pharmacol** 1995 Oct;47(10):837–45

BIOSYNTHESIS

Cellular location influences copper-dependent topaquinone formation for phenylethylamine oxidase expressed in Escherichia coli K-12. Hanlon SP, et al. **FEMS Microbiol Lett** 1995 Nov 15;133(3):271–5

BLOOD

Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease. Boomsma F, et al. **Life Sci** 1995;57(19):1753–9

CHEMISTRY

cDNA sequences of variant forms of human placenta diamine oxidase. Zhang X, et al. **Biochem Genet** 1995 Aug; 33(7–8):261–8

Half-site reactivity with p-nitrophenylhydrazine and subunit separation of the dimeric copper-containing amine oxidase from Aspergillus niger. Frébort I, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1207–16

The copper-topaquinone-phenylhydrazine-adduct geometry in Escherichia coli amine oxidase derivatized with phenylhydrazines substituted with 19F-NMR relaxation measurements. Steinebach V, et al. **Eur J Biochem** 1996 Jun 15;238(3):683–9

The free radical site in pea seedling copper amine oxidase probed by resonance Raman spectroscopy and generated by photolysis of caged substrate. Johnson SA, et al. **FEBS Lett** 1996 Feb 12;380(1–2):183–7

Intermediates in the catalytic cycle of copper-quinoprotein amine oxidase from Escherichia coli. Steinebach V, et al. **J Biol Chem** 1996 Mar 8;271(10):5580–8

Isolation of 2,4,5-trihydroxyphenylalanine quinone (topa quinone) from copper amine oxidases. Janes SM, et al. **Methods Enzymol** 1995;258:20–34

Spectrophotometric detection of topa quinone. Palcic MM, et al. **Methods Enzymol** 1995;258:34–8

Catalytic aerobic deamination of activated primary amines by a model for the quinone cofactor of mammalian copper amine oxidases. Sayre LM, et al. **Methods Enzymol** 1995; 258:53–69

Copper amine oxidase: a novel use for a tyrosine [comment] Fontecave M, et al. **Structure** 1995 Nov 15;3(11):1127–9 (22 ref.). Comment on: Structure 1995 Nov 15;3(11):1171–84.

Crystal structure of a quinoenzyme: copper amine oxidase of Escherichia coli at 2 A resolution [see comments] Parsons MR, et al. **Structure** 1995 Nov 15;3(11):1171–84. Comment in: Structure 1995 Nov 15;3(11):1127–9.

DRUG EFFECTS

Influence of proliferative stimulation on the activity of rat intestinal diamine oxidase. Schwelberger HG, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S66–7

[Plasma activity of diamine oxidase after heparin in patients with diabetic enteropathy] Loba J, et al. **Pol Arch Med Wewn** 1995 Feb;93(2):114–21 (Eng. Abstr.) **(Pol)**

GENETICS

Molecular and functional studies of copper amine oxidase from Arabidopsis thaliana. Møller SG, et al. **Biochem Soc Trans** 1995 Nov;23(4):630S

ISOLATION & PURIFICATION

Identification of topaquinone, as illustrated for pig kidney diamine oxidase and Escherichia coli amine oxidase. Steinebach V, et al. **Anal Biochem** 1995 Sep 1;230(1):159–66

Purification of human intestinal diamine oxidase. Schwelberger HG, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S50–1

METABOLISM

Formaldehyde produced endogenously via deamination of methylamine. A potential risk factor for initiation of endothelial injury. Yu PH, et al. **Atherosclerosis** 1996 Feb; 120(1–2):189–97

Molecular and functional studies of copper amine oxidase from Arabidopsis thaliana. Møller SG, et al. **Biochem Soc Trans** 1995 Nov;23(4):630S

The reaction mechanism of copper amine oxidase: detection of intermediates by the use of substrates and inhibitors. Medda R, et al. **Biochemistry** 1995 Dec 19;34(50):16375–81

Evaluation of the significance of polyamines and their oxidases in the aetiology of human cervical carcinoma. Fernandez C, et al. **Br J Cancer** 1995 Nov;72(5):1194–9

Superoxide anion radical generation during the oxidation of various amines by diamine oxidase. Silva IJ, et al. **Free Radic Res** 1996 Mar;24(3):167–75

Activity of histamine metabolizing and catabolizing enzymes during reperfusion of isolated, globally ischemic rat hearts. Valen G, et al. **Inflamm Res** 1996 Mar;45(3):145–9

Biogenesis of novel quinone coenzymes. Tanizawa K. **J Biochem (Tokyo)** 1995 Oct;118(4):671–8 (52 ref.)

Biosynthesis of topa quinone cofactor in bacterial amine oxidases. Solvent origin of C-2 oxygen determined by Raman spectroscopy. Nakamura N, et al. **J Biol Chem** 1996 Mar 1;271(9):4718–24

Intermediates in the catalytic cycle of copper-quinoprotein amine oxidase from Escherichia coli. Steinebach V, et al. **J Biol Chem** 1996 Mar 8;271(10):5580–8

Diamine oxidase-gold ultrastructural localization of histamine in isolated human lung mast cells stimulated to undergo anaphylactic degranulation and recovery in vitro. Dvorak AM, et al. **J Leukoc Biol** 1996 Jun;59(6):824–34

Semicarbazide-sensitive amine oxidase activity in white adipose tissue of the insulin-deficient rat. Conforti L, et al. **J Pharm Pharmacol** 1995 May;47(5):420–4

Detection of reaction intermediates in topa quinone enzymes. Hartmann C, et al. **Methods Enzymol** 1995;258:69–90

Catalytic aerobic deamination of activated primary amines by a model for the quinone cofactor of mammalian copper amine oxidases. Sayre LM, et al. **Methods Enzymol** 1995; 258:53–69

Metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors. Holt A, et al. **Prog Brain Res** 1995;106:187–97

AMINE OXIDASE (FLAVIN-CONTAINING) see **MONOAMINE OXIDASE**

AMINE OXIDOREDUCTASES

ANALYSIS

Characterization of amine oxidase activities in macrophages from human peripheral blood. Seiler N, et al. **Biochem Cell Biol** 1995 May–Jun;73(5–6):275–81

In situ substrate specificity and ultrastructural localization of polyamine oxidase activity in unfixed rat tissues. Van den Munckhof RJ, et al. **J Histochem Cytochem** 1995 Nov; 43(11):1155–62

ANTAGONISTS & INHIBITORS

Reaction mechanism for the inactivation of the quinoprotein methylamine dehydrogenase by phenylhydrazine. Davidson VL, et al. **Biochim Biophys Acta** 1995 Sep 27; 1252(1):146–50

Effects of inhibitors of deoxyhypusine synthase on the differentiation of mouse neuroblastoma and erythroleukemia cells. Chen ZP, et al. **Cancer Lett** 1996 Aug 2;105(2):233–9

Mechanism-based inhibition of L-pipecolate oxidase by 4,5-dehydro-L-pipecolic acid. Zabriskie TM. **J Med Chem** 1996 Aug 2;39(16):3046–8

BIOSYNTHESIS

Two distinct quinoprotein amine oxidases are induced by n-butylamine in the mycelia of Aspergillus niger AKU 3302. Purification, characterization, cDNA cloning and sequencing. Frébort I, et al. **Eur J Biochem** 1996 Apr 1; 237(1):255–65

Molecular cloning and functional expression of Neurospora deoxyhypusine synthase cDNA and identification of yeast deoxyhypusine synthase cDNA. Tao Y, et al. **J Biol Chem** 1995 Oct 13;270(41):23984–7

Cloning of mammalian topa quinone-containing enzymes. Mu D, et al. **Methods Enzymol** 1995;258:114–22

BLOOD

Extended substrate specificity of serum amine oxidase: possible involvement in protein posttranslational modification. Wang X, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):91–7

Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Jacques PF, et al. **Circulation** 1996 Jan 1;93(1):7–9

Half-of-the-sites reactivity of bovine serum amine oxidase. Reactivity and chemical identity of the second site. De Biase D, et al. **Eur J Biochem** 1996 Apr 1;237(1):93–9

Mass spectrometric studies of the primary sequence and structure of bovine liver and serum amine oxidase. Adams GW, et al. **Methods Enzymol** 1995;258:90–114

CHEMISTRY

Purification, properties and primary structure of H2-forming N5 ,N10 -methylenetetrahydromethanopterin dehydrogenase from Methanococcus thermolithotrophicus. Hartmann GC, et al. **Arch Microbiol** 1996 Mar; 165(3):187–93

Intermolecular electron transfer from substrate-reduced methylamine dehydrogenase to amicyanin is linked to proton transfer. Bishop GR, et al. **Biochemistry** 1995 Sep 19;34(37):12082–6

Properties of the selenium- and molybdenum-containing nicotinic acid hydroxylase from Clostridium barkeri. Gladyshev VN, et al. **Biochemistry** 1996 Jan 9;35(1):212–23

Evidence for a methylammonium-binding site on methylamine dehydrogenase of Thiobacillus versutus. Gorren AC, et al. **Biochemistry** 1995 Oct 10; 34(40):12926–31

Electrostatic environment of the tryptophylquinone cofactor in methylamine dehydrogenase: evidence from resonance Raman spectroscopy of model compounds. Moënne-Loccoz P, et al. **Biochemistry** 1996 Apr 16; 35(15):4713–20

Two amine oxidases from Aspergillus niger AKU 3302 contain topa quinone as the cofactor: unusual cofactor link to the glutamyl residue occurs only at one of the enzymes. Frébort I, et al. **Biochim Biophys Acta** 1996 Jun 7; 1295(1):59–72

Limited proteolysis of Hansenula polymorpha yeast amine oxidase: isolation of a C-terminal fragment containing both a copper and quino-cofactor. Plastino J, et al. **FEBS Lett** 1995 Sep 11;371(3):276–8

Limited proteolysis of Hansenula polymorpha yeast amine oxidase: isolation of a C-terminal fragment containing both a copper and quino-cofactor (FEBS 15979). Plastino J, et al. **FEBS Lett** 1996 Jan 29;379(2):202

Enzymatic and electron transfer activities in crystalline protein complexes. Merli A, et al. **J Biol Chem** 1996 Apr 19;271(16):9177–80

Mass spectrometric studies of the primary sequence and structure of bovine liver and serum amine oxidase. Adams GW, et al. **Methods Enzymol** 1995;258:90–114

Detection of intermediates in tryptophan tryptophylquinone enzymes. Davidson VL, et al. **Methods Enzymol** 1995;

258:176–90
Resonance Raman spectroscopy of quinoproteins. Dooley DM, et al. **Methods Enzymol** 1995;258:132–40
Redox–cycling detection of dialyzable pyrroloquinoline quinone and quinoproteins. Flückiger R, et al. **Methods Enzymol** 1995;258:140–9
Tryptophan tryptophylquinone in bacterial amine dehydrogenases. McIntire WS. **Methods Enzymol** 1995; 258:149–64
X–ray studies of quinoproteins. Mathews FS. **Methods Enzymol** 1995;258:191–216
Cloning of mammalian topa quinone–containing enzymes. Mu D, et al. **Methods Enzymol** 1995;258:114–22
Stereochemistry and cofactor identity status of semicarbazide–sensitive amine oxidases. Palcic MM, et al. **Prog Brain Res** 1995;106:41–7 (28 ref.)
Polyamine oxidase, properties and functions. Seiler N. **Prog Brain Res** 1995;106:333–44 (51 ref.)

DEFICIENCY

Long term treatment with betaine in methylenetetrahydrofolate reductase deficiency. Ronge E, et al. **Arch Dis Child** 1996 Mar;74(3):239–41
Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Rozen R. **Clin Invest Med** 1996 Jun; 19(3):171–8 (18 ref.)

GENETICS

Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease [see comments] Kluijtmans LA, et al. **Am J Hum Genet** 1996 Jan;58(1):35–41. Comment in: Am J Hum Genet 1996 Jan;58(1):17–20.
Cloning, nucleotide sequencing, and expression of an opine dehydrogenase gene from Arthrobacter sp. strain 1C. Dairi T, et al. **Appl Environ Microbiol** 1995 Aug;61(8):3169–71
Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Wilcken DE, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):878–82
Molecular cloning and functional expression of human deoxyhypusine synthase cDNA based on expressed sequence tag information. Yan YP, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):429–34
Database cloning human delta 1–pyrroline–5–carboxylate synthetase (P5CS) cDNA: a bifunctional enzyme catalyzing the first 2 steps in proline biosynthesis. Aral B, et al. **C R Acad Sci III** 1996 Mar;319(3):171–8
Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Rozen R. **Clin Invest Med** 1996 Jun; 19(3):171–8 (18 ref.)
Molecular characterization of a cDNA encoding functional human deoxyhypusine synthase and chromosomal mapping of the corresponding gene locus. Bevec D, et al. **FEBS Lett** 1996 Jan 8;378(2):195–8
Deoxyhypusine synthase gene is essential for cell viability in the yeast Saccharomyces cerevisiae. Sasaki K, et al. **FEBS Lett** 1996 Apr 15;384(2):151–4
Isolation, characterization, and chromosomal location of a gene encoding the delta 1–pyrroline–5–carboxylate synthetase in Arabidopsis thaliana. Savouré A, et al. **FEBS Lett** 1995 Sep 18;372(1):13–9
Cloning, sequencing, and growth phase–dependent transcription of the coenzyme F420–dependent N5,N10–methylenetetrahydromethanopterin reductase–encoding genes from Methanobacterium thermoautotrophicum delta H and Methanopyrus kandleri. Nölling J, et al. **J Bacteriol** 1995 Dec;177(24):7238–44
Molecular cloning and functional expression of Neurospora deoxyhypusine synthase cDNA and identification of yeast deoxyhypusine synthase cDNA. Tao Y, et al. **J Biol Chem** 1995 Oct 13;270(41):23984–7
Spina bifida, 677T–>C mutation, and role of folate [letter; comment] de Franchis R, et al. **Lancet** 1995 Dec 23–30; 346(8991–8992):1703. Comment on: Lancet 1995 Oct 21;346(8982):1070–1.
Enzyme defect as a risk factor for spina bifida [letter; comment] Lucock MD, et al. **Lancet** 1995 Dec 2; 346(8988):1495–6. Comment on: Lancet 1995 Oct 21;346(8982):1070–1.
Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida [see comments] van der Put NM, et al. **Lancet** 1995 Oct 21;346(8982):1070–1. Comment in: Lancet 1995 Dec 2;346(8988):1495–6. Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1703. Comment in: Lancet 1996 Feb 3;347(8997):340.
Relevance to spina bifida of mutated methylenetetrahydrofolate reductase [letter; comment] Wilcken DE, et al. **Lancet** 1996 Feb 3;347(8997):340. Comment on: Lancet 1995 Oct 21;346(8982):1070–1.
Abnormal folate metabolism and neural tube defects [letter] Davis RE. **Med J Aust** 1996 Apr 15;164(8):509–10
Baculovirus expression and purification of rat 10–formyltetrahydrofolate dehydrogenase. Krupenko SA, et al. **Protein Expr Purif** 1995 Aug;6(4):457–64
A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. Whitehead AS, et al. **QJM** 1995 Nov;88(11):763–6

ISOLATION & PURIFICATION

Identification of topaquinone, as illustrated for pig kidney diamine oxidase and Escherichia coli amine oxidase. Steinebach V, et al. **Anal Biochem** 1995 Sep 1;230(1):159–66
Purification, properties and primary structure of H2–forming N5 ,N10 –methylenetetrahydromethanopterin dehydrogenase from Methanococcus thermolithotrophicus. Hartmann GC, et al. **Arch Microbiol** 1996 Mar; 165(3):187–93
Baculovirus expression and purification of rat 10–formyltetrahydrofolate dehydrogenase. Krupenko SA, et al. **Protein Expr Purif** 1995 Aug;6(4):457–64

METABOLISM

Kinetic characterization of soybean seedling amine oxidase. Di Paolo ML, et al. **Arch Biochem Biophys** 1995 Nov 10; 323(2):329–34
Thermodynamic analysis of the oxidative deamination of polyamines by bovine serum amine oxidase. Stevanato R, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):374–8
Evidence for a tryptophan tryptophylquinone aminosemiquinone intermediate in the physiologic reaction between methylamine dehydrogenase and amicyanin. Bishop GR, et al. **Biochemistry** 1996 Jul 9;35(27):8948–54
Electron transfer from copper to heme within the methylamine dehydrogenase––amicyanin––cytochrome c–551i complex. Davidson VL, et al. **Biochemistry** 1996 Jun 25;35(25):8120–5
Properties of the selenium– and molybdenum–containing nicotinic acid hydroxylase from Clostridium barkeri. Gladyshev VN, et al. **Biochemistry** 1996 Jan 9;35(1):212–23
Electron transfer reactions between aromatic amine dehydrogenase and azurin. Hyun YL, et al. **Biochemistry** 1995 Sep 26;34(38):12249–54
Evaluation of the significance of polyamines and their oxidases in the aetiology of human cervical carcinoma. Fernandez C, et al. **Br J Cancer** 1995 Nov;72(5):1194–9
Hydrogen isotope effects in the reactions catalyzed by H2–forming N5,N10–methylenetetrahydromethanopterin dehydrogenase from methanogenic Archaea. Klein AR, et al. **Eur J Biochem** 1995 Oct 1;233(1):372–6
Glucose, glutathione, and cellular response to spermine oxidation products. Agostinelli E, et al. **Free Radic Biol Med** 1996;20(5):649–56
Biogenesis of novel quinone coenzymes. Tanizawa K. **J Biochem (Tokyo)** 1995 Oct;118(4):671–8 (52 ref.)
Complex formation with methylamine dehydrogenase affects the pathway of electron transfer from amicyanin to cytochrome c–551i. Davidson VL, et al. **J Biol Chem** 1995 Oct 13;270(41):23941–3
In situ substrate specificity and ultrastructural localization of polyamine oxidase activity in unfixed rat tissues. Van den Munckhof RJ, et al. **J Histochem Cytochem** 1995 Nov; 43(11):1155–62
Detection of reaction intermediates in topa quinone enzymes. Hartmann C, et al. **Methods Enzymol** 1995;258:69–90
Interaction between primary and secondary metabolism in Streptomyces coelicolor A3(2): role of pyrroline–5–carboxylate dehydrogenase. Smith DD, et al. **Microbiology** 1995 Jul;141 (Pt 7):1739–44
Semicarbazide–sensitive amine oxidases: some biochemical properties and general considerations. Buffoni F. **Prog Brain Res** 1995;106:323–31 (62 ref.)
Some aspects of the pathophysiology of semicarbazide–sensitive amine oxidase enzymes. Callingham BA, et al. **Prog Brain Res** 1995;106:305–21 (109 ref.)
Substrate–specificity of mammalian tissue–bound semicarbazide–sensitive amine oxidase. Lyles GA. **Prog Brain Res** 1995;106:293–303 (82 ref.)
Polyamine oxidase, properties and functions. Seiler N. **Prog Brain Res** 1995;106:333–44 (51 ref.)
[Flavin–containing polyaminooxidase in the liver: spectral properties and localization] Gasparian VK. **Biokhimiia** 1995 Oct;60(10):1632–6 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Modulation of K+ channel currents by serum amineoxidase in neurons. Wu L, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):47–52
Inactivation of human immunodeficiency virus type 1 by the amine oxidase–peroxidase system. Klebanoff SJ, et al. **J Clin Microbiol** 1995 Aug;33(8):2054–7

PHYSIOLOGY

Interaction between primary and secondary metabolism in Streptomyces coelicolor A3(2): role of pyrroline–5–carboxylate dehydrogenase. Smith DD, et al. **Microbiology** 1995 Jul;141 (Pt 7):1739–44

AMINES

Stearylamine liposome as a new efficient reagent for DNA transfection of eukaryotic cells. Wang D, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):450–5

ADVERSE EFFECTS

Cancer occurrence among dyestuff workers exposed to aromatic amines. A long term follow–up study. Naito S, et al. **Cancer** 1995 Oct 15;76(8):1445–52
p53 mutations in bladder tumors from arylamine–exposed workers. Taylor JA, et al. **Cancer Res** 1996 Jan 15; 56(2):294–8
Aromatic amine exposure and oesophageal cancer [letter; comment] Schulte PA. **Int J Epidemiol** 1996 Feb; 25(1):226–7. Comment on: Int J Epidemiol 1995 Apr;24(2):266–75.
Factors affecting the occurrence of urothelial tumors in dye workers exposed to aromatic amines. Shinka T, et al. **Int J Urol** 1995 Sep;2(4):243–8
The food–derived heterocyclic amines and breast cancer: a 1995 perspective. Synderwine EG. **Recent Results Cancer Res** 1996;140:17–25 (54 ref.)

ANALYSIS

Occurrence of nitrosatable amines in some Nigerian medicinal plants. Uhegbu FO, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):643–9
Evaluation of hamburgers and hot dogs for the presence of mutagens. Stavric B, et al. **Food Chem Toxicol** 1995 Oct; 33(10):815–20
Airborne mutagens produced by frying beef, pork and a soy–based food. Thiébaud HP, et al. **Food Chem Toxicol** 1995 Oct;33(10):821–8
Biomonitoring of urinary aromatic amines and arylamine hemoglobin adducts in exposed workers and nonexposed control persons. Riffelmann M, et al. **Int Arch Occup Environ Health** 1995;68(1):36–43
Determination of heterocyclic amines by pneumatically assisted electrospray liquid chromatography–mass spectrometry. Galceran MT, et al. **J Chromatogr A** 1996 Apr 12;730(1–2):185–94
Derivatization reactions for the determination of amines by gas chromatography and their applications in environmental analysis. Kataoka H. **J Chromatogr A** 1996 May 10;733(1–2):19–34 (178 ref.)
Detection of secondary amines on solid phase. Vojkovsky T. **Pept Res** 1995 Jul–Aug;8(4):236–7
Chemical safety of U.S. Navy Fleet soda lime. Lillo RS, et al. **Undersea Hyperb Med** 1996 Mar;23(1):43–53

CHEMICAL SYNTHESIS

Bis–naphthalimides 3: synthesis and antitumor activity of N,N'–bis[2–(1,8–naphthalimido)–ethyl] alkanediamines. Braña MF, et al. **Anticancer Drug Des** 1996 Jun; 11(4):297–309
Synthesis of novel phosphoramidite reagents for the attachment of antisense oligonucleotides to various regions of the benzophenanthridine ring system. Chen JK, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):473–82
Agents for the treatment of overactive detrusor. IX. Synthesis and pharmacological properties of metabolites of N–tert–Butyl–4,4–diphenyl–2–cyclopentenylamine (FK584) in human urine. Taniguchi K, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun;44(6):1188–95
Aminodiol HIV protease inhibitors. Synthesis and structure–activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity. Chen P, et al. **J Med Chem** 1996 May 10;39(10):1991–2007
Thiophene congeners of morpholine and allylamine type antifungals––syntheses and biological activities. Bracher F, et al. **Pharmazie** 1995 Aug;50(8):525–7

CHEMISTRY

Amination of polystyrene microwells: application to the covalent grafting of DNA probes for hybridization assays. Zammatteo N, et al. **Anal Biochem** 1996 Apr 5;236(1):85–94
Inhibition of 2,5–hexanedione–induced protein cross–linking by biological thiols: chemical mechanisms and toxicological implications. Zhu M, et al. **Chem Res Toxicol** 1995 Jul–Aug; 8(5):764–71
Study of the forces of stabilizing complexes between chlorophylls and heterocyclic amine mutagens. Dashwood R, et al. **Environ Mol Mutagen** 1996;27(3):211–8
The effect of teas on the in vitro mutagenic potential of heterocyclic aromatic amines. Stavric B, et al. **Food Chem Toxicol** 1996 Jun;34(6):515–23
Investigation of (Oxodioxolenyl)methyl carbamates as nonchiral bioreversible prodrug moieties for chiral amines. Alexander J, et al. **J Med Chem** 1996 Jan 19;39(2):480–6
Synthetic pyridopurines derived from food pyrolysis products: intercalation, interactions with membranes, cyclodextrin complexation, and biological mitogenic properties. Debouzy JC, et al. **J Pharm Sci** 1996 Feb; 85(2):200–5
Site specific labelling of sugar residues in oligoribonucleotides: reactions of aliphatic isocyanates with 2' amino groups. Sigurdson ST, et al. **Nucleic Acids Res** 1996 Aug 15;24(16):3129–33
Molecular organization of histidine–tagged biomolecules at self–assembled lipid interfaces using a novel class of chelator lipids. Dietrich C, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9014–8
Tolerance space and molecular similarity. Basak SC, et al. **SAR QSAR Environ Res** 1995;3(4):265–77

ISOLATION & PURIFICATION

Separation of nanoliter samples of biological amines by a comprehensive two–dimensional microcolumn liquid chromatography system. Holland LA, et al. **Anal Chem**

1995 Sep 15;67(18):3275–83

Isolation by solid–phase extraction and liquid chromatographic determination of mutagenic amines in beef extracts. Galceran MT, et al. **J Chromatogr A** 1996 Jan 5;719(1):203–12

Detection and identification of amines in bacterial vaginosis. Kubota T, et al. **J Obstet Gynaecol** 1995 Feb;21(1):51–5

METABOLISM

DRD4 dopamine receptor genotype and CSF monoamine metabolites in Finnish alcoholics and controls. Adamson MD, et al. **Am J Med Genet** 1995 Jun 19;60(3):199–205

Formation of DNA adducts by the co–mutagen norharman with aromatic amines. Mori M, et al. **Carcinogenesis** 1996 Jul;17(7):1499–503

Enhanced rates of cytochrome P450 metabolic–intermediate complex formation from nonmacrolide amines in rifampicin–treated rabbit liver microsomes. Franklin MR. **Drug Metab Dispos** 1995 Dec;23(12):1379–82

Superoxide anion radical generation during the oxidation of various amines by diamine oxidase. Silva IJ, et al. **Free Radic Res** 1996 Mar;24(3):167–75

More on adducts and addicts. Slow N–acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Coggon D. **Hum Exp Toxicol** 1995 Jun;14(6):538–9

Alkaline protease catalysis of a secondary amine to form a peptide bond. Chen ST, et al. **Int J Pept Protein Res** 1995 Sep–Oct;46(3–4):314–9

Factor– and energy–free peptide synthesis promoted by aromatic tertiary amines including nucleic acid–related compounds. Nitta I, et al. **J Biochem (Tokyo)** 1995 Oct; 118(4):850–4

Some aspects of the role of cytochrome P–450 isozymes in the N–oxidative transformation of secondary and tertiary amine compounds. Hlavica P, et al. **J Biochem Toxicol** 1995 Oct;10(5):275–285 (86 ref.)

Effects of Hemerocallis flava on motor activity and the concentration of central monoamines and its metabolites in rats. Hsieh MT, et al. **J Ethnopharmacol** 1996 Jun; 52(2):71–6

Methcathinone: an initial study of its effects on monoaminergic systems. Gygi MP, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1066–72

The role of peroxidase–catalyzed activation of aromatic amines in breast cancer. Josephy PD. **Mutagenesis** 1996 Jan;11(1):3–7 (65 ref.)

Expression of the extraneuronal monoamine transporter (uptake2) in human glioma cells. Streich S, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Feb; 353(3):328–33

Metabolic activation of carcinogenic arylamines by rapid acetylator, slow acetylator, and chimeric recombinant Syrian hamster NAT2 allozymes. Hein DW, et al. **Proc West Pharmacol Soc** 1995;38:59–62

Trace amines in hepatic encephalopathy. Mousseau DD, et al. **Prog Brain Res** 1995;106:277–84 (43 ref.)

An evolutionary view of drug–receptor interaction: the bioamine receptor family. Vernier P, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):375–81 (56 ref.)

Aminium cation radical mechanism proposed for monoamine oxidase B catalysis: are there alternatives? Edmondson DE. **Xenobiotica** 1995 Jul;25(7):735–53 (53 ref.)

On the mechanism of amine oxidations by P450. Karki SB, et al. **Xenobiotica** 1995 Jul;25(7):711–24 (55 ref.)

Haemoprotein–mediated metabolism of enamines and the possible involvement of one–electron oxidations. Sayre LM, et al. **Xenobiotica** 1995 Jul;25(7):769–75

Species– and gender–related differences in amine, alcohol and phenol sulphoconjugations. Shiraga T, et al. **Xenobiotica** 1995 Nov;25(10):1063–71

PHARMACOKINETICS

Some aspects of the role of cytochrome P–450 isozymes in the N–oxidative transformation of secondary and tertiary amine compounds. Hlavica P, et al. **J Biochem Toxicol** 1995 Oct;10(5):275–285 (86 ref.)

PHARMACOLOGY

Bis–naphthalimides 3: synthesis and antitumor activity of N,N'–bis[2–(1,8–naphthalimido)–ethyl] alkanediamines. Braña MF, et al. **Anticancer Drug Des** 1996 Jun; 11(4):297–309

Efficacy of topical tuaminoheptane combined with N–acetyl–cysteine in reducing nasal resistance. A double–blind rhinomanometric study versus xylometazoline and placebo. Cogo A, et al. **Arzneimittelforschung** 1996 Apr;46(4):385–8

The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Webb MS, et al. **Biochim Biophys Acta** 1995 Sep 13;1238(2):147–55

Influence of amino acids on the formation of mutagenic/carcinogenic heterocyclic amines in a model system. Johansson MA, et al. **Carcinogenesis** 1995 Oct; 16(10):2553–60

Cytotoxicity of aromatic amines in rat liver and oxidative stress. Hillesheim W, et al. **Chem Biol Interact** 1995 Oct 20;98(1):85–95

Agents for the treatment of overactive detrusor. IX. Synthesis and pharmacological properties of metabolites of N–tert–Butyl–4,4–diphenyl–2–cyclopentenylamine (FK584) in human urine. Taniguchi K, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun;44(6):1188–95

Action of beta–phenylethylamine and related amines on nigrostriatal dopamine neurotransmission. Barroso N, et al. **Eur J Pharmacol** 1996 Feb 22;297(3):195–203

Effect of insect–growth–disrupting amines and amides on Schistosoma mansoni in vitro. Foster JM, et al. **J Parasitol** 1996 Apr;82(2):340–3

Hepatic membrane transport of organic cations using isolated rat hepatocyte membrane vesicles: structure–transport relationships. Kwon Y, et al. **Pharm Res** 1995 Jul; 12(7):1109–14

Effects of chemical modifiers on recombinant factor VIII activity. Manning F, et al. **Thromb Res** 1995 Nov 1; 80(3):247–54

THERAPEUTIC USE

A rationale for the selection of nasal decongestants in lacrimal drainage surgery. Hosal BM, et al. **Ophthal Plast Reconstr Surg** 1995 Sep;11(3):215–20 (29 ref.)

TOXICITY

Extrapolation of heterocyclic amine carcinogenesis data from rodents and nonhuman primates to humans. Adamson RH, et al. **Arch Toxicol Suppl** 1996;18:303–18 (56 ref.)

Mechanistic study on toxicity of positively charged liposomes containing stearylamine to blood. Nishiya T, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(4):505–12

Induction of cytochrome P450 isoforms by carcinogenic aromatic amines and carcinogenic susceptibility of rodent animals. Hashimoto Y, et al. **Pharmacogenetics** 1995;5 Spec No:S80–3 (22 ref.)

Acute and chronic toxicity of aromatic amines studied in the isolated perfused rat liver. Ambs S, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):186–94

AMINES, BIOGENIC see **BIOGENIC AMINES**

AMINES, SYMPATHOMIMETIC see **SYMPATHOMIMETICS**

AMINO ACID ACTIVATING ENZYMES see **AMINO ACYL T RNA SYNTHETASES**

AMINO ACID ACTIVATION

see related
AMINO ACYL T RNA SYNTHETASES

Mutational analysis suggests the same design for editing activities of two tRNA synthetases. Lin L, et al. **Biochemistry** 1996 Apr 30;35(17):5596–601

Self–activation of N–phosphoamino acids and N–phosphodipeptides in oligopeptide formation. Zhao Y, et al. **Int J Pept Protein Res** 1995 Jun;45(6):514–8

AMINO ACID CHLOROMETHYL KETONES

CHEMISTRY

Active site structure of a hemagglutinating protease from Porphyromonas gingivalis: similarity to clostripain. Nishikata M, et al. **Biochem Mol Biol Int** 1995 Oct; 37(3):547–53

Inhibition of thrombin by arginine–containing peptide chloromethyl ketones and bis chloromethyl ketone–albumin conjugates. Odake S, et al. **J Enzym Inhib** 1995;9(1):17–27

X–ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Brandstetter H, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9796–800

METABOLISM

Active site labeling with dansyl–glutamyl–glycyl–arginyl chloromethyl ketone demonstrates the full activity of the refolded and purified tissue–type plasminogen activator variant BM 06.022. Kohnert U, et al. **Appl Biochem Biotechnol** 1995 Nov;55(2):157–66

PHARMACOLOGY

A cleavage–site–directed inhibitor of interleukin–1 beta–converting enzyme–like proteases inhibits apoptosis in primary cultures of rat hepatocytes. Cain K, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):27–32

Benzyloxycarbonyl–Val–Ala–Asp (OMe) fluoromethylketone (Z–VAD.FMK) inhibits apoptosis by blocking the processing of CPP32. Slee EA, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):21–4

A study of the pH dependence of the reaction of benzyloxycarbonyltryptophanylchloromethane with chymotrypsin. Mahon MM, et al. **Biochem Soc Trans** 1996 Feb;24(1):131S

A 1H–NMR study of the histidine resonance's of native subtilisin and of subtilisin inhibited by benzyloxycarbonylglycylglycylphenylalanyl–chloromethane. O'Connell TP, et al. **Biochem Soc Trans** 1996 Feb;24(1):135S

15N and 1H NMR spectroscopy of the catalytic histidine in chloromethyl ketone–inhibited complexes of serine proteases. Tsilikounas E, et al. **Biochemistry** 1996 Feb 20; 35(7):2437–44

Effect of interleukin–1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Estrov Z, et al. **Blood** 1995 Dec 15;86(12):4594–602

Inhibition of thrombin by arginine–containing peptide chloromethyl ketones and bis chloromethyl ketone–albumin conjugates. Odake S, et al. **J Enzym Inhib** 1995;9(1):17–27

AMINO ACID DECARBOXYLASES, AROMATIC see **AROMATIC AMINO ACID DECARBOXYLASES**

AMINO ACID ISOMERASES

ANALYSIS

Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain. Ott DE, et al. **AIDS Res Hum Retroviruses** 1995 Sep; 11(9):1003–6

A novel strategy to identify maternal and paternal inheritance in the mouse. Römer I, et al. **Electrophoresis** 1995 May; 16(5):823–30

In situ detection of cyclosporin A: evidence for nuclear localization of cyclosporine and cyclophilins. Le Hir M, et al. **Lab Invest** 1995 Nov;73(5):727–33

ANTAGONISTS & INHIBITORS

Inhibition of peptidyl–prolyl cis/trans isomerase activity by substrate analog structures: thioxo tetrapeptide–4–nitroanilides. Schutkowski M, et al. **Biochemistry** 1995 Oct 10;34(40):13016–26

Cyclosporin analogs modified in the 3,7,8–positions: substituent effects on peptidylprolyl isomerase inhibition and immunosuppressive activity are nonadditive. Hu MK, et al. **J Med Chem** 1995 Oct 13;38(21):4164–70

BIOSYNTHESIS

Retina–specifically expressed novel subtypes of bovine cyclophilin. Ferreira PA, et al. **J Biol Chem** 1995 Sep 29; 270(39):23179–88

CHEMISTRY

Estimation of age from the teeth of unidentified corpses using the amino acid racemization method with reference to actual cases. Ohtani S. **Am J Forensic Med Pathol** 1995 Sep;16(3):238–42

Identification of a nuclear–specific cyclophilin which interacts with the proteinase inhibitor eglin c. Wang BB, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):313–9

Peptidyl–prolyl cis–trans isomerase of Bacillus subtilis: identification of residues involved in cyclosporin A affinity and catalytic efficiency. Göthel SF, et al. **Biochemistry** 1996 Mar 19;35(11):3636–40

Prolyl isomerase as a probe of stability of slow–folding intermediates. Veeraraghavan S, et al. **Biochemistry** 1995 Oct 3;34(39):12892–902

Autocatalyzed protein folding. Veeraraghavan S, et al. **Biochemistry** 1996 Aug 20;35(33):10601–7

Mechanistic implication of crystal structures of the cyclophilin–dipeptide complexes. Zhao Y, et al. **Biochemistry** 1996 Jun 11;35(23):7362–8

Crystal structure implies that cyclophilin predominantly catalyzes the trans to cis isomerization. Zhao Y, et al. **Biochemistry** 1996 Jun 11;35(23):7356–61

Evidence that human milk isolated cyclophilin B corresponds to a truncated form. Mariller C, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):31–8

Molecular and biochemical characterization of a Plasmodium falciparum cyclophilin containing a cleavable signal sequence. Hirtzlin J, et al. **Eur J Biochem** 1995 Sep 15; 232(3):765–72

Trigger factor, one of the Escherichia coli chaperone proteins, is an original member of the FKBP family. Callebaut I, et al. **FEBS Lett** 1995 Oct 30;374(2):211–5

Identification of the prolyl isomerase domain of Escherichia coli trigger factor. Hesterkamp T, et al. **FEBS Lett** 1996 Apr 29;385(1–2):67–71

Small–angle X–ray solution scattering study on the dimerization of the FKBP25mem from Legionella pneumophila. Schmidt B, et al. **FEBS Lett** 1995 Sep 25; 372(2–3):169–72

An 11.8 kDa proteolytic fragment of the E. coli trigger factor represents the domain carrying the peptidyl–prolyl cis/trans isomerase activity. Stoller G, et al. **FEBS Lett** 1996 Apr 15;384(2):117–22

Characterization of a radical intermediate in the lysine 2,3–aminomutase reaction. Reed GH, et al. **Methods Enzymol** 1995;258:362–79

Receptor (immunophilin–binding) assay for immunosuppressive drugs. Soldin SJ. **Ther Drug Monit** 1995 Dec;17(6):574–6 (18 ref.)

DRUG EFFECTS

Molecular characterization of a cyclosporin A–insensitive cyclophilin from the parasitic nematode Brugia malayi. Page AP, et al. **Biochemistry** 1995 Sep 12;34(36):11545–50

GENETICS

Cloning and biochemical characterization of the cyclophilin homologues from the free-living nematode Caenorhabditis elegans. Page AP, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):179–85

A multicopy suppressor of a cell cycle defect in S. pombe encodes a heat shock-inducible 40 kDa cyclophilin-like protein. Weisman R, et al. **EMBO J** 1996 Feb 1; 15(3):447–56

Characterization of a cDNA encoding a cytosolic peptidylprolyl cis-trans-isomerase from Blattella germanica. Martinez-Gonzalez J, et al. **Eur J Biochem** 1995 Nov 15;234(1):284–92

Cyclophilin A, the major intracellular receptor for the immunosuppressant cyclosporin A, maps to chromosome 7p11.2–p13: four pseudogenes map to chromosomes 3, 10, 14, and 18. Willenbrink W, et al. **Genomics** 1995 Jul 1; 28(1):101–4

Gene for aspartate racemase from the sulfur-dependent hyperthermophilic archaeum, Desulfurococcus strain SY. Yohda M, et al. **J Biol Chem** 1996 Sep 6;271(36):22017–21

The substrate-binding site in Escherichia coli cyclophilin A preferably recognizes a cis-proline isomer or a highly distorted form of the trans isomer. Konno M, et al. **J Mol Biol** 1996 Mar 15;256(5):897–908

Cloning and characterization of a Plasmodium falciparum cyclophilin gene that is stage-specifically expressed. Reddy GR. **Mol Biochem Parasitol** 1995 Jul;73(1–2):111–21

Characterization of an Escherichia coli rotA mutant, affected in periplasmic peptidyl-prolyl cis/trans isomerase. Kleerebezem M, et al. **Mol Microbiol** 1995 Oct;18(2):313–20

Identification and characterization of an immunophilin expressed during the clonal expansion phase of adipocyte differentiation. Yeh WC, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11081–5

A cyclophilin gene-like sequence maps to human X-chromosome. Kandpal G, et al. **Somat Cell Mol Genet** 1996 Jan;22(1):67–73

ISOLATION & PURIFICATION

Purification and characterization of cytosolic and microsomal cyclophilins from maize (Zea mays). Sheldon PS, et al. **Biochem J** 1996 May 1;315 (Pt 3):965–70

A ribosome-associated peptidyl-prolyl cis/trans isomerase identified as the trigger factor. Stoller G, et al. **EMBO J** 1995 Oct 16;14(20):4939–48

METABOLISM

Estimation of age from dentin by using the racemization reaction of aspartic acid. Ohtani S. **Am J Forensic Med Pathol** 1995 Jun;16(2):158–61

Interactions of HIV-1 proteins with human T-cell cyclophilin A. Hammerschmid F, et al. **Ann N Y Acad Sci** 1996 May 15;782:456–61

Cyclophilin B mediates cyclosporin A incorporation in human blood T-lymphocytes through the specific binding of complexed drug to the cell surface. Allain F, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):565–70

Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Kay JE. **Biochem J** 1996 Mar 1;314 (Pt 2):361–85 (308 ref.)

Involvement of the N-terminal part of cyclophilin B in the interaction with specific Jurkat T-cell binding sites. Mariller C, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):571–6

Effects of cyclolinopeptide A on T lymphocyte activation and peptidyl prolyl isomerase activity. Gaymes TJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):90S

Lysine 2,3-aminomutase: rapid mix-freeze-quench electron paramagnetic resonance studies establishing the kinetic competence of a substrate-based radical intermediate. Chang CH, et al. **Biochemistry** 1996 Aug 27;35(34):11081–4

Chaotropic agents and increased matrix volume enhance binding of mitochondrial cyclophilin to the inner mitochondrial membrane and sensitize the mitochondrial permeability transition to [Ca2+]. Connern CP, et al. **Biochemistry** 1996 Jun 25;35(25):8172–80

Kinetic analysis of cyclophilin-catalyzed prolyl cis/trans isomerization by dynamic NMR spectroscopy. Kern D, et al. **Biochemistry** 1995 Oct 17;34(41):13594–602

Characterization of the slow folding reactions of trp aporepressor from Escherichia coli by mutational analysis of prolines and catalysis by a peptidyl-prolyl isomerase. Mann CJ, et al. **Biochemistry** 1995 Nov 7;34(44):14573–80

Crystal structure implies that cyclophilin predominantly catalyzes the trans to cis isomerization. Zhao Y, et al. **Biochemistry** 1996 Jun 11;35(23):7356–61

Mechanistic implication of crystal structures of the cyclophilin-dipeptide complexes. Zhao Y, et al. **Biochemistry** 1996 Jun 11;35(23):7362–8

Protein folding. Prolyl isomerases join the fold. Schmid FX. **Curr Biol** 1995 Sep 1;5(9):993–4 (12 ref.)

Trigger factor is involved in GroEL-dependent protein degradation in Escherichia coli and promotes binding of GroEL to unfolded proteins. Kandror O, et al. **EMBO J** 1995 Dec 1;14(23):6021–7

Early events in preprotein recognition in E. coli: interaction of SRP and trigger factor with nascent polypeptides. Valent QA, et al. **EMBO J** 1995 Nov 15;14(22):5494–505

Protein disulphide isomerase and a lumenal cyclophilin-type peptidyl prolyl cis-trans isomerase are in transient contact with secretory proteins during late stages of translocation. Klappa P, et al. **Eur J Biochem** 1995 Sep 15;232(3):755–64

Involvement of cyclophilin D in the activation of a mitochondrial pore by Ca2+ and oxidant stress. Tanveer A, et al. **Eur J Biochem** 1996 May 15;238(1):166–72

The Escherichia coli trigger factor. Hesterkamp T, et al. **FEBS Lett** 1996 Jun 24;389(1):32–4 (21 ref.)

Identification of the prolyl isomerase domain of Escherichia coli trigger factor. Hesterkamp T, et al. **FEBS Lett** 1996 Apr 29;385(1–2):67–71

Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, and cyclosporin A-sensitive channel. Nicolli A, et al. **J Biol Chem** 1996 Jan 26;271(4):2185–92

Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. Okadome T, et al. **J Biol Chem** 1996 Sep 6;271(36):21687–90

Cyclophilin 40 (CyP-40), mapping of its hsp90 binding domain and evidence that FKBP52 competes with CyP-40 for hsp90 binding. Ratajczak T, et al. **J Biol Chem** 1996 Feb 9;271(6):2961–5

Autocatalytic folding of the folding catalyst FKBP12. Scholz C, et al. **J Biol Chem** 1996 May 31;271(22):12703–7

The multiple carrier model of nonribosomal peptide biosynthesis at modular multienzymatic templates. Stein T, et al. **J Biol Chem** 1996 Jun 28;271(26):15428–35

Myristoylation of calcineurin B is not required for function or interaction with immunophilin-immunosuppressant complexes in the yeast Saccharomyces cerevisiae. Zhu D, et al. **J Biol Chem** 1995 Oct 20;270(42):24831–8

The substrate-binding site in Escherichia coli cyclophilin A preferably recognizes a cis-proline isomer or a highly distorted form of the trans isomer. Konno M, et al. **J Mol Biol** 1996 Mar 15;256(5):897–908

The involvement of p23, hsp90, and immunophilins in the assembly of progesterone receptor complexes. Johnson J, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):31–7

Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization. Colgan J, et al. **J Virol** 1996 Jul;70(7):4299–310

The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811. Dorfman T, et al. **J Virol** 1996 Sep;70(9):5751–7

Characterization of a radical intermediate in the lysine 2,3-aminomutase reaction. Reed GH, et al. **Methods Enzymol** 1995;258:362–79

Hymenolepis diminuta and H. microstoma: uptake of cyclosporin A and drug binding to parasite cyclophilins. Roberts HC, et al. **Parasitology** 1995 Dec;111 (Pt 5):591–7

Posttranslational amino acid epimerization: enzyme-catalyzed isomerization of amino acid residues in peptide chains. Heck SD, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4036–9

Escherichia coli trigger factor is a prolyl isomerase that associates with nascent polypeptide chains. Hesterkamp T, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4437–41

PHARMACOLOGY

Cyclophilin-facilitated bradykinin inactivation in the perfused rat lung. Merker MP, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2085–91

PHYSIOLOGY

Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. Braaten D, et al. **J Virol** 1996 Jul;70(7):4220–7

Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. Braaten D, et al. **J Virol** 1996 Jun;70(6):3551–60

Immunophilins and the nervous system. Snyder SH, et al. **Nat Med** 1995 Jan;1(1):32–7 (82 ref.)

A human peptidyl-prolyl isomerase essential for regulation of mitosis. Lu KP, et al. **Nature** 1996 Apr 11; 380(6574):544–7

AMINO ACID METABOLISM, INBORN ERRORS

BLOOD

Screening for tyrosinaemia type I. Hutchesson AC, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 May;74(3):F191–4

Isovaleric acidemia appearing as diabetic ketoacidosis. Attia N, et al. **J Inherit Metab Dis** 1996;19(1):85–6

COMPLICATIONS

Early detection of lung involvement in lysinuric protein intolerance: role of high-resolution computed tomography and radioisotopic methods. Santamaria F, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):731–5

Neurological deterioration in patients with urea cycle disorders under valproate therapy--a cause for concern [letter] Sewell AC, et al. **Eur J Pediatr** 1995 Jul; 154(7):593–4

Mitochondrial complex deficiencies in a male with cardiomyopathy and 3-methylglutaconic aciduria. Besley GT, et al. **J Inherit Metab Dis** 1995;18(2):221–3

Acute pancreatitis in propionic acidaemia. Burlina AB, et al. **J Inherit Metab Dis** 1995;18(2):169–72

Non-ketotic hyperglycinaemia presenting as pachygyria. Fletcher JM, et al. **J Inherit Metab Dis** 1995;18(6):665–8

Glutathione deficiency as a complication of methylmalonic acidemia: response to high doses of ascorbate. Treacy E, et al. **J Pediatr** 1996 Sep;129(3):445–8

Efficacy of low-dose dextromethorphan in the treatment of nonketotic hyperglycinemia. Alemzadeh R, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):924–6

DIAGNOSIS

Urea cycle disorders: diagnosis, pathophysiology, and therapy. Brusilow SW, et al. **Adv Pediatr** 1996;43:127–70 (59 ref.)

Fetal polycystic kidney disease associated with glutaric aciduria type II: an inborn error of energy metabolism. Whitfield J, et al. **Am J Perinatol** 1996 Apr;13(3):131–4

Propionic acidemia presenting as pyloric stenosis. Katzman PJ, et al. **Clin Pediatr (Phila)** 1995 Nov;34(11):613–5

Critical points for determining moderate hyperhomocyst(e)inaemia. Kang SS. **Eur J Clin Invest** 1995 Nov;25(11):806–8 (15 ref.)

Transient glutamic acidaemia. Franz AR, et al. **Eur J Pediatr** 1996 Apr;155(4):308–10

Diagnosis of a new case of trimethylaminuria using direct proton NMR spectroscopy of urine. Abeling NG, et al. **J Inherit Metab Dis** 1995;18(2):182–4

Folinic acid responsive seizures: a new syndrome? Hyland K, et al. **J Inherit Metab Dis** 1995;18(2):177–81

Glutaric aciduria type 1 in adulthood [letter] Prevett MC, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):352–3

Hyperhomocysteinaemia; with reference to its neuroradiological aspects. van den Berg M, et al. **Neuroradiology** 1995 Jul;37(5):403–11 (78 ref.)

A case of tyrosinaemia type I with normal level of succinylacetone in the amniotic fluid. Grenier A, et al. **Prenat Diagn** 1996 Mar;16(3):239–42

HPLC analysis of amino acids in inborn errors of metabolism. Matteson KJ. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:120–2

High performance liquid chromatography (HPLC) method for confirming thin layer chromatography (TLC) findings in inborn errors of metabolism children in Malaysia. Yahya NA, et al. **Southeast Asian J Trop Med Public Health** 1995; 26 Suppl 1:130–3

DRUG THERAPY

Benzoate therapy and carnitine deficiency in non-ketotic hyperglycinemia. Van Hove JL, et al. **Am J Med Genet** 1995 Dec 4;59(4):444–53

Methylmalonic acidemia: brain lesions in a case of vitamin B12 non-responsive (mut0) type. Yamaguchi K, et al. **Clin Neuropathol** 1995 Jul–Aug;14(4):216–22

Propionylcarnitine excretion is not affected by metronidazole administration to patients with disorders of propionate metabolism. Burns SP, et al. **Eur J Pediatr** 1996 Jan; 155(1):31–5

Ketamine and strychnine treatment of an infant with nonketotic hyperglycinaemia. Tegtmeyer-Metzdorf H, et al. **Eur J Pediatr** 1995 Aug;154(8):649–53

Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC. Bird S, et al. **J Inherit Metab Dis** 1995;18(2):123–6

Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC). Pronicka E, et al. **J Inherit Metab Dis** 1996;19(2):234–8

Glycine and L-carnitine therapy in 3-methylcrotonyl-CoA carboxylase deficiency. Rutledge SL, et al. **J Inherit Metab Dis** 1995;18(3):299–305

Isovaleric acidemia: response to a leucine load after three weeks of supplementation with glycine, L-carnitine, and combined glycine-carnitine therapy. Fries MH, et al. **J Pediatr** 1996 Sep;129(3):449–52

Long-term treatment of girls with ornithine transcarbamylase deficiency. Maestri NE, et al. **N Engl J Med** 1996 Sep 19;335(12):855–9

ENZYMOLOGY

Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease [see comments] Kluijtmans LA, et al. **Am J Hum Genet** 1996 Jan;58(1):35–41. Comment in: Am J Hum Genet 1996 Jan;58(1):17–20.

3-Phosphoglycerate dehydrogenase deficiency and 3-phosphoserine phosphatase deficiency: inborn errors of serine biosynthesis. Jaeken J, et al. **J Inherit Metab Dis** 1996;19(2):223–6

D-2-hydroxyglutaric acidaemia: identification of a new enzyme, D-2-hydroxyglutarate dehydrogenase, localized in mitochondria. Wanders RJ, et al. **J Inherit Metab Dis** 1995;18(2):194–6

Characterization of the wild-type form of 4a-carbinolamine dehydratase and two naturally occurring mutants associated with hyperphenylalaninemia. Johnen G, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12384–8

AMINO ACID METABOLISM, INBORN ERRORS

EPIDEMIOLOGY

Long-term follow-up of 77 patients with isolated methylmalonic acidaemia. Baumgarter ER, et al. **J Inherit Metab Dis** 1995;18(2):138–42

ETIOLOGY

[Inborn errors of GABA metabolism] Divry P, et al. **Arch Pediatr** 1996;3 Suppl 1:169s–171s **(Fre)**

GENETICS

Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease [see comments] Kluijtmans LA, et al. **Am J Hum Genet** 1996 Jan;58(1):35–41. Comment in: Am J Hum Genet 1996 Jan;58(1):17–20.

Isolated persistent hypermethioninemia. Mudd SH, et al. **Am J Hum Genet** 1995 Oct;57(4):882–92

Familial richner-Hanhart syndrome in Kuwait: twelve-year clinical reassessment by a multidisciplinary approach [letter] el-Badramany MH, et al. **Am J Med Genet** 1995 Oct 9;60(5):353–5

Pancreatic secretory trypsin inhibitor gene is highly expressed in the liver of adult-onset type II citrullinemia. Kobayashi K, et al. **FEBS Lett** 1995 Sep 18;372(1):69–73

Variable gene expression within human tyrosinemia type 1 liver may reflect region-specific dysplasia. Haber BA, et al. **Hepatology** 1996 Jul;24(1):65–71

Nature and frequency of mutations in the argininosuccinate synthetase gene that cause classical citrullinemia. Kobayashi K, et al. **Hum Genet** 1995 Oct;96(4):454–63

Identification of four novel splice site mutations in the ornithine transcarbamylase gene. Oppliger Leibundgut E, et al. **Hum Genet** 1996 Feb;97(2):209–13

Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship. Ploos van Amstel JK, et al. **Hum Genet** 1996 Jan;97(1):51–9

A novel missense mutation in the exon containing the putative ornithine-binding domain of the OTC enzyme in a female [letter] Demmer LA, et al. **Hum Mutat** 1996;7(3):279

Heterozygosity for an exon 12 splicing mutation and a W234G missense mutation in an American child with chronic tyrosinemia type 1. Hahn SH, et al. **Hum Mutat** 1995;6(1):66–73

Fumarylacetoacetase mutations in tyrosinaemia type I. Rootwelt H, et al. **Hum Mutat** 1996;7(3):239–43

Simple detection of a (Finnish) hereditary tyrosinemia type 1 mutation [letter] St-Louis M, et al. **Hum Mutat** 1996;7(4):379–80

Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I. Timmers C, et al. **Hum Mutat** 1996;7(4):367–9

Ornithine transcarbamylase deficiency in females: an often overlooked cause of treatable encephalopathy. Pridmore CL, et al. **J Child Neurol** 1995 Sep;10(5):369–74

Demyelination of the brain is associated with methionine adenosyltransferase I/III deficiency. Chamberlin ME, et al. **J Clin Invest** 1996 Aug 15;98(4):1021–7

Molecular mechanisms of an inborn error of methionine pathway. Methionine adenosyltransferase deficiency. Ubagai T, et al. **J Clin Invest** 1995 Oct;96(4):1943–7

Identification of two new aberrant splicings in the ornithine carbamoyltransferase (OCT) gene in two patients with early and late onset OCT deficiency. Matsuura T, et al. **J Inherit Metab Dis** 1995;18(3):273–82

PAH deficiency in Italy: correlation of genotype with phenotype in the Sicilian population. Romano V, et al. **J Inherit Metab Dis** 1996;19(1):15–24

Transient neonatal hyperphenylalaninaemia is not related to mutations at the phenylalanine hydroxylase gene. Zschocke J, et al. **J Inherit Metab Dis** 1995;18(3):369–70

Fungal metabolic model for human type I hereditary tyrosinaemia. Fernández-Cañón JM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9132–6

IMMUNOLOGY

Immunological abnormalities in a patient with tyrosinaemia type III. D'Eufemia PD, et al. **J Inherit Metab Dis** 1995;18(3):355–6

Immunological abnormality in patients with lysinuric protein intolerance. Yoshida Y, et al. **J Neurol Sci** 1995 Dec;134(1–2):178–82

METABOLISM

3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis. Jaeken J, et al. **Arch Dis Child** 1996 Jun;74(6):542–5

The oxidant stress of hyperhomocyst(e)inemia [editorial; comment] Loscalzo J. **J Clin Invest** 1996 Jul 1;98(1):5–7 . Comment on: J Clin Invest 1996 Jul 1;98(1):24–9. Comment on: J Clin Invest 1996 Jul 1;98(1):177–84.

International database of tetrahydrobiopterin deficiencies. Blau N, et al. **J Inherit Metab Dis** 1996;19(1):8–14

On the differences between urinary metabolite excretion and odd-numbered fatty acid production in propionic and methylmalonic acidaemias. Wendel U, et al. **J Inherit Metab Dis** 1995;18(5):584–91

Mice lacking ornithine-delta-aminotransferase have paradoxical neonatal hypoornithinaemia and retinal degeneration. Wang T, et al. **Nat Genet** 1995 Oct;11(2):185–90

[Inborn errors of amino acid metabolism] Owada M. **Ryoikibetsu Shokogun Shirizu** 1995;(8):352–7 (23 ref.) **(Jpn)**

[Urea cycle disorders] Tazawa Y. **Ryoikibetsu Shokogun Shirizu** 1995;(8):367–9 (9 ref.) **(Jpn)**

MORTALITY

Survival after early treatment for carbamyl phosphate synthetase (CPS) I deficiency associated with increase of intramitochondrial CPS I. Zimmer KP, et al. **Lancet** 1995 Dec 9;346(8989):1530–1

PATHOLOGY

Necropsy findings in lysinuric protein intolerance. McManus DT, et al. **J Clin Pathol** 1996 Apr;49(4):345–7

Mice lacking ornithine-delta-aminotransferase have paradoxical neonatal hypoornithinaemia and retinal degeneration. Wang T, et al. **Nat Genet** 1995 Oct;11(2):185–90

PHYSIOPATHOLOGY

Histidinaemia: a benign metabolic disorder. Lam WK, et al. **Arch Dis Child** 1996 Apr;74(4):343–6

RADIOGRAPHY

Pseudotumours of hepatic imaging. Kane PA, et al. **Clin Radiol** 1996 May;51(5):362–5

SURGERY

Liver transplantation in nine Spanish patients with tyrosinaemia type I. Pérez-Cerdá C, et al. **J Inherit Metab Dis** 1995;18(2):119–22

Liver transplantation in tyrosinaemia type I: the Groningen experience. Wijburg FA, et al. **J Inherit Metab Dis** 1995;18(2):115–8

Histological improvement in native liver after auxiliary partial liver transplantation for ornithine transcarbamylase deficiency [letter] Inui A, et al. **Lancet** 1996 Sep 14;348(9029):751–2

THERAPY

Gene therapy for ornithine transcarbamylase deficiency. Kiwaki K, et al. **Acta Paediatr Jpn** 1996 Apr;38(2):189–92 (31 ref.)

Urea cycle disorders: diagnosis, pathophysiology, and therapy. Brusilow SW, et al. **Adv Pediatr** 1996;43:127–70 (59 ref.)

Use of human somatotrophin in the treatment of a patient with methylmalonic aciduria. Bain MD, et al. **Eur J Pediatr** 1995 Oct;154(10):850–2

Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. Ye X, et al. **J Biol Chem** 1996 Feb 16;271(7):3639–46

Tyrosinaemia--treatment and outcome. Kvittingen EA. **J Inherit Metab Dis** 1995;18(4):375–9 (16 ref.)

Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation. van Spronsen FJ, et al. **J Inherit Metab Dis** 1995;18(2):111–4

Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I [see comments] Overturf K, et al. **Nat Genet** 1996 Mar;12(3):266–73. Comment in: Nat Genet 1996 Mar;12(3):232–3.

Round two for liver gene therapy [news; comment] Wilson JM. **Nat Genet** 1996 Mar;12(3):232–3. Comment on: Nat Genet 1996 Mar;12(3):266–73.

Glutaric aciduria: improved MR appearance after aggressive therapy. Cho CH, et al. **Pediatr Radiol** 1995;25(6):484–5

URINE

Identification of N-acetyl-S-(3-oxo-3-carboxy-n-propyl)cysteine in the urine of a patient with cystathioninuria using LC/APCI-MS. Zhang J, et al. **J Inherit Metab Dis** 1995;18(6):675–81

AMINO ACID NAPHTHYLAMIDASES

BLOOD

[Arylamidase] Seki T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:409–11 (10 ref.) **(Jpn)**

AMINO ACID NEUROTRANSMITTERS

see related
RECEPTORS, AMINO ACID

CHEMISTRY

Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives. Weng JH, et al. **Bioorg Med Chem** 1996 Apr;4(4):563–73

METABOLISM

Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives. Weng JH, et al. **Bioorg Med Chem** 1996 Apr;4(4):563–73

Glucagon-like peptide-1(7-36)amide induces the release of aspartic acid and glutamine by the ventromedial hypothalamus of the conscious rat. Calvo JC, et al. **Brain Res Bull** 1995;38(5):435–9

A comparison between the stimulated and paroxysmal release of endogenous amino acids from rat cerebellar, striatal and hippocampal slices: a manifestation of spreading depression? Davies JA, et al. **J Neurol Sci** 1995 Jul;131(1):8–14

Preoptic rather than mediobasal hypothalamic amino acid neurotransmitter release regulates GnRH secretion during the estrogen-induced LH surge in the ovariectomized rat. Jarry H, et al. **Neuroendocrinology** 1995 Nov;62(5):479–86

GM1 ganglioside inhibits ischemic release of amino acid neurotransmitters from rat cortex. Phillis JW, et al. **Neuroreport** 1995 Oct 23;6(15):2010–2

Effects of long-term treatment with a monoamine oxidase B inhibitor, selegeline (L-deprenyl), on amino acid transmitter systems in the ageing rat brain. Saransaari P, et al. **Proc West Pharmacol Soc** 1995;38:13–7

[The effect of amiridine and tacrine on reversible capture of neuromediators in experimental memory disorders] Burov IuV, et al. **Biull Eksp Biol Med** 1995 May;119(5):512–4 **(Rus)**

PHARMACOLOGY

Effects of inhibitory amino acids on the frequency components in sympathetic nerve discharge. Clement ME, et al. **Brain Res** 1995 Oct 23;696(1–2):258–61

PHYSIOLOGY

Neurotransmitters and vulnerability of the developing brain. Johnston MV. **Brain Dev** 1995 Sep–Oct;17(5):301–6 (42 ref.)

Amino acids in neurotransmission and disease. Kalloniatis M. **J Am Optom Assoc** 1995 Dec;66(12):750–7 (57 ref.)

D-AMINO-ACID OXIDASE

CHEMICAL SYNTHESIS

Synthesis, characterization and preliminary crystallographic data of N6-(6-carbamoylhexyl)-FAD-D-amino-acid oxidase from pig kidney, a semi-synthetic oxidase. Stocker A, et al. **Eur J Biochem** 1996 Jun 1;238(2):519–28

CHEMISTRY

Reactivity of sulfhydryl groups of Rhodotorula gracilis D-amino acid oxidase. Pollegioni L, et al. **Biochem Soc Trans** 1996 Feb;24(1):21S

Structures of charge-transfer complexes of flavoenzyme D-amino acid oxidase: a study by resonance Raman spectroscopy and extended Hückel molecular orbital method. Nishina Y, et al. **J Biochem (Tokyo)** 1995 Sep;118(3):614–20

GENETICS

Localization of the candidate gene D-amino acid oxidase outside the refined I-cM region of spinocerebellar ataxia 2 [letter] Gispert S, et al. **Am J Hum Genet** 1995 Oct;57(4):972–5

METABOLISM

The lysopine and octopine dehydrogenase activities of Mytilus edulis are catalysed by a single enzyme. Coughlan M, et al. **Biochem Soc Trans** 1996 Feb;24(1):128S

Reactivity of sulfhydryl groups of Rhodotorula gracilis D-amino acid oxidase. Pollegioni L, et al. **Biochem Soc Trans** 1996 Feb;24(1):21S

Synthesis, characterization and preliminary crystallographic data of N6-(6-carbamoylhexyl)-FAD-D-amino-acid oxidase from pig kidney, a semi-synthetic oxidase. Stocker A, et al. **Eur J Biochem** 1996 Jun 1;238(2):519–28

AMINO ACID OXIDOREDUCTASES

Enzymatic-chemical preparation of quinoxaline derivatives from L-amino acids for gas chromatographic-mass spectrometric analyses. Schadewaldt P, et al. **Anal Biochem** 1995 Aug 10;229(2):153–61

ADMINISTRATION & DOSAGE

Complementation of defective leucine decarboxylation in fibroblasts from a maple syrup urine disease patient by retrovirus-mediated gene transfer. Mueller GM, et al. **Gene Ther** 1995 Sep;2(7):461–8

ANALYSIS

Distribution and properties of fructosyl amino acid oxidase in fungi. Yoshida N, et al. **Appl Environ Microbiol** 1995 Dec;61(12):4487–9

[Alanine dehydrogenase from the cyanobacterium

Plectonema boryanum] Perepelitsa SI, et al. **Ukr Biokhim Zh** 1995 Jan-Feb;67(1):38-45 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Structure and expression of three genes encoding ACC oxidase homologs from melon (Cucumis melo L.). Lasserre E, et al. **Mol Gen Genet** 1996 Apr 24;251(1):81-90

Alternative splicing results in two different transcripts for H-protein of the glycine cleavage system in the C4 species Flaveria trinervia. Kopriva S, et al. **Plant J** 1995 Sep; 8(3):435-41

Induction of nopaline synthase promoter activity by H2O2 has no direct correlation with salicylic acid. Dai Z, et al. **Plant Physiol** 1995 Dec;109(4):1191-7

CHEMISTRY

Expression, lipoylation and structure determination of recombinant pea H-protein in Escherichia coli. Macherel D, et al. **Eur J Biochem** 1996 Feb 15;236(1):27-33

L-aspartate oxidase from Escherichia coli. I. Characterization of coenzyme binding and product inhibition. Mortarino M, et al. **Eur J Biochem** 1996 Jul 15;239(2):418-26

Glycine decarboxylase: protein chemistry and molecular biology of the major protein in leaf mitochondria. Oliver DJ, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):407-14 (57 ref.)

A role for quaternary structure in the substrate specificity of leucine dehydrogenase. Baker PJ, et al. **Structure** 1995 Jul 15;3(7):693-705

GENETICS

Construction and partial characterization of an L-amino acid oxidase-free Synechococcus PCC 7942 mutant and localization of the L-amino acid oxidase in the corresponding wild type. Bockholt R, et al. **Biochim Biophys Acta** 1996 Jun 3;1307(1):111-21

Structure and expression analysis of the gdcsPA and gdcsPB genes encoding two P-isoproteins of the glycine-cleavage system from Flaveria pringlei. Bauwe H, et al. **Eur J Biochem** 1995 Nov 15;234(1):116-24

Glycine reductase of Clostridium litorale. Cloning, sequencing, and molecular analysis of the grdAB operon that contains two in-frame TGA codons for selenium incorporation. Kreimer S, et al. **Eur J Biochem** 1995 Nov 15;234(1):192-9

Regulation of expression of the valine (branched-chain amino acid) dehydrogenase-encoding gene from Streptomyces coelicolor. Tang L, et al. **Gene** 1995 Aug 30;162(1):69-74

Genetics of the synthesis of serine from glycine and the utilization of glycine as sole nitrogen source by Saccharomyces cerevisiae. Sinclair DA, et al. **Genetics** 1995 Aug;140(4):1213-22

Proteus mirabilis amino acid deaminase: cloning, nucleotide sequence, and characterization of aad. Massad G, et al. **J Bacteriol** 1995 Oct;177(20):5878-83

H-protein of glycine decarboxylase is encoded by multigene families in Flaveria pringlei and F. cronquistii (Asteraceae). Kopriva S, et al. **Mol Gen Genet** 1995 Nov 1;249(1):111-6

Specific induction by glycine of the gene for the P-subunit of glycine decarboxylase from Saccharomyces cerevisiae. Sinclair DA, et al. **Mol Microbiol** 1996 Feb;19(3):611-23

Submergence enhances expression of a gene encoding 1-aminocyclopropane-1-carboxylate oxidase in deepwater rice. Mekhedov SI, et al. **Plant Cell Physiol** 1996 Jun; 37(4):531-7

Differential expression of the 1-aminocyclopropane-1-carboxylate oxidase gene family of tomato. Barry CS, et al. **Plant J** 1996 Apr;9(4):525-35

Induction of nopaline synthase promoter activity by H2O2 has no direct correlation with salicylic acid. Dai Z, et al. **Plant Physiol** 1995 Dec;109(4):1191-7

Light-dependent and tissue-specific expression of the H-protein of the glycine decarboxylase complex. Srinivasan R, et al. **Plant Physiol** 1995 Sep;109(1):161-8

ISOLATION & PURIFICATION

On the holoenzyme reconstitution process in native and truncated Rhodotorula gracilis D-amino acid oxidase. Pollegioni L, et al. **Arch Biochem Biophys** 1996 Aug 1; 332(1):58-62

Partial amino acid sequence of an L-amino acid oxidase from the cyanobacterium Synechococcus PCC6301, cloning and DNA sequence analysis of the aoxA gene. Bockholt R, et al. **Biochim Biophys Acta** 1995 Dec 27;1264(3):289-93

Purification and properties of D-aspartate oxidase from Cryptococcus humicolus UJ1. Yamada R, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):153-8

[Isoforms of L-lysine-alpha-oxidase from Trichoderma sp. mushrooms] Vesa VS, et al. **Biull Eksp Biol Med** 1996 Apr; 121(4):404-6 **(Rus)**

METABOLISM

Oxidation-reduction and transient kinetic studies of spinach ferredoxin-dependent glutamate synthase. Hirasawa M, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):209-15

Characterization of the ferrous ion binding sites of apple 1-aminocyclopropane-1-carboxylate oxidase by site-directed mutagenesis. Shaw JF, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):697-700

Glycine decarboxylase and pyruvate dehydrogenase complexes share the same dihydrolipoamide dehydrogenase in pea leaf mitochondria: evidence from mass spectrometry and primary-structure analysis. Bourguignon J, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):229-34

Temperature-nearly-independent binding constant in several biochemical systems. The underlying entropy-driven binding mechanism and its practical significance. Miklavc A. **Biochem Pharmacol** 1996 Mar 22;51(6):723-9

The lysopine and octopine dehydrogenase activities of Mytilus edulis are catalysed by a single enzyme. Coughlan M, et al. **Biochem Soc Trans** 1996 Feb;24(1):128S

Purification and properties of D-aspartate oxidase from Cryptococcus humicolus UJ1. Yamada R, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):153-8

Purification and characterization of protein PB of betaine reductase and its relationship to the corresponding proteins glycine reductase and sarcosine reductase from Eubacterium acidaminophilum. Meyer M, et al. **Eur J Biochem** 1995 Nov 15;234(1):184-91

L-aspartate oxidase from Escherichia coli. I. Characterization of coenzyme binding and product inhibition. Mortarino M, et al. **Eur J Biochem** 1996 Jul 15;239(2):418-26

L-aspartate oxidase from Escherichia coli. II. Interaction with C4 dicarboxylic acids and identification of a novel L-aspartate: fumarate oxidoreductase activity. Tedeschi G, et al. **Eur J Biochem** 1996 Jul 15;239(2):427-33

Fractionation of carbon (13C/12C) isotopes in glycine decarboxylase reaction. Ivlev AA, et al. **FEBS Lett** 1996 May 20;386(2-3):174-6

Glycine decarboxylase: protein chemistry and molecular biology of the major protein in leaf mitochondria. Oliver DJ, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):407-14 (57 ref.)

Biosynthesis of topa quinone cofactor in bacterial amine oxidases. Solvent origin of C-2 oxygen determined by Raman spectroscopy. Nakamura N, et al. **J Biol Chem** 1996 Mar 1;271(9):4718-24

A role for quaternary structure in the substrate specificity of leucine dehydrogenase. Baker PJ, et al. **Structure** 1995 Jul 15;3(7):693-705

[Oxidases of l-amino acids and outlook for their practical application] Iaroshik LV, et al. **Ukr Biokhim Zh** 1995 Mar-Apr;67(2):17-24 (24 ref.) (Eng. Abstr.) **(Rus)**

[Alanine dehydrogenase of the cyanobacterium Plectonema boryanum in the early period of cyanophage LPP-3 development] Perepelitsa SI, et al. **Ukr Biokhim Zh** 1995 Jul-Aug;67(4):47-52 (Eng. Abstr.) **(Rus)**

TOXICITY

Identification of the snake venom substance that induces apoptosis. Suhr SM, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):134-9

AMINO ACID RECEPTORS see **RECEPTORS, AMINO ACID**

AMINO ACID SEQUENCE

LIGM-DB/IMGT: an integrated database of Ig and TcR, part of the immunogenetics database. Lefranc MP, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:47-9

Determination of N-myristoyl peptide sequence both by MALDI TOF MASS and with an N-myristoyl cleaving enzyme (polymyxin acylase). Misumi S, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):632-9

Effect of serine O-glycosylation on cis-trans proline isomerization. Pao YL, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):157-62

Comparison of primary structures and substrate specificities of two pullulan-hydrolyzing alpha-amylases, TVA I and TVA II, from Thermoactinomyces vulgaris R-47. Tonozuka T, et al. **Biochim Biophys Acta** 1995 Sep 27; 1252(1):35-42

Technical report. Using a world wide web server as a local organizer for protein and DNA sequences. Atwell R, et al. **Biotechniques** 1995 Dec;19(6):966-70

Protein sequence interpretation using a spreadsheet program. Shaw G. **Biotechniques** 1995 Dec;19(6):978-83

Compression of protein sequence databases. Strelets VB, et al. **Comput Appl Biosci** 1995 Oct;11(5):557-61

Protein structure prediction: recognition of primary, secondary, and tertiary structural features from amino acid sequence. Eisenhaber F, et al. **Crit Rev Biochem Mol Biol** 1995;30(1):1-94 (487 ref.)

Application of capillary electrophoresis to amino acid sequencing of peptide. Kim NJ, et al. **Electrophoresis** 1995 Apr;16(4):510-5

Primary structure and homology [letter] Whyte B, et al. **FEBS Lett** 1996 Feb 19;380(3):301

Automated construction and graphical presentation of protein blocks from unaligned sequences. Henikoff S, et al. **Gene** 1995 Oct 3;163(2):GC17-26

Using Dirichlet mixture priors to derive hidden Markov models for protein families. Brown M, et al. **Ismb** 1993; 1:47-55

Predicting protein folding classes without overly relying on homology. Craven MW, et al. **Ismb** 1995;3:98-106

A divide and conquer approach to multiple alignment. Dress A, et al. **Ismb** 1995;3:107-13

Neural net representations of empirical protein potentials. Grossman T, et al. **Ismb** 1995;3:154-61

3-D lookup: fast protein structure database searches at 90% reliability. Holm L, et al. **Ismb** 1995;3:179-87

Evaluating regularizers for estimating distributions of amino acids. Karplus K. **Ismb** 1995;3:188-96

Maximum entropy weighting of aligned sequences of proteins or DNA. Krogh A, et al. **Ismb** 1995;3:215-21

BONSAI Garden: parallel knowledge discovery system for amino acid sequences. Shoudai T, et al. **Ismb** 1995;3:359-66

Recursive dynamic programming for adaptive sequence and structure alignment. Thiele R, et al. **Ismb** 1995;3:384-92

Identification of protein motifs using conserved amino acid properties and partitioning techniques. Wu TD, et al. **Ismb** 1995;3:402-10

Algorithms for protein structural motif recognition. Berger B. **J Comput Biol** 1995 Spring;2(1):125-38

Restructuring the genome data base: a model for a federation of biological databases. Fasman KH. **J Comput Biol** 1994 Summer;1(2):165-71

Wilson's disease: a new gene and an animal model for an old disease. Cuthbert JA. **J Investig Med** 1995 Aug; 43(4):323-36 (121 ref.)

The unveiling of calreticulin--a clinically relevant tour of modern cell biology. Sontheimer RD, et al. **J Investig Med** 1995 Aug;43(4):362-70 (92 ref.)

Editing for amino-acid type in CBCACONH experiments based on the 13C beta-13C gamma coupling. Dötsch V, et al. **J Magn Reson B** 1996 Jun;111(3):310-3

Separation of NOEs from degenerate amide protons in 13C/15N-labeled proteins using a 3D 13C'-edited NOESY-H(N)CO experiment. Zhang W, et al. **J Magn Reson B** 1996 Jun;111(3):305-9

From structure to sequence and back again. Hinds DA, et al. **J Mol Biol** 1996 Apr 26;258(1):201-9

Partition of aminoacyl-tRNA synthetases in two different structural classes dating back to early metabolism: implications for the origin of the genetic code and the nature of protein sequences. Delarue M. **J Mol Evol** 1995 Dec;41(6):703-11 (52 ref.)

Phylogeny reconstruction for protein sequences based on amino acid properties. Schmidt W. **J Mol Evol** 1995 Oct; 41(4):522-30

Superfamily classification in PIR-International Protein Sequence Database. Barker WC, et al. **Methods Enzymol** 1996;266:59-71

Three-dimensional profiles for measuring compatibility of amino acid sequence with three-dimensional structure. Bowie JU, et al. **Methods Enzymol** 1996;266:598-616

SRS: information retrieval system for molecular biology data banks. Etzold T, et al. **Methods Enzymol** 1996;266:114-28

Inferring phylogenies from protein sequences by parsimony, distance, and likelihood methods. Felsenstein J. **Methods Enzymol** 1996;266:418-27

Progressive alignment of amino acid sequences and construction of phylogenetic trees from them. Feng DF, et al. **Methods Enzymol** 1996;266:368-82

GOR method for predicting protein secondary structure from amino acid sequence. Garnier J, et al. **Methods Enzymol** 1996;266:540-53

PIR-International Protein Sequence Database. George DG, et al. **Methods Enzymol** 1996;266:41-59

Identification of sequence pattern with profile analysis. Gribskov M, et al. **Methods Enzymol** 1996;266:198-212

Combined DNA and protein alignment. Hein J, et al. **Methods Enzymol** 1996;266:402-18

Blocks database and its applications. Henikoff JG, et al. **Methods Enzymol** 1996;266:88-105

Using CLUSTAL for multiple sequence alignments. Higgins DG, et al. **Methods Enzymol** 1996;266:383-402

Alignment of three-dimensional protein structures: network server for database searching. Holm L, et al. **Methods Enzymol** 1996;266:653-62

Discrimination of common protein folds: application of protein structure to sequence/structure comparisons. Johnson MS, et al. **Methods Enzymol** 1996;266:575-98

Protein sequence comparison at genome scale. Koonin EV, et al. **Methods Enzymol** 1996;266:295-322

Identification of functional residues and secondary structure from protein multiple sequence alignment. Livingstone CD, et al. **Methods Enzymol** 1996;266:497-512

Prediction and analysis of coiled-coil structures. Lupas A. **Methods Enzymol** 1996;266:513-25

Applications of network BLAST server. Madden TL, et al. **Methods Enzymol** 1996;266:131-41

SSAP: sequential structure alignment program for protein structure comparison. Orengo CA, et al. **Methods Enzymol** 1996;266:617-35

Consensus approaches in detection of distant homologies. Patthy L. **Methods Enzymol** 1996;266:184-98

Effective protein sequence comparison. Pearson WR. **Methods Enzymol** 1996;266:227-58

Converting sequence block alignments into structural insights. Poch O, et al. **Methods Enzymol** 1996;266:662-80

Entrez: molecular biology database and retrieval system. Schuler GD, et al. **Methods Enzymol** 1996;266:141-62

Information services of the European Bioinformatics Institute. Shomer B, et al. **Methods Enzymol** 1996;266:3-27

Indexing and using sequence databases. Staden R. **Methods Enzymol** 1996;266:105-14

Multiple protein sequence alignment: algorithms and gap insertion. Taylor WR. **Methods Enzymol** 1996;266:343-67

AMINO ACID SEQUENCE

Analysis of compositionally biased regions in sequence databases. Wootton JC, et al. **Methods Enzymol** 1996; 266:554–71

Iterative template refinement: protein–fold prediction using iterative search and hybrid sequence/structure templates. Yi TM, et al. **Methods Enzymol** 1996;266:322–39

SEQHUNT. A program to screen aligned nucleotide and amino acid sequences. Johnson G, et al. **Methods Mol Biol** 1995;51:1–15

Sequence databases and homology searching using the World Wide Web. Paterson M. **Mol Med Today** 1996 Mar; 2(3):98–102

One–step evolution of a dimer from a monomeric protein. Green SM, et al. **Nat Struct Biol** 1995 Sep;2(9):746–51

The SWISS–PROT protein sequence data bank and its new supplement TREMBL. Bairoch A, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):21–5

The helix–hairpin–helix DNA–binding motif: a structural basis for non–sequence–specific recognition of DNA. Doherty AJ, et al. **Nucleic Acids Res** 1996 Jul 1; 24(13):2488–97

The PIR–International Protein Sequence Database. George DG, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):17–20

The Genome Sequence DataBase (GSDB): meeting the challenge of genomic sequencing. Keen G, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):13–6

The European Bioinformatics Institute (EBI) databases. Rodriguez–Tomé P, et al. **Nucleic Acids Res** 1996 Jan 1; 24(1):6–12

A 15 amino acid stretch close to the Grb2–binding domain defines two differentially expressed hSos1 isoforms with markedly different Grb2 binding affinity and biological activity. Rojas JM, et al. **Oncogene** 1996 Jun 6; 12(11):2291–300

How are close residues of protein structures distributed in primary sequence? Brocchieri L, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12136–40

Prediction of protein folding class using global description of amino acid sequence. Dubchak I, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8700–4

Global properties of the mapping between local amino acid sequence and local structure in proteins. Han KF, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5814–8

Sequence similarity analysis of Escherichia coli proteins: functional and evolutionary implications. Koonin EV, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11921–5

Sequence tag identification of intact proteins by matching tanden mass spectral data against sequence data bases. Mørtz E, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6; 93(16):8264–7

In search of the ideal protein sequence. Godzik A. **Protein Eng** 1995 May;8(5):409–16

Independence divergence–generated binary trees of amino acids. Tusnády GE, et al. **Protein Eng** 1995 May; 8(5):417–23

Are proteins ideal mixtures of amino acids? Analysis of energy parameter sets. Godzik A, et al. **Protein Sci** 1995 Oct;4(10):2107–17

PROMOTIF—a program to identify and analyze structural motifs in proteins. Hutchinson EG, et al. **Protein Sci** 1996 Feb;5(2):212–20

Binary patterning of polar and nonpolar amino acids in the sequences and structures of native proteins. West MW, et al. **Protein Sci** 1995 Oct;4(10):2032–9

Structural superposition of proteins with unknown alignment and detection of topological similarity using a six–dimensional search algorithm. Diederichs K. **Proteins** 1995 Oct;23(2):187–95

Not the "Dark Ages" [letter; comment] Barker WC, et al. **Science** 1996 Jul 12;273(5272):165. Comment on: Science 1996 May 17;272(5264):946.

Bioinformatics. Working the Web with a virtual lab and some Java [news] Fischman J. **Science** 1996 Aug 2; 273(5275):591–3

Which came first, protein sequence or structure? [comment] Karkar M. **Science** 1996 Aug 2;273(5275):610. Comment on: Science 1996 Aug 2;273(5275):666–9.

Emergence of preferred structures in a simple model of protein folding [see comments] Li H, et al. **Science** 1996 Aug 2;273(5275):666–9. Comment in: Science 1996 Aug 2;273(5275):610.

Teams tackle protein prediction [news] Pennisi E. **Science** 1996 Jul 26;273(5274):426–8

Computational molecular biology. Software matchmakers help make sense of sequences [news] Taubes G. **Science** 1996 Aug 2;273(5275):588–90

Biopolymer sequence availability [letter; comment] Yep D, et al. **Science** 1995 Nov 10;270(5238):900. Comment on: Science 1995 Sep 8;269(5229):1356–8.

Serotype analysis of Indian patients with HIV infection. Sehgal S, et al. **Trop Med Int Health** 1996 Apr;1(2):199–204

IMMUNOLOGY

Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. Stryhn A, et al. **Eur J Immunol** 1996 Aug;26(8):1911–8

Ligand binding kinetics of IL–2 and IL–15 to heteromers formed by extracellular domains of the three IL–2 receptor subunits. Balasubramanian S, et al. **Int Immunol** 1995 Nov; 7(11):1839–49

Probing immunogenicity of a T cell epitope by L–alanine and D–amino acid scanning. Maillère B, et al. **Mol Immunol** 1995 Oct;32(14–15):1073–80

Fine chemical modifications at N– and C–termini enhance peptide presentation to T cells by increasing the lifespan of both free and MHC–complexed peptides. Maillère B, et al. **Mol Immunol** 1995 Dec;32(17–18):1377–85

Characterization of a monoclonal antibody directed against the NH2 terminal area of interleukin–2 (IL–2) and inhibiting specifically the binding of IL–2 to IL–2 receptor beta chain (IL–2R beta). Moreau JL, et al. **Mol Immunol** 1995 Oct;32(14–15):1047–56

PHYSIOLOGY

A biological function for the XP motif within the N terminus of major histocompatibility complex class II–associated peptides. Breloer M, et al. **Eur J Immunol** 1996 Aug; 26(8):1825–9

AMINO ACID–SPECIFIC TRANSFER RNA see **RNA, TRANSFER, AMINO ACID–SPECIFIC**

AMINO ACID–SPECIFIC TRNA see **RNA, TRANSFER, AMINO ACID–SPECIFIC**

AMINO ACIDS

see related
RECEPTORS, AMINO ACID

Enzymatic synthesis of alpha–deuterated amino acids. Milne JJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):133S

No–carrier–added (4–fluoro–3–[131I]iodobenzyl)guanidine and (3–[211At]astato–4–fluorobenzyl)guanidine. Vaidyanathan G, et al. **Bioconjug Chem** 1996 Jan–Feb; 7(1):102–7

Capillary gas chromatographic analysis of protein amino acids as their N(O,S)–isobutoxycarbonyl methyl ester derivatives. Matsumura S, et al. **Biomed Chromatogr** 1995 Sep–Oct;9(5):205–10

Synthesis and biological evaluation of novel NK–1 tachykinin receptor antagonists: the use of cycloalkyl amino acids as a template. Sisto A, et al. **Biopolymers** 1995 Oct; 36(4):511–24

Taste responses to binary mixtures of amino acids in the sea catfish, Arius felis. Kohbara J, et al. **Chem Senses** 1996 Feb;21(1):45–53

Amino acid residue: is it structural or functional? Golovanov AP, et al. **FEBS Lett** 1995 Nov 13;375(1–2):162–6

DNA strand breaks induced through active oxygen radicals by fragrant component 4–hydroxy–2–hydroxymethyl–5–methyl–3(2H)–furanone in Maillard reaction of hexose/amino acid. Hiramoto K, et al. **Food Chem Toxicol** 1995 Oct;33(10):803–14

Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid–based formula. Kelly KJ, et al. **Gastroenterology** 1995 Nov;109(5):1503–12

Effect of adjacent histidine and cysteine residues on the spontaneous degradation of asparaginyl– and aspartyl–containing peptides. Brennan TV, et al. **Int J Pept Protein Res** 1995 Jun;45(6):547–53

Comparison of the effects of ozone on the modification of amino acid residues in glutamine synthetase and bovine serum albumin. Berlett BS, et al. **J Biol Chem** 1996 Feb 23;271(8):4177–82

Assignment of aliphatic side–chain 1HN/15N resonances in perdeuterated proteins. Farmer BT 2nd, et al. **J Biomol NMR** 1996 Jan;7(1):59–71

Efficacy and safety of hydrolyzed cow milk and amino acid–derived formulas in infants with cow milk allergy. Isolauri E, et al. **J Pediatr** 1995 Oct;127(4):550–7

Effects of low–protein diet supplemented with ketoacids on plasma lipids in adult chronic renal failure. Bernard S, et al. **Miner Electrolyte Metab** 1996;22(1–3):143–6

Consistencies of individual DNA base–amino acid interactions in structures and sequences. Lustig B, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4707–11

Atomic solvation parameters in the analysis of protein–protein docking results. Cummings MD, et al. **Protein Sci** 1995 Oct;4(10):2087–99

Are proteins ideal mixtures of amino acids? Analysis of energy parameter sets. Godzik A, et al. **Protein Sci** 1995 Oct;4(10):2107–17

The amino acid requirements of Staphylococcus aureus isolated from cases of bovine mastitis. Lincoln RA, et al. **Vet Microbiol** 1995 Jul;45(2–3):275–9

[Stability of amino acids and vitamins in total nutrient admixture] Huang D, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):269–72 (Eng. Abstr.) **(Chi)**

[In vitro antibacterial activities of carbapenems and other antibiotics against Pseudomonas aeruginosa determined using low–amino–acid agar] Kouda M, et al. **Jpn J Antibiot** 1995 Oct;48(10):1590–6 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Value of specialty intravenous amino acid solutions. Melnik G. **Am J Health Syst Pharm** 1996 Mar 15;53(6):671–4 (29 ref.)

Low birthweight infants and total parenteral nutrition immediately after birth. II. Randomised study of biochemical tolerance of intravenous glucose, amino acids, and lipid. Murdock N, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F8–12

Rebalancing essential amino acids intake by self–selection in the rat. Fromentin G, et al. **Br J Nutr** 1996 May; 75(5):669–82

Protein and amino acids in nutritional support. McNurlan MA, et al. **Crit Care Clin** 1995 Jul;11(3):635–50 (114 ref.)

Report on the working group on protein and amino acid requirements. Clugston G, et al. **Eur J Clin Nutr** 1996 Feb; 50 Suppl 1:S193–5

Whole–body protein turnover in obese subjects during two very low energy diets of differing amino acid composition. Gougeon R, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19(10):739–48

Effect of feeding reduced protein, amino acid–supplemented diets on nitrogen and energy balance in grower pigs. Kerr BJ, et al. **J Anim Sci** 1995 Oct;73(10):3000–8

Meal patterns reveal differential effects of vagotomy and tropisetron on responses to indispensable amino acid deficiency in rats. Erecius LF, et al. **J Nutr** 1996 Jun; 126(6):1722–31

Effect of parenteral amino acids on leucine and urea kinetics in preterm infants. Battista MA, et al. **J Pediatr** 1996 Jan; 128(1):130–4

Prevention by methionine of enhancement of hepatocarcinogenesis by coadministration of a choline–deficient L–amino acid–defined diet and ethionine in rats. Tsujiuchi T, et al. **Jpn J Cancer Res** 1995 Dec; 86(12):1136–42

Aminoacid infusions to prevent postoperative hypothermia. Duthie DJ. **Lancet** 1996 May 4;347(9010):1199

Microdialysis as a tool to measure dietary and regional effects on the complete profile of extracellular amino acids in the hypothalamus of rats. Currie PJ, et al. **Life Sci** 1995; 57(21):1911–23

Intraperitoneal amino acids in children receiving chronic peritoneal dialysis. Balfe JW. **Perit Dial Int** 1996;16 Suppl 1:S515–6

Intraperitoneal amino acids: a therapy whose time has come? Jones MR. **Perit Dial Int** 1995;15(5 Suppl):S67–74 (68 ref.)

Protein and amino acid intake in cafeteria fed obese rats. Lladó I, et al. **Physiol Behav** 1995 Sep;58(3):513–9

Renal hemodynamic response to intravenous and oral amino acids in animals. Lang F, et al. **Semin Nephrol** 1995 Sep; 15(5):415–8 (65 ref.)

Renal effects of intravenous amino acid administration in humans with and without renal disease: hormonal correlates. ter Wee PM. **Semin Nephrol** 1995 Sep; 15(5):426–32 (76 ref.)

[New findings in nutritional pharmacology] Kábrt J. **Sb Lek** 1995;96(4):441–5 **(Cze)**

[Role of new nitrogen substrates during peri–operative artificial nutrition in adults] Cynober L. **Ann Fr Anesth Reanim** 1995;14 Suppl 2:102–6 (Eng. Abstr.) **(Fre)**

[Postoperative infusion therapy: electrolyte solution in comparison with hypocaloric glucose and carbohydrate exchange–amino acid solutions] Jauch KW, et al. **Zentralbl Chir** 1995;120(9):682–8 (Eng. Abstr.) **(Ger)**

[The use of protein preparations in the combined treatment of pneumonia patients] Novozhenov VG, et al. **Voen Med Zh** 1996 Mar;317(3):38–9 **(Rus)**

[Cerebrolysin in the treatment of partial optic atrophy in children] Sidorenko EI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):51–4 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Alfalfa, vitamin E, and autoimmune disorders [letter; comment] Whittam J, et al. **Am J Clin Nutr** 1995 Nov; 62(5):1025–6. Comment on: Am J Clin Nutr 1994 Oct;60(4):639–40.

ANALYSIS

Effects of experimental round window membrane laceration on the free amino acid profile of perilymph. Haruta A, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):504–8

Polyamine changes in the vestibular nuclei of guinea pigs following labyrinthectomy. Salzer TA, et al. **Am J Otol** 1994 Nov;15(6):728–34

Light chain cardiomyopathy. Structural analysis of the light chain tissue deposits [see comments] Gallo G, et al. **Am J Pathol** 1996 May;148(5):1397–406. Comment in: Am J Pathol 1996 May;148(5):1339–44.

Cation–exchange resins release amino acids: consequences for tracer studies. Cayol M, et al. **Anal Biochem** 1995 May 20;227(2):392–4

Determination of 2–oxohistidine by amino acid analysis. Lewisch SA, et al. **Anal Biochem** 1995 Nov 1;231(2):440–6

Phosphoamino acid analysis by semidry electrophoresis on cellulose thin–layer plates using the Pharmacia/LKB Multiphor or Atto flatbed apparatus. Mahoney CW, et al. **Anal Biochem** 1996 Jun 15;238(1):96–8

Quantitation of L–amino acids by substrate recycling between an aminotransferase and a dehydrogenase: application to the determination of L–phenylalanine in human blood. Nakamura K, et al. **Anal Biochem** 1996 Feb 1;234(1):19–22

Enzymatic–chemical preparation of quinoxaline derivatives from L–amino acids for gas chromatographic–mass spectrometric analyses. Schadewaldt P, et al.

Anal Biochem 1995 Aug 10;229(2):153–61

Analysis of amino acids in biological fluids by pentafluorobenzyl chloroformate derivatization and detection by electron capture negative ionization mass spectrometry. Simpson JT, et al. **Anal Biochem** 1996 Jan 1;233(1):58–66

Determination of 2-(9-anthryl)ethyl chloroformate-labeled amino acids by capillary electrophoresis and liquid chromatography with absorbance or fluorescence detection. Engström A, et al. **Anal Chem** 1995 Sep 1; 67(17):3018–22

On-line NMR detection of amino acids and peptides in microbore LC. Wu N, et al. **Anal Chem** 1995 Sep 15; 67(18):3101–7

Amino acid data processing [letter] Briddon A. **Ann Clin Biochem** 1995 Nov;32 (Pt 6):595

Amino acid concentration in dementia of the Alzheimer type and multi-infarct dementia. Mochizuki Y, et al. **Ann Clin Lab Sci** 1996 May-Jun;26(3):275–8

Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with osteoarthritis or rheumatoid arthritis. Takahashi M, et al. **Ann Rheum Dis** 1996 May; 55(5):324–7

Proteins and their amino acid compositions: uniqueness, variability, and applications. Galat A, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):229–37

Amino acid profile in Down's syndrome. Heggarty HJ, et al. **Arch Dis Child** 1996 Apr;74(4):347–9

Type X collagen isolated from the hypertrophic cartilage of embryonic chick tibiae contains both hydroxylysyl- and lysylpyridinoline cross-links. Orth MW, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):301–5

Rapid protein identification using N-terminal "sequence tag" and amino acid analysis. Wilkins MR, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):609–13

Purification and N-terminal amino-acid sequence analysis of rabbit neutrophil cathepsin G. Cavarra E, et al. **Biol Chem Hoppe Seyler** 1995 Jun;376(6):371–7

Determination of D-amino acids, derivatized with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F), in wine samples by high-performance liquid chromatography. Kato M, et al. **Biomed Chromatogr** 1995 Jul-Aug;9(4):193–4

Capillary gas chromatographic analysis of protein amino acids as their N(O,S)-isobutoxycarbonyl methyl ester derivatives. Matsumura S, et al. **Biomed Chromatogr** 1995 Sep-Oct;9(5):205–10

A new procedure for the labeling of peptides and amino acids. Barton DH, et al. **Bioorg Med Chem** 1995 Jan;3(1):79–84

Amino acid composition of rat and human liver microsomes in normal and pathological conditions. Benga G, et al. **Biosci Rep** 1995 Apr;15(2):111–6

Amino acid investigations of tumor-associated antigen of Mc31 transformed cells. Wesselinova D. **Cancer Biochem Biophys** 1995 Nov;15(2):103–6

Deletion of amino acids from the carboxy-terminal end of actin. Xia D, et al. **Cell Motil Cytoskeleton** 1995; 32(3):163–72

Evaluation of the concentration and enantiomeric purity of selected free amino acids in fermented malt beverages (beers). Ekborg-Ott KH, et al. **Chirality** 1996;8(1):49–57

Free amino acids in amniotic fluid and the prenatal diagnosis of homocystinuria with methylmalonic aciduria. Parvy P, et al. **Clin Chem** 1995 Nov;41(11):1663–4

Gramine and free amino acids as indicators of fluoride-induced stress in barley and its consequences to insect herbivory. Hautala EL, et al. **Ecotoxicol Environ Saf** 1995 Aug;31(3):238–45

Enantiomeric separation of amino acids using micellar electrokinetic chromatography after pre-column derivatization with the chiral reagent 1-(9-fluorenyl)-ethyl chloroformate. Chan KC, et al. **Electrophoresis** 1995 Apr; 16(4):504–9

Spermatocytes and round spermatids of rat testis: protein patterns. Cossio G, et al. **Electrophoresis** 1995 Jul; 16(7):1225–30

Amino acid compositions of proteins and their identities. Galat A, et al. **Electrophoresis** 1995 Jul;16(7):1095–103

Analysis of underivatized amino acids by capillary electrophoresis using constant potential amperometric detection. Guo Y, et al. **Electrophoresis** 1995 Apr; 16(4):493–7

Separation and detection of amino acids and their enantiomers by capillary electrophoresis: a review. Issaq HJ, et al. **Electrophoresis** 1995 Apr;16(4):467–80 (81 ref.)

Microchip electrophoresis with sample stacking. Jacobson SC, et al. **Electrophoresis** 1995 Apr;16(4):481–6

Determination of amino acids by on-line capillary electrophoresis-electrospray ionization mass spectrometry [published erratum appears in Electrophoresis 1995 Jul;16(7):1325] Lu W, et al. **Electrophoresis** 1995 Apr; 16(4):487–92

Direct determination of amino acids by capillary electrophoresis/electrochemistry using a copper microelectrode and zwitterionic buffers. Zhou J, et al. **Electrophoresis** 1995 Apr;16(4):498–503

Free amino acid concentrations in normal and abnormal third trimester placental villi. Morris NH, et al. **Eur J Clin Invest** 1995 Oct;25(10):796–8

A 15N-leucine-dilution method to measure endogenous contribution to luminal nitrogen in the human upper jejunum. Gaudichon C, et al. **Eur J Clin Nutr** 1996 Apr; 50(4):261–8

Elective abdominal operations alter the free amino acid content of the human intestinal mucosa. Ahlman B, et al. **Eur J Surg** 1995 Aug;161(8):593–601

A new method for identifying the amino acid attached to a particular RNA in the cell. Suzuki T, et al. **FEBS Lett** 1996 Mar 4;381(3):195–8

Molecular biological studies on teeth, and inquests. Yamamoto K. **Forensic Sci Int** 1996 Jun 28;80(1-2):79–87 (21 ref.)

Neutral and cationic amino acids in striated rectus muscle are generally in excess of those in smooth uterine muscle of term pregnant women. Steingrímsdóttir T, et al. **Gynecol Obstet Invest** 1996;41(3):177–82

Determination of the ratios of the aromatic amino acid residues by first- or second-derivative UV spectrometry for a simple characterization of peptides. Miclo L, et al. **Int J Pept Protein Res** 1995 Aug;46(2):186–92

The prediction of the degree of exposure to solvent of amino acid residues via genetic programming. Handley S. **Ismb** 1994;2:156–60

Evaluating regularizers for estimating distributions of amino acids. Karplus K. **Ismb** 1995;3:188–96

Relation between protein structure, sequence homology and composition of amino acids. Mayoraz E, et al. **Ismb** 1995; 3:240–8

Estimation by regression analysis of endogenous amino acid levels in digesta collected from the distal ileum of pigs. Fan MZ, et al. **J Anim Sci** 1995 Aug;73(8):2319–28

Influence of sampling time and diet on amino acid composition of protozoal and bacterial fractions from bovine ruminal contents. Martin C, et al. **J Anim Sci** 1996 May;74(5):1157–63

A new long shelf life formulation of modified Ham's F-10 medium: biochemical and clinical evaluation. Weathersbee PS, et al. **J Assist Reprod Genet** 1995 Mar;12(3):175–9

High-performance liquid chromatography of amino acids after derivatization with 9-isothiocyanatoacridine. Oravec P, et al. **J Biochem Biophys Methods** 1995 Jun; 30(2-3):145–52

Amino acid analysis using derivatisation with 9-fluorenylmethyl chloroformate and reversed-phase high-performance liquid chromatography. Haynes PA, et al. **J Chromatogr** 1991 Mar 1;540(1-2):177–85

Liquid chromatographic determination of D- and L-amino acids by derivatization with o-phthaldialdehyde and N-isobutyryl-L-cysteine. Applications with reference to the analysis of peptidic antibiotics, toxins, drugs and pharmaceutically used amino acids. Brückner H, et al. **J Chromatogr A** 1995 Sep 8;711(1):201–15

Large-scale amino-acid analysis for proteome studies. Yan JX, et al. **J Chromatogr A** 1996 Jun 7;736(1-2):291–302

Influence of mastitis on D-amino acid content of milk. Csapó J, et al. **J Dairy Sci** 1995 Nov;78(11):2375–81

Two-dimensional nuclear magnetic resonance method for identifying the HN/N signals of amino-acid residues following glycine. Gehring K, et al. **J Magn Reson B** 1995 Nov;109(2):206–8

The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa. Barth AL, et al. **J Med Microbiol** 1996 Aug; 45(2):110–9

Characterisation of extracellular amino acids in striatum of freely moving rats by in vivo microdialysis. Semba J, et al. **J Neural Transm Gen Sect** 1995;100(1):39–52

Developmental changes of free amino acid concentrations in fetal fluids of pigs. Wu G, et al. **J Nutr** 1995 Nov; 125(11):2859–68

Intestinal amino acid content in critically ill patients. Ahlman B, et al. **JPEN J Parenter Enteral Nutr** 1995 Jul-Aug; 19(4):272–8

The solubility of calcium and phosphate in two specialty amino acid solutions. MacKay MW, et al. **JPEN J Parenter Enteral Nutr** 1996 Jan-Feb;20(1):63–6

Analysis of the IgE-epitope of Der f 2, a major mite allergen, by in vitro mutagenesis. Nishiyama C, et al. **Mol Immunol** 1995 Oct;32(14-15):1021–9

Amino acid concentrations and selected enzyme activities in rat auditory, olfactory, and visual systems. Ross CD, et al. **Neurochem Res** 1995 Dec;20(12):1483–90

Chemical analysis of neurotransmitter candidates in clonal cell lines from Drosophila central nervous system, II: Neuropeptides and amino acids. Ui-Tei K, et al. **Neurosci Lett** 1995 Aug 11;195(3):187–90

Identity of PSA purified from seminal fluid by different methods: comparison by amino acid analysis and assigned extinction coefficients. Stamey TA, et al. **Prostate** 1995 Oct; 27(4):198–203

Predicting protein structural classes from amino acid composition: application of fuzzy clustering. Zhang CT, et al. **Protein Eng** 1995 May;8(5):425–35

Effect of domoic acid on brain amino acid levels. Durán R, et al. **Rev Esp Fisiol** 1995 Mar;51(1):23–7

Amino acid content of the brain in rats focal penicillin induced epilepsy. Hategan D, et al. **Rom J Neurol Psychiatry** 1995 Apr-Jun;33(2):103–8

Identification of critical amino acids within the foot-and-mouth disease virus leader protein, a cysteine protease. Roberts PJ, et al. **Virology** 1995 Oct 20; 213(1):140–6

[Evaluation of different markers for the determination of microbial nitrogen flow into the duodenum of dairy cows] Schönhusen U, et al. **Arch Tierernahr** 1995;48(1-2):147–58 (Eng. Abstr.) **(Ger)**

[Mineral and amino acid contents of edible, cultivated shii-take mushrooms (Lentinus edodes)] Vetter J. **Z Lebensm Unters Forsch** 1995 Jul;201(1):17–9 (Eng. Abstr.) **(Ger)**

[Surface localization of amino acids in influenza virus hemagglutinin during functional transformation of virions by acidic pH] Ksenofontov AL, et al. **Mol Biol (Mosk)** 1995 May-Jun;29(3):635–44 (Eng. Abstr.) **(Rus)**

[The dynamics of the amino acid concentration in cadaveric organs in the late postmortem period] Alybaeva KN. **Sud Med Ekspert** 1995 Jul-Sep;38(3):13–5 **(Rus)**

[The determination of the time of death by the content of free amino acids in the liver and lungs of cadavers using high-performance liquid chromatography] Mel'nikov IuL, et al. **Sud Med Ekspert** 1995 Jul-Sep;38(3):10–3 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Biocatalytic syntheses of aromatics from D-glucose: renewable microbial sources of aromatic compounds. Frost JW, et al. **Annu Rev Microbiol** 1995;49:557–79 (81 ref.)

Aromatic amino-acid biosynthesis in Candida albicans: identification of the ARO4 gene encoding a second DAHP synthase. Pereira SA, et al. **Curr Genet** 1996 Apr; 29(5):441–5

Metabolic operons in Lactococci. Renault P, et al. **Dev Biol Stand** 1995;85:431–41

The apparent coupling between synthesis and posttranslational modification of Escherichia coli acyl carrier protein is due to inhibition of amino acid biosynthesis. Keating DH, et al. **J Bacteriol** 1996 May; 178(9):2662–7

A new stable isotope tracer technique to assess human neonatal amino acid synthesis. Miller RG, et al. **J Pediatr Surg** 1995 Sep;30(9):1325–9

Compartmentation of endogenously synthesized amino acids in neonates. Miller RG, et al. **J Surg Res** 1996 Jun; 63(1):199–203

Expression of an amino acid biosynthesis gene in tomato flowers: developmental upregulation and MeJa response are parenchyma-specific and mutually compatible. Samach A, et al. **Plant J** 1995 Sep;8(3):391–406

BLOOD

Neutral and basic amino acid concentrations in plasma during the day in subjects fed with two model rural and two model urban Mexican diets. Tovar AR, et al. **Am J Clin Nutr** 1996 Mar;63(3):335–41

Quantification of incorporation of [15N]ammonia into plasma amino acids and urea. Patterson BW, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E508–15

Enteral glutamate is almost completely metabolized in first pass by the gastrointestinal tract of infant pigs. Reeds PJ, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E413–8

Serum amino acid concentrations in growing rats fed intact protein versus enzymatic protein hydrolysate-based diets. Baró L, et al. **Biol Neonate** 1995;68(1):55–61

Determination of D-amino acids in serum from patients with renal dysfunction. Fukushima T, et al. **Biol Pharm Bull** 1995 Aug;18(8):1130–2

Plasma amino acid ratios related to brain serotonin synthesis in response to food intake in bulimia nervosa. Pijl H, et al. **Biol Psychiatry** 1995 Nov 15;38(10):659–68

Low serum tryptophan to large neutral amino acids ratio in idiopathic infantile autism. D'Eufemia P, et al. **Biomed Pharmacother** 1995;49(6):288–92

Human plasma preservation for amino acid analysis by immediate low temperature freezing. Hubbard RW, et al. **Clin Biochem** 1995 Jun;28(3):318–20

Assay of serum pyridinoline: a potential marker for bone resorption. Hata K, et al. **Clin Chim Acta** 1995 Mar 31; 235(2):221–7

Renal, metabolic, and hormonal responses to proteins of different origin in normotensive, nonproteinuric type I diabetic patients. Kontessis PA, et al. **Diabetes Care** 1995 Sep;18(9):1233

The effect of recombinant human IGF-I on protein metabolism in post-operative patients without nutrition compared to effects in experimental animals. Sandström R, et al. **Eur J Clin Invest** 1995 Oct;25(10):784–92

The plasma level of some amino acids and physical and mental fatigue. Newsholme EA, et al. **Experientia** 1996 May 15;52(5):413–5 (14 ref.)

Neuroendocrine control of osmotic regulation in the freshwater shrimp Macrobrachium olfersii (Wiegmann) (Crustacea, decapoda): free amino acid concentrations in the hemolymph. Freire CA, et al. **Gen Comp Endocrinol** 1995 Oct;100(1):83–91

Plasma amino acid concentration under human growth hormone treatment in uremic children. Szabó A, et al. **Horm Res** 1995;44(6):265–7

Serum amino acids and genesis of protein energy malnutrition. Phadke MA, et al. **Indian Pediatr** 1995 Mar; 32(3):301–6

Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss. Breum L, et al. **Int J Obes Relat Metab Disord** 1996 Feb; 20(2):147–53

Plasma amino acid consumption and pancreatic secretion during and after cerulein-induced pancreatitis in rats.

Fischer H, et al. **Int J Pancreatol** 1995 Oct;18(2):127–34
Cholecystokinin (CCK) in the amino acid uptake and enzyme protein secretion by the pancreas in humans. Konturek JW, et al. **Int J Pancreatol** 1995 Feb;17(1):55–61
Unaccustomed high–mileage vs intensity training–related changes in performance and serum amino acid levels. Lehmann M, et al. **Int J Sports Med** 1996 Apr;17(3):187–92
Early metabolic treatment after liver transplant: amino acid tolerance. Iapichino G, et al. **Intensive Care Med** 1995 Oct; 21(10):802–7
Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. Ureña P, et al. **J Bone Miner Res** 1995 Jun;10(6):932–9
Validation of the determination of amino acids in plasma by high–performance liquid chromatography using automated pre–column derivatization with o–phthaldialdehyde. Fekkes D, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):177–86
Simultaneous profile analysis of plasma amino and organic acids by capillary gas chromatography. Hušek P. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):352–7
Evidence for a catabolic role of glucagon during an amino acid load. Charlton MR, et al. **J Clin Invest** 1996 Jul 1; 98(1):90–9
Insulin and insulin–like growth factor–I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. Fryburg DA, et al. **J Clin Invest** 1995 Oct;96(4):1722–9
Estimates of the effect of feeding on whole–body protein degradation in women vary with the amino acid used as tracer. Berthold HK, et al. **J Nutr** 1995 Oct;125(10):2516–27
Enteral glutamine supplementation for the very low birthweight infant: plasma amino acid concentrations. Roig JC, et al. **J Nutr** 1996 Apr;126(4 Suppl):1115S–20S
Effects of spinach leaf protein concentrate on the serum cholesterol and amino acid concentrations in rats fed a cholesterol–free diet. Satoh A, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Oct;41(5):563–73
Plasma amino acid concentrations in healthy, full–term infants fed hydrolysate infant formula. Decsi T, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):62–7
Supplementation of enteral nutrition with butyrate leads to increased portal efflux of amino acids in growing pigs with short bowel syndrome. Welters CF, et al. **J Pediatr Surg** 1996 Apr;31(4):526–9
Early plasma amino acid pool alterations in patients with military gunshot/missile wounds. Zunić G, et al. **J Trauma** 1996 Mar;40(3 Suppl):S152–6
Effect of enteral and parenteral nutrition on amino acid levels in cancer patients. Pearlstone DB, et al. **JPEN J Parenter Enteral Nutr** 1995 May–Jun;19(3):204–8
Estrogen effects on blood amino acid compartmentation. Proenza AM, et al. **Life Sci** 1995;57(17):1589–97
Comparison of the effects of amino acid mixture and placebo on plasma tryptophan to large neutral amino acid ratio. Wolfe BE, et al. **Life Sci** 1995 Mar 17;56(17):1395–400
Serum phosphate control: what about calcium salts of keto–amino acids? [letter; comment] Macia M, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2159–60. Comment on: Nephrol Dial Transplant 1994;9(10):1366–7.
Changes in hepatic nitrogen balance in plasma concentrations of amino acids and hormones and in cell volume after overnight fasting in perinatal and adult rat. Blommaart PJ, et al. **Pediatr Res** 1995 Dec;38(6):1018–25
Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Rashed MS, et al. **Pediatr Res** 1995 Sep;38(3):324–31
Effects of lactitol [correction of lactilol] on hepatic encephalopathy and plasma amino–acid imbalance. Trovato GM, et al. **Recenti Prog Med** 1995 Jul–Aug;86(7–8):299–303
HPLC analysis of amino acids in inborn errors of metabolism. Matteson KJ. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:120–2
High performance liquid chromatography (HPLC) method for confirming thin layer chromatography (TLC) findings in inborn errors of metabolism children in Malaysia. Yahya NA, et al. **Southeast Asian J Trop Med Public Health** 1995; 26 Suppl 1:130–3
Inborn errors of metabolic diseases in Malaysia: a preliminary report of maple syrup urine diseases for 1993. Zakiah I, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:134–6
Serum amino acid changes in rats with thioacetamide–induced liver cirrhosis. Fontana L, et al. **Toxicology** 1996 Jan 8;106(1–3):197–206
[Effect of feeding protected arginine on food intake, milk yield and growth hormone and amino acid levels in blood plasma of cows during the summer feeding period with grass] Kirchgessner M, et al. **Arch Tierernahr** 1993; 45(1):57–69 (Eng. Abstr.) **(Ger)**
[Effect of extrahepatic cholestasis on amino acid metabolism in the animal experiment] Sachs M, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:30–2 (Eng. Abstr.) **(Ger)**
[Effect of high concentration insulin during glucose clamp on blood amino acids and lipids] Noguchi Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):184 **(Jpn)**
[Free amino acids] Kohno M, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:481–5 (16 ref.) **(Jpn)**
[Homocysteine--an independent risk factor of premature vascular disease] Mansoor MA, et al. **Tidsskr Nor Laegeforen** 1996 May 30;116(14):1663–7 (41 ref.) **(Nor)**
[Increased plasma level of homocysteine as cardiovascular risk factor] Ueland PM, et al. **Tidsskr Nor Laegeforen** 1996 May 30;116(14):1661–2 **(Nor)**
[The effect of long term erythropoietin treatment on levels of free amino acids in patients with long term hemodialysis] Boratyńska M, et al. **Przegl Lek** 1996;53(5):398–401 (Eng. Abstr.) **(Pol)**
[The content of free amino acids in the blood of children with intellectual disorders] Baryshnikov VA. **Sud Med Ekspert** 1995 Oct–Dec;38(4):37–9 (Eng. Abstr.) **(Rus)**
[The characteristics of amino acid metabolism in premature infants on different types of feeding] Netrebenko OK, et al. **Vopr Pitan** 1995;(4):20–3 (Eng. Abstr.) **(Rus)**
[The role of proteins and amino acids in acute phase response] Rakarić–Poznanović M, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:107–9 (Eng. Abstr.) **(Scr)**
[Nutritional status and plasma amino acid levels in hemodialysis] Sanz A, et al. **Nutr Hosp** 1995 Nov–Dec; 10(6):348–53 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Excitability of neurons in the ventromedial nucleus in rat hypothalamic slices: modulation by amino acids at cerebrospinal fluid levels. Nishimura F, et al. **Brain Res** 1995 Sep 11;691(1–2):217–22
Effects of prostaglandin E2 and capsaicin on behavior and cerebrospinal fluid amino acid concentrations of unanesthetized rats: a microdialysis study. Malmberg AB, et al. **J Neurochem** 1995 Nov;65(5):2185–93
Aggression and personality: association with amino acids and monoamine metabolites. Møller SE, et al. **Psychol Med** 1996 Mar;26(2):323–31

CHEMICAL SYNTHESIS

N,N–dialkoxycarbonylamino acids from the sodium hydride–mediated reaction of alkyl chloroformates with mixed anhydrides of N–alkoxycarbonylamino acids. Benoiton NL, et al. **Int J Pept Protein Res** 1995 May; 45(5):466–70
Aza–peptide analogs as potent human immunodeficiency virus type–1 protease inhibitors with oral bioavailability. Fässler A, et al. **J Med Chem** 1996 Aug 2;39(16):3203–16
On the synthesis of pyridazomycin congeners. Part 2: L–alpha–Amino acids bearing a terminal azinium or diazinium system. Easmon J, et al. **Pharmazie** 1996 Feb; 51(2):76–83
Synthesis and anticonvulsant activity of some amino acid derivatives. Part 2: Derivatives of Gly, Ala, Leu, Pro, Trp, Phe(4 Cl), Ala(alpha–Me). Paruszewski R, et al. **Pharmazie** 1996 Apr;51(4):212–5

CHEMISTRY

An amino acid substitution in the pyruvate dehydrogenase E1 alpha gene, affecting mitochondrial import of the precursor protein. Takakubo F, et al. **Am J Hum Genet** 1995 Oct;57(4):772–80
Polypeptide amino acid composition and isoelectric point. II. Comparison between experiment and theory. Patrickios CS, et al. **Anal Biochem** 1995 Oct 10;231(1):82–91
Direct measurement of crosslinks, pyridinoline, deoxypyridinoline, and pentosidine, in the hydrolysate of tissues using high–performance liquid chromatography. Takahashi M, et al. **Anal Biochem** 1995 Dec 10; 232(2):158–62
Racemization of amino acids in solid–phase peptide synthesis investigated by capillary electrophoresis. Riester D, et al. **Anal Chem** 1996 Jul 15;68(14):2361–5
An amino acid derived from aldol crosslink of elastin and collagen: structure, distribution, aging, and two models of hyperglycemia. Nakamura F, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):167–73
Binding of amino acids to the cationic surfactant cetyltrimethylammoniumbromide. Cserháti T, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):555–62
The role of acidic amino acid residues in the structural stability of snake cardiotoxins. Chiang CM, et al. **Biochemistry** 1996 Jul 16;35(28):9177–86
Modeling unfolded states of peptides and proteins. Creamer TP, et al. **Biochemistry** 1995 Dec 19;34(50):16245–50
Mg coordination by amino acid side chains is not required for assembly and function of the special pair in bacterial photosynthetic reaction centers. Goldsmith JO, et al. **Biochemistry** 1996 Feb 20;35(7):2421–8
Mutagenesis of photosystem I in the region of the ferredoxin cross–linking site: modifications of positively charged amino acids. Hanley J, et al. **Biochemistry** 1996 Jul 2; 35(26):8563–71
Contributions of the ionizable amino acids to the stability of staphylococcal nuclease. Meeker AK, et al. **Biochemistry** 1996 May 21;35(20):6443–9
Structure effects of double D–amino acid replacements: a nuclear magnetic resonance and circular dichroism study using amphipathic model helices. Rothemund S, et al. **Biochemistry** 1995 Oct 10;34(40):12954–62
Solvation energies of amino acid side chains and backbone in a family of host–guest pentapeptides. Wimley WC, et al. **Biochemistry** 1996 Apr 23;35(16):5109–24
A general method for mapping tertiary contacts between amino acid residues in membrane–embedded proteins. Yu H, et al. **Biochemistry** 1995 Nov 21;34(46):14963–9
Availability of phenylisothiocyanate for the amino acid sequence/configuration determination of peptides containing D/L–amino acids. Imai K, et al. **Biomed Chromatogr** 1995 Jul–Aug;9(4):195–6
Antitumor activity of titanocene amino acid complexes. Köpf–Maier P, et al. **Biometals** 1996 Jul;9(3):267–71
Computational screening of combinatorial libraries. Zheng Q, et al. **Bioorg Med Chem** 1996 May;4(5):631–8
Urethane–protected alpha–amino acid N–carboxyanhydrides and peptide synthesis. Fuller WD, et al. **Biopolymers** 1996; 40(2):183–205 (56 ref.)
Conformational characteristics of peptides containing alpha, beta–dehydroamino acid residues. Jain R, et al. **Biopolymers** 1996;40(1):105–19 (80 ref.)
Applicability of a continuum solvation model to the octanol water transfer: CFF91 based model for amino acids. Schmidt AB, et al. **Biopolymers** 1995 Nov;36(5):599–605
Chou–Fasman conformational amino acid parameters and the genetic code. Siemion IZ, et al. **Biosystems** 1995; 36(3):231–8
Effects of three microbial probiotics on postprandial porto–arterial concentration differences of glucose, galactose and amino–nitrogen in the young pig. Rychen G, et al. **Br J Nutr** 1995 Jul;74(1):19–26
Metabolic activation of PCBs to quinones: reactivity toward nitrogen and sulfur nucleophiles and influence of superoxide dismutase. Amaro AR, et al. **Chem Res Toxicol** 1996 Apr–May;9(3):623–9
Alkylation of oxytocin by S–(2–chloroethyl)glutathione and characterization of adducts by tandem mass spectrometry and Edman degradation. Erve JC, et al. **Chem Res Toxicol** 1995 Apr–May;8(3):414–21
Chiral aminophosphonate eluent for enantiomeric analysis of amino acids. Belov YP, et al. **Chirality** 1996;8(1):122–5
Co–inertia analysis of amino–acid physico–chemical properties and protein composition with the ADE package. Thioulouse J, et al. **Comput Appl Biosci** 1995 Jun; 11(3):321–9
[3H]1–aminocyclopropanecarboxylic acid, a novel probe for strychnine– insensitive glycine receptors. Popik P, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):221–7
Modification of the potent peptide FK888 with unusual aminoacids: effects on activity on neurokinin receptors. Caliendo G, et al. **Farmaco** 1996 Mar;51(3):197–201
Structural identification of valine hydroperoxides and hydroxides on radical–damaged amino acid, peptide, and protein molecules. Fu S, et al. **Free Radic Biol Med** 1995 Sep;19(3):281–92
Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA–B53. Smith KJ, et al. **Immunity** 1996 Mar; 4(3):215–28
Passive adsorption of immunologically active and inactive synthetic peptides to polystyrene is influenced by the proportion of non–polar residues in the peptide. Sällberg M, et al. **Immunol Lett** 1995 May;46(1–2):25–30
Importance of specific amino acids in protein binding sites for heparin and heparan sulfate. Caldwell EE, et al. **Int J Biochem Cell Biol** 1996 Feb;28(2):203–16
Amino acid grafting of beta–lactoglobulin mediated by phosphorus oxychloride. Sitohy M, et al. **Int J Biol Macromol** 1995 Oct;17(5):269–72
Peptidyl substrates containing unnatural amino acid at the P'1 position are potent inhibitors of prohormone convertases. Basak A, et al. **Int J Pept Protein Res** 1995 Sep–Oct;46(3–4):228–37
Self–activation of N–phosphoamino acids and N–phosphodipeptides in oligopeptide formation. Zhao Y, et al. **Int J Pept Protein Res** 1995 Jun;45(6):514–8
The induction of metachromasia and circular dichroism of coomassie brilliant blue R–250 with collagen and histone H1 is due to the low content of hydrophobic amino acid residues in these proteins. Hattori S, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):400–6
Charge distribution of flanking amino acids influences O–glycan acquisition in vivo. Nehrke K, et al. **J Biol Chem** 1996 Mar 22;271(12):7061–5
Free radicals generated during the glycation reaction of amino acids by methylglyoxal. A model study of protein–cross–linked free radicals. Yim HS, et al. **J Biol Chem** 1995 Nov 24;270(47):28228–33
Cell–free synthesis and amino acid–selective stable isotope labeling of proteins for NMR analysis. Kigawa T, et al. **J Biomol NMR** 1995 Sep;6(2):129–34
Classification of amino acid spin systems using PFG HCC(CO)NH–TOCSY with constant–time aliphatic 13C frequency labeling. Tashiro M, et al. **J Biomol NMR** 1995 Sep;6(2):211–6
A simple flexible program for the computational analysis of amino acyl residue distribution in proteins: application to the distribution of aromatic versus aliphatic hydrophobic amino acids in transmembrane alpha–helical spanners of integral membrane transport proteins. Tsang S, et al. **J Comput Biol** 1996 Spring;3(1):185–90
T cell recognition of MHC class II–associated peptides is independent of peptide affinity for MHC and sodium dodecyl sulfate stability of the peptide/MHC complex. Effects of conservative amino acid substitutions at anchor position 1 of influenza matrix protein19–31. Wu S, et al.

J Immunol 1996 May 15;156(10):3815–20

Amino–acid–type–selective triple–resonance experiments. Dötsch V, et al. **J Magn Reson B** 1996 Jan;110(1):107–11

Amino–acid–type identification for deuterated proteins with a beta–carbon–edited HNCOCACB experiment. Dötsch V, et al. **J Magn Reson B** 1996 Jul;112(1):95–100

Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. Kotretsou S, et al. **J Med Chem** 1995 Nov 10; 38(23):4710–9

3D–quantitative structure–activity relationships of human immunodeficiency virus type–1 proteinase inhibitors: comparative molecular field analysis of 2–heterosubstituted statine derivatives–implications for the design of novel inhibitors. Kroemer RT, et al. **J Med Chem** 1995 Dec 8; 38(25):4917–28

Microsphere formation in a series of derivatized alpha–amino acids: properties, molecular modeling, and oral delivery of salmon calcitonin. Leone–Bay A, et al. **J Med Chem** 1995 Oct 13;38(21):4257–62

N–acylated alpha–amino acids as novel oral delivery agents for proteins. Leone–Bay A, et al. **J Med Chem** 1995 Oct 13;38(21):4263–9

Residue–residue potentials with a favorable contact pair term and an unfavorable high packing density term, for simulation and threading. Miyazawa S, et al. **J Mol Biol** 1996 Mar 1;256(3):623–44

Complex salt bridges in proteins: statistical analysis of structure and function. Musafia B, et al. **J Mol Biol** 1995 Dec 8;254(4):761–70

Helix propensities of basic amino acids increase with the length of the side–chain. Padmanabhan S, et al. **J Mol Biol** 1996 Apr 5;257(3):726–34

Comparison between the phi distribution of the amino acids in the protein database and NMR data indicates that amino acids have various phi propensities in the random coil conformation. Serrano L. **J Mol Biol** 1995 Nov 24; 254(2):322–33

Dynamics of bacteriophage T4 DNA polymerase function: identification of amino acid residues that affect switching between polymerase and 3' –> 5' exonuclease activities. Stocki SA, et al. **J Mol Biol** 1995 Nov 17;254(1):15–28

Genetic studies of the Lac repressor. XV: 4000 single amino acid substitutions and analysis of the resulting phenotypes on the basis of the protein structure. Suckow J, et al. **J Mol Biol** 1996 Aug 30;261(4):509–23

Statistical potentials extracted from protein structures: how accurate are they? Thomas PD, et al. **J Mol Biol** 1996 Mar 29;257(2):457–69

The use of amino acid patterns of classified helices and strands in secondary structure prediction. Zhu ZY, et al. **J Mol Biol** 1996 Jul 12;260(2):261–76

Phylogeny reconstruction for protein sequences based on amino acid properties. Schmidt W. **J Mol Evol** 1995 Oct; 41(4):522–30

Solvent effects on chemical processes. 11. Solvent effects on the kinetics of decarboxylative dechlorination of N–chloro amino acids in binary aqueous–organic solvents. LePree JM, et al. **J Pharm Sci** 1996 Jun;85(6):560–6

Critical amino acids responsible for conferring calcium channel characteristics are located on the surface and around beta–turn potentials of channel proteins. Murakami M. **J Protein Chem** 1995 Apr;14(3):111–4

Phosphorylation of beta–lactoglobulin using amino acids as the sole base and nucleophile of the reaction. Sitohy M, et al. **J Protein Chem** 1995 Apr;14(3):145–50

Role of oxidized amino acids in protein breakdown and stability. Stadtman ER. **Methods Enzymol** 1995;258:379–93 (56 ref.)

Synthesis of long prebiotic oligomers on mineral surfaces [see comments] Ferris JP, et al. **Nature** 1996 May 2; 381(6577):59–61. Comment in: Nature 1996 May 2;381(6577):20–1.

In vivo effects of lamprey GnRH–I and cyclized analogs: a structure–activity study. Sower SA, et al. **Neuropeptides** 1995 Sep;29(3):151–6

Hydrophobic contribution constants of amino acid residues to the hydrophobicities of oligopeptides. Gao H, et al. **Pharm Res** 1995 Sep;12(9):1279–83

Synthesis and coupling reactions of alpha,alpha–dialkylated amino acids with nucleobase side chains. Azumaya I, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12013–6

Temperature effects in hydrophobic interaction chromatography. Haidacher D, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2290–5

A simple algorithm for the calculation of multiple site titration curves. Karshikoff A. **Protein Eng** 1995 Mar; 8(3):243–8

Independence divergence–generated binary trees of amino acids. Tusnády GE, et al. **Protein Eng** 1995 May; 8(5):417–23

Fuzzy cluster analysis of simple physicochemical properties of amino acids for recognizing secondary structure in proteins. Mocz G. **Protein Sci** 1995 Jun;4(6):1178–87

Automatic recognition of hydrophobic clusters and their correlation with protein folding units. Zehfus MH. **Protein Sci** 1995 Jun;4(6):1188–202

Empirical evaluation of the influence of side chains on the conformational entropy of the polypeptide backbone. Stites WE, et al. **Proteins** 1995 Jun;22(2):132–40

Amino acid racemization and the preservation of ancient DNA [see comments] Poinar HN, et al. **Science** 1996 May 10;272(5263):864–6. Comment in: Science 1996 May 10;272(5263):810.

Just how old is that DNA, anyway? [news; comment] Service RF. **Science** 1996 May 10;272(5263):810. Comment on: Science 1996 May 10;272(5263):864–6.

An amino acid polymorphism in histidine–rich glycoprotein (HRG) explains 59% of the variance in plasma HRG levels. Hennis BC, et al. **Thromb Haemost** 1995 Dec;74(6):1497–50

[Surface potential energy of peptides and conformation of amino acid residues in proteins. Preliminary results of processing using databank protein structures] Basharov MA. **Biofizika** 1995 Mar–Apr;40(2):260–73 (50 ref.) (Eng. Abstr.) **(Rus)**

[Characteristics of distribution of nonpolar amino acid residues in amino acid sequences of different groups of globular proteins] Trikulenko AV. **Biokhimiia** 1996 Mar; 61(3):461–3 (Eng. Abstr.) **(Rus)**

[Photoaffinity modification of amino acid derivatives of oligonucleotides in a complementary complex] Godovikova TS, et al. **Bioorg Khim** 1995 Nov; 21(11):858–67 (Eng. Abstr.) **(Rus)**

[p–Sulfotetrafluorophenyl hydrophilic activated esters of amino acids in peptide synthesis] Medvedkin VN, et al. **Bioorg Khim** 1995 Sep;21(9):684–90 (Eng. Abstr.) **(Rus)**

[Antioxidant properties of products of the interaction of amino acids with carbohydrates under conditions of the Maillard reaction] Kaytka VV, et al. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):71–5 (Eng. Abstr.) **(Ukr)**

DEFICIENCY

Indispensable amino acid deficiency and increased seizure susceptibility in rats. Gietzen DW, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R18–24

Alpha 2 noradrenoceptors in the anterior piriform cortex decline with acute amino acid deficiency. Gietzen DW, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):41–6

Reversible large–body formation from nuclear bodies upon amino acid(s) starvation in T24 cells. Kamei H. **Exp Cell Res** 1996 May 1;224(2):302–11

The prolyl 4–hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline–deficient L–amino acid–defined diet. Sakaida I, et al. **Hepatology** 1996 Apr;23(4):755–63

Induction of high affinity glutamate transport activity by amino acid deprivation in renal epithelial cells does not involve an increase in the amount of transporter protein. Nicholson B, et al. **J Biol Chem** 1996 May 24; 271(21):12159–64

Meal patterns reveal differential effects of vagotomy and tropisetron on responses to indispensable amino acid deficiency in rats. Erecius LF, et al. **J Nutr** 1996 Jun; 126(6):1722–31

Impact of enteral feeding of a glutamine–supplemented formula on the hypoaminoacidemic response in trauma patients. Long CL, et al. **J Trauma** 1996 Jan;40(1):97–102

DIAGNOSTIC USE

Amino acid loading disrupts whole kidney proximal glomerular–tubular balance in humans. Tack I, et al. **Clin Nephrol** 1996 Jan;45(1):42–50

DRUG EFFECTS

Glucocorticoid–dependent induction of interleukin–6 receptor expression in human hepatocytes facilitates interleukin–6 stimulation of amino acid transport. Fischer CP, et al. **Ann Surg** 1996 May;223(5):610–8; discussion 618–9

The effect of recombinant human IGF–I on protein metabolism in post–operative patients without nutrition compared to effects in experimental animals. Sandström R, et al. **Eur J Clin Invest** 1995 Oct;25(10):784–92

Glucocorticoids and acidosis stimulate protein and amino acid catabolism in vivo. May RC, et al. **Kidney Int** 1996 Mar;49(3):679–83

Estrogen effects on blood amino acid compartmentation. Proenza AM, et al. **Life Sci** 1995;57(17):1589–97

Effects of interleukin–1 beta and interleukin–2 on amino acids levels in mouse cortex and hippocampus. Bianchi M, et al. **Neuroreport** 1995 Aug 21;6(12):1689–92

Effect of domoic acid on brain amino acid levels. Durán R, et al. **Rev Esp Fisiol** 1995 Mar;51(1):23–7

GENETICS

On the statistical distribution of amino acid residue in randomly synthesized peptides. De O Cavalcanti AR, et al. **An Acad Bras Cienc** 1995;67(4):401–2

Environment of copper in Pseudomonas aeruginosa azurin probed by binding of exogenous ligands to Met121X (X = Gly, Ala, Val, Leu, or Asp) mutants. Bonander N, et al. **Biochemistry** 1996 Feb 20;35(7):2429–36

Construction of single amino acid substitution mutants of cloned Bacillus stearothermophilus DNA polymerase I which lack 5'–>3' exonuclease activity. Riggs MG, et al. **Biochim Biophys Acta** 1996 Jun 7;1307(2):178–86

Chou–Fasman conformational amino acid parameters and the genetic code. Siemion IZ, et al. **Biosystems** 1995; 36(3):231–8

Metabolic operons in Lactococci. Renault P, et al. **Dev Biol Stand** 1995;85:431–41

Control of ilvIH transcription during amino acid downshift in stringent and relaxed strains of Escherichia coli. Baccigalupi L, et al. **FEMS Microbiol Lett** 1995 Aug 15; 131(1):95–8

Localization of D–amino acid oxidase mRNA in the mouse kidney and the effect of testosterone treatment. Koibuchi N, et al. **Histochem Cell Biol** 1995 Nov;104(5):349–55

Amino acid polymorphisms of PrP with reference to onset of scrapie in Suffolk and Corriedale sheep in Japan. Ikeda T, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2577–81

Model of amino acid substitution in proteins encoded by mitochondrial DNA. Adachi J, et al. **J Mol Evol** 1996 Apr; 42(4):459–68

Kinetics of synonymous codon change for an amino acid of arbitrary degeneracy. Berg OG. **J Mol Evol** 1995 Sep; 41(3):345–52

A method to estimate effects of amino acid substitutions in blood coagulation factor IX from hemophilia B patients. Furutani H. **Medinfo** 1995;8 Pt 2:909

IMMUNOLOGY

Characterization of an HLA–DQ2–specific monoclonal antibody. Influence of amino acid substitutions in DQ beta 1*0202. Viken HD, et al. **Hum Immunol** 1995 Apr; 42(4):319–27

Residues near the amino and carboxyl termini of staphylococcal enterotoxin E independently mediate TCR V beta–specific interactions. Lamphear JG, et al. **J Immunol** 1996 Mar 15;156(6):2178–85

T cell recognition of MHC class II–associated peptides is independent of peptide affinity for MHC and sodium dodecyl sulfate stability of the peptide/MHC complex. Effects of conservative amino acid substitutions at anchor position 1 of influenza matrix protein19–31. Wu S, et al. **J Immunol** 1996 May 15;156(10):3815–20

ISOLATION & PURIFICATION

Separation of amino acid enantiomers by micellar electrokinetic capillary chromatography using synthetic chiral surfactants. Swartz ME, et al. **Anal Biochem** 1995 Oct 10;231(1):65–71

Chiral separation by high–speed countercurrent chromatography. Ma Y, et al. **Anal Chem** 1995 Sep 1; 67(17):3069–74

Affinity countercurrent chromatography using a ligand in the stationary phase. Ma Y, et al. **Anal Chem** 1996 Apr 1;68(7):1207–11

Facile liquid chromatographic enantioresolution of native amino acids and peptides using a teicoplanin chiral stationary phase. Berthod A, et al. **J Chromatogr A** 1996 Apr 19;731(1–2):123–37

METABOLISM

Amino–acid release from human cerebral cortex during simulated ischaemia in vitro. Hegstad E, et al. **Acta Neurochir (Wien)** 1996;138(2):234–41

Effect of ethanol on amino acids and related compounds in rat plasma, heart, aorta, bronchus, and pancreas. Abdel–Nabi R, et al. **Alcohol** 1996 Mar–Apr;13(2):171–4

Response of hepatic amino acid consumption to chronic metabolic acidosis. Boon L, et al. **Am J Physiol** 1996 Jul; 271(1 Pt 2):F198–202

Sensitive methods to study human apolipoprotein B metabolism using stable isotope–labeled amino acids. Demant T, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E1022–36

Anoxic brain failure in an ectothermic vertebrate: release of amino acids and K+ in rainbow trout thalamus. Hylland P, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1077–84

Is gamma–actin a regulator of amino acid transport? Lin G, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1647–55

Leucine activates system A amino acid transport in L6 rat skeletal muscle cells. McDowell HE, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1287–94

Adaptive regulation of amino acid transport in nutrient–deprived human hepatomas. Wasa M, et al. **Am J Surg** 1996 Jan;171(1):163–9

The role of the Opaque2 transcriptional factor in the regulation of protein accumulation and amino acid metabolism in maize seeds. Yunes JA, et al. **An Acad Bras Cienc** 1994;66 Su 1 (Pt 2):227–37; quiz 237–8 (60 ref.)

Transport mutants and transport genes of Corynebacterium glutamicum. Eggeling L, et al. **Ann N Y Acad Sci** 1996 May 15;782:191–201 (32 ref.)

Amino acid and protein depletion in medium of cell cultures infected with Cowdria ruminantium. Neitz AW, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:24–34

Dinaline inhibits amino acid transport and proliferation of colon carcinoma cells in vitro. Schaider H, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2501–9

Characterization and transcriptional analysis of the gene cluster for coronafacic acid, the polyketide component of the phytotoxin coronatine. Liyanage H, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3843–8

An intracellular aminopeptidase from Streptomyces rimosus that prefers basic amino acids. Vitale L, et al. **Arch Microbiol** 1996 Jun;165(6):409–14

Nutritional value of protein hydrolysis products (oligopeptides and free amino acids) as a consequence of absorption and metabolism kinetics. Rérat A.

Arch Tierernahr 1995;48(1–2):23–36

Long–term depletion of brain histamine induced by alpha–fluoromethylhistidine increases feeding–associated locomotor activity in mice with a modulation of brain amino acid levels. Sakai N, et al. **Behav Brain Res** 1995 Dec 14;72(1–2):83–8

The 4F2hc surface antigen is necessary for expression of system L–like neutral amino acid–transport activity in C6–BU–1 rat glioma cells: evidence from expression studies in Xenopus laevis oocytes. Bröer S, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):863–70

Role of PM–ATPase, amino acid transport and free amino acid pool in the salt stress of, Candida membranefaciens. Khaware RK, et al. **Biochem Mol Biol Int** 1996 Mar; 38(3):635–43

Status of membrane lipids and amino acid transport in morphological mutants of Candida albicans. Koul A, et al. **Biochem Mol Biol Int** 1995 May;35(6):1215–22

Direct determination of the membrane affinities of individual amino acids. Thorgeirsson TE, et al. **Biochemistry** 1996 Feb 13;35(6):1803–9

Formation of the amino acid–DNA complexes by hexavalent and trivalent chromium in vitro: importance of trivalent chromium and the phosphate group. Zhitkovich A, et al. **Biochemistry** 1996 Jun 4;35(22):7275–82

Influence of leucine on intestinal baclofen absorption as a model compound of neutral alpha–aminoacids. Cercós–Fortea T, et al. **Biopharm Drug Dispos** 1995 Oct; 16(7):563–77

Membrane potential of rat hepatoma cells in culture: influence of factors affecting amino acid transport. Mouat MF, et al. **Biosci Rep** 1995 Aug;15(4):173–84

Metabolic and endocrine changes induced by chronic heat exposure in broiler chickens: biological and endocrinological variables. Geraert PA, et al. **Br J Nutr** 1996 Feb;75(2):205–16

Splanchnic–bed transfers of amino acids in sheep blood and plasma, as monitored through use of a multiple U–13C–labelled amino acid mixture. Lobley GE, et al. **Br J Nutr** 1996 Feb;75(2):217–35

Kinetics of amino acid and glucose absorption following pancreatic diversion in the pig. Rérat A, et al. **Br J Nutr** 1996 Feb;75(2):175–93

Amino acid partitioning and milk protein synthesis [letter] Wilde CJ, et al. **Br J Nutr** 1996 Jan;75(1):139–40

The effect of cottonseed condensed tannins on the ileal digestibility of amino acids in casein and cottonseed kernel. Yu F, et al. **Br J Nutr** 1996 May;75(5):683–98

Incorporation of amino acids into the axoplasm is enhanced by electrical stimulation of the fiber. Eugenin J, et al. **Brain Res** 1995 Apr 24;677(2):319–25

Intrastriatal injections of the succinate dehydrogenase inhibitor, malonate, cause a rise in extracellular amino acids that is blocked by MK–801. Messam CA, et al. **Brain Res** 1995 Jul 3;684(2):221–4

Release of excitatory and inhibitory amino acids from the locus coeruleus of conscious rats by cardiovascular stimuli and various forms of acute stress. Singewald N, et al. **Brain Res** 1995 Dec 15;704(1):42–50

Accumulation of anthracenyl–amino acid topoisomerase I and II inhibitors in drug–sensitive and drug–resistant human ovarian cancer cell lines determined by high–performance liquid chromatography. Cummings J, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):103–9

Tumor cell invasion of basement membrane in vitro is regulated by amino acids. Singh RK, et al. **Cancer Invest** 1996;14(1):6–18

Changes in intracellular concentration of amino acids in human saphenous vein during preparation for coronary artery bypass grafting. Suleiman MS, et al. **Cardiovasc Res** 1995 Nov;30(5):747–54

A 24–patient experience in hyperalimentation for acute renal insufficiency: emphasis on amino acid determination. Kung SP, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Oct; 56(4):252–7

The concentrations of free amino acids in human liver tissue obtained during laparoscopic surgery. Barle H, et al. **Clin Physiol** 1996 May;16(3):217–27

Muscle protein and amino acid turnover in rats in vivo: effects of short–term and prolonged starvation. de Blaauw I, et al. **Clin Sci (Colch)** 1996 Jun;90(6):457–66

Free amino acids in the hemolymph of the cockroach, Blaberus discoidalis. Sowa SM, et al. **Comp Biochem Physiol A Physiol** 1996 Feb;113(2):131–4

Activities of carbohydrate and amino acid metabolizing enzymes from liver of mink (Mustela vison) and preliminary observations on steady state kinetics of the enzymes. Sørensen PG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Sep; 112(1):59–64

Amino acid transporters. Kinne RK. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):412–5 (36 ref.)

Flow cytometric determination of aminopeptidase activities in viable cells using fluorogenic rhodamine 110 substrates. Ganesh S, et al. **Cytometry** 1995 Aug 1;20(4):334–40

Differential responsiveness of protein synthesis and degradation to amino acid availability in humans. Giordano M, et al. **Diabetes** 1996 Apr;45(4):393–9

Contribution of amino acids and insulin to protein anabolism during meal absorption. Volpi E, et al. **Diabetes** 1996 Sep; 45(9):1245–52

Effects of tryptophan load on amino acid metabolism in type 1 diabetic patients. Fierabracci V, et al. **Diabetes Metab** 1996 Feb;22(1):51–6

Critical amino acid residues for ligand binding are clustered in a predicted beta–turn of the third N–terminal repeat in the integrin alpha 4 and alpha 5 subunits. Irie A, et al. **EMBO J** 1995 Nov 15;14(22):5550–6

Biosynthetically directed fractional 13C–labeling of proteinogenic amino acids. An efficient analytical tool to investigate intermediary metabolism. Szyperski T. **Eur J Biochem** 1995 Sep 1;232(2):433–48

Excretion of amino acid residues from diets based on low–fibre wheat or high–fibre rye bread in human subjects with ileostomies. Abrahamsson M, et al. **Eur J Clin Nutr** 1995 Aug;49(8):589–95

Excretion of amino acid residues from diets based on wheat flour or oat bran in human subjects with ileostomies. Abrahamsson M, et al. **Eur J Clin Nutr** 1995 Aug; 49(8):596–604

Quantitative evaluation of neutral amino acid transport in cerebral gliomas using positron emission tomography and fluorine–18 fluorophenylalanine. Ogawa T, et al. **Eur J Nucl Med** 1996 Aug;23(8):889–95

Dual inhibitory action of enadoline (CI977) on release of amino acids in the rat hippocampus. Millan MH, et al. **Eur J Pharmacol** 1995 Jun 6;279(1):75–81

Effect of alpha 2–adrenergic drugs dexmedetomidine and atipamezole on extracellular amino acid levels in vivo. Valtonen P, et al. **Eur J Pharmacol** 1995 Oct 24; 285(3):239–46

Insulin stimulates cationic amino acid transport activity in the isolated perfused rat pancreas. Muñoz M, et al. **Exp Physiol** 1995 Sep;80(5):745–53

Effect of nonprotein thiols on protein synthesis in isolated rat hepatocytes. Asensi M, et al. **Experientia** 1996 Feb 15; 52(2):111–4

The stimulation of Na,K,Cl cotransport and of system A for neutral amino acid transport is a mechanism for cell volume increase during the cell cycle. Bussolati O, et al. **FASEB J** 1996 Jun;10(8):920–6 (49 ref.)

Identification of critical amino acids involved in alpha1–beta interaction in voltage–dependent Ca?+ channels. De Waard M, et al. **FEBS Lett** 1996 Feb 19;380(3):272–6

Carbohydrate and amino acid metabolism in Giardia: a review. Jarroll EL, et al. **Folia Parasitol (Praha)** 1995; 42(2):81–9 (49 ref.)

Role of intraduodenal proteases in plasma cholecystokinin and pancreaticobiliary responses to protein and amino acids. Thimister PW, et al. **Gastroenterology** 1996 Feb; 110(2):567–75

Amino acid substitutions in the structured domains of histones H3 and H4 partially relieve the requirement of the yeast SWI/SNF complex for transcription. Kruger W, et al. **Genes Dev** 1995 Nov 15;9(22):2770–9

Aminoacid utilization by Helicobacter pylori. Mendz GL, et al. **Int J Biochem Cell Biol** 1995 Oct;27(10):1085–93

Brain large neutral amino acids and catecholamines in parenterally nourished preterm rabbits. Lopez SM, et al. **Int J Dev Neurosci** 1995 Oct;13(6):619–26

The importance of the hydrophobic components of the binding energies in the interaction of omega–amino acid ligands with isolated kringle polypeptide domains of human plasminogen. Menhart N, et al. **Int J Pept Protein Res** 1995 Dec;46(6):464–70

Effects of tumor necrosis factor alpha on skeletal muscle amino acid metabolism studied in–vivo. Tayek JA. **J Am Coll Nutr** 1996 Apr;15(2):164–8

Failure of intestinal amino acid absorptive mechanisms in sepsis. Gardiner KR, et al. **J Am Coll Surg** 1995 Nov; 181(5):431–6

Regulation of organic nutrient metabolism during transition from late pregnancy to early lactation. Bell AW. **J Anim Sci** 1995 Sep;73(9):2804–19 (117 ref.)

Determination of apparent ileal amino acid digestibility in barley and canola meal for pigs with the direct, difference, and regression methods. Fan MZ, et al. **J Anim Sci** 1995 Aug;73(8):2364–74

Effect of intraruminal propionic acid infusion on metabolism of mesenteric– and portal–drained viscera in growing steers fed a forage diet: II. Ammonia, urea, amino acids, and peptides. Seal CJ, et al. **J Anim Sci** 1996 Jan;74(1):245–56

Amino acid requirements and peptidase activities of Streptococcus salivarius subsp. thermophilus. Neviani E, et al. **J Appl Bacteriol** 1995 Sep;79(3):302–7

Amino acids induce expression of BAP2, a branched–chain amino acid permease gene in Saccharomyces cerevisiae. Didion T, et al. **J Bacteriol** 1996 Apr;178(7):2025–9

Formation of indigo and related compounds from indolecarboxylic acids by aromatic acid–degrading bacteria: chromogenic reactions for cloning genes encoding dioxygenases that act on aromatic acids. Eaton RW, et al. **J Bacteriol** 1995 Dec;177(23):6983–8

A modified two–component regulatory system is involved in temperature–dependent biosynthesis of the Pseudomonas syringae phytotoxin coronatine. Ullrich M, et al. **J Bacteriol** 1995 Nov;177(21):6160–9

Functional analysis of sequences adjacent to dapE of Corynebacterium glutamicum reveals the presence of aroP, which encodes the aromatic amino acid transporter. Wehrmann A, et al. **J Bacteriol** 1995 Oct;177(20):5991–3

Kinetics and specificity of a H+/amino acid transporter from Arabidopsis thaliana. Boorer KJ, et al. **J Biol Chem** 1996 Jan 26;271(4):2213–20

Short and long range functions of amino acids in the transmembrane region of the sarcoplasmic reticulum ATPase. A mutational study. Chen L, et al. **J Biol Chem** 1996 May 3;271(18):10745–52

Platelet–derived growth factor regulates vascular smooth muscle cell proliferation by inducing cationic amino acid transporter gene expression. Durante W, et al. **J Biol Chem** 1996 May 17;271(20):11838–43

The role of carboxyl–terminal basic amino acids in Gqalpha–dependent activation, particulate association, and nuclear localization of phospholipase C–beta1. Kim CG, et al. **J Biol Chem** 1996 Aug 30;271(35):21187–92

Role of oxoproline in the regulation of neutral amino acid transport across the blood–brain barrier. Lee WJ, et al. **J Biol Chem** 1996 Aug 9;271(32):19129–33

Effects of truncation of the COOH–terminal region of a Na+–independent neutral and basic amino acid transporter on amino acid transport in Xenopus oocytes. Miyamoto K, et al. **J Biol Chem** 1996 Jul 12;271(28):16758–63

Retinoid X receptor alters the determination of DNA binding specificity by the P–box amino acids of the thyroid hormone receptor. Nelson CC, et al. **J Biol Chem** 1996 Aug 9;271(32):19464–74

Identification of essential residues for the catalytic function of 85–kDa cytosolic phospholipase A2. Probing the role of histidine, aspartic acid, cysteine, and arginine. Pickard RT, et al. **J Biol Chem** 1996 Aug 9;271(32):19225–31

Expression of vaccinia virus K3L protein in yeast inhibits eukaryotic initiation factor–2 kinase GCN2 and the general amino acid control pathway. Qian W, et al. **J Biol Chem** 1996 May 31;271(22):13202–7

Cloning and functional characterization of a system ASC–like Na+–dependent neutral amino acid transporter. Utsunomiya–Tate N, et al. **J Biol Chem** 1996 Jun 21; 271(25):14883–90

Amino acid residue at codon 268 determines both activity and nucleotide–sugar donor substrate specificity of human histo–blood group A and B transferases. In vitro mutagenesis study. Yamamoto F, et al. **J Biol Chem** 1996 May 3;271(18):10515–20

Dependence of adaptative regulation for IL–1 beta action on system A activity in human synovial cells. Le Maire V, et al. **J Cell Physiol** 1996 Sep;168(3):721–6

Secondary elevation of extracellular neurotransmitter amino acids in the reperfusion phase following focal cerebral ischemia. Matsumoto K, et al. **J Cereb Blood Flow Metab** 1996 Jan;16(1):114–24

Evidence for an interaction between cationic and neutral amino acids at the blood–facing aspect of the lactating rat mammary epithelium. Calvert DT, et al. **J Dairy Res** 1996 Feb;63(1):25–33

Effects of forage percentage and canola seed on ruminal protein metabolism and duodenal flows of amino acids in steers. Hussein HS, et al. **J Dairy Sci** 1996 Jan;79(1):98–104

Influence of moist heat treatment on ruminal and intestinal disappearance of amino acids from canola meal. Moshtaghi Nia SA, et al. **J Dairy Sci** 1995 Jul;78(7):1552–60

Demonstration of in vivo metabolic effects of 3,5–di–iodothyronine. Cimmino M, et al. **J Endocrinol** 1996 May;149(2):319–25

Inhibition of protein synthesis and amino acid transport by crystal violet in Trypanosoma cruzi. Hoffmann ME, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):293–7

Amino–acid–dependent modulation of amino acid transport in Xenopus laevis oocytes. Taylor PM, et al. **J Exp Biol** 1996 Apr;199 (Pt 4):923–31

In vivo amino acid fluxes in regenerating liver after two–thirds hepatectomy in the rat. Brand HS, et al. **J Hepatol** 1995 Sep;23(3):333–40

The acute effects of TNF–alpha on the isolated perfused rat liver. Shattuck KE, et al. **J Investig Med** 1996 Feb; 44(2):64–9

Amino acid current through anion channels in cultured human glial cells. Roy G. **J Membr Biol** 1995 Sep; 147(1):35–44

The role of the proton electrochemical gradient in the transepithelial absorption of amino acids by human intestinal Caco–2 cell monolayers. Thwaites DT, et al. **J Membr Biol** 1995 Jun;145(3):245–56

Two amino acid residues from the DNA–binding domain of MalT play a crucial role in transcriptional activation. Danot O, et al. **J Mol Biol** 1996 Sep 13;262(1):1–11

Tetanus toxin–induced effects on extracellular amino acid levels in rat hippocampus: an in vivo microdialysis study. Britton P, et al. **J Neurochem** 1996 Jul;67(1):324–9

N–system amino acid transport at the blood—CSF barrier. Keep RF, et al. **J Neurochem** 1995 Dec;65(6):2571–6

Quantitative changes of amino acid distributions in the rat vestibular nuclear complex after unilateral vestibular ganglionectomy. Li H, et al. **J Neurochem** 1996 Apr; 66(4):1550–64

Acute and repeated systemic amphetamine administration: effects on extracellular glutamate, aspartate, and serine levels in rat ventral tegmental area and nucleus accumbens. Xue CJ, et al. **J Neurochem** 1996 Jul;67(1):352–63

Spinal amino acid release and precipitated withdrawal in rats chronically infused with spinal morphine. Jhamandas KH, et al. **J Neurosci** 1996 Apr 15;16(8):2758–66

Capillary electrophoresis with laser–induced fluorescence detection: a sensitive method for monitoring extracellular concentrations of amino acids in the periaqueductal grey matter. Bergquist J, et al. **J Neurosci Methods** 1996 Mar;

65(1):33–42

Release of brain amino acids during hyposmolar stress and energy deprivation. Haugstad TS, et al. **J Neurosurg Anesthesiol** 1996 Apr;8(2):159–68

Recombinant bovine somatotropin decreases hepatic amino acid catabolism in female rats. Blemings KP, et al. **J Nutr** 1996 Jun;126(6):1657–61

Ribonucleic acid nucleotides in maternal and fetal tissues derive almost exclusively from synthesis de novo in pregnant mice. Boza JJ, et al. **J Nutr** 1996 Jul; 126(7):1749–58

Gut endogenous nitrogen and amino acid excretions in adult domestic cats fed a protein-free diet or an enzymatically hydrolyzed casein-based diet. Hendriks WH, et al. **J Nutr** 1996 Apr;126(4):955–62

Interactions between ruminal degradable nitrogen intake and in vitro addition of substrates on patterns of amino acid metabolism in isolated ovine hepatocytes. Mutsvangwa T, et al. **J Nutr** 1996 Jan;126(1):209–18

Ruminal microbial metabolism of peptides and amino acids. Wallace RJ. **J Nutr** 1996 Apr;126(4 Suppl):1326S–34S (79 ref.)

Recent advances in methods of assessing dietary amino acid requirements for adult humans. Zello GA, et al. **J Nutr** 1995 Dec;125(12):2907–15 (64 ref.)

Differential effects of unique profile antipsychotic drugs on extracellular amino acids in the ventral pallidum and globus pallidus of rats. Chapman MA, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1586–94

Deamination of amino acids as a source for ammonia production in human skeletal muscle during prolonged exercise. van Hall G, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):251–61

Amino acids critical for the functions of the bovine papillomavirus type 1 E2 transactivator. Brokaw JL, et al. **J Virol** 1996 Jan;70(1):23–9

Microdialysis as a tool to measure dietary and regional effects on the complete profile of extracellular amino acids in the hypothalamus of rats. Currie PJ, et al. **Life Sci** 1995; 57(21):1911–23

Effect of stress on amino acids and related compounds in various tissues of the rat. Decker R, et al. **Life Sci** 1995; 57(19):1781–90

The effects of arginine administration on the levels of arginine, other amino acids and related amino compounds in the plasma, heart, aorta, vena cava, bronchi and pancreas of the rat. Noeh FM, et al. **Life Sci** 1996;58(8):PL131–8

Estrogen effects on blood amino acid compartmentation. Proenza AM, et al. **Life Sci** 1995;57(17):1589–97

Proton exchange rates from amino acid side chains—implications for image contrast. Liepinsh E, et al. **Magn Reson Med** 1996 Jan;35(1):30–42

Role of oxidized amino acids in protein breakdown and stability. Stadtman ER. **Methods Enzymol** 1995;258:379–93 (56 ref.)

Uptake of amino acids by the parasitic, flagellated protist Trichomonas vaginalis. Zuo X, et al. **Microbiology** 1995 Oct;141 (Pt 10):2637–42

Acid-extractable amino acid pool in Escherichia coli: possible role in energy-independent amino acid accumulation and protein synthesis. Miseta A, et al. **Microbios** 1995;84(341):207–19

Neurotransmitter and monoaminergic amino acid precursor levels in rat brain: effects of chronic renal failure and of malnutrition. Schmid G, et al. **Miner Electrolyte Metab** 1996;22(1–3):115–8

Amino acid uptake in skeletal muscle of rats bearing the Yoshida AH-130 ascites hepatoma. García-Martínez C, et al. **Mol Cell Biochem** 1995 Jul 5;148(1):17–23

Evidence for two aromatic amino acid-binding sites, one ATP-dependent and the other ATP-independent, in the Escherichia coli regulatory protein TyrR. Wilson TJ, et al. **Mol Microbiol** 1995 Aug;17(3):483–92

Ribozyme-catalysed amino-acid transfer reactions. Lohse PA, et al. **Nature** 1996 May 30;381(6581):442–4

The imbalance of brain large-chain aminoacid availability in amyotrophic lateral sclerosis patients treated with high doses of branched-chain aminoacids. Bastone A, et al. **Neurochem Int** 1995 Dec;27(6):467–72

Effects of aging on regional rates of cerebral protein synthesis in the Sprague-Dawley rat: examination of the influence of recycling of amino acids derived from protein degradation into the precursor pool. Smith CB, et al. **Neurochem Int** 1995 Oct-Nov;27(4–5):407–16

In vivo studies on NMDA-evoked release of amino acids in the rat spinal cord. Sundström E, et al. **Neurochem Int** 1995 Aug;27(2):185–93

CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Shaw PJ, et al. **Neurodegeneration** 1995 Jun;4(2):209–16

Serial positron emission tomography imaging of changes in amino acid metabolism in low grade astrocytoma after radio- and chemotherapy— Case report. Sato K, et al. **Neurol Med Chir (Tokyo)** 1995 Nov;35(11):808–12

Changes in brain amino acid content induced by hyposmolar stress and energy deprivation. Haugstad TS, et al. **Neurol Res** 1995 Dec;17(6):402–8

Effect of lamotrigine on the electrically-evoked release of endogenous amino acids from slices of dorsal horn of the rat spinal cord. Teoh H, et al. **Neuropharmacology** 1995 Oct;34(10):1273–8

Effects of interleukin-1 beta and interleukin-2 on amino acids levels in mouse cortex and hippocampus. Bianchi M, et al. **Neuroreport** 1995 Aug 21;6(12):1689–92

Effect of local cholecystokinin-8 administration on extracellular levels of amino acids and glycolytic products monitored by in vivo microdialysis in the fronto-parietal cortex of the rat. Godukhin O, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):29–32

Aminoacid recovery via microdialysis and photoinduced focal cerebral ischemia in brain cortex of rats. Montalbetti L, et al. **Neurosci Lett** 1995 Jun 16;192(3):153–6

Characteristics of substance P-evoked release of amino acids from neonatal rat spinal cord. Maehara T, et al. **Neuroscience** 1995 Sep;68(2):577–84

Covalent cross-linking of liver collagen by pyridinoline increases in the course of experimental alveolar echinococcosis. Ricard-Blum S, et al. **Parasite** 1995 Jun; 2(2):113–8

Intracellular amino acid concentrations in children with chronic renal insufficiency. Kist-van Holthe tot Echten J, et al. **Pediatr Nephrol** 1996 Feb;10(1):46–50

Changes in amino acid levels in rat plasma, cisternal cerebrospinal fluid, and brain tissue induced by intravenously infused arginine-vasopressin. Reichel A, et al. **Peptides** 1995;16(5):965–71

Renal handling of drugs and amino acids after impairment of kidney or liver function—influences of maturity and protective treatment. Fleck C, et al. **Pharmacol Ther** 1995; 67(1):53–77 (341 ref.)

Effects of electromagnetic fields and gender on neurotransmitters and amino acids in rats. Chance WT, et al. **Physiol Behav** 1995 Oct;58(4):743–8

Amino acid transport in the small intestine [corrected and republished with original paging, article originally printed in Physiol Res 1994;43(6):335–45] Munck LK, et al. **Physiol Res** 1995;44(2):335–46 (116 ref.)

A new 1-aminocyclopropane-1-carboxylic acid-conjugating activity in tomato fruit. Martin MN, et al. **Plant Physiol** 1995 Nov;109(3):917–26

Dietary formulation with cottonseed meal on a total amino acid versus a digestible amino acid basis. Fernandez SR, et al. **Poult Sci** 1995 Jul;74(7):1168–79

Metabolizable energy and amino acid availability of full-fat seeds, meals, and oils of flax and canola. Lee KH, et al. **Poult Sci** 1995 Aug;74(8):1341–8

Aromatic amino acid transamination and methionine recycling in trypanosomatids. Berger BJ, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4126–30

Altered tissue amino acid metabolism in acute T-2 toxicosis. Meloche JL, et al. **Proc Soc Exp Biol Med** 1995 Dec; 210(3):260–5

Neutral amino acid availability in two major psychiatric disorders. Lucca A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):615–26

The use of natural and unnatural amino acid substrates to define the substrate specificity differences of Escherichia coli aspartate and tyrosine aminotransferases. Onuffer JJ, et al. **Protein Sci** 1995 Sep;4(9):1743–9

Influence of organic cations on basic amino-acid uptake by human placental villi. Krishna RB, et al. **Reprod Fertil Dev** 1995;7(6):1491–4

Quantitative aspects of blood and amino acid flows in cattle. Lescoat P, et al. **Reprod Nutr Dev** 1996;36(2):137–74 (158 ref.)

Comment on "Convergent evolution of amino acid usage in archaebacterial and eubacterial lineages adapted to high salt", by M. Gandbhir et al. (Res. Microbiol., 1995, 146, 113–120) [letter; comment] Oren A. **Res Microbiol** 1995 Nov-Dec;146(9):805–6. Comment on: Res Microbiol 1995 Feb;146(2):113–20.

Amino acid metabolism and the vascular endothelium: regulation and disease implications [editorial] Pan M, et al. **Shock** 1995 Aug;4(2):79–88 (96 ref.)

Sequential alterations in gut mucosal amino acid and glucose transport after 70% small bowel resection. Sarac TP, et al. **Surgery** 1996 Sep;120(3):503–8

Changes in cerebellar amino acid neurotransmitter concentrations and receptors following administration of the neurotoxin L-2-chloropropionic acid. Widdowson PS, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):57–66

Renal amino acid transport in immature and adult rats during thallium-induced nephrotoxicity. Fleck C, et al. **Toxicology** 1996 Jan 8;106(1–3):229–36

Unique organ specific characteristics of amino acid metabolism in early development. Battaglia FC, et al. **Trans Am Clin Climatol Assoc** 1994;106:141–9; discussion 149–50 (22 ref.)

Interactions in glycine and methionine uptake, conversion and incorporation into proteins in the preimplantation mouse embryo. Khatchadourian C, et al. **Zygote** 1994 Nov; 2(4):301–6

[Changes of amino acids release in rat's hippocampus during kainic acid induced epilepsy and acupuncture] Liu J, et al. **Chen Tzu Yen Chiu** 1995;20(3):50–4 (Eng. Abstr.) **(Chi)**

[Dynamic changes of amino acids in extracellular fluid in rat hippocampus in cases of cerebral ischemia] Li J, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Apr;76(4):294–6 (Eng. Abstr.) **(Chi)**

[Time course of amino acid absorption in growing rats after feeding of a 15N-labeled wheat/yeast ration] Krawielitzki K, et al. **Arch Tierernahr** 1995;48(1–2):37–51 (Eng. Abstr.) **(Ger)**

[Determination of true digestibility of amino acids from the small intestine of dairy cows] Lebzien P, et al. **Arch Tierernahr** 1994;45(4):355–62 (Eng. Abstr.) **(Ger)**

[Concurrent characterization of spinal amino acid release and touch-evoked allodynia produced by spinal glycine or GABAA receptor antagonists] Ishikawa T, et al. **Masui** 1996 Apr;45(4):439–44 (Eng. Abstr.) **(Jpn)**

[Increase in extracellular levels of serotonin and amino acids in the rat brain following cyanide-induced energy failure] Yamazaki Y, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Aug; 15(4):323–33 (Eng. Abstr.) **(Jpn)**

[The characteristics of amino acid transport in the small intestine of chicks with avitaminosis A] Basova NA, et al. **Fiziol Zh Im I M Sechenova** 1995 Jul;81(7):40–7 (Eng. Abstr.) **(Rus)**

[The effect of autolysis on characteristics of amino acid mixtures, obtained using ethanol-assimilating yeasts] Belousova NI, et al. **Prikl Biokhim Mikrobiol** 1995 Jul-Aug;31(4):458–62 (Eng. Abstr.) **(Rus)**

[The amino acid pool of the liver during activation of glutathione synthesis] Nefedov LI, et al. **Ukr Biokhim Zh** 1995 Jul-Aug;67(4):24–9 (Eng. Abstr.) **(Rus)**

[Brain and liver amino acids in rats with portacaval anastomosis in acute alcoholic intoxication] Ostrovskiĭ SIu, et al. **Ukr Biokhim Zh** 1995 Sep-Oct;67(5):93–9 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Tumour growth results in changes in placental amino acid transport in the rat: a tumour necrosis factor alpha-mediated effect. Carbó N, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):77–82

In vitro adsorption of amino acids onto isolated rat erythrocyte membranes. Pico C, et al. **Int J Biochem Cell Biol** 1995 Aug;27(8):761–5

1-Aminocyclopropanecarboxylic acid: mouse to man interspecies pharmacokinetic comparisons and allometric relationships. Cherkofsky SC. **J Pharm Sci** 1995 Oct; 84(10):1231–5

Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7–36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Young AA, et al. **Metabolism** 1996 Jan; 45(1):1–3

Is a clinical application of hybrid liver support systems limited by an initial disorder in cellular amino acid and alpha-keto acid metabolism, rather than by later gradual loss of primary hepatocyte function? Gerlach JC, et al. **Transplantation** 1996 Jul 27;62(2):224–8

PHARMACOLOGY

Efficacy of high dose amino acid solution on spinal cord injury induced by focal Nd:YAG laser irradiation. Colak A, et al. **Acta Neurochir (Wien)** 1995;133(1–2):73–9

Functional properties of mesothelial cells after prolonged exposure to dialysate effluent. Breborowicz A, et al. **Adv Perit Dial** 1995;11:15–8

Effect of angiotensin II on the renal response to amino acid in rats. Garcia GE, et al. **Am J Kidney Dis** 1996 Jul; 28(1):115–23

Response of leucine metabolism to hyperinsulinemia under amino acid replacement in experimental hyperthyroidism. Tauveron I, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E499–507

Renal responses to amino acids in the sheep fetus. Woods LL, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1226–30

In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain. Cavadas C, et al. **Arzneimittelforschung** 1995 Jul; 45(7):753–5

Detailed behavioral analysis of water maze acquisition under systemic NMDA or muscarinic antagonism: nonspatial pretraining eliminates spatial learning deficits. Saucier D, et al. **Behav Neurosci** 1996 Feb;110(1):103–16

Effects of new endogenous nonprotein amino acids, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives, on behavior of mice. Nakagawa H, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):1027–34

Rhodamine 123 efflux transporter in Haloferax volcanii is induced when cultured under 'metabolic stress' by amino acids: the efflux system resembles that in a doxorubicin-resistant mutant. Kaidoh K, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):355–9

NAD-glutamate dehydrogenase from Halobacterium halobium: inhibition and activation by TCA intermediates and amino acids. Bonete MJ, et al. **Biochim Biophys Acta** 1996 Feb 9;1289(1):14–24

Stability studies on pig heart mitochondrial malate dehydrogenase: the effect of salts and amino acids. Jensen WA, et al. **Biochim Biophys Acta** 1996 Aug 15; 1296(1):23–34

Protective effects of neutral amino acids against amphipathic drug-induced hemolysis. Morimoto Y, et al. **Biol Pharm Bull** 1995 Nov;18(11):1535–8

Protective effects of some neutral amino acids against hypotonic hemolysis. Morimoto Y, et al. **Biol Pharm Bull** 1995 Oct;18(10):1417–22

Calcification of pericardial tissue pretreated with different

amino acids. Jorge-Herrero E, et al. **Biomaterials** 1996 Mar; 17(6):571-5

Brain tissue hydrolysate acts on presynaptic adenosine receptors in the rat hippocampus. Xiong H, et al. **Can J Physiol Pharmacol** 1995 Aug;73(8):1194-7

Tumor cell invasion of basement membrane in vitro is regulated by amino acids. Singh RK, et al. **Cancer Invest** 1996;14(1):6-18

Influence of amino acids on the formation of mutagenic/carcinogenic heterocyclic amines in a model system. Johansson MA, et al. **Carcinogenesis** 1995 Oct; 16(10):2553-60

Imprinting effects of three amino acids (alanine, lysine and glycine) and their oligopeptides in Tetrahymena pyriformis. Data from the hormone and hormone receptor evolution. Csaba G, et al. **Cell Biol Int** 1996 May;20(5):339-42

In vitro study of the metabolic effects of D-amino acids. Ercal N, et al. **Chirality** 1996;8(1):24-9

Metabolic, thermal and circulatory effects of intravenous infusion of amino acids in tetraplegic patients. Aksnes AK, et al. **Clin Physiol** 1995 Jul;15(4):377-96

Computer-aided comparison of the inhibition of arginase and nitric oxide synthase in macrophages by amino acids not related to arginine. Hrabák A, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Feb; 113(2):375-81

Interaction between propranolol and amino acids in the single-pass isolated, perfused rat liver. Semple HA, et al. **Drug Metab Dispos** 1995 Aug;23(8):794-8

Gastrin sensitivity of primary human colorectal cancer: the effect of gastrin receptor antagonism. Watson SA, et al. **Eur J Cancer** 1995 Nov;31A(12):2086-92

High and low affinity transport of L-arginine in rat brain synaptosomes. Tan CH, et al. **Experientia** 1995 Nov 15; 51(11):1052-4

Intraduodenal fat and amino acids activate gallbladder motility in the rainbow trout, Oncorhynchus mykiss. Aldman G, et al. **Gen Comp Endocrinol** 1995 Oct; 100(1):27-32

Protection by selective amino acid solutions against doxorubicin induced growth inhibition of Escherichia coli. Amash HS, et al. **Gen Pharmacol** 1995 Sep;26(5):983-7

Effects of amino acids on the development of in-vitro matured/in-vitro fertilization bovine embryos in a simple protein-free medium. Liu Z, et al. **Hum Reprod** 1995 Nov; 10(11):2985-91

Effect of form of nitrogen on growth of ruminal microbes in continuous culture. Griswold KE, et al. **J Anim Sci** 1996 Feb;74(2):483-91

Amino-acid-dependent modulation of amino acid transport in Xenopus laevis oocytes. Taylor PM, et al. **J Exp Biol** 1996 Apr;199 (Pt 4):923-31

Regulatory volume decrease in cultured kidney cells (A6): role of amino acids. De Smet P, et al. **J Gen Physiol** 1995 Sep;106(3):525-42

Protective properties of amino acids in liver preservation: effects of glycine and a combination of amino acids on anaerobic metabolism and energetics. Churchill TA, et al. **J Hepatol** 1995 Dec;23(6):720-6

Residues in TAP2 peptide transporters controlling substrate specificity. Momburg F, et al. **J Immunol** 1996 Mar 1; 156(5):1756-63

Defects in courtship and vision caused by amino acid substitutions in a putative RNA-binding protein encoded by the no-on-transient A (nonA) gene of Drosophila. Rendahl KG, et al. **J Neurosci** 1996 Feb 15;16(4):1511-22

Amino acids and glucose differentially increased extracellular 5-hydroxyindoleacetic acid in the rat brain. Yamauchi A, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun;41(3):325-40

c-myc mRNA is stabilized by deprivation of amino acids in primary cultured rat hepatocytes. Yokota T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Aug;41(4):455-63

Effect of parenteral amino acids on leucine and urea kinetics in preterm infants. Battista MA, et al. **J Pediatr** 1996 Jan; 128(1):130-4

Amino acid-induced [Ca2+]i oscillations in single mouse pancreatic islets of Langerhans. Martin F, et al. **J Physiol (Lond)** 1995 Jul 15;486 (Pt 2):361-71

The effects of light exposure on the in vitro hepatic response to an amino acid-vitamin solution. Shattuck KE, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep-Oct;19(5):398-402

Development of responses to excitatory and inhibitory amino acids in spiking cells during retinal regeneration in the adult newt. Chiba C, et al. **Jpn J Physiol** 1995;45(5):869-87

Responses mediated by excitatory and inhibitory amino acid receptors in solitary spiking cells from normal newt retina. Chiba C, et al. **Jpn J Physiol** 1995;45(5):849-67

Microdialysis as a tool to measure dietary and regional effects on the complete profile of extracellular amino acids in the hypothalamus of rats. Currie PJ, et al. **Life Sci** 1995; 57(21):1911-23

End-product control of enzymes of branched-chain amino acid biosynthesis in Streptomyces coelicolor. Potter CA, et al. **Microbiology** 1996 Aug;142 (Pt 8):1945-52

Sustained exposure to 1-aminocyclopropanecarboxylic acid, a glycine partial agonist, alters N-methyl-D-aspartate receptor function and subunit composition. Fossom LH, et al. **Mol Pharmacol** 1995 Dec;48(6):981-7

Pharmacology of the inhibitory glycine receptor: agonist and antagonist actions of amino acids and piperidine carboxylic acid compounds. Schmieden V, et al. **Mol Pharmacol** 1995 Nov;48(5):919-27

Analysis of stimulatory and inhibitory amino acids for development of hamster one-cell embryos in vitro. McKiernan SH, et al. **Mol Reprod Dev** 1995 Oct; 42(2):188-99

Effect of amino acids on the excretions of purine bases and oxypurinol. Yamamoto T, et al. **Nephron** 1996;73(1):41-7

Pharmacology of metabotropic glutamate receptor-mediated enhancement of responses to excitatory and inhibitory amino acids on rat spinal neurones in vivo. Bond A, et al. **Neuropharmacology** 1995 Aug;34(8):1015-23

Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study. Francis-Turner L, et al. **Neurosci Lett** 1996 Jan 5;202(3):193-6

An electrophysiological study on amino acid sensors in the hepato-portal system in the rat. Niijima A, et al. **Obes Res** 1995 Dec;3 Suppl 5:741S-745S

Liver denervation attenuates the hypophagia produced by an imbalanced amino acid diet. Bellinger LL, et al. **Physiol Behav** 1996 Apr-May;59(4-5):925-9

Coi1-dependent expression of an Arabidopsis vegetative storage protein in flowers and siliques and in response to coronatine or methyl jasmonate. Benedetti CE, et al. **Plant Physiol** 1995 Oct;109(2):567-72

Effects of amino acids on the growth of an anaerobic rumen fungus Neocallimastix sp N 13. Onoda A, et al. **Reprod Nutr Dev** 1996;36(3):311-20

Comparative changes in the liver of female Fischer-344 rats after short-term feeding of a semipurified or a semisynthetic L-amino acid-defined choline-deficient diet. Nakae D, et al. **Toxicol Pathol** 1995 Sep-Oct;23(5):583-90

[Interference observed in creatinine assays in peritoneal dialysis solutions containing amino-acids (letter)] Parent X, et al. **Ann Biol Clin (Paris)** 1995;53(6):357-8 **(Fre)**

[Growth inhibition effect of amino acids on obligate oligotrophs isolated from clinical materials] Tada Y. **Kansenshogaku Zasshi** 1995 Jul;69(7):846-7 **(Jpn)**

[Suppression of anti-Candida activity of human neutrophils by glucose and diminishment of the glucose effect by an amino acid mixture] Tansho T, et al. **Kansenshogaku Zasshi** 1996 May;70(5):463-9 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links [see comments] Gunja-Smith Z, et al. **Am J Pathol** 1996 May;148(5):1639-48. Comment in: Am J Pathol 1996 May;148(5):1345-50.

Role of hydrophobic amino acids at position 74 of DRB1 chain in rheumatoid arthritis. Cerná M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):139-44 (40 ref.)

Suppression of Ca2+ oscillations in glucagon-producing alpha 2-cells by insulin/glucose and amino acids. Berts A, et al. **Biochim Biophys Acta** 1996 Feb 2;1310(2):212-6

Amino acid residues on the I-Ak alpha-chain required for the binding and stability of two antigenic peptides. Nelson CA, et al. **J Immunol** 1996 Jan 1;156(1):176-82

Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. Shastri N, et al. **J Immunol** 1995 Nov 1; 155(9):4339-46

Isolation and characterization of IS10 transposase separation of function mutants: identification of amino acid residues in transposase that are important for active site function and the stability of transposition intermediates. Kennedy AK, et al. **J Mol Biol** 1996 Mar 1;256(3):533-47

New views on the pathogenesis of kwashiorkor: methionine and other amino acids. Roediger WE. **J Pediatr Gastroenterol Nutr** 1995 Aug;21(2):130-6 (75 ref.)

Eukaryotic gene expression: metabolite control by amino acids. Laine RO, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:219-48 (110 ref.)

[Amino acid chemoreception and motor activity in the frog Rana lessonae (Amphibia)] Kruzhalov NB. **Zh Obshch Biol** 1995 Nov-Dec;56(6):776-81 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

[A quantitative in-vitro analysis of the effects of magnetic fields and radiofrequencies on amino acid metabolism] Lagalla R, et al. **Radiol Med (Torino)** 1996 Apr;91(4):467-70 (Eng. Abstr.) **(Ita)**

SECRETION

Oxidative stress, hypoxia, and ischemia-like conditions increase the release of endogenous amino acids by distinct mechanisms in cultured retinal cells. Rego AC, et al. **J Neurochem** 1996 Jun;66(6):2506-16

STANDARDS

Do athletes need more dietary protein and amino acids? Lemon PW. **Int J Sport Nutr** 1995 Jun;5 Suppl:S39-61 (91 ref.)

THERAPEUTIC USE

Preoperative infusion of amino acids prevents postoperative hypothermia. Selldén E, et al. **Br J Anaesth** 1996 Feb; 76(2):227-34

Intraosseous resuscitation of hemorrhagic shock in a pediatric animal model using a low sodium hypertonic fluid. Sheikh AA, et al. **Crit Care Med** 1996 Jun;24(6):1054-61

Early metabolic treatment after liver transplant: amino acid tolerance. Iapichino G, et al. **Intensive Care Med** 1995 Oct; 21(10):802-7

Aminosyn PF or trophamine: which provides more protection from cholestasis associated with total parenteral nutrition? Forchielli ML, et al. **J Pediatr Gastroenterol Nutr** 1995 Nov;21(4):374-82

Effect of amino acid infusion on glucose production in trauma patients. Long CL, et al. **J Trauma** 1996 Mar;40(3):335-41

Clinical evaluation of an optimized 1.1% amino-acid solution for peritoneal dialysis. Faller B, et al. **Nephrol Dial Transplant** 1995;10(8):1432-7

Application of organic bound chrome in disturbed glycoregulation therapy. Djordjević PB, et al. **Transplant Proc** 1995 Dec;27(6):3333-4

[The efficacy and safety of glucosamine sulfate in the treatment of gonarthritis] Giordano N, et al. **Clin Ter** 1996 Mar;147(3):99-105 (Eng. Abstr.) **(Ita)**

[Cerebrolysin in treatment of acute ischemic stroke] Domżał T, et al. **Neurol Neurochir Pol** 1995 May-Jun;29(3):325-31 (Eng. Abstr.) **(Pol)**

TOXICITY

Evaluation of in vitro cytotoxicity of carboranyl amino acids, their chemical precursors and nido carboranyl amino acids for boron neutron capture therapy. Yong JH, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2039-43

NMDA receptors are involved at the ventrolateral nucleus tractus solitarii for termination of inspiration. Berger I, et al. **Eur J Pharmacol** 1995 Apr 24;277(2-3):195-208

Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC12 cells requires the Tat amino acid 49-58 basic domain. Weeks BS, et al. **J Neurosci Res** 1995 Sep 1;42(1):34-40

URINE

Urinary pyridinoline cross-links in Ehlers-Danlos syndrome type VI [letter] Steinmann B, et al. **Am J Hum Genet** 1995 Dec;57(6):1505-8

Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma. Massidda B, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2221-3

Automatic-interactive measurement of resorption cavities in transiliac bone biopsies and correlation with deoxypyridinoline. Roux JP, et al. **Bone** 1995 Aug; 17(2):153-6

Changes in urinary deoxypyridinoline level and vertebral bone mass in the development of adjuvant-induced arthritis in rats. Segawa Y, et al. **Bone** 1995 Jul;17(1):57-62

Urinary levels of Pyridinoline and deoxypyridinoline may be influenced by turnover of non-osseous tissues in patients with join disease [letter] Pearce D, et al. **Br J Rheumatol** 1995 Dec;34(12):1186-7

Receiver operating characteristic analysis of urinary pyridinium cross-links in arthritis [letter] Takahashi M, et al. **Br J Rheumatol** 1995 Aug;34(8):792-3

Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Ikeda I, et al. **Br J Urol** 1996 Jan;77(1):102-6

Urinary biochemical markers for bone resorption during the menstrual cycle. Gorai I, et al. **Calcif Tissue Int** 1995 Aug; 57(2):100-4

Urinary excretion of pyridinoline and deoxypyridinoline measured by immunoassay in hypothyroidism. Nakamura H, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):447-51

Simultaneous assessment of bone collagen synthesis and degradation in patients with different malignant tumours. Comparison with the results of 99mTc-methylene bisphosphonate bone scintigraphy. Withold W, et al. **Eur J Clin Chem Clin Biochem** 1995 Aug;33(8):479-85

Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by chromatographic and immunoassay methods. Kamel S, et al. **J Bone Miner Res** 1995 Sep;10(9):1385-92

Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. Bettica P, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):542-6

Short-term changes in calcium but not protein intake alter the rate of bone resorption in healthy subjects as assessed by urinary pyridinium cross-link excretion. Shapses SA, et al. **J Nutr** 1995 Nov;125(11):2814-21

Hereditary osteo-onycho-renal dysplasia with excess urinary pyridinoline cross-links and abnormal kidney collagen cross-linking. Lubec B, et al. **Nephron** 1995;70(2):255-9

Changes with age in the urinary excretion of hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP). Açil Y, et al. **Scand J Clin Lab Invest** 1996 May; 56(3):275-83

[Contribution of ion exchange chromatography of amino acids to the diagnosis of aspartylglucosaminuria (letter)] Candito M, et al. **Ann Biol Clin (Paris)** 1995;53(3):145-6 **(Fre)**

[Biochemical markers of bone turnover in urine--pyridinoline, deoxypyridinoline and aminoterminal cross-links of type I collagen] Hayashi Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:523-6 (7 ref.) **(Jpn)**

AMINO ACIDS, BRANCHED-CHAIN

[Food, drugs or doping? Some branched-chain amino acids and an evening paper!] Sundh UB. **Lakartidningen** 1996 May 29;93(22):2161-3 **(Swe)**

ADMINISTRATION & DOSAGE

Severe recurrent hepatic encephalopathy that responded to oral branched chain amino acids. Chalasani N, et al. **Am J Gastroenterol** 1996 Jun;91(6):1266-8 (12 ref.)

[Effects of prolonged administration of branched-chain amino acids on body composition and physical fitness] Candeloro N, et al. **Minerva Endocrinol** 1995 Dec; 20(4):217-23 (Eng. Abstr.) **(Ita)**

[Comparative study of two lipid emulsions in the parenteral nutrition of the septic patient] Garnacho Montero J, et al. **Nutr Hosp** 1996 Jan-Feb;11(1):47-53 (Eng. Abstr.) **(Spa)**

[Effects of branched-chain amino acids (BCAA) in complete hypocaloric nutrition of surgical patients with neoplasms of the digestive tract] Ruiz Coracho P, et al. **Nutr Hosp** 1991 May-Jun;6(3):178-85 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Metabolic effects of inhibitors of two enzymes of the branched-chain amino acid pathway in Salmonella typhimurium. Epelbaum S, et al. **J Bacteriol** 1996 Feb; 178(4):1187-96

End-product control of enzymes of branched-chain amino acid biosynthesis in Streptomyces coelicolor. Potter CA, et al. **Microbiology** 1996 Aug;142 (Pt 8):1945-52

CHEMISTRY

An analysis of side chain interactions and pair correlations within antiparallel beta-sheets: the differences between backbone hydrogen-bonded and non-hydrogen-bonded residue pairs. Wouters MA, et al. **Proteins** 1995 Jun; 22(2):119-31

METABOLISM

BAP2, a gene encoding a permease for branched-chain amino acids in Saccharomyces cerevisiae. Grauslund M, et al. **Biochim Biophys Acta** 1995 Nov 30;1269(3):275-80

Cloning, sequencing and expression of the ilvBNC gene cluster from Streptomyces avermitilis. De Rossi E, et al. **Gene** 1995 Dec 1;166(1):127-32

Astrocyte leucine metabolism: significance of branched-chain amino acid transamination. Yudkoff M, et al. **J Neurochem** 1996 Jan;66(1):378-85

Acidosis and glucocorticoids induce branched-chain amino acid catabolism. England BK, et al. **Miner Electrolyte Metab** 1996;22(1-3):69-71 (26 ref.)

Lipopolysaccharide (LPS) increases the in vivo oxidation of branched-chain amino acids in the rat: a cytokine-mediated effect. García-Martínez C, et al. **Mol Cell Biochem** 1995 Jul 5;148(1):9-15

Cloning and characterization of brnQ, a gene encoding a low-affinity, branched-chain amino acid carrier in Lactobacillus delbrückii subsp. lactis DSM7290. Stucky K, et al. **Mol Gen Genet** 1995 Dec 20;249(6):682-90

PHARMACOKINETICS

The imbalance of brain large-chain aminoacid availability in amyotrophic lateral sclerosis patients treated with high doses of branched-chain aminoacids. Bastone A, et al. **Neurochem Int** 1995 Dec;27(6):467-72

PHARMACOLOGY

Effect of angiotensin II on the renal response to amino acid in rats. Garcia GE, et al. **Am J Kidney Dis** 1996 Jul; 28(1):115-23

Changes in the ratio of branched-chain to aromatic amino acids affect the secretion of albumin in cultured rat hepatocytes. Okuno M, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1045-50

Oral supplementation with branched-chain amino acids improves transthyretin turnover in rats with carbon tetrachloride-induced liver cirrhosis. Usui T, et al. **J Nutr** 1996 May;126(5):1412-20

Ingestion of branched-chain amino acids and tryptophan during sustained exercise in man: failure to affect performance. van Hall G, et al. **J Physiol (Lond)** 1995 Aug 1;486 (Pt 3):789-94

[Effects of prolonged administration of branched-chain amino acids on body composition and physical fitness] Candeloro N, et al. **Minerva Endocrinol** 1995 Dec; 20(4):217-23 (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Carbohydrates, branched-chain amino acids, and endurance: the central fatigue hypothesis. Davis JM. **Int J Sport Nutr** 1995 Jun;5 Suppl:S29-38 (42 ref.)

THERAPEUTIC USE

Branched chains revisited [editorial; comment] Charlton MR. **Gastroenterology** 1996 Jul;111(1):252-5. Comment on: Gastroenterology 1996 Jul;111(1):127-37.

Response of phenylalanine and leucine kinetics to branched chain-enriched amino acids and insulin in patients with cirrhosis [see comments] Tessari P, et al. **Gastroenterology** 1996 Jul;111(1):127-37. Comment in: Gastroenterology 1996 Jul;111(1):252-5.

Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. Cangiano C, et al. **J Natl Cancer Inst** 1996 Apr 17;88(8):550-2

Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. Fabbri A, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar-Apr;20(2):159-64 (44 ref.)

[Branched-chain amino acids and their therapeutic use] **Internist (Berl)** 1992 Dec;(12 Suppl):1-8 **(Ger)**

AMINO ACIDS, DIAMINO

GENETICS

Complementation of an Arabidopsis thaliana biotin auxotroph with an Escherichia coli biotin biosynthetic gene. Patton DA, et al. **Mol Gen Genet** 1996 Jun 12;251(3):261-6

METABOLISM

Obligatory amino acid exchange via systems bo,+-like and y+L-like. A tertiary active transport mechanism for renal reabsorption of cystine and dibasic amino acids. Chillarón J, et al. **J Biol Chem** 1996 Jul 26;271(30):17761-70

PHARMACOLOGY

The neurotoxin, beta-N-methylamino-L-alanine (BMAA) interacts with the strychnine-insensitive glycine modulatory site of the N-methyl-D-aspartate receptor. Allen CN, et al. **Neuropharmacology** 1995 Jun;34(6):651-8

AMINO ACIDS, DIBASIC see **AMINO ACIDS, DIAMINO**

AMINO ACIDS, DICARBOXYLIC

CHEMICAL SYNTHESIS

Tandem enzymatic resolution yielding L-alpha-aminoalkanedioic acid omega-esters. Nishino N, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):212-4

(2S,4S)-2-amino-4-(4,4-diphenylbut-1-yl)-pentane-1,5-dioic acid: a potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylate cyclase. Wermuth CG, et al. **J Med Chem** 1996 Feb 16;39(4):814-6

METABOLISM

The transport of acidic amino acids and their analogues across monolayers of human intestinal absorptive (Caco-2) cells in vitro. Nicklin PL, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):176-86

PHARMACOLOGY

(2S,4S)-2-amino-4-(4,4-diphenylbut-1-yl)-pentane-1,5-dioic acid: a potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylate cyclase. Wermuth CG, et al. **J Med Chem** 1996 Feb 16;39(4):814-6

Pharmacological characterization of MCCG and MAP4 at the mGluR1b, mGluR2 and mGluR4a human metabotropic glutamate receptor subtypes. Knöpfel T, et al. **Neuropharmacology** 1995 Aug;34(8):1099-102

AMINO ACIDS, ESSENTIAL

How is lean body mass conserved with the very-low protein diet regimen? Maroni BJ, et al. **Miner Electrolyte Metab** 1996;22(1-3):54-7

ADMINISTRATION & DOSAGE

Glutamine--a conditionally essential amino acid in cirrhosis? Teran JC, et al. **Am J Clin Nutr** 1995 Nov;62(5):897-900 (40 ref.)

The requirements of adult man for indispensable amino acids. Waterlow JC. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S151-76; discussion S176-9 (160 ref.)

Pattern of amino acid requirements in humans: an interspecies comparison using published amino acid requirement recommendations. McLarney MJ, et al. **J Nutr** 1996 Jul; 126(7):1871-82 (55 ref.)

Effect of glutamic acid on broilers given submarginal crude protein with adequate essential amino acids using feeds high and low in potassium. Moran ET Jr, et al. **Poult Sci** 1996 Jan;75(1):120-9

METABOLISM

The requirements of adult man for indispensable amino acids. Waterlow JC. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S151-76; discussion S176-9 (160 ref.)

Metabolism of essential amino acids in growing rats at graded levels of soybean protein isolate. Tanaka H, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Aug;41(4):433-43

PHARMACOKINETICS

Studies on the transport in vitro of lysine, histidine, arginine and ammonia across the mucosa of the equine colon. Bochröder B, et al. **Equine Vet J** 1994 Mar;26(2):131-3

PHARMACOLOGY

Essential amino acids regulate fatty acid synthase expression through an uncharged transfer RNA-dependent mechanism. Dudek SM, et al. **J Biol Chem** 1995 Dec 8; 270(49):29323-9

PHYSIOLOGY

Pattern of amino acid requirements in humans: an interspecies comparison using published amino acid requirement recommendations. McLarney MJ, et al. **J Nutr** 1996 Jul; 126(7):1871-82 (55 ref.)

THERAPEUTIC USE

Effect of essential amino acid supplementation in acute renal failure. Mocan MZ, et al. **Int Urol Nephrol** 1995; 27(4):503-10

Nutritional value of essential amino acids in the treatment of adults with phenylketonuria. Dotremont H, et al. **J Inherit Metab Dis** 1995;18(2):127-30

AMINO ACIDS, EXCITATORY see **EXCITATORY AMINO ACIDS**

AMINO ACIDS, EXCITATORY, AGONISTS see **EXCITATORY AMINO ACID AGONISTS**

AMINO ACIDS, EXCITATORY, ANTAGONISTS see **EXCITATORY AMINO ACID ANTAGONISTS**

AMINO ACIDS, SECONDARY see **IMINO ACIDS**

AMINO ACIDS, SULFUR

ADMINISTRATION & DOSAGE

The response of highly productive rabbits to dietary sulphur amino acid content for reproduction and growth. Taboada E, et al. **Reprod Nutr Dev** 1996;36(2):191-203

METABOLISM

Nutritional and hormonal regulation of glutathione homeostasis. Taylor CG, et al. **Curr Top Cell Regul** 1996; 34:189-208 (129 ref.)

Competition for peptides and amino acids among periodontal bacteria. Tang-Larsen J, et al. **J Periodontal Res** 1995 Nov; 30(6):390-5

Effects of the naked neck (Na) gene on the sulfur-containing amino acid requirements of broilers. Pesti GM, et al. **Poult Sci** 1996 Mar;75(3):375-80

PHARMACOLOGY

Hepatic betaine-homocysteine methyltransferase activity in the chicken is influenced by dietary intake of sulfur amino acids, choline and betaine. Emmert JL, et al. **J Nutr** 1996 Aug;126(8):2050-8

URINE

Twenty-four hour feline excretion patterns in entire and castrated cats. Hendriks WH, et al. **Physiol Behav** 1995 Sep;58(3):467-9

AMINO ACYL T RNA SYNTHETASES

Mammalian aminoacyl-tRNA synthetases. Yang DC. **Curr Top Cell Regul** 1996;34:101-36 (192 ref.)

[Mechanism of tRNA-recognition by aminoacyl-tRNA synthetases] Nureki S, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1609-19 (37 ref.) **(Jpn)**

ANALYSIS

Protein translation components are colocalized in granules in oligodendrocytes. Barbarese E, et al. **J Cell Sci** 1995 Aug;108 (Pt 8):2781-90

BIOSYNTHESIS

Asparaginyl-tRNA synthetase from Thermus thermophilus HB8. Sequence of the gene and crystallization of the enzyme expressed in Escherichia coli. Seignovert L, et al. **Eur J Biochem** 1996 Jul 15;239(2):501-8

CHEMISTRY

C-terminal zinc-containing peptide required for RNA recognition by a class I tRNA synthetase. Glasfeld E, et al. **Biochemistry** 1996 Apr 2;35(13):4139-45

Asparaginyl-tRNA synthetase from Thermus thermophilus HB8. Sequence of the gene and crystallization of the enzyme expressed in Escherichia coli. Seignovert L, et al. **Eur J Biochem** 1996 Jul 15;239(2):501-8

Widespread use of the glu-tRNAGln transamidation pathway among bacteria. A member of the alpha purple bacteria lacks glutaminyl-trna synthetase. Gagnon Y, et al. **J Biol Chem** 1996 Jun 21;271(25):14856-63

Eleven down and nine to go. Cusack S. **Nat Struct Biol** 1995 Oct;2(10):824-31 (38 ref.)

[High molecular weight forms of aminoacyl-tRNA

synthetases in animals. I. Amount and enzymatic composition of high molecular weight synthetase in cytosol from rabbit liver] Berbeć H, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:29–34 (Eng. Abstr.) **(Pol)**

[High molecular weight forms of aminoacyl-tRNA synthetases in animals. II. High molecular weight aminoacyl-tRNA synthetase complexes in lower animals] Berbeć H, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:35–42 (Eng. Abstr.) **(Pol)**

[Tyrosine tRNA(Q*psiA) from bovine liver. Identification of its sites of interaction with homologous aminoacyl-trna synthetase using chemical modification] Kalachniuk LH, et al. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):60–5 (Eng. Abstr.) **(Ukr)**

GENETICS

Lactobacillus bulgaricus asparagine synthetase and asparaginyl-tRNA synthetase: coregulation by transcription antitermination? Kim SI, et al. **J Bacteriol** 1996 Apr;178(8):2459–61

Amber suppression in mammalian cells dependent upon expression of an Escherichia coli aminoacyl-tRNA synthetase gene. Drabkin HJ, et al. **Mol Cell Biol** 1996 Mar;16(3):907–13

Aminoacyl-tRNA synthetase gene regulation in Bacillus subtilis: induction, repression and growth-rate regulation. Putzer H, et al. **Mol Microbiol** 1995 May;16(4):709–18

Cloning and sequencing of the first plant GlnRS and GluRS genes. Siatecka M, et al. **Nucleic Acids Symp Ser** 1995; (33):160–2

Two types of aminoacyl-tRNA synthetases could be originally encoded by complementary strands of the same nucleic acid. Rodin SN, et al. **Orig Life Evol Biosph** 1995 Dec;25(6):565–89

IMMUNOLOGY

An immunodominant antigen of Brugia malayi is an asparaginyl-tRNA synthetase. Kron M, et al. **FEBS Lett** 1995 Oct 23;374(1):122–4

METABOLISM

Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Rogers MJ, et al. **Biochem Biophys Res Commun** 1996 Jul 25; 224(3):863–9

Crucial role of an idiosyncratic insertion in the Rossman fold of class 1 aminoacyl-tRNA synthetases: the case of methionyl-tRNA synthetase. Fourmy D, et al. **Biochemistry** 1995 Dec 5;34(48):15681–8

C-terminal zinc-containing peptide required for RNA recognition by a class I tRNA synthetase. Glasfeld E, et al. **Biochemistry** 1996 Apr 2;35(13):4139–45

Species-specific microhelix aminoacylation by a eukaryotic pathogen tRNA synthetase dependent on a single base pair. Quinn CL, et al. **Biochemistry** 1995 Oct 3;34(39):12489–95

Interaction of 5SrRNA-L5 protein complex, methionyl-tRNA, and methionyl-tRNA synthetase in the macromolecular ARS complex. Ogata K, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):750–7

Widespread use of the glu-tRNAGln transamidation pathway among bacteria. A member of the alpha purple bacteria lacks glutaminyl-trna synthetase. Gagnon Y, et al. **J Biol Chem** 1996 Jun 21;271(25):14856–63

Functional connectivity between tRNA binding domains in glutaminyl-tRNA synthetase. Sherman JM, et al. **J Mol Biol** 1996 Mar 15;256(5):818–28

Partition of aminoacyl-tRNA synthetases in two different structural classes dating back to early metabolism: implications for the origin of the genetic code and the nature of protein sequences. Delarue M. **J Mol Evol** 1995 Dec;41(6):703–11 (52 ref.)

The discriminator bases G73 in human tRNA(Ser) and A73 in tRNA(Leu) have significantly different roles in the recognition of aminoacyl-tRNA synthetases. Breitschopf K, et al. **Nucleic Acids Res** 1996 Feb 1;24(3):405–10

Synthesis of cysteine-containing dipeptides by aminoacyl-tRNA synthetases. Jakubowski H. **Nucleic Acids Res** 1995 Nov 25;23(22):4608–15

Asn-tRNA in Lactobacillus bulgaricus is formed by asparaginylation of tRNA and not by transamidation of Asp-tRNA. Kim SI, et al. **Nucleic Acids Res** 1996 Jul 15; 24(14):2648–51

Substrate selection by aminoacyl-tRNA synthetases. Ibba M, et al. **Nucleic Acids Symp Ser** 1995;(33):40–2 (12 ref.)

Molecular recognition of tRNA(Pro) by Escherichia coli proline-tRNA synthetase. Liu H, et al. **Nucleic Acids Symp Ser** 1995;(33):176–8

Interactions between tRNA identity nucleotides and their recognition sites in glutaminyl-tRNA synthetase determine the cognate amino acid affinity of the enzyme. Ibba M, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6953–8

Evidence for a conserved relationship between an acceptor stem and a tRNA for aminoacylation. Hou YM, et al. **RNA** 1995 Sep;1(7):707–13

Transfer RNA aminoacylation: identification of a critical ribose 2'-hydroxyl-base interaction. Yap LP, et al. **RNA** 1995 Jun;1(4):418–24

AMINO ACYL TRNA see **RNA, TRANSFER, AMINO ACYL**

AMINO ALCOHOLS

METABOLISM

Intralysosomal glycerophospholipid catabolism in liver: hydrolysis of amino alcohol-containing phospholipids and their metabolites. Kunze H. **Biochim Biophys Acta** 1993 Sep 8;1169(3):273–9

AMINO SUGARS

ADMINISTRATION & DOSAGE

Liver targeting of adenine arabinoside monophosphate (ara-AMP) by coupling to lactosaminated human serum albumin. Fiume L, et al. **Ital J Gastroenterol** 1995 May; 27(4):189–92

ANALYSIS

The Beta-subunit of the rabbit H,K-ATPase:a glycoprotein with all terminal lactosamine units capped with alpha-linked galactose residues. Tyagarajan K, et al. **Biochemistry** 1996 Mar 12;35(10):3238–46

N-acetyl-lactosamine in the rat olfactory system: expression and potential role in neurite growth. Puche AC, et al. **J Comp Neurol** 1996 Jan 8;364(2):267–78

BLOOD

Enzymatic analysis of cell surface lactosaminyl glycans by flow cytometry. Bollheimer LC, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):30–40

CHEMICAL SYNTHESIS

High-yield synthesis of N-acetyllactosamine by regioselective transglycosylation. Vetere A, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):6–13

CHEMISTRY

Fucosylated glycoconjugates of the human spermatozoon. Comparison of the domains of these glycoconjugates with the alpha-fucosyl binding sites, and with lactosaminic glycoconjugates and beta-D-galactosyl binding site domains. de Cerezo JM, et al. **Biocell** 1996 Apr;20(1):11–20

IMMUNOLOGY

Expression of alpha-3/4-monofucosylated polylactosaminoglycan epitope, as defined by monoclonal antibody FW6, is a marker of the colorectal adenoma-carcinoma sequence. Baldus SE, et al. **Cancer** 1995 Sep 15;76(6):954–60

METABOLISM

Control and function of complex-type oligosaccharide synthesis. Novel variants of the lacNAc pathway. Van den Eijnden DH, et al. **Adv Exp Med Biol** 1995;376:47–52 (26 ref.)

Monitoring biosynthetic transformations of N-acetyllactosamine using fluorescently labeled oligosaccharides and capillary electrophoretic separation. Zhang Y, et al. **Anal Biochem** 1995 May 20;227(2):368–76

Glycans with N-acetyllactosamine type 2-like residues covering adult Schistosoma mansoni, and glycomimesis as a putative mechanism of immune evasion. Schmidt J. **Parasitology** 1995 Sep;111 (Pt 3):325–36

PHARMACOLOGY

Potentiating effects on pilocarpine-induced saliva secretion, by extracts and N-containing sugars derived from mulberry leaves, in streptozocin-diabetic mice. Chen F, et al. **Biol Pharm Bull** 1995 Dec;18(12):1676–80

Methyl 3-amino-3-deoxy-beta-D-galactopyranosyl-(1-->4)-2-acetamido-2- deoxy-beta-D-glucopyranoside: an inhibitor of UDP-D-galactose: beta-D-galactopyranosyl-(1-->4)-2-acetamido-2-deoxy-D-glucose (1-->3)-alpha-D-galactopyranosyltransferase. Helland AC, et al. **Carbohydr Res** 1995 Oct 16;276(1):91–8

Inhibitory effect of diglucosylamines on two beta-glucosidases. Kolarova N, et al. **Carbohydr Res** 1995 Aug 22;273(1):109–13

Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs. Glinsky GV, et al. **Clin Exp Metastasis** 1996 May;14(3):253–67

Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route. Fiume L, et al. **Hepatology** 1995 Oct; 22(4 Pt 1):1072–7

THERAPEUTIC USE

[The efficacy and safety of glucosamine sulfate in the treatment of gonarthritis] Giordano N, et al. **Clin Ter** 1996 Mar;147(3):99–105 (Eng. Abstr.) **(Ita)**

AMINOACETIC ACID see **GLYCINE**

AMINOACIDURIA, RENAL

METABOLISM

Congenital non-progressive encephalopathy and deafness with intermittent episodes of coma and hyperkynureninuria. Cheminal R, et al. **J Inherit Metab Dis** 1996;19(1):25–30

URINE

Identification of the D-enantiomer of 2-hydroxyglutaric acid in glutaric aciduria type II. Watanabe H, et al. **Clin Chim Acta** 1995 Jul 14;238(2):115–24

9-AMINOACRIDINE see **AMINACRINE**

AMINOACRIDINES

Microanalysis of glycosaminoglycan-derived disaccharides labeled with the fluorophore 2-aminoacridone by capillary electrophoresis and high-performance liquid chromatography. Kitagawa H, et al. **Anal Biochem** 1995 Nov 20;232(1):114–21

CHEMICAL SYNTHESIS

Structure-activity relationship for antineoplastic imidazoacridinones: synthesis and antileukemic activity in vivo. Cholody WM, et al. **J Med Chem** 1996 Mar 1; 39(5):1028–32

CHEMISTRY

High resolution and rapid analysis of branched oligosaccharides by capillary electrophoresis. Camilleri P, et al. **Anal Biochem** 1995 Sep 1;230(1):115–22

Synthesis and binding properties of oligonucleotides covalently linked to an acridine derivative: new study of the influence of the dye attachment site. Asseline U, et al. **Bioconjug Chem** 1996 May-Jun;7(3):369–79

Synthesis and properties of an oligonucleotide modified with an acridine derivative at the artificial abasic site. Fukui K, et al. **Bioconjug Chem** 1996 May-Jun;7(3):349–55

PHARMACOLOGY

Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Skladanowski A, et al. **Mol Pharmacol** 1996 May; 49(5):772–80

[Acridine mutagen ICR-170 induced developmental suppression of ovary and vitelline gland in female Schistosoma japonicum] Lu Q, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):200–2 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Structure-activity relationship for antineoplastic imidazoacridinones: synthesis and antileukemic activity in vivo. Cholody WM, et al. **J Med Chem** 1996 Mar 1; 39(5):1028–32

TOXICITY

Imidazoacridinones arrest cell-cycle progression in the G2 phase of L1210 cells. Augustin E, et al. **Cancer Chemother Pharmacol** 1996;38(1):39–44

Potential neurotoxicity of a novel aminoacridine analogue. Walker TM, et al. **Hum Exp Toxicol** 1995 Jun;14(6):469–74

2-AMINOADIPIC ACID

ANALOGS & DERIVATIVES

Chemical synthesis of allysine ethylene acetal and conversion in situ into 1-piperideine-6-carboxylic acid: key intermediate of the alpha-aminoadipic acid for beta-lactam antibiotics biosynthesis. Rumbero A, et al. **Bioorg Med Chem** 1995 Sep;3(9):1237–40

CHEMICAL SYNTHESIS

Chemical synthesis of allysine ethylene acetal and conversion in situ into 1-piperideine-6-carboxylic acid: key intermediate of the alpha-aminoadipic acid for beta-lactam antibiotics biosynthesis. Rumbero A, et al. **Bioorg Med Chem** 1995 Sep;3(9):1237–40

PHARMACOLOGY

L-alpha-aminoadipic acid as a regulator of kynurenic acid production in the hippocampus: a microdialysis study in freely moving rats. Wu HQ, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):55–61

Effects of Müller cell disruption on mouse photoreceptor cell development. Rich KA, et al. **Exp Eye Res** 1995 Aug; 61(2):235–48

Selective ablation of astrocytes by intracerebral injections of alpha-aminoadipate. Khurgel M, et al. **Glia** 1996 Apr; 16(4):351–8

URINE

Treatment with vigabatrin may mimic alpha-aminoadipic aciduria. Vallat C, et al. **Epilepsia** 1996 Aug;37(8):803–5

P-AMINOAZOBENZENE

ANALOGS & DERIVATIVES

Ionic lead, but not other ionic metals (Ni2+, Co2+ and Cd2+), suppresses 2-methoxy-4-aminoazobenzene-mediated cytochrome P450IA2 (CYP1A2) induction in rat liver. Degawa M, et al. **Biol Pharm Bull** 1995 Sep;18(9):1215-8

[Effect of soluble streptocide on the function of type III glucocorticoid receptors in rat liver cytosol] Golikov PP, et al. **Patol Fiziol Eksp Ter** 1995 Jul-Sep;(3):21-3 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Adding p-aminoazobenzene may increase the sensitivity of the European standard series in detecting contact allergy to dyes, but carries the risk of active sensitization. Arnold WP, et al. **Contact Dermatitis** 1995 Dec;33(6):444

PHARMACOLOGY

Effect of nonionic surfactant on transport of model drugs in emulsions. Yoon KA, et al. **Pharm Res** 1996 Mar; 13(3):433-9

4-AMINOBENZOIC ACID

ADMINISTRATION & DOSAGE

[A pharmacokinetic study of para-aminobenzoic acid administered into the rabbit eye by phonophoresis] Panova IG, et al. **Izv Akad Nauk Ser Biol** 1995 Jul-Aug;(4):487-9 (Eng. Abstr.) **(Rus)**

ANALOGS & DERIVATIVES

Indirect examination of exocrine pancreatic function in vivo by determination of chymotrypsin activity in animal intestine using a synthetic substrate. Kaštel R, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):311-4

Differential induction of peroxisomal enzymes by hypolipidaemics in human (HepG2) and rat (MH1C1) hepatoma cell lines. Stangl H, et al. **Eur J Clin Chem Clin Biochem** 1995 Nov;33(11):775-83

Crystal structures of apolipoprotein(a) kringle IV37 free and complexed with 6-aminohexanoic acid and with p-aminomethylbenzoic acid: existence of novel and expected binding modes. Mikol V, et al. **J Mol Biol** 1996 Mar 8;256(4):751-61

para-cetamidobenzoylglutamate is a suitable indicator of folate catabolism in rats. Geoghegan FL, et al. **J Nutr** 1995 Oct;125(10):2563-70

Formulation factors affecting release of drug from topical vehicles. II. Effect of solubility on in vitro delivery of a series of n-alkyl p-aminobenzoates. Lalor CB, et al. **J Pharm Sci** 1995 Jun;84(6):673-6

Identification of putative 5-hydroxytryptamine(4) (5-HT4) receptors in guinea pig stomach: The effect of TKS159, a novel agonist, on gastric motility and acetylcholine release. Matsuyama S, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):989-95

[BT-PABA test] Koizumi M, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:1088-91 (12 ref.) **(Jpn)**

ANALYSIS

Indirect examination of exocrine pancreatic function in vivo by determination of chymotrypsin activity in animal intestine using a synthetic substrate. Kaštel R, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):311-4

METABOLISM

Preliminary assessment of glycine conjugation of para-aminobenzoic acid as a quantitative test of liver function. Duffy LF, et al. **Clin Biochem** 1995 Oct; 28(5):527-30

Glycine conjugation of para-aminobenzoic acid (PABA): a quantitative test of liver function. Furuya KN, et al. **Clin Biochem** 1995 Oct;28(5):531-40

PHARMACOKINETICS

[A pharmacokinetic study of para-aminobenzoic acid administered into the rabbit eye by phonophoresis] Panova IG, et al. **Izv Akad Nauk Ser Biol** 1995 Jul-Aug;(4):487-9 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats. Esposito M, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2541-7

Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans. Tisdale JE, et al. **J Clin Pharmacol** 1995 Sep;35(9):902-10

[Effect of para-aminobenzoic acid on the fibrinolytic activity of blood] Andreenko GV, et al. **Dokl Akad Nauk** 1996 Jan;346(2):268-70 **(Rus)**

RADIATION EFFECTS

Photochemical formation of singlet molecular oxygen (1O2) in illuminated aqueous solutions of p-aminobenzoic acid (PABA). Allen JM, et al. **J Photochem Photobiol B** 1996 Jan;32(1-2):33-7

THERAPEUTIC USE

[Action of para-aminobenzoic acid and its combination with acyclovir in herpetic infection] Akberova SI, et al. **Antibiot Khimioter** 1995 Oct;40(10):25-9 (Eng. Abstr.) **(Rus)**

P-AMINOBENZOIC ACID see **4-AMINOBENZOIC ACID**

AMINOBENZOIC ACIDS

CHEMICAL SYNTHESIS

Synthesis of new 2-([(phenoxy or phenyl)acetyl]amino)benzoic acid derivatives as 3 alpha-hydroxysteroid dehydrogenase inhibitors and potential antiinflammatory agents. Daidone G, et al. **Arch Pharm (Weinheim)** 1995 Oct;328(10):705-8

CHEMISTRY

Fluorogenic peptide substrates for assay of aspartyl proteinases. Filippova IY, et al. **Anal Biochem** 1996 Feb 15;234(2):113-8

[Thrombin substrates containing aminobenzoic acids] Gershkovich AA, et al. **Ukr Biokhim Zh** 1995 Jan-Feb; 67(1):57-64 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

In search of a selective inhibitor of the induced transport of small solutes in Plasmodium falciparum-infected erythrocytes: effects of arylaminobenzoates. Kirk K, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):761-8

Identification of a retinoic acid receptor alpha subtype specific agonist. Teng M, et al. **J Med Chem** 1996 Aug 2;39(16):3035-8

LY353433, a potent, orally effective, long-acting 5-HT(4) receptor antagonist: comparison to cisapride and RS23597-190. Cohen ML, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):97-104

Effects of the class III antiarrhythmic drug ambasilide on outward currents in human atrial myocytes. Koidl B, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):226-32

A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase. Jedrzejas MJ, et al. **Proteins** 1995 Oct;23(2):264-77

O-AMINOBENZOIC ACIDS see **ANTHRANILIC ACIDS**

AMINOBIPHENYL COMPOUNDS

Direct effects of testosterone, dihydrotestosterone and estrogen on 3,2'-dimethyl-4-aminobiphenyl-induced prostate carcinogenesis in castrated F344 rats. Mori T, et al. **Jpn J Cancer Res** 1996 Jun;87(6):570-4

ADVERSE EFFECTS

DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Vineis P, et al. **Int J Cancer** 1996 Jan 26;65(3):314-6

Characterization of 4-aminobiphenyl-hemoglobin adducts in maternal and fetal blood-samples. Myers SR, et al. **J Toxicol Environ Health** 1996 Apr 19;47(6):553-66

BLOOD

HPLC and GC/MS determination of 4-aminobiphenyl haemoglobin adducts in fetuses exposed to the tobacco smoke carcinogen in utero. Pinorini-Godly MT, et al. **Toxicology** 1996 Mar 18;107(3):209-17

METABOLISM

Glucuronide conjugates of 4-aminobiphenyl and its N-hydroxy metabolites. pH stability and synthesis by human and dog liver. Babu SR, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1679-85

Metabolism of 4-aminobiphenyl and 4-acetylaminobiphenyl in perfused guinea pig liver. Yoshihara S, et al. **Biol Pharm Bull** 1995 Jun;18(6):872-5

Immunohistochemical demonstration of 3,2'-dimethyl-4-aminobiphenyl DNA adduct formation in various organs of Syrian golden hamsters. Yaono M, et al. **Cancer Lett** 1996 Jan 2;98(2):145-9

Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Curigliano G, et al. **Carcinogenesis** 1996 May; 17(5):911-6

32P-postlabeling analysis of adducts generated by peroxidase-mediated binding of N-hydroxy-4-acetylaminobiphenyl to DNA. Hatcher JF, et al. **Carcinogenesis** 1995 Sep;16(9):2149-57

Effect of acetylator genotype on 3,2'-dimethyl-4-aminobiphenyl induced aberrant crypt foci in the colon of hamsters. Paulsen JE, et al. **Carcinogenesis** 1996 Mar;17(3):459-65

Quantitative immunohistochemical analysis of 4-aminobiphenyl-DNA in cultured cells and mice: comparison to gas chromatography/mass spectroscopy analysis. al-Atrash J, et al. **Chem Res Toxicol** 1995 Jul-Aug; 8(5):747-52

PHARMACOLOGY

Unexpected antagonistic action of 3,2'-dimethyl-4-aminobiphenyl on aberrant crypt induction by 1,2-dimethylhydrazine or azoxymethane in rat colon. Steffensen IL, et al. **Carcinogenesis** 1995 Dec; 16(12):2981-8

TOXICITY

Inhibitory effect of caloric restriction on tumorigenicity induced by 4-aminobiphenyl and 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine (PhIP) in the CD1 newborn mouse bioassay. Von Tungeln LS, et al. **Cancer Lett** 1996 Jul 12;104(2):133-6

Acetylator genotype (NAT2)-dependent formation of aberrant crypts in congenic Syrian hamsters administered 3,2'-dimethyl-4-aminobiphenyl. Feng Y, et al. **Cancer Res** 1996 Feb 1;56(3):527-31

DNA adduct formation and tumorigenesis in mice during the chronic administration of 4-aminobiphenyl at multiple dose levels. Poirier MC, et al. **Carcinogenesis** 1995 Dec; 16(12):2917-21

Histopathological analysis of invasive bladder carcinomas induced by 3,2'-dimethyl-4-aminobiphenyl in hamsters. Cui L, et al. **Jpn J Cancer Res** 1996 Jan;87(1):37-43

Site-specific effects of testosterone propionate on the prostate of rat pretreated with 3,2'-dimethyl-4-aminobiphenyl: dose-dependent induction of invasive carcinomas. Shirai T, et al. **Jpn J Cancer Res** 1995 Jul;86(7):645-8

AMINOBUTYRATE AMINOTRANSFERASE

ANTAGONISTS & INHIBITORS

The irreversible gamma-aminobutyrate transaminase inhibitor vigabatrin in the treatment of the alcohol withdrawal syndrome [letter] Stuppaeck CH, et al. **Alcohol Alcohol** 1996 Jan;31(1):109-11

Vigabatrin-associated reversible acute psychosis in a child. Cánovas Martínez A, et al. **Ann Pharmacother** 1995 Nov; 29(11):1115-7 (10 ref.)

Effect of the GABA-transaminase inhibitor vigabatrin on exploratory behaviour in socially isolated rats. Sherif F, et al. **Behav Brain Res** 1995 Dec 14;72(1-2):135-40

Inactivation of gamma-aminobutyric acid aminotransferase by L-3-chloroalanine hydroxamate. Silverman RB, et al. **Bioorg Med Chem** 1995 Jan;3(1):11-8

Chemical modification of bacterial 4-aminobutyrate aminotransferase by phenylglyoxal. Tunnicliff G. **J Enzym Inhib** 1995;9(4):309-16

Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues. Lightcap ES, et al. **J Med Chem** 1996 Feb 2;39(3):686-94

CHEMISTRY

Active site model for gamma-aminobutyrate aminotransferase explains substrate specificity and inhibitor reactivities. Toney MD, et al. **Protein Sci** 1995 Nov; 4(11):2366-74

GENETICS

Characterization of the ugatA gene of Ustilago maydis, isolated by homology to the gatA gene of Aspergillus nidulans. Straffon MJ, et al. **Curr Genet** 1996 Mar; 29(4):360-9

THERAPEUTIC USE

Treatment with vigabatrin may mimic alpha-aminoadipic aciduria. Vallat C, et al. **Epilepsia** 1996 Aug;37(8):803-5

4-AMINOBUTYRIC ACID see **GABA**

AMINOBUTYRIC ACIDS

see related **RECEPTORS, GABA-A**

ANALYSIS

Agromyces mediolanus sp. nov., nom. rev., comb. nov., a species for "Corynebacterium mediolanum" Mamoli 1939 and for some aniline-assimilating bacteria which contain 2,4-diaminobutyric acid in the cell wall peptidoglycan. Suzuki K, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):88-93

A comparative study of direct hemoperfusion and hemodialysis for the removal of glufosinate ammonium. Tanaka J, et al. **J Toxicol Clin Toxicol** 1995;33(6):691-4

[Aminobutyric acid] Endo M, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:486-8 (12 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Separation of enantiomeric beta-methyl amino acids and of beta-methyl amino acid containing peptides. Péter A, et al. **J Chromatogr A** 1996 Mar 29;728(1-2):455-65

AMINOBUTYRIC ACIDS

METABOLISM

Substrate specificity of the Escherichia coli 4-aminobutyrate carrier encoded by gabP. Uptake and counterflow of structurally diverse molecules. Brechtel CE, et al. **J Biol Chem** 1996 Jan 12;271(2):783-8

Male sterility in transgenic tobacco plants induced by tapetum-specific deacetylation of the externally applied non-toxic compound N-acetyl-L-phosphinothricin. Kriete G, et al. **Plant J** 1996 Jun;9(6):809-18

PHARMACOLOGY

ERG OFF response in frog retina: light adaptation and effect of 2-amino-4-phosphonobutyrate. Popova E, et al. **Acta Physiol Scand** 1995 Jul;154(3):377-86

In vivo search for butyrate responsive sequences using transgenic mice carrying A gamma gene promoter mutants. Pace BS, et al. **Blood** 1996 Aug 1;88(3):1079-83

A comparison of the effects of selective metabotropic glutamate receptor agonists on synaptically evoked whole cell currents of rat spinal ventral horn neurones in vitro. Cao CQ, et al. **Br J Pharmacol** 1995 Aug;115(8):1469-74

[3H]-L-2-amino-4-phosphonobutyrate labels a metabotropic glutamate receptor, mGluR4a. Eriksen L, et al. **Br J Pharmacol** 1995 Dec;116(8):3279-87

A differential effect of APB on ON- and OFF-center ganglion cells in the dark adapted rabbit retina. Jin XT, et al. **Brain Res** 1996 Feb 5;708(1-2):191-6

Identification of 2-amino-2-methyl-4-phosphonobutanoic acid as an antagonist at the mGlu4a receptor. Johansen PA, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):R1-3

Development and regulation of dendritic stratification in retinal ganglion cells by glutamate-mediated afferent activity. Bodnarenko SR, et al. **J Neurosci** 1995 Nov; 15(11):7037-45

Pharmacological characterization of MCCG and MAP4 at the mGluR1b, mGluR2 and mGluR4a human metabotropic glutamate receptor subtypes. Knöpfel T, et al. **Neuropharmacology** 1995 Aug;34(8):1099-102

The effects of L-AP4 and L-serine-O-phosphate on inhibition in primary somatosensory cortex of the adult rat in vivo. Wan H, et al. **Neuropharmacology** 1995 Aug; 34(8):1053-62

Central activity of 2-amino-4-phosphonobutyric acid (AP4). Zalewska A, et al. **Pol J Pharmacol** 1995 Jan-Feb; 47(1):9-17

TOXICITY

Male sterility in transgenic tobacco plants induced by tapetum-specific deacetylation of the externally applied non-toxic compound N-acetyl-L-phosphinothricin. Kriete G, et al. **Plant J** 1996 Jun;9(6):809-18

6-AMINOCAPROIC ACID

[Use of a new hemostatic preparation kaprofer in therapeutic endoscopy] Skriabin ON, et al. **Klin Med (Mosk)** 1995; 73(4):90-1 **(Rus)**

ADVERSE EFFECTS

Fatal aortic thrombosis in a neonate during infusion of epsilon-aminocaproic acid. Hocker JR, et al. **J Pediatr Surg** 1995 Oct;30(10):1490-2

ANALOGS & DERIVATIVES

Antifertility effects of (+)-S-2-amino-6-iodoacetamidohexanoic acid (2-AIHA) in female rats. Chamorro G, et al. **Contraception** 1996 Apr; 53(4):247-51

The influence of some cations on PAF-induced gastric mucosal damage in rats. Nechifor M, et al. **Rom J Physiol** 1993 Jul-Dec;30(3-4):151-4

CHEMISTRY

Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands epsilon-aminocaproic acid and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid. Mathews II, et al. **Biochemistry** 1996 Feb 27;35(8):2567-76

Stabilization of plasmin by lysine derivatives. Ueshima S, et al. **Clin Chim Acta** 1996 Feb 9;245(1):7-18

IMMUNOLOGY

Immunological properties of allergen chemically modified with synthetic copolymer of N-vinylpyrrolidone and maleic anhydride. Babakhin AA, et al. **Allergy Proc** 1995 Sep-Oct;16(5):261-8

METABOLISM

Crystal structures of apolipoprotein(a) kringle IV37 free and complexed with 6-aminohexanoic acid and with p-aminomethylbenzoic acid: existence of novel and expected binding modes. Mikol V, et al. **J Mol Biol** 1996 Mar 8;256(4):751-61

THERAPEUTIC USE

Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. Djulbegovic B, et al. **Am J Hematol** 1996 Feb; 51(2):168-70

Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. Menichetti A, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):401-7

Effect of antiproteolytic drugs: epsilon-aminocaproic acid (EACA) and aprotinin on experimental anti-GBM nephritis. Hruby Z, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):32-9

AMINOCAPROIC ACIDS

ADVERSE EFFECTS

Positivity of patch tests in cutaneous reaction to aminocaproic acid: two case reports. González Gutiérrez ML, et al. **Allergy** 1995 Sep;50(9):745-6

THERAPEUTIC USE

Concomitant treatment with factor IX concentrates and antifibrinolytics in hemophilia B. Djulbegovic B, et al. **Acta Haematol** 1995;94 Suppl 1:43-7; discussion 48

AMINOCAPROIC LACTAM see **CAPROLACTAM**

1-AMINOCYCLOPENTANECARBOXYLIC ACID see **CYCLOLEUCINE**

AMINOETHANOLS see **ETHANOLAMINES**

2-AMINOETHYLISOTHIURONIUM BROMIDE see **AET**

AMINOETHYLPHOSPHONIC ACID

CHEMISTRY

Structural analysis of a novel triphosphonoglycosphingolipid from the egg of the sea hare, Aplysia kurodai. Yamada S, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):794-9

METABOLISM

Molecular cloning, mapping, and regulation of Pho regulon genes for phosphonate breakdown by the phosphonatase pathway of Salmonella typhimurium LT2. Jiang W, et al. **J Bacteriol** 1995 Nov;177(22):6411-21

2-AMINOETHYLPHOSPHONIC ACID see **AMINOETHYLPHOSPHONIC ACID**

AMINOGLUTETHIMIDE

ANALOGS & DERIVATIVES

Development and validation of a chiral high-performance liquid chromatography assay for rogletimide and rogletimide-N-oxide isomers in plasma. Etienne MC, et al. **Cancer Chemother Pharmacol** 1996;38(4):343-8

Liquid chromatographic separation and measurement of optical isomers of aminoglutethimide and its acetyl metabolite in plasma, saliva, and urine. Alshowaier IA, et al. **Ther Drug Monit** 1995 Oct;17(5):538-43

ANALYSIS

Liquid chromatographic separation and measurement of optical isomers of aminoglutethimide and its acetyl metabolite in plasma, saliva, and urine. Alshowaier IA, et al. **Ther Drug Monit** 1995 Oct;17(5):538-43

PHARMACOLOGY

Effects of aminoglutethimide, alone and in combination with surgical castration, on pancreatic carcinogenesis in rats and hamsters. Visser CJ, et al. **Int J Cancer** 1995 Nov 27; 63(5):732-7

THERAPEUTIC USE

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Murray R, et al. **Breast Cancer Res Treat** 1995 Sep;35(3):249-53

[Comparison between the roles of aminoglutethimide and hydroxyprogesterone caproates in the treatment of endometrial cancer] Liu XS, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):479-82 (Eng. Abstr.) **(Chi)**

AMINOGLYCOSIDE ANTIBIOTICS see **ANTIBIOTICS, AMINOGLYCOSIDE**

AMINOGLYCOSIDES

ADMINISTRATION & DOSAGE

Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Barclay ML, et al. **Aust N Z J Med** 1995 Jun;25(3):230-5

ADVERSE EFFECTS

Allergy due to topical medications in chronic otitis externa and chronic otitis media. Van Ginkel CJ, et al. **Clin Otolaryngol** 1995 Aug;20(4):326-8

Susceptibility mutations in the mitochondrial small ribosomal RNA gene in aminoglycoside induced deafness. Bacino C, et al. **Pharmacogenetics** 1995 Jun;5(3):165-72

BLOOD

Absorption of some aminoglycoside drugs by barrier gels in sampling tubes. Alcantarilla G, et al. **Clin Chem** 1996 May;42(5):771

PHARMACOKINETICS

Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis. Bailie GR, et al. **J Antimicrob Chemother** 1995 May;35(5):563-7 (33 ref.)

A semisynthetic Quillaja saponin as a drug delivery agent for aminoglycoside antibiotics. Recchia J, et al. **Pharm Res** 1995 Dec;12(12):1917-23

PHARMACOLOGY

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615-22 (46 ref.)

Aminoglycosides lower serum magnesium concentrations in patients with cystic fibrosis: a retrospective study. Holben DH, et al. **J Am Diet Assoc** 1995 Oct;95(10):1152-4

Nonstop treatment of cystic fibrosis [letter; comment] Dietz HC, et al. **Nat Med** 1996 Jun;2(6):608-9. Comment on: Nat Med 1996 Apr;2(4):467-9.

Resistance to aminoglycosides and other antibiotics among clinical isolates of Enterococcus spp. Tripodi MF, et al. **New Microbiol** 1995 Jul;18(3):319-23

THERAPEUTIC USE

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615-22 (46 ref.)

Allergy due to topical medications in chronic otitis externa and chronic otitis media. Van Ginkel CJ, et al. **Clin Otolaryngol** 1995 Aug;20(4):326-8

TOXICITY

Protection of auditory neurons from aminoglycoside toxicity by neurotrophin-3. Ernfors P, et al. **Nat Med** 1996 Apr; 2(4):463-7

6-AMINOHEXANOIC ACID see **6-AMINOCAPROIC ACID**

4-AMINOHIPPURIC ACID see **P-AMINOHIPPURIC ACID**

P-AMINOHIPPURIC ACID

ADVERSE EFFECTS

[Solvent emissions in a school building after using a construction moisture protection substance] Bent S, et al. **Gesundheitswesen** 1996 Apr;58(4):234-6 (Eng. Abstr.) **(Ger)**

ANALYSIS

Airborne exposure to polycyclic aromatic hydrocarbons (PAHs) and urinary excretion of 1-hydroxypyrene of carbon anode plant workers. Petry T, et al. **Ann Occup Hyg** 1996 Jun;40(3):345-57

DIAGNOSTIC USE

Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance. Toto RD. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):505-9; discussion 503-4 (21 ref.)

[Paraaminohippuric acid clearance] Nagase S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1082-4 (7 ref.) **(Jpn)**

METABOLISM

Comparison of 5-hydroxyindole-acetic acid and para-amino hippurate clearances in newborn rabbits. Sulyok E, et al. **Clin Chim Acta** 1995 Sep 15;240(2):155-61

Specificity of p-aminohippurate transport system in the OK kidney epithelial cell line. Nagai J, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1161-6

PHARMACOKINETICS

System identification of the low-dose kinetics of p-aminohippuric acid. Estelberger W, et al. **Eur J Clin Chem Clin Biochem** 1995 Nov;33(11):847-53

Modification of cisplatin-induced renal p-aminohippurate uptake alteration and lipid peroxidation by thiols, Ginkgo biloba extract, deferoxamine and torbafylline. Inselmann G, et al. **Nephron** 1995;70(4):425-9

PHARMACOLOGY

Mechanism mediating basolateral transport of 2,4-dichlorophenoxyacetic acid in rat kidney. Villalobos AR, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):582-9

Pretreatment with p-aminohippurate inhibits the renal uptake

and accumulation of injected inorganic mercury in the rat. Zalups RK, et al. **Toxicology** 1995 Nov 20;103(1):23–35

AMINOHYDROLASES

BIOSYNTHESIS

Cloning of the Rhodobacter sphaeroides hisL gene: unifunctionality of the encoded protein and lack of linkage to other his genes. Oriol E, et al. **Microbiology** 1996 Aug; 142 (Pt 8):2071–8

Transgenic tobacco plants expressing the Arabidopsis thaliana nitrilase II enzyme. Schmidt RC, et al. **Plant J** 1996 May;9(5):683–91

CHEMISTRY

The N-terminal, dehydrogenase/cyclohydrolase domain of yeast cytoplasmic trifunctional C1-tetrahydrofolate synthase requires the C-terminal, synthetase domain for the catalytic activity in vitro. Song JM, et al. **FEBS Lett** 1995 Dec 4;376(3):229–32

GENETICS

Transfer of human adenine deaminase gene into murine hematopoietic stem cells: sequential study of spleen colony-forming units from bone marrow of living mice and the requirement of the microenvironment. Cook PC, et al. **Acta Haematol** 1996;96(2):57–63

Primary structure of cyclohydrolase (Mch) from Methanobacterium thermoautotrophicum (strain Marburg) and functional expression of the mch gene in Escherichia coli. Vaupel M, et al. **Eur J Biochem** 1996 Feb 15; 236(1):294–300

Structure of the gene encoding nitrilase 1 from Arabidopsis thaliana. Hillebrand H, et al. **Gene** 1996 May 8; 170(2):197–200

Cloning of the Rhodobacter sphaeroides hisL gene: unifunctionality of the encoded protein and lack of linkage to other his genes. Oriol E, et al. **Microbiology** 1996 Aug; 142 (Pt 8):2071–8

METABOLISM

Biosynthesis of riboflavin. Bifunctional pyrimidine deaminase/reductase of Escherichia coli and Bacillus subtilis. Fischer M, et al. **Biochem Soc Trans** 1996 Feb; 24(1):35S

Binding and interconversion of tetrahydrofolates at a single site in the bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase. Pelletier JN, et al. **Biochemistry** 1995 Oct 3;34(39):12673–80

PHYSIOLOGY

Role of adenine deaminase in purine salvage and nitrogen metabolism and characterization of the ade gene in Bacillus subtilis. Nygaard P, et al. **J Bacteriol** 1996 Feb; 178(3):846–53

AMINOIMIDAZOLE CARBOXAMIDE

ANALOGS & DERIVATIVES

Effect of acadesine treatment on postischemic damage to small intestine. Schoenberg MH, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1752–9

Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. **Anesthesiology** 1995 Oct; 83(4):658–73

Degradation of iprodione by a soil Arthrobacter-like strain. Athiel P, et al. **Appl Environ Microbiol** 1995 Sep; 61(9):3216–20

Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR--an activator of AMP-activated protein kinase. Young ME, et al. **FEBS Lett** 1996 Mar 11;382(1-2):43–7

Evaluation of modified dichloran 18% glycerol (DG18) agar for enumerating fungi in wheat flour: a collaborative study. Beuchat LR, et al. **Int J Food Microbiol** 1996 Apr; 29(2-3):161–6

Protection against injury during ischemia and reperfusion by acadesine derivatives GP-1-468 and GP-1-668. Studies in the transplanted rat heart. Galiñanes M, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):752–61

Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational Acadesine Study Group. Menasché P, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1096–106

Acadesine and lipopolysaccharide-evoked pulmonary dysfunction after resuscitation from traumatic shock. Fabian TC, et al. **Surgery** 1996 Mar;119(3):302–15

Acadesine reduces the frequency of coronary artery reocclusion following rt-PA induced thrombolysis in the dog. Young MA, et al. **Thromb Haemost** 1995 Nov; 74(5):1348–52

AMINOISOBUTYRIC ACIDS

ANALYSIS

Pathway for Ca2+ influx into cells by trichosporin-B-VIa, an alpha-aminoisobutyric acid-containing peptide, from the fungus Trichoderma polysporum. Tachikawa E, et al. **Biochim Biophys Acta** 1996 Jun 13;1282(1):140–8

DIAGNOSTIC USE

Application of alpha-aminoisobutyric acid, L-methionine, thymidine and 2-fluoro-2-deoxy-D-glucose to monitor effects of chemotherapy in a human colon carcinoma cell line. Schaider H, et al. **Eur J Nucl Med** 1996 Jan; 23(1):55–60

METABOLISM

Uptake of neutral alpha- and beta-amino acids by human proximal tubular cells. Jessen H, et al. **Biochim Biophys Acta** 1996 Jul 25;1282(2):225–32

The biosynthesis of monensin-A: thymine, beta-aminoisobutyrate and methacrylate metabolism in Streptomyces cinnamonensis. O'Hagan D, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1280–7

Insulin-like growth factor-1 stimulates amino acid uptake by the cultured human placental trophoblast. Karl PI. **J Cell Physiol** 1995 Oct;165(1):83–8

Calcium dependence of alpha-aminoisobutyric acid transfer in human bilaterally perfused placental lobules. Krishna BR, et al. **J Perinat Med** 1995;23(5):343–51

PHARMACOKINETICS

Amino acid uptake in skeletal muscle of rats bearing the Yoshida AH-130 ascites hepatoma. García-Martínez C, et al. **Mol Cell Biochem** 1995 Jul 5;148(1):17–23

AMINOLEVULINATE HYDRO-LYASE see **AMINOLEVULINIC ACID DEHYDRATASE**

AMINOLEVULINIC ACID

Fluorescence and photosensitization of experimental endometriosis in the rat after systemic 5-aminolevulinic acid administration: a potential new approach to the diagnosis and treatment of endometriosis. Yang JZ, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):154–60

Mechanism of oxidative DNA damage induced by delta-aminolevulinic acid in the presence of copper ion. Hiraku Y, et al. **Cancer Res** 1996 Apr 15;56(8):1786–93

ADMINISTRATION & DOSAGE

Structural and functional effects of endometrial photodynamic therapy in a rat model. Fehr MK, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):115–21

Fluorescence and photosensitization of experimental endometriosis in the rat after systemic 5-aminolevulinic acid administration: a potential new approach to the diagnosis and treatment of endometriosis. Yang JZ, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):154–60

Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Martin A, et al. **Arch Dermatol Res** 1995; 287(7):665–74

Feasibility of photodynamic therapy using endogenous photosensitization for colon cancer. Fromm D, et al. **Arch Surg** 1996 Jun;131(6):667–9

[Photodynamic therapy and breast-plasty of a extensive superficial trunk skin basalioma of the breast. An effective combination therapy with photodynamic diagnosis] Fritsch C, et al. **Hautarzt** 1996 Jun;47(6):438–42 (Eng. Abstr.) **(Ger)**

ANALYSIS

[delta-Aminolevulinic acid (ALA)] Tajima Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:877–80 (22 ref.) **(Jpn)**

BLOOD

A reference value for delta-aminolevulinic acid in plasma in the population occupationally unexposed to lead. Morita Y, et al. **Ind Health** 1996;34(1):57–60

delta-Aminolevulinic acid in plasma or whole blood as a sensitive indicator of lead effects, and its relation to the other heme-related parameters. Sakai T, et al. **Int Arch Occup Environ Health** 1996;68(2):126–32

DIAGNOSTIC USE

delta-Aminolevulinic acid induced fluorescence in tumour-bearing mice. Cubeddu R, et al. **J Photochem Photobiol B** 1995 Sep;30(1):23–7

Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence [see comments] Kriegmair M, et al. **J Urol** 1996 Jan;155(1):105–9; discussion 109–10 . Comment in: J Urol 1996 Jan;155(1):122.

Fluorescence cystoscopy following intravesical instillation of 5-aminolevulinic acid: a new procedure with high sensitivity for detection of hardly visible urothelial neoplasias. Kriegmair M, et al. **Urol Int** 1995;55(4):190–6

METABOLISM

Accumulation of 5-aminolevulinic acid-induced protoporphyrin IX in normal and neoplastic human endometrial epithelial cells. Wyss-Desserich MT, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):819–24

Increased delta aminolevulinic acid and decreased pineal melatonin production. A common event in acute porphyria studies in the rat. Puy H, et al. **J Clin Invest** 1996 Jan 1;97(1):104–10

PHARMACOKINETICS

Selective photosensitizer distribution in vulvar condyloma acuminatum after topical application of 5-aminolevulinic acid. Fehr MK, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):951–7

Photosensitization of the endometrium with topical 5-aminolevulinic acid. Gannon MJ, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1826–8

Kinetics and localisation of PpIX fluorescence after topical and systemic ALA application, observed in skin and skin tumours of UVB-treated mice. van der Veen N, et al. **Br J Cancer** 1996 Apr;73(7):925–30

Biodistribution of protoporphyrin IX in rat urinary bladder after intravesical instillation of 5-aminolevulinic acid. Chang SC, et al. **J Urol** 1996 May;155(5):1744–8

PHARMACOLOGY

The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells. Berg K, et al. **Br J Cancer** 1996 Sep;74(5):688–97

Photodynamic therapy on the normal rabbit larynx with phthalocyanine and 5-aminolaevulinic acid induced protoporphyrin IX photosensitisation. Kleemann D, et al. **Br J Cancer** 1996 Jul;74(1):49–58

The effect of aminolaevulinic acid-induced, protoporphyrin IX-mediated photodynamic therapy on the cremaster muscle microcirculation in vivo. Leveckis J, et al. **Br J Cancer** 1995 Nov;72(5):1113–9

Apoptosis and necrosis induced with light and 5-aminolaevulinic acid-derived protoporphyrin IX. Noodt BB, et al. **Br J Cancer** 1996 Jul;74(1):22–9

A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model. Orenstein A, et al. **Br J Cancer** 1996 Apr; 73(8):937–44

Induction of tumor necrosis by delta-aminolevulinic acid and 1,10-phenanthroline photodynamic therapy. Rebeiz N, et al. **Cancer Res** 1996 Jan 15;56(2):339–44

Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells in vitro. Riesenberg R, et al. **Eur J Cancer** 1996 Feb;32A(2):328–34

The prooxidant effect of 5-aminolevulinic acid in the brain tissue of rats: implications in neuropsychiatric manifestations in porphyrias. Demasi M, et al. **Free Radic Biol Med** 1996;20(3):291–9

How do Ca2+ and 5-aminolevulinic acid-derived oxyradicals promote injury to isolated mitochondria? Hermes-Lima M. **Free Radic Biol Med** 1995 Sep; 19(3):381–90 (87 ref.)

Wavelength dependency of photodynamic effects after sensitization with 5-aminolevulinic acid in vitro and in vivo. Szeimies RM, et al. **J Invest Dermatol** 1995 Nov; 105(5):672–7

Formation of water-soluble porphyrins and protoporphyrin IX in 5-aminolevulinic-acid-incubated carcinoma cells. Dietel W, et al. **J Photochem Photobiol B** 1996 May; 33(3):225–31

HepG2 human hepatocarcinoma cells: an experimental model for photosensitization by endogenous porphyrins. Vonarx-Coinsman V, et al. **J Photochem Photobiol B** 1995 Oct;30(2-3):201–8

Photosensitization of the rat endometrium following 5-aminolevulinic acid induced photodynamic therapy. Steiner RA, et al. **Lasers Surg Med** 1996;18(3):301–8

The effect of ALA and radiation on porphyrin/heme biosynthesis in endothelial cells. He D, et al. **Photochem Photobiol** 1995 Jun;61(6):656–61

Photosensitization of murine tumor, vasculature and skin by 5-aminolevulinic acid-induced porphyrin. Henderson BW, et al. **Photochem Photobiol** 1995 Oct;62(4):780–9

Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Peng Q, et al. **Photochem Photobiol** 1995 Nov;62(5):906–13

Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid. Steinbach P, et al. **Photochem Photobiol** 1995 Nov; 62(5):887–95

Subcellular damage kinetics within co-cultivated WI38 and VA13-transformed WI38 human fibroblasts following 5-aminolevulinic acid-induced protoporphyrin IX formation. Uberriegler KP, et al. **Photochem Photobiol** 1995 Dec;62(6):1052–7

THERAPEUTIC USE

Efficacy of intravenous delta-aminolaevulinic acid photodynamic therapy on rabbit papillomas. Lofgren LA, et al. **Br J Cancer** 1995 Oct;72(4):857–64

Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Fijan S,

et al. **Br J Dermatol** 1995 Aug;133(2):282–8
Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Kriegmair M, et al. **Br J Urol** 1996 May;77(5):667–71
Topical photodynamic therapy in verrucae. A pilot study. Ammann R, et al. **Dermatology** 1995;191(4):346–7
Intra-operative laser-induced photodynamic therapy in the treatment of experimental hepatic tumours. Liu DL, et al. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1073–80
Photodynamic therapy for condylomata acuminata with local application of 5-aminolevulinic acid. Frank RG, et al. **Genitourin Med** 1996 Feb;72(1):70–1
Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. Calzavara-Pinton PG. **J Photochem Photobiol B** 1995 Jul;29(1):53–7
Photodynamic therapy on rat urinary bladder with intravesical instillation of 5-aminolevulinic acid: light diffusion and histological changes. Chang SC, et al. **J Urol** 1996 May;155(5):1749–53
Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX [see comments] Barr H, et al. **Lancet** 1996 Aug 31;348(9027):584–5. Comment in: Lancet 1996 Aug 31;348(9027):561–2.
Management of Barrett's oesophagus [comment] Kelley DJ, et al. **Lancet** 1996 Aug 31;348(9027):561–2. Comment on: Lancet 1996 Aug 31;348(9027):584–5.
Problems associated with the use of broad-band illumination sources for photodynamic therapy [letter] Stringer MR. **Phys Med Biol** 1995 Oct;40(10):1733–5

TOXICITY

Does delta-aminolaevulinic acid induce genotoxic effects? Fiedler DM, et al. **J Photochem Photobiol B** 1996 Mar; 33(1):39–44

URINE

The delta-aminolaevulinic acid level as an indication of lead contamination in school children. Swięs Z, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:149–52
An improved direct method for the measurement of urinary delta-aminolevulinic acid. Buttery JE, et al. **Clin Biochem** 1995 Aug;28(4):477–80
Postlabeling analysis of DNA adducts in white blood cells from lead smelter workers [letter] Ichiba M, et al. **Ind Health** 1994;32(4):253–6
Correlation between lead in plasma and other indicators of lead exposure among lead-exposed workers. Hirata M, et al. **Int Arch Occup Environ Health** 1995;68(1):58–63
Visual evoked potentials N75 and P100 latencies correlate with urinary delta-aminolevulinic acid, suggesting gamma-aminobutyric acid involvement in their generation. Solliway BM, et al. **J Neurol Sci** 1995 Dec;134(1-2):89–94

AMINOLEVULINIC ACID DEHYDRATASE

ANALYSIS

[delta-Aminolevulinic acid dehydratase] Tajima Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:886–90 (25 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism. Richardson DR, et al. **Blood** 1996 Apr 15;87(8):3477–88

BLOOD

Delta-aminolevulinic acid dehydratase: a sensitive indicator of lead exposure in broiler chicks (Gallus domesticus). Bakalli RI, et al. **Bull Environ Contam Toxicol** 1995 Dec; 55(6):833–9

CHEMISTRY

Purification, metal cofactor, N-terminal sequence and subunit composition of a 5-aminolevulinic acid dehydratase from the unicellular green alga Scenedesmus obliquus, mutant C-2A'. Stolz M, et al. **Eur J Biochem** 1996 Mar 1; 236(2):600–8
Evidence of an essential lysine in pig liver 5-aminolevulinic acid dehydratase. Sopena de Kracoff YE, et al. **Int J Biochem Cell Biol** 1995 Dec;27(12):1331–9
The phylogenetically conserved histidines of Escherichia coli porphobilinogen synthase are not required for catalysis. Mitchell LW, et al. **J Biol Chem** 1995 Oct 13; 270(41):24054–9
Bradyrhizobium japonicum porphobilinogen synthase uses two Mg(II) and monovalent cations. Petrovich RM, et al. **J Biol Chem** 1996 Apr 12;271(15):8692–9

DEFICIENCY

delta-Aminolevulinic acid dehydratase deficiency porphyria (ADP) with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in a 69-year-old woman. Muraoka A, et al. **Kobe J Med Sci** 1995 Apr;41(1-2):23–31

DRUG EFFECTS

Kinetics of aluminum-induced inhibition of delta-aminolevulinic acid dehydratase in vitro. Schroeder TM, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):927–31

GENETICS

Associations of delta-aminolevulinic acid dehydratase genotype with plant, exposure duration, and blood lead and zinc protoporphyrin levels in Korean lead workers. Schwartz BS, et al. **Am J Epidemiol** 1995 Oct 1; 142(7):738–45
Distribution of ACP1, AK1 and ALAD polymorphisms in northern Portugal. Amorim A, et al. **Gene Geogr** 1994 Aug; 8(2):147–50
Structure and expression of the Chlorobium vibrioforme hemB gene and characterization of its encoded enzyme, porphobilinogen synthase. Rhie G, et al. **J Biol Chem** 1996 Apr 5;271(14):8176–82
ALA-D genotype is not associated with HT or HB levels among workers exposed to low levels of lead. Smith CM, et al. **Med Lav** 1995 May-Jun;86(3):229–35
Genetic regulation of delta-aminolevulinate dehydratase during erythropoiesis. Bishop TR, et al. **Nucleic Acids Res** 1996 Jul 1;24(13):2511–8

METABOLISM

Delta-aminolevulinic acid dehydratase activity in weanling and adult rats exposed to lead acetate. Rodrigues AL, et al. **Bull Environ Contam Toxicol** 1996 Jul;57(1):47–53
The affinity of human erythrocyte porphobilinogen synthase for Zn2+ and Pb2+. Simons TJ. **Eur J Biochem** 1995 Nov 15;234(1):178–83
Porphobilinogen synthase, the first source of heme's asymmetry. Jaffe EK. **J Bioenerg Biomembr** 1995 Apr; 27(2):169–79 (76 ref.)
The phylogenetically conserved histidines of Escherichia coli porphobilinogen synthase are not required for catalysis. Mitchell LW, et al. **J Biol Chem** 1995 Oct 13; 270(41):24054–9

PHARMACOLOGY

On the formation of the mixed pyrrole catalysed by porphobilinogen synthase from Rhodobacter spheroides. Lüönd RM, et al. **Biochim Biophys Acta** 1996 Feb 9; 1289(1):83–6

AMINOLEVULINIC ACID SYNTHETASE

ANALYSIS

[delta-Aminolevulinic acid synthase(ALAS)] Kondo M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:881–5 (27 ref.) **(Jpn)**

BIOSYNTHESIS

Phenobarbital-induced activation of CYP2H1 and 5-aminolevulinate synthase genes in chick embryo hepatocytes is blocked by an inhibitor of protein phosphorylation. Dogra SC, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):271–8
Ferrochelatase binds the iron-responsive element present in the erythroid 5-aminolevulinate synthase mRNA. Ferreira GC. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):875–8
Induction of 5-aminolevulinate synthase by drugs is independent of increased apocytochrome P450 synthesis. Jover R, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):152–7
Inhibition of hemoglobin expression by heterologous production of nitric oxide synthase in the K562 erythroleukemic cell line. Rafferty SP, et al. **Blood** 1996 Aug 1;88(3):1070–8

GENETICS

Active site of 5-aminolevulinate synthase resides at the subunit interface. Evidence from in vivo heterodimer formation. Tan D, et al. **Biochemistry** 1996 Jul 9; 35(27):8934–41
Molecular defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia. Bottomley SS, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):161–8 (50 ref.)
Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts [see comments] Cotter PD, et al. **J Clin Invest** 1995 Oct;96(4):2090–6. Comment in: J Clin Invest 1995 Oct;96(4):1605.

METABOLISM

Active site of 5-aminolevulinate synthase resides at the subunit interface. Evidence from in vivo heterodimer formation. Tan D, et al. **Biochemistry** 1996 Jul 9; 35(27):8934–41
5-Aminolevulinate synthase and the first step of heme biosynthesis. Ferreira GC, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):151–9 (84 ref.)
The effects of bromocriptine and prolactin on porphyrin biosynthesis and morphology in the female hamster harderian gland. Shah SW, et al. **J Comp Physiol [B]** 1996; 166(2):144–9

1-AMINONAPHTHALENE see **1-NAPHTHYLAMINE**

2-AMINONAPHTHALENE see **2-NAPHTHYLAMINE**

6-AMINONICOTINAMIDE

METABOLISM

Mechanisms of resistance to 6-aminonicotinamide. Saunders PP, et al. **Anticancer Res** 1996 Mar-Apr;16(2):843–8

PHARMACOLOGY

13C and 31P NMR investigation of effect of 6-aminonicotinamide on metabolism of RIF-1 tumor cells in vitro. Street JC, et al. **J Biol Chem** 1996 Feb 23; 271(8):4113–9
Age-dependent susceptibility of CNS glial populations in situ to the antimetabolite 6-aminonicotinamide. Krum JM. **Mol Chem Neuropathol** 1995 Oct;26(2):79–94

TOXICITY

The effect of 6-aminonicotinamide on testicular development in the rat. Bolin DC, et al. **Vet Hum Toxicol** 1996 Apr; 38(2):85–8

AMINOOXYACETATE see **AMINOOXYACETIC ACID**

AMINOOXYACETIC ACID

DIAGNOSTIC USE

Aminooxy acetic acid: a selective inhibitor of alanine:glyoxylate aminotransferase and its use in the diagnosis of primary hyperoxaluria type I. Andy V, et al. **Clin Chim Acta** 1995 Dec 29;243(2):105–14

PHARMACOLOGY

Aminooxy acetic acid: a selective inhibitor of alanine:glyoxylate aminotransferase and its use in the diagnosis of primary hyperoxaluria type I. Andy V, et al. **Clin Chim Acta** 1995 Dec 29;243(2):105–14
Stimulation by aminooxyacetate of fluorescein uptake in rat renal tubules in vitro: role of intracellular alpha-ketoglutarate. Nikiforov AA. **J Pharmacol Exp Ther** 1995 Sep;274(3):1204–8
Differential neuronal vulnerability to amino-oxyacetate and quinolinate in the rat parahippocampal region. Eid T, et al. **Neuroscience** 1995 Oct;68(3):645–56

AMINOPEPTIDASE N see **ANTIGENS, CD13**

AMINOPEPTIDASES

ANALYSIS

Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study. Moehrle MC, et al. **J Cutan Pathol** 1995 Jun;22(3):241–7
[Glycylproline dipeptidyl aminopeptidase (GPDAP)] Matsuda Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:365–8 (20 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Acetaldehyde inhibits serum aminopeptidases. Brecher AS, et al. **Alcohol** 1996 Mar-Apr;13(2):125–31
Aminopeptidase inhibitor ubenimex (bestatin) inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity. Inoi K, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2081–7
Inhibition and metal ion activation of pig kidney aminopeptidase P. Dependence on nature of substrate. Lloyd GS, et al. **Biochem Pharmacol** 1996 Jul 26; 52(2):229–36
The structure of the Aeromonas proteolytica aminopeptidase complexed with a hydroxamate inhibitor. Involvement in catalysis of Glu151 and two zinc ions of the co-catalytic unit. Chevrier B, et al. **Eur J Biochem** 1996 Apr 15; 237(2):393–8
An aminopeptidase inhibitor, bestatin, enhances progesterone and oestradiol secretion by porcine granulosa cells stimulated with follicle stimulating hormone in vitro. Tachibana T, et al. **Hum Reprod** 1996 Mar;11(3):497–502
Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. Prechel MM, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1136–42
Peptides inhibitory to endopeptidase and aminopeptidase from Lactococcus lactis ssp. lactis MG1363, released from bovine beta-casein by chymosin, trypsin or chymotrypsin. Stepaniak L, et al. **Z Lebensm Unters Forsch** 1996 Apr; 202(4):329–33

BIOSYNTHESIS

Expression of aminopeptidase A, an angiotensinase, in glomerular mesangial cells. Troyanovskaya M, et al. **Hypertension** 1996 Mar;27(3 Pt 2):518–22

BLOOD

Flow cytometric determination of aminopeptidase activities in viable cells using fluorogenic rhodamine 110 substrates. Ganesh S, et al. **Cytometry** 1995 Aug 1;20(4):334–40

Recognition of lactoferrin and aminopeptidase M–modified lactoferrin by the liver: involvement of the remnant receptor. Ziere GJ, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:118–21

CHEMISTRY

Characterisation of porcine aminopeptidase A: a type II integral membrane protein. Hesp JR, et al. **Biochem Soc Trans** 1995 Nov;23(4):550S

Chemical modification of aminopeptidase P: identification of a critical histidyl residue. Lim J, et al. **Biochem Soc Trans** 1995 Nov;23(4):549S

The structure of the Aeromonas proteolytica aminopeptidase complexed with a hydroxamate inhibitor. Involvement in catalysis of Glu151 and two zinc ions of the co-catalytic unit. Chevrier B, et al. **Eur J Biochem** 1996 Apr 15; 237(2):393–8

Aminopeptidase from Streptomyces griseus: primary structure and comparison with other zinc-containing aminopeptidases. Maras B, et al. **Eur J Biochem** 1996 Mar 15;236(3):843–6

The C-terminal domain of peptide deformylase is disordered and dispensable for activity. Meinnel T, et al. **FEBS Lett** 1996 Apr 29;385(1–2):91–5

Bacterial aminopeptidases: properties and functions. Gonzales T, et al. **FEMS Microbiol Rev** 1996 Jul;18(4):319–44 (252 ref.)

Identification of glutamate residues essential for catalytic activity and zinc coordination in aminopeptidase A. Vazeux G, et al. **J Biol Chem** 1996 Apr 12;271(15):9069–74

Mapping of the active site zinc ligands of peptide deformylase. Meinnel T, et al. **J Mol Biol** 1995 Nov 24; 254(2):175–83

DRUG EFFECTS

[Change in activity of enkephalinase from various structures of the rat brain during administration of naloxone and in morphine tolerance] Panchenko LF, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):492–4 **(Rus)**

GENETICS

Glomerular mRNA expression of angiotensinase A after renal ablation. Wolf G, et al. **Exp Nephrol** 1995 Jul–Aug; 3(4):240–8

Identification of regulatory proteins that might be involved in carbon catabolite repression of the aminopeptidase I gene of the yeast Saccharomyces cerevisiae. Bordallo J, et al. **FEBS Lett** 1995 Nov 27;376(1–2):120–4

Regulation of the yeast vacuolar aminopeptidase Y gene (APY1) expression. Herrera-Camacho I, et al. **FEMS Microbiol Lett** 1996 Jun 1;139(2–3):127–32

Cloning and sequence analysis of the aminopeptidase My gene from Mycoplasma salivarium. Shibata K, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):19–24

Prolyl aminopeptidase is also present in Enterobacteriaceae: cloning and sequencing of the Hafnia alvei enzyme-gene and characterization of the expressed enzyme. Kitazono A, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):468–74

Puromycin-sensitive aminopeptidase. Sequence analysis, expression, and functional characterization. Constam DB, et al. **J Biol Chem** 1995 Nov 10;270(45):26931–9

Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. Keller SR, et al. **J Biol Chem** 1995 Oct 6;270(40):23612–8

[Expression of GP160 mRNA in renal cell carcinoma: an attempt to predict the sensitivity of IFN-alpha therapy] Kimura F, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1424–8 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Regulation of B cell precursor proliferation by aminopeptidase A. Welch PA. **Int Immunol** 1995 May; 7(5):737–46

ISOLATION & PURIFICATION

The proteolytic system of Lactobacillus sanfrancisco CB1: purification and characterization of a proteinase, a dipeptidase, and an aminopeptidase. Gobbetti M, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3220–6

Aminopeptidase from Streptomyces griseus: primary structure and comparison with other zinc-containing aminopeptidases. Maras B, et al. **Eur J Biochem** 1996 Mar 15;236(3):843–6

Proline iminopeptidase from the outer cell envelope of the human oral spirochete Treponema denticola ATCC 35405. Mäkinen KK, et al. **Infect Immun** 1996 Mar;64(3):702–8

Capnocytophaga gingivalis aminopeptidase: a potential virulence factor. Spratt DA, et al. **Microbiology** 1995 Dec; 141 (Pt 12):3087–93

METABOLISM

Two novel metallopeptidases with a specificity for basic residues: functional properties, structure and cellular distribution. Foulon T, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:106–20 (49 ref.)

An intracellular aminopeptidase from Streptomyces rimosus that prefers basic amino acids. Vitale L, et al. **Arch Microbiol** 1996 Jun;165(6):409–14

Recognition of lactoferrin and aminopeptidase M–modified lactoferrin by the liver: involvement of proteoglycans and the remnant receptor. Ziere GJ, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):289–95

Inhibition and metal ion activation of pig kidney aminopeptidase P. Dependence on nature of substrate. Lloyd GS, et al. **Biochem Pharmacol** 1996 Jul 26; 52(2):229–36

The characterization of two aminopeptidase activities from the cyanobacterium Anabaena flos-aquae. Niven GW. **Biochim Biophys Acta** 1995 Dec 6;1253(2):193–8

Characterization of the aminopeptidase activity of epidermal leukotriene A4 hydrolase against the opioid dynorphin fragment 1–7. Nissen JB, et al. **Br J Dermatol** 1995 Nov; 133(5):742–9

Decrease in cytosolic Aspartyl-aminopeptidase but not in Alanyl-aminopeptidase activity in the frontal cortex of the aged rat. Iribar C, et al. **Brain Res** 1995 Jul 31; 687(1–2):211–3

Monocyte- and cytokine-induced downregulation of angiotensin-converting enzyme in cultured human and porcine endothelial cells. Papapetropoulos A, et al. **Circ Res** 1996 Sep;79(3):512–23

Comparison of leucine aminopeptidase and aminopeptidase III activities in lens. Sharma KK, et al. **Curr Eye Res** 1996 Jul;15(7):774–81

Angiotensinase A gene expression and enzyme activity in isolated glomeruli of diabetic rats. Thaiss F, et al. **Diabetologia** 1996 Mar;39(3):275–80

Yeast aminopeptidase I is post-translationally sorted from the cytosol to the vacuole by a mechanism mediated by its bipartite N-terminal extension. Seguí-Real B, et al. **EMBO J** 1995 Nov 15;14(22):5476–84

Chemical modification of porcine kidney aminopeptidase P indicates the involvement of two critical histidine residues. Lim J, et al. **FEBS Lett** 1996 Mar 4;381(3):188–90

Identification and characterization of an exercise-sensitive pool of glucose transporters in skeletal muscle. Coderre L, et al. **J Biol Chem** 1995 Nov 17;270(46):27584–8

Genetic and phenotypic overlap between autophagy and the cytoplasm to vacuole protein targeting pathway. Harding TM, et al. **J Biol Chem** 1996 Jul 26;271(30):17621–4

Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. Keller SR, et al. **J Biol Chem** 1995 Oct 6;270(40):23612–8

Characterization of the insulin-regulated membrane aminopeptidase in 3T3-L1 adipocytes. Ross SA, et al. **J Biol Chem** 1996 Feb 9;271(6):3328–32

Identification of a cytoplasm to vacuole targeting determinant in aminopeptidase I. Oda MN, et al. **J Cell Biol** 1996 Mar;132(6):999–1010

Acid, basic and neutral soluble and membrane-bound aminopeptidase activities after lidocaine administration in discrete areas of the rat brain. de Gandarias JM, et al. **J Hirnforsch** 1995;36(3):349–52

Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. Mentzel S, et al. **J Histochem Cytochem** 1996 May;44(5):445–61

Proteolytic enzyme activity and Plasmodium falciparum sporogonic development in three species of Anopheles mosquitoes. Chege GM, et al. **J Parasitol** 1996 Feb; 82(1):11–6

Phosphorylation of enkephalins enhances their proteolytic stability. Dass C, et al. **Life Sci** 1996;58(13):1039–45

Membrane-bound tyrosine aminopeptidase activities in the rat brain throughout the estrous cycle. de Gandarias JM, et al. **Life Sci** 1996;59(13):1097–101

A non-essential glutamyl aminopeptidase is required for optimal growth of Lactococcus lactis MG1363 in milk. l'Anson KJ, et al. **Microbiology** 1995 Nov;141 (Pt 11):2873–81

Changes in puromycin-sensitive aminopeptidases in postmortem schizophrenic brain regions. Hui M, et al. **Neurochem Int** 1995 Oct–Nov;27(4–5):433–41

Histochemical evaluation of placental angiotensinase A in pre-eclampsia: enzyme activity in villous trophoblast indicates an enhanced likelihood of gestational proteinuric hypertension. Neudeck H, et al. **Placenta** 1996 Mar–Apr; 17(2–3):155–63

Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases. Li X, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12357–61

HPr: heteromorphous protein. Vadeboncoeur C. **Res Microbiol** 1995 Sep;146(7):525–30 (41 ref.)

[Electron-histochemical data on localizing aminopeptidase M in the liver] Ryvniak VV, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):312–4 **(Rus)**

PHYSIOLOGY

Bacterial aminopeptidases: properties and functions. Gonzales T, et al. **FEMS Microbiol Rev** 1996 Jul;18(4):319–44 (252 ref.)

AMINOPHENAZONE see **AMINOPYRINE**

AMINOPHENOLS

METABOLISM

Reactivity of glutathione adducts of 4-(dimethylamino)phenol. Involvement of reactive oxygen species during the interaction with oxyhemoglobin. Ludwig E, et al. **Chem Res Toxicol** 1995 Apr–May;8(3):363–8

TOXICITY

Evaluation of cross-sensitization among dye-intermediate agents using a modified lymphocyte transformation test. Li Q, et al. **Arch Toxicol** 1996;70(7):414–9

Genotoxic effects of p-aminophenol in Chinese hamster ovary and mouse lymphoma cells: results of a multiple endpoint test. Majeska JB, et al. **Environ Mol Mutagen** 1995;26(2):163–70

Toxicity evaluation of two treatment regimens for cyanide poisoning. Bhattacharya R, et al. **J Appl Toxicol** 1995 Nov–Dec;15(6):439–41

In vitro studies on the genotoxicity of 2,4-dichloro-6-nitrophenol ammonium (DCNPA) and its major metabolite. Heng ZC, et al. **Mutat Res** 1996 Jun 12;368(2):149–55

Nephrotoxicity of 4-amino-2-chlorophenol and 2-amino-4-chlorophenol in the Fischer 344 rat. Hong SK, et al. **Toxicology** 1996 Jun 17;110(1–3):47–58

Susceptibility of primary cultures of proximal tubular and distal tubular cells from rat kidney to chemically induced toxicity. Lash LH, et al. **Toxicology** 1995 Nov 30; 103(2):85–103

2-AMINO-5-PHOSPHONOPENTANOIC ACID see **2-AMINO-5-PHOSPHONOVALERATE**

2-AMINO-5-PHOSPHONOVALERATE

ANALOGS & DERIVATIVES

Ethanol withdrawal hyperexcitability in vitro is selectively decreased by a competitive NMDA receptor antagonist. Ripley TL, et al. **Brain Res** 1995 Nov 13;699(1):1–11

Effects of the competitive NMDA receptor antagonist CGP 37849 on performance of reference and working memory tasks by rats. Deacon RM, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):239–42

Digestion of rhizocticins to (Z)-L-2-amino-5-phosphono-3-pentenoic acid: revision of the absolute configuration of plumbemycins A and B. Fredenhagen A, et al. **J Antibiot (Tokyo)** 1995 Sep; 48(9):1043–5

Systemic NMDA receptor antagonist CGP-40116 does not impair memory acquisition but protects against NMDA neurotoxicity in rhesus monkeys. Gutnikov SA, et al. **J Neurosci** 1996 Jun 15;16(12):4041–5

Systemic NMDA antagonist CGP-37849 produces non-specific impairment in a working memory task: the effect does not resemble those of AP5 and of lesions of the hippocampus or fornix. Gutnikov SA, et al. **Neuropsychologia** 1996 Apr;34(4):311–4

Inhibition of [3H]CGP 39653 binding to NMDA receptors by a P2 antagonist, suramin. Balcar VJ, et al. **Neuroreport** 1995 Dec 29;7(1):69–72

PHARMACOLOGY

Detailed behavioral analysis of water maze acquisition under APV or CNQX: contribution of sensorimotor disturbances to drug-induced acquisition deficits. Cain DP, et al. **Behav Neurosci** 1996 Feb;110(1):86–102

Taste-potentiated odor conditioning: impairment produced by infusion of an N-methyl-D-aspartate antagonist into basolateral amygdala. Hatfield T, et al. **Behav Neurosci** 1995 Aug;109(4):663–8

Sleep effects following intrathecal administration of the 5-HT1A agonist 8-OH-DPAT and the NMDA antagonist AP-5 in rats. Bjørkum AA, et al. **Brain Res** 1995 Sep 18; 692(1–2):251–8

Tolerance to ketamine-induced blockade of cortical spreading depression transfers to MK-801 but not to AP5 in rats. Rashidy-Pour A, et al. **Brain Res** 1995 Sep 25; 693(1–2):64–9

Neurotoxicity of dopamine and protective effects of the NMDA receptor antagonist AP-5 differ between male and female dopaminergic neurons. Lieb K, et al. **Exp Neurol** 1995 Aug;134(2):222–9

The muscarine antagonist methscopolamine and the NMDA antagonist AP-5 injected unilaterally into the nucleus accumbens cause mice to rotate in opposite directions. Svensson A, et al. **J Neural Transm Gen Sect** 1995; 101(1–3):149–57

Importance of NMDA receptors for multimodal integration in the deep layers of the cat superior colliculus. Binns KE, et al. **J Neurophysiol** 1996 Feb;75(2):920–30

NMDA receptor upregulation: molecular studies in cultured mouse cortical neurons after chronic antagonist exposure. Follesa P, et al. **J Neurosci** 1996 Apr 1;16(7):2172–8

Protection by MK-801 against hypoxia-, excitotoxin-, and depolarization-induced neuronal damage in vitro. Schurr A, et al. **Neurochem Int** 1995 May;26(5):519–25

Systemic NMDA antagonist CGP-37849 produces non-specific impairment in a working memory task: the

2-AMINO-5-PHOSPHONOVALERATE

effect does not resemble those of AP5 and of lesions of the hippocampus or fornix. Gutnikov SA, et al. **Neuropsychologia** 1996 Apr;34(4):311-4

Glutamate receptor blockade at cortical synapses disrupts development of thalamocortical and columnar organization in somatosensory cortex. Fox K, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5584-9

2-AMINO-5-PHOSPHONOVALERIC ACID see **2-AMINO-5-PHOSPHONOVALERATE**

AMINOPHYLLINE

Aminophylline: could it act as an antioxidant in vivo? Lapenna D, et al. **Eur J Clin Invest** 1995 Jul;25(7):464-70

ADMINISTRATION & DOSAGE

Nebulized fenoterol versus i.v. aminophylline treatment of acute severe asthma [letter] Pan JF, et al. **Am J Emerg Med** 1995 Nov;13(6):677-80

Asthma treatment in pregnancy: a randomized controlled study. Wendel PJ, et al. **Am J Obstet Gynecol** 1996 Jul; 175(1):150-4

Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate. Gomaa A, et al. **BMJ** 1996 Jun 15; 312(7045):1512-5

[Early effects of intravenous steroid therapy on cell recruitment in sputum of chronic asthmatics] Maeda Y, et al. **Arerugi** 1995 Sep;44(9):1111-6 (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Kinetics of theophylline in apnea of prematurity in small for gestational age babies. Chaudhuri M, et al. **Indian Pediatr** 1996 Mar;33(3):181-7

PHARMACOLOGY

Different effects of acute administration of aminophylline and nitroglycerin on exercise capacity in patients with syndrome X. Radice M, et al. **Am J Cardiol** 1996 Jul 1; 78(1):88-92

Synthesis, toxicological, pharmacological, and bronchodilating activity in vitro of some xanthineacetic acid derivatives. Peikov P, et al. **Arch Pharm (Weinheim)** 1995 Jul-Aug;328(7-8):615-8

Aminophylline inhibits adaptation to ischaemia during angioplasty. Role of adenosine in ischaemic preconditioning [see comments] Claeys MJ, et al. **Eur Heart J** 1996 Apr; 17(4):539-44. Comment in: Eur Heart J 1996 Apr;17(4):490-1.

Effects of intracerebroventricular administration of aminophylline on hyperbaric-induced increase in carotid blood flow. Guerrero F, et al. **Eur J Appl Physiol** 1995; 71(1):87-94

Aminophylline and Doppler time-averaged mean velocity in the middle cerebral artery in preterm neonates. Govan JJ, et al. **J Paediatr Child Health** 1995 Oct;31(5):461-4

The effect of aminophylline on the contraction threshold of rat diaphragm fibers and its modification by 9-aminoacridine. Losavio AS, et al. **Life Sci** 1996; 58(13):1031-7

Carotid bodies and ventilatory response to hypoxia in aminophylline-treated piglets. Cattarossi L, et al. **Pediatr Pulmonol** 1995 Aug;20(2):94-100

THERAPEUTIC USE

Aminophylline versus caffeine citrate... [letter] Duc G, et al. **Acta Paediatr** 1995 Oct;84(10):1210; discussion 1099

Reversal of atropine-resistant atrioventricular block with intravenous aminophylline in the early phase of inferior wall acute myocardial infarction following treatment with streptokinase. Goodfellow J, et al. **Eur Heart J** 1995 Jun; 16(6):862-5

Impact of theophylline use in Wolff-Parkinson-White syndrome. Agwunobi J, et al. **J Natl Med Assoc** 1996 Jul; 88(7):450-2

Comparison of aminophylline and insulin infusions in treatment of hyperkalemia in patients with end-stage renal disease [letter] Duranay M, et al. **Nephron** 1996;73(1):105

[Practical experiences in the therapy of postoperative uremic crises] Bilkei G, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jun;108(6):230-2 (Eng. Abstr.) **(Ger)**

TOXICITY

Synthesis, toxicological, pharmacological, and bronchodilating activity in vitro of some xanthineacetic acid derivatives. Peikov P, et al. **Arch Pharm (Weinheim)** 1995 Jul-Aug;328(7-8):615-8

Pyridoxine as therapy in theophylline-induced seizures. Glenn GM, et al. **Vet Hum Toxicol** 1995 Aug;37(4):342-5

AMINOPROPANOLS see **PROPANOLAMINES**

3-AMINOPROPIONIC ACID see **BETA-ALANINE**

AMINOPROPIONITRILE

see related
LATHYRISM

PHARMACOKINETICS

Pharmacokinetic analysis of beta-aminopropionitrile in rabbits. Sevil MB, et al. **Vet Res** 1996;27(2):117-23

PHARMACOLOGY

Influence of dietary osteolathyrogens on the ultrastructure of shell and membranes of eggs from laying hens. Chowdhury SD, et al. **Br Poult Sci** 1995 Sep;36(4):575-83

[Effect of benzquercin on the connective tissue of lathyritic mice. Optic and electron microscopic study] Azzi G, et al. **Pathol Biol (Paris)** 1995 May;43(5):448-60 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Immune response of mice infected with Schistosoma mansoni is modulated by antifibrotic treatment. Giboda M, et al. **Ann Trop Med Parasitol** 1995 Aug;89(4):415-24

3-AMINOPROPYLENE see **ALLYLAMINE**

AMINOPROPYLTRANSFERASE see **PROPYLAMINE TRANSFERASE**

AMINOPTERIN

ANALOGS & DERIVATIVES

Studies on the antitumor effects of analogues of 5,8-dideazaisofolic acid and 5,8-dideazaisoaminopterin. Hagan RL, et al. **Biochem Pharmacol** 1995 Sep 7; 50(6):803-9

Radiation recall dermatitis induced by edatrexate in a patient with breast cancer. Perez EA, et al. **Cancer Invest** 1995; 13(6):604-7

Schedule-dependent edatrexate toxicity [letter; comment] Perez EA. **J Clin Oncol** 1996 Jan;14(1):322-3. Comment on: J Clin Oncol 1995 Jul;13(7):1649-55.

Analogues of 10-deazaaminopterin and 5-alkyl-5,10-dideazaaminopterin with the 4-substituted 1-naphthoyl group in the place of 4-substituted benzoyl. Piper JR, et al. **J Med Chem** 1996 Jan 19;39(2):614-8

Edatrexate studies in non-small cell lung cancer. Gralla RJ. **Lung Cancer** 1995 Apr;12 Suppl 1:S187-91 (21 ref.)

METABOLISM

Ligand-directed immunoaffinity purification and properties of the one-carbon, reduced folate transporter. Interspecies immuno-cross-reactivity and expression of the native transporter in murine and human tumor cells and their transport-altered variants. Chiao JH, et al. **J Biol Chem** 1995 Dec 15;270(50):29698-704

PHARMACOLOGY

Differential effects of the antifolates methotrexate, aminopterin and trimetrexate on murine haemopoietic progenitor cells. Stromhaug A, et al. **Br J Haematol** 1996 Mar;92(3):514-20

Import of a DHFR hybrid protein into glycosomes in vivo is not inhibited by the folate-analogue aminopterin. Häusler T, et al. **J Cell Biol** 1996 Feb;132(3):311-24

2-AMINOPURINE

NMR study of the conformation of the 2-aminopurine:cytosine mismatch in DNA. Fagan PA, et al. **Biochemistry** 1996 Apr 2;35(13):4026-33

ANALOGS & DERIVATIVES

Famciclovir: efficacy in zoster and issues in the assessment of pain. Boon RJ, et al. **Adv Exp Med Biol** 1996;394:17-31 (37 ref.)

Effects of famiciclovir in acute herpes zoster [letter] Tirelli U. **Ann Intern Med** 1996 Apr 15;124(8):775

Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Thackray AM, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):846-51

Oligonucleotides containing 2-aminoadenine and 2-thiothymine act as selectively binding complementary agents. Kutyavin IV, et al. **Biochemistry** 1996 Aug 27; 35(34):11170-6

Use of famciclovir and valaciclovir in the treatment of viral keratitis [letter] Gatchel S. **Clin Infect Dis** 1996 May; 22(5):886

Use of penciclovir and famciclovir in the management of genital herpes. Sacks SL. **Curr Probl Dermatol** 1996; 24:219-26 (34 ref.)

Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Perry CM, et al. **Drugs** 1995 Aug;50(2):396-415 (64 ref.)

Famciclovir for the treatment of herpes zoster. Gordon A. **J Fam Pract** 1996 Apr;42(4):350

New nucleoside analogues--time for caution? [letter] Nathwani D. **J Infect** 1995 Jul;31(1):82

Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. Thackray AM, et al. **J Infect Dis** 1996 Feb;173(2):291-9

Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. Sacks SL, et al. **JAMA** 1996 Jul 3;276(1):44-9

Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster. Boon RJ, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S76-7 (9 ref.)

Medicinal chemistry of difluoropurines. Andis SL, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):54-60

Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. Filer CW, et al. **Xenobiotica** 1995 May;25(5):477-90

PHARMACOLOGY

Phenobarbital-induced activation of CYP2H1 and 5-aminolevulinate synthase genes in chick embryo hepatocytes is blocked by an inhibitor of protein phosphorylation. Dogra SC, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):271-8

Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Wang GL, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):669-75

2-Aminopurine selectively inhibits splicing of tumor necrosis factor alpha mRNA. Jarrous N, et al. **Mol Cell Biol** 1996 Jun;16(6):2814-22

4-AMINOPYRIDINE

ANALOGS & DERIVATIVES

3,4-Diaminopyridine-evoked noradrenaline release in rat hippocampal slices: facilitation by endogenous or exogenous nitric oxide. Lauth D, et al. **Brain Res** 1995 Sep 18;692(1-2):174-82

3,4-Diaminopyridine and choline increase in vivo acetylcholine release in rat striatum. Buyukuysal RL, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):179-85

Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. Adler M, et al. **Toxicon** 1996 Feb;34(2):237-49

Failure of 3,4-diaminopyridine and edrophonium to produce significant clinical benefit in neurotoxicity following the bite of Papuan taipan (Oxyuranus scutellatus canni). Trevett AJ, et al. **Trans R Soc Trop Med Hyg** 1995 Jul-Aug; 89(4):444-6

[The central hemodynamic changes and reaction of the sympathoadrenal system with the use of an original Russian analgesic fenaridin as the analgetic component of general anesthesia during aortocoronary bypass operations in patients with chronic ischemic heart disease] Tenshibaeva DA, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):51-5 (Eng. Abstr.) **(Rus)**

[3,4-diaminopyridine in the treatment of myasthenic syndromes. Practical aspects (letter)] Vilchez JJ, et al. **Med Clin (Barc)** 1996 Jan 13;106(1):37-8 **(Spa)**

ANTAGONISTS & INHIBITORS

[Potassium channel openers antagonize 4-aminopyridine induced histamine release from rat peritoneal mast cells] Chen ZG, et al. **Yao Hsueh Hsueh Pao** 1995;30(10):736-40 (Eng. Abstr.) **(Chi)**

METABOLISM

Closed- and open-state binding of 4-aminopyridine to the cloned human potassium channel Kv1.5. Bouchard R, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):864-76

PHARMACOLOGY

Molecular mechanisms of K+ channel blockade: 4-aminopyridine interaction with a cloned cardiac transient K+ (Kv1.4) channel. Rasmusson RL, et al. **Adv Exp Med Biol** 1995;382:11-22

Modulation of action potential duration by inhibition of the transient outward current in sheep cardiac Purkinje fibers. Berger F, et al. **Basic Res Cardiol** 1995 May-Jun; 90(3):185-91

The pharmacological properties of K+ currents from rabbit isolated aortic smooth muscle cells. Halliday FC, et al. **Br J Pharmacol** 1995 Dec;116(8):3139-48

BaCl2- and 4-aminopyridine-evoked phasic contractions in the rat vas deferens. Huang Y. **Br J Pharmacol** 1995 Jul; 115(5):845-51

4-Aminopyridine differentially affects the spontaneous release of radiolabelled transmitters from rat brain slices in vitro. Versteeg DH, et al. **Brain Res** 1995 Jul 24; 686(2):233-8

Outward currents underlying repolarization in human atrial myocytes. Firek L, et al. **Cardiovasc Res** 1995 Jul;30(1):31-8

4-Aminopyridine-induced phasic contractions in rat caudal epididymis are mediated through release of noradrenaline. Huang Y. **Eur J Pharmacol** 1995 Jul 4;280(2):231-4

Use-dependent features of 4-aminopyridine block of transient outward current in rat ventricular myocytes. Christé G, et al. **Gen Physiol Biophys** 1995 Apr;14(2):75-89

4-aminopyridine acts as a weak base and a Ca2+ mobilizing agent in triggering oocyte meiosis reinitiation and activation in the Japanese clam Ruditapes philippinarum.

Gobet I, et al. **Int J Dev Biol** 1995 Jun;39(3):485–91

Effect of K+ channel blockade on fatigue in rat diaphragm muscle. Van Lunteren E, et al. **J Appl Physiol** 1995 Sep; 79(3):738–47

Effects of felbamate on muscarinic and metabotropic–glutamate agonist–mediated responses and magnesium–free or 4–aminopyridine–induced epileptiform activity in guinea pig olfactory cortex neurons in vitro. Libri V, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1759–69

Osmo– and mechanosensitivity of the transient outward K+ current in a mammalian neuronal cell line. Schoenmakers TJ, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):419–30

Potassium currents underlying the oscillatory response in hair cells of the goldfish sacculus. Sugihara I, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):443–53

Cellular mechanisms of 4–aminopyridine–induced synchronized after–discharges in the rat hippocampal slice. Traub RD, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):127–40

Preferential stimulation of glutamate release by 4–aminopyridine in rat striatum in vivo. Morales–Villagrán A, et al. **Neurochem Int** 1996 Jan;28(1):35–40

Opposite modulation of 4–aminopyridine and hypoxic hyperexcitability by A1 and A2 adenosine receptor ligands in rat hippocampal slices. Longo R, et al. **Neurosci Lett** 1995 Nov 10;200(1):21–4

POISONING

Atypical presentation of 4–aminopyridine overdose. Pickett TA, et al. **Ann Emerg Med** 1996 Mar;27(3):382–5

[Severe 4–aminopyridine poisoning in a body–builder (letter)] Oosterhuis HJ. **Ned Tijdschr Geneeskd** 1996 Feb 24; 140(8):452 **(Dut)**

[Severe poisoning by 4–aminopyridine in a body builder] Smeets JW, et al. **Ned Tijdschr Geneeskd** 1995 Dec 23; 139(51):2667–9 (Eng. Abstr.) **(Dut)**

THERAPEUTIC USE

Weak electromagnetic fields potentiate the effects of 4–aminopyridine in multiple sclerosis [letter] Sandyk R. **Int J Neurosci** 1996 Mar;85(1–2):125–9

Effect of calcium chloride and 4–aminopyridine therapy on desipramine toxicity in rats. Wananukul W, et al. **J Toxicol Clin Toxicol** 1996;34(5):499–506

AMINOPYRIDINES

Purification of 2–aminopyridine derivatives of oligosaccharides and related compounds by cation–exchange chromatography. Fan JQ, et al. **Anal Biochem** 1995 Nov 20;232(1):65–8

Nitric oxide synthase inhibitor facilitates focal seizures induced by aminopyridine in rat. Boda B, et al. **Neurosci Lett** 1996 May 3;209(1):37–40

ADVERSE EFFECTS

Contact dermatitis due to a new fungicide used in the tulip bulb industry. Bruynzeel DP, et al. **Contact Dermatitis** 1995 Jul;33(1):8–11

CHEMISTRY

Multi–dimensional mapping of pyridylamine–labeled N–linked oligosaccharides by capillary electrophoresis. Zieske LR, et al. **J Chromatogr A** 1996 Jan 12; 720(1–2):395–407

PHARMACOLOGY

Flupirtine protects neurons against excitotoxic or ischemic damage and inhibits the increase in cytosolic Ca2+ concentration. Rupalla K, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):469–73

4–(2'–Methoxyphenyl)–1–[2'–[N–(2"–pyridinyl)–p–iodobenzamido]ethyl] piperazine and 4–(2'–methoxyphenyl)–1–[2'–[N–(2"–pyridinyl)–p–fluorobenzamido]ethyl]piperazine, two new antagonists at pre– and postsynaptic serotonin–1A receptors. Thielen RJ, et al. **J Pharmacol Exp Ther** 1996 May;277(2):661–70

Antagonism of botulinum toxin–induced muscle weakness by 3,4–diaminopyridine in rat phrenic nerve–hemidiaphragm preparations. Adler M, et al. **Toxicon** 1995 Apr; 33(4):527–37

THERAPEUTIC USE

Protection of rabbit retina from ischemic injury by flupirtine. Osborne NN, et al. **Invest Ophthalmol Vis Sci** 1996 Feb; 37(2):274–80

Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Perovic S, et al. **Neurodegeneration** 1995 Dec;4(4):369–74

[Effectiveness of flupirtine in chronic tension headache. Results of a double–blind study versus placebo] Wörz R, et al. **Fortschr Med** 1995 Nov 20;113(32):463–8 (Eng. Abstr.) **(Ger)**

AMINOPYRINE

ADVERSE EFFECTS

[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121–4 (50 ref.) (Eng. Abstr.) **(Hun)**

BLOOD

Determination of aminopyrine and dipyrone metabolites in urine [letter] Agúndez JA, et al. **Ther Drug Monit** 1996 Feb;18(1):104–7

The determination of aminopyrine and dipyrone metabolites [letter] Zylber–Katz E, et al. **Ther Drug Monit** 1996 Feb; 18(1):103–4

DIAGNOSTIC USE

Aminopyrine breath test: development of a 13C–breath test for quantitative assessment of liver function in humans. Mion F, et al. **Hepatogastroenterology** 1995 Nov–Dec; 42(6):931–8

Aminopyrine infusion breath test for the determination of changes in P450 metabolism in vivo. Kuwahara SK, et al. **Xenobiotica** 1995 Sep;25(9):973–80

METABOLISM

Helicobacter pylori stimulates gastric acid secretion via platelet activating factor. Sobhani I, et al. **J Physiol Pharmacol** 1996 Mar;47(1):177–85

Continuous monitoring of 13C–aminopyrine metabolism in rats: effects of cold exposure and noradrenaline. Mion F, et al. **Life Sci** 1996;58(12):1001–8

AMINOPYRINE N–DEMETHYLASE

BLOOD

Stress response and drug metabolism in mice. Matamoros RA, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):255–63

METABOLISM

[Effect of heterochronic parabiosis on liver microsomal enzyme oxidation] Frol'kis VV, et al. **Dokl Akad Nauk** 1996 Apr;347(6):828–30 **(Rus)**

AMINOQUINOLINES

Characterization of N–(6–methoxy–8–quinolyl)–p–toluenesulfonamide for the detection of zinc in living sperm cells. Andrews JC, et al. **Cytometry** 1995 Oct 1;21(2):153–9

BLOOD

Quantification of the individual enantiomer plasma concentrations of the candidate antimalarial agent N4–[2,6–dimethoxy–4–methyl–5–[(3–trifluoromethyl) phenoxy]–8–quinolinyl] – 1,4–pentanediamine (WR 238,605). Karle JM, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):251–7

CHEMICAL SYNTHESIS

[Synthesis of estimated metabolites of 9–amino–2,3,5,6,7,8–hexahydro–1H–cyclopenta[b]quinoline monohydrochloride monohydrate (NIK–247). I. Synthesis of mono–hydroxylated metabolites] Komatsu T, et al. **Yakugaku Zasshi** 1995 Dec; 115(12):1016–21 (Eng. Abstr.) **(Jpn)**

[Synthesis of estimated metabolites of 9–amino–2,3,5,6,7,8–hexahydro–1H–cyclopenta[b]quinoline monohydrochloride monohydrate (NIK–247). II. Synthesis of dihydroxylated metabolites] Komatsu T, et al. **Yakugaku Zasshi** 1995 Dec; 115(12):1022–6 (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

The role of drug accumulation in 4–aminoquinoline antimalarial potency. The influence of structural substitution and physicochemical properties. Hawley SR, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):723–33

PHARMACOLOGY

Immunomodulating and antiviral activities of the imidazoquinoline S–28463. Tomai MA, et al. **Antiviral Res** 1995 Nov;28(3):253–64

Properties of the reversible, K(+)–competitive inhibitor of the gastric (H+/K+)–ATPase, SK&F 97574. II. Pharmacological properties. Parsons ME, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1551–6

Properties of the reversible K(+)–competitive inhibitor of the gastric (H+/K+)–ATPase, SK&F 97574. I. In vitro activity. Pope AJ, et al. **Biochem Pharmacol** 1995 Nov 9; 50(10):1543–9

SCH 51344 inhibits ras transformation by a novel mechanism. Kumar CC, et al. **Cancer Res** 1995 Nov 1;55(21):5106–17

Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH–diaphorase. Luo D, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):247–51

Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S–27609. Gibson SJ, et al. **J Interferon Cytokine Res** 1995 Jun;15(6):537–45

Block of cyclic nucleotide–gated channels in salamander olfactory receptor neurons by the guanylyl cyclase inhibitor LY83583. Leinders–Zufall T, et al. **J Neurophysiol** 1995 Dec;74(6):2759–62

H+–K+ ATPase inhibitors cause relaxation of guinea pig and human airway smooth muscle in vitro. Rhoden KJ, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):897–903

THERAPEUTIC USE

New drugs for hyperprolactinaemia. **Drug Ther Bull** 1995 Sep;33(9):65–7 (24 ref.)

Comparison among different dopamine–agonists of new formulation in the clinical management of macroprolactinomas. Colao A, et al. **Horm Res** 1995; 44(5):222–8

4–AMINOSALICYLIC ACID see **P–AMINOSALICYLIC ACID**

P–AMINOSALICYLIC ACID

THERAPEUTIC USE

Current problems with tuberculosis treatment. Grosset J. **Res Microbiol** 1996 Jan–Feb;147(1–2):10–6 (32 ref.)

AMINOSALICYLIC ACIDS

Diluted effect from diluted mesalamine rectal suspension? [letter; comment] Wiita B, et al. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2136–7. Comment on: Am J Hosp Pharm 1994 Dec 1;51(23):2955–7.

ADMINISTRATION & DOSAGE

A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Kam L, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1338–42

An oral preparation of mesalamine as long–term maintenance therapy for ulcerative colitis. A randomized, placebo–controlled trial. The Mesalamine Study Group. **Ann Intern Med** 1996 Jan 15;124(2):204–11

Coated oral 5–aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double–blind study. Ardizzone S, et al. **J Clin Gastroenterol** 1995 Dec;21(4):287–9

Comparison between high dose 5–aminosalicylic acid and 6–methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double–blind study. German 5–ASA Study Group. Gross V, et al. **Z Gastroenterol** 1995 Oct;33(10):581–4

[Crohn disease: prevention and drug therapy] Gross V, et al. **Chirurg** 1995 Aug;66(8):757–63 (42 ref.) (Eng. Abstr.) **(Ger)**

[5–aminosalicylic acid and chronic inflammatory bowel diseases in children] Klotz U. **Klin Padiatr** 1995 Sep–Oct; 207(5):285–7 (18 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Cutaneous hypersensitivity reaction to mesalazine [letter] Aparicio J, et al. **Am J Gastroenterol** 1996 Mar;91(3):620–1

Mesalamine–induced lung toxicity. Bitton A, et al. **Am J Gastroenterol** 1996 May;91(5):1039–40 (10 ref.)

Folliculitis and mesalamine [letter] Lizasoain J, et al. **Am J Gastroenterol** 1996 Apr;91(4):819–20

Nephrotoxicity associated with olsalazine. Wilcox GM, et al. **Am J Med** 1996 Feb;100(2):238–40

Adverse pulmonary effects of mesalamine [letter; comment] Muzzi A, et al. **Chest** 1995 Oct;108(4):1181. Comment on: Chest 1992 May;101(5):1469–71.

Pleuropericarditis related to the use of mesalamine. Gujral N, et al. **Dig Dis Sci** 1996 Mar;41(3):624–6 (12 ref.)

Mesalazine induced exacerbation of ulcerative colitis. Kapur KC, et al. **Gut** 1995 Dec;37(6):838–9

Leukopenia and thrombocytopenia as adverse effects of treatment with 5–aminosalicylic suppositories. Casellas F, et al. **J Clin Gastroenterol** 1996 Mar;22(2):160–1

Drug induced otalgia due to mesalazine and sulphasalazine. Wareing M, et al. **J Laryngol Otol** 1996 May;110(5):466–7

Mesalazine–associated interstitial nephritis. World MJ, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):614–21

[Ulcerative colitis and pericarditis. The role of mesalazine hypersensitivity] Loizeau E. **Rev Med Suisse Romande** 1995 Nov;115(11):935–8 **(Fre)**

[Mesalazine (letter)] Netzer P. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):42 **(Ger)**

[Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease] Netzer P. **Schweiz Med Wochenschr** 1995 Dec 16;125(50):2438–42 (Eng. Abstr.) **(Ger)**

BLOOD

Pharmacokinetics of 5–aminosalicylic acid from controlled–release capsules in man. Yu DK, et al. **Eur J Clin Pharmacol** 1995;48(3–4):273–7

CONTRAINDICATIONS

Olsalazine is contraindicated during pelvic radiation therapy: results of a double–blind, randomized clinical trial. Martenson JA Jr, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):299–303

METABOLISM

Interaction of 5–aminosalicylic acid with nitric oxide on rat aortic strips and human platelets. Pallapies D, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):145–9

AMINOSALICYLIC ACIDS

PHARMACOKINETICS

Distribution and concentrations of 5-aminosalicylic acid in rectosigmoid biopsy specimens after rectal administration. Schoonjans R, et al. **Dis Colon Rectum** 1996 Jul; 39(7):788–93

Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man. Yu DK, et al. **Eur J Clin Pharmacol** 1995;48(3–4):273–7

Bioavailability of controlled release mesalazine (5-ASA) preparations. Rasmussen SN. **J Gastroenterol** 1995 Nov;30 Suppl 8:112–4

Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission. Ewe K, et al. **Z Gastroenterol** 1996 Apr;34(4):225–9

PHARMACOLOGY

Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products. Lauritsen K, et al. **Adv Exp Med Biol** 1995;371B:1301–6 (66 ref.)

Antioxidant properties of 5-aminosalicylic acid: potential mechanism for its protective effect in ulcerative colitis. Miles AM, et al. **Adv Exp Med Biol** 1995;371B:1317–21 (20 ref.)

Comparison of the effects of sulphasalazine, 5-aminosalicylic acid and sulphapyridine on the humoral response to antigen in vivo. Sheldon P, et al. **Adv Exp Med Biol** 1995; 371B:905–8

Effects of mesalazine on lamina propria white cell functions. Verspaget HW. **Adv Exp Med Biol** 1995;371A:317–20 (20 ref.)

Leukocyte-endothelial cell interactions: potential targets for mesalazine in Crohn's disease. Wakefield AJ, et al. **Adv Exp Med Biol** 1995;371B:1307–11 (72 ref.)

The effects of aminosalicylic acid derivatives on nitric oxide in a cell-free system. Reynolds PD, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):491–5

The effect of 5-aminosalicylic acid, hydrocortisone and indomethacin on gamma interferon induced expression of HLA-DR antigens on colonic epithelium. Radwan P, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:104–8

Sulphasalazine, sulphapyridine or 5-aminosalicylic acid—which is the active moiety in rheumatoid arthritis? Bird HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:16–9 (11 ref.)

Endogenous antioxidant status in neoplastic and adjacent tissues in 1,2-dimethylhydrazine-induced colon cancer in rats: effects of olsalazine. Moghadasian MH, et al. **Carcinogenesis** 1996 May;17(5):983–7

Distribution and anti-inflammatory effect of mesalazine on carrageenan-induced colitis in the rabbit. Kitano A, et al. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):305–9

Chromonyl-aminosalicylic acid derivatives as possible antimycobacterial agents. Lácová M, et al. **Farmaco** 1995 Dec;50(12):885–8

5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferon. Di Paolo MC, et al. **Gut** 1996 Jan;38(1):115–9

THERAPEUTIC USE

Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Lémann M, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):557–62

Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease. Brzezinski A, et al. **Cleve Clin J Med** 1995 Sep–Oct;62(5):317–23 (37 ref.)

Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Florent C, et al. **Eur J Gastroenterol Hepatol** 1996 Mar;8(3):229–33

Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group [see comments] Fockens P, et al. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1025–30. Comment in: Eur J Gastroenterol Hepatol 1995 Nov;7(11):1017–9.

5-aminosalicylates in inflammatory bowel disease—the more the merrier? [editorial; comment] Forbes A. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1017–9. Comment on: Eur J Gastroenterol Hepatol 1995 Nov;7(11):1025–30.

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Modigliani R, et al. **Gastroenterology** 1996 Mar;110(3):688–93

A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Lee FI, et al. **Gut** 1996 Feb;38(2):229–33

Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. Munakata A, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:108–11

Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. Nakajima H, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:115–7

Aminosalicylates for the treatment of inflammatory bowel disease. Leichtner AM. **J Pediatr Gastroenterol Nutr** 1995 Oct;21(3):245–52 (66 ref.)

[Aminosalicylates in the treatment of idiopathic inflammatory bowel disease] Lukáš K. **Vnitr Lek** 1996 Feb;42(2):117–9 **(Cze)**

[Pharmaclinics—how I treat... Crohn disease] Belaiche J. **Rev Med Liege** 1995 Oct;50(10):409–10 **(Fre)**

[5-Aminosalicylic acid in the prevention of recurrences of Crohn's disease] Del Corso L, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1723–7 (Eng. Abstr.) **(Ger)**

[Autoimmune hemolytic anemia and ulcerative colitis] Rebocho L, et al. **Acta Med Port** 1995 Dec;8(12):701–3 (Eng. Abstr.) **(Por)**

AMINOSIDINE see **PAROMOMYCIN**

AMINOTRANSFERASES

ANALYSIS

Coupled enzymatic assay for estimation of branched-chain L-amino acid aminotransferase activity with 2-Oxo acid substrates. Schadewaldt P, et al. **Anal Biochem** 1996 Jun 15;238(1):65–71

Effect of administering cyclophosphamide and vitamin E on the levels of tumor-marker enzymes in rats with experimentally induced fibrosarcoma. Vinitha R, et al. **Jpn J Med Sci Biol** 1995 Jun;48(3):145–56

[Liver damage and obesity in pediatric age] Iughetti L, et al. **Pediatr Med Chir** 1996 Jan–Feb;18(1):57–9 (Eng. Abstr.) **(Ita)**

BIOSYNTHESIS

Cloning and expression of the mammalian cytosolic branched chain aminotransferase isoenzyme. Hutson SM, et al. **J Biol Chem** 1995 Dec 22;270(51):30344–52

Expression of a recoded nuclear gene inserted into yeast mitochondrial DNA is limited by mRNA-specific translational activation. Steele DF, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5253–7

BLOOD

The relationship between serum transaminase activities and fatty liver in children with simple obesity. Noguchi H, et al. **Acta Paediatr Jpn** 1995 Oct;37(5):621–5

Subclinical Addison's disease: a cause of persistent abnormalities in transaminase values. Boulton R, et al. **Gastroenterology** 1995 Oct;109(4):1324–7

Methotrexate therapy and liver disease [letter] Dufour JJ, et al. **N Engl J Med** 1996 Sep 19;335(12):898–9

[Addison disease: a rare cause of elevated serum aminotransferase activity (letter)] Lesur G, et al. **Gastroenterol Clin Biol** 1996;20(5):515–6 **(Fre)**

[Studies on predictive factors of prolonged cases in type C acute sporadic hepatitis—serial analysis of transaminase and anti-HCV markers] Harada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:515–20 **(Jpn)**

[Maculopapular exanthema caused by ritodrine, accompanied by transaminase increase (letter)] del Pozo Hernando LJ, et al. **Med Clin (Barc)** 1995 Sep 9;105(7):277–8 **(Spa)**

[The prevalence of hepatitis C antibodies among volunteer blood donors with elevated blood transaminase and antibodies to the B virus core antigen] Gavilán Carrasco JC, et al. **Rev Clin Esp** 1996 May;196(5):277–80 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Some fluorescent properties of non-enzymic transamination and measurement of the relative molecular mass of protein. He RQ, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):447–57

Analysis of the substrate-recognition mode of aromatic amino acid aminotransferase by combined use of quasisubstrates and site-directed mutagenesis: systematic hydroxy-group addition/deletion studies to probe the enzyme-substrate interactions. Hayashi H, et al. **Biochemistry** 1996 May 28; 35(21):6754–61

Cloning and expression of the mammalian cytosolic branched chain aminotransferase isoenzyme. Hutson SM, et al. **J Biol Chem** 1995 Dec 22;270(51):30344–52

Catalytic ability and stability of two recombinant mutants of D-amino acid transaminase involved in coenzyme binding. Van Ophem PW, et al. **Protein Sci** 1995 Dec; 4(12):2578–86

GENETICS

Phosphoserine aminotransferase from Bacillus circulans subsp. alkalophilus: purification, gene cloning and sequencing. Battchikova N, et al. **Biochim Biophys Acta** 1996 Jul 18;1295(2):187–94

Escherichia coli aminodeoxychorismate synthase: analysis of pabB mutations affecting catalysis and subunit association. Rayl EA, et al. **Biochim Biophys Acta** 1996 Jun 7; 1295(1):81–8

Molecular analysis of the yeast SER1 gene encoding 3-phosphoserine aminotransferase: regulation by general control and serine repression. Meicher K, et al. **Curr Genet** 1995 May;27(6):501–8

Doppelganger. Goldfarb P. **Hum Exp Toxicol** 1995 Nov; 14(11):932–3

The 46-kilodalton-hemolysin gene from Treponema denticola encodes a novel hemolysin homologous to aminotransferases. Chu L, et al. **Infect Immun** 1995 Nov; 63(11):4448–55

Evolutionary recruitment of biochemically specialized subdivisions of Family I within the protein superfamily of aminotransferases. Jensen RA, et al. **J Bacteriol** 1996 Apr; 178(8):2161–71 (68 ref.)

Fidelity of translation initiation of mRNA for the precursor of rat mitochondrial serine:pyruvate/alanine:glyoxylate aminotransferase. Funai T, et al. **J Biochem (Tokyo)** 1995 May;117(5):1008–16

Cloning and functional expression of a soluble form of kynurenine/alpha-aminoadipate aminotransferase from rat kidney. Buchli R, et al. **J Biol Chem** 1995 Dec 8; 270(49):29330–5

Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases. Eden A, et al. **J Biol Chem** 1996 Aug 23;271(34):20242–5

ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. Schuldiner O, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7143–8

IMMUNOLOGY

Immunological characterization of serine-glyoxylate aminotransferase and hydroxypyruvate reductase from a methylotrophic bacterium, Hyphomicrobium methylovorum GM2. Hagishita T, et al. **FEMS Microbiol Lett** 1996 Aug 15;142(1):49–52

ISOLATION & PURIFICATION

Phosphoserine aminotransferase from Bacillus circulans subsp. alkalophilus: purification, gene cloning and sequencing. Battchikova N, et al. **Biochim Biophys Acta** 1996 Jul 18;1295(2):187–94

METABOLISM

Enzymatic method for determination of branched-chain amino acid aminotransferase activity. Schadewaldt P, et al. **Anal Biochem** 1995 Sep 20;230(2):199–204

Analysis of the substrate-recognition mode of aromatic amino acid aminotransferase by combined use of quasisubstrates and site-directed mutagenesis: systematic hydroxy-group addition/deletion studies to probe the enzyme-substrate interactions. Hayashi H, et al. **Biochemistry** 1996 May 28; 35(21):6754–61

Interaction of pyridoxal 5'-phosphate with tryptophan-139 at the subunit interface of dimeric D-amino acid transaminase. Martinez del Pozo A, et al. **Biochemistry** 1996 Feb 20;35(7):2112–6

Escherichia coli aminodeoxychorismate synthase: analysis of pabB mutations affecting catalysis and subunit association. Rayl EA, et al. **Biochim Biophys Acta** 1996 Jun 7; 1295(1):81–8

4-O-phosphoryl-L-threonine, a substrate of the pdxC(serC) gene product involved in vitamin B6 biosynthesis. Drewke C, et al. **FEBS Lett** 1996 Jul 22;390(2):179–82

Kinetic characterization of 4-amino 4-deoxychorismate synthase from Escherichia coli. Viswanathan VK, et al. **J Bacteriol** 1995 Oct;177(20):5918–23

Glutamine:fructose-6-phosphate amidotransferase activity in cultured human skeletal muscle cells: relationship to glucose disposal rate in control and non-insulin-dependent diabetes mellitus subjects and regulation by glucose and insulin. Daniels MC, et al. **J Clin Invest** 1996 Mar 1; 97(5):1235–41

An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease. Pearson SJ, et al. **J Neural Transm Gen Sect** 1995;102(1):67–73

Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syndrome. Baran H, et al. **Life Sci** 1996;58(21):1891–9

L-alanine: 4,5-dioxovalerate transaminase in Leishmania donovani that differs from mammalian enzyme. Sagar R, et al. **Microbiol Res** 1995 Nov;150(4):419–23

Glutamine transaminase K is not a major cysteine S-conjugate beta-lyase of rat kidney mitochondria: evidence that a high-molecular weight enzyme fulfills this role. Abraham DG, et al. **Mol Pharmacol** 1995 Nov; 48(5):855–60

Catalytic ability and stability of two recombinant mutants of D-amino acid transaminase involved in coenzyme binding. Van Ophem PW, et al. **Protein Sci** 1995 Dec; 4(12):2578–86

PHYSIOLOGY

A role for pabAB, a p-aminobenzoate synthase gene of Streptomyces venezuelae ISP5230, in chloramphenicol biosynthesis. Brown MP, et al. **Microbiology** 1996 Jun;142 (Pt 6):1345–55

URINE

Urinary enzyme changes in children undergoing cineangiographic evaluation using iopromid. Kavukçu S, et al. **Int Urol Nephrol** 1995;27(2):131–5

AMINOTRIAZOLE see **AMITROLE**

AMIODARONE

ADMINISTRATION & DOSAGE

Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group [see comments] Kowey PR, et al. **Circulation** 1995 Dec 1;92(11):3255-63. Comment in: Circulation 1995 Dec 1;92(11):3154-5.

Intravenous amiodarone. Another option in the acute management of sustained ventricular tachyarrhythmias [editorial; comment] Naccarelli GV, et al. **Circulation** 1995 Dec 1;92(11):3154-5. Comment on: Circulation 1995 Dec 1;92(11):3255-63. Comment on: Circulation 1995 Dec 1;92(11):3264-72.

Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group [see comments] Scheinman MM, et al. **Circulation** 1995 Dec 1;92(11):3264-72. Comment in: Circulation 1995 Dec 1;92(11):3154-5.

Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. Di Biasi P, et al. **Eur J Cardiothorac Surg** 1995;9(10):587-91

Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. Galve E, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1079-82

Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. Levine JH, et al. **J Am Coll Cardiol** 1996 Jan;27(1):67-75

Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. Perry JC, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1246-50

Dangers of European resuscitation guidelines [letter] O'Kane D, et al. **Lancet** 1996 Feb 10;347(8998):400-1

Amiodarone in congestive heart failure [letter] Colli A. **N Engl J Med** 1995 Dec 14;333(24):1640; discussion 1640-1

[The reduction of beta-adrenoceptor density and the suppression of ectopic ventricular activity with low doses of amiodarone] Perna S, et al. **Cardiologia** 1992 Jul; 37(7):475-9 (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Amiodarone and sexual dysfunction [letter] Ahmad S. **Am Heart J** 1995 Dec;130(6):1320-1

Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. Boriani G, et al. **Am Heart J** 1996 Jun;131(6):1214-6

Danger of amiodarone therapy and elevated inspired oxygen concentrations in mice. Donica SK, et al. **Am J Cardiol** 1996 Jan 1;77(1):109-10

Reevaluation of amiodarone [letter; comment] Ahmad S. **Ann Intern Med** 1995 Nov 15;123(10):809. Comment on: Ann Intern Med 1995 May 1;122(9):689-700.

Reevaluation of amiodarone [letter; comment] Ahmed Z, et al. **Ann Intern Med** 1995 Nov 15;123(10):809. Comment on: Ann Intern Med 1995 May 1;122(9):689-700.

Insidiously evolving, occult drug interaction involving warfarin and amiodarone. Cheung B, et al. **BMJ** 1996 Jan 13;312(7023):107-8

Monitoring may need to be prolonged in patients given warfarin and amiodarone [letter] Tomlinson B, et al. **BMJ** 1996 Aug 3;313(7052):301-2

Lymphocytic pleural exudate in a patient receiving amiodarone. Carmichael LC, et al. **Br J Clin Pract** 1996 Jun;50(4):228-30

Amiodarone and reversible benign intracranial hypertension [letter] Ahmad S. **Cardiology** 1996 Jan-Feb;87(1):90

Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy. Macarri G, et al. **Ital J Gastroenterol** 1995 Oct-Nov;27(8):436-8 (18 ref.)

Ultrastructural evidence of thyroid damage in amiodarone-induced thyrotoxicosis. Cappiello E, et al. **J Endocrinol Invest** 1995 Dec;18(11):862-8

Treatment guidelines for hyperthyroidism and hypothyroidism [letter; comment] Ahmad S. **JAMA** 1995 Oct 4;274(13):1011; discussion 1011-2. Comment on: JAMA 1995 Mar 8;273(10):808-12.

A case of amiodarone-associated pulmonary toxicity. Kwon KH, et al. **Korean J Intern Med** 1995 Jul;10(2):155-9

European guidelines on resuscitation [letter] Dick W, et al. **Lancet** 1996 Jun 1;347(9014):1558

Amiodarone induced lipidosis similar to Niemann-Pick C disease. Biochemical and morphological study. Palmeri S, et al. **Life Sci** 1995;57(21):1963-71

Amiodarone in congestive heart failure [letter] Sechi LA, et al. **N Engl J Med** 1995 Dec 14;333(24):1640-1

An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity. Reasor MJ, et al. **Proc Soc Exp Biol Med** 1996 Sep;212(4):297-304 (89 ref.)

Amiodarone pneumonitis: no safe dose [letter] Hargreaves MR, et al. **Respir Med** 1996 Feb;90(2):119

Amiodarone-induced bronchiolitis obliterans organizing pneumonia (BOOP). Oren S, et al. **Respir Med** 1996 Mar; 90(3):167-9

Amiodarone-induced neuromyopathy mimicking polymyositis [letter] Bonnet C, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):468

Skin side-effects of amiodarone therapy. Ettler K, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl** 1993;36(4-5):305-15

Recurrent amiodarone pulmonary toxicity. Chendrasekhar A, et al. **South Med J** 1996 Jan;89(1):85-6

Nongoitrous (type I) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo. Brennan MD, et al. **Thyroid** 1995 Jun;5(3):177-83

[Early diagnosis of amiodarone-induced pulmonary toxicity: are repeated lung function tests of any value?] Ulrik CS, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3445-7 (17 ref.) (Eng. Abstr.) **(Dan)**

[Hyperthyroidism induced by amiodarone and hyperthyroidism induced by iodine. Histologic, immunohistochemical and ultrastructural aspects] Guyétant S, et al. **Ann Pathol** 1995;15(6):431-7 (Eng. Abstr.) **(Fre)**

[Value of thyroidectomy in amiodarone-induced hyperthyroidism. Apropos of 3 cases] Painvin I, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):445-9 (Eng. Abstr.) **(Fre)**

[Effects of amiodarone on thyroid function] Caron P. **Presse Med** 1995 Dec 2;24(37):1747-51 (25 ref.) (Eng. Abstr.) **(Fre)**

[Torsade de pointes during quinidine and amiodarone therapy] Genth S, et al. **Med Klin** 1996 Mar 15;91(3):171-3 **(Ger)**

[Symptomatic bradycardia with amiodarone in patients with pre-existing conduction disorders] Hofmann R, et al. **Wien Klin Wochenschr** 1995;107(21):640-4 (Eng. Abstr.) **(Ger)**

[Adverse reactions to amiodarone] Edoute Y, et al. **Harefuah** 1995 Jul;129(1-2):57-61 (28 ref.) **(Heb)**

[Acute hepatotoxicity from amiodarone] Tosetti C, et al. **Minerva Med** 1995 Sep;86(9):387-90 (21 ref.) (Eng. Abstr.) **(Ita)**

[Pancreatitis and inappropriate ADH secretion syndrome associated with amiodarone] Muñoz Ruiz AI, et al. **An Med Interna** 1996 Mar;13(3):125-6 (Eng. Abstr.) **(Spa)**

[Recurrent amiodarone lung toxicity after withdrawal of the drug and treatment with corticoids] Donado Uña JR, et al. **Arch Bronconeumol** 1995 Oct;31(8):426-8 (13 ref.) (Eng. Abstr.) **(Spa)**

[Acute hepatitis caused by intravenous amiodarone] Paniagua Clusells J, et al. **Rev Esp Cardiol** 1996 May;49(5):384-5 (Eng. Abstr.) **(Spa)**

[Osteoporosis is a suspected adverse effect of amiodarone] Linde C, et al. **Lakartidningen** 1996 Sep 4;93(36):3050-2 **(Swe)**

ANALOGS & DERIVATIVES

An external quality assessment scheme for amiodarone and desethylamiodarone: initial results. Starkey BJ, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):154-6

Structure-function relationship of the inhibition of the 3,5,3'-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs. van Beeren HC, et al. **Endocrinology** 1996 Jul; 137(7):2807-14

Dihydropyridine-like effects of amiodarone and desethylamiodarone on thyrotropin secretion and intracellular calcium concentration in rat pituitary. Roussel JP, et al. **Eur J Endocrinol** 1995 Oct;133(4):489-98

Measurement of serum amiodarone and desethylamiodarone by HPLC: its usefulness in the follow-up of arrhythmic patients treated with amiodarone. Manfredi C, et al. **Int J Clin Pharmacol Res** 1995;15(2):87-93

Electrophysiological effects of a novel, short-acting and potent ester derivative of amiodarone, ATI-2001, in guinea pig isolated heart. Raatikainen MJ, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1454-63

Desethylamiodarone is a competitive inhibitor of the binding of thyroid hormone to the thyroid hormone alpha 1-receptor protein. van Beeren HC, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):15-9

Radiolabeling and biodistribution of amiodarone and desethylamiodarone. Bellen JC, et al. **Nucl Med Biol** 1995 Oct;22(7):953-5

A systematic review and critical comparison of internal standards for the routine liquid chromatographic assay of amiodarone and desethylamiodarone. Pollak PT. **Ther Drug Monit** 1996 Apr;18(2):168-78 (53 ref.)

Metabolism of amiodarone following intratracheal instillation in hamsters. Blake TL, et al. **Toxicol Lett** 1995 Nov 15; 81(2-3):223-8

ANALYSIS

A systematic review and critical comparison of internal standards for the routine liquid chromatographic assay of amiodarone and desethylamiodarone. Pollak PT. **Ther Drug Monit** 1996 Apr;18(2):168-78 (53 ref.)

BLOOD

An external quality assessment scheme for amiodarone and desethylamiodarone: initial results. Starkey BJ, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):154-6

Measurement of serum amiodarone and desethylamiodarone by HPLC: its usefulness in the follow-up of arrhythmic patients treated with amiodarone. Manfredi C, et al. **Int J Clin Pharmacol Res** 1995;15(2):87-93

CHEMICAL SYNTHESIS

Radiolabeling and biodistribution of amiodarone and desethylamiodarone. Bellen JC, et al. **Nucl Med Biol** 1995 Oct;22(7):953-5

CHEMISTRY

Incompatibility of amiodarone hydrochloride and sodium bicarbonate injections [letter] Korth-Bradley JM, et al. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2340

Incompatibility of amiodarone hydrochloride and evacuated glass bottles [letter] Strozyk WR, et al. **Am J Health Syst Pharm** 1996 Jan 15;53(2):184

METABOLISM

Metabolism of amiodarone following intratracheal instillation in hamsters. Blake TL, et al. **Toxicol Lett** 1995 Nov 15; 81(2-3):223-8

Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats. Reasor MJ, et al. **Toxicology** 1996 Jan 8;106(1-3):139-47

PHARMACOKINETICS

Susceptibility to amiodarone-induced pulmonary toxicity: relationship to the uptake of amiodarone by isolated lung cells. Wilson BD, et al. **Lung** 1996;174(1):31-41

Radiolabeling and biodistribution of amiodarone and desethylamiodarone. Bellen JC, et al. **Nucl Med Biol** 1995 Oct;22(7):953-5

[Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals] Gaete LE, et al. **Rev Med Chil** 1995 Jun;123(6):713-9 (18 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Kennedy JA, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):273-80

Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Chatelain P, et al. **Br J Pharmacol** 1995 Oct;116(3):1949-56

Structure-function relationship of the inhibition of the 3,5,3'-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs. van Beeren HC, et al. **Endocrinology** 1996 Jul; 137(7):2807-14

Dihydropyridine-like effects of amiodarone and desethylamiodarone on thyrotropin secretion and intracellular calcium concentration in rat pituitary. Roussel JP, et al. **Eur J Endocrinol** 1995 Oct;133(4):489-98

Effects of amiodarone on beating rate and Na-K-ATPase activity in cultured neonatal rat heart myocytes. Bergman M, et al. **Gen Pharmacol** 1995 Mar;26(2):285-90

QT prolongation and polymorphous ventricular tachycardia associated with trasodone-amiodarone combination. Mazur A, et al. **Int J Cardiol** 1995 Nov 10;52(1):27-9

Amiodarone is a dose-dependent noncompetitive and competitive inhibitor of T3 binding to thyroid hormone receptor subtype beta 1, whereas disopyramide, lignocaine, propafenone, metoprolol, dl-sotalol, and verapamil have no inhibitory effect. Drvota V, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):222-6

Acute amiodarone terminates ventricular fibrillation by modifying cellular Ca++ homeostasis in isolated perfused rat hearts. Kojima S, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):254-62

Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts. Sosunov EA, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):906-12

Effect of amiodarone on release of cytokines from mouse alveolar macrophages pretreated with eicosapentaenoic acid. Futamura Y. **Jpn J Pharmacol** 1995 Dec;69(4):335-41

[The influence of amiodarone on results of the signal-averaged electrocardiogram] Kubik L, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):299-306 (Eng. Abstr.) **(Pol)**

POISONING

[Computerized tomography aspects of amiodarone poisoning] Pitton MB, et al. **Aktuelle Radiol** 1995 Jul;5(4):222-6 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Singh BN. **Am J Cardiol** 1996 Aug 29; 78(4A):41-53 (64 ref.)

Amiodarone for prevention of atrial fibrillation [letter; comment] van 't Hof AW, et al. **Am J Cardiol** 1996 Feb 1;77(4):327. Comment on: Am J Cardiol 1995 Jul 1;76(1):47-50.

Amiodarone for ventricular tachycardia after coronary artery bypass grafting [letter] [see comments] Terada Y, et al. **Ann Thorac Surg** 1995 Oct;60(4):1155. Comment in: Ann Thorac Surg 1996 Jun;61(6):1874.

Amiodarone for ventricular tachycardia after coronary artery bypass grafting [letter; comment] Wood MK. **Ann Thorac Surg** 1996 Jun;61(6):1874. Comment on: Ann Thorac Surg 1995 Oct;60(4):1155.

AMIODARONE

The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. Kerin NZ, et al. **Arch Intern Med** 1996 Jan 8;156(1):49–53

Intravenous amiodarone for the conversion of atrial fibrillation [letter] Storch HD. **Arch Intern Med** 1996 Sep 9;156(16):1889

Successful treatment of supraventricular tachycardia–induced cardiomyopathy with amiodarone: case report and review of literature. Chen RP, et al. **Can J Cardiol** 1995 Nov;11(10):918–22 (20 ref.)

Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Moran JL, et al. **Crit Care Med** 1995 Nov;23(11):1816–24

Should post–infarction asymptomatic ventricular arrhythmias be treated? The need for caution. Sleight P. **Eur Heart J** 1995 Jul;16 Suppl E:49 (29 ref.)

Amiodarone in congestive heart failure: unravelling the GESICA and CHF–STAT differences [editorial] Hammill SC, et al. **Heart** 1996 Jan;75(1):6–7

Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction. Rodríguez LM, et al. **Heart** 1996 Jan;75(1):23–8

Comparison of electrophysiologic effects and efficacy of single–dose intravenous and long–term oral amiodarone therapy in patients with AV nodal reentrant tachycardia. Gambhir DS, et al. **Indian Heart J** 1996 Mar–Apr; 48(2):133–7

Amiodarone and phenytoin: interaction [letter] Ahmad S. **J Am Geriatr Soc** 1995 Dec;43(12):1449–50

Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents—focus on amiodarone. Scheinman MM. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):914–9 (34 ref.)

Acute antiarrhythmic effects of intravenously administered amiodarone on canine ventricular arrhythmia. Awaji T, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):869–78

Effects of a new amiodarone–like agent, SR 33589, in comparison to amiodarone, D,L–sotalol, and lignocaine, on ischemia–induced ventricular arrhythmias in anesthetized pigs. Finance O, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):570–6

Digoxin–quinidine and digoxin–amiodarone interactions: frequency of occurrence and monitoring in Australian repatriation hospitals. Freitag D, et al. **J Clin Pharm Ther** 1995 Jun;20(3):179–83

Intravenous amiodarone. **Med Lett Drugs Ther** 1995 Dec 8; 37(963):114–5

Amiodarone in congestive heart failure [letter] Silver MJ, et al. **N Engl J Med** 1995 Dec 14;333(24):1639–40; discussion 1640–1

Management of patients with life–threatening sustained ventricular tachyarrhythmias—the role of guided antiarrhythmic drug therapy. Steinbeck G, et al. **Prog Cardiovasc Dis** 1996 May–Jun;38(6):419–28

Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. Kumar A. **South Med J** 1996 Aug; 89(8):779–85

[Combination of celiprolol and amiodarone in the treatment of recurrent ventricular tachycardia] Tonet J, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jan;45(1):18–23 (Eng. Abstr.) **(Fre)**

[Anti–arrhythmic therapy and cardiac failure] Cosnay P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:35–41 (44 ref.) (Eng. Abstr.) **(Fre)**

[Clinical use of intravenous amiodarone for supraventricular arrhythmias] Assadi S, et al. **Harefuah** 1995 Dec 15; 129(12):583–6 (24 ref.) **(Heb)**

TOXICITY

Effects of amiodarone–induced phospholipidosis on pulmonary host defense functions in rats. Reasor MJ, et al. **Proc Soc Exp Biol Med** 1996 Apr;211(4):346–52

Comparative evaluation of amiodarone–induced phospholipidosis and drug accumulation in Fischer–344 and Sprague–Dawley rats. Reasor MJ, et al. **Toxicology** 1996 Jan 8;106(1–3):139–47

Amiodarone–induced pulmonary fibrosis in Fischer 344 rats. Reinhart PG, et al. **Toxicology** 1996 Jun 17;110(1–3):95–101

AMITHIOZONE see **THIOACETAZONE**

AMITRIPTYLINE

ADMINISTRATION & DOSAGE

Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. Kuhs H, et al. **J Affect Disord** 1996 Feb 12;37(1):31–41

Dosing of antidepressants—the unknown art. Jerling M. **J Clin Psychopharmacol** 1995 Dec;15(6):435–9

Intravenous amitriptyline in pediatrics. Collins JJ, et al. **J Pain Symptom Manage** 1995 Aug;10(6):471–5

Correlation of mono and combined amitriptyline/lithium therapy with therapeutic and side effects. Timotijevic I, et al. **Rom J Physiol** 1994 Jan–Dec;31(1–4):103–11

[Treatment of depression with a neuro–thymoleptic combination in general practice] Schirmer G. **Psychiatr Prax** 1996 Mar;23(2):99–100 **(Ger)**

ADVERSE EFFECTS

Development of mania in close association with tricyclic antidepressant administration in children. A report of two cases. Briscoe JJ, et al. **Eur Child Adolesc Psychiatry** 1995 Oct;4(4):280–3

Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders? Miyaoka H, et al. **Int Clin Psychopharmacol** 1995 Nov;10(4):265–7

Another cause for acute carpal tunnel syndrome: tricyclic overdose. Hargreaves DG, et al. **J Accid Emerg Med** 1995 Jun;12(2):158–9

Case 7: the addled nonagenarian. Shader RI, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):378

Correlation of mono and combined amitriptyline/lithium therapy with therapeutic and side effects. Timotijevic I, et al. **Rom J Physiol** 1994 Jan–Dec;31(1–4):103–11

ANALOGS & DERIVATIVES

Potential interference of cyclobenzaprine and norcyclobenzaprine with HPLC measurement of amitriptyline and nortriptyline: resolution by GC–MS analysis. Wong EC, et al. **J Anal Toxicol** 1995 Jul–Aug; 19(4):218–24

Low back pain [letter] Lexchin J. **J Emerg Med** 1995 Nov–Dec;13(6):820

Five–year multicenter retrospective review of cyclobenzaprine toxicity. Spiller HA, et al. **J Emerg Med** 1995 Nov–Dec;13(6):781–5 (14 ref.)

ANALYSIS

Potential interference of cyclobenzaprine and norcyclobenzaprine with HPLC measurement of amitriptyline and nortriptyline: resolution by GC–MS analysis. Wong EC, et al. **J Anal Toxicol** 1995 Jul–Aug; 19(4):218–24

BLOOD

[Tricyclic antidepressants (imipramine, desipramine, amitriptyline, nortriptyline)] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:934–7 (20 ref.) **(Jpn)**

METABOLISM

N–demethylation of amitriptyline in vitro: role of cytochrome P–450 3A (CYP3A) isoforms and effect of metabolic inhibitors. Schmider J, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):592–7

PHARMACOKINETICS

Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Wong SL, et al. **Clin Pharmacol Ther** 1996 Jul;60(1):48–53

Biotransformation of amitriptyline by Cunninghamella elegans. Zhang D, et al. **Drug Metab Dispos** 1995 Dec; 23(12):1417–25

Amitriptyline metabolism in elderly depressed patients and normal controls in relation to hypothalamic–pituitary–adrenal system function. Schmider J, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):250–8

PHARMACOLOGY

The effects of imipramine, amitriptyline and clonidine administered by iontophoresis on the pain threshold. Taniguchi K, et al. **Acta Anaesthesiol Belg** 1995; 46(3–4):121–5

Intrathecal amitriptyline. Antinociceptive interactions with intravenous morphine and intrathecal clonidine, neostigmine, and carbamylcholine in rats. Eisenach JC, et al. **Anesthesiology** 1995 Nov;83(5):1036–45

Reversal of multidrug resistance by amitriptyline in vitro. Varga A, et al. **Anticancer Res** 1996 Jan–Feb;16(1):209–11

Potent block of potassium currents in rat isolated sympathetic neurones by the uncharged form of amitriptyline and related tricyclic compounds. Wooltorton JR, et al. **Br J Pharmacol** 1995 Oct;116(4):2191–200

Effects of different types of stress on histamine–H3 receptors in the rat cortex. Ghi P, et al. **Brain Res** 1995 Aug 28; 690(1):104–7

Biochemical and behaviour changes induced by acute stress in a chronic variate stress model of depression: the effect of amitriptyline. Ferretti C, et al. **Eur J Pharmacol** 1995 Jun 23;280(1):19–26

Effect of amitriptyline on blood glucose level in rabbits. Gupta B, et al. **Indian J Physiol Pharmacol** 1995 Jul; 39(3):279–82

Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants. Souêtre E, et al. **Int Clin Psychopharmacol** 1996 Mar;11(1):45–52

Test–dependent relationship of the antidepressant and analgesic effects of amitriptyline. Casas J, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):583–8

The effect of amitriptyline on the cell–mediated immunity of stressed rats. Kubera M, et al. **Pol J Pharmacol** 1995 Mar–Apr;47(2):137–42

Effect of repeated amitriptyline administration to mice on the T lymphocyte proliferative activity and natural killer cell cytotoxicity. Kubera M, et al. **Pol J Pharmacol** 1995 Jul–Aug;47(4):321–6

[The effect of amitriptyline on the pathological crying and other pseudobulbar signs] Szczudlik A, et al. **Neurol Neurochir Pol** 1995 Sep–Oct;29(5):663–74 (Eng. Abstr.) **(Pol)**

[Prodigiozan modulation of the specific activity of antidepressants] Sibiriak SV, et al. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):9–12 (Eng. Abstr.) **(Rus)**

POISONING

Decreased R–R variation: a criterium for overdosage of tricyclic psychotropic drugs. Rechlin T. **Intensive Care Med** 1995 Jul;21(7):598–601

[Toxic tricyclic drug plasma level caused by fluoxetine] Hambrecht M. **Psychiatr Prax** 1995 Nov;22(6):252–3 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Pituitary–adrenal–system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Heuser IJ, et al. **Am J Psychiatry** 1996 Jan;153(1):93–9

An evaluation of antidepressants in rheumatic pain conditions. Rani PU, et al. **Anesth Analg** 1996 Aug; 83(2):371–5

Intrathecal amitriptyline acts as an N–methyl–D–aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Eisenach JC, et al. **Anesthesiology** 1995 Nov;83(5):1046–54

Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Carette S, et al. **Arthritis Rheum** 1995 Sep;38(9):1211–7

Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Bryson HM, et al. **Drugs Aging** 1996 Jun;8(6):459–76 (111 ref.)

A 3–year follow–up of a group of treatment–resistant depressed patients with a MAOI/tricyclic combination. Berlanga C, et al. **J Affect Disord** 1995 Jun 8;34(3):187–92

Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. Engel PA. **J Am Geriatr Soc** 1996 Sep;44(9):1072–4

A double–blind comparison of Org 3770, amitriptyline, and placebo in major depression. Bremner JD. **J Clin Psychiatry** 1995 Nov;56(11):519–25

A non–selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension–type headache. Bendtsen L, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep; 61(3):285–90

Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Eija K, et al. **Pain** 1996 Feb; 64(2):293–302

A comparison of amitriptyline, vasopressin and amitriptyline with vasopressin in nocturnal enuresis. Burke JR, et al. **Pediatr Nephrol** 1995 Aug;9(4):438–40

A controlled study of the efficacy and safety of mianserin and amitriptyline in depressive inpatients. Möller HJ, et al. **Pharmacopsychiatry** 1995 Nov;28(6):249–52

Identifying delirious states and autonomic cardiovascular dysfunction associated with amitriptyline treatment by standardized analysis of heart rate. Rechlin T, et al. **Psychiatry Res** 1995 Apr 28;56(3):279–87

Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo. Laakman G, et al. **Psychopharmacology (Berl)** 1995 Jul;120(1):109–15

The efficacy of amitriptyline and acetaminophen in the management of acute low back pain. Stein D, et al. **Psychosomatics** 1996 Jan–Feb;37(1):63–70

Imipramine and amitriptyline in hyperactive children [letter] Mills IH. **QJM** 1996 Apr;89(4):321–2

Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double–blind randomized trial in major depression. Staner L, et al. **Sleep** 1995 Jul;18(6):470–7

[The effect of amitriptyline on the pathological crying and other pseudobulbar signs] Szczudlik A, et al. **Neurol Neurochir Pol** 1995 Sep–Oct;29(5):663–74 (Eng. Abstr.) **(Pol)**

AMITROLE

PHARMACOLOGY

Effects of aminotriazole on ethanol, water, and food intake and on brain catalase in UChA and UChB rats. Tampier L, et al. **Alcohol** 1995 Jul–Aug;12(4):341–4

The inhibitory effect of 3–amino–1,2,4–triazole on relaxation induced by hydroxylamine and sodium azide but not hydrogen peroxide or glyceryl trinitrate in rat aorta. Mian KB, et al. **Br J Pharmacol** 1995 Dec;116(8):3302–8

Catalase inhibition with 3–amino–1,2,4–triazole does not abolish infarct size reduction in heat–shocked rats. Auyeung Y, et al. **Circulation** 1995 Dec 1;92(11):3318–22

Relevance of oxidative stress to the limited replicative capacity of cultured human diploid cells: the limit of cumulative population doublings increases under low concentrations of oxygen and decreases in response to aminotriazole. Yuan H, et al. **Mech Ageing Dev** 1995 Jul 14;81(2–3):159–68

POISONING

Herbicide: fatal ammonium thiocyanate and aminotriazole poisoning. Legras A, et al. **J Toxicol Clin Toxicol** 1996; 34(4):441–6

AMLODIPINE

ADMINISTRATION & DOSAGE

Predictive value of ambulatory blood pressure shortly after withdrawal of antihypertensive drugs in primary care patients. Beltman FW, et al. **BMJ** 1996 Aug 17; 313(7054):404–6

Cardiac implications of amlodipine–dantrolene combinations. Freysz M, et al. **Can J Anaesth** 1996 Jan;43(1):50–5

ADVERSE EFFECTS

[Leukocytoclastic vasculitis in relation to amlodipine administration (letter)] del Río Fernández MC, et al. **Rev Clin Esp** 1995 Oct;195(10):738–9 **(Spa)**

BLOOD

Sensitive high-performance liquid chromatographic analysis of amlodipine in human plasma with amperometric detection and a single-step solid-phase sample preparation. Josefsson M, et al. **J Chromatogr B Biomed Appl** 1995 Oct 20;672(2):310–3

METABOLISM

Slow association of positively charged Ca2+ channel antagonist amlodipine to dihydropyridine receptor sites in rat brain membranes. Qu YL, et al. **Gen Pharmacol** 1996 Jan;27(1):137–40

PHARMACOKINETICS

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov;50(5):896] Haria M, et al. **Drugs** 1995 Sep;50(3):560–86 (196 ref.)

PHARMACOLOGY

Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. Leenen FH, et al. **Am J Cardiol** 1996 Jul 15;78(2):203–7

Effect of amlodipine and felodipine on sympathetic activity and baroreflex function in normal humans. Goldsmith SR. **Am J Hypertens** 1995 Sep;8(9):902–8

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov;50(5):896] Haria M, et al. **Drugs** 1995 Sep;50(3):560–86 (196 ref.)

Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Dworkin LD, et al. **Hypertension** 1996 Feb;27(2):245–50

Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial. Kloner RA, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):471–6

Mechanism of the antiischemic effect of mibefradil, a selective T calcium channel blocker in dogs: comparison with amlodipine. Roux S, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):132–9

Endothelium-dependent relaxation in resistance arteries from spontaneously hypertensive rats: effect of long-term treatment with perindopril, quinapril, hydralazine or amlodipine. Bennett MA, et al. **J Hypertens** 1996 Mar; 14(3):389–97

[Tolerance of amlodipine in left ventricular dysfunction of ischemic origin] Feder JM, et al. **Arch Mal Coeur Vaiss** 1996 Mar;89(3):305–10 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Blood glucose levels in hypertensive patients during treatment with different antihypertensive agents. Ahaneku JE. **Acta Med Okayama** 1996 Apr;50(2):107–10

Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Kloner RA, et al. **Am J Cardiol** 1996 Apr 1; 77(9):713–22

Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients. Sennesael JJ, et al. **Am J Kidney Dis** 1996 May;27(5):701–8

The chronic treatment of amlodipine in regressing hypertrophy. Patel VB, et al. **Biochem Soc Trans** 1995 Aug; 23(3):460S

Comparison of the efficacy and safety of nifedipine coat-core versus amlodipine in the treatment of patients with mild-to-moderate essential hypertension. Hypertension Study Group. Zidek W, et al. **Clin Ther** 1995 Jul–Aug; 17(4):686–700

Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Velussi M, et al. **Diabetes** 1996 Feb;45(2):216–22

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov;50(5):896] Haria M, et al. **Drugs** 1995 Sep;50(3):560–86 (196 ref.)

Treatment effects on the total ischaemic burden and variables with prognostic implications. Deanfield JE. **Eur Heart J** 1995 Jul;16 Suppl E:62–3

Effects of amlodipine on transient myocardial ischaemia in patients with a severe coronary condition treated with a beta-blocker. Amlor-Holter Study Investigators [see comments] Madjlessi-Simon T, et al. **Eur Heart J** 1995 Dec;16(12):1780–8. Comment in: Eur Heart J 1995 Dec;16(12):1754–6.

Pointers from recent multicentre trials using ambulatory monitoring--placing placebo in perspective [editorial; comment] Mulcahy D. **Eur Heart J** 1995 Dec;16(12):1754–6 . Comment on: Eur Heart J 1995 Dec;16(12):1780–8.

Antihypertensive treatment with verapamil and amlodipine. Their effect on the functional autonomic and cardiovascular stress responses. Nazzaro P, et al. **Eur Heart J** 1995 Sep;16(9):1277–84

Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension. Woodmansey PA, et al. **Heart** 1996 Feb;75(2):171–3

Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. Frishman WH, et al. **J Clin Pharmacol** 1995 Nov;35(11):1060–6

Effects of amlodipine on 24-hour ambulatory blood pressure profiles, electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension. Skoularigis J, et al. **J Clin Pharmacol** 1995 Nov;35(11):1052–9

Comparison of amlodipine and quinapril on ambulatory blood pressure and platelet function in hypertension. Ding YA, et al. **J Hum Hypertens** 1995 Aug;9(8):637–41

Office and ambulatory blood pressure: a comparison between amlodipine and felodipine ER. Danish Multicentre Group. Høegholm A, et al. **J Hum Hypertens** 1995 Aug;9(8):611–6

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. Packer M, et al. **N Engl J Med** 1996 Oct 10;335(15):1107–14

[Personal clinical experience in the treatment of arterial hypertension using amlodipine] Zicha J. **Vnitr Lek** 1996 Mar;42(3):153–6 (Eng. Abstr.) **(Cze)**

[Evaluation of amlodipine in stable effort angina. Comparison with diltiazem in terms of efficacy, tolerability and maintenance of the anti-ischemic action 24 hours after the last dose] Marchand X, et al. **Ann Cardiol Angeiol (Paris)** 1996 Feb;45(2):74–82 (Eng. Abstr.) **(Fre)**

[Amlodipine in heart failure: initial results of the PRAISE study] Steffen HM. **Herz** 1995 Aug;20 Suppl 2:3–4 **(Ger)**

AMMOIDIN see **METHOXSALEN**

AMMONIA

Evaluation of chemical amendments to reduce ammonia volatilization from poultry litter. Moore PA Jr, et al. **Poult Sci** 1996 Mar;75(3):315–20

[Examination of feed and slurry additives for decrease of ammonia emissions in swine housing] Krieger R, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Aug;102(8):316–20 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Prediction of complications following caustic ingestion in adults. Christesen HB. **Clin Otolaryngol** 1995 Jun; 20(3):272–8

ADVERSE EFFECTS

Prediction of complications following caustic ingestion in adults. Christesen HB. **Clin Otolaryngol** 1995 Jun; 20(3):272–8

Effect of ammonia on cell-cycle progression of human gastric cancer cells. Matsui T, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S79–81

A 23-year-old maintenance employee in a fertilizer manufacturing plant was exposed to a high concentration of ammonia vapor after a pipe ruptured. **J Occup Environ Med** 1995 Oct;37(10):1187–8

ANALYSIS

Air quality in an animal facility: particulates, ammonia, and volatile organic compounds. Kacergis JB, et al. **Am Ind Hyg Assoc J** 1996 Jul;57(7):634–40

Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Birkett A, et al. **Am J Clin Nutr** 1996 May;63(5):766–72

A lifetime-based fluorescence resonance energy transfer sensor for ammonia. Chang Q, et al. **Anal Biochem** 1995 Nov 20;232(1):92–7

Mediated amperometric determination of ammonia with a methanol dehydrogenase from Pseudomonas sp. AM-1 immobilized carbon paste electrode. Suye S, et al. **Biosens Bioelectron** 1996;11(5):529–34

Urea ammoniation effects on the feeding value of guineagrass (Panicum maximum) hay. Brown WF, et al. **J Anim Sci** 1995 Oct;73(10):3085–93

The dust content, dust generation, ammonia production, and absorption properties of three different rodent bedding types. Potgieter FJ, et al. **Lab Anim** 1996 Jan;30(1):79–87

Lung function and chronic respiratory symptoms of pig farmers: focus on exposure to endotoxins and ammonia and use of disinfectants. Preller L, et al. **Occup Environ Med** 1995 Oct;52(10):654–60

Absorption of ammonia by high water content hydrogel lenses: an inexpensive method of analysis. LaMotte J, et al. **Optom Vis Sci** 1995 Sep;72(9):605–7

Solar and thermal radiation in Jupiter's atmosphere: initial results of the Galileo probe net flux radiometer. Sromovsky LA, et al. **Science** 1996 May 10;272(5263):851–4

Chemical safety of U.S. Navy Fleet soda lime. Lillo RS, et al. **Undersea Hyperb Med** 1996 Mar;23(1):43–53

[Correlation between concentration of ammonia in the air of pigsties and the activity of fattening pigs in deep litter] Hoy S. **DTW Dtsch Tierarztl Wochenschr** 1995 Aug; 102(8):323–6 (Eng. Abstr.) **(Ger)**

[Invention of a forced-air-ventilated micro-isolation cage and rack system--environment within cages: temperature and ammonia concentration] Yoshida K, et al. **Exp Anim** 1995 Oct;43(5):703–10 (Eng. Abstr.) **(Jpn)**

BLOOD

The effect of carnitine supplementation in valproate-induced hyperammonaemia. Böhles H, et al. **Acta Paediatr** 1996 Apr;85(4):446–9

Urea cycle disorders: diagnosis, pathophysiology, and therapy. Brusilow SW, et al. **Adv Pediatr** 1996;43:127–70 (59 ref.)

Ammonia clearance as a rapid index of viability in liver transplantation [letter; comment] Fukuzawa K, et al. **Am J Gastroenterol** 1995 Dec;90(12):2264. Comment on: Am J Gastroenterol 1994 Dec;89(12):2283–4.

Free and esterified coenzyme A in the liver and muscles of chronically hyperammonemic mice treated with sodium benzoate. Michalak A, et al. **Biochem Mol Med** 1995 Apr; 54(2):96–104

Tissue acylcarnitine and acyl-coenzyme A profiles in chronically hyperammonemic mice treated with sodium benzoate and supplementary L-carnitine. Michalak A, et al. **Biomed Pharmacother** 1995;49(7–8):350–7

Relationship between lactate and ammonia thresholds in heart transplant patients. Chicharro JL, et al. **Chest** 1996 Sep; 110(3):693–7

Arterial blood ammonia during orthotopic liver transplantation as an indicator of waste elimination by the new liver [letter] Huizenga JR, et al. **Clin Chim Acta** 1995 Jul 31;239(1):103–6

Determination of ammonia in ear-lobe capillary blood is an alternative to arterial blood ammonia. Huizenga JR, et al. **Clin Chim Acta** 1995 Jul 31;239(1):65–70

Effect of prostaglandin E1 on ammonia concentration in blood of patients with hepatic resection. Aono T, et al. **Dig Dis Sci** 1996 Jan;41(1):126–30

The influence of pH and various anions on the distribution of NH4+ in human blood. da Fonseca-Wollheim F. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):289–94

Neurological deterioration in patients with urea cycle disorders under valproate therapy—a cause for concern [letter] Sewell AC, et al. **Eur J Pediatr** 1995 Jul; 154(7):593–4

Ammonia response to exercise in patients with congestive heart failure. Ogino K, et al. **Heart** 1996 Apr;75(4):343–8

Identification of four novel splice site mutations in the ornithine transcarbamylase gene. Oppliger Leibundgut E, et al. **Hum Genet** 1996 Feb;97(2):209–13

Effects of acute non-selective beta-adrenergic blockade on plasma ammonia levels in exercising dogs. Matthys D, et al. **Int J Sports Med** 1995 Aug;16(6):373–7

Ornithine transcarbamylase deficiency in females: an often overlooked cause of treatable encephalopathy. Pridmore CL, et al. **J Child Neurol** 1995 Sep;10(5):369–74

Effects of intraruminal infusion of propionate on the concentrations of ammonia and insulin in peripheral blood of cows receiving an intraruminal infusion of urea. Choung JJ, et al. **J Dairy Res** 1995 Nov;62(4):549–57

Neonatal hyperammonemia caused by a defect of carnitine-acylcarnitine translocase. Ogier de Baulny H, et al. **J Pediatr** 1995 Nov;127(5):723–8

Ornithine transcarbamylase deficiency: case report and review. Bueno JD, et al. **Kans Med** 1995 Fall;96(3):135–8

Hyperammonaemia in cirrhosis and Helicobacter pylori infection [letter; comment] Plevris JN, et al. **Lancet** 1995 Oct 21;346(8982):1104. Comment on: Lancet 1995 Jul 8;346(8967):124–5.

Hyperammonemia in a patient with short bowel syndrome and chronic renal failure. Yokoyama K, et al. **Nephron** 1996;72(4):693–5

Na+,K(+)-ATPase activities are increased in brain in both congenital and acquired hyperammonemic syndromes. Ratnakumari L, et al. **Neurosci Lett** 1995 Sep 8;197(2):89–92

Clinical quiz. Hyperammonemic coma secondary to pyelonephritis. Arnold WC, et al. **Pediatr Nephrol** 1995 Oct;9(5):667–8

Apparent segregation of null alleles ascribed to deletions of the ornithine transcarbamylase gene in congenital hyperammonaemia. Segues B, et al. **Prenat Diagn** 1995 Aug; 15(8):757–61

Hyperammonaemia in Irish wolfhounds [letter; comment] [see comments] Kerr MG. **Vet Rec** 1996 Feb 17; 138(7):167–8. Comment on: Vet Rec 1996 Feb 3;138(5):105–7. Comment in: Vet Rec 1996 Mar

23;138(12):288.
Acute encephalopathy and hyperammonaemia in a horse without evidence of liver disease. Mair TS, et al. **Vet Rec** 1995 Dec 16;137(25):642–3
Transient metabolic hyperammonaemia in young Irish wolfhounds [see comments] Meyer HP, et al. **Vet Rec** 1996 Feb 3;138(5):105–7. Comment in: Vet Rec 1996 Feb 17;138(7):167–8. Comment in: Vet Rec 1996 Mar 23;138(12):288.
Hyperammonemia with severe methanol intoxication. Foster WA, et al. **West J Med** 1995 Oct;163(4):377–9
[Hyperammonemia encephalopathy after ureterosigmoidostomy] Donnard G, et al. **Cah Anesthesiol** 1996;44(2):149–51 (Eng. Abstr.) **(Fre)**
[Emergency therapy of neonatal hyperammonemia with high dosage glucose] Vossbeck S, et al. **Z Geburtshilfe Neonatol** 1995 Nov–Dec;199(6):245–7 (Eng. Abstr.) **(Ger)**
[Ammonia nitrogen] Imawari M. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:478–80 (7 ref.) **(Jpn)**
[Massive ascites as an initial sign, plasmacytoma of the cervical supine, and hyperammonemic consciousness disturbance in a patient with biclonal type multiple myeloma] Ohmoto A, et al. **Rinsho Ketsueki** 1996 Apr; 37(4):346–51 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Optimization of the mass spectrometric analysis of triacylglycerols using negative-ion chemical ionization with ammonia. Laakso P, et al. **Lipids** 1996 Jan;31(1):33–42
Condensation of methane, ammonia, and water and the inhibition of convection in giant planets. Guillot T. **Science** 1995 Sep 22;269(5231):1697–9

DIAGNOSTIC USE

Noninvasive quantification of myocardial blood flow in humans. A direct comparison of the [13N]ammonia and the [15O]water techniques. Nitzsche EU, et al. **Circulation** 1996 Jun 1;93(11):2000–6
Quantification of myocardial blood flow using dynamic nitrogen-13-ammonia PET studies and factor analysis of dynamic structures. Wu HM, et al. **J Nucl Med** 1995 Nov; 36(11):2087–93

ISOLATION & PURIFICATION

Nitrogen and phosphorus removal for swine wastewater by ammonium crystallization and intermittent aeration process. Liao CM, et al. **J Environ Sci Health B** 1995 Sep; 30(5):733–58

METABOLISM

Effects of chronic Cl depletion alkalosis on proximal tubule transport and renal production of ammonium. DuBose TD Jr, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):F508–14
Quantification of incorporation of [15N]ammonia into plasma amino acids and urea. Patterson BW, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E508–15
NH3 permeability of principal cells and intercalated cells measured by confocal fluorescence imaging. Yip KP, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):F545–50
Comparative analysis of nitrifying bacteria associated with freshwater and marine aquaria. Hovanec TA, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2888–96
Influence of Avotan on the microflora and concentrations of ammonia and volatile fatty acids in the rumen. Sommer A, et al. **Arch Tierernahr** 1993;45(1):49–55
Dependence of in vivo glutamine synthetase activity on ammonia concentration in rat brain studied by 1H – 15N heteronuclear multiple-quantum coherence-transfer NMR. Kanamori K, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):681–8
The fate of absorbed and exogenous ammonia as influenced by forage or forage-concentrate diets in growing sheep. Lobley GE, et al. **Br J Nutr** 1996 Aug;76(2):231–48
Rats with gastritis have increased sensitivity to the gastrin stimulatory effects of luminal ammonia. Dial EJ, et al. **Gastroenterology** 1996 Mar;110(3):801–8
Decreased ureagenesis from alanine, but not from ammonia and glutamine, in the perfused rat liver after partial hepatectomy. Moriyama M, et al. **Hepatology** 1996 Jun; 23(6):1584–90
Control of ammonia formation during Bacillus subtilis fermentation of legumes. Allagheny N, et al. **Int J Food Microbiol** 1996 Apr;29(2–3):321–33
Studies on ammonia-metabolizing enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice. Agrawal A, et al. **Int J Parasitol** 1996 Apr; 26(4):451–5
Effect of intraruminal propionic acid infusion on metabolism of mesenteric- and portal-drained viscera in growing steers fed a forage diet: II. Ammonia, urea, amino acids, and peptides. Seal CJ, et al. **J Anim Sci** 1996 Jan;74(1):245–56
A mass isotopomer study of urea and glutamine synthesis from 15N-labeled ammonia in the perfused rat liver. Brosnan JT, et al. **J Biol Chem** 1996 Jul 5;271(27):16199–207
Deamination of amino acids as a source for ammonia production in human skeletal muscle during prolonged exercise. van Hall G, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):251–61
Adaptive cytoprotection by ammonia and urea-urease system in the rat gastric mucosa. Brzozowski T, et al. **J Physiol Pharmacol** 1995 Dec;46(4):471–88
A patient with ammonia-producing multiple myeloma showing hyperammonemic encephalopathy. Takimoto Y, et al. **Leukemia** 1996 May;10(5):918–9
An apical permeability barrier to NH3/NH4+ in isolated, perfused colonic crypts. Singh SK, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11573–7
Metabolic implications of ammonia production in the ruminant. Parker DS, et al. **Proc Nutr Soc** 1995 Jul; 54(2):549–63 (88 ref.)

PHARMACOKINETICS

Studies on the transport in vitro of lysine, histidine, arginine and ammonia across the mucosa of the equine colon. Bochröder B, et al. **Equine Vet J** 1994 Mar;26(2):131–3
The relationship between membrane fluidity and permeabilities to water, solutes, ammonia, and protons. Lande MB, et al. **J Gen Physiol** 1995 Jul;106(1):67–84

PHARMACOLOGY

Monoclonal antibody against a major latex allergen reacts with latex products and ammoniated natural latex. Lu LJ, et al. **Allergy** 1995 Jul;50(7):545–50
Ammonia prevents activation of NMDA receptors by glutamate in rat cerebellar neuronal cultures. Marcaida G, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2389–96
Influence of breathing-zone ammonia on human exposures to acid aerosol pollution. Clark KW, et al. **J Air Waste Manag Assoc** 1995 Nov;45(11):923–5
The concentration of ammonia regulates nitrogen metabolism in Saccharomyces cerevisiae. ter Schure EG, et al. **J Bacteriol** 1995 Nov;177(22):6672–5
Ammonia inhibits cAMP-regulated intestinal Cl- transport. Asymmetric effects of apical and basolateral exposure and implications for epithelial barrier function. Prasad M, et al. **J Clin Invest** 1995 Nov;96(5):2142–51
Studies on renal growth regulation by urea and ammonia in normal rat kidney cells. Logan JL. **Nephron** 1995; 71(4):433–41
Effect of ammonia on endocytosis and cytokine production by immortalized human microglia and astroglia cells. Atanassov CL, et al. **Neurochem Int** 1995 Oct–Nov; 27(4–5):417–24
Impaired pial arteriolar reactivity to hypercapnia during hyperammonemia depends on glutamine synthesis. Hirata T, et al. **Stroke** 1996 Apr;27(4):729–36

POISONING

[Protective effect of M- and N-cholinergic receptor blockaders during acute ammonia poisoning] Kosenko EA, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):489–92 **(Rus)**

TOXICITY

Blindness after hysteroscopic surgery [letter; comment] Rosenberg MK. **Anesth Analg** 1996 Jul;83(1):196. Comment on: Anesth Analg 1995 Oct;81(4):880–1.
Sublethal effects of mixtures of copper and ammonia on selected biochemical and physiological parameters in the catfish Heteropneustes fossilis (Bloch). James R, et al. **Bull Environ Contam Toxicol** 1995 Aug;55(2):187–94
The effect of catabolite concentration on the viability and functions of isolated rat hepatocytes. Catapano G, et al. **Int J Artif Organs** 1996 Apr;19(4):245–50
Role of cysteine proteases and protease inhibitors in gastric mucosal damage induced by ethanol or ammonia in the rat. Nagy L, et al. **J Clin Invest** 1996 Aug 15;98(4):1047–54

AMMONIUM CHLORIDE

ADVERSE EFFECTS

Effect of ammonia on cell-cycle progression of human gastric cancer cells. Matsui T, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S79–81
[General argyria caused by administration of tobacco-withdrawal tablets containing silver acetate] Van Garsse L, et al. **Ned Tijdschr Geneeskd** 1995 Dec 23; 139(51):2658–61 (Eng. Abstr.) **(Dut)**

PHARMACOLOGY

NH4Cl-induced hypertrophy is mediated by weak base effects and is independent of cell cycle processes. Franch HA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C932–8
Investigation into intraerythrocytic and extraerythrocytic acid-base and electrolyte changes after long-term ammonium chloride administration in dogs. Schober KE. **Am J Vet Res** 1996 May;57(5):743–9
Posttranslational regulation of nitrogenase activity by fixed nitrogen in Azotobacter chroococcum. Muñoz-Centeno MC, et al. **Biochim Biophys Acta** 1996 Aug 29;1291(1):67–74
The effect of lethal acid stress on Na+/H+ exchanger isoforms in cultured inner medullary collecting duct cells: deletion of NHE-2 and over expression of NHE-1. Singh G, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):74–80
Effects of sodium ascorbate, sodium saccharin and ammonium chloride on the male rat urinary bladder. Cohen SM, et al. **Carcinogenesis** 1995 Nov;16(11):2743–50
Spontaneous firing of NG108-15 cells induced by transient exposure to ammonium chloride. Kowtha VC, et al. **Cell Mol Neurobiol** 1996 Feb;16(1):1–9
Initiation of anterior head-specific gene expression in uncommitted ectoderm of Xenopus laevis by ammonium chloride. Mathers PH, et al. **Dev Biol** 1995 Oct; 171(2):641–54
An ultrastructure study of the in vitro effects of L-leucine methyl ester and ammonium chloride on Trypanosoma cruzi epimastigotes. Bogitsh BJ, et al. **Parasitol Res** 1996; 82(4):285–90

POISONING

Use of ammonium chloride in falconry in the Middle East. Samour JH, et al. **Vet Rec** 1995 Sep 9;137(11):269–70

AMMONIUM COMPOUNDS

see related
PYRIDINIUM COMPOUNDS
QUINOLINIUM COMPOUNDS

Activation of osmium ammine by SO2-generating chemicals for EM Feulgen-type staining of DNA. Vázquez-Nin GH, et al. **Eur J Histochem** 1995;39(2):101–6
Monitoring of black widow spider venom (BWSV) induced exo- and endocytosis in living frog motor nerve terminals with FM1-43. Henkel AW, et al. **Neuropharmacology** 1995 Nov;34(11):1397–406
1H solid-state nuclear magnetic resonance study of the mobility of the tetrapropylammonium template in a purely siliceous MFI-type zeolite. Gougeon R, et al. **Solid State Nucl Magn Reson** 1995 Jul;4(5):281–93
[The epidural administration of pentamine as a method for stimulating the functions of the small intestine in the early postoperative period] Dol'nikov NA, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):24–6 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Immediate-type allergy to the hair dye basic blue 99 in a hairdresser. Wigger-Alberti W, et al. **Allergy** 1996 Jan; 51(1):64–5

ANALYSIS

Amperometric ammonium ion and urea determination with enzyme-based probes. Bertocchi P, et al. **Biosens Bioelectron** 1996;11(1–2):1–10
Results of the Galileo probe nephelometer experiment. Ragent B, et al. **Science** 1996 May 10;272(5263):854–6

ANTAGONISTS & INHIBITORS

Staurosporine blocks evoked release of FM1-43 but not acetylcholine from frog motor nerve terminals. Henkel AW, et al. **J Neurosci** 1995 Dec;15(12):8246–58

CHEMICAL SYNTHESIS

Studies on 3'-quaternary ammonium cephalosporins. II. Synthesis and antibacterial activity of 7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-cephalospori n derivatives bearing various quaternary ammonium methyl groups at the 3 position. Ohki H, et al. **J Antibiot (Tokyo)** 1995 Sep; 48(9):1049–51

CHEMISTRY

2,6,6-Trimethyl-2-oxo-1,3-dioxa-6-azonia-2-phosphocyclooctane iodide. Kumaravel G, et al. **Acta Crystallogr C** 1995 Sep 15;51 (Pt 9):1919–21
Zeolitic ammonium ion exchange for portable hemodialysis dialysate regeneration [letter; comment] Roberts M. **ASAIO J** 1995 Oct–Dec;41(4):899. Comment on: ASAIO J 1995 Apr–Jun;41(2):221–6.
The counterion influence on cationic lipid-mediated transfection of plasmid DNA. Aberle AM, et al. **Biochim Biophys Acta** 1996 Feb 16;1299(3):281–3
Degradation of citrinin using ammoniation. Castegnaro M, et al. **IARC Sci Publ** 1991;(113):17–22
Degradation of patulin using ammoniation. Fremy JM, et al. **IARC Sci Publ** 1991;(113):41–5
Destruction of patulin in animal litter using ammoniation. Lunn G, et al. **IARC Sci Publ** 1991;(113):31–33
Direct detection of hepatitis C virus (HCV) RNA from whole blood, and comparison with HCV RNA in plasma and peripheral blood mononuclear cells. Schmidt WN, et al. **J Med Virol** 1995 Oct;47(2):153–60
Study of a microencapsulation process of a virucide agent by a solvent evaporation technique. Legrand J, et al. **J Microencapsul** 1995 Nov–Dec;12(6):639–49
Fluorescence behavior of tryptophan residues of bovine and human serum albumins in ionic surfactant solutions: a comparative study of the two and one tryptophan(s) of bovine and human albumins. Moriyama Y, et al. **J Protein Chem** 1996 Apr;15(3):265–72
Use of ammonium halides as co-matrices for matrix-assisted laser desorption/ionization studies of oligonucleotides. Cheng SW, et al. **Rapid Commun Mass Spectrom** 1996; 10(8):907–10
Potentiometric, enantioselective sensors for alkyl and aryl ammonium ions of pharmaceutical significance, based on lipophilic cyclodextrins. Kataky R, et al. **Scand J Clin Lab Invest** 1995 Aug;55(5):409–19

Nuclear magnetic resonance proton dynamics study of [N(CH3)2H2]3Bi2I9 at low temperature. Piślewski N, et al. **Solid State Nucl Magn Reson** 1995 Jul;4(5):323–5

Bittering agents: their potential application in reducing ingestions of engine coolants and windshield wash. Jackson MH, et al. **Vet Hum Toxicol** 1995 Aug;37(4):323–6

DIAGNOSTIC USE

Technical note: dynamic analysis of the pharynx during swallowing using Turbo-FLASH magnetic resonance imaging combined with an oral positive contrast agent—a preliminary study. Suto Y, et al. **Br J Radiol** 1995 Oct; 68(814):1099–102

Ferric ammonium citrate–cellulose paste for opacification of the esophageal lumen on MRI. Ogawa Y, et al. **J Comput Assist Tomogr** 1996 May–Jun;20(3):455–9

FM1-43 dye ultrastructural localization in and release from frog motor nerve terminals. Henkel AW, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1918–23

[MR imaging of colonic cancer with retrograde administration of contrast material containing ferric ammonium citrate] Mizuguchi M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Dec; 55(15):1063–5 (Eng. Abstr.) **(Jpn)**

[The use of high concentration ferric ammonium citrate (FAC) solution as a negative bowel contrast agent: application in MR cholangiography] Takahara T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Aug; 55(9):697–9 (Eng. Abstr.) **(Jpn)**

METABOLISM

Heterogeneity of NH+4 transport in mouse inner medullary collecting duct cells. Wall SM, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):F536–44

Sequence-specific binding of antitumour bisquaternary ammonium heterocycles to DNA and inhibition of polymerase activity in vitro. Kittler L, et al. **Anticancer Drug Des** 1996 Mar;11(2):101–15

Parameters influencing the introduction of plasmid DNA into cells by the use of synthetic amphiphiles as a carrier system. van der Woude I, et al. **Biochim Biophys Acta** 1995 Nov 22;1240(1):34–40

Roles of SpoT and FNR in NH4+ assimilation and osmoregulation in GOGAT (glutamate synthase)-deficient mutants of Escherichia coli. Saroja GN, et al. **J Bacteriol** 1996 Jul;178(14):4105–14

The permeation of ammonium through a voltage-independent K+ channel in the plasma membrane of rye roots. White PJ. **J Membr Biol** 1996 Jul;152(1):89–99

The enhancement of ammonium assimilation in Rhizobium etli prevents nodulation of Phaseolus vulgaris. Mendoza A, et al. **Mol Plant Microbe Interact** 1995 Jul–Aug; 8(4):584–92

Plant biology. At the roots of nutrition [news; comment] Schroeder JI. **Nature** 1995 Dec 7;378(6557):560–1. Comment on: Nature 1995 Dec 7;378(6557):626–9.

Further investigation of ionic diffusive properties and of NH4+ pathways in Xenopus laevis oocyte cell membrane. Cougnon M, et al. **Pflugers Arch** 1996 Feb;431(4):658–67

The selectivity of different external binding sites for quaternary ammonium ions in cloned potassium channels. Jarolimek W, et al. **Pflugers Arch** 1995 Sep;430(5):672–81

An apical permeability barrier to NH3/NH4+ in isolated, perfused colonic crypts. Singh SK, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11573–7

Discovery of the ammonium substrate site on glutamine synthetase, a third cation binding site. Liaw SH, et al. **Protein Sci** 1995 Nov;4(11):2358–65

Protein recognition of ammonium cations using side-chain aromatics: a structural variation for secondary ammonium ligands. Raine AR, et al. **Protein Sci** 1995 Dec;4(12):2625–8

PHARMACOKINETICS

Ammonium ion minisensors form self-assembled bilayer lipid membranes using gramicidin as an ionophore. Modulation of ammonium selectivity by platelet-activating factor. Nikolelis DP, et al. **Anal Chem** 1996 May 15;68(10):1735–41

Internalization of styryl dye FM1-43 in the hair cells of lateral line organs in Xenopus larvae. Nishikawa S, et al. **J Histochem Cytochem** 1996 Jul;44(7):733–41

Mechanisms for the hepatic uptake and biliary excretion of tributylmethylammonium: studies with rat liver plasma membrane vesicles. Moseley RH, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):561–7

Primary interactions of three quaternary ammonium compounds with blastospores of Candida albicans (MEN strain). Schep LJ, et al. **Pharm Res** 1995 May;12(5):649–52

PHARMACOLOGY

Rapid kinetics of second messenger production in bitter taste. Spielman AI, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C926–31

Methantheline improves the reactivation by HI 6 of human erythrocyte acetylcholinesterase inhibited by soman in vitro. Hallek M, et al. **Arch Toxicol** 1995;70(1):16–9

Effect of quaternary ammonium salts on energy-yielding and energy-requiring processes in Salmonella typhimurium. Majtán V, et al. **Arzneimittelforschung** 1995 Sep; 45(9):1021–3

The effect of crown ethers, tetraalkylammonium salts, and polyoxyethylene amphiphiles on pirarubicin incorporation in K562 resistant cells. Borrel MN, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2069–76

Identification of a mechanism of iron uptake by cells which is stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction. Richardson DR, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):105–14

The pharmacological properties of K+ currents from rabbit isolated aortic smooth muscle cells. Halliday FC, et al. **Br J Pharmacol** 1995 Dec;116(8):3139–48

Regulation of valine catabolism by ammonium in Streptomyces ambofaciens, producer of spiramycin. Lounès A, et al. **Can J Microbiol** 1995 Sep;41(9):800–8

Antimicrobial activity of glycerine-ichthammol in otitis externa. Ahmed K, et al. **Clin Otolaryngol** 1995 Jun; 20(3):201–3

Regulation of transferrin receptor synthesis by human cytotrophoblast cells in culture. Kroos MJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):231–4

General biological properties of antioxidant permeatoxins and their influence on natural and model membranes. Witek S, et al. **Folia Microbiol (Praha)** 1994;39(6):559–60

Studies on 3'-quaternary ammonium cephalosporins. II. Synthesis and antibacterial activity of 7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-cephalospori n derivatives bearing various quaternary ammonium methyl groups at the 3 position. Ohki H, et al. **J Antibiot (Tokyo)** 1995 Sep; 48(9):1049–51

Ammonium/urea-dependent generation of a proton electrochemical potential and synthesis of ATP in Bacillus pasteurii. Jahns T. **J Bacteriol** 1996 Jan;178(2):403–9

Presence of a second mechanism for the posttranslational regulation of nitrogenase activity in Azospirillum brasilense in response to ammonium. Zhang Y, et al. **J Bacteriol** 1996 May;178(10):2948–53

Architecture of the neuronal nicotinic acetylcholine receptor ion channel at the binding site of bis-ammonium blockers. Brovtsyna NB, et al. **J Membr Biol** 1996 Jul;152(1):77–87

Quaternary ammonium ion blockade of IK in nerve axons revisited. Open channel block vs. state independent block. Clay JR. **J Membr Biol** 1995 Sep;147(1):23–34

Direct measurement of lipid hydroperoxides in iron-dependent spinal neuronal injury. Zhang JR, et al. **J Neurochem** 1996 Jan;66(1):355–61

Activation of recombinant mouse acetylcholine receptors by acetylcholine, carbamylcholine and tetramethylammonium. Zhang Y, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):189–206

Effect of quaternary ammonium salts and amine oxides on Pseudomonas aeruginosa. Majtán V, et al. **Microbios** 1995; 84(338):41–51

Structure-activity relationship of quaternary ammonium ions at the external tetraethylammonium binding site of cloned potassium channels. Jarolimek W, et al. **Mol Pharmacol** 1996 Jan;49(1):165–71

Further investigation of ionic diffusive properties and of NH4+ pathways in Xenopus laevis oocyte cell membrane. Cougnon M, et al. **Pflugers Arch** 1996 Feb;431(4):658–67

An ammonium pulse inhibits fluid secretion. Lau KR, et al. **Pflugers Arch** 1996 Jan;431(3):415–8

DNA banding by hexamethylene-tethered ammonium ions. Strauss JK, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9515–20

Use-dependent blockers and exit rate of the last ion from the multi-ion pore of a K+ channel. Baukrowitz T, et al. **Science** 1996 Feb 2;271(5249):653–6

[A quaternary ammonium salt of oligomer 25 conidine accelerates skin wound healing in rats] Golenchenko VA, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):407–9 **(Rus)**

[The interaction of organosilicon bisammonium compounds with the cholinesterases of Far-Eastern squids and vertebrates. The comparative enzymological, kinetic and conformational aspects] Rozengart EV, et al. **Zh Evol Biokhim Fiziol** 1995 Sep–Dec;31(5–6):546–55 **(Rus)**

POISONING

Intracardiac injection of T-61, a veterinary euthanasia drug. Hantson P, et al. **J Toxicol Clin Toxicol** 1996;34(2):235–9

[Ventricular tachycardia secondary to phenylpropanolamine poisoning: apropos a case] Barriales Villa R, et al. **Rev Esp Cardiol** 1995 Nov;48(11):762–4 (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

Electron paramagnetic resonance evidence of the generation of superoxide (O2.-) and hydroxyl (.OH) radicals by irradiation of a new photodynamic therapy photosensitizer, Victoria Blue BO. Viola A, et al. **J Photochem Photobiol B** 1996 Jan;32(1-2):49–58

THERAPEUTIC USE

Antimicrobial activity of glycerine-ichthammol in otitis externa. Ahmed K, et al. **Clin Otolaryngol** 1995 Jun; 20(3):201–3

Glycerol and ichthammol: medicinal solution or mythical potion? Nilssen E, et al. **J Laryngol Otol** 1996 Apr; 110(4):319–21

[The combined preparation ligentin in the treatment of inflammatory disease of the urogenital organs] Kisina VI. **Antibiot Khimioter** 1995 Jul;40(7):43–4 (Eng. Abstr.) **(Rus)**

[Lipid peroxidation in an experimental study of an erosion-ulcer lesion of the stomach as affected by the new high-protein products and ethonium] Fediv OI, et al. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):79–85 (Eng. Abstr.) **(Ukr)**

TOXICITY

Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes. Konopka K, et al. **Biochim Biophys Acta** 1996 Jul 24;1312(3):186–96

Acute toxicity of some synthetic cationic and zwitterionic surfactants to freshwater amphipod Echinogammarus tibaldii. Pantani C, et al. **Bull Environ Contam Toxicol** 1995 Aug;55(2):179–86

Quantification of the hemolysis associated with use of T-61 as a euthanasia agent in rabbits—a comparison with Euthanyl (pentobarbital sodium) and the impact on serum hexosaminidase measurements. Doughty MJ, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1274–80

Ocular and dermal irritation studies of some quaternary ammonium compounds. Lin GH, et al. **Food Chem Toxicol** 1996 Feb;34(2):177–82

Dose- (and time-) dependent blockade of pregnancy in Sprague-Dawley rats administered ammonium dinitramide in drinking water. Kinkead ER, et al. **Toxicol Ind Health** 1996 Jan–Feb;12(1):59–67

AMMONIUM SULFATE

Ammonium persulfate: a safe alternative oxidizing reagent for measuring urinary iodine. Pino S, et al. **Clin Chem** 1996 Feb;42(2):239–43

ADVERSE EFFECTS

Early reaction type allergies and diseases of the respiratory passages in employees from persulphate production. Wrbitzky R, et al. **Int Arch Occup Environ Health** 1995; 67(6):413–7

A cross sectional study of chemical industry workers with occupational exposure to persulphates. Merget R, et al. **Occup Environ Med** 1996 Jun;53(6):422–6

CHEMISTRY

Structures of charge-transfer complexes of flavoenzyme D-amino acid oxidase: a study by resonance Raman spectroscopy and extended Hückel molecular orbital method. Nishina Y, et al. **J Biochem (Tokyo)** 1995 Sep; 118(3):614–20

METABOLISM

Absolute requirement of ammonium sulfate for reconstitution of active 70S ribosomes from the extreme halophilic archaeon Haloferax mediterranei. Sánchez E, et al. **Eur J Biochem** 1995 Nov 1;233(3):809–14

The CCAAT box-binding factor stimulates ammonium assimilation in Saccharomyces cerevisiae, defining a new cross-pathway regulation between nitrogen and carbon metabolisms. Dang VD, et al. **J Bacteriol** 1996 Apr; 178(7):1842–9

PHARMACOLOGY

High-ionic strength interference of ribosomal inhibition produced by aminoglycoside antibiotics. Marin I, et al. **Biochemistry** 1995 Dec 19;34(50):16519–23

Effect of encapsulated ammonium persulfate on DNA banding in sequencing gels. Kamps-Holtzapple C, et al. **Biotechniques** 1995 Jun;18(6):1006–7

Dual effect of ammonium persulfate on the generation of leukotrienes from human neutrophil granulocytes. Köller M, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):318–24

Mammalian phospholipase D: activation by ammonium sulfate and nucleotides. Nakamura S, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12319–22

TOXICITY

Toxicity of chlorine and other chlorinated compounds to some Australian aquatic organisms. Manning TM, et al. **Bull Environ Contam Toxicol** 1996 Jun;56(6):971–6

AMMON'S HORN see HIPPOCAMPUS

AMNESIA

A minibus driver with amnesia. Gray P, et al. **Practitioner** 1995 Oct;239(1555):567–72 (0 ref.)

CHEMICALLY INDUCED

Inhibitors of cyclooxygenases produce amnesia for a passive avoidance task in the chick. Hölscher C. **Eur J Neurosci** 1995 Jun 1;7(6):1360–5

Amnesia after diazepam infusion into basolateral but not central amygdala of Rattus norvegicus. Silva MA, et al. **Neuropsychobiology** 1995;32(1):31–6

Pregnenolone sulfate antagonizes dizocilpine amnesia: role for allopregnanolone. Cheney DL, et al. **Neuroreport** 1995 Aug 21;6(12):1697–700

AMNESIA

[Antagonism of piracetam on the amnestic effect of diazepam in mice] Pan JC, et al. **Yao Hsueh Hsueh Pao** 1996; 31(2):91–4 (Eng. Abstr.) **(Chi)**

DIAGNOSIS

The MILD interview: evaluating complaints of memory loss. Meharg SS, et al. **Am Fam Physician** 1996 Jul;54(1):167–72 (20 ref.)

Subjective memory complaints prior to and following electroconvulsive therapy. Coleman EA, et al. **Biol Psychiatry** 1996 Mar 1;39(5):346–56

Transient global amnesia and cerebral infarct: a case report. Raffaele R, et al. **Brain Inj** 1995 Nov–Dec;9(8):815–8

Sex offenders who claim amnesia for their alleged offense. Bourget D, et al. **Bull Am Acad Psychiatry Law** 1995; 23(2):299–307

Adapting symptom validity testing to evaluate suspicious complaints of amnesia in medicolegal evaluations. Frederick RI, et al. **Bull Am Acad Psychiatry Law** 1995; 23(2):231–7

Reliability of the Rey–Osterrieth Complex Figure in use with memory–impaired patients. Tupler LA, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):566–79

Topographic amnesia: spatial memory disorder, perceptual dysfunction, or category specific semantic memory impairment? McCarthy RA, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):318–25

Assessment of post–traumatic amnesia after severe closed head injury: retrospective or prospective? McMillan TM, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):422–7

The detection of exaggerated or simulated memory disorder by neuropsychological methods. Leng NR, et al. **J Psychosom Res** 1995 Aug;39(6):767–76 (37 ref.)

The Autobiographical Memory Interview (AMI) in organic and psychogenic amnesia. Kopelman MD. **Memory** 1994 Jun;2(2):211–35 (66 ref.)

Autobiographical experience and word meaning. Snowden JS, et al. **Memory** 1995 Sep–Dec;3(3–4):225–46

Hemorrhagic pituitary adenoma manifesting as transient global amnesia. Honma Y, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):234–6

DRUG THERAPY

Involvement of sigma 1 receptor in (+)-N–allylnormetazocine–stimulated hippocampal cholinergic functions in rats. Matsuno K, et al. **Brain Res** 1995 Sep 4;690(2):200–6

Reversal of scopolamine induced amnesia in rats by the steroid sulfatase inhibitor estrone–3–O–sulfamate. Li PK, et al. **Brain Res Cogn Brain Res** 1995 Oct;2(4):251–4

Studies on cognitive enhancing agents. I. Antiamnestic and antihypoxic activities of 2–dimethylaminoethyl ethers and related compounds. Ono S, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1483–7

Studies on cognitive enhancing agents. II. Antiamnestic and antihypoxic activities of 1–aryl–2–(2–aminoethoxy)ethanols. Ono S, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1488–91

Studies on cognitive enhancing agents. III. Antiamnestic and antihypoxic activities of a series of 1–bicycloaryl–2–(omega–aminoalkoxy)ethanols. Ono S, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1492–6

Effects of dynorphin A–(1–13) on carbon monoxide–induced delayed amnesia in mice studied in a step–down type passive avoidance task. Hiramatsu M, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):185–91

EPIDEMIOLOGY

The Gospel Oak Study stage IV: the clinical relevance of subjective memory impairment in older people. Tobiansky R, et al. **Psychol Med** 1995 Jul;25(4):779–86

ETIOLOGY

An increased frequency of patent foramen ovale in patients with transient global amnesia. Analysis of 53 consecutive patients. Klötzsch C, et al. **Arch Neurol** 1996 Jun; 53(6):504–8

A pure reversible amnesic syndrome following tuberculous meningoencephalitis. Ceccaldi M, et al. **Eur Neurol** 1995; 35(6):363–7

Autobiographical memory across personalities in dissociative identity disorder: a case report. Bryant RA. **J Abnorm Psychol** 1995 Nov;104(4):625–31

Assessment of post–traumatic amnesia after severe closed head injury: retrospective or prospective? McMillan TM, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):422–7

Very severe amnesia with acute onset after isolated hippocampal damage due to systemic lupus erythematosus [letter] Schnider A, et al. **J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):644–6

Memory without context: amnesia with confabulations after infarction of the right capsular genu. Schnider A, et al. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):186–93

Global transient amnesia and subclavian steal syndrome [letter] Blasco MR, et al. **Lancet** 1996 Jun 8;347(9015):1636

Reversal of beta–amyloid–induced retention deficit after exposure to training and state cues. McDonald MP, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):35–47

[Amnestic syndrome—research update] Wetterling T. **Fortschr Neurol Psychiatr** 1995 Oct;63(10):402–10 (134 ref.) (Eng. Abstr.) **(Ger)**

[A case of amnesic syndrome caused by hematoma in the left anterior medial thalamus] Maeshima S, et al. **No Shinkei Geka** 1996 Jan;24(1):53–6 (Eng. Abstr.) **(Jpn)**

[A neuropharmacological study of amnesia in animals induced by ultra high frequency electromagnetic irradiation] Iasnetsov VV, et al. **Med Tr Prom Ekol** 1995; (7):40–2 **(Rus)**

NURSING

Cognitive effects of electroconvulsive therapy: a clinical review for nurses. Durr AL, et al. **Convuls Ther** 1995 Sep; 11(3):192–201 (33 ref.)

PATHOLOGY

Double dissociation of memory capacities after bilateral occipital–lobe or medial temporal–lobe lesions. Keane MM, et al. **Brain** 1995 Oct;118 (Pt 5):1129–48

PHYSIOPATHOLOGY

Correlation of fornix damage with memory impairment in six cases of colloid cyst removal. McMackin D, et al. **Acta Neurochir (Wien)** 1995;135(1–2):12–8

Posttraumatic Amnesia as a predictor of outcome after severe closed head injury. Prospective assessment. Ellenberg JH, et al. **Arch Neurol** 1996 Aug;53(8):782–91

Intact delay–eyeblink classical conditioning in amnesia. Gabrieli JD, et al. **Behav Neurosci** 1995 Oct;109(5):819–27

Distinctive forms of partial retrograde amnesia after asymmetric temporal lobe lesions: possible role of the occipitotemporal gyri in memory. Eslinger PJ, et al. **Cereb Cortex** 1996 May–Jun;6(3):530–9

Selective impairments within episodic memories. Sirigu A, et al. **Cortex** 1996 Mar;32(1):83–95

The hippocampus and long–term object memory in the rat. Vnek N, et al. **J Neurosci** 1996 Apr 15;16(8):2780–7

Marked retrograde and anterograde amnesia of a visual discrimination task in rats with selective lesions of the perirhinal cortex. Myhrer T, et al. **Neurobiol Learn Mem** 1996 May;65(3):244–52

Transient topographical amnesia and cingulate cortex damage: a case report. Cammalleri R, et al. **Neuropsychologia** 1996 Apr;34(4):321–6

Memory and consciousness: a selective review of issues and data. Rugg MD. **Neuropsychologia** 1995 Sep;33(9):1131–41 (66 ref.)

Transient global amnesia. Sandson TA, et al. **Semin Neurol** 1995 Jun;15(2):183–7 (51 ref.)

[The molecular basis of dopamine synapse activity in the mechanisms of learning and amnesia] Podgornaia EK, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):122–8 (Eng. Abstr.) **(Rus)**

[Transient global amnesia. Case–control study of 24 cases] Moreno–Lugris XC, et al. **Rev Neurol** 1996 May; 24(129):554–7 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

[Vestibular–protective and anti–amnesia properties of adrenocorticotropic hormone fragments and their analogs] Iasnetsov VV, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):634–6 **(Rus)**

PSYCHOLOGY

Neural Mechanisms in dissociative amnesia for childhood abuse: relevance to the current controversy surrounding the "false memory syndrome". Bremner JD, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):71–82 (124 ref.)

On the acquisition of new declarative knowledge in amnesia. Hamann SB, et al. **Behav Neurosci** 1995 Dec;109(6):1027–44

Different components in word–list forgetting of pure amnesics, degenerative demented and healthy subjects. Carlesimo GA, et al. **Cortex** 1995 Dec;31(4):735–45

Forgetting from long–term memory in dementia and pure amnesia: role of task, delay of assessment and aetiology of cerebral damage. Carlesimo GA, et al. **Cortex** 1995 Jun; 31(2):285–300

Spared retrograde memory with anterograde amnesia and widespread cognitive deficits. Siegert RJ, et al. **Cortex** 1996 Mar;32(1):177–85

Dense amnesia in a professional musician following herpes simplex virus encephalitis. Wilson BA, et al. **J Clin Exp Neuropsychol** 1995 Oct;17(5):668–81

Level–of–processing effects in word–completion priming: a neuropsychological study. Hamann SB, et al. **J Exp Psychol Learn Mem Cogn** 1996 Jul;22(4):933–47

Learning about categories in the absence of memory. Squire LR, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19; 92(26):12470–4

Acute stress response: a comparison of head injured and non–head injured patients. Bryant RA, et al. **Psychol Med** 1995 Jul;25(4):869–73

Encoding, remembering and awareness in lorazepam–induced amnesia. Curran HV, et al. **Psychopharmacology (Berl)** 1995 Nov;122(2):187–93

A neostriatal habit learning system in humans [see comments] Knowlton BJ, et al. **Science** 1996 Sep 6;273(5280):1399–402 . Comment in: Science 1996 Sep 6;273(5280):1353–4.

[Unknown patient—psychogenic amnesia treated with hypnosis] Wallin M. **Duodecim** 1994;110(6):592–4 **(Fin)**

RADIONUCLIDE IMAGING

Persistent post–traumatic retrograde amnesia: a neuropsychological and (18F)FDG PET study. Mattioli F, et al. **Cortex** 1996 Mar;32(1):121–9

A single photon emission computed tomography study of cerebral regional perfusion changes induced by a learning task in subjects with mild memory impairment. Robert PH, et al. **Psychiatry Res** 1995 Nov 10;61(4):231–41

REHABILITATION

Use of a comprehensive programme of external cueing to enhance procedural memory in a patient with dense amnesia. Kime SK, et al. **Brain Inj** 1996 Jan;10(1):17–25

The method of vanishing cues: an evaluation of its effectiveness in teaching memory–impaired individuals. Hunkin NM, et al. **Neuropsychologia** 1995 Oct; 33(10):1255–79

THERAPY

[Unknown patient (letter)] Hirvenoja R. **Duodecim** 1994; 110(18):1737–8 **(Fin)**

[Unknown patient—psychogenic amnesia treated with hypnosis] Wallin M. **Duodecim** 1994;110(6):592–4 **(Fin)**

AMNESIA, RETROGRADE

CHEMICALLY INDUCED

Amnesia from sarin poisoning [letter] Hatta K, et al. **Lancet** 1996 May 11;347(9011):1343

DIAGNOSIS

Two tests for assessing remote public knowledge: a tool for assessing retrograde amnesia. Mayes AR, et al. **Memory** 1994 Jun;2(2):183–210

ETIOLOGY

[A case of transient amnesia caused by cerebral thrombophlebitis: contribution of neuroimaging to physiopathogenesis of transient amnesia] Attarian S, et al. **Rev Neurol (Paris)** 1995 Oct;151(10):552–8 (32 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Persistent retrograde, amnesia following a minor trauma. De Renzi E, et al. **Cortex** 1995 Sep;31(3):531–42

PSYCHOLOGY

Focal retrograde amnesia: a multi–faceted disorder? Parkin AJ. **Acta Neurol Belg** 1996 Mar;96(1):43–50 (37 ref.)

A new case of retrograde amnesia with abnormal forgetting rate. Maravita A, et al. **Cortex** 1995 Dec;31(4):653–67

Self–knowledge of an amnesic patient: toward a neuropsychology of personality and social psychology. Klein SB, et al. **J Exp Psychol Gen** 1996 Sep;125(3):250–60

RADIONUCLIDE IMAGING

Right temporofrontal cortex as critical locus for the ecphory of old episodic memories. Calabrese P, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep;61(3):304–10

AMNIOCENTESIS

see related

CHORIONIC VILLI SAMPLING

Prenatal diagnosis of familial dysautonomia by analysis of linked CA–repeat polymorphisms on chromosome 9q31–q33. Eng CM, et al. **Am J Med Genet** 1995 Nov 20; 59(3):349–55

Maternal uniparental disomy of chromosome 2 in a baby with trisomy 2 mosaicism in amniotic fluid culture. Harrison K, et al. **Am J Med Genet** 1995 Aug 28;58(2):147–51

Is polyhydramnios in an ultrasonographically normal fetus an indication for genetic evaluation? Barnhard Y, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1523–7

Maternal serum screening should not replace amniocentesis [letter] Hsu LY, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):977–8

Comparison of multiple–marker screening with amniocentesis for the detection of fetal aneuploidy in women > or = 35 years old [see comments] Wenstrom KD, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1287–92. Comment in: Am J Obstet Gynecol 1996 Jun;174(6):1941–2.

The effects of fetal blood sampling and placental puncture on umbilical artery and fetal arterial vessels blood flow velocity waveforms. Capponi A, et al. **Am J Perinatol** 1996 Apr;13(3):185–90

First trimester biochemical screening for trisomy 21 [letter] Reynolds TM. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):512–3

Successful outcome with serial amniocenteses for polyhydramnios complicating cystic adenomatoid malformation of the lung. Meagher SE, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):326–8

Children whose mothers had second trimester amniocentesis: follow up at school age. Finegan JA, et al. **Br J Obstet Gynaecol** 1996 Mar;103(3):214–8

Familial supernumerary chromosome and malignancy. Milunsky JM, et al. **Cancer Genet Cytogenet** 1996 Jul 15; 89(2):170–2

Free amino acids in amniotic fluid and the prenatal diagnosis of homocystinuria with methylmalonic aciduria. Parvy P, et al. **Clin Chem** 1995 Nov;41(11):1663–4
Intestinal atresia following intraamniotic use of dyes. Glüer S. **Eur J Pediatr Surg** 1995 Aug;5(4):240–2
Management of platelet and RhD maternal immunizations by PCR phenotypings after early amniocentesis. Sagot P, et al. **Fetal Diagn Ther** 1995 Nov–Dec;10(6):373–80
Complete and precise characterization of marker chromosomes by application of microdissection in prenatal diagnosis. Müller–Navia J, et al. **Hum Genet** 1995 Dec; 96(6):661–7
Predictive value of amniotic fluid index for oligohydramnios in patients with prolonged pregnancies. O'Reilly–Green CP, et al. **J Matern Fetal Med** 1996 Jul–Aug;5(4):218–26
Exencephaly–anencephaly sequence: proof by ultrasound imaging and amniotic fluid cytology. Timor–Tritsch IE, et al. **J Matern Fetal Med** 1996 Jul–Aug;5(4):182–5
Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group. Piggott M, et al. **J Med Screen** 1994 Jan;1(1):45–9
Down's syndrome screening in the UK [letter; comment] Reynolds TM. **Lancet** 1996 Mar 30;347(9005):907. Comment on: Lancet 1996 Feb 3;347(8997):330.
Chorionic villus sampling and amniocentesis: recommendations for prenatal counseling. Centers for Disease Control and Prevention. **MMWR Morb Mortal Wkly Rep** 1995 Jul 21; 44(RR–9):1–12
Epidemiology of Down's syndrome in a Scottish city. Lopez PM, et al. **Paediatr Perinat Epidemiol** 1995 Jul;9(3):331–40
Prenatal diagnosis of Roberts syndrome: two new cases. Benzacken B, et al. **Prenat Diagn** 1996 Feb;16(2):125–30
Prenatal diagnosis of uniparental disomy 15 following trisomy 15 mosaicism. Christian SL, et al. **Prenat Diagn** 1996 Apr; 16(4):323–32
Prenatal diagnosis of Smith–Lemli–Opitz syndrome is possible by measurement of 7–dehydrocholesterol in amniotic fluid. Dallaire L, et al. **Prenat Diagn** 1995 Sep; 15(9):855–8
Prenatal diagnosis of ring chromosome 6. Dawson AJ, et al. **Prenat Diagn** 1995 Sep;15(9):872–4
Increased incidence of cytogenetic abnormalities in chorionic villus samples from pregnancies established by in vitro fertilization and embryo transfer (IVF–ET). In't Veld PA, et al. **Prenat Diagn** 1995 Oct;15(10):975–80
Twin–twin transfusion syndrome––possible roles for Doppler ultrasound and amniocentesis [letter; comment] Machin GA. **Prenat Diagn** 1995 Jul;15(7):681–2. Comment on: Prenat Diagn 1995 Jan;15(1):60–3.
Prenatal diagnosis of Herlitz junctional epidermolysis bullosa by amniocentesis. Marinkovich MP, et al. **Prenat Diagn** 1995 Nov;15(11):1027–34
Prenatal diagnosis of mitochondrial fatty acid oxidation defects. Nada MA, et al. **Prenat Diagn** 1996 Feb; 16(2):117–24
Early amniocentesis and fetal nuchal translucency in women requesting karyotyping for advanced maternal age. Salvesen DR, et al. **Prenat Diagn** 1995 Oct;15(10):971–4
Cross–hybridization of the chromosome 13/21 alpha satellite DNA probe to chromosome 22 in the prenatal screening of common chromosomal aneuploidies by FISH. Verlinsky Y, et al. **Prenat Diagn** 1995 Sep;15(9):831–4
Early amniocentesis: a clinical review. Wilson RD. **Prenat Diagn** 1995 Dec;15(13):1259–73 (97 ref.)
Prenatal diagnosis of glycogen storage disease type 1a by direct mutation detection. Wong LJ. **Prenat Diagn** 1996 Feb;16(2):105–8
[Amniocentesis and single choroid plexus cyst. Current status] Morales–Roselló J, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):412–6 (30 ref.) (Eng. Abstr.) **(Fre)**
–Amniocentesis or chorionic villi sampling––when and why?– Hebisch G. **Arch Gynecol Obstet** 1995;256 Suppl:S182–92 (17 ref.) **(Ger)**
[Prenatal determination of fetal rhesus factor in amnionic cells using polymerase chain reaction] Crombach G, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):577–9 (Eng. Abstr.) **(Ger)**
[Insulin–like–growth–factor–binding–protein 1 (IGFBP–1) and fetal fibronectin in diagnosis of premature rupture of fetal membranes] Ragosch V, et al. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):291–6 (Eng. Abstr.) **(Ger)**
[Early amniocentesis––already an alternative? (editorial)] Rauskolb R. **Z Geburtshilfe Neonatol** 1995 Jul–Aug; 199(4):131 **(Ger)**
[Prenatal diagnosis of Hunter syndrome in a carrier and her twin sisters] Sakai N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jan;48(1):65–8 **(Jpn)**
[The formation of risk groups and the performance of invasive prenatal diagnosis] Arbuzova SB, et al. **Tsitol Genet** 1995 Sep–Oct;29(5):76–81 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Further complications in the stuck twin syndrome: decubiti ulcerations and iatrogenic exsanguination. Westover T, et al. **Am J Perinatol** 1995 Nov;12(6):401–3
Sepsis due to Clostridium perfringens after second–trimester amniocentesis [letter] Hovav Y, et al. **Clin Infect Dis** 1995 Jul;21(1):235–6
Doppler assessment of umbilical flow after genetic amniocentesis. Martinez JM, et al. **Early Hum Dev** 1996 Feb 23;44(2):105–11
Pregnancy outcome following genetic amniocentesis at 11–14 versus 16–19 weeks' gestation. Brumfield CG, et al. **Obstet Gynecol** 1996 Jul;88(1):114–8
Early amniocentesis at 10–12 weeks' gestation. Diaz Vega M, et al. **Prenat Diagn** 1996 Apr;16(4):307–12
Blood contamination of amniotic fluid after amniocentesis in relation to placental location. Giorlandino C, et al. **Prenat Diagn** 1996 Feb;16(2):180–2
Fetal fibronectin in cervical secretions after mid–trimester amniocentesis [letter] Rizzo G, et al. **Prenat Diagn** 1995 Nov;15(11):1087–8
[Hemorrhagic shock caused by intraperitoneal hemorrhage after amniocentesis] Jung V, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):411–3 (Eng. Abstr.) **(Ger)**

CONTRAINDICATIONS

[Does the risk of complications after amniocentesis depend on the indications for intervention? An evaluation of 2,066 punctures] Plöckinger B, et al. **Geburtshilfe Frauenheilkd** 1996 Mar;56(3):128–31 (Eng. Abstr.) **(Ger)**

ECONOMICS

Justifying prenatal screening and genetic amniocentesis programs by cost–effectiveness analyses: a re–evaluation. Ganiats TG. **Med Decis Making** 1996 Jan–Mar;16(1):45–50 (61 ref.)

INSTRUMENTATION

Management of amniocentesis in women with oligohydramnios due to membrane rupture: evaluation of a cervical adapter. Vaitkiene D, et al. **Gynecol Obstet Invest** 1995;40(1):28–31

METHODS

Early sonographically guided amniocenteses with filtration technique: follow–up on 249 procedures. Sundberg K, et al. **J Ultrasound Med** 1995 Aug;14(8):585–90
Modified stylet technique for tenting of amniotic membranes. Dombrowski MP, et al. **Obstet Gynecol** 1996 Mar; 87(3):455–6
[Rh typing by PCR on amniotic cells] Mannessier L, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):827–8 **(Fre)**
[Prenatal diagnosis of fetal varicella in the second trimester of pregnancy] Pons JC, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):829–38 (59 ref.) (Eng. Abstr.) **(Fre)**
[Maternal serum markers of fetal trisomy 21] Muller F, et al. **Presse Med** 1995 Sep 23;24(27):1265–9 (Eng. Abstr.) **(Fre)**
[Reliability of invasive prenatal diagnosis in the first trimester in comparison with standard amniocentesis] Crombach G, et al. **Gynakologe** 1995 Oct;28(5):302–14 (93 ref.) (Ger)
[Early amniocentesis in prenatal diagnosis] Pawlowska B, et al. **Ginekol Pol** 1995 May;66(5):262–6 (Eng. Abstr.) **(Pol)**

STANDARDS

Experience with early amniocentesis. Sundberg K, et al. **J Perinat Med** 1995;23(3):149–58 (35 ref.)

STATISTICS & NUMERICAL DATA

Amniocentesis rate and the detection of Down syndrome and other chromosomal anomalies in Israel. Shohat M, et al. **Prenat Diagn** 1995 Oct;15(10):967–70

UTILIZATION

Racial–ethnic differences in prenatal diagnostic test use and outcomes: preferences, socioeconomics, or patient knowledge? Kuppermann M, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):675–82

AMNION

Amnioinfusion in women with previous cesarean births: a preliminary report. Ouzounian JG, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):783–6
Second–trimester echogenic bowel and intraamniotic bleeding: association between fetal bowel echogenicity and amniotic fluid spectrophotometry at 410 nm. Sepulveda W, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):839–42
Amnion rupture in the second trimester. Hewitt B, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):323–5
Amnioinfusion: a question of benefits and risks [letter; comment] Hofmeyr GJ. **Br J Obstet Gynaecol** 1996 Mar; 103(3):288–9. Comment on: Br J Obstet Gynaecol 1992 Jun;99(6):449–51.
Intrapartum use of fetal heart rate monitoring, contraction monitoring, and amnioinfusion. Cusick W, et al. **Clin Perinatol** 1995 Dec;22(4):875–906 (130 ref.)
A case of life–threatening pulmonary edema associated with amnioinfusion during labor. Wegnelius G, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):237–9
Transabdominal amnioinfusion in preterm pregnancies complicated by fetal growth restriction, oligohydramnios and umbilical cord compression. Sarno AP, et al. **Fetal Diagn Ther** 1995 Nov–Dec;10(6):408–14
Pitfalls in the diagnosis of nonconjoined monoamniotic twins. Strohbehn K, et al. **J Perinatol** 1995 Nov–Dec;15(6):484–93 (56 ref.)
Amnioinfusion for preventing puerperal infection. A prospective study. Monahan E, et al. **J Reprod Med** 1995 Oct;40(10):721–3
Pumps and warmers during amnioinfusion: is either necessary? Glantz JC, et al. **Obstet Gynecol** 1996 Jan; 87(1):150–5
Islet cell implantation into the pouched amniotic membrane on the side of the portal vein in dogs. Ghanavi J, et al. **Transplant Proc** 1995 Oct;27(5):2644
[Vaginal delivery of monochorionic, monoamniotic twins. Clinical case] Dubecq–Princeteau F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):634–5 (Eng. Abstr.) **(Fre)**
[Amnio–infusion, a technique worth developing (letter)?] Kauffmann E, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):573–4 **(Fre)**

CHEMISTRY

Expression of parathyroid hormone–related peptide and its receptor messenger ribonucleic acid in human amnion and chorion–decidua: implications for secretion and function. Bruns ME, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):739–46
Amniochorion: a source of interleukin–8. Fortunato SJ, et al. **Am J Reprod Immunol** 1995 Sep;34(3):156–62
Nuclear microanalysis of the monovalent ion distribution in the human amnion. I. Effect of magnesium. Bara M, et al. **Magnes Res** 1995 Sep;8(3):207–14
[Sedative and antistress action of a peptide complex isolated from human amnion] Borshchevskaia MI, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):57–9 **(Rus)**

CYTOLOGY

Expression of markers for both neuronal and glial cells in human amniotic epithelial cells. Sakuragawa N, et al. **Neurosci Lett** 1996 May 3;209(1):9–12
[Chromosomal mosaicism of extraembryonic cell membrane, detected during prenatal diagnosis] Zolotukhina TV, et al. **Genetika** 1995 Sep;31(9):1317–21 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

The controversial role of cAMP on amnionic prostaglandin release: effect of adenylate cyclase inhibition. Vesce F, et al. **Gynecol Obstet Invest** 1995;40(2):73–9
Macrophage inflammatory protein–I alpha regulates prostaglandin E2 and interleukin–6 production by human gestational tissues in vitro. Dudley DJ, et al. **J Soc Gynecol Investig** 1996 Jan–Feb;3(1):12–6
Comparative studies of Ca N–acetylhomotaurinate and Ca N–acetyltaurinate. II. Preventive and opposing actions of the acute ethanol depletive effect on the ionic transfer through the isolated human amnion. Guiet–Bara A, et al. **Methods Find Exp Clin Pharmacol** 1995 Jul–Aug; 17(6):361–8
The induction of cyclooxygenase–2 (COX–2) in intact human amnion tissue by interleukin–4. Spaziani EP, et al. **Prostaglandins** 1996 Mar;51(3):215–23

EMBRYOLOGY

A candidate gene for the amnionless gastrulation stage mouse mutation encodes a TRAF–related protein. Wang X, et al. **Dev Biol** 1996 Jul 10;177(1):274–90

ENZYMOLOGY

Elevated protease activities in human amnion and chorion correlate with preterm premature rupture of membranes. Draper D, et al. **Am J Obstet Gynecol** 1995 Nov; 173(5):1506–12
92–kDa gelatinase (matrix metalloproteinase–9) is induced in rat amnion immediately prior to parturition. Lei H, et al. **Biol Reprod** 1995 Aug;53(2):339–44
Messenger RNA encoding thiol protein disulphide isomerase in amnion, chorion and placenta in human term and preterm labour. Morrison JJ, et al. **Br J Obstet Gynaecol** 1996 Sep; 103(9):873–8
Prostaglandin H synthase–2 expression increases in human gestational tissues with spontaneous labour onset. Hirst JJ, et al. **Reprod Fertil Dev** 1995;7(3):633–7
Activation of phospholipase D in cultured human amnion cells. Inamori K, et al. **Reprod Fertil Dev** 1995;7(6):1591–4

INJURIES

Teratogenic effects of amniotic sac puncture: a mouse model. MacIntyre DJ, et al. **J Anat** 1995 Jun;186 (Pt 3):527–39

METABOLISM

Effectors of cyclic adenosine 5'–monophosphate up–regulating–oxytocin receptors in rabbit amnion cells: isoproterenol, parathyroid hormone–related protein, and potentiation by cortisol. Jeng YJ, et al. **Biol Reprod** 1995

Nov;53(5):1051–6

Involvement of methionine in the synthesis of certain membrane–associated nucleotide sugars by human amnion (WISH) cells. Wood RC. **Cancer Lett** 1996 Feb 27; 100(1–2):37–40

Human amniotic tumor that induces new bone formation in vivo produces growth–regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. Izbicka E, et al. **Cancer Res** 1996 Feb 1; 56(3):633–6

Human amnion contains a novel laminin variant, laminin 7, which like laminin 6, covalently associates with laminin 5 to promote stable epithelial–stromal attachment. Champliaud MF, et al. **J Cell Biol** 1996 Mar;132(6):1189–98

A comparative study of progesterone synthesis by term human fetal amnion and chorion. Gunasegaram R, et al. **J Perinat Med** 1995;23(5):371–7

Regulation of fetal fibronectin production in human amnion cells. Jackson GM, et al. **J Soc Gynecol Investig** 1996 Mar–Apr;3(2):85–8

Comparative studies of Ca N–acetylhomotaurinate and Ca N–acetyltaurinate. I. Effects on the ionic transfer through the isolated human amnion. Bara M, et al. **Methods Find Exp Clin Pharmacol** 1995 May;17(4):233–40

Comparative studies of Ca N–acetylhomotaurinate and Ca N–acetyltaurinate. II. Preventive and opposing actions of the acute ethanol depletive effect on the ionic transfer through the isolated human amnion. Guiet–Bara A, et al. **Methods Find Exp Clin Pharmacol** 1995 Jul–Aug; 17(6):361–8

Endothelin receptors in the human amnion, chorion laeve, decidua vera and placenta. Hasegawa M, et al. **Reprod Fertil Dev** 1995;7(6):1585–9

Studies on glucocorticoid hormone actions in the regulation of human amnion PGHS. Zakar T, et al. **Reprod Fertil Dev** 1995;7(3):517–20 (12 ref.)

[Biochemical changes in extracellular matrix components of the amniotic sac during its premature rupture] Rechberger T, et al. **Ginekol Pol** 1996 Mar;67(3):117–24 (Eng. Abstr.) **(Pol)**

[Alpha–2–adrenergic receptors of the chick embryo amnion] Boĭko OV, et al. **Dokl Akad Nauk** 1996 Apr;347(5):704–6 **(Rus)**

PHYSIOLOGY

[The modifying action of a complex of physiologically active substances isolated from the human amnion on chromosome damage] Timchenko OI, et al. **Tsitol Genet** 1995 Sep–Oct; 29(5):49–54 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Intra–amniotic maternal hemorrhage in preterm labor: a case report. Kurata H, et al. **J Perinat Med** 1995;23(3):229–32

SURGERY

Early versus late amniotomy for labor induction: a randomized trial. Mercer BM, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1321–5

A randomised controlled trial of early versus delayed use of amniotomy and oxytocin infusion in nulliparous labour. Cammu H, et al. **Br J Obstet Gynaecol** 1996 Apr; 103(4):313–8

A randomised controlled trial of early versus delayed use of amniotomy and oxytocin infusion in nulliparous labour [letter] Geary M. **Br J Obstet Gynaecol** 1996 Sep; 103(9):939–40

Induction of labour: a randomised clinical trial of amniotomy versus amniotomy with oxytocin infusion. Moldin PG, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):306–12

Amniotomy to induce labor. Busowski JD, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):246–58 (41 ref.)

The effect of routine early amniotomy on spontaneous labor: a meta–analysis. Brisson–Carroll G, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):891–6

TRANSPLANTATION

Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. Kim JC, et al. **Cornea** 1995 Sep;14(5):473–84

ULTRASONOGRAPHY

Prospective determination of chorionicity, amnionicity, and zygosity in twin gestations. Scardo JA, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1376–80

Yolk sac number, size and morphologic features in monochorionic monoamniotic twin pregnancy. Levi CS, et al. **Can Assoc Radiol J** 1996 Apr;47(2):98–100

The empty amnion: a sign of early pregnancy failure. McKenna KM, et al. **J Ultrasound Med** 1995 Feb; 14(2):117–21

Measurement of amniochorionic membrane thickness using high–frequency ultrasound. Frigo P, et al. **Prenat Diagn** 1996 Apr;16(4):313–7

ULTRASTRUCTURE

Studies of hemidesmosomes in human amnion: the use of a detergent extraction protocol for compositional and ultrastructural analysis and preparation of a hemidesmosome–enriched fraction from tissue. Behzad F, et al. **Acta Anat (Basel)** 1995;152(3):170–84

Microscopic and biochemical analysis of the viability and permeability of guinea pig amnion and chorion leave in vitro. Goldhawk DE, et al. **J Exp Zool** 1996 Aug 1; 275(5):383–97

AMNIONITIS see **CHORIOAMNIONITIS**

AMNIOTIC BAND SYNDROME

COMPLICATIONS

Intrapartum death due to an amniotic band. Eriksen L, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):388–90

Clubfeet in congenital annular constricting bands. Gomez VR. **Clin Orthop** 1996 Feb;(323):155–62

EMBRYOLOGY

Cleft lip and amniotic bands [letter] Kumar P. **Br J Plast Surg** 1996 Jan;49(1):74–5

PATHOLOGY

Congenital constriction band syndrome. Perdue PS, et al. **J South Orthop Assoc** 1996 Spring;5(1):71–5 (12 ref.)

SURGERY

Congenital annular constricting band: a case report with pseudarthrosis and review of the literature. Martinot–Duquennoy V, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):380–4 (23 ref.)

Clubfeet associated with congenital constriction bands of the ipsilateral lower extremity. Allington NJ, et al. **J Pediatr Orthop** 1995 Sep–Oct;15(5):599–603

Amniotic band syndrome in fetal lambs. I: Fetoscopic release and morphometric outcome. Crombleholme TM, et al. **J Pediatr Surg** 1995 Jul;30(7):974–8

ULTRASONOGRAPHY

Amniotic band attachment to a fetal limb: demonstration with real–time sonography. Laberge LC, et al. **Ann Plast Surg** 1995 Sep;35(3):316–9

[Amniotic adhesions. A case report] Matar N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):850–2 (Eng. Abstr.) **(Fre)**

AMNIOTIC BANDS see **AMNIOTIC BAND SYNDROME**

AMNIOTIC FLUID

see related
EMBOLISM, AMNIOTIC FLUID
OLIGOHYDRAMNIOS
POLYHYDRAMNIOS

Antepartum surveillance in diabetic pregnancies: predictors of fetal distress in labor. Kjos SL, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1532–9

Intraamniotic deamino(D–Arg8)–vasopressin: prolonged effects on ovine fetal urine flow and swallowing. Kullama LK, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):78–84

How frequently should the amniotic fluid index be performed during the course of antepartum testing? Wing DA, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):33–6

Amniotic fluid index and perinatal morbidity. Dizon–Townson D, et al. **Am J Perinatol** 1996 May; 13(4):231–4

Responsiveness to the odour of amniotic fluid in the human neonate. Schaal B, et al. **Biol Neonate** 1995;67(6):397–406

Respiration of amniotic fluid in near–term foetal rabbit. Haddad B, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):247–50

Amniotic fluid pressure in twin–to–twin transfusion syndrome: an objective prognostic factor. Ville Y, et al. **Fetal Diagn Ther** 1996 May–Jun;11(3):176–80

Investigations into the rheological characteristics of bovine amniotic fluid. Dasari G, et al. **J Biochem Biophys Methods** 1995 Nov;30(4):217–25

Fetal echogenic bowel [letter] Sepulveda W. **Lancet** 1996 Apr 13;347(9007):1043

Meconium–stained amniotic fluid–associated infectious morbidity: a randomized, double–blind trial of ampicillin–sulbactam prophylaxis. Adair CD, et al. **Obstet Gynecol** 1996 Aug;88(2):216–20

Maternal and perinatal outcome of patients with preterm labor and meconium–stained amniotic fluid. Mazor M, et al. **Obstet Gynecol** 1995 Nov;86(5):830–3

Can meconium in the amniotic fluid injure the fetal brain? [letter; comment] Montgomery LD, et al. **Obstet Gynecol** 1996 Feb;87(2):320. Comment on: Obstet Gynecol 1995 Nov;86(5):720–4.

Can meconium in the amniotic fluid injure the fetal brain? [see comments] Naeye RL. **Obstet Gynecol** 1995 Nov; 86(5):720–4. Comment in: Obstet Gynecol 1996 Feb;87(2):320.

Amniotic fluid meconium: a fetal environmental hazard. Ramin KD, et al. **Obstet Gynecol** 1996 Feb;87(2):181–4

Blood contamination of amniotic fluid after amniocentesis in relation to placental location. Giorlandino C, et al. **Prenat Diagn** 1996 Feb;16(2):180–2

Prolongation of survival of rat kidney allografts by transforming growth factor–beta 2. Thompson DA, et al. **Transplant Proc** 1996 Jun;28(3):1948–51

[Evaluation of the usefulness and reference values for the amniotic fluid index in normal pregnancy between 30 and 42 weeks of gestation] Heimrath J, et al. **Ginekol Pol** 1995 Feb;66(2):85–8 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Endometrial and fetoplacental markers in pregnancies with fetal congenital nephrosis. Heinonen S, et al. **Acta Obstet Gynecol Scand** 1996 Jul;75(6):526–30

Development and validation of an in–house radioimmunoassay for erythropoietin. Fingerová H, et al. **Acta Univ Palacki Olomuc Fac Med** 1994;138:21–3

Prediction of fetal lung maturity in infants of diabetic mothers using the FLM S/A and disaturated phosphatidylcholine tests. Tanasijevic MJ, et al. **Am J Clin Pathol** 1996 Jan; 105(1):17–22

Second–trimester echogenic bowel and intraamniotic bleeding: association between fetal bowel echogenicity and amniotic fluid spectrophotometry at 410 nm. Sepulveda W, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):839–42

The coelomic cavity—a reservoir for metals. Wathen NC, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1884–8

Sensitive method for the determination of pulmonary surfactant phospholipid/sphingomyelin ratio in human amniotic fluids for the diagnosis of respiratory distress syndrome by thin–layer chromatography–immunostaining. Iwamori M, et al. **Anal Biochem** 1996 Jun 15;238(1):29–33

Glycosaminoglycan accumulation in amniotic fluid during early pregnancy. Sloan R, et al. **Biochem Soc Trans** 1996 Feb;24(1):103S

The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis. Denomme GA, et al. **Br J Haematol** 1995 Nov;91(3):742–6

Low cyclic guanosine monophosphate levels in the amniotic fluid of pre–eclamptic pregnancies. Rizzo G, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):834–7

Diagnosis of premature rupture of membranes with an improved alpha–fetoprotein monoclonal antibody kit. Kishida T, et al. **Clin Chem** 1995 Oct;41(10):1500–3

Prostaglandin D2 synthase: a component of human amniotic fluid and its association with fetal abnormalities. Melegos DN, et al. **Clin Chem** 1996 Jul;42(7):1042–50

Free amino acids in amniotic fluid and the prenatal diagnosis of homocystinuria with methylmalonic aciduria. Parvy P, et al. **Clin Chem** 1995 Nov;41(11):1663–4

The typing of fetal antigen 2 in human amniotic fluid. Price KM, et al. **Clin Chim Acta** 1995 May 15;236(2):181–94

Steroids in human intrauterine fluids of early pregnancy. Atkinson G, et al. **Clin Endocrinol (Oxf)** 1996 Apr; 44(4):435–40

Relaxin levels in amniotic fluid, extraembryonic coelomic fluid and maternal serum in early human pregnancy. Wathen NC, et al. **Early Hum Dev** 1995 Aug 30;43(1):71–4

Amniotic fluid and plasma levels of parathyroid hormone–related protein and hormonal modulation of its secretion by amniotic fluid cells [see comments] Dvir R, et al. **Eur J Endocrinol** 1995 Sep;133(3):277–82. Comment in: Eur J Endocrinol 1995 Sep;133(3):272–4.

Identification of sex in hatchling loggerhead turtles (Caretta caretta) by analysis of steroid concentrations in chorioallantoic/amniotic fluid. Gross TS, et al. **Gen Comp Endocrinol** 1995 Aug;99(2):204–10

Rheumatoid factor–associated high–molecular–weight complexes in the menstrual and amniotic fluids. Halperin R, et al. **Gynecol Obstet Invest** 1996;41(3):220–3

Amniotic fluid prealbumin as a potential marker of fetal abnormalities. Lolis D, et al. **Gynecol Obstet Invest** 1995; 40(4):231–5

Prostate specific antigen in non–serum samples from women [letter] Filella X, et al. **Int J Biol Markers** 1995 Oct–Dec; 10(4):238–9

A comparison of three tests for determining fetal pulmonary maturity. Rodriguez–Macias KA. **Int J Gynaecol Obstet** 1995 Oct;51(1):39–42

Amniotic fluid insulin and C peptide levels in diabetic and nondiabetic women during early pregnancy. Fallucca F, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):137–9

Predictive value of amniotic fluid index for oligohydramnios in patients with prolonged pregnancies. O'Reilly–Green CP, et al. **J Matern Fetal Med** 1996 Jul–Aug;5(4):218–26

Amniotic fluid alpha fetoprotein (AFAFP) and maternal serum alpha fetoprotein (MSAFP) in abdominal pregnancies: correlation with extent and site of placental implantation and clinical implications. Shumway JB, et al. **J Matern Fetal Med** 1996 May–Jun;5(3):120–3

Developmental changes of free amino acid concentrations in fetal fluids of pigs. Wu G, et al. **J Nutr** 1995 Nov; 125(11):2859–68

Mid–second trimester organic acids in severe open neural tube defects. Legge M. **J Obstet Gynaecol** 1995 Oct; 21(5):483–7

Amniotic fluid levels of CA 19.9 and CA 15.3 in normal and Down's syndrome pregnancies. Noci I, et al. **J Perinat Med** 1995;23(3):237–41

Soluble tumor necrosis factor receptors and soluble interleukin–6 receptor in fetal and maternal sera, coelomic and amniotic fluids in normal and pre–eclamptic pregnancies. Opsjøn SL, et al. **J Reprod Immunol** 1995 Jul; 29(2):119–34

Interleukin–2 in human amniotic fluid during pregnancy and

parturition: implications for prostaglandin E2 release by fetal membranes. Zicari A, et al. **J Reprod Immunol** 1995 Oct;29(3):197–208

Maternal plasma and amniotic fluid cortisol and progesterone concentrations between women with and without term labor. A comparison. Ohana E, et al. **J Reprod Med** 1996 Feb;41(2):80–6

Outcome of amniotic fluid analysis and neonatal respiratory status in diabetic and nondiabetic pregnancies. Piper JM, et al. **J Reprod Med** 1995 Nov;40(11):780–4

Amniotic fluid epidermal growth factor levels in normal and abnormal pregnancies. Varner MW, et al. **J Soc Gynecol Investig** 1996 Jan–Feb;3(1):17–9

Cytokine production and visualized effects in the feto–maternal unit. Quantitative and topographic data on cytokines during intrauterine disease. Stallmach T, et al. **Lab Invest** 1995 Sep;73(3):384–92

Prediction of respiratory distress syndrome by the novel dipalmitoyl phosphatidylcholine test. Alvarez JG, et al. **Obstet Gynecol** 1996 Mar;87(3):429–33

The effect of maternal blood contamination on amniotic fluid glucose and white blood cell count from preterm gestations. Carlan SJ, et al. **Obstet Gynecol** 1996 Feb;87(2):185–7

Fetal hyperinsulinism at 14–20 weeks and subsequent gestational diabetes. Carpenter MW, et al. **Obstet Gynecol** 1996 Jan;87(1):89–93

Elevations of amniotic fluid macrophage inflammatory protein–1 alpha concentrations in women during term and preterm labor. Dudley DJ, et al. **Obstet Gynecol** 1996 Jan; 87(1):94–8

Soluble tumor necrosis factor receptors and interleukin–6 levels in patients with severe preeclampsia. Kupferminc MJ, et al. **Obstet Gynecol** 1996 Sep;88(3):420–7

Use of the TDx–FLM assay in evaluating fetal lung maturity in an insulin–dependent diabetic population. The Diabetes and Fetal Maturity Study Group. Livingston EG, et al. **Obstet Gynecol** 1995 Nov;86(5):826–9

Second–trimester amniotic fluid or maternal serum interleukin–10 levels and small for gestational age neonates. Spong CY, et al. **Obstet Gynecol** 1996 Jul;88(1):24–8

Prenatal diagnosis of the RhD fetal blood type on amniotic fluid by polymerase chain reaction. Van Den Veyver, IB, et al. **Obstet Gynecol** 1996 Mar;87(3):419–22

Prognostic significance of unexplained elevated amniotic fluid alpha–fetoprotein. Wenstrom KD, et al. **Obstet Gynecol** 1996 Feb;87(2):213–6

Gastric fluid analysis for determining gestational cocaine exposure. Garcia DC, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):291–3

Prenatal diagnosis of Smith–Lemli–Opitz syndrome is possible by measurement of 7–dehydrocholesterol in amniotic fluid. Dallaire L, et al. **Prenat Diagn** 1995 Sep; 15(9):855–8

A case of tyrosinaemia type I with normal level of succinylacetone in the amniotic fluid. Grenier A, et al. **Prenat Diagn** 1996 Mar;16(3):239–42

Alpha–fetoprotein and acetylcholinesterase activity in first– and early second–trimester amniotic fluid. Jørgensen FS, et al. **Prenat Diagn** 1995 Jul;15(7):621–5

Quantification of 7–dehydrocholesterol in plasma and amniotic fluid by liquid chromatography/particle beam–mass spectrometry as a biochemical diagnostic marker for the Smith–Lemli–Opitz syndrome. Sattler W, et al. **Rapid Commun Mass Spectrom** 1995;9(13):1288–92

Amniotic fluid composition and fetal and placental growth rates in genetically hypertensive and normotensive rats. Erkadius E, et al. **Reprod Fertil Dev** 1995;7(6):1563–7

Amniotic fluid phospholipids. New predictive values of L/S and PG/S ratios. Ruiz–Budria J, et al. **Rev Esp Fisiol** 1995 Mar;51(1):17–21

Predicting fetal lung maturity by visual assessment of amniotic fluid turbidity: comparison with fluorescence polarization assay. Adair CD, et al. **South Med J** 1995 Oct; 88(10):1031–3

[Observations on serum and amniotic fluid hormone levels and ultrastructure of uterine myometrium before and during term labor] Yan J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jul;30(7):391–4 (Eng. Abstr.) **(Chi)**

[Detection of erythropoietin in amniotic fluid] Büscher U, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):243–7 (Eng. Abstr.) **(Ger)**

[Reliability of the detection of fetal fibronectin using monoclonal antibody FDC–6] Pütz I, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):703–6 (Eng. Abstr.) **(Ger)**

[Insulin–like–growth–factor–binding–protein 1 (IGFBP–1) and fetal fibronectin in diagnosis of premature rupture of fetal membranes] Ragosch V, et al. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):291–6 (Eng. Abstr.) **(Ger)**

[Detection of premature rupture of fetal membranes by determining insulin–like–growth–factor–binding protein–1] Woltmann W, et al. **Z Geburtshilfe Neonatol** 1995 Nov–Dec;199(6):243–4 (Eng. Abstr.) **(Ger)**

[Fluorides in the body of the mother and in the fetus. III. Fluorides in amniotic fluid] Chlubek D, et al. **Ginekol Pol** 1995 Nov;66(11):614–7 (Eng. Abstr.) **(Pol)**

[Concentration of magnesium in the amniotic fluid of a patient with diabetes] Doraczynska E, et al. **Ginekol Pol** 1995 Dec;66(12):653–5 (Eng. Abstr.) **(Pol)**

[Fetal metabolism in post–term pregnancy based on biochemical examinations of amniotic fluid. V. Glucose, bilirubin, H+ ions, hormones and tests of lung maturation] Wójcicka–Jagodzińska J, et al. **Ginekol Pol** 1995 May; 66(5):257–61 (Eng. Abstr.) **(Pol)**

[Fetal metabolism in post term pregnancy based on biochemical investigations of amniotic fluid. IV. Ion composition] Wójcicka–Jagodzińska J, et al. **Ginekol Pol** 1995 May;66(5):253–6 (Eng. Abstr.) **(Pol)**

[The alpha–fetoprotein level analysis in open neural tube defects and chromosomal aberrations in the fetus] Ilnicka A, et al. **Neurol Neurochir Pol** 1996 Jan–Feb;30(1):65–75 (Eng. Abstr.) **(Pol)**

CYTOLOGY

Is the 15–in situ clone protocol necessary to detect amniotic fluid mosaicism? Cheng EY, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1025–30

Molecular genotyping of fetal platelet antigens with uncultured amniocytes. Khouzami AN, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1202–6

Accuracy of prenatal determination of RhD type status by polymerase chain reaction with amniotic cells. Lighten AD, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1182–5

Prenatal diagnosis of chromosomal aneuploidies by fluorescence in situ hybridization on uncultured amniotic cells: experience with 630 samples. Mercier S, et al. **Ann Genet** 1995;38(3):151–7

An improved method for the detection of Down's syndrome aneuploidy in uncultured amniocytes. Pierluigi M, et al. **Clin Genet** 1996 Jan;49(1):32–6

Management of platelet and RhD maternal immunizations by PCR phenotypings after early amniocentesis. Sagot P, et al. **Fetal Diagn Ther** 1995 Nov–Dec;10(6):373–80

A new approach to analysing fluorescence in situ hybridisation data for rapid detection of aneuploidy in amniocytes. Palomaki GE, et al. **J Med Screen** 1994 Apr; 1(2):96–7

Interphase fluorescence in situ hybridization in a Turner syndrome variant with IsoXq. A case report. Chang SD, et al. **J Reprod Med** 1996 Mar;41(3):175–8

Early sonographically guided amniocenteses with filtration technique: follow–up on 249 procedures. Sundberg K, et al. **J Ultrasound Med** 1995 Aug;14(8):585–90

The effect of maternal blood contamination on amniotic fluid glucose and white blood cell count from preterm gestations. Carlan SJ, et al. **Obstet Gynecol** 1996 Feb;87(2):185–7

Determination of fetal RhD status from uncultured amniocytes. Dildy GA, et al. **Obstet Gynecol** 1996 Aug; 88(2):207–10

Amniotic fluid culture failure: clinical significance and association with aneuploidy. Reid R, et al. **Obstet Gynecol** 1996 Apr;87(4):588–92

Maternal blood C–reactive protein, white blood cell count, and temperature in preterm labor: a comparison with amniotic fluid white blood cell count. Yoon BH, et al. **Obstet Gynecol** 1996 Feb;87(2):231–7

[Rh typing by PCR on amniotic cells] Mannessier L, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):827–8 (Fre)

[Prenatal determination of fetal rhesus factor in amnionic cells using polymerase chain reaction] Crombach G, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):577–9 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Garlic ingestion by pregnant women alters the odor of amniotic fluid. Mennella JA, et al. **Chem Senses** 1995 Apr; 20(2):207–9

Mifepristone (RU 486) and its incidence on amniotic fluid volume in near term fetal macaque monkeys. Haddad B, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun; 66(2):179–82

Effect of indomethacin on individual amniotic fluid indices in multiple gestations. Hill LM, et al. **J Ultrasound Med** 1996 May;15(5):395–9

ENZYMOLOGY

Evaluation of amniotic fluid elastolytic activity: can it be a method of fetal lung maturity assessment? A comparison with Gluck's L/S test. Bażowska G, et al. **Acta Genet Med Gemellol (Roma)** 1994;43(3–4):185–92

Determination of alkaline phosphatase isozymes in amniotic fluid. Sembaj A, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):281–4

IMMUNOLOGY

Amniotic fluid interleukin–10 concentrations increase through pregnancy and are elevated in patients with preterm labor associated with intrauterine infection. Greig PC, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1223–7

GRO alpha in the fetomaternal and amniotic fluid compartments during pregnancy and parturition. Cohen J, et al. **Am J Reprod Immunol** 1996 Jan;35(1):23–9

IL–6 and G–CSF levels in amniotic fluid during the second trimester in normal and abnormal pregnancies. Weimann E, et al. **Arch Gynecol Obstet** 1995;256(3):125–30

Abnormal amniotic fetal antigen 2 concentrations in trisomy 18 and trisomy 21. Price KM, et al. **Hum Reprod** 1995 Sep;10(9):2438–40

METABOLISM

Acute maternal hydration in third–trimester oligohydramnios: effects on amniotic fluid volume, uteroplacental perfusion, and fetal blood flow and urine output [see comments] Flack NJ, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1186–91. Comment in: Am J Obstet Gynecol 1996 Jul;175(1):237.

Inflammatory cytokine (interleukins 1, 6 and 8 and tumor necrosis factor–alpha) release from cultured human fetal membranes in response to endotoxic lipopolysaccharide mirrors amniotic fluid concentrations. Fortunato SJ, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1855–61; discussion 1861–2

Levels of hepatocyte growth factor in maternal serum and amniotic fluid [see comments] Horibe N, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):937–42. Comment in: Am J Obstet Gynecol 1996 Jun;174(6):1946.

Soluble tumor necrosis factor receptors in maternal plasma and second–trimester amniotic fluid. Kupferminc MJ, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):900–5

Increased matrix metalloproteinase activity and reduced tissue inhibitor of metalloproteinases–1 levels in amniotic fluids from pregnancies complicated by premature rupture of membranes. Vadillo–Ortega F, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1371–6

Maternal plasma and amniotic fluid 17 beta–estradiol, progesterone and cortisol concentrations in women with successfully and unsuccessfully treated preterm labor. Mazor M, et al. **Arch Gynecol Obstet** 1996;258(2):89–96

Garlic ingestion by pregnant women alters the odor of amniotic fluid. Mennella JA, et al. **Chem Senses** 1995 Apr; 20(2):207–9

Inhibition of prostaglandin E2 production in myometrial and amniotic cells in culture by human amniotic fluid. Loss of inhibition after intra–uterine fetal death. Cabrol D, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):135–40

The concentration of hepatocyte growth factor (HGF) in human amniotic fluid at second trimester: relation to fetal birth weight. Kurauchi O, et al. **Horm Metab Res** 1995 Jul;27(7):335–8

Increased amniotic fluid divalent cation concentration in preeclampsia. Weiss M, et al. **J Basic Clin Physiol Pharmacol** 1995;6(1):71–7

Midkine (MK) expression in extraembryonic tissues, amniotic fluid, and cerebrospinal fluid during mouse embryogenesis. Obama H, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):88–93

Amniotic and allantoic fluid concentrations of thyroxine, 3,3',5'–tri–iodothyronine, 3,3'–di–iodothyronine and 3',5'–di–iodothyronine in the pig during the period of gestation. Brzezińska–Slebodzińska E, et al. **J Endocrinol** 1995 Nov;147(2):245–51

Differential release of interleukin–6 from human gestational tissues in association with labour and in vitro endotoxin treatment. Laham N, et al. **J Endocrinol** 1996 Jun; 149(3):431–9

Relationship between amniotic fluid insulin and maternal blood glucose concentrations in patients with carbohydrate intolerance during pregnancy. Crombach G, et al. **J Perinat Med** 1996;24(1):77–84

Prenatal diagnosis of organic acidemias based on amniotic fluid levels of acylcarnitines. Shigematsu Y, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):680–4

Parathyroid hormone–related protein (PTHrP) concentrations in human amniotic fluid during gestation and at the time of labour. Wlodek ME, et al. **Reprod Fertil Dev** 1995;7(6):1509–13

[A study of interleukin–6 and soluble interleukin–6 receptors during pregnancy and delivery] Ishizaki S. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1230–6 (Eng. Abstr.) **(Jpn)**

[Relationship between catecholamine levels in amniotic fluid and fetal blood flow in fetal distress] Sekizawa A, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Oct; 47(10):1063–8 (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Bacterial 16S rDNA polymerase chain reaction in the detection of intra–amniotic infection. Jalava J, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):664–9

The role of bacterial vaginosis and vaginal bacteria in amniotic fluid infection in women in preterm labor with intact fetal membranes. Hillier SL, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S276–8

Eradication of viridans streptococci from the amniotic cavity by parenteral antibiotic administration. A case report. Mazor M, et al. **J Reprod Med** 1995 Nov;40(11):820–2

PARASITOLOGY

A new set of primers for the detection of Toxoplasma gondii in amniotic fluid using polymerase chain reaction. Pelloux H, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):11–5

PHYSIOLOGY

1–Deamino–[8–D–arginine] vasopressin–induced maternal plasma hypoosmolality increases ovine amniotic fluid volume. Ross MG, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1118–25; discussion 1125–7

Effects of maternal smoking on amniotic fluid volume and fetal urine output. Coulson CC, et al. **Am J Perinatol** 1996 May;13(4):195–7

AMNIOTIC FLUID

The effect of bovine amniotic fluid on in vitro maturation of bovine oocytes. Ocaña Quero JM, et al. **Br Vet J** 1995 Sep–Oct;151(5):547–54

Pregnancy outcome after early amniotic fluid leakage after transabdominal multifetal reduction [see comments] Lipitz S, et al. **Fertil Steril** 1996 May;65(5):1055–8. Comment in: Fertil Steril 1996 May;65(6):909–11.

Intrapartum amniotic fluid index for predicting fetal acidemia. Results of receiver operating characteristic curve analysis. Chauhan SP, et al. **J Reprod Med** 1995 Aug; 40(8):561–4

ULTRASONOGRAPHY

Ultrasonographic measurement of amniotic fluid volume in normal diamniotic twin pregnancies. Chau AC, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1003–7

Amniotic fluid accumulation in the first trimester. Birnholz JC, et al. **J Ultrasound Med** 1995 Aug;14(8):597–602

Accuracy of ultrasonography in evaluating amniotic fluid volume at less than 24 weeks' gestation. Magann EF, et al. **J Ultrasound Med** 1995 Dec;14(12):895–7

Normal values for amniotic fluid index during uncomplicated twin pregnancy. Porter TF, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):699–702

Ultrasonic features of intra-amniotic "unidentified debris' at 14–16 weeks' gestation. Zimmer EZ, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):178–81

VIROLOGY

Detection of viral deoxyribonucleic acid in the amniotic fluid of low-risk pregnancies by polymerase chain reaction. McLean LK, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1282–6

A rapid and safe method to detect fetal parvovirus B19 infection in amniotic fluid by polymerase chain reaction: report of a case. Nikkari S, et al. **Am J Perinatol** 1995 Nov;12(6):447–9

Polymerase chain reaction for prenatal diagnosis of congenital human cytomegalovirus infection. Revello MG, et al. **J Med Virol** 1995 Dec;47(4):462–6

AMNIOTIC MEMBRANE DRESSINGS see **BIOLOGICAL DRESSINGS**

AMOBARBITAL

DIAGNOSTIC USE

The value of PET scan (and MRI and Wada test) in patients with bitemporal epileptiform abnormalities. Benbadis SR, et al. **Arch Neurol** 1995 Nov;52(11):1062–8

Results from the intracarotid amytal procedure in patients with uni or bitemporal lobe epilepsy and mesial sclerosis. Caner-Cukiert AR, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3–B):613–8

Functional MRI measurement of language lateralization in Wada-tested patients. Desmond JE, et al. **Brain** 1995 Dec; 118 (Pt 6):1411–9

Objective criteria for reporting language dominance by intracarotid amobarbital procedure. Benbadis SR, et al. **J Clin Exp Neuropsychol** 1995 Oct;17(5):682–90

Intracarotid amobarbital procedure. The Wada test. Trenerry MR, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):721–8 (41 ref.)

PHARMACOLOGY

Relation between intracarotid amobarbital memory asymmetry scores and hippocampal sclerosis in patients undergoing anterior temporal lobe resections. Davies KG, et al. **Epilepsia** 1996 Jun;37(6):522–5

AMODIAQUINE

ANALOGS & DERIVATIVES

The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Tingle MD, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1113–9

METABOLISM

The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Tingle MD, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1113–9

PHARMACOLOGY

[Sensitivity in vivo and in vitro of Plasmodium falciparum to chloroquine and amodiaquine in Bangangte (west Cameroon)] Agnamey PP, et al. **Bull Soc Pathol Exot** 1995 Mar;88(4):149–51 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

A randomised controlled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine and Fansidar in the treatment of uncomplicated malaria in children. Anabwani GM, et al. **East Afr Med J** 1996 Mar;73(3):155–8

Response of Plasmodium falciparum to chloroquine and Fansidar in vivo and chloroquine and amodiaquine in vitro in Uganda. Nevill CG, et al. **East Afr Med J** 1995 Jun; 72(6):349–54

Chloroquine versus amodiaquine in the treatment of Plasmodium falciparum malaria in northeast India. Misra SP, et al. **Indian J Med Res** 1995 Sep;102:119–23

Sensitivity of Plasmodium falciparum to amodiaquine and chloroquine in central Africa: a comparative study in vivo and in vitro. Brasseur P, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct;89(5):528–30

A randomized trial of chloroquine, amodiaquine and pyrimethamine–sulphadoxine in Gambian children with uncomplicated malaria. Müller O, et al. **Trop Med Int Health** 1996 Feb;1(1):124–32

AMOEBA

see related
AMEBICIDES

CHEMISTRY

Dictyopterin appears at amoebae emergence during spore germination in Dictyostelium. Klein R, et al. **C R Acad Sci III** 1996 Apr;319(4):289–94

CYTOLOGY

Reconstitution in vitro of the motile apparatus from the amoeboid sperm of Ascaris shows that filament assembly and bundling move membranes. Italiano JE Jr, et al. **Cell** 1996 Jan 12;84(1):105–14

Differences in the motility of Amoeba proteus isolated fragments are determined by F-actin arrangement and cell nucleus presence. Grębecka L, et al. **Cell Biol Int** 1995 Oct;19(10):847–54

DRUG EFFECTS

Axenic growth and drug sensitivity studies of Balamuthia mandrillaris, an agent of amebic meningoencephalitis in humans and other animals. Schuster FL, et al. **J Clin Microbiol** 1996 Feb;34(2):385–8

GENETICS

[A stochastic model of induced genome instability] Geras'kin SA, et al. **Radiats Biol Radioecol** 1995 Jul–Aug; 35(4):451–62 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Quantitation of free-living amoebae and bacterial populations in eyewash stations relative to flushing frequency. Bowman EK, et al. **Am Ind Hyg Assoc J** 1996 Jul;57(7):626–33

Axenic growth and drug sensitivity studies of Balamuthia mandrillaris, an agent of amebic meningoencephalitis in humans and other animals. Schuster FL, et al. **J Clin Microbiol** 1996 Feb;34(2):385–8

ISOLATION & PURIFICATION

Balamuthia mandrillaris: a newly recognized agent for amebic meningoencephalitis. Rowen JL, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):705–10 (30 ref.)

METABOLISM

[Polyamines and cell growth: specific aspects in Amoeba proteus and in certain cancer cell lines] Dubois J, et al. **Bull Mem Acad R Med Belg** 1995;150(5–6):252–7; discussion 257–8 (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

The s29x gene of symbiotic bacteria in Amoeba proteus with a novel promoter. Pak JW, et al. **Gene** 1996 May 24; 171(1):89–93

ULTRASTRUCTURE

The nuclear membrane-associated honeycomb structure of the unicellular organism Amoeba proteus: on the search for homologies with the nuclear lamina of metazoa. Schmidt M, et al. **Eur J Cell Biol** 1995 Jul;67(3):199–208

AMOEBIASIS see **AMEBIASIS**

AMOEBIDA

ISOLATION & PURIFICATION

Amebic keratitis in a wearer of disposable contact lenses due to a mixed Vahlkampfia and Hartmannella infection. Aitken D, et al. **Ophthalmology** 1996 Mar;103(3):485–94

AMOSITE ASBESTOS see **ASBESTOS, AMOSITE**

AMOXAPINE

POISONING

Amoxapine overdose in a young man: a transient mitochondrial abnormality? Mancias P, et al. **Pharmacotherapy** 1995 Jul–Aug;15(4):528–32

AMOXICILLIN

ADMINISTRATION & DOSAGE

Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment. van der Hulst RW, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):165–71

Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Bertoni G, et al. **Am J Gastroenterol** 1996 Feb;91(2):258–63

Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence. Porro GB, et al. **Am J Gastroenterol** 1996 Apr; 91(4):695–700

Recurrence of duodenal ulcers during five years of follow-up after cure of Helicobacter pylori infection. Miehlke S, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):975–8

Optimal dose of omeprazole in combination with amoxicillin in eradicating H. pylori and preventing relapses in duodenal ulcer patients. Rokkas T, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):842–6

Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori. Furuta T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S107–11

Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing. Nakata H, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S118–20

Clinical efficacy of lansoprazole–amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method. Shimada T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S100–3

Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients. Shirai T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S128–31

Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. Sugiyama T, et al. **J Clin Gastroenterol** 1995; 20 Suppl 2:S104–6

Preparation and characterization of freeze-dried chitosan-poly(ethylene oxide) hydrogels for site-specific antibiotic delivery in the stomach. Patel VR, et al. **Pharm Res** 1996 Apr;13(4):588–93

Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. Hatlebakk JG, et al. **Scand J Gastroenterol** 1995 Nov;30(11):1053–7

Treatment of Helicobacter pylori infection by topical administration of antimicrobial agents. Satoh K. **Scand J Gastroenterol Suppl** 1996;214:56; discussion 57–60

Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study. Labenz J, et al. **Z Gastroenterol** 1995 Oct;33(10):590–3

Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. Schütze K, et al. **Z Gastroenterol** 1995 Nov;33(11):651–3

[Comment on the Stolte/Domschke letter-discussion (letter)] Hentschel E. **Z Gastroenterol** 1996 Apr;34(4):XXII **(Ger)**

[Is the omeprazole and amoxicillin combination useful in the treatment eradicating Helicobacter pylori in Spain?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):99–106 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Deterioration of renal function in a nephropathic diabetic patient during omeprazole plus amoxicillin therapy for Helicobacter pylori-associated duodenal ulcer [letter] Lorenzetti M, et al. **Acta Diabetol** 1995 Oct;32(3):209–10

Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. García Rodríguez LA, et al. **Arch Intern Med** 1996 Jun 24;156(12):1327–32

Amoxycillin-induced hallucinations—a variant of Hoigne's syndrome? Stell IM, et al. **Br J Clin Pract** 1996 Jul–Aug; 50(5):279

Selective fixed drug eruption to amoxycillin. Arias J, et al. **Clin Exp Dermatol** 1995 Jul;20(4):339–40

Clostridium difficile in a healthcare worker [letter] Kaplan N, et al. **J Hosp Infect** 1996 Apr;32(4):322

Effect of Lactobacillus acidophilus on antibiotic-associated gastrointestinal morbidity: a prospective randomized trial. Witsell DL, et al. **J Otolaryngol** 1995 Aug;24(4):230–3

Amoxycillin-clavulanic acid prescribing remains high in the elderly despite warnings of drug-associated jaundice [letter] Parkes AJ. **Med J Aust** 1995 Oct 16;163(8):446

Otitis media in children [letter] Mokry C. **N Engl J Med** 1995 Oct 26;333(17):1151; discussion 1152

[Acute hemorrhagic colitis after intake of amoxicillin (letter)] Choulot JJ, et al. **Arch Pediatr** 1996 May;3(5):508–9 **(Fre)**

[Acute cholangitis caused by an amoxicillin-clavulanic acid combination (letter)] Boucher E, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):957–8 **(Fre)**

[Cholestatic jaundice after ingestion of amoxicillin and clavulanic acid] Friess G, et al. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1356–60 (Eng. Abstr.) **(Ger)**

[Cholestatic jaundice induced by amoxicillin and clavulanic acid (letter)] Kurowski V. **Dtsch Med Wochenschr** 1996

Mar 22;121(12):390–1 **(Ger)**

[Acute pancreatitis associated with hepatotoxicity induced by amoxicillin–clavulanic acid] Galindo C, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):597–600 (23 ref.) (Eng. Abstr.) **(Spa)**

[Spektramox and liver damage] **Lakartidningen** 1996 Feb 7; 93(6):490 **(Swe)**

METABOLISM

Reduced amoxicillin uptake into human gastric mucosa when gastric juice pH is high. Cardaci G, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2084–7

PHARMACOKINETICS

Amoxicillin concentrations in nasal secretions of patients with acute uncomplicated sinusitis and in paranasal sinus mucosa of patients with chronic sinusitis. Kment G, et al. **Eur Arch Otorhinolaryngol** 1995;252(4):236–8

Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice [see comments] Goddard AF, et al. **Gastroenterology** 1996 Aug; 111(2):358–67. Comment in: Gastroenterology 1996 Aug;111(2):521–3.

The influence of uptake from the gastrointestinal tract and first–pass effect on oral bioavailability of (Z)–alkyloxyimino penicillins. Mizen L, et al. **J Pharm Pharmacol** 1995 Sep; 47(9):725–30

Pharmacokinetics of amoxicillin/clavulanic acid combination after intravenous and oral administration in goats. Carceles CM, et al. **Vet Q** 1995 Dec;17(4):134–8

Depletion of the residues of colistin and amoxicillin in turkeys following simultaneous subcutaneous administration. Tomasi L, et al. **Vet Res Commun** 1996;20(2):175–82

Pharmacokinetics, intramuscular bio–availability, and bioequivalence of amoxycillin in donkeys. Lavy E, et al. **Zentralbl Veterinarmed [B]** 1995 Jul;42(5):284–92

[Assessment of the role of enterocyte ion exchange in the intestinal absorption of amoxicillin, based on a study of the interaction with amiloride] Westphal JF, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):590–5 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Amoxicillin dose–effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Azoulay–Dupuis E, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):941–6

Bactericidal and morphological effects of amoxicillin on Helicobacter pylori. Berry V, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1859–61

Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis [published erratum appears in Antimicrob Agents Chemother 1995 Dec;39(12):2835] Mainardi JL, et al. **Antimicrob Agents Chemother** 1995 Sep; 39(9):1984–7

Activity of CI–960 alone and in combination with amoxycillin against Listeria monocytogenes, and comparison with other quinolones. Boisivon A, et al. **J Antimicrob Chemother** 1995 Sep;36(3):527–30

Influence of amoxicillin, erythromycin and metronidazole on adherence of Helicobacter pylori. Brenciaglia MI, et al. **New Microbiol** 1995 Jul;18(3):283–8

[Bactericidal activity of combinations of ticarcillin–clavulanic acid or other beta–lactams (amoxicillin, piperacillin–tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium] Leclercq R, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):245–52 (Eng. Abstr.) **(Fre)**

POISONING

Amoxicillin overdose manifested by hematuria and acute renal failure. Belko J, et al. **Pediatr Infect Dis J** 1995 Oct; 14(10):917–9

STANDARDS

[Pharmaceutical quality of amoxicillin–containing tablets for veterinary use] Pellicaan CH, et al. **Tijdschr Diergeneeskd** 1996 Mar 1;121(5):126–30 (Eng. Abstr.) **(Dut)**

THERAPEUTIC USE

Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double–blind, randomized trial. Bell GD, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):513–20

One–week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. Labenz J, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):207–10

Triple therapy with sucralfate, amoxycillin and metronidazole for healing duodenal ulcer and eradicating Helicobacter pylori infection. Stupnicki T, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):193–7

Cure of Helicobacter pylori infection: role of duration of treatment with omeprazole and amoxicillin. Adamek RJ, et al. **Am J Gastroenterol** 1996 Jan;91(1):98–100

Prevalence of Helicobacter pylori infection in patients with large gastric folds: evaluation and follow–up with endoscopic ultrasound before and after antimicrobial therapy. Avunduk C, et al. **Am J Gastroenterol** 1995 Nov; 90(11):1969–73

Low eradication rates of Helicobacter pylori with omeprazole plus amoxycillin combination in a Turkish population [letter] Simsek H, et al. **Am J Gastroenterol** 1996 May;91(5):1062

Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects. Thijs JC, et al. **Am J Gastroenterol** 1996 Jan;91(1):93–7

Short–term low–dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication [letter] Tursi A, et al. **Am J Gastroenterol** 1996 Aug;91(8):1668–70

Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double–blind, randomized, controlled trial. Luft BJ, et al. **Ann Intern Med** 1996 May 1;124(9):785–91

Amoxicillin dose–effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Azoulay–Dupuis E, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):941–6

Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. Lindbaek M, et al. **BMJ** 1996 Aug 10;313(7053):325–9

Comparison of oral ciprofloxacin and amoxycillin in treating infective exacerbations of bronchiectasis in Hong Kong. Chan TH, et al. **Chemotherapy** 1996 Mar–Apr;42(2):150–6

Treatment of otitis media [letter; comment] van der Meer JW, et al. **Clin Infect Dis** 1995 Oct;21(4):1069. Comment on: Clin Infect Dis 1994 Nov;19(5):823–33.

Outcome–oriented managed care comparing efficacies of cefaclor and amoxicillin in acute and recurrent acute otitis media. Perry BP, et al. **Ear Nose Throat J** 1995 Dec; 74(12):840–4

Percutaneous endoscopic gastrostomy (PEG): comparison of push and pull methods and evaluation of antibiotic prophylaxis. Akkersdijk WL, et al. **Endoscopy** 1995 May; 27(4):313–6

Evaluation of a new bismuth–free triple therapy in nude mice and humans. Karita M, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S31–4

Treatment of community–acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin–clavulanic acid and erythromycin [see comments] Lode H, et al. **Eur Respir J** 1995 Dec;8(12):1999–2007. Comment in: Eur Respir J 1995 Dec;8(12):1996–8.

Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Marchioni CF, et al. **Int J Clin Pharmacol Ther** 1995 Nov;33(11):612–8

Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community–acquired pneumonia. French Study Group. Portier H, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:83–91

Prevention and treatment of low–grade B–cell primary gastric lymphoma by anti–H. pylori therapy. Cammarota G, et al. **J Clin Gastroenterol** 1995 Sep;21(2):118–22

Randomized, controlled trial of amoxicillin prophylaxis for prevention of catheter–related infections in newborn infants with central venous silicone elastomer catheters. Harms K, et al. **J Pediatr** 1995 Oct;127(4):615–9

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59–69 (66 ref.)

Amoxicillin or erythromycin for the treatment of antenatal chlamydial infection: a meta–analysis. Turrentine MA, et al. **Obstet Gynecol** 1995 Dec;86(6):1021–5

Treatment of acute maxillary sinusitis—comparing cefpodoxime proxetil with amoxicillin. von Sydow C, et al. **Scand J Infect Dis** 1995;27(3):229–34

[How to eradicate Helicobacter pylori?] Cayla R. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S119–S130 (83 ref.) **(Fre)**

[How to eradicate Helicobacter pylori in 1995? Critical review of available treatments] Deltenre M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S44–S52 (122 ref.) **(Fre)**

[Endocarditis caused by Corynebacterium diphtheriae tolerant to amoxicillin (letter)] Dupont C, et al. **Presse Med** 1995 Jul 1–8;24(24):1135 **(Fre)**

[Dynamic imaging of gastric ulcer healing using the most modern Morph–Software] Jaspersen D, et al. **Bildgebung** 1996 Jun;63(2):101–4 (Eng. Abstr.) **(Ger)**

[Amoxicillin: choice in the treatment of acute otitis media (letter)] Raigal Martín MY, et al. **Aten Primaria** 1995 Sep 30;16(5):293–4 **(Spa)**

[Helicobacter pylori eradication heals the duodenal ulcer. Randomized, simple, and controlled study with omeprazole] Piñero R, et al. **G E N** 1995 Apr–Jun; 49(2):111–5 (Eng. Abstr.) **(Spa)**

[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr–Jun; 49(2):116–22 (21 ref.) (Eng. Abstr.) **(Spa)**

[Omeprazole and amoxycillin in the eradicating treatment of Helicobacter pylori] Gisbert JP, et al. **Rev Clin Esp** 1995 Nov;195(11):787–91 (74 ref.) **(Spa)**

[Comparison of 2 treatment schemes to eradicate Helicobacter pylori] Hoffenberg P, et al. **Rev Med Chil** 1995 Feb;123(2):185–91 (Eng. Abstr.) **(Spa)**

AMP see ADENOSINE MONOPHOSPHATE

AMP AMINASE see AMP DEAMINASE

AMP DEAMINASE

BIOSYNTHESIS

Characterization of human AMP deaminase 2 (AMPD2) gene expression reveals alternative transcripts encoding variable N–terminal extensions of isoform L. Van den Bergh F, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):401–10

DEFICIENCY

Double trouble: combined myophosphorylase and AMP deaminase deficiency in a child homozygous for nonsense mutations at both loci. Tsujino S, et al. **Neuromuscul Disord** 1995 Jul;5(4):263–6

[Inherited AMP–deaminase deficiency—molecular basis of the defect] Kaletha K, et al. **Postepy Biochem** 1995; 41(3):183–7 (28 ref.) **(Pol)**

GENETICS

Cloning, sequence and characterization of the human AMPD2 gene: evidence for transcriptional regulation by two closely spaced promoters. Mahnke–Zizelman DK, et al. **Biochim Biophys Acta** 1996 Aug 14;1308(2):122–32

Characterization of the human AMPD3 gene reveals that 5' exon useage is subject to transcriptional control by three tandem promoters and alternative splicing. Mahnke–Zizelman DK, et al. **Biochim Biophys Acta** 1996 Apr 10;1306(1):75–92

Reversion in Chinese hamster lines amplified at the AMPD2 locus: spontaneous and benzamide–stimulated gradual loss of amplified alleles of marker genes. Lunel–Orsini C, et al. **Mutat Res** 1996 Jan 17;349(1):63–75

[Inherited AMP–deaminase deficiency—molecular basis of the defect] Kaletha K, et al. **Postepy Biochem** 1995; 41(3):183–7 (28 ref.) **(Pol)**

METABOLISM

[Functional role and properties of AMP–deaminase] Lushchak VI. **Biokhimiia** 1996 Feb;61(2):195–211 (59 ref.) (Eng. Abstr.) **(Rus)**

5'–AMP NUCLEOTIDASE see 5'–NUCLEOTIDASE

AMP PHOSPHATASE see 5'–NUCLEOTIDASE

AMP PYROPHOSPHORYLASE see ADENINE PHOSPHORIBOSYLTRANSFERASE

AMPA see ALPHA–AMINO–3–HYDROXY–5–METHYL–4–ISOXAZOLEPROPIONIC ACID

AMPA RECEPTORS see RECEPTORS, AMPA

AMPHETAMINE

Amphetamine use: return of an old scourge in a consultation psychiatry setting. Baberg HT, et al. **Am J Psychiatry** 1996 Jun;153(6):789–93

Levels and correlates of polydrug use among heroin users and regular amphetamine users. Darke S, et al. **Drug Alcohol Depend** 1995 Oct;39(3):231–5

An investigation of junior high students' attitudes toward amphetamine use and related forms of behavior. Chen JW, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Oct; 11(10):557–63

ADVERSE EFFECTS

Polygraphic sleep measures differentiate alcoholics and stimulant abusers during short–term abstinence. Thompson PM, et al. **Biol Psychiatry** 1995 Dec 15;38(12):831–6

SSRI and sympathomimetic interaction [letter] Blue P. **Br J Psychiatry** 1996 May;168(5):653

Amphetamine, not MDMA, is associated with intracranial hemorrhage [letter; comment] Galloway G, et al. **J Accid Emerg Med** 1995 Sep;12(3):231–2. Comment on: Arch Emerg Med 1993 Dec;10(4):372–4.

Regional differences in the effects of amphetamine withdrawal on dopamine dynamics in the striatum. Analysis of circadian patterns using automated on–line microdialysis. Paulson PE, et al. **Neuropsychopharmacology** 1996 May; 14(5):325–37

[Epileptic insults, cerebral infarct and rhabdomyolysis as complication of amphetamine use (letter)] Roebroek RM, et al. **Ned Tijdschr Geneeskd** 1996 Jul 20;140(29):1519 **(Dut)**

ANALOGS & DERIVATIVES see AMPHETAMINES

AMPHETAMINE

ANALYSIS

Determination of morphine analogues, caffeine and amphetamine in biological fluids by capillary electrophoresis with the marker technique. Hyötyläinen T, et al. **J Chromatogr A** 1996 May 31;735(1–2):439–47

Capillary electrophoresis–laser–induced fluorescence detection of amphetamine in the brain. Páez X, et al. **J Chromatogr A** 1996 May 31;735(1–2):263–9

Simultaneous determination of amphetamine, methamphetamine, 3,4–methylenedioxyamphetamine and 3,4–methylenedioxymethamphetamine in human hair by gas chromatography–mass spectrometry. Kintz P, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):162–6

METABOLISM

Characterization of the human cDNA and genomic DNA encoding CART: a cocaine– and amphetamine–regulated transcript. Douglass J, et al. **Gene** 1996 Mar 9;169(2):241–5

PHARMACOLOGY

Amphetamine–induced hyperactivity: differences between rats with high or low preference for alcohol. Fahlke C, et al. **Alcohol** 1995 Jul–Aug;12(4):363–7

Coordination of side–to–side head movements and walking in amphetamine–treated rats: a stereotyped motor pattern as a stable equilibrium in a dynamical system. Kafkafi N, et al. **Biol Cybern** 1996 Jun;74(6):487–95

Administration of amphetamine does not increase the functional efficacy of dopaminergic grafts made in infancy. Abrous DN, et al. **Brain Res** 1996 Feb 5;708(1–2):21–8

Sex differences in the effect of amphetamine on immediate early gene expression in the rat dorsal striatum. Castner SA, et al. **Brain Res** 1996 Mar 18;712(2):245–57

Prenatal stress in rats facilitates amphetamine–induced sensitization and induces long–lasting changes in dopamine receptors in the nucleus accumbens. Henry C, et al. **Brain Res** 1995 Jul 10;685(1–2):179–86

DOI, a 5–HT2A/2C receptor agonist, potentiates amphetamine–induced dopamine release in rat striatum. Ichikawa J, et al. **Brain Res** 1995 Nov 6;698(1–2):204–8

Amygdaloid neurons respond to clozapine rather than haloperidol in behaving rats pretreated with intra–amygdaloid amphetamine. Wang Z, et al. **Brain Res** 1996 Mar 4;711(1–2):64–72

Release of serotonin induced by 3,4–methylenedioxymethamphetamine (MDMA) and other substituted amphetamines in cultured fetal raphe neurons: further evidence for calcium–independent mechanisms of release. Wichems CH, et al. **Brain Res** 1995 Oct 9; 695(1):10–8

Amphetamine and vigabatrin down regulate aromatic L–amino acid decarboxylase mRNA levels. Buckland PR, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):69–76

Effect of apomorphine on rat motor activity induced by fencamfamine and other indirect psychostimulant drugs. Aizenstein ML, et al. **Braz J Med Biol Res** 1995 Sep; 28(9):995–8

Drug–induced heat–shock preconditioning improves postischemic ventricular recovery after cardiopulmonary bypass. Maulik N, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II381–8

Possible involvement of medial prefrontal cortex in amphetamine–induced sensitization of mesolimbic dopamine function. Banks KE, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):157–67

Effects of amphetamine at the beginning of the light cycle on multiple indices of motor activity in the rat. Gaytan O, et al. **Eur J Pharmacol** 1996 Apr 4;300(1–2):1–8

R(+)–8–OH–DPAT, a 5–HT1A receptor agonist, inhibits amphetamine–induced dopamine release in rat striatum and nucleus accumbens. Ichikawa J, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):179–84

Psychostimulant–like effects of p–fluoroamphetamine in the rat. Marona–Lewicka D, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):105–13

Isolation rearing prevents the reinforcing properties of amphetamine in a conditioned place preference paradigm. Wongwitdecha N, et al. **Eur J Pharmacol** 1995 Jun 6; 279(1):99–103

Subchronic morphine increases amphetamine–induced potentiation of brain stimulation reward: reversal by DNQX. Bespalov AYu, et al. **Eur Neuropsychopharmacol** 1995 Jun;5(2):89–93

Quantitative assessment of amphetamine induced behavioural changes in rhesus monkeys, Macaca mulatta. Palit G. **Indian J Exp Biol** 1995 Dec;33(12):980–2

Mechanisms of the in vitro effects of amphetamine on rat sinus node automaticity and membrane potentials of atrial fibers. Aileru AA, et al. **J Electrocardiol** 1996 Apr; 29(2):123–30

Differential effects of D1 and D2 dopamine receptor antagonists on acute amphetamine– or methamphetamine–induced up–regulation of zif/268 mRNA expression in rat forebrain. Wang JQ, et al. **J Neurochem** 1995 Dec;65(6):2706–15

Acute and repeated systemic amphetamine administration: effects on extracellular glutamate, aspartate, and serine levels in rat ventral tegmental area and nucleus accumbens. Xue CJ, et al. **J Neurochem** 1996 Jul;67(1):352–63

Stress–induced sensitization and glucocorticoids. I. Sensitization of dopamine–dependent locomotor effects of amphetamine and morphine depends on stress–induced corticosterone secretion. Deroche V, et al. **J Neurosci** 1995 Nov;15(11):7181–8

Effects of chronic haloperidol on reaction time and errors in a sustained attention task: partial reversal by anticholinergics and by amphetamine. Brockel BJ, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1090–8

Locally application of amphetamine into the ventral tegmental area enhances dopamine release in the nucleus accumbens and the medial prefrontal cortex through noradrenergic neurotransmission. Pan WH, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):725–31

Amphetamine produces sensitized increases in locomotion and extracellular dopamine preferentially in the nucleus accumbens shell of rats administered repeated cocaine. Pierce RC, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):1019–29

Evidence for involvement of ventral tegmental area cyclic AMP systems in behavioral sensitization to psychostimulants. Tolliver BK, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):411–20

Effects of amphetamine on cell mediated immune response in mice. Núñez–Iglesias MJ, et al. **Life Sci** 1996;58(2):PL 29–33

Reserpine inhibits amphetamine action in ventral midbrain culture. Sulzer D, et al. **Mol Pharmacol** 1996 Feb; 49(2):338–42

Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Giros B, et al. **Nature** 1996 Feb 15;379(6566):606–12

The effects of repeated amphetamine administration on the thyrotropin–releasing hormone level. Its release and receptors in the rat brain. Jaworska–Feil L, et al. **Neuropeptides** 1995 Sep;29(3):171–6

Prenatal exposure to cocaine selectively disrupts motor responding to D–amphetamine in young and mature rabbits. Simansky KJ, et al. **Neuropharmacology** 1996 Jan; 35(1):71–8

Dose–dependent effects of chronic amphetamine administration in local cerebral glucose utilization in rat. Huang YH, et al. **Neuropsychobiology** 1995;32(3):149–55

Effects of age on dopamine release in the nucleus accumbens and amphetamine–induced locomotor activity in rats. Huang RL, et al. **Neurosci Lett** 1995 Nov 10;200(1):61–4

Prenatal corticosterone increases spontaneous and d–amphetamine induced locomotor activity and brain dopamine metabolism in prepubertal male and female rats. Diaz R, et al. **Neuroscience** 1995 May;66(2):467–73

Repeated amphetamine administration induces a prolonged augmentation of phosphorylated cyclase response element–binding protein and Fos–related antigen immunoreactivity in rat striatum. Simpson JN, et al. **Neuroscience** 1995 Nov;69(2):441–57

A single injection of amphetamine or methamphetamine induces dynamic alterations in c–fos, zif/268 and preprodynorphin messenger RNA expression in rat forebrain. Wang JQ, et al. **Neuroscience** 1995 Sep; 68(1):83–95

Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioral sensitization to amphetamine: comparison with N–methyl–D–aspartate antagonists. Wolf ME, et al. **Neuroscience** 1995 Nov;69(2):417–39

Effects of prenatal maternal ethanol on male offspring progressive–ratio performance and response to amphetamine. Gentry GD, et al. **Neurotoxicol Teratol** 1995 Nov–Dec;17(6):673–7

Altered behavioral responses in 2,4–dichlorophenoxyacetic acid treated and amphetamine challenged rats. Evangelista de Duffard AM, et al. **Neurotoxicology** 1995 Fall; 16(3):479–88

Effects of morphine, pentobarbital and amphetamine on formalin–induced behaviours in infant rats: sedation versus specific suppression of pain. Abbott FV, et al. **Pain** 1995 Sep;62(3):303–12

Mixed D2/5–HT2A antagonism of amphetamine–induced facilitation of brain stimulation reward. Frank RA, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):799–804

Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Pontieri FE, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12304–8

Adrenocortical suppression blocks the memory–enhancing effects of amphetamine and epinephrine. Roozendaal B, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1429–33

Dexamethasone pretreatment reduces the psychomotor stimulant effects induced by cocaine and amphetamine in mice. Capasso A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Oct; 19(6):1063–79

Neuropsychological effects of amphetamine may correlate with personality characteristics. Fleming K, et al. **Psychopharmacol Bull** 1995;31(2):357–62

A comparison of the behavioral effects of minaprine, amphetamine and stress. Cabib S, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):73–80

D1 and D2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine. Wang JQ, et al. **Synapse** 1996 Feb;22(2):114–22

POISONING

"ADAM' or "EVE'?—a toxicological conundrum. Cox DE, et al. **Forensic Sci Int** 1996 Jan 12;77(1–2):101–8

[Myocardial infarction during amphetamine poisoning (letter)] Le Gac JM, et al. **Presse Med** 1996 Jun 15; 25(21):995 **(Fre)**

[Fatal neuroleptic malignant syndrome caused by cocaine and amphetamine overdose (letter)] Nolla–Salas J, et al. **Med Clin (Barc)** 1996 May 11;106(18):717–8 **(Spa)**

THERAPEUTIC USE

Amphetamine in recovery from brain injury. Hornstein A, et al. **Brain Inj** 1996 Feb;10(2):145–8

Decreased incidence of spontaneous mammary gland neoplasms in female F344 rats treated with amphetamine, methylphenidate, or codeine. Dunnick JK, et al. **Cancer Lett** 1996 Apr 19;102(1–2):77–83

[Treatment of hyperactivity and attention deficit with amphetamine. Experience with five adult prisoners] Stovner AM, et al. **Tidsskr Nor Laegeforen** 1996 Jun 30; 116(17):2002–5 (Eng. Abstr.) **(Nor)**

TOXICITY

The role of hyperthermia in amphetamine's interactions with NMDA receptors, nitric oxide, and age to produce neurotoxicity. Bowyer JF. **Ann N Y Acad Sci** 1995 Sep 15;765:309–10

Parenterally administered 3–nitropropionic acid and amphetamine can combine to produce damage to terminals and cell bodies in the striatum. Bowyer JF, et al. **Brain Res** 1996 Mar 18;712(2):221–9

Expression of glial fibrillary acidic protein in the rat retina after exposure to psychostimulants. Silva–Araújo AL, et al. **Retina** 1995;15(3):241–7

URINE

Detection of amphetamines in urine using head space–solid phase microextraction and chemical ionization selected ion monitoring. Yashiki M, et al. **Forensic Sci Int** 1995 Dec 29;76(3):169–77

Rapid GC–MS confirmation of urinary amphetamine and methamphetamine as their propylchloroformate derivatives. Meatherall R. **J Anal Toxicol** 1995 Sep; 19(5):316–22

GC–MS determination of amphetamine and methamphetamine in human urine for 12 hours following oral administration of dextro–methamphetamine: lack of evidence supporting the established forensic guidelines for methamphetamine confirmation. Valentine JL, et al. **J Anal Toxicol** 1995 Nov–Dec;19(7):581–90

Amphetamine and methamphetamine determination in urine by reversed–phase high–performance liquid chromatography with sodium 1,2–naphthoquinone 4–sulfonate as derivatizing agent and solid–phase extraction for sample clean–up. Molíns Legua C, et al. **J Chromatogr B Biomed Appl** 1995 Oct 6;672(1):81–8

Methamphetamine and amphetamine derived from the metabolism of selegiline. Romberg RW, et al. **J Forensic Sci** 1995 Nov;40(6):1100–2

Screening for urinary amphetamine in truck drivers and drug addicts. Pidetcha P, et al. **J Med Assoc Thai** 1995 Oct; 78(10):554–8

D–AMPHETAMINE see **DEXTROAMPHETAMINE**

L–AMPHETAMINE see **AMPHETAMINE**

AMPHETAMINES

see related
APPETITE DEPRESSANTS
CENTRAL NERVOUS SYSTEM STIMULANTS

Amphetamine addiction during pregnancy: 14–year follow–up of growth and school performance. Cernerud L, et al. **Acta Paediatr** 1996 Feb;85(2):204–8

Amphetamine misuse in southern Italy [letter] Reccia L, et al. **BMJ** 1995 Nov 25;311(7017):1433

Addiction to cocaine and amphetamine. Hyman SE. **Neuron** 1996 May;16(5):901–4

ADMINISTRATION & DOSAGE

Amphetamine use [letter; comment] Markham CH. **Aviat Space Environ Med** 1995 Aug;66(8):802. Comment on: Aviat Space Environ Med 1995 Mar;66(3):260–3.

ADVERSE EFFECTS

When does amphetamine–induced psychosis become schizophrenia? [clinical conference] Flaum M, et al. **Am J Psychiatry** 1996 Jun;153(6):812–5

[Epileptic insults, cerebral infarct and rhabdomyolysis as as complications of amphetamine use (letter)] Hofland E, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23;140(12):681 **(Dut)**

[Main cardiotoxic drugs] Pettirossi G, et al. **Clin Ter** 1996 Jan–Feb;147(1–2):67–77 (34 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

Gas chromatographic procedure for simultaneous determination of selegiline metabolites, amphetamine,

methamphetamine and demethyl-deprenyl in pig plasma. Szebeni G, et al. **Acta Physiol Hung** 1995;83(2):135-41
Rapid analysis of amphetamines in blood using head space-solid phase microextraction and selected ion monitoring. Nagasawa N, et al. **Forensic Sci Int** 1996 Apr 2;78(2):95-102

DIAGNOSTIC USE

Error analysis of autoradiography method for measurement of cerebral blood flow by 123I-IMP brain SPECT: a comparison study with table look-up method and microsphere model method. Ito H, et al. **Ann Nucl Med** 1995 Nov;9(4):185-190
Quantifying brain tumor blood flow by the microsphere model with N-isopropyl-p-[123I]iodoamphetamine super-early SPECT. Namba H, et al. **Ann Nucl Med** 1996 Feb;10(1):161-4
New design of N-isopropyl-p-[123I]iodoamphetamine (123I-IMP) lung imaging in the patient with lung cancer. Tanaka E, et al. **Ann Nucl Med** 1995 Nov;9(4):209-13
The clinical utility of visual evaluation of scintigraphic perfusion patterns for Alzheimer's disease using I-123 IMP SPECT. Ishii K, et al. **Clin Nucl Med** 1996 Feb; 21(2):106-10
Increased uptake of I-123 IMP in peritoneal metastases of hepatocellular carcinoma. Kodama F, et al. **Clin Nucl Med** 1996 Jan;21(1):70
Accumulation of I-123 IMP in hepatic cell adenoma. Suto Y, et al. **Clin Nucl Med** 1995 Jul;20(7):643-4
Redistribution on I-123 IMP SPECT in children and adolescents with partial seizures. Takahashi K, et al. **Clin Nucl Med** 1996 Mar;21(3):227-35
A multicenter validated comparison of regional cerebral blood flow quantitation using [123I]iodoamphetamine and single photon emission computed tomography. Iida H, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):781-93
Cerebral blood flow measurement with iodine-123-IMP SPECT, calibrated standard input function and venous blood sampling [see comments] Ito H, et al. **J Nucl Med** 1995 Dec;36(12):2339-42. Comment in: J Nucl Med 1995 Dec;36(12):2343-4.
Cerebral blood flow quantitation in clinical routine studies: how far have we now come? [editorial; comment] Lassen NA. **J Nucl Med** 1995 Dec;36(12):2343-4. Comment on: J Nucl Med 1995 Dec;36(12):2339-42.
Super-early iodine-123-iodoamphetamine SPECT imaging of human primary motor cortex. Oku N, et al. **J Nucl Med** 1995 Dec;36(12):2180-5
Hepatic distribution of blood flow from the superior or inferior mesenteric vein mapped by portal scintigraphy with iodine-123-iodoamphetamine. Shiomi S, et al. **J Nucl Med** 1996 Jan;37(1):51-4
Can the microsphere model by applied to cerebral blood flow measurement using N-isopropyl-p-[123I]iodoamphetamine with SPET regardless of washout from brain tissue? Ohkubo M, et al. **Nucl Med Commun** 1995 Dec; 16(12):1026-33
Accumulation of 123I-IMP in extrahepatic metastases of hepatocellular carcinoma. Suto Y, et al. **Nucl Med Commun** 1995 Nov;16(11):905-11
Scintigraphic study of malignant melanoma with 123I-iodoamphetamine. Watanabe N, et al. **Nucl Med Commun** 1996 Feb;17(2):153-9
A comparative study of three fast algorithms to estimate cerebral blood flow and distribution volume using N-isopropyl-p-[123I]iodoamphetamine and two SPECT scans. Yokoi T, et al. **Phys Med Biol** 1995 Sep; 40(9):1499-515
[A time-saving approach for quantifying regional cerebral blood flow and application to split-dose method with 123I-IMP SPECT using a single-head rotating gamma-camera] Inoue T, et al. **Kaku Igaku** 1995 Nov; 32(11):1217-26 (Eng. Abstr.) **(Jpn)**
[Normal CBF values by the ARG method using IMP SPECT: comparison with a conventional microsphere model method] Ito H, et al. **Kaku Igaku** 1996 Feb; 33(2):175-8 (Eng. Abstr.) **(Jpn)**
[Comparison of cerebral vasoreactivity to acetazolamide in normal volunteer among 123I-IMP, 99mTc-ECD and 99mTc-HMPAO] Makino K, et al. **Kaku Igaku** 1996 May; 33(5):551-5 (Eng. Abstr.) **(Jpn)**
[Modifications of fractional uptake method for 123I-IMP] Miyazaki Y, et al. **Kaku Igaku** 1996 Mar;33(3):285-91 (Eng. Abstr.) **(Jpn)**
[Quantitation of cerebral blood flow and partition coefficient using 123I-IMP dynamic SPECT with single arterial blood sampling] Mizumura S, et al. **Kaku Igaku** 1996 Mar; 33(3):251-9 (Eng. Abstr.) **(Jpn)**
[A new method for measurement of both regional cerebral blood flow and distribution volume using N-isopropyl-p-[123I]iodoamphetamine (123I-IMP) and SPECT] Ohkubo M, et al. **Kaku Igaku** 1996 Mar; 33(3):241-9 (Eng. Abstr.) **(Jpn)**
[A study on accuracy of rCBF measurements using the conventional microsphere method with N-isopropyl-p-[123I]iodoamphetamine and SPECT] Ohkubo M, et al. **Kaku Igaku** 1995 Dec;32(12):1323-31 (Eng. Abstr.) **(Jpn)**
[Changes of regional perfusion in metastatic brain tumor and peritumoral area after radiosurgery: a study by 123I-IMP dynamic SPECT] Sugou N, et al. **Kaku Igaku** 1996 Feb; 33(2):123-30 (Eng. Abstr.) **(Jpn)**

METABOLISM

Characterization of novel isocyanate-derived metabolites of the formamide N-formylamphetamine with the combined use of electrospray mass spectrometry and stable isotope methodology. Borel AG, et al. **Chem Res Toxicol** 1995 Sep; 8(6):891-9
Metabolism of methoxyphenamine and 2-methoxyamphetamine in P4502D6-transfected cells and cell preparations. Geertsen S, et al. **Xenobiotica** 1995 Sep; 25(9):895-906

PHARMACOLOGY

Addictive drugs as reinforcers: multiple partial actions on memory systems. White NM. **Addiction** 1996 Jul; 91(7):921-49; discussion 951-65 (304 ref.)
Human placental monoamine transporters as targets for amphetamines. Ramamoorthy JD, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1782-7
Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients. Wappler F, et al. **Anesthesiology** 1996 Jun; 84(6):1280-7
Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Yamada J, et al. **Biol Pharm Bull** 1995 Nov;18(11):1580-3
Long-term antidepressant treatments alter 5-HT2A and 5-HT2C receptor-mediated hyperthermia in Fawn-Hooded rats. Aulakh CS, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):65-70
Modulation of rat neocortical high-voltage spindle activity by 5-HT1/5-HT2 receptor subtype specific drugs. Jäkälä P, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):39-55
Psychostimulant-like effects of p-fluoroamphetamine in the rat. Marona-Lewicka D, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):105-13
Effects of metamfetamine on auditory P3 component of event-related potentials in rats. Iwanami A, et al. **Eur Neuropsychopharmacol** 1995 Jun;5(2):103-6
D1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. Vezina P. **J Neurosci** 1996 Apr 1; 16(7):2411-20
The effects of chronic amphetamine treatment on prenatal ethanol-induced changes in dopamine receptor function: electrophysiological findings. Shen RY, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1054-60
Behavioral effects of (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, (DOI) in the elevated plus-maze test. Onaivi ES, et al. **Life Sci** 1995 Nov 17;57(26):2455-66
Lack of cross-tolerance for hypophagia induced by DOI versus m-CPP suggests separate mediation by 5-HT2A and 5-HT2C receptors, respectively. Aulakh CS, et al. **Neuropsychopharmacology** 1995 Aug;13(1):1-8
Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Marona-Lewicka D, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):99-105
Amphetamine analogs have differential effects on DRL 36-s schedule performance. Sabol KE, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):57-65
[Effects of serotonin 2 receptor agonists on skeletal muscle preparations in patients with a disposition toward malignant hyperthermia] Wappler F, et al. **Anaesthesist** 1995 Aug; 44(8):538-44 (Eng. Abstr.) **(Ger)**
[Role of cerebral opioid and serotoninergic receptors in mechanisms of stereotypy and hyperthermia] Tiurina IV, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):242-3 **(Rus)**

TOXICITY

Detection of amphetamines in fingernails: an alternative to hair analysis [letter] Cirimele V, et al. **Arch Toxicol** 1995; 70(1):68-9
On the neurotoxicity of MDMA and related amphetamine derivatives [letter] McConn UD, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):295-6

URINE

On-line derivatization into precolumns for the determination of drugs by liquid chromatography and column switching: determination of amphetamines in urine. Herráez-Hernández R, et al. **Anal Chem** 1996 Mar 1; 68(5):734-9
Enantiomeric composition of amphetamine and methamphetamine derived from the precursor compound famprofazone. Cody JT. **Forensic Sci Int** 1996 Jul 12; 80(3):189-99
Analysis of time-lapse changes of d- and l-enantiomers of racemic ethylamphetamine and stereoselective metabolism in rat urine by HPLC determination. Nagai T, et al. **J Anal Toxicol** 1995 Jul-Aug;19(4):225-8
Benzathine as a cause for a false-positive test result for amphetamines [letter; comment] Berthier M, et al. **J Pediatr** 1995 Oct;127(4):669-70. Comment on: J Pediatr 1995 Jan;126(1):135-40.

AMPHIBIA

A non-lens member of the beta gamma-crystallin superfamily in a vertebrate, the amphibian Cynops [letter] Wistow G, et al. **Exp Eye Res** 1995 Nov;61(5):637-9
Microchip implant system used for animal identification in laboratory rabbits, guineapigs, woodchucks and in amphibians. Mrozek M, et al. **Lab Anim** 1995 Jul; 29(3):339-44

ANATOMY & HISTOLOGY

The harderian gland: a tercentennial review. Payne AP. **J Anat** 1994 Aug;185 (Pt 1):1-49 (263 ref.)
[The formation of the karyosphere in the oogenesis of insects and amphibians] Gruzova MN, et al. **Tsitologiia** 1995; 37(8):744-69 (156 ref.) (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Swedish contributions to the understanding of amphibian embryogenesis --a phenomenon of the past? Mattson MO, et al. **Int J Dev Biol** 1995 Oct;39(5):703-4
Neural induction and neurogenesis in amphibian embryos. Chitnis A, et al. **Perspect Dev Neurobiol** 1995;3(1):3-15 (63 ref.)

GENETICS

Cloning and characterization of extended hammerheads from a diverse set of caudate amphibians. Zhang Y, et al. **Gene** 1996 Jun 26;172(2):183-90
Phylogenetic relationships of amphibian families inferred from DNA sequences of mitochondrial 12S and 16S ribosomal RNA genes. Hay JM, et al. **Mol Biol Evol** 1995 Sep;12(5):928-37

GROWTH & DEVELOPMENT

Tadpole competence and tissue-specific temporal regulation of amphibian metamorphosis: roles of thyroid hormone and its receptors. Shi YB, et al. **Bioessays** 1996 May;18(5):391-9 (63 ref.)
Possible interrelations among environmental toxicants, amphibian development, and decline of amphibian populations. Carey C, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:13-7 (39 ref.)
Swedish contributions to the understanding of amphibian embryogenesis --a phenomenon of the past? Mattson MO, et al. **Int J Dev Biol** 1995 Oct;39(5):703-4

INJURIES

Rehabilitation of native reptiles and amphibians in DuPage County, Illinois. Hartup BK. **J Wildl Dis** 1996 Jan; 32(1):109-12

METABOLISM

Purification and structural characterization of insulin from a caecilian, Typhlonectes natans (Amphibia: Gymnophiona). Conlon JM, et al. **Peptides** 1995; 16(8):1385-8
[Water homeostasis in amphibia: vasotocin and hydrins] Acher R. **C R Seances Soc Biol Fil** 1995;189(2):199-214 (59 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Veterinary nutritional management of amphibians and reptiles. Donoghue S. **J Am Vet Med Assoc** 1996 Jun 1; 208(11):1816-20 (22 ref.)
Disorientation of animals in microgravity. Mori S. **Nagoya J Med Sci** 1995 Dec;58(3-4):71-81
The application of mass spectrometry to the study of evolutionary trends in amphibians. Steinborner ST, et al. **Rapid Commun Mass Spectrom** 1996;10(1):92-5
Transdifferentiation as a basis for amphibian limb regeneration. Tsonis PA, et al. **Semin Cell Biol** 1995 Jun; 6(3):127-35 (58 ref.)
[Spermatogenesis in amphibians analyzed by culture systems] Abe S. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(13):1912-26 (40 ref.) **(Jpn)**
[The thrombogenic properties and thromboresistance of the vessels in amphibians and reptiles] Petrishchev NN, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):105-8 (Eng. Abstr.) **(Rus)**

AMPHIBIAN VENOMS

PHARMACOKINETICS

[Percutaneous absorption of venenum bufonis in vitro] Yu J, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep; 20(9):539-41, 575 (Eng. Abstr.) **(Chi)**

POISONING

Toad venom poisoning: failure of a monoclonal digoxin immunoassay to cross-react with the cardioactive steroids [letter] Brubacher JR, et al. **J Toxicol Clin Toxicol** 1996; 34(5):529-30
Lethal ingestion of Chinese herbal tea containing ch'an su. Ko RJ, et al. **West J Med** 1996 Jan;164(1):71-5

AMPHIBOLE ASBESTOS see **ASBESTOS, AMPHIBOLE**

AMPHIUMA see **URODELA**

AMPHOLINES see **AMPHOLYTE MIXTURES**

AMPHOLYTE MIXTURES

ADMINISTRATION & DOSAGE

Polyols, breath hydrogen and fermentation revisited [letter] Livesey G. **Br J Nutr** 1995 Dec;74(6):867–8

AMPHOTERICIN B

Lipid formulations for amphotericin B: does the emperor need new clothes? [editorial] Graybill JR. **Ann Intern Med** 1996 May 15;124(10):921–3

ADMINISTRATION & DOSAGE

Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Behre GF, et al. **Ann Hematol** 1995 Dec;71(6):287–91

Administration of lipid–emulsion versus conventional amphotericin B in patients with neutropenia. Pascual B, et al. **Ann Pharmacother** 1995 Dec;29(12):1197–201

Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. van Etten EW, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1954–8

Combination chemotherapy of canine and feline cryptococcosis using subcutaneously administered amphotericin B. Malik R, et al. **Aust Vet J** 1996 Apr; 73(4):124–8

Comments concerning 'The penetration of amphotericin B from an Intralipid formulation into fibrin loci in a rabbit model of candidiasis' [letter; comment] Washington C, et al. **Biopharm Drug Dispos** 1995 Aug;16(6):529–31. Comment on: Biopharm Drug Dispos 1994 Aug;15(6):485–92.

Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. Oravcová E, et al. **Chemotherapy** 1995 Nov–Dec;41(6):473–6

The use of collagen shields impregnated with amphotericin B to treat Aspergillus keratomycosis. Mendicute J, et al. **CLAO J** 1995 Oct;21(4):252–5

Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses over a relatively short period [letter; comment] Churchill D, et al. **Clin Infect Dis** 1995 Nov;21(5):1352–3. Comment on: Clin Infect Dis 1995 Feb;20(2):263–6.

Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Fan–Havard P, et al. **Clin Infect Dis** 1995 Oct;21(4):960–5

Lipid formulations of amphotericin B: recent progress and future directions. Hiemenz JW, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S133–44 (83 ref.)

Two–day continuous bladder irrigation with amphotericin B [letter; comment] Hsu CC, et al. **Clin Infect Dis** 1995 Jun;20(6):1570–1. Comment on: Clin Infect Dis 1993 Jan;16(1):145–7. Comment on: Clin Infect Dis 1993 Oct;17(4):812–3.

Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Kline S, et al. **Clin Infect Dis** 1995 Nov;21(5):1154–8

Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus [letter] Laguna F, et al. **Clin Infect Dis** 1995 Sep;21(3):711–2

Intrathecal amphotericin B therapy for cerebral mucormycosis [letter; comment] McCormack JG. **Clin Infect Dis** 1995 Nov;21(5):1352. Comment on: Clin Infect Dis 1994 Dec;19(6):1133–7.

The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Oppenheim BA, et al. **Clin Infect Dis** 1995 Nov;21(5):1145–53

Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Rex JH, et al. **Clin Infect Dis** 1995 Oct;21(4):994–6

Liposomal amphotericin B (AmBisome) in the treatment of complicated kala–azar under field conditions. Seaman J, et al. **Clin Infect Dis** 1995 Jul;21(1):188–93

Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Sorkine P, et al. **Crit Care Med** 1996 Aug;24(8):1311–5

Deposition of amphotericin B aerosols in pulmonary aspergilloma. Diot P, et al. **Eur Respir J** 1995 Aug; 8(8):1263–8

Comparison of regimens of amphotericin B deoxycholate in kala–azar. Thakur CP, et al. **Indian J Med Res** 1996 May; 103:259–63

PCR monitoring of response to liposomal amphotericin B treatment of systemic candidiasis in neutropenic mice. van Deventer AJ, et al. **J Clin Microbiol** 1996 Jan;34(1):25–8

Liposomal amphotericin B in three lung transplant recipients. The Groningen Lung Transplantation Group. Mannes GP, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):781–4

Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). Russo R, et al. **J Infect** 1996 Mar;32(2):133–7

Systemic candidiasis in Sprague–Dawley rats. Schmidt A. **J Med Vet Mycol** 1996 Mar–Apr;34(2):99–104

Continuous versus intermittent bladder irrigation of amphotericin B for the treatment of candiduria [see comments] Trinh T, et al. **J Urol** 1995 Dec;154(6):2032–4 . Comment in: J Urol 1996 Aug;156(2 Pt 1):485.

Re: Continuous versus intermittent bladder irrigation of amphotericin B for the treatment of candiduria [letter; comment] Wise GJ. **J Urol** 1996 Aug;156(2 Pt 1):485. Comment on: J Urol 1995 Dec;154(6):2032–4.

The use of lipid formulations of amphotericin B for systemic fungal infections. Leenders AC, et al. **Leukemia** 1996 Oct; 10(10):1570–5 (55 ref.)

A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis. Rodriguez LV, et al. **Mem Inst Oswaldo Cruz** 1995 Jul–Aug;90(4):525–8

Something new in coping with invasive fungal infections? Nardini S. **Monaldi Arch Chest Dis** 1995 Oct;50(5):405–6

Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony–stimulating factor, and surgery: report of five cases. Dornbusch HJ, et al. **Pediatr Hematol Oncol** 1995 Nov–Dec;12(6):577–86

Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Purcell IF, et al. **Thorax** 1995 Dec;50(12):1321–3

Treatment of pulmonary aspergilloma in cystic fibrosis by percutaneous instillation of amphotericin B via indwelling catheter [see comments] Ryan PJ, et al. **Thorax** 1995 Jul; 50(7):809–10. Comment in: Thorax 1995 Jul;50(7):812–3.

Apparently successful treatment of two cases of post kala–azar dermal leishmaniasis with liposomal amphotericin B. Hashim FA, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):440

[Treatment and prevention of generalized mycoses (letter; comment)] van der Spoel JI. **Ned Tijdschr Geneeskd** 1995 Oct 21;139(42):2164–5. Comment on: Ned Tijdschr Geneeskd 1995 Jul 15;139(28):1436–41. **(Dut)**

[Use of selective intestinal decontamination with non–absorbable antibiotics] Müller C, et al. **Z Gastroenterol** 1995 Nov;33(11):685–6 **(Ger)**

[Chronic necrotizing pulmonary aspergillosis treated with itraconazole and inhaled amphotericin B] Sato A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1141–5 (Eng. Abstr.) **(Jpn)**

[Multiple candida liver abscesses successfully treated by continuous intrahepatic arterial infusion of amphotericin B using a reservoir in a case with acute myelocytic leukemia (M2)] Miyata A, et al. **Rinsho Ketsueki** 1995 Oct; 36(10):1217–22 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Cytosine arabinoside and amphotericin B–induced parkinsonism [letter] Kulkantrakorn K, et al. **Ann Neurol** 1996 Mar;39(3):413–4

Amphotericin B infusion–related toxicity: comparison of two– and four–hour infusions. Nicholl TA, et al. **Ann Pharmacother** 1995 Nov;29(11):1081–7

Population pharmacokinetics and renal function–sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Amantea MA, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2042–7

Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Kline S, et al. **Clin Infect Dis** 1995 Nov;21(5):1154–8

Amphotericin–induced heart–rate decrease in children. Levy M, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):358–64

Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Sorkine P, et al. **Crit Care Med** 1996 Aug;24(8):1311–5

Anaphylaxis due to liposomal amphotericin (AmBisome) [letter] Bates CM, et al. **Genitourin Med** 1995 Dec;71(6):414

Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties [editorial] Sawaya BP, et al. **J Am Soc Nephrol** 1995 Aug;6(2):154–64 (133 ref.)

Amphotericin B–induced leukoencephalopathy in a patient with cryptococcal meningitis. Liu JS, et al. **J Formos Med Assoc** 1995 Jul;94(7):432–4

Infusion–related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Arning M, et al. **Mycoses** 1995 Nov–Dec;38(11–12):459–65

Recurrent hemiparesis under amphotericin B for Candida albicans peritonitis. Devuyst O, et al. **Nephrol Dial Transplant** 1995;10(5):699–701

Potassium depletion potentiates amphotericin–B–induced toxicity to renal tubules. Bernardo JF, et al. **Nephron** 1995; 70(2):235–41

[Lipoid pneumonia combined with pulmonary nocardiosis caused by inhalation of amphotericin–B after renal transplantation] Abe M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun; 34(6):737–40 (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

MS–8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie. Adjou KT, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2810–2

Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. Bowden RA, et al. **J Infect Dis** 1996 May; 173(5):1208–15

[Metamphocin in the treatment of ocular mycoses] Maichuk IuF, et al. **Antibiot Khimioter** 1995 Nov–Dec; 40(11–12):55–6 (Eng. Abstr.) **(Rus)**

BLOOD

Simultaneous determination of itraconazole, hydroxy–itraconazole and amphotericin B in human plasma by HPLC with photodiode array detection. Lacroix C, et al. **Ann Biol Clin (Paris)** 1995;53(5):293–7

CEREBROSPINAL FLUID

Determination of amphotericin B in cerebrospinal fluid by solid–phase extraction and liquid chromatography. Liu H, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1395–400

CHEMISTRY

Amphotericin B formulated in a lipid emulsion [editorial] Cleary JD. **Ann Pharmacother** 1996 Apr;30(4):409–12

Theoretical study of the self–association of amphotericin B. Caillet J, et al. **Biochim Biophys Acta** 1995 Dec 13; 1240(2):179–95

Identification of the structural elements of amphotericin B and other polyene macrolide antibiotics of the hepteane group influencing the ionic selectivity of the permeability pathways formed in the red cell membrane. Cybulska B, et al. **Biochim Biophys Acta** 1995 Dec 13;1240(2):167–78

Molecular dynamics of amphotericin B. II. Dimer in water. Mazerski J, et al. **Biophys Chem** 1996 Jan;57(2–3):205–17

Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Tollemar J, et al. **Drug Saf** 1995 Oct; 13(4):207–18 (86 ref.)

Structure and toxicity of amphotericin B/triglyceride emulsion formulations. Lance MR, et al. **J Antimicrob Chemother** 1995 Jul;36(1):119–28

Liposomal and lipid–based formulations of amphotericin B. de Marie S. **Leukemia** 1996 Jun;10 Suppl 2:s93–6 (34 ref.)

[Amphotericin B into parenteral lipid emulsions. Galenic stability of mixtures. Preliminary results] Blancard A, et al. **Pathol Biol (Paris)** 1996 May;44(5):384–8 (Eng. Abstr.) **(Fre)**

METABOLISM

Nephrotoxicity of amphotericin B in rats: effects of the time of administration. LeBrun M, et al. **Life Sci** 1996; 58(11):869–76

PHARMACOKINETICS

Population pharmacokinetics and renal function–sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Amantea MA, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2042–7

Clinical and pharmacokinetic evaluation of a new lipid–based delivery system of amphotericin B in AIDS patients. Villani P, et al. **Arzneimittelforschung** 1996 Apr;46(4):445–9

Pharmacokinetics of amphotericin B in rats as a function of dose following constant–rate intravenous infusion. Chow HH, et al. **Biopharm Drug Dispos** 1995 Aug;16(6):461–73

Deposition of amphotericin B aerosols in pulmonary aspergilloma. Diot P, et al. **Eur Respir J** 1995 Aug; 8(8):1263–8

Elimination of liposomal amphotericin by hemodiafiltration [letter] Tomlin M, et al. **Intensive Care Med** 1995 Aug; 21(8):699–700

[Amphotericin B—bioavailability in the cornea. Studies with local administration of liposome incorporated amphotericin B] Pleyer U, et al. **Ophthalmologe** 1995 Aug;92(4):469–75 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Currie B, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1934–7

Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Scheven M, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1779–83

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907–12 (46 ref.)

Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Walsh TJ, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1361–4

Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B–resistant Candida isolates. Wanger A, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2520–2

Fluorescence studies on the molecular action of amphotericin B on susceptible and resistant fungal cells. Haynes MP, et al. **Biochemistry** 1996 Jun 18;35(24):7983–92

Osmotic stress sensitizes sterol–free phospholipid bilayers to the action of Amphotericin B. Wolf BD, et al. **Biochim Biophys Acta** 1995 Sep 13;1238(2):156–62

Effects of amphotericin B on glucose metabolism in Candida albicans blastospores evidenced by 13C NMR. Rabaste F, et al. **Can J Microbiol** 1996 Jul;42(7):705–710

Amphotericin B susceptibility of Candida species assessed by rapid flow cytometric membrane potential assay. Ordóñez JV, et al. **Cytometry** 1995 Jun 15;22(2):154–7

Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection

with Candida glabrata in immunocompromised mice. Atkinson BA, et al. **J Antimicrob Chemother** 1995 May; 35(5):631–40

The effects of amphotericin B, fluconazole and miconazole on neutrophil and lymphocyte function in a guinea pig model. Drummond DC, et al. **J Antimicrob Chemother** 1995 Aug;36(2):375–84

Lipid-based formulations of amphotericin B [letter; comment] Swenson CE, et al. **J Antimicrob Chemother** 1995 May;35(5):709–13. Comment on: J Antimicrob Chemother 1994 Mar;33(3):603–13.

Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test. van Eldere J, et al. **J Clin Microbiol** 1996 Apr;34(4):842–7

On the one-sided action of amphotericin B on lipid bilayer membranes. Brutyan RA, et al. **J Gen Physiol** 1996 Jan; 107(1):69–78

Comparisons of the susceptibilities of planktonic and adherent Candida albicans to antifungal agents: a modified XTT tetrazolium assay using synchronised C. albicans cells. Hawser S. **J Med Vet Mycol** 1996 Mar–Apr;34(2):149–52

Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. Ramos H, et al. **J Membr Biol** 1996 Jul;152(1):65–75

Influence of free or liposomal amphotericin B on killing of Candida species by human peritoneal macrophages. Allwinn R, et al. **Methods Find Exp Clin Pharmacol** 1995 Apr;17(3):163–7

Quantitative screening for fluconazole-amphotericin B antagonism in several Candida albicans strains by a comparative agar diffusion assay. Scheven M, et al. **Mycoses** 1996 Mar–Apr;39(3–4):111–4

Post-antibiotic effect and post-expositional polyene antagonism of azole antifungal agents in Candida albicans: dependence on substance lipophilia. Scheven M, et al. **Mycoses** 1995 Nov–Dec;38(11–12):435–42

Use of digoxigenin-labeled RNA probe to test hepatitis A virus antiviral drugs. Cuyck-Gandré HV, et al. **Pathol Biol (Paris)** 1995 May;43(5):411–5

Amphotericin B. Abadi J. **Pediatr Rev** 1995 Oct;16(10):363–4

Use of amphotericin B to clear fungal contamination of islet tissue isolated from contaminated source pancreas. Fraga DW, et al. **Transplant Proc** 1995 Dec;27(6):3279

THERAPEUTIC USE

Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Anaissie EJ, et al. **Am J Med** 1996 Aug;101(2):170–6

Continuous ambulatory peritoneal dialysis complicated by Aureobasidium pullulans peritonitis. Clark EC, et al. **Am J Nephrol** 1995;15(4):353–5

Cryptococcal meningitis in pregnancy. Chen CP, et al. **Am J Perinatol** 1996 Jan;13(1):35–6

Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Denning DW, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1809–14

Liposomal amphotericin B therapy of murine histoplasmosis. Graybill JR, et al. **Antimicrob Agents Chemother** 1995 Aug; 39(8):1885–7

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907–12 (46 ref.)

Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Valero G, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2588–90

Visceral leishmaniasis: rapid response to AmBisome treatment. Smith OP, et al. **Arch Dis Child** 1995 Aug; 73(2):157–9

Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Nguyen MH, et al. **Arch Intern Med** 1995 Dec 11–25; 155(22):2429–35

Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Strasser MD, et al. **Arch Intern Med** 1996 Feb 12;156(3):337–9 (21 ref.)

Amphotericin B: an update. Abu-Salah KM. **Br J Biomed Sci** 1996 Jun;53(2):122–33 (148 ref.)

Experience with liposomal Amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation. Krüger W, et al. **Br J Haematol** 1995 Nov;91(3):684–90

A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours. Finlay PM, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):23–5

Breakthrough fungemia due to Hansenula anomala in a leukemic patient successfully treated with amphotericin B [letter] Kunová A, et al. **Chemotherapy** 1996 Mar–Apr; 42(2):157–8

Zygomycotic lung abscess: a case report. Chen JS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Aug; 56(2):129–33

Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Dromer F, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S154–60

Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Gallis HA. **Clin Infect Dis** 1996 May;22 Suppl 2:S145–7 (18 ref.)

Use of amphotericin B lipid complex for treatment of disseminated cutaneous fusarium infection in a neutropenic patient [letter] Wolff MA, et al. **Clin Infect Dis** 1995 Jun; 20(6):1568–9

Amphotericin B lipid complex treatment of a leukemic child with disseminated Fusarium solani infection. Patterson TS, et al. **Clin Pediatr (Phila)** 1996 May;35(5):257–60

Successful treatment of catheter-related fusarial infection in immunocompromised children. Velasco E, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):697–9

The changing epidemiology of fungal infections: are the lipid-forms of amphotericin B an advance? Herbrecht R. **Eur J Haematol Suppl** 1996;57:12–7 (24 ref.)

Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Lister J. **Eur J Haematol Suppl** 1996;57:18–23

Recurrence of Fusarium solani abscess formation in an otherwise healthy patient. Leu HS, et al. **Infection** 1995 Sep–Oct;23(5):303–5

Breakthrough fungemia caused by Candida stellatoidea in a patient with lymphoma associated with shock, successfully treated with amphotericin B lipid complex [letter] Sufliarsky J, et al. **Infection** 1995 Jul–Aug; 23(4):246–7

Amphotericin B: emergency challenge in a neutropenic, asthmatic patient with fungal sepsis. Kemp SF, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):425–7

Nasopharyngeal conidiobolomycosis in a horse. Zamos DT, et al. **J Am Vet Med Assoc** 1996 Jan 1;208(1):100–1

Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B [letter] Mishra M. **J Assoc Physicians India** 1995 Apr;43(4):306

Controversy in the regimens of treatment with amphotericin B in resistant cases of kala-azar [letter] Thakur CP. **J Assoc Physicians India** 1995 Nov;43(11):813–4

Amphotericin B responsive Scedosporium apiospermum infection in a patient with acute myeloid leukaemia. Cunningham R, et al. **J Clin Pathol** 1996 Jan;49(1):93–4

Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. Sundar S, et al. **J Infect Dis** 1996 Mar;173(3):762–5

Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole. Goldani LZ, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):267–70 (22 ref.)

Treatment of chronic disseminated Geotrichum capitatum infection with high cumulative dose of colloidal amphotericin B and itraconazole in a leukaemia patient. Cofrancesco E, et al. **Mycoses** 1995 Sep–Oct; 38(9–10):377–84

Port-a-cath-related Fusarium oxysporum infection in an HIV-infected patient: treatment with liposomal amphotericin B. Eljaschewitsch J, et al. **Mycoses** 1996 Mar–Apr;39(3–4):115–9

Systemic Fusarium nygamai infection in a patient with lymphoblastic non-Hodgkin's lymphoma. Krulder JW, et al. **Mycoses** 1996 Mar–Apr;39(3–4):121–3

Management of postoperative Acremonium endophthalmitis. Weissgold DJ, et al. **Ophthalmology** 1996 May; 103(5):749–56

Successful treatment of cryptococcosis in a premature neonate. Gavai M, et al. **Pediatr Infect Dis J** 1995 Nov; 14(11):1009–10

Blood culture as a parameter of treatment effectiveness in experimental histoplasmosis of the hamster. Finquelievich J, et al. **Rev Inst Med Trop Sao Paulo** 1995 Mar–Apr; 37(2):99–102

Candida albicans meningitis in a 27 weeks premature infant treated with liposomal amphotericin-B (AmBisome) Jarløv JO, et al. **Scand J Infect Dis** 1995;27(4):419–20

Treatment of cryptococcal meningitis with triple combination of amphotericin B, flucytosine and itraconazole. Chotmongkol V, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):381–3

Amphotericin B in the treatment of candida meningitis in three neonates. Aydin M, et al. **Turk J Pediatr** 1995 Jul–Sep;37(3):247–52

The management of renal candidiasis in the newborn. Uçsel R, et al. **Turk J Pediatr** 1996 Apr–Jun;38(2):239–43

[Palliative percutaneous treatment under x-ray computed tomographic control of inoperable pulmonary aspergilloma. Apropos of 30 cases] Giron J, et al. **Rev Mal Respir** 1995;12(6):593–9 (Eng. Abstr.) **(Fre)**

[Rhinocerebral mucormycosis: a case report] Simoncelli C, et al. **Acta Otorhinolaryngol Ital** 1995 Jun,15(3):229–32 (Eng. Abstr.) **(Ita)**

[Procedures for Candida albicans systemic infections in premature infants] Lauterbach R. **Ginekol Pol** 1995 May; 66(5):289–93 (13 ref.) (Eng. Abstr.) **(Pol)**

[Visceral leishmaniasis refractory to treatment: the efficacy of amphotericin B] Pérez Brea A, et al. **An Esp Pediatr** 1996 Feb;44(2):161–3 (8 ref.) **(Spa)**

TOXICITY

Structure and toxicity of amphotericin B/triglyceride emulsion formulations. Lance MR, et al. **J Antimicrob Chemother** 1995 Jul;36(1):119–28

AMPICILLIN

Contamination of ampicillin was probably due to reuse of disposable stoppers [letter] Jeene H. **BMJ** 1996 Aug 10; 313(7053):364–5

Improved glutaminate-starch-penicillin agar for the isolation and enumeration of Aeromonas hydrophila from seawater by membrane filtration. Papapetropoulou M, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):622–7

ADMINISTRATION & DOSAGE

Application of polylactic acid polymer in the treatment of acute maxillary sinusitis in rabbits. Min YG, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):548–52

Treatment of experimental acute otitis media with ibuprofen and ampicillin. Diven WF, et al. **Int J Pediatr Otorhinolaryngol** 1995 Oct;33(2):127–39

Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. Brandt CM, et al. **J Infect Dis** 1996 Apr;173(4):909–13

ADVERSE EFFECTS

Ampicillin-induced maculopapular versus urticarial rash. Marra CA, et al. **Ann Pharmacother** 1996 Apr;30(4):401–2

Ampicillin-specific rashes. Adcock BB, et al. **Arch Fam Med** 1996 May;5(5):301–4

An unusual drug eruption to ampicillin. Lim JT, et al. **Cutis** 1995 Sep;56(3):163–4

[Importance of the leukotriene C4 liberation test for the diagnosis of drug allergy (preliminary results)] Sainte-Laudy J, et al. **Allerg Immunol (Paris)** 1996 Feb; 28(2):44–7 (Eng. Abstr.) **(Fre)**

ANALOGS & DERIVATIVES

Pharmacokinetics of bacampicillin in equids. Sarasola P, et al. **Am J Vet Res** 1995 Nov;56(11):1486–92

CHEMISTRY

Ciprofloxacin–ampicillin sulbactam incompatibility [letter] Melonakos TK. **Ann Pharmacother** 1996 Jan;30(1):87

Effect of manufacturing technology on the dissolution of ampicillin tablets. González M, et al. **Boll Chim Farm** 1995 Sep;134(8):448–53

Two-dimensional electrophoresis of human serum proteins modified by ampicillin during therapeutic treatment. Magi B, et al. **Electrophoresis** 1995 Jul;16(7):1190–2

On the electrostatic and steric similarity of lactam compounds and the natural substrate for bacterial cell-wall biosynthesis. Frau J, et al. **J Comput Aided Mol Des** 1996 Apr;10(2):107–22

Metal ion interaction with penicillins—Part VII: Mixed-ligand complex formation of cobalt(II), nickel(II), copper(II), and Zinc(II) with ampicillin and nucleic bases. Mukherjee G, et al. **J Inorg Biochem** 1995 Sep;59(4):827–33

ISOLATION & PURIFICATION

Evaluation of liquid chromatography methods for the separation of ampicillin and its related substances. Zhu Y, et al. **J Pharm Biomed Anal** 1996 Mar;14(5):631–9

PHARMACOKINETICS

Cephalosporin and carbacephem nephrotoxicity. Roles of tubular cell uptake and acylating potential. Tune BM, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):557–61

Intracellular distribution of ampicillin in murine macrophages infected with Salmonella typhimurium and treated with (3H)ampicillin-loaded nanoparticles. Balland O, et al. **J Antimicrob Chemother** 1996 Jan;37(1):105–15

Chronokinetics of liposomal encapsulated ampicillin in fasting and nonfasting rats. Pardue RL, et al. **J Pharm Sci** 1996 Mar;85(3):309–12

Disposition kinetics of ampicillin administered intravenously and intraosseously to canine puppies. Lavy E, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):379–81

Modeling residue uptake by eggs. 1. Similar drug residue patterns in developing yolks following injection with ampicillin or oxytetracycline. Donoghue DJ, et al. **Poult Sci** 1996 Mar;75(3):321–8

Pharmacokinetics of ampicillin administered intravenously and intraosseously to kittens. Goldstein R, et al. **Res Vet Sci** 1995 Sep;59(2):186–7

Comparative pharmacokinetics of an ampicillin/sulbactam combination administered intramuscularly in lactating sheep and goats. Escudero E, et al. **Vet Res** 1996; 27(3):201–8

PHARMACOLOGY

Effects of inhibitors of protein synthesis on lysis of Escherichia coli induced by beta-lactam antibiotics. Rodionov DG, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):899–903

Comparison of cefoxitin, cefotetan, and ampicillin/sulbactam as prophylaxis for polymicrobial infection in mice. Brook I. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S376–7

Two-dimensional gel electrophoresis and immunoblotting of human serum albumin modified by reaction with penicillins.

AMPICILLIN

Marzocchi B, et al. **Electrophoresis** 1995 May;16(5):851-3

Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. Pankuch GA, et al. **J Antimicrob Chemother** 1995 Jun;35(6):883-8

Comparison of in-house and commercially prepared haemophilus test media for disk diffusion testing of ampicillin against Haemophilus species. Laue RR, et al. **J Clin Microbiol** 1995 Sep;33(9):2240-3

FT-IR spectroscopy study of perturbations induced by antibiotic on bacteria (Escherichia coli). Zeroual W, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):300-5

[Comparative in vitro activity of ampicillin, cefoperazone, their combinations with sulbactam and other antibiotics with respect to staphylococci and pneumococci] Sidorenko SV, et al. **Antibiot Khimioter** 1995 Mar;40(3):22-7 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Ampicillin/sulbactam versus ampicillin alone for cesarean section prophylaxis: a randomized double-blind trial. Rijhsinghani A, et al. **Am J Perinatol** 1995 Sep;12(5):322-4

Eradication of viridans streptococci from the amniotic cavity by parenteral antibiotic administration. A case report. Mazor M, et al. **J Reprod Med** 1995 Nov;40(11):820-2

Effects of chitosan on experimental abscess with Staphylococcus aureus in dogs. Okamoto Y, et al. **J Vet Med Sci** 1995 Aug;57(4):765-7

Meconium-stained amniotic fluid-associated infectious morbidity: a randomized, double-blind trial of ampicillin-sulbactam prophylaxis. Adair CD, et al. **Obstet Gynecol** 1996 Aug;88(2):216-20

[Sulacillin (a combination of ampicillin and sulbactam)--a new combined drug form for treatment of bacterial infections] Bogomolova NS, et al. **Antibiot Khimioter** 1995 Jun;40(6):43-8 (Eng. Abstr.) **(Rus)**

[Amoxycillin: 25 years of use in clinical practice] Iakovlev SV. **Antibiot Khimioter** 1995 Jun;40(6):49-55 (13 ref.) **(Rus)**

TOXICITY

Cephalosporin and carbacephem nephrotoxicity. Roles of tubular cell uptake and acylating potential. Tune BM, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):557-61

AMPICILLIN PIVALOYL ESTER see **PIVAMPICILLIN**

AMPICILLIN RESISTANCE

Detection of "lost" plasmids from Escherichia coli using excess ampicillin. Wright AD, et al. **Anal Biochem** 1996 Apr 5;236(1):181-2

Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Stapleton P, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2478-83

The virgin population of Neisseria gonorrhoeae in Stockholm has decreased and antimicrobial resistance is increasing. Bäckman M, et al. **Genitourin Med** 1995 Aug;71(4):234-8

Resistant enterococci: a prospective study of prevalence, incidence, and factors associated with colonization in a university hospital. Weinstein JW, et al. **Infect Control Hosp Epidemiol** 1996 Jan;17(1):36-41

Increasing incidence of penicillin- and ampicillin-resistant middle ear pathogens. Rodriguez WJ, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1075-8

GENETICS

Beta-lactam resistance in normal faecal flora from South Africa. Shanahan PM, et al. **Epidemiol Infect** 1995 Oct; 115(2):243-53

A new set of useful cloning and expression vectors derived from pBlueScript. Mayer MP. **Gene** 1995 Sep 22; 163(1):41-6

Construction of beta-lactamase-encoding ApR gene cassettes for rapid identification of cloned genes. Yokochi T, et al. **Gene** 1996 Apr 17;170(1):143-4

Transformation of Coxiella burnetii to ampicillin resistance. Suhan ML, et al. **J Bacteriol** 1996 May;178(9):2701-8

Amino acid sequence determinants of beta-lactamase structure and activity. Huang W, et al. **J Mol Biol** 1996 May 17;258(4):688-703

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Sato Y, et al. **Science** 1996 Jul 19;273(5273):352-4

AMPLIFIERS

Dosimetry measurements using a probe tube microphone in the ear canal. Shotland LI. **J Acoust Soc Am** 1996 Feb; 99(2):979-84

The perception of amplified speech by listeners with hearing loss: acoustic correlates. Stelmachowicz PG, et al. **J Acoust Soc Am** 1995 Sep;98(3):1388-99

Comparison of probe insertion methods on estimates of ear canal SPL. Dirks DD, et al. **J Am Acad Audiol** 1996 Jan; 7(1):31-8

ADVERSE EFFECTS

Potential risk of hearing damage associated with exposure to highly amplified music. Hétu R, et al. **J Am Acad Audiol** 1995 Sep;6(5):378-86 (43 ref.)

AMPROLIUM

PHARMACOKINETICS

Kinetic behaviour of sulphaquinoxaline and amprolium in chickens. el-Sayed MG, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec;102(12):481-5

AMPULLA OF VATER see **VATER'S AMPULLA**

AMPUTATION

Knee joint proprioception in below-knee amputees. Liao KI, et al. **Am J Knee Surg** 1995 Summer;8(3):105-9

Predictors of amputation for popliteal artery injuries. Fainzilber G, et al. **Am J Surg** 1995 Dec;170(6):568-70; discussion 570-1

Arterial emboli of the lower limbs: analysis of risk factors for mortality and amputation. Association Universitaire de Recherche en Chirurgie. Becquemin JP, et al. **Ann Vasc Surg** 1995;9 Suppl:S32-8

Revascularization versus amputation for elderly patients. Bunt TJ. **AORN J** 1995 Sep;62(3):433-5 (7 ref.)

Composite graft survival. An auricular amputation model. Henrich DE, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct;121(10):1137-42

Bacterial discitis caused by limb gangrene requiring below-knee amputation. Nicholas JJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3):301-4

Amputation rates as a measure of vascular surgical results. Luther M, et al. **Br J Surg** 1996 Feb;83(2):241-4

Skin from the amputated limb should not be wasted. Okoye BO, et al. **Br J Surg** 1996 Jun;83(6):797

Outcome of amputations in patients with major burns. Viscardi PJ, et al. **Burns** 1995 Nov;21(7):526-9

Changes in hip muscles after above-knee amputation. Jaegers SM, et al. **Clin Orthop** 1995 Oct;(319):276-84

An electromyographic study of the hip muscles of transfemoral amputees in walking. Jaegers SM, et al. **Clin Orthop** 1996 Jul;(328):119-28

Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach? Larsson J, et al. **Diabet Med** 1995 Sep; 12(9):770-6

Increased foot pressures after great toe amputation in diabetes. Lavery LA, et al. **Diabetes Care** 1995 Nov; 18(11):1460-2

Preventing amputation in the patient with diabetes. Levin ME. **Diabetes Care** 1995 Oct;18(10):1383-94 (117 ref.)

The development of foot deformities and ulcers after great toe amputation in diabetes. Quebedeaux TL, et al. **Diabetes Care** 1996 Feb;19(2):165-7

Risk factors for lower extremity amputation in persons with diabetes. Selby JV, et al. **Diabetes Care** 1995 Apr; 18(4):509-16

Hindquarter amputation for lymphangiomatosis. Jenkins MP, et al. **Eur J Surg Oncol** 1996 Feb;22(1):116-7

Walking ability and quality of life as outcome measures in a comparison of arterial reconstruction and leg amputation for the treatment of vascular disease. Albers M, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):308-14

Quality of life [letter; comment] Perkins JM, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):511. Comment on: Eur J Vasc Endovasc Surg 1995 Apr;9(3):310-3.

Longitudinal deficiency of the fibula. Operative treatment. Fulp T, et al. **J Bone Joint Surg Am** 1996 May;78(5):674-82

Amputation for reflex sympathetic dystrophy [letter; comment] Thomas M, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):836. Comment on: J Bone Joint Surg Br 1995 Mar;77(2):270-3.

Large-scale reorganization at multiple levels of the somatosensory pathway follows therapeutic amputation of the hand in monkeys. Florence SL, et al. **J Neurosci** 1995 Dec;15(12):8083-95

Amputation versus reconstruction in traumatic defects of the leg: outcome and costs. Hertel R, et al. **J Orthop Trauma** 1996;10(4):223-9

Phantom limb pain and etiology of amputation in unilateral lower extremity amputees. Weiss SA, et al. **J Pain Symptom Manage** 1996 Jan;11(1):3-17

Function after amputation, arthrodesis, or arthroplasty for tumors about the shoulder. Kneisl JS. **J South Orthop Assoc** 1995 Fall;4(3):228-36 (36 ref.)

Are type IIIC lower extremity injuries an indication for primary amputation. Quirke TE, et al. **J Trauma** 1996 Jun; 40(6):992-6 (45 ref.)

Treatment of femur fracture with associated vascular injury. Starr AJ, et al. **J Trauma** 1996 Jan;40(1):17-21

Polytetrafluoroethylene bypasses to infrapopliteal arteries without cuffs or patches: a better option than amputation in patients without autologous vein. Parsons RE, et al. **J Vasc Surg** 1996 Feb;23(2):347-54; discussion 355-6

Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). Bergman PJ, et al. **J Vet Intern Med** 1996 Mar-Apr;10(2):76-81

Amputation of a useless limb. Pearce RL, et al. **Med J Aust** 1996 Apr 1;164(7):407-8

Long-term effects of finger amputation on stump skin sensibility and digital nerve conduction. Chu NS. **Muscle Nerve** 1996 Aug;19(8):1049-51

Amputation surgery and prostheses. Rodriguez RP. **Orthop Clin North Am** 1996 Jul;27(3):525-39 (59 ref.)

Late outcome of amputees with premature atherosclerosis. Valentine RJ, et al. **Surgery** 1996 May;119(5):487-93

[Reduced frequency of amputation in diabetic patients] Holstein P, et al. **Nord Med** 1996 May;111(5):142-4, 160 (Eng. Abstr.) **(Dan)**

[Phantom pain following leg amputation: retrospective study of incidence, therapy and the effect of preoperative analgesia] Zuurmond WW, et al. **Ned Tijdschr Geneeskd** 1996 May 18;140(20):1080-3 (Eng. Abstr.) **(Dut)**

[The fate of patients with diabetes mellitus after amputation of a lower limb as a consequence of gangrene] Karnafel W, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):349-56 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Recombinant human erythropoietin: effect on the functional performance of anemic orthopedic patients. Green D, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3):242-6

Syme's amputation revisited: a review of 46 cases. Gaine WJ, et al. **J Bone Joint Surg Br** 1996 May;78(3):461-7

Osseous overgrowth after amputation in adolescents and children. O'Neal ML, et al. **J Pediatr Orthop** 1996 Jan-Feb; 16(1):78-84

Deep vein thrombosis associated with lower extremity amputation. Yeager RA, et al. **J Vasc Surg** 1995 Nov; 22(5):612-5

ECONOMICS

The costs of diabetes-related lower extremity amputations in the Netherlands. van Houtum WH, et al. **Diabet Med** 1995 Sep;12(9):777-81

Cost-efficacy issues in the treatment of peripheral vascular disease: primary amputation or revascularization for limb-threatening ischemia. Perler BA. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):111S-115S (28 ref.)

[Reconstruction or amputation in complex fractures of the tibia. A comparative study with special reference to insurance medicine aspects] Ramseier EW, et al. **Swiss Surg** 1995;(2):103-6 (Eng. Abstr.) **(Ger)**

HISTORY

James Moore, John Hunter and amputation under analgesia in 1784. Willetts IE. **Ann R Coll Surg Engl** 1995 Nov;77(6 Suppl):310-1

METHODS

Preventing neuroma formation in finger amputation. De Smet L. **Acta Orthop Belg** 1996 Mar;62(1):69-70

Prevention of neuroma in elective digital amputations by utilization of neurovascular island flap. St-Laurent JY, et al. **Ann Chir Main Memb Super** 1996;15(1):50-4

Syme amputation: results in patients with severe forefoot ischemia. Weaver FA, et al. **Cardiovasc Surg** 1996 Feb; 4(1):81-6

Alternative methods for below-knee amputation: reappraisal of the Kendrick procedure. Kaufman JL. **J Am Coll Surg** 1995 Dec;181(6):511-6

Proximal femoral focal deficiency: results of rotationplasty and Syme amputation. Alman BA, et al. **J Bone Joint Surg Am** 1995 Dec;77(12):1876-82

Syme's amputation revisited: a review of 46 cases. Gaine WJ, et al. **J Bone Joint Surg Br** 1996 May;78(3):461-7

Translumbar amputation: the longest survivor--a case update. Mackenzie AR. **Mt Sinai J Med** 1995 Sep; 62(4):305-7

[Forefoot gangrene and infra-crural bypass: sequential amputation] Cheynel-Hocquet C, et al. **J Mal Vasc** 1996; 21 Suppl A:174-7 (Eng. Abstr.) **(Fre)**

[Forefoot gangrene and infra-crural bypass: simultaneous amputation] Jacobs MJ. **J Mal Vasc** 1996;21 Suppl A:171-3 (Eng. Abstr.) **(Fre)**

[Surgical therapy of soft tissue sarcomas II. Sarcomas of the extremities and their surgical resection] Karakousis CP. **Chirurg** 1995 Oct;66(10):1006-15 (9 ref.) (Eng. Abstr.) **(Ger)**

[Transgenicular amputation with special reference to partial secondary femoral condyle resection] Seiler S, et al. **Vasa** 1995;24(4):368-72 (Eng. Abstr.) **(Ger)**

[Amputations in patients with arterial obliterating diseases] Lebedev LV, et al. **Vestn Khir Im I I Grek** 1995; 154(3):88-90 **(Rus)**

[Method of reamputation of the limb at the thigh level] Gribenko VV, et al. **Klin Khir** 1995;(7-8):34 **(Ukr)**

MORTALITY

Amputation risk and survival after embolectomy for acute arterial ischaemia. Time trends in a defined Swedish population. Ljungman C, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):176-82

PSYCHOLOGY

Are you a fraud? Am I a fraud? Is PM&R a fraud? [editorial] Meier RH 3rd. **Am J Phys Med Rehabil** 1996 Jan-Feb; 75(1):2

REHABILITATION

Effects of a skiing experience on adolescents with limb deficiencies: an occupational adaptation perspective. Pasek PB, et al. **Am J Occup Ther** 1996 Jan;50(1):24–31

Functional outcome and comorbidity indexes in the rehabilitation of the traumatic versus the vascular unilateral lower limb amputee. Melchiorre PJ, et al. **Am J Phys Med Rehabil** 1996 Jan–Feb;75(1):9–14

Rehabilitation in limb deficiency. 3. The geriatric amputee. Andrews KL. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S14–7 (41 ref.)

Rehabilitation in limb deficiency. 1. Gait and motion analysis. Czerniecki JM. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S3–8 (41 ref.)

Rehabilitation in limb deficiency. 4. Limb amputation. Esquenazi A, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S18–28 (42 ref.)

Rehabilitation in limb deficiency. 2. The pediatric amputee. Jain S. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S9–13 (42 ref.)

Mobility after amputation of a lower limb [letter] Kulkarni JR. **BMJ** 1995 Dec 16;311(7020):1643–4

Mobility after lower–limb amputation [letter; comment] Kulkarni JR. **Br J Surg** 1996 Jan;83(1):134. Comment on: Br J Surg 1995 Aug;82(8):1010–1.

The long–term outcome of upper limb amputees treated at a rehabilitation centre in Sydney, Australia. Jones LE, et al. **Disabil Rehabil** 1995 Nov–Dec;17(8):437–42

Is a pre–discharge checklist useful? Hunter J, et al. **J R Coll Physicians Lond** 1996 Mar–Apr;30(2):162–3

Major lower limb amputation for vascular disease in the Grampian area: the outcome of rehabilitation. Kanellopoulos G, et al. **J R Coll Surg Edinb** 1996 Apr; 41(2):114–5

The effect of prosthetic alignment on relative limb loading in persons with trans–tibial amputation: a preliminary report. Pinzur MS, et al. **J Rehabil Res Dev** 1995 Nov; 32(4):373–7

The influence of lower–extremity muscle force on gait characteristics in individuals with below–knee amputations secondary to vascular disease. Powers CM, et al. **Phys Ther** 1996 Apr;76(4):369–77; discussion 378–85

Introduction of a modified Krukenberg operation. Gu YD, et al. **Plast Reconstr Surg** 1996 Jan;97(1):222–6

Late outcome of amputees with premature atherosclerosis. Valentine RJ, et al. **Surgery** 1996 May;119(5):487–93

STANDARDS

[Quality assurance in amputation of the lower extremities due to vascular insufficiency] Thomsen NO, et al. **Nord Med** 1995;110(10):258–60 (Eng. Abstr.) **(Dan)**

STATISTICS & NUMERICAL DATA

Long–term incidence of lower–extremity amputations in a diabetic population. Moss SE, et al. **Arch Fam Med** 1996 Jul–Aug;5(7):391–8

Reduction of gangrene and amputations in diabetic renal transplant patients: the role of a special foot clinic. Foster AV, et al. **Diabet Med** 1995 Jul;12(7):632–5

Variation in the incidence and proportion of diabetes–related amputations in minorities. Lavery LA, et al. **Diabetes Care** 1996 Jan;19(1):48–52

Major limb amputation in adults, Zaria, Nigeria. Yakubu A, et al. **J R Coll Surg Edinb** 1996 Apr;41(2):102–4

[Amputation and arterial reconstruction in peripheral occlusive arterial diseases in Denmark 1977–1993] Seidelin CM, et al. **Ugeskr Laeger** 1995 Oct 23;157(43):5985–8 (Eng. Abstr.) **(Dan)**

UTILIZATION

[Amputation of the lower extremities, contribution of collaboration with a vascular surgeon] Jirava D, et al. **Rozhl Chir** 1996 Feb;75(2):97–9 (Eng. Abstr.) **(Cze)**

VETERINARY

Femoral head and neck excision in a dog that had previously undergone contralateral hind limb amputation. Carpenter LG, et al. **J Am Vet Med Assoc** 1996 Mar 1;208(5):695–6

Amputation and prosthesis. St. Jean G. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):249–61 (13 ref.)

Docking of puppies' tails [letter] Chick S. **Vet Rec** 1995 Sep 30;137(14):356

Docking and other practices [letter; comment] [see comments] Cooper JE. **Vet Rec** 1995 Jul 8;137(2):52. Comment on: Vet Rec 1995 Mar 18;136(11):274. Comment in: Vet Rec 1995 Jul 22;137(4):103.

Docking of puppies' tails [letter] Hoare C. **Vet Rec** 1995 Sep 30;137(14):355–6

Docking of puppies' tails [letter] Mason D. **Vet Rec** 1995 Dec 2;137(23):599

Castration and/or tail docking of lambs [letter] Mellor DJ, et al. **Vet Rec** 1995 Aug 26;137(9):227

Docking and other practices [letter; comment] Morton DB. **Vet Rec** 1995 Jul 22;137(4):103. Comment on: Vet Rec 1995 Jul 8;137(2):52.

Docking of puppies' tails [letter] [see comments] Sinclair E. **Vet Rec** 1995 Sep 30;137(14):356. Comment in: Vet Rec 1995 Oct 14;137(16):411–2.

[Preventative tail amputation in fattening bulls] Busch B, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar; 102(3):127–9 (Eng. Abstr.) **(Ger)**

AMPUTATION, INTRAUTERINE see **AMNIOTIC BAND SYNDROME**

AMPUTATION STUMPS

see related

PHANTOM LIMB

Precision of surface measurements for below–knee residua. Commean PK, et al. **Arch Phys Med Rehabil** 1996 May; 77(5):477–86

Operative treatment of bone overgrowth in children who have an aquired or congenital amputation [letter] Abraham E. **J Bone Joint Surg Am** 1996 Aug;78(8):1287–8

Operative treatment of bone overgrowth in children who have an acquired or congenital amputation. Davids JR, et al. **J Bone Joint Surg Am** 1995 Oct;77(10):1490–7

Calcaneal fillet flap: a new osteocutaneous free tissue transfer for emergency salvage of traumatic below–knee amputation stumps. Januszkiewicz JS, et al. **Plast Reconstr Surg** 1996 Sep;98(3):538–41

Salvage of traumatic below–knee amputation stumps utilizing the filet of foot free flap: critical evaluation of six cases. Kasabian AK, et al. **Plast Reconstr Surg** 1995 Oct; 96(5):1145–53

Validation of spiral CT and optical surface scanning for lower limb stump volumetry. Smith KE, et al. **Prosthet Orthot Int** 1995 Aug;19(2):97–107

[Use of tissue expansion on defective amputation stumps of the lower limbs. Apropos of 5 cases] Manise O, et al. **Ann Chir Plast Esthet** 1996 Apr;41(2):155–60 (Eng. Abstr.) **(Fre)**

[Transgenicular amputation with special reference to partial secondary femoral condyle resection] Seiler S, et al. **Vasa** 1995;24(4):368–72 (Eng. Abstr.) **(Ger)**

BLOOD SUPPLY

[Surgical treatment of ischemia of the stump of the lower extremity] Zoloev GK, et al. **Khirurgiia (Mosk)** 1996; (1):46–8 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Stump pemphigoid. Brodell RT, et al. **Cutis** 1996 Apr; 57(4):245–6

PHYSIOPATHOLOGY

A reassessment of center–of–mass dynamics as a determinate of the metabolic inefficiency of above–knee amputee ambulation. Gitter A, et al. **Am J Phys Med Rehabil** 1995 Sep–Oct;74(5):332–8

RADIOGRAPHY

Residual–limb shape change: three–dimensional CT scan measurement and depiction in vivo. Smith KE, et al. **Radiology** 1996 Sep;200(3):843–50

SURGERY

Reconstruction of the upper leg and knee with a reversed flow saphenous island flap based on the medial inferior genicular artery. Tsai CC, et al. **Ann Plast Surg** 1995 Nov; 35(5):480–4

Restoration of apposition function in residual hand by the Ilizarov method: a case report. Samchukov ML, et al. **Bull Hosp Jt Dis** 1993–95;53(4):13–6

Closure of an open high below–knee guillotine amputation wound using a skin–stretching device. Har–Shai Y, et al. **Injury** 1995 Jul;26(6):401–4

Introduction of a modified Krukenberg operation. Gu YD, et al. **Plast Reconstr Surg** 1996 Jan;97(1):222–6

Tissue expansion: a method to preserve bone length and joints following traumatic amputations of the leg––a follow–up of five legs amputated at different levels. Wieslander JB, et al. **Plast Reconstr Surg** 1996 Apr;97(5):1065–71

[Role of microvascular free flaps in the treatment of amputation stumps] Fasano D, et al. **Ann Ital Chir** 1996 Jan–Feb;67(1):65–8; discussion 69 (Eng. Abstr.) **(Ita)**

[Surgical treatment of ischemia of the stump of the lower extremity] Zoloev GK, et al. **Khirurgiia (Mosk)** 1996; (1):46–8 (Eng. Abstr.) **(Rus)**

AMPUTATION, TRAUMATIC

see related

REPLANTATION

The effects of weapons: surgical challenge and medical dilemma. Coupland RM. **J R Coll Surg Edinb** 1996 Apr; 41(2):65–71 (6 ref.)

COMPLICATIONS

Pantalar fusion for correction of painful equinus after traumatic Chopart's amputation––a report of 2 cases. Persson BM, et al. **Acta Orthop Scand** 1996 Jun;67(3):300–2

Osseous overgrowth after amputation in adolescents and children. O'Neal ML, et al. **J Pediatr Orthop** 1996 Jan–Feb; 16(1):78–84

EPIDEMIOLOGY

Left–hand dominance and hand trauma. Taras JS, et al. **J Hand Surg [Am]** 1995 Nov;20(6):1043–6

ETIOLOGY

Male genital self–mutilation. Romilly CS, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):427–31 (24 ref.)

Amputation of distal penile glans during neonatal ritual circumcision––a rare complication. Neulander E, et al. **Br J Urol** 1996 Jun;77(6):924–5

Amputations with use of adult–size scissors–type circumcision clamps on infants. **Health Devices** 1995 Jul; 24(7):286–7

Finger injuries from infant mittens; a continuing but preventable hazard. Stringer MD, et al. **Injury** 1996 Apr; 27(3):157–8

Pattern and mechanism of traumatic amputation by explosive blast. Hull JB, et al. **J Trauma** 1996 Mar;40(3 Suppl):S198–205

Partial amputation of glans penis during Mogen clamp circumcision. Strimling BS. **Pediatrics** 1996 Jun;97(6 Pt 1):906–7

[Accident with protective gloves. Case report (letter)] Schmidt A. **Hautarzt** 1995 Sep;46(9):663 **(Ger)**

NURSING

Scalp replantation after traumatic injury. Rivera ML, et al. **AORN J** 1995 Aug;62(2):175–80, 182, 184

PATHOLOGY

Pulse oximetry for preoperative vascular assessment in a thumb near–amputation [see comments] Schumer E, et al. **J Emerg Med** 1995 Nov–Dec;13(6):753–5 (20 ref.). Comment in: J Emerg Med 1995 Nov–Dec;13(6):815–6.

The histopathology of injury to the accessory malleolar ossification center. Ogden JA, et al. **J Pediatr Orthop** 1996 Jan–Feb;16(1):61–2

[Irreversible ischemic damages in the skeletal muscle of the severed extremity depending on the duration of the ischemia and the temperature] Islamov RR, et al. **Morfologiia** 1994 Apr–Jun;106(4–6):145–50 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Insulin resistance and autonomic function in traumatic lower limb amputees. Peles E, et al. **Clin Auton Res** 1995 Oct; 5(5):279–88

PSYCHOLOGY

Psychosocial consequences of upper limb injury. Paterson MC, et al. **J Hand Surg [Br]** 1995 Dec;20(6):776–81

RADIOGRAPHY

[Hand injuries due to fireworks explosion] Grassi R, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):6–12 (Eng. Abstr.) **(Ita)**

REHABILITATION

Chopart prosthesis and semirigid foot orthosis in traumatic forefoot amputation. Comparative gait analysis. Hirsch G, et al. **Am J Phys Med Rehabil** 1996 Jul–Aug;75(4):283–91

Functional outcome and comorbidity indexes in the rehabilitation of the traumatic versus the vascular unilateral lower limb amputee. Melchiorre PJ, et al. **Am J Phys Med Rehabil** 1996 Jan–Feb;75(1):9–14

[The restoration of the weight–bearing capacity of the lower extremities and the gait of patients with traumatic detachments] Diakov R, et al. **Khirurgiia (Sofiia)** 1995; 48(3):20–3 (Eng. Abstr.) **(Bul)**

SURGERY

Microsurgical reconstruction of a stiff jointless thumb after an avulsion injury. Smrčka V, et al. **Acta Chir Plast** 1996; 38(1):24–9

Delayed microsurgical repair of avulsion injury [letter] Lucas TL Jr. **Am Fam Physician** 1996 Jul;54(1):65

Transfer of vessels in the management of thumb and ring avulsion injuries. Adani R, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):51–7

The "stub" operation––modification of the Furnas and Vilkki technique in traumatic and congenital carpal hand reconstruction. Foucher G. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):73–6

Sequential flap transplantations for total reconstruction of avulsion amputation of the fingers––a case report. Hung LK, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):138–40

Flap reconstruction in the upper limb. Ikuta Y, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):124–30 (10 ref.)

The role of microsurgery and free tissue transfer in the reconstruction of the paediatric upper extremity. Kay S, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):113–23 (50 ref.)

Combined free flap, Ilizarov lengthening and prosthetic fitting in the reconstruction of a proximal forearm amputation––a case report. Kour AK, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):135–7

A preliminary report of tissue preservation with University of Wisconsin cold storage solution in major limb replantation. Kour AK, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):37–41

Digital replantations under local anaesthesia. Kour AK, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):68–72

Major limb replantation: a Thai experience. Patradul A, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):82–8

Current concepts of replantation. Raskin KB, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):131–4 (29 ref.)

Thumb reconstruction with a big toe microvascular wrap-around flap: a report of fifteen cases. Songcharoen P, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):46–50

Upper limb digital replantation and revascularisation in children. Tan AB, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):32–6

Reverse neurovascular homodigital island flap. Adani R, et al. **Ann Plast Surg** 1995 Jul;35(1):77–82

Reconstruction of the totally degloved little finger with a bilobed digital neurovascular island flap. Tsai CC, et al. **Ann Plast Surg** 1995 Nov;35(5):529–33

Intraosseous wiring in toe-to-hand transplantation. Yim KK, et al. **Ann Plast Surg** 1995 Jul;35(1):66–9

Scalp replantation after traumatic injury. Rivera ML, et al. **AORN J** 1995 Aug;62(2):175–80, 182, 184

Microvascular replantation of a traumatically amputated ear. Funk GF, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):184–6

Temporary ectopic implantation for salvage of amputated digits. Graf P, et al. **Br J Plast Surg** 1996 Apr;49(3):174–7

Secondary procedures to improve function after toe-to-hand transfers. Yim KK, et al. **Br J Plast Surg** 1995 Oct; 48(7):487–91

Toe-to-hand transfer. Current concepts, techniques, and research. Wei FC, et al. **Clin Plast Surg** 1996 Jan; 23(1):103–16 (64 ref.)

Reimplantation and lengthening with use of the Ilizarov apparatus after a traumatic amputation of the leg. A case report. Mirzoyan AE. **J Bone Joint Surg Am** 1996 Mar; 78(3):437–8

Thumb reconstruction with extended twisted toe flap. Iglesias M, et al. **J Hand Surg [Am]** 1995 Sep;20(5):731–6

Osseointegrated thumb prostheses: a concept for fixation of digit prosthetic devices. Lundborg G, et al. **J Hand Surg [Am]** 1996 Mar;21(2):216–21

Nail regeneration in digits replanted after amputation through the distal phalanx. Nishi G, et al. **J Hand Surg [Am]** 1996 Mar;21(2):229–33

Benefits and use of digital prostheses. Pereira BP, et al. **J Hand Surg [Am]** 1996 Mar;21(2):222–8

A neurovascular island flap for volar-oblique fingertip amputations. Analysis of long-term results. Tsai TM, et al. **J Hand Surg [Br]** 1996 Feb;21(1):94–8

Circumcision: successful glanular reconstruction and survival following traumatic amputation. Sherman J, et al. **J Urol** 1996 Aug;156(2 Pt 2):842–4

Multivariate analysis of factors influencing the functional recovery after finger replantation or revascularization. Chiu HY, et al. **Microsurgery** 1995;16(10):713–7

Plea to save the great toe in total thumb reconstruction. Foucher G, et al. **Microsurgery** 1995;16(6):373–6 (23 ref.)

Thumb reconstruction with a free neurovascular wrap-around flap from the big toe: long-term follow-up of thirty cases. Lee KS, et al. **Microsurgery** 1995; 16(10):692–7

Two immediate synchronous free flap transfers in a severe traumatic mid-hand defect: a case report. Lin CH, et al. **Microsurgery** 1995;16(8):586

Replantation of a large amputated segment of the face: a new technique. Tanaka Y, et al. **Microsurgery** 1995; 16(9):594–7

Conduction study of digital nerve function recovery following toe-to-digit transplantation and a comparison with digit-to-digit replantation. Chu NS, et al. **Muscle Nerve** 1995 Nov;18(11):1257–64

An unusually avulsed penis successfully replanted by using microsurgical technique [letter] Fan J, et al. **Plast Reconstr Surg** 1996 Sep;98(3):571–3

Great toe-to-hand transfer nourished by arterial inflow through the venous system. Iglesias M, et al. **Plast Reconstr Surg** 1996 Apr;97(5):1024–6

Calcaneal fillet flap: a new osteocutaneous free tissue transfer for emergency salvage of traumatic below-knee amputation stumps. Januszkiewicz JS, et al. **Plast Reconstr Surg** 1996 Sep;98(3):538–41

Fingertip replantations: clinical evaluation of 135 digits. Kim WK, et al. **Plast Reconstr Surg** 1996 Sep;98(3):470–6

Eight cases of nine-digit and ten-digit replantations. Kim WK, et al. **Plast Reconstr Surg** 1996 Sep;98(3):477–84

Free combined thin wrap-around flap with a second toe proximal interphalangeal joint transfer for reconstruction of the thumb. Koshima I, et al. **Plast Reconstr Surg** 1995 Oct;96(5):1205–10

Successful replantation in 10-digit complete amputations. Qing-tai L, et al. **Plast Reconstr Surg** 1996 Aug; 98(2):348–53

Aesthetic refinements in toe-to-hand transfer surgery. Wei FC, et al. **Plast Reconstr Surg** 1996 Sep;98(3):485–90

Tissue expansion: a method to preserve bone length and joints following traumatic amputations of the leg—a follow-up of five legs amputated at different levels. Wieslander JB, et al. **Plast Reconstr Surg** 1996 Apr;97(5):1065–71

Complications and salvage of an ectopically replanted thumb. Yousif NJ, et al. **Plast Reconstr Surg** 1996 Mar;97(3):637–40

Cold-induced vasospasm after finger replantation; abnormal sensory regeneration and sensitisation of cold nociceptors. Povlsen B. **Scand J Plast Reconstr Surg Hand Surg** 1996 Mar;30(1):63–6

[Successful replantation in ten-digit complete amputation: a case report] Li Q, et al. **Chung Hua Wai Ko Tsa Chih** 1995 May;33(5):283–4 (Eng. Abstr.) **(Chi)**

[Reconstruction surgery after traumatic amputation of the thumb] Foucher G. **Ann Chir Plast Esthet** 1996 Apr; 41(2):197–207 (Eng. Abstr.) **(Fre)**

[Reconstruction of amputated thumb: 20 years of development of techniques and indications] Merle M. **Bull Acad Natl Med** 1996 Jan;180(1):195–210; discussion 211–4 (Eng. Abstr.) **(Fre)**

[Traumatic amputation of the thumb. Indications for replantation, technique and long-term outcome] Brenner P, et al. **Chirurg** 1995 Nov;66(11):1110–4 (Eng. Abstr.) **(Ger)**

[Heterotopic replantation] Ada S, et al. **Handchir Mikrochir Plast Chir** 1995 Nov;27(6):315–8 (Eng. Abstr.) **(Ger)**

[Traumatic hemipelvectomy. Experiences with 11 cases] Pohlemann T, et al. **Unfallchirurg** 1996 Apr;99(4):304–12 (45 ref.) (Eng. Abstr.) **(Ger)**

AMPUTEES

Gait analysis of transfemoral amputee patients using prostheses with two different knee joints. Boonstra AM, et al. **Arch Phys Med Rehabil** 1996 May;77(5):515–20

The prediction of metabolic energy expenditure during gait from mechanical energy of the limb: a preliminary study. Foerster SA, et al. **J Rehabil Res Dev** 1995 May; 32(2):128–34

Gait initiation of persons with below-knee amputation: the characterization and comparison of force profiles. Rossi SA, et al. **J Rehabil Res Dev** 1995 May;32(2):120–7

Energy expenditure during ambulation in dysvascular and traumatic below-knee amputees: a comparison of five prosthetic feet. Torburn L, et al. **J Rehabil Res Dev** 1995 May;32(2):111–9

Cortical reorganization in human amputees and mislocalization of painful stimuli to the phantom limb. Knecht S, et al. **Neurosci Lett** 1995 Dec 15;201(3):262–4

Design and manufacture of a high performance water-ski seating system for use by an individual with bilateral trans-femoral amputations. Buckley M, et al. **Prosthet Orthot Int** 1995 Aug;19(2):120–3

Energy cost during ambulation in transfemoral amputees: a knee joint with a mechanical swing phase control vs a knee joint with a pneumatic swing phase control. Boonstra AM, et al. **Scand J Rehabil Med** 1995 Jun;27(2):77–81

Exercise performance of lower-extremity amputees. Ward KH, et al. **Sports Med** 1995 Oct;20(4):207–14 (50 ref.)

PSYCHOLOGY

Knee joint proprioception in below-knee amputees. Liao KI, et al. **Am J Knee Surg** 1995 Summer;8(3):105–9

REHABILITATION

Functional outcomes in a lower limb amputee population. Sapp L, et al. **Prosthet Orthot Int** 1995 Aug;19(2):92–6

The rehabilitation of the amputee in the developing world: a review of the literature. Staats TB. **Prosthet Orthot Int** 1996 Apr;20(1):45–50

Driving appliances for upper limb amputees. Verrall T, et al. **Prosthet Orthot Int** 1995 Aug;19(2):124–7

AMRINONE

ADMINISTRATION & DOSAGE

The direct and interactive effects of phosphodiesterase inhibition and beta-adrenergic stimulation on myocyte contractile function after hypothermic cardioplegic arrest. Dorman BH, et al. **Anesth Analg** 1995 Nov;81(5):925–31

[Effects of amrinon and prostaglandin E1 on intraoperative central and peripheral temperatures during peripheral arterial surgery] Nonaka A, et al. **Masui** 1996 May; 45(5):576–81 (Eng. Abstr.) **(Jpn)**

BLOOD

HPLC micromethod for amrinone and metabolites in patients receiving concurrent cephalosporin therapy. Pappas JB, et al. **Clin Chem** 1996 May;42(5):761–5

METABOLISM

HPLC micromethod for amrinone and metabolites in patients receiving concurrent cephalosporin therapy. Pappas JB, et al. **Clin Chem** 1996 May;42(5):761–5

PHARMACOLOGY

Hemodynamic effects of amrinone in children after Fontan surgery. Sorensen GK, et al. **Anesth Analg** 1996 Feb; 82(2):241–6

Comparative vasoactive effects of amrinone on systemic and pulmonary arteries in rabbits. Lee TS, et al. **Chest** 1995 Nov;108(5):1364–7

Beneficial effect of amrinone on murine cardiac allograft survival. Hirozane T, et al. **Clin Exp Immunol** 1995 Oct; 102(1):186–91

Endothelium-dependent relaxation of rat thoracic aorta by amrinone-induced nitric oxide release. Mori K, et al. **Eur Heart J** 1996 Feb;17(2):308–16

Influence of age on venodilator effect of isoproterenol and amrinone. Harada K, et al. **Eur J Clin Pharmacol** 1996; 50(1–2):37–40

Relaxation of human isolated pulmonary arteries by amrinone. Ono S, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):177–81

Comparison of venodilatory effect of amrinone and theophylline in human subjects. Harada K, et al. **J Clin Pharmacol** 1995 Nov;35(11):1067–70

[Hemodynamic effects of amrinone during emergence from cardiopulmonary bypass] Nakata F, et al. **Masui** 1995 Dec; 44(12):1632–8 (Eng. Abstr.) **(Jpn)**

[Amrinone administration exerts no deleterious effect on platelet counts and blood transfusion volume during CABG] Senami K, et al. **Masui** 1996 May;45(5):638–41 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

A comparison of amrinone with sodium nitroprusside for control of hemodynamics during infrarenal abdominal aortic surgery. Dentz ME, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):486–90

Amrinone prevents the inhibition of muscle pyruvate dehydrogenase complex activity during sepsis. Vary TC. **Shock** 1996 Mar;5(3):229–32

The efficacy of amrinone or adrenaline on low cardiac output following cardiopulmonary bypass in patients with coronary artery disease undergoing preoperative beta-blockade. Günnicker M, et al. **Thorac Cardiovasc Surg** 1995 Jun;43(3):153–60

[Hemodynamic effects of amrinone, dobutamine and dopamine in the cardiac low output syndrome following open-heart surgery] Husedžinović I, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:32–4 (Eng. Abstr.) **(Scr)**

M-AMSA see **AMSACRINE**

AMSACRINE

ANALOGS & DERIVATIVES

Kinetics and mechanism of general acid-catalysed thiolytic cleavage of 9-anilinoacridine. Khan MN, et al. **Bioorg Med Chem** 1995 Jul;3(7):881–90

The 1′-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity. Rene B, et al. **Mol Pharmacol** 1996 Feb;49(2):343–50

CHEMISTRY

Interaction of a DNA-threading netropsin-amsacrine combilexin with DNA and chromatin. Bourdouxhe-Housiaux C, et al. **Biochemistry** 1996 Apr 9; 35(14):4251–64

PHARMACOLOGY

Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA. Lin JH, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):293–9

Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility. Borgnetto ME, et al. **Cancer Res** 1996 Apr 15;56(8):1855–62

Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents. Hsiung Y, et al. **Cancer Res** 1996 Jan 1;56(1):91–9

From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Finlay GJ, et al. **Eur J Cancer** 1996 Apr; 32A(4):708–14

The 1′-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity. Rene B, et al. **Mol Pharmacol** 1996 Feb;49(2):343–50

TOXICITY

Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine. Ferguson LR, et al. **Environ Mol Mutagen** 1996; 27(4):255–62

Cell cycle traverse in AHH-1 tk +/- human lymphoblastoid cells exposed to the chromosomal mutagen, m-amsa. Morris SM, et al. **Environ Mol Mutagen** 1996;27(1):10–8

AMYGDALA see **AMYGDALOID BODY**

AMYGDALIN

METABOLISM

Small-intestinal transfer mechanism of prunasin, the primary metabolite of the cyanogenic glycoside amygdalin. Strugala GJ, et al. **Hum Exp Toxicol** 1995 Nov;14(11):895-901

AMYGDALOID BODY

Recognizing facial emotion [letter] Hamann SB, et al. **Nature** 1996 Feb 8;379(6565):497

ABNORMALITIES

[Minor cranio-cervical injuries, cerebral malformations and chronic headaches] Foletti G, et al. **Rev Med Suisse Romande** 1995 Nov;115(11):901-3 (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Two distinct descending inputs to the cricothyroid motoneuron in the medulla originating from the amygdala and the lateral hypothalamic area. Arita H, et al. **Adv Exp Med Biol** 1995;393:53-8 (10 ref.)

The adrenergic innervation of the rat central amygdaloid nucleus: a light and electron microscopic immunocytochemical study using phenylethanolamine N-methyltransferase as a marker. Asan E. **Anat Embryol (Berl)** 1995 Nov;192(5):471-81

Quantitative MRI of the temporal lobe, amygdala, and hippocampus in normal human development: ages 4-18 years. Giedd JN, et al. **J Comp Neurol** 1996 Mar 4; 366(2):223-30

Temporal lobe lesion-induced obesity in rats: an anatomical investigation of the posterior amygdala and hippocampal formation. King BM, et al. **Physiol Behav** 1996 Apr-May; 59(4-5):843-8

CHEMISTRY

Allocation of perineuronal nets and parvalbumin-, calbindin-D28k- and glutamic acid decarboxylase-immunoreactivity in the amygdala of the rhesus monkey. Härtig W, et al. **Brain Res** 1995 Nov 6; 698(1-2):265-9

Connectivity between brainstem autonomic structures and expression of c-fos following electrical stimulation of the central nucleus of the amygdala in rat. Petrov T, et al. **Cell Tissue Res** 1996 Mar;283(3):367-74

Differential localization of NMDA and AMPA receptor subunits in the lateral and basal nuclei of the amygdala: a light and electron microscopic study. Farb CR, et al. **J Comp Neurol** 1995 Nov 6;362(1):86-108

Comparative ultrastructural localization of the NMDAR1 glutamate receptor in the rat basolateral amygdala and bed nucleus of the stria terminalis. Gracy KN, et al. **J Comp Neurol** 1995 Nov 6;362(1):71-85

Sexually dimorphic expression of androgen receptor immunoreactivity by somatostatin neurones in rat hypothalamic periventricular nucleus and bed nucleus of the stria terminalis. Herbison AE. **J Neuroendocrinol** 1995 Jul;7(7):543-53

Intra-amygdaloid projections of the basolateral and basomedial nuclei in the cat: Phaseolus vulgaris-leucoagglutinin anterograde tracing at the light and electron microscopic level. Paré D, et al. **Neuroscience** 1995 Nov;69(2):567-83

Opposite regulation by the beta-adrenoceptor-cyclic AMP system of synaptic plasticity in the medial and lateral amygdala in vitro. Watanabe Y, et al. **Neuroscience** 1996 Apr;71(4):1031-5

CYTOLOGY

Amygdala efferents form inhibitory-type synapses with a subpopulation of catecholaminergic neurons in the rat Nucleus tractus solitarius. Pickel VM, et al. **J Comp Neurol** 1995 Nov 27;362(4):510-23

Intrinsic connections of the rat amygdaloid complex: projections originating in the basal nucleus. Savander V, et al. **J Comp Neurol** 1995 Oct 16;361(2):345-68

Synaptology of prefrontal cortical projections to the basolateral amygdala: an electron microscopic study in the rat. Brinley-Reed M, et al. **Neurosci Lett** 1995 Dec 29; 202(1-2):45-8

Association between intermale social aggression and cellular density within the central amygdaloid nucleus in rats with lithium/pilocarpine-induced seizures. Desjardins D, et al. **Percept Mot Skills** 1995 Oct;81(2):635-41

[Topographic organization of the ventral striatum afferent projection from amygdaloid complex and hippocampal formation] Kunishio K, et al. **No To Shinkei** 1996 Jun; 48(6):534-42 (Eng. Abstr.) **(Jpn)**

[Projections of the tegmental ventral field, substantia nigra formations and amygdaloid nuclei to different segments of the caudate nucleus and nucleus accumbens in the dog] Gorbachevskaia AI. **Morfologiia** 1994 Apr-Jun; 106(4-6):63-74 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Effects of a microinjection of morphine into the amygdala on the acquisition and expression of conditioned fear and hypoalgesia in rats. Good AJ, et al. **Behav Neurosci** 1995 Aug;109(4):631-41

Taste-potentiated odor conditioning: impairment produced by infusion of an N-methyl-D-aspartate antagonist into basolateral amygdala. Hatfield T, et al. **Behav Neurosci** 1995 Aug;109(4):663-8

Effects of administration of cholecystokinin into the VTA on DA overflow in nucleus accumbens and amygdala of freely moving rats. Hamilton ME, et al. **Brain Res** 1995 Aug 7;688(1-2):134-42

Priming of experimental anxiety by repeated subthreshold GABA blockade in the rat amygdala. Sanders SK, et al. **Brain Res** 1995 Nov 20;699(2):250-9

Amygdaloid neurons respond to clozapine rather than haloperidol in behaving rats pretreated with intra-amygdaloid amphetamine. Wang Z, et al. **Brain Res** 1996 Mar 4;711(1-2):64-72

Effects of neurotensin on neurons in the rat central amygdaloid nucleus in vitro. Lu YF, et al. **Brain Res Bull** 1996;40(2):135-41

Inhibition of neurons in the rat medial amygdaloid nucleus in vitro by somatostatin. Lu YF, et al. **Can J Physiol Pharmacol** 1995 May;73(5):670-4

The alpha 2-adrenoreceptor agonist clonidine suppresses seizures, whereas the alpha 2-adrenoreceptor antagonist idazoxan promotes seizures in amygdala-kindled kittens: a comparison of amygdala and pontine microinfusion effects. Shouse MN, et al. **Epilepsia** 1996 Aug;37(8):709-17

Amygdaloid kindling by repeated focal N-methyl-D-aspartate administration: comparison with electrical kindling. Croucher MJ, et al. **Eur J Pharmacol** 1995 Nov 24;286(3):265-71

GABAA receptor antagonism in the extended amygdala decreases ethanol self-administration in rats. Hyytiä P, et al. **Eur J Pharmacol** 1995 Sep 5;283(1-3):151-9

NMDA and non-NMDA receptors contribute to synaptic transmission between the medial geniculate body and the lateral nucleus of the amygdala. Li XF, et al. **Exp Brain Res** 1995;105(1):87-100

Isoproterenol potentiates synaptic transmission primarily by enhancing presynaptic calcium influx via P- and/or Q-type calcium channels in the rat amygdala. Huang CC, et al. **J Neurosci** 1996 Feb 1;16(3):1026-33

Microinfusion of mu but not delta or kappa opioid agonists into the basolateral amygdala results in inhibition of the tail flick reflex in pentobarbital-anesthetized rats. Helmstetter FJ, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):381-8

The memory enhancing effects of cholecystokinin octapeptide are dependent on an intact stria terminalis. Flood JF, et al. **Neurobiol Learn Mem** 1995 Sep; 64(2):139-45

Amygdala beta-noradrenergic influences on memory storage involve cholinergic activation. Introini-Collison IB, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):57-64

Stimulation of the amygdala by glutamate facilitates corticotropin-releasing factor release from the median eminence and activation of the hypothalamic-pituitary-adrenal axis in stressed rats. Gabr RW, et al. **Neuroendocrinology** 1995 Oct;62(4):333-9

Different neuronal and glial cell groups in corticomedial amygdala react differently to neonatally administered estrogen. Drekić D, et al. **Neuroscience** 1995 May; 66(2):475-81

Investigations on the mechanism of tetrahydro-9-aminoacridine-induced presynaptic inhibition in the rat amygdala. Wang SJ, et al. **Neuroscience** 1996 Jan;70(2):409-15

Regulation of anxiety by GABAA receptors in the rat amygdala. Sanders SK, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):701-6

Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures: the amygdala is by far the most sensitive. Flood JF, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7; 92(23):10806-10

Prednisolone blocks extreme intermale social aggression in seizure-induced, brain-damaged rats: implications for the amygdaloid central nucleus, corticotrophin-releasing factor, and electrical seizures. Bedard AW, et al. **Psychol Rep** 1995 Aug;77(1):3-9

Behavioural activation produced by CRH but not alpha-helical CRH (CRH-receptor antagonist) when microinfused into the central nucleus of the amygdala under stress-free conditions. Wiersma A, et al. **Psychoneuroendocrinology** 1995;20(4):423-32

Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Heilig M. **Regul Pept** 1995 Oct 20;59(2):201-5

Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Liebsch G, et al. **Regul Pept** 1995 Oct 20; 59(2):229-39

EMBRYOLOGY

Neurogenesis of the sexually dimorphic vasopressin cells of the bed nucleus of the stria terminalis and amygdala of rats. al-Shamma HA, et al. **J Neurobiol** 1996 Jan;29(1):91-8

ENZYMOLOGY

The adrenergic innervation of the rat central amygdaloid nucleus: a light and electron microscopic immunocytochemical study using phenylethanolamine N-methyltransferase as a marker. Asan E. **Anat Embryol (Berl)** 1995 Nov;192(5):471-81

Fyn tyrosine kinase is required for normal amygdala kindling. Cain DP, et al. **Epilepsy Res** 1995 Oct;22(2):107-14

METABOLISM

Histoautoradiographic detection of oxytocin- and vasopressin-binding sites in the amygdala of the rat. Veinante P, et al. **Adv Exp Med Biol** 1995;395:347-8

Thrombopoietin and its alternatively spliced form are expressed in human amygdala and hippocampus [letter] Li B, et al. **Blood** 1996 Jun 15;87(12):5382-4

Effects of the dopamine D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Caine SB, et al. **Brain Res** 1995 Sep 18;692(1-2):47-56

Action potential-dependent output of 5-hydroxytryptamine in the anaesthetized rat amygdalopiriform cortex is strongly inhibited by tonic 5-HT1B-receptor stimulation. Kikvadze I, et al. **Brain Res** 1995 Sep 18;692(1-2):111-7

Effects of immobilization on in vivo release of norepinephrine in the bed nucleus of the stria terminalis in conscious rats. Pacak K, et al. **Brain Res** 1995 Aug 7;688(1-2):242-6

Catecholamine and NPY efferents from the ventrolateral medulla to the amygdala in the rat. Zardetto-Smith AM, et al. **Brain Res Bull** 1995;38(3):253-60

Changes in cholecystokinin mRNA expression after amygdala kindled seizures: an in situ hybridization study. Zhang LX, et al. **Brain Res Mol Brain Res** 1996 Jan; 35(1-2):278-84

The role of amygdala norepinephrine in memory formation: involvement in the memory enhancing effect of peripheral epinephrine. Liang KC, et al. **Chin J Physiol** 1995; 38(2):81-91

Regional increases in brain-derived neurotrophic factor and nerve growth factor mRNAs during amygdaloid kindling, but not in acidic and basist growth factor mRNAs. Sato K, et al. **Epilepsia** 1996 Jan;37(1):6-14

Time-course of neuropeptide changes in peri-ischemic zone and amygdala following focal ischemia in rats. Cheung RT, et al. **J Comp Neurol** 1995 Sep 11;360(1):101-20

Distribution of small vasopressinergic neurons in golden hamsters. Ferris CF, et al. **J Comp Neurol** 1995 Oct 2; 360(4):589-98

Distribution of parvalbumin-immunoreactive cells and fibers in the human amygdaloid complex. Sorvari H, et al. **J Comp Neurol** 1995 Sep 18;360(2):185-212

Convergent influence of the central nucleus of the amygdala and the paraventricular hypothalamic nucleus upon brainstem autonomic neurons as revealed by c-fos expression and anatomical tracing. Petrov T, et al. **J Neurosci Res** 1995 Dec 15;42(6):835-45

Focal cerebral ischemia induces CRH mRNA in rat cerebral cortex and amygdala. Wong ML, et al. **Neuroreport** 1995 Sep 11;6(13):1785-8

Rapid but transient increases in cholecystokinin mRNA levels in cerebral cortex following amygdaloid-kindled seizures in the rat. Burazin TC, et al. **Neurosci Lett** 1996 May 3; 209(1):65-8

Distinct pharmacological regulation of evoked dopamine efflux in the amygdala and striatum of the rat in vivo. Garris PA, et al. **Synapse** 1995 Jul;20(3):269-79

Dopamine transporter immunohistochemistry in median eminence, amygdala, and other areas of the rat brain. Revay R, et al. **Synapse** 1996 Feb;22(2):93-9

PATHOLOGY

Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey. Forno LS, et al. **Adv Neurol** 1996;69:217-28

Involvement of the amygdala, dentate and hippocampus in motor neuron disease. Anderson VE, et al. **J Neurol Sci** 1995 May;129 Suppl:75-8

Impaired gustatory neophobia following traumatic brain injury in rats. Hamm RJ, et al. **J Neurotrauma** 1995 Jun; 12(3):307-14

MRI of amygdala fails to diagnose early Alzheimer's disease. Laakso MP, et al. **Neuroreport** 1995 Nov 27;6(17):2414-8

Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Lehtovirta M, et al. **Neuroscience** 1995 Jul; 67(1):65-72

Manual and digitizer measurements of amygdalohippocampal volume: reliability in comparison to computer-based measurement. Hoshida T, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S223-5

[Histopathological analysis of herniated cerebellar tonsils resected from the patients with Chiari type I malformation with syringomyelia] Koga H, et al. **No To Shinkei** 1995 Nov;47(11):1075-9 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Evidence that the amygdala is involved in the inhibitory effects of 5-HT3 receptor antagonists on alcohol drinking in rats. Dyr W, et al. **Alcohol** 1995 Jul-Aug;12(4):387-91

Lesion of central nucleus of amygdala promotes fat gain without preventing effect of exercise on energy balance. Bovetto S, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R781–6

Basolateral amygdala lesions do not disrupt latent inhibition. Weiner I, et al. **Behav Brain Res** 1995 Dec 14;72(1–2):73–81

Effects of lesions to amygdala, ventral subiculum, medial prefrontal cortex, and nucleus accumbens on the reaction to novelty: implication for limbic–striatal interactions. Burns LH, et al. **Behav Neurosci** 1996 Feb;110(1):60–73

Amygdala stimulation enhances the rat eyeblink reflex through a short-latency mechanism. Canli T, et al. **Behav Neurosci** 1996 Feb;110(1):51–9

Differential effects of pretraining inactivation of the right or left amygdala on retention of inhibitory avoidance training. Coleman–Mesches K, et al. **Behav Neurosci** 1995 Aug;109(4):642–7

Disruptive effects of posttraining perirhinal cortex lesions on conditioned fear: contributions of contextual cues. Corodimas KP, et al. **Behav Neurosci** 1995 Aug; 109(4):613–9

Lateral habenula neurons are necessary for the hormonal onset of maternal behavior and for the display of postpartum estrus in naturally parturient female rats. Matthews–Felton T, et al. **Behav Neurosci** 1995 Dec; 109(6):1172–88

Anterior rhinal cortex and amygdala: dissociation of their contributions to memory and food preference in rhesus monkeys. Murray EA, et al. **Behav Neurosci** 1996 Feb; 110(1):30–42

Spared retention of inhibitory avoidance learning after posttraining amygdala lesions. Parent MB, et al. **Behav Neurosci** 1995 Aug;109(4):803–7

Brief, high-frequency stimulation of the corticomedial amygdala induces a delayed and prolonged increase of aggressiveness in male Syrian golden hamsters. Potegal M, et al. **Behav Neurosci** 1996 Apr;110(2):401–12

Hyperexcitability: exaggerated fear-potentiated startle produced by partial amygdala kindling. Rosen JB, et al. **Behav Neurosci** 1996 Feb;110(1):43–50

Amygdala central nucleus lesions attenuate acoustic startle stimulus–evoked heart rate changes in rats. Young BJ, et al. **Behav Neurosci** 1996 Apr;110(2):228–37

The limbic system of tetrapods: a comparative analysis of cortical and amygdalar populations. Bruce LL, et al. **Brain Behav Evol** 1995;46(4–5):224–34 (90 ref.)

Amygdaloid input to transiently tyrosine hydroxylase immunoreactive neurons in the bed nucleus of the stria terminalis of the rat. Beltramino CA, et al. **Brain Res** 1996 Jan 8;706(1):37–46

Amygdala kindling in rats with brainstem bisection. Chiba S, et al. **Brain Res** 1995 Jun 5;682(1–2):50–4

An electrophysiological characterization of the projection from the central nucleus of the amygdala to the periaqueductal gray of the rat: the role of opioid receptors. da Costa Gomez TM, et al. **Brain Res** 1995 Aug 14; 689(1):21–31

Simultaneous single unit recording in the medial nucleus of the medial geniculate nucleus and amygdaloid central nucleus throughout habituation, acquisition, and extinction of the rabbit's classically conditioned heart rate. McEchron MD, et al. **Brain Res** 1995 Jun 5;682(1–2):157–66

Potent and long-lasting anticonvulsant effects of 1-naphthylacetyl spermine, an analogue of Joro spider toxin, against amygdaloid kindled seizures in rats. Takazawa A, et al. **Brain Res** 1996 Jan 8;706(1):173–6

Different effect of hippocampal granule cell destruction on amygdaloid kindling in Sprague–Dawley and Wistar rats. Tsunoda K, et al. **Brain Res** 1995 Sep 11;691(1–2):18–24

Nitric oxide is involved in long-term potentiation in the medial but not lateral amygdala neuron synapses in vitro. Watanabe Y, et al. **Brain Res** 1995 Aug 7;688(1–2):233–6

Parabrachial nucleus projection to the amygdala in the rat: electrophysiological and anatomical observations. Jhamandas JH, et al. **Brain Res Bull** 1996;39(2):115–26

The possible involvement of the nonstrial pathway of the amygdala in neural control of sexual behavior in male rats. Kondo Y, et al. **Brain Res Bull** 1995;38(1):37–40

Effects of neurotensin on neurons in the rat central amygdaloid nucleus in vitro. Lu YF, et al. **Brain Res Bull** 1996;40(2):135–41

Effects of lesions of amygdaloid nuclei and substantia nigra on aversive responses induced by electrical stimulation of the inferior colliculus. Maisonnette SS, et al. **Brain Res Bull** 1996;40(2):93–8

Differential effects of unilateral lesions in the medial amygdala on spontaneous and induced ovulation. Sanchez MA, et al. **Brain Res Bull** 1995;38(4):313–7

Neuroanatomical and neurochemical mechanisms underlying amygdaloid control of defensive rage behavior in the cat. Shaikh MB, et al. **Braz J Med Biol Res** 1994 Dec; 27(12):2759–79 (43 ref.)

Connectivity between brainstem autonomic structures and expression of c-fos following electrical stimulation of the central nucleus of the amygdala in rat. Petrov T, et al. **Cell Tissue Res** 1996 Mar;283(3):367–74

Amygdala kindling of forebrain seizures and the occurrence of brainstem seizures in genetically epilepsy-prone rats. Coffey LL, et al. **Epilepsia** 1996 Feb;37(2):188–97

Repeated penicillin-induced amygdala epileptic focus in freely moving cats. EEG, polysomnographic (23-h recording), and brain mapping study. Fernández-Guardiola A, et al. **Epilepsy Res** 1995 Oct;22(2):127–36

The effect of amygdaloid kindling on heart period and heart period variability. Healy B, et al. **Epilepsy Res** 1995 Jun; 21(2):109–14

Antecedent tone presentation significantly delays rate of amygdala kindling. Hernandez TD, et al. **Epilepsy Res** 1995 Sep;22(1):35–41

Cholinergic activation of the electrocorticogram: an amygdaloid activating system. Dringenberg HC, et al. **Exp Brain Res** 1996 Mar;108(2):285–96

NMDA and non-NMDA receptors contribute to synaptic transmission between the medial geniculate body and the lateral nucleus of the amygdala. Li XF, et al. **Exp Brain Res** 1995;105(1):87–100

Information acquired by the hippocampus interferes with acquisition of the amygdala-based conditioned-cue preference in the rat. McDonald RJ, et al. **Hippocampus** 1995;5(3):189–97

The medial amygdaloid nucleus and medial preoptic area mediate steroidal control of sexual behavior in the male Syrian hamster. Wood RI, et al. **Horm Behav** 1995 Sep; 29(3):338–53

Organization of projections from the medial nucleus of the amygdala: a PHAL study in the rat. Canteras NS, et al. **J Comp Neurol** 1995 Sep 18;360(2):213–45

Efferent projections of the paraventricular thalamic nucleus in the rat. Moga MM, et al. **J Comp Neurol** 1995 Aug 21;359(2):221–38

Medial amygdala enhances synaptic transmission and synaptic plasticity in the dentate gyrus of rats in vivo. Ikegaya Y, et al. **J Neurophysiol** 1995 Nov;74(5):2201–3

Bursting and oscillating neurons of the cat basolateral amygdaloid complex in vivo: electrophysiological properties and morphological features. Paré D, et al. **J Neurophysiol** 1995 Sep;74(3):1179–91

Specific involvement of human parietal systems and the amygdala in the perception of biological motion. Bonda E, et al. **J Neurosci** 1996 Jun 1;16(11):3737–44

Role of the amygdala in the coordination of behavioral, neuroendocrine, and prefrontal cortical monoamine responses to psychological stress in the rat. Goldstein LE, et al. **J Neurosci** 1996 Aug 1;16(15):4787–98

The central nucleus of the amygdala contributes to the production of morphine antinociception in the rat tail-flick test. Manning BH, et al. **J Neurosci** 1995 Dec; 15(12):8199–213

Synaptic plasticity in the basolateral amygdala induced by hippocampal formation stimulation in vivo. Maren S, et al. **J Neurosci** 1995 Nov;15(11):7548–64

Nerve growth factor facilitates cholinergic neurotransmission between nucleus basalis and the amygdala in rat: an electrophysiological analysis. Moises HC, et al. **J Neurosci** 1995 Dec;15(12):8131–42

Projection cells and interneurons of the lateral and basolateral amygdala: distinct firing patterns and differential relation to theta and delta rhythms in conscious cats. Paré D, et al. **J Neurosci** 1996 May 15;16(10):3334–50

The amygdala and emotional memory [letter] Cahill L, et al. **Nature** 1995 Sep 28;377(6547):295–6

Influence of separate and combined septal and amygdala lesions on memory, acoustic startle, anxiety, and locomotor activity in rats. Decker MW, et al. **Neurobiol Learn Mem** 1995 Sep;64(2):156–68

Neuroanatomical and functional specificity of the basolateral amygdaloid nucleus in taste-potentiated odor aversion. Ferry B, et al. **Neurobiol Learn Mem** 1995 Sep;64(2):169–80

Memory for magnitude of reinforcement: dissociation between the amygdala and hippocampus. Kesner RP, et al. **Neurobiol Learn Mem** 1995 Nov;64(3):237–44

Fear conditioning enhances short-latency auditory responses of lateral amygdala neurons: parallel recordings in the freely behaving rat. Quirk GJ, et al. **Neuron** 1995 Nov; 15(5):1029–39

Amnesia after diazepam infusion into basolateral but not central amygdala of Rattus norvegicus. Silva MA, et al. **Neuropsychobiology** 1995;32(1):31–6

Quenching: inhibition of development and expression of amygdala kindled seizures with low frequency stimulation. Weiss SR, et al. **Neuroreport** 1995 Nov 13;6(16):2171–6

Single unit responses of the amygdala after conditioned taste aversion in conscious rats. Yasoshima Y, et al. **Neuroreport** 1995 Nov 27;6(17):2424–8

Recovery of behavioral functions following the transplantation of the embryonal striatum into the damaged amygdala of the rat brain. Ermakova IV, et al. **Neurosci Behav Physiol** 1996 Jan–Feb;26(1):11–2

High-frequency stimulation of the basolateral amygdala facilitates the induction of long-term potentiation in the dentate gyrus in vivo. Ikegaya Y, et al. **Neurosci Res** 1995 May;22(2):203–7

Responses of the medial prefrontal cortex to stimulation of the amygdala in the rat: a study with laminar field potential recording. Matsuda Y, et al. **Neurosci Res** 1995 Oct; 23(3):281–8

Relation of the enhancement of entorhinal tetanic responses by 50-Hz amygdala stimulation to the progression of kindling in the rat. Tanaka K, et al. **Neurosci Res** 1995 Oct;23(3):249–55

Susceptibility of different cell layers of the anterior and posterior part of the piriform cortex to electrical stimulation and kindling: comparison with the basolateral amygdala and "area tempestas". Löscher W, et al. **Neuroscience** 1995 May;66(2):265–76

Neuronal responsiveness to various sensory stimuli, and associative learning in the rat amygdala. Uwano T, et al. **Neuroscience** 1995 Sep;68(2):339–61

Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioral sensitization to amphetamine: comparison with N-methyl-D-aspartate antagonists. Wolf ME, et al. **Neuroscience** 1995 Nov;69(2):417–39

The central nucleus of the amygdala contributes to the production of morphine antinociception in the formalin test. Manning BH, et al. **Pain** 1995 Nov;63(2):141–52

Enhancements in swim stress–induced hypothermia, but not analgesia, following amygdala lesions in rats. Pavlovic ZW, et al. **Physiol Behav** 1996 Jan;59(1):77–82

Mercaptoacetate–induced feeding is impaired by central nucleus of the amygdala lesions. Ritter S, et al. **Physiol Behav** 1995 Dec;58(6):1215–20

Estradiol, but not dihydrotestosterone, in the medial amygdala facilitates male hamster sex behavior. Wood RI. **Physiol Behav** 1996 Apr–May;59(4–5):833–41

Amygdala role in conditioned associative learning. Ono T, et al. **Prog Neurobiol** 1995 Jul;46(4):401–22 (142 ref.)

Molecular changes of NMDA receptor subunit mRNA in amygdala–kindled rat. Kikuchi S, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S217–8

Epileptic activity in the cat perirhinal cortex in response to amygdala kindling. Orita A, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S290–2

[Role of the amygdaloid complex of the brain in the regulation of blood coagulation] Nadirian MV, et al. **Gematol Transfuziol** 1995 Sep–Oct;40(5):6–8 (Eng. Abstr.) **(Rus)**

[The amygdaloid body of the brain: some topics for discussion and little-studied problems] Akmaev IG, et al. **Usp Fiziol Nauk** 1995 Jan–Mar;26(1):3–24 (111 ref.) (Eng. Abstr.) **(Rus)**

[The role of the neurochemical mechanisms of the basolateral amygdaloid nucleus in anxiety states of different aversive origins] Talalaenko AN, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):184–7 **(Rus)**

[The role of the basolateral nuclei of the rat amygdala in organizing rapid food–acquisition movements] Moroz VM, et al. **Fiziol Zh** 1994 Sep–Dec;40(5–6):3–9 (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

There's no such thing as the amygdala [editorial] Kirkpatrick B. **Biol Psychiatry** 1996 Mar 1;39(5):309–10

Effect of electrolytic and chemical lesion by ibotenic acid of the amygdala on salt intake. Saad WA, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2903–7

Persistence of kindling: effect of partial kindling, retention interval, kindling site, and stimulation parameters. Dennison Z, et al. **Epilepsy Res** 1995 Jul;21(3):171–82

Amygdalar involvement in pain. Mena NB, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):339–46

Memory without context: amnesia with confabulations after infarction of the right capsular genu. Schnider A, et al. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):186–93

Amygdaloid nuclei lesions differentially affect glucocorticoid–induced memory enhancement in an inhibitory avoidance task. Roozendaal B, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):1–8

Role of dopamine D–1 and D–2 antagonists in a model of focal epilepsy induced by electrical stimulation of hippocampus and amygdala in the rabbit. Bo P, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):917–30

[Influence of aging on the unilateral and the contralateral amygdaloid kindling in rats] Kamata S. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):95–104 (Eng. Abstr.) **(Jpn)**

[The effect of stereotaxic injuries on the medial temporal brain structures on memorization of successively or simultaneously presented material] Luczywek E, et al. **Neurol Neurochir Pol** 1996 Jan–Feb;30(1):101–12 (Eng. Abstr.) **(Pol)**

SURGERY

Selective amygdalohippocampectomy for hippocampal sclerosis: postoperative MR appearance. Renowden SA, et al. **AJNR Am J Neuroradiol** 1995 Oct;16(9):1855–61

Stereotactic volumetric radiofrequency lesioning of intracranial structures for control of intractable seizures. Patil AA, et al. **Stereotact Funct Neurosurg** 1995; 64(3):123–33

First selective amygdalohippocampal radiosurgery for 'mesial temporal lobe epilepsy'. Régis J, et al. **Stereotact Funct Neurosurg** 1995;64 Suppl 1:193–201

[Psychiatric morbidity in connection with surgical treatment of epilepsy. A short-term follow-up of patients with amygdalohippocampectomy] Naylor AS, et al. **Ugeskr Laeger** 1995 Sep 18;157(38):5245–50 (Eng. Abstr.) **(Dan)**

ULTRASTRUCTURE

Amygdala N-methyl-D-aspartate receptors participate in the induction of long-term potentiation in the dentate gyrus in vivo. Ikegaya Y, et al. **Neurosci Lett** 1995 Jun 16; 192(3):193–6

Intra-amygdaloid projections of the basolateral and

basomedial nuclei in the cat: Phaseolus vulgaris-leucoagglutinin anterograde tracing at the light and electron microscopic level. Paré D, et al. **Neuroscience** 1995 Nov;69(2):567–83

VIROLOGY

Transneuronal spread of the pseudorabies virus after injection into the central nucleus of the amygdala in the rat. Jasmin L, et al. **Gene Ther** 1994;1 Suppl 1:S74

AMYGDALOSIDE see **AMYGDALIN**

AMYL NITRITE

Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite. Edwards RJ, et al. **J Accid Emerg Med** 1995 Jun;12(2):138–42 (41 ref.)

POISONING

[Acute voluntary poisoning by inhalation of "poppers" (letter)] Badoual T, et al. **Presse Med** 1996 Feb 24;25(7):304 **(Fre)**

AMYLASES

ADMINISTRATION & DOSAGE

Role of amylase-treated, energy-dense liquid diet in the nutritional management of acute shigellosis in children: a controlled clinical trial. Rahman MM, et al. **Acta Paediatr** 1995 Aug;84(8):867–72

Pancreatic enzyme supplementation in acute pancreatitis. Patankar RV, et al. **HPB Surg** 1995 Jun;8(3):159–62

ADVERSE EFFECTS

Gut inflammation in children with cystic fibrosis on high-dose enzyme supplements [see comments] Croft NM, et al. **Lancet** 1995 Nov 11;346(8985):1265–7. Comment in: Lancet 1996 Feb 3;347(8997):327.

Gut inflammation in children with cystic fibrosis on high-dose enzyme supplementation [letter; comment] Doull I, et al. **Lancet** 1996 Feb 3;347(8997):327. Comment on: Lancet 1995 Nov 11;346(8985):1265–7.

ANALYSIS

Elaboration of amylase activity and changes in paste viscosity of some common Indian legumes during germination. Sumathi A, et al. **Plant Foods Hum Nutr** 1995 Jun; 47(4):341–7

ANTAGONISTS & INHIBITORS

Vesicle-associated membrane protein 2 is essential for cAMP-regulated exocytosis in rat parotid acinar cells. The inhibition of cAMP-dependent amylase release by botulinum neurotoxin B. Fujita-Yoshigaki J, et al. **J Biol Chem** 1996 May 31;271(22):13130–4

BIOSYNTHESIS

[Acquired amylase production induced by radiotherapy in a myeloma patient] Yamakawa T, et al. **Rinsho Ketsueki** 1995 Oct;36(10):1175–81 (Eng. Abstr.) **(Jpn)**

BLOOD

Biochemical markers of cerebral injury in patients with minor head trauma and ethanol intoxication. Levitt MA, et al. **Acad Emerg Med** 1995 Aug;2(8):675–80

Origin of hyperamylasaemia in HIV-infected patients [letter] Boix V, et al. **AIDS** 1996 May;10(5):553–5

Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Gottlieb K, et al. **Am J Gastroenterol** 1996 Aug;91(8):1553–7

Serum Amylase elevation following hepatic resection in patients with chronic liver disease. Miyagawa S, et al. **Am J Surg** 1996 Feb;171(2):235–8

Pancreatitis with normal serum amylase associated with sodium valproate: a case report. Otusbo S, et al. **Brain Dev** 1995 May-Jun;17(3):219–21 (7 ref.)

Analytical evaluation of a newly developed ELISA mass assay for pancreatic amylase. Bhayana V, et al. **Clin Biochem** 1995 Jun;28(3):255–61

Serum lipase and amylase ratio in acute alcoholic and nonalcoholic pancreatitis by using Dupont ACA discrete clinical analyzer. Ansari E, et al. **Dig Dis Sci** 1996 Sep; 41(9):1823–7

Characteristics of choledochal cysts in neonates and early infants. Todani T, et al. **Eur J Pediatr Surg** 1995 Jun; 5(3):143–5

Does hyperamylasemia in choledochal cyst indicate true pancreatitis? An experimental study. Urushihara N, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):139–42

Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Testoni PA, et al. **Gastrointest Endosc** 1995 Oct;42(4):301–5

Hyperlipaemia intensifies the course of acute oedematous and acute necrotising pancreatitis in the rat. Hofbauer B, et al. **Gut** 1996 May;38(5):753–8

Effects of pancreatic duct ligation and aging on acute taurocholate-induced pancreatitis. Experiments in the perfused pancreas in rats. Kimura W, et al. **Int J Pancreatol** 1996 Apr;19(2):117–27

The effects of ruminal acidosis on volatile fatty acid absorption and plasma activities of pancreatic enzymes in lambs. Krehbiel CR, et al. **J Anim Sci** 1995 Oct; 73(10):3111–21

Early prediction of aetiology and severity of acute pancreatitis by serum amylase and lipase assays. Manes G, et al. **Minerva Gastroenterol Dietol** 1995 Sep;41(3):211–5

Hyperamylasaemia in multiple myeloma. Bloemendal HJ, et al. **Neth J Med** 1996 Jul;49(1):38–41

Carboxylic ester hydrolase and amylase in ischemic pancreatitis in the guinea pig. Blind PJ, et al. **Pancreas** 1996 May;12(4):388–95

Abnormal circulating pancreatic enzyme activities in more than twenty-five percent of recent-onset insulin-dependent diabetic patients: association of hyperlipasemia with high-titer islet cell antibodies. Belgian Diabetes Registry. Semakula C, et al. **Pancreas** 1996 May;12(4):321–33

Maternal serum amylase and lipase profiles in pregnancy [letter] Saade GR. **South Med J** 1996 Jul;89(7):741

Maternal serum amylase and lipase profiles in pregnancy: determinations in both once-sampled and multisampled patient cohorts. Xydas NP, et al. **South Med J** 1996 Feb; 89(2):199–203

Hyperamylasemia in kidney transplant recipients. Yokoyama I, et al. **Transplant Proc** 1996 Jun;28(3):1476–7

[Can the L/A ratio identify acute alcoholic pancreatitis?] Deltenre P, et al. **Acta Gastroenterol Belg** 1995 Mar-Apr; 58(2):222–9 (Eng. Abstr.) **(Fre)**

[Asymptomatic increase of pancreatic enzymes associated with ciprofloxacin therapy (letter)] Lambert M, et al. **Gastroenterol Clin Biol** 1996;20(3):316–7 **(Fre)**

[Macroamylase] Hayakawa T, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:442–4 (13 ref.) **(Jpn)**

[Serum amylase] Hayakawa T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:311–3 (7 ref.) **(Jpn)**

CHEMISTRY

Aggregation and concentration-dependent sorting of exocrine regulated secretory proteins. Gorr SU, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):82–8

Biochemical properties of amylase isozymes from Gammarus palustris. A comparative study. Guarna MM, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):619–28

GENETICS

RFLPs at the amylase 1 locus in cattle. Elduque C, et al. **Anim Genet** 1996 Jun;27(3):213

An EcoRI polymorphism at the amylase 1 (AMY1) locus in cattle. Elduque C, et al. **Anim Genet** 1995 Oct;26(5):367

Glucocorticoid receptor concentration modulates glucocorticoid-regulated gene expression in rat pancreatic AR42J cells. Kaiser A, et al. **Digestion** 1996;57(3):149–60

Molecular evolution of the duplicated Amy locus in the Drosophila melanogaster species subgroup: concerted evolution only in the coding region and an excess of nonsynonymous substitutions in speciation. Shibata H, et al. **Genetics** 1995 Sep;141(1):223–36

Variation in sex-, stage- and tissue-specific expression of the amylase genes in Drosophila ananassae. Da Lage JL, et al. **Heredity** 1996 Jan;76 (Pt 1):9–18

Cloning and sequencing analysis of three amylase cDNAs in the shrimp Penaeus vannamei (Crustacea decapoda): evolutionary aspects. Van Wormhoudt A, et al. **J Mol Evol** 1996 May;42(5):543–51

Adaptive significance of amylase polymorphism in Drosophila. X. Analysis of alpha-amylase activity of two amylase variants in individual Drosophila subobscura flies. Stojiljković V, et al. **Jpn J Genet** 1995 Aug;70(4):487–95

Interchromosomal exchange of genetic information between gene arrangements on the third chromosome of Drosophila pseudoobscura. Popadić A, et al. **Mol Biol Evol** 1995 Sep; 12(5):938–43

IMMUNOLOGY

[Interference of antibody reaction with porcine pancreatic amylase in enzymatic assay of total calcium] Uenishi E, et al. **Rinsho Byori** 1996 Apr;44(4):384–9 (Eng. Abstr.) **(Jpn)**

METABOLISM

High-affinity CCK receptors are coupled to phospholipase A2 pathways to mediate pancreatic amylase secretion. Tsunoda Y, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):G435–44

Interactions of streptococcal glucosyltransferases with alpha-amylase and starch on the surface of saliva-coated hydroxyapatite. Vacca-Smith AM, et al. **Arch Oral Biol** 1996 Mar;41(3):291–8

Normalization of pancreatic exocrine enzymes by islet transplantation in diabetic rats. Lee PC, et al. **Biochem Cell Biol** 1995 May-Jun;73(5–6):269–73

Effect of gamma-hexachlorocyclohexane on amylolytic microorganisms of soil and amylase activity. Zargar MY, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):426–30

Characterization and distribution of amylases during vegetative cell growth and sporulation of Clostridium perfringens. Shih NJ, et al. **Can J Microbiol** 1996 Jul; 42(7):628–33

Effect of genistein on amylase release and protein tyrosine phosphorylation in parotid acinar cells. Takuma T, et al. **FEBS Lett** 1996 Feb 12;380(1–2):83–6

Recepto-secretory mechanism in histamine-stimulated amylase release from rat parotid gland. Hashioka T. **Inflamm Res** 1995 Jun;44(6):245–7

Adrenalectomy induces a decrease in the light scatter properties and amylase content of isolated zymogen granules from rat pancreas as analyzed by flow cytometry. Garcia-Montero AC, et al. **J Endocrinol** 1995 Dec; 147(3):431–40

Improved energy intakes using amylase-digested weaning foods in Tanzanian children with acute diarrhea. Darling JC, et al. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):73–81

Endogenous amylase levels and response to supplemental feed enzymes in male turkeys from hatch to eight weeks of age. Ritz CW, et al. **Poult Sci** 1995 Aug;74(8):1317–22

[Preliminary study on physiology and biochemistry in Fritillaria thunbergii Miq. in the alternate process of new and old organs] Gao W, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Dec;20(12):719–21, 762 (Eng. Abstr.) **(Chi)**

[Improvement of result coherence in clinical enzymology: multicenter study of gamma-glutamyltransferase, alkaline phosphatase and amylase activities] Lessinger JM, et al. **Ann Biol Clin (Paris)** 1995;53(3):147–54 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Effect of amylase treatment on the consistency of cooked, fermented oat bran porridge. Raheem D. **Int J Food Sci Nutr** 1995 Aug;46(3):189–93

Salivary amylase promotes adhesion of oral streptococci to hydroxyapatite. Scannapieco FA, et al. **J Dent Res** 1995 Jul;74(7):1360–6

Growth and intestinal morphology of male turkeys as influenced by dietary supplementation of amylase and xylanase. Ritz CW, et al. **Poult Sci** 1995 Aug;74(8):1329–34

PHYSIOLOGY

Amylolytic enzymes and products derived from starch: a review. Guzmán-Maldonado H, et al. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):373–403 (190 ref.)

SECRETION

Ca(2+)-dependent amylase secretion from SLO-permeabilized rat pancreatic acini requires diffusible cytosolic proteins. Padfield PJ, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G647–52

EGF inhibits secretagogue-induced cAMP production and amylase secretion by Gi proteins in pancreatic acini. Stryjek-Kaminska D, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G676–82

Protein tyrosine kinase inhibitors promote amylase secretion and inhibit ornithine decarboxylase induction in sialagogue-stimulated rat parotid explants. Kinoshita F, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):170–4

Intracellular control of IP3-independent Ca2+ oscillations in pancreatic acini. Tsunoda Y, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):265–72

Regulation of phosphorylation of Gi2 alpha protein controls the secretory response to isoproterenol in rat parotid tissues. Amano I, et al. **Biochim Biophys Acta** 1996 Aug 28;1313(2):146–56

Epidermal growth factor induces the differential release of GP2 and amylase from AR4-2J cells. Koshlukova S, et al. **Cell Signal** 1995 Aug;7(6):559–69

Effect of beer, yeast-fermented glucose, and ethanol on pancreatic enzyme secretion in healthy human subjects. Chari ST, et al. **Dig Dis Sci** 1996 Jun;41(6):1216–24

Intracellular Ca2+ dynamics and in vitro secretory response in acute pancreatitis induced by a choline-deficient, ethionine-supplemented diet in mice. Okada N, et al. **Digestion** 1995;56(6):502–8

Inhibitory effect of thyrotropin-releasing hormone on enzyme secretion from isolated rat pancreatic acinar cells. Kemmer TP, et al. **Horm Metab Res** 1995 Aug;27(8):367–71

Chronic oral administration of synthetic trypsin inhibitor camostate reduces amylase release from isolated rat pancreatic acini. Otsuki M, et al. **Int J Pancreatol** 1995 Oct;18(2):135–43

The significance of membrane lipids in exocytosis: control of liposome-evoked amylase release from secretory granules isolated from the rat parotid gland. Mizuno-Kamiya M, et al. **J Biochem (Tokyo)** 1995 Oct; 118(4):693–9

Secretin potentiates cholecystokinin-stimulated amylase release by AR4-2J cells via a stimulation of phospholipase C. Bold RJ, et al. **J Cell Physiol** 1995 Oct;165(1):172–6

Betacellulin and activin A coordinately convert amylase-secreting pancreatic AR42J cells into insulin-secreting cells. Mashima H, et al. **J Clin Invest** 1996 Apr 1;97(7):1647–54

Tryptophan modulates exocrine secretory function in rat pancreatic acini. Okutani T, et al. **J Gastroenterol** 1996 Apr; 31(2):254–9

Evidence for involvement of a zymogen granule Na+/H+ exchanger in enzyme secretion from rat pancreatic acinar cells. Anderie I, et al. **J Membr Biol** 1996 Aug; 152(3):195–205

AMYLASES

Potentiation of cholecystokinin-induced amylase release by peptide VIP in guinea pig pancreatic acini. Tanaka K, et al. **Jpn J Physiol** 1995;45(2):241-56

Effect of adenosine and adenosine agonists on amylase release from rat pancreatic lobules. Rodríguez-Nodal F, et al. **Life Sci** 1995;57(17):PL253-8

Effect of vanadate on amylase secretion and protein tyrosine phosphatase activity in the rat parotid gland. Purushotham KR, et al. **Mol Cell Biochem** 1995 Nov 8;152(1):87-94

The role of magnesium in regulating CCK-8-evoked secretory responses in the exocrine rat pancreas. Wisdom DM, et al. **Mol Cell Biochem** 1996 Jan 26;154(2):123-32

Different implications of Ca2+i and and Ca2+e in CCK/gastrin-induced amylase secretion in AR4-2J cells. Bertrand V, et al. **Pancreas** 1995 Oct;11(3):230-5

Modulation of the relationship between amylase and chymotrypsinogen secretion in atropine- and MK329-infused rats. Maouyo D, et al. **Pancreas** 1995 Nov; 11(4):330-40

Pancreatic enzyme activity after a pylorus-preserving pancreaticoduodenectomy reconstructed with pancreaticogastrostomy. Takada T, et al. **Pancreas** 1995 Oct;11(3):276-82

Effects of diet on cholecystokinin-stimulated amylase secretion by pancreatic Acini and amylase mRNA levels in rat pancreas. Takaori K, et al. **Pancreas** 1995 Nov; 11(4):402-7

Effect of the microtubule-disrupting drug colchicine on rat cerulein-induced pancreatitis in comparison with the microtubule stabilizer taxol. Ueda T, et al. **Pancreas** 1995 Oct;11(3):294-302

Pituitary adenylate cyclase-activating peptide stimulates amylase release and cyclic adenosine monophosphate production in pancreatic acinar cells. Kimball BC, et al. **Surgery** 1996 Sep;120(3):554-9

URINE

Correlation between cystoscopic biopsy results and hypoamylasuria in bladder-drained pancreas transplants. Benedetti E, et al. **Surgery** 1995 Nov;118(5):864-72

AMYLOBARBITONE see **AMOBARBITAL**

AMYLOGLUCOSIDASE see **GLUCAN 1,4-ALPHA-GLUCOSIDASE**

AMYLOID

see related

AMYLOID NEUROPATHIES

[New pancreatic polypeptide amylin] German SV. **Klin Med (Mosk)** 1995;73(5):7-11 (51 ref.) **(Rus)**

ADMINISTRATION & DOSAGE

Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat. Clementi G, et al. **Experientia** 1996 Jul 15;52(7):677-9

ANALYSIS

Leptomeningeal amyloid and variant transthyretins [comment] Benson MD. **Am J Pathol** 1996 Feb; 148(2):351-4 (19 ref.). Comment on: Am J Pathol 1996 Feb;148(2):361-6.

Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Masliah E, et al. **Am J Pathol** 1996 Jan;148(1):201-10

Islet amyloid in type 2 (non-insulin-dependent) diabetes. Clark A, et al. **APMIS** 1996 Jan;104(1):12-8 (47 ref.)

Amylin-immunoreactivity is co-stored in a serotonin cell subpopulation of the vertebrate stomach and duodenum. D'Este L, et al. **Arch Histol Cytol** 1995 Dec;58(5):537-47

Interstitial amyloid deposits in the pituitary gland. Morphometry, immunohistology, and correlation to diseases. Röcken C, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1055-60

Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Kobayashi H, et al. **Br J Rheumatol** 1996 Jan;35(1):44-9

Comparative immunohistochemical distribution of amylin-like and calcitonin gene related peptide like immunoreactivity in the rat central nervous system. Skofitsch G, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):945-56

Hepatic amyloidosis in Japan: histological and morphometric analysis based on amyloid proteins. Iwata T, et al. **Hum Pathol** 1995 Oct;26(10):1148-53

[A rare cause of cardiopulmonary insufficiency] Scheffold N, et al. **Internist (Berl)** 1996 Apr;37(4):387-91 **(Ger)**

[Nature of pseudo-amyloid masses in lymphocytic pneumonitis] Kogan EA, et al. **Arkh Patol** 1995 Jul-Aug; 57(4):84-6 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden. Nitsch RM, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:175-82 (28 ref.)

Differential antagonism of amylin's metabolic and vascular actions with amylin receptor antagonists. Beaumont K, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1025-9

BIOSYNTHESIS

Differential activity of trans-acting hammerhead ribozymes targeted to beta amyloid peptide precursor mRNA by altering the symmetry of helices I and III. Denman RB, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):71-8

'In vitro' amyloid fibril formation from transthyretin: the influence of ions and the amyloidogenicity of TTR variants. Bonifácio MJ, et al. **Biochim Biophys Acta** 1996 May 24; 1316(1):35-42

Anti-amyloid drugs: potential in the treatment of diseases associated with aging. Kisilevsky R. **Drugs Aging** 1996 Feb; 8(2):75-83 (70 ref.)

Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. Westermark P, et al. **FEBS Lett** 1996 Feb 5;379(3):203-6

Pancreatic islet amyloid formation in patients with noninsulin-dependent diabetes mellitus. Implication for therapeutic strategy. Oosterwijk C, et al. **Int J Pancreatol** 1995 Aug;18(1):7-14 (68 ref.)

Extracellular matrix regulates the amount of the beta-amyloid precursor protein and its amyloidogenic fragments. Bronfman FC, et al. **J Cell Physiol** 1996 Feb; 166(2):360-9

Lung, ileum and heart are predilection sites for AApoAII amyloid deposition in CD-1 Swiss mice used for toxicity studies. Pulmonary amyloid indicates AApoAII. Gruys E, et al. **Lab Anim** 1996 Jan;30(1):28-34

Apolipoprotein E and amyloidogenesis [editorial; comment] Castaño EM, et al. **Lab Invest** 1995 Oct;73(4):457-60. Comment on: Lab Invest 1995 Oct;73(4):469-75.

Amyloid enhancing factor is produced by rats and amyloid-resistant CE/J mice. Gonnerman WA, et al. **Lab Invest** 1996 Jan;74(1):259-64

In vitro AL-amyloid formation by rat and human mesangial cells. Tagouri YM, et al. **Lab Invest** 1996 Jan;74(1):290-302

Amyloid formation in response to beta cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. Westermark G, et al. **Mol Med** 1995 Jul;1(5):542-53

Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Janson J, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7283-8

Amylin immunoreactivity in the rat trachea and characterization of the interaction of amylin and somatostatin on airway mucus secretion. Wagner U, et al. **Res Exp Med (Berl)** 1995;195(5):289-96

Glycation in neuropathies [letter; comment] Colaco C. **Trends Neurosci** 1995 Aug;18(8):341-2. Comment on: Trends Neurosci 1995 Apr;18(4):172-6.

BLOOD

Plasma amylin and insulin concentrations in normoglycemic and hyperglycemic cats. Lutz TA, et al. **Can Vet J** 1996 Jan;37(1):27-34

Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma [see comments] Percy AJ, et al. **Clin Chem** 1996 Apr;42(4):576-85. Comment in: Clin Chem 1996 Apr;42(4):495-5.

Increased plasma levels of islet amyloid polypeptide in patients with primary hyperparathyroidism. Valdermarsson S, et al. **Eur J Endocrinol** 1996 Mar;134(3):320-5

Lack of islet amyloid polypeptide/amylin-immunoreactivity in urine collected from healthy volunteers after ingestion of a carbohydrate-rich meal. van Hulst KL, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):177-9

Effect of race and hypertension on plasma amylin concentrations. Dimsdale JE, et al. **Hypertension** 1996 Jun; 27(6):1273-6

Alpha 2-adrenoceptors and the regulation of glucose, insulin and amylin levels in diabetic rats. Guillot E, et al. **Life Sci** 1995;57(23):2081-90

CHEMISTRY

C-terminal fragments of alpha- and beta-tubulin form amyloid fibrils in vitro and associate with amyloid deposits of familial cerebral amyloid angiopathy, British type. Baumann MH, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):238-42

The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis. Soto C, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):701-7

Effect of pH and insulin on fibrillogenesis of islet amyloid polypeptide in vitro. Chargé SB, et al. **Biochemistry** 1995 Nov 7;34(44):14588-93

The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Lai Z, et al. **Biochemistry** 1996 May 21; 35(20):6470-82

Toward understanding amyloid aggregation. Kominos D. **Biophys J** 1995 Sep;69(3):739-40

Alternative conformations of amyloidogenic proteins govern their behavior. Kelly JW. **Curr Opin Struct Biol** 1996 Feb; 6(1):11-7 (44 ref.)

Pathology of the vessels in cerebral amyloid angiopathy. Liberski PP, et al. **Folia Neuropathol** 1995;33(4):207-14 (68 ref.)

Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. Perfetti V, et al. **Haematologica** 1995 Sep-Oct;80(5):409-15

Pore formation by the cytotoxic islet amyloid peptide amylin. Mirzabekov TA, et al. **J Biol Chem** 1996 Jan 26; 271(4):1988-92

Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Gustavsson A, et al. **Lab Invest** 1995 Nov;73(5):703-8

Sand in the sheets [comment] Diehl SR. **Nat Med** 1995 Feb; 1(2):120-2. Comment on: Nat Med 1995 Feb;1(2):143-8.

Efficient transfection of DNA by mixing cells in suspension with calcium phosphate. Song W, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3609-11

Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Miyata T, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2353-8

Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. Schormann N, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9490-4

CLASSIFICATION

[Amyloidosis: definition and classification] Adle-Biassette H, et al. **Arch Anat Cytol Pathol** 1996;44(2-3):101-5 (Eng. Abstr.) **(Fre)**

[Classification of amyloidosis] Husby G. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):234-7 (40 ref.) (Eng. Abstr.) **(Nor)**

GENETICS

Genetic studies in Alzheimer's disease with an NACP/alpha-synuclein polymorphism. Xia Y, et al. **Ann Neurol** 1996 Aug;40(2):207-15

Insulin upstream factor 1 and a novel ubiquitous factor bind to the human islet amyloid polypeptide/amylin gene promoter. Bretherton-Watt D, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):495-502

An approach for identifying simple sequence repeat DNA polymorphisms near cloned cDNAs and genes. Linkage studies of the islet amyloid polypeptide/amylin and liver glycogen synthase genes and NIDDM. Gambino V, et al. **Diabetes** 1996 Mar;45(3):291-4

Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Sakagashira S, et al. **Diabetes** 1996 Sep; 45(9):1279-81

Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. Badman MK, et al. **FEBS Lett** 1996 Jan 15;378(3):227-31

Insertion of a pathogenic mutation into a yeast artificial chromosome containing the human amyloid precursor protein gene. Duff K, et al. **Gene Ther** 1994 Jan;1(1):70-5

Expression of human amyloid precursor proteins in cultured neuronal cells through the use of HSV-1 defective vectors. Wyborski RJ, et al. **Gene Ther** 1994;1 Suppl 1:S83

Identification and characterization of a kappa B/Rel binding site in the regulatory region of the amyloid precursor protein gene. Grilli M, et al. **J Biol Chem** 1995 Nov 10; 270(45):26774-7

Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Verchere CB, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3492-6

Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation. Ciulla TA, et al. **Surv Ophthalmol** 1995 Nov-Dec; 40(3):197-206 (123 ref.)

[Amylin: from humans and mice] Fehmann HC, et al. **Z Gastroenterol** 1995 Sep;33(9):551-2 **(Ger)**

IMMUNOLOGY

Potential of endogenous peptides to induce immunological reactions as observed in type I diabetes, a study in mice. Petersen KG, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(3):162-7

Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain. Sunaga K, et al. **Neurosci Lett** 1995 Nov 17;200(2):133-6

ISOLATION & PURIFICATION

Apolipoprotein AI-derived pulmonary vascular amyloid in aged dogs. Roertgen KE, et al. **Am J Pathol** 1995 Nov; 147(5):1311-7

Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Westermark P, et al. **Am J Pathol** 1995 Nov;147(5):1186-92

Western blot mapping of disease-specific amyloid in various animal species and humans with transmissible spongiform encephalopathies using a high-yield purification method. Beekes M, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2567-76

Diagnosing amyloidosis [editorial] Westermark P. **Scand J Rheumatol** 1995;24(6):327-9 (12 ref.)

METABOLISM

Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden. Nitsch RM, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:175-82 (28 ref.)

Binding sites for islet amyloid polypeptide in mammalian lung: species variation and effects on adenylyl cyclase. Bhogal R, et al. **Can J Physiol Pharmacol** 1995 Jul;

73(7):1030–6
Extremely active murine amyloid enhancing factor. Shtrasburg S, et al. **Clin Exp Rheumatol** 1996 Jan–Feb; 14(1):37–42
Rapid deposition of amyloid in human islets transplanted into nude mice. Westermark P, et al. **Diabetologia** 1995 May; 38(5):543–9
Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. De Strooper B, et al. **EMBO J** 1995 Oct 16;14(20):4932–8
Glycosaminoglycans in intervertebral disc amyloid deposits. Athanasou NA, et al. **Eur Spine J** 1995;4(5):308–12
Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. Badman MK, et al. **FEBS Lett** 1996 Jan 15;378(3):227–31
Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis. Brancaccio D, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1262–70
Gerstmann–Sträussler–Scheinker disease (PRNP P102L): amyloid deposits are best recognized by antibodies directed to epitopes in PrP region 90–165. Piccardo P, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):790–801
Islet amyloid polypeptide (amylin) is expressed in sensory neurons. Mulder H, et al. **J Neurosci** 1995 Nov; 15(11):7625–32
Beta 2 microglobulin isoforms in healthy individuals and in amyloid deposits. Argilés A, et al. **Kidney Int** 1995 Nov; 48(5):1397–405
Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity. Young AA, et al. **Metabolism** 1995 Dec;44(12):1581–9
Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents. Mulder H, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):101–9
Amyloid formation in response to beta cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. Westermark G, et al. **Mol Med** 1995 Jul;1(5):542–53
Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome [see comments] Teller JK, et al. **Nat Med** 1996 Jan;2(1):93–5. Comment in: Nat Med 1996 Jan;2(1):31–2.
Highly sulphated glycosaminoglycans in articular cartilage and other tissues containing beta 2 microglobulin dialysis amyloid deposits. Athanasou NA, et al. **Nephrol Dial Transplant** 1995;10(9):1672–8
Amyloid deposition in the thyroid gland in patients with amyloidosis: an incidence study with fine-needle aspiration biopsy of the thyroid [letter] Ertürk S, et al. **Nephrol Dial Transplant** 1995;10(8):1473
Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Morris JC, et al. **Neurology** 1996 Mar; 46(3):707–19
Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Nagy Z, et al. **Neuroscience** 1995 Dec; 69(3):757–61
Pancreatic amylin content in human diabetic subjects and its relation to diabetes. Tasaka Y, et al. **Pancreas** 1995 Oct; 11(3):303–8
Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Verchere CB, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3492–6
NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Yoshimoto M, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9141–5
The amyloid peptide and its precursor in Alzheimer's disease. Octave JN. **Rev Neurosci** 1995 Oct–Dec;6(4):287–316 (289 ref.)

PHARMACOKINETICS

Permeability of the blood–brain barrier to amylin. Banks WA, et al. **Life Sci** 1995;57(22):1993–2001

PHARMACOLOGY

Regulation of muscle glycogen metabolism by CGRP and amylin: CGRP receptors not involved. Beaumont K, et al. **Br J Pharmacol** 1995 Jul;115(5):713–5
Effects of amylin on appetite regulation and memory. Morley JE, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1042–6 (60 ref.)
Inhibitory effect of amylin (islet amyloid polypeptide) on insulin response to non-glucose stimuli. Study in perfused rat pancreas. Salas M, et al. **Diabete Metab** 1995 Oct; 21(4):269–73
Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat. Clementi G, et al. **Experientia** 1996 Jul 15;52(7):677–9
Amylin-induced relaxation of the perfused mesenteric arterial bed: meditation by calcitonin gene-related peptide receptors. Westfall TC, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):932–6
The amyloidogenic peptide human amylin augments the inflammatory activities of eosinophils. Hom JT, et al. **J Leukoc Biol** 1995 Nov;58(5):526–32
Hypertrophic effects of calcitonin gene-related peptide (CGRP) and amylin on adult mammalian ventricular cardiomyocytes. Bell D, et al. **J Mol Cell Cardiol** 1995 Nov;27(11):2433–43
Anti-inflammatory activity of amylin and CGRP in different experimental models of inflammation. Clementi G, et al. **Life Sci** 1995;57(14):PL193–7
Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7–36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Young AA, et al. **Metabolism** 1996 Jan; 45(1):1–3
Inhibitory effect of amylin on growth hormone responsiveness to growth-hormone-releasing hormone in the rat. Netti C, et al. **Neuroendocrinology** 1995 Sep; 62(3):313–8
Amylin decreases meal size in rats. Lutz TA, et al. **Physiol Behav** 1995 Dec;58(6):1197–202
Activity of amylin at CGRP1-preferring receptors coupled to positive contractile response in rat ventricular cardiomyocytes. Bell D, et al. **Regul Pept** 1995 Dec 14; 60(2–3):125–33
Pharmacology of receptors for calcitonin gene-related peptide and amylin. Poyner D. **Trends Pharmacol Sci** 1995 Dec;16(12):424–8 (56 ref.)
Circadian anorectic effects of peripherally administered amylin in rats. Lutz TA, et al. **Z Ernahrungswiss** 1995 Sep; 34(3):214–9

PHYSIOLOGY

Amyloid fibril toxicity in Alzheimer's disease and diabetes. Lorenzo A, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:89–95 (12 ref.)
Lactate production from the rat hindlimb is increased after glucose administration and is suppressed by a selective amylin antagonist: evidence for action of endogenous amylin in skeletal muscle. Vine W, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):554–9
Amylin—a glucoregulatory hormone involved in the pathogenesis of diabetes mellitus? [editorial; comment] Sacks DV. **Clin Chem** 1996 Apr;42(4):494–5. Comment on: Clin Chem 1996 Apr;42(4):576–85.
Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Couce M, et al. **Diabetes** 1996 Aug;45(8):1094–101
1995 EASD meetings. Immunology, insulin, amylin, obesity, retinopathy, and neuropathy [news] Bloomgarden ZT. **Diabetes Care** 1996 May;19(5):550–4
The age related amyloids: a growing family of unique biochemical substances. Cornwell GG 3rd, et al. **J Clin Pathol** 1995 Nov;48(11):984–9 (41 ref.)
Amyloid associated muscle pseudohypertrophy: amelioration of motor dysfunction with plasmapheresis and dimethylsulphoxide [letter] Komiyama A, et al. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):591–2

SECRETION

Inhibition of protein phosphatase 1 stimulates secretion of Alzheimer amyloid precursor protein. da Cruz e Silva EF, et al. **Mol Med** 1995 Jul;1(5):535–41
Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans. Larsson H, et al. **Pancreas** 1995 Aug;11(2):201–5
Osseous metaplasia associated with amyloid-producing plasmacytoma of bone: a report of two cases. Karasick D, et al. **Skeletal Radiol** 1996 Apr;25(3):263–7

THERAPEUTIC USE

Compound could help diabetic patients walk tightrope between heperglycemia, hypoglycemia. Lowry F. **Can Med Assoc J** 1996 Mar 1;154(5):705–7
Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Kolterman OG, et al. **Diabetes Care** 1995 Aug; 18(8):1179–82
Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Kolterman OG, et al. **Diabetologia** 1996 Apr;39(4):492–9

ULTRASTRUCTURE

Effect of pH and insulin on fibrillogenesis of islet amyloid polypeptide in vitro. Chargé SB, et al. **Biochemistry** 1995 Nov 7;34(44):14588–93
Examination of the structure of the transthyretin amyloid fibril by image reconstruction from electron micrographs. Serpell LC, et al. **J Mol Biol** 1995 Nov 24;254(2):113–8

URINE

Lack of islet amyloid polypeptide/amylin-immunoreactivity in urine collected from healthy volunteers after ingestion of a carbohydrate-rich meal. van Hulst KL, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):177–9

AMYLOID A PROTEIN see **AMYLOID PROTEIN AA**

AMYLOID A4 PROTEIN PRECURSOR see **AMYLOID BETA-PROTEIN PRECURSOR**

AMYLOID ANGIOPATHY, CEREBRAL see **CEREBRAL AMYLOID ANGIOPATHY**

AMYLOID BETA-PROTEIN

see related
CEREBRAL AMYLOID ANGIOPATHY

Beta-amyloidosis in normal aging and transmitter signaling in human temporal lobe. Perry EK, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:388–92
[Trial to produce animal model of Alzheimer's disease by continuous infusion of beta-amyloid protein into the rat cerebral ventricle] Nabeshima T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Oct; 15(5):411–8 (27 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Amyloid, aluminium and the aetiology of Alzheimer's disease [see comments] Storey E, et al. **Med J Aust** 1995 Sep 4; 163(5):256–9 (49 ref.). Comment in: Med J Aust 1996 Feb 19;164(4):252–3. Comment in: Med J Aust 1996 Mar 18;164(6):382–3.
Amyloid, aluminium and the aetiology of Alzheimer's disease [letter; comment] Walton JR. **Med J Aust** 1996 Mar 18; 164(6):382–3. Comment on: Med J Aust 1995 Sep 4;163(5):256–9.
Reversal of beta-amyloid-induced retention deficit after exposure to training and state cues. McDonald MP, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):35–47
Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion. Pollack SJ, et al. **Neurosci Lett** 1995 Sep 15;197(3):211–4

ANALOGS & DERIVATIVES

Properties of some peptides related to amyloid beta-peptide. el-Agnaf OM, et al. **Biochem Soc Trans** 1996 Feb;24(1):59S
Suppression of mitochondrial succinate dehydrogenase, a primary target of beta-amyloid, and its derivative racemized at Ser residue. Kaneko I, et al. **J Neurochem** 1995 Dec;65(6):2585–93

ANALYSIS

High levels of circulating beta-amyloid peptide do not cause cerebral beta-amyloidosis in transgenic mice. Fukuchi K, et al. **Am J Pathol** 1996 Jul;149(1):219–27
Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques. Fukumoto H, et al. **Am J Pathol** 1996 Jan; 148(1):259–65
P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Higgins LS, et al. **Am J Pathol** 1996 Aug; 149(2):585–96
Electrophoretic separation of betaA4 peptides (1–40) and (1–42). Klafki HW, et al. **Anal Biochem** 1996 May 15; 237(1):24–9
Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). Mann DM, et al. **Ann Neurol** 1996 Aug; 40(2):149–56
Amyloid beta protein and its 3-kDa fragment are present in the axoplasm fraction of the white matter in human brain. Tokuda T, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):165–9
Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Jefferies WA, et al. **Brain Res** 1996 Mar 11;712(1):122–6
Quantitation of Alzheimer's amyloid peptide and identification of related amyloid proteins by dot-blot immunoassay. Permanne B, et al. **Brain Res** 1995 Jul 10; 685(1–2):154–62
Size heterogeneity of amyloid fibril proteins of beta-2-microglobulin origin in hemodialysis and disease-specific antibodies. Linke RP, et al. **Contrib Nephrol** 1995;112:65–76
Dementia characterized by abundant neurofibrillary tangles and scarce senile plaques: a quantitative pathological study. Itoh, et al. **Eur Neurol** 1996;36(2):94–7
High-resolution separation of amyloid beta-peptides: structural variants present in Alzheimer's disease amyloid. Näslund J, et al. **J Neurochem** 1996 Jul;67(1):294–301
Increased serum neopterin concentrations in a patient with Creutzfeldt-Jakob disease [letter] Leblhuber F, et al. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):211–2
Colocalization of lysosomal hydrolase and beta-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimer's disease and Down's syndrome. Cataldo AM, et al. **J Neuropathol Exp Neurol** 1996 Jun;55(6):704–15
Immunohistochemical characterization of alterations in the distribution of amyloid precursor proteins and beta-amyloid peptide after experimental brain injury in the rat. Pierce JE, et al. **J Neurosci** 1996 Feb 1;16(3):1083–90
Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein [see comments] Polvikoski T, et al. **N Engl J Med** 1995 Nov 9;333(19):1242–7. Comment in: N Engl J Med 1995 Nov 9;333(19):1283–4. Comment in: N Engl J Med 1996 Feb 29;334(9):599–600.
Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury [see comments] Nicoll JA, et al. **Nat Med** 1995 Feb;1(2):135–7

. Comment in: Nat Med 1995 Jul;1(7):603–4. Comment in: Nat Med 1995 Sep;1(9):852.

Factors determining the morphology of beta-amyloid (A beta) deposits in Down's syndrome. Armstrong RA. **Neurodegeneration** 1995 Jun;4(2):179–86

Association of A beta 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. Fukumoto H, et al. **Neurodegeneration** 1996 Mar;5(1):13–7

Microwave treatment enhances the immunostaining of amyloid deposits in both the transmissible and non-transmissible brain amyloidoses. Liberski PP, et al. **Neurodegeneration** 1996 Mar;5(1):95–9

Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly. Zhan SS, et al. **Neurodegeneration** 1995 Sep;4(3):291–7

Granules in glial cells of patients with Alzheimer's disease are immunopositive for C-terminal sequences of beta-amyloid protein. Akiyama H, et al. **Neurosci Lett** 1996 Mar 15;206(2–3):169–72

Is the clustering of beta-amyloid (A beta) deposits in the frontal cortex of Alzheimer patients determined by blood vessels? Armstrong RA. **Neurosci Lett** 1995 Aug 4; 195(2):121–4

Amyloid beta protein in rat soleus muscle in chloroquine-induced myopathy using end-specific antibodies for A beta 40 and A beta 42: immunohistochemical evidence for amyloid beta protein. Tsuzuki K, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):77–80

Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Hsiao K, et al. **Science** 1996 Oct 4;274(5284):99–102

ANTAGONISTS & INHIBITORS

A new compound (AZ36041) promotes the survival of the neurons and reduces neurotoxicity of Alzheimer's beta-amyloid protein. Hasegawa Y, et al. **Biol Pharm Bull** 1995 Dec;18(12):1750–4

Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. Tomiyama T, et al. **J Biol Chem** 1996 Mar 22;271(12):6839–44

Selective inhibition of Abeta fibril formation. Wood SJ, et al. **J Biol Chem** 1996 Feb 23;271(8):4086–92

Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease. Schenk DB, et al. **J Med Chem** 1995 Oct 13;38(21):4141–54 (181 ref.)

Inhibition of beta A4 production by specific modulation of beta-secretase activity. Urmoneit B, et al. **J Mol Neurosci** 1995;6(1):23–32

Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion. Pollack SJ, et al. **Neurosci Lett** 1995 Sep 15;197(3):211–4

Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Gozes I, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):427–32

BIOSYNTHESIS

The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Selkoe DJ, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:57–64 (19 ref.)

Missense mutations associated with familial Alzheimer's disease in Sweden lead to the production of the amyloid peptide without internalization of its precursor. Essalmani R, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):89–96

Intracellular generation of amyloid beta-protein from amyloid beta-protein precursor fragment by direct cleavage with beta- and gamma-secretase. Iizuka T, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):238–42

Nuclear and cytoplasmic localization of the beta-amyloid peptide (1–43) in transfected 293 cells. Johnstone EM, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):710–8

Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. De Strooper B, et al. **EMBO J** 1995 Oct 16;14(20):4932–8

Baculovirus-infected cells do not produce the amylcid peptide of Alzheimer's disease from its precursor. Essalmani R, et al. **FEBS Lett** 1996 Jul 1;389(2):157–61

A mechanism for beta-amyloid overproduction in Alzheimer's disease: precursor-independent generation of beta-amyloid via antisense RNA-primed mRNA synthesis. Volloch V. **FEBS Lett** 1996 Jul 22;390(2):124–8 (31 ref.)

Beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25–35) and lipopolysaccharide. Bitting L, et al. **J Biol Chem** 1996 Jul 5;271(27):16084–9

Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. Bodovitz S, et al. **J Biol Chem** 1996 Feb 23;271(8):4436–40

Differential effects of a Rab6 mutant on secretory versus amyloidogenic processing of Alzheimer's beta-amyloid precursor protein. McConlogue L, et al. **J Biol Chem** 1996 Jan 19;271(3):1343–8

Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. Nitsch RM, et al. **J Biol Chem** 1996 Feb 23;271(8):4188–94

Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus. Thinakaran G, et al. **J Biol Chem** 1996 Apr 19; 271(16):9390–7

The production of an amyloidogenic metabolite of the Alzheimer amyloid beta precursor protein (APP) in thyroid cells is stimulated by interleukin 1 beta, but inhibited by interferon gamma. Schmitt TL, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1666–9

Increased production of 4 kDa amyloid beta peptide in serum deprived human primary neuron cultures: possible involvement of apoptosis. LeBlanc A. **J Neurosci** 1995 Dec; 15(12):7837–46

Amyloidogenic processing of the human amyloid precursor protein in primary cultures of rat hippocampal neurons. Simons M, et al. **J Neurosci** 1996 Feb 1;16(3):899–908

Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome [see comments] Teller JK, et al. **Nat Med** 1996 Jan;2(1):93–5. Comment in: Nat Med 1996 Jan;2(1):31–2.

Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Link CD. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9368–72

[Inclusion body myositis] Serratrice G. **Presse Med** 1996 Jun 15;25(21):985–8 (23 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs. Martel CL, et al. **Neurosci Lett** 1996 Mar 15; 206(2–3):157–60

CEREBROSPINAL FLUID

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Motter R, et al. **Ann Neurol** 1995 Oct;38(4):643–8

Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain. Pirttilä T, et al. **Arch Neurol** 1996 Feb;53(2):189–93

Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Koudinov AR, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):592–7

Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Southwick PC, et al. **J Neurochem** 1996 Jan;66(1):259–65

CHEMISTRY

Alzheimer's disease amyloid beta peptide 25–35 is localized in the membrane hydrocarbon core: x-ray diffraction analysis. Mason RP, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):78–82

The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis. Soto C, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):701–7

Properties of some peptides related to amyloid beta-peptide. el-Agnaf OM, et al. **Biochem Soc Trans** 1996 Feb;24(1):59S

The interaction of the neurodegenerative fragment of the beta-amyloid peptide with phospholipid membranes. van Veen M, et al. **Biochem Soc Trans** 1995 Nov;23(4):547S

Conformations of synthetic beta peptides in solid state and in aqueous solution: relation to toxicity in PC12 cells. Buchet R, et al. **Biochim Biophys Acta** 1996 Jan 17; 1315(1):40–6

In vitro fibril formation from alpha 1-antitrypsin-derived C-terminal peptides. Janciauskiene S, et al. **Biol Chem Hoppe Seyler** 1995 Jul;376(7):415–23

Toward understanding amyloid aggregation. Kominos D. **Biophys J** 1995 Sep;69(3):739–40

Solvent effects on self-assembly of beta-amyloid peptide. Shen CL, et al. **Biophys J** 1995 Aug;69(2):640–51

Structure of amyloid A4-(1–40)-peptide of Alzheimer's disease. Sticht H, et al. **Eur J Biochem** 1995 Oct 1; 233(1):293–8

Interaction between human amphipathic apolipoproteins and amyloid beta-peptide: surface plasmon resonance studies. Shuvaev VV, et al. **FEBS Lett** 1996 Mar 25;383(1–2):9–12

Correlation among secondary structure, amyloid precursor protein accumulation, and neurotoxicity of amyloid beta(25–35) peptide as analyzed by single alanine substitution. Sato K, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1108–11

Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. Kuo YM, et al. **J Biol Chem** 1996 Feb 23;271(8):4077–81

Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. Pike CJ, et al. **J Biol Chem** 1995 Oct 13;270(41):23895–8

Amyloid beta-protein and the genetics of Alzheimer's disease. Selkoe DJ. **J Biol Chem** 1996 Aug 2; 271(31):18295–8 (93 ref.)

Conformational analysis of the beta-amyloid peptide fragment, beta(12–28). Jayawickrama D, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):229–44

Self-association of beta-amyloid peptide (1–40) in solution and binding to lipid membranes. Terzi E, et al. **J Mol Biol** 1995 Oct 6;252(5):633–42

Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta. Wood SJ, et al. **J Mol Biol** 1996 Mar 15; 256(5):870–7

Zinc-induced aggregation of human and rat beta-amyloid peptides in vitro. Esler WP, et al. **J Neurochem** 1996 Feb; 66(2):723–32

Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide [see comments] Lansbury PT Jr, et al. **Nat Struct Biol** 1995 Nov;2(11):990–8. Comment in: Nat Struct Biol 1995 Nov;2(11):926–8.

Untangling the pathophysiochemistry of beta-amyloid [news; comment] Mattson MP. **Nat Struct Biol** 1995 Nov; 2(11):926–8. Comment on: Nat Struct Biol 1995 Nov;2(11):990–8.

Soluble multimeric Alzheimer beta(1–40) pre-amyloid complexes in dilute solution. Levine H 3rd. **Neurobiol Aging** 1995 Sep–Oct;16(5):755–64

beta-Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for Alzheimer's disease. Harris ME, et al. **Neuroreport** 1995 Oct 2;6(14):1875–9

Fibrillogenesis of synthetic amyloid-beta peptides is dependent on their initial secondary structure. Soto C, et al. **Neurosci Lett** 1995 Nov 17;200(2):105–8

On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Lomakin A, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1125–9

Misfolding the way to disease [news] Taubes G. **Science** 1996 Mar 15;271(5255):1493–5

GENETICS

Missense mutations associated with familial Alzheimer's disease in Sweden lead to the production of the amyloid peptide without internalization of its precursor. Essalmani R, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):89–96

A beta A4 amyloid precursor protein gene and Alzheimer's disease. Hendriks L, et al. **Eur J Biochem** 1996 Apr 1; 237(1):6–15 (123 ref.)

A mechanism for beta-amyloid overproduction in Alzheimer's disease: precursor-independent generation of beta-amyloid via antisense RNA-primed mRNA synthesis. Volloch V. **FEBS Lett** 1996 Jul 22;390(2):124–8 (31 ref.)

Amyloid beta-protein and the genetics of Alzheimer's disease. Selkoe DJ. **J Biol Chem** 1996 Aug 2; 271(31):18295–8 (93 ref.)

Amyloid, aluminum and the aetiology of Alzheimer's disease [letter; comment] Exley C. **Med J Aust** 1996 Feb 19; 164(4):252–3. Comment on: Med J Aust 1995 Sep 4;163(5):256–9.

Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Link CD. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9368–72

IMMUNOLOGY

Development and characterization of a monoclonal antibody 369.2B specific for the carboxyl-terminus of the beta A4 peptide. König G, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:344–55

Thrombin causes cell spreading and redistribution of beta-amyloid immunoreactivity in cultured hippocampal neurons. Brewer GJ. **J Neurochem** 1996 Jul;67(1):119–30

Early amyloid-beta deposits show different immunoreactivity to the amino- and carboxy-terminal regions of beta-peptide in Alzheimer's disease and Down's syndrome brain. Kida E, et al. **Neurosci Lett** 1995 Jun 30;193(2):105–8

Ubiquitinated inclusions in inclusion-body myositis patients are immunoreactive for cathepsin D but not beta-amyloid. Sherriff FE, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):37–40

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Solomon B, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):452–5

METABOLISM

beta PP and Tau interaction. A possible link between amyloid and neurofibrillary tangles in Alzheimer's disease. Giaccone G, et al. **Am J Pathol** 1996 Jan;148(1):79–87

Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Mann DM, et al. **Am J Pathol** 1996 Apr;148(4):1257–66

Selective binding of soluble Abeta1–40 and Abeta1–42 to a subset of senile plaques. Prior R, et al. **Am J Pathol** 1996 Jun;148(6):1749–56

Dehydroepiandrosterone augments M1-muscarinic receptor-stimulated amyloid precursor protein secretion in desensitized PC12M1 cells. Danenberg HD, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:300–3

Amyloid beta-protein, APOE genotype and head injury. Nicoll JA, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:271–5 (9 ref.)

Synergistic induction of nitric oxide by beta-amyloid and cytokines in astrocytes. Rossi F, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):474–8

Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Webster S, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):869–75

Apolipoprotein J and Alzheimer's amyloid beta solubility. Matsubara E, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):671–9

Lysosomal processing of amyloid precursor protein to A beta

peptides: a distinct role for cathepsin S. Munger JS, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):299-305

Amyloid beta 1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs. Wisniewski T, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):575-80

Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide A beta. Chan W, et al. **Biochemistry** 1996 Jun 4;35(22):7123-30

In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics. Esler WP, et al. **Biochemistry** 1996 Jan 23;35(3):749-57

Candidate gamma-secretases in the generation of the carboxyl terminus of the Alzheimer's disease beta A4 amyloid: possible involvement of cathepsin D. Evin G, et al. **Biochemistry** 1995 Oct 31;34(43):14185-92

Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's beta-amyloid peptide in cultured vascular smooth muscle cells. Mazur-Kolecka B, et al. **Brain Res** 1995 Nov 6; 698(1-2):217-22

Production and increased detection of amyloid beta protein and amyloidogenic fragments in brain microvessels, meningeal vessels and choroid plexus in Alzheimer's disease. Kalaria RN, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1-2):58-68

The role of beta-amyloid in the development of Alzheimer's disease. Ii K. **Drugs Aging** 1995 Aug;7(2):97-109 (154 ref.)

beta-Amyloid increases enzyme activity and protein levels of glutamine synthetase in cultured astrocytes. Pike CJ, et al. **Exp Neurol** 1996 May;139(1):167-71

Interaction between human amphipathic apolipoproteins and amyloid beta-peptide: surface plasmon resonance studies. Shuvaev VV, et al. **FEBS Lett** 1996 Mar 25;383(1-2):9-12

Protein kinase C and F-actin are essential for stimulation of neuronal FAK tyrosine phosphorylation by G-proteins and amyloid beta protein. Zhang C, et al. **FEBS Lett** 1996 May 20;386(2-3):185-8

Specificity in recognition of amyloid-beta peptide by the serpin-enzyme complex receptor in hepatoma cells and neuronal cells. Boland K, et al. **J Biol Chem** 1995 Nov 24;270(47):28022-8

The serpin-enzyme complex receptor recognizes soluble, nontoxic amyloid-beta peptide but not aggregated, cytotoxic amyloid-beta peptide. Boland K, et al. **J Biol Chem** 1996 Jul 26;271(30):18032-44

The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. Golabek AA, et al. **J Biol Chem** 1996 May 3;271(18):10602-6

Alzheimer's disease betaA4 protein release and amyloid precursor protein sorting are regulated by alternative splicing. Hartmann T, et al. **J Biol Chem** 1996 May 31; 271(22):13208-14

Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. Kuo YM, et al. **J Biol Chem** 1996 Feb 23;271(8):4077-81

Intracellular accumulation of beta-amyloid in cells expressing the Swedish mutant amyloid precursor protein. Martin BL, et al. **J Biol Chem** 1995 Nov 10;270(45):26727-30

Enhanced release of amyloid beta-protein from codon 670/671 "Swedish" mutant beta-amyloid precursor protein occurs in both secretory and endocytic pathways. Perez RG, et al. **J Biol Chem** 1996 Apr 12;271(15):9100-7

Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. Qiu WQ, et al. **J Biol Chem** 1996 Apr 5;271(14):8443-51

Coagulation factor XIa cleaves the RHDS sequence and abolishes the cell adhesive properties of the amyloid beta-protein. Saporito-Irwin SM, et al. **J Biol Chem** 1995 Nov 3;270(44):26265-9

Arrest of beta-amyloid fibril formation by a pentapeptide ligand. Tjernberg LO, et al. **J Biol Chem** 1996 Apr 12; 271(15):8545-8

Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. Turner RS, et al. **J Biol Chem** 1996 Apr 12; 271(15):8966-70

Self-association of beta-amyloid peptide (1-40) in solution and binding to lipid membranes. Terzi E, et al. **J Mol Biol** 1995 Oct 6;252(5):633-42

Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease. Clements A, et al. **J Neurochem** 1996 Feb;66(2):740-7

Fate of cerebrospinal fluid-borne amyloid beta-peptide rapid clearance into blood and appreciable accumulation by cerebral arteries. Ghersi-Egea JF, et al. **J Neurochem** 1996 Aug;67(2):880-3

Immunolocalization and redistribution of the FAC1 protein in Alzheimer's disease. Schoonover S, et al. **J Neuropathol Exp Neurol** 1996 Apr;55(4):444-55

Interaction of synthetic Alzheimer beta-protein-derived analogs with aqueous aluminum: a low-field 27Al NMR investigation. Vyas SB, et al. **J Protein Chem** 1995 Nov; 14(8):633-44

Catastrophe and Alzheimer's disease [letter] Larner AJ. **J R Coll Physicians Lond** 1995 Nov-Dec;29(6):549

Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Cummings BJ, et al. **Lancet** 1995 Dec 9;346(8989):1524-8

beta-Amyloid vasoactivity in Alzheimer's disease [letter] Gurwitz D. **Lancet** 1996 May 25;347(9013):1492

beta-Amyloid vasoactivity in Alzheimer's disease [letter] Kalaria RN, et al. **Lancet** 1996 May 25;347(9013):1492-3

Localisation and association of pathomorphological changes at the brainstem in Alzheimer's disease. Giess R, et al. **Mech Ageing Dev** 1995 Oct 27;84(3):209-26

The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Haass C, et al. **Nat Med** 1995 Dec;1(12):1291-6

Alzheimer's amyloid of another flavour [comment] Selkoe DJ. **Nat Med** 1995 Oct;1(10):998-9. Comment on: Nat Med 1995 Oct;1(10):1062-6.

GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease [see comments] Yanagisawa K, et al. **Nat Med** 1995 Oct; 1(10):1062-6. Comment in: Nat Med 1995 Oct;1(10):998-9.

A specific structural interaction of Alzheimer's peptide A beta 1-42 with alpha 1-antichymotrypsin [letter] Jancauskiene S, et al. **Nat Struct Biol** 1996 Aug;3(8):668-71

Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils [see comments] El Khoury J, et al. **Nature** 1996 Aug 22;382(6593):716-9. Comment in: Nature 1996 Aug 22;382(6593):674.

Alzheimer's disease. Amyloid ox-tox transducers [news; comment] Mattson MP, et al. **Nature** 1996 Aug 22; 382(6593):674-5. Comment on: Nature 1996 Aug 22;382(6593):685-91. Comment on: Nature 1996 Aug 22;382(6593):716-9.

Alzheimer's disease. A radical vascular connection [news; comment] Stamler JS. **Nature** 1996 Mar 14; 380(6570):108-11. Comment on: Nature 1996 Mar 14;380(6570):168-71.

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease [see comments] Yan SD, et al. **Nature** 1996 Aug 22;382(6593):685-91. Comment in: Nature 1996 Aug 22;382(6593):674.

Accumulation of beta-amyloid fibrils in pancreas of transgenic mice. Kawarabayashi T, et al. **Neurobiol Aging** 1996 Mar-Apr;17(2):215-22

Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Klunk WE, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):541-8

A beta-associated cerebral angiopathy and senile plaques with neurofibrillary tangles and cerebral hemorrhage in an aged wolverine (Gulo gulo). Roertgen KE, et al. **Neurobiol Aging** 1996 Mar-Apr;17(2):243-7

Age-specific onset of beta-amyloid in beagle brains. Russell MJ, et al. **Neurobiol Aging** 1996 Mar-Apr;17(2):269-73

Amyloid beta protein (A beta) removal by neuroglial cells in culture. Shaffer LM, et al. **Neurobiol Aging** 1995 Sep-Oct;16(5):737-45

Intraneuronal beta-amyloid immunoreactivity in the CNS. Sparks DL. **Neurobiol Aging** 1996 Mar-Apr;17(2):291-9

Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains. Tekirian TL, et al. **Neurobiol Aging** 1996 Mar-Apr;17(2):249-57

Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Cummings BJ, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):11-23

A comparison of beta-amyloid deposition in the medial temporal lobe in sporadic Alzheimer's disease, Down's syndrome and normal elderly brains. Armstrong RA, et al. **Neurodegeneration** 1996 Mar;5(1):35-41

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Inestrosa NC, et al. **Neuron** 1996 Apr;16(4):881-91

Mechanisms of neuronal degeneration in Alzheimer's disease. Yankner BA. **Neuron** 1996 May;16(5):921-32 (172 ref.)

The post-translational incorporation of arginine into a beta-amyloid peptide increases the probability of alpha-helix formation. Bongiovanni G, et al. **Neuroreport** 1995 Dec 29;7(1):326-8

Experimental deposition of Alzheimer amyloid beta-protein in canine leptomeningeal vessels. Prior R, et al. **Neuroreport** 1995 Sep 11;6(13):1747-51

Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-beta-peptides. Alvarez A, et al. **Neurosci Lett** 1995 Dec 1;201(1):49-52

A serine protease in Alzheimer's disease cells cleaves a 16K-peptide with flanking residues upstream to beta-amyloid-N-terminus as natural substrate. Matsumoto A, et al. **Neurosci Lett** 1995 Aug 11;195(3):171-4

Carboxyl end-specific monoclonal antibodies to amyloid beta protein (A beta) subtypes (A beta 40 and A beta 42(43)) differentiate A beta in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys. Nakamura S, et al. **Neurosci Lett** 1995 Dec 8;201(2):151-4

Paired helical filament-like phosphorylation of tau, deposition of beta/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Arendt T, et al. **Neuroscience** 1995 Dec;69(3):691-8

Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Howell S, et al. **Peptides** 1995;16(4):647-52

Reduced beta-amyloid response in lymphocytes of patients with Alzheimer's disease. Bondy B, et al. **Pharmacopsychiatry** 1995 Jul;28(4):143-6

Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. Arispe N, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1710-5

Two-hybrid system as a model to study the interaction of beta-amyloid peptide monomers. Hughes ST, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2065-70

Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Kelly JF, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25; 93(13):6753-8

Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Saito Y, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10227-31

NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Yoshimoto M, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9141-5

Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Zlokovic BV, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4229-34

PHARMACOLOGY

beta-APP cognitive function versus beta-amyloid--induced cell death. Gschwind M, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:293-6

Free radicals in the neurotoxic actions of beta-amyloid. Richardson JS, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:362-7

Amyloid beta-protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Van Nostrand WE, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:297-302 (19 ref.)

beta-Amyloid 25-35 and/or quinolinic acid injections into the basal forebrain of young male Fischer-344 rats: behavioral, neurochemical and histological effects. Sigurdsson EM, et al. **Behav Brain Res** 1995 Dec 14; 72(1-2):141-56

Alzheimer's peptides A beta 1-40 and A beta 1-28 inhibit the plasma cholesterol esterification rate. Koudinov AR, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):747-52

Activation of phospholipase A2 by amyloid beta-peptides in vitro. Lehtonen JY, et al. **Biochemistry** 1996 Jul 23; 35(29):9407-14

Beta-amyloid peptide blocks the fast-inactivating K+ current in rat hippocampal neurons. Good TA, et al. **Biophys J** 1996 Jan;70(1):296-304

Microglial release of nitric oxide by the synergistic action of beta-amyloid and IFN-gamma. Goodwin JL, et al. **Brain Res** 1995 Sep 18;692(1-2):207-14

Beta-amyloid (1-42) affects cholinergic but not parvalbumin-containing neurons in the septal complex of the rat. Harkany T, et al. **Brain Res** 1995 Nov 6; 698(1-2):270-4

Neuronal membrane conductance activated by amyloid beta peptide: importance of peptide conformation. Li WY, et al. **Brain Res** 1995 Jun 5;682(1-2):207-11

Physiological levels of beta-amyloid increase tyrosine phosphorylation and cytosolic calcium. Luo YQ, et al. **Brain Res** 1995 May 29;681(1-2):65-74

Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate beta-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons. Woods AG, et al. **Brain Res** 1995 Oct 30;697(1-2):53-62

Beta-amyloid1-40 inhibits electrically stimulated release of [3H]norepinephrine and enhances the internal calcium response to low potassium in rat cortex: prevention with a free radical scavenger. Li M, et al. **Brain Res Bull** 1996; 39(5):299-303

Alzheimer amyloid beta-peptides exhibit ionophore-like properties in human erythrocytes. Engström I, et al. **Eur J Clin Invest** 1995 Jul;25(7):471-6

beta-Amyloid-(1-40) increases long-term potentiation in rat hippocampus in vitro. Wu J, et al. **Eur J Pharmacol** 1995 Sep 25;284(3):R1-3

Cultured rat microglia express C1q and receptor for C1q: implications for amyloid effects on microglia. Korotzer AR, et al. **Exp Neurol** 1995 Aug;134(2):214-21

Beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide. Bitting L, et al. **J Biol Chem** 1996 Jul 5;271(27):16084-9

Coagulation factor XIa cleaves the RHDS sequence and abolishes the cell adhesive properties of the amyloid beta-protein. Saporito-Irwin SM, et al. **J Biol Chem** 1995 Nov 3;270(44):26265-9

Beta-amyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes and microglial cells. Meda L, et al. **J Immunol** 1996 Aug 1;157(3):1213-8

Enhancement of beta-amyloid peptide A beta(1-40)-mediated neurotoxicity by glutamine synthetase. Aksenov MYu, et al. **J Neurochem** 1995 Oct; 65(4):1899-902

Differential induction of immediate early gene proteins in cultured neurons by beta-amyloid (A beta): association of c-Jun with A beta-induced apoptosis. Anderson AJ, et al. **J Neurochem** 1995 Oct;65(4):1487-98

Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. Deb S, et al. **J Neurochem** 1996 Apr;66(4):1641-7

Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity.

Goodman Y, et al. **J Neurochem** 1996 Feb;66(2):869–72
Amyloid beta peptide (25–35) inhibits Na+–dependent glutamate uptake in rat hippocampal astrocyte cultures. Harris ME, et al. **J Neurochem** 1996 Jul;67(1):277–86
Beta-amyloid-induced cell toxicity: enhancement of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-dependent cell death. Hertel C, et al. **J Neurochem** 1996 Jul;67(1):272–6
Suppression of mitochondrial succinate dehydrogenase, a primary target of beta-amyloid, and its derivative racemized at Ser residue. Kaneko I, et al. **J Neurochem** 1995 Dec;65(6):2585–93
beta-Amyloid1–40 increases expression of beta-amyloid precursor protein in neuronal hybrid cells. Le W, et al. **J Neurochem** 1995 Nov;65(5):2373–6
Thrombin attenuates neuronal cell death and modulates astrocyte reactivity induced by beta-amyloid in vitro. Pike CJ, et al. **J Neurochem** 1996 Apr;66(4):1374–82
Amyloid beta protein primes cultured rat microglial cells for an enhanced phorbol 12-myristate 13-acetate-induced respiratory burst activity. Van Muiswinkel FL, et al. **J Neurochem** 1996 Jun;66(6):2468–76
beta-Amyloid induces increased release of interleukin-1 beta from lipopolysaccharide-activated human monocytes. Lorton D, et al. **J Neuroimmunol** 1996 Jun;67(1):21–9
Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. Kar S, et al. **J Neurosci** 1996 Feb 1;16(3):1034–40
beta-Amyloid peptide fragment 25–35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices. Arias C, et al. **J Neurosci Res** 1995 Jul 1;41(4):561–6
Change in membrane permeability induced by amyloid beta-protein fragment 25–35 in brain neurons dissociated from rats. Oyama Y, et al. **Jpn J Pharmacol** 1995 May; 68(1):77–83
In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Kingston IB, et al. **Nat Med** 1995 Feb;1(2):138–42
Reversal of beta-amyloid-induced retention deficit after exposure to training and state cues. McDonald MP, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):35–47
Transforming growth factor beta induces a beta-responsive calcium fluxes in neurons. Wolozin B, et al. **Neuroreport** 1995 Jul 10;6(10):1429–33
beta-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Wu J, et al. **Neuroreport** 1995 Nov 27; 6(17):2409–13
Amyloid beta peptide induces cytoplasmic accumulation of amyloid protein precursor via tau protein kinase I/glycogen synthase kinase-3 beta in rat hippocampal neurons. Takashima A, et al. **Neurosci Lett** 1995 Sep 29; 198(2):83–6
Changes in ciliary neurotrophic factor content in the rat brain after continuous intracerebroventricular infusion of beta-amyloid(1–40) protein. Yamada K, et al. **Neurosci Lett** 1995 Dec 8;201(2):155–8
Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells. Gitter BD, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10738–41
Neurocytopathic effects of beta-amyloid-stimulated monocytes: a potential mechanism for central nervous system damage in Alzheimer disease. London JA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4147–52

PHYSIOLOGY

Physiological and pathological interrelationships of amyloid beta peptide and the amyloid precursor protein. Larner AJ. **Bioessays** 1995 Sep;17(9):819–24 (45 ref.)
Neurodegeneration mediated by glutamate and beta-amyloid peptide: a comparison and possible interaction. Gray CW, et al. **Brain Res** 1995 Sep 11;691(1–2):169–79
Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Pollard HB, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):513–26 (67 ref.)
Physiologic levels of beta-amyloid activate phosphatidylinositol 3-kinase with the involvement of tyrosine phosphorylation. Luo Y, et al. **J Neurochem** 1996 Sep;67(3):978–87
Lymphocytes and neutrophils as peripheral models to study the effect of beta-amyloid on cellular calcium signalling in Alzheimer's disease. Eckert A, et al. **Life Sci** 1996; 59(5–6):499–510 (47 ref.)
Soluble beta-amyloid induces Alzheimer's disease features in human fibroblasts and in neuronal tissues. Etcheberrigaray R, et al. **Life Sci** 1996;59(5–6):491–8 (42 ref.)
Neuropathology in the Down's syndrome brain [comment] Tanzi RE. **Nat Med** 1996 Jan;2(1):31–2. Comment on: Nat Med 1996 Jan;2(1):93–5.
New clues to Alzheimer's disease: unraveling the roles of amyloid and tau [comment] Yankner BA. **Nat Med** 1996 Aug;2(8):850–2 (22 ref.). Comment on: Nat Med 1996 Aug;2(8):864–70.
beta-Amyloid-mediated vasoactivity and vascular endothelial damage [see comments] Thomas T, et al. **Nature** 1996 Mar 14;380(6570):168–71. Comment in: Nature 1996 Mar 14;380(6570):108.
Free radicals and disruption of neuronal ion homeostasis in AD: a role for amyloid beta-peptide? [comment] Mattson MP. **Neurobiol Aging** 1995 Jul–Aug;16(4):679–82; discussion 683 (40 ref.). Comment on: Neurobiol Aging 1995 Jul–Aug;16(4):661–74.
K+ currents of human T-lymphocytes are unaffected by Alzheimer's disease and amyloid beta protein. Cohen CD, et al. **Neurosci Lett** 1996 Jan 5;202(3):177–80

POISONING

Participation of gene expression in the protection against amyloid beta-peptide toxicity by the beta-amyloid precursor protein. Barger SW, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:303–9

SECRETION

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease [see comments] Scheuner D, et al. **Nat Med** 1996 Aug;2(8):864–70. Comment in: Nat Med 1996 Aug;2(8):850–2.

TOXICITY

17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Behl C, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):473–82
The role of iron in beta amyloid toxicity. Schubert D, et al. **Biochem Biophys Res Commun** 1995 Nov 13; 216(2):702–7
In vitro toxicity of beta-amyloid [letter] Exley C. **Biochem J** 1996 Mar 1;314 (Pt 2):709–10
The toxicity in vitro of beta-amyloid protein. Iversen LL, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):1–16 (255 ref.)
Activation of c-Fos contributes to amyloid beta-peptide-induced neurotoxicity. Gillardon F, et al. **Brain Res** 1996 Jan 8;706(1):169–72
Cell death induced by beta-amyloid 1–40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosis. Le WD, et al. **Brain Res** 1995 Jul 17;686(1):49–60
beta-Amyloid-induced toxicity in rat hippocampal cells: in vitro evidence for the involvement of free radicals. Manelli AM, et al. **Brain Res Bull** 1995;38(6):569–76
Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Pollard HB, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):513–26 (67 ref.)
Neurotoxicity of beta-amyloid protein: cytochemical changes and apoptotic cell death investigated in organotypic cultures. Allen YS, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):370–1
Inhibition of age-induced beta-amyloid neurotoxicity in rat hippocampal cells. Puttfarcken PS, et al. **Exp Neurol** 1996 Mar;138(1):73–81
Correlation among secondary structure, amyloid precursor protein accumulation, and neurotoxicity of amyloid beta(25–35) peptide as analyzed by single alanine substitution. Sato K, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6).1108–11
Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. Frederikse PH, et al. **J Biol Chem** 1996 Apr 26; 271(17):10169–74
Morphology and toxicity of Abeta-(1–42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. Roher AE, et al. **J Biol Chem** 1996 Aug 23; 271(34):20631–5
Clusterin (Apo J) protects against in vitro amyloid-beta (1–40) neurotoxicity. Boggs LN, et al. **J Neurochem** 1996 Sep;67(3):1324–7
Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons. Prehn JH, et al. **Mol Pharmacol** 1996 Feb;49(2):319–28
Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Miyata M, et al. **Nat Genet** 1996 Sep;14(1):55–61
Effects of chronic beta-amyloid treatment on fatty acid incorporation into rat brain. Brining SK, et al. **Neurobiol Aging** 1996 Mar–Apr;17(2):301–9
Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits. Frautschy SA, et al. **Neurobiol Aging** 1996 Mar–Apr;17(2):311–21
Beta amyloid is neurotoxic in hippocampal slice cultures. Harrigan MR, et al. **Neurobiol Aging** 1995 Sep–Oct; 16(5):779–89
Cytotoxicity of prion protein peptide (PrP106–126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25–35. Hope J, et al. **Neurodegeneration** 1996 Mar;5(1):1–11
Sulphated compounds attenuate beta-amyloid toxicity by inhibiting its association with cells. Sadler II, et al. **Neuroreport** 1995 Dec 29;7(1):49–53
Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Barger SW, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9328–32
Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. Davis J, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2996–3000
A model for beta-amyloid aggregation and neurotoxicity based on the free radical generating capacity of the peptide: implications of "molecular shrapnel" for Alzheimer's disease. Hensley K, et al. **Proc West Pharmacol Soc** 1995; 38:113–20

ULTRASTRUCTURE

Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Gearing M, et al. **Ann Neurol** 1996 Mar;39(3):395–9
Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. Janciauskiene S, et al. **J Biol Chem** 1995 Nov 3;270(44):26041–4

AMYLOID BETA-PROTEIN PRECURSOR

Cerebral beta amyloid deposition in patients with malignant neoplasms: its prevalence with aging and effects of radiation therapy on vascular amyloid. Sugihara S, et al. **Acta Neuropathol (Berl)** 1995;90(2):135–41

ANALOGS & DERIVATIVES

Studies on the metabolism and biological function of APLP2. Sisodia SS, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:77–81
Selective localization of amyloid precursor-like protein 1 in the cerebral cortex postsynaptic density. Kim TW, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):36–44
Characterization of the genomic structure of the mouse APLP1 gene. Zhong S, et al. **Genomics** 1996 Feb 15; 32(1):159–62

ANALYSIS

Microglial cells and amyloid beta protein (A beta) deposition; association with A beta 40-containing plaques. Mann DM, et al. **Acta Neuropathol (Berl)** 1995;90(5):472–7
Immunogold labelling of paired helical filaments and amyloid fibrils by specific monoclonal and polyclonal antibodies. Reig S, et al. **Acta Neuropathol (Berl)** 1995;90(5):441–7
P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Higgins LS, et al. **Am J Pathol** 1996 Aug; 149(2):585–96
beta-Amyloid precursor protein (beta APP) in human gut with special reference to the enteric nervous system. Cabal A, et al. **Brain Res Bull** 1995;38(5):417–23
Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils. Hall ED, et al. **Exp Neurol** 1995 Sep;135(1):17–27
Immunohistochemical characterization of alterations in the distribution of amyloid precursor proteins and beta-amyloid peptide after experimental brain injury in the rat. Pierce JE, et al. **J Neurosci** 1996 Feb 1;16(3):1083–90
Quantification of beta APP immunoreactive pre-alpha cells in the entorhinal cortex using image analysis. McKenzie JE, et al. **Neurodegeneration** 1995 Sep;4(3):299–306
Expression of beta-amyloid precursor protein in axons of periventricular leukomalacia brains. Arai Y, et al. **Pediatr Neurol** 1995 Sep;13(2):161–3
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Hsiao K, et al. **Science** 1996 Oct 4;274(5284):99–102

BIOSYNTHESIS

Transcriptional inhibition of the beta-amyloid precursor protein by interferon-gamma. Ringheim GE, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):246–51
Expression of the amyloid protein precursor of Alzheimer's disease in the developing rat olfactory system. Clarris HJ, et al. **Brain Res Dev Brain Res** 1995 Aug 28;88(1):87–95
Heat shock factor-1 mediates the transcriptional activation of Alzheimer's beta-amyloid precursor protein gene in response to stress. Dewji NN, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):325–8
Transcriptional activation of Alzheimer's beta-amyloid precursor protein gene by stress. Dewji NN, et al. **Brain Res Mol Brain Res** 1995 Nov;33(2):245–53
Changes in expression of lymphocyte amyloid precursor protein mRNA isoforms in normal aging and Alzheimer's disease. Ebstein RP, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):260–8
Expression of the amyloid precursor protein of Alzheimer's disease on the surface of transfected HeLa cells. Culvenor JG, et al. **Exp Cell Res** 1995 Oct;220(2):474–81
Amyloid precursor protein (APP) expression in multiple sclerosis lesions. Gehrmann J, et al. **Glia** 1995 Oct; 15(2):141–51
Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties. Bouillot C, et al. **J Biol Chem** 1996 Mar 29; 271(13):7640–4
Exchanging the extracellular domain of amyloid precursor protein for horseradish peroxidase does not interfere with alpha-secretase cleavage of the beta-amyloid region, but randomizes secretion in Madin-Darby canine kidney cells. De Strooper B, et al. **J Biol Chem** 1995 Dec 22; 270(51):30310–4
Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. Rockenstein

EM, et al. **J Biol Chem** 1995 Nov 24;270(47):28257–67
Serine proteinase inhibitors in human skeletal muscle: expression of beta–amyloid protein precursor and alpha 1–antichymotrypsin in vivo and during myogenesis in vitro. Akaaboune M, et al. **J Cell Physiol** 1995 Dec;165(3):503–11
Induction of connexin43 and gap junctional communication in PC12 cells overexpressing the carboxy terminal region of amyloid precursor protein. Nagy JI, et al. **J Neurosci Res** 1996 Apr 15;44(2):124–32
Non–enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta–peptide. Yan SD, et al. **Nat Med** 1995 Jul;1(7):693–9
Expression of APP in transgenic mice: a comparison of neuron–specific promoters. Andrä K, et al. **Neurobiol Aging** 1996 Mar–Apr;17(2):183–90
Transgenic mice expressing APP–C100 in the brain. Neve RL, et al. **Neurobiol Aging** 1996 Mar–Apr;17(2):191–203
Calpain inhibitor I decreases beta A4 secretion from human embryonal kidney cells expressing beta–amyloid precursor protein carrying the APP670/671 double mutation. Klafki HW, et al. **Neurosci Lett** 1995 Dec 1;201(1):29–32
Amyloid beta peptide induces cytoplasmic accumulation of amyloid protein precursor via tau protein kinase I/glycogen synthase kinase–3 beta in rat hippocampal neurons. Takashima A, et al. **Neurosci Lett** 1995 Sep 29; 198(2):83–6

CEREBROSPINAL FLUID

Amyloid beta–peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. Lannfelt L, et al. **Neurosci Lett** 1995 Oct 27; 199(3):203–6

CHEMISTRY

Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP and collagen type I. Beher D, et al. **J Biol Chem** 1996 Jan 19; 271(3):1613–20
Beta–amyloid precursor protein. Location of transmembrane domain and specificity of gamma–secretase cleavage. Tischer E, et al. **J Biol Chem** 1996 Sep 6;271(36):21914–9
Enhanced plasmin inhibition by a reactive center lysine mutant of the Kunitz–type protease inhibitor domain of the amyloid beta–protein precursor. Van Nostrand WE, et al. **J Biol Chem** 1995 Sep 29;270(39):22827–30
Soluble multimeric Alzheimer beta(1–40) pre–amyloid complexes in dilute solution. Levine H 3rd. **Neurobiol Aging** 1995 Sep–Oct;16(5):755–64

GENETICS

The amyloid peptide precursor in Alzheimer's disease. Octave JN. **Acta Neurol Belg** 1995 Dec;95(4):197–209 (70 ref.)
Lack of point mutation of the APP gene in sporadic Alzheimer's disease in Japanese. Nonomura Y, et al. **Acta Neurol Scand** 1996 Feb–Mar;93(2–3):138–41
Predominant deposition of amyloid–beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Mann DM, et al. **Am J Pathol** 1996 Apr;148(4):1257–66
Atrophy of the hippocampal formation in early familial Alzheimer's disease. A longitudinal MRI study of at–risk members of a family with an amyloid precursor protein 717Val–Gly mutation. Fox NC, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:226–32
Neurotrophic and neuroprotective effects of hAPP in transgenic mice. Mucke L, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:82–8
Mice homozygous for a modified beta–amyloid precursor protein (beta APP) gene show impaired behavior and high incidence of agenesis of the corpus callosum. Müller U, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:65–73
APP gene family. Alternative splicing generates functionally related isoforms. Sandbrink R, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:281–7
Mice deficient for the amyloid precursor protein gene. Zheng H, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:421–6
Suppression of Alzheimer amyloid precursor protein (APP) expression by exogenous APP mRNA. Ramakrishna N, et al. **Arch Biochem Biophys** 1996 Feb 15;326(2):243–51
White matter lesions and cognitive deterioration in presymptomatic carriers of the amyloid precursor protein gene codon 693 mutation. Bornebroek M, et al. **Arch Neurol** 1996 Jan;53(1):43–8
Missense mutations associated with familial Alzheimer's disease in Sweden lead to the production of the amyloid peptide without internalization of its precursor. Essalmani R, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):89–96
Nuclear and cytoplasmic localization of the beta–amyloid peptide (1–43) in transfected 293 cells. Johnstone EM, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):710–8
Transcriptional inhibition of the beta–amyloid precursor protein by interferon–gamma. Ringheim GE, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):246–51
Reported sequence homology between Alzheimer amyloid770 and the MRC OX–2 antigen does not predict function [letter] Richards SJ, et al. **Brain Res Bull** 1995; 38(3):305–6
The helix–loop–helix transcription factor USF interacts with the basal promoter of human amyloid precursor protein. Bourbonnière M, et al. **Brain Res Mol Brain Res** 1996 Jan; 35(1–2):304–8
Promoter activity of the gene encoding the beta–amyloid precursor protein is up–regulated by growth factors, phorbol ester, retinoic acid and interleukin–1. Lahiri DK, et al. **Brain Res Mol Brain Res** 1995 Sep;32(2):233–40
Amyloid beta amyloidosis in Alzheimer's disease. Price DL, et al. **Curr Opin Neurol** 1995 Aug;8(4):268–74 (71 ref.)
Negative transactivation of cAMP response element by familial Alzheimer's mutants of APP. Ikezu T, et al. **EMBO J** 1996 May 15;15(10):2468–75
Intrinsic signaling function of APP as a novel target of three V642 mutations linked to familial Alzheimer's disease. Okamoto T, et al. **EMBO J** 1996 Aug 1;15(15):3769–77
Expression of V642 APP mutant causes cellular apoptosis as Alzheimer trait–linked phenotype. Yamatsuji T, et al. **EMBO J** 1996 Feb 1;15(3):498–509
Facilitator oligonucleotides increase ribozyme RNA binding to full–length RNA substrates in vitro. Denman RB. **FEBS Lett** 1996 Mar 11;382(1–2):116–20
Developmental regulation of Xenopus beta–amyloid precursor protein gene expression. Okado H, et al. **Gerontology** 1995;41 Suppl 1:7–12
The upstream stimulatory factor functionally interacts with the Alzheimer amyloid beta–protein precursor gene. Kovacs DM, et al. **Hum Mol Genet** 1995 Sep;4(9):1527–33
Molecular analysis of the promoter region of the gene encoding the beta–amyloid precursor protein. Lahiri DK. **Indian J Biochem Biophys** 1995 Dec;32(6):329–35
Interleukin–1beta and glutamate activate the NF–kappaB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. Grilli M, et al. **J Biol Chem** 1996 Jun 21; 271(25):15002–7
Intracellular accumulation of beta–amyloid in cells expressing the Swedish mutant amyloid precursor protein. Martin BL, et al. **J Biol Chem** 1995 Nov 10;270(45):26727–30
The initiator element and proximal upstream sequences affect transcriptional activity and start site selection in the amyloid beta–protein precursor promoter. Quitschke WW, et al. **J Biol Chem** 1996 Sep 6;271(36):22231–9
Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. Rockenstein EM, et al. **J Biol Chem** 1995 Nov 24;270(47):28257–67
Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta–secretase" site occurs in the golgi apparatus. Thinakaran G, et al. **J Biol Chem** 1996 Apr 19; 271(16):9390–7
The mouse APLP2 gene. Chromosomal localization and promoter characterization. von Koch CS, et al. **J Biol Chem** 1995 Oct 27;270(43):25475–80
Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. West RL, et al. **J Mol Neurosci** 1995;6(2):141–6
Characterization of muscarinic acetylcholine receptors in cultured adult skin fibroblasts: effects of the Swedish Alzheimer's disease APP 670/671 mutation on binding levels. Vestling M, et al. **J Neural Transm Park Dis Dement Sect** 1995;10(1):1–10
Nerve growth factor and ras regulate beta–amyloid precursor protein gene expression in PC12 cells. Cosgaya JM, et al. **J Neurochem** 1996 Jul;67(1):98–104
The Swedish mutation causes early–onset Alzheimer's disease by beta–secretase cleavage within the secretory pathway. Haass C, et al. **Nat Med** 1995 Dec;1(12):1291–6
Secreted amyloid beta–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease [see comments] Scheuner D, et al. **Nat Med** 1996 Aug;2(8):864–70. Comment in: Nat Med 1996 Aug;2(8):850–2.
Artifactual strain–specific signs of incipient brain amyloidosis in APP transgenic mice. Ali SM, et al. **Neurobiol Aging** 1996 Mar–Apr;17(2):223–34
Expression of APP in transgenic mice: a comparison of neuron–specific promoters. Andrä K, et al. **Neurobiol Aging** 1996 Mar–Apr;17(2):183–90
APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Greenberg BD, et al. **Neurobiol Aging** 1996 Mar–Apr; 17(2):153–71 (323 ref.)
Striving for useful phenotypes in beta–APP transgenic mice [comment] Higgins LS, et al. **Neurobiol Aging** 1995 Jul–Aug;16(4):707–9. Comment on: Neurobiol Aging 1995 Jul–Aug;16(4):685–99.
Mutant and native human beta–amyloid precursor proteins in transgenic mouse brain [see comments] Howland DS, et al. **Neurobiol Aging** 1995 Jul–Aug;16(4):685–99. Comment in: Neurobiol Aging 1995 Jul–Aug;16(4):701–3. Comment in: Neurobiol Aging 1995 Jul–Aug;16(4):705–6. Comment in: Neurobiol Aging 1995 Jul–Aug;16(4):707–9. Comment in: Neurobiol Aging 1995 Jul–Aug;16(4):711–3; discussion 715–8.
beta–Amyloid precursor protein gene in squirrel monkeys with cerebral amyloid angiopathy. Levy E, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):805–8
Japanese siblings with missense mutation (717Val —> Ile) in amyloid precursor protein of early–onset Alzheimer's disease. Matsumura Y, et al. **Neurology** 1996 Jun; 46(6):1721–3
Age–related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Hsiao KK, et al. **Neuron** 1995 Nov;15(5):1203–18
A mutation in codon 717 of the amyloid precursor protein gene in an Australian family with Alzheimer's disease. Brooks WS, et al. **Neurosci Lett** 1995 Oct 27;199(3):183–6
Calpain inhibitor I decreases beta A4 secretion from human embryonal kidney cells expressing beta–amyloid precursor protein carrying the APP670/671 double mutation. Klafki HW, et al. **Neurosci Lett** 1995 Dec 1;201(1):29–32
Polymerase chain reaction quantification of lymphoid amyloid precursor protein mRNAs in Alzheimer's disease and Down's syndrome. Ledoux S, et al. **Neurosci Lett** 1995 Jun 30;193(2):137–9
Generation of mice with a 200–kb amyloid precursor protein gene deletion by Cre recombinase–mediated site–specific recombination in embryonic stem cells. Li ZW, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6158–62
Screening for mutations at codon 717 of the amyloid precursor protein gene in Alzheimer's disease. Dai XY, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):175–8
Genetic clues to Alzheimer's disease. Dewji NN, et al. **Science** 1996 Jan 12;271(5246):159–60
[Molecular mechanisms in Alzheimer disease] Simons VM. **Fortschr Med** 1995 Nov 10;113(31):441–2 (Eng. Abstr.) **(Ger)**
[The search for a mutation in the gene coding the beta–amyloid protein precursor gene in patients with Alzheimer–type dementias] Golimbet VE, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):75–8 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Relationship of amyloid beta/A4 protein to the neurofibrillary tangles in Guamanian parkinsonism–dementia. Schwab C, et al. **Acta Neuropathol (Berl)** 1995;90(3):287–98
White matter amyloid in Alzheimer's disease brain. Uchihara T, et al. **Acta Neuropathol (Berl)** 1995;90(1):51–6

METABOLISM

Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Jendroska K, et al. **Acta Neuropathol (Berl)** 1995;90(5):461–6
Novel neuritic clusters with accumulations of amyloid precursor protein and amyloid precursor–like protein 2 immunoreactivity in brain regions damaged by thiamine deficiency. Calingasan NY, et al. **Am J Pathol** 1996 Sep; 149(3):1063–71
Predominant deposition of amyloid–beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Mann DM, et al. **Am J Pathol** 1996 Apr;148(4):1257–66
Regulation of APP expression, biogenesis and metabolism by extracellular matrix and cytokines. Beyreuther K, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:74–6 (17 ref.)
A novel brain cysteine protease forms an SDS stable complex with the beta–amyloid precursor protein. Chang T, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:183–8
Dehydroepiandrosterone augments M1–muscarinic receptor–stimulated amyloid precursor protein secretion in desensitized PC12M1 cells. Danenberg HD, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:300–3
The role of arachidonic acid in the secretion of the amyloid precursor protein (APP). Emmerling MR, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:310–5
The effect of cholinesterase inhibitors on the secretion of APPS from rat brain cortex. Giacobini E, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:393–8
Defective protein kinase C alpha leads to impaired secretion of soluble beta–amyloid precursor protein from Alzheimer's disease fibroblasts. Govoni S, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:332–7
Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer's disease–associated amyloid beta peptide. Hensley K, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:120–34 (49 ref.)
Metabotropic glutamate receptors regulate APP processing in hippocampal neurons and cortical astrocytes derived from fetal rats. Lee RK, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:338–43
Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden. Nitsch RM, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:175–82 (28 ref.)
Altered expression of amyloid beta precursor mRNAs in cerebral vessels, meninges, and choroid plexus in Alzheimer's disease. Premkumar DR, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:288–92
The role of APP processing and trafficking pathways in the formation of amyloid beta–protein. Selkoe DJ, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:57–64 (19 ref.)
Molecular physiology, biochemistry, and pharmacology of Alzheimer's amyloid precursor protein (APP). Suh YH, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:169–83 (59 ref.)
Differential regulation of APP secretion by apolipoprotein E3 and E4. Wolozin BL, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:322–6
Fractionation of amyloid beta–protein (A beta) in

Alzheimer's disease and Down's syndrome brains. Presence of membrane-bound A beta. Yanagisawa K, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:184-94

The role of glycosylation in synthesis and secretion of beta-amyloid precursor protein by Chinese hamster ovary cells. Påhlsson P, et al. **Arch Biochem Biophys** 1996 Jul 15;331(2):177-86

Intracellular generation of amyloid beta-protein from amyloid beta-protein precursor fragment by direct cleavage with beta- and gamma-secretase. Iizuka T, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):238-42

The fibril forming region of the beta-amyloid precursor differs from that of the amyloid A precursor in its interaction with lipids. Liang JS, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):962-7

Lysosomal processing of amyloid precursor protein to A beta peptides: a distinct role for cathepsin S. Munger JS, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):299-305

Alzheimer's amyloid precursor protein is expressed on the surface of hematopoietic cells upon activation. Bullido MJ, et al. **Biochim Biophys Acta** 1996 Aug 21;1313(1):54-62

Axonal degeneration promotes abnormal accumulation of amyloid beta-protein in ascending gracile tract of gracile axonal dystrophy (GAD) mouse. Ichihara N, et al. **Brain Res** 1995 Oct 16;695(2):173-8

Amyloid beta-protein ending at Thr43 is a minor component of some diffuse plaques in the Alzheimer's disease brain, but is not found in cerebrovascular amyloid. Iizuka T, et al. **Brain Res** 1995 Dec 8;702(1-2):275-8

Co-localization of amyloid-associated proteins with amyloid beta in rat soleus muscle in chloroquine-induced myopathy: a possible model for amyloid beta formation in Alzheimer's disease. Tsuzuki K, et al. **Brain Res** 1995 Nov 20; 699(2):260-5

Chronic elevation of S100 beta protein does not alter APP mRNA expression or promote beta-amyloid deposition in the brains of aging transgenic mice. Yao J, et al. **Brain Res** 1995 Dec 8;702(1-2):32-6

Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Oda T, et al. **Exp Neurol** 1995 Nov;136(1):22-31

Baculovirus-infected cells do not produce the amyloid peptide of Alzheimer's disease from its precursor. Essalmani R, et al. **FEBS Lett** 1996 Jul 1;389(2):157-61

Gelatinase A possesses a beta-secretase-like activity in cleaving the amyloid protein precursor of Alzheimer's disease. LePage RN, et al. **FEBS Lett** 1995 Dec 18; 377(2):267-70

Brain cathepsin B but not metalloendopeptidases degrade rAPP751 with production of amyloidogenic fragments. Comparison with synthetic peptides emulating beta- and gamma-secretase sites. Marks N, et al. **Int J Pept Protein Res** 1995 Sep-Oct;46(3-4):306-13

Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP and collagen type I. Beher D, et al. **J Biol Chem** 1996 Jan 19; 271(3):1613-20

Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. Bodovitz S, et al. **J Biol Chem** 1996 Feb 23;271(8):4436-40

APP-BP1, a novel protein that binds to the carboxyl-terminal region of the amyloid precursor protein. Chow N, et al. **J Biol Chem** 1996 May 10;271(19):11339-46

The regions of the Fe65 protein homologous to the phosphotyrosine interaction/phosphotyrosine binding domain of Shc bind the intracellular domain of the Alzheimer's amyloid precursor protein. Fiore F, et al. **J Biol Chem** 1995 Dec 29;270(52):30853-6

Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. Frederikse PH, et al. **J Biol Chem** 1996 Apr 26; 271(17):10169-74

Alzheimer's disease betaA4 protein release and amyloid precursor protein sorting are regulated by alternative splicing. Hartmann T, et al. **J Biol Chem** 1996 May 31; 271(22):13208-14

Differential effects of a Rab6 mutant on secretory versus amyloidogenic processing of Alzheimer's beta-amyloid precursor protein. McConlogue L, et al. **J Biol Chem** 1996 Jan 19;271(3):1343-8

Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. Nitsch RM, et al. **J Biol Chem** 1996 Feb 23;271(8):4188-94

Enhanced release of amyloid beta-protein from codon 670/671 "Swedish" mutant beta-amyloid precursor protein occurs in both secretory and endocytic pathways. Perez RG, et al. **J Biol Chem** 1996 Apr 12;271(15):9100-7

Coagulation factor XIa cleaves the RHDS sequence and abolishes the cell adhesive properties of the amyloid beta-protein. Saporito-Irwin SM, et al. **J Biol Chem** 1995 Nov 3;270(44):26265-9

Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus. Thinakaran G, et al. **J Biol Chem** 1996 Apr 19; 271(16):9390-7

Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein. Xu H, et al. **J Biol Chem** 1995 Oct 6;270(40):23243-5

Extracellular matrix regulates the amount of the beta-amyloid precursor protein and its amyloidogenic fragments. Bronfman FC, et al. **J Cell Physiol** 1996 Feb; 166(2):360-9

Thyroid epithelial cells produce large amounts of the Alzheimer beta-amyloid precursor protein (APP) and generate potentially amyloidogenic APP fragments. Schmitt TL, et al. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3513-9

The production of an amyloidogenic metabolite of the Alzheimer amyloid beta precursor protein (APP) in thyroid cells is stimulated by interleukin 1 beta, but inhibited by interferon gamma. Schmitt TL, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1666-9

Characterization of the high affinity heparin binding site of the Alzheimer's disease beta A4 amyloid precursor protein (APP) and its enhancement by zinc(II). Multhaup G, et al. **J Mol Recognit** 1995 Jul-Aug;8(4):247-57

In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. Aplin AE, et al. **J Neurochem** 1996 Aug; 67(2):699-707

Evaluation of cathepsins D and G and EC 3.4.24.15 as candidate beta-secretase proteases using peptide and amyloid precursor protein substrates. Brown AM, et al. **J Neurochem** 1996 Jun;66(6):2436-45

Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. Checler F. **J Neurochem** 1995 Oct;65(4):1431-44 (101 ref.)

Intracellular cyclic AMP inhibits constitutive and phorbol ester-stimulated secretory cleavage of amyloid precursor protein. Efthimiopoulos S, et al. **J Neurochem** 1996 Aug; 67(2):872-5

beta-Amyloid1-40 increases expression of beta-amyloid precursor protein in neuronal hybrid cells. Le W, et al. **J Neurochem** 1995 Nov;65(5):2373-6

Amyloid precursor protein metabolism in primary cell cultures of neurons, astrocytes, and microglia. LeBlanc AC, et al. **J Neurochem** 1996 Jun;66(6):2300-10

Affinity purification of proteoglycans that bind to the amyloid protein precursor of Alzheimer's disease. Williamson TG, et al. **J Neurochem** 1995 Nov;65(5):2201-8

Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. Mrak RE, et al. **J Neuropathol Exp Neurol** 1996 Mar;55(3):273-9

Regulated secretion of beta-amyloid precursor protein in rat brain. Farber SA, et al. **J Neurosci** 1995 Nov; 15(11):7442-51

Increased antioxidant enzyme activity in amyloid beta protein-resistant cells. Sagara Y, et al. **J Neurosci** 1996 Jan 15;16(2):497-505

Amyloidogenic processing of the human amyloid precursor protein in primary cultures of rat hippocampal neurons. Simons M, et al. **J Neurosci** 1996 Feb 1;16(3):899-908

APPL, the Drosophila member of the APP-family, exhibits differential trafficking and processing in CNS neurons. Torroja L, et al. **J Neurosci** 1996 Aug 1;16(15):4638-50

Changes of beta-amyloid precursor protein after compression trauma to the spinal cord: an experimental study in the rat using immunohistochemistry. Li GL, et al. **J Neurotrauma** 1995 Jun;12(3):269-77

Amyloidogenic processing of Alzheimer's amyloid precursor protein in vitro and its modulation by metal ions and tacrine. Chong YH, et al. **Life Sci** 1996;59(7):545-57

Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Lannfelt L, et al. **Nat Med** 1995 Aug;1(8):829-32

Tau protein directly interacts with the amyloid beta-protein precursor: implications for Alzheimer's disease. Smith MA, et al. **Nat Med** 1995 Apr;1(4):365-9

Decreases in protease nexins in Alzheimer's disease brain. Choi BH, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):557-62

Understanding the biology of beta-amyloid precursor proteins in transgenic mice [comment] Hsiao KK. **Neurobiol Aging** 1995 Jul-Aug;16(4):705-6. Comment on: Neurobiol Aging 1995 Jul-Aug;16(4):685-99.

The potential utility of transgenic mice harboring beta-amyloid precursor protein [comment] Schenk D, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):711-3; discussion 715-8. Comment on: Neurobiol Aging 1995 Jul-Aug;16(4):685-99.

Deposits of A beta fibrils are not toxic to cortical and hippocampal neurons in vitro. Wujek JR, et al. **Neurobiol Aging** 1996 Jan-Feb;17(1):107-13

Mechanisms of neuronal degeneration in Alzheimer's disease. Yankner BA. **Neuron** 1996 May;16(5):921-32 (172 ref.)

High levels of amyloid-beta protein from S182 (Glu246) familial Alzheimer's cells. Martins RN, et al. **Neuroreport** 1995 Dec 29;7(1):217-20

Defective phorbol ester-stimulated secretion of beta-amyloid precursor protein from Alzheimer's disease fibroblasts. Bergamaschi S, et al. **Neurosci Lett** 1995 Dec 1;201(1):1-5

The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype. Mann DM, et al. **Neurosci Lett** 1995 Aug 18; 196(1-2):105-8

Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Howell S, et al. **Peptides** 1995;16(4):647-52

Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Saito Y, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10227-31

Metabolism of Alzheimer beta-amyloid precursor protein: regulation by protein kinase A in intact cells and in a cell-free system. Xu H, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4081-4

The amyloid peptide and its precursor in Alzheimer's disease. Octave JN. **Rev Neurosci** 1995 Oct-Dec;6(4):287-316 (289 ref.)

The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Multhaup G, et al. **Sciepce** 1996 Mar 8;271(5254):1406-9

[Problems of the amyloid beta precursor protein in pathogenesis of the Alzheimer type dementia] Shoji M, et al. **Nippon Ronen Igakkai Zasshi** 1996 Mar;33(3):164-8 **(Jpn)**

PHARMACOLOGY

Participation of gene expression in the protection against amyloid beta-peptide toxicity by the beta-amyloid precursor protein. Barger SW, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:303-9

The secreted form of the Alzheimer's beta-amyloid precursor protein stimulates a membrane-associated guanylate cyclase. Barger SW, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):45-7

Cholinotoxic effects of beta-amyloid (1-42) peptide on cortical projections of the rat nucleus basalis magnocellularis. Harkany T, et al. **Brain Res** 1995 Oct 9; 695(1):71-5

Growth regulation of rat thyrocytes (FRTL-5 cells) by the secreted ectodomain of beta-amyloid precursor-like proteins. Popp GM, et al. **Endocrinology** 1996 May; 137(5):1975-83

Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display. Dennis MS, et al. **J Biol Chem** 1995 Oct 27;270(43):25411-7

Protease nexin-2/amyloid beta-protein precursor inhibits factor Xa in the prothrombinase complex. Mahdi F, et al. **J Biol Chem** 1995 Oct 6;270(40):23468-74

Enhanced plasmin inhibition by a reactive center lysine mutant of the Kunitz-type protease inhibitor domain of the amyloid beta-protein precursor. Van Nostrand WE, et al. **J Biol Chem** 1995 Sep 29;270(39):22827-30

The amyloidogenic peptide human amylin augments the inflammatory activities of eosinophils. Hom JT, et al. **J Leukoc Biol** 1995 Nov;58(5):526-32

Defective phorbol ester-stimulated secretion of beta-amyloid precursor protein from Alzheimer's disease fibroblasts. Bergamaschi S, et al. **Neurosci Lett** 1995 Dec 1;201(1):1-5

Oxidative stress after acute and chronic application of beta-amyloid fragment 25-35 in cortical cultures. Café C, et al. **Neurosci Lett** 1996 Jan 12;203(1):61-5

Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Takashima A, et al. **Neurosci Lett** 1996 Jan 12;203(1):33-6

PHYSIOLOGY

Regulation of APP processing by intra- and intercellular signals. Buxbaum JD, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:327-31 (17 ref.)

beta-APP cognitive function versus beta-amyloid--induced cell death. Gschwind M, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:293-6

Cellular signaling pathways and cytoskeletal organization. Kosik KS, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:114-20 (28 ref.)

Neurotrophic and neuroprotective effects of hAPP in transgenic mice. Mucke L, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:82-8

Physiological and pathological interrelationships of amyloid beta peptide and the amyloid precursor protein. Larner AJ. **Bioessays** 1995 Sep;17(9):819-24 (45 ref.)

Expression of V642 APP mutant causes cellular apoptosis as Alzheimer trait-linked phenotype. Yamatsuji T, et al. **EMBO J** 1996 Feb 1;15(3):498-509

The molecular significance of amyloid beta-peptide for Alzheimer's disease. Haass C. **Eur Arch Psychiatry Clin Neurosci** 1996;246(3):118-23 (54 ref.)

Inflammatory reaction in experimental autoimmune encephalomyelitis (EAE) is accompanied by a microglial expression of the beta A4-amyloid precursor protein (APP). Banati RB, et al. **Glia** 1995 Jul;14(3):209-15

Distribution of an APP homolog, APLP2, in the mouse olfactory system: a potential role for APLP2 in axogenesis. Thinakaran G, et al. **J Neurosci** 1995 Oct;15(10):6314-26

Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Furukawa K, et al. **Nature** 1996 Jan 4;379(6560):74-8

Secreted beta-APP stimulates MAP kinase and phosphorylation of tau in neurons. Greenberg SM, et al. **Neurobiol Aging** 1995 May-Jun;16(3):403-7; discussion 407-8

Amino-terminal region of the beta-amyloid precursor protein activates mitogen-activated protein kinase. Greenberg SM, et al. **Neurosci Lett** 1995 Sep 22;198(1):52-6

Propagation of intercellular calcium waves in PC12 cells overexpressing a carboxy-terminal fragment of amyloid

precursor protein. Lynn BD, et al. **Neurosci Lett** 1995 Oct 13;199(1):21–4

Transfer of beta–amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Askanas V, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1314–9

Expression of the C terminus of the amyloid precursor protein alters growth factor responsiveness in stably transfected PC12 cells. Sandhu FA, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2180–5

G protein–mediated neuronal DNA fragmentation induced by familial Alzheimer's disease–associated mutants of APP. Yamatsuji T, et al. **Science** 1996 May 31;272(5266):1349–52

SECRETION

The secreted form of the Alzheimer's beta–amyloid precursor protein stimulates a membrane–associated guanylate cyclase. Barger SW, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):45–7

Expression in brain of amyloid precursor protein mutated in the alpha–secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. Moechars D, et al. **EMBO J** 1996 Mar 15; 15(6):1265–74

Growth regulation of rat thyrocytes (FRTL–5 cells) by the secreted ectodomain of beta–amyloid precursor–like proteins. Popp GM, et al. **Endocrinology** 1996 May; 137(5):1975–83

TOXICITY

Neurotoxicity of a carboxyl–terminal fragment of the Alzheimer's amyloid precursor protein. Kim SH, et al. **J Neurochem** 1996 Sep;67(3):1172–82

beta–Amyloid toxicity in organotypic hippocampal cultures: protection by EUK–8, a synthetic catalytic free radical scavenger. Bruce AJ, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2312–6

ULTRASTRUCTURE

Overexpression of amyloid precursor protein of Alzheimer's type in brains of intoxicated children. Maślińska D, et al. **Folia Neuropathol** 1995;33(3):129–33

AMYLOID FIBRIL PROTEIN AA see **AMYLOID PROTEIN AA**

AMYLOID FIBRIL PROTEIN (ALZHEIMER'S) see **AMYLOID BETA–PROTEIN**

AMYLOID NEUROPATHIES

BLOOD

Decreased affinity of apolipoprotein AII to high–density lipoprotein in patients with transthyretin–related amyloidosis (Met30, Gln89, Pro36, and Thr34). Nakamura M, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):316–21

COMPLICATIONS

Notalgia paraesthetica and macular amyloidosis [letter; comment] Cerroni L, et al. **Clin Exp Dermatol** 1995 Mar; 20(2):178. Comment on: Clin Exp Dermatol 1994 Jul;19(4):346–9.

Lymphoma, paraproteinaemia, and neuropathy [clinical conference] Wokke JH, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):684–9

[Familial amyloidosis of the Finnish type (FAP) with extraocular muscle involvement] Sadamoto K, et al. **Rinsho Shinkeigaku** 1995 Sep;35(9):1034–6 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Primary systemic amyloidosis presenting with polyneuropathy characterized by very long survival. Rinaldi R, et al. **Acta Neurol Scand** 1995 Jun;91(6):511–3

[The use of FD–6 monoclonal antibody in diagnosing and detecting the carriers of familial amyloidotic polyneuropathy type I] López Domínguez JM, et al. **Neurologia** 1996 Mar;11(3):93–8 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Occupational and other risk factors for clinically overt familial amyloid polyneuropathy. Hardell L, et al. **Epidemiology** 1995 Nov;6(6):598–601

Anticipation of age–of–onset in familial amyloidotic polyneuropathy and its pathogenesis [editorial; comment] Araki S. **Intern Med** 1995 Aug;34(8):703–4. Comment on: Intern Med 1995 Aug;34(8):748–50.

Change in the age of onset in patients with familial amyloidotic polyneuropathy type I [see comments] Tashima K, et al. **Intern Med** 1995 Aug;34(8):748–50. Comment in: Intern Med 1995 Aug;34(8):703–4.

GENETICS

Leptomeningeal amyloid and variant transthyretins [comment] Benson MD. **Am J Pathol** 1996 Feb; 148(2):351–4 (19 ref.). Comment on: Am J Pathol 1996 Feb;148(2):361–6.

Haplotype analysis in gelsolin–related amyloidosis reveals independent origin of identical mutation (G654A) of gelsolin in Finland and Japan. Paunio T, et al. **Hum Mutat** 1995;6(1):60–5

Haplotype analysis of French, British and other European patients with familial amyloid polyneuropathy (met 30 and tyr 77). Reilly MM, et al. **J Neurol** 1995 Oct;242(10):664–8

What is genetic anticipation? [letter] Ando Y, et al. **Lancet** 1996 Aug 3;348(9023):331–2

Lattice corneal dystrophy type II associated with familial amyloid polyneuropathy type IV. Akiya S, et al. **Ophthalmology** 1996 Jul;103(7):1106–10

Ocular amyloidosis, with special reference to the hereditary forms with vitreous involvement. Sandgren O. **Surv Ophthalmol** 1995 Nov–Dec;40(3):173–96 (261 ref.)

[An attempt to generate a closer mouse model of familial amyloidotic polyneuropathy, an autosomal dominantly inherited disease] Maeda S, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2204–13 (30 ref.) **(Jpn)**

[Familial amyloidotic polyneuropathy and liver transplantation (editorial)] Buades Reinés J, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):480–2 (23 ref.) **(Spa)**

[The use of FD–6 monoclonal antibody in diagnosing and detecting the carriers of familial amyloidotic polyneuropathy type I] López Domínguez JM, et al. **Neurologia** 1996 Mar;11(3):93–8 (Eng. Abstr.) **(Spa)**

METABOLISM

'In vitro' amyloid fibril formation from transthyretin: the influence of ions and the amyloidogenicity of TTR variants. Bonifácio MJ, et al. **Biochim Biophys Acta** 1996 May 24; 1316(1):35–42

Examination of the structure of the transthyretin amyloid fibril by image reconstruction from electron micrographs. Serpell LC, et al. **J Mol Biol** 1995 Nov 24;254(2):113–8

PATHOLOGY

Familial amyloid polyneuropathy associated with transthyretin Gly42 mutation: a quantitative light and electron microscopic study of the peripheral nervous system. Toyooka K, et al. **Acta Neuropathol (Berl)** 1995; 90(5):516–25

Massive appearance of corpora amylacea in postnatal anoxic encephalopathy. Abe H, et al. **Clin Neuropathol** 1995 Jul–Aug;14(4):207–10

Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation. Ciulla TA, et al. **Surv Ophthalmol** 1995 Nov–Dec; 40(3):197–206 (123 ref.)

RADIONUCLIDE IMAGING

[123I–MIBG myocardial SPECT in two patients with familial amyloid polyneuropathy] Itoh A, et al. **Kaku Igaku** 1995 Oct;32(10):1113–6 (Eng. Abstr.) **(Jpn)**

SURGERY

Liver transplantation in familial amyloidotic polyneuropathy. Follow–up of the first 20 Swedish patients. Suhr OB, et al. **Transplantation** 1995 Nov 15;60(9):933–8

AMYLOID P COMPONENT

ANALYSIS

The distribution of fibronectin and P component in Descemet's membrane: an immunoelectron microscopic study. Levy SG, et al. **Curr Eye Res** 1995 Sep;14(9):865–70

[Effect of sex steroids on serum amyloid P–component (female protein) in rats] Hashimoto S, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Oct; 47(10):1041–7 (Eng. Abstr.) **(Jpn)**

DIAGNOSTIC USE

Imaging amyloidosis with radiolabelled SAP [editorial] Hawkins PN, et al. **Eur J Nucl Med** 1995 Jul;22(7):595–9 (29 ref.)

GENETICS

Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Introna M, et al. **Blood** 1996 Mar 1;87(5):1862–72

Promoter structure and transcriptional activation of the murine TSG–14 gene encoding a tumor necrosis factor/interleukin–1–inducible pentraxin protein. Altmeyer A, et al. **J Biol Chem** 1995 Oct 27;270(43):25584–90

ISOLATION & PURIFICATION

Isolation of a pentraxin–like protein from rainbow trout serum. Jensen LE, et al. **Dev Comp Immunol** 1995 Jul–Aug; 19(4):305–14

METABOLISM

Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis. Hachulla E, et al. **Am J Med** 1996 Jul; 101(1):77–87

Ligand–binding sites in human serum amyloid P component. Heegaard NH, et al. **Eur J Biochem** 1996 Aug 1; 239(3):850–6

Serum amyloid P component binding to C4b–binding protein. García de Frutos P, et al. **J Biol Chem** 1995 Nov 10; 270(45):26950–5

Characterization of the binding of serum amyloid P to type IV collagen. Zahedi K. **J Biol Chem** 1996 Jun 21; 271(25):14897–902

Demonstration of a heparin–binding site in serum amyloid P component using affinity capillary electrophoresis as an adjunct technique. Heegaard NH, et al. **J Chromatogr A** 1995 Nov 24;717(1–2):83–90

[Scintigraphy of iodine 123 labelled serum amyloid P component in beta 2–microglobulin amyloidosis of hemodialysis] Flipo RM, et al. **Nephrologie** 1995; 16(6):419–25 (Eng. Abstr.) **(Fre)**

AMYLOID POLYNEUROPATHIES see **AMYLOID NEUROPATHIES**

AMYLOID PROTEIN AA

ANALYSIS

Serum amyloid A protein in humans and four animal species: a comparison by two dimensional electrophoresis. Bruun CF, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct;112(2):227–34

Serum amyloid A protein in the prediction of postburn complications and fatal outcome in patients with severe burns. Casl MT, et al. **Eur J Clin Chem Clin Biochem** 1996 Jan;34(1):31–5

Alveolar hydatid cyst (AHC): inflammation–induced reactive gastrointestinal (GL) amyloidosis in AHC–infected mice and chemical characterization of the GL amyloid. Li W, et al. **Exp Parasitol** 1996 Jun;83(1):1–10

Hepatic amyloidosis in Japan: histological and morphometric analysis based on amyloid proteins. Iwata T, et al. **Hum Pathol** 1995 Oct;26(10):1148–53

Mechanism for antigen detection on deplasticized epoxy sections. Brorson SH, et al. **Micron** 1995;26(4):301–10

The diagnostic capacity of serum amyloid A protein for early recognition of kidney allograft rejection. Casl MT, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1901–4

BIOSYNTHESIS

Age–related changes of mRNA expression of amyloid precursor protein in the brain of senescence–accelerated mouse. Cho HS, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):399–404

Unstimulated peripheral blood mononuclear cells from patients with the hyper–IgD syndrome produce cytokines capable of potent induction of C–reactive protein and serum amyloid A in Hep3B cells. Drenth JP, et al. **J Immunol** 1996 Jul 1;157(1):400–4

A novel cis–acting element is essential for cytokine–mediated transcriptional induction of the serum amyloid A gene in nonhepatic cells. Ray A, et al. **Mol Cell Biol** 1996 Apr; 16(4):1584–94

CHEMISTRY

Chicken joint amyloid protein is of the AA–type. I. Characterization of the amyloid protein. Landman WJ, et al. **Scand J Immunol** 1996 Feb;43(2):210–8

DRUG EFFECTS

Effect of poly(vinylsulfonate) on murine AA amyloid: a high–resolution ultrastructural study. Inoue S, et al. **Lab Invest** 1996 Jun;74(6):1081–90

Arresting amyloidosis in vivo using small–molecule anionic sulphonates or sulphates: implications for Alzheimer's disease [see comments] Kisilevsky R, et al. **Nat Med** 1995 Feb;1(2):143–8. Comment in: Nat Med 1995 Feb;1(2):120–2.

GENETICS

Developmental regulation of expression of rabbit C–reactive protein and serum amyloid A genes. Rygg M, et al. **Biochim Biophys Acta** 1996 Jun 3;1307(1):89–96

Cytokine–induced differential expression of serum amyloid A genes in fetal and neonatal rabbits. Rygg M. **Clin Exp Immunol** 1996 Feb;103(2):335–42

Wallaby serum amyloid A protein: cDNA cloning, sequence and evolutionary analysis. Uhlar CM, et al. **Scand J Immunol** 1996 Mar;43(3):271–6

ISOLATION & PURIFICATION

Both murine SAA1 and SAA2 yield AA amyloid in alveolar hydatid cyst–infected mice. Bell AW, et al. **Scand J Immunol** 1996 Feb;43(2):173–80

Chicken joint amyloid protein is of the AA–type. I. Characterization of the amyloid protein. Landman WJ, et al. **Scand J Immunol** 1996 Feb;43(2):210–8

METABOLISM

The fibril forming region of the beta–amyloid precursor differs from that of the amyloid A precursor in its interaction with lipids. Liang JS, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):962–7

Hyperimmunoglobulin M syndrome associated with systemic

AMYLOID PROTEIN AA

amyloidosis type AA [letter] Oner A, et al. **Eur J Pediatr** 1995 Dec;154(12):995

Association of apolipoprotein E with murine amyloid A protein amyloid [see comments] Kindy MS, et al. **Lab Invest** 1995 Oct;73(4):469–75. Comment in: Lab Invest 1995 Oct;73(4):457–60.

Serum amyloid A protein levels in haemodialysis patients [letter] Polat H, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1492–3

Degradation of serum amyloid A in amyloid–susceptible and amyloid–resistant mouse strains. Elliott–Bryant R, et al. **Scand J Immunol** 1996 Sep;44(3):223–8

Experimental AA–amyloidosis in mice is inhibited by treatment with the anti–rheumatic drug tenidap. Husebekk A, et al. **Scand J Immunol** 1996 May;43(5):551–5

[Variations of serum amyloid A protein and interleukin–6 in patients with low concentration of serum C–reactive protein] Shimetani N, et al. **Rinsho Byori** 1996 Jul; 44(7):669–75 (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

A high resolution ultrastructural study of experimental murine AA amyloid. Inoue S, et al. **Lab Invest** 1996 Mar; 74(3):670–83

Effect of poly(vinylsulfonate) on murine AA amyloid: a high–resolution ultrastructural study. Inoue S, et al. **Lab Invest** 1996 Jun;74(6):1081–90

AMYLOID PROTEIN A4 see **AMYLOID BETA–PROTEIN**

AMYLOID PROTEIN PRECURSOR see **AMYLOID BETA–PROTEIN PRECURSOR**

AMYLOID PROTEIN SAA

ANALYSIS

Alveolar hydatid cyst (AHC): inflammation–induced reactive gastrointestinal (GL) amyloidosis in AHC–infected mice and chemical characterization of the GL amyloid. Li W, et al. **Exp Parasitol** 1996 Jun;83(1):1–10

[Serum amyloid A (SAA)] Yamada T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:237–9 (13 ref.) **(Jpn)**

BIOSYNTHESIS

Beta–nerve growth factor as a mediator of the acute phase response in vivo. Nonogaki K, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):956–61

CHEMISTRY

A protein AA–variant derived from a novel serum AA protein, SAA1 delta, in an individual from Papua New Guinea. Westermark P, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):320–3

GENETICS

A protein AA–variant derived from a novel serum AA protein, SAA1 delta, in an individual from Papua New Guinea. Westermark P, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):320–3

Ribozyme mediated cleavage of acute phase serum amyloid A (A–SAA) mRNA in vitro. Gaughan DJ, et al. **FEBS Lett** 1995 Oct 30;374(2):241–5

ISOLATION & PURIFICATION

Both murine SAA1 and SAA2 yield AA amyloid in alveolar hydatid cyst–infected mice. Bell AW, et al. **Scand J Immunol** 1996 Feb;43(2):173–80

PHARMACOLOGY

Inhibition of Alzheimer beta–peptide fibril formation by serum amyloid P component. Janciauskiene S, et al. **J Biol Chem** 1995 Nov 3;270(44):26041–4

Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin–sensitive signaling pathway. Badolato R, et al. **J Immunol** 1995 Oct 15;155(8):4004–10

Serum amyloid A binds specific extracellular matrix glycoproteins and induces the adhesion of resting CD4+ T cells. Preciado–Patt L, et al. **J Immunol** 1996 Feb 1; 156(3):1189–95

AMYLOID SERUM PROTEIN SAA see **AMYLOID PROTEIN SAA**

AMYLOIDOSIS

Amyloidosis. Hawkins PN. **Blood Rev** 1995 Jun;9(2):135–42 (53 ref.)

Renal amyloidosis in childhood. An overview of the topic with 25 years experience. Tinaztepe K. **Turk J Pediatr** 1995 Oct–Dec;37(4):357–73 (18 ref.)

Basic fibroblast growth factor–heparan sulphate complex in the human dialysis–related amyloidosis. Morita H, et al. **Virchows Arch** 1995;427(4):395–400

[Pleural amyloidosis. Apropos of a case and review of the literature] Quinquenel ML, et al. **Rev Pneumol Clin** 1996; 52(1):39–41 (12 ref.) (Eng. Abstr.) **(Fre)**

[Amyloidosis: state of the art (editorial)] Di Monaco C, et al. **Minerva Med** 1995 Jul–Aug;86(7–8):291–7 (Eng. Abstr.) **(Ita)**

[Immunoglobulin light–chain type amyloidosis] Isobe T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1112–6 (5 ref.) **(Jpn)**

[Amyloidosis] Gondo T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):284–7 (14 ref.) **(Jpn)**

BLOOD

Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis. Hachulla E, et al. **Am J Med** 1996 Jul; 101(1):77–87

The effect of desmopressin on platelet aggregation defect in systemic amyloidosis: a preliminary report. Demiroğlu H, et al. **Eur J Haematol** 1996 May;56(5):283–6

CHEMICALLY INDUCED

Extremely active murine amyloid enhancing factor. Shtrasburg S, et al. **Clin Exp Rheumatol** 1996 Jan–Feb; 14(1):37–42

Experimental AA–amyloidosis in mice is inhibited by treatment with the anti–rheumatic drug tenidap. Husebekk A, et al. **Scand J Immunol** 1996 May;43(5):551–5

CLASSIFICATION

Amyloidosis and silicone synovitis: updated classification, updated pathophysiology, and synovial articular abnormalities. Goldman AB, et al. **Radiol Clin North Am** 1996 Mar;34(2):375–94, xi (73 ref.)

[Amyloidosis: definition and classification] Adle–Biassette H, et al. **Arch Anat Cytol Pathol** 1996;44(2–3):101–5 (Eng. Abstr.) **(Fre)**

[Classification of amyloidosis] Husby G. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):234–7 (40 ref.) (Eng. Abstr.) **(Nor)**

COMPLICATIONS

Retroperitoneal amyloidosis, factor IX and X deficiency,and gastrointestinal bleeding. Figler TJ, et al. **Abdom Imaging** 1996 May–Jun;21(3):266–8

Hyporeninaemic hypoaldosteronism and systemic amyloidosis [letter] Malik WA, et al. **Ann Clin Biochem** 1995 Nov;32 (Pt 6):593–4

Resolution of heart failure in patients with AL amyloidosis. Dubrey S, et al. **Ann Intern Med** 1996 Sep 15;125(6):481–4

Giant cell arteritis and amyloidosis: comment on the article by Salvarani et al [letter; comment] Gonzalez–Gay MA, et al. **Arthritis Rheum** 1996 Jun;39(6):1073–4. Comment on: Arthritis Rheum 1994 Nov;37(11):1621–6.

Amyloidosis of the conjunctiva. O'Donnell B, et al. **Aust N Z J Ophthalmol** 1995 Aug;23(3):207–12

Secondary amyloidosis of the urinary bladder: a rare cause of massive haematuria. Hinsch R, et al. **Aust N Z J Surg** 1996 Feb;66(2):127

Grand rounds—Hammersmith Hospital. Reactive (AA) systemic amyloidosis. A cause of refractory nephrotic syndrome [clinical conference] **BMJ** 1996 Apr 27; 312(7038):1087–9

Stridor in rheumatoid arthritis may be caused by laryngeal amyloidosis [letter; comment] Watkinson JC. **BMJ** 1996 May 11;312(7040):1227. Comment on: BMJ 1996 Feb 3;312(7026):295–6.

Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Dubrey S, et al. **Br Heart J** 1995 Nov; 74(5):541–4

Macular amyloidosis with widespread diffuse pigmentation. Wang CK, et al. **Br J Dermatol** 1996 Jul;135(1):135–8

Primary systemic amyloidosis complicated by massive thrombosis. Cools FJ, et al. **Chest** 1996 Jul;110(1):282–4

Secondary amyloidosis complicating arthropathic psoriasis. Tsuda S, et al. **Clin Exp Dermatol** 1996 Mar;21(2):141–4

Ga–67 and Tc–99m (V) DMSA imaging in non–Hodgkin's lymphoma with amyloid tumor. Ohta H, et al. **Clin Nucl Med** 1995 Nov;20(11):998–9

Cutaneous amyloidosis in patients with progressive systemic sclerosis. Ogiyama Y, et al. **Cutis** 1996 Jan;57(1):28–32

Hyperimmunoglobulin M syndrome associated with systemic amyloidosis type AA [letter] Oner A, et al. **Eur J Pediatr** 1995 Dec;154(12):995

'Fragile' liver and massive hepatic haemorrhage due to hereditary amyloidosis. Harrison RF, et al. **Gut** 1996 Jan; 38(1):151–2

Atrial systolic failure in a 46–year–old man. Seki I, et al. **Hosp Pract (Off Ed)** 1996 Jun 15;31(6):177–9

Laryngeal squamous carcinoma associated with longstanding localised amyloidosis. A case report. Navani SS, et al. **Indian J Cancer** 1995 Mar;32(1):43–5 (7 ref.)

A case of primary localized amyloidosis of the penile urethra. Sakuma S, et al. **Int J Urol** 1996 Mar;3(2):163–4

Juvenile rheumatoid arthritis and renal amyloidosis (case report). Kavukçu S, et al. **Int Urol Nephrol** 1995; 27(3):251–6

Giant basal cell carcinoma associated with systemic amyloidosis. Yamamoto S, et al. **J Dermatol** 1996 May; 23(5):329–34

Inflammatory linear verrucose epidermal nevus coexisting with lichen amyloidosus. Zhuang L, et al. **J Dermatol** 1996 Jun;23(6):415–8

Systemic amyloidosis in a patient with hypogammaglobulinaemia. Kotilainen P, et al. **J Intern Med** 1996 Aug;240(2):103–6

Myopathy in primary systemic amyloidosis. Gertz MA, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):655–60

Long–term favourable outcome of portal hypertension complicating primary systemic amyloidosis. Horsmans Y, et al. **Liver** 1995 Dec;15(6):332–4

When does amyloidosis complicate systemic lupus erythematosus? Orellana C, et al. **Lupus** 1995 Oct; 4(5):415–7 (26 ref.)

Disseminated cutaneous infection due to Mycobacterium chelonae in a patient with rheumatoid arthritis, amyloidosis, and renal failure. Forslund T, et al. **Nephrol Dial Transplant** 1995;10(7):1234–6

Occult adrenal insufficiency secondary to amyloidosis in the context of chronic renal failure. Harvey CJ, et al. **Nephrol Dial Transplant** 1995;10(7):1237–9

Amyloid—the great pretender. Korzets Z, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1938–9

Behçet's syndrome presenting as end–stage chronic renal failure due to amyloidosis [letter] Utas C, et al. **Nephrol Dial Transplant** 1995;10(8):1472–3

A patient with amyloidosis, vesicoureteral reflux and renal cell adenoma complicated by intrarenal calcification and acquired cystic renal disease [letter] Akpolat I, et al. **Nephron** 1996;72(2):322

Renal amyloidosis complicating Takayasu's arteritis: a case report [letter] Ateş K, et al. **Nephron** 1996;73(1):111–2

Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman's disease [letter] Paydas S, et al. **Nephron** 1995;71(4):463–4

Severe hypoglycemia in a patient with chronic renal failure due to amyloidosis [letter] Topeli A, et al. **Nephron** 1996; 72(2):330–1

Torsade de pointes and sudden death in a patient with amyloidosis–associated nephropathy [letter] Yang CW, et al. **Nephron** 1995;70(4):499

Pulseless disease with renal amyloidosis [letter] Rath B, et al. **Pediatr Nephrol** 1996 Feb;10(1):129–30

Amyloidosis–related cauda equina compression in long–term hemodialysis patients. Three case reports. Marcelli C, et al. **Spine** 1996 Feb 1;21(3):381–5

Spontaneous liver rupture in amyloidosis. Ooi LL, et al. **Surgery** 1996 Jul;120(1):117–9 (9 ref.)

Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity. Marcatti M, et al. **Thromb Res** 1995 Nov 15;80(4):333–7

Amyloid goiter in cystic fibrosis. Samuels MH, et al. **Thyroid** 1995 Jun;5(3):213–5

[Hodgkin disease and amyloidosis] Jekunen A, et al. **Duodecim** 1994;110(6):602–6 **(Fin)**

[Systemic embolism and thrombosis of the left atrium in a patient in sinus rhythm with cardiac amyloidosis] Roudaut R, et al. **Ann Cardiol Angeiol (Paris)** 1996 Mar;45(3):119–21 (Eng. Abstr.) **(Fre)**

[Colonic pseudo–obstruction caused by digestive amyloidosis in a chronic hemodialyzed patient. Apropos of a case] Tiffet O, et al. **Ann Chir** 1996;50(3):279–82 (11 ref.) (Eng. Abstr.) **(Fre)**

[Cardiac amyloidosis disclosed by abdominal arterial embolism [letter] Kaltenbach G, et al. **Rev Med Interne** 1995;16(9):726–7 **(Fre)**

[Primary AL–type amyloidosis disclosed by Horton disease] Tron AM, et al. **Rev Med Interne** 1995;16(11):850–3 (16 ref.) (Eng. Abstr.) **(Fre)**

[Differential diagnostic challenge in pericardial effusion] Wilke A, et al. **Internist (Berl)** 1995 Sep;36(9):909–11 **(Ger)**

[Amyloidosis of the iris and sclera in the pathogenesis of glaucoma] Ziangirova GG, et al. **Izv Akad Nauk Ser Biol** 1995 Sep–Oct;(5):586–9 (Eng. Abstr.) **(Rus)**

[Morphological features of senile and secondary amyloidosis of the iris and sclera in patients with glaucoma] Krasnov MM, et al. **Vestn Oftalmol** 1996 Jan–Mar;112(1):24–6 (Eng. Abstr.) **(Rus)**

[Amyloid intestinal pseudo–obstruction as initial manifestation of IgA multiple myeloma] Domingo–García P, et al. **An Med Interna** 1995 Jun;12(6):283–5 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Primary systemic amyloidosis presenting with polyneuropathy characterized by very long survival. Rinaldi R, et al. **Acta Neurol Scand** 1995 Jun;91(6):511–3

Musculoskeletal case of the day. Amyloid arthropathy. Kaplan PA, et al. **AJR Am J Roentgenol** 1996 Jul; 167(1):254, 257–8

Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Dubrey SW, et al. **Am J Cardiol** 1996 Feb 1;77(4):313–5

Twenty–one years survival with systemic AL–amyloidosis. Goldsmith DJ, et al. **Am J Kidney Dis** 1996 Aug; 28(2):278–82 (24 ref.)

Musculoskeletal amyloid disease: MRI features. Comesaña L, et al. **Ann Radiol (Paris)** 1995;38(3):150–2

Non–Alzheimer's disease amyloidoses of the nervous system. Castaño EM, et al. **Curr Opin Neurol** 1995 Aug;8(4):279–85 (57 ref.)

Primary amyloidosis presenting as renal infarction. Arias M,

et al. **Eur Radiol** 1996;6(3):346–8

Pleural amyloidosis: thoracoscopic aspects. Bontemps F, et al. **Eur Respir J** 1995 Jun;8(6):1025–7

Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. Perfetti V, et al. **Haematologica** 1995 Sep–Oct;80(5):409–15

Unusual presentation of two rare cases of systemic amyloidosis— a case report. Duggal B, et al. **J Assoc Physicians India** 1996 Jan;44(1):65–6

Unifocal primary amyloidoma of the spine causing compression of the cervical spinal cord: MR findings. Meyers SP, et al. **J Comput Assist Tomogr** 1996 Jul–Aug; 20(4):592–3

Diffuse interstitial pulmonary amyloidosis in rheumatoid arthritis. Sumiya M, et al. **J Rheumatol** 1996 May; 23(5):933–6

Primary amyloidosis of gut presenting with dysphagia. Abbas Z, et al. **JPMA J Pak Med Assoc** 1995 Oct;45(10):274–5

Diagnostic pitfalls and treatment in a young man with systemic amyloidosis [letter] Persey MR, et al. **Lancet** 1996 Aug 17;348(9025):484–5

Primary amyloidosis co-presenting with cervical and massive intra-abdominal lymphadenopathy. Segalov E, et al. **Leuk Lymphoma** 1995 Nov;19(5–6):519–20

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 23–1996. A 62-year-old woman with progressive dyspnea and diffuse reticulonodular pulmonary infiltrates [clinical conference] **N Engl J Med** 1996 Jul 25;335(4):266–73

Amyloidoma of the skull: plain radiographs, CT and MRI. Hidalgo F, et al. **Neuroradiology** 1996 Jan;38(1):44–6

Clinical and computed tomographic characteristics of amyloid tumor of the lacrimal gland. Massry GG, et al. **Ophthalmology** 1996 Aug;103(8):1233–6 (11 ref.)

Combined amyloidosis of the upper and lower respiratory tract. Schulz C, et al. **Respiration** 1995;62(3):163–6

Diagnosing amyloidosis [editorial] Westermark P. **Scand J Rheumatol** 1995;24(6):327–9 (12 ref.)

Primary systemic amyloidosis and the gastrointestinal tract. Fogarty DG, et al. **Ulster Med J** 1995 Oct;64(2):191–6

[Primary amyloidosis of bones. MRI aspects] Faure C, et al. **J Radiol** 1995 Nov;76(11):1025–7 (Eng. Abstr.) **(Fre)**

[Presumed transudative pleural effusion?] Berger P, et al. **Rev Mal Respir** 1995;12(4):377–9 (Eng. Abstr.) **(Fre)**

[Primary localized bronchopulmonary amyloidosis] Beji M, et al. **Rev Pneumol Clin** 1996;52(1):36–8 (Eng. Abstr.) **(Fre)**

[The gastrointestinal manifestations of amyloidosis] Neef B, et al. **Dtsch Med Wochenschr** 1995 Nov 17; 120(46):1597–602 (50 ref.) **(Ger)**

[Macular amyloidosis with systemic involvement?] Braun-Falco M. **Hautarzt** 1995 Aug;46(8):582 **(Ger)**

[A rare cause of cardiopulmonary insufficiency] Scheffold N, et al. **Internist (Berl)** 1996 Apr;37(4):387–91 **(Ger)**

[Cardiac amyloidosis] Meierhenrich R, et al. **Med Klin** 1995 Oct 15;90(10):599–605 (53 ref.) **(Ger)**

[Primary amyloid tumor of the breast. Case report and review of the literature] Bisceglia M, et al. **Pathologica** 1995 Apr; 87(2):162–7 (20 ref.) (Eng. Abstr.) **(Ita)**

[Thyroid amyloidosis diagnosed by echo-guided needle aspiration with a fine needle] Gimondo P, et al. **Radiol Med (Torino)** 1996 Mar;91(3):316–8 (6 ref.) **(Ita)**

[Is early diagnosis of amyloidosis AL possible? Consideration on a representative case] Vivaldi P. **Recenti Prog Med** 1996 Apr;87(4):158–60 (Eng. Abstr.) **(Ita)**

[A case of localized amyloidosis of the ureter] Awakura Y, et al. **Hinyokika Kiyo** 1996 Feb;42(2):135–8 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Diffuse tracheobronchial amyloidosis with airflow limitation and repeated pneumonias] Iwanaga T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):90–5 (Eng. Abstr.) **(Jpn)**

[Primary amyloidosis localized in the bladder] Vicioso Recio L, et al. **Arch Esp Urol** 1995 Nov;48(9):963–6 (8 ref.) (Eng. Abstr.) **(Spa)**

[Anaemia and macroglossia as the first clinical features of multiple myeloma and amyloidosis (letter)] Balaña Quintero C, et al. **Sangre (Barc)** 1995 Oct;40(5):435–6 **(Spa)**

DRUG THERAPY

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Skinner M, et al. **Am J Med** 1996 Mar;100(3):290–8

Anti-amyloid drugs: potential in the treatment of diseases associated with aging. Kisilevsky R. **Drugs Aging** 1996 Feb; 8(2):75–83 (70 ref.)

Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation [letter] Stables RH, et al. **Heart** 1996 Apr; 75(4):426

Extensive lichen amyloidosus refractory to DMSO. Kobayashi T, et al. **J Dermatol** 1995 Oct;22(10):755–8

Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease [see comments] Kisilevsky R, et al. **Nat Med** 1995 Feb;1(2):143–8. Comment in: Nat Med 1995 Feb;1(2):120–2.

Muckle-Wells syndrome nephropathy: lack of response to colchicine therapy. Bustorff MM, et al. **Nephrol Dial Transplant** 1995;10(5):709–10

Effect of colchicine on schistosoma-induced renal amyloidosis in Syrian golden hamsters. Sobh M, et al. **Nephron** 1995;70(4):478–85

EPIDEMIOLOGY

Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Kobayashi H, et al. **Br J Rheumatol** 1996 Jan;35(1):44–9

An estimate of the prevalence of reactive systemic amyloidosis in ankylosing spondylitis [letter; comment] Escalante A, et al. **J Rheumatol** 1995 Nov;22(11):2192–3. Comment on: J Rheumatol 1991 Jan;18(1):100–3.

ETIOLOGY

Dialysis-related amyloidosis in a large CAPD population. Catizone L, et al. **Adv Perit Dial** 1995;11:213–7

Renal amyloidosis secondary to chronic rheumatic inflammatory disease [letter] Thysell H, et al. **Am J Kidney Dis** 1996 Jun;27(6):916

Dialysis-related beta-2-microglobulin amyloidosis after long-term dialysis, and the effect of renal transplantation and cyclosporin therapy [letter; comment] Goldsmith DJ, et al. **Am J Med** 1996 May;100(5):587–8. Comment on: Am J Med 1995 Sep;99(3):243–8.

Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Shapiro DL, et al. **Arthritis Rheum** 1995 Dec;38(12):1851–4 (24 ref.)

Beta 2-microglobulin amyloidosis: why and how to look for it. Schaeffer J, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S3–9 (93 ref.)

Dialysis-related amyloidosis: from raw clinical facts to unresolved questions. Charra B. **Contrib Nephrol** 1995; 112:119–28 (48 ref.)

Role of macrophages in beta 2-microglobulin-related dialysis amyloidosis. Gejyo F, et al. **Contrib Nephrol** 1995; 112:97–104 (18 ref.)

Influence of dialysis membranes on the development of dialysis-related amyloidosis. Miura Y, et al. **Contrib Nephrol** 1995;112:129–36

Beta 2-microglobulin modified with the AGE products of the Maillard reaction in dialysis-related amyloidosis. Miyata T, et al. **Contrib Nephrol** 1995;112:52–64 (52 ref.)

Clinical aspects of dialysis-related amyloidosis. Schäffer J, et al. **Contrib Nephrol** 1995;112:90–6 (36 ref.)

Pathogenesis of dialysis-related amyloidosis. Miyata T, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):493–7 (51 ref.)

Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Couce M, et al. **Diabetes** 1996 Aug;45(8):1094–101

Alveolar hydatid cyst (AHC): inflammation-induced reactive gastrointestinal (GL) amyloidosis in AHC-infected mice and chemical characterization of the GL amyloid. Li W, et al. **Exp Parasitol** 1996 Jun;83(1):1–10

Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis. Brancaccio D, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1262–70

Thyroid epithelial cells produce large amounts of the Alzheimer beta-amyloid precursor protein (APP) and generate potentially amyloidogenic APP fragments. Schmitt TL, et al. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3513–9

Systemic amyloidosis following ankylosing spondylitis associated with congestive heart failure. A case report. Fujito T, et al. **Jpn Heart J** 1995 Sep;36(5):681–8 (17 ref.)

Apolipoprotein E and amyloidogenesis [editorial; comment] Castaño EM, et al. **Lab Invest** 1995 Oct;73(4):457–60. Comment on: Lab Invest 1995 Oct;73(4):469–75.

Association of apolipoprotein E with murine amyloid A protein amyloid [see comments] Kindy MS, et al. **Lab Invest** 1995 Oct;73(4):469–75. Comment in: Lab Invest 1995 Oct;73(4):457–60.

Sand in the sheets [comment] Diehl SR. **Nat Med** 1995 Feb; 1(2):120–2. Comment on: Nat Med 1995 Feb;1(2):143–8.

Eluate from beta 2MG adsorbent beads enhances the expression of IL-1 beta from human monocyte [letter] Inoue H, et al. **Nephrol Dial Transplant** 1995 Nov; 10(11):2161–2

Systemic amyloidosis secondary to pyonephrosis. Resolution after nephrectomy. Mazuecos A, et al. **Nephrol Dial Transplant** 1996 May;11(5):875–8

Pathogenetic and diagnostic aspects of dialysis-related amyloidosis. Schaeffer J, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:4–8 (66 ref.)

Frequency of renal amyloidosis secondary to tuberculosis [letter] Erk O, et al. **Nephron** 1995;71(3):367

New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure. Miyata T. **Nippon Jinzo Gakkai Shi** 1996 May;38(5):191–7 (51 ref.)

Amyloidosis secondary to inflammatory pseudotumor: a rare association [letter] Noyan A, et al. **Pediatr Nephrol** 1995 Dec;9(6):792–3

Increased matrix metalloproteinases as possible cause of osseoarticular tissue destruction in long-term haemodialysis and beta 2-microglobulin amyloidosis. Ohashi K, et al. **Virchows Arch** 1996 Apr;428(1):37–46

[IgG kappa monoclonal gammopathy complicated by AL amyloidosis with symptomatic involvement of the temporal artery (letter)] Nguyen TB, et al. **Rev Med Interne** 1996; 17(6):502 **(Fre)**

[Systemic amyloidosis. Its pathogenesis, clinical picture and therapy] Hetzel GR, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1479–85 (50 ref.) **(Ger)**

[A young woman with rheumatoid arthritis who rapidly developed secondary amyloidosis] Tanimoto K, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):83–9 (Eng. Abstr.) **(Jpn)**

[Diffuse alveolar septal amyloidosis associated with multiple myeloma (IgA lambda type)] Ishiura Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Mar; 34(3):317–21 (Eng. Abstr.) **(Jpn)**

[Countermeasure for patients with amyloidosis due to hemodialysis] Gejo F. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1673–7 (5 ref.) **(Jpn)**

GENETICS

A protein AA-variant derived from a novel serum AA protein, SAA1 delta, in an individual from Papua New Guinea. Westermark P, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):320–3

Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. McCutchen SL, et al. **Biochemistry** 1995 Oct 17;34(41):13527–36

A frame shift mutation in the fibrinogen A alpha chain gene in a kindred with renal amyloidosis. Uemichi T, et al. **Blood** 1996 May 15;87(10):4197–203

Homozygosity and heterozygosity for the transthyretin Leu64 mutation: clinical, biochemical and molecular findings. Ferlini A, et al. **Clin Genet** 1996 Jan;49(1):10–4

Cerebrovascular amyloidosis in squirrel monkeys and rhesus monkeys: apolipoprotein E genotype. Morelli L, et al. **FEBS Lett** 1996 Jan 29;379(2):132–4

Familial AL-amyloidosis in three Italian siblings. Miliani A, et al. **Haematologica** 1996 Mar–Apr;81(2):105–9

Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. Booth DR, et al. **J Clin Invest** 1996 Jun 15;97(12):2714–21

Accelerated senile amyloidosis induced by amyloidogenic Apoa-II gene shortens the life span of mice but does not accelerate the rate of senescence. Higuchi K, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):B295–302

A 38-year-old man with nephrotic syndrome, episodic fever and abdominal pain [clinical conference] Gadallah MF, et al. **J La State Med Soc** 1995 Nov;147(11):493–9

Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis. Helms LR, et al. **J Mol Biol** 1996 Mar 22;257(1):77–86

Coexistence of type I familial amyloid polyneuropathy and spinocerebellar ataxia type 1. Clinical and genetic studies of a Japanese family [letter] Ikeda S, et al. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):586–8

Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Gustavsson A, et al. **Lab Invest** 1995 Nov;73(5):703–8

Lack of beta-amyloidosis in transgenic mice expressing low levels of familial Alzheimer's disease missense mutations. Malherbe P, et al. **Neurobiol Aging** 1996 Mar–Apr; 17(2):205–14

A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis. Jenne DE, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6302–7

A new apolipoprotein AI variant, Trp50Arg, causes hereditary amyloidosis. Booth DR, et al. **QJM** 1995 Oct; 88(10):695–702 (43 ref.)

[Finnish hereditary amyloidosis: a mutation in the gelsolin gene] Maury P. **Duodecim** 1994;110(7):675–80 (27 ref.) **(Fin)**

[Apropos of a case of bilateral perforating corneal ulcer in a patient with Portugese amyloidosis] Donati G, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):360–1 (Eng. Abstr.) **(Fre)**

[Familial amyloidosis, Finnish type with marked anhidrosis] Ishiguchi H, et al. **Rinsho Shinkeigaku** 1996 Mar; 36(3):436–41 (Eng. Abstr.) **(Jpn)**

[Clinical characteristics and genetic background of secondary amyloidosis associated with rheumatoid arthritis in Japanese] Nakai H, et al. **Ryumachi** 1996 Feb;36(1):25–33 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Molecular anatomy and the pathological expression of antibody light chains [comment] Schiffer M. **Am J Pathol** 1996 May;148(5):1339–44 (31 ref.). Comment on: Am J Pathol 1996 May;148(5):1397–406.

Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. Schormann N, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9490–4

METABOLISM

Histological beta-2-microglobulin amyloidosis 10 years after a successful renal transplantation. Jadoul M, et al. **Am J Kidney Dis** 1996 Jun;27(6):888–90

Advanced glycation end products are associated with beta 2-microglobulin amyloidosis [letter] Miyazaki S, et al. **Am J Nephrol** 1995;15(6):535–6

Glycosaminoglycans in dialysis-related amyloidosis. Morita H, et al. **Contrib Nephrol** 1995;112:83–9

Biochemical and histopathological study of beta 2-microglobulin amyloidosis. Ogawa H, et al.

AMYLOIDOSIS

Contrib Nephrol 1995;112:105–10

Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis. Brancaccio D, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1262–70

The age related amyloids: a growing family of unique biochemical substances. Cornwell GG 3rd, et al. **J Clin Pathol** 1995 Nov;48(11):984–9 (41 ref.)

Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Niwa T, et al. **Kidney Int** 1995 Sep;48(3):771–8

Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Niwa T, et al. **Kidney Int** 1996 Mar;49(3):861–7

Amyloid deposition in the thyroid gland in patients with amyloidosis: an incidence study with fine-needle aspiration biopsy of the thyroid [letter] Ertürk S, et al. **Nephrol Dial Transplant** 1995;10(8):1473

Expression of inflammatory cytokines and adhesion molecules in haemodialysis-associated amyloidosis. Inoue H, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2077–82

Immunohistochemical localization of beta 2-microglobulin and advanced glycation end products in amyloid-enriched carpal tunnel ligament [letter] Morita H, et al. **Nephron** 1996;73(1):117–8

Amyloidosis, advanced glycation end products and Alzheimer disease [letter; comment] Smith MA, et al. **Neuroreport** 1995 Aug 21;6(12):1595–6. Comment on: Neuroreport 1995 Apr 19;6(6):866–8.

Degradation of serum amyloid A in amyloid-susceptible and amyloid-resistant mouse strains. Elliott-Bryant R, et al. **Scand J Immunol** 1996 Sep;44(3):223–8

Misfolding the way to disease [news] Taubes G. **Science** 1996 Mar 15;271(5255):1493–5

Proteoglycans in haemodialysis-related amyloidosis. Ohashi K, et al. **Virchows Arch** 1995;427(1):49–59

[A histopathological study of corneal amyloidosis secondary to trichiasis] Kigasawa K, et al. **Nippon Ganka Gakkai Zasshi** 1996 May;100(5):394–400 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

High levels of circulating beta-amyloid peptide do not cause cerebral beta-amyloidosis in transgenic mice. Fukuchi K, et al. **Am J Pathol** 1996 Jul;149(1):219–27

Apolipoprotein AI-derived pulmonary vascular amyloid in aged dogs. Roertgen KE, et al. **Am J Pathol** 1995 Nov; 147(5):1311–7

Atrophic outpouchings of abdominal skin. Nodular cutaneous amyloidosis. Carroll CB, et al. **Arch Dermatol** 1996 Feb; 132(2):223–4, 226–7

Interstitial amyloid deposits in the pituitary gland. Morphometry, immunohistology, and correlation to diseases. Röcken C, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1055–60

Intracerebral A lambda amyloidoma diagnosed by stereotactic biopsy. Schröder R, et al. **Clin Neuropathol** 1995 Nov–Dec;14(6):347–50 (34 ref.)

Lichen amyloidosus and human immunodeficiency virus infection. Buezo GF, et al. **Dermatology** 1995;191(1):56–8

Severe islet amyloidosis in congenital generalized lipodystrophy. Garg A, et al. **Diabetes Care** 1996 Jan; 19(1):28–31

Massive intestinal hemorrhage associated with intestinal amyloidosis. An investigation of underlying pathologic processes. Kaiserling E, et al. **Gen Diagn Pathol** 1995 Oct; 141(2):147–54

Hepatic amyloidosis in Japan: histological and morphometric analysis based on amyloid proteins. Iwata T, et al. **Hum Pathol** 1995 Oct;26(10):1148–53

Localized cutaneous amyloidosis simulating lichen simplex chronicus. Muramatsu T, et al. **J Dermatol** 1995 Oct; 22(10):759–63

Giant primary amyloidoma of the tonsil. López Amado M, et al. **J Laryngol Otol** 1996 Jun;110(6):613–5 (20 ref.)

Localized amyloidosis of the genito-urinary tract [letter] Coyne JD, et al. **J R Soc Med** 1995 Dec;88(12):722–3

A high resolution ultrastructural study of experimental murine AA amyloid. Inoue S, et al. **Lab Invest** 1996 Mar; 74(3):670–83

Immunohistochemical localization of beta 2-microglobulin and advanced glycation end products in amyloid-enriched carpal tunnel ligament [letter] Morita H, et al. **Nephron** 1996;73(1):117–8

Artifactual strain-specific signs of incipient brain amyloidosis in APP transgenic mice. Ali SM, et al. **Neurobiol Aging** 1996 Mar–Apr;17(2):223–34

Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits. Frautschy SA, et al. **Neurobiol Aging** 1996 Mar–Apr;17(2):311–21

Lack of beta-amyloidosis in transgenic mice expressing low levels of familial Alzheimer's disease missense mutations. Malherbe P, et al. **Neurobiol Aging** 1996 Mar–Apr; 17(2):205–14

Cerebral amyloid angiopathy and plaques, and visceral amyloidosis in aged macaques. Uno H, et al. **Neurobiol Aging** 1996 Mar–Apr;17(2):275–81

Nodular amyloidosis of the larynx. Ferrara G, et al. **Pathologica** 1995 Feb;87(1):94–6

Calcifying amyloidoma of the breast. Symonds DA, et al. **South Med J** 1995 Nov;88(11):1169–72

Ocular amyloidosis, with special reference to the hereditary forms with vitreous involvement. Sandgren O. **Surv Ophthalmol** 1995 Nov–Dec;40(3):173–96 (261 ref.)

Primary amyloidosis presenting as an isolated mediastinal mass: diagnosis by fine needle biopsy. Hiller N, et al. **Thorax** 1995 Aug;50(8):908–9

Increased matrix metalloproteinases as possible cause of osseoarticular tissue destruction in long-term haemodialysis and beta 2-microglobulin amyloidosis. Ohashi K, et al. **Virchows Arch** 1996 Apr;428(1):37–46

[Clinical case of the month. Growing cutaneous nodules in a 60-year-old] Jebali A, et al. **Rev Med Liege** 1995 Aug; 50(8):315–6 **(Fre)**

[Primary pulmonary amyloidosis with multiple nodules] Shinohara Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1150–4 (Eng. Abstr.) **(Jpn)**

[The detection of secondary amyloidosis in rheumatoid arthritis by aspiration biopsy of the subcutaneous fatty tissue] Päi S, et al. **Ter Arkh** 1995;67(11):73–5 (Eng. Abstr.) **(Rus)**

[Role of local amyloidosis of the fundus oculi tissues in the pathogenesis of senile maculopathy] Ermilov VV, et al. **Vestn Oftalmol** 1995 Oct–Dec;111(4):24–7 (Eng. Abstr.) **(Rus)**

[Localized laryngeal amyloidosis. Treatment with CO2 laser] de Vergas Gutiérrez J, et al. **Acta Otorrinolaringol Esp** 1995 Sep–Oct;46(5):381–3 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Beta-amyloidosis in normal aging and transmitter signaling in human temporal lobe. Perry EK, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:388–92

QT interval in cardiac amyloidosis [letter] Dubrey S, et al. **Clin Cardiol** 1996 May;19(5):A22, 442

Myopathy in primary systemic amyloidosis. Gertz MA, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):655–60

[Cardiac involvement in amyloidosis. Apropos of a case of hereditary amyloidosis of neurologic expression] Dujardin X, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jan;45(1):30–3 (Eng. Abstr.) **(Fre)**

[Amyloidosis, protein conformation dynamics and neurologic diseases] Tranchant C, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):153–7 (26 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Prevention of dialysis-related amyloidosis using the polyacrylonitrile AN69 membrane. Chanard J. **Contrib Nephrol** 1995;112:137–44 (23 ref.)

PSYCHOLOGY

Reduced taste perception in AL amyloidosis. A frequently unnoticed sensory impairment. Marinone MG, et al. **Haematologica** 1996 Mar–Apr;81(2):110–5

RADIOGRAPHY

Castleman disease with renal amyloidosis: imaging findings and clinical significance. Moon WK, et al. **Abdom Imaging** 1995 Jul–Aug;20(4):376–8

Pulmonary amyloidosis. The Mayo Clinic experience from 1980 to 1993. Utz JP, et al. **Ann Intern Med** 1996 Feb 15; 124(4):407–13

[Localized tracheobronchial amyloidosis. The usefulness of computed tomography] Sánchez Antuña A, et al. **Arch Bronconeumol** 1995 Dec;31(10):540–2 (23 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis. Hachulla E, et al. **Am J Med** 1996 Jul; 101(1):77–87

131I-beta 2-microglobulin scintigraphy in patients with dialysis amyloidosis. Gejyo F, et al. **Clin Nephrol** 1995 Nov; 44 Suppl 1:S14–8

Soft-tissue uptake of Tc-99m DPD (dicarboxypropane diphosphonate) in amyloidosis. De Haro FJ, et al. **Clin Nucl Med** 1996 Jun;21(6):509

Ga-67 and Tc-99m (V) DMSA imaging in non-Hodgkin's lymphoma with amyloid tumor. Ohta H, et al. **Clin Nucl Med** 1995 Nov;20(11):998–9

Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Aprile C, et al. **Eur J Nucl Med** 1995 Dec;22(12):1393–401

Imaging amyloidosis with radiolabelled SAP [editorial] Hawkins PN, et al. **Eur J Nucl Med** 1995 Jul;22(7):595–9 (29 ref.)

Diagnostic radionuclide imaging of dialysis-related amyloidosis. Kiyota A, et al. **Nephrol Dial Transplant** 1995; 10 Suppl 3:9–12

[Scintigraphy of iodine 123 labelled serum amyloid P component in beta 2-microglobulin amyloidosis of hemodialysis] Flipo RM, et al. **Nephrologie** 1995; 16(6):419–25 (Eng. Abstr.) **(Fre)**

SURGERY

Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival. Dubrey S, et al. **Am J Cardiol** 1995 Oct 1;76(10):739–41

Amyloidosis of the conjunctiva. O'Donnell B, et al. **Aust N Z J Ophthalmol** 1995 Aug;23(3):207–12

Role of heart transplantation in systemic amyloidosis [letter] Hawkins PN, et al. **J Heart Lung Transplant** 1996 Mar; 15(3):321–2

Staged endoscopic treatment of laryngeal amyloidosis. Walker PA, et al. **Otolaryngol Head Neck Surg** 1996 Jun; 114(6):801–5

[Liver transplantation in familial amyloidosis (letter)] Gundel UF. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1339 **(Ger)**

[Recurrence of AL type primary localized pulmonary amyloidosis] Zennami S, et al. **Kyobu Geka** 1996 Feb; 49(2):167–71 (Eng. Abstr.) **(Jpn)**

[Localized laryngeal amyloidosis. Treatment with CO2 laser] de Vergas Gutiérrez J, et al. **Acta Otorrinolaringol Esp** 1995 Sep–Oct;46(5):381–3 (Eng. Abstr.) **(Spa)**

THERAPY

High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement [letter] Moreau P, et al. **Blood** 1996 Apr 1; 87(7):3063–4

Pulmonary amyloidosis: treatment with laser therapy and systemic steroids. Nugent AM, et al. **Respir Med** 1996 Aug; 90(7):433–5

[Countermeasure for patients with amyloidosis due to hemodialysis] Gejo F. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1673–7 (5 ref.) **(Jpn)**

[Secondary gastrointestinal amyloidosis: successful treatment with TPN, prednisolone and colchicine therapy. Report of a case] Muramatsu S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct;92(10):1770–5 **(Jpn)**

ULTRASONOGRAPHY

Castleman disease with renal amyloidosis: imaging findings and clinical significance. Moon WK, et al. **Abdom Imaging** 1995 Jul–Aug;20(4):376–8

Amyloidosis of the shoulder in patients on chronic hemodialysis: sonographic findings. Cardinal E, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):153–6

Ultrasonographic evaluation of the carpal tunnel syndrome in hemodialysis patients. Ikegaya N, et al. **Clin Nephrol** 1995 Oct;44(4):231–7

Case report: ultrasound of primary generalised AL amyloid of the small bowel. Whitby EH, et al. **Clin Radiol** 1996 Jun;51(6):447–8

Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. Tei C, et al. **J Am Coll Cardiol** 1996 Sep;28(3):658–64

VETERINARY

A monoclonal gammopathy-induced canine renal amyloidosis. Brown G. **Can Vet J** 1996 Feb;37(2):105

Immunohistochemical study on the deposition of apolipoprotein E in cerebral and islet amyloidoses in cynomolgus monkeys (Macaca fascicularis). Nakamura S, et al. **Exp Anim** 1996 Apr;45(2):199–203

Splenic vein thrombosis resulting in acute anemia: an unusual manifestation of nephrotic syndrome in a Chinese shar pei with reactive amyloidosis. Clements CA, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct;31(5):411–5

Amyloidosis: author's response [letter; comment] Loeven KO. **J Am Anim Hosp Assoc** 1995 Jul–Aug;31(4):276–7. Comment on: J Am Anim Hosp Assoc 1995 Mar–Apr;31(2):100.

Diabetes mellitus and islet amyloidosis in cynomolgus monkeys. Wagner JD, et al. **Lab Anim Sci** 1996 Feb; 46(1):36–41

Cutaneous amyloidosis in a horse with lymphoma. Gliatto JM, et al. **Vet Rec** 1995 Jul 15;137(3):68–9

Inflammatory syndrome of footpads in puppies and AA-amyloidosis [letter] Gruys E. **Vet Rec** 1996 Mar 16; 138(11):264

VIROLOGY

Epstein-Barr virus-related primary cutaneous amyloidosis. Successful treatment with acyclovir and interferon-alpha. Drago F, et al. **Br J Dermatol** 1996 Jan;134(1):170–4

AMYLOPECTIN

BIOSYNTHESIS

From glycogen to amylopectin: a model for the biogenesis of the plant starch granule. Ball S, et al. **Cell** 1996 Aug 9;86(3):349–52 (18 ref.)

METABOLISM

Expression of Escherichia coli branching enzyme in tubers of amylose-free transgenic potato leads to an increased branching degree of the amylopectin. Kortstee AJ, et al. **Plant J** 1996 Jul;10(1):83–90

PHARMACOLOGY

Amylopectin starch induces nonreversible insulin resistance in rats. Wiseman CE, et al. **J Nutr** 1996 Feb;126(2):410–5

AMYLOPECTIN BRANCHING ENZYME see **1,4-ALPHA-GLUCAN BRANCHING ENZYME**

AMYLOPECTINOSIS see **GLYCOGEN STORAGE DISEASE TYPE IV**

AMYLOSE

ADMINISTRATION & DOSAGE

Influence of dietary retrograded starch on the metabolism of neutral steroids and bile acids in rats. Verbeek MJ, et al. **Br J Nutr** 1995 Dec;74(6):807–20

CHEMISTRY

Hydration of alpha–maltose and amylose: molecular modelling and thermodynamics study. Fringant C, et al. **Carbohydr Res** 1995 Nov 30;278(1):27–41

The influence of amylose on starch granule structure. Jenkins PJ, et al. **Int J Biol Macromol** 1995 Dec;17(6):315–21

METABOLISM

Molecular modelling of the interaction between the catalytic site of pig pancreatic alpha–amylase and amylose fragments. Casset F, et al. **Eur J Biochem** 1995 Aug 15; 232(1):284–93

Inclusion/exclusion of fatty acids in amylose complexes as a function of the fatty acid chain length. Godet MC, et al. **Int J Biol Macromol** 1995 Dec;17(6):405–8

Cyclization reaction catalyzed by branching enzyme. Takata H, et al. **J Bacteriol** 1996 Mar;178(6):1600–6

AMYOPLASIA CONGENITA see **ARTHROGRYPOSIS**

AMYOTROPHIC LATERAL SCLEROSIS

Amyotrophic lateral sclerosis. Eisen A. **Intern Med** 1995 Sep; 34(9):824–32 (93 ref.)

Lessons from Rodriquez v. British Columbia. Milton N. **Issues Law Med** 1995 Fall;11(2):123–48

Neuroepidemiology of amyotrophic lateral sclerosis: clues to aetiology and pathogenesis. Román GC. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):131–7 (87 ref.)

BLOOD

Effect of the type of serum in the medium on sodium ascorbate–induced cytotoxicity. Sakagami H, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1937–41

Vitamin A and E levels are normal in amyotrophic lateral sclerosis. Iwasaki Y, et al. **J Neurol Sci** 1995 Oct; 132(2):193–4

Cytotoxic effects of ALS serum on human cell lines. Jansson I, et al. **J Neurol Sci** 1995 May;129 Suppl:138–9

Dehydroepiandrosterone sulphate (DHEAS) concentrations and amyotrophic lateral sclerosis. Eisen A, et al. **Muscle Nerve** 1995 Dec;18(12):1481–3

[The level of Interleukin–6 in patients with amyotrophic lateral sclerosis] Klimek A, et al. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):537–44 (Eng. Abstr.) **(Pol)**

CEREBROSPINAL FLUID

Association of polyclonal anti–GM1 IgM and anti–neurofilament antibodies with CSF oligoclonal bands in a young with amyotrophic lateral sclerosis. Annunziata P, et al. **Acta Neurol Scand** 1995 Nov;92(5):387–93

Neurofilament phosphorylation is increased in ventral horn neurons of neonatal rat spinal cord exposed to cerebrospinal fluid from patients with amyotrophic lateral sclerosis. Rao MS, et al. **Neurodegeneration** 1995 Dec;4(4):397–401

Amyotrophic lateral sclerosis cerebrospinal fluid is not toxic to cultured spinal motor neurons. Iwasaki Y, et al. **Neurol Res** 1995 Oct;17(5):393–5

alpha–Tocopherol quinone level is remarkably low in the cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Tohgi H, et al. **Neurosci Lett** 1996 Mar 22;207(1):5–8

COMPLICATIONS

Sympathetic skin response in patients with amyotrophic lateral sclerosis. Masur H, et al. **Funct Neurol** 1995 May–Jun;10(3):131–5

Thoracic radicular symptoms in amyotrophic lateral sclerosis. Newman DS, et al. **J Neurol Sci** 1995 May;129 Suppl:38–41

The influence of speaking rate on vowel space and speech intelligibility for individuals with amyotrophic lateral sclerosis. Turner GS, et al. **J Speech Hear Res** 1995 Oct; 38(5):1001–13

[Acoustic parameters of voice and speech in a case of bulbar amyotrophic lateral sclerosis] Crevier–Buchman L, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(4):169–73 (Eng. Abstr.) **(Fre)**

[Frontal type dementia and amyotrophic lateral sclerosis. 3 cases with (HmPAO Tc99m) single–photon emission tomography study] Vercelletto M, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):640–7 (43 ref.) (Eng. Abstr.) **(Fre)**

[An experience of surgery for thymolipoma in a patient with amyotrophic lateral sclerosis] Yoshida H, et al. **Kyobu Geka** 1995 Dec;48(13):1092–5 (Eng. Abstr.) **(Jpn)**

[A case of emergency admission for CO2 narcosis in a patient with amyotrophic lateral sclerosis] Shichinohe Y, et al. **Masui** 1995 Sep;44(9):1246–9 (Eng. Abstr.) **(Jpn)**

[AIDS and primary lateral sclerosis? (letter)] de la Fuente–Fernández R. **Med Clin (Barc)** 1996 Jan 13; 106(1):36 **(Spa)**

DIAGNOSIS

Somatosensory evoked potentials in the differential diagnosis between spinal cord compression and amyotrophic lateral sclerosis. de Carvalho M, et al. **Acta Neurol Scand** 1995 Jul;92(1):72–6

The anterolateral funiculus in the spinal cord in amyotrophic lateral sclerosis. Oyanagi K, et al. **Acta Neuropathol (Berl)** 1995;90(3):221–7

Atypical amyotrophic lateral sclerosis. Ben Hamida M, et al. **Adv Neurol** 1995;68:153–5 (9 ref.)

Natural history of amyotrophic lateral sclerosis. Quantification of symptoms, signs, strength, and function. Brooks BR, et al. **Adv Neurol** 1995;68:163–84 (27 ref.)

Clues to the diagnosis of amyotrophic lateral sclerosis. Cambier J, et al. **Adv Neurol** 1995;68:161–2 (12 ref.)

Megaslope, natural course, and historical controls in amyotrophic lateral sclerosis trials. Conradi S, et al. **Adv Neurol** 1995;68:219–24 (7 ref.)

Amyotrophic lateral sclerosis. A multifactorial disease. Eisen AA. **Adv Neurol** 1995;68:121–34 (108 ref.)

Natural history of amyotrophic lateral sclerosis. Observations with the Charing Cross Amyotrophic Lateral Sclerosis Rating Scales. Guiloff RJ, et al. **Adv Neurol** 1995;68:185–98 (28 ref.)

Natural history of amyotrophic lateral sclerosis. A discussion. Meininger V, et al. **Adv Neurol** 1995;68:199–207 (18 ref.)

The diagnosis of amyotrophic lateral sclerosis. Pouget J, et al. **Adv Neurol** 1995;68:143–52 (82 ref.)

Overview of the pathogenesis and therapy of amyotrophic lateral sclerosis. Serratrice GT, et al. **Adv Neurol** 1995; 68:1–5

The diagnosis of amyotrophic lateral sclerosis. A discussion. Swash M. **Adv Neurol** 1995;68:157–60 (21 ref.)

Remarks concerning root clinical manifestation of amyotrophic lateral sclerosis (coincidence or evolution of the disease). Krasińska–Czerlunczakiewicz H, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:163–7

The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I–II Study Group. **Arch Neurol** 1996 Feb;53(2):141–7

Caring for the terminally Ill. Bascom PB, et al. **Hosp Pract (Off Ed)** 1996 May 15;31(5):75–8, 82–4, 89; discussion 89–90

The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinicopathological study. Chaudhuri KR, et al. **J Neurol Sci** 1995 May;129 Suppl:11–2

Transcranial magnetic stimulation as a diagnostic and prognostic test in amyotrophic lateral sclerosis. Claus D, et al. **J Neurol Sci** 1995 May;129 Suppl:30–4

Superoxide dismutase and free radicals in sporadic amyotrophic lateral sclerosis: relationship to clinical data. Ihara Y, et al. **J Neurol Sci** 1995 Dec;134(1–2):51–6

Prenatal diagnosis of X–linked spinal and bulbar muscular atrophy in a Greek family. Yapijakis C, et al. **Prenat Diagn** 1996 Mar;16(3):262–5

Sleep and breathing in amyotrophic lateral sclerosis [letter] Ferguson KA, et al. **Sleep** 1995 Jul;18(6):514

[Chronic progressive spinobulbar spasticity (primary lateral sclerosis)] Heene R, et al. **Fortschr Neurol Psychiatr** 1996 May;64(5):192–203 (42 ref.) (Eng. Abstr.) **(Ger)**

[To disclose to the patients the diagnosis and information about the likely course of amyotrophic lateral sclerosis] Hayashi H. **No To Shinkei** 1996 May;48(5):409–15 (22 ref.) **(Jpn)**

[Needle electromyography in the thoracic paraspinal muscles of motor neuron disease] Kyuno K, et al. **No To Shinkei** 1996 Jul;48(7):637–42 (Eng. Abstr.) **(Jpn)**

[Prognostic factors in amyotrophic lateral sclerosis] Martí–Fàbregas J, et al. **Neurologia** 1996 May;11(5):174–81 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Neurotrophic factors and amyotrophic lateral sclerosis. Askanas V. **Adv Neurol** 1995;68:241–4 (14 ref.)

Should N–methyl–D–aspartate or non–N–methyl–D–aspartate glutamate receptor antagonist be used in amyotrophic lateral sclerosis? Blin O. **Adv Neurol** 1995;68:259–61 (16 ref.)

Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis. Potential and pitfalls. Henderson CE. **Adv Neurol** 1995;68:235–40 (22 ref.)

Excitotoxic blocking strategies in amyotrophic lateral sclerosis. Hugon J. **Adv Neurol** 1995;68:245–52; discussion 253–8 (56 ref.)

The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis. Malta E. **Adv Neurol** 1995; 68:263–9; discussion 271–5

Pathogenesis and therapy of amyotrophic lateral sclerosis. Introduction. Serratrice GT, et al. **Adv Neurol** 1995; 68:xix–xx

Use of growth factors in the treatment of motor neuron diseases. Windebank AJ. **Adv Neurol** 1995;68:229–34 (22 ref.)

Potential use of gabapentin and lamotrigine. Cory PR, et al. **Ann Pharmacother** 1995 Nov;29(11):1160–1 (10 ref.)

Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis. Welty DF, et al. **Ann Pharmacother** 1995 Nov;29(11):1164–7

Reduction of fasciculations in patients with amyotrophic lateral sclerosis with the use of gabapentin [letter] Romano JG. **Arch Neurol** 1996 Aug;53(8):716

The pharmacokinetics of subcutaneously administered recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis: relation to parameters of the acute–phase response. The ALS CNTF Treatment Study (ACTS) Phase I–II Study Group. **Clin Neuropharmacol** 1995 Dec;18(6):500–14

A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I–II Study Group. **Clin Neuropharmacol** 1995 Dec; 18(6):515–32

A controlled one–year trial of dextromethorphan in amyotrophic lateral sclerosis. Blin O, et al. **Clin Neuropharmacol** 1996 Apr;19(2):189–92

New hope for treatment of Lou Gehrig's disease. Piascik P. **J Am Pharm Assoc (Wash)** 1996 Jun;NS36(6):355–6

The insulin–like growth factor signaling system and ALS neurotrophic factor treatment strategies. Festoff BW, et al. **J Neurol Sci** 1995 May;129 Suppl:114–21 (60 ref.)

Pharmacokinetics and tolerability of ventricularly administered superoxide dismutase in monkeys and preliminary clinical observations in familial ALS. Smith RA, et al. **J Neurol Sci** 1995 May;129 Suppl:13–8

Riluzole and amyotrophic lateral sclerosis [letter; comment] Guiloff RJ, et al. **Lancet** 1996 Aug 3;348(9023):336–7. Comment on: Lancet 1996 May 25;347(9013):1425–31.

Dose–ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II [see comments] Lacomblez L, et al. **Lancet** 1996 May 25;347(9013):1425–31. Comment in: Lancet 1996 Aug 3;348(9023):336–7.

Riluzole for amyotrophic lateral sclerosis. **Med Lett Drugs Ther** 1995 Dec 8;37(963):113–4

A clinical trial of verapamil in amyotrophic lateral sclerosis. Miller RG, et al. **Muscle Nerve** 1996 Apr;19(4):511–5

Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Aebischer P, et al. **Nat Med** 1996 Jun;2(6):696–9

A double–blind placebo–controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. **Neurology** 1996 May; 46(5):1244–9

Controlled trial of nimodipine in amyotrophic lateral sclerosis. Miller RG, et al. **Neuromuscul Disord** 1996 Mar; 6(2):101–4

ENZYMOLOGY

Two novel mutations in the gene for copper zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis. Enayat ZE, et al. **Hum Mol Genet** 1995 Jul;4(7):1239–40

Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. Lim GP, et al. **J Neurochem** 1996 Jul;67(1):251–9

Cu,Zn SOD in German families with ALS. Bachus R, et al. **J Neurol Sci** 1995 May;129 Suppl:93–5

Superoxide dismutase activity in lymphoblastoid cells from motor neurone disease/amyotrophic lateral sclerosis (MND/ALS) patients. Garofalo O, et al. **J Neurol Sci** 1995 May;129 Suppl:90–2

Blood superoxide dismutase, catalase and glutathione peroxidase activities in familial and sporadic amyotrophic lateral sclerosis. Przedborski S, et al. **Neurodegeneration** 1996 Mar;5(1):57–64

Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene. Ikeda M, et al. **Neurology** 1995 Nov;45(11):2038–42

Increased Cu/Zn superoxide dismutase–like immunoreactivity in the swollen axons of rats intoxicated chronically with beta,beta'–iminodipropionitrile. Nishiyama K, et al. **Neurosci Lett** 1995 Jul 21;194(3):205–8

Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis. Siddons MA, et al. **Neurosci Lett** 1996 Apr 12;208(1):65–8

A gain–of–function of an amyotrophic lateral sclerosis–associated Cu,Zn–superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Yim MB, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5709–14

Mutant enzyme provides new insights into the cause of ALS [news; comment] Marx J. **Science** 1996 Jan 26; 271(5248):446–7. Comment on: Science 1996 Jan 26;271(5248):515–8.

Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis [see comments] Wiedau–Pazos M, et al. **Science** 1996 Jan 26;271(5248):515–8. Comment in: Science 1996 Jan 26;271(5248):446–7.

Analysis of aldehyde oxidase and xanthine dehydrogenase/oxidase as possible candidate genes for autosomal recessive familial amyotrophic lateral sclerosis. Berger R, et al. **Somat Cell Mol Genet** 1995 Mar; 21(2):121–31

AMYOTROPHIC LATERAL SCLEROSIS

EPIDEMIOLOGY

Amyotrophic lateral sclerosis, heterogeneous susceptibility, trauma, and epidemiology. Riggs JE. **Arch Neurol** 1996 Mar;53(3):225–7

Amyotrophic lateral sclerosis and occupational history. A pilot case–control study. Strickland D, et al. **Arch Neurol** 1996 Aug;53(8):730–3

Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. Lee JR, et al. **J Neurol Sci** 1995 Oct; 132(2):207–15

MND risk factors: an epidemiological study in the north west of England. Mitchell JD, et al. **J Neurol Sci** 1995 May;129 Suppl:61–4

Clinical epidemiology of amyotrophic lateral sclerosis. Brooks BR. **Neurol Clin** 1996 May;14(2):399–420 (298 ref.)

Unchanged incidence and prevalence of amyotrophic lateral sclerosis in the canton of Zürich. Huber S, et al. **Schweiz Arch Neurol Psychiatr** 1995;146(2):52–4

[Amyotrophic lateral sclerosis] Martí-Fàbregas J, et al. **Neurologia** 1996 Mar;11(3):99–108 (157 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Autoimmunity as an etiological factor in sporadic amyotrophic lateral sclerosis. Appel SH, et al. **Adv Neurol** 1995;68:47–57 (88 ref.)

Amyotrophic lateral sclerosis. A multifactorial disease. Eisen AA. **Adv Neurol** 1995;68:121–34 (108 ref.)

The viral hypothesis. Gastaut JL. **Adv Neurol** 1995;68:135–7 (33 ref.)

The possible role of a secondary pathogenetic factor in amyotrophic lateral sclerosis. Pinelli P, et al. **Adv Neurol** 1995;68:29–40 (25 ref.)

Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Rothstein JD. **Adv Neurol** 1995;68:7–20; discussion 21–7 (80 ref.)

Amyotrophic lateral sclerosis with paraproteins and autoantibodies. Rowland LP. **Adv Neurol** 1995;68:93–105; discussion 107–11 (136 ref.)

Anti-calcium channel autoantibodies in amyotrophic lateral sclerosis. A review of the evidence. Seagar MJ, et al. **Adv Neurol** 1995;68:67–72 (30 ref.)

Pathogenesis and therapy of amyotrophic lateral sclerosis. Introduction. Serratrice GT, et al. **Adv Neurol** 1995; 68:xix–xx

Overview of the pathogenesis and therapy of amyotrophic lateral sclerosis. Serratrice GT, et al. **Adv Neurol** 1995; 68:1–5

Trauma, axonal injury, and amyotrophic lateral sclerosis: a clinical correlate of a neuropharmacologic model. Riggs JE. **Clin Neuropharmacol** 1995 Jun;18(3):273–6

Amyotrophic lateral sclerosis after accidental injection of mercury [letter] Schwarz S, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):698

Subunit-destabilizing mutations in Drosophila copper/zinc superoxide dismutase: neuropathology and a model of dimer dysequilibrium [see comments] Phillips JP, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8574–8. Comment in: Proc Natl Acad Sci U S A 1995 Sep 12;92(19):8533–4.

[Amyotrophic lateral sclerosis—causative role of trace elements] Yase Y. **Nippon Rinsho** 1996 Jan;54(1):123–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Multiple sclerosis and amyotrophic lateral sclerosis. The development of concepts of their etiology and pathogenesis] Zavalishin IA. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):24–8 (Eng. Abstr.) **(Rus)**

[Amyotrophic lateral sclerosis] Martí-Fàbregas J, et al. **Neurologia** 1996 Mar;11(3):99–108 (157 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Reduced fecundity in male ALS gene-carriers. Johnson WG, et al. **Am J Med Genet** 1995 Nov 6;59(2):149–53

Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Bristol LA, et al. **Ann Neurol** 1996 May;39(5):676–9

Analysis of chromosome 5q13 genes in amyotrophic lateral sclerosis: homozygous NAIP deletion in a sporadic case. Jackson M, et al. **Ann Neurol** 1996 Jun;39(6):796–800

Difficulties in distinguishing sporadic from familial amyotrophic lateral sclerosis. Orrell RW, et al. **Ann Neurol** 1996 Jun;39(6):810–2

SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Rouleau GA, et al. **Ann Neurol** 1996 Jan;39(1):128–31

Use of tissue culture models to study environmental–genetic interactions relevant to neurodegenerative diseases. Durham HD, et al. **Clin Exp Pharmacol Physiol** 1995 May; 22(5):366–7

Motor neuron disease caused by mutations in superoxide dismutase 1. Wong PC, et al. **Curr Opin Neurol** 1995 Aug; 8(4):294–301 (77 ref.)

Superoxide dismutase 1: identification of a novel mutation in a case of familial amyotrophic lateral sclerosis. Kostrzewa M, et al. **Hum Genet** 1996 Jul;98(1):48–50

Familial amyotrophic lateral sclerosis/motor neurone disease (FALS): a review of current developments. de Belleroche J, et al. **J Med Genet** 1995 Nov;32(11):841–7 (65 ref.)

Clinical characteristics of familial amyotrophic lateral sclerosis with Cu/Zn superoxide dismutase gene mutations. Abe K, et al. **J Neurol Sci** 1996 Mar;136(1–2):108–16

A new familial disorder presenting with amyotrophic lateral sclerosis-like manifestation: a clinicopathological study. Ono S, et al. **J Neurol Sci** 1995 Dec;134(1–2):160–6

Investigation of a null mutation of the CNTF gene in familial amyotrophic lateral sclerosis. Orrell RW, et al. **J Neurol Sci** 1995 Oct;132(2):126–8

Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Chiu AY, et al. **Mol Cell Neurosci** 1995 Aug;6(4):349–62

Evidence for DNA damage in amyotrophic lateral sclerosis [letter] Fitzmaurice PS, et al. **Muscle Nerve** 1996 Jun; 19(6):797–8

Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Aebischer P, et al. **Nat Med** 1996 Jun;2(6):696–9

Toxic mutants in Charcot's sclerosis [letter; comment] Cleveland DW, et al. **Nature** 1995 Nov 23;378(6555):342–3 . Comment on: Nature 1995 Apr 6;374(6522):504–5.

Mice overexpressing the human neurofilament heavy gene as a model of ALS. Julien JP, et al. **Neurobiol Aging** 1995 May–Jun;16(3):487–90; discussion 490–2

Variable clinical symptoms in familial amyotrophic lateral sclerosis with a novel point mutation in the Cu/Zn superoxide dismutase gene. Ikeda M, et al. **Neurology** 1995 Nov;45(11):2038–42

Analysis of the KSP repeat of the neurofilament heavy subunit in familiar amyotrophic lateral sclerosis. Rooke K, et al. **Neurology** 1996 Mar;46(3):789–90

Identification of three novel mutations in the gene for Cu/Zn superoxide dismutase in patients with familial amyotrophic lateral sclerosis. Sapp PC, et al. **Neuromuscul Disord** 1995 Sep;5(5):353–7

Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis. Siddons MA, et al. **Neurosci Lett** 1996 Apr 12;208(1):65–8

Modeling Lou Gehrig's disease in the fruit fly [comment] McCabe ER. **Proc Natl Acad Sci U S A** 1995 Sep 12; 92(19):8533–4. Comment on: Proc Natl Acad Sci U S A 1995 Sep 12;92(19):8574–8.

The Golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease. Mourelatos Z, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5472–7

Analysis of aldehyde oxidase and xanthine dehydrogenase/oxidase as possible candidate genes for autosomal recessive familial amyotrophic lateral sclerosis. Berger R, et al. **Somat Cell Mol Genet** 1995 Mar; 21(2):121–31

[Hope for amyotrophic lateral sclerosis? (editorial)] Jokelainen M. **Duodecim** 1994;110(16):1499–501 (15 ref.) **(Fin)**

[Familial amyotrophic lateral sclerosis showing variable clinical courses with (Leu84—>Val) mutation of Cu/Zn superoxide dismutase] Ohnishi A, et al. **Rinsho Shinkeigaku** 1996 Mar;36(3):485–7 (Eng. Abstr.) **(Jpn)**

[Two siblings of familial amyotrophic lateral sclerosis with multisystemic degeneration characterized by mild involvement of the middle root zone of the posterior column, Clarke's nuclei and spinocerebellar tract] Yoshida M, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):589–99 (27 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Association of polyclonal anti-GM1 IgM and anti-neurofilament antibodies with CSF oligoclonal bands in a young with amyotrophic lateral sclerosis. Annunziata P, et al. **Acta Neurol Scand** 1995 Nov;92(5):387–93

Neuronal targets of serum and cerebrospinal fluid autoantibodies in amyotrophic lateral sclerosis. Greiner A, et al. **Acta Neuropathol (Berl)** 1996;91(1):67–71

Amyotrophic lateral sclerosis. An autoimmune disease? Drachman DB, et al. **Adv Neurol** 1995;68:59–65 (54 ref.)

Antibodies against microglia/brain macrophages in the cerebrospinal fluid of a patient with acute amyotrophic lateral sclerosis and presenile dementia. Banati RB, et al. **Clin Neuropathol** 1995 Jul–Aug;14(4):197–200

Expression of calbindin-D28K in motoneuron hybrid cells after retroviral infection with calbindin-D28K cDNA prevents amyotrophic lateral sclerosis IgG-mediated cytotoxicity. Ho BK, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6796–801

The role of immune processes in amyotrophic lateral sclerosis pathogenesis. Alexianu ME. **Rom J Neurol Psychiatry** 1995 Jul–Dec;33(3–4):215–27

Immunological findings in amyotrophic lateral sclerosis. Antel JP, et al. **Springer Semin Immunopathol** 1995; 17(1):17–28 (103 ref.)

[Hope for amyotrophic lateral sclerosis? (editorial)] Jokelainen M. **Duodecim** 1994;110(16):1499–501 (15 ref.) **(Fin)**

METABOLISM

Amyotrophic lateral sclerosis. A multifactorial disease. Eisen AA. **Adv Neurol** 1995;68:121–34 (108 ref.)

Copper/zinc superoxide dismutase mutations and free radical damage in amyotrophic lateral sclerosis. Hosler BA, et al. **Adv Neurol** 1995;68:41–6 (24 ref.)

Animal models of amyotrophic lateral sclerosis. Mitsumoto H, et al. **Adv Neurol** 1995;68:73–87; discussion 89–91 (80 ref.)

The possible role of a secondary pathogenetic factor in amyotrophic lateral sclerosis. Pinelli P, et al. **Adv Neurol** 1995;68:29–40 (25 ref.)

Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Rothstein JD. **Adv Neurol** 1995;68:7–20; discussion 21–7 (80 ref.)

Amyotrophic lateral sclerosis with paraproteins and autoantibodies. Rowland LP. **Adv Neurol** 1995;68:93–105; discussion 107–11 (136 ref.)

Ciliary neurotrophic factor (CNTF) genotypes and CNTF contents in human sciatic nerves as measured by a sensitive enzyme-linked immunoassay. Takahashi R, et al. **J Neurochem** 1996 Aug;67(2):525–9

Ciliary neurotrophic factor receptor expression in spinal cord and motor cortex in amyotrophic lateral sclerosis. Duberley RM, et al. **J Neurol Sci** 1995 May;129 Suppl:109–13

HTLV tax-rex DNA and antibodies in idiopathic amyotrophic lateral sclerosis. Ferrante P, et al. **J Neurol Sci** 1995 May;129 Suppl:140–4

Superoxide dismutase and free radicals in sporadic amyotrophic lateral sclerosis: relationship to clinical data. Ihara Y, et al. **J Neurol Sci** 1995 Dec;134(1–2):51–6

Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. Kasarskis EJ, et al. **J Neurol Sci** 1995 Jun;130(2):203–8

Decrease of medullary catecholaminergic neurons in multiple system atrophy and Parkinson's disease and their preservation in amyotrophic lateral sclerosis. Kato S, et al. **J Neurol Sci** 1995 Oct;132(2):216–21

Individuals with amyotrophic lateral sclerosis are in caloric balance despite losses in mass. Nau KL, et al. **J Neurol Sci** 1995 May;129 Suppl:47–9

Synaptic vesicle proteins, synaptophysin and chromogranin A in amyotrophic lateral sclerosis. Schiffer D, et al. **J Neurol Sci** 1995 May;129 Suppl:68–74

Regional changes of ciliary neurotrophic factor and nerve growth factor levels in post mortem spinal cord and cerebral cortex from patients with motor disease. Anand P, et al. **Nat Med** 1995 Feb;1(2):168–72

The imbalance of brain large-chain aminoacid availability in amyotrophic lateral sclerosis patients treated with high doses of branched-chain aminoacids. Bastone A, et al. **Neurochem Int** 1995 Dec;27(6):467–72

Studies on cellular free radical protection mechanisms in the anterior horn from patients with amyotrophic lateral sclerosis. Shaw IC, et al. **Neurodegeneration** 1995 Dec; 4(4):391–6

[3H]phorbol 12,13-dibutyrate/PKC binding in thoracic spinal cord: no change in amyotrophic lateral sclerosis. Krieger C, et al. **Neuroreport** 1995 Jul 10;6(10):1381–4

Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Abe K, et al. **Neurosci Lett** 1995 Oct 20;199(2):152–4

Detection by 4-parameter microscopic imaging and increase of rare mononuclear blood leukocyte types expressing the Fc gamma RIII receptor (CD16) for immunoglobulin G in human sporadic amyotrophic lateral sclerosis (ALS). Schubert W, et al. **Neurosci Lett** 1995 Sep 22;198(1):29–32

Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. Engelhardt JI, et al. **Synapse** 1995 Jul;20(3):185–99

MORTALITY

Mortality risk stratification in amyotrophic lateral sclerosis. Louwerse ES, et al. **J Neurol Sci** 1995 May;129 Suppl:27

Gompertzian analysis of amyotrophic lateral sclerosis mortality in Italy, 1957–1987; application to birth cohorts. Chiò A, et al. **Neuroepidemiology** 1995;14(6):269–77

Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors. Preux PM, et al. **Neuroepidemiology** 1996;15(3):153–60

PATHOLOGY

Changes of unmyelinated nerve fibers in sural nerve in amyotrophic lateral sclerosis, Parkinson's disease and multiple system atrophy. Kanda T, et al. **Acta Neuropathol (Berl)** 1996;91(2):145–54

Amyotrophic lateral sclerosis with marked neurological asymmetry: clinicopathological study. Mochizuki Y, et al. **Acta Neuropathol (Berl)** 1995;90(1):44–50

The anterolateral funiculus in the spinal cord in amyotrophic lateral sclerosis. Oyanagi K, et al. **Acta Neuropathol (Berl)** 1995;90(3):221–7

Synaptic loss in the proximal axon of anterior horn neurons in motor neuron disease. Sasaki S, et al. **Acta Neuropathol (Berl)** 1995;90(2):170–5

Neuropathology of the cortex in amyotrophic lateral sclerosis with dementia. Pellissier JF, et al. **Adv Neurol** 1995; 68:139–41 (41 ref.)

Motor neuron disease with involvement of the pallido-luysio-nigral system and mesencephalic tegmentum. Kato S, et al. **Clin Neuropathol** 1995 Jul–Aug; 14(4):241–4 (15 ref.)

Cerebral magnetic resonance imaging pathology and cerebro-spinal fluid protein in sporadic amyotrophic lateral sclerosis (sALS). Westarp ME, et al. **Clin Neuropathol** 1995

Jul-Aug;14(4):228-32
Trauma, axonal injury, and amyotrophic lateral sclerosis: a clinical correlate of a neuropharmacologic model. Riggs JE. **Clin Neuropharmacol** 1995 Jun;18(3):273-6
Magnetic resonance signal abnormalities along the pyramidal tracts in amyotrophic lateral sclerosis. Carella F, et al. **Ital J Neurol Sci** 1995 Nov;16(8):511-5
Clinical characteristics of familial amyotrophic lateral sclerosis with Cu/Zn superoxide dismutase gene mutations. Abe K, et al. **J Neurol Sci** 1996 Mar;136(1-2):108-16
Amyotrophic lateral sclerosis associated with multiple myeloma, endocrinopathy and skin changes suggestive of a POEMS syndrome variant. Gericke CA, et al. **J Neurol Sci** 1995 May;129 Suppl:58-60
Preliminary results of proton magnetic resonance spectroscopy in motor neurone disease (amytrophic lateral sclerosis). Jones AP, et al. **J Neurol Sci** 1995 May;129 Suppl:85-9
A new familial disorder presenting with amyotrophic lateral sclerosis-like manifestation: a clinicopathological study. Ono S, et al. **J Neurol Sci** 1995 Dec;134(1-2):160-6
Magnetic resonance imaging of the corticospinal tracts in amyotrophic lateral sclerosis. Terao S, et al. **J Neurol Sci** 1995 Nov;133(1-2):66-72
Apoptosis in ALS is not restricted to motoneurons: Bcl-2 expression is increased in post-central cortex, adjacent to the affected motor cortex. Troost D, et al. **J Neurol Sci** 1995 May;129 Suppl:79-80
Pathological findings in a patient with amyotrophic lateral sclerosis and multifocal motor neuropathy with conduction block. Veugelers B, et al. **J Neurol Sci** 1996 Mar; 136(1-2):64-70
Sporadic ALS/MND: a global neurodegeneration with retroviral involvement? Westarp ME, et al. **J Neurol Sci** 1995 May;129 Suppl:145-7
Corpus callosum atrophy in amyotrophic lateral sclerosis. Yamauchi H, et al. **J Neurol Sci** 1995 Dec;134(1-2):189-96
Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis. Ikonomidou C, et al. **J Neuropathol Exp Neurol** 1996 Feb; 55(2):211-24
Alterations in nitrogen monoxide-synthesizing cortical neurons in amyotrophic lateral sclerosis with dementia. Kuljis RO, et al. **J Neuropathol Exp Neurol** 1996 Jan; 55(1):25-35
Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement. Shibata N, et al. **J Neuropathol Exp Neurol** 1996 Apr;55(4):481-90
Skin involvement in amyotrophic lateral sclerosis. Kolde G, et al. **Lancet** 1996 May 4;347(9010):1226-7
Ultrastructural abnormalities with inclusions in Onuf's nucleus in motor neuron disease (amyotrophic lateral sclerosis). Pullen AH, et al. **Neuropathol Appl Neurobiol** 1995 Aug;21(4):327-40
Apoptosis in amyotrophic lateral sclerosis is not restricted to motor neurons. Bcl-2 expression is increased in unaffected post-central gyrus. Troost D, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):498-504
The Golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease. Mourelatos Z, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5472-7
Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Tu PH, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3155-60

PHYSIOPATHOLOGY

Respiratory function deterioration is not time-linked with upper-limb onset in amyotrophic lateral sclerosis. Martí-Fàbregas J, et al. **Acta Neurol Scand** 1995 Sep; 92(3):261-4
Electrically induced blink reflex and clinical blinking ability in patients with amyotrophic lateral sclerosis. Shimoda M, et al. **Acta Neurol Scand** 1995 Aug;92(2):141-4
Natural history of amyotrophic lateral sclerosis. Quantification of symptoms, signs, strength, and function. Brooks BR, et al. **Adv Neurol** 1995;68:163-84 (27 ref.)
Megaslope, natural course, and historical controls in amyotrophic lateral sclerosis trials. Conradi S, et al. **Adv Neurol** 1995;68:219-24 (7 ref.)
Natural history of amyotrophic lateral sclerosis. Observations with the Charing Cross Amyotrophic Lateral Sclerosis Rating Scales. Guiloff RJ, et al. **Adv Neurol** 1995;68:185-98 (28 ref.)
Natural history of amyotrophic lateral sclerosis. A discussion. Meininger V, et al. **Adv Neurol** 1995;68:199-207 (18 ref.)
Animal models of amyotrophic lateral sclerosis. Mitsumoto H, et al. **Adv Neurol** 1995;68:73-87; discussion 89-91 (80 ref.)
Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Kasarskis EJ, et al. **Am J Clin Nutr** 1996 Jan;63(1):130-7
Neuroprotective effects of free radical scavengers and energy repletion in animal models of neurodegenerative disease. Schulz JB, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:100-10; discussion 116-8 (56 ref.)
A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Julien JP. **Biochem Cell Biol** 1995 Sep-Oct; 73(9-10):593-7 (45 ref.)
Sleep-disordered breathing in amyotrophic lateral sclerosis. Ferguson KA, et al. **Chest** 1996 Sep;110(3):664-9
Hyposensitivity of peripheral alpha-adrenoceptors in respirator-dependent amyotrophic lateral sclerosis assessed by intravenous norepinephrine infusion. Shimizu T, et al. **Clin Auton Res** 1995 Jun;5(3):165-9
Superoxide dismutase in familial amyotrophic lateral sclerosis: models for gain of function. Brown RH Jr. **Curr Opin Neurobiol** 1995 Dec;5(6):841-6 (48 ref.)
Abnormal excitability of the corticospinal pathway in patients with amyotrophic lateral sclerosis: a single motor unit study using transcranial magnetic stimulation. Kohara N, et al. **Electroencephalogr Clin Neurophysiol** 1996 Feb; 101(1):32-41
The electrophysiological study of differential diagnosis between amyotrophic lateral sclerosis and cervical spondylotic myelopathy. Kang DX, et al. **Electromyogr Clin Neurophysiol** 1995 Jun-Jul;35(4):231-8
Eye movement in amyotrophic lateral sclerosis: a longitudinal study. Palmowski A, et al. **Ger J Ophthalmol** 1995 Nov; 4(6):355-62
Stapedial reflex in amyotrophic lateral sclerosis. Shimizu T, et al. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):544-8
A positron emission tomography study of frontal lobe function (verbal fluency) in amyotrophic lateral sclerosis. Abrahams S, et al. **J Neurol Sci** 1995 May;129 Suppl:44-6
Oxidative stress: its role in the pathogenesis of amyotrophic lateral sclerosis. Bergeron C. **J Neurol Sci** 1995 May;129 Suppl:81-4 (57 ref.)
Phrenic nerve conduction in amyotrophic lateral sclerosis. Evangelista T, et al. **J Neurol Sci** 1995 May;129 Suppl:35-7
The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies. Festoff BW, et al. **J Neurol Sci** 1995 May;129 Suppl:114-21 (60 ref.)
Prognostic values of electroneurographic and electromyographic features in amyotrophic lateral sclerosis. Louwerse ES, et al. **J Neurol Sci** 1995 May;129 Suppl:29
Increased sympathetic outflow to muscles in patients with amyotrophic lateral sclerosis: a comparison with other neuromuscular patients. Shindo K, et al. **J Neurol Sci** 1995 Dec;134(1-2):57-60
Amyotrophic lateral sclerosis and pregnancy. Vincent O, et al. **J Neurol Sci** 1995 May;129 Suppl:42-3
Slow motor conduction mainly limited to motor root in amyotrophic lateral sclerosis. Ertaş M, et al. **Muscle Nerve** 1996 Aug;19(8):1003-8
Thenar motor unit number estimates using the multiple point stimulation technique: reproducibility studies in ALS patients and normal subjects. Felice KJ. **Muscle Nerve** 1995 Dec;18(12):1412-6
Decreased heart rate variability in amyotrophic lateral sclerosis. Pisano F, et al. **Muscle Nerve** 1995 Nov; 18(11):1225-31
Does muscle reinnervation produce electromechanical dissociation in amyotrophic lateral sclerosis? Venkatesh S, et al. **Muscle Nerve** 1995 Nov;18(11):1335-7
Cortical projections to spinal motoneurons: changes with aging and amyotrophic lateral sclerosis. Eisen A, et al. **Neurology** 1996 May;46(5):1396-404
Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group. McGuire D, et al. **Neurology** 1996 May; 46(5):1442-4

PSYCHOLOGY

Cognitive deficits in non-demented amyotrophic lateral sclerosis patients: a neuropsychological investigation. Abrahams S, et al. **J Neurol Sci** 1995 May;129 Suppl:54-5
Primary lateral sclerosis: a neuropsychological study. Caselli RJ, et al. **Neurology** 1995 Nov;45(11):2005-9
Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group. McGuire D, et al. **Neurology** 1996 May; 46(5):1442-4
[The meeting between patients and professionals who treat them. Qualitative interview of patients with amyotrophic lateral sclerosis and their closest relatives] Timm HU. **Ugeskr Laeger** 1996 Mar 25;158(13):1812-7 (Eng. Abstr.) **(Dan)**

REHABILITATION

[Discontinuing ventilation of patients with amyotrophic lateral sclerosis. Medical, legal and ethical aspects] Borasio GD. **Med Klin** 1996 Apr 12;91 Suppl 2:51-2 **(Ger)**
[Possibilities and limits of ventilation in amyotrophic lateral sclerosis] Hein H, et al. **Med Klin** 1996 Apr 12;91 Suppl 2:48-9 **(Ger)**

THERAPY

The design of clinical trials in amyotrophic lateral sclerosis. Azulay JP. **Adv Neurol** 1995;68:225-7 (13 ref.)
Megaslope, natural course, and historical controls in amyotrophic lateral sclerosis trials. Conradi S, et al. **Adv Neurol** 1995;68:219-24 (7 ref.)
Issues in amyotrophic lateral sclerosis clinical trial design. Munsat TL. **Adv Neurol** 1995;68:209-18 (33 ref.)
Overview of the pathogenesis and therapy of amyotrophic lateral sclerosis. Serratrice GT, et al. **Adv Neurol** 1995; 68:1-5
Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation. Advance care planning and outcomes. Moss AH, et al. **Chest** 1996 Jul;110(1):249-55
Hyposensitivity of peripheral alpha-adrenoceptors in respirator-dependent amyotrophic lateral sclerosis assessed by intravenous norepinephrine infusion. Shimizu T, et al. **Clin Auton Res** 1995 Jun;5(3):165-9
Caring for the terminally Ill. Bascom PB, et al. **Hosp Pract (Off Ed)** 1996 May 15;31(5):75-8, 82-4, 89; discussion 89-90
Ethical issues in the care of patients with amyotrophic lateral sclerosis. Società Italiana di Neurologia (SIN) Working Group "Bioethics and Neurology". **Ital J Neurol Sci** 1995 Jun;16(5):329-32
Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. Mazzini L, et al. **J Neurol** 1995 Oct;242(10):695-8
World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House "Therapeutic Trials in ALS" Workshop Contributors. **J Neurol Sci** 1995 May;129 Suppl:1-10 (0 ref.)
Baseline assessments in amyotrophic lateral sclerosis trials. Bossuyt PM, et al. **J Neurol Sci** 1995 May;129 Suppl:28
Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. Pinto AC, et al. **J Neurol Sci** 1995 May;129 Suppl:19-26
Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Mezaki T, et al. **Neurology** 1996 Mar;46(3):845-6

VIROLOGY

The viral hypothesis. Gastaut JL. **Adv Neurol** 1995;68:135-7 (33 ref.)
Absence of serological evidence for foamy virus infection in patients with amyotrophic lateral sclerosis. Rösener M, et al. **J Med Virol** 1996 Mar;48(3):222-6
Sporadic ALS/MND: a global neurodegeneration with retroviral involvement? Westarp ME, et al. **J Neurol Sci** 1995 May;129 Suppl:145-7
Search for persistent infection with poliovirus or other enteroviruses in amyotrophic lateral sclerosis-motor neurone disease. Swanson NR, et al. **Neuromuscul Disord** 1995 Nov;5(6):457-65

AMYXIN see **TILORONE**

ANABAENA

CHEMISTRY

Solution structure of reduced plastocyanin from the blue-green alga Anabaena variabilis. Badsberg U, et al. **Biochemistry** 1996 Jun 4;35(22):7021-31
Structure-function relationships in the ferredoxin/ferredoxin: NADP+ reductase system from Anabaena. Hurley JK, et al. **Biochimie** 1995;77(7-8):539-48
Antitumor-promoting activities of various synthetic 1-O-acyl-3-O-(6'-O-acyl-beta-D-galactopyranosyl)-sn-glycerols related to natural product from freshwater cyanobacterium Anabaena flos-aquae f. flos-aquae. Shirahashi H, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul; 44(7):1404-6
Actin-related proteins in Anabaena spp. and Escherichia coli. Guerrero-Barrera AL, et al. **Microbiology** 1996 May;142 (Pt 5):1133-40
Interference of nucleases in cyanobacterium ferredoxin purification. Bes MT, et al. **Prep Biochem** 1995 Aug; 25(3):89-97
Crystal structure of thioredoxin-2 from Anabaena. Saarinen M, et al. **Structure** 1995 Oct 15;3(10):1097-108

ENZYMOLOGY

Characterization of two recombinant forms of ferredoxin-NADP+ reductase from Anabaena PCC 7119 (presentation reference 204). Martinez-Julvez M, et al. **Biochem Soc Trans** 1996 Feb;24(1):36S
Kinetic characterization of Anabaena ferredoxin-NADP+ reductase mutants. Martínez-Júlvez M, et al. **Biochem Soc Trans** 1996 Feb;24(1):33S
Crystal structures of a ferredoxin: NADP+ reductase and of a complex with NADP+. Serre L, et al. **Biochem Soc Trans** 1996 Feb;24(1):10S
Site-directed mutagenesis of lysine382, the activator-binding site, of ADP-glucose pyrophosphorylase from Anabaena PCC 7120. Sheng J, et al. **Biochemistry** 1996 Mar 5; 35(9):3115-21
The characterization of two aminopeptidase activities from the cyanobacterium Anabaena flos-aquae. Niven GW. **Biochim Biophys Acta** 1995 Dec 6;1253(2):193-8
Biochemical characterization of purified zeta-carotene desaturase from Anabaena PCC 7120 after expression in Escherichia coli. Albrecht M, et al. **Eur J Biochem** 1996 Feb 15;236(1):115-20
Molecular biological analysis of a bidirectional hydrogenase from cyanobacteria. Schmitz O, et al. **Eur J Biochem** 1995 Oct 1;233(1):266-76
Reversible hydrogenase of Anabaena variabilis ATCC 29413:

catalytic properties and characterization of redox centres. Serebryakova LT, et al. **FEBS Lett** 1996 Mar 25; 383(1–2):79–82

Proteolytic degradation of dinitrogenase reductase from Anabaena variabilis (ATCC 29413) as a consequence of ATP depletion and impact of oxygen. Durner J, et al. **J Bacteriol** 1996 Feb;178(3):606–10

Cloning, sequencing, and regulation of the glutathione reductase gene from the cyanobacterium Anabaena PCC 7120. Jiang F, et al. **J Biol Chem** 1995 Sep 29; 270(39):22882–9

A second nitrogenase in vegetative cells of a heterocyst-forming cyanobacterium. Thiel T, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9358–62

GENETICS

Conformational switches involved in orchestrating the successive steps of group I RNA splicing. Golden BL, et al. **Biochemistry** 1996 Mar 26;35(12):3754–63

Long tandemly repeated repetitive (LTRR) sequences in the filamentous cyanobacterium Anabaena sp. PCC 7120. Masepohl B, et al. **Biochim Biophys Acta** 1996 Jun 3; 1307(1):26–30

Active photosynthesis in cyanobacterial mutants with directed modifications in the ligands for two iron–sulfur clusters on the PsaC protein of photosystem I. Mannan RM, et al. **EMBO J** 1996 Apr 15;15(8):1826–33

Molecular biological analysis of a bidirectional hydrogenase from cyanobacteria. Schmitz O, et al. **Eur J Biochem** 1995 Oct 1;233(1):266–76

A comparison of gene organization in the zwf region of the genomes of the cyanobacteria Synechococcus sp. PCC 7942 and Anabaena sp. PCC 7120. Newman J, et al. **FEMS Microbiol Lett** 1995 Nov 1;133(1–2):187–93

Cloning and sequence of ftsZ and flanking regions from the cyanobacterium Anabaena PCC 7120. Doherty HM, et al. **Gene** 1995 Sep 22;163(1):93–6

A novel insertion sequence (IS)–like element of the thermophilic bacterium PS3 promotes expression of the alanine carrier protein–encoding gene. Murai N, et al. **Gene** 1995 Sep 22;163(1):103–7

The hglK gene is required for localization of heterocyst-specific glycolipids in the cyanobacterium Anabaena sp. strain PCC 7120. Black K, et al. **J Bacteriol** 1995 Nov;177(22):6440–8

Evidence that the hanA gene coding for HU protein is essential for heterocyst differentiation in, and cyanophage A–4(L) sensitivity of, Anabaena sp. strain PCC 7120. Khudyakov I, et al. **J Bacteriol** 1996 Jun;178(12):3572–7

Transcription of the Anabaena sp. strain PCC 7120 ntcA gene: multiple transcripts and NtcA binding. Ramasubramanian TS, et al. **J Bacteriol** 1996 Feb; 178(3):922–6

Isolation of the Anabaena sp. strain PCC 7120 sigA gene in a transcriptional-interference selection. Ramasubramanian TS, et al. **J Bacteriol** 1995 Nov; 177(22):6676–8

Nitrate reductase activity and heterocyst suppression on nitrate in Anabaena sp. strain PCC 7120 require moeA. Ramaswamy KS, et al. **J Bacteriol** 1996 Jul;178(13):3893–8

Isolation and characterization of the VnfEN genes of the cyanobacterium Anabaena variabilis. Thiel T. **J Bacteriol** 1996 Aug;178(15):4493–9

Cloning, sequencing, and regulation of the glutathione reductase gene from the cyanobacterium Anabaena PCC 7120. Jiang F, et al. **J Biol Chem** 1995 Sep 29; 270(39):22882–9

Characterization of a nitrogen–fixation (nif) gene cluster from Anabaena azollae 1a shows that closely related cyanobacteria have highly variable but structured intergenic regions. Jackman DM, et al. **Microbiology** 1995 Sep;141 (Pt 9):2235–44

Distinct and differently regulated Mo–dependent nitrogen–fixing systems evolved for heterocysts and vegetative cells of Anabaena variabilis ATCC 29413: characterization of the fdxH1/2 gene regions as part of the nif1/2 gene clusters. Schrautemeier B, et al. **Mol Microbiol** 1995 Oct;18(2):357–69

Transaldolase genes from the cyanobacteria Anabaena variabilis and Synechocystis sp. PCC 6803: comparison with other eubacterial and eukaryotic homologues. Köhler U, et al. **Plant Mol Biol** 1996 Jan;30(1):213–8

Analysis of genes encoding the cell division protein FtsZ and a glutathione synthetase homologue in the cyanobacterium Anabaena sp. PCC 7120. Zhang CC, et al. **Res Microbiol** 1995 Jul–Aug;146(6):445–55

METABOLISM

Cyanylation of the thiol of the cysteine of flavodoxin from Anabaena PCC 7119. Gallagher ME, et al. **Biochem Soc Trans** 1996 Feb;24(1):40S

Photoaccumulation in photosystem I does produce a phylloquinone (A1.–) radical. Heathcote P, et al. **Biochemistry** 1996 May 28;35(21):6644–50

Active photosynthesis in cyanobacterial mutants with directed modifications in the ligands for two iron–sulfur clusters on the PsaC protein of photosystem I. Mannan RM, et al. **EMBO J** 1996 Apr 15;15(8):1826–33

Isolation, characterization and electron microscopy analysis of a hemidiscoidal phycobilisome type from the cyanobacterium Anabaena sp. PCC 7120. Ducret A, et al. **Eur J Biochem** 1996 Mar 15;236(3):1010–24

PHYSIOLOGY

Expression of ferredoxin–NADP+ reductase in heterocysts from Anabaena sp. Razquin P, et al. **Biochem J** 1996 May 15;316 (Pt 1):157–60

GvpCs with reduced numbers of repeating sequence elements bind to and strengthen cyanobacterial gas vesicles. Kinsman R, et al. **Mol Microbiol** 1995 Jul;17(1):147–54

RADIATION EFFECTS

Ultraviolet–B photodestruction of a light–harvesting complex. Lao K, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5258–63

ANABASINE

CHEMISTRY

[Effect of a hydrophilic cadmium complex with anabasine on energized rat liver mitochondria] Korotkov SM, et al. **Dokl Akad Nauk** 1996 Feb;346(4):552–4 **(Rus)**

ANABOLIC STEROIDS

Apocrine metaplasia in gynecomastia by fine needle aspiration as a possible indicator of anabolic steroid use. A report of two cases. Fowler LJ, et al. **Acta Cytol** 1996 Jul–Aug;40(4):734–8

Narcissism and empathy in steroid users. Porcerelli JH, et al. **Am J Psychiatry** 1995 Nov;152(11):1672–4

The Adolescents Training and Learning to Avoid Steroids (ATLAS) prevention program. Background and results of a model intervention. Goldberg L, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):713–21

Three cases of nalbuphine hydrochloride dependence associated with anabolic steroid use. McBride AJ, et al. **Br J Sports Med** 1996 Mar;30(1):69–70

Resistance trained athletes using or not using anabolic steroids compared to runners: effects on cardiorespiratory variables, body composition, and plasma lipids. Yeater R, et al. **Br J Sports Med** 1996 Mar;30(1):11–4

Anabolic steroid abuse and male infertility. Apakama I, et al. **Br J Urol** 1995 Dec;76(6):802–3

Fat–free mass index in users and nonusers of anabolic–androgenic steroids. Kouri EM, et al. **Clin J Sport Med** 1995 Oct;5(4):223–8

Insulin–like growth factor (IGF)–I levels in postmenopausal women receiving tibolone. Hopkins KD, et al. **Horm Metab Res** 1995 Aug;27(8):387–8

Beyond performance enhancement: polypharmacy among collegiate users of steroids. Meilman PW, et al. **J Am Coll Health** 1995 Nov;44(3):98–104

Anabolic steroid abuse and renal–cell carcinoma [letter] Bryden AA, et al. **Lancet** 1995 Nov 11;346(8985):1306–7

Anabolic steroids—a contemporary perspective [letter] Uzych L. **S Afr Med J** 1996 Jun;86(6):700–1

Anabolic steroid use and associated health risk behaviours. Middleman AB, et al. **Sports Med** 1996 Apr;21(4):251–5 (26 ref.)

[Anabolic androgenic steroids: a nightmare for control of doping or a drug?] Stárka L. **Cas Lek Cesk** 1996 Mar 6; 135(5):131–4 (Eng. Abstr.) **(Cze)**

[The use of anabolic hormones and growth promoters in meat production and its consequences to man] Maghuin–Rogister G. **J Pharm Belg** 1995 Sep–Oct;50(5):455–60 **(Fre)**

ADMINISTRATION & DOSAGE

Social physique anxiety, body esteem, and social anxiety in bodybuilders and self–reported anabolic steroid users. Schwerin MJ, et al. **Addict Behav** 1996 Jan–Feb;21(1):1–8

Body image and steroid use in male bodybuilders. Blouin AG, et al. **Int J Eat Disord** 1995 Sep;18(2):159–65

Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Lovejoy JC, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19(9):614–24

Prevention of post–oophorectomy bone loss with Tibolone. Lyritis GP, et al. **Maturitas** 1995 Nov;22(3):247–53

ADVERSE EFFECTS

Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements, and ethanol: response to ursodeoxycholic acid treatment. Singh C, et al. **Am J Gastroenterol** 1996 Apr;91(4):783–5

Rupture of the triceps tendon associated with steroid injections [letter; comment] Lambert MI, et al. **Am J Sports Med** 1995 Nov–Dec;23(6):778. Comment on: Am J Sports Med 1993 May–Jun;21(3):482–5.

CNS effects and abuse liability of anabolic–androgenic steroids. Lukas SE. **Annu Rev Pharmacol Toxicol** 1996; 36:333–57 (125 ref.)

Anabolic steroid abuse by body builders and male subfertility. Lloyd FH, et al. **BMJ** 1996 Jul 13;313(7049):100–1

Testosterone, androgens and the risk of myocardial infarction [editorial; comment] Crook D. **Br J Clin Pract** 1996 Jun; 50(4):180–1. Comment on: Br J Clin Pract 1996 Jun;50(4):222–3.

Myocardial infarction with extensive intracoronary thrombus induced by anabolic steroids [see comments] Fisher M, et al. **Br J Clin Pract** 1996 Jun;50(4):222–3. Comment in: Br J Clin Pract 1996 Jun;50(4):180–1.

Gynaecomastia in bodybuilders [comment] Neild D. **Br J Clin Pract** 1995 Jul–Aug;49(4):172. Comment on: Br J Clin Pract 1995 Jul–Aug;49(4):177–9.

Surgical correction of gynaecomastia in bodybuilders [see comments] Reyes RJ, et al. **Br J Clin Pract** 1995 Jul–Aug; 49(4):177–9. Comment in: Br J Clin Pract 1995 Jul–Aug;49(4):172.

Anabolic steroids and psoriasis exacerbation [letter] Lear JT, et al. **Br J Dermatol** 1996 Apr;134(4):809

Bilateral rupture of the quadriceps tendon associated with anabolic steroids. Liow RY, et al. **Br J Sports Med** 1995 Jun;29(2):77–9

Evolution of serum lipids in two male bodybuilders using anabolic steroids. Lajarin F, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):970–2

Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. Kosaka A, et al. **J Gastroenterol** 1996 Jun; 31(3):450–4 (24 ref.)

Adverse effects of anabolic steroids. Goldberg L. **JAMA** 1996 Jul 17;276(3):257

Anabolic steroids and the mind. Corrigan B. **Med J Aust** 1996 Aug 19;165(4):222–6 (51 ref.)

The effects of anabolic androgenic steroids on serum ubiquinone and dolichol levels among steroid abusers. Karila T, et al. **Metabolism** 1996 Jul;45(7):844–7

Endometriosis and osteoporosis in practice [letter; comment] Maartens R. **S Afr Med J** 1995 Nov;85(11):1201. Comment on: S Afr Med J 1995 Feb;85(2):117.

Anabolic steroids—a contemporary view [letter; comment] Millar AP. **S Afr Med J** 1995 Dec;85(12):1303–4. Comment on: S Afr Med J 1994 Aug;84(8 Pt 1):468–9. Comment on: S Afr Med J 1995 Apr;85(4):290–1.

[Health risks associated with the use of anabolic steroids] Huhtaniemi I. **Duodecim** 1994;110(10):1020–8 (33 ref.) **(Fin)**

[HDL breakdown in an athlete taking anabolic steroids (letter)] Heim J, et al. **Presse Med** 1996 Mar 16;25(9):458 **(Fre)**

[Doping—anabolic steroid abuse—careless homicide] Schneider V, et al. **Versicherungsmedizin** 1996 Jun 1; 48(3):104–6 (Eng. Abstr.) **(Ger)**

[Anabolic steroid abuse and mental disorder] Nakatani Y, et al. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Oct; 30(5):333–47 (45 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Anabolic steroids, athletic drug testing, and the Olympic Games [editorial; comment] Bowers LD, et al. **Clin Chem** 1996 Jul;42(7):999–1000. Comment on: Clin Chem 1996 Jul;42(7):1001–20.

CHEMISTRY

Gas chromatography/mass spectometry identification of long–term excreted metabolites of the anabolic steroid 4–chloro–1,2–dehydro–17alpha–methyltestosterone in humans. Schanzer W, et al. **J Steroid Biochem Mol Biol** 1996 Mar;57(5–6):363–76

METABOLISM

Metabolism of anabolic androgenic steroids [see comments] Schänzer W. **Clin Chem** 1996 Jul;42(7):1001–20 (95 ref.). Comment in: Clin Chem 1996 Jul;42(7):999–1000.

Metabolism of anabolic steroids in humans: synthesis of 6 beta–hydroxy metabolites of 4–chloro–1,2–dehydro–17 alpha–methyltestosterone, fluoxymesterone, and metandienone. Schänzer W, et al. **Steroids** 1995 Apr; 60(4):353–66

PHARMACOLOGY

Short term blood pressure and metabolic effects of tibolone in postmenopausal women with non–insulin dependent diabetes. Feher MD, et al. **Br J Obstet Gynaecol** 1996 Mar; 103(3):281–3

Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Kouri EM, et al. **Drug Alcohol Depend** 1995 Nov;40(1):73–9

Induction of "male–specific" cytochrome P450 isozymes in female rats by oxandrolone. Waskiewicz MJ, et al. **Drug Metab Dispos** 1995 Nov;23(11):1291–6

The effect of add–back treatment with tibolone (Livial) on patients treated with the gonadotropin–releasing hormone agonist triptorelin (Decapeptyl). Lindsay PC, et al. **Fertil Steril** 1996 Feb;65(2):342–8

Production responses to various doses and ratios of estradiol benzoate and trenbolone acetate implants in steers and heifers. Herschler RC, et al. **J Anim Sci** 1995 Oct; 73(10):2873–81

Effect of a combined trenbolone acetate and estradiol implant on feedlot performance, carcass characteristics, and carcass composition of feedlot steers. Johnson BJ, et al. **J Anim Sci** 1996 Feb;74(2):363–71

Stimulation of circulating insulin–like growth factor I (IGF–I) and insulin–like growth factor binding proteins (IGFBP) due to administration of a combined trenbolone acetate and estradiol implant in feedlot cattle. Johnson BJ, et al. **J Anim Sci** 1996 Feb;74(2):372–9

Chronic anabolic–androgenic steroid treatment affects brain

GABA(A) receptor-gated chloride ion transport. Bitran D, et al. **Life Sci** 1996;58(7):573–83

Cardiovascular effects of androgenic-anabolic steroids. Melchert RB, et al. **Med Sci Sports Exerc** 1995 Sep; 27(9):1252–62 (114 ref.)

Anabolic-androgenic steroid increases running endurance in rats. Van Zyl CG, et al. **Med Sci Sports Exerc** 1995 Oct; 27(10):1385–9

Effects of the anabolic steroid nandrolone decanoate on plasma lipids and coronary arteries of female cynomolgus macaques. Obasanjo IO, et al. **Metabolism** 1996 Apr; 45(4):463–8

[3H]dexamethasone binding activity in liver microsomes is modulated differently by 17 alpha-alkylated androgens and testosterone in vivo. Fernández L, et al. **Pharmacol Toxicol** 1995 Oct;77(4):264–9

Effect of anabolic steroids on behavior and physiological characteristics of female mice. Bronson FH, et al. **Physiol Behav** 1996 Jan;59(1):49–55

[A comparative study of the anabolic action of ecdysten, leveton and Prime Plus, preparations of plant origin] Gadzhieva RM, et al. **Eksp Klin Farmakol** 1995 Sep–Oct; 58(5):46–8 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Growth promotion by oxandrolone in a girl with short stature and early pubertal development treated with growth hormone and gonadotropin-releasing hormone-analogue. A case study. Hermanussen M. **Acta Paediatr** 1995 Oct; 84(10):1207–10

Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Schols AM, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1268–74

Anabolic hormones in cardiomyoplasty [letter; comment] Chekanov V. **Ann Thorac Surg** 1995 Nov;60(5):1461–2. Comment on: Ann Thorac Surg 1995 Apr;59(4):961–9; discussion 969–70.

Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Hengge UR, et al. **Br J Nutr** 1996 Jan; 75(1):129–38

Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Geusens P. **Clin Rheumatol** 1995 Sep;14 Suppl 3:32–9 (52 ref.)

The effect of prolonged administration of an anabolic steroid (oxandrolone) on growth in boys with constitutionally delayed growth and puberty. Schroor EJ, et al. **Eur J Pediatr** 1995 Dec;154(12):953–7

Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. Nilsson KO, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):635–40

Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. Mendenhall CL, et al. **JPEN J Parenter Enteral Nutr** 1995 Jul–Aug;19(4):258–65

Changes in sex behaviour after menopause: effects of tibolone. Palacios S, et al. **Maturitas** 1995 Sep;22(2):155–61

Clenbuterol: a substitute for anabolic steroids? Prather ID, et al. **Med Sci Sports Exerc** 1995 Aug;27(8):1118–21 (24 ref.)

Evolution of serum erythropoietin after androgen administration to hemodialysis patients: a prospective study. Teruel JL, et al. **Nephron** 1995;70(3):282–6

Oxandrolone therapy in constitutionally delayed growth and puberty. Bio-Technology General Corporation Cooperative Study Group. Wilson DM, et al. **Pediatrics** 1995 Dec;96(6):1095–100

A decreasing CD4+/CD8+ ratio after one month of treatment with stanazolol in postmenopausal women. Zofková I, et al. **Steroids** 1995 Jul;60(7):430–3

[Myelodysplastic syndrome with CREST syndrome successfully treated with metenolone—A case report] Hamamoto K, et al. **Rinsho Ketsueki** 1996 Apr;37(4):362–5 (Eng. Abstr.) **(Jpn)**

TOXICITY

Toxic effects of anabolic-androgenic steroids in primary rat hepatic cell cultures. Welder AA, et al. **J Pharmacol Toxicol Methods** 1995 Aug;33(4):187–95

ANACONDA see **BOIDAE**

ANAE see **NAPHTHOL AS D ESTERASE**

ANAEROBIC BACTERIA see **BACTERIA, ANAEROBIC**

ANAEROBIC THRESHOLD

The effect of an aerobic interval training program on intermittent anaerobic performance. Gaiga MC, et al. **Can J Appl Physiol** 1995 Dec;20(4):452–64

Determination of accumulated O2 deficit in exhaustive short-duration exercise. Hill DW. **Can J Appl Physiol** 1996 Feb;21(1):63–74

An aid to the determination of the ventilatory threshold. Bischoff MM, et al. **Eur J Appl Physiol** 1995;71(1):65–70

Exercise intensity prescription in cardiovascular disease. Theoretical basis for anaerobic threshold determination. Gordon NF, et al. **J Cardpulm Rehabil** 1995 May–Jun; 15(3):193–6 (20 ref.)

Value of gas exchange analysis in heart disease [see comments] McConnell TR, et al. **J Cardpulm Rehabil** 1995 Jul–Aug;15(4):257–61. Comment in: J Cardpulm Rehabil 1996 Mar–Apr;16(2):136. Comment in: J Cardpulm Rehabil 1996 Mar–Apr;16(2):137.

Failure of hyperoxic gas to alter the arterial lactate anaerobic threshold. Sadowsky S, et al. **J Cardpulm Rehabil** 1995 Mar–Apr;15(2):114–21

The concept of lactate threshold. A short review. Antonutto G, et al. **J Sports Med Phys Fitness** 1995 Mar;35(1):6–12 (39 ref.)

Determination of the heart rate deflection point by the Dmax method. Kara M, et al. **J Sports Med Phys Fitness** 1996 Mar;36(1):31–4

Measurement and validity of the ventilatory threshold in patients with congenital heart disease. Ohuchi H, et al. **Pediatr Cardiol** 1996 Jan–Feb;17(1):7–14

Blood coagulability changes during exercise and its relationship with the anaerobic threshold. Chicharro JL, et al. **Thromb Res** 1995 Sep 15;79(5–6):515–22

[Reduced glutathione and anaerobic threshold] Pigozzi F, et al. **Clin Ter** 1996 Jan–Feb;147(1–2):13–24 (Eng. Abstr.) **(Ita)**

[Expired gas analysis—focused on VO2 max and anaerobic threshold] Omiya K. **Rinsho Byori** 1996 Jul;44(7):605–10 (Eng. Abstr.) **(Jpn)**

[Doppler echographic criteria in determination of the aerobic threshold and ischemia of the lower limbs] Ivanov SV, et al. **Med Tekh** 1995 Sep–Oct;(5):3–6 (Eng. Abstr.) **(Rus)**

[Accuracy and validity of the lactic threshold compared to other noninvasive methods of measuring the anaerobic threshold in patients with metabolic myopathies] Fernández Guerra J, et al. **Arch Bronconeumol** 1996 Apr;32(4):176–82 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Anaerobic threshold in total artificial heart animals. Chiang BY, et al. **ASAIO J** 1994 Jul–Sep;40(3):M335–8

The role of anaerobic power in human tolerance to simulated aerial combat maneuvers. Wiegman JF, et al. **Aviat Space Environ Med** 1995 Oct;66(10):938–42

Allometry of anaerobic performance: a gender comparison. Batterham AM, et al. **Can J Appl Physiol** 1996 Feb; 21(1):48–62

Anaerobic capacity: a maximal anaerobic running test versus the maximal accumulated oxygen deficit. Maxwell NS, et al. **Can J Appl Physiol** 1996 Feb;21(1):35–47

Anaerobic threshold in children: determination from saliva analysis in field tests. Chicharro JL, et al. **Eur J Appl Physiol** 1995;70(6):541–4

Does the threshold of transcutaneous partial pressure of carbon dioxide represent the respiratory compensation point or anaerobic threshold? Liu Y, et al. **Eur J Appl Physiol** 1995;71(4):326–31

Fatty acid kinetic responses to running above or below lactate threshold. Kanaley JA, et al. **J Appl Physiol** 1995 Aug;79(2):439–47

Ventilatory thresholds during wheelchair exercise in individuals with spinal cord injuries. Coutts KD, et al. **Paraplegia** 1995 Jul;33(7):419–22

[Comparison of NYHA classification with cardiopulmonary function in patients with chronic heart failure] Genth S, et al. **Z Kardiol** 1996 Jun;85(6):428–34 (Eng. Abstr.) **(Ger)**

[Metabolic and ventilatory thresholds during exercise. Physiological and methodological aspects] Ribeiro JP. **Arq Bras Cardiol** 1995 Feb;64(2):171–81 (178 ref.) **(Por)**

ANAEROBIOSIS

Is the intracellular pH threshold an anaerobic threshold from the view point of intracellular events?: a brief review. Iwanaga K, et al. **Appl Human Sci** 1996 Mar;15(2):59–65 (53 ref.)

ANAL DRUG ADMINISTRATION see **ADMINISTRATION, RECTAL**

ANAL FISSURE see **FISSURE IN ANO**

ANAL FISTULA see **RECTAL FISTULA**

ANAL GLAND see **ANUS**

ANAL GLAND NEOPLASMS

PATHOLOGY

Ectopic perianal gland tumor in a timber wolf. Wheler CL, et al. **Can Vet J** 1996 Jan;37(1):41–2

[Adenocarcinoma of the anal glands (letter)] Hoang C, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):854–5 **(Fre)**

ANAL SACS

ANATOMY & HISTOLOGY

Anatomy and cholinergic innervation of the sinus paranalis in dogs. Salazar I, et al. **Anat Histol Embryol** 1996 Mar; 25(1):49–53

ANAL SPHINCTER see **ANUS**

ANAL STAGE

The anal world of a six-year-old boy. Rosegrant J. **Int J Psychoanal** 1995 Dec;76 (Pt 6):1233–43

Examining the specificity of the orality-depression link: anal personality traits and depressive symptoms. Lewis CA. **J Psychol** 1996 Mar;130(2):221–3

ANAL ULCER see **FISSURE IN ANO**

ANALEPTICS see **CENTRAL NERVOUS SYSTEM STIMULANTS**

ANALGESIA

Thoracic paravertebral analgesia [see comments] Richardson J, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1005–15 (94 ref.). Comment in: Acta Anaesthesiol Scand 1995 Nov;39(8):1003–4.

Why withhold analgesia in the emergency department? **Am J Nurs** 1995 Dec;95(12):15

Tropical benzocaine: does it alleviate pain? Who knows? [letter; comment] Harper DM. **Am J Obstet Gynecol** 1996 Mar;174(3):1077–8. Comment on: Am J Obstet Gynecol 1995 Sep;173(3 Pt 1):772–4.

The effect of topical 20% benzocaine on pain during loop electrosurgical excision of the cervix [see comments] Lipscomb GH, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):772–4. Comment in: Am J Obstet Gynecol 1996 Mar;174(3):1077–8.

Herpes simplex labialis after epidural or parenteral morphine: a randomized prospective trial in an Australian obstetric population. Boyle RK. **Anaesth Intensive Care** 1995 Aug; 23(4):433–7

Analgesia for acute musculoskeletal trauma: low-dose subcutaneous infusion of ketamine. Gurnani A, et al. **Anaesth Intensive Care** 1996 Feb;24(1):32–6

Continuous intravenous administration of ketorolac reduces pain and morphine consumption after total hip or knee arthroplasty. Etches RC, et al. **Anesth Analg** 1995 Dec; 81(6):1175–80

Ondansetron blocks nifedipine-induced analgesia in rats. Hunt TE, et al. **Anesth Analg** 1996 Mar;82(3):498–500

The effects of intrathecal neostigmine on somatic and visceral pain: improvement by association with a peripheral anticholinergic. Lauretti GR, et al. **Anesth Analg** 1996 Mar; 82(3):617–20

Postarthroscopic meniscus repair analgesia with intraarticular ketorolac or morphine. Reuben SS, et al. **Anesth Analg** 1996 May;82(5):1036–9

Comparison of the spinal actions of the mu-opioid remifentanil with alfentanil and morphine in the rat. Buerkle H, et al. **Anesthesiology** 1996 Jan;84(1):94–102

Intrathecal amitriptyline. Antinociceptive interactions with intravenous morphine and intrathecal clonidine, neostigmine, and carbamylcholine in rats. Eisenach JC, et al. **Anesthesiology** 1995 Nov;83(5):1036–45

Influence of timing of administration on the analgesic effect of bupivacaine infiltration in carrageenin-injected rats. Fletcher D, et al. **Anesthesiology** 1996 May;84(5):1129–37

Preemptive analgesia. Why its effect is not always obvious [editorial] Kissin I. **Anesthesiology** 1996 May;84(5):1015–9

Randomized, single-blinded trial of laparoscopic versus open appendectomy in children: effects on postoperative analgesia. Lejus C, et al. **Anesthesiology** 1996 Apr; 84(4):801–6

Preemptive analgesia: intraperitoneal local anesthetic in laparoscopic cholecystectomy. A randomized, double-blind, placebo-controlled study. Pasqualucci A, et al. **Anesthesiology** 1996 Jul;85(1):11–20

Location and characteristics of nitric oxide synthase in sheep spinal cord and its interaction with alpha(2)-adrenergic and cholinergic antinociception. Xu Z, et al. **Anesthesiology** 1996 Apr;84(4):890–9

Effects of preemptive or postinjury intrathecal local anesthesia on persistent nociceptive responses in rats. Confounding influences of peripheral inflammation and the general anesthetic regimen. Yashpal K, et al. **Anesthesiology** 1996 May;84(5):1119–28

Comparison of intraarticular bupivacaine with the addition of morphine or fentanyl for analgesia after arthroscopic surgery. Uysalel A, et al. **Arthroscopy** 1995 Dec;11(6):660–3

Remembrance of times past: the significance of c-fos in pain [editorial; comment] Munglani R, et al. **Br J Anaesth** 1996 Jan;76(1):1–4. Comment on: Br J Anaesth 1996 Jan;76(1):99–105.

New molecules in analgesia. Rang HP, et al. **Br J Anaesth** 1995 Aug;75(2):145–56 (145 ref.)

Analgesic effect in humans of subanaesthetic isoflurane concentrations evaluated by evoked potentials. Roth D, et al. **Br J Anaesth** 1996 Jan;76(1):38–42

Relationship between morphine analgesia and cortical extracellular fluid levels of morphine and its metabolites in the rat: a microdialysis study. Barjavel MJ, et al. **Br J Pharmacol** 1995 Dec;116(8):3205–10

Relationship between analgesia and extracellular morphine in brain and spinal cord in awake rats. Matos FF, et al. **Brain Res** 1995 Sep 25;693(1–2):187–95

Comparative effects of three doses of intravenous ketorolac or morphine on emesis and analgesia for restorative dental

surgery in children. Purday JP, et al. **Can J Anaesth** 1996 Mar;43(3):221–5
Pain management in children. Rice LJ. **Can J Anaesth** 1996 May;43(5 Pt 2):R155–62 (31 ref.) **(Eng, Fre)**
Intravenous ketorolac vs diclofenac for analgesia after maxillofacial surgery. Tarkkila P, et al. **Can J Anaesth** 1996 Mar;43(3):216–20
Circumcision without tears [letter] Katz MS. **Can Med Assoc J** 1996 Sep 1;155(5):507–8; discussion 508–9
Analgesic properties of electromagnetic field therapy in patients with chronic pelvic pain. Varcaccio–Garofalo G, et al. **Clin Exp Obstet Gynecol** 1995;22(4):350–4
Sex differences and the effect of gonadectomy on morphine–induced antinociception and dependence in rats and mice. Ali BH, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):342–4
Pain mechanisms and management: an update. Siddall PJ, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):679–88 (91 ref.)
Recent developments in analgesia during labour. Kan RE, et al. **Drugs** 1995 Sep;50(3):417–22 (41 ref.)
Onset time of topical analgesia with EMLA 5%: no reduction with glyceryl trinitrate. Nott MR, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):17–20
Post–operative analgesia for craniotomy patients: current attitudes among neuroanaesthetists. Stoneham MD, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):571–5
Transgenic superoxide dismutase mice differ in opioid–induced analgesia. Elmer GI, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):227–32
Evidence for the involvement of nitric oxide in the antinociceptive effect of ketorolac. Granados–Soto V, et al. **Eur J Pharmacol** 1995 Apr 24;277(2–3):281–4
Antinociceptive effect of a kappa–opioid receptor agonist that minimally crosses the blood–brain barrier (ICI 204448) in a rat model of mononeuropathy. Keita H, et al. **Eur J Pharmacol** 1995 Apr 24;277(2–3):275–80
Possible involvement of nitric oxide in red nucleus stimulation–induced analgesia in the rat. Kumar A, et al. **Eur J Pharmacol** 1995 Jun 6;279(1):1–5
Inflammation enhances peripheral mu–opioid receptor–mediated analgesia, but not mu–opioid receptor transcription in dorsal root ganglia. Schäfer M, et al. **Eur J Pharmacol** 1995 Jun 12;279(2–3):165–9
Eutectic lidocaine/prilocaine 5% cream and patch may provide satisfactory analgesia for excisional biopsy or curettage with electrosurgery of cutaneous lesions. A randomized, controlled, parallel group study. Gupta AK, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):419–23
No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia. Stein C, et al. **J Clin Invest** 1996 Aug 1;98(3):793–9
Respiratory monitoring during postoperative analgesia. Gordh T, et al. **J Clin Monit** 1995 Nov;11(6):365–72
MUJA: manipulation under joint anesthesia/analgesia: a treatment approach for recalcitrant low back pain of synovial joint origin. Dreyfuss P, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):537–46 (107 ref.)
Electrical stimulation at traditional acupuncture sites in periphery produces brain opioid–receptor–mediated antinociception in rats. Chen XH, et al. **J Pharmacol Exp Ther** 1996 May;277(2):654–60
Evaluation of detomidine–induced analgesia in horses with chronic hoof pain. Owens HG, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):179–84
Characterization of endothelin–induced nociception in mice: evidence for a mechanistically distinct analgesic model. Raffa RB, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):1–7
Neurotoxin–induced lesions to central serotonergic, noradrenergic and dopaminergic systems modify caffeine–induced antinociception in the formalin test and locomotor stimulation in rats. Sawynok J, et al. **J Pharmacol Exp Ther** 1996 May;277(2):646–53
A rabbit tooth–pulp assay to quantify efficacy and duration of antinociception by local anesthetics infiltrated into maxillary tissues. Thut PD, et al. **J Pharmacol Toxicol Methods** 1995 Aug;33(4):231–6
Analgesia for venous cannulation [letter; comment] Ulahannan TJ. **J R Soc Med** 1996 Apr;89(4):237. Comment on: J R Soc Med 1995 May;88(5):264–7.
Outcome analysis of the modified Mathieu hypospadias repair: comparison of stented and unstented repairs. Hakim S, et al. **J Urol** 1996 Aug;156(2 Pt 2):836–8
Exploring central issues in analgesia [news] Bonn D. **Lancet** 1996 Feb 24;347(9000):530
Study of the antinociceptive effect of tetrahydro–papaveroline derivatives. Interaction with opioids. Fialip J, et al. **Life Sci** 1996;59(11):PL133–9
In vivo injection of antibodies directed against the cloned mu opioid receptor blocked supraspinal analgesia induced by mu–agonists in mice. Garzón J, et al. **Life Sci** 1995; 56(14):PL237–42
Polyamine deprivation provokes an antalgic effect. Kergozien S, et al. **Life Sci** 1996;58(24):2209–15
Where are the parents? [letter] Armstrong HC. **MCN Am J Matern Child Nurs** 1995 Jan–Feb;20(1):44–5
Obtaining automated diagnostic information and pain relief. Collins HW. **Med Hypotheses** 1995 Oct;45(4):389–91
Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits. Standifer KM, et al. **Mol Pharmacol** 1996 Aug;50(2):293–8
Involvement of opioid receptors in the antinociception produced by intracerebroventricularly administered spantide in mice. Tan–No K, et al. **Neuropeptides** 1995 Nov; 29(5):293–9
Endogenous analgesia in the chicken. Gentle MJ, et al. **Neurosci Lett** 1995 Dec 15;201(3):211–4
Propofol (Diprivan) [letter] Young RF. **Neurosurgery** 1995 Jul;37(1):160–1
New regimen for interpleural block in children. Giaufré E, et al. **Paediatr Anaesth** 1995;5(2):125–8
The effect of ketorolac as an adjuvant to local anaesthetic infiltration for analgesia in paediatric umbilical hernia surgery. Graham SG, et al. **Paediatr Anaesth** 1995; 5(3):161–3
The safety of continuous pleural lignocaine after thoracotomy in children and adolescents. Stayer SA, et al. **Paediatr Anaesth** 1995;5(5):307–10
Analgesic effects induced by TENS and electroacupuncture with different types of stimulating electrodes on deep tissues in human subjects. Ishimaru K, et al. **Pain** 1995 Nov; 63(2):181–7
Sex differences in the expression and antagonism of swim stress–induced analgesia in deer mice vary with the breeding season. Kavaliers M, et al. **Pain** 1995 Dec; 63(3):327–34
Neonatal testosterone exposure influences neurochemistry of non–opioid swim stress–induced analgesia in adult mice. Sternberg WF, et al. **Pain** 1995 Dec;63(3):321–6
Involvement of different subtypes of cholecystokinin receptors in opioid antinociception in the mouse. Suh HW, et al. **Peptides** 1995;16(7):1229–34
Role of contextual stimuli in tolerance to stress–induced analgesia. Blustein JE, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):841–4
Effect of p–chlorophenylalanine and alpha–methyltyrosine on the antinociceptive effect of antidepressant drugs. Sierralta F, et al. **Pharmacol Toxicol** 1995 Oct;77(4):276–80
Opioid and nonopioid swim stress–induced analgesia: a parametric analysis in mice. Mogil JS, et al. **Physiol Behav** 1996 Jan;59(1):123–32
Enhancements in swim stress–induced hypothermia, but not analgesia, following amygdala lesions in rats. Pavlovic ZW, et al. **Physiol Behav** 1996 Jan;59(1):77–82
Analgesic effects of cranial laser treatment in two rat nociception models. Wedlock P, et al. **Physiol Behav** 1996 Mar;59(3):445–8
Absence of opioid stress–induced analgesia in mice lacking beta–endorphin by site–directed mutagenesis. Rubinstein M, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30; 93(9):3995–4000
Can pre–emptive interpleural block reduce perioperative anesthetic and analgesic requirements? Abdulatif M, et al. **Reg Anesth** 1995 Jul–Aug;20(4):296–302
Long–term use of subarachnoid clonidine for analgesia in refractory reflex sympathetic dystrophy. Case report. Kabeer AA, et al. **Reg Anesth** 1996 May–Jun;21(3):249–52
Double–blind randomized evaluation of intercostal nerve blocks as an adjuvant to subarachnoid administered morphine for post–thoracotomy analgesia. Liu M, et al. **Reg Anesth** 1995 Sep–Oct;20(5):418–25
[Role of locus coeruleus in analgesia caused by stimulation of supraoptic nucleus] You ZD, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):320–6 (Eng. Abstr.) **(Chi)**
[Analgesia and sedation in children under mechanical ventilation (letter)] Ramet J, et al. **Arch Pediatr** 1996;3 Suppl 1:338s–339s **(Fre)**
[Ureteroscopy under local anesthesia with or without intravenous analgesia] Deliveliotis C, et al. **Prog Urol** 1995 Sep;5(4):548–50 (Eng. Abstr.) **(Fre)**
[Anesthesiologic problems in polytrauma patients] Radke J. **Anaesthesiol Reanim** 1995;20(2):32–6 (6 ref.) (Eng. Abstr.) **(Ger)**
[Principles of analgesia and sedation] Behne M. **Anaesthesist** 1995 Dec;44 Suppl 3:S535–9 (21 ref.) (Eng. Abstr.) **(Ger)**
[Pre–emptive analgesia] Wilder–Smith OH. **Anaesthesist** 1995 Dec;44 Suppl 3:S529–34 (49 ref.) (Eng. Abstr.) **(Ger)**
[Pharmacokinetics and effects of xylazine (Rompun) in dogs] Rector E, et al. **Berl Munch Tierarztl Wochenschr** 1996 Jan;109(1):18–22 (Eng. Abstr.) **(Ger)**
[Stress–induced analgesia. The role of corticosteroids] Bogdanov AI, et al. **Fiziol Zh Im I M Sechenova** 1995 Mar;81(3):61–7 (Eng. Abstr.) **(Rus)**
[Stress–induced analgesia. The role of the hormones of the hypophyseal–adrenocortical system] Filaretov AA, et al. **Fiziol Zh Im I M Sechenova** 1995 Feb;81(2):40–6 (Eng. Abstr.) **(Rus)**
[Cardiorespiratory and analgesic effects of continuous infusion of propofol in swine as experimental animals] Tendillo FJ, et al. **Rev Esp Anestesiol Reanim** 1996 Apr; 43(4):126–9 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Complications of conscious sedation. Benjamin SB. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):277–86 (18 ref.)
Loss of resistance technique to air for identifying the epidural space in infants and children. Use an appropriate technique! [letter; comment] Busoni P, et al. **Paediatr Anaesth** 1995; 5(6):397. Comment on: Paediatr Anaesth 1995;5(1):41–6.
Accidents following extradural analgesia in children. The results of a retrospective study [letter; comment] Thomas VL. **Paediatr Anaesth** 1995;5(6):396–7. Comment on: Paediatr Anaesth 1995;5(1):41–6.
Atropine reverses antinociception induced by 2,5–hexanedione in rats. Pereira ME, et al. **Pharmacol Toxicol** 1995 Aug;77(2):91–4

HISTORY

Early French accounts of self–inhalation of ether and conscious analgesia [letter] Defalque RJ, et al. **Anesthesiology** 1995 Dec;83(6):1370–1
James Moore, John Hunter and amputation under analgesia in 1784. Willetts IE. **Ann R Coll Surg Engl** 1995 Nov;77(6 Suppl):310–1
[Opium, mandrake and henbane. Control of surgical pain in the pre–anesthesiological era of surgery] Bauer AW. **Z Orthop Ihre Grenzgeb** 1996 May–Jun;134(3):Oa7–9 **(Ger)**

METHODS

Balanced analgesia improves recovery and outcome after outpatient tubal ligation. Eriksson H, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):151–5
Postoperative pulmonary complications and morbidity after abdominal aneurysmectomy: a comparison of postoperative epidural versus parenteral opioid analgesia. Major CP Jr, et al. **Am Surg** 1996 Jan;62(1):45–51
Evaluation of intrapleural analgesia in the management of blunt traumatic chest wall pain: a clinical trial. Short K, et al. **Am Surg** 1996 Jun;62(6):488–93 (50 ref.)
Analgesia for day surgery. Evaluation of the effect of diclofenac given before or after surgery with or without bupivacaine infiltration. Chan A, et al. **Anaesthesia** 1996 Jun;51(6):592–5
Assessment and control of pain in children [editorial] Lloyd–Thomas A. **Anaesthesia** 1995 Sep;50(9):753–5 (43 ref.)
Thoracic paravertebral space location. A new method using pressure measurement. Richardson J, et al. **Anaesthesia** 1996 Feb;51(2):137–9
Topical ibuprofen for skin analgesia prior to venepuncture. Smith AJ, et al. **Anaesthesia** 1996 May;51(5):495–7
The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Ferrante FM, et al. **Anesth Analg** 1996 Jan;82(1):91–7
Oral clonidine premedication enhances the quality of postoperative analgesia by intrathecal morphine. Goyagi T, et al. **Anesth Analg** 1996 Jun;82(6):1192–6
Dose–response study of intrathecal morphine versus intrathecal neostigmine, their combination, or placebo for postoperative analgesia in patients undergoing anterior and posterior vaginoplasty. Lauretti GR, et al. **Anesth Analg** 1996 Jun;82(6):1182–7
The effects of electrical stimulation at different frequencies on perception and pain in human volunteers: epidural versus intravenous administration of fentanyl. Liu SS, et al. **Anesth Analg** 1996 Jan;82(1):98–102
Preoperative multimodal analgesia facilitates recovery after ambulatory laparoscopic cholecystectomy. Michaloliakou C, et al. **Anesth Analg** 1996 Jan;82(1):44–51
Comparison of intravenous ketorolac, meperidine, and both (balanced analgesia) for renal colic. Cordell WH, et al. **Ann Emerg Med** 1996 Aug;28(2):151–8
Analgesic practice for acute orthopedic trauma pain in Costa Rican emergency departments. Jantos TJ, et al. **Ann Emerg Med** 1996 Aug;28(2):145–50
Comparison of diclofenac sodium and morphine sulphate for postoperative analgesia after day case inguinal hernia surgery. McEvoy A, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):363–6
Analgesic effect of sucrose. Heel pricks were unnecessarily painful [letter; comment] Barker D, et al. **BMJ** 1995 Sep 16;311(7007):747. Comment on: BMJ 1995 Jun 10;310(6993):1498–500.
Comparison of the effects of adrenaline, clonidine and ketamine on the duration of caudal analgesia produced by bupivacaine in children. Cook B, et al. **Br J Anaesth** 1995 Dec;75(6):698–701
Pre–emptive analgesia with NSAID—what does it achieve? [letter; comment] Hudspith MJ, et al. **Br J Anaesth** 1996 Jul;77(1):128–9. Comment on: Br J Anaesth 1996 Feb;76(2):209–13.
Intra–articular analgesia for arthroscopic meniscectomy. Lyons B, et al. **Br J Anaesth** 1995 Nov;75(5):552–5
A prospective, randomized comparison of interpleural and paravertebral analgesia in thoracic surgery. Richardson J, et al. **Br J Anaesth** 1995 Oct;75(4):405–8
Low doses of neurotensin in the preoptic area produce hyperthermia. Comparison with other brain sites and with neurotensin–induced analgesia. Benmoussa M, et al. **Brain Res Bull** 1996;39(5):275–9
Teaching cancer pain management: durability of educational effects of a role model program. Janjan NA, et al. **Cancer** 1996 Mar 1;77(5):996–1001
Practice parameters for intravenous analgesia and sedation [letter; comment] Collins P, et al. **Crit Care Med** 1996 Feb; 24(2):367–9. Comment on: Crit Care Med 1995 Sep;23(9):1596–600.
Analgesia induced by morphine microinjection into the lateral hypothalamus of the rat. Fuchs PN, et al.

Exp Neurol 1995 Aug;134(2):277–80

Analgesic effect of extracorporeal shock-wave therapy on chronic tennis elbow. Rompe JD, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):233–7

Pro: intrapleural anesthesia is useful for thoracic analgesia [see comments] McIlvaine WB. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):425–8 (41 ref.) . Comment in: J Cardiothorac Vasc Anesth 1996 Apr;10(3):429–31.

Target-controlled infusion delivery systems: application outside the operating room. Bovill JG, et al. **J Clin Anesth** 1996 May;8(3 Suppl):21S–25S (33 ref.)

Monitored anesthesia care: how much sedation, how much analgesia? Smith I. **J Clin Anesth** 1996 May;8(3 Suppl):76S–80S (19 ref.)

Intravenous anesthesia and analgesia: what is the role of target-controlled infusion? White PF. **J Clin Anesth** 1996 May;8(3 Suppl):26S–28S (22 ref.)

Propofol analgesia in central pain: preliminary clinical observations. Canavero S, et al. **J Neurol** 1995 Sep; 242(9):561–7

EMLA and venepuncture [letter; comment] Nott MR, et al. **J R Soc Med** 1995 Nov;88(11):664. Comment on: J R Soc Med 1995 May;88(5):264–7.

Sickle cell pain crisis [letter; comment] [see comments] Ward SJ. **Lancet** 1996 Jan 27;347(8996):261. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

Effects of hypothalamic paraventricular nucleus: electrical stimulation produce marked analgesia in rats. Shiraishi T, et al. **Neurobiology (Bp)** 1995;3(3–4):393–403

Mechanism research of cryoanalgesia. Zhou L, et al. **Neurol Res** 1995 Aug;17(4):307–11

A comparison between ilioinguinal–iliohypogastric nerve block performed by anaesthetist or surgeon for postoperative analgesia following groin surgery in children. Trotter C, et al. **Paediatr Anaesth** 1995;5(6):363–7

The attentional control of pain: methodological and theoretical concerns. Eccleston C. **Pain** 1995 Oct; 63(1):3–10 (45 ref.)

Progress in the treatment of pain. Mehta M. **Practitioner** 1996 Apr;240(1561):214–24 (11 ref.)

Intravenous ketorolac and subarachnoid opioid analgesia in the management of acute postoperative pain. Gwirtz KH, et al. **Reg Anesth** 1995 Sep–Oct;20(5):395–401

Antisense oligodeoxynucleotide to a delta-opioid receptor blocks the antinociception induced by cold water swimming. Mizoguchi H, et al. **Regul Pept** 1995 Oct 20; 59(2):255–9

[Postoperative analgesia] Radev R, et al. **Khirurgiia (Sofiia)** 1995;48(5):29–32 (Eng. Abstr.) **(Bul)**

[Postoperative pain relief in children] Hansen TG, et al. **Ugeskr Laeger** 1996 Apr 15;158(16):2241–5 (40 ref.) (Eng. Abstr.) **(Dan)**

[Pediatric anesthesia in Denmark—a debate on the organization of pediatric anesthesia/surgery, intensive care and pain relief] Walther-Larsen S. **Ugeskr Laeger** 1996 Apr 15;158(16):2265–6 **(Dan)**

[Avoiding certainty while treating the pain (letter)] Orko R. **Duodecim** 1994;110(21):2026–7 **(Fin)**

[Cupping as evaluated by the client] Vaskilampi T, et al. **Duodecim** 1994;110(16):1505–9 **(Fin)**

[Evaluation of the activity of a postoperative analgesia department in a Canadian hospital] Fugère F, et al. **Ann Fr Anesth Reanim** 1996;15(3):313–9 (Eng. Abstr.) **(Fre)**

[Development of locoregional anesthesia and management of postoperative pain: inadequate! (editorial)] Bonnet F. **Can Anesthesiol** 1995;43(3):229 **(Fre)**

[Study of a protocol of intra-articular analgesia after arthroscopy of the knee] Dalger JM, et al. **Can Anesthesiol** 1996;44(1):97–100 (Eng. Abstr.) **(Fre)**

[Postoperative analgesia in children: techniques] Ecoffey C. **Can Anesthesiol** 1995;43(3):305–6 **(Fre)**

[Analgesia in surgery of the foot. Apropos of 1373 patients] Frédéric A, et al. **Can Anesthesiol** 1996;44(2):115–8 (Eng. Abstr.) **(Fre)**

[Conduction anesthesia and analgesia in emergency cases. From pain to its treatment] Puidupin M, et al. **Can Anesthesiol** 1995;43(6):605–15 (Eng. Abstr.) **(Fre)**

[Does neuroplasticity have a role on postoperative pain?] Viel E, et al. **Can Anesthesiol** 1995;43(3):231–7 (Eng. Abstr.) **(Fre)**

[Postoperative analgesia in children: what is new?] Murat I. **Rev Med Suisse Romande** 1996 Apr;116(4):247–50 (18 ref.) **(Fre)**

[CT-guided pain treatment] Proske M, et al. **Schweiz Med Wochenschr** 1996 Jul 20;126(29):1270–3 (Eng. Abstr.) **(Ger)**

[Hypnosis in dentistry 2. Amnesia, analgesia, loss of time perception: spontaneous manifestations during use of hypnosis in dentistry] Fábián TK. **Fogorv Sz** 1995 Jul; 88(7):237–42 (Eng. Abstr.) **(Hun)**

[Post-thoracotomy analgesia in pediatric heart surgery: comparison of 2 different techniques] Picardo S, et al. **Minerva Anestesiol** 1995 Jun;61(6):277–82 (Eng. Abstr.) **(Ita)**

[Postoperative management following open heart surgery by thoracic epidural anesthesia] Konishi A, et al. **Masui** 1995 Aug;44(8):1113–7 (Eng. Abstr.) **(Jpn)**

[Ureteroscopy with pseudoanalgesia in the treatment of ureteral lithiasis] Chesa Ponce N, et al. **Actas Urol Esp** 1996 Apr;20(4):361–4 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Attitudes to pain and pain relief in adult surgical patients. Brydon CW, et al. **Anaesthesia** 1996 Mar;51(3):279–81

Attitudes and preferences of patients to routes of analgesic administration [letter] Skinner TA, et al. **Anaesthesia** 1996 Mar;51(3):290–1

STANDARDS

Postoperative pain in children. Goddard JM, et al. **Anaesthesia** 1996 Jun;51(6):588–90

Practice guidelines for sedation and analgesia by non-anesthesiologists. A report by the American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. **Anesthesiology** 1996 Feb; 84(2):459–71

Acute pain services. Work is needed to show that good quality analgesia improves outcome of surgery [letter; comment] Fischer HB, et al. **BMJ** 1995 Oct 14; 311(7011):1023–4. Comment on: BMJ 1995 Aug 5;311(7001):360–1.

Clinical practice guidelines as a new source of middle-range theory: focus on acute pain. Good M, et al. **Nurs Outlook** 1996 Mar–Apr;44(2):74–9

UTILIZATION

Legal opioid consumption in Denmark 1981–1993. Groth Clausen T, et al. **Eur J Clin Pharmacol** 1995;48(5):321–5

VETERINARY

Assessment of intrathecal lignocaine analgesia for open castration of rams. Scott PR, et al. **Br Vet J** 1996 Jul; 152(4):481–3

Treating moderate and severe pain in small animals. Brock N. **Can Vet J** 1995 Oct;36(10):658–60 (3 ref.)

Comparison of intra-articular and epidural morphine for analgesia following stifle arthrotomy in dogs. Day TK, et al. **Vet Surg** 1995 Nov–Dec;24(6):522–30

ANALGESIA, ACUPUNCTURE see **ACUPUNCTURE ANALGESIA**

ANALGESIA, CONGENITAL see **PAIN INSENSITIVITY, CONGENITAL**

ANALGESIA, EPIDURAL

Distance from the skin to the cervical epidural space. Lin CH, et al. **Acta Anaesthesiol Sin** 1995 Sep;33(3):161–4

Intra-operative epidural morphine, fentanyl, and droperidol for control of pain after spinal surgery. A prospective, randomized, placebo-controlled, and double-blind trial. Rainov NG, et al. **Acta Neurochir (Wien)** 1996;138(1):33–9

Effect of epidural analgesia on postoperative ileus after ileal pouch-anal anastomosis. Kanazi GE, et al. **Am Surg** 1996 Jun;62(6):499–502

The effect of epidural analgesia on the return of peristalsis and the length of stay after elective colonic surgery. Lehman JF, et al. **Am Surg** 1995 Nov;61(11):1009–12

Herpes simplex labialis after epidural or parenteral morphine: a randomized prospective trial in an Australian obstetric population. Boyle RK. **Anaesth Intensive Care** 1995 Aug; 23(4):433–7

Cardiac arrest following epidural overdose [letter] Dawson P. **Anaesth Intensive Care** 1995 Oct;23(5):650–5

Patient-controlled epidural analgesia following caesarean delivery: a comparison of pethidine and fentanyl. Goh JL, et al. **Anaesth Intensive Care** 1996 Feb;24(1):45–50

Clinical experience with patient-controlled and staff-administered intermittent bolus epidural analgesia in labour. Paech MJ, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):459–63

Rectal indomethacin potentiates spinal morphine analgesia after caesarean delivery. Pavy TJ, et al. **Anaesth Intensive Care** 1995 Oct;23(5):555–9

Tunnelling epidural catheters [letter] Cook TM, et al. **Anaesthesia** 1996 Aug;51(8):798

Pregnancy-induced hypertension or a normal variant? [letter] O'Hanlon J. **Anaesthesia** 1995 Nov;50(11):1014

Epidural morphine for postherpetic neuralgia. Watt JW, et al. **Anaesthesia** 1996 Jul;51(7):647–51

Maternal and neonatal fentanyl and bupivacaine concentrations after epidural infusion during labor. Bader AM, et al. **Anesth Analg** 1995 Oct;81(4):829–32

Comparison of intravenous and epidural clonidine for postoperative patient-controlled analgesia. Bernard JM, et al. **Anesth Analg** 1995 Oct;81(4):706–12

Determination of the minimum local analgesic concentrations of epidural bupivacaine and lidocaine in labor. Columb MO, et al. **Anesth Analg** 1995 Oct;81(4):833–7

Epidural clonidine or sufentanil for intraoperative and postoperative analgesia. De Kock M, et al. **Anesth Analg** 1995 Dec;81(6):1154–62

Pharmacokinetics of epidural fentanyl [letter] dos Santos JE. **Anesth Analg** 1996 Sep;83(3):666

Patient-controlled epidural analgesia after thoracotomy: a comparison of meperidine with and without bupivacaine. Etches RC, et al. **Anesth Analg** 1996 Jul;83(1):81–6

The analgesic efficacy and adverse effects of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. Hansdóttir V, et al. **Anesth Analg** 1996 Aug; 83(2):394–400

The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. Hansdóttir V, et al. **Anesth Analg** 1996 Aug;83(2):401–6

Mode and site of analgesic action of epidural buprenorphine in humans. Inagaki Y, et al. **Anesth Analg** 1996 Sep; 83(3):530–6

The dermatomal spread of epidural bupivacaine with and without prior intrathecal sufentanil. Leighton BL, et al. **Anesth Analg** 1996 Sep;83(3):526–9

Transition from intrathecal analgesia to epidural anesthesia for emergency cesarean section using a combined spinal epidural technique [letter] Mercier FJ, et al. **Anesth Analg** 1996 Aug;83(2):434

Refractory idiopathic erythromelalgia. Rauck RL, et al. **Anesth Analg** 1996 May;82(5):1097–101

The effects of epidural morphine and epidural butorphanol on maternal outcomes after cesarean delivery [letter; comment] Wittels B, et al. **Anesth Analg** 1995 Dec; 81(6):1317–8. Comment on: Anesth Analg 1994 Jun;78(6):1099–104.

Adding fentanyl 0.0002% to epidural bupivacaine 0.125% does not delay gastric emptying in laboring parturients. Zimmermann DL, et al. **Anesth Analg** 1996 Mar;82(3):612–6

Epidural catheter insertion and satisfactory analgesia [letter; comment] Belin Y. **Anesthesiology** 1996 Jun;84(6):1524–5. Comment on: Anesthesiology 1996 Jan;84(1):88–93.

Epinephrine should not be part of an epidural test dose [letter; comment] Das BB. **Anesthesiology** 1996 Jun;84(6):1519–20 . Comment on: Anesthesiology 1995 Dec;83(6):1355–9.

Pharmacokinetics and analgesic effect of ropivacaine during continuous epidural infusion for postoperative pain relief. Erichsen CJ, et al. **Anesthesiology** 1996 Apr;84(4):834–42

Local anesthetic test dose to predict effective epidural opioid analgesia: II [letter; comment] Kempen PM. **Anesthesiology** 1996 Feb;84(2):487–8; discussion 489. Comment on: Anesthesiology 1995 Jul;83(1):96–100.

Pediatric caudal epidural catheter sequestration: an unusual complication. Lenox WC, et al. **Anesthesiology** 1995 Nov; 83(5):1112–4

Role of epidural anesthesia and analgesia on postoperative patient outcome [letter; comment] Leung JM. **Anesthesiology** 1995 Nov;83(5):1132. Comment on: Anesthesiology 1995 Jun;82(6):1474–506.

Effects of perioperative analgesic technique on rate of recovery after colon surgery. Liu SS, et al. **Anesthesiology** 1995 Oct;83(4):757–65

Epidural meperidine after cesarean section. A dose-response study. Ngan Kee WD, et al. **Anesthesiology** 1996 Aug; 85(2):289–94

Effect of epidural analgesia on fundal dominance during spontaneous active-phase nulliparous labor. Nielsen PE, et al. **Anesthesiology** 1996 Mar;84(3):540–4; discussion 29A

Local anesthetic test dose to predict effective epidural opioid analgesia: III [letter; comment] Pavy TJ, et al. **Anesthesiology** 1996 Feb;84(2):488–9. Comment on: Anesthesiology 1995 Jul;83(1):96–100.

Prophylactic use of epidural mepivacaine/morphine, systemic diclofenac, and metamizole reduces postoperative morphine consumption after major abdominal surgery. Rockemann MG, et al. **Anesthesiology** 1996 May; 84(5):1027–34

Postoperative analgesia using epidural infusions of fentanyl with bupivacaine. A prospective analysis of 1,014 patients. Scott DA, et al. **Anesthesiology** 1995 Oct;83(4):727–37

Local anesthetic test dose to predict effective epidural opioid analgesia: I [letter; comment] Stevens RA, et al. **Anesthesiology** 1996 Feb;84(2):486–7; discussion 489. Comment on: Anesthesiology 1995 Jul;83(1):96–100.

Epinephrine should not be part of an epidural test dose [letter] Waltuck BL. **Anesthesiology** 1996 Jun;84(6):1519–20

Absence of an early pre-emptive effect after thoracic extradural bupivacaine in thoracic surgery. Aguilar JL, et al. **Br J Anaesth** 1996 Jan;76(1):72–6

Removal of lumbar extradural catheters [letter; comment] Christie IW. **Br J Anaesth** 1995 Nov;75(5):666. Comment on: Br J Anaesth 1995 Jun;74(6):722.

Patient-controlled extradural analgesia with bupivacaine, fentanyl, or a mixture of both, after Caesarean section. Cooper DW, et al. **Br J Anaesth** 1996 May;76(5):611–5

A multifactorial analysis to explain inadequate surgical analgesia after extradural block. Curatolo M, et al. **Br J Anaesth** 1995 Sep;75(3):274–81

A double-blind comparison of 0.25% ropivacaine and 0.25% bupivacaine for extradural analgesia in labour. Eddleston JM, et al. **Br J Anaesth** 1996 Jan;76(1):66–71

Comparison of ropivacaine and bupivacaine for extradural analgesia [letter; comment] Lyons G, et al. **Br J Anaesth** 1995 Sep;75(3):373–4. Comment on: Br J Anaesth 1995 Mar;74(3):261–5.

Hormonal effects of thoracic extradural analgesia for cardiac surgery. Moore CM, et al. **Br J Anaesth** 1995 Oct; 75(4):387–93

Ambulatory extradural analgesia [letter; comment] Wee M. **Br J Anaesth** 1995 Aug;75(2):248. Comment on: Br J Anaesth 1995 Mar;74(3):350.

Continuous epidural infusion of ropivacaine for the prevention of postoperative pain after major orthopaedic surgery: a dose-finding study. Badner NH, et al. **Can J Anaesth** 1996 Jan;43(1):17–22

Epidural analgesia for labour and delivery: fentanyl or sufentanil? Cohen S, et al. **Can J Anaesth** 1996 Apr; 43(4):341–6

The clinical utility of epidural midazolam for inguinal hernia repair in children [editorial; comment] Goresky GV. **Can J Anaesth** 1995 Sep;42(9):755–7. Comment on: Can J Anaesth 1995 Sep;42(9):758–64. **(Eng, Fre)**

Midazolam for caudal analgesia in children: comparison with caudal bupivacaine [see comments] Naguib M, et al. **Can J Anaesth** 1995 Sep;42(9):758–64. Comment in: Can J Anaesth 1995 Sep;42(9):755–7.

Acute respiratory distress in a parturient under effective epidural analgesia [letter] Reuveni MA, et al. **Can J Anaesth** 1995 Nov;42(11):1063–4

Haemodynamic consequences and uterine contractions following 0.5 or 1.0 litre crystalloid infusion before obstetric epidural analgesia. Zamora JE, et al. **Can J Anaesth** 1996 Apr;43(4):347–52

0.0625% bupivacaine with 0.0002% fentanyl via patient–controlled epidural analgesia for pain of labor and delivery. Ferrante FM, et al. **Clin J Pain** 1995 Jun; 11(2):121–6

Patient–controlled epidural analgesia during labor [letter] Paech M. **Clin J Pain** 1996 Mar;12(1):79

Patient–controlled epidural diamorphine for post–operative pain: verbal rating and visual analogue assessments of pain. Kunst G, et al. **Eur J Anaesthesiol** 1996 Mar;13(2):117–29

Adrenaline, cyclic AMP and potassium during general anaesthesia with and without epidural analgesia. Löfgren A, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):487–94

The post–operative analgesic action of midazolam following epidural administration. Nishiyama T. **Eur J Anaesthesiol** 1995 Jul;12(4):369–74

Con: unreliable benefit after thoracotomy—epidural is a better choice [comment] Riegler FX. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):429–31 (20 ref.) . Comment on: J Cardiothorac Vasc Anesth 1996 Apr;10(3):425–8.

Effects of thoracic epidural analgesia on coronary hemodynamics and myocardial metabolism in coronary artery bypass surgery. Stenseth R, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):503–9

Bowel function recovery after radical hysterectomies: thoracic epidural bupivacaine–morphine versus intravenous patient–controlled analgesia with morphine: a pilot study. de Leon–Casasola OA, et al. **J Clin Anesth** 1996 Mar; 8(2):87–92

Long–term intraspinal infusions of opioids in the treatment of neuropathic pain. Hassenbusch SJ, et al. **J Pain Symptom Manage** 1995 Oct;10(7):527–43

Continuous thoracic epidural infusions for postoperative analgesia after pectus deformity repair. McBride WJ, et al. **J Pediatr Surg** 1996 Jan;31(1):105–7; discussion 107–8

Re: Continuous epidural anesthesia after ureteroneocystostomy in children [letter; comment] Greenberg RS, et al. **J Urol** 1996 Aug;156(2 Pt 1):482–3 . Comment on: J Urol 1995 Aug;154(2 Pt 2):791–3.

Re: Continuous epidural anesthesia after ureteroneocystostomy in children [letter; comment] Krane EJ. **J Urol** 1996 Aug;156(2 Pt 1):481–2; discussion 482–3 . Comment on: J Urol 1995 Aug;154(2 Pt 2):791–3.

Hemodynamic and oxygenation variables during radical cystectomy. Does the anesthetic technique really matter? Atallah MM, et al. **Middle East J Anesthesiol** 1995 Jun; 13(2):157–74

Randomized trial of epidural versus intravenous analgesia during labor [letter; comment] Lee JS, et al. **Obstet Gynecol** 1996 Mar;87(3):481–2. Comment on: Obstet Gynecol 1995 Nov;86(5):783–9.

Randomized trial of epidural versus intravenous analgesia during labor [see comments] Ramin SM, et al. **Obstet Gynecol** 1995 Nov;86(5):783–9. Comment in: Obstet Gynecol 1996 Mar;87(3):480–2. Comment in: Obstet Gynecol 1996 Mar;87(3):481–2.

Randomized trial of epidural versus intravenous analgesia during labor [letter; comment] Viscomi CM. **Obstet Gynecol** 1996 Mar;87(3):480–2. Comment on: Obstet Gynecol 1995 Nov;86(5):783–9.

Caudal analgesia with buprenorphine for postoperative pain relief in children. Kamal RS, et al. **Paediatr Anaesth** 1995; 5(2):101–6

Use of epidural somatostatin for postoperative analgesia is not justifiable [letter; comment] Asai T. **Pain** 1995 Sep; 62(3):388. Comment on: Pain 1994 Oct;59(1):135–40.

A pharmacokinetic approach to resolving spinal and systemic contributions to epidural alfentanil analgesia and side–effects. Coda BA, et al. **Pain** 1995 Sep;62(3):329–37

Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Eisenach JC, et al. **Pain** 1995 Jun;61(3):391–9

A double–blind randomised comparison of the effects of epidural clonidine, lignocaine and the combination of clonidine and lignocaine in patients with chronic pain. Glynn C, et al. **Pain** 1996 Feb;64(2):337–43

Efficacy of epidural steroid injections for low–back pain and sciatica: a systematic review of randomized clinical trials. Koes BW, et al. **Pain** 1995 Dec;63(3):279–88

Long–term epidural analgesia for pregnancy–induced intercostal neuralgia. Samlaska S, et al. **Pain** 1995 Aug; 62(2):245–8

Epidural diamorphine and bupivacaine stability study. Kreeger L, et al. **Palliat Med** 1995 Oct;9(4):315–8

Stability of bupivacaine hydrochloride with diamorphine hydrochloride in an epidural infusion. Barnes AR, et al. **Pharm World Sci** 1995 May 26;17(3):87–92

Development of a HPLC–system for quantitative measurement of lidocaine and bupivacaine in patients plasma during postoperative epidural pain therapy. Sattler A, et al. **Pharmazie** 1995 Nov;50(11):741–4

Comparison of morphine with and without fentanyl for epidural analgesia after major abdominal surgery. Chrubasik S, et al. **Reg Anesth** 1996 May–Jun;21(3):175–81

Epidural analgesia in a preeclamptic parturient after normalization of a prolonged bleeding time with DDAVP. Fragneto RY, et al. **Reg Anesth** 1995 Sep–Oct;20(5):448–51

Spinal analgesia during labor with low–dose bupivacaine, sufentanil, and epinephrine. A comparison with epidural analgesia. Kartawiadi L, et al. **Reg Anesth** 1996 May–Jun; 21(3):191–6

Effects of epidural bupivacaine after thoracotomy. Liu S, et al. **Reg Anesth** 1995 Jul–Aug;20(4):303–10

0.1% bupivacaine does not reduce the requirement for epidural fentanyl infusion after major abdominal surgery. Salomäki TE, et al. **Reg Anesth** 1995 Sep–Oct;20(5):435–43

Outcome of epidural analgesia versus patient–controlled analgesia in cancer patients [letter; comment] Walker S. **Reg Anesth** 1995 Nov–Dec;20(6):549. Comment on: Reg Anesth 1994 Sep–Oct;19(5):307–15.

Comparison of intravenous nalbuphine infusion versus saline as an adjuvant for epidural morphine. Wang JJ, et al. **Reg Anesth** 1996 May–Jun;21(3):214–8

Evaluation of epidural sensory block by thermal stimulation, laser stimulation, and recording of somatosensory evoked potentials. Zaric D, et al. **Reg Anesth** 1996 Mar–Apr; 21(2):124–38

[A combination of normal physiologic management of delivery and epidural analgesia] Kahánek J, et al. **Ceska Gynekol** 1996 Apr;61(2):82–5 (Eng. Abstr.) **(Cze)**

[The effect of the duration of administration of epidural analgesia on delivery] Nagy J. **Ceska Gynekol** 1996 Apr; 61(2):78–82 (Eng. Abstr.) **(Cze)**

[Postoperative analgesia after ligamentoplasty of the knee. Comparison of epidural morphine and intravenous nalbuphine] Brenet O, et al. **Can Anesthesiol** 1995; 43(3):319–23 (Eng. Abstr.) **(Fre)**

[Does ambulation under epidural analgesia during labor modify the conditions of fetal extraction?] Asselineau D. **Contracept Fertil Sex** 1996 Jun;24(6):505–8 (Eng. Abstr.) **(Fre)**

[Spontaneous rupture of an unscarred uterus during labor and epidural anesthesia Manouana M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):557–60 (Eng. Abstr.) **(Fre)**

[Combination of intravenous patient–controlled analgesia with epidural anesthesia for postoperative pain therapy] Kentner R, et al. **Anaesthesiol Reanim** 1996;21(3):69–75 (Eng. Abstr.) **(Ger)**

[Epidural analgesia in delivery] Schneider MC, et al. **Anaesthesist** 1996 Apr;45(4):393–409 (16 ref.) **(Ger)**

[Repeated addition of fentanyl to bupivacaine peridural analgesia in labor. Clinical action and fentanyl plasma level] Vettermann J, et al. **Anaesthesist** 1996 May;45(5):428–36 (Eng. Abstr.) **(Ger)**

[Para–spinal analgesia in obstetrics] Schockenhoff B, et al. **Z Geburtshilfe Neonatol** 1995 May–Jun;199(3):99–102 (Eng. Abstr.) **(Ger)**

[Peridural anesthesia in postoperative pain therapy] Standl T. **Zentralbl Chir** 1995;120(12):916–26 (80 ref.) (Eng. Abstr.) **(Ger)**

[Epidural analgesia for postoperative pain in infants and children] Efrat R, et al. **Harefuah** 1996 Mar 1;130(5):304–7, 358 (28 ref.) (Eng. Abstr.) **(Heb)**

[Efficacy of continuous intercostal analgesia versus epidural analgesia on post–thoracotomy pain] Nicolosi M, et al. **Minerva Chir** 1996 Mar;51(3):103–7 (Eng. Abstr.) **(Ita)**

[Epidural buprenorphine does not improve diaphragmatic function after upper abdominal surgery] Fujimura N, et al. **Masui** 1996 Apr;45(4):428–32 (Eng. Abstr.) **(Jpn)**

[A case of RSD with complete disappearance of symptoms following intravenous ketamine infusion combined with stellate ganglion block and continuous epidural block] Kishimoto N, et al. **Masui** 1995 Dec;44(12):1680–4 (Eng. Abstr.) **(Jpn)**

[Epidural analgesia for surgery and postoperative pain] Kosaka Y. **Masui** 1995;44 Suppl:S78–82 (28 ref.) **(Jpn)**

[Epidural anesthesia and postoperative analgesia] Yokoyama K. **Nippon Ika Daigaku Zasshi** 1995 Oct;62(5):413–9 (30 ref.) **(Jpn)**

[Total intravenous anesthesia and postoperative continuous epidural infusion in thoracic esophageal cancer surgery] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):661–2 **(Jpn)**

[Postoperative analgesia with epidural administration of a combination of tramadol and clonidine] Masár O, et al. **Bratisl Lek Listy** 1995 Dec;96(12):669–70 (Eng. Abstr.) **(Slo)**

[Reduction of the need for isoflurane and of postoperative pain with preanesthetic intrathecal morphine (letter; comment)] Sabaté A. **Rev Esp Anestesiol Reanim** 1995 Oct; 42(8):349–51. Comment on: Rev Esp Anestesiol Reanim 1995 Feb;42(2):41–6. **(Spa)**

ADVERSE EFFECTS

Safe perioperative spinal and epidural analgesia: importance of drug combinations, segmental site of injection, training and monitoring [editorial; comment] Breivik H. **Acta Anaesthesiol Scand** 1995 Oct;39(7):869–71. Comment on: Acta Anaesthesiol Scand 1995 Oct;39(7):872–80.

Effect of P–6 acupressure on prevention of nausea and vomiting after epidural morphine for post–cesarean section pain relief. Ho CM, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):372–5

Menstrual stage influences postoperative nausea and vomiting following epidural buprenorphine. Kitamura A, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):368–71

Headache during epidural top–ups in labour—a sign of reduced intracranial compliance. Murthy BV, et al. **Anaesth Intensive Care** 1995 Dec;23(6):744–6

An avoidable cause of inadvertent dural puncture [letter] Ball AJ. **Anaesthesia** 1995 Sep;50(9):830–1

Prolapsed intervertebral disc after epidural analgesia in labour. Forster MR, et al. **Anaesthesia** 1996 Aug; 51(8):773–5

Respiratory arrest in a parturient following intrathecal injection of sufentanil and bupivacaine. Greenhalgh CA. **Anaesthesia** 1996 Feb;51(2):173–5

Subdural or epidural? Confirmation with magnetic resonance imaging. Ralph CJ, et al. **Anaesthesia** 1996 Feb;51(2):175–7

Misplacement of multihole epidural catheters—a report of two cases. Sala–Blanch X, et al. **Anaesthesia** 1996 Apr; 51(4):386–8

Subdural or epidural? [letter] Scrutton M, et al. **Anaesthesia** 1996 Jul;51(7):708–9

An unusual complication of epidural analgesia in a morbidly obese parturient [letter] Hershan DB, et al. **Anesth Analg** 1996 Jan;82(1):217–8

Recurrence of herpes simplex virus blepharitis after cesarean section and epidural morphine. James CF. **Anesth Analg** 1996 May;82(5):1094–6 (17 ref.)

Naloxone versus nalbuphine infusion for prophylaxis of epidural morphine–induced pruritus. Kendrick WD, et al. **Anesth Analg** 1996 Mar;82(3):641–7

Spinal cord infarction after surgery in a patient in the hyperlordotic position. Amoiridis G, et al. **Anesthesiology** 1996 Jan;84(1):228–30

Paraplegia, epidural analgesia, and thoracic aneurysmectomy [see comments] Fitzgibbon DR, et al. **Anesthesiology** 1995 Dec;83(6):1355–9. Comment in: Anesthesiology 1996 Jun;84(6):1519–20.

Vertebral osteomyelitis as a cause of back pain after epidural anesthesia. Pinczower GR, et al. **Anesthesiology** 1996 Jan; 84(1):215–7

Epidural and intravenous opioid–induced neuroexcitation. Rozan JP, et al. **Anesthesiology** 1995 Oct;83(4):860–3

Enoxaparin and epidural analgesia [letter] Weitz SR, et al. **Anesthesiology** 1996 Aug;85(2):432–4

Recent advances in obstetrics. Epidural analgesia in labour [letter; comment] [see comments] Buggy DJ. **BMJ** 1996 Feb 10;312(7027):379. Comment on: BMJ 1995 Nov 4;311(7014):1209–12. Comment in: BMJ 1996 Apr 13;312(7036):974–5.

Sudden onset of subarachnoid block after subdural catheterization: a case of arachnoid rupture? Elliott DW, et al. **Br J Anaesth** 1996 Feb;76(2):322–4

Inadvertent infusion of glucose saline into the extradural space [letter] Mphanza T. **Br J Anaesth** 1996 Feb;76(2):332

A testing time. Rogers R, et al. **Br J Hosp Med** 1995 Nov 1–14;54(9):478

Meningitis following a combined spinal–epidural technique in a labouring term parturient. Cascio M, et al. **Can J Anaesth** 1996 Apr;43(4):399–402

Side effects of intrathecal and epidural opioids. Chaney MA. **Can J Anaesth** 1995 Oct;42(10):891–903 (187 ref.)

Bacterial meningitis and cauda equina syndrome after epidural steroid injections. Cooper AB, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):471–4

Escherichia coli meningitis and septicemia associated with an epidural catheter [letter] Watanakunakorn C. **Clin Infect Dis** 1995 Sep;21(3):713–4

The risk of infection associated with epidural analgesia. Brooks K, et al. **Infect Control Hosp Epidemiol** 1995 Dec; 16(12):725–8

Compartment syndromes associated with postoperative epidural analgesia. A case report. Price C, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):597–9

Epidural scopolamine administration in preventing nausea after epidural morphine. Moscovici R, et al. **J Clin Anesth** 1995 Sep;7(6):474–6

Epidural analgesia in labor. Robbins CW, et al. **J Fam Pract** 1996 Mar;42(3):227–8

Infections following epidural catheterization. Holt HM, et al. **J Hosp Infect** 1995 Aug;30(4):253–60

Loss of resistance technique to air for identifying the epidural space in infants and children. Use an appropriate technique! [letter; comment] Busoni P, et al. **Paediatr Anaesth** 1995; 5(6):397. Comment on: Paediatr Anaesth 1995;5(1):41–6.

Complications of extradural analgesia in infants [letter] Cooper MG. **Paediatr Anaesth** 1996;6(2):159–60

Accidents following extradural analgesia [letter] Lewis IH, et al. **Paediatr Anaesth** 1996;6(2):159

Epidural hematoma after epidural pain control and concomitant postoperative anticoagulation [letter] Badenhorst CH. **Reg Anesth** 1996 May–Jun;21(3):272–3

Side–effects during patient–assisted epidural analgesia [letter; comment] Chrubasik S, et al. **Reg Anesth** 1995 May–Jun; 20(3):258–60. Comment on: Reg Anesth 1994

May-Jun;19(3):206-11.
Postulated mechanisms for postdural puncture headache and review of laboratory models. Clinical experience. Hatfalvi BI. **Reg Anesth** 1995 Jul-Aug;20(4):329-36
Failure of the thiopental precipitation test to detect cerebrospinal fluid after dural puncture with current epidural solutions for labor analgesia [letter] Lowenwirt I, et al. **Reg Anesth** 1995 Sep-Oct;20(5):459-60
[Infections in connection with epidural catheterization] Holt HM, et al. **Ugeskr Laeger** 1996 Jul 29;158(31):4403-5 (Eng. Abstr.) **(Dan)**
[Evaluation of regional analgesia and surgical trauma on selected factors of the human immune system] Gajdosz R. **Folia Med Cracov** 1994;35(1-4):69-86 (Eng. Abstr.) **(Pol)**

INSTRUMENTATION

No additional metal particle formation using the needle-through-needle combined epidural/spinal technique. Herman N, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):227-31
Evaluation of a disposable device for patient-controlled epidural analgesia after caesarean section. Ngan Kee WD, et al. **Anaesth Intensive Care** 1996 Feb;24(1):51-5
Lumbar epidurography with multi-orifice and single orifice epidural catheters. Magides AD, et al. **Anaesthesia** 1996 Aug;51(8):757-63
Starch, gloves and extradural catheters. Green MA, et al. **Br J Anaesth** 1995 Dec;75(6):768-70
Pain relief following iliac crest bone harvesting. Wilson PA. **Br J Oral Maxillofac Surg** 1995 Aug;33(4):242-3
New device for the securement of epidural catheters [letter] Corn SB, et al. **Reg Anesth** 1995 Nov-Dec;20(6):545-6
Combined end-multiple lateral holes epidural catheter [letter] Eldor J. **Reg Anesth** 1996 May-Jun;21(3):271-2

METHODS

The effect of tunnelling on epidural catheter migration. Bougher RJ, et al. **Anaesthesia** 1996 Feb;51(2):191-4
A comparison of epidural infusions of fentanyl or pethidine with bupivacaine in the management of postoperative pain. Cox CR, et al. **Anaesthesia** 1996 Jul;51(7):695-8
Use of liposome-associated bupivacaine in a cancer pain syndrome. Lafont ND, et al. **Anaesthesia** 1996 Jun; 51(6):578-9
'Walking' epidurals in labour [editorial] Morgan BM. **Anaesthesia** 1995 Oct;50(10):839-40
Epidural infusion of low-dose bupivacaine and opioid in labour. Does reducing motor block increase the spontaneous delivery rate? Russell R, et al. **Anaesthesia** 1996 Mar;51(3):266-73
Through the needle approach for difficult epidurals [letter] Sellers WF. **Anaesthesia** 1996 May;51(5):513
Avoid dural punctures [letter] Serpell MG. **Anaesthesia** 1996 Feb;51(2):203
A simple and reliable method of subcutaneous tunneling of epidural catheters [letter] Balamoutsos NG, et al. **Anesth Analg** 1996 Jun;82(6):1303-4
Epinephrine decreases postoperative requirements for continuous thoracic epidural fentanyl infusions. Baron CM, et al. **Anesth Analg** 1996 Apr;82(4):760-5
The optimal distance that a multiorifice epidural catheter should be threaded into the epidural space [letter; comment] Baylis R, et al. **Anesth Analg** 1996 Apr; 82(4):894-5. Comment on: Anesth Analg 1995 Aug;81(2):301-4.
Postoperative analgesia with continuous epidural sufentanil and bupivacaine: a prospective study in 614 patients. Broekema AA, et al. **Anesth Analg** 1996 Apr;82(4):754-9
When not to give a test dose: one more reason? [letter; comment] Cross DA. **Anesth Analg** 1996 Jan;82(1):221-2. Comment on: Anesth Analg 1995 May;80(5):861-3. Comment on: Anesth Analg 1995 May;80(5):864-9.
The effect of postoperative analgesia with continuous epidural bupivacaine after cesarean section on the amount of breast feeding and infant weight gain. Hirose M, et al. **Anesth Analg** 1996 Jun;82(6):1166-9
How far should a catheter be inserted into the epidural space? [letter; comment] Kempen PM. **Anesth Analg** 1996 Apr; 82(4):893-4. Comment on: Anesth Analg 1995 Aug;81(2):301-4.
On rotating the epidural needle [letter; comment] Norris MC. **Anesth Analg** 1996 Feb;82(2):429-30. Comment on: Anesth Analg 1995 Jul;81(1):209-10.
Epidural ropivacaine infusion for postoperative analgesia after major lower abdominal surgery--a dose finding study. Scott DA, et al. **Anesth Analg** 1995 Nov;81(5):982-6
The role of the phrenic nerves in stress response in upper abdominal surgery. Segawa H, et al. **Anesth Analg** 1996 Jun;82(6):1215-24
Analgesia after thoracotomy: effects of epidural fentanyl concentration/infusion rate. Thomson CA, et al. **Anesth Analg** 1995 Nov;81(5):973-81
Prospective examination of epidural catheter insertion [see comments] D'Angelo R, et al. **Anesthesiology** 1996 Jan; 84(1):88-93. Comment in: Anesthesiology 1996 Jun;84(6):1524-5.
Sustained-release morphine for epidural analgesia in rats. Kim T, et al. **Anesthesiology** 1996 Aug;85(2):331-8
Extradural analgesia with clonidine and fentanyl compared with 0.25% bupivacaine in the first stage of labour [see comments] Buggy DJ, et al. **Br J Anaesth** 1996 Feb; 76(2):319-21. Comment in: Br J Anaesth 1996 Jun;76(6):886-7.
Epidurals redefined in analgesia and anesthesia: a distinction with a difference. Youngstrom PC, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):350-4 (14 ref.)
Continuous epidural block for pain control in bladder exstrophy: report of a case and description of technique. Messeri A, et al. **Paediatr Anaesth** 1995;5(4):229-32
Thoracic versus lumbar administration of fentanyl using patient-controlled epidural after thoracotomy. Bouchard F, et al. **Reg Anesth** 1995 Sep-Oct;20(5):385-8
Pre-emptive epidural analgesia may prevent phantom limb pain [letter; comment] Schug SA, et al. **Reg Anesth** 1995 May-Jun;20(3):256. Comment on: Reg Anesth 1993 Mar-Apr;18(2):121-7. Comment on: Reg Anesth 1994 May-Jun;19(3):217-8.
[Combined spinal and epidural analgesia in urology] Bovianska N. **Khirurgiia (Sofiia)** 1995;48(5):33-5 (Eng. Abstr.) **(Bul)**
[The use of continuous epidural analgesia in the combined treatment of chronic arterial obstruction in the lower extremities] Chernaev V, et al. **Khirurgiia (Sofiia)** 1995; 48(1):90-6 (Eng. Abstr.) **(Bul)**
[Treatment of postoperative pain with peridural administration of opioids] Chrubasik S, et al. **Anaesthesiol Reanim** 1995;20(1):16-25 (148 ref.) (Eng. Abstr.) **(Ger)**
[Lumbar epidural injections in orthopedic pain therapy. Standards--guidelines--current techniques--results] Krämer J, et al. **Z Orthop Ihre Grenzgeb** 1996 May-Jun; 134(3):Oa12-7 **(Ger)**
[Epidural injection for postoperative pain relief after thoracoscopic surgery] Nogimura H, et al. **Kyobu Geka** 1995 Aug;48(9):756-8 (Eng. Abstr.) **(Jpn)**
[Efficacy of epidural neurolysis] Hongo T, et al. **Masui** 1995 Nov;44(11):1537-41 (Eng. Abstr.) **(Jpn)**
[Comparative study of continuous epidural analgesia versus intermittent, patient-controlled, epidural analgesia during labor] Vilaplana J, et al. **Rev Esp Anestesiol Reanim** 1995 Aug-Sep;42(7):269-73 (Eng. Abstr.) **(Spa)**

NURSING

Home epidural analgesic infusion for non-cancer pain. Ploughe B. **J Neurosci Nurs** 1995 Aug;27(4):245-51

STANDARDS

Standardization of epidural preparations for postoperative analgesia. Dollard JV, et al. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2565-7
Epidural analgesia during labor: continuous infusion or patient-controlled administration? Benhamou D. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S55-6 (9 ref.)
Effects of epidural analgesia on the progress of labor and the mode of delivery. Finster M. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S31-3 (35 ref.)
Role of patient-controlled epidural analgesia in obstetrics. Gambling DR, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S39-46 (45 ref.)
Is an epidural test dose mandatory? Morgan B. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S57-8
Combined spinal and epidural blockade for analgesia in labour. Morgan B. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S59-60
Influence of epidural analgesia on fetal and neonatal well-being. Scherer R, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S17-29 (118 ref.)
Pain during childbirth [editorial] Van Aken H, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S1
Labor pain relief using bupivacaine and sufentanil: patient controlled epidural analgesia versus intermittent injections. Vandermeulen EP, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S47-54
Opioids in combination with local anesthetics for epidural analgesia during labor. Vertommen JD. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S35-8 (23 ref.)

UTILIZATION

Epidural analgesia as a risk factor for operative delivery. Hemminki E, et al. **Int J Gynaecol Obstet** 1996 May; 53(2):125-32

VETERINARY

Epidural abscess and discospondylitis in a dog after administration of a lumbosacral epidural analgesic. Remedios AM, et al. **Can Vet J** 1996 Feb;37(2):106-7
Epidural administration of bupivacaine, morphine, or their combination for postoperative analgesia in dogs. Hendrix PK, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):598-607

ANALGESIA, OBSTETRICAL

The efficacy of intrathecal injection of sufentanil using a microspinal catheter for labor analgesia. Abboud TK, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):210-5
Additive analgesic effect of codeine and paracetamol can be detected in strong, but not moderate, pain after Caesarean section. Baseline pain-intensity is a determinant of assay-sensitivity in a postoperative analgesic trial [see comments] Bjune K, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):399-407. Comment in: Acta Anaesthesiol Scand 1996 Apr;40(4):397-8.
The effect of intrathecal bupivacaine with combined fentanyl in cesarean section. Chu CC, et al. **Acta Anaesthesiol Sin** 1995 Sep;33(3):149-54
The preemptive effect of regional anesthesia on post-cesarean section pain. Wang JJ, et al. **Acta Anaesthesiol Sin** 1995 Dec;33(4):211-6
Clinical experience with patient-controlled and staff-administered intermittent bolus epidural analgesia in labour. Paech MJ, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):459-63
Pregnancy-induced hypertension or a normal variant? [letter] O'Hanlon J. **Anaesthesia** 1995 Nov;50(11):1014
Maternal and neonatal fentanyl and bupivacaine concentrations after epidural infusion during labor. Bader AM, et al. **Anesth Analg** 1995 Oct;81(4):829-32
Determination of the minimum local analgesic concentrations of epidural bupivacaine and lidocaine in labor. Columb MO, et al. **Anesth Analg** 1995 Oct;81(4):833-7
Bolus metoclopramide does not enhance morphine analgesia after cesarean section. Driver RP Jr, et al. **Anesth Analg** 1996 May;82(5):1033-5
The dermatomal spread of epidural bupivacaine with and without prior intrathecal sufentanil. Leighton BL, et al. **Anesth Analg** 1996 Sep;83(3):526-9
The effects of epidural morphine and epidural butorphanol on maternal outcomes after cesarean delivery [letter; comment] Wittels B, et al. **Anesth Analg** 1995 Dec; 81(6):1317-8. Comment on: Anesth Analg 1994 Jun;78(6):1099-104.
Adding fentanyl 0.0002% to epidural bupivacaine 0.125% does not delay gastric emptying in laboring parturients. Zimmermann DL, et al. **Anesth Analg** 1996 Mar;82(3):612-6
Epidural catheter insertion and satisfactory analgesia [letter; comment] Belin Y. **Anesthesiology** 1996 Jun;84(6):1524-5. Comment on: Anesthesiology 1996 Jan;84(1):88-93.
Epidural meperidine after cesarean section. A dose-response study. Ngan Kee WD, et al. **Anesthesiology** 1996 Aug; 85(2):289-94
Effect of epidural analgesia on fundal dominance during spontaneous active-phase nulliparous labor. Nielsen PE, et al. **Anesthesiology** 1996 Mar;84(3):540-4; discussion 29A
A double-blind comparison of 0.25% ropivacaine and 0.25% bupivacaine for extradural analgesia in labour. Eddleston JM, et al. **Br J Anaesth** 1996 Jan;76(1):66-71
Visceral pain during caesarean section [letter; comment] Fairfield MC. **Br J Anaesth** 1996 Jan;76(1):167. Comment on: Br J Anaesth 1995 Sep;75(3):266-8.
Dose requirements, efficacy and side effects of morphine and pethidine delivered by patient-controlled analgesia after gynaecological surgery. Stanley G, et al. **Br J Anaesth** 1996 Apr;76(4):484-6
Optimal labour analgesia 1996 [editorial] Breen TW. **Can J Anaesth** 1996 Apr;43(4):327-32 **(Eng, Fre)**
Epidural analgesia for labour and delivery: fentanyl or sufentanil? Cohen S, et al. **Can J Anaesth** 1996 Apr; 43(4):341-6
Acute respiratory distress in a parturient under effective epidural analgesia [letter] Reuveni MA, et al. **Can J Anaesth** 1995 Nov;42(11):1063-4
Haemodynamic consequences and uterine contractions following 0.5 or 1.0 litre crystalloid infusion before obstetric epidural analgesia. Zamora JE, et al. **Can J Anaesth** 1996 Apr;43(4):347-52
0.0625% bupivacaine with 0.0002% fentanyl via patient-controlled epidural analgesia for pain of labor and delivery. Ferrante FM, et al. **Clin J Pain** 1995 Jun; 11(2):121-6
Patient-controlled epidural analgesia during labor [letter] Paech M. **Clin J Pain** 1996 Mar;12(1):79
Labour analgesia. A risk-benefit analysis. Eberle RL, et al. **Drug Saf** 1996 Apr;14(4):239-51 (88 ref.)
Randomized trial of epidural versus intravenous analgesia during labor [letter; comment] Lee JS, et al. **Obstet Gynecol** 1996 Mar;87(3):481-2. Comment on: Obstet Gynecol 1995 Nov;86(5):783-9.
Randomized trial of epidural versus intravenous analgesia during labor [see comments] Ramin SM, et al. **Obstet Gynecol** 1995 Nov;86(5):783-9. Comment in: Obstet Gynecol 1996 Mar;87(3):480-2. Comment in: Obstet Gynecol 1996 Mar;87(3):481-2.
Randomized trial of epidural versus intravenous analgesia during labor [letter; comment] Viscomi CM. **Obstet Gynecol** 1996 Mar;87(3):480-2. Comment on: Obstet Gynecol 1995 Nov;86(5):783-9.
Epidural analgesia in a preeclamptic parturient after normalization of a prolonged bleeding time with DDAVP. Fragneto RY, et al. **Reg Anesth** 1995 Sep-Oct;20(5):448-51
Spinal analgesia during labor with low-dose bupivacaine, sufentanil, and epinephrine. A comparison with epidural analgesia. Kartawiadi L, et al. **Reg Anesth** 1996 May-Jun; 21(3):191-6
Hemodynamic effects of subarachnoid fentanyl in laboring parturients. Mandell GL, et al. **Reg Anesth** 1996 Mar-Apr; 21(2):103-11

ANALGESIA, OBSTETRICAL

[Influence of dihydroetorphine hydrochloride and tramadol on labor pain and umbilical blood gas] Li E, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jun;30(6):345–8 (Eng. Abstr.) **(Chi)**

[A combination of normal physiologic management of delivery and epidural analgesia] Kahánek J, et al. **Ceska Gynekol** 1996 Apr;61(2):82–5 (Eng. Abstr.) **(Cze)**

[The effect of the duration of administration of epidural analgesia on delivery] Nagy J. **Ceska Gynekol** 1996 Apr; 61(2):78–82 (Eng. Abstr.) **(Cze)**

[Combined spinal and epidural anesthesia or epidural anesthesia in obstetrics?] Benhamou D. **Cah Anesthesiol** 1996;44(2):157–8 **(Fre)**

[Epidural anesthesia for labor] Dailland P, et al. **Cah Anesthesiol** 1996;44(2):127–43 (24 ref.) (Eng. Abstr.) **(Fre)**

[Does ambulation under epidural analgesia during labor modify the conditions of fetal extraction?] Asselineau D. **Contracept Fertil Sex** 1996 Jun;24(6):505–8 (Eng. Abstr.) **(Fre)**

[Spontaneous rupture of an unscarred uterus during labor and epidural anesthesia Manouana M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):557–60 (Eng. Abstr.) **(Fre)**

[Epidural analgesia in delivery] Schneider MC, et al. **Anaesthesist** 1996 Apr;45(4):393–409 (16 ref.) **(Ger)**

[Addition of fentanyl to bupivacaine—peridural analgesia in cesarean section] Thomas H, et al. **Anaesthesist** 1996 Jul; 45(7):635–42 (Eng. Abstr.) **(Ger)**

[Repeated addition of fentanyl to bupivacaine peridural analgesia in labor. Clinical action and fentanyl plasma level] Vettermann J, et al. **Anaesthesist** 1996 May;45(5):428–36 (Eng. Abstr.) **(Ger)**

[Administration of pethidine in labor with meconium contaminated amniotic fluid: effect on fetal outcome and respiratory disorders] Riehn A, et al. **Z Geburtshilfe Neonatol** 1995 May–Jun;199(3):103–6 (Eng. Abstr.) **(Ger)**

[Para-spinal analgesia in obstetrics] Schockenhoff B, et al. **Z Geburtshilfe Neonatol** 1995 May–Jun;199(3):99–102 (Eng. Abstr.) **(Ger)**

[Epidural anesthesia as a method of labor analgesia preserving motor activity of parturient women] Gedzh P, et al. **Akush Ginekol (Mosk)** 1995;(4):46 **(Rus)**

[Spinal opiates in obstetrics. Theoretical aspects and criteria for practical use] Miranda A. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):369–77 (113 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Effect of P-6 acupressure on prevention of nausea and vomiting after epidural morphine for post-cesarean section pain relief. Ho CM, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):372–5

Headache during epidural top-ups in labour—a sign of reduced intracranial compliance. Murthy BV, et al. **Anaesth Intensive Care** 1995 Dec;23(6):744–6

An avoidable cause of inadvertent dural puncture [letter] Ball AJ. **Anaesthesia** 1995 Sep;50(9):830–1

Gas kinetics during nitrous oxide analgesia for labour. Einarsson S, et al. **Anaesthesia** 1996 May;51(5):449–52

Prolapsed intervertebral disc after epidural analgesia in labour. Forster MR, et al. **Anaesthesia** 1996 Aug; 51(8):773–5

Respiratory arrest in a parturient following intrathecal injection of sufentanil and bupivacaine. Greenhalgh CA. **Anaesthesia** 1996 Feb;51(2):173–5

Subdural or epidural? Confirmation with magnetic resonance imaging. Ralph CJ, et al. **Anaesthesia** 1996 Feb;51(2):175–7

Subdural or epidural? [letter] Scrutton M, et al. **Anaesthesia** 1996 Jul;51(7):708–9

An unusual complication of epidural analgesia in a morbidly obese parturient [letter] Hershan DB, et al. **Anesth Analg** 1996 Jan;82(1):217–8

Recurrence of herpes simplex virus blepharitis after cesarean section and epidural morphine. James CF. **Anesth Analg** 1996 May;82(5):1094–6 (17 ref.)

Naloxone versus nalbuphine infusion for prophylaxis of epidural morphine-induced pruritus. Kendrick WD, et al. **Anesth Analg** 1996 Mar;82(3):641–7

High sensory block after intrathecal sufentanil for labor analgesia. Hamilton CL, et al. **Anesthesiology** 1995 Nov; 83(5):1118–21

Recent advances in obstetrics. Epidural analgesia in labour [letter; comment] [see comments] Buggy DJ. **BMJ** 1996 Feb 10;312(7027):379. Comment on: BMJ 1995 Nov 4;311(7014):1209–12. Comment in: BMJ 1996 Apr 13;312(7036):974–5.

Sudden onset of subarachnoid block after subdural catheterization: a case of arachnoid rupture? Elliott DW, et al. **Br J Anaesth** 1996 Feb;76(2):322–4

Maternal sequelae of childbirth [editorial] Reynolds F. **Br J Anaesth** 1995 Nov;75(5):515–7 (26 ref.)

A testing time. Rogers R, et al. **Br J Hosp Med** 1995 Nov 1–14;54(9):478

Meningitis following a combined spinal–epidural technique in a labouring term parturient. Cascio M, et al. **Can J Anaesth** 1996 Apr;43(4):399–402

The risk of infection associated with epidural analgesia. Brooks K, et al. **Infect Control Hosp Epidemiol** 1995 Dec; 16(12):725–8

Epidural analgesia in labor. Robbins CW, et al. **J Fam Pract** 1996 Mar;42(3):227–8

Failure of the thiopental precipitation test to detect cerebrospinal fluid after dural puncture with current epidural solutions for labor analgesia [letter] Lowenwirt I, et al. **Reg Anesth** 1995 Sep–Oct;20(5):459–60

Transient motor deficit without sensory loss following subarachnoid sufentanil [letter; comment] Nagasandra V. **Reg Anesth** 1995 May–Jun;20(3):253–4. Comment on: Anesthesiology 1994 Feb;80(2):468–71.

[Compression stockings as prevention of hypotension in Cesarean section during spinal anesthesia] Jørgensen J, et al. **Ugeskr Laeger** 1996 Mar 11;158(11):1526–9 (Eng. Abstr.) **(Dan)**

[Staphylococcus aureus meningitis after obstetrical epidural anesthesia (letter)] Marsaudon E, et al. **Ann Fr Anesth Reanim** 1996;15(3):389–90 **(Fre)**

[Management of neurologic manifestations after obstetrical epidural anesthesia] Frangié S, et al. **Cah Anesthesiol** 1995; 43(5):455–60 (43 ref.) (Eng. Abstr.) **(Fre)**

METHODS

The intensity of labor pain in grand multiparas. Ranta P, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):250–4

'Walking' epidurals in labour [editorial] Morgan BM. **Anaesthesia** 1995 Oct;50(10):839–40

Epidural infusion of low-dose bupivacaine and opioid in labour. Does reducing motor block increase the spontaneous delivery rate? Russell R, et al. **Anaesthesia** 1996 Mar;51(3):266–73

Through the needle approach for difficult epidurals [letter] Sellers WF. **Anaesthesia** 1996 May;51(5):513

When not to give a test dose: one more reason? [letter; comment] Cross DA. **Anesth Analg** 1996 Jan;82(1):221–2. Comment on: Anesth Analg 1995 May;80(5):861–3. Comment on: Anesth Analg 1995 May;80(5):864–9.

The effect of postoperative analgesia with continuous epidural bupivacaine after cesarean section on the amount of breast feeding and infant weight gain. Hirose M, et al. **Anesth Analg** 1996 Jun;82(6):1166–9

Prospective examination of epidural catheter insertion [see comments] D'Angelo R, et al. **Anesthesiology** 1996 Jan; 84(1):88–93. Comment in: Anesthesiology 1996 Jun;84(6):1524–5.

Extradural analgesia with clonidine and fentanyl compared with 0.25% bupivacaine in the first stage of labour [see comments] Buggy DJ, et al. **Br J Anaesth** 1996 Feb; 76(2):319–21. Comment in: Br J Anaesth 1996 Jun;76(6):886–7.

NSAID for caesarean section [letter; comment] Jones SF. **Br J Anaesth** 1995 Nov;75(5):666. Comment on: Br J Anaesth 1995 Jun;74(6):643–6.

Intrathecal narcotics: new approach for labor analgesia. Manning J. **J Obstet Gynecol Neonatal Nurs** 1996 Mar–Apr; 25(3):221–4 (9 ref.)

Epidurals redefined in analgesia and anesthesia: a distinction with a difference. Youngstrom PC, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):350–4 (14 ref.)

Effect of labor analgesia with nalbuphine hydrochloride on fetal response to vibroacoustic stimulation. Poehlmann S, et al. **J Reprod Med** 1995 Oct;40(10):707–10

[Combined spinal and epidural analgesia for labor. Prolongation by addition of a minidose of clonidine to sufentanil. An initial study] Mercier FJ, et al. **Ann Fr Anesth Reanim** 1996;15(3):263–5 (Eng. Abstr.) **(Fre)**

[Spinal analgesia for labor] Mercier FJ, et al. **Cah Anesthesiol** 1996;44(2):173–9 (Eng. Abstr.) **(Fre)**

[Drugs for labor pain] Jage J. **Arch Gynecol Obstet** 1995; 257(1–4):135–8 (11 ref.) **(Ger)**

[Comparative study of continuous epidural analgesia versus intermittent, patient-controlled, epidural analgesia during labor] Vilaplana J, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep;42(7):269–73 (Eng. Abstr.) **(Spa)**

STANDARDS

Epidural analgesia during labor: continuous infusion or patient-controlled administration? Benhamou D. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S55–6 (9 ref.)

Effects of epidural analgesia on the progress of labor and the mode of delivery. Finster M. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S31–3 (35 ref.)

Role of patient-controlled epidural analgesia in obstetrics. Gambling DR, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S39–46 (45 ref.)

Combined spinal and epidural blockade for analgesia in labour. Morgan B. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S59–60

Influence of epidural analgesia on fetal and neonatal well-being. Scherer R, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S17–29 (118 ref.)

Pain during childbirth [editorial] Van Aken H, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S1

Labor pain relief using bupivacaine and sufentanil: patient controlled epidural analgesia versus intermittent injections. Vandermeulen EP, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S47–54

Opioids in combination with local anesthetics for epidural analgesia during labor. Vertommen JD. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S35–8 (23 ref.)

UTILIZATION

Epidural analgesia as a risk factor for operative delivery. Hemminki E, et al. **Int J Gynaecol Obstet** 1996 May; 53(2):125–32

ANALGESIA, PATIENT-CONTROLLED

The efficacy of adding a continuous intravenous morphine infusion to patient-controlled analgesia (PCA) in abdominal surgery. Dawson PJ, et al. **Anaesth Intensive Care** 1995 Aug;23(4):453–8

Patient-controlled epidural analgesia following caesarean delivery: a comparison of pethidine and fentanyl. Goh JL, et al. **Anaesth Intensive Care** 1996 Feb;24(1):45–50

Failure of Baxter PCA system [letter] Lam KK, et al. **Anaesth Intensive Care** 1995 Oct;23(5):652–3

Clinical experience with patient-controlled and staff-administered intermittent bolus epidural analgesia in labour. Paech MJ, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):459–63

Precipitation in PCA mixtures [letter] McCoy DG, et al. **Anaesthesia** 1995 Oct;50(10):919

Efficacy of patient controlled analgesia may have a diurnal rhythm! [letter] Richardson NG, et al. **Anaesthesia** 1996 Apr;51(4):409–10

An assessment of morphine requirement after wisdom tooth extraction under general anaesthesia. Tighe KE, et al. **Anaesthesia** 1995 Sep;50(9):816–8

Systemic piroxicam as an adjunct to patient-controlled analgesia with alfentanil for postoperative pain relief. Van Lancker P, et al. **Anaesthesia** 1996 Jul;51(7):658–62

Comparison of intravenous and epidural clonidine for postoperative patient-controlled analgesia. Bernard JM, et al. **Anesth Analg** 1995 Oct;81(4):706–12

Equivalent outcomes during postoperative patient-controlled intravenous analgesia with lidocaine plus morphine versus morphine alone. Cepeda MS, et al. **Anesth Analg** 1996 Jul; 83(1):102–6

Patient-controlled epidural analgesia after thoracotomy: a comparison of meperidine with and without bupivacaine. Etches RC, et al. **Anesth Analg** 1996 Jul;83(1):81–6

Drug delivery system to improve the perioperative administration of intravenous drugs: computer assisted continuous infusion (CACI) [editorial; comment] Glass PS, et al. **Anesth Analg** 1995 Oct;81(4):665–7. Comment on: Anesth Analg 1995 Oct;81(4):671–9.

Sustained-release ibuprofen as an adjunct to morphine patient-controlled analgesia. Plummer JL, et al. **Anesth Analg** 1996 Jul;83(1):92–6

A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia. Rapp SE, et al. **Anesth Analg** 1996 May;82(5):1043–8

Computer-controlled infusion of alfentanil versus patient-controlled administration of morphine for postoperative analgesia: a double-blind randomized trial [see comments] van den Nieuwenhuyzen MC, et al. **Anesth Analg** 1995 Oct;81(4):671–9. Comment in: Anesth Analg 1995 Oct;81(4):665–7.

Therapeutic suggestion has not effect on postoperative morphine requirements. van der Laan WH, et al. **Anesth Analg** 1996 Jan;82(1):148–52

Effects of perioperative analgesic technique on rate of recovery after colon surgery. Liu SS, et al. **Anesthesiology** 1995 Oct;83(4):757–65

Does patient-controlled analgesia achieve better control of pain and fewer adverse effects than intramuscular analgesia? A prospective randomized trial. Nitschke LF, et al. **Arch Surg** 1996 Apr;131(4):417–23

Patient-controlled extradural analgesia with bupivacaine, fentanyl, or a mixture of both, after Caesarean section. Cooper DW, et al. **Br J Anaesth** 1996 May;76(5):611–5

Dose requirements, efficacy and side effects of morphine and pethidine delivered by patient-controlled analgesia after gynaecological surgery. Stanley G, et al. **Br J Anaesth** 1996 Apr;76(4):484–6

Comparison of morphine and morphine with ketamine for postoperative analgesia. Javery KB, et al. **Can J Anaesth** 1996 Mar;43(3):212–5

Patient-controlled analgesia (PCA) in the domiciliary care of tumour patients. Meuret G, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:137–40

0.0625% bupivacaine with 0.0002% fentanyl via patient-controlled epidural analgesia for pain of labor and delivery. Ferrante FM, et al. **Clin J Pain** 1995 Jun; 11(2):121–6

Patient-controlled epidural analgesia during labor [letter] Paech M. **Clin J Pain** 1996 Mar;12(1):79

Patient-controlled epidural diamorphine for post-operative pain: verbal rating and visual analogue assessments of pain. Kunst G, et al. **Eur J Anaesthesiol** 1996 Mar;13(2):117–29

Age-related postoperative morphine requirements in children following major surgery—an assessment using patient-controlled analgesia (PCA). Hansen TG, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):29–31

Intravenous antispasmodic and patient-controlled analgesia

are of benefit for screening flexible sigmoidoscopy. Saunders BP, et al. **Gastrointest Endosc** 1995 Aug; 42(2):123–7

Efficacy of patient–controlled analgesia in women cholecystectomy patients. Knapp–Spooner C, et al. **Int J Nurs Stud** 1995 Oct;32(5):434–42

Bowel function recovery after radical hysterectomies: thoracic epidural bupivacaine–morphine versus intravenous patient–controlled analgesia with morphine: a pilot study. de Leon–Casasola OA, et al. **J Clin Anesth** 1996 Mar; 8(2):87–92

Patient–controlled intraoperative sedation. Herrick IA. **J Clin Anesth** 1996 May;8(3 Suppl):73S–75S (13 ref.)

The name of the game [editorial] Lehmann KA. **J Clin Anesth** 1996 Feb;8(1):1–3

Patient–controlled analgesia with sufentanil: a comparison of two different methods of administration. Sinatra RS, et al. **J Clin Anesth** 1996 Mar;8(2):123–9

Patient–controlled intranasal analgesia (PCINA) for the management of postoperative pain: a pilot study. Striebel HW, et al. **J Clin Anesth** 1996 Feb;8(1):4–8

Patient–controlled analgesia in Thai patients. Sanansilp V, et al. **J Med Assoc Thai** 1995 Oct;78(10):532–41

Use of patient–controlled analgesia for pain control for children receiving bone marrow transplant. Dunbar PJ, et al. **J Pain Symptom Manage** 1995 Nov;10(8):604–11

Patient controlled analgesia for shock wave lithotripsy: the effect of self–administered alfentanil on pain intensity and drug requirement [see comments] Schelling G, et al. **J Urol** 1996 Jan;155(1):43–7. Comment in: J Urol 1996 Jan;155(1):56–7.

Morphine consumption and respiratory depression in children receiving postoperative analgesia from continuous morphine infusion or patient controlled analgesia. Bray RJ, et al. **Paediatr Anaesth** 1996;6(2):129–34

A double–blind comparison of morphine infusion and patient controlled analgesia in children. Bray RJ, et al. **Paediatr Anaesth** 1996;6(2):121–7

Intrathecal morphine (ITM) for postoperative pain control in children: a comparison with nalbuphine patient controlled analgesia (PCA). Krechel SW, et al. **Paediatr Anaesth** 1995;5(3):177–83

Transnasal butorphanol for postoperative analgesia following paediatric surgery in a Third World country. Tobias JD, et al. **Paediatr Anaesth** 1995;5(1):63–6

The influence of lockout intervals and drug selection on patient–controlled analgesia following gynecological surgery. Ginsberg B, et al. **Pain** 1995 Jul;62(1):95–100

Does patient–controlled analgesia lead to delayed diagnosis of lower limb compartment syndrome? [letter] O'Sullivan ST, et al. **Plast Reconstr Surg** 1996 Apr;97(5):1087–8

Pain relief for thoracotomy. Comparison of morphine requirements using an extrapleural infusion of bupivacaine. Carabine UA, et al. **Reg Anesth** 1995 Sep–Oct;20(5):412–7

Outcome of epidural analgesia versus patient–controlled analgesia in cancer patients [letter; comment] Walker S. **Reg Anesth** 1995 Nov–Dec;20(6):549. Comment on: Reg Anesth 1994 Sep–Oct;19(5):307–15.

[Patient–controlled analgesia in cancer pain: practical aspects] Lakdja F, et al. **Cah Anesthesiol** 1995;43(6):583–6 (Eng. Abstr.) **(Fre)**

[Patient–controlled analgesia (PCA) after urologic interventions] Gust VR, et al. **Anaesthesiol Reanim** 1995; 20(5):134–8 (Eng. Abstr.) **(Ger)**

[Combination of intravenous patient–controlled analgesia with epidural anesthesia for postoperative pain therapy] Kentner R, et al. **Anaesthesiol Reanim** 1996;21(3):69–75 (Eng. Abstr.) **(Ger)**

[Patient–controlled analgesia with clonidine and piritramide] Sümpelmann R, et al. **Anaesthesist** 1996 Jan;45(1):88–94 (Eng. Abstr.) **(Ger)**

[Differential indications of non–opioid drugs for postoperative analgesia II. Quantification of the analgesic effect of a combination of metamizol plus diclofenac via patient–controlled analgesia] Steffen P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):216–21 (Eng. Abstr.) **(Ger)**

[Differential administration of non–opioids in postoperative analgesia, I. Quantification of the analgesic effect of metamizole using patient–controlled analgesia] Steffen P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr;31(3):143–7 (Eng. Abstr.) **(Ger)**

[Patient–controlled analgesia with pethidine in acute intermittent porphyria (letter)] Muehlenberg K, et al. **Dtsch Med Wochenschr** 1995 Oct 20;120(42):1454 **(Ger)**

[Patient–controlled analgesia as a method for postoperative anesthesia] Lebedeva RN, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):66–71 (145 ref.) **(Rus)**

[Comparative study of continuous epidural analgesia versus intermittent, patient–controlled, epidural analgesia during labor] Vilaplana J, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep;42(7):269–73 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Patient–controlled analgesia and prolonged ileus after uncomplicated colectomy. Petros JG, et al. **Am J Surg** 1995 Oct;170(4):371–4

Respiratory arrest with patient–controlled analgesia [letter; comment] Barnes N, et al. **Anaesth Intensive Care** 1996 Feb;24(1):117–9. Comment on: Anaesth Intensive Care 1995 Feb;23(1):119–20.

Comparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient–controlled analgesia. Alexander R, et al. **Anaesthesia** 1995 Dec;50(12):1086–8

Postoperative cognitive impairment in the elderly. Choice of patient–controlled analgesia opioid. Herrick IA, et al. **Anaesthesia** 1996 Apr;51(4):356–60

A comparison of retrospective versus contemporaneous nausea scores with patient–controlled analgesia. McIndoe AK, et al. **Anaesthesia** 1996 Apr;51(4):333–7

Respiratory depression associated with patient–controlled analgesia [letter] Ngan Kee WD, et al. **Can J Anaesth** 1995 Oct;42(10):953–4

Respiratory depression: an adverse outcome during patient controlled analgesia therapy. Looi–Lyons LC, et al. **J Clin Anesth** 1996 Mar;8(2):151–6

The management of opioid and benzodiazepine dependence in infants, children, and adolescents. Yaster M, et al. **Pediatrics** 1996 Jul;98(1):135–40 (41 ref.)

Side–effects during patient–assisted epidural analgesia [letter; comment] Chrubasik S, et al. **Reg Anesth** 1995 May–Jun; 20(3):258–60. Comment on: Reg Anesth 1994 May–Jun;19(3):206–11.

ECONOMICS

Payment for routine postoperative patient–controlled analgesia [letter; comment] Waun JE. **Anesthesiology** 1996 Jan;84(1):237–8. Comment on: Anesthesiology 1995 Aug;83(2):433–4.

Cost–effectiveness analysis of patient–controlled analgesia, intramuscular q.i.d. injection and p.r.n. injection for postoperative pain relief. Sanansilp V, et al. **J Med Assoc Thai** 1995 Nov;78(11):600–4

INSTRUMENTATION

Evaluation of a disposable device for patient–controlled epidural analgesia after caesarean section. Ngan Kee WD, et al. **Anaesth Intensive Care** 1996 Feb;24(1):51–5

Untoward incident with PCA extension set [letter] Bull PT. **Anaesthesia** 1996 May;51(5):515–6

Overdose of morphine during PCA [letter] Kwan A. **Anaesthesia** 1995 Oct;50(10):919

A hazard with the Abbott Provider 5500 [letter] McAndrew PE. **Anaesthesia** 1995 Sep;50(9):829

Defective anti–reflux valve [letter] Mason DG. **Anaesthesia** 1996 Jun;51(6):608

Disposable PCA devices: the lockout interval may not be what it seems [letter] Smith AJ. **Anaesthesia** 1995 Sep; 50(9):828

Intravenous dead space and patient safety in patient–controlled analgesia [letter] Doyle DJ, et al. **Can J Anaesth** 1995 Jul;42(7):658

Patient–controlled analgesic infusion pumps. Nobel JJ. **Pediatr Emerg Care** 1995 Oct;11(5):319–21

METHODS

Patient–controlled alfentanil. Target–controlled infusion for postoperative analgesia. Irwin MG, et al. **Anaesthesia** 1996 May;51(5):427–30

Variable–dose patient–controlled analgesia. A preliminary report. Owen H, et al. **Anaesthesia** 1995 Oct;50(10):855–7

Patient–controlled intranasal analgesia: a method for noninvasive postoperative pain management. Striebel HW, et al. **Anesth Analg** 1996 Sep;83(3):548–51

Patient–controlled analgesia for conscious sedation during endoscopic retrograde cholangiopancreatography: a randomized controlled trial. Jowell PS, et al. **Gastrointest Endosc** 1996 May;43(5):490–4

Thoracic versus lumbar administration of fentanyl using patient–controlled epidural after thoracotomy. Bouchard F, et al. **Reg Anesth** 1995 Sep–Oct;20(5):385–8

NURSING

Impact of patient–controlled analgesia on required nursing time and duration of postoperative recovery. Chan VW, et al. **Reg Anesth** 1995 Nov–Dec;20(6):506–14

Nurses' adoption of a patient–controlled analgesia approach. Fulton TR. **West J Nurs Res** 1996 Aug;18(4):383–96

PSYCHOLOGY

Patients' experiences of patient–controlled analgesia. Taylor NM, et al. **Anaesthesia** 1996 Jun;51(6):525–8

Psychological characteristics and patient–controlled analgesia [letter] [see comments] McConaghy PM. **Br J Anaesth** 1995 Sep;75(3):376. Comment in: Br J Anaesth 1996 Apr;76(4):595.

Expanding the applications of patient–controlled techniques [letter] Mackenzie J. **Br J Anaesth** 1995 Sep;75(3):377

Psychological characteristics and patient–controlled analgesia [letter; comment] Thomas VJ, et al. **Br J Anaesth** 1996 Apr;76(4):595. Comment on: Br J Anaesth 1995 Sep;75(3):376.

To control or to be controlled? From health locus of control to morphine control during patient–controlled analgesia. Reynaert C, et al. **Psychother Psychosom** 1995;64(2):74–81

STANDARDS

Epidural analgesia during labor: continuous infusion or patient–controlled administration? Benhamou D. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S55–6 (9 ref.)

Role of patient–controlled epidural analgesia in obstetrics. Gambling DR, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S39–46 (45 ref.)

Pain during childbirth [editorial] Van Aken H, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S1

Labor pain relief using bupivacaine and sufentanil: patient controlled epidural analgesia versus intermittent injections. Vandermeulen EP, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S47–54

ANALGESIA TESTS see **PAIN MEASUREMENT**

ANALGESIC CUTANEOUS ELECTROSTIMULATION see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

ANALGESICS

Pediatric sedation and analgesia [letter; comment] Sacchetti AD, et al. **Acad Emerg Med** 1995 Mar;2(3):240–1. Comment on: Acad Emerg Med 1994 Jul–Aug;1(4):368–72.

Controlled drugs—do current handling practices disguise substance abuse? [letter] Smith AF. **Anaesthesia** 1996 Apr; 51(4):403

Analgesic effects of sucrose were known to the prophet [letter] Katme AM. **BMJ** 1995 Oct 28;311(7013):1169

Comparison of morphine and morphine with ketamine for postoperative analgesia. Javery KB, et al. **Can J Anaesth** 1996 Mar;43(3):212–5

Pain mechanisms and management: an update. Siddall PJ, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):679–88 (91 ref.)

High frequency of urothelial cancers in patients with kidney transplantations for end–stage analgesic nephropathy [letter] Bokemeyer C, et al. **Eur J Cancer** 1996 Jan; 32A(1):175–6

Prevalence of abuse and dependency in chronic pain patients. Hoffmann NG, et al. **Int J Addict** 1995 Jun;30(8):919–27

Study of the antinociceptive effect of tetrahydro–papaveroline derivatives. Interaction with opioids. Fialip J, et al. **Life Sci** 1996;59(11):PL133–9

Possible diversion of pain medication occurs in home hospice setting. Thornton ES. **Oncol Nurs Forum** 1996 Jan–Feb; 23(1):118

Sucrose reduces pain reaction to heel lancing in preterm infants: a placebo–controlled, randomized and masked study. Bucher HU, et al. **Pediatr Res** 1995 Sep;38(3):332–5

A new way to spell relief: v–e–n–o–m. A toxin from killer sea snails promises a better painkiller [news] Gibbs WW. **Sci Am** 1996 Feb;274(2):28, 30

Clinical comparison of medetomidine with xylazine/l–methadone in dogs. Kramer S, et al. **Vet Rec** 1996 Feb 10;138(6):128–33

Denovo urothelial carcinoma of the upper and lower urinary tract in kidney—transplant patients with end–stage analgesic nephropathy. Thon WF, et al. **World J Urol** 1995; 13(4):254–61

[Mechanism of analgesic action of Y–23023, a new non–steroidal anti–inflammatory drug] Ochi H, et al. **Nippon Yakurigaku Zasshi** 1995 Oct;106(4):271–7 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Pain management in the emergency department [letter] Ducharme J, et al. **Acad Emerg Med** 1995 Sep;2(9):850–2

Chest tube removal practices in critical care units in the United States. Kinney MR, et al. **Am J Crit Care** 1995 Nov;4(6):419–24

Analgesic administration, pain intensity, and patient satisfaction in cardiac surgical patients. Meehan DA, et al. **Am J Crit Care** 1995 Nov;4(6):435–42

Anesthesia induced in pigs by use of a combination of medetomidine, butorphanol, and ketamine and its reversal by administration of atipamezole. Sakaguchi M, et al. **Am J Vet Res** 1996 Apr;57(4):529–34

Patient consent and rectal drug administration [letter; comment] Barker I, et al. **Anaesthesia** 1996 Apr;51(4):402 . Comment on: Anaesthesia 1995 Nov;50(11):983–4.

Patient consent and rectal drug administration [letter; comment] Bonner S, et al. **Anaesthesia** 1996 Apr; 51(4):401–2. Comment on: Anaesthesia 1995 Nov;50(11):983–4.

Patient consent and rectal administration [letter; comment] Griffith NW. **Anaesthesia** 1996 Apr;51(4):402. Comment on: Anaesthesia 1995 Nov;50(11):983–4.

Attitudes and preferences of patients to routes of analgesic administration [letter] Skinner TA, et al. **Anaesthesia** 1996 Mar;51(3):290–1

Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain. Belfrage M, et al. **Anesth Analg** 1995 Oct; 81(4):713–7

Comparison of intravenous and epidural clonidine for postoperative patient–controlled analgesia. Bernard JM, et al. **Anesth Analg** 1995 Oct;81(4):706–12

Gender–associated differences in emergency department pain management. Raftery KA, et al. **Ann Emerg Med** 1995 Oct; 26(4):414–21

Sucrose as an analgesic agent for infants during immunization injections. Allen KD, et al. **Arch Pediatr Adolesc Med** 1996

Mar;150(3):270–4
Efficacy of intra–muscular analgesics for acute pain in sheep. Grant C, et al. **Aust Vet J** 1996 Apr;73(4):129–32
Comparison of i.m. and local infiltration of ketorolac with and without local anaesthetic. Ben–David B, et al. **Br J Anaesth** 1995 Oct;75(4):409–12
Introducing an acute pain service. Hall PA, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):15–7 (10 ref.)
Continuous epidural morphine/butorphanol infusion following selective dorsal rhizotomy in children. Lawhorn CD, et al. **Childs Nerv Syst** 1995 Nov;11(11):621–4
The use of topical 5% lignocaine ointment for the relief of pain associated with post–operative nasal packing. Kuo MJ, et al. **Clin Otolaryngol** 1995 Aug;20(4):357–9
Clinical management of herpes zoster in the elderly patient. Beutner KR. **Compr Ther** 1996 Mar;22(3):183–6 (6 ref.)
Drugs to treat the tissue complications of diabetes: peripheral neuropathy. Emanuele NV, et al. **Compr Ther** 1995 Oct; 21(10):579–82 (30 ref.)
Management of painful procedures in the newborn. Stevens B. **Curr Opin Pediatr** 1996 Apr;8(2):102–7 (55 ref.)
The post–operative analgesic action of midazolam following epidural administration. Nishiyama T. **Eur J Anaesthesiol** 1995 Jul;12(4):369–74
Post–operative analgesia for craniotomy patients: current attitudes among neuroanaesthetists. Stoneham MD, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):571–5
Intra–articular injection of bupivacaine in knee–replacement operations. Results of use for analgesia and for preemptive blockade. Badner NH, et al. **J Bone Joint Surg Am** 1996 May;78(5):734–8
The use of intrapleural clonidine for postoperative pain control. Canver CC, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):183–5
Retrocrural splanchnic nerve alcohol neurolysis with a CT–guided anterior transaortic approach. Fields S. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):157–60
Evaluation of topical viscous 2% lidocaine jelly as an adjunct during the management of alveolar osteitis. Betts NJ, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1140–4
Intravenous amitriptyline in pediatrics. Collins JJ, et al. **J Pain Symptom Manage** 1995 Aug;10(6):471–5
Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. Roy SD, et al. **J Pharm Sci** 1995 Oct; 84(10):1190–6
Pharmacologic treatment of cancer pain. Levy MH. **N Engl J Med** 1996 Oct 10;335(15):1124–32 (101 ref.)
Involvement of opioid receptors in the antinociception produced by intracerebroventricularly administered spantide in mice. Tan–No K, et al. **Neuropeptides** 1995 Nov; 29(5):293–9
Modification by analgesics of the susceptibility to antibiotics in Serratia marcescens. Puig M, et al. **New Microbiol** 1995 Oct;18(4):385–90
National survey of drug use in palliative care. Drummond SH, et al. **Palliat Med** 1996 Apr;10(2):119–24
Peak pain relief is delayed and duration of relief is extended following intravenous phentolamine infusion. Preliminary report. Galer BS. **Reg Anesth** 1995 Sep–Oct;20(5):444–7
Concerns about analgesics among patients and family caregivers in a hospice setting. Ward SE, et al. **Res Nurs Health** 1996 Jun;19(3):205–11 (31 ref.)
The use of access devices in cancer pain control. Brant JM. **Semin Oncol Nurs** 1995 Aug;11(3):203–12 (44 ref.)
Lumbar zygapophysial (facet) joint injections. Dreyfuss PH, et al. **Spine** 1995 Sep 15;20(18):2040–7 (89 ref.)
[Registration in medical journals of prescriptions for strong analgesics prescribed by general practitioners] Sørensen HT, et al. **Ugeskr Laeger** 1995 Oct 2;157(40):5538–40 (Eng. Abstr.) **(Dan)**
[Cancer pain: beneficial effect of ketamine addition to spinal administration of morphine–clonidine–lidocaine mixture] Muller A, et al. **Ann Fr Anesth Reanim** 1996;15(3):271–6 (Eng. Abstr.) **(Fre)**
[Analgesia after surgery of the spine in adults and adolescents] Bernard JM, et al. **Cah Anesthesiol** 1995; 43(6):557–64 (78 ref.) (Eng. Abstr.) **(Fre)**
[Postoperative analgesia in children: techniques] Ecoffey C. **Cah Anesthesiol** 1995;43(3):305–6 **(Fre)**
[Audit of the management of postoperative pain] Poisson–Salomon AS, et al. **Presse Med** 1996 Jun 22; 25(22):1013–7 (Eng. Abstr.) **(Fre)**
[The analgesic effect of iontophoresis with magnesium sulfate] Mizutani A, et al. **Masui** 1995 Aug;44(8):1076–9 (Eng. Abstr.) **(Jpn)**
[Postoperative analgesic requirements after various operations] Shima T, et al. **Masui** 1996 Mar;45(3):370–3 (Eng. Abstr.) **(Jpn)**
[Analgesic effect of dextromethorphan for postherpetic neuralgia] Suzuki T, et al. **Masui** 1996 May;45(5):629–33 (Eng. Abstr.) **(Jpn)**
[Unilateral injection with the patient in lateral position. Simpler pain blockade in pancreatic cancer] Rykowski JJ, et al. **Lakartidningen** 1996 May 22;93(21):2075–7 **(Swe)**

ADVERSE EFFECTS

Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin. Buckalew VM Jr. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S7–13 (31 ref.)
Combination analgesic–induced kidney disease: the Australian experience. Duggin GG. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S39–47 (41 ref.)
Combination analgesic involvement in the pathogenesis of analgesic nephropathy: the European perspective. Elseviers MM, et al. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S48–55 (20 ref.)
Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation [see comments] Henrich WL, et al. **Am J Kidney Dis** 1996 Jan;27(1):162–5. Comment in: Am J Kidney Dis 1996 Jun;27(6):917–8.
Over–the–counter analgesics and kidney disease [letter; comment] Lipton RB, et al. **Am J Kidney Dis** 1996 Jun; 27(6):917–8. Comment on: Am J Kidney Dis 1996 Jan;27(1):162–5.
Pathophysiologic mechanisms in analgesic–induced papillary necrosis. Sabatini S. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S34–8 (37 ref.)
Concerns with chronic analgesic therapy in elderly patients. Gloth FM 3rd. **Am J Med** 1996 Jul 31;101(1A):19S–24S (39 ref.)
Case report: analgesic nephropathy: a soda and a powder. Appel RG, et al. **Am J Med Sci** 1995 Oct;310(4):161–6
Beware of routine procedures. Lilley LL, et al. **Am J Nurs** 1995 Oct;95(10):18
Intravenous ketorolac tromethamine worsens platelet function during knee arthroscopy under spinal anesthesia. Thwaites BK, et al. **Anesth Analg** 1996 Jun;82(6):1176–81
Intraoperative ketorolac and posttonsillectomy bleeding. Judkins JH, et al. **Arch Otolaryngol Head Neck Surg** 1996 Sep;122(9):937–40
Does patient–controlled analgesia achieve better control of pain and fewer adverse effects than intramuscular analgesia? A prospective randomized trial. Nitschke LF, et al. **Arch Surg** 1996 Apr;131(4):417–23
Gastrointestinal blood loss induced by bromfenac sodium, aspirin, and placebo. Cohen A. **Clin Ther** 1995 Nov–Dec; 17(6):1110–7
Allergic contact dermatitis from butoxyethyl nicotinic acid and Centella asiatica extract. Bilbao I, et al. **Contact Dermatitis** 1995 Dec;33(6):435–6
Analgesic rebound headache. How great is the problem and what can be done? Silberstein SD, et al. **Drug Saf** 1995 Sep;13(3):133–44 (62 ref.)
Headaches associated with chronic use of analgesics: a therapeutic approach. Pini LA, et al. **Headache** 1996 Jul–Aug;36(7):433–9
Analgesic rebound headache in clinical practice: data from a physician survey. Rapoport A, et al. **Headache** 1996 Jan; 36(1):14–9
Psychoactive medication, alcohol use, and falls among older adults. Sheahan SL, et al. **J Behav Med** 1995 Apr; 18(2):127–40
Effect of ketorolac tromethamine on bleeding and on requirements for analgesia after total knee arthroplasty [letter; comment] Dodenhoff RM. **J Bone Joint Surg Am** 1996 Jun;78(6):968. Comment on: J Bone Joint Surg Am 1995 Jul;77(7):998–1002.
Effect of ketorolac tromethamine on bleeding and on requirements for analgesia after total knee arthroplasty [letter; comment] Linville D. **J Bone Joint Surg Am** 1996 Jun;78(6):967–8. Comment on: J Bone Joint Surg Am 1995 Jul;77(7):998–1002.
Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study [see comments] Strom BL, et al. **JAMA** 1996 Feb 7; 275(5):376–82. Comment in: JAMA 1996 Aug 7;276(5):372.
High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. Elseviers MM, et al. **Kidney Int** 1995 Oct; 48(4):1316–23
A long–term prospective controlled study of analgesic abuse in Belgium. Elseviers MM, et al. **Kidney Int** 1995 Dec; 48(6):1912–9
Occupational allergy to propacetamol [letter] Barbaud A, et al. **Lancet** 1995 Sep 30;346(8979):902
Acetaminophen, NSAIDs and alcohol. **Med Lett Drugs Ther** 1996 Jun 21;38(977):55–6
Evaluation of diagnostic criteria for analgesic nephropathy in patients with end–stage renal failure: results of the ANNE study. Analgesic Nephropathy Network of Europe. Elseviers MM, et al. **Nephrol Dial Transplant** 1995; 10(6):808–14
Is analgesic nephropathy a problem in the south–west region of Poland? [letter] Franek E, et al. **Nephron** 1996;72(2):353
High mortality from urothelial carcinoma despite regular tumor screening in patients with analgesic nephropathy after renal transplantation. Kliem V, et al. **Transpl Int** 1996; 9(3):231–5
[Liver cirrhosis and granulomatous hepatitis after prolonged ingestion of lysine acetylsalicylate] D'Abrigeon G, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):944–7 (Eng. Abstr.) **(Fre)**
[The effects of long–term sedation on intestinal function] Zielmann S, et al. **Anaesthesist** 1995 Dec;44 Suppl 3:S549–58 (Eng. Abstr.) **(Ger)**

ANALYSIS

Determination of flunixin in milk by liquid chromatography with confirmation by gas chromatography/mass spectrometry and selected ion monitoring. Rupp HS, et al. **J AOAC Int** 1995 Jul–Aug;78(4):959–67

ANTAGONISTS & INHIBITORS

Ondansetron blocks nifedipine–induced analgesia in rats. Hunt TE, et al. **Anesth Analg** 1996 Mar;82(3):498–500
Antagonism of the antinocifensive action of halothane by intrathecal administration of GABAA receptor antagonists. Mason P, et al. **Anesthesiology** 1996 May;84(5):1205–14
Antisense oligodeoxynucleotides to the kappa–1 receptor block the antinociceptive effects of delta 9–THC in the spinal cord. Pugh G Jr, et al. **Brain Res** 1995 Aug 14; 689(1):157–8
Piracetam and aniracetam antagonism of centrally active drug–induced antinociception. Galeotti N, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):943–50

BLOOD

Extraction of selected drugs from serum using microwave irradiation. Franke M, et al. **Forensic Sci Int** 1996 Jul 31; 81(1):51–9

CHEMICAL SYNTHESIS

Synthesis and trazodone–like analgesic activity of 4–phenyl–6–aryl–2–[3–(4–arylpiperazin–1–yl) propyl]pyridazin –3–ones. Rohet F, et al. **Chem Pharm Bull (Tokyo)** 1996 May;44(5):980–6
Synthesis and enantioselectivity of the enantiomers of PG9 and SM21, new potent analgesic and cognition–enhancing drugs. Romanelli MN, et al. **Chirality** 1996;8(3):225–33
Synthesis and pharmacological properties of thieno[2',3':4,5]pyrimido [2,1–b][1,3,4]thiadiazine derivatives. Santagati A, et al. **Farmaco** 1995 Sep; 50(9):605–9
Similarities and differences in the structure–activity relationships of capsaicin and resiniferatoxin analogues. Walpole CS, et al. **J Med Chem** 1996 Jul 19;39(15):2939–52

CHEMISTRY

Ipriflavone, an antiostheophorotic agent. Böcskei Z, et al. **Acta Crystallogr C** 1996 Apr 15;52 (Pt 4):1022–4
Asymmetric synthesis and enantiospecificity of binding of 2–(1,2,3,4–tetrahydro–1–isoquinolyl)–ethanol derivatives to mu and kappa receptors. Wanner KT, et al. **Arch Pharm (Weinheim)** 1996 Jan;329(1):11–22
Absolute configurations and conformations of the opioid agonist and antagonist enantiomers of picenadol. Froimowitz M, et al. **Chirality** 1995;7(7):518–25

METABOLISM

Further characterization of [3H]U69593 binding sites in the rat heart. Jin WQ, et al. **J Mol Cell Cardiol** 1995 Aug; 27(8):1507–11
Time–dependent antinociceptive interactions between opioids and nucleoside transport inhibitors. Keil GJ 2nd, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1387–92

PHARMACOKINETICS

Clinical pharmacokinetics in patients with burns. Jaehde U, et al. **Clin Pharmacokinet** 1995 Jul;29(1):15–28 (75 ref.)
Pharmacokinetic optimisation of drug therapy in elderly patients. Parker BM, et al. **Drugs Aging** 1995 Jul;7(1):10–8 (38 ref.)
Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. Roy SD, et al. **J Pharm Sci** 1995 Oct; 84(10):1190–6
Periventricular penetration and disappearance of ICV Tyr–MIF–1, DAMGO, tyrosine, and albumin. Maness LM, et al. **Peptides** 1996;17(2):247–50

PHARMACOLOGY

Effects of a combination of detomidine and butorphanol on respiratory function in horses with or without chronic obstructive pulmonary disease. Lavoie JP, et al. **Am J Vet Res** 1996 May;57(5):705–9
Hemodynamic effects of medetomidine–midazolam–butorphanol and medetomidine–midazolam–buprenorphine combinations and reversibility by atipamezole in dogs. Pypendop B, et al. **Am J Vet Res** 1996 May;57(5):724–30
Intrathecal clonidine and tizanidine in conscious dogs: comparison of analgesic and hemodynamic effects. Kroin JS, et al. **Anesth Analg** 1996 Mar;82(3):627–35
Preemptive analgesic effects of steroid anesthesia with alphaxalone in the rat formalin test. Evidence for differential GABA(A) Receptor modulation in persistent nociception. Gilron I, et al. **Anesthesiology** 1996 Mar; 84(3):572–9
Spinal antinociceptive action of an N–Type voltage–dependent calcium channel blocker and the synergistic interaction with morphine. Omote K, et al. **Anesthesiology** 1996 Mar;84(3):636–43
Analgesic activity of the lysozyme peptide N–(N–L–threonyl–L–alpha–aspartyl)–L–tyrosine in the monkey and the dog. Munt PL, et al. **Arzneimittelforschung** 1995 Jul;45(7):805–9
delta Opioid receptor in neuronal cells undergoes acute and homologous desensitization. Cai Y, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):342–7
Short treatment of osteoclasts in bone marrow culture with calcitonin causes prolonged suppression of calcitonin

receptor mRNA. Rakopoulos M, et al. **Bone** 1995 Nov; 17(5):447–53

Molecular biology of pain. Munglani R, et al. **Br J Anaesth** 1995 Aug;75(2):186–92 (84 ref.)

New molecules in analgesia. Rang HP, et al. **Br J Anaesth** 1995 Aug;75(2):145–56 (145 ref.)

Effects of flurbiprofen enantiomers on pain–related chemo–somatosensory evoked potentials in human subjects. Lötsch J, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):339–46

The antinociceptive effect of 1–(2–trifluoromethylphenyl) imidazole (TRIM), a potent inhibitor of neuronal nitric oxide synthase in vitro, in the mouse. Handy RL, et al. **Br J Pharmacol** 1995 Nov;116(5):2349–50

Central versus peripheral site of action of the tachykinin NK1–antagonist RP 67580 in inhibiting chemonociception. Holzer–Petsche U, et al. **Br J Pharmacol** 1995 Jun; 115(3):486–90

Involvement of bulbospinal pathways in the antinociceptive effect of clomipramine in the rat. Ardid D, et al. **Brain Res** 1995 Oct 16;695(2):253–6

Haloperidol and reduced haloperidol–induced exacerbation of the dystonia produced by the kappa opioid U50,488H in guinea–pigs is associated with inhibition of sigma binding sites: behavioural and autoradiographical studies. Brent PJ. **Brain Res** 1995 Jul 3;684(2):115–26

kappa–opioid agonist U50488 inhibits P–type Ca2+ channels by two mechanisms. Kanemasa T, et al. **Brain Res** 1995 Dec 8;702(1–2):207–12

The 'glibenclamide–shift' of centrally–acting antinociceptive agents in mice. Raffa RB, et al. **Brain Res** 1995 Apr 24; 677(2):277–82

Prolactin induced analgesia is dependent on ATP sensitive potassium channels. Shewade DG, et al. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):635–6

NSAID: an update on their analgesic effects. Walker JS. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):855–60

Evidence for the involvement of opioid peptides in phagocytosis, conformation, granulation and aggregation of immunocompetent Lumbricus terrestris amoebocytes. Renzelli–Cain R, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):205–11

Lack of activity of azapropazone in the hot–plate test and in 5–HT1A and 5–HT2 receptor subtypes in rat brain membranes. Pini LA, et al. **Drugs Exp Clin Res** 1995; 21(5):181–6

Anti–nociception induced by systemic or PAG–microinjected lysine–acetylsalicylate in rats. Effects on tail–flick related activity of medullary off– and on–cells. Tortorici V, et al. **Eur J Neurosci** 1995 Sep 1;7(9):1857–65

In vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect of vapreotide, an analgesic cyclic analog of somatostatin. Bétoin F, et al. **Eur J Pharmacol** 1995 Jun 12;279(2–3):241–9

Properties of TAN–67, a nonpeptidic delta–opioid receptor agonist, at cloned human delta– and mu–opioid receptors. Knapp RJ, et al. **Eur J Pharmacol** 1995 Oct 15; 291(2):129–34

Stimulation of spinal delta–opioid receptors in mice selectively enhances the attenuation of delta–opioid receptor–mediated antinociception by antisense oligodeoxynucleotide. Narita M, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):185–9

Inhibition of protein kinase C, but not of protein kinase A, blocks the development of acute antinociceptive tolerance to an intrathecally administered mu–opioid receptor agonist in the mouse. Narita M, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):R1–3

Chronopharmacological study of acetylsalicylic acid in mice. Ohdo S, et al. **Eur J Pharmacol** 1995 Jul 1;293(2):151–7

Antinociception by adenosine analogs and an adenosine kinase inhibitor: dependence on formalin concentration. Poon A, et al. **Eur J Pharmacol** 1995 Nov 14;286(2):177–84

Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist. Valverde O, et al. **Eur J Pharmacol** 1995 Nov 3;286(1):79–93

Modulation of somatocardiac sympathetic reflexes mediated by opioid receptors at the spinal and brainstem level. Sato A, et al. **Exp Brain Res** 1995;105(1):1–6

Regulation of L–valine absorption by opioids interacting with mu–receptors in rabbit ileum. Meyer G, et al. **Experientia** 1995 Nov 15;51(11):1045–51

Non–competitive antagonism of N–methyl–D–aspartate receptor inhibits tolerance to the analgesic action of U–50,488H, a kappa–opiate receptor agonist in the rat. Bhargava HN. **Gen Pharmacol** 1995 Sep;26(5):1055–60

Antinociceptive effects of clebopride in the mouse. Bittencourt SC, et al. **Gen Pharmacol** 1995 Sep;26(5):1083–7

Effect of the intraperitoneal administration of salmon–calcitonin on the "in vitro" actions of opioid agonists. Martin MI, et al. **Gen Pharmacol** 1995 Dec; 26(8):1695–9

Analysis of the mechanisms underlying the antinociceptive effect of the extracts of plants from the genus Phyllanthus. Santos AR, et al. **Gen Pharmacol** 1995 Nov;26(7):1499–1506

Comparison of effects of calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers. Murray FE, et al. **Gut** 1996 Jan;38(1):11–4

Antinociceptive action of Azadirachta indica (neem) in mice: possible mechanisms involved. Khanna N, et al. **Indian J Exp Biol** 1995 Nov;33(11):848–50

Antinociceptive activities of non–steroidal antiinflammatory drugs (NSAIDs) following intracerebroventricular (i.c.v.) and intrathecal (i.t.) administration in mice. Walter TL, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S133–4

Involvement of delta–opioid receptors in immunosuppression. Cheido M, et al. **Int J Neurosci** 1996 Feb;84(1–4):195–203

Comparative study of the analgesic and paralytic effects induced by intrathecal dynorphin a in rats. Xue JC, et al. **Int J Neurosci** 1995 May;82(1–2):83–93

Effects of triclosan on the rat phrenic nerve–diaphragm preparation. Kjaerheim V, et al. **J Clin Periodontol** 1995 Jun;22(6):488–93

Analgesic activity of Psychotria colorata (Willd. ex R. & S.) Muell. Arg. alkaloids. Elisabetsky E, et al. **J Ethnopharmacol** 1995 Oct;48(2):77–83

Ethnopharmacology of bear gall bladder: I. Li YW, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):27–31

Effects of an ethanolic extract of Desmodium adscendens on central nervous system in rodents. N'gouemo P, et al. **J Ethnopharmacol** 1996 Jun;52(2):77–83

Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC–51089, a potent PGE2 antagonist, and its analogs. Hallinan EA, et al. **J Med Chem** 1996 Jan 19;39(2):609–13

Opioid regulation of intracellular free calcium in cultured mouse dorsal root ganglion neurons. Tang T, et al. **J Neurosci Res** 1996 May 15;44(4):338–43

Safety of lidocaine–prilocaine cream in the treatment of preterm neonates. Taddio A, et al. **J Pediatr** 1995 Dec; 127(6):1002–5

The peristaltic reflex in the rat ileum: evidence for functional mu– and delta–opiate receptors. Coupar IM. **J Pharm Pharmacol** 1995 Aug;47(8):643–6

Blood–to–central nervous system entry and stability of biphalin, a unique double–enkephalin analog, and its halogenated derivatives. Abbruscato TJ, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1049–57

Fentanyl–related 4–heteroanilido piperidine OHM3295 augments splenic natural killer activity and induces analgesia through opioid receptor pathways. Baker ML, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1285–92

Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide–mediated "knock–down" of opioid receptor in vivo. Bilsky EJ, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):491–501

Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212–2, and is potentiated by the cannabinoid antagonist, SR 141716A. Gifford AN, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1431–6

Enkephalin analog prodrugs: assessment of in vitro conversion, enzyme cleavage characterization and blood–brain barrier permeability. Greene DL, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1366–75

Antinociception and delta–1 opioid receptors in the rat spinal cord: studies with intrathecal 7–benzylidenenaltrexone. Hammond DL, et al. **J Pharmacol Exp Ther** 1995 Sep; 274(3):1317–24

Microinfusion of mu but not delta or kappa opioid agonists into the basolateral amygdala results in inhibition of the tail flick reflex in pentobarbital–anesthetized rats. Helmstetter FJ, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):381–8

Felbamate relieves several abnormal pain sensations in rats with an experimental peripheral neuropathy. Imamura Y, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):177–82

Investigation of brain sites mediating cannabinoid–induced antinociception in rats: evidence supporting periaqueductal gray involvement. Lichtman AH, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):585–93

Evaluation of detomidine–induced analgesia in horses with chronic hoof pain. Owens HG, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):179–84

The role of serotonin in the effects of opioids in squirrel monkeys responding under a titration procedure: I. Kappa opioids. Powell KR, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1305–16

Characterization of two cloned human CB1 cannabinoid receptor isoforms. Rinaldi–Carmona M, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):871–8

kappa–Opioid agonist, U50,488H, stimulates ovine fetal pituitary–adrenal function via hypothalamic arginine–vasopressin and corticotrophin–releasing factor. Taylor CC, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):877–84

Pharmacology of 5–chloro–7–trifluoromethyl–1,4–dihydro–2,3–quinoxalinedione: a novel systemically active ionotropic glutamate receptor antagonist. Woodward RM, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1209–18

Effects of propofol on nociceptive response and power spectra of electroencephalographic and systemic arterial pressure signals in the rat: correlation with plasma concentration. Yang CH, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1568–74

Opioid depression of respiration in neonatal rats. Greer JJ, et al. **J Physiol (Lond)** 1995 Jun 15;485 (Pt 3):845–55

Profiles of the antinociceptive effect of R–84760, a selective kappa–opioid receptor agonist, in the formalin test in mice. Fujibayashi K, et al. **Jpn J Pharmacol** 1995 May;68(1):57–63

Antinociceptive activity of filenadol on inflammatory pain. Bustos G, et al. **Life Sci** 1995;57(14):PL181–6

Synthesis, characterization and pharmacological profile of tropicamide enantiomers. Dei S, et al. **Life Sci** 1996; 58(23):2147–53

Central cholinergic antinociception induced by 5HT4 agonists: BIMU 1 and BIMU 8. Ghelardini C, et al. **Life Sci** 1996;58(25):2297–309

Ligand binding profiles of U–69, 593–sensitive and–insensitive sites in human cerebral cortex membranes: evidence of kappa opioid receptors heterogeneity. Kim KW, et al. **Life Sci** 1996;58(19):1671–9

Receptor reserve and affinity of mu opioid agonists in mouse antinociception: correlation with receptor binding. Zernig G, et al. **Life Sci** 1995;57(23):2113–25

Analgesic effects of myrrh [letter] Dolara P, et al. **Nature** 1996 Jan 4;379(6560):29

Characterization of the opioid receptor subtypes mediating the negative inotropic effects of DAMGO, DPDPE and U–50, 488H in isolated human right atria strips. Llobell F, et al. **Neuropeptides** 1995 Aug;29(2):115–9

Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Wiley JL, et al. **Neuropharmacology** 1995 Jun;34(6):669–76

Antinociceptive defect of beige–J mice reversed by i.c.v. IP3 or myo–inositol. Raffa RB, et al. **Neuroreport** 1995 Jul 10; 6(10):1434–6

Treatment with the NMDA antagonist memantine attenuates nociceptive responses to mechanical stimulation in neuropathic rats. Carlton SM, et al. **Neurosci Lett** 1995 Sep 29;198(2):115–8

RP67580, a neurokinin1 receptor antagonist, decreased restraint stress–induced defecation in rat. Ikeda K, et al. **Neurosci Lett** 1995 Sep 29;198(2):103–6

[D–Pen2,D–Pen5]enkephalin, a delta opioid agonist reduces endogenous aluminum content in the rat central nervous system. Gulya K, et al. **Neuroscience** 1995 May; 66(2):499–506

Ontogeny of nociception and antinociception. Barr GA. **NIDA Res Monogr** 1995;158:172–201 (56 ref.)

ACEA–1011, a novel NMDA receptor/glycine site antagonist, produces antinociception but not tolerance in the formalin test in mice. Lutfy K, et al. **NIDA Res Monogr** 1995;147:220–33

Effects of ipriflavone and its metabolites on human articular chondrocytes cultivated in clusters. Bassleer CT, et al. **Osteoarthritis Cartilage** 1996 Mar;4(1):1–8

Spinal mu and delta, but not kappa, opioid–receptor agonists attenuate responses to noxious colorectal distension in the rat. Danzebrink RM, et al. **Pain** 1995 Oct;63(1):39–47

Changes in neuronal markers in a mononeuropathic rat model relationship between neuropeptide Y, pre–emptive drug treatment and long–term mechanical hyperalgesia. Munglani R, et al. **Pain** 1995 Oct;63(1):21–31

Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Park KM, et al. **Pain** 1995 Nov;63(2):163–72

Hypnotic analgesia and reflex activity [letter] Sharav Y, et al. **Pain** 1995 Dec;63(3):391–2

Morphine–3–glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Smith GD, et al. **Pain** 1995 Jul;62(1):51–60

Activation of a NO–cyclic GMP system by NO donors potentiates beta–endorphin–induced antinociception in the mouse. Xu JY, et al. **Pain** 1995 Dec;63(3):377–83

Involvement of different subtypes of cholecystokinin receptors in opioid antinociception in the mouse. Suh HW, et al. **Peptides** 1995;16(7):1229–34

Effect of antagonism of the NMDA receptor on tolerance to [D–Pen2,D–Pen5]enkephalin, a delta 1–opioid receptor agonist. Zhao GM, et al. **Peptides** 1996;17(2):233–36

Effects of beta–FNA on sympathoadrenal, cardiovascular, and analgesic responses to DAMPGO at rest and during stress. Houdi AA, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):927–33

Variations of motor activity following intraventricular (D–Pen2, D–Pen5)–enkephalin administration: interaction with acute uncontrollable foot–shock in mice. Mendella PD, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):877–83

Characteristics of carbon dioxide–induced antinociception. Mischler SA, et al. **Pharmacol Biochem Behav** 1996 Jan; 53(1):205–12

Novel met–enkephalin analogue: a potent systemic mu agonist antinociceptive agent. Nath C, et al. **Pharmacol Res** 1995 May;31(5):269–73

Effects of acute and chronic administration of dizocilpine on the pharmacological responses to U–50,488H and brain and spinal cord kappa–opioid receptors in the rat. Bhargava HN, et al. **Pharmacology** 1995 Nov;51(5):323–30

Spasmolytic flavonols from Artemisia abrotanum [letter] Bergendorff O, et al. **Planta Med** 1995 Aug;61(4):370–1

Anti–inflammatory and analgesic activity of Baccharis trimera: identification of its active constituents. Gené RM, et al. **Planta Med** 1996 Jun;62(3):232–5

Analgesic and antipyretic activities of an aqueous extract and of the flavone linarin of Buddleia cordata. Martinez–Vázquez M, et al. **Planta Med** 1996 Apr; 62(2):137–40

Chemical and preliminary analgesic evaluation of geraniin and furosin isolated from Phyllanthus sellowianus. Miguel

OG, et al. **Planta Med** 1996 Apr;62(2):146–9

Antinociceptive properties of steroids isolated from Phyllanthus corcovadensis in mice. Santos AR, et al. **Planta Med** 1995 Aug;61(4):329–32

The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity. Crawford CA, et al. **Psychopharmacology (Berl)** 1995 Aug;120(4):392–9

Delta opioid receptors: reflexive, defensive and vocal affective responses in female rats. Haney M, et al. **Psychopharmacology (Berl)** 1995 Sep;121(2):204–12

Reward shifts and motor responses following microinjections of opiate-specific agonists into either the core or shell of the nucleus accumbens. Johnson PI, et al. **Psychopharmacology (Berl)** 1995 Jul;120(2):195–202

Effects of morphiceptin in the medial preoptic area on male sexual behavior. Matuszewich L, et al. **Psychopharmacology (Berl)** 1995 Dec;122(4):330–5

Inhibition of adenylyl cyclase activity by the cholecystokinin analog SNF 9007 in neuroblastoma x glioma NG108-15 hybrid cells. Roerig SC, et al. **Regul Pept** 1996 Jan 16; 61(1):51–6

Changes in the analgesic effects of mianserin associated with altered plasma protein binding in experimental cancer. Torres I, et al. **Res Commun Mol Pathol Pharmacol** 1995 Sep;89(3):341–50

Selective opioid inhibition of small nociceptive neurons. Taddese A, et al. **Science** 1995 Nov 24;270(5240):1366–9

The sedative and analgesic effects of detomidine (Domosedan) in donkeys. Mostafa MB, et al. **Zentralbl Veterinarmed A** 1995 Jul;42(5):351–6

[Effects of analgesia and sedation on cerebrovascular circulation, cerebral blood volume, cerebral metabolism and intracranial pressure] Werner C. **Anaesthesist** 1995 Dec; 44 Suppl 3:S566–72 (83 ref.) (Eng. Abstr.) **(Ger)**

[Drug treatment of migraine attacks. Pharmacological considerations] Salvesen R. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2176–9 (41 ref.) (Eng. Abstr.) **(Nor)**

[Mediated participation of the opioid system in regulation of pain sensitivity by peptide fragments MP1 and MP2] Maliukova IV, et al. **Biokhimiia** 1996 Mar;61(3):440–4 (Eng. Abstr.) **(Rus)**

[Physiological effects of dermorphin and its analog (dAlA4)-dermorphin] Emel'ianova TG, et al. **Dokl Akad Nauk** 1996 Jan;346(2):271–4 **(Rus)**

[The genetic characteristics of the analgesic action of substance P, bradykinin and thyroliberin in the rats of 2 inbred strains] Sudakov SK, et al. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):13–5 (Eng. Abstr.) **(Rus)**

[The role of the brain serotoninergic system in the mechanisms of the effect of kyotorphin on animal behavior] Semenova TP, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):170–2 **(Rus)**

[New mechanisms of analgesic action. I.] Luján M. **Gac Med Mex** 1995 Mar–Apr;131(2):233–5 **(Spa)**

[New mechanisms of action of analgesics. II] Luján M. **Gac Med Mex** 1995 May–Jun;131(3):359–62 **(Spa)**

POISONING

Admissions due to overdoses of aromatic analgesics have increased in Scotland [letter; comment] Hagen S, et al. **BMJ** 1996 Jun 15;312(7045):1538. Comment on: BMJ 1996 Mar 2;312(7030):543–4.

[Intraventricular arrhythmia after propoxyphene poisoning (letter)] Staikowsky F, et al. **Presse Med** 1995 Sep 2–9; 24(25):1179 **(Fre)**

STANDARDS

Standardization of epidural preparations for postoperative analgesia. Dollard JV, et al. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2565–7

SUPPLY & DISTRIBUTION

Availability of over-the-counter drugs for arthritis in Sao Paulo, Brazil. Ferraz MB, et al. **Soc Sci Med** 1996 Apr; 42(8):1129–31

THERAPEUTIC USE

Etidronate and calcitonin for cancer bone pain [letter] Schnur W. **Am Fam Physician** 1996 Sep 15;54(4):1212

Postpoliomyelitis pain treated with gabapentin [letter] Zapp JJ. **Am Fam Physician** 1996 Jun;53(8):2442, 2445

When patients refuse pain medications. Wallace KG. **Am J Nurs** 1996 Feb;96(2):20–1

Effect of mexiletine on spinal cord injury dysesthetic pain. Chiou-Tan FY, et al. **Am J Phys Med Rehabil** 1996 Mar–Apr;75(2):84–7

A comparison of diclofenac with ketorolac for pain relief after knee arthroscopy. Dennis AR, et al. **Anaesthesia** 1995 Oct;50(10):904–6

An evaluation of antidepressants in rheumatic pain conditions. Rani PU, et al. **Anesth Analg** 1996 Aug; 83(2):371–5

Refractory idiopathic erythromelalgia. Rauck RL, et al. **Anesth Analg** 1996 May;82(5):1097–101

Prescribing of analgesic agents in a south african patient population [letter] Truter I, et al. **Ann Pharmacother** 1995 Dec;29(12):1302–3

New pharmacological strategies for pain relief. Dray A, et al. **Annu Rev Pharmacol Toxicol** 1996;36:253–80 (193 ref.)

Ketorolac vs chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Shrestha M, et al. **Arch Intern Med** 1996 Aug 12–26;156(15):1725–8

Analgesic efficacy and safety of paracetamol–codeine combinations versus paracetamol alone: a systematic review. de Craen AJ, et al. **BMJ** 1996 Aug 10; 313(7053):321–5

The clinical utility of epidural midazolam for inguinal hernia repair in children [editorial; comment] Goresky GV. **Can J Anaesth** 1995 Sep;42(9):755–7. Comment on: Can J Anaesth 1995 Sep;42(9):758–64. **(Eng, Fre)**

Midazolam for caudal analgesia in children: comparison with caudal bupivacaine [see comments] Naguib M, et al. **Can J Anaesth** 1995 Sep;42(9):758–64. Comment in: Can J Anaesth 1995 Sep;42(9):755–7.

Effectiveness of notification and group education in modifying prescribing of regulated analgesics [see comments] Anderson JF, et al. **Can Med Assoc J** 1996 Jan 1;154(1):31–9. Comment in: Can Med Assoc J 1996 Apr 1;154(7):1005–6; discussion 1006–7. Comment in: Can Med Assoc J 1996 Apr 1;154(7):1006; discussion 1006–7. Comment in: Can Med Assoc J 1996 May 15;154(10):1470, 1472. Comment in: Can Med Assoc J 1996 May 15;154(10):1472, 1474; discussion 1476–7. Comment in: Can Med Assoc J 1996 May 15;154(10):1474; discussion 1476–7. Comment in: Can Med Assoc J 1996 May 15;154(10):1476; discussion 1476–7.

Analgesics and NSAIDs in the treatment of the acute migraine attack. Pfaffenrath V, et al. **Cephalalgia** 1995 Oct; 15 Suppl 15:14–20 (53 ref.)

Early-phase clinical trials in migraine: efficacy, safety and dose-finding. Pilgrim AJ. **Cephalalgia** 1995 Oct;15 Suppl 15:10–3 (13 ref.)

Guidelines for trials of drug treatments in tension-type headache. First edition: International Headache Society Committee on Clinical Trials. Schoenen J. **Cephalalgia** 1995 Jun;15(3):165–79

Felbamate relieved trigeminal neuralgia. Cheshire WP. **Clin J Pain** 1995 Jun;11(2):139–42

Moclobemide in chronic neuropathic pain: preliminary case reports. Menkes DB, et al. **Clin J Pain** 1995 Jun;11(2):134–8

Gabapentin adjunctive therapy in neuropathic pain states. Rosner H, et al. **Clin J Pain** 1996 Mar;12(1):56–8

The use of topical 5% lignocaine ointment for the relief of pain associated with post-operative nasal packing. Kuo MJ, et al. **Clin Otolaryngol** 1995 Aug;20(4):357–9

A comparison of crossover versus parallel-group design in the evaluation of analgesic efficacy after molar extraction. Margarone JE, et al. **Clin Pharmacol Ther** 1995 Oct; 58(4):453–8

Acute treatment of migraine attacks. Ferrari MD, et al. **Curr Opin Neurol** 1995 Jun;8(3):237–42 (34 ref.)

Moclobemide in the prophylactic treatment of migraine. A retrospective analysis of 44 cases. Meienberg O, et al. **Eur Neurol** 1996;36(2):109–10

Treatments for postherpetic neuralgia—a systematic review of randomized controlled trials. Volmink J, et al. **Fam Pract** 1996 Feb;13(1):84–91

Analgesic use in cluster headache. Gallagher RM, et al. **Headache** 1996 Feb;36(2):105–7

Headaches associated with chronic use of analgesics: a therapeutic approach. Pini LA, et al. **Headache** 1996 Jul–Aug;36(7):433–9

Protection of rabbit retina from ischemic injury by flupirtine. Osborne NN, et al. **Invest Ophthalmol Vis Sci** 1996 Feb; 37(2):274–80

Use of analgesics during propofol sedation: a comparison of ketorolac, dezocine, and fentanyl. Ramirez-Ruiz M, et al. **J Clin Anesth** 1995 Sep;7(6):481–5

Low back pain [letter] Lexchin J. **J Emerg Med** 1995 Nov–Dec;13(6):820

Just a spoonful of sugar.... Ebell MH. **J Fam Pract** 1995 Oct; 41(4):403–4

Antinociceptive effects of R(-)- and S(+)-flurbiprofen on rat spinal dorsal horn neurons rendered hyperexcitable by an acute knee joint inflammation. Neugebauer V, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):618–28

When will adequate pain treatment be the norm? [editorial; comment] [see comments] Hill CS Jr. **JAMA** 1995 Dec 20;274(23):1881–2. Comment on: JAMA 1995 Dec 20;274(23):1870–3. Comment on: JAMA 1995 Dec 20;274(23):1874–80. Comment in: JAMA 1996 May 1;275(17):1310; discussion 1311. Comment in: JAMA 1996 May 1;275(17):1310–1. Comment in: JAMA 1996 May 1;275(17):1311.

The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation [see comments] Jadad AR, et al. **JAMA** 1995 Dec 20;274(23):1870–3 (40 ref.). Comment in: JAMA 1995 Dec 20;274(23):1881–2. Comment in: JAMA 1996 Mar 20;275(11):835; discussion 836. Comment in: JAMA 1996 Mar 20;275(11):835–6.

The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Tfelt-Hansen P, et al. **Lancet** 1995 Oct 7; 346(8980):923–6

Analgesia at the department of intensive care. Kolonič V. **Lijec Vjesn** 1995 Jun;117 Suppl 2:112–3

Cancer pain. O'Neill WM. **Middle East J Anesthesiol** 1996 Feb;13(4):373–8 (7 ref.)

Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Perovic S, et al. **Neurodegeneration** 1995 Dec;4(4):369–74

Patterns of pain experiences and use of analgesics among hospitalized cancer patients in Korea. Lee EO, et al. **Nurs Clin North Am** 1995 Dec;30(4):647–57

Pharmacologic management of cancer pain. Niles R. **Nurs Clin North Am** 1995 Dec;30(4):745–63 (83 ref.)

Analgesic efficacy and safety of tramadol enantiomers in comparison with the racemate: a randomised, double-blind study with gynaecological patients using intravenous patient-controlled analgesia. Grond S, et al. **Pain** 1995 Sep; 62(3):313–20

Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. McQuay H, et al. **Pain** 1996 Feb;64(2):331–5

Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE2 and in the chronic hyperalgesia in rats with streptozotocin-induced diabetes. Nakamura-Craig M, et al. **Pain** 1995 Oct;63(1):33–7

Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Zech DF, et al. **Pain** 1995 Oct;63(1):65–76

Intravenous ketorolac for pain management in a ventilator-dependent patient with thermal injury. Tran HT, et al. **Pharmacotherapy** 1996 Jan–Feb;16(1):75–8

Analysis of pain management in critically ill patients. Whipple JK, et al. **Pharmacotherapy** 1995 Sep–Oct;15(5):592–9

Relief of suffering: where the art and science of medicine meet. O'Brien ME. **Postgrad Med** 1996 Jun;99(6):189–92, 197–200, 206–8 (14 ref.)

[Vitamin B 12 in zoster neuralgia] Kaipainen WJ. **Duodecim** 1994;110(19):1789–91 **(Fin)**

[Comparative study of buprenorphine and its combination to ketoprofen or propacetamol for postoperative analgesia in urologic surgery] Tauzin-Fin P, et al. **Ann Fr Anesth Reanim** 1996;15(1):41–6 (Eng. Abstr.) **(Fre)**

[Efficacy of propacetamol in postoperative pain based on two modes of intravenous administration] Farhat F, et al. **Cah Anesthesiol** 1995;43(4):351–6 (Eng. Abstr.) **(Fre)**

[Antalgic treatment in pelvic pain] Valade D. **Contracept Fertil Sex** 1996 Mar;24(3):207–12 (0 ref.) (Eng. Abstr.) **(Fre)**

[Strategy of treatment of cancer pain in children] Pichard-Léandri E, et al. **Rev Med Interne** 1995; 16(9):708–16 (28 ref.) (Eng. Abstr.) **(Fre)**

[Rational use of analgesics] Dayer P. **Rev Med Suisse Romande** 1996 Apr;116(4):295–8 **(Fre)**

[Stabilization treatments of migraine] Regli F, et al. **Schweiz Rundsch Med Prax** 1995 Sep 19;84(38):1032–5 (Eng. Abstr.) **(Fre)**

[Analgesia and sedation on patients with sepsis syndrome] Adams HA. **Anaesthesist** 1995 Dec;44 Suppl 3:S573–9 (30 ref.) (Eng. Abstr.) **(Ger)**

[Analgesia and sedation in patients with head-brain trauma] Gremmelt A, et al. **Anaesthesist** 1995 Dec;44 Suppl 3:S559–65 (71 ref.) (Eng. Abstr.) **(Ger)**

[Pain management in cancer patients] Willenbrink HJ, et al. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1363–6 (13 ref.) **(Ger)**

[Effectiveness of flupirtine in chronic tension headache. Results of a double-blind study versus placebo] Wörz R, et al. **Fortschr Med** 1995 Nov 20;113(32):463–8 (Eng. Abstr.) **(Ger)**

[Drug treatment of tumor pain] Larsen B, et al. **Internist (Berl)** 1996 Apr;37(4):425–40 (10 ref.) **(Ger)**

[Migraine: diagnosis, differential diagnosis and treatment] Ludin HP, et al. **Schweiz Med Wochenschr** 1996 Jan 20; 126(3):86–91 (Eng. Abstr.) **(Ger)**

[Ambulatory pain treatment in tumor patients] Keseberg A. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):328–34 (0 ref.) (Eng. Abstr.) **(Ger)**

[Capsaicin for arthritic pain] Niv D, et al. **Harefuah** 1996 Mar 15;130(6):415–20 (43 ref.) **(Heb)**

[Effect of etimizol on development of a neuropathic pain syndrome] Gorizontova MP, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):258–61 **(Rus)**

[The effects of preparations that influence the brain monoaminergic systems in pain syndromes] Danilova EI, et al. **Eksp Klin Farmakol** 1995 Jul–Aug;58(4):14–7 **(Rus)**

[The efficacy of osteoquin in treating the postmenopausal and senile forms of osteoporosis] Rodionova SS. **Ter Arkh** 1995;67(10):43–5 (Eng. Abstr.) **(Rus)**

[Anti-pain effect of salmon calcitonin in bone metastases of malignant tumors with the exception of breast and prostatic carcinoma] Jelić S, et al. **Vojnosanit Pregl** 1995 Mar–Apr; 52(2):151–4 (Eng. Abstr.) **(Scr)**

[Specific problems of analgesic therapy in hospital environment] Baños JE, et al. **Med Clin (Barc)** 1996 Feb 17;106(6):222–6 (59 ref.) **(Spa)**

[Postoperative analgesia in herniated disk surgery. Comparative study of diclofenac , lysine acetylsalicylate, and ketorolac] Izquierdo E, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):316–9 (Eng. Abstr.) **(Spa)**

[Analgesics and non-steroidal anti-inflammatory agents in the treatment of migraine] Iglesias F, et al. **Rev Neurol** 1995;23 Suppl 2:S157–61 (20 ref.) **(Spa)**

[Intake patterns of analgesics in patients with headache who came to the neurologist] Monzón MJ, et al. **Rev Neurol** 1995 Jul–Aug;23(122):779–83 (Eng. Abstr.) **(Spa)**

TOXICITY

A novel analgesic toxin (hannalgesin) from the venom of king cobra (Ophiophagus hannah). Pu XC, et al. **Toxicon** 1995 Nov;33(11):1425–31

[Voluntary drug poisoning cases admitted to an emergency care unit] Staikowsky F, et al. **Presse Med** 1995 Sep 30; 24(28):1296–300 (Eng. Abstr.) **(Fre)**

ANALGESICS, ADDICTIVE see **ANALGESICS, OPIOID**

ANALGESICS, ANTI-INFLAMMATORY see **ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL**

ANALGESICS, NARCOTIC see **ANALGESICS, OPIOID**

ANALGESICS, NON-NARCOTIC

Comparison of intravenous ketorolac, meperidine, and both (balanced analgesia) for renal colic. Cordell WH, et al. **Ann Emerg Med** 1996 Aug;28(2):151–8

Intravenous ketorolac vs diclofenac for analgesia after maxillofacial surgery. Tarkkila P, et al. **Can J Anaesth** 1996 Mar;43(3):216–20

3,5–Disubstituted analogues of paracetamol. Synthesis, analgesic activity and cytotoxicity. Bessems JG, et al. **Chem Biol Interact** 1995 Dec 22;98(3):237–50

Intravenous antispasmodic and patient–controlled analgesia are of benefit for screening flexible sigmoidoscopy. Saunders BP, et al. **Gastrointest Endosc** 1995 Aug; 42(2):123–7

Ketorolac and propofol anesthesia in a patient taking chronic monoamine oxidase inhibitors. Fischer SP, et al. **J Clin Anesth** 1996 May;8(3):245–7

Drugs and sedation for colonoscopy. Phillips MS. **Prim Care** 1995 Sep;22(3):433–43 (33 ref.)

ADMINISTRATION & DOSAGE

Additive analgesic effect of codeine and paracetamol can be detected in strong, but not moderate, pain after Caesarean section. Baseline pain–intensity is a determinant of assay–sensitivity in a postoperative analgesic trial [see comments] Bjune K, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):399–407. Comment in: Acta Anaesthesiol Scand 1996 Apr;40(4):397–8.

Continuous intravenous administration of ketorolac reduces pain and morphine consumption after total hip or knee arthroplasty. Etches RC, et al. **Anesth Analg** 1995 Dec; 81(6):1175–80

Intraoperative ketorolac has an opioid–sparing effect in women after diagnostic laparoscopy but not after laparoscopic tubal ligation. Green CR, et al. **Anesth Analg** 1996 Apr;82(4):732–7

Recovery and complications after tonsillectomy in children: a comparison of ketorolac and morphine. Gunter JB, et al. **Anesth Analg** 1995 Dec;81(6):1136–41

Postarthroscopic meniscus repair analgesia with intraarticular ketorolac or morphine. Reuben SS, et al. **Anesth Analg** 1996 May;82(5):1036–9

Intraarticular ketorolac [letter; comment] Wilkinson DJ. **Anesth Analg** 1996 Feb;82(2):433. Comment on: Anesth Analg 1995 Jun;80(6):1154–7.

Comparison of analgesic effect of locally and systemically administered ketorolac in mastectomy patients. Bosek V, et al. **Ann Surg Oncol** 1996 Jan;3(1):62–6

Post–operative pain [letter] Lyons HJ. **Br Dent J** 1996 Jan 6;180(1):9

Pain relief and quality–of–life assessment following intravenous and oral clodronate in hormone–escaped metastatic prostate cancer. Cresswell SM, et al. **Br J Urol** 1995 Sep;76(3):360–5

Plasma concentrations after high–dose (45 mg.kg–1) rectal acetaminophen in children. Montgomery CJ, et al. **Can J Anaesth** 1995 Nov;42(11):982–6

Comparative effects of three doses of intravenous ketorolac or morphine on emesis and analgesia for restorative dental surgery in children. Purday JP, et al. **Can J Anaesth** 1996 Mar;43(3):221–5

Endoscopic assessment of the effects of dipyrone (metamizol) in comparison to paracetamol and placebo on the gastric and duodenal mucosa of healthy adult volunteers. Bianchi Porro G, et al. **Digestion** 1996;57(3):186–90

Carbamazepine and cocaine–cue reactivity. Hersh D, et al. **Drug Alcohol Depend** 1995 Oct;39(3):213–21

A comparison between ketorolac and diclofenac in laparoscopic sterilization. Chui PT, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):597–601

Pre–emptive versus post–surgical administration of ketorolac for hysterectomy. Parke TJ, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):549–53

Apoptotic cell death in activated monocytes following incorporation of clodronate–liposomes. Schmidt–Weber CB, et al. **J Leukoc Biol** 1996 Aug;60(2):230–44

Research into analgesia by inhaling analgesic. Huang X, et al. **J Tradit Chin Med** 1996 Mar;16(1):7–14

Nitrous oxide and morphine in children with sickle cell crisis [letter] Carbajal R, et al. **Lancet** 1996 Jun 8;347(9015):1621

Subcutaneous clodronate [letter] Walker P, et al. **Lancet** 1996 Aug 3;348(9023):345–6

Pharmacokinetics of rectal paracetamol after major surgery in children. Anderson BJ, et al. **Paediatr Anaesth** 1995; 5(4):237–42

The effect of ketorolac as an adjuvant to local anaesthetic infiltration for analgesia in paediatric umbilical hernia surgery. Graham SG, et al. **Paediatr Anaesth** 1995; 5(3):161–3

Postoperative morphine requirements, nausea and vomiting following anaesthesia for tonsillectomy. Comparison of intravenous morphine and non–opioid analgesic techniques. Mather SJ, et al. **Paediatr Anaesth** 1995;5(3):185–8

Intravenous ketorolac and subarachnoid opioid analgesia in the management of acute postoperative pain. Gwirtz KH, et al. **Reg Anesth** 1995 Sep–Oct;20(5):395–401

A comparison of the effect of intramuscular diclofenac, ketorolac or piroxicam on postoperative pain following laparoscopy. O'Hanlon JJ, et al. **Ulster Med J** 1996 May; 65(1):51–4

[Differential indications of non–opioid drugs for postoperative analgesia II. Quantification of the analgesic effect of a combination of metamizol plus diclofenac via patient–controlled analgesia] Steffen P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):216–21 (Eng. Abstr.) **(Ger)**

[Paracetamol and metoclopramide in fixed combination?] Chrubasik S, et al. **Med Monatsschr Pharm** 1996 Apr; 19(4):110 **(Ger)**

ADVERSE EFFECTS

The relationship between the content of aggressive and protective components in gastric juice and endoscopic findings after naproxen sodium and acetaminophen administration. Marcinkiewicz M, et al. **Am J Gastroenterol** 1996 Feb;91(2):360–5

Analgesic nephropathy. Proceedings of a symposium. June 1995. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S1–70

Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Barrett BJ. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S14–9 (15 ref.)

Acetaminophen: acute and chronic effects on renal function. Blantz RC. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S3–6 (23 ref.)

Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin. Buckalew VM Jr. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S7–13 (31 ref.)

Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti–inflammatory agents. Matzke GR. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S63–70 (38 ref.)

Gas kinetics during nitrous oxide analgesia for labour. Einarsson S, et al. **Anaesthesia** 1996 May;51(5):449–52

Gastrointestinal complications associated with intramuscular ketorolac tromethamine therapy in the elderly. Maliekal J, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):698–701

Vasculitis in a fixed drug eruption due to paracetamol. Harris A, et al. **Br J Dermatol** 1995 Nov;133(5):790–1

Electrophysiological evaluation of the sodium–channel blocker carbamazepine in healthy human subjects. Kennebäck G, et al. **Cardiovasc Drugs Ther** 1995 Oct; 9(5):709–14

Vaccine immune response and side effects with the use of acetaminophen with influenza vaccine. Gross PA, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):134–8

Ulcerative skin reaction from subcutaneous infusion of isotonic methotrimeprazine and diamorphine. Hatton MQ, et al. **Clin Oncol (R Coll Radiol)** 1995;7(4):268–9

Serum interferon–gamma level in a patient with carbamazepine–induced erythroderma. Koga T, et al. **Contact Dermatitis** 1995 Oct;33(4):275

Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors. Kwan D, et al. **Dig Dis Sci** 1995 Sep;40(9):1951–5

Ergotamine–induced complex rectovaginal fistula. Report of a case. Pfeifer J, et al. **Dis Colon Rectum** 1995 Nov; 38(11):1224–6

Acetaminophen–induced hepatotoxicity: protection by enzyme inhibition [comment] Park BK. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):747–8. Comment on: Eur J Gastroenterol Hepatol 1995 Aug;7(8):757–62.

Acetaminophen–induced hypotension. Brown G. **Heart Lung** 1996 Mar–Apr;25(2):137–40

Effect of ketorolac on bleeding time and postoperative pain in children: a double–blind, placebo–controlled comparison with meperidine. Bean–Lijewski JD, et al. **J Clin Anesth** 1996 Feb;8(1):25–30

New ways of looking at an old molecule [editorial; comment] Brent J. **J Toxicol Clin Toxicol** 1996;34(2):149–53. Comment on: J Toxicol Clin Toxicol 1996;34(2):145–7.

Does acetaminophen damage the heart? [see comments] Lip GY, et al. **J Toxicol Clin Toxicol** 1996;34(2):145–7 (23 ref.) . Comment in: J Toxicol Clin Toxicol 1996;34(2):149–53. Comment in: J Toxicol Clin Toxicol 1996;34(2):155–6.

APAP–induced heart injury? Maybe yes, maybe no. Next question? [editorial; comment] Smilkstein MJ. **J Toxicol Clin Toxicol** 1996;34(2):155–6. Comment on: J Toxicol Clin Toxicol 1996;34(2):145–7.

Risk of operative site bleeding with parenteral ketorolac [letter; comment] Gumprecht T. **JAMA** 1996 Aug 7; 276(5):372. Comment on: JAMA 1996 Feb 7;275(5):376–82.

Neurotoxicity from overuse of nitrous oxide [letter; comment] Seppelt IM. **Med J Aust** 1995 Sep 4;163(5):280 . Comment on: Med J Aust 1995 Jul 3;163(1):50–1.

Adverse reactions associated with nefopam. Pillans PI, et al. **N Z Med J** 1995 Sep 22;108(1008):382–4

Chronic use of symptomatic headache medications. Von Korff M, et al. **Pain** 1995 Aug;62(2):179–86

Ketorolac–induced acute renal failure in a previously healthy adolescent. Buck ML, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):294–6

Acetaminophen–induced toxicity to human epidermoid cell line A431 and hepatoblastoma cell line Hep G2, in vitro, is diminished by silymarin. Shear NH, et al. **Skin Pharmacol** 1995;8(6):279–91

Ketorolac–induced postoperative acute renal failure: a case report. Patel NY, et al. **Wis Med J** 1995;94(8):445–7

[Paracetamol and leukocytoclastic vasculitis: apropos of a case (letter)] Bouhanick B, et al. **Therapie** 1995 Sep–Oct; 50(5):489–91 **(Fre)**

[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121–4 (50 ref.) (Eng. Abstr.) **(Hun)**

[Acute gastrointestinal hemorrhage in a 12–month–old child following treatment with panadol] Czerwionka–Szaflarska M, et al. **Pediatr Pol** 1996 May;71(5):471–2 (Eng. Abstr.) **(Pol)**

ANALYSIS

Spectrofluorimetric determination of paracetamol in pharmaceuticals and biological fluids. Vilchez JL, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1119–25

ANTAGONISTS & INHIBITORS

Volatile anaesthetics antagonize nitrous oxide and morphine–induced analgesia in the rat. Goto T, et al. **Br J Anaesth** 1996 May;76(5):702–6

BLOOD

Plasma concentrations after high–dose (45 mg.kg–1) rectal acetaminophen in children. Montgomery CJ, et al. **Can J Anaesth** 1995 Nov;42(11):982–6

[Carbamazepine] Gomita Y, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:907–10 (8 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

N–substituted–2–oxo–(2H)1–benzopyran–3–carboxamide derivatives with analgesic and/or diuretic activities. Artizzu N, et al. **Farmaco** 1995 Dec;50(12):853–6

Synthesis and pharmacological evaluation of thieno[2,3–d]pyrimidin–2,4–dione and 5H–pyrimido [5,4–b]indol–2,4–dione derivatives. Santagati NA, et al. **Farmaco** 1995 Oct;50(10):689–95

Synthesis of new 1–(3–(4–phenylpiperazinyl–1)–imidazolidine derivatives. Kulinski T, et al. **Pharmazie** 1995 Dec; 50(12):821–2

Synthesis of new 1–aryl–2–imino–3–arylsulfonylimidazolidines and their pharmacological activity. Rzadkowska M, et al. **Pharmazie** 1995 Dec;50(12):822

CHEMISTRY

Studies on the Chinese crude drug "shoma." IX. Three novel cyclolanostanol xylosides, cimicifugosides H–1, H–2 and H–5, from cimicifuga rhizome. Koeda M, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):771–6

Approaches for improving the stability of ketorolac in powder blends. Brandl M, et al. **J Pharm Sci** 1995 Oct; 84(10):1151–3

METABOLISM

The price of silence. Park BK. **Hum Exp Toxicol** 1996 Apr; 15(4):362–3

Acetaminophen–arylated proteins are detected in hepatic subcellular fractions and numerous extra–hepatic tissues in CD–1 and C57B1/6J mice. Bulera SJ, et al. **Toxicology** 1996 May 17;109(2–3):85–99

PHARMACOKINETICS

The effect of caffeine on the pharmacokinetics of acetaminophen in man. Iqbal N, et al. **Biopharm Drug Dispos** 1995 Aug;16(6):481–7

The proportional cumulative area under the curve of paracetamol used as an index of gastric emptying in diabetic patients with symptoms of gastroparesis. van Wyk M, et al. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):637–40

Metabolism of paracetamol in children with chronic liver disease. al–Obaidy SS, et al. **Eur J Clin Pharmacol** 1996; 50(1–2):69–76

Omeprazole has no effect on acetaminophen kinetics in the rat. Melzer E, et al. **Eur J Drug Metab Pharmacokinet** 1995 Apr–Jun;20(2):125–8

Cyclization–activated prodrugs: N–(substituted 2–hydroxyphenyl and 2–hydroxypropyl)carbamates based on ring–opened derivatives of active benzoxazolones and oxazolidinones as mutual prodrugs of acetaminophen. Vigroux A, et al. **J Med Chem** 1995 Sep 29;38(20):3983–94

Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. Lee CA, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):287–91

Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose. Stork CM, et al. **J Toxicol Clin Toxicol** 1996;34(2):157–62

Pharmacokinetics of oral ketorolac in the rat. Granados–Soto V, et al. **Methods Find Exp Clin Pharmacol** 1995 Oct; 17(8):535–8

Pharmacokinetics of rectal paracetamol after major surgery

in children. Anderson BJ, et al. **Paediatr Anaesth** 1995; 5(4):237–42

Relationship between gelation rate of controlled-release acetaminophen tablets containing polyethylene oxide and colonic drug release in dogs. Sako K, et al. **Pharm Res** 1996 Apr;13(4):594–8

Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasted and fed conditions in humans. Shameem M, et al. **Pharm Res** 1995 Jul;12(7):1049–54

PHARMACOLOGY

Multiple mechanisms mediate antipyretic action of glucocorticoids. Coelho MM, et al. **Am J Physiol** 1995 Sep; 269(3 Pt 2):R527–35

Hypnotic and analgesic effects of the alpha 2-adrenergic agonist dexmedetomidine in morphine-tolerant rats. Hayashi Y, et al. **Anesth Analg** 1996 Sep;83(3):606–10

Ketorolac and platelet function [letter; comment] Pivalizza EG, et al. **Anesth Analg** 1996 Feb;82(2):428–9. Comment on: Anesth Analg 1995 Jul;81(1):119–24.

The effects of intrathecally administered FK480, a cholecystokinin-A receptor antagonist, and YM022, a cholecystokinin-B receptor antagonist, on the formalin test in the rat. Yamamoto T, et al. **Anesth Analg** 1996 Jul; 83(1):107–13

Characteristics of the analgesic effects and drug interactions of intrathecal carbachol in rats. Abram SE, et al. **Anesthesiology** 1995 Oct;83(4):844–9

Dexmedetomidine injection into the locus ceruleus produces antinociception. Guo TZ, et al. **Anesthesiology** 1996 Apr; 84(4):873–81

Role of pertussis toxin-sensitive G-proteins in the analgesic and anesthetic actions of alpha 2-adrenergic agonists in the rat. Hayashi Y, et al. **Anesthesiology** 1995 Oct; 83(4):816–22

Effects of peripherally and centrally acting analgesics on somato-sensory evoked potentials. Moore UJ, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):111–7

Antinociceptive effects of epidural and intravenous ketamine to somatic and visceral stimuli in rats. Alam S, et al. **Can J Anaesth** 1996 Apr;43(4):408–13

Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Elomaa I, et al. **Eur J Cancer** 1996 Jun;32A(7):1166–70

Tolerance to the antinociceptive effect of epibatidine after acute and chronic administration in mice. Damaj MI, et al. **Eur J Pharmacol** 1996 Apr 4;300(1–2):51–7

Evidence for the involvement of nitric oxide in the antinociceptive effect of ketorolac. Granados-Soto V, et al. **Eur J Pharmacol** 1995 Apr 24;277(2–3):281–4

Reduced distensibility of the common carotid artery in patients treated with ergotamine. Barenbrock M, et al. **Hypertension** 1996 Jul;28(1):115–9

Effects of metamizol on nociceptive responses to stimulation of the ureter and on ureter motility in anaesthetised rats. Laird JM, et al. **Inflamm Res** 1996 Mar;45(3):150–4

Modification by clodronate and fluoride of hydroxyapatite-induced neutrophil chemiluminescence in vitro. Hyvönen PM, et al. **J Clin Lab Immunol** 1995; 46(2):63–72

Acetaminophen does not decrease hepatic 3'-phosphoadenosine 5'-phosphosulfate in mice. Kim HJ, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1506–11

Characterization of the antinociceptive properties of cimetidine and a structural analog. Li BY, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):500–8

Pediatric ibuprofen and leukopenia [letter; comment] Lesko SM, et al. **JAMA** 1996 Apr 3;275(13):986. Comment on: JAMA 1995 Mar 22–29;273(12):929–33.

Determination of analgesic interaction between acetaminophen and d-propoxyphene obtained by means of the surface of synergistic interaction. López-Muñoz FJ, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun; 17(5):311–20

Evidence of a central antinociceptive effect of paracetamol involving spinal 5HT3 receptors. Pelissier T, et al. **Neuroreport** 1995 Jul 31;6(11):1546–8

Aspirin and acetaminophen reduced both Fos expression in rat lumbar spinal cord and inflammatory signs produced by carrageenin inflammation. Honoré P, et al. **Pain** 1995 Dec;63(3):365–75

An attempt to attenuate experimental pain in humans by dextromethorphan, an NMDA receptor antagonist. Kauppila T, et al. **Pharmacol Biochem Behav** 1995 Nov; 52(3):641–4

Analgesic and antipyretic activities of an aqueous extract and of the flavone linarin of Buddleia cordata. Martínez-Vázquez M, et al. **Planta Med** 1996 Apr; 62(2):137–40

Is the analgesic activity of epibatidine caused by a chemical reaction with the morphine opioid receptor? Brandt W, et al. **SAR QSAR Environ Res** 1993;1(4):345–8

[Epibatidine—a nicotine-related, analgesic alkaloid from poison-dart frogs] Müller CE. **Pharm Unserer Zeit** 1996 Apr;25(2):85–92 (27 ref.) **(Ger)**

[The effect of paracetamol and its combinations with acetylsalicylic and ascorbic acids on lipid peroxidation processes in the rat liver] Chaĭka LA, et al. **Eksp Klin Farmakol** 1996 Jan–Feb;59(1):43–6 (Eng. Abstr.) **(Rus)**

POISONING

Acetaminophen and salicylate serum levels in patients with suicidal ingestion or altered mental status. Sporer KA, et al. **Am J Emerg Med** 1996 Sep;14(5):443–6

Acetaminophen overdose: need to consider intravenous preparation of N-acetylcysteine in the United States [letter] Dhawan A, et al. **Am J Gastroenterol** 1996 Jul;91(7):1476

Serial measurements of serum Gc-globulin in acetaminophen intoxication. Schiødt FV, et al. **Eur J Gastroenterol Hepatol** 1995 Jul;7(7):635–40

A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987–1993). Makin AJ, et al. **Gastroenterology** 1995 Dec;109(6):1907–16

Cholestasis as a liver protective factor in paracetamol acute overdose. Acevedo C, et al. **Gen Pharmacol** 1995 Nov; 26(7):1619–24

Acetaminophen toxicity: report of case and review of the literature. Schueler L, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1208–12 (13 ref.)

The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning. Clark RF, et al. **J Toxicol Clin Toxicol** 1996;34(2):163–7

Extended-release acetaminophen overdose [letter] Cetaruk EW, et al. **JAMA** 1996 Mar 6;275(9):686

Management of paracetamol poisoning [letter; comment] Connor P. **Lancet** 1995 Nov 4;346(8984):1236. Comment on: Lancet 1995 Aug 26;346(8974):547–52.

Management of paracetamol poisoning [letter] Matthey F. **Lancet** 1995 Nov 4;346(8984):1237

Management of paracetamol poisoning [letter; comment] Ward SJ. **Lancet** 1995 Nov 4;346(8984):1236. Comment on: Lancet 1995 Aug 26;346(8974):547–52.

Management of paracetamol poisoning [letter; comment] Wendon JA, et al. **Lancet** 1995 Nov 4;346(8984):1236. Comment on: Lancet 1995 Aug 26;346(8974):547–52.

Hyperglycaemia induced by paracetamol [letter] Lawrence IG, et al. **Postgrad Med J** 1995 Nov;71(841):702

[Paracetamol poisoning (letter)] Ring-Larsen H. **Ugeskr Laeger** 1995 Aug 7;157(32):4470–1 **(Dan)**

[Paracetamol poisoning—case report] Filipović-Grčić B, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:91–2 (Eng. Abstr.) **(Scr)**

[Poisonings with analgesics. Paracetamol and dextropropoxyphene dominate and cause the most severe symptoms in a 3-year material] Torell E, et al. **Lakartidningen** 1996 May 15;93(20):1955–60 **(Swe)**

THERAPEUTIC USE

Is preoperative ketorolac a useful adjunct to regional anesthesia for inguinal herniorrhaphy? Ben-David B, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):358–63

Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Bruland OS, et al. **Acta Oncol** 1996;35(3):381–4

Nonopioid analgesics shorten the duration of postoperative ileus. Ferraz AA, et al. **Am Surg** 1995 Dec;61(12):1079–83

Ketorolac and strabismus surgery [letter; comment] Munro HM, et al. **Anesth Analg** 1996 Apr;82(4):889–90. Comment on: Anesth Analg 1995 Jun;80(6):1129–33.

Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine [letter; comment] Christensen MF. **Arch Dis Child** 1995 Aug;73(2):183. Comment on: Arch Dis Child 1995 Jan;72(1):48–50.

A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Winner P, et al. **Arch Neurol** 1996 Feb; 53(2):180–4

A double-blind placebo-controlled study to assess the efficacy of a compound analgesic to prevent postoperative pain following oral surgery. Sandhu S, et al. **Br Dent J** 1996 May 11;180(9):335–8

Experimental pain techniques [letter] Walker JS, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):349–50

Ketorolac does not decrease postoperative pain in elderly men after transvesical prostatectomy. Fredman B, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):438–41

Indomethacin and ketorolac given preoperatively are equally effective in reducing early postoperative pain after laparoscopic cholecystectomy. Forse A, et al. **Can J Surg** 1996 Feb;39(1):26–30

Ketoprofen, paracetamol and placebo in the treatment of episodic tension-type headache. Dahlöf CG, et al. **Cephalalgia** 1996 Apr;16(2):117–23

Long-term intrathecal administration of midazolam and clonidine. Borg PA, et al. **Clin J Pain** 1996 Mar;12(1):63–8

Ketorolac versus fentanyl for postoperative pain management in outpatients. Twersky RS, et al. **Clin J Pain** 1995 Jun; 11(2):127–33

Comparative study of ibuprofen lysine and acetaminophen in patients with postoperative dental pain. Mehlisch DR, et al. **Clin Ther** 1995 Sep–Oct;17(5):852–60

Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Bryson HM, et al. **Drugs Aging** 1996 Jun;8(6):459–76 (111 ref.)

A comparative study of ketorolac and diclofenac on post-laparoscopic cholecystectomy pain. Fredman B, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):501–4

Paracetamol prescribing—an epidemic? Dawson KP, et al. **Fam Pract** 1996 Apr;13(2):179–81

Dihydroergotamine and metoclopramide in the treatment of organic headache. Gross DW, et al. **Headache** 1995 Nov-Dec;35(10):637–8

The placebo effect in acute headache management: ketorolac, mepcridine, and saline in the emergency department. Harden RN, et al. **Headache** 1996 Jun;36(6):352–6

Effect of clodronate on established collagen-induced arthritis in rats. Osterman T, et al. **Inflamm Res** 1995 Jun; 44(6):258–63

Choice of antipyretic in children. Khubchandani RP, et al. **J Assoc Physicians India** 1995 Sep;43(9):614–6

Efficacy of ketorolac in the management of pain associated with root canal treatment. Battrum D, et al. **J Can Dent Assoc** 1996 Jan;62(1):36–42

Effect of ketorolac on bleeding time and postoperative pain in children: a double-blind, placebo-controlled comparison with meperidine. Bean-Lijewski JD, et al. **J Clin Anesth** 1996 Feb;8(1):25–30

Ketorolac for early postoperative analgesia. Parke TJ, et al. **J Clin Anesth** 1995 Sep;7(6):465–9

A comparison of EMLA cream versus nitrous oxide for pediatric venous cannulation. Vetter TR. **J Clin Anesth** 1995 Sep;7(6):486–90

The analgesic efficacy of ketorolac for acute pain. Catapano MS. **J Emerg Med** 1996 Jan–Feb;14(1):67–75 (101 ref.)

Lamotrigine control of idiopathic trigeminal neuralgia [letter] Canavero S, et al. **J Neurol Neurosurg Psychiatry** 1995 Dec; 59(6):646

Safety of intravenous ketorolac therapy in children and cost savings with a unit dosing system. Houck CS, et al. **J Pediatr** 1996 Aug;129(2):292–6

A comparison of 2 analgesic regimens for the control of postoperative periodontal discomfort. Tucker PW, et al. **J Periodontol** 1996 Feb;67(2):125–9

The treatment of pain in bone metastasis of cancer with the analgesic decoction of cancer and the acupoint therapeutic apparatus. Guo R, et al. **J Tradit Chin Med** 1995 Dec; 15(4):262–4

Treatment of migraine with modified chuanxiong powder--a report of 30 cases. Ju J, et al. **J Tradit Chin Med** 1995 Sep;15(3):183–4

Controlling cancerous pain with analgesic powder for cancers. Yang G, et al. **J Tradit Chin Med** 1995 Sep; 15(3):174–7

Dr. Zhou Chaofan's experience in the treatment of migraine. Yu Z, et al. **J Tradit Chin Med** 1995 Sep;15(3):198–202

Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Eija K, et al. **Pain** 1996 Feb; 64(2):293–302

Fever in uncomplicated Plasmodium falciparum malaria: randomized double-blind comparison of ibuprofen and paracetamol treatment. Krishna S, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct;89(5):507–9

[153Sm-EDTMP for moderate and severe bone cancer pain] Deng H, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):391–4 (Eng. Abstr.) **(Chi)**

[Drugs for labor pain] Jage J. **Arch Gynecol Obstet** 1995; 257(1–4):135–8 (11 ref.) **(Ger)**

[Effectiveness of fixed analgesic combinations exemplified by thomapyrin] Aicher B, et al. **Wien Klin Wochenschr** 1996;108(8):219–33 (104 ref.) (Eng. Abstr.) **(Ger)**

[Analgesic efficacy of E2078 (dynorphin analog) in patients following abdominal surgery] Fujimoto K, et al. **Masui** 1995 Sep;44(9):1233–7 (Eng. Abstr.) **(Jpn)**

TOXICITY

Acetaminophen/aspirin mixtures: experimental data. Porter GA. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S30–3 (11 ref.)

Mechanism of acetaminophen-induced hepatotoxicity: covalent binding versus oxidative stress. Gibson JD, et al. **Chem Res Toxicol** 1996 Apr–May;9(3):580–5

Protection against acetaminophen hepatotoxicity by a single dose of clofibrate: effects on selective protein arylation and glutathione depletion. Manautou JE, et al. **Fundam Appl Toxicol** 1996 Feb;29(2):229–37

Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice. Kröger H, et al. **Gen Pharmacol** 1996 Jan;27(1):79–82

In vivo effects of acetaminophen on rat RBC and role of vitamin E. Suhail M, et al. **Indian J Exp Biol** 1995 Apr; 33(4):269–71

Prevention of acetaminophen- and naphthalene-induced cataract and glutathione loss by CySSME. Rathbun WB, et al. **Invest Ophthalmol Vis Sci** 1996 Apr;37(5):923–9

Role of CYP2E1 in the hepatotoxicity of acetaminophen. Lee SS, et al. **J Biol Chem** 1996 May 17;271(20):12063–7

Series: current issues in mutagenesis and carcinogenesis, No. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view. Bergman K, et al. **Mutat Res** 1996 Feb 1;349(2):263–88 (103 ref.)

Evaluation of the ability of paracetamol to produce chromosome aberrations in man. Hantson P, et al. **Mutat Res** 1996 Jul 5;368(3–4):293–300

Induction of chromosome aberrations in vivo in bone-marrow cells of mice by paracetamol. Severin E, et al. **Rom J Morphol Embryol** 1995 Jul–Dec;41(3–4):117–20

Acetaminophen nephrotoxicity in the CD-1 mouse. II. Protection by probenecid and AT-125 without diminution of renal covalent binding. Emeigh Hart SG, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):161–9

Protective effects of garlic and related organosulfur compounds on acetaminophen-induced hepatotoxicity in mice. Wang EJ, et al. **Toxicol Appl Pharmacol** 1996 Jan;

136(1):146–54
Cell injury and protection in long-term incubation of liver slices after in vivo initiation with paracetamol: cell injury after in vivo initiation with paracetamol. Beales D, et al. **Toxicology** 1995 Nov 30;103(2):113–9
Protection in the late stages of paracetamol-induced liver cell injury with fructose, cyslosporin A and trifluoperazine. Beales D, et al. **Toxicology** 1996 Mar 18;107(3):201–8
Cell protection by fructose is independent of adenosine triphosphate (ATP) levels in paracetamol injury to rat liver slices. Martin FL, et al. **Toxicology** 1996 Mar 18; 107(3):177–87
Adenosine triphosphate (ATP) levels in paracetamol-induced cell injury in the rat in vivo and in vitro. Martin FL, et al. **Toxicology** 1995 Dec 15;104(1–3):91–7
Comparison of protection by fructose against paracetamol injury with protection by glucose and fructose-1,6-diphosphate. Martin FL, et al. **Toxicology** 1996 Apr 30;108(3):175–84
Protective effects of Osbeckia octandra against paracetamol-induced liver injury. Thabrew MI, et al. **Xenobiotica** 1995 Sep;25(9):1009–17

ANALGESICS, OPIOID

see related
NARCOTICS
Efficacy and safety of combined meperidine and midazolam for EGD sedation compared with midazolam alone. Diab FH, et al. **Am J Gastroenterol** 1996 Jun;91(6):1120–5
Rectal indomethacin potentiates spinal morphine analgesia after caesarean delivery. Pavy TJ, et al. **Anaesth Intensive Care** 1995 Oct;23(5):555–9
Anaesthesia and adverse effects after intrathecal pethidine hydrochloride for urological surgery. Grace D, et al. **Anaesthesia** 1995 Dec;50(12):1036–40
Epidural infusion of low-dose bupivacaine and opioid in labour. Does reducing motor block increase the spontaneous delivery rate? Russell R, et al. **Anaesthesia** 1996 Mar;51(3):266–73
Remifentanil: a novel, short-acting, mu-opioid. Bürkle H, et al. **Anesth Analg** 1996 Sep;83(3):646–51 (52 ref.)
Spinal anesthesia with bupivacaine and fentanyl in geriatric patients. Fernandez-Galinski D, et al. **Anesth Analg** 1996 Sep;83(3):537–41
Mode and site of analgesic action of epidural buprenorphine in humans. Inagaki Y, et al. **Anesth Analg** 1996 Sep; 83(3):530–6
Comparison of the spinal actions of the mu-opioid remifentanil with alfentanil and morphine in the rat. Buerkle H, et al. **Anesthesiology** 1996 Jan;84(1):94–102
Epidural meperidine after cesarean section. A dose-response study. Ngan Kee WD, et al. **Anesthesiology** 1996 Aug; 85(2):289–94
Comparison of intravenous ketorolac, meperidine, and both (balanced analgesia) for renal colic. Cordell WH, et al. **Ann Emerg Med** 1996 Aug;28(2):151–8
Comparison of diclofenac sodium and morphine sulphate for postoperative analgesia after day case inguinal hernia surgery. McEvoy A, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):363–6
Extradural analgesia with clonidine and fentanyl compared with 0.25% bupivacaine in the first stage of labour [see comments] Buggy DJ, et al. **Br J Anaesth** 1996 Feb; 76(2):319–21. Comment in: Br J Anaesth 1996 Jun;76(6):886–7.
Patient-controlled extradural analgesia with bupivacaine, fentanyl, or a mixture of both, after Caesarean section. Cooper DW, et al. **Br J Anaesth** 1996 May;76(5):611–5
Effect of the addition of alfentanil to lignocaine during axillary brachial plexus anaesthesia. Gormley WP, et al. **Br J Anaesth** 1996 Jun;76(6):802–5
Remifentanil--an opioid for the 21st century [editorial] Thompson JP, et al. **Br J Anaesth** 1996 Mar;76(3):341–3
Comparison of continuous brachial plexus infusion of butorphanol, mepivacaine and mepivacaine-butorphanol mixtures for postoperative analgesia. Wajima Z, et al. **Br J Anaesth** 1995 Nov;75(5):548–51
Surgical pain is followed not only by spinal sensitization but also by supraspinal antinociception. Wilder-Smith OH, et al. **Br J Anaesth** 1996 Jun;76(6):816–21
Suppression of naloxone-precipitated withdrawal jumps in morphine-dependent mice by stimulation of prostaglandin EP3 receptor. Nakagawa T, et al. **Br J Pharmacol** 1995 Nov;116(6):2661–6
Comparison of morphine and morphine with ketamine for postoperative analgesia. Javery KB, et al. **Can J Anaesth** 1996 Mar;43(3):212–5
Modifying prescribing of regulated analgesics [letter; comment] Hux JE. **Can Med Assoc J** 1996 Apr 1; 154(7):1005–6; discussion 1006–7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.
Modifying prescribing of regulated analgesics [letter; comment] Murray M. **Can Med Assoc J** 1996 Apr 1; 154(7):1006; discussion 1006–7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.
Modifying prescribing of regulated analgesics [letter] Panton WD. **Can Med Assoc J** 1996 Apr 1;154(7):1006; discussion 1006–7
Tolerance to opioid analgesics: clinical aspects. Portenoy RK. **Cancer Surv** 1994;21:49–65 (80 ref.)
Perspectives on opioid tolerance from basic research: behavioural studies after spinal administration in rodents. Stevens CW. **Cancer Surv** 1994;21:25–47 (51 ref.)
0.0625% bupivacaine with 0.0002% fentanyl via patient-controlled epidural analgesia for pain of labor and delivery. Ferrante FM, et al. **Clin J Pain** 1995 Jun; 11(2):121–6
Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia. Lemmens HJ. **Clin Pharmacokinet** 1995 Oct;29(4):231–42 (69 ref.)
Legal opioid consumption in Denmark 1981–1993. Groth Clausen T, et al. **Eur J Clin Pharmacol** 1995;48(5):321–5
Codeine self-medication in a headache patient. Eng EL, et al. **Headache** 1996 Jul-Aug;36(7):452–5
Epidural administration of bupivacaine, morphine, or their combination for postoperative analgesia in dogs. Hendrix PK, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):598–607
Chemical restraint and anesthesia of sea otters affected by the oil spill in Prince William Sound, Alaska. Sawyer DC, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1831–4
Remifentanil: a new opioid. Glass PS. **J Clin Anesth** 1995 Nov;7(7):558–63 (24 ref.)
Patient controlled analgesia for shock wave lithotripsy: the effect of self-administered alfentanil on pain intensity and drug requirement [see comments] Schelling G, et al. **J Urol** 1996 Jan;155(1):43–7. Comment in: J Urol 1996 Jan;155(1):56–7.
Capture of wood bison (Bison bison athabascae) using carfentanil-based mixtures. Haigh JC, et al. **J Wildl Dis** 1995 Jan;31(1):37–42
Carfentanil, bison, and statistics: the last word? [letter] Jenkins SH. **J Wildl Dis** 1995 Jan;31(1):104–5
Immobilization of black bears (Ursus americanus) with orally administered carfentanil citrate. Ramsay EC, et al. **J Wildl Dis** 1995 Jul;31(3):391–3
Pain control and the World Health Organization analgesic ladder [letter; comment] Reidenberg MM. **JAMA** 1996 Mar 20;275(11):835; discussion 836. Comment on: JAMA 1995 Dec 20;274(23):1870–3.
Pain control and the World Health Organization analgesic ladder [letter; comment] Ventafridda V, et al. **JAMA** 1996 Mar 20;275(11):835–6. Comment on: JAMA 1995 Dec 20;274(23):1870–3.
Is intra-articular pethidine an alternative to local anaesthetics in arthroscopy? A double-blind study comparing prilocaine with pethidine. Ekblom A, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):189–94
Illicit fentanyl in Europe [letter] Berens AI, et al. **Lancet** 1996 May 11;347(9011):1334–5
Discovery of Novel Opioid Medications. Proceedings of a conference. July 28–29, 1993. **NIDA Res Monogr** 1995; 147:1–298
Tramadol: a new analgesic. Kupecz D. **Nurse Pract** 1995 Nov;20(11 Pt 1):96–8
A double-blind comparison of morphine infusion and patient controlled analgesia in children. Bray RJ, et al. **Paediatr Anaesth** 1996;6(2):121–7
Morphine consumption and respiratory depression in children receiving postoperative analgesia from continuous morphine infusion or patient controlled analgesia. Bray RJ, et al. **Paediatr Anaesth** 1996;6(2):129–34
Drugs and sedation for colonoscopy. Phillips MS. **Prim Care** 1995 Sep;22(3):433–43 (33 ref.)
Is spinal anesthesia produced only by local anesthetics? [editorial; comment] Butterworth J, et al. **Reg Anesth** 1996 Mar-Apr;21(2):81–3. Comment on: Reg Anesth 1996 Mar-Apr;21(2):84–8.
A comparison of meperidine and lidocaine for spinal anesthesia for postpartum tubal ligation [see comments] Norris MC, et al. **Reg Anesth** 1996 Mar-Apr;21(2):84–8. Comment in: Reg Anesth 1996 Mar-Apr;21(2):81–3.
Alfentanil for conscious sedation during colonoscopy [letter; comment] Balaklaw LA. **South Med J** 1996 Mar; 89(3):357–8. Comment on: South Med J 1995 Jun;88(6):630–4.
Alfentanil for sedation during colonoscopy [letter; comment] Hill TR. **South Med J** 1996 Mar;89(3):356–7; discussion 357–8. Comment on: South Med J 1995 Jun;88(6):630–4.
[Clinical use of sufentanil] Toftegaard M, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3483–6 (33 ref.) **(Dan)**
[Prospects of balanced anesthesia--mainly focusing on combined induction of midazolam with barbiturate and epidural opioid with local anesthetics] Arita H, et al. **Masui** 1995;44 Suppl:S167–72; discussion S173–6 **(Jpn)**
[Epidural buprenorphine does not improve diaphragmatic function after upper abdominal surgery] Fujimura N, et al. **Masui** 1996 Apr;45(4):428–32 (Eng. Abstr.) **(Jpn)**
[The central hemodynamic changes and reaction of the sympathoadrenal system with the use of an original Russian analgesic fenaridin as the analgetic component of general anesthesia during aortocoronary bypass operations in patients with chronic ischemic heart disease] Tenshibaeva DA, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):51–5 (Eng. Abstr.) **(Rus)**
[Prescription rules for narcotics are too complicated (letter)] Almkvist H, et al. **Lakartidningen** 1996 Mar 13;93(11):987 **(Swe)**

ADMINISTRATION & DOSAGE

Evaluation of morphine for patient controlled analgesia with the Infusor system after opiate-free locoregional anesthesia for osteotomy of the foot. Van Lancker P, et al. **Acta Anaesthesiol Belg** 1995;46(3–4):113–20
Continuous cervical intrathecal administration of morphine with a new infusion pump, the Anschütz IP 35.1: a case report. Van Melkebeke S, et al. **Acta Anaesthesiol Belg** 1995;46(2):87–91
The efficacy of intrathecal injection of sufentanil using a microspinal catheter for labor analgesia. Abboud TK, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):210–5
Respiratory changes during treatment of postoperative pain with high dose transdermal fentanyl. Bülow HH, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):835–9
Opioid in peripheral analgesia: intra-articular morphine for pain control after arthroscopic knee surgery. Liu K, et al. **Acta Anaesthesiol Sin** 1995 Dec;33(4):217–21
Spinal cord stimulation versus spinal infusion for low back and leg pain. Hassenbusch SJ, et al. **Acta Neurochir Suppl (Wien)** 1995;64:109–15
Intra-operative epidural morphine, fentanyl, and droperidol for control of pain after spinal surgery. A prospective, randomized, placebo-controlled, and double-blind trial. Rainov NG, et al. **Acta Neurochir (Wien)** 1996;138(1):33–9
Drug-use evaluation of transdermal fentanyl [letter] Shamilian A. **Am J Health Syst Pharm** 1995 Nov 15; 52(22):2597–8
Treating neonates in pain. Bell SG. **Am J Nurs** 1996 Jan; 96(1):59
Using high-dose fentanyl patches. Lilley LL, et al. **Am J Nurs** 1996 Jul;96(7):18–20, 22
Planning for breakthrough cancer pain. McCaffery M, et al. **Am J Nurs** 1996 Jun;96(6):24
Disposition of transdermally administered fentanyl in dogs. Kyles AE, et al. **Am J Vet Res** 1996 May;57(5):715–9
Postoperative pulmonary complications and morbidity after abdominal aneurysmectomy: a comparison of postoperative epidural versus parenteral opioid analgesia. Major CP Jr, et al. **Am Surg** 1996 Jan;62(1):45–51
The efficacy of adding a continuous intravenous morphine infusion to patient-controlled analgesia (PCA) in abdominal surgery. Dawson PJ, et al. **Anesth Intensive Care** 1995 Aug;23(4):453–8
Patient-controlled epidural analgesia following caesarean delivery: a comparison of pethidine and fentanyl. Goh JL, et al. **Anaesth Intensive Care** 1996 Feb;24(1):45–50
The effect of increasing the dose of buprenorphine on the haemodynamic response associated with tracheal intubation. Khan FA, et al. **Anaesthesia** 1996 Mar; 51(3):274–9
An assessment of morphine requirement after wisdom tooth extraction under general anaesthesia. Tighe KE, et al. **Anaesthesia** 1995 Sep;50(9):816–8
Equivalent outcomes during postoperative patient-controlled intravenous analgesia with lidocaine plus morphine versus morphine alone. Cepeda MS, et al. **Anesth Analg** 1996 Jul; 83(1):102–6
Large-dose intrathecal morphine for coronary artery bypass grafting. Chaney MA, et al. **Anesth Analg** 1996 Aug; 83(2):215–22
Epidural clonidine or sufentanil for intraoperative and postoperative analgesia. De Kock M, et al. **Anesth Analg** 1995 Dec;81(6):1154–62
Bolus metoclopramide does not enhance morphine analgesia after cesarean section. Driver RP Jr, et al. **Anesth Analg** 1996 May;82(5):1033–5
Continuous intravenous administration of ketorolac reduces pain and morphine consumption after total hip or knee arthroplasty. Etches RC, et al. **Anesth Analg** 1995 Dec; 81(6):1175–80
Oral clonidine premedication enhances the quality of postoperative analgesia by intrathecal morphine. Goyagi T, et al. **Anesth Analg** 1996 Jun;82(6):1192–6
Recovery and complications after tonsillectomy in children: a comparison of ketorolac and morphine. Gunter JB, et al. **Anesth Analg** 1995 Dec;81(6):1136–41
A multicenter evaluation of total intravenous anesthesia with remifentanil and propofol for elective inpatient surgery. Hogue CW Jr, et al. **Anesth Analg** 1996 Aug;83(2):279–85
Intravenous tramadol versus epidural morphine for postthoracotomy pain relief: a placebo-controlled double-blind trial. James MF, et al. **Anesth Analg** 1996 Jul; 83(1):87–91
Time course characteristics of acute tolerance development to continuously infused alfentanil in rats. Kissin I, et al. **Anesth Analg** 1996 Sep;83(3):600–5
Dose-response study of intrathecal morphine versus intrathecal neostigmine, their combination, or placebo for postoperative analgesia in patients undergoing anterior and posterior vaginoplasty. Lauretti GR, et al. **Anesth Analg** 1996 Jun;82(6):1182–7
The dermatomal spread of epidural bupivacaine with and without prior intrathecal sufentanil. Leighton BL, et al. **Anesth Analg** 1996 Sep;83(3):526–9
The effects of electrical stimulation at different frequencies on perception and pain in human volunteers: epidural versus intravenous administration of fentanyl. Liu SS, et al. **Anesth Analg** 1996 Jan;82(1):98–102
Oral transmucosal fentanyl citrate for premedication in adults. Macaluso AD, et al. **Anesth Analg** 1996 Jan; 82(1):158–61
Prevention of pain on injection of propofol: a comparison of lidocaine with alfentanil. Nathanson MH, et al. **Anesth Analg** 1996 Mar;82(3):469–71
Sustained-release ibuprofen as an adjunct to morphine

patient-controlled analgesia. Plummer JL, et al. **Anesth Analg** 1996 Jul;83(1):92-6

A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia. Rapp SE, et al. **Anesth Analg** 1996 May;82(5):1043-8

Postarthroscopic meniscus repair analgesia with intraarticular ketorolac or morphine. Reuben SS, et al. **Anesth Analg** 1996 May;82(5):1036-9

Analgesia after thoracotomy: effects of epidural fentanyl concentration/infusion rate. Thomson CA, et al. **Anesth Analg** 1995 Nov;81(5):973-81

Computer-controlled infusion of alfentanil versus patient-controlled administration of morphine for postoperative analgesia: a double-blind randomized trial [see comments] van den Nieuwenhuyzen MC, et al. **Anesth Analg** 1995 Oct;81(4):671-9. Comment in: Anesth Analg 1995 Oct;81(4):665-7.

The effects of epidural morphine and epidural butorphanol on maternal outcomes after cesarean delivery [letter; comment] Wittels B, et al. **Anesth Analg** 1995 Dec; 81(6):1317-8. Comment on: Anesth Analg 1994 Jun;78(6):1099-104.

Adding fentanyl 0.0002% to epidural bupivacaine 0.125% does not delay gastric emptying in laboring parturients. Zimmermann DL, et al. **Anesth Analg** 1996 Mar;82(3):612-6

Continuous intrathecal administration of shortlasting mu opioids remifentanil and alfentanil in the rat. Buerkle H, et al. **Anesthesiology** 1996 Apr;84(4):926-35

Prophylactic use of epidural mepivacaine/morphine, systemic diclofenac, and metamizole reduces postoperative morphine consumption after major abdominal surgery. Rockemann MG, et al. **Anesthesiology** 1996 May; 84(5):1027-34

Postoperative analgesia using epidural infusions of fentanyl with bupivacaine. A prospective analysis of 1,014 patients. Scott DA, et al. **Anesthesiology** 1995 Oct;83(4):727-37

Fentanyl remaining in a transdermal system following three days of continuous use. Marquardt KA, et al. **Ann Pharmacother** 1995 Oct;29(10):969-71

Randomised, double blind trial of two loading dose regimens of diamorphine in ventilated newborn infants. Barker DP, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F22-6

Femoral nerve block as an alternative to parenteral narcotics for pain control after anterior cruciate ligament reconstruction. Edkin BS, et al. **Arthroscopy** 1995 Aug; 11(4):404-9

Comparison of intraarticular bupivacaine with the addition of morphine or fentanyl for analgesia after arthroscopic surgery. Uysalel A, et al. **Arthroscopy** 1995 Dec;11(6):660-3

Self-injecting morphine for toothache? [letter] Ngeow WC. **Br Dent J** 1996 May 11;180(9):327

Intra-articular analgesia for arthroscopic meniscectomy. Lyons B, et al. **Br J Anaesth** 1995 Nov;75(5):552-5

Influence of dose and timing of administration of morphine on postoperative pain and analgesic requirements. Mansfield MD, et al. **Br J Anaesth** 1996 Mar;76(3):358-61

Comparison of i.v. and s.c. diamorphine infusions for the treatment of acute pain in children. Semple D, et al. **Br J Anaesth** 1996 Feb;76(2):310-2

Dose requirements, efficacy and side effects of morphine and pethidine delivered by patient-controlled analgesia after gynaecological surgery. Stanley G, et al. **Br J Anaesth** 1996 Apr;76(4):484-6

Epidural analgesia for labour and delivery: fentanyl or sufentanil? Cohen S, et al. **Can J Anaesth** 1996 Apr; 43(4):341-6

Comparative effects of three doses of intravenous ketorolac or morphine on emesis and analgesia for restorative dental surgery in children. Purday JP, et al. **Can J Anaesth** 1996 Mar;43(3):221-5

Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Yang CY, et al. **Can J Anaesth** 1996 Apr;43(4):379-83

Patient-controlled analgesia (PCA) in the domiciliary care of tumour patients. Meuret G, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:137-40

Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations. Watanabe S, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:131-6

Post-operative intravenous continuous analgesia: comparison of buprenorphine, fentanyl and nalbuphine. Lejus C, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):57-65

Age-related postoperative morphine requirements in children following major surgery--an assessment using patient-controlled analgesia (PCA). Hansen TG, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):29-31

Patient-controlled analgesia for conscious sedation during endoscopic retrograde cholangiopancreatography: a randomized controlled trial. Jowell PS, et al. **Gastrointest Endosc** 1996 May;43(5):490-4

Epidural administration of methylprednisolone and morphine for pain after a spinal operation. A randomized, prospective, comparative study. McNeill TW, et al. **J Bone Joint Surg Am** 1995 Dec;77(12):1814-8

Dose effects of morphine and butorphanol alone and in combination after burn injury in the rat. Osgood PF, et al. **J Burn Care Rehabil** 1995 Jul-Aug;16(4):394-9

Comparison of intrapleural versus intravenous morphine for postthoracotomy pain management. Aykaç B, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):538-40

Beta-selective monoamine oxidase inhibitors and cardiac anesthesia. Cerza RF. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):717-9

Pain outcomes after thoracotomy: lumbar epidural hydromorphone versus intrapleural bupivacaine. Gaeta RR, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):534-7

Effects of thoracic epidural analgesia on coronary hemodynamics and myocardial metabolism in coronary artery bypass surgery. Stenseth R, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):503-9

The effect of midazolam at two plasma concentrations of hemodynamics and sufentanil requirement in coronary artery surgery. van der Maaten JM, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):356-63

Low-dose caudal morphine for postoperative analgesia in infants and children: a report of 500 cases. Mayhew JF, et al. **J Clin Anesth** 1995 Dec;7(8):640-2

Blunt needle infusion of local anesthetics or narcotic analgesics into operative wounds or joints. Rozencwaig R, et al. **J La State Med Soc** 1995 Nov;147(11):516-7

Cost-effectiveness analysis of patient-controlled analgesia, intramuscular q.i.d. injection and p.r.n. injection for postoperative pain relief. Sanansilp V, et al. **J Med Assoc Thai** 1995 Nov;78(11):600-4

Patient-controlled analgesia in Thai patients. Sanansilp V, et al. **J Med Assoc Thai** 1995 Oct;78(10):532-41

Identification of patients treated with strong analgesics: an assessment of two Danish information systems with respect to epidemiological research. Sørensen HT, et al. **J Med Syst** 1996 Feb;20(1):57-65

Use of patient-controlled analgesia for pain control for children receiving bone marrow transplant. Dunbar PJ, et al. **J Pain Symptom Manage** 1995 Nov;10(8):604-11

More on the conversion of transdermal fentanyl to morphine [letter; comment] Storey P. **J Pain Symptom Manage** 1995 Nov;10(8):581-2. Comment on: J Pain Symptom Manage 1995 Feb;10(2):87.

Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design. Roy SD, et al. **J Pharm Sci** 1996 May; 85(5):491-5

Effects of intrathecal and intracerebroventricular buprenorphine on a C-fiber reflex in the rat. Guirimand F, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):629-37

Fentazin anesthesia for labyrinthine surgery in guinea pigs. Sansom AJ, et al. **J Vestib Res** 1996 Jan-Feb;6(1):49-52

Nitrous oxide and morphine in children with sickle cell crisis [letter] Carbajal R, et al. **Lancet** 1996 Jun 8;347(9015):1621

Oral morphine protocol for sickle cell crisis pain. Conti C, et al. **Md Med J** 1996 Jan;45(1):33-5

The use of controlled release morphine sulfate (MS Contin) in Queensland 1990-1993 [letter; comment] Arnold P. **Med J Aust** 1995 Nov 20;163(10):559. Comment on: Med J Aust 1995 Aug 21;163(4):181-2.

Nurse-administered boluses enhance comfort at the end of life. Zeisberg L. **Oncol Nurs Forum** 1995 Nov-Dec; 22(10):1573-4

Total spinal anaesthesia following caudal block with bupivacaine and buprenorphine. Afshan G, et al. **Paediatr Anaesth** 1996;6(3):239-42

Caudal analgesia with buprenorphine for postoperative pain relief in children. Kamal RS, et al. **Paediatr Anaesth** 1995; 5(2):101-6

Intrathecal morphine (ITM) for postoperative pain control in children: a comparison with nalbuphine patient controlled analgesia (PCA). Krechel SW, et al. **Paediatr Anaesth** 1995;5(3):177-83

Postoperative morphine requirements, nausea and vomiting following anaesthesia for tonsillectomy. Comparison of intravenous morphine and non-opioid analgesic techniques. Mather SJ, et al. **Paediatr Anaesth** 1995;5(3):185-8

Transnasal butorphanol for postoperative analgesia following paediatric surgery in a Third World country. Tobias JD, et al. **Paediatr Anaesth** 1995;5(1):63-6

Age is the best predictor of postoperative morphine requirements. Macintyre PE, et al. **Pain** 1996 Feb; 64(2):357-64

National survey of drug use in palliative care. Drummond SH, et al. **Palliat Med** 1996 Apr;10(2):119-24

Transdermal delivery of fentanyl by electroporation. I. Influence of electrical factors. Vanbever R, et al. **Pharm Res** 1996 Apr;13(4):559-65

Biological rhythms in pain and in the effects of opioid analgesics. Labrecque G, et al. **Pharmacol Ther** 1995; 68(1):129-47 (80 ref.)

Antinociception and side effects of L- and D-dipalmitoylphosphatidyl choline liposome-encapsulated alfentanil after spinal delivery in rats. Isackson J, et al. **Pharmacol Toxicol** 1995 Nov;77(5):333-40

Thoracic versus lumbar administration of fentanyl using patient-controlled epidural after thoracotomy. Bouchard F, et al. **Reg Anesth** 1995 Sep-Oct;20(5):385-8

Pain relief for thoracotomy. Comparison of morphine requirements using an extrapleural infusion of bupivacaine. Carabine UA, et al. **Reg Anesth** 1995 Sep-Oct;20(5):412-7

Intravenous ketorolac and subarachnoid opioid analgesia in the management of acute postoperative pain. Gwirtz KH, et al. **Reg Anesth** 1995 Sep-Oct;20(5):395-401

Spinal analgesia during labor with low-dose bupivacaine, sufentanil, and epinephrine. A comparison with epidural analgesia. Kartawiadi L, et al. **Reg Anesth** 1996 May-Jun; 21(3):191-6

Double-blind randomized evaluation of intercostal nerve blocks as an adjuvant to subarachnoid administered morphine for post-thoracotomy analgesia. Liu M, et al. **Reg Anesth** 1995 Sep-Oct;20(5):418-25

Subarachnoid fentanyl augments lidocaine spinal anesthesia for cesarean delivery. Palmer CM, et al. **Reg Anesth** 1995 Sep-Oct;20(5):389-94

0.1% bupivacaine does not reduce the requirement for epidural fentanyl infusion after major abdominal surgery. Salomäki TE, et al. **Reg Anesth** 1995 Sep-Oct;20(5):435-43

Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Sörensen J, et al. **Scand J Rheumatol** 1995;24(6):360-5

Intrathecal infusion systems for treatment of chronic low back and leg pain of noncancer origin. Tutak U, et al. **South Med J** 1996 Mar;89(3):295-300

[Influence of dihydroetorphine hydrochloride and tramadol on labor pain and umbilical blood gas] Li E, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jun;30(6):345-8 (Eng. Abstr.) **(Chi)**

[Opioids and receptor blocking (letter)] Andersen S, et al. **Ugeskr Laeger** 1995 Oct 9;157(41):5734-5 **(Dan)**

[Postoperative pain relief in children] Hansen TG, et al. **Ugeskr Laeger** 1996 Apr 15;158(16):2241-5 (40 ref.) (Eng. Abstr.) **(Dan)**

[Intrathecal administration of morphine and bupivacaine in the treatment of severe pain in chronic pancreatitis] Verheijen R, et al. **Ned Tijdschr Geneeskd** 1996 Jul 6; 140(27):1410-2 (Eng. Abstr.) **(Dut)**

[Spinal analgesia for labor] Mercier FJ, et al. **Cah Anesthesiol** 1996;44(2):173-9 (Eng. Abstr.) **(Fre)**

[Treatment of postoperative pain with peridural administration of opioids] Chrubasik S, et al. **Anaesthesiol Reanim** 1995;20(1):16-25 (148 ref.) (Eng. Abstr.) **(Ger)**

[Patient-controlled analgesia (PCA) after urologic interventions] Gust VR, et al. **Anaesthesiol Reanim** 1995; 20(5):134-8 (Eng. Abstr.) **(Ger)**

[Combination of intravenous patient-controlled analgesia with epidural anesthesia for postoperative pain therapy] Kentner R, et al. **Anaesthesiol Reanim** 1996;21(3):69-75 (Eng. Abstr.) **(Ger)**

[Patient-controlled analgesia with clonidine and piritramide] Sümpelmann R, et al. **Anaesthesist** 1996 Jan;45(1):88-94 (Eng. Abstr.) **(Ger)**

[Pharmacokinetics of buprenorphine in subcutaneous administration] Gralow I, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):412-6 (Eng. Abstr.) **(Ger)**

[Patient-controlled analgesia with pethidine in acute intermittent porphyria (letter)] Muehlenberg K, et al. **Dtsch Med Wochenschr** 1995 Oct 20;120(42):1454 **(Ger)**

[Intra-articular morphine versus steroid administration to the acutely painful joint in gonarthrosis and arthritis (letter)] Stein A, et al. **Dtsch Med Wochenschr** 1996 Feb 23; 121(8):255 **(Ger)**

[Long-term treatment of chronic pain with tilidine-naloxone. An analysis of 50 patients with chronic pain conditions of non-malignant origin] Wörz R, et al. **Fortschr Med** 1995 Sep 30;113(27):388-92 (Eng. Abstr.) **(Ger)**

[Acceptability of high colonoscopy using different premedication--a comparison of the effect of midazolam versus midazolam and pethidine from the viewpoint of the patient and the physician] Ehrle UB, et al. **Z Gastroenterol** 1995 Dec;33(12):704-8 (Eng. Abstr.) **(Ger)**

[Continuous spinal analgesia in home care of oncologic pain] Ricci V, et al. **Minerva Med** 1995 Oct;86(10):409-14 (30 ref.) (Eng. Abstr.) **(Ita)**

[Cancer-pain management in home care] Mizuguchi T. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1453-5 (Eng. Abstr.) **(Jpn)**

[Epidural injection for postoperative pain relief after thoracoscopic surgery] Nogimura H, et al. **Kyobu Geka** 1995 Aug;48(9):756-8 (Eng. Abstr.) **(Jpn)**

[The relief of postoperative pain by suppositories of buprenorphine or NSAID] Akatsuka M, et al. **Masui** 1996 Mar;45(3):298-303 (Eng. Abstr.) **(Jpn)**

[Prolonged antinociceptive effect after epidural injection of polyethylene glycol-morphine composites in rats] Okuda T, et al. **Masui** 1996 May;45(5):571-5 (Eng. Abstr.) **(Jpn)**

[Postoperative analgesia with epidural administration of a combination of tramadol and clonidine] Masár O, et al. **Bratisl Lek Listy** 1995 Dec;96(12):669-70 (Eng. Abstr.) **(Slo)**

[Spinal opiates in obstetrics. Theoretical aspects and criteria for practical use] Miranda A. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):369-77 (113 ref.) (Eng. Abstr.) **(Spa)**

[Reduction of the need for isoflurane and of postoperative pain with preanesthetic intrathecal morphine (letter; comment)] Sabaté A. **Rev Esp Anestesiol Reanim** 1995 Oct; 42(8):349-51. Comment on: Rev Esp Anestesiol Reanim 1995 Feb;42(2):41-6. **(Spa)**

ADVERSE EFFECTS

Respiratory changes during treatment of postoperative pain with high dose transdermal fentanyl. Bülow HH, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):835-9

Effect of P-6 acupressure on prevention of nausea and vomiting after epidural morphine for post-cesarean section pain relief. Ho CM, et al. **Acta Anaesthesiol Scand** 1996

Mar;40(3):372–5
Menstrual stage influences postoperative nausea and vomiting following epidural buprenorphine. Kitamura A, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):368–71
Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. Tarkkila P, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):983–6
Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants. Devulder J, et al. **Acta Clin Belg** 1996;51(3):184–6
No need to fear analgesia. Hinnant DC, et al. **Am J Nurs** 1996 Jul;96(7):23
Minimizing meperidine use. Hinnant DC. **Am J Nurs** 1996 Aug;96(8):18
Nonopioid analgesics shorten the duration of postoperative ileus. Ferraz AA, et al. **Am Surg** 1995 Dec;61(12):1079–83
Complications of intrathecal administration of pethidine [letter] Critchley LA, et al. **Anaesthesia** 1996 Jul; 51(7):711–2
Fentanyl-induced laryngospasm [letter; comment] Hadi NG, et al. **Anaesthesia** 1996 Jan;51(1):94. Comment on: Anaesthesia 1995 Sep;50(9):827.
Postoperative cognitive impairment in the elderly. Choice of patient-controlled analgesia opioid. Herrick IA, et al. **Anaesthesia** 1996 Apr;51(4):356–60
A comparison of retrospective versus contemporaneous nausea scores with patient-controlled analgesia. McIndoe AK, et al. **Anaesthesia** 1996 Apr;51(4):333–7
How much droperidol in combination with PCA morphine? [letter] Morrow BC, et al. **Anaesthesia** 1996 Jan;51(1):92
Fentanyl-induced laryngospasm? [letter] van den Bergh AA, et al. **Anaesthesia** 1996 Feb;51(2):206
Recurrence of herpes simplex virus blepharitis after cesarean section and epidural morphine. James CF. **Anesth Analg** 1996 May;82(5):1094–6 (17 ref.)
Naloxone versus nalbuphine infusion for prophylaxis of epidural morphine-induced pruritus. Kendrick WD, et al. **Anesth Analg** 1996 Mar;82(3):641–7
Dantrolene treatment of opioid-induced myoclonus. Mercadante S. **Anesth Analg** 1995 Dec;81(6):1307–8
High sensory block after intrathecal sufentanil for labor analgesia. Hamilton CL, et al. **Anesthesiology** 1995 Nov; 83(5):1118–21
Acute toxic delirium: an uncommon reaction to transdermal fentanyl. Kuzma PJ, et al. **Anesthesiology** 1995 Oct; 83(4):869–71
After transdermal fentanyl: acute toxic delirium or central anticholinergic syndrome? [letter] Link J. **Anesthesiology** 1996 Aug;85(2):436–7
Transient muscular spasm after a large dose of intrathecal sufentanil. Malinovsky JM, et al. **Anesthesiology** 1996 Jun; 84(6):1513–5
Epidural and intravenous opioid-induced neuroexcitation. Rozan JP, et al. **Anesthesiology** 1995 Oct;83(4):860–3
Opioid-induced muscle activity: implications for managing chronic pain. Sylvester RK, et al. **Ann Pharmacother** 1995 Nov;29(11):1118–21
Tramadol [letter; comment] Fenn GC, et al. **Br J Anaesth** 1995 Oct;75(4):501. Comment on: Br J Anaesth 1995 Mar;74(3):247–9.
Ventilatory arrest after a fluid challenge in a neonate receiving s.c. morphine. Wolf AR, et al. **Br J Anaesth** 1995 Dec;75(6):787–9
Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Thompson PI, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):145–52
Temporary back and leg pain after bupivacaine and morphine spinal anaesthesia. Ong B, et al. **Can J Anaesth** 1995 Sep; 42(9):805–7
The cognitive and psychomotor effects of opioid drugs in cancer pain management. O'Neill WM. **Cancer Surv** 1994; 21:67–84
Ulcerative skin reaction from subcutaneous infusion of isotonic methotrimeprazine and diamorphine. Hatton MQ, et al. **Clin Oncol (R Coll Radiol)** 1995;7(4):268–9
The use of lignocaine to reduce pain on i.v. injection of diluted nalbuphine. van den Berg AA, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):513–6
Effect of ketorolac on bleeding time and postoperative pain in children: a double-blind, placebo-controlled comparison with meperidine. Bean-Lijewski JD, et al. **J Clin Anesth** 1996 Feb;8(1):25–30
Incidence of nausea and vomiting in outpatients undergoing general anesthesia in relation to selection of intraoperative opioid. Cepeda MS, et al. **J Clin Anesth** 1996 Jun;8(4):324–8
Bowel function recovery after radical hysterectomies: thoracic epidural bupivacaine-morphine versus intravenous patient-controlled analgesia with morphine: a pilot study. de Leon-Casasola OA, et al. **J Clin Anesth** 1996 Mar; 8(2):87–92
Chest wall rigidity during infusion of fentanyl in a two-month-old infant after heart surgery. MacGregor DA, et al. **J Clin Anesth** 1996 May;8(3):251–4
Meperidine associated mental status changes in a patient with chronic renal failure. Stock SL, et al. **J Fla Med Assoc** 1996 May;83(5):315–9 (16 ref.)
Reduction of nausea and vomiting from epidural opioids by adding droperidol to the infusate in home-bound patients. Aldrete JA. **J Pain Symptom Manage** 1995 Oct;10(7):544–7
From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Apr 24;275(16):1224
Sickle cell pain crisis [letter; comment] [see comments] Meltzer BA. **Lancet** 1996 Jan 27;347(8996):262. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.
Algorithm helps healthcare practitioners manage opioid-induced sedation. Skalla K. **Oncol Nurs Forum** 1996 Apr;23(3):542–3
Comments on Stubhaug, Grimstad and Breivik, PAIN, 62 (1995) 111–118 [letter] Vielvoye-Kerkmeer PE. **Pain** 1996 Feb;64(2):401–2
Chronic use of symptomatic headache medications. Von Korff M, et al. **Pain** 1995 Aug;62(2):179–86
An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Sykes NP. **Palliat Med** 1996 Apr;10(2):135–44
Intranasal butorphanol-induced apraxia reversed by naloxone. Gora-Harper ML, et al. **Pharmacotherapy** 1995 Nov-Dec;15(6):798–800
Comment on spinal-epidural anesthesia case report by Eldor et al [letter; comment] Camann W. **Reg Anesth** 1995 Sep-Oct;20(5):460–1. Comment on: Reg Anesth 1994 Nov-Dec;19(6):418–22.
Transient motor deficit without sensory loss following subarachnoid sufentanil [letter; comment] Nagasandra V. **Reg Anesth** 1995 May-Jun;20(3):253–4. Comment on: Anesthesiology 1994 Feb;80(2):468–71.
[Cutaneous symptoms after continuous subcutaneous injection of morphine] Rasmussen YH, et al. **Ugeskr Laeger** 1996 Jun 17;158(25):3623–4 (Eng. Abstr.) **(Dan)**
[Early detection of opiate-induced respiratory depression in the postoperative phase] Graf R, et al. **Anaesthesiol Reanim** 1995;20(2):38–41 (Eng. Abstr.) **(Ger)**
[Watch for misuse of analgesics! (letter)] Eldhagen LG. **Lakartidningen** 1996 Apr 3;93(14):1321 **(Swe)**

ANTAGONISTS & INHIBITORS

Volatile anaesthetics antagonize nitrous oxide and morphine-induced analgesia in the rat. Goto T, et al. **Br J Anaesth** 1996 May;76(5):702–6
Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Yuan CS, et al. **Clin Pharmacol Ther** 1996 Apr;59(4):469–75
mu- and delta-opioid receptor antisense oligodeoxynucleotides antagonize morphine-induced growth hormone secretion in rats. Idänpään-Heikkilä JJ, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):227–30
Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits. Standifer KM, et al. **Mol Pharmacol** 1996 Aug;50(2):293–8
Inhibition by intrathecal prazosin but not yohimbine of fentanyl-induced muscular rigidity in the rat. Lui PW, et al. **Neurosci Lett** 1995 Dec 8;201(2):167–70
Differential blockade of morphine and morphine-6 beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein alpha subunits in rats. Rossi GC, et al. **Neurosci Lett** 1995 Sep 29;198(2):99–102
Intranasal butorphanol-induced apraxia reversed by naloxone. Gora-Harper ML, et al. **Pharmacotherapy** 1995 Nov-Dec;15(6):798–800
Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Crain SM, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7; 92(23):10540–4
Cholecystokinin octapeptide (CCK-8): a negative feedback control mechanism for opioid analgesia. Han JS. **Prog Brain Res** 1995;105:263–71 (20 ref.)
Effects of neuropeptide FF analogs on morphine analgesia in the nucleus raphe dorsalis. Dupouy V, et al. **Regul Pept** 1995 Nov 10;59(3):349–56

BLOOD

Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients. Miller RS, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):553–6
Therapeutic monitoring of nalbuphine: transplacental transfer and estimated pharmacokinetics in the neonate. Nicolle E, et al. **Eur J Clin Pharmacol** 1996;49(6):485–9
Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. Sindrup SH, et al. **Eur J Clin Pharmacol** 1996; 49(6):503–9
Availability of reliable serum methadone determination for management of symptomatic patients. Borg L, et al. **J Addict Dis** 1995;14(3):83–96
Rapid measurement of plasma methadone in a clinical setting using florescence polarization immunoassay. Kell MJ, et al. **J Addict Dis** 1996;15(2):69–83
Sensitive and selective assay for fentanyl using gas chromatography with mass selective detection. Szeitz A, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):33–42
Metabolism of dynorphin A 1–13 in human blood and plasma. Müller S, et al. **Pharm Res** 1995 Aug;12(8):1165–70
[Change in plasma morphine level and pain sensitivity in prenatally morphinized rats] Chobanov NG, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):273–5 **(Rus)**

CEREBROSPINAL FLUID

The effect of prior dural puncture on cisternal cerebrospinal fluid morphine concentrations in sheep after administration of lumbar epidural morphine. Swenson JD, et al. **Anesth Analg** 1996 Sep;83(3):523–5

CHEMICAL SYNTHESIS

Structure-activity relationships of dermorphin analogues containing chiral piperazin-2-one and piperazine derivatives. Yamashita T, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):856–9
Asymmetric syntheses, opioid receptor affinities, and antinociceptive effects of 8-amino-5,9-methanobenzocyclooctenes, a new class of structural analogues of the morphine alkaloids. Schultz AG, et al. **J Med Chem** 1996 May 10;39(10):1956–66
[Synthesis and biological activity of dynorphin A-(1-13) analogs] Chen YL, et al. **Yao Hsueh Hsueh Pao** 1995 Dec; 30(12):904–9 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Stability of bupivacaine hydrochloride and hydromorphone hydrochloride during simulated epidural coadministration. Christen C, et al. **Am J Health Syst Pharm** 1996 Jan 15; 53(2):170–3

ISOLATION & PURIFICATION

Schistosoma mansoni: the presence and potential use of opiate-like substances. Leung MK, et al. **Exp Parasitol** 1995 Sep;81(2):208–15

METABOLISM

Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Tateishi T, et al. **Anesth Analg** 1996 Jan; 82(1):167–72
Biotransformation of tritiated fentanyl in human liver microsomes. Monitoring metabolism using phenylacetic acid and 2-phenylethanol. Tateishi T, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1921–4
The synthesis and opioid receptor binding affinities of analogues of dermorphin and its N-terminal tetrapeptide fragment with dibasic acids in position 2. Misicka A, et al. **Life Sci** 1995;57(18):1633–40
Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Smith GD, et al. **Pain** 1995 Jul;62(1):51–60
Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Wolff T, et al. **Pain** 1995 Aug;62(2):147–54
The pharmacogenetics of codeine hypoalgesia. Sindrup SH, et al. **Pharmacogenetics** 1995 Dec;5(6):335–46 (91 ref.)
Endogenous morphine. Hosztafi S, et al. **Pharmacol Res** 1995 Jul-Aug;32(1–2):15–20 (51 ref.)
Persistent pain associated with long-term intrathecal morphine administration. Parris WC, et al. **South Med J** 1996 Apr;89(4):417–9
[The mu, delta and kappa properties of various opioids] Ohta S, et al. **Masui** 1995 Sep;44(9):1228–32 (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Rectal administration of morphine in children. Pharmacokinetic evaluation after a single-dose. Lundeberg S, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):445–51
Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Gibson TP. **Am J Med** 1996 Jul 31;101(1A):47S–53S (30 ref.)
Disposition of transdermally administered fentanyl in dogs. Kyles AE, et al. **Am J Vet Res** 1996 May;57(5):715–9
The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. Hansdóttir V, et al. **Anesth Analg** 1996 Aug;83(2):401–6
Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Dershwitz M, et al. **Anesthesiology** 1996 Apr;84(4):812–20
Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Egan TD, et al. **Anesthesiology** 1996 Apr;84(4):821–33
Linearity of pharmacokinetics and model estimation of sufentanil. Gepts E, et al. **Anesthesiology** 1995 Dec; 83(6):1194–204
Measured context-sensitive half-times of remifentanil and alfentanil. Kapila A, et al. **Anesthesiology** 1995 Nov; 83(5):968–75
Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ripamonti C, et al. **Ann Oncol** 1995 Oct;6(8):841–3
The effect of aging on the pharmacokinetics of nalbuphine in rabbits. Ho ST, et al. **Biopharm Drug Dispos** 1995 Nov; 16(8):695–703
Pharmacokinetics of analgesics, sedatives and anaesthetic agents during cardiopulmonary bypass. Gedney JA, et al. **Br J Anaesth** 1995 Sep;75(3):344–51 (74 ref.)
Pharmacokinetics of butorphanol nasal spray in patients with

renal impairment. Shyu WC, et al. **Br J Clin Pharmacol** 1996 May;41(5):397–402

Failure of meperidine wound infiltration to reduce pain after laparoscopic tubal ligation. Forgach L, et al. **Can J Anaesth** 1995 Dec;42(12):1085–9

Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Egan TD. **Clin Pharmacokinet** 1995 Aug;29(2):80–94 (41 ref.)

Pharmacokinetic–pharmacodynamic relationships of controlled–release oxycodone. Kaiko RF, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):52–61

Follicular fluid levels of midazolam, fentanyl, and alfentanil during transvaginal oocyte retrieval. Soussis I, et al. **Fertil Steril** 1995 Nov;64(5):1003–7

Study of the bioequivalence of two controlled–release formulations of morphine. Bourget P, et al. **Int J Clin Pharmacol Ther** 1995 Nov;33(11):588–94

Study of the bioequivalence of two controlled–release formulations of morphine [letter] Miller AJ, et al. **Int J Clin Pharmacol Ther** 1996 Mar;34(3):138

Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. Frenkel C, et al. **Intensive Care Med** 1995 Dec;21(12):981–8

The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. Kirvela M, et al. **J Clin Anesth** 1996 Feb;8(1):13–8

Steady–state pharmacokinetic evaluation of a novel, controlled–release morphine suppository and subcutaneous morphine in cancer pain. Bruera E, et al. **J Clin Pharmacol** 1995 Jul;35(7):666–72

Epidural diamorphine and bupivacaine stability study. Kreeger L, et al. **Palliat Med** 1995 Oct;9(4):315–8

PHARMACOLOGY

Can alpha 2–adrenoceptor agonists reverse or prevent tolerance to the antinociceptive activity of opioids in rats? De Kock M, et al. **Acta Anaesthesiol Belg** 1995; 46(3–4):141–52

Systemic and central effects of morphine on gastroduodenal motility. Thörn SE, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):177–86

Effects of fentanyl administration on general and cerebral haemodynamics in sick newborn infants. Hamon I, et al. **Acta Paediatr** 1996 Mar;85(3):361–5

A novel approach to the pharmacology of analgesics. Raffa RB. **Am J Med** 1996 Jul 31;101(1A):40S–46S (33 ref.)

Effects of intramuscular or interpleural administration of morphine and interpleural administration of bupivacaine on pulmonary function in dogs that have undergone median sternotomy. Dhokarikar P, et al. **Am J Vet Res** 1996 Mar; 57(3):375–80

Comparison of sedative and cardiorespiratory effects of medetomidine and medetomidine–butorphanol combination in dogs. Ko JC, et al. **Am J Vet Res** 1996 Apr;57(4):535–40

Evaluation of pulmonary function and analgesia in dogs after intercostal thoracotomy and use of morphine administered intramuscularly or intrapleurally and bupivacaine administered intrapleurally. Stobie D, et al. **Am J Vet Res** 1995 Aug;56(8):1098–109

An investigation of the effects of heparin, low molecular weight heparin, protamine, and fentanyl on the balance of pro– and anti–inflammatory cytokines in in–vitro monocyte cultures. McBride WT, et al. **Anaesthesia** 1996 Jul;51(7):634–40

Human brain activity response to fentanyl imaged by positron emission tomography. Firestone LL, et al. **Anesth Analg** 1996 Jun;82(6):1247–51

The effects of transnasal butorphanol on mood and psychomotor functioning in healthy volunteers. Zacny JP, et al. **Anesth Analg** 1996 May;82(5):931–5

Intravenous opioids stimulate norepinephrine and acetylcholine release in spinal cord dorsal horn. Systematic studies in sheep and an observation in a human. Bouaziz H, et al. **Anesthesiology** 1996 Jan;84(1):143–54

Concurrent spinal infusion of MK801 blocks spinal tolerance and dependence induced by chronic intrathecal morphine in the rat. Dunbar S, et al. **Anesthesiology** 1996 May; 84(5):1177–88

Intrathecal amitriptyline. Antinociceptive interactions with intravenous morphine and intrathecal clonidine, neostigmine, and carbamylcholine in rats. Eisenach JC, et al. **Anesthesiology** 1995 Nov;83(5):1036–45

Validation of the alfentanil canonical univariate parameter as a measure of opioid effect on the electroencephalogram. Gambús PL, et al. **Anesthesiology** 1995 Oct;83(4):747–56

Equianalgesic doses of subcutaneous but not intrathecal morphine alter phenotypic expression of cell surface markers and mitogen–induced proliferation in rat lymphocytes. Hamra JG, et al. **Anesthesiology** 1996 Aug; 85(2):355–65

Concomitant administration of morphine and an N–methyl–D–aspartate receptor antagonist profoundly reduces inflammatory evoked spinal c–Fos expression. Honoré P, et al. **Anesthesiology** 1996 Jul;85(1):150–60

Anesthetic potency of remifentanil in dogs. Michelsen LG, et al. **Anesthesiology** 1996 Apr;84(4):865–72

Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. Pavlin DJ, et al. **Anesthesiology** 1996 Jan;84(1):23–37

Oligogenic determination of morphine analgesic magnitude: a genetic analysis of selectively bred mouse lines. Mogil JS, et al. **Behav Genet** 1995 Jul;25(4):397–406

Tramadol [letter; comment] Budd K. **Br J Anaesth** 1995 Oct; 75(4):500. Comment on: Br J Anaesth 1995 Mar;74(3):247–9.

Effect of tramadol on depth of anaesthesia. Coetzee JF, et al. **Br J Anaesth** 1996 Mar;76(3):415–8

Remifentanil reduces auditory and somatosensory evoked responses during isoflurane anaesthesia in a dose–dependent manner. Crabb I, et al. **Br J Anaesth** 1996 Jun;76(6):795–801

Interaction of extradural morphine and lignocaine on ventilatory response [see comments] Saito Y, et al. **Br J Anaesth** 1995 Oct;75(4):394–8. Comment in: Br J Anaesth 1996 May;76(5):747–8.

Effects of morphine on human nasal cilia beat frequency in vitro. Selwyn DA, et al. **Br J Anaesth** 1996 Feb;76(2):274–7

Fentanyl increases intracellular Ca2+ concentrations in SH–SY5Y cells. Wandless AL, et al. **Br J Anaesth** 1996 Mar;76(3):461–3

Effects of peripherally and centrally acting analgesics on somato–sensory evoked potentials. Moore UJ, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):111–7

Effect of morphine on the nerve terminal impulse and transmitter release from sympathetic varicosities innervating the mouse vas deferens. Lavidis NA. **Br J Pharmacol** 1995 Dec;116(7):2852–9

Effect of chronic morphine treatment on transmitter release from sympathetic varicosities of the mouse vas deferens. Lavidis NA. **Br J Pharmacol** 1995 Dec;116(7):2860–5

Interaction between the mu–agonist dermorphin and the delta–agonist [D–Ala2, Glu4]deltorphin in supraspinal antinociception and delta–opioid receptor binding. Negri L, et al. **Br J Pharmacol** 1995 Dec;116(7):2931–8

Alterations in L–type calcium channels in the brain and spinal cord of acutely treated and morphine–tolerant mice. Bernstein MA, et al. **Brain Res** 1995 Oct 23;696(1–2):83–8

Lithium treatment prolongs shock–induced hypoalgesia. Teixeira NA, et al. **Braz J Med Biol Res** 1995 Jul; 28(7):791–9

A comparison of the haemodynamic effects of intrathecal meperidine, meperidine–bupivacaine mixture and hyperbaric bupivacaine. Conway F, et al. **Can J Anaesth** 1996 Jan;43(1):23–9

Do different opioid analgetics affect the plasma concentration of atrial natriuretic factor differently in man? [letter] Pedersen CB, et al. **Clin Nephrol** 1996 Feb;45(2):134–5

Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Egan TD. **Clin Pharmacokinet** 1995 Aug;29(2):80–94 (41 ref.)

Influence of spasmolytic analgesics on motility of sphincter of Oddi. Brandstätter G, et al. **Dig Dis Sci** 1996 Sep; 41(9):1814–8

Analysis of the antinociceptive actions of the kappa–opioid agonist enadoline (CI–977) in neonatal and adult rats: comparison to kappa–opioid receptor mRNA ontogeny. McLaughlin CR, et al. **Drug Alcohol Depend** 1995 Jun; 38(3):261–9

Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Gillis JC, et al. **Drugs** 1995 Jul; 50(1):157–75 (47 ref.)

The peripherally acting kappa–opiate agonist EMD 61753 and analogues: opioid activity versus peripheral selectivity. Gottschlich R, et al. **Drugs Exp Clin Res** 1995;21(5):171–4

The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects. Hanks GW, et al. **Eur J Clin Pharmacol** 1995;48(6):455–60

The cognitive and psychomotor effects of opioid analgesics. I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects. O'Neill WM, et al. **Eur J Clin Pharmacol** 1995; 48(6):447–53

Opioids in combination with local anesthetics for epidural analgesia during labor. Vertommen JD. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S35–8 (23 ref.)

Buprenorphine blocks diffuse noxious inhibitory controls in the rat. Guirimand F, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):651–9

Antinociceptive and antitussive effects of morphine in the DA–bg/bg (beige) rat. Kamei J, et al. **Eur J Pharmacol** 1996 Apr 4;300(1–2):75–8

Potentiation of morphine analgesic action in mice by beta–carotene. Penn NW. **Eur J Pharmacol** 1995 Sep 15; 284(1–2):191–3

kappa–Opioid receptor agonist protects against ischemic reduction of 2–deoxyglucose uptake in morphine–tolerant rats. Shibata S, et al. **Eur J Pharmacol** 1995 Jun 12; 279(2–3):197–202

Discriminative stimulus properties of morphine mediated by mu 1–opioid receptors. Suzuki T, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):195–8

A correlogram analysis of the activity in the rostral ventromedial medulla of awake rats and in rats anesthetized with ketamine or pentobarbital following the administration of morphine. McGaraughty S, et al. **Exp Brain Res** 1995; 106(2):283–90

Multiplicative interaction between intrathecally and intracerebroventricularly administered morphine for antinociception in the mouse: effects of spinally and supraspinally injected 3–isobutyl–1–methylxanthine, cholera toxin, and pertussis toxin. Suh HW, et al. **Gen Pharmacol** 1995 Nov;26(7):1597–602

Electrophysiological effects of Mu–selective opioids on hilar neurons in the hippocampus in vivo. Mayer JH, et al. **Hippocampus** 1995;5(6):557–68

Testicular lactate dehydrogenase and sorbitol dehydrogenase activity after intratesticular injection of dynorphin and morphine in male rats. Sreenivasan P, et al. **Indian J Exp Biol** 1996 Apr;34(4):363–5

Role of stress in histamine–morphine interactions. Hough LB, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S40–1

Morphine affects cytostatic activity of macrophages by the modulation of nitric oxide release. Pacifici R, et al. **Int J Immunopharmacol** 1995 Sep;17(9):771–7

Opioid pharmacodynamics in neonatal dogs: differences between morphine and fentanyl. Bragg P, et al. **J Appl Physiol** 1995 Nov;79(5):1519–24

Adenylylcyclase supersensitization in mu–opioid receptor–transfected Chinese hamster ovary cells following chronic opioid treatment. Avidor–Reiss T, et al. **J Biol Chem** 1995 Dec 15;270(50):29732–8

The pharmacokinetics and pharmacodynamics of remifentanil in volunteers with severe hepatic or renal dysfunction. Dershwitz M, et al. **J Clin Anesth** 1996 May;8(3 Suppl):88S–90S

No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia. Stein C, et al. **J Clin Invest** 1996 Aug 1;98(3):793–9

Effects of continuous infusion fentanyl citrate on cerebrovascular and systemic prostanoids in postsurgical newborn piglets. Modanlou HD, et al. **J Investig Med** 1996 Aug;44(6):362–9

A calcitonin gene–related peptide receptor antagonist prevents the development of tolerance to spinal morphine analgesia. Menard DP, et al. **J Neurosci** 1996 Apr 1; 16(7):2342–51

Dihydroetorphine is a mu–receptor–selective ligand. Wang DX, et al. **J Pharm Pharmacol** 1995 Aug;47(8):669–73

Effects of naloxone and D–Phe–Cys–Tyr–D–Trp–Arg–Thr–Pen–Thr–NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. Bilsky EJ, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):484–90

Agonist and antagonist effects of dynorphin A–(1–13) in a thermal antinociception assay in rhesus monkeys. Butelman ER, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):374–80

Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. Codd EE, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1263–70

Mu–opioid receptor regulation during opioid tolerance and supersensitivity in rat central nervous system. Diaz A, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1545–51

Regulation of dihydropyridine–sensitive Ca++ channels during opioid tolerance and supersensitivity in rats. Díaz A, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1538–44

Mouse strain differences in immunosuppression by opioids in vitro. Eisenstein TK, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1484–9

Buprenorphine's physical dependence potential: antagonist–precipitated withdrawal in humans. Eissenberg T, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):449–59

Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats. Fecho K, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):626–36

Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats. Fecho K, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):633–45

Antinociceptive effects of cocaine/opioid combinations in rhesus monkeys. Gatch MB, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1346–54

Discriminative stimulus effects of nalbuphine in rhesus monkeys. Gerak LR, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):523–31

Differential contribution of descending controls to the antinociceptive actions of kappa and mu opioids: an analysis of formalin–evoked C–fos expression. Gogas KR, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):801–9

Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. Mandema JW, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1185–94

Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: influence of nociceptive assay. Mogil JS, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):532–44

In vivo injection of antisense oligodeoxynucleotides to G alpha subunits and supraspinal analgesia evoked by mu and delta opioid agonists. Sánchez–Blázquez P, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1590–6

Relative analgesic potency of mu, delta and kappa opioids after spinal administration in amphibians. Stevens CW. **J Pharmacol Exp Ther** 1996 Feb;276(2):440–8

Characterization of the spinal antinociceptive activity of constrained peptidomimetic opioids. Yaksh TL, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):63–72

Tolerance of hypothalamic beta–endorphin neurons to mu–opioid receptor activation after chronic morphine. Zhang G, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):551–8

Hot plate versus tail flick: evaluation of acute tolerance to continuous morphine infusion in the rat model. Langerman

L, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):23–7

Modern opioids: uses defined by chrono–pharmacology, not receptor selectivity. Fox AW. **J R Soc Med** 1995 Sep; 88(9):502–4 (12 ref.)

Effect of fentanyl citrate analgesia on glucose production following trauma in rats. Yoshida S, et al. **J Surg Res** 1996 Mar;61(2):537–42

Role of GABAergic systems in the development of morphine tolerance in formalin–treated mice. Rahman AF, et al. **Jpn J Pharmacol** 1995 Jun;68(2):207–11

Use of butorphanol as an anesthetic adjunct in turkeys. Reim DA, et al. **Lab Anim Sci** 1995 Dec;45(6):696–7

Behavioral effects of MK–801 in morphine–dependent and non–dependent mice. Belozertseva I, et al. **Life Sci** 1995; 58(4):PL55–61

Buprenorphine exerts its antinociceptive activity via mu 1–opioid receptors. Kamei J, et al. **Life Sci** 1995 Mar 3; 56(15):PL285–90

The synthesis and opioid receptor binding affinities of analogues of dermorphin and its N–terminal tetrapeptide fragment with dibasic acids in position 2. Misicka A, et al. **Life Sci** 1995;57(18):1633–40

Synthesis and biological properties of gamma–glutamyl–dermorphin, a prodrug. Misicka A, et al. **Life Sci** 1996;58(11):905–11

A Gi2alpha antisense oligonucleotide differentiates morphine antinociception, constipation and acute dependence in mice. Raffa RB, et al. **Life Sci** 1996;58(5):PL 73–6

Diazepam pretreatment suppresses morphine withdrawal signs in the mouse. Suzuki T, et al. **Life Sci** 1995; 58(4):349–57

Opioids inhibit dopamine secretion from PC12 rat pheochromocytoma cells in a naloxone–reversible manner. Venihaki M, et al. **Life Sci** 1996;58(1):75–82

Determination of analgesic interaction between acetaminophen and d–propoxyphene obtained by means of the surface of synergistic interaction. López–Muñoz FJ, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun; 17(5):311–20

Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Lee YW, et al. **Neurosci Lett** 1995 Oct 20;199(2):111–4

Inhibition by spinal morphine of the tail–flick response is attenuated in rats with nerve ligation injury. Ossipov MH, et al. **Neurosci Lett** 1995 Oct 20;199(2):83–6

The loss of antinociceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by reducing spinal afferent drive. Ossipov MH, et al. **Neurosci Lett** 1995 Oct 20;199(2):87–90

The peripheral antinociceptive effect of morphine in a rat model of facial pain. Eisenberg E, et al. **Neuroscience** 1996 May;72(2):519–25

Spinal cord mechanisms of opioid tolerance and dependence: Fos–like immunoreactivity expression increases in subpopulations of spinal cord neurons during withdrawal. Rohde DS, et al. **Neuroscience** 1996 May;72(1):233–42

Comparison of the effects of meperidine and nalbuphine on intrapartum fetal heart rate tracings [letter; comment] Dawes GS. **Obstet Gynecol** 1996 Jan;87(1):158–9. Comment on: Obstet Gynecol 1995 Sep;86(3):441–5.

Paediatric ventilatory effects of morphine and buprenorphine revisited. Olkkola KT, et al. **Paediatr Anaesth** 1995; 5(5):303–5

The development of opioid tolerance in the formalin test in the rat. Detweiler DJ, et al. **Pain** 1995 Nov;63(2):251–4

The central nucleus of the amygdala contributes to the production of morphine antinociception in the formalin test. Manning BH, et al. **Pain** 1995 Nov;63(2):141–52

Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Mao J, et al. **Pain** 1995 Jun;61(3):353–64

Morphine–3–glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Smith GD, et al. **Pain** 1995 Jul;62(1):51–60

Relationship between hypothalamic–pituitary–adrenal activity and blockade of tolerance to morphine analgesia by pain: a strain comparison. Vaccarino AL, et al. **Pain** 1995 Dec;63(3):385–9

Effect of dermorphin on thermoregulation in rats at selected ambient temperatures. Emel'yanova TG, et al. **Peptides** 1996;17(2):241–5

The pharmacogenetics of codeine hypoalgesia. Sindrup SH, et al. **Pharmacogenetics** 1995 Dec;5(6):335–46 (91 ref.)

Effects of calcitonin gene–related peptide on acute and chronic effects of morphine. Azarov AV, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):595–9

Oxymorphone–induced analgesia and colonic motility measured in colorectal distension. Briggs SL, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):561–3

Oxytocin blocks the development of heroin–fentanyl cross–tolerance in mice. Kriván M, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):591–4

EEG power spectra and behavioral correlates in rats given chronic morphine. Lack of residual long–term EEG and neuronal changes. Sala M, et al. **Pharmacol Res** 1995 Jul–Aug;32(1–2):95–103

The effect of mu and kappa opioid receptor agonists on cAMP level in hippocampus of kainic acid–treated rats. Dziedzicka–Wasylewska M, et al. **Pol J Pharmacol** 1995 Mar–Apr;47(2):121–6

Attenuation of the fentanyl–induced muscle rigidity by the selective 5HT1A agonist 8–OH–DPAT. Jaros T, et al. **Pol J Pharmacol** 1995 Jan–Feb;47(1):19–24

Absence of opioid stress–induced analgesia in mice lacking beta–endorphin by site–directed mutagenesis. Rubinstein M, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30; 93(9):3995–4000

Hemodynamic effects of subarachnoid fentanyl in laboring parturients. Mandell GL, et al. **Reg Anesth** 1996 Mar–Apr; 21(2):103–11

1994 John J. Bonica Lecture. The clinical effects of morphine pharmacology. Mather LE. **Reg Anesth** 1995 Jul–Aug; 20(4):263–82 (95 ref.)

[Studies on the synthesis and structure–activity relation of deltorphin I analogues] Hu XY, et al. **Yao Hsueh Hsueh Pao** 1995;30(9):679–84 (Eng. Abstr.) (Chi)

[Combination of propofol–sufentanil on somatosensory evoked potentials in surgery of the spine] Borrissov B, et al. **Ann Fr Anesth Reanim** 1995;14(4):326–30 (Eng. Abstr.) (Fre)

[Analgesic effect of morphine and its metabolites administered by an intracerebroventricular route] Serrié A. **Bull Acad Natl Med** 1995 Jun;179(6):1237–52; discussion 1252–3 (20 ref.) (Eng. Abstr.) (Fre)

[Interactions between opioids and local anesthetics at the level of the dorsal horn of the spinal cord] Brasseur L, et al. **Cah Anesthesiol** 1995;43(4):363–6 (Eng. Abstr.) (Fre)

[Change in activity of enkephalinase from various structures of the rat brain during administration of naloxone and in morphine tolerance] Panchenko LF, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):492–4 (Rus)

[Features of hereditary sensitivity to morphine in hybrid rats F1 WAG/G–Fischer–344] Sudakov SK, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):291–3 (Rus)

[The effect of solvents on the activity of new morphinan series analgesics] Tolstikova TG, et al. **Dokl Akad Nauk** 1995 Jul;343(3):414–6 (Rus)

[The opiate–like and antimicrobial bioactivities of food protein peptides] Kharchenko EP. **Fiziol Zh Im I M Sechenova** 1996 Feb;82(2):71–8 (Eng. Abstr.) (Rus)

POISONING

Fentanyl neurotoxicity [letter] Adair JC, et al. **Ann Emerg Med** 1996 Jun;27(6):791–2

Compound opioid/paracetamol analgesics: misuse and dependence. McBride AJ, et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):268–9

[Poisonings with analgesics. Paracetamol and dextropropoxyphene dominate and cause the most severe symptoms in a 3–year material] Torell E, et al. **Lakartidningen** 1996 May 15;93(20):1955–60 (Swe)

STANDARDS

Stability of bupivacaine hydrochloride with diamorphine hydrochloride in an epidural infusion. Barnes AR, et al. **Pharm World Sci** 1995 May 26;17(3):87–92

THERAPEUTIC USE

Premedication with sublingual buprenorphine for out–patient arthroscopy: reduced need for postoperative pethidine but higher incidence of nausea. Juhlin–Dannfelt M, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):633–6

High sugar intake in a group of women on methadone maintenance in south western Sydney, Australia. Zador D, et al. **Addiction** 1996 Jul;91(7):1053–61

Oral morphine eases chronic non–cancer pain, with little risk of addiction [news] **Am J Health Syst Pharm** 1996 Apr 15;53(8):836, 838

'My pain is God's will'. Kumasaka L, et al. **Am J Nurs** 1996 Jun;96(6):45–7

Pain during sickle–cell crises. Nichols R. **Am J Nurs** 1996 Jan;96(1):59–60

A comparison of epidural infusions of fentanyl or pethidine with bupivacaine in the management of postoperative pain. Cox CR, et al. **Anaesthesia** 1996 Jul;51(7):695–8

Patient–controlled alfentanil. Target–controlled infusion for postoperative analgesia. Irwin MG, et al. **Anaesthesia** 1996 May;51(5):427–30

Epidural morphine for postherpetic neuralgia. Watt JW, et al. **Anaesthesia** 1996 Jul;51(7):647–51

Patient–controlled epidural analgesia after thoracotomy: a comparison of meperidine with and without bupivacaine. Etches RC, et al. **Anesth Analg** 1996 Jul;83(1):81–6

Preoperative wound infiltration with bupivacaine reduces early and late opioid requirement after hysterectomy. Hannibal K, et al. **Anesth Analg** 1996 Aug;83(2):376–81

The analgesic efficacy and adverse effects of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. Hansdóttir V, et al. **Anesth Analg** 1996 Aug; 83(2):394–400

Alfentanil dose–response relationships for relief of postoperative pain. Tverskoy M, et al. **Anesth Analg** 1996 Aug;83(2):387–93

Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. Warner DS, et al. **Anesth Analg** 1996 Aug;83(2):348–53

Role of magnesium sulfate in postoperative analgesia. Tramer MR, et al. **Anesthesiology** 1996 Feb;84(2):340–7

Microbiologic and economic evaluation of multiday infusion pumps for control of cancer pain. Ohlsson LJ, et al. **Ann Pharmacother** 1995 Oct;29(10):972–6

Treatment for cancer pain [letter; comment] Ahmedzai S, et al. **BMJ** 1995 Oct 7;311(7010):951. Comment on: BMJ 1995 Aug 5;311(7001):387.

A double–blind placebo–controlled study to assess the efficacy of a compound analgesic to prevent postoperative pain following oral surgery. Sandhu S, et al. **Br Dent J** 1996 May 11;180(9):335–8

Peripheral analgesic effect of morphine [letter; comment] Mallick A, et al. **Br J Anaesth** 1995 Dec;75(6):822–3. Comment on: Br J Anaesth 1995 Jul;75(1):23–6.

Pain control after hysterectomy: an observer–blind, randomised trial of lornoxicam versus tramadol. Ilias W, et al. **Br J Clin Pract** 1996 Jun;50(4):197–202

Regulated analgesics and pain control [letter; comment] Clark AJ, et al. **Can Med Assoc J** 1996 May 15;154(10):1472, 1474; discussion 1476–7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.

Regulated analgesics and pain control [letter; comment] Goldman B. **Can Med Assoc J** 1996 May 15;154(10):1474; discussion 1476–7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.

Regulated analgesics and pain control [letter; comment] Hagen NA, et al. **Can Med Assoc J** 1996 May 15; 154(10):1470, 1472. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.

Regulated analgesics and pain control [letter; comment] Jovey RD. **Can Med Assoc J** 1996 May 15;154(10):1476; discussion 1476–7. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.

Treating moderate and severe pain in small animals. Brock N. **Can Vet J** 1995 Oct;36(10):658–60 (3 ref.)

Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Bruera E, et al. **Cancer** 1996 Aug 15;78(4):852–7

Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cherny NJ, et al. **Cancer** 1995 Oct 1;76(7):1283–93

Oncologists and primary care physicians' attitudes toward pain control and morphine prescribing in France [see comments] Larue F, et al. **Cancer** 1995 Dec 1; 76(11):2375–82. Comment in: Cancer 1995 Dec 1;76(11):2181–5.

Decreased incidence of spontaneous mammary gland neoplasms in female F344 rats treated with amphetamine, methylphenidate, or codeine. Dunnick JK, et al. **Cancer Lett** 1996 Apr 19;102(1–2):77–83

Neurophysiology of opioid poorly responsive pain. Dickenson AH. **Cancer Surv** 1994;21:5–16 (49 ref.)

Patient–controlled epidural diamorphine for post–operative pain: verbal rating and visual analogue assessments of pain. Kunst G, et al. **Eur J Anaesthesiol** 1996 Mar;13(2):117–29

A peaceful death: how to manage pain and provide quality care. A roundtable discussion: Part 2. Butler RN, et al. **Geriatrics** 1996 Jun;51(6):32–5, 39–40, 42

The placebo effect in acute headache management: ketorolac, meperidine, and saline in the emergency department. Harden RN, et al. **Headache** 1996 Jun;36(6):352–6

Pharmacologic management of cancer pain [published erratum appears in Hosp Pract (Off Ed) 1996 Jan 15;31(1):86] Cleary J, et al. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):41–9

Availability of reliable serum methadone determination for management of symptomatic patients. Borg L, et al. **J Addict Dis** 1995;14(3):83–96

Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence. Compton PA, et al. **J Addict Dis** 1995;14(3):97–114 (56 ref.)

Urine toxicology as an outcome measure in drug abuse clinical trials: must every sample be analyzed? Compton PA, et al. **J Addict Dis** 1996;15(2):85–92

Rapid measurement of plasma methadone in a clinical setting using florescence polarization immunoassay. Kell MJ, et al. **J Addict Dis** 1996;15(2):69–83

Community based heroin addicts who turn to experimental treatment rather than conventional care. Michaels J, et al. **J Addict Dis** 1995;14(2):33–42

Prevalence and improvement in psychopathology in opioid dependent patients participating in methadone maintenance. Musselman DL, et al. **J Addict Dis** 1995; 14(3):67–82

Effect of ketorolac on bleeding time and postoperative pain in children: a double–blind, placebo–controlled comparison with meperidine. Bean–Lijewski JD, et al. **J Clin Anesth** 1996 Feb;8(1):25–30

High–dose oral morphine in cancer pain management: a report of twelve cases. Radbruch L, et al. **J Clin Anesth** 1996 Mar;8(2):144–50

Patient–controlled analgesia with sufentanil: a comparison of two different methods of administration. Sinatra RS, et al. **J Clin Anesth** 1996 Mar;8(2):123–9

Patient–controlled intranasal analgesia (PCINA) for the management of postoperative pain: a pilot study. Striebel HW, et al. **J Clin Anesth** 1996 Feb;8(1):4–8

Meperidine: therapeutic use and toxicity. Clark RF, et al. **J Emerg Med** 1995 Nov–Dec;13(6):797–802 (62 ref.)

Influence of intravenous fentanyl on fetal biophysical

parameters during labor. Smith CV, et al. **J Matern Fetal Med** 1996 Mar–Apr;5(2):89–92

Analgesic effect of topical opioids on painful skin ulcers [letter] Back IN, et al. **J Pain Symptom Manage** 1995 Oct; 10(7):493

Implementation of a formal treatment agreement for outpatient management of chronic nonmalignant pain with opioid analgesics. Burchman SL, et al. **J Pain Symptom Manage** 1995 Oct;10(7):556–63 (19 ref.)

Is this opioid analgesic tolerance? Fainsinger RL, et al. **J Pain Symptom Manage** 1995 Oct;10(7):573–7

Principles of opioid pharmacotherapy: practical implications of basic mechanisms. Ferrante FM. **J Pain Symptom Manage** 1996 May;11(5):265–73 (64 ref.)

Oral methadone for managing chronic nonmalignant pain. Gardner–Nix JS. **J Pain Symptom Manage** 1996 May; 11(5):321–8

Long–term intraspinal infusions of opioids in the treatment of neuropathic pain. Hassenbusch SJ, et al. **J Pain Symptom Manage** 1995 Oct;10(7):527–43

Government regulatory influences on opioid prescribing and their impact on the treatment of pain of nonmalignant origin. Hill CS Jr. **J Pain Symptom Manage** 1996 May; 11(5):287–98 (38 ref.)

Long–term opioid therapy: assessment of consequences and risks. Savage SR. **J Pain Symptom Manage** 1996 May; 11(5):274–86 (73 ref.)

A comparison of 2 analgesic regimens for the control of postoperative periodontal discomfort. Tucker PW, et al. **J Periodontol** 1996 Feb;67(2):125–9

Opioid antinociception in a rat model of visceral pain: systemic versus local drug administration. Craft RM, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1535–42

Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neuropathic pain in rats. Nichols ML, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1339–45

What is adequate and appropriate pain treatment? [letter; comment] Brenner SR. **JAMA** 1996 May 1;275(17):1310; discussion 1311. Comment on: JAMA 1995 Dec 20;274(23):1881–2.

What is adequate and appropriate pain treatment? [letter; comment] Jacobson L, et al. **JAMA** 1996 May 1; 275(17):1310–1. Comment on: JAMA 1995 Dec 20;274(23):1881–2.

What is adequate and appropriate pain treatment? [letter; comment] Murphy D. **JAMA** 1996 May 1;275(17):1311. Comment on: JAMA 1995 Dec 20;274(23):1881–2.

Methadone for treatment of cancer pain [letter; comment] O'Rourke MA, et al. **JAMA** 1996 Feb 21;275(7):519. Comment on: JAMA 1995 Oct 25;274(16):1307.

What is adequate and appropriate pain treatment? [letter; comment] White WG. **JAMA** 1996 May 1;275(17):1311. Comment on: JAMA 1995 Dec 20;274(23):1881–2.

Opioids as novel intra–articular agents for analgesia following arthroscopic knee surgery [published erratum appears in Knee Surg Sports Traumatol Arthrosc 1994;2(4):202] Lehrberger K, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(3):174–5

Sickle cell pain crisis [letter; comment] [see comments] Forbes K, et al. **Lancet** 1996 Jan 27;347(8996):262. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

Randomised trial of oral morphine for chronic non–cancer pain. Moulin DE, et al. **Lancet** 1996 Jan 20;347(8995):143–7

Barriers to controlling pain in patients with cancer [see comments] Reidenberg MM. **Lancet** 1996 May 11; 347(9011):1278. Comment in: Lancet 1996 Jul 13;348(9020):134.

Morphine for relief of cancer pain [letter] [see comments] Ripamonti C, et al. **Lancet** 1996 May 4;347(9010):1262–3 . Comment in: Lancet 1996 Jul 13;348(9020):138.

Sickle cell pain crisis [letter; comment] [see comments] Simini B. **Lancet** 1996 Jan 27;347(8996):261–2. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

Coproxamol revisited [letter] Sykes JV, et al. **Lancet** 1996 Aug 10;348(9024):408

Opioids in chronic pain of non–malignant origin: an interim consensus [letter] Jones D, et al. **N Z Med J** 1995 Nov 24;108(1012):492

Sublingual and oral morphine administration. Review and new findings. Robison JM, et al. **Nurs Clin North Am** 1995 Dec;30(4):725–43 (51 ref.)

Efficacy of controlled–release codeine in chronic non–malignant pain: a randomized, placebo–controlled clinical trial. Arkinstall W, et al. **Pain** 1995 Aug; 62(2):169–78

Analgesia and oral opioid consumption: strengths and shortcomings of methods [letter] Backonja MM, et al. **Pain** 1996 Feb;64(2):398–401

Custom–made capsules and suppositories of methadone for patients on high–dose opioids for cancer pain. Bruera E, et al. **Pain** 1995 Aug;62(2):141–6

Ketamine as an adjunct to morphine in the treatment of pain. Cherry DA, et al. **Pain** 1995 Jul;62(1):119–21

Massive opioid resistance in an infant with a localized metastasis to the midbrain periaqueductal gray. Collins JJ, et al. **Pain** 1995 Nov;63(2):271–5

Comments on Pentland and Donald [letter] Genis D, et al. **Pain** 1996 Feb;64(2):402–3

The influence of lockout intervals and drug selection on patient–controlled analgesia following gynecological surgery. Ginsberg B, et al. **Pain** 1995 Jul;62(1):95–100

Comments on Fitzgibbon and Galer, PAIN, 58 (1994) 429–431 [letter; comment] Lipman AG. **Pain** 1995 Oct; 63(1):135. Comment on: Pain 1994 Sep;58(3):429–31.

Age is the best predictor of postoperative morphine requirements. Macintyre PE, et al. **Pain** 1996 Feb; 64(2):357–64

Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Paix A, et al. **Pain** 1995 Nov;63(2):263–9

Lack of analgesic effect of 50 and 100 mg oral tramadol after orthopaedic surgery: a randomized, double–blind, placebo and standard active drug comparison. Stubhaug A, et al. **Pain** 1995 Jul;62(1):111–8

A regional survey of opioid use by patients receiving specialist palliative care. Brooks DJ, et al. **Palliat Med** 1995 Jul;9(3):229–38

Reappraisal of lytic cocktail/demerol, phenergan, and thorazine (DPT) for the sedation of children [letter; comment] Parks BR, et al. **Pediatrics** 1996 May; 97(5):779–80. Comment on: Pediatrics 1995 Apr;95(4):598–602.

Effective management of chronic pain. The analgesic dilemma. Stacey BR. **Postgrad Med** 1996 Sep;100(3):281–4, 287–90, 293 passim (27 ref.)

Expression of corticotropin–releasing factor in inflamed tissue is required for intrinsic peripheral opioid analgesia. Schafer M, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11; 93(12):6096–100

Comparison of morphine with and without fentanyl for epidural analgesia after major abdominal surgery. Chrubasik S, et al. **Reg Anesth** 1996 May–Jun;21(3):175–81

Preoperative spinal bupivacaine does not reduce postoperative morphine requirement in women undergoing total abdominal hysterectomy. Dakin MJ, et al. **Reg Anesth** 1996 Mar–Apr;21(2):99–102

The effect of pre–emptive fentanyl on formalin pain in mice. Fu ES, et al. **Reg Anesth** 1995 Jul–Aug;20(4):291–5

Effects of brachial plexus fentanyl on supraclavicular block. A randomized, double–blind study. Kardash K, et al. **Reg Anesth** 1995 Jul–Aug;20(4):311–5

1994 John J. Bonica Lecture. The clinical effects of morphine pharmacology. Mather LE. **Reg Anesth** 1995 Jul–Aug; 20(4):263–82 (95 ref.)

Analgesic effect of incisional morphine following inguinal herniotomy under spinal anesthesia. Rosenstock C, et al. **Reg Anesth** 1996 Mar–Apr;21(2):93–8

Intra–articular morphine and bupivacaine for pain relief after therapeutic arthroscopic knee surgery. Chan ST. **Singapore Med J** 1995 Feb;36(1):35–7

Persistent pain associated with long–term intrathecal morphine administration. Parris WC, et al. **South Med J** 1996 Apr;89(4):417–9

Reversal of the OKT3–related shivering and chest tightness by intravenous meperidine [letter] Abdallah KA, et al. **Transplantation** 1996 Jul 15;62(1):145–6

[Avoiding certainty while treating the pain (letter)] Orko R. **Duodecim** 1994;110(21):2026–7 **(Fin)**

[Post–appendectomy fistulas of the cecum. Apropos of 22 cases] Genier F, et al. **J Chir (Paris)** 1995 Oct;132(10):393–8 (17 ref.) (Eng. Abstr.) **(Fre)**

[Pharma–clinics. Drug of the month. Tramadol (Dolzam)] Scheen AJ. **Rev Med Liege** 1996 Jun;51(6):443–5 **(Fre)**

[Clinical aspects and evaluation of methadone substitution therapy] Déglon JJ. **Therapie** 1995 Nov–Dec;50(6):537–42 (Eng. Abstr.) **(Fre)**

[Oral opioids for long–term treatment of chronic non–cancer pain] Dertwinkel R, et al. **Anaesthesist** 1996 Jun; 45(6):495–505 (53 ref.) (Eng. Abstr.) **(Ger)**

[Preventive pain therapy. Preventive tramadol infusion versus bolus application in the early postoperative phase] Hartjen K, et al. **Anaesthesist** 1996 Jun;45(6):538–44 (Eng. Abstr.) **(Ger)**

[Remarks on the work of A. Willweber–Strumpf et al. Directions for treatment of chronic pain with opioids. Results from the Sertürner workshop "chronic opioid therapy"] Stadler T, et al. **Anaesthesist** 1996 Apr; 45(4):386–7 **(Ger)**

[Oral opioids in chronic non–cancer pain. Prospective controlled studies needed! (editorial)] Stein C. **Anaesthesist** 1996 Jun;45(6):493–4 **(Ger)**

[A comparative study of intravenous opioid analgesia. Sufentanil and alfentanil for extracorporeal shock–wave lithotripsy in urologic patients] Weninger E, et al. **Anaesthesist** 1996 Apr;45(4):330–6 (Eng. Abstr.) **(Ger)**

[Drugs for labor pain] Jage J. **Arch Gynecol Obstet** 1995; 257(1–4):135–8 (11 ref.) **(Ger)**

[Drug treatment of tumor pain] Larsen B, et al. **Internist (Berl)** 1996 Apr;37(4):425–40 (10 ref.) **(Ger)**

[Pain crises in patients with sickle cell diseases. Pathogenesis, clinical aspects, therapy] Dickerhoff R, et al. **Klin Padiatr** 1995 Nov–Dec;207(6):321–5 (29 ref.) (Eng. Abstr.) **(Ger)**

[Ambulatory pain treatment in tumor patients] Keseberg A. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):328–34 (0 ref.) (Eng. Abstr.) **(Ger)**

[Post–thoracotomy analgesia in pediatric heart surgery: comparison of 2 different techniques] Picardo S, et al. **Minerva Anestesiol** 1995 Jun;61(6):277–82 (Eng. Abstr.) **(Ita)**

[A pharmacological analysis of the antiedematous action of GABA–ergic and opioidergic agents in craniocerebral trauma] Novikov VE, et al. **Eksp Klin Farmakol** 1995 Nov–Dec;58(6):67–9 (Eng. Abstr.) **(Rus)**

[The Methadone Maintenance Program for intravenous heroin addicts. What information do primary care physicians have?] Velarde Mayol C, et al. **Aten Primaria** 1996 May 31;17(9):581–4 (Eng. Abstr.) **(Spa)**

TOXICITY

Opioid neurotoxicity: neuropathologic effects in rats of different fentanyl congeners and the effects of hexamethonium–induced normotension. Kofke WA, et al. **Anesth Analg** 1996 Jul;83(1):141–6

Toxicological evaluation of mu–agonists. Part II: Assessment of toxicity following 30 days of repeated oral dosing of male and female rats with levo–alpha–noracetylmethadol HCl (NorLAAM). Borzelleca JF, et al. **J Appl Toxicol** 1995 Sep–Oct;15(5):339–55

URINE

Urinary excretion of meperidine and normeperidine in man upon acute and chronic exposure to high altitude. Ritschel WA, et al. **Methods Find Exp Clin Pharmacol** 1996 Jan–Feb; 18(1):49–53

[A combination of chromatographic analysis methods in determining narcotic analgesics in biological fluids] Berezentsev OM, et al. **Sud Med Ekspert** 1995 Jul–Sep; 38(3):30–2 (Eng. Abstr.) **(Rus)**

ANALGIN see **DIPYRONE**

ANALOG–DIGITAL CONVERSION

Digital images & sound. Khademi JA. **J Dent Educ** 1996 Jan;60(1):41–6

The accuracy of a high–precision digitizer for CAD/CAM of crowns. Persson M, et al. **J Prosthet Dent** 1995 Sep; 74(3):223–9

Techniques and tools for digitizing analog video for use in CD–ROM–based health education programs. Van Biervliet A, et al. **Medinfo** 1995;8 Pt 2:1222–5

Conversion of analog signals into computer oriented data. Malik D, et al. **Pacing Clin Electrophysiol** 1995 Oct; 18(10):1947–51

[Analysis of the human wrist motion in three dimensions using a video–digitizer] Nakamura K, et al. **Nippon Seikeigeka Gakkai Zasshi** 1995 Jul;69(7):450–9 (Eng. Abstr.) **(Jpn)**

ANALOGUE PAIN SCALE see **PAIN MEASUREMENT**

ANALPHALIPOPROTEINEMIA see **TANGIER DISEASE**

ANALYSIS OF VARIANCE

Tests for the analysis of variance of crossover designs with correlated errors. Bellavance F, et al. **Biometrics** 1996 Jun; 52(2):607–12

Estimating variance functions in developmental toxicity studies. Bowman D, et al. **Biometrics** 1995 Dec; 51(4):1523–8

Analyzing bivariate repeated measures for discrete and continuous outcome variables. Rochon J. **Biometrics** 1996 Jun;52(2):740–50

Comparing several groups using analysis of variance. Altman DG, et al. **BMJ** 1996 Jun 8;312(7044):1472–3

Parametric or non–parametric: a case for comparing the distribution of a continuous variable between two populations using Epi Info [letter] Siziya S. **Cent Afr J Med** 1995 Aug;41(8):262–3

Univariate analysis of dichotomous or ordinal data from twin pairs: a simulation study comparing structural equation modeling and logistic regression. Ramakrishnan V, et al. **Genet Epidemiol** 1996;13(1):79–90

Rates of change of genetic parameters of body weight in selected mouse lines. Heath SC, et al. **Genet Res** 1995 Aug; 66(1):19–25

Approximate variance of nucleotide divergence between two sequences estimated from restriction fragment data [letter] González–Candelas F, et al. **Genetics** 1995 Aug; 140(4):1443–6

More on the means comparison with unequal variances problem. Ames MH. **J Biopharm Stat** 1996 May;6(2):177–83

Power of a test that is robust against variance heterogeneity. Overall JE, et al. **Psychol Rep** 1995 Aug;77(1):155–9

Tests that are robust against variance heterogeneity in k x 2 designs with unequal cell frequencies. Overall JE, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):1011–7

Testing independence when the form of the bivariate distribution is unspecified. Geisser S, et al. **Stat Med** 1995 Aug 15;14(15):1621–39

Comparison of median survival times with adjustment for covariates. Karrison T. **Stat Med** 1995 Dec 15; 14(23):2537–53

Effects of model misspecification in the estimation of variance components and intraclass correlation for paired data. Lyles RH, et al. **Stat Med** 1995 Aug 15;14(15):1693–706

Robustness and power of analysis of covariance applied to data distorted from normality by floor effects: homogeneous regression slopes. Sullivan LM, et al.

Stat Med 1996 Mar 15;15(5):477–96
Logistic regression with incompletely observed categorical covariates—investigating the sensitivity against violation of the missing at random assumption. Vach W, et al. **Stat Med** 1995 Jun 30;14(12):1315–29
The homogenetic estimate for the variance of survival rate. Zhao G. **Stat Med** 1996 Jan 15;15(1):51–60

ANALYZERS, NEURAL see **NEURAL ANALYZERS**

ANANKASTIC PERSONALITY see **COMPULSIVE PERSONALITY DISORDER**

ANAPHASE

Frontier questions about sister chromatid separation in anaphase. Yanagida M. **Bioessays** 1995 Jun;17(6):519–26 (70 ref.)
Anaphase chromatid motion: involvement of type II DNA topoisomerases. Duplantier B, et al. **Biophys J** 1995 Oct; 69(4):1596–605
Association of yeast SIN1 with the tetratrico peptide repeats of CDC23. Shpungin S, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8274–7

GENETICS

Separation of sister chromatids in mitosis requires the Drosophila pimples product, a protein degraded after the metaphase/anaphase transition. Stratmann R, et al. **Cell** 1996 Jan 12;84(1):25–35
Impaired chromosome segregation in plant anaphase after moderate hypomethylation of DNA. Leyton C, et al. **Cell Prolif** 1995 Sep;28(9):481–96

PHYSIOLOGY

DSK1, a novel kinesin-related protein from the diatom Cylindrotheca fusiformis that is involved in anaphase spindle elongation. Wein H, et al. **J Cell Biol** 1996 May; 133(3):595–604
Pds1p is required for faithful execution of anaphase in the yeast, Saccharomyces cerevisiae. Yamamoto A, et al. **J Cell Biol** 1996 Apr;133(1):85–97
Pds1p, an inhibitor of anaphase in budding yeast, plays a critical role in the APC and checkpoint pathway(s). Yamamoto A, et al. **J Cell Biol** 1996 Apr;133(1):99–110
Kinetochore microtubule dynamics and the metaphase-anaphase transition. Zhai Y, et al. **J Cell Biol** 1995 Nov;131(3):721–34
'Anaphase' and cytokinesis in the absence of chromosomes [see comments] Zhang D, et al. **Nature** 1996 Aug 1; 382(6590):466–8. Comment in: Nature 1996 Aug 1;382(6590):397–8.

ANAPHYLACTOID PURPURA see **PURPURA, SCHOENLEIN-HENOCH**

ANAPHYLATOXINS

ANALYSIS

Inflammatory peptides at the beginning of hemodialysis in asymptomatic patients treated or not with angiotensin I-converting inhibitors [letter] Marceau F, et al. **Nephron** 1995;71(4):474–6

BIOSYNTHESIS

Neutrophil and macrophage activation and anaphylatoxin formation in orthotopic liver transplantation without the use of veno-venous bypass. Tomasdottir H, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):250–5
Complement-derived anaphylatoxins in human donor corneas treated with excimer laser. Gardner BP, et al. **Ophthalmic Surg Lasers** 1995 Nov-Dec;26(6):568–71

ANAPHYLAXIS

Preventing fatalities from anaphylaxis: an allergist-immunologist's perspective [editorial] Lieberman P. **Allergy Proc** 1995 May-Jun;16(3):109–11
Fatal and near fatal idiopathic anaphylaxis. Patterson R, et al. **Allergy Proc** 1995 May-Jun;16(3):103–8
Anaphylactic intestinal response to milk proteins during malnutrition in guinea pigs. Darmon N, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G442–8
Local reaction secondary to insulin injection. A potential role for latex antigens in insulin vials and syringes. Towse A, et al. **Diabetes Care** 1995 Aug;18(8):1195–7
Anaphylaxis. Friday GA Jr, et al. **Ear Nose Throat J** 1996 Jan;75(1):21–4 (4 ref.)
Anaphylactic shock: mechanisms and treatment [see comments] Brown AF. **J Accid Emerg Med** 1995 Jun; 12(2):89–100 (92 ref.). Comment in: J Accid Emerg Med 1996 Mar;13(2):150.
Peanut anaphylaxis from food cross-contamination [letter] Kemp SF, et al. **JAMA** 1996 Jun 5;275(21):1636–7
Anaphylaxis. How to recognize, treat and prevent potentially fatal attacks. Wyatt R. **Postgrad Med** 1996 Aug; 100(2):87–90, 96–9 (10 ref.)

CHEMICALLY INDUCED

Muscle relaxants and histamine release. Moss J. **Acta Anaesthesiol Scand Suppl** 1995;106:7–12 (30 ref.)
Complement activation and histamine release following administration of roentgen contrast media. Vik H, et al. **Acta Radiol Suppl** 1995;399:83–9
Life-threatening anaphylactoid reaction after iv injection of gadoterate meglumine [letter] Meuli RA, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):729
Anaphylactoid reaction to Haemaccel [letter; comment] Fenwick DG, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):521–2. Comment on: Anaesth Intensive Care 1994 Feb;22(1):90–2. Comment on: Anaesth Intensive Care 1994 Jun;22(3):317–8.
Anaesthesia for the patient with allergy to latex. Spears FD, et al. **Anaesth Intensive Care** 1995 Oct;23(5):623–5
A lesson in the management of anaphylactic reactions [letter] Harper M, et al. **Anaesthesia** 1996 Jul;51(7):705–6
Latex anaphylaxis: another case, another cause. Ballantyne JC, et al. **Anesth Analg** 1995 Dec;81(6):1303–4
Anaphylactic reaction to latex in health care workers [letter; comment] Konrad C, et al. **Anesth Analg** 1996 May; 82(5):1107. Comment on: Anesth Analg 1995 Oct;81(4):878–9.
Anaphylactoid reaction to protamine confirmed by plasma tryptase in a diabetic patient during open heart surgery. Takenoshita M, et al. **Anesthesiology** 1996 Jan;84(1):233–5
Bezalip-induced anaphylaxis [letter] Toubi E, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):370
Coronary artery spasm during anaphylaxis [letter] Machiels JP, et al. **Ann Emerg Med** 1996 May;27(5):674–5
Anaphylaxis and leather protectors [letter; comment] McHugh DF. **Ann Emerg Med** 1995 Dec;26(6):756. Comment on: Ann Emerg Med 1995 Jun;25(6):841–4.
Anaphylactic shock following povidone. Gonzalo Garijo MA, et al. **Ann Pharmacother** 1996 Jan;30(1):37–40
Aprotinin in staged heart transplantation: anaphylactic potential of repeated exposure [letter; comment] Martinelli L, et al. **Ann Thorac Surg** 1996 Apr;61(4):1288–9. Comment on: Ann Thorac Surg 1995 May;59(5):1063–7; discussion 1068.
Anaphylactic shock following indocyanine green angiography [letter] Olsen TW, et al. **Arch Ophthalmol** 1996 Jan;114(1):97
GABA-mediated inhibition of the anaphylactic response in the guinea-pig trachea. Gentilini G, et al. **Br J Pharmacol** 1995 Jun;115(3):389–94
National Advisory Committee on Immunization (NACI). Supplementary statement MMR vaccine and anaphylactic hypersensitivity to egg or egg-related antigens. **Can Commun Dis Rep** 1996 Jul 15;22(14):113–5 **(Eng, Fre)**
Anaphylaxis: statement on initial management in nonhospital settings. Laboratory Centre for Disease Control. **Can Med Assoc J** 1996 May 15;154(10):1519–22 **(Eng, Fre)**
Anaphylactoid reactions to methotrexate. Alkins SA, et al. **Cancer** 1996 May 15;77(10):2123–6 (13 ref.)
Latex versus iodinated contrast media anaphylaxis in the cardiac cath lab. Myers GE, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):228–31
Life-threatening anaphylactic shock due to skin application of chlorhexidine [letter] Torricelli R, et al. **Clin Exp Allergy** 1996 Jan;26(1):112
Fatal reaction to urografin. Atnafu A. **Ethiop Med J** 1996 Jan;34(1):51–3
Anaphylaxis due to liposomal amphotericin (AmBisome) [letter] Bates CM, et al. **Genitourin Med** 1995 Dec;71(6):414
Anaphylaxis following oral cotrimoxazole [letter] Ghosh JB. **Indian Pediatr** 1995 Jul;32(7):827
Treatment of anaphylaxis following oral co-trimoxazole [letter] Kumar AS. **Indian Pediatr** 1996 Mar;33(3):249–50
Anaphylaxis from bacitracin and polymyxin B (Polysporin) ointment. Knowles SR, et al. **Int J Dermatol** 1995 Aug; 34(8):572–3
A hapten model of topically-induced ocular anaphylaxis in the rat. Trocmé SD, et al. **Invest Ophthalmol Vis Sci** 1987 Feb;28(2):264–9
Anaphylaxis caused by linseed (flaxseed) intake. Alonso L, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):469–70
Anaphylaxis to trimethoprim [letter] Cabañas R, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):137–8
Nizatidine anaphylaxis. Mira-Perceval JL, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):855–6
Anaphylaxis to 6-alpha-methylprednisolone in an eight-year-old child. Moreno-Ancillo A, et al. **J Allergy Clin Immunol** 1996 May;97(5):1169–71
Severe anaphylactic reaction to topical administration of framycetin. Proebstle TM, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):429–30
Independent anaphylaxis to cefazolin without allergy to other beta-lactam antibiotics. Warrington RJ, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):460–2
Drug induced emergencies. Kapadia FN. **J Assoc Physicians India** 1995 Apr;43(4):269–72
Anaphylactic reaction to aprotinin [letter] Ceriana P, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):477–8
Anaphylactic reaction to cefazolin in pregnancy. Konno R, et al. **J Obstet Gynaecol** 1995 Dec;21(6):577–9
Ondansetron: reasons to be restrictive [letter; comment] Frigerio C, et al. **Lancet** 1996 May 25;347(9013):1484–5. Comment on: Lancet 1996 Mar 2;347(9001):584–5.
Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Broome CB, et al. **Med Pediatr Oncol** 1996 Feb;26(2):105–10
Induction of immune tolerance in a 7-year-old hemophiliac with an anaphylactoid inhibitor. Harper JL, et al. **Thromb Haemost** 1995 Oct;74(4):1039–41
Successful heparin desensitization after heparin-induced anaphylactic shock. al-Eryani AY, et al. **Thromb Res** 1995 Sep 15;79(5–6):523–6
[Anaphylactic reaction to protamine in cardiovascular surgery] Hrubý M, et al. **Rozhl Chir** 1995 Sep;74(6):282–3 (Eng. Abstr.) **(Cze)**
[Drug induced fatal anaphylactic shock in Denmark 1968–1990] Lenler-Petersen P, et al. **Ugeskr Laeger** 1996 Jun 3;158(23):3316–8 (Eng. Abstr.) **(Dan)**
[Anaphylactic shock after morphine injection? (letter)] Beaudouin S, et al. **Therapie** 1996 Mar-Apr;51(2):193–4 **(Fre)**
[Anaphylactoid reactions to an injectable solution of a cremophor-containing solution of multivitamins] Mounier P, et al. **Therapie** 1995 Nov-Dec;50(6):571–3 (Eng. Abstr.) **(Fre)**
[Fulminant, rapidly reversible hepatitis and life-threatening anaphylaxis following rifampicin in an HIV-positive female patient with latent adrenal cortex insufficiency] Canova CR, et al. **Schweiz Med Wochenschr** 1996 Mar 9; 126(10):392–7 (Eng. Abstr.) **(Ger)**
[Latex allergy—not only a threatening danger to patients. A case report from an anesthesiological department] Konrad C, et al. **Schweiz Rundsch Med Prax** 1996 Apr 9;85(15):482–5 (Eng. Abstr.) **(Ger)**
[Anaphylactoid reactions to radiocontrast media] Confino-Cohen R, et al. **Harefuah** 1995 Jul;129(1–2):55–7 (17 ref.) **(Heb)**
[Dextran-induced anaphylactoid reactions in two patients with gastrointestinal cancer] Miyamoto Y, et al. **Masui** 1996 Apr;45(4):500–3 (Eng. Abstr.) **(Jpn)**
[Fatal anaphylactic shock caused by rifampicin in a patient with HIV infection (letter)] Inmaculada Rubio M, et al. **Enferm Infecc Microbiol Clin** 1996 Mar;14(3):200–1 **(Spa)**
[Anaphylactoid reaction caused by intravenous gadopentetate dimeglumine in magnetic resonance (letter)] Campos A, et al. **Med Clin (Barc)** 1996 Feb 10;106(5):197 **(Spa)**
[Anaphylactic shock after ingestion of a laxative: usefulness of an allergologic study (letter; comment)] Lleonart Bellfill R, et al. **Med Clin (Barc)** 1996 Mar 16;106(10):396. Comment on: Med Clin (Barc) 1995 Apr 15;104(14):559. **(Spa)**
[Anaphylaxis caused by cefixime with tolerance to other beta lactams (letter)] Vilas Martínez F, et al. **Med Clin (Barc)** 1996 Mar 23;106(11):439 **(Spa)**

COMPLICATIONS

Treatment of acute anaphylaxis. Teachers need to know the basics too [letter; comment] Finlay F, et al. **BMJ** 1995 Nov 25;311(7017):1436. Comment on: BMJ 1995 Sep 16;311(7007):731–3.
Nitric oxide synthase inhibition is detrimental to cardiac function and promotes bronchospasm in anaphylaxis in rabbits. Mitsuhata H, et al. **Shock** 1995 Aug;4(2):143–8
[Panic disorder secondary to anaphylactic reaction (letter)] Sanz-Carrillo C, et al. **Med Clin (Barc)** 1995 Sep 16; 105(8):318 **(Spa)**

DIAGNOSIS

Allergy to bumblebee venom. I. Occupational anaphylaxis to bumblebee venom: diagnosis and treatment. de Groot H, et al. **Allergy** 1995 Jul;50(7):581–4
Diagnostic work-up for food-dependent, exercise-induced anaphylaxis. Romano A, et al. **Allergy** 1995 Oct; 50(10):817–24
Treatment of acute anaphylaxis. Investigations help to confirm diagnosis [letter; comment] Robinson SM. **BMJ** 1995 Nov 25;311(7017):1435. Comment on: BMJ 1995 Sep 16;311(7007):731–3.
Undifferentiated somatoform idiopathic anaphylaxis: nonorganic symptoms mimicking idiopathic anaphylaxis. Choy AC, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):893–900
Insect-sting challenges—all risk and no benefit? [letter; comment] Feigenbaum BA. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):704–5. Comment on: J Allergy Clin Immunol 1994 Aug;94(2 Pt 1):137–8. Comment on: J Allergy Clin Immunol 1994 Aug;94(2 Pt 1):151–9.
Analysis of insect-sting study [letter; comment] Lin RY. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):704. Comment on: J Allergy Clin Immunol 1994 Aug;94(2 Pt 1):151–9.
Sting challenges as criteria for venom immunotherapy [letter; comment] Novey HS. **J Allergy Clin Immunol** 1995 Nov; 96(5 Pt 1):703–4. Comment on: J Allergy Clin Immunol 1994 Aug;94(2 Pt 1):137–8. Comment on: J Allergy Clin Immunol 1994 Aug;94(2 Pt 1):151–9.
Insect sting challenges: do no harm [letter; comment] Reisman RE. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):702–3. Comment on: J Allergy Clin Immunol 1994 Aug;94(2 Pt 1):137–8. Comment on: J Allergy Clin Immunol 1994 Aug;94(2 Pt 1):151–9.
Clinical problem-solving. The domino principle. Jaffe R, et al. **N Engl J Med** 1996 Aug 1;335(5):340–1
[Usefulness of measurement of mast cell tryptase for differential diagnosis of anaphylaxis and anaphylactoid

reaction] Saitoh J, et al. **Masui** 1995 Sep;44(9):1265–8 (Eng. Abstr.) **(Jpn)**

[Usefulness of the prick test for anaphylactoid reaction in intravenous fluorescein administration] Matsuura M, et al. **Nippon Ganka Gakkai Zasshi** 1996 Apr;100(4):313–7 (Eng. Abstr.) **(Jpn)**

[Diagnosis of allergy to venom of Hymenoptera (editorial)] Nittner–Marszalska M, et al. **Pneumonol Alergol Pol** 1995; 63(9–10):479–83 **(Pol)**

DRUG THERAPY

Out–of–hospital provider use of epinephrine for allergic reactions: pilot program. Lindbeck GH, et al. **Acad Emerg Med** 1995 Jul;2(7):592–6

Improper treatment of anaphylaxis. Knight A. **Allergy** 1996 Jan;51(1):67

Don't get stung with the adrenergic blockers (beta or alpha)! Watson A. **Aust Fam Physician** 1995 Oct;24(10):1879

Treatment of acute anaphylaxis. Avoid subcutaneous or intramuscular adrenaline [letter; comment] Alexander R, et al. **BMJ** 1995 Nov 25;311(7017):1434–5. Comment on: BMJ 1995 Sep 16;311(7007):731–3.

Treatment of acute anaphylaxis. Expressing the dose of adrenaline in milligrams is easier [letter; comment] Campbell S. **BMJ** 1995 Nov 25;311(7017):1435. Comment on: BMJ 1995 Sep 16;311(7007):731–3.

Treatment of acute anaphylaxis. Treatment takes precedence over monitoring [letter; comment] Clear J, et al. **BMJ** 1995 Nov 25;311(7017):1435. Comment on: BMJ 1995 Sep 16;311(7007):731–3.

Treatment of acute anaphylaxis. Patients should be taught how to inject adrenaline [letter; comment] Davies H, et al. **BMJ** 1996 Mar 9;312(7031):638. Comment on: BMJ 1995 Nov 25;311(7017):1434.

Treatment of acute anaphylaxis. Benign allergic reactions should not be treated with adrenaline [letter; comment] [see comments] Hourihane JO, et al. **BMJ** 1995 Nov 25; 311(7017):1434. Comment on: BMJ 1995 Sep 16;311(7007):731–3. Comment in: BMJ 1996 Mar 9;312(7031):637–8. Comment in: BMJ 1996 Mar 9;312(7031):638.

Treatment of acute anaphylaxis. Chart helps with calculation of dose of adrenaline for children [letter; comment] Stuart J. **BMJ** 1995 Nov 25;311(7017):1435–6. Comment on: BMJ 1995 Sep 16;311(7007):731–3.

Anaphylaxis: statement on initial management in nonhospital settings. Laboratory Centre for Disease Control. **Can Med Assoc J** 1996 May 15;154(10):1519–22 **(Eng, Fre)**

Magnesium protects against anaphylactic shock and cardiac myolysis in guinea–pigs. Kusniec F, et al. **J Basic Clin Physiol Pharmacol** 1994 Jan–Mar;5(1):45–58

Assisted suicide [letter] Frazier CA. **J S C Med Assoc** 1996 Jul;92(7):323

A needless death [letter] Frazier CA. **Nebr Med J** 1996 Jan; 81(1):5

Epinephrine for anaphylazis [editorial] Frazier CA. **Nebr Med J** 1996 Jan;81(1):6–7

[Self–administration of adrenaline aerosol in anaphylactic reactions after insect stings] Ackermann RW, et al. **Ugeskr Laeger** 1996 Aug 5;158(32):4497–9 (27 ref.) (Eng. Abstr.) **(Dan)**

[Adrenaline in anaphylaxis (editorial)] Mosbech H. **Ugeskr Laeger** 1996 Aug 5;158(32):4495 **(Dan)**

[Adrenaline for self treatment of anaphylactic reactions. Indications, available preparations and prescription rules] Rønborg SM, et al. **Ugeskr Laeger** 1996 Aug 5; 158(32):4539–43 (Eng. Abstr.) **(Dan)**

ENZYMOLOGY

Anaphylactoid reaction to protamine confirmed by plasma tryptase in a diabetic patient during open heart surgery. Takenoshita M, et al. **Anesthesiology** 1996 Jan;84(1):233–5

Is unrecognized anaphylaxis a cause of sudden unexpected death? Schwartz HJ, et al. **Clin Exp Allergy** 1995 Sep; 25(9):866–70

Basal secretion and anaphylactic release of rat mast cell protease–II (RMCP–II) from ex vivo perfused rat jejunum: translocation of RMCP–II into the gut lumen and its relation to mucosal histology. Scudamore CL, et al. **Gut** 1995 Aug;37(2):235–41

EPIDEMIOLOGY

[Food–induced anaphylaxis. A new French multicenter survey] Moneret–Vautrin DA, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Sep;31(4):256–63 (Eng. Abstr.) **(Fre)**

ETIOLOGY

First report of anaphylactic reaction after fig (Ficus carica) ingestion. Dechamp C, et al. **Allergy** 1995 Jun;50(6):514–6

Allergy to bumblebee venom. I. Occupational anaphylaxis to bumblebee venom: diagnosis and treatment. de Groot H, et al. **Allergy** 1995 Jul;50(7):581–4

Human seminal plasma anaphylaxis (HSPA): case report and literature review. Ebo DG, et al. **Allergy** 1995 Sep; 50(9):747–50 (30 ref.)

Skin–prick–test–induced anaphylaxis. Novembre E, et al. **Allergy** 1995 Jun;50(6):511–3

Adverse reactions associated with skin testing and immunotherapy. Lockey RF. **Allergy Proc** 1995 Nov–Dec; 16(6):293–6 (11 ref.)

Anaphylactoid reaction in a surgeon to surgical rubber gloves [see comments] Yoshino A, et al. **Anesth Analg** 1995 Oct; 81(4):878–9. Comment in: Anesth Analg 1996 May;82(5):1107.

Intraoperative latex anaphylaxis observed in a farmer [letter] Baykara N, et al. **Anesthesiology** 1996 Feb;84(2):476–7

Noncompliance with immunotherapy secondary to adverse effects [letter; comment] [published erratum appears in Ann Allergy Asthma Immunol 1995 Dec;75(6 Pt 1):474] Craig TJ, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):290 . Comment on: Ann Allergy Asthma Immunol 1995 Mar;74(3):241–6.

Oral allergy syndrome or anaphylaxis? [letter] Detjen P. **Ann Allergy Asthma Immunol** 1996 Sep;77(3):254

Coexistent anaphylaxis to Diptera and Hymenoptera. Freye HB, et al. **Ann Allergy Asthma Immunol** 1996 Mar; 76(3):270–2

Anaphylaxis to disodium cromoglycate [see comments] Ibañez MD, et al. **Ann Allergy Asthma Immunol** 1996 Sep; 77(3):185–6. Comment in: Ann Allergy Asthma Immunol 1996 Sep;77(3):165.

Anaphylaxis following ingestion of carmine [letter] Kägi MK, et al. **Ann Allergy Asthma Immunol** 1996 Mar;76(3):296

A fatality from idiopathic anaphylaxis. Krasnick J, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):376–8

Anaphylaxis to disodium cromoglycate [editorial; comment] Shearer WT. **Ann Allergy Asthma Immunol** 1996 Sep; 77(3):165. Comment on: Ann Allergy Asthma Immunol 1996 Sep;77(3):185–6.

Immediate hypersensitivity in the Flinders rat: further evidence for a possible link between susceptibility to allergies and depression. Djurić VJ, et al. **Brain Behav Immun** 1995 Sep;9(3):196–206

Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Stellato C, et al. **Chem Immunol** 1995;62:108–31 (94 ref.)

Selective IgA deficiency and anaphylactoid transfusion reaction: a case report. Wei CH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Feb;57(2):165–8

Anaphylactic reaction to lychee fruit: evidence for sensitization to profilin. Fäh J, et al. **Clin Exp Allergy** 1995 Oct;25(10):1018–23

IgE–mediated (and food–induced) intestinal disease. Strobel S. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:3–6 (61 ref.)

Anaphylactic reaction after a first filgrastim (granulocyte–colony stimulating factor) injection [letter] Batel–Copel L, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2428

Anaphylactoid reaction to BCG vaccine containing high molecular weight dextran [letter] Rudin C, et al. **Eur J Pediatr** 1995 Nov;154(11):941–2

Idiopathic anaphylaxis: a purely internal reaction. Patterson R, et al. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):47–51, 55–8, 64 (0 ref.)

Structural characteristics of peptidoglycan fragments required to prime mice for induction of anaphylactoid reactions by lipopolysaccharides. Takada H, et al. **Infect Immun** 1996 Feb;64(2):657–9

Antigen–induced anaphylactic death in mice. Lei HY, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):407–12

Systemic anaphylaxis after eating storage–mite–contaminated food. Matsumoto T, et al. **Int Arch Allergy Immunol** 1996 Feb;109(2):197–200

Recurrent anaphylaxis caused by Anisakis simplex parasitizing fish. Audicana MT, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):558–60

Royal jelly–induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Leung R, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):1004–7

Hymenoptera sting challenge of 348 patients: relation to subsequent field stings. van Halteren HK, et al. **J Allergy Clin Immunol** 1996 May;97(5):1058–63

Epidemiology, diagnosis, precautions, and policies of intraoperative anaphylaxis to latex [letter; comment] Barnett MP. **J Am Coll Surg** 1996 Jan;182(1):79. Comment on: J Am Coll Surg 1995 Jun;180(6):754–61.

Epidemiology, diagnosis, precautions, and policies of intraoperative anaphylaxis to latex [letter; comment] Stock JA, et al. **J Am Coll Surg** 1996 Jan;182(1):78–9. Comment on: J Am Coll Surg 1995 Jun;180(6):754–61.

Anaphylaxis to kiwi fruit in a 12–year–old boy. Shimizu T, et al. **J Asthma** 1995;32(2):159–60

Anaphylactoid reactions in children receiving high–dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. Theis JG, et al. **J Clin Oncol** 1995 Oct;13(10):2508–16

Anaphylaxis after laboratory rat bite: an occupational hazard. Hesford JD, et al. **J Emerg Med** 1995 Nov–Dec;13(6):765–8

Mustard allergy: three cases of systemic reaction to ingestion of mustard sauce. Jorro G, et al. **J Investig Allergol Clin Immunol** 1995 Jan–Feb;5(1):54–6

Exercise–induced anaphylaxis related to specific foods [letter; comment] Policastro AM. **J Pediatr** 1996 May;128(5 Pt 1):724. Comment on: J Pediatr 1995 Oct;127(4):587–9.

Exercise–induced anaphylaxis related to specific foods [see comments] Tilles S, et al. **J Pediatr** 1995 Oct;127(4):587–9 . Comment in: J Pediatr 1996 May;128(5 Pt 1):724.

Anaphylaxis associated with white–cell reduction filter [letter] Sano H, et al. **Lancet** 1996 Apr 13;347(9007):1053

Anaphylactoid reactions during haemodialysis in sheep are mediated by bradykinin and can be prevented by bradykinin receptor antagonist [letter; comment] Van der Niepen P, et al. **Nephrol Dial Transplant** 1995 Nov; 10(11):2156–7. Comment on: Nephrol Dial Transplant 1995;10(4):509–13.

Anaphylaxis after treatment with recombinant factor VIII. Shopnick RI, et al. **Transfusion** 1996 Apr;36(4):358–61

Anaphylactic reactions associated with anti–Chido Antibody following platelet transfusions [letter] Wibaut B, et al. **Vox Sang** 1995;69(2):150–1

Allergic reaction to a wasp sting [letter] Frazier CA. **W V Med J** 1996 May–Jun;92(3):145

[Intraoperative anaphylactic shock following the percutaneous puncture of a hepatic echinococcal cyst] Stoianov G, et al. **Khirurgiia (Sofiia)** 1995;48(4):12–3 (Eng. Abstr.) **(Bul)**

[Anaphylactic reaction to Aspergillus] Drouet M, et al. **Allerg Immunol (Paris)** 1996 Mar;28(3):88–9 (Eng. Abstr.) **(Fre)**

[Latex hypersensitivity: a foreseeable accident?] Delorme M, et al. **Can Anesthesiol** 1995;43(5):467–70 (Eng. Abstr.) **(Fre)**

[Anesthesiologic pecularities in patients with latex allergy (see comments)] Kisch H, et al. **Anaesthesist** 1996 Jul; 45(7):587–96 (88 ref.) (Eng. Abstr.). Comment in: Anaesthesist 1996 Jul;45(7):585–6. **(Ger)**

[Exercise–induced urticaria and anaphylaxis] von Vigier R, et al. **Dtsch Med Wochenschr** 1995 Oct 13;120(41):1381–6 (Eng. Abstr.) **(Ger)**

[A shock reaction from insect bites in patients with urticaria pigmentosa] Poroshina IuA, et al. **Ter Arkh** 1995; 67(10):33–5 (Eng. Abstr.) **(Rus)**

[Other pictures with possible involvement of food sensitization] Nieto García DA. **Allergol Immunopathol (Madr)** 1996;24 Suppl 1:24–31 **(Spa)**

[Anaphylaxis caused by human seminal fluid] Rubira N, et al. **Allergol Immunopathol (Madr)** 1995 Mar–Apr;23(2):91–3 (Eng. Abstr.) **(Spa)**

[Puncture of adrenal cyst and anaphylaxis (letter)] López P, et al. **Enferm Infecc Microbiol Clin** 1996 Mar;14(3):201–2 **(Spa)**

HISTORY

Pioneers in allergy and anaphylaxis. Shafrir E. **Isr J Med Sci** 1996 May;32(5):344

IMMUNOLOGY

Anaphylaxis induced by streptomycin in cell media. Pérez R, et al. **Allergy** 1996 Feb;51(2):135–6

Allergic urticaria and angioedema caused by a hemostatic sponge of bovine fibrin used in tooth extraction. Wüthrich B, et al. **Allergy** 1996 Jan;51(1):49–51

Anaphylaxis to mustard as a masked allergen in "chicken dips". Kanny G, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):340–2

Transgenic mice expressing the human high–affinity immunoglobulin (Ig) E receptor alpha chain respond to human IgE in mast cell degranulation and in allergic reactions. Fung–Leung WP, et al. **J Exp Med** 1996 Jan 1;183(1):49–56

Study of complement–mediated anaphylaxis in humans. The role of IgG subclasses (IgG1 and/or IgG4) in the complement–activating capacity of immune complexes. Bergamaschini L, et al. **J Immunol** 1996 Feb 1; 156(3):1256–61

Anaphylaxis mediated through a humanized high affinity IgE receptor. Dombrowicz D, et al. **J Immunol** 1996 Aug 15; 157(4):1645–51

[Anaphylactic shock after lipid exchange chromatography in a patient with congenital IgA deficiency] Enk AH, et al. **Hautarzt** 1995 Aug;46(8):573–5 (Eng. Abstr.) **(Ger)**

[Anaphylaxis caused by royal jelly] Roger A, et al. **Allergol Immunopathol (Madr)** 1995 May–Jun;23(3):133–5 (Eng. Abstr.) **(Spa)**

METABOLISM

Effects of in vitro mast cell degranulation on human lung beta–receptor binding parameters. Casale TB. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):140–6

[The effect of fatty compounds with different ratios of the polyunsaturated fatty acids of the omega–3 and omega–6 families on the expression of food–related anaphylaxis, on the liver cytochrome P–450 system and on 17–hydroxycorticosteroid metabolism in guinea pigs] Malikova NA, et al. **Vopr Pitan** 1995;(4):13–6 (Eng. Abstr.) **(Rus)**

MORTALITY

[A single sting of wasp and bee as a cause of fatal anaphylaxis] Hirvonen J, et al. **Duodecim** 1995;111(3):260–2 **(Fin)**

PHYSIOPATHOLOGY

Evaluation of left ventricular diastolic function in IgE–mediated anaphylaxis in dogs. Mitsuhata H, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):791–6

Association between the renin angiotensin system and anaphylaxis. Hermann K, et al. **Adv Exp Med Biol** 1995; 377:299–309

Naloxone exacerbates intestinal and systemic anaphylaxis in

the rat. Djurić VJ, et al. **Brain Behav Immun** 1995 Jun; 9(2):87–100

Progesterone modulation of anaphylactically induced ion transport in uterus and intestine. Harari Y, et al. **Int Arch Allergy Immunol** 1995 Oct;108(2):134–41

Gender risk for anaphylactoid reactions to contrast material [letter; comment] Lasser EC. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):1019–20. Comment on: J Allergy Clin Immunol 1995 Apr;95(4):813–7.

Role of nitric oxide in anaphylactic shock. Mitsuhata H, et al. **J Clin Immunol** 1995 Nov;15(6):277–83 (63 ref.)

Release of the mucosal mast cell granule chymase, rat mast cell protease–II, during anaphylaxis is associated with the rapid development of paracellular permeability to macromolecules in rat jejunum. Scudamore CL, et al. **J Exp Med** 1995 Dec 1;182(6):1871–81

Anaphylactic reactions to bee-sting challenges in allergic children are not modified by endogenous catecholamines. Hauk P, et al. **Pediatr Res** 1995 Dec;38(6):998–1002

[Anaphylactic shock] Kaeser P, et al. **Schweiz Rundsch Med Prax** 1995 Nov 7;84(45):1307–13 (30 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy. Díez Gómez ML, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec;23(6):277–84 (40 ref.)

Management of anaphylactic reactions to food [letter; comment] Vickers D. **Arch Dis Child** 1995 Aug;73(2):184–5 . Comment on: Arch Dis Child 1995 Mar;72(3):274.

Protective effect of furosemide combined with non-steroidal anti-inflammatory drugs administered by inhalation route on guinea-pigs anaphylaxis model. Berti F, et al. **Arzneimittelforschung** 1995 Oct;45(10):1098–102

Suppression of anaphylactic shock in sensitized guinea pigs by cytochalasin D. Semyonov AV, et al. **Immunol Lett** 1995 Jul–Aug;47(1–2):59–62

Successful prophylaxis of wheat-dependent exercise-induced anaphylaxis with terfenadine. Fujimoto S, et al. **Intern Med** 1995 Jul;34(7):654–6

Recombinant soluble form of the human high-affinity receptor for IgE prevents anaphylactic shock in mice. Naito K, et al. **J Allergy Clin Immunol** 1996 Mar; 97(3):773–80

Reticulin-M, an antianaphylactic peptide secreted by reticulo-endothelial system. Baciu I, et al. **Rom J Physiol** 1993 Jul–Dec;30(3–4):183–92

[Anesthesia in a patient with history of multiple drug allergies] Horiguchi Y, et al. **Masui** 1995 Nov;44(11):1542–6 (Eng. Abstr.) **(Jpn)**

THERAPY

Preventing fatalities from anaphylaxis: an emergency medicine physician's perspective [editorial] Zull DN. **Allergy Proc** 1995 May–Jun;16(3):113–4

ED management of insect stings. Jerrard DA. **Am J Emerg Med** 1996 Jul;14(4):429–33 (44 ref.)

Significance of Africanized bees for public health. A review. Schumacher MJ, et al. **Arch Intern Med** 1995 Oct 23; 155(19):2038–43 (49 ref.)

Treatment of acute anaphylaxis [see comments] Fisher M. **BMJ** 1995 Sep 16;311(7007):731–3 (29 ref.). Comment in: BMJ 1995 Nov 25;311(7017):1434. Comment in: BMJ 1995 Nov 25;311(7017):1434–5. Comment in: BMJ 1995 Nov 25;311(7017):1435. Comment in: BMJ 1995 Nov 25;311(7017):1435–6. Comment in: BMJ 1995 Nov 25;311(7017):1436.

Treatment of acute anaphylaxis. Letters contained errors of logic [letter; comment] Fisher M. **BMJ** 1996 Mar 9; 312(7031):637–8. Comment on: BMJ 1995 Nov 25;311(7017):1434.

Treatment of acute anaphylaxis. Surviving the journey is a good prognostic indicator [letter; comment] Luke LC. **BMJ** 1995 Nov 25;311(7017):1434. Comment on: BMJ 1995 Sep 16;311(7007):731–3.

Treatment of acute anaphylaxis. Remove the patient from contact with the allergen [letter; comment] Scadding GK. **BMJ** 1995 Nov 25;311(7017):1434. Comment on: BMJ 1995 Sep 16;311(7007):731–3.

National Advisory Committee on Immunization (NACI). Anaphylaxis: statement on initial management in non-hospital settings. **Can Commun Dis Rep** 1995 Nov 30; 21(22):200–3 **(Eng, Fre)**

Anaphylactic shock [letter; comment] McHugh D. **J Accid Emerg Med** 1996 Mar;13(2):150. Comment on: J Accid Emerg Med 1995 Jun;12(2):89–100.

Sting challenges [letter; comment] Coleman M. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):705. Comment on: J Allergy Clin Immunol 1994 Aug;94(2 Pt 1):137–8.

Treatment of adverse reactions to radiographic contrast media in adults. Cohan RH, et al. **Radiol Clin North Am** 1996 Sep;34(5):1055–76 (105 ref.)

[Efficacy of the artificial ventilation for the treatment of IgE-mediated anaphylactic shock in dog] Takeuchi H, et al. **Masui** 1995 Nov;44(11):1513–9 (Eng. Abstr.) **(Jpn)**

URINE

Cysteinyl leukotriene production in anaphylactic reactions. Denzlinger C, et al. **Int Arch Allergy Immunol** 1995 Oct; 108(2):158–64

VETERINARY

[Anaphylaxis in cattle (news)] Kamphuis A. **Tijdschr Diergeneeskd** 1996 May 1;121(9):267 **(Dut)**

ANAPHYLAXIS, PASSIVE CUTANEOUS see **PASSIVE CUTANEOUS ANAPHYLAXIS**

ANAPLASMA

GROWTH & DEVELOPMENT

Strategies to interrupt the development of Anaplasma marginale in its tick vector. The effect of bovine-derived antibodies. Kocan KM, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:157–65 (57 ref.)

Establishment of the tick (Acari:Ixodidae)-borne cattle pathogen Anaplasma marginale (Rickettsiales:Anaplasmataceae) in tick cell culture. Munderloh UG, et al. **J Med Entomol** 1996 Jul;33(4):656–64

IMMUNOLOGY

Preliminary studies on the effect of Anaplasma marginale antibodies ingested by Dermacentor andersoni ticks (Acari:Ixodidae) with their blood meal on infections in salivary glands. Kocan KM, et al. **Exp Appl Acarol** 1996 Jun;20(6):297–311

Expression of major surface protein 2 antigenic variants during acute Anaplasma marginale rickettsemia. Eid G, et al. **Infect Immun** 1996 Mar;64(3):836–41

Evaluation of Anaplasma marginale major surface protein 3 (MSP3) as a diagnostic test antigen. Alleman AR, et al. **J Clin Microbiol** 1996 Feb;34(2):270–76

ISOLATION & PURIFICATION

Detection of Anaplasma marginale DNA in bovine erythrocytes by slot-blot and in situ hybridization with a PCR-mediated digoxigenin-labeled DNA probe. Ge NL, et al. **J Vet Diagn Invest** 1995 Oct;7(4):465–72

PHYSIOLOGY

Morphology and development of Anaplasma marginale in midgut of engorged female ticks of Boophilus microplus. Ribeiro MF, et al. **Vet Parasitol** 1996 Jan;61(1–2):31–9

ANAPLASMATACEAE INFECTIONS

VETERINARY

Haemobartonella canis infection following splenectomy and transfusion. Lester SJ, et al. **Can Vet J** 1995 Jul;36(7):444–5

ANAPLASMOSIS

DIAGNOSIS

Comparative sensitivity of two tests for the diagnosis of multiple hemoparasite infection of cattle. Figueroa JV, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:117–27

Evaluation of Anaplasma marginale major surface protein 3 (MSP3) as a diagnostic test antigen. Alleman AR, et al. **J Clin Microbiol** 1996 Feb;34(2):270–76

Detection of Anaplasma marginale DNA in bovine erythrocytes by slot-blot and in situ hybridization with a PCR-mediated digoxigenin-labeled DNA probe. Ge NL, et al. **J Vet Diagn Invest** 1995 Oct;7(4):465–72

Improving the specificity of indirect immunofluorescence for the serological diagnosis of bovine anaplasmosis. Lawrence JA, et al. **Onderstepoort J Vet Res** 1996 Mar;63(1):53–5

EPIDEMIOLOGY

An assessment of the role of white-tailed deer in the epizootiology of anaplasmosis in the southeastern United States. Keel MK, et al. **J Wildl Dis** 1995 Jul;31(3):378–85

[High serological prevalence of bovine anaplasmosis in North-Cameroon] Chollet JY. **Rev Elev Med Vet Pays Trop** 1995;48(1):17–8 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Expression of major surface protein 2 antigenic variants during acute Anaplasma marginale rickettsemia. Eid G, et al. **Infect Immun** 1996 Mar;64(3):836–41

Susceptibility of elk (Cervus elaphus) to experimental infection with Anaplasma marginale and A. ovis. Zaugg JL, et al. **J Wildl Dis** 1996 Jan;32(1):62–6

Field observations on the duration of immunity in cattle after vaccination against Anaplasma and Babesia species. Tjornehoj K, et al. **Onderstepoort J Vet Res** 1996 Mar; 63(1):1–5

PREVENTION & CONTROL

Enrofloxacin to control Anaplasma marginale infections. Guglielmone AA, et al. **Ann N Y Acad Sci** 1996 Jul 23; 791:471–2

Strategies to interrupt the development of Anaplasma marginale in its tick vector. The effect of bovine-derived antibodies. Kocan KM, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:157–65 (57 ref.)

ANASTOMOSIS, ROUX-EN-Y

Randomized trial of fibrin glue to seal mechanical oesophagojejunal anastomosis. Fernandez Fernandez L, et al. **Br J Surg** 1996 Jan;83(1):40–1

Comparing reconstruction with Roux-en-Y to a pouch following total gastrectomy. Bozzetti F, et al. **J Am Coll Surg** 1996 Sep;183(3):243–8

Laparoscopic conversion of polya gastrectomy to Roux-en-Y. Macpherson SC, et al. **J Laparoendosc Surg** 1996 Apr;6(2):127–9

ADVERSE EFFECTS

Jaundice due to afferent loop obstruction following hepatectomy for a hilar cholangiocarcinoma. Moriura S, et al. **Abdom Imaging** 1996 May–Jun;21(3):226–7

The intussusception antireflux valve is ineffective in preventing cholangitis in biliary atresia. Sartorelli KH, et al. **J Pediatr Surg** 1996 Mar;31(3):403–6

Sump syndrome complicating Roux-en-Y hepaticojejunostomy: case report and review of the literature. Morrissey PE, et al. **Surgery** 1996 Apr; 119(4):403–5

Bile duct carcinoma arising from the anastomotic site of hepaticojejunostomy after the excision of congenital biliary dilatation: a case report. Yamamoto J, et al. **Surgery** 1996 Apr;119(4):476–9 (10 ref.)

[Functional gastric stasis: specific complications after Roux operation] Tyvonchuk AS. **Klin Khir** 1995;(5):46–9 **(Rus)**

METHODS

Elimination of the Roux stasis syndrome using a new type of "uncut Roux" limb. Tu BN, et al. **Am J Surg** 1995 Oct; 170(4):381–6

The intussusception antireflux valve is ineffective in preventing cholangitis in biliary atresia. Sartorelli KH, et al. **J Pediatr Surg** 1996 Mar;31(3):403–6

Laparoscopic treatment of biliary and gastric outlet obstruction. Schöb OM, et al. **Surg Laparosc Endosc** 1995 Aug;5(4):288–95

Reconstruction of the food passage after total gastrectomy: randomized trial. Fuchs KH, et al. **World J Surg** 1995 Sep–Oct;19(5):698–705; discussion 705–6

ANASTOMOSIS, SURGICAL

Association between perioperative blood transfusion and dehiscence of anastomosis after rectal resection for cancer. Chiarugi M, et al. **Acta Chir Belg** 1996 Jun;96(3):108–11

Dilation of strictures after esophageal resection and reconstruction. Tóta J, et al. **Acta Chir Hung** 1995–96; 35(1–2):137–47

Frequent TIA in the territory fed by the anastomosed STA after combined therapeutic ICA occlusion and extracranial-intracranial bypass: case report. Takeuchi S, et al. **Acta Neurochir (Wien)** 1995;133(3–4):206–10

Is routine drainage of pelvic anastomosis necessary? Scott H, et al. **Am Surg** 1996 Jun;62(6):452–7

Blalock-Taussig operation with an assist of venovenous extracorporeal membrane oxygenation. Miyamura H, et al. **Ann Thorac Surg** 1996 Aug;62(2):565–6

Revascularization of the ischemic gastric tube using the left internal thoracic artery. Petsikas D, et al. **Ann Thorac Surg** 1996 Aug;62(2):568–70

End-to-end anastomosis at the duodenojejunal flexure: is it safe? Singh G, et al. **Aust N Z J Surg** 1995 Dec;65(12):884–6

Cross-face facial nerve anastomosis: historical notes. Scaramella LF. **Ear Nose Throat J** 1996 Jun;75(6):343, 347–52, 354 (11 ref.)

Effect of colectomy with ileo-anal anastomosis on the biliary lipids. Galatola G, et al. **Eur J Clin Invest** 1995 Jul; 25(7):534–8

Anastomotic breaking strength and healing of anastomoses in rat intestine with and without chronic radiation damage. Jahnson S, et al. **Eur J Surg** 1995 Jun;161(6):425–30

Compliance mismatch and formation of distal anastomotic intimal hyperplasia in externally stiffened and lumen-adapted venous grafts. Trubel W, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):415–23

Anastomotic tissue oxygen tension during esophagectomy in patients with esophageal carcinoma. Jacobi CA, et al. **Eur Surg Res** 1996;28(1):26–31

Intestinal anastomosis healing in rat: collagen concentration and histochemical characterization by Picrosirius red staining and polarizing microscopy. Rabau MY, et al. **Exp Mol Pathol** 1995 Jun;62(3):160–5

Laparoscopic rescue after tubal anastomosis failure. Lee CL, et al. **Hum Reprod** 1995 Jul;10(7):1806–9

Morphological changes in the myenteric plexus of rat ileum after transection and end-to-end anastomosis. Karaosmanoğlu T, et al. **J Anat** 1996 Apr;188 (Pt 2):323–31

Effects of deoxyspergualin on bronchial anastomosis healing in canine pulmonary allografts [letter] Kawahara K, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):799–800

Intestinal neuronal dysplasia as a cause of surgical failure in Hirschsprung's disease: a new modality for surgical management. Banani SA, et al. **J Pediatr Surg** 1996 Apr; 31(4):572–4

Long-term effects of gastric transposition in children: a physiological study. Davenport M, et al. **J Pediatr Surg**

1996 Apr;31(4):588–93

Restorative proctocolectomy for ulcerative colitis in children—is the J-pouch better than straight pull-through? Rintala RJ, et al. **J Pediatr Surg** 1996 Apr;31(4):530–3

Do superoxide radicals in blood indicate anastomotic patency after microvascular tissue reperfusion? Yokoyama K, et al. **J Reconstr Microsurg** 1995 Nov;11(6):467–71

Fibrin glue and conventional sutured vasal anastomosis in the rat. Küçükaydin M, et al. **J Surg Res** 1995 Nov; 59(5):601–5

A randomized prospective clinical trial of the Taylor patch [letter] Wright JG. **J Vasc Surg** 1996 Feb;23(2):376–7

Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis [see comments] Vasen HF, et al. **Lancet** 1996 Aug 17;348(9025):433–5. Comment in: Lancet 1996 Aug 17;348(9025):422.

Superior nerve anastomosis using a low-output CO2 laser on fibrin membrane. Ochi M, et al. **Lasers Surg Med** 1995; 17(1):64–73

Prostacyclin production at the human microvascular anastomosis: its effect on initial platelet deposition. Restifo RJ, et al. **Plast Reconstr Surg** 1996 Apr;97(4):784–91

A3–A3 side-to-side anastomosis in the anterior communicating artery aneurysm surgery: report of four cases. Mabuchi S, et al. **Surg Neurol** 1995 Aug;44(2):122–7

The effect of pancreatopeptidase E (elastase) on anastomotic intimal thickness in two types of vascular prosthesis. Akimoto F. **Surg Today** 1995;25(12):1027–33

Synchronous double cancers of the remnant stomach and pancreas: report of a case. Miyaguni T, et al. **Surg Today** 1995;25(12):1038–42

Ileal pouch–anal anastomosis as the first choice operation in patients with familial adenomatous polyposis: a ten-year experience. Kartheuser AH, et al. **Surgery** 1996 Jun; 119(6):615–23

Functional perineal colostomy with pudendal nerve anastomosis following anorectal resection: an experimental study. Sato T, et al. **Surgery** 1996 Jun;119(6):641–51

Manual versus mechanical esophagogastric anastomosis after resection for carcinoma: a controlled trial. French Associations for Surgical Research. Valverde A, et al. **Surgery** 1996 Sep;120(3):476–83

Infraperitoneal colorectal anastomosis: hand-sewn versus circular staples [letter; comment] Weissberg D. **Surgery** 1995 Nov;118(5):914. Comment on: Surgery 1994 Sep;116(3):484–90.

Preservation of renal perfusion and postoperative renal function by side-to-side cavo-caval anastomosis in liver transplant recipients. Durand F, et al. **Transpl Int** 1995; 8(5):407–10

Outcome of 49 repairs of bile duct injuries after laparoscopic cholecystectomy. Schol FP, et al. **World J Surg** 1995 Sep–Oct;19(5):753–6; discussion 756–7

[A local course on conventional and laparoscopic surgical techniques. A supplement to surgical education] Bardram L, et al. **Ugeskr Laeger** 1995 Oct 16;157(42):5845–8 (Eng. Abstr.) **(Dan)**

[Endo- and exo-bronchial schwannoma treated by resection-anastomosis of the left bronchial stump] Michel JL, et al. **Rev Mal Respir** 1995;12(6):628–30 (Eng. Abstr.) **(Fre)**

[Delayed stenosis after esophageal reconstruction with colon interposition 35 years ago] Bohndorf M. **Laryngorhinootologie** 1995 Dec;74(12):768–71 (Eng. Abstr.) **(Ger)**

[Anastomotic pseudoaneurysm, true para-anastomotic aneurysm and recurrent aneurysm following surgery for abdominal aortic aneurysm. Is a unifying theory possible?] De Monti M, et al. **Minerva Cardioangiol** 1995 Sep; 43(9):367–73 (Eng. Abstr.) **(Ita)**

[Patency restoration of the obliterated larynx] Ziętek E, et al. **Otolaryngol Pol** 1995;49(3):201–5 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Operative injury to the hepatic artery. Consequences of a biliary-enteric anastomosis and principles for rational management [see comments] Majno PE, et al. **Arch Surg** 1996 Feb;131(2):211–5. Comment in: Arch Surg 1996 Jul;131(7):788.

Lightweight suction drainage-feeding system for oesophagogastric anastomotic leaks. Cameron DC, et al. **Australas Radiol** 1995 Aug;39(3):314–9

Bladder-to-duodenal stump reflux simulating a urinoma in a patient with renal and pancreaticoduodenal transplantation. Kim CK, et al. **Clin Nucl Med** 1996 May; 21(5):402–4

Endovascular exclusion of juxtarenal anastomotic pseudoaneurysm. Lindblad B, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):116–8

Long-term complications in cases of isolated esophageal atresia treated with esophageal anastomosis. Lindahl H, et al. **J Pediatr Surg** 1995 Aug;30(8):1222–3

Unusual complication seven years after successful aortic recoarctation repair with a Dacron graft: acute thromboembolic leg ischemia caused by a mobile thrombus at the distal suture line. Berzins R, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):842–4

Pancreatojejunal sutural insufficiency occurring after pancreatoduodenectomy and countermeasures. Kinoshita H, et al. **Kurume Med J** 1995;42(4):221–9

Unilateral pulmonary oedema after the modified B-T shunt [letter] Nakayama H, et al. **Paediatr Anaesth** 1995; 5(5):341–2

[Aneurysm developed at the level of a femoropopliteal bypass with ex-situ venous graft 10 years later (letter)] Desoutter P, et al. **Presse Med** 1996 Jun 22;25(22):1039 **(Fre)**

CONTRAINDICATIONS

Pulmonary artery banding is not contraindicated in double inlet left ventricle with transposition and aortic arch obstruction. Webber SA, et al. **Eur J Cardiothorac Surg** 1995;9(9):515–20

INSTRUMENTATION

Is it worth using mechanical sutures in gastric surgery? Valdivieso A, et al. **Acta Chir Belg** 1995;95(4 Suppl):179–81

Clinical experience with a microvascular anastomotic device in head and neck reconstruction. DeLacure MD, et al. **Am J Surg** 1995 Nov;170(5):521–3

Microsurgical reconstruction of the lower extremity using the 3M microvascular coupling device in venous anastomoses. Denk MJ, et al. **Ann Plast Surg** 1995 Dec; 35(6):601–6

Use of a mechanical microvascular anastomotic device in head and neck free tissue transfer. Shindo ML, et al. **Arch Otolaryngol Head Neck Surg** 1996 May;122(5):529–32

New anastomotic gun for biofragmentable anastomotic ring in low anterior resection. Chen TC, et al. **Dis Colon Rectum** 1995 Nov;38(11):1214–6

Ligation device assisting low anterior anastomosis. Gingold BS, et al. **Dis Colon Rectum** 1995 Dec;38(12):1322–4

Rehbein's anterior resection in Hirschsprung's disease, using a circular stapler. Wester T, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):358–62

Aortic spoon-jaw clamp for aorto-saphenous vein anastomosis. Robicsek F. **J Card Surg** 1995 Sep;10(5):583–5

Experimental evaluation and clinical use in the head and neck of a 3M/Precise microvascular anastomotic device. Borja-Morant A, et al. **J Craniomaxillofac Surg** 1995 Oct; 23(5):305–11

A fixed anastomotic coupling device. Oguchi H, et al. **J Reconstr Microsurg** 1995 Jul;11(4):281–2

A new guiding device for safer introduction of the blunt-ended stapler from the anus in low anterior anastomosis. Sadahiro S, et al. **J Surg Oncol** 1996 Aug; 62(4):298–9

Laser welding with albumin-based solder: experimental full-tubed skin graft urethroplasty. Kirsch AJ, et al. **Lasers Surg Med** 1996;18(3):225–30

Limited thrombogenicity of low temperature, laser-welded vascular anastomoses. Self SB, et al. **Lasers Surg Med** 1996; 18(3):241–7

Anastomotic vortex generator. Shanebrook JR, et al. **Med Biol Eng Comput** 1996 May;34(3):262–5

A simple atraumatic technique to hold tendon stumps during flexor or extensor tendon tenorrhaphy. Lanzetta M, et al. **Plast Reconstr Surg** 1996 May;97(6):1253

A novel paper cuff for vascular reconstruction in canine liver transplantation. Fukumoto T, et al. **Surg Today** 1996; 26(4):295–7

Esophageal transection using a biofragmentable anastomosis ring in dogs. Han SL, et al. **Surg Today** 1995;25(9):802–5

Sutureless anastomosis using a biofragmentable anastomosis ring. Konishi F, et al. **Surg Today** 1995;25(9):783–9

Video-assisted endoscopic esophagectomy with stapled intrathoracic esophagogastric anastomosis. Liu HP, et al. **World J Surg** 1995 Sep–Oct;19(5):745–7

METHODS

Hypoglosso-facial nerve anastomosis. Linnet J, et al. **Acta Neurochir (Wien)** 1995;133(3–4):112–5

Dorsocranial liver resection and direct hepatoatrial anastomosis for hepatic venous outflow obstruction: long-term outcome and functional results. Vogt PR, et al. **Am J Gastroenterol** 1996 Mar;91(3):539–44

Cancer of the oesophagus and gastric cardia. Standard oesophagectomy and anastomotic technique. Fok M, et al. **Ann Chir Gynaecol** 1995;84(2):179–83

Acute adverse effects of blunt adventitial stripping. Lohman R, et al. **Ann Plast Surg** 1995 Jul;35(1):60–5

Manually constructed and stapled anastomoses [letter; comment] Woodman KS. **Ann Surg** 1996 Apr;223(4):449–50 . Comment on: Ann Surg 1995 Feb;221(2):176–84.

Sequential distal anastomosis in aortofemoral bypass. Gewertz BL, et al. **Ann Vasc Surg** 1995 Nov;9(6):583–4

Suprahyoid and inferior constrictor release for laryngeal lowering. Zitsch RP 3rd, et al. **Arch Otolaryngol Head Neck Surg** 1995 Nov; 121(11):1310–3

Flow study of surgical coronary artery fistula as an alternative to sequential bypass. Nishida H, et al. **Cardiovasc Surg** 1995 Aug;3(4):375–80

Laparoscopic very low anterior resection and coloanal anastomosis using the pull-through technique. Ramos JR. **Dis Colon Rectum** 1995 Nov;38(11):1217–9

Posterior sagittal anorectoplasty: functional results of primary and secondary operations in comparison to the pull-through method in anorectal malformations. Mulder W, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):170–3

Nerve coaptation studies with and without a gap in rabbits. Hasegawa J, et al. **J Hand Surg [Am]** 1996 Mar;21(2):259–65

Long-term results of vein grafts interposed in arterial defects using the telescoping anastomotic technique and fibrin glue. Saitoh S, et al. **J Hand Surg [Br]** 1996 Feb;21(1):47–52

Techniques for bronchial anastomosis. Anderson MB, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 1):1090–4

Reverse telescope anastomotic technique reduces the incidence of bronchial stricture. Rabinov M, et al. **J Heart Lung Transplant** 1996 Mar;15(3):243–8

Sutureless cholecystojejunostomy in pigs using an absorbable intraluminal stent and fibrin glue. Detweiler MB, et al. **J Invest Surg** 1996 Jan–Feb;9(1):13–26

Gastrointestinal sutureless anastomosis using fibrin glue: reinforcement of the sliding absorbable intraluminal nontoxic stent and development of a stent placement device. Detweiler MB, et al. **J Invest Surg** 1996 Mar–Apr; 9(2):111–30

Donor vascular grafts for arterial reconstruction in pediatric liver transplantation. López Santamaria M, et al. **J Pediatr Surg** 1996 Apr;31(4):600–3

Mucosal proctectomy and colo-anal anastomosis as treatment of rectal atresia. Vaneerdeweg W, et al. **J Pediatr Surg** 1995 Dec;30(12):1722–3

Skin paddle salvage in the fibula osteocutaneous free flap with secondary skin paddle vascular anastomosis. Weber RA, et al. **J Reconstr Microsurg** 1995 Jul;11(4):239–41; discussion 242–4

Different types of sleeve anastomosis. Zhang L, et al. **J Reconstr Microsurg** 1995 Nov;11(6):461–5

Influence of suture technique and suture material selection on the mechanics of end-to-end and end-to-side anastomoses. Baumgartner N, et al. **J Thorac Cardiovasc Surg** 1996 May;111(5):1063–72

Benign anastomotic strictures after transhiatal esophagectomy and cervical esophagogastrostomy: risk factors and management. Honkoop P, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1141–6; discussion 1147–8

Conversion of modified Fontan procedure to lateral atrial tunnel cavopulmonary anastomosis. Kreutzer J, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1169–76

New use of Foley catheter for precise vesicourethral anastomosis during radical retropubic prostatectomy. Petroski RA, et al. **J Urol** 1996 Apr;155(4):1376–7

Comparison of the telescoping anastomotic technique with the end-to-end technique utilizing vein grafts for venous defects: short- and long-term results. Saitoh S, et al. **Microsurgery** 1995;16(9):631–8

Reconstruction of the spinal accessory nerve with an anastomosis to the dorsal C3 branch: technical note. Braun V, et al. **Neurosurgery** 1996 Jan;38(1):208–10

Bypass coaptation procedures for cervical nerve root avulsion. Yamada S, et al. **Neurosurgery** 1996 Jun; 38(6):1145–51; discussion 1151–2

Microvascular anastomoses. A comparative study of fibrinogen adhesive and interrupted suture techniques. Bowen CV, et al. **Plast Reconstr Surg** 1996 Apr; 97(4):792–800

An easy maneuver to improve exposure in difficult end-to-side anastomoses [letter] Cavadas PC. **Plast Reconstr Surg** 1996 Jul;98(1):187

The 3M precise microvascular anastomotic system for implanting PTFE microvenous prostheses into the rat femoral vein. Oguchi H, et al. **Plast Reconstr Surg** 1996 Mar;97(3):662–5

Laparoscopic and minilaparotomy proximal gastrectomy and esophagogastrostomy: technique and case report. Uyama I, et al. **Surg Laparosc Endosc** 1995 Dec;5(6):487–91

Lymphatic vessel-to-isolated-vein anastomosis for secondary lymphedema in a canine model. Kinjo O, et al. **Surg Today** 1995;25(7):633–9

The use of cyanoacrylate tissue adhesive in high-risk intestinal anastomoses. Tebala GD, et al. **Surg Today** 1995; 25(12):1069–72

Anastomotic artery stenosis in living related kidney transplantation: the impact of anastomotic technique. Ersöz S, et al. **Transplant Proc** 1996 Aug;28(4):2331–2

Avoidance of atrioventricular valve incompetence following orthotopic heart transplantation using direct bicaval anastomosis. Forni A, et al. **Transplant Proc** 1995 Dec; 27(6):3478–82

Reduced incidence of cardiac arrhythmias after orthotopic heart transplantation with direct bicaval anastomosis. Forni A, et al. **Transplant Proc** 1996 Feb;28(1):289–92

Four-quadrant running-suture arterial anastomosis technique in renal transplantation: a preliminary report. Haberal M, et al. **Transplant Proc** 1996 Aug;28(4):2334–5

Cholecystocholedochostomy for biliary tract anastomosis in hamster-to-rat liver xenotransplantation. Ohdan H, et al. **Transplant Proc** 1996 Jun;28(3):1420–1

The ileopsoas tunnel, a new antireflux technique for ureteroileal reimplantation: an experimental study in dogs. Kato H, et al. **Urol Res** 1996;24(2):113–7; discussion 117–8

[Segmental bile duct bypass in obstruction of the liver hilus: only an alternative?] Maurer CA, et al. **Chirurg** 1995 Aug; 66(8):794–9 (Eng. Abstr.) **(Ger)**

[Esophago-jejunal anastomosis after total gastrectomy with circular suturing: using a personal method] Ceraudo E, et al. **Minerva Chir** 1995 Dec;50(12):1115–7 (Eng. Abstr.) **(Ita)**

VETERINARY

Jejunal intussusception: a complication of functional end-to-end stapled anastomoses in two ponies. Frankeny RL, et al. **Vet Surg** 1995 Nov-Dec;24(6):515–7

ANATOMIC MODELS see MODELS, ANATOMIC

ANATOMY

see related
DISSECTION

The 10th European Anatomical Congress, with the participation of the American Association of Anatomists. Florence, September 17–21, 1995. Abstracts. **Acta Anat (Basel)** 1995;152(4):237–366

Reducing the levels of formaldehyde exposure in gross anatomy laboratories. Coleman R. **Anat Rec** 1995 Dec; 243(4):531–3

Monitoring surface shape variations on the human body. Pilgrim LJ. **Australas Phys Eng Sci Med** 1996 Mar; 19(1):17–25

100th Meetings of the Japanese Association of Anatomists. **Kaibogaku Zasshi** 1995 Nov;70 Suppl:S1–219 **(Eng, Jpn)**

Hazard to pathologists and anatomists from vena-caval (Greenfield) filters [letter] Abraham JL, et al. **Lancet** 1995 Oct 21;346(8982):1100

A new representation of knowledge concerning human anatomy and function. Höhne KH, et al. **Nat Med** 1995 Jun;1(6):506–11 (33 ref.)

Enhancements of anatomical information in UMLS knowledge sources. Rosse C, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:873–7

[Report on computer demonstration in Human-Body Plastination Exhibit] Mjasuda Y, et al. **Kaibogaku Zasshi** 1995 Oct;70(5):478–81 **(Jpn)**

[Histochemistry of the organs—application of histochemistry to anatomy] Nagata T. **Kaibogaku Zasshi** 1995 Oct; 70(5):448–71 (175 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical and surgical importance of anatomosurgical segments and subsegments of the organs of the human body] DiDio LJ, et al. **Rev Assoc Med Bras** 1995 May-Jun; 41(3):167–77 (Eng. Abstr.) **(Por)**

EDUCATION

Directed case study method for teaching human anatomy and physiology. Cliff WH, et al. **Am J Physiol** 1996 Jun; 270(6 Pt 3):S19–28

Understanding physiology by acting out concepts. Yucha CB. **Am J Physiol** 1995 Dec;269(6 Pt 3):S50–4

Uncommon valor is a common virtue. Skandalakis JE. **Am Surg** 1996 Jun;62(6):512–3

The efficacy of a computer-assisted preoperative tutorial for clinical clerks. Hong D, et al. **Can J Surg** 1996 Jun; 39(3):221–4

A clinical anatomy curriculum for the medical student of the 21st century: gross anatomy. **Clin Anat** 1996;9(2):71–99

Reaffirming the importance of dissection [editorial] Amadio PC. **Clin Anat** 1996;9(2):136–7

Basic surgical training. 4: American and British scenes compared. Ger R. **Clin Anat** 1996;9(3):173–4 (2 ref.)

The future of gross anatomy teaching. Malamed S, et al. **Clin Anat** 1995;8(4):294–6 (13 ref.)

Basic surgical training. 3: A view from Ireland. Monkhouse S. **Clin Anat** 1996;9(3):171–2 (0 ref.)

Preclinical student reactions to dissection, death, and dying. Nnodim JO. **Clin Anat** 1996;9(3):175–82

Basic surgical training. 1: Postgraduate surgical examinations in the UK and Ireland. Raftery AT. **Clin Anat** 1996; 9(3):163–6 (1 ref.)

What future for dissection in courses of human topographical anatomy in universities in the UK? Utting M, et al. **Clin Anat** 1995;8(6):414–7

Basic surgical training. 2: Interactions with the undergraduate medical curriculum. Willan P. **Clin Anat** 1996;9(3):167–70 (1 ref.)

Teaching of anatomy: a job for a biologist or a surgeon? [letter] Andrea VD, et al. **Eur J Surg** 1996 Apr;162(4):350

Clinical detachment [letter] Taxy JB. **Hum Pathol** 1996 Mar; 27(3):313–5

Cytogenetic evaluation of medical students exposed to formaldehyde vapor in the gross anatomy dissection laboratory. Vasudeva N, et al. **J Am Coll Health** 1996 Jan; 44(4):177–9

Teaching of human anatomy: a role for computer animation. Habbal OA, et al. **J Audiov Media Med** 1995 Jun; 18(2):69–73

Teaching human anatomy to medical students. **Med Health R I** 1996 Jan;79(1):10–34

Evolutionary morphology at Brown: what's it all about? Goslow GE Jr. **Med Health R I** 1996 Jan;79(1):4–7

Anatomy and more. Newman LF. **Med Health R I** 1996 Jan; 79(1):7

The interactive image tool: adding structure to images. Constantinou P, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:508–11

General medical practice as a guideline for preclinical anatomy teaching? The veins. Fasel JH. **Surg Radiol Anat** 1996;18(2):143–6

Plastination for gross anatomy teaching using low cost equipment. O'Sullivan E, et al. **Surg Radiol Anat** 1995; 17(3):277–81

Teaching applied anatomy to senior medical students with an emphasis on surgery and radiology. Teichgräber UK, et al. **Surg Radiol Anat** 1996;18(2):141–2

Anatomy lessons. Mahler S. **West J Med** 1995 Aug; 163(2):175–6

[Actual example of microanatomy education in Kyorin university medical school] Hirano H. **Kaibogaku Zasshi** 1995 Oct;70(5):472–7 **(Jpn)**

[Means for shaping professional interest during the study of human anatomy] Ioffe AIu, et al. **Morfologiia** 1995; 108(2):84–5 **(Rus)**

[The potentials and means for raising the cognitive activity of students in departments of anatomy] Kirichenko MN. **Morfologiia** 1994 Jul-Dec;107(7–12):174–8 **(Rus)**

[Experience with early specialization in the teaching of operative surgery and topographic anatomy] Konoplëv AA. **Morfologiia** 1995;108(2):86–7 **(Rus)**

HISTORY

One hundred years of anatomical terminology [editorial] O'Rahilly R. **Acta Anat (Basel)** 1995;154(2):167–8

János Szentágothai. (1912–1994). Székely G. **Acta Biol Hung** 1995;46(1):3–7

Rosenthal and the spiral canal of the modiolus. Moralee SJ. **Am J Otol** 1996 Jan;17(1):171

Frederic Wood Jones: it was a large nerve and not an artery. Christophers BE. **Aust N Z J Surg** 1996 Feb;66(2):110–7

The eponym of the supinator arch [letter] Fuss FK. **Surg Radiol Anat** 1996;18(2):158

[From the library of the Nederlands Tijdschrift voor Geneeskunde: the legacy of Frederik Ruysch (1638–1731)] Rigter RB. **Ned Tijdschr Geneeskd** 1995 Sep 30; 139(39):1989–95 **(Dut)**

[The thesis of Reininger (1722) in the history of pituitary sinuses] Terrier G, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(3):131–7 (Eng. Abstr.) **(Fre)**

METHODS

Biometrics, biomathematics and the morphometric synthesis. Bookstein FL. **Bull Math Biol** 1996 Mar;58(2):313–65

ANATOMY, ARTISTIC

Atlas of blood disease on the internet [letter] Ichihashi T, et al. **Blood** 1996 Jan 1;87(1):417–8

A new representation of knowledge concerning human anatomy and function. Höhne KH, et al. **Nat Med** 1995 Jun;1(6):506–11 (33 ref.)

Web-based access to an online atlas of anatomy: the digital anatomist Common Gateway Interface. Bradley SW, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:512–6

[New kinds of 3-dimensional atlases of the anatomy and function of the human body] Höhne KH, et al. **Z Arztl Fortbild (Jena)** 1995 Aug;89(4):430–5 (Eng. Abstr.) **(Ger)**

HISTORY

De formato foetu liber singulairs, aeneis figuris exornatus... Longo LD. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):292–3

John Evelyn's tables of veins and arteries: a rediscovered letter. Aspin RK. **Med Hist** 1995 Oct;39(4):493–9

Gaetano Giulio Zumbo. The founder of anatomic wax modeling. Puccetti ML, et al. **Pathol Annu** 1995;30 Pt 2:269–81

The proportion of the face in younger adults using the thumb rule of Leonardo da Vinci. Oguz O. **Surg Radiol Anat** 1996; 18(2):111–4

[From the library of the Nederlands Tijdschrift voor Geneeskunde: The anatomic atlases of Bernhard Siegfried Albinus] Luyendijk-Elshout AM. **Ned Tijdschr Geneeskd** 1995 Aug 26;139(34):1748–51 **(Dut)**

[The omentum presented by our ancestors...] Firmin F. **Ann Chir Plast Esthet** 1995 Apr;40(2):189–91 **(Fre)**

[Anatomic drawings by Leonardo da Vinci] Tillmann B. **Fortschr Kiefer Gesichtschir** 1995;40:5–11 **(Ger)**

METHODS

Painting anatomy on anatomy. Cody J. **J Biocommun** 1995; 22(2):14–7

ANATOMY, COMPARATIVE

Developmental genetics and traditional homology. Bolker JA, et al. **Bioessays** 1996 Jun;18(6):489–94

EDUCATION

Rotation of dissecting groups among different cadavers provides students of anatomy with increased opportunity to observe human variations. Champney TH, et al. **Clin Anat** 1995;8(6):412–3

HISTORY

Observations on Barclay's elephant. Kaufman MH. **J R Coll Surg Edinb** 1996 Apr;41(2):75–81

ANATOMY, REGIONAL

The impact of organ structure on radiation response. Marks LB. **Int J Radiat Oncol Biol Phys** 1996 Mar 15; 34(5):1165–71

ANATOMY, VETERINARY

[Photo-CD—a new medium in veterinary anatomy] Wenthe VM, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 May; 102(5):200–2 (Eng. Abstr.) **(Ger)**

ANATOXINS see TOXOIDS

ANCHORED PCR see POLYMERASE CHAIN REACTION

ANCHORIN CII see ANNEXIN V

ANCIENT HISTORY see HISTORY OF MEDICINE, ANCIENT

ANCIENT HISTORY (MEDICINE) see HISTORY OF MEDICINE, ANCIENT

ANCIENT HISTORY OF MEDICINE see HISTORY OF MEDICINE, ANCIENT

ANCIENT MEDICINE see HISTORY OF MEDICINE, ANCIENT

ANCILLARY INFORMATION SYSTEMS see INFORMATION SYSTEMS

ANCILLARY SERVICES, HOSPITAL

ECONOMICS

Evaluation of two interventions to reduce the ancillary costs of outpatient care for rheumatoid arthritis. Katz JN, et al. **Arthritis Rheum** 1996 Jan;39(1):177–8

UTILIZATION

Surgeon volume and hospital resource utilization. Arndt M, et al. **Inquiry** 1995–96 Winter;32(4):407–17

ANCITABINE

PHARMACOLOGY

In vitro antileukemic activity and chemical transformation of the 5'-chloro-5'-deoxy derivative of cyclocytidine. Stankovičová M, et al. **Neoplasma** 1995;42(5):255–8

[Anti-herpes simplex virus action of combined therapy with cyclocytidine and ganciclovir] Chen Z, et al. **Chung Hua Yen Ko Tsa Chih** 1996 Jan;32(1):25–8 (Eng. Abstr.) **(Chi)**

ANCROD

ADMINISTRATION & DOSAGE

Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein IIb/IIIa-receptor antagonist Ro 43-8857. Rübsamen K, et al. **Thromb Haemost** 1995 Nov; 74(5):1353–60

METABOLISM

The morphologic change of endothelial cells by ancrod-generated fibrin is triggered by alpha v beta 3 integrin binding and the subsequent activation of a G-protein coupled phospholipase C. Chang MC, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):115–21

Glycosylation of recombinant ancrod from Agkistrodon rhodostoma after expression in mouse epithelial cells. Geyer H, et al. **Eur J Biochem** 1996 Apr 1;237(1):113–27

THERAPEUTIC USE

Enoxaparin for unstable angina and ancrod for cardiac surgery following heparin allergy. Smith RE, et al. **Ann Pharmacother** 1996 May;30(5):476–80

Ancrod for coronary angioplasty. Pothoulakis AJ, et al. **Tex Heart Inst J** 1995;22(4):342–6

ANCYLOSTOMA

CLASSIFICATION

Differentiation between the human hookworms Ancylostoma duodenale and Necator americanus using PCR-RFLP. Hawdon JM. **J Parasitol** 1996 Aug;82(4):642–7

DRUG EFFECTS

In vitro studies on the relative sensitivity to ivermectin of Necator americanus and Ancylostoma ceylanicum. Richards JC, et al. **Int J Parasitol** 1995 Oct;25(10):1185–91

ENZYMOLOGY

Characterization and localization of cathepsin B proteinases expressed by adult Ancylostoma caninum hookworms. Harrop SA, et al. **Mol Biochem Parasitol** 1995 May; 71(2):163–71

Anticoagulant repertoire of the hookworm Ancylostoma caninum. Stassens P, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2149–54

ANCYLOSTOMA

GENETICS

Characterization and localization of cathepsin B proteinases expressed by adult Ancylostoma caninum hookworms. Harrop SA, et al. **Mol Biochem Parasitol** 1995 May; 71(2):163–71

GROWTH & DEVELOPMENT

Evidence for larval hypobiosis in Australian strains of Ancylostoma duodenale. Prociv P, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):379

IMMUNOLOGY

Immunoglobulin G subclass antibodies against excretory/secretory antigens of Ancylostoma caninum in human enteric infections. Loukas A, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):672–6

Immunochemical characterization of Ancylostoma caninum antigens. Schnieder T, et al. **Appl Parasitol** 1996 Jun; 37(2):146–52

ISOLATION & PURIFICATION

Ancylostoma genettae, A. protelesis, A. somaliense: three new species from wild Carnivora in the Somali Republic. Macchioni G. **Parassitologia** 1995 Dec;37(2–3):219–28 (26 ref.)

METABOLISM

Cloning and characterization of Ancylostoma-secreted protein. A novel protein associated with the transition to parasitism by infective hookworm larvae. Hawdon JM, et al. **J Biol Chem** 1996 Mar 22;271(12):6672–8

PATHOGENICITY

Wrong hookworm [letter; comment] Conn DB. **Science** 1996 May 24;272(5265):1086. Comment on: Science 1996 Mar 29;271(5257):1800–1.

ANCYLOSTOMA CANINUM see **ANCYLOSTOMA**

ANCYLOSTOMA DUODENALE see **ANCYLOSTOMA**

ANCYLOSTOMATOIDEA

Cryopreservation of sheathed third-stage larvae of Gaigeria pachyscelis (Sandveld hookworm). Titoy GA, et al. **Onderstepoort J Vet Res** 1995 Mar;62(1):63–4

An improved technique for the cryopreservation of Gaigeria pachyscelis (Sandveld hookworm). Titoy GA. **Onderstepoort J Vet Res** 1995 Sep;62(3):215

ISOLATION & PURIFICATION

Quantitative interpretation of coprocultures in a population infected with Oesophagostomum bifurcum. Krepel HP, et al. **Trop Geogr Med** 1995;47(4):157–9

ANCYLOSTOMIASIS

DIAGNOSIS

More intestinal worms on colonoscopy [letter] Dunzendorfer T, et al. **Am J Gastroenterol** 1996 Aug;91(8):1677–8

Differentiation between the human hookworms Ancylostoma duodenale and Necator americanus using PCR-RFLP. Hawdon JM. **J Parasitol** 1996 Aug;82(4):642–7

Abdominal pain, pan-gut eosinophilia, and dog hookworm infection [letter] Khoshoo V, et al. **J Pediatr Gastroenterol Nutr** 1995 Nov;21(4):481

[Subretinal manifestations as the chief findings in parasitic diseases in germany] Bialasiewicz AA, et al. **Ophthalmologe** 1995 Oct;92(5):737–40 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Persistent cutaneous larva migrans due to Ancylostoma species. Richey TK, et al. **South Med J** 1996 Jun; 89(6):609–11

EPIDEMIOLOGY

[Ancylostomiasis and strongyloidiasis: clinico-epidemiologic comparative study of travelers coming from endemic areas] Vilalta E, et al. **Med Clin (Barc)** 1995 Sep 16;105(8):292–4 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Immunoglobulin G subclass antibodies against excretory/secretory antigens of Ancylostoma caninum in human enteric infections. Loukas A, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):672–6

TRANSMISSION

Evidence for larval hypobiosis in Australian strains of Ancylostoma duodenale. Prociv P, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):379

VETERINARY

Efficacy of an ivermectin and pyrantel pamoate combination against adult hookworm, Ancylostoma braziliense, in dogs. Shoop WL, et al. **Aust Vet J** 1996 Mar;73(3):84–5

High prevalence of Ancylostoma spp. infection in dogs, associated with endemic focus of human cutaneous larva migrans, in Tacuarembo, Uruguay. Malgor R, et al. **Parasite** 1996 Jun;3(2):131–4

Ancylostoma genettae, A. protelesis, A. somaliense: three new species from wild Carnivora in the Somali Republic. Macchioni G. **Parassitologia** 1995 Dec;37(2–3):219–28 (26 ref.)

ANDERSEN'S DISEASE see **GLYCOGEN STORAGE DISEASE TYPE IV**

ANDERSON-FABRY DISEASE see **FABRY'S DISEASE**

ANDRESEN APPLIANCE see **ACTIVATOR APPLIANCES**

ANDROBLASTOMA

[Ovarian cancer and pregnancy] Ayoubi J, et al. **Rev Fr Gynecol Obstet** 1995 Jul–Sep;90(7–9):335–41 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Mixed tumor: mucinous papillary cystadenocarcinoma associated with arrhenoblastoma. Curea M, et al. **Rom J Morphol Embryol** 1995 Jul–Dec;41(3–4):129–31

ANDROGEN ANALOGS see **ANDROGENS, SYNTHETIC**

ANDROGEN ANTAGONISTS

ADMINISTRATION & DOSAGE

The abnormal development of male sex organs in the rat using a pure antiandrogen and a 5 alpha-reductase inhibitor during gestation. Hib J, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(1):27–33

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Small EJ, et al. **Cancer** 1995 Oct 15;76(8):1428–34

Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism. Dodin S, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):575–82

Patient compliance with crucial drug regimens: implications for prostate cancer. Urquhart J. **Eur Urol** 1996;29 Suppl 2:124–31 (62 ref.)

Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection. Portmann GA, et al. **J Pharm Biomed Anal** 1995 Aug; 13(9):1189–93

High-dose bicalutamide monotherapy for the treatment of prostate cancer. Blackledge GR. **Urology** 1996 Jan;47(1A Suppl):44–7; discussion 48–53

Low-dose cyproterone acetate plus mini-dose diethylstilbestrol—a protocol for reversible medical castration. Goldenberg SL, et al. **Urology** 1996 Jun; 47(6):882–4

A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. Narayan P, et al. **Urology** 1996 Apr;47(4):497–504

[Indications of antiandrogens in benign hyperplasia of the prostate (letter)] Benassayag E. **J Urol (Paris)** 1995; 101(2):109–10 **(Fre)**

[Ovarian suppression with Diane 35/50] Erdmann D, et al. **Geburtshilfe Frauenheilkd** 1994 Nov;54(11):627–33 (Eng. Abstr.) **(Ger)**

[Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization] Grunwald K, et al. **Geburtshilfe Frauenheilkd** 1994 Nov;54(11):634–45 (Eng. Abstr.) **(Ger)**

[Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer] Kotake T, et al. **Hinyokika Kiyo** 1996 Feb;42(2):143–53 (Eng. Abstr.) **(Jpn)**

[Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer] Kotake T, et al. **Hinyokika Kiyo** 1996 Feb;42(2):157–68 (Eng. Abstr.) **(Jpn)**

[Effects of androgen regulation system on bladder carcinogenesis in male mice] Imada S, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Nov;86(11):1666–72 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Response of bidimensionally measurable metastases to flutamide withdrawal in a patient with advanced prostate cancer. Warren GP, et al. **Indiana Med** 1996 May–Jun; 89(3):274–7

Flutamide-induced liver toxicity including fatal hepatic necrosis. Crownover RL, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):911–5

Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Rosenthal SA, et al. **Radiology** 1996 May; 199(2):451–5

[Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape] Barthélémy Y, et al. **Prog Urol** 1996 Feb;6(1):93–7 (Eng. Abstr.) **(Fre)**

[Hot flashes and hormonal treatment of prostate cancer] Lanfrey P, et al. **Prog Urol** 1996 Feb;6(1):17–22 (31 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Concentration of the endogenous antiandrogen epitestosterone and androgenic C19-steroids in hyperplastic prostatic tissue. Hill M, et al. **Prostate** 1996 Jun;28(6):347–51

BLOOD

Radioimmunological analysis of cyproterone acetate in human serum. Comparison with a gas chromatographic/mass spectrometric method and influence of each method on the outcome of a bioequivalence trial. Baumann A, et al. **Arzneimittelforschung** 1996 Apr; 46(4):412–8

CHEMICAL SYNTHESIS

Antiandrogen. III. 11-oxapregnane steroids. Takegawa S, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):746–8

CHEMISTRY

Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection. Portmann GA, et al. **J Pharm Biomed Anal** 1995 Aug; 13(9):1189–93

ECONOMICS

Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Bennett CL, et al. **Cancer** 1996 May 1;77(9):1854–61

METABOLISM

Cyproterone acetate is an integral part of hepatic DNA adducts induced by this steroidal drug. Topinka J, et al. **Carcinogenesis** 1996 Jan;17(1):167–9

Accumulation and persistence of DNA adducts of the synthetic steroid cyproterone acetate in rat liver. Werner S, et al. **Carcinogenesis** 1995 Oct;16(10):2369–72

Enantioselective metabolism and pharmacokinetics of Casodex in the male rat. McKillop D, et al. **Xenobiotica** 1995 Jun;25(6):623–33

PHARMACOKINETICS

Radioimmunological analysis of cyproterone acetate in human serum. Comparison with a gas chromatographic/mass spectrometric method and influence of each method on the outcome of a bioequivalence trial. Baumann A, et al. **Arzneimittelforschung** 1996 Apr; 46(4):412–8

Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen. Denis L, et al. **Urology** 1996 Jan;47(1A Suppl):26–8; discussion 29–32

PHARMACOLOGY

Therapeutic options in patients with hormone-refractory prostate cancer [letter; comment] Anand A. **Am J Med** 1996 Feb;100(2):243–4. Comment on: Am J Med 1995 Apr;98(4):412–4.

Aberrant hormone balance in fetal autoimmune NZB/W mice following prenatal exposure to testosterone excess or the androgen blocker flutamide. Keisler LW, et al. **Biol Reprod** 1995 Nov;53(5):1190–7

Cytochrome c oxidase in rat adrenal and liver: effects of anti-androgen treatment and studies in testicular feminized rats. el-Migdadi F, et al. **Endocr Res** 1996 Feb;22(1):59–75

Suppression of mouse spermatogenesis by a gonadotropin-releasing hormone antagonist and antiandrogen: failure to protect against radiation-induced gonadal damage. Kangasniemi M, et al. **Endocrinology** 1996 Mar;137(3):949–55

Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: implications for the actions of androgens and antiandrogens. Kuil CW, et al. **Endocrinology** 1996 May;137(5):1870–7

The antiandrogen cyproterone acetate induces synthesis of transforming growth factor beta 1 in the parenchymal cells of the liver accompanied by an enhanced sensitivity to undergo apoptosis and necrosis without inflammation. Oberhammer F, et al. **Hepatology** 1996 Feb;23(2):329–37

Sexual preference and feminine and masculine sexual behavior of male rats prenatally exposed to antiandrogen or antiestrogen. Vega Matuszczyk JV, et al. **Horm Behav** 1995 Jun;29(2):191–206

Hormonal protection from cyclophosphamide-induced inactivation of rat stem spermatogonia. Meistrich ML, et al. **J Androl** 1995 Jul–Aug;16(4):334–41

Effects of two non-steroidal antiandrogens on testicular function in prepubertal rats. Rulli SB, et al. **J Androl** 1995 May–Jun;16(3):225–32

Anti-androgen effects of the aromatase inhibitor, atamestane. Shao TC, et al. **J Androl** 1995 Mar–Apr;16(2):100–7

Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. Kuil CW, et al.

J Biol Chem 1995 Nov 17;270(46):27569-76

The effect of non-steroidal antiandrogen flutamide on luteinizing hormone pulsatile secretion in male-to-female transsexual subjects. Giusti M, et al.
J Endocrinol Invest 1995 Jun;18(6):420-6

Lack of feminization of the cremaster nucleus by prenatal flutamide administration in the rat and pig. Barthold JS, et al. **J Urol** 1996 Aug;156(2 Pt 2):767-71

Effects of an in ovo injection of an anti-androgen on embryonic and posthatching growth of broiler chicks. Burke WH. **Poult Sci** 1996 May;75(5):648-55

Gender differences in behaviour: activating effects of cross-sex hormones. Van Goozen SH, et al.
Psychoneuroendocrinology 1995;20(4):343-63

Flutamide-induced cryptorchidism in the rat is associated with altered gubernacular morphology. Cain MP, et al. **Urology** 1995 Oct;46(4):553-8

The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Furr BJ, et al. **Urology** 1996 Jan;47(1A Suppl):13-25; discussion 29-32

Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization. Kemppainen JA, et al. **Urology** 1996 Jul;48(1):157-63

[The effects of antiandrogen TZP-4238 on plasma testosterone and LH and steroidogenesis in rat and canine testis] Honma S, et al. **Nippon Naibunpi Gakkai Zasshi** 1995 Jul 20;71(5):679-94 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Intermittent androgen therapy. Abi Aad AS, et al.
Acta Urol Belg 1996 May;64(2):91-2

Complete hormonal blockage--antiandrogens. Bierkens AF, et al. **Acta Urol Belg** 1996 May;64(2):77-9

Controversies surrounding hormonal deprivation. Denis LJ.
Acta Urol Belg 1996 May;64(2):81-4

Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense? Schulman CC, et al.
Acta Urol Belg 1996 May;64(2):57-61 (32 ref.)

Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. Chen M, et al.
AJR Am J Roentgenol 1996 May;166(5):1157-63

Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Koivisto P, et al. **Am J Pathol** 1995 Dec;147(6):1608-14

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Vailancourt L, et al.
Am J Surg Pathol 1996 Jan;20(1):86-93

Maximal androgen blockade (MAB) for the treatment of prostate cancer [letter] Kirby RS. **Br J Clin Pract** 1996 Jul-Aug;50(5):287

Compliance with hormonal treatment for prostate cancer. Kaisary AV. **Br J Hosp Med** 1996 Mar 20-Apr 2; 55(6):359-66 (59 ref.)

Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results. Abbas F, et al. **Br J Urol** 1996 Mar;77(3):423-8

Anti-androgens in the treatment of prostate cancer. Newling DW. **Br J Urol** 1996 Jun;77(6):776-84 (51 ref.)

Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Bennett CL, et al. **Cancer** 1996 May 1;77(9):1854-61

Estimating the cost-effectiveness of flutamide in metastatic cancer. Hillner BE. **Cancer Treat Rev** 1996 Jan;22 Suppl A:103-8

Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a). Denti L, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1176-81

Prostate Cancer: Current Issues, New Approaches. Proceedings of an international congress. London, England, October 19-21, 1995. **Eur Urol** 1996;29 Suppl 2:1-135

Clinical progress with a new antiandrogen, Casodex (bicalutamide). Blackledge GR. **Eur Urol** 1996;29 Suppl 2:96-104 (15 ref.)

Combined androgen blockade. Crawford ED. **Eur Urol** 1996; 29 Suppl 2:54-61 (28 ref.)

Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument for. Debruyne FM. **Eur Urol** 1996;29 Suppl 2:34-6 (8 ref.)

Advances and trends in hormonal therapy for advanced prostate cancer. Debruyne FM, et al. **Eur Urol** 1995; 28(3):177-88 (98 ref.)

Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against. Fitzpatrick JM. **Eur Urol** 1996;29 Suppl 2:37-9 (7 ref.)

The development of Casodex (bicalutamide): preclinical studies. Furr BJ. **Eur Urol** 1996;29 Suppl 2:83-95 (53 ref.)

Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2). Jørgensen T, et al.
Eur Urol 1995;28(1):40-6

A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group. Kaisary AV, et al. **Eur Urol** 1995;28(3):215-22

Androgens, antiandrogens and androgen receptor abnormalities. Kuil CW, et al. **Eur Urol** 1996;29 Suppl 2:78-82 (30 ref.)

The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Robinson MR, et al. **Eur Urol** 1995;28(4):273-83

The role of induction androgen deprivation prior to radical prostatectomy. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:114-8 (27 ref.)

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:105-9

Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate. Voges GE, et al. **Eur Urol** 1995; 28(3):209-14

The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism. Müderris II, et al. **Fertil Steril** 1996 Aug;66(2):220-2

Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial. Grigoriou O, et al. **Gynecol Endocrinol** 1996 Apr; 10(2):119-23

Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. Pucci E, et al. **Gynecol Endocrinol** 1995 Sep;9(3):221-8

Antiandrogens for penile surgery [letter; comment] Paulson JE, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1058-9. Comment on: J Am Acad Dermatol 1995 Jan;32(1):1-21; quiz 22-4.

The future of antihormone therapy: innovations based on an established principle. Parczyk K, et al.
J Cancer Res Clin Oncol 1996;122(7):383-96 (82 ref.)

Maximal androgen blockade in combination with methotrexate for treatment of metastatic prostate cancer. Sagaster P, et al. **J Cancer Res Clin Oncol** 1996; 122(3):171-76

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate). Juul A, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):3059-67

Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. Chang A, et al. **J Clin Oncol** 1996 Aug; 14(8):2250-7

One hundred thirteen men with hormone-refractory prostate cancer died today [editorial; comment] Vogelzang NJ. **J Clin Oncol** 1996 Jun;14(6):1753-5. Comment on: J Clin Oncol 1996 Jun;14(6):1756-64.

Policing "perversions": Depo-Provera and John Money's new sexual order. Tsang DC. **J Homosex** 1995;28(3-4):397-426 (110 ref.)

Survey shows M.D.s' ambivalence about maximum androgen blockade [news] Randal J. **J Natl Cancer Inst** 1995 Dec 20;87(24):1827-9

Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Hackenberg R, et al.
J Steroid Biochem Mol Biol 1996 Jan;56(1-6 Spec No):113-7 (56 ref.)

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer [see comments] Gleave ME, et al. **J Urol** 1996 Jan; 155(1):213-9. Comment in: J Urol 1996 Jan;155(1):226-7.

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. Goldenberg SL, et al. **J Urol** 1996 Sep;156(3):873-7

Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy.
Kruithof-Dekker IG, et al. **J Urol** 1996 Sep;156(3):1194-7

RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment [letter; comment] Small EJ. **J Urol** 1996 May;155(5):1704-5. Comment on: J Urol 1995 Aug;154(2 Pt 1):448-53.

RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment [letter; comment] Walsh PC. **J Urol** 1996 May;155(5):1705. Comment on: J Urol 1995 Aug;154(2 Pt 1):448-53.

Haematogenous dissemination of prostate epithelial cells during surgery [letter; comment] Hamdy FC, et al.
Lancet 1996 Feb 3;347(8997):325. Comment on: Lancet 1995 Dec 9;346(8989):1528-30.

Anti-androgens in treatment of prostate cancer [letter; comment] Labrie F, et al. **Lancet** 1995 Oct 14; 346(8981):1030-1. Comment on: Lancet 1995 Jul 29;346(8970):265-9.

Anti-androgens in treatment of prostate cancer [letter; comment] Quartey P. **Lancet** 1995 Oct 14;346(8981):1031 . Comment on: Lancet 1995 Jul 29;346(8970):265-9.

Anti-androgens in treatment of prostate cancer [letter; comment] Waxman J, et al. **Lancet** 1995 Oct 14; 346(8981):1030. Comment on: Lancet 1995 Jul 29;346(8970):265-9.

The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate. Middleman MN, et al. **Pharmacotherapy** 1996 May-Jun; 16(3):376-81

Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice? Denis L. **Prostate** 1995 Nov;27(5):233-40 (43 ref.)

Effects of a new steroidal antiandrogen, TZP-4238 (17 alpha-acetoxy-6-chloro-2-oxa-4, 6-pregnadiene-3, 20-dione), on spontaneously developed canine benign prostatic hyperplasia. Takezawa Y, et al. **Prostate** 1995 Dec;27(6):321-8

Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Van der Kwast TH, et al. **Prostate** 1996 Apr;28(4):227-31

Current status of neoadjuvant therapy in localized prostate cancer. Witjes WP, et al. **Prostate** 1995 Dec;27(6):297-303 (69 ref.)

Histopathological effects of androgen deprivation in prostatic cancer. Civantos F, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):22-31

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Gleave ME, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):39-45; discussion 46-7 (26 ref.)

Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer. Roach M 3rd. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):32-7; discussion 38 (33 ref.)

Bicalutamide (Casodex): The Critical Issues 1996. Proceedings of a meeting. Boston, Massachusetts, July 6-9, 1995. **Urology** 1996 Jan;47(1A Suppl):1-96

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Bales GT, et al.
Urology 1996 Jan;47(1A Suppl):38-43; discussion 48-53

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Chodak G, et al. **Urology** 1995 Dec; 46(6):849-55

Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. Gomella LG, et al. **Urology** 1996 Jun;47(6):870-7

Worldwide activity and safety of bicalutamide: a summary review. Kolvenbag GJ, et al. **Urology** 1996 Jan;47(1A Suppl):70-9; discussion 80-4 (29 ref.)

Androgen deprivation and radiation therapy [letter; comment] McKenzie MR. **Urology** 1996 Feb;47(2):286. Comment on: Urology 1995 Apr;45(4):616-23.

Defining the role of antiandrogens in the treatment of prostate cancer. McLeod DG, et al. **Urology** 1996 Jan; 47(1A Suppl):85-9; discussion 90-6 (40 ref.)

Combined androgen blockade for the treatment of metastatic cancer of the prostate. Schellhammer PF. **Urology** 1996 May;47(5):622-8 (46 ref.)

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. Soloway MS, et al. **Urology** 1996 Jan;47(1A Suppl):33-7; discussion 48-53

[Hormonal treatments for disorders of sexual conduct] Cordier B, et al. **Bull Acad Natl Med** 1996 Mar; 180(3):599-605; discussion 605-10 (15 ref.) (Eng. Abstr.) **(Fre)**

[Indications of antiandrogens in benign hyperplasia of the prostate (letter)] Benassayag E. **J Urol (Paris)** 1995; 101(2):109-10 **(Fre)**

[Treatment of metastatic cancer of the prostate] Fournier G, et al. **Presse Med** 1995 Oct 28;24(32):1465-70 (10 ref.) (Eng. Abstr.) **(Fre)**

[Current drug therapy of benign prostatic hyperplasia] Schmidbauer CP, et al. **Wien Med Wochenschr** 1996; 146(8):161-4 (12 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacologic treatment for polycystic ovary syndrome] Maciejewska M. **Ginekol Pol** 1995 Oct;66(10):569-77 (Eng. Abstr.) **(Pol)**

[Clinical treatment results of treating androgenization symptoms in women with preparation Diane-35] Marianowski L, et al. **Wiad Lek** 1994 Oct;47(19-20):745-6 (Eng. Abstr.) **(Pol)**

[Permixon in the treatment of benign prostatic hyperplasia] Gorilovskiĭ LM. **Ter Arkh** 1995;67(8):62-4 **(Rus)**

[Cyproterone acetate (Androcur-depo) in the treatment of inoperable prostatic cancer] Stepanov VN, et al.
Urol Nefrol (Mosk) 1995 Nov-Dec;(6):33-6 (Eng. Abstr.) **(Rus)**

TOXICITY

Health effects of DDE [news] **Environ Health Perspect** 1995 Nov;103(11):990-1

Effects of cyproterone acetate in C57B1/10J mice. Tucker MJ, et al. **Hum Exp Toxicol** 1996 Jan;15(1):64-66

Functional, biochemical, and morphological hepatobiliary effects in rats chronically exposed to a steroidal antiandrogen. Descotes G, et al.
Toxicol Appl Pharmacol 1996 Mar;137(1):23-33

ANDROGEN-BINDING PROTEINS

BIOSYNTHESIS

Effects of photoperiod on testicular inhibin-alpha and androgen binding protein mRNA expression during

postnatal development in Siberian hamsters, Phodopus sungorus. Rao JN, et al. **Life Sci** 1995;57(19):1761–70

BLOOD

Hepatic expression of sex hormone-binding globulin associated with the postnatal surge of serum androgen-binding activity in the Djungarian hamster. Cates JM, et al. **J Steroid Biochem Mol Biol** 1995 Nov; 55(2):147–58

GENETICS

The androgen-specific probasin response element 2 interacts differentially with androgen and glucocorticoid receptors. Claessens F, et al. **J Biol Chem** 1996 Aug 9;271(32):19013–6

METABOLISM

Glucocorticoid regulation of androgen binding protein expression in primary Sertoli cell cultures from rats. Lim K, et al. **Biochem Biophys Res Commun** 1996 Jan 17; 218(2):490–4

PHYSIOLOGY

p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Shibata MA, et al. **Cancer Res** 1996 Jul 1;56(13):2998–3003

SECRETION

Ductal heterogeneity in rat dorsal-lateral prostate. Kinbara H, et al. **Prostate** 1996 Jan;28(1):58–64

ANDROGEN RECEPTORS see **RECEPTORS, ANDROGEN**

ANDROGENS

see related
ANDROGEN ANTAGONISTS
RECEPTORS, ANDROGEN

Dihydrotestosterone affects the growth of hormone-unresponsive breast cancer cells: an indirect action. Di Monaco M, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2581–4

Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cher ML, et al. **Cancer Res** 1996 Jul 1;56(13):3091–102

CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Nagabhushan M, et al. **Cancer Res** 1996 Jul 1;56(13):3042–6

Fat-free mass index in users and nonusers of anabolic-androgenic steroids. Kouri EM, et al. **Clin J Sport Med** 1995 Oct;5(4):223–8

Progestogens, progesterone antagonists, progesterone, and androgens: synthesis, classification, and uses. Peterson CM. **Clin Obstet Gynecol** 1995 Dec;38(4):813–20 (13 ref.)

Androgen action. Roy AK, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(2):157–76 (170 ref.)

A novel substitution (Leu707Arg) in exon 4 of the androgen receptor gene causes complete androgen resistance. Lumbroso S, et al. **J Clin Endocrinol Metab** 1996 May; 81(5):1984–8

Induction of programmed death/apoptosis androgen-dependent mouse mammary tumor cell line (Shionogi Carcinoma 115) by androgen withdrawal. Furuya Y, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1159–65

Androgens in men—uses and abuses. Bagatell CJ, et al. **N Engl J Med** 1996 Mar 14;334(11):707–14 (91 ref.)

ADMINISTRATION & DOSAGE

Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Lovejoy JC, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19(9):614–24

ADVERSE EFFECTS

Rupture of the triceps tendon associated with steroid injections [letter; comment] Lambert MI, et al. **Am J Sports Med** 1995 Nov–Dec;23(6):778. Comment on: Am J Sports Med 1993 May–Jun;21(3):482–5.

Finasteride inhibits 5 alpha-reductase activity in human dermal fibroblasts: prediction of its therapeutic application in androgen-related skin diseases. Nguyen QH, et al. **Int J Dermatol** 1995 Oct;34(10):720–5

[Steroid-induced liver tumor] Nishizawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):449–52 (21 ref.) **(Jpn)**

ANALOGS & DERIVATIVES see ANDROGENS, SYNTHETIC

ANALYSIS

[Determination of naturally occurring sex steroid hormones (androgens and progestagens) in beef] Hartwig M, et al. **Z Lebensm Unters Forsch** 1995 Dec;201(6):533–6 (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS see ANDROGEN ANTAGONISTS

BIOSYNTHESIS

DHEA and peripheral androgen and estrogen formation: intracinology. Labrie F, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:16–28 (70 ref.)

Granulosa cell modulation of luteinizing hormone-dependent androgen production by ovarian theca-interstitial cells: a temporal switch from suppression to augmentation stimulated by follicle-stimulating hormone in vitro. Zachow RJ, et al. **Biol Reprod** 1995 Oct;53(4):758–65

Chemical sympathectomy blocks androgen biosynthesis during prepuberty. Rosa-e-Silva AA, et al. **Braz J Med Biol Res** 1995 Oct;28(10):1109–12

In vitro acute and prolonged effects of melatonin on purified rat Leydig cell steroidogenesis and adenosine 3',5'-monophosphate production. Valenti S, et al. **Endocrinology** 1995 Dec;136(12):5357–62

Adrenal androgen production in polycystic ovary syndrome. McKenna TJ, et al. **Eur J Endocrinol** 1995 Oct;133(4):383–9 (35 ref.)

Adrenal steroidogenesis is related to insulin in hyperandrogenic women. Martikainen H, et al. **Fertil Steril** 1996 Oct;66(4):564–70

Evidence for diminished midcycle ovarian androgen production in older reproductive aged women. Mushayandebvu T, et al. **Fertil Steril** 1996 Apr;65(4):721–3

In vitro biosynthesis of androgens in the Australian lungfish, Neoceratodus forsteri. Joss JM, et al. **Gen Comp Endocrinol** 1996 Mar;101(3):256–63

A paradoxical inhibition of androgenic hyperproduction by a Sertoli-Leydig cell tumour ovary. Amato G, et al. **Hum Reprod** 1995 Nov;10(11):2967–9

Regulation of ovarian androgen production: a key parameter to success during ovarian stimulation? Andersen CY. **Hum Reprod** 1995 Sep;10(9):2227–33 (58 ref.)

Somatostatin action on rat ovarian steroidogenesis. Andreani CL, et al. **Hum Reprod** 1995 Aug;10(8):1968–73

Androgen production by monkey luteal cell subpopulations at different stages of the menstrual cycle. Sanders SL, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):591–6

Inhibin and activin differentially regulate androgen production and 17 alpha-hydroxylase expression in human ovarian thecal-like tumor cells. Sawetawan C, et al. **J Endocrinol** 1996 Feb;148(2):213–21

Cytochrome P450 17 alpha-hydroxylase gene expression in differentiating rat trophoblast cells. Yamamoto T, et al. **J Endocrinol** 1996 Jul;150(1):161–8

High androgen production by ovarian thecal interstitial cells: a mechanism for delayed ovulation in a tropical vespertilionid bat, Scotophilus heathi. Abhilasha, et al. **J Reprod Fertil** 1996 Mar;106(2):207–11

Molecular genetics of androgenic 17 beta-hydroxysteroid dehydrogenases. Andersson S. **J Steroid Biochem Mol Biol** 1995 Dec;55(5–6):533–4 (20 ref.)

Cigarette smoking is associated with elevated adrenal androgen response to adrenocorticotropin. Hautanen A, et al. **J Steroid Biochem Mol Biol** 1993 Aug;46(2):245–51

In utero and lactational exposure of the male rat to 2,3,7,8-tetrachlorodibenzo-p-dioxin: impaired prostate growth and development without inhibited androgen production. Roman BL, et al. **Toxicol Appl Pharmacol** 1995 Oct;134(2):241–50

[Biosynthesis of steroids in the ovaries] Suchanek E. **Lijec Vjesn** 1996 Mar;118 Suppl 1:11–2 (Eng. Abstr.) **(Scr)**

BLOOD

Raised serum androgens and increased responsiveness to luteinizing hormone in men with acne vulgaris. Ramsay B, et al. **Acta Derm Venereol** 1995 Jul;75(4):293–6

Plasma lipids, lipoproteins and apolipoproteins in hirsute women. Castelo-Branco C, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):261–5

Relation of energy, fat, and fiber intakes to plasma concentrations of estrogens and androgens in premenopausal women. Dorgan JF, et al. **Am J Clin Nutr** 1996 Jul;64(1):25–31

Role of androgens in the aetiology of rheumatoid arthritis [letter] Brennan P, et al. **Ann Rheum Dis** 1996 Jun;55(6):404

Opposite effects of breakfast vs. oral glucose on circulating androgen levels in healthy women. Parra A, et al. **Arch Med Res** 1995 Winter;26(4):379–83

Serum androgen changes during meal-induced hyperinsulinemia and after acute sequential blockade and hyperstimulation of insulin release in women with polycystic ovary syndrome. Parra A, et al. **Arch Med Res** 1995;26 Spec No:S209–17

Endocrinological late effects after chemotherapy for testicular cancer. Berger CC, et al. **Br J Cancer** 1996 May; 73(9):1108–14

Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. Barth JH, et al. **Br J Dermatol** 1996 Jun;134(6):1057–9

Daily variation of serum cortisol, 17-hydroxyprogesterone and five androgens in healthy women. Mikulecky M, et al. **Braz J Med Biol Res** 1995 Apr;28(4):485–90

Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Wu AH, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov;4(7):735–41

Androgen levels in women using a single implant of nomegestrol acetate. Barbosa I, et al. **Contraception** 1996 Jan;53(1):37–40

Changes in androgens during treatment with four low-dose contraceptives. Coenen CM, et al. **Contraception** 1996 Mar; 53(3):171–6

The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial. Moutos D, et al. **Contraception** 1995 Aug;52(2):105–9

Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Wiegratz I, et al. **Contraception** 1995 Jun;51(6):341–6

Relation of steroid hormones to glucose tolerance and plasma insulin levels in men. Importance of visceral adipose tissue. Tchernof A, et al. **Diabetes Care** 1995 Mar;18(3):292–9

Body mass and physical activity are important predictors of serum androgen concentrations in young healthy men. Mantzoros CS, et al. **Epidemiology** 1995 Jul;6(4):432–5

No changes of peripheral insulin resistance in polycystic ovary syndrome after long-term reduction of endogenous androgens with leuprolide. Lasco A, et al. **Eur J Endocrinol** 1995 Dec;133(6):718–22

Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with the CD4 cell counts. Laudat A, et al. **Eur J Endocrinol** 1995 Oct;133(4):418–24

Relationship between sex steroid hormone levels and CD4 lymphocytes in HIV infected men. Christeff N, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):130–6

The relationship between plasma levels of gonadotropins, androgens, and prolactin in azoospermic men with their testicular spermatogenic pattern. Bar-On E, et al. **Fertil Steril** 1995 Nov;64(5):1043–5

Comparison of androgen levels in conception vs. non-conception cycles following controlled ovarian stimulation using the luteal phase gonadotropin-releasing hormone agonist protocol. Check JH, et al. **Gynecol Endocrinol** 1995 Sep;9(3):209–14

Serum levels of androgens and estrogens and 'steroid-sensitive' liver proteins in early human pregnancy: influence on the gender of the offspring. Skjöldebrand Sparre L, et al. **Gynecol Obstet Invest** 1995;40(3):145–50

Hormonal responses of male gerbils to stimuli from their mate and pups. Brown RE, et al. **Horm Behav** 1995 Dec; 29(4):474–91

Moderate alcohol consumption and its relation to visceral fat and plasma androgens in healthy women. Cigolini M, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):206–12

Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. Soygür T, et al. **Int Urol Nephrol** 1996; 28(1):55–9

Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. Apter D, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2966–73

High androgen levels in chronic fatigue patients [letter; comment] Baschetti R. **J Clin Endocrinol Metab** 1996 Jul; 81(7):2752–3. Comment on: J Clin Endocrinol Metab 1995 Nov;80(11):3390–1.

High androgen levels in chronic fatigue patients [letter] [see comments] Goldberg M, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3390–1. Comment in: J Clin Endocrinol Metab 1996 Jul;81(7):2752–3.

Nitrendipine treatment in women with polycystic ovarian syndrome: evidence for a lack of effects of calcium channel blockers on insulin, androgens, and sex hormone-binding globulin. Pasquali R, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3346–50

Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. Vermeulen A, et al. **J Clin Endocrinol Metab** 1996 May; 81(5):1821–6

Androgen status in adolescent women with acne vulgaris. Aizawa H, et al. **J Dermatol** 1995 Jul;22(7):530–2

The effect of prepubertal androgen exposure on adult penile length. Sutherland RS, et al. **J Urol** 1996 Aug;156(2 Pt 2):783–7; discussion 787

[Evaluation of hyperandrogenism: what levels?] Dewailly D. **Contracept Fertil Sex** 1995 Dec;23(12):717–9 **(Fre)**

[Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization] Grunwald K, et al. **Geburtshilfe Frauenheilkd** 1994 Nov;54(11):634–45 (Eng. Abstr.) **(Ger)**

[Andropause: myth or reality?] Tomer Y, et al. **Harefuah** 1995 Jun 15;128(12):785–8 (51 ref.) **(Heb)**

[Concentration of dihydroepiandrosterone, dihydroepiandrosterone sulphate and testosterone during premature menopause in women chronically exposed to carbon disulfide] Stanosz S, et al. **Med Pr** 1995;46(4):337–40 (Eng. Abstr.) **(Pol)**

CHEMICAL SYNTHESIS

Synthesis of C-6 fluoroandrogens: evaluation of ligands for tumor receptor imaging. Choe YS, et al. **Steroids** 1995 May; 60(5):414–22

DEFICIENCY

Early induction of alterations in cancellous and cortical bone histology after orchiectomy in mature rats. Gunness M, et al. **J Bone Miner Res** 1995 Nov;10(11):1735–44

[Endocrinology update. II] Burgstaller M, et al. **Med Klin** 1996 Apr 10;91(4):207–17 (171 ref.) **(Ger)**

GENETICS

DNA fingerprinting confirms isogenicity of androgenetically derived rainbow trout lines. Young WP, et al. **J Hered** 1996 Jan–Feb;87(1):77–80

METABOLISM

Primary cultures of human synovial macrophages metabolize androgens. Cutolo M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:534–41

The response of human gingival fibroblasts to interleukin–1 in their metabolic conversion of two androgenic substrates. Kasasa SC, et al. **Arch Oral Biol** 1995 Oct;40(10):979–81

Tissue specific and androgen–regulated expression of human prostate–specific transglutaminase. Dubbink HJ, et al. **Biochem J** 1996 May 1;315 (Pt 3):901–8

Clinical, ultrasound and hormonal markers of androgenicity in acne vulgaris. Walton S, et al. **Br J Dermatol** 1995 Aug; 133(2):249–53

Wedge resection to improve insulin resistance in polycystic ovary syndrome: a study among Chinese women. Wu XK, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):822–5

In vitro characterization of prolactin–induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Janssen T, et al. **Cancer** 1996 Jan 1;77(1):144–9

Effects of gonadal androgens on adrenal androgen levels [letter; comment] Cutolo M. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):490–1. Comment on: Clin Endocrinol (Oxf) 1995 Oct;43(4):415–21.

Identification and endocrine control of sex steroid binding sites in the lacrimal gland. Sullivan DA, et al. **Curr Eye Res** 1996 Mar;15(3):279–91

Antiandrogenic activity and endocrinological profile of a novel antiandrogen, TZP–4238, in the rat. Mieda M, et al. **Endocr J** 1994 Aug;41(4):445–52

Transforming growth factor–beta1 is a mediator of androgen–regulated growth arrest in an androgen–responsive prostatic cancer cell line, LNCaP. Kim IY, et al. **Endocrinology** 1996 Mar;137(3):991–9

Effect of growth hormone on follicular fluid androgen levels in patients treated with gonadotropins before in vitro fertilization. Bergh C, et al. **Eur J Endocrinol** 1996 Feb; 134(2):190–6

Gonadotrophin–regulated production of immunoactive inhibin and androgen by cultured testicular cells from chicken embryos. Rombauts L, et al. **Gen Comp Endocrinol** 1995 Aug;99(2):152–60

Localisation of androgen receptors in dermal fibroblasts, grown in vitro, from normal subjects and from patients with androgen insensitivity syndrome. Jacobson W, et al. **Horm Res** 1995;44(2):75–84

Comparative evaluation of the androgenicity of four low–dose, fixed–combination oral contraceptives. Coenen CM, et al. **Int J Fertil Menopausal Stud** 1995;40 Suppl 2:92–7

Corpus albicans–like structures in the gonads in androgen insensitivity syndrome. Siegler RW, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):177–80

Search for androgen response elements in the proximal promoter of the canine prostate arginine esterase gene. Dubé JY, et al. **J Androl** 1995 Jul–Aug;16(4):304–11

The androgen–specific probasin response element 2 interacts differentially with androgen and glucocorticoid receptors. Claessens F, et al. **J Biol Chem** 1996 Aug 9;271(32):19013–6

Partial androgen insensitivity caused by an androgen receptor mutation at amino acid 907 (Gly––>Arg) that results in decreased ligand binding affinity and reduced androgen receptor messenger ribonucleic acid levels. Choong CS, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):236–43

Acute hyperinsulinemia, androgen homeostasis and insulin sensitivity in healthy man. Ebeling P, et al. **J Endocrinol** 1995 Jul;146(1):63–9

Antiproliferative effect of a prostatic cell–derived activity on the human androgen–dependent prostatic carcinoma cell line LNCaP. Abolhassani M, et al. **J Interferon Cytokine Res** 1995 Feb;15(2):179–85

Mouse androgen–dependent epididymal glycoprotein CRISP–1 (DE/AEG): isolation, biochemical characterization, and expression in recombinant form. Eberspaecher U, et al. **Mol Reprod Dev** 1995 Oct; 42(2):157–72

Androgen receptor in the rat pancreas: genetic expression and steroid regulation. Díaz–Sánchez V, et al. **Pancreas** 1995 Oct;11(3):241–5

PHARMACOLOGY

Effect of dehydroepiandrosterone sulfate on fetal middle cerebral artery flow velocity waveforms in term pregnancy. Hata T, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):343–6

The synthetic retinoid N–(4–hydroxyphenyl) retinamide (4–HPR) exerts antiproliferative and apoptosis–inducing effects in the androgen–independent human prostatic JCA–1 cells. Hsieh TC, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):499–506

Restoration of normal adult penile erectile response in aged rats by long–term treatment with androgens. Garban H, et al. **Biol Reprod** 1995 Dec;53(6):1365–72

Lesions of the melatonin– and androgen–responsive tissue of the dorsomedial nucleus of the hypothalamus block the gonadal response of male Syrian hamsters to programmed infusions of melatonin. Maywood ES, et al. **Biol Reprod** 1996 Feb;54(2):470–7

Effects of androgens on subpopulations of the human osteosarcoma cell line SaOS2. Kasperk CH, et al. **Calcif Tissue Int** 1996 May;58(5):376–82

Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line, LNCaP. Perry JE, et al. **Cancer Res** 1996 Apr 1;56(7):1539–44

Androgen regulation of a laryngeal–specific myosin heavy chain mRNA isoform whose expression is sexually differentiated. Catz DS, et al. **Dev Biol** 1995 Oct; 171(2):448–57

Sex differences in the steroidogenic and respiratory electron transport chains in the rat adrenal cortex. el–Migdadi F, et al. **Endocr Res** 1995 Feb–May;21(1–2):109–14

Adrenal steroid precursors exert potent androgenic action in the hamster sebaceous glands of flank organs and ears. Chen C, et al. **Endocrinology** 1996 May;137(5):1752–7

Androgen–regulated proliferation and gene transcription in a prostate smooth muscle cell line (PS–1). Gerdes MJ, et al. **Endocrinology** 1996 Mar;137(3):864–72

Regulation of steroid glucuronosyltransferase activities and transcripts by androgen in the human prostatic cancer LNCaP cell line. Guillemette C, et al. **Endocrinology** 1996 Jul;137(7):2872–9

Deoxyribonucleic acid–binding ability of androgen receptors in whole cells: implications for the actions of androgens and antiandrogens. Kuil CW, et al. **Endocrinology** 1996 May;137(5):1870–7

Mechanism of androgen–induced thymolysis in rats. Kumar N, et al. **Endocrinology** 1995 Nov;136(11):4887–93

Induction of spermatogenesis by androgens in gonadotropin–deficient (hpg) mice. Singh J, et al. **Endocrinology** 1995 Dec;136(12):5311–21

Androgen–dependent sex differences in the hypothalamic serotoninergic system. Borisova NA, et al. **Eur J Endocrinol** 1996 Feb;134(2):232–5

Identification and androgen regulation of a 156–kDa hemeprotein in the harderian gland of the Syrian hamster. Vilchis F, et al. **Gen Comp Endocrinol** 1996 Mar; 101(3):297–303

Role of endothelium in the vasodilating effect of progestins and androgens on the rat thoracic aorta. Perusquía M, et al. **Gen Pharmacol** 1996 Jan;27(1):181–5

Neuronal regulation of ornithine decarboxylase induced by androgens in the mouse kidney. Tovar A, et al. **Gen Pharmacol** 1995 Sep;26(5):997–1001

Biological implications of estrogen and androgen effects on androgen receptor and its mRNA levels in human uterine endometrium. Fujimoto J, et al. **Gynecol Endocrinol** 1995 Jun;9(2):149–55

In vivo effects of various therapies on complement–sensitive erythrocytes in paroxysmal nocturnal hemoglobinuria. Shichishima T, et al. **Int J Hematol** 1996 Jun;63(4):291–302

Sterility in neonatally androgenized female rats and the decidual cell reaction. Ohta Y. **Int Rev Cytol** 1995;160:1–52 (250 ref.)

Parturition and periparturient reproductive and metabolic hormone concentrations in prenatally androgenized beef heifers. Aldrich SL, et al. **J Anim Sci** 1995 Dec; 73(12):3712–8

Use of genetically identical (clone) steers to determine the effects of estrogenic and androgenic implants on beef quality and palatability characteristics. Gerken CL, et al. **J Anim Sci** 1995 Nov;73(11):3317–24

Acute prenatal androgen treatment increases birth weights and growth rates in lambs. Gill JW, et al. **J Anim Sci** 1995 Sep;73(9):2600–8

Two androgen response regions cooperate in steroid hormone regulated activity of the prostate–specific antigen promoter. Cleutjens KB, et al. **J Biol Chem** 1996 Mar 15; 271(11):6379–88

Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. Raisz LG, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):37–43

Androgen–controlled specific gene expression in neuroblastoma cells. Yerramilli–Rao P, et al. **J Neurol Sci** 1995 May;129 Suppl:131–5

Opposing actions of androgen and estrogen on in vitro firing frequency of neuronal oscillators in the electromotor system. Schaefer Je, et al. **J Neurosci** 1996 Apr 15; 16(8):2860–8

Spatial cognition in humans: possible modulation by androgens and estrogens. Hampson E. **J Psychiatry Neurosci** 1995 Nov;20(5):397–404 (66 ref.)

Characterization of the promoter of the gene for a mouse vas deferens protein related to the aldo–keto reductase superfamily: effect of steroid hormones and phorbol esters. Fabre S, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(3–4):315–25

Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. Joly–Pharaboz MO, et al. **J Steroid Biochem Mol Biol** 1995 Oct;55(1):67–76

Anabolic–androgenic steroid increases running endurance in rats. Van Zyl CG, et al. **Med Sci Sports Exerc** 1995 Oct; 27(10):1385–9

Developmental pattern and regulation by androgens of androgen receptor expression in the urogenital tract of the rat. Bentvelsen FM, et al. **Mol Cell Endocrinol** 1995 Sep 22;113(2):245–53

Androgen–independent effects of prolactin on the different lobes of the immature rat prostate. Reiter E, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):113–22

The human FGF–8 gene localizes on chromosome 10q24 and is subjected to induction by androgen in breast cancer cells. Payson RA, et al. **Oncogene** 1996 Jul 4;13(1):47–53

Influences of sex, castration, and androgens on the eumelanin and pheomelanin contents of different feathers in wild mallards. Haase E, et al. **Pigment Cell Res** 1995 Jun; 8(3):164–70

Androgen and progestagen effects on plasma lipids. Bagatell CJ, et al. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):255–71 (125 ref.)

Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25–dihydroxycholecalciferol, all–trans retinoic acid, 9–cis retinoic acid, and phenylacetate. Esquenet M, et al. **Prostate** 1996 Mar;28(3):182–94

Changes in gene expression of growth factors and their receptors during castration–induced involution and androgen–induced regrowth of rat prostates. Nishi N, et al. **Prostate** 1996 Mar;28(3):139–52

Growth factors as mediators of androgen action during male urogenital development. Cunha GR. **Prostate Suppl** 1996; 6:22–5 (33 ref.)

Genetic regulation of androgen action. Kallio PJ, et al. **Prostate Suppl** 1996;6:45–51 (46 ref.)

Role of androgen in prostate growth and regression: stromal–epithelial interaction. Lee C. **Prostate Suppl** 1996; 6:52–6 (26 ref.)

Androgen regulation of gene expression. Perry JE, et al. **Prostate Suppl** 1996;6:79–81 (22 ref.)

Role of dihydrotestosterone in androgen action. Wilson JD. **Prostate Suppl** 1996;6:88–92 (32 ref.)

Gender differences in behaviour: activating effects of cross–sex hormones. Van Goozen SH, et al. **Psychoneuroendocrinology** 1995;20(4):343–63

Effects of gonadal steroids on the growth of human pituitary adenomas in vitro. Caronti B, et al. **Tumour Biol** 1995; 16(6):353–64

PHYSIOLOGY

Incomplete androgen insensitivity (testicular feminization) syndrome: two case reports. Hakverdi AU, et al. **Acta Obstet Gynecol Scand** 1996 Jul;75(6):588–92

Neural, endocrine and immune regulation of secretory component production by lacrimal gland acinar cells. Lambert RW, et al. **Adv Exp Med Biol** 1995;371A:221–4

Androgens, brain, and behavior. Rubinow DR, et al. **Am J Psychiatry** 1996 Aug;153(8):974–84 (179 ref.)

Active immunization against LHRH alone or combined with LHRH–analogue treatment impedes growth of androgen–dependent prostatic carcinoma. Ladd A, et al. **Am J Reprod Immunol** 1995 Sep;34(3):200–6

Body fat distribution, peripheral indicators of androgenic activity, and blood pressure in women. Muti P, et al. **Ann Epidemiol** 1996 May;6(3):181–7

Adrenal androgen action in breast cancer. Boccuzzi G, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:349–61 (55 ref.)

Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms. Colombel M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:63–9 (20 ref.)

Androgen regulation of the rat keratinocyte growth factor (KGF/FGF7) promoter. Fasciana C, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):858–63

Urinary 3 alpha,17 beta–androstanediol glucuronide is a measure of androgenic status in Eld's deer stags (Cervus eldi thamin). Monfort SL, et al. **Biol Reprod** 1995 Sep; 53(3):700–6

Hormones and/or growth factors in prostate hypertrophy, pathophysiology and treatment [editorial] Mathé G. **Biomed Pharmacother** 1995;49(7–8):317–8

Modulation of aromatase activity by growth factors in an androgen sensitive human prostate cancer cell line, LNCaP. Block JL, et al. **Cancer Lett** 1996 Apr 19;102(1–2):167–72

Osteopenia as a feature of the androgen insensitivity syndrome. Soule SG, et al. **Clin Endocrinol (Oxf)** 1995 Dec; 43(6):671–5

Evidence for target regulation of the development of androgen sensitivity in rat spinal motoneurons. Lubischer JL, et al. **Dev Neurosci** 1995;17(2):106–17

Activities and androgenic regulation of lysosomal enzymes in the epididymis of rhesus monkey. Gupta G, et al. **Endocr Res** 1995 Nov;21(4):733–41

Stimulation of epidermal growth factor gene expression during the fetal mouse reproductive tract differentiation: role of androgen and its receptor. Gupta C, et al. **Endocrinology** 1996 Feb;137(2):705–11

Androgens, antiandrogens and androgen receptor abnormalities. Kuil CW, et al. **Eur Urol** 1996;29 Suppl 2:78–82 (30 ref.)

Specificity of androgenic regulation of input to sexually dimorphic motoneurons in male rat lumbar spinal cord. Tanaka J, et al. **Exp Neurol** 1995 Dec;136(2):258–60

ANDROGENS

Hormones, sex, and status in women. Cashdan E. **Horm Behav** 1995 Sep;29(3):354–66

Hormonal regulation of NADP-linked isocitrate dehydrogenase in rat liver. Zirulnik F, et al. **Horm Metab Res** 1995 Jul;27(7):339–40

Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Holmes SJ, et al. **Horm Res** 1996;45(1–2):86–93 (96 ref.)

Influence of growth hormone and androgens on body composition in adults. Jørgensen JO, et al. **Horm Res** 1996; 45(1–2):94–8 (31 ref.)

Human androgen insensitivity due to point mutations encoding amino acid substitutions in the androgen receptor steroid-binding domain. Murono K, et al. **Hum Mutat** 1995; 6(2):152–62

Expression and androgenic regulation of human prostate-specific kallikreins. Young CY, et al. **J Androl** 1995 Mar–Apr;16(2):97–9 (16 ref.)

Does peace prevent homosexuality? Schmidt G, et al. **J Homosex** 1995;28(3–4):269–75

Androgen and estrogen effects on vasopressin messenger RNA expression in the medial amygdaloid nucleus in male and female rats. Wang Z, et al. **J Neuroendocrinol** 1995 Nov;7(11):827–31

Autonomous testicular hormonal control of fetal gubernaculum development in rabbits: a re-examination of histological slides in the legacy of the late Professor Alfred Jost. van der Schoot P. **J Reprod Fertil** 1996 Jan; 106(1):153–9

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):107–11 (36 ref.)

Androgens are not major down-regulators of androgen receptor levels during growth of the immature rat penis [published erratum appears in J Steroid Biochem Mol Biol 1996 Apr;58(1):137] Shen R, et al. **J Steroid Biochem Mol Biol** 1996 Mar;57(5–6):301–13

5 alpha-reduced androgens play a key role in murine parturition. Mahendroo MS, et al. **Mol Endocrinol** 1996 Apr;10(4):380–92

Growth factors as mediators of androgen action during the development of the male urogenital tract. Cunha GR, et al. **World J Urol** 1995;13(5):264–76 (124 ref.)

Keratinocyte growth factor: an androgen-regulated mediator of stromal–epithelial interactions in the prostate. Peehl DM, et al. **World J Urol** 1995;13(5):312–7 (43 ref.)

[Androgens and feminine behavior] Kerdelhue B, et al. **Contracept Fertil Sex** 1996 May;24(5):407–12 (28 ref.) (Eng. Abstr.) **(Fre)**

[Cryptorchism—assessment from an andrologic viewpoint] Weidner W, et al. **Urologe A** 1996 Mar;35(2):111–4 (31 ref.) (Eng. Abstr.) **(Ger)**

[The effects of androgens and other sex hormones on serum lipoproteins] Reiner Z. **Lijec Vjesn** 1996 Mar;118 Suppl 1:33–7 (55 ref.) (Eng. Abstr.) **(Scr)**

SECRETION

Thyroid hormone induces a 52 kDa soluble protein in goat testis Leydig cell which stimulates androgen release. Jana NR, et al. **Biochim Biophys Acta** 1996 Feb 8;1292(2):209–14

The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome. Paoletti AM, et al. **Fertil Steril** 1996 Oct;66(4):527–32

[Functional adrenal hyperandrogenism: changing perspectives during its historical evolution] Devoto E, et al. **Rev Med Chil** 1995 Aug;123(8):1016–24 (Eng. Abstr.) **(Spa)**

STANDARDS

The rational use of androgens in hormone replacement therapy. Peterson CM. **Clin Obstet Gynecol** 1995 Dec; 38(4):915–20 (20 ref.)

THERAPEUTIC USE

Intermittent androgen therapy. Abi Aad AS, et al. **Acta Urol Belg** 1996 May;64(2):91–2

Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Hackenberg R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):113–7 (56 ref.)

ANDROGENS, SYNTHETIC

ADMINISTRATION & DOSAGE

[Androgens in the treatment of women] Flöter A, et al. **Lakartidningen** 1996 Jan 3;93(1–2):52–5 (46 ref.) **(Swe)**

DIAGNOSTIC USE

Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. Bonasera TA, et al. **J Nucl Med** 1996 Jun;37(6):1009–15

METABOLISM

Hormone-binding and solubility properties of fusion proteins containing the ligand-binding domain of the human androgen receptor. Cooper B, et al. **J Steroid Biochem Mol Biol** 1996 Feb;57(3–4):251–7

PHARMACOLOGY

Restoration of cytochrome P450 2C11 in vitamin A–deficient rat liver by exogenous androgen. Murray M, et al. **FASEB J** 1996 Jul;10(9):1058–63

Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. Joly-Pharaboz MO, et al. **J Steroid Biochem Mol Biol** 1995 Oct;55(1):67–76

THERAPEUTIC USE

Influence of androgen therapy on lacrimal autoimmune disease in a mouse model of Sjögren's syndrome. Sullivan DA, et al. **Adv Exp Med Biol** 1995;371B:1199–202

ANDROLOGY see **UROLOGY**

ANDROSTADIENES

ADMINISTRATION & DOSAGE

The efficacy and tolerability of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis. Boner A, et al. **Allergy** 1995 Jun;50(6):498–505

Once daily fluticasone propionate aqueous nasal spray controls symptoms of most patients with seasonal allergic rhinitis. Pedersen B, et al. **Allergy** 1995 Oct;50(10):794–9

Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Noonan M, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1467–73

Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Bleehen SS, et al. **Br J Dermatol** 1995 Oct;133(4):592–7

The effect of topical fluticasone propionate on intranasal histamine challenge in subjects with perennial allergic rhinitis. Birchall MA, et al. **Clin Otolaryngol** 1995 Jun; 20(3):204–10

Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis. Callen J. **Cutis** 1996 Feb;57(2 Suppl):45–50

A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of eczema. Delescluse J, et al. **Cutis** 1996 Feb; 57(2 Suppl):32–8

Comparison of fluticasone propionate cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, in the treatment of eczema. Juhlin L. **Cutis** 1996 Feb;57(2 Suppl):51–6

Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. Lebwohl M. **Cutis** 1996 Feb;57(2 Suppl):62–8

A comparison of fluticasone propionate ointment, 0.005%, and hydrocortisone-17-butyrate ointment, 0.1%, in the treatment of psoriasis. Nurnberger FG. **Cutis** 1996 Feb;57(2 Suppl):39–44

Efficacy and safety of fluticasone propionate 0.005% ointment in the treatment of psoriasis. Olsen EA. **Cutis** 1996 Feb;57(2 Suppl):57–61

Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis. Roberts DT. **Cutis** 1996 Feb;57(2 Suppl):27–31

A comparison of twice-daily and once-daily administration of fluticasone propionate cream, 0.05%, in the treatment of eczema. Tharp MD. **Cutis** 1996 Feb;57(2 Suppl):19–26

Once-a-day topical corticosteroids. **Drug Ther Bull** 1995 Mar;33(3):21–2 (15 ref.)

Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. Foresi A, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):274–82

Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis. Jordana G, et al. **J Allergy Clin Immunol** 1996 Feb; 97(2):588–95

Regulation of glucocorticoid receptor mRNA in nasal mucosa by local administration of fluticasone and budesonide. Knutsson PU, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):655–61

A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. Wasserman SI, et al. **J Asthma** 1996;33(4):265–74

Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Todd G, et al. **Lancet** 1996 Jul 6;348(9019):27–9

[Fluticasone propionate—a new inhalation steroid for the treatment of bronchial asthma] Lange P, et al. **Ugeskr Laeger** 1996 Jan 22;158(4):439–44 **(Dan)**

ADVERSE EFFECTS

Fluticasone propionate is associated with severe infection after endoscopic polypectomy. Mostafa BE. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):729–31

Fluticasone propionate sensitivity in a patient with contact allergy to multiple corticosteroids. Venning VA. **Contact Dermatitis** 1995 Jul;33(1):48–9

Fluticasone propionate: safety profile. Johnson M. **Cutis** 1996 Feb;57(2 Suppl):10–2 (15 ref.)

Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Todd G, et al. **Lancet** 1996 Jul 6;348(9019):27–9

CHEMISTRY

Vinyl fluoride as a mimic of the "intermediate' enol form in the 5 alpha-reductase transformation: synthesis and in vitro activity of (N-1',1'-dimethylethyl)-3-haloandrost-3,5-diene-17 beta-carboxamides. Li X, et al. **Bioorg Med Chem** 1996 Jan;4(1):55–60

Andrastins A-C, new protein farnesyltransferase inhibitors produced by Penicillium sp. FO-3929. II. Structure elucidation and biosynthesis. Uchida R, et al. **J Antibiot (Tokyo)** 1996 May;49(5):418–24

Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. Norman BH, et al. **J Med Chem** 1996 Mar 1;39(5):1106–11

Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-diones. Effects of length and configuration of 6-alkyl group. Numazawa M, et al. **J Med Chem** 1996 Mar 1;39(5):1033–8

ISOLATION & PURIFICATION

Andrastins A-C, new protein farnesyltransferase inhibitors produced by Penicillium sp. FO-3929. I. Producing strain, fermentation, isolation, and biological activities. Omura S, et al. **J Antibiot (Tokyo)** 1996 May;49(5):414–7

PHARMACOLOGY

Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Llewellyn-Jones CG, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):616–21

A transgenic mouse model provides a novel biological assay of topical glucocorticosteroid potency. Katchman SD, et al. **Arch Dermatol** 1995 Nov;131(11):1274–8

Differential regulation of insulin-stimulated tyrosine phosphorylation of IRS-1 and SHC by Wortmannin in intact cells. Li PM, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):80–4

Different pathways of inhibitory effects of wortmannin on exocytosis are revealed by video-enhanced light microscope. Ozawa K, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):243–8

Phosphatidylinositol 3-kinase activity is required for the activation process of focal adhesion kinase by platelet-derived growth factor. Saito Y, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):23–6

Glucose-dependent insulinotropic polypeptide stimulates insulin secretion via increased cyclic AMP and [Ca2+]1 and a wortmannin-sensitive signalling pathway. Straub SG, et al. **Biochem Biophys Res Commun** 1996 Jul 16; 224(2):369–74

Disruption of GLUT1 glucose carrier trafficking in L6E9 and Sol8 myoblasts by the phosphatidylinositol 3-kinase inhibitor wortmannin. Kaliman P, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):471–7

Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Sparks JD, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):567–74

The phosphatidylinositol 3-kinase inhibitor, wortmannin, inhibits insulin-induced activation of phosphatidylcholine hydrolysis and associated protein kinase C translocation in rat adipocytes. Standaert ML, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):1039–46

Thrombin stimulates wortmannin-inhibitable phosphoinositide 3-kinase and membrane blebbing in CHRF-288 cells. Vemuri GS, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):805–10

Biochemical and pharmacological studies with KT7692 and LY294002 on the role of phosphatidylinositol 3-kinase in Fc epsilon RI-mediated signal transduction. Yano H, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):145–50

Wortmannin enhances tumour necrosis factor alpha-stimulated neutrophil apoptosis. Murray J, et al. **Biochem Soc Trans** 1996 Feb;24(1):80S

Wortmannin influences insulin regulation of gene 33 expression in rat hepatoma cells. Yang SH, et al. **Biochem Soc Trans** 1995 Nov;23(4):545S

Characterization of a soluble adrenal phosphatidylinositol 4-kinase reveals wortmannin sensitivity of type III phosphatidylinositol kinases. Downing GJ, et al. **Biochemistry** 1996 Mar 19;35(11):3587–94

Vinyl fluoride as a mimic of the "intermediate' enol form in the 5 alpha-reductase transformation: synthesis and in vitro activity of (N-1',1'-dimethylethyl)-3-haloandrost-3,5-diene-17 beta-carboxamides. Li X, et al. **Bioorg Med Chem** 1996 Jan;4(1):55–60

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Zilembo N, et al. **Br J Cancer** 1995 Oct;72(4):1007–12

The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Price BD, et al. **Cancer Res** 1996 Jan 15;

56(2):246–50
Special issue on AIDS. **Cell Mol Biol (Noisy-le-grand)** 1995; 41 Suppl 1:S1–161
The effects of wortmannin, a potent inhibitor of phosphatidylinositol 3–kinase, on insulin–stimulated glucose transport, GLUT4 translocation, antilipolysis, and DNA synthesis. Evans JL, et al. **Cell Signal** 1995 May; 7(4):365–76
Effects of inhaled fluticasone propionate and oral prednisolone on lymphocyte beta 2–adrenoceptor function in asthmatic patients. Tan KS, et al. **Chest** 1996 Feb; 109(2):343–7
The effect of topical fluticasone propionate on intranasal histamine challenge in subjects with perennial allergic rhinitis. Birchall MA, et al. **Clin Otolaryngol** 1995 Jun; 20(3):204–10
Topical corticosteroids potentiate mucin secretion in the normal nose. MacGregor FB, et al. **Clin Otolaryngol** 1996 Feb;21(1):76–9
Wortmannin inhibits insulin secretion in pancreatic islets and beta–TC3 cells independent of its inhibition of phosphatidylinositol 3–kinase. Gao Z, et al. **Diabetes** 1996 Jul;45(7):854–62
Effects of wortmannin on glucose uptake and protein kinase C activity in rat adipocytes. Ishizuka T, et al. **Diabetes Res Clin Pract** 1995 Sep;29(3):143–52
An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Lönnebo A, et al. **Eur J Clin Pharmacol** 1996;49(6):459–63
Wortmannin inhibits transcytosis of dimeric IgA by the polymeric immunoglobulin receptor. Cardone M, et al. **FEBS Lett** 1995 Nov 27;376(1–2):74–6
Wortmannin inhibits store–mediated calcium entry and protein tyrosine phosphorylation in human platelets. Jenner S, et al. **FEBS Lett** 1996 Mar 4;381(3):249–51
Wortmannin inhibits the activation of MAP kinase following vasopressin V1 receptor stimulation. Nishioka N, et al. **FEBS Lett** 1995 Dec 27;377(3):393–8
Insulin and ATP stimulate actin polymerization in U937 cells by a wortmannin–sensitive mechanism. Walters RJ, et al. **FEBS Lett** 1996 Aug 19;392(1):66–70
Both CD28 ligands CD80 (B7–1) and CD86 (B7–2) activate phosphatidylinositol 3–kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL–2 secretion. Ueda Y, et al. **Int Immunol** 1995 Jun;7(6):957–66
Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. Foresi A, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):274–82
Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3–kinase. Cross MJ, et al. **J Biol Chem** 1995 Oct 27;270(43):25352–5
Chemotactic peptide–induced activation of MEK–2, the predominant isoform in human neutrophils. Inhibition by wortmannin. Downey GP, et al. **J Biol Chem** 1996 Aug 30;271(35):21005–1011
Wortmannin inhibits mitogen–activated protein kinase activation by platelet–activating factor through a mechanism independent of p85/p110–type phosphatidylinositol 3–kinase. Ferby IM, et al. **J Biol Chem** 1996 May 17;271(20):11684–8
End–joining of free radical–mediated DNA double–strand breaks in vitro is blocked by the kinase inhibitor wortmannin at a step preceding removal of damaged 3' termini. Gu XY, et al. **J Biol Chem** 1996 Aug 16; 271(33):19660–3
Wortmannin, an inhibitor of phosphoinositide 3–kinase, inhibits transcytosis in polarized epithelial cells. Hansen SH, et al. **J Biol Chem** 1995 Nov 24;270(47):28425–32
Aggregation of the FcepsilonRI on mast cells stimulates c–Jun amino–terminal kinase activity. A response inhibited by wortmannin. Ishizuka T, et al. **J Biol Chem** 1996 May 31;271(22):12762–6
Wortmannin–sensitive trafficking pathways in Chinese hamster ovary cells. Differential effects on endocytosis and lysosomal sorting. Martys JL, et al. **J Biol Chem** 1996 May 3;271(18):10953–62
A wortmannin–sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase–activating polypeptide. Straub SG, et al. **J Biol Chem** 1996 Jan 19;271(3):1660–8
Wortmannin–sensitive activation of p70s6k by endogenous and heterologously expressed Gi–coupled receptors. Wilson M, et al. **J Biol Chem** 1996 Apr 12;271(15):8537–40
Different sensitivity to wortmannin of two vacuolar sorting signals indicates the presence of distinct sorting machineries in tobacco cells. Matsuoka K, et al. **J Cell Biol** 1995 Sep; 130(6):1307–18
Potential sites of PI–3 kinase function in the endocytic pathway revealed by the PI–3 kinase inhibitor, wortmannin. Shpetner H, et al. **J Cell Biol** 1996 Feb;132(4):595–605
Insulin–stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. Zeng G, et al. **J Clin Invest** 1996 Aug 15;98(4):894–8
The phosphatidylinositol 3–kinase inhibitor wortmannin blocks mast cell exocytosis but not IL–6 production. Marquardt DL, et al. **J Immunol** 1996 Mar 1;156(5):1942–5
Studies on the mechanism of phosphatidylinositol 3–kinase inhibition by wortmannin and related analogs. Norman BH, et al. **J Med Chem** 1996 Mar 1;39(5):1106–11
Time–dependent inactivation of aromatase by 6–alkylandrosta–1,4–diene–3,17–diones. Effects of length and configuration of 6–alkyl group. Numazawa M, et al. **J Med Chem** 1996 Mar 1;39(5):1033–8
Effects of wortmannin analogs on bone in vitro and in vivo. Sato M, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):543–50
Inhibition of phosphatidylinositol–3'–kinase prevents induction of endotoxin tolerance in vitro. Bowling WM, et al. **J Surg Res** 1996 Jun;63(1):287–92
Wortmannin, a specific inhibitor of phosphatidylinositol–3–kinase, inhibits erythropoietin–induced erythroid differentiation of K562 cells. Kubota Y, et al. **Leukemia** 1996 Apr;10(4):720–6
Wortmannin blocks lipid and protein kinase activities associated with PI 3–kinase and inhibits a subset of responses induced by Fc epsilon R1 cross–linking. Barker SA, et al. **Mol Biol Cell** 1995 Sep;6(9):1145–58
Wortmannin inactivates phosphoinositide 3–kinase by covalent modification of Lys–802, a residue involved in the phosphate transfer reaction. Wymann MP, et al. **Mol Cell Biol** 1996 Apr;16(4):1722–33
Wortmannin and LY294002 inhibit the insulin–induced down–regulation of IRS–1 in 3T3–L1 adipocytes. Smith LK, et al. **Mol Cell Endocrinol** 1995 Aug 30;113(1):73–81
Endothelin–1–induced mitogenic responses of Chinese hamster ovary cells expressing human endothelinA: the role of a wortmannin–sensitive signaling pathway. Sugawara F, et al. **Mol Pharmacol** 1996 Mar;49(3):447–57
Phosphatidylinositol 3–kinase inhibitor, wortmannin, inhibits 5–hydroxytryptamine–mediated potentiation of platelet aggregation induced by epinephrine. Shah BH, et al. **Res Commun Mol Pathol Pharmacol** 1995 Aug;89(2):157–64
Fluticasone propionate--an update on preclinical and clinical experience. Fuller R, et al. **Respir Med** 1995 Sep;89 Suppl A:3–18 (59 ref.)
Effects of wortmannin, a novel myosin light–chain kinase inhibitor, on bile canalicular contraction in vitro and in vivo. Suzuki S, et al. **Scand J Gastroenterol** 1996 Apr; 31(4):391–7
Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Clark DJ, et al. **Thorax** 1996 Mar;51(3):262–6
[Generation of tumor necrosis factor alpha by human nasal epithelial cells and inhibition by fluticasone propionate] Ohnishi M, et al. **Arerugi** 1995 Oct;44(10):1216–22 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Bootsma GP, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):924–30
Fluticasone propionate compared with theophylline for mild–to–moderate asthma. Galant SP, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):112–8
Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. Okamoto LJ, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):455–61
Effect of intranasal fluticasone proprionate on the immediate and late allergic reaction and nasal hyperreactivity in patients with a house dust mite allergy. de Graaf–in't Veld C, et al. **Clin Exp Allergy** 1995 Oct;25(10):966–73
A placebo–controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non–allergic perennial rhinitis. Scadding GK, et al. **Clin Exp Allergy** 1995 Aug;25(8):737–43
Topical corticosteroids in clinical practice: focus on fluticasone propionate. Piacquadio DJ. **Cutis** 1996 Feb;57(2 Suppl):4–9 (19 ref.)
Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. Bronsky EA, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):915–21
Better drug trials: reply [letter; comment] Chervinsky P. **J Allergy Clin Immunol** 1995 Oct;96(4):568. Comment on: J Allergy Clin Immunol 1995 May;95(5 Pt 1):1063.
Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group. Sheffer AL, et al. **J Fam Pract** 1996 Apr; 42(4):369–75
Inhaled steroids and psoriasis [letter] Harries M. **Lancet** 1995 Dec 9;346(8989):1567
Effect of fluticasone on growth in children with asthma [letter] Whitaker K, et al. **Lancet** 1996 Jul 6;348(9019):63–4
Pharmaceutical Benefits Advisory Committee: some questions answered [letter] Bandouvakis J. **Med J Aust** 1996 Jan 1;164(1):51–2
Fluticasone propionate for chronic asthma. **Med Lett Drugs Ther** 1996 Sep 13;38(983):83–4
Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Bootsma GP, et al. **Thorax** 1995 Oct;50(10):1044–50
[Pharma–clinics. Drug of the month. Fluticasone propionate (Flixotide)] Scheen AJ. **Rev Med Liege** 1996 Feb; 51(2):195–7 **(Fre)**
[Introductory clinical evaluation of fluticasone propionate efficacy for treatment of allergic rhinitis in children] Hofman J, et al. **Pneumonol Alergol Pol** 1995;63 Suppl 2:83–6 (Eng. Abstr.) **(Pol)**

ANDROSTANAZOL see STANOZOLOL

5–ANDROSTANE–3,17–DIOL

ANALOGS & DERIVATIVES

5 alpha–androstane–3 alpha, 17 beta–diol and 5 alpha–androstane–3 alpha, 17 beta–diol–glucuronide in plasma of normal children, adults and patients with idiopathic hirsutism: a mass spectrometric study. Wudy SA, et al. **Eur J Endocrinol** 1996 Jan;134(1):87–92
Time–dependent changes in serum 3 alpha–androstanediol glucuronide correlate with hirsutism scores after ovarian suppression. Carmina E, et al. **Gynecol Endocrinol** 1995 Sep; 9(3):215–20
Synthesis and quantitative structure–activity relationship of 17 beta–(hydrazonomethyl)–5 beta–androstane–3 beta,14 beta–diol derivatives that bind to Na+,K(+)–ATPase receptor. Quadri L, et al. **J Med Chem** 1996 Aug 16; 39(17):3385–93

BLOOD

5 alpha–androstane–3 alpha, 17 beta–diol and 5 alpha–androstane–3 alpha, 17 beta–diol–glucuronide in plasma of normal children, adults and patients with idiopathic hirsutism: a mass spectrometric study. Wudy SA, et al. **Eur J Endocrinol** 1996 Jan;134(1):87–92
Accumulation of 5 alpha–reduced androgen glucosiduronates associated with impaired removal in young male hemodialysis patients. Boudou P, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3489–93
[Androstanediol] Kinouchi T. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:604–10 (38 ref.) **(Jpn)**

URINE

Urinary 3 alpha,17 beta–androstanediol glucuronide is a measure of androgenic status in Eld's deer stags (Cervus eldi thamin). Monfort SL, et al. **Biol Reprod** 1995 Sep; 53(3):700–6

ANDROSTANES

CHEMICAL SYNTHESIS

Synthesis and testosterone 5 alpha–reductase–inhibitory activity of 4–aza–5 alpha–androstane–17–carboxamide compound with an aromatic moiety in the C–17 carbamoyl group. Kurata H, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):115–21

PHARMACOLOGY

Synthesis and testosterone 5 alpha–reductase–inhibitory activity of 4–aza–5 alpha–androstane–17–carboxamide compound with an aromatic moiety in the C–17 carbamoyl group. Kurata H, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):115–21

ANDROSTANOLONE see STANOLONE

ANDROSTANOLS

Rocuronium: the newest aminosteroid neuromuscular blocking drug [editorial] Hunter JM. **Br J Anaesth** 1996 Apr;76(4):481–3 (30 ref.)
Clinical Experiences with Esmeron. Luxembourg, 27–29 January 1995. Proceedings of an international meeting. **Eur J Anaesthesiol Suppl** 1995 Sep;11:1–112
Onset time and evaluation of intubating conditions: rocuronium in perspective. Agoston S. **Eur J Anaesthesiol Suppl** 1995 Sep;11:31–7 (14 ref.)
Rocuronium with alfentanil and propofol allows intubation within 45 seconds. Crul JF, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:111–2
The effect of dose and the rate of stimulation on the action of rocuronium. Feldman SA, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:15–7
Time–course of action and intubating conditions with rocuronium bromide under propofol–alfentanil anaesthesia. Hofmockel R, et al. **Eur J Anaesthesiol Suppl** 1995 Sep; 11:69–72
Rocuronium bromide in the ICU: dose finding and pharmacokinetics. Khuenl–Brady KS, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:79–80
Dose–response and time–course of effect of rocuronium bromide in paediatric patients. Meretoja OA, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:19–22
Dose–response and time–course of action of rocuronium bromide. Mirakhur RK. **Eur J Anaesthesiol Suppl** 1995 Sep; 11:23–5
Dose–response, time–course of action and recovery of rocuronium bromide in children during halothane anaesthesia. Motsch J, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:73–8
Intubation conditions and time–course of action of low–dose rocuronium bromide in day–case dental surgery. Pollard BJ, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:81–3
1 x ED90 dose of rocuronium bromide: tracheal intubation conditions and time–course of action. Prien T, et al.

Eur J Anaesthesiol Suppl 1995 Sep;11:85-90

Priming studies with rocuronium and vecuronium. Redai I, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:11-3

Rocuronium- and mivacurium-induced neuromuscular block and intubating conditions: a comparison with vecuronium. van den Broek L, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:27-30

ADMINISTRATION & DOSAGE

Safety not speed [letter; comment] Findlay GP. **Anaesthesia** 1995 Oct;50(10):918. Comment on: Anaesthesia 1995 May;50(5):474.

Intubating conditions and onset of action after rocuronium, vecuronium, and atracurium in young children. Scheiber G, et al. **Anesth Analg** 1996 Aug;83(2):320-4

Pain on injection of rocuronium bromide [letter; comment] Steegers MA, et al. **Anesth Analg** 1996 Jul;83(1):203. Comment on: Anesth Analg 1995 May;80(5):1067.

Comparison of rocuronium and mivacurium to succinylcholine during outpatient laparoscopic surgery. Tang J, et al. **Anesth Analg** 1996 May;82(5):994-8

Intramuscular rocuronium in infants and children--is there a need? [editorial; comment] Berry FA Jr. **Anesthesiology** 1996 Aug;85(2):229-30. Comment on: Anesthesiology 1996 Aug;85(2):231-9.

Intramuscular rocuronium in infants and children. Dose-ranging and tracheal intubating conditions [see comments] Reynolds LM, et al. **Anesthesiology** 1996 Aug; 85(2):231-9. Comment in: Anesthesiology 1996 Aug;85(2):229-30.

Continuous infusion of rocuronium in a paediatric intensive care unit. Tobias JD. **Can J Anaesth** 1996 Apr;43(4):353-7

ADVERSE EFFECTS

Pain on administration of rocuronium [letter] Robertson EN. **Anaesthesia** 1996 Jan;51(1):93

CHEMICAL SYNTHESIS

Synthesis and quantitative structure-activity relationship of 17 beta-(hydrazonomethyl)-5 beta-androstane-3 beta,14 beta-diol derivatives that bind to Na+,K(+)-ATPase receptor. Quadri L, et al. **J Med Chem** 1996 Aug 16; 39(17):3385-93

IMMUNOLOGY

Cross-reactivity of rocuronium with other neuromuscular blocking agents. Laxenaire MC, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:55-64

METABOLISM

Aromatase inhibitors: effect of ring A and ring B unsaturation on aromatase inhibition by 4-thiosubstituted derivatives of 4-androstene-3,17-dione. Abul-Hajj YJ, et al. **Steroids** 1995 May;60(5):423-7

PHARMACOKINETICS

Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. McCoy EP, et al. **Br J Anaesth** 1996 Jan;76(1):29-33

The influence of hypothermia (surface cooling) on the time-course of action and on the pharmacokinetics of rocuronium in humans. Beaufort AM, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:95-106

Pharmacokinetics of rocuronium bromide in patients with and without renal failure. Cooper RA, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:43-4

The pharmacokinetics of rocuronium bromide in hepatic cirrhosis. Hunter JM. **Eur J Anaesthesiol Suppl** 1995 Sep; 11:39-41 (6 ref.)

Rocuronium bromide: time-course of action in underweight, normal weight, overweight and obese patients. Pühringer FK, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:107-10

Hypothermic cardiopulmonary bypass influences the concentration-response relationship and the biodisposition of rocuronium. Smeulers NJ, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:91-4

Effects of hypothermic cardiopulmonary bypass on the pharmacodynamics and pharmacokinetics of rocuronium. Smeulers NJ, et al. **J Cardiothorac Vasc Anesth** 1995 Dec; 9(6):700-5

PHARMACOLOGY

Comparison of intubating conditions after rocuronium and suxamethonium following "rapid-sequence induction" with thiopentone in elective cases. Sparr HJ, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):425-30

Rocuronium in the myasthenic patient [letter] Baraka A, et al. **Anaesthesia** 1995 Nov;50(11):1007

The onset of rocuronium, but not of vecuronium or mivacurium, is modified by tourniquet inflation. Audibert G, et al. **Anesth Analg** 1996 Apr;82(4):848-53

Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. Servin FS, et al. **Anesthesiology** 1996 May;84(5):1092-100

Regulation of angiotensinogen gene expression in the rat forebrain by adrenal steroids and relation to salt appetite. Riftina F, et al. **Brain Res Mol Brain Res** 1995 Nov; 33(2):201-8

Evaluation of neuromuscular effects and antagonism of rocuronium bromide: a preliminary report. Davis L, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:65-8

Rocuronium bromide: time-course of action in underweight, normal weight, overweight and obese patients. Pühringer FK, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:107-10

Effects of hypothermic cardiopulmonary bypass on the pharmacodynamics and pharmacokinetics of rocuronium. Smeulers NJ, et al. **J Cardiothorac Vasc Anesth** 1995 Dec; 9(6):700-5

Synthesis and quantitative structure-activity relationship of 17 beta-(hydrazonomethyl)-5 beta-androstane-3 beta,14 beta-diol derivatives that bind to Na+,K(+)-ATPase receptor. Quadri L, et al. **J Med Chem** 1996 Aug 16; 39(17):3385-93

THERAPEUTIC USE

Rocuronium bromide in dental day case anaesthesia--a comparison with atracurium and vecuronium. Chetty MS, et al. **Anaesth Intensive Care** 1996 Feb;24(1):37-41

Tetanus and rocuronium in the intensive care unit [letter] Anandaciva S, et al. **Anaesthesia** 1996 May;51(5):505-6

Rocuronium pretreatment reduces suxamethonium-induced myalgia: comparison with vecuronium. Findlay GP, et al. **Br J Anaesth** 1996 Apr;76(4):526-9

5-ANDROSTENE-3,17-DIOL

METABOLISM

7 alpha-Hydroxylation of the adrenal androgens dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol predominates in differentiating human adipose stromal cells. Khalil MW, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:316-8

THERAPEUTIC USE

Successful treatment of vitiligo with a sex steroid-thyroid hormone mixture. Muto M, et al. **J Dermatol** 1995 Oct; 22(10):770-2

ANDROSTENEDIOL DIPROPIONATE see **5-ANDROSTENE-3,17-DIOL**

ANDROSTENEDIONE

ADMINISTRATION & DOSAGE

Production of premature delivery in pregnant rhesus monkeys by androstenedione infusion. Mecenas CA, et al. **Nat Med** 1996 Apr;2(4):443-8

ANALOGS & DERIVATIVES

Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Gazet JC, et al. **Br J Cancer** 1996 Mar;73(6):758-62

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Murray R, et al. **Breast Cancer Res Treat** 1995 Sep;35(3):249-53

Inhibition of aromatase activity and growth suppression by 4-methoxy-4-androstene-3,17-dione in an androgen sensitive human prostatic carcinoma cell line. Block JL, et al. **Cancer Lett** 1996 Mar 29;101(2):143-8

The synthesis of 19-norandrostenedione from dehydroepiandrosterone in equine placenta is inhibited by aromatase inhibitors 4-hydroxyandrostenedione and fadrozole. Moslemi S, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):613-8

Anti-androgen effects of the aromatase inhibitor, atamestane. Shao TC, et al. **J Androl** 1995 Mar-Apr;16(2):100-7

Evaluation of 6,7-aziridinyl steroids and related compounds as inhibitors of aromatase (P-450arom). Njar VC, et al. **J Enzym Inhib** 1995;9(3):195-202

Probing the hydrophobic pocket of the active site of aromatase with 4-phenoxy-7 alpha-(phenylthio)-4-androstene-3,17-dione. Liu XP, et al. **J Med Chem** 1995 Sep 29;38(20):4135-8

Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. Noberasco C, et al. **Oncology** 1995 Nov-Dec;52(6):454-7

Aromatase inhibitors: effect of ring A and ring B unsaturation on aromatase inhibition by 4-thiosubstituted derivatives of 4-androstene-3,17-dione. Abul-Hajj YJ, et al. **Steroids** 1995 May;60(5):423-7

A simple synthesis of 11,19-oxidosteroids. Boudi A, et al. **Steroids** 1995 May;60(5):411-3

Further studies on 6-alkylandrost-4-ene-3,17-diones as aromatase inhibitors: elongation of the 6-alkyl chain. Numazawa M, et al. **Steroids** 1995 Aug;60(8):506-11

ANALYSIS

Concentration of the endogenous antiandrogen epitestosterone and androgenic C19-steroids in hyperplastic prostatic tissue. Hill M, et al. **Prostate** 1996 Jun;28(6):347-51

ANTAGONISTS & INHIBITORS

Effect of aromatase inhibitor, TZA-2209, on the prostate of androstenedione-treated castrated dogs: changes in prostate volume and histopathological findings. Suzuki K, et al. **Prostate** 1996 May;28(5):328-37

BIOSYNTHESIS

The effect of transforming growth factor-beta on steroidogenesis and expression of key steroidogenic enzymes with a human ovarian thecal-like tumor cell model. Carr BR, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1109-16; discussion 1116-7

3 beta-hydroxysteroid dehydrogenase/isomerase and aromatase activity in primary cultures of developing zebra finch telencephalon: dehydroepiandrosterone as substrate for synthesis of androstenedione and estrogens. Vanson A, et al. **Gen Comp Endocrinol** 1996 Jun;102(3):342-50

Inhibitory effects of melatonin on testosterone but not on androstenedione production during winter in the vespertilionid bat, Scotophilus heathi. Singh K, et al. **J Pineal Res** 1995 Oct;19(3):127-32

BLOOD

Semiautomated method for the quantitation of plasma or sera androstenedione, testosterone, and dihydrotestosterone in population studies. Walker VR, et al. **Anal Biochem** 1996 Feb 15;234(2):194-203

Blunted adrenocorticotropin and increased adrenal steroid response to human corticotropin-releasing hormone in Alzheimer's disease. Näsman B, et al. **Biol Psychiatry** 1996 Mar 1;39(5):311-8

Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women [see comments] Barrett-Connor E, et al. **BMJ** 1995 Nov 4; 311(7014):1193-6. Comment in: BMJ 1996 Mar 23;312(7033):777.

Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Lipworth L, et al. **Epidemiology** 1996 Jan; 7(1):96-100

Relationship between serum dehydroepiandrosterone sulfate, androstenedione, and sex hormones in men and women. Phillips GB. **Eur J Endocrinol** 1996 Feb;134(2):201-6

Dose-response effect of depot leuprolide acetate on serum androgens in hirsute women. Rittmaster RS, et al. **Fertil Steril** 1996 May;65(5):912-5

17 alpha-hydroxyprogesterone, 4-androstenedione, and testosterone profiled by routine stable isotope dilution/gas chromatography-mass spectrometry in plasma of children. Wudy SA, et al. **Pediatr Res** 1995 Jul;38(1):76-80

[Androstenedione] Kambegawa A. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:491-4 (17 ref.) **(Jpn)**

CHEMISTRY

Mechanism of proton transfer in the isomerization of 5-androstene-3, 17-dione by 3-oxo-delta 5-steroid isomerase and its D38E mutant. Zawrotny ME, et al. **Biochemistry** 1996 May 21;35(20):6438-42

METABOLISM

Effects of guanethidine-induced sympathectomy on the spermatogenic and steroidogenic testicular functions of prepubertal to mature rats. Carvalho TL, et al. **Andrologia** 1996 Mar-Apr;28(2):117-22

Mechanism of proton transfer in the isomerization of 5-androstene-3, 17-dione by 3-oxo-delta 5-steroid isomerase and its D38E mutant. Zawrotny ME, et al. **Biochemistry** 1996 May 21;35(20):6438-42

Intraadrenal steroid metabolism in the guinea pig: guinea pig adrenal microsomes metabolize androstenedione in a manner distinct from liver microsomes. Black VH, et al. **Endocr Res** 1995 Feb-May;21(1-2):315-28

Gonadal in vitro androstenedione metabolism and changes in some plasma and gonadal steroid hormones during sex inversion of the protandrous sea bass, Lates calcarifer. Guiguen Y, et al. **Gen Comp Endocrinol** 1995 Oct; 100(1):106-18

Why so much oestriol? A comparison of the aromatisation of androstenedione and 16 alpha-hydroxyandrostenedione when incubated alone or together with human placental microsomes. Othman YS, et al. **J Endocrinol** 1996 Mar; 148(3):399-407

In vitro and in vivo evidence on the site of neutralization of equine chorionic gonadotrophin (eCG) by an eCG antiserum. Wang X, et al. **J Reprod Fertil** 1995 Jul; 104(2):237-41

Sex hormone status and bone mineral density in men with rheumatoid arthritis. Mateo L, et al. **J Rheumatol** 1995 Aug; 22(8):1455-60

Biotransformation XXXIX. Metabolism of testosterone, androstenedione, progesterone and testosterone derivatives in Absidia coerulea culture. Brzezowska E, et al. **J Steroid Biochem Mol Biol** 1996 Mar;57(5-6):357-62

Aromatase inhibitors: effect of ring A and ring B unsaturation on aromatase inhibition by 4-thiosubstituted derivatives of 4-androstene-3,17-dione. Abul-Hajj YJ, et al. **Steroids** 1995 May;60(5):423-7

PHARMACOLOGY

Daily and hourly temporal association between delta4-androstenedione-induced preterm myometrial contractions and maternal plasma estradiol and oxytocin

concentrations in the 0.8 gestation rhesus monkey. Giussani DA, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1050–5
The effects of androgens on the mechanical properties of primate bone. Kasra M, et al. **Bone** 1995 Sep;17(3):265–70
Inhibition of aromatase activity and growth suppression by 4–methoxy–4–androstene–3,17–dione in an androgen sensitive human prostatic carcinoma cell line. Block JL, et al. **Cancer Lett** 1996 Mar 29;101(2):143–8
Effect of androstenedione administration on the maternal hypothalamo–pituitary–adreno–placental axis in the pregnant rhesus monkey. Giussani DA, et al. **Endocrinology** 1996 Feb;137(2):608–14
The relative effectiveness of androstenedione, testosterone, and estrone, precursors to estradiol, in sex reversal in the red–eared slider (Trachemys scripta), a turtle with temperature–dependent sex determination. Crews D, et al. **Gen Comp Endocrinol** 1995 Oct;100(1):119–27
Effects of epidermal growth factor, transforming growth factor alpha and androstenedione on follicular growth and aromatization in culture. Almahbobi G, et al. **Hum Reprod** 1995 Oct;10(10):2767–72
Dual regulation of luteal progesterone production by androstenedione during spontaneous and RU486–induced luteolysis in pregnant rats. Telleria CM, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(3–4):385–93
Androstenedione increases thromboxane A2 receptors in human erythroleukemia cells. Zucker TP, et al. **Life Sci** 1996;58(8):683–90

SECRETION

Lipopolysaccharide inhibits rat ovarian thecal–interstitial cell steroid secretion in vitro. Taylor CC, et al. **Endocrinology** 1995 Dec;136(12):5527–32

THERAPEUTIC USE

Successful treatment of vitiligo with a sex steroid–thyroid hormone mixture. Muto M, et al. **J Dermatol** 1995 Oct; 22(10):770–2

ANDROSTENES

ANALYSIS

Factors regulating the concentrations of 16–androstene steroids in submaxillary salivary glands of pigs. Babol J, et al. **J Anim Sci** 1996 Feb;74(2):413–9

CHEMICAL SYNTHESIS

Synthesis and structure–activity relationships of 6–substituted androst–4–ene analogs as aromatase inhibitors. Numazawa M, et al. **J Med Chem** 1996 May 24;39(11):2245–52
The synthesis and reactivity of 3 beta–(2–alkynylsulfonyl)– and 3 beta–(2–alkynylsulfonylmethyl) androst–5–en–17–ones as inhibitors of glucose–6–phosphate dehydrogenase. Williams JR, et al. **Steroids** 1995 Oct; 60(10):699–708

CHEMISTRY

Synthesis and structure–activity relationships of 6–substituted androst–4–ene analogs as aromatase inhibitors. Numazawa M, et al. **J Med Chem** 1996 May 24;39(11):2245–52
Homogeneous catalytic dehalodimerization of 17–iodo–delta 16 steroids. Skoda–Földes R, et al. **Steroids** 1995 Dec; 60(12):786–90
Steroidal alkenylphosphonates via palladium–catalyzed coupling reactions. Skoda–Földes R, et al. **Steroids** 1995 Dec;60(12):791–5
Palladium–catalyzed homogeneous coupling reactions of steroids with organostannanes. Skoda–Földes R, et al. **Steroids** 1995 Dec;60(12):812–6

METABOLISM

Differential effects of trilostane and cyanoketone on the 3 beta–hydroxysteroid dehydrogenase–isomerase reactions in androgen and 16–androstene biosynthetic pathways in the pig testis. Cooke GM. **J Steroid Biochem Mol Biol** 1996 Apr;58(1):95–101

PHARMACOLOGY

Enhanced sensitivity to androstenone following regular exposure to pemenone. Stevens DA, et al. **Chem Senses** 1995 Aug;20(4):413–9
Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3–kinase. Cross MJ, et al. **J Biol Chem** 1995 Oct 27;270(43):25352–5

ANDROSTENOLS

METABOLISM

Effect of phospholipids and organic solvents on the formation of 5,16–androstadien–3 beta–ol from pregnenolone in adrenal and testicular microsomes. Meadus WJ, et al. **Steroids** 1995 May;60(5):395–400

PHARMACOLOGY

Special issue on AIDS. **Cell Mol Biol (Noisy–le–grand)** 1995; 41 Suppl 1:S1–161
Synthesis and anti–HIV activity of steroidal prodrugs of 3'–azido–3'–deoxythymidine (AZT). Balagopala MI, et al. **Cell Mol Biol (Noisy–le–grand)** 1995;41 Suppl 1:S1–7

ANDROSTERONE

ANALOGS & DERIVATIVES

Accumulation of 5 alpha–reduced androgen glucosiduronates associated with impaired removal in young male hemodialysis patients. Boudou P, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3489–93

BLOOD

Serum androsterone levels in children. Ueshiba H, et al. **Horm Metab Res** 1996 Apr;28(4):190–2
[Androsterone] Kambegawa A. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:487–90 (13 ref.) **(Jpn)**

ANECDOTES

A psychiatrist's personal description of a panic attack [letter] Benjamin J. **Am J Psychiatry** 1996 Apr;153(4):582–3
Anecdotes and empiricism [editorial] Macnaughton J. **Br J Gen Pract** 1995 Nov;45(400):571–2
Anecdotes and clinical trials: the story of clenbuterol [editorial; comment] Derksen FJ. **Equine Vet J** 1994 Jul; 26(4):256–8. Comment on: Equine Vet J 1994 Jul;26(4):331–6.
The place of stories in the practice of medicine. Eide BL. **JAMA** 1996 Oct 2;276(13):1098

ANEMIA

Anemia of pregnancy. Mani S, et al. **Clin Perinatol** 1995 Sep; 22(3):593–607 (41 ref.)
A 73–year–old man with hyperglycemia, skin rashes, anemia and weight loss. Henry JG, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2428–33
OSDH nutrition program successful in reducing childhood anemia rate [news] **J Okla State Med Assoc** 1996 Jun; 89(6):219
Anemia. Erickson JM. **Semin Oncol Nurs** 1996 Feb;12(1):2–14 (64 ref.)

BLOOD

Hemoglobin concentration in pregnant women. Experience from Moshi, Tanzania. Bergsjo P, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):241–4
Pregnancy associated alpha–glycoprotein (SP–III) in Nigerian pregnant women. Onyemelukwe GC, et al. **Afr J Med Med Sci** 1995 Mar;24(1):17–20
Erythropoietin and cytokine levels in the anemia of severe alcoholic liver disease. Means RT Jr, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):355–8
Interactions between mutant and wild–type band 3 subunits in hereditary Southeast Asian ovalocytic red blood cell membranes. Salhany JM, et al. **Biochemistry** 1996 Jan 9; 35(1):251–7
Flow cytometric reticulocyte maturity index: a useful laboratory parameter of erythropoietic activity in anemia. Davis BH, et al. **Cytometry** 1995 Mar 15;22(1):35–9
Red blood cell polyamines, anaemia and tumour growth in the rat. Quemener V, et al. **Eur J Cancer** 1996 Feb; 32A(2):316–21
Blunted erythropoietin response to anaemia in tuberculosis. Ebrahim O, et al. **Eur J Haematol** 1995 Oct;55(4):251–4
Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Siciliano M, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1132–5
The role of thymosin F5 on anemia in hypercholesterolemic rabbits. Gökkuşu C, et al. **Horm Metab Res** 1995 Oct; 27(10):465–8
Alteration of circulating micronutrients with overt and occult infections in anaemic Guatemalan preschool children. Ruz M, et al. **Int J Food Sci Nutr** 1995 Aug;46(3):257–65
Effect of recombinant human erythropoietin (rHuEPO) on protein, zinc (Zn), nickel (Ni) and manganese (Mn) in patients undergoing chronic haemodialysis. Hosokawa S, et al. **Int Urol Nephrol** 1995;27(2):207–14
Anaemia and raised erythrocyte sedimentation rate [letter] Balakrishnan C, et al. **J Assoc Physicians India** 1995 Apr; 43(4):303
Opposite effects of urea on hemoglobin–oxygen affinity in anemia of chronic renal failure. Monti JP, et al. **Kidney Int** 1995 Sep;48(3):827–31
Physiological response to experimentally induced anemia in rats: a comparative study. Redondo PA, et al. **Lab Anim Sci** 1995 Oct;45(5):578–83
Lipid peroxidation of erythrocytes during anemia of the hamsters infected with Leishmania donovani. Biswas T, et al. **Mol Cell Biochem** 1995 May 24;146(2):99–105
Images in clinical medicine. Spur cells. Doll DC. **N Engl J Med** 1995 Nov 2;333(18):1183
Effects of haemodialysis and continuous ambulatory peritoneal dialysis on the plasma clearance of an albumin–bound furan dicarboxylic acid. Costigan MG, et al. **Nephrol Dial Transplant** 1995;10(5):648–52
The determination of plasma transferrin receptor as good index of erythropoietic activity in renal anemia and after renal transplantation. de Paoli Vitali E, et al. **Nephron** 1996; 72(4):552–6
[Quality improvement project 'Laboratory diagnosis by family physicians' leads to substantial reduction in the number of laboratory analyses (letter)] Smit EM. **Ned Tijdschr Geneeskd** 1996 May 18;140(20):1093; discussion 1093–4 **(Dut)**
[Clinical measurement of serum transferrin receptor—a promising new measure for the diagnosis of anemia] Punnonen K, et al. **Duodecim** 1995;111(2):144–8 **(Fin)**
[How I examine... Anemia (1)] Beguin Y. **Rev Med Liege** 1995 Oct;50(10):443–4 **(Fre)**
[Sport–anemia: studies on hematological status in high school boy athletes] Sakurada K, et al. **Rinsho Byori** 1996 Jul; 44(7):616–21 (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Nonsteroidal antiinflammatory drug–induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis. Davies NM, et al. **Arthritis Rheum** 1996 Feb; 39(2):321–4 (15 ref.)
Systemic hematologic effects of PEG–rHuMGDF–induced megakaryocyte hyperplasia in mice. Ulich TR, et al. **Blood** 1996 Jun 15;87(12):5006–15
IL–6–induced anaemia in rats: possible pathogenetic implications for anemia observed in chronic inflammations. Jongen–Lavrencic M, et al. **Clin Exp Immunol** 1996 Feb; 103(2):328–34
Systemic treatment with epidermal growth factor induces anaemia in Goettingen minipigs. Juhl CO, et al. **Clin Sci (Colch)** 1995 Oct;89(4):453–8
Cisplatin–associated anaemia in patients with solid tumours. A retrospective evaluation and considerations relative to erythropoietin administration. Locatelli MC, et al. **Support Care Cancer** 1996 May;4(3):218–9
Chronic cadmium exposure–induced renal anemia in ovariectomized rats. Hiratsuka H, et al. **Toxicol Appl Pharmacol** 1996 Apr;137(2):228–36
Angiotensin converting enzyme inhibitor induced anemia in a kidney transplant recipient. Kuriyama R, et al. **Transplant Proc** 1996 Jun;28(3):1635
[Cholestatic hepatitis and anemia induced by ticlopidine] Pascual S, et al. **Gastroenterol Hepatol** 1996 Apr; 19(4):208–9 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Use of a functional classification of anemia in myelodysplastic syndromes to identify subgroups of patients responsive to recombinant human–erythropoietin therapy [letter] Bucalossi A, et al. **Eur J Haematol** 1996 Jan–Feb; 56(1–2):106–8

COMPLICATIONS

The spontaneous resolution of cystic hygroma (CH), hydrops fetalis (HF), and fetal anemia [letter; comment] Weissman A, et al. **Am J Perinatol** 1995 Sep;12(5):375. Comment on: Am J Perinatol 1993 Nov;10(6):455–9.
Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Peeters HR, et al. **Ann Rheum Dis** 1996 Mar;55(3):162–8
Hyperventilation in febrile Nigerian children without pneumonia: an evaluation of the influence of anaemia. Meremikwu MM, et al. **Cent Afr J Med** 1995 Aug; 41(8):248–52
57–year old woman with anemia and rash. Farraj R, et al. **Mayo Clin Proc** 1996 Mar;71(3):303–6
Microcytic anaemia and depression in hyperthyroidism [letter] Demiroglu H. **N Z Med J** 1995 Nov 10; 108(1011):465–6
Treatment with recombinant human erythropoietin in children with malignancies. Bolonaki I, et al. **Pediatr Hematol Oncol** 1996 Mar–Apr;13(2):111–21
[Anterior resection for rectal carcinoma in an anemic Jehovah's Witness] Haphtel L, et al. **Harefuah** 1996 Apr 15;130(8):517–8, 584, 583 (Eng. Abstr.) **(Heb)**

DIAGNOSIS

Using clinical signs to diagnose anaemia in African children. Luby SP, et al. **Bull World Health Organ** 1995;73(4):477–82
An expert system to diagnose anemia and report results directly on hematology forms. Birndorf NI, et al. **Comput Biomed Res** 1996 Feb;29(1):16–26
Screening for anemia in pregnancy with copper sulfate densitometry. Pistorius LR, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):33–6
Glycosylated haemoglobin and transient erythroblastopenia of childhood [letter] Karsten J, et al. **Lancet** 1996 Jan 27; 347(8996):273
[How I examine... anemia (2)] Beguin Y. **Rev Med Liege** 1995 Nov;50(11):487–8 **(Fre)**
[Perioperative and postoperative normovolemic anemia. Physiological compensation, monitoring and risk evaluation] Ostgaard G. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):57–60 (43 ref.) (Eng. Abstr.) **(Nor)**
[Normocytic anemia and hypercholesterolemia as the manifestation of a variant of Hashimoto's thyroiditis] Buitrago Ramirez F, et al. **An Esp Pediatr** 1996 Jul; 45(1):76–8 (10 ref.) **(Spa)**
[Reference values in the diagnosis of anemia in the elderly] Gilsanz F, et al. **Rev Clin Esp** 1996 May;196(5):289–92 (Eng. Abstr.) **(Spa)**

[Hematologic causes of vascular diseases of the central nervous system] Arboix A, et al. **Rev Neurol** 1995;23 Suppl 1:S41-9 (62 ref.) **(Spa)**

DRUG THERAPY

Erythropoietin and the anemia of cancer. Beguin Y. **Acta Clin Belg** 1996;51(1):36-52 (104 ref.)

Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Kuriyama S, et al. **Am J Hypertens** 1996 May;9(5):426-31

Treatment of anemia of nephrotic syndrome with recombinant erythropoietin. Gansevoort RT, et al. **Am J Kidney Dis** 1996 Aug;28(2):274-7 (14 ref.)

L-carnitine and erythropoietin requirements in hemodialysis patients [letter] Kavadias D, et al. **Am J Kidney Dis** 1996 Jul;28(1):156

Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Moreno F, et al. **Am J Kidney Dis** 1996 Apr;27(4):548-56

The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states. Thamer M, et al. **Am J Kidney Dis** 1996 Aug;28(2):235-49

Recombinant erythropoietin for zidovudine-induced anemia in AIDS. Kuehl AK, et al. **Ann Pharmacother** 1995 Jul-Aug;29(7-8):778-9 (15 ref.)

Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Garton JP, et al. **Arch Intern Med** 1995 Oct 23;155(19):2069-74

Recombinant human erythropoietin: effect on the functional performance of anemic orthopedic patients. Green D, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3):242-6

Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Osterborg A, et al. **Blood** 1996 Apr 1; 87(7):2675-82

Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. Bible KC, et al. **Br J Haematol** 1996 May;93(2):406-8

Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy [letter; comment] Anand A, et al. **Cancer** 1996 May 1;77(9):1960-1. Comment on: Cancer 1995 Dec 1;76(11):2319-29.

Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy [see comments] Ludwig H, et al. **Cancer** 1995 Dec 1;76(11):2319-29. Comment in: Cancer 1996 May 1;77(9):1960-1.

Recombinant human erythropoietin in chemotherapy-associated anemia. Cascinu S, et al. **Cancer Treat Rev** 1996 Nov;21(6):553-64 (61 ref.)

Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Perera R, et al. **Clin Auton Res** 1995 Sep;5(4):211-3

The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Fishbane S, et al. **Clin Nephrol** 1995 Oct;44(4):238-40

The effect of erythropoietin on lactate, pyruvate and excess lactate under physical exercise in dialysis patients. Meierhenrich R, et al. **Clin Nephrol** 1996 Feb;45(2):90-7

Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system. Radermacher J, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S56-60 (51 ref.)

Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations. Steffensen G, et al. **Clin Nephrol** 1996 Feb;45(2):98-103

Recombinant human erythropoietin for anaemia in Chinese cancer patients on chemotherapy [letter] Chan AT, et al. **Clin Oncol (R Coll Radiol)** 1995;7(4):272

Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Dunn CJ, et al. **Drugs** 1996 Feb; 51(2):299-318 (91 ref.)

Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients. Dunn CJ, et al. **Drugs Aging** 1995 Aug;7(2):131-56 (186 ref.)

Use of a functional classification of anemia in myelodysplastic syndromes to identify subgroups of patients responsive to recombinant human-erythropoietin therapy [letter] Bucalossi A, et al. **Eur J Haematol** 1996 Jan-Feb; 56(1-2):106-8

A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. Di Raimondo F, et al. **Eur J Haematol** 1996 Jan-Feb;56(1-2):7-11

Treating the anaemia of a pregnancy with heterozygous beta thalassaemia with recombinant human erythropoietin (r-HuEPO) [letter] Juncà J, et al. **Eur J Haematol** 1995 Oct;55(4):277-8

Study of the effect of recombinant erythropoietin on renal anaemia in predialysis patients with chronic renal failure. Dimitrakov D, et al. **Folia Med (Plovdiv)** 1994;36(3):31-6

Recombinant human erythropoietin for long-term treatment of anemia in paroxysmal nocturnal hemoglobinuria. Balleari E, et al. **Haematologica** 1996 Mar-Apr;81(2):143-7

One-year experience of very low doses of subcutaneous erythropoietin in continuous ambulatory peritoneal dialysis and its effect on haemostasis. Huraib S, et al. **Haemostasis** 1995 Nov-Dec;25(6):299-304

Correction of anemia and iron deficiency in vegetarians by administration of ascorbic acid. Sharma DC, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):403-6

Effect of recombinant human erythropoietin (rHuEPO) on protein, zinc (Zn), nickel (Ni) and manganese (Mn) in patients undergoing chronic haemodialysis. Hosokawa S, et al. **Int Urol Nephrol** 1995;27(2):207-14

Hereditary hemorrhagic telangiectasia showing severe anemia which was successfully treated with estrogen. Hisada T, et al. **Intern Med** 1995 Jun;34(6):589-92

Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure. Marrades RM, et al. **J Clin Invest** 1996 May 1;97(9):2092-100

Cellular bioenergetics after erythropoietin therapy in chronic renal failure. Marrades RM, et al. **J Clin Invest** 1996 May 1;97(9):2101-10

Hematologic effect of vitamin A supplementation in anemic Pakistani children. Khan I, et al. **JPMA J Pak Med Assoc** 1996 Feb;46(2):34-8

Excessive level of parathyroid hormone may induce the reduction of recombinant human erythropoietin effect on renal anemia. Fujita Y, et al. **Miner Electrolyte Metab** 1995; 21(1-3):50-4

Recombinant erythropoietin for anemia in inflammatory bowel disease [letter] Fischer T. **N Engl J Med** 1996 Sep 5;335(10):751-2

The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease [see comments] Ifudu O, et al. **N Engl J Med** 1996 Feb 15; 334(7):420-5. Comment in: N Engl J Med 1996 Feb 15;334(7):461-3. Comment in: N Engl J Med 1996 Jun 20;334(25):1669; discussion 1670-1. Comment in: N Engl J Med 1996 Jun 20;334(25):1669-70; discussion 1670-1. Comment in: N Engl J Med 1996 Jun 20;334(25):1670; discussion 1670-1.

Resistance to erythropoietin [editorial; comment] Lacombe C. **N Engl J Med** 1996 Mar 7;334(10):660-2. Comment on: N Engl J Med 1996 Mar 7;334(10):619-23. Comment on: N Engl J Med 1996 Mar 7;334(10):630-3.

Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease [see comments] Schreiber S, et al. **N Engl J Med** 1996 Mar 7;334(10):619-23. Comment in: N Engl J Med 1996 Mar 7;334(10):660-2.

Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Albitar S, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:40-3

Effect of recombinant human erythropoietin on soluble interleukin 2 receptor (SIL-2R) levels in haemodialysis patients [letter] Altun B, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2164

Subcutaneous erythropoietin administration in predialysis patients: a single centre prospective study. Branger B, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:36-9

Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. Caravaca F, et al. **Nephrol Dial Transplant** 1995; 10(9):1720-4

Haemodynamic changes and exercise tolerance in dialysis patients treated with erythropoietin. Jurić M, et al. **Nephrol Dial Transplant** 1995;10(8):1398-404

rHuEpo before dialysis and in dialysed patients. López-Gómez JM, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:31-5 (39 ref.)

Poor response to erythropoietin: practical guidelines on investigation and management. Macdougall IC. **Nephrol Dial Transplant** 1995;10(5):607-14 (62 ref.)

Treatment of anaemia resistant to conventional erythropoietin therapy with thymopentin in haemodialysis patients. Raiola P, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:48-50

Successful trial of steroids in two haemodialysis patients with inflammatory disease and anaemia unresponsive to recombinant erythropoietin [letter] Tzanakis I, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):400-1

Effectiveness of subcutaneous low-dose erythropoietin in patients with chronic renal failure despite functional iron deficiency [letter] Bedani PL, et al. **Nephron** 1995; 71(4):459-60

Effect of erythropoietin on systolic and diastolic left ventricular function in chronic renal failure with anemia [letter] Ozakgun R, et al. **Nephron** 1995;71(1):103-4

Folic acid supplementation improves erythropoietin response. Pronai W, et al. **Nephron** 1995;71(4):395-400

Erythropoietin modified the cardiac action of ouabain in chronically anaemic-uraemic rats. Wald M, et al. **Nephron** 1995;71(2):190-6

Reduced glutathione for the treatment of anemia during hemodialysis: a preliminary communication. Zachée P, et al. **Nephron** 1995;71(3):343-9

Anemia of chronic renal failure: characterization in the mouse and correction with human recombinant erythropoietin. Zhang F, et al. **Nephron** 1996;72(4):654-61

Erythropoietin treatment of erythropoietin-deficient anemia without renal disease during pregnancy. Harris SA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):812-4

Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Australian and New Zealand Paediatric Nephrology Association. Burke JR. **Pediatr Nephrol** 1995 Oct;9(5):558-61

Interdependence of vitamin A and iron: an important association for programmes of anaemia control. Bloem MW. **Proc Nutr Soc** 1995 Jul;54(2):501-8 (39 ref.)

Recombinant human erythropoietin treatment of anemia in renal transplant patients. Lezaic V, et al. **Ren Fail** 1995 Nov;17(6):705-14

Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study. Heiss MM, et al. **Surgery** 1996 May;119(5):523-7

[Role of recombinant erythropoietin during the preoperative period] Janssens M, et al. **Ann Fr Anesth Reanim** 1995;14 Suppl 1:98-106 **(Fre)**

[Human recombinant erythropoietin in the treatment of anemia in obstetric-gynecologic patients. Evaluation of such treatment as an alternative to blood transfusion] Delzanno G, et al. **Minerva Ginecol** 1996 Mar;48(3):115-8 (Eng. Abstr.) **(Ita)**

[Successful treatment of splenomegaly and anemia by VP therapy in idiopathic myelofibrosis complicated with acromegaly: a case report] Imai Y, et al. **Rinsho Ketsueki** 1995 Oct;36(10):1233-6 (Eng. Abstr.) **(Jpn)**

[Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view] Duclos J, et al. **Rev Med Chil** 1995 Apr;123(4):451-5 (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Comparison of pancuronium and vecuronium for fetal neuromuscular blockade during invasive procedures. Watson WJ, et al. **J Matern Fetal Med** 1996 May-Jun; 5(3):151-4

EPIDEMIOLOGY

Nutritional influences on growth and prevalence of anaemia in children during the war in Sarajevo. Cemerlic-Zecevic E, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 2:S43-5

[A nutritional survey in Tibet] Kolsteren P, et al. **Sante** 1995 Jul-Aug;5(4):247-52 (Eng. Abstr.) **(Fre)**

[The prevalence of anemia in women of reproductive age belonging to rural Somali communities] Omar MM, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):571-5 (Eng. Abstr.) **(Ita)**

ETHNOLOGY

Haematological traits, religion and rural/urban residence among the Lepchas of Kalimpong subdivision, Darjeeling district, West Bengal (India). Mukhopadhyay B, et al. **Anthropol Anz** 1996 Mar;54(1):35-43

ETIOLOGY

The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Foley RN, et al. **Am J Kidney Dis** 1996 Jul;28(1):53-61

L-carnitine and erythropoietin requirements in hemodialysis patients [letter] Kavadias D, et al. **Am J Kidney Dis** 1996 Jul;28(1):156

Anemia in copper-deficient rats: role of alterations in erythrocyte membrane fluidity and oxidative damage. Rock E, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1245-9

Studies on Plasmodium falciparum parasitemia and development of anemia in Nigerian infants during their first year of life. Achidi EA, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):138-43

Energy expenditure and anaemia of autonomic failure [letter] Ducla-Soares JL, et al. **Clin Auton Res** 1995 Jun;5(3):179

Nutritional anemias in infancy. Gallagher PG, et al. **Clin Perinatol** 1995 Sep;22(3):671-92 (127 ref.)

Anemia due to reduced serum erythropoietin concentration in non-uremic diabetic patients. Kojima K, et al. **Diabetes Res Clin Pract** 1995 Mar;27(3):229-33

Severe anaemia as first sign of metastatic alveolar rhabdomyosarcoma [letter] Di Mario A, et al. **Eur J Haematol** 1996 Jul;57(1):109-10

Anemia of cancer. Moliterno AR, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):345-63 (78 ref.)

Pulsatile sternal mass in an anemic woman. Hariharan R, et al. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):76O, 76R

Severe recurrent epistaxis causing antepartum fetal distress [letter] Braithwaite JM, et al. **Int J Gynaecol Obstet** 1995 Aug;50(2):197-8

Zonary placenta. Steemers NY, et al. **Int J Gynaecol Obstet** 1995 Dec;51(3):251-3 (3 ref.)

A clinical approach to "idiopathic" normocytic-normochromic anemia. Elis A, et al. **J Am Geriatr Soc** 1996 Jul;44(7):832-4

Epidemiology of anemia in older patients with hip fracture [letter] Lombardi G, et al. **J Am Geriatr Soc** 1996 Jun; 44(6):740-1

Sinusoidal fetal heart rate pattern during chemotherapy in a pregnant woman with acute myelogenous leukemia. Hsu KF, et al. **J Formos Med Assoc** 1995 Sep;94(9):562-5

Fetal and neonatal haemodilution associated with multiple placental chorioangioma: case report. Montan S, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):43-6

Copper deficiency [letter] Logan JI.
J R Coll Physicians Lond 1995 Sep–Oct;29(5):449
Osteopetrosis, anemia, thrombocytopenia, and marrow necrosis in beef calves naturally infected with bovine virus diarrhea virus. Scruggs DW, et al. **J Vet Diagn Invest** 1995 Oct;7(4):555–9
Erythropoiesis and erythropoietin in multiple myeloma. Beguin Y. **Leuk Lymphoma** 1995 Aug;18(5–6):413–21 (135 ref.)
Intensity of hemodialysis and response to erythropoietin [letter; comment] Kotanko P. **N Engl J Med** 1996 Jun 20; 334(25):1670; discussion 1670–1. Comment on: N Engl J Med 1996 Feb 15;334(7):420–5.
Intensity of hemodialysis and response to erythropoietin [letter; comment] Uréna P, et al. **N Engl J Med** 1996 Jun 20;334(25):1669; discussion 1670–1. Comment on: N Engl J Med 1996 Feb 15;334(7):420–5.
Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function. Nampoory MR, et al.
Nephrol Dial Transplant 1996 Jan;11(1):177–81
Effect of angiotensin-converting enzyme inhibitors on anemia in hemodialyzed patients [letter] Teruel JL, et al. **Nephron** 1996;73(1):113
Anemia of chronic renal failure: characterization in the mouse and correction with human recombinant erythropoietin. Zhang F, et al. **Nephron** 1996;72(4):654–61
The anemia of inflammation. A common cause of childhood anemia. Abshire TC. **Pediatr Clin North Am** 1996 Jun; 43(3):623–37 (72 ref.)
Profound anaemia in an elderly man. Swain DG.
Postgrad Med J 1996 Jun;72(848):369–70
The aetiology of anaemia in pregnancy in West Africa. van den Broek N. **Trop Doct** 1996 Jan;26(1):5–7 (16 ref.)
The effect of L-thyroxine on the anaemia response in Trypanosoma congolense infected rabbits. Lomo PO, et al. **Vet Parasitol** 1995 Jun;58(3):227–34
[Relationship between tumour necrosis factor and anemia of malaria] Hou Y, et al.
Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih 1995;13(2):134–7 (Eng. Abstr.) **(Chi)**
[Treatment of anemia in patients with tumors] Tesařová P, et al. **Cas Lek Cesk** 1995 Oct 18;134(20):647–50 (29 ref.) (Eng. Abstr.) **(Cze)**
[Transient erythroblastopenia in children; a harmless form of anemia] Yska AM, et al. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):613–5 (Eng. Abstr.) **(Dut)**
[Small bowel endoscopy during surgery in the treatment and diagnosis of angiodysplasias] Saarnio J, et al. **Duodecim** 1994;110(5):506–8 **(Fin)**
[Is there a magnesium-deficiency anemia?] Szelényi H, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):886 **(Ger)**
[Hereditary hemorrhagic telangiectasia presenting with hematuria and severe anemia] Paz A, et al. **Harefuah** 1995 Jul;129(1–2):24–5, 79, 78 (Eng. Abstr.) **(Heb)**
[Recombinant human erythropoietin in the treatment of anemic patients undergoing chemotherapy for cancer] Bösze P, et al. **Orv Hetil** 1995 Nov 19;136(47):2567–72 (Eng. Abstr.) **(Hun)**
[Anemia and hemostasis dysfunction in patients with immunoproliferative disorders] Suehiro A, et al.
Nippon Naika Gakkai Zasshi 1995 Jul 10;84(7):1091–5 (5 ref.) **(Jpn)**
[Hematologic disturbances in patients with nonhematologic neoplasms. I. Anemias] Kwiatkowski A, et al.
Przegl Lek 1995;52(8):407–9 (11 ref.) **(Pol)**
[Anaemia and macroglossia as the first clinical features of multiple myeloma and amyloidosis (letter)] Balaña Quintero C, et al. **Sangre (Barc)** 1995 Oct;40(5):435–6 **(Spa)**

GENETICS

Interactions between mutant and wild-type band 3 subunits in hereditary Southeast Asian ovalocytic red blood cell membranes. Salhany JM, et al. **Biochemistry** 1996 Jan 9; 35(1):251–7
Xerocytosis with concomitant intrauterine ascites: first description and therapeutic approach [letter] Entezami M, et al. **Blood** 1996 Jun 15;87(12):5392–3
Unusual and unrelated polyclonality in a case of myeloid disease. Sandberg AA, et al. **Cancer Genet Cytogenet** 1996 Apr;87(2):156–60
Hematopoietic stem cells in the hereditarily anemic Belgrade laboratory (b/b) rat [see comments] Ivanović Z, et al. **Exp Hematol** 1995 Oct;23(11):1218–23. Comment in: Exp Hematol 1995 Oct;23(11):1152.
The Belgrade laboratory (b/b) rat and the role of hypoxia in the maintenance of hematopoietic stem cells [letter; comment] Rolović Z. **Exp Hematol** 1995 Oct;23(11):1152 . Comment on: Exp Hematol 1995 Oct;23(11):1218–23.

IMMUNOLOGY

Red blood cells expressing fetal antigens: their presence in adults with certain forms of anemia. Lunghi M, et al. **Acta Haematol** 1996;96(1):29–35
Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia [letter; comment] Peces R, et al. **N Engl J Med** 1996 Aug 15; 335(7):523–4. Comment on: N Engl J Med 1996 Mar 7;334(10):630–3.
Reactivity of anti-erythrocyte antibody induced by Babesia gibsoni infection against aged erythrocytes. Morita T, et al. **Vet Parasitol** 1995 Jul;58(4):291–9

METABOLISM

Increased erythropoietin production in children with severe malarial anemia. Burchard GD, et al.
Am J Trop Med Hyg 1995 Nov;53(5):547–51
Acute dilutional anemia and critical left anterior descending coronary artery stenosis impairs end organ oxygen delivery. Levy PS, et al. **J Trauma** 1996 Sep;41(3):416–23
Modulation of erythropoietin production by selective adenosine agonists and antagonists in normal and anemic rats. Nagashima K, et al. **Life Sci** 1996;59(9):761–71

MORTALITY

Childhood deaths from anaemia in Accra, Ghana [see comments] Commey JO, et al. **West Afr J Med** 1995 Apr–Jun;14(2):101–4. Comment in: West Afr J Med 1995 Apr–Jun;14(2):70–1.

PATHOLOGY

The effects of anaemia on heart, placenta and body weight, and blood pressure in fetal and neonatal rats. Crowe C, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):515–9
The seeding efficiency of normal and hereditarily anemic (b/b) rat bone marrow colony forming units-spleen as determined in a "rat to mouse" assay. Ivanović ZB, et al. **Stem Cells (Dayt)** 1995 Nov;13(6):666–70

PHYSIOPATHOLOGY

Right ventricular function in chronically anemic fetal lambs. Davis LE, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1289–94
Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease. Jongen-Lavrencic M, et al. **Clin Rheumatol** 1995 Sep;14(5):519–25 (93 ref.)
Anemia increases gastric blood flow in noncirrhotic and cirrhotic patients. Cirera I, et al. **Gastrointest Endosc** 1995 Nov;42(5):403–7
Effect of anemia on intrapulmonary shunt during atelectasis in rabbits. Deem S, et al. **J Appl Physiol** 1995 Dec; 79(6):1951–7
The effects of anaemia on heart, placenta and body weight, and blood pressure in fetal and neonatal rats. Crowe C, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):515–9
Physiological response to experimentally induced anemia in rats: a comparative study. Redondo PA, et al.
Lab Anim Sci 1995 Oct;45(5):578–83
Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. Caravaca F, et al. **Nephrol Dial Transplant** 1995; 10(9):1720–4
Role of endogenous atrial natriuretic peptide in chronic anemia in the ovine fetus: effects of a non-peptide antagonist for atrial natriuretic peptide receptor. Silberbach M, et al. **Pediatr Res** 1995 Nov;38(5):722–8
Anemia and erythropoietin levels in lung transplant recipients. End A, et al. **Transplantation** 1995 Dec 15; 60(11):1245–51

PREVENTION & CONTROL

Anthelmintic therapy and iron supplementation of pregnant women [letter; comment] Pawlowski ZS.
Am J Clin Nutr 1995 Nov;62(5):1023–4. Comment on: Am J Clin Nutr 1994 Aug;60(2):286–92.
Erythropoiesis, erythropoietin, and iron metabolism in elective surgery: preoperative strategies for avoiding allogeneic blood exposure. Goldberg MA. **Am J Surg** 1995 Dec;170(6A Suppl):37S–43S
Management of chemotherapy-induced anemia. Eguchi K. **Curr Opin Oncol** 1995 Jul;7(4):316–9 (33 ref.)
Effects of recombinant human erythropoietin in infants with very low birth weights. Samanci N, et al.
J Int Med Res 1996 Mar–Apr;24(2):190–8
Guidelines for dietary supplementation of pregnant women in a Rwandan refugee camp. Duckett JR.
J R Army Med Corps 1996 Feb;142(1):13–4
Adult screening for anemia and hemoglobinopathies.
Nurse Pract 1995 Dec;20(12):48–51 (9 ref.)
Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Wurnig C, et al. **Transfusion** 1996 Feb;36(2):155–9
The effect of L-thyroxine on the anaemia response in Trypanosoma congolense infected rabbits. Lomo PO, et al. **Vet Parasitol** 1995 Jun;58(3):227–34
Nutritional guidance for mothers of anaemic infants [letter] Hokama T. **World Health Forum** 1995;16(3):273–5
[Evaluation of the impact of iron treatment. Interference of malaria] Schneider D, et al. **Bull Soc Pathol Exot** 1995 Apr;88(5):260–4 (Eng. Abstr.) **(Fre)**
[Comparison of the ability to control anemia in patients on hemodialysis and peritoneal dialysis considering iron reserves and plasma erythropoietin] Majdan M, et al.
Pol Arch Med Wewn 1996 Apr;95(4):307–12 (Eng. Abstr.) **(Pol)**
[Results of preoperative autotransfusion with ferrous ascorbate prophylaxis in orthopedic surgery patients] Guinea JM, et al. **Sangre (Barc)** 1996 Feb;41(1):25–8 (Eng. Abstr.) **(Spa)**

THERAPY

Enhancement of erythropoiesis by erythropoietin, bovine protein and energy fortified mother's milk during anaemia of prematurity. Rønnestad A, et al. **Acta Paediatr** 1995 Jul; 84(7):809–11
Health care outcomes case study: anemia in end-stage renal disease. Turco TF. **Am J Health Syst Pharm** 1995 Oct 1; 52(19 Suppl 4):S19–23
L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Dario Labonia W.
Am J Kidney Dis 1995 Nov;26(5):757–64
Successful use of recombinant human erythropoietin in a pregnant woman with lupus nephritis. Kontessis PS, et al.
Am J Kidney Dis 1995 Nov;26(5):781–4
Recombinant human erythropoietin in the treatment of anemia of prematurity. Chen JY, et al. **Am J Perinatol** 1995 Sep;12(5):314–8
Morbidity risk assessment in the surgically anemic patient. Carson JL. **Am J Surg** 1995 Dec;170(6A Suppl):32S–36S (53 ref.)
Logarithmic quantitation model using serum ferritin to estimate iron overload in secondary haemochromatosis. Güngör T, et al. **Arch Dis Child** 1996 Apr;74(4):323–7
Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Cazzola M, et al. **Blood** 1995 Dec 15;86(12):4446–53
Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy [letter] van Kaam AH, et al.
Cancer 1996 Sep 1;78(5):1144–5
The use of epoetin beta in anemic predialysis patients with chronic renal failure. Koch KM, et al. **Clin Nephrol** 1995 Sep;44(3):201–8
Surgical management of patients with severe anaemia due to acute blood loss: a case for withholding perioperative blood transfusion. Elechi EN, et al. **East Afr Med J** 1995 Jun;72(6):343–4
Engraftment of W/c-kit mutant mice is determined by stem cell competition, not by increased marrow 'space'. Fleishman RA. **Exp Hematol** 1996 Feb;24(2):209–13
Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis. Acharya VN, et al. **J Assoc Physicians India** 1995 Aug;43(8):539–42
Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. Monti M, et al.
J Pain Symptom Manage 1996 Jul;12(1):18–22
Relation between blood pressure and hematocrit in anephric patients treated by means of recombinant DNA human erythropoietin [letter] Iorio L, et al. **Nephron** 1996; 72(2):373–4
Endocrinology and PD: optimal treatment of anemia in peritoneal dialysis patients. Bárány P. **Perit Dial Int** 1996; 16 Suppl 1:S260–6 (65 ref.)
Delayed reaction following ABO-incompatible transfusion [letter] Cheng MS. **Transfusion** 1995 Sep;35(9):791
The hemostatic effect of adequate red cell transfusion in patients with anemia and thrombocytopenia [letter] Ho CH.
Transfusion 1996 Mar;36(3):290
[Treatment of anemia in patients with tumors] Tesařová P, et al. **Cas Lek Cesk** 1995 Oct 18;134(20):647–50 (29 ref.) (Eng. Abstr.) **(Cze)**
[Evaluation of treatment of anemia with erythropoietin in patients with multiple myeloma] Adam Z, et al.
Vnitr Lek 1995 Nov;41(11):767–72 (Eng. Abstr.) **(Cze)**
[Erythropoietin in oncology. II. Evaluation of the effectiveness of erythropoietin in hematologic and oncologic diseases] Adam Z, et al. **Vnitr Lek** 1996 May; 42(5):351–8 (82 ref.) (Eng. Abstr.) **(Cze)**
[Erythropoietin in hematology and oncology. I. Chronic anemia in malignant disease and the pharmacology of erythropoietin] Adam Z, et al. **Vnitr Lek** 1996 Apr; 42(4):285–9 (39 ref.) (Eng. Abstr.) **(Cze)**
[Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases—chronic lymphadenosis and multiple myeloma] Haber J, et al. **Vnitr Lek** 1996 Apr;42(4):262–7 (Eng. Abstr.) **(Cze)**
[Erythropoietin in the treatment of anemias] Spička I, et al. **Vnitr Lek** 1996 Mar;42(3):197–9 (Eng. Abstr.) **(Cze)**
[Erythropoiesis and use of hematopoietic growth factors in children] Illum NO. **Ugeskr Laeger** 1996 Jul 15; 158(29):4171–4 (10 ref.) **(Dan)**
[Pharma-clinics. How I treat... anemia (3)] Beguin Y.
Rev Med Liege 1995 Dec;50(12):497–8 **(Fre)**
[Autologous placental blood for therapy of anemia in premature infants] Nickel S. **Fortschr Med** 1995 Dec 20; 113(35–36):509 **(Ger)**
[Blood transfusion in benign obstetric-gynecologic disorders] Barbieri F, et al. **Minerva Ginecol** 1995 Sep;47(9):365–8 (Eng. Abstr.) **(Ita)**
[Countermeasure for patients with anemia due to hemodialysis] Suzuki M. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1663–7 (5 ref.) **(Jpn)**
[The successful use of recombinant human erythropoietin therapy to anemia of granular lymphocyte proliferative disorder] Suzuki A, et al. **Rinsho Ketsueki** 1995 Oct; 36(10):1193–8 (Eng. Abstr.) **(Jpn)**
[The level of erythropoietin in patients with anemia and myeloma multiplex treated with erythropoietin] Ciepluch H, et al. **Pol Arch Med Wewn** 1995 Aug;94(2):153–8 (Eng. Abstr.) **(Pol)**

[Treatment of multiple myeloma associated anemia with human recombinant erythropoietin in a hemodialysis patient] Muszytowski M, et al. **Pol Arch Med Wewn** 1995 Jan;93(1):77–9 (Eng. Abstr.) **(Pol)**

[Evaluation of treating anemia in patients undergoing chronic dialysis with small doses of human recombinant erythropoietin] Marusza W, et al. **Pol Tyg Lek** 1995 Oct; 50(40–44):15–8, 31 (Eng. Abstr.) **(Pol)**

URINE

Diagnosis of microcytic anemia by urinalysis [letter; comment] Chen AL. **Arch Fam Med** 1995 Dec;4(12):1002 . Comment on: Arch Fam Med 1995 Jun;4(6):547–9.

VETERINARY

Flow cytometric analysis of punctate and aggregate reticulocyte responses in phlebotomized cats. Perkins PC, et al. **Am J Vet Res** 1995 Dec;56(12):1564–9

Methemoglobinemia and anemia in a dog with acetaminophen toxicity. Schlesinger DP. **Can Vet J** 1995 Aug;36(8):515–7

The effects of changing demographics on the distribution of marine anemia in farmed salmon in British Columbia. Stephen RC, et al. **Can Vet J** 1995 Sep;36(9):557–62

Trypanosoma congolense: high erythropoietic potential in infected yearling cattle during the acute phase of the anemia. Andrianarivo AG, et al. **Exp Parasitol** 1996 Mar; 82(2):104–11

Splenic vein thrombosis resulting in acute anemia: an unusual manifestation of nephrotic syndrome in a Chinese shar pei with reactive amyloidosis. Clements CA, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct;31(5):411–5

Onion powder in baby food may induce anemia in cats [letter] Kaplan AJ. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1405

Preventive effects of recombinant human erythropoietin administration on anemia associated with repeated hemodialysis in nephrectomized dogs. Oishi A, et al. **J Vet Med Sci** 1995 Oct;57(5):989–90

Canine plasma erythropoietin levels in 124 cases of anemia. Oishi A, et al. **J Vet Med Sci** 1995 Aug;57(4):747–9

Effect of nutritional level on bodyweight, degree of anaemia and carcase composition of sheep infected with Trypanosoma congolense. Katunguka-Rwakishaya E. **Res Vet Sci** 1996 Jan;60(1):29–32

Spleen and kidney of Atlantic salmon (Salmo salar L.) show histochemical changes early in the course of experimentally induced infectious salmon anaemia (ISA). Falk K, et al. **Vet Immunol Immunopathol** 1995 Nov;49(1–2):115–26

A sequential study of the light and electron microscopic liver lesions of infectious anemia in Atlantic salmon (Salmo salar L.). Speilberg L, et al. **Vet Pathol** 1995 Sep;32(5):466–78

Demonstration of infectious salmon anaemia (ISA) viral antigens in cell cultures and tissue sections. Falk K, et al. **Vet Res** 1995;26(5–6):499–504

VIROLOGY

Recurrent human parvovirus B19-induced anemia: initial manifestation of humoral immunodeficiency [letter] Murray JC, et al. **J Pediatr Hematol Oncol** 1996 Feb;18(1):97–8

ANEMIA, ADDISON'S see **ANEMIA, PERNICIOUS**

ANEMIA, APLASTIC

Bone marrow failure in children. Vlachos A, et al. **Curr Opin Pediatr** 1996 Feb;8(1):33–41 (41 ref.)

BLOOD

Circulating erythropoietin in patients with acquired aplastic anaemia. Kojima S, et al. **Acta Haematol** 1995;94(3):117–22

Measurement of endogenous plasma granulocyte colony-stimulating factor in patients with acquired aplastic anemia by a sensitive chemiluminescent immunoassay. Kojima S, et al. **Blood** 1996 Feb 15;87(4):1303–8

Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Lyman SD, et al. **Blood** 1995 Dec 1;86(11):4091–6

Aplastic anaemia and paroxysmal nocturnal haemoglobinuria: a study of the GPI-anchored proteins on human platelets. Vu T, et al. **Br J Haematol** 1996 Jun 1;93(3):586–9

Production of hematopoietic regulatory cytokines by peripheral blood mononuclear cells in patients with aplastic anemia. Hsu HC, et al. **Exp Hematol** 1996 Jan;24(1):31–6

[Evaluation of the Serono System 9020+ hematologic analyzer in oncohematologic patients (letter) (see comments)] Aulesa C, et al. **Sangre (Barc)** 1995 Jun; 40(3):232–3. Comment in: Sangre (Barc) 1995 Oct;40(5):435. **(Spa)**

CHEMICALLY INDUCED

Sustained granulocyte recovery after G-CSF in a patient with ticlopidine-induced severe aplastic anemia [letter] Arribalzaga K, et al. **Am J Hematol** 1995 Dec;50(4):313

Aplastic anemia with ticlopidine therapy in two Chinese patients [letter] Dunn P. **Ann Pharmacother** 1996 May; 30(5):547

Widespread ocular use of topical chloramphenicol: is there justifiable concern regarding idiosyncratic aplastic anaemia? McGhee CN, et al. **Br J Ophthalmol** 1996 Feb; 80(2):182–4

Severe aplastic anemia induced by ticlopidine: report of a case. Su CC, et al. **J Formos Med Assoc** 1995 Nov; 94(11):689–91 (8 ref.)

Aplastic anemia associated with ticlopidine. Shapiro CM, et al. **Neurology** 1996 Jul;47(1):300

[A case of rheumatoid arthritis complicated with salazosulfapyridine-induced aplastic anemia] Suwa A, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb; 18(1):116–22 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Hypothyroidism and hypoparathyroidism in an 11 year old boy with hemochromatosis secondary to aplastic anemia. Himoto Y, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):534–6

Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7. Hashino S, et al. **Ann Hematol** 1996 May;72(5):337–9

Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia. Nagarajan S, et al. **Blood** 1995 Dec 15;86(12):4656–61

Correction of aplastic anaemia complicating paroxysmal nocturnal haemoglobinuria: absence of eradication of the PNH clone and dependence of response on cyclosporin A administration. Stoppa AM, et al. **Br J Haematol** 1996 Apr;93(1):42–4

The novel monoclonal antibody By114 helps detect the early emergence of a paroxysmal nocturnal hemoglobinuria clone in aplastic anemia. Tooze JA, et al. **Exp Hematol** 1995 Dec; 23(14):1484–91

Infections in febrile granulocytopenic patients: clinical features and pathogens. Wang FD, et al. **J Formos Med Assoc** 1996 May;95(5):410–3

Ecthyma gangrenosum associated with aplastic anemia. Chun WH, et al. **J Korean Med Sci** 1996 Feb;11(1):64–7

[Aplastic anemia associated with ovarian bleeding] Nehashi Y, et al. **Rinsho Ketsueki** 1995 Nov;36(11):1329–31 (Eng. Abstr.) **(Jpn)**

[Aplastic anemia complicated with secondary hemochromatosis after allogenic bone marrow transplantation] Oguchi T, et al. **Rinsho Ketsueki** 1995 Oct; 36(10):1188–92 (Eng. Abstr.) **(Jpn)**

[Thrombotic complication in the course of aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome; possible involvement of dysplasminogenemia (plasminogen Tochigi) in the pathogenesis of thrombosis] Takahashi H, et al. **Rinsho Ketsueki** 1996 Mar;37(3):249–54 (Eng. Abstr.) **(Jpn)**

[The course and prognosis of septic shock in patients with hemoblastoses and aplastic anemia in a state of agranulocytosis] Galstian GM, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):18–23 (Eng. Abstr.) **(Rus)**

[2 cases of neutropenic enteropathy and bone marrow hypoplasia. An association not reported in Mexico] Gamboa-Domínguez A, et al. **Rev Invest Clin** 1995 Jul–Aug;47(4):303–9 (25 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Retrospective diagnosis of sickle cell-hemoglobin C disease and parvovirus infection by molecular DNA analysis of postmortem tissue. Goldstein LJ, et al. **Hum Pathol** 1995 Dec;26(12):1375–8

Aplastic anaemia versus hypocellular myelodysplastic syndrome. Varma N, et al. **Indian J Cancer** 1995 Sep; 32(3):110–5

Magnetic resonance imaging for evaluation of childhood aplastic anemia. Kanwar VS, et al. **J Pediatr Hematol Oncol** 1995 Nov;17(4):284–9

[Diagnosis of blood consumptive disease instead of "xuelao" in hematologia diseases--observation on immune function of red blood cells] Liang YJ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun; 15(6):368–70 **(Chi)**

[25-year-old patient with pancytopenia] Meusser S, et al. **Internist (Berl)** 1995 Oct;36(10):999–1004 **(Ger)**

DRUG THERAPY

Sustained granulocyte recovery after G-CSF in a patient with ticlopidine-induced severe aplastic anemia [letter] Arribalzaga K, et al. **Am J Hematol** 1995 Dec;50(4):313

First report of a B cell lymphoproliferative disorder arising in a patient treated with immune suppressants for severe aplastic anemia. Dorr V, et al. **Am J Hematol** 1996 Jun; 52(2):108–13

Treatment of chemotherapy-induced or idiopathic bone marrow aplasia with granulocyte colony-stimulating factor (G-CSF). Robak T, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(5–6):433–8

Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Brodsky RA, et al. **Blood** 1996 Jan 15;87(2):491–4

Correction of aplastic anaemia complicating paroxysmal nocturnal haemoglobinuria: absence of eradication of the PNH clone and dependence of response on cyclosporin A administration. Stoppa AM, et al. **Br J Haematol** 1996 Apr;93(1):42–4

Evolution of severe aplastic anemia to myelodysplasia with monosomy 7 following granulocyte colony-stimulating factor, erythropoietin and high-dose methylprednisolone combination therapy [see comments] Ohsaka A, et al. **Intern Med** 1995 Sep;34(9):892–5. Comment in: Intern Med 1995 Sep;34(9):820–1.

Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. Kosaka A, et al. **J Gastroenterol** 1996 Jun; 31(3):450–4 (24 ref.)

Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy. Hurwitz N, et al. **Leuk Lymphoma** 1996 Jan;20(3–4):337–40

[Recent developments of traditional Chinese medical therapy in treating aplastic anemia] Feng J, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun; 15(6):376–8 (21 ref.) **(Chi)**

EPIDEMIOLOGY

Severe aplastic anaemia in the Nordic countries: a population based study of incidence, presentation, course, and outcome. Clausen N, et al. **Arch Dis Child** 1996 Apr; 74(4):319–22

An association of aplastic anaemia in Thailand with low socioeconomic status. Aplastic Anemia Study Group. Issaragrisil S, et al. **Br J Haematol** 1995 Sep;91(1):80–4

ETIOLOGY

Aplastic anemia as the sole presentation of systemic lupus erythematosus. Chute JP, et al. **Am J Hematol** 1996 Mar; 51(3):237–9

Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Siciliano R, et al. **Ann Ital Med Int** 1995 Jul–Sep; 10(3):193–4 (10 ref.)

A case-control study of aplastic anaemia: occupational exposures. The French Cooperative Group for Epidemiological Study of Aplastic Anaemia. Guiguet M, et al. **Int J Epidemiol** 1995 Oct;24(5):993–9

B19 parvovirus infection and transient aplastic crisis in a child with sickle cell anemia. Rao SP, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):175–7

Aplastic anaemia after HGV infection [letter] Zaidi Y, et al. **Lancet** 1996 Aug 17;348(9025):471–2

Transient aplastic crisis in a leukemic child caused by parvovirus B19 infection. Mihál V, et al. **Pediatr Hematol Oncol** 1996 Mar–Apr;13(2):173–7

GENETICS

Analysis of PIG-A gene in a patient who developed reciprocal translocation of chromosome 12 and paroxysmal nocturnal hemoglobinuria during follow-up of aplastic anemia. Nishimura JI, et al. **Am J Hematol** 1996 Mar; 51(3):229–33

Aplastic anaemia patients with clonal X-chromosome inactivation pattern in haemopoietic cells exhibit polyclonal TCRgamma and IgH gene rearrangements. Melenhorst JJ, et al. **Br J Haematol** 1996 May;93(2):326–32

Response to immunosuppressive therapy and an HLA-DRB1 allele in patients with aplastic anaemia: HLA-DRB1*1501 does not predict response to antithymocyte globulin. Nakao S, et al. **Br J Haematol** 1996 Jan;92(1):155–8

Absence of N-RAS point mutations in peripheral blood cells of patients with aplastic anaemia and paroxysmal nocturnal haemoglobinurea. White JR, et al. **Br J Haematol** 1995 Dec;91(4):921–3

Trisomy 14: a recurring cytogenetic abnormality associated with myeloid disorders. Poirel H, et al. **Leuk Lymphoma** 1995 May;17(5–6):455–7

IMMUNOLOGY

Normal granulocyte function but impaired monocyte function in a patient with aplastic anemia. Zabernigg A, et al. **Acta Haematol** 1995;94(2):109–11

Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Maciejewski JP, et al. **Br J Haematol** 1995 Sep;91(1):245–52

Aplastic anaemia patients with clonal X-chromosome inactivation pattern in haemopoietic cells exhibit polyclonal TCRgamma and IgH gene rearrangements. Melenhorst JJ, et al. **Br J Haematol** 1996 May;93(2):326–32

Inhibition of hematopoiesis by a plasma factor in a case of aplastic anemia associated with systemic lupus erythematosus. Marqués JA, et al. **P R Health Sci J** 1995 Dec;14(4):293–6

Bone marrow fibroblasts from children with aplastic anemia exhibit reduced interleukin-6 production in response to cytokines and viral challenge. Dilloo D, et al. **Pediatr Res** 1995 Nov;38(5):716–21

[Humoral antiviral immunity in children with hematologic neoplasms] Nisevich LL, et al. **Vopr Virusol** 1995 Jul–Aug; 40(4):177–81 (Eng. Abstr.) **(Rus)**

METABOLISM

Overproduction of inhibitory hematopoietic cytokines by lipopolysaccharide-activated peripheral blood mononuclear cells in patients with aplastic anemia. Hsu HC, et al. **Ann Hematol** 1995 Dec;71(6):281–6

Adhesion molecule expression on CD34+ progenitor cells from normal and aplastic anaemia bone marrow. Karakantza M, et al. **Br J Haematol** 1995 Dec;91(4):800–3

Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic

syndromes and aplastic anemia. Koike M, et al. **Leuk Res** 1995 Sep;19(9):639–44

MICROBIOLOGY

[Cutaneous candidiasis due to Candida parapsilosis occurring in the course of idiopathic aplastic anemia] Machet MC, et al. **Ann Pathol** 1995;15(4):276–9 (Eng. Abstr.) **(Fre)**

NURSING

Hematologic problems in pediatric patients. Cahill M. **Semin Oncol Nurs** 1996 Feb;12(1):38–50 (42 ref.)

PATHOLOGY

Deficiency of CD34+ c-kit+ and CD34+38- hematopoietic precursors in aplastic anemia after immunosuppressive treatment. Manz CY, et al. **Am J Hematol** 1996 Aug; 52(4):264–74

Adhesion receptors on bone marrow stromal cells: in vivo expression of vascular cell adhesion molecule-1 by reticular cells and sinusoidal endothelium in normal and gamma-irradiated mice. Jacobsen K, et al. **Blood** 1996 Jan 1;87(1):73–82

A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Maciejewski JP, et al. **Blood** 1996 Sep 15;88(6):1983–91

Clonal hematopoiesis as defined by polymorphic X-linked loci occurs infrequently in aplastic anemia. Raghavachar A, et al. **Blood** 1995 Oct 15;86(8):2938–47

Aplastic anemia: evidence for dysfunctional bone marrow progenitor cells and the corrective effect of granulocyte colony-stimulating factor in vitro. Scopes J, et al. **Blood** 1996 Apr 15;87(8):3179–85

Haemopoietic growth factor production by normal and aplastic anaemia stroma in long-term bone marrow culture. Gibson FM, et al. **Br J Haematol** 1995 Nov;91(3):551–61

Relative erythroid hyperplasia in the bone marrow at diagnosis of aplastic anaemia: a predictive marker for a favourable response to cyclosporine therapy. Nakao S, et al. **Br J Haematol** 1996 Feb;92(2):318–23

The effect of human flt-3 ligand on committed progenitor cell production from normal, aplastic anaemia and Diamond-Blackfan anaemia bone marrow. Scopes J, et al. **Br J Haematol** 1995 Nov;91(3):544–50

Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Philpott NJ, et al. **Exp Hematol** 1995 Dec;23(14):1642–8

Classification of hematopoietic regions in out-of-phase T1-weighted images: a quantitative comparison study with T1-weighted and STIR images. Amano Y, et al. **Radiat Med** 1995 Jul-Aug;13(4):153–5

[Morphological observation of a process of bone marrow hypoplastic formation in a case of aplastic anemia] Utsugisawa T, et al. **Rinsho Ketsueki** 1995 Oct; 36(10):1157–62 (Eng. Abstr.) **(Jpn)**

[The colony-forming capacity of the precursor cells of granulomonocytopoesis in bone marrow aplasia] Balashova VA, et al. **Morfologiia** 1994 Jul-Dec;107(7-12):14–22 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Effect of haemoglobin and endogenous erythropoietin on hypothalamic-pituitary thyroidal and gonadal secretion: an analysis of anaemic (high EPO) and polycythaemic (low EPO) patients. Ramirez G, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):167–74

Persistent growth impairment of bone marrow stroma after antilymphocyte globulin treatment for severe aplastic anaemia and its association with relapse. Nissen C, et al. **Eur J Haematol** 1995 Oct;55(4):255–61

SURGERY

Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Roychowdhury DF, et al. **Bone Marrow Transplant** 1995 Sep;16(3):471–2

Splenectomy as an adjuvant measure in the treatment of severe aplastic anaemia. Speck B, et al. **Br J Haematol** 1996 Mar;92(4):818–24

Selective engraftment of the granulocyte compartment after allogeneic bone marrow transplantation in a patient with severe aplastic anemia. Barriga FJ, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):216–7

[The role of splenectomy in treating severe aplastic anemia] Fedorovskaia NA, et al. **Gematol Transfuziol** 1995 Nov-Dec;40(6):19–21 (Eng. Abstr.) **(Rus)**

THERAPY

Recombinant interleukin-1 followed by immunosuppressive therapy for aplastic anemia [letter] Doney K, et al. **Am J Hematol** 1996 May;52(1):61–2

Final height of patients who underwent bone marrow transplantation during childhood. Cohen A, et al. **Arch Dis Child** 1996 May;74(5):437–40

Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year followup. McKendry RJ, et al. **Arthritis Rheum** 1996 Jul; 39(7):1246–53

Graft failure after an umbilical cord blood transplant in a patient with severe aplastic anemia [letter; comment] Cancelas JA, et al. **Blood** 1995 Nov 1;86(9):3610. Comment on: Blood 1995 May 15;85(10):2991–2.

Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Deeg HJ, et al. **Blood** 1996 Jan 1; 87(1):386–92

Acceleration of hematopoietic reconstitution with a synthetic cytokine (SC-55494) after radiation-induced bone marrow aplasia. Farese AM, et al. **Blood** 1996 Jan 15;87(2):581–91

Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor. MacVittie TJ, et al. **Blood** 1996 May 15; 87(10):4129–35

Acute hemolysis during cyclosporine therapy successfully treated with vitamin E. Azuma E, et al. **Bone Marrow Transplant** 1995 Aug;16(2):321–2

Remission of a lymphoproliferative disorder occurring after second BMT from an unrelated donor in a 5-year-old boy with severe aplastic anemia. Bader P, et al. **Bone Marrow Transplant** 1995 Sep;16(3):479–81

High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Carella AM, et al. **Bone Marrow Transplant** 1996 Feb;17(2):201–5

Multiple granulocyte transfusions facilitating successful unrelated bone marrow transplantation in a patient with very severe aplastic anemia complicated by suspected fungal infection. Clarke K, et al. **Bone Marrow Transplant** 1995 Nov;16(5):723–6

Successful treatment of parvovirus B19 infection and red cell aplasia occurring after an allogeneic bone marrow transplant. Corbett TJ, et al. **Bone Marrow Transplant** 1995 Nov;16(5):711–3

Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis. Vazquez JA, et al. **Bone Marrow Transplant** 1995 Dec;16(6):849–53

Recombinant human interleukin-3 in refractory severe aplastic anaemia: a phase I/II trial. Bargetzi MJ, et al. **Br J Haematol** 1995 Oct;91(2):306–12

Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Langston AA, et al. **Br J Haematol** 1996 Mar;92(3):758–65

Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Margolis D, et al. **Br J Haematol** 1996 Jul;94(1):65–72

Effects of high-dose granulocyte colony-stimulating factor on neutrophil functions. Yasui K, et al. **Br J Haematol** 1996 Mar;92(3):571–3

Recombinant human G-CSF-mobilized peripheral blood stem cells for second allogeneic transplant after bone marrow graft rejection in children. Zecca M, et al. **Br J Haematol** 1996 Feb;92(2):432–4

Allogeneic bone marrow transplantation for fourteen patients with severe aplastic anemia. Hsueh EJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Apr; 57(4):247–53

Granulocyte-macrophage colony-stimulating factor therapy in patients with chemotherapy-induced aplasia and Clostridium difficile enterocolitis [letter] Geiger R, et al. **Eur J Cancer** 1995 Dec;31A(13-14):2416–7

Combined transplantation with related HLA-identical cord blood and bone marrow in a child with severe acquired aplastic anaemia [letter] Dallorso S, et al. **Eur J Haematol** 1996 Apr;56(4):256–8

Persistent growth impairment of bone marrow stroma after antilymphocyte globulin treatment for severe aplastic anaemia and its association with relapse. Nissen C, et al. **Eur J Haematol** 1995 Oct;55(4):255–61

Immunosuppressive therapy in bone marrow aplasia: the stroma functions normally to support hematopoiesis. Novitzky N, et al. **Exp Hematol** 1995 Dec;23(14):1472–7

Combined immunosuppressive therapy in aplastic anaemia. Osman I, et al. **Indian J Med Res** 1995 Sep;102:143–6

Treatment of aplastic anaemia with antilymphocyte globulin and cyclosporin. Marsh JC, et al. **Int J Hematol** 1995 Oct; 62(3):133–44 (79 ref.)

Aplastic anaemia with a trilineage response to erythropoietin therapy. Bernell P. **J Intern Med** 1996 Jan;239(1):79–81 (11 ref.)

Bone marrow transplantation in pediatric patients with severe aplastic anemia: cyclophosphamide and anti-thymocyte globulin conditioning followed by recombinant human granulocyte-macrophage colony stimulating factor. Bunin N, et al. **J Pediatr Hematol Oncol** 1996 Feb;18(1):68–71

Sweet syndrome in a child with aplastic anemia receiving recombinant granulocyte colony-stimulating factor. Shimizu T, et al. **J Pediatr Hematol Oncol** 1996 Aug; 18(3):282–4

Anti-lymphocyte globulin therapy in aplastic anaemia--a university hospital experience. Leong KW, et al. **Med J Malaysia** 1995 Jun;50(2):158–61

Successful pregnancy following aplastic anaemia. Leong KW, et al. **Postgrad Med J** 1995 Oct;71(840):625–7

Bone marrow transplantation. Storb R. **Transplant Proc** 1995 Oct;27(5):2649–52 (6 ref.)

Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. Wagner JL, et al. **Transplantation** 1996 Jan 15;61(1):54–61

[G-CSF (Neupogen Roche) in the treatment of patients with chronic aplastic anemia with severe neutropenia] Novotný J, et al. **Vnitr Lek** 1995 Oct;41(10):692–5 (Eng. Abstr.) **(Cze)**

[Treatment of severe acquired aplastic anemia] Jacobsen N. **Nord Med** 1995;110(12):314–5 (Eng. Abstr.) **(Dan)**

[Therapeutic approaches of hematopoietic syndrome following accidental total whole body irradiation] Thierry D, et al. **Bull Cancer (Paris)** 1996 May;83(5):361–70 (40 ref.) (Eng. Abstr.) **(Fre)**

[10 years transplantation of bone marrow and hematopoietic stem cells in adults at the Hannover Medical School] Link H, et al. **Med Klin** 1996 Apr 12;91 Suppl 3:3–17 (Eng. Abstr.) **(Ger)**

[Two patients with aplastic anemia successfully treated with G-CSF and erythropoietin] Hanamura A, et al. **Rinsho Ketsueki** 1995 Dec;36(12):1347–52 (Eng. Abstr.) **(Jpn)**

[Aplastic anemia with giant splenomegaly and myelofibrosis successfully treated with antilymphocyte globulin] Kaito K, et al. **Rinsho Ketsueki** 1995 Aug;36(8):786–91 (Eng. Abstr.) **(Jpn)**

[Interleukin-3 therapy in patients with aplastic anemia refractory to prior therapies] Miyairi Y, et al. **Rinsho Ketsueki** 1996 Jan;37(1):22–8 (Eng. Abstr.) **(Jpn)**

[Urgent allogeneic bone marrow transplantation using a preparative regimen of cyclophosphamide anti-human thymocytes rabbit globulin in a patient with severe aplastic anemia with pneumonia] Okamoto T, et al. **Rinsho Ketsueki** 1996 Jan;37(1):72–6 (Eng. Abstr.) **(Jpn)**

[Resolution of psoriasis vulgaris following allogeneic bone marrow transplantation for aplastic anemia] Yokota A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):35–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Results of treatment for severe acquired aplastic anemia in children] Ochocka M, et al. **Pediatr Pol** 1995 Mar; 70(3):205–11 (Eng. Abstr.) **(Pol)**

[The treatment results in patients with aplastic anemia using different doses of antilymphocyte globulin] Abdulkadyrov KM, et al. **Ter Arkh** 1995;67(8):51–4 (Eng. Abstr.) **(Rus)**

[Allogenic bone marrow transplantation in the treatment of malignant hematologic disease] Barriga F, et al. **Rev Med Chil** 1995 May;123(5):605–11 (Eng. Abstr.) **(Spa)**

VETERINARY

Myeloid and megakaryocytic hypoplasia in related standardbreds. Kohn CW, et al. **J Vet Intern Med** 1995 Sep-Oct;9(5):315–23

VIROLOGY

Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Langnas AN, et al. **Hepatology** 1995 Dec;22(6):1661–5

B19 parvovirus infection and transient aplastic crisis in a child with sickle cell anemia. Rao SP, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):175–7

Hepatitis G-associated aplastic anaemia [letter] Byrnes JJ, et al. **Lancet** 1996 Aug 17;348(9025):472

Severe aplastic anaemia due to B19 parvovirus infection in renal transplant recipient. Bertoni E, et al. **Nephrol Dial Transplant** 1995;10(8):1462–3

[Parvovirus B19--a ubiquitous, little know virus. From erythema infectiosum and arthropathy to chronic anemia] Frickhofen N. **Fortschr Med** 1995 Sep 10;113(25):351–3 **(Ger)**

ANEMIA, COOLEY'S see **BETA-THALASSEMIA**

ANEMIA, DIAMOND-BLACKFAN see **FANCONI'S ANEMIA**

ANEMIA, DYSERYTHROPOIETIC, CONGENITAL

Congenital dyserythropoietic anemias. Marks PW, et al. **Am J Hematol** 1996 Jan;51(1):55–63 (91 ref.)

BLOOD

The cisternae decorating the red blood cell membrane in congenital dyserythropoietic anemia (type II) originate from the endoplasmic reticulum. Alloisio N, et al. **Blood** 1996 May 15;87(10):4433–9

Composition of the intra-erythroblastic precipitates in thalassaemia and congenital dyserythropoietic anaemia (CDA): identification of a new type of CDA with intra-erythroblastic precipitates not reacting with monoclonal antibodies to alpha- and beta-globin chains. Wickramasinghe SN, et al. **Br J Haematol** 1996 Jun 1; 93(3):576–85

COMPLICATIONS

Malignant lymphoma in congenital dyserythropoietic anaemia type III. McCluggage WG, et al. **J Clin Pathol** 1996 Jul;49(7):599–602

[Congenital dyserythropoietic type II anemia complicated by extramedullary hematopoiesis in the posterior mediastinum] Indrák K, et al. **Vnitr Lek** 1995 Oct; 41(10):704–9 (Eng. Abstr.) **(Cze)**

ANEMIA, DYSERYTHROPOIETIC, CONGENITAL

PATHOLOGY

Ultrastructural features in two cases of congenital dyserythropoietic anemia type II. Moldoveanu E, et al. **Rom J Morphol Embryol** 1994 Jul–Dec;40(3–4):133–6

PHYSIOPATHOLOGY

Clinical features and studies of erythropoiesis in Israeli Bedouins with congenital dyserythropoietic anemia type I. Tamary H, et al. **Blood** 1996 Mar 1;87(5):1763–70

ANEMIA, ERYTHROBLASTIC see **BETA-THALASSEMIA**

ANEMIA, FANCONI see **FANCONI'S ANEMIA**

ANEMIA, HEMOLYTIC

Hemolytic anemias in pregnancy. Leduc L. **Clin Obstet Gynecol** 1995 Sep;38(3):463–71 (44 ref.)

Hemolytic anemia in the newborn. Matsunaga AT, et al. **Clin Perinatol** 1995 Sep;22(3):803–28 (76 ref.)

[Hereditary spherocytosis is more common than expected. Hemolysis, anemia and splenomegaly are among the symptoms] Rudolphi O, et al. **Lakartidningen** 1996 May 1;93(18):1745–8 **(Swe)**

BLOOD

Priapism following splenectomy in an unstable hemoglobin: hemoglobin Olmsted beta 141 (H19) Leu—>Arg. Thuret I, et al. **Am J Hematol** 1996 Feb;51(2):133–6

Cholesterol–loading of membranes of normal erythrocytes inhibits phospholipid repair and arachidonoyl–CoA:1–palmitoyl–sn–glycero–3–phosphocholine acyl transferase. A model of spur cell anemia. Allen DW, et al. **Blood** 1996 Apr 15;87(8):3489–93

Southeast Asian ovalocytosis in a South African kindred with hemolytic anemia [letter] Coetzer TL, et al. **Blood** 1996 Feb 15;87(4):1656–7

Osmotic scan ektacytometry in clinical diagnosis. Johnson RM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):122–9 (33 ref.)

CHEMICALLY INDUCED

Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. Mach–Pascual S, et al. **Am J Hematol** 1996 Aug;52(4):310–2

Glyburide–induced acute haemolysis in a G6PD–deficient patient with NIDDM. Meloni G, et al. **Br J Haematol** 1996 Jan;92(1):159–60

Fatal ceftriaxone–induced hemolysis in a child with acquired immunodeficiency syndrome. Borgna–Pignatti C, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1116–7

COMPLICATIONS

[Hypertensive crisis in a female patient on a prolonged hemodialysis program treated with erythropoietin for nephrogenic anemia] Syzdół P, et al. **Pol Arch Med Wewn** 1996 Feb;95(2):142–4 (Eng. Abstr.) **(Pol)**

[Zieve's syndrome. A case report] Fernández Pérez FJ, et al. **Rev Esp Enferm Dig** 1996 Mar;88(3):226–9 (Eng. Abstr.) **(Spa)**

CONGENITAL see **ANEMIA, HEMOLYTIC, CONGENITAL**

DIAGNOSIS

A case of Zieve's syndrome presenting with myalgia: not to be confused with polymyalgia rheumatica [letter] Martin JC, et al. **Br J Rheumatol** 1996 May;35(5):495–6

Osmotic scan ektacytometry in clinical diagnosis. Johnson RM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):122–9 (33 ref.)

Hepatic manifestation of hemolytic uremic syndrome in an allogeneic bone marrow transplant recipient. Böcher WO, et al. **Z Gastroenterol** 1995 Sep;33(9):543–5

[Reversible cerebral MRI findings in acute microangiopathic hemolytic anemia] Horn M, et al. **Nervenarzt** 1996 Jun; 67(6):502–5 (Eng. Abstr.) **(Ger)**

[Acute hemolysis—diagnosis and management] Sułek K. **Pol Arch Med Wewn** 1995 May;93(5):395–400 (10 ref.) **(Pol)**

[Hemolytic anemia and kidney failure in a female splenectomy patient] Vargas Pabón M, et al. **Rev Clin Esp** 1996 May;196(5):335–6, 339 (10 ref.) **(Spa)**

DRUG THERAPY

Acute hemolysis during cyclosporine therapy successfully treated with vitamin E. Azuma E, et al. **Bone Marrow Transplant** 1995 Aug;16(2):321–2

EMBRYOLOGY

Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. Weiner CP, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):547–51

ENZYMOLOGY

Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: tabulation of mutant enzymes. Miwa S, et al. **Am J Hematol** 1996 Feb;51(2):122–32 (105 ref.)

Study of the molecular defects in glucose phosphate isomerase–deficient patients affected by chronic hemolytic anemia. Baronciani L, et al. **Blood** 1996 Sep 15; 88(6):2306–10

ETIOLOGY

Hemolytic anemia in a patient with subacute bacterial endocarditis due to Streptococcus sanguis. Inada T, et al. **Acta Haematol** 1995;94(2):95–7

Ovarian dermoid cyst–associated autoimmune hemolytic anemia: a case report with emphasis on pathogenic mechanisms. Cobo F, et al. **Am J Clin Pathol** 1996 May; 105(5):567–71

Acute hemolytic anemia precipitated by myocardial infarction and pericardial tamponade in G6PD deficiency [letter] Lee DH, et al. **Am J Hematol** 1996 Feb;51(2):174–5

Hemolytic anemia: an unusual presentation of congenital heart disease. Daubeney PE, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):109–11

A case of bioprosthetic mitral valve dysfunction presenting as haemolytic anaemia [letter] Chan DK, et al. **Aust N Z J Med** 1995 Oct;25(5):543

Passenger B–lymphocyte–induced severe hemolytic disease after allogeneic peripheral blood stem cell transplantation [letter] Toren A, et al. **Blood** 1996 Jan 15;87(2):843–4

Microangiopathic haemolytic anaemia and systemic vasculitis. Ross CN, et al. **Br J Rheumatol** 1996 Apr; 35(4):377–9

Hemolytic anemia and cancer. Diehl LF, et al. **Cancer Treat Rev** 1996 Jan;22(1):33–73 (298 ref.)

Hemolytic disorders associated with cancer. Rytting M, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):365–76 (87 ref.)

Mechanisms of hemolysis with mitral prosthetic regurgitation. Study using transesophageal echocardiography and fluid dynamic simulation. Garcia MJ, et al. **J Am Coll Cardiol** 1996 Feb;27(2):399–406

Acute transient hemolytic anemia with a positive Donath–Landsteiner test following parvovirus B19 infection. Chambers LA, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):178–81

Life–threatening hemolysis following a brown recluse spider bite. Leung LK, et al. **J Tenn Med Assoc** 1995 Oct; 88(10):396–7

Valvular (external hinge) leakage of the CarboMedics mitral valve. Hashimoto K, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):277–8

Haemolytic anaemia after mitral valve repair [letter; comment] Dol YL, et al. **Lancet** 1996 May 11; 347(9011):1330–1. Comment on: Lancet 1996 Mar 16;347(9003):765.

Outcome of an enterohaemorrhagic Escherichia coli O157 infection in monozygotic twins [letter] Ludwig K, et al. **Lancet** 1996 Jan 20;347(8995):196–7

Transfusion–requiring haemolytic anaemia after mitral–valve repair [letter] [see comments] Stoschitzky K, et al. **Lancet** 1996 Mar 16;347(9003):765. Comment in: Lancet 1996 May 11;347(9011):1330–1.

The anemia of inflammation. A common cause of childhood anemia. Abshire TC. **Pediatr Clin North Am** 1996 Jun; 43(3):623–37 (72 ref.)

Microangiopathic hemolytic anemia, thrombocytopenia, and renal injury during continuous venovenous hemodialysis in a neonate [letter] Sherbotie JR. **Pediatr Nephrol** 1995 Dec;9(6):789–90

Fragmentation hemolysis: an unusual indication for valve replacement in native valve infective endocarditis. Gradon JD, et al. **South Med J** 1996 Aug;89(8):818–20 (7 ref.)

Hemolytic anemia in chronic large granular lymphocytic leukemia of natural killer cells: cytotoxicity of natural killer cells against autologous red cells is associated with hemolysis. Gilsanz F, et al. **Transfusion** 1996 May; 36(5):463–6

[A case of failure of mitroflow pericardial valve with severe hemolytic anemia] Ohkado A, et al. **Kyobu Geka** 1995 Nov; 48(12):1013–5 (Eng. Abstr.) **(Jpn)**

[Transjugular intrahepatic portosystemic shunt and intravascular hemolysis (letter)] Montes J, et al. **Med Clin (Barc)** 1995 Oct 7;105(11):439 **(Spa)**

GENETICS

Molecular analysis of glucose phosphate isomerase deficiency associated with hereditary hemolytic anemia. Kanno H, et al. **Blood** 1996 Sep 15;88(6):2321–5

A novel silent posttranslational mechanism converts methionine to aspartate in hemoglobin Bristol (beta 67[E11] Val–Met–>Asp). Rees DC, et al. **Blood** 1996 Jul 1; 88(1):341–8

A new alpha chain variant Hb Sallanches [alpha 2 104(G11) Cys—>Tyr] associated with HbH disease in one homozygous patient. Morlé F, et al. **Br J Haematol** 1995 Nov;91(3):608–11

Five unknown mutations in the LR pyruvate kinase gene associated with severe hereditary nonspherocytic haemolytic anaemia in France. Rouger H, et al. **Br J Haematol** 1996 Mar;92(4):825–30

Structure, organization, and expression of the human band 7.2b gene, a candidate gene for hereditary hydrocytosis. Gallagher PG, et al. **J Biol Chem** 1995 Nov 3; 270(44):26358–63

Candidate gene acting as a suppressor of the RH locus in most cases of Rh–deficiency. Cherif–Zahar B, et al. **Nat Genet** 1996 Feb;12(2):168–73

Red cell enzymopathies as a model of inborn errors of metabolism. Miwa S, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:112–9 (39 ref.)

[RHnull syndrome—diagnostic and therapeutic problems] Kuśnierz–Alejska G, et al. **Acta Haematol Pol** 1996; 27(1):89–95 (Eng. Abstr.) **(Pol)**

HISTORY

[Scientific raisins from 127 years SMW (Swiss Medical Weekly). Hemolytic–uremic syndrome: bilateral kidney cortex necrosis in acute acquired hemolytic anemia. 1925 (classical article)] Gasser C, et al. **Schweiz Med Wochenschr** 1995 Dec 26;125(51–52):2528–32 **(Ger)**

IMMUNOLOGY

Restricted immunoglobulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. Efremov DG, et al. **Blood** 1996 May 1; 87(9):3869–76

Antibody–mediated hemolytic anemia following ABO–mismatched organ transplantation: contributory role of HLA matching and polyclonal antilymphocyte globulin. Fabrega AJ, et al. **Clin Transplant** 1996 Apr;10(2):166–9

[Hemolytic anemia, myocardial infarction and xenotransplantation: what do they have in common?] Schifferli JA. **Schweiz Med Wochenschr** 1995 Nov 18; 125(46):2217–25 (Eng. Abstr.) **(Fre)**

METABOLISM

Profile of urinary bile acids in familial intrahepatic cholestasis with Coombs' negative haemolytic anaemia. Kimura A, et al. **Acta Paediatr** 1995 Oct;84(10):1119–24

Hemolytic anemia does not increase entry into, nor alter rate of clearance of bilirubin from rat brain. Hansen TW, et al. **Biol Neonate** 1996;69(4):268–74

Cellular mechanisms underlying the increased duodenal iron absorption in rats in response to phenylhydrazine–induced haemolytic anaemia [see comments] O'Riordan DK, et al. **Eur J Clin Invest** 1995 Oct;25(10):722–7. Comment in: Eur J Clin Invest 1995 Oct;25(10):721.

MICROBIOLOGY

Clostridium perfringens sepsis with intravascular hemolysis following laparoscopic cholecystectomy: a newly reported complication. Bush GW, et al. **Am Surg** 1996 Apr; 62(4):326–7

PATHOLOGY

Rapidly progressive glomerulonephritis following hemolytic crisis [letter] Borràs M, et al. **Nephron** 1996;72(4):734–5

PHYSIOPATHOLOGY

Case report: diabetic microangiopathic hemolytic anemia and thrombocytopenia with antiphospholipid syndrome. Morita H, et al. **Am J Med Sci** 1996 Mar;311(3):148–51

PREVENTION & CONTROL

[Iron prophylaxis and maternal hematological levels during pregnancy] Siimes MA, et al. **Duodecim** 1994; 110(14):1329–32 **(Fin)**

[Quality assurance and prevention of immuno–hemolytic incidents in blood transfusion] Boëlle PY, et al. **Transfus Clin Biol** 1996;3(1):27–34 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[Acute hemolysis—diagnosis and management] Sułek K. **Pol Arch Med Wewn** 1995 May;93(5):395–400 (10 ref.) **(Pol)**

ULTRASONOGRAPHY

Diagnosis of fetal anemia with Doppler ultrasound in the pregnancy complicated by maternal blood group immunization. Mari G, et al. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):400–5

VETERINARY

Hemolytic transfusion reactions in a dog with an alloantibody to a common antigen. Callan MB, et al. **J Vet Intern Med** 1995 Jul–Aug;9(4):277–9

Haemolytic anaemia in an embryo transfer calf [letter] Baxter K. **Vet Rec** 1996 Apr 6;138(14):339

VIROLOGY

Haemolytic anaemia complicating Epstein–Barr virus infection. Whitelaw F, et al. **Br J Clin Pract** 1995 Jul–Aug; 49(4):212–3

Cytomegalovirus–induced thrombocytopenia and haemolysis in an immunocompetent adult. van Spronsen DJ, et al. **Br J Haematol** 1996 Jan;92(1):218–20

[Cytomegalovirus pneumopathy and hemolytic anemia in an immunocompetent patient (letter)] Welker Y, et al. **Presse Med** 1996 Mar 30;25(11):557 **(Fre)**

ANEMIA, HEMOLYTIC, ACQUIRED see ANEMIA, HEMOLYTIC

ANEMIA, HEMOLYTIC, AUTOIMMUNE

BLOOD

An unusual case of autoimmune hemolytic anemia with reticulocytopenia, erythroid dysplasia, and an IgG2 autoanti-U. Roush GR, et al. **Transfusion** 1996 Jun; 36(6):575-80

CHEMICALLY INDUCED

Autoimmune hemolytic anemia induced by diclofenac [letter] López A, et al. **Ann Pharmacother** 1995 Jul-Aug; 29(7-8):787

Tacrolimus-related posttransplant lymphoproliferative disorder presenting as autoimmune hemolytic anemia. DiGiuseppe JA, et al. **Arch Pathol Lab Med** 1996 Mar; 120(3):282-5

Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Maclean R, et al. **Br J Haematol** 1996 Mar;92(3):768-9

Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Myint H, et al. **Br J Haematol** 1995 Oct;91(2):341-4

Administration of interleukin-5 or -10 activates peritoneal B-1 cells and induces autoimmune hemolytic anemia in anti-erythrocyte autoantibody-transgenic mice. Nisitani S, et al. **Eur J Immunol** 1995 Nov;25(11):3047-52

Autoimmune hemolytic anemia during alpha interferon treatment in nine patients with hematological diseases. Andriani A, et al. **Haematologica** 1996 May-Jun; 81(3):258-60

Microangiopathic hemolytic anemia secondary to cyclosporine therapy in a heart and liver transplant recipient [letter] Oteo JF, et al. **J Heart Lung Transplant** 1996 Mar;15(3):322-4

Species specificity of 2-aryl carbapenem-induced immune-mediated hemolytic anemia in primates. Lankas GR, et al. **Toxicology** 1996 Apr 30;108(3):207-15

[A case of SLE-like syndrome and severe hemolytic anemia caused by methyldopa] Sakurai Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2069-71 (9 ref.) **(Jpn)**

[Fludarabine and fatal hemolytic anemia (letter)] López L, et al. **Sangre (Barc)** 1995 Aug;40(4):335-6 **(Spa)**

COMPLICATIONS

Selective IgA deficiency with unusual features: development of common variable immunodeficiency, Sjögren's syndrome, autoimmune hemolytic anemia and immune thrombocytopenic purpura. Sanal O, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):526-9

Leukopenia, thrombocytopenia, and acute autoimmune hemolytic anemia associated with an unusual (type 2/4) Hodgkin's disease: case report [letter] Costello RT, et al. **Am J Hematol** 1996 Aug;52(4):333-4

Autoimmune hemolytic anemia in patients with de novo acute myelocytic leukemia. Tamura H, et al. **Ann Hematol** 1996 Jan;72(1):45-7

Management of cold agglutinemia with intermittent warm blood cardioplegia and normothermia [letter] Mastrogiovanni G, et al. **Ann Thorac Surg** 1996 Jul; 62(1):317

Autoimmune hemolytic anemia in chronic mucocutaneous candidiasis. Oyefara BI, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):38-43

A case of herpetiform pemphigus associated with autoimmune hemolytic anemia: detection of autoantibodies against multiple epidermal antigens. Shimizu K, et al. **Dermatology** 1996;192(2):179-82

Monoclonal gammopathy and cold agglutinin disease in non-Hodgkin's lymphoma [letter] Pascali E. **Eur J Haematol** 1996 Jan-Feb;56(1-2):114-5

Intravenous immunoglobulin therapy in an infant with autoimmune hemolytic anemia associated with necrotic hepatitis and peliosis. Lachaux A, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):99-102

Immune thrombocytopenia and hemolytic anemia associated with Hodgkin disease. Shah SJ, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):227-9

Renal cell carcinoma and autoimmune hemolytic anemia. Lands R, et al. **South Med J** 1996 Apr;89(4):444-5

Upper extremity arterial thrombosis associated with immunohemolytic anemia. Lipski DA, et al. **Surgery** 1996 Mar;119(3):354-5

[Acute pancreatitis, an unknown complication of acute intravascular hemolysis (letter)] Bréchignac X, et al. **Rev Med Interne** 1996;17(2):172-3 **(Fre)**

[Autoimmune hemolytic anemia and ulcerative colitis] Rebocho L, et al. **Acta Med Port** 1995 Dec;8(12):701-3 (Eng. Abstr.) **(Por)**

[Autoimmune hemolytic anemia associated with Castleman's disease. Response of both diseases to glucocorticoid treatment (letter; comment)] Gómez-Espuch J, et al. **Med Clin (Barc)** 1996 May 4;106(17):677-8. Comment on: Med Clin (Barc) 1995 Nov 11;105(16):638-9. **(Spa)**

DIAGNOSIS

The value of gel test and ELAT in autoimmune haemolytic anaemia. Fabijanska-Mitek J, et al. **Clin Lab Haematol** 1995 Dec;17(4):311-6

ACP Broadsheet No 145--Investigation of patients with autoimmune haemolytic anaemia and provision of blood for transfusion [letter; comment] de Silva M, et al. **J Clin Pathol** 1996 Feb;49(2):187. Comment on: J Clin Pathol 1995 Jul;48(7):602-10.

ACP Broadsheet No. 145: July 1995. Investigation of patients with autoimmune haemolytic anaemia and provision of blood for transfusion [see comments] Sokol RJ, et al. **J Clin Pathol** 1995 Jul;48(7):602-10. Comment in: J Clin Pathol 1996 Feb;49(2):187.

Anaemia in a child. Berberoğlu S. **Postgrad Med J** 1995 Nov; 71(841):689-91

[3 patients with autoimmune hemolytic anemia in a peripheral hospital] Ermens AA, et al. **Ned Tijdschr Geneeskd** 1995 Sep 16;139(37):1865-7 **(Dut)**

[Chlamydia pneumoniae infection associated with autoimmune hemolytic anemia due to warm antibodies] Belda J, et al. **Arch Bronconeumol** 1996 May;32(5):251-2 (7 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Intractable acute autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia successfully treated with vincristine-loaded platelet infusion [letter] Sigler E, et al. **Am J Hematol** 1995 Dec;50(4):313-5

Lactoferrin lowers the incidence of positive Coombs' test in New Zealand black mice. Zimecki M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(3-4):207-9

Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Emilia G, et al. **Br J Haematol** 1996 May;93(2):341-4

Evans syndrome. Results of a pilot study utilizing a multiagent treatment protocol. Scaradavou A, et al. **J Pediatr Hematol Oncol** 1995 Nov;17(4):290-5

[A case of Evans's syndrome in which thrombocytopenia and hemolysis was improved by Sairei-to] Horikoshi A, et al. **Rinsho Ketsueki** 1995 Oct;36(10):1237-9 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Combined autoimmune cytopenias. Martino R, et al. **Haematologica** 1995 Jul-Aug;80(4):305-10 (25 ref.)

ETIOLOGY

A case of autoimmune hemolytic anemia induced by IFN-beta therapy for type-C chronic hepatitis. Kazuta Y, et al. **Fukushima J Med Sci** 1995 Jun;41(1):43-9

Von Hippel-Lindau disease complicated by acute pancreatitis and Evan's syndrome. Tenner S, et al. **Int J Pancreatol** 1995 Dec;18(3):271-5

Unremitting severe autoimmune haemolytic anaemia as a presenting feature of Hodgkin's disease with minimum tumour load. Majumdar G. **Leuk Lymphoma** 1995 Dec; 20(1-2):169-72

Evans' syndrome, myelofibrosis and systemic lupus erythematosus: role of procollagens in myelofibrosis. Ramakrishna R, et al. **Pathology** 1995 Jul;27(3):255-9 (23 ref.)

[A case of drug-induced immune hemolytic anemia during alpha-interferon therapy for renal cell carcinoma] Yanaihara H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):714-7 (Eng. Abstr.) **(Jpn)**

[Silicosis associated with autoimmune hemolytic anemia] Sunami K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov;33(11):1297-301 (Eng. Abstr.) **(Jpn)**

[A case of Evans's syndrome with antiphospholipid antibody syndrome] Hirayama Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):611-3 **(Jpn)**

[Mixed warm and cold antibody type autoimmune hemolytic anemia associated with systemic lupus erythematosus] Watanabe A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):77-81 (Eng. Abstr.) **(Jpn)**

[Autoimmune hemolytic anemia during the course of pancreatic abscess--case history] Sołowiej D, et al. **Przegl Lek** 1995;52(8):405-6 (Eng. Abstr.) **(Pol)**

GENETICS

Trisomy 3 is a consistent chromosome change in malignant lymphoproliferative disorders preceded by cold agglutinin disease. Michaux L, et al. **Br J Haematol** 1995 Oct; 91(2):421-4

More on MHC class II deficiency [letter] Hauber I, et al. **N Engl J Med** 1996 Sep 26;335(13):977-8

IMMUNOLOGY

Immunoglobulin gene use by naturally occurring cold agglutinins. Jefferies LC, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:433-5

[125I]IgM (KAU) human monoclonal cold agglutinin: labelling and studies on its biological activity. Vigorito E, et al. **Appl Radiat Isot** 1995 Oct;46(10):975-9

Diverse antigen specificity of erythrocyte-reactive monoclonal autoantibodies from NZB mice. de Sá Oliveira GG, et al. **Clin Exp Immunol** 1996 Aug;105(2):313-20

Enzyme-linked antiglobulin test for the evaluation of the amount of IgG autoantibodies on red blood cells. Namirska-Krzton H, et al. **Clin Lab Haematol** 1995 Sep; 17(3):221-4

Autoreactive T cell specificity in autoimmune hemolytic anemia of the NZB mouse. Perry FE, et al. **Eur J Immunol** 1996 Jan;26(1):136-41

Aggressive CD5-positive diffuse large B cell lymphoma showing c-myc rearrangements developed in a patient with autoimmune hemolytic anemia. Sonoki T, et al. **Int J Hematol** 1996 Jan;63(1):71-6

An unusual case of autoimmune hemolytic anemia with reticulocytopenia, erythroid dysplasia, and an IgG2 autoanti-U. Roush GR, et al. **Transfusion** 1996 Jun; 36(6):575-80

PHYSIOPATHOLOGY

Images in clinical medicine. Seasonal hemolysis due to cold-agglutinin syndrome. Lyckholm LJ, et al. **N Engl J Med** 1996 Feb 15;334(7):437

SURGERY

[Splenectomy under celioscopy] Parent S, et al. **Ann Chir** 1995;49(6):477-81 (Eng. Abstr.) **(Fre)**

[A hematologist's point of view] Varet B. **Ann Chir** 1995; 49(6):490-2 **(Fre)**

VETERINARY

Central nervous system rendez-vous--canine progressive posterior paresis. Little PB. **Can Vet J** 1996 Jan;37(1):55-6

Canine immune-mediated diabetes mellitus: a case report. Elie M, et al. **J Am Anim Hosp Assoc** 1995 Jul-Aug; 31(4):295-9

Red blood cell glycophorins as B and T-cell antigens in canine autoimmune haemolytic anaemia. Barker RN, et al. **Vet Immunol Immunopathol** 1995 Aug;47(3-4):225-38

[What is your diagnosis? Idiopathic immunohemolytic anemia in a dog] Komáromy AM, et al. **Schweiz Arch Tierheilkd** 1995;137(10):485-9 **(Ger)**

ANEMIA, HEMOLYTIC, CONGENITAL

BLOOD

Red cell genetic disorders and plasma lipids. el-Hazmi MA, et al. **J Trop Pediatr** 1995 Aug;41(4):202-5

[Unstable Santa Ana hemoglobin or alpha 2 beta 2 88 (F4) Leu-Pro detected in a Slovak girl] Divoký V, et al. **Vnitr Lek** 1996 Apr;42(4):258-61 (Eng. Abstr.) **(Cze)**

ENZYMOLOGY

Erythrocyte pyruvate kinase deficiency. The influence of physiologically important metabolites on the function of normal and defective enzymes. Lakomek M, et al. **Enzyme Protein** 1994-95;48(3):149-63

ETIOLOGY

[Diagnosis of pyruvate kinase deficiency in the presence of an elevated reticulocyte count] Pekrun A, et al. **Dtsch Med Wochenschr** 1995 Nov 24;120(47):1620-4 (Eng. Abstr.) **(Ger)**

GENETICS

Molecular basis and haplotyping of the alphaII domain polymorphisms of spectrin: application to the study of hereditary elliptocytosis and pyropoikilocytosis. Gallagher PG, et al. **Am J Hum Genet** 1996 Aug;59(2):351-9

Molecular defect of a phosphoglycerate kinase variant associated with haemolytic anaemia and neurological disorders in a large kindred. Turner G, et al. **Br J Haematol** 1995 Sep;91(1):60-5

Hb Hakkari or alpha 2 beta 2 31(B13)Leu-->Arg, a severely unstable hemoglobin variant associated with numerous intra-erythroblastic inclusions and erythroid hyperplasia of the bone marrow. Gürgey A, et al. **Hemoglobin** 1995 May-Jul;19(3-4):165-72

Hb Bibba or alpha 2 136(H19)Leu-->Pro beta 2 in a Caucasian family from Alabama. Prchal JT, et al. **Hemoglobin** 1995 May-Jul;19(3-4):151-64

A novel intrachromosomal rearrangement in the beta-globin gene found in an African-American family. Rahbar S, et al. **Hemoglobin** 1995;19(6):375-88

Band 4.2 Komatsu: 523 GAT-->TAT (175 Asp-->Tyr) in exon 4 of the band 4.2 gene associated with total deficiency of band 4.2, hemolytic anemia with ovalostomatocytosis and marked disruption of the cytoskeletal network. Kanzaki A, et al. **Int J Hematol** 1995 Jun;61(4):165-78

[Five cases of hereditary high red cell membrane phosphatidylcholine hemolytic anemia in three families] Wakita M, et al. **Rinsho Ketsueki** 1996 Mar;37(3):265-70 (Eng. Abstr.) **(Jpn)**

SURGERY

Thrombo-embolic disease after splenectomy for hereditary

stomatocytosis. Stewart GW, et al. **Br J Haematol** 1996 May;93(2):303–10

ANEMIA, HEMOLYTIC, CONGENITAL NONSPHEROCYTIC

BLOOD

Three cases of hereditary nonspherocytic hemolytic anemia associated with red blood cell glutathione deficiency. Hirono A, et al. **Blood** 1996 Mar 1;87(5):2071–4 (28 ref.)

DIAGNOSIS

PK Mondor: prenatal diagnosis of a frameshift mutation in the LR pyruvate kinase gene associated with severe hereditary non-spherocytic haemolytic anaemia. Rouger H, et al. **Prenat Diagn** 1996 Feb;16(2):97–104

ENZYMOLOGY

Pyruvate kinase deficiency of mice associated with nonspherocytic hemolytic anemia and cure of the anemia by marrow transplantation without host irradiation. Morimoto M, et al. **Blood** 1995 Dec 1;86(11):4323–30

GENETICS

Primary structure of murine red blood cell-type pyruvate kinase (PK) and molecular characterization of PK deficiency identified in the CBA strain. Kanno H, et al. **Blood** 1995 Oct 15;86(8):3205–10

Molecular abnormality of a phosphoglycerate kinase variant (PGK–Alabama). Yoshida A, et al. **Blood Cells Mol Dis** 1995;21(3):179–81

Mutations in pyruvate kinase. Beutler E, et al. **Hum Mutat** 1996;7(1):1–6 (40 ref.)

Case report: pyruvate kinase deficiency. Rothman JM. **N J Med** 1995 Sep;92(9):587–8

PK Mondor: prenatal diagnosis of a frameshift mutation in the LR pyruvate kinase gene associated with severe hereditary non-spherocytic haemolytic anaemia. Rouger H, et al. **Prenat Diagn** 1996 Feb;16(2):97–104

THERAPY

Pyruvate kinase deficiency of mice associated with nonspherocytic hemolytic anemia and cure of the anemia by marrow transplantation without host irradiation. Morimoto M, et al. **Blood** 1995 Dec 1;86(11):4323–30

ANEMIA, HEMOLYTIC, IDIOPATHIC ACQUIRED see **ANEMIA, HEMOLYTIC, AUTOIMMUNE**

ANEMIA, HYPOCHROMIC

Anaemia in pregnancy: perceptions of patients in Dar-es-Salaam. Massawe S, et al. **East Afr Med J** 1995 Aug;72(8):498–503

BLOOD

Postpartum anaemia is not related to maternal iron status in the third trimester. Lao TT, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):7–10

[Extreme increase in the blood erythroblast count in a patient with iron-deficiency anemia and asplenia] Ramos Fernández de Soria R, et al. **Sangre (Barc)** 1996 Feb; 41(1):65–7 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Laboratory diagnosis of iron deficiency anemia. Newton W. **J Fam Pract** 1995 Oct;41(4):404–5

Parameters of iron deficiency in children with cyanotic congenital heart disease. Olcay L, et al. **Pediatr Cardiol** 1996 May–Jun;17(3):150–4

ETIOLOGY

[Iron: perspective on the athletic woman] Castillo MC, et al. **Sangre (Barc)** 1995 Jun;40(3):199–205 (82 ref.) **(Spa)**

GENETICS

The flaky skin (fsn) mutation in mice: map location and description of the anemia. Beamer WG, et al. **Blood** 1995 Oct 15;86(8):3220–6

THERAPY

[Erythropoietin, a milestone in the history of nephrology] Uehlinger DE, et al. **Ther Umsch** 1995 Oct;52(10):672–7 (16 ref.) (Eng. Abstr.) **(Ger)**

ANEMIA, HYPOPLASTIC see **ANEMIA, APLASTIC**

ANEMIA, HYPOPLASTIC, CONGENITAL see **FANCONI'S ANEMIA**

ANEMIA, IRON-DEFICIENCY

Iron deficiency anemia in pregnancy. Schwartz WJ 3rd, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):443–54 (45 ref.)

The young athlete with chronic disease. Small E, et al. **Clin Sports Med** 1995 Jul;14(3):709–26 (144 ref.)

Dietary deficiency of iron—an extreme example. McGovern MC, et al. **Ulster Med J** 1995 Oct;64(2):197–8

BLOOD

An inappropriate erythropoietic response to iron deficiency anaemia in the elderly. Matsuo T, et al. **Clin Lab Haematol** 1995 Dec;17(4):317–21

Anaemia in children aged 6 to 23 months attending the paediatric acute assessment unit in south Auckland. Rive S, et al. **N Z Med J** 1996 Feb 23;109(1016):58

Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients. Baldus M, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):486–91

Plasma transferrin receptor helps to predict iron deficiency in the anemia of chronic disease. Fleming D, et al. **Nutr Rev** 1995 Jun;53(6):167–9 (23 ref.)

Iron related indices in iron deficiency anemia of geriatric Korean patients. Lee JH, et al. **Yonsei Med J** 1996 Apr; 37(2):104–11

[The effect of the diet on the iron status and incidence of anemia in pregnant women] Ivanova L, et al. **Akush Ginekol (Sofiia)** 1995;34(1):6–8 (Eng. Abstr.) **(Bul)**

[Sex differences in the electrokinetic properties of the erythrocytes in normal children and in iron-deficiency anemia] Matiushichev VB, et al. **Tsitologiia** 1996; 38(3):390–6 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

One person's view of iron deficiency, development, and cognitive function [see comments] Beard J. **Am J Clin Nutr** 1995 Oct;62(4):709–10 (21 ref.). Comment in: Am J Clin Nutr 1996 Jul;64(1):120–1.

Iron deficiency, development, and cognitive function [letter; comment] Walker AR. **Am J Clin Nutr** 1996 Jul;64(1):120–1 . Comment on: Am J Clin Nutr 1995 Oct;62(4):709–10.

Iron deficiency anaemia and febrile convulsions: case–control study in children under 2 years. Pisacane A, et al. **BMJ** 1996 Aug 10;313(7053):343

The influence of maternal iron deficiency anaemia on the haemoglobin concentration of the infant. Türkay S, et al. **J Trop Pediatr** 1995 Dec;41(6):369–71

Carotid artery thrombus associated with severe iron-deficiency anemia and thrombocytosis. Akins PT, et al. **Stroke** 1996 May;27(5):1002–5

Toxic 'sock' syndrome bezoar formation and pancreatitis associated with iron deficiency and pica. Adler AI, et al. **West J Med** 1995 Nov;163(5):480–2

DIAGNOSIS

Red blood cell indices and iron status according to feeding practices in infants and young children. Kim SK, et al. **Acta Paediatr** 1996 Feb;85(2):139–44

Diagnosis of iron deficiency in dialysis patients [letter; comment] Phelps KR. **Am J Kidney Dis** 1996 May; 27(5):762–4. Comment on: Am J Kidney Dis 1995 Aug;26(2):292–9.

Prediction of iron deficiency in chronic inflammatory rheumatic disease anaemia. Baumann Kurer S, et al. **Br J Haematol** 1995 Dec;91(4):820–6

New indices from the H*2 analyser improve differentiation between heterozygous beta or delta beta thalassaemia and iron-deficiency anaemia. Jimenez CV, et al. **Clin Lab Haematol** 1995 Jun;17(2):151–5

Failure of hematocrit to detect iron deficiency in infants. Kazal LA Jr. **J Fam Pract** 1996 Mar;42(3):237–40

Iron deficiency in adolescent boys [letter; comment] Hallberg L, et al. **J Intern Med** 1996 Jan;239(1):84–8. Comment on: J Intern Med 1995 Feb;237(2):187–94.

Clinical problem-solving: if at first you don't succeed [letter; comment] Gambino R, et al. **N Engl J Med** 1996 Apr 4; 334(14):918–9; discussion 920. Comment on: N Engl J Med 1995 Dec 7;333(23):1557–60.

Is zinc protoporphyrin an indicator of iron-deficient erythropoiesis in maintenance haemodialysis patients? Braun J, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):492–7

Plasma transferrin receptor helps to predict iron deficiency in the anemia of chronic disease. Fleming D, et al. **Nutr Rev** 1995 Jun;53(6):167–9 (23 ref.)

Appropriateness of iron prescribing: a retrospective study. Abernathy KA, et al. **Pharmacotherapy** 1996 May–Jun; 16(3):473–6

DIET THERAPY

Purified ferritin and soybean meal can be sources of iron for treating iron deficiency in rats. Beard JL, et al. **J Nutr** 1996 Jan;126(1):154–60

Effects of fructooligosaccharides on the absorption of iron, calcium and magnesium in iron-deficient anemic rats. Ohta A, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun; 41(3):281–91

DRUG THERAPY

Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Silverberg DS, et al. **Am J Kidney Dis** 1996 Feb;27(2):234–8

Injectable medications for hemodialysis patients. Stivelman JC. **Am J Nephrol** 1996;16(1):73–8 (55 ref.)

Supplemental vitamin A enhances the recovery from iron deficiency in rats with chronic vitamin A deficiency. Roodenburg AJ, et al. **Br J Nutr** 1996 Apr;75(4):623–36

Does iron prevent effects of lead exposure? [letter; comment] Robertson WO. **Can Med Assoc J** 1996 Apr 15;154(8):1146, 1148. Comment on: Can Med Assoc J 1996 Jan 1;154(1):13–4.

Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study. Benagiano G, et al. **Fertil Steril** 1996 Aug;66(2):223–9

Excessive tea consumption can inhibit the efficacy of oral iron treatment in iron-deficiency anemia. Gabrielli GB, et al. **Haematologica** 1995 Nov–Dec;80(6):518–20

Correction of anemia and iron deficiency in vegetarians by administration of ascorbic acid. Sharma DC, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):403–6

Brain iron and behavior of rats are not normalized by treatment of iron deficiency anemia during early development. Felt BT, et al. **J Nutr** 1996 Mar; 126(3):693–701

How to diagnose and correct iron deficiency during r-huEPO therapy--a consensus report. Hörl WH, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):246–50 (38 ref.)

[Iron and pregnancy] Beaufrère B, et al. **Arch Pediatr** 1995 Dec;2(12):1209–18 (65 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of iron deficiency in infancy with iron-acetyl transferrin] Careddu P, et al. **Pediatr Med Chir** 1996 Mar–Apr;18(2):155–60 (Eng. Abstr.) **(Ita)**

[Comparison of the effectiveness and tolerance of Aktiferrin, a ferrous sulfate capsule preparation and Tardyferon pills in patients with uncomplicated sideropenic anemia] Mistrík M, et al. **Cas Lek Cesk** 1995 Oct 18;134(20):666–8 (Eng. Abstr.) **(Slo)**

[Costs of the treatment of iron-deficiency anemia (letter)] Castro Pazos M, et al. **Aten Primaria** 1996 Apr 30; 17(7):480–2 **(Spa)**

ECONOMICS

[Costs of the treatment of iron-deficiency anemia (letter)] Castro Pazos M, et al. **Aten Primaria** 1996 Apr 30; 17(7):480–2 **(Spa)**

EMBRYOLOGY

[The effect of benzine and formaldehyde on the prenatal development of rats with induced iron trace-element disorder] Senichenkova IN, et al. **Ontogenez** 1996 Mar–Apr;27(2):108–13 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Relationship between blood lead and dietary iron intake in preschool children. A cross-sectional study. Hammad TA, et al. **Ann Epidemiol** 1996 Jan;6(1):30–3

The prevalence and correlates of anaemia among young children and women of childbearing age in Al Ain, United Arab Emirates. Hossain MM, et al. **Ann Trop Paediatr** 1995 Sep;15(3):227–35

Effect of supplementation with an iron-fortified milk on incidence of diarrhea and respiratory infection in urban-resident infants. Heresi G, et al. **Scand J Infect Dis** 1995;27(4):385–9

[Iron deficiency in the inhabitants of Siberia] Zhuravskaia EIa, et al. **Klin Lab Diagn** 1996 Mar–Apr;(2):16–8 **(Rus)**

ETHNOLOGY

Iron deficiency in Massachusetts communities: Socioeconomic and demographic risk factors among children. Sargent JD, et al. **Am J Public Health** 1996 Apr; 86(4):544–50

ETIOLOGY

Long-term follow-up of older patients with iron deficiency anemia after a negative GI evaluation. Gordon S, et al. **Am J Gastroenterol** 1996 May;91(5):885–9

Microcytic anemia with iron malabsorption: an inherited disorder of iron metabolism. Hartman KR, et al. **Am J Hematol** 1996 Apr;51(4):269–75

Hyperhidrosis and iron deficiency. Labib M, et al. **Ann Clin Biochem** 1995 Sep;32 (Pt 5):509–10

Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Cazzola M, et al. **Blood** 1996 Jun 1;87(11):4824–30

Use of whole gut perfusion to investigate gastrointestinal blood loss in patients with iron deficiency anaemia. Ferguson A, et al. **Gut** 1996 Jan;38(1):120–4

Iron deficiency anemia after negative GI evaluation. Hale W. **J Fam Pract** 1996 Aug;43(2):117–8

Intensity of hemodialysis and response to erythropoietin [letter; comment] Ballinger AB, et al. **N Engl J Med** 1996 Jun 20;334(25):1670; discussion 1670–1. Comment on: N Engl J Med 1996 Feb 15;334(7):420–5.

Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Sepandj F, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):319–22

[A case of resistant sideropenic anemia. Adult celiac disease] Vivaldi P, et al. **Recenti Prog Med** 1995 Sep;86(9):345–7 (Eng. Abstr.) **(Ita)**

METABOLISM

Mechanism underlying the inhibitory effect of high calcium carbonate intake on iron bioavailability from ferrous sulphate in anaemic rats. Wienk KJ, et al. **Br J Nutr** 1996 Jan;75(1):109–20

Effects of chronic iron deficiency anemia on brain metabolism. Tanaka M, et al. **Jpn J Physiol** 1995; 45(2):257–63

NURSING

Hematologic problems in pediatric patients. Cahill M. **Semin Oncol Nurs** 1996 Feb;12(1):38–50 (42 ref.)

PARASITOLOGY

Wrong hookworm [letter; comment] Conn DB. **Science** 1996 May 24;272(5265):1086. Comment on: Science 1996 Mar 29;271(5257):1800–1.

PATHOLOGY

Placental histomorphometry and morphometric diffusing capacity of the villous membrane in pregnancies complicated by maternal iron-deficiency anemia. Reshetnikova OS, et al. **Am J Obstet Gynecol** 1995 Sep; 173(3 Pt 1):724–7

PHYSIOPATHOLOGY

Serum transferrin and ferritin in pubertal boys: relations to body growth, pubertal stage, erythropoiesis, and iron deficiency. Anttila R, et al. **Am J Clin Nutr** 1996 Feb; 63(2):179–83

Experimental iron deficiency in rats: mechanical and electrophysiological alterations in the cardiac muscle. Goldstein D, et al. **Clin Sci (Colch)** 1996 Aug;91(2):233–9

Dietary iron and exposure to lead influence susceptibility to seizures. Barzideh O, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):971–6

PREVENTION & CONTROL

Fortification of drinking water with iron: a new strategy for combating iron deficiency in Brazil [letter; comment] Dutra-de-Oliveira JE, et al. **Am J Clin Nutr** 1996 Apr; 63(4):612–4. Comment on: Am J Clin Nutr 1995 May;61(5):1153–63.

Iron supplementation during pregnancy: is it effective? [editorial; comment] Yip R. **Am J Clin Nutr** 1996 Jun; 63(6):853–5. Comment on: Am J Clin Nutr 1996 Jun;63(6):884–90.

Prevention of anaemia in inner city toddlers by an iron supplemented cows' milk formula. Daly A, et al. **Arch Dis Child** 1996 Jul;75(1):9–16

Neonatal prevention of iron deficiency [editorial] [see comments] Pisacane A. **BMJ** 1996 Jan 20;312(7024):136–7 . Comment in: BMJ 1996 Apr 27;312(7038):1102–3. Comment in: BMJ 1996 Apr 27;312(7038):1103.

Operational problems of an iron supplementation programme for pregnant women: an assessment of UNRWA experience. Pappagallo S, et al. **Bull World Health Organ** 1996;74(1):25–33

Iron fortification of domestic drinking water to prevent anemia among low socioeconomic families in Brazil. de Oliveira JE, et al. **Int J Food Sci Nutr** 1996 May;47(3):213–9

[Are there grounds for iron supplementation? (letter)] Hemminki E. **Duodecim** 1994;110(19):1812–3; discussion 1814–5 **(Fin)**

[Mothers and iron (letter)] Pakkala S. **Duodecim** 1994; 110(19):1811–2; discussion 1814–5 **(Fin)**

[Recovered state of iron in female blood donors—after taking an iron supplement] Kumagai E, et al. **Rinsho Byori** 1995 Nov;43(11):1168–72 (Eng. Abstr.) **(Jpn)**

[Cost-effectiveness analysis of serum ferritin screening in periodic physical examinations of women at the fertile age] Bermejo B, et al. **Med Clin (Barc)** 1996 Mar 30; 106(12):445–50 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

[Mother-child interaction and child behavior in preschool children with a history of iron-deficiency anemia in infancy] De Andraca Oyarzún I, et al. **Arch Latinoam Nutr** 1993 Sep;43(3):191–8 (Eng. Abstr.) **(Spa)**

THERAPY

Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract. Braga M, et al. **Br J Surg** 1995 Dec;82(12):1637–40

Iron-deficiency anemia and infant development: effects of extended oral iron therapy. Lozoff B, et al. **J Pediatr** 1996 Sep;129(3):382–9

[Hypobaric hypoxia in the treatment of chronic anemia] Novikov VS, et al. **Voen Med Zh** 1995 Nov;(11):36–9, 80 (Eng. Abstr.) **(Rus)**

VETERINARY

Effect of iron on erythropoietin production in anaemic piglets. Sjaastad OV, et al. **Acta Vet Scand** 1996;37(2):133–8

ANEMIA, MACROCYTIC

Macrocytic anemia [see comments] Davenport J. **Am Fam Physician** 1996 Jan;53(1):155–62 (30 ref.). Comment in: Am Fam Physician 1996 Aug;54(2):465, 468.

BLOOD

[Changes in the serum level of vitamin B12 binding protein in gastrectomized patients: preliminary report] Nomura K, et al. **Nippon Geka Gakkai Zasshi** 1995 Dec;96(12):819 **(Jpn)**

DIAGNOSIS

Requesting vitamin B12 and folate assays [letter; comment] Carmel R. **Lancet** 1995 Oct 7;346(8980):973. Comment on: Lancet 1995 Aug 12;346(8972):446–7.

Requesting vitamin B12 and folate assays [letter; comment] MacMahon M. **Lancet** 1995 Oct 7;346(8980):973. Comment on: Lancet 1995 Aug 12;346(8972):446–7.

ETIOLOGY

Evaluation of macrocytosis by general practitioners. Seppä K, et al. **J Stud Alcohol** 1996 Jan;57(1):97–100

[Ileal malabsorption of vitamin B12 in the chronic alcoholics (letter)] Kaltenbach G, et al. **Gastroenterol Clin Biol** 1995 May;19(5):544–5 **(Fre)**

ANEMIA, MEDITERRANEAN see **BETA-THALASSEMIA**

ANEMIA, MEGALOBLASTIC

Megaloblastic anemia in pregnancy. Campbell BA. **Clin Obstet Gynecol** 1995 Sep;38(3):455–62 (44 ref.)

BLOOD

A study of serum vitamin B12 and folate levels in patients of megaloblastic anaemia in northern Pakistan. Modood-ul-Mannan, et al. **JPMA J Pak Med Assoc** 1995 Jul;45(7):187–8

CHEMICALLY INDUCED

Megaloblastic cytopenia in an AIDS patient treated with trimethoprim-sulfamethoxazole. Shami PJ, et al. **N C Med J** 1995 Dec;56(12):602–4

[A case of ulcerative colitis with sulphasalazine induced megaloblastic anemia] Kato Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1915–6 **(Jpn)**

CONGENITAL

[Congenital megaloblastic anemia in a 22-month-old boy] Minarowska A, et al. **Pediatr Pol** 1995 Mar;70(3):259–61 (Eng. Abstr.) **(Pol)**

ETIOLOGY

Transient 7q- in association with megaloblastic anemia due to dietary folate and vitamin B12 deficiency. Wollman MR, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):162–5

GENETICS

Selective intestinal malabsorption of vitamin B12 displays recessive mendelian inheritance: assignment of a locus to chromosome 10 by linkage. Aminoff M, et al. **Am J Hum Genet** 1995 Oct;57(4):824–31

Transient 7q- in association with megaloblastic anemia due to dietary folate and vitamin B12 deficiency. Wollman MR, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):162–5

PATHOLOGY

Nucleic acid composition of bone marrow mononuclear cells in cobalamin deficiency. Ramsahoye BH, et al. **Blood** 1996 Mar 1;87(5):2065–70

ANEMIA, MICROANGIOPATHIC see **ANEMIA, HEMOLYTIC**

ANEMIA, NEONATAL

New variant of congenital dyserythropoietic anemia with trilineage myelodysplasia. Hirose M, et al. **Acta Haematol** 1995;94(2):102–4

Hemolytic anemia in the newborn. Matsunaga AT, et al. **Clin Perinatol** 1995 Sep;22(3):803–28 (76 ref.)

DRUG THERAPY

Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. Brown MS, et al. **J Pediatr** 1996 Apr;128(4):512–7

Enteral administration of recombinant erythropoietin to preterm infants. Britton JR, et al. **J Perinatol** 1995 Jul-Aug; 15(4):281–3

ETIOLOGY

The role of haemopoietic growth factors in the pathogenesis of the early anaemia of premature infants. Han P, et al. **Br J Haematol** 1995 Oct;91(2):327–9

PARASITOLOGY

The consequences of malaria infection in pregnant women and their infants. Chimsuku L, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:1–2

PHYSIOPATHOLOGY

The physiologic impact of anemia in the neonate. Alverson DC. **Clin Perinatol** 1995 Sep;22(3):609–25 (61 ref.)

PREVENTION & CONTROL

Erythropoietin (Epo), protein and iron supplementation and the prevention of anaemia of prematurity: effects on serum immunoreactive Epo, growth and protein and iron metabolism. Bechensteen AG, et al. **Acta Paediatr** 1996 Apr;85(4):490–5

THERAPY

Decreased ferritin levels, despite iron supplementation, during erythropoietin therapy in anaemia of prematurity. Bader D, et al. **Acta Paediatr** 1996 Apr;85(4):496–501

Recombinant human erythropoietin in neonatal anemia. Shannon K. **Clin Perinatol** 1995 Sep;22(3):627–40 (26 ref.)

Is the use of recombinant human erythropoietin in anaemia of prematurity cost-effective? Meyer MP, et al. **S Afr Med J** 1996 Mar;86(3):251–3

Small volume red blood cell transfusions for neonatal patients. Hume H, et al. **Transfus Med Rev** 1995 Jul; 9(3):187–99 (65 ref.)

A cost analysis comparing erythropoietin and red cell transfusions in the treatment of anemia of prematurity. Fain J, et al. **Transfusion** 1995 Nov-Dec;35(11):936–43

[Evaluation of treatment results for anemia of prematurity treated with various doses of human recombinant erythropoietin] Lauterbach R, et al. **Pediatr Pol** 1995 Sep; 70(9):739–44 (Eng. Abstr.) **(Pol)**

ANEMIA, PERNICIOUS

BLOOD

Effect of omeprazole and feeding on plasma gastrin in patients with achlorhydria. Banerjee S, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):507–12

COMPLICATIONS

Pernicious anaemia and cancer risk in Denmark. Mellemkjaer L, et al. **Br J Cancer** 1996 Apr;73(8):998–1000

Chronic angio-oedema of the tongue associated with pernicious anaemia and Hashimoto's thyroiditis. Peltz S, et al. **Clin Exp Dermatol** 1995 Jul;20(4):351–2

Pernicious anaemia and hypoparathyroidism in a patient with Kearns-Sayre syndrome with mitochondrial DNA duplication. Abramowicz MJ, et al. **J Inherit Metab Dis** 1996;19(2):109–11

[Watermelon stomach: a cause of chronic blood loss in the elderly] Eilat-Tsanani S, et al. **Harefuah** 1996 Mar 1; 130(5):313–5, 359 (Eng. Abstr.) **(Heb)**

DIAGNOSIS

Gastric cancer and pernicious anemia appearing as pseudoachalasia. el-Newihi HM, et al. **South Med J** 1996 Sep;89(9):906–10 (30 ref.)

[Diagnostic and therapeutic aspects of B12-deficiency anemia] Demidova AV, et al. **Klin Med (Mosk)** 1996; 74(1):59–60 **(Rus)**

EPIDEMIOLOGY

Prevalence of undiagnosed pernicious anemia in the elderly. Carmel R. **Arch Intern Med** 1996 May 27;156(10):1097–100

ETIOLOGY

A 73-year-old woman with anemia and thrombocytopenia [clinical conference] Mitchell B, et al. **J Am Geriatr Soc** 1996 Jun;44(6):723–6

[A Chinese patient with pernicious anemia; a medical experience from the Indonesian period] Zuidema PJ. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):561–3 (Eng. Abstr.) **(Dut)**

HISTORY

[Scientific raisins from 125 years SMW (Swiss Medical Weekly). Biermer's anemia and hypothyroidism. 1940 (classical article)] Vannotti A. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1653–5 **(Fre)**

THERAPY

[Diagnostic and therapeutic aspects of B12-deficiency anemia] Demidova AV, et al. **Klin Med (Mosk)** 1996; 74(1):59–60 **(Rus)**

ANEMIA, REFRACTORY

BLOOD

Fluctuations of haemoglobin values in myelodysplastic syndrome [letter] Demiroglu H, et al. **N Z Med J** 1996 Mar 8;109(1017):82–3

ANEMIA, REFRACTORY

DIAGNOSIS

Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection. Friedman HD, et al. **Ann Hematol** 1996 Feb;72(2):85-8 (23 ref.)

DRUG THERAPY

High-dose intravenous methylprednisolone therapy for patients with Diamond-Blackfan anemia refractory to conventional doses of prednisone. Bernini JC, et al. **J Pediatr** 1995 Oct;127(4):654-9

Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Omoto E, et al. **Leukemia** 1996 Apr;10(4):609-14

GENETICS

The thrombin receptor gene is centromeric to the common proximal breakpoint in patients with the 5q- syndrome: identification of a previously unrecognized chromosome 5 inversion. Demetrick DJ, et al. **Br J Haematol** 1996 Feb; 92(2):339-43

A case of refractory anaemia with p53 point mutation at codon 249 (AGG to ATG). Kikukawa M, et al. **Br J Haematol** 1996 Mar;92(4):831-3

Spontaneous remission in a patient with therapy-related myelodysplastic syndrome (t-MDS) with monosomy 7. Renneboog B, et al. **Br J Haematol** 1996 Mar;92(3):696-8

Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts [see comments] Cotter PD, et al. **J Clin Invest** 1995 Oct;96(4):2090-6. Comment in: J Clin Invest 1995 Oct;96(4):1605.

Molecular analysis of the 5q- chromosome. Nagarajan L. **Leuk Lymphoma** 1995 May;17(5-6):361-6 (37 ref.)

THERAPY

Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Anderson JE, et al. **Blood** 1996 Jan 1; 87(1):51-8

Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Negrin RS, et al. **Blood** 1996 May 15; 87(10):4076-81

Cardiac hemolysis and anemia refractory to erythropoietin: on anemia in dialysis patients [letter] Evers J. **Nephron** 1995; 71(1):108

ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS

BLOOD

Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Delforge M, et al. **Blood** 1995 Nov 15;86(10):3660-7

[Refractory anemia with excess of blasts (RAEB) with a high level of HbF that preceded apparent pancytopenia] Matsuda A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):60-4 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Myelodysplastic syndrome presenting as cutaneous vasculitis. O'Donnell BF, et al. **Clin Exp Dermatol** 1995 Sep; 20(5):439-42

Cerebral venous sinus thrombosis associated with refractory anaemia with excess of blasts. Vayá A, et al. **Nouv Rev Fr Hematol** 1995;37(3):201-3

[Prevention of infections in a case with myelodysplastic syndrome by an intermittent subcutaneous administration of G-CSF] Saburi Y, et al. **Kansenshogaku Zasshi** 1996 May;70(5):506-11 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[The appearance of Sweet's syndrome during the transition from a myelodysplastic syndrome to erythroleukemia] Grüne S, et al. **Dtsch Med Wochenschr** 1996 Jul 26; 121(30):939-42 (18 ref.) (Eng. Abstr.) **(Ger)**

[Therapy-related leukemia with t(8;21) initially diagnosed as MDS (RAEB in T)] Hanamura A, et al. **Rinsho Ketsueki** 1995 Aug;36(8):755-61 (15 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

[Successful treatment of a 74-year-old man with refractory anemia with excess of blasts in transformation (RAEB in T) by low-dose Ara-C injection] Wataya S, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jun;32(6):438-41 (Eng. Abstr.) **(Jpn)**

GENETICS

Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613-4 (7 ref.)

Loss of telomeric sequences in a ring derived from chromosome 8 in refractory anemia with excess of blasts in transformation. Fugazza G, et al. **Cancer Genet Cytogenet** 1996 Jul 1;89(1):31-3

Two karyotypically unrelated clones with 5q- and 20q- in a primary myelodysplastic syndrome patient evolving into acute nonlymphocytic leukemia. Hirokawa M, et al. **Int J Hematol** 1995 Aug;62(2):121-5

[Mast cell leukemia evolved from RAEB-T (5q-syndrome) in a 12 year-old girl] Sugita K, et al. **Rinsho Ketsueki** 1996 May;37(5):430-6 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Successful prevention of Pneumocystis carinii infection with 1,920 mg of trimethoprim-sulfamethoxazole daily in patients with malignant hematopoietic diseases] Lemež P, et al. **Vnitr Lek** 1995 Oct;41(10):688-91 (Eng. Abstr.) **(Cze)**

PHYSIOPATHOLOGY

Myelodysplastic syndrome associated with erythrophagocytosis by blasts and myeloid cells. Kuyama J, et al. **Int J Hematol** 1995 Dec;62(4):243-6 (14 ref.)

THERAPY

Long-term remission obtained by intensive chemotherapy against a leukemic relapse and subsequent graft-versus-host disease following an allogeneic BMT in a patient with myelodysplastic syndrome [letter] Azuno Y, et al. **Bone Marrow Transplant** 1996 Mar;17(3):463-4

ANEMIA, SICKLE CELL

see related

ANTISICKLING AGENTS

Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. Koshy M, et al. **Blood** 1995 Nov 15;86(10):3676-84

Sickle cell anemia in septuagenarians [letter] Steinberg MH, et al. **Blood** 1995 Nov 15;86(10):3997-8

Pregnancy complicated by sickle hemoglobinopathy. Rust OA, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):472-84 (42 ref.)

Hospital information systems: a database for a sickle-cell clinic. Hyde K, et al. **Medinfo** 1995;8 Pt 1:577-80

Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Smith JA, et al. **Obstet Gynecol** 1996 Feb;87(2):199-204

[Death during sickle cell anemia crisis: possible role of morphine? (letter)] Ayass N, et al. **Arch Pediatr** 1995 Aug; 2(8):803-4 **(Fre)**

BLOOD

Uric acid, creatinine and urea in normal, glucose-6-phosphate dehydrogenase-deficient and Hb SS Saudi subjects. al-Ali AK, et al. **Acta Haematol** 1995; 94(2):114-6

Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality. Pearson HA. **Adv Pediatr** 1996;43:309-34 (57 ref.)

Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Browne PV, et al. **Am J Hematol** 1996 Apr;51(4):296-301

Filterability of mixtures of sickle and normal erythrocytes. Hasegawa S, et al. **Am J Hematol** 1995 Oct;50(2):91-7

High density sickle cell erythrocyte core membrane skeletons demonstrate slow temperature dependent dissociation. Shartava A, et al. **Am J Hematol** 1996 Mar;51(3):214-9

Deoxygenation-induced alterations in sickle cell membrane cholesterol exchange. Kavecansky J, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1105-11

Serum zinc and copper levels in sickle cell anaemia and beta-thalassaemia in North Jordan. Bashir NA. **Ann Trop Paediatr** 1995 Dec;15(4):291-3

Possible role of bone marrow fat in the development of an inflammatory response to sickled erythrocytes: comment on the article by Mann and Schumacher [letter; comment] McCarty DJ, et al. **Arthritis Rheum** 1995 Sep;38(9):1349-50 . Comment on: Arthritis Rheum 1995 Feb;38(2):284-7.

Identification of the disulfide-linked peptide in irreversibly sickled cell beta-actin. Bencsath FA, et al. **Biochemistry** 1996 Apr 9;35(14):4403-8

Visualization of IgG-binding loci on the surface of sickle erythrocytes [letter] Green GA. **Blood** 1996 Mar 15; 87(6):2609

Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Hofstra TC, et al. **Blood** 1996 May 15;87(10):4440-7

Glycoprotein IV-independent adhesion of sickle red blood cells to immobilized thrombospondin under flow conditions. Joneckis CC, et al. **Blood** 1996 Jun 1; 87(11):4862-70

Adhesion of sickle red blood cells and damage to interleukin-1 beta stimulated endothelial cells under flow in vitro. Natarajan M, et al. **Blood** 1996 Jun 1; 87(11):4845-52

Extremely high avidity association of Fe(III) with the sickle red cell membrane. Shalev O, et al. **Blood** 1996 Jul 1; 88(1):349-52

Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Wood BL, et al. **Blood** 1996 Sep 1; 88(5):1873-80

Platelet count and platelet factor 3 (PF-3) availability in sickle cell disease. Famodu AA, et al. **Br J Biomed Sci** 1995 Dec;52(4):323-4

Determinants of haemoglobin level in steady-state homozygous sickle cell disease. Serjeant G, et al. **Br J Haematol** 1996 Jan;92(1):143-9

Macular blood flow velocity in sickle cell disease: relation to red cell density. Roy MS, et al. **Br J Ophthalmol** 1995 Aug;79(8):742-5

Optimal haematocrit and haemoglobin S levels in pregnant women with sickle cell disease. Howard RJ, et al. **Clin Lab Haematol** 1995 Jun;17(2):157-61

Evaluation of the automated leucocyte count and differential from the Cell-Dyn 3500 in sickle cell disease. Joyner RE, et al. **Clin Lab Haematol** 1995 Dec;17(4):329-33

Estimation of fetal hemoglobin levels in individual red cells via fluorescence image cytometry. Horiuchi K, et al. **Cytometry** 1995 Jul 1;20(3):261-7

Sickling in vitro of reticulocytes from patients with sickle cell disease at venous oxygen tension. Horiuchi K, et al. **Exp Hematol** 1996 Jan;24(1):68-76

Red cell membrane remodeling in sickle cell anemia. Sequestration of membrane lipids and proteins in Heinz bodies. Liu SC, et al. **J Clin Invest** 1996 Jan 1;97(1):29-36

Variation in serum electrolytes and enzyme concentrations in patients with sickle cell disease. Nduka N, et al. **J Clin Pathol** 1995 Jul;48(7):648-51

To tell the truth: will the real CD36 please stand up? [editorial; comment] Asch A. **J Lab Clin Med** 1996 Apr; 127(4):321-5. Comment on: J Lab Clin Med 1996 Apr;127(4):340-7.

CD36-positive stress reticulocytosis in sickle cell anemia [see comments] Browne PV, et al. **J Lab Clin Med** 1996 Apr; 127(4):340-7. Comment in: J Lab Clin Med 1996 Apr;127(4):321-5.

Fatty-acid peroxidation in relation to trace elements in serum of patients with homozygous sickle-cell anemia and beta-thalassemia: a gas-chromatographic study. Preoteasa EA, et al. **Nutrition** 1995 Sep-Oct;11(5 Suppl):546-50

Sickle cell vaso-occlusive crisis is associated with abnormalities in the ratio of vasoconstrictor to vasodilator prostanoids. Setty BN, et al. **Pediatr Res** 1995 Jul; 38(1):95-102

The presence of sickle cells in the peripheral blood film. Specificity and sensitivity of diagnosis of homozygous sickle cell disease in Kenya. Aluoch JR. **Trop Geogr Med** 1995;47(2):89-91

[Note on hemoglobins encountered in Haiti (letter)] Molez JF, et al. **Med Trop (Mars)** 1995;55(4):391 **(Fre)**

COMPLICATIONS

Evaluation of pulse oximetry in sickle cell anemia patients presenting to the emergency department in acute vasoocclusive crisis. Comber JT, et al. **Am J Emerg Med** 1996 Jan;14(1):16-8

Chronic hepatitis C in patients with sickle cell disease. Hasan MF, et al. **Am J Gastroenterol** 1996 Jun;91(6):1204-6

Sickle cell intrahepatic cholestasis: approach to a difficult problem. Shao SH, et al. **Am J Gastroenterol** 1995 Nov; 90(11):2048-50

Autoimmune hepatitis in a patient with sickle cell disease. el Younis CM, et al. **Am J Gastroenterol** 1996 May; 91(5):1016-8 (26 ref.)

Cardiovascular function during rest and exercise in patients with sickle-cell anemia and coexisting alpha thalassemia-2. Braden DS, et al. **Am J Hematol** 1996 Jun;52(2):96-102

Hyperkalemic hyperchloremic metabolic acidosis in a patient with sickle cell beta-thalassemia [letter] Elisaf M, et al. **Am J Hematol** 1995 Oct;50(2):151-2

Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review. Lowenthal EA, et al. **Am J Hematol** 1996 Mar;51(3):207-13

Core decompression in avascular necrosis of the hip in sickle-cell disease. Styles LA, et al. **Am J Hematol** 1996 Jun;52(2):103-7

Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Ware RE, et al. **Am J Hematol** 1995 Oct;50(2):140-3

Pain during sickle-cell crises. Nichols R. **Am J Nurs** 1996 Jan;96(1):59-60

Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolism. Godeau B, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1691-6

Transverse rectus abdominis musculocutaneous flap breast reconstruction in sickle cell disease. Hawes AS, et al. **Ann Plast Surg** 1995 Nov;35(5):511-3; discussion 513-4

Mitral valve reconstruction in sickle cell disease. Pagani FD, et al. **Ann Thorac Surg** 1996 Jun;61(6):1841-3

Pathological case of the month. Thrombocytosis in sickle cell anemia. Quintana P, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):763-4

Possible role of bone marrow fat in the development of an inflammatory response to sickled erythrocytes: comment on the article by Mann and Schumacher [letter; comment] McCarty DJ, et al. **Arthritis Rheum** 1995 Sep;38(9):1349-50 . Comment on: Arthritis Rheum 1995 Feb;38(2):284-7.

Paradoxical increase of painful crises in sickle cell patients with alpha-thalassemia [letter; comment] Billett HH, et al.

Blood 1995 Dec ;;86(11):4382. Comment on: Blood 1995 Jul 15;86(2):776–83.

Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Styles LA, et al. **Blood** 1996 Mar 15; 87(6):2573–8

Managing patients with an absent or dysfunctional spleen. Under half of doctors know that antibiotic prophylaxis should be life long [letter; comment] Palejwala AA, et al. **BMJ** 1996 May 25;312(7042):1360; discussion 1361. Comment on: BMJ 1996 Feb 17;312(7028):430–4.

Managing patients with an absent or dysfunctional spleen. Guidelines should highlight risk of Salmonella infection in sickle cell disease [letter; comment] Workman MR, et al. **BMJ** 1996 May 25;312(7042):1359–60; discussion 1361. Comment on: BMJ 1996 Feb 17;312(7028):430–4.

Effects of cognitive coping skills training on coping strategies and experimental pain sensitivity in African American adults with sickle cell disease. Gil KM, et al. **Health Psychol** 1996 Jan;15(1):3–10

Sickle cell disease: the clinical manifestations. Childs JW. **J Am Osteopath Assoc** 1995 Oct;95(10):593–8 (46 ref.)

Case 2—1996. Anesthetic management of a patient with hemoglobin SS disease and mitral insufficiency for mitral valve repair [clinical conference] Kingsley CP, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):419–24

Myocardial infarction in sickle cell disease. Martin CR, et al. **J Natl Med Assoc** 1996 Jul;88(7):428–32

Penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae causing sepsis and meningitis in children with sickle cell disease [see comments] Chesney PJ, et al. **J Pediatr** 1995 Oct;127(4):526–32. Comment in: J Pediatr 1996 Jun;128(6):862–3.

Biliary sludge in sickle cell disease [see comments] Walker TM, et al. **J Pediatr** 1996 Sep;129(3):443–5. Comment in: J Pediatr 1996 Sep;129(3):321–2.

Is biliary sludge a stone-in-waiting? [editorial; comment] Werlin SL, et al. **J Pediatr** 1996 Sep;129(3):321–2. Comment on: J Pediatr 1996 Sep;129(3):443–5.

Testosterone induced priapism in two adolescents with sickle cell disease. Slayton W, et al. **J Pediatr Endocrinol Metab** 1995 Jul-Sep;8(3):199–203

TCD in sickle cell disease [letter] Adams RJ. **J Pediatr Hematol Oncol** 1996 Aug;18(3):331–4

Does sleep-disordered breathing contribute to the clinical severity of sickle cell anemia? [see comments] Brooks LJ, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):135–9. Comment in: J Pediatr Hematol Oncol 1996 May;18(2):104–5.

Obstructive sleep apnea and sickle cell disease [editorial; comment] Kemp JS. **J Pediatr Hematol Oncol** 1996 May; 18(2):104–5. Comment on: J Pediatr Hematol Oncol 1996 May;18(2):135–9.

B19 parvovirus infection and transient aplastic crisis in a child with sickle cell anemia. Rao SP, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):175–7

Outpatient therapy with ceftriaxone and oral cefixime for selected febrile children with sickle cell disease. Williams LL, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):257–61

Laparoscopic cholecystectomy in patients with sickle cell disease. Meshikhes AN, et al. **J R Coll Surg Edinb** 1995 Dec;40(6):383–5

Priapism associated with sickle cell hemoglobinopathy in children: long-term effects on potency. Chakrabarty A, et al. **J Urol** 1996 Apr;155(4):1419–23

Painful crises in sickle-cell disease [letter; comment] Serjeant G, et al. **Lancet** 1996 Apr 27;347(9009):1190–1. Comment on: Lancet 1996 Jan 27;347(8996):261. Comment on: Lancet 1996 Jan 27;347(8996):261–2. Comment on: Lancet 1996 Jan 27;347(8996):263.

Oral morphine protocol for sickle cell crisis pain. Conti C, et al. **Md Med J** 1996 Jan;45(1):33–5

Genotypic evaluation of ocular pathologies in sickle cell diseases. Anyanwu E, et al. **Metab Pediatr Syst Ophthalmol** 1994;17(1–4):29–33

Incentive spirometry in sickle cell crisis [letter; comment] Merrill WW. **N Engl J Med** 1996 Jan 11;334(2):124–5. Comment on: N Engl J Med 1995 Sep 14;333(11):699–703.

Vertebral bone destruction in sickle cell disease: infection, infarction or both. Kooy A, et al. **Neth J Med** 1996 Jun; 48(6):227–31 (11 ref.)

Diagnosis of acute bone/bone marrow infarction of the mandible in sickle hemoglobinopathy. Report of a case. Podlesh SW, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):547–9

Increased prolactin level and pituitary adenoma as a cause of headache in two patients with sickle cell disease. Sabbagh R, et al. **Pediatr Hematol Oncol** 1996 Jan-Feb; 13(1):101–5

Detection of cerebrovascular disease in patients with sickle cell disease using transcranial Doppler sonography: correlation with MRI, MRA and conventional angiography. Verlhac S, et al. **Pediatr Radiol** 1995 Nov; 25 Suppl 1:S14–9

Cognitive functioning and brain magnetic resonance imaging in children with sickle Cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Armstrong FD, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):864–70

Lower limb salvage by microvascular free-tissue transfer in patients with homozygous sickle cell disease. Weinzweig N, et al. **Plast Reconstr Surg** 1995 Oct;96(5):1154–61

Cerebral infarction in sickle cell disease: transcranial Doppler US versus neurologic examination. Siegel MJ, et al. **Radiology** 1995 Oct;197(1):191–4

Systemic lupus erythematosus in a child with sickle cell disease. Eissa MM, et al. **South Med J** 1995 Nov; 88(11):1176–8 (14 ref.)

Sequential endoscopic/laparoscopic management of sickle hemoglobinopathy-associated cholelithiasis and suspected choledocholithiasis. Gholson CF, et al. **South Med J** 1995 Nov;88(11):1131–5

Bacterial causes of acute osteomyelitis in sickle cell anaemia: changing infection profile. Aken'Ova YA, et al. **West Afr J Med** 1995 Oct-Dec;14(4):255–8

[Resistant pneumococcal meningitis revealing sickle cell anemia: efficacy of cefotaxime-vancomycin combination (letter)] Agbo P, et al. **Arch Pediatr** 1995 Aug;2(8):799–800 **(Fre)**

[Arterial pressure and urinary excretion of albumin in adults with sickle cell disease] Foucan L, et al. **Presse Med** 1995 Oct 21;24(31):1428–32 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Automated HPLC screening of newborns for sickle cell anemia and other hemoglobinopathies. Eastman JW, et al. **Clin Chem** 1996 May;42(5):704–10

Sickle-cell disease simulating Burkitt's lymphoma: case report. Endeley EM, et al. **Indian J Med Sci** 1995 Jan; 49(1):9–10

Sickle cell thalassemia in pregnancy: a case report. Carpani G, et al. **J Matern Fetal Med** 1996 Jan-Feb;5(1):28–30

Sickle cell disease. Lane PA. **Pediatr Clin North Am** 1996 Jun;43(3):639–64 (108 ref.)

Health supervision for children with sickle cell diseases and their families. American Academy of Pediatrics. Committee on Genetics. **Pediatrics** 1996 Sep;98(3 Pt 1):467–72

Prenatal diagnosis of beta-thalassaemia and sickle cell anaemia in Turkey. Tüzmen S, et al. **Prenat Diagn** 1996 Mar;16(3):252–8

The presence of sickle cells in the peripheral blood film. Specificity and sensitivity of diagnosis of homozygous sickle cell disease in Kenya. Aluoch JR. **Trop Geogr Med** 1995;47(2):89–91

DRUG THERAPY

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. el-Hazmi MA, et al. **Acta Haematol** 1995;94(3):128–34

Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality. Pearson HA. **Adv Pediatr** 1996;43:309–34 (57 ref.)

First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Claster S, et al. **Blood** 1996 Sep 15;88(6):1951–3

Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Ferster A, et al. **Blood** 1996 Sep 15;88(6):1960–4

Use of calcitonin in sickle cell bone crisis [letter] Quevedo SF. **Blood** 1996 Aug 15;88(4):1520

Bencyclane as an anti-sickling agent. Koçak R, et al. **Br J Haematol** 1996 Feb;92(2):329–31

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy [letter] Bourantas K, et al. **Eur J Haematol** 1996 May;56(5):326–8

Monoclonal antibody-based methods for quantitation of hemoglobins: application to evaluating patients with sickle cell anemia treated with hydroxyurea. Epstein N, et al. **Eur J Haematol** 1996 Jul;57(1):17–24

Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease [see comments] Brugnara C, et al. **J Clin Invest** 1996 Mar 1;97(5):1227–34. Comment in: J Clin Invest 1996 Mar 1;97(5):1135.

Sickle cell disease: a step closer to the dream [editorial; comment] Mohandas N, et al. **J Clin Invest** 1996 Mar 1; 97(5):1135. Comment on: J Clin Invest 1996 Mar 1;97(5):1227–34.

Antibiotic-resistant pneumococci [letter; comment] Friedland IR. **J Pediatr** 1996 Jun;128(6):862–3. Comment on: J Pediatr 1995 Oct;127(4):526–32.

Hydroxyurea therapy in children severely affected with sickle cell disease. Scott JP, et al. **J Pediatr** 1996 Jun; 128(6):820–8

Sickle cell pain crisis [letter; comment] [see comments] Davies SC, et al. **Lancet** 1996 Jan 27;347(8996):263. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

Sickle cell pain crisis [letter; comment] [see comments] Forbes K, et al. **Lancet** 1996 Jan 27;347(8996):262. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

Sickle cell pain crisis [letter; comment] [see comments] Meltzer BA. **Lancet** 1996 Jan 27;347(8996):262. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

Sickle cell pain crisis [letter; comment] [see comments] Simini B. **Lancet** 1996 Jan 27;347(8996):261–2. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

Sickle cell pain crisis [letter; comment] [see comments] Ward SJ. **Lancet** 1996 Jan 27;347(8996):261. Comment on: Lancet 1995 Nov 25;346(8987):1408–11 Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

Hydroxyurea in sickle cell disease. Burke SM. **MCN Am J Matern Child Nurs** 1996 Jul-Aug;21(4):210

Hydroxyurea in sickle cell disease [letter; comment] Adams-Graves P, et al. **N Engl J Med** 1996 Feb 1; 334(5):333–4. Comment on: N Engl J Med 1995 May 18;332(20):1317–22.

Hydroxyurea in sickle cell disease [letter; comment] Schechter AN, et al. **N Engl J Med** 1996 Feb 1;334(5):333. Comment on: N Engl J Med 1995 May 18;332(20):1317–22.

Sickle cell paths converge on hydroxyurea. Platt OS. **Nat Med** 1995 Apr;1(4):307–8

ENZYMOLOGY

Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Styles LA, et al. **Blood** 1996 Mar 15; 87(6):2573–8

EPIDEMIOLOGY

[Sickle cell anemia in the south of Zaire. Study of two series of 251 and 340 patients followed-up 1988–1992] Tshilolo L, et al. **Arch Pediatr** 1996 Feb;3(2):104–11 (Eng. Abstr.) **(Fre)**

[Sickle-cell anemia in the 1st 5 years of life] Svarch E, et al. **Sangre (Barc)** 1996 Feb;41(1):43–6 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Uric acid, creatinine and urea in normal, glucose-6-phosphate dehydrogenase-deficient and Hb SS Saudi subjects. al-Ali AK, et al. **Acta Haematol** 1995; 94(2):114–6

GENETICS

Analysis of chimerism by PCR using mutant-specific primers and sequencing of B-gene region after allogenic bone marrow transplantation in sickle cell anemia [letter] Gürgey A, et al. **Am J Hematol** 1995 Dec;50(4):318–9

Fetal hemoglobin in sickle cell anemia: relation to regulatory sequences cis to the beta-globin gene. Multicenter Study of Hydroxyurea. Lu ZH, et al. **Blood** 1996 Feb 15; 87(4):1604–11

Age dependence of the gene frequency of alpha-thalassemia in sickle cell anemia in Cuba [letter] Martinez G, et al. **Blood** 1996 Sep 1;88(5):1898–9

Sickle cell disease and pregnancy. Koshy M. **Blood Rev** 1995 Sep;9(3):157–64 (60 ref.)

Implications of prenatal diagnosis of sickle cell disease. de Montalembert M, et al. **Genet Couns** 1996;7(1):9–15

Utilization of monoclonal-antibody-based assay (HemoCard in screening for and differentiating between genotypes of sickle cell disease and other hemoglobinopathies. Schultz JC. **J Clin Lab Anal** 1995;9(6):366–74

Relationship between Fc receptor IIA polymorphism and infection in children with sickle cell disease. Norris CF, et al. **J Pediatr** 1996 Jun;128(6):813–9

Glucose-6-phosphate dehydrogenase deficiency and sickle cell genes in Bisha. el-Hazmi MA, et al. **J Trop Pediatr** 1995 Aug;41(4):225–9

Selective embryonic survival of conceptuses with sickle-cell and beta-thalassaemia traits? [letter; comment] Hook EB. **Lancet** 1996 May 4;347(9010):1269. Comment on: Lancet 1996 Mar 9;347(9002):691–2.

Sickle cell anaemia in a Cook Island child. Bradley SK, et al. **N Z Med J** 1996 Jul 12;109(1025):260–1

Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Cole-Strauss A, et al. **Science** 1996 Sep 6;273(5280):1386–9

Current status of thalassemia and the sickle cell syndromes in Greece. Loukopoulos D. **Semin Hematol** 1996 Jan; 33(1):76–86 (63 ref.)

Acceptability of prenatal diagnosis of sickle cell anaemia (SCA) by female patients and parents of SCA patients in Nigeria. Durosinmi MA, et al. **Soc Sci Med** 1995 Aug; 41(3):433–6

[Sickle cell anemia: model of variability in expression of monogenic disease (editorial)] Labie D, et al. **Arch Pediatr** 1996 Feb;3(2):101–3 (10 ref.) **(Fre)**

IMMUNOLOGY

Immunoglobulin levels in malaria infected Nigerians with and without abnormal haemoglobin. Odegbemi JO, et al. **Afr J Med Med Sci** 1995 Mar;24(1):21–5

New concepts in the immunology of sickle cell disease. Moore CM, et al. **Ann Allergy Asthma Immunol** 1996 May; 76(5):385–400; quiz 400–3 (182 ref.)

Complement activation during painful crisis in sickle cell anemia. Mold C, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):314–20

Anti-pneumococcal antibody levels three to seven years after first booster immunization in children with sickle cell disease, and after a second booster. Rao SP, et al. **J Pediatr** 1995 Oct;127(4):590–2

Prevalence of antibodies to hepatitis C virus among normal blood donors and multi-transfused sickle-cell anaemia patients in Nigeria. Adewuyi JO. **Trop Doct** 1996 Jan; 26(1):29–30

ANEMIA, SICKLE CELL

METABOLISM

Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Arya R, et al. **Br J Haematol** 1996 Jun 2;93(4):817–21

The release of nitric oxide and superoxide anion by neutrophils and mononuclear cells from patients with sickle cell anaemia. Dias–Da–Motta P, et al. **Br J Haematol** 1996 May;93(2):333–40

[Stimulation of fetal hemoglobin production in children with sickle cell anemia (editorial)] de Montalembert M. **Arch Pediatr** 1996 Mar;3(3):207–9 (27 ref.) **(Fre)**

MICROBIOLOGY

Colonization with antibiotic–resistant Streptococcus pneumoniae in children with sickle cell disease. Steele RW, et al. **J Pediatr** 1996 Apr;128(4):531–5

Antibiotic–resistant pneumococcal infection in children with sickle cell disease in the United States. Wang WC, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):140–4

MORTALITY

Improved survival in homozygous sickle cell disease: lessons from a cohort study. Lee A, et al. **BMJ** 1995 Dec 16; 311(7020):1600–2

[Sickle cell anemia: study of the pediatric mortality in Ile de France from 1985 to 1992] Thomas C, et al. **Arch Pediatr** 1996 May;3(5):445–51 (Eng. Abstr.) **(Fre)**

NURSING

Sickle cell and thalassaemia: some priorities for nursing research [editorial] Anionwu EN. **J Adv Nurs** 1996 May; 23(5):853–6

Nursing management of children with sickle cell disease: an update. Gribbons D, et al. **J Pediatr Nurs** 1995 Aug; 10(4):232–42 (59 ref.)

Hematologic problems in pediatric patients. Cahill M. **Semin Oncol Nurs** 1996 Feb;12(1):38–50 (42 ref.)

PATHOLOGY

The spectrum of brain MR abnormalities in sickle–cell disease: a report from the Cooperative Study of Sickle Cell Disease. Moser FG, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):965–72

Pathological case of the month. Thrombocytosis in sickle cell anemia. Quintana P, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):763–4

Survival of F–reticulocytes in sickle cell disease. Horiuchi K, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):924–30

Vascular cell adhesion molecule–1 is involved in mediating hypoxia–induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Setty BN, et al. **Blood** 1996 Sep 15;88(6):2311–20

Maxillary sinus marrow hyperplasia in sickle cell anemia. Fernandez M, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S209–11

PHYSIOPATHOLOGY

Delayed sexual maturation in sickle cell anaemia patients—observations in one practice. Oyedeji GA. **Ann Trop Paediatr** 1995 Sep;15(3):197–201

Factors affecting prepubertal growth in homozygous sickle cell disease. Singhal A, et al. **Arch Dis Child** 1996 Jun; 74(6):502–6

The heart in sickle cell anemia. The Cooperative Study of Sickle Cell Disease (CSSCD). Covitz W, et al. **Chest** 1995 Nov;108(5):1214–9

The sickle cell painful crisis in adults: phases and objective signs. Ballas SK. **Hemoglobin** 1995;19(6):323–33 (47 ref.)

In vivo demonstration of red cell–endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. Kaul DK, et al. **J Clin Invest** 1995 Dec;96(6):2845–53

Sickle red blood cells stimulate endothelial cell production of eicosanoids and diacylglycerol. Setty BN, et al. **J Lab Clin Med** 1996 Sep;128(3):313–21

Early detection and the course of glomerular injury in patients with sickle cell anemia. Guasch A, et al. **Kidney Int** 1996 Mar;49(3):786–91

Pathophysiology and management of sickle cell pain crisis. Report of a Meeting of Physicians and Scientists, University of Texas Health Science Center at Houston, Texas [clinical conference] [see comments] **Lancet** 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Jan 27;347(8996):261. Comment in: Lancet 1996 Jan 27;347(8996):261–2. Comment in: Lancet 1996 Jan 27;347(8996):262. Comment in: Lancet 1996 Jan 27;347(8996):263.

Nitrous oxide and morphine in children with sickle cell crisis [letter] Carbajal R, et al. **Lancet** 1996 Jun 8;347(9015):1621

Reverse sequestration in a case of sickle crisis. Lee ES, et al. **Postgrad Med J** 1996 Aug;72(850):487–8

Liver transplantation in a patient with sickle cell anemia. Kindscher JD, et al. **Transplantation** 1995 Oct 15; 60(7):762–4

[Study of hemoglobinopathies found in Belgium] Fondu P. **Bull Mem Acad R Med Belg** 1995;150(10–11):367–75; discussion 376–8 (Eng. Abstr.) **(Fre)**

[Sickle cell anemia: its clinical implications in dental care] Finet B. **Rev Med Liege** 1995 Oct;50(10):430–2 **(Fre)**

[Pain crises in patients with sickle cell diseases. Pathogenesis, clinical aspects, therapy] Dickerhoff R, et al. **Klin Padiatr** 1995 Nov–Dec;207(6):321–5 (29 ref.) (Eng. Abstr.) **(Ger)**

[Abnormal autonomic cardiovascular responses in patients with sickle cell anemia] Romero–Vecchione E, et al. **Sangre (Barc)** 1995 Oct;40(5):393–9 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Neonatal screening for sickle cell disorders: what about the carrier infants? Laird L, et al. **BMJ** 1996 Aug 17; 313(7054):407–11 (51 ref.)

Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial. Gupta VL, et al. **J Assoc Physicians India** 1995 Jul; 43(7):467–9

Newborn screening for sickle cell disease: 4 years of experience from California's newborn screening program. Shafer FE, et al. **J Pediatr Hematol Oncol** 1996 Feb; 18(1):36–41

An audit of sickle cell screening in a paediatric hospital population. Baraka A, et al. **Scott Med J** 1994 Jun; 39(3):84–5

[Genetic hemoglobin diseases. Prevention at centers for family planning and education of maternal–child protection in Marseille] Lena–Russo D, et al. **Presse Med** 1996 Feb 3;25(4):151–3 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Factors associated with lowered intelligence in homozygous sickle cell disease. Knight S, et al. **Arch Dis Child** 1995 Oct;73(4):316–20

The effects of sickle cell disease on the families of affected children [letter] Oyedeji GA. **Cent Afr J Med** 1995 Oct; 41(10):333–4

Peer relationships and emotional well–being of youngsters with sickle cell disease. Noll RB, et al. **Child Dev** 1996 Apr;67(2):423–36

Pediatric compliance and the roles of distinct treatment characteristics, treatment attitudes, and family stress: a preliminary report. Van Sciver MM, et al. **J Dev Behav Pediatr** 1995 Oct;16(5):350–8

RADIOGRAPHY

[Sickle cell anemia: how to interpret a radiological bone lesion] Tomasini P, et al. **Med Trop (Mars)** 1995; 55(3):216–20 (8 ref.) **(Fre)**

RADIONUCLIDE IMAGING

Ga–67 imaging in bone marrow hyperplasia. Nguyen J, et al. **Clin Nucl Med** 1996 May;21(5):404–6

SURGERY

Persistence of fetal hemoglobin production after successful transplantation of cord blood stem cells in a patient with sickle cell anemia. Brichard B, et al. **J Pediatr** 1996 Feb; 128(2):241–3

THERAPY

Review: selective filtration—a phlebotomy strategy for sickle cell therapy. Nusbaum NJ. **Am J Med Sci** 1995 Dec; 310(6):264–6 (12 ref.)

Oxygen inhalation in nonhypoxic sickle cell patients during vaso–occlusive crisis [letter] Khoury H, et al. **Blood** 1995 Nov 15;86(10):3998

Neurologic complications following bone marrow transplantation for sickle cell disease. Abboud MR, et al. **Bone Marrow Transplant** 1996 Mar;17(3):405–7

Pregnancy in sickle cell disease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Howard RJ, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):947–51

Automated erythrocytapheresis in sickle cell anaemia [letter] Marques Júnior JF, et al. **Int J Artif Organs** 1995 Jun; 18(6):345–6

Effect of transfusion in acute chest syndrome of sickle cell disease. Emre U, et al. **J Pediatr** 1995 Dec;127(6):901–4

Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. Falletta JM, et al. **J Pediatr** 1995 Nov;127(5):685–90

Long–term central venous access in patients with sickle cell disease. Incidence of thrombotic and infectious complications. Abdul–Rauf A, et al. **J Pediatr Hematol Oncol** 1995 Nov;17(4):342–5

Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. Adams DM, et al. **J Pediatr Hematol Oncol** 1996 Feb;18(1):46–50

Malaria, anaemia, and HIV–1 transmission in central Africa [letter] Binda ki Muaka P, et al. **Lancet** 1995 Nov 11; 346(8985):1294–5

Conservative versus aggressive transfusion regimens in sickle cell disease [letter] Apfelroth S. **N Engl J Med** 1995 Dec 14;333(24):1641–2

Conservative versus aggressive transfusion regimens in sickle cell disease [letter] Buchanan GR, et al. **N Engl J Med** 1995 Dec 14;333(24):1641; discussion 1641–2

Bone marrow transplantation in sickle cell anemia—the dilemma of choice [editorial; comment] Platt OS, et al. **N Engl J Med** 1996 Aug 8;335(6):426–8. Comment on: N Engl J Med 1996 Aug 8;335(6):369–76.

Bone marrow transplantation for sickle cell disease [see comments] Walters MC, et al. **N Engl J Med** 1996 Aug 8;335(6):369–76. Comment in: N Engl J Med 1996 Aug 8;335(6):426–8.

MR marrow signs of iron overload in transfusion–dependent patients with sickle cell disease. Levin TL, et al. **Pediatr Radiol** 1995;25(8):614–9

Lack of evidence of permanent engraftment after in utero fetal stem cell transplantation in congenital hemoglobinopathies. Westgren M, et al. **Transplantation** 1996 Apr 27;61(8):1176–9

Post–transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Cullis JO, et al. **Vox Sang** 1995;69(4):355–7

New treatments of sickle cell disease. Embury SH. **West J Med** 1996 May;164(5):444

[Is peroperative transfusion of autologous blood beneficial to a patient with homozygotic sickle cell disease? (letter)] Almanza L, et al. **Ann Fr Anesth Reanim** 1995;14(5):456–7 **(Fre)**

[INSERM clinical research network on sickle cell anemia: a tool for therapeutic care and research] Girot R. **Arch Pediatr** 1996;3 Suppl 1:321s–323s (9 ref.) **(Fre)**

ULTRASONOGRAPHY

Increased renal reflectivity in sickle cell disease [letter; comment] Davidson AJ. **Clin Radiol** 1996 Mar;51(3):231. Comment on: Clin Radiol 1995 Aug;50(8):566–9.

VIROLOGY

B19 parvovirus infection and transient aplastic crisis in a child with sickle cell anemia. Rao SP, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):175–7

ANEMIA, SIDEROBLASTIC

CHEMICALLY INDUCED

Acquired sideroblastic anaemia induced by a copper–chelating agent. Perry AR, et al. **Int J Hematol** 1996 Jul;64(1):69–72

COMPLICATIONS

Trichothiodystrophy with sideroblastic anaemia and developmental delay. Lynch SA, et al. **Arch Dis Child** 1995 Sep;73(3):249–51

Familial sideroblastic anemia with emergence of monosomy 5 and myelodysplastic syndrome. Kardos G, et al. **Med Pediatr Oncol** 1996 Jan;26(1):54–6

ENZYMOLOGY

Molecular defects of erythroid 5–aminolevulinate synthase in X–linked sideroblastic anemia. Bottomley SS, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):161–8 (50 ref.)

ETIOLOGY

Erythropoietic protoporphyria without cutaneous photosensitivity and with ringed sideroblasts in an atomic bomb survivor [letter] Takeda Y, et al. **Lancet** 1996 Feb 10;347(8998):395–6

GENETICS

A heteroplasmic point mutation of mitochondrial tRNALeu(CUN) in non–lymphoid haemopoietic cell lineages from a patient with acquired idiopathic sideroblastic anaemia. Gattermann N, et al. **Br J Haematol** 1996 Jun 2;93(4):845–55

Molecular defects of erythroid 5–aminolevulinate synthase in X–linked sideroblastic anemia. Bottomley SS, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):161–8 (50 ref.)

Late–onset X–linked sideroblastic anemia. Missense mutations in the erythroid delta–aminolevulinate synthase (ALAS2) gene in two pyridoxine–responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts [see comments] Cotter PD, et al. **J Clin Invest** 1995 Oct;96(4):2090–6. Comment in: J Clin Invest 1995 Oct;96(4):1605.

Late–onset hereditary anemia: why the delay? [editorial; comment] Kushner JP. **J Clin Invest** 1995 Oct;96(4):1695 . Comment on: J Clin Invest 1995 Oct;96(4):2090–6.

Familial sideroblastic anemia with emergence of monosomy 5 and myelodysplastic syndrome. Kardos G, et al. **Med Pediatr Oncol** 1996 Jan;26(1):54–6

[The molecular basis and genetics of diseases associated with disorders of heme biosynthesis] Fuchs O. **Cas Lek Cesk** 1996 Jan 17;135(2):54–8 (42 ref.) (Eng. Abstr.) **(Cze)**

METABOLISM

[The molecular basis and genetics of diseases associated with disorders of heme biosynthesis] Fuchs O. **Cas Lek Cesk** 1996 Jan 17;135(2):54–8 (42 ref.) (Eng. Abstr.) **(Cze)**

PATHOLOGY

[Metastatic aspergillus panniculitis in blast transformation of a myelodysplastic syndrome and agranulocytosis] Skaria

AM, et al. **Hautarzt** 1995 Aug;46(8):579–81 (Eng. Abstr.) **(Ger)**

ANEMIA, SPLENIC see HYPERSPLENISM

ANENCEPHALY

Anencephalic infants as organ donors [letter; comment] Eide BL. **JAMA** 1995 Dec 13;274(22):1757; discussion 1758–9. Comment on: JAMA 1995 May 24–31;273(20):1614–8.

Anencephalic infants as organ donors [letter; comment] Ferguson M. **JAMA** 1995 Dec 13;274(22):1757–8; discussion 1758–9. Comment on: JAMA 1995 May 24–31;273(20):1614–8.

Anencephalic infants as organ donors [letter; comment] Khan JH. **JAMA** 1995 Dec 13;274(22):1758; discussion 1758–9. Comment on: JAMA 1995 May 24–31;273(20):1614–8.

Anencephalic infants as organ donors [letter; comment] McQuillen MP. **JAMA** 1995 Dec 13;274(22):1758; discussion 1758–9. Comment on: JAMA 1995 May 24–31;273(20):1614–8.

Reconsideration of AMA opinion on anencephalic neonates as organ donors [letter] Plows CW. **JAMA** 1996 Feb 14; 275(6):443–4

In re Baby K. Rhodes AM.
MCN Am J Matern Child Nurs 1995 Sep–Oct;20(5):251

Expectant management of twin pregnancies discordant for anencephaly. Lipitz S, et al. **Obstet Gynecol** 1995 Dec; 86(6):969–72

BLOOD

Circulating levels of growth hormone, insulin-like growth factor-I and prolactin in normal, growth retarded and anencephalic human fetuses. Arosio M, et al.
J Endocrinol Invest 1995 May;18(5):346–53

CHEMICALLY INDUCED

An acardiac acephalic monster following in-utero anti-epileptic drug exposure. Kutlay B, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Apr;65(2):245–8

COMPLICATIONS

[Evaluation of pathogenesis of encephalocele, high spina bifida and congenital clubfoot not forming part of any known syndrome: a case report] Colombo P, et al.
Minerva Pediatr 1996 Mar;48(3):105–11 (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Exencephaly-anencephaly sequence: proof by ultrasound imaging and amniotic fluid cytology. Timor-Tritsch IE, et al. **J Matern Fetal Med** 1996 Jul–Aug;5(4):182–5

[Anencephaly: a still unresolved problem] Zarcone R, et al.
Minerva Ginecol 1996 Apr;48(4):135–8 (Eng. Abstr.) **(Ita)**

EMBRYOLOGY

Human fetal pituitary gland in holoprosencephaly and anencephaly. Kjaer I, et al. **J Craniofac Genet Dev Biol** 1995 Oct–Dec;15(4):222–9

ETHNOLOGY

Hispanic origin and neural tube defects in Houston/Harris County, Texas. II. Risk factors. Canfield MA, et al.
Am J Epidemiol 1996 Jan 1;143(1):12–24

Hispanic origin and neural tube defects in Houston/Harris County, Texas. I. Descriptive epidemiology. Canfield MA, et al. **Am J Epidemiol** 1996 Jan 1;143(1):1–11

GENETICS

Recurrent anencephaly as a primary manifestation of the acrocallosal syndrome [letter] Kedar I, et al.
Am J Med Genet 1996 Apr 24;62(4):415–6

Disruption of the MacMARCKS gene prevents cranial neural tube closure and results in anencephaly. Chen J, et al.
Proc Natl Acad Sci U S A 1996 Jun 25;93(13):6275–9

METABOLISM

Mid-second trimester organic acids in severe open neural tube defects. Legge M. **J Obstet Gynaecol** 1995 Oct; 21(5):483–7

Pulmonary gastrin-releasing peptide expression in anencephaly. Jaramillo MA, et al.
Pediatr Pathol Lab Med 1995 May–Jun;15(3):377–87

PATHOLOGY

Alteration in facial shape in the anencephalic human foetus. Trenouth MJ. **Br J Orthod** 1996 May;23(2):129–36

Cephalometric investigations concerning the geometry of the viscerocranium of human anencephalic fetuses. Radlanski RJ, et al. **Fortschr Kieferorthop** 1996 Jun;57(3):186–93 **(Eng, Ger)**

Pulmonary gastrin-releasing peptide expression in anencephaly. Jaramillo MA, et al.
Pediatr Pathol Lab Med 1995 May–Jun;15(3):377–87

PHYSIOPATHOLOGY

[Morphophysiological analysis of the formation of mechanisms of the activity-rest cycle in human ontogenesis] Belich AI, et al.
Vestn Ross Akad Med Nauk 1996;(3):55–61 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Prenatal folic acid treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 homeobox gene. Zhao Q, et al. **Nat Genet** 1996 Jul;13(3):275–83

[Prevention of anencephaly-spina bifida (letter)] Antal R, et al. **Orv Hetil** 1996 Jan 14;137(2):100 **(Hun)**

THERAPY

What is left of futility? The convergence of anencephaly and the Emergency Medical Treatment and Active Labor Act. Diekema DS. **Arch Pediatr Adolesc Med** 1995 Oct; 149(10):1156–9

Guidelines on the care of anencephalic infants: a response to baby K. Paris JJ, et al. **J Perinatol** 1995 Jul–Aug; 15(4):318–24

ULTRASONOGRAPHY

[The exencephaly-anencephaly sequence. Ultrasound diagnosis in early pregnancy] Beinder E, et al.
Ultraschall Med 1995 Aug;16(4):192–5 (Eng. Abstr.) **(Ger)**

ANESTHESIA

The laryngeal mask airway—anatomical and physiological implications. Brimacombe J, et al.
Acta Anaesthesiol Scand 1996 Feb;40(2):201–9 (124 ref.)

Effects of posture and pneumoperitoneum during anaesthesia on the indices of left ventricular filling. Gannedahl P, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):160–6

Control of body temperature during abdominal aortic surgery. Gregorini P, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):187–90

Increase of interleukin-6 plasma concentrations and HLA-DR positive T-lymphocytes after hypotensive anaesthesia with sodium nitroprusside. Heesen M, et al.
Acta Anaesthesiol Scand 1995 Oct;39(7):965–9

QT interval of the ECG, heart rate and arterial pressure during anaesthetic induction: comparative effects of alfentanil and esmolol. Korpinen R, et al.
Acta Anaesthesiol Scand 1995 Aug;39(6):809–13

Comparison of the effects of neostigmine and edrophonium on the duration of action of suxamethonium. McCoy EP, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):744–7

Perioperative monitoring of neuromuscular transmission using acceleromyography prevents residual neuromuscular block following pancuronium. Mortensen CR, et al.
Acta Anaesthesiol Scand 1995 Aug;39(6):797–801

The influence of alfentanil pre-treatment on ventilatory effects of doxapram following induction of anaesthesia with propofol. O'Connor B, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):156–9

Evaluation of saccadic eye movements as an objective test of recovery from anaesthesia. Paut O, et al.
Acta Anaesthesiol Scand 1995 Nov;39(8):1117–24

Synergism between mivacurium and pancuronium in adults. Rautoma P, et al. **Acta Anaesthesiol Scand** 1995 Aug; 39(6):733–7

The influence of anaesthetic drugs on the lower oesophageal sphincter in propofol/nitrous oxide anaesthetized dogs. Pressure profilometry in an animal model. van der Hoeven CW, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):822–6

Ventilatory responses to hypoxia and hypercapnia in relation to anesthetic practice [editorial; comment] Wu RS.
Acta Anaesthesiol Sin 1995 Dec;33(4):i–ii. Comment on: Acta Anaesthesiol Sin 1995 Dec;33(4):223–6.

Influence of forebrain lesions and isoflurane anaesthesia, respectively, on responses to the intracarotid infusion of angiotensin II in sheep. Eriksson S, et al.
Acta Physiol Scand 1995 Dec;155(4):427–34

Effect of anesthetic technique on cardiac morbidity following carotid artery surgery. Ombrellaro MP, et al.
Am J Surg 1996 Apr;171(4):387–90

Head injury in an adult with previously undiagnosed Dandy-Walker syndrome: a review of the condition and discussion of its anaesthetic implications. Cone AM.
Anaesth Intensive Care 1995 Oct;23(5):613–5

Anaesthesia for the patient with allergy to latex. Spears FD, et al. **Anaesth Intensive Care** 1995 Oct;23(5):623–5

Insertion methods of the laryngeal mask airway. A survey of current practice in Wales. Dingley J, et al.
Anaesthesia 1996 Jun;51(6):596–9

Consistency of the ASA classification [letter; comment] Dixon J. **Anaesthesia** 1995 Sep;50(9):826. Comment on: Anaesthesia 1995 Mar;50(3):195–9.

Molecular sieves: an alternative method of carbon dioxide removal which does not generate compound A during simulated low-flow sevoflurane anaesthesia. Fee JP, et al.
Anaesthesia 1995 Oct;50(10):841–5

Immunomodulation: an important concept in modern anaesthesia. McBride WT, et al. **Anaesthesia** 1996 May; 51(5):465–73 (86 ref.)

Consistency of the ASA classification [letter; comment] Muñoz-Ramon JM. **Anaesthesia** 1995 Sep;50(9):826. Comment on: Anaesthesia 1995 Mar;50(3):195–9.

Smoking and anaesthesia revisited [editorial] Nel MR, et al.
Anaesthesia 1996 Apr;51(4):309–11

Clonidine—and adjunct in isoflurane N2O/O2 relaxant anaesthesia [letter] Savva D. **Anaesthesia** 1996 Mar; 51(3):293

Where's the evidence? The Cochrane Collaboration and anaesthesia [letter] Smith AF, et al. **Anaesthesia** 1995 Dec; 50(12):1091–2

Metabolic gas exchange during anaesthesia [letter; comment] Walsh T, et al. **Anaesthesia** 1996 Jan;51(1):99–100. Comment on: Anaesthesia 1995 Apr;50(4):304–7.

Anaesthetic assistance during electroconvulsive therapy [letter; comment] Watts J. **Anaesthesia** 1996 Jun;51(6):609 . Comment on: Anaesthesia 1995 Nov;50(11):1009–10.

The effect of extradural ketamine on onset time and sensory block in extradural anaesthesia with bupivacaine. Yanli Y, et al. **Anaesthesia** 1996 Jan;51(1):84–6

The struggle for power in anaesthetic studies [editorial] Yentis SM. **Anaesthesia** 1996 May;51(5):413–4

International Anesthesia Research Society 70th Clinical and Scientific Congress. Washington, D.C., March 8–12, 1996. Abstracts. **Anesth Analg** 1996 Feb;82(2 Suppl):S1–567

Society of Cardiovascular Anesthesiologists 18th annual meeting. Salt Lake City, Utah, May 4–8, 1996. Abstracts. **Anesth Analg** 1996 Apr;82(4 Suppl):SCA1–146

Infection control precautions and anesthesia [letter] Arron BL. **Anesth Analg** 1996 Feb;82(2):427–8

Inadvertent extubation in infants fails to trigger the low pressure alarm of the Ohmeda Model 7000 anesthesia ventilator [letter] Azzam FJ. **Anesth Analg** 1996 Feb; 82(2):436–7

Pericardial tamponade: a case for awake endotracheal intubation [letter] Breen PH, et al. **Anesth Analg** 1996 Sep; 83(3):658

Sevoflurane for outpatient anesthesia: a comparison with propofol. Fredman B, et al. **Anesth Analg** 1995 Oct; 81(4):823–8

The effect of acute normovolemic hemodilution (ANH) on myocardial contractility in anesthetized dogs. Habler OP, et al. **Anesth Analg** 1996 Sep;83(3):451–8

Anesthesia, blood loss, and coagulopathy during transurethral resection of the prostate [letter; comment] Hahn RG.
Anesth Analg 1996 Jul;83(1):195. Comment on: Anesth Analg 1995 Oct;81(4):680–5.

Flexible coordination allows more cases [letter; comment] Johnstone RE. **Anesth Analg** 1996 Jul;83(1):194. Comment on: Anesth Analg 1995 Dec;81(6):1263–8.

Motor and sensory disability has a strong relationship to induction dose of thiopental in patients with the hypertropic variety of Charcot-Marie-Tooth syndrome. Kotani N, et al. **Anesth Analg** 1996 Jan;82(1):182–6

Simple modification of a medium concentration (Hudson type) oxygen mask improves patient comfort and respiratory monitoring with capnography [letter] Langer RA. **Anesth Analg** 1996 Jul;83(1):202

A simple device for preventing retrograde flow of blood into intravenous lines caused by blood pressure measurements [letter] Maekawa N, et al. **Anesth Analg** 1996 Sep;83(3):665

The effect of midazolam on left ventricular pump performance and contractility in anesthetized patients with coronary artery disease: effect of preoperative ejection fraction. Messina AG, et al. **Anesth Analg** 1995 Oct; 81(4):793–9

Surgical patients' attitudes regarding participation in clinical anesthesia research [see comments] Mingus ML, et al.
Anesth Analg 1996 Feb;82(2):332–7. Comment in: Anesth Analg 1996 Aug;83(2):438.

Neuroanesthesia adjunct therapy (mannitol and hyperventilation) is as effective as cerebrospinal fluid drainage for prevention of paraplegia after descending thoracic aortic cross-clamping in the dog. Mutch WA, et al. **Anesth Analg** 1995 Oct;81(4):800–5

Cardiac anesthetic: is it unique? [editorial; comment] Reves JG, et al. **Anesth Analg** 1995 Nov;81(5):895–6. Comment on: Anesth Analg 1995 Nov;81(5):900–10.

Memory during anesthesia: gone but not forgotten? [editorial; comment] Sebel PS. **Anesth Analg** 1995 Oct;81(4):668–70 . Comment on: Anesth Analg 1995 Oct;81(4):728–36.

Decreased cerebrospinal fluid pressure with mannitol and hypocapnia [letter] Shapira Y, et al. **Anesth Analg** 1996 Sep;83(3):662–3

Obtaining informed consent for anesthesia research [letter; comment] Sikich N, et al. **Anesth Analg** 1996 Aug;83(2):438 . Comment on: Anesth Analg 1996 Feb;82(2):332–7.

Video as a patient teaching tool: does it add to the preoperative anesthetic visit? Zvara DA, et al.
Anesth Analg 1996 May;82(5):1065–8

Unitary versus multiple mechanisms of anesthesia [letter; comment] Eger EI 2nd, et al. **Anesthesiology** 1995 Dec; 83(6):1368. Comment on: Anesthesiology 1995 Jul;83(1):6–7. Comment on: Anesthesiology 1995 Jul;83(1):101–8.

Binding of halothane to serum albumin: relevance to theories of narcosis [letter; comment] Eger EI 2nd, et al.
Anesthesiology 1995 Dec;83(6):1384–5. Comment on: Anesthesiology 1995 Aug;83(2):316–24.

Development and effectiveness of an anesthesia preoperative evaluation clinic in a teaching hospital [see comments] Fischer SP. **Anesthesiology** 1996 Jul;85(1):196–206. Comment in: Anesthesiology 1996 Jul;85(1):1–3.

Parental presence during induction of anesthesia. A randomized controlled trial. Kain ZN, et al.
Anesthesiology 1996 May;84(5):1060–7

Preservation of the ration of cerebral blood flow/metabolic rate for oxygen during prolonged anesthesia with isoflurane, sevoflurane, and halothane in humans. Kuroda Y, et al. **Anesthesiology** 1996 Mar;84(3):555–61

Difficult airway warning with automated anesthesia recording [letter; comment] Pasqual RT, et al. **Anesthesiology** 1996 Jul;85(1):220. Comment on: Anesthesiology 1995 Dec;83(6):1373–4.

Annual meeting of the Society of Neurosurgical Anesthesia and Critical Care. Atlanta, Georgia, October 20, 1995. Patel P. **Anesthesiology** 1996 Apr;84(4):1012–4

Interaction of isoflurane and nitrous oxide combinations similar for median electroencephalographic frequency and clinical anesthesia. Röpcke H, et al. **Anesthesiology** 1996 Apr;84(4):782–8

Metaphor and anesthesia. Shafer A. **Anesthesiology** 1995 Dec; 83(6):1331–42

Rate of coronary flow adaptation in response to changes in heart rate before and during anesthesia for coronary artery surgery. van Wezel HB, et al. **Anesthesiology** 1996 May; 84(5):1107–18

More on the changing indications for transfusion of blood and blood components during anesthesia [editorial] Weiskopf RB. **Anesthesiology** 1996 Mar;84(3):498–501

Influence of anesthetic regimens on the intestinal absorption of 5–fluorouracil in rats. Yuasa H, et al. **Biol Pharm Bull** 1995 May;18(5):747–52

Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. Koshy M, et al. **Blood** 1995 Nov 15;86(10):3676–84

Cutaneous heat loss during anaesthesia [letter; comment] English MJ, et al. **Br J Anaesth** 1995 Oct;75(4):505–6. Comment on: Br J Anaesth 1995 Mar;74(3):306–10.

The world of Null–A [letter; comment] Miller BM. **Br J Anaesth** 1995 Nov;75(5):668–9. Comment on: Br J Anaesth 1995 Jul;75(1):1–2.

Positive pressure ventilation and the laryngeal mask airway in ophthalmic anaesthesia [letter; comment] Wainwright AC. **Br J Anaesth** 1995 Aug;75(2):249–50. Comment on: Br J Anaesth 1994 Oct;73(4):543–4. Comment on: Br J Anaesth 1995 Apr;74(4):489–90.

Awareness during anaesthesia: when is an anaesthetic not an anaesthetic? [editorial] Aitkenhead AR. **Can J Anaesth** 1996 Mar;43(3):206–11 **(Eng, Fre)**

Hysteroscopy and anaesthesia. Ananthanarayan C, et al. **Can J Anaesth** 1996 Jan;43(1):56–64 (56 ref.)

Practical infection control. Berry AJ. **Can J Anaesth** 1995 Nov;42(11):1051–3

Patients prefer scented face masks [letter] Carson K, et al. **Can J Anaesth** 1995 Sep;42(9):842

Anaesthetic care and audit: 150 years on [editorial; comment] Davies JM. **Can J Anaesth** 1996 Apr;43(4):323–6. Comment on: Can J Anaesth 1996 Apr;43(4):333–40. **(Eng, Fre)**

Dose–response relationships for edrophonium antagonism of mivacurium–induced neuromuscular block during N2O–enflurane–alfentanil anaesthesia. Marcotte J, et al. **Can J Anaesth** 1995 Oct;42(10):879–83

Reuse of syringes in anaesthesia practice [letter] Skidmore GB. **Can J Anaesth** 1996 Apr;43(4):418

Meeting the challenge: providing anesthesia services in rural hospitals [editorial] [see comments] Barry AW. **Can Med Assoc J** 1995 Nov 15;153(10):1455–6. Comment in: Can Med Assoc J 1996 Feb 1;154(3):300.

Role of the general practitioner in the delivery of surgical and anesthesia services in rural western Canada [see comments] Chiasson PM, et al. **Can Med Assoc J** 1995 Nov 15;153(10):1447–52. Comment in: Can Med Assoc J 1996 Mar 1;154(5):631–2.

The use of fiberoptic endoscopy in anesthesia. Lee AC, et al. **Chest Surg Clin N Am** 1996 May;6(2):329–47 (45 ref.)

Children's development effecting blood oxygen desaturation following apnea. Xue F, et al. **Chin Med J (Engl)** 1995 Jun;108(6):434–7

Pharmacokinetic–pharmacodynamic relationships for opioids in balanced anaesthesia. Lemmens HJ. **Clin Pharmacokinet** 1995 Oct;29(4):231–42 (69 ref.)

Induction of anaesthesia by propofol and hepatic blood flow in the rabbit. Demeure dit Latte D, et al. **Clin Physiol** 1995 Sep;15(5):515–22

Long–term follow up to patients with frozen shoulder after mobilization under anesthesia, with special reference to the rotator cuff. Weber M, et al. **Clin Rheumatol** 1995 Nov; 14(6):686–91

Autonomic regulations in non–transplant cardiac surgery. Baumert JH, et al. **Clin Sci (Colch)** 1996;91 Suppl:16–8

Anaesthesia for a patient undergoing thoracoscopic assisted trans–hiatal oesophagectomy. Green DT, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):483–6

Effects of sevoflurane anaesthesia on renal function—duration of administration and area under the curve and rate of decrease of serum inorganic fluoride. Nishiyama T, et al. **Eur J Anaesthesiol** 1995 Sep; 12(5):477–82

Clinical Experiences with Esmeron. Luxembourg, 27–29 January 1995. Proceedings of an international meeting. **Eur J Anaesthesiol Suppl** 1995 Sep;11:1–112

Onset time and evaluation of intubating conditions: rocuronium in perspective. Agoston S. **Eur J Anaesthesiol Suppl** 1995 Sep;11:31–7 (14 ref.)

Rocuronium with alfentanil and propofol allows intubation within 45 seconds. Crul JF, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:111–2

The effect of dose and the rate of stimulation on the action of rocuronium. Feldman SA, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:15–7

Propofol versus propofol with midazolam for laryngeal mask insertion. Godsiff L, et al. **Eur J Anaesthesiol Suppl** 1995 Nov;12:35–40

Time–course of action and intubating conditions with rocuronium bromide under propofol–alfentanil anaesthesia. Hofmockel R, et al. **Eur J Anaesthesiol Suppl** 1995 Sep; 11:69–72

Rocuronium bromide in the ICU: dose finding and pharmacokinetics. Khuenl–Brady KS, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:79–80

Dose–response and time–course of effect of rocuronium bromide in paediatric patients. Meretoja OA, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:19–22

Dose–response and time–course of action of rocuronium bromide. Mirakhur RK. **Eur J Anaesthesiol Suppl** 1995 Sep; 11:23–5

Dose–response, time–course of action and recovery of rocuronium bromide in children during halothane anaesthesia. Motsch J, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:73–8

Intubation conditions and time–course of action of low–dose rocuronium bromide in day–case dental surgery. Pollard BJ, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:81–3

1 x ED90 dose of rocuronium bromide: tracheal intubation conditions and time–course of action. Prien T, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:85–90

Priming studies with rocuronium and vecuronium. Redai I, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:11–3

Rocuronium– and mivacurium–induced neuromuscular block and intubating conditions: a comparison with vecuronium. van den Broek L, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:27–30

The brain histamine (HA) and pituitary luteinizing hormone (LH) levels in female rats anesthetized with ether on proestrus. Kim CY, et al. **Exp Anim** 1996 Apr;45(2):175–7

Anesthesia for pediatric endoscopy [letter] Gilger MA. **Gastrointest Endosc** 1995 Dec;42(6):596

Automatic record keeping in anaesthesia—a nine–year Italian experience. Lanza V. **Int J Clin Monit Comput** 1996 Feb; 13(1):35–43

Computerization of the preoperative anesthesia interview. Vitkun SA, et al. **Int J Clin Monit Comput** 1995 May; 12(2):71–6

Patient's evaluation and recall of the preoperative anaesthetic visit. Ali S, et al. **Ir Med J** 1996 Mar–Apr;89(2):74–5

The impact of different types of anesthesia on in vitro fertilization–embryo transfer treatment outcome. Gonen O, et al. **J Assist Reprod Genet** 1995 Nov;12(10):678–82

Mechanism of the decline in vagal cardiac acceleration in dogs in neuroleptanaesthesia. Roossien A, et al. **J Auton Nerv Syst** 1995 Jul 14;54(1):1–8

Lung separation: a final, final word [letter; comment] Benumof JL. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):618 . Comment on: J Cardiothorac Vasc Anesth 1995 Feb;9(1):116.

Neural and endothelial control of the peripheral circulation—implications for anesthesia: Part I. Neural control of the peripheral vasculature. Ebert TJ, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):147–58 (124 ref.)

The accuracy of references in the Journal of Cardiothoracic and Vascular Anesthesia [letter] Nishina K, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):622–4

Neural and endothelial control of the peripheral circulation—implications for anesthesia: Part II, Endothelium–mediated effects in the normal and diseased circulation. Stowe DF, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):159–71 (161 ref.)

Proceedings of the 10th SAMBA (Society for Ambulatory Anesthesia) annual meeting. Indian Wells, California, April 27–30, 1995. **J Clin Anesth** 1995 Nov;7(7):555–633

Desflurane advantage? Lower solubility or improved vaporizer? [letter; comment] Aldrete JA. **J Clin Anesth** 1996 Mar;8(2):169–71. Comment on: J Clin Anesth 1995 Feb;7(1):49–53.

Efficacy and safety of divided dose administration of mivacurium for a 90–second tracheal intubation. Ali HH, et al. **J Clin Anesth** 1996 Jun;8(4):276–81

Antibiotic therapy and the anesthesiologist. Cheng EY, et al. **J Clin Anesth** 1995 Aug;7(5):425–39 (97 ref.)

A post–anesthetic discharge scoring system for home readiness after ambulatory surgery. Chung F, et al. **J Clin Anesth** 1995 Sep;7(6):500–6

Anesthesia with antiphospholipid antibodies: anesthetic management of a parturient with lupus anticoagulant and anticardiolipin antibody. Fahy BG, et al. **J Clin Anesth** 1996 Feb;8(1):49–53

A comparison of mivacurium dosage requirements during isoflurane and desflurane anesthesia. Gan TJ, et al. **J Clin Anesth** 1996 Jun;8(4):301–6

Effect of oral clonidine premedication on anesthetic requirement, hormonal response, hemodynamics, and recovery in coronary artery bypass graft surgery patients. Howie MB, et al. **J Clin Anesth** 1996 Jun;8(4):263–72

Compatibility of propofol, fentanyl, and vecuronium mixtures designed for potential use in anesthesia and patient transport. Isert PR, et al. **J Clin Anesth** 1996 Jun; 8(4):329–36

The demographics of inpatient pediatric anesthesia: implications for credentialing policy. Macario A, et al. **J Clin Anesth** 1995 Sep;7(6):507–11

Anesthesia for interventional neuroradiology. Manninen PH, et al. **J Clin Anesth** 1995 Sep;7(6):448–52

Desflurane is not associated with faster operating room exit times in outpatients. Patel N, et al. **J Clin Anesth** 1996 Mar; 8(2):130–5

Transient neonatal myasthenia gravis and pyloric stenosis. Regenbaum S, et al. **J Clin Anesth** 1995 Sep;7(6):515–8

A simple method of blood pressure determination in pediatric patients when automated noninvasive blood pressure measurement fails [letter] Stevenson GW, et al. **J Clin Anesth** 1995 Sep;7(6):549–50

Factors that influence an anesthesiologist's decision to cancel elective surgery for the child with an upper respiratory tract infection. Tait AR, et al. **J Clin Anesth** 1995 Sep; 7(6):491–9

Nicardipine: applications in anesthesia practice. Tobias JD. **J Clin Anesth** 1995 Sep;7(6):525–33 (56 ref.)

Italy publishes anesthesia monitoring protocols [news] Torri G, et al. **J Clin Monit** 1995 Jan;11(1):71–2

Monitoring evoked potentials during surgery to assess the level of anaesthesia. Jordan C, et al. **J Med Eng Technol** 1995 Mar–Jun;19(2–3):77–9

Low–threshold neuronal activity of spinal dorsal horn neurons increases during REM sleep in cats: comparison with effects of anesthesia. Kishikawa K, et al. **J Neurophysiol** 1995 Aug;74(2):763–9

International Symposium on Neurointensive Care and Neuroanaesthesia—Feb. 18–19, 1995—a report. Chaturvedi A. **J Neurosurg Anesthesiol** 1996 Apr;8(2):183–4

Active cooling during anesthesia and critical care. Illievich UM, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):78–82 (56 ref.)

Do recently developed techniques for skull base surgery increase the risk of difficult airway management? Assessment of pseudoankylosis of the mandible following surgical manipulation of the temporalis muscle. Kawaguchi M, et al. **J Neurosurg Anesthesiol** 1995 Jul;7(3):183–6

Predicting perioperative stroke. Kim J, et al. **J Neurosurg Anesthesiol** 1995 Jul;7(3):211–5 (24 ref.)

Electrophysiological monitoring and mild hypothermia. Kochs E. **J Neurosurg Anesthesiol** 1995 Jul;7(3):222–8 (56 ref.)

Brain tumors do not affect thiopental dosing requirements. Veselis RA, et al. **J Neurosurg Anesthesiol** 1995 Oct; 7(4):248–53

Anaesthesia and craniofacial surgery. Karapurkar SA, et al. **J Postgrad Med** 1994 Jan–Mar;40(1):3–6 (6 ref.)

Carbon dioxide at anesthetic levels protects against irreversible damage during spinal cord ischemia. Vacanti FX, et al. **J Surg Res** 1996 Apr;62(1):59–62

Fundamental frequency and tracheal pressure during three types of vocalizations elicited from anesthetized dogs. Solomon NP, et al. **J Voice** 1995 Dec;9(4):403–12

Anaesthesia or sedation for drug misusers [letter; comment] Brewer C. **Lancet** 1996 Mar 30;347(9005):904. Comment on: Lancet 1996 Jan 13;347(8994):97–100. Comment on: Lancet 1996 Feb 10;347(8998):373–6.

Prophylactic effects of intravenous magnesium on hypertensive emergencies after cataract surgery. A new contribution to the pharmacological use of magnesium in anaesthesiology. Nastou H, et al. **Magnes Res** 1995 Sep; 8(3):271–6

Brain–stem auditory evoked potentials study during isoflurane–N2O anesthesia—a measure of depth of anesthesia. el–Dawlatly AA, et al. **Middle East J Anesthesiol** 1995 Feb;13(1):61–70

Airway protection by the laryngeal mask airway in children. Samarkandi AH, et al. **Middle East J Anesthesiol** 1995 Feb; 13(1):107–13

Anesthesia in Che'diak–Higashi syndrome—case report. Ulsoy H, et al. **Middle East J Anesthesiol** 1995 Feb; 13(1):101–5

Intracortical facilitation and inhibition after paired magnetic stimulation in humans under anesthesia. Nakamura H, et al. **Neurosci Lett** 1995 Oct 20;199(2):155–7

Parental presence during induction of anaesthesia [editorial] Kain ZN. **Paediatr Anaesth** 1995;5(4):209–12

Down's syndrome and anaesthesia. Mitchell V, et al. **Paediatr Anaesth** 1995;5(6):379–84 (49 ref.)

Assessment of the effect of head and neck position on upper airway anatomy in sedated paediatric patients using magnetic resonance imaging. Shorten GD, et al. **Paediatr Anaesth** 1995;5(4):243–8

Anaesthesia in children with viral respiratory tract infections. Van der Walt J. **Paediatr Anaesth** 1995;5(4):257–62 (25 ref.)

Anaesthetic management of a 2.900 kg neonate with a C3–C4 dislocation. Vischoff D, et al. **Paediatr Anaesth** 1995; 5(1):71–4

Pediatric oncology procedures: to sleep or perchance to dream? [editorial; comment] Berde C. **Pain** 1995 Jul; 62(1):1–2. Comment on: Pain 1995 Jul;62(1):3–9.

The influence of colonic temperature changes in anaesthetised rats on tail skin temperatures and repeated testing of tail–flick latencies. Sapsed–Byrne S, et al. **Pain** 1995 Nov;63(2):255–61

Blunt urogenital trauma in prepubescent female patients: more than meets the eye! Lynch JM, et al. **Pediatr Emerg Care** 1995 Dec;11(6):372–5

Evaluation and preparation of pediatric patients undergoing anesthesia. American Academy of Pediatrics. Section on Anesthesiology. **Pediatrics** 1996 Sep;98(3 Pt 1):502–8

Effects of TRH and atropine on induction and duration of anesthesia with propofol in rats. Larsson JE, et al. **Peptides** 1996;17(2):293–7

Effects of gender, pregnancy, and anesthesia on the pharmacokinetics of zidovudine in rats. Huang CS, et al. **Pharm Res** 1995 Nov;12(11):1647–51

Molecular mechanisms of neuromuscular blocking agents: is the increased understanding of importance to the practising anaesthetist? Aglan MY, et al. **Pharmacol Ther** 1995; 68(3):365–83 (76 ref.)

Pavlovian fear conditioning in mice anesthetized with halothane. Pang R, et al. **Physiol Behav** 1996 Apr–May; 59(4–5):873–5

Can pre–emptive interpleural block reduce perioperative anesthetic and analgesic requirements? Abdulatif M, et al. **Reg Anesth** 1995 Jul–Aug;20(4):296–302

Attitudes towards parental presence at induction of anaesthesia. Bösenberg AT, et al. **S Afr Med J** 1996 Jun; 86(6):664–7

Teaching airway management on anaesthetised patients. Martin PD, et al. **Scott Med J** 1994 Aug;39(4):111–3

Microscopic lung alterations and reduction of respiration rate in insonated anesthetized swine [letter] Harrison GH, et al. **Ultrasound Med Biol** 1995;21(7):981–3

[Progresses in anesthesiology in China, 1995] Jin Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):746–7 (0 ref.) **(Chi)**

[Risks in minimally invasive surgery from the viewpoint of the anesthesiologist] Spunda J. **Rozhl Chir** 1996 Feb; 75(2):67–70 (Eng. Abstr.) **(Cze)**

[Surgery, anesthesia and lithium treatment (letter)] Schou M. **Ugeskr Laeger** 1996 Jan 22;158(4):435 **(Dan)**

[Pediatric anesthesia] Walther–Larsen S. **Ugeskr Laeger** 1996 Apr 15;158(16):2235–6 **(Dan)**

[French Society of Anesthesia and Intensive Care. Arterial catheterization and invasive measurement of blood pressure in anesthesia and intensive care in adults] **Ann Fr Anesth Reanim** 1995;14(5):444–53 (6611 ref.) (Eng. Abstr.) **(Fre)**

[37th National Congress of Anesthesia and Resuscitation. Xth Meeting French–Quebec. Paris, 14–17 September 1995. Abstracts] **Ann Fr Anesth Reanim** 1995;14 Suppl 3:R1–367 **(Fre)**

[Indications for the use of magnesium in anesthesia and intensive care] Delhumeau A, et al. **Ann Fr Anesth Reanim** 1995;14(5):406–16 (113 ref.) (Eng. Abstr.) **(Fre)**

[Quality assessment in anesthesia] Kupperwasser B. **Ann Fr Anesth Reanim** 1996;15(1):57–70 (Eng. Abstr.) **(Fre)**

[Myocardial ischemia and anesthesia] Lehot JJ, et al. **Ann Fr Anesth Reanim** 1995;14(2):176–97 (210 ref.) (Eng. Abstr.) **(Fre)**

[Effects of anesthesia on postoperative micturition and urinary retention] Pertek JP, et al. **Ann Fr Anesth Reanim** 1995;14(4):340–51 (44 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of professional practice and health care organization in anesthesia and intensive care: a strategic approach (editorial)] Petit J. **Ann Fr Anesth Reanim** 1996; 15(1):9–12 **(Fre)**

[Transfusion of erythrocyte concentrates. An evaluation in anesthesia and intensive care] Quaranta JF, et al. **Ann Fr Anesth Reanim** 1996;15(1):20–6 (Eng. Abstr.) **(Fre)**

[Plea for systematic preoperative tests] Cousin MT. **Cah Anesthesiol** 1996;44(1):81–5 **(Fre)**

[Value of selective prescription of preanesthetic laboratory tests] Mignonsin D, et al. **Cah Anesthesiol** 1996;44(1):13–7 (Eng. Abstr.) **(Fre)**

[Diabetes and anesthesia: care of diabetics during the intraoperative period. Recommendations of ALFEDIAM (French Language Association for the Study of Diabetes and Metabolic Diseases)] Brogard JM, et al. **Diabete Metab** 1995 Jun;21(3):197–206 **(Fre)**

[Analysis of heart rate variability. Background, method, and possible use in anesthesia] Baumert JH, et al. **Anaesthesist** 1995 Oct;44(10):677–86 (79 ref.) (Eng. Abstr.) **(Ger)**

[Intubation conditions following administration of atracurium and vecuronium. Bolus method versus priming technique] Bissinger U, et al. **Anaesthesist** 1996 Jun;45(6):512–7 (Eng. Abstr.) **(Ger)**

[Anesthesia and intensive care management of severely burned children of Jehovah's Witnesses] Donner B, et al. **Anaesthesist** 1996 Feb;45(2):171–5 (Eng. Abstr.) **(Ger)**

[Remarks on the work of A. Klockgether–Radke et al. The effect of propofol on vomiting in children following strabismus surgery (letter)] Holas A, et al. **Anaesthesist** 1996 May;45(5):464–7 **(Ger)**

[Incidence and quality of dreaming during anesthesia with propofol in comparison with enflurane] Käsmacher H, et al. **Anaesthesist** 1996 Feb;45(2):146–53 (Eng. Abstr.) **(Ger)**

[Anesthesiologic pecularities in patients with latex allergy (see comments)] Kisch H, et al. **Anaesthesist** 1996 Jul; 45(7):587–96 (88 ref.) (Eng. Abstr.). Comment in: Anaesthesist 1996 Jul;45(7):585–6. **(Ger)**

[Difficult intubation in adults] Langenstein H, et al. **Anaesthesist** 1996 Apr;45(4):372–83 (39 ref.) (Eng. Abstr.) **(Ger)**

[Analgesia–sedation for maxillo–facial surgery with midazolam–pentazocine and miazolam–ketamine. Clinical double–blind study of anxiety, analgesia, sedation and amnesia] Lipp M, et al. **Anaesthesist** 1995 Aug;44(8):566–72 (Eng. Abstr.) **(Ger)**

[Awakening from anesthesia and recovery of cognitive function after desflurane or isoflurane] Loscar M, et al. **Anaesthesist** 1996 Feb;45(2):140–5 (Eng. Abstr.) **(Ger)**

[Anesthesiologic problems in patients with fibrodysplasia ossificans progressiva] Meier R, et al. **Anaesthesist** 1996 Jul;45(7):631–4 (Eng. Abstr.) **(Ger)**

[Anesthesia and the liver] Nöldge–Schomburg GF, et al. **Anaesthesist** 1996 Jun;45(6):567–83 (10 ref.) **(Ger)**

[Online recording of monitor data. The artifact problem] Petry A. **Anaesthesist** 1995 Dec;44(12):818–25 (Eng. Abstr.) **(Ger)**

[Efficiency of a mobile oxygen concentrator for mechanical ventilation in anesthesia. Studies with a metabolic lung model and early clinical results] Rathgeber J, et al. **Anaesthesist** 1995 Sep;44(9):643–50 (Eng. Abstr.) **(Ger)**

[Intraoperative cardiac risk and preoperative examinations from the anesthetic viewpoint] Rolf N, et al. **Dtsch Med Wochenschr** 1996 Apr 5;121(14):453–8 (47 ref.) **(Ger)**

[Anesthesia in experimental single–lung transplantation: hemodynamic and respiratory changes during prostaglandin E1 and nitroglycerin infusion] Della Rocca G, et al. **Minerva Anestesiol** 1995 May;61(5):207–18 (Eng. Abstr.) **(Ita)**

[Prospects of balanced anesthesia––mainly focusing on combined induction of midazolam with barbiturate and epidural opioid with local anesthetics] Arita H, et al. **Masui** 1995;44 Suppl:S167–72; discussion S173–6 **(Jpn)**

[Premedication in children: a comparison of oral midazolam and rectal bromazepam] Kambara N, et al. **Masui** 1995 Dec; 44(12):1707–11 (Eng. Abstr.) **(Jpn)**

[Anesthetic management for endoscopic surgery] Kazama T. **Masui** 1995;44 Suppl:S83–92 (11 ref.) **(Jpn)**

[A case of metastatic lung cancer detected by intraoperative fiberoptic bronchoscopy] Misawa K, et al. **Masui** 1995 Sep; 44(9):1250–3 (Eng. Abstr.) **(Jpn)**

[Anesthetic management for thoracoscopic lung biopsy] Moriyama K, et al. **Masui** 1995 Dec;44(12):1623–6 (Eng. Abstr.) **(Jpn)**

[Balanced anesthesia for postoperative management] Namiki A, et al. **Masui** 1995;44 Suppl:S162–6; discussion S173–6 (1 ref.) **(Jpn)**

[Anticancer therapy and anesthetic implications] Nishino T. **Masui** 1995;44 Suppl:S40–4 (16 ref.) **(Jpn)**

[The present state of balanced anesthesia––combination of intravenous and inhaled anesthetics] Sumikawa K, et al. **Masui** 1995;44 Suppl:S149–52; discussion S156–7 (10 ref.) **(Jpn)**

[The anesthetic management of a patient with Fabry's disease] Watanabe H, et al. **Masui** 1995 Sep;44(9):1258–60 (Eng. Abstr.) **(Jpn)**

[Anesthesiological care in removal of jugular glomus tumor. First experience with the use of urapidil] Lubnin AIu, et al. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):50–3 **(Rus)**

[Use of propofol (diprivan) for induction of anesthesia in neurosurgical patients. I. Pressor reaction to laryngoscopy and intubation of the trachea] Tseitlin AM, et al. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):46–9 (Eng. Abstr.) **(Rus)**

[The systemic hemodynamics of waking and anesthetized male cats during noradrenaline infusion] Eremeev VS, et al. **Fiziol Zh Im I M Sechenova** 1995 Jul;81(7):57–63 (Eng. Abstr.) **(Rus)**

[Can permanent sinus arrhythmia in conscious dogs be suppressed with anesthesia?] Bernadič M, et al. **Bratisl Lek Listy** 1996 May;97(5):273–8 (Eng. Abstr.) **(Slo)**

[The effect of experimental gastroesophageal reflux on the cough reflex in anesthetized cats] Tatár M, et al. **Bratisl Lek Listy** 1996 May;97(5):284–8 (Eng. Abstr.) **(Slo)**

[Anesthetic management of the anephric patient] Eliza M. **Bol Asoc Med P R** 1995 May–Jun;87(5–6):103–5 **(Spa)**

[I National Meeting on Anesthesiology in experimental surgery. Conclusions (letter)] Cruz JI. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):151 **(Spa)**

[Anesthesia in a patient with spinal muscular atrophy of the Kugelberg–Welander type (letter)] García–Miguel FJ, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):402–3 **(Spa)**

[Anesthesia in a case of Freeman–Sheldon syndrome (letter)] Ortega JP, et al. **Rev Esp Anestesiol Reanim** 1996 Apr; 43(4):152–3 **(Spa)**

[Propofol in continuous perfusion as anesthetic in experimental surgery in the rabbit] Pérez–Martínez A, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep;42(7):253–6 (Eng. Abstr.) **(Spa)**

[Physiopathologic implications of the anesthesiologic management of pediatric laparoscopic surgery] Reinoso–Barbero F, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep;42(7):277–82 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Evaluation of anaesthesias in malignant hyperthermia negative patients. Islander G, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):819–21

The treatment of postanaesthetic shivering: a double blind comparison between alfentanil and pethidine. Lyons B, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):979–82

Age– and anesthesia–related changes in accessory pathway conduction in children with Wolff–Parkinson–White syndrome. Chang RK, et al. **Am J Cardiol** 1995 Nov 15; 76(14):1074–6

Gastro–oesophageal reflux and adverse respiratory events in children under anaesthesia. Milross JG, et al. **Anaesth Intensive Care** 1995 Oct;23(5):587–90

A testing torticollis [letter] Russell K, et al. **Anaesth Intensive Care** 1996 Feb;24(1):126–7

Minimising cardiac anaesthetic risk: the tortoise or the hare? Juste RN, et al. **Anaesthesia** 1996 Mar;51(3):255–62 (63 ref.)

The cost efficacy of hypothetically eliminating adverse anesthetic outcomes from high–risk, but neither low– nor moderate–risk, surgical operations [see comments] Dexter F, et al. **Anesth Analg** 1995 Nov;81(5):939–44. Comment in: Anesth Analg 1995 Nov;81(5):897–9. Comment in: Anesth Analg 1996 Jul;83(1):203–4.

Smith–Lemli–Opitz syndrome and malignant hyperthermia [letter; comment] Haji–Michael PG, et al. **Anesth Analg** 1996 Jul;83(1):200. Comment on: Anesth Analg 1995 Mar;80(3):606–8.

Severe neurologic deficit after nitrous oxide anesthesia. Hadzic A, et al. **Anesthesiology** 1995 Oct;83(4):863–6 (14 ref.)

The 34th Rovenstine Lecture. 40 years behind the mask: safety revisited. Pierce EC Jr. **Anesthesiology** 1996 Apr; 84(4):965–75

Cardiovascular events in the postanesthesia care unit: contribution of risk factors. Rose DK, et al. **Anesthesiology** 1996 Apr;84(4):772–81

Atelectasis and chest wall shape during halothane anesthesia. Warner DO, et al. **Anesthesiology** 1996 Jul;85(1):49–59

Incidents and critical incidents [letter] Lack A, et al. **Br J Anaesth** 1995 Oct;75(4):505

Litigation in anaesthesia. Coleman NA. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):62–4

Abdominal anaesthesia [letter] Heriot JA. **Br J Hosp Med** 1995 Jul 12–Aug 15;54(2–3):115

Anaesthetic–associated mortality and anaesthetic contributory death: the South African medicolegal approach. Moar JJ. **Forensic Sci Int** 1996 Apr 23; 78(3):219–30

Distortion–product otoacoustic emissions and their anaesthesia sensitivity in the European starling and the chicken. Kettembeil S, et al. **Hear Res** 1995 Jun; 86(1–2):47–62

Anesthesiologic problems in Williams syndrome: the CACNL2A locus is not involved. Mammi I, et al. **Hum Genet** 1996 Sep;98(3):317–20

The etiology and management of inadvertent perioperative hypothermia. Forstot RM. **J Clin Anesth** 1995 Dec; 7(8):657–74 (188 ref.)

Anesthesia crisis resource management: real–life simulation training in operating room crises. Holzman RS, et al. **J Clin Anesth** 1995 Dec;7(8):675–87

Transfusion vs anesthesia–related hepatitis [letter; comment] Abouleish AE, et al. **JAMA** 1996 Feb 7;275(5):361–2. Comment on: JAMA 1995 Nov 1;274(17):1368–73.

Impact of anesthetic management on the outcome of cardiac patients for non–cardiac surgery. Gabriel FS. **Middle East J Anesthesiol** 1996 Feb;13(4):385–93 (20 ref.)

Whooping cough and anaesthesia [letter] Sandström K, et al. **Paediatr Anaesth** 1995;5(1):76

[Remarks on the letter of U. Schult–Sasse. Manufacturer warning for the routine administration of succinylcholine in children] Link J, et al. **Anaesthesist** 1996 Feb;45(2):183–7 **(Ger)**

[Laparoscopic cholecystectomy: evaluation of intraoperative complications with respect to 2 different kinds of anesthesia] Delogu G, et al. **Minerva Chir** 1995 Oct; 50(10):863–9 (Eng. Abstr.) **(Ita)**

[Free radicals in anesthesia and the role of exogenous antioxidants] Neri S, et al. **Riv Eur Sci Med Farmacol** 1994 Sep–Dec;16(5–6):125–30 (Eng. Abstr.) **(Ita)**

[Survey on anesthesia related accident in 1993] **Masui** 1996 Mar;45(3):374–8 **(Jpn)**

[The quality improvement system at Hamamatsu University School of Medicine] Yamamoto Y, et al. **Masui** 1995;44 Suppl:S183–8 **(Jpn)**

[A case of malignant hyperthermia: anesthesia and recovery] Galán J, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep; 42(7):274–6 (Eng. Abstr.) **(Spa)**

CONTRAINDICATIONS

Anaesthetic considerations for a possible malignant hyperthermia susceptible fetus [letter] Hersch PE, et al. **Anaesthesia** 1996 Jan;51(1):99

The risk of anesthesia in the asthmatic child. Pradal M, et al. **Pediatr Pulmonol Suppl** 1995;11:51–2

ECONOMICS

A cost–benefit evaluation of using propofol and alfentanil for a short gynecological procedure. Enlund M, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):416–20

Anaesthesia––value for money [editorial] Edge G, et al. **Anaesthesia** 1996 Feb;51(2):105–6

Economic analysis and pharmaceutical policy. Rovira J. **Anaesthesia** 1995 Oct;50 Suppl:49–51

Cost containment: at what expense? [editorial; comment] Kapur PA. **Anesth Analg** 1995 Nov;81(5):897–9. Comment

on: Anesth Analg 1995 Nov;81(5):939–44.
Forget the costs: use what is best [letter; comment] Jacoby J. **Anesthesiology** 1996 May;84(5):1258–9. Comment on: Anesthesiology 1995 Aug;83(2):250–7.
Comparison of estimated variable costs is a surrogate for actual cost experience [letter; comment] Johnstone RE. **Anesthesiology** 1995 Dec;83(6):1387. Comment on: Anesthesiology 1995 Aug;83(2):250–7.
Use of anesthesia selection in controlling surgery costs in an HMO hospital. Suver J, et al. **Clin Ther** 1995 May–Jun; 17(3):561–71; discussion 516
Cost analysis of propofol versus thiopental induction anesthesia in outpatient laparoscopic gynecologic surgery. Wagner BK, et al. **Clin Ther** 1995 Jul–Aug;17(4):770–6
A multifactorial approach to understanding anesthesia selection. Suver JD, et al. **Health Care Manage Rev** 1995 Summer;20(3):7–15
Application of cost–utility and quality–adjusted life years analyses to monitored anesthesia care for sedation only. Dexter F. **J Clin Anesth** 1996 Jun;8(4):286–8
Understanding cost analyses: Part 1. A practitioner's guide to cost behavior. Lubarsky DA. **J Clin Anesth** 1995 Sep; 7(6):519–21

EDUCATION see ANESTHESIOLOGY/education

HISTORY

Ether before anaesthesia. Ball C, et al. **Anaesth Intensive Care** 1996 Feb;24(1):3
Exponentials and the anaesthetist. 1964 [classical article] Mapleson WW. **Anaesthesia** 1995 Oct;50(10):879–89
Problems of oxygenation and oxygen transport during haemorrhage. 1964 [classical article] Nunn JF, et al. **Anaesthesia** 1995 Sep;50(9):795–800; discussion 794
A question of priority: who introduced the CO2 absorption method with circle breathing into anaesthesia practice? [letter; comment] Foregger R. **Anaesthesist** 1995 Dec; 44(12):917–8. Comment on: Anaesthesist 1994 Mar;43(3):194–210.
Fires and explosions with anaesthetics [letter] Franco A, et al. **Br J Anaesth** 1995 Dec;75(6):821–2
The delayed arrival: from Davy (1800) to Morton (1846). Adams AK. **J R Soc Med** 1996 Feb;89(2):96P–100P
Status lymphaticus, II. Essentials of General Anaesthesia with Special Reference to Dentistry (1940) [classical article] Macintosh RR, et al. **Paediatr Anaesth** 1995;5(6):388
Status lymphaticus, I. 1940 [classical article] Macintosh RR, et al. **Paediatr Anaesth** 1995;5(6):354
[Otto Kappeler––a pioneer in anesthesia in German–speaking regions] Goerig M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):426–35 (Eng. Abstr.) **(Ger)**

INSTRUMENTATION see ANESTHESIOLOGY/instrumentation

METHODS

Low flow anaesthesia reduces occupational exposure to inhalation anaesthetics. Environmental and biological measurements in operating room personnel. Imberti R, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):586–91
Obesity: an anaesthetic challenge. Oberg B, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):191–200 (88 ref.)
Two methods of anesthesia for rhinoplasty in outpatient setting. Niechajev I, et al. **Aesthetic Plast Surg** 1996 Mar–Apr;20(2):159–63
Analysis of 1500 laryngeal mask uses by one anaesthetist in adults undergoing routine anaesthesia. Brimacombe J. **Anaesthesia** 1996 Jan;51(1):76–80
Anaesthetic problems in the Nance Insley syndrome. Denton R. **Anaesthesia** 1996 Jan;51(1):100–1
Peri–operative management of diabetic patients. Any changes for the better since 1985? [see comments] Eldridge AJ, et al. **Anaesthesia** 1996 Jan;51(1):45–51. Comment in: Anaesthesia 1996 May;51(5):502–3.
Recovery from outpatient anaesthesia. Factors affecting outcome. Korttila K. **Anaesthesia** 1995 Oct;50 Suppl:22–8 (63 ref.)
Anaesthetic rooms––the debate continues [letter; comment] Smith MG, et al. **Anaesthesia** 1996 May;51(5):509. Comment on: Anaesthesia 1995 Dec;50(12):1095.
Breathe in, breathe out [letter] Stone SB. **Anesth Analg** 1996 Jan;82(1):222
Propofol induction is more effective than ondansetron in prophylaxis of postoperative nausea, but not vomiting [letter; comment] Tezcan C, et al. **Anesth Analg** 1996 Jan; 82(1):219. Comment on: Anesth Analg 1995 May;80(5):861–3.
Nonsteroidal antiinflammatory drugs, opioids, and routine anesthesia [letter; comment] van den Berg AA. **Anesth Analg** 1995 Nov;81(5):1110–1. Comment on: Anesth Analg 1994 Dec;79(6):1178–90.
Detection of carbon monoxide with mass spectroscopy during anesthesia [letter; comment] Breen PH. **Anesthesiology** 1995 Dec;83(6):1383–4. Comment on: Anesthesiology 1995 Jul;83(1):213–7.
Preoxygenation technique is not ideal [letter; comment] Butler P, et al. **Anesthesiology** 1996 Jan;84(1):238–9. Comment on: Anesthesiology 1995 Aug;83(2):429.
Measuring the performance of anesthetic depth indicators. Smith WD, et al. **Anesthesiology** 1996 Jan;84(1):38–51 (61 ref.)
Vomiting and recovery after outpatient tonsillectomy and adenoidectomy in children. Comparison of four anesthetic techniques using nitrous oxide with halothane or propofol. Ved SA, et al. **Anesthesiology** 1996 Jul;85(1):4–10
Cricoid pressure decreases lower oesophageal sphincter tone in anaesthetized pigs. Chassard D, et al. **Can J Anaesth** 1996 Apr;43(4):414–7
Anaesthesia for thyroplasty. Donnelly M, et al. **Can J Anaesth** 1995 Sep;42(9):813–5
Anaesthetic management of a patient with myasthenia gravis and tracheal stenosis. Froelich J, et al. **Can J Anaesth** 1996 Jan;43(1):84–9
Anaesthetic management of a child with Bartter's syndrome. Kannan S, et al. **Can J Anaesth** 1995 Sep;42(9):808–12
The anaesthetic management of the child with Eisenmenger's syndrome. Lyons B, et al. **Can J Anaesth** 1995 Oct; 42(10):904–9
Ankylosing spondylitis and neuraxial anaesthesia––a 10 year review. Schelew BL, et al. **Can J Anaesth** 1996 Jan; 43(1):65–8
Anaesthetic management of a patient with glycogen storage disease type 1b. Shenkman Z, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):467–70
Anesthesia for patients undergoing surgery for emphysema. Bussières JS. **Chest Surg Clin N Am** 1995 Nov;5(4):869–78
Anaesthetic management of a patient with von Hippel–Lindau disease: a combination of bilateral phaeochromocytoma and spinal cord haemangioblastoma. Ercan M, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):81–3
Co–induction of anaesthesia: the rationale. Amrein R, et al. **Eur J Anaesthesiol Suppl** 1995 Nov;12:5–11 (41 ref.)
Induction of anaesthesia: one drug or two? [editorial] Park GR, et al. **Eur J Anaesthesiol Suppl** 1995 Nov;12:1
Anesthetic considerations for descending thoracic aortic surgery: Part 1. O'Connor CJ, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):581–8 (63 ref.)
Monitored anesthesia care: how much sedation, how much analgesia? Smith I. **J Clin Anesth** 1996 May;8(3 Suppl):76S–80S (19 ref.)
Preparing for the unanticipated difficult airway [letter] Sommer RM. **J Clin Anesth** 1995 Dec;7(8):688–9
Anesthesia for carotid stent procedures. Kharrazi MR. **J Endovasc Surg** 1996 May;3(2):211–6 (8 ref.)
Fentazin anesthesia for labyrinthine surgery in guinea pigs. Sansom AJ, et al. **J Vestib Res** 1996 Jan–Feb;6(1):49–52
Acid–base status and cardiovascular function in mink (Mustela vison) anaesthetized with ketamine/midazolam. Wamberg S, et al. **Lab Anim** 1996 Jan;30(1):55–66
Combined spinal–epidural–general anesthesia. Eldor J. **Med Hypotheses** 1995 Jul;45(1):86–90
Anesthesia and head trauma. McGrath BJ, et al. **New Horiz** 1995 Aug;3(3):523–33 (103 ref.)
A comparison of topical and retrobulbar anesthesia for cataract surgery. Patel BC, et al. **Ophthalmology** 1996 Aug; 103(8):1196–203
Absence of corpus callosum and history of slow recovery [letter] Waite I, et al. **Paediatr Anaesth** 1995;5(4):273–4
Noninvasive mitigation of peripheral vasoconstriction [letter; comment] Freda JJ. **Reg Anesth** 1995 Nov–Dec;20(6):548–9 . Comment on: Reg Anesth 1995 Jan–Feb;20(1):82–3.
Comment on combined spinal–epidural–general anesthesia [letter; comment] Kang WB. **Reg Anesth** 1995 May–Jun; 20(3):260–1. Comment on: Reg Anesth 1994 Sep–Oct;19(5):365–6.
Combined epidural–spinal–general anesthesia [letter; comment] King HK, et al. **Reg Anesth** 1995 Nov–Dec; 20(6):548. Comment on: Reg Anesth 1994 Sep–Oct;19(5):365–6.
Laparoscopic cholecystectomy during pregnancy. Review of anesthetic management, surgical considerations. Steinbrook RA, et al. **Surg Endosc** 1996 May;10(5):511–5
Anesthesia for living related donor liver transplantation. Jawan B, et al. **Transplant Proc** 1996 Aug;28(4):2409–11 (39 ref.)
Anesthetic considerations in the geriatric patient. Burney TL, et al. **Urol Clin North Am** 1996 Feb;23(1):19–26 (20 ref.)
[Anesthesiological and resuscitation problems in the surgical treatment of acute massive pulmonary thromboembolisms] Aleksandrov V, et al. **Khirurgiia (Sofiia)** 1995;48(1):84–6 (Eng. Abstr.) **(Bul)**
[Anesthesia problems in patients with an infravesical obstruction] Bovianska N. **Khirurgiia (Sofiia)** 1995; 48(5):39–42 (Eng. Abstr.) **(Bul)**
[Pediatric anesthesia in Denmark––a debate on the organization of pediatric anesthesia/surgery, intensive care and pain relief] Walther–Larsen S. **Ugeskr Laeger** 1996 Apr 15;158(16):2265–6 **(Dan)**
[Diabetes and anesthesia: perioperative management of the diabetic patient] Brogard JM, et al. **Ann Fr Anesth Reanim** 1995;14(6):523–31 (28 ref.) **(Fre)**
[Equipment safety and conditions of failure (editorial)] Cazalaà JB, et al. **Ann Fr Anesth Reanim** 1995;14(4):317–9 **(Fre)**
[Anesthesia and implantable automatic defibrillator] Stojeba N, et al. **Ann Fr Anesth Reanim** 1996;15(3):295–303 (Eng. Abstr.) **(Fre)**
[Anesthesia for cataract surgery. Result of a national survey] Lalanne B, et al. **Presse Med** 1996 Jan 27;25(3):99–101 (Eng. Abstr.) **(Fre)**
[Pediatric anesthesia. Induction, sustaining, awakening] Bissonnette B. **Rev Med Suisse Romande** 1996 Apr; 116(4):239–42 (16 ref.) **(Fre)**
[Anesthesia for ambulatory surgery in children] Flubacher P. **Rev Med Suisse Romande** 1996 Apr;116(4):251–3 **(Fre)**
[Transthoracic endoscopic sympathectomy––anesthetic aspects] Rozenberg B, et al. **Harefuah** 1996 Mar 15; 130(6):430–2 (21 ref.) **(Heb)**
[Anesthetic management of a neonate with primary cardiac rhabdomyoma] Matsumoto N, et al. **Masui** 1995 Nov; 44(11):1547–9 (Eng. Abstr.) **(Jpn)**
[The importance of SpO2 and FIO2 for anesthetic management for Norwood's operation] Taguchi A, et al. **Masui** 1995 Sep;44(9):1269–72 (Eng. Abstr.) **(Jpn)**
[Anesthesia using clofelin in different types of arterial hypertension in middle–aged and elderly patients] Dolina OA, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):4–6 (Eng. Abstr.) **(Rus)**
[Experience with using the laryngeal mask during anesthesia in pediatric traumatology] Ostreĭkov IF, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):62–3 **(Rus)**
[The current approach and basis for anesthesiological support in the surgical treatment of wounded patients at medical evacuation stages] Rudenko MI. **Voen Med Zh** 1995 Oct; (10):31–4 **(Rus)**
[Anesthesia by physiotherapy methods] Ushakov AA. **Voen Med Zh** 1992 Feb;(2):47–50 **(Rus)**
[Anesthesia in experimental animals. Basic principles] Cruz JI. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):99–107 (54 ref.) (Eng. Abstr.) **(Spa)**
[Special anesthesia care in heart transplantation. The management of right ventricular failure] Gómez–Arnau J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:60–4 (22 ref.) (Eng. Abstr.) **(Spa)**

MORTALITY

Deaths attributed to anaesthesia in New South Wales, 1984–1990. Warden JC, et al. **Anaesth Intensive Care** 1996 Feb;24(1):66–73
Deaths associated with anaesthesia––a lesson for South Africa [editorial; comment] James MF, et al. **S Afr Med J** 1996 Apr;86(4):325–6. Comment on: S Afr Med J 1996 Apr;86(4):338–42.
Mortality associated with anaesthesia at Zimbabwean teaching hospitals [see comments] McKenzie AG. **S Afr Med J** 1996 Apr;86(4):338–42. Comment in: S Afr Med J 1996 Apr;86(4):325–6.
[Death under anesthesia. Definition, causes, risk factors and prevention] Maaløe R, et al. **Ugeskr Laeger** 1995 Nov 20; 157(47):6561–5 (38 ref.) (Eng. Abstr.) **(Dan)**
[Death under anesthesia (editorial)] Møller JT, et al. **Ugeskr Laeger** 1995 Nov 20;157(47):6559 **(Dan)**
[Collection of cases of death from anesthesia based on death certificates. A feasibility study. Report to the General Direction of health] Hatton F, et al. **Ann Fr Anesth Reanim** 1996;15(1):75–85 **(Fre)**

NURSING

The perioperative nurse's role in anesthesia management. Stein RH. **AORN J** 1995 Nov;62(5):794–8, 801, 803–4 (21 ref.)

PSYCHOLOGY

Patients' desire for information about anaesthesia: change in Scottish attitudes over five years. Kennedy S, et al. **Health Bull (Edinb)** 1996 Mar;54(2):118–21
Reducing the anxiety of children undergoing surgery: parental presence during anaesthetic induction. Cameron JA, et al. **J Paediatr Child Health** 1996 Feb;32(1):51–6

STANDARDS

Improvements in anaesthetic care resulting from a critical incident reporting programme. Short TG, et al. **Anaesthesia** 1996 Jul;51(7):615–21
Cost–effective modeling [letter; comment] Metzger SE, et al. **Anesth Analg** 1996 Jul;83(1):203–4. Comment on: Anesth Analg 1995 Nov;81(5):939–44.
Instructional review improves performance of anesthesia apparatus checkout procedures. Olympio MA, et al. **Anesth Analg** 1996 Sep;83(3):618–22

STATISTICS & NUMERICAL DATA

Compliance with an incident report scheme in anaesthesia. Jayasuriya JP, et al. **Anaesthesia** 1995 Oct;50(10):846–9

TRENDS

[Prospects of balanced anesthesia––combination with propofol] Shingu K, et al. **Masui** 1995;44 Suppl:S158–61; discussion S173–6 (6 ref.) **(Jpn)**

VETERINARY

Comparison of two techniques of narcotic–induced anesthesia for use during recording of magnetic motor evoked potentials in dogs. Van Ham LM, et al. **Am J Vet Res** 1996 Feb;57(2):142–6
The use of tiletamine hydrochloride and zolazepam hydrochloride for sedation of the mountain brushtial possum, Trichosurus caninus Ogilby (Phalangeridae: Marsupialia). Viggers KL, et al. **Aust Vet J** 1995 Jun; 72(6):215–6

Most commonly asked questions about anesthetic equipment. Brock N. **Can Vet J** 1996 Jun;37(6):373–4
Equine anaesthesia: Horserace Betting Levy Board (HBLB) workshop. 31 October 1995 [see comments] **Equine Vet J** 1996 Jan;28(1):10–4. Comment in: Equine Vet J 1996 Jan;28(1):3–4.
HBLB Workshop on Equine Anaesthesia: the importance of pharmacodynamics and pharmacokinetics [editorial; comment] Lees P. **Equine Vet J** 1996 Jan;28(1):3–4. Comment on: Equine Vet J 1996 Jan;28(1):10–14.
Chemical restraint and anesthesia of sea otters affected by the oil spill in Prince William Sound, Alaska. Sawyer DC, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1831–4
Doppler ultrasonographic, oscillometric sphygmomanometric, and photoplethysmographic techniques for noninvasive blood pressure measurement in anesthetized cats. Binns SH, et al. **J Vet Intern Med** 1995 Nov–Dec;9(6):405–14
Induction of anaesthesia with halothane and isoflurane in the rabbit: a comparison of the use of a face-mask or an anaesthetic chamber. Flecknell PA, et al. **Lab Anim** 1996 Jan;30(1):67–74
Use of butorphanol as an anesthetic adjunct in turkeys. Reim DA, et al. **Lab Anim Sci** 1995 Dec;45(6):696–7
Anesthetic management of the trauma patient. Cuvelliez S, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1073–92 (42 ref.)
Gastro–oesophageal reflux during anaesthesia in the dog: the effect of preoperative fasting and premedication. Galatos AD, et al. **Vet Rec** 1995 Nov 4;137(19):479–83
Gastro–oesophageal reflux during anaesthesia in the dog: the effect of age, positioning and type of surgical procedure. Galatos AD, et al. **Vet Rec** 1995 Nov 11;137(20):513–6
Influences of type of anaesthesia on cortisol, beta-endorphin and heart rate in pigs. Gerard H, et al. **Vet Res** 1996; 27(3):219–26
Modification of a nonrebreathing circuit adapter to prevent barotrauma in anesthetized patients. McMurphy RM, et al. **Vet Surg** 1995 Jul–Aug;24(4):352–5
[Ketamine–midazolam combination for anesthesia of rabbits—results of neuroelectrophysiologic studies using evoked potentials] Troitzsch D, et al. **Berl Munch Tierarztl Wochenschr** 1995 Apr;108(4):143–7 (Eng. Abstr.) **(Ger)**
[Sedation and anesthesia in dogs and cats with cardiovascular diseases. I. Anesthesia plan considering risk assessment, hemodynamic effects of drugs and monitoring] Skarda RT, et al. **Schweiz Arch Tierheilkd** 1995;137(7):312–21 (13 ref.) (Eng. Abstr.) **(Ger)**
[Sedation and anesthesia in dogs and cats with cardiovascular disease. II. Anesthesia planning with respect to pathophysiology, heart arrhythmia] Skarda RT, et al. **Schweiz Arch Tierheilkd** 1995;137(12):543–51 (Eng. Abstr.) **(Ger)**
[Oximetry in veterinary anesthesia: the continuous determination of mixed venous oxygen saturation in dogs and horses] Alef M, et al. **Tierarztl Prax** 1996 Apr; 24(2):117–28 (Eng. Abstr.) **(Ger)**

ANESTHESIA, ACUPUNCTURE see **ACUPUNCTURE ANESTHESIA**

ANESTHESIA ADJUVANTS

Induction of anaesthesia with midazolam and a target-controlled propofol infusion. Tzabar Y, et al. **Anaesthesia** 1996 Jun;51(6):536–8
The effect of droperidol on objective markers of patient cooperation and vital signs during esophagogastroduodenoscopy: a randomized, double-blind, placebo-controlled, prospective investigation. Barthel JS, et al. **Gastrointest Endosc** 1995 Jul;42(1):45–50
Intravenous sedation in pediatric upper gastrointestinal endoscopy. Chuang E, et al. **Gastrointest Endosc** 1995 Aug; 42(2):156–60
Effect of intrathecal sufentanil on isoflurane requirements during lower abdominal surgery. Swenson JD, et al. **J Clin Anesth** 1995 Sep;7(6):477–80
Depression of excitatory effects of propofol induction by fentanyl. Ghabash M, et al. **Middle East J Anesthesiol** 1996 Feb;13(4):419–25
Nasal midazolam in children, plasma concentrations and the effect on respiration. Fösel T, et al. **Paediatr Anaesth** 1995; 5(6):347–53
Clonidine–mepivacaine mixture vs plain mepivacaine in paediatric surgery. Ivani G, et al. **Paediatr Anaesth** 1996; 6(2):111–4
Assessment of the effect of head and neck position on upper airway anatomy in sedated paediatric patients using magnetic resonance imaging. Shorten GD, et al. **Paediatr Anaesth** 1995;5(4):243–8
[Midazolam versus placebo before spinal anesthesia] Fletcher D, et al. **Cah Anesthesiol** 1995;43(5):497–9 (Eng. Abstr.) **(Fre)**
[Plasma catecholamine level and clinical parameters—quality criteria for premedication in childhood] Burkhardt U, et al. **Anaesthesiol Reanim** 1995;20(4):88–96 (Eng. Abstr.) **(Ger)**
[Neuromuscular blockade after atracurium and alcuronium with propofol and thiopental] Ginz HF, et al. **Anaesthesist** 1996 Jan;45(1):47–51 (Eng. Abstr.) **(Ger)**
[Analgesia-sedation for maxillo-facial surgery with midazolam–pentazocine and miazolam–ketamine. Clinical double-blind study of anxiety, analgesia, sedation and amnesia] Lipp M, et al. **Anaesthesist** 1995 Aug;44(8):566–72 (Eng. Abstr.) **(Ger)**
[Addition of fentanyl to bupivacaine—peridural analgesia in cesarean section] Thomas H, et al. **Anaesthesist** 1996 Jul; 45(7):635–42 (Eng. Abstr.) **(Ger)**
[Effect of premedication and barbiturate hypnotics on motor evoked potentials induced by magnetic cortex stimulation] Nadstawek J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):361–5 (Eng. Abstr.) **(Ger)**
[Prospects of balanced anesthesia—mainly focusing on combined induction of midazolam with barbiturate and epidural opioid with local anesthetics] Arita H, et al. **Masui** 1995;44 Suppl:S167–72; discussion S173–6 **(Jpn)**
[Efficacy of the EMLA cream in the reduction of pain caused by venipuncture in children premedicated with oral midazolam] Cassinello F, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):360–3 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Rectal indomethacin potentiates spinal morphine analgesia after caesarean delivery. Pavy TJ, et al. **Anaesth Intensive Care** 1995 Oct;23(5):555–9
The comparison of epidural fentanyl, epidural lidocaine, and intravenous fentanyl in patients undergoing gastrectomy. Harukuni I, et al. **Anesth Analg** 1995 Dec;81(6):1169–74
Should the routine use of atropine before succinylcholine in children be reconsidered? McAuliffe G, et al. **Can J Anaesth** 1995 Aug;42(8):724–9
Intrathecal fentanyl prolongs sensory bupivacaine spinal block. Singh H, et al. **Can J Anaesth** 1995 Nov; 42(11):987–91
The effects of midazolam followed by administration of either vecuronium or atracurium on the QT interval in humans. Michaloudis DG, et al. **Eur J Anaesthesiol** 1995 Nov; 12(6):577–83
The post-operative analgesic action of midazolam following epidural administration. Nishiyama T. **Eur J Anaesthesiol** 1995 Jul;12(4):369–74
A placebo-controlled trial using intravenous atropine as an adjunct to conscious sedation in pediatric esophagogastroduodenoscopy. Hofley MA, et al. **Gastrointest Endosc** 1995 Nov;42(5):457–60
The effect of ketorolac as an adjuvant to local anaesthetic infiltration for analgesia in paediatric umbilical hernia surgery. Graham SG, et al. **Paediatr Anaesth** 1995; 5(3):161–3
Ketamine plus midazolam, a most effective paediatric oral premedicant. Warner DL, et al. **Paediatr Anaesth** 1995; 5(5):293–5
Subarachnoid fentanyl augments lidocaine spinal anesthesia for cesarean delivery. Palmer CM, et al. **Reg Anesth** 1995 Sep–Oct;20(5):389–94
0.1% bupivacaine does not reduce the requirement for epidural fentanyl infusion after major abdominal surgery. Salomäki TE, et al. **Reg Anesth** 1995 Sep–Oct;20(5):435–43
[Jet injection, a new method for the induction of anesthesia in children] Zsigmond KE, et al. **Orv Hetil** 1995 Nov 5; 136(45):2459–62 (Eng. Abstr.) **(Hun)**

ADVERSE EFFECTS

Accidental prolonged mydriasis in anesthesiologists [letter] Tabboush ZS. **Anesth Analg** 1995 Dec;81(6):1312–3
Neostigmine, atropine, and glycopyrrolate: does neostigmine cross the placenta? Clark RB, et al. **Anesthesiology** 1996 Feb;84(2):450–2
Trimetaphan may cause coronary artery spasm. Higa K, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):529–32

BLOOD

The effect of midazolam at two plasma concentrations of hemodynamics and sufentanil requirement in coronary artery surgery. van der Maaten JM, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):356–63
Diazepam serum concentration-sedative effect relationship in patients with liver disease. Bozkurt P, et al. **Middle East J Anesthesiol** 1996 Feb;13(4):405–13

PHARMACOKINETICS

Pharmacokinetics of alcuronium in children with acyanotic and cyanotic cardiac disease undergoing cardiopulmonary bypass surgery. Weekes LM, et al. **Paediatr Anaesth** 1995; 5(6):369–74

PHARMACOLOGY

Influence of sufentanil on propofol anesthesia using a target controlled infusion system. Los GJ, et al. **Acta Anaesthesiol Belg** 1995;46(3–4):153–9
Effects of midazolam on heart rate variability during surgery under spinal anaesthesia. Kawamoto M, et al. **Anaesth Intensive Care** 1995 Aug;23(4):464–8
Role of pentobarbitone anaesthesia and sympathetic tone in the haemodynamic effects of isosorbide dinitrate in rats with cirrhosis. Kirstetter P, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):230–5
The bispectral index during induction of anesthesia with midazolam and propofol. Hoffman WE, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):15–20
Effect of fentanyl citrate anesthesia on protein turnover in patients with esophagectomy. Yoshida S, et al. **J Surg Res** 1996 Aug;64(2):120–7
[Influence of droperidol on the hypnotic effect of thiopental] Manani G, et al. **Cah Anesthesiol** 1995;43(5):435–9 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Use of glycopyrrolate as a prophylaxis for vaso-vagal syncope during retinal photocoagulation [letter] Yang YF, et al. **Br J Ophthalmol** 1996 Apr;80(4):381
Comparison of intranasal midazolam and sufentanil premedication in pediatric outpatients. Zedie N, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):341–8

TOXICITY

Chronic subarachnoid midazolam (Dormicum) in the rat. Morphologic evidence of spinal cord neurotoxicity. Svensson BA, et al. **Reg Anesth** 1995 Sep–Oct;20(5):426–34

ANESTHESIA ASSISTANTS see **PHYSICIAN ASSISTANTS**

ANESTHESIA, CAUDAL

Randomized comparison of agents for caudal anaesthesia in anal surgery. Adebamowo CA, et al. **Br J Surg** 1996 Mar; 83(3):364–5
Continuous caudal anaesthesia with chloroprocaine as an adjunct to general anaesthesia in neonates. Tobias JD, et al. **Can J Anaesth** 1996 Jan;43(1):69–72
Comparison of bupivacaine plus buprenorphine with bupivacaine alone by caudal blockade for post-operative pain relief after hip and knee arthroplasty. Gao F, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):471–6
The use of caudal epidural anesthesia in clubfoot surgery. Foulk DA, et al. **J Pediatr Orthop** 1995 Sep–Oct; 15(5):604–7
Nasal midazolam in children, plasma concentrations and the effect on respiration. Fösel T, et al. **Paediatr Anaesth** 1995; 5(6):347–53
Clonidine–mepivacaine mixture vs plain mepivacaine in paediatric surgery. Ivani G, et al. **Paediatr Anaesth** 1996; 6(2):111–4
[Caudal epidural anesthesia in 70 children] Dieng P, et al. **Dakar Med** 1994;39(1):95–7 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Is caudal anaesthesia a safe-choice for infant hernia repair? [letter] Elliott S. **Anaesthesia** 1996 May;51(5):514

METHODS

[Caudal anesthesia in children] Giaufré E. **Cah Anesthesiol** 1995;43(3):281–6 (Eng. Abstr.) **(Fre)**
[Priapism. Apropos of a case in a 10-year old child] Monote S, et al. **J Urol (Paris)** 1995;101(2):107–8 (Eng. Abstr.) **(Fre)**

ANESTHESIA, CLOSED-CIRCUIT

Low-flow anaesthesia. Baum JA, et al. **Anaesthesia** 1995 Oct; 50 Suppl:37–44 (43 ref.)
Sevoflurane degradation by soda lime in a circle breathing system. Munday IT, et al. **Anaesthesia** 1996 Jul;51(7):622–6
Efficiency of a circle system for short surgical cases: comparison of desflurane with isoflurane. Lee DJ, et al. **Br J Anaesth** 1996 Jun;76(6):780–2
Accumulation of foreign gases during closed-system anaesthesia. Versichelen L, et al. **Br J Anaesth** 1996 May; 76(5):668–72
Positive end-expiratory pressure: effect on delivered tidal volume [letter] Pan PH, et al. **J Clin Anesth** 1995 Aug; 7(5):443–4

HISTORY

[Carbon dioxide absorption] Böhrer H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):185–6 **(Ger)**

INSTRUMENTATION

Breathing systems reclassified. Miller DM. **Anaesth Intensive Care** 1995 Jun;23(3):281–3
An enclosed efferent afferent reservoir system: the Maxima. Miller DM. **Anaesth Intensive Care** 1995 Jun;23(3):284–91
Maxima and Bain breathing systems compared in controlled ventilation. Miller DM. **Anaesth Intensive Care** 1995 Jun; 23(3):292–5
Comparison in spontaneous ventilation of the Maxima with the Humphrey ADE breathing system and between four methods for detecting rebreathing. Miller DM, et al. **Anaesth Intensive Care** 1995 Jun;23(3):296–301
Circle systems with a coaxial inspiratory limb. Investigation with a lung model. Cook LB, et al. **Anaesthesia** 1996 Mar; 51(3):247–54
Measuring rebreathing in spontaneous ventilation. A new lung model. Cook LB, et al. **Anaesthesia** 1996 Mar; 51(3):241–6
Reliability of monitoring [letter] Pollock CG. **Anaesthesia** 1996 Jun;51(6):612

ANESTHESIA, CLOSED-CIRCUIT

Comparison of the Jackson-Rees circuit, the pediatric circle, and the MERA F breathing system for pediatric anesthesia. Nakae Y, et al. **Anesth Analg** 1996 Sep;83(3):488-92

Obstruction due to retained carbon dioxide absorber canister wrapping. Norman PH, et al. **Anesth Analg** 1996 Aug; 83(2):425-6

Raising the operating table causing a sudden anesthesia system obstruction [letter] Silver L, et al. **Anesth Analg** 1996 May;82(5):1107-8

A method and apparatus for testing the anesthesia machine circuit unidirectional values [letter] Corn SB. **J Clin Anesth** 1996 May;8(3):261-2

[Anesthesia with low fresh gas flow in clinical routine use (see comments)] Hargasser S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):268-75 (79 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug;30(5):265-7. **(Ger)**

[High frequency ventilation and low-flow: anesthesiologic aspects beyond conventional anesthesia and ventilation techniques (editorial; comment)] Krier C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):265-7. Comment on: Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug;30(5):268-75. Comment on: Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug;30(5):276-82. **(Ger)**

METHODS

Molecular sieves: an alternative method of carbon dioxide removal [letter] Hanning CD. **Anaesthesia** 1996 Mar; 51(3):282-3

Rebreathing improves accuracy of ventilatory monitoring. Bowie JR, et al. **J Clin Monit** 1995 Nov;11(6):354-7

ANESTHESIA, CONDUCTION

Morphine/prilocaine combination for intravenous regional anesthesia. Erciyes N, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):845-6

Intra-arterial regional anaesthesia for hand surgery with alkalinized 0.5% lignocaine. Koscielniak-Nielsen ZJ, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1048-52

The preemptive effect of regional anesthesia on post-cesarean section pain. Wang JJ, et al. **Acta Anaesthesiol Sin** 1995 Dec;33(4):211-6

Effect of injection pressure on the success rate of peribulbar block. Gillart T, et al. **Anaesthesia** 1996 Aug;51(8):779-82

The addition of tenoxicam to prilocaine for intravenous regional anaesthesia. Jones NC, et al. **Anaesthesia** 1996 May;51(5):446-8

Lignocaine for acute phantom limb pain reactivation by regional anaesthesia [letter] Lamacraft G. **Anaesthesia** 1996 Aug;51(8):800

Regional anaesthesia for repeat Caesarean section in a patient with phantom limb pain. Uncles DR, et al. **Anaesthesia** 1996 Jan;51(1):69-70

Antiplatelet therapy, regional anesthesia, and spinal hematomas [letter; comment] Maclean A. **Anesth Analg** 1995 Nov;81(5):1116. Comment on: Anesth Analg 1995 Feb;80(2):303-9.

General versus regional anesthesia for peripheral vascular surgery [letter; comment] de Leon-Casasola OA, et al. **Anesthesiology** 1996 Jul;85(1):224-5. Comment on: Anesthesiology 1996 Jan;84(1):1-2. Comment on: Anesthesiology 1996 Jan;84(1):3-13.

Anesthetic techniques for pediatric thoracoscopy. McGahren ED, et al. **Ann Thorac Surg** 1995 Oct;60(4):927-30

Prilocaine 3% is superior to a mixture of bupivacaine and lignocaine for peribulbar anaesthesia. Döpfmer UR, et al. **Br J Anaesth** 1996 Jan;76(1):77-80

Effect of the addition of alfentanil to lignocaine during axillary brachial plexus anaesthesia. Gormley WP, et al. **Br J Anaesth** 1996 Jun;76(6):802-5

Haemostatic changes caused by i.v. regional anaesthesia with lignocaine. Niemi TT, et al. **Br J Anaesth** 1996 Jun; 76(6):822-8

Intravenous regional anaesthesia for circumcision [letter] Ng WT, et al. **Br J Urol** 1996 Apr;77(4):620-1

Peribulbar anaesthesia: the role of local anaesthetic volumes and Thiomucase in motor block and intraocular pressure. Ortiz M, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):603-7

A tide of change in the management of an old fracture? Kendall JM, et al. **J Accid Emerg Med** 1995 Sep;12(3):187-8

Is fasting necessary before prilocaine Bier's block? O Sullivan I, et al. **J Accid Emerg Med** 1996 Mar;13(2):105-7

Major conduction anesthesia in a patient with Klippel-Trenaunay Syndrome. Gaiser RR, et al. **J Clin Anesth** 1995 Jun;7(4):316-9

MUJA: manipulation under joint anesthesia/analgesia: a treatment approach for recalcitrant low back pain of synovial joint origin. Dreyfuss P, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):537-46 (107 ref.)

Late follow-up results of operative ankle arthroscopy in patients under local anaesthesia. Valentin A, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):250-4

Clinical aspects of CRNA practice. Regional anesthesia. Spitzer LE. **Nurs Clin North Am** 1996 Sep;31(3):643-65 (20 ref.)

A regional anesthetic technique for ankle arthroscopy [letter] Hannenberg AA. **Reg Anesth** 1995 Jul-Aug;20(4):357-8

The pregnant patient with an intracranial arteriovenous malformation. Cesarean or vaginal delivery using regional or general anesthesia? Sharma SK, et al. **Reg Anesth** 1995 Sep-Oct;20(5):455-8

Cerebral oximetry in patients undergoing carotid endarterectomy under regional anesthesia [letter] Fearn SJ, et al. **Stroke** 1996 Aug;27(8):1436-7

Cerebral oximetry in patients undergoing carotid endarterectomy under regional anesthesia. Samra SK, et al. **Stroke** 1996 Jan;27(1):49-55

[Conduction anesthesia and acquired disorders of hemostasis: under what conditions is the association possible?] Bonnet F, et al. **Cah Anesthesiol** 1995;43(6):525-8 **(Fre)**

[Development of locoregional anesthesia and management of postoperative pain: inadequate! (editorial)] Bonnet F. **Cah Anesthesiol** 1995;43(3):229 **(Fre)**

[Conduction anesthesia in patients with heart diseases] Boogaerts J, et al. **Cah Anesthesiol** 1995;43(6):541-5 (Eng. Abstr.) **(Fre)**

[Arguments for conduction anesthesia in children] Ecoffey C. **Cah Anesthesiol** 1995;43(6):529-32 (Eng. Abstr.) **(Fre)**

[Arguments against conduction anesthesia in children] Lejus C, et al. **Cah Anesthesiol** 1995;43(6):533-40 (Eng. Abstr.) **(Fre)**

[Conduction anesthesia on an outpatient basis] Mahiou P. **Cah Anesthesiol** 1995;43(6):617-24 (Eng. Abstr.) **(Fre)**

[Conduction anesthesia and the newborn infant] Palot M, et al. **Cah Anesthesiol** 1995;43(6):547-53 (Eng. Abstr.) **(Fre)**

[Conduction anesthesia and analgesia in emergency cases. From pain to its treatment] Puidupin M, et al. **Cah Anesthesiol** 1995;43(6):605-15 (Eng. Abstr.) **(Fre)**

[Reflex sympathetic algodystrophies. Preventive and therapeutic aspects] Viel E, et al. **Cah Anesthesiol** 1995; 43(6):565-71 (69 ref.) (Eng. Abstr.) **(Fre)**

[Analgesia and sedation to supplement incomplete regional anesthesia] Wresch KP. **Anaesthesist** 1995 Dec;44 Suppl 3:S580-7 (102 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Anaphylactoid skin reactions after intravenous regional anaesthesia using 0.5% prilocaine with or without preservative--a double-blind study. Kajimoto Y, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):782-4

Systemic vascular resistance index determined by thoracic electrical bioimpedance predicts the risk for maternal hypotension during regional anesthesia for cesarean delivery. Ouzounian JG, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1019-25

Regional anesthesia and local anesthetic-induced seizures [letter; comment] Stemp LI. **Anesth Analg** 1996 Mar; 82(3):669-70. Comment on: Anesth Analg 1995 Aug;81(2):321-8.

Cardiac outcome after peripheral vascular surgery. Comparison of general and regional anesthesia [see comments] Bode RH Jr, et al. **Anesthesiology** 1996 Jan; 84(1):3-13. Comment in: Anesthesiology 1996 Jan;84(1):1-2. Comment in: Anesthesiology 1996 Jul;85(1):224-5.

Cardiac outcomes after regional or general anesthesia. Do we have the answer? [editorial; comment] [see comments] Go AS, et al. **Anesthesiology** 1996 Jan;84(1):1-2. Comment on: Anesthesiology 1996 Jan;84(1):3-13. Comment in: Anesthesiology 1996 Jul;85(1):224-5.

Inadvertent perforation of the globe during regional anaesthesia. Polkinghorne PJ. **Aust N Z J Ophthalmol** 1996 Feb;24(1):43-5

A complication of combined regional anesthesia techniques for ophthalmic surgery. Joseph A, et al. **J Clin Anesth** 1996 May;8(3):248-50

Loss of resistance technique to air for identifying the epidural space in infants and children. Use an appropriate technique! [letter; comment] Busoni P, et al. **Paediatr Anaesth** 1995; 5(6):397. Comment on: Paediatr Anaesth 1995;5(1):41-6.

Accidents following extradural analgesia in children. The results of a retrospective study [see comments] Flandin-Bléty C, et al. **Paediatr Anaesth** 1995;5(1):41-6. Comment in: Paediatr Anaesth 1995;5(1):3-9. Comment in: Paediatr Anaesth 1995;5(4):273. Comment in: Paediatr Anaesth 1995;5(6):396-7. Comment in: Paediatr Anaesth 1995;5(6):397.

Complications in regional anaesthesia [editorial; comment] [see comments] Goldman LJ. **Paediatr Anaesth** 1995; 5(1):3-9. Comment on: Paediatr Anaesth 1995;5(1):41-6. Comment in: Paediatr Anaesth 1995;5(6):396.

Accidents following extradural analgesia in children. The results of a retrospective study [letter; comment] Thomas VL. **Paediatr Anaesth** 1995;5(6):396-7. Comment on: Paediatr Anaesth 1995;5(1):41-6.

Complications in regional anaesthesia [letter; comment] Tobias JD. **Paediatr Anaesth** 1995;5(6):396. Comment on: Paediatr Anaesth 1995;5(1):3-9.

[What are the complications likely to lead to medicolegal problems? How to manage them?] Samii K, et al. **Cah Anesthesiol** 1995;43(6):521-4 (20 ref.) **(Fre)**

ECONOMICS

Practical, cost-effective regional anesthesia for ambulatory surgery. Greenberg CP. **J Clin Anesth** 1995 Nov; 7(7):614-21 (32 ref.)

HISTORY

Regional anesthesia and chronic pain management in the 1920s and 1930s. The influence of the American Society of Regional Anesthesia. Bacon DR, et al. **Reg Anesth** 1995 May-Jun;20(3):185-92

INSTRUMENTATION

Type of needle point and nerve damage [letter; comment] Rice AS. **Anaesthesia** 1996 Jan;51(1):98-9. Comment on: Anaesthesia 1995 Jun;50(6):573.

METHODS

Another use of the intravenous regional block technique [letter] Papakalou EP, et al. **Anesth Analg** 1996 Feb; 82(2):427

Effects of adrenaline and hyaluronidase on plasma concentrations of lignocaine and bupivacaine after peribulbar anaesthesia. Barr J, et al. **Br J Anaesth** 1995 Dec;75(6):692-7

Laparoscopic transabdominal preperitoneal herniorrhaphy using abdominal wall-lifting method under regional anesthesia: a preliminary report. Tagaya N, et al. **J Laparoendosc Surg** 1995 Aug;5(4):215-20

Use of the peridural catheter with subcutaneous port in a 13-year-old girl: 120 anesthesia procedures in 31 months. Zadra N, et al. **J Pediatr Surg** 1995 Oct;30(10):1493-4

Intraosseous regional anesthesia as an alternative to intravenous regional anesthesia. Waisman M, et al. **J Trauma** 1995 Dec;39(6):1153-6

Anesthetic management of a massively morbidly obese patient. Friederich JA, et al. **Reg Anesth** 1995 Nov-Dec; 20(6):538-42

The regional anesthesia "learning curve". What is the minimum number of epidural and spinal blocks to reach consistency? Kopacz DJ, et al. **Reg Anesth** 1996 May-Jun; 21(3):182-90

[Which operations can be done without general anesthesia?] Tarkkila P, et al. **Duodecim** 1995;111(4):365-9 (5 ref.) **(Fin)**

[Locoregional anesthesia for endoscopic surgery of the carpal tunnel] Dagrenat P, et al. **Ann Fr Anesth Reanim** 1995; 14(3):306-9 (Eng. Abstr.) **(Fre)**

[Endarterectomy of the carotid artery with the patient remaining conscious] Lebedev LV, et al. **Vestn Khir Im I I Grek** 1995;154(2):14-6 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Predictors of patient satisfaction with regional anesthesia. De Andrés J, et al. **Reg Anesth** 1995 Nov-Dec;20(6):498-505

TRENDS

[What is new in pediatric loco-regional anesthesia?] Ecoffey C. **Rev Med Suisse Romande** 1996 Apr;116(4):243-6 (28 ref.) **(Fre)**

ANESTHESIA, DENTAL

Rocuronium bromide in dental day case anaesthesia--a comparison with atracurium and vecuronium. Chetty MS, et al. **Anaesth Intensive Care** 1996 Feb;24(1):37-41

Local anaesthesia for pain relief following wisdom teeth extraction under general anaesthesia [letter] Mackenzie DW, et al. **Anaesthesia** 1996 Feb;51(2):200-1

An assessment of morphine requirement after wisdom tooth extraction under general anaesthesia. Tighe KE, et al. **Anaesthesia** 1995 Sep;50(9):816-8

The effect of pre-incisional infiltration with lignocaine on postoperative pain after molar teeth extraction under general anaesthesia. Tordoff SG, et al. **Anaesthesia** 1996 Jun;51(6):585-7

Local anaesthesia for pain relief following wisdom teeth extraction under general anaesthesia [letter] Whitehead PN. **Anaesthesia** 1996 Feb;51(2):200

Patient-controlled sedation: a comparison of sedation prior to and until the end of minor oral surgery. Rodrigo C, et al. **Aust Dent J** 1996 Jun;41(3):159-63

The use of acupuncture in dentistry [letter] Rosted P. **Aust Dent J** 1996 Feb;41(1):61

New guidance on general anaesthesia, resuscitation and sedation [news] **Br Dent J** 1996 Jun 8;180(11):403

Post-operative pain control [letter] Brett I, et al. **Br Dent J** 1996 Jan 20;180(2):50

A survey of in-dwelling intravenous cannula use in general dental practice. Dickenson AJ, et al. **Br Dent J** 1995 Aug 5;179(3):89-92

Response to intravenous midazolam sedation in general dental practice. Ellis S. **Br Dent J** 1996 Jun 8; 180(11):417-20

Sedation in primary and secondary dental health care [letter] Girdler NM. **Br Dent J** 1996 May 11;180(9):325

General anaesthesia [letter] Pike D. **Br Dent J** 1996 Jun 22; 180(12):448

Is general anaesthesia for orthodontic extractions in children necessary? Shaw L, et al. **Br Dent J** 1996 Jul 6;181(1):6-7

Dental chair anaesthesia--'unexpected hazard' defined by the High Court. White GM. **Br Dent J** 1996 Jan 20;180(2):73-5

Comparison of desflurane and isoflurane in anaesthesia for dental surgery. Loan PB, et al. **Br J Anaesth** 1995 Sep; 75(3):289-92

Four common mandibular nerve anomalies that lead to local anesthesia failures. DeSantis JL, et al. **J Am Dent Assoc** 1996 Jul;127(7):1081–6 (25 ref.)
Sedation—guidelines and controls [letter] Getter L, et al. **J Am Dent Assoc** 1996 Jan;127(1):20, 22
Oral midazolam in pediatric dentistry. Naqvi A. **Middle East J Anesthesiol** 1996 Feb;13(4):427–40
A comparison of cardiac rate–pressure product and pressure–rate quotient in healthy and medically compromised patients. Campbell RL, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Aug;80(2):145–52
Conscious sedation of pediatric dental patients using chloral hydrate, hydroxyzine, and nitrous oxide—a retrospective study of 382 sedations. Needleman HL, et al. **Pediatr Dent** 1995 Nov–Dec;17(7):424–31
A review of important elements in sedation study methodology. Wilson S. **Pediatr Dent** 1995 Nov–Dec; 17(7):406–12 (57 ref.)
[5 years' experience with conscious sedation with midazolam (Dormicum Roche) in stomatology] Pávek V, et al. **Sb Lek** 1995;96(1):49–52 (Eng. Abstr.) **(Cze)**
[General ambulatory anesthesia in oral medicine and maxillofacial surgery] Boufflers E, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):247–58 (22 ref.) **(Fre)**
[The use of Dormicum in general anesthesia for oral surgery] Judit J, et al. **Fogorv Sz** 1995 Dec;88(12):399–403 (Eng. Abstr.) **(Hun)**

ADVERSE EFFECTS

Mortality and morbidity in general anaesthesia [letter] Holden CG, et al. **Br Dent J** 1996 Apr 20;180(8):286
Inferior dental block [letter; comment] McGroarty A. **Br Dent J** 1995 Oct 21;179(8 Spec No):283. Comment on: Br Dent J 1995 Aug 5;179(3):97–8.
Post-treatment bacteremia [letter; comment] Bender IB. **J Am Dent Assoc** 1995 Nov;126(11):1474, 1476. Comment on: J Am Dent Assoc 1995 Aug;126(8):1145–9.
Nerve damage and nerve blocks [letter; comment] Hutchings ML. **J Am Dent Assoc** 1996 Jan;127(1):25. Comment on: J Am Dent Assoc 1995 Aug;126(8):1150–5.
Nerve damage associated with inferior alveolar nerve blocks [see comments] Pogrel MA, et al. **J Am Dent Assoc** 1995 Aug;126(8):1150–5. Comment in: J Am Dent Assoc 1996 Jan;127(1):25.
Methemoglobinemia in a renal transplant patient: case report. Hardwick FK, et al. **Pediatr Dent** 1995 Nov–Dec; 17(7):460–3
Occurrence of adenylate kinase in cerebrospinal fluid after isoflurane anaesthesia and orthognathic surgery. Enlund M, et al. **Ups J Med Sci** 1996;101(1):97–111

INSTRUMENTATION

A means of stabilising laryngeal mask airways during dental procedures [letter] Christie IW. **Anaesthesia** 1996 Jun; 51(6):604

METHODS

Anaesthetic techniques for chair dental anaesthesia [letter] Davies MW, et al. **Anaesthesia** 1995 Oct;50(10):922–3
Anaesthesia for exodontia in young children—a snapshot survey of European practice [letter] Davies MW, et al. **Anaesthesia** 1996 Jul;51(7):713
A randomized double-blind trial of chloral hydrate/hydroxyzine versus midazolam/acetaminophen in the sedation of pediatric dental outpatients. Reeves ST, et al. **ASDC J Dent Child** 1996 Mar–Apr;63(2):95–100
Dental anaesthesia report [letter] Crawford AN. **Br Dent J** 1995 Oct 7;179(7):244
Sedation in general practice [letter] Ellis S. **Br Dent J** 1996 Feb 10;180(3):88
Assessing the duration of mandibular soft tissue anesthesia. Hersh EV, et al. **J Am Dent Assoc** 1995 Nov;126(11):1531–6
Midazolam intravenous conscious sedation in oral surgery. A retrospective study of 372 cases. Runes J, et al. **Swed Dent J** 1996;20(1–2):29–33
[Hypnotic desensitization as a supplemental method in dental care of patients with panic disorder. Report of a case] Fábián TK. **Fogorv Sz** 1996 Feb;89(2):57–62 (19 ref.) **(Hun)**
[Hypnosis in dentistry 2. Amnesia, analgesia, loss of time perception: spontaneous manifestations during use of hypnosis in dentistry] Fábián TK. **Fogorv Sz** 1995 Jul; 88(7):237–42 (Eng. Abstr.) **(Hun)**
[Highlights in the subject of low frequency–high intensity TENS (review)] Galletti SP, et al. **Minerva Stomatol** 1995 Sep;44(9):421–9 (41 ref.) (Eng. Abstr.) **(Ita)**

STATISTICS & NUMERICAL DATA

Demand for dental extractions performed under general anaesthesia for children by Leicestershire Community Dental Service. Landes DP, et al. **Community Dent Health** 1996 Jun;13(2):105–10

VETERINARY

Romifidine as a premedicant to propofol induction and infusion anaesthesia in the dog. England GC, et al. **J Small Anim Pract** 1996 Feb;37(2):79–83

ANESTHESIA DEPARTMENT, HOSPITAL

Automatic record keeping in anaesthesia—a nine-year Italian experience. Lanza V. **Int J Clin Monit Comput** 1996 Feb; 13(1):35–43
Integrating computerized anesthesia charting into a hospital information system. Wang X, et al. **Int J Clin Monit Comput** 1995 May;12(2):61–70
Parental presence during induction of anaesthesia: practice differences between the United States and Great Britain. Kain ZN, et al. **Paediatr Anaesth** 1996;6(3):187–93
Parents in the anaesthetic room: a questionnaire survey of departments of anaesthesia. McCormick AS, et al. **Paediatr Anaesth** 1996;6(3):183–6
[Documentation and information processing in clinical anesthesia] Hofmockel R, et al. **Anaesthesiol Reanim** 1995; 20(2):42–53 (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Teaching airway management on anaesthetised patients. Martin PD, et al. **Scott Med J** 1994 Aug;39(4):111–3
Anaesthesia in The Gambia. Soyannwo OA, et al. **West Afr J Med** 1995 Jul–Sep;14(3):169–73

ANESTHESIA, ELECTRIC see **ELECTRONARCOSIS**

ANESTHESIA, EPIDURAL

Post-surgery epidural blockade with local anaesthetics attenuates the catecholamine and thermogenic response to perioperative hypothermia. Carli F, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1041–7
Transpulmonary disposition of prilocaine, mepivacaine, and bupivacaine in humans in the course of epidural anaesthesia. Kietzmann D, et al. **Acta Anaesthesiol Scand** 1995 Oct; 39(7):885–90
Comparison of spinal anaesthesia with epidural anaesthesia in paediatric surgery. Kokki H, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):896–900
Shivering during epidural anesthesia [letter] Sessler DL. **Acta Anaesthesiol Scand** 1996 Mar;40(3):393–4
Epidural anesthesia modifies cardiovascular responses to severe hypoxia in dogs. Shibata K, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):748–53
The effect of continuous epidural infusion of ropivacaine (0.1%, 0.2% and 0.3%) on nerve conduction velocity and postural control in volunteers. Zaric D, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):342–9
Can safe be safer? Hip arthroplasty by hypotensive epidural anesthesia [editorial; comment] Santavirta S. **Acta Orthop Scand** 1996 Feb;67(1):1. Comment on: Acta Orthop Scand 1996 Feb;67(1):91–107.
Hypotensive epidural anesthesia for total hip arthroplasty: a review [see comments] Sharrock NE, et al. **Acta Orthop Scand** 1996 Feb;67(1):91–107 (105 ref.). Comment in: Acta Orthop Scand 1996 Feb;67(1):1.
A review of anatomical and immunological links between epidural morphine and herpes simplex labialis in obstetric patients. Boyle RK. **Anaesth Intensive Care** 1995 Aug; 23(4):425–32 (41 ref.)
EMLA cream prior to insertion of elective epidurals. Elson JA, et al. **Anaesth Intensive Care** 1995 Jun;23(3):339–41
Epidural caesarean section in a patient with congenital antithrombin III deficiency. Rowbottom SJ. **Anaesth Intensive Care** 1995 Aug;23(4):493–5
Gravity feed and epidural infusions [letter] Tuck M. **Anaesth Intensive Care** 1995 Jun;23(3):408
The anaesthetic management of Caesarean section for placenta praevia: a questionnaire survey [see comments] Bonner SM, et al. **Anaesthesia** 1995 Nov;50(11):992–4. Comment in: Anaesthesia 1996 Apr;51(4):403.
Shortcomings in the combined spinal–extradural technique [letter] Holt M, et al. **Anaesthesia** 1996 Aug;51(8):801–2
Safety of lignocaine test dose to detect intravenous injection [letter; comment] Miline SE. **Anaesthesia** 1995 Sep; 50(9):830. Comment on: Anaesthesia 1995 Mar;50(3):211–3.
Wearing of masks for obstetric regional anaesthesia. A postal survey. Panikkar KK, et al. **Anaesthesia** 1996 Apr; 51(4):398–400
A trainer for identification of the epidural space [letter] Paw HG. **Anaesthesia** 1995 Oct;50(10):914
Depth of the epidural space in children [letter] Yamashita M. **Anaesthesia** 1996 Mar;51(3):291
Radiographic findings of unilateral epidural block. Asato F, et al. **Anesth Analg** 1996 Sep;83(3):519–22
Spinal versus epidural anesthesia for cesarean section [letter; comment] Colclough GW. **Anesth Analg** 1995 Dec; 81(6):1318–9. Comment on: Anesth Analg 1995 Apr;80(4):709–12.
The analgesic efficacy and adverse effects of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. Hansdóttir V, et al. **Anesth Analg** 1996 Aug; 83(2):394–400
The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. Hansdóttir V, et al. **Anesth Analg** 1996 Aug;83(2):401–6
The comparison of epidural fentanyl, epidural lidocaine, and intravenous fentanyl in patients undergoing gastrectomy. Harukuni I, et al. **Anesth Analg** 1995 Dec;81(6):1169–74
The effect of thoracic epidural anesthesia on hypoxic pulmonary vasoconstriction in dogs: an analysis of the pressure–flow curve. Ishibe Y, et al. **Anesth Analg** 1996 May;82(5):1049–55
Patient comfort: spinal versus epidural anesthesia for cesarean section [letter; comment] Keohane M. **Anesth Analg** 1996 Jan;82(1):219. Comment on: Anesth Analg 1995 Apr;80(4):709–12.
Paraplegia in a patient who by chance missed the insertion of an epidural catheter [letter] Konstantinidou AS, et al. **Anesth Analg** 1996 May;82(5):1110
Propofol blood concentration and the Bispectral Index predict suppression of learning during propofol/epidural anesthesia in volunteers. Leslie K, et al. **Anesth Analg** 1995 Dec;81(6):1269–74
Hemodynamic responses to an epinephrine test dose in adults during epidural or combined epidural–general anesthesia. Liu SS. **Anesth Analg** 1996 Jul;83(1):97–101
Bupivacaine plasma concentrations during continuous epidural anesthesia in infants and children. Luz G, et al. **Anesth Analg** 1996 Feb;82(2):231–4
Transition from intrathecal analgesia to epidural anesthesia for emergency cesarean section using a combined spinal epidural technique [letter] Mercier FJ, et al. **Anesth Analg** 1996 Aug;83(2):434
The effects of dobutamine and phenylephrine on atrioventricular conduction during combined use of halothane and thoracic epidural lidocaine. Nishikawa K, et al. **Anesth Analg** 1996 Mar;82(3):551–7
The effects of epidural anesthesia on ventilatory response to hypercapnia and hypoxia in elderly patients. Sakura S, et al. **Anesth Analg** 1996 Feb;82(2):306–11
Mechanism of action of an epidural top-up in combined spinal epidural anesthesia. Stienstra R, et al. **Anesth Analg** 1996 Aug;83(2):382–6
Dural puncture with a 26-gauge spinal needle affects spread of epidural anesthesia. Suzuki N, et al. **Anesth Analg** 1996 May;82(5):1040–2
The effect of prior dural puncture on cisternal cerebrospinal fluid morphine concentrations in sheep after administration of lumbar epidural morphine. Swenson JD, et al. **Anesth Analg** 1996 Sep;83(3):523–5
Epidural test dose: isoproterenol is a reliable marker for intravascular injection in anesthetized adults. Tanaka M. **Anesth Analg** 1996 May;82(5):1056–9
Ephedrine-induced increases in arterial blood pressure accelerate regression of epidural block. Ueda W, et al. **Anesth Analg** 1995 Oct;81(4):703–5
Combined spinal/epidural anesthesia for outpatient surgery [letter; comment] Joshi GP. **Anesthesiology** 1996 Feb; 84(2):481–2. Comment on: Anesthesiology 1995 Sep;83(3):528–34.
Role of epidural anesthesia and analgesia on postoperative patient outcome [letter; comment] Leung JM. **Anesthesiology** 1995 Nov;83(5):1132. Comment on: Anesthesiology 1995 Jun;82(6):1474–506.
Heat flow and distribution during epidural anesthesia. Matsukawa T, et al. **Anesthesiology** 1995 Nov;83(5):961–7
Uterine inversion and anaesthesia [letter] Rogers NJ. **Aust Fam Physician** 1996 Jan;25(1):101
Pharmacokinetics of epidurally administered nicomorphine with its metabolites and glucuronide conjugates in patients undergoing pulmonary surgery during combined epidural local anaesthetic block and general anaesthesia. Koopman-Kimenai PM, et al. **Biopharm Drug Dispos** 1995 Aug;16(6):507–20
Extradurals and infection [letter; comment] Brosnan CM, et al. **Br J Anaesth** 1996 Jun;76(6):887–8. Comment on: Br J Anaesth 1995 Nov;75(5):536–40.
Intrathecal insertion of an extradural catheter during combined spinal–extradural anaesthesia [letter; comment] Camann W. **Br J Anaesth** 1996 Jan;76(1):169. Comment on: Br J Anaesth 1995 Sep;75(3):355–7.
Extradural clonidine for postoperative pain relief [letter; comment] Cook B, et al. **Br J Anaesth** 1996 Jun;76(6):881–2 . Comment on: Br J Anaesth 1994 Mar;72(3):258–62. Comment on: Br J Anaesth 1996 Jan;76(1):171.
Optimum opioid for extradural administration [letter; comment] Cook TM, et al. **Br J Anaesth** 1995 Aug; 75(2):250–1. Comment on: Br J Anaesth 1995 Feb;74(2):121–2.
Temporal summation during extradural anaesthesia. Curatolo M, et al. **Br J Anaesth** 1995 Nov;75(5):634–5
A multifactorial analysis to explain inadequate surgical analgesia after extradural block. Curatolo M, et al. **Br J Anaesth** 1995 Sep;75(3):274–81
Does pre-incisional thoracic extradural block combined with diclofenac reduce postoperative pain after abdominal hysterectomy? [see comments] Espinet A, et al. **Br J Anaesth** 1996 Feb;76(2):209–13. Comment in: Br J Anaesth 1996 Jul;77(1):128–9.
Extradural analgesia in the first stage of labour [letter; comment] Fernando R, et al. **Br J Anaesth** 1996 Jun; 76(6):886–7. Comment on: Br J Anaesth 1996 Feb;76(2):319–21.
Elective forceps delivery and extradural anaesthesia in a primigravida with portal hypertension and oesophageal varices. Heriot JA, et al. **Br J Anaesth** 1996 Feb;76(2):325–7
Pregnancy complicated by aortic dissection: caesarean delivery during extradural anaesthesia. Jayaram A, et al. **Br J Anaesth** 1995 Sep;75(3):358–60
Intrathecal insertion of an extradural catheter during combined spinal–extradural anaesthesia [letter; comment]

Lee JS, et al. **Br J Anaesth** 1996 Jan;76(1):169–70. Comment on: Br J Anaesth 1995 Sep;75(3):355–7.

Accidental intrathecal insertion of an extradural catheter during combined spinal–extradural anaesthesia for caesarean section [see comments] Robbins PM, et al. **Br J Anaesth** 1995 Sep;75(3):355–7. Comment in: Br J Anaesth 1996 Jan;76(1):169. Comment in: Br J Anaesth 1996 Jan;76(1):169–70.

Extensive extradural spread in the elderly may not relate to decreased leakage through intervertebral foramina. Saitoh K, et al. **Br J Anaesth** 1995 Dec;75(6):688–91

A hypertensive parturient with a supraventricular tachycardia. Lima J, et al. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):625–6

The effect of maternal epidural analgesia on fetal oxygen saturation. Johnson N, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):776–8

Anaesthetic management for caesarean section in a patient with Kawasaki disease. Alam S, et al. **Can J Anaesth** 1995 Nov;42(11):1024–6

Maternal death following epidural anaesthesia [letter] Bourne TM, et al. **Can J Anaesth** 1996 Mar;43(3):318–9

A double–blind comparison of ropivacaine 0.5%, 0.75%, 1.0% and bupivacaine 0.5%, injected epidurally, in patients undergoing abdominal hysterectomy. Finucane BT, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):442–9

Anaesthetic management of labour and delivery in a woman taking long–term MAOI. Pavy TJ, et al. **Can J Anaesth** 1995 Jul;42(7):618–20

Continuous epidural infusion of local anesthetics and shorter duration of acute zoster–associated pain. Manabe H, et al. **Clin J Pain** 1995 Sep;11(3):220–8

Failure rate of epidural anaesthesia for foot and ankle surgery. A comparison with other surgical procedures. Curatolo M, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):363–7

The post–operative analgesic action of midazolam following epidural administration. Nishiyama T. **Eur J Anaesthesiol** 1995 Jul;12(4):369–74

Origin of intravascular fluid recruited by vasodilatation during epidural anaesthesia. Hahn RG. **Eur Surg Res** 1996; 28(1):70–4

Pancreaticoduodenectomy under epidural anesthesia without endotracheal intubation for the elderly. Nakashima H, et al. **Int Surg** 1995 Apr–Jun;80(2):125–7

Epidural anesthesia in an in vitro fertilization and embryo transfer program. Botta G, et al. **J Assist Reprod Genet** 1995 Mar;12(3):187–90

A complication of combined regional anesthesia techniques for ophthalmic surgery. Joseph A, et al. **J Clin Anesth** 1996 May;8(3):248–50

Laparoscopic pelvic lymphadenectomy during epidural anesthesia. Kelly D, et al. **J Clin Anesth** 1995 Dec; 7(8):648–51

Cardiovascular reflexes during anesthesia induction and tracheal intubation in elderly patients: the influence of thoracic epidural anesthesia. Licker M, et al. **J Clin Anesth** 1995 Jun;7(4):281–7

Reflex sympathetic dystrophy [letter] Smith H, et al. **J Hand Surg [Am]** 1995 Jul;20(4):698–9

Fetal effects of prophylactic ephedrine and maternal hypotension during regional anesthesia for cesarean section. Shearer VE, et al. **J Matern Fetal Med** 1996 Mar–Apr; 5(2):79–84

Combined thoracic epidural with light general anesthesia for thymectomy in myasthenia gravis. Suwanchinda V, et al. **J Med Assoc Thai** 1995 Nov;78(11):605–10

Cognitive effects after epidural vs general anesthesia [letter; comment] Witt WO. **JAMA** 1995 Nov 15;274(19):1510. Comment on: JAMA 1995 Jul 5;274(1):44–50.

Combined spinal–epidural or standard epidural analgesia in labour [letter; comment] Brüssel T, et al. **Lancet** 1995 Nov 4;346(8984):1229. Comment on: Lancet 1995 Jun 3;345(8962):1413–6.

Combined spinal–epidural–general anesthesia. Eldor J. **Med Hypotheses** 1995 Jul;45(1):86–90

Low dose epidural lidocaine/sufentanil is effective for outpatient lithotripsy. Kwa AM, et al. **Middle East J Anesthesiol** 1995 Feb;13(1):71–8

Electrophysiological evaluation of spinal reflexes during epidural anesthesia in an experimental model. Navarro X, et al. **Muscle Nerve** 1996 Jan;19(1):29–36

Neurologic complications of lumbar epidural anesthesia and analgesia. Yuen EC, et al. **Neurology** 1995 Oct; 45(10):1795–801

Resolution of pachymeningeal enhancement following dural puncture and blood patch. Gordon RE, et al. **Neuroradiology** 1995 Oct;37(7):557–8

Pain dysfunction syndrome of the knee. Neuschwander D, et al. **Orthopedics** 1996 Jan;19(1):27–32

Caudal block in a child with osteogenesis imperfecta, type II [letter] Barros F. **Paediatr Anaesth** 1995;5(3):202–3

Anaesthetic management of the child with myotonic dystrophy: epidural anaesthesia as an alternative to general anaesthesia. Tobias JD. **Paediatr Anaesth** 1995;5(5):335–8

Comments on combined spinal–epidural anesthesia [letter] Birnbach DJ, et al. **Reg Anesth** 1996 May–Jun;21(3):275

Managing intraoperative priapism [letter; comment] Corke PJ. **Reg Anesth** 1995 Nov–Dec;20(6):546. Comment on: Reg Anesth 1994 Nov–Dec;19(6):423–8.

Epidural anesthesia in a patient with single ventricle. del Pozo D, et al. **Reg Anesth** 1995 Sep–Oct;20(5):452–4

Combined general and epidural anesthesia for a patient with Takayasu's arteritis. Case report. Gozal Y, et al. **Reg Anesth** 1995 May–Jun;20(3):246–8

Combined spinal–epidural–general anesthesia revisited [letter; comment] Gudin JA, et al. **Reg Anesth** 1995 Sep–Oct; 20(5):465–6. Comment on: Reg Anesth 1994 Sep–Oct;19(5):365–6. Comment on: Reg Anesth 1994 Nov–Dec;19(6):418–22.

Inhalation of nitrous oxide expands epidural air bubbles. Petty R, et al. **Reg Anesth** 1996 Mar–Apr;21(2):144–8

Systemic vascular uptake of epinephrine from the lumbar epidural space in parturients. Ramanathan S, et al. **Reg Anesth** 1995 May–Jun;20(3):199–205

0.1% bupivacaine does not reduce the requirement for epidural fentanyl infusion after major abdominal surgery. Salomäki TE, et al. **Reg Anesth** 1995 Sep–Oct;20(5):435–43

Comment on anesthesia technique described by Eldor [letter; comment] Stienstra R. **Reg Anesth** 1995 Jul–Aug; 20(4):359–60. Comment on: Reg Anesth 1994 Sep–Oct;19(5):365–6.

Effect of epidural bupivacaine block on midazolam hypnotic requirements. Tverskoy M, et al. **Reg Anesth** 1996 May–Jun;21(3):209–13

The effect of posture on the induction of epidural anesthesia for peripheral vascular surgery. Whalley DG, et al. **Reg Anesth** 1995 Sep–Oct;20(5):407–11

Evaluation of epidural sensory block by thermal stimulation, laser stimulation, and recording of somatosensory evoked potentials. Zaric D, et al. **Reg Anesth** 1996 Mar–Apr; 21(2):124–38

[Epidural anesthesia in the treatment of painful diabetic neuropathy (letter)] Tigerstedt I, et al. **Duodecim** 1995; 111(9):890–1 **(Fin)**

[Epidural anesthesia in the treatment of painful diabetic neuropathy] Vanamo R, et al. **Duodecim** 1995;111(3):263–6 **(Fin)**

[Epidural anesthesia for labor] Dailland P, et al. **Cah Anesthesiol** 1996;44(2):127–43 (24 ref.) (Eng. Abstr.) **(Fre)**

[Epidural anesthesia—at any time] Vidil C. **Cah Anesthesiol** 1995;43(6):555–6 **(Fre)**

[The high risk cardiac patient in anesthesia] Francke A. **Anaesthesiol Reanim** 1996;21(2):32–42 (89 ref.) (Eng. Abstr.) **(Ger)**

[Combination of intravenous patient–conirolled analgesia with epidural anesthesia for postoperative pain therapy] Kentner R, et al. **Anaesthesiol Reanim** 1996;21(3):69–75 (Eng. Abstr.) **(Ger)**

[Interactions between renal and general hemodynamics in fentanyl, droperidol, ketamine, thiopental and in peridural anesthesia—animal studies] Schenk HD, et al. **Anaesthesiol Reanim** 1995;20(3):60–70 (Eng. Abstr.) **(Ger)**

[Concerning: Krähenbühl F, Frei E: Early results of the initial 100 laparoscopic hernia operations under peridural anesthesia (Schweiz Med Wochenschr 1995; 125: 1279–1285) (letter; comment)] Zinden S, et al. **Schweiz Med Wochenschr** 1996 Jan 20;126(3):97–8. Comment on: Schweiz Med Wochenschr 1995 Jul 1;125(26):1279–85. **(Ger)**

[Para–spinal analgesia in obstetrics] Schockenhoff B, et al. **Z Geburtshilfe Neonatol** 1995 May–Jun;199(3):99–102 (Eng. Abstr.) **(Ger)**

[Anesthetic management of patients with Young's syndrome] Fujiwara M, et al. **Masui** 1995 Dec;44(12):1695–9 (Eng. Abstr.) **(Jpn)**

[Anesthetic and postoperative care of a patient with Crigler–Najjar syndrome type II] Hamada T, et al. **Masui** 1996 Mar;45(3):345–7 (Eng. Abstr.) **(Jpn)**

[Cardiovascular interaction and anesthesia] Hoka S. **Masui** 1995;44 Suppl:S52–8 (15 ref.) **(Jpn)**

[Stress hormone response during midazolam/fentanyl anesthesia combined with epidural anesthesia for abdominal total hysterectomy] Mizutani A, et al. **Masui** 1996 Mar; 45(3):276–80 (Eng. Abstr.) **(Jpn)**

[Anesthesia for funnel chest operation] Morimoto A, et al. **Masui** 1995 Oct;44(10):1377–80 (Eng. Abstr.) **(Jpn)**

[Temperature changes and thermoregulatory responses during epidural anesthesia in women undergoing cesarean delivery] Negishi C, et al. **Masui** 1996 May;45(5):558–64 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Perioperative management of a patient with severe bronchial asthma attack] Ochiai N, et al. **Masui** 1995 Aug; 44(8):1124–7 (Eng. Abstr.) **(Jpn)**

[Anesthesia for hepatectomy in a patient with glycogen storage disease] Ogawa M, et al. **Masui** 1995 Dec; 44(12):1703–6 (Eng. Abstr.) **(Jpn)**

[The effects of prostaglandin E1 and epidural anesthesia on peripheral blood flow] Sakuma K, et al. **Masui** 1995 Oct; 44(10):1350–5 (Eng. Abstr.) **(Jpn)**

[Plasma concentration of lidocaine in patients undergoing hepatectomy with continuous epidural anesthesia—influence of extent of hepatectomy and prostaglandin E1 infusion] Satoh O, et al. **Masui** 1996 May; 45(5):624–8 (Eng. Abstr.) **(Jpn)**

[Anesthesia for cesarean section in a patient with intracranial A–V malformation] Terao M, et al. **Masui** 1995 Dec; 44(12):1700–2 (Eng. Abstr.) **(Jpn)**

[Blood coagulation–fibrinolysis system during transurethral resection evaluated by thrombelastography] Tomiyama Y, et al. **Masui** 1996 May;45(5):565–70 (Eng. Abstr.) **(Jpn)**

[Changes in dementia rating scale scores of elderly patients with femoral neck fracture during perioperative period] Wajima Z, et al. **Masui** 1995 Nov;44(11):1489–97 (Eng. Abstr.) **(Jpn)**

[Balanced anesthesia with epidural anesthesia] Yuge O, et al. **Masui** 1995;44 Suppl:S153–5; discussion S156–7 (13 ref.) **(Jpn)**

[Epidural anesthesia and postoperative analgesia] Yokoyama K. **Nippon Ika Daigaku Zasshi** 1995 Oct;62(5):413–9 (30 ref.) **(Jpn)**

[A case report of vaginal delivery controlled by epidural anesthesia in a woman with high spinal cord injury] Kase H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep; 47(9):957–60 (14 ref.) **(Jpn)**

[Epidural anesthesia as a method of labor analgesia preserving motor activity of parturient women] Gedzh P, et al. **Akush Ginekol (Mosk)** 1995;(4):46 **(Rus)**

[Advantages of epidural anesthesia in patients with end–stage chronic renal failure] Kazimirov VG, et al. **Anesteziol Reanimatol** 1995 Jul–Aug:(4):63–6 (Eng. Abstr.) **(Rus)**

[Spinal–epidural anesthesia: hemodynamics and hemostasis] Nikolaev EK, et al. **Anesteziol Reanimatol** 1995 Jul–Aug: (4):61–3 (Eng. Abstr.) **(Rus)**

[Metabolic components of anesthesiological provision in surgery of suppurative–inflammatory diseases of the abdominal cavity] Tumanian SV, et al. **Anesteziol Reanimatol** 1995 Sep–Oct;(5):31–4 (Eng. Abstr.) **(Rus)**

[Epidural anesthesia in vascular surgery in patients with chronic obstructive lung disease] Zanić–Matanić D, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:101–3 (Eng. Abstr.) **(Scr)**

[Anesthesia for cesarean delivery in a case of myotonia congenita] Arcas M, et al. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):147–9 (Eng. Abstr.) **(Spa)**

[Intradural anesthesia in a case of paramyotonia congenita (letter)] Bermejo MA, et al. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):155 **(Spa)**

[Comparison of changes in plasma concentrations of ACTH and beta–endorphin in cholecystectomy under general anesthesia and general plus epidural anesthesia] Caba F, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):364–8 (Eng. Abstr.) **(Spa)**

[Cervical epidural anesthesia for carotid mycotic aneurysms] Llorente A, et al. **Rev Esp Anestesiol Reanim** 1995 Oct; 42(8):341–3 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Neurological complications after anaesthesia. A follow–up of 18,000 spinal and epidural anaesthetics performed over three years [see comments] Dahlgren N, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):872–80. Comment in: Acta Anaesthesiol Scand 1995 Oct;39(7):859–68. Comment in: Acta Anaesthesiol Scand 1995 Oct;39(7):869–71.

Neurological complications of central nerve blocks [editorial; comment] Renck H. **Acta Anaesthesiol Scand** 1995 Oct; 39(7):859–68 (93 ref.). Comment on: Acta Anaesthesiol Scand 1995 Oct;39(7):872–80.

Spinal subdural haematoma following combined spinal–epidural anaesthesia. Bougher RJ, et al. **Anaesth Intensive Care** 1995 Jun;23(3):373–5

Prolonged unilateral lower limb paresis following abdominal surgery with epidural and general anaesthesia. Lyons B, et al. **Anaesth Intensive Care** 1995 Aug;23(4):507–9

Misplacement of multihole epidural catheters—a report of two cases. Sala–Blanch X, et al. **Anaesthesia** 1996 Apr; 51(4):386–8

Spinal anesthesia after failed epidural anesthesia [letter; comment] Gupta A. **Anesth Analg** 1996 Jan;82(1):214–5. Comment on: Anesth Analg 1994 Dec;79(6):1206–7.

Epiduroscopic changes in patients undergoing single and repeated epidural injections. Kitamura A, et al. **Anesth Analg** 1996 Jan;82(1):88–90

Pulmonary function changes during epidural anesthesia for cesarean delivery. Yun E, et al. **Anesth Analg** 1996 Apr; 82(4):750–3

Infectious complications after epidural anesthesia [letter] Kindler CH, et al. **Anesthesiology** 1996 Aug;85(2):444–5

Epidural anaesthesia and low back pain after delivery: a prospective cohort study. Macarthur A, et al. **BMJ** 1995 Nov 18;311(7016):1336–9

Epidural anaesthesia and low back pain after delivery [letter] McQuay H, et al. **BMJ** 1996 Mar 2;312(7030):581

The risk of extradural abscess [editorial] Carson D, et al. **Br J Anaesth** 1995 Nov;75(5):520–1 (13 ref.)

Accidental insertion of an extradural catheter [letter] Fox A, et al. **Br J Anaesth** 1996 Feb;76(2):336

Extradural anaesthesia for repeated surgical treatment in the presence of infection [see comments] Jakobsen KB, et al. **Br J Anaesth** 1995 Nov;75(5):536–40. Comment in: Br J Anaesth 1996 Jun;76(6):887–8.

Reducing the potential morbidity of an unintentional spinal anaesthetic by aspirating cerebrospinal fluid. Southorn P, et al. **Br J Anaesth** 1996 Mar;76(3):467–9

Another complication of the combined extradural–subarachnoid technique [letter; comment] Stallard N, et al. **Br J Anaesth** 1995 Sep;75(3):370–1. Comment on: Br J Anaesth 1994 Oct;73(4):545–7.

Neurological symptoms attributed to epidural analgesia in labour: an observational study of seven cases. Tubridy N, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):832–3

Epidural blood patch in a seven–year–old child. Roy L, et

al. **Can J Anaesth** 1995 Jul;42(7):621–4
Impaired haemostasis and regional anaesthesia.
Stafford-Smith M. **Can J Anaesth** 1996 May;43(5 Pt 2):R129–41 (33 ref.) **(Eng, Fre)**
Coronary artery spasm induced under lumbar epidural anaesthesia. Hoka S, et al. **Eur J Anaesthesiol** 1995 Nov; 12(6):609–12
Malignant hyperthermia during epidural anesthesia. Motegi Y, et al. **J Clin Anesth** 1996 Mar;8(2):157–60
Infections following epidural catheterization. Holt HM, et al. **J Hosp Infect** 1995 Aug;30(4):253–60
Epidurals redefined in analgesia and anesthesia: a distinction with a difference. Youngstrom PC, et al.
J Obstet Gynecol Neonatal Nurs 1996 May;25(4):350–4 (14 ref.)
Epidural anaesthesia and urinary dysfunction: the risks in total hip replacement. Williams A, et al. **J R Soc Med** 1995 Dec;88(12):699p–701p
Accidents following extradural analgesia in children. The results of a retrospective study [letter; comment] Luz G, et al. **Paediatr Anaesth** 1995;5(4):273. Comment on: Paediatr Anaesth 1995;5(1):41–6.
Comment on spinal–epidural anesthesia case report by Eldor et al [letter; comment] Camann W. **Reg Anesth** 1995 Sep–Oct;20(5):460–1. Comment on: Reg Anesth 1994 Nov–Dec;19(6):418–22.
Delayed respiratory arrest in combined spinal–epidural anesthesia [letter; comment] Carrie LE, et al.
Reg Anesth 1995 Nov–Dec;20(6):546–7. Comment on: Reg Anesth 1994 Nov–Dec;19(6):418–22.
Unintentional combined epidural and subdural block. Case report. Chauhan S, et al. **Reg Anesth** 1995 May–Jun; 20(3):249–51
Auditory, ocular, and facial complications of central neural block. A review of possible mechanisms. Day CJ, et al. **Reg Anesth** 1996 May–Jun;21(3):197–201 (28 ref.)
Severe lumbar pain and epidural anesthesia [letter; comment] Devulder J, et al. **Reg Anesth** 1995 Sep–Oct;20(5):461–2. Comment on: Reg Anesth 1995 Jan–Feb;20(1):69–74.
Aseptic meningitis due to metallic particles in the needle-through-needle technique [letter] Eldor J, et al.
Reg Anesth 1995 Jul–Aug;20(4):360
Response to postblock epidural hematoma causing paraplegia [letter; comment] Hsu DT, et al. **Reg Anesth** 1995 May–Jun; 20(3):254–5. Comment on: Reg Anesth 1994 Jan–Feb;19(1):62–5.
An in vitro comparison of fluid leakage after dural puncture with Atraucan, Sprotte, Whitacre, and Quincke needles. Morrison LM, et al. **Reg Anesth** 1996 Mar–Apr; 21(2):139–43
High spinal anesthesia after epidural test dose administration in five obstetric patients. Richardson MG, et al.
Reg Anesth 1996 Mar–Apr;21(2):119–23
Comment on severe lumbar back pain following epidural anesthesia [letter; comment] Saberski L, et al.
Reg Anesth 1995 Nov–Dec;20(6):550. Comment on: Reg Anesth 1995 Jan–Feb;20(1):69–74.
Cardiac arrest caused by coronary spasm in two patients during recovery from epidural anesthesia. Sprung J, et al.
Reg Anesth 1996 May–Jun;21(3):253–60
Headache and backache after epidural block for postpartum sterilisation [letter] [see comments] Downing SE, et al.
S Afr Med J 1994 Nov;84(11):788. Comment in: S Afr Med J 1995 Jun;85(6):546, 548. Comment in: S Afr Med J 1995 Jun;85(6):548; discussion 548–9. Comment in: S Afr Med J 1995 Dec;85(12):1309–10.
Epidural block for postpartum sterilisation [letter; comment] Rout CC, et al. **S Afr Med J** 1995 Dec;85(12):1309–10. Comment on: S Afr Med J 1994 Nov;84(11):788. Comment on: S Afr Med J 1995 Jun;85(6):546, 548. Comment on: S Afr Med J 1995 Jun;85(6):548; discussion 548–9.
Postpartum surveillance of urinary retention by ultrasonography: the effect of epidural analgesia. Weissman A, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):130–4
[Infections in connection with epidural catheterization] Holt HM, et al. **Ugeskr Laeger** 1996 Jul 29;158(31):4403–5 (Eng. Abstr.) **(Dan)**
[Blood-patch treatment of headache occurring after post-dural puncture at the thoracic level] Marandon JY, et al. **Ann Fr Anesth Reanim** 1995;14(5):435–7 (Eng. Abstr.) **(Fre)**
[Staphylococcus aureus meningitis after obstetrical epidural anesthesia (letter)] Marsaudon E, et al.
Ann Fr Anesth Reanim 1996;15(3):389–90 **(Fre)**
[Management of neurologic manifestations after obstetrical epidural anesthesia] Frangié S, et al. **Cah Anesthesiol** 1995; 43(5):455–60 (43 ref.) (Eng. Abstr.) **(Fre)**
[Transient complete left bundle branch block during epidural anesthesia with mepivacaine] Asao Y, et al. **Masui** 1996 Apr;45(4):483–6 (Eng. Abstr.) **(Jpn)**
[Intraoperative acute myocardial infarction during total gastrectomy under general anesthesia combined with thoracic epidural anesthesia] Ishiyama T, et al. **Masui** 1996 Apr;45(4):449–52 (Eng. Abstr.) **(Jpn)**
[Subdural catheterization uncovered by severe hypotension during epidural plus general anesthesia] Okuyama A, et al. **Masui** 1995 Oct;44(10):1373–6 (Eng. Abstr.) **(Jpn)**
[Permanent paraplegia following epidural and general anesthesia: two case reports] Uefuji T, et al. **Masui** 1996 Apr;45(4):453–7 (Eng. Abstr.) **(Jpn)**
[Advantages of epidural anesthesia in patients with end-stage chronic renal failure] Kazimirov VG, et al.
Anesteziol Reanimatol 1995 Jul–Aug;(4):63–6 (Eng. Abstr.) **(Rus)**
[Puncture of the dura mater, diagnosis and treatment in obstetrics] Villalpando Bravo J, et al.
Ginecol Obstet Mex 1996 Feb;64:85–9 (35 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Labor epidural catheter reactivation or spinal anesthesia for delayed postpartum tubal ligation: a cost comparison. Viscomi CM, et al. **J Clin Anesth** 1995 Aug;7(5):380–3

INSTRUMENTATION

Tunnelled epidural catheters [letter] Molnar R.
Anaesth Intensive Care 1995 Jun;23(3):404–5
Tunnelled epidural catheters [letter] Rowney DA, et al.
Anaesth Intensive Care 1995 Jun;23(3):404
Equipment failure during epidural catheter placement [letter] Williams G, et al. **Anaesthesia** 1995 Sep;50(9):831
All epidural needles are not created equal [letter] Dunn SM, et al. **Anesth Analg** 1996 Sep;83(3):659
Lumbar stenosis complicating retained epidural catheter tip. Staats PS, et al. **Anesthesiology** 1995 Nov;83(5):1115–8
Three-way tap for identifying the epidural space [letter] Dagli G, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):437–8
Sterile but contaminated epidural trays [letter] Busch RL.
Reg Anesth 1995 Sep–Oct;20(5):464–5
New device for the securement of epidural catheters [letter] Corn SB, et al. **Reg Anesth** 1995 Nov–Dec;20(6):545–6
Combined end-multiple lateral holes epidural catheter [letter] Eldor J. **Reg Anesth** 1996 May–Jun;21(3):271–2
An in vitro comparison of fluid leakage after dural puncture with Atraucan, Sprotte, Whitacre, and Quincke needles. Morrison LM, et al. **Reg Anesth** 1996 Mar–Apr; 21(2):139–43
[An atraumatic needle for continuous epidural and plexus anesthesia] Sprotte G. **Anaesthesist** 1995 Nov;44(11):789–92 (Eng. Abstr.) **(Ger)**
[The clinical usefulness and problem of combined spinal epidural needle] Kitamura A, et al. **Masui** 1995 Nov; 44(11):1533–6 (Eng. Abstr.) **(Jpn)**
[Usefulness and radiopacity of the two radiopaque epidural catheters] Nishiyama T, et al. **Masui** 1995 Dec; 44(12):1712–4 (Eng. Abstr.) **(Jpn)**
[Evaluation of 26G pencil point spinal needle in combined epidural-spinal anesthesia] Sonoda H, et al. **Masui** 1995 Oct;44(10):1410–4 (Eng. Abstr.) **(Jpn)**
[Pencil-point needles: possible disadvantages to the shape of the needle (letter)] Quintana FB, et al.
Rev Esp Anestesiol Reanim 1995 Dec;42(10):437–8 **(Spa)**

METHODS

Awake epidural anesthesia is associated with improved natural killer cell cytotoxicity and a reduced stress response. Koltun WA, et al. **Am J Surg** 1996 Jan; 171(1):68–72; discussion 72–3
Sacral intervertebral approach for epidural anaesthesia in infants and children: application of "drip and tube" method. Kumagai M, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):469–71
Skin-epidural distance in children. Bösenberg AT, et al.
Anaesthesia 1995 Oct;50(10):895–7
Gastric intramucosal pH [letter] Male DA, et al.
Anaesthesia 1996 Jul;51(7):711
Arnold-chiari malformation in pregnancy. Semple DA, et al. **Anaesthesia** 1996 Jun;51(6):580–2
The level is TEE-FORE [letter] Camann W.
Anesth Analg 1996 Feb;82(2):439
Epidural test dosing [letter; comment] Colclough GW.
Anesth Analg 1996 Jan;82(1):219–20. Comment on: Anesth Analg 1995 May;80(5):861–3.
Spinal needle deflection in the combined spinal–epidural technique [letter] Eldor J. **Anesth Analg** 1996 Sep;83(3):663
Spinal anesthesia after failed epidural anesthesia [letter; comment] Gupta A. **Anesth Analg** 1996 Jan;82(1):214–5. Comment on: Anesth Analg 1994 Dec;79(6):1206–7.
Combined spinal epidural anesthesia: a new "hanging drop" [letter; comment] Kopacz DJ, et al. **Anesth Analg** 1996 Feb; 82(2):433–4. Comment on: Anesth Analg 1995 Apr;80(4):821–6.
Don't abandon test doses [letter; comment] Mulroy MF, et al. **Anesth Analg** 1996 Jan;82(1):220. Comment on: Anesth Analg 1995 May;80(5):861–3.
The effect of abdominal massage on the onset of epidural blockade in laboring women [letter; comment] Parke TJ, et al. **Anesth Analg** 1996 Apr;82(4):887. Comment on: Anesth Analg 1993 Apr;76(4):783–5.
Efficacy of simulated epidural test doses in adult patients anesthetized with isoflurane: a dose-response study [see comments] Tanaka M, et al. **Anesth Analg** 1995 Nov; 81(5):987–92. Comment in: Anesth Analg 1996 Jun;82(6):1304–5.
Thoracic epidural anesthesia via the lumbar approach in infants and children. Blanco D, et al. **Anesthesiology** 1996 Jun;84(6):1312–6
Thoracic epidural anesthesia improves outcome after breast surgery. Lynch EP, et al. **Ann Surg** 1995 Nov;222(5):663–9
Anaesthetic dilemma: half a spinal is better than none. Smith AF, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12; 54(10):513–4
Alkalinization of lidocaine 2% does not influence the quality of epidural anaesthesia for elective caesarean section. Gaggero G, et al. **Can J Anaesth** 1995 Dec;42(12):1080–4
Intravenous trimethaphan during epidural plus general anesthesia decreases the direct radial artery pressure lower than the brachial artery pressure. Nagata N, et al.
J Clin Anesth 1996 May;8(3):180–7
Comment on syringe medium [letter] Ananthanarayan C, et al. **Reg Anesth** 1995 Sep–Oct;20(5):463
Loss-of-resistance technique using both air and saline [letter; comment] Barros S. **Reg Anesth** 1995 Sep–Oct;20(5):462–3 . Comment on: Reg Anesth 1994 Jul–Aug;19(4):294.
Importance of the needle bevel during spinal and epidural anesthesia. Baumgarten RK. **Reg Anesth** 1995 May–Jun; 20(3):234–8
Aging reduces the reliability of epidural epinephrine test doses. Guinard JP, et al. **Reg Anesth** 1995 May–Jun; 20(3):193–8
Misalignment of the spinal needle during the spinal epidural combined anesthesia [letter] Pedraza I, et al.
Reg Anesth 1995 May–Jun;20(3):256–8
[Combined spinal and epidural analgesia for labor. Prolongation by addition of a minidose of clonidine to sufentanil. An initial study] Mercier FJ, et al.
Ann Fr Anesth Reanim 1996;15(3):263–5 (Eng. Abstr.) **(Fre)**
[Combined spinal and epidural anesthesia or epidural anesthesia in obstetrics?] Benhamou D. **Cah Anesthesiol** 1996;44(2):157–8 **(Fre)**
[Sequential anesthesia-analgesia] Brassier J.
Cah Anesthesiol 1996;44(2):167–71 (Eng. Abstr.) **(Fre)**
[Epidural anesthesia and esophageal atresia. Apropos of a case] Courrèges P, et al. **Cah Anesthesiol** 1995;43(5):471–4 (Eng. Abstr.) **(Fre)**
[Lumbar and sacral epidural anesthesia in children] Murat I. **Cah Anesthesiol** 1995;43(3):287–90 (Eng. Abstr.) **(Fre)**
[Ultrasonography-guided identification of the lumbar epidural space] Bonazzi M, et al. **Minerva Anestesiol** 1995 May;61(5):201–5 (Eng. Abstr.) **(Ita)**
[Anesthetic management for colon resection in a patient with polymyositis] Fujita A, et al. **Masui** 1996 Mar;45(3):334–6 (Eng. Abstr.) **(Jpn)**
[Postoperative management following open heart surgery by thoracic epidural anesthesia] Konishi A, et al. **Masui** 1995 Aug;44(8):1113–7 (Eng. Abstr.) **(Jpn)**
[Cesarean section in a myasthenia gravis patient (letter)] Facorro E, et al. **Rev Esp Anestesiol Reanim** 1996 Mar; 43(3):115 **(Spa)**

STANDARDS

Anaesthesia for caesarean section (epidural and general): effects on the neonate. Dick WF.
Eur J Obstet Gynecol Reprod Biol 1995 May;59 Suppl:S61–7 (42 ref.)

UTILIZATION

Attitudes and practices of New Zealand anaesthetists with regard to epidural and subarachnoid anaesthesia. Rodgers A, et al. **Anaesth Intensive Care** 1996 Feb;24(1):79–86

VETERINARY

Complication after the use of a combination of lignocaine and xylazine for epidural anaesthesia in a mare. Chopin JB, et al. **Aust Vet J** 1995 Sep;72(9):354–5
The effect of xylazine epidural anaesthesia on blood gas and acid–base parameters in rams. Aminkov BY, et al.
Br Vet J 1995 Sep–Oct;151(5):579–85
Anesthesia for canine cesarian section. Brock N.
Can Vet J 1996 Feb;37(2):117–8
Effects of restraint and isolation stress and epidural blockade on endocrine and blood metabolite status, muscle glycogen metabolism, and incidence of dark-cutting longissimus muscle of sheep. Apple JK, et al. **J Anim Sci** 1995 Aug; 73(8):2295–307
[Epidural anesthesia (letter)] Vrij JP.
Tijdschr Diergeneeskd 1996 Mar 15;121(6):170 **(Dut)**

ANESTHESIA, EXTRADURAL see **ANESTHESIA, EPIDURAL**

ANESTHESIA, GENERAL

Midlatency auditory evoked potentials during anaesthesia with increasing endexpiratory concentrations of desflurane. Schwender D, et al. **Acta Anaesthesiol Scand** 1996 Feb; 40(2):171–6
Clinical assessment of oxygen delivery and consumption during hypotensive anaesthesia--a clinical application of The Deep Picture. Ueda N, et al.
Acta Anaesthesiol Scand Suppl 1995;107:189–93
The anesthetic management of a patient with streptococcal toxic shock-like syndrome--a case report. Liu K, et al.
Acta Anaesthesiol Sin 1995 Sep;33(3):195–8
Postural control after propofol anaesthesia in minor surgery. Ledin T, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:313–6
CT-assessment of dependent lung densities in man during general anaesthesia. Lundquist H, et al. **Acta Radiol** 1995 Nov;36(6):626–32
The effect of anesthesia type on needle localization breast biopsy: another point of view [see comments] Papa MZ, et al. **Am J Surg** 1996 Feb;171(2):242–3. Comment in: Am

J Surg 1996 Jul;172(1):93–4.

Anaesthesia for an anterior mediastinal mass with ketamine and midazolam infusion. Frawley G, et al. **Anaesth Intensive Care** 1995 Oct;23(5):610–2

Anaesthesia in epiglottitis [letter; comment] Morgan–Hughes JO, et al. **Anaesth Intensive Care** 1995 Aug;23(4):519. Comment on: Anaesth Intensive Care 1994 Dec;22(6):738.

Anaesthesia for adults with cystic fibrosis. Weeks AM, et al. **Anaesth Intensive Care** 1995 Jun;23(3):332–8

Cricoid pressure: are two hands better than one? Cook TM. **Anaesthesia** 1996 Apr;51(4):365–8

The use of a non–invasive method to measure intrapulmonary shunt during one–lung anaesthesia. Dingley J, et al. **Anaesthesia** 1996 Jul;51(7):654–7

Safety not speed [letter; comment] Findlay GP. **Anaesthesia** 1995 Oct;50(10):918. Comment on: Anaesthesia 1995 May;50(5):474.

Upper and lower limb blood pressures during general anaesthesia [comment] Howat DD. **Anaesthesia** 1995 Oct; 50(10):918. Comment on: Anaesthesia 1995 Jun;50(6):553–5.

Postanaesthetic shivering in children. Lyons B, et al. **Anaesthesia** 1996 May;51(5):442–5

Dose–response and minimum time to satisfactory intubation conditions after mivacurium in children. McCluskey A, et al. **Anaesthesia** 1996 May;51(5):438–41

A case of intra–operative awareness during balanced anaesthesia with sufentanil [letter] Maeckelmann S, et al. **Anaesthesia** 1996 Aug;51(8):802

Gastric regurgitation during general anaesthesia in different positions with the laryngeal mask airway. el Mikatti N, et al. **Anaesthesia** 1995 Dec;50(12):1053–5

Evaluation of the Upsherscope. A new rigid fibrescope. Pearce AC, et al. **Anaesthesia** 1996 Jun;51(6):561–4

Effects of magnesium sulphate on suxamethonium–induced complications during rapid–sequence induction of anaesthesia. Stacey MR, et al. **Anaesthesia** 1995 Nov; 50(11):933–6

Laryngospasm following extubation in children [letter; comment] [see comments] Young A, et al. **Anaesthesia** 1995 Sep;50(9):827. Comment on: Anaesthesia 1995 Apr;50(4):375. Comment in: Anaesthesia 1996 Jan;51(1):94.

Deliberate oxygen deprivation in children: ethical considerations [letter; comment] Coté CJ. **Anesth Analg** 1996 Mar;82(3):671–2. Comment on: Anesth Analg 1995 Jun;80(6):1248–9.

Decreases in anesthesia–controlled time cannot permit one additional surgical operation to be reliably scheduled during the workday [see comments] Dexter F, et al. **Anesth Analg** 1995 Dec;81(6):1263–8. Comment in: Anesth Analg 1996 Jul;83(1):194.

Addition of low–dose ketamine to general anesthesia does not improve cardiovascular response during conventional abdominal surgery [letter; comment] Hirata S, et al. **Anesth Analg** 1995 Nov;81(5):1111–2. Comment on: Anesth Analg 1993 Dec;77(6):1161–5.

A prospective randomized study comparing short– and intermediate–term perioperative outcome variables after spinal or general anesthesia for lumbar disk and laminectomy surgery. Jellish WS, et al. **Anesth Analg** 1996 Sep;83(3):559–64

Continuous hypopharyngeal pH measurements in spontaneously breathing anesthetized outpatients: laryngeal mask airway versus tracheal intubation [see comments] Joshi GP, et al. **Anesth Analg** 1996 Feb;82(2):254–7. Comment in: Anesth Analg 1996 Aug;83(2):441–2.

Perioperative changes in cardiac autonomic control in patients receiving either general or local anesthesia for ophthalmic surgery. Keyl C, et al. **Anesth Analg** 1996 Jan; 82(1):113–8

The anesthetic management of patients with multiple pterygium syndrome. Kuzma PJ, et al. **Anesth Analg** 1996 Aug;83(2):430–2

Hemodynamic responses to an epinephrine test dose in adults during epidural or combined epidural–general anesthesia. Liu SS. **Anesth Analg** 1996 Jul;83(1):97–101

Tangier disease. Mentis SW. **Anesth Analg** 1996 Aug; 83(2):427–9

Prone positioning improves pulmonary function in obese patients during general anesthesia. Pelosi P, et al. **Anesth Analg** 1996 Sep;83(3):578–83

The effects of anesthesia with increasing end–expiratory concentrations of sevoflurane on midlatency auditory evoked potentials. Schwender D, et al. **Anesth Analg** 1995 Oct;81(4):817–22

A retrospective comparison of spinal and general anesthesia for vaginal hysterectomy: a time analysis. Tessler MJ, et al. **Anesth Analg** 1995 Oct;81(4):694–6

Therapeutic suggestion has not effect on postoperative morphine requirements. van der Laan WH, et al. **Anesth Analg** 1996 Jan;82(1):148–52

A pilot study of the effects of a perflubron emulsion, AF 0104, on mixed venous oxygen tension in anesthetized surgical patients. Wahr JA, et al. **Anesth Analg** 1996 Jan; 82(1):103–7

Neostigmine, atropine, and glycopyrrolate: does neostigmine cross the placenta? Clark RB, et al. **Anesthesiology** 1996 Feb;84(2):450–2

General versus regional anesthesia for peripheral vascular surgery [letter; comment] de Leon–Casasola OA, et al. **Anesthesiology** 1996 Jul;85(1):224–5. Comment on: Anesthesiology 1996 Jan;84(1):1–2. Comment on: Anesthesiology 1996 Jan;84(1):3–13.

Differences in respiratory reflex responses from the larynx, trachea, and bronchi in anesthetized female subjects. Nishino T, et al. **Anesthesiology** 1996 Jan;84(1):70–4

Hepatic heat shock and acute–phase gene expression are induced simultaneously after celiotomy in the anesthetized pig. Pannen BH, et al. **Anesthesiology** 1995 Oct;83(4):850–9

Is general anesthesia required? [letter; comment] Pinsker MC, et al. **Anesthesiology** 1996 Jun;84(6):1529–30. Comment on: Anesthesiology 1995 Aug;83(2):422–4.

Complication of the Univent tube [letter] Thielmeier KA, et al. **Anesthesiology** 1996 Feb;84(2):491

Thoracic epidural anesthesia improves outcome after breast surgery. Lynch EP, et al. **Ann Surg** 1995 Nov;222(5):663–9

Anesthetic techniques for pediatric thoracoscopy. McGahren ED, et al. **Ann Thorac Surg** 1995 Oct;60(4):927–30

Effect of general anaesthesia on prolonged intraoesophageal pH monitoring. McCallion WA, et al. **Arch Dis Child** 1995 Sep;73(3):235–8

Levels of consciousness and ventilatory parameters in young children during sedation with oral midazolam and nitrous oxide [see comments] Litman RS, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):671–5. Comment in: Arch Pediatr Adolesc Med 1996 Jul;150(7):665–7.

Comparison of propofol and methohexitone in anaesthesia for ECT: effect on seizure duration and outcome. Kirkby KC, et al. **Aust N Z J Psychiatry** 1995 Jun;29(2):299–303

BreathSim, a mathematical model–based simulation of the anesthesia breathing circuit, may facilitate testing and evaluation of respiratory gas monitoring equipment. Goldman JM, et al. **Biomed Sci Instrum** 1996;32:293–8

Pharmacokinetics of epidurally administered nicomorphine with its metabolites and glucuronide conjugates in patients undergoing pulmonary surgery during combined epidural local anaesthetic block and general anaesthesia. Koopman–Kimenai PM, et al. **Biopharm Drug Dispos** 1995 Aug;16(6):507–20

New guidance on general anaesthesia, resuscitation and sedation [news] **Br Dent J** 1996 Jun 8;180(11):403

General anaesthesia [letter] Pike D. **Br Dent J** 1996 Jun 22; 180(12):448

Is general anaesthesia for orthodontic extractions in children necessary? Shaw L, et al. **Br Dent J** 1996 Jul 6;181(1):6–7

Haemodynamic effects of moderate normovolaemic haemodilution in conscious and anaesthetized patients. Biboulet P, et al. **Br J Anaesth** 1996 Jan;76(1):81–4

Tramadol [letter; comment] Budd K. **Br J Anaesth** 1995 Oct; 75(4):500. Comment on: Br J Anaesth 1995 Mar;74(3):247–9.

Post traumatic stress disorders [letter] Cundy JM. **Br J Anaesth** 1995 Oct;75(4):501–2

Haemodynamic responses to incision and sternotomy in relation to the auditory evoked potential and spontaneous EEG. de Beer NA, et al. **Br J Anaesth** 1996 May; 76(5):685–93

Suxamethonium in children [letter; comment] Fiacchino F, et al. **Br J Anaesth** 1996 Jun;76(6):883; discussion 884. Comment on: Br J Anaesth 1995 Dec;75(6):675–7.

Day–case cataract surgery [letter] Goold JE. **Br J Anaesth** 1996 Feb;76(2):333

Anaesthetic experience of vertical banded gastroplasty. Goulding ST, et al. **Br J Anaesth** 1995 Sep;75(3):301–6

Assessment of changes in left ventricular wall stress from the end–systolic pressure–area product. Greim CA, et al. **Br J Anaesth** 1995 Nov;75(5):583–7

Failed intubation revisited: 17–yr experience in a teaching maternity unit. Hawthorne L, et al. **Br J Anaesth** 1996 May; 76(5):680–4

Early effects of total hepatectomy on haemodynamic state and organ uptake of catecholamines in the pig. James MF, et al. **Br J Anaesth** 1996 May;76(5):713–20

Removal of the laryngeal mask airway in children: anaesthetized compared with awake. Kitching AJ, et al. **Br J Anaesth** 1996 Jun;76(6):874–6

Comparison of desflurane and isoflurane in anaesthesia for dental surgery. Loan PB, et al. **Br J Anaesth** 1995 Sep; 75(3):289–92

Evaluation of the Pneupac Ventipac portable ventilator: comparison of performance in a mechanical lung and anaesthetized patients. McCluskey A, et al. **Br J Anaesth** 1995 Nov;75(5):645–50

Recovery after electroconvulsive therapy: comparison of propofol with methohexitone anaesthesia. Matters RM, et al. **Br J Anaesth** 1995 Sep;75(3):297–300

Effect of antagonism of mivacurium on recovery of extraocular muscle function. Mellor DJ, et al. **Br J Anaesth** 1996 May;76(5):621–3

Laryngeal mask airway performance: effect of cuff deflation during anaesthesia. Morris GN, et al. **Br J Anaesth** 1996 Mar;76(3):456–8

Double–blind, randomized trial of cessation of smoking after audiotape suggestion during anaesthesia. Myles PS, et al. **Br J Anaesth** 1996 May;76(5):694–8

Recall during intermittent propofol anaesthesia. Nordström O, et al. **Br J Anaesth** 1996 May;76(5):699–701

Anaesthesia and juvenile hyaline fibromatosis. Norman B, et al. **Br J Anaesth** 1996 Jan;76(1):163–6

Effects of carbon dioxide embolism with nitrous oxide in the inspired gas in piglets. Nyarwaya JB, et al. **Br J Anaesth** 1996 Mar;76(3):428–34

The auditory evoked potential and paediatric anaesthesia. O'Kelly SW, et al. **Br J Anaesth** 1995 Oct;75(4):428–30

Use of near infrared spectroscopy to estimate cerebral blood flow in conscious and anaesthetized adult subjects [see comments] Owen–Reece H, et al. **Br J Anaesth** 1996 Jan; 76(1):43–8. Comment in: Br J Anaesth 1996 Jul;77(1):131.

Volumetric analysis of aeration in the lungs during general anaesthesia. Reber A, et al. **Br J Anaesth** 1996 Jun; 76(6):760–6

Isolated forearm technique [letter; comment] Russell IF, et al. **Br J Anaesth** 1996 Jun;76(6):884–6. Comment on: Br J Anaesth 1995 Dec;75(6):819–21.

Intraoperative awareness and the isolated forearm technique [letter] [see comments] Russell IF. **Br J Anaesth** 1995 Dec; 75(6):819–21. Comment in: Br J Anaesth 1996 Jun;76(6):884–6.

Improving preoxygenation [letter; comment] Smith AF. **Br J Anaesth** 1996 May;76(5):748. Comment on: Br J Anaesth 1995 Dec;75(6):777–8.

Preoperative fasting for paediatric anaesthesia [letter; comment] Stack CG, et al. **Br J Anaesth** 1995 Sep;75(3):375 . Comment on: Br J Anaesth 1995 Mar;74(3):349.

General anaesthesia for day–case cataract surgery [letter; comment] Whitehead PN. **Br J Anaesth** 1995 Aug; 75(2):252–3. Comment on: Br J Anaesth 1995 Feb;74(2):145–8.

The gasman and the water board: let's work together [editorial] Barton IK, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):160–1

Anaesthesia for patients with renal impairment. Cranshaw J, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):171–5 (23 ref.)

Hypotensive anaesthesia. Hack H, et al. **Br J Hosp Med** 1996 Apr 17–30;55(8):482–5

Anaesthesia for day–case surgery. Hitchcock M, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):202–6 (20 ref.)

Eisenmenger's syndrome and problems with anaesthesia. Jones P, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):214

Learning during anaesthesia: a review. Andrade J. **Br J Psychol** 1995 Nov;86 (Pt 4):479–506 (110 ref.)

Chronic ankle instability: the value of talar tilt under general anaesthesia. McCaskie AW, et al. **Br J Sports Med** 1995 Jun;29(2):103–4

Anesthesia during hormone administration abolishes the estrogen induction of preproenkephalin mRNA in ventromedial hypothalamus of female rats. Quiñones–Jenab V, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):297–303

Anaesthesia for major vascular surgery. Beattie C. **Can J Anaesth** 1996 May;43(5 Pt 2):R3–13 (5 ref.) **(Eng, Fre)**

The patient with a pacemaker or related device. Bourke ME. **Can J Anaesth** 1996 May;43(5 Pt 2):R24–41 (28 ref.) **(Eng, Fre)**

Trends in neuroanaesthesia. Cottrell JE. **Can J Anaesth** 1996 May;43(5 Pt 2):R61–74 (73 ref.) **(Eng, Fre)**

Complications associated with removal of the laryngeal mask airway: a comparison of removal in deeply anaesthetised versus awake patients. Gataure PS, et al. **Can J Anaesth** 1995 Dec;42(12):1113–6

A combination of low dose spinal and general anaesthesia for laparoscopic cholecystectomy [letter] Gurmarnik S, et al. **Can J Anaesth** 1996 Jan;43(1):95

Laryngoscopy and arrhythmias in children [letter] Morrison JE Jr, et al. **Can J Anaesth** 1995 Aug;42(8):748–9

Anaesthetic considerations in progressive familial intrahepatic cholestasis (Byler's disease). Müller G, et al. **Can J Anaesth** 1995 Dec;42(12):1126–33

The diabetic patient: a challenge or just routine? Ralley FE. **Can J Anaesth** 1996 May;43(5 Pt 2):R14–23 (18 ref.) **(Eng, Fre)**

The patient with heart disease. Ramsay J. **Can J Anaesth** 1996 May;43(5 Pt 2):R99–107 (28 ref.) **(Eng, Fre)**

Anaesthesia and the transplanted patient. Sharpe MD. **Can J Anaesth** 1996 May;43(5 Pt 2):R89–98 (9 ref.) **(Eng, Fre)**

Continuous caudal anaesthesia with chloroprocaine as an adjunct to general anaesthesia in neonates. Tobias JD, et al. **Can J Anaesth** 1996 Jan;43(1):69–72

One–shot percutaneous ethanol injection of liver tumors under general anaesthesia: preliminary data on efficacy and complications. Giorgio A, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):27–31

False–low carbon monoxide diffusing capacity measurement after general anesthesia [letter] Gilbert R, et al. **Chest** 1996 Feb;109(2):592

Glycosylated and non–glycosylated prolactin forms are increased after opioid administration as part of surgical anaesthesia. Priou A, et al. **Clin Endocrinol (Oxf)** 1995 Aug; 43(2):213–7

Subarachnoid neurolytic block under general anesthesia in a 3–year–old with neuroblastoma. Patt RB, et al. **Clin J Pain** 1995 Jun;11(2):143–6

Combined alfentanil–methohexital anesthesia in electroconvulsive therapy. Dinwiddie SH, et al. **Convuls Ther** 1995 Sep;11(3):170–6

Anaesthesia for laparoscopic closure of perforated peptic ulcer—any harm or benefit? Eypasch E, et al. **Endosc Surg Allied Technol** 1995 Aug;3(4):171–3

Anaesthesia for laparoscopic cholecystectomy in high–risk patients [editorial; comment] Stuttmann R. **Endosc Surg Allied Technol** 1995 Aug;3(4):154–5. Comment on: Endosc Surg Allied Technol 1995 Aug;3(4):156–61. Comment on: Endosc Surg Allied Technol 1995 Aug;3(4):162–6. Comment on: Endosc Surg Allied Technol 1995 Aug;3(4):167–70. Comment on: Endosc Surg Allied

Technol 1995 Aug;3(4):174–9. Comment on: Endosc Surg Allied Technol 1995 Aug;3(4):180–2.

Preoperative morbidity and anaesthesia-related negative events in patients undergoing conventional or laparoscopic cholecystectomy [see comments] Stuttmann R, et al. **Endosc Surg Allied Technol** 1995 Aug;3(4):156–61. Comment in: Endosc Surg Allied Technol 1995 Aug;3(4):154–5.

Comparison of maintenance and recovery characteristics of sevoflurane-nitrous oxide and enflurane-nitrous oxide anaesthesia. Blanco E, et al. **Eur J Anaesthesiol** 1995 Sep; 12(5):517–23

Haemorrhage during anaesthesia and surgery: continuous measurement of microcirculatory blood flow in the kidney, liver, skin and skeletal muscle. Erni D, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):423–9

Adrenaline, cyclic AMP and potassium during general anaesthesia with and without epidural analgesia. Löfgren A, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):487–94

A general anaesthesia service for magnetic resonance imaging. Zorab JS. **Eur J Anaesthesiol** 1995 Jul; 12(4):387–95

The differing effects of regional and general anaesthesia on cerebral metabolism during carotid endarterectomy. McCleary AJ, et al. **Eur J Vasc Endovasc Surg** 1996 Aug; 12(2):173–81

The modified recalcification time (MRT) test assesses suppressive effect of general anesthesia (GA) on monocyte function. Ponnudurai R, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S193

Pancreaticoduodenectomy under epidural anesthesia without endotracheal intubation for the elderly. Nakashima H, et al. **Int Surg** 1995 Apr–Jun;80(2):125–7

Anesthetic considerations for descending thoracic aortic surgery: part II. O'Connor CJ, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):734–47 (126 ref.)

Anesthesia for living-related (lobar) lung transplantation. Quinlan JJ, et al. **J Cardiothorac Vasc Anesth** 1996 Apr; 10(3):391–6 (35 ref.)

Anesthetic management of coronary artery bypass via minithoracotomy with video assistance. Wasnick JD, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):731–3

Anesthetic management of a patient with obstructive sleep apnea syndrome and difficult airway access. Biro P, et al. **J Clin Anesth** 1995 Aug;7(5):417–21

Pre-induction skin-surface warming minimizes intraoperative core hypothermia. Camus Y, et al. **J Clin Anesth** 1995 Aug; 7(5):384–8

Incidence of nausea and vomiting in outpatients undergoing general anesthesia in relation to selection of intraoperative opioid. Cepeda MS, et al. **J Clin Anesth** 1996 Jun;8(4):324–8

Pediatric ambulatory anesthesia: role of parents. Hannallah RS. **J Clin Anesth** 1995 Nov;7(7):597–9

Local anesthesia infiltration as a cause of intraoperative tension pneumothorax in a young healthy woman undergoing breast augmentation with general anesthesia. Kaye AD, et al. **J Clin Anesth** 1995 Aug;7(5):422–4

Recovery advantages of regional anesthesia compared with general anesthesia: adult patients. Mingus ML. **J Clin Anesth** 1995 Nov;7(7):628–33 (69 ref.)

Pediatric ambulatory anesthesia: NPO—before or after surgery? Schreiner MS, et al. **J Clin Anesth** 1995 Nov; 7(7):589–96 (41 ref.)

Use of alfentanil for in vitro fertilization oocyte retrieval. Shapira SC, et al. **J Clin Anesth** 1996 Jun;8(4):282–5

Effect of intrathecal sufentanil on isoflurane requirements during lower abdominal surgery. Swenson JD, et al. **J Clin Anesth** 1995 Sep;7(6):477–80

Role of pentobarbitone anaesthesia and sympathetic tone in the haemodynamic effects of isosorbide dinitrate in rats with cirrhosis. Kirstetter P, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):230–5

Combined thoracic epidural with light general anesthesia for thymectomy in myasthenia gravis. Suwanchinda V, et al. **J Med Assoc Thai** 1995 Nov;78(11):605–10

Induced hypotensive anesthesia for adolescent orthognathic surgery patients. Precious DS, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):680–3; discussion 683–4

Effects of anesthesia on urodynamic studies in the primate model. Ghoniem GM, et al. **J Urol** 1996 Jul;156(1):233–6

Cognitive effects after epidural vs general anesthesia [letter; comment] Witt WO. **JAMA** 1995 Nov 15;274(19):1510. Comment on: JAMA 1995 Jul 5;274(1):44–50.

General anesthesia with and without nitrous oxide (N2O) and the weight of middle ear effusion in children undergoing adenoidectomy and tympanostomy. Koivunen P, et al. **Laryngoscope** 1996 Jun;106(6):724–6

Combined spinal-epidural-general anesthesia. Eldor J. **Med Hypotheses** 1995 Jul;45(1):86–90

Pipecuronium bromide: a new steroid muscle relaxant—a clinical study. Jasser MT. **Middle East J Anesthesiol** 1995 Jun;13(2):181–95

The anesthetic and intensive care management of pulmonary hemosiderosis in a child—case report. Salti RA, et al. **Middle East J Anesthesiol** 1995 Jun;13(2):213–20

An information processing theory of anaesthesia. Flohr H. **Neuropsychologia** 1995 Sep;33(9):1169–80 (74 ref.)

Focal cerebral ischemia during anesthesia with etomidate, isoflurane, or thiopental: a comparison of the extent of cerebral injury. Drummond JC, et al. **Neurosurgery** 1995 Oct;37(4):742–8; discussion 748–9

The laryngeal mask airway for fibreoptic bronchoscopy in children. Baraka A, et al. **Paediatr Anaesth** 1995;5(3):197–8

Anaesthetic management of bone marrow transplant recipients less than two years of age. Beebe DS, et al. **Paediatr Anaesth** 1995;5(2):107–14

Anaesthetic considerations for the patient with cri du chat syndrome. Brislin RP, et al. **Paediatr Anaesth** 1995; 5(2):139–41

Anaesthesia for Rett syndrome. Dearlove OR, et al. **Paediatr Anaesth** 1996;6(2):155–8

Nasal midazolam in children, plasma concentrations and the effect on respiration. Fösel T, et al. **Paediatr Anaesth** 1995; 5(6):347–53

Parental presence during induction of anaesthesia: practice differences between the United States and Great Britain. Kain ZN, et al. **Paediatr Anaesth** 1996;6(3):187–93

Larsen's syndrome: anaesthetic implications. Six case reports. Lauder GR, et al. **Paediatr Anaesth** 1995;5(2):133–8

Preoperative evaluation of the cervical spine in children with trisomy-21: results of a questionnaire study. Litman RS, et al. **Paediatr Anaesth** 1995;5(6):355–61

Parents in the anaesthetic room: a questionnaire survey of departments of anaesthesia. McCormick AS, et al. **Paediatr Anaesth** 1996;6(3):183–6

Postoperative morphine requirements, nausea and vomiting following anaesthesia for tonsillectomy. Comparison of intravenous morphine and non-opioid analgesic techniques. Mather SJ, et al. **Paediatr Anaesth** 1995;5(3):185–8

Anaesthesia for a child with centronuclear myopathy. Price SR, et al. **Paediatr Anaesth** 1995;5(4):267–8

Anaesthesia and the Beckwith-Wiedemann syndrome. Suan C, et al. **Paediatr Anaesth** 1996;6(3):231–3

Anaesthesia and recently vaccinated children. van der Walt JH, et al. **Paediatr Anaesth** 1996;6(2):135–41 (18 ref.)

A comparative study of cognitive behavior therapy versus general anesthesia for painful medical procedures in children [see comments] Jay S, et al. **Pain** 1995 Jul;62(1):3–9 . Comment in: Pain 1995 Jul;62(1):1–2.

Timing of elective surgery on the genitalia of male children with particular reference to the risks, benefits, and psychological effects of surgery and anesthesia. American Academy of Pediatrics. **Pediatrics** 1996 Apr;97(4):590–4

Combined general and epidural anesthesia for a patient with Takayasu's arteritis. Case report. Gozal Y, et al. **Reg Anesth** 1995 May–Jun;20(3):246–8

Combined spinal–epidural–general anesthesia revisited [letter; comment] Gudin JA, et al. **Reg Anesth** 1995 Sep–Oct; 20(5):465–6. Comment on: Reg Anesth 1994 Sep–Oct;19(5):365–6. Comment on: Reg Anesth 1994 Nov–Dec;19(6):418–22.

The pregnant patient with an intracranial arteriovenous malformation. Cesarean or vaginal delivery using regional or general anesthesia? Sharma SK, et al. **Reg Anesth** 1995 Sep–Oct;20(5):455–8

Comment on anesthesia technique described by Eldor [letter; comment] Stienstra R. **Reg Anesth** 1995 Jul–Aug; 20(4):359–60. Comment on: Reg Anesth 1994 Sep–Oct;19(5):365–6.

Anesthetic management for bilateral volume reduction surgery. Triantafillou AN. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):94–8

Development of postoperative delirium in relation to a room change in the general surgical unit. Tsutsui S, et al. **Surg Today** 1996;26(4):292–4

Anesthetic actions within the spinal cord: contributions to the state of general anesthesia. Collins JG, et al. **Trends Neurosci** 1995 Dec;18(12):549–53 (42 ref.)

[Awareness during general anesthesia (editorial)] Ranta S, et al. **Duodecim** 1994;110(21):1967–9 (15 ref.) **(Fin)**

[Cerebrovascular reactivity to CO2 during general anesthesia measured by transcranial Doppler ultrasonography (letter)] Grenier B, et al. **Ann Fr Anesth Reanim** 1995;14(6):533–4 **(Fre)**

[Cerebrovascular reactivity to CO2 during general anesthesia maintained with either isoflurane–N2O or propofol–N2O. A comparative study by transcranial Doppler velocimetry] Salord F, et al. **Ann Fr Anesth Reanim** 1995;14(2):166–71 (Eng. Abstr.) **(Fre)**

[Are atrial natriuretic factor, renin, aldosterone and catecholamines modified during general anesthesia for total hip arthroplasty?] Hachimi A, et al. **Can Anesthesiol** 1995; 43(5):449–53 **(Fre)**

[General ambulatory anesthesia in oral medicine and maxillofacial surgery] Boufflers E, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):247–58 (22 ref.) **(Fre)**

[EEG changes during propofol-alfentanil-nitrous oxide anesthesia] Arndt VM, et al. **Anaesthesiol Reanim** 1995; 20(5):126–33 (Eng. Abstr.) **(Ger)**

[The high risk cardiac patient in anesthesia] Francke A. **Anaesthesiol Reanim** 1996;21(2):32–42 (89 ref.) (Eng. Abstr.) **(Ger)**

[Postoperative vomiting after pars plana vitrectomy] Heinke W, et al. **Anaesthesiol Reanim** 1996;21(2):47–50 (Eng. Abstr.) **(Ger)**

[Comparison of various methods of anesthesia by plasma catecholamine determination] Hertel VG, et al. **Anaesthesiol Reanim** 1995;20(5):116–25 (Eng. Abstr.) **(Ger)**

[Comparison of neuromuscular blockade by mivacurium and atracurium] Hofmockel R, et al. **Anaesthesiol Reanim** 1995; 20(1):4–11 (Eng. Abstr.) **(Ger)**

[Anesthesiologic problems in polytrauma patients] Radke J. **Anaesthesiol Reanim** 1995;20(2):32–6 (6 ref.) (Eng. Abstr.) **(Ger)**

[Interactions between renal and general hemodynamics in fentanyl, droperidol, ketamine, thiopental and in peridural anesthesia—animal studies] Schenk HD, et al. **Anaesthesiol Reanim** 1995;20(3):60–70 (Eng. Abstr.) **(Ger)**

[Muscle relaxation with atracurium in myasthenia gravis] Walz R, et al. **Anaesthesiol Reanim** 1996;21(2):43–6 (Eng. Abstr.) **(Ger)**

[Comments on the contribution by K. Sterzik et al. The effect of different anesthesia procedures on hormone regulation in the woman (letter)] Thiel A, et al. **Anaesthesist** 1996 Jan;45(1):95–6 **(Ger)**

[Profile of the effect of succinylcholine after pre-curarization with atracurium, vecuronium or pancuronium] Ebeling BJ, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun;31(5):304–8 (Eng. Abstr.) **(Ger)**

[Anesthesiologic management in cardiomyoplasty] Haussmann R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):488–91 (Eng. Abstr.) **(Ger)**

[Adrenergic beta receptors in anesthesia and intensive care medicine] Heesen M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Mar; 31(2):62–71 (154 ref.) (Eng. Abstr.) **(Ger)**

[Etomidate versus propofol for anesthesia in ambulatory cardioversion] Kick O, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):288–92 (Eng. Abstr.) **(Ger)**

[Medicamentous prevention of acid aspiration syndrome] Kurz-Müller K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):261–5 (77 ref.) **(Ger)**

[Laparoscopic surgery—surgical and anesthesiological status (editorial)] Larsen R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):436–7 **(Ger)**

[Antagonists in anesthesia] Lauven PM, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):331–6 (34 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of aspiration of gastric contents] Müller E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):265–9 (24 ref.) **(Ger)**

[Effect of halothane, enflurane and isoflurane on the pharmacodynamics of mivacurium in children] Neidhart G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):293–7 (Eng. Abstr.) **(Ger)**

[Postoperative mediastinal and subcutaneous emphysema after intubation narcosis] Obenhaus T. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):318–20 (Eng. Abstr.) **(Ger)**

[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery] Schüttler J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):341–9 (Eng. Abstr.) **(Ger)**

[Clinical potency of nitrous oxide—is MAC the gold standard?] Schwilden H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):337–40 (23 ref.) (Eng. Abstr.) **(Ger)**

[Clonidine increases the anesthetic effectiveness of thiopental] Tonner PH, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):357–60 (Eng. Abstr.) **(Ger)**

[Do general anesthetics act on specific receptors?] Urban BW, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct;30(6):375–82 (55 ref.) (Eng. Abstr.) **(Ger)**

[Anesthesiologic procedures in laparoscopic cholecystectomy] Wilhelm W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):450–4 (18 ref.) **(Ger)**

[Anesthesiology and intensive care medicine in geriatric gynecologic surgery] Jaeger M, et al. **Arch Gynecol Obstet** 1995;257(1–4):57–68 **(Ger)**

–Complications of hysteroscopy and laparoscopy from the anesthesiologic viewpoint– Zollinger A. **Arch Gynecol Obstet** 1995;256 Suppl:S12–20 (25 ref.) **(Ger)**

[ENT anesthesia: the German Society of Anesthesia and Intensive Care Medicine on the use of succinylcholine (comment)] **HNO** 1995 Nov;43(11):640–1. Comment on: HNO 1995 Nov;43(11):676–9. **(Ger)**

[Risk assessment before elective visceral surgery interventions] Klotz HP, et al. **Swiss Surg** 1995;(3):136–9 (Eng. Abstr.) **(Ger)**

[Preoperative assessment in an area without continuous medical anesthesia service] Scharplatz D. **Swiss Surg** 1995; (3):162–4 (Eng. Abstr.) **(Ger)**

[Preoperative assessment from the viewpoint of the anesthetist (editorial)] Scheidegger D. **Swiss Surg** 1995; (3):128–9 **(Ger)**

[Complications of patient positioning] Staender S. **Swiss Surg** 1995;(3):152–5 (16 ref.) (Eng. Abstr.) **(Ger)**

[The use of Dormicum in general anesthesia for oral surgery] Judit J, et al. **Fogorv Sz** 1995 Dec;88(12):399–403 (Eng. Abstr.) **(Hun)**

[Balanced anesthesia—historical aspect] Dohi S. **Masui** 1995; 44 Suppl:S141–3; discussion S147–8 (10 ref.) **(Jpn)**

[Anesthetic management of patients with Young's syndrome]

Fujiwara M, et al. **Masui** 1995 Dec;44(12):1695–9 (Eng. Abstr.) **(Jpn)**

[Anesthetic and postoperative care of a patient with Crigler–Najjar syndrome type II] Hamada T, et al. **Masui** 1996 Mar;45(3):345–7 (Eng. Abstr.) **(Jpn)**

[Cardiovascular interaction and anesthesia] Hoka S. **Masui** 1995;44 Suppl:S52–8 (15 ref.) **(Jpn)**

[Bronchospasm during anesthesia in a patient with Prader–Willi syndrome] Kawahito S, et al. **Masui** 1995 Dec;44(12):1675–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

[HELP syndrome and anesthetic management] Kinouchi K, et al. **Masui** 1996 May;45(5):617–23 (Eng. Abstr.) **(Jpn)**

[Anesthesia with transesophageal echocardiography for removal of pheochromocytoma] Matsuura T, et al. **Masui** 1995 Oct;44(10):1388–90 (Eng. Abstr.) **(Jpn)**

[Effects of amrinon and prostaglandin E1 on intraoperative central and peripheral temperatures during peripheral arterial surgery] Nonaka A, et al. **Masui** 1996 May; 45(5):576–81 (Eng. Abstr.) **(Jpn)**

[Anesthesia for hepatectomy in a patient with glycogen storage disease] Ogawa M, et al. **Masui** 1995 Dec; 44(12):1703–6 (Eng. Abstr.) **(Jpn)**

[Four cases of noncardiac surgery after PTCA] Sengoku S, et al. **Masui** 1995 Oct;44(10):1396–400 (Eng. Abstr.) **(Jpn)**

[Anesthesia for cesarean section in a patient with intracranial A–V malformation] Terao M, et al. **Masui** 1995 Dec; 44(12):1700–2 (Eng. Abstr.) **(Jpn)**

[Calcitonin gene-related peptide and human atrial natriuretic hormone levels in response to cardiac operation under high dose fentanyl anesthesia] Terazawa E, et al. **Masui** 1995 Sep;44(9):1202–7 (Eng. Abstr.) **(Jpn)**

[Changes in dementia rating scale scores of elderly patients with femoral neck fracture during perioperative period] Wajima Z, et al. **Masui** 1995 Nov;44(11):1489–97 (Eng. Abstr.) **(Jpn)**

[Extracorporeal circulation for removal of carcinoma of the lung invading the left atrium] Wake M, et al. **Masui** 1995 Dec;44(12):1671–4 (Eng. Abstr.) **(Jpn)**

[Anesthetic experiences in 3 patients with multiple myeloma] Wake M, et al. **Masui** 1995 Sep;44(9):1282–4 (Eng. Abstr.) **(Jpn)**

[Intraoperative changes in blood lactate level and body temperature in younger and elderly adults] Yamada T, et al. **Masui** 1995 Aug;44(8):1102–6 (Eng. Abstr.) **(Jpn)**

[The utility of thermistor attached tracheal tube for pediatric patients in cardiac surgery] Yamauchi M, et al. **Masui** 1995 Aug;44(8):1159–64 (Eng. Abstr.) **(Jpn)**

[Balanced anesthesia with epidural anesthesia] Yuge O, et al. **Masui** 1995;44 Suppl:S153–5; discussion S156–7 (13 ref.) **(Jpn)**

[Central and cerebral hemodynamics during general anesthesia in intracranial interventions in a sitting position] Polushin IuS, et al. **Anesteziol Reanimatol** 1995 Jul–Aug; (4):41–4 (Eng. Abstr.) **(Rus)**

[Comparison of changes in plasma concentrations of ACTH and beta-endorphin in cholecystectomy under general anesthesia and general plus epidural anesthesia] Caba F, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):364–8 (Eng. Abstr.) **(Spa)**

[Anesthesia preferences among the medical population (letter)] Isla-Baranda A, et al. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):117 **(Spa)**

ADVERSE EFFECTS

Postoperative complaints after spinal and thiopentone–isoflurane anaesthesia in patients undergoing orthopaedic surgery. Spinal versus general anaesthesia. Standl T, et al. **Acta Anaesthesiol Scand** 1996 Feb; 40(2):222–6

Prolonged unilateral lower limb paresis following abdominal surgery with epidural and general anaesthesia. Lyons B, et al. **Anaesth Intensive Care** 1995 Aug;23(4):507–9

Postoperative morbidity following cataract surgery. A comparison of local and general anaesthesia. Barker JP, et al. **Anaesthesia** 1996 May;51(5):435–7

The effect of passive smoking on the incidence of airway complications in children undergoing general anaesthesia. Lyons B, et al. **Anaesthesia** 1996 Apr;51(4):324–6

Renal and hepatic function in surgical patients after low-flow sevoflurane or isoflurane anesthesia. Bito H, et al. **Anesth Analg** 1996 Jan;82(1):173–6

Anesthetic hazards in a previously unsuspected case of posterior mediastinal paraganglioma. Mitra S, et al. **Anesth Analg** 1995 Nov;81(5):1097–8

Coagulopathies in patients after transurethral resection of the prostate: spinal versus general anesthesia [see comments] Smyth R, et al. **Anesth Analg** 1995 Oct;81(4):680–5. Comment in: Anesth Analg 1996 Jul;83(1):195.

Illicit cocaine ingestion during anesthesia. Bernards CM, et al. **Anesthesiology** 1996 Jan;84(1):218–20

Cardiac outcome after peripheral vascular surgery. Comparison of general and regional anesthesia [see comments] Bode RH Jr, et al. **Anesthesiology** 1996 Jan; 84(1):3–13. Comment in: Anesthesiology 1996 Jan;84(1):1–2. Comment in: Anesthesiology 1996 Jul;85(1):224–5.

Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. Daniel M, et al. **Anesthesiology** 1996 Jan;84(1):75–80

Postoperative onset of idiopathic brachial neuritis. Fibuch EE, et al. **Anesthesiology** 1996 Feb;84(2):455–8

Cardiac outcomes after regional or general anesthesia. Do we have the answer? [editorial; comment] [see comments] Go AS, et al. **Anesthesiology** 1996 Jan;84(1):1–2. Comment on: Anesthesiology 1996 Jan;84(1):3–13. Comment in: Anesthesiology 1996 Jul;85(1):224–5.

Propofol and postoperative pancreatitis. Leisure GS, et al. **Anesthesiology** 1996 Jan;84(1):224–7

General anaesthesia as a factor releasing pseudomyasthenic syndrome. Pilarczyk M, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:115–8

Dental injuries during general anaesthesia [letter] Field JM. **Br Dent J** 1996 Jul 6;181(1):11

Mortality and morbidity in general anaesthesia [letter] Holden CG, et al. **Br Dent J** 1996 Apr 20;180(8):286

Preoperative infusion of amino acids prevents postoperative hypothermia. Selldén E, et al. **Br J Anaesth** 1996 Feb; 76(2):227–34

Unintentional intraoperative awareness during sufentanil anaesthesia for cardiac surgery. Gilron I, et al. **Can J Anaesth** 1996 Mar;43(3):295–8

Anaesthesiology. Schoeffler P, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):262–4

Dapsone-induced methemoglobinemia: an anesthetic risk. Szeremeta W, et al. **Int J Pediatr Otorhinolaryngol** 1995 Aug;33(1):75–80

Post-anesthesia uncal herniation secondary to a previously unsuspected temporal glioma. Vender JR, et al. **J Forensic Sci** 1995 Sep;40(5):900–2

Psychogenic coma after use of general anesthesia for ethmoidectomy. Weber JG, et al. **Mayo Clin Proc** 1996 Aug;71(8):797–800

Acute lung injury following lung resection: is one lung anaesthesia to blame? [editorial] Williams EA, et al. **Thorax** 1996 Feb;51(2):114–6 (41 ref.)

Iatrogenic acute angle closure glaucoma masked by general anaesthesia and intensive care. Lotery AJ, et al. **Ulster Med J** 1995 Oct;64(2):178–80

[Hypotension during anesthesia induction in a young patient] Boucher JM, et al. **Union Med Can** 1995 Mar;124(1):20–2 **(Fre)**

[Pidotimod, a new biological response modifier, is able to partially prevent immune response changes related to surgical stress] Pasqui AL, et al. **Drugs Exp Clin Res** 1993; 19 Suppl:45–53 **(Ita)**

[Intraoperative acute myocardial infarction during total gastrectomy under general anesthesia combined with thoracic epidural anesthesia] Ishiyama T, et al. **Masui** 1996 Apr;45(4):449–52 (Eng. Abstr.) **(Jpn)**

[Subdural catheterization uncovered by severe hypotension during epidural plus general anesthesia] Okuyama A, et al. **Masui** 1995 Oct;44(10):1373–6 (Eng. Abstr.) **(Jpn)**

[Permanent paraplegia following epidural and general anesthesia: two case reports] Uefuji T, et al. **Masui** 1996 Apr;45(4):453–7 (Eng. Abstr.) **(Jpn)**

[Diabetes insipidus. A possibly life-threatening condition during anesthesia] Brink M, et al. **Lakartidningen** 1995 Nov 1;92(44):4098–9 **(Swe)**

[Lung collapse. A common phenomenon during anesthesia] Hedenstierna G, et al. **Lakartidningen** 1996 Jun 12; 93(24):2323–5 **(Swe)**

CLASSIFICATION

[Attempt at a definition of the individual anesthesia level by repetitive pain stimulation: correlation with EEG findings] Entholzner E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):155–62 (Eng. Abstr.) **(Ger)**

CONTRAINDICATIONS

[Preoperative risk assessment of children with Duchenne muscular dystrophy and relevance for anesthesia and intra- and postoperative course] Wollinsky KH, et al. **Med Klin** 1996 Apr 12;91 Suppl 2:34–7 (Eng. Abstr.) **(Ger)**

ECONOMICS

Practical cost-effective choices: ambulatory general anesthesia. Philip BK. **J Clin Anesth** 1995 Nov;7(7):606–13 (31 ref.)

HISTORY

Thiopentone anaesthesia at Pearl Harbor [see comments] Bennetts FE. **Br J Anaesth** 1995 Sep;75(3):366–8. Comment in: Br J Anaesth 1995 Dec;75(6):823.

[The "narcotization statistics" of Ernst Julius Gurlt of 1895—an early contribution to quality control in anesthesia] Röse W. **Anaesthesiol Reanim** 1995;20(6):157–61 (Eng. Abstr.) **(Ger)**

[Origins of preoperative fasting] Goerig M. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):245–8 **(Ger)**

[Comment on: Legal outcome of crime under anesthesia (letter; comment)] Panning B. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):461. Comment on: Anasthesiol Intensivmed Notfallmed Schmerzther 1994 Dec;29(8):510–1. **(Ger)**

[A 100-year-old transatlantic contribution to anesthesiologic quality control] Röse W. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):511–5 (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

A study of the incorrect use of ventilator disconnection alarms. Campbell RM, et al. **Anaesthesia** 1996 Apr; 51(4):369–70

An evaluation of the Universal PAC and Oxford Miniature Vaporizers for paediatric field anaesthesia. Craig GR, et al. **Anaesthesia** 1995 Sep;50(9):789–93

The Ohmeda Universal PAC drawover apparatus. A technical and clinical evaluation. Lunn DV, et al. **Anaesthesia** 1995 Oct;50(10):870–4

Mechanical chin support during general anesthesia [letter] Aranda M, et al. **Anesth Analg** 1996 Feb;82(2):431

Defective carbon dioxide absorber as a cause for a leak in a breathing circuit [letter] Kshatri AM, et al. **Anesthesiology** 1996 Feb;84(2):475–6

Intelligent monitor for an anesthesia breathing circuit. Narus SP, et al. **Proc Annu Symp Comput Appl Med Care** 1995; :96–100

Use of the laryngeal mask in off-floor anesthesia for hepatic angiography in pediatric liver transplant candidates. Fung ST, et al. **Transplant Proc** 1996 Jun;28(3):1723–4

[Evaluating error values of pressure measuring systems and their clinical relevance] Albrecht DM, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(1 Suppl):S2–5 **(Ger)**

[Capnography for bronchoscopy with rigid technique using high frequency jet ventilation (HFJV) (see comments)] Klein U, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):276–82 (Eng. Abstr.). Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug;30(5):265–7. **(Ger)**

METHODS

The laryngeal mask airway—another trick [letter] Adejumo SW, et al. **Anaesthesia** 1996 Jun;51(6):604

Anaesthesia and partial deletion of chromosome 4 [letter] Dearlove OR, et al. **Anaesthesia** 1996 Feb;51(2):206

A prospective study of anaesthesia for quinsy tonsillectomy. Fagan JJ, et al. **Anaesthesia** 1995 Sep;50(9):783–5

Assessment of recovery following day-case arthroscopy. A comparison between propofol and isoflurane-based anaesthesia. Gupta A, et al. **Anaesthesia** 1995 Nov; 50(11):937–42

Anaesthetic management in maple syrup urine disease. Kahraman S, et al. **Anaesthesia** 1996 Jun;51(6):575–8

Anaesthesia in a child with Patau's syndrome. Martlew RA, et al. **Anaesthesia** 1995 Nov;50(11):980–2

Review of uses of the laryngeal mask in ENT anaesthesia [see comments] Nair I, et al. **Anaesthesia** 1995 Oct; 50(10):898–900 (27 ref.). Comment in: Anaesthesia 1996 Apr;51(4):409.

Anaesthesia for quinsy tonsillectomy [letter] Ravalia A, et al. **Anaesthesia** 1996 Mar;51(3):292–3

Anaesthesia for cardioversion. Stoneham MD. **Anaesthesia** 1996 Jun;51(6):565–70 (69 ref.)

Anaesthesia for Cockayne syndrome. Three case reports. Wooldridge WJ, et al. **Anaesthesia** 1996 May;51(5):478–81

Inhalation agents: a young anesthetist's dilemma [letter] Geiser JF. **Anesth Analg** 1996 Apr;82(4):896

Propofol–opioid mixtures during prolonged infusions [letter] Ghouri AF, et al. **Anesth Analg** 1996 Apr;82(4):888–9

The use of heliox and the laryngeal mask airway in a child with an anterior mediastinal mass. Polaner DM. **Anesth Analg** 1996 Jan;82(1):208–10

Efficacy of epidural test doses? [letter; comment] Ware PD, et al. **Anesth Analg** 1996 Jun;82(6):1304–5. Comment on: Anesth Analg 1995 Nov;81(5):987–92.

Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. Daniel M, et al. **Anesthesiology** 1996 Jan;84(1):75–80

General anesthesia in a child with a dynamic, vascular anterior mediastinal mass. Furst SR, et al. **Anesthesiology** 1996 Apr;84(4):976–9

Prediction of movement during propofol/nitrous oxide anesthesia. Performance of concentration, electroencephalographic, pupillary, and hemodynamic indicators. Leslie K, et al. **Anesthesiology** 1996 Jan; 84(1):52–63

Hemodynamic responses to intravascular injection of epinephrine-containing epidural test doses in adults during general anesthesia. Liu SS, et al. **Anesthesiology** 1996 Jan; 84(1):81–7

Anaesthetic implications of aortic stent surgery [see comments] Greiff JM, et al. **Br J Anaesth** 1995 Dec; 75(6):779–81. Comment in: Br J Anaesth 1996 Jun;76(6):882–3.

Difficult laryngoscopy in cleft lip and palate surgery [see comments] Gunawardana RH. **Br J Anaesth** 1996 Jun; 76(6):757–9. Comment in: Br J Anaesth 1996 Jun;76(6):755–6.

Airway management in cleft lip and palate surgery [editorial; comment] Hatch DJ. **Br J Anaesth** 1996 Jun;76(6):755–6 . Comment on: Br J Anaesth 1996 Jun;76(6):757–9.

Airway management for patients with a tracheal bronchus. Ikeno S, et al. **Br J Anaesth** 1996 Apr;76(4):573–5

Treacher Collins syndrome [letter; comment] Gomersall CD, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):175. Comment on: Br J Hosp Med 1995 Apr 19–May 2;53(8):419.

Anaesthesia for heart transplantation. Hussain A.

Br J Hosp Med 1995 Nov 1–14;54(9):466–8 (5 ref.)
Anaesthesia for cerebral aneurysm surgery. Nathanson M, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):405–8 (12 ref.)
Twelve hour anaesthesia in a patient with epidermolysis bullosa. Yonker-Sell AE, et al. **Can J Anaesth** 1995 Aug; 42(8):735–9 (25 ref.)
General anesthesia with endotracheal intubation for cryotherapy for retinopathy of prematurity. Sullivan TJ, et al. **Eur J Ophthalmol** 1995 Jul–Sep;5(3):187–91
A new route, jet-injection for anesthetic induction in children: I. Midazolam dose-range finding studies. Zsigmond EK, et al. **Int J Clin Pharmacol Ther** 1995 Oct; 33(10):580–4
Intravenous trimethaphan during epidural plus general anesthesia decreases the direct radial artery pressure lower than the brachial artery pressure. Nagata N, et al. **J Clin Anesth** 1996 May;8(3):180–7
Clinical aspects of CRNA practice. General anesthesia. Ouellette SM. **Nurs Clin North Am** 1996 Sep;31(3):623–42 (102 ref.)
Anaesthetic management for ischiopagus tetrapus conjoined twins separation [letter] Clemessy JL, et al. **Paediatr Anaesth** 1996;6(2):160–2
Malignant hyperthermia susceptibility in patients with osteogenesis imperfecta [letter] Peluso A, et al. **Paediatr Anaesth** 1995;5(6):398–9
Anaesthesia for patients with trisomy 13 (Patau's syndrome). Pollard RC, et al. **Paediatr Anaesth** 1996;6(2):151–3
Effect of anesthetic technique on acute formalin-induced pain in mice. Fu ES, et al. **Reg Anesth** 1995 May–Jun; 20(3):217–21
Acute lung injury following lung resection: is one lung anaesthesia to blame? [editorial] Williams EA, et al. **Thorax** 1996 Feb;51(2):114–6 (41 ref.)
[Sluder's adenotonsillectomy: with or without endotracheal intubation?] Mulder JJ, et al. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2730–2 (Eng. Abstr.) **(Dut)**
[Does outpatient general anesthesia fulfill all expectations? (editorial)] Lindgren L, et al. **Duodecim** 1995;111(9):815–7 **(Fin)**
[Anesthesia and intensive care of subarachnoid hemorrhage. A survey on practice in 32 centres] Audibert G, et al. **Ann Fr Anesth Reanim** 1996;15(3):338–41 (Eng. Abstr.) **(Fre)**
[General anesthesia in a patient with catecholaminergic polymorph ventricular tachycardia] Bing J, et al. **Ann Fr Anesth Reanim** 1995;14(3):289–92 (Eng. Abstr.) **(Fre)**
[Anesthesia and critical care for endovascular occlusion of ruptured intracranial aneurysms with electrically detachable coils] Krivosic-Horber R, et al. **Ann Fr Anesth Reanim** 1996;15(3):354–8 (Eng. Abstr.) **(Fre)**
[Sluder tonsillectomy in children: can intratracheal intubation be discussed? (letter)] Lebrun T, et al. **Ann Fr Anesth Reanim** 1995;14(3):311–2 **(Fre)**
[Laparoscopic cholecystectomy in a patient with Steinert disease] Mercier MF, et al. **Ann Fr Anesth Reanim** 1996; 15(3):310–2 (Eng. Abstr.) **(Fre)**
[Tracheal compression by mediastinal mass in children. Value of fiberoptic tracheobronchoscopy for anesthetic management] Monrigal JP, et al. **Ann Fr Anesth Reanim** 1995;14(2):225–9 (Eng. Abstr.) **(Fre)**
[Continuous administration of mivacurium for short procedures. Delayed onset and recovery from neuromuscular blockade] Pellissier D, et al. **Ann Fr Anesth Reanim** 1995;14(6):467–71 (Eng. Abstr.) **(Fre)**
[Curarization in surgery for strabismus in children: what is it worth? (letter)] Zenner C, et al. **Ann Fr Anesth Reanim** 1995;14(4):376 **(Fre)**
[Effects of preoxygenation methods on the course of PaO2 and PaCO2 in anesthetic post-induction apnea] Fleureaux O, et al. **Can Anesthesiol** 1995;43(4):367–70 (Eng. Abstr.) **(Fre)**
[Pediatric anesthesia: introduction] Bissonnette B, et al. **Rev Med Suisse Romande** 1996 Apr;116(4):233 **(Fre)**
[Hospital day-surgery: comparative evaluation of 3 general anesthesia techniques] Rossi AE, et al. **Minerva Anestesiol** 1995 Jun;61(6):265–9 (Eng. Abstr.) **(Ita)**
[General anesthesia for expandable endotracheobronchial metal stent insertion] Fujii K, et al. **Masui** 1996 Apr; 45(4):464–70 (Eng. Abstr.) **(Jpn)**
[Effectiveness of the J-shaped LMA-holding forceps—F-forceps for LMA insertion] Fukuhara T. **Masui** 1995 Nov;44(11):1568–75 (Eng. Abstr.) **(Jpn)**
[Anesthetic management of a patient with ornithine transcarbamylase deficiency] Iida R, et al. **Masui** 1996 May; 45(5):642–5 (Eng. Abstr.) **(Jpn)**
[Anesthetic management of a patient with cardiac sarcoidosis] Iwashita H, et al. **Masui** 1995 Dec;44(12):1692–4 (Eng. Abstr.) **(Jpn)**
[Anesthetic management for laparoscopic cholecystectomy in a patient with dilated cardiomyopathy] Nomura K, et al. **Masui** 1995 Aug;44(8):1118–23 (Eng. Abstr.) **(Jpn)**
[Use of a laryngeal mask airway for anesthesia in a patient with bronchomalacia] Yamaguchi S, et al. **Masui** 1996 Mar; 45(3):348–51 (Eng. Abstr.) **(Jpn)**
[The central hemodynamic changes and reaction of the sympathoadrenal system with the use of an original Russian analgesic fenaridin as the analgetic component of general anesthesia during aortocoronary bypass operations in patients with chronic ischemic heart disease] Tenshibaeva DA, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):51–5 (Eng. Abstr.) **(Rus)**
[Implantable automatic cardioverter-defibrillator: anesthesia experience] Izquierdo E, et al. **Rev Esp Anestesiol Reanim** 1995 Dec;42(10):424–7 (Eng. Abstr.) **(Spa)**
[Application of the laryngeal mask in pediatric anesthesiology] López Gil T, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):332–5 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Patient satisfaction with general anaesthesia. Too difficult to measure? Whitty PM, et al. **Anaesthesia** 1996 Apr; 51(4):327–32
Psychological and hypnotic preparation for anesthesia and surgery: an individual differences perspective. Kessler R, et al. **Int J Clin Exp Hypn** 1996 Jul;44(3):189–207 (60 ref.)
Spinal phobia: survey results of patient attitudes and preferences regarding anesthesia. Sosis MB, et al. **J Clin Anesth** 1995 Aug;7(5):389–94
Factors associated with mothers selecting general anesthesia for lower segment caesarean section. Holdcroft A, et al. **J Psychosom Obstet Gynaecol** 1995 Sep;16(3):167–70
[Awareness during general anesthesia. Definition, incidence, clinical relevance, causes, avoidance and medicolegal aspects] Schwender D, et al. **Anaesthesist** 1995 Nov; 44(11):743–54 (84 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Anaesthesia for electroconvulsive therapy. Personnel and facilities. Lee D, et al. **Anaesthesia** 1996 Jun;51(6):583–4
Anaesthesia for caesarean section (epidural and general): effects on the neonate. Dick WF. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S61–7 (42 ref.)
[Assessment of the adequacy of anesthesia] Yli-Hankala A. **Duodecim** 1994;110(2):133–8 **(Fin)**

STATISTICS & NUMERICAL DATA

Demand for dental extractions performed under general anaesthesia for children by Leicestershire Community Dental Service. Landes DP, et al. **Community Dent Health** 1996 Jun;13(2):105–10

UTILIZATION

The use of general anaesthesia for tooth extraction in young handicapped adults in France. Maestre C. **Br Dent J** 1996 Apr 20;180(8):297–302

VETERINARY

Anaesthetics for general anaesthesia in growing pigs. Henrikson H, et al. **Acta Vet Scand** 1995;36(4):401–11
Evaluation of propofol for general anesthesia in premedicated horses. Mama KR, et al. **Am J Vet Res** 1996 Apr; 57(4):512–6
Anesthesia induced in pigs by use of a combination of medetomidine, butorphanol, and ketamine and its reversal by administration of atipamezole. Sakaguchi M, et al. **Am J Vet Res** 1996 Apr;57(4):529–34
Confidential enquiry of perioperative equine fatalities (CEPEF-1): preliminary results. Johnston GM, et al. **Equine Vet J** 1995 May;27(3):193–200
Evaluation of five common induction protocols by comparison of hemodynamic responses to surgical manipulation in halothane-anesthetized horses. Wagner AE, et al. **J Am Vet Med Assoc** 1996 Jan 15;208(2):252–7
Cardiovascular changes associated with anaesthesia induced by medetomidine combined with ketamine in cats. Dobromylskyj P. **J Small Anim Pract** 1996 Apr; 37(4):169–72
A transport and monitoring unit for piglets under general anaesthesia. Søfteland E, et al. **Lab Anim** 1995 Jul; 29(3):282–5
Ventricular arrhythmogenic dose of adrenaline during sevoflurane, isoflurane, and halothane anaesthesia either with or without ketamine or thiopentone in cats. Hikasa Y, et al. **Res Vet Sci** 1996 Mar;60(2):134–7

ANESTHESIA, INFILTRATION see **ANESTHESIA, LOCAL**

ANESTHESIA, INHALATION

Peripheral blood flow in the elderly during inhalational anaesthesia. Dwyer R, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):939–44
Hypoxic and hypercapnic ventilatory responses during isoflurane sedation and anaesthesia in women. Sollevi A, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):931–8
Ventilatory responses to hypoxia and hypercapnia during inhalation anaesthesia and subparalytical muscle relaxation in humans [see comments] Lindahl SG. **Acta Anaesthesiol Sin** 1995 Dec;33(4):223–6 (13 ref.). Comment in: Acta Anaesthesiol Sin 1995 Dec;33(4):i–ii.
Comparison of total intravenous, balanced inhalational and combined intravenous-inhalational anaesthesia for tympanoplasty, septorhinoplasty and adenotonsillectomy. Van den Berg AA, et al. **Anaesth Intensive Care** 1995 Oct; 23(5):574–82
The effect of a cervical collar on the tidal volume of anaesthetised adult patients. Dodd FM, et al. **Anaesthesia** 1995 Nov;50(11):961–3
Effect of general anaesthesia and surgery on neutrophil function. Khan FA, et al. **Anaesthesia** 1995 Sep; 50(9):769–75
Sevoflurane versus isoflurane in single-breath induction [letter] Abramson DC, et al. **Anesth Analg** 1996 Sep; 83(3):662
Cortical reactivity during isoflurane burst-suppression anesthesia. Hartikainen KM, et al. **Anesth Analg** 1995 Dec; 81(6):1223–8
The comparative effects of sevoflurane versus propofol in the induction and maintenance of anesthesia in adult patients. Jellish WS, et al. **Anesth Analg** 1996 Mar; 82(3):479–85
Sevoflurane in pediatric anesthesia. Lerman J. **Anesth Analg** 1995 Dec;81(6 Suppl):S4–10 (47 ref.)
Spondyloepiphyseal dysplasia congenita syndrome: anesthetic implications [letter] Mogera C, et al. **Anesth Analg** 1996 Aug;83(2):433–4
The effect of halothane on phrenic and chemoreceptor responses to hypoxia in anesthetized kittens. Morray JP, et al. **Anesth Analg** 1996 Aug;83(2):329–35
Sevoflurane versus desflurane for outpatient anesthesia: a comparison of maintenance and recovery profiles. Nathanson MH, et al. **Anesth Analg** 1995 Dec;81(6):1186–90
Inorganic fluoride kinetics and renal tubular function after sevoflurane anesthesia in chronic renal failure patients receiving hemodialysis. Nishiyama T, et al. **Anesth Analg** 1996 Sep;83(3):574–7
Posterior hypothalamic noradrenaline release during emergence from sevoflurane anesthesia in rats. Ohkawa H, et al. **Anesth Analg** 1995 Dec;81(6):1289–91
A multicenter comparison of maintenance and recovery with sevoflurane or isoflurane for adult ambulatory anesthesia. The Sevoflurane Multicenter Ambulatory Group. Philip BK, et al. **Anesth Analg** 1996 Aug;83(2):314–9
Preventing desaturation during single-lung anesthesia [letter] Sheinbaum R. **Anesth Analg** 1996 May;82(5):1107
The role of sevoflurane in outpatient anesthesia. Smith I, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S67–72 (24 ref.)
Hemodynamic effects of intravenous ephedrine in infants and children anesthetized with halothane and nitrous oxide. Taguchi N, et al. **Anesth Analg** 1996 Mar;82(3):568–73
Isoflurane anesthesia does not add to the bronchodilating effect of a beta 2-adrenergic agonist after tracheal intubation. Wu RS, et al. **Anesth Analg** 1996 Aug; 83(2):238–41
Quantitation of depth of thiopental anesthesia in the rat. Gustafsson LL, et al. **Anesthesiology** 1996 Feb;84(2):415–27
Desflurane and isoflurane exert modest beneficial actions on left ventricular diastolic function during myocardial ischemia in dogs. Pagel PS, et al. **Anesthesiology** 1995 Nov; 83(5):1021–35
Diagnosis of congenital bronchoesophageal fistula during anesthesia [letter; comment] Saldanha R, et al. **Ann Thorac Surg** 1996 Jun;61(6):1875–6. Comment on: Ann Thorac Surg 1995 Apr;59(4):887–9; discussion 890. Comment on: Ann Thorac Surg 1995 Jul;60(1):151–5.
Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. McCoy EP, et al. **Br J Anaesth** 1996 Jan;76(1):29–33
Sevoflurane-nitrous oxide or halothane-nitrous oxide for paediatric bronchoscopy and gastroscopy. Meretoja OA, et al. **Br J Anaesth** 1996 Jun;76(6):767–71
Analysis of ethanol in expired air during low-flow isoflurane anaesthesia. Olsson J, et al. **Br J Anaesth** 1996 Jan; 76(1):85–9
Surgical stimulation increases median nerve somatosensory evoked responses during isoflurane-nitrous oxide anaesthesia. Rundshagen I, et al. **Br J Anaesth** 1995 Nov; 75(5):598–602
Effects of surgical skin incision on respiration in patients anaesthetized with enflurane. Sutherland RW, et al. **Br J Anaesth** 1996 Jun;76(6):777–9
Eisenmenger's syndrome and problems with anaesthesia. Jones P, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):214
The choice of anaesthetic for carotid endarterectomy: does it matter? [editorial] Archer DP, et al. **Can J Anaesth** 1995 Jul;42(7):566–70 **(Eng, Fre)**
Haemodynamic instability and myocardial ischaemia during carotid endarterectomy: a comparison of propofol and isoflurane. Mutch WA, et al. **Can J Anaesth** 1995 Jul; 42(7):577–87
Decreased hypothalamic prostaglandin D2 and prostaglandin E2 contents during isoflurane anaesthesia in rats. Sato T, et al. **Can J Anaesth** 1995 Nov;42(11):1031–4
Effects of enflurane and isoflurane anesthesia on the pharmacokinetics of pancuronium in adult patients. Xue F, et al. **Chin Med J (Engl)** 1996 Mar;109(3):233–7
Breathing routes and inhalational induction of anaesthesia [editorial; comment] Campbell IT. **Eur J Anaesthesiol** 1996 Jan;13(1):1–2. Comment on: Eur J Anaesthesiol 1996 Jan;13(1):21–6.
A comparison between total intravenous anaesthesia using a propofol/alfentanil mixture and an inhalational technique for laparoscopic gynaecological sterilization. Collins SJ, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):33–7

A comparison of intravenous and inhalational maintenance anaesthesia for endoscopic procedures in the aspirin intolerance syndrome. Novak-Jankovič V, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):345–9

Adaptive segmentation of burst-suppression pattern in isoflurane and enflurane anesthesia. Lipping T, et al. **Int J Clin Monit Comput** 1995;12(3):161–7

Desflurane controls the hemodynamic response to surgical stimulation more rapidly than isoflurane. Bennett JA, et al. **J Clin Anesth** 1995 Jun;7(4):288–91

Intraoperative EEG changes in relation to the surgical procedure during isoflurane–nitrous oxide anesthesia: hysterectomy versus mastectomy. Bischoff P, et al. **J Clin Anesth** 1996 Feb;8(1):36–43

Pressure support improves efficiency of spontaneous breathing during inhalation anesthesia. Bosek V, et al. **J Clin Anesth** 1996 Feb;8(1):9–12

Comparison of sevoflurane and halothane anesthesia in children undergoing outpatient ear, nose, and throat surgery. Greenspun JC, et al. **J Clin Anesth** 1995 Aug; 7(5):398–402

Cardiovascular reflexes during anesthesia induction and tracheal intubation in elderly patients: the influence of thoracic epidural anesthesia. Licker M, et al. **J Clin Anesth** 1995 Jun;7(4):281–7

Patient simulator identifies faulty H-cylinder. Euliano TY, et al. **J Clin Monit** 1995 Nov;11(6):394–5

Suppression of spinal and cortical somatosensory evoked potentials by desflurane anesthesia. Haghighi SS, et al. **J Neurosurg Anesthesiol** 1996 Apr;8(2):148–53

Nitrous oxide compared with intravenous regional anesthesia in pediatric forearm fracture manipulation. Gregory PR, et al. **J Pediatr Orthop** 1996 Mar–Apr;16(2):187–91

General anesthesia with and without nitrous oxide (N2O) and the weight of middle ear effusion in children undergoing adenoidectomy and tympanostomy. Koivunen P, et al. **Laryngoscope** 1996 Jun;106(6):724–6

Hemodynamic and oxygenation variables during radical cystectomy. Does the anesthetic technique really matter? Atallah MM, et al. **Middle East J Anesthesiol** 1995 Jun; 13(2):157–74

Respiratory complications in children emerging from halothane anesthesia--awake vs deep extubation. Karam R, et al. **Middle East J Anesthesiol** 1995 Jun;13(2):221–9

Evaluation of different induction techniques for tracheal intubation. Merk HJ, et al. **Middle East J Anesthesiol** 1995 Feb;13(1):23–35

Sinus node recovery function is relatively well preserved under halothane anaesthesia in children. Iwai M, et al. **Paediatr Anaesth** 1995;5(4):233–6

Anaesthetic management of the Kenny-Caffey syndrome using the laryngeal mask. Janke EL, et al. **Paediatr Anaesth** 1996;6(3):235–8 (16 ref.)

Behavioural changes and children's memories after intravenous, inhalation and rectal induction of anaesthesia. Kotiniemi LH, et al. **Paediatr Anaesth** 1996;6(3):201–7

Sevoflurane in paediatric anaesthesia: effects on respiration and circulation during induction and recovery. Mori N, et al. **Paediatr Anaesth** 1996;6(2):95–102

Implicit memory for stimuli presented during inhalation anesthesia in children. Kalff AC, et al. **Psychol Rep** 1995 Oct;77(2):371–5

Determination of cardiorespiratory function and the optimum anesthetic regimen during laparoscopic surgery in the rat model. Dalton M, et al. **Surg Endosc** 1996 Mar; 10(3):297–300

Problems in extubation of endotracheal tube in anaesthesia in the West African sub-region. Soyanwo OA, et al. **West Afr J Med** 1995 Apr–Jun;14(2):124–6

Secretion of neutral and acid DNases in cultivated human lymphocytes after incubation with DNA; possible consequences for inhalation anesthesia. Reitz M, et al. **Z Naturforsch [C]** 1995 May–Jun;50(5–6):419–24

[Nasal catheters versus Hudson face mask in oxygen therapy] Lund J, et al. **Ugeskr Laeger** 1996 Jul 8;158(28):4077–9 (Eng. Abstr.) **(Dan)**

[Effect of halothane, enflurane and isoflurane on the pharmacodynamics of mivacurium in children] Neidhart G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):293–7 (Eng. Abstr.) **(Ger)**

[Clinical potency of nitrous oxide—is MAC the gold standard?] Schwilden H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):337–40 (23 ref.) (Eng. Abstr.) **(Ger)**

[Comparison of airway complications on tracheal extubation in deeply sevoflurane anesthetized versus awake children] Goyagi T, et al. **Masui** 1995 Sep;44(9):1242–5 (Eng. Abstr.) **(Jpn)**

[Anesthesia in a patient with history of multiple drug allergies] Horiguchi Y, et al. **Masui** 1995 Nov;44(11):1542–6 (Eng. Abstr.) **(Jpn)**

[Alterations of the brain stem and mid-latency evoked potentials under oxygen-nitrous oxide-sevoflurane anesthesia] Kadoi Y, et al. **Masui** 1995 Dec;44(12):1618–22 (Eng. Abstr.) **(Jpn)**

[Effects of nitrous oxide on electroencephalographic activity during sevoflurane anesthesia: a zero-crossing analysis] Kaneda T, et al. **Masui** 1995 Nov;44(11):1498–505 (Eng. Abstr.) **(Jpn)**

[An advanced anesthetic management for small children] Kitamura S, et al. **Masui** 1995;44 Suppl:S93–9 (27 ref.) **(Jpn)**

[The effects of sevoflurane and isoflurane on hepatic blood flow in man] Kobayashi M. **Masui** 1996 Mar;45(3):281–6 (Eng. Abstr.) **(Jpn)**

[Halothane concentration inhaled by anesthesiologists during anesthesia through face masks] Kojima Y. **Masui** 1995 Dec; 44(12):1667–70 (Eng. Abstr.) **(Jpn)**

[Anesthesia for funnel chest operation] Morimoto A, et al. **Masui** 1995 Oct;44(10):1377–80 (Eng. Abstr.) **(Jpn)**

[Arterial plasma keton body levels during isoflurane anesthesia and surgery] Murakawa T, et al. **Masui** 1995 Nov;44(11):1506–12 (Eng. Abstr.) **(Jpn)**

[Multiple regression analysis of pre- and intra-operative factors in relation to post-operative liver and renal functions] Tabo E, et al. **Masui** 1995 Nov;44(11):1482–8 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a Paget's disease patient complicated with Parkinson disease] Tomioka T, et al. **Masui** 1995 Oct;44(10):1384–7 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of Nd-YAG laser surgery in the airway using a larengeal mask] Yamaguchi S, et al. **Masui** 1995 Dec;44(12):1685–8 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a patient with congenital cystic adenomatoid malformation] Yamaguchi S, et al. **Masui** 1995 Dec;44(12):1689–91 (Eng. Abstr.) **(Jpn)**

[Effects of preoperatively administered flurbiprofen axetil on the action of inhaled anesthesia and postoperative pain] Yamazaki Y, et al. **Masui** 1995 Sep;44(9):1238–41 (Eng. Abstr.) **(Jpn)**

[Comparative assessment of the hormonal status during N2O and xenon anesthesia using similar methods] Burov NE, et al. **Anesteziol Reanimatol** 1995 Jul–Aug;(4):57–60 (Eng. Abstr.) **(Rus)**

[Reduction of the need for isoflurane and of postoperative pain with preanesthetic intrathecal morphine (letter; comment)] Sabaté A. **Rev Esp Anestesiol Reanim** 1995 Oct; 42(8):349–51. Comment on: Rev Esp Anestesiol Reanim 1995 Feb;42(2):41–6. **(Spa)**

ADVERSE EFFECTS

Epiglottitis after anaesthesia with a laryngeal mask. McKinney B, et al. **Anaesth Intensive Care** 1995 Oct; 23(5):618–9

Loss of alveolar macrophages during anesthesia and operation in humans. Kotani N, et al. **Anesth Analg** 1995 Dec;81(6):1255–62

The hemodynamic and renal effects of sevoflurane and isoflurane in patients with coronary artery disease and chronic hypertension. Sevoflurane Ischemia Study Group. Rooke GA, et al. **Anesth Analg** 1996 Jun;82(6):1159–65

Comparison of haemodynamic changes induced by sevoflurane and halothane in paediatric patients. Kawana S, et al. **Can J Anaesth** 1995 Jul;42(7):603–7

Effect of nitrous oxide on middle ear pressure: a comparison between inhalational anaesthesia with nitrous oxide and TIVA. Karabiyik L, et al. **Eur J Anaesthesiol** 1996 Jan; 13(1):27–32

Inhalation versus intravenous anesthesia: a fictitious debate between E.I. Eger II and P.F. White. Shafer SL, et al. **J Clin Anesth** 1996 May;8(3 Suppl):38S–41S

Vitamin B12 myeloneuropathy precipitated by nitrous oxide anaesthesia [letter] Nestor PJ, et al. **Med J Aust** 1996 Aug 5;165(3):174

[Anesthesia for celiosurgery] Schoeffler P, et al. **Ann Chir** 1995;49(10):878–80 (19 ref.) **(Fre)**

[Convulsive seizure after craniotomy--comparison of isoflurane anesthesia and sevoflurane anesthesia] Hashimoto K, et al. **Masui** 1995 Aug;44(8):1139–42 (Eng. Abstr.) **(Jpn)**

[A case of inspiratory unidirectional value malfunction detected by an abnormal capnogram pattern] Kono M, et al. **Masui** 1995 Oct;44(10):1406–9 (Eng. Abstr.) **(Jpn)**

HISTORY

Esmarch's mask. Ball C. **Anaesth Intensive Care** 1995 Jun; 23(3):273

The Schimmelbusch mask. Ball C. **Anaesth Intensive Care** 1995 Aug;23(4):417

Bellamy Gardner's open ether mask. Ball C. **Anaesth Intensive Care** 1995 Dec;23(6):665

Doctor Dee's ether apparatus. Sudarshan G, et al. **Anaesthesia** 1996 Feb;51(2):158–60

[150 years ether narcosis (1846–1996) (editorial)] Stoeckel H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Mar; 31(2):61 **(Ger)**

INSTRUMENTATION

The impact of heat and moisture exchanging humidifiers on work of breathing. Johnson PA, et al. **Anaesth Intensive Care** 1995 Dec;23(6):697–701

The circuit mount [letter] Sexton A. **Anaesth Intensive Care** 1995 Dec;23(6):754–5

Respiratory pattern and rebreathing in the Mapleson A, C and D breathing systems with spontaneous ventilation. A theory. Cook LB. **Anaesthesia** 1996 Apr;51(4):371–85

The importance of the expiratory pause. Comparison of the Mapleson A, C and D breathing systems using a lung model. Cook LB. **Anaesthesia** 1996 May;51(5):453–60

Inadvertent PEEP in a paediatric breathing system [letter] Jones RM. **Anaesthesia** 1996 Feb;51(2):203–4

Missing O-rings and volatile agents [letter] Nott MR, et al. **Anaesthesia** 1995 Nov;50(11):1001–2

Sudden increase in end-tidal nitrogen due to changing vaporizers. Pennant JH. **Anesth Analg** 1995 Dec; 81(6):1305–6

Nitrogen and CO2 monitoring. Storch J. **Biomed Instrum Technol** 1995 Jul–Aug;29(4):358–60

Pumping effect in Ohmeda Tec 5 vaporizers [letter] Loeb R, et al. **J Clin Monit** 1995 Sep;11(5):348

Do you know your MGVS? Or what do anesthesiologists know about their MGVS? Peterson TG. **J Clin Monit** 1995 Nov;11(6):415–6

An anaesthetic mask for use on guinea pigs (Cavia porcellus) in a stereotaxic frame: technical note. Klapwyk JC, et al. **Lab Anim** 1995 Oct;29(4):407–10

[Inhalation anesthesia in unusual situations: the Eole 2 NA ventilator] Neidhardt A, et al. **Cah Anesthesiol** 1996; 44(1):91–5 (Eng. Abstr.) **(Fre)**

[Improved climatization of anesthetic gases by modifying the Sulla 808 V anesthesia equipment] Kleemann PP. **Anaesthesiol Reanim** 1995;20(3):71–5 (Eng. Abstr.) **(Ger)**

[Water permeability of breathing filters] Frankenberger H, et al. **Anaesthesist** 1995 Aug;44(8):581–4 (Eng. Abstr.) **(Ger)**

[Prevention, diagnosis and therapy of intubation injury of the larynx (editorial; comment)] Schürg R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):279–80. Comment on: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Jun;31(5):281–7. **(Ger)**

[A case of inspiratory unidirectional value malfunction detected by an abnormal capnogram pattern] Kono M, et al. **Masui** 1995 Oct;44(10):1406–9 (Eng. Abstr.) **(Jpn)**

[Vaporizers in anesthesia] Uña R, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):392–8 **(Spa)**

METHODS

Inhalation anaesthesia at the extremes of age: geriatric anaesthesia. Conzen P, et al. **Anaesthesia** 1995 Oct;50 Suppl:29–33 (33 ref.)

The quality of breathing and capnography during laryngeal mask and facemask ventilation. Ivens D, et al. **Anaesthesia** 1995 Oct;50(10):858–62

Anaesthesia and Robinow syndrome [letter] Macdonald I, et al. **Anaesthesia** 1995 Dec;50(12):1097

Inhalational anaesthesia at the extremes of age: paediatric anaesthesia. Olsson GL. **Anaesthesia** 1995 Oct;50 Suppl:34–6 (21 ref.)

Factors affecting the production of carbon monoxide in inhalation anesthetic use [letter; comment] Callan CM. **Anesth Analg** 1996 Jun;82(6):1306–7. Comment on: Anesth Analg 1995 Jun;80(6):1187–93.

Sevoflurane versus isoflurane for maintenance of anesthesia: are serum inorganic fluoride ion concentrations of concern? Goldberg ME, et al. **Anesth Analg** 1996 Jun;82(6):1268–72

Sevoflurane versus isoflurane: induction and recovery characteristics with single-breath inhaled inductions of anesthesia. Sloan MH, et al. **Anesth Analg** 1996 Mar; 82(3):528–32

Simulation of an epidural test dose with intravenous isoproterenol in awake and in halothane-anesthetized children. Kozek-Langenecker S, et al. **Anesthesiology** 1996 Aug;85(2):277–80

Fuzzy logic control of inspired isoflurane and oxygen concentrations using minimal flow anaesthesia. Curatolo M, et al. **Br J Anaesth** 1996 Feb;76(2):245–50

Airway control in a patient with an unstable cervical fracture and delirium tremens. Harding D, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):59

Stridor in the small infant. Herbertson MJ, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):418

[Anaesthesia for esophageal reconstruction with abdominal viscera in non-thoracotomy] Yang W, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Aug;33(8):463–5 (Eng. Abstr.) **(Chi)**

[Anesthesia in hypertrophic pyloric stenosis] Moschini V, et al. **Minerva Anestesiol** 1995 Jun;61(6):259–64 (Eng. Abstr.) **(Ita)**

[Perioperative managements of a mentally retarded child with obstructive sleep apnea syndrome for adeno-tonsillectomy] Oohata H, et al. **Masui** 1996 Apr;45(4):458–63 (Eng. Abstr.) **(Jpn)**

[Anesthesia in a case of mitochondrial myopathy (letter)] Torres MD, et al. **Rev Esp Anestesiol Reanim** 1996 Mar; 43(3):114–5 **(Spa)**

[Patient with tricuspid atresia undergoing orthopedic surgery: anesthetic considerations] Vidal Marcos A, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):336–40 (Eng. Abstr.) **(Spa)**

VETERINARY

Effect of intravenous administration of fluids on packed cell volume, blood pressure, and total protein and blood glucose concentrations in healthy halothane-anesthetized dogs. Gaynor JS, et al. **J Am Vet Med Assoc** 1996 Jun 15; 208(12):2013–5

Anesthetic and postanesthetic management of sea turtles. Moon PF, et al. **J Am Vet Med Assoc** 1996 Mar 1; 208(5):720–6

Rapid inhalation induction of anesthesia by halothane, enflurane, isoflurane and sevoflurane and their cardiopulmonary effects in dogs. Mutoh T, et al. **J Vet Med Sci** 1995 Dec;57(6):1007–13

Clinical application of rapid inhalation induction of anesthesia using isoflurane and sevoflurane with nitrous oxide in dogs. Mutoh T, et al. **J Vet Med Sci** 1995 Dec;57(6):1121–4

Isoflurane as an inhalation anesthetic for muskrats (Ondatra zibethicus). Belant JL. **J Wildl Dis** 1995 Oct;31(4):573–5

Desflurane in equine anaesthesia: a preliminary trial. Jones NY, et al. **Vet Rec** 1995 Dec 9;137(24):618–20

Gastric myoelectric and motor activity in dogs after isoflurane anesthesia. Hall JA, et al. **Vet Surg** 1995 Sep–Oct; 24(5):456–63

The minimum alveolar concentration of desflurane in cats. McMurphy RM, et al. **Vet Surg** 1995 Sep–Oct;24(5):453–5

ANESTHESIA, INTRATRACHEAL

Displacement of the endotracheal tube caused by change of head position in pediatric anesthesia: evaluation by fiberoptic bronchoscopy. Sugiyama K, et al. **Anesth Analg** 1996 Feb;82(2):251–3

Airway management in Ludwig's angina. Young P, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):239

[Cervicofacial cellulitis of dental origin and tracheal intubation] Reyford H, et al. **Ann Fr Anesth Reanim** 1995; 14(3):256–60 (Eng. Abstr.) **(Fre)**

[Postoperative mediastinal and subcutaneous emphysema after intubation narcosis] Obenhaus T. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):318–20 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Massive subcutaneous emphysema during emergence from anesthesia followed by seizures [letter] Oberoi MP, et al. **Anesth Analg** 1996 Mar;82(3):675

HISTORY

Magill's endotracheal catheter device for use during repair of cleft lip and palate. Hatch DJ. **Paediatr Anaesth** 1995; 5(3):199–201

INSTRUMENTATION

[High frequency ventilation and low-flow: anesthesiologic aspects beyond conventional anesthesia and ventilation techniques (editorial; comment)] Krier C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):265–7. Comment on: Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug;30(5):268–75. Comment on: Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug;30(5):276–82. **(Ger)**

[Intubation trauma of the larynx--a literature review with special reference to arytenoid cartilage dislocation (see comments)] Rieger A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):281–7 (37 ref.) (Eng. Abstr.). Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Jun;31(5):279–80. **(Ger)**

[A flexible fiber endoscope is useful in complicated anesthetic interventions (letter)] Lagerkranser M, et al. **Lakartidningen** 1996 Jan 31;93(5):341 **(Swe)**

METHODS

[Rupture of the sinus of Valsalva--the anesthesiological and resuscitation problems] Aleksandrov V, et al. **Khirurgiia (Sofiia)** 1995;48(1):87–9 (Eng. Abstr.) **(Bul)**

[Submental introduction of tracheal tube in endotracheal anesthesia. (Modified tracheal intubation method for cases of simultaneous maxillofacial injuries and osteotomies)] Bögi I, et al. **Fogorv Sz** 1996 Jan;89(1):3–6 (Eng. Abstr.) **(Hun)**

[Difficult airway management is a weakness in the training of anesthesiologists (editorial)] Gomar C. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):121–2 **(Spa)**

ANESTHESIA, INTRAVENOUS

Morphine/prilocaine combination for intravenous regional anesthesia. Erciyes N, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):845–6

Disturbance of hepatocellular integrity associated with propofol anaesthesia in surgical patients. Tiainen P, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):840–4

Intubating conditions and neuromuscular effects of mivacurium during propofol-alfentanil anaesthesia. Van Aken H, et al. **Acta Anaesthesiol Scand Suppl** 1995;106:26–9

Flumazenil and midazolam in anaesthesia. Whitwam JG. **Acta Anaesthesiol Scand Suppl** 1995;108:15–22 (67 ref.)

Anaesthesia and moyamoya disease. Henderson MA, et al. **Anaesth Intensive Care** 1995 Aug;23(4):503–6

Cerebral effects of propofol following bolus administration in sheep. Ludbrook GL, et al. **Anaesth Intensive Care** 1996 Feb;24(1):26–31

Comparison of total intravenous, balanced inhalational and combined intravenous-inhalational anaesthesia for tympanoplasty, septorhinoplasty and adenotonsillectomy. Van den Berg AA, et al. **Anaesth Intensive Care** 1995 Oct; 23(5):574–82

Lung aeration. The effect of pre-oxygenation and hyperoxygenation during total intravenous anaesthesia. Reber A, et al. **Anaesthesia** 1996 Aug;51(8):733–7

Processing familiar and unfamiliar auditory stimuli during general anesthesia. Donker AG, et al. **Anesth Analg** 1996 Mar;82(3):452–5

A multicenter evaluation of total intravenous anesthesia with remifentanil and propofol for elective inpatient surgery. Hogue CW Jr, et al. **Anesth Analg** 1996 Aug;83(2):279–85

The comparative effects of sevoflurane versus propofol in the induction and maintenance of anesthesia in adult patients. Jellish WS, et al. **Anesth Analg** 1996 Mar; 82(3):479–85

Total intravenous anesthesia and endotracheal oxygen insufflation for repair of tracheoesophageal fistula in an adult. Joynt GM, et al. **Anesth Analg** 1996 Mar;82(3):661–3

Nonlinear measures of heart rate variability after fentanyl-based induction of anesthesia. Storella RJ, et al. **Anesth Analg** 1995 Dec;81(6):1292–4

Performance of computer-controlled infusion of propofol: an evaluation of five pharmacokinetic parameter sets. Vuyk J, et al. **Anesth Analg** 1995 Dec;81(6):1275–82

Spectral analysis of arterial pressure variability during induction of propofol anesthesia. Wang H, et al. **Anesth Analg** 1996 May;82(5):914–9

Faster recovery after anesthesia in infants after intravenous induction with methohexital instead of thiopental. Beskow A, et al. **Anesthesiology** 1995 Nov;83(5):976–9

The use of diazepam and ketamine for i.v. conscious sedation in outpatient surgery settings. Ringler JD. **AORN J** 1995 Oct;62(4):638–45

Comparison of propofol and methohexitone in anaesthesia for ECT: effect on seizure duration and outcome. Kirkby KC, et al. **Aust N Z J Psychiatry** 1995 Jun;29(2):299–303

A survey of in-dwelling intravenous cannula use in general dental practice. Dickenson AJ, et al. **Br Dent J** 1995 Aug 5;179(3):89–92

Effect of i.v. lignocaine on the breathing of patients anaesthetized with propofol. Goodman NW, et al. **Br J Anaesth** 1995 Nov;75(5):573–7

Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans. Ilkjaer S, et al. **Br J Anaesth** 1996 Jun;76(6):829–34

Haemostatic changes caused by i.v. regional anaesthesia with lignocaine. Niemi TT, et al. **Br J Anaesth** 1996 Jun; 76(6):822–8

Total i.v. anaesthesia for transcranial magnetic evoked potential spinal cord monitoring. Watt JW, et al. **Br J Anaesth** 1996 Jun;76(6):870–1

Anaesthesia for the insertion of a catheter for peritoneal dialysis. Haslett RC, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):49–50

Anaesthesia for day-case surgery. Hitchcock M, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):202–6 (20 ref.)

Eisenmenger's syndrome and problems with anaesthesia. Jones P, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):214

The choice of anaesthetic for carotid endarterectomy: does it matter? [editorial] Archer DP, et al. **Can J Anaesth** 1995 Jul;42(7):566–70 **(Eng, Fre)**

Thiopentone pretreatment for propofol injection pain in ambulatory patients. Haugen RD, et al. **Can J Anaesth** 1995 Dec;42(12):1108–12

Should the routine use of atropine before succinylcholine in children be reconsidered? McAuliffe G, et al. **Can J Anaesth** 1995 Aug;42(8):724–9

Intravenous anaesthesia: new drugs, new concepts, and clinical applications. Miller DR. **Can J Anaesth** 1996 May; 43(5 Pt 2):R142–54 (18 ref.) **(Eng, Fre)**

Haemodynamic instability and myocardial ischaemia during carotid endarterectomy: a comparison of propofol and isoflurane. Mutch WA, et al. **Can J Anaesth** 1995 Jul; 42(7):577–87

High-dose vecuronium neuromuscular block: a comparison of arrhythmias and onset of block during sufentanil anaesthesia. Sharpe MD, et al. **Can J Anaesth** 1995 Aug; 42(8):716–23

A comparison between total intravenous anaesthesia using a propofol/alfentanil mixture and an inhalational-technique for laparoscopic gynaecological sterilization. Collins SJ, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):33–7

A comparison of intravenous and inhalational maintenance anaesthesia for endoscopic procedures in the aspirin intolerance syndrome. Novak-Jankovič V, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):345–9

Co-induction of anaesthesia: the cardiac patient. Duthie DJ. **Eur J Anaesthesiol Suppl** 1995 Nov;12:21–4 (26 ref.)

Intravenous anaesthetic drug interactions: practical applications. Vinik HR. **Eur J Anaesthesiol Suppl** 1995 Nov; 12:13–9 (23 ref.)

Co-induction of anaesthesia: day-case surgery. Whitwam JG. **Eur J Anaesthesiol Suppl** 1995 Nov;12:25–34 (50 ref.)

AICD implantation and it's implications for the anaesthesiologist. Mehta Y, et al. **Indian Heart J** 1996 Jan-Feb;48(1):68–70

Evaluation of right ventricular function by assessment of cardiac efficiency: influence of induction of anaesthesia in coronary artery bypass grafting patients. Tassani P, et al. **Int J Clin Monit Comput** 1995;12(3):169–73

Case 2--1996. Anesthetic management of a patient with hemoglobin SS disease and mitral insufficiency for mitral valve repair [clinical conference] Kingsley CP, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):419–24

Continuous infusions of alfentanil and propofol for coronary artery surgery. Roekaerts PM, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):362–7

Propofol infusion for induction and maintenance of anesthesia in elderly patients: recovery and hemodynamic profiles. Chan VW, et al. **J Clin Anesth** 1996 Jun;8(4):317–23

Epidemiology of the adverse hemodynamic events occurring during "clonidine anesthesia": a prospective open trial of intraoperative intravenous clonidine. De Kock M, et al. **J Clin Anesth** 1995 Aug;7(5):403–10

A comparison of alfentanil, esmolol, lidocaine, and thiopental sodium on the hemodynamic response to insertion of headrest skull pins. Doblar DD, et al. **J Clin Anesth** 1996 Feb;8(1):31–5

Propofol and alfentanil mixture for outpatient surgery [letter; comment] Isert P. **J Clin Anesth** 1995 Jun;7(4):357. Comment on: J Clin Anesth 1994 Mar-Apr;6(2):166–7.

Propofol-based anesthesia as compared with standard anesthetic techniques for middle ear surgery. Jellish WS, et al. **J Clin Anesth** 1995 Jun;7(4):292–6

Total intravenous anesthesia for children undergoing brief diagnostic or therapeutic procedures. McDowall RH, et al. **J Clin Anesth** 1995 Jun;7(4):273–80

Propofol: an alternative general anesthetic for outpatient oral surgery. Pastuovic MN, et al. **J Oral Maxillofac Surg** 1996 Aug;54(8):943–8

Nitrous oxide compared with intravenous regional anesthesia in pediatric forearm fracture manipulation. Gregory PR, et al. **J Pediatr Orthop** 1996 Mar-Apr;16(2):187–91

Hemodynamic and oxygenation variables during radical cystectomy. Does the anesthetic technique really matter? Atallah MM, et al. **Middle East J Anesthesiol** 1995 Jun; 13(2):157–74

Total intravenous anesthesia--a pharmacokinetic approach. Bovill JG. **Middle East J Anesthesiol** 1995 Feb;13(1):37–60 (36 ref.)

Depression of excitatory effects of propofol induction by fentanyl. Ghabash M, et al. **Middle East J Anesthesiol** 1996 Feb;13(4):419–25

Total intravenous anesthesia for diagnostic endoscopy in myasthenia gravis child--a case report. Khan RM, et al. **Middle East J Anesthesiol** 1996 Feb;13(4):415–8

Total intravenous anaesthesia for patients with osteogenesis imperfecta [letter] Baines D. **Paediatr Anaesth** 1995;5(2):144

Behavioural changes and children's memories after intravenous, inhalation and rectal induction of anaesthesia. Kotiniemi LH, et al. **Paediatr Anaesth** 1996;6(3):201–7

Role of propofol in paediatric anaesthetic practice [editorial] Meakin G. **Paediatr Anaesth** 1995;5(3):147–9

[Effect of duration of infusion on elimination rate of alfentanil] Castor G, et al. **Anaesthesiol Reanim** 1995; 20(4):97–100 (Eng. Abstr.) **(Ger)**

[Postoperative vomiting after pars plana vitrectomy] Heinke W, et al. **Anaesthesiol Reanim** 1996;21(2):47–50 (Eng. Abstr.) **(Ger)**

[Total intravenous anesthesia (TIVA) in geriatric surgery. S-(+)-ketamine versus alfentanil] Adams HA, et al. **Anaesthesist** 1995 Dec;44 Suppl 3:S540–8 (Eng. Abstr.) **(Ger)**

[Remarks on the work of H. Harke et al. Quality comparison of modified neurolept-, balanced, and intravenous anesthesia. 1. Study design and patient analysis in the Krefelder study, 1992] Dudziak R. **Anaesthesist** 1996 Apr; 45(4):384–5 **(Ger)**

[Quality comparison of modified neurolept-, balanced and intravenous anesthesia. 1. Study design and patient analysis of the Krefelder study 1992] Harke H, et al. **Anaesthesist** 1995 Aug;44(8):531–7 (Eng. Abstr.) **(Ger)**

[Qualitative comparison of modified neurolept-, balanced and intravenous anesthesia. 2. Results of a clinical study, 1992] Harke H, et al. **Anaesthesist** 1995 Oct;44(10):687–94 (Eng. Abstr.) **(Ger)**

[The effect of propofol on vomiting after strabismus surgery in children] Klockgether-Radke A, et al. **Anaesthesist** 1995 Nov;44(11):755–60 (Eng. Abstr.) **(Ger)**

[Anesthesia with propanidid in a liposomal preparation. An experimental study in swine] Klockgether-Radke A, et al. **Anaesthesist** 1995 Aug;44(8):573–80 (Eng. Abstr.) **(Ger)**

[Etomidate versus propofol for anesthesia in ambulatory cardioversion] Kick O, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):288–92 (Eng. Abstr.) **(Ger)**

[Gamma-hydroxybutyric acid--significance for anesthesia and intensive care medicine?] Kleinschmidt S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):393–402 (59 ref.) (Eng. Abstr.) **(Ger)**

[Effect of premedication and barbiturate hypnotics on motor evoked potentials induced by magnetic cortex stimulation] Nadstawek J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):361–5 (Eng. Abstr.) **(Ger)**

[Intravenous anesthesia--current aspects] Schraag S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):469–78 (72 ref.) (Eng. Abstr.) **(Ger)**

[The treatment of benign laryngeal pathologies using CO2 laser in direct microlaryngoscopy with propofol-induced endovenous anesthesia in spontaneous respiration without intubation] Macarone Palmieri A, et al. **Acta Otorhinolaryngol Ital** 1995 Oct;15(5):361–7 (Eng. Abstr.) **(Ita)**

[Effects of anesthetic drugs and temperature on brain stem and mid-latency evoked potentials] Kadoi Y, et al. **Masui** 1995 Sep;44(9):1213–7 (Eng. Abstr.) **(Jpn)**

[Stress hormone response during midazolam/fentanyl anesthesia combined with epidural anesthesia for abdominal total hysterectomy] Mizutani A, et al. **Masui** 1996 Mar; 45(3):276–80 (Eng. Abstr.) **(Jpn)**

[Anesthesia for funnel chest operation] Morimoto A, et al.

Masui 1995 Oct;44(10):1377–80 (Eng. Abstr.) **(Jpn)**

[Total intravenous anesthesia and postoperative continuous epidural infusion in thoracic esophageal cancer surgery] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):661–2 **(Jpn)**

[Ketamine–clofelin anesthesia in children] Berlinskiĭ VV, et al. **Anesteziol Reanimatol** 1995 Sep–Oct;(5):38–40 (Eng. Abstr.) **(Rus)**

[Metabolic components of anesthesiological provision in surgery of suppurative-inflammatory diseases of the abdominal cavity] Tumanian SV, et al. **Anesteziol Reanimatol** 1995 Sep–Oct;(5):31–4 (Eng. Abstr.) **(Rus)**

[Anesthesia with continuous + infusion of propofol for trans-sternal thymectomy in myasthenic patients] García-Aguado R, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep;42(7):283–5 (Eng. Abstr.) **(Spa)**

[Anesthetic complications in sequential bipulmonary transplantation in patients with cystic fibrosis. Apropos of 6 cases] López LM, et al. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):108–12 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Anaphylactoid skin reactions after intravenous regional anaesthesia using 0.5% prilocaine with or without preservative—a double-blind study. Kajimoto Y, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):782–4

Cardiac arrest during major spinal scoliosis surgery in a patient with Duchenne's muscular dystrophy undergoing intravenous anaesthesia. Irwin MG, et al. **Anaesth Intensive Care** 1995 Oct;23(5):626–9

Lidocaine and no carrier fluid for the prevention of pain due to injection of propofol [letter; comment] Gozal Y. **Anesth Analg** 1996 May;82(5):1111. Comment on: Anesth Analg 1995 Nov;81(5):1087–8.

Fixed drug eruption associated with anaesthesia. Bremang JA, et al. **Can J Anaesth** 1995 Jul;42(7):628–30

Effect of nitrous oxide on middle ear pressure: a comparison between inhalational anaesthesia with nitrous oxide and TIVA. Karabiyik L, et al. **Eur J Anaesthesiol** 1996 Jan; 13(1):27–32

Inhalation versus intravenous anesthesia: a fictitious debate between E.I. Eger II and P.F. White. Shafer SL, et al. **J Clin Anesth** 1996 May;8(3 Suppl):38S–41S

HISTORY

Thiopentone anaesthesia at Pearl Harbor [letter; comment] Kidd AG, et al. **Br J Anaesth** 1995 Dec;75(6):823. Comment on: Br J Anaesth 1995 Sep;75(3):366–8.

[Intravenous anesthesia with inhalation anesthetics] Poetter C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):383–6 (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Evaluation of a new method for determining tracheal tube length in children. Freeman JA, et al. **Anaesthesia** 1995 Dec;50(12):1050–2

Prevention of reflux of blood into infusion tubing [letter] Ravalia A, et al. **Anaesthesia** 1996 Feb;51(2):206–7

Bubbles, bubbles, everywhere [letter] Stevenson GW, et al. **Paediatr Anaesth** 1995;5(3):205–6

METHODS

The role of muscle relaxants in total intravenous anaesthesia. Pollard BJ. **Acta Anaesthesiol Scand Suppl** 1995;106:58–61

Microlaryngeal surgery without a tracheal tube [letter] MacGillivray RG, et al. **Anaesthesia** 1995 Sep;50(9):832–3

Induction of anaesthesia with midazolam and a target-controlled propofol infusion. Tzabar Y, et al. **Anaesthesia** 1996 Jun;51(6):536–8

Treacher Collins syndrome [letter; comment] Gomersall CD, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):175. Comment on: Br J Hosp Med 1995 Apr 19–May 2;53(8):419.

Anaesthesia with failed intubations [letter; comment] Lim W, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):414. Comment on: Br J Hosp Med 1995 Apr 5–18;53(7):359.

Anaesthesia with failed intubations [letter; comment] Williams EG. **Br J Hosp Med** 1995 Oct 18–31;54(8):414. Comment on: Br J Hosp Med 1995 Apr 5–18;53(7):359.

A bolus plus continuous infusion protocol for controlling neuromuscular blockade during anesthesia. Botman JM, et al. **Int J Clin Monit Comput** 1995 May;12(2):89–95

Second opinion on brevital [letter] Salamon SM. **J Cataract Refract Surg** 1996 Apr;22(3):281–2

Implications of automation surprises in aviation for the future of total intravenous anesthesia (TIVA). Cook RI, et al. **J Clin Anesth** 1996 May;8(3 Suppl):29S–37S (49 ref.)

Intravenous anesthesia and analgesia: what is the role of target-controlled infusion? White PF. **J Clin Anesth** 1996 May;8(3 Suppl):26S–28S (22 ref.)

Clinical aspects of CRNA practice. General anesthesia. Ouellette SM. **Nurs Clin North Am** 1996 Sep;31(3):623–42 (102 ref.)

[Anesthesia in a case of mitochondrial myopathy (letter)] Torres MD, et al. **Rev Esp Anestesiol Reanim** 1996 Mar; 43(3):114–5 **(Spa)**

PSYCHOLOGY

Psychological and cardiovascular predictors of anaesthesia induction, operative and post-operative complications in minor gynaecological surgery. Abbott J, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):613–25

VETERINARY

Evaluation of thiopentone–midazolam–fentanyl anaesthesia in pigs. Søfteland E, et al. **Lab Anim** 1995 Jul;29(3):269–75

Total intravenous anaesthesia in ponies using detomidine, ketamine and guaiphenesin: pharmacokinetics, cardiopulmonary and endocrine effects. Taylor PM, et al. **Res Vet Sci** 1995 Jul;59(1):17–23

[Intravenous anesthesia in the horse: comparison of xylazine–ketamine and xylazine–tiletamine–zolazepam combinations] Cuvelliez S, et al. **Can Vet J** 1995 Oct; 36(10):613–8 **(Fre)**

ANESTHESIA, LOCAL

see related
ANESTHETICS, LOCAL

Comparison trial of four injectable anesthetics for laceration repair [see comments] Ernst AA, et al. **Acad Emerg Med** 1996 Mar;3(3):228–33. Comment in: Acad Emerg Med 1996 Mar;3(3):198–200.

What is the role of diphenhydramine in local anesthesia? [editorial; comment] Green SM. **Acad Emerg Med** 1996 Mar;3(3):198–200 (11 ref.). Comment on: Acad Emerg Med 1996 Mar;3(3):228–33.

Functional endoscopic sinus surgery under local anaesthesia: possibilities and limitations. Jorissen M, et al. **Acta Otorhinolaryngol Belg** 1996;50(1):1–12

Conscious midazolam sedation in third molar surgery—aspects of post-operative patient evaluation. Bremerich A, et al. **Acta Stomatol Belg** 1995 Sep; 92(3):101–4

Use of an anesthetic cream before infiltration with local anesthesia in aesthetic surgery. Abenavoli FM, et al. **Aesthetic Plast Surg** 1995 Nov–Dec;19(6):555–6

Effects of breathing route, temperature and volume of inspired gas, and airway anesthesia on the response of respiratory output to varying inspiratory flow. Georgopoulos D, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):168–75

The effect of anesthesia type on needle localization breast biopsy: another point of view [see comments] Papa MZ, et al. **Am J Surg** 1996 Feb;171(2):242–3. Comment in: Am J Surg 1996 Jul;172(1):93–4.

Local anaesthesia for eye surgery [letter; comment] Seppelt I. **Anaesth Intensive Care** 1995 Aug;23(4):516. Comment on: Anaesth Intensive Care 1995 Feb;23(1):114–6.

Pain and vomiting after vitreoretinal surgery: a potential role for local anaesthesia. Williams N, et al. **Anaesth Intensive Care** 1995 Aug;23(4):444–8

Lignocaine to aid the insertion of the laryngeal mask airway with thiopentone. A comparison between topical and intravenous administration. Cook TM, et al. **Anaesthesia** 1996 Aug;51(8):787–90

Local anaesthesia for pain relief following wisdom teeth extraction under general anaesthesia [letter] Mackenzie DW, et al. **Anaesthesia** 1996 Feb;51(2):200–1

Infiltration anaesthesia in the management of Caesarean section in a patient with peripartum cardiomyopathy [letter] Mellor DJ, et al. **Anaesthesia** 1996 Apr;51(4):409

Local anaesthesia for pain relief following wisdom teeth extraction under general anaesthesia [letter] Whitehead PN. **Anaesthesia** 1996 Feb;51(2):200

Myringotomy tube placement—another role for EMLA cream? [letter] Beerle BJ, et al. **Anesth Analg** 1996 Aug; 83(2):435

Perioperative changes in cardiac autonomic control in patients receiving either general or local anesthesia for ophthalmic surgery. Keyl C, et al. **Anesth Analg** 1996 Jan; 82(1):113–8

Cocaine, lidocaine, tetracaine: which is best for topical nasal anesthesia? Noorily AD, et al. **Anesth Analg** 1995 Oct; 81(4):724–7

Lidocaine plasma concentrations in pediatric patients after providing airway topical anesthesia from a calibrated device. Sitbon P, et al. **Anesth Analg** 1996 May;82(5):1003–6

Effective topical anesthesia for awake tracheal intubation [letter] Hronek I, et al. **Anesthesiology** 1996 Mar;84(3):749

Performance of local anesthetic and placebo splanchnic blocks via indwelling catheters to predict benefit from thoracoscopic splanchnicectomy in a patient with intractable pancreatic pain. Strickland TC, et al. **Anesthesiology** 1996 Apr;84(4):980–3

Digital replantations under local anaesthesia. Kour AK, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):68–72

Efficacy of the topical anesthetic cream, EMLA, in alleviating both needle insertion and injection pain. Raveh T, et al. **Ann Plast Surg** 1995 Dec;35(6):576–9

Tension-free mesh hernia repair: review of 1098 cases using local anaesthesia in a day unit [see comments] Kark AE, et al. **Ann R Coll Surg Engl** 1995 Jul;77(4):299–304. Comment in: Ann R Coll Surg Engl 1995 Nov;77(6):466–7. Comment in: Ann R Coll Surg Engl 1995 Nov;77(6):467.

Tension-free mesh hernia repair: review of 1098 cases using local anaesthesia in a day unit [letter; comment] Notaras MJ. **Ann R Coll Surg Engl** 1995 Nov;77(6):466–7. Comment on: Ann R Coll Surg Engl 1995 Jul;77(4):299–304.

Efficacy of topical anesthesia in children. Vinci RJ, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):466–9

Post-operative pain control [letter] Brett I, et al. **Br Dent J** 1996 Jan 20;180(2):50

Effect of nebulized lignocaine on airway irritation and haemodynamic changes during induction of anaesthesia with desflurane [see comments] Bunting HE, et al. **Br J Anaesth** 1995 Nov;75(5):631–3. Comment in: Br J Anaesth 1996 Apr;76(4):596.

Quantitative evaluation of tourniquet leak during i.v. regional anaesthesia of the upper and lower limbs in human volunteers. Hoffmann AC, et al. **Br J Anaesth** 1995 Sep; 75(3):269–73

Effect of transdermal hyoscine on nausea and vomiting during and after middle ear surgery under local anaesthesia [see comments] Honkavaara P. **Br J Anaesth** 1996 Jan; 76(1):49–53. Comment in: Br J Anaesth 1996 May;76(5):749–50.

Day-case cataract surgery [letter] Maltby JR, et al. **Br J Anaesth** 1996 Feb;76(2):333

Warming lignocaine reduces the pain of injection during peribulbar local anaesthesia for cataract surgery. Bell RW, et al. **Br J Ophthalmol** 1995 Nov;79(11):1015–7

Intra-arterial lignocaine in embolectomy. Campbell WB, et al. **Br J Surg** 1996 Feb;83(2):244

Cataract-operation with topical anesthesia and i.v. sedation. Huyghe P, et al. **Bull Soc Belge Ophtalmol** 1994;254:45–7

Retrobulbar anesthesia with 7.5 vs. 0.75 IU/mL of hyaluronidase. DeBroff BM, et al. **Can J Ophthalmol** 1995 Aug;30(5):262–4

Lignocaine with adrenaline: is it as effective as cocaine in rhinological practice? Kasemsuwan L, et al. **Clin Otolaryngol** 1996 Apr;21(2):127–9

Local anesthetics. Skidmore RA, et al. **Dermatol Surg** 1996 Jun;22(6):511–22; quiz 523–4 (83 ref.)

Effect of injection speed on anaesthetic spread during axillary block using the orthogonal two-needle technique. Rucci FS, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):505–11

A prospective audit of simple mastectomy under local anaesthesia. Oakley N, et al. **Eur J Surg Oncol** 1996 Apr; 22(2):134–6

Topical anaesthesia for phacoemulsification surgery. Duguid IG, et al. **Eye** 1995;9 (Pt 4):456–9

Serum lidocaine and MEGX concentrations after pharyngeal anesthesia for gastroscopy. Gandolfi L. **Gastrointest Endosc** 1995 Sep;42(3):282–3

Flexible fibreoptic bronchoscopy in 582 children—value of route, sedation and local anesthetic. Somu N, et al. **Indian Pediatr** 1995 May;32(5):543–7

Four common mandibular nerve anomalies that lead to local anesthesia failures. DeSantis JL, et al. **J Am Dent Assoc** 1996 Jul;127(7):1081–6 (25 ref.)

Management of patellar clunk under local anesthesia. Messieh M. **J Arthroplasty** 1996 Feb;11(2):202–3

Con: unreliable benefit after thoracotomy—epidural is a better choice [comment] Riegler FX. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):429–31 (20 ref.) . Comment on: J Cardiothorac Vasc Anesth 1996 Apr;10(3):425–8.

Perilimbal anesthesia [letter; comment] Corbin WL. **J Cataract Refract Surg** 1996 Jan–Feb;22(1):4. Comment on: J Cataract Refract Surg 1995 Sep;21(5):504–7.

Modified stretch technique for small pupil phacoemulsification with topical anesthesia. Dinsmore SC. **J Cataract Refract Surg** 1996 Jan–Feb;22(1):27–30

Upper arm tourniquet pain in local anaesthetic surgery. Ogufere WE, et al. **J Hand Surg [Br]** 1995 Jun;20(3):413–4

Flexible endoscopic tracheo-oesophageal puncture under local anaesthetic. Hong GS, et al. **J Laryngol Otol** 1995 Nov;109(11):1077–9

Local anaesthesia in flexible nasendoscopy. A comparison between cocaine and co-phenylcaine. Lennox P, et al. **J Laryngol Otol** 1996 Jun;110(6):540–2

Laryngotracheal separation under local anaesthesia for intractable salivary aspiration: cricoidectomy with fibrin glue support. Sone M, et al. **J Laryngol Otol** 1996 Jan; 110(1):72–4

Day-case septal surgery under general anaesthesia and local anaesthesia with sedation. Srinivasan V, et al. **J Laryngol Otol** 1995 Jul;109(7):614–7

Electrocardiographic changes in cardiac patients undergoing dental extractions under local anesthesia. Blinder D, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):162–5; discussion 165–6

Topical anaesthesia for minor lacerations: MAC versus TAC. Kuhn M, et al. **Med J Aust** 1996 Mar 4;164(5):277–80

Techniques to reduce the discomfort of paediatric laceration repair. Roberts PA, et al. **Med J Aust** 1996 Jan 1; 164(1):32–5 (37 ref.)

Surgery of astrocytomas in the motor and premotor cortex under local anesthesia: report of 11 cases. Ebeling U, et al. **Minim Invasive Neurosurg** 1995 Jun;38(2):51–9

Effects of local anaesthesia on formalin-induced Fos expression in the rat dorsal horn. Tokunaga A, et al. **Neuroreport** 1995 Nov 27;6(17):2301–4

Vaginal correction of pelvic organ relaxation using local anesthesia. Miklos JR, et al. **Obstet Gynecol** 1995 Dec; 86(6):922–4

Endoscopic orbital decompression under local anesthesia. Metson R, et al. **Otolaryngol Head Neck Surg** 1995 Dec; 113(6):661–7

Local anaesthetic agents in infancy. Eyres RL. **Paediatr Anaesth** 1995;5(4):213–8 (47 ref.)
Regional variations in skin perfusion and skin thickness may contribute to varying efficacy of topical, local anaesthetics in neonates. Larsson BA, et al. **Paediatr Anaesth** 1996; 6(2):107–10
Transcutaneous electric nerve stimulation (TENS) during distension shoulder arthrography: a controlled trial. Morgan B, et al. **Pain** 1996 Feb;64(2):265–7
Lidocaine and epinephrine levels in tumescent technique liposuction. Burk RW 3rd, et al. **Plast Reconstr Surg** 1996 Jun;97(7):1379–84
Breast reduction under intravenous sedation: a review of 50 cases. Zukowski ML, et al. **Plast Reconstr Surg** 1996 Apr; 97(5):952–6; discussion 957–8
Epinephrine prolongs duration of subcutaneous infiltration of local anesthesia in a dose-related manner. Correlation with magnitude of vasoconstriction. Liu S, et al. **Reg Anesth** 1995 Sep–Oct;20(5):378–84
Topography of peribulbar anesthesia. Ortiz M, et al. **Reg Anesth** 1995 Jul–Aug;20(4):337–42
Local anesthesia for urologic procedures. Leach GE. **Urology** 1996 Aug;48(2):284–8
[Topical anesthesia for cataract surgery in adults] Lebuisson DA, et al. **J Fr Ophtalmol** 1996;19(3):181–9 (Eng. Abstr.) **(Fre)**
[Phacoemulsification and topical anesthesia. Apropos of 40 cases] Roman S, et al. **J Fr Ophtalmol** 1996;19(1):32–8 (Eng. Abstr.) **(Fre)**
[Ureteroscopy under local anesthesia with or without intravenous analgesia] Deliveliotis C, et al. **Prog Urol** 1995 Sep;5(4):548–50 (Eng. Abstr.) **(Fre)**
[Transinguinal preperitoneal mesh-plasty in inguinal hernia using local anesthesia] Schumpelick V, et al. **Chirurg** 1996 Apr;67(4):419–24 (Eng. Abstr.) **(Ger)**
[Miniplate osteosynthesis of mandibular fracture in local anesthesia—indications and outcome in 316 patients] Walz C, et al. **Fortschr Kiefer Gesichtschir** 1996;41:133–5 (Eng. Abstr.) **(Ger)**
[0.15 mg clonidine as oral premedication in retrobulbar anesthesia] Weindler J, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):410–3 (Eng. Abstr.) **(Ger)**
[Principles of pain therapy with local anesthesia] Klaus E. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):127–30 (Eng. Abstr.) **(Ger)**
[Use of topical anesthesia—EMLA cream] Raveh T, et al. **Harefuah** 1996 Apr 1;130(7):490–1 (26 ref.) **(Heb)**
[Local anesthesia in breast augmentation] Martinazzoli A, et al. **G Chir** 1995 Nov–Dec;16(11–12):510–11 (Eng. Abstr.) **(Ita)**
[Efficacy and complications of topical cocaine anesthesia in functional endoscopic sinus surgery] Kubo N, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Aug;98(8):1263–9 (Eng. Abstr.) **(Jpn)**
[Anesthesia preferences among the medical population (letter)] Isla-Baranda A, et al. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):117 **(Spa)**

ADVERSE EFFECTS

Postoperative morbidity following cataract surgery. A comparison of local and general anaesthesia. Barker JP, et al. **Anaesthesia** 1996 May;51(5):435–7
Temporary facial nerve palsy during carotid endarterectomy under local anesthesia [see comments] Szocik JF, et al. **Anesth Analg** 1995 Nov;81(5):1106–7. Comment in: Anesth Analg 1996 Aug;83(2):434. Comment in: Anesth Analg 1996 Aug;83(2):441.
Confirmation by magnetic resonance imaging of optic nerve injury after retrobulbar anesthesia [letter] Horton JC, et al. **Arch Ophthalmol** 1996 Mar;114(3):351–3
Local anaesthetic sprays and pneumonia after gastroscopy [letter; comment] Scott BB. **Gut** 1995 Sep;37(3):445. Comment on: Gut 1995 Mar;36(3):462–7.
Retinal detachment secondary to ocular perforation during retrobulbar anaesthesia. Gopal L, et al. **Indian J Ophthalmol** 1995 Mar;43(1):13–5
Vertical strabismus after local anesthesia [letter; comment] Tejedor J, et al. **Ophthalmology** 1996 Apr;103(4):545–6. Comment on: Ophthalmology 1995 Mar;102(3):501–9.
Retrobulbar anesthesia complicated by combined central retinal vein and artery occlusion and massive vitreoretinal fibrosis. Giuffrè G, et al. **Retina** 1995;15(5):439–41
Checking for globe perforation after retrobulbar injection [letter; comment] Feibel RM. **Surv Ophthalmol** 1995 Jul–Aug;40(1):86. Comment on: Surv Ophthalmol 1995 Jan–Feb;39(4):344–5.
[Induction of oral aphthae after anesthesia in a patient with Behcet's disease] Seoane J, et al. **Acta Otorrinolaringol Esp** 1996 Mar–Apr;47(2):167–8 **(Spa)**

INSTRUMENTATION

On the anesthetic effect of low-power infrared lasers with different mode of irradiation in complications after stomatologic treatment. Vladimirov S. **Folia Med (Plovdiv)** 1995;37(4A Suppl):108
Lid speculum for surgery without lid block [letter] Anderson CJ. **J Cataract Refract Surg** 1996 Jan–Feb;22(1):4–5

METHODS

Non-retrobulbar anaesthesia for trabeculectomy. Agbeja AM. **Afr J Med Med Sci** 1995 Jun;24(2):165–7
Women cannot discriminate between different paracervical block techniques applied to opposite sides of the cervix. Grossman RA. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):935–6
Subtenon's local anesthesia for optic nerve sheath fenestration. Rizzuto PR, et al. **Am J Ophthalmol** 1996 Mar; 121(3):326–7
Local anaesthesia and venous cannulation [letter; comment] Mehta S. **Anaesthesia** 1996 Apr;51(4):410. Comment on: Anaesthesia 1995 May;50(5):400–2. Comment on: Anaesthesia 1995 Nov;50(11):1005. Comment on: Anaesthesia 1995 Nov;50(11):1005–6.
Peribulbar anaesthesia using the immobile needle technique [letter] Smith MG, et al. **Anaesthesia** 1995 Oct;50(10):915
Simultaneous repair of bilateral inguinal hernias under local anesthesia. Amid PK, et al. **Ann Surg** 1996 Mar; 223(3):249–52
A comparison of peribulbar and retrobulbar anesthesia for vitreoretinal surgical procedures [letter; comment] Schepens CL. **Arch Ophthalmol** 1996 Apr;114(4):502. Comment on: Arch Ophthalmol 1995 Jul;113(7):908–13.
Single medial injection peribulbar anaesthesia [letter; comment] Xifaras GP. **Br J Anaesth** 1995 Nov;75(5):668. Comment on: Br J Anaesth 1995 Jul;75(1):88–92.
Intraocular pressure changes after peribulbar injections with and without ocular compression. Bowman R, et al. **Br J Ophthalmol** 1996 May;80(5):394–7
Should myopes have routine axial length measurements before retrobulbar or peribulbar injections? Churchill A, et al. **Br J Ophthalmol** 1996 Jun;80(6):498
Cataract-operation with topical anesthesia and i.v. sedation. Huyghe P, et al. **Bull Soc Belge Ophtalmol** 1994;254:45–7
Peribulbar anaesthesia [letter; comment] Prosser DP, et al. **Can J Anaesth** 1995 Sep;42(9):838–9. Comment on: Can J Anaesth 1993 Sep;40(9):835–8.
Optimizing local anesthesia. The heat is on [comment] Dzubow LM. **Dermatol Surg** 1996 Aug;22(8):681. Comment on: Dermatol Surg 1996 Aug;22(8):687–90. Comment on: Dermatol Surg 1996 Aug;22(8):707–9.
Problems of tumescent anesthesia for dermabrasion [letter] Field LM. **Dermatol Surg** 1996 Aug;22(8):734–5
Comparison of room temperature and warmed local anesthetic solution for tumescent liposuction. A randomized double-blind study [see comments] Kaplan B, et al. **Dermatol Surg** 1996 Aug;22(8):707–9. Comment in: Dermatol Surg 1996 Aug;22(8):681.
Randomised trial of topical versus sub-Tenon's local anaesthesia for small-incision cataract surgery. Manners TD, et al. **Eye** 1996;10 (Pt 3):367–70
Laparoscopically assisted gamete intrafallopian transfer with local anesthesia and intravenous sedation. Padilla SL, et al. **Fertil Steril** 1996 Sep;66(3):404–7
Pro: intrapleural anesthesia is useful for thoracic analgesia [see comments] McIlvaine WB. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):425–8 (41 ref.). Comment in: J Cardiothorac Vasc Anesth 1996 Apr;10(3):429–31.
Drop, then decide approach to topical anesthesia [see comments] Dinsmore SC. **J Cataract Refract Surg** 1995 Nov;21(6):666–71. Comment in: J Cataract Refract Surg 1996 Mar;22(2):156–8.
Delivery of perilimbal anesthesia [letter] Kondrot EC, et al. **J Cataract Refract Surg** 1996 Mar;22(2):155
Topical anesthesia technique [letter; comment] Nattis RJ. **J Cataract Refract Surg** 1996 Mar;22(2):156–8. Comment on: J Cataract Refract Surg 1995 Nov;21(6):666–71.
Topical anesthesia for phacoemulsification: initial 20-case series with one month follow-up. Novak KD, et al. **J Cataract Refract Surg** 1995 Nov;21(6):672–5
Sutureless scleral tunnel cataract surgery using topical and low dose perilimbal anesthesia [see comments] Pallan LA, et al. **J Cataract Refract Surg** 1995 Sep;21(5):504–7. Comment in: J Cataract Refract Surg 1996 Jan–Feb;22(1):4.
Topical versus peribulbar anesthesia in clear corneal cataract surgery. Zehetmayer M, et al. **J Cataract Refract Surg** 1996 May;22(4):480–4
The effect of local anesthesia with vasoconstrictor on gingival blood flow during Le Fort I osteotomy. Dodson TB, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):810–4; discussion 815
Peribulbar anaesthesia and needle length. Scott RA, et al. **J R Soc Med** 1995 Oct;88(10):594P–596P
Limbal sub-Tenon's administration of retrobulbar anesthesia using a blunt irrigating cannula. Bergman L, et al. **Ophthalmic Surg Lasers** 1996 Feb;27(2):106–12
Retrobulbar anesthesia with a flexible catheter. Dantas PE, et al. **Ophthalmic Surg Lasers** 1996 Apr;27(4):275–8
Direct sub-Tenon's ocular anesthesia for strabismus surgery. Fujishima H, et al. **Ophthalmologica** 1995;209(4):208–11
Tumescent technique for local anesthesia. Klein JA. **West J Med** 1996 Jun;164(6):517
[Voluminous inguinal hernias can also be treated under local anesthesia] Chiotasso P, et al. **Ann Chir** 1995;49(10):936–40 (Eng. Abstr.) **(Fre)**
[Pharmacokinetics of lidocaine and bupivacaine after peribulbar block with additional hyaluronidase] Ben Rhaiem A, et al. **Ann Fr Anesth Reanim** 1995;14(2):162–5 (Eng. Abstr.) **(Fre)**
[EMLA cream: prudent use and warnings (letter)] Chevaleraud E, et al. **Ann Fr Anesth Reanim** 1995;14(5):459 **(Fre)**
[Peri-bulbar anesthesia for cataract surgery] Haimeur C, et al. **Can Anesthesiol** 1995;43(5):505–7 (Eng. Abstr.) **(Fre)**
[Local anesthesia for cataract surgery in adults. Retrospective study of peribulbar, subconjunctival and topical anesthesia] Lebuisson DA. **J Fr Ophtalmol** 1995;18(8–9):502–9 (Eng. Abstr.) **(Fre)**
[Technique of peribulbar anesthesia] Vo Tan P, et al. **J Fr Ophtalmol** 1996;19(5):382–4 (Eng. Abstr.) **(Fre)**
[Advantages and disadvantages of periocular analgesia] Rybczyńska I, et al. **Klin Oczna** 1995 Mar–Apr; 97(3–4):72–3 (Eng. Abstr.) **(Pol)**
[EMLA: topical anesthesia of the skin. A step forward in pediatric anesthesia standards (editorial)] Santacana-Rillo E, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):353–4 **(Spa)**

TRENDS

[What is new in pediatric loco-regional anesthesia?] Ecoffey C. **Rev Med Suisse Romande** 1996 Apr;116(4):243–6 (28 ref.) **(Fre)**

UTILIZATION

Local anaesthesia and venous cannulation [letter; comment] [see comments] O'Connor PJ, et al. **Anaesthesia** 1995 Nov; 50(11):1005. Comment on: Anaesthesia 1995 May;50(5):400–2. Comment in: Anaesthesia 1996 Apr;51(4):410.
Local anaesthesia and venous cannulation [letter] [see comments] Paton RH. **Anaesthesia** 1995 Nov;50(11):1005–6. Comment in: Anaesthesia 1996 Apr;51(4):410.

ANESTHESIA, OBSTETRICAL

Desflurane: a new volatile anesthetic for cesarean section. Maternal and neonatal effects. Abboud TK, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):723–6
Shivering during epidural anesthesia [letter] Sessler DL. **Acta Anaesthesiol Scand** 1996 Mar;40(3):393–4
A review of anatomical and immunological links between epidural morphine and herpes simplex labialis in obstetric patients. Boyle RK. **Anaesth Intensive Care** 1995 Aug; 23(4):425–32 (41 ref.)
EMLA cream prior to insertion of elective epidurals. Elson JA, et al. **Anaesth Intensive Care** 1995 Jun;23(3):339–41
Rectal indomethacin potentiates spinal morphine analgesia after caesarean delivery. Pavy TJ, et al. **Anaesth Intensive Care** 1995 Oct;23(5):555–9
Epidural caesarean section in a patient with congenital antithrombin III deficiency. Rowbottom SJ. **Anaesth Intensive Care** 1995 Aug;23(4):493–5
Fibreoptic oral intubation: a solution to difficult intubation in a parturient [letter] Sidhu VS, et al. **Anaesth Intensive Care** 1995 Oct;23(5):651
The fetus comes of age [editorial] Holdcroft A. **Anaesthesia** 1995 Nov;50(11):925–7
Standard error of the mean or standard deviation—does it matter? [letter; comment] Malagon I. **Anaesthesia** 1996 Jun; 51(6):609. Comment on: Anaesthesia 1996 Feb;51(2):128–32.
Delayed amniotic fluid embolism following caesarean section under spinal anaesthesia. Margarson MP. **Anaesthesia** 1995 Sep;50(9):804–6
Safety of lignocaine test dose to detect intravenous injection [letter; comment] Miline SE. **Anaesthesia** 1995 Sep; 50(9):830. Comment on: Anaesthesia 1995 Mar;50(3):211–3.
Wearing of masks for obstetric regional anaesthesia. A postal survey. Panikkar KK, et al. **Anaesthesia** 1996 Apr; 51(4):398–400
Effect of intravenous fluid preload on vasoactive peptide secretion during Caesarean section under spinal anaesthesia [see comments] Pouta AM, et al. **Anaesthesia** 1996 Feb; 51(2):128–32. Comment in: Anaesthesia 1996 Jun;51(6):609.
Ethics in obstetric anaesthesia [editorial] Scott WE. **Anaesthesia** 1996 Aug;51(8):717–8
Maternal position during induction of spinal anaesthesia for caesarean section [letter; comment] Serpell MG, et al. **Anaesthesia** 1995 Oct;50(10):921–2. Comment on: Anaesthesia 1995 Apr;50(4):363–5.
Regional anaesthesia for repeat Caesarean section in a patient with phantom limb pain. Uncles DR, et al. **Anaesthesia** 1996 Jan;51(1):69–70
Spinal versus epidural anesthesia for cesarean section [letter; comment] Colclough GW. **Anesth Analg** 1995 Dec; 81(6):1318–9. Comment on: Anesth Analg 1995 Apr;80(4):709–12.
Patient comfort: spinal versus epidural anesthesia for cesarean section [letter; comment] Keohane M. **Anesth Analg** 1996 Jan;82(1):219. Comment on: Anesth Analg 1995 Apr;80(4):709–12.
Transition from intrathecal analgesia to epidural anesthesia for emergency cesarean section using a combined spinal epidural technique [letter] Mercier FJ, et al. **Anesth Analg** 1996 Aug;83(2):434
Society for Obstetric Anesthesia and Perinatology. Montreal, Canada, May 17–20, 1995. Camann WR, et al. **Anesthesiology** 1995 Dec;83(6):1393–4
Uterine inversion and anaesthesia [letter] Rogers NJ. **Aust Fam Physician** 1996 Jan;25(1):101
CSF progesterone concentrations in pregnancy [letter; comment] Baliga N. **Br J Anaesth** 1996 Jun;76(6):886. Comment on: Br J Anaesth 1995 Dec;75(6):683–7.

Intrathecal insertion of an extradural catheter during combined spinal–extradural anaesthesia [letter; comment] Camann W. **Br J Anaesth** 1996 Jan;76(1):169. Comment on: Br J Anaesth 1995 Sep;75(3):355–7.

Extradural analgesia in the first stage of labour [letter; comment] Fernando R, et al. **Br J Anaesth** 1996 Jun; 76(6):886–7. Comment on: Br J Anaesth 1996 Feb;76(2):319–21.

Failed intubation revisited: 17–yr experience in a teaching maternity unit. Hawthorne L, et al. **Br J Anaesth** 1996 May; 76(5):680–4

Elective forceps delivery and extradural anaesthesia in a primigravida with portal hypertension and oesophageal varices. Heriot JA, et al. **Br J Anaesth** 1996 Feb;76(2):325–7

Cerebrospinal fluid progesterone in pregnant women [see comments] Hirabayashi Y, et al. **Br J Anaesth** 1995 Dec; 75(6):683–7. Comment in: Br J Anaesth 1996 Jun;76(6):886.

Visceral pain during caesarean section: effect of varying dose of spinal amethocaine [see comments] Hirabayashi Y, et al. **Br J Anaesth** 1995 Sep;75(3):266–8. Comment in: Br J Anaesth 1996 Jan;76(1):167.

Volume preloading is not essential to prevent spinal–induced hypotension at caesarean section [see comments] Jackson R, et al. **Br J Anaesth** 1995 Sep;75(3):262–5. Comment in: Br J Anaesth 1995 Sep;75(3):257–9.

Pregnancy complicated by aortic dissection: caesarean delivery during extradural anaesthesia. Jayaram A, et al. **Br J Anaesth** 1995 Sep;75(3):358–60

Increase in Mallampati score during pregnancy [letter; comment] Kinsella SM, et al. **Br J Anaesth** 1995 Dec; 75(6):822. Comment on: Br J Anaesth 1995 Jun;74(6):638–42.

Volume preloading, spinal anaesthesia and Caesarean section [letter] Lawes EG. **Br J Anaesth** 1996 Feb;76(2):334–5

Intrathecal insertion of an extradural catheter during combined spinal–extradural anaesthesia [letter; comment] Lee JS, et al. **Br J Anaesth** 1996 Jan;76(1):169–70. Comment on: Br J Anaesth 1995 Sep;75(3):355–7.

Volume preloading, spinal anaesthesia and Caesarean section [letter] Mallick A, et al. **Br J Anaesth** 1996 Feb;76(2):335–6

Accidental intrathecal insertion of an extradural catheter during combined spinal–extradural anaesthesia for caesarean section [see comments] Robbins PM, et al. **Br J Anaesth** 1995 Sep;75(3):355–7. Comment in: Br J Anaesth 1996 Jan;76(1):169. Comment in: Br J Anaesth 1996 Jan;76(1):169–70.

Randomized trial of bolus phenylephrine or ephedrine for maintenance of arterial pressure during spinal anaesthesia for Caesarean section. Thomas DG, et al. **Br J Anaesth** 1996 Jan;76(1):61–5

Hydroxyethylstarch compared with modified gelatin as volume preload before spinal anaesthesia for Caesarean section. Vercauteren MP, et al. **Br J Anaesth** 1996 May; 76(5):731–3

The effect of maternal epidural analgesia on fetal oxygen saturation. Johnson N, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):776–8

Anaesthetic management for caesarean section in a patient with Kawasaki disease. Alam S, et al. **Can J Anaesth** 1995 Nov;42(11):1024–6

Maternal death following epidural anaesthesia [letter] Bourne TM, et al. **Can J Anaesth** 1996 Mar;43(3):318–9

Use of LMA for awake intubation for caesarean section. Godley M, et al. **Can J Anaesth** 1996 Mar;43(3):299–302

Anaesthesia for caesarean hysterectomy in a patient with a preoperative diagnosis of placenta percreta with invasion of the urinary bladder. Hunter T, et al. **Can J Anaesth** 1996 Mar;43(3):246–8; discussion 249–51

Spinal anaesthesia in obstetrics. Morgan P. **Can J Anaesth** 1995 Dec;42(12):1145–63 (134 ref.)

Anaesthetic management of labour and delivery in a woman taking long–term MAOI. Pavy TJ, et al. **Can J Anaesth** 1995 Jul;42(7):618–20

Anaesthetic management of labour and delivery in the parturient with mitochondrial myopathy. Rosaeg OP, et al. **Can J Anaesth** 1996 Apr;43(4):403–7

Obstetrical anaesthesia in Ontario [editorial] Smedstad KG. **Can J Anaesth** 1995 Dec;42(12):1071–5 **(Eng, Fre)**

The choice of anaesthetic technique for caesarean section does not affect plasma beta–endorphin levels in the neonate. Aktürk G, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):525–7

Ketamine and thiopentone in caesarean section [letter; comment] Maleck W. **Eur J Anaesthesiol** 1995 Sep; 12(5):533. Comment on: Eur J Anaesthesiol 1994 Mar;11(2):115–22.

Anesthesia with antiphospholipid antibodies: anesthetic management of a parturient with lupus anticoagulant and anticardiolipin antibody. Fahy BG, et al. **J Clin Anesth** 1996 Feb;8(1):49–53

Major conduction anesthesia in a patient with Klippel–Trenaunay Syndrome. Gaiser RR, et al. **J Clin Anesth** 1995 Jun;7(4):316–9

Cesarean section in a pregnant patient with an anterior mediastinal mass and failed supradiaphragmatic irradiation. Martin WJ. **J Clin Anesth** 1995 Jun;7(4):312–5

Elective tracheostomy in an obstetric patient [letter] Ovassapian A, et al. **J Clin Anesth** 1996 Jun;8(4):337–8

Combined spinal–epidural or standard epidural analgesia in labour [letter; comment] Brüssel T, et al. **Lancet** 1995 Nov 4;346(8984):1229. Comment on: Lancet 1995 Jun 3;345(8962):1413–6.

Ranitidine versus cimetidine prior to emergency obstetric anesthesia. Osman H. **Middle East J Anesthesiol** 1995 Jun; 13(2):205–11

Resolution of pachymeningeal enhancement following dural puncture and blood patch. Gordon RE, et al. **Neuroradiology** 1995 Oct;37(7):557–8

Nitrous oxide inhalation: effects on maternal and fetal circulations at term. Polvi HJ, et al. **Obstet Gynecol** 1996 Jun;87(6):1045–8

Subarachnoid fentanyl augments lidocaine spinal anesthesia for cesarean delivery. Palmer CM, et al. **Reg Anesth** 1995 Sep–Oct;20(5):389–94

Systemic vascular uptake of epinephrine from the lumbar epidural space in parturients. Ramanathan S, et al. **Reg Anesth** 1995 May–Jun;20(3):199–205

The pregnant patient with an intracranial arteriovenous malformation. Cesarean or vaginal delivery using regional or general anesthesia? Sharma SK, et al. **Reg Anesth** 1995 Sep–Oct;20(5):455–8

[Conduction anesthesia and the newborn infant] Palot M, et al. **Cah Anesthesiol** 1995;43(6):547–53 (Eng. Abstr.) **(Fre)**

[Epidural anesthesia—at any time] Vidil C. **Cah Anesthesiol** 1995;43(6):555–6 **(Fre)**

[Anesthesiologic aspects of pregnancy and delivery in a patient following a modified Fontan procedure] Braun U, et al. **Anaesthesist** 1996 Jun;45(6):545–9 (Eng. Abstr.) **(Ger)**

[Addition of fentanyl to bupivacaine—peridural analgesia in cesarean section] Thomas H, et al. **Anaesthesist** 1996 Jul; 45(7):635–42 (Eng. Abstr.) **(Ger)**

[Para–spinal analgesia in obstetrics] Schockenhoff B, et al. **Z Geburtshilfe Neonatol** 1995 May–Jun;199(3):99–102 (Eng. Abstr.) **(Ger)**

[Obstetrical anesthesia in Hungary (letter)] Iffy L. **Orv Hetil** 1995 Oct 8;136(41):2255–6 **(Hun)**

[HELP syndrome and anesthetic management] Kinouchi K, et al. **Masui** 1996 May;45(5):617–23 (Eng. Abstr.) **(Jpn)**

[Temperature changes and thermoregulatory responses during epidural anesthesia in women undergoing cesarean delivery] Negishi C, et al. **Masui** 1996 May;45(5):558–64 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Anesthesia for cesarean section in a patient with intracranial A–V malformation] Terao M, et al. **Masui** 1995 Dec; 44(12):1700–2 (Eng. Abstr.) **(Jpn)**

[A case report of vaginal delivery controlled by epidural anesthesia in a woman with high spinal cord injury] Kase H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep; 47(9):957–60 (14 ref.) **(Jpn)**

[Anesthesia for cesarean delivery in a case of myotonia congenita] Arcas M, et al. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):147–9 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Phenylephrine in treating maternal hypotension due to spinal anaesthesia for caesarean delivery: effects on neonatal catecholamine concentrations, acid base status and Apgar scores. LaPorta RF, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):901–5

Systemic vascular resistance index determined by thoracic electrical bioimpedance predicts the risk for maternal hypotension during regional anesthesia for cesarean delivery. Ouzounian JG, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):1019–25

Misplacement of multihole epidural catheters—a report of two cases. Sala–Blanch X, et al. **Anaesthesia** 1996 Apr; 51(4):386–8

Spinal anesthesia after failed epidural anesthesia [letter; comment] Gupta A. **Anesth Analg** 1996 Jan;82(1):214–5. Comment on: Anesth Analg 1994 Dec;79(6):1206–7.

Prevention of hypotension after spinal anesthesia for cesarean section: six percent hetastarch versus lactated Ringer's solution [see comments] Riley ET, et al. **Anesth Analg** 1995 Oct;81(4):838–42. Comment in: Anesth Analg 1996 May;82(5):1108–9.

Epidural anaesthesia and low back pain after delivery: a prospective cohort study. Macarthur A, et al. **BMJ** 1995 Nov 18;311(7016):1336–9

Epidural anaesthesia and low back pain after delivery [letter] McQuay H, et al. **BMJ** 1996 Mar 2;312(7030):581

Accidental insertion of an extradural catheter [letter] Fox A, et al. **Br J Anaesth** 1996 Feb;76(2):336

Volume preloading is not essential to prevent spinal–induced hypotension at caesarean section [see comments] Jackson R, et al. **Br J Anaesth** 1995 Sep;75(3):262–5. Comment in: Br J Anaesth 1995 Sep;75(3):257–9.

Effect of crystalloid and colloid preloading on uteroplacental and maternal haemodynamic state during spinal anaesthesia for caesarean section. Karinen J, et al. **Br J Anaesth** 1995 Nov;75(5):531–5

Maternal sequelae of childbirth [editorial] Reynolds F. **Br J Anaesth** 1995 Nov;75(5):515–7 (26 ref.)

Volume preloading, spinal hypotension and caesarean section [editorial; comment] Rocke DA, et al. **Br J Anaesth** 1995 Sep;75(3):257–9. Comment on: Br J Anaesth 1995 Sep;75(3):262–5.

Another complication of the combined extradural–subarachnoid technique [letter; comment] Stallard N, et al. **Br J Anaesth** 1995 Sep;75(3):370–1. Comment on: Br J Anaesth 1994 Oct;73(4):545–7.

Cardiac arrest at induction of anaesthesia for Caesarean section [letter] Wilson JA. **Br J Anaesth** 1996 Feb; 76(2):332–3

Neurological symptoms attributed to epidural analgesia in labour: an observational study of seven cases. Tubridy N, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):832–3

Delayed recovery after spinal anaesthesia using 0.5% cinchocaine. Nirmalan M, et al. **Ceylon Med J** 1995 Sep; 40(3):118–9

Epidurals redefined in analgesia and anesthesia: a distinction with a difference. Youngstrom PC, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):350–4 (14 ref.)

Piercing of dura during spinal anaesthesia [news] Brahams D. **Lancet** 1995 Dec 2;346(8988):1484

Respiratory depression associated with spinal narcotic anaesthesia [letter] Barratt P, et al. **Med J Aust** 1995 Oct 2;163(7):389

High spinal anesthesia after epidural test dose administration in five obstetric patients. Richardson MG, et al. **Reg Anesth** 1996 Mar–Apr;21(2):119–23

Backache after spinal anesthesia [letter; comment] Shutt LE. **Reg Anesth** 1995 May–Jun;20(3):253. Comment on: Reg Anesth 1994 Sep–Oct;19(5):364–5.

[Intradural anesthesia in cesarean sections (letter; comment)] de la Cruz Pérez CA. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):351–2. Comment on: Rev Esp Anestesiol Reanim 1994 Jul–Aug;41(4):217–20. **(Spa)**

ECONOMICS

Labor epidural catheter reactivation or spinal anesthesia for delayed postpartum tubal ligation: a cost comparison. Viscomi CM, et al. **J Clin Anesth** 1995 Aug;7(5):380–3

HISTORY

The supine hypotensive syndrome. 1960 [classical article] Holmes F. **Anaesthesia** 1995 Nov;50(11):972–7

INSTRUMENTATION

Equipment failure during epidural catheter placement [letter] Williams G, et al. **Anaesthesia** 1995 Sep;50(9):831

METHODS

Women cannot discriminate between different paracervical block techniques applied to opposite sides of the cervix. Grossman RA. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):935–6

The anaesthetic management of Caesarean section for placenta praevia: a questionnaire survey [see comments] Bonner SM, et al. **Anaesthesia** 1995 Nov;50(11):992–4. Comment in: Anaesthesia 1996 Apr;51(4):403.

Anaesthesia for caesarean section in a patient with Klippel–Feil syndrome. The use of a microspinal catheter. Dresner MR, et al. **Anaesthesia** 1995 Sep;50(9):807–9

Anaesthetic management of placenta praevia [letter; comment] Howard J, et al. **Anaesthesia** 1996 Apr;51(4):403 . Comment on: Anaesthesia 1995 Nov;50(11):992–4.

Infiltration anaesthesia in the management of Caesarean section in a patient with peripartum cardiomyopathy [letter] Mellor DJ, et al. **Anaesthesia** 1996 Apr;51(4):409

Spinal anaesthesia—sitting or lateral positions? [letter] Russell IF. **Anaesthesia** 1996 Feb;51(2):198–9

Arnold–chiari malformation in pregnancy. Semple DA, et al. **Anaesthesia** 1996 Jun;51(6):580–2

Spinal anesthesia after failed epidural anesthesia [letter; comment] Gupta A. **Anesth Analg** 1996 Jan;82(1):214–5. Comment on: Anesth Analg 1994 Dec;79(6):1206–7.

Ilioinguinal iliohypogastric nerve blocks—before or after cesarean delivery under spinal anesthesia? Huffnagle HJ, et al. **Anesth Analg** 1996 Jan;82(1):8–12

Anaesthetic management of acute puerperal uterine inversion. Abouleish E, et al. **Br J Anaesth** 1995 Oct;75(4):486–7

Anaesthetic management of caesarean section in a patient with active recurrent genital herpes and AIDS–related dementia. Birnbach DJ, et al. **Br J Anaesth** 1995 Nov; 75(5):639–41

Spinal anaesthesia for Caesarean section in women with incomplete extradural analgesia [letter] Stoneham M, et al. **Br J Anaesth** 1996 Mar;76(3):476

A hypertensive parturient with a supraventricular tachycardia. Lima J, et al. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):625–6

Anaesthetic dilemma: half a spinal is better than none. Smith AF, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12; 54(10):513–4

Alkalinization of lidocaine 2% does not influence the quality of epidural anaesthesia for elective caesarean section. Gaggero G, et al. **Can J Anaesth** 1995 Dec;42(12):1080–4

A double–blind randomized comparison of lidocaine and saline for cervical anesthesia. Miller L, et al. **Obstet Gynecol** 1996 Apr;87(4):600–4

Prospective survey of continuous versus single–injection spinal anesthesia in obstetrics. Bayhi D, et al. **South Med J** 1995 Oct;88(10):1043–8

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the anesthesiologist] Hamza J. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:97–107 (49 ref.) **(Fre)**

[Hospital day–surgery: comparative evaluation of 3 general anesthesia techniques] Rossi AE, et al. **Minerva Anestesiol** 1995 Jun;61(6):265–9 (Eng. Abstr.) **(Ita)**

[Puncture of the dura mater, diagnosis and treatment in

obstetrics] Villalpando Bravo J, et al. **Ginecol Obstet Mex** 1996 Feb;64:85-9 (35 ref.) (Eng. Abstr.) **(Spa)**

[Cesarean section in a myasthenia gravis patient (letter)] Facorro E, et al. **Rev Esp Anestesiol Reanim** 1996 Mar; 43(3):115 **(Spa)**

PSYCHOLOGY

Factors associated with mothers selecting general anesthesia for lower segment caesarean section. Holdcroft A, et al. **J Psychosom Obstet Gynaecol** 1995 Sep;16(3):167-70

STANDARDS

The use of obstetric emergency drug trays: room for improvement? [letter] Bryden D, et al. **Anaesthesia** 1996 Jul;51(7):709-10

STATISTICS & NUMERICAL DATA

Obstetrical anaesthesia in Ontario. Oyston J. **Can J Anaesth** 1995 Dec;42(12):1117-25

VETERINARY

Anesthesia for canine cesarian section. Brock N. **Can Vet J** 1996 Feb;37(2):117-8

[Anesthesia in cesarean section in dogs] Hellebrekers LJ. **Tijdschr Diergeneeskd** 1996 Jan 15;121(2):54 **(Dut)**

[Epidural anesthesia (letter)] Vrij JP. **Tijdschr Diergeneeskd** 1996 Mar 15;121(6):170 **(Dut)**

ANESTHESIA, PERIDURAL see **ANESTHESIA, EPIDURAL**

ANESTHESIA, REBREATHING see **ANESTHESIA, CLOSED-CIRCUIT**

ANESTHESIA RECOVERY PERIOD

see related
POSTANESTHESIA NURSING

Spontaneous recovery or evoked reversal of neuromuscular block. Mirakhur RK. **Acta Anaesthesiol Scand Suppl** 1995; 106:62-5 (25 ref.)

Assessment of recovery following day-case arthroscopy. A comparison between propofol and isoflurane-based anaesthesia. Gupta A, et al. **Anaesthesia** 1995 Nov; 50(11):937-42

Recovery from outpatient anaesthesia. Factors affecting outcome. Korttila K. **Anaesthesia** 1995 Oct;50 Suppl:22-8 (63 ref.)

Clonidine--and adjunct in isoflurane N2O/O2 relaxant anaesthesia [letter] Savva D. **Anaesthesia** 1996 Mar; 51(3):293

Spontaneous versus edrophonium-induced recovery from paralysis with mivacurium. Brandom BW, et al. **Anesth Analg** 1996 May;82(5):999-1002

Recovery profile after desflurane with or without ondansetron compared with propofol in patients undergoing outpatient gynecological laparoscopy. Eriksson H, et al. **Anesth Analg** 1996 Mar;82(3):533-8

Sevoflurane versus desflurane for outpatient anesthesia: a comparison of maintenance and recovery profiles. Nathanson MH, et al. **Anesth Analg** 1995 Dec;81(6):1186-90

Massive subcutaneous emphysema during emergence from anesthesia followed by seizures [letter] Oberoi MP, et al. **Anesth Analg** 1996 Mar;82(3):675

Technique for quantifying the duration of intravenous anesthetic effect [see comments] Bailey JM. **Anesthesiology** 1995 Nov;83(5):1095-103. Comment in: Anesthesiology 1995 Nov;83(5):902-5.

Faster recovery after anesthesia in infants after intravenous induction with methohexital instead of thiopental. Beskow A, et al. **Anesthesiology** 1995 Nov;83(5):976-9

Evolving clinically useful predictors of recovery from intravenous anesthetics [editorial; comment] Schnider TW, et al. **Anesthesiology** 1995 Nov;83(5):902-5. Comment on: Anesthesiology 1995 Nov;83(5):1095-103.

Mivacurium and prolonged neuromuscular block [letter; comment] [see comments] Davis L. **Br J Anaesth** 1995 Sep; 75(3):374. Comment on: Br J Anaesth 1995 Feb;74(2):234-6. Comment on: Br J Anaesth 1995 Feb;74(2):237-8. Comment in: Br J Anaesth 1995 Dec;75(6):823.

Heart rate variability in patients recovering from general anaesthesia. Ireland N, et al. **Br J Anaesth** 1996 May; 76(5):657-62

Recovery after electroconvulsive therapy: comparison of propofol with methohexitone anaesthesia. Matters RM, et al. **Br J Anaesth** 1995 Sep;75(3):297-300

Recovery room problems or problems in the PACU. Rose DK. **Can J Anaesth** 1996 May;43(5 Pt 2):R116-28 (50 ref.) **(Eng, Fre)**

Postobstructive pulmonary edema induced by endotracheal tube occlusion. Dicpinigaitis PV, et al. **Intensive Care Med** 1995 Dec;21(12):1048-50

Assessing the duration of mandibular soft tissue anesthesia. Hersh EV, et al. **J Am Dent Assoc** 1995 Nov;126(11):1531-6

Propofol infusion for induction and maintenance of anesthesia in elderly patients: recovery and hemodynamic profiles. Chan VW, et al. **J Clin Anesth** 1996 Jun;8(4):317-23

Pediatric postanesthesia recovery care. Hall SC. **J Clin Anesth** 1995 Nov;7(7):600-5 (27 ref.)

Recovery advantages of regional anesthesia compared with general anesthesia: adult patients. Mingus ML. **J Clin Anesth** 1995 Nov;7(7):628-33 (69 ref.)

Respiratory complications in children emerging from halothane anesthesia--awake vs deep extubation. Karam R, et al. **Middle East J Anesthesiol** 1995 Jun;13(2):221-9

Delayed recovery from anaesthesia in Rubinstein-Taybi syndrome [letter] Dunkley CJ, et al. **Paediatr Anaesth** 1996; 6(3):245-6

Absence of corpus callosum and history of slow recovery [letter] Waite I, et al. **Paediatr Anaesth** 1995;5(4):273-4

[Desflurane and isoflurane. A comparison of recovery and circulatory parameters in surgical interventions] Wilhelm W, et al. **Anaesthesist** 1996 Jan;45(1):37-46 (Eng. Abstr.) **(Ger)**

[Rates of awakening, circulatory parameters and side-effects with sevoflurane and enflurane. An open, randomized, comparative phase III study] Wiesner G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):290-6 (Eng. Abstr.) **(Ger)**

[Anesthetic pharmacology in recovery rooms (editorial; comment)] García RC. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):301-2. Comment on: Rev Esp Anestesiol Reanim 1995 Oct;42(8):303-5. Comment on: Rev Esp Anestesiol Reanim 1995 Oct;42(8):344-8. **(Spa)**

ANESTHESIA, RECTAL

Behavioural changes and children's memories after intravenous, inhalation and rectal induction of anaesthesia. Kotiniemi LH, et al. **Paediatr Anaesth** 1996;6(3):201-7

[Rectal administration of anesthetic agents] Ceriana P, et al. **Minerva Anestesiol** 1995 May;61(5):219-28 (33 ref.) (Eng. Abstr.) **(Ita)**

ANESTHESIA, REFRIGERATION see **HYPOTHERMIA, INDUCED**

ANESTHESIA, REGIONAL see **ANESTHESIA, CONDUCTION**

ANESTHESIA, SACRAL EPIDURAL see **ANESTHESIA, CAUDAL**

ANESTHESIA, SPINAL

Management of a spinal catheter that became intravascular. Gaggero G, et al. **Acta Anaesthesiol Scand** 1995 Nov; 39(8):1131-3

A double blind comparison of lidocaine 2% with or without glucose for spinal anesthesia. Harbers JB, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):881-4

The influence of aging on skin temperature and hemodynamic changes during spinal anesthesia. Hirose M, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):891-5

Pharmacodynamics of subarachnoid hyperbaric 5% lignocaine. Jones RD, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):350-7

Comparison of spinal anaesthesia with epidural anaesthesia in paediatric surgery. Kokki H, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):896-900

Spinal anesthesia attenuates myocardial ischemia during coronary artery spasm induced by intraaortic methacholine in rats. Mizuyama K, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):802-8

The effect of intrathecal bupivacaine with combined fentanyl in cesarean section. Chu CC, et al. **Acta Anaesthesiol Sin** 1995 Sep;33(3):149-54

Combined spinal and interscalene blocks [letter] Hack HA, et al. **Anaesth Intensive Care** 1995 Oct;23(5):653-4

Effects of midazolam on heart rate variability during surgery under spinal anaesthesia. Kawamoto M, et al. **Anaesth Intensive Care** 1995 Aug;23(4):464-8

The anaesthetic management of Caesarean section for placenta praevia: a questionnaire survey [see comments] Bonner SM, et al. **Anaesthesia** 1995 Nov;50(11):992-4. Comment in: Anaesthesia 1996 Apr;51(4):403.

Shortcomings in the combined spinal-extradural technique [letter] Holt M, et al. **Anaesthesia** 1996 Aug;51(8):801-2

Delayed amniotic fluid embolism following caesarean section under spinal anaesthesia. Margarson MP. **Anaesthesia** 1995 Sep;50(9):804-6

Wearing of masks for obstetric regional anaesthesia. A postal survey. Panikkar KK, et al. **Anaesthesia** 1996 Apr; 51(4):398-400

Effect of intravenous fluid preload on vasoactive peptide secretion during Caesarean section under spinal anaesthesia [see comments] Pouta AM, et al. **Anaesthesia** 1996 Feb; 51(2):128-32. Comment in: Anaesthesia 1996 Jun;51(6):609.

Maternal position during induction of spinal anaesthesia for caesarean section [letter; comment] Serpell MG, et al. **Anaesthesia** 1995 Oct;50(10):921-2. Comment on: Anaesthesia 1995 Apr;50(4):363-5.

Spinal anaesthesia in acute colonic pseudo-obstruction [letter] Simini B. **Anaesthesia** 1995 Dec;50(12):1103

Effect of bupivacaine-induced spinal block on the hypnotic requirement of propofol. Tverskoy M, et al. **Anaesthesia** 1996 Jul;51(7):652-3

Hyperbaric lidocaine spinal anesthesia: do we need an alternative? [editorial; comment] Carpenter RL. **Anesth Analg** 1995 Dec;81(6):1125-8. Comment on: Anesth Analg 1995 Dec;81(6):1148-53.

Spinal versus epidural anesthesia for cesarean section [letter; comment] Colclough GW. **Anesth Analg** 1995 Dec; 81(6):1318-9. Comment on: Anesth Analg 1995 Apr;80(4):709-12.

Spinal anesthesia with bupivacaine and fentanyl in geriatric patients. Fernandez-Galinski D, et al. **Anesth Analg** 1996 Sep;83(3):537-41

Spinal anesthesia after failed epidural anesthesia [letter; comment] Gupta A. **Anesth Analg** 1996 Jan;82(1):214-5. Comment on: Anesth Analg 1994 Dec;79(6):1206-7.

Transient neurologic symptoms after spinal anesthesia [see comments] Hampl KF, et al. **Anesth Analg** 1995 Dec; 81(6):1148-53. Comment in: Anesth Analg 1995 Dec;81(6):1125-8. Comment in: Anesth Analg 1996 Aug;83(2):437-8.

A prospective randomized study comparing short- and intermediate-term perioperative outcome variables after spinal or general anesthesia for lumbar disk and laminectomy surgery. Jellish WS, et al. **Anesth Analg** 1996 Sep;83(3):559-64

Patient comfort: spinal versus epidural anesthesia for cesarean section [letter; comment] Keohane M. **Anesth Analg** 1996 Jan;82(1):219. Comment on: Anesth Analg 1995 Apr;80(4):709-12.

Comparison of 5% with dextrose, 1.5% with dextrose, and 1.5% dextrose-free lidocaine solutions for spinal anesthesia in human volunteers. Liu S, et al. **Anesth Analg** 1995 Oct; 81(4):697-702

Transition from intrathecal analgesia to epidural anesthesia for emergency cesarean section using a combined spinal epidural technique [letter] Mercier FJ, et al. **Anesth Analg** 1996 Aug;83(2):434

Spinal anesthesia by local anesthetics stimulates the enzyme protein kinase C and induces the expression of an immediate early oncogene, c-Fos. Nivarthi RN, et al. **Anesth Analg** 1996 Sep;83(3):542-7

Crystalloids, colloids, and spinal anesthesia [letter; comment] Puri GD. **Anesth Analg** 1996 May;82(5):1108-9. Comment on: Anesth Analg 1995 Oct;81(4):838-42.

Intrathecal bleeding after the intraoperative use of heparin and urokinase during continuous spinal anesthesia. Rabito SF, et al. **Anesth Analg** 1996 Feb;82(2):409-11

Mechanism of action of an epidural top-up in combined spinal epidural anesthesia. Stienstra R, et al. **Anesth Analg** 1996 Aug;83(2):382-6

The effect of prior dural puncture on cisternal cerebrospinal fluid morphine concentrations in sheep after administration of lumbar epidural morphine. Swenson JD, et al. **Anesth Analg** 1996 Sep;83(3):523-5

A retrospective comparison of spinal and general anesthesia for vaginal hysterectomy: a time analysis. Tessler MJ, et al. **Anesth Analg** 1995 Oct;81(4):694-6

Spinal anesthesia and midazolam hypnotic requirements [letter; comment] Tverskoy M, et al. **Anesth Analg** 1996 Jul;83(1):198-9. Comment on: Anesth Analg 1995 Sep;81(3):525-8.

Combined spinal/epidural anesthesia for outpatient surgery [letter; comment] Joshi GP. **Anesthesiology** 1996 Feb; 84(2):481-2. Comment on: Anesthesiology 1995 Sep;83(3):528-34.

Reduction in the shivering threshold is proportional to spinal block height. Leslie K, et al. **Anesthesiology** 1996 Jun; 84(6):1327-31

Shivering threshold during spinal anesthesia is reduced in elderly patients. Vassilieff N, et al. **Anesthesiology** 1995 Dec;83(6):1162-6

Effects of preemptive or postinjury intrathecal local anesthesia on persistent nociceptive responses in rats. Confounding influences of peripheral inflammation and the general anesthetic regimen. Yashpal K, et al. **Anesthesiology** 1996 May;84(5):1119-28

CSF progesterone concentrations in pregnancy [letter; comment] Baliga N. **Br J Anaesth** 1996 Jun;76(6):886. Comment on: Br J Anaesth 1995 Dec;75(6):683-7.

Intrathecal insertion of an extradural catheter during combined spinal-extradural anaesthesia [letter; comment] Camann W. **Br J Anaesth** 1996 Jan;76(1):169. Comment on: Br J Anaesth 1995 Sep;75(3):355-7.

Hypotension during subarachnoid anaesthesia: haemodynamic effects of colloid and metaraminol. Critchley LA, et al. **Br J Anaesth** 1996 May;76(5):734-6

Postoperative brachial plexus neuropathy after total knee replacement under spinal anaesthesia. Eggers KA, et al. **Br J Anaesth** 1995 Nov;75(5):642-4

Effect of i.v. diamorphine on regression of spinal block [letter; comment] Findlay GP. **Br J Anaesth** 1995 Oct; 75(4):509. Comment on: Br J Anaesth 1995 May;74(5):610-1.

Spinal clonidine produces less urinary retention than spinal morphine. Gentili M, et al. **Br J Anaesth** 1996 Jun; 76(6):872-3

Cerebrospinal fluid progesterone in pregnant women [see comments] Hirabayashi Y, et al. **Br J Anaesth** 1995 Dec; 75(6):683-7. Comment in: Br J Anaesth 1996 Jun;76(6):886.

Visceral pain during caesarean section: effect of varying dose of spinal amethocaine [see comments] Hirabayashi Y, et al. **Br J Anaesth** 1995 Sep;75(3):266-8. Comment in: Br J Anaesth 1996 Jan;76(1):167.

Maternal and uteroplacental haemodynamic state in pre-eclamptic patients during spinal anaesthesia for Caesarean section. Karinen J, et al. **Br J Anaesth** 1996 May; 76(5):616-20

Volume preloading, spinal anaesthesia and Caesarean section [letter] Lawes EG. **Br J Anaesth** 1996 Feb;76(2):334–5
Intrathecal insertion of an extradural catheter during combined spinal–extradural anaesthesia [letter; comment] Lee JS, et al. **Br J Anaesth** 1996 Jan;76(1):169–70. Comment on: Br J Anaesth 1995 Sep;75(3):355–7.
Volume preloading, spinal anaesthesia and Caesarean section [letter] Mallick A, et al. **Br J Anaesth** 1996 Feb;76(2):335–6
Accidental intrathecal insertion of an extradural catheter during combined spinal–extradural anaesthesia for caesarean section [see comments] Robbins PM, et al. **Br J Anaesth** 1995 Sep;75(3):355–7. Comment in: Br J Anaesth 1996 Jan;76(1):169. Comment in: Br J Anaesth 1996 Jan;76(1):169–70.
Reducing the potential morbidity of an unintentional spinal anaesthetic by aspirating cerebrospinal fluid. Southorn P, et al. **Br J Anaesth** 1996 Mar;76(3):467–9
Spinal anaesthesia for Caesarean section in women with incomplete extradural analgesia [letter] Stoneham M, et al. **Br J Anaesth** 1996 Mar;76(3):476
Randomized trial of bolus phenylephrine or ephedrine for maintenance of arterial pressure during spinal anaesthesia for Caesarean section. Thomas DG, et al. **Br J Anaesth** 1996 Jan;76(1):61–5
Hydroxyethylstarch compared with modified gelatin as volume preload before spinal anaesthesia for Caesarean section. Vercauteren MP, et al. **Br J Anaesth** 1996 May; 76(5):731–3
Problems caused by osteogenesis imperfecta. Walker RW, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):182
A combination of low dose spinal and general anaesthesia for laparoscopic cholecystectomy [letter] Gurmarnik S, et al. **Can J Anaesth** 1996 Jan;43(1):95
Hypobaric spinal anaesthesia with bupivacaine (0.1%) gives selective sensory block for ano–rectal surgery. Maroof M, et al. **Can J Anaesth** 1995 Aug;42(8):691–4
Spinal anaesthesia in obstetrics. Morgan P. **Can J Anaesth** 1995 Dec;42(12):1145–63 (134 ref.)
Delayed bilateral spinal anaesthesia following interscalene brachial plexus block. Norris D, et al. **Can J Anaesth** 1996 Mar;43(3):303–5
Spinal ketamine anaesthesia for hemithyroidectomy [letter] Sekaran NK, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):537–8
Intrathecal fentanyl prolongs sensory bupivacaine spinal block. Singh H, et al. **Can J Anaesth** 1995 Nov; 42(11):987–91
Dysregulation in blood pressure homeostasis during spinal anaesthesia in elderly patients. Röhrle G, et al. **Clin Sci (Colch)** 1996;91 Suppl:95–6
Hemodynamic effects of intrathecal fentanyl in nonlaboring term parturients. Grant GJ, et al. **J Clin Anesth** 1996 Mar; 8(2):99–103
Cesarean section in a pregnant patient with an anterior mediastinal mass and failed supradiaphragmatic irradiation. Martin WJ. **J Clin Anesth** 1995 Jun;7(4):312–5
Spinal anesthesia for outpatients: appropriate agents and techniques. Mulroy MF, et al. **J Clin Anesth** 1995 Nov; 7(7):622–7 (39 ref.)
Re: Spinal phobia: survey results of patient attitudes and preferences regarding anesthesia [letter] Parnass SM, et al. **J Clin Anesth** 1996 Jun;8(4):340
Spinal anesthesia for spine and lower extremity surgery in infants. Aronsson DD, et al. **J Pediatr Orthop** 1996 Mar–Apr;16(2):259–63
Combined spinal–epidural or standard epidural analgesia in labour [letter; comment] Brüssel T, et al. **Lancet** 1995 Nov 4;346(8984):1229. Comment on: Lancet 1995 Jun 3;345(8962):1413–6.
Combined spinal–epidural–general anesthesia. Eldor J. **Med Hypotheses** 1995 Jul;45(1):86–90
Continuous spinal anaesthesia—early experience in University Hospital, Kuala Lumpur. Vijayan R, et al. **Med J Malaysia** 1995 Dec;50(4):401–10
Total spinal anaesthesia following caudal block with bupivacaine and buprenorphine. Afshan G, et al. **Paediatr Anaesth** 1996;6(3):239–42
Spinal anaesthesia in newborns: total and free bupivacaine plasma concentration. Beauvoir C, et al. **Paediatr Anaesth** 1996;6(3):195–9
Comments on combined spinal–epidural anesthesia [letter] Birnbach DJ, et al. **Reg Anesth** 1996 May–Jun;21(3):275
Is spinal anesthesia produced only by local anesthetics? [editorial; comment] Butterworth J, et al. **Reg Anesth** 1996 Mar–Apr;21(2):81–3. Comment on: Reg Anesth 1996 Mar–Apr;21(2):84–8.
Preoperative spinal bupivacaine does not reduce postoperative morphine requirement in women undergoing total abdominal hysterectomy. Dakin MJ, et al. **Reg Anesth** 1996 Mar–Apr;21(2):99–102
Correct dose of tetracaine in infants [letter; comment] Fortuna A, et al. **Reg Anesth** 1995 Jul–Aug;20(4):358. Comment on: Reg Anesth 1994 Sep–Oct;19(5):325–9.
Treatment of supraventricular tachycardia under spinal anesthesia [letter] Gajraj NM, et al. **Reg Anesth** 1995 Jul–Aug;20(4):359
Combined spinal–epidural–general anesthesia revisited [letter; comment] Gudin JA, et al. **Reg Anesth** 1995 Sep–Oct; 20(5):465–6. Comment on: Reg Anesth 1994 Sep–Oct;19(5):365–6. Comment on: Reg Anesth 1994 Nov–Dec;19(6):418–22.
Hyperosmolarity does not contribute to transient radicular irritation after spinal anesthesia with hyperbaric 5% lidocaine. Hampl KF, et al. **Reg Anesth** 1995 Sep–Oct; 20(5):363–8
Spinal analgesia during labor with low-dose bupivacaine, sufentanil, and epinephrine. A comparison with epidural analgesia. Kartawiadi L, et al. **Reg Anesth** 1996 May–Jun; 21(3):191–6
A comparison of meperidine and lidocaine for spinal anesthesia for postpartum tubal ligation [see comments] Norris MC, et al. **Reg Anesth** 1996 Mar–Apr;21(2):84–8. Comment in: Reg Anesth 1996 Mar–Apr;21(2):81–3.
Subarachnoid fentanyl augments lidocaine spinal anesthesia for cesarean delivery. Palmer CM, et al. **Reg Anesth** 1995 Sep–Oct;20(5):389–94
Analgesic effect of incisional morphine following inguinal herniotomy under spinal anesthesia. Rosenstock C, et al. **Reg Anesth** 1996 Mar–Apr;21(2):93–8
Comment on anesthesia technique described by Eldor [letter; comment] Stienstra R. **Reg Anesth** 1995 Jul–Aug; 20(4):359–60. Comment on: Reg Anesth 1994 Sep–Oct;19(5):365–6.
Spinal anesthesia. Volume or concentration—what matters? Van Zundert AA, et al. **Reg Anesth** 1996 Mar–Apr; 21(2):112–8
[Should a 5% solution of hyperbaric lidocaine be used in spinal anesthesia? (letter)] Erichsen CJ, et al. **Ugeskr Laeger** 1996 Jan 15;158(3):288 **(Dan)**
[Spinal anesthesia in children] Ecoffey C. **Cah Anesthesiol** 1995;43(3):277–80 **(Fre)**
[Midazolam versus placebo before spinal anesthesia] Fletcher D, et al. **Cah Anesthesiol** 1995;43(5):497–9 (Eng. Abstr.) **(Fre)**
[The effect of puncture needle on the subarachnoid catheter position in continuous spinal anesthesia] Standl T, et al. **Anaesthesist** 1995 Dec;44(12):826–30 (Eng. Abstr.) **(Ger)**
[Objective quantification of spinal anesthesia by somatosensory evoked potentials after tibial nerve stimulation] Ebeling BJ, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):366–9 (Eng. Abstr.) **(Ger)**
[Urethrovesical morphology in continent women in spinal anesthesia] Hanzal E, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35(3):173–4 (Eng. Abstr.) **(Ger)**
[Density, specific gravity and baricity of various spinal anesthetics and those of normal human cerebrospinal fluid in Japanese] Masuda R, et al. **Masui** 1995 Nov; 44(11):1527–32 (Eng. Abstr.) **(Jpn)**
[The use of low dose midazolam for the management of spinal anesthesia] Nagahama H, et al. **Masui** 1996 May;45(5):593–8 (Eng. Abstr.) **(Jpn)**
[Perioperative management of a patient with severe bronchial asthma attack] Ochiai N, et al. **Masui** 1995 Aug; 44(8):1124–7 (Eng. Abstr.) **(Jpn)**
[Spinal–epidural anesthesia: hemodynamics and hemostasis] Nikolaev EK, et al. **Anesteziol Reanimatol** 1995 Jul–Aug; (4):61–3 (Eng. Abstr.) **(Rus)**
[Mechanisms of the favorable effect of spinal anesthesia in traumatic shock] Cernak I, et al. **Vojnosanit Pregl** 1994 Mar–Apr;51(2):107–13 (Eng. Abstr.) **(Scr)**

ADVERSE EFFECTS

Safe perioperative spinal and epidural analgesia: importance of drug combinations, segmental site of injection, training and monitoring [editorial; comment] Breivik H. **Acta Anaesthesiol Scand** 1995 Oct;39(7):869–71. Comment on: Acta Anaesthesiol Scand 1995 Oct;39(7):872–80.
Neurological complications after anaesthesia. A follow-up of 18,000 spinal and epidural anaesthetics performed over three years [see comments] Dahlgren N, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):872–80. Comment in: Acta Anaesthesiol Scand 1995 Oct;39(7):859–68. Comment in: Acta Anaesthesiol Scand 1995 Oct;39(7):869–71.
Phenylephrine in treating maternal hypotension due to spinal anaesthesia for caesarean delivery: effects on neonatal catecholamine concentrations, acid base status and Apgar scores. LaPorta RF, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):901–5
Postdural puncture headache (PDPH): onset, duration, severity, and associated symptoms. An analysis of 75 consecutive patients with PDPH. Lybecker H, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):605–12
Neurological complications of central nerve blocks [editorial; comment] Renck H. **Acta Anaesthesiol Scand** 1995 Oct; 39(7):859–68 (93 ref.). Comment on: Acta Anaesthesiol Scand 1995 Oct;39(7):872–80.
Postoperative complaints after spinal and thiopentone–isoflurane anaesthesia in patients undergoing orthopaedic surgery. Spinal versus general anaesthesia. Standl T, et al. **Acta Anaesthesiol Scand** 1996 Feb; 40(2):222–6
Spinal subdural haematoma following combined spinal–epidural anaesthesia. Bougher RJ, et al. **Anaesth Intensive Care** 1995 Jun;23(3):373–5
Convulsion following spinal anaesthesia [letter] Sun KO. **Anaesth Intensive Care** 1995 Aug;23(4):520–1
Back pain—must be the anaesthetic! [letter; comment] Cartwright PD. **Anaesthesia** 1996 Jun;51(6):608–9. Comment on: Anaesthesia 1994 Aug;49(8):700–2. Comment on: Anaesthesia 1996 Feb;51(2):178–81.
Ondansetron for the treatment of pruritus after spinal opioids [letter] Crighton IM, et al. **Anaesthesia** 1996 Feb; 51(2):199–200
Transient radicular irritation after single subarachnoid injection of isobaric 2% lignocaine for spinal anaesthesia [see comments] Hampl KF, et al. **Anaesthesia** 1996 Feb; 51(2):178–81. Comment in: Anaesthesia 1996 Jun;51(6):608–9.
Delayed paraplegia following spinal anaesthesia. Spinal subdural haematoma following dural puncture with a 25 G pencil point needle at T12–L1 in a patient taking aspirin. Pryle BJ, et al. **Anaesthesia** 1996 Mar;51(3):263–5
Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine. Salmela L, et al. **Anaesthesia** 1996 Apr;51(4):391–3
Transient neurologic symptoms after spinal anesthesia [letter; comment] Erian R, et al. **Anesth Analg** 1996 Aug; 83(2):437–8. Comment on: Anesth Analg 1995 Dec;81(6):1148–53.
Combined use of spinal anesthesia and midazolam sedation increases the risk of hypoxemia [letter; comment] Muñoz HR, et al. **Anesth Analg** 1996 Jul;83(1):195–6. Comment on: Anesth Analg 1995 Sep;81(3):525–8.
Long–term postdural puncture auditory symptoms: effective relief after epidural blood patch [letter] Narchi P, et al. **Anesth Analg** 1996 Jun;82(6):1303
Prevention of hypotension after spinal anesthesia for cesarean section: six percent hetastarch versus lactated Ringer's solution [see comments] Riley ET, et al. **Anesth Analg** 1995 Oct;81(4):838–42. Comment in: Anesth Analg 1996 May;82(5):1108–9.
Coronary perfusion pressure during cardiopulmonary resuscitation after spinal anesthesia in dogs. Rosenberg JM, et al. **Anesth Analg** 1996 Jan;82(1):84–7
Coagulopathies in patients after transurethral resection of the prostate: spinal versus general anesthesia [see comments] Smyth R, et al. **Anesth Analg** 1995 Oct;81(4):680–5. Comment in: Anesth Analg 1996 Jul;83(1):195.
Intrathecal hyperbaric 0.5% tetracaine as a possible cause of transient neurologic toxicity. Sumi M, et al. **Anesth Analg** 1996 May;82(5):1076–7
Intravenous ketorolac tromethamine worsens platelet function during knee arthroscopy under spinal anesthesia. Thwaites BK, et al. **Anesth Analg** 1996 Jun;82(6):1176–81
Permanent unilateral vestibulocochlear dysfunction after spinal anesthesia. Wemama JP, et al. **Anesth Analg** 1996 Feb;82(2):406–8
Pneumocephalus after spinal anesthesia. Avellanal M, et al. **Anesthesiology** 1996 Aug;85(2):423–5
Coronary artery spasm after ephedrine in a patient with high spinal anesthesia. Hirabayashi Y, et al. **Anesthesiology** 1996 Jan;84(1):221–4
Prospective study of the incidence of transient radicular irritation in patients undergoing spinal anesthesia. Pollock JE, et al. **Anesthesiology** 1996 Jun;84(6):1361–7
Volume preloading is not essential to prevent spinal–induced hypotension at caesarean section [see comments] Jackson R, et al. **Br J Anaesth** 1995 Sep;75(3):262–5. Comment in: Br J Anaesth 1995 Sep;75(3):257–9.
Effect of crystalloid and colloid preloading on uteroplacental and maternal haemodynamic state during spinal anaesthesia for caesarean section. Karinen J, et al. **Br J Anaesth** 1995 Nov;75(5):531–5
Volume preloading, spinal hypotension and caesarean section [editorial; comment] Rocke DA, et al. **Br J Anaesth** 1995 Sep;75(3):257–9. Comment on: Br J Anaesth 1995 Sep;75(3):262–5.
Bilateral severe pain at L3–4 after spinal anaesthesia with hyperbaric 5% lignocaine. Rodríguez–Chinchilla R, et al. **Br J Anaesth** 1996 Feb;76(2):328–9
Another complication of the combined extradural–subarachnoid technique [letter; comment] Stallard N, et al. **Br J Anaesth** 1995 Sep;75(3):370–1. Comment on: Br J Anaesth 1994 Oct;73(4):545–7.
Anterior epidural haematoma following subarachnoid block [letter] Bartoli F, et al. **Can J Anaesth** 1996 Jan;43(1):94
Leg pains after spinal anaesthesia [letter] Cozanitis DA. **Can J Anaesth** 1995 Jul;42(7):657
Temporary back and leg pain after bupivacaine and morphine spinal anaesthesia. Ong B, et al. **Can J Anaesth** 1995 Sep; 42(9):805–7
Impaired haemostasis and regional anaesthesia. Stafford–Smith M. **Can J Anaesth** 1996 May;43(5 Pt 2):R129–41 (33 ref.) **(Eng, Fre)**
Delayed recovery after spinal anaesthesia using 0.5% cinchocaine. Nirmalan M, et al. **Ceylon Med J** 1995 Sep; 40(3):118–9
Postoperative transient bradycardia and asystole after bilateral bunionectomies performed using spinal anesthesia. Agostinelli JR, et al. **J Foot Ankle Surg** 1995 Sep–Oct; 34(5):498–500; discussion 511–2
Piercing of dura during spinal anaesthesia [news] Brahams D. **Lancet** 1995 Dec 2;346(8988):1484
Respiratory depression associated with spinal narcotic anaesthesia [letter] Barratt P, et al. **Med J Aust** 1995 Oct 2;163(7):389
Comment on spinal–epidural anesthesia case report by Eldor et al [letter; comment] Camann W. **Reg Anesth** 1995 Sep–Oct;20(5):460–1. Comment on: Reg Anesth 1994 Nov–Dec;19(6):418–22.
Delayed respiratory arrest in combined spinal–epidural anesthesia [letter; comment] Carrie LE, et al. **Reg Anesth** 1995 Nov–Dec;20(6):546–7. Comment on: Reg

Anesth 1994 Nov-Dec;19(6):418-22.
Auditory, ocular, and facial complications of central neural block. A review of possible mechanisms. Day CJ, et al. **Reg Anesth** 1996 May-Jun;21(3):197-201 (28 ref.)
Aseptic meningitis due to metallic particles in the needle-through-needle technique [letter] Eldor J, et al. **Reg Anesth** 1995 Jul-Aug;20(4):360
Postdural puncture headache and air travel after spinal anesthesia with a 24-gauge Sprotte needle [letter] Panadero A, et al. **Reg Anesth** 1995 Sep-Oct;20(5):463-4
Wrapping of the legs reduces the decrease in blood pressure following spinal anesthesia. A study in men undergoing urologic procedures. Pollard J, et al. **Reg Anesth** 1995 Sep-Oct;20(5):402-6
Backache after spinal anesthesia [letter; comment] Shutt LE. **Reg Anesth** 1995 May-Jun;20(3):253. Comment on: Reg Anesth 1994 Sep-Oct;19(5):364-5.
[Compression stockings as prevention of hypotension in Cesarean section during spinal anesthesia] Jørgensen J, et al. **Ugeskr Laeger** 1996 Mar 11;158(11):1526-9 (Eng. Abstr.) **(Dan)**
[Headache after spinal anesthesia treated with sumatriptan (letter)] Rohmer C, et al. **Ann Fr Anesth Reanim** 1995; 14(2):237 **(Fre)**
[Delayed low back pain after spinal anesthesia] Sardin B, et al. **Ann Fr Anesth Reanim** 1995;14(2):230-2 (Eng. Abstr.) **(Fre)**
[A new two-chamber model for examination and demonstration of transdural fluid leakage after spinal anesthesia] Enk D, et al. **Anaesthesist** 1995 Nov; 44(11):761-9 (Eng. Abstr.) **(Ger)**
[Intradural anesthesia in cesarean sections (letter; comment)] de la Cruz Pérez CA. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):351-2. Comment on: Rev Esp Anestesiol Reanim 1994 Jul-Aug;41(4):217-20. **(Spa)**
[Subdural hematoma after spinal anesthesia. A rare but serious complication] Vojin CD, et al. **Lakartidningen** 1995 Oct 18;92(42):3904, 3907 **(Swe)**

ECONOMICS

Labor epidural catheter reactivation or spinal anesthesia for delayed postpartum tubal ligation: a cost comparison. Viscomi CM, et al. **J Clin Anesth** 1995 Aug;7(5):380-3

HISTORY

The supine hypotensive syndrome. 1960 [classical article] Holmes F. **Anaesthesia** 1995 Nov;50(11):972-7
Maternal sequelae of childbirth [letter] Hutter CD. **Br J Anaesth** 1996 Mar;76(3):474-5
Huber needle and Tuohy catheter [letter] Eldor J. **Reg Anesth** 1995 May-Jun;20(3):252-3
[Priority conflict concerning the discovery of lumbar anesthesia between August Bier and August Hildebrandt] Goerig M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Mar; 31(2):111-9 (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Sprotte needle introducers [letter; comment] Simmons S. **Anaesth Intensive Care** 1995 Aug;23(4):516-7. Comment on: Anaesth Intensive Care 1995 Apr;23(2):259-60.
Are pencil point needles the answer for peripheral neural blockade? [letter; comment] Lam EW, et al. **Anaesthesia** 1995 Dec;50(12):1102. Comment on: Anaesthesia 1995 Jun;50(6):573.
Lessons from in vitro testing of spinal needles [see comments] Lyons G, et al. **Anaesthesia** 1995 Nov;50(11):964-8. Comment in: Anaesthesia 1996 Jun;51(6):610.
Clinical characteristics of commonly used spinal needles [letter; comment] Parry M, et al. **Anaesthesia** 1995 Dec; 50(12):1095-6. Comment on: Anaesthesia 1995 Jun;50(6):523-5.
Unilateral spinal anesthesia using low-flow injection through a 29-gauge Quincke needle. Meyer J, et al. **Anesth Analg** 1996 Jun;82(6):1188-91
Comparison of 26-gauge Atraucan and 25-gauge Whitacre needles: insertion characteristics and complications. Sharma SK, et al. **Can J Anaesth** 1995 Aug;42(8):706-10
A directional needle improves effectiveness and reduces complications of microcatheter continuous spinal anaesthesia. Standl T, et al. **Can J Anaesth** 1995 Aug; 42(8):701-5
Comparison of 25 G and 29 G Quincke spinal needles in paediatric day case surgery. A prospective randomized study of the puncture characteristics, success rate and postoperative complaints. Kokki H, et al. **Paediatr Anaesth** 1996;6(2):115-9
Sprotte spinal needle: a new design [letter] Currir DS, et al. **Reg Anesth** 1996 Mar-Apr;21(2):172-3
Modified Tuohy needle for spinal anesthesia in a morbidly obese patient [letter] McVeigh JR, et al. **Reg Anesth** 1996 Mar-Apr;21(2):173
[Acute spinal subdural hematoma after attempted spinal anesthesia] Likar R, et al. **Anaesthesist** 1996 Jan;45(1):66-9 (Eng. Abstr.) **(Ger)**
[An atraumatic needle for continuous epidural and plexus anesthesia] Sprotte G. **Anaesthesist** 1995 Nov;44(11):789-92 (Eng. Abstr.) **(Ger)**
[The clinical usefulness and problem of combined spinal epidural needle] Kitamura A, et al. **Masui** 1995 Nov; 44(11):1533-6 (Eng. Abstr.) **(Jpn)**
[Evaluation of 26G pencil point spinal needle in combined epidural-spinal anesthesia] Sonoda H, et al. **Masui** 1995 Oct;44(10):1410-4 (Eng. Abstr.) **(Jpn)**

METHODS

Spinal anaesthesia induced by intrathecal magnesium sulphate. Bahar M, et al. **Anaesthesia** 1996 Jul;51(7):627-33
The effect of cerebrospinal fluid dilution of isobaric 0.5% bupivacaine used for spinal anaesthesia. Cherng YG, et al. **Anaesthesia** 1995 Oct;50(10):906-9
Anaesthesia for caesarean section in a patient with Klippel-Feil syndrome. The use of a microspinal catheter. Dresner MR, et al. **Anaesthesia** 1995 Sep;50(9):807-9
Anaesthesia and adverse effects after intrathecal pethidine hydrochloride for urological surgery. Grace D, et al. **Anaesthesia** 1995 Dec;50(12):1036-40
Spinal anaesthesia--sitting or lateral positions? [letter] Russell IF. **Anaesthesia** 1996 Feb;51(2):198-9
'More than meets the eye' [letter; comment] Sarmah A, et al. **Anaesthesia** 1996 Jun;51(6):610. Comment on: Anaesthesia 1995 Nov;50(11):964-8.
The level is TEE-FORE [letter] Camann W. **Anesth Analg** 1996 Feb;82(2):439
Spinal needle deflection in the combined spinal-epidural technique [letter] Eldor J. **Anesth Analg** 1996 Sep;83(3):663
Hemodynamic effects of spinal anesthesia in the elderly: single dose versus titration through a catheter. Favarel-Garrigues JF, et al. **Anesth Analg** 1996 Feb; 82(2):312-6
Ilioinguinal iliohypogastric nerve blocks--before or after cesarean delivery under spinal anesthesia? Huffnagle HJ, et al. **Anesth Analg** 1996 Jan;82(1):8-12
Unilateral spinal anesthesia using low-flow injection through a 29-gauge Quincke needle. Meyer J, et al. **Anesth Analg** 1996 Jun;82(6):1188-91
Continuous extrapleural paravertebral infusion of bupivacaine for post-thoracotomy analgesia in young infants. Karmakar MK, et al. **Br J Anaesth** 1996 Jun;76(6):811-5
Anaesthetic dilemma: half a spinal is better than none. Smith AF, et al. **Br J Hosp Med** 1995 Nov 15-Dec 12; 54(10):513-4
Factors associated with improving success rates with gamete intrafallopian transfer under thin-needle spinal anesthesia. Silva PD, et al. **J Assist Reprod Genet** 1995 Oct; 12(9):569-73
Importance of the needle bevel during spinal and epidural anesthesia. Baumgarten RK. **Reg Anesth** 1995 May-Jun; 20(3):234-8
Effect of anesthetic technique on acute formalin-induced pain in mice. Fu ES, et al. **Reg Anesth** 1995 May-Jun; 20(3):217-21
Misalignment of the spinal needle during the spinal epidural combined anesthesia [letter] Pedraza I, et al. **Reg Anesth** 1995 May-Jun;20(3):256-8
Influence of baricity on the outcome of spinal anesthesia with bupivacaine for lumbar spine surgery. Tetzlaff JE, et al. **Reg Anesth** 1995 Nov-Dec;20(6):533-7
Prospective survey of continuous versus single-injection spinal anesthesia in obstetrics. Bayhi D, et al. **South Med J** 1995 Oct;88(10):1043-8
[Combined spinal and epidural analgesia in urology] Bovianska N. **Khirurgiia (Sofiia)** 1995;48(5):33-5 (Eng. Abstr.) **(Bul)**
[Combined spinal and epidural analgesia for labor. Prolongation by addition of a minidose of clonidine to sufentanil. An initial study] Mercier FJ, et al. **Ann Fr Anesth Reanim** 1996;15(3):263-5 (Eng. Abstr.) **(Fre)**
[Combined spinal and epidural anesthesia or epidural anesthesia in obstetrics?] Benhamou D. **Cah Anesthesiol** 1996;44(2):157-8 **(Fre)**
[Sequential anesthesia-analgesia] Brassier J. **Cah Anesthesiol** 1996;44(2):167-71 (Eng. Abstr.) **(Fre)**
[Spinal analgesia for labor] Mercier FJ, et al. **Cah Anesthesiol** 1996;44(2):173-9 (Eng. Abstr.) **(Fre)**
[Hemodynamic effect of intrathecal clonidine] Rubin L, et al. **Cah Anesthesiol** 1995;43(3):307-12 (Eng. Abstr.) **(Fre)**
[Experience with the use of cerebrospinal anesthesia in a garrison hospital] Vashanov AA, et al. **Voen Med Zh** 1996 Feb;317(2):28-9 **(Rus)**

PSYCHOLOGY

Spinal phobia: survey results of patient attitudes and preferences regarding anesthesia. Sosis MB, et al. **J Clin Anesth** 1995 Aug;7(5):389-94

STANDARDS

Combined spinal and epidural blockade for analgesia in labour. Morgan B. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S59-60
Factors associated with improving success rates with gamete intrafallopian transfer under thin-needle spinal anesthesia. Silva PD, et al. **J Assist Reprod Genet** 1995 Oct; 12(9):569-73

ANESTHESIOLOGY

The image of the Swedish anaesthesia and intensive care system to a visiting Romanian doctor [letter] Cardan E. **Acta Anaesthesiol Scand** 1995 Oct;39(7):996
The accuracy of reference lists in Acta Anaesthesiologica Scandinavica. Nishina K, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):577-8
ASA physical status and age are not factors predicting morbidity, mortality, and survival after pancreatoduodenectomy. Chijiiwa K, et al. **Am Surg** 1996 Sep;62(9):701-5
Acute pain management in Australia and New Zealand. Goucke CR, et al. **Anaesth Intensive Care** 1995 Dec; 23(6):715-7
Attitudes and practices of New Zealand anaesthetists with regard to epidural and subarachnoid anaesthesia. Rodgers A, et al. **Anaesth Intensive Care** 1996 Feb;24(1):79-86
Decision-making in anaesthesia. Rudge BA. **Anaesth Intensive Care** 1995 Oct;23(5):597-9
Stress [editorial] Dickson DE. **Anaesthesia** 1996 Jun; 51(6):523-4
Drug labelling--a place for colour coding? [letter; comment] Heneghan CP. **Anaesthesia** 1996 Jun;51(6):600-1. Comment on: Anaesthesia 1996 Jan;51(1):1-2.
Bad backs and anaesthetists [letter] Johnson IG. **Anaesthesia** 1996 May;51(5):507
Hidden sharps [letter] Pandya KS, et al. **Anaesthesia** 1996 May;51(5):515
The practice of anaesthesia--a stressor for the middle-aged? Seeley HF. **Anaesthesia** 1996 Jun;51(6):571-4 (16 ref.)
Injury to an anaesthetist during patient transfer [letter] Toomey PJ. **Anaesthesia** 1996 Mar;51(3):294
Anaesthesia and the Internet. Yentis SM, et al. **Anaesthesia** 1996 Jul;51(7):677-82
Research activity among Japanese anesthetists [letter] Asano M, et al. **Anesth Analg** 1996 Jan;82(1):220-1
The routine wearing of gloves: impact on the frequency of needlestick and percutaneous injury and on surface contamination in the operating room. Ben-David B, et al. **Anesth Analg** 1996 Sep;83(3):623-8
Force and torque vary between laryngoscopists and laryngoscope blades. Hastings RH, et al. **Anesth Analg** 1996 Mar;82(3):462-8
Critical care anesthesiology--an alternative viewpoint [letter; comment] Pond WW. **Anesth Analg** 1996 Aug;83(2):435-6 . Comment on: Anesth Analg 1995 Sep;81(3):439-40.
How much do they really want to know? Preoperative patient interviews and the anesthesiologist [editorial; comment] Roizen MF, et al. **Anesth Analg** 1996 Mar; 82(3):443-4. Comment on: Anesth Analg 1996 Mar;82(3):445-51.
Accidental prolonged mydriasis in anesthesiologists [letter] Tabboush ZS. **Anesth Analg** 1995 Dec;81(6):1312-3
Critical care anesthesiology is not perioperative medicine [letter; comment] Turnage WS. **Anesth Analg** 1996 Aug; 83(2):435. Comment on: Anesth Analg 1995 Sep;81(3):439-40. Comment on: Anesth Analg 1995 Sep;81(3):441-5.
Anesthesia and perioperative medicine: a department of anesthesiology changes its name. Alpert CC, et al. **Anesthesiology** 1996 Mar;84(3):712-5
Evolution of anesthesiology [editorial; comment] Deutschman CS, et al. **Anesthesiology** 1996 Jul;85(1):1-3. Comment on: Anesthesiology 1996 Jul;85(1):196-206.
Should renaming the specialty begin with the Journal? [letter; comment] McLoughlin TM Jr. **Anesthesiology** 1995 Nov; 83(5):1132-3. Comment on: Anesthesiology 1995 Jul;83(1):191-7.
The Penn State Anesthesia Electronic Case Conference [letter] Taekman JM, et al. **Anesthesiology** 1995 Oct; 83(4):887-8
Do ophthalmologists, anesthesiologists, and internists agree about preoperative testing in healthy patients undergoing cataract surgery? [see comments] Bass EB, et al. **Arch Ophthalmol** 1995 Oct;113(10):1248-56. Comment in: Arch Ophthalmol 1995 Oct;113(10):1241-2.
Anaesthesia in the United States. Anaesthesia is an unpopular specialty in the United States [letter] Berry C. **BMJ** 1996 Aug 24;313(7055):495-6
Anaesthesia in the United States. Anaesthesia in Britain is as bad as in the United States [letter] Cornish EM. **BMJ** 1996 Aug 24;313(7055):495
Anaesthesia in the United States. Changes in specialty's name reflect greater involvement in preoperative and postoperative care [letter] Ellison N. **BMJ** 1996 Aug 24; 313(7055):496
The new deal revisited. Survey showed most anaesthetists have no experience of shifts [letter; comment] Pickersgill T. **BMJ** 1995 Nov 4;311(7014):1231-2. Comment on: BMJ 1995 Jul 29;311(7000):331-2.
European Association of Cardiothoracic Anaesthesiologists 11th annual meeting. Leuven, Belgium, 22-25 May 1996. Abstracts. **Br J Anaesth** 1996 May;76 Suppl 1:1-55
European Society of Anaesthesiologists annual congress. London, 1-5 June 1996. Abstracts. **Br J Anaesth** 1996 Jun; 76 Suppl 2:1-146
The role of an anaesthetist in a field hospital during the cholera epidemic among Rwandan refugees in Goma. Ginosar Y, et al. **Br J Anaesth** 1995 Dec;75(6):810-6
Occupational x-ray exposure of anaesthetists. McGowan C, et al. **Br J Anaesth** 1996 Jun;76(6):868-9
Impact factors in anaesthesia journals [editorial] Smith G. **Br J Anaesth** 1996 Jun;76(6):753-4
The 11th World Congress of Anaesthesiology [editorial] Smith G. **Br J Anaesth** 1996 Apr;76(4):479-80
Technology assessment: a Canadian perspective. Byrick RJ. **Can J Anaesth** 1996 May;43(5 Pt 2):R108-15 (20 ref.) **(Eng, Fre)**

Authorship in anaesthesia journals [letter] Gajraj NM, et al. **Can J Anaesth** 1995 Aug;42(8):749–50

Quality in anaesthesia: an integrated and constructive model. Hardy JF, et al. **Can J Anaesth** 1996 May;43(5 Pt 2):R75–88 (23 ref.) **(Eng, Fre)**

Detrimental effects of noise on anaesthetists. Murthy VS, et al. **Can J Anaesth** 1995 Jul;42(7):608–11

Canadian Anaesthetistis' Society Gold Medal. Sandinson JW, et al. **Can J Anaesth** 1995 Nov;42(11):1060–2 **(Eng, Fre)**

Patient data management systems in anaesthesia: an emerging technology. Weiss YG, et al. **Can J Anaesth** 1995 Oct; 42(10):914–21 (32 ref.)

Anesthetists taking drugs: is overwork the cause? [letter; comment] Nauth-Misir RC. **Can Med Assoc J** 1995 Dec 1;153(11):1567. Comment on: Can Med Assoc J 1995 Aug 15;153(4):449–52.

Post-operative analgesia for craniotomy patients: current attitudes among neuroanaesthetists. Stoneham MD, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):571–5

Ethics and research [editorial] Szulc R. **Eur J Anaesthesiol** 1996 Mar;13(2):93–4

Clinicians' opinions on alarm limits and urgency of therapeutic responses. Koski EM, et al. **Int J Clin Monit Comput** 1995 May;12(2):85–8

Use of esophageal or precordial stethoscopes by anesthesia providers: are we listening to our patients? Prielipp RC, et al. **J Clin Anesth** 1995 Aug;7(5):367–72

Receptor regulation: why should an anesthesiologist care? Smiley RM. **J Clin Anesth** 1996 May;8(3 Suppl):42S–47S (40 ref.)

Is it ok to read during OR cases? [letter] **J Clin Monit** 1995 Nov;11(6):417–8

Is it ok to read during OR cases? [letter] Black DK. **J Clin Monit** 1995 Nov;11(6):416

Is it ok to read during OR cases? [letter] Cohen DJ. **J Clin Monit** 1995 Nov;11(6):417

Is it ok to read during OR cases [letter] Feinstein R. **J Clin Monit** 1995 Nov;11(6):416–7

Is it ok to read during OR cases? [letter] Goihl PV. **J Clin Monit** 1995 Nov;11(6):417

Do you know your MGVS? Or what do anesthesiologists know about their MGVS? Peterson TG. **J Clin Monit** 1995 Nov;11(6):415–6

Is it ok to read during OR cases? [letter] Saenz JM. **J Clin Monit** 1995 Nov;11(6):417

"Helper:" A critical events prompter for unexpected emergencies. Schneider AJ, et al. **J Clin Monit** 1995 Nov; 11(6):358–64

Is it ok to read during OR cases? [letter] Siler JN. **J Clin Monit** 1995 Nov;11(6):417

What is a paediatric anaesthesiologist? The American perspective [editorial] Downes JJ. **Paediatr Anaesth** 1995; 5(5):277–8

Accuracy of references in Paediatric Anaesthesia [letter] Nishina K, et al. **Paediatr Anaesth** 1995;5(2):142

Anesthesia and public image [letter] Eldor J. **Reg Anesth** 1995 Sep–Oct;20(5):466

1994 Gaston Labat Lecturer. Rudolph H. de Jong. Winnie AP. **Reg Anesth** 1995 Nov–Dec;20(6):471–3

Hepatitis B in South African anaesthesiologists [letter; comment] Hodgson E. **S Afr Med J** 1996 Apr;86(4):384. Comment on: S Afr Med J 1995 Oct;85(10):993–5.

Immunisation against hepatitis B viral infection--a study of South African anaesthesiologists [see comments] Hodgson RE, et al. **S Afr Med J** 1995 Oct;85(10):993–5. Comment in: S Afr Med J 1996 Apr;86(4):384.

Injury prevention in anesthesiology. Berry AJ. **Surg Clin North Am** 1995 Dec;75(6):1123–32 (21 ref.)

[Effective preoperative studies in outpatient anesthesiology] Langemeijer JJ, et al. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1723–6 (Eng. Abstr.) **(Dut)**

[The prehospital anesthesia consultation in French speaking Switzerland (Letter)] Klopfenstein CE, et al. **Can J Anaesth** 1996 Mar;43(3):317–8 **(Fre)**

[Annual meeting of the Swiss Society of Intensive Medicine and the Swiss Society of Anesthesiology and Resuscitation. Zurich-Irchel, 28–30 September 1995. Abstracts] **Schweiz Med Wochenschr Suppl** 1995;73:3S–23S **(Fre, Ger)**

[Occupational medicine and safety technology concerns for the permanent anesthetist] **Anaesthesist** 1995 Oct;44(10):724 **(Ger)**

[Central European Anesthesiology Congress '95--end an era. Vienna, September 4–8, 1995] Rösaling W. **Anaesthesist** 1995 Dec;44(12):923–8 **(Ger)**

[Halothane concentration inhaled by anesthesiologists during anesthesia through face masks] Kojima Y. **Masui** 1995 Dec; 44(12):1667–70 (Eng. Abstr.) **(Jpn)**

[The quality improvement system at Hamamatsu University School of Medicine] Yamamoto Y, et al. **Masui** 1995;44 Suppl:S183–8 **(Jpn)**

[Experience in introducing monitoring computer systems in anesthesiology and intensive care units] Chalyi PI, et al. **Med Tekh** 1996 Mar–Apr;(2):41 (Eng. Abstr.) **(Rus)**

[Current situation of anesthesiology research in Andalucia and Extremadura. Comparative study with the rest of Spain] Caba F, et al. **Rev Esp Anestesiol Reanim** 1995 Dec; 42(10):420–3 (Eng. Abstr.) **(Spa)**

ECONOMICS

Anesthesia providers, patient outcomes, and costs [see comments] Abenstein JP, et al. **Anesth Analg** 1996 Jun; 82(6):1273–83. Comment in: Anesth Analg 1996 Jun;82(6):1117–8.

Perspective from a chairman of anesthesia outside Minnesota: anesthesia providers, patient outcomes, and costs [editorial] [see comments] James FM 3rd. **Anesth Analg** 1996 Jun; 82(6):1120–1. Comment in: Anesth Analg 1996 Jun;82(6):1117–8.

Perspective from the editor-in-chief: anesthesia providers, patient outcomes, and costs [editorial; comment] Miller RD. **Anesth Analg** 1996 Jun;82(6):1117–8. Comment on: Anesth Analg 1996 Jun;82(6):1119. Comment on: Anesth Analg 1996 Jun;82(6):1120–1. Comment on: Anesth Analg 1996 Jun;82(6):1273–83.

Perspective from a chairman of anesthesia in Minnesota: anesthesia providers, patient outcomes, and costs [editorial] [see comments] Rorie DK. **Anesth Analg** 1996 Jun; 82(6):1119. Comment in: Anesth Analg 1996 Jun;82(6):1117–8.

Meaningful cost reduction. Penny wise, pound foolish [editorial; comment] Orkin FK. **Anesthesiology** 1995 Dec; 83(6):1135–7. Comment on: Anesthesiology 1995 Dec;83(6):1138–44.

Managing pharmaceutical sales activities in an academic anesthesiology department. Johnstone RE, et al. **J Clin Anesth** 1995 Sep;7(6):544–8

Understanding cost analyses: Part 1. A practitioner's guide to cost behavior. Lubarsky DA. **J Clin Anesth** 1995 Sep; 7(6):519–21

Betrayal by the surgeons [see comments] Light DW. **Lancet** 1996 Mar 23;347(9004):812–3. Comment in: Lancet 1996 May 18;347(9012):1404; discussion 1405. Comment in: Lancet 1996 May 18;347(9012):1404–5. Comment in: Lancet 1996 May 18;347(9012):1405.

EDUCATION

The European Diploma in Anaesthesiology and Intensive Care of the European Academy of Anaesthesiology. Zorab JS. **Acta Anaesthesiol Scand** 1995 Jul;39(5):579–81

Learning fibreoptic skills in ear, nose and throat clinics. Burke LP, et al. **Anaesthesia** 1996 Jan;51(1):81–3

Resuscitation skills of trainee anaesthetists [letter; comment] Cook B. **Anaesthesia** 1995 Dec;50(12):1094. Comment on: Anaesthesia 1995 Aug;50(8):692–4.

Trainee representation in anaesthesia--past, present and future [editorial] Geddes S. **Anaesthesia** 1996 Mar; 51(3):209–10

The electronic anesthetic logbook: the value of supervision [letter] Hammond EJ, et al. **Anaesthesia** 1996 Mar;51(3):284

Training, education, risk management and the trainee anaesthetist [letter] Hammond EJ, et al. **Anaesthesia** 1996 Jun;51(6):606–7

Departmental database for training [letter] Hammond EJ, et al. **Anaesthesia** 1996 Jun;51(6):607

Resuscitation skills of trainee anaesthetists [letter] Harrod S. **Anaesthesia** 1995 Dec;50(12):1095

Costs and benefits of keeping a log-book [letter] Isaac J. **Anaesthesia** 1996 Aug;51(8):793

Teaching fibreoptic nasotracheal intubation via the laryngeal mask airway [letter] Marjot R, et al. **Anaesthesia** 1996 May; 51(5):511–2

A trainer for identification of the epidural space [letter] Paw HG. **Anaesthesia** 1995 Oct;50(10):914

Use of the Olympus LF-P fibreoptic laryngoscope by trainees in paediatric anaesthesia [letter] Stevenson GW, et al. **Anaesthesia** 1996 Feb;51(2):201–2

Teaching airway management skills: what about patient consent? [letter] Allen G, et al. **Anesthesiology** 1996 Aug; 85(2):437–9

In defense of Waters, Blalock, and Taylor [letter] Bacon DR, et al. **Anesthesiology** 1996 Aug;85(2):442–3

Fiberoptic intubation using anesthetized, paralyzed, apneic patients. Results of a resident training program. Cole AF, et al. **Anesthesiology** 1996 May;84(5):1101–6

Formal instruction in difficult airway management. A survey of anesthesiology residency programs. Koppel JN, et al. **Anesthesiology** 1995 Dec;83(6):1343–6

Computerized approach to processing the American Board of Anesthesiology training report [letter] Kraidin J. **Anesthesiology** 1996 Mar;84(3):752–3

Laryngeal mask airway in pediatric practice: a prospective study of skill acquisition by anesthesia residents. Lopez-Gil M, et al. **Anesthesiology** 1996 Apr;84(4):807–11

Resident workforce in a time of U.S. health-care system transition. Reves JG, et al. **Anesthesiology** 1996 Mar; 84(3):700–11

Anaesthetics training in the United States. America offers far less experience than Britain [letter; comment] Hambly PR. **BMJ** 1995 Oct 14;311(7011):1024. Comment on: BMJ 1995 Jul 29;311(7000):332.

Anaesthesia in the United States. Educational experience for trainees is better than in Britain [letter] Mackenzie CF. **BMJ** 1996 Aug 24;313(7055):496

Anaesthetics training in the United States. Three year residency produces equivalent of competent middle grade registrar [letter; comment] Nathanson M, et al. **BMJ** 1995 Oct 14;311(7011):1024. Comment on: BMJ 1995 Jul 29;311(7000):332.

Anaesthesia in the United States. Trainees have much to gain from working in the United States [letter] Parr M, et al. **BMJ** 1996 Aug 24;313(7055):496

Virtual reality in anaesthesia. Burt DE. **Br J Anaesth** 1995 Oct;75(4):472–80 (20 ref.)

Measurement of competence [editorial] Ellis FR. **Br J Anaesth** 1995 Dec;75(6):673–4

A statistical approach to measuring the competence of anaesthetic trainees at practical procedures. Kestin IG. **Br J Anaesth** 1995 Dec;75(6):805–9

Simulation: it's a start [editorial; comment] Davies JM, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):425–9. Comment on: Can J Anaesth 1996 May;43(5 Pt 1):430–4. **(Eng, Fre)**

Anaesthesia simulators [letter] Devitt JH, et al. **Can J Anaesth** 1995 Oct;42(10):952

Anaesthesia simulators [letter] Gaba DM. **Can J Anaesth** 1995 Oct;42(10):952–3

Anaesthesia crisis resource management training: an intimidating concept, a rewarding experience [see comments] Kurrek MM, et al. **Can J Anaesth** 1996 May; 43(5 Pt 1):430–4. Comment in: Can J Anaesth 1996 May;43(5 Pt 1):425–9.

Teaching cancer pain management: durability of educational effects of a role model program. Janjan NA, et al. **Cancer** 1996 Mar 1;77(5):996–1001

Validation of a test of competence in transesophageal echocardiography [see comments] Konstadt SN, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):311–3. Comment in: J Cardiothorac Vasc Anesth 1996 Apr;10(3):309–10.

Training, certification, and credentialing in transesophageal echocardiography [editorial; comment] Thys DM. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):309–10. Comment on: J Cardiothorac Vasc Anesth 1996 Apr;10(3):311–3.

Anesthesia crisis resource management: real-life simulation training in operating room crises. Holzman RS, et al. **J Clin Anesth** 1995 Dec;7(8):675–87

C.P.R. in the curriculum. Elias M. **Middle East J Anesthesiol** 1996 Feb;13(4):379–84

Training in anaesthesia: the US perspective. Strang TI, et al. **Postgrad Med J** 1996 Jun;72(848):343–6

The regional anesthesia "learning curve". What is the minimum number of epidural and spinal blocks to reach consistency? Kopacz DJ, et al. **Reg Anesth** 1996 May–Jun; 21(3):182–90

Epidural block for postpartum sterilisation [letter; comment] Rout CC, et al. **S Afr Med J** 1995 Dec;85(12):1309–10. Comment on: S Afr Med J 1994 Nov;84(11):788. Comment on: S Afr Med J 1995 Jun;85(6):546, 548. Comment on: S Afr Med J 1995 Jun;85(6):548; discussion 548–9.

[Education and research in emergency medicine. Responsibilities of the anesthesiology specialty (editorial)] Dirks B, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):125–6 **(Ger)**

[Contributions of AINS (Anesthesiology, Intensive Care Medicine, Emergency Medicine, Pain Therapy) to qualifying graduate education (editorial)] Schmucker P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun;31(5):278–9 **(Ger)**

[Difficult airway management is a weakness in the training of anesthesiologists (editorial)] Gomar C. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):121–2 **(Spa)**

[Analysis of knowledge about the anesthesiology specialty among a population of medical students] Onrubia X, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):324–9 (Eng. Abstr.) **(Spa)**

HISTORY

Kocher's mask. Ball C. **Anaesth Intensive Care** 1995 Oct; 23(5):535

Early proponents of cardiac massage. Böhrer H, et al. **Anaesthesia** 1995 Nov;50(11):969–71

Classic paper: a fibreoptic endoscope used for tracheal intubation [letter] Calder I, et al. **Anaesthesia** 1996 Jun; 51(6):602

Amylene, a blemish on Snow? Conacher ID. **Anaesthesia** 1996 Feb;51(2):155–7

Doctor Dee's ether apparatus. Sudarshan G, et al. **Anaesthesia** 1996 Feb;51(2):158–60

In defense of Waters, Blalock, and Taylor [letter] Bacon DR, et al. **Anesthesiology** 1996 Aug;85(2):442–3

Iconography in anesthesiology. The importance of society seals in the 1920s and 30s. Bacon DR. **Anesthesiology** 1996 Aug;85(2):414–9

Richard von Foregger, Ph.D., 1872–1960. Manufacturer of anesthesia equipment. Foregger R. **Anesthesiology** 1996 Jan; 84(1):190–200

Austin Lamont and the evolution of modern academic American anesthesiology. Muravchick A, et al. **Anesthesiology** 1996 Feb;84(2):436–41

Fires and explosions [letter] Goerig M. **Br J Anaesth** 1995 Nov;75(5):666–7

Fifty years in anaesthesia [see comments] Hill NP. **Can J Anaesth** 1995 Oct;42(10):948–51. Comment in: Can J Anaesth 1995 Oct;42(10):845–7.

Our links with the past: the value of knowing our history [editorial; comment] Shephard DA. **Can J Anaesth** 1995 Oct;42(10):845–7. Comment on: Can J Anaesth 1995 Oct;42(10):948–51. **(Eng, Fre)**

The contribution of Canadian anaesthetists to the evolution of cardiac surgery. Wynands JE. **Can J Anaesth** 1996 May; 43(5 Pt 1):518–34

Ralph Waters and the beginnings of academic anesthesiology in the United States: the Wisconsin Template. Bacon DR,

et al. **J Clin Anesth** 1995 Sep;7(6):534–43
Davy comes to America: Woodhouse, Barton, and the nitrous oxide crossing. Wright AJ. **J Clin Anesth** 1995 Jun; 7(4):347–55
A celebration of women in anaesthesia 1894–1994. Clarke RS, et al. **J R Soc Med** 1995 Sep;88(9):519P–521P
Sir Lambert Ormsby—expatriate New Zealander. Hutchinson BR. **N Z Med J** 1996 Jun 14;109(1023):214
Sherlock Holmes and his gasogene. Bergman NA. **Pharos** 1995 Summer;58(3):35–7
[60th anniversary of the 1st French Society of Anesthesia (letter; comment)] Winckler C. **Ann Fr Anesth Reanim** 1995; 14(2):242. Comment on: Ann Fr Anesth Reanim 1994;13(6):779–80. **(Fre)**
[Scientific anesthesiology of John Snow] Ellis R. **Cah Anesthesiol** 1995;43(5):509–11 **(Fre)**
[The life of John Snow. Abridged translation of the biography by Benjamin W. Richardson] Lassner J. **Cah Anesthesiol** 1995;43(4):397–9 **(Fre)**
[The beginnings of anesthesiology in Lausanne. Observations concerning Rene Bussien's article in RMSR, 115:925–930, 1995 (letter)] Naef AP. **Rev Med Suisse Romande** 1996 Feb; 116(2):139–40 **(Fre)**
[Early contributions from Erlangen to the theory and practice of ether and chloroform anesthesia. 1. Heyfelder's clinical trial with ether and chloroform] Hintzenstern Uv, et al. **Anaesthesist** 1996 Feb;45(2):131–9 (Eng. Abstr.) **(Ger)**
[Lasting and ephemeral trends in medicine and naturopathy] Stelzner F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Mar; 31(2):72–6 **(Ger)**

INSTRUMENTATION

The laryngeal mask in ophthalmic surgery [letter] von Euler C. **Acta Anaesthesiol Scand** 1995 Oct;39(7):997
Paediatric capnography [letter] Ball AJ. **Anaesthesia** 1995 Sep;50(9):833–4
Dangers of alarms [letter] Elliot B, et al. **Anaesthesia** 1996 Aug;51(8):799–800
"Prongs" on double-lumen tubes [letter] Garfield MJ. **Anaesthesia** 1996 Jan;51(1):101
Filters and Ayre's T-piece [letter] Goddard JM, et al. **Anaesthesia** 1996 Jun;51(6):605
Rotameter sequence—a variant of 'read the label' [letter] James RH. **Anaesthesia** 1996 Jan;51(1):87–8
HME filter and Ayre's T piece [letter] Jerwood DC, et al. **Anaesthesia** 1995 Oct;50(10):915–6
Resistance, reverse flow and opening pressure of unidirectional valves. Leibundgut D, et al. **Anaesthesia** 1995 Dec;50(12):1065–9
Rotameter sequence [letter] Moon JR. **Anaesthesia** 1996 May; 51(5):508
Unrecognised environmental pollution by desflurane [letter] Radcliffe JJ, et al. **Anaesthesia** 1996 Jan;51(1):100
Low pressure leakage in anaesthetic machines. Evaluation by positive and negative pressure tests. Somprakit P, et al. **Anaesthesia** 1996 May;51(5):461–4
Pressure testing the anaesthetic machine and breathing system [letter] Strong TS, et al. **Anaesthesia** 1996 Jan;51(1):88–9
One-way valve malfunction in a circle system [letter] Thomson AR, et al. **Anaesthesia** 1995 Oct;50(10):920–1
Dangers of CO2 cylinders on anesthetic machines [letter] Todd DB. **Anaesthesia** 1995 Oct;50(10):911–2
Nasal packing forceps as a part of anaesthesia armamentarium [letter] Vas L. **Anaesthesia** 1996 May;51(5):514
Another problem with a circle system [letter] Walker T. **Anaesthesia** 1996 Jan;51(1):89–90
Infusion systems [editorial] Wallace PG. **Anaesthesia** 1996 Jul;51(7):613–4
A leaky circuit [letter] Williams N. **Anaesthesia** 1996 Apr; 51(4):406–7
Unusual cause for a circle system leak [letter] Biro P. **Anesth Analg** 1996 Jul;83(1):196
Instructional review improves performance of anesthesia apparatus checkout procedures. Olympio MA, et al. **Anesth Analg** 1996 Sep;83(3):618–22
Breathe in, breathe out [letter] Stone SB. **Anesth Analg** 1996 Jan;82(1):222
Visual display format affects the ability of anesthesiologists to detect acute physiologic changes. A laboratory study employing a clinical display simulator. Gurushanthaiah K, et al. **Anesthesiology** 1995 Dec;83(6):1184–93
Reply from Compressed Gas Association, Inc [letter; comment] Johnson CT. **Anesthesiology** 1995 Oct;83(4):879 . Comment on: Anesthesiology 1995 Oct;83(4):871–4.
Color of compressed gas cylinders [letter] Priestley M. **Anesthesiology** 1996 Aug;85(2):445–6
Effect of apparatus on functional residual capacity. Drummond GB. **Br J Anaesth** 1996 Apr;76(4):560–2
A subtle cause of circle system failure [letter] Findlay GP, et al. **Br J Anaesth** 1995 Nov;75(5):667–8
Comparison of two administration techniques of inhaled nitric oxide on nitrogen dioxide production. Dubé L, et al. **Can J Anaesth** 1995 Oct;42(10):922–7
Filling Tec 5 vaporizers [letter] Dunphy JA, et al. **Can J Anaesth** 1995 Sep;42(9):839
Filters and breathing circuit contamination [letter] Friesen JH. **Can J Anaesth** 1995 Oct;42(10):954–5
Positive end-expiratory pressure and lung compliance: effect on delivered tidal volume. Pan PH, et al. **Can J Anaesth** 1995 Sep;42(9):831–5
Most commonly asked questions about anesthetic equipment. Brock N. **Can Vet J** 1996 Jun;37(6):373–4
Five oxygen-nitrous oxide proportioning systems compared. Feigenwinter P, et al. **Eur J Anaesthesiol** 1996 Jan; 13(1):73–80
Anesthesia systems. **Health Devices** 1996 May–Jun; 25(5–6):158–211 (25 ref.)
Non-localizable alarm. Block FE Jr. **Int J Clin Monit Comput** 1996 Feb;13(1):57–8
Safety factors in the remote control of infusion devices. Cantraine FR, et al. **Int J Clin Monit Comput** 1996 Feb; 13(1):45–55
Airway sealing pressures of the laryngeal mask airway in pediatric patients. Epstein RH, et al. **J Clin Anesth** 1996 Mar;8(2):93–8
Potential risk associated with anesthesia machines with single oxygen cylinders [letter] McDade W, et al. **J Clin Anesth** 1996 May;8(3):260–1
Prospective, randomized comparison of the Flotem Iie and Hotline fluid warmers in anesthetized adults. Patel N, et al. **J Clin Anesth** 1996 Jun;8(4):307–16
Potential for air embolism using Hotline Model HL90 fluid warmer [letter] Wolin J, et al. **J Clin Anesth** 1996 Feb; 8(1):81–2
Reprocessing of anaesthetic and ventilatory equipment. Geiss HK. **J Hosp Infect** 1995 Jun;30 Suppl:414–20
Field trial of oxygen concentrators in upper Egypt. Dobson M, et al. **Lancet** 1996 Jun 8;347(9015):1597–9
A potentially dangerous design fault in an oxygen analyser [letter; comment] James MF. **S Afr Med J** 1994 Nov; 84(11):779. Comment on: S Afr Med J 1994 Sep;84(9):633–4.
Laryngeal mask airway: uses in anesthesiology. Pinosky M. **South Med J** 1996 Jun;89(6):551–5 (21 ref.)
Modification of a nonrebreathing circuit adapter to prevent barotrauma in anesthetized patients. McMurphy RM, et al. **Vet Surg** 1995 Jul–Aug;24(4):352–5
[Equipment safety and conditions of failure (editorial)] Cazalaà JB, et al. **Ann Fr Anesth Reanim** 1995;14(4):317–9 **(Fre)**
[Computerized anesthesia record. How far have we gone?] Landais A, et al. **Cah Anesthesiol** 1996;44(1):27–33 (Eng. Abstr.) **(Fre)**
[Problems and limits in noninvasive oxygen monitoring] Bardenheuer HJ, et al. **Anaesthesist** 1996 Jul;45(7):614–25 (86 ref.) (Eng. Abstr.) **(Ger)**
[Preclinical control of intubation and artificial respiration. Animal experiment and literature review] Petroianu G, et al. **Anaesthesist** 1995 Sep;44(9):613–23 (Eng. Abstr.) **(Ger)**
[Efficiency of a mobile oxygen concentrator for mechanical ventilation in anesthesia. Studies with a metabolic lung model and early clinical results] Rathgeber J, et al. **Anaesthesist** 1995 Sep;44(9):643–50 (Eng. Abstr.) **(Ger)**
[Survey on anesthesia related accident in 1993] **Masui** 1996 Mar;45(3):374–8 **(Jpn)**

LEGISLATION & JURISPRUDENCE

Medical ethics and legal standards [editorial; comment] [see comments] Duncan PG, et al. **Anesth Analg** 1996 Jan; 82(1):1–3. Comment on: Anesth Analg 1996 Jan;82(1):4–7. Comment in: Anesth Analg 1996 Aug;83(2):436. Comment in: Anesth Analg 1996 Aug;83(2):438–9. Comment in: Anesth Analg 1996 Aug;83(2):439–40. Comment in: Anesth Analg 1996 Aug;83(2):440–1.
Dental chair anaesthesia—'unexpected hazard' defined by the High Court. White GM. **Br Dent J** 1996 Jan 20;180(2):73–5
The strange case of the misplaced suppository. Richmond C. **Can Med Assoc J** 1995 Oct 1;153(7):980–1
Sedation—guidelines and controls [letter] Getter L, et al. **J Am Dent Assoc** 1996 Jan;127(1):20, 22
[Liquidation of elective anesthesiological performance in delegation and representation—revision of GOA (1996)] Weissauer W. **Chirurg** 1996 Jun;67(6):Suppl 127–32 **(Ger)**
[Closed claims analysis of anesthesia in Japan] Ito Y. **Masui** 1995;44 Suppl:S179–82 (7 ref.) **(Jpn)**

MANPOWER

Recognition of the anaesthetists: a Spanish view [letter; comment] Garcia MA, et al. **Anaesthesia** 1995 Oct; 50(10):923. Comment on: Anaesthesia 1995 May;50(5):381–2.
Need for GP anesthetists [letter; comment] Kearney RA, et al. **Can Med Assoc J** 1996 Feb 1;154(3):300. Comment on: Can Med Assoc J 1995 Nov 15;153(10):1455–6.
[Plea for a better utilization of human resources in anesthesiology, and the creation of a replacement center for the use of French-speaking anesthetists] Bussien R. **Rev Med Suisse Romande** 1995 Nov;115(11):925–30 **(Fre)**

METHODS

Telephone reporting of blood analysis results into the operating room. Gaiser RR, et al. **Anesth Analg** 1996 Jun; 82(6):1284–6
Tracheal intubation through the laryngeal mask airway [letter] Asai T. **Anesthesiology** 1996 Aug;85(2):439
Changing anesthesiologists' practice patterns. Can it be done? Cohen MM, et al. **Anesthesiology** 1996 Aug;85(2):260–9
A useful maneuver when intravenous access is difficult [letter] Kondo K. **Anesthesiology** 1996 Aug;85(2):444
Electrocardiogram ordering practices among anesthesiologists [letter] McKinley AC, et al. **Anesthesiology** 1996 Jan;84(1):240–1
Measuring the performance of anesthetic depth indicators. Smith WD, et al. **Anesthesiology** 1996 Jan;84(1):38–51 (61 ref.)
Anaesthesia and autologous transfusion. Borghi B, et al. **Int J Artif Organs** 1995 Mar;18(3):159–66
Failed emergency transtracheal ventilation through a 14-gauge intravenous catheter. Metz S, et al. **J Clin Anesth** 1996 Feb;8(1):58–62
Evaluating anesthesia health care delivery for cardiac surgery. The role of process and structure variables. London MJ, et al. **Med Care** 1995 Oct;33(10 Suppl):OS66–75
[Recommendations concerning the relation between anesthetists, surgeons and other health care professionals] **Ann Chir** 1995;49(6):557–60 **(Fre)**
[Cooperation between surgeons and anesthesiologists studied by the Polish Society of Surgery (editorial)] **Ginekol Pol** 1995 Jul;66(7):381–5 **(Pol)**

ORGANIZATION & ADMINISTRATION

Should we keep the anaesthetic room? [letter; comment] [see comments] Claxton AR. **Anaesthesia** 1995 Dec;50(12):1095 . Comment on: Anaesthesia 1992 Dec;47(12):1021–2. Comment in: Anaesthesia 1996 May;51(5):509.
In defence of the Arkive [letter; comment] Sanderson IC, et al. **Br J Anaesth** 1995 Oct;75(4):502–3. Comment on: Br J Anaesth 1995 May;74(5):619–26.
Anaesthesia in The Gambia. Soyannwo OA, et al. **West Afr J Med** 1995 Jul–Sep;14(3):169–73

STANDARDS

Performance of the anesthesiologists in 12 Departments of Anesthesia in Greece [see comments] Fassoulaki A, et al. **Acta Anaesthesiol Belg** 1995;46(2):79–86. Comment in: Acta Anaesthesiol Belg 1995;46(2):63–4.
Similarity in standards and safety of practice within Europe: reality or fantasy? [editorial; comment] Vercauteren M. **Acta Anaesthesiol Belg** 1995;46(2):63–4. Comment on: Acta Anaesthesiol Belg 1995;46(2):79–86.
Anaesthetic assistants during electroconvulsive therapy [letter] [see comments] Dunkley CJ. **Anaesthesia** 1995 Nov; 50(11):1009–10. Comment in: Anaesthesia 1996 Jun;51(6):609.
Reading in the operating theatre [letter] Morris GN. **Anaesthesia** 1995 Dec;50(12):1089–90
Anesthesia providers, patient outcomes, and costs [see comments] Abenstein JP, et al. **Anesth Analg** 1996 Jun; 82(6):1273–83. Comment in: Anesth Analg 1996 Jun;82(6):1117–8.
Preoperative pregnancy testing in adolescents [see comments] Azzam FJ, et al. **Anesth Analg** 1996 Jan;82(1):4–7. Comment in: Anesth Analg 1996 Jan;82(1):1–3. Comment in: Anesth Analg 1996 Aug;83(2):438–9. Comment in: Anesth Analg 1996 Aug;83(2):439. Comment in: Anesth Analg 1996 Aug;83(2):439–40.
Medical ethics and legal standards [editorial; comment] [see comments] Duncan PG, et al. **Anesth Analg** 1996 Jan; 82(1):1–3. Comment on: Anesth Analg 1996 Jan;82(1):4–7. Comment in: Anesth Analg 1996 Aug;83(2):436. Comment in: Anesth Analg 1996 Aug;83(2):438–9. Comment in: Anesth Analg 1996 Aug;83(2):439–40. Comment in: Anesth Analg 1996 Aug;83(2):440–1.
Perspective from a chairman of anesthesia outside Minnesota: anesthesia providers, patient outcomes, and costs [editorial] [see comments] James FM 3rd. **Anesth Analg** 1996 Jun; 82(6):1120–1. Comment in: Anesth Analg 1996 Jun;82(6):1117–8.
Perspective from the editor-in-chief: anesthesia providers, patient outcomes, and costs [editorial; comment] Miller RD. **Anesth Analg** 1996 Jun;82(6):1117–8. Comment on: Anesth Analg 1996 Jun;82(6):1119. Comment on: Anesth Analg 1996 Jun;82(6):1120–1. Comment on: Anesth Analg 1996 Jun;82(6):1273–83.
Medical guidelines by other societies: should we ignore or influence them? [editorial] Roizen MF, et al. **Anesth Analg** 1996 Apr;82(4):679–80
Perspective from a chairman of anesthesia in Minnesota: anesthesia providers, patient outcomes, and costs [editorial] [see comments] Rorie DK. **Anesth Analg** 1996 Jun; 82(6):1119. Comment in: Anesth Analg 1996 Jun;82(6):1117–8.
Practice guidelines for sedation and analgesia by non-anesthesiologists. A report by the American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. **Anesthesiology** 1996 Feb; 84(2):459–71
The 34th Rovenstine Lecture. 40 years behind the mask: safety revisited. Pierce EC Jr. **Anesthesiology** 1996 Apr; 84(4):965–75
The demographics of inpatient pediatric anesthesia: implications for credentialing policy. Macario A, et al. **J Clin Anesth** 1995 Sep;7(6):507–11

STATISTICS & NUMERICAL DATA

Electronic anaesthetic logbooks; standards for data entry [letter] Hammond E, et al. **Anaesthesia** 1996 Jan;51(1):93–4
Percutaneous injuries in anesthesia personnel. Greene ES, et al. **Anesth Analg** 1996 Aug;83(2):273–8

ANESTHESIOLOGY

TRENDS

The Geoffrey Kaye Oration. ASA AGM, Nadi, Fiji, October 10, 1994. Hains J. **Anaesth Intensive Care** 1995 Jun; 23(3):376–8

Planning the future of anesthesiology [editorial] Longnecker DE. **Anesthesiology** 1996 Mar;84(3):495–7

Research in anaesthesia—the key to the future [editorial] Smith G. **Br J Anaesth** 1995 Oct;75(4):383–6 (5 ref.)

Anesthesiology. Saidman LJ. **JAMA** 1996 Jun 19; 275(23):1795–7

[Operative medicine in the year 2000. 38th Kasseler Symposium, June 23–24, 1995] **Anaesthesist** 1995 Sep; 44(9):659–62 **(Ger)**

[Praktische medicine—what's new and important? 20th interdisciplinry forum of the Federal Medical Council, Koln, January 1996] Stiefelhagen P. **Anaesthesist** 1996 Apr; 45(4):388–91 **(Ger)**

ANESTHETIC GAS SCAVENGERS see **GAS SCAVENGERS**

ANESTHETICS

see related

ANESTHESIA ADJUVANTS

Anaesthetics for general anaesthesia in growing pigs. Henrikson H, et al. **Acta Vet Scand** 1995;36(4):401–11

Spinal anaesthesia induced by intrathecal magnesium sulphate. Bahar M, et al. **Anaesthesia** 1996 Jul;51(7):627–33

Controlled drugs—do current handling practices disguise substance abuse? [letter] Smith AF. **Anaesthesia** 1996 Apr; 51(4):403

The struggle for power in anaesthetic studies [editorial] Yentis SM. **Anaesthesia** 1996 May;51(5):413–4

Sevoflurane for outpatient anesthesia: a comparison with propofol. Fredman B, et al. **Anesth Analg** 1995 Oct; 81(4):823–8

Substance abuse in the perioperative setting. Dillmann JM. **AORN J** 1995 Jul;62(1):111–2

Awareness during anaesthesia: when is an anaesthetic not an anaesthetic? [editorial] Aitkenhead AR. **Can J Anaesth** 1996 Mar;43(3):206–11 **(Eng, Fre)**

Anaesthesia drug cost, control and utilization in Canada [see comments] Kantor GS, et al. **Can J Anaesth** 1996 Jan; 43(1):9–16. Comment in: Can J Anaesth 1996 Jan;43(1):4–8.

Anaesthesia drug costs and utilization—time for a critical re-appraisal [editorial; comment] Miller DR. **Can J Anaesth** 1996 Jan;43(1):4–8. Comment on: Can J Anaesth 1996 Jan;43(1):9–16.

Evaluation of five common induction protocols by comparison of hemodynamic responses to surgical manipulation in halothane-anesthetized horses. Wagner AE, et al. **J Am Vet Med Assoc** 1996 Ja.; 15;208(2):252–7

Immobilization of Rocky Mountain elk with Telazol and xylazine hydrochloride, and antagonism by yohimbine hydrochloride [published erratum appears in J Wildl Dis 1995 Oct;31(4):599] Millspaugh JJ, et al. **J Wildl Dis** 1995 Apr;31(2):259–62

Sevoflurane for general anesthesia. **Med Lett Drugs Ther** 1995 Oct 27;37(960):96–7

[Prospects of balanced anesthesia—mainly focusing on combined induction of midazolam with barbiturate and epidural opioid with local anesthetics] Arita H, et al. **Masui** 1995;44 Suppl:S167–72; discussion S173–6 **(Jpn)**

[Balanced anesthesia for postoperative management] Namiki A, et al. **Masui** 1995;44 Suppl:S162–6; discussion S173–6 (1 ref.) **(Jpn)**

[Balanced anesthesia with epidural anesthesia] Yuge O, et al. **Masui** 1995;44 Suppl:S153–5; discussion S156–7 (13 ref.) **(Jpn)**

[Anesthesia using clofelin in different types of arterial hypertension in middle-aged and elderly patients] Dolina OA, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):4–6 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Pharmacological properties of endothelins and big endothelins in ketamine/xylazine or urethane anesthetized rats. Gratton JP, et al. **Am J Hypertens** 1995 Nov; 8(11):1121–7

A prospective study of rectal methohexital: efficacy and side effects in 648 cases. Audenaert SM, et al. **Anesth Analg** 1995 Nov;81(5):957–61

The comparative effects of equimolar sevoflurane and isoflurane in isolated hearts. Graf BM, et al. **Anesth Analg** 1995 Nov;81(5):1026–32

Sphenoidal electrode insertion using topical anesthesia. Bazil CW, et al. **Epilepsia** 1996 Jan;37(1):102–3

Induction of anaesthesia: one drug or two? [editorial] Park GR, et al. **Eur J Anaesthesiol Suppl** 1995 Nov;12:1

Romifidine as a premedicant to propofol induction and infusion anaesthesia in the dog. England GC, et al. **J Small Anim Pract** 1996 Feb;37(2):79–83

[Anesthetics] Larbuisson R, et al. **Rev Med Liege** 1996 Jan; 51(1):129–32 **(Fre)**

ADVERSE EFFECTS

Complication after the use of a combination of lignocaine and xylazine for epidural anaesthesia in a mare. Chopin JB, et al. **Aust Vet J** 1995 Sep;72(9):354–5

Neurological and psychiatric adverse effects of anaesthetics: epidemiology and treatment. Klafta JM, et al. **Drug Saf** 1995 Nov;13(5):281–95 (137 ref.)

Nausea and vomiting after laparoscopic surgery: a comparison of propofol and thiopentone/halothane anaesthesia. Klockgether-Radke A, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):3–9

Anaesthetic-associated mortality and anaesthetic contributory death: the South African medicolegal approach. Moar JJ. **Forensic Sci Int** 1996 Apr 23; 78(3):219–30

[Effects of anesthesia on postoperative micturition and urinary retention] Pertek JP, et al. **Ann Fr Anesth Reanim** 1995;14(4):340–51 (44 ref.) (Eng. Abstr.) **(Fre)**

[Masseter muscle spasm—approach to patient] Ben-Abraham R, et al. **Harefuah** 1995 Aug;129(3–4):135–8 (20 ref.) **(Heb)**

[Free radicals in anesthesia and the role of exogenous antioxidants] Neri S, et al. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;16(5–6):125–30 (Eng. Abstr.) **(Ita)**

[Exposure to anesthetic gases] Aasmoe L, et al. **Tidsskr Nor Laegeforen** 1995 Sep 10;115(21):2652–5 (Eng. Abstr.) **(Nor)**

ANALYSIS

Interference of volatile anaesthetics with infrared analysis of carbon dioxide and nitrous oxide tested in the Dräger Cicero EM using sevoflurane. Wilkes AR, et al. **Br J Anaesth** 1996 May;76(5):737–9

[Measurement of expired alcohol concentrations with a new electrochemical sensor. A model investigation to determine interference with volatile anesthetics and clinical application] Gehring H, et al. **Anaesthesist** 1996 Feb; 45(2):154–62 (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

[Antagonists in anesthesia] Lauven PM, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):331–6 (34 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Isomerism and anaesthetic drugs. Calvey TN. **Acta Anaesthesiol Scand Suppl** 1995;106:83–90 (50 ref.)

Molecular sieves: an alternative method of carbon dioxide removal which does not generate compound A during simulated low-flow sevoflurane anaesthesia. Fee JP, et al. **Anaesthesia** 1995 Oct;50(10):841–5

Effects of the anesthetic steroid alphaxalone and its inactive delta 16-analog on the thermotropic properties of membrane bilayers. A model for membrane perturbation. Mavromoustakos T, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):257–64

ECONOMICS

Meaningful cost reduction. Penny wise, pound foolish [editorial; comment] Orkin FK. **Anesthesiology** 1995 Dec; 83(6):1135–7. Comment on: Anesthesiology 1995 Dec;83(6):1138–44.

Managing pharmaceutical sales activities in an academic anesthesiology department. Johnstone RE, et al. **J Clin Anesth** 1995 Sep;7(6):544–8

METABOLISM

Analysis of sevoflurane degradation products in vapor phase samples. Cunningham DD, et al. **J Chromatogr B Biomed Appl** 1995 Jun 9;668(1):41–52

[Cytochrome P450-dependent monooxygenase system and anesthetics] Chen TL, et al. **Acta Anaesthesiol Sin** 1995 Sep;33(3):185–94 (64 ref.) (Eng. Abstr.) **(Chi)**

PHARMACOKINETICS

Stereochemistry and anesthetic pharmacology: joining hands with the medicinal chemists [editorial; comment] Egan TD. **Anesth Analg** 1996 Sep;83(3):447–50. Comment on: Anesth Analg 1996 Sep;83(3):552–8.

A nuclear magnetic resonance advance. Imaging fluorinated anesthetics in the brain [editorial; comment] Litt L. **Anesthesiology** 1995 Oct;83(4):651–3. Comment on: Anesthesiology 1995 Oct;83(4):766–74.

Fluorine-19 nuclear magnetic resonance imaging and spectroscopy of sevoflurane uptake, distribution, and elimination in rat brain [see comments] Xu Y, et al. **Anesthesiology** 1995 Oct;83(4):766–74. Comment in: Anesthesiology 1995 Oct;83(4):651–3.

Pharmacokinetics of analgesics, sedatives and anaesthetic agents during cardiopulmonary bypass. Gedney JA, et al. **Br J Anaesth** 1995 Sep;75(3):344–51 (74 ref.)

Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis. Tonsuwannont W, et al. **J Med Assoc Thai** 1996 May;79(5):309–19

Total intravenous anaesthesia in ponies using detomidine, ketamine and guaiphenesin: pharmacokinetics, cardiopulmonary and endocrine effects. Taylor PM, et al. **Res Vet Sci** 1995 Jul;59(1):17–23

[The fundamentals of pharmacokinetics] Lauven PM, et al. **Anaesthesist** 1995 Sep;44(9):663–76 (14 ref.) **(Ger)**

[Rectal administration of anesthetic agents] Ceriana P, et al. **Minerva Anestesiol** 1995 May;61(5):219–28 (33 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

The effects of midazolam, droperidol, fentanyl, and alfentanil on phagocytosis and killing of bacteria by polymorphonuclear leukocytes in vitro. Krumholz W, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):624–7

Effects of sevoflurane on respiratory activities in the phrenic nerve of decerebrate cats. Masuda A, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):774–81

The influence of anaesthetic drugs on the lower oesophageal sphincter in propofol/nitrous oxide anaesthetized dogs. Pressure profilometry in an animal model. van der Hoeven CW, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):822–6

Analgesic, hemodynamic, and respiratory effects of caudal epidurally administered xylazine hydrochloride solution in mares. Skarda RT, et al. **Am J Vet Res** 1996 Feb; 57(2):193–200

Immunomodulation: an important concept in modern anaesthesia. McBride WT, et al. **Anaesthesia** 1996 May; 51(5):465–73 (86 ref.)

The influence of anaesthetic technique upon the immune response to hysterectomy. A comparison of propofol infusion and isoflurane. Pirttikangas CO, et al. **Anaesthesia** 1995 Dec;50(12):1056–61

Propofol induces dilation and inhibits constriction in guinea pig basilar arteries. Gelb AW, et al. **Anesth Analg** 1996 Sep;83(3):472–6

The effects of anesthesia with increasing end-expiratory concentrations of sevoflurane on midlatency auditory evoked potentials. Schwender D, et al. **Anesth Analg** 1995 Oct;81(4):817–22

Muscarinic signaling in the central nervous system. Recent developments and anesthetic implications. Durieux ME. **Anesthesiology** 1996 Jan;84(1):173–89 (171 ref.)

Preemptive analgesic effects of steroid anesthesia with alphaxalone in the rat formalin test. Evidence for differential GABA(A) Receptor modulation in persistent nociception. Gilron I, et al. **Anesthesiology** 1996 Mar; 84(3):572–9

Role of pertussis toxin-sensitive G-proteins in the analgesic and anesthetic actions of alpha 2-adrenergic agonists in the rat. Hayashi Y, et al. **Anesthesiology** 1995 Oct; 83(4):816–22

Anesthetic potency of remifentanil in dogs. Michelsen LG, et al. **Anesthesiology** 1996 Apr;84(4):865–72

One-day hypothermic preservation of isolated hearts with halothane improves cardiac function better than low calcium. Stowe DF, et al. **Anesthesiology** 1995 Nov; 83(5):1065–77

Concentration-effect relationships of eltanolone given as a bolus dose or constant rate intravenous infusion to healthy male volunteers. Wessén A, et al. **Anesthesiology** 1996 Jun; 84(6):1317–26

Effects of anesthesia and K+ ATP channel blockade on interstitial adenosine accumulation in ischemic rabbit myocardium. Cohen MV, et al. **Basic Res Cardiol** 1995 Sep-Oct;90(5):410–7

Inductive effect of Telazol on hepatic expression of cytochrome P450 2B in rats. Wong A, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):735–42

Anaesthetic agents decrease the activity of nitric oxide synthase from human polymorphonuclear leucocytes. Galley HF, et al. **Br J Anaesth** 1995 Sep;75(3):326–9

Voltage-sensitive Ca2+ channels and anaesthesia [editorial] Hirota K, et al. **Br J Anaesth** 1996 Mar;76(3):344–6

Sevoflurane, enflurane and isoflurane have no persistent postanaesthetic effects on the central nervous system in cats. Kurata J, et al. **Br J Anaesth** 1996 May;76(5):721–5

Potentiation by neurosteroids of muscimol/adenosine interactions in rat hippocampus. Akhondzadeh S, et al. **Brain Res** 1995 Apr 24;677(2):311–8

Reduction in firing rate of substantia nigra pars reticulata neurons by valproate: influence of different types of anesthesia in rats. Löscher W, et al. **Brain Res** 1995 Dec 8;702(1–2):133–44

Effects of anesthetics on ormaplatin biotransformations in the Fischer 344 rat [letter] Thompson DC, et al. **Cancer Invest** 1995;13(5):555–7

Propofol. An update of its use in anaesthesia and conscious sedation. Bryson HM, et al. **Drugs** 1995 Sep;50(3):513–59 (622 ref.)

Pharmacokinetics of ketamine in mules and mammoth asses premedicated with xylazine. Matthews NS, et al. **Equine Vet J** 1994 May;26(3):241–3

Subanesthetic concentrations of drugs inhibit cytochrome P450-mediated metabolism of aniline. LaBella FS, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):231–5

Excitatory responses evoked in prefrontal cortex by mediodorsal thalamic nucleus stimulation: influence of anaesthesia. Pirot S, et al. **Eur J Pharmacol** 1995 Oct 4; 285(1):45–54

Actions of anesthetics on ligand-gated ion channels: role of receptor subunit composition. Harris RA, et al. **FASEB J** 1995 Nov;9(14):1454–62 (59 ref.)

Influence of pentobarbital, propofol and ketamine on skeletal muscle capillary perfusion during hemorrhage: a comparative study in the rabbit. Gustafsson U, et al. **Int J Microcirc Clin Exp** 1995 Jul-Aug;15(4):163–9

Differential effects of anesthetics on in vivo skeletal muscle contractile function in the mouse. Ingalls CP, et al. **J Appl Physiol** 1996 Jan;80(1):332–40

Several anesthetics, but not diethyl ether, cause marked elevation of serum parathyroid hormone concentration in

rats. Schultz VL, et al. **J Bone Miner Res** 1995 Sep; 10(9):1298–302

An anesthetic-sensitive superfamily of neurotransmitter-gated ion channels. Franks NP, et al. **J Clin Anesth** 1996 May;8(3 Suppl):3S–7S (32 ref.)

Anesthetic-dependent pial arteriolar response to ethanol. Gordon EL, et al. **J Neurosurg** 1995 Nov;83(5):875–7

Influence of anesthetics on the peripheral blood microfilaremia of Brugia malayi in the Mongolian jird, Meriones unguiculatus. Beerntsen BT, et al. **J Parasitol** 1996 Apr;82(2):327–30

Preparation, characterization, and anesthetic properties of 2-hydroxypropyl-beta-cyclodextrin complexes of pregnanolone and pregnenolone in rat and mouse. Brewster ME, et al. **J Pharm Sci** 1995 Oct;84(10):1154–9

Anesthetics produce subunit-selective actions on glutamate receptors. Dildy-Mayfield JE, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1058–65

Contrasting effects of anesthetics in tadpole bioassays. Downes H, et al. **J Pharmacol Exp Ther** 1996 Jul; 278(1):284–96

Effect of anesthetic variables on dermatomal somatosensory-evoked potential monitoring in elective lumbar spinal surgery. Coscia MF, et al. **J Spinal Disord** 1995 Dec;8(6):451–6

Effects of intravenous anesthetics on function and metabolism in the reperfused working rat heart. Oguchi T, et al. **Jpn J Pharmacol** 1995 Aug;68(4):413–21

Midazolam in combination with fentanyl/fluanisone and nitrous oxide as anaesthesia in rabbits--cardiovascular parameters. Hexeberg E, et al. **Lab Anim** 1995 Oct; 29(4):400–6

Volatile and intravenous anesthetics selectively attenuate the release of endothelium-derived hyperpolarizing factor elicited by bradykinin in the coronary microcirculation. Lischke V, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):346–9

Inactivation of hippocampus or caudate nucleus with lidocaine differentially affects expression of place and response learning. Packard MG, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):65–72

The effects of four general anesthetics on intracellular [Ca2+] in cultured rat hippocampal neurons. Bleakman D, et al. **Neuropharmacology** 1995 May;34(5):541–51

Decrease of anesthetics activity by electroacupuncture on Jen-Chung point in rabbits. Chang CL, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):93–6

Failure of the steroid anaesthetic alphaxalone to inhibit CRF-induced ACTH secretion in rats in the fast feedback time domain. Hinz B, et al. **Pharmazie** 1996 Jun;51(6):433–4

Cognitive and EEG recovery following bolus intravenous administration of anesthetic agents. La Marca S, et al. **Psychopharmacology (Berl)** 1995 Aug;120(4):426–32

A phenomenological model describing pharyngeal pulsing in the nematode Caenorhabditis elegans anesthetized by alcohol. Biswas SN, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):233–44

Total intravenous anaesthesia in ponies using detomidine, ketamine and guaiphenesin: pharmacokinetics, cardiopulmonary and endocrine effects. Taylor PM, et al. **Res Vet Sci** 1995 Jul;59(1):17–23

Anesthetics decreased the microdialysis extraction fraction of norepinephrine but not dopamine in the medial prefrontal cortex. Pan WH, et al. **Synapse** 1995 Sep; 21(1):85–92

Anesthetic activity of monoketones in mice: relationship to hydrophobicity and in vivo effects on Na+/K+ -ATPase activity and membrane fluidity. Tanii H. **Toxicol Lett** 1996 Apr;85(1):41–7

Anesthetic actions within the spinal cord: contributions to the state of general anesthesia. Collins JG, et al. **Trends Neurosci** 1995 Dec;18(12):549–53 (42 ref.)

[Does outpatient general anesthesia fulfill all expectations? (editorial)] Lindgren L, et al. **Duodecim** 1995;111(9):815–7 **(Fin)**

[Effects of anesthesia on the lower sphincter of the esophagus] Chassard D, et al. **Ann Fr Anesth Reanim** 1996; 15(3):277–83 (61 ref.) (Eng. Abstr.) **(Fre)**

[The angle under anesthesia and elongation of the lateral rectus muscle in primary esotropia] Oğuz V, et al. **J Fr Ophtalmol** 1996;19(5):322–6 (Eng. Abstr.) **(Fre)**

[Interactions between renal and general hemodynamics in fentanyl, droperidol, ketamine, thiopental and in peridural anesthesia--animal studies] Schenk HD, et al. **Anaesthesiol Reanim** 1995;20(3):60–70 (Eng. Abstr.) **(Ger)**

[Do general anesthetics act on specific receptors?] Urban BW, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct;30(6):375–82 (55 ref.) (Eng. Abstr.) **(Ger)**

[Signal transduction systems of nerve growth cone: effects of anesthetics on the machinery] Saito S, et al. **Masui** 1995; 44 Suppl:S113–8 (15 ref.) **(Jpn)**

[The effects of sevoflurane on the coronary circulation in the instrumented dog with or without coronary stenosis] Watanabe S, et al. **Masui** 1995 Aug;44(8):1080–90 (Eng. Abstr.) **(Jpn)**

[Anesthetics and the glutamate receptor channels expressed in Xenopus oocytes] Yamakura T, et al. **Masui** 1995;44 Suppl:S121–4 (14 ref.) **(Jpn)**

[Effect of verapamil and anesthetics on the level of sodium and potassium ions in frog muscles. Role of hydrophobic interactions] Nesterov VP, et al. **Biofizika** 1996 Jan–Feb; 41(1):110–5 (Eng. Abstr.) **(Rus)**

[Anesthetic pharmacology in recovery rooms (editorial; comment)] García RC. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):301–2. Comment on: Rev Esp Anestesiol Reanim 1995 Oct;42(8):303–5. Comment on: Rev Esp Anestesiol Reanim 1995 Oct;42(8):344–8. **(Spa)**

STANDARDS

Anesthetic management of the trauma patient. Cuvelliez S, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1073–92 (42 ref.)

THERAPEUTIC USE

The effects of anesthetic technique on the hemodynamic response and recovery profile in coronary revascularization patients [see comments] Mora CT, et al. **Anesth Analg** 1995 Nov;81(5):900–10. Comment in: Anesth Analg 1995 Nov;81(5):895–6.

Sevoflurane improves neurological outcome after incomplete cerebral ischaemia in rats. Werner C, et al. **Br J Anaesth** 1995 Dec;75(6):756–60

Propofol. An update of its use in anaesthesia and conscious sedation. Bryson HM, et al. **Drugs** 1995 Sep;50(3):513–59 (622 ref.)

Recovery characteristics following anaesthesia with sevoflurane or propofol in adults undergoing out-patient surgery. Wandel C, et al. **Eur J Clin Pharmacol** 1995; 48(3–4):185–8

TOXICITY

Influence of anesthetics on formation of brain edema [letter; comment] Kolbitsch C, et al. **Anesth Analg** 1996 Feb; 82(2):435. Comment on: Anesth Analg 1995 Jun;80(6):1108–15.

Distortion-product otoacoustic emissions and their anaesthesia sensitivity in the European starling and the chicken. Kettembeil S, et al. **Hear Res** 1995 Jun; 86(1–2):47–62

HFA-134a (1,1,1,2-tetrafluoroethane); lack of oncogenicity in rodents after inhalation. Alexander DJ, et al. **Hum Exp Toxicol** 1995 Sep;14(9):706–14

An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane). Alexander DJ, et al. **Hum Exp Toxicol** 1995 Sep;14(9):715–20 (8 ref.)

ANESTHETICS, CONDUCTION-BLOCKING see **ANESTHETICS, LOCAL**

ANESTHETICS, DISSOCIATIVE

The effect of extradural ketamine on onset time and sensory block in extradural anaesthesia with bupivacaine. Yanli Y, et al. **Anaesthesia** 1996 Jan;51(1):84–6

The use of diazepam and ketamine for i.v. conscious sedation in outpatient surgery settings. Ringler JD. **AORN J** 1995 Oct;62(4):638–45

The use of tiletamine hydrochloride and zolazepam hydrochloride for sedation of the mountain brushtial possum, Trichosurus caninus Ogilby (Phalangeridae: Marsupialia). Viggers KL, et al. **Aust Vet J** 1995 Jun; 72(6):215–6

Immobilization of guanacos by use of tiletamine/zolazepam. Sarno RJ, et al. **J Am Vet Med Assoc** 1996 Feb 1; 208(3):408–9

Immobilization of muskrats (Ondatra zibethicus) with ketamine and xylazine. Belant JL. **J Wildl Dis** 1996 Jan; 32(1):152–5

Immobilization of ocelots and bobcats with ketamine hydrochloride and xylazine hydrochloride. Beltrán JF, et al. **J Wildl Dis** 1995 Jan;31(1):43–8

Ventricular arrhythmogenic dose of adrenaline during sevoflurane, isoflurane, and halothane anaesthesia either with or without ketamine or thiopentone in cats. Hikasa Y, et al. **Res Vet Sci** 1996 Mar;60(2):134–7

Effects of cadmium and verapamil on ketamine-induced anesthesia in mice. Shen Y, et al. **Vet Hum Toxicol** 1995 Jun;37(3):201–3

A standard water provocative test for dogs anaesthetized with acepromazine-ketamine. Martin E, et al. **Zentralbl Veterinarmed A** 1995 Jun;42(4):267–73

[Analgesia-sedation for maxillo-facial surgery with midazolam-pentazocine and midazolam-ketamine. Clinical double-blind study of anxiety, analgesia, sedation and amnesia] Lipp M, et al. **Anaesthesist** 1995 Aug;44(8):566–72 (Eng. Abstr.) **(Ger)**

[Ketamine-clofelin anesthesia in children] Berlinskiĭ VV, et al. **Anesteziol Reanimatol** 1995 Sep–Oct;(5):38–40 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Anesthesia induced in pigs by use of a combination of medetomidine, butorphanol, and ketamine and its reversal by administration of atipamezole. Sakaguchi M, et al. **Am J Vet Res** 1996 Apr;57(4):529–34

Anaesthesia for an anterior mediastinal mass with ketamine and midazolam infusion. Frawley G, et al. **Anaesth Intensive Care** 1995 Oct;23(5):610–2

Chemical restraint of southern elephant seals (Mirounga Leonina); use of medetomidine, ketamine and atipamezole and comparison with other cyclohexamine-based combinations. Woods R, et al. **Br Vet J** 1996 Mar; 152(2):213–24

Spinal ketamine anaesthesia for hemithyroidectomy [letter] Sekaran NK, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):537–8

Cardiovascular changes associated with anaesthesia induced by medetomidine combined with ketamine in cats. Dobromylskyj P. **J Small Anim Pract** 1996 Apr; 37(4):169–72

Ketamine plus midazolam, a most effective paediatric oral premedicant. Warner DL, et al. **Paediatr Anaesth** 1995; 5(5):293–5

Efficacy of oral ketamine for providing sedation and analgesia to children requiring laceration repair [letter] Hollman GA, et al. **Pediatr Emerg Care** 1995 Dec;11(6):399

A comparison of sedation techniques for outpatient rhinoplasty: midazolam versus midazolam plus ketamine. Moscona RA, et al. **Plast Reconstr Surg** 1995 Oct; 96(5):1066–74

Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Sörensen J, et al. **Scand J Rheumatol** 1995;24(6):360–5

[Ketamine at low doses + etomidate or diazepam--a comparative clinical study of anesthesia in urology] Tablov V, et al. **Khirurgiia (Sofiia)** 1995;48(5):36–8 (Eng. Abstr.) **(Bul)**

ANTAGONISTS & INHIBITORS

Potential physiologic mechanism for ketamine-induced emergence delirium [letter; comment] Gutstein HB. **Anesthesiology** 1996 Feb;84(2):474. Comment on: Anesthesiology 1995 May;82(5):1117–25.

BLOOD

Pharmacokinetics of ketamine enantiomers [letter] Geisslinger G, et al. **Br J Anaesth** 1995 Oct;75(4):506–7

PHARMACOKINETICS

Pharmacokinetics of ketamine in mules and mammoth asses premedicated with xylazine. Matthews NS, et al. **Equine Vet J** 1994 May;26(3):241–3

PHARMACOLOGY

In vitro myocardial depression by ketamine or thiopental is dependent on the underlying beta-adrenergic tone. Thurston TA, et al. **Acta Anaesthesiol Scand** 1996 Mar; 40(3):338–41

Ketamine, at clinical concentrations, does not alter the function of cardiac sarcoplasmic reticulum calcium release channels. Connelly TJ, et al. **Anesth Analg** 1995 Oct; 81(4):849–54

The effects of ketamine-isomers on neuronal injury and regeneration in rat hippocampal neurons. Himmelseher S, et al. **Anesth Analg** 1996 Sep;83(3):505–12

The effects of ketamine on renal sympathetic nerve activity and phrenic nerve activity in rabbits (with vagotomy) with and without afferent inputs from peripheral receptors. Sasao J, et al. **Anesth Analg** 1996 Feb;82(2):362–7

Nonstereospecific actions of ketamine isomers on the force of contraction, spontaneous beating rate, and Ca2+ current in the guinea pig heart. Sekino N, et al. **Anesth Analg** 1996 Jul;83(1):75–80

Analgesic efficacy of low-dose ketamine. Somatosensory-evoked responses in relation to subjective pain ratings. Kochs E, et al. **Anesthesiology** 1996 Aug; 85(2):304–14

Inhibitory effects of ketamine and halothane on recombinant potassium channels from mammalian brain. Kulkarni RS, et al. **Anesthesiology** 1996 Apr;84(4):900–9

Ketamine inhibits K+ evoked [3H] noradrenaline release from SH-SY5Y cells by reducing calcium influx. Sikand KS, et al. **Biochem Soc Trans** 1995 Aug;23(3):417S

Central nuclei and spinal pathways in feedback inhibitory spinal cord potentials in ketamine-anaesthetized rats. Denda S, et al. **Br J Anaesth** 1996 Feb;76(2):258–65

Relaxant effect of ketamine and its isomers on histamine-induced contraction of tracheal smooth muscle. Hirota K, et al. **Br J Anaesth** 1996 Feb;76(2):266–70

Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans. Ilkjaer S, et al. **Br J Anaesth** 1996 Jun;76(6):829–34

Differential effects of propofol, thiamylal and ketamine on the cricothyroid and posterior cricoarytenoid muscles of the canine larynx. Iwasaki H, et al. **Can J Anaesth** 1996 Jan;43(1):39–43

Differential effects of ketamine and midazolam on heart rate variability. Komatsu T, et al. **Can J Anaesth** 1995 Nov; 42(11):1003–9

Effects of intravenous ketamine on gastrointestinal motility in the dog. Fass J, et al. **Intensive Care Med** 1995 Jul; 21(7):584–9

Effects of anesthesia on urodynamic studies in the primate model. Ghoniem GM, et al. **J Urol** 1996 Jul;156(1):233–6

Differential effects of Ketaset/Rompun anesthesia on hypothermia-induced retrograde amnesia and its recovery. Metzger MM, et al. **Neurobiol Learn Mem** 1995 Nov; 64(3):245–56

Influences of type of anaesthesia on cortisol, beta-endorphin and heart rate in pigs. Gerard H, et al. **Vet Res** 1996;

ANESTHETICS, DISSOCIATIVE

27(3):219–26

Chemical restraint by medetomidine–ketamine and its cardiopulmonary effects in pigs. Sakaguchi M, et al. **Zentralbl Veterinarmed A** 1995 Jul;42(5):293–9

THERAPEUTIC USE

Acute phantom limb pain controlled by ketamine. Knox DJ, et al. **Anaesth Intensive Care** 1995 Oct;23(5):620–2

Randomized, double-blind, placebo-controlled trial of intravenous ketamine in acute asthma. Howton JC, et al. **Ann Emerg Med** 1996 Feb;27(2):170–5

Ketamine as an adjunct to morphine in the treatment of pain. Cherry DA, et al. **Pain** 1995 Jul;62(1):119–21

NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Felsby S, et al. **Pain** 1996 Feb;64(2):283–91

ANESTHETICS, GENERAL

Clinical aspects of CRNA practice. General anesthesia. Ouellette SM. **Nurs Clin North Am** 1996 Sep;31(3):623–42 (102 ref.)

Ventricular arrhythmogenic dose of adrenaline during sevoflurane, isoflurane, and halothane anaesthesia either with or without ketamine or thiopentone in cats. Hikasa Y, et al. **Res Vet Sci** 1996 Mar;60(2):134–7

ADMINISTRATION & DOSAGE

Premedication with famotidine augments core hypothermia during general anesthesia. Hirose M, et al. **Anesthesiology** 1995 Dec;83(6):1179–83

ADVERSE EFFECTS

Cognitive failures after general anaesthesia for day-case surgery. Tzabar Y, et al. **Br J Anaesth** 1996 Feb;76(2):194–7

Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Stellato C, et al. **Chem Immunol** 1995;62:108–31 (94 ref.)

Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. Genovese A, et al. **Int Arch Allergy Immunol** 1996 May; 110(1):13–22 (102 ref.)

PHARMACOLOGY

Actions of general anaesthetics on 5-HT3 receptors in N1E–115 neuroblastoma cells. Jenkins A, et al. **Br J Pharmacol** 1996 Apr;117(7):1507–15

A discrete site for general anesthetics on a postsynaptic receptor. Forman SA, et al. **Mol Pharmacol** 1995 Oct; 48(4):574–81

[Regulatory actions of general anesthetics on inhibitory receptor channels] Akagi H. **Masui** 1995;44 Suppl:S125–6 (4 ref.) **(Jpn)**

STANDARDS

The use of obstetric emergency drug trays: room for improvement? [letter] Bryden D, et al. **Anaesthesia** 1996 Jul;51(7):709–10

ANESTHETICS, INHALATION

Which inhalation anaesthetic agent is best for pediatric use? Lindahl SG. **Acta Anaesthesiol Belg** 1996;47(1):23–7 (14 ref.)

Adult clinical experience with sevoflurane and pharmaco-economic aspects. Young CJ, et al. **Acta Anaesthesiol Belg** 1996;47(1):29–42 (180 ref.)

Desflurane: a new volatile anesthetic for cesarean section. Maternal and neonatal effects. Abboud TK, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):723–6

Diffusion of anaesthetic gases through different polymers. Marx T, et al. **Acta Anaesthesiol Scand** 1996 Feb; 40(2):275–81

Hypoxic and hypercapnic ventilatory responses during isoflurane sedation and anaesthesia in women. Sollevi A, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):931–8

Breathing patterns under enflurane, halothane and propofol sedation in humans. Nagyova B, et al. **Adv Exp Med Biol** 1995;393:101–4

Comparison of two techniques of narcotic-induced anesthesia for use during recording of magnetic motor evoked potentials in dogs. Van Ham LM, et al. **Am J Vet Res** 1996 Feb;57(2):142–6

Pressure support ventilation during isoflurane anaesthesia. Bhatt SB, et al. **Anaesthesia** 1995 Dec;50(12):1026–30

A comparison of the induction characteristics of sevoflurane and halothane in children. Black A, et al. **Anaesthesia** 1996 Jun;51(6):539–42

Carbon monoxide, soda lime and volatile agents [letter] Davies MW, et al. **Anaesthesia** 1996 Jan;51(1):90

The influence of isoflurane on a continuous infusion of mivacurium. De Mey JC, et al. **Anaesthesia** 1995 Nov; 50(11):947–9

Assessment of recovery following day-case arthroscopy. A comparison between propofol and isoflurane-based anaesthesia. Gupta A, et al. **Anaesthesia** 1995 Nov; 50(11):937–42

Anaesthesia for day-care arthroscopy. A comparison between desflurane and isoflurane. Gupta A, et al. **Anaesthesia** 1996 Jan;51(1):56–62

Is there a need for a new inhalational anaesthetic agent? Jones RM, et al. **Anaesthesia** 1995 Oct;50 Suppl:1–2

Doxacurium pharmacodynamics in children during volatile and opioid-based anaesthesia. Kern C, et al. **Anaesthesia** 1996 Apr;51(4):361–4

Unrecognised environmental pollution by desflurane [letter] Radcliffe JJ, et al. **Anaesthesia** 1996 Jan;51(1):100

Clonidine—and adjunct in isoflurane N2O/O2 relaxant anaesthesia [letter] Savva D. **Anaesthesia** 1996 Mar; 51(3):293

A comparison of the recovery characteristics of sevoflurane and halothane in children. Sury MR, et al. **Anaesthesia** 1996 Jun;51(6):543–6

The neuromuscular blocking effects of vecuronium during sevoflurane, halothane and balanced anaesthesia in children. Taivainen T, et al. **Anaesthesia** 1995 Dec; 50(12):1046–9

Sevoflurane: introduction and overview. Brown B Jr. **Anesth Analg** 1995 Dec;81(6 Suppl):S1–3

Inhalation agents: a young anesthetist's dilemma [letter] Geiser JF. **Anesth Analg** 1996 Apr;82(4):896

Sevoflurane versus isoflurane for maintenance of anesthesia: are serum inorganic fluoride ion concentrations of concern? Goldberg ME, et al. **Anesth Analg** 1996 Jun;82(6):1268–72

Comparison of isoflurane and desflurane anesthetic depth using burst suppression of the electroencephalogram in neurosurgical patients. Hoffman WE, et al. **Anesth Analg** 1995 Oct;81(4):811–6

Sevoflurane in pediatric anesthesia. Lerman J. **Anesth Analg** 1995 Dec;81(6 Suppl):S4–10 (47 ref.)

Inorganic fluoride kinetics and renal tubular function after sevoflurane anesthesia in chronic renal failure patients receiving hemodialysis. Nishiyama T, et al. **Anesth Analg** 1996 Sep;83(3):574–7

Quantitation of depth of thiopental anesthesia in the rat. Gustafsson LL, et al. **Anesthesiology** 1996 Feb;84(2):415–27

Simulation of an epidural test dose with intravenous isoproterenol in awake and in halothane-anesthetized children. Kozek-Langenecker S, et al. **Anesthesiology** 1996 Aug;85(2):277–80

Prediction of movement during propofol/nitrous oxide anesthesia. Performance of concentration, electroencephalographic, pupillary, and hemodynamic indicators. Leslie K, et al. **Anesthesiology** 1996 Jan; 84(1):52–63

Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Lien CA, et al. **Anesthesiology** 1996 Feb;84(2):300–8

Differences in respiratory reflex responses from the larynx, trachea, and bronchi in anesthetized female subjects. Nishino T, et al. **Anesthesiology** 1996 Jan;84(1):70–4

Effects of halogenated and non-halogenated anesthetics on diaspirin cross-linked hemoglobin induced contractions of porcine pulmonary veins. Jing M, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(4):487–94

Effect of tramadol on depth of anaesthesia. Coetzee JF, et al. **Br J Anaesth** 1996 Mar;76(3):415–8

Remifentanil reduces auditory and somatosensory evoked responses during isoflurane anaesthesia in a dose-dependent manner. Crabb I, et al. **Br J Anaesth** 1996 Jun;76(6):795–801

Efficiency of a circle system for short surgical cases: comparison of desflurane with isoflurane. Lee DJ, et al. **Br J Anaesth** 1996 Jun;76(6):780–2

Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. McCoy EP, et al. **Br J Anaesth** 1996 Jan;76(1):29–33

Sevoflurane–nitrous oxide or halothane–nitrous oxide for paediatric bronchoscopy and gastroscopy. Meretoja OA, et al. **Br J Anaesth** 1996 Jun;76(6):767–71

Remembrance of times past: the significance of c-fos in pain [editorial; comment] Munglani R, et al. **Br J Anaesth** 1996 Jan;76(1):1–4. Comment on: Br J Anaesth 1996 Jan;76(1):99–105.

Analysis of ethanol in expired air during low-flow isoflurane anaesthesia. Olsson J, et al. **Br J Anaesth** 1996 Jan; 76(1):85–9

Sevoflurane—a long-awaited volatile anaesthetic. Smith I, et al. **Br J Anaesth** 1996 Mar;76(3):435–45 (92 ref.)

Effects of surgical skin incision on respiration in patients anaesthetized with enflurane. Sutherland RW, et al. **Br J Anaesth** 1996 Jun;76(6):777–9

Recovery after desflurane anaesthesia in the infant: comparison with isoflurane. Wolf AR, et al. **Br J Anaesth** 1996 Mar;76(3):362–4

The choice of anaesthetic for carotid endarterectomy: does it matter? [editorial] Archer DP, et al. **Can J Anaesth** 1995 Jul;42(7):566–70 **(Eng, Fre)**

Haemodynamic instability and myocardial ischaemia during carotid endarterectomy: a comparison of propofol and isoflurane. Mutch WA, et al. **Can J Anaesth** 1995 Jul; 42(7):577–87

Renal sympathetic and heart rate baroreflex function in conscious and isoflurane anaesthetized normotensive and chronically hypertensive rabbits. Bell LB, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):701–10

Inhalational anesthetics in the intensive care unit. Kong KL. **Crit Care Clin** 1995 Oct;11(4):887–902 (74 ref.)

Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia. Patel SS, et al. **Drugs** 1996 Apr;51(4):658–700 (471 ref.)

Comparison of maintenance and recovery characteristics of sevoflurane–nitrous oxide and enflurane–nitrous oxide anaesthesia. Blanco E, et al. **Eur J Anaesthesiol** 1995 Sep; 12(5):517–23

Effects of sevoflurane anaesthesia on renal function--duration of administration and area under the curve and rate of decrease of serum inorganic fluoride. Nishiyama T, et al. **Eur J Anaesthesiol** 1995 Sep; 12(5):477–82

Dose-response, time-course of action and recovery of rocuronium bromide in children during halothane anaesthesia. Motsch J, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:73–8

Anesthetic and postanesthetic management of sea turtles. Moon PF, et al. **J Am Vet Med Assoc** 1996 Mar 1; 208(5):720–6

Desflurane controls the hemodynamic response to surgical stimulation more rapidly than isoflurane. Bennett JA, et al. **J Clin Anesth** 1995 Jun;7(4):288–91

A comparison of mivacurium dosage requirements during isoflurane and desflurane anesthesia. Gan TJ, et al. **J Clin Anesth** 1996 Jun;8(4):301–6

Desflurane is not associated with faster operating room exit times in outpatients. Patel N, et al. **J Clin Anesth** 1996 Mar; 8(2):130–5

A comparison of sevoflurane with halothane in outpatient adenotomy in children with mild upper respiratory tract infections. Rieger A, et al. **J Clin Anesth** 1996 May; 8(3):188–97

Effect of intrathecal sufentanil on isoflurane requirements during lower abdominal surgery. Swenson JD, et al. **J Clin Anesth** 1995 Sep;7(6):477–80

Inhalational anesthetics: desflurane and sevoflurane. Young CJ, et al. **J Clin Anesth** 1995 Nov;7(7):564–77 (198 ref.)

Clinical application of rapid inhalation induction of anesthesia using isoflurane and sevoflurane with nitrous oxide in dogs. Mutoh T, et al. **J Vet Med Sci** 1995 Dec;57(6):1121–4

Rapid inhalation induction of anesthesia by halothane, enflurane, isoflurane and sevoflurane and their cardiopulmonary effects in dogs. Mutoh T, et al. **J Vet Med Sci** 1995 Dec;57(6):1007–13

Isoflurane as an inhalation anesthetic for muskrats (Ondatra zibethicus). Belant JL. **J Wildl Dis** 1995 Oct;31(4):573–5

Brain-stem auditory evoked potentials study during isoflurane–N2O anesthesia—a measure of depth of anesthesia. el-Dawlatly AA, et al. **Middle East J Anesthesiol** 1995 Feb;13(1):61–70

Sinus node recovery function is relatively well preserved under halothane anaesthesia in children. Iwai M, et al. **Paediatr Anaesth** 1995;5(4):233–6

Sevoflurane in paediatric anaesthesia: effects on respiration and circulation during induction and recovery. Mori N, et al. **Paediatr Anaesth** 1996;6(2):95–102

Pressure antagonism of nitrous oxide depression of intracellular calcium in a neuroblastoma cell line. Resendes MC, et al. **Undersea Hyperb Med** 1996 Mar;23(1):27–30

[Halothane and obese patients (letter; comment)] Pedersen FM. **Ugeskr Laeger** 1995 Nov 20;157(47):6592–3. Comment on: Ugeskr Laeger 1995 Aug 21;157(34):4691–4. **(Dan)**

[Sevoflurane] Murat I, et al. **Ann Fr Anesth Reanim** 1995; 14(6):489–501 (149 ref.) (Eng. Abstr.) **(Fre)**

[Sevoflurane: new inhalation anesthetic for clinical practice. Workshop proceedings. Wiesbaden, 23–24 June 1995] **Anaesthesist** 1996 Feb;45 Suppl 1:S1–70 **(Ger)**

[A comparative study of the use of sevoflurane and propofol in ambulatory surgery] Motsch J, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S57–62 (Eng. Abstr.) **(Ger)**

[Changes in somatosensory evoked potentials after sevoflurane and isoflurane. A randomized phase III study] Schindler E, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S52–6 (Eng. Abstr.) **(Ger)**

[Comparison of sevoflurane and isoflurane in ambulatory surgery. Results of a multicenter study] Scholz J, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S63–70 (Eng. Abstr.) **(Ger)**

[Superimposed high-frequency jet ventilation (SHFJV) in the administration of NO. Technical basis and early clinical results with ARDS] Schragl E, et al. **Anaesthesist** 1995 Dec;44(12):843–9 (Eng. Abstr.) **(Ger)**

[Intraoperative awareness and auditory evoked potentials] Schwender D, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S46–51 (30 ref.) (Eng. Abstr.) **(Ger)**

[Desflurane and isoflurane. A comparison of recovery and circulatory parameters in surgical interventions] Wilhelm W, et al. **Anaesthesist** 1996 Jan;45(1):37–46 (Eng. Abstr.) **(Ger)**

[Clinical potency of nitrous oxide—is MAC the gold standard?] Schwilden H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):337–40 (23 ref.) (Eng. Abstr.) **(Ger)**

[Rates of awakening, circulatory parameters and side-effects with sevoflurane and enflurane. An open, randomized, comparative phase III study] Wiesner G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):290–6 (Eng. Abstr.) **(Ger)**

[Isoflurane in angiography with magnetic resonance] Carriero A, et al. **Radiol Med (Torino)** 1995 Jul–Aug; 90(1–2):88–92 (Eng. Abstr.) **(Ita)**

[Comparison of airway complications on tracheal extubation in deeply sevoflurane anesthetized versus awake children] Goyagi T, et al. **Masui** 1995 Sep;44(9):1242–5 (Eng. Abstr.) **(Jpn)**

[Anesthesia in a patient with history of multiple drug allergies] Horiguchi Y, et al. **Masui** 1995 Nov;44(11):1542–6 (Eng. Abstr.) **(Jpn)**

[Alterations of the brain stem and mid-latency evoked potentials under oxygen-nitrous oxide-sevoflurane anesthesia] Kadoi Y, et al. **Masui** 1995 Dec;44(12):1618–22 (Eng. Abstr.) **(Jpn)**

[Effects of nitrous oxide on electroencephalographic activity during sevoflurane anesthesia: a zero-crossing analysis] Kaneda T, et al. **Masui** 1995 Nov;44(11):1498–505 (Eng. Abstr.) **(Jpn)**

[The present state of balanced anesthesia—combination of intravenous and inhaled anesthetics] Sumikawa K, et al. **Masui** 1995;44 Suppl:S149–52; discussion S156–7 (10 ref.) **(Jpn)**

[Multiple regression analysis of pre- and intra-operative factors in relation to post-operative liver and renal functions] Tabo E, et al. **Masui** 1995 Nov;44(11):1482–8 (Eng. Abstr.) **(Jpn)**

[Effects of preoperatively administered flurbiprofen axetil on the action of inhaled anesthesia and postoperative pain] Yamazaki Y, et al. **Masui** 1995 Sep;44(9):1238–41 (Eng. Abstr.) **(Jpn)**

[Comparative assessment of the hormonal status during N2O and xenon anesthesia using similar methods] Burov NE, et al. **Anesteziol Reanimatol** 1995 Jul–Aug;(4):57–60 (Eng. Abstr.) **(Rus)**

[The narcotic properties of xenon and the prospects for its use in anesthesiology] Damir EA, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):71–5 (88 ref.) **(Rus)**

[Comparison of changes in plasma concentrations of ACTH and beta-endorphin in cholecystectomy under general anesthesia and general plus epidural anesthesia] Caba F, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):364–8 (Eng. Abstr.) **(Spa)**

[Isoflurane versus propofol for sedation after heart surgery] Gómez JI, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep; 42(7):261–8 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Influence of forebrain lesions and isoflurane anaesthesia, respectively, on responses to the intracarotid infusion of angiotensin II in sheep. Eriksson S, et al. **Acta Physiol Scand** 1995 Dec;155(4):427–34

The effect of different end-tidal volatile agent and carbon dioxide concentrations upon the incidence of postoperative shivering. Harwood RJ, et al. **Anaesthesia** 1995 Sep; 50(9):786–8

Implications of chemical and physical properties of desflurane for longer surgery. Weiskopf RB. **Anaesthesia** 1995 Oct;50 Suppl:9–13 (57 ref.)

Sevoflurane versus isoflurane in single-breath induction [letter] Abramson DC, et al. **Anesth Analg** 1996 Sep; 83(3):662

Recovery profile after desflurane with or without ondansetron compared with propofol in patients undergoing outpatient gynecological laparoscopy. Eriksson H, et al. **Anesth Analg** 1996 Mar;82(3):533–8

Sevoflurane-based anesthesia in a patient with myotonia dystrophica [letter] Gupta A, et al. **Anesth Analg** 1996 Aug; 83(2):442

Cortical reactivity during isoflurane burst-suppression anesthesia. Hartikainen KM, et al. **Anesth Analg** 1995 Dec; 81(6):1223–8

The comparative effects of sevoflurane versus propofol in the induction and maintenance of anesthesia in adult patients. Jellish WS, et al. **Anesth Analg** 1996 Mar; 82(3):479–85

Intraoperative myogenic motor evoked potentials induced by direct electrical stimulation of the exposed motor cortex under isoflurane and sevoflurane. Kawaguchi M, et al. **Anesth Analg** 1996 Mar;82(3):593–9

Sevoflurane versus desflurane for outpatient anesthesia: a comparison of maintenance and recovery profiles. Nathanson MH, et al. **Anesth Analg** 1995 Dec;81(6):1186–90

The effects of dobutamine and phenylephrine on atrioventricular conduction during combined use of halothane and thoracic epidural lidocaine. Nishikawa K, et al. **Anesth Analg** 1996 Mar;82(3):551–7

Posterior hypothalamic noradrenaline release during emergence from sevoflurane anesthesia in rats. Ohkawa H, et al. **Anesth Analg** 1995 Dec;81(6):1289–91

A multicenter comparison of maintenance and recovery with sevoflurane or isoflurane for adult ambulatory anesthesia. The Sevoflurane Multicenter Ambulatory Group. Philip BK, et al. **Anesth Analg** 1996 Aug;83(2):314–9

Sevoflurane versus isoflurane: induction and recovery characteristics with single-breath inhaled inductions of anesthesia. Sloan MH, et al. **Anesth Analg** 1996 Mar; 82(3):528–32

The role of sevoflurane in outpatient anesthesia. Smith I, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S67–72 (24 ref.)

Hemodynamic effects of intravenous ephedrine in infants and children anesthetized with halothane and nitrous oxide. Taguchi N, et al. **Anesth Analg** 1996 Mar;82(3):568–73

Isoflurane anesthesia does not add to the bronchodilating effect of a beta 2-adrenergic agonist after tracheal intubation. Wu RS, et al. **Anesth Analg** 1996 Aug; 83(2):238–41

Interaction of isoflurane and nitrous oxide combinations similar for median electroencephalographic frequency and clinical anesthesia. Röpcke H, et al. **Anesthesiology** 1996 Apr;84(4):782–8

Cardiovascular stimulation induced by rapid increases in desflurane concentration in humans results from activation of tracheopulmonary and systemic receptors. Weiskopf RB, et al. **Anesthesiology** 1995 Dec;83(6):1173–8

Fuzzy logic control of inspired isoflurane and oxygen concentrations using minimal flow anaesthesia. Curatolo M, et al. **Br J Anaesth** 1996 Feb;76(2):245–50

Effect of age on MAC in humans: a meta-analysis. Mapleson WW. **Br J Anaesth** 1996 Feb;76(2):179–85

Effects of sevoflurane and isoflurane on systemic vascular resistance: use of cardiopulmonary bypass as a study model. Rödig G, et al. **Br J Anaesth** 1996 Jan;76(1):9–12

Analgesic effect in humans of subanaesthetic isoflurane concentrations evaluated by evoked potentials. Roth D, et al. **Br J Anaesth** 1996 Jan;76(1):38–42

Halogenated gas embolism prevention by Intralipid [letter; comment] Gould DB. **Can J Anaesth** 1995 Sep;42(9):836–7 . Comment on: Can J Anaesth 1995 Feb;42(2):173–6.

Laryngoscopy and arrhythmias in children [letter] Morrison JE Jr, et al. **Can J Anaesth** 1995 Aug;42(8):748–9

Adaptation of ICU ventilator to deliver isoflurane [letter] Sullivan M, et al. **Can J Anaesth** 1995 Sep;42(9):841–2

Adaptive segmentation of burst-suppression pattern in isoflurane and enflurane anesthesia. Lipping T, et al. **Int J Clin Monit Comput** 1995;12(3):161–7

Intravenous drug delivery systems: toward an intravenous "vaporizer". Egan TD. **J Clin Anesth** 1996 May;8(3 Suppl):8S–14S (38 ref.)

Comparison of sevoflurane and halothane anesthesia in children undergoing outpatient ear, nose, and throat surgery. Greenspun JC, et al. **J Clin Anesth** 1995 Aug; 7(5):398–402

Do you know your MGVS? Or what do anesthesiologists know about their MGVS? Peterson TG. **J Clin Monit** 1995 Nov;11(6):415–6

Induction of anaesthesia with halothane and isoflurane in the rabbit: a comparison of the use of a face-mask or an anaesthetic chamber. Flecknell PA, et al. **Lab Anim** 1996 Jan;30(1):67–74

Duration of apnoea in anaesthetized children required for desaturation of haemoglobin to 95%: comparison of three different breathing gases. Kinouchi K, et al. **Paediatr Anaesth** 1995;5(2):115–9

Conscious sedation of pediatric dental patients using chloral hydrate, hydroxyzine, and nitrous oxide—a retrospective study of 382 sedations. Needleman HL, et al. **Pediatr Dent** 1995 Nov–Dec;17(7):424–31

Volatile anesthetic modulation of lung injury and outcome in a murine model of multiple organ dysfunction syndrome. Shayevitz JR, et al. **Shock** 1995 Jul;4(1):61–7

Desflurane in equine anaesthesia: a preliminary trial. Jones NY, et al. **Vet Rec** 1995 Dec 9;137(24):618–20

[A case of status asthmatics relieved by long-term inhalation of isoflurane] Takeyama K, et al. **Masui** 1995 Nov; 44(11):1559–62 (Eng. Abstr.) **(Jpn)**

[Nitrous oxide is superior to other anesthetics in colonoscopy] Hedenbro J, et al. **Lakartidningen** 1996 Jan 24;93(4):257–8 **(Swe)**

ADVERSE EFFECTS

Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle. Hartung E, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):437–44

Hepatic necrosis after cardiac surgery [letter; comment] Strunin L, et al. **Anaesth Intensive Care** 1995 Dec; 23(6):755–6. Comment on: Anaesth Intensive Care 1995 Apr;23(2):225–7.

Hypothesis: halothane hepatitis—has thymol been overlooked? [letter] Hutter CD. **Anaesthesia** 1995 Dec; 50(12):1098

Renal and hepatic function in surgical patients after low-flow sevoflurane or isoflurane anesthesia. Bito H, et al. **Anesth Analg** 1996 Jan;82(1):173–6

The safety of sevoflurane has not been adequately established [letter] Eger EI 2nd, et al. **Anesth Analg** 1996 Feb; 82(2):431–3

Does nitrous oxide cause vomiting? [editorial; comment] Fisher DM. **Anesth Analg** 1996 Jul;83(1):4–5. Comment on: Anesth Analg 1996 Jul;83(1):114–6.

Twenty-four of twenty-seven studies show a greater incidence of emesis associated with nitrous oxide than with alternative anesthetics [see comments] Hartung J. **Anesth Analg** 1996 Jul;83(1):114–6. Comment in: Anesth Analg 1996 Jul;83(1):4–5.

The organ toxicity of inhaled anesthetics. Kenna JG, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S51–66 (143 ref.)

Loss of alveolar macrophages during anesthesia and operation in humans. Kotani N, et al. **Anesth Analg** 1995 Dec;81(6):1255–62

Prolonged sevoflurane inhalation was not nephrotoxic in two patients with refractory status asthmaticus. Mori N, et al. **Anesth Analg** 1996 Jul;83(1):189–91

Enflurane decreases the threshold for vasoconstriction more than isoflurane or halothane. Nebbia SP, et al. **Anesth Analg** 1996 Sep;83(3):595–9

Porphyria, cardiopulmonary bypass, and volatile anesthetics [letter] Pivalizza EG, et al. **Anesth Analg** 1996 Sep;83(3):658

The hemodynamic and renal effects of sevoflurane and isoflurane in patients with coronary artery disease and chronic hypertension. Sevoflurane Ischemia Study Group. Rooke GA, et al. **Anesth Analg** 1996 Jun;82(6):1159–65

Severe neurologic deficit after nitrous oxide anesthesia. Hadzic A, et al. **Anesthesiology** 1995 Oct;83(4):863–6 (14 ref.)

Inhalation toxicity study of a haloalkene degradant of sevoflurane, Compound A (PIFE), in Sprague-Dawley rats. Keller KA, et al. **Anesthesiology** 1995 Dec; 83(6):1220–32

Hepatotoxicity after desflurane anesthesia. Martin JL, et al. **Anesthesiology** 1995 Nov;83(5):1125–9

Atelectasis and chest wall shape during halothane anesthesia. Warner DO, et al. **Anesthesiology** 1996 Jul;85(1):49–59

Controlling dental occupational exposure to nitrous oxide [letter] Girdler NM. **Br Dent J** 1996 Jun 8;180(11):409

Effect of nebulized lignocaine on airway irritation and haemodynamic changes during induction of anaesthesia with desflurane [see comments] Bunting HE, et al. **Br J Anaesth** 1995 Nov;75(5):631–3. Comment in: Br J Anaesth 1996 Apr;76(4):596.

Nebulized lignocaine before gaseous induction with desflurane [letter; comment] Nay PG. **Br J Anaesth** 1996 Apr;76(4):596. Comment on: Br J Anaesth 1995 Nov;75(5):631–3.

Effects of carbon dioxide embolism with nitrous oxide in the inspired gas in piglets. Nyarwaya JB, et al. **Br J Anaesth** 1996 Mar;76(3):428–34

Omitting nitrous oxide in general anaesthesia: meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials. Tramèr M, et al. **Br J Anaesth** 1996 Feb;76(2):186–93

Movement associated with high cerebral concentrations of isoflurane: no evidence of seizure activity. Antognini JF. **Can J Anaesth** 1996 Mar;43(3):310–4

Ventilatory depression by halothane in infants and children. Brown KA, et al. **Can J Anaesth** 1995 Jul;42(7):588–96

Comparison of haemodynamic changes induced by sevoflurane and halothane in paediatric patients. Kawana S, et al. **Can J Anaesth** 1995 Jul;42(7):603–7

Increased micronucleus formation in nurses with occupational nitrous oxide exposure in operating theaters. Chang WP, et al. **Environ Mol Mutagen** 1996;27(2):93–7

Hyperkalemic periodic paralysis episode during halothane anesthesia in a horse. Bailey JE, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1859–65

Target-controlled infusions: stress free anesthesia? Kenny GN, et al. **J Clin Anesth** 1996 May;8(3 Suppl):15S–20S (46 ref.)

Tension pneumocephalus following posterior cranial fossa surgery in sitting position. Tripathy P, et al. **J Indian Med Assoc** 1995 Mar;93(3):109–10

Severe combined degeneration of the spinal cord after nitrous oxide anaesthesia in a vegetarian [letter] Rösener M, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):354

Vitamin B12 myeloneuropathy precipitated by nitrous oxide anaesthesia [letter] Nestor PJ, et al. **Med J Aust** 1996 Aug 5;165(3):174

Drug-induced hepatotoxicity [letter; comment] Palleschi GT. **N Engl J Med** 1996 Mar 28;334(13):863–4; discussion 864 . Comment on: N Engl J Med 1995 Oct 26;333(17):1118–27.

Delayed recovery from anaesthesia in Rubinstein-Taybi syndrome [letter] Dunkley CJ, et al. **Paediatr Anaesth** 1996; 6(3):245–6

Inhalation of nitrous oxide expands epidural air bubbles. Petty R, et al. **Reg Anesth** 1996 Mar–Apr;21(2):144–8

A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically-based pharmacokinetic modeling. Cronin WJ 4th, et al. **Risk Anal** 1995 Oct;15(5):555–65

Occurrence of adenylate kinase in cerebrospinal fluid after isoflurane anaesthesia and orthognathic surgery. Enlund M, et al. **Ups J Med Sci** 1996;101(1):97–111

[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys] Wiesner G, et al. **Anaesthesist** 1996 Jan;45(1):31–6 (Eng. Abstr.) **(Ger)**

[Contamination by inhalational anesthetics on the intensive care unit—sequelae of an unnecessary sedation regimen? (editorial)] Schulte am Esch J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):465–6 **(Ger)**

[Convulsive seizure after craniotomy—comparison of isoflurane anesthesia and sevoflurane anesthesia] Hashimoto K, et al. **Masui** 1995 Aug;44(8):1139–42 (Eng. Abstr.) **(Jpn)**

[Comparison of the effect of isoflurane and that of sevoflurane on hepatic circulation and oxygen metabolism during acute hypoxia in dogs] Sugai M. **Masui** 1996 May; 45(5):608–16 (Eng. Abstr.) **(Jpn)**

[Mild variant of malignant hyperthermia following succinylcholine and halogenated agent exposure (letter)] Fernández-García V, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):401–2 **(Spa)**

ANALYSIS

Low flow anaesthesia reduces occupational exposure to inhalation anaesthetics. Environmental and biological measurements in operating room personnel. Imberti R, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):586–91

Anesthetic gas-scavenging in the laboratory [letter]

Perouansky M, et al. **Anesthesiology** 1996 Mar;84(3):751

The quantitative analysis of inhalational anaesthetics in forensic samples by gas chromatography/mass spectrometry/selected ion monitoring. Maruyama K, et al. **Biomed Chromatogr** 1995 Jul–Aug;9(4):179–82

A modified tracheal tube mount for sampling gases from the distal shaft of the laryngeal mask airway [letter] Newell S, et al. **J Clin Anesth** 1995 Aug;7(5):444–5

The minimum alveolar concentration of desflurane in cats. McMurphy RM, et al. **Vet Surg** 1995 Sep–Oct;24(5):453–5

[A cause for error in automatic detection of halogenated agents: alcoholic intoxication (letter)] Bouyssou H, et al. **Ann Fr Anesth Reanim** 1995;14(3):313–4 **(Fre)**

[Anesthetic gas pollution in operating rooms: the health and hygiene and management problems] D'Alessandro D, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):821–33 (Eng. Abstr.) **(Ita)**

ANTAGONISTS & INHIBITORS

Alfentanil modifies the neurocirculatory responses to desflurane. Yonker–Sell AE, et al. **Anesth Analg** 1996 Jan; 82(1):162–6

Antagonism of the antinocifensive action of halothane by intrathecal administration of GABAA receptor antagonists. Mason P, et al. **Anesthesiology** 1996 May;84(5):1205–14

BLOOD

A new measure of anaesthetic potency [letter; comment] Barnes NW, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):523–4. Comment on: Anaesth Intensive Care 1994 Aug;22(4):363–73.

CHEMISTRY

Physicochemical properties and pharmacodynamics of desflurane. Eger EI 2nd. **Anaesthesia** 1995 Oct;50 Suppl:3–8 (41 ref.)

Sevoflurane degradation by soda lime in a circle breathing system. Munday IT, et al. **Anaesthesia** 1996 Jul;51(7):622–6

Factors affecting production of compound A from the interaction of sevoflurane with Baralyme and soda lime. Fang ZX, et al. **Anesth Analg** 1996 Apr;82(4):775–81

19F nuclear magnetic resonance investigation of stereoselective binding of isoflurane to bovine serum albumin. Xu Y, et al. **Biophys J** 1996 Jan;70(1):532–8

In vitro uptake and elimination of isoflurane by different membrane oxygenators. Hickey S, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):352–5

Desflurane advantage? Lower solubility or improved vaporizer? [letter; comment] Aldrete JA. **J Clin Anesth** 1996 Mar;8(2):169–71. Comment on: J Clin Anesth 1995 Feb;7(1):49–53.

DIAGNOSTIC USE

Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family [see comments] Serfas KD, et al. **Anesthesiology** 1996 Feb; 84(2):322–9. Comment in: Anesthesiology 1996 Feb;84(2):29A–30A.

ECONOMICS

Economic analysis and pharmaceutical policy: a consideration of the economics of the use of desflurane. Eger EI 2nd. **Anaesthesia** 1995 Oct;50 Suppl:45–8 (22 ref.)

Cost of volatile agents [letter] Barker I. **Br J Anaesth** 1996 May;76(5):749

HISTORY

Bellamy Gardner's open ether mask. Ball C. **Anaesth Intensive Care** 1995 Dec;23(6):665

Amylene, a blemish on Snow? Conacher ID. **Anaesthesia** 1996 Feb;51(2):155–7

Early French accounts of self–inhalation of ether and conscious analgesia [letter] Defalque RJ, et al. **Anesthesiology** 1995 Dec;83(6):1370–1

The delayed arrival: from Davy (1800) to Morton (1846). Adams AK. **J R Soc Med** 1996 Feb;89(2):96P–100P

[History of anesthesia: the return of nitrous oxide] Duncum B. **Can Anesthesiol** 1996;44(2):185–6 **(Fre)**

[History of anesthesia: Frederic Hewitt and nitrous oxide anesthesia] Howat DC. **Can Anesthesiol** 1996;44(2):187–9 **(Fre)**

[History of anesthesia: nitrous oxides and their historical onset] Pring J. **Can Anesthesiol** 1996;44(2):181–4 **(Fre)**

[The "narcotization statistics" of Ernst Julius Gurlt of 1895—an early contribution to quality control in anesthesia] Röse W. **Anaesthesiol Reanim** 1995;20(6):157–61 (Eng. Abstr.) **(Ger)**

[Early contributions from Erlangen to the theory and practice of ether and chloroform anesthesia. 1. Heyfelder's clinical trial with ether and chloroform] Hintzenstern Uv, et al. **Anaesthesist** 1996 Feb;45(2):131–9 (Eng. Abstr.) **(Ger)**

[Cyclopropane] Böhrer H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):313–4 **(Ger)**

[Intravenous anesthesia with inhalation anesthetics] Poetter C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):383–6 (Eng. Abstr.) **(Ger)**

[150 years ether narcosis (1846–1996) (editorial)] Stoeckel H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Mar; 31(2):61 **(Ger)**

[Remembering Juan Vicente Hedo's ether (1847). Chronicle of an unexplained oversight (letter+ +)] Franco A, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep;42(7):297 **(Spa)**

METABOLISM

Metabolism and toxicity of the new anesthetic agents. Kharasch ED. **Acta Anaesthesiol Belg** 1996;47(1):7–14 (46 ref.)

Factors affecting the production of carbon monoxide in inhalation anesthetic use [letter; comment] Callan CM. **Anesth Analg** 1996 Jun;82(6):1306–7. Comment on: Anesth Analg 1995 Jun;80(6):1187–93.

Binding of halothane to serum albumin: relevance to theories of narcosis [letter; comment] Eger EI 2nd, et al. **Anesthesiology** 1995 Dec;83(6):1384–5. Comment on: Anesthesiology 1995 Aug;83(2):316–24.

Compound A concentrations during sevoflurane anesthesia in children. Frink EJ Jr, et al. **Anesthesiology** 1996 Mar; 84(3):566–71

Mass spectrometry provides warning of carbon monoxide exposure via trifluoromethane. Woehick HJ, et al. **Anesthesiology** 1996 Jun;84(6):1489–93

Minimum structural requirement for an inhalational anesthetic binding site on a protein target. Johansson JS, et al. **Biochim Biophys Acta** 1996 May 21;1290(1):63–8

The effects of temperature on the interactions between volatile general anaesthetics and a neuronal nicotinic acetylcholine receptor. Dickinson R, et al. **Br J Pharmacol** 1995 Dec;116(7):2949–56

Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. Garton KJ, et al. **Drug Metab Dispos** 1995 Dec;23(12):1426–30

Inhibitory effects of corticoids on reductive halothane dehalogenation. Fujii K. **Drug Metabol Drug Interact** 1995; 12(1):37–43

An inhalational anesthetic binding domain in the nicotinic acetylcholine receptor. Eckenhoff RG. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2807–10

Isoflurane acts as an inhibitor of oxidative dehalogenation while acting as an accelerator of reductive dehalogenation of halothane in guinea pig liver microsomes. Fujii K. **Toxicology** 1995 Dec 15;104(1–3):123–8

PHARMACOKINETICS

Inhalational anaesthetics: an update. Jones RM. **Acta Anaesthesiol Belg** 1996;47(1):3–6

MAC for halothane and isoflurane during normothermia and hypothermia in the newborn piglet. Satas S, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):452–6

The twenty first century uptake and distribution of anesthetic gases [editorial; comment] Wong CS. **Acta Anaesthesiol Sin** 1995 Sep;33(3):i. Comment on: Acta Anaesthesiol Sin 1995 Sep;33(3):173–83.

What is the role of absorption atelectasis in the genesis of perioperative pulmonary collapse? Joyce CJ, et al. **Anaesth Intensive Care** 1995 Dec;23(6):691–6 (57 ref.)

Uptake of desflurane during anaesthesia. Walker TJ, et al. **Anaesthesia** 1996 Jan;51(1):33–36

The relationship between anaesthetic uptake and cardiac output. Watt SJ, et al. **Anaesthesia** 1996 Jan;51(1):24–8

Biotransformation of sevoflurane. Kharasch ED. **Anesth Analg** 1995 Dec;81(6 Suppl):S27–38 (68 ref.)

Chronic cocaine administration reversibly increases isoflurane minimum alveolar concentration in sheep. Bernards CM, et al. **Anesthesiology** 1996 Jul;85(1):91–5

Temperature dependence of the potency of volatile general anesthetics: implications for in vitro experiments. Franks NP, et al. **Anesthesiology** 1996 Mar;84(3):716–20

Plasma inorganic fluoride concentrations after sevoflurane anesthesia in children. Levine MF, et al. **Anesthesiology** 1996 Feb;84(2):348–53

In vivo 19F–NMR spectroscopic study of halothane uptake in rabbit brain. Venkatasubramanian PN, et al. **Biochim Biophys Acta** 1995 Oct 19;1245(2):262–8

Nitrous oxide and the rate of gas uptake from an unventilated lung in dogs. Joyce CJ, et al. **Br J Anaesth** 1996 Feb; 76(2):292–6

Sepsis reduces isoflurane MAC in a normotensive animal model of sepsis. Gill R, et al. **Can J Anaesth** 1995 Jul; 42(7):631–5

Sevoflurane elimination kinetics in children. Landais A, et al. **Paediatr Anaesth** 1995;5(5):297–301

Estimation of pharmacokinetic model parameters. Timcenko A, et al. **Proc Annu Symp Comput Appl Med Care** 1995; :47–51

A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically–based pharmacokinetic modeling. Cronin WJ 4th, et al. **Risk Anal** 1995 Oct;15(5):555–65

[Uptake of anaesthetic gases and vapours (see comments)] Lin CY. **Acta Anaesthesiol Sin** 1995 Sep;33(3):173–83 (16 ref.). Comment in: Acta Anaesthesiol Sin 1995 Sep;33(3):i. **(Chi)**

[Uptaken distribution and metabolism of sevoflurane] Dudziak R, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S1–9 (Eng. Abstr.) **(Ger)**

[Sevoflurane or halothane in inhalational anesthesia induction in childhood. Anesthesia quality and fluoride level] Funk W, et al. **Anaesthesist** 1996 Jan;45(1):22–30 (Eng. Abstr.) **(Ger)**

[Sevoflurane in pediatric anesthesia] Hobbhahn J, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S22–7 (35 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Cardiovascular and autonomic effects of sevoflurane. Ebert TJ. **Acta Anaesthesiol Belg** 1996;47(1):15–21 (22 ref.)

Peripheral blood flow in the elderly during inhalational anaesthesia. Dwyer R, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):939–44

Propofol and isoflurane induced EEG burst suppression patterns in rabbits. Hartikainen K, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):814–8

Nitrous oxide and cerebral haemodynamics [letter] Kolbitsch C, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):392

Oxygen tension–associated changes on secondary immune response in halothane or isoflurane anesthetized mice. Puig NR, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):945–8

Are the cardiovascular actions of dopamine altered by isoflurane? Raner C, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):678–84

Midlatency auditory evoked potentials during anaesthesia with increasing endexpiratory concentrations of desflurane. Schwender D, et al. **Acta Anaesthesiol Scand** 1996 Feb; 40(2):171–6

Cardiovascular responses to experimental infra–renal aortic cross–clamping. Modulating effects of isoflurane, sodium nitroprusside and milrinone. Seeman–Lodding H, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):408–15

Nitrous oxide is a potent cerebrovasodilator in humans when added to isoflurane. A transcranial Doppler study. Strebel S, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):653–8

Vasodilator effects of desflurane and isoflurane in the feline small intestine. Sundeman H, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1105–10

Effects of halothane and isoflurane on antigen– and leukotriene–D4–induced constriction of guinea pig trachea. Tudoric N, et al. **Acta Anaesthesiol Scand** 1995 Nov; 39(8):1111–6

Cardiopulmonary effects of desflurane in cats. McMurphy RM, et al. **Am J Vet Res** 1996 Mar;57(3):367–70

Effects of inhalation anesthetic agents on response of horses to three hours of hypoxemia. Whitehair KJ, et al. **Am J Vet Res** 1996 Mar;57(3):351–60

Circulatory effects of desflurane. Coriat P. **Anaesthesia** 1995 Oct;50 Suppl:18–21 (19 ref.)

Influence of nitrous oxide on propofol dosage and recovery after intravenous anaesthesia [letter; comment] Heath KJ, et al. **Anaesthesia** 1995 Dec;50(12):1101–2. Comment on: Anaesthesia 1995 May;50(5):397–9.

Quantifying the effect of isoflurane on mivacurium infusion requirements. Kansanaho M, et al. **Anaesthesia** 1996 Feb; 51(2):133–6

A comparison of the effects of isoflurane and desflurane on the neuromuscular effects of mivacurium. Kumar N, et al. **Anaesthesia** 1996 Jun;51(6):547–50

Anaesthesia and the QT interval in humans. The effects of isoflurane and halothane. Michaloudis D, et al. **Anaesthesia** 1996 Mar;51(3):219–24

Clonidine—an adjunct in isoflurane–N20/02–relaxant anaesthesia [letter; comment] Savva D. **Anaesthesia** 1995 Nov;50(11):1013–4. Comment on: Anaesthesia 1995 Apr;50(4):290–6.

Cardiovascular effects of desflurane in experimental animals and volunteers. Weiskopf RB. **Anaesthesia** 1995 Oct;50 Suppl:14–7 (29 ref.)

Choice of inspiratory vapor concentrations in comparative studies of inhaled anesthetic induction in children [letter] Allison CE. **Anesth Analg** 1996 Jul;83(1):199

Cardiovascular responses to noxious stimuli during isoflurane anesthesia are minimally affected by anesthetic action in the brain. Antognini JF, et al. **Anesth Analg** 1995 Oct; 81(4):843–8

The effects of sevoflurane on contractile and electrophysiologic properties in isolated guinea pig papillary muscles. Azuma M, et al. **Anesth Analg** 1996 Mar; 82(3):486–91

Subanesthetic concentrations of desflurane and propofol suppress recall of emotionally charged information [see comments] Chortkoff BS, et al. **Anesth Analg** 1995 Oct; 81(4):728–36. Comment in: Anesth Analg 1995 Oct;81(4):668–70.

Concentrations of desflurane and propofol that suppress response to command in humans. Chortkoff BS, et al. **Anesth Analg** 1995 Oct;81(4):737–43

Single versus multiple sites and mechanisms of inhaled anesthetics [letter; comment] Cohen PJ. **Anesth Analg** 1996 Jul;83(1):205. Comment on: Anesth Analg 1994 Dec;79(6):1043–8. Comment on: Anesth Analg 1996 Jan;82(1):218–9.

Isoflurane–induced coronary vasodilation is preserved in reperfused myocardium. Crystal GJ, et al. **Anesth Analg** 1996 Jan;82(1):22–8

Halothane resistance in Drosophila melanogaster: development of a model and gene localization techniques. Dapkus D, et al. **Anesth Analg** 1996 Jul;83(1):147–55

Cardiovascular responses to sevoflurane: a review. Ebert TJ,

et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S11–22 (43 ref.)
Does sleep enhance the effect of subanesthetic isoflurane on hypoxic ventilation? Foo IT, et al. **Anesth Analg** 1995 Oct; 81(4):751–6
The hepatic effects of sevoflurane. Frink EJ Jr. **Anesth Analg** 1995 Dec;81(6 Suppl):S46–50 (29 ref.)
The effects of halothane on arginine-vasopressin-induced Ca2+ mobilization from the intracellular stores and the receptor-mediated Ca2+ entry from the extracellular space in single cultured smooth muscle cells of rat aorta. Fujihara H, et al. **Anesth Analg** 1996 Sep;83(3):584–90
Sevoflurane is equivalent to isoflurane for attenuating bupivacaine-induced arrhythmias and seizures in rats. Fukuda H, et al. **Anesth Analg** 1996 Sep;83(3):570–3
Desflurane attenuates the somatosympathetic reflex in rats. Ganjoo P, et al. **Anesth Analg** 1996 Jul;83(1):55–61
Intravenous lidocaine does not attenuate the cardiovascular and catecholamine response to a rapid increase in desflurane concentration. Gormley WP, et al. **Anesth Analg** 1996 Feb;82(2):358–61
The ventilatory effects of sevoflurane. Green WB Jr. **Anesth Analg** 1995 Dec;81(6 Suppl):S23–6 (19 ref.)
The direct effects of enflurane on coronary blood flow, myocardial oxygen consumption, and myocardial segmental shortening in in situ canine hearts. Gurevicius J, et al. **Anesth Analg** 1996 Jul;83(1):68–74
In vivo imaging of human limbic responses to nitrous oxide inhalation. Gyulai FE, et al. **Anesth Analg** 1996 Aug; 83(2):291–8
Isoflurane, fentanyl, thiopental, and brain edema [letter; comment] Hartung J. **Anesth Analg** 1996 Mar;82(3):672. Comment on: Anesth Analg 1995 Jun;80(6):1108–15.
The dose-dependent effects of halothane on right ventricular contraction pattern and regional inotropy in swine. Heerdt PM, et al. **Anesth Analg** 1996 Jun;82(6):1152–8
Biochemical characterization of the stimulatory effects of halothane and propofol on purified brain protein kinase C. Hemmings HC Jr, et al. **Anesth Analg** 1995 Dec; 81(6):1216–22
Glyburide, a KATP channel antagonist, attenuates the cardioprotective effects of isoflurane in stunned myocardium. Kersten JR, et al. **Anesth Analg** 1996 Jul; 83(1):27–33
The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. Kurahashi K, et al. **Anesth Analg** 1996 May; 82(5):942–7
Sevoflurane and renal function. Malan TP Jr. **Anesth Analg** 1995 Dec;81(6 Suppl):S39–45 (34 ref.)
Isoflurane preserves adenosine triphosphate levels in anoxic isolated rat hepatocytes by stimulating glycolytic adenosine triphosphate formation. Matsushita M, et al. **Anesth Analg** 1996 Jun;82(6):1261–7
1 + (−1) = 0, or not all anesthetic sites are created equal [letter; comment] [see comments] Morgan PG. **Anesth Analg** 1996 Jan;82(1):218–9. Comment on: Anesth Analg 1994 Dec;79(6):1043–8. Comment in: Anesth Analg 1996 Jul;83(1):205.
The effect of halothane on phrenic and chemoreceptor responses to hypoxia in anesthetized kittens. Morray JP, et al. **Anesth Analg** 1996 Aug;83(2):329–35
Protein kinase C-induced contraction is inhibited by halothane but enhanced by isoflurane in rat coronary arteries. Park KW, et al. **Anesth Analg** 1996 Aug; 83(2):286–90
Steady-state myogenic response of rat coronary microvessels is preserved by isoflurane but not by halothane. Park KW, et al. **Anesth Analg** 1996 May;82(5):969–74
Comparison of the effects of enflurane/N2O on the 40-Hz auditory steady-state response versus the auditory middle-latency response. Plourde G, et al. **Anesth Analg** 1996 Jan;82(1):75–83
The effects of sevoflurane, enflurane, and isoflurane on baroreceptor-sympathetic reflex in rabbits. Saeki Y, et al. **Anesth Analg** 1996 Feb;82(2):342–8
Some effects of d-tubocurarine alone and combined with halothane or isoflurane on neuromuscular transmission. Sokoll MD, et al. **Anesth Analg** 1995 Oct;81(4):763–7
Effect of halothane and isoflurane on in situ diameter responses of small mesenteric veins to acute graded hypercapnia. Stekiel TA, et al. **Anesth Analg** 1996 Feb; 82(2):349–57
Intensity of halothane- and hypercapnia-induced cerebral hyperemia is strain-dependent in rats. Takahashi H, et al. **Anesth Analg** 1996 Aug;83(2):359–65
The effects of sevoflurane, isoflurane, halothane, and enflurane on hemodynamic responses during an inhaled induction of anesthesia via a mask in humans. Tanaka S, et al. **Anesth Analg** 1996 Apr;82(4):821–6
The effects of sevoflurane and isoflurane anesthesia on renal tubular function in patients with moderately impaired renal function. Tsukamoto N, et al. **Anesth Analg** 1996 May; 82(5):909–13
The acute and residual effects of subanesthetic concentrations of isoflurane/nitrous oxide combinations on cognitive and psychomotor performance in healthy volunteers. Zacny JP, et al. **Anesth Analg** 1996 Jan;82(1):153–7
Dual actions of halothane on intracellular calcium stores of vascular smooth muscle. Akata T, et al. **Anesthesiology** 1996 Mar;84(3):580–95
Desflurane slightly increases the sweating threshold but produces marked, nonlinear decreases in the vasoconstriction and shivering thresholds. Annadata R, et al. **Anesthesiology** 1995 Dec;83(6):1205–11
Demonstration of halothane-induced hepatic lipid peroxidation in rats by quantification of F2-isoprostanes. Awad JA, et al. **Anesthesiology** 1996 Apr;84(4):910–6
Volatile and intravenous anesthetics decrease glutamate release from cortical brain slices during anoxia. Bickler PE, et al. **Anesthesiology** 1995 Dec;83(6):1233–40
Cardiac and regional hemodynamic interactions between halothane and nitric oxide synthase activity in dogs. Chelly JE, et al. **Anesthesiology** 1996 Jul;85(1):142–9
Vasomotor effects of isoflurane in the coronary circulation [letter; comment] Crystal GJ. **Anesthesiology** 1996 Jun; 84(6):1516–8. Comment on: Anesthesiology 1995 Dec;83(6):1323–30.
Ventilatory response to hypoxia in humans. Influences of subanesthetic desflurane. Dahan A, et al. **Anesthesiology** 1996 Jul;85(1):60–8
Halothane modulates thermosensitive hypothalamic neurons in rat brain slices. Farber NE, et al. **Anesthesiology** 1995 Dec;83(6):1241–53
Volatile anesthetics selectively inhibit the Ca(2+)-transporting ATPase in neuronal and erythrocyte plasma membranes. Fomitcheva I, et al. **Anesthesiology** 1996 May;84(5):1189–95
Nitrous oxide depresses spinal F waves in rats. Friedman Y, et al. **Anesthesiology** 1996 Jul;85(1):135–41
Activation of endogenous protein kinase C by halothane in synaptosomes. Hemmings HC Jr, et al. **Anesthesiology** 1996 Mar;84(3):652–62
Isoflurane and sevoflurane modulate inactivation kinetics of Ca2+ currents in single bullfrog atrial myocytes. Hirota K, et al. **Anesthesiology** 1996 Feb;84(2):377–83
Effects of halothane and isoflurane on carbon monoxide-induced relaxations in the rat aorta. Jing M, et al. **Anesthesiology** 1996 Aug;85(2):347–54
Nonanesthetic haloalkanes and nicotinic acetylcholine receptor desensitization kinetics [letter] Johansson JS. **Anesthesiology** 1996 Aug;85(2):430–2
Halothane and isoflurane inhibit endothelium-derived relaxing factor-dependent cyclic guanosine monophosphate accumulation in endothelial cell-vascular smooth muscle co-cultures independent of an effect on guanylyl cyclase activation. Johns RA, et al. **Anesthesiology** 1995 Oct;83(4):823–34
Effect of volatile anesthetics on hydrogen peroxide-induced injury in aortic and pulmonary arterial endothelial cells. Johnson ME, et al. **Anesthesiology** 1996 Jan;84(1):103–16
Pontine cholinergic mechanisms modulate the cortical electroencephalographic spindles of halothane anesthesia. Keifer JC, et al. **Anesthesiology** 1996 Apr;84(4):945–54
Direct inhibitory mechanisms of halothane on human platelet aggregation. Kohro S, et al. **Anesthesiology** 1996 Jul; 85(1):96–106; discussion 30A
Preservation of the ration of cerebral blood flow/metabolic rate for oxygen during prolonged anesthesia with isoflurane, sevoflurane, and halothane in humans. Kuroda Y, et al. **Anesthesiology** 1996 Mar;84(3):555–61
Desflurane reduces the gain of thermoregulatory arteriovenous shunt vasoconstriction in humans. Kurz A, et al. **Anesthesiology** 1995 Dec;83(6):1212–9
Induction, recovery, and safety characteristics of sevoflurane in children undergoing ambulatory surgery. A comparison with halothane. Lerman J, et al. **Anesthesiology** 1996 Jun; 84(6):1332–40
Influence of volatile anesthetics on left ventricular afterload in vivo. Differences between desflurane and sevoflurane Lowe D, et al. **Anesthesiology** 1996 Jul;85(1):112–20
Cardiovascular effects of sevoflurane compared with those of isoflurane in volunteers. Malan TP Jr, et al. **Anesthesiology** 1995 Nov;83(5):918–28
Direct cerebrovasodilatory effects of halothane, isoflurane, and desflurane during propofol-induced isoelectric electroencephalogram in humans. Matta BF, et al. **Anesthesiology** 1995 Nov;83(5):980–5; discussion 27A
Inhaled anesthetics alter the determinants of coronary collateral blood flow in the dog. Mignella R, et al. **Anesthesiology** 1995 Oct;83(4):799–808
Genetic differences affecting the potency of stereoisomers of isoflurane. Morgan PG, et al. **Anesthesiology** 1996 Aug; 85(2):385–92
Desflurane-mediated neurocirculatory activation in humans. Effects of concentration and rate of change on responses. Muzi M, et al. **Anesthesiology** 1996 May;84(5):1035–42
Effects of hypothermia, pentobarbital, and isoflurane on postdepolarization amino acid release during complete global cerebral ischemia. Nakashima K, et al. **Anesthesiology** 1996 Jul;85(1):161–8
Effect of volatile anesthetics with and without verapamil on intracellular activity in vascular smooth muscle. Namba H, et al. **Anesthesiology** 1996 Jun;84(6):1465–74
Dose-dependent increases in the renal sympathetic nerve activity during rapid increase in isoflurane concentration in intact, lower airway-deafferented, and baroreceptor-deafferented rabbits. Okamoto H, et al. **Anesthesiology** 1996 May;84(5):1196–204
Desflurane and isoflurane exert modest beneficial actions on left ventricular diastolic function during myocardial ischemia in dogs. Pagel PS, et al. **Anesthesiology** 1995 Nov; 83(5):1021–35
Myocardial depressant effects of sevoflurane. Mechanical and electrophysiologic actions in vitro. Park WK, et al. **Anesthesiology** 1996 May;84(5):1166–76
Effects of anesthetics and vasodilators on aortic input impedance [letter; comment] Prys-Roberts C, et al. **Anesthesiology** 1996 Feb;84(2):478–9. Comment on: Anesthesiology 1995 Aug;83(2):361–73.
Anesthetic and nonanesthetic halogenated volatile compounds have dissimilar activities on nicotinic acetylcholine receptor desensitization kinetics. Raines DE. **Anesthesiology** 1996 Mar;84(3):663–71
Volatile anesthetics depress spinal motor neurons. Rampil IJ, et al. **Anesthesiology** 1996 Jul;85(1):129–34
Central nervous system sodium channels are significantly suppressed at clinical concentrations of volatile anesthetics. Rehberg B, et al. **Anesthesiology** 1996 May;84(5):1223–33; discussion 27A
Spontaneous ventilation with halothane in children. A comparative study between endotracheal tube and laryngeal mask airway. Reignier J, et al. **Anesthesiology** 1995 Oct;83(4):674–8
Acute pain and central nervous system arousal do not restore impaired hypoxic ventilatory response during sevoflurane sedation. Sarton E, et al. **Anesthesiology** 1996 Aug; 85(2):295–303
Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. Servin FS, et al. **Anesthesiology** 1996 May;84(5):1092–100
Tolerance to propofol generally does not develop in pediatric patients undergoing radiation therapy. Setlock MA, et al. **Anesthesiology** 1996 Jul;85(1):207–9
Effects of halothane and isoflurane on bradykinin-evoked Ca2+ influx inbovine aortic endothelial cells. Simoneau C, et al. **Anesthesiology** 1996 Aug;85(2):366–79
Isoform-dependent effects of halothane in human skinned striated fibers. Tavernier BM, et al. **Anesthesiology** 1996 May;84(5):1138–47
Analysis of halothane effects on myocardial force-interval relationships at anesthetic concentrations depressing twitches but not tetanic contractions. Vogel SM, et al. **Anesthesiology** 1995 Nov;83(5):1055–64
Chest wall responses to rebreathing in halothane-anesthetized dogs. Warner DO, et al. **Anesthesiology** 1995 Oct; 83(4):835–43
Mechanical significance of respiratory muscle activity in humans during halothane anesthesia. Warner DO, et al. **Anesthesiology** 1996 Feb;84(2):309–21
Isoflurane produces marked and nonlinear decreases in the vasoconstriction and shivering thresholds. Xiong J, et al. **Anesthesiology** 1996 Aug;85(2):240–5
Halothane and isoflurane inhibit vasodilation due to constitutive but not inducible nitric oxide synthase. Implications for the site of anesthetic inhibition of the nitric oxide/guanylyl cyclase signaling pathway. Zuo Z, et al. **Anesthesiology** 1996 May;84(5):1156–65
Spermidine attenuation of volatile anesthetic inhibition of glutamate-stimulated [3H](5D,10S)-(+)-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine ([3H]MK-801) binding to N-methyl-D-aspartate (NMDA) receptors in rat brain. Martin DC, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1373–7
Effects of halothane on mu opioid binding in SH-SY5Y cells. Campbell DJ, et al. **Biochem Soc Trans** 1995 Aug; 23(3):416S
Effects of halothane, enflurane and isoflurane on contraction of rat aorta induced by endothelin-1. Boillot A, et al. **Br J Anaesth** 1995 Dec;75(6):761–7
Effects of propofol and isoflurane on right ventricular function [letter; comment] Boyd O, et al. **Br J Anaesth** 1996 Apr;76(4):598. Comment on: Br J Anaesth 1995 Nov;75(5):578–82.
Do nitrous oxide and halothane influence opioid receptor binding in SH-SY5Y human neuroblastoma cells? Campbell DJ, et al. **Br J Anaesth** 1995 Dec;75(6):752–5
Slow ventilatory dynamics after isocapnic hypoxia and voluntary hyperventilation in humans: effects of isoflurane. Dahan A, et al. **Br J Anaesth** 1996 Mar;76(3):374–81
Changes in blood volume distribution between legs and trunk during halothane anaesthesia. Drummond GB, et al. **Br J Anaesth** 1995 Dec;75(6):707–12
Halothane and potassium channels in airway smooth muscle. Fukushima T, et al. **Br J Anaesth** 1996 Jun;76(6):847–53
Volatile anaesthetics antagonize nitrous oxide and morphine-induced analgesia in the rat. Goto T, et al. **Br J Anaesth** 1996 May;76(5):702–6
Intrathecal administration of N-methyl-D-aspartate receptor antagonist reduces the minimum alveolar anaesthetic concentration of isoflurane in rats. Ishizaki K, et al. **Br J Anaesth** 1995 Nov;75(5):636–8
Effects of inspired gas composition during anaesthesia for abdominal hysterectomy on postoperative lung volumes. Joyce CJ, et al. **Br J Anaesth** 1995 Oct;75(4):417–21
Comparison of the effects of propofol and isoflurane anaesthesia on right ventricular function and shunt fraction during thoracic surgery [see comments] Kellow NH, et al. **Br J Anaesth** 1995 Nov;75(5):578–82. Comment in: Br J Anaesth 1996 Apr;76(4):598.
Differential effects of desflurane and halothane on peripheral airway smooth muscle. Mazzeo AJ, et al. **Br J Anaesth** 1996 Jun;76(6):841–6
Time course of potentiation of mivacurium by halothane and isoflurane in children. Meretoja OA, et al.

Br J Anaesth 1996 Feb;76(2):235–8

Comparison of the effects of sub–hypnotic concentrations of propofol and halothane on the acute ventilatory response to hypoxia. Nagyova B, et al. **Br J Anaesth** 1995 Dec; 75(6):713–8

Effects of 3 MAC of halothane, enflurane and isoflurane on cilia beat frequency of human nasal epithelium in vitro. Raphael JH, et al. **Br J Anaesth** 1996 Jan;76(1):116–21

Recovery of respiratory ciliary function after depression by inhalation anaesthetic agents: an in vitro study using nasal turbinate explants. Raphael JH, et al. **Br J Anaesth** 1996 Jun;76(6):854–9

Effect of neuromuscular block on depth of anaesthesia as measured by the auditory evoked response. Richmond CE, et al. **Br J Anaesth** 1996 Mar;76(3):446–8

Effect of halothane on myocardial reoxygenation injury in the isolated rat heart. Schlack W, et al. **Br J Anaesth** 1996 Jun;76(6):860–7

Nitrous oxide or halothane, or both, fail to suppress c–fos expression in rat spinal cord dorsal horn neurones after subcutaneous formalin [see comments] Sun WZ, et al. **Br J Anaesth** 1996 Jan;76(1):99–105. Comment in: Br J Anaesth 1996 Jan;76(1):1–4.

Effect of isoflurane and sevoflurane on the magnitude and time course of neuromuscular block produced by vecuronium, pancuronium and atracurium. Vanlinthout LE, et al. **Br J Anaesth** 1996 Mar;76(3):389–95

Volatile anaesthetic actions on norepinephrine–induced contraction of small splanchnic resistance arteries. Akata T, et al. **Can J Anaesth** 1995 Nov;42(11):1040–50

Clinical comparison of sevoflurane and isoflurane when administered with nitrous oxide for surgical procedures of intermediate duration. Campbell C, et al. **Can J Anaesth** 1995 Oct;42(10):884–90

Isoflurane and halothane impair both systolic and diastolic function in the newborn pig. Graham MR, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):495–502

Choice of anaesthetic regimen influences haemodynamic response to cemented arthroplasty. Guest CB, et al. **Can J Anaesth** 1995 Oct;42(10):928–36

Distribution of diaphragm blood flow during sevoflurane anaesthesia in dogs. Ide T, et al. **Can J Anaesth** 1996 Jan; 43(1):44–9

Decreased hypothalamic prostaglandin D2 and prostaglandin E2 contents during isoflurane anaesthesia in rats. Sato T, et al. **Can J Anaesth** 1995 Nov;42(11):1031–4

Spreading depression [editorial; comment] Chopp M. **Cephalalgia** 1996 Apr;16(2):77. Comment on: Cephalalgia 1996 Apr;16(2):87–92.

Inhalational anesthetics inhibit spreading depression: relevance to migraine [see comments] Piper RD, et al. **Cephalalgia** 1996 Apr;16(2):87–92. Comment in: Cephalalgia 1996 Apr;16(2):77.

The site of action of general anaesthetics in insect olfactory receptor neurons. Stange G, et al. **Chem Senses** 1995 Aug; 20(4):421–32

Effects of enflurane and isoflurane anesthesia on the pharmacokinetics of pancuronium in adult patients. Xue F, et al. **Chin Med J (Engl)** 1996 Mar;109(3):233–7

Effect of halothane on phenylephrine–induced vascular smooth muscle contractions in endotoxin–exposed rat aortic rings. Grissom TE, et al. **Crit Care Med** 1996 Feb; 24(2):287–93

Desflurane. A review of its pharmacodynamic and pharmacokinetic properties and its efficacy in general anaesthesia. Patel SS, et al. **Drugs** 1995 Oct;50(4):742–67 (201 ref.)

Changes in respiratory pattern during induction of anaesthesia with sevoflurane: comparison of nasal and the oral breathing [see comments] Ishii M, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):21–6. Comment in: Eur J Anaesthesiol 1996 Jan;13(1):1–2.

Suppressive effects of volatile anesthetics on cytokine release in human peripheral blood mononuclear cells. Mitsuhata H, et al. **Int J Immunopharmacol** 1995 Jun;17(6):529–34

How do volatile anesthetics inhibit Ca(2+)–ATPases? Lopez MM, et al. **J Biol Chem** 1995 Nov 24;270(47):28239–45

Comparison of the alteration of cardiac function by sevoflurane, isoflurane, and halothane in the isolated working rat heart. Skeehan TM, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):706–12

Myocardial depression by isoflurane is dependent on the underlying beta–adrenergic tone. Thurston TA, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):855–8

Pharmacologic drugs for controlled hypotension. Testa LD, et al. **J Clin Anesth** 1995 Jun;7(4):326–37 (64 ref.)

Mutations that affect ion channels change the sensitivity of Drosophila melanogaster to volatile anesthetics. Leibovitch BA, et al. **J Neurogenet** 1995 Apr;10(1):1–13

Halothane–induced synaptic depression at both in vivo and in vitro reconstructed synapses between identified Lymnaea neurons. Spencer GE, et al. **J Neurophysiol** 1995 Dec;74(6):2604–13

A comparison of the electrophysiologic characteristics of EEG burst–suppression as produced by isoflurane, thiopental, etomidate, and propofol. Akrawi WP, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):40–6

Effect of desflurane anesthesia on transcortical motor evoked potentials. Haghighi SS, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):47–51

Suppression of spinal and cortical somatosensory evoked potentials by desflurane anesthesia. Haghighi SS, et al. **J Neurosurg Anesthesiol** 1996 Apr;8(2):148–53

Comparison of extracellular dopamine concentration in awake unstressed and postsurgical nitrous oxide sedated rats. Kofke WA, et al. **J Neurosurg Anesthesiol** 1995 Oct; 7(4):280–3

The role of nitric oxide in cerebrocortical laser Doppler flow response to halothane in the rat. Smith JJ, et al. **J Neurosurg Anesthesiol** 1995 Jul;7(3):187–95

Halothane constricts bovine pulmonary arteries by release of intracellular calcium. Fehr DM, et al. **J Pharmacol Exp Ther** 1996 May;277(2):706–13

Inhibition of rho1 receptor GABAergic currents by alcohols and volatile anesthetics. Mihic SJ, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):411–6

Relative potencies of volatile anesthetics in altering the kinetics of ion channels in BC3H1 cells. Wachtel RE. **J Pharmacol Exp Ther** 1995 Sep;274(3):1355–61

Volatile anaesthetic enhancement of paired–pulse depression investigated in the rat hippocampus in vitro. Pearce RA. **J Physiol (Lond)** 1996 May 1;492 (Pt 3):823–40

Effects of anesthesia with halothane and methoxyflurane on plasma corticosterone concentration in rats at rest and after exercise. Carlberg KA, et al. **Lab Anim Sci** 1995 Oct; 45(5):584–7

Effects of halothane and isoflurane on rat ventricular action potentials recorded in situ. Hayes ES, et al. **Life Sci** 1996; 58(16):1375–85

Haemodynamic and haemoximetric aspects of experimental orthotopic liver transplantation: comparison between two different doses of propofol. Fabbri LP, et al. **Minerva Anestesiol** 1995 Nov;61(11):441–50

Molecular genetic analysis of volatile–anesthetic action. Keil RL, et al. **Mol Cell Biol** 1996 Jul;16(7):3446–53

Nitrous oxide inhalation: effects on maternal and fetal circulations at term. Polvi HJ, et al. **Obstet Gynecol** 1996 Jun;87(6):1045–8

The effects of nitrous oxide on behavior and physiological parameters during conscious sedation with a moderate dose of chloral hydrate and hydroxyzine. McCann W, et al. **Pediatr Dent** 1996 Jan–Feb;18(1):35–41

The effects of sevoflurane and isoflurane on recovery from outpatient surgery. O'Hara DA, et al. **Pharmacotherapy** 1996 May–Jun;16(3):446–52

Influence of halothane on the level of enkephalins in discrete brain areas of rabbits. Chmielnicki Z, et al. **Pol J Pharmacol** 1995 Jan–Feb;47(1):37–41

Gastric myoelectric and motor activity in dogs after isoflurane anesthesia. Hall JA, et al. **Vet Surg** 1995 Sep–Oct; 24(5):456–63

[Incidence and quality of dreaming during anesthesia with propofol in comparison with enflurane] Käsmacher H, et al. **Anaesthesist** 1996 Feb;45(2):146–53 (Eng. Abstr.) **(Ger)**

[Awakening from anesthesia and recovery of cognitive function after desflurane or isoflurane] Loscar M, et al. **Anaesthesist** 1996 Feb;45(2):140–5 (Eng. Abstr.) **(Ger)**

[Effects of sevoflurane on the area of the liver and spleen] Schindler E, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S29–31 (30 ref.) (Eng. Abstr.) **(Ger)**

[Effect of halothane, enflurane and isoflurane on the pharmacodynamics of mivacurium in children] Neidhart G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):293–7 (Eng. Abstr.) **(Ger)**

[Enflurane blocks ion current through the nicotinic acetylcholine receptor] Scheller M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):370–4 (Eng. Abstr.) **(Ger)**

[Isoflurane and sevoflurane impair left ventricular relaxation in dogs with fixed heart rate] Iseki A, et al. **Masui** 1996 Apr;45(4):415–20 (Eng. Abstr.) **(Jpn)**

[The effects of sevoflurane and isoflurane on hepatic blood flow in man] Kobayashi M. **Masui** 1996 Mar;45(3):281–6 (Eng. Abstr.) **(Jpn)**

[Anesthetics and second messenger system--analysis using mRNA injected Xenopus oocyte] Okamura A, et al. **Masui** 1995;44 Suppl:S127–33 **(Jpn)**

[Effect of sevoflurane on release of TNF–alpha and IL–1 beta from human monocytes] Sato W, et al. **Masui** 1996 Mar;45(3):309–12 (Eng. Abstr.) **(Jpn)**

[Comparative neuromuscular inhibitory effects of volatile anesthetics] Suzuki T, et al. **Masui** 1996 May;45(5):599–607 (Eng. Abstr.) **(Jpn)**

[Potential of succinylcholine–induced neuromuscular blockade by nitrous oxide] Tsuchiya A. **Masui** 1995 Dec; 44(12):1608–13 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

The effects of isoflurane on repeated nociceptive stimuli (central temporal summation). Petersen–Felix S, et al. **Pain** 1996 Feb;64(2):277–81

Comparison of the effects of propofol and halothane on acute myocardial ischaemia and myocardial reperfusion injury. Coetzee A. **S Afr Med J** 1996 Apr;86 Suppl 2:C85–90

[New aspects of pain research and therapy and inhalation anesthetics] Christ F, et al. **Anaesthesist** 1995 Dec; 44(12):928–9 **(Ger)**

[Comparison of the effects of halothane, isoflurane and sevoflurane in the treatment of severe asthmatic attack: a case report] Ohyama A, et al. **Masui** 1996 Mar;45(3):362–6 (Eng. Abstr.) **(Jpn)**

TOXICITY

Metabolism and toxicity of the new anesthetic agents. Kharasch ED. **Acta Anaesthesiol Belg** 1996;47(1):7–14 (46 ref.)

Fluoride ion toxicity in human kidney collecting duct cells. Cittanova ML, et al. **Anesthesiology** 1996 Feb;84(2):428–35

Desflurane, sevoflurane, and isoflurane impair canine left ventricular–arterial coupling and mechanical efficiency. Hettrick DA, et al. **Anesthesiology** 1996 Aug;85(2):403–13

Role of the vagus nerve in the antidysrhythmic effect of dexmedetomidine on halothane/epinephrine dysrhythmias in dogs. Kamibayashi T, et al. **Anesthesiology** 1995 Nov; 83(5):992–9

Attenuated hypoxic pulmonary vasoconstriction during isoflurane anesthesia is abolished by cyclooxygenase inhibition in chronically instrumented dogs. Lennon PF, et al. **Anesthesiology** 1996 Feb;84(2):404–14

Possible involvement of superoxide radical in biochemical lesions induced by nitrous oxide. Nair CP, et al. **Indian J Exp Biol** 1995 Apr;33(4):275–7

Focal cerebral ischemia during anesthesia with etomidate, isoflurane, or thiopental: a comparison of the extent of cerebral injury. Drummond JC, et al. **Neurosurgery** 1995 Oct;37(4):742–8; discussion 748–9

Stress through handling for vaginal screening, serotonin, and ACTH response to ether. Sfikakis A, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):965–70

Isoflurane acts as an inhibitor of oxidative dehalogenation while acting as an accelerator of reductive dehalogenation of halothane in guinea pig liver microsomes. Fujii K. **Toxicology** 1995 Dec 15;104(1–3):123–8

[Nephrotoxicity and fluoride from the viewpoint of the nephrologist] Bosch T. **Anaesthesist** 1996 Feb;45 Suppl 1:S41–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[Toxicology and clinical significance of base–catalized degradation of sevoflurane to Compound A] Jones RM, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S10–3 (Eng. Abstr.) **(Ger)**

[Fluoride–induced nephrotoxicity: factor fiction?] Nuscheler M, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S32–40 (54 ref.) (Eng. Abstr.) **(Ger)**

[The cardiovascular effects of sevoflurane] Rolf N, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S14–21 (Eng. Abstr.) **(Ger)**

URINE

Anesthetic in urine as biological index of exposure in operating–room personnel. Imbriani M, et al. **J Toxicol Environ Health** 1995 Oct;46(2):249–60

ANESTHETICS, INTRAVENOUS

Combination fentanyl and diazepam for pediatric conscious sedation. Pohlgeers AP, et al. **Acad Emerg Med** 1995 Oct; 2(10):879–83

Influence of sufentanil on propofol anesthesia using a target controlled infusion system. Los GJ, et al. **Acta Anaesthesiol Belg** 1995;46(3–4):153–9

Breathing patterns under enflurane, halothane and propofol sedation in humans. Nagyova B, et al. **Adv Exp Med Biol** 1995;393:101–4

Evaluation of propofol for general anesthesia in premedicated horses. Mama KR, et al. **Am J Vet Res** 1996 Apr; 57(4):512–6

Comparison of two techniques of narcotic–induced anesthesia for use during recording of magnetic motor evoked potentials in dogs. Van Ham LM, et al. **Am J Vet Res** 1996 Feb;57(2):142–6

The taste of propofol [letter] Low SW. **Anaesth Intensive Care** 1995 Dec;23(6):753–4

Assessment of recovery following day–case arthroscopy. A comparison between propofol and isoflurane–based anaesthesia. Gupta A, et al. **Anaesthesia** 1995 Nov; 50(11):937–42

Influence of nitrous oxide on propofol dosage and recovery after intravenous anaesthesia [letter; comment] Heath KJ, et al. **Anaesthesia** 1995 Dec;50(12):1101–2. Comment on: Anaesthesia 1995 May;50(5):397–9.

Doxacurium pharmacodynamics in children during volatile and opioid–based anaesthesia. Kern C, et al. **Anaesthesia** 1996 Apr;51(4):361–4

Is propofol infusion better than inhalational anaesthesia for paediatric MRI? [letter] MacIntyre PA, et al. **Anaesthesia** 1996 May;51(5):517

A case of intra–operative awareness during balanced anaesthesia with sufentanil [letter] Maeckelmann S, et al. **Anaesthesia** 1996 Aug;51(8):802

Topical lignocaine and thiopentone for the insertion of a laryngeal mask airway; a comparison with propofol. Seavell CR, et al. **Anaesthesia** 1996 Jul;51(7):699–701

Induction of anaesthesia with midazolam and a target–controlled propofol infusion. Tzabar Y, et al. **Anaesthesia** 1996 Jun;51(6):536–8

Growth of microorganisms in propofol, thiopental, and a 1:1 mixture of propofol and thiopental. Crowther J, et al. **Anesth Analg** 1996 Mar;82(3):475–8

Motor and sensory disability has a strong relationship to induction dose of thiopental in patients with the hypertropic variety of Charcot–Marie–Tooth syndrome. Kotani N, et al. **Anesth Analg** 1996 Jan;82(1):182–6

The neuromuscular effects of mivacurium chloride during

propofol anesthesia in children. Shorten GD, et al. **Anesth Analg** 1996 Jun;82(6):1170–5

Faster recovery after anesthesia in infants after intravenous induction with methohexital instead of thiopental. Beskow A, et al. **Anesthesiology** 1995 Nov;83(5):976–9

Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. Daniel M, et al. **Anesthesiology** 1996 Jan;84(1):75–80

Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Lien CA, et al. **Anesthesiology** 1996 Feb;84(2):300–8

Effects of halogenated and non-halogenated anesthetics on diaspirin cross-linked hemoglobin induced contractions of porcine pulmonary veins. Jing M, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(4):487–94

Comparison of propofol and methohexitone in anaesthesia for ECT: effect on seizure duration and outcome. Kirkby KC, et al. **Aust N Z J Psychiatry** 1995 Jun;29(2):299–303

Effect of i.v. lignocaine on the breathing of patients anaesthetized with propofol. Goodman NW, et al. **Br J Anaesth** 1995 Nov;75(5):573–7

Recovery after electroconvulsive therapy: comparison of propofol with methohexitone anaesthesia. Matters RM, et al. **Br J Anaesth** 1995 Sep;75(3):297–300

Recall during intermittent propofol anaesthesia. Nordström O, et al. **Br J Anaesth** 1996 May;76(5):699–701

The choice of anaesthetic for carotid endarterectomy: does it matter? [editorial] Archer DP, et al. **Can J Anaesth** 1995 Jul;42(7):566–70 **(Eng, Fre)**

Intravenous anaesthesia: new drugs, new concepts, and clinical applications. Miller DR. **Can J Anaesth** 1996 May; 43(5 Pt 2):R142–54 (18 ref.) **(Eng, Fre)**

Haemodynamic instability and myocardial ischaemia during carotid endarterectomy: a comparison of propofol and isoflurane. Mutch WA, et al. **Can J Anaesth** 1995 Jul; 42(7):577–87

A comparison of the effects of the propofol versus midazolam during total intravenous anesthesia for gynecological surgery procedures. Ye T, et al. **Chin Med Sci J** 1995 Sep; 10(3):181–4

Combined alfentanil–methohexital anesthesia in electroconvulsive therapy. Dinwiddie SH, et al. **Convuls Ther** 1995 Sep;11(3):170–6

Co-induction of anaesthesia: the rationale. Amrein R, et al. **Eur J Anaesthesiol Suppl** 1995 Nov;12:5–11 (41 ref.)

Rocuronium with alfentanil and propofol allows intubation within 45 seconds. Crul JF, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:111–2

Propofol versus propofol with midazolam for laryngeal mask insertion. Godsiff L, et al. **Eur J Anaesthesiol Suppl** 1995 Nov;12:35–40

Time-course of action and intubating conditions with rocuronium bromide under propofol–alfentanil anaesthesia. Hofmockel R, et al. **Eur J Anaesthesiol Suppl** 1995 Sep; 11:69–72

Anaesthetic drugs and bacterial contamination. Magee L, et al. **Eur J Anaesthesiol Suppl** 1995 Nov;12:41–3

Intravenous anaesthetic drug interactions: practical applications. Vinik HR. **Eur J Anaesthesiol Suppl** 1995 Nov; 12:13–9 (23 ref.)

Propofol infusion for induction and maintenance of anesthesia in elderly patients: recovery and hemodynamic profiles. Chan VW, et al. **J Clin Anesth** 1996 Jun;8(4):317–23

Evaluation of pain following electrocautery tubal ligation and effect of intraoperative fentanyl. Curry CS, et al. **J Clin Anesth** 1996 May;8(3):216–9

Ketorolac and propofol anesthesia in a patient taking chronic monoamine oxidase inhibitors. Fischer SP, et al. **J Clin Anesth** 1996 May;8(3):245–7

Hemodynamic effects of intrathecal fentanyl in nonlaboring term parturients. Grant GJ, et al. **J Clin Anesth** 1996 Mar; 8(2):99–103

Propofol and alfentanil mixture for outpatient surgery [letter; comment] Isert P. **J Clin Anesth** 1995 Jun;7(4):357. Comment on: J Clin Anesth 1994 Mar–Apr;6(2):166–7.

Compatibility of propofol, fentanyl, and vecuronium mixtures designed for potential use in anesthesia and patient transport. Isert PR, et al. **J Clin Anesth** 1996 Jun; 8(4):329–36

Propofol-based anesthesia as compared with standard anesthetic techniques for middle ear surgery. Jellish WS, et al. **J Clin Anesth** 1995 Jun;7(4):292–6

Propofol permits tracheal intubation but does not affect postoperative myalgias. Mingus ML, et al. **J Clin Anesth** 1996 May;8(3):220–4

Use of alfentanil for in vitro fertilization oocyte retrieval. Shapira SC, et al. **J Clin Anesth** 1996 Jun;8(4):282–5

Potency of doxacurium in infants, children, and adolescents during N2O–O2–alfentanil anesthesia. Taivainen TR, et al. **J Clin Anesth** 1996 May;8(3):225–8

Anesthetic implications of Larsen syndrome. Tobias JD. **J Clin Anesth** 1996 May;8(3):255–7

Propofol analgesia in central pain: preliminary clinical observations. Canavero S, et al. **J Neurol** 1995 Sep; 242(9):561–7

Evaluation of thiopentone–midazolam–fentanyl anaesthesia in pigs. Søfteland E, et al. **Lab Anim** 1995 Jul;29(3):269–75

Depression of excitatory effects of propofol induction by fentanyl. Ghabash M, et al. **Middle East J Anesthesiol** 1996 Feb;13(4):419–25

Total intravenous anesthesia for diagnostic endoscopy in myasthenia gravis child—a case report. Khan RM, et al. **Middle East J Anesthesiol** 1996 Feb;13(4):415–8

Low dose epidural lidocaine/sufentanil is effective for outpatient lithotripsy. Kwa AM, et al. **Middle East J Anesthesiol** 1995 Feb;13(1):71–8

Propofol and postoperative infections [letter; comment] Bach A, et al. **N Engl J Med** 1995 Nov 30;333(22):1505–6; discussion 1507. Comment on: N Engl J Med 1995 Jul 20;333(3):147–54.

Propofol and postoperative infections [letter; comment] Grounds RM. **N Engl J Med** 1995 Nov 30;333(22):1506; discussion 1507. Comment on: N Engl J Med 1995 Jul 20;333(3):147–54.

Propofol and postoperative infections [letter; comment] Kolbitsch C, et al. **N Engl J Med** 1995 Nov 30; 333(22):1506–7. Comment on: N Engl J Med 1995 Jul 20;333(3):147–54.

Clinical aspects of CRNA practice. General anesthesia. Ouellette SM. **Nurs Clin North Am** 1996 Sep;31(3):623–42 (102 ref.)

Propofol reduces the incidence of vomiting after tonsillectomy in children. Barst SM, et al. **Paediatr Anaesth** 1995;5(4):249–52

Anaesthesia for a child with centronuclear myopathy. Price SR, et al. **Paediatr Anaesth** 1995;5(4):267–8

Breast reduction under intravenous sedation: a review of 50 cases. Zukowski ML, et al. **Plast Reconstr Surg** 1996 Apr; 97(5):952–6; discussion 957–8

Retrobulbar versus peribulbar block: alfentanil in eye blocks [letter] de Córdoba JL, et al. **Reg Anesth** 1996 Mar–Apr; 21(2):171

[The lipid peroxidation level and antioxidant status of the plasma in patients operated on under propofol (Diprivan) anesthesia] Khinev S, et al. **Khirurgiia (Sofiia)** 1995; 48(5):23–5 (Eng. Abstr.) **(Bul)**

[Intravenous anesthesia in the horse: comparison of xylazine–ketamine and xylazine–tiletamine–zolazepam combinations] Cuvelliez S, et al. **Can Vet J** 1995 Oct; 36(10):613–8 **(Fre)**

[Anxiolysis, sedation, and stress reduction following oral premedication with midazolam in adults. A comparison with dipotassium clorazepate and placebo] Berendes E, et al. **Anaesthesist** 1996 Jun;45(6):506–11 (Eng. Abstr.) **(Ger)**

[Neuromuscular blockade after atracurium and alcuronium with propofol and thiopental] Ginz HF, et al. **Anaesthesist** 1996 Jan;45(1):47–51 (Eng. Abstr.) **(Ger)**

[Qualitative comparison of modified neuroleptˆ-, balanced and intravenous anesthesia. 2. Results of a clinical study, 1992] Harke H, et al. **Anaesthesist** 1995 Oct;44(10):687–94 (Eng. Abstr.) **(Ger)**

[The effect of propofol on vomiting after strabismus surgery in children] Klockgether–Radke A, et al. **Anaesthesist** 1995 Nov;44(11):755–60 (Eng. Abstr.) **(Ger)**

[Anesthesia with propanidid in a liposomal preparation. An experimental study in swine] Klockgether–Radke A, et al. **Anaesthesist** 1995 Aug;44(8):573–80 (Eng. Abstr.) **(Ger)**

[Endotracheal intubation with propofol and fentanyl] Striebel HW, et al. **Anaesthesist** 1995 Dec;44(12):809–17 (Eng. Abstr.) **(Ger)**

[Intravenous anesthesia—current aspects] Schraag S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):469–78 (72 ref.) (Eng. Abstr.) **(Ger)**

[Hospital day-surgery: comparative evaluation of 3 general anesthesia techniques] Rossi AE, et al. **Minerva Anestesiol** 1995 Jun;61(6):265–9 (Eng. Abstr.) **(Ita)**

[Cardiocirculatory stability and early extubation in patients undergoing thoracic surgery with propofol as the single anesthetic agent] Tommasi Rosso M, et al. **Minerva Anestesiol** 1995 May;61(5):183–9 (Eng. Abstr.) **(Ita)**

[Effects of anesthetic drugs and temperature on brain stem and mid-latency evoked potentials] Kadoi Y, et al. **Masui** 1995 Sep;44(9):1213–7 (Eng. Abstr.) **(Jpn)**

[Stress hormone response during midazolam/fentanyl anesthesia combined with epidural anesthesia for abdominal total hysterectomy] Mizutani A, et al. **Masui** 1996 Mar; 45(3):276–80 (Eng. Abstr.) **(Jpn)**

[Prospects of balanced anesthesia—combination with propofol] Shingu K, et al. **Masui** 1995;44 Suppl:S158–61; discussion S173–6 (6 ref.) **(Jpn)**

[The present state of balanced anesthesia—combination of intravenous and inhaled anesthetics] Sumikawa K, et al. **Masui** 1995;44 Suppl:S149–52; discussion S156–7 (10 ref.) **(Jpn)**

[Calcitonin gene-related peptide and human atrial natriuretic hormone levels in response to cardiac operation under high dose fentanyl anesthesia] Terazawa E, et al. **Masui** 1995 Sep;44(9):1202–7 (Eng. Abstr.) **(Jpn)**

[Comparison of changes in plasma concentrations of ACTH and beta-endorphin in cholecystectomy under general anesthesia and general plus epidural anesthesia] Caba F, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):364–8 (Eng. Abstr.) **(Spa)**

[Isoflurane versus propofol for sedation after heart surgery] Gómez JI, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep; 42(7):261–8 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

The role of muscle relaxants in total intravenous anaesthesia. Pollard BJ. **Acta Anaesthesiol Scand Suppl** 1995;106:58–61

Intubating conditions and neuromuscular effects of mivacurium during propofol-alfentanil anaesthesia. Van Aken H, et al. **Acta Anaesthesiol Scand Suppl** 1995;106:26–9

Long-term propofol infusion and airway management in a patient with Goldenhar's syndrome. Fan SZ, et al. **Acta Anaesthesiol Sin** 1995 Dec;33(4):233–6

Anaesthesia for an anterior mediastinal mass with ketamine and midazolam infusion. Frawley G, et al. **Anaesth Intensive Care** 1995 Oct;23(5):610–2

Propofol and epilepsy [letter] Slater BL. **Anaesth Intensive Care** 1995 Aug;23(4):517

Metoclopramide and prochlorperazine do not decrease propofol hypnotic requirements. Ali PB, et al. **Anaesthesia** 1995 Nov;50(11):990–1

Is rectal administration of propofol effective? [letter] Ceriana R, et al. **Anaesthesia** 1996 May;51(5):504

A novel device for patient-controlled sedation: laboratory and clinical evaluation of the Baxter Intermate LV250 infusor and patient-control module. Hamid SK, et al. **Anaesthesia** 1996 Feb;51(2):145–50

Effect of bupivacaine-induced spinal block on the hypnotic requirement of propofol. Tverskoy M, et al. **Anaesthesia** 1996 Jul;51(7):652–3

The effects of propofol on hemodynamics and renal blood flow in healthy and in septic sheep, and combined with fentanyl in septic sheep. Booke M, et al. **Anesth Analg** 1996 Apr;82(4):738–43

Recovery profile after desflurane with or without ondansetron compared with propofol in patients undergoing outpatient gynecological laparoscopy. Eriksson H, et al. **Anesth Analg** 1996 Mar;82(3):533–8

Propofol-opioid mixtures during prolonged infusions [letter] Ghouri AF, et al. **Anesth Analg** 1996 Apr;82(4):888–9

Lidocaine and no carrier fluid for the prevention of pain due to injection of propofol [letter; comment] Gozal Y. **Anesth Analg** 1996 May;82(5):1111. Comment on: Anesth Analg 1995 Nov;81(5):1087–8.

The comparison of epidural fentanyl, epidural lidocaine, and intravenous fentanyl in patients undergoing gastrectomy. Harukuni I, et al. **Anesth Analg** 1995 Dec;81(6):1169–74

A multicenter evaluation of total intravenous anesthesia with remifentanil and propofol for elective inpatient surgery. Hogue CW Jr, et al. **Anesth Analg** 1996 Aug;83(2):279–85

The effect of carrier intravenous fluid speed on the injection pain of propofol [see comments] Huang CL, et al. **Anesth Analg** 1995 Nov;81(5):1087–8. Comment in: Anesth Analg 1996 May;82(5):1111.

The comparative effects of sevoflurane versus propofol in the induction and maintenance of anesthesia in adult patients. Jellish WS, et al. **Anesth Analg** 1996 Mar; 82(3):479–85

Comparison of eltanolone and propofol on a pressure-volume analysis of the heart. Mulier JP, et al. **Anesth Analg** 1996 Aug;83(2):233–7

Nonlinear measures of heart rate variability after fentanyl-based induction of anesthesia. Storella RJ, et al. **Anesth Analg** 1995 Dec;81(6):1292–4

Computer-controlled infusion of alfentanil versus patient-controlled administration of morphine for postoperative analgesia: a double-blind randomized trial [see comments] van den Nieuwenhuyzen MC, et al. **Anesth Analg** 1995 Oct;81(4):671–9. Comment in: Anesth Analg 1995 Oct;81(4):665–7.

Performance of computer-controlled infusion of propofol: an evaluation of five pharmacokinetic parameter sets. Vuyk J, et al. **Anesth Analg** 1995 Dec;81(6):1275–82

Spectral analysis of arterial pressure variability during induction of propofol anesthesia. Wang H, et al. **Anesth Analg** 1996 May;82(5):914–9

Dose of propofol for laryngeal mask airway insertion in children: effect of premedication with midazolam. Martlew RA, et al. **Br J Anaesth** 1996 Feb;76(2):308–9

Manual compared with target-controlled infusion of propofol. Russell D, et al. **Br J Anaesth** 1995 Nov; 75(5):562–6

Prospective evaluation of pharmacokinetic model-controlled infusion of propofol in adult patients. Short TG, et al. **Br J Anaesth** 1996 Feb;76(2):313–5

Sudden unexpected sneezing during the insertion of peribulbar block under propofol sedation. Abramson DC. **Can J Anaesth** 1995 Aug;42(8):740–3

Propofol emulsion and bacterial contamination. McHugh GJ, et al. **Can J Anaesth** 1995 Sep;42(9):801–4

High-dose vecuronium neuromuscular block: a comparison of arrhythmias and onset of block during sufentanil anaesthesia. Sharpe MD, et al. **Can J Anaesth** 1995 Aug; 42(8):716–23

A comparison between total intravenous anaesthesia using a propofol/alfentanil mixture and an inhalational technique for laparoscopic gynaecological sterilization. Collins SJ, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):33–7

EEG analysis and pharmacodynamic modelling after intravenous bolus injection of eltanolone (pregnanolone). Hering W, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):407–15

Co-induction of anaesthesia: the cardiac patient. Duthie DJ. **Eur J Anaesthesiol Suppl** 1995 Nov;12:21–4 (26 ref.)

Co-induction of anaesthesia: day-case surgery. Whitwam JG. **Eur J Anaesthesiol Suppl** 1995 Nov;12:25–34 (50 ref.)

Oral self-administration of gamma-hydroxybutyric acid in the rat. Colombo G, et al. **Eur J Pharmacol** 1995 Oct 4; 285(1):103–7

Laparoscopically assisted gamete intrafallopian transfer with

local anesthesia and intravenous sedation. Padilla SL, et al. **Fertil Steril** 1996 Sep;66(3):404–7

Beta-selective monoamine oxidase inhibitors and cardiac anesthesia. Cerza RF. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):717–9

Serum lipid and glucose concentrations with a propofol infusion for cardiac surgery. Myles PS, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):373–8

Continuous infusions of alfentanil and propofol for coronary artery surgery. Roekaerts PM, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):362–7

Comparison of the use of a propofol infusion in cardiac surgical patients with normal and low cardiac output states. Sherry KM, et al. **J Cardiothorac Vasc Anesth** 1995 Aug; 9(4):368–72

Second opinion on brevital [letter] Salamon SM. **J Cataract Refract Surg** 1996 Apr;22(3):281–2

The bispectral index during induction of anesthesia with midazolam and propofol. Hoffman WE, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):15–20

Methohexital infusion technique for conscious sedation. Johns FR, et al. **J Oral Maxillofac Surg** 1996 May;54(5):578–81; discussion 581–2

Propofol: an alternative general anesthetic for outpatient oral surgery. Pastuovic MN, et al. **J Oral Maxillofac Surg** 1996 Aug;54(8):943–8

Role of propofol in paediatric anaesthetic practice [editorial] Meakin G. **Paediatr Anaesth** 1995;5(3):147–9

Deep sedation with propofol in preschool children undergoing radiation therapy. Scheiber G, et al. **Paediatr Anaesth** 1996;6(3):209–13

Computer-assisted continuous infusion for the delivery of target-controlled infusions of propofol during outpatient surgery. Arndt GA, et al. **Pharmacotherapy** 1995 Jul–Aug; 15(4):512–6

[Ketamine at low doses + etomidate or diazepam—a comparative clinical study of anesthesia in urology] Tablov V, et al. **Khirurgiia (Sofiia)** 1995;48(5):36–8 (Eng. Abstr.) **(Bul)**

[Anesthesia with continuous + infusion of propofol for trans-sternal thymectomy in myasthenic patients] García-Aguado R, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep;42(7):283–5 (Eng. Abstr.) **(Spa)**

[Propofol in continuous perfusion as anesthetic in experimental surgery in the rabbit] Pérez-Martínez A, et al. **Rev Esp Anestesiol Reanim** 1995 Aug–Sep;42(7):253–6 (Eng. Abstr.) **(Spa)**

[Cardiorespiratory and analgesic effects of continuous infusion of propofol in swine as experimental animals] Tendillo FJ, et al. **Rev Esp Anestesiol Reanim** 1996 Apr; 43(4):126–9 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Disturbance of hepatocellular integrity associated with propofol anaesthesia in surgical patients. Tiainen P, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):840–4

Infections linked to lax handling of propofol [news] **Am J Health Syst Pharm** 1995 Oct 1;52(19):2061, 2066

Fatal cardiovascular collapse following propofol induction in high-risk patients and dilemmas in the selection of a short-acting induction agent [see comments] Warden JC, et al. **Anaesth Intensive Care** 1995 Aug;23(4):485–7. Comment in: Anaesth Intensive Care 1996 Feb;24(1):125–6.

The effect of temperature upon pain during injection of propofol. Fletcher GC, et al. **Anaesthesia** 1996 May; 51(5):498–9

The haemodynamic effects of propofol in combination with ephedrine. Gamlin F, et al. **Anaesthesia** 1996 May; 51(5):488–91

Propofol—an interesting new side effect? [letter] Hocking G. **Anaesthesia** 1996 Jan;51(1):101

Modification of pain on injection of propofol. A comparison of pethidine and lignocaine. Lyons B, et al. **Anaesthesia** 1996 Apr;51(4):394–5

Upper airway closure: a primary source of difficult ventilation with sufentanil induction of anesthesia. Abrams JT, et al. **Anesth Analg** 1996 Sep;83(3):629–32

Anticholinergic treatment for choreoathetosis in a child after induction with propofol [letter] Diltoer MW, et al. **Anesth Analg** 1996 Mar;82(3):670

Reducing pain during propofol injection: the role of the solvent. Doenicke AW, et al. **Anesth Analg** 1996 Mar; 82(3):472–4

Opisthotonus and thiopental. Hooda S, et al. **Anesth Analg** 1995 Dec;81(6):1309–10

Propofol-induced myotonia in myotonic dystrophy [letter] Kinney MA, et al. **Anesth Analg** 1996 Sep;83(3):665–6

Prevention of pain on injection of propofol: a comparison of lidocaine with alfentanil. Nathanson MH, et al. **Anesth Analg** 1996 Mar;82(3):469–71

Reversal of a paradoxical reaction to midazolam with flumazenil. Thurston TA, et al. **Anesth Analg** 1996 Jul; 83(1):192

Propofol and postoperative pancreatitis. Leisure GS, et al. **Anesthesiology** 1996 Jan;84(1):224–7

Magnetic resonance imaging of the upper airway. Effects of propofol anesthesia and nasal continuous positive airway pressure in humans [see comments] Mathru M, et al. **Anesthesiology** 1996 Feb;84(2):273–9. Comment in: Anesthesiology 1996 Feb;84(2):253–5.

Exacerbation or unmasking of focal neurologic deficits by sedatives. Thal GD, et al. **Anesthesiology** 1996 Jul; 85(1):21–5; discussion 29A–30A

Pancreatitis after propofol administration: is there a relationship? [letter] Wingfield TW. **Anesthesiology** 1996 Jan;84(1):236–7

Testing the porphyrinogenicity of propofol in a primed rat model [see comments] Böhrer H, et al. **Br J Anaesth** 1995 Sep;75(3):334–8. Comment in: Br J Anaesth 1996 Jan;76(1):171–2. Comment in: Br J Anaesth 1996 Jan;76(1):172.

Unilateral convulsion after induction of anaesthesia with propofol. Cochran D, et al. **Br J Anaesth** 1996 Apr; 76(4):570–2

Porphyria, propofol and rats [letter; comment] Gorchein A. **Br J Anaesth** 1996 Jan;76(1):172. Comment on: Br J Anaesth 1995 Sep;75(3):334–8.

Porphyria, propofol and rats [letter; comment] Tidmarsh MD. **Br J Anaesth** 1996 Jan;76(1):171–2. Comment on: Br J Anaesth 1995 Sep;75(3):334–8.

Anaesthesia during carotid surgery [letter] Smith M. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):54

Prophylaxis against the systemic hypotension induced by propofol during rapid-sequence intubation. el-Beheiry H, et al. **Can J Anaesth** 1995 Oct;42(10):875–8

Fixed drug eruption associated with anaesthesia. Bremang JA, et al. **Can J Anaesth** 1995 Jul;42(7):628–30

Unintentional intraoperative awareness during sufentanil anaesthesia for cardiac surgery. Gilron I, et al. **Can J Anaesth** 1996 Mar;43(3):295–8

Thiopentone pretreatment for propofol injection pain in ambulatory patients. Haugen RD, et al. **Can J Anaesth** 1995 Dec;42(12):1108–12

Prolonged myoclonus and meningism following propofol. Hughes NJ, et al. **Can J Anaesth** 1995 Aug;42(8):744–6

Propofol myoclonus [letter] Strachan AN, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):536–7

Propofol bashing: the time to stop is now! [letter; comment] Reed MD, et al. **Crit Care Med** 1996 Jan;24(1):175–6. Comment on: Crit Care Med 1995 Feb;23(2):405–9.

Case 2—1995. Seizures associated with propofol anesthesia [clinical conference] Eimerl D, et al. **Isr J Med Sci** 1996 May;32(5):334–6

Epidemiology of the adverse hemodynamic events occurring during "clonidine anesthesia": a prospective open trial of intraoperative intravenous clonidine. De Kock M, et al. **J Clin Anesth** 1995 Aug;7(5):403–10

Hemodynamic effects of intrathecal fentanyl in nonlaboring term parturients. Grant GJ, et al. **J Clin Anesth** 1996 Mar; 8(2):99–103

Target-controlled infusions: stress free anesthesia? Kenny GN, et al. **J Clin Anesth** 1996 May;8(3 Suppl):15S–20S (46 ref.)

Chest wall rigidity during infusion of fentanyl in a two-month-old infant after heart surgery. MacGregor DA, et al. **J Clin Anesth** 1996 May;8(3):251–4

Propylene glycol toxicity caused by prolonged infusion of etomidate. Van de Wiele B, et al. **J Neurosurg Anesthesiol** 1995 Oct;7(4):259–62

Propylene glycol toxicity following continuous etomidate infusion for the control of refractory cerebral edema. Levy ML, et al. **Neurosurgery** 1995 Aug;37(2):363–9; discussion 369–71

Propofol (Diprivan) [letter] Young RF. **Neurosurgery** 1995 Jul;37(1):160–1

Delayed recovery from anaesthesia in Rubinstein-Taybi syndrome [letter] Dunkley CJ, et al. **Paediatr Anaesth** 1996; 6(3):245–6

Propofol and green urine [letter] Tirosh R, et al. **Paediatr Anaesth** 1996;6(3):244

[A case of generalized convulsion during induction with Diprivan] Karadimov D, et al. **Khirurgiia (Sofiia)** 1994; 47(5):41–2 (Eng. Abstr.) **(Bul)**

[Anesthetic complications in sequential bipulmonary transplantation in patients with cystic fibrosis. Apropos of 6 cases] López LM, et al. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):108–12 (Eng. Abstr.) **(Spa)**

ANTAGONISTS & INHIBITORS

Sedative and ventilatory effects of midazolam infusion: effect of flumazenil reversal. Mora CT, et al. **Can J Anaesth** 1995 Aug;42(8):677–84

Attenuation of midazolam-induced EEG activation in rats by both flumazenil and hyperbaric oxygen. Russell GB, et al. **J Neurosurg Anesthesiol** 1995 Oct;7(4):271–9

BLOOD

Comparison of arterialized venous with arterial blood propofol concentrations during sub-anaesthetic infusions in volunteers. Johnston KR, et al. **Br J Anaesth** 1996 Mar; 76(3):401–4

The effect of midazolam at two plasma concentrations of hemodynamics and sufentanil requirement in coronary artery surgery. van der Maaten JM, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):356–63

Quantitation of propofol in whole blood by gas chromatography-mass spectrometry. Guitton J, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):358–65

Determination of (R)-(+)- and (S)-(-)-isomers of thiopentone in plasma by chiral high-performance liquid chromatography. Jones DJ, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):174–9

Protein binding of methohexital. Study of parameters and modulating factors using the equilibrium dialysis technique. Girard I, et al. **J Pharm Biomed Anal** 1996 Mar;14(5):583–91

[The plasma concentration measurement of local anesthetics, thiobarbiturates and mexiletine by HPLC with automatic pre-treatment system] Kakinohana O, et al. **Masui** 1995 Aug;44(8):1165–70 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Failure of the thiopental precipitation test to detect cerebrospinal fluid after dural puncture with current epidural solutions for labor analgesia [letter] Lowenwirt I, et al. **Reg Anesth** 1995 Sep–Oct;20(5):459–60

ECONOMICS

An economic evaluation of propofol/fentanyl compared with midazolam/fentanyl on recovery in the ICU following cardiac surgery. Sherry KM, et al. **Anaesthesia** 1996 Apr; 51(4):312–7

HISTORY

Thiopentone anaesthesia at Pearl Harbor [see comments] Bennetts FE. **Br J Anaesth** 1995 Sep;75(3):366–8. Comment in: Br J Anaesth 1995 Dec;75(6):823.

Thiopentone anaesthesia at Pearl Harbor [letter; comment] Kidd AG, et al. **Br J Anaesth** 1995 Dec;75(6):823. Comment on: Br J Anaesth 1995 Sep;75(3):366–8.

METABOLISM

Identification of cytochrome P450 3A1/2 as the major P450 isoform responsible for the metabolism of fentanyl by rat liver microsomes. Feierman DE. **Anesth Analg** 1996 May; 82(5):936–41

Glucuronidation of propofol in microsomal fractions from various tissues and species including humans: effect of different drugs. Le Guellec C, et al. **Anesth Analg** 1995 Oct;81(4):855–61

Interaction of i.v. anaesthetic agents with 5-HT3 receptors. Appadu BL, et al. **Br J Anaesth** 1996 Feb;76(2):271–3

PHARMACOKINETICS

Maternal and neonatal fentanyl and bupivacaine concentrations after epidural infusion during labor. Bader AM, et al. **Anesth Analg** 1995 Oct;81(4):829–32

Pharmacokinetics of epidural fentanyl [letter] dos Santos JE. **Anesth Analg** 1996 Sep;83(3):666

Propofol concentrations—an alternative explanation [letter; comment] Eger EI 2nd. **Anesth Analg** 1996 Feb;82(2):438–9 . Comment on: Anesth Analg 1995 Jul;81(1):175–8.

Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental [see comments] Nguyen KT, et al. **Anesth Analg** 1996 Sep;83(3):552–8. Comment in: Anesth Analg 1996 Sep;83(3):447–50.

Performance of computer-controlled infusion of propofol: an evaluation of five pharmacokinetic parameter sets. Vuyk J, et al. **Anesth Analg** 1995 Dec;81(6):1275–82

Technique for quantifying the duration of intravenous anesthetic effect [see comments] Bailey JM. **Anesthesiology** 1995 Nov;83(5):1095–103. Comment in: Anesthesiology 1995 Nov;83(5):902–5.

Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. Bailey JM, et al. **Anesthesiology** 1996 Jun;84(6):1288–97

Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. Fiset P, et al. **Anesthesiology** 1995 Nov;83(5):944–55

Pharmacokinetics of propofol after a single dose in children aged 1–3 years with minor burns. Comparison of three data analysis approaches. Murat I, et al. **Anesthesiology** 1996 Mar;84(3):526–32

Evolving clinically useful predictors of recovery from intravenous anesthetics [editorial; comment] Schnider TW, et al. **Anesthesiology** 1995 Nov;83(5):902–5. Comment on: Anesthesiology 1995 Nov;83(5):1095–103.

Pulmonary uptake of sufentanil during and after constant rate infusion. Boer F, et al. **Br J Anaesth** 1996 Feb;76(2):203–8

Extrahepatic glucuronidation of propofol in man: possible contribution of gut wall and kidney. Raoof AA, et al. **Eur J Clin Pharmacol** 1996;50(1–2):91–6

Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. Russo H, et al. **Eur J Clin Pharmacol** 1995;49(1–2):127–37

Pharmacokinetic and pharmacodynamic principles in providing "fast-track" recovery. Glass PS. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):16–20 (29 ref.)

Sufentanil plasma concentrations following lower extremity tourniquet release. Okum GS, et al. **J Clin Anesth** 1996 May;8(3):210–5

Total intravenous anesthesia—a pharmacokinetic approach. Bovill JG. **Middle East J Anesthesiol** 1995 Feb;13(1):37–60 (36 ref.)

Estimation of pharmacokinetic model parameters. Timcenko A, et al. **Proc Annu Symp Comput Appl Med Care** 1995; :47–51

Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. Lee HS, et al. **Ther Drug Monit** 1995 Aug;17(4):336–41

[Effect of duration of infusion on elimination rate of

alfentanil] Castor G, et al. **Anaesthesiol Reanim** 1995; 20(4):97–100 (Eng. Abstr.) **(Ger)**

[Gamma-hydroxybutyric acid—significance for anesthesia and intensive care medicine?] Kleinschmidt S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):393–402 (59 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacokinetics of propofol during liver transplantation in small pigs] Mashimo T, et al. **Masui** 1996 Mar; 45(3):293–7 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Comparison of propofol and increased doses of thiopentone for laryngeal mask insertion. Brown GW, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1103–4

A cost–benefit evaluation of using propofol and alfentanil for a short gynecological procedure. Enlund M, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):416–20

The effect of edothelium on the response to propofol on bovine coronary artery rings. Gacar N, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1080–3

Propofol and isoflurane induced EEG burst suppression patterns in rabbits. Hartikainen K, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):814–8

QT interval of the ECG, heart rate and arterial pressure during anaesthetic induction: comparative effects of alfentanil and esmolol. Korpinen R, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):809–13

High-dose fentanyl does not suppress interleukin-1 beta-induced increases in plasma ACTH and corticosterone in rats. Numai T, et al. **Acta Anaesthesiol Scand** 1996 Feb; 40(2):143–50

The influence of alfentanil pre-treatment on ventilatory effects of doxapram following induction of anaesthesia with propofol. O'Connor B, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):156–9

Evaluation of saccadic eye movements as an objective test of recovery from anaesthesia. Paut O, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1117–24

Propofol influences the electroretinogram to a lesser degree than thiopentone. Tanskanen P, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):480–5

In vitro myocardial depression by ketamine or thiopental is dependent on the underlying beta-adrenergic tone. Thurston TA, et al. **Acta Anaesthesiol Scand** 1996 Mar; 40(3):338–41

Comparative responses to propofol anaesthesia alone and with alpha 2-adrenergic medications in a canine model. Bufalari A, et al. **Acta Vet Scand** 1996;37(2):187–201

Cerebral effects of propofol following bolus administration in sheep. Ludbrook GL, et al. **Anaesth Intensive Care** 1996 Feb;24(1):26–31

Effect of propofol infusion on the endocrine response to cardiac surgery. NG A, et al. **Anaesth Intensive Care** 1995 Oct;23(5):543–7

Spontaneous movement after injection of propofol. Chan A, et al. **Anaesthesia** 1996 Jul;51(7):663–6

Middle latency auditory evoked potentials during repeated transitions from consciousness to unconsciousness. Davies FW, et al. **Anaesthesia** 1996 Feb;51(2):107–13

Propofol-induced bronchodilation in status asthmaticus? [letter] Parmar M, et al. **Anaesthesia** 1995 Nov; 50(11):1003–4

Propofol infusion anaesthesia and the immune response in elderly patients undergoing ophthalmic surgery. Pirttikangas CO, et al. **Anaesthesia** 1996 Apr;51(4):318–23

Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Beilin B, et al. **Anesth Analg** 1996 Mar;82(3):492–7

The effect of a cyclodextrin vehicle on the cardiovascular profile of propofol in rats. Bielen SJ, et al. **Anesth Analg** 1996 May;82(5):920–4

Effects of temperature and propofol on hepatic blood flow [letter; comment] Carmichael FJ. **Anesth Analg** 1996 Feb; 82(2):426. Comment on: Anesth Analg 1995 May;80(5):1007–14.

Direct relaxant effects of intravenous anesthetics on airway smooth muscle. Cheng EY, et al. **Anesth Analg** 1996 Jul; 83(1):162–8

Large-dose propofol alone in adult epileptic patients: electrocorticographic results. Cheng MA, et al. **Anesth Analg** 1996 Jul;83(1):169–74

Concentrations of desflurane and propofol that suppress response to command in humans. Chortkoff BS, et al. **Anesth Analg** 1995 Oct;81(4):737–43

Subanesthetic concentrations of desflurane and propofol suppress recall of emotionally charged information [see comments] Chortkoff BS, et al. **Anesth Analg** 1995 Oct; 81(4):728–36. Comment in: Anesth Analg 1995 Oct;81(4):668–70.

Brain nitric oxide synthase activity is decreased by intravenous anesthetics. Galley HF, et al. **Anesth Analg** 1996 Sep;83(3):591–4

Propofol and ethanol produce additive hypnotic and anesthetic effects in the mouse. Garfield JM, et al. **Anesth Analg** 1996 Jul;83(1):156–61

Inhibition of a fast inwardly rectifying potassium conductance by barbiturates. Gibbons SJ, et al. **Anesth Analg** 1996 Jun;82(6):1242–6

Isoflurane, fentanyl, thiopental, and brain edema [letter; comment] Hartung J. **Anesth Analg** 1996 Mar;82(3):672. Comment on: Anesth Analg 1995 Jun;80(6):1108–15.

Biochemical characterization of the stimulatory effects of halothane and propofol on purified brain protein kinase C. Hemmings HC Jr, et al. **Anesth Analg** 1995 Dec; 81(6):1216–22

Pink urine during propofol anesthesia [letter] Masuda A, et al. **Anesth Analg** 1996 Sep;83(3):666–7

The effect of midazolam on left ventricular pump performance and contractility in anesthetized patients with coronary artery disease: effect of preoperative ejection fraction. Messina AG, et al. **Anesth Analg** 1995 Oct; 81(4):793–9

Propofol-associated dilation of rat distal coronary arteries is mediated by multiple substances, including endothelium-derived nitric oxide. Park KW, et al. **Anesth Analg** 1995 Dec;81(6):1191–6

The effects of propofol on the 40-Hz auditory steady-state response and on the electroencephalogram in humans. Plourde G. **Anesth Analg** 1996 May;82(5):1015–22

Propofol produces differences in behavior but not chloride channel function between selected lines of mice. Simpson VJ, et al. **Anesth Analg** 1996 Feb;82(2):327–31

Acidosis accentuates thiopental-induced myocardial depression in vitro. Thurston TA, et al. **Anesth Analg** 1996 Sep;83(3):636–8

Sigma receptor activation does not mediate fentanyl-induced attenuation of muscarinic coronary contraction. Tsuchida H, et al. **Anesth Analg** 1996 May;82(5):982–7

Inhibition of regulated neuropeptide secretion from mouse pituitary cells by propofol. YaDeau JT. **Anesth Analg** 1996 Sep;83(3):611–7

Alfentanil modifies the neurocirculatory responses to desflurane. Yonker-Sell AE, et al. **Anesth Analg** 1996 Jan; 82(1):162–6

Propofol reduces neuronal transmission damage and attenuates the changes in calcium, potassium, and sodium during hyperthermic anoxia in the rat hippocampal slice. Amorim P, et al. **Anesthesiology** 1995 Dec;83(6):1254–65

Technique for quantifying the duration of intravenous anesthetic effect [see comments] Bailey JM. **Anesthesiology** 1995 Nov;83(5):1095–103. Comment in: Anesthesiology 1995 Nov;83(5):902–5.

Propofol modulates the effects of chemoconvulsants acting at GABAergic, glycinergic, and glutamate receptor subtypes. Bansinath M, et al. **Anesthesiology** 1995 Oct; 83(4):809–15

Volatile and intravenous anesthetics decrease glutamate release from cortical brain slices during anoxia. Bickler PE, et al. **Anesthesiology** 1995 Dec;83(6):1233–40

Comparison of the effects of etomidate, propofol, and thiopental on respiratory resistance after tracheal intubation. Eames WO, et al. **Anesthesiology** 1996 Jun; 84(6):1307–11

Inotropic effects of propofol, thiopental, midazolam, etomidate, and ketamine on isolated human atrial muscle. Gelissen HP, et al. **Anesthesiology** 1996 Feb;84(2):397–403

Etomidate and thiopental inhibit the release of endothelium-derived hyperpolarizing factor in the human renal artery. Kessler P, et al. **Anesthesiology** 1996 Jun; 84(6):1485–8

Propofol alters left ventricular afterload as evaluated by aortic input impedance in dogs. Lowe D, et al. **Anesthesiology** 1996 Feb;84(2):368–76

Synaptic mechanisms of thiopental-induced alterations in synchronized cortical activity. Lukatch HS, et al. **Anesthesiology** 1996 Jun;84(6):1425–34

Thiopental uncouples hippocampal and cortical synchronized electroencephalographic activity. MacIver MB, et al. **Anesthesiology** 1996 Jun;84(6):1411–24

Effects of intravenous anesthetics on atrial wavelength and atrioventricular nodal conduction in guinea pig heart. Potential antidysrhythmic properties and clinical implications. Napolitano CA, et al. **Anesthesiology** 1996 Aug;85(2):393–402

Reconciling differences between in vitro and in vivo effects of propofol [letter] Orser BA, et al. **Anesthesiology** 1996 Mar;84(3):749–50

Effect of propofol on affective state as assessed by place conditioning paradigm in rats. Pain L, et al. **Anesthesiology** 1996 Jul;85(1):121–8

In vitro effects of eltanolone on rat myocardium. Riou B, et al. **Anesthesiology** 1995 Oct;83(4):792–8

Propofol and cellular calcium homeostasis [letter; comment] Sztark F, et al. **Anesthesiology** 1995 Dec;83(6):1386. Comment on: Anesthesiology 1994 Nov;81(5):1220–9.

Effect of propofol on spinal dorsal horn neurons. Comparison with lack of ketamine effects. Uchida H, et al. **Anesthesiology** 1995 Dec;83(6):1312–22

Pharmacodynamic interaction between propofol and alfentanil when given for induction of anesthesia. Vuyk J, et al. **Anesthesiology** 1996 Feb;84(2):288–99

Effects of thiopental on regional blood flows in the rat. Wada DR, et al. **Anesthesiology** 1996 Mar;84(3):596–604

Effects of sufentanil on cerebral hemodynamics and intracranial pressure in patients with brain injury. Werner C, et al. **Anesthesiology** 1995 Oct;83(4):721–6

Inhibitory effects of thiopental, ketamine, and propofol on voltage-dependent Ca2+ channels in porcine tracheal smooth muscle cells. Yamakage M, et al. **Anesthesiology** 1995 Dec;83(6):1274–82

Propofol inhibits cardiac L-type calcium current in guinea pig ventricular myocytes. Yang CY, et al. **Anesthesiology** 1996 Mar;84(3):626–35

Haemodynamic response to simulated haemorrhage in the rabbit: interaction of i.v. anaesthesia and hypoxia. Blake DW, et al. **Br J Anaesth** 1995 Nov;75(5):610–5

Effects of propofol and isoflurane on right ventricular function [letter; comment] Boyd O, et al. **Br J Anaesth** 1996 Apr;76(4):598. Comment on: Br J Anaesth 1995 Nov;75(5):578–82.

Difference between in vivo and in vitro effects of propofol on defluorination and metabolic activities of hamster hepatic cytochrome P450-dependent mono-oxygenases. Chen TL, et al. **Br J Anaesth** 1995 Oct;75(4):462–6

Is there implicit memory after propofol sedation? Cork RC, et al. **Br J Anaesth** 1996 Apr;76(4):492–8

Propofol-induced alterations in the microcirculation of hamster striated muscle. Holzmann A, et al. **Br J Anaesth** 1995 Oct;75(4):452–6

Effects of propofol on isolated rabbit mesenteric arteries and veins. Kamitani K, et al. **Br J Anaesth** 1995 Oct; 75(4):457–61

Comparison of the effects of propofol and isoflurane anaesthesia on right ventricular function and shunt fraction during thoracic surgery [see comments] Kellow NH, et al. **Br J Anaesth** 1995 Nov;75(5):578–82. Comment in: Br J Anaesth 1996 Apr;76(4):598.

Effect of propofol and thiopentone on free radical mediated oxidative stress of the erythrocyte. Murphy PG, et al. **Br J Anaesth** 1996 Apr;76(4):536–43

Comparison of the effects of sub-hypnotic concentrations of propofol and halothane on the acute ventilatory response to hypoxia. Nagyova B, et al. **Br J Anaesth** 1995 Dec; 75(6):713–8

Effects of graded infusion rates of propofol on cardiovascular haemodynamics, coronary circulation and myocardial metabolism in dogs. Nakaigawa Y, et al. **Br J Anaesth** 1995 Nov;75(5):616–21

A perfusion system for in vitro measurement of human cilia beat frequency. Selwyn DA, et al. **Br J Anaesth** 1996 Jan; 76(1):111–5

EEG arousal during laryngoscopy and intubation [letter] Shannon C, et al. **Br J Anaesth** 1996 Mar;76(3):472–3

Activation of the electrocorticogram by propofol during surgery for epilepsy. Smith M, et al. **Br J Anaesth** 1996 Apr;76(4):499–502

Changes in chest wall compartment volumes on induction of anaesthesia with eltanolone, propofol and thiopentone. Spens HJ, et al. **Br J Anaesth** 1996 Mar;76(3):369–73

Effects of propofol on rabbit mesenteric arteries and veins [letter] Stratford N. **Br J Anaesth** 1996 Feb;76(2):333–4

EEG arousal during laryngoscopy and intubation: comparison of thiopentone or propofol supplemented with nitrous oxide. Wilder-Smith OH, et al. **Br J Anaesth** 1995 Oct;75(4):441–6

Anaesthesia during carotid surgery [letter] Andrzejowski J, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):54

Changes in intraocular pressure during low dose intravenous sedation with propofol before cataract surgery. Neel S, et al. **Br J Ophthalmol** 1995 Dec;79(12):1093–7

Choice of anaesthetic regimen influences haemodynamic response to cemented arthroplasty. Guest CB, et al. **Can J Anaesth** 1995 Oct;42(10):928–36

Divided doses of methohexitone improves ECT outcome [letter] Gurmarnik S, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):535

Differential effects of propofol, thiamylal and ketamine on the cricothyroid and posterior cricoarytenoid muscles of the canine larynx. Iwasaki H, et al. **Can J Anaesth** 1996 Jan;43(1):39–43

Differential effects of ketamine and midazolam on heart rate variability. Komatsu T, et al. **Can J Anaesth** 1995 Nov; 42(11):1003–9

Sedative and ventilatory effects of midazolam infusion: effect of flumazenil reversal. Mora CT, et al. **Can J Anaesth** 1995 Aug;42(8):677–84

Phosphatidylinositol responses are involved in the vascular effects of thiamylal and fentanyl. Shibata O, et al. **Can J Anaesth** 1995 Dec;42(12):1164–70

Thiopentone inhibits beta-adrenergic responses in myocardial tissue. Thurston TA, et al. **Can J Anaesth** 1995 Oct; 42(10):944–7

The effects of propofol on laryngeal reactivity and the haemodynamic response to laryngeal mask insertion. Acalovschi I, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):351–6

The pulmonary vascular response to propofol in the isolated perfused rat lung. Erdemli O, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):617–23

EEG analysis and pharmacodynamic modelling after intravenous bolus injection of eltanolone (pregnanolone). Hering W, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):407–15

The effect of urethane anesthesia on evoked potentials in dentate gyrus. Shirasaka Y, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):11–7

Urethane directly inhibits chemoreflex excitation of medullary vasomotor neurons in rats. Sun MK, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):237–43

Inhibitory effect of propofol on sympathetic neurotransmission results in changes of plasma neuropeptide Y in rats. Chang CL, et al. **J Auton Pharmacol** 1996 Feb;16(1):29–33

Pharmacokinetic and pharmacodynamic principles in providing "fast-track" recovery. Glass PS. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):16–20 (29 ref.)

ANESTHETICS, INTRAVENOUS

Onset of segmental relaxation dysfunction with decreased myocardial tissue perfusion: modulation by propofol. Vermeyen KM, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):379–88

Pharmacodynamics as a research tool. Bailey JM. **J Clin Anesth** 1996 May;8(3 Suppl):48S–52S (12 ref.)

Electropharmacological actions of propofol on calcium current in guinea-pig ventricular myocytes. Luk HN, et al. **J Electrocardiol** 1995 Oct;28(4):332–3

A comparison of the electrophysiologic characteristics of EEG burst-suppression as produced by isoflurane, thiopental, etomidate, and propofol. Akrawi WP, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):40–6

Effect of propofol on in vitro lipid peroxidation induced by different free radical generating systems: a comparison with vitamin E. Hans P, et al. **J Neurosurg Anesthesiol** 1996 Apr;8(2):154–8

Suppression of cerebral metabolic rate for oxygen (CMRO2) by mild hypothermia compared with thiopental. Nemoto EM, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):52–9

Acid-base status and cardiovascular function in mink (Mustela vison) anaesthetized with ketamine/midazolam. Wamberg S, et al. **Lab Anim** 1996 Jan;30(1):55–66

The effect of propofol on CA1 pyramidal cell excitability and GABAA-mediated inhibition in the rat hippocampal slice. Albertson TE, et al. **Life Sci** 1996 May 24; 58(26):2397–407

Direct effects of fentanyl on canine coronary artery rings. Introna RP, et al. **Life Sci** 1995 Mar 3;56(15):1265–73

Haemodynamic and haemoximetric aspects of experimental orthotopic liver transplantation: comparison between two different doses of propofol. Fabbri LP, et al. **Minerva Anestesiol** 1995 Nov;61(11):441–50

Amnesia after diazepam infusion into basolateral but not central amygdala of Rattus norvegicus. Silva MA, et al. **Neuropsychobiology** 1995;32(1):31–6

The effects of propofol on rat transcranial magnetic motor evoked potentials. Fishback AS, et al. **Neurosurgery** 1995 Nov;37(5):969–74

The protective effects of thiopental on brain stem ischemia. Guo J, et al. **Neurosurgery** 1995 Sep;37(3):490–5

Chloralose/ketamine anaesthesia preserves a form of postprandial sodium chloride balance in Wistar rats. Metz CJS, et al. **Pflugers Arch** 1996 Sep;432(5):944–7

The influence of selected antiarrhythmic drugs on the hemodynamic parameters in rabbits during anesthesia. Part I. Propofol anesthesia. Orszulak-Michalak D. **Pol J Pharmacol** 1995 Mar-Apr;47(2):143–52

The influence of selected antiarrhythmic drugs on the hemodynamic parameters in rabbits during anesthesia. Part II. Thiopental anesthesia. Orszulak-Michalak D, et al. **Pol J Pharmacol** 1995 Mar-Apr;47(2):153–62

[Combination of propofol-sufentanil on somatosensory evoked potentials in surgery of the spine] Borrissov B, et al. **Ann Fr Anesth Reanim** 1995;14(4):326–30 (Eng. Abstr.) **(Fre)**

[Incidence and quality of dreaming during anesthesia with propofol in comparison with enflurane] Käsmacher H, et al. **Anaesthesist** 1996 Feb;45(2):146–53 (Eng. Abstr.) **(Ger)**

[Clonidine increases the anesthetic effectiveness of thiopental] Tonner PH, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):357–60 (Eng. Abstr.) **(Ger)**

[Effects of propofol on contractility and electrophysiological properties of canine single cardiomyocytes] Shibuya N, et al. **Masui** 1996 Apr;45(4):408–14 (Eng. Abstr.) **(Jpn)**

[Use of propofol (diprivan) for induction of anesthesia in neurosurgical patients. I. Pressor reaction to laryngoscopy and intubation of the trachea] Tseitlin AM, et al. **Anesteziol Reanimatol** 1996 Mar-Apr;(2):46–9 (Eng. Abstr.) **(Rus)**

POISONING

Suicidal chloral hydrate poisoning. Ludwigs U, et al. **J Toxicol Clin Toxicol** 1996;34(1):97–9

Chloral hydrate toxicity from oral and intravenous administration. Sing K, et al. **J Toxicol Clin Toxicol** 1996; 34(1):101–6

THERAPEUTIC USE

A prospective evaluation of the safety and efficacy of methohexital in the emergency department [see comments] Lerman B, et al. **Am J Emerg Med** 1996 Jul;14(4):351–4 . Comment in: Am J Emerg Med 1996 Jul;14(4):440.

Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Krishnamurthy KB, et al. **Epilepsia** 1996 Sep;37(9):863–7

Perioperative use of propofol for cardiac surgery. Jain U. **J Clin Anesth** 1996 May;8(3 Suppl):61S–66S (81 ref.)

Nifedipine versus fentanyl to prevent the pressor response to tracheal intubation. Abdel-Razek A, et al. **Middle East J Anesthesiol** 1995 Feb;13(1):88–99

[The treatment of benign laryngeal pathologies using CO2 laser in direct microlaryngoscopy with propofol-induced endovenous anesthesia in spontaneous respiration without intubation] Macarone Palmieri A, et al. **Acta Otorhinolaryngol Ital** 1995 Oct;15(5):361–7 (Eng. Abstr.) **(Ita)**

[Infusion of propofol as anesthetic and antiemetic drug] Castaño I, et al. **Rev Esp Anestesiol Reanim** 1995 Aug-Sep; 42(7):257–60 (Eng. Abstr.) **(Spa)**

TOXICITY

Inhibitory effects of propofol on catecholamine secretion and uptake in cultured bovine adrenal medullary cells. Minami K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Apr; 353(5):572–8

Focal cerebral ischemia during anesthesia with etomidate, isoflurane, or thiopental: a comparison of the extent of cerebral injury. Drummond JC, et al. **Neurosurgery** 1995 Oct;37(4):742–8; discussion 748–9

ANESTHETICS, LOCAL

Comparison trial of four injectable anesthetics for laceration repair [see comments] Ernst AA, et al. **Acad Emerg Med** 1996 Mar;3(3):228–33. Comment in: Acad Emerg Med 1996 Mar;3(3):198–200.

What is the role of diphenhydramine in local anesthesia? [editorial; comment] Green SM. **Acad Emerg Med** 1996 Mar;3(3):198–200 (11 ref.). Comment on: Acad Emerg Med 1996 Mar;3(3):228–33.

Infiltration pain and local anesthetic effects of buffered vs plain 1% diphenhydramine. Singer AJ, et al. **Acad Emerg Med** 1995 Oct;2(10):884–8

EMLA prevents pain during local anesthesia for cataract surgery. Pappa X, et al. **Acta Anaesthesiol Belg** 1995; 46(2):75–8

Use of an anesthetic cream before infiltration with local anesthesia in aesthetic surgery. Abenavoli FM, et al. **Aesthetic Plast Surg** 1995 Nov-Dec;19(6):555–6

Effects of interpleural bupivacaine on pleural chest tube removal pain: a randomized controlled trial. Puntillo KA. **Am J Crit Care** 1996 Mar;5(2):102–8

Endosonography-guided celiac plexus injection for abdominal pain due to chronic pancreatitis [letter] Faigel DO, et al. **Am J Gastroenterol** 1996 Aug;91(8):1675

An evaluation of two concentrations of hyaluronidase for supplementation of peribulbar anaesthesia [see comments] Brydon CW, et al. **Anaesthesia** 1995 Nov;50(11):998–1000 . Comment in: Anaesthesia 1996 May;51(5):515.

Analgesia for day surgery. Evaluation of the effect of diclofenac given before or after surgery with or without bupivacaine infiltration. Chan A, et al. **Anaesthesia** 1996 Jun;51(6):592–5

The addition of tenoxicam to prilocaine for intravenous regional anaesthesia. Jones NC, et al. **Anaesthesia** 1996 May;51(5):446–8

Topical lignocaine and thiopentone for the insertion of a laryngeal mask airway; a comparison with propofol. Seavell CR, et al. **Anaesthesia** 1996 Jul;51(7):699–701

The effect of epidural blockade on gastric intramucosal pH in the peri-operative period. Sutcliffe NP, et al. **Anaesthesia** 1996 Jan;51(1):37–40

The effect of pre-incisional infiltration with lignocaine on postoperative pain after molar teeth extraction under general anaesthesia. Tordoff SG, et al. **Anaesthesia** 1996 Jun;51(6):585–7

The effect of extradural ketamine on onset time and sensory block in extradural anaesthesia with bupivacaine. Yanli Y, et al. **Anaesthesia** 1996 Jan;51(1):84–6

Spinal anesthesia with bupivacaine and fentanyl in geriatric patients. Fernandez-Galinski D, et al. **Anesth Analg** 1996 Sep;83(3):537–41

Cocaine, lidocaine, tetracaine: which is best for topical nasal anesthesia? Noorily AD, et al. **Anesth Analg** 1995 Oct; 81(4):724–7

Heat flow and distribution during epidural anesthesia. Matsukawa T, et al. **Anesthesiology** 1995 Nov;83(5):961–7

Efficacy of the topical anesthetic cream, EMLA, in alleviating both needle insertion and injection pain. Raveh T, et al. **Ann Plast Surg** 1995 Dec;35(6):576–9

Efficacy of topical anesthesia in children. Vinci RJ, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):466–9

Absence of an early pre-emptive effect after thoracic extradural bupivacaine in thoracic surgery. Aguilar JL, et al. **Br J Anaesth** 1996 Jan;76(1):72–6

Extradural analgesia with clonidine and fentanyl compared with 0.25% bupivacaine in the first stage of labour [see comments] Buggy DJ, et al. **Br J Anaesth** 1996 Feb; 76(2):319–21. Comment in: Br J Anaesth 1996 Jun;76(6):886–7.

Patient-controlled extradural analgesia with bupivacaine, fentanyl, or a mixture of both, after Caesarean section. Cooper DW, et al. **Br J Anaesth** 1996 May;76(5):611–5

Prilocaine 3% is superior to a mixture of bupivacaine and lignocaine for peribulbar anaesthesia. Döpfmer UR, et al. **Br J Anaesth** 1996 Jan;76(1):77–80

Effect of the addition of alfentanil to lignocaine during axillary brachial plexus anaesthesia. Gormley WP, et al. **Br J Anaesth** 1996 Jun;76(6):802–5

Comparison of ropivacaine and bupivacaine for extradural analgesia [letter; comment] al-Kaisy AA. **Br J Anaesth** 1995 Aug;75(2):246. Comment on: Br J Anaesth 1995 Mar;74(3):261–5.

Evaluation of an amethocaine gel preparation for percutaneous analgesia before venous cannulation in children. Lawson RA, et al. **Br J Anaesth** 1995 Sep; 75(3):282–5

Comparison of ropivacaine and bupivacaine for extradural analgesia [letter; comment] Lyons G, et al. **Br J Anaesth** 1995 Sep;75(3):373–4. Comment on: Br J Anaesth 1995 Mar;74(3):261–5.

Ropivacaine. McClure JH. **Br J Anaesth** 1996 Feb; 76(2):300–7 (88 ref.)

Nebulized lignocaine before gaseous induction with desflurane [letter; comment] Nay PG. **Br J Anaesth** 1996 Apr;76(4):596. Comment on: Br J Anaesth 1995 Nov;75(5):631–3.

Analgesic and anti-inflammatory effects of lignocaine-prilocaine (EMLA) cream in human burn injury. Pedersen JL, et al. **Br J Anaesth** 1996 Jun; 76(6):806–10

Extradural, paravertebral and intercostal nerve blocks for post-thoracotomy pain. Perttunen K, et al. **Br J Anaesth** 1995 Nov;75(5):541–7

Continuous extradural infusion of ropivacaine for prevention of postoperative pain after major orthopaedic surgery. Turner G, et al. **Br J Anaesth** 1996 May;76(5):606–10

Comparison of continuous brachial plexus infusion of butorphanol, mepivacaine and mepivacaine-butorphanol mixtures for postoperative analgesia. Wajima Z, et al. **Br J Anaesth** 1995 Nov;75(5):548–51

Randomized comparison of agents for caudal anaesthesia in anal surgery. Adebamowo CA, et al. **Br J Surg** 1996 Mar; 83(3):364–5

Intra-arterial lignocaine in embolectomy. Campbell WB, et al. **Br J Surg** 1996 Feb;83(2):244

Pain relief after inguinal hernia repair: a randomized controlled trial [letter; comment] Raithatha D, et al. **Br J Surg** 1996 Mar;83(3):427. Comment on: Br J Surg 1995 Sep;82(9):1245–7.

EMLA cream anaesthesia for frenuloplasty. Brough RJ, et al. **Br J Urol** 1995 Nov;76(5):653–4

EMLA during local anaesthetic vasectomy [letter; comment] Bryden AA, et al. **Br J Urol** 1995 Dec;76(6):813. Comment on: Br J Urol 1995 May;75(5):671.

Assessment of intrathecal lignocaine analgesia for open castration of rams. Scott PR, et al. **Br Vet J** 1996 Jul; 152(4):481–3

Is lidocaine-prilocaine cream (EMLA) always useful for venous puncture in preoperative autologous blood donation? Vivien B, et al. **Can J Anaesth** 1996 Mar; 43(3):232–7

Severe toxic keratopathy secondary to topical anesthetic abuse. Rocha G, et al. **Can J Ophthalmol** 1995 Jun; 30(4):198–202

Combined acupuncture and medicinal anesthesia for neolarynx reconstruction. Huang H. **Chin Med J (Engl)** 1995 Nov;108(11):870–1

0.0625% bupivacaine with 0.0002% fentanyl via patient-controlled epidural analgesia for pain of labor and delivery. Ferrante FM, et al. **Clin J Pain** 1995 Jun; 11(2):121–6

An evaluation of the suitability of benzocaine as a positive control skin sensitizer. Basketter DA, et al. **Contact Dermatitis** 1995 Jul;33(1):28–32

Local anesthetics. Skidmore RA, et al. **Dermatol Surg** 1996 Jun;22(6):511–22; quiz 523–4 (83 ref.)

Comparison of bupivacaine plus buprenorphine with bupivacaine alone by caudal blockade for post-operative pain relief after hip and knee arthroplasty. Gao F, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):471–6

Effect of injection speed on anaesthetic spread during axillary block using the orthogonal two-needle technique. Rucci FS, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):505–11

Knee arthroscopy under local anaesthesia: results and evaluation of patients' satisfaction. Iossifidis A. **Injury** 1996 Jan;27(1):43–4

Topical anaesthesia for children's lacerations: an acceptable approach? Kendall JM, et al. **J Accid Emerg Med** 1996 Mar;13(2):119–22

Is fasting necessary before prilocaine Bier's block? O'Sullivan I, et al. **J Accid Emerg Med** 1996 Mar;13(2):105–7

Analgesic efficacy of topical butamben picrate. Armstrong DG, et al. **J Am Podiatr Med Assoc** 1995 Dec;85(12):738–40

Epidural administration of bupivacaine, morphine, or their combination for postoperative analgesia in dogs. Hendrix PK, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):598–607

Spinal anesthesia for outpatients: appropriate agents and techniques. Mulroy MF, et al. **J Clin Anesth** 1995 Nov; 7(7):622–7 (39 ref.)

EMLA and venepuncture [letter; comment] Nott MR, et al. **J R Soc Med** 1995 Nov;88(11):664. Comment on: J R Soc Med 1995 May;88(5):264–7.

Urethral meatotomy in the office using topical EMLA cream for anesthesia. Cartwright PC, et al. **J Urol** 1996 Aug;156(2 Pt 2):857–8; discussion 858–9

Is intra-articular pethidine an alternative to local anaesthetics in arthroscopy? A double-blind study comparing prilocaine with pethidine. Ekbiom A, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):189–94

Topical anaesthesia for minor lacerations: MAC versus TAC. Kuhn M, et al. **Med J Aust** 1996 Mar 4;164(5):277–80

Low dose epidural lidocaine/sufentanil is effective for outpatient lithotripsy. Kwa AM, et al. **Middle East J Anesthesiol** 1995 Feb;13(1):71–8

Local anaesthetic agents in infancy. Eyres RL. **Paediatr Anaesth** 1995;5(4):213–8 (47 ref.)

Clonidine-mepivacaine mixture vs plain mepivacaine in paediatric surgery. Ivani G, et al. **Paediatr Anaesth** 1996; 6(2):111–4

Regional variations in skin perfusion and skin thickness may contribute to varying efficacy of topical, local anaesthetics

in neonates. Larsson BA, et al. **Paediatr Anaesth** 1996; 6(2):107–10

Femoral and lateral femoral cutaneous nerve block for muscle biopsies in children. Maccani RM, et al. **Paediatr Anaesth** 1995;5(4):223–7

A comparison between ilioinguinal–iliohypogastric nerve block performed by anaesthetist or surgeon for postoperative analgesia following groin surgery in children. Trotter C, et al. **Paediatr Anaesth** 1995;5(6):363–7

Tetracaine, adrenaline, and cocaine (TAC) confusion [letter; comment] Bischof RO. **Pediatrics** 1996 Feb;97(2):287–8. Comment on: Pediatrics 1995 Feb;95(2):255–8.

Breast reduction under intravenous sedation: a review of 50 cases. Zukowski ML, et al. **Plast Reconstr Surg** 1996 Apr; 97(5):952–6; discussion 957–8

Early sign of successful bupivacaine interscalene block: the "money sign" [letter] Brown AR, et al. **Reg Anesth** 1996 Mar–Apr;21(2):166–7

Is spinal anesthesia produced only by local anesthetics? [editorial; comment] Butterworth J, et al. **Reg Anesth** 1996 Mar–Apr;21(2):81–3. Comment on: Reg Anesth 1996 Mar–Apr;21(2):84–8.

Preoperative spinal bupivacaine does not reduce postoperative morphine requirement in women undergoing total abdominal hysterectomy. Dakin MJ, et al. **Reg Anesth** 1996 Mar–Apr;21(2):99–102

A comparison of meperidine and lidocaine for spinal anesthesia for postpartum tubal ligation [see comments] Norris MC, et al. **Reg Anesth** 1996 Mar–Apr;21(2):84–8. Comment in: Reg Anesth 1996 Mar–Apr;21(2):81–3.

Cutaneous application of ethyl chloride spray [letter] Sapir DA. **Reg Anesth** 1995 May–Jun;20(3):260

A double–blind comparison of the abdominal wall relaxation produced by epidural 0.75% ropivacaine and 0.75% bupivacaine in gynecologic surgery. Tuttle AA, et al. **Reg Anesth** 1995 Nov–Dec;20(6):515–20

The efficacy of two bupivacaine hydrochloride injection products. Müller FO, et al. **S Afr Med J** 1996 Jun; 86(6):667–9

A receptor interaction model for phenylcarbamate local anesthetics. Kettmann V, et al. **Z Naturforsch [C]** 1995 Sep–Oct;50(9–10):708–14

[Should a 5% solution of hyperbaric lidocaine be used in spinal anesthesia? (letter)] Erichsen CJ, et al. **Ugeskr Laeger** 1996 Jan 15;158(3):288 **(Dan)**

[Combined "3–in–1"/sciatic nerve block. Block effectiveness, serum level and side effects using 700 mg mepivacaine 1% without and with adrenaline and prilocaine 1%] Eifert B, et al. **Anaesthesist** 1996 Jan;45(1):52–8 (Eng. Abstr.) **(Ger)**

[Conduction block in man is stimulation frequency dependent] Stevens MF, et al. **Anaesthesist** 1996 Jun; 45(6):533–7 (Eng. Abstr.) **(Ger)**

[Addition of fentanyl to bupivacaine–peridural analgesia in cesarean section] Thomas H, et al. **Anaesthesist** 1996 Jul; 45(7):635–42 (Eng. Abstr.) **(Ger)**

[Objective quantification of spinal anesthesia by somatosensory evoked potentials after tibial nerve stimulation] Ebeling BJ, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):366–9 (Eng. Abstr.) **(Ger)**

[Peridural anesthesia in postoperative pain therapy] Standl T. **Zentralbl Chir** 1995;120(12):916–26 (80 ref.) (Eng. Abstr.) **(Ger)**

[Use of topical anesthesia–EMLA cream] Raveh T, et al. **Harefuah** 1996 Apr 1;130(7):490–1 (26 ref.) **(Heb)**

[Prospects of balanced anesthesia–mainly focusing on combined induction of midazolam with barbiturate and epidural opioid with local anesthetics] Arita H, et al. **Masui** 1995;44 Suppl:S167–72; discussion S173–6 **(Jpn)**

[Anesthesia in a patient with history of multiple drug allergies] Horiguchi Y, et al. **Masui** 1995 Nov;44(11):1542–6 (Eng. Abstr.) **(Jpn)**

[Density, specific gravity and baricity of various spinal anesthetics and those of normal human cerebrospinal fluid in Japanese] Masuda R, et al. **Masui** 1995 Nov; 44(11):1527–32 (Eng. Abstr.) **(Jpn)**

[Efficacy and complications of topical cocaine anesthesia in functional endoscopic sinus surgery] Kubo N, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Aug;98(8):1263–9 (Eng. Abstr.) **(Jpn)**

[The use of an analgin–novocaine–platyphylline mixture for arresting the pain attack and treating trigeminal neuralgia] Sheshelovskiĭ EG, et al. **Stomatologiia (Mosk)** 1996;75(1):44 **(Rus)**

[Leocaine–a new generation of local anesthetics] Leonidov NB, et al. **Vestn Oftalmol** 1995 Oct–Dec;111(4):19–21 (Eng. Abstr.) **(Rus)**

[Formulation of lidocaine–chloride gels with cellulose derivatives] Gazikalović E, et al. **Vojnosanit Pregl** 1994 Nov–Dec;51(6):505–9 (Eng. Abstr.) **(Scr)**

[Efficacy of the EMLA cream in the reduction of pain caused by venipuncture in children premedicated with oral midazolam] Cassinello F, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):360–3 (Eng. Abstr.) **(Spa)**

[EMLA: topical anesthesia of the skin. A step forward in pediatric anesthesia standards (editorial)] Santacana–Rillo E, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):353–4 **(Spa)**

ADMINISTRATION & DOSAGE

Comparison of preoperative with postoperative topical lidocaine spray on pain after tonsillectomy. Elhakim M, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1032–5

A double blind comparison of lidocaine 2% with or without glucose for spinal anesthesia. Harbers JB, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):881–4

Intra–arterial regional anaesthesia for hand surgery with alkalinized 0.5% lignocaine. Koscielniak–Nielsen ZJ, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1048–52

Better topical anesthetic. Ochsenreither JM. **Am J Nurs** 1996 May;96(5):21–2

Tropical benzocaine: does it alleviate pain? Who knows? [letter; comment] Harper DM. **Am J Obstet Gynecol** 1996 Mar;174(3):1077–8. Comment on: Am J Obstet Gynecol 1995 Sep;173(3 Pt 1):772–4.

The effect of topical 20% benzocaine on pain during loop electrosurgical excision of the cervix [see comments] Lipscomb GH, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):772–4. Comment in: Am J Obstet Gynecol 1996 Mar;174(3):1077–8.

Evaluation of intrapleural analgesia in the management of blunt traumatic chest wall pain: a clinical trial. Short K, et al. **Am Surg** 1996 Jun;62(6):488–93 (50 ref.)

EMLA cream prior to insertion of elective epidurals. Elson JA, et al. **Anaesth Intensive Care** 1995 Jun;23(3):339–41

The effect of cerebrospinal fluid dilution of isobaric 0.5% bupivacaine used for spinal anaesthesia. Cherng YG, et al. **Anaesthesia** 1995 Oct;50(10):906–9

The effect of a combination of rectal diclofenac and caudal bupivacaine on postoperative analgesia in children. Gadiyar V, et al. **Anaesthesia** 1995 Sep;50(9):820–2

Effect of injection pressure on the success rate of peribulbar block. Gillart T, et al. **Anaesthesia** 1996 Aug;51(8):779–82

Use of liposome–associated bupivacaine in a cancer pain syndrome. Lafont ND, et al. **Anaesthesia** 1996 Jun; 51(6):578–9

Epidural infusion of low–dose bupivacaine and opioid in labour. Does reducing motor block increase the spontaneous delivery rate? Russell R, et al. **Anaesthesia** 1996 Mar;51(3):266–73

Painless lignocaine [letter] Sainsbury MC. **Anaesthesia** 1996 Feb;51(2):205

Compound motor action potential recording distinguishes differential onset of motor block of the obturator nerve in response to etidocaine or bupivacaine. Atanassoff PG, et al. **Anesth Analg** 1996 Feb;82(2):317–20

Myringotomy tube placement–another role for EMLA cream? [letter] Beerle BJ, et al. **Anesth Analg** 1996 Aug; 83(2):435

Hyperbaric lidocaine spinal anesthesia: do we need an alternative? [editorial; comment] Carpenter RL. **Anesth Analg** 1995 Dec;81(6):1125–8. Comment on: Anesth Analg 1995 Dec;81(6):1148–53.

Equivalent outcomes during postoperative patient–controlled intravenous analgesia with lidocaine plus morphine versus morphine alone. Cepeda MS, et al. **Anesth Analg** 1996 Jul; 83(1):102–6

Determination of the minimum local analgesic concentrations of epidural bupivacaine and lidocaine in labor. Columb MO, et al. **Anesth Analg** 1995 Oct;81(4):833–7

Patient–controlled epidural analgesia after thoracotomy: a comparison of meperidine with and without bupivacaine. Etches RC, et al. **Anesth Analg** 1996 Jul;83(1):81–6

Hemodynamic effects of spinal anesthesia in the elderly: single dose versus titration through a catheter. Favarel–Garrigues JF, et al. **Anesth Analg** 1996 Feb; 82(2):312–6

The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Ferrante FM, et al. **Anesth Analg** 1996 Jan;82(1):91–7

Lidocaine and no carrier fluid for the prevention of pain due to injection of propofol [letter; comment] Gozal Y. **Anesth Analg** 1996 May;82(5):1111. Comment on: Anesth Analg 1995 Nov;81(5):1087–8.

Preoperative wound infiltration with bupivacaine reduces early and late opioid requirement after hysterectomy. Hannibal K, et al. **Anesth Analg** 1996 Aug;83(2):376–81

The analgesic efficacy and adverse effects of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. Hansdóttir V, et al. **Anesth Analg** 1996 Aug; 83(2):394–400

The effect of postoperative analgesia with continuous epidural bupivacaine after cesarean section on the amount of breast feeding and infant weight gain. Hirose M, et al. **Anesth Analg** 1996 Jun;82(6):1166–9

The dermatomal spread of epidural bupivacaine with and without prior intrathecal sufentanil. Leighton BL, et al. **Anesth Analg** 1996 Sep;83(3):526–9

Comparison of 5% with dextrose, 1.5% with dextrose, and 1.5% dextrose–free lidocaine solutions for spinal anesthesia in human volunteers. Liu S, et al. **Anesth Analg** 1995 Oct; 81(4):697–702

Prevention of pain on injection of propofol: a comparison of lidocaine with alfentanil. Nathanson MH, et al. **Anesth Analg** 1996 Mar;82(3):469–71

The effects of dobutamine and phenylephrine on atrioventricular conduction during combined use of halothane and thoracic epidural lidocaine. Nishikawa K, et al. **Anesth Analg** 1996 Mar;82(3):551–7

Intraperitoneal application of bupivacaine during laparoscopic cholecystectomy–risk or benefit? Raetzell M, et al. **Anesth Analg** 1995 Nov;81(5):967–72

Dural puncture with a 26–gauge spinal needle affects spread of epidural anesthesia. Suzuki N, et al. **Anesth Analg** 1996 May;82(5):1040–2

Digital pressure during interscalene block is clinically ineffective in preventing anesthetic spread to the cervical plexus. Urmey WF, et al. **Anesth Analg** 1996 Aug; 83(2):366–70

Adding fentanyl 0.0002% to epidural bupivacaine 0.125% does not delay gastric emptying in laboring parturients. Zimmermann DL, et al. **Anesth Analg** 1996 Mar;82(3):612–6

Continuous intracisternal and high cervical intrathecal bupivacaine analgesia in refractory head and neck pain [see comments] Appelgren L, et al. **Anesthesiology** 1996 Feb; 84(2):256–72. Comment in: Anesthesiology 1996 Feb;84(2):249–52.

Refractory head and neck pain. A difficult problem and a new alternative therapy [editorial; comment] Carpenter RL, et al. **Anesthesiology** 1996 Feb;84(2):249–52. Comment on: Anesthesiology 1996 Feb;84(2):256–72.

Prolonged regional nerve blockade. Injectable biodegradable bupivacaine/polyester microspheres. Curley J, et al. **Anesthesiology** 1996 Jun;84(6):1401–10

Influence of timing of administration on the analgesic effect of bupivacaine infiltration in carrageenin–injected rats. Fletcher D, et al. **Anesthesiology** 1996 May;84(5):1129–37

Preemptive analgesia: intraperitoneal local anesthetic in laparoscopic cholecystectomy. A randomized, double–blind, placebo–controlled study. Pasqualucci A, et al. **Anesthesiology** 1996 Jul;85(1):11–20

Prophylactic use of epidural mepivacaine/morphine, systemic diclofenac, and metamizole reduces postoperative morphine consumption after major abdominal surgery. Rockemann MG, et al. **Anesthesiology** 1996 May; 84(5):1027–34

Postoperative analgesia using epidural infusions of fentanyl with bupivacaine. A prospective analysis of 1,014 patients. Scott DA, et al. **Anesthesiology** 1995 Oct;83(4):727–37

Effects of preemptive or postinjury intrathecal local anesthesia on persistent nociceptive responses in rats. Confounding influences of peripheral inflammation and the general anesthetic regimen. Yashpal K, et al. **Anesthesiology** 1996 May;84(5):1119–28

Is one needle better than two? Should anybody care? [letter] Pronchik D, et al. **Ann Emerg Med** 1996 May;27(5):675–6

Preincisional infiltration with bupivacaine in tonsillectomy. Johansen M, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):261–3

Delayed hypersensitivity rash to the knee after injection of arthroscopy portals with bupivacine (Marcaine) [letter; comment] Magsamen BF. **Arthroscopy** 1995 Aug; 11(4):512–3. Comment on: Arthroscopy 1994 Jun;10(3):305–8.

Comparison of intraarticular bupivacaine with the addition of morphine or fentanyl for analgesia after arthroscopic surgery. Uysalel A, et al. **Arthroscopy** 1995 Dec;11(6):660–3

Pharmacodynamics of a liposomal preparation for local anaesthesia. Peters H, et al. **Arzneimittelforschung** 1995 Dec;45(12):1253–6

Comparison of i.m. and local infiltration of ketorolac with and without local anaesthetic. Ben–David B, et al. **Br J Anaesth** 1995 Oct;75(4):409–12

Biodistribution of liposome–associated bupivacaine after extradural administration to rabbits. Boogaerts JG, et al. **Br J Anaesth** 1995 Sep;75(3):319–25

Liposomal local anaesthetics [editorial] Duncan L, et al. **Br J Anaesth** 1995 Sep;75(3):260–1

A double–blind comparison of 0.25% ropivacaine and 0.25% bupivacaine for extradural analgesia in labour. Eddleston JM, et al. **Br J Anaesth** 1996 Jan;76(1):66–71

Maximum doses of local anaesthetics [letter; comment] Grange C. **Br J Anaesth** 1995 Oct;75(4):502. Comment on: Br J Anaesth 1995 Jun;74(6):704–5.

Visceral pain during caesarean section: effect of varying dose of spinal amethocaine [see comments] Hirabayashi Y, et al. **Br J Anaesth** 1995 Sep;75(3):266–8. Comment in: Br J Anaesth 1996 Jan;76(1):167.

Continuous extrapleural paravertebral infusion of bupivacaine for post–thoracotomy analgesia in young infants. Karmakar MK, et al. **Br J Anaesth** 1996 Jun;76(6):811–5

A prospective, randomized comparison of interpleural and paravertebral analgesia in thoracic surgery. Richardson J, et al. **Br J Anaesth** 1995 Oct;75(4):405–8

Postoperative analgesia by continuous extradural infusion of ropivacaine after upper abdominal surgery. Schug SA, et al. **Br J Anaesth** 1996 Apr;76(4):487–91

Maximum dose of lignocaine for brachial plexus block [letter; comment] Sun KO. **Br J Anaesth** 1995 Dec;75(6):823–4. Comment on: Br J Anaesth 1995 Jun;74(6):704–5.

Transcervical analgesia for laparoscopic sterilisation. Hunter A, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):378–80

An assessment of the value of intraperitoneal bupivacaine for analgesia after laparoscopic sterilisation. Kelly MC. **Br J Obstet Gynaecol** 1996 Aug;103(8):837–9

Intraocular pressure changes after peribulbar injections with and without ocular compression. Bowman R, et al. **Br J Ophthalmol** 1996 May;80(5):394–7

Urodynamic changes during therapeutic intravesical instillations of capsaicin. Chandiramani VA, et al. **Br J Urol** 1996 Jun;77(6):792–7

Urethral anaesthesia with topical bupivacaine. A role for a longer–acting agent. Dawkins GP, et al. **Br J Urol** 1995

Oct;76(4):484–7
Continuous epidural infusion of ropivacaine for the prevention of postoperative pain after major orthopaedic surgery: a dose–finding study. Badner NH, et al. **Can J Anaesth** 1996 Jan;43(1):17–22
A double–blind comparison of ropivacaine 0.5%, 0.75%, 1.0% and bupivacaine 0.5%, injected epidurally, in patients undergoing abdominal hysterectomy. Finucane BT, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):442–9
Hypobaric spinal anaesthesia with bupivacaine (0.1%) gives selective sensory block for ano–rectal surgery. Maroof M, et al. **Can J Anaesth** 1995 Aug;42(8):691–4
Intrathecal fentanyl prolongs sensory bupivacaine spinal block. Singh H, et al. **Can J Anaesth** 1995 Nov; 42(11):987–91
Continuous caudal anaesthesia with chloroprocaine as an adjunct to general anaesthesia in neonates. Tobias JD, et al. **Can J Anaesth** 1996 Jan;43(1):69–72
The efficacy of topical corneal anesthesia with 0.5% bupivacaine eyedrops. Carruthers JD, et al. **Can J Ophthalmol** 1995 Aug;30(5):264–6
Retrobulbar anesthesia with 7.5 vs. 0.75 IU/mL of hyaluronidase. DeBroff BM, et al. **Can J Ophthalmol** 1995 Aug;30(5):262–4
Peribulbar injection of bupivacaine for the control of pain and nausea in vitreoretinal surgery. Maberley DA, et al. **Can J Ophthalmol** 1995 Oct;30(6):317–9
New vascular sheath for subcutaneous drug administration: design, animal testing, and clinical application for pain prevention after angioplasty. Lambert CR, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):68–72
Continuous epidural infusion of local anesthetics and shorter duration of acute zoster–associated pain. Manabe H, et al. **Clin J Pain** 1995 Sep;11(3):220–8
Lignocaine with adrenaline: is it as effective as cocaine in rhinological practice? Kasemsuwan L, et al. **Clin Otolaryngol** 1996 Apr;21(2):127–9
Iatrogenic outbreak of M. chelonae skin abscesses. Camargo D, et al. **Epidemiol Infect** 1996 Aug;117(1):113–9
Peribulbar anaesthesia: the role of local anaesthetic volumes and Thiomucase in motor block and intraocular pressure. Ortiz M, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):603–7
Randomised trial of topical versus sub–Tenon's local anaesthesia for small–incision cataract surgery. Manners TD, et al. **Eye** 1996;10 (Pt 3):367–70
Pain control in abortion. Wiebe ER, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):41–6
Eutectic lidocaine/prilocaine 5% cream and patch may provide satisfactory analgesia for excisional biopsy or curettage with electrosurgery of cutaneous lesions. A randomized, controlled, parallel group study. Gupta AK, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):419–23
Assessing the duration of mandibular soft tissue anesthesia. Hersh EV, et al. **J Am Dent Assoc** 1995 Nov;126(11):1531–6
Intra–articular injection of bupivacaine in knee–replacement operations. Results of use for analgesia and for preemptive blockade. Badner NH, et al. **J Bone Joint Surg Am** 1996 May;78(5):734–8
Pain outcomes after thoracotomy: lumbar epidural hydromorphone versus intrapleural bupivacaine. Gaeta RR, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):534–7
Lidocaine and the inhibition of postoperative pain in coronary artery bypass patients. Insler SR, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):541–6
Topical anesthesia in patients with communication deficits [letter] Bernstein RM. **J Cataract Refract Surg** 1995 Sep; 21(5):487–8
Delivery of topical anesthesia [letter; comment] Claoué C. **J Cataract Refract Surg** 1996 Mar;22(2):155–6. Comment on: J Cataract Refract Surg 1995 Sep;21(5):499–503.
Drop, then decide approach to topical anesthesia [see comments] Dinsmore SC. **J Cataract Refract Surg** 1995 Nov;21(6):666–71. Comment in: J Cataract Refract Surg 1996 Mar;22(2):156–8.
Topical anesthesia for phacoemulsification: initial 20–case series with one month follow–up. Novak KD, et al. **J Cataract Refract Surg** 1995 Nov;21(6):672–5
Topical versus peribulbar anesthesia in clear corneal cataract surgery. Zehetmayer M, et al. **J Cataract Refract Surg** 1996 May;22(4):480–4
Blunt needle infusion of local anesthetics or narcotic analgesics into operative wounds or joints. Rozencwaig R, et al. **J La State Med Soc** 1995 Nov;147(11):516–7
Intraperitoneal local anesthetic after laparoscopic cholecystectomy [letter] Mack P. **J Laparoendosc Surg** 1995 Oct;5(5):343–4
Evaluation of topical viscous 2% lidocaine jelly as an adjunct during the management of alveolar osteitis. Betts NJ, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1140–4
Local anaesthetic on Filshie clips [letter; comment] Brandon HA, et al. **Lancet** 1995 Oct 14;346(8981):1033; discussion 1033–4. Comment on: Lancet 1995 Jul 8;346(8967):82–5.
Local anaesthetic on Filshie clips [letter; comment] Broome SC, et al. **Lancet** 1995 Oct 14;346(8981):1032–3; discussion 1033–4. Comment on: Lancet 1995 Jul 8;346(8967):82–5.
Local anaesthetic on Filshie clips [letter; comment] Goodman NW. **Lancet** 1995 Oct 14;346(8981):1033; discussion 1033–4 . Comment on: Lancet 1995 Jul 8;346(8967):82–5.
Limbal sub–Tenon's administration of retrobulbar anesthesia using a blunt irrigating cannula. Bergman L, et al. **Ophthalmic Surg Lasers** 1996 Feb;27(2):106–12
Retrobulbar anesthesia with a flexible catheter. Dantas PE, et al. **Ophthalmic Surg Lasers** 1996 Apr;27(4):275–8
A comparison of topical and retrobulbar anesthesia for cataract surgery. Patel BC, et al. **Ophthalmology** 1996 Aug; 103(8):1196–203
The effect of solution temperature on the pain of peribulbar anesthesia. Ursell PG, et al. **Ophthalmology** 1996 May; 103(5):839–41
Total spinal anaesthesia following caudal block with bupivacaine and buprenorphine. Afshan G, et al. **Paediatr Anaesth** 1996;6(3):239–42
New regimen for interpleural block in children. Giaufré E, et al. **Paediatr Anaesth** 1995;5(2):125–8
The effect of ketorolac as an adjuvant to local anaesthetic infiltration for analgesia in paediatric umbilical hernia surgery. Graham SG, et al. **Paediatr Anaesth** 1995; 5(3):161–3
The safety of continuous pleural lignocaine after thoracotomy in children and adolescents. Stayer SA, et al. **Paediatr Anaesth** 1995;5(5):307–10
Anaesthetic management of the child with myotonic dystrophy: epidural anaesthesia as an alternative to general anaesthesia. Tobias JD. **Paediatr Anaesth** 1995;5(5):335–8
Comments on Jaffe and Rowe [letter; comment] Sotgiu ML, et al. **Pain** 1995 Aug;62(2):250–1. Comment on: Pain 1995 Feb;60(2):167–74.
Topical ophthalmic anaesthesia for severe facial pain due to recurrent head and neck carcinoma [letter] Blackwell N, et al. **Palliat Med** 1995 Jul;9(3):255–6
Preparation and stability testing of a hydrogel for topical analgesia. Nortier YL, et al. **Pharm World Sci** 1995 Nov 24;17(6):214–7
Microemulsions containing local anaesthetics. Part 6: Influence of microemulsion vehicle on in vivo effect of pentacaine. Zabka M, et al. **Pharmazie** 1995 Oct; 50(10):703–4
Alkalinization of local anesthetics. Which block, which local anesthetic? Capogna G, et al. **Reg Anesth** 1995 Sep–Oct; 20(5):369–77
Pain relief for thoracotomy. Comparison of morphine requirements using an extrapleural infusion of bupivacaine. Carabine UA, et al. **Reg Anesth** 1995 Sep–Oct;20(5):412–7
Hyperosmolarity does not contribute to transient radicular irritation after spinal anesthesia with hyperbaric 5% lidocaine. Hampl KF, et al. **Reg Anesth** 1995 Sep–Oct; 20(5):363–8
Ultrasound imaging for stellate ganglion block: direct visualization of puncture site and local anesthetic spread. A pilot study. Kapral S, et al. **Reg Anesth** 1995 Jul–Aug; 20(4):323–8
Spinal analgesia during labor with low–dose bupivacaine, sufentanil, and epinephrine. A comparison with epidural analgesia. Kartawiadi L, et al. **Reg Anesth** 1996 May–Jun; 21(3):191–6
Epinephrine prolongs duration of subcutaneous infiltration of local anesthesia in a dose–related manner. Correlation with magnitude of vasoconstriction. Liu S, et al. **Reg Anesth** 1995 Sep–Oct;20(5):378–84
Subarachnoid fentanyl augments lidocaine spinal anesthesia for cesarean delivery. Palmer CM, et al. **Reg Anesth** 1995 Sep–Oct;20(5):389–94
0.1% bupivacaine does not reduce the requirement for epidural fentanyl infusion after major abdominal surgery. Salomäki TE, et al. **Reg Anesth** 1995 Sep–Oct;20(5):435–43
Influence of baricity on the outcome of spinal anesthesia with bupivacaine for lumbar spine surgery. Tetzlaff JE, et al. **Reg Anesth** 1995 Nov–Dec;20(6):533–7
Interpleural block for acute combined cervical and thoracic herpes zoster [letter] Thwaites BK, et al. **Reg Anesth** 1995 May–Jun;20(3):255–6
Spinal anesthesia. Volume or concentration––what matters? Van Zundert AA, et al. **Reg Anesth** 1996 Mar–Apr; 21(2):112–8
Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Sörensen J, et al. **Scand J Rheumatol** 1995;24(6):360–5
Bupivicaine arthrography of the post–arthroplasty hip. Braunstein EM, et al. **Skeletal Radiol** 1995 Oct;24(7):519–21
A double–blinded evaluation of intraperitoneal bupivacaine vs saline for the reduction of postoperative pain and nausea after laparoscopic cholecystectomy. Szem JW, et al. **Surg Endosc** 1996 Jan;10(1):44–8
[Intrathecal administration of morphine and bupivacaine in the treatment of severe pain in chronic pancreatitis] Verheijen R, et al. **Ned Tijdschr Geneeskd** 1996 Jul 6; 140(27):1410–2 (Eng. Abstr.) **(Dut)**
[Voluminous inguinal hernias can also be treated under local anesthesia] Chiotasso P, et al. **Ann Chir** 1995;49(10):936–40 (Eng. Abstr.) **(Fre)**
[Use of EMLA cream in premature and full–term newborn infants. Study of efficacy and tolerance] Gourrier E, et al. **Arch Pediatr** 1995 Nov;2(11):1041–6 (Eng. Abstr.) **(Fre)**
[New routes for infiltration: surgical wound infiltration] Bouaziz H, et al. **Cah Anesthesiol** 1995;43(3):273–5 (Eng. Abstr.) **(Fre)**
[New routes for infiltration: intraperitoneal injections] Narchi P. **Cah Anesthesiol** 1995;43(3):267–72 (Eng. Abstr.) **(Fre)**
[Topical anesthesia for cataract surgery in adults] Lebuisson DA, et al. **J Fr Ophtalmol** 1996;19(3):181–9 (Eng. Abstr.) **(Fre)**
[Antipruritic effect of antihistaminic and local anesthetic topical agents after iontophoretic histamine stimulation] Weisshaar E, et al. **Hautarzt** 1996 May;47(5):355–60 (Eng. Abstr.) **(Ger)**
[Evaluation of postoperative pain in spinal surgery––usefulness of the administration of local anesthetics into the peridural cavity] Hashimoto K, et al. **Masui** 1996 May;45(5):634–7 (Eng. Abstr.) **(Jpn)**
[Subarachnoid administration of lidocaine reduces delayed neuronal damage due to forebrain ischemia in rats] Mizunuma T, et al. **Masui** 1996 Apr;45(4):421–7 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Anaphylactoid skin reactions after intravenous regional anaesthesia using 0.5% prilocaine with or without preservative––a double–blind study. Kajimoto Y, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):782–4
Viability of fat obtained by syringe suction lipectomy: effects of local anesthesia with lidocaine. Moore JH Jr, et al. **Aesthetic Plast Surg** 1995 Jul–Aug;19(4):335–9
Bicarbonate buffering of local anesthetics [letter] Schwab RA, et al. **Am J Emerg Med** 1996 May;14(3):339
Cardiopulmonary arrest after retrobulbar anesthesia in a patient with an orbital roof defect. Weidenthal DT, et al. **Am J Ophthalmol** 1995 Oct;120(4):535–6
Methemoglobinemia associated with prilocaine use in neonatal circumcision. Tse S, et al. **Am J Perinatol** 1995 Sep;12(5):331–2
Back pain––must be the anaesthetic! [letter; comment] Cartwright PD. **Anaesthesia** 1996 Jun;51(6):608–9. Comment on: Anaesthesia 1994 Aug;49(8):700–2. Comment on: Anaesthesia 1996 Feb;51(2):178–81.
Transient radicular irritation after single subarachnoid injection of isobaric 2% lignocaine for spinal anaesthesia [see comments] Hampl KF, et al. **Anaesthesia** 1996 Feb; 51(2):178–81. Comment in: Anaesthesia 1996 Jun;51(6):608–9.
Safety of lignocaine test dose to detect intravenous injection [letter; comment] Miline SE. **Anaesthesia** 1995 Sep; 50(9):830. Comment on: Anaesthesia 1995 Mar;50(3):211–3.
Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine. Salmela L, et al. **Anaesthesia** 1996 Apr;51(4):391–3
Transient neurologic symptoms after spinal anesthesia [letter; comment] Erian R, et al. **Anesth Analg** 1996 Aug; 83(2):437–8. Comment on: Anesth Analg 1995 Dec;81(6):1148–53.
Transient neurologic symptoms after spinal anesthesia [see comments] Hampl KF, et al. **Anesth Analg** 1995 Dec; 81(6):1148–53. Comment in: Anesth Analg 1995 Dec;81(6):1125–8. Comment in: Anesth Analg 1996 Aug;83(2):437–8.
Regional anesthesia and local anesthetic–induced seizures [letter; comment] Stemp LI. **Anesth Analg** 1996 Mar; 82(3):669–70. Comment on: Anesth Analg 1995 Aug;81(2):321–8.
Intrathecal hyperbaric 0.5% tetracaine as a possible cause of transient neurologic toxicity. Sumi M, et al. **Anesth Analg** 1996 May;82(5):1076–7
Prospective study of the incidence of transient radicular irritation in patients undergoing spinal anesthesia. Pollock JE, et al. **Anesthesiology** 1996 Jun;84(6):1361–7
Heated lidocaine [letter; comment] Kapur A. **Ann Emerg Med** 1996 Jul;28(1):104. Comment on: Ann Emerg Med 1995 Dec;26(6):677–81.
Misuse of nonophthalmic and ophthalmic drops due to packaging similarity [letter] Steinemann TL, et al. **Arch Ophthalmol** 1995 Dec;113(12):1578–9
Cocaine and phenylephrine [letter; comment] Noorily SH, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb; 122(2):207–8. Comment on: Arch Otolaryngol Head Neck Surg 1995 Jun;121(6):681–4.
Can injected lignocaine cause allergic contact dermatitis? Bassett IB, et al. **Australas J Dermatol** 1996 Aug; 37(3):155–6
Dangers of cocaine and adrenaline paste. Exceeding the recommended dose may have serious sequelae [letter; comment] [see comments] Burton M, et al. **BMJ** 1995 Oct 21;311(7012):1089. Comment on: BMJ 1995 Jul 22;311(6999):250–1. Comment in: BMJ 1996 Feb 10;312(7027):381.
Dangers of cocaine and adrenaline paste. Other aspects of anaesthetic technique may have added to danger [letter; comment] [see comments] Ellis PD, et al. **BMJ** 1995 Oct 21;311(7012):1089–90. Comment on: BMJ 1995 Jul 22;311(6999):250–1. Comment in: BMJ 1996 Feb 10;312(7027):381.
Dangers of cocaine and adrenaline paste. Combination is still widely used [letter; comment] Farrell RW. **BMJ** 1995 Oct 21;311(7012):1089. Comment on: BMJ 1995 Jul 22;311(6999):250–1.
Long term backache after childbirth: prospective search for causative factors. Russell R, et al. **BMJ** 1996 Jun 1; 312(7043):1384–8
Dangers of cocaine and adrenaline paste. Accurate measurement of dose and patience are important [letter; comment] [see comments] Williamson P, et al. **BMJ** 1995 Oct 21;311(7012):1089. Comment on: BMJ 1995 Jul 22;311(6999):250–1. Comment in: BMJ 1996 Feb 10;312(7027):381.
Inferior dental block injection [letter] Chaudry Z, et al. **Br Dent J** 1996 Jan 20;180(2):52
Spinal clonidine produces less urinary retention than spinal

morphine. Gentili M, et al. **Br J Anaesth** 1996 Jun; 76(6):872–3

Bilateral severe pain at L3–4 after spinal anaesthesia with hyperbaric 5% lignocaine. Rodríguez–Chinchilla R, et al. **Br J Anaesth** 1996 Feb;76(2):328–9

Neurotoxicity of 5% lignocaine [letter] Strichartz GR, et al. **Br J Anaesth** 1995 Sep;75(3):376

Cognitive failures after general anaesthesia for day–case surgery. Tzabar Y, et al. **Br J Anaesth** 1996 Feb;76(2):194–7

Temporary back and leg pain after bupivacaine and morphine spinal anaesthesia. Ong B, et al. **Can J Anaesth** 1995 Sep; 42(9):805–7

Delayed recovery after spinal anaesthesia using 0.5% cinchocaine. Nirmalan M, et al. **Ceylon Med J** 1995 Sep; 40(3):118–9

Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil–active cytokines. Ohnishi T, et al. **Clin Exp Immunol** 1996 May;104(2):325–31

Allergic contact dermatitis and systemic contact dermatitis from cinchocaine. Marques C, et al. **Contact Dermatitis** 1995 Dec;33(6):443

Sensitization to benzocaine on a condom. Placucci F, et al. **Contact Dermatitis** 1996 Apr;34(4):293

Ambulatory phlebectomy. A rare complication of local anesthetic: case report and literature review. Olivencia JA. **Dermatol Surg** 1996 Jan;22(1):53–5 (15 ref.)

Coronary artery spasm induced under lumbar epidural anaesthesia. Hoka S, et al. **Eur J Anaesthesiol** 1995 Nov; 12(6):609–12

Alkaline chemical ocular injury from Emla cream [letter] Brahma AK, et al. **Eye** 1995;9 (Pt 5):658–9

Topical upper airway anaesthesia with lidocaine increases airway resistance by impairing glottic function. Beydon L, et al. **Intensive Care Med** 1995 Nov;21(11):920–6

Adverse reactions to local anesthetics: analysis of 197 cases. Gall H, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):933–7 (20 ref.)

Bowel function recovery after radical hysterectomies: thoracic epidural bupivacaine–morphine versus intravenous patient–controlled analgesia with morphine: a pilot study. de Leon–Casasola OA, et al. **J Clin Anesth** 1996 Mar; 8(2):87–92

Local anesthesia infiltration as a cause of intraoperative tension pneumothorax in a young healthy woman undergoing breast augmentation with general anesthesia. Kaye AD, et al. **J Clin Anesth** 1995 Aug;7(5):422–4

Localized reactions to injected therapeutic materials. Part 2. Surgical agents. Morgan AM. **J Cutan Pathol** 1995 Aug; 22(4):289–303 (65 ref.)

The effect of temperature on the discomfort caused by topical local anaesthesia. Callear AB. **J R Soc Med** 1995 Dec; 88(12):709p–11p

Corneal anesthetic abuse and Candida keratitis. Chern KC, et al. **Ophthalmology** 1996 Jan;103(1):37–40

Vertical strabismus after local anesthesia [letter; comment] Tejedor J, et al. **Ophthalmology** 1996 Apr;103(4):545–6. Comment on: Ophthalmology 1995 Mar;102(3):501–9.

Methemoglobinemia in a renal transplant patient: case report. Hardwick FK, et al. **Pediatr Dent** 1995 Nov–Dec; 17(7):460–3

Unintentional combined epidural and subdural block. Case report. Chauhan S, et al. **Reg Anesth** 1995 May–Jun; 20(3):249–51

1995 Gaston Labat Lecture. Ropivacaine. White knight or dark horse? de Jong RH. **Reg Anesth** 1995 Nov–Dec; 20(6):474–81 (37 ref.)

Ketamine anaesthesia for electrocochleography in children. Are psychic side effects really rare? Valentin N, et al. **Scand Audiol** 1996;25(1):39–43

[Risk of methemoglobinemia after Emla application in premature infants (letter; comment)] Gourrier E, et al. **Arch Pediatr** 1995 Oct;2(10):1021–2. Comment on: Arch Pediatr 1995 Mar;2(3):291–2. **(Fre)**

[Cutaneous problems after application of EMLA in premature infants (letter)] Gourrier E, et al. **Arch Pediatr** 1996 Mar;3(3):289–90 **(Fre)**

[The use of pulse oximetry in prilocaine induced methemoglobinemia] Rudlof B, et al. **Anaesthesist** 1995 Dec;44(12):887–91 (Eng. Abstr.) **(Ger)**

[Transient complete left bundle branch block during epidural anesthesia with mepivacaine] Asao Y, et al. **Masui** 1996 Apr;45(4):483–6 (Eng. Abstr.) **(Jpn)**

[Intradural anesthesia in cesarean sections (letter; comment)] de la Cruz Pérez CA. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):351–2. Comment on: Rev Esp Anestesiol Reanim 1994 Jul–Aug;41(4):217–20. **(Spa)**

ANALYSIS

Stability of epinephrine hydrochloride in an extemporaneously compounded topical anesthetic solution of lidocaine, racepinephrine, and tetracaine. Larson TA, et al. **Am J Health Syst Pharm** 1996 Mar 15;53(6):659–62

Development and validation of chromatographic methods (HPLC and GC) for the determination of the active components (benzocaine, tyrothricin and menthol) of a pharmaceutical preparation. Ortiz–Boyer F, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1297–303

BLOOD

Lidocaine plasma concentrations in pediatric patients after providing airway topical anesthesia from a calibrated device. Sitbon P, et al. **Anesth Analg** 1996 May;82(5):1003–6

Effects of adrenaline and hyaluronidase on plasma concentrations of lignocaine and bupivacaine after peribulbar anaesthesia. Barr J, et al. **Br J Anaesth** 1995 Dec;75(6):692–7

Smaller children have greater bupivacaine plasma concentrations after ilioinguinal block. Smith T, et al. **Br J Anaesth** 1996 Mar;76(3):452–5

Perioperative changes in alpha 1–acid glycoprotein concentrations [letter; comment] Tucker GT. **Br J Anaesth** 1996 Jul;77(1):130. Comment on: Br J Anaesth 1996 Mar;76(3):365–8.

Regulatory significance of procaine residues in plasma and urine samples: preliminary communication. Harkins JD, et al. **Equine Vet J** 1996 Mar;28(2):121–5

Serum lidocaine and MEGX concentrations after pharyngeal anesthesia for gastroscopy. Gandolfi L. **Gastrointest Endosc** 1995 Sep;42(3):282–3

Determination of benzocaine in rainbow trout plasma. Bernardy JA, et al. **J AOAC Int** 1996 May–Jun;79(3):623–7

Determination of free concentration of ropivacaine and bupivacaine in blood plasma by ultrafiltration and coupled–column liquid chromatography. Arvidsson T, et al. **J Chromatogr B Biomed Appl** 1995 Jun 9;668(1):91–8

Spinal anaesthesia in newborns: total and free bupivacaine plasma concentration. Beauvoir C, et al. **Paediatr Anaesth** 1996;6(3):195–9

Development of a HPLC–system for quantitative measurement of lidocaine and bupivacaine in patients plasma during postoperative epidural pain therapy. Sattler A, et al. **Pharmazie** 1995 Nov;50(11):741–4

Lidocaine levels in suction–assisted lipectomy [letter] Yrausquin E. **Plast Reconstr Surg** 1996 Sep;98(4):753

Simultaneous determination of lidocaine, bupivacaine, and their two main metabolites using gas chromatography and a nitrogen–phosphorus detector: selection of stationary phase and chromatographic conditions [letter] Demedts P, et al. **Ther Drug Monit** 1996 Apr;18(2):208–9

[The plasma concentration measurement of local anesthetics, thiobarbiturates and mexiletine by HPLC with automatic pre–treatment system] Kakinohana O, et al. **Masui** 1995 Aug;44(8):1165–70 (Eng. Abstr.) **(Jpn)**

CEREBROSPINAL FLUID

Reducing the potential morbidity of an unintentional spinal anaesthetic by aspirating cerebrospinal fluid. Southorn P, et al. **Br J Anaesth** 1996 Mar;76(3):467–9

CHEMICAL SYNTHESIS

Quaternary ammonium derivative of lidocaine as a long–acting local anesthetic [see comments] Wang GK, et al. **Anesthesiology** 1995 Dec;83(6):1293–301. Comment in: Anesthesiology 1996 Jul;85(1):226–7.

Synthesis of esters of aliphatic and aromatic carbamic acids. A comparative study of properties and local anesthetic activity of these compounds. Gregán F, et al. **Boll Chim Farm** 1995 Sep;134(8):454–8

Synthesis and local anesthetic activity of two homological series of diastereomeric phenylcarbamates. Gregáň F, et al. **Farmaco** 1995 Dec;50(12):829–39

Effect of local anesthetic [2–(alkyloxy)phenyl]–2–(1–piperidinyl)ethyl esters of carbamic acid on the activity of purified sarcoplasmic reticulum (Ca–Mg)ATPase. Andriamainty F, et al. **Pharmazie** 1996 Apr;51(4):242–5

Preparation, local anaesthetic and antiarrhythmic activity of pyrrolidinomethylcyclohexyl esters of alkoxysubstituted phenylcarbamic acids. Bučiová L, et al. **Pharmazie** 1995 Aug;50(8):566–7

CHEMISTRY

Study of the influence of the auxiliary substances on the surface tension of the aqueous solutions of some substituted phenylcarbamic acid derivatives. Vitková Z, et al. **Acta Pharm Hung** 1995 Sep;65(5):143–5

Stability of bupivacaine hydrochloride and hydromorphone hydrochloride during simulated epidural coadministration. Christen C, et al. **Am J Health Syst Pharm** 1996 Jan 15; 53(2):170–3

Tolperisone: evaluation of the lidocaine–like activity by molecular modeling. Fels G. **Arch Pharm (Weinheim)** 1996 Apr;329(4):171–8

Alkalinization of lidocaine 2% does not influence the quality of epidural anaesthesia for elective caesarean section. Gaggero G, et al. **Can J Anaesth** 1995 Dec;42(12):1080–4

Alkalinization of local anaesthetics [editorial] Morison DH. **Can J Anaesth** 1995 Dec;42(12):1076–9 **(Eng, Fre)**

Isolation and characterization of two major degradation products of dyclonine hydrochloride. Liang CY, et al. **J Pharm Sci** 1995 Sep;84(9):1141–3

Preparation and stability testing of a hydrogel for topical analgesia [letter] Boer Y. **Pharm World Sci** 1996 Apr; 18(2):85

Preparation and stability testing of a hydrogel for topical analgesia. Nortier YL, et al. **Pharm World Sci** 1995 Nov 24;17(6):214–7

Alkalinization of local anesthetics. Which block, which local anesthetic? Capogna G, et al. **Reg Anesth** 1995 Sep–Oct; 20(5):369–77

Failure of the thiopental precipitation test to detect cerebrospinal fluid after dural puncture with current epidural solutions for labor analgesia [letter] Lowenwirt I, et al. **Reg Anesth** 1995 Sep–Oct;20(5):459–60

[Changing compatibility by temperature of local anesthetics with sodium bicarbonate] Koitabashi T, et al. **Masui** 1996 Mar;45(3):313–6 (Eng. Abstr.) **(Jpn)**

[Interactions of surfactants with model and biological membranes. XXII. Spectrophotometric determination of partition coefficient of heptacaine, a local anesthetic, between the phospholipid liposome and water phase] Hammel M, et al. **Ceska Slov Farm** 1996 Mar;45(2):58–66 (Eng. Abstr.) **(Slo)**

DIAGNOSTIC USE

Fluorescein as an easy, low–cost, indirect, or reverse intraoperative marker to rule out perilymph versus local injection. Arenberg IK, et al. **Am J Otol** 1996 Mar; 17(2):259–62

Local anesthetic test dose to predict effective epidural opioid analgesia: II [letter; comment] Kempen PM. **Anesthesiology** 1996 Feb;84(2):487–8; discussion 489. Comment on: Anesthesiology 1995 Jul;83(1):96–100.

Local anesthetic test dose to predict effective epidural opioid analgesia: III [letter; comment] Pavy TJ, et al. **Anesthesiology** 1996 Feb;84(2):488–9. Comment on: Anesthesiology 1995 Jul;83(1):96–100.

Local anesthetic test dose to predict effective epidural opioid analgesia: I [letter; comment] Stevens RA, et al. **Anesthesiology** 1996 Feb;84(2):486–7; discussion 489. Comment on: Anesthesiology 1995 Jul;83(1):96–100.

The utility of comparative local anesthetic blocks versus placebo–controlled blocks for the diagnosis of cervical zygapophysial joint pain. Lord SM, et al. **Clin J Pain** 1995 Sep;11(3):208–13

ECONOMICS

Local anaesthesia in flexible nasendoscopy. A comparison between cocaine and co–phenylcaine. Lennox P, et al. **J Laryngol Otol** 1996 Jun;110(6):540–2

HISTORY

Revisiting ancient times [letter; comment] Nelson MS. **Am J Emerg Med** 1996 Jan;14(1):113. Comment on: Am J Emerg Med 1995 May;13(3):315–7.

Looking back at a century of cocaine––use and abuse. Bailey BJ. **Laryngoscope** 1996 Jun;106(6):681–3

IMMUNOLOGY

Adverse reactions to local anesthetics: analysis of 197 cases. Gall H, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):933–7 (20 ref.)

METABOLISM

Distinct local anesthetic affinities in Na+ channel subtypes. Wang DW, et al. **Biophys J** 1996 Apr;70(4):1700–8

Functional consequences of lidocaine binding to slow–inactivated sodium channels. Balser JR, et al. **J Gen Physiol** 1996 May;107(5):643–58

Binding of bupivacaine to human serum proteins, isolated albumin and isolated alpha–1–acid glycoprotein. Differences between the two enantiomers are partly due to cooperativity. Mazoit JX, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):109–15

Transfer of lidocaine and bupivacaine across the isolated perfused human placenta. Ala–Kokko TI, et al. **Pharmacol Toxicol** 1995 Aug;77(2):142–8

PHARMACOKINETICS

Lung uptake of lidocaine during hyperoxia and hypoxia in the dog. Hasegawa K, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):489–95

Transpulmonary disposition of prilocaine, mepivacaine, and bupivacaine in humans in the course of epidural anaesthesia. Kietzmann D, et al. **Acta Anaesthesiol Scand** 1995 Oct; 39(7):885–90

Bupivacaine disposition and pharmacologic effects after intravenous and epidural administrations in dogs. Franquelo C, et al. **Am J Vet Res** 1995 Aug;56(8):1087–91

Maternal and neonatal fentanyl and bupivacaine concentrations after epidural infusion during labor. Bader AM, et al. **Anesth Analg** 1995 Oct;81(4):829–32

Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers. Emanuelsson BM, et al. **Anesth Analg** 1995 Dec; 81(6):1163–8

The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. Hansdóttir V, et al. **Anesth Analg** 1996 Aug;83(2):401–6

The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade. Nathan N, et al. **Anesth Analg** 1996 May;82(5):1060–4

Pharmacokinetics and analgesic effect of ropivacaine during continuous epidural infusion for postoperative pain relief. Erichsen CJ, et al. **Anesthesiology** 1996 Apr;84(4):834–42

Derivation and cross–validation of pharmacokinetic parameters for computer–controlled infusion of lidocaine in pain therapy. Schnider TW, et al. **Anesthesiology** 1996 May;84(5):1043–50

Cerebrospinal fluid progesterone in pregnant women [see comments] Hirabayashi Y, et al. **Br J Anaesth** 1995 Dec;

75(6):683–7. Comment in: Br J Anaesth 1996 Jun;76(6):886.
Subarachnoid spread of isobaric tetracaine in adolescents [letter; comment] King HK, et al. **Br J Anaesth** 1995 Aug; 75(2):245–6. Comment on: Br J Anaesth 1995 Jan;74(1):41–5.
Effect of digital pressure on the neurovascular sheath during perivascular axillary block. Koschielniak–Nielsen ZJ, et al. **Br J Anaesth** 1995 Dec;75(6):702–6
Interpleural local anaesthesia: anatomical basis for mechanism of action. McKenzie AG, et al. **Br J Anaesth** 1996 Feb; 76(2):297–9
Extensive extradural spread in the elderly may not relate to decreased leakage through intervertebral foramina. Saitoh K, et al. **Br J Anaesth** 1995 Dec;75(6):688–91
Application of saliva for drug monitoring. An in vivo model for transmembrane transport. Haeckel R, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):171–91 (179 ref.)
Serum lidocaine concentrations after subcutaneous administration in patients undergoing cardiac catheterization in a pediatric institution. Cassidy SC, et al. **J Pediatr** 1996 Sep;129(3):464–6
Pharmacokinetics of bupivacaine enantiomers in sheep: influence of dosage regimen and study design. Mather LE, et al. **J Pharmacokinet Biopharm** 1994 Dec;22(6):481–98
Lidocaine elimination and monoethylglycinexylidide formation in the dehydrated camel. Ben–Zvi Z, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):442–5
The pharmacokinetics of bupivacaine following interpleural nerve block in infants of very low birthweight. Weston PJ, et al. **Paediatr Anaesth** 1995;5(4):219–22
Epidural diamorphine and bupivacaine stability study. Kreeger L, et al. **Palliat Med** 1995 Oct;9(4):315–8
Pharmacokinetics of lignocaine in Icelandic horses after infiltration anaesthesia. Kristinsson J, et al. **Vet Rec** 1996 Feb 3;138(5):111–2
[Feasibility assessment of skin permeation for the local anesthetic lidocaine] Cheng YH, et al. **Yao Hsueh Hsueh Pao** 1995;30(8):615–20 (Eng. Abstr.) **(Chi)**
[Changes in the pharmacokinetics of trimecaine in patients with liver cirrhosis] Perlík F, et al. **Sb Lek** 1991; 93(9–10):287–92 (Eng. Abstr.) **(Cze)**
Phonophoretic permeation of procaine hydrochloride through an MDCK cell monolayer Hehn B, et al. **Pharmazie** 1996 May;51(5):341–5 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Post–surgery epidural blockade with local anaesthetics attenuates the catecholamine and thermogenic response to perioperative hypothermia. Carli F, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1041–7
Comparison of vascular effects of ropivacaine and lidocaine on isolated rings of human arteries. Gherardini G, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):765–8
Pharmacodynamics of subarachnoid hyperbaric 5% lignocaine. Jones RD, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):350–7
An antiinflammatory effect of lidocaine? [editorial; comment] Lisander B. **Acta Anaesthesiol Scand** 1996 Mar;40(3):285–6 . Comment on: Acta Anaesthesiol Scand 1996 Mar;40(3):287–92.
Purine metabolite washout and platelet aggregation at reflow after tourniquet ischemia: effect of intravenous regional lidocaine. Naesh O, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1053–8
The effect of continuous epidural infusion of ropivacaine (0.1%, 0.2% and 0.3%) on nerve conduction velocity and postural control in volunteers. Zaric D, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):342–9
Effect of lidocaine injection of EOAE in patients with tinnitus. Haginomori S, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):488–92
Effects of intramuscular or interpleural administration of morphine and interpleural administration of bupivacaine on pulmonary function in dogs that have undergone median sternotomy. Dhokarikar P, et al. **Am J Vet Res** 1996 Mar; 57(3):375–80
Evaluation of pulmonary function and analgesia in dogs after intercostal thoracotomy and use of morphine administered intramuscularly or intrapleurally and bupivacaine administered intrapleurally. Stobie D, et al. **Am J Vet Res** 1995 Aug;56(8):1098–109
The effect of alkalinisation of lignocaine on axillary brachial plexus anaesthesia. Gormley WP, et al. **Anaesthesia** 1996 Feb;51(2):185–8
Gastric intramucosal pH [letter] Male DA, et al. **Anaesthesia** 1996 Jul;51(7):711
Effects of topical benzocaine and lignocaine on upper airway reflex sensitivity. Raphael JH, et al. **Anaesthesia** 1996 Feb; 51(2):114–8
Effect of bupivacaine–induced spinal block on the hypnotic requirement of propofol. Tverskoy M, et al. **Anaesthesia** 1996 Jul;51(7):652–3
Comparative electrophysiologic and hemodynamic effects of several amide local anesthetic drugs in anesthetized dogs. Bruelle P, et al. **Anesth Analg** 1996 Mar;82(3):648–56
Mechanisms of local anesthetic action [letter; comment] Butterworth J 4th. **Anesth Analg** 1996 Mar;82(3):673–4. Comment on: Anesth Analg 1995 Sep;81(3):480–5.
Intravenous lidocaine does not attenuate the cardiovascular and catecholamine response to a rapid increase in desflurane concentration. Gormley WP, et al. **Anesth Analg** 1996 Feb;82(2):358–61
The effect of thoracic epidural anesthesia on hypoxic pulmonary vasoconstriction in dogs: an analysis of the pressure–flow curve. Ishibe Y, et al. **Anesth Analg** 1996 May;82(5):1049–55
Spinal cord blood flow after intrathecal injection of ropivacaine: a screening for neurotoxic effects. Kristensen JD, et al. **Anesth Analg** 1996 Mar;82(3):636–40
Spinal anesthesia by local anesthetics stimulates the enzyme protein kinase C and induces the expression of an immediate early oncogene, c–Fos. Nivarthi RN, et al. **Anesth Analg** 1996 Sep;83(3):542–7
Mechanism of action of an epidural top–up in combined spinal epidural anesthesia. Stienstra R, et al. **Anesth Analg** 1996 Aug;83(2):382–6
Intravenous lidocaine and bupivacaine dose–dependently attenuate bronchial hyperreactivity in awake volunteers. Groeben H, et al. **Anesthesiology** 1996 Mar;84(3):533–9
New local anesthetic agents [letter; comment] Gyermek L. **Anesthesiology** 1996 Jul;85(1):226–7. Comment on: Anesthesiology 1995 Dec;83(6):1293–301.
Differential nerve block. Direct measurements on individual myelinated and unmyelinated dorsal root axons. Jaffe RA, et al. **Anesthesiology** 1996 Jun;84(6):1455–64
Tolperisone: evaluation of the lidocaine–like activity by molecular modeling. Fels G. **Arch Pharm (Weinheim)** 1996 Apr;329(4):171–8
Interaction of alkanols and local anesthetics with spin–labeled Ca(2+)–ATPase of sarcoplasmic reticulum vesicles. Anteneodo C, et al. **Biochim Biophys Acta** 1996 Jun 11; 1281(2):150–6
Use of a novel method for determination of partition coefficients to compare the effect of local anesthetics on membrane structure. de Paula E, et al. **Biochim Biophys Acta** 1995 Nov 22;1240(1):25–33
Use–dependent inhibition of Na+ currents by benzocaine homologs. Quan C, et al. **Biophys J** 1996 Jan;70(1):194–201
Distinct local anesthetic affinities in Na+ channel subtypes. Wang DW, et al. **Biophys J** 1996 Apr;70(4):1700–8
Synthesis of esters of aliphatic and aromatic carbamic acids. A comparative study of properties and local anesthetic activity of these compounds. Gregán F, et al. **Boll Chim Farm** 1995 Sep;134(8):454–8
Effect of i.v. lignocaine on the breathing of patients anaesthetized with propofol. Goodman NW, et al. **Br J Anaesth** 1995 Nov;75(5):573–7
Hormonal effects of thoracic extradural analgesia for cardiac surgery. Moore CM, et al. **Br J Anaesth** 1995 Oct; 75(4):387–93
Haemostatic changes caused by i.v. regional anaesthesia with lignocaine. Niemi TT, et al. **Br J Anaesth** 1996 Jun; 76(6):822–8
Interaction of extradural morphine and lignocaine on ventilatory response [see comments] Saito Y, et al. **Br J Anaesth** 1995 Oct;75(4):394–8. Comment in: Br J Anaesth 1996 May;76(5):747–8.
Intradermal actions of hypertonic saline involve neural and vascular mechanisms. Sharara AM, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):98–100
Nitric oxide as a mediator of cocaine–induced penile erection in the rat. Chan JY, et al. **Br J Pharmacol** 1996 May; 118(1):155–61
A comparison of the haemodynamic effects of intrathecal meperidine, meperidine–bupivacaine mixture and hyperbaric bupivacaine. Conway F, et al. **Can J Anaesth** 1996 Jan;43(1):23–9
Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes. Valenzuela C, et al. **Circulation** 1995 Nov 15;92(10):3014–24
The effects of lidocaine and bupivacaine on the rabbit retina. Zemel E, et al. **Doc Ophthalmol** 1995;90(2):189–99
Determination of highest no effect dose (HNED) for local anaesthetic responses to procaine, cocaine, bupivacaine and benzocaine. Harkins JD, et al. **Equine Vet J** 1996 Jan; 28(1):30–7
Onset time of topical analgesia with EMLA 5%: no reduction with glyceryl trinitrate. Nott MR, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):17–20
Attenuation of the oculocardiac reflex after topically applied lignocaine during surgery for strabismus in children. Ruta U, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):11–5
Opioids in combination with local anesthetics for epidural analgesia during labor. Vertommen JD. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S35–8 (23 ref.)
Local anesthetics reduce the inhibitory neurotransmitter–induced current in dissociated hippocampal neurons of the rat. Hara M, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):83–9
Lidocaine action and conformational changes in cytoskeletal protein network in human red blood cells. Nishiguchi E, et al. **Eur J Pharmacol** 1995 Nov 3;286(1):1–8
Local anesthetic [2–(decyloxy)phenyl]–2–(1–piperidinyl)ethyl ester of carbamic acid perturbs phosphatidylcholine bilayer. Gallová J, et al. **Gen Physiol Biophys** 1995 Feb;14(1):61–5
Superior laryngeal nerve blockade and inspiratory resistive load detection in normal subjects. Fitzpatrick MF, et al. **J Appl Physiol** 1995 Nov;79(5):1567–70
Functional consequences of lidocaine binding to slow–inactivated sodium channels. Balser JR, et al. **J Gen Physiol** 1996 May;107(5):643–58
Acid, basic and neutral soluble and membrane–bound aminopeptidase activities after lidocaine administration in discrete areas of the rat brain. de Gandarias JM, et al. **J Hirnforsch** 1995;36(3):349–52
Cocaine concentration–effect relationship in the presence and absence of lidocaine: evidence of competitive binding between cocaine and lidocaine. Liu D, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):568–77
A rabbit tooth–pulp assay to quantify efficacy and duration of antinociception by local anesthetics infiltrated into maxillary tissues. Thut PD, et al. **J Pharmacol Toxicol Methods** 1995 Aug;33(4):231–6
A review of the pharmacology, pharmacokinetics, and regulatory control in the US of local anaesthetics in the horse. Harkins JD, et al. **J Vet Pharmacol Ther** 1995 Dec; 18(6):397–406 (56 ref.)
Local anaesthesia induces immediate receptive field changes in nucleus gracilis and cortex. Panetsos F, et al. **Neuroreport** 1995 Dec 29;7(1):150–2
Effects of local anaesthesia on formalin–induced Fos expression in the rat dorsal horn. Tokunaga A, et al. **Neuroreport** 1995 Nov 27;6(17):2301–4
Intranasal anesthetic effects of lidocaine and tetracaine compared. Noorily AD, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):370–4
Effects of intrathecal local anesthetics on spinal excitability and on the development of autotomy. Luo L, et al. **Pain** 1995 Nov;63(2):173–9
Formalin–evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase–2 activity. Puig S, et al. **Pain** 1996 Feb;64(2):345–55
Cocaine analgesia: an in vivo structure–activity study. Schuelke GS, et al. **Pharmacol Biochem Behav** 1996 Jan; 53(1):133–40
Synergistic effect of various diastereoisomeric phenylcarbamates with local anaesthetic activities. Gregáň F, et al. **Pharmazie** 1995 Nov;50(11):772–3
Local anesthetic effect of carbisocaine and its enantiomers. Stankovičová T, et al. **Pharmazie** 1995 Sep;50(9):622–3
Local anesthetics enhance nitric oxide production by human peripheral neutrophils. Mamiya K, et al. **Physiol Chem Phys Med NMR** 1995;27(2):111–9
Molecular determinants of drug access to the receptor site for antiarrhythmic drugs in the cardiac Na+ channel. Qu Y, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5; 92(25):11839–43
The response of umbilical vessels, with and without vascular endothelium, to local anesthesia in low PO2 and hypercarbia. Halevy S, et al. **Reg Anesth** 1995 Jul–Aug; 20(4):316–22
Bactericidal activity of clinically used local anesthetics on Staphylococcus aureus. Sakuragi T, et al. **Reg Anesth** 1996 May–Jun;21(3):239–42
Effect of epidural bupivacaine block on midazolam hypnotic requirements. Tverskoy M, et al. **Reg Anesth** 1996 May–Jun;21(3):209–13
[Prevention of increase of blood pressure and intracranial pressure during endotracheal intubation in neurosurgery: esmolol versus lidocaine] Samaha T, et al. **Ann Fr Anesth Reanim** 1996;15(1):36–40 (Eng. Abstr.) **(Fre)**
[Interactions between opioids and local anesthetics at the level of the dorsal horn of the spinal cord] Brasseur L, et al. **Can Anesthesiol** 1995;43(4):363–6 (Eng. Abstr.) **(Fre)**
[Conduction anesthesia and the newborn infant] Palot M, et al. **Can Anesthesiol** 1995;43(6):547–53 (Eng. Abstr.) **(Fre)**
[Alkalinization of local anesthetics: theoretically justified but clinically useless] Chassard D, et al. **Can J Anaesth** 1996 Apr;43(4):384–93 (68 ref.) (Eng. Abstr.) **(Fre)**
[Local anesthetics: indications and complications] De Torrenté G, et al. **Rev Med Suisse Romande** 1996 Jun; 116(6):463–71 **(Fre)**
[Effects of systemic lidocaine, mepivacaine and bupivacaine on passive avoidance learning in mice] Nakai T, et al. **Masui** 1995 Oct;44(10):1356–61 (Eng. Abstr.) **(Jpn)**
[The influence of local anesthetics on human leukocyte functions studied by micro whole blood collection and flowcytometry] Okuno S, et al. **Masui** 1996 Mar; 45(3):317–25 (Eng. Abstr.) **(Jpn)**
[The effects of systemic bupivacaine on baroreflex sensitivity in dogs] Watanabe Y, et al. **Masui** 1995 Aug;44(8):1097–101 (Eng. Abstr.) **(Jpn)**
[The effect of inhibitors of sodium permeability (novocaine and tetrodotoxin) on the trace depolarization of myelinated nerve fibers] Katalymov LL. **Fiziol Zh Im I M Sechenova** 1995 Sep;81(9):127–33 (Eng. Abstr.) **(Rus)**
[Use of benzofurocaine in stimulation of regenerative processes in the surgical treatment of patients with chronic suppurative otitis media] Semenov FV, et al. **Vestn Otorinolaringol** 1996 Mar–Apr;(2):45–8 (Eng. Abstr.) **(Rus)**
[The reflex and direct actions of novocaine on the rhythm of the heart beats in rats in early postnatal ontogeny] Kulaev BS, et al. **Zh Evol Biokhim Fiziol** 1995 Jan–Feb; 31(1):38–43 (Eng. Abstr.) **(Rus)**
[The effect of quaternization on local anesthetic effects of trimecaine] Stankovičová T, et al. **Ceska Slov Farm** 1995 Oct;44(5):265–7 (Eng. Abstr.) **(Slo)**

STANDARDS

Stability of bupivacaine hydrochloride with diamorphine hydrochloride in an epidural infusion. Barnes AR, et al. **Pharm World Sci** 1995 May 26;17(3):87–92

THERAPEUTIC USE

Does a local anaesthetic cream (EMLA) alleviate pain from heel–lancing in neonates? Larsson BA, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1028–31

Small–bowel obstruction and the effects of lidocaine, atropine and hexamethonium on inflammation and fluid losses [see comments] Nellgård P, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):287–92. Comment in: Acta Anaesthesiol Scand 1996 Mar;40(3):285–6.

Lidocaine attenuates hyperoxic lung injury in rabbits. Takao Y, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):318–25

Effect of lidocaine injection of EOAE in patients with tinnitus. Haginomori S, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):488–92

Tumescent and syringe liposculpture: a logical partnership. Hunstad JP. **Aesthetic Plast Surg** 1995 Jul–Aug; 19(4):321–33

Does warming local anesthetic reduce the pain of subcutaneous injection? Martin S, et al. **Am J Emerg Med** 1996 Jan;14(1):10–2

Lignocaine for acute phantom limb pain reactivation by regional anaesthesia [letter] Lamacraft G. **Anaesthesia** 1996 Aug;51(8):800

Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats [see comments] Chaplan SR, et al. **Anesthesiology** 1995 Oct;83(4):775–85. Comment in: Anesthesiology 1995 Oct;83(4):654–5.

Protracted relief of experimental neuropathic pain by systemic local anesthetics. How, where, and when [editorial; comment] Strichartz G. **Anesthesiology** 1995 Oct; 83(4):654–5. Comment on: Anesthesiology 1995 Oct;83(4):775–85.

GI cocktail [letter; comment] Rosenberg CA. **Ann Emerg Med** 1996 Jul;28(1):104–5. Comment on: Ann Emerg Med 1995 Dec;26(6):687–90.

Local anesthetics. Sklar DP. **Ann Emerg Med** 1996 Apr; 27(4):464–5 (10 ref.)

Comparison of bupivacaine and lidocaine/bupivacaine for local anesthesia/digital nerve block. Valvano MN, et al. **Ann Emerg Med** 1996 Apr;27(4):490–2

Lidocaine and rapid sequence intubation [letter; comment] Walls RM. **Ann Emerg Med** 1996 Apr;27(4):528–9. Comment on: Ann Emerg Med 1995 Nov;26(5):660.

Post–tonsillectomy infiltration with bupivacaine reduces immediate postoperative pain in children. Wong AK, et al. **Can J Anaesth** 1995 Sep;42(9):770–4

The use of lignocaine to reduce pain on i.v. injection of diluted nalbuphine. van den Berg AA, et al. **Eur J Anaesthesiol** 1995 Sep;12(5):513–6

Intravenous lignocaine in the management of primary fibromyalgia syndrome. Bennett MI, et al. **Int J Clin Pharmacol Res** 1995;15(3):115–9

Cases 1A and 1B. 1995 intravenous lidocaine infusion for chronic pain therapy [clinical conference] Avidan A, et al. **Isr J Med Sci** 1996 May;32(5):331–4

Use of EMLA cream in the treatment of post–herpetic neuralgia. Litman SJ, et al. **J Clin Anesth** 1996 Feb; 8(1):54–7

A comparison of EMLA cream versus nitrous oxide for pediatric venous cannulation. Vetter TR. **J Clin Anesth** 1995 Sep;7(6):486–90

The use of a topical refrigerant anesthetic to reduce injection pain in children. Abbott K, et al. **J Pain Symptom Manage** 1995 Nov;10(8):584–90

Baseline correlates of the response to the treatment of chronic localized myofascial pain syndrome by injection of local anaesthetic. Scicchitano J, et al. **J Psychosom Res** 1996 Jan;40(1):75–85

The skinache syndrome. Bassøe CF. **J R Soc Med** 1995 Oct; 88(10):565–9

Control of pain after photorefractive keratectomy. Verma S, et al. **J Refract Surg** 1996 Mar–Apr;12(3):358–64 (37 ref.)

Evaluation of a new topical anesthetic agent: a pilot study. Lander J, et al. **Nurs Res** 1996 Jan–Feb;45(1):50–3

The treatment of pain following excimer laser photorefractive keratectomy: additive effect of local anesthetic drops, topical diclofenac, and bandage soft contact. Cherry PM. **Ophthalmic Surg Lasers** 1996 May; 27(5 Suppl):S477–80

Localized fibromyalgia in a child. Bassan H, et al. **Paediatr Anaesth** 1995;5(4):263–5

A double–blind randomised comparison of the effects of epidural clonidine, lignocaine and the combination of clonidine and lignocaine in patients with chronic pain. Glynn C, et al. **Pain** 1996 Feb;64(2):337–43

Comments on Schwarzer et al., PAIN, 58 (1994) 195–200 [letter] Graziotti P, et al. **Pain** 1995 Dec;63(3):394–6

Comparison of topical anesthetics without cocaine to tetracaine–adrenaline–cocaine and lidocaine infiltration during repair of lacerations: bupivacaine–norepinephrine is an effective new topical anesthetic agent. Smith GA, et al. **Pediatrics** 1996 Mar;97(3):301–7

1995 Gaston Labat Lecture. Ropivacaine. White knight or dark horse? de Jong RH. **Reg Anesth** 1995 Nov–Dec; 20(6):474–81 (37 ref.)

Effects of epidural bupivacaine after thoracotomy. Liu S, et al. **Reg Anesth** 1995 Jul–Aug;20(4):303–10

Intra–articular morphine and bupivacaine for pain relief after therapeutic arthroscopic knee surgery. Chan ST. **Singapore Med J** 1995 Feb;36(1):35–7

[Post–thoracotomy analgesia in pediatric heart surgery: comparison of 2 different techniques] Picardo S, et al. **Minerva Anestesiol** 1995 Jun;61(6):277–82 (Eng. Abstr.) (Ita)

[Efficacy of continuous intercostal analgesia versus epidural analgesia on post–thoracotomy pain] Nicolosi M, et al. **Minerva Chir** 1996 Mar;51(3):103–7 (Eng. Abstr.) (Ita)

[The combined preparation ligentin in the treatment of inflammatory disease of the urogenital organs] Kisina VI. **Antibiot Khimioter** 1995 Jul;40(7):43–4 (Eng. Abstr.) (Rus)

TOXICITY

Decreased coronary blood flow is not responsible for myocardial dysfunction during bupivacaine–induced cardiotoxicity. Fujita Y, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):216–21

Sevoflurane is equivalent to isoflurane for attenuating bupivacaine–induced arrhythmias and seizures in rats. Fukuda H, et al. **Anesth Analg** 1996 Sep;83(3):570–3

Epinephrine dysrhythmogenicity is not enhanced by subtoxic bupivacaine in dogs. Kulier AH, et al. **Anesth Analg** 1996 Jul;83(1):62–7

Comparison of the toxicities of cisplatin and a new cisplatin–procaine complex to rat renal cortical slices. Zhang JG, et al. **Hum Exp Toxicol** 1996 Jan;15(1):59–63

Neurotoxicity of subarachnoid hyperbaric bupivacaine in dogs. Ganem EM, et al. **Reg Anesth** 1996 May–Jun; 21(3):234–8

Nitric oxide synthesis inhibition enhances bupivacaine cardiotoxicity. Heavner JE, et al. **Reg Anesth** 1996 May–Jun;21(3):243–8

URINE

Study of local anesthetics. Part 128. HPLC study of the degradation of heptacaine and carbisocaine in urine, human and rabbit serums. Lehotay J, et al. **Acta Pharm Hung** 1995 May;65(3):95–6

Regulatory significance of procaine residues in plasma and urine samples: preliminary communication. Harkins JD, et al. **Equine Vet J** 1996 Mar;28(2):121–5

ANESTRUS

Endocrine bases of lactational anoestrus in the sow. Quesnel H, et al. **Reprod Nutr Dev** 1995;35(4):395–414 (107 ref.)

BLOOD

Effects of administration of N–methyl–D,L–aspartate (NMA) on gonadotropin secretion in untreated and steroid–treated ovariectomized mares during the breeding season and in intact and ovariectomized mares during anestrus. Fitzgerald BP. **Domest Anim Endocrinol** 1996 May; 13(3):211–8

PHYSIOLOGY

Glucoprivic treatments that induce anestrus, but do not affect food intake, increase FOS–like immunoreactivity in the area postrema and nucleus of the solitary tract in Syrian hamsters. Schneider JE, et al. **Brain Res** 1995 Nov 6; 698(1–2):107–13

Effects of exogenous oxytocin and progesterone on GnRH–induced short luteal phases in anoestrous ewes. Beard AP, et al. **J Reprod Fertil** 1996 Jan;106(1):55–61

ANETHOLE TRITHIONE

CHEMISTRY

Use of linoleic acid radiolysis for assay of antioxidant action of anethole dithiolethione. Christen MO, et al. **Methods Enzymol** 1995;252:324–31

Cold light fluorimetry: a microtitration technology for cell culture to evaluate anethole dithiolethione and other biothiols. Rat P, et al. **Methods Enzymol** 1995;252:331–40

PHARMACOLOGY

Inhibition of NF–kappa B activation in human T–cell lines by anetholdithiolthione. Sen CK, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):148–53

Anethole dithiolethione: biochemical considerations. Christen MO. **Methods Enzymol** 1995;252:316–23 (40 ref.)

Assessment of the role of glutathione conjugation in the protection afforded by anethol dithiolthione against hexachloro–1,3–butadiene–induced nephrotoxicity. Bouthillier L, et al. **Toxicol Appl Pharmacol** 1996 Jul; 139(1):177–85

ANETHOLTRITHION see ANETHOLE TRITHIONE

ANEUPLOIDY

High cell proliferation activity determined by DNA flow cytometry and prognosis in epidermoid lung carcinoma. Visakorpi T, et al. **Acta Oncol** 1995;34(5):605–9

Multivariate DNA cytometry discriminates between Spitz nevi and malignant melanomas because large polymorphic nuclei in Spitz nevi are not aneuploid. Vogt T, et al. **Am J Dermatopathol** 1996 Apr;18(2):142–50

Association between nondisjunction and maternal age in meiosis–II human oocytes. Dailey T, et al. **Am J Hum Genet** 1996 Jul;59(1):176–84

The relationship between paternal age, sex ratios, and aneuploidy frequencies in human sperm, as assessed by multicolor FISH. Martin RH, et al. **Am J Hum Genet** 1995 Dec;57(6):1395–9

Assessment of aneuploidy for chromosomes 8, 9, 13, 16, and 21 in human sperm by using primed in situ labeling technique. Pellestor F, et al. **Am J Hum Genet** 1996 Apr; 58(4):797–802

Aneuploidy in human sperm: the use of multicolor FISH to test various theories of nondisjunction. Spriggs EL, et al. **Am J Hum Genet** 1996 Feb;58(2):356–62

Infant with mos45,x/46,XY/47,XYY/48,XYYY: genetic and clinical findings. Fox JE, et al. **Am J Med Genet** 1995 Dec 4;59(4):435–40

Aneuploidy among prenatally detected neural tube defects. Hume RF Jr, et al. **Am J Med Genet** 1996 Jan 11; 61(2):171–3

Screening should not be compared with diagnosis [letter; comment] Kornman LH, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1941–2. Comment on: Am J Obstet Gynecol 1995 Oct;173(4):1287–92.

Rapid aneuploid diagnosis of high–risk fetuses by fluorescence in situ hybridization. Lapidot–Lifson Y, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):886–90

Are DADs (discriminant aneuploidy detection) as good as MOMs (multiples of the median)? [letter] Palomaki GE, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1895–7

MOMs (multiples of the median) may know best: there are insufficient data to suggest that DADs (discriminant aneuploidy detection) are superior [letter] Reynolds TM. **Am J Obstet Gynecol** 1995 Dec;173(6):1895

Comparison of multiple–marker screening with amniocentesis for the detection of fetal aneuploidy in women > or = 35 years old [see comments] Wenstrom KD, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1287–92. Comment in: Am J Obstet Gynecol 1996 Jun;174(6):1941–2.

Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c–erbB2 overexpression in breast cancer. Järvinen TA, et al. **Am J Pathol** 1996 Jun;148(6):2073–82

Aneuploidy occurrence in human tumours: a logical–automaton approach. Kiss R, et al. **Anal Cell Pathol** 1995 Sep;9(2):95–111

Assessment and significance of diploid–range epithelial populations in DNA aneuploid breast carcinomas using multi–parametric flow cytometry. Visscher DW, et al. **Anal Cell Pathol** 1995 Jun;8(4):267–77

Prenatal diagnosis of chromosomal aneuploidies by fluorescence in situ hybridization on uncultured amniotic cells: experience with 630 samples. Mercier S, et al. **Ann Genet** 1995;38(3):151–7

K–ras2 mutation spectrum, DNA aneuploidy, and epithelial cell proliferation in colorectal adenomas. Giaretti W, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:261–3

Prognostic value of Ki–67 expression, ploidy and S–phase fraction in patients with pancreatic cancer. Lundin J, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2659–68

Effects of some diethylstilbestrol metabolites and analogs on cytotoxicity and aneuploidy induction in Chinese hamster V79 cells. Oda T, et al. **Biol Pharm Bull** 1995 Oct; 18(10):1435–8

Multicolor fluorescence in situ hybridization analysis of aneuploidy and diploidy frequencies in 225,846 sperm from 10 normal men. Martin RH, et al. **Biol Reprod** 1996 Feb; 54(2):394–8

Tumor–specific aneuploidy not detected in CD19+ B–lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis. McSweeney PA, et al. **Blood** 1996 Jul 15;88(2):622–32

Flow cytometric analysis of neoplastic nodules and hepatocellular carcinomas induced by ciprofibrate in the rat. Goolsby CL, et al. **Br J Cancer** 1996 Jan;73(2):197–202

DNA aneuploidy in early breast cancer. Ottesen GL, et al. **Br J Cancer** 1995 Oct;72(4):832–9

Extensive areas of aneuploidy are present in the respiratory epithelium of lung cancer patients. Smith AL, et al. **Br J Cancer** 1996 Jan;73(2):203–9

Aneuploidy in actinic keratosis and Bowen's disease—increased risk for invasive squamous cell carcinoma? Biesterfeld S, et al. **Br J Dermatol** 1995 Oct; 133(4):557–60

Echogenic foci in the fetal heart: a marker of chromosomal abnormalities [letter] **Br J Obstet Gynaecol** 1996 Jul; 103(7):724–5

Non–invasive prenatal diagnosis by isolation of both trophoblasts and fetal nucleated red blood cells from the peripheral blood of pregnant women. Durrant L, et al. **Br J Obstet Gynaecol** 1996 Mar;103(3):219–22

Study on aneuploidy and p53 mutations in astrocytomas. Campomenosi P, et al. **Cancer Genet Cytogenet** 1996 Jun; 88(2):95–102

Near–hexaploid Ph–positive acute myeloid leukemia with major–BCR/ABL transcript. Iwama H, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):61–4

Correlation of loss of heterozygosity with cytogenetic

analysis using G-banding and fluorescence in situ hybridization in aneuploid cultures from two human testicular germ-cell tumors. al-Jehani RM, et al. **Cancer Genet Cytogenet** 1995 Nov;85(1):26–36

Heterogeneity, polyploidy, aneusomy, and 9p deletion in human glioblastoma multiforme. Park SH, et al. **Cancer Genet Cytogenet** 1995 Sep;83(2):127–35

Multiple polysomies in nasal polyps in children. Speleman F, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):86–7 (13 ref.)

Detection of aneuploidy in interphase nuclei from non-small cell lung carcinomas by fluorescence in situ hybridization using chromosome-specific repetitive DNA probes. Taguchi T, et al. **Cancer Genet Cytogenet** 1996 Jul 15; 89(2):120–5

Hexasomy of chromosome 8 and trisomy of chromosome 11 characterize two karyotypically independent clones in a case of acute non-lymphocytic leukemia. Conventional cytogenetic and FISH investigation. Trakhtenbrot L, et al. **Cancer Genet Cytogenet** 1995 Nov;85(1):1–4

Tetrasomy 21 as a sole abnormality in erythroleukemia. Udayakumar AM, et al. **Cancer Genet Cytogenet** 1995 Nov; 85(1):85–7

p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer. Brotherick I, et al. **Cancer Immunol Immunother** 1995 Sep;41(3):146–50

Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Ried T, et al. **Cancer Res** 1995 Nov 15;55(22):5415–23

Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Weber-Hall S, et al. **Cancer Res** 1996 Jul 15;56(14):3220–4

Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. Sargent LM, et al. **Carcinogenesis** 1996 May;17(5):1051–6

Toxicology of halogenated aliphatic hydrocarbons: structural and molecular determinants for the disturbance of chromosome segregation and the induction of lipid peroxidation. Crebelli R, et al. **Chem Biol Interact** 1995 Nov 17;98(2):113–29

An improved method for the detection of Down's syndrome aneuploidy in uncultured amniocytes. Pierluigi M, et al. **Clin Genet** 1996 Jan;49(1):32–6

Mosaic "tetrasomy" 8p: case report and review of the literature. Winters J, et al. **Clin Genet** 1995 Oct;48(4):195–8 (9 ref.)

Towards the development of a fluorescent in situ hybridization based genotoxicologic assay for aneuploidy detection in sperm. Mark HF, et al. **Cytobios** 1995; 82(330):171–80

FISH and PRINS, a strategy for rapid chromosome screening: application to the assessment of aneuploidy in human sperm. Pellestor F, et al. **Cytogenet Cell Genet** 1996; 72(1):34–6

Flow cytometric and clinicopathologic study of 197 hydatidiform moles with special reference to the significance of cytometric aneuploidy and literature review. Fukunaga M, et al. **Cytometry** 1995 Jun 15;22(2):135–8 (21 ref.)

False DNA aneuploidy possibly caused by viral DNA [letter] Overton WR. **Cytometry** 1995 Jun 15;22(2):158

Evaluation of sensitivity of flow cytometry in detecting aneuploidy in wheat using disomic and ditelosomic wheat-rye addition lines. Pfosser M, et al. **Cytometry** 1995 Dec 1;21(4):387–93

Aneuploidy in breast cancer: a fluorescence in situ hybridization study. Shackney SE, et al. **Cytometry** 1995 Dec 15;22(4):282–91

Origins and clinical implications of aneuploidy in early bladder cancer. Shackney SE, et al. **Cytometry** 1995 Dec 15;22(4):307–16

DNA aneuploidy in acute myeloblastic leukemia is associated with a high expression of lymphoid markers. Vidriales MB, et al. **Cytometry** 1995 Mar 15;22(1):22–5

Detection of chromosome aneuploidy in breast lesions with fluorescence in situ hybridization: comparison of whole nuclei to thin tissue sections and correlation with flow cytometric DNA analysis. Visscher DW, et al. **Cytometry** 1995 Sep 1;21(1):95–100

Indications for a threshold of chemically-induced aneuploidy in vitro in human lymphocytes. Elhajouji A, et al. **Environ Mol Mutagen** 1995;26(4):292–304

Aneuploidy in salivary gland adenomas. Atula T, et al. **Eur Arch Otorhinolaryngol** 1995;252(7):395–400

Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Christiansen H, et al. **Eur J Cancer** 1995;31A(4):541–4

Aneuploidy 16 in human embryos increases significantly with maternal age. Benadiva CA, et al. **Fertil Steril** 1996 Aug; 66(2):248–55

Impact of abnormal second-trimester maternal serum single, double, and triple screening on patient choices about prenatal diagnosis. Lowry DL, et al. **Fetal Diagn Ther** 1995 Sep-Oct;10(5):286–9

First-trimester translucency: aneuploidy, sonographic findings, and maternal age. Mahieu-Caputo D, et al. **Fetal Diagn Ther** 1996 May-Jun;11(3):199–204

Dandy-Walker malformation in a fetus with pentasomy X (49,XXXXX) prenatally diagnosed by fluorescence in situ hybridization technique. Myles TD, et al. **Fetal Diagn Ther** 1995 Sep-Oct;10(5):333–36

Nuclear vlimata and aneuploidy in embryonic cells is caused by meiosis. Behaviour and properties of meiotic cells. Logothetou-Rella H. **Histol Histopathol** 1995 Jul; 10(3):541–66

The effect of Y-chromosome alpha-satellite array length on the rate of sex chromosome disomy in human sperm. Abruzzo MA, et al. **Hum Genet** 1996 Jun;97(6):819–23

Tetrasomy 18p de novo: identification by FISH with conventional and microdissection probes and analysis of parental origin and formation by short sequence repeat typing. Eggermann T, et al. **Hum Genet** 1996 May; 97(5):568–72

Direct detection of disomy in human sperm by the PRINS technique. Pellestor F, et al. **Hum Genet** 1996 Jan; 97(1):21–5

Uniparental maternal disomy 6 in a renal transplant patient. van den Berg-Loonen EM, et al. **Hum Immunol** 1996 Jan; 45(1):46–51

Gain and loss of chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers. König JJ, et al. **Hum Pathol** 1996 Jul; 27(7):720–7

Pregnancy and lifestyle study: the long-term use of the contraceptive pill and the risk of age-related miscarriage. Ford JH, et al. **Hum Reprod** 1995 Jun;10(6):1397–402

Aetiology of age-associated aneuploidy: a mechanism based on the 'free radical theory of ageing'. Tarín JJ. **Hum Reprod** 1995 Jun;10(6):1563–5 (25 ref.)

Pregnancies following pre-conception diagnosis of common aneuploidies by fluorescent in-situ hybridization. Verlinsky Y, et al. **Hum Reprod** 1995 Jul;10(7):1923–7

The incidence, origin, and etiology of aneuploidy. Griffin DK. **Int Rev Cytol** 1996;167:263–96 (89 ref.)

Polar body diagnosis of common aneuploidies by FISH. Verlinsky Y, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):157–62

Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1. Chen J, et al. **J Clin Invest** 1996 Apr 15; 97(8):1983–8

Significance of aneuploidy in non-Hodgkin lymphomas. Vučković J, et al. **J Clin Lab Anal** 1995;9(6):343–6

Multiple marker screening test: identification of fetal cystic hygroma, hydrops, and sex chromosome aneuploidy. Wenstrom KD, et al. **J Matern Fetal Med** 1996 Jan-Feb; 5(1):31–5

A new approach to analysing fluorescence in situ hybridisation data for rapid detection of aneuploidy in amniocytes. Palomaki GE, et al. **J Med Screen** 1994 Apr; 1(2):96–7

Comparison of fluorescence in situ hybridization, cytogenetic analysis, and DNA index analysis to detect chromosomes 4 and 10 aneuploidy in pediatric acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Martin PL, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):113–21

The influence of intrinsic and extrinsic factors on the developmental potential and chromosomal normality of the human oocyte. Van Blerkom J. **J Soc Gynecol Investig** 1996 Jan-Feb;3(1):3–11 (38 ref.)

Ultrasonography in the detection of aneuploidy in the first trimester. Cullen MT, et al. **J Ultrasound Med** 1995 Aug; 14(8):559–63

Isolated fetal choroid plexus cysts and karyotype analysis: is it necessary? Shields LE, et al. **J Ultrasound Med** 1996 May;15(5):389–94

Sonographic manifestation and Doppler blood flow study in fetal triploidy syndrome: report of two cases. Wu RT, et al. **J Ultrasound Med** 1995 Jul;14(7):555–8

Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Flactif M, et al. **Leukemia** 1995 Dec; 9(12):2109–14

Chromosomal analysis in young vs. senescent human fibroblasts by fluorescence in situ hybridization: a selection hypothesis. Mukherjee AB, et al. **Mech Ageing Dev** 1995 Apr 21;80(1):11–23

DNA aneuploidy in morphologically normal colons from patients with colon cancer. Fleischhacker M, et al. **Mod Pathol** 1995 May;8(4):360–5

A practical strategy for detection of major chromosome aneuploidies using ratio-mixing fluorescence in situ hybridization. Mohaddes SM, et al. **Mol Cell Probes** 1996 Apr;10(2):147–54

Reliability of aneuploidy estimates in human sperm: results of fluorescence in situ hybridization studies using two different scoring criteria. Martin RH, et al. **Mol Reprod Dev** 1995 Sep;42(1):89–93

Carbendazim (MBC) disrupts oocyte spindle function and induces aneuploidy in hamsters exposed during fertilization (meiosis II). Zuelke KA, et al. **Mol Reprod Dev** 1995 Oct; 42(2):200–9

Chloral hydrate induced spindle aberrations, metaphase I arrest and aneuploidy in mouse oocytes. Eichenlaub-Ritter U, et al. **Mutagenesis** 1995 Nov;10(6):477–86

Mitotic non-disjunction as a mechanism for in vitro aneuploidy induction by X-rays in primary human cells. Kirsch-Volders M, et al. **Mutagenesis** 1996 Jul;11(4):307–13

Cytogenetic effects of caffeine during in vivo mouse oocyte maturation. Mailhes JB, et al. **Mutagenesis** 1996 Jul; 11(4):395–9

Dose-response study and threshold estimation of griseofulvin-induced aneuploidy during female mouse meiosis I and II. Marchetti F, et al. **Mutagenesis** 1996 Mar; 11(2):195–200

Chromosome segregation and aneuploidy. Parry EM. **Mutagenesis** 1995 Nov;10(6):561–3

Comparison of separated erythrocyte preparations and manual smears of bone marrow in showing micronucleus induction by clastogens and aneuploidogens in mouse. Vigagni F, et al. **Mutagenesis** 1995 Jul;10(4):365–9

Analysis of chromosome segregation in cytokinesis-blocked human lymphocytes: non-disjunction is the prevalent damage resulting from low dose exposure to spindle poisons. Zijno A, et al. **Mutagenesis** 1996 Jul;11(4):335–40

Advantages and limitations of using fluorescence in situ hybridization for the detection of aneuploidy in interphase human cells. Eastmond DA, et al. **Mutat Res** 1995 Dec; 348(4):153–62 (46 ref.)

Aneuploidies and micronuclei in the germ cells of male mice of advanced age. Lowe X, et al. **Mutat Res** 1995 Oct; 338(1–6):59–76

Important biological variables that can influence the degree of chemical-induced aneuploidy in mammalian oocyte and zygotes. Mailhes JB. **Mutat Res** 1995 Oct;339(3):155–76 (144 ref.)

The detection and evaluation of aneugenic chemicals. Parry JM, et al. **Mutat Res** 1996 Jun 12;353(1–2):11–46 (90 ref.)

A study of the structural basis of the ability of chlorinated alkanes and alkenes to induce aneuploidy and toxicity in the mold Aspergillus nidulans. Rosenkranz HS, et al. **Mutat Res** 1996 Jul 22;354(2):183–93

Sex chromosome aneuploidy and aging. Stone JF, et al. **Mutat Res** 1995 Oct;338(1–6):107–13 (51 ref.)

Detection of aneuploidy in human and rodent sperm using FISH and applications of sperm assays of genetic damage in heritable risk evaluation. Wyrobek AJ, et al. **Mutat Res** 1996 Jun 10;352(1–2):173–9

Second-trimester minor ultrasound anomalies: impact on the risk of aneuploidy associated with advanced maternal age. Drugan A, et al. **Obstet Gynecol** 1996 Aug;88(2):203–6

Intrauterine diagnosis of sex chromosome aneuploidy. Linden MG, et al. **Obstet Gynecol** 1996 Mar;87(3):468–75 (51 ref.)

Amniotic fluid culture failure: clinical significance and association with aneuploidy. Reid R, et al. **Obstet Gynecol** 1996 Apr;87(4):588–92

Antibody response to sheep red blood cells in major histocompatibility (B) complex aneuploid line of chickens. LePage KT, et al. **Poult Sci** 1996 Mar;75(3):346–50

Crown-rump length in aneuploid fetuses: implications for first-trimester biochemical screening for aneuploidies. Macintosh MC, et al. **Prenat Diagn** 1995 Aug;15(8):691–4

Isolation of fetal cells from transcervical samples by micromanipulation: molecular confirmation of their fetal origin and diagnosis of fetal aneuploidy. Tutschek B, et al. **Prenat Diagn** 1995 Oct;15(10):951–60

Cross-hybridization of the chromosome 13/21 alpha satellite DNA probe to chromosome 22 in the prenatal screening of common chromosomal aneuploidies by FISH. Verlinsky Y, et al. **Prenat Diagn** 1995 Sep;15(9):831–4

17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Galipeau PC, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):7081–4

Three-probe fluorescence in situ hybridization to assess chromosome X, Y, and 8 aneuploidy in sperm of 14 men from two healthy groups: evidence for a paternal age effect on sperm aneuploidy. Robbins WA, et al. **Reprod Fertil Dev** 1995;7(4):799–809

Acute exposure of female hamsters to carbendazim (MBC) during meiosis results in aneuploid oocytes with subsequent arrest of embryonic cleavage and implantation. Jeffay SC, et al. **Reprod Toxicol** 1996 May-Jun;10(3):183–9

Acquisition of multiple copies of a mutant topoisomerase IIalpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines. Campain JA, et al. **Somat Cell Mol Genet** 1995 Nov; 21(6):451–71

Tumor ploidy as a risk factor for disease recurrence and short survival in surgically treated Dukes' B2 colon cancer patients. Nori D, et al. **Tumour Biol** 1996;17(2):75–80

The relationship between aneuploidy and p53 overexpression during genesis of colorectal adenocarcinoma [letter; comment] Biesterfeld S, et al. **Virchows Arch** 1995; 427(4):459. Comment on: Virchows Arch 1994;424(4):343–7.

[Flow-cytometric study of aneuploidy and proliferative activity of endometrial cancer cells as indicators of tumor aggressiveness] Bychkova NV, et al. **Vopr Onkol** 1996; 42(2):57–62 (Eng. Abstr.) **(Rus)**

ANEURIN see **THIAMINE**

ANEURYSM

Enlarging splenic vein aneurysm associated with stagnation of splenic venous blood flow. Shirohara H, et al. **Am J Gastroenterol** 1996 Feb;91(2):385–7

Venous aneurysms [letter; comment] Dieter RA Jr. **Angiology** 1996 May;47(5):531–2. Comment on: Angiology 1995 Mar;46(3):265–7.

Giant aneurysm of main pulmonary artery. Chen YF, et al. **Ann Thorac Surg** 1996 Jul;62(1):272–4 (8 ref.)
Popliteal vein aneurysm. al Zahrani HA. **Cardiovasc Surg** 1995 Oct;3(5):505–7 (11 ref.)
3D–high resolution imaging of tumors and aneurysms at the cranial base–comparison of CT and MR. Atzor KR, et al. **Comput Biol Med** 1995 Mar;25(2):277–91
True aneurysm of the inferior thyroid artery. Case report and review of the literature. Raso AM, et al. **J Cardiovasc Surg (Torino)** 1995 Oct;36(5):493–5 (8 ref.)
Aneurysms of the infrapopliteal arteries. Marmorale A, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):324–6 (4 ref.)
[Venous aneurysms] Suchý T. **Rozhl Chir** 1995 Sep; 74(6):284–6 (Eng. Abstr.) **(Cze)**
[Aneurysms of the external jugular vein] Porcellini M, et al. **G Chir** 1996 May;17(5):238–41 (Eng. Abstr.) **(Ita)**
[Atherosclerotic aneurysm of a branch of the deep femoral artery] Rampoldi V, et al. **Minerva Cardioangiol** 1996 Jan–Feb;44(1–2):29–32 (Eng. Abstr.) **(Ita)**
[Aneurysms of the popliteal artery. A clinical case and revision of the literature] Giani L, et al. **Minerva Chir** 1995 Nov;50(11):1019–23 (21 ref.) (Eng. Abstr.) **(Ita)**
[Popliteal aneurysm] Giavazzi T, et al. **Minerva Chir** 1995 Sep;50(9):763–5 (Eng. Abstr.) **(Ita)**
[Aneurysm of the hepatic artery. A case report] Amatucci G, et al. **Minerva Gastroenterol Dietol** 1995 Sep;41(3):251–4 (Eng. Abstr.) **(Ita)**
[Pseudoaneurysm of the lingual artery. Report of a case] Boccardi A, et al. **Radiol Med (Torino)** 1996 Jun; 91(6):819–20 **(Ita)**
[Extrahepatic portal vein aneurysm] Iwasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):180–3 (24 ref.) **(Jpn)**
[Hepatic artery aneurysm] Kojima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):199–201 (10 ref.) **(Jpn)**
[Intrahepatic portal vein aneurysm] Toshima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):218–20 (19 ref.) **(Jpn)**
[Hepatic artery aneurysm. Diagnosis and treatment] Røkke O, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):487–9 (Eng. Abstr.) **(Nor)**
[Aneurysms of the extracranial supraaortic vessels--8 years' experience] Sefránek V, et al. **Bratisl Lek Listy** 1996 Mar; 97(3):147–52 (Eng. Abstr.) **(Slo)**
[Aneurysms of the splenic artery in patients with liver transplantation] Jiménez Almonacid P, et al. **Rev Clin Esp** 1996 Mar;196(3):171–3 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Aneurysms of the pancreaticoduodenal artery associated with occlusion of the celiac artery. Uher P, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):470–3 (22 ref.)
Enteric fistulization of a common iliac artery aneurysm: an unusual cause of gastrointestinal hemorrhage and shock. Nicolaou DD, et al. **Am J Emerg Med** 1996 May; 14(3):272–5
Contralateral pulmonary oedema. Rose M, et al. **Anaesth Intensive Care** 1995 Jun;23(3):352–3
F.P. Weber syndrome associated with a brachial artery aneurysm. A case report. Bartels C, et al. **Angiology** 1995 Nov;46(11):1039–42
Spontaneous haemothorax caused by an internal mammary artery aneurysm. Chan LW, et al. **Aust N Z J Surg** 1996 May;66(5):332–3
Right aortic arch with aberrant left subclavian artery: aneurysmal dilatation causing symptomatic compression of the right main bronchus in an adult. Patiniotis TC, et al. **Aust N Z J Surg** 1995 Sep;65(9):690–2 (9 ref.)
Atrial septal aneurysm plus a patent foramen ovale. A predisposing factor for paradoxical embolism and refractory hypoxemia during pulmonary embolism. Estagnasié P, et al. **Chest** 1996 Sep;110(3):846–8
Case report: petrous internal carotid artery aneurysm: an unusual cause of eustachian tube dysfunction. Goodman TR, et al. **Clin Radiol** 1996 Sep;51(9):658–60
Case report: giant aneurysm of the intrapetrous carotid artery presenting as a cerebellopontine angle mass. Love MH, et al. **Clin Radiol** 1996 Aug;51(8):587–8
Extrahepatic biliary obstruction resulting from a pancreatic pseudoaneurysm. Sharara AI, et al. **Gastrointest Endosc** 1995 Aug;42(2):176–7
Splenic aneurysm with arteriovenous fistula. A case report. Kelekis D, et al. **Hepatogastroenterology** 1995 Jul–Aug; 42(4):352–5
Aneurysm of the superficial palmar arch. A case report. Iossifidis A, et al. **Int Orthop** 1995;19(6):403–4
Aspergillus aneurysm of the middle cerebral artery causing a fatal subarachnoid hemorrhage. Suzuki K, et al. **Intern Med** 1995 Jun;34(6):550–3
Microembolization from atheroembolic disease or aneurysm. A case study. Caldwell BD, et al. **J Am Podiatr Med Assoc** 1996 Jun;86(6):249–52
Aneurysm of an anomalous right subclavian artery. Hiddema A, et al. **J Belge Radiol** 1995 Aug;78(4):231
Aneurysm of a branch of the subclavian artery with multiple arteriovenous fistulae. Egami J, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):355–7
Post stenotic aneurysm of the inferior mesenteric artery: case report and discussion. Raso AM, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):359–62
Intrapetrous carotid artery aneurysm presenting as epistaxis and otalgia. Banfield GK, et al. **J Laryngol Otol** 1995 Sep; 109(9):865–7
Recurrent massive epistaxis due to traumatic intracavernous internal carotid artery aneurysm. Bhatoe HS, et al. **J Laryngol Otol** 1995 Jul;109(7):650–2
Pseudoaneurysm of the carotid artery with haemorrhage into the hypopharynx. Tanaka S, et al. **J Laryngol Otol** 1995 Sep;109(9):889–91
Thrombosis within an external jugular venous aneurysm. Beale TJ, et al. **J R Coll Surg Edinb** 1996 Jun;41(3):181–2
Deep venous thrombosis with pulmonary embolus after selective embolization of an internal iliac artery aneurysm. Su WT, et al. **J Vasc Surg** 1996 Jan;23(1):152–5 (13 ref.)
Systemic multiple aneurysms of the intracranial arteries and visceral arteries: case report. Fuse T, et al. **Surg Neurol** 1996 Sep;46(3):258–61; discussion 261–2 (13 ref.)
Bleeding gastric varices as a result of splenic vein compression by a celiac arterial aneurysm. Kimura H, et al. **Surgery** 1996 Jul;120(1):106–10
[Renovascular hypertension and hydronephrosis due to a renal artery aneurysm] Hering M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):176–8 (12 ref.) **(Ger)**
[Bilateral thrombosis of a femoral pseudoaneurysm] Morbidelli A, et al. **Minerva Chir** 1995 Nov;50(11):1013–8 (Eng. Abstr.) **(Ita)**
[A true aneurysm of the right internal mammary artery, accompanied by diminished grasping power of the right hand] Tabata T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1330–3 (Eng. Abstr.) **(Jpn)**
[Polyangiitis overlap syndrome with multiple pulmonary aneurysms and renal vascular hypertension] Taguchi T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr; 34(4):428–33 (Eng. Abstr.) **(Jpn)**
[A case of cholangiocarcinoma with temporary subsegmental fatty liver and intrahepatic portal aneurysm] Miyanaga O, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1297–303 (9 ref.) **(Jpn)**
[Splenic artery aneurysm in patients with hepato-splenic schistosomiasis mansoni and portal hypertension. Report of 3 cases] Herman P, et al. **Arq Gastroenterol** 1994 Oct–Dec;31(4):149–53 (Eng. Abstr.) **(Por)**
[Hypertension secondary to intrarenal aneurysms in childhood] Oliver Llinares FJ, et al. **Arch Esp Urol** 1995 Dec;48(10):1038–9 (Eng. Abstr.) **(Spa)**
[Aneurysm of the hepatic artery as a rare cause of obstructive jaundice (letter)] Sevilla Redondo G, et al. **Rev Clin Esp** 1996 Mar;196(3):200–1 **(Spa)**

CONGENITAL

[Indirect azygos vein continuation syndrome with segmental agenesis and saccular aneurysm of the inferior vena cava] Bergmann K, et al. **Radiologe** 1995 Aug;35(8):524–7 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Severe spontaneous carotid artery dissection and multiple aneurysmal dilatations. A case report. Plaschke M, et al. **Angiology** 1996 Sep;47(9):919–23
Pulmonary venous aneurysm presenting as a middle mediastinal mass. DeBoer DA, et al. **Ann Thorac Surg** 1996 Apr;61(4):1261–2
Retinal microaneurysm counts and 10-year progression of diabetic retinopathy. Klein R, et al. **Arch Ophthalmol** 1995 Nov;113(11):1386–91
Multidisciplinary approach to pseudoaneurysms complicating pancreatic pseudocysts. Impact of pretreatment diagnosis. Marshall GT, et al. **Arch Surg** 1996 Mar;131(3):278–83
Disappearance and formation rates of microaneurysms in early diabetic retinopathy. Hellstedt T, et al. **Br J Ophthalmol** 1996 Feb;80(2):135–9
Pulmonary artery aneurysm: review and case report. Lopez-Candales A, et al. **Clin Cardiol** 1995 Dec; 18(12):738–40 (15 ref.)
An aneurysm of the internal jugular vein. Refson JS, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):371–2 (5 ref.)
Recurrent retinal artery obstruction as a presenting symptom of ophthalmic artery aneurysm: a case report. Beiran I, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Jul; 233(7):444–7
Skin capillary aneurysms detected by indocyanine green in type I diabetes with and without retinal microaneurysms. Zaugg-Vesti BR, et al. **Int J Microcirc Clin Exp** 1995 Jul–Aug;15(4):193–8
A theory of aneurysm sounds. Mast TD, et al. **J Biomech** 1995 Sep;28(9):1045–53
Pseudoaneurysm of the superficial palmar arch. Sterett WI. **J Bone Joint Surg Am** 1996 Jul;78(7):1089–91
Late lateral displacement of the humeral head after closed reduction of glenohumeral dislocation: a sign of vascular injury. Report of a case. Waxman DL, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):907–10
Uterine cirsoid aneurysm: MRI and MRA. Joja I, et al. **J Comput Assist Tomogr** 1996 Mar–Apr;20(2):290–4
Magnetic resonance imaging of petrous carotid aneurysms. Patrick JT. **J Neuroimaging** 1996 Jul;6(3):177–9
True infrapopliteal artery aneurysms: report of two cases and literature review. Mönig SP, et al. **J Vasc Surg** 1996 Aug; 24(2):276–8 (20 ref.)
Aneurysms of the pancreaticoduodenal artery. Paty PS, et al. **J Vasc Surg** 1996 Apr;23(4):710–3 (12 ref.)
MR and CT diagnosis of carotid pseudoaneurysm in children following surgical resection of craniopharyngioma. Lakhanpal SK, et al. **Pediatr Radiol** 1995;25(4):249–51
Bilateral multiple arterial aneurysms. Schatz H. **Retina** 1995; 15(4):348–9; discussion 349–50
Living kidney donor with splenic artery aneurysm. Orlić P, et al. **Transplant Proc** 1996 Feb;28(1):368
[Aneurysms of the renal artery] Lacombe M. **J Mal Vasc** 1995;20(4):257–63 (Eng. Abstr.) **(Fre)**
[True popliteal venous aneurysm. 2 cases (letter)] Vuong PN, et al. **Presse Med** 1996 Apr 27;25(15):733 **(Fre)**
[Thrombosed anastomotic aneurysm of the vena saphena parva] Sommer T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Apr;164(4):350–2 **(Ger)**
[Diagnostic approach to popliteal venous aneurysm] Ravelli C, et al. **Minerva Cardioangiol** 1996 Jan–Feb;44(1–2):9–14 (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Epidemiological study of the systemic ophthalmological effects of carbon disulfide. Vanhoorne M, et al. **Arch Environ Health** 1996 May–Jun;51(3):181–8
The incidence of iliac, femoral, and popliteal artery aneurysms in hospitalized patients. Lawrence PF, et al. **J Vasc Surg** 1995 Oct;22(4):409–15; discussion 415–6
Aneurysms of the digital artery: a review and report of three cases. Yajima H, et al. **Microsurgery** 1995;16(8):566–70 (19 ref.)

ETIOLOGY

Chronic consumption coagulopathy and popliteal aneurysm [letter] Kaplanski G, et al. **Am J Hematol** 1996 Mar; 51(3):245–6
Neurofibromatosis and arterial aneurysms. Huppman JL, et al. **Am Surg** 1996 Apr;62(4):311–4
Paraumbilical vein aneurysm. Case reports. Ohhira M, et al. **Angiology** 1996 May;47(5):517–21
Renal aneurysms and IgA nephropathy [letter] Cecchin E, et al. **Ann Intern Med** 1995 Nov 15;123(10):810
Complicated right subclavian artery pseudoaneurysm after central venipuncture. Baldwin RT, et al. **Ann Thorac Surg** 1996 Aug;62(2):581–2
Multiple nonanastomotic aneurysms in an external velour ringed Dacron femoropopliteal vascular prosthesis. AbuRahma AF, et al. **Ann Vasc Surg** 1995 Sep;9(5):493–6
Internal iliac artery aneurysm following aortic reconstruction. Brings HA, et al. **Ann Vasc Surg** 1996 Jan; 10(1):59–62
Arterial complications of percutaneous transhepatic biliary drainage. L'Hermine C, et al. **Cardiovasc Intervent Radiol** 1996 May–Jun;19(3):160–4
Ventricular aneurysm and myocarditis in a child with the hyperimmunoglobulin E syndrome. el Noor IB, et al. **Eur Heart J** 1995 May;16(5):714–5
Multiple aneurysms in a young patient--aetiological considerations. Hammarsten O, et al. **Eur J Surg** 1996 Jan; 162(1):71–5
Aneurysms due to intimomedial mucoid degeneration. Abdool-Carrim AT, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):324–9
Arterial complications of the thoracic outlet syndrome. Desai Y, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):362–5
Aneurysm formation in modified human umbilical vein grafts. Strobel R, et al. **Eur J Vasc Endovasc Surg** 1996 May; 11(4):417–20
Popliteal artery pseudoaneurysm revealed by deep vein thrombosis after arthroscopic meniscectomy. Guermazi A, et al. **Eur Radiol** 1996;6(2):217–9
Pseudo-aneurysm of the lateral circumflex humeral artery following external fixation of a free fibular transfer. Dujon D, et al. **Injury** 1995 Oct;26(8):551–2
Selective embolization of pseudo-aneurysms of the renal artery after blunt abdominal injury in a patient with a single kidney. Steffens MG, et al. **Injury** 1996 Apr;27(3):219–20
Effect of defective connective tissue on the formation of aneurysmal-like structures in the rat testicular artery. Coutard M, et al. **Int J Exp Pathol** 1996 Apr;77(2):53–62
Wegener's granulomatosis complicated by arterial aneurysm. Aoki N, et al. **Intern Med** 1995 Aug;34(8):790–3 (14 ref.)
Bilateral common iliac artery aneurysms secondary to fibromuscular dysplasia accompanied with a coronary aneurysm. A case report. Tsukamoto S, et al. **J Cardiovasc Surg (Torino)** 1995 Dec;36(6):587–90
Arterial lesions in Behçet's disease. A study in 25 patients. Lê Thi Huong D, et al. **J Rheumatol** 1995 Nov; 22(11):2103–13
Pseudoaneurysm of the brachiocephalic artery caused by blunt chest trauma. de Jose Maria B, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):863–5
Blunt carotid artery injury: devastating consequences of undetected pseudoaneurysm. Prêtre R, et al. **J Trauma** 1995 Nov;39(5):1012–4
A rare case of a traumatic aneurysm of the inferior thyroid artery [letter] Siegmeth A, et al. **J Vasc Surg** 1995 Dec; 22(6):812–3
Macrohaematuria and bilateral renal aneurysms in a patient with mesangial glomerulonephritis. Cecchin E, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):529–31
Capillary macroaneurysms in central retinal vein occlusion.

Battaglia Parodi M, et al. **Ophthalmologica** 1995; 209(5):248–50

Nasal septal perforation and carotid cavernous aneurysm: unusual manifestations of systemic lupus erythematosus. Lerner DN. **Otolaryngol Head Neck Surg** 1996 Jul; 115(1):163–6

Aneurysm of the transverse cervical artery occurring in association with a cavernous hemangioma as a complication of Klippel–Trénaunay syndrome: report of a case. Nakamura K, et al. **Surg Today** 1995;25(11):978–81

Aneurysm following ligation of patent ductus arteriosus [see comments] De DH, et al. **Tex Heart Inst J** 1995;22(4):324–6 . Comment in: Tex Heart Inst J 1996;23(1):71–2.

Brachial artery pseudoaneurysm following blood donation [letter] Kumar S, et al. **Transfusion** 1995 Sep;35(9):791

[Post-traumatic pseudoaneurysm of the posterior tibial artery] Skomorowska EI, et al. **Ugeskr Laeger** 1995 Dec 4;157(49):6883–4 (Eng. Abstr.) **(Dan)**

[A rare etiology of celiac trunk aneurysm] Wagner M, et al. **Ann Pathol** 1996;16(1):57–8 **(Fre)**

[Association of extrahepatic aneurysm of the hepatic artery and aneurysm of the portal trunk in a patient with liver cirrhosis (letter)] Rifflet H, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):958–60 **(Fre)**

[Late diagnosis of a traumatic pseudo-aneurysm of the subclavian artery] Coulier B, et al. **J Belge Radiol** 1996 Feb;79(1):26–8 (Eng. Abstr.) **(Fre)**

[Aneurysm developed at the level of a femoropopliteal bypass with ex-situ venous graft 10 years later (letter)] Desoutter P, et al. **Presse Med** 1996 Jun 22;25(22):1039 **(Fre)**

-Aneurysm of the pulmonary artery and pulmonary artery hypertension 22 years after Mustard reversal operation in transposition of great vessels- Wagdi P, et al. **Z Kardiol** 1996 Feb;85(2):104–7 (Eng. Abstr.) **(Ger)**

[Pseudoaneurysms after carotid endarterectomy] Zanetti PP, et al. **Minerva Chir** 1995 Oct;50(10):889–93 (Eng. Abstr.) **(Ita)**

GENETICS

Unravelling the familial tendency to aneurysmal disease: popliteal aneurysm, hypertension and fibrillin genotype. MacSweeney ST, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):162–6

PATHOLOGY

Pedal aneurysms [letter] Herrmann M. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):250

Macroaneurysm of a cilioretinal artery [letter] Meller D, et al. **Ger J Ophthalmol** 1995 Sep;4(5):320

Aneurysmal and haemangiopericytoma-like fibrous histiocytoma. Zelger BW, et al. **J Clin Pathol** 1996 Apr; 49(4):313–8

CT and MRI of intracavernous carotid artery aneurysm with occlusion of the cervical internal carotid artery. Holemans JA, et al. **J Comput Assist Tomogr** 1995 Nov–Dec; 19(6):1006–7

Surgical treatment of splanchnic artery aneurysms secondary to medial degeneration: report of two cases. Doğan R, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):230–3

PHYSIOPATHOLOGY

Hemodynamics in aneurysm. Kumar BV, et al. **Comput Biomed Res** 1996 Apr;29(2):119–39

Aneurysmal bone cyst of the temporal bone presenting as hearing loss in a child. Sawin PD, et al. **Int J Pediatr Otorhinolaryngol** 1995 Nov;33(3):275–84

[Dysphagia, dysphonia and Horner's syndrome as a form of presentation of right subclavian artery aneurysm (letter)] Díaz-Villoslada P, et al. **Rev Neurol** 1996 Jul;24(131):868 **(Spa)**

RADIOGRAPHY

New approach in the diagnosis of and therapy for Hughes–Stovin syndrome [letter] Mahlo HR, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):817–8

Aortic coarctation with two intercostal aneurysms, appearing radiographically as a subclavian aneurysm. A case report. Kelsay DE, et al. **Angiology** 1996 Jan;47(1):103–6

Computed tomography appearance of idiopathic aneurysm of the azygos vein. Mehta M, et al. **Can Assoc Radiol J** 1996 Aug;47(4):288–90

Case 5. Presentation. Penetrating injury with pseudoaneurysm of lateral femoral circumflex artery. Stein LA, et al. **Can J Surg** 1995 Oct;38(5):401, 414

Portal hypertension with intra- and extrasplenic arterial aneurysms and large venous varices. Ueda J, et al. **Cardiovasc Intervent Radiol** 1995 Jul–Aug;18(4):243–6

Hilar mass in a patient with chest pain. Chetty KG, et al. **Chest** 1996 Jun;109(6):1643–4

Aneurysm of an anomalous right subclavian artery. Hiddema A, et al. **J Belge Radiol** 1995 Aug;78(4):231

Splenic artery aneurysm. Wassenaar RP, et al. **J Belge Radiol** 1995 Aug;78(4):244

CT and MRI of intracavernous carotid artery aneurysm with occlusion of the cervical internal carotid artery. Holemans JA, et al. **J Comput Assist Tomogr** 1995 Nov–Dec; 19(6):1006–7

Regressing microaneurysms in 5 cases of hepatitis B virus related polyarteritis nodosa. Darras-Joly C, et al. **J Rheumatol** 1995 May;22(5):876–80

Aneurysm of an artery of Buhler: an unusual case [letter] Kugai T, et al. **J Vasc Surg** 1996 Mar;23(3):537–8

Left hilar mass in a 62-year-old man: severe pulmonary valvular stenosis with a poststenotic aneurysm. Rumbak MJ, et al. **South Med J** 1996 Aug;89(8):824–5

RADIONUCLIDE IMAGING

Incidental detection of arterial aneurysms with Tc-99m human serum albumin. Aoyagi K, et al. **Clin Nucl Med** 1996 Jun;21(6):485–6

Radionuclide captopril renography in postpartum renal artery aneurysms. Turpin S, et al. **J Nucl Med** 1996 Aug; 37(8):1368–71

SURGERY

Insertion of an aortic and pulmonary homograft for simultaneous reconstruction of the left and right ventricular outflow tracts. A case report. Beyens T, et al. **Acta Chir Belg** 1995 Sep–Oct;95(5):237–40

Emergency aorto-iliac aneurysm surgery with low mortality and morbidity. Tobon Morales R, et al. **Acta Chir Belg** 1995 Sep–Oct;95(5):223–5

Endovascular stents and stented grafts for the treatment of aneurysms and other arterial lesions. Marin ML, et al. **Adv Surg** 1996;29:93–109 (50 ref.)

Perioperative management of aneurysmal subarachnoid hemorrhage: Part I. Operative management. Guy J, et al. **Anesth Analg** 1995 Nov;81(5):1060–72 (154 ref.)

Aneurysm of the left pulmonary artery: surgical allograft repair. Casselman F, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1423–5 (6 ref.)

Repair of an aneurysm of the left main coronary artery. Lepojärvi M, et al. **Ann Thorac Surg** 1996 Apr;61(4):1247–9 (11 ref.)

Surgical therapy of pulmonary arterial aneurysms in Behçet's syndrome. Tüzün H, et al. **Ann Thorac Surg** 1996 Feb; 61(2):733–5

Ruptured and unruptured intracranial aneurysms--surgical outcome. Dix GA, et al. **Can J Neurol Sci** 1995 Aug; 22(3):187–91

Venous aneurysm of extremities: a case report and literature review. Legnani G, et al. **Cardiovasc Surg** 1995 Aug; 3(4):445–6

Surgical management of concurrent, coeliac and bilateral iliac artery aneurysms. Rodrigus IE, et al. **Cardiovasc Surg** 1995 Oct;3(5):501–3

The present status of endoluminal stented grafts for the treatment of aneurysms, traumatic injuries and arterial occlusions. Veith FJ, et al. **Cardiovasc Surg** 1996 Feb; 4(1):3–7 (30 ref.)

True aneurysm of the uterine artery. Davidsen MB, et al. **Eur J Surg** 1995 Oct;161(10):775–6

A safe combined surgical/radiological approach to endoluminal graft stenting of a popliteal aneurysm. Joyce WP, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):489–91

Successful resection of simultaneous aneurysms of the superior mesenteric and right renal artery. Rupprecht H, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):492–5

Aneurysm of a congenitally persistent sciatic artery presenting as a soft-tissue mass of the buttock. A case report. Benevenia J, et al. **J Bone Joint Surg Am** 1995 Nov; 77(11):1724–8 (33 ref.)

Internal carotid artery aneurysm. A case report. Auer AI, et al. **J Cardiovasc Surg (Torino)** 1996 Feb;37(1):21–3

Surgical treatment of mesenteric infarction, thoracoabdominal aortic aneurysm, and proper hepatic aneurysm in a middle-aged woman with Takayasu's arteritis. Koyama M, et al. **J Cardiovasc Surg (Torino)** 1995 Aug;36(4):337–41

Stent graft for popliteal aneurysms. Six cases with Cragg Endo-Pro System 1 Mintec. Marcadé JP. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:41–4

Stent graft for popliteal aneurysms. Six cases with Cragg Endo-Pro System 1 Mintec. Marcadé JP. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):41–4

Hepatic artery aneurysm: an ever present danger. Salcuni PF, et al. **J Cardiovasc Surg (Torino)** 1995 Dec;36(6):595–9

Isolated true atherosclerotic aneurysms of the deep femoral artery. Case report and literature review. Yahel J, et al. **J Cardiovasc Surg (Torino)** 1996 Feb;37(1):17–20 (23 ref.)

Extracranial internal carotid artery aneurysms: results of a surgical series with long-term follow-up. Faggioli GL, et al. **J Vasc Surg** 1996 Apr;23(4):587–94; discussion 594–5

Endovascular repair of subclavian artery aneurysm [letter] MacSweeney ST, et al. **J Vasc Surg** 1996 Aug;24(2):304–5

Acute median nerve compression at the distal forearm caused by a thrombosed aneurysm of an epineural vessel: case report. Fricker R, et al. **Neurosurgery** 1996 Jan;38(1):194–6

Surgical treatment of an enormous aneurysmal portahepatic venous fistula: report of a case. Miyauchi A, et al. **Surg Today** 1995;25(9):855–8 (11 ref.)

Vein aneurysms of the lower extremities [letter] Volteas SK, et al. **Surgery** 1996 Mar;119(3):356–7

Aneurysm following ligation of patent ductus arteriosus [see comments] De DH, et al. **Tex Heart Inst J** 1995;22(4):324–6 . Comment in: Tex Heart Inst J 1996;23(1):71–2.

Combined membranous obstruction and saccular aneurysm of the inferior vena cava. Augustin N, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):223–6 (30 ref.)

Surgical treatment of splanchnic artery aneurysms secondary to medial degeneration: report of two cases. Doğan R, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):230–3

Immediate impotence after penetrating perineal trauma: restoration of erections with penile artery revascularization, corpus cavernosum aneurysm repair, and deep penile venous ligation. Licht MR, et al. **Urology** 1995 Oct; 46(4):577–80

[Aneurysms of the popliteal artery. Intravascular bypass using the internal saphenous vein] Roux D, et al. **Presse Med** 1995 Dec 16–23;24(39):1899–1900 (Eng. Abstr.) **(Fre)**

[Isolated, true aneurysm of the tibiofibular trunk--a rarity among peripheral aneurysms] Nahrstedt U, et al. **Vasa** 1995; 24(4):373–6 (Eng. Abstr.) **(Ger)**

[Aneurysm of the popliteal artery in a patient over 80 years of age] Bellitti R, et al. **Minerva Cardioangiol** 1995 Jun; 43(6):287–8 (Eng. Abstr.) **(Ita)**

[Aneurysm of the iliac artery] Morbidelli A, et al. **Minerva Chir** 1995 Sep;50(9):767–71 (Eng. Abstr.) **(Ita)**

[Problems of indications for the treatment of aneurysm of the visceral arteries] Palumbo N, et al. **Minerva Chir** 1995 Sep;50(9):747–55 (Eng. Abstr.) **(Ita)**

[Surgery of aneurysm of the left subclavian artery applying imaged thoracoscopy--a case report] Yamada K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1012–5 (Eng. Abstr.) **(Jpn)**

[Anterior choroidal artery territory infarction with transcortical sensory aphasia after a neck clipping of left internal carotid artery aneurysms: a case report] Takei A, et al. **No Shinkei Geka** 1996 Jan;24(1):63–7 (Eng. Abstr.) **(Jpn)**

[Diagnosis and treatment of lesions of the subclavian artery] Shor NA. **Klin Khir** 1995;(7–8):4–6 **(Rus)**

[The multistage surgical treatment of multiple spontaneous arterial aneurysms] Ermolaev VL, et al. **Vestn Khir Im I I Grek** 1992 Nov–Dec;149(11–12):340–2 **(Rus)**

[The resection of a femoral artery aneurysm in a patient with Waldenström's syndrome] Ukhanov AP, et al. **Vestn Khir Im I I Grek** 1992 Mar;148(3):306–7 **(Rus)**

THERAPY

Histologic effects of collagen-filled interlocking detachable coils in the ablation of experimental aneurysms in swine. Dawson RC 3rd, et al. **AJNR Am J Neuroradiol** 1996 May; 17(5):853–8

Curing a consumption coagulopathy with transcatheter embolization of a visceral artery aneurysm. Suhocki PV, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):982–4

Embolization of hepatic artery pseudo-aneurysm facilitated by selective injection of thrombin and thrombin-soaked coils. Landy P, et al. **Australas Radiol** 1995 Aug;39(3):257–9

Successful exclusion of a large femoropopliteal aneurysm with a covered nitinol stent. Dorffner R, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):117–9

Case report: treatment of a carotid artery pseudoaneurism with a polyester covered nitinol stent. Nicholson A, et al. **Clin Radiol** 1995 Dec;50(12):872–3

The radiological treatment of hepatic artery aneurysms. O'Connor PJ, et al. **Clin Radiol** 1995 Nov;50(11):792–6

Selective embolization of pseudo-aneurysms of the renal artery after blunt abdominal injury in a patient with a single kidney. Steffens MG, et al. **Injury** 1996 Apr;27(3):219–20

Closure of a persistent femoral artery pseudoaneurysm complicating coronary angioplasty using the femostop compression device and direct ultrasound visualization. Sabri N, et al. **Int J Card Imaging** 1995 Dec;11(4):273–5

Selective embolization of a superior gluteal artery pseudoaneurysm associated with von Willebrand's disease. De Foer B, et al. **J Belge Radiol** 1996 Jun;79(3):135–6

Embolization of bleeding gastroduodenal pseudoaneurysm in pancreatitis. Stockx L, et al. **J Belge Radiol** 1995 Oct; 78(5):271–3

Hepatic artery aneurysms: the management of 22 patients. Lumsden AB, et al. **J Surg Res** 1996 Feb 1;60(2):345–50

Effect of Guglielmi detachable coils on experimental carotid artery aneurysms in primates. Tenjin H, et al. **Stroke** 1995 Nov;26(11):2075–80

Options for treatment of persistent aneurysm perfusion after endovascular repair. Ivancev K, et al. **World J Surg** 1996 Jul–Aug;20(6):673–8

[Pseudoaneurysm of the femoral artery treated with color Doppler ultrasonography-guided compression] Sillesen HH, et al. **Ugeskr Laeger** 1995 Sep 11;157(37):5101–3 (Eng. Abstr.) **(Dan)**

[Selective embolization of an aneurysm in a massive angiomyolipoma of the kidney] De Wever W, et al. **J Belge Radiol** 1996 Jun;79(3):137–8 (Eng. Abstr.) **(Dut)**

[Percutaneous treatment of popliteal aneurysms using a covered stent: preliminary clinical experience] Gieskes L, et al. **J Mal Vasc** 1995;20(4):264–7 (Eng. Abstr.) **(Fre)**

[Experiences with the endovascular embolization therapy of aneurysms of the splanchnic arteries--a report on 13 cases] Kramann B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):417–23 (35 ref.) (Eng. Abstr.) **(Ger)**

[The initial results of percutaneous therapy of popliteal aneurysms with stents] Link J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):244–8 (Eng. Abstr.) **(Ger)**

[Management of an iliac artery aneurysm with percutaneous placement of a Dacron-nitinol vascular endoprosthesis] Sievert H, et al. **Z Kardiol** 1995 Oct;84(10):860–2 (Eng.

Abstr.) **(Ger)**

[Hand fatigue? An alternative compression method in pseudoaneurysm (letter)] Ax G. **Lakartidningen** 1996 Jun 19;93(25):2408 **(Swe)**

[Pseudoaneurysm is most easily cured with ulrasound] Geijer H, et al. **Lakartidningen** 1996 May 15;93(20):1941–3 **(Swe)**

ULTRASONOGRAPHY

Azygos vein aneurysm: contribution of transesophageal echography. Léna H, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1253–5 (7 ref.)

A pulsatile gluteal mass due to sciatic artery aneurysm. Chleboun JO, et al. **Aust N Z J Surg** 1995 Dec; 65(12):907–10 (18 ref.)

Popliteal vein compression due to popliteal artery aneurysm: effects of aneurysm size. Kotval PS, et al. **J Ultrasound Med** 1995 Nov;14(11):805–11

[2 cases of giant aneurysm of the splenic artery: contribution of Doppler echography] Louvegny S, et al. **J Belge Radiol** 1995 Jun;78(3):177–9 (Eng. Abstr.) **(Fre)**

[Differential diagnosis of malignant neck tumors. Aneurysm of the common carotid artery] Ganz H. **HNO** 1995 Dec; 43(12):737–9 (Eng. Abstr.) **(Ger)**

[Splenic vein aneurysm: diagnosis with color-coded duplex ultrasound] Schmidt HG. **Leber Magen Darm** 1995 Sep; 25(5):227–8, 231 (Eng. Abstr.) **(Ger)**

[Aneurysm of the right hepatic artery. Diagnosis by color Doppler echography] Cozza S, et al. **Radiol Med (Torino)** 1995 Dec;90(6):834–7 (17 ref.) **(Ita)**

ANEURYSM, ARTERIOVENOUS see **ARTERIOVENOUS FISTULA**

ANEURYSM, BACTERIAL see **ANEURYSM, INFECTED**

ANEURYSM, CORONARY see **CORONARY ANEURYSM**

ANEURYSM, DISSECTING

Spontaneous dissection of the hepatic artery. Müller MF, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):462–5 (13 ref.)

Myocardial infarction and coronary artery dissection in pregnancy. Coulson CC, et al. **Am J Perinatol** 1995 Sep; 12(5):328–30

Management of descending aortic dissection. Orend KH, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):821–4 (8 ref.)

Three-channeled aortic dissection. Ishikawa S, et al. **Ann Thorac Surg** 1995 Dec;60(6):1816–8

Pregnancy complicated by aortic dissection: caesarean delivery during extradural anaesthesia. Jayaram A, et al. **Br J Anaesth** 1995 Sep;75(3):358–60

[Multiple spontaneous coronary dissection. Case report and review of the literature] Piovaccari G, et al. **Cardiologia** 1995 May;40(5):361–4 (Eng. Abstr.) **(Ita)**

[Localized dissection of the abdominal aorta. Diagnosis and surgical treatment] Esposito G, et al. **Minerva Chir** 1995 Jul–Aug;50(7–8):713–6 (Eng. Abstr.) **(Ita)**

[Pathophysiology and clinical aspects of dissecting aortic aneurysms] Szabóová-Tomoriová E, et al. **Vnitr Lek** 1995 Jul;41(7):480–4 (36 ref.) (Eng. Abstr.) **(Slo)**

BLOOD

[Influence of acute aortic dissection, on platelet function second department of surgery, department of pharmacy: preliminary report] Moriyama Y, et al. **Nippon Geka Gakkai Zasshi** 1995 Oct;96(10):725 **(Jpn)**

CHEMICALLY INDUCED

Intermittent cocaine use associated with recurrent dissection of the thoracic and abdominal aorta. Chang RA, et al. **Chest** 1995 Dec;108(6):1758–62

COMPLICATIONS

Cranial nerve palsies due to internal carotid artery dissection: seven cases. Gobert M, et al. **Acta Neurol Belg** 1996 Mar; 96(1):55–61

Spontaneous coronary artery dissection in a young man with inferior wall myocardial infarction. Shah C, et al. **Am Heart J** 1996 Sep;132(3):696–8

Acute myocardial infarction in a patient with primary coronary dissection and severe coronary vasospasm. A case report. Imamura M, et al. **Angiology** 1995 Oct;46(10):951–5

Aortic aneurysm and dissection in giant cell arteritis [letter] Ginsburg R. **Ann Intern Med** 1996 Mar 15;124(6):615

Survival after aortic dissection in giant cell arteritis [letter] Richardson MP, et al. **Ann Rheum Dis** 1996 May; 55(5):332–3 (20 ref.)

Right ventricular obstruction in aortic dissection: a mechanism of hemodynamic collapse. Downey RJ, et al. **Ann Thorac Surg** 1996 Mar;61(3):988–90

Type B aortic dissection involving an isolated right-sided aortic arch. Masiello P, et al. **Ann Thorac Surg** 1996 Sep; 62(3):887–8

Lymphoplasmacytic aortitis and acute aortic dissection. An uncommon association. Faye-Petersen OM, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):402–4 (20 ref.)

Myocardial infarction resulting from coronary artery dissection in an adolescent with Ehlers-Danlos syndrome type IV due to a type III collagen mutation. Adès LC, et al. **Br Heart J** 1995 Aug;74(2):112–6

Acute infectious mitroaortic endocarditis in association with acute aortic dissection. Surgical management of an unusual combination of diseases. Abad C. **Cardiovasc Surg** 1995 Dec;3(6):605–6

Case report: critical lower limb ischaemia due to aortic dissection relieved by percutaneous transfemoral fenestration. Cowling MG, et al. **Clin Radiol** 1995 Sep; 50(9):654–7

Spontaneous coronary artery dissection in mitral stenosis. Fournier JA, et al. **Eur Heart J** 1995 Jun;16(6):869–71

Spontaneous coronary artery dissection: a neglected cause of acute myocardial ischaemia and sudden death. Basso C, et al. **Heart** 1996 May;75(5):451–4

Follow up after spontaneous coronary artery dissection: a report of five cases. Zampieri P, et al. **Heart** 1996 Feb; 75(2):206–9

Raeder's syndrome. Report of two cases. Zournas C, et al. **Int Angiol** 1995 Dec;14(4):415–7

Sudden death caused by retrograde aortic dissection during repair of a descending thoracic aneurysm. O'Connor CJ, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):380–3

Sudden death from coronary artery dissection [see comments] Bateman AC, et al. **J Clin Pathol** 1995 Aug;48(8):781–4. Comment in: J Clin Pathol 1996 May;49(5):437.

Subarachnoid haemorrhage and myths about saccular aneurysms. Weller RO. **J Clin Pathol** 1995 Dec; 48(12):1078–81 (29 ref.)

Aortic dissection presenting as a neurological emergency. Garrard P, et al. **J R Soc Med** 1996 May;89(5):271–2

Acute aortic dissection with intramural hematoma: possibility of transition to classic dissection or aneurysm. Ide K, et al. **J Thorac Imaging** 1996 Winter;11(1):46–52

Aortic dissection: percutaneous management of ischemic complications with endovascular stents and balloon fenestration. Slonim SM, et al. **J Vasc Surg** 1996 Feb; 23(2):241–51; discussion 251–3

Cranial nerve palsy in spontaneous dissection of the extracranial internal carotid artery. Mokri B, et al. **Neurology** 1996 Feb;46(2):356–9

Internal carotid artery redundancy is significantly associated with dissection [letter; comment] Ben Hamouda-M'Rad I, et al. **Stroke** 1995 Oct;26(10):1962. Comment on: Stroke 1994 Jun;25(6):1201–6.

Traumatic laceration of the intracranial vertebral artery causing fatal subarachnoid hemorrhage: case report. Asai T, et al. **Surg Neurol** 1996 Jun;45(6):566–8; discussion 568–9

[Dissecting aortic aneurysm combined with hepatorenal syndrome] Procházka J, et al. **Vnitr Lek** 1995 Jul; 41(7):462–6 (Eng. Abstr.) **(Cze)**

[Dissection of a vertebral artery as a complication of neck manipulation] Löfberg M, et al. **Duodecim** 1994; 110(12):1155–9 **(Fin)**

[Spontaneous dissection of the cervical arteries] Venne D, et al. **Ann Chir** 1995;49(8):743–8 (Eng. Abstr.) **(Fre)**

[Involvement of the major hypoglossal nerve disclosing dissection of internal carotid artery] Auzou P, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(1):45–7 (Eng. Abstr.) **(Fre)**

[Myocardial infarction by spontaneous dissection of coronary arteries in a subject with type IV Ehlers-Danlos syndrome] Catanese V, et al. **Presse Med** 1995 Oct 7;24(29):1345–7 (Eng. Abstr.) **(Fre)**

[Dissection of the epiaortic vessels: an emergency pathology as the cause of focal cerebral ischemia. The evaluation of a case load of 7 patients] Landini G, et al. **Ann Ital Med Int** 1996 Jan–Mar;11(1):12–6 (Eng. Abstr.) **(Ita)**

[Aortic dissection similar to giant cell arteritis: diagnostic difficulties and efficacy of steroid therapy] Cordioli E, et al. **Minerva Med** 1995 Jul–Aug;86(7–8):331–5 (Eng. Abstr.) **(Ita)**

[Raeder's syndrome (the paratrigeminal syndrome): its etiology related to carotid artery dissection. A case report] Monti L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):473–5 (16 ref.) **(Ita)**

[Two case reports of Stanford type A acute aortic dissection complicated with thrombosed false lumen and sacculer aneurysm formation] Jinno T, et al. **Kyobu Geka** 1995 Oct; 48(11):937–40 (Eng. Abstr.) **(Jpn)**

[The shock patients with the cardiac tamponade resulting from acute type A aortic dissection] Murata N, et al. **Kyobu Geka** 1996 Jun;49(6):460–3 (Eng. Abstr.) **(Jpn)**

[A successful repair of the aortic dissection (DeBakey type I) with ischemic complications of the kidney and lower extremities] Uwabe K, et al. **Kyobu Geka** 1995 Aug; 48(9):792–5 (Eng. Abstr.) **(Jpn)**

[A case of dissecting aneurysm of the basilar artery presented as superior pons type of Foville's syndrome] Nakaso K, et al. **Rinsho Shinkeigaku** 1995 Sep;35(9):1040–3 (Eng. Abstr.) **(Jpn)**

[Arterial hypertension complicated by aortic dissection. Clinical analysis, results of conservative treatment] Grajek S, et al. **Przegl Lek** 1996;53(2):60–6 (Eng. Abstr.) **(Pol)**

[Coronary artery dissection without acute myocardial infarction] da Rocha AS, et al. **Arq Bras Cardiol** 1995 Jun; 64(6):557–8 (Eng. Abstr.) **(Por)**

[Rupture of type A aortic dissection into right cardiac cavities] Salas Lobato A, et al. **Rev Esp Cardiol** 1996 Mar; 49(3):233–5 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Dissection of the internal carotid artery: aetiology, symptomatology, clinical and neurosonological follow-up, and treatment in 60 consecutive cases. Desfontaines P, et al. **Acta Neurol Belg** 1995 Dec;95(4):226–34

Cervicocranial artery dissection. Detection by Doppler ultrasound and MR angiography. Bakke SJ, et al. **Acta Radiol** 1996 Jul;37(4):529–34

Flow-related enhancement in the vertebral plexus mimicking an intramural hematoma [letter] Miaux Y, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):191–2

Traumatic internal carotid artery dissection presenting as delayed hemilingual paresis. Pica RA Jr, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):86–8

Primary dissecting aneurysm of the hepatic artery: sonographic, CT, and angiographic findings. Garcia P, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1316–8

Dissection of the internal carotid and vertebral arteries: imaging features. Provenzale JM. **AJR Am J Roentgenol** 1995 Nov;165(5):1099–104 (53 ref.)

Follow-up of chronic thoracic aortic dissection: comparison of transesophageal echocardiography and magnetic resonance imaging. Masani ND, et al. **Am Heart J** 1996 Jun;131(6):1156–63

Chest pain and aortic dissection [letter; comment] Bazarian JJ, et al. **Ann Emerg Med** 1995 Oct;26(4):526–7. Comment on: Ann Emerg Med 1995 Feb;25(2):274–99.

Detecting acute thoracic aortic dissection in the emergency department: time constraints and choice of the optimal diagnostic test [see comments] Sarasin FP, et al. **Ann Emerg Med** 1996 Sep;28(3):278–88. Comment in: Ann Emerg Med 1996 Sep;28(3):349–51.

Thoracic aortic dissection: ruling in and ruling out [editorial; comment] Wolfson AB, et al. **Ann Emerg Med** 1996 Sep; 28(3):349–51. Comment on: Ann Emerg Med 1996 Sep;28(3):278–88.

Acute dissection of the aorta: options for diagnostic imaging. Razavi M. **Cleve Clin J Med** 1995 Nov–Dec;62(6):360–5 (16 ref.)

Management of aortic dissection. Westaby S. **Curr Opin Cardiol** 1995 Sep;10(5):505–10 (17 ref.)

Primary dissection of the abdominal aorta. Satta J, et al. **Eur J Surg** 1995 Jul;161(7):527–9

Three-dimensional time-of-flight MR angiography and MR imaging versus conventional angiography in carotid artery dissections. Stringaris K, et al. **Int Angiol** 1996 Mar; 15(1):20–5

Spontaneous dissection of the vertebral artery. Van Ruyssevelt C, et al. **J Belge Radiol** 1995 Aug;78(4):242

Spontaneous vertebral dissection: clinical, conventional angiographic, CT, and MR findings. Provenzale JM, et al. **J Comput Assist Tomogr** 1996 Mar–Apr;20(2):185–93

Evaluation of thoracic aortic dissection using breath-holding cine MRI. Sakuma H, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):45–50

Magnetic resonance angiography of spontaneous vertebral artery dissection suspected on Doppler ultrasonography. Röther J, et al. **J Neurol** 1995 Jul;242(7):430–6

Sequential MR signal change of the thrombus in the false lumen of thrombosed aortic dissection. Kaminaga T, et al. **Magn Reson Imaging** 1995;13(6):773–9

Fast spoiled gradient-recalled MR imaging of thoracic aortic dissection: preliminary clinical experience at 1.5 T. Summers RM, et al. **Magn Reson Imaging** 1996;14(1):1–9

Spontaneous extracranial carotid artery dissection in children. Patel H, et al. **Pediatr Neurol** 1995 Jul;13(1):55–60 (26 ref.)

Internal carotid artery dissection: MR imaging features and clinical-radiologic correlation. Ozdoba C, et al. **Radiology** 1996 Apr;199(1):191–8

Aortic dissection: a comparative study of diagnosis with spiral CT, multiplanar transesophageal echocardiography, and MR imaging. Sommer T, et al. **Radiology** 1996 May; 199(2):347–52

Spontaneous dissecting aneurysm of the anterior cerebral artery: report of two cases. Koyama S, et al. **Surg Neurol** 1996 Jul;46(1):55–61 (15 ref.)

[Exploration of the thoracic aorta, excluding the aortic valve] Douek P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):552–60 (12 ref.) (Eng. Abstr.) **(Fre)**

[Aortic dissection and pregnancy. Apropos of a case] Helms E, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):397–9 (Eng. Abstr.) **(Fre)**

[Aortic dissection. Symptoms with indications for surgery] Defraigne JO, et al. **Rev Med Liege** 1996 Jun;51(6):411–25 (49 ref.) **(Fre)**

[Clinical evaluation and neurological ultrasonography in 60 cases of carotid dissection] Despland PA, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):591–6 (29 ref.) **(Fre)**

[Dissection of the carotid artery and vertebral artery--diagnosis and therapy] Sperling W, et al. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):153–60 (37 ref.) (Eng. Abstr.) **(Ger)**

[Cerebral artery dissection] Sturzenegger M, et al. **Ther Umsch** 1996 Jul;53(7):544–51 (32 ref.) (Eng. Abstr.) **(Ger)**

[Intramural hemorrhage of the thoracic aorta as a precursor of dissection] Kodolitsch Y, et al. **Z Kardiol** 1995 Nov; 84(11):939–46 (Eng. Abstr.) **(Ger)**

[Diagnostic accuracy of transesophageal echocardiography in the diagnosis of aortic dissection: comparison with

computerized axial tomography] Nicosia A, et al. **Cardiologia** 1995 May;40(5):329–39 (Eng. Abstr.) **(Ita)**

[Total atrioventricular block as the primary clinical manifestation of undiagnosed aortic dissection] Lorenzoni R, et al. **G Ital Cardiol** 1995 Aug;25(8):1031–5 (12 ref.) (Eng. Abstr.) **(Ita)**

[Spontaneous dissection of the left vertebral artery in a young woman. A report and the diagnostic considerations of a case] La Brocca A, et al. **Minerva Med** 1996 Jan–Feb; 87(1–2):41–4 (23 ref.) (Eng. Abstr.) **(Ita)**

[A case of recanalized basilar artery following basilar artery occlusion due to spontaneous dissection] Hashimoto Y, et al. **Rinsho Shinkeigaku** 1995 Nov;35(11):1225–9 (Eng. Abstr.) **(Jpn)**

[Unusual clinical course of ruptured aortic aneurysms--report of three cases] Mitkowski P, et al. **Pol Arch Med Wewn** 1995 Jan;93(1):69–76 (Eng. Abstr.) **(Pol)**

[Unusual clinical course of ruptured aortic aneurysms--reports of three cases (corrected and republished article originally printed in Pol Arch Med Wewn 1995 Jan;93(1):69–76)] Mitkowski P, et al. **Pol Arch Med Wewn** 1995 Feb;93(2):171–8 (Eng. Abstr.) **(Pol)**

[Aortic intramural hematoma. An atypical pattern equivalent to aortic dissection] López-Mínguez JR, et al. **Rev Esp Cardiol** 1995 Sep;48(9):634–7 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Thrombolytic drugs and acute aortic dissection [letter; comment] Menon V, et al. **Am Heart J** 1995 Dec; 130(6):1312–3. Comment on: Am Heart J 1994 Dec;128(6 Pt 1):1234–7.

Successful thrombolysis treatment of a spontaneous left main coronary artery dissection without subsequent surgery [letter] Leclercq F, et al. **Eur Heart J** 1996 Feb;17(2):320–1

EPIDEMIOLOGY

Thoracic and thoracoabdominal aortic aneurysm and dissection: an investigation based on autopsy. Svensjö S, et al. **Br J Surg** 1996 Jan;83(1):68–71

Aortic dissection in Taiwan. Liao WB, et al. **Jpn Heart J** 1995 Sep;36(5):639–45

Recurrent spontaneous arterial dissections: risk in familial versus nonfamilial disease. Schievink WI, et al. **Stroke** 1996 Apr;27(4):622–4

ETIOLOGY

Aortic dissection complicating coronary angioplasty in cystic medial necrosis. Pande AK, et al. **Am Heart J** 1996 Jun; 131(6):1221–3

Myocardial infarction and coronary artery dissection during pregnancy associated with type IV Ehlers–Danlos syndrome. Athanassiou AM, et al. **Am J Perinatol** 1996 Apr;13(3):181–3

Dissection of an allograft ascending aorta after aortic root replacement. Smith JA, et al. **Ann Thorac Surg** 1996 Mar; 61(3):1011–2

Aortic dissection in a 5-year old girl with Marfan's syndrome [letter] Ruiz ME, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):440–2 (14 ref.)

Traumatic carotid and vertebral artery dissection in a professional jockey: a cautionary tale. Fletcher J, et al. **Br J Sports Med** 1995 Jun;29(2):143–4

Late development of dissecting aneurysm following balloon angioplasty of native aortic coarctation [see comments] Aydogan U, et al. **Cathet Cardiovasc Diagn** 1995 Nov; 36(3):226–9. Comment in: Cathet Cardiovasc Diagn 1995 Nov;36(3):230–1.

Coronary dissection resulting from angioplasty with slow oscillating vs. rapid inflation and slow vs. rapid deflation. Blankenship JC, et al. **Cathet Cardiovasc Diagn** 1995 Mar; 34(3):202–9

Aneurysm associated with balloon angioplasty of aortic coarctation: future prevention and treatment [editorial; comment] Ruiz CE, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):230–1. Comment on: Cathet Cardiovasc Diagn 1995 Nov;36(3):226–9.

A closed-chest porcine model of coronary dissection and thrombosis. Bikkina M, et al. **Coron Artery Dis** 1995 Aug; 6(8):651–5

Post coital coronary artery dissection [letter] Pierli C, et al. **Eur Heart J** 1995 Dec;16(12):2004–5

The pathogenesis of spontaneous arterial dissection. Davies MJ, et al. **Heart** 1996 May;75(5):434–5

Aortic dissection in a cardiac allograft recipient: a case report. Pak PH, et al. **J Heart Lung Transplant** 1995 Sep–Oct;14(5):1003–5

Vascular complications of total abdominal perfusion and aortic stop-flow infusion. Klein ES, et al. **J Surg Oncol** 1996 Jan;61(1):17–9

Acute aortic dissection after blunt chest trauma. Gammie JS, et al. **J Trauma** 1996 Jan;40(1):126–7

Whiplash injury associated with acute bilateral internal carotid arterial dissection. Janjua KJ, et al. **J Trauma** 1996 Mar;40(3):456–8

Antiplatelet and anticoagulant therapy after coronary-artery stenting [letter] Cequier A, et al. **N Engl J Med** 1996 Oct 10;335(15):1160–1

Chronic aortic dissection: presentation as acute renal failure. Manso C, et al. **Nephrol Dial Transplant** 1995;10(5):690–2

Dissection of the internal carotid artery after chiropractic manipulation of the neck. Peters M, et al. **Neurology** 1995 Dec;45(12):2284–6

Dissection of the atrial wall after mitral valve replacement. Lukács L, et al. **Tex Heart Inst J** 1996;23(1):62–4

Aortic dissection after aortic valve replacement. Report of a case with an aortocameral fistula. Tayama K, et al. **Thorac Cardiovasc Surg** 1995 Oct;43(5):299–301

[Dissection of a vertebral artery as a complication of neck manipulation] Löfberg M, et al. **Duodecim** 1994; 110(12):1155–9 **(Fin)**

[Horton disease and aortic involvement (letter; comment)] Lévesque H, et al. **Presse Med** 1995 Oct 21;24(31):1447. Comment on: Presse Med 1995 May 27;24(19):915. **(Fre)**

[Traumatic injury of the internal carotid artery in the extracranial segment. Description of a severe late complication] Wurm G, et al. **Chirurg** 1995 Sep;66(9):916–9 (Eng. Abstr.) **(Ger)**

[A case of aortic dissection associated with congenital bicuspid aortic valve] Fujiyoshi K, et al. **Kyobu Geka** 1996 Jun;49(6):468–70 (Eng. Abstr.) **(Jpn)**

GENETICS

Iris flocculi and familial aortic dissection. Lewis RA, et al. **Arch Ophthalmol** 1995 Oct;113(10):1330–1

Recurrent spontaneous arterial dissections: risk in familial versus nonfamilial disease. Schievink WI, et al. **Stroke** 1996 Apr;27(4):622–4

Familial aorto-cervicocephalic arterial dissections and congenitally bicuspid aortic valve. Schievink WI, et al. **Stroke** 1995 Oct;26(10):1935–40

[Another case of dissecting aortic aneurysm with familial incidence] Conte MR, et al. **Cardiologia** 1992 Jul; 37(7):513–7 (19 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Four-barrel aortic dissection involving the ascending aorta. A case report. Ohte N, et al. **Angiology** 1995 Nov; 46(11):1059–62

Concurrent pulmonary arterial dissection and saccular aneurysm associated with primary pulmonary hypertension. Masuda S, et al. **Arch Pathol Lab Med** 1996 Mar; 120(3):309–12

Coronary artery dissection [letter; comment] Mooney EE, et al. **J Clin Pathol** 1996 May;49(5):437. Comment on: J Clin Pathol 1995 Aug;48(8):781–4.

Middle cerebral artery dissection: a clinicopathologic study. Sharif AA, et al. **Neurology** 1995 Oct;45(10):1929–31

Aortitis with dissection complicating systemic lupus erythematosus. Guard RW, et al. **Pathology** 1995 Jul; 27(3):224–8

Aortic dissection in giant-cell arteritis. Liu G, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):160–71

PHYSIOPATHOLOGY

Electrocardiographic abnormalities in patients with acute aortic dissection. Hirata K, et al. **Am J Cardiol** 1995 Dec 1;76(16):1207–12

Traumatic dissection of the internal carotid artery as unusual cause of hypoglossal nerve dysfunction. Lemmerling M, et al. **Clin Neurol Neurosurg** 1996 Feb;98(1):52–4

Spontaneous dissecting aneurysm of the anterior cerebral artery: report of two cases. Koyama S, et al. **Surg Neurol** 1996 Jul;46(1):55–61 (15 ref.)

[Eight cases of extracranial vertebral artery dissection] Pego R, et al. **Rev Neurol** 1996 Feb;24(126):172–5 (Eng. Abstr.) **(Spa)**

[Spontaneous dissection of the vertebral artery] Plaza I, et al. **Rev Neurol** 1996 Feb;24(126):163–71 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Iatrogenic dissecting aneurysm of the internal carotid artery. Kinugasa K, et al. **Acta Neurochir (Wien)** 1995; 137(3–4):226–31

Case quiz. Low VH. **Australas Radiol** 1995 Nov;39(4):415–6

Middle cerebral artery dissecting aneurysm with persistent patent pseudolumen. Case report. Mizutani T. **J Neurosurg** 1996 Feb;84(2):267–8

Rotational digital angiography of ulcer-like projection of pelvis. Tajima H, et al. **Radiat Med** 1996 Jan–Feb; 14(1):49–51

MR imaging in the diagnosis of aortic dissection [letter; comment] Hartnell GG. **Radiology** 1995 Oct;197(1):314–5 . Comment on: Radiology 1995 Feb;194(2):331–6.

Thoracic aortic aneurysm and aortic dissection: new endoscopic mode for three-dimensional CT display of aorta. Kimura F, et al. **Radiology** 1996 Feb;198(2):573–8

Helical CT for the diagnosis of extracranial internal carotid artery dissection. Leclerc X, et al. **Stroke** 1996 Mar; 27(3):461–6

[Contribution of the cervical scanner with injection in the diagnosis of vertebral artery dissection] Klinkert A, et al. **J Radiol** 1995 Aug;76(8):491–6 (Eng. Abstr.) **(Fre)**

[Circular dissection of the ascending aorta with intimo-intimal invagination. CT diagnosis of a rare form of aortic dissection] Hillemanns A, et al. **Radiologe** 1996 May;36(5):446–8 (Eng. Abstr.) **(Ger)**

[Long-term follow-up after acute myocardial infarct cause by non-arteriosclerotic spontaneous coronary artery dissection] Strick S, et al. **Z Kardiol** 1996 Mar;85(3):183–7 (Eng. Abstr.) **(Ger)**

[Late phase contrast enhanced-CT analysis of thrombosed type aortic dissection] Hayashi H, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(12):845–54 (Eng. Abstr.) **(Jpn)**

[Virtual CT endoscopy "Cruising Eye View": development and clinical applications] Hayashi H, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Feb; 56(3):135–6 (Eng. Abstr.) **(Jpn)**

[Vertebral artery dissection without subarachnoid hemorrhage studied by serial angiography] Akiyama Y, et al. **No Shinkei Geka** 1996 May;24(5):443–9 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Renal scintigraphy in the diagnosis of aortic dissection affecting the renal arteries. Gorenberg M, et al. **Clin Nucl Med** 1995 Sep;20(9):840–1

SURGERY

Critical-illness polyneuropathy complicating cardiac operation. Alhan HC, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1237–9 (8 ref.)

Embolization of biologic glue during repair of aortic dissection. Carrel T, et al. **Ann Thorac Surg** 1995 Oct; 60(4):1118–20

Repeat cardiac operation in a patient with osteogenesis imperfecta [letter; comment] Cusimano RJ. **Ann Thorac Surg** 1996 Apr;61(4):1294. Comment on: Ann Thorac Surg 1995 Nov;60(5):1395–7. Comment on: Ann Thorac Surg 1995 Nov;60(5):1397–9. Comment on: Ann Thorac Surg 1995 Nov;60(5):1439–43.

Operation for type A aortic dissection [letter] Lemole GM. **Ann Thorac Surg** 1995 Dec;60(6):1863–4

Embolization of biological glue after repair of acute aortic dissection [letter] Mastroroberto P, et al. **Ann Thorac Surg** 1996 Sep;62(3):946–7

Acute aortic dissection in a patient with osteogenesis imperfecta [see comments] Moriyama Y, et al. **Ann Thorac Surg** 1995 Nov;60(5):1397–9 (8 ref.). Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Selective management of acute type B aortic dissection: long-term follow-up. Schor JS, et al. **Ann Thorac Surg** 1996 May;61(5):1339–41

Aortoesophageal fistula after repair of descending aortic dissection. Wong RS, et al. **Ann Thorac Surg** 1996 Aug; 62(2):588–90

Dissecting descending thoracic and thoracoabdominal aortic aneurysms: Part II. Panneton JM, et al. **Ann Vasc Surg** 1995 Nov;9(6):596–605 (56 ref.)

Acute aortic dissection as a complication of coronary artery surgery. Subramaniam P, et al. **Aust N Z J Surg** 1996 Jul; 66(7):498–500

Acute infectious mitroaortic endocarditis in association with acute aortic dissection. Surgical management of an unusual combination of diseases. Abad C. **Cardiovasc Surg** 1995 Dec;3(6):605–6

Rupture of a dissecting thoracic aortic aneurysm into the pulmonary artery: successful surgical repair. Coselli JS, et al. **Cardiovasc Surg** 1995 Dec;3(6):697–701 (34 ref.)

Surgical management of aortic dissection during a 30-year period. Fann JI, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II113–21

Determining surgical indications for acute type B dissection based on enlargement of aortic diameter during the chronic phase. Kato M, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II107–12

Management of aortic dissection. Westaby S. **Curr Opin Cardiol** 1995 Sep;10(5):505–10 (17 ref.)

Acute ascending aortic dissection combined with chronic degenerative thoraco-abdominal aortic aneurysm [letter; comment] Abad C. **Eur J Cardiothorac Surg** 1995; 9(10):604–5. Comment on: Eur J Cardiothorac Surg 1994;8(11):616–8.

Aortic root replacement with a composite graft. Factors influencing immediate and long-term results. Bachet J, et al. **Eur J Cardiothorac Surg** 1996;10(3):207–13

Fate of the native aorta after repair of acute type A dissection: a magnetic resonance imaging study. Moore NR, et al. **Heart** 1996 Jan;75(1):62–6

Intraaortic mass after repair of an aortic dissection. Rosenzweig BP, et al. **J Am Soc Echocardiogr** 1996 Jan–Feb;9(1):100–3

Surgical management of instrumentation-induced coronary artery dissection. Robicsek F, et al. **J Card Surg** 1995 Nov; 10(6):626–31

Cardiopulmonary bypass in a post-lung-transplant patient. Cerza RF. **J Cardiothorac Vasc Anesth** 1996 Apr; 10(3):384–6

Detection of cerebral malperfusion in chronic type "A" aortic dissection: the importance of bilateral arterial monitoring. Patla VR, et al. **J Cardiothorac Vasc Anesth** 1996 Apr; 10(3):378–9

Simultaneous Bentall's procedure and sternal turnover in a patient with Marfan syndrome. Chien HF, et al. **J Cardiovasc Surg (Torino)** 1995 Dec;36(6):559–62

A fatal, chronically growing basilar artery: a new type of dissecting aneurysm. Mizutani T. **J Neurosurg** 1996 Jun; 84(6):962–71

Repair of aortic transection associated with ductal diverticular aneurysm. McKeown PP, et al. **J Pediatr Surg** 1995 Sep;30(9):1351-3

Renal autotransplantation for aortic dissection in Marfan's syndrome. Thomson SD, et al. **J R Soc Med** 1995 Sep; 88(9):532P-533P

Aortic valve preservation in acute type A dissection: is it sound? von Segesser LK, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):381-90; discussion 390-1

Endovascular graft placement in experimental dissection of the thoracic aorta. Boudghène F, et al. **J Vasc Interv Radiol** 1995 Jul-Aug;6(4):501-7

Spontaneous dissection in the common carotid artery--case report. Kawajiri K, et al. **Neurol Med Chir (Tokyo)** 1995 Jun;35(6):373-6

Ruptured dissecting aneurysm of the peripheral anterior cerebral artery--case report. Yano H, et al. **Neurol Med Chir (Tokyo)** 1995 Jul;35(7):450-3 (17 ref.)

Graft replacement of the dissecting aneurysm originating in the suprarenal abdominal aorta. A case report. Urayama H, et al. **Panminerva Med** 1996 Mar;38(1):37-40

Single-stage replacement of the entire thoracic aorta via transverse thoracosternotomy. Detterbeck FC, et al. **South Med J** 1996 Mar;89(3):348-52

Alterations in coagulation and fibrinolysis after surgery for aortic aneurysm. Oba J, et al. **Surg Today** 1995;25(6):532-5

Surgical treatment of type A aortic dissections [letter; comment] Browdie DA, et al. **Tex Heart Inst J** 1996; 23(1):70. Comment on: Tex Heart Inst J 1995;22(3):250-3; discussion 253-4.

Surgical treatment of type A aortic dissections. Results with profound hypothermia and circulatory arrest [see comments] Ehrlich M, et al. **Tex Heart Inst J** 1995; 22(3):250-3; discussion 253-4. Comment in: Tex Heart Inst J 1996;23(1):70.

[The strategy and procedure in the surgical treatment of thoracic aortic aneurysms] Nachev G, et al. **Khirurgiia (Sofiia)** 1995;48(1):11-7 (Eng. Abstr.) **(Bul)**

[Surgical treatment of ascending aortic dissecting aneurysm with Cabrol's operation in 3 patients] Yang C, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):561-2 (Eng. Abstr.) **(Chi)**

[Surgery FOR annulo-dystrophic disease of the ascending aorta. Apropos of 203 cases] Guilmet D, et al. **Arch Mal Coeur Vaiss** 1996 Jan;89(1):19-25 (Eng. Abstr.) **(Fre)**

[Cerebral protection by selective cerebral perfusion during surgery on the aortic arch] Le Mee F, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1601-7 (Eng. Abstr.) **(Fre)**

[Surgical treatment for ascending aortic aneurysm using a transthoracic left ventricular venting] Emmoto T, et al. **Kyobu Geka** 1996 Feb;49(2):89-92; discussion 93-4 (Eng. Abstr.) **(Jpn)**

[Long-term results of Bentall and modified Bentall procedure in aortic root replacement] Ishibashi Y, et al. **Kyobu Geka** 1995 Oct;48(11):929-32 (Eng. Abstr.) **(Jpn)**

[A case report of acute aortic dissection with aortic regurgitation and cardiac tamponade: intimal tear just above commissure of right coronary cusp and left coronary cusp] Kashiwagi J, et al. **Kyobu Geka** 1995 Nov; 48(12):1039-42 (Eng. Abstr.) **(Jpn)**

[An approach to the emergency surgery for arch and/or ascending aortic aneurysm] Katoh T, et al. **Kyobu Geka** 1996 Jun;49(6):456-9 (Eng. Abstr.) **(Jpn)**

[A case report on concomitant graft replacement of the total aortic root and the transverse aortic arch for type A acute aortic dissection associated with annuloaortic ectasia] Kawaharada N, et al. **Kyobu Geka** 1996 Apr;49(4):312-4 (Eng. Abstr.) **(Jpn)**

[A case of type A acute aortic dissection successfully treated with a ringed intraluminal graft: a new technique of graft insertion] Mukohara N, et al. **Kyobu Geka** 1995 Sep; 48(10):857-60 (Eng. Abstr.) **(Jpn)**

[Separate perfusion of upper and lower body under mild hypothermia during operation on the thoracoabdominal aorta] Ohmi M, et al. **Kyobu Geka** 1995 Aug;48(9):725-9; discussion 730-1 (Eng. Abstr.) **(Jpn)**

[Emergency surgical salvage for a type A early thrombosed aortic dissection complicated cardiac tamponade in a 80-year-old-patient] Ono Y, et al. **Kyobu Geka** 1996 Jun; 49(6):495-7 (Eng. Abstr.) **(Jpn)**

[A surgical treatment of ruptured aortic dissection with non-opacified false lumen] Sakamoto Y, et al. **Kyobu Geka** 1995 Oct;48(11):957-9 (Eng. Abstr.) **(Jpn)**

[A surgically treated case of ruptured true aortic arch aneurysm in association with Stanford type A chronic dissection] Takagi H, et al. **Kyobu Geka** 1996 Mar; 49(3):239-42 (Eng. Abstr.) **(Jpn)**

[Percutaneous placement of intraluminal stent-graft for aortic dissection: experimental study] Hashimoto M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Nov; 55(14):939-45 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of acute aortic dissections--a clinical study using a ringed intraluminal graft] Fujii H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1611-6 (Eng. Abstr.) **(Jpn)**

[Treatment of patients with chronic dissecting aortic aneurysm (DeBakey type IIIb) presenting with compromised renal perfusion] Fuwa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct;43(10):1730-5 (Eng. Abstr.) **(Jpn)**

[A report of surgical treatment for atherosclerotic aneurysm in the aortic arch associated with type III acute aortic dissection] Hara Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):516-8 (Eng. Abstr.) **(Jpn)**

[Hiatal hernia incarceration during cardiopulmonary bypass in patient with acute aortic dissection--a case report] Hasegawa Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1680-3 (Eng. Abstr.) **(Jpn)**

[Acute aortic dissection with leg ischemia] Hata M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):499-504 (Eng. Abstr.) **(Jpn)**

[A case report of bentall type operation for annuloaortic ectasia with anomalous origin of the right coronary artery complicated by aortic dissection] Hirai M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1044-9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Single-stage surgery for annulo aortic ectasia, Stanford type-A aortic dissection and pectus excavatum in a patient with Marfan's syndrome] Ichikawa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):575-9 (Eng. Abstr.) **(Jpn)**

[Rupture of dissecting aortic aneurysm associated with the right-sided aortic arch and anomalous course of the left brachiocephalic vein--a case report] Kanoh M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1086-91 (14 ref.) (Eng. Abstr.) **(Jpn)**

[A case of visceral ischemia associated with acute type IIIb aortic dissection] Moizumi Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1023-7 (Eng. Abstr.) **(Jpn)**

[Successful surgical treatment in a case of type IIIb acute aortic dissection complicated with acute myocardial infarction] Morota T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1972-6 (Eng. Abstr.) **(Jpn)**

[Replacement of descending thoracic aorta using open proximal anastomosis under hypothermic circulatory arrest] Murata S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):9-13 (Eng. Abstr.) **(Jpn)**

[Acute type A aortic dissection after replacement of descending thoracic aorta for type B aortic dissection] Okada K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):848-52 (Eng. Abstr.) **(Jpn)**

[Factors affecting the occurrence of anastomotic leakage after graft replacement of type A aortic dissection] Sako H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct; 43(10):1736-40 (Eng. Abstr.) **(Jpn)**

[The graft replacement of the patient with aortic arch aneurysm and thrombosed aortic dissection] Sasaki A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug; 43(8):1191-4 (Eng. Abstr.) **(Jpn)**

[Surgical treatment for Stanford type A acute aortic dissection] Suda H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1890-4 (Eng. Abstr.) **(Jpn)**

[Renal autotransplantation for dissecting aneurysm] Takahashi A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1553-8 (Eng. Abstr.) **(Jpn)**

[Myocardial infarction caused by spontaneous coronary artery dissection associated with significant mitral regurgitation--a successful surgical case] Uchita S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1228-33 (Eng. Abstr.) **(Jpn)**

[Replacement of the total thoracic aorta in a single stage using selective cerebral perfusion] Yanagiya A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct; 43(10):1778-82 (Eng. Abstr.) **(Jpn)**

[A case of anterior cerebral artery dissecting aneurysm] Araki T, et al. **No Shinkei Geka** 1996 Jan;24(1):87-91 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Spontaneous dissecting aneurysm of the superficial temporal artery: a case report] Fujii S, et al. **No Shinkei Geka** 1995 Sep;23(9):797-800 (Eng. Abstr.) **(Jpn)**

[Aortic dissection] Myhre HO, et al. **Tidsskr Nor Laegeforen** 1995 Sep 20;115(22):2754 **(Nor)**

[Aortic dissection. A 8-year material from health region 5] Myrmel T, et al. **Tidsskr Nor Laegeforen** 1995 Sep 20; 115(22):2773-6 (Eng. Abstr.) **(Nor)**

[Ischemic complications of dissecting aneurysm of the aorta. Treatment with percutaneous stents and fenestration] Nyman U, et al. **Lakartidningen** 1996 Feb 14;93(7):577-82 **(Swe)**

THERAPY

Spontaneous dissection of the celiac and hepatic arteries treated by transcatheter embolization. Takeda H, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1288-9

Bailout stenting for extensive dissection complicating direct infarct angioplasty. Altmann DB, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):191-2

Treatment of spontaneous coronary artery dissection with intracoronary stenting. Hong MK, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):200-2

Intracoronary stenting of a coronary occlusion resulting from an aortic dissection. Ikari Y, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):160-3

Spontaneous coronary dissection resulting in acute myocardial infarction: successful treatment with primary angioplasty. Stone GW, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):62-6

Cardiovascular shock. Rodgers KG. **Emerg Med Clin North Am** 1995 Nov;13(4):793-810 (61 ref.)

How does a continuous coronary perfusion catheter work in coronary artery dissection? Assessment by intravascular ultrasound [letter] Görge G, et al. **Eur Heart J** 1996 Jan; 17(1):151-2

Intravascular stenting of traumatic abdominal aortic dissection. Marty-Ané CH, et al. **J Vasc Surg** 1996 Jan; 23(1):156-61 (13 ref.)

The autoperfusion balloon catheter with special attention to its use as a bail-out device. Bonnier JJ. **Z Kardiol** 1995; 84 Suppl 2:79-82 (17 ref.)

[Transfemoral fenestration and stent implantation in aorto-iliac dissection] Farber A, et al. **Vasa** 1995; 24(4):389-91 (Eng. Abstr.) **(Ger)**

[Acute thrombosed aortic dissection--its clinical manifestation and treatment for Stanford A type] Saitoh Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Nov; 43(11):1789-94 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Intravascular ultrasound in the management of acute coronary artery dissection: a case report. Labinaz M, et al. **Cathet Cardiovasc Diagn** 1995 Mar;34(3):251-4

Extensive intramural hematoma as the cause of failed coronary angioplasty: diagnosis by intravascular ultrasound and treatment by stent implantation. Werner GS, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):173-8

Intramural aortic haematoma following intra-aortic balloon counterpulsation. Documentation by transoesophageal echocardiography [letter] Vilacosta I, et al. **Eur Heart J** 1995 Dec;16(12):2015-6

Prolapse of an aortic dissection flap imaged by transoesophageal echocardiography. Richens T, et al. **Heart** 1996 Jan;75(1):34

Diagnosis of ascending aortic dissection by transesophageal echocardiography: utility of M-mode in recognizing artifacts. Evangelista A, et al. **J Am Coll Cardiol** 1996 Jan; 27(1):102-7

Accuracy of biplane and multiplane transesophageal echocardiography in diagnosis of typical acute aortic dissection and intramural hematoma. Keren A, et al. **J Am Coll Cardiol** 1996 Sep;28(3):627-36

Transesophageal echocardiographic diagnosis of thoracic aortic dissection with the completely thrombosed false lumen: differentiation from true aortic aneurysm with mural thrombus. Nishino M, et al. **J Am Soc Echocardiogr** 1996 Jan-Feb;9(1):79-85

Hypotension on initiation of cardiopulmonary bypass. Trunfio G. **J Cardiothorac Vasc Anesth** 1995 Aug; 9(4):469-70

Diagnosis of coronary artery dissection following blunt chest trauma by transesophageal echocardiography. Cherng WJ, et al. **J Trauma** 1995 Oct;39(4):772-4

Pseudodissection of the abdominal aorta on color Doppler imaging. Crotty JM, et al. **J Ultrasound Med** 1995 Nov; 14(11):853-7

Evaluation of extracranial vertebral artery dissection with duplex color-flow imaging. Bartels E, et al. **Stroke** 1996 Feb;27(2):290-5

Transcranial Doppler in the evaluation of internal carotid artery dissection. Srinivasan J, et al. **Stroke** 1996 Jul; 27(7):1226-30

[Diagnosis of suspected thoracic aortic dissection. Focused on transesophageal echocardiography] Ivarsen HR, et al. **Ugeskr Laeger** 1996 Aug 12;158(33):4643-8 (Eng. Abstr.) **(Dan)**

[Aortic dissection demonstrated by ultrasound scanning] Thomsen F, et al. **Ugeskr Laeger** 1995 Nov 20; 157(47):6587-8 (Eng. Abstr.) **(Dan)**

[The main indications for transesophageal echocardiography] Lesbre JP. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):547-51 (21 ref.) (Eng. Abstr.) **(Fre)**

[Color-coded duplex ultrasound in chronic dissecting abdominal aortic aneurysm. Differentiation between true and false aortic lumen with reference to the blood supply to larger abdominal arteries] Risse JH, et al. **Radiologe** 1995 Oct;35(10):759-66 (Eng. Abstr.) **(Ger)**

[Dissection of the extracranial vertebral artery. Color duplex ultrasound findings and follow-up of 20 patients] Bartels E. **Ultraschall Med** 1996 Apr;17(2):55-63 (Eng. Abstr.) **(Ger)**

[Takayasu arteritis--a rare differential diagnosis in aortic dissection. A case report] Wildburg G, et al. **Z Kardiol** 1995 Dec;84(12):1033-8 (Eng. Abstr.) **(Ger)**

ANEURYSM, FALSE

COMPLICATIONS

Gastrointestinal bleeding from a false aneurysm of the hepatic artery after cholecystectomy. Srivastava DN, et al. **Am J Gastroenterol** 1996 Feb;91(2):395-7

Left hilar mass with obstruction of the main bronchus due to localized pseudoaneurysm of the thoracic aorta. Lukanich JM, et al. **Can J Surg** 1996 Feb;39(1):63-6

Coronary artery bypass graft pseudoaneurysm communicating with the right atrium: a case report and review. Nathaniel C, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):80-2

Pseudoaneurysm causing partial obliteration of the left atrium: case report and review. Nathaniel C, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):83–6

Bacteremia and hemoptysis due to an infected false left ventricular aneurysm associated with a bronchoventricular fistula. Khatib R, et al. **Clin Infect Dis** 1996 May; 22(5):874–5

Clinical profile and management of post infarction left ventricular pseudoaneurysm. Sharma S, et al. **Indian Heart J** 1995 Jul–Aug;47(4):369–71

Acquired aortopulmonary fistula in pseudoaneurysm of the aorta six years after a Bentall operation. Chevalier P, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1143–4

Carotid artery pseudoaneurysm and pellet embolism to the middle cerebral artery following a shotgun wound of the neck. Cogbill TH, et al. **J Trauma** 1995 Oct;39(4):763–7 (16 ref.)

Primary aortoenteric fistula from a posttraumatic pseudoaneurysm. Napoli PJ, et al. **J Trauma** 1996 Jul; 41(1):149–52

Popliteal vein thrombosis associated with femoral osteochondroma and popliteal artery pseudoaneurysm. Scott EM, et al. **Postgrad Med J** 1995 Jul;71(837):441–2

Acute abdominal pain in chronic pancreatitis: hemorrhage from a pseudoaneurysm? [published erratum appears in Z Gastroenterol 1995 Oct;33(10):following table of contents] Mahike R, et al. **Z Gastroenterol** 1995 Jul;33(7):404–7

[Traumatic aneurysm of the superior mesenteric artery as the cause of massive upper gastrointestinal hemorrhage] Reichert V, et al. **Leber Magen Darm** 1995 Sep;25(5):221–2, 225 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Traumatic internal carotid artery dissection presenting as delayed hemilingual paresis. Pica RA Jr, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):86–8

Presentation of Ehlers-Danlos syndrome: iliac artery pseudoaneurysm rupture. Meldon S, et al. **Ann Emerg Med** 1996 Aug;28(2):231–4 (14 ref.)

Late rupture of femoropopliteal Dacron grafts: a rare complication. Vrancken Peeters MT, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):243–6 (5 ref.)

Sequential MR signal change of the thrombus in the false lumen of thrombosed aortic dissection. Kaminaga T, et al. **Magn Reson Imaging** 1995;13(6):773–9

Radial artery pseudoaneurysm complicating a Brescia–Cimino dialysis fistula. Labus TP, et al. **Nephron** 1996;72(4):673–5

False traumatic aneurysm of the dorsal wall of the supraclinoid internal carotid artery—case report. Saito K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):886–91 (26 ref.)

Post-traumatic false aneurysm—a frequently missed condition in penetrating injuries. Golpak V. **P N G Med J** 1995 Mar;38(1):57–61

[Post-traumatic aneurysma spurium of the right atrium] Janssen G, et al. **Z Kardiol** 1996 May;85(5):351–6 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Anastomotic femoral aneurysms: increase in interval between primary operation and aneurysm formation. Levi N, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):207–9

Aneurysms of the digital artery: a review and report of three cases. Yajima H, et al. **Microsurgery** 1995;16(8):566–70 (19 ref.)

ETIOLOGY

Aneurysm complicating high tibial osteotomy: a case report. Tandon SC, et al. **Acta Orthop Scand** 1996 Feb;67(1):73–4

Breast pseudoaneurysm after core biopsy [letter] Smith SM. **AJR Am J Roentgenol** 1996 Sep;167(3):817

Axillary artery pseudoaneurysm and axillary nerve palsy: delayed sequelae of anterior shoulder dislocation [letter] Emadian SM, et al. **Am J Emerg Med** 1996 Jan;14(1):108–9

Coronary pseudoaneurysm after angioplasty. Flum DR, et al. **Am Surg** 1995 Dec;61(12):1035–8 (40 ref.)

Mycotic pseudoaneurysm complicating flap closure of an infected median sternotomy. O'Connell JB, et al. **Ann Plast Surg** 1995 Oct;35(4):420–2

Post-stenting enlarging false aneurysm of a saphenous vein graft. Katsumata T, et al. **Ann Thorac Surg** 1995 Oct; 60(4):1121–3

Color duplex-guided compression therapy for postcatheterization pseudoaneurysms in a community hospital. Langella RL, et al. **Ann Vasc Surg** 1996 Jan; 10(1):27–35

Hemobilia complicating elective laparoscopic cholecystectomy: a case report. Yelle JD, et al. **Can J Surg** 1996 Jun;39(3):240–2

Traumatic fistula between the left anterior descending coronary artery and a left ventricular pseudoaneurysm. Haapanen YT, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):272–4 (11 ref.)

Prolonged survival of a patient with left ventricular pseudoaneurysm following myocardial infarction and mitral valve replacement. Fazia RB, et al. **Chest** 1996 Feb; 109(2):577–9

False aneurysm of the anterior tibial artery following removal of tibial plate. Maxwell-Armstrong CA, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):505–6

Infected false aneurysms of the carotid arteries after carotid endarterectomy. Raptis S, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):148–52

Native hepatic artery pseudoaneurysm after liver transplantation: an unusual presentation with biliary leak. Soin AS, et al. **Eur J Vasc Endovasc Surg** 1995 Oct; 10(3):376–9 (9 ref.)

Right coronary artery pseudoaneurysm after blunt injury to the chest. Iemura J, et al. **Heart** 1996 Jul;76(1):86

Traumatic aneurysm of the maxillary artery: the role of interventional radiology. A report of two cases. Rogers SN, et al. **Int J Oral Maxillofac Surg** 1995 Oct;24(5):336–9

False aneurysm of the femoral artery as a late complication of an intertrochanteric fracture. A case report. Fernández González J, et al. **Int Orthop** 1995;19(3):187–9

Pseudoaneurysm of the brachial artery caused by an osteochondroma. A report of two cases. Villanueva-Garcia E, et al. **Int Orthop** 1995;19(4):248–50

False aneurysm of the brachial artery after an attempt to place an axillary venous access [letter] Vialet R, et al. **Intensive Care Med** 1995 Jan;21(1):97

Traumatic pseudoaneurysm of the superficial temporal artery associated with facial nerve palsy. Lalak NJ, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):119–23 (54 ref.)

Vascular complications of total abdominal perfusion and aortic stop-flow infusion. Klein ES, et al. **J Surg Oncol** 1996 Jan;61(1):17–9

Pseudoaneurysm of the proper hepatic artery with duodenal fistula appearing as a late complication of blunt abdominal trauma. Aboujaoude M, et al. **J Trauma** 1996 Jan; 40(1):123–5

Embolization of splenic artery branch pseudoaneurysm after blunt abdominal trauma. James CA, et al. **J Trauma** 1996 May;40(5):835–7

Pseudoaneurysms of the intraparenchymal splenic artery after blunt abdominal trauma: a complication of nonoperative therapy and its management. Sugg SL, et al. **J Trauma** 1995 Sep;39(3):593–5

Renal artery pseudoaneurysm after blunt abdominal trauma: case report and literature review. Swana HS, et al. **J Trauma** 1996 Mar;40(3):459–61 (15 ref.)

Pseudoaneurysm of the descending genicular artery after arthroscopic meniscectomy: report of a case. Tozzi A, et al. **J Trauma** 1996 Aug;41(2):340–1

Surgical complications of transaxillary arteriography: a case-control study. Chitwood RW, et al. **J Vasc Surg** 1996 May;23(5):844–9; discussion 849–50

A case of Pott's disease of the spine eroding into the suprarenal aorta. Hagino RT, et al. **J Vasc Surg** 1996 Sep; 24(3):482–6

Ruptured axillary pseudoaneurysm from chronic shoulder dislocation [letter] Orecchia PM, et al. **J Vasc Surg** 1996 Sep;24(3):499–500

Infected iliac pseudoaneurysm after uncomplicated percutaneous balloon angioplasty and (Palmaz) stent insertion: a case report and literature review. Weinberg DJ, et al. **J Vasc Surg** 1996 Jan;23(1):162–6 (17 ref.)

Traumatic abdominal pseudoaneurysm secondary to child abuse. Roche KJ, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S247–8

False aneurysm of the thyrocervical trunk. Elariny HA, et al. **South Med J** 1996 May;89(5):519–21

Pseudoaneurysm of the superficial temporal artery. Nemade SS, et al. **South Med J** 1996 Aug;89(8):815–7

Pseudoaneurysm of the free wall of the left ventricle without obstruction of major coronary arteries. Tesler UF, et al. **Tex Heart Inst J** 1996;23(1):58–61

[Increased association of cardiac and thoracic vascular lesions after closed trauma of the thorax] Pretre R, et al. **Ann Chir** 1995;49(9):854–7 (Eng. Abstr.) **(Fre)**

[False aneurysm of the brachiocephalic artery following subclavian vein catheterization] Soury P, et al. **Ann Fr Anesth Reanim** 1995;14(3):293–5 (Eng. Abstr.) **(Fre)**

[False aneurysm of the posterior tibial artery complicating fracture of the tibia and fibula] Guiral J, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(6):546–8 (Eng. Abstr.) **(Fre)**

[Traumatic injury of the internal carotid artery in the extracranial segment. Description of a severe late complication] Wurm G, et al. **Chirurg** 1995 Sep;66(9):916–9 (Eng. Abstr.) **(Ger)**

[Local vascular complications after iatrogenic femoral artery puncture] Fruhwirth J, et al. **Wien Klin Wochenschr** 1996; 108(7):196–200 (Eng. Abstr.) **(Ger)**

[Posttraumatic pseudoaneurysm of the middle meningeal artery: a case report] Kimura T, et al. **No Shinkei Geka** 1995 Nov;23(11):1021–5 (Eng. Abstr.) **(Jpn)**

HISTORY

Delayed presentation of splenic artery pseudoaneurysms following blunt abdominal trauma [letter; comment] Nance FC, et al. **J Trauma** 1995 Sep;39(3):620–1. Comment on: J Trauma 1995 Mar;38(3):444–7.

PHYSIOPATHOLOGY

False traumatic aneurysm of the dorsal wall of the supraclinoid internal carotid artery—case report. Saito K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):886–91 (26 ref.)

RADIOGRAPHY

Left ventricular false aneurysm: an unusually prolonged natural history. Bolognesi R, et al. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):46–50; discussion 51–2

Angiographic diagnosis of true and false LV aneurysms after inferior wall myocardial infarction. al-Saadon K, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):266–9

Traumatic aneurysm of the maxillary artery: the role of interventional radiology. A report of two cases. Rogers SN, et al. **Int J Oral Maxillofac Surg** 1995 Oct;24(5):336–9

Twice sealed-rupture of a small abdominal aortic aneurysm with unusual computed tomography findings. A case report. Ohtake H, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):249–50

[An opacity in the aorto-pulmonary window] Jougon J, et al. **Rev Pneumol Clin** 1996;52(1):26–8 **(Fre)**

SURGERY

Percutaneous transcatheter repair of a coronary aneurysm using a composite autologous cephalic vein–coated Palmaz-Schatz biliary stent. Wong SC, et al. **Am J Cardiol** 1995 Nov 1;76(12):990–1

New approach for operative management of vascular lesions of the infratemporal internal carotid artery. Catalano PJ, et al. **Am J Otol** 1994 Jul;15(4):495–501

Angioplasty-induced pseudoaneurysm successfully treated with a Palmaz stent. A case report. Castañeda F, et al. **Angiology** 1995 Nov;46(11):1021–5

Post-stenting enlarging false aneurysm of a saphenous vein graft. Katsumata T, et al. **Ann Thorac Surg** 1995 Oct; 60(4):1121–3

Successful repair of a ruptured postinfarct pseudoaneurysm of the left ventricle. Yaku H, et al. **Ann Thorac Surg** 1995 Oct;60(4):1097–8

Ruptured ulnar artery pseudoaneurysm. Erdoes LS, et al. **Ann Vasc Surg** 1995 Jul;9(4):394–6

Pseudoaneurysm of the inferior epigastric artery. Pathogenesis, diagnosis, and treatment. Ferrer JV, et al. **Arch Surg** 1996 Jan;131(1):102–3

Bleeding pancreatic pseudoaneurysms. Grønlund J, et al. **Eur J Surg** 1995 Oct;161(10):767–70

False aneurysm of the thyrocervical trunk: an unconventional surgical approach. Abrokwah J, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):373–4 (4 ref.)

Clinical profile and management of post infarction left ventricular pseudoaneurysm. Sharma S, et al. **Indian Heart J** 1995 Jul–Aug;47(4):369–71

Ligation of the common carotid artery for the management of a mycotic pseudoaneurysm of an extracranial internal carotid artery. A case report and review of the literature. Lueg EA, et al. **Int J Pediatr Otorhinolaryngol** 1995 Aug; 33(1):67–74 (21 ref.)

Hemodilution in complicated high velocity vascular injuries of limbs. Mackay Z, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):217–21

Endovascular covered stent repair of an intercostal artery patch dehiscence from a descending thoracic aortic aneurysm graft. Dorros G, et al. **J Endovasc Surg** 1996 Aug;3(3):299–305

Repair of femoral pseudoaneurysm after cardiac catheterization: utility of extraperitoneal iliac control. Garofalo M, et al. **Panminerva Med** 1995 Dec;37(4):202–3

[Risk of development of false aneurysm and graft infection after aorta-femoral bypass graft. Retrospective study. Report of 211 cases] Aguiar ET, et al. **J Mal Vasc** 1996; 21(1):36–9 (Eng. Abstr.) **(Fre)**

[Late complications of abdominal aortic prostheses: false aneurysms and aorta-digestive fistulas] Alimi Y, et al. **J Mal Vasc** 1995;20(3):172–6 (Eng. Abstr.) **(Fre)**

[Traumatic rupture of the inferior thyroid artery] Siegmeth A, et al. **Unfallchirurg** 1996 May;99(5):368–70 (Eng. Abstr.) **(Ger)**

[A case report of a successful Redo Bentall operation] Imamaki M, et al. **Kyobu Geka** 1996 Jun;49(6):502–4 (Eng. Abstr.) **(Jpn)**

[Successful treatment of an infected pseudoaneurysm of the ascending aorta with omental transfer—a case report] Inoue T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug; 43(8):1166–70 (Eng. Abstr.) **(Jpn)**

[Reoperation of a pseudoaneurysm eroding the sternum under hypothermic arrest of the brain through left thoracotomy] Kubo K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):188–91 (Eng. Abstr.) **(Jpn)**

[Left ventricular pseudoaneurysm at the apex—a case report of successful resection of the enlarging pseudoaneurysm following mitral valve replacement, which was caused by closed mitral commissurotomy 23 years ago] Nogami Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul; 43(7):1039–43 (Eng. Abstr.) **(Jpn)**

[A case report of pseudo-false aneurysm of the left ventricle perforated into the right ventricle] Yamanaka J, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):58–62 (Eng. Abstr.) **(Jpn)**

THERAPY

Percutaneous transluminal treatment of an iliac pseudoaneurysm with endoprosthesis implantation. A case report. Christensen L, et al. **Acta Radiol** 1996 Jul; 37(4):542–4

Use of intravascular stents in the treatment of internal carotid

and extracranial vertebral artery pseudoaneurysms. Horowitz MB, et al. **AJNR Am J Neuroradiol** 1996 Apr; 17(4):693–6

Repair of a pseudoaneurysm in the neck by sonographically guided compression [letter] Meyer R, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):994

Delayed closure of a postcatheterization pseudoaneurysm of the brachial artery by sonographically guided digital compression [letter; comment] Sugawara Y, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):220. Comment on: AJR Am J Roentgenol 1993 Feb;160(2):383–4.

Endovascular treatment of a kitchen knife pseudoaneurysm of the cervical internal carotid artery. Tu RK, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):704

Endovascular stented graft repair of a pseudoaneurysm of the subclavian artery caused by percutaneous internal jugular vein cannulation: case report. Pastores SM, et al. **Am J Crit Care** 1995 Nov;4(6):472–5

Color duplex-guided compression therapy for postcatheterization pseudoaneurysms in a community hospital. Langella RL, et al. **Ann Vasc Surg** 1996 Jan; 10(1):27–35

Treatment of iatrogenic false aneurysm by compression ultrasonography. Davies AH, et al. **Br J Surg** 1995 Sep; 82(9):1230–1

Successful embolization of a large superior gluteal artery pseudoaneurysm emerging during anticoagulant therapy. Gabata T, et al. **Cardiovasc Intervent Radiol** 1995 Sep–Oct; 18(5):327–9

Embolization of an hepatic artery pseudoaneurysm following laparoscopic cholecystectomy. Rivitz SM, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):43–6

Retained contrast after embolization of a right gastric artery pseudoaneurysm. Winick AB, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):110–2

Post-traumatic intrasplenic pseudoaneurysm successfully managed by embolization. Chiarugi M, et al. **Injury** 1995 Dec;26(10):705–6

Embolization of splenic artery branch pseudoaneurysm after blunt abdominal trauma. James CA, et al. **J Trauma** 1996 May;40(5):835–7

Ultrasound-guided compression closure of postcatheterization pseudoaneurysms during concurrent anticoagulation: a review of seventy-seven patients. Dean SM, et al. **J Vasc Surg** 1996 Jan;23(1):28–34, discussion 34–5

Ultrasound-guided compression of iatrogenic femoral pseudoaneurysm failure, recurrence, and long-term results. Hajarizadeh H, et al. **J Vasc Surg** 1995 Oct;22(4):425–30; discussion 430–3

Angioembolization of multiple intrasplenic pseudoaneurysms as a result of blunt trauma [letter] Patel NY, et al. **J Vasc Surg** 1996 Aug;24(2):299–301

Endovascular repair of aortic aneurysms, arteriovenous fistulas, and false aneurysms. Parodi JC. **World J Surg** 1996 Jul–Aug;20(6):655–63

Arterial pseudoaneurysm as a complication of percutaneous transhepatic biliary drainage: treatment by embolization. Gückel C, et al. **Z Gastroenterol** 1995 Oct;33(10):602–4

[Treatment of post-coronarography femoral false aneurysm by compression, guided by Doppler echography] Naïmi A, et al. **J Radiol** 1996 Apr;77(4):247–52 (Eng. Abstr.) **(Fre)**

[Experiences with the endovascular embolization therapy of aneurysms of the splanchnic arteries—a report on 13 cases] Kramann B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):417–23 (35 ref.) (Eng. Abstr.) **(Ger)**

[Selective embolization with an adhesive fluid of complicated aneurysms of the hepatic artery: 3 cases] Cotroneo AR, et al. **Radiol Med (Torino)** 1996 Apr;91(4):492–6 (21 ref.) **(Ita)**

[Treatment of iatrogenic renal vascular lesions using selective renal embolization] Kemka S, et al. **Rozhl Chir** 1995 Nov; 74(7):369–72 (Eng. Abstr.) **(Slo)**

ULTRASONOGRAPHY

Pseudoaneurysm of the breast. Wilkes AN, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):625–6

Facial artery pseudoaneurysm: diagnosis by colour Doppler ultrasonography. Partridge E, et al. **Can Assoc Radiol J** 1995 Dec;46(6):458–60

Transesophageal echocardiographic diagnosis of thoracic aortic dissection with the completely thrombosed false lumen: differentiation from true aortic aneurysm with mural thrombus. Nishino M, et al. **J Am Soc Echocardiogr** 1996 Jan–Feb;9(1):79–85

Intrasplenic posttraumatic pseudoaneurysm: echo color doppler diagnosis. Goletti O, et al. **J Trauma** 1996 Sep; 41(3):542–5

False aneurysm of a digital artery in a softball catcher evaluated by sonography: a case report. Yasuda T, et al. **J Trauma** 1996 Jul;41(1):153–5

ANEURYSM, INFECTED

Infected internal iliac artery aneurysm: a case report. Hassan D, et al. **Can J Surg** 1996 Feb;39(1):67–9

COMPLICATIONS

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)

Bacteremia and hemoptysis due to an infected false left ventricular aneurysm associated with a bronchoventricular fistula. Khatib R, et al. **Clin Infect Dis** 1996 May; 22(5):874–5

Brachial plexopathy secondary to mycotic subclavian-axillary artery aneurysm. Veilleux M, et al. **Muscle Nerve** 1996 Jan;19(1):92–3

DIAGNOSIS

Clinicopathological conference: young man with syncope [clinical conference] Hartoch RS, et al. **Acad Emerg Med** 1995 Oct;2(10):934–8

Ruptured infected popliteal artery aneurysm. Wilson P, et al. **Ann Vasc Surg** 1995 Sep;9(5):497–9

Pulmonary artery aneurysm presenting as a lung mass. Chung CW, et al. **Chest** 1995 Oct;108(4):1164–6 (10 ref.)

Two cases of infected atherosclerotic aneurysms and a comparison with infective endocarditis. Peacock SJ, et al. **Eur J Clin Microbiol Infect Dis** 1995 Nov;14(11):1004–8

DRUG THERAPY

[Ruptured mycotic aneurysm of the middle cerebral artery: a case report] Suzuki K, et al. **No Shinkei Geka** 1995 Nov; 23(11):981–4 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Infected aortic aneurysm and vertebral osteomyelitis after intravesical bacillus Calmette-Guérin therapy. Rozenblit A, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):711–3

Mycotic pseudoaneurysm complicating flap closure of an infected median sternotomy. O'Connell JB, et al. **Ann Plast Surg** 1995 Oct;35(4):420–2

Salmonella mycotic aneurysm of the aortic arch: case report and review. Meerkin D, et al. **Clin Infect Dis** 1995 Sep; 21(3):523–8 (32 ref.)

Infected false aneurysms of the carotid arteries after carotid endarterectomy. Raptis S, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):148–52

Mycotic aortic aneurysm in patients who have lumbar vertebral osteomyelitis. A report of two cases. Rubery PT, et al. **J Bone Joint Surg Am** 1995 Nov;77(11):1729–32

Escherichia coli infection of an abdominal aortic aneurysm. Khaira HS, et al. **J Infect** 1996 Mar;32(2):161–3 (14 ref.)

A case of Pott's disease of the spine eroding into the suprarenal aorta. Hagino RT, et al. **J Vasc Surg** 1996 Sep; 24(3):482–6

Infected iliac pseudoaneurysm after uncomplicated percutaneous balloon angioplasty and (Palmaz) stent insertion: a case report and literature review. Weinberg DJ, et al. **J Vasc Surg** 1996 Jan;23(1):162–6 (17 ref.)

[Bacterial intracranial aneurysm associated with infective endocarditis: a case showing enlargement of aneurysm size] Tashima T, et al. **No Shinkei Geka** 1995 Nov;23(11):985–9 (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

A case of abdominal aortic aneurysm infected by Nocardia asteroides [letter] Bocchetti M, et al. **Biomed Pharmacother** 1996;50(1):36

Salmonellosis complicated by myocardial abscess and cerebral mycotic aneurysms. Sproule MW, et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):273–4

Contained rupture of infected abdominal aortic aneurysm due to systemic candidiasis. Ikeda M, et al. **Cardiovasc Surg** 1995 Dec;3(6):711–4 (30 ref.)

Double clostridial mycotic aneurysms of the aorta. Messa CA 3rd, et al. **Cardiovasc Surg** 1995 Dec;3(6):687–92 (28 ref.)

Mycotic aneurysm of the carotid artery due to Salmonella enteritidis associated with multiple brain abscesses. Lloret MD, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):250–2

Melioidosis causing a mycotic aneurysm [letter] Steinmetz I, et al. **Lancet** 1996 Jun 1;347(9014):1564–5

PATHOLOGY

Atypical cerebral aneurysm in a young child. Stehbens WE, et al. **Pediatr Neurosurg** 1995;23(2):97–100

[A clinicopathological study of ruptured infectious aneurysms] Origuchi N, et al. **Nippon Ronen Igakkai Zasshi** 1995 Aug–Sep;32(8–9):553–9 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Mycotic aneurysm: a diagnostic challenge. Leo PJ, et al. **Am J Emerg Med** 1996 Jan;14(1):70–3

Diagnostic imaging of Salmonella-related mycotic aneurysm of aorta by CT. Lee MH, et al. **Clin Imaging** 1996 Jan–Mar; 20(1):26–30

SURGERY

In situ prosthetic graft replacement for mycotic thoracoabdominal aneurysms. Cordero JA Jr, et al. **Am Surg** 1996 Jan;62(1):35–9

Fringed valve prosthesis for aortic root abscess. Hayashi J, et al. **Ann Thorac Surg** 1996 Jul;62(1):262–4

Using aortic allograft material to treat mycotic aneurysms of the thoracic aorta [see comments] Knosalla C, et al. **Ann Thorac Surg** 1996 Apr;61(4):1146–52. Comment in: Ann Thorac Surg 1996 Apr;61(4):1053–4.

Mycotic aneurysm of the aorta: evolving surgical concept [editorial; comment] Pasic M. **Ann Thorac Surg** 1996 Apr; 61(4):1053–4 (16 ref.). Comment on: Ann Thorac Surg 1996 Apr;61(4):1146–52.

Eradication of aortic infections with the use of cryopreserved arterial homografts. Vogt PR, et al. **Ann Thorac Surg** 1996 Sep;62(3):640–5

Retroperitoneal approach for repair of inflammatory aortic aneurysms. Todd GJ, et al. **Ann Vasc Surg** 1995 Nov; 9(6):525–34

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)

Cryopreserved arterial homografts for in situ reconstruction of mycotic aneurysms and prosthetic graft infection. Vogt PR, et al. **Eur J Cardiothorac Surg** 1995;9(9):502–6

Ligation of the common carotid artery for the management of a mycotic pseudoaneurysm of an extracranial internal carotid artery. A case report and review of the literature. Lueg EA, et al. **Int J Pediatr Otorhinolaryngol** 1995 Aug; 33(1):67–74 (21 ref.)

In situ repair of mycotic abdominal aortic aneurysms with rifampin-bonded gelatin-impregnated Dacron grafts: a preliminary case report. Gupta AK, et al. **J Vasc Surg** 1996 Sep;24(3):472–6

Surgical treatment of a cerebral mycotic aneurysm using the stereo-angiographic localizer. D'Angelo V, et al. **Surg Neurol** 1995 Sep;44(3):263–4

Computerized tomography (CT) localized stereotactic craniotomy for excision of a bacterial intracranial aneurysm. Elowiz EH, et al. **Surg Neurol** 1995 Sep; 44(3):265–9

Mycotic aneurysm of the internal iliac artery caused by Klebsiella pneumoniae. Tatebe S, et al. **Vasa** 1996; 25(2):184–7

[Surgical treatment of mycotic coronary artery aneurysm associated with infective endocarditis: a case report] Doi H, et al. **Kyobu Geka** 1995 Dec;48(13):1122–5 (Eng. Abstr.) **(Jpn)**

[Successful treatment of an infected pseudoaneurysm of the ascending aorta with omental transfer—a case report] Inoue T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug; 43(8):1166–70 (Eng. Abstr.) **(Jpn)**

[Cervical epidural anesthesia for carotid mycotic aneurysms] Llorente A, et al. **Rev Esp Anestesiol Reanim** 1995 Oct; 42(8):341–3 (Eng. Abstr.) **(Spa)**

THERAPY

Glue embolisation of a ruptured pancreaticoduodenal artery aneurysm. Hammer FD, et al. **Eur Radiol** 1996;6(4):514–7

Endovascular treatment of bacterial intracranial aneurysms. Scotti G, et al. **Neuroradiology** 1996 Feb;38(2):186–9

ULTRASONOGRAPHY

A negative transthoracic echocardiogram obviates the need for transesophageal echocardiography in patients with suspected native valve active infective endocarditis. Irani WN, et al. **Am J Cardiol** 1996 Jul 1;78(1):101–3

ANEURYSM, MYCOTIC see **ANEURYSM, INFECTED**

ANEURYSM, RUPTURED

Spontaneous dissection of the hepatic artery. Müller MF, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):462–5 (13 ref.)

Infected internal iliac artery aneurysm: a case report. Hassan D, et al. **Can J Surg** 1996 Feb;39(1):67–9

Aspergillus aneurysm of the middle cerebral artery causing a fatal subarachnoid hemorrhage. Suzuki K, et al. **Intern Med** 1995 Jun;34(6):550–3

Ruptured aneurysm of the middle meningeal artery associated with occlusion of the posterior cerebral artery. Case report. Ushikoshi S, et al. **J Neurosurg** 1996 Feb;84(2):269–71

[Fissured aneurysm of the superior mesenteric vein. Report of a case] Catalano O. **Radiol Med (Torino)** 1995 Jul–Aug; 90(1–2):148–9 (19 ref.) **(Ita)**

[Rupture of the aneurysm of the sinus valsalva: thirteen years after the initial diagnosis] Shida T, et al. **Kyobu Geka** 1996 Jun;49(6):479–81 (Eng. Abstr.) **(Jpn)**

[Hepatic artery aneurysm. Diagnosis and treatment] Røkke O, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):487–9 (Eng. Abstr.) **(Nor)**

BLOOD

Serum elastase and alpha-1-antitrypsin levels in patients with ruptured and unruptured cerebral aneurysms. Baker CJ, et al. **Neurosurgery** 1995 Jul;37(1):56–61; discussion 61–2

Hemostasis in spontaneous subarachnoid hemorrhage. Fujii Y, et al. **Neurosurgery** 1995 Aug;37(2):226–34

COMPLICATIONS

Influence of aneurysm location on the development of chronic hydrocephalus following SAH. Pietilä TA, et al. **Acta Neurochir (Wien)** 1995;137(1–2):70–3

Intra-arterial infusion of papaverine combined with intravenous administration of high-dose nicardipine for cerebral vasospasm. Yoshimura S, et al. **Acta Neurochir (Wien)** 1995;135(3–4):186–90

The haemodynamic effect of transcranial Doppler-guided high-dose nimodipine treatment in established vasospasm after subarachnoid haemorrhage. Zygmunt SC, et al. **Acta Neurochir (Wien)** 1995;135(3-4):179-85

Rapidly progressive destruction of the hip. Case report and review of the literature. Puylaert D, et al. **Acta Orthop Belg** 1995;61(4):312-4 (5 ref.)

Massive hemopericardium as a first manifestation of coronary aneurysm: successful surgical management. Iga K, et al. **Am Heart J** 1996 Mar;131(3):618-20

Superior pancreaticoduodenal artery aneurysm rupture presenting with hemorrhage from the ampulla of Vater into the gastrointestinal tract. Krmpotich PT, et al. **Am J Gastroenterol** 1995 Nov;90(11):2046-7

Cardiac tamponade due to spontaneous rupture of right coronary artery aneurysm. Wan S, et al. **Ann Thorac Surg** 1996 Aug;62(2):575-6

Liver abscess concomitant with hemobilia due to rupture of hepatic artery aneurysm: a case report. Liou TC, et al. **Hepatogastroenterology** 1996 Jan-Feb;43(7):241-4

Primary aortogastric fistula: a complication of ruptured aortic aneurysm. Lorimer JW, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):363-6

Subarachnoid haemorrhage and myths about saccular aneurysms. Weller RO. **J Clin Pathol** 1995 Dec; 48(12):1078-81 (29 ref.)

Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t-PA for the prevention of vasospasm. Bell TE, et al. **J Neurosci Nurs** 1996 Apr;28(2):107-13 (37 ref.)

Age-related multifactorial causes of neurological deterioration after early surgery for aneurysmal subarachnoid hemorrhage. Yoshimoto Y, et al. **J Neurosurg** 1995 Dec;83(6):984-8

Anomalous internal carotid artery-anterior cerebral artery anastomosis associated with fenestration and cerebral aneurysm. Fujimura M, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):229-33 (26 ref.)

Treatment of ruptured cerebral aneurysm in moyamoya disease. Kodama N, et al. **Surg Neurol** 1996 Jul;46(1):62-6 (12 ref.)

Pulmonary arterial aneurysm presenting as an endobronchial mass. Gibbs PM, et al. **Thorax** 1995 Sep;50(9):1013-4; discussion 1016-7

Life-threatening gastrointestinal bleeding after liver transplantation due to hepatic artery pseudoaneurysm perforating into the common bile duct. A case report. Riedmann B, et al. **Transpl Int** 1995;8(6):492-5

Isolated internal iliac artery aneurysm and urinary retention. Hodasi WM. **West Afr J Med** 1995 Jul-Sep;14(3):184-5

Acute abdominal pain in chronic pancreatitis: hemorrhage from a pseudoaneurysm? [published erratum appears in Z Gastroenterol 1995 Oct;33(10):following table of contents] Mahlke R, et al. **Z Gastroenterol** 1995 Jul;33(7):404-7

[Clinical picture and diagnosis of subarachnoid hemorrhage in ruptured aneurysms] Krajíčková D. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(1 Suppl):75-9 (Eng. Abstr.) **(Cze)**

[Spontaneous dissection of the cervical arteries] Venne D, et al. **Ann Chir** 1995;49(8):743-8 (Eng. Abstr.) **(Fre)**

[Neuroanesthesia and intensive care in subarachnoid hemorrhage caused by aneurysm rupture] Boulard G, et al. **Ann Fr Anesth Reanim** 1996;15(3):320-1 **(Fre)**

[Arteriovenous and arterial-digestive system fistulas complicating isolated iliac aneurysm] Chambon JP, et al. **J Chir (Paris)** 1995 Oct;132(10):371-4 (Eng. Abstr.) **(Fre)**

[Hemorrhage caused by rupture into the duodenum of aneurysm of a branch of the pancreaticoduodenal artery (posterior superior or retroduodenal pancreaticoduodenal artery)] Maragliano S, et al. **G Chir** 1996 Jan-Feb; 17(1-2):19-21 (Eng. Abstr.) **(Ita)**

[Massive hemoptysis caused by disruption of a bronchial aneurysm diagnosed by microscopic examination of the resected lung] Nakamura S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun;34(6):721-5 (Eng. Abstr.) **(Jpn)**

[Neurofibromatosis associated with multiple intracranial vascular lesions: stenosis of the internal carotid artery and peripheral aneurysm of the Heubner's artery; report of a case] Sasaki J, et al. **No Shinkei Geka** 1995 Sep;23(9):813-7 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Cognitive dysfunction following anterior communicating artery aneurysm rupture. Comparison with alcoholic Korsakoff syndrome on neuropsychological performance] Mimura M, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):850-4 (Eng. Abstr.) **(Jpn)**

[Late complications of subarachnoid hemorrhage from ruptured aneurysms treated with early and delayed surgery] Sloniewski P. **Pol Tyg Lek** 1995 Sep;50(36-39):21-3, 28 (Eng. Abstr.) **(Pol)**

[Acute neurogenic pulmonary edema: a case report] Brito JC, et al. **Arq Neuropsiquiatr** 1995 Jun;53(2):288-93 (Eng. Abstr.) **(Por)**

[Prognosis of ischemic complications following early surgical treatment of cerebral aneurysms] Krylov VV, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Oct-Dec; (4):11-3 (Eng. Abstr.) **(Rus)**

[Digestive hemorrhage and hemoperitoneum as complications of visceral aneurysms] Domingo C, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):601-4 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Clinicopathological conference: young man with syncope [clinical conference] Hartoch RS, et al. **Acad Emerg Med** 1995 Oct;2(10):934-8

Ruptured splenic artery aneurysm [letter] Maertens SR, et al. **Acad Emerg Med** 1995 Jul;2(7):663-5

Early cerebral blood flow and vascular reactivity to acetazolamide in predicting the outcome after ruptured cerebral aneurysm. Yoshida K, et al. **Acta Neurol Scand Suppl** 1996;166:131-4

Cerebral aneurysms associated with seizures but without clinical signs of rupture: seemingly distinctive MR imaging findings in two patients. Provenzale JM, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):230-2

Presentation of Ehlers-Danlos syndrome: iliac artery pseudoaneurysm rupture. Meldon S, et al. **Ann Emerg Med** 1996 Aug;28(2):231-4 (14 ref.)

Ruptured infected popliteal artery aneurysm. Wilson P, et al. **Ann Vasc Surg** 1995 Sep;9(5):497-9

An unusual presentation of a ruptured abdominal aortic aneurysm. Haddad FS, et al. **J Accid Emerg Med** 1995 Sep; 12(3):220-1

Deep femoral artery aneurysm rupture. A case report. el Nakadi BE, et al. **J Cardiovasc Surg (Torino)** 1996 Aug; 37(4):353-4

Ruptured splenic aneurysm: case report in a young adult. Tolmas HC. **J La State Med Soc** 1995 Dec;147(12):551-2

Massive haemobilia. Skinner S, et al. **Postgrad Med J** 1996 Jun;72(848):371-3

Very poor prognosis in cases with extravasation of the contrast medium during angiography. Yasui T, et al. **Surg Neurol** 1996 Jun;45(6):560-4; discussion 564-5

[Postpartum rupture of an aneurysm of the arteria lienalis] Rust M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):321-4 (Eng. Abstr.) **(Ger)**

[Rupture of a renal artery aneurysm in polyarteritis nodosa: evaluation by DSA and comparison with MR angiography] Schmid MR, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Apr;164(4):353-5 **(Ger)**

[Periarteritis nodosa with ruptures of the renal vessels and the persistence of the hepatitis B and C viruses in the blood] Semenkova EN, et al. **Klin Med (Mosk)** 1995;73(3):108-9 **(Rus)**

[Ruptured aneurysm without abdominal symptoms. Unexpected fatal intraabdominal bleeding after a traffic accident] Pedersen JC. **Lakartidningen** 1996 Mar 27; 93(13):1250 **(Swe)**

DRUG THERAPY

Hypotensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage. Porchet F, et al. **Acta Neurochir (Wien)** 1995;137(1-2):62-9

[Ruptured mycotic aneurysm of the middle cerebral artery: a case report] Suzuki K, et al. **No Shinkei Geka** 1995 Nov; 23(11):981-4 (Eng. Abstr.) **(Jpn)**

ECONOMICS

Predicting length of hospital stay and cost by aneurysm grade on admission. Elliott JP, et al. **J Neurosurg** 1996 Sep; 85(3):388-91

EPIDEMIOLOGY

Rupture of true profunda femoris artery aneurysms. Two new cases. Levi N, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):117-8 (9 ref.)

Cerebral arterial aneurysm formation and rupture in 20,767 elderly patients: hypertension and other risk factors. Taylor CL, et al. **J Neurosurg** 1995 Nov;83(5):812-9

ETIOLOGY

Rupture of a cerebral aneurysm during embolization for a cerebral arteriovenous malformation. Abe T, et al. **AJNR Am J Neuroradiol** 1995 Oct;16(9):1818-20

A case of a giant renal aneurysm. Dom PG, et al. **Br J Urol** 1996 Apr;77(4):611-2

Aortic arch interruption associated with ruptured cerebral aneurysm. Hu WY, et al. **Can Assoc Radiol J** 1996 Feb; 47(1):20-3

Ruptured axillary pseudoaneurysm from chronic shoulder dislocation [letter] Orecchia PM, et al. **J Vasc Surg** 1996 Sep;24(3):499-500

[A case of ruptured thoracoabdominal aortic aneurysm complicated with high aortic occlusion] Satokawa H, et al. **Kyobu Geka** 1995 Nov;48(12):1053-6 (Eng. Abstr.) **(Jpn)**

[A case of metastatic choriocarcinoma associated with cerebral thrombosis and aneurysmal formation] Komeichi T, et al. **No Shinkei Geka** 1996 May;24(5):463-7 (Eng. Abstr.) **(Jpn)**

[Application of alteplase in prevention of cerebral vasospasm and its sequelae in patients after aneurysmal subarachnoid hemorrhage from ruptured cerebral aneurysm] Majchrzak H, et al. **Neurol Neurochir Pol** 1995 May-Jun;29(3):379-87 (Eng. Abstr.) **(Pol)**

GENETICS

Familial cerebral aneurysms: a study of 13 families. Leblanc R, et al. **Neurosurgery** 1995 Oct;37(4):633-8; discussion 638-9

Familial cerebral aneurysms. A bias for women. Leblanc R. **Stroke** 1996 Jun;27(6):1050-4

MICROBIOLOGY

Relevance of bacterial cultures of abdominal aortic aneurysm contents. van der Vliet JA, et al. **Surgery** 1996 Feb; 119(2):129-32

MORTALITY

The influence of age on operative mortality and long-term relative survival following emergency abdominal aortic aneurysm operations. Aune S, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):338-41

Trends in mortality and hospital morbidity due to abdominal aortic aneurysms. Millar WJ, et al. **Health Rep** 1995; 7(1):19-27, 21-30 **(Eng, Fre)**

The incidence of acute cocaine or methamphetamine intoxication in deaths due to ruptured cerebral (berry) aneurysms. Davis GG, et al. **J Forensic Sci** 1996 Jul; 41(4):626-8

PATHOLOGY

Carotid-cavernous sinus fistula and aneurysmal rupture associated with fibromuscular dysplasia. A case report. Hirai T, et al. **Acta Radiol** 1996 Jan;37(1):49-51 (8 ref.)

Atypical cerebral aneurysm in a young child. Stehbens WE, et al. **Pediatr Neurosurg** 1995;23(2):97-100

[Segmental mediolytic arteriopathy] Ludvíková M, et al. **Cesk Patol** 1995 Dec;31(4):125-8 (Eng. Abstr.) **(Cze)**

[Case 3/95. Instituto do Coração do Hospital das Clinicas FMUSP (clinical conference)] **Arq Bras Cardiol** 1995 May; 64(5):469-74 **(Por)**

PHYSIOPATHOLOGY

Significance of ST segment elevation in electrocardiograms in patients with ruptured cerebral aneurysms. Kuroiwa T, et al. **Acta Neurochir (Wien)** 1995;133(3-4):141-6

Protection of the brain after aneurysmal rupture. Weir B. **Can J Neurol Sci** 1995 Aug;22(3):177-86 (73 ref.)

Ruptured aneurysm of the distal posterior inferior cerebellar artery in a neonate--case report. Hosotani K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):892-5 (11 ref.)

Posterior cerebral artery aneurysm associated with unilateral internal carotid artery agenesis--Case report. Ide M, et al. **Neurol Med Chir (Tokyo)** 1995 Nov;35(11):825-9

Hemodynamic assessment of the development and rupture of intracranial aneurysms using computational simulations. Chitanvis SM, et al. **Neurol Res** 1995 Dec;17(6):426-34

Computer modeling of intracranial saccular and lateral aneurysms for the study of their hemodynamics. Burleson AC, et al. **Neurosurgery** 1995 Oct;37(4):774-82; discussion 782-4

Complications of Swan-Ganz catheterization for hemodynamic monitoring in patients with subarachnoid hemorrhage. Rosenwasser RH, et al. **Neurosurgery** 1995 Nov;37(5):872-5; discussion 875-6 (21 ref.)

PREVENTION & CONTROL

Effectiveness of preventive surgery for asymptomatic unruptured intracranial aneurysms. Inomiya K, et al. **Medinfo** 1995;8 Pt 2:889-93

PSYCHOLOGY

Distinctive forms of partial retrograde amnesia after asymmetric temporal lobe lesions: possible role of the occipitotemporal gyri in memory. Eslinger PJ, et al. **Cereb Cortex** 1996 May-Jun;6(3):530-9

RADIOGRAPHY

Isolated common iliac artery aneurysm rupturing into small bowel: CT appearance. Noh HM, et al. **Abdom Imaging** 1995 Nov-Dec;20(6):521-2

Ruptured renal artery aneurysm due to Behçet's disease. Sueyoshi E, et al. **Abdom Imaging** 1996 Mar-Apr; 21(2):166-7

Ruptured aneurysm of the basilar artery simulating nonaneurysmal perimesencephalic subarachnoid hemorrhage [letter] Friedman DP. **AJR Am J Roentgenol** 1996 Jul;167(1):283-4

Spontaneous disappearance of a ruptured anterior communicating artery aneurysm [letter] Isoda H, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):536-7

Rupture of splenic artery pseudoaneurysm. Toscano RL, et al. **Am Surg** 1995 Nov;61(11):940-2

Ruptured suprarenal artery aneurysm: angiographic diagnosis and treatment by selective embolization. Perona F, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):291-3

Case report: ruptured adrenal artery aneurysm. Birchall D, et al. **Clin Radiol** 1995 Oct;50(10):732-3

Ruptured aneurysm at the origin of duplication of the middle cerebral artery--case report. Koyama S, et al. **Neurol Med Chir (Tokyo)** 1995 Sep;35(9):671-3 (24 ref.)

[Diagnosis of ruptured and unruptured cerebral aneurysms with three-dimensional CT angiography (3D-CTA)] Tanabe S, et al. **No Shinkei Geka** 1995 Sep;23(9):787-95 (Eng. Abstr.) **(Jpn)**

SURGERY

Ruptured splenic artery aneurysm [letter] Maertens SR, et al. **Acad Emerg Med** 1995 Jul;2(7):663–5

Study on early re-rupture of intracranial aneurysms. Aoyagi N, et al. **Acta Neurochir (Wien)** 1996;138(1):12–8

Vasospasm diagnosis: theoretical and real transcranial Doppler sensitivity. Creissard P, et al. **Acta Neurochir (Wien)** 1995;136(3–4):181–5

Anatomical and technical aspects of the contralateral approach for multiple aneurysms. de Oliveira E, et al. **Acta Neurochir (Wien)** 1996;138(1):1–11; discussion 11

Effect of ultra-early referral on management outcome in subarachnoid haemorrhage. Inagawa T. **Acta Neurochir (Wien)** 1995;136(1–2):51–61

Acute subdural haematoma from ruptured intracranial aneurysms. Nowak G, et al. **Acta Neurochir (Wien)** 1995; 136(3–4):163–7

Does a routine operation for intracranial aneurysm incur brain damage? Rabow L, et al. **Acta Neurochir (Wien)** 1995; 133(1–2):13–6

Timing of operation for ruptured cerebral aneurysm and long-term recovery of cognitive functions. Satzger W, et al. **Acta Neurochir (Wien)** 1995;136(3–4):168–74

Successful repair of a ruptured postinfarct pseudoaneurysm of the left ventricle. Yaku H, et al. **Ann Thorac Surg** 1995 Oct;60(4):1097–8

Isolated atherosclerotic aneurysms of the iliac arteries. Desiron Q, et al. **Ann Vasc Surg** 1995;9 Suppl:S62–6

Quality of life and cognitive deficits after subarachnoid haemorrhage. Hütter BO, et al. **Br J Neurosurg** 1995; 9(4):465–75

Behavioural training during acute brain trauma rehabilitation: an empirical case study. Slifer KJ, et al. **Brain Inj** 1995 Aug–Sep;9(6):585–93

Ruptured and unruptured intracranial aneurysms—surgical outcome. Dix GA, et al. **Can J Neurol Sci** 1995 Aug; 22(3):187–91

Ruptured aneurysms of the internal iliac artery. Report of two cases. Lozano P, et al. **J Cardiovasc Surg (Torino)** 1995 Dec;36(6):591–4

Spinal arachnoid cyst developing after surgical treatment of a ruptured vertebral artery aneurysm: a possible complication of topical use of fibrin glue. Case report. Taguchi Y, et al. **J Neurosurg** 1996 Mar;84(3):526–9

Postoperative rupture of a hepatic artery aneurysm. A case report. McNamara MF. **J Reprod Med** 1995 Oct; 40(10):736–8

Ruptured dissecting aneurysm of the peripheral anterior cerebral artery—case report. Yano H, et al. **Neurol Med Chir (Tokyo)** 1995 Jul;35(7):450–3 (17 ref.)

Balloon angioplasty immediately after surgical clipping for symptomatic vasospasm on admission. Report of four cases. Fujii Y, et al. **Neurosurg Rev** 1995;18(2):79–84

Effect of balloon angioplasty on high grade symptomatic vasospasm after subarachnoid hemorrhage. Fujii Y, et al. **Neurosurg Rev** 1995;18(1):7–13

Intracranial aneurysm surgery in the 8th and 9th decades of life: impact on population-based management outcome. Fridriksson SM, et al. **Neurosurgery** 1995 Oct;37(4):627–31; discussion 631–2

Titanium aneurysm clips: Part III—Clinical application in 16 patients with subarachnoid hemorrhage. Lawton MT, et al. **Neurosurgery** 1996 Jun;38(6):1170–5

Intracerebral microdialysis of glutamate and aspartate in two vascular territories after aneurysmal subarachnoid hemorrhage. Säveland H, et al. **Neurosurgery** 1996 Jan; 38(1):12–9; discussion 19–20

Subarachnoid hemorrhage secondary to a ruptured inflammatory aneurysm: a possible manifestation of neurocysticercosis: case report. Soto-Hernandez JL, et al. **Neurosurgery** 1996 Jan;38(1):197–9; discussion 199–200

Approaches to MCA aneurysms [letter] Csécsei GI. **Surg Neurol** 1996 Jun;45(6):590–2

Computerized tomography (CT) localized stereotactic craniotomy for excision of a bacterial intracranial aneurysm. Elowiz EH, et al. **Surg Neurol** 1995 Sep; 44(3):265–9

Treatment of ruptured cerebral aneurysm in moyamoya disease. Kodama N, et al. **Surg Neurol** 1996 Jul;46(1):62–6 (12 ref.)

Rupture of an isolated internal iliac artery aneurysm into the rectum: report of a case. Katoh J, et al. **Surg Today** 1995;25(6):554–6

Relevance of bacterial cultures of abdominal aortic aneurysm contents. van der Vliet JA, et al. **Surgery** 1996 Feb; 119(2):129–32

Critical increase of blood flow velocities after subarachnoid haemorrhage: vasospasm versus hyperaemia. Meixensberger J, et al. **Zentralbl Neurochir** 1996;57(2):70–5

[Titanium aneurysm clips and their advantages in diagnostic imaging] Piepgras A, et al. **Radiologe** 1995 Nov; 35(11):830–3 (Eng. Abstr.) **(Ger)**

[Traumatic rupture of the inferior thyroid artery] Siegmeth A, et al. **Unfallchirurg** 1996 May;99(5):368–70 (Eng. Abstr.) **(Ger)**

[Acute rupture of an aneurysm of the popliteal artery: case report] Manouguian S. **Zentralbl Chir** 1996;121(5):405–7 (Eng. Abstr.) **(Ger)**

[Separate perfusion of upper and lower body under mild hypothermia during operation on the thoracoabdominal aorta] Ohmi M, et al. **Kyobu Geka** 1995 Aug;48(9):725–9; discussion 730–1 (Eng. Abstr.) **(Jpn)**

[Indication of early surgery in elderly patients with ruptured intracranial aneurysms—the comparison between surgical and conservative therapy] Ikawa F, et al. **No To Shinkei** 1996 Jan;48(1):59–63 (Eng. Abstr.) **(Jpn)**

THERAPY

Endovascular therapy for the carotid blowout syndrome in head and neck surgical patients: diagnostic and managerial considerations. Chaloupka JC, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):843–52

Embolization for ruptured superior mesenteric artery aneurysms. Ishii A, et al. **Br J Radiol** 1996 Apr; 69(820):296–300

Ruptured suprarenal artery aneurysm: angiographic diagnosis and treatment by selective embolization. Perona F, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):291–3

Glue embolisation of a ruptured pancreaticoduodenal artery aneurysm. Hammer FD, et al. **Eur Radiol** 1996;6(4):514–7

Embolisation of recently ruptured intracranial aneurysms. Byrne JV, et al. **J Neurol Neurosurg Psychiatry** 1995 Dec; 59(6):616–20

Endovascular treatment of bacterial intracranial aneurysms. Scotti G, et al. **Neuroradiology** 1996 Feb;38(2):186–9

Early treatment of ruptured aneurysms with Guglielmi detachable coils: effect on subsequent bleeding. Graves VB, et al. **Neurosurgery** 1995 Oct;37(4):640–7; discussion 647–8

Aneurysm rupture after parent vessel sacrifice: treatment with Guglielmi detachable coil embolization via retrograde catheterization: case report. Gurian JH, et al. **Neurosurgery** 1995 Dec;37(6):1216–20; discussion 1220–1

Ruptured bronchial artery aneurysm associated with pleural telangiectasis and tortuous portal obstruction: report of a case. Ishizaki N, et al. **Surg Today** 1995;25(9):852–4

[Anesthesia and critical care for endovascular occlusion of ruptured intracranial aneurysms with electrically detachable coils] Krivosic-Horber R, et al. **Ann Fr Anesth Reanim** 1996;15(3):354–8 (Eng. Abstr.) **(Fre)**

[Subarachnoid hemorrhage caused by aneurysm rupture. Surgery or embolization?] Marchal JC, et al. **Ann Fr Anesth Reanim** 1996;15(3):342–7 (Eng. Abstr.) **(Fre)**

[Subarachnoid hemorrhage caused by aneurysm rupture. Initial management of patients] Sztark F, et al. **Ann Fr Anesth Reanim** 1996;15(3):322–7 (Eng. Abstr.) **(Fre)**

[Selective embolization with an adhesive fluid of complicated aneurysms of the hepatic artery: 3 cases] Cotroneo AR, et al. **Radiol Med (Torino)** 1996 Apr;91(4):492–6 (21 ref.) **(Ita)**

ULTRASONOGRAPHY

Amount of subarachnoid blood and vasospasm: current aspects. A transcranial Doppler study. Schaller C, et al. **Acta Neurochir (Wien)** 1995;136(1–2):67–71

Superficial femoral artery aneurysm—an uncommon site of aneurysm formation. Atallah C, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):502–4

[Vasospasm after rupture of aneurysms of the anterior communicating artery. Sensitivity and specificity of transcranial Doppler] Proust F, et al. **Neurochirurgie** 1995; 41(6):385–90 (Eng. Abstr.) **(Fre)**

ANF see **ATRIAL NATRIURETIC FACTOR**

ANF RECEPTORS see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

ANGEL DUST ABUSE see **PHENCYCLIDINE ABUSE**

ANGELMAN SYNDROME

COMPLICATIONS

Cortical myoclonus in Angelman syndrome. Guerrini R, et al. **Ann Neurol** 1996 Jul;40(1):39–48

DIAGNOSIS

Diagnostic testing for Prader-Willi and Angleman syndromes: Report of the ASHG/ACMG Test and Technology Transfer Committee. **Am J Hum Genet** 1996 May;58(5):1085–8

Allele-specific replication of 15q11–q13 loci: a diagnostic test for detection of uniparental disomy. White LM, et al. **Am J Hum Genet** 1996 Aug;59(2):423–30

PW71 methylation test for Prader-Willi and Angelman syndromes [letter] Dittrich B, et al. **Am J Med Genet** 1996 Jan 11;61(2):196–7

Clinical, cytogenetic, and molecular diagnosis of Angelman syndrome: estimated prevalence rate in a Danish county [letter] Petersen MB, et al. **Am J Med Genet** 1995 Jun 19; 60(3):261–2

Fluorescent in situ hybridization for evaluation of Prader-Willi and Angelman syndromes [letter; comment] Wenger SL, et al. **Am J Med Genet** 1995 Jul 17;57(4):639 . Comment on: Am J Med Genet 1994 Aug 1;52(1):85–91.

4p(–) syndrome: a chromosomal disorder associated with a particular EEG pattern. Sgrò V, et al. **Epilepsia** 1995 Dec; 36(12):1206–14

Genetic testing for Prader-Willi and Angelman syndromes. Schad CR, et al. **Mayo Clin Proc** 1995 Dec;70(12):1195–6

[Practical information on Angelman syndrome (letter)] Kyllerman M. **Lakartidningen** 1996 May 1;93(18):1710 **(Swe)**

EPIDEMIOLOGY

On the prevalence of Angelman syndrome [letter] Kyllerman M. **Am J Med Genet** 1995 Nov 20;59(3):405; discussion 403–4

Autism in Angelman syndrome: a population-based study. Steffenburg S, et al. **Pediatr Neurol** 1996 Feb;14(2):131–6

GENETICS

Familial cryptic translocation resulting in Angelman syndrome:implications for imprinting or location of the Angelman gene? Burke LW, et al. **Am J Hum Genet** 1996 Apr;58(4):777–84

Gene structure, DNA methylation, and imprinted expression of the human SNRPN gene. Glenn CC, et al. **Am J Hum Genet** 1996 Feb;58(2):335–46

DNA methylation patterns in human tissues of uniparental origin using a zinc-finger gene (ZNF127) from the Angelman/Prader-Willi region. Mowery-Rushton PA, et al. **Am J Med Genet** 1996 Jan 11;61(2):140–6

Angelman syndrome. Williams CA, et al. **Curr Probl Pediatr** 1995 Aug;25(7):216–31 (89 ref.)

Establishment of sequence-tagged sites on 15q11–q13 by Alu-vector PCR cloning of YAC-generated fragments. Kim WS, et al. **Dis Markers** 1996 Mar;12(4):241–6

DNA methylation pattern in Angelman syndrome. Stefanova M. **Folia Med (Plovdiv)** 1995;37(4A Suppl):67

Angelman syndrome in an inbred family. Beuten J, et al. **Hum Genet** 1996 Mar;97(3):294–8

Routine screening for microdeletions by FISH in 77 patients suspected of having Prader-Willi or Angelman syndromes using YAC clone 273A2 (D15S10). Erdel M, et al. **Hum Genet** 1996 Jun;97(6):784–93

Homologous association of oppositely imprinted chromosomal domains. LaSalle JM, et al. **Science** 1996 May 3;272(5262):725–8

[Angelman syndrome. A developmental disorder with important significance for understanding genetic imprinting] Pålsson-Ståe U, et al. **Lakartidningen** 1996 Mar 6;93(10):921–4 **(Swe)**

PHYSIOPATHOLOGY

Seizure and EEG patterns in Angelman's syndrome. Viani F, et al. **J Child Neurol** 1995 Nov;10(6):467–71

RADIONUCLIDE IMAGING

Decrease in benzodiazepine receptor binding in a patient with Angelman syndrome detected by iodine-123 iomazenil and single-photon emission tomography. Odano I, et al. **Eur J Nucl Med** 1996 May;23(5):598–604

ANGER

A school-based anger management program for developmentally and emotionally disabled high school students. Kellner MH, et al. **Adolescence** 1995 Winter; 30(120):813–25

Psychosocial characteristics and recurrent events after percutaneous transluminal coronary angioplasty. Mendes de Leon CF, et al. **Am J Cardiol** 1996 Feb 1;77(4):252–5

Anger in nurses: don't lose it, use it. Droppleman PG, et al. **Am J Nurs** 1996 Apr;96(4):26–31; quiz 32 (11 ref.)

Anger theory and management: a historical analysis. Kemp S, et al. **Am J Psychol** 1995 Fall;108(3):397–417

Violence, mental health, and substance abuse in patients who are seen in primary care settings. Wyshak G, et al. **Arch Fam Med** 1996 Sep;5(9):441–7

Gender differences in sexual desire: the effects of anger and anxiety. Beck JG, et al. **Arch Sex Behav** 1995 Dec; 24(6):595–612

Links between expressed emotion and burden of care in relatives of patients with schizophrenia. Scazufca M, et al. **Br J Psychiatry** 1996 May;168(5):580–7

Experiencing a shame response as a precursor to violence. Thomas HE. **Bull Am Acad Psychiatry Law** 1995; 23(4):587–93

Mood still angry following bitter Saskatchewan strike. **Can Med Assoc J** 1996 Apr 15;154(8):1236–8

Getting angry at peers: associations with linking of the provocateur. Fabes RA, et al. **Child Dev** 1996 Jun; 67(3):942–56

Display rules for anger, sadness, and pain: it depends on who is watching. Zeman J, et al. **Child Dev** 1996 Jun; 67(3):957–73

The association between childhood irritability and liability to substance use in early adolescence: a 2-year follow-up study of boys at risk for substance abuse. Tarter RE, et al. **Drug Alcohol Depend** 1995 Oct;39(3):253–61

Self-defense against verbal assault: shame, anger, and the social bond. Scheff TJ. **Fam Process** 1995 Sep;34(3):271–86

Negative family environment as a predictor of boys' future status on measures of hostile attitudes, interview behavior, and anger expression. Matthews KA, et al. **Health Psychol** 1996 Jan;15(1):30–7

Hostility, anger-in, and cardiovascular reactivity in white women. Powch IG, et al. **Health Psychol** 1996 May; 15(3):200–8

Relationship of trait anger to resting blood pressure: a meta-analysis. Suls J, et al. **Health Psychol** 1995 Sep; 14(5):444–56

Management of the angry parents of severely ill children. Sardesai U, et al. **Indian Pediatr** 1995 Jan;32(1):123–7

Triggers of myocardial ischemia during daily life in patients with coronary artery disease: physical and mental activities, anger and smoking. Gabbay FH, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):585–92

Extrapunitive and intropunitive anger of HIV caregivers: nursing implications. Phillips KD, et al. **J Assoc Nurses AIDS Care** 1996 Mar–Apr;7(2):17–27

Assessing individual differences in constructive versus destructive responses to anger across the lifespan. Tangney JP, et al. **J Pers Soc Psychol** 1996 Apr;70(4):780–96

Relation of shame and guilt to constructive versus destructive responses to anger across the lifespan. Tangney JP, et al. **J Pers Soc Psychol** 1996 Apr;70(4):797–809

Toward an anthropology of senility: anger, weakness, and Alzheimer's in Banaras, India. Cohen L. **Med Anthropol Q** 1995 Sep;9(3):314–34

Personal accounts. Can institution-induced anger prolong hospitalization for patients who repress anger? Watson BE. **Psychiatr Serv** 1996 Apr;47(4):363–4

Anger attacks in eating disorders. Fava M, et al. **Psychiatry Res** 1995 Apr 28;56(3):205–12

Self-criticism and dependency in relation to anger. Dunkley DM, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1342

Humor preferences among angered males and females: associations with humor content and sexual desire. Prerost FJ. **Psychol Rep** 1995 Aug;77(1):227–34

Brief cognitive behavioural therapy with male adolescent offenders in open custody or on probation: an evaluation of management of anger. Valliant PM, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):1056–8

Cardiovascular risk factors in depression. The role of anxiety and anger. Fava M, et al. **Psychosomatics** 1996 Jan–Feb; 37(1):31–7

Dimensions of anger and hostility in cardiac patients, hypertensive patients, and controls. Ricci Bitti PE, et al. **Psychother Psychosom** 1995;64(3–4):162–72

DRUG EFFECTS

Paroxetine treatment of anger associated with depression. Albritton J, et al. **J Nerv Ment Dis** 1995 Oct;183(10):666–7

PHYSIOLOGY

Vital exhaustion, anger expression, and pituitary and adrenocortical hormones. Implications for the insulin resistance syndrome. Keltikangas-Järvinen L, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):275–80

The relationship between habitual anger coping style and serum lipid and lipoprotein concentrations. Müller MM, et al. **Biol Psychol** 1995 Aug;41(1):69–81

Reversible cardiogenic shock in an angry woman--case report and review of the literature. Kovacs KA, et al. **Can J Cardiol** 1996 Jul;12(7):689–93 (52 ref.)

Life-threatening cardiovascular consequences of anger in patients with coronary heart disease. Verrier RL, et al. **Cardiol Clin** 1996 May;14(2):289–307 (112 ref.)

Cynical hostility influences anger, but not cardiovascular reactivity during competition with harassment. Felsten G. **Int J Psychophysiol** 1995 Apr;19(3):223–31

Chronic fatigue syndrome [letter; comment] Fisk JW. **N Z Med J** 1995 Sep 22;108(1008):393. Comment on: N Z Med J 1995 Jul 28;108(1004):301.

Serum cholesterol and perception of anger and sadness. Guggenheim CB, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1343–5

Effects of anger/hostility, defensiveness, gender, and family history of hypertension on cardiovascular reactivity. Shapiro D, et al. **Psychophysiology** 1995 Sep;32(5):425–35

ANGIITIS see **VASCULITIS**

ANGIITIS, ALLERGIC CUTANEOUS see **VASCULITIS, ALLERGIC CUTANEOUS**

ANGIITIS, ALLERGIC GRANULOMATOUS see **CHURG-STRAUSS SYNDROME**

ANGIITIS, HYPERSENSITIVITY see **VASCULITIS, HYPERSENSITIVITY**

ANGIITIS, LEUKOCYTOCLASTIC see **VASCULITIS, HYPERSENSITIVITY**

ANGINA AT REST see **ANGINA, UNSTABLE**

ANGINA, MICROVASCULAR see **SYNDROME X**

ANGINA PECTORIS

Characterization and identification of women with angina pectoris. Holdright DR, et al. **Eur Heart J** 1996 Apr; 17(4):510–7 (70 ref.)

Angina: an update for dentistry. Herman WW, et al. **J Am Dent Assoc** 1996 Jan;127(1):98–104 (62 ref.)

[A health system that does not live up to expectations. A primary health care team attempt at an integrated approach to a case (letter)] Cárdenas Rodríguez M, et al. **Aten Primaria** 1996 Feb 29;17(3):232–3 **(Spa)**

BLOOD

Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. de Maat MP, et al. **Arterioscler Thromb Vasc Biol** 1996 Sep; 16(9):1156–62

Prognostic efficacy of troponin T measurement in angina pectoris. Yang Z, et al. **Chin Med J (Engl)** 1995 Aug; 108(8):626–30

Neutrophil hyper-reactivity after exercise-induced angina pectoris. Ott I, et al. **Coron Artery Dis** 1995 Jul;6(7):525–32

Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. Salomone OA, et al. **J Am Coll Cardiol** 1996 Jul;28(1):14–9

Waiting for Godot: use of chemical markers in the emergency department evaluation of chest pain [editorial; comment] Cannon CP, et al. **J Emerg Med** 1995 Jul–Aug;13(4):533–5 . Comment on: J Emerg Med 1995 Jul–Aug;13(4):471–80.

Patterns of practice in emergency department management of chest pain of suspected cardiac origin: clinical utility of single stat creatine kinase (CK) [see comments] Tsang T, et al. **J Emerg Med** 1995 Jul–Aug;13(4):471–80. Comment in: J Emerg Med 1995 Jul–aug;13(4):533–5.

Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction. Results of the ECAT Angina Pectoris Study Group. Haverkate F, et al. **Thromb Haemost** 1995 Apr;73(4):561–7

Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease. Pedersen OD, et al. **Thromb Haemost** 1995 May;73(5):835–40

[Lipoprotein(a) and hemostasis-activation markers in angina pectoris (letter)] Stein D, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):151 **(Ger)**

CHEMICALLY INDUCED

Losartan and angina pectoris. Ahmad S. **Tex Heart Inst J** 1995;22(4):347–8

CLASSIFICATION

Subclassification of patients with angina and normal coronary angiograms [editorial] Kübler W. **Eur Heart J** 1995 Oct; 16(10):1313–5

COMPLICATIONS

Prevalence of coronary artery disease in obese versus lean men with angina pectoris and positive exercise stress test. Bahadori B, et al. **Am J Cardiol** 1996 May 1;77(11):1000–1

Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Thompson SG, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):357–62

Can panic disorder be considered as an angina equivalent? [letter] Gallerani M, et al. **Eur Heart J** 1995 Dec; 16(12):2013–4

Acute heavy alcohol intake increases silent myocardial ischaemia in patients with stable angina pectoris. Rossinen J, et al. **Heart** 1996 Jun;75(6):563–7

Preinfarction angina [letter; comment] Kloner RA, et al. **N Engl J Med** 1996 Jul 4;335(1):59–60; discussion 60–1. Comment on: N Engl J Med 1996 Jan 4;334(1):7–12.

Preinfarction angina [letter; comment] Migrino RQ, et al. **N Engl J Med** 1996 Jul 4;335(1):59; discussion 60–1. Comment on: N Engl J Med 1996 Jan 4;334(1):7–12.

Angina, functional impairment and physical inactivity among Mexican-American women with depressive symptoms. Portillo CJ, et al. **Prog Cardiovasc Nurs** 1995 Summer; 10(3):18–25

[Temporal arteritis associated with hyperthyroidism and complicated by angina pectoris. A case report] Bertola G, et al. **Minerva Med** 1996 Mar;87(3):105–8 (Eng. Abstr.) **(Ita)**

[Ischemic preconditioning to pharmacologic activation of the ATP-dependent potassium channels] Rossi G. **Recenti Prog Med** 1996 Apr;87(4):172–4 **(Ita)**

[A case of surgically treated hypertrophic obstructive cardiomyopathy suffering from angina pectoris during hemodialysis] Yamada M, et al. **Kyobu Geka** 1996 Mar; 49(3):247–9 (Eng. Abstr.) **(Jpn)**

[Anomalous origin of the circumflex artery and coronary spasm] Moreira AE, et al. **Arq Bras Cardiol** 1995 Apr; 64(4):341–3 (Eng. Abstr.) **(Por)**

DIAGNOSIS

Multicenter study of creatine kinase-MB use: effect on chest pain clinical decision making. Hedges JR, et al. **Acad Emerg Med** 1996 Jan;3(1):7–15

Three-dimensional respiratory-gated MR angiography of coronary arteries: comparison with conventional coronary angiography. Post JC, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1399–404

American College of Emergency Physicians information paper: chest pain units in emergency departments--a report from the Short-Term Observation Services Section. Graff L, et al. **Am J Cardiol** 1995 Nov 15;76(14):1036–9

Association between angina pectoris and ischemic indexes during exercise testing and ambulatory monitoring. Krittayaphong R, et al. **Am J Cardiol** 1996 Aug 1; 78(3):266–70

Gender bias in the evaluation of chest pain in the emergency department. Lehmann JB, et al. **Am J Cardiol** 1996 Mar 15;77(8):641–4

Evaluation of a prehospital chest pain protocol. Wuerz RC, et al. **Ann Emerg Med** 1995 Nov;26(5):595–7

Investigating chest pain. Aylward P. **Aust Fam Physician** 1996 Jul;25(7):1061, 1064–5

Angina-like chest pain. Heart, esophagus, or something else? [editorial; comment] Richter JE. **Chest** 1996 May; 109(5):1139–40. Comment on: Chest 1996 May;109(5):1210–4.

Prevalence of esophageal disorders in patients with chest pain newly referred to the cardiologist [see comments] Voskuil JH, et al. **Chest** 1996 May;109(5):1210–4. Comment in: Chest 1996 May;109(5):1139–40.

ST-segment/heart rate loop analysis on treadmill exercise testing can provide diagnostic and prognostic information in patients with stable effort angina. Kamata J, et al. **Coron Artery Dis** 1995 Jul;6(7):547–54

Single coronary artery: morphological and functional evaluation by magnetic resonance imaging [letter] van Campen LC, et al. **Eur Heart J** 1995 Dec;16(12):2003–4

Somatic awareness and coronary artery disease in women with chest pain. Warner CD. **Heart Lung** 1995 Nov–Dec; 24(6):436–43

Recurrent myocardial infarction with angina and normal coronary arteries. Lip GY, et al. **Int J Cardiol** 1995 Aug; 51(1):65–71

Assessing the significance of preinfarction angina [letter] Barron HV, et al. **J Am Coll Cardiol** 1996 May;27(6):1550–1

Repeatability and validity of the Rose questionnaire for angina pectoris in the Atherosclerosis Risk in Communities Study. Sorlie PD, et al. **J Clin Epidemiol** 1996 Jul; 49(7):719–25

[Angina pectoris and myocardial infarct in infants] Jager MJ, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2537–40 **(Dut)**

[Diagnostic and differential diagnostic value of troponins] Prellwitz W, et al. **Med Klin** 1996 Jun 15;91(6):336–42 (Eng. Abstr.) **(Ger)**

[Sinoatrial block caused by gastroesophageal reflux. The role of simultaneous 24 hr. esophageal pH-metry and Holter-ECG in the differential diagnosis of angina pectoris] Patai A, et al. **Orv Hetil** 1996 Mar 31;137(13):687–90 (38 ref.) (Eng. Abstr.) **(Hun)**

[A chest-pain-unit. A complement to the department of myocardial infarction] Herlitz J, et al. **Lakartidningen** 1996 May 8;93(19):1835–6 **(Swe)**

[Myocardial infarction is diagnosed in every 20th case of acute chest pain. Good consistency between 2 emergency admission departments] Iwarson A, et al. **Lakartidningen** 1996 May 8;93(19):1830–2 **(Swe)**

[Expert advice is not expected from everyday practice. Patients on regular check-ups are often getting sicker with time] Overby A. **Lakartidningen** 1995 Sep 20;92(38):3445–6 **(Swe)**

DRUG THERAPY

Cardiac function improvement 24 hours after isradipine SRO in patients with chronic stable angina: a double-blind randomized study. Doat M, et al. **Acta Cardiol** 1996; 51(2):155–64

Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group. Bakx AL, et al. **Am Heart J** 1995 Oct;130(4):748–57

Heart rate reduction in the treatment of chronic stable angina pectoris: experiences with a sinus node inhibitor [editorial] Frishman WH, et al. **Am Heart J** 1996 Jan;131(1):204–10 (63 ref.)

Usefulness of heart rate variability in predicting drug efficacy (metoprolol vs diltiazem) in patients with stable angina pectoris. Brouwer J, et al. **Am J Cardiol** 1995 Oct 15; 76(11):759–63

Prognosis of patients with stable angina pectoris on antianginal drug therapy. Hjemdahl P, et al. **Am J Cardiol** 1996 Jun 20;77(16):6D–15D (67 ref.)

Effects of angiotensin-converting enzyme inhibitor alacepril in patients with stable effort angina during chronic isosorbide dinitrate treatment. Murohara T, et al. **Am J Cardiol** 1996 Jun 1;77(14):1159–63

Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage. 5-ISMN headache study group. Cleophas TJ, et al. **Angiology** 1996 Jul;47(7):679–85

Effect of sustained release diltiazem (Diltiazem-R) in patients with stable effort angina. Kaku T, et al. **Artery** 1994; 21(4):193–207

Pharmacological profile of semotiadil fumarate, a novel calcium antagonist, in rat experimental angina model. Mori T, et al. **Br J Pharmacol** 1995 Sep;116(1):1668–72

Therapy of angina pectoris with long-acting nitrates: which agent and when? Abrams J. **Can J Cardiol** 1996 May;12 Suppl C:9C–16C

Potential problems with intermittent nitrate therapy. Parker JD. **Can J Cardiol** 1996 May;12 Suppl C:22C–24C

Nitrate tolerance--problems both new and old. Parker JO. **Can J Cardiol** 1996 May;12 Suppl C:5C–8C

Short-term effects of captopril on exercise tolerance in patients with chronic stable angina pectoris and normal left ventricular function. Steffensen R, et al. **Cardiology**

1995;86(6):445–50

Intermittent or continuous transdermal nitroglycerin: still an issue, or is the case closed? Klemsdal TO, et al. **Cardiovasc Drugs Ther** 1996 Mar;10(1):5–10 (61 ref.)

Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina. Kuhn A, et al. **Cardiovasc Drugs Ther** 1995 Aug;9(4):595–600

Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina. Sakata K, et al. **Cardiovasc Drugs Ther** 1995 Aug;9(4):601–7

Effects of diuretic therapy on the development of tolerance to nitroglycerin and exercise capacity in patients with chronic stable angina. Parker JD, et al. **Circulation** 1996 Feb 15;93(4):691–6

Medical management of stable angina and unstable angina in the elderly with coronary artery disease. Olson HG, et al. **Clin Geriatr Med** 1996 Feb;12(1):121–40 (72 ref.)

A cross-over study comparing the efficacy of a combination of atenolol and nifedipine at different doses in angina pectoris. Metcalfe MJ, et al. **Curr Med Res Opin** 1995; 13(5):251–6

Nicorandil for angina. **Drug Ther Bull** 1995 Dec;33(12):89–92 (26 ref.)

Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Brogden RN, et al. **Drugs** 1995 Sep; 50(3):495–512 (82 ref.)

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov;50(5):896] Haria M, et al. **Drugs** 1995 Sep;50(3):560–86 (196 ref.)

Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Dunn CJ, et al. **Drugs Aging** 1995 Nov; 7(5):394–411 (111 ref.)

Anti-ischaemic efficacy of L-propionylcarnitine--a promising novel metabolic approach to ischaemia? Bartels GL, et al. **Eur Heart J** 1996 Mar;17(3):414–20

Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Dargie HJ, et al. **Eur Heart J** 1996 Jan;17(1):104–12

The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Fox KM, et al. **Eur Heart J** 1996 Jan;17(1):96–103

Are antianginal drugs effective in secondary prevention after myocardial infarction? Julian DG. **Eur Heart J** 1995 Jul; 16 Suppl E:38–40 (13 ref.)

Pointers from recent multicentre trials using ambulatory monitoring--placing placebo in perspective [editorial; comment] Mulcahy D. **Eur Heart J** 1995 Dec;16(12):1754–6 . Comment on: Eur Heart J 1995 Dec;16(12):1780–8.

Does the exercise protocol matter when assessing the anti-anginal effects of drug therapy? [see comments] Patel DJ, et al. **Eur Heart J** 1995 Dec;16(12):1773–9. Comment in: Eur Heart J 1995 Dec;16(12):1757–9.

The preventative effects of vasodilating beta-blockers in cardiovascular disease. Raftery EB. **Eur Heart J** 1996 Apr; 17 Suppl B:30–8

Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Rehnqvist N, et al. **Eur Heart J** 1996 Jan; 17(1):76–81

Calcium channel blockers or beta receptor antagonists for patients with ischaemic heart disease. What is the best choice? [editorial] Rydén L, et al. **Eur Heart J** 1996 Jan; 17(1):1–3

Are antianginal drugs effective in post-myocardial infarction secondary prevention? Sleight P. **Eur Heart J** 1995 Jul;16 Suppl E:36–7 (11 ref.)

Relevance of the pharmacokinetic profile in the treatment of angina pectoris: the need for 24 h control. Tamargo J, et al. **Eur Heart J** 1995 Jul;16 Suppl E:57–61 (33 ref.)

Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris. Boman K, et al. **Eur J Clin Pharmacol** 1995;49(1–2):27–30

Nicorandil suppressed myocardial purine metabolism during exercise in patients with angina pectoris. Ogino K, et al. **Eur J Clin Pharmacol** 1995;48(3–4):189–94

Abrupt cessation of short-term continuous treatment with isosorbide dinitrate may cause a rebound increase in silent myocardial ischaemia in patients with stable angina pectoris. Martsevich SY, et al. **Heart** 1996 May; 75(5):447–50

Differences in ischemic threshold and nitrate efficacy between normotensive and hypertensive patients with stable angina pectoris. Marmor A, et al. **Hypertens Res** 1995 Jun;18(2):119–24

A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina. Walker JM, et al. **Int J Cardiol** 1996 Feb;53(2):117–26

Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group. Braun S, et al. **J Am Coll Cardiol** 1996 Feb;27(2):317–22

Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial. Leschke M, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):575–84

Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. Savonitto S, et al. **J Am Coll Cardiol** 1996 Feb; 27(2):311–6

Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1. Chirkov YY, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):961–6

Clinical efficacy and safety of once-daily diltiazem in patients with stable angina pectoris switched from twice-daily diltiazem. Savard D, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):85–9

Antianginal and antiischemic efficacy of monotherapy extended-release nisoldipine (Coat Core) in chronic stable angina. Glasser SP, et al. **J Clin Pharmacol** 1995 Aug; 35(8):780–4

New arguments in favour of cardioselective beta-blockers [letter] Cleophas TJ, et al. **Neth J Med** 1995 Dec; 47(6):308–10

Effect of beta adrenergic receptor blockade on cardiac autonomic tone in patients with chronic stable angina. Burger AJ, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):411–7

Chronic stable angina pectoris. Strategies for effective drug therapy. Thadani U, et al. **Postgrad Med** 1995 Dec; 98(6):175–6, 179–83, 187–8 (28 ref.)

Calcium channel antagonists in the management of anginal syndromes: changing concepts in relation to the role of coronary vasospasm. Opie LH. **Prog Cardiovasc Dis** 1996 Jan-Feb;38(4):291–314 (154 ref.)

[Antianginal therapy 95] Stejfa M. **Vnitr Lek** 1996 Feb; 42(2):71–7 (Eng. Abstr.) (Cze)

[Treatment of Angina pectoris using nitrates] van Wijngaarden J, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13; 140(15):819–22 (25 ref.) (Dut)

[The cholesterol hypothesis has been proved true at last (editorial)] Huttunen J. **Duodecim** 1995;111(5):385–6 (Fin)

[Comparative study of verapamil LI 120 mg 3 times a day and verapamil LP 120 mg twice a day in stable exertion-induced angina. A multicenter study] Belin A, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):365–71 (Eng. Abstr.) (Fre)

[Evaluation of amlodipine in stable effort angina. Comparison with diltiazem in terms of efficacy, tolerability and maintenance of the anti-ischemic action 24 hours after the last dose] Marchand X, et al. **Ann Cardiol Angeiol (Paris)** 1996 Feb;45(2):74–82 (Eng. Abstr.) (Fre)

[Comparison of the antispastic effect of Bi-Tildiem 120 mg and Tildiem 60mg] Yvorra S, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):372–7 (Eng. Abstr.) (Fre)

[Calcium antagonists and primary prevention of coronary disease] Rehnqvist N. **Arch Mal Coeur Vaiss** 1995 Sep;88 Spec No 4:13–6 (Eng. Abstr.) (Fre)

[Calcium antagonist protects the heart from ischemia and thrombosis (news)] Beuckelmann DJ. **Fortschr Med** 1996 Apr 10;114(10):8 (Ger)

[Controlled clinical studies of tolerance development and dosing problems in nitrate therapy] Abshagen U. **Herz** 1996 Jun;21 Suppl 1:23–30 (18 ref.) (Eng. Abstr.) (Ger)

[Nitrates--1996 current therapy concept? (editorial)] Kübler W. **Herz** 1996 Jun;21 Suppl 1:2–3 (Ger)

[Characteristics of angina pectoris therapy with nitrates] Silber S. **Herz** 1996 Jun;21 Suppl 1:4–22 (331 ref.) (Eng. Abstr.) (Ger)

[Drug therapy in angina pectoris] Follath F. **Schweiz Rundsch Med Prax** 1995 Oct 17;84(42):1186–9 (22 ref.) (Eng. Abstr.) (Ger)

[Local drug administration systems, preclinical and clinical use: perspectives and limitations] Gonschior P, et al. **Z Kardiol** 1996 Mar;85(3):155–65 (59 ref.) (Eng. Abstr.) (Ger)

[Efficacy and tolerability of felodipine and nifedipine in stable angina refractory to beta-blocker therapy] Mazzotta G, et al. **G Ital Cardiol** 1996 Apr;26(4):407–17 (Eng. Abstr.) (Ita)

[Calcium antagonist therapy of middle-aged and aged patients with angina pectoris during the outpatient stage of rehabilitation] Pimenov LT, et al. **Klin Med (Mosk)** 1995; 73(5):69–71 (Rus)

[Carcinoid syndrome with angina pectoris treated with corinfar] Starovoitova SP, et al. **Klin Med (Mosk)** 1995; 73(5):62–3 (Rus)

[Comparative evaluation of long-acting nitro preparations in patients with ischemic heart disease and stable angina pectoris of different functional classes] Zhebel' VN, et al. **Klin Med (Mosk)** 1995;73(5):74 (Rus)

[The use of the delayed-action form of korinfar in arterial hypertension, stenocardia and hypertrophic cardiomyopathy] Barats SS, et al. **Ter Arkh** 1996; 68(1):39–42 (Eng. Abstr.) (Rus)

[New drug forms of molsidomine, Corvaton-forte and Corvaton-retard, and their antianginal efficacy in stenocardia patients] Kukushkin SK, et al. **Ter Arkh** 1996; 68(1):29–30 (Rus)

ECONOMICS

Can improved quality of care reduce the costs of managing angina pectoris? Cleland JG. **Eur Heart J** 1996 Mar;17 Suppl A:29–40 (74 ref.)

Measuring heart patients' willingness to pay for changes in angina symptoms. Chestnut LG, et al. **Med Decis Making** 1996 Jan-Mar;16(1):65–77

[The cost of angina. Reduction of productivity is as expensive as medical treatment] Andersson F, et al. **Lakartidningen** 1996 Aug 28;93(34):2842–4 (Swe)

[Angina pectoris is as expensive as myocardial infarction. An unexpected result of a study] Andersson F, et al. **Lakartidningen** 1995 Sep 20;92(38):3420–2 (Swe)

EPIDEMIOLOGY

Epidemiologic assessment of angina before and after myocardial infarction: The Framingham study. Brand FN, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):174–8

Risk factors of recurrent angina pectoris and of non-fatal myocardial infarction after coronary artery bypass surgery. Risum O, et al. **Eur J Cardiothorac Surg** 1996;10(3):173–8

Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). Coronary Artery Surgery Study. Cameron AA, et al. **J Am Coll Cardiol** 1995 Oct;26(4):895–9

Risk factors and angiographic profile of coronary artery disease in young. Biswas PK, et al. **J Indian Med Assoc** 1995 Mar;93(3):90–2, 94

[Isolated disease of the descending anterior artery: the relationship between the angiographic characteristics and the occurrence of angina after myocardial revascularization] Patrício L, et al. **Rev Port Cardiol** 1995 Nov;14(11):881–4 (Por)

ETIOLOGY

Microvascular angina in systemic hypertension: diagnosis and treatment with enalapril. Iriarte MM, et al. **Am J Cardiol** 1995 Nov 2;76(13):31D–34D (18 ref.)

An unsuspected cause for recurrent angina: subclavian artery stenosis. Edwards WH. **Am Surg** 1995 Dec;61(12):1057–60

Paravalvular aortic rupture causing angina following aortic valve replacement. Reddy ER, et al. **Cardiovasc Intervent Radiol** 1995 Sep-Oct;18(5):321–2

Renal artery stenosis presenting as crescendo angina pectoris. Tami LF, et al. **Cathet Cardiovasc Diagn** 1995 Jul; 35(3):252–6

Upper endoscopy in patients with angina and normal coronary angiograms. Frøbert O, et al. **Endoscopy** 1995 Jun;27(5):365–70

Aggressive pattern of angina after successful coronary angioplasty: the role of clinical and angiographic factors. Chen L, et al. **Eur Heart J** 1995 Aug;16(8):1085–91

Microvascular angina in patients with normal coronary arteries and with other ischaemic syndromes. Cianflone D, et al. **Eur Heart J** 1995 Aug;16 Suppl I:96–103 (77 ref.)

Nodal re-entry tachycardia with angina treated with adenosine [letter] Nyberg G, et al. **Eur Heart J** 1996 Apr; 17(4):643

Anomalous aortic origin of the right coronary artery. An unusual cause of angina pectoris and its surgical correction. Tsang GM, et al. **Eur J Cardiothorac Surg** 1995;9(12):715–6

Migraine and angina pectoris by coronary artery spasm. Lafitte C, et al. **Headache** 1996 May;36(5):332–4 (14 ref.)

Correlates and in-hospital outcome of painless presentation of acute myocardial infarction: a prospective study of a consecutive series of patients admitted to the coronary care unit. Madias JE, et al. **J Investig Med** 1995 Dec; 43(6):567–74

Vasospastic angina in patients with systemic triglyceride storage disease with Jordans' anomaly and cardiomyopathy. Ando S, et al. **Jpn Circ J** 1996 Feb; 60(2):124–9

47-year-old woman with chronic renal failure, chest pain, and a cardiac murmur. Rini JN, et al. **Mayo Clin Proc** 1996 Jan;71(1):63–6

The evaluation of chest pain in women. Douglas PS, et al. **N Engl J Med** 1996 May 16;334(20):1311–5 (55 ref.)

[Angina pectoris and myocardial infarct in infants (letter)] Bogers AJ, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23; 140(12):680–1 (Dut)

[Atresia of the left coronary artery: a case in a marathon runner. Review of the literature] Bouchiat C, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):485–7 (10 ref.) (Eng. Abstr.) (Fre)

[Isolated anomalous origin of a septal artery from a third coronary ostium. Apropos of a case] Elhadad S, et al. **Arch Mal Coeur Vaiss** 1996 Mar;89(3):371–3 (Eng. Abstr.) (Fre)

[Angina pectoris as a symptom of gastric volvulus] Argov S, et al. **Harefuah** 1996 Feb 15;130(4):236–9; 295 (Eng. Abstr.) (Heb)

[An 85-year-old case of Basedow's disease associated with high output heart failure and angina pectoris] Araki T, et al. **Nippon Ronen Igakkai Zasshi** 1996 Mar;33(3):191–5 (Eng. Abstr.) (Jpn)

GENETICS

Parental history of premature coronary heart disease: an

independent risk factor of myocardial infarction. Jousilahti P, et al. **J Clin Epidemiol** 1996 May;49(5):497–503

Vasospastic angina in two sisters. Tachibana K, et al. **Jpn Heart J** 1995 Sep;36(5):669–73

METABOLISM

Clinical pharmacokinetics of molsidomine. Rosenkranz B, et al. **Clin Pharmacokinet** 1996 May;30(5):372–84

Breath pentane and plasma lipid peroxides in ischemic heart disease. Mendis S, et al. **Free Radic Biol Med** 1995 Nov; 19(5):679–84

Fibrin generation and digestion in patients with angina pectoris. Prisco D, et al. **Int J Clin Lab Res** 1995; 25(4):222–5

Impaired glucose tolerance with late hypersecretion of insulin during oral glucose tolerance test in patients with vasospastic angina. Suzuki M, et al. **J Am Coll Cardiol** 1996 May;27(6):1458–63

Delayed metabolic recovery of hibernating myocardium after percutaneous transluminal coronary angioplasty: assessment with iodine-123-betamethyl-p-iodophenyl-pentadecanoic acid imaging. Takeishi Y, et al. **J Cardiol** 1996 Jul;28(1):17–25

PATHOLOGY

Differential progression of complex culprit stenoses in patients with stable and unstable angina pectoris. Chen L, et al. **J Am Coll Cardiol** 1996 Sep;28(3):597–603

The natural history of unheralded complex coronary plaques. Chester MR, et al. **J Am Coll Cardiol** 1996 Sep;28(3):604–8

Angioscopic evaluation of atherosclerotic plaques: validation by histomorphologic analysis and association with stable and unstable coronary syndromes. Thieme T, et al. **J Am Coll Cardiol** 1996 Jul;28(1):1–6

PHYSIOPATHOLOGY

Negative U waves in coronary disease [letter; comment] Tomcsányi J, et al. **Am Heart J** 1995 Dec;130(6):1315–7 . Comment on: Am Heart J 1994 Oct;128(4):816–20.

Adaptation to myocardial ischemia during repeated dynamic exercise in relation to findings at cardiac catheterization. Ylitalo K, et al. **Am Heart J** 1996 Apr;131(4):689–97

Evidence of compensatory preload adjustment on early filling phase in patients with stable angina pectoris and good left ventricular systolic function. Cucchini F, et al. **Am J Cardiol** 1995 Dec 15;76(17):1302–5

Effect of spinal cord stimulation on myocardial blood flow assessed by positron emission tomography in patients with refractory angina pectoris. Hautvast RW, et al. **Am J Cardiol** 1996 Mar 1;77(7):462–7

Relation between blood pressure at rest and perception of angina pectoris during exercise testing. Krittayaphong R, et al. **Am J Cardiol** 1996 Jun 1;77(14):1224–6

An impaired carotid sinus distensibility and baroreceptor sensitivity alter autonomic activity in patients with effort angina associated with significant coronary artery disease. Tomiyama H, et al. **Am J Cardiol** 1996 Jul 15;78(2):225–7

Comparative study of left ventricular function in patients with unstable angina, non-Q wave myocardial infarction and stable angina pectoris: assessment with atrial pacing and digital ventriculography. Hussain KM, et al. **Angiology** 1995 Oct;46(10):867–76

Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Egashira K, et al. **Circulation** 1996 Jul 15;94(2):130–4

Circadian variation in coronary tone in patients with stable angina. Protective role of the endothelium. el-Tamimi H, et al. **Circulation** 1995 Dec 1;92(11):3201–5

Differences in vasodilatory response to dipyridamole between patients with angina and normal coronary arteries and patients with successful coronary angioplasty. Finocchiaro ML, et al. **Coron Artery Dis** 1995 Jun; 6(6):479–87

Autonomic balance in patients with angina and a normal coronary angiogram. Frøbert O, et al. **Eur Heart J** 1995 Oct;16(10):1356–60

Angina, exercise and food [editorial; comment] Harcombe AA, et al. **Eur Heart J** 1996 Mar;17(3):335–6. Comment on: Eur Heart J 1996 Mar;17(3):394–8.

The effect of meals of differing composition on exercise tolerance in patients with angina pectoris [see comments] Lam FY, et al. **Eur Heart J** 1996 Mar;17(3):394–8. Comment in: Eur Heart J 1996 Mar;17(3):335–6.

Exercise-induced angina with intermittent ST-segment elevation. Inomata T, et al. **Intern Med** 1995 Jun; 34(6):597–601

Effect of angina pectoris on myocardial protection in patients with reperfused anterior wall myocardial infarction: retrospective clinical evidence of preconditioning? [letter; comment] Haider AW, et al. **J Am Coll Cardiol** 1995 Oct; 26(4):1113–4. Comment on: J Am Coll Cardiol 1995 Apr;25(5):1076–83.

Coronary angioplasty ameliorates hypoperfusion-induced endothelial dysfunction in patients with stable angina pectoris. Komaru T, et al. **J Am Coll Cardiol** 1996 Jan; 27(1):30–7

Coronary flow velocity changes after intravenous dipyridamole infusion: measurements using intravascular Doppler guide wire. A documentation of flow inhomogeneity. Voudris V, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1148–55

Cardiac reflex effects of intracoronary bradykinin in humans. Schaefer S, et al. **J Investig Med** 1996 Apr;44(4):160–7

Angina reassessed: pain or protector? [see comments] Yellon DM, et al. **Lancet** 1996 Apr 27;347(9009):1159–62 (45 ref.) . Comment in: Lancet 1996 Jul 20;348(9021):204.

Effect of beta adrenergic receptor blockade on cardiac autonomic tone in patients with chronic stable angina. Burger AJ, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):411–7

Reproducibility of time and frequency domain analysis of heart rate variability in patients with chronic stable angina. Kamalesh M, et al. **Pacing Clin Electrophysiol** 1995 Nov; 18(11):1991–4

Left ventricular hypercontractility in hypertensive patients with anginal pain and normal coronary angiograms. Wehling M, et al. **Z Kardiol** 1995 Aug;84(8):606–13

[Pharmacology of nitrates and other NO donors] Dendorfer A. **Herz** 1996 Jun;21 Suppl 1:38–49 (54 ref.) (Eng. Abstr.) **(Ger)**

[Relationship between ischemic ST depression and oxygen uptake kinetics during ramp exercise test in patients with effort angina] Yokoyama Y, et al. **J Cardiol** 1996 May; 27(5):241–6 (Eng. Abstr.) **(Jpn)**

[Reflex constriction of resistance vessels in people with varying pathogenetic mechanisms of angina of effort] Kuleshova EV, et al. **Fiziol Cheloveka** 1996 Mar–Apr; 22(2):101–3 **(Rus)**

PREVENTION & CONTROL

Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial. Rapola JM, et al. **JAMA** 1996 Mar 6;275(9):693–8

[Risk predictors and secondary prevention in angina pectoris and after myocardial infarct] Huber K, et al. **Internist (Berl)** 1995 Sep;36(9):883–90 (74 ref.) **(Ger)**

PSYCHOLOGY

Acupuncture in angina pectoris: do psycho-social and neurophysiological factors relate to the effect? Ballegaard S, et al. **Acupunct Electrother Res** 1995 Apr–Jul; 20(2):101–16

Psychological determinants of anginal pain perception during exercise testing of stable patients after recovery from acute myocardial infarction or unstable angina pectoris. Freedland KE, et al. **Am J Cardiol** 1996 Jan 1;77(1):1–4

Relation between blood pressure at rest and perception of angina pectoris during exercise testing. Krittayaphong R, et al. **Am J Cardiol** 1996 Jun 1;77(14):1224–6

The memorable patient who changed our practice [letter] Gupta AK, et al. **J Assoc Physicians India** 1995 Jul; 43(7):514

Gender differences in the management of acute chest pain. Support for the "Yentl syndrome". Johnson PA, et al. **J Gen Intern Med** 1996 Apr;11(4):209–17

Angina patients' ratings of current health and health without angina: associations with severity of angina and comorbidity [see comments] Chen AY, et al. **Med Decis Making** 1996 Apr–Jun;16(2):169–77. Comment in: Med Decis Making 1996 Apr–Jun;16(2):195–6.

Disease spectrum and health-status perceptions [editorial; comment] Dawson NV. **Med Decis Making** 1996 Apr–Jun; 16(2):195–6. Comment on: Med Decis Making 1996 Apr–Jun;16(2):169–77.

The relationship between cardiac functional capacity and patients' symptom-specific utilities for angina: some findings and methodologic lessons. Nichol G, et al. **Med Decis Making** 1996 Jan–Mar;16(1):78–85

Psychometric properties of a specific quality of life questionnaire in angina pectoris patients. Marquis P, et al. **Qual Life Res** 1995 Dec;4(6):540–6

RADIOGRAPHY

Clinical markers, management, and long-term follow-up of early ischemia after coronary artery bypass grafting. Pimentel CX, et al. **Am J Cardiol** 1995 Nov 1;76(12):967–70

Angina pectoris and disease progression [editorial; comment] Falk E, et al. **Circulation** 1995 Oct 15;92(8):2033–5. Comment on: Circulation 1995 Oct 15;92(8):2058–65.

Rapid angiographic progression of coronary artery disease in patients with angina pectoris. The role of complex stenosis morphology. Kaski JC, et al. **Circulation** 1995 Oct 15;92(8):2058–65

Upper endoscopy in patients with angina and normal coronary angiograms. Frøbert O, et al. **Endoscopy** 1995 Jun;27(5):365–70

Usefulness of hyperventilation thallium-201 single photon emission computed tomography for the diagnosis of vasospastic angina. Masuoka T, et al. **Jpn Heart J** 1995 Jul;36(4):405–20

RADIONUCLIDE IMAGING

Effect of spinal cord stimulation on myocardial blood flow assessed by positron emission tomography in patients with refractory angina pectoris. Hautvast RW, et al. **Am J Cardiol** 1996 Mar 1;77(7):462–7

Patterns of use and clinical utility of exercise thallium-201 single photon emission-computed tomography in a community hospital. McClellan JR, et al. **Cardiology** 1996 Mar-Apr;87(2):134–40

Technetium-99m-sestamibi imaging with nitrate infusion to detect viable hibernating myocardium and predict postrevascularization recovery. Bisi G, et al. **J Nucl Med** 1995 Nov;36(11):1994–2000

Clinical significance of decreased myocardial uptake of 123I-BMIPP in patients with stable effort angina pectoris. Takeishi Y, et al. **Nucl Med Commun** 1995 Dec; 16(12):1002–8

Comparison of myocardial ischaemia in post-infarction patients with and without angina: assessment by dipyridamole 201Tl imaging. Yang CC, et al. **Nucl Med Commun** 1995 Aug;16(8):647–54

REHABILITATION

Safety of medically supervised exercise in a cardiac rehabilitation center. Vongvanich P, et al. **Am J Cardiol** 1996 Jun 15;77(15):1383–5

Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Pocock SJ, et al. **Circulation** 1996 Jul 15;94(2):135–42

A comparison of three measures of perceived distress: results from a study of angina patients in general practice in Northern Ireland. O'Neill C, et al. **J Epidemiol Community Health** 1996 Apr;50(2):202–6

Cardiac rehabilitation: how can it be improved? [editorial] Thompson DR. **J Psychosom Res** 1995 Jul;39(5):519–23 (20 ref.)

[The effect of iodobromide baths on the physical work capacity and extrasystole in patients with ischemic heart disease and stable stenocardia] Klemenko SV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec; (6):11–4 (Eng. Abstr.) **(Rus)**

[The effect of carbon dioxide baths on the physical work capacity and extrasystole of patients with ischemic heart disease and stable stenocardia] Klemenkov SV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Jul–Aug;(4):3–5 (Eng. Abstr.) **(Rus)**

SURGERY

Histologic appearance of transmyocardial laser channels after 4 1/2 weeks. Burkhoff D, et al. **Ann Thorac Surg** 1996 May;61(5):1532–4; discussion 1534–5

Revascularization using angioplasty and minimally invasive techniques documented by thermal imaging. Emery RW, et al. **Ann Thorac Surg** 1996 Aug;62(2):591–3

Can early closure and restenosis after endoluminal stenting be predicted from clinical, procedural, and angiographic variables at the time of intervention? Eeckhout E, et al. **Br Heart J** 1995 Dec;74(6):592–7

Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. The MACB Study Group. **Eur Heart J** 1995 Dec; 16(12):1825–32

The management of patients with stable angina and multivessel disease. PTCA or coronary bypass surgery? Gersh BJ. **Eur Heart J** 1995 Jul;16 Suppl E:32–5 (20 ref.)

Risk factors of recurrent angina pectoris and of non-fatal myocardial infarction after coronary artery bypass surgery. Risum O, et al. **Eur J Cardiothorac Surg** 1996;10(3):173–8

Characteristics of patients younger than 40 years of age operated for coronary artery disease. Wagner J, et al. **Herz** 1996 Jun;21(3):183–91

Intra-coronary stents--extending the role of angioplasty in angina--initial experience. Sheahan RG, et al. **Ir Med J** 1993 May;86(3):102–4

Transmyocardial laser revascularization: operative techniques and clinical results at two years. Horvath KA, et al. **J Thorac Cardiovasc Surg** 1996 May;111(5):1047–53

Myocardial revascularization using both attached internal thoracic arteries. Mid-term clinical evaluation of 117 cases. Chocron S, et al. **Minerva Cardioangiol** 1995 Jul–Aug; 43(7–8):299–302

[Value of percutaneous carotid angioplasty before cardiac surgery] Babatasi G, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jan;45(1):24–9 (Eng. Abstr.) **(Fre)**

[A surgical case report of angina pectoris with multiple coronary giant aneurysms] Imazeki T, et al. **Kyobu Geka** 1996 Jun;49(6):491–4 (Eng. Abstr.) **(Jpn)**

[Coronary arterial bypass grafting for angina pectoris suspected with aortitis syndrome: a case report] Nakamura N, et al. **Kyobu Geka** 1996 Jun;49(6):487–90 (Eng. Abstr.) **(Jpn)**

[Experiences of the approaches to heart for a patient with a tracheostoma] Sakurai Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1684–9 (Eng. Abstr.) **(Jpn)**

THERAPY

Acupuncture in angina pectoris: do psycho-social and neurophysiological factors relate to the effect? Ballegaard S, et al. **Acupunct Electrother Res** 1995 Apr–Jul; 20(2):101–16

Cyclic flow variations after angioplasty: a rare phenomenon predictive of immediate complications. DEBATE Investigator's Group. Sunamura M, et al. **Am Heart J** 1996 May;131(5):843–8

Treatment of a "lost" unexpanded intracoronary stent in a patient with unstable angina. Miketic S, et al.

Am J Cardiol 1995 Dec 15;76(17):1317–8

Impact of intensive physical exercise and low-fat diet on collateral vessel formation in stable angina pectoris and angiographically confirmed coronary artery disease. Niebauer J, et al. **Am J Cardiol** 1995 Oct 15;76(11):771–5

North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management angina. North of England Stable Angina Guideline Development Group. **BMJ** 1996 Mar 30;312(7034):827–32 (123 ref.)

North of England evidence based guidelines development project: methods of guideline development. Eccles M, et al. **BMJ** 1996 Mar 23;312(7033):760–2

Guidelines on managing stable angina omit important point [letter] Norris RM. **BMJ** 1996 Jun 29;312(7047):1675

A mechanism of ischemic preconditioning during percutaneous transluminal coronary angioplasty. Inoue T, et al. **Cardiology** 1996 May-Jun;87(3):216–23

Right coronary artery pseudo-transection due to mechanical straightening during coronary angioplasty. Blankenship JC. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):43–5 (7 ref.)

Pilot prospective evaluation of counterpulsation with different intra-aortic balloon volumes on cardiac performance in humans. Cohen M, et al. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):82–7; discussion 88–9

Angioscopy guided intracoronary thrombolysis and stent deployment in a patient with postinfarction angina. Eltchaninoff H, et al. **Cathet Cardiovasc Diagn** 1995 Jul; 35(3):282–6

Efficacy of marker wire for intracoronary stenting [see comments] Oda H, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):447–51. Comment in: Cathet Cardiovasc Diagn 1996 Apr;37(4):452.

Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Pocock SJ, et al. **Circulation** 1996 Jul 15;94(2):135–42

Management of unstable angina in patients over 75 years old. Eggeling T, et al. **Coron Artery Dis** 1995 Nov;6(11):891–6

Coronary angioplasty versus coronary surgery in the management of angina. Rickards AF, et al. **Curr Opin Cardiol** 1995 Jul;10(4):399–403 (15 ref.)

Can improved quality of care reduce the costs of managing angina pectoris? Cleland JG. **Eur Heart J** 1996 Mar;17 Suppl A:29–40 (74 ref.)

Angioscopic evaluation of prolonged vs standard balloon inflations during coronary angioplasty. A randomized study. Cribier A, et al. **Eur Heart J** 1995 Jul;16(7):930–6

Education from RITA. Randomized Intervention Treatment of Angina. Hampton JR. **Eur Heart J** 1995 Jul;16(7):878–81 (20 ref.)

Vein plasma endothelin-1 and cyclic GMP increase during coronary angioplasty is related to myocardial ischaemia. Kyriakides ZS, et al. **Eur Heart J** 1995 Jul;16(7):894–8

Long-term clinical outcome after stent implantation in saphenous vein grafts. de Jaegere PP, et al. **J Am Coll Cardiol** 1996 Jul;28(1):89–96

Coronary angioplasty ameliorates hypoperfusion-induced endothelial dysfunction in patients with stable angina pectoris. Komaru T, et al. **J Am Coll Cardiol** 1996 Jan; 27(1):30–7

Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. Macaya C, et al. **J Am Coll Cardiol** 1996 Feb;27(2):255–61

Comparison of medical treatment, coronary angioplasty and coronary artery bypass surgery in patients with chronic stable angina. Gogna A, et al. **J Assoc Physicians India** 1995 Aug;43(8):548–52 (33 ref.)

Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery [see comments] Pocock SJ, et al. **Lancet** 1995 Nov 4;346(8984):1184–9. Comment in: Lancet 1995 Nov 4;346(8984):1174–5. Comment in: Lancet 1995 Dec 16;346(8990):1626. Comment in: Lancet 1996 Jan 27;347(8996):271; discussion 272–3. Comment in: Lancet 1996 Jan 27;347(8996):271–2; discussion 272–3.

Does counselling for angina and hypertension work? Browne D. **Practitioner** 1995 Nov;239(1556):679–81 (13 ref.)

Psychosocial effects of enhanced external counterpulsation in the angina patient. Fricchione GL, et al. **Psychosomatics** 1995 Sep-Oct;36(5):494–7

Recurrent angina pectoris in patients with internal mammary artery to coronary artery bypass: treatment with coil embolization of unligated side branches. Chavan A, et al. **Radiology** 1996 Aug;200(2):433–6

[Coronary heart disease with a marked vasospastic component associated with the menstrual cycle and its treatment] Lomíček M, et al. **Vnitr Lek** 1995 Oct; 41(10):710–2 (Eng. Abstr.) **(Cze)**

[Long term course over 10 years after balloon dilatation in stable and unstable angina pectoris] Espinola-Klein C, et al. **Dtsch Med Wochenschr** 1996 May 3;121(18):577–82 (Eng. Abstr.) **(Ger)**

[Quality assurance in invasive cardiology. A prospective study for the evaluation of indications for coronary angiography and coronary dilatation using the Rand Corporation method] Kadel C, et al. **Dtsch Med Wochenschr** 1996 Apr 12;121(15):465–71 (Eng. Abstr.) **(Ger)**

[Normalization of myocardial perfusion reserve after coronary stent implantation in comparison with balloon angioplasty alone] Haude M, et al. **Z Kardiol** 1996 Apr; 85(4):260–72 (Eng. Abstr.) **(Ger)**

-Recanalization of chronic coronary artery occlusions: effect on clinical symptoms and left ventricular function- Heyder M, et al. **Z Kardiol** 1996 Feb;85(2):125–32 (Eng. Abstr.) **(Ger)**

[Epidural electrostimulation in the treatment of refractory angina pectoris in elderly patients: preliminary results] Romanò M, et al. **Cardiologia** 1995 Jun;40(6):399–405 (32 ref.) (Eng. Abstr.) **(Ita)**

[Effects on myocardial perfusion of epidural spinal cord stimulation in refractory angina. Description of a case studied with positron emission tomography] Neri G, et al. **G Ital Cardiol** 1996 Mar;26(3):299–302 (Eng. Abstr.) **(Ita)**

[Endovascular stenting for a recurrent angina patient] Ohtake H, et al. **Kyobu Geka** 1996 Mar;49(3):225–7 (Eng. Abstr.) **(Jpn)**

[Four cases of noncardiac surgery after PTCA] Sengoku S, et al. **Masui** 1995 Oct;44(10):1396–400 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Evidence of compensatory preload adjustment on early filling phase in patients with stable angina pectoris and good left ventricular systolic function. Cucchini F, et al. **Am J Cardiol** 1995 Dec 15;76(17):1302–5

Dobutamine echocardiography: usefulness of digital image processing. Castini D, et al. **Eur Heart J** 1995 Oct; 16(10):1420–4

A new noninvasive method of diagnosing vasospastic angina based on dilation response of the left main coronary artery to nitroglycerin as measured by echocardiography. Morita H, et al. **J Am Coll Cardiol** 1996 May;27(6):1450–7

ANGINA PECTORIS, VARIANT

BLOOD

Elevation of the plasma histamine concentration in the coronary circulation in patients with variant angina. Sakata Y, et al. **Am J Cardiol** 1996 May 15;77(12):1121–6

CHEMICALLY INDUCED

[Variant angina pectoris related to the treatment of migraine] Gómez Barrado JJ, et al. **Rev Esp Cardiol** 1995 Sep; 48(9):628–30 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Does prevalence of migraine and Raynaud's phenomenon also increase in Korean patients with proven variant angina? Koh KK, et al. **Int J Cardiol** 1995 Aug;51(1):37–46

Significant characteristics of variant angina patients with associated syncope. Kishida H, et al. **Jpn Heart J** 1996 May;37(3):317–26

DIAGNOSIS

A case of Prinzmetal angina. Asaid A. **Aust Fam Physician** 1995 Oct;24(10):1911

Clinical observation of spontaneous anginal attacks and multivessel spasm in variant angina pectoris with normal coronary arteries: evaluation by 24-hour 12-lead electrocardiography with computer analysis. Onaka H, et al. **J Am Coll Cardiol** 1996 Jan;27(1):38–44

Ergonovine echocardiography as a screening test for diagnosis of vasospastic angina before coronary angiography [see comments] Song JK, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1156–61. Comment in: J Am Coll Cardiol 1996 Apr;27(5):1162–3.

DRUG THERAPY

Effect of calcium antagonists in variant or Prinzmetal angina. Pepine CJ. **Can J Cardiol** 1995 Nov;11(10):952–6 (44 ref.)

Ineffectiveness of angiotensin converting enzyme inhibition (enalapril) on overt and silent myocardial ischemia in vasospastic angina and comparison with verapamil. Guazzi M, et al. **Clin Pharmacol Ther** 1996 Apr;59(4):476–81

Mechanism of the antiischemic effect of mibefradil, a selective T calcium channel blocker in dogs: comparison with amlodipine. Roux S, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):132–9

ETIOLOGY

Variant angina after successful coronary atherectomy. Ruygrok PN, et al. **Am Heart J** 1995 Dec;130(6):1309–11

Post-exercise vasospastic angina in a patient with normal coronary arteries: presentation and follow up of an unusual case of variant angina. Schotborgh CE, et al. **Heart** 1996 Jul;76(1):87

METABOLISM

Basal release of endothelium-derived nitric oxide at site of spasm in patients with variant angina. Egashira K, et al. **J Am Coll Cardiol** 1996 May;27(6):1444–9

PHYSIOPATHOLOGY

Frequency of systemic microvascular dysfunction in syndrome X and in variant angina. Bøtker HE, et al. **Am J Cardiol** 1996 Jul 15;78(2):182–6

Induction of polymorphic ventricular tachycardia by programmed ventricular stimulation in vasospastic angina pectoris. Nishizaki M, et al. **Am J Cardiol** 1996 Feb 15; 77(5):355–60

Heart period variability in patients with variant angina. Tsuchiya T, et al. **Am J Cardiol** 1996 May 1;77(11):932–6

Progression and regression of coronary stenosis in the long-term follow-up of vasospastic angina. Ozaki Y, et al. **Circulation** 1995 Nov 1;92(9):2446–56

Relation of basal coronary tone and vasospastic activity in patients with variant angina. Ozaki Y, et al. **Heart** 1996 Mar;75(3):267–73

Diffuse disorder of coronary artery vasomotility in patients with coronary spastic angina. Hyperreactivity to the constrictor effects of acetylcholine and the dilator effects of nitroglycerin. Okumura K, et al. **J Am Coll Cardiol** 1996 Jan;27(1):45–52

Increased basal tone and hyperresponsiveness to acetylcholine and ergonovine in spasm related coronary arteries in patients with variant angina--basal coronary artery tone in patients with variant angina. Park SJ, et al. **J Korean Med Sci** 1996 Feb;11(1):17–25

Improvement of coronary vasomotion with eicosapentaenoic acid does not inhibit acetylcholine-induced coronary vasospasm in patients with variant angina. Yamamoto H, et al. **Jpn Circ J** 1995 Sep;59(9):608–16

Sympathetic hyperactivity in patients with vasospastic angina--assessment by spectral analysis of heart rate and arterial pressure variabilities. Yamasaki F, et al. **Jpn Circ J** 1996 Jan;60(1):10–6

RADIOGRAPHY

Fluctuation of spastic location in patients with vasospastic angina: a quantitative angiographic study. Ozaki Y, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1606–14

RADIONUCLIDE IMAGING

Utility of iodine-123-BMIPP in the diagnosis and follow-up of vasospastic angina. Nakajima K, et al. **J Nucl Med** 1995 Nov;36(11):1934–40

[Assessment of myocardial fatty acid metabolism in patients with vasospastic angina using 123I-BMIPP myocardial SPECT] Ito K, et al. **Kaku Igaku** 1995 Oct;32(10):1099–106 (Eng. Abstr.) **(Jpn)**

ANGINA PECTORIS WITH NORMAL CORONARY ARTERIOGRAM see **SYNDROME X**

ANGINA, PREINFARCTION see **ANGINA, UNSTABLE**

ANGINA, UNSTABLE

Detection and significance of myocardial ischemia in women versus men within six months of acute myocardial infarction or unstable angina. The Multicenter Myocardial Ischemia Research Group. Moriel M, et al. **Am J Cardiol** 1996 Apr 15;77(10):798–804

[Unstable angina pectoris. Pathogenesis, treatment and prognosis] Kirkebøen KA. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3376–81 (67 ref.) (Eng. Abstr.) **(Nor)**

BLOOD

Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Kikuta K, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):101–7

Unstable angina [letter] Mikhailidis DP, et al. **Am Heart J** 1996 Jun;131(6):1234–5

Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial). Becker RC, et al. **Am J Cardiol** 1996 Jul 15;78(2):142–7

Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. Merlini PA, et al. **Blood** 1995 Nov 1;86(9):3327–32

Prospective study of the role of cardiac troponin T in patients admitted with unstable angina. Stubbs P, et al. **BMJ** 1996 Aug 3;313(7052):262–4

Elevated platelet-derived microparticle levels during unstable angina. Singh N, et al. **Can J Cardiol** 1995 Dec; 11(11):1015–21

Elevated levels of interleukin-6 in unstable angina. Biasucci LM, et al. **Circulation** 1996 Sep 1;94(5):874–7

Lipoprotein (a) is increased in acute coronary syndromes (unstable angina pectoris and myocardial infarction), but it is not predictive of the severity of coronary lesions. Brunelli C, et al. **Clin Cardiol** 1995 Sep;18(9):526–9

The effect of coronary angioplasty on superoxide anion generation and lipid peroxidation. Propriety of pharmacological intervention. Kowalski J, et al. **Pol J Pharmacol** 1995 Mar-Apr;47(2):163–8

[Detection of circulating endothelial cells: a new diagnostic test of angina at rest] Bory M, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1827–31 (Eng. Abstr.) **(Fre)**

[Cardiac troponin I in unstable angina] Musso P, et al. **Minerva Cardioangiol** 1996 Apr;44(4):187–95 (Eng. Abstr.) **(Ita)**

[Adhesion and aggregation of neutrophils in patients with unstable angina] Kowalski J, et al. **Przegl Lek** 1995; 52(8):385–7 (Eng. Abstr.) **(Pol)**

ANGINA, UNSTABLE

CHEMICALLY INDUCED

Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. Bar Dayan Y, et al. **Isr J Med Sci** 1996 May;32(5):288–91

COMPLICATIONS

Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Biasucci LM, et al. **Am J Cardiol** 1996 Jan 1;77(1):85–7

The effect on the heart of hypoxaemia in patients with severe coronary artery disease. Smith HL, et al. **Anaesthesia** 1996 Mar;51(3):211–8

Spontaneous iliopsoas hematoma in patients with unstable coronary syndromes receiving intravenous heparin in therapeutic doses. Sasson Z, et al. **Can J Cardiol** 1996 May; 12(5):490–4 (35 ref.)

Thrombin activity and early outcome in unstable angina pectoris. Ardissino D, et al. **Circulation** 1996 May 1; 93(9):1634–9

Blood pressure variations, hemorheological determinants, and platelet aggregation in hypertensive patients with unstable angina. Melina G, et al. **Clin Exp Hypertens** 1995 Nov; 17(8):1145–56

Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction [see comments] Andreotti F, et al. **N Engl J Med** 1996 Jan 4;334(1):7–12. Comment in: N Engl J Med 1996 Jan 4;334(1):51–2. Comment in: N Engl J Med 1996 Jul 4;335(1):59; discussion 60–1. Comment in: N Engl J Med 1996 Jul 4;335(1):59–60; discussion 60–1.

Acute myocardial infarction—the value of being prepared [editorial; comment] Braunwald E. **N Engl J Med** 1996 Jan 4;334(1):51–2. Comment on: N Engl J Med 1996 Jan 4;334(1):7–12.

DIAGNOSIS

Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group [see comments] Lindahl B, et al. **Circulation** 1996 May 1;93(9):1651–7. Comment in: Circulation 1996 May 1;93(9):1618–20.

Risk stratification in patients with unstable angina: 'déjà vu all over again'? [editorial; comment] Pitt B. **Circulation** 1996 May 1;93(9):1618–20 (21 ref.). Comment on: Circulation 1996 May 1;93(9):1651–7.

The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non–Q wave myocardial infarction. Larsson H, et al. **Eur Heart J** 1995 Jul; 16(7):888–93

Deep T-wave inversion in an elderly man. Hancock EW. **Hosp Pract (Off Ed)** 1995 Sep 15;30(9):16–8

Ischemia monitoring with on–line vectorcardiography compared with results from a predischarge exercise test in patients with acute ischemic heart disease. Lundin P, et al. **J Electrocardiol** 1995 Oct;28(4):277–85

Unstable angina pectoris. What is the likelihood of further cardiac events? Bankwala Z, et al. **Postgrad Med** 1995 Dec; 98(6):155–8, 161–2, 164–5 (18 ref.)

[Unstable angina. Physiopathology, clinical course and therapeutic principles] Aubry P, et al. **Presse Med** 1995 Dec 9;24(38):1788–94 (30 ref.) (Eng. Abstr.) **(Fre)**

[Suspicion of unstable angina and myocardial infarct. Evaluation and prehospital management by the practitioner] Gaspoz JM. **Schweiz Rundsch Med Prax** 1995 Nov 7;84(45):1289–91 (Eng. Abstr.) **(Fre)**

[Diagnostic and differential diagnostic value of troponins] Prellwitz W, et al. **Med Klin** 1996 Jun 15;91(6):336–42 (Eng. Abstr.) **(Ger)**

[The relationship between the presentation and classification of unstable angina and the clinical and coronary angiographic characteristics and left ventricular function] Brizida L, et al. **Rev Port Cardiol** 1995 Nov;14(11):911–3 **(Por)**

[Structural and functional disorders of the left ventricle as a predictor of the subsequent course of the disease in patients with unstable angina] Bobrov VA, et al. **Lik Sprava** 1995 Jul–Aug;(7–8):9–11 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in–hospital clinical events in unstable angina and non–Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Becker RC, et al. **Am Heart J** 1996 Mar;131(3):421–33 (66 ref.)

Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonists. Ferrari R. **Am J Cardiol** 1996 Jun 20; 77(16):22D–25D (44 ref.)

Comparison of outcome of patients with unstable angina and non–Q–wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry). Kleiman NS, et al. **Am J Cardiol** 1996 Feb 1;77(4):227–31

Clinical applications of new antithrombotic agents. Beijering RJ, et al. **Ann Hematol** 1996 Apr;72(4):177–83 (52 ref.)

Enoxaparin for unstable angina and ancrod for cardiac surgery following heparin allergy. Smith RE, et al. **Ann Pharmacother** 1996 May;30(5):476–80

Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Eisenberg MJ, et al. **Arch Intern Med** 1996 Jul 22;156(14):1506–10 (34 ref.)

Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Langford EJ, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):51–5

Changes in wall motion in patients treated for unstable angina. A suggestion of the stunned and hibernating myocardium in humans. UNASEM Collaborative Study Group. Unstable Angina Study Using Eminase. de Zwaan C, et al. **Chest** 1995 Oct;108(4):903–11

Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study [see comments] Théroux P, et al. **Circulation** 1996 Sep 1; 94(5):899–905. Comment in: Circulation 1996 Sep 1;94(5):866–8.

Inhibitors of platelet glycoprotein IIb/IIIa receptors. Will they be useful when given chronically? [editorial; comment] Willerson JT. **Circulation** 1996 Sep 1;94(5):866–8. Comment on: Circulation 1996 Sep 1;94(5):899–905.

Treatment of silent ischemia in unstable angina: a randomized comparison of sustained–release verapamil versus metoprolol. Singh N, et al. **Clin Cardiol** 1995 Nov; 18(11):653–8

Medical management of stable angina and unstable angina in the elderly with coronary artery disease. Olson HG, et al. **Clin Geriatr Med** 1996 Feb;12(1):121–40 (72 ref.)

Antiplatelet, antithrombotic, and lytic therapy for unstable angina, and the appropriate role of revascularization. de Feyter PJ, et al. **Curr Opin Cardiol** 1995 Jul;10(4):389–98 (36 ref.)

Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Monreal M, et al. **Drugs Aging** 1996 Mar;8(3):171–82 (52 ref.)

r–hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study. Fox KA. **Eur Heart J** 1995 Jul;16 Suppl D:28–32 (15 ref.)

Calcium antagonism in perspective: new data on diltiazem in unstable angina [editorial] van Gilst WH, et al. **Eur Heart J** 1996 Apr;17(4):485–6

Comparison of the therapeutic efficacy of continuous and intermittent injection of isosorbide dinitrate: a randomized study on unstable angina. Miyazaki S, et al. **Intern Med** 1995 Sep;34(9):856–62

Treating unstable angina. Strickland C, et al. **J Fam Pract** 1995 Dec;41(6):603–4

Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta–analysis. Oler A, et al. **JAMA** 1996 Sep 11;276(10):811–5

Intravenous thrombolysis in refractory unstable angina pectoris. Anderson HV. **Lancet** 1995 Oct 28; 346(8983):1113–4

Medical management of unstable angina. Cairns JA. **Lancet** 1995 Dec 23–30;346(8991–8992):1644–5

Intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris [letter] Cruickshank JK. **Lancet** 1996 Mar 9;347(9002):688

Randomised, double–blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris. Göbel EJ, et al. **Lancet** 1995 Dec 23–30; 346(8991–8992):1653–7

Intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris [letter] Murdoch DR, et al. **Lancet** 1996 Mar 9;347(9002):688; discussion 688–9

The effect of simultaneous intravenous administration of nitroglycerin and heparin on partial thromboplastin time. Williams H, et al. **Mil Med** 1995 Sep;160(9):449–52

A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. **N Engl J Med** 1996 Sep 12; 335(11):775–82

Successful heparin desensitization after heparin–induced anaphylactic shock. al–Eryani AY, et al. **Thromb Res** 1995 Sep 15;79(5–6):523–6

[Treatment of unstable angina pectoris] Luomanmäki K. **Duodecim** 1995;111(8):715–22 (37 ref.) **(Fin)**

–New perspectives in therapy of unstable angina– Hamm CW. **Herz** 1996 Feb;21(1):37–43 (69 ref.) (Eng. Abstr.) **(Ger)**

[Analysis of heart rhythm variability in evaluation of treatment for unstable angina pectoris] Petelenz T, et al. **Pol Arch Med Wewn** 1995 Jul;94(1):32–9 (Eng. Abstr.) **(Pol)**

[Contemporary opinions on the use of aspirin, heparin and thrombolytic therapy in unstable angina pectoris—pathogenetic findings versus results of many clinical tests] Popiel M, et al. **Przegl Lek** 1996;53(1):33–40 (40 ref.) (Eng. Abstr.) **(Pol)**

[The efficacy of emoxipin and neoton in unstable stenocardia] Golikov AP, et al. **Ter Arkh** 1996;68(1):31–3 (Eng. Abstr.) **(Rus)**

[Diltiazem versus intravenous nitroglycerin in the treatment of unstable angina pectoris. A randomized study] Castro P, et al. **Rev Med Chil** 1995 Jul;123(7):823–9 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Angiotensin–converting enzyme insertion/deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectoris. Kasi JC, et al. **Am J Cardiol** 1996 Apr 15;77(10):875–7

Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. Biasucci LM, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):611–6

EPIDEMIOLOGY

Incidence and hospital mortality of acute coronary artery disease among civilians in Zagreb during air–raid alarms. Mihatov S, et al. **Acta Med Croatica** 1995;49(2):49–52

ETIOLOGY

Takayasu's arteritis with unstable angina and aortic insufficiency. Trazzera S, et al. **Am Heart J** 1995 Nov; 130(5):1122–4

Morphological and functional significance of findings in unstable atherothrombotic plaque underlying acute coronary syndromes: a review. Baroldi G. **Int J Cardiol** 1995 Aug;49 Suppl:S3–9 (18 ref.)

[Unstable angina pectoris associated with surgically treated coronary artery atresia] Vaszily M, et al. **Orv Hetil** 1995 Oct 22;136(43):2343–6 (Eng. Abstr.) **(Hun)**

IMMUNOLOGY

Expression of neutrophil and monocyte CD11B/CD18 adhesion molecules at different sites of the coronary tree in unstable angina pectoris. de Servi S, et al. **Am J Cardiol** 1996 Sep 1;78(5):564–8

Clinical and angiographic correlates of leukocyte activation in unstable angina. De Servi S, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1146–50

METABOLISM

Impaired myocardial fatty acid metabolism detected by 123I–BMIPP in patients with unstable angina pectoris: comparison with perfusion imaging by 99mTc–sestamibi. Takeishi Y, et al. **Ann Nucl Med** 1995 Aug;9(3):125–30

Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. Merlini PA, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1675–9

Breath pentane and plasma lipid peroxides in ischemic heart disease. Mendis S, et al. **Free Radic Biol Med** 1995 Nov; 19(5):679–84

MORTALITY

Influence of race, sex, and age on management of unstable angina and non–Q–wave myocardial infarction: The TIMI III registry. Stone PH, et al. **JAMA** 1996 Apr 10; 275(14):1104–12

PATHOLOGY

Correlation between clinical and morphologic findings in unstable angina. De Servi S, et al. **Am J Cardiol** 1996 Jan 15;77(2):128–32

Angioscopic evaluation of atherosclerotic plaques: validation by histomorphologic analysis and association with stable and unstable coronary syndromes. Thieme T, et al. **J Am Coll Cardiol** 1996 Jul;28(1):1–6

PHYSIOPATHOLOGY

Heart rate and heart rate variability in acute coronary heart disease. Catipović–Veselica K, et al. **Acta Med Croatica** 1996;50(2):75–9

Heart rate variability depression in patients with unstable angina. Huang J, et al. **Am Heart J** 1995 Oct;130(4):772–9

Prevalence, resolution, and determinants of late potentials in patients with unstable angina and left ventricular wall motion abnormalities. Tamura K, et al. **Am Heart J** 1996 Apr;131(4):731–5

Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Biasucci LM, et al. **Am J Cardiol** 1996 Jan 1;77(1):85–7

Adaptation mechanisms during myocardial ischemia in chronic unstable angina pectoris. Cortina R, et al. **Am J Cardiol** 1995 Nov 1;76(12):874–6

Correlation between clinical and morphologic findings in unstable angina. De Servi S, et al. **Am J Cardiol** 1996 Jan 15;77(2):128–32

Percutaneous cardiopulmonary bypass–supported coronary angioplasty in patients with unstable angina pectoris or myocardial infarction and a left ventricular ejection fraction < or = 25%. Shawl FA, et al. **Am J Cardiol** 1996 Jan 1;77(1):14–9

Left ventricular diastolic function in hypertensive patients with unstable angina and single coronary artery disease. Islim IF, et al. **Am J Hypertens** 1995 Aug;8(8):837–41

Prior myocardial infarction and prognostic outcome in patients with unstable angina in a postdischarge follow–up. Dini FL, et al. **Angiology** 1996 Apr;47(4):321–7

Application of translesional pressure and flow velocity assessment in a severely calcified coronary narrowing in a patient with unstable angina. Moore JA, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):270–6

Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina [see comments] Fujita M, et al. **Circulation** 1996 Aug 15;94(4):610–3. Comment in: Circulation 1996 Aug 15;94(4):600–1.

Early continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram. Patel DJ, et al. **Heart** 1996 Mar;75(3):222–8

Dynamic on–line vectorcardiography improves and simplifies in–hospital ischemia monitoring of patients with unstable angina. Dellborg M, et al. **J Am Coll Cardiol** 1995 Nov 15;26(6):1501–7

Preinfarction angina as a major predictor of left ventricular function and long–term prognosis after a first Q wave myocardial infarction [letter; comment] Haider AW, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):954–5. Comment on: J Am Coll Cardiol 1995 Aug;26(2):319–27.

[Left ventricular diastolic dysfunction in patients with angina decubitus] Chen J, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Nov;34(11):750–2 (Eng. Abstr.) **(Chi)**

[Unstable angina pectoris. Pathogenesis, risk assessment and therapy] Schoebel FC, et al. **Dtsch Med Wochenschr** 1996 Mar 8;121(10):310–7 (63 ref.) **(Ger)**

[Analysis of heart rhythm variability in evaluation of treatment for unstable angina pectoris] Petelenz T, et al. **Pol Arch Med Wewn** 1995 Jul;94(1):32–9 (Eng. Abstr.) **(Pol)**

[The clinico–functional status of patients with unstable stenocardia (based on Holter electrocardiographic monitoring data)] Bobrov VO, et al. **Lik Sprava** 1995 May–Jun;(5–6):145–7 (Eng. Abstr.) **(Ukr)**

RADIOGRAPHY

Angina pectoris and disease progression [editorial; comment] Falk E, et al. **Circulation** 1995 Oct 15;92(8):2033–5. Comment on: Circulation 1995 Oct 15;92(8):2058–65.

Rapid angiographic progression of coronary artery disease in patients with angina pectoris. The role of complex stenosis morphology. Kaski JC, et al. **Circulation** 1995 Oct 15;92(8):2058–65

[Correlations between clinical picture and coronary angiography in unstable angina] Zöllei E, et al. **Orv Hetil** 1996 Mar 10;137(10):519–22 (Eng. Abstr.) **(Hun)**

RADIONUCLIDE IMAGING

Prognostic value of predischarge dipyridamole technetium 99m sestamibi myocardial tomography in medically treated patients with unstable angina. Stratmann HG, et al. **Am Heart J** 1995 Oct;130(4):734–40

Impaired myocardial fatty acid metabolism detected by 123I–BMIPP in patients with unstable angina pectoris: comparison with perfusion imaging by 99mTc–sestamibi. Takeishi Y, et al. **Ann Nucl Med** 1995 Aug;9(3):125–30

[Diagnostic usefulness of myocardial SPECT with 123I–beta–methyl–iodophenyl pentadecanoic acid and 201Tl in unstable angina] Nakazawa Y, et al. **Kaku Igaku** 1995 Sep;32(9):953–8 (Eng. Abstr.) **(Jpn)**

[Detection of angina–related coronary artery in patients with unstable angina pectoris by using 123I–BMIPP myocardial scintigraphy] Oka T, et al. **Kaku Igaku** 1996 Mar;33(3):279–84 (Eng. Abstr.) **(Jpn)**

SURGERY

Coronary bypass after ascending aorta to femoral graft placement running head: CABG after ascending aorta–bifemoral graft. Cusimano RJ, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):161–3

[Significance of hot shot in patients with unstable angina undergoing emergency coronary artery bypass graft surgery] Otani H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):123–9 (Eng. Abstr.) **(Jpn)**

THERAPY

Cyclic flow variations after angioplasty: a rare phenomenon predictive of immediate complications. DEBATE Investigator's Group. Sunamura M, et al. **Am Heart J** 1996 May;131(5):843–8

Combined percutaneous carotid stenting and coronary angioplasty during acute ischemic neurologic and coronary syndromes. Shawl FA, et al. **Am J Cardiol** 1996 May 15;77(12):1109–12

Percutaneous cardiopulmonary bypass–supported coronary angioplasty in patients with unstable angina pectoris or myocardial infarction and a left ventricular ejection fraction < or = 25%. Shawl FA, et al. **Am J Cardiol** 1996 Jan 1;77(1):14–9

Double balloon catheter for concomitant augmentation of abdominal organ perfusion during intraaortic balloon counterpulsation. Katsumata T, et al. **Artif Organs** 1996 Feb;20(2):162–5

Unstable angina. An approach to management. Tonkin A. **Aust Fam Physician** 1996 Jul;25(7):1079–81, 1084–5

Effect of the increasing use of coronary angioplasty on outcome at one year in patients with unstable angina. De Servi S, et al. **Br Heart J** 1995 Dec;74(6):680–4

Lesion–directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. Gurbel PA, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):382–91

EPILOG and CAPTURE trials halted because of positive interim results [news] Ferguson JJ 3rd. **Circulation** 1996 Feb 15;93(4):637

One–year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue–type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non–Q wave myocardial infarction. Anderson HV, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1643–50

A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. Grines CL, et al. **J Am Coll Cardiol** 1996 May;27(6):1381–6

Angioplasty of complex lesions in ischemic rest angina: results of the Thrombolysis and Angioplasty in Unstable Angina (TAUSA) trial. Mehran R, et al. **J Am Coll Cardiol** 1995 Oct;26(4):961–6

Are "nonsignificant differences" significant? [letter; comment] Ong JJ, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):753–4 . Comment on: J Am Coll Cardiol 1995 Sep;26(3):577–82.

Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina. Rupprecht HJ, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1637–42

Cardiologists versus internists in the care of unstable angina [letter; comment] Soloman NA. **J Am Coll Cardiol** 1996 Mar 1;27(3):753. Comment on: J Am Coll Cardiol 1995 Sep;26(3):577–82.

Treatment strategies for patients with ischemic chest pain [letter] Algazy JI. **JAMA** 1996 Aug 28;276(8):606

Influence of race, sex, and age on management of unstable angina and non–Q–wave myocardial infarction: The TIMI III registry. Stone PH, et al. **JAMA** 1996 Apr 10;275(14):1104–12

Unstable angina. Strategies to minimize myocardial injury. Blake–Inada LM, et al. **Postgrad Med** 1996 Aug;100(2):139–42, 147–9, 153–4 (20 ref.)

The challenge of unstable angina. Jackson G. **Practitioner** 1996 Jun;240(1563):390–3

Coronary artery bypass grafting after failed percutaneous angioplasty compared to direct coronary bypass grafting in patients with unstable angina. Bartram U, et al. **Thorac Cardiovasc Surg** 1996 Feb;44(1):31–4

[Treatment of refractory unstable angina by transluminal coronary angioplasty] Baladier V, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):181–6 (28 ref.) (Eng. Abstr.) **(Fre)**

[Management of refractory unstable angina in 1996 (editorial)] Vacheron A. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):179 **(Fre)**

[Unstable angina. Physiopathology, clinical course and therapeutic principles] Aubry P, et al. **Presse Med** 1995 Dec 9;24(38):1788–94 (30 ref.) (Eng. Abstr.) **(Fre)**

[Long term course over 10 years after balloon dilatation in stable and unstable angina pectoris] Espinola–Klein C, et al. **Dtsch Med Wochenschr** 1996 May 3;121(18):577–82 (Eng. Abstr.) **(Ger)**

[Clinical aspects and therapy of unstable angina pectoris] Rupprecht HJ, et al. **Med Klin** 1996 Jun 15;91(6):366–71 (54 ref.) **(Ger)**

[Early results and many years of observing treatment of unstable angina] Adamowicz–Czoch E, et al. **Pol Arch Med Wewn** 1995 Sep;94(3):235–42 (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Influence of plaque composition on mechanisms of percutaneous transluminal coronary balloon angioplasty assessed by ultrasound imaging. Gil R, et al. **Am Heart J** 1996 Mar;131(3):591–7

Long–term prognostic importance of exercise echocardiography after an episode of unstable angina. Eriksson SV, et al. **Cardiology** 1995;86(5):426–31

Detection of unstable coronary atherosclerotic lesions by intracoronary ultrasound. Tian J, et al. **Chin Med J (Engl)** 1996 Apr;109(4):329–30

ANGIOCARDIOGRAPHY

Safety and efficacy of Xenetix, a new iodinated contrast agent, in pediatric angiocardiography. Rossignol AM, et al. **Acta Radiol Suppl** 1996;400:81–4

Standards for training in adult cardiac catheterization and angiography. Canadian Cardiovascular Society Committee. Miller RM, et al. **Can J Cardiol** 1996 May;12(5):470–2

Selective right ventricular angiography in apparently idiopathic ventricular fibrillation. Peters S, et al. **Heart Vessels** 1995;10(4):211–3

Data compression of x–ray cardio–angiographic image series. Breeuwer M, et al. **Int J Card Imaging** 1995;11 Suppl 3:179–86

Angiographic determination of left and right ventricular volumes and left ventricular mass in normal infants and children. Akiba T, et al. **Tohoku J Exp Med** 1995 Oct;177(2):153–60

[The correlation between the severity of chronic mitral regurgitation evaluated by color–coded echo–Doppler and by angiocardiography with the "v" wave index in pulmonary capillary pressure/left ventricular systolic pressure] Gonçalves L, et al. **Rev Port Cardiol** 1995 Oct;14(10):721–4 **(Por)**

HISTORY

[Cardiac radiology] Struyven J. **J Belge Radiol** 1995 Oct;78(5):297–8 (Eng. Abstr.) **(Fre)**

[Scientific raisins from 125 years SMW (Swiss Medical Weekly). Angiocardiography in congenital heart defects. 1948 (classical article)] Rossi E, et al. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2090–100 **(Ger)**

[The history of angiocardiopneumography. Its beginnings] Quijano Pitman F. **Arch Inst Cardiol Mex** 1995 Sep–Oct;65(5):468–71 **(Spa)**

METHODS

A new, simple and accurate method for determining ejection fraction by Doppler echocardiography. Dumesnil JG, et al. **Can J Cardiol** 1995 Dec;11(11):1007–14

Automated determination of left ventricular volume curves from bi–plane digital angiography without explicit use of edge detection algorithms. Raff U, et al. **Int J Card Imaging** 1996 Mar;12(1):31–45

ANGIODYSPLASIA

COMPLICATIONS

Concurrent colon polyp with angiodysplasia causes lower gastrointestinal bleeding: a case report. Hsu CH, et al. **Chang Keng I Hsueh** 1995 Sep;18(3):280–4

Angiodysplasia as the cause of massive lower gastrointestinal hemorrhage in a young adult. Report of a case. Greason KL, et al. **Dis Colon Rectum** 1996 Jun;39(6):702–4 (12 ref.)

Upper–gastrointestinal bleeding from angiodysplasia of the minor papilla. Mabee CL, et al. **J Clin Gastroenterol** 1996 Mar;22(2):138–40

Reversal of aortic stenosis, bleeding gastrointestinal angiodysplasia, and von Willebrand syndrome by aortic valve replacement [letter; comment] Anderson RP, et al. **Lancet** 1996 Mar 9;347(9002):689–90. Comment on: Lancet 1992 Jul 4;340(8810):35–7.

von Recklinghausen's disease associated with angiodysplasia of colon and end–stage renal disease [letter] Serin E, et al. **Nephron** 1995;71(2):243

Diffuse severe digestive angiodysplasia in Bernard–Soulier syndrome. Improvement of bleeding by oestroprogestative therapy [letter] Bellucci S, et al. **Thromb Haemost** 1995 Dec;74(6):1610–2

[Massive lower digestive hemorrhages. Diagnostic and therapeutic approach] Raoul JL. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B41–6 **(Fre)**

[Intestinal angiodysplasias as initially unrecognizable cause of recurrent gastrointestinal hemorrhage] Horstmann R, et al. **Dtsch Med Wochenschr** 1995 Nov 3;120(44):1502–6 (Eng. Abstr.) **(Ger)**

[Intestinal angiodysplasia as the cause of recurring gastrointestinal hemorrhage (letter)] Schulte F. **Dtsch Med Wochenschr** 1996 Apr 12;121(15):500 **(Ger)**

[Colonic angiodysplasia: an important cause of digestive hemorrhage] Giordano P, et al. **Minerva Chir** 1995 Sep;50(9):737–40 (Eng. Abstr.) **(Ita)**

[Angiodysplasia of the colon associated with aortic stenosis and renal insufficiency. Apropos of a case with massive digestive hemorrhage (letter)] Garcia Roman JM, et al. **An Med Interna** 1995 Dec;12(12):620–1 **(Spa)**

[Digestive hemorrhage due to duodenal angiodysplasia in the periampullary area] Pamplona J, et al. **Gastroenterol Hepatol** 1996 May;19(5):250–2 (22 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL see ARTERIOVENOUS MALFORMATIONS

DIAGNOSIS

[Angiodysplasia of the right colon and aortic stenosis. A case report] Arcidiacono G, et al. **Minerva Cardioangiol** 1996 Apr;44(4):173–7 (25 ref.) (Eng. Abstr.) **(Ita)**

[Angiodysplasia of the right colon] Accordino R, et al. **Minerva Chir** 1995 Jul–Aug;50(7–8):703–6 (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Watermelon stomach. An unusual cause of recurrent upper GI tract bleeding in the uraemic patient: efficient treatment with oestrogen–progesterone therapy. Hermans C, et al. **Nephrol Dial Transplant** 1996 May;11(5):871–4 (29 ref.)

EPIDEMIOLOGY

A prospective controlled evaluation of endoscopic detection of angiodysplasia and its association with aortic valve disease [see comments] Bhutani MS, et al. **Gastrointest Endosc** 1995 Nov;42(5):398–402. Comment in: Gastrointest Endosc 1995 Nov;42(5):491–3.

ETIOLOGY

Angiodysplasia and aortic valve disease: let's close the book on this association [editorial; comment] Gostout CJ. **Gastrointest Endosc** 1995 Nov;42(5):491–3. Comment on: Gastrointest Endosc 1995 Nov;42(5):398–402.

Watermelon stomach. An unusual cause of recurrent upper GI tract bleeding in the uraemic patient: efficient treatment with oestrogen–progesterone therapy. Hermans C, et al.

ANGIODYSPLASIA

Nephrol Dial Transplant 1996 May;11(5):871–4 (29 ref.)

PATHOLOGY

Management of congenital angiodysplasia of the lower limb: magnetic resonance imaging and angiography versus conventional angiography. Huch Böni RA, et al. **Br J Radiol** 1995 Dec;68(816):1308–15

RADIOGRAPHY

Vascular ectasia of the gastric antrum: angiographic findings. Robertson IR, et al. **AJR Am J Roentgenol** 1996 Jan; 166(1):87–9

SURGERY

Endoscopic treatment of gastric angiodysplasia with elastic band ligation. Campo R, et al. **Gastrointest Endosc** 1996 May;43(5):502–4

Clinical and histological features of gastric antral vascular ectasia: successful treatment with endoscopic laser therapy. Ng I, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):270–4

Colectomy: the role of laparoscopy. Scott HJ, et al. **Surg Laparosc Endosc** 1995 Oct;5(5):382–6

[Small bowel endoscopy during surgery in the treatment and diagnosis of angiodysplasias] Saarnio J, et al. **Duodecim** 1994;110(5):506–8 **(Fin)**

THERAPY

Permanent therapeutic embolization of cecal angiodysplasia [letter] Bilbao JI, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1287–8

[Multidisciplinary approach to maxillofacial angiodysplasia] Breviere GM, et al. **Rev Stomatol Chir Maxillofac** 1995; 96(4):215–26 **(Fre)**

ANGIOEDEMA see **ANGIONEUROTIC EDEMA**

ANGIOFIBROMA

[Features of rhinologic and otoneurologic symptoms and complications in intracranial tumors growing into the nose and paranasal sinuses] Blagoveshchenskaia NS, et al. **Vestn Otorinolaringol** 1995 Nov–Dec;(6):5–10 (Eng. Abstr.) **(Rus)**

[Angiofibroma of the base of the skull in children] Bogomil'skiĭ MR, et al. **Vestn Otorinolaringol** 1995 Sep–Oct;(5):27–9 (Eng. Abstr.) **(Rus)**

DIAGNOSIS

[Possibilities of the cytological method in intraoperative diagnosis of pigmented tumors of the skin] Vakhturova ZM, et al. **Klin Lab Diagn** 1995 Sep–Oct;(5):4–6 **(Rus)**

DRUG THERAPY

[Chemotherapy of juvenile angiofibroma—an alternative?] Schick B, et al. **HNO** 1996 Mar;44(3):148–52 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Unilateral facial angiofibromas—a segmental form of tuberous sclerosis. McGrae JD Jr, et al. **Br J Dermatol** 1996 Apr;134(4):727–30

METABOLISM

Expression of growth factors, proto-oncogenes, and p53 in nasopharyngeal angiofibromas. Nagai MA, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):190–5

PATHOLOGY

Giant cell angiofibroma. A distinctive orbital tumor in adults. Dei Tos AP, et al. **Am J Surg Pathol** 1995 Nov; 19(11):1286–93

Angiofibroma. Changes in staging and treatment. Radkowski D, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb; 122(2):122–9

Angiomyofibroblastoma of the vulva and vagina. Nielsen GP, et al. **Mod Pathol** 1996 Mar;9(3):284–91 (25 ref.)

Juvenile nasopharyngeal angiofibroma and familial adenomatous polyposis: an association? Ferouz AS, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):435–9

[Possibilities of the cytological method in intraoperative diagnosis of pigmented tumors of the skin] Vakhturova ZM, et al. **Klin Lab Diagn** 1995 Sep–Oct;(5):4–6 **(Rus)**

RADIOTHERAPY

Treatment of adenoma sebaceum with the copper vapor laser. Kaufman AJ, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):770–4

ANGIOFOLLICULAR LYMPHOID HYPERPLASIA see **GIANT LYMPH NODE HYPERPLASIA**

ANGIOGENESIS FACTOR

[Regulators of angiogenesis] Sato Y. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):109–17 (51 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Yoshiji H, et al. **Cancer Res** 1996 May 1; 56(9):2013–6

A novel angiogenic molecule produced at the time of chondrocyte hypertrophy during endochondral bone formation. Alini M, et al. **Dev Biol** 1996 May 25; 176(1):124–32

BLOOD

Endothelial stimulating angiogenic factor in early fracture healing. Kurdy NM, et al. **Injury** 1996 Mar;27(2):143–5

Increased serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease. Burgmann H, et al. **J Clin Pathol** 1996 Jun;49(6):508–10

Measurement of serum angiogenic factor in devascularized experimental tibial fractures. Wallace AL, et al. **J Orthop Trauma** 1995;9(4):324–32

CHEMISTRY

Solution structure of bovine angiogenin by 1H nuclear magnetic resonance spectroscopy. Lequin O, et al. **Biochemistry** 1996 Jul 9;35(27):8870–80

The C-terminal region of human angiogenin has a dual role in enzymatic activity. Russo N, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3243–7

IMMUNOLOGY

[Modulation of the tumoral progression by anti-idiotypic antibodies of angiogenesis factors] Ortéga N, et al. **C R Acad Sci III** 1996 May;319(5):411–5 (Eng. Abstr.) **(Fre)**

METABOLISM

Angiogenesis factor in endometrial carcinoma: a new prognostic indicator? Kirschner CV, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1879–82; discussion 1882–4

Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Shimoyama S, et al. **Cancer Res** 1996 Jun 15;56(12):2703–6

HIV-tat protein is a heparin-binding angiogenic growth factor. Albini A, et al. **Oncogene** 1996 Jan 18;12(2):289–97

The C-terminal region of human angiogenin has a dual role in enzymatic activity. Russo N, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3243–7

[Quantitative determination of cattle angiogenin] Rogov IA, et al. **Biokhimiia** 1995 Aug;60(8):1344–8 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis [see comments] Pearlman JD, et al. **Nat Med** 1995 Oct;1(10):1085–9. Comment in: Nat Med 1995 Oct;1(10):996–7.

PHYSIOLOGY

Endothelial-cell-stimulating angiogenesis factor (ESAF) activates progelatinase A (72 kDa type IV collagenase), prostromelysin 1 and procollagenase and reactivates their complexes with tissue inhibitors of metalloproteinases: a role for ESAF in non-inflammatory angiogenesis. McLaughlin B, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):739–45

Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Anan K, et al. **Surgery** 1996 Mar;119(3):333–9

ANGIOGENESIS, PATHOLOGIC see **NEOVASCULARIZATION, PATHOLOGIC**

ANGIOGENESIS, PHYSIOLOGIC see **NEOVASCULARIZATION, PHYSIOLOGIC**

ANGIOGRANULOMA see **GRANULOMA, PYOGENIC**

ANGIOGRAPHY

Hemodynamics of small hepatocellular carcinomas (5 cm or less in diameter): cases with discrepant findings between dynamic MR images and hepatic arteriograms. Imaeda T, et al. **Abdom Imaging** 1995 Nov–Dec;20(6):534–40

Clinical tolerance and diagnostic efficacy of iobitridol 300 in lower limb angiography. Stockx L, et al. **Acta Radiol Suppl** 1996;400:72–4

Preoperative spinal angiography for lateral extracavitary approach to thoracic and lumbar spine [letter; comment] Tartaro A, et al. **AJNR Am J Neuroradiol** 1995 Oct; 16(9):1947–8. Comment on: AJNR Am J Neuroradiol 1994 Jan;15(1):73–7.

Three-dimensional helical CT angiography of skull base meningiomas. Tsuchiya K, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):933–6

MR angiography of tibial runoff vessels: imaging with the head coil compared with conventional arteriography. Cortell ED, et al. **AJR Am J Roentgenol** 1996 Jul; 167(1):147–51

Cardiac-gated MR angiography of the entire lower extremity: a prospective comparison with conventional angiography. Glickerman DJ, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):445–51

Value of three-dimensional spiral CT hepatic angiography. Kanematsu M, et al. **AJR Am J Roentgenol** 1996 Mar; 166(3):585–91

Preoperative staging of cancer of the pancreas: value of MR angiography versus conventional angiography in detecting portal venous invasion. McFarland EG, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):37–43

Vascular ectasia of the gastric antrum: angiographic findings. Robertson IR, et al. **AJR Am J Roentgenol** 1996 Jan; 166(1):87–9

CT angiography [see comments] Zeman RK, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1079–88 (65 ref.) . Comment in: AJR Am J Roentgenol 1996 May;166(5):1227–9.

A simple method of achieving rapid haemostasis in PTFE grafts after on-table angiography. Whyman MR, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):388–9

Comparison of spiral CT scan and arteriography for evaluation of renal and visceral arteries. Cikrit DF, et al. **Ann Vasc Surg** 1996 Mar;10(2):109–16

A prospective study of carbon dioxide-digital subtraction vs standard contrast arteriography in the evaluation of the renal arteries. Schreier DZ, et al. **Arch Surg** 1996 May; 131(5):503–7; discussion 507–8

Interventional radiology in the treatment of blunt liver trauma: case report with review of literature. Harms J, et al. **Bildgebung** 1996 Mar;63(1):51–4 (22 ref.)

Left ventricular impairment in arrhythmogenic right ventricular dysplasia: what we can learn from angiography. Peters S. **Cardiology** 1995;86(6):473–6

Critical role of pulmonary angiography in the diagnosis of pulmonary emboli following cardiac surgery. Ramos RS, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):112–7; discussion 118

Core curriculum for the training of pediatric invasive/interventional cardiologists: report of the Society for Cardiac Angiography and Interventions Committee on Pediatric Cardiology Training Standards. Ruiz CE, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):409–24

Current usage of contrast agents, anticoagulant and antiplatelet drugs in angiography and angioplasty in the UK. Jackson DM, et al. **Clin Radiol** 1995 Oct; 50(10):699–704

Radiation exposure to the hands of operators during angiographic procedures. Damilakis J, et al. **Eur J Radiol** 1995 Nov;21(1):72–5

Feasibility, safety and clinical utility of angiography in patients with suspected pulmonary embolism. van Beek EJ, et al. **Eur Radiol** 1996;6(4):415–9

Angiographic-guided embolization of metastatic invasive mole. Method MW, et al. **Gynecol Oncol** 1996 Jun; 61(3):442–5

Spiral CT angiography for preoperative planning in patients with epigastric tumors: comparison with arteriography. Freund M, et al. **J Comput Assist Tomogr** 1996 Sep–Oct; 20(5):786–91

Intraperitoneal drop metastases from hepatocellular carcinoma: CT and angiographic findings. Kim TK, et al. **J Comput Assist Tomogr** 1996 Jul–Aug;20(4):638–42

Helical CT imaging of bronchial arteries with curved reformation technique in comparison with selective bronchial arteriography: preliminary report. Murayama S, et al. **J Comput Assist Tomogr** 1996 Sep–Oct;20(5):749–55

Microvascular anatomy of dural arteriovenous abnormalities of the spine: a microangiographic study. McCutcheon IE, et al. **J Neurosurg** 1996 Feb;84(2):215–20

Vascular variation of the radial forearm flap: a case report. Mordick TG. **J Reconstr Microsurg** 1995 Sep;11(5):345–6

Malignant hepatic hilar tumors: can ultrasonography be used as an alternative to angiography with CT arterial portography for determination of resectability? Hann LE, et al. **J Ultrasound Med** 1996 Jan;15(1):37–45

Clinical and angiographic selection factors for thrombolysis as initial therapy for acute lower limb ischemia. McNamara TO, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):36S–47S

Interpretations and treatment decisions based on MR angiography versus conventional arteriography in symptomatic lower extremity ischemia. Snidow JJ, et al. **J Vasc Interv Radiol** 1995 Jul–Aug;6(4):595–603

Is completion arteriography mandatory after reversed-vein bypass grafting? Dalman RL, et al. **J Vasc Surg** 1996 Apr; 23(4):637–44

Quantitation of intracranial aneurysm neck size from diagnostic angiograms based on a biomathematical model. Hademenos GJ, et al. **Neurol Res** 1995 Oct;17(5):322–8

Right ventricular size and function as assessed by echocardiography and angiography in patients with different volume load. Norgård G, et al. **Pediatr Cardiol** 1995 Sep–Oct;16(5):209–15

Arteriography and interventional therapy for diseases of the hand. Loring LA, et al. **Radiographics** 1995 Nov; 15(6):1299–310 (25 ref.)

Effectiveness of lead aprons in vascular radiology: results of clinical measurements. Kicken PJ, et al. **Radiology** 1995 Nov;197(2):473–8

High-dose administration of nonionic contrast media: a retrospective review. Rosovsky MA, et al. **Radiology** 1996

Jul;200(1):119–22
Cardiovascular/interventional radiology. Soulen MC, et al. **Radiology** 1996 Mar;198(3):933–6
Angiographic evaluation of focal liver masses. Soulen MC. **Semin Roentgenol** 1995 Oct;30(4):362–74
The arterial blood supply of the pancreas: a review. III. The inferior pancreaticoduodenal artery. An anatomical review and a radiological study. Bertelli E, et al. **Surg Radiol Anat** 1996;18(2):67–74 (42 ref.)
[Diagnosis using x-ray computed angiotomography of an iliac artery aneurysm in an infant] Arnould V, et al. **Can Assoc Radiol J** 1996 Aug;47(4):260–4 (Eng. Abstr.) **(Fre)**
[Indocyanine green angiography in posterior uveitis] Herbort CP, et al. **Klin Monatsbl Augenheilkd** 1996 May; 208(5):321–6 (Eng. Abstr.) **(Fre)**
[Value of indocyanine green angiography in localization of occult choroid neovascularization] Piguet B, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):327–9 (Eng. Abstr.) **(Fre)**
[Value of indocyanine green videoangiography in differential diagnosis of nonpigmented tumors of the choroid] Schalenbourg A, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):330–2 (Eng. Abstr.) **(Fre)**
[Effects of fluorescein and indocyanine green angiography on subsequent dark adaptation and the electroretinogram] Bartz-Schmidt KU, et al. **Klin Monatsbl Augenheilkd** 1996 Apr;208(4):224–8 (Eng. Abstr.) **(Ger)**
[CT angiography versus intra-arterial DSA in abdominal aortic aneurysms] Rieker O, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):17–23 (Eng. Abstr.) **(Ger)**
[Malignant schwannoma of the abdomen (clinical conference)] Krämer SC, et al. **Rontgenpraxis** 1996 May; 49(5):121–3 **(Ger)**
[Leiomyoma of the jejunum. The role of selective angiography. A case report] Fuochi C, et al. **Radiol Med (Torino)** 1995 Oct;90(4):503–6 **(Ita)**
[Congenital anomalies of the inferior vena cava: role of imaging] Manfredi R, et al. **Radiol Med (Torino)** 1995 Oct; 90(4):424–30 (Eng. Abstr.) **(Ita)**
[Methods of determination and ways of lowering radiation loads in x-ray angiography room personnel] Verkhovskiĭ VS, et al. **Vestn Rentgenol Radiol** 1995 Nov–Dec;(6):48–51 **(Rus)**
[Angiography in the diagnosis of vasculitides] Lesný P. **Bratisl Lek Listy** 1995 Oct;96(10):552–7 (Eng. Abstr.) **(Slo)**

ADVERSE EFFECTS

Vasodilatative and vasoconstrictive effects of angiography contrast media. Karstoft J, et al. **Acta Radiol Suppl** 1995; 399:164–9 (41 ref.)
Risk of pulmonary angiography [letter; comment] Pearl RG. **Anesth Analg** 1995 Nov;81(5):1118–9. Comment on: Anesth Analg 1995 Mar;80(3):614–6.
Treatment of iatrogenic false aneurysm by compression ultrasonography. Davies AH, et al. **Br J Surg** 1995 Sep; 82(9):1230–1
Re: complication of pulmonary arteriography: contrast extravasation from a wedged pigtail-shaped catheter [letter] Ray CE Jr, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):305–6
Entanglement of a pigtail catheter by the chordae tendineae of the tricuspid valve during pulmonary angiography. Winrow D, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):275–7
Case report: low femoral artery puncture: a cause of diagnostic error. Murray JG, et al. **Clin Radiol** 1996 Jul; 51(7):515–7
Detection of air emboli in radiographic contrast media by microwave radiometry. Shaeffer J, et al. **Eur Radiol** 1996; 6(4):570–3
Rupture of pulmonary artery induced by balloon occlusion pulmonary angiography. Sumita S, et al. **Intensive Care Med** 1995 Jan;21(1):79–81
Regarding "complications of peripheral arteriography" [letter] Athanasoulis CA. **J Vasc Surg** 1996 Aug;24(2):301
Surgical complications of transaxillary arteriography: a case–control study. Chitwood RW, et al. **J Vasc Surg** 1996 May;23(5):844–9; discussion 849–50
Complications of peripheral arteriography: a new system to identify patients at increased risk. Egglin TK, et al. **J Vasc Surg** 1995 Dec;22(6):787–94
Atheroembolic renal failure after invasive procedures. Natural history based on 52 histologically proven cases. Thadhani RI, et al. **Medicine (Baltimore)** 1995 Nov; 74(6):350–8
Transbrachial fine-needle arteriography with special focus on haemodialysis shunt imaging. Bücker A, et al. **Nephrol Dial Transplant** 1995;10(6):838–41
Evaluation of coagulation tests as predictors of angiographic bleeding complications. Darcy MD, et al. **Radiology** 1996 Mar;198(3):741–4
Pulmonary angiography performed with iopamidol: complications in 1,434 patients. Hudson ER, et al. **Radiology** 1996 Jan;198(1):61–5

ECONOMICS

Cost-effectiveness of colour duplex sonography compared with angiography of the pelvis and lower limb. Geitung JT, et al. **Eur Radiol** 1996;6(4):481–4
Renal computed tomography with 3-dimensional angiography and simultaneous measurement of plasma contrast clearance reduce the invasiveness and cost of evaluating living renal donor candidates. Lindgren BW, et al. **Transplantation** 1996 Jan 27;61(2):219–23

HISTORY

The history of angiography. Wilms G, et al. **J Belge Radiol** 1995 Oct;78(5):299–302

INSTRUMENTATION

Re: complication of pulmonary arteriography: contrast extravasation from a wedged pigtail-shaped catheter [letter] Ray CE Jr, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):305–6
Entanglement of a pigtail catheter by the chordae tendineae of the tricuspid valve during pulmonary angiography. Winrow D, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):275–7
Retrograde pulmonary vein wedge angiography: a new technique. Bahl VK, et al. **Cathet Cardiovasc Diagn** 1995 Mar;34(3):259–60; discussion 261–2
Nonselective angiography of the internal mammary artery: a fast, reliable, and safe technique. Bhatt SN, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):194–8
Femo-Stop II System Femoral Compression Arch [letter] Bresnihan E, et al. **Clin Radiol** 1996 Aug;51(8):599
Material degradation of angiographic catheters. **Health Devices** 1995 Oct;24(10):421–2
Performance of angiographic catheters. Marshall I, et al. **J Med Eng Technol** 1995 Jan–Feb;19(1):17–21
Complement activation by angiographic catheters in vitro. Kuroki K, et al. **J Vasc Interv Radiol** 1995 Sep–Oct; 6(5):819–26
A combined CT and angiography suite with a pivoting table. Capasso P, et al. **Radiology** 1996 May;199(2):561–3
[Digital vascular radiology] Clerc T, et al. **J Radiol** 1995;76(5 Suppl):30–2 **(Fre)**
[Reducing radiation exposure in angiography] Imhof K. **Aktuelle Radiol** 1995 Nov;5(6):385–8 (Eng. Abstr.) **(Ger)**
[Observations of choroid pulsation] Bischoff P, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):318–20 (Eng. Abstr.) **(Ger)**
[Simultaneous digital indocyanine green and fluorescein angiography] Török B, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):333–6 (Eng. Abstr.) **(Ger)**
[Local vascular complications after iatrogenic femoral artery puncture] Fruhwirth J, et al. **Wien Klin Wochenschr** 1996; 108(7):196–200 (Eng. Abstr.) **(Ger)**

METHODS

CT angiography: shaded surface versus maximum intensity projection [letter; comment] Alberico RA, et al. **AJR Am J Roentgenol** 1996 May;166(5):1227–9. Comment on: AJR Am J Roentgenol 1995 Nov;165(5):1079–88.
Automated bone editing algorithm for CT angiography: preliminary results. Fishman EK, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):669–72
The use of power Doppler and color power angiography in fetal imaging. Fortunato SJ. **Am J Obstet Gynecol** 1996 Jun;174(6):1828–31; discussion 1831–3
Indocyanine green angiographic findings in serpiginous choroidopathy. Giovannini A, et al. **Br J Ophthalmol** 1996 Jun;80(6):536–40
Technical note: femoral angiography using the reverse shuffle technique. Oxtoby JW, et al. **Br J Radiol** 1995 Sep; 68(813):1014–6
Femoral angiography using the reverse shuffle technique [letter] Rose JF. **Br J Radiol** 1996 Mar;69(819):283–4
Radial artery approach for outpatient peripheral arteriography [letter] Bishop NL. **Clin Radiol** 1996 Aug; 51(8):598–9
Transbrachial arteriography: indications and complications. Heenan SD, et al. **Clin Radiol** 1996 Mar;51(3):205–9
Arterial angiography in high-kilovoltage technique with gadolinium as the contrast agent: first clinical experience. Fobbe F, et al. **Eur Radiol** 1996;6(2):224–9
Reevaluation of duplex criteria for diagnosis of high-grade carotid artery stenosis: when do we need angiography and when can we operate without angiography? Karacagil S, et al. **Int Angiol** 1995 Dec;14(4):410–4 (14 ref.)
Small hepatocellular carcinomas undetected on two-phased incremental computed tomography. Angiographic and clinicopathologic findings. Honda H, et al. **Invest Radiol** 1995 Aug;30(8):458–65
Minimally invasive diagnosis of renal artery stenosis by spiral computed tomography angiography. Olbricht CJ, et al. **Kidney Int** 1995 Oct;48(4):1332–7
Spiral CT scanning angiography for assessing systemic-to-pulmonary shunt in children [letter] Hamaoka K, et al. **Lancet** 1996 Aug 3;348(9023):341
Automatic correction of biplane projection imaging geometry. Close R, et al. **Med Phys** 1996 Jan;23(1):133–9
Three-dimensional reconstruction of vascular trees: experimental evaluation. Henri CJ, et al. **Med Phys** 1996 May;23(5):617–27
Spiral CT angiography--can we forget about arteriography to diagnose renal artery stenosis? [editorial] Olbricht CJ, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1227–31 (28 ref.)
Assessment of microcirculation of an axial skin flap using indocyanine green fluorescence angiography. Eren S, et al. **Plast Reconstr Surg** 1995 Dec;96(7):1636–49
Clinical applications of spiral CTA. Blazaskie MJ, et al. **Radiol Technol** 1995 Sep–Oct;67(1):79–82
Use of the laryngeal mask in off-floor anesthesia for hepatic angiography in pediatric liver transplant candidates. Fung ST, et al. **Transplant Proc** 1996 Jun;28(3):1723–4
CO2 angiography--a technique for vascular imaging in renal allograft dysfunction. Kuo PC, et al. **Transplantation** 1996 Feb 27;61(4):652–4
[Ultrasonic angiography: principles and clinical use] Skjoldbye B, et al. **Ugeskr Laeger** 1995 Oct 2; 157(40):5530–3 (8 ref.) (Eng. Abstr.) **(Dan)**
[CT angiography in the follow-up after carotid endarterectomy] Link J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Sep;163(3):215–8 (Eng. Abstr.) **(Ger)**
[Carbon dioxide as an alternative contrast medium in peripheral angiography] Zwaan M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 May;164(5):445–8 (Eng. Abstr.) **(Ger)**
[The angiographic application of spiral computed tomography] Ballerini GR. **Cardiologia** 1996 Mar; 41(3):279–83 **(Ita)**
[Ambulatory angiologic diagnosis using the Doppler c.w. (continuous wave) method] Urbano O, et al. **Minerva Cardioangiol** 1995 May;43(5):199–204 (Eng. Abstr.) **(Ita)**
[Spiral computed tomography with arteriography in the diagnosis of digestive system hemorrhages of obscure origin] Ettorre GC, et al. **Radiol Med (Torino)** 1995 Dec; 90(6):726–33 (Eng. Abstr.) **(Ita)**
[The biochemical and rheological properties of the blood during the performance of angiography using Ultravist] Poliaev IuA, et al. **Eksp Klin Farmakol** 1996 Jan–Feb; 59(1):61–3 (Eng. Abstr.) **(Rus)**

STANDARDS

Angiographic and duplex grading of internal carotid stenosis: can we overcome the confusion? Nicolaides AN, et al. **J Endovasc Surg** 1996 May;3(2):158–65 (32 ref.)

STATISTICS & NUMERICAL DATA

Accuracy and precision of angiographic volumetry methods for left and right ventricle. Beier J, et al. **Int J Cardiol** 1996 Feb;53(2):179–88

TRENDS

Evolution of the filmless cardiac angiography suite: promise and perils of the evolving digital era. Nissen SE. **Am J Cardiol** 1996 Aug 14;78(3A):41–4
Newer techniques for noninvasive vascular imaging. Lynch TG, et al. **Nebr Med J** 1995 Oct;80(10):299–305
[The future of angiography] Picard JD. **Bull Mem Acad R Med Belg** 1995;150(3–4):179–85; discussion 186–8 (Eng. Abstr.) **(Fre)**

ANGIOGRAPHY, CEREBRAL see **CEREBRAL ANGIOGRAPHY**

ANGIOGRAPHY, CORONARY see **CORONARY ANGIOGRAPHY**

ANGIOGRAPHY, DIGITAL SUBTRACTION

Spatial resolution requirements in digital radiography of scaphoid fractures. An ROC analysis. Jónsson A, et al. **Acta Radiol** 1996 Jul;37(4):555–60
Clinical experience with iobitridol 250–300 in digital subtraction angiography. Double-blind randomized studies vs. iopromide and iohexol. Bouard JC, et al. **Acta Radiol Suppl** 1996;400:85–8
Duplication of the extracranial internal carotid artery. Chess MA, et al. **AJNR Am J Neuroradiol** 1995 Aug;16(7):1545–7
Spiral CT angiography and selective digital subtraction angiography of internal carotid artery stenosis. Link J, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):89–94
Helical CT angiography compared with arteriography in the detection of renal artery stenosis. Beregi JP, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):495–501
Carbon dioxide/digital subtraction arteriography-assisted transluminal angioplasty. Frankhouse JH, et al. **Ann Vasc Surg** 1995 Sep;9(5):448–52
A prospective study of carbon dioxide–digital subtraction vs standard contrast arteriography in the evaluation of the renal arteries. Schreier DZ, et al. **Arch Surg** 1996 May; 131(5):503–7; discussion 507–8
Total anomalous pulmonary venous connection to the portal vein. Wyttenbach M, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):113–6
Applicability of prostaglandin E1 indirect portal vein angiography in patients with portal hypertension. Peng Z, et al. **Chin Med J (Engl)** 1995 May;108(5):323–7
Quantification of volumetric coronary blood flow with dual-energy digital subtraction angiography. Molloi S, et al. **Circulation** 1996 May 15;93(10):1919–27
Colour Doppler ultrasound in renal transplant artery stenosis:

which Doppler index? Baxter GM, et al. **Clin Radiol** 1995 Sep;50(9):618–22

A novel radiological approach for the experimental study of angiogenesis: angiography of the chick embryo and its chorioallantoic membrane. Siamblis D, et al. **Eur J Radiol** 1996 Feb;21(3):220–4

Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase–III trial. Fischbach R, et al. **Eur Radiol** 1996;6(1):9–13

Quantitative analysis of digital subtraction renal vasography in patients with autosomal dominant polycystic kidney disease correlated with clinical and paraclinical data. Velkova K, et al. **Folia Med (Plovdiv)** 1994;36(4):37–43

Three–dimensional time–of–flight MR angiography and MR imaging versus conventional angiography in carotid artery dissections. Stringaris K, et al. **Int Angiol** 1996 Mar; 15(1):20–5

In–vivo validation of videodensitometric coronary cross–sectional area measurement using dual–energy digital subtraction angiography. Molloi S, et al. **Int J Card Imaging** 1995 Dec;11(4):223–31

Pulmonary hypertension. Response of vasoactive peptides to a nonionic contrast medium in patients undergoing pulmonary angiography. Szolar DH, et al. **Invest Radiol** 1995 Sep;30(9):511–6

Accuracy of DSA in the evaluation of patency of infrapopliteal vessels. Oser RF, et al. **J Vasc Interv Radiol** 1995 Jul–Aug;6(4):589–94

Comparison of intravascular ultrasonography and intraarterial digital subtraction angiography after directional atherectomy of short lesions in femoropopliteal arteries. Tielbeek AV, et al. **J Vasc Surg** 1996 Mar; 23(3):436–45

Iodixanol in intra–arterial cerebral digital subtraction angiography: a comparison with iohexol. Kendall BE, et al. **Neuroradiology** 1995 Oct;37(7):512–4

Predictive value of digital subtraction angiography in patients with tuberculous meningitis. Rojas–Echeverri LA, et al. **Neuroradiology** 1996 Jan;38(1):20–4

Rotational digital angiography of ulcer–like projection of pelvis. Tajima H, et al. **Radiat Med** 1996 Jan–Feb; 14(1):49–51

Renal vasculature in potential renal transplant donors: comparison of MR imaging and digital subtraction angiography. Adamis MK, et al. **Radiology** 1995 Nov; 197(2):467–72

Renal arteries: clinical comparison of three–dimensional time–of–flight MR angiographic sequences and radiographic angiography. Borrello JA, et al. **Radiology** 1995 Dec;197(3):793–9

Pulmonary embolism: interobserver agreement in the interpretation of conventional angiographic and DSA images in patients with nondiagnostic lung scan results. van Beek EJ, et al. **Radiology** 1996 Mar;198(3):721–4

Three–compartment wrist arthrography: direct comparison of digital subtraction with nonsubtraction images. Yin Y, et al. **Radiology** 1995 Oct;197(1):287–90

Cerebrovascular disease assessed by color–flow and power Doppler ultrasonography. Comparison with digital subtraction angiography in internal carotid artery stenosis. Griewing B, et al. **Stroke** 1996 Jan;27(1):95–100

Preoperative assessment of the carotid bifurcation. Can magnetic resonance angiography and duplex ultrasonography replace contrast arteriography? Patel MR, et al. **Stroke** 1995 Oct;26(10):1753–8

Variability in measurement of extracranial internal carotid artery stenosis as displayed by both digital subtraction and magnetic resonance angiography: an assessment of three caliper techniques and visual impression of stenosis. Young GR, et al. **Stroke** 1996 Mar;27(3):467–73

Hemodynamic evaluation with dynamic DSA during the treatment of cerebral vasospasm: a retrospective study. Touho H. **Surg Neurol** 1995 Jul;44(1):63–73; discussion 73–4

[The evaluation of 3DFT time–of–flight MR–angiography versus angiography in the study of carotid atheromatous lesions with a review of the literature] Auffray–Calvier E, et al. **J Neuroradiol** 1995 Dec;22(4):272–87 (30 ref.) (Eng. Abstr.) **(Fre)**

[Digital vascular radiology] Fabrega D, et al. **J Radiol** 1996 May;77(5 Suppl):42–5 **(Fre)**

[Spiral scanning angiography of pulmonary embolism] Rémy J, et al. **J Radiol** 1996 May;77(5):325–38 (60 ref.) **(Fre)**

[Can pharmaco–DSA of the kidney replace intraoperative rapid biopsy diagnosis?] Will CH, et al. **Aktuelle Radiol** 1996 Mar;6(2):87–90 (Eng. Abstr.) **(Ger)**

[Angiographic quantification of stenoses of the internal carotid artery] Bartylla K, et al. **Radiologe** 1995 Nov; 35(11):801–7 (Eng. Abstr.) **(Ger)**

[3–D–TONE magnetic resonance angiography in the detection of intracranial aneurysms compared with digital subtraction angiography. A prospective study] Falk A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jan;164(1):31–7 (Eng. Abstr.) **(Ger)**

[Intraarterial digital subtraction angiography (i.a. DSA) of the lower limb using fine needle technique] Koch JA, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Dec;163(6):515–22 (Eng. Abstr.) **(Ger)**

[Contrast media in peripheral angiography: does cost reduction mean loss of quality and safety? A reevaluation based on a randomized double–blind comparative study of ioxaglate versus iopromide] Lammer J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 May;164(5):432–6 (Eng. Abstr.) **(Ger)**

[CT angiography versus intra–arterial DSA in abdominal aortic aneurysms] Rieker O, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):17–23 (Eng. Abstr.) **(Ger)**

[Rupture of a renal artery aneurysm in polyarteritis nodosa: evaluation by DSA and comparison with MR angiography] Schmid MR, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Apr;164(4):353–5 **(Ger)**

[The diagnosis of acute pulmonary embolism: a comparison between spiral CT and DSA in an animal experiment] Schmitz–Rode T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):345–9 (Eng. Abstr.) **(Ger)**

[DSA of the pelvic–leg blood vessels with Imeron 400 and Optiray 350. Does a higher iodine delivery rate provide better vascular imaging?] Busch HP, et al. **Rontgenpraxis** 1995 Aug;48(8):223–5 **(Ger)**

[Determining the degree of stenosis of the internal carotid artery in the surgical specimen after eversion TEA—comparison with cw–Doppler ultrasound and DSA] Post K, et al. **Rontgenpraxis** 1995 Oct;48(10):277–80 **(Ger)**

[Normalization of myocardial perfusion reserve after coronary stent implantation in comparison with balloon angioplasty alone] Haude M, et al. **Z Kardiol** 1996 Apr; 85(4):260–72 (Eng. Abstr.) **(Ger)**

[Digital subtraction angiography in the diagnosis of Fallot 's tetralogy] Ivanitskiĭ AV, et al. **Vestn Rentgenol Radiol** 1995 Mar–Apr;(2):27–32 (Eng. Abstr.) **(Rus)**

INSTRUMENTATION

A frameless stereotaxic localisation system using MRI, CT and DSA. Rousseau J, et al. **Acta Neurochir Suppl (Wien)** 1995;64:40–4

Digital subtraction angiographic equipment—main aspects and clinical application. Velkova K. **Folia Med (Plovdiv)** 1995;37(4A Suppl):71

Intravenous coronary angiography with dichromography using synchrotron radiation. Hamm CW, et al. **Herz** 1996 Apr;21(2):127–31 (13 ref.)

[A method of computer–assisted, 3–dimensional subtraction angiography using spiral roentgen computerized tomography] Englmeier KH, et al. **Radiologe** 1996 Apr; 36(4):360–4 (Eng. Abstr.) **(Ger)**

METHODS

Clinical use of lossy image compression in digital angiography [editorial; comment] Elion JL, et al. **Am J Cardiol** 1996 Jul 15;78(2):219–20. Comment on: Am J Cardiol 1996 Jul 15;78(2):131–5.

Compression of digital coronary angiograms does not affect visual or quantitative assessment of coronary artery stenosis severity [see comments] Rigolin VH, et al. **Am J Cardiol** 1996 Jul 15;78(2):131–5. Comment in: Educ Dent (Ica) 1996 Jul 15;78(2):219–20.

Technical note: inspiration or expiration? Reducing motion artefact in digital subtraction arch angiography of the extracranial carotid arteries. Withers DJ, et al. **Br J Radiol** 1995 Sep;68(813):1017–20

Non–invasive assessment of arterial disease: a comparison of Quickscan with intra–arterial digital subtraction angiography. Zhang Q, et al. **Br J Surg** 1996 Feb; 83(2):231–4

Spiral computed tomographic angiography of the renal arteries: a prospective comparison with intravenous and intraarterial digital subtraction angiography. Farrés MT, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr; 19(2):101–6

Lower extremity angiography: improved image quality and outflow vessel detection with bilaterally antegrade selective digital subtraction angiography. A blinded prospective intraindividual comparison with aortic flush digital subtraction angiography. Jacob AL, et al. **Invest Radiol** 1996 Apr;31(4):184–93

Transplant renal artery stenosis. Evaluation of diagnosis with magnetic resonance angiography compared with color duplex sonography and arteriography. Loubeyre P, et al. **Transplantation** 1996 Aug 27;62(4):446–50

[The accuracy of angiography and CT angiography of the carotid bifurcation compared to macro–morphological correlation] Post K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):196–200 (Eng. Abstr.) **(Ger)**

STANDARDS

Contrast, noise, and blur affect performance and appreciation of digital radiographs. van Overveld IM. **J Digit Imaging** 1995 Nov;8(4):168–79

UTILIZATION

A simple maneuver in follow–up digital subtraction angiography for multiple coronary–aorta bypass grafts. Mitsui H, et al. **Tohoku J Exp Med** 1995 Apr;175(4):219–23

VETERINARY

Intraoperative use of subtraction angiography and an ultrasonic aspirator to improve identification and isolation of an intrahepatic portosystemic shunt in a dog. Tobias KS, et al. **J Am Vet Med Assoc** 1996 Mar 15;208(6):888–90

ANGIOGRAPHY, GATED RADIONUCLIDE see **GATED BLOOD–POOL IMAGING**

ANGIOGRAPHY, MAGNETIC RESONANCE see **MAGNETIC RESONANCE ANGIOGRAPHY**

ANGIOGRAPHY, RADIONUCLIDE see **RADIONUCLIDE ANGIOGRAPHY**

ANGIOHEMOPHILIA see **VON WILLEBRAND'S DISEASE**

ANGIOID STREAKS

DIAGNOSIS

[Fluorescein angiography of angioid streaks] Szedélyová L. **Cesk Slov Oftalmol** 1996 Apr;52(2):88–92 (Eng. Abstr.) **(Slo)**

ETIOLOGY

Pseudoxanthoma elasticum and its complications: two case reports. Weenink AC, et al. **Neth J Med** 1996 Jul;49(1):24–9

ANGIOIMMUNOBLASTIC LYMPHADENOPATHY see **IMMUNOBLASTIC LYMPHADENOPATHY**

ANGIOKERATOMA

DIAGNOSIS

Scrotal angiokeratoma in a young man [letter] Hisa T, et al. **Acta Derm Venereol** 1996 Jan;76(1):75

ETIOLOGY

[Angiokeratoma and fucosidosis. Immunohistochemical and ultrastructural study] Venencie PY, et al. **Ann Dermatol Venereol** 1995;122(6–7):432–5 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Of APACHEs and PALEFACEs [letter; comment] Puig L. **Am J Dermatopathol** 1995 Apr;17(2):209–11. Comment on: Am J Dermatopathol 1994 Apr;16(2):130–3.

Cutaneous and cerebral haemangiomas associated with eruptive angiokeratomas. Ostlere L, et al. **Br J Dermatol** 1996 Jul;135(1):98–101

SURGERY

Laser treatment of recurrent vulvar angiokeratoma associated with Noonan syndrome. Meyer WR, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):863–5

ANGIOKERATOMA CORPORIS DIFFUSUM see **FABRY'S DISEASE**

ANGIOLEIOMYOMA see **ANGIOMYOMA**

ANGIOLIPOMA

Angiolipoma of suprasellar region. Shuangshoti S, et al. **J Med Assoc Thai** 1995 Nov;78(11):631–4 (7 ref.)

COMPLICATIONS

Hepatic angiomyelolipoma and tuberous sclerosis. Yeo W, et al. **J Gastroenterol Hepatol** 1996 Feb;11(2):196–8

[An adult case of intussusception due to inverted Meckel's diverticulum accompanied by angiolipoma] Kaneko T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):260–5 (14 ref.) **(Jpn)**

DIAGNOSIS

Spinal angiolipomas: MR features. Provenzale JM, et al. **AJNR Am J Neuroradiol** 1996 Apr;17(4):713–9

Spinal angiolipoma mimicking extradural lipomatosis. O'Donovan NA, et al. **Can Assoc Radiol J** 1996 Feb; 47(1):51–3

Spinal extradural angiolipoma. Bouramas D, et al. **J Spinal Disord** 1995 Aug;8(4):324–7

[Angiolipoma of the cecum] Saroglia G, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):59–62 (5 ref.) (Eng. Abstr.) **(Ita)**

[Thoracic epidural angiolipoma. Report of a case] Balbo RJ, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3–B):659–61 (Eng. Abstr.) **(Por)**

GENETICS

Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Fletcher CD, et al. **Am J Pathol** 1996 Feb;148(2):623–30

PATHOLOGY

Cavernous angioma associated with oligo–astrocytoma–like proliferation. Report of two cases and review of the

literature with a reappraisal of the term "angioglioma". Palma L, et al. **Acta Neurochir (Wien)** 1995;133(3-4):169-73 (36 ref.)
Cellular angiolipoma. Kanik AB, et al. **Am J Dermatopathol** 1995 Jun;17(3):312-5
Vascular myxolipoma ("angiomyxolipoma") of the spermatic cord. Mai KT, et al. **Am J Surg Pathol** 1996 Sep; 20(9):1145-8
Spinal extradural angiolipoma. Krishnan VB, et al. **Aust N Z J Surg** 1996 Mar;66(3):194-6 (13 ref.)
Multiple lipomas, angiolipomas, and parathyroid adenomas in a patient with Birt-Hogg-Dube syndrome. Chung JY, et al. **Int J Dermatol** 1996 May;35(5):365-7
Angiolipoma of the cheek: report of a case. Ali MH, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):213-5 (17 ref.)
Tuberous sclerosis has several angiolipomata in both kidneys? Bernstein J. **Pediatr Nephrol** 1996 Feb;10(1):21

RADIOGRAPHY

Clinics in diagnostic imaging (4). Renal angiomyolipoma with spontaneous perinephric haemorrhage. Peh WC, et al. **Singapore Med J** 1995 Jun;36(3):322-4

SURGERY

Spinal extradural angiolipoma. Bouramas D, et al. **J Spinal Disord** 1995 Aug;8(4):324-7

ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA

COMPLICATIONS

Effects of cyclosporine, azathioprine and prednisone on Kimura's disease and focal segmental glomerulosclerosis in renal transplant patients. Senel MF, et al. **Clin Nephrol** 1996 Jan;45(1):18-21
Angiolymphoid hyperplasia with eosinophilia and nephrotic syndrome. Altman DA, et al. **Cutis** 1995 Dec;56(6):334-6; quiz 342
A chorioretinal lesion in a patient with Kimura's disease. Aonuma H, et al. **Jpn J Ophthalmol** 1995;39(2):193-7
Kimura's disease and minimal-change nephrotic syndrome. Sud K, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1349-51 (13 ref.)

DIAGNOSIS

Three cases of eosinophilic lymphfolliculoid granuloma of the soft tissue originating from the parotid gland. Mitsui M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:130-2
[Kimura's disease in a 25-year old man] Erlendsson AK, et al. **Ugeskr Laeger** 1996 Mar 4;158(10):1382-3 (Eng. Abstr.) **(Dan)**

DRUG THERAPY

Angiolymphoid hyperplasia with eosinophilia: successful treatment with indomethacin farnesil [letter] Nomura K, et al. **Br J Dermatol** 1996 Jan;134(1):189-90

ETIOLOGY

Angiolymphoid hyperplasia with eosinophils in HIV infection [letter] D'Offizi G, et al. **AIDS** 1995 Jul;9(7):813-4
Angiolymphoid hyperplasia with eosinophilia associated with immunotherapy. Alonso L, et al. **Allergy** 1996 Mar; 51(3):199-200

METABOLISM

Kimura's disease and angiolymphoid hyperplasia with eosinophilia: new observations from immunohistochemical studies of lymphocyte markers, endothelial antigens, and granulocyte proteins. Helander SD, et al. **J Cutan Pathol** 1995 Aug;22(4):319-26

PATHOLOGY

Kimura's disease involving the median nerve: a case report. Lee YS, et al. **Ann Acad Med Singapore** 1995 May; 24(3):462-4
Pathologic quiz case 1. Kimura disease. Taskin M, et al. **Arch Otolaryngol Head Neck Surg** 1996 Aug;122(8):892, 894-5
Angiolymphoid hyperplasia with eosinophilia of the vulva. Scurry J, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug; 35(3):347-8
Angiolymphoid hyperplasia with eosinophilia affecting the oral mucosa: report of a case and a review of the literature. Bartralot R, et al. **Br J Dermatol** 1996 Apr;134(4):744-8 (28 ref.)
Angiolymphoid hyperplasia with eosinophilia (Kimura's disease) of the conjunctiva [letter] Jayamanne DG, et al. **Br J Ophthalmol** 1995 Nov;79(11):1053-4
Fine-needle aspiration cytology in Kimura's disease. Jayaram G, et al. **Diagn Cytopathol** 1995 Nov;13(4):295-9
Kimura's disease and angiolymphoid hyperplasia with eosinophilia: new observations from immunohistochemical studies of lymphocyte markers, endothelial antigens, and granulocyte proteins. Helander SD, et al. **J Cutan Pathol** 1995 Aug;22(4):319-26

PREVENTION & CONTROL

Effects of cyclosporine, azathioprine and prednisone on Kimura's disease and focal segmental glomerulosclerosis in renal transplant patients. Senel MF, et al. **Clin Nephrol** 1996 Jan;45(1):18-21

RADIONUCLIDE IMAGING

Tl-201 SPECT in Kimura's disease involving the parotid glands and cervical nodes. Nagamachi S, et al. **Clin Nucl Med** 1996 Feb;21(2):125-8

SURGERY

Three cases of eosinophilic lymphfolliculoid granuloma of the soft tissue originating from the parotid gland. Mitsui M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:130-2

VIROLOGY

HHV8 DNA in angiolymphoid hyperplasia of the skin [letter] Gyulai R, et al. **Lancet** 1996 Jun 29;347(9018):1837

ANGIOMA see **HEMANGIOMA**

ANGIOMA, SCLEROSING see **DERMATOFIBROMA**

ANGIOMATOSIS

see related
TELANGIECTASIA, HEREDITARY HEMORRHAGIC

[Diffuse gastric angiomatosis. A clinical case. Review of the literature] Germain MA, et al. **Chirurgie** 1996;121(1):11-4 (20 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Polyneuropathy associated with nerve angiomatosis and multiple soft tissue tumors. A newly recognized syndrome. Giannini C, et al. **Am J Surg Pathol** 1995 Nov; 19(11):1325-32
Angiomatous malformation of the floor of the mouth associated with fluctuating macroglossia in an adult: an unusual case report. Murthy P, et al. **J Laryngol Otol** 1995 Jul;109(7):665-8
[A case of angiosarcoma of the pelvis associated with angiomatosis of the spine] Uribe Uribe NO, et al. **Rev Invest Clin** 1996 Jan-Feb;48(1):49-53 (9 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Cystic angiomatosis: case report and review of the literature. Levey DS, et al. **Skeletal Radiol** 1996 Apr;25(3):287-93 (45 ref.)

ULTRASONOGRAPHY

Angiodysgenetic necrotizing encephalopathy or diffuse meningocerebral angiomatosis. Arvanitis DL, et al. **Pediatr Neurol** 1996 Feb;14(2):155-7

ANGIOMATOSIS, BACILLARY

Bacillary angiomatosis: microbiology, histopathology, clinical presentation, diagnosis and management. Ramírez Ramírez CR, et al. **Bol Asoc Med P R** 1995 Jul-Sep; 87(7-9):140-6 (22 ref.)
Bacillary angiomatosis. Manders SM. **Clin Dermatol** 1996 May-Jun;14(3):295-9 (51 ref.)
[Bartonella (Rochalimaea) infections: cat-scratch disease and bacillary angiomatosis] Sander A, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):65-9 (47 ref.) **(Ger)**

COMPLICATIONS

Human immunodeficiency virus-related bacillary angiomatosis of the penis. Eden CG, et al. **Br J Urol** 1996 Feb;77(2):323-4
Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus: clinical characteristics in a case-control study. Mohle-Boetani JC, et al. **Clin Infect Dis** 1996 May;22(5):794-800
Bacillary angiomatosis and parenchymal peliosis: frequent absence of mucocutaneous lesions [editorial] Schwartzman WA. **Clin Infect Dis** 1996 May;22(5):801-2 (14 ref.)
Intra-abdominal mass associated with gastrointestinal hemorrhage: a new manifestation of bacillary angiomatosis. Koehler JE, et al. **Gastroenterology** 1995 Dec;109(6):2011-4
Strategy to detect and identify Bartonella species in routine clinical laboratory yields Bartonella henselae from human immunodeficiency virus-positive patient and unique Bartonella strain from his cat. Clarridge JE 3rd, et al. **J Clin Microbiol** 1995 Aug;33(8):2107-13
Bacillary angiomatosis and mycobacterium infection coexisting in a cutaneous lesion in a patient with AIDS. Chiewchanvit S, et al. **J Med Assoc Thai** 1996 May; 79(5):337-40

DIAGNOSIS

Detection of Bartonella (Rochalimaea) henselae bacteremia using BacT/Alert blood culture system [see comments] Tierno PM Jr, et al. **Am J Clin Pathol** 1995 Nov; 104(5):530-6. Comment in: Am J Clin Pathol 1995 Nov;104(5):487-90.
Colonic bacillary angiomatosis. Huh YB, et al. **Ann Intern Med** 1996 Apr 15;124(8):735-7
Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus: clinical characteristics in a case-control study. Mohle-Boetani JC, et al. **Clin Infect Dis** 1996 May;22(5):794-800
Bacillary angiomatosis and parenchymal peliosis: frequent absence of mucocutaneous lesions [editorial] Schwartzman WA. **Clin Infect Dis** 1996 May;22(5):801-2 (14 ref.)
Neurologic complications of Bartonella henselae infection. Marra CM. **Curr Opin Neurol** 1995 Jun;8(3):164-9 (65 ref.)
Multiple recurrent bacillary angiomatosis due to Bartonella quintana in an HIV-infected patient [letter] Colson P, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):178-80
Kaposi's sarcoma versus bacillary angiomatosis. Caldwell BD, et al. **J Am Podiatr Med Assoc** 1996 Jun;86(6):260-2
Bacillary angiomatosis mimicking pyogenic granuloma in the hand: a case report. Bastug DF, et al. **J Hand Surg [Am]** 1996 Mar;21(2):307-8
Bacillary angiomatosis presenting as a nasal mass with epistaxis. Vickery CL, et al. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):443-6
Bacillary angiomatosis--another South African case [letter] Burgin S, et al. **S Afr Med J** 1996 Jan;86(1):95-6

ETIOLOGY

An HIV-1-positive child with fever and a scalp nodule. Malane MS, et al. **Lancet** 1995 Dec 2;346(8988):1466

MICROBIOLOGY

Bacillary angiomatosis in HIV-infected patients: report of three cases with different clinical courses and identification of Rochalimaea quintana as the aetiological agent. Bachelez H, et al. **Br J Dermatol** 1995 Dec;133(6):983-9
[Bacillary angiomatosis, cat-scratch disease and trench fever: are these diseases caused by the same bacteria?] Kragballe K. **Ugeskr Laeger** 1996 Jan 8;158(2):174-5 **(Dan)**

PATHOLOGY

Fine needle aspiration diagnosis of intramuscular bacillary angiomatosis. A case report. Sanchez MA, et al. **Acta Cytol** 1996 Jul-Aug;40(4):751-5
Widespread cutaneous bacillary angiomatosis and a large fungating mass in an HIV-positive man. Fagan WA, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):285-7

RADIOGRAPHY

Bacillary angiomatosis in patients with AIDS: multiorgan imaging findings [published erratum appears in Radiology 1995 Nov;197(2):549] Moore EH, et al. **Radiology** 1995 Oct; 197(1):67-72

ANGIOMATOSIS, EPITHELIOID see **ANGIOMATOSIS, BACILLARY**

ANGIOMYOLIPOMA

Renal angiomyolipoma: report of three cases with regional lymph node involvement and/or with renal cell carcinoma. Csanaky G, et al. **Tumori** 1995 Nov-Dec;81(6):469-74
[Clinical studies of 15 cases of renal angiomyolipoma] Tsujimura A, et al. **Hinyokika Kiyo** 1995 Aug;41(8):581-4 (Eng. Abstr.) **(Jpn)**
[Lipomatous tumors (lipoma, angiomyolipoma, myelolipoma, focal fatty change) in the liver] Imaoka S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):288-91 (24 ref.) **(Jpn)**

BLOOD SUPPLY

[Selective embolization of an aneurysm in a massive angiomyolipoma of the kidney] De Wever W, et al. **J Belge Radiol** 1996 Jun;79(3):137-8 (Eng. Abstr.) **(Dut)**

COMPLICATIONS

How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Bernstein SM, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2138-43
Angiomyolipoma of kidney--a cause of recurrent retroperitoneal haemorrhage. O'Donnell M, et al. **Br J Urol** 1995 Oct;76(4):521-2
Multifocal angiomyolipoma in a patient with tuberous sclerosis. Sola JE, et al. **Clin Imaging** 1996 Apr-Jun; 20(2):99-102
Extrathoracic angiomyolipomas in lymphangioleiomyomatosis. Maziak DE, et al. **Eur Respir J** 1996 Mar;9(3):402-5
[Renal angiomyolipoma with locoregional lymph node localization associated with pulmonary tuberous sclerosis: a case report] Ambrosiani L, et al. **Arch Ital Urol Androl** 1995 Sep;67(4):283-7 (Eng. Abstr.) **(Ita)**
[Bourneville's syndrome: diagnostic and urologic implications] Geromino A, et al. **Arch Ital Urol Androl** 1995 Sep;67(4):261-3 (Eng. Abstr.) **(Ita)**
[Monolateral renal angiomyolipoma: a case of Wunderlich's syndrome] Revetria P, et al. **Minerva Chir** 1995 Jun; 50(6):599-602 **(Ita)**
[Echographic diagnosis of a large, asymptomatic, perirenal

hematoma caused by a bleeding angiomyolipoma in tuberous sclerosis] Cammarota T, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):5–8 (Eng. Abstr.) **(Ita)**

[A case of renal angiomyolipoma with peri-renal hemorrhage] Tahara Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1169–71 **(Jpn)**

CONGENITAL

Angiomyolipoma located in the lumbar region of a newborn. Gündoğdu ZH, et al. **Turk J Pediatr** 1995 Jul–Sep; 37(3):263–7

DIAGNOSIS

Extrathoracic angiomyolipomas in lymphangioleiomyomatosis. Maziak DE, et al. **Eur Respir J** 1996 Mar;9(3):402–5

Management of small renal neoplasms and angiomyolipoma: a growing problem [editorial; comment] Wills JS. **Radiology** 1995 Dec;197(3):583–6. Comment on: Radiology 1995 Dec;197(3):589–97. Comment on: Radiology 1995 Dec;197(3):598–602.

[Renal angiomyolipoma causing an acute abdomen] Artese L, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):901–7 (Eng. Abstr.) **(Ita)**

[A case of hemorrhagic complication revealing renal angiomyolipoma] De Cenzo S, et al. **Arch Ital Urol Androl** 1995 Sep;67(4):279–81 (Eng. Abstr.) **(Ita)**

[Renal angiomyolipoma: diagnosis and treatment] Arima K, et al. **Hinyokika Kiyo** 1995 Sep;41(9):737–43 (Eng. Abstr.) **(Jpn)**

[Renal angiomyolipoma located intrasinusally. An anomalous location which poses diagnostic problems] Franco A, et al. **Actas Urol Esp** 1995 Mar;19(3):239–41; discussion 241–2 (7 ref.) (Eng. Abstr.) **(Spa)**

[Renal angiomyolipoma] Mothe G, et al. **Medicina (B Aires)** 1991;51(6):533–8 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Angiomyolipoma arising in the colon. Maesawa C, et al. **Am J Gastroenterol** 1996 Sep;91(9):1852–4

GENETICS

Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Henske EP, et al. **Genes Chromosomes Cancer** 1995 Aug;13(4):295–8

Clonality of tuberous sclerosis harmatomas shown by non-random X-chromosome inactivation. Green AJ, et al. **Hum Genet** 1996 Feb;97(2):240–3

METABOLISM

Hepatic angiomyolipoma: value of proton (fat/water) chemical shift fast low angle shot (FLASH) MR imaging technique in detecting fatty tissue content. Martín J, et al. **Magn Reson Imaging** 1995;13(6):903–6

PATHOLOGY

Fine needle aspiration cytology of renal and retroperitoneal angiomyolipoma. Report of two cases with cytologic findings and clinicopathologic pitfalls in diagnosis. Wadih GE, et al. **Acta Cytol** 1995 Sep–Oct;39(5):945–50

Hepatic angiomyolipoma. A report of four cases with immunohistochemical and DNA-flow cytometric studies. Terris B, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):68–72

Renal angiomyolipoma with nodal involvement. A 20 year follow up. Agarwal R, et al. **Br J Urol** 1995 Oct;76(4):517

Renal angiomyolipoma with extension into renal vein. Chen SS, et al. **Br J Urol** 1996 Jun;77(6):927–8

Angiomyolipoma of the kidney with extension into the inferior vena cava. Hibi H, et al. **Int J Urol** 1995 Nov; 2(5):332–5 (14 ref.)

Renal angiomyolipoma: growth followed up with CT and/or US [see comments] Lemaitre L, et al. **Radiology** 1995 Dec; 197(3):598–602. Comment in: Radiology 1995 Dec;197(3):583–6.

Renal angiomyolipoma with extrarenal involvement--in vascular, lymph-node and perirenal tissue. Reports of four cases. Maffezzini M, et al. **Scand J Urol Nephrol** 1995 Sep; 29(3):327–9

Multicentric renal angiomyolipoma associated with pulmonary lymphangioleiomyomatosis: case report, with histologic, immunohistochemical, and DNA content analyses. Tawfik O, et al. **Urology** 1996 Sep;48(3):476–80

[Angiomyolipoma: the role of puncture-aspiration cytodiagnosis] Farina LA, et al. **Prog Urol** 1995 Sep; 5(4):575–7 (36 ref.) (Eng. Abstr.) **(Fre)**

[Rapidly growing renal angiomyolipoma associated with pregnancy (letter; comment)] Fariña LA. **Actas Urol Esp** 1995 May;19(5):425–7. Comment on: Actas Urol Esp 1994 Jul–Aug;18(7):755–7. **(Spa)**

RADIOGRAPHY

Complications of renal angiomyolipomas: CT evaluation. Antonopoulos P, et al. **Abdom Imaging** 1996 Jul–Aug; 21(4):357–60

A case of angiomyolipoma diagnosed by thin slice non-enhanced CT and needle biopsy. Sekido N, et al. **Int J Urol** 1996 Jan;3(1):77–9

[Giant and bilateral renal angiomyolipomas] Coulier B, et al. **J Belge Radiol** 1995 Dec;78(6):342–4 (Eng. Abstr.) **(Fre)**

SURGERY

Non-traumatic rupture of the urinary tract during pregnancy. Wolff JM, et al. **Br J Urol** 1995 Nov;76(5):645–8

In situ perfusion by retrograde cannulation of a tumor artery for nephron-sparing surgery. Masaki Z, et al. **Int J Urol** 1995 Jul;2(3):161–5

Cryotherapy for renal cell carcinoma and angiomyolipoma. Delworth MG, et al. **J Urol** 1996 Jan;155(1):252–4; discussion 254–5

[Monolateral renal angiomyolipoma: a case of Wunderlich's syndrome] Revetria P, et al. **Minerva Chir** 1995 Jun; 50(6):599–602 **(Ita)**

ULTRASONOGRAPHY

Case report: renal adenocarcinoma with ultrasonographic appearances suggestive of angiomyolipoma. Morrison ID, et al. **Clin Radiol** 1995 Sep;50(9):659–61

Angiomyolipoma: ultrasonographic signs of lipomatous hepatic tumors. Yeh HC, et al. **J Ultrasound Med** 1996 Apr;15(4):337–42

Angiomyolipoma and renal cell carcinoma: US differentiation. Siegel CL, et al. **Radiology** 1996 Mar; 198(3):789–93

ANGIOMYOMA

[Smooth muscle tumors of the extra-hepatic bile duct] Saito K. **Ryoikibetsu Shokogun Shirizu** 1996;(9):64–7 (22 ref.) **(Jpn)**

COMPLICATIONS

[Angioleiomyoma of the small intestine as a cause of recurrence of hemorrhage] Pidoprigora AP, et al. **Klin Khir** 1995;(4):48 **(Ukr)**

DIAGNOSIS

Imaging of angioleiomyoma. Sardanelli F, et al. **J Clin Ultrasound** 1996 Jun;24(5):268–71

GENETICS

An angiomyoma with t(X;10)(q22;q23.2). Sonobe H, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):54–6 (17 ref.)

PATHOLOGY

Angioleiomyoma of the upper lip: report of a case. Anastassov GE, et al. **Int J Oral Maxillofac Surg** 1995 Aug;24(4):301–2

Histogenesis of vascular tumours [letter] Beranek JT. **J Hand Surg [Br]** 1996 Apr;21(2):288–9

Vascular leiomyoma in an index finger undergoing malignant transformation. Herren DB, et al. **J Hand Surg [Br]** 1995 Aug;20(4):484–7

Angiomyofibroblastoma of the vulva and vagina. Nielsen GP, et al. **Mod Pathol** 1996 Mar;9(3):284–91 (25 ref.)

Vascular leiomyoma of the nasal septum. Ardekian L, et al. **Otolaryngol Head Neck Surg** 1996 Jun;114(6):798–800

RADIOGRAPHY

Vascular leiomyoma of the finger causing bone erosion. Glowacki KA, et al. **J Hand Surg [Am]** 1995 Nov; 20(6):1011–3

SURGERY

Angiomyoma (vascular leiomyoma) of the median nerve. Piers W, et al. **J Hand Surg [Am]** 1996 Mar;21(2):285–6

Angioleiomyomas of the hand. A report of 14 cases. Lawson GM, et al. **J Hand Surg [Br]** 1995 Aug;20(4):479–83

[A case of vascular leiomyoma in the larynx] Kamata T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Jul;98(7):1119–24 (29 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Angioleiomyoma of the nasopharynx in a dog. Carpenter JL, et al. **Vet Pathol** 1995 Nov;32(6):721–3

ANGIOMYXOMA see **MYXOMA**

ANGIONEUROTIC EDEMA

Urticaria and angioedema: a clinical spectrum. Charlesworth EN. **Ann Allergy Asthma Immunol** 1996 Jun;76(6):484–95; quiz 495–9 (90 ref.)

CHEMICALLY INDUCED

Angioedema associated with sumatriptan administration. Dachs R, et al. **Am J Med** 1995 Dec;99(6):684–5

Angioedema associated with droperidol administration. Palombaro JF, et al. **Ann Emerg Med** 1996 Mar; 27(3):379–81

Angio-oedema and ACE inhibitors [letter] Black PN, et al. **Aust N Z J Med** 1995 Dec;25(6):746; discussion 747

Angio-oedema and ACE inhibitors [letter] Boyd IW. **Aust N Z J Med** 1995 Dec;25(6):746–7

A QA perspective--report on ACE inhibitor angio-oedema [editorial; comment] Duggan JM. **Aust N Z J Med** 1995 Jun;25(3):189. Comment on: Aust N Z J Med 1995 Jun;25(3):241–2.

Failure to recognise the association of life-threatening angio-oedema and angiotensin-converting enzyme inhibitor therapy [see comments] Weiner JM. **Aust N Z J Med** 1995 Jun;25(3):241–2. Comment in: Aust N Z J Med 1995 Jun;25(3):189.

Angio-oedema associated with risperidone. Cooney C, et al. **BMJ** 1995 Nov 4;311(7014):1204

Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Brown NJ, et al. **Clin Pharmacol Ther** 1996 Jul;60(1):8–13

Fever, rash, and angioedema after a course of allopurinol. Yale SH, et al. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):92–4

Accupril- and Cozaar-induced angioedema in the same patient [letter] Boxer M. **J Allergy Clin Immunol** 1996 Aug; 98(2):471

Angio-oedema induced by ACE inhibitors [letter] Marinella MA. **J Intern Med** 1996 Apr;239(4):371–2

Pseudo-allergic reactions to corticosteroids: diagnosis and alternatives. Valdivieso R, et al. **J Investig Allergol Clin Immunol** 1995 May–Jun;5(3):171–4

Perioperative angioedema in a patient on long-term angiotensin-converting enzyme (ACE)-inhibitor therapy. Ogbureke KU, et al. **J Oral Maxillofac Surg** 1996 Jul; 54(7):917–20 (18 ref.)

Angioedema induced by the angiotensin II blocker losartan [letter] Acker CG, et al. **N Engl J Med** 1995 Dec 7; 333(23):1572

Glottic angioedema, ciprofloxacin, and ACE inhibitors [letter] Langauer Messmer S, et al. **Postgrad Med J** 1996 Jun;72(848):383

[Angioneurotic edema in relation to therapeutic use of angiotensin-converting enzyme inhibitor] Johansen EC, et al. **Ugeskr Laeger** 1996 Jan 1;158(1):59–60 (Eng. Abstr.) **(Dan)**

[Life-threatening postoperative angioedema following treatment with an angiotensin converting enzyme inhibitor] Maier C. **Anaesthesist** 1995 Dec;44(12):875–9 (Eng. Abstr.) **(Ger)**

[Clinicopharmacological case report (3). Drug-induced angioedema] Kind B, et al. **Schweiz Rundsch Med Prax** 1996 Apr 23;85(17):567–9 (27 ref.) (Eng. Abstr.) **(Ger)**

[Angioedema following treatment with ACE inhibitors] Ekborn A, et al. **Lakartidningen** 1996 Feb 7;93(6):468–70 **(Swe)**

COMPLICATIONS

Acute severe urticaria and angioedema leading to myocardial infarction [clinical conference] Vaswani SK, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):101–4

Colorectal intussusception: an unusual gastrointestinal complication of hereditary angioedema. Witschi A, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):96–8

DIAGNOSIS

C-1-inhibitor binding monoclonal immunoglobins in three patients with acquired angioneurotic edema. Chevailler A, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):998–1008

DRUG THERAPY

Update on urticaria and angioedema (hives). Fox RW. **Allergy Proc** 1995 Nov–Dec;16(6):289–92 (20 ref.)

Hypodermic epinephrine spray and uvular angioedema revisited [letter] Peltz S, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):717–8

Can C1 esterase inhibitor concentrate be a cause of the exacerbation of hereditary angioneurotic oedema? [letter] Nomura S, et al. **Vox Sang** 1995;69(1):85

ETIOLOGY

Secondary cutaneous manifestations of acute schistosomiasis mansoni. Rocha MO, et al. **Ann Trop Med Parasitol** 1995 Aug;89(4):425–30

Chronic angio-oedema of the tongue associated with pernicious anaemia and Hashimoto's thyroiditis. Peltz S, et al. **Clin Exp Dermatol** 1995 Jul;20(4):351–2

GENETICS

Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema [see comments] Verpy E, et al. **Am J Hum Genet** 1996 Aug;59(2):308–19. Comment in: Am J Hum Genet 1996 Aug;59(2):289–91.

Hereditary angioedema caused by a point mutation of exon 7 in the C1 inhibitor gene. Ishii N, et al. **Br J Dermatol** 1996 Apr;134(4):731–3

A point mutation in exon 7 of the C1-inhibitor gene causing type I hereditary angioedema. Ono H, et al. **Hum Genet** 1996 Oct;98(4):452–3

Colorectal intussusception: an unusual gastrointestinal complication of hereditary angioedema. Witschi A, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):96–8

Impaired production of both normal and mutant C1 inhibitor proteins in type I hereditary angioedema with a duplication in exon 8. Ernst SC, et al. **J Immunol** 1996 Jul 1; 157(1):405–10

Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. Nielsen EW, et al. **J Intern Med** 1996 Feb; 239(2):119-30

Hereditary angioedema: report of a family in Malaysia [letter] Leong WK, et al. **Med J Malaysia** 1995 Jun;50(2):197-8

A mutation unique in serine protease inhibitors (serpins) identified in a family with type II hereditary angioneurotic edema. Ocejo-Vinyals JG, et al. **Mol Med** 1995 Sep; 1(6):700-5

[The use of a C1-inhibior concentrate for short-term preoperative prophylaxis in two patients with hereditary angioedema] Mohr M, et al. **Anaesthesist** 1996 Jul; 45(7):626-30 (Eng. Abstr.) **(Ger)**

[24-year-old patient with acute abdomen and ascites] Lessing P, et al. **Internist (Berl)** 1995 Oct;36(10):995-8 **(Ger)**

IMMUNOLOGY

Allergic urticaria and angioedema caused by a hemostatic sponge of bovine fibrin used in tooth extraction. Wüthrich B, et al. **Allergy** 1996 Jan;51(1):49-51

C-1-inhibitor binding monoclonal immunoglobins in three patients with acquired angioneurotic edema. Chevailler A, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):998-1008

Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. Nielsen EW, et al. **J Intern Med** 1996 Feb; 239(2):119-30

C3 is activated in hereditary angioedema, and C1/C1-inhibitor complexes rise during physical stress in untreated patients. Nielsen EW, et al. **Scand J Immunol** 1995 Dec;42(6):679-85

Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Nielsen EW, et al. **Scand J Immunol** 1996 Aug; 44(2):185-92

METABOLISM

Impaired production of both normal and mutant C1 inhibitor proteins in type I hereditary angioedema with a duplication in exon 8. Ernst SC, et al. **J Immunol** 1996 Jul 1; 157(1):405-10

Factor VIIa in patients with C1-inhibitor deficiency. Nielsen EW, et al. **Thromb Haemost** 1995 Oct;74(4):1103-6

MICROBIOLOGY

Picture of the month. Polyarteritis nodosa with angioedema. Cron RQ, et al. **Arch Pediatr Adolesc Med** 1996 Aug; 150(8):875-6

PATHOLOGY

Acquired C1-esterase inhibitor deficiency: three case reports and commentary on the syndrome. Lipscombe TK, et al. **Australas J Dermatol** 1996 Aug;37(3):145-8

PREVENTION & CONTROL

Hereditary angioedema: prophylaxis management in the puerperium [letter] Hawthorne LA, et al. **Anaesthesia** 1996 Mar;51(3):283-4

RADIOGRAPHY

Images in clinical medicine. Angioedema of the intestine. Gregory KW, et al. **N Engl J Med** 1996 Jun 20;334(25):1641

THERAPY

Hereditary angioedema: report of a family in Malaysia [letter] Leong WK, et al. **Med J Malaysia** 1995 Jun;50(2):197-8

Hereditary angioedema [editorial; comment] Cicardi M, et al. **N Engl J Med** 1996 Jun 20;334(25):1666-7. Comment on: N Engl J Med 1996 Jun 20;334(25):1630-4.

Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate [see comments] Waytes AT, et al. **N Engl J Med** 1996 Jun 20;334(25):1630-4. Comment in: N Engl J Med 1996 Jun 20;334(25):1666-7.

ANGIOPLASTY

see related

ENDARTERECTOMY

Importance of case mix during training in interventional cardiology. Eisenberg MJ, et al. **Am J Cardiol** 1996 May 1;77(11):1010-3

Surgical angioplasty of the left main coronary artery: follow-up with magnetic resonance imaging. Briffa NP, et al. **Ann Thorac Surg** 1996 Aug;62(2):550-2

Revascularization using angioplasty and minimally invasive techniques documented by thermal imaging. Emery RW, et al. **Ann Thorac Surg** 1996 Aug;62(2):591-3

Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Ito H, et al. **Circulation** 1996 Jun 1;93(11):1993-9

Current usage of contrast agents, anticoagulant and antiplatelet drugs in angiography and angioplasty in the UK. Jackson DM, et al. **Clin Radiol** 1995 Oct; 50(10):699-704

The significance of increased 111indium platelet accumulation at post-angioplasty sites. Nyamekye I, et al. **Clin Radiol** 1996 Jul;51(7):507-10

The surgeon as an endovascular interventionist. Why and how? Criado FJ. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):17-25

Angioscopy in the operating room. Marzelle J. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):11-6

The ideal guidance imaging system for endovascular interventions. Verbin CS, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):5-9

The role of angioplasty and stenting in the treatment of occlusive lesions of supra-aortic trunks. Criado FJ, et al. **J Mal Vasc** 1996;21 Suppl A:132-8

Renal artery angioplasty: technical results and clinical outcome in 320 patients. Goldman SM. **J Urol** 1996 Jul; 156(1):308

Angioplasty for renal artery stenosis. Ames R. **JAMA** 1996 May 15;275(19):1476

Concern about safety of carotid angioplasty [letter] Brown MM, et al. **Stroke** 1996 Aug;27(8):1435-6

Concern about safety of carotid angioplasty [letter; comment] Roubin GS, et al. **Stroke** 1996 Jun;27(6):1130-1. Comment on: Stroke 1996 Feb;27(2):197-8.

Surgical patch ostiumplasty of the left main coronary artery. Schmuziger M, et al. **Thorac Cardiovasc Surg** 1996 Feb; 44(1):27-30

[Seminar on management in interventional coronary angioplasty and high-frequency ablative therapy. Wuppertal, June 10-11, 1994. Proceedings] **Z Kardiol** 1995; 84 Suppl 2:1-169 **(Ger)**

[Radiation-induced coronary ostial stenosis, a case of redo coronary bypass for the restenosis following patch angioplasty] Takewa Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):220-5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Acute myocardial infarction: pharmacological reperfusion or angioplasty? (editorial)] Kauffmann R. **Rev Med Chil** 1995 Jun;123(6):749-50 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis. A nonhuman primate model of restenosis. Geary RL, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):34-43

New vascular sheath for subcutaneous drug administration: design, animal testing, and clinical application for pain prevention after angioplasty. Lambert CR, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):68-72

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Mark DB, et al. **Circulation** 1996 Aug 15;94(4):629-35

Peripheral vascular complications following coronary interventional procedures. Nasser TK, et al. **Clin Cardiol** 1995 Nov;18(11):609-14 (54 ref.)

Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. Häyry P, et al. **FASEB J** 1995 Oct;9(13):1336-44

Does the choice of material influence early morbidity in patients undergoing carotid patch angioplasty? Katz SG, et al. **Surgery** 1996 Mar;119(3):297-301

[A case of new stenosis in the distal portion following transaortic patch angioplasty for the left main coronary stenosis] Arioka I, et al. **Kyobu Geka** 1996 Jun;49(6):464-7 (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

New device for wire and catheter capturing: in vivo experiments and first clinical experience. Vorwerk D, et al. **Cardiovasc Intervent Radiol** 1995 Sep-Oct;18(5):312-4

A novel approach to the placement of Palmaz-Schatz biliary stents in saphenous vein grafts. Núñez BD, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):350-3 discussion 354

A fluid dynamics study of the Trac catheter. Desaraju G, et al. **Med Eng Phys** 1996 Mar;18(2):161-6

[Local vascular complications after iatrogenic femoral artery puncture] Fruhwirth J, et al. **Wien Klin Wochenschr** 1996; 108(7):196-200 (Eng. Abstr.) **(Ger)**

METHODS

Ultrasound guidance in direct graft puncture thrombolysis and transpopliteal angioplasty [letter] Buckenham TM, et al. **Clin Radiol** 1996 Mar;51(3):230-2

Ultrasound guidance in direct graft puncture thrombolysis and transpopliteal angioplasty [letter; comment] Morse MH. **Clin Radiol** 1996 Mar;51(3):230. Comment on: Clin Radiol 1994 May;49(5):351-3. Comment on: Clin Radiol 1994 Nov;49(11):824-7; discussion 827-8.

Technical report: Recanalisation of all three infrapopliteal arteries by subintimal angioplasty. Nydahl S, et al. **Clin Radiol** 1996 May;51(5):366-7

Percutaneous arterial approach revisited [editorial] Geschwind HJ. **Eur Heart J** 1995 May;16(5):579-80

Outcome of selective patching following carotid endarterectomy. Golledge J, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):458-63

Carotid endarterectomy and patch angioplasty, utilizing a segment of autogenous endarterectomized superficial femoral artery. A case report. Bastounis EA, et al. **Int Angiol** 1995 Jun;14(2):209-13

Principles of angioplasty guidance using ultrasound. Ramaswami G, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3 Suppl 1):27-31

On becoming an endovascular surgeon [editorial] Criado FJ. **J Endovasc Surg** 1996 May;3(2):140-5

Endovascular surgical approach to intracranial vascular diseases. Higashida RT, et al. **J Endovasc Surg** 1996 May; 3(2):146-57 (57 ref.)

Evaluation of cases with combined bronchoplasty and pulmonary arterioplasty for the treatment of lung cancer. Wada H, et al. **Lung Cancer** 1995 Oct;13(2):113-20

Analytic representation of the dose from a 32P-coated stent. Prestwich WV. **Med Phys** 1996 Jan;23(1):9-13

[Protected carotid angioplasty and carotid stents] Theron J. **J Mal Vasc** 1996;21 Suppl A:113-22 (Eng. Abstr.) **(Fre)**

[Angioplasty and coronary restoration using the internal mammary artery] Barra JA, et al. **Presse Med** 1995 Nov 18;24(35):1648-50 (Eng. Abstr.) **(Fre)**

[Preliminary clinical results with intracoronary ultrasound angioplasty] Steffen W, et al. **Dtsch Med Wochenschr** 1995 Nov 24;120(47):1609-13 (Eng. Abstr.) **(Ger)**

STANDARDS

Concern about safety of carotid angioplasty [editorial] [see comments] Beebe HG, et al. **Stroke** 1996 Feb;27(2):197-8 . Comment in: Stroke 1996 Jun;27(6):1130-1.

ANGIOPLASTY, BALLOON

Effects of acute percutaneous transluminal recanalization on cerebral embolism. Takasago T, et al. **Acta Neurol Scand Suppl** 1996;166:99-103

Long-term results of percutaneous transluminal angioplasty in renovascular hypertension. von Knorring J, et al. **Acta Radiol** 1996 Jan;37(1):36-40

Angioplasty of the occluded internal carotid artery. Spearman MP, et al. **AJNR Am J Neuroradiol** 1995 Oct; 16(9):1791-6; discussion 1797-9

Renal artery stenosis with contralateral renal cell carcinoma: an indication for prophylactic angioplasty? [letter] Cooper SG. **AJR Am J Roentgenol** 1995 Dec;165(6):1553-4

Spontaneous regression of postangioplasty restenosis in common iliac artery [letter] Hirai T, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):728-9

Renovascular hypertension resulting from nonspecific aortoarteritis in children: midterm results of percutaneous transluminal renal angioplasty and predictors of restenosis. Sharma S, et al. **AJR Am J Roentgenol** 1996 Jan; 166(1):157-62

Intravascular sonographic evaluation of iliac artery angioplasty: what is the mechanism of angioplasty and can intravascular sonography predict clinical outcome? van Lankeren W, et al. **AJR Am J Roentgenol** 1996 Jun; 166(6):1355-60

Rotational atherectomy with adjunctive balloon angioplasty versus conventional percutaneous transluminal coronary angioplasty in type B2 lesions: results of a randomized study. Guérin Y, et al. **Am Heart J** 1996 May;131(5):879-83

Directional coronary atherectomy and progressive coronary dilatation: a comparative analysis of acute outcome. Jackson BD, et al. **Am Heart J** 1995 Nov;130(5):966-70

Vascular repair mechanisms after directional atherectomy or percutaneous transluminal coronary angioplasty in atherosclerotic rabbit iliac arteries. Wilensky RL, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):13-22

Carotid stent-supported angioplasty: a neurovascular intervention to prevent stroke. Roubin GS, et al. **Am J Cardiol** 1996 Aug 14;78(3A):8-12

Local catheter-based intracoronary radiation therapy for restenosis. Waksman R. **Am J Cardiol** 1996 Aug 14; 78(3A):23-8

Comparative analysis of percutaneous transluminal angioplasty and operation for renal revascularization. Erdoes LS, et al. **Am J Kidney Dis** 1996 Apr;27(4):496-503

Percutaneous transluminal angioplasty in critical limb ischaemia. Matsi P. **Ann Chir Gynaecol** 1995;84(4):359-62

Occlusion of the superior mesenteric artery in a patient with polycythemia vera: resolution with percutaneous transluminal angioplasty. Bertrán X, et al. **Ann Hematol** 1996 Feb;72(2):89-91

Colour-coded duplex ultrasonography in selection of patients for transluminal angioplasty. Lai DT, et al. **Australas Radiol** 1995 Aug;39(3):243-5

Interventional neuroradiology. Pelz DM. **Baillieres Clin Neurol** 1995 Aug;4(2):297-315 (60 ref.)

Influence of plaque morphology on the mechanism of luminal enlargement after directional coronary atherectomy and balloon angioplasty. Marsico F, et al. **Br Heart J** 1995 Aug; 74(2):134-9

Should balloon angioplasty be used instead of surgery for native aortic coarctation? [editorial] Rao PS. **Br Heart J** 1995 Dec;74(6):578-9

Blood flow in the lower limb after balloon angioplasty of the superficial femoral artery. Hussain ST, et al. **Br J Surg** 1996 Jun;83(6):791-5

Intravascular ultrasound imaging of peripheral arteries as an adjunct to balloon angioplasty and atherectomy. Korogi Y, et al. **Cardiovasc Intervent Radiol** 1996 Jan-Feb;19(1):1-9 (39 ref.)

Venous recanalization by metallic stents after failure of balloon angioplasty or surgery: four-year experience. Nazarian GK, et al. **Cardiovasc Intervent Radiol** 1996

Jul-Aug;19(4):227-33
Percutaneous transluminal angioplasty of an innominate artery occlusion. Watura R, et al. **Cardiovasc Intervent Radiol** 1995 Nov-Dec;18(6):396-8
Ankle-arm index, angiography, and duplex ultrasonography after recanalization of occlusions in femoropopliteal arteries: comparison of long-term results. Winter-Warnars HAO, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug; 19(4):234-8
The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. Groves PH, et al. **Cardiovasc Res** 1995 Jul;30(1):87-96
Balloon mitral valvotomy in patients with systemic and suprasystemic pulmonary artery pressures. Bahl VK, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):211-5
Balloon angioplasty of the internal mammary artery trunk for early postoperative ischemia: a case report. Kollar A, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):49-51
Early restenosis following percutaneous transluminal balloon angioplasty for the treatment of the superior vena caval syndrome due to pacemaker-induced stenosis. Marzo KP, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):128-31
Use of a snare-loop device as an adjunct to Palmaz stent placement. Sapoval MR, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):269-71
Long-term effects of balloon coarctation angioplasty on arterial blood pressure in adolescent and adult patients. Schräder R, et al. **Cathet Cardiovasc Diagn** 1995 Nov; 36(3):220-5
Gradual angioplasty and stent implantation to treat complete superior vena cava occlusion after Mustard procedure. Schranz D, et al. **Cathet Cardiovasc Diagn** 1996 May; 38(1):87-90; discussion 91
Geometric remodeling [letter; comment] Currier JW, et al. **Circulation** 1995 Dec 15;92(12):3581-3. Comment on: Circulation 1994 Dec;90(6):3001-8.
Quantitative echocardiographic analysis of the aortic arch predicts outcome of balloon angioplasty of native coarctation of the aorta. Kaine SF, et al. **Circulation** 1996 Sep 1;94(5):1056-62
Images in cardiovascular medicine. Percutaneous balloon angioplasty with adjunctive stent placement in the mesenteric vessels in a patient with Takayasu's arteritis. Ozdil E, et al. **Circulation** 1996 May 15;93(10):1940-1
Peripheral artery recanalization in humans using balloon and laser angioplasty. Barbeau GR, et al. **Clin Cardiol** 1996 Mar; 19(3):232-8
Case report: iliac artery rupture--percutaneous treatment by stent insertion. Kelly AJ. **Clin Radiol** 1995 Dec; 50(12):876-7
A coronary porcine organ culture system for studies of postangioplasty cell proliferation. Voisard R, et al. **Coron Artery Dis** 1995 Aug;6(8):657-65
Percutaneous revascularization in peripheral arterial disease. Rosenfield K, et al. **Curr Probl Cardiol** 1996 Jan;21(1):7-93 (228 ref.)
Quality of life following percutaneous transluminal angioplasty for claudication. Cook TA, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):191-4
No additional benefit from laser in balloon angioplasty of the superficial femoral artery. Fisher CM, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):349-52
Intravascular ultrasound predictors of outcome after peripheral balloon angioplasty. Gussenhoven EJ, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):279-88
Percutaneous transluminal angioplasty of the infrarenal aorta: initial outcome and long-term clinical and angiographic results. Hedeman Joosten PP, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):201-6
Superior mesenteric artery occlusion treated with PTA and stent placement. Lindblad B, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):493-5
New concepts of the renin-angiotensin system--implications for vascular and endovascular surgery. O'Donohoe MK, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):393-401 (117 ref.)
Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial. Perkins JM, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):409-13
Randomised controlled trial of percutaneous transluminal angioplasty for intermittent claudication. Whyman MR, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):167-72
Percutaneous transluminal angioplasty of subclavian stenosis to improve inflow to internal mammary coronary arterial grafts. Wallis F, et al. **Eur Radiol** 1996;6(2):220-3
Percutaneous transluminal renal angioplasty in patients with renovascular hypertension: long-term results. Karagiannis A, et al. **Hypertens Res** 1995 Mar;18(1):27-31
An unusually hard lesion in an aortocoronary saphenous vein graft refractory to standard balloon angioplasty. Kyriakidis M, et al. **Int J Cardiol** 1995 Nov 24;52(2):115-7
A prescreening system for potential antiproliferative agents: implications for local treatment strategies of postangioplasty restenosis. Voisard R, et al. **Int J Cardiol** 1995 Aug;51(1):15-28
The various therapeutic approaches to aortic coarctation: is it fair to compare? [editorial; comment] Hanley FL. **J Am Coll Cardiol** 1996 Feb;27(2):471-2. Comment on: J Am Coll Cardiol 1996 Feb;27(2):462-70.
Five- to nine-year follow-up results of balloon angioplasty of native aortic coarctation in infants and children [see comments] Rao PS, et al. **J Am Coll Cardiol** 1996 Feb; 27(2):462-70. Comment in: J Am Coll Cardiol 1996 Feb;27(2):471-2.
Cervical carotid artery stenosis: which technique, balloon angioplasty or surgery? Bergeron P, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):73-5
Cervical carotid artery stenosis: which technique, balloon angioplasty or surgery? Bergeron P, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:73-5
Long-term results with a Palmaz stent in the femoropopliteal arteries. Chatelard P, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:67-72
Endovascular recanalization of the aorto-iliac segment: imaging and approaches. Criado FJ. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:51-7
Results of transluminal angioplasty of infra-popliteal arteries. Favre JP, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:33-7
Angioplasty of distal venous bypasses: is it worth the cost? Favre JP, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:59-65
Results of transluminal angioplasty of infra-popliteal arteries. Favre JP, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):33-7
Angioplasty of distal venous bypasses: is it worth the cost? Favre JP, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):59-65
Carotid angioplasty and stenting: will periprocedural transcranial Doppler monitoring be important? Benichou H, et al. **J Endovasc Surg** 1996 May;3(2):217-23
Sigmoid sinus thrombosis associated with internal jugular venous occlusion: direct thrombolytic treatment. Gurley MB, et al. **J Endovasc Surg** 1996 Aug;3(3):306-14
Intravascular ultrasound assessment in carotid interventions. Reid DB, et al. **J Endovasc Surg** 1996 May;3(2):203-10 (9 ref.)
Carotid angioplasty: a word of caution [letter] Welch HJ. **J Endovasc Surg** 1996 Aug;3(3):359-60
Balloon angioplasty significantly increases collagen content but does not alter collagen subtype I/III ratios in the atherosclerotic rabbit iliac model. Coats WD Jr, et al. **J Mol Cell Cardiol** 1996 Feb;28(2):441-6
Vertebral artery stenting following percutaneous transluminal angioplasty. Technical note. Storey GS, et al. **J Neurosurg** 1996 May;84(5):883-7
An audit of percutaneous transluminal angioplasties in the treatment of lower limb ischaemia in a district general hospital over a period of 10 years. Heath DI, et al. **J R Coll Surg Edinb** 1996 Apr;41(2):108-13
Percutaneous endovascular covered stenting of a distal superficial femoral artery occlusion. Goodwin AT, et al. **J R Soc Med** 1995 Aug;88(8):477P-478P
Posttraumatic Budd-Chiari syndrome treated with thrombolytic therapy and angioplasty. Patel NH, et al. **J Trauma** 1996 Feb;40(2):294-8
Angioplasty for the treatment of visceral ischemia. Hallisey MJ, et al. **J Vasc Interv Radiol** 1995 Sep-Oct;6(5):785-91 (26 ref.)
Thrombolytic therapy compared with mechanical recanalization in non-acute peripheral arterial occlusions: a randomized trial. Meyerovitz MF, et al. **J Vasc Interv Radiol** 1995 Sep-Oct;6(5):775-81
Hepatic artery angioplasty after liver transplantation: experience in 21 allografts. Orons PD, et al. **J Vasc Interv Radiol** 1995 Jul-Aug;6(4):523-9
Thrombogenicity of the human arterial wall after interventional thermal injury. Post MJ, et al. **J Vasc Res** 1996 Mar-Apr;33(2):156-63
Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Sarembock IJ, et al. **J Vasc Res** 1996 Jul-Aug;33(4):308-14
Mesenteric angioplasty in the treatment of chronic intestinal ischemia. Allen RC, et al. **J Vasc Surg** 1996 Sep; 24(3):415-21; discussion 421-3
Regarding "should percutaneous transluminal angioplasty be recommended for treatment of infrageniculate popliteal artery or tibioperoneal trunk stenosis?" [letter] Bell PR, et al. **J Vasc Surg** 1996 Aug;24(2):298-9
Regarding "Endovascular arterial intervention: expression of concern" [letter; comment] Gibbs BF. **J Vasc Surg** 1996 Mar;23(3):541-2. Comment on: J Vasc Surg 1995 Jun;21(6):995-7.
Regarding "percutaneous transluminal angioplasty for emboligenic arterial lesions after radiotherapy of axillary arteries" [letter] Lorenzi G, et al. **J Vasc Surg** 1996 Aug; 24(2):297-8
Does donor iliac artery percutaneous transluminal angioplasty or stent placement influence the results of femorofemoral bypass? Analysis of 70 consecutive cases with long-term follow-up. Perler BA, et al. **J Vasc Surg** 1996 Sep;24(3):363-9; discussion 369-70
Retrograde iliofemoral endarterectomy facilitated by balloon angioplasty. Queral LA, et al. **J Vasc Surg** 1995 Dec; 22(6):742-8; discussion 748-50
Iliac artery stenoses after percutaneous transluminal angioplasty: follow-up with dupiex ultrasonography. Spijkerboer AM, et al. **J Vasc Surg** 1996 Apr;23(4):691-7
Efficacy of balloon angioplasty of the superficial femoral artery and popliteal artery in the relief of leg ischemia. Stanley B, et al. **J Vasc Surg** 1996 Apr;23(4):679-85
Should percutaneous transluminal angioplasty be recommended for treatment of infrageniculate popliteal artery or tibioperoneal trunk stenosis? Treiman GS, et al. **J Vasc Surg** 1995 Oct;22(4):457-63; discussion 464-5
Angiographic assessment of the stretch-recoil-gain relation after balloon coarctation angioplasty and its relation to late restenosis. Ino T, et al. **Jpn Circ J** 1996 Feb;60(2):102-7
Angioplasty for lower-limb ischaemia: time for randomised controlled trials [see comments] Bradbury AW, et al. **Lancet** 1996 Feb 3;347(8997):277-8. Comment in: Lancet 1996 Mar 23;347(9004):830.
Emergency percutaneous carotid stenting during stroke [letter] Shawl FA. **Lancet** 1995 Nov 4;346(8984):1223
Reversal of the nephrotic syndrome due to renovascular hypertension by successful percutaneous angioplasty and stenting. Ben-Chitrit S, et al. **Nephrol Dial Transplant** 1995; 10(8):1460-1
Acute thrombolytic therapy and subsequent angioplasty for atherosclerotic stenosis of the basilar artery--case report. Nakano S, et al. **Neurol Med Chir (Tokyo)** 1995 Sep; 35(9):674-7
Intravascular ultrasonography of supra-aortic arteries as an adjunct to percutaneous transluminal angioplasty. Hirai T, et al. **Neuroradiology** 1995 Jul;37(5):395-9
Balloon angioplasty immediately after surgical clipping for symptomatic vasospasm on admission. Report of four cases. Fujii Y, et al. **Neurosurg Rev** 1995;18(2):79-84
Effect of balloon angioplasty on high grade symptomatic vasospasm after subarachnoid hemorrhage. Fujii Y, et al. **Neurosurg Rev** 1995;18(1):7-13
Percutaneous transluminal balloon angioplasty of abdominal aortic coarctation in an infant. Adwani S, et al. **Pediatr Cardiol** 1996 Sep-Oct;17(5):346-8
Magnetic resonance imaging demonstration of "remodeling" of the aorta following balloon angioplasty of discrete native coarctation. Weber HS, et al. **Pediatr Cardiol** 1996 May-Jun;17(3):184-8
Percutaneous transluminal renal angioplasty in neurofibromatosis. Fossali E, et al. **Pediatr Nephrol** 1995 Oct;9(5):623-5
Infrapopliteal percutaneous transluminal angioplasty: what we know [comment] Bakal CW, et al. **Radiology** 1996 Jul; 200(1):36-43 (58 ref.). Comment on: Radiology 1996 Jul;200(1):33-6.
Percutaneous transluminal angioplasty of the infrapopliteal vessels: the evidence [see comments] Fraser SC, et al. **Radiology** 1996 Jul;200(1):33-6 (44 ref.). Comment in: Radiology 1996 Jul;200(1):36-43.
Iliac artery patency before and immediately after percutaneous transluminal angioplasty: assessment with time-of-flight MR angiography. Laissy JP, et al. **Radiology** 1995 Nov;197(2):455-9
Cerebral vasospastic vessels: histologic changes after percutaneous transluminal angioplasty. Ohkawa M, et al. **Radiology** 1996 Jan;198(1):179-84
Outcome of percutaneous intervention in iliac artery stents. Sapoval MR, et al. **Radiology** 1996 Feb;198(2):481-6
Aortic and iliac stenoses: follow-up results of stent placement after insufficient balloon angioplasty in 118 cases. Vorwerk D, et al. **Radiology** 1996 Jan;198(1):45-8
Late reobstruction in iliac arterial stents: percutaneous treatment. Vorwerk D, et al. **Radiology** 1995 Nov; 197(2):479-83
Options for therapy of ischemic nephropathy: role of angioplasty and surgery. Novick AC. **Semin Nephrol** 1996 Jan;16(1):53-60 (61 ref.)
The influence of surgical insults on restenosis after transluminal balloon angioplasty. Yasuhara H, et al. **Surg Today** 1995;25(10):897-900
Percutaneous transluminal angioplasty in a transplanted kidney with fibromuscular dysplasia [letter] Surlan M, et al. **Transpl Int** 1996;9(1):86-7
Percutaneous transluminal angioplasty for transplant renal artery stenosis. Lo CY, et al. **Transplant Proc** 1996 Jun; 28(3):1468-9
Percutaneous transluminal angioplasty for renovascular hypertension 9 years after hypoplastic kidney transplantation: report of a case. Saito K, et al. **Transplant Proc** 1996 Jun;28(3):1595-7
[Angioplasty for subclavian artery stenosis: report of two cases] Fang BR, et al. **J Formos Med Assoc** 1995 Jun;94 Suppl 1:S50-3 (Eng. Abstr.) **(Chi)**
[Evaluation, by flow cytometry, of activated platelet levels after coronarography and intraluminal angioplasty] Teysseire N, et al. **Ann Biol Clin (Paris)** 1995;53(3):135-40 (Eng. Abstr.) **(Fre)**
[Value of percutaneous carotid angioplasty before cardiac surgery] Babatasi G, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jan;45(1):24-9 (Eng. Abstr.) **(Fre)**
[Endovascular treatment of vasospasm] Bracard S, et al. **Ann Fr Anesth Reanim** 1996;15(3):382-6 (Eng. Abstr.) **(Fre)**
[Percutaneous closure of patent ductus arteriosus: results and costs compared to surgical closure] Vieu T, et al. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1431-5 (Eng. Abstr.) **(Fre)**
[Renal revascularization for kidney salvage or preservation] Van Damme H, et al. **Rev Med Liege** 1996 Feb;51(2):175-86 (47 ref.) **(Fre)**
[Percutaneous local thrombolytic therapy and thrombectomy in occlusion of extremity arteries] Schneider E, et al. **Internist (Berl)** 1996 Jun;37(6):607-12 (23 ref.) **(Ger)**
[Percutaneous transluminal angioplasty (PTA) of isolated crural arterial stenoses in critical arterial occlusive disease]

Häuser H, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Mar;164(3):238–43 (Eng. Abstr.) **(Ger)**

[The initial results of percutaneous therapy of popliteal aneurysms with stents] Link J, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Mar;164(3):244–8 (Eng. Abstr.) **(Ger)**

[Therapy of coronary steal syndrome by percutaneous transluminal angioplasty] Voges E, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995 Sep;163(3):269–70 **(Ger)**

[Initial experiences with dilatation of dialysis shunts with color-coded duplex ultrasonography monitoring] Wittenberg G, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Jan;164(1):38–41 (Eng. Abstr.) **(Ger)**

[Transfemoral fenestration and stent implantation in aorto-iliac dissection] Farber A, et al. **Vasa** 1995; 24(4):389–91 (Eng. Abstr.) **(Ger)**

[Leriche syndrome: treatment with local lysis and subsequent percutaneous transluminal angioplasty] Katzenschlager R, et al. **Vasa** 1996;25(2):180–3 (Eng. Abstr.) **(Ger)**

[Quality of life after an episode of myocardial infarct] Borrello G, et al. **Minerva Cardioangiol** 1995 Jul–Aug; 43(7–8):315–27 (39 ref.) (Eng. Abstr.) **(Ita)**

[Usefulness of the 201TlCl exercise leg perfusion scintigraphy inarteriosclerosis obliterans (ASO)—with evaluation of leg perfusion comparing before and after PTA] Kijima T, et al. **Kaku Igaku** 1995 Sep;32(9):935–41 (Eng. Abstr.) **(Jpn)**

[The effect on higher cortical dysfunction of percutaneous transluminal angioplasty for internal carotid artery stenosis] Maeshima S, et al. **No Shinkei Geka** 1995 Nov;23(11):971–6 (Eng. Abstr.) **(Jpn)**

[Percutaneous transluminal angioplasty. An efficient alternative in the treatment of peripheral obstructive arteriopathy] Kisileczky N, et al.
Rev Hosp Clin Fac Med Sao Paulo 1995 Jul–Aug; 50(4):185–8 (Eng. Abstr.) **(Por)**

[Percutaneous transluminal angioplasty of the vena cava inferior] Ledesma Velasco M, et al.
Arch Inst Cardiol Mex 1995 May–Jun;65(3):255–9 (7 ref.) (Eng. Abstr.) **(Spa)**

[Percutaneous transluminal angioplasty with a balloon catheter in native aortic coarctation: long-term experience] Palacios Rodríguez JM, et al. **Arch Inst Cardiol Mex** 1995 May–Jun;65(3):237–44 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Asymptomatic peripheral embolism during balloon angioplasty [letter; comment] Abraham P, et al.
AJR Am J Roentgenol 1996 May;166(5):1230–1. Comment on: AJR Am J Roentgenol 1995 Jun;164(6):1516–8.

Re: Atheromatous macroembolism after balloon angioplasty of the superficial femoral artery [letter; comment] Murphy TP. **AJR Am J Roentgenol** 1996 Jan;166(1):219. Comment on: AJR Am J Roentgenol 1995 Jun;164(6):1516–8.

Angioplasty-induced pseudoaneurysm successfully treated with a Palmaz stent. A case report. Castañeda F, et al. **Angiology** 1995 Nov;46(11):1021–5

Synergistic inhibitory effect of angiotensin-converting enzyme inhibitor and heparin on intimal hyperplasia after rat aorta injury. Park JS, et al. **Angiology** 1996 Jan; 47(1):9–14

Role of intimal hyperplasia and arterial remodeling after balloon angioplasty: an experimental study in the atherosclerotic rabbit model. Guzman LA, et al.
Arterioscler Thromb Vasc Biol 1996 Mar;16(3):479–87

Kinetics of smooth muscle cell proliferation and intimal thickening in a pig carotid model of balloon injury. Groves PH, et al. **Atherosclerosis** 1995 Sep;117(1):83–96

FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty. Seki J, et al. **Atherosclerosis** 1995 Sep;117(1):97–106

Spasms of the hepatic artery following percutaneous transluminal angioplasty and tolazoline administration in a liver transplant patient. Propst A, et al.
Cardiovasc Intervent Radiol 1996 May–Jun;19(3):181–3

Late development of dissecting aneurysm following balloon angioplasty of native aortic coarctation [see comments] Aydogan U, et al. **Cathet Cardiovasc Diagn** 1995 Nov; 36(3):226–9. Comment in: Cathet Cardiovasc Diagn 1995 Nov;36(3):230–1.

Balloon expandable stent implantation after iatrogenic arterial dissection of the left subclavian artery. Galli M, et al.
Cathet Cardiovasc Diagn 1995 Aug;35(4):355–7

Acute cyanosis following balloon angioplasty of residual arch obstruction after the Norwood I operation. Recto MR, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):72–4

Aneurysm associated with balloon angioplasty of aortic coarctation: future prevention and treatment [editorial; comment] Ruiz CE, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):230–1. Comment on: Cathet Cardiovasc Diagn 1995 Nov;36(3):226–9.

Fatal aortic rupture following balloon angioplasty of aortic restenosis in aortoarteritis. Sharma S, et al.
Cathet Cardiovasc Diagn 1995 Oct;36(2):132–3

In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Strauss BH, et al. **Circ Res** 1996 Sep; 79(3):541–50

Remodeling rather than neointimal formation explains luminal narrowing after deep vessel wall injury: insights from a porcine coronary (re)stenosis model. Andersen HR, et al. **Circulation** 1996 May 1;93(9):1716–24

Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Jang Y, et al. **Circulation** 1995 Nov 15;92(10):3041–50

Relation between activated clotting time during angioplasty and abrupt closure. Narins CR, et al. **Circulation** 1996 Feb 15;93(4):667–71

Effect of thrombin inhibition with desulfatohirudin on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits. Ragosta M, et al. **Circulation** 1996 Mar 15;93(6):1194–200

Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Speidel CM, et al. **Circulation** 1995 Dec 1;92(11):3323–30

Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Wilensky RL, et al. **Circulation** 1995 Nov 15; 92(10):2995–3005

Severe arterial bleeding after percutaneous transhepatic cholangiographic drainage. Born P, et al. **Endoscopy** 1995 May;27(4):343

Intentional extraluminal recanalisation of the femoropopliteal segment following perforation during percutaneous transluminal angioplasty. Nasim A, et al.
Eur J Vasc Endovasc Surg 1996 Aug;12(2):246–9

Inhibition of intimal hyperplasia in balloon injured arteries with adjunctive phthalocyanine sensitised photodynamic therapy. Nyamekye I, et al. **Eur J Vasc Endovasc Surg** 1996 Jan;11(1):19–28

Endothelin receptor subtypes in the pathogenesis of angioplasty-induced neointima formation in the rat: a comparison of selective ETA receptor antagonism and dual ETA/ETB receptor antagonism using BQ-123 and SB 209670. Douglas SA, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 3:S186–9

Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. Chang MW, et al. **J Clin Invest** 1995 Nov; 96(5):2260–8

Complications associated with extracranial carotid artery interventions. Dorros G. **J Endovasc Surg** 1996 May; 3(2):166–70 (15 ref.)

Infected iliac pseudoaneurysm after uncomplicated percutaneous balloon angioplasty and (Palmaz) stent insertion: a case report and literature review. Weinberg DJ, et al. **J Vasc Surg** 1996 Jan;23(1):162–6 (17 ref.)

Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Sluiter W, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):233–8 (44 ref.)

Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery. Chang MW, et al. **Mol Med** 1995 Jan;1(2):172–81

A case of renovascular hypertension with marked polyuria after percutaneous transluminal renal angioplasty. Tamatani M, et al. **Nephron** 1996;73(1):79–85

Successful surgical removal of partially expanded Palmaz stent from external iliac artery. Gersak B, et al.
Panminerva Med 1995 Jun;37(2):92–4

[Endovascular treatment of arteries with cerebral destination: failures and limits] Bergeron P, et al. **J Mal Vasc** 1996;21 Suppl A:123–31 (Eng. Abstr.) **(Fre)**

[The reduction of the extent of vascular lesions during angioplasty by the use of a sheath] Söldner J, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995 Oct;163(4):341–4 (Eng. Abstr.) **(Ger)**

[Displacement of the guidewire into the arterial system during machine-guided injection via a Y connector] Vogel H.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Feb;164(2):166–7 **(Ger)**

HISTORY

Angioplasty from bench to bedside to bench. King SB 3rd. **Circulation** 1996 May 1;93(9):1621–9

INSTRUMENTATION

Traumatic bilateral carotid-cavernous fistulas treated with detachable balloon. A case report. Kim JK, et al.
Acta Radiol 1996 Jan;37(1):46–8 (6 ref.)

Use of large-caliber coronary guiding catheters for neurointerventional applications. Putman CM, et al.
AJNR Am J Neuroradiol 1996 Apr;17(4):697–704

The 'gooseneck' concept in microvascular retrieval. Tytle TL, et al. **AJNR Am J Neuroradiol** 1995 Aug;16(7):1469–71

Use of a perfusion balloon angioplasty catheter during femoral artery angioplasty. Polak JF, et al.
AJR Am J Roentgenol 1995 Dec;165(6):1485–6

Re: Comparison of efficacy in crossing femoropopliteal artery occlusions with movable core and hydrophilic guidewires [letter; comment] Hartnell GG.
Cardiovasc Intervent Radiol 1995 Jul–Aug;18(4):274–5. Comment on: Cardiovasc Intervent Radiol 1994 Nov–Dec;17(6):319–22.

Budd-Chiari syndrome caused by obstruction of the hepatic inferior vena cava: immediate and 2-year treatment results of transluminal angioplasty and metallic stent placement. Xu K, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb; 19(1):32–6

Juxtaposed "kissing" stents as a technique to preserve both limbs of a bifurcating renal artery. Avula S, et al.
Cathet Cardiovasc Diagn 1995 Oct;36(2):143–5; discussion 146–7

Mitral dilatation with the Multi-Track system: an alternative approach. Bonhoeffer P, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):189–93

Kinetics of drug delivery to the arterial wall via polyurethane-coated removable nitinol stent: comparative study of two drugs. Dev V, et al.
Cathet Cardiovasc Diagn 1995 Mar;34(3):272–8

Localized drug delivery in atherosclerotic arteries via a new balloon angioplasty catheter with intramural channels for simultaneous local drug delivery. Hong MK, et al.
Cathet Cardiovasc Diagn 1995 Mar;34(3):263–70; discussion 271

Pure beta-particle-emitting stents inhibit neointima formation in rabbits. Hehrlein C, et al. **Circulation** 1996 Feb 15; 93(4):641–5

Angioplasty balloon compliance: can in vivo size be predicted from in vitro pressure profile measurements? More RS, et al. **Clin Cardiol** 1996 May;19(5):393–7

Removal of a ruptured angioplasty balloon catheter with use of a nitinol goose neck snare. Kirsch MJ, et al.
J Vasc Interv Radiol 1995 Jul–Aug;6(4):537–8

Thrombolysis and angioplasty of chronic iliac artery occlusions. Motarjeme A, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):66S–72S

Autoperfusion balloon catheter for treatment of vertebral artery stenosis. Sampei K, et al. **Neuroradiology** 1995 Oct; 37(7):561–3

Management of 100 consecutive direct carotid-cavernous fistulas: results of treatment with detachable balloons [letter; comment] Parkinson D. **Neurosurgery** 1995 Aug; 37(2):357. Comment on: Neurosurgery 1995 Feb;36(2):239–44; discussion 244–5.

Successful surgical removal of partially expanded Palmaz stent from external iliac artery. Gersak B, et al.
Panminerva Med 1995 Jun;37(2):92–4

Femoropopliteal and crural artery recanalization using subintimal angioplasty. Bolia A, et al. **Semin Vasc Surg** 1995 Sep;8(3):253–64

Haemorrhage due to laceration of an aberrant inferior epigastric artery during femoropopliteal PTA in an obese patient; a rare complication of a high antegrade femoral puncture. Lampmann LE, et al. **Vasa** 1995;24(4):382–4

Endovascular repair of abdominal aortic aneurysms using the EGS tube and bifurcated graft systems. Colburn MD, et al. **World J Surg** 1996 Jul–Aug;20(6):664–72 (44 ref.)

Options for treatment of persistent aneurysm perfusion after endovascular repair. Ivancev K, et al. **World J Surg** 1996 Jul–Aug;20(6):673–8

Indications and results of balloon angioplasty for arterial occlusive lesions. Kalman PG, et al. **World J Surg** 1996 Jul–Aug;20(6):630–4

Endovascular repair of aortic aneurysms, arteriovenous fistulas, and false aneurysms. Parodi JC. **World J Surg** 1996 Jul–Aug;20(6):655–63

Endovascular technology and its impact on the relationships among vascular surgeons, interventional radiologists, and other specialists. Veith FJ, et al. **World J Surg** 1996 Jul–Aug;20(6):687–91 (36 ref.)

[Endovascular reconstruction of infrarenal abdominal aortic aneurysm] Allenberg JR, et al. **Chirurg** 1995 Sep; 66(9):870–7 (24 ref.) (Eng. Abstr.) **(Ger)**

[The reduction of the extent of vascular lesions during angioplasty by the use of a sheath] Söldner J, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995 Oct;163(4):341–4 (Eng. Abstr.) **(Ger)**

[Displacement of the guidewire into the arterial system during machine-guided injection via a Y connector] Vogel H.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Feb;164(2):166–7 **(Ger)**

[Management of an iliac artery aneurysm with percutaneous placement of a Dacron-nitinol vascular endoprosthesis] Sievert H, et al. **Z Kardiol** 1995 Oct;84(10):860–2 (Eng. Abstr.) **(Ger)**

METHODS

What is the role of intraarterial vasodilators during angioplasty? Which and how much vasodilator should we use? Wittich GR. **AJR Am J Roentgenol** 1996 May; 166(5):1225

Percutaneous renal artery stent placement for hypertension and azotemia: pilot study. Rundback JH, et al.
Am J Kidney Dis 1996 Aug;28(2):214–9

Open operative balloon angioplasty of the internal carotid artery: a technique in evolution. Ballard JL, et al.
Ann Vasc Surg 1995 Jul;9(4):390–3

Carbon dioxide/digital subtraction arteriography-assisted transluminal angioplasty. Frankhouse JH, et al.
Ann Vasc Surg 1995 Sep;9(5):448–52

Percutaneous transluminal angioplasty for lower-limb critical ischaemia [see comments] London NJ, et al. **Br J Surg** 1995 Sep;82(9):1232–5. Comment in: Br J Surg 1996 Jan;83(1):135–6.

Clinical outcome and restenosis following percutaneous transluminal angioplasty for ischaemic rest pain or ulceration [see comments] Ray SA, et al. **Br J Surg** 1995 Sep;82(9):1217–21. Comment in: Br J Surg 1996 Jan;83(1):135–6.

"Kissing-balloon" technique for abdominal aorta angioplasty. Initial results and long term outcome. Sagic D, et al. **Int Angiol** 1995 Dec;14(4):364–7

Endovascular recanalization of the aorto-iliac segment: imaging and approaches. Criado FJ. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):51–7

Principles of angioplasty guidance using ultrasound. Ramaswami G, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37 Suppl 1:27–31

Carotid angioplasty and stenting: is endovascular treatment for cerebrovascular disease justified [editorial] Bergeron P. **J Endovasc Surg** 1996 May;3(2):129–31 (12 ref.)

Indications for carotid artery stenting: a preview of the potential derived from early clinical experience [editorial] Diethrich EB. **J Endovasc Surg** 1996 May;3(2):132–9 (15 ref.)

Percutaneous techniques for endoluminal carotid interventions. Diethrich EB, et al. **J Endovasc Surg** 1996 May;3(2):182–202 (8 ref.)

Anesthesia for carotid stent procedures. Kharrazi MR. **J Endovasc Surg** 1996 May;3(2):211–6 (8 ref.)

Percutaneous transluminal angioplasty of supra-aortic vessels. Motarjeme A. **J Endovasc Surg** 1996 May; 3(2):171–81

Percutaneous treatment of aortoiliac atherosclerosis: a case report. Maynar M, et al. **J La State Med Soc** 1996 Jan; 148(1):24–7

Transluminal angioplasty for arteriosclerotic disease of the distal vertebral and basilar arteries. Terada T, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):377–81

Percutaneous removal of a misplaced Palmaz stent with a coaxial snare technique. Hartnell GG, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):799–801

Treatment of renovascular hypertension: one year results of renal angioplasty. Jensen G, et al. **Kidney Int** 1995 Dec; 48(6):1936–45

Femoropopliteal artery: initial and 6-month results of color duplex US-guided percutaneous transluminal angioplasty [see comments] Katzenschlager R, et al. **Radiology** 1996 May;199(2):331–4. Comment in: Radiology 1996 May;199(2):317–8.

Femoropopliteal angioplasty with US guidance: an example of a niche market [editorial; comment] Polak JF. **Radiology** 1996 May;199(2):317–8. Comment on: Radiology 1996 May;199(2):331–4.

Interventional thermal injury of the arterial wall: unfolding of von Willebrand factor and its increased binding to collagen after 55 degrees C heating. Post MJ, et al. **Thromb Haemost** 1996 Mar;75(3):515–9

[Evolution of serum creatinine level 48 hours after angioplasty for renal artery stenosis in 91 patients] Boyer L, et al. **Ann Radiol (Paris)** 1995;38(7–8):447–50 (Eng. Abstr.) **(Fre)**

[Value of interventional angiology in carotid stenosis] Zanella FE. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2046–52 (33 ref.) (Eng. Abstr.) **(Ger)**

[Percutaneous transluminal angioplasty in the treatment of iliac stenosis. The authors' new guideline for 100 patients] Maspes F, et al. **Radiol Med (Torino)** 1995 Dec;90(6):772–80 (Eng. Abstr.) **(Ita)**

[Transcutaneous balloon angioplasty in the treatment of subclavian steal syndrome. Characteristics of vertebral basal flow with transcranial Doppler technique] Malek AK, et al. **Pol Tyg Lek** 1995 Oct;50(40–44):19–22 (Eng. Abstr.) **(Pol)**

[Ischemic complications of dissecting aneurysm of the aorta. Treatment with percutaneous stents and fenestration] Nyman U, et al. **Lakartidningen** 1996 Feb 14;93(7):577–82 **(Swe)**

NURSING

Patient preparation and monitoring for carotid stenting: the operating room nurse's perspective. Plat S, et al. **J Endovasc Surg** 1996 May;3(2):224–7 (6 ref.)

STANDARDS

[Percutaneous transluminal angioplasty of the iliac arteries: methodological and technical innovation and the need for standard guidelines] Maspes F, et al. **Radiol Med (Torino)** 1995 Dec;90(6):781–8 **(Ita)**

UTILIZATION

Angioplasty for intermittent claudication [letter; comment] Vanmaele RG. **Lancet** 1996 Mar 23;347(9004):830. Comment on: Lancet 1996 Feb 3;347(8997):277–8.

ANGIOPLASTY, BALLOON, CORONARY see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

ANGIOPLASTY, BALLOON, LASER-ASSISTED

Usefulness of a prototype directional catheter for excimer laser coronary angioplasty in narrowings unfavorable for conventional excimer or balloon angioplasty. Rechavia E, et al. **Am J Cardiol** 1995 Dec 1;76(16):1144–6

Mechanisms of lumen enlargement after excimer laser coronary angioplasty. An intravascular ultrasound study. Mintz GS, et al. **Circulation** 1995 Dec 15;92(12):3408–14

Holmium laser-assisted coronary angioplasty in acute ischemic syndromes. de Marchena E, et al. **Clin Cardiol** 1996 Apr;19(4):315–9

No additional benefit from laser in balloon angioplasty of the superficial femoral artery. Fisher CM, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):349–52

Do excimer laser angioplasty and rotational atherectomy facilitate balloon angioplasty? Implications for lesion-specific coronary intervention. Safian RD, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):552–9

Immediate and late outcome of excimer laser and balloon coronary angioplasty: a quantitative angiographic comparison based on matched lesions. Strikwerda S, et al. **J Am Coll Cardiol** 1995 Oct;26(4):939–46

Nd:Yag laser-assisted balloon angioplasty of superficial femoral artery occlusions in a diabetic population. Field CK, et al. **J Diabetes Complications** 1995 Jul–Sep;9(3):186–9

Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease. Appelman YE, et al. **Lancet** 1996 Jan 13; 347(8994):79–84

[Progresses in laser medicine in China, 1995] Xu S. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):774–6 (0 ref.) **(Chi)**

[Excimer laser assisted angioplasty. Immediate results in the treatment of complex coronary lesions] Escojido H, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):407–15 (29 ref.) (Eng. Abstr.) **(Fre)**

[The popliteal artery entrapment syndrome in an older patient. Its diagnosis after unsuccessful laser-assisted percutaneous transluminal angioplasty] Bail DH, et al. **Dtsch Med Wochenschr** 1996 Mar 15;121(11):336–40 (18 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Comparison of tissue disruption caused by excimer and midinfrared lasers in clinical simulation. Quan KJ, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):50–5

ECONOMICS

A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. Sculpher M, et al. **Int J Technol Assess Health Care** 1996 Winter;12(1):104–25

INSTRUMENTATION

Laser for optical thrombolysis and facilitation of balloon angioplasty in acute myocardial infarction following failed pharmacologic thrombolysis. Topaz O, et al. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):38–42

Whose fault is it? Notes on "true" versus "pseudo" laser failure [editorial] Topaz O. **Cathet Cardiovasc Diagn** 1995 Sep; 36(1):1–4

[PTCA or alternative techniques? Balloon angioplasty remains dominant] Reifart N. **Z Kardiol** 1995;84 Suppl 2:43–52 (30 ref.) (Eng. Abstr.) **(Ger)**

METHODS

New devices in interventional cardiology: present and future. Beyar R. **Isr J Med Sci** 1996 Jul;32(7):515–25 (42 ref.)

ANGIOPLASTY, CORONARY BALLOON see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

ANGIOPLASTY, EXCIMER LASER see **ANGIOPLASTY, BALLOON, LASER-ASSISTED**

ANGIOPLASTY, LASER

Peripheral artery recanalization in humans using balloon and laser angioplasty. Barbeau GR, et al. **Clin Cardiol** 1996 Mar; 19(3):232–8

Cardiac allograft vasculopathy: the potential role for transmyocardial laser revascularization. March RJ, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S242–6

Excimer laser induced bubble: dimensions, theory, and implications for laser angioplasty. van Leeuwen TG, et al. **Lasers Surg Med** 1996;18(4):381–90

[Radiation exposure in interventional radiology as exemplified by the chemoembolization of hepatocellular carcinoma and laser angioplasty of the pelvic arteries] Hidajat N, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):249–56 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Effect of intracoronary saline infusion on dissection during excimer laser coronary angioplasty: a randomized trial. The Percutaneous Excimer Laser Coronary Angioplasty (PELCA) Investigators. Deckelbaum LI, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1264–9

INSTRUMENTATION

Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups [see comments] Foley DP, et al. **Eur Heart J** 1995 Oct; 16(10):1331–46. Comment in: Eur Heart J 1995 Oct;16(10):1307–8.

METHODS

[In vitro studies on pulsed laser angioplasty in liquid and gaseous medium] Zwaan M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jan;164(1):68–71 (Eng. Abstr.) **(Ger)**

ANGIOPLASTY, LASER-ASSISTED, BALLOON see **ANGIOPLASTY, BALLOON, LASER-ASSISTED**

ANGIOPLASTY, TRANSLUMINAL see **ANGIOPLASTY, BALLOON**

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY

Radiation-induced skin injury after percutaneous transluminal coronary angioplasty. Case report. Søvik E, et al. **Acta Radiol** 1996 May;37(3 Pt 1):305–6

Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Abdelmeguid AE, et al. **Am Heart J** 1996 Jun; 131(6):1097–105

Effect of percutaneous transluminal coronary angioplasty on exercise ventilation in patients with coronary artery disease and normal left ventricular function. Ajisaka R, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):48–53

Bailout stenting for extensive dissection complicating direct infarct angioplasty. Altmann DB, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):191–2

Reduction in angioplasty complications after the introduction of coronary stents: results from a consecutive series of 2242 patients. Altmann DB, et al. **Am Heart J** 1996 Sep; 132(3):503–7

Traumatic occlusion of the right coronary artery resulting in cardiogenic shock successfully treated with primary angioplasty. Bokelman TA, et al. **Am Heart J** 1996 Feb; 131(2):411–3

Multiple early percutaneous transluminal coronary angioplasty failures related to lupus anticoagulant. Chambers JD Jr, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):189–90

Roles of percutaneous transluminal coronary angioplasty and bypass graft surgery for the treatment of coronary artery disease. Cishek MB, et al. **Am Heart J** 1996 May; 131(5):1012–7 (58 ref.)

Angiographic presence of myocardial bridge after successful percutaneous transluminal coronary angioplasty. Colleran JA, et al. **Am Heart J** 1996 Jan;131(1):196–8

Management of restenosis after coronary intervention. Dangas G, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):428–36 (58 ref.)

Comparison of elective Wiktor stent placement with conventional balloon angioplasty for new-onset lesions of the right coronary artery. Eeckhout E, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):263–8

Unplanned use of intracoronary stents for the treatment of a suboptimal angiographic result after conventional balloon angioplasty. Eeckhout E, et al. **Am Heart J** 1995 Dec; 130(6):1164–7

Influence of plaque composition on mechanisms of percutaneous transluminal coronary balloon angioplasty assessed by ultrasound imaging. Gil R, et al. **Am Heart J** 1996 Mar;131(3):591–7

Acute changes in atrial natriuretic peptide, insulin-like growth factor-1, and lactate levels during left anterior descending coronary artery angioplasty. Gill JS, et al. **Am Heart J** 1995 Oct;130(4):717–22

Rotational atherectomy with adjunctive balloon angioplasty versus conventional percutaneous transluminal coronary angioplasty in type B2 lesions: results of a randomized study. Guérin Y, et al. **Am Heart J** 1996 May;131(5):879–83

Serial changes of plasma plasminogen activator inhibitor activity in acute myocardial infarction: difference between thrombolytic therapy and direct coronary angioplasty. Hirashima O, et al. **Am Heart J** 1995 Nov;130(5):933–9

Influence of percutaneous transluminal coronary rotational atherectomy with adjunctive percutaneous transluminal coronary angioplasty on coronary blood flow. Khoury AF, et al. **Am Heart J** 1996 Apr;131(4):631–8

Clinical use of posterior electrocardiographic leads: a prospective electrocardiographic analysis during coronary occlusion. Kulkarni AU, et al. **Am Heart J** 1996 Apr; 131(4):736–41

Decreased free radical scavengers with reperfusion after coronary angioplasty in patients with acute myocardial infarction. Lafont A, et al. **Am Heart J** 1996 Feb; 131(2):219–23

Stand-alone stenting of the left main coronary artery and 16-month patency despite sepsis and complicated hospital course. Lee S, et al. **Am Heart J** 1995 Dec;130(6):1289–92

Influence of plaque composition on luminal gain after balloon angioplasty, directional atherectomy, and coronary stenting. Marsico F, et al. **Am Heart J** 1995 Nov;

130(5):971–5
Periprocedural Doppler coronary blood flow predictors of myocardial perfusion abnormalities and cardiac events after successful coronary interventions. Miller DD, et al. **Am Heart J** 1996 Jun;131(6):1058–66
High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Miyata M, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):269–73
Distal coronary flow velocity immediately after direct angioplasty for acute myocardial infarction. Nakamura M, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):251–7
Microparticle deposition in periarterial microvasculature and intramural dissections after porous balloon delivery into atherosclerotic vessels: quantitation and localization by confocal scanning laser microscopy. Nasser TK, et al. **Am Heart J** 1996 May;131(5):892–8
Correlation of regional wall motion abnormalities detected by two-dimensional echocardiography with perfusion defect determined by technetium 99m sestamibi imaging in patients treated with reperfusion therapy during acute myocardial infarction. Oh JK, et al. **Am Heart J** 1996 Jan; 131(1):32–7
Feasibility and effectiveness of repeated balloon dilatation of restenosed congenital obstructions after previous balloon valvuloplasty/angioplasty. Rao PS, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):403–7
Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Sakata K, et al. **Am Heart J** 1996 Jan;131(1):1–6
Acute stent thrombosis associated with exercise testing after successful percutaneous transluminal coronary angioplasty. Samuels B, et al. **Am Heart J** 1995 Nov;130(5):1120–2 (15 ref.)
Influence of vessel dilatation on restenosis after successful percutaneous transluminal coronary angioplasty. Schmitz HJ, et al. **Am Heart J** 1996 May;131(5):884–91
Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Smith AJ, et al. **Am Heart J** 1996 Mar;131(3):434–9
Cyclic flow variations after angioplasty: a rare phenomenon predictive of immediate complications. DEBATE Investigator's Group. Sunamura M, et al. **Am Heart J** 1996 May;131(5):843–8
Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions. Terres W, et al. **Am Heart J** 1995 Oct;130(4):711–6
Superoxide dismutase activity as a predictor of myocardial reperfusion and salvage in acute myocardial infarction. Tomoda H, et al. **Am Heart J** 1996 May;131(5):849–56
Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Watanabe K, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):23–9
Risk factors for restenosis after percutaneous transluminal coronary angioplasty: role of lipoprotein (a). Yamamoto H, et al. **Am Heart J** 1995 Dec;130(6):1168–73
Electron-beam computed tomographic detection of coronary calcification in patients undergoing percutaneous transluminal coronary angioplasty: predictability of restenosis. A preliminary report. Stanford W, et al. **Am J Card Imaging** 1995 Oct;9(4):257–60
Effect of beta blockade on heart rate variability during vessel occlusion at the time of coronary angioplasty. Airaksinen KE, et al. **Am J Cardiol** 1996 Jan 1;77(1):20–4
Direct angioplasty and stenting of the infarct-related artery in acute myocardial infarction. Antoniucci D, et al. **Am J Cardiol** 1996 Sep 1;78(5):568–71
Impact of plaque morphology and composition on the mechanisms of lumen enlargement using intracoronary ultrasound and quantitative angiography after balloon angioplasty. Baptista J, et al. **Am J Cardiol** 1996 Jan 15; 77(2):115–21
Progression in nondilated sites and restenosis: a time-dependent relation [letter] Bonnet J, et al. **Am J Cardiol** 1996 Aug 1;78(3):379–80
Angiographic correlates of lesion relevance and suitability for percutaneous transluminal coronary angioplasty and coronary artery bypass grafting in the Bypass Angioplasty Revascularization Investigation study (BARI). Botas J, et al. **Am J Cardiol** 1996 Apr 15;77(10):805–14
Effect of reperfusion modality on outcome in nonsmokers and smokers with acute myocardial infarction (a Primary Angioplasty in Myocardial Infarction [PAMI] substudy). PAMI Investigators. Bowers TR, et al. **Am J Cardiol** 1996 Sep 1;78(5):511–5
Stent jail: a minimum-security prison. Caputo RP, et al. **Am J Cardiol** 1996 Jun 1;77(14):1226–9
Incidence and treatment of elastic recoil occurring in the 15 minutes following successful percutaneous transluminal coronary angioplasty. Daniel WC, et al. **Am J Cardiol** 1996 Aug 1;78(3):253–9
Percutaneous balloon dilatation of aortic coarctation in adults. deGiovanni JV, et al. **Am J Cardiol** 1996 Feb 15; 77(5):435–9
Value of visual versus central quantitative measurements of angiographic success after percutaneous transluminal coronary angioplasty. NHLBI PTCA Registry Investigators. Faxon DP, et al. **Am J Cardiol** 1996 May 15;77(12):1067–72
Elective percutaneous transluminal coronary angioplasty after acute myocardial infarction: is later better? Flood RD Jr, et al. **Am J Cardiol** 1995 Nov 1;76(12):966–7
Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty. Freed M, et al. **Am J Cardiol** 1995 Dec 1; 76(16):1185–8
Effect of delayed percutaneous transluminal coronary angioplasty of occluded coronary arteries after acute myocardial infarction. Garot J, et al. **Am J Cardiol** 1996 May 1;77(11):915–21
Uncomplicated successful percutaneous transluminal coronary angioplasty does not affect cardiac troponin T plasma concentrations [letter] Genser N, et al. **Am J Cardiol** 1996 Jul 1;78(1):127–8
Evidence for free radical generation after primary percutaneous transluminal coronary angioplasty recanalization in acute myocardial infarction. Grech ED, et al. **Am J Cardiol** 1996 Jan 15;77(2):122–7
Aggressive intervention for myocardial infarction: angioplasty, stents, and intra-aortic balloon pumping. Grines CL. **Am J Cardiol** 1996 Aug 14;78(3A):29–34
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Harrington RA, et al. **Am J Cardiol** 1995 Dec 15;76(17):1222–7
Postischemic functional recovery and BMIPP uptake after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction. Hashimoto A, et al. **Am J Cardiol** 1996 Jan 1;77(1):25–30
Dobutamine stress echocardiography predicts early wall motion improvement after elective percutaneous transluminal coronary angioplasty. Kao HL, et al. **Am J Cardiol** 1995 Oct 1;76(10):652–6
Results of direct percutaneous transluminal coronary angioplasty in octogenarians. Laster SB, et al. **Am J Cardiol** 1996 Jan 1;77(1):10–3
Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Lefkovits J, et al. **Am J Cardiol** 1996 May 15;77(12):1045–51
Effects of endoluminal coronary stents on the frequency of coronary artery bypass grafting after unsuccessful percutaneous transluminal coronary vascularization. Lindsay J, et al. **Am J Cardiol** 1996 Mar 15;77(8):647–9
Value of rescue percutaneous transluminal coronary angioplasty following unsuccessful thrombolytic therapy in patients with acute myocardial infarction. Thrombolysis in Myocardial Infarction Investigators. McKendall GR, et al. **Am J Cardiol** 1995 Dec 1;76(16):1108–11
Indications, practice, and procedural outcomes of percutaneous transluminal coronary angioplasty in northern New England in the early 1990s. The Northern New England Cardiovascular Disease Study Group. Malenka DJ. **Am J Cardiol** 1996 Aug 1;78(3):260–5
Axial plaque redistribution as a mechanism of percutaneous transluminal coronary angioplasty. Mintz GS, et al. **Am J Cardiol** 1996 Feb 15;77(5):427–30
Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. O'Keefe JH Jr, et al. **Am J Cardiol** 1996 Mar 15;77(8):649–52
Usefulness of a prototype directional catheter for excimer laser coronary angioplasty in narrowings unfavorable for conventional excimer or balloon angioplasty. Rechavia E, et al. **Am J Cardiol** 1995 Dec 1;76(16):1144–6
Time course and mechanism of early luminal diameter loss after percutaneous transluminal coronary angioplasty. Rodriguez AE, et al. **Am J Cardiol** 1995 Dec 1; 76(16):1131–4
Coronary stenting in patients undergoing percutaneous transluminal coronary angioplasty during acute myocardial infarction. Rodriguez AE, et al. **Am J Cardiol** 1996 Apr 1;77(9):685–9
Single-stage coronary angiography and angioplasty: a new standard [letter; comment] Rozenman Y, et al. **Am J Cardiol** 1995 Dec 15;76(17):1321. Comment on: Am J Cardiol 1995 Jan 1;75(1):75–6.
Influence of coronary angioplasty on the progression of coronary atherosclerosis. Rozenman Y, et al. **Am J Cardiol** 1995 Dec 1;76(16):1126–30
Adjunctive intracoronary urokinase therapy during percutaneous transluminal coronary angioplasty. Schächinger V, et al. **Am J Cardiol** 1996 Jun 1; 77(14):1174–8
Percutaneous cardiopulmonary bypass-supported coronary angioplasty in patients with unstable angina pectoris or myocardial infarction and a left ventricular ejection fraction < or = 25%. Shawl FA, et al. **Am J Cardiol** 1996 Jan 1;77(1):14–9
Combined percutaneous carotid stenting and coronary angioplasty during acute ischemic neurologic and coronary syndromes. Shawl FA, et al. **Am J Cardiol** 1996 May 15; 77(12):1109–12
Comparison of percutaneous transluminal coronary angioplasty outcome and hospital costs for low-volume and high-volume operators. Shook TL, et al. **Am J Cardiol** 1996 Feb 15;77(5):331–6
A meta-analysis of randomized trials comparing coronary artery bypass grafting with percutaneous transluminal coronary angioplasty in multivessel coronary artery disease. Sim I, et al. **Am J Cardiol** 1995 Nov 15; 76(14):1025–9
Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy. Stone GW, et al. **Am J Cardiol** 1996 Jul 1;78(1):19–25
Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE. **Am J Cardiol** 1996 Aug 14; 78(3A):35–40 (27 ref.)
Long-term results after successful percutaneous transluminal coronary angioplasty in patients over 75 years of age. ten Berg JM, et al. **Am J Cardiol** 1996 Apr 1;77(9):690–5
Comparison of intravascular ultrasonic findings after coronary balloon angioplasty evaluated in vitro with histology. van der Lugt A, et al. **Am J Cardiol** 1995 Oct 1;76(10):661–6
Relation of lumen size to restenosis after percutaneous transluminal coronary balloon angioplasty. Lovastatin Restenosis Trial Group. Waksman R, et al. **Am J Cardiol** 1996 Jul 15;78(2):221–4
Thrombolysis of primary angioplasty? An ongoing controversy in the management of acute myocardial infarction. Futterman LG, et al. **Am J Crit Care** 1996 Mar; 5(2):160–66 (20 ref.)
"Cloggology" (unclogging pipes) revisited: radiologist to the rescue? Vingan HL. **Am J Gastroenterol** 1995 Dec; 90(12):2241–3
In situ detection of platelet-derived growth factor-A and -B chain mRNA in human coronary arteries after percutaneous transluminal coronary angioplasty. Ueda M, et al. **Am J Pathol** 1996 Sep;149(3):831–43
Prolonged luminal narrowing of internal mammary artery graft after percutaneous transluminal angioplasty. Ishizaka N, et al. **Angiology** 1996 Jul;47(7):735–8
Percutaneous transluminal coronary angioplasty of anomalous coronary arteries. Case reports. Oral D, et al. **Angiology** 1996 Jan;47(1):77–82
Efficacy and issues of emergent percutaneous transluminal coronary angioplasty. Comparison of clinical results in younger and elderly patients. Yabe Y, et al. **Angiology** 1995 Dec;46(12):1085–95
Multiresolution wavelet analysis of the body surface ECG before and after angioplasty. Gramatikov B, et al. **Ann Biomed Eng** 1995 Sep-Oct;23(5):553–61
Comparison of clinical outcomes of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in renal dialysis patients. Koyanagi T, et al. **Ann Thorac Surg** 1996 Jun;61(6):1793–6
Initial and subsequent angiographic outcome of percutaneous transluminal angioplasty performed on internal mammary artery grafts. Ishizaka N, et al. **Br Heart J** 1995 Dec; 74(6):615–9
Combined mechanical and thrombolytic treatment for totally occluded bypass grafts. Lotan C, et al. **Br Heart J** 1995 Oct;74(4):455–9
Percutaneous transluminal coronary angioplasty in patients 70 years of age or older: 12 years' experience. Tan KH, et al. **Br Heart J** 1995 Sep;74(3):310–7
Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial. Foley DP, et al. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:40–53 (53 ref.)
Clinical outcome and restenosis following percutaneous transluminal angioplasty for ischaemic rest pain or ulceration. Percutaneous transluminal angioplasty for lower-limb critical ischaemia [letter; comment] Skinner PP, et al. **Br J Surg** 1996 Jan;83(1):135–6. Comment on: Br J Surg 1995 Sep;82(9):1217–21. Comment on: Br J Surg 1995 Sep;82(9):1232–5.
Spontaneous pericardial tamponade during PTCA. Howlett JG, et al. **Can J Cardiol** 1995 Nov;11(10):927–30
Standards for coronary angioplasty training. Canadian Cardiovascular Society Committee. Marquis JF, et al. **Can J Cardiol** 1996 May;12(5):472
Direct angioplasty in acute myocardial infarction. State of the art and current controversies. Horrigan MC, et al. **Cardiol Clin** 1995 Aug;13(3):321–38 (108 ref.)
Managing acute myocardial infarction in a renal transplant recipient. Conte FJ, et al. **Cardiology** 1996 May-Jun; 87(3):257–9
Aggressive interventional treatment of acute myocardial infarction. Lessons from the animal laboratory applied to the catheterization suite. Feld S, et al. **Cardiology** 1995; 86(5):365–73 (65 ref.)
A mechanism of ischemic preconditioning during percutaneous transluminal coronary angioplasty. Inoue T, et al. **Cardiology** 1996 May-Jun;87(3):216–23
Coronary angioplasty and surgical revascularization: emerging concepts. Philippides GJ, et al. **Cardiology** 1995; 86(4):324–38 (53 ref.)
Gender differences in percutaneous interventional therapy of coronary artery disease. Bergelson BA, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):1–4
Coronary rotablation and reserve: can they occur together? [editorial; comment] Bowers TR, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):277. Comment on: Cathet Cardiovasc Diagn 1995 Nov;36(3):272–6.
The "dented bladder": diagnosis of a retroperitoneal hematoma. Chambers CE, et al. **Cathet Cardiovasc Diagn** 1995 Mar;34(3):224–6
Primary angioplasty using a urokinase-coated hydrogel

balloon in acute myocardial infarction during pregnancy. Glazier JJ, et al. **Cathet Cardiovasc Diagn** 1995 Nov; 36(3):216–9

Early discharge after direct angioplasty for acute myocardial infarction [editorial; comment] Guy SR. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):191. Comment on: Cathet Cardiovasc Diagn 1995 Jul;35(3):187–90.

Early hospital discharge after direct angioplasty for acute myocardial infarction [see comments] Hanlon JT, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):187–90. Comment in: Cathet Cardiovasc Diagn 1995 Jul;35(3):191.

Influence of adjunctive balloon angioplasty on coronary blood flow after rotational atherectomy [see comments] Khoury AF, et al. **Cathet Cardiovasc Diagn** 1995 Nov; 36(3):272–6. Comment in: Cathet Cardiovasc Diagn 1995 Nov;36(3):277.

Angioplasty therapy of acute myocardial infarction in the real world [editorial; comment] Kinn JW, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):209–10. Comment on: Cathet Cardiovasc Diagn 1995 Nov;36(3):203–8.

Morphologic characteristics of restenotic lesions following coronary interventions: balloon angioplasty versus directional atherectomy: can we speculate about the mechanism of restenosis from morphologic analysis? Moreu J, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):103–9; discussion 110–1

Assessment of collateral flow during balloon coronary occlusion by intracoronary blood flow velocity analysis. Piek JJ, et al. **Cathet Cardiovasc Diagn** 1995 Aug; 35(4):362–7

Intracoronary thrombus: still a risk factor for PTCA failure? Reeder GS, et al. **Cathet Cardiovasc Diagn** 1995 Mar; 34(3):191–5

Spontaneous coronary dissection resulting in acute myocardial infarction: successful treatment with primary angioplasty. Stone GW, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):62–6

Predictors of short term clinical and angiographic outcome after coronary angioplasty for acute myocardial infarction [see comments] Zimarino M, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):203–8. Comment in: Cathet Cardiovasc Diagn 1995 Nov;36(3):209–10.

The role of thrombin and thrombin inhibitors in coronary angioplasty. Ali MN, et al. **Chest** 1995 Nov;108(5):1409–19 (78 ref.)

Antithrombotic therapy in patients undergoing coronary angioplasty [published erratum appears in Chest 1996 Jan;109(1):295–6] Popma JJ, et al. **Chest** 1995 Oct;108(4 Suppl):486S–501S (133 ref.)

Cardiopulmonary support mitigates the effects of experimental myocardial ischemia. Ward HB, et al. **Chest** 1996 Mar;109(3):773–9

Relationship between coronary angioscopic and intravascular ultrasound imaging and restenosis. Xu S, et al. **Chin Med J (Engl)** 1995 Oct;108(10):743–9

First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation [news] **Circulation** 1996 Mar 1;93(5):847

Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. Improvement of cardiac ischemia at 1 year after PTCA and CABG. Bourassa MG, et al. **Circulation** 1995 Nov 1; 92(9 Suppl):II1–7

Significance of CK values after coronary angioplasty [letter; comment] Danchin N. **Circulation** 1996 Jan 15;93(2):397–8 . Comment on: Circulation 1995 Jun 1;91(11):2733–41.

NHLI BARI clinical alert on diabetics treated with angioplasty [news] Ferguson JJ. **Circulation** 1995 Dec 15; 92(12):3371

Platelet function in acute myocardial infarction treated with direct angioplasty. Gawaz M, et al. **Circulation** 1996 Jan 15;93(2):229–37

Limb vasoconstriction after successful angioplasty of the left anterior descending coronary artery. Indolfi C, et al. **Circulation** 1995 Oct 15;92(8):2109–12

Application of percutaneous transluminal coronary angioplasty to coronary arterial stenosis in Kawasaki disease. Ino T, et al. **Circulation** 1996 May 1;93(9):1709–15

Mechanisms of lumen enlargement after excimer laser coronary angioplasty. An intravascular ultrasound study. Mintz GS, et al. **Circulation** 1995 Dec 15;92(12):3408–14

Intramural delivery of agent via a novel drug-delivery sleeve. Histological and functional evaluation. Moura A, et al. **Circulation** 1995 Oct 15;92(8):2299–305

Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Pocock SJ, et al. **Circulation** 1996 Jul 15;94(2):135–42

Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Savage MP, et al. **Circulation** 1995 Dec 1;92(11):3194–200

Enhanced intracoronary thrombosis using a novel local drug delivery system [letter; comment] Tønnesen KH. **Circulation** 1996 Feb 1;93(3):615–6. Comment on: Circulation 1995 Feb 1;91(3):785–93.

Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty. van Bockxmeer FM, et al. **Circulation** 1995 Oct 15; 92(8):2066–71

Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty: a quantitative angiographic analysis. Violaris AG, et al. **Circulation** 1996 Mar 1;93(5):889–97

Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. Zhao XQ, et al. **Circulation** 1996 Jun 1;93(11):1954–62

Should community hospitals perform angioplasty for acute myocardial infarction? Weaver WD, et al. **Cleve Clin J Med** 1996 Jan-Feb;63(1):57–61

Coronary angioplasty for the control of intractable ventricular arrhythmia. Bhaskaran A, et al. **Clin Cardiol** 1995 Aug;18(8):480–3

Restenosis—an open file. Gottsauner-Wolf M, et al. **Clin Cardiol** 1996 May;19(5):347–56 (118 ref.)

Percutaneous transluminal coronary angioplasty in the elderly. Thompson RC, et al. **Clin Geriatr Med** 1996 Feb; 12(1):181–94 (106 ref.)

Elective coronary angioplasty with and without surgical standby: clinical and angiographic criteria for the selection of patients. Dellavalle A, et al. **Coron Artery Dis** 1995 Jun; 6(6):513–20

Management of unstable angina in patients over 75 years old. Eggeling T, et al. **Coron Artery Dis** 1995 Nov;6(11):891–6

Vasoreactivity and restenosis after coronary angioplasty in the atherosclerotic pig model. Hata H, et al. **Coron Artery Dis** 1995 Jun;6(6):503–11

Prevention of restenosis by bezafibrate after successful coronary angioplasty. Ishiwata S, et al. **Coron Artery Dis** 1995 Nov;6(11):883–9

Characterization of platelet activation and thrombin generation accompanying percutaneous transluminal coronary angioplasty. Vaitkus PT, et al. **Coron Artery Dis** 1995 Jul;6(7):587–92

Effect of cilazapril on vascular restenosis after percutaneous transluminal coronary angioplasty. Yamabe T, et al. **Coron Artery Dis** 1995 Jul;6(7):573–9

The importance of early patency after acute myocardial infarction. Grover A, et al. **Curr Opin Cardiol** 1995 Jul; 10(4):361–6 (29 ref.)

Coronary angioplasty versus coronary surgery in the management of angina. Rickards AF, et al. **Curr Opin Cardiol** 1995 Jul;10(4):399–403 (15 ref.)

Direct angioplasty for acute myocardial infarction. Stewart RE, et al. **Curr Opin Cardiol** 1995 Jul;10(4):367–71 (32 ref.)

Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Monreal M, et al. **Drugs Aging** 1996 Mar;8(3):171–82 (52 ref.)

Vital exhaustion, extent of atherosclerosis, and the clinical course after successful percutaneous transluminal coronary angioplasty. Appels A, et al. **Eur Heart J** 1995 Dec; 16(12):1880–5

Aminophylline inhibits adaptation to ischaemia during angioplasty. Role of adenosine in ischaemic preconditioning [see comments] Claeys MJ, et al. **Eur Heart J** 1996 Apr; 17(4):539–44. Comment in: Eur Heart J 1996 Apr;17(4):490–1.

Angiographic findings and catheterization laboratory events in patients with primary coronary angioplasty or streptokinase therapy for acute myocardial infarction [see comments] de Boer MJ, et al. **Eur Heart J** 1995 Oct; 16(10):1347–55. Comment in: Eur Heart J 1995 Oct;16(10):1310–1.

Resurrecting coronary angioplasty in acute myocardial infarction [editorial; comment] De Servi S, et al. **Eur Heart J** 1995 Oct;16(10):1310–1. Comment on: Eur Heart J 1995 Oct;16(10):1347–55.

The management of patients with stable angina and multivessel disease. PTCA or coronary bypass surgery? Gersh BJ. **Eur Heart J** 1995 Jul;16 Suppl E:32–5 (20 ref.)

Multivessel angioplasty versus bypass surgery. A case for PTCA. Grines CL, et al. **Eur Heart J** 1995 Jul;16 Suppl E:29–31 (13 ref.)

Restenosis after coronary angioplasty. Hamon M, et al. **Eur Heart J** 1995 Aug;16 Suppl I:33–48 (163 ref.)

The effects of calcium antagonists after PTCA. Hoberg E. **Eur Heart J** 1995 Aug;16 Suppl H:9–12 (12 ref.)

Exercise echocardiography performed early and late after percutaneous transluminal coronary angioplasty for prediction of restenosis. Hoffmann R, et al. **Eur Heart J** 1995 Dec;16(12):1872–9

The reactivity of the contralateral artery at the time of balloon dilation during coronary angioplasty. Kyriakides ZS, et al. **Eur Heart J** 1995 Jun;16(6):794–8

Vein plasma endothelin-1 and cyclic GMP increase during coronary angioplasty is related to myocardial ischaemia. Kyriakides ZS, et al. **Eur Heart J** 1995 Jul;16(7):894–8

Exercise tolerance in patients with mitral stenosis before and after acute percutaneous mitral valvuloplasty. Role of lung diffusing capacity limitation? Messner-Pellenc P, et al. **Eur Heart J** 1996 Apr;17(4):595–605

First clinical experience with a new flexible low profile metallic stent and delivery system. Priestley KA, et al. **Eur Heart J** 1996 Mar;17(3):438–44

Percutaneous transluminal coronary angioplasty of aorta ostial, non-aorta ostial, and branch ostial stenoses: acute and long-term outcome. Tan KH, et al. **Eur Heart J** 1995 May;16(5):631–9

More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials [editorial] van de Werf F. **Eur Heart J** 1996 Mar;17(3):325–6

Primary PTCA for acute myocardial infarction--a logistic comment [editorial; comment] Wilcox RG. **Eur Heart J** 1996 Mar;17(3):337–8. Comment on: Eur Heart J 1996 Mar;17(3):382–7.

Mortality, reinfarction, left ventricular ejection fraction and costs following reperfusion therapies for acute myocardial infarction [see comments] Zijlstra F, et al. **Eur Heart J** 1996 Mar;17(3):382–7. Comment in: Eur Heart J 1996 Mar;17(3):337–8.

Progression of coronary artery disease in non-dilated sites in the months following balloon angioplasty: time-dependent relation with restenosis. Benchimol D, et al. **Eur J Clin Invest** 1995 Dec;25(12):935–41

Assessment of myocardial area at risk by technetium-99m sestamibi during coronary artery occlusion: comparison between three tomographic methods of quantification. Ceriani L, et al. **Eur J Nucl Med** 1996 Jan;23(1):31–9

Exertional atrioventricular block presenting with recurrent syncope: successful treatment by coronary angioplasty. Deaner A, et al. **Heart** 1996 Jun;75(6):640–1

Combining coronary angiography and angioplasty. Meier B. **Heart** 1996 Jan;75(1):8–10

Planning for coronary angioplasty: guidelines for training and continuing competence. British Cardiac Society (BCS) and British Cardiovascular Intervention Society (BCIS) working group on interventional cardiology. Parker DJ, et al. **Heart** 1996 Apr;75(4):419–25

Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study. Tanizawa S, et al. **Heart** 1996 Jun;75(6):549–56

Long term follow-up of percutaneous transluminal renal angioplasty with special reference to aorto-arteritis. Chatterjee SS, et al. **Indian Heart J** 1995 Mar-Apr; 47(2):120–4

Primary angioplasty with elective coronary stenting in acute myocardial infarction. Gambhir DS, et al. **Indian Heart J** 1995 Jul-Aug;47(4):365–8

Percutaneous transluminal rotational atherectomy for treatment of in-stent restenosis. Khanolkar UB. **Indian Heart J** 1996 May-Jun;48(3):281–2

Multiple renal artery stenting with half (disarticulated) Palmaz-Schatz coronary stents and simultaneous coronary angioplasty. Mehan VK, et al. **Indian Heart J** 1995 May-Jun;47(3):259–60

Significance of ST alternans during percutaneous transluminal coronary angioplasty. Shah D, et al. **Indian Heart J** 1995 May-Jun;47(3):248–52

National PTCA Registry of India: data for 1995. Sharma S, et al. **Indian Heart J** 1996 May-Jun;48(3):295–9

Does it matter how coronary projections are combined to assess restenosis following PTCA? Morton BC, et al. **Int J Card Imaging** 1995 Sep;11(3):145–9

Progression of coronary artery disease in patients receiving percutaneous transluminal coronary angioplasty: angiographic comparison of angioplasty and non-angioplasty sites. Ohtani R, et al. **Intern Med** 1995 Jul;34(7):611–7

Emergency primary coronary angioplasty in patients with acute myocardial infarction who are unsuitable for intravenous thrombolysis. McKenna CJ, et al. **Ir J Med Sci** 1995 Oct-Dec;164(4):276–8

Immediate and follow-up results of coronary angioplasty--lessons for the future. el Gaylani N, et al. **Ir Med J** 1996 Mar-Apr;89(2):60–1

Intra-coronary stents--extending the role of angioplasty in angina--initial experience. Sheahan RG, et al. **Ir Med J** 1993 May;86(3):102–4

Percutaneous revascularization of ostial saphenous vein graft stenoses. Abdel-Meguid AE, et al. **J Am Coll Cardiol** 1995 Oct;26(4):955–60

The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome. Brack MJ, et al. **J Am Coll Cardiol** 1995 Oct;26(4):947–54

Importance of infarct-related artery patency for recovery of left ventricular function and late survival after primary angioplasty for acute myocardial infarction. Brodie BR, et al. **J Am Coll Cardiol** 1996 Aug;28(2):319–25

Repeated coronary artery occlusions during routine balloon angioplasty do not induce myocardial preconditioning in humans. Dupouy P, et al. **J Am Coll Cardiol** 1996 May; 27(6):1374–80

A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. Grines CL, et al. **J Am Coll Cardiol** 1996 May;27(6):1381–6

Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis [see comments] Hasdai D, et al. **J Am Coll Cardiol** 1996 Aug;28(2):361–7. Comment in: J Am Coll Cardiol 1996 Aug;28(2):368–70.

The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. Hueb WA, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1600–5

Decreased prevalence of late potentials with mechanical

versus thrombolysis-induced reperfusion in acute myocardial infarction. Karam C, et al. **J Am Coll Cardiol** 1996 May;27(6):1343–8

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. Kereiakes DJ, et al. **J Am Coll Cardiol** 1996 Mar 1; 27(3):536–42

Influence of stenotic lesion morphology on immediate and long-term (6 months) angiographic outcome: comparative analysis of directional coronary atherectomy versus standard balloon angioplasty. Kimball BP, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):543–51

Coronary angioplasty ameliorates hypoperfusion-induced endothelial dysfunction in patients with stable angina pectoris. Komaru T, et al. **J Am Coll Cardiol** 1996 Jan; 27(1):30–7

Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. Macaya C, et al. **J Am Coll Cardiol** 1996 Feb;27(2):255–61

Angioplasty of complex lesions in ischemic rest angina: results of the Thrombolysis and Angioplasty in Unstable Angina (TAUSA) trial. Mehran R, et al. **J Am Coll Cardiol** 1995 Oct;26(4):961–6

Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? Mickelson JK, et al. **J Am Coll Cardiol** 1996 Aug;28(2):345–53

Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization. Mintz GS, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1678–87

Another step toward resolving the contrast controversy [editorial] Moliterno DJ, et al. **J Am Coll Cardiol** 1996 May;27(6):1387–9

Relation between preexistent coronary collateral circulation and the incidence of restenosis after successful primary coronary angioplasty for acute myocardial infarction. Nakae I, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1688–92

Electrophysiologic effects of ischemic preconditioning on QT dispersion during coronary angioplasty. Okishige K, et al. **J Am Coll Cardiol** 1996 Jul;28(1):70–3

Three-year follow-up of the Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease (ERACI). Rodriguez A, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1178–84

Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina. Rupprecht HJ, et al. **J Am Coll Cardiol** 1995 Dec; 26(7):1637–42

Clinical outcome 10 years after attempted percutaneous transluminal coronary angioplasty in 856 patients. Ruygrok PN, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1669–77

Do excimer laser angioplasty and rotational atherectomy facilitate balloon angioplasty? Implications for lesion-specific coronary intervention. Safian RD, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):552–9

Immediate and late outcome of excimer laser and balloon coronary angioplasty: a quantitative angiographic comparison based on matched lesions. Strikwerda S, et al. **J Am Coll Cardiol** 1995 Oct;26(4):939–46

Ten-year follow-up of percutaneous transluminal coronary angioplasty for proximal left anterior descending coronary artery stenosis in 351 patients. Ten Berg JM, et al. **J Am Coll Cardiol** 1996 Jul;28(1):82–8

Comparison of medical treatment, coronary angioplasty and coronary artery bypass surgery in patients with chronic stable angina. Gogna A, et al. **J Assoc Physicians India** 1995 Aug;43(8):548–52 (33 ref.)

Role of percutaneous transluminal coronary angioplasty in patients of exercise induced ST segment elevation in infarct related leads. Mehta AB, et al. **J Assoc Physicians India** 1995 Sep;43(9):619–20

Clinical aspects of preconditioning and implications for the cardiac surgeon. Kloner RA, et al. **J Card Surg** 1995 Jul; 10(4 Suppl):369–75 (38 ref.)

Intraoperative coronary artery dilatation with angioscopic guidance. Siegel SB, et al. **J Card Surg** 1995 Jul;10(4 Pt 1):298–301

Delayed metabolic recovery of hibernating myocardium after percutaneous transluminal coronary angioplasty: assessment with iodine-123-betamethyl-p-iodophenyl-pentadecanoic acid imaging. Takeishi Y, et al. **J Cardiol** 1996 Jul;28(1):17–25

When should femoral artery sheaths be removed after post-PTCA emergency CABG surgery? [letter] Chauhan S, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):785–6

Analysis of high-resolution ECG changes during percutaneous transluminal coronary angioplasty. Lander P, et al. **J Electrocardiol** 1995;28 Suppl:39–40

Bilateral forearm compartment syndromes resulting from neuroleptic malignant syndrome. Schneider JM, et al. **J Hand Surg [Am]** 1996 Mar;21(2):287–9

Technetium-99m-sestamibi SPECT to detect restenosis after successful percutaneous coronary angioplasty. Milan E, et al. **J Nucl Med** 1996 Aug;37(8):1300–5

Reverse redistribution of technetium-99m-sestamibi following direct PTCA in acute myocardial infarction. Takeishi Y, et al. **J Nucl Med** 1996 Aug;37(8):1289–94

The expanded role of coronary angioplasty during pregnancy. Mardini AH, et al. **J Tenn Med Assoc** 1995 Nov;88(11):423–4

Atherosclerotic lesions of the gastroepiploic artery: one case requiring postoperative dilation and some interesting postmortem observations. Carrel T, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1768–70

Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. Jones RH, et al. **J Thorac Cardiovasc Surg** 1996 May;111(5):1013–25

Coronary angioplasty procedure volume and major complications [letter; comment] Phillips KA, et al. **JAMA** 1996 Feb 28;275(8):595; discussion 596. Comment on: JAMA 1995 Oct 11;274(14):1137–42.

Coronary angioplasty procedure volume and major complications [letter; comment] Reis GJ. **JAMA** 1996 Feb 28;275(8):595–6. Comment on: JAMA 1995 Oct 11;274(14):1137–42.

Distal vasoconstriction following coronary angioplasty--comparison of emergent and elective PTCA. Nakata A, et al. **Jpn Circ J** 1995 Aug;59(8):531–40

Granulocyte activation in restenosis after percutaneous transluminal coronary angioplasty. Tsutsui M, et al. **Jpn Circ J** 1996 Jan;60(1):27–34

Role of collateral flow in a pharmacological stress test (a combination of low-dose dobutamine and a vasodilator) as a predictor of wall motion reversibility. Yamaoka O, et al. **Jpn Circ J** 1995 Oct;59(10):673–84

Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Lee YJ, et al. **Jpn Heart J** 1996 May;37(3):327–32

Comparison of long-term efficacy of medical treatment versus coronary artery bypass grafting (CABG) in multivessel coronary artery disease. Nishiyama S, et al. **Jpn Heart J** 1995 Nov;36(6):709–17

Comparison of long-term efficacy of medical treatment versus percutaneous transluminal coronary angioplasty (PTCA) in single-vessel disease. Nishiyama S, et al. **Jpn Heart J** 1995 Sep;36(5):565–72

Evaluation of repeated balloon inflation in angioplasty as a clinical model of ischemic preconditioning. Sasaki Y, et al. **Jpn Heart J** 1995 Nov;36(6):719–28

Angioplasty for myocardial infarction. Vine DL. **Kans Med** 1995 Summer;96(2):102

First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants [see comments] **Lancet** 1995 Nov 4; 346(8984):1179–84. Comment in: Lancet 1995 Nov 4;346(8984):1174–5. Comment in: Lancet 1995 Dec 16;346(8990):1626.

Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation [letter] Angelini GD, et al. **Lancet** 1996 Mar 16;347(9003):757–8

Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease. Appelman YE, et al. **Lancet** 1996 Jan 13; 347(8994):79–84

Angioplasty versus bypass surgery [letter; comment] Butler J. **Lancet** 1996 Jan 27;347(8996):271; discussion 272–3. Comment on: Lancet 1995 Nov 4;346(8984):1174–5. Comment on: Lancet 1995 Nov 4;346(8984):1184–9.

Angioplasty versus bypass surgery [letter; comment] Marchbank AJ, et al. **Lancet** 1995 Dec 16;346(8990):1626 . Comment on: Lancet 1995 Nov 4;346(8984):1179–84. Comment on: Lancet 1995 Nov 4;346(8984):1184–9.

Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery [see comments] Pocock SJ, et al. **Lancet** 1995 Nov 4;346(8984):1184–9. Comment in: Lancet 1995 Nov 4;346(8984):1174–5. Comment in: Lancet 1995 Dec 16;346(8990):1626. Comment in: Lancet 1996 Jan 27;347(8996):271; discussion 272–3. Comment in: Lancet 1996 Jan 27;347(8996):271–2; discussion 272–3

Angioplasty versus bypass surgery [letter; comment] Taggart DP. **Lancet** 1996 Jan 27;347(8996):271–2; discussion 272–3 . Comment on: Lancet 1995 Nov 4;346(8984):1184–9.

Coronary angioplasty plus stent in LAD disease [letter; comment] Townend JN, et al. **Lancet** 1996 Mar 9; 347(9002):689. Comment on: Lancet 1996 Jan 27;347(8996):263–4.

Primary angioplasty for acute myocardial infarction: is the balloon half full or half empty? Verheugt FW. **Lancet** 1996 May 11;347(9011):1276–7

Angioplasty versus bypass surgery [comment] [see comments] White HD. **Lancet** 1995 Nov 4;346(8984):1174–5. Comment on: Lancet 1995 Nov 4;346(8984):1179–84. Comment on: Lancet 1995 Nov 4;346(8984):1184–9. Comment in: Lancet 1996 Jan 27;347(8996):271; discussion 272–3.

Hostility predicts restenosis after percutaneous transluminal coronary angioplasty. Goodman M, et al. **Mayo Clin Proc** 1996 Aug;71(8):729–34

Changes in health after elective percutaneous coronary revascularization. A comparison of generic and specific measures. Krumholz HM, et al. **Med Care** 1996 Aug; 34(8):754–9

Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators [see comments] **N Engl J Med** 1996 Jul 25;335(4):217–25. Comment in: N Engl J Med 1996 Jul 25;335(4):275–7.

Myocardial revascularization--bypass surgery or angioplasty? [editorial; comment] Simoons ML. **N Engl J Med** 1996 Jul 25;335(4):275–7. Comment on: N Engl J Med 1996 Jul 25;335(4):217–25.

The effect of coronary angioplasty on superoxide anion generation and lipid peroxidation. Propriety of pharmacological intervention. Kowalski J, et al. **Pol J Pharmacol** 1995 Mar–Apr;47(2):163–8

Thallium imaging in management of post-revascularization patients. Alazraki P, et al. **Q J Nucl Med** 1996 Mar; 40(1):85–90 (26 ref.)

Spontaneous haemothorax as a complication of anti-coagulation following coronary angioplasty. Robinson NM, et al. **Respir Med** 1995 Oct;89(9):629–30

Treatment of acute myocardial infarction by invasive cardiology techniques. Morris DC. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):184–90 (42 ref.)

Improvement in cerebral hemodynamics after carotid angioplasty. Markus HS, et al. **Stroke** 1996 Apr;27(4):612–6

Rotational ablation of discrete lesions in the coronary arteries is safe. A nonrandomized comparison with percutaneous transluminal coronary angioplasty. Cheirif J, et al. **Tex Heart Inst J** 1995;22(3):237–42

Coronary angioplasty of anomalous left anterior descending artery with the left coronary artery originating from the right coronary sinus of Valsalva. Ozdil E, et al. **Tex Heart Inst J** 1995;22(4):339–41

Ancrod for coronary angioplasty. Pothoulakis AJ, et al. **Tex Heart Inst J** 1995;22(4):342–6

Coronary artery bypass grafting after failed percutaneous angioplasty compared to direct coronary bypass grafting in patients with unstable angina. Bartram U, et al. **Thorac Cardiovasc Surg** 1996 Feb;44(1):31–4

Use of the internal mammary artery as a graft in emergency coronary artery bypass grafting after failed PTCA. Nollert G, et al. **Thorac Cardiovasc Surg** 1995 Jun;43(3):142–7

Association of antibodies to heat-shock protein-65 with percutaneous transluminal coronary angioplasty and subsequent restenosis. Mukherjee M, et al. **Thromb Haemost** 1996 Feb;75(2):258–60

Inhibitory effect of argatroban on thrombin-antithrombin III complex after percutaneous transluminal coronary angioplasty [letter] Sakamoto S, et al. **Thromb Haemost** 1995 Aug;74(2):801–2

The impact of performing a clinical trial on patient outcomes: lessons from the Emory Angioplasty vs. Surgery Trial. King SB 3rd. **Trans Am Clin Climatol Assoc** 1995; 107:68–77; discussion 77–8

Percutaneous transluminal coronary angioplasty for ostial stenosis of the left coronary artery--a case report and literature review. Lee HY. **Yonsei Med J** 1995 Nov; 36(5):462–5

Cell biology of restenosis post-angioplasty. Badimon L, et al. **Z Kardiol** 1995;84 Suppl 4:145–9 (25 ref.)

Cardiogenic shock in acute myocardial infarction. Improving survival rates by primary coronary angioplasty. Emmerich K, et al. **Z Kardiol** 1995;84 Suppl 2:25–42

Primary mechanical recanalization of occluded coronary arteries without prior thrombolytic therapy in patients with acute myocardial infarction. A single-center study reporting acute results and complications. Emmerich K, et al. **Z Kardiol** 1995;84 Suppl 2:5–23

Interrelation between atherosclerosis and restenosis. Kranzhöfer R, et al. **Z Kardiol** 1995;84 Suppl 4:125–8 (28 ref.)

Role of basic fibroblast growth factor and platelet-derived growth factor (B-chain) in neointima formation after arterial injury. Lindner V. **Z Kardiol** 1995;84 Suppl 4:137–44

Angioplasty or thrombolysis for acute infarction? Reeder GS. **Z Kardiol** 1995;84 Suppl 2:1–4 (14 ref.)

[Progress in the interventional therapy of coronary disease] Wang L, et al. **Chung Hua Nei Ko Tsa Chih** 1995 May; 34(5):347–9 (17 ref.) **(Chi)**

[Changes in platelet activity in invasive cardiologic procedures] Malý J, et al. **Vnitr Lek** 1996 May;42(5):314–9 (Eng. Abstr.) **(Cze)**

[Intravascular ultrasound and percutaneous transluminal angioplasty. Preliminary results] Vogt KC, et al. **Ugeskr Laeger** 1995 Nov 6;157(45):6256–60 (Eng. Abstr.) **(Dan)**

[Favorable long-term results of primary percutaneous transluminal coronary angioplasty in acute myocardial infarction compared to intravenous streptokinase treatment; a randomized study] Liem AL, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2564–7 (Eng. Abstr.) **(Dut)**

[15 years of coronary angioplasty: focus on the different techniques] Dupouy P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):433–7 (31 ref.) (Eng. Abstr.) **(Fre)**

[Guidelines of the French Society of Cardiology on the training of specialists in coronary angiography and angioplasty, the organization and the equipment of coronary angiography and angioplasty centers. Groupe de travail Angiographic et Cardiologie Interventionnelle Groupe de Réflexion et d'Ethique] **Arch Mal Coeur Vaiss** 1996 Jun;89(6):747–53 **(Fre)**

[Is percutaneous transluminal coronary angioplasty in chronic total coronary occlusion justified? Long term results in a series of 201 patients] Angioï M, et al. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1383–9 (Eng. Abstr.) **(Fre)**

[Treatment of refractory unstable angina by transluminal coronary angioplasty] Baladier V, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):181–6 (28 ref.) (Eng.

Abstr.) (Fre)
[Is plasma lipoprotein (a) level a reliable indicator predicting restenosis after angioplasty?] Bussière JL, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):425–9 (24 ref.) (Eng. Abstr.) (Fre)
[Balloon angioplasty for restenosis of coronary endoprostheses] Debbas N, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):987–91 (Eng. Abstr.) (Fre)
[Excimer laser assisted angioplasty. Immediate results in the treatment of complex coronary lesions] Escojido H, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):407–15 (29 ref.) (Eng. Abstr.) (Fre)
[Synchronized anterograde perfusion during percutaneous transluminal coronary angioplasty: preliminary clinical study] Farcot JC, et al. **Arch Mal Coeur Vaiss** 1995 Mar; 88(3):371–9 (Eng. Abstr.) (Fre)
[Calcium antagonists and prevention of post–angioplasty restenosis] Hoberg E. **Arch Mal Coeur Vaiss** 1995 Sep;88 Spec No 4:29–34 (Eng. Abstr.) (Fre)
[Emergency angioplasty for total thrombosis of the left main coronary artery. Apropos of a case] Laurent G, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):265–8 (Eng. Abstr.) (Fre)
[Mechanisms of restenosis after coronary angioplasty] Leclercq F, et al. **Arch Mal Coeur Vaiss** 1996 Mar; 89(3):359–65 (42 ref.) (Eng. Abstr.) (Fre)
[Delayed angioplasty of residual coronary stenosis after thrombolysis of myocardial infarction: prognostic factors of left ventricular function] Marek A, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):337–43 (Eng. Abstr.) (Fre)
[Relation between progression of atherosclerosis and the phenomenon of restenosis after coronary angioplasty] Passard F, et al. **Arch Mal Coeur Vaiss** 1996 Apr; 89(4):393–7 (Eng. Abstr.) (Fre)
[Coronary angioplasty in cardiac transplantation] Rashdan I, et al. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1375–80 (Eng. Abstr.) (Fre)
[Changes in the high–amplification electrocardiogram after myocardial revascularization. Comparison between coronary artery bypass and angioplasty] Richard A, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1609–14 (Eng. Abstr.) (Fre)
[Indications of coronary angioplasty after thrombolysis] Vahanian A, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88 Spec No 3:19–24 (30 ref.) (Eng. Abstr.) (Fre)
[Coronary artery stenting without antivitamin K. Results after a month] Zemour G, et al. **Arch Mal Coeur Vaiss** 1996 Mar;89(3):291–7 (Eng. Abstr.) (Fre)
[Disappearance of a 35 mm film in coronarography: chronicle of an announced demise (editorial)] Crochet D. **J Radiol** 1995 Aug;76(8):485–6 (Fre)
[Angioplasty or bypass for multitruncal coronary disease. Viewpoint of the cardiologist] Urban P. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2062–6 (30 ref.) (Eng. Abstr.) (Fre)
[Coronary angioplasty in elderly patients] Eeckhout E, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):168–71 (18 ref.) (Eng. Abstr.) (Fre)
[Long term course over 10 years after balloon dilatation in stable and unstable angina pectoris] Espinola–Klein C, et al. **Dtsch Med Wochenschr** 1996 May 3;121(18):577–82 (Eng. Abstr.) (Ger)
[Recanalization of chronically stenosed infarct vessels in one–vessel coronary disease (letter)] Jaedicke W. **Dtsch Med Wochenschr** 1996 Mar 1;121(9):288–9 (Ger)
[Percutaneous transluminal coronary angioplasty (PTCA) as primary therapy in acute myocardial infarct] Krakau I, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):896–901 (Eng. Abstr.) (Ger)
[The recanalization of the chronically occluded infarct vessel in single–vessel coronary disease. The reduction of cardiac events in long–term clinical follow–up] Seggewiss H, et al. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1305–11 (Eng. Abstr.) (Ger)
[Immediate PTCA in acute myocardial infarct—results and indications] Deutsch HJ, et al. **Herz** 1996 Jun;21(3):201–6 (30 ref.) (Ger)
–Differential antithrombotic therapy in patients with low and high PTCA risk– Silber S, et al. **Herz** 1996 Feb;21(1):44–59 (213 ref.) (Eng. Abstr.) (Ger)
[Risk predictors and secondary prevention after PTCA and bypass operations] Gulba DC, et al. **Internist (Berl)** 1995 Sep;36(9):891–901 (82 ref.) (Ger)
[Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures] Leschke M, et al. **Internist (Berl)** 1996 Jun;37(6):597–606 (50 ref.) (Ger)
[PTCA or bypass surgery in multi–vessel coronary disease? Viewpoint of the surgeon] Althaus U. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2067–73 (Eng. Abstr.) (Ger)
[Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs] Noll G, et al. **Schweiz Med Wochenschr** 1996 Feb 3;126(5):164–76 (81 ref.) (Eng. Abstr.) (Ger)
[Coronary angioplasty versus aortocoronary bypass surgery in older patients. Role of coronary angioplasty] Pfisterer M. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2080–3 (Eng. Abstr.) (Ger)
–Recanalization of chronic coronary artery occlusions: effect on clinical symptoms and left ventricular function– Heyder M, et al. **Z Kardiol** 1996 Feb;85(2):125–32 (Eng. Abstr.) (Ger)
–Value of activated blood coagulation time in monitoring anticoagulation during coronary angioplasty– Kunert M, et al. **Z Kardiol** 1996 Feb;85(2):118–24 (Eng. Abstr.) (Ger)
[Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty (PTCA) by intracoronary dipyridamole: hemodynamic, contractile and dynamic ventricular consequences] Strauer BE, et al. **Z Kardiol** 1995 Nov;84(11):898–910 (Eng. Abstr.) (Ger)
[Angioplasty for vein grafts and native coronary arteries after previous coronary artery bypass grafting] Avital S, et al. **Harefuah** 1995 Aug;129(3–4):96–9, 159 (Eng. Abstr.) (Heb)
[Direct percutaneous transluminal coronary angioplasty] Ilia R, et al. **Harefuah** 1996 Mar 15;130(6):375–6, 439 (Eng. Abstr.) (Heb)
[Coronary angioplasty or drug therapy. Reading "between the lines" of major trials] Montorsi P. **Cardiologia** 1996 Apr; 41(4):307–8 (Ita)
[Coronary arteriography: much more than a simple morphologic test] Russo G, et al. **Cardiologia** 1996 Apr; 41(4):327–30 (Ita)
[Myocardial stunning during coronary angioplasty: significance and clinical relevance] Trevi G, et al. **Cardiologia** 1996 May;41(5):427–33 (70 ref.) (Ita)
[Primary coronary angioplasty for acute myocardial infarction associated with severe left ventricular dysfunction. Results in 50 patients] Antoniucci D, et al. **G Ital Cardiol** 1995 Oct;25(10):1265–71 (Eng. Abstr.) (Ita)
[A case of radiation–induced coronary occlusion treated with elective and emergency PTCA] Fontanelli A, et al. **G Ital Cardiol** 1995 Jul;25(7):877–84 (Eng. Abstr.) (Ita)
[Rotational atherectomy and PTCA in complex coronary lesions (B2 and C): the immediate and long–term results] Isabella G, et al. **G Ital Cardiol** 1995 Sep;25(9):1127–38 (Eng. Abstr.) (Ita)
[Rescue angioplasty: when?] Klugmann S, et al. **G Ital Cardiol** 1995 Nov;25(11):1439–46 (11 ref.) (Ita)
[Coronary angioplasty in chronic total occlusion: angiography results, complications, and predictive factors] Leonzi O, et al. **G Ital Cardiol** 1995 Jul;25(7):807–14 (Eng. Abstr.) (Ita)
[Indications for and choice of coronary stents] Salvadè P. **G Ital Cardiol** 1995 Nov;25(11):1495–7 (Ita)
[Surgical or percutaneous revascularization in multi–vessel coronary disease] Zingone B. **G Ital Cardiol** 1995 Dec; 25(12):1607–19 (123 ref.) (Eng. Abstr.) (Ita)
[Myointimal hyperplasia in peripheral artery reconstruction] Benedetti–Valentini F, et al. **Minerva Cardioangiol** 1995 May;43(5):219–29 (Ita)
[Usefulness of percutaneous transluminal coronary angioplasty in silent myocardial ischemia] Hou M. **J Cardiol** 1996 Apr;27(4):179–86 (Eng. Abstr.) (Jpn)
[Initial and short–term results of percutaneous transluminal coronary angioplasty in patients over 70 years old: recent improvements in effectiveness] Kishi K, et al. **J Cardiol** 1995 Oct;26(4):227–31 (Eng. Abstr.) (Jpn)
[Four cases of noncardiac surgery after PTCA] Sengoku S, et al. **Masui** 1995 Oct;44(10):1396–400 (Eng. Abstr.) (Jpn)
[Indication and limitation of interventional therapy in ischemic heart disease] Nobuyoshi M. **Nippon Geka Gakkai Zasshi** 1996 Mar;97(3):197–201 (Jpn)
[Comparison of long–term prognosis between medical therapy PTCA and CABG for multiple coronary vessel disease] Sasako Y. **Nippon Geka Gakkai Zasshi** 1996 Mar; 97(3):215–9 (Eng. Abstr.) (Jpn)
[Reasonable indication for PTCA or CABG in Japanese patients with coronary artery disease—on the basis of 11 years follow–up] Yamaguchi H, et al. **Nippon Geka Gakkai Zasshi** 1996 Mar;97(3):191–6 (Eng. Abstr.) (Jpn)
[Acute myocardial infarction and silent myocardial ischemia in the elderly—clinical features and effectiveness of therapy in an era of coronary intervention] Haze K, et al. **Nippon Ronen Igakkai Zasshi** 1996 May;33(5):346–52 (Eng. Abstr.) (Jpn)
[Treatment with ticlodipine after intracoronary stent implantation] Myreng Y, et al. **Tidsskr Nor Laegeforen** 1996 Jun 10;116(15):1789–91 (Eng. Abstr.) (Nor)
[Clinical and angiographic profile and selection of patients for coronary angioplasty of restenosis (editorial; comment)] Gottschall CA. **Arq Bras Cardiol** 1995 Sep;65(3):259–61. Comment on: Arq Bras Cardiol 1995 Sep;65(3):215–9. (Por)
[Angioplasty, surgical, or clinical treatment. Therapeutic options for obstructive coronary artery disease (editorial)] Hueb WA, et al. **Arq Bras Cardiol** 1995 Jul;65(1):7–10 (28 ref.) (Por)
[Coronary angioplasty in patients with restenosis. Characterization of clinical and angiographic profiles, hospital clinical course, and implications for the selection of patients (see comments)] Nunes GL, et al. **Arq Bras Cardiol** 1995 Sep;65(3):215–9 (Eng. Abstr.). Comment in: Arq Bras Cardiol 1995 Sep;65(3):259–61. (Por)
[Coronary angioplasty in acute myocardial infarct: the immediate results and follow–up] Faria H, et al. **Rev Port Cardiol** 1995 Nov;14(11):833–6 (Por)
[Usefulness and safety of early stress test after coronary angioplasty] Escudero X, et al. **Arch Inst Cardiol Mex** 1996 Jan–Feb;66(1):38–43 (Eng. Abstr.) (Spa)
[Percutaneous coronary angioscopy: 200 observations in 100 candidates for angioplasty] Escudero X, et al. **Arch Inst Cardiol Mex** 1995 Jul–Aug;65(4):307–14 (Eng. Abstr.) (Spa)
[Coronary angioscopy: initial experience during coronary interventions] Alfonso F, et al. **Rev Esp Cardiol** 1995 Dec; 48(12):798–806 (Eng. Abstr.) (Spa)
[Morphological and quantitative analysis of the mechanism of balloon angioplasty. An intravascular ultrasonic study] Domínguez Arganda L, et al. **Rev Esp Cardiol** 1996 Jan; 49(1):13–21 (Eng. Abstr.) (Spa)
[Primary coronary angioplasty as a choice treatment in the 1st 6 hours following acute myocardial infarction] Chamorro H, et al. **Rev Med Chil** 1995 Jun;123(6):727–34 (Eng. Abstr.) (Spa)
[Complex and multiple vessel angioplasty] Rodríguez A, et al. **Rev Med Panama** 1995 Sep;20(3):72–8 (Eng. Abstr.) (Spa)
[The effect of angioplasty on cerebral vasomotor reactivity in patients with important stenosis of the internal carotid artery] Arenas C, et al. **Rev Neurol** 1996 Feb;24(126):224–6 (12 ref.) (Eng. Abstr.) (Spa)

ADVERSE EFFECTS

Changes in patient treatment after abrupt closure complicating percutaneous transluminal coronary angioplasty: a historic perspective. Danchin N, et al. **Am Heart J** 1995 Dec;130(6):1158–63
Atrial natriuretic peptide release during myocardial ischemia induced by percutaneous transluminal coronary angioplasty. Nigri A, et al. **Am Heart J** 1996 Sep; 132(3):698–9
Aortic dissection complicating coronary angioplasty in cystic medial necrosis. Pande AK, et al. **Am Heart J** 1996 Jun; 131(6):1221–3
Coronary pseudoaneurysm after angioplasty. Flum DR, et al. **Am Surg** 1995 Dec;61(12):1035–8 (40 ref.)
Guide wire–induced coronary artery spasm during percutaneous transluminal coronary angioplasty. A case report. Takahashi M, et al. **Angiology** 1996 Mar;47(3):305–9
N–acetylcysteine diminishes injury induced by balloon angioplasty of the carotid artery in rabbits. Mass H, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):613–8
Diastolic aortic pressure rise during percutaneous transluminal coronary angioplasty: an index of left ventricular systolic dysfunction. Paraskevaidis IA, et al. **Br Heart J** 1995 Sep;74(3):242–6
Plasma mediated neutrophil stimulation during coronary angioplasty: autocrine effect of platelet activating factor. Siminiak T, et al. **Br Heart J** 1995 Dec;74(6):625–30
Durability of emergency coronary artery bypass for complications of failed angioplasty. Ladowski JS, et al. **Cardiovasc Surg** 1996 Feb;4(1):23–7
Bailout Palmaz–Schatz coronary stenting in 39 patients with occlusive dissection complicating conventional angioplasty [see comments] Antoniucci D, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):204–9. Comment in: Cathet Cardiovasc Diagn 1995 Jul;35(3):210.
Millimeters and Minutes—Yes: Kilopascals—? [editorial; comment] Cumpston N. **Cathet Cardiovasc Diagn** 1995 Jul; 35(3):203. Comment on: Cathet Cardiovasc Diagn 1995 Jul;35(3):198–202.
High balloon dilatation pressures in percutaneous transluminal coronary angioplasty are not associated with higher rate of significant complications [see comments] Ebersole DG, et al. **Cathet Cardiovasc Diagn** 1995 Jul; 35(3):198–202. Comment in: Cathet Cardiovasc Diagn 1995 Jul;35(3):203.
Improving the results of bail–out stenting [editorial; comment] Herrmann HC, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):210. Comment on: Cathet Cardiovasc Diagn 1995 Jul;35(3):204–9.
Subintimal wire position during angioplasty of a chronic total coronary occlusion: detection and subsequent procedural guidance by intravascular ultrasound. Kimura BJ, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):262–5
A new adjustable temporary stent catheter for management of acute dissection during balloon angioplasty. Stefanadis C, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):89–98
Relation of coronary angioscopic findings at coronary angioplasty to angiographic restenosis. Bauters C, et al. **Circulation** 1995 Nov 1;92(9):2473–9
Intracoronary heparin delivery in humans. Acute feasibility and long–term results. Camenzind E, et al. **Circulation** 1995 Nov 1;92(9):2463–72
Utilization of the coronary balloon–expandable coil stent without anticoagulation or intravascular ultrasound. Goods CM, et al. **Circulation** 1996 May 15;93(10):1803–8
Contributions of frequency distribution analysis to the understanding of coronary restenosis. A reappraisal of the gaussian curve. Lehmann KG, et al. **Circulation** 1996 Mar 15;93(6):1123–32
Collagen gene expression in postangioplasty stenosis [letter; comment] Nerlich AG. **Circulation** 1995 Nov 1; 92(9):2760–1. Comment on: Circulation 1995 Apr 1;91(7):2049–57.
Neointimal thickening after severe coronary artery injury is limited by a short–term administration of a factor Xa

inhibitor. Results in a porcine model. Schwartz RS, et al. **Circulation** 1996 Apr 15;93(8):1542–8

Long-term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis [letter; comment] Serruys PW. **Circulation** 1995 Nov 1;92(9):2759–60. Comment on: Circulation 1995 Mar 15;91(6):1689–96.

Intracoronary low-dose beta-irradiation inhibits neointima formation after coronary artery balloon injury in the swine restenosis model. Waksman R, et al. **Circulation** 1995 Nov 15;92(10):3025–31

Coronary thrombi increase PTCA risk. Angioscopy as a clinical tool. White CJ, et al. **Circulation** 1996 Jan 15; 93(2):253–8

Restenosis following coronary angioplasty: clinical presentations and therapeutic options. Levine GN, et al. **Clin Cardiol** 1995 Dec;18(12):693–703 (80 ref.)

Invasive staphylococcal infections complicating percutaneous transluminal coronary angioplasty: three cases and review. Cleveland KO, et al. **Clin Infect Dis** 1995 Jul;21(1):93–6 (17 ref.)

A closed-chest porcine model of coronary dissection and thrombosis. Bikkina M, et al. **Coron Artery Dis** 1995 Aug; 6(8):651–5

Aggressive pattern of angina after successful coronary angioplasty: the role of clinical and angiographic factors. Chen L, et al. **Eur Heart J** 1995 Aug;16(8):1085–91

Myocardial protection with calcium-channel blockers during ischaemia and reperfusion by PTCA. Chouairi S, et al. **Eur Heart J** 1995 Aug;16 Suppl H:3–8 (42 ref.)

Isolated acute occlusion of a large right ventricular branch of the right coronary artery following coronary balloon angioplasty. The only true 'model' to study ECG changes in acute, isolated right ventricular infarction. van der Bolt CL, et al. **Eur Heart J** 1996 Feb;17(2):247–50

Efficacy and safety of collagen implants for haemostasis of the vascular access site after coronary balloon angioplasty and coronary stent implantation. A randomized study. von Hoch F, et al. **Eur Heart J** 1995 May;16(5):640–6

Thrombotic occlusion of the left main coronary artery during stenting: successful management with intracoronary urokinase and autoperfusion balloon. Gambhir DS, et al. **Indian Heart J** 1996 May–Jun;48(3):273–5

Closure of a persistent femoral artery pseudoaneurysm complicating coronary angioplasty using the femostop compression device and direct ultrasound visualization. Sabri N, et al. **Int J Card Imaging** 1995 Dec;11(4):273–5

Coronary ventricular fistula as a complication of PTCA: a case report and literature review. el-Omar MM, et al. **Int J Cardiol** 1995 Sep;51(2):113–6 (10 ref.)

Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). Berger PB, et al. **J Am Coll Cardiol** 1996 Jan;27(1):1–7

Abrupt closure: the CAVEAT I experience. Coronary Angioplasty Versus Excisional Atherectomy Trial. Holmes DR Jr, et al. **J Am Coll Cardiol** 1995 Nov 15;26(6):1494–500

Development and validation of simplified predictive index for major complications in contemporary percutaneous transluminal coronary angioplasty practice. The Registry Committee of the Society for Cardiac Angiography and Interventions. Kimmel SE, et al. **J Am Coll Cardiol** 1995 Oct;26(4):931–8

Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. Neumann FJ, et al. **J Am Coll Cardiol** 1996 Mar 15; 27(4):819–24

Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). Omoigui NA, et al. **J Am Coll Cardiol** 1995 Oct;26(4):922–30

Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. Unterberg C, et al. **J Am Coll Cardiol** 1995 Dec; 26(7):1747–54

Septic arthritis and bilateral endogenous endophthalmitis associated with percutaneous transluminal coronary angioplasty [letter] Siddiqui MA, et al. **J Am Geriatr Soc** 1996 Apr;44(4):476–7

A new therapeutic monoclonal antibody. Freeman PR. **J Am Pharm Assoc (Wash)** 1996 Feb;NS36(2):90–1

Changes in high-frequency QRS components during prolonged coronary artery occlusion in humans. Pettersson J, et al. **J Electrocardiol** 1995;28 Suppl:225–7

Recent insights into the mechanisms of iatrogenic arteriosclerosis [editorial] Ferns GA, et al. **J Pathol** 1995 Aug;176(4):331–2 (15 ref.)

The relationship between coronary angioplasty procedure volume and major complications [see comments] Kimmel SE, et al. **JAMA** 1995 Oct 11;274(14):1137–42. Comment in: JAMA 1995 Oct 11;274(14):1169–70. Comment in: JAMA 1996 Feb 28;275(8):595; discussion 596. Comment in: JAMA 1996 Feb 28;275(8):595–6.

Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. Fukuyama J, et al. **Jpn J Pharmacol** 1996 Apr;70(4):321–7

The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Fuster V, et al. **Thromb Haemost** 1995 Jul;74(1):552–9 (55 ref.)

Outcome of percutaneous transluminal coronary angioplasty in patients with subclinical hypothyroidism. Mantzoros CS, et al. **Thyroid** 1995 Oct;5(5):383–7

[The experimental observation on the procedure of atherosclerotic restenosis following PTCA] Sun B, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Aug;34(8):528–30 (Eng. Abstr.) (Chi)

[Restenosis: physiopathology, treatments and prevention] Lafont A, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep; 44(7):349–53 (31 ref.) (Eng. Abstr.) (Fre)

[Risks in diagnostic and therapeutic invasive cardiological procedures] Seiler C, et al. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):559–65 (25 ref.) (Eng. Abstr.) (Ger)

[The stent in the treatment of acute coronary occlusion after angioplasty] Piovaccari G. **G Ital Cardiol** 1995 Nov; 25(11):1491–3 (Ita)

[Emergency coronary artery bypass grafting (CABG) in a case of coronary occlusion secondary to long segmental dissection of left anterior descending artery after percutaneous transluminal coronary angioplasty (PTCA)] Yokomuro M, et al. **Kyobu Geka** 1996 Apr;49(4):288–93 (Eng. Abstr.) (Jpn)

[A rare case of coronary artery perforation by a PTCA guide wire complicating with postinfarction cardiac rupture after thrombolytic therapy] Ogino H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1151–4 (Eng. Abstr.) (Jpn)

[Restenosis after percutaneous transluminal coronary angioplasty in the elderly—risk factor analysis] Ishikawa Y, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jul;32(7):491–6 (Eng. Abstr.) (Jpn)

[The effect of the implantation of a Wiktor stent on the curvature of 2 coronary segments. A medium-term follow-up] Loureiro J, et al. **Rev Port Cardiol** 1995 Nov; 14(11):837–40 (Por)

[Acute occlusion of the coronary artery after transluminal balloon coronary angioplasty] Savchenko AP, et al. **Vestn Rentgenol Radiol** 1995 Mar–Apr;(2):10–4 (Eng. Abstr.) (Rus)

[Coronary endovascular prostheses (stents) in the treatment of imminent or acute occlusion as a complication of coronary angioplasty] Escudero X, et al. **Arch Inst Cardiol Mex** 1995 Sep–Oct;65(5):413–9 (Eng. Abstr.) (Spa)

[Reperfusion in myocardial infarction: a two-edged sword] Emanuelsson H, et al. **Lakartidningen** 1996 Mar 20; 93(12):1112–5 (20 ref.) (Swe)

[Antithrombotic treatment in connection with PTCA. New substances and regimes are coming] Scherstén F, et al. **Lakartidningen** 1996 Jun 26;93(26–27):2499–502 (29 ref.) (Swe)

CONTRAINDICATIONS

Angioplasty may be contraindicated in occlusions which are composed mainly of thrombus [letter] Ilia R, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):377

Clinical alert—bypass over angioplasty for patients with diabetes. **Del Med J** 1995 Nov;67(11):594

ECONOMICS

A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction. de Boer MJ, et al. **Am J Cardiol** 1995 Oct 15;76(11):830–3

A cost analysis of coronary stenting without anticoagulation versus stenting with anticoagulation using warfarin. Goods CM, et al. **Am J Cardiol** 1996 Aug 1;78(3):334–6

Impact of the operating physician on costs of percutaneous transluminal coronary angioplasty. Heidenreich PA, et al. **Am J Cardiol** 1996 Jun 1;77(14):1169–73

Cost and therapeutic modification of intracoronary ultrasound-assisted coronary angioplasty. Talley JD, et al. **Am J Cardiol** 1996 Jun 15;77(15):1278–82

Analysis of costs associated with CABG and PTCA. Hlatky MA. **Ann Thorac Surg** 1996 Feb;61(2 Suppl):S30–2; discussion S33–4

Implications of cost in treatment selection for patients with coronary heart disease. Mark DB. **Ann Thorac Surg** 1996 Feb;61(2 Suppl):S12–5; discussion S33–4

Cost comparison between two modes of Palmaz Schatz coronary stent implantation: transradial bare stent technique vs. transfemoral sheath-protected stent technique. Kiemeneij F, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):301–8, discussion 309

A single center randomized trial assessing use of a vascular hemostasis device vs. conventional manual compression following PTCA: what are the potential resource savings? Slaughter PM, et al. **Cathet Cardiovasc Diagn** 1995 Mar; 34(3):210–4

In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators. Cohen DJ, et al. **Circulation** 1995 Nov 1;92(9):2480–7

A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). Weintraub WS, et al. **Circulation** 1995 Nov 15;92(10):2831–40

Cost-efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty [see comments] Mak KH, et al. **J Am Coll Cardiol** 1996 Jul;28(1):106–11. Comment in: J Am Coll Cardiol 1996 Jul;28(1):112–3.

Should percutaneous transluminal coronary angioplasty catheters be reused? [editorial; comment] Natarajan S, et al. **J Am Coll Cardiol** 1996 Jul;28(1):112–3. Comment on: J Am Coll Cardiol 1996 Jul;28(1):106–11.

HISTORY

[Víctor Rubio and Rodolfo Limón. Initiators of the interventionist cardiology] Quijano Pitman F. **Gac Med Mex** 1995 Mar–Apr;131(2):242–3 (Spa)

INSTRUMENTATION

Reuse of coronary angioplasty equipment: technical and clinical issues [editorial] Mak K-H, et al. **Am Heart J** 1996 Mar;131(3):624–30 (49 ref.)

Randomized comparison of flexible versus nonflexible femoral sheaths on patient comfort after angioplasty. Waksman R, et al. **Am Heart J** 1996 Jun;131(6):1076–8

Heparin delivery at the site of angioplasty with a novel drug delivery sleeve. Kaplan AV, et al. **Am J Cardiol** 1996 Feb 1;77(4):307–10

Angiographic and procedural outcome after coronary angioplasty in high-risk subsets using a decremental diameter (tapered) balloon catheter. Tapered Balloon Registry Investigators. Laird JR, et al. **Am J Cardiol** 1996 Mar 15;77(8):561–8

Guide wire-induced coronary artery spasm during percutaneous transluminal coronary angioplasty. A case report. Takahashi M, et al. **Angiology** 1996 Mar;47(3):305–9

Coronary artery enarterectomy for retrieval of entrapped percutaneous angioplasty catheter. Rosario PG, et al. **Ann Thorac Surg** 1996 Jan;61(1):218–9

A total delivery system of genetically engineered drugs or cells for diseased vessels. Concept, materials, and fabricated prototype device. Kito H, et al. **ASAIO J** 1994 Jul–Sep; 40(3):M260–6

Directional coronary atherectomy in the era of stents [editorial; comment] Webster MW, et al. **Aust N Z J Med** 1995 Dec;25(6):661–2. Comment on: Aust N Z J Med 1995 Dec;25(6):676–806.

Guide wire extension may not be essential to pass an over-the-wire balloon catheter. Ahmad T, et al. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):59–60; discussion 61–2

Maintenance of coronary guidewire position during guide catheter exchange [see comments] Azrin MA, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):453–4. Comment in: Cathet Cardiovasc Diagn 1996 Apr;37(4):455.

Right coronary artery pseudo-transection due to mechanical straightening during coronary angioplasty. Blankenship JC. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):43–5 (7 ref.)

Coronary dissection resulting from angioplasty with slow oscillating vs. rapid inflation and slow vs. rapid deflation. Blankenship JC, et al. **Cathet Cardiovasc Diagn** 1995 Mar; 34(3):202–9

Oscillating balloon angioplasty: does pressure oscillation reach the balloon? Blankenship JC, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):109–12

Initial experience using Prostar: a new device for percutaneous suture-mediated closure of arterial puncture sites [see comments] Carere RG, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):367–72. Comment in: Cathet Cardiovasc Diagn 1996 Apr;37(4):373–4.

Left ventriculography revisited [editorial; comment] Cumpston N. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):455. Comment on: Cathet Cardiovasc Diagn 1996 Apr;37(4):453–4.

A perspective: sound—an Aladdin's cave? [editorial] Cumpston N, et al. **Cathet Cardiovasc Diagn** 1995 Mar; 34(3):189–90

Management of coronary artery rupture: covered stent or microcoil embolization. Dorros G, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):148–54; discussion 155

Dual guiding catheters for saphenous venous graft protection during native coronary angioplasty. Freund N, et al. **Cathet Cardiovasc Diagn** 1995 Mar;34(3):255–8

Retrieval of directional coronary atherectomy guiding catheter with angioplasty balloon catheter. el Ghamry Sabe AA, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):237–9

Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. Gurbel PA, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):382–91

Whoops, I didn't realize it was so long! [editorial; comment] Hodgson JM. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):452. Comment on: Cathet Cardiovasc Diagn 1996 Apr;37(4):447–51.

Management of balloon rupture during rigid stent deployment. Keelan ET, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):211–5

Method of preparing, mounting, and implanting a Palmaz-Schatz coronary half-stent from the stent delivery system. Koh TH. **Cathet Cardiovasc Diagn** 1995 Oct; 36(2):164–70; discussion 171–2

Femoral artery hemostasis using an implantable device (Angio-Seal) after coronary angioplasty [see comments] Kussmaul WG, et al. **Cathet Cardiovasc Diagn** 1996 Apr; 37(4):362–5. Comment in: Cathet Cardiovasc Diagn 1996 Apr;37(4):366.

Intravascular ultrasound in the management of acute coronary artery dissection: a case report. Labinaz M, et

al. **Cathet Cardiovasc Diagn** 1995 Mar;34(3):251–4

Coronary angioplasty of bifurcational lesions with the protecting branch technique using 6 French guiding catheter. Metz D, et al. **Cathet Cardiovasc Diagn** 1995 Aug; 35(4):343–7; discussion 348–9

Efficacy of marker wire for intracoronary stenting [see comments] Oda H, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):447–51. Comment in: Cathet Cardiovasc Diagn 1996 Apr;37(4):452.

Influence of expanded balloon diameter on Palmaz–Schatz stent recoil. Rechavia E, et al. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):11–6

Combined percutaneous balloon mitral valvotomy and coronary angioplasty with stent implantation. Röthlisberger C, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):183–5

Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin [see comments] Sankardas MA, et al.
Cathet Cardiovasc Diagn 1996 Apr;37(4):355–9. Comment in: Cathet Cardiovasc Diagn 1996 Apr;47(4):360–1.

Percutaneous hemostatic closure systems: is the cost worth the price? [editorial; comment] Satler LF, et al.
Cathet Cardiovasc Diagn 1996 Apr;37(4):373–4. Comment on: Cathet Cardiovasc Diagn 19906 Apr;37(4):367–72.

Bacteremia associated with percutaneous transluminal coronary angioplasty. Shea KW, et al.
Cathet Cardiovasc Diagn 1995 Sep;36(1):5–9; discussion 10

Do you need IVUS guidance for coronary stent deployment? [editorial; comment] Tobis JM, et al.
Cathet Cardiovasc Diagn 1996 Apr;37(4):360–1. Comment on: Cathet Cardiovasc Diagn 1996 Apr;37(4):355–9.

Has the time come for the plug? [editorial; comment] Vainer J, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):366. Comment on: Cathet Cardiovasc Diagn 1996 Apr;37(4):362–5.

Extensive intramural hematoma as the cause of failed coronary angioplasty: diagnosis by intravascular ultrasound and treatment by stent implantation. Werner GS, et al.
Cathet Cardiovasc Diagn 1995 Oct;36(2):173–8

Intracoronary stents. Wong SC, et al. **Curr Opin Cardiol** 1995 Jul;10(4):404–11 (37 ref.)

Intravascular stents: current applications. Bailey SR, et al. **Curr Probl Cardiol** 1995 Sep;20(9):614–78 (191 ref.)

Angioscopic evaluation of prolonged vs standard balloon inflations during coronary angioplasty. A randomized study. Cribier A, et al. **Eur Heart J** 1995 Jul;16(7):930–6

Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups [see comments] Foley DP, et al. **Eur Heart J** 1995 Oct; 16(10):1331–46. Comment in: Eur Heart J 1995 Oct;16(10):1307–8.

How does a continuous coronary perfusion catheter work in coronary artery dissection? Assessment by intravascular ultrasound [letter] Görge G, et al. **Eur Heart J** 1996 Jan; 17(1):151–2

Assessment of coronary artery stenosis during PTCA by measurement of the trans-stenotic pressure gradient. Comparison with quantitative coronary angiography. Lamm C, et al. **Eur Heart J** 1995 Oct;16(10):1367–74

Restenosis after coronary interventions and device specificity [editorial; comment] Wijns W. **Eur Heart J** 1995 Oct; 16(10):1307–8. Comment on: Eur Heart J 1995 Oct;16(10):1331–46.

Effects of balloon compliance on angiographic and clinical outcomes after PTCA. Goel P, et al. **Int J Cardiol** 1995 Aug;51(1):1–4

The value of computed tomography in combination with a percutaneous transluminal coronary angioplasty guide wire for identifying the definite course of an anomalous left anterior descending artery. van Straalen MJ, et al.
Int J Cardiol 1996 Feb;53(2):189–92

Cost–efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty [see comments] Mak KH, et al. **J Am Coll Cardiol** 1996 Jul;28(1):106–11. Comment in: J Am Coll Cardiol 1996 Jul;28(1):112–3.

Should percutaneous transluminal coronary angioplasty catheters be reused? [editorial; comment] Natarajan S, et al. **J Am Coll Cardiol** 1996 Jul;28(1):112–3. Comment on: J Am Coll Cardiol 1996 Jul;28(1):106–11.

Activated-guidewire technique for treating chronic coronary artery occlusion. Rees MR, et al. **Lancet** 1995 Oct 7; 346(8980):943–4

Treatment of diffuse coronary artery and vein graft disease with a 60–mm–long balloon: early clinical experience. Harris WO, et al. **Mayo Clin Proc** 1995 Nov;70(11):1061–7

Angioplasty pressure–volume measurement. Murray A, et al. **Med Biol Eng Comput** 1995 Sep;33(5):747–8

The autoperfusion balloon catheter with special attention to its use as a bail–out device. Bonnier JJ. **Z Kardiol** 1995; 84 Suppl 2:79–82 (17 ref.)

Coronary stents. Sigwart U. **Z Kardiol** 1995;84 Suppl 2:65–77 (75 ref.)

[Evaluation of the systematic use of wide lumen 6 French guiding catheters in conventional coronary angioplasty] Metz D, et al. **Arch Mal Coeur Vaiss** 1995 Sep;88(9):1291–9 (Eng. Abstr.) **(Fre)**

–Anticoagulation after intracoronary stent implantation– Bode C, et al. **Herz** 1996 Feb;21(1):60–3 (21 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities for reducing radiation dosage in the heart catheterization laboratory] Schätzl M, et al.
Rontgenpraxis 1996 Mar;49(3):55–7 **(Ger)**

[Lumen enlargement in coronary angioplasty: qualitative and quantitative analysis of vascular mechanisms with intravascular ultrasound] Burkhard–Meier, et al.
Z Kardiol 1996 Apr;85(4):281–9 (Eng. Abstr.) **(Ger)**

[Local drug administration systems, preclinical and clinical use: perspectives and limitations] Gonschior P, et al.
Z Kardiol 1996 Mar;85(3):155–65 (59 ref.) (Eng. Abstr.) **(Ger)**

[Normalization of myocardial perfusion reserve after coronary stent implantation in comparison with balloon angioplasty alone] Haude M, et al. **Z Kardiol** 1996 Apr; 85(4):260–72 (Eng. Abstr.) **(Ger)**

[Effect of high insufflation pressures on elastic recoil forces and vascular resistance after balloon dilatation] Hering D, et al. **Z Kardiol** 1996 Apr;85(4):273–80 (Eng. Abstr.) **(Ger)**

[Drug and instrumental therapeutic approaches for prevention of restenosis] Höfling B, et al. **Z Kardiol** 1995; 84 Suppl 4:151–8 (36 ref.) (Eng. Abstr.) **(Ger)**

[PTCA or alternative techniques? Balloon angioplasty remains dominant] Reifart N. **Z Kardiol** 1995;84 Suppl 2:43–52 (30 ref.) (Eng. Abstr.) **(Ger)**

[Noninvasive evaluation of the patency of coronary vessel stents using electron beam tomography segment images with administration of contrast media] Schmermund A, et al. **Z Kardiol** 1995 Nov;84(11):892–7 (Eng. Abstr.) **(Ger)**

[Comment on the contribution by Dr. P. Stähr et al. on the topic "Experimental ultrasound angioplasty: in vitro dissolution of thrombi" (letter; comment)] Steffen W.
Z Kardiol 1995 Dec;84(12):1046–7. Comment on: Z Kardiol 1995 May;84(5):365–72. **(Ger)**

[Stent: from the dental cast to the coronary endoprosthesis] Bartorelli AL. **Cardiologia** 1996 May;41(5):399–401 **(Ita)**

[Experience with the Palmaz–Schatz intracoronary stent] Pereira H, et al. **Rev Port Cardiol** 1995 Nov;14(11):829–32 **(Por)**

METHODS

Perforation of chronic total occlusion with laser guide wire followed by multiple stent deployment: usefulness of three–dimensional intracoronary ultrasound guidance. Prati F, et al. **Am Heart J** 1995 Dec;130(6):1285–9

Effects of prolonged sequential balloon inflations on results of coronary angioplasty. Eltchaninoff H, et al.
Am J Cardiol 1996 May 15;77(12):1062–6

Cost and therapeutic modification of intracoronary ultrasound–assisted coronary angioplasty. Talley JD, et al.
Am J Cardiol 1996 Jun 15;77(15):1278–82

Assessment of a percutaneous Hemopump in high risk coronary angioplasty patients. Dubois–Randé JL, et al.
ASAIO J 1994 Jul–Sep;40(3):M486–8

Coronary 'Y' stenting: a technique for angioplasty of bifurcation stenoses. Fort S, et al. **Can J Cardiol** 1996 Jul; 12(7):678–82

Plasma plasminogen activator inhibitor–1, tissue plasminogen activator and serum lipoprotein(a) after reperfusion therapy in acute myocardial infarction: comparison between sequential and direct percutaneous transluminal coronary angioplasty. Hara M, et al. **Cardiology** 1995;86(5):407–10

Technical considerations in deploying the sheathed Palmaz–Schatz stent in distal coronary artery and bypass graft lesions [see comments] Agarwal R, et al.
Cathet Cardiovasc Diagn 1996 Jan;37(1):73–5. Comment in: Cathet Cardiovasc Diagn 1996 Jan;37(1):76.

In–hospital outcome of percutaneous transluminal coronary angioplasty for long lesions and diffuse coronary artery disease. Kaul U, et al. **Cathet Cardiovasc Diagn** 1995 Aug; 35(4):294–300

Treatment of unprotected left main stenoses with Palmaz–Schatz stenting [see comments] Laham RJ, et al.
Cathet Cardiovasc Diagn 1996 Jan;37(1):77–80. Comment in: Cathet Cardiovasc Diagn 1996 Jan;37(1):81–2.

Coronary angioplasty of bifurcational lesions with the protecting branch technique using 6 French guiding catheter. Metz D, et al. **Cathet Cardiovasc Diagn** 1995 Aug; 35(4):343–7; discussion 348–9

The advantage of anticipating the need for a short guiding catheter [editorial; comment] Satler LF.
Cathet Cardiovasc Diagn 1996 Jan;37(1):76. Comment on: Cathet Cardiovasc Diagn 1996 Jan;37(1):73–5.

Has the time come for percutaneous intervention of left main coronary artery disease? [editorial; comment] Tommaso CL. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):81–2. Comment on: Cathet Cardiovasc Diagn 1996 Jan;37(1):77–80.

EPILOG and CAPTURE trials halted because of positive interim results [news] Ferguson JJ 3rd. **Circulation** 1996 Feb 15;93(4):637

Percutaneous coronary revascularization versus coronary bypass surgery in multivessel disease. Banka VS, et al.
Indian Heart J 1996 Jan–Feb;48(1):73–7 (24 ref.)

Elective stenting for type B and C lesions: immediate results and follow–up angiographic restenosis. Gambhir DS, et al. **Indian Heart J** 1996 Jan–Feb;48(1):53–8

Directional atherectomy for the dilatation of bifurcation stenoses in the coronary arteries. Gambhir DS, et al.
Indian Heart J 1995 Mar–Apr;47(2):115–9

Intra–arterial 90Y brachytherapy: preliminary dosimetric study using a specially modified angioplasty balloon. Popowski Y, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):713–7

New devices in interventional cardiology: present and future. Beyar R. **Isr J Med Sci** 1996 Jul;32(7):515–25 (42 ref.)

Coronary stenting with a novel stainless steel balloon–expandable stent: determinants of neointimal formation and changes in arterial geometry after placement in an atherosclerotic model. Carter AJ, et al.
J Am Coll Cardiol 1996 Apr;27(5):1270–7

High–risk coronary angioplasty assisted by active hemoperfusion. A feasibility study. Angelini P, et al.
Tex Heart Inst J 1996;23(1):15–23

[Treatment policy in coronary sclerosis in The Netherlands: suitable and less suitable indications for invasive interventions] Rigter H, et al. **Ned Tijdschr Geneeskd** 1996 Aug 3;140(31):1584–7 (14 ref.) **(Dut)**

[New tools in coronary artery angioplasty (editorial)] Peuhkurinen K, et al. **Duodecim** 1994;110(6):541–5 (21 ref.) **(Fin)**

[Does gender affect long–term results of coronary angioplasty in patients with multivessel disease?] Le Feuvre C, et al. **Arch Mal Coeur Vaiss** 1996 Jan;89(1):27–33 (Eng. Abstr.) **(Fre)**

[Myocardial adaptation to ischemia. A study during repeated prolonged coronary occlusions in angioplasty] Tron C, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):399–406 (27 ref.) (Eng. Abstr.) **(Fre)**

[Is coronary angioplasty the best treatment of acute myocardial infarction?] Himbert D, et al. **Presse Med** 1995 Dec 9;24(38):1831–5 (32 ref.) (Eng. Abstr.) **(Fre)**

[New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)] Schächinger V, et al. **Z Kardiol** 1995 Sep;84(9):651–67 (152 ref.) (Eng. Abstr.) **(Ger)**

[Percutaneous transluminal coronary angioplasty and myocardial revascularization. Current status and role of clinical trials] Mullany CJ, et al. **Arq Bras Cardiol** 1995 Jun;64(6):511–4 **(Por)**

[Coronary angioplasty through the transradial approach] Pessanha A, et al. **Arq Bras Cardiol** 1995 May;64(5):465–8 (Eng. Abstr.) **(Por)**

MORTALITY

Death following direct infarct angioplasty: lessons that we've learned [editorial; comment] Kahn JK.
Cathet Cardiovasc Diagn 1995 Jul;35(3):197. Comment on: Cathet Cardiovasc Diagn 1995 Jul;35(3):192–6.

Timing, mode, and predictors of death after direct angioplasty for acute myocardial infarction [see comments] Krikorian RK, et al. **Cathet Cardiovasc Diagn** 1995 Jul; 35(3):192–6. Comment in: Cathet Cardiovasc Diagn 1995 Jul;35(3):197.

Potentiation of vasculopathy by insulin: implications from an NHLBI clinical alert [editorial] Sobel BE.
Circulation 1996 May 1;93(9):1613–5 (20 ref.)

[Transluminal coronary angioplasty in patients with left ventricular dysfunction; immediate and long term results] Beurrier D, et al. **Arch Mal Coeur Vaiss** 1995 Feb; 88(2):225–30 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Psychosocial characteristics and recurrent events after percutaneous transluminal coronary angioplasty. Mendes de Leon CF, et al. **Am J Cardiol** 1996 Feb 1;77(4):252–5

[Quality of life following coronary surgery and balloon angioplasty; more chest pain and social inhibition following angioplasty] van Berkel TF, et al.
Ned Tijdschr Geneeskd 1995 Aug 26;139(34):1733–7 (Eng. Abstr.) **(Dut)**

[Psychosomatic determinants of restenosis after percutaneous transluminal coronary angioplasty] Titscher G, et al.
Z Psychosom Med Psychoanal 1996;42(2):154–68 (Eng. Abstr.) **(Ger)**

REHABILITATION

Safety of medically supervised exercise in a cardiac rehabilitation center. Vongvanich P, et al.
Am J Cardiol 1996 Jun 15;77(15):1383–5

Behavioral differences and effects of cardiac rehabilitation in diabetic patients following cardiac events. Milani RV, et al. **Am J Med** 1996 May;100(5):517–23

Life after a cardiac event: women's experience in healing. Fleury J, et al. **Heart Lung** 1995 Nov–Dec;24(6):474–82

Diagnostic and functional exercise testing: test selection and interpretation. Franklin BA. **J Cardiovasc Nurs** 1995 Oct; 10(1):8–29 (57 ref.)

[Occupational rehabilitation after percutaneous transluminal coronary angioplasty (PTCA)—correlation with subjective and objective parameters] Albrecht D, et al. **Z Kardiol** 1995 Nov;84(11):885–91 (Eng. Abstr.) **(Ger)**

[What determines disease outcome after PTCA? (letter)] Herrmann C, et al. **Z Kardiol** 1996 Apr;85(4):290–1 **(Ger)**

STANDARDS

President's page: quantity and quality—Is 75 the answer? [news] Kennedy JW. **J Am Coll Cardiol** 1996 Jan; 27(1):236–7

Primary angioplasty and thrombolysis for acute myocardial

infarction: an evidence summary [see comments] Lieu TA, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):737–50 (76 ref.) . Comment in: J Am Coll Cardiol 1996 Mar 1;27(3):736.
[Quality assurance in invasive cardiology. A prospective study for the evaluation of indications for coronary angiography and coronary dilatation using the Rand Corporation method] Kadel C, et al.
Dtsch Med Wochenschr 1996 Apr 12;121(15):465–71 (Eng. Abstr.) **(Ger)**
[Guidelines of the Brazilian Cardiology Society on coronary transluminal angioplasty] **Arq Bras Cardiol** 1995 May; 64(5):491–500 **(Por)**

STATISTICS & NUMERICAL DATA

European survey on cardiac interventions: open-heart surgery, percutaneous transluminal coronary angioplasty and cardiac catheterization in 1993. A preliminary report by the Institute for Cardiac Survey of the European Academy of Sciences and Arts. Unger F.
Cardiovasc Surg 1995 Dec;3(6):569–71

TRENDS

Changing outcome of angioplasty in the elderly. Thompson RC, et al. **J Am Coll Cardiol** 1996 Jan;27(1):8–14

UTILIZATION

Revascularization options: implications for critical transport [letter] Silbergleit R, et al. **Acad Emerg Med** 1995 Jun; 2(6):568–9
Effect of the increasing use of coronary angioplasty on outcome at one year in patients with unstable angina. De Servi S, et al. **Br Heart J** 1995 Dec;74(6):680–4
Coronary interventions in Europe 1992 [editorial; comment] Erbel R. **Eur Heart J** 1995 Jul;16(7):873–4. Comment on: Eur Heart J 1995 Jul;16(7):922–9.
Coronary interventions in Europe 1992. The Working Group on Coronary Circulation of the European Society of Cardiology [see comments] Röthlisberger C, et al.
Eur Heart J 1995 Jul;16(7):922–9. Comment in: Eur Heart J 1995 Jul;16(7):873–4.
Contemporary practice of coronary revascularization in U.S. hospitals and hospitals participating in the bypass angioplasty revascularization investigation (BARI). Detre KM, et al. **J Am Coll Cardiol** 1996 Sep;28(3):609–15
Care of acute myocardial infarction by noninvasive and invasive cardiologists: procedure use, cost and outcome. Di Salvo TT, et al. **J Am Coll Cardiol** 1996 Feb;27(2):262–9
The relationship between coronary angioplasty procedure volume and major complications [see comments] Kimmel SE, et al. **JAMA** 1995 Oct 11;274(14):1137–42. Comment in: JAMA 1995 Oct 11;274(14):1169–70. Comment in: JAMA 1996 Feb 28;275(8):595; discussion 596. Comment in: JAMA 1996 Feb 28;275(8):595–6.
The critical question of procedure volume minimums for coronary angioplasty [editorial; comment] Ryan TJ.
JAMA 1995 Oct 11;274(14):1169–70. Comment on: JAMA 1995 Oct 11;274(14):1137–42.
[The summary results of percutaneous transluminal coronary angioplasty at the Sveta Ekaterina State University Hospital in 1991–1994] Dzhorgova Iu, et al.
Khirurgiia (Sofiia) 1995;48(1):51–8 (Eng. Abstr.) **(Bul)**

ANGIOSARCOMA see **HEMANGIOSARCOMA**

ANGIOSCOPY

Findings of coronary angioscopy in angiographically normal coronary segments of patients with coronary artery disease. Alfonso F, et al. **Am Heart J** 1995 Nov;130(5):987–93
Coronary angioscopy confirms the presence of red thrombus in acute myocardial infarction after blunt chest trauma. Jessurun GA, et al. **Am Heart J** 1996 Jun;131(6):1216–8
Angioscopic detection of residual pulmonary thrombi in the differential diagnosis of pulmonary embolism. Uchida Y, et al. **Am Heart J** 1995 Oct;130(4):854–9
Usefulness of adjunctive angioscopy and extraction atherectomy before stent implantation in high-risk aortocoronary saphenous vein grafts. Kaplan BM, et al. **Am J Cardiol** 1995 Oct 15;76(11):822–4
Acute popliteal arterial injury: the role of angioscopy. Alimi Y, et al. **Ann Vasc Surg** 1995 Jul;9(4):361–8
Value of angioscopy for intraoperative assessment of carotid endarterectomy. Branchereau A, et al. **Ann Vasc Surg** 1995; 9 Suppl:S67–75
Angioscopy in vascular surgery: the state of the art. Pevec WC. **Ann Vasc Surg** 1996 Jan;10(1):66–75 (71 ref.)
Role of vascular endoscopy in aortoiliac and femoropopliteal thromboendarterectomy. Kogel H, et al.
Cardiovasc Surg 1996 Feb;4(1):93–6
Angioscopy guided intracoronary thrombolysis and stent deployment in a patient with postinfarction angina. Eltchaninoff H, et al. **Cathet Cardiovasc Diagn** 1995 Jul; 35(3):282–6
Clinical application of coronary angioscopic examination. Wang SP, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Oct;56(4):220–5
Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases. Blockmans D, et al.
Clin Rheumatol 1996 Mar;15(2):148–53
Angioscopy for quality control of saphenous vein during bypass grafting. Wilson YG, et al.
Eur J Vasc Endovasc Surg 1996 Jan;11(1):12–8
Angioscopically-assisted in situ saphenous vein bypass for infrainguinal revascularisation. Wilson YG, et al.
Eur J Vasc Endovasc Surg 1996 Aug;12(2):223–9
Coronary angioscopy: exploring new frontiers. Shaw D, et al. **Indian Heart J** 1995 May-Jun;47(3):269–73 (51 ref.)
Angiovideo-assisted hemodynamic correction of varicose veins. Zamboni P, et al. **Int Angiol** 1995 Jun;14(2):202–8
Intracoronary morphology of culprit lesions after reperfusion in acute myocardial infarction: serial angioscopic observations. Ueda Y, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):606–10
Intraoperative coronary artery dilatation with angioscopic guidance. Siegel SB, et al. **J Card Surg** 1995 Jul;10(4 Pt 1):298–301
Angioscopy in the operating room. Marzelle J.
J Cardiovasc Surg (Torino) 1996 Jun;37 Suppl 1:11–6
Angioscopy in the operating room. Marzelle J.
J Cardiovasc Surg (Torino) 1996 Jun;37(3 Suppl 1):11–6
Virtual MR angioscopy of the pulmonary artery tree. Ladd ME, et al. **J Comput Assist Tomogr** 1996 Sep–Oct; 20(5):782–5
[Comparison between the CHIVA cure and stripping in the treatment of varicose veins of the legs: follow-up of 3 years] Cappelli M, et al. **J Mal Vasc** 1996;21(1):40–6 (Eng. Abstr.) **(Fre)**
[Video-assisted venous surgery] Zamboni P, et al.
Ann Ital Chir 1995 May-Jun;66(3):379–86 (Eng. Abstr.) **(Ita)**
[Percutaneous coronary angioscopy: 200 observations in 100 candidates for angioplasty] Escudero X, et al.
Arch Inst Cardiol Mex 1995 Jul-Aug;65(4):307–14 (Eng. Abstr.) **(Spa)**
[Coronary angioscopy: initial experience during coronary interventions] Alfonso F, et al. **Rev Esp Cardiol** 1995 Dec; 48(12):798–806 (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Angioscopic evaluation of prolonged vs standard balloon inflations during coronary angioplasty. A randomized study. Cribier A, et al. **Eur Heart J** 1995 Jul;16(7):930–6
Aortoscopy: a guidance system for endoluminal aortic surgery. Hill BB, et al. **J Vasc Surg** 1996 Sep;24(3):439–47; discussion 448
Angioscopy of arm veins. Miller A, et al.
Semin Vasc Surg 1995 Sep;8(3):188–95
[Angioscopy as intraoperative outcome control after reconstructive surgery of the renal arteries: presentation of a new method] Reiher L, et al. **Chirurg** 1995 Sep; 66(9):914–5 (Eng. Abstr.) **(Ger)**

METHODS

Human aorta: preliminary results with virtual endoscopy based on three-dimensional MR imaging data sets. Davis CP, et al. **Radiology** 1996 Apr;199(1):37–40

ANGIOSTRONGYLUS

Angiostrongylus costaricensis: first record of its occurrence in the State of Espirito Santo, Brazil, and a review of its geographic distribution. Pena GP, et al.
Rev Inst Med Trop Sao Paulo 1995 Jul-Aug;37(4):369–74
[Abdominal angiostrongyliasis: its prevention by the destruction of infecting larvae in food treated with salt, vinegar or sodium hypochlorite] Zanini GM, et al.
Rev Soc Bras Med Trop 1995 Oct-Dec;28(4):389–92 (Eng. Abstr.) **(Por)**

GROWTH & DEVELOPMENT

In vitro cultivation of Angiostrongylus costaricensis eggs to first stage larvae in chemically defined medium. Hata H.
Int J Parasitol 1996 Mar;26(3):281–6

ISOLATION & PURIFICATION

Angiostrongylus costaricensis in a black-eared marmoset. Brack M, et al. **Trop Geogr Med** 1995;47(3):136–8
Role of chronic disseminated intravascular coagulation in a case of canine angiostrongylosis. Ramsey IK, et al.
Vet Rec 1996 Apr 13;138(15):360–3

PHYSIOLOGY

Presence of Strongyluris-like larvae (Nematoda) in some terrestrial molluscs in Brazil. Thiengo SC.
Mem Inst Oswaldo Cruz 1995 Sep–Oct;90(5):619–20

ANGIOSTRONGYLUS CANTONENSIS

L ferritin accumulation in macrophages infiltrating the lung during rat Angiostrongylus cantonensis infection. Lee HH, et al. **Exp Parasitol** 1996 Jun;83(1):55–61
The susceptibility of five stains mice to infections with Angiostrongylus cantonensis. Wang JJ, et al.
Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1995 Nov; 11(11):599–603
Eosinophilic meningitis. Is angiostrongylus cantonensis endemic in Jamaica? Barrow KO, et al.
West Indian Med J 1996 Jun;45(2):70–1
[Ingestion of raw fish: a cause of eosinophilic meningitis caused by Angiostrongylus cantonensis after a trip to Tahiti (letter)] Thobois S, et al. **Presse Med** 1996 Mar 23; 25(10):508 **(Fre)**
[Eosinophil meningoradiculitis caused by Angiostrongylus cantonensis] Vuadens P, et al. **Rev Neurol (Paris)** 1995 May; 151(5):354–6 (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Effects of PF1022A on adult Angiostrongylus cantonensis in the pulmonary arteries and larvae migrating into the central nervous system of rats. Kachi S, et al.
Parasitol Res 1995;81(8):631–7
In vitro effects of VD-99-11 on Angiostrongylus cantonensis and isolated frog rectus. Lee HH, et al. **Parasitol Res** 1995; 81(7):615–21

GENETICS

Stage-specifically expressed genes of Angiostrongylus cantonensis: identification by differential display. Joshua GW, et al. **Mol Biochem Parasitol** 1995 May;71(2):285–9

IMMUNOLOGY

Detection of antibodies to surface antigens of Angiostrongylus cantonensis by ELISA. Chang JH, et al.
Ann Trop Med Parasitol 1995 Oct;89(5):569–72
Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5R alpha-deficient mice. Yoshida T, et al. **Immunity** 1996 May; 4(5):483–94

ANGIOTENSIN see **ANGIOTENSIN II**

ANGIOTENSIN I

Angiotensin type 1 receptor antagonists CV-11974 and EXP 3174 cause selective renal vasodilatation in conscious spontaneously hypertensive rats. Li XC, et al.
Clin Sci (Colch) 1996 Aug;91(2):147–54
Stimulation of cortisol production through angiotensin AT2 receptors in bovine fasciculata cells. Defaye G, et al.
Endocr Res 1995 Feb-May;21(1-2):183–7

ADVERSE EFFECTS

Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I. Inglessis N, et al. **J Cardiovasc Pharmacol** 1995 Jun; 25(6):986–93

ANALOGS & DERIVATIVES

Effects of des-Asp-angiotensin I on the electrically stimulated contraction of the rabbit pulmonary artery. Sim MK, et al. **Eur J Pharmacol** 1995 Sep 15;284(1-2):215–9

ANTAGONISTS & INHIBITORS

The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Sladek T, et al. **Cardiovasc Res** 1996 Apr;31(4):568–76
Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men. Goldberg MR, et al.
Clin Pharmacol Ther 1996 Jan;59(1):72–82

BIOSYNTHESIS

Activation of angiotensin-generating systems in the developing rat kidney. Yosipiv IV, et al. **Hypertension** 1996 Feb;27(2):281–6
[Alternative pathways of angiotensin I. The glimpse of new possibilities in the treatment of hypertension and heart failure (editorial)] Francischetti EA. **Arq Bras Cardiol** 1995 Mar;64(3):191–4 (49 ref.) **(Por)**

BLOOD

Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. Campbell DJ, et al.
J Cardiovasc Pharmacol 1995 Aug;26(2):233–40
[Angiotensin I] Arita M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:695–8 (12 ref.) **(Jpn)**

METABOLISM

The contribution of AT1 and AT2 angiotensin receptors to its cognitive effects. Braszko J.
Acta Neurobiol Exp (Warsz) 1996;56(1):49–54
Metabolism of angiotensin I in isolated rat hearts. Effect of angiotensin converting enzyme inhibitors. Neves LA, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1451–9
Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Brown DC, et al. **Br J Pharmacol** 1996 May;118(2):414–20
Effect of chronic treatment with ME3221 on blood pressure and mortality in aged stroke-prone spontaneously hypertensive rats. Nagura J, et al.
Clin Exp Pharmacol Physiol 1995 Dec;22 Suppl 1:S363–5
Renal pharmacology of GR138950, a novel non-peptide angiotensin AT1 receptor antagonist. Clark KL, et al.
Eur J Pharmacol 1995 Jul 4;280(2):195–203
Identification of atypical (non-AT1, non-AT2) angiotensin binding sites with high affinity for angiotensin I on IEC-18 rat intestinal epithelial cells. Smith RD. **FEBS Lett** 1995 Oct 16;373(3):199–202

ANGIOTENSIN I

Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Bloem LJ, et al. **Hypertension** 1996 Jan;27(1):62-6

Effects of dietary salt on angiotensin peptides in kidney. Meng QC, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1209-15

Converting enzyme inhibition and its withdrawal in spontaneously hypertensive rats. Campbell DJ, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):426-36

Molecular biology of angiotensin receptors and their role in human cardiovascular disease. Regitz-Zagrosek V, et al. **J Mol Med** 1996 May;74(5):233-51 (229 ref.)

Angiotensin II-forming activity in a reconstructed ancestral chymase. Chandrasekharan UM, et al. **Science** 1996 Jan 26;271(5248):502-5

PHARMACOLOGY

[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Korshak OL, et al. **Fiziol Zh** 1994 Sep-Dec;40(5-6):15-9 (Eng. Abstr.) **(Ukr)**

ANGIOTENSIN II

see related

RENIN-ANGIOTENSIN SYSTEM

New angiotensin-II blocker. Lilley LL, et al. **Am J Nurs** 1996 Mar;96(3):20

Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Sadoshima J, et al. **Circ Res** 1995 Dec;77(6):1040-52

Isolation and identification of angiotensin-like peptides from the plasma of the snake Bothrops jararaca. Borgheresi RA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar;113(3):467-73

Regional hemodynamic effects of the AT1 receptor antagonist CV-11974 in conscious renal hypertensive rats. Li XC, et al. **Hypertension** 1995 Dec;26(6 Pt 1):989-97

Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase. Hou J, et al. **J Clin Invest** 1995 Nov;96(5):2469-77

Charge heterogeneity of the AT1 angiotensin II receptor subtype in the rat lung. Montiel M, et al. **J Endocrinol** 1995 Oct;147(1):153-9

ADMINISTRATION & DOSAGE

Acute and chronic angiotensin hypertension: neural and nonneural components, time course, and dose dependency. Li Q, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R200-7

Smooth muscle DNA replication in response to angiotensin II is regulated differently in the neointima and media at different times after balloon injury in the rat carotid artery. Role of AT1 receptor expression. deBlois D, et al. **Arterioscler Thromb Vasc Biol** 1996 Sep;16(9):1130-7

Progesterone administration to ovariectomized rats reduces water and salt intake induced by central administration of angiotensin II. do-Vale CF, et al. **Braz J Med Biol Res** 1995 Sep;28(9):999-1002

Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects. Jamerson KA, et al. **Hypertension** 1996 Apr;27(4):854-8

Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Munzenmaier DH, et al. **Hypertension** 1996 Mar;27(3 Pt 2):760-5

Hypertensive intra-arterial chemotherapy for endometrial carcinoma assessed by transvaginal Doppler ultrasound and magnetic resonance imaging. Hata K, et al. **J Clin Ultrasound** 1995 Sep;23(7):407-11

Chronic infusion of low-dose angiotensin II potentiates the adrenergic response in vivo. Dowell FJ, et al. **J Hypertens** 1996 Feb;14(2):177-82

Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. Hopkins PN, et al. **J Hypertens** 1996 Feb; 14(2):199-207

201Tl and 99Tcm-human serum albumin for assessment of the effect of hypertensive treatment with angiotensin II infusion on tumour circulation. Kinuya S, et al. **Nucl Med Commun** 1996 Feb;17(2):160-3

Dose and time dependency of angiotensin II inhibition of hippocampal long-term potentiation. Wayner MJ, et al. **Peptides** 1995;16(6):1079-82

[A case of intrahepatic infusion chemotherapy with angiotensin II human for liver metastasis from early gastric cancer] Iwasaki Y, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1674-8 (Eng. Abstr.) **(Jpn)**

AGONISTS

Differences in backbone structure between angiotensin II agonists and type I antagonists. Matsoukas JM, et al. **J Med Chem** 1995 Nov 10;38(23):4660-9

ANALOGS & DERIVATIVES

Design and pharmacology of peptide mimetics. Moore GJ, et al. **Adv Pharmacol** 1995;33:91-41 (112 ref.)

Physiological doses of [Ile5]- and [Val5]-Angiotensin II fail to increase plasma catecholamines at the peak pressor response in rats. Butler DG, et al. **Arch Int Pharmacodyn Ther** 1995 Mar-Apr;329(2):272-82

Distribution of AT4 receptors in the Macaca fascicularis brain. Moeller I, et al. **Brain Res** 1996 Mar 18;712(2):307-24

Autoradiographic identification of brain angiotensin IV binding sites and differential c-Fos expression following intracerebroventricular injection of angiotensin II and IV in rats. Roberts KA, et al. **Brain Res** 1995 Jun 5; 682(1-2):13-21

Specific binding sites for (3-8)angiotensin in C6 glioma cells. Wyse B, et al. **Brain Res** 1995 May 29;681(1-2):41-6

Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Santos RA, et al. **Hypertension** 1996 Apr;27(4):875-84

Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. Kerins DM, et al. **J Clin Invest** 1995 Nov;96(5):2515-20

Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications. Zhang WJ, et al. **J Med Chem** 1996 Jul 5; 39(14):2738-44

Angiotensin II is a potent stimulator of MAP-kinase activity in neonatal rat cardiac fibroblasts. Schorb W, et al. **J Mol Cell Cardiol** 1995 May;27(5):1151-60

Tachyphylaxis to angiotensin II and [Phe4]-angiotensin II in the rat mesentery in vivo. Tofovic SP, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):13-20

Characterization of a functional angiotensin IV receptor on coronary microvascular endothelial cells. Hall KL, et al. **Regul Pept** 1995 Aug 22;58(3):107-15

Effect of [1-Sar,8-Thr]-angiotensin II on the hyperglycemic response to hemorrhage in adrenodemedullated and guanethidine-treated rats. Machado LJ, et al. **Regul Pept** 1995 Dec 7;60(1):69-77

[Angiotensin IV, a new component of the renin-angiotensin system, which acts on kidney cells] Ardaillou R, et al. **Bull Acad Natl Med** 1996 Feb;180(2):475-86; discussion 486-8 (Eng. Abstr.) **(Fre)**

ANALYSIS

Sensitive bioassay for the detection and quantification of angiotensin II in tissue culture medium. Lin C, et al. **Biotechniques** 1995 Jun;18(6):1014-20

Ontogeny of angiotensin II receptors. Shanmugam S, et al. **Cell Biol Int** 1996 Mar;20(3):169-76 (42 ref.)

Determination of renin, angiotensin converting enzyme and angiotensin II levels in human placenta, chorion and amnion from women with pregnancy induced hypertension. Kalenga MK, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):429-33

Separation of eleven angiotensin II analogs by capillary electrophoresis with a nonionic surfactant in acidic media. Matsubara N, et al. **Electrophoresis** 1995 Apr;16(4):580-3

Localization and distribution of angiotensin II in the rat epididymis. Zhao W, et al. **J Endocrinol** 1996 May; 149(2):217-22

Co-localization of angiotensin II and gamma-aminobutyric acid in axon terminals in the rat subfornical organ. Pickel VM, et al. **Neurosci Lett** 1995 Jun 30;193(2):89-92

Application of the fast-evaporation sample preparation method for improving quantification of angiotensin II by matrix-assisted laser desorption/ionization. Nicola AJ, et al. **Rapid Commun Mass Spectrom** 1995;9(12):1164-71

ANTAGONISTS & INHIBITORS

Angiotensin II antagonists block ethanol effects on the aerial righting reflex. Tracy HA Jr, et al. **Alcohol** 1996 May-Jun; 13(3):287-9

Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Awan NA, et al. **Am Heart J** 1996 Jan; 131(1):177-85 (81 ref.)

Angiotensin II receptor blockers. A new class of antihypertensive drugs. Velasquez MT. **Arch Fam Med** 1996 Jun;5(6):351-6 (60 ref.)

Physiological doses of [Ile5]- and [Val5]-Angiotensin II fail to increase plasma catecholamines at the peak pressor response in rats. Butler DG, et al. **Arch Int Pharmacodyn Ther** 1995 Mar-Apr;329(2):272-82

Effects of losartan, an angiotensin II antagonist, on the development of cardiac hypertrophy due to volume overload. Ishiye M, et al. **Biol Pharm Bull** 1995 May; 18(5):700-4

The effect of HN-65021 on responses to angiotensin II in human forearm vasculature. Cockcroft JR, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):591-3

Angiotensin II receptor subtypes and phosphoinositide hydrolysis in rat adrenal medulla. Israel A, et al. **Brain Res Bull** 1995;38(5):441-6

Inhibitory effect of DUP-753 on the drinking responses of rats to central administration of noradrenaline and angiotensin II and to dehydration. Reis LC, et al. **Braz J Med Biol Res** 1996 Apr;29(4):507-10

Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade. Kiely DG, et al. **Cardiovasc Res** 1995 Dec;30(6):875-80

Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Furukawa Y, et al. **Circulation** 1996 Jan 15;93(2):333-9

Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system [editorial] Pratt RE, et al. **Circulation** 1996 Mar 1; 93(5):848-52

Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men. Goldberg MR, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):72-82

Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man. Schmitt F, et al. **Clin Sci (Colch)** 1996 Mar;90(3):205-13

Angiotensin II receptor antagonism: losartan - sites and mechanisms of action. Triggle DJ. **Clin Ther** 1995 Nov-Dec;17(6):1005-30 (132 ref.)

Disposition of DMP 811 (L-708,404), a potent angiotensin II receptor antagonist, in the rat, monkey, and chimpanzee. Zhang KE, et al. **Drug Metab Dispos** 1995 Oct; 23(10):1104-9

In vitro pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors. Chang RS, et al. **Eur J Pharmacol** 1995 Dec 29;294(2-3):429-37

In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors. Kivlighn SD, et al. **Eur J Pharmacol** 1995 Dec 29; 294(2-3):439-50

Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension. Ito K, et al. **Hypertens Res** 1995 Mar;18(1):69-75

Nitric oxide and the depressor response to angiotensin blockade in hypertension. Guan H, et al. **Hypertension** 1996 Jan;27(1):19-24

Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Oliveira DR, et al. **Hypertension** 1996 Jun;27(6):1284-90

Discovery of an angiotensin II binding inhibitor from a Cytospora sp. using semi-automated screening procedures. Stevens-Miles S, et al. **J Antibiot (Tokyo)** 1996 Feb; 49(2):119-23

Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. Campbell DJ, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):233-40

Effects of losartan on contractile responses of conductance and resistance arteries from rats. Corriu C, et al. **J Cardiovasc Pharmacol** 1995 Nov;26(5):688-92

Effects of the angiotensin II receptor antagonist losartan on 24-hour blood pressure profiles of primary and secondary hypertensive rats. Schnecko A, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):214-21

Effects of angiotensin II antagonists on the contractile and hydrosmotic effect of AT II and AT III in the toad (Bufo arenarum). Peral de Bruno M, et al. **J Comp Physiol [B]** 1996;165(7):565-70

Losartan: the first angiotensin receptor antagonist in clinical use. Beevers DG. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S1

Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. Dahlöf B. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S37-44 (84 ref.)

The future role of losartan. Hansson L. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S55-8 (24 ref.)

Evolution of blockade of the renin-angiotensin system. Johnston CI, et al. **J Hum Hypertens** 1995 Jun;9(6):375-80 (46 ref.)

Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? Moan A, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S45-50

Discovery of losartan, the first angiotensin II receptor antagonist. Timmermans PB, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S3-18 (199 ref.)

Angiotensin II receptor antagonist CV-11974 and cerebral blood flow autoregulation. Vraamark T, et al. **J Hypertens** 1995 Jul;13(7):755-61

Diphenylpropionic acids as new AT1 selective angiotensin II antagonists. Almansa C, et al. **J Med Chem** 1996 May 24;39(11):2197-206

Differences in backbone structure between angiotensin II agonists and type I antagonists. Matsoukas JM, et al. **J Med Chem** 1995 Nov 10;38(23):4660-9

4-(Heteroarylthio)-2-biphenylyltetrazoles as nonpeptide angiotensin II antagonists. Norman MH, et al. **J Med Chem** 1995 Nov 10;38(23):4670-8

The angiotensin receptor antagonist 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV11974) attenuates the tubuloglomerular feedback response during NO synthase blockade in rats. Kawata T, et al. **J Pharmacol Exp Ther** 1996 May;277(2):572-7

Comparable effects of angiotensin II and converting enzyme blockade on hemodynamics and cardiac hypertrophy in spontaneously hypertensive rats. Mori T, et al. **Jpn Circ J** 1995 Sep;59(9):624-30

Nitric oxide antagonizes the actions of angiotensin II to enhance tubuloglomerular feedback responsiveness. Braam B, et al. **Kidney Int** 1995 Nov;48(5):1406-11

Prodrugs to improve the oral bioavailability of a diacidic nonpeptide angiotensin II antagonist. Aungst BJ, et al. **Pharm Res** 1995 May;12(5):763-7

The role of the renin-angiotensin system in cisplatin nephrotoxicity. Deegan PM, et al. **Ren Fail** 1995 Nov; 17(6):665-74

[Hormonal contribution to short-term variability of blood pressure in a renovascular hypertension model] Ponchon

P, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88(8):1203–7 (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

Mechanisms of angiotensin II formation in humans. Urata H, et al. **Eur Heart J** 1995 Dec;16 Suppl N:79–85 (63 ref.)

Human urinary kallikrein can generate angiotensin II from homologous renin substrates. Sasaguri M, et al. **Hypertens Res** 1995 Mar;18(1):33–7

Activation of angiotensin-generating systems in the developing rat kidney. Yosipiv IV, et al. **Hypertension** 1996 Feb;27(2):281–6

Inhibitory effect of an angiotensin II type 1 receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Kubo A, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):58–63

Expression of angiotensin II and its receptor subtypes in endometrial hyperplasia: a possible role in dysfunctional menstruation. Li XF, et al. **Lab Invest** 1996 Aug; 75(2):137–45

Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Takai S, et al. **Life Sci** 1996;58(7):591–7

Potentiation by enalaprilat of fenoldopam-evoked natriuresis is due to blockade of intrarenal production of angiotensin-II in rats. Chen C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug; 352(2):194–200

Effects of long-term treatment with angiotensin-converting enzyme inhibitor on angiotensin II and prostacyclin release from mesenteric arteries in spontaneously hypertensive rats. Ito M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov;53(5):359–63

[Alternative pathways of angiotensin I. The glimpse of new possibilities in the treatment of hypertension and heart failure (editorial)] Francischetti EA. **Arq Bras Cardiol** 1995 Mar;64(3):191–4 (49 ref.) **(Por)**

BLOOD

Influence of humoral and neurohormonal factors on cardiovascular hypertrophy in untreated essential hypertensives. Schroeder AP, et al. **Am J Hypertens** 1996 Mar;9(3):207–15

Angiotensin II-induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin. Sigusch HH, et al. **Cardiovasc Res** 1996 Apr;31(4):546–54

Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Harrap SB, et al. **Circulation** 1996 Mar 15;93(6):1148–54

Participation of the renin-angiotensin system in regulating the excretory response to acute sodium ingestion. Duggan KA, et al. **Clin Exp Pharmacol Physiol** 1995 Jun-Jul; 22(6-7):455–6

Radioimmunoassay of angiotensin-II: methodology and standardization. Lall SB, et al. **Indian J Exp Biol** 1995 Dec; 33(12):921–5

Angiotensin converting enzyme inhibition of the gonadotropin-stimulated rabbit: effect on estradiol production. Morris RS, et al. **J Assist Reprod Genet** 1995 May;12(5):326–9

[Angiotensin II] Wanaka Y, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:699–701 (9 ref.) **(Jpn)**

CHEMISTRY

Conformational study of angiotensin II. Shin YA, et al. **Biopolymers** 1996 Feb;38(2):183–90

Application of capillary electrophoresis to amino acid sequencing of peptide. Kim NJ, et al. **Electrophoresis** 1995 Apr;16(4):510–5

Proposals for the angiotensin II receptor-bound conformation by comparative computer modeling of AII and cyclic analogs. Joseph MP, et al. **Int J Pept Protein Res** 1995 Dec;46(6):514–26

Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. Noda K, et al. **J Biol Chem** 1995 Dec 1;270(48):28511–4

Characterization of radiation-induced thymine-tyrosine crosslinks by electrospray ionization mass spectrometry. Weir Lipton MS, et al. **Radiat Res** 1996 Jun;145(6):681–6

[Comparative study of the structure and molecular functions of angiotensin II and vasopressin receptors] Clauser E. **C R Seances Soc Biol Fil** 1995;189(2):179–90 (37 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSTIC USE

The angiotensin sensitivity test and low-dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. Kyle PM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):865–72

DRUG EFFECTS

Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Ruzicka M, et al. **Circulation** 1995 Dec 15;92(12):3568–73

GENETICS

Molecular basis of human hypertension: the role of angiotensin. Peters J. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):657–78 (80 ref.)

Multiple growth factors modulate mRNA expression of angiotensin II type-2 receptor in R3T3 cells. Ichiki T, et al. **Circ Res** 1995 Dec;77(6):1070–6

Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy. Dieguez-Lucena JL, et al. **Hypertension** 1996 Jul;28(1):98–103

Cloning, characterization, and genetic mapping of the rat type 2 angiotensin II receptor gene. Koike G, et al. **Hypertension** 1995 Dec;26(6 Pt 1):998–1002

Angiotensin II type 2 receptor mRNA expression in the developing cardiopulmonary system of the rat. Shanmugam S, et al. **Hypertension** 1996 Jul;28(1):91–7

Gene expression of angiotensin II receptor in blood cells of Cushing's syndrome. Shibata H, et al. **Hypertension** 1995 Dec;26(6 Pt 1):1003–10

Distinct mechanisms of upregulation of type 1A angiotensin II receptor gene expression in kidney and adrenal gland. Wang DH, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1134–7

The roles of CRE, TRE, and TRE-adjacent S1 nuclease sensitive element in the regulation of tyrosine hydroxylase gene promoter activity by angiotensin II. Kim EL, et al. **J Neurochem** 1996 Jul;67(1):26–36

METABOLISM

The contribution of AT1 and AT2 angiotensin receptors to its cognitive effects. Braszko J. **Acta Neurobiol Exp (Warsz)** 1996;56(1):49–54

Angiotensin peptides in the brain. Campbell DJ. **Adv Exp Med Biol** 1995;377:349–55 (30 ref.)

The angiotensin type 1 and type 2 receptor families. Siblings or cousins? Fluharty SJ, et al. **Adv Exp Med Biol** 1995; 377:193–215 (99 ref.)

Cloning, expression and regulation of angiotensin II receptors. Inagami T, et al. **Adv Exp Med Biol** 1995; 377:311–7 (36 ref.)

Regulation of angiotensin II receptor expression in ovarian follicles. A review. Nielsen AH, et al. **Adv Exp Med Biol** 1995;377:407–10 (19 ref.)

Brain angiotensin and the female reproductive cycle. Phillips MI, et al. **Adv Exp Med Biol** 1995;377:357–70 (19 ref.)

AT1 receptors and angiotensin actions in the brain and neuronal cultures of normotensive and hypertensive rats. Raizada MK, et al. **Adv Exp Med Biol** 1995;377:331–48 (124 ref.)

Angiotensin II receptors. Structural and functional considerations. Speth RC, et al. **Adv Exp Med Biol** 1995; 377:169–92 (170 ref.)

Chymase-dependent angiotensin II forming systems in humans. Urata H, et al. **Am J Hypertens** 1996 Mar; 9(3):277–84 (63 ref.)

General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties. Kito G, et al. **Arzneimittelforschung** 1996 Jun; 46(6):572–9

Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. Kondo T, et al. **Arzneimittelforschung** 1996 Jun;46(6):594–600

Gene transcription of angiotensin II type 2 receptor is repressed by growth factors and glucocorticoids in PC12 cells. Kijima K, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):359–66

Angiotensin II receptors are exclusively of the AT1 subtype in cultured human vascular smooth muscle cells. Schachter M, et al. **Biochem Soc Trans** 1995 Aug;23(3):458S

Enhancement of intrarenal angiotensin II levels in 2 kidney 1 clip and angiotensin II induced hypertension. Navar LG, et al. **Blood Press Suppl** 1995;2:88–92 (23 ref.)

Effect of endotoxin on the angiotensin II receptor in cultured vascular smooth muscle cells. Burnier M, et al. **Br J Pharmacol** 1995 Nov;116(5):2524–30

Cells expressing angiotensin II receptors in fibrous tissue of rat heart. Sun Y, et al. **Cardiovasc Res** 1996 Apr; 31(4):518–25

Role of nitric oxide in impaired coronary circulation and improvement by angiotensin II receptor antagonist in spontaneously hypertensive rats. Fujita H, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S148–50

Effect of an antihypertensive drug on brain angiotensin II levels in renal and spontaneously hypertensive rats. Morishita R, et al. **Clin Exp Pharmacol Physiol** 1995 Sep; 22(9):665–9

Mapping of angiotensin II receptor subtypes in peripheral tissues of spontaneously hypertensive rats by in vitro autoradiography. Song K, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S17–9

Conversion of angiotensin II into active fragments by an endosomal pathway in bovine adrenal medullary cells in primary culture. Wang JM, et al. **Endocrinology** 1995 Dec; 136(12):5274–82

Angiotensin II-dependent down-regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats. Yoshimoto T, et al. **Endocrinology** 1996 Mar;137(3):1102–7

In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. Cazes M, et al. **Eur J Pharmacol** 1995 Sep 15;284(1-2):157–70

Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Mizuno M, et al. **Eur J Pharmacol** 1995 Oct 16;285(2):181–8

The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. Zorad S, et al. **Gen Physiol Biophys** 1995 Oct;14(5):383–91 (43 ref.)

Regulation of angiotensin II receptor subtypes by dexamethasone in rat mesangial cells. Chansel D, et al. **Hypertension** 1996 Apr;27(4):867–74

Vascular smooth muscle polyploidy and cardiac hypertrophy in genetic hypertension. Dominiczak AF, et al. **Hypertension** 1996 Mar;27(3 Pt 2):752–9

Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling. Schieffer B, et al. **Hypertension** 1996 Mar;27(3 Pt 2):476–80 (51 ref.)

Renal accumulation of circulating angiotensin II in angiotensin II-infused rats. Zou LX, et al. **Hypertension** 1996 Mar;27(3 Pt 2):658–62

Effects of dietary salt on angiotensin peptides in kidney. Meng QC, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1209–15

Identification of a negative cis-regulatory element and trans-acting protein that inhibit transcription of the angiotensin II type 1a receptor gene. Murasawa S, et al. **J Biol Chem** 1995 Oct 13;270(41):24282–6

Converting enzyme inhibition and its withdrawal in spontaneously hypertensive rats. Campbell DJ, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):426–36

Development and validation of column-switching high-performance liquid chromatographic methods for the determination of a potent AII receptor antagonist, TCV-116, and its metabolites in human serum and urine. Lee JW, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):287–98

Angiotensin II receptor characteristics and subtype expression in uterine arteries and myometrium during pregnancy. Cox BE, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):49–58

Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule. Cheng HF, et al. **J Clin Invest** 1996 Jun 15;97(12):2745–52

Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. Niimura F, et al. **J Clin Invest** 1995 Dec;96(6):2947–54

Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. Hanatani A, et al. **J Mol Cell Cardiol** 1995 Sep; 27(9):1905–14

A monoclonal antibody to mammalian angiotensin II AT1 receptor recognizes one of the angiotensin II receptor isoforms expressed by the eel (Anguilla anguilla). Marsigliante S, et al. **J Mol Endocrinol** 1996 Feb; 16(1):45–56

Molecular biology of angiotensin receptors and their role in human cardiovascular disease. Regitz-Zagrosek V, et al. **J Mol Med** 1996 May;74(5):233–51 (229 ref.)

SB 203220: a novel angiotensin II receptor antagonist and renoprotective agent. Brooks DP, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1222–7

Selective peptide and nonpeptide ligands differentially bind to angiotensin II AT2 receptor and a non-angiotensin II CGP42112 binding site. Ciuffo GM, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1129–34

Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, U-97018. Kushida H, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1042–53

Angiotensin-converting enzyme (ACE) polymorphisms, angiotensin II, ACE inhibitors and glomerulosclerosis--a hypothesis [letter] Roy-Chaudhury P, et al. **Nephron** 1995; 71(3):359

The effect of the angiotensin II (AT1A) receptor stably transfected into human neuroblastoma SH-SY5Y cells on noradrenaline release and changes in intracellular calcium. McDonald RL, et al. **Neurosci Lett** 1995 Oct 20; 199(2):115–8

Glutamate stimulation of arcuate nucleus inhibits responses of subfornical organ neurons to plasma hypernatremia and angiotensin II. Rosas-Arellano MP, et al. **Neurosci Lett** 1995 Oct 6;198(3):201–4

Lead alters growth and reduces angiotensin II receptor density of rat aortic smooth muscle cells. Carsia RV, et al. **Proc Soc Exp Biol Med** 1995 Nov;210(2):180–90

Modulation of angiotensin II receptor (AT2) mRNA levels in R3T3 cells. Camp HS, et al. **Receptor** 1995 Summer; 5(2):123–32

Angiotensin II-forming activity in a reconstructed ancestral chymase. Chandrasekharan UM, et al. **Science** 1996 Jan 26;271(5248):502–5

Angiotensin II and endothelin-1 circulating and interstitial myocardial release following brain death. el-Abbassi K, et al. **Transplant Proc** 1996 Feb;28(1):45–7

[Role of afferent renal nerves in 2K2C Goldblatt hypertension] Wang Q, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):366–72 (Eng. Abstr.) **(Chi)**

[Comparative study of the structure and molecular functions of angiotensin II and vasopressin receptors] Clauser E. **C R Seances Soc Biol Fil** 1995;189(2):179–90 (37 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

Pharmacokinetics of regional angiotensin-II: a novel biologic response modifier. Wu Y, et al. **Ann Surg Oncol** 1996 Jan; 3(1):24–8

Mechanisms involved in iontophoretic transport of angiotensin. Clemessy M, et al. **Pharm Res** 1995 Jul; 12(7):998–1002

PHARMACOLOGY

Influence of forebrain lesions and isoflurane anaesthesia, respectively, on responses to the intracarotid infusion of angiotensin II in sheep. Eriksson S, et al. **Acta Physiol Scand** 1995 Dec;155(4):427–34

Effects of exercise–training on hypoxia and angiotensin II–induced pulmonary vasoconstrictions. Kashimura O, et al. **Acta Physiol Scand** 1995 Nov;155(3):291–5

Excitation–contraction coupling in ventricular myocytes: effects of angiotensin II. Barry WH, et al. **Adv Exp Med Biol** 1995;382:31–9

In field–stimulated guinea–pig atria an AT1–receptor mediated increase of noradrenaline release by angiotensin II is seen only in the presence of prejunctional autoinhibition. Brasch H, et al. **Adv Exp Med Biol** 1995; 377:293–8

Design and pharmacology of peptide mimetics. Moore GJ, et al. **Adv Pharmacol** 1995;33:91–41 (112 ref.)

Different vascular responses to subpressor angiotensin II administration in the mesenteric and renal circulation of rats. Cserep G, et al. **Am J Hypertens** 1996 Apr;9(4 Pt 1):385–92

Angiotensins differentially activate phospholipase D in vascular smooth muscle cells from spontaneously hypertensive and Wistar–Kyoto rats. Freeman EJ, et al. **Am J Hypertens** 1995 Nov;8(11):1105–11

Diurnal variation in angiotensin sensitivity in pregnancy. Delemarre FM, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):259–61

The effects of atrial natriuretic factor and angiotensin II on fetal–placental perfusion pressure in the ex vivo cotyledon model. Markenson GR, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1143–7

Subcellular mechanisms of angiotensin II and arginine vasopressin activation of area postrema neurons. Consolim–Colombo FM, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R34–41

Angiotensin II stimulates sodium–dependent proton extrusion in perfused ferret heart. Grace AA, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1687–94

Effects of peroxide and superoxide on coronary artery: ANG II response and sarcoplasmic reticulum Ca2+ pump. Grover AK, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C546–53

Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. Henegar JR, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1564–9

Comparison of ANG II with other growth factors on Egr–1 and matrix gene expression in cardiac fibroblasts. Iwami K, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2100–7

Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. Kim NN, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E426–37

Angiotensin II and contraction of isolated myocytes from human, guinea pig, and infarcted rat hearts. Lefroy DC, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2060–9

ANG II–induced tyrosine phosphorylation stimulates phospholipase C–gamma 1 and Cl–channels in mesangial cells. Marrero MB, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1834–42

Lateral parabrachial serotonergic mechanisms: angiotensin–induced pressor and drinking responses. Menani JV, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1044–9

Angiotensin II modulates arterial baroreflex function via a central alpha 1–adrenoceptor mechanism in rabbits. Nishida Y, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1009–16

Chronic ouabain infusion does not cause hypertension in sheep. Pidgeon GB, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E386–92

Biphasic effect of angiotensin II on intracellular sodium concentration in rat proximal tubules. Reilly AM, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):F374–80

Pulmonary vascular response to angiotensin II in canine pacing–induced heart failure. Roy BJ, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H222–7

Role of protein kinase C in angiotensin II–induced renal vasoconstriction in genetically hypertensive rats. Ruan X, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):F945–52

Neuroendocrine and cardiovascular effects of serotonin: selective role of brain angiotensin on vasopressin. Saydoff JA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E513–21

Extracellular glucose reduces the responsiveness of mesangial cell ion channels to angiotensin II. Seal EE, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):F389–97

Comparative effects of contraction and angiotensin II on growth of adult feline cardiocytes in primary culture. Wada H, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H29–37

Effects of angiotensin II on electrolyte transport in the early and late distal tubule in rat kidney. Wang T, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F143–9

Regulation of luminal alkalinization and acidification in the cortical collecting duct by angiotensin II. Weiner ID, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):F730–8

Physiological doses of [Ile5]– and [Val5]–Angiotensin II fail to increase plasma catecholamines at the peak pressor response in rats. Butler DG, et al. **Arch Int Pharmacodyn Ther** 1995 Mar–Apr;329(2):272–82

Differences between rapid and longer–term actions of angiotensin II in isolated rat hepatocytes. Effects on phosphorylase a activity and c–fos expression. García–Sáinz JA, et al. **Arch Med Res** 1995;26 Spec No:S189–93

Effects of atrial natriuretic factor on norepinephrine release evoked by angiotensins II and III in the rat adrenal medulla. Papouchado ML, et al. **Arch Physiol Biochem** 1995 Apr; 103(1):55–8

Angiotensin II increases cGMP content via endothelial angiotensin II AT1 subtype receptors in the rat carotid artery. Caputo L, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1646–51

Angiotensin II–modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Keidar S, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):97–105

Angiotensin II–induced progression of neointimal thickening in the balloon–injured rat carotid artery is AT1 receptor mediated. van Kleef EM, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):857–63

Tyrosine kinase is involved in angiotensin II–stimulated phospholipase D activation in aortic smooth muscle cells: function of Ca2+ influx. Suzuki A, et al. **Atherosclerosis** 1996 Mar;121(1):119–27

Activation of calcium sparks by angiotensin II in vascular myocytes. Arnaudeau S, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):809–15

Angiotensin II attenuates vascular contractility in the rabbit mesenteric artery. Oike M, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):208–14

Identification of regions in the human angiotensin II receptor type 1 responsible for Gi and Gq coupling by mutagenesis study. Shibata T, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):383–9

Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3–kinase in rat heart. Saad MJ, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):741–4

CV–11974, the active metabolite of TCV–116 (Candesarten), inhibits the synergistic or additive effect of different growth factors on angiotensin II–induced proliferation of vascular smooth muscle cells. Sachinidis A, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):123–6

Tyrosine phosphorylation, MAPK and PLD in AII stimulated mitogenesis. Morton C, et al. **Biochem Soc Trans** 1995 Aug;23(3):426S

Vascular smooth muscle cells from spontaneously hypertensive rats exhibit increased MAPK response to angiotensin II and phorbol ester stimulation. Wilkie N, et al. **Biochem Soc Trans** 1996 Feb;24(1):65S

Recovery from acute challenge with noradrenaline, vasopressin and angiotensin II in isolated rat hepatocytes. Aggarwal SR, et al. **Biochim Biophys Acta** 1996 Feb 29; 1310(3):284–92

Angiotensin II induces TIMP–1 production in rat heart endothelial cells. Chua CC, et al. **Biochim Biophys Acta** 1996 May 28;1311(3):175–80

Hormonal modulation of c–fos expression in isolated hepatocytes. Effects of angiotensin II and phorbol myristate acetate on transcription and mRNA degradation. González–Espinosa C, et al. **Biochim Biophys Acta** 1996 Feb 2;1310(2):217–22

The enhancement of phosphatidylcholine biosynthesis by angiotensin II in H9c2 cells. Tran K, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):283–90

Effects of atrial natriuretic peptide on angiotensin II–induced antinatriuresis in anesthetized dogs. Tomura Y, et al. **Biol Pharm Bull** 1995 Sep;18(9):1211–4

Role of angiotensin II in the transforming growth factor–beta 1 expression of rat kidney in anti–glomerular basement membrane antiserum–induced glomerulonephritis. Yayama K, et al. **Biol Pharm Bull** 1995 May;18(5):687–90

Angiotensin II interferes with steroidogenesis in porcine granulosa cells. Li XM, et al. **Biol Reprod** 1995 Oct; 53(4):791–9

Angiotensin II changes inositol–1,4,5–trisphosphate content in the pituitary and hypothalamus but not in cerebral cortex of the rat brain. Lachowicz A, et al. **Biol Signals** 1995 Jul–Aug;4(4):206–11

Opposite influences of hypertension and diabetes mellitus on pressor responses induced by different alpha–adrenoceptor agonists and angiotensin II in pithed rats. Beenen OH, et al. **Blood Press** 1996 Jan;5(1):57–63

Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Brown DC, et al. **Br J Pharmacol** 1996 May;118(2):414–20

Action of angiotensin II, 5–hydroxytryptamine and adenosine triphosphate on ionic currents in single ear artery cells of the rabbit. Hughes AD, et al. **Br J Pharmacol** 1995 Oct; 116(3):2148–54

Mechanisms of angiotensin II chronotropic effect in anaesthetized dogs. Lambert C. **Br J Pharmacol** 1995 Jul; 115(5):795–800

Angiotensin II–activated Ca2+ entry–induced release of Ca2+ from intracellular stores in rat portal vein myocytes. Morel JL, et al. **Br J Pharmacol** 1996 May;118(1):73–8

Angiotensin II–elicited signal transduction via AT1 receptors in endothelial cells. Pueyo ME, et al. **Br J Pharmacol** 1996 May;118(1):79–84

Cardiovascular effects of angiotensin–II in chickens. Robinzon B, et al. **Br Poult Sci** 1995 Sep;36(4):655–65

Intrastriatal angiotensin II induces turning behaviour in 6–hydroxydopamine lesioned rats. Jenkins TA, et al. **Brain Res** 1995 Sep 11;691(1–2):213–6

Effects of lidocaine injections into the lateral parabrachial nucleus on dipsogenic and pressor responses to central angiotensin II in rats. Menani JV, et al. **Brain Res** 1995 Oct 16;695(2):250–2

Autoradiographic identification of brain angiotensin IV binding sites and differential c–Fos expression following intracerebroventricular injection of angiotensin II and IV in rats. Roberts KA, et al. **Brain Res** 1995 Jun 5; 682(1–2):13–21

Angiotensin II receptor subtypes in the duck subfornical organ: an electrophysiological and receptor autoradiographic investigation. Schäfer F, et al. **Brain Res** 1996 Mar 4;711(1–2):118–24

The role of angiotensin AT1 receptors in the diuretic, natriuretic, kaliuretic and blood pressure responses induced by angiotensin II activation of the median preoptic nucleus in conscious rats. Ferreira–do–Vale C, et al. **Braz J Med Biol Res** 1995 Oct;28(10):1097–101

Atrial natriuretic peptide modulates the effect of angiotensin II on the concentration of free calcium in the cytosol of Mandin–Darby canine kidney cells. Nascimento–Gomes G, et al. **Braz J Med Biol Res** 1995 May;28(5):609–13

Effects of angiotensin II on plasma atrial natriuretic factor in nonpregnant and pregnant ewes. Fan L, et al. **Can J Physiol Pharmacol** 1995 May;73(5):644–50

Low concentrations of angiotensin II unmask vasoconstrictory alpha 2–adrenoceptors in isolated perfused kidneys of spontaneously hypertensive rats. Bohmann C, et al. **Cardiovasc Res** 1995 Dec;30(6):857–65

Ca(2+)–growth coupling in angiotensin II–induced hypertrophy in cultured rat cardiac cells. Kinugawa K, et al. **Cardiovasc Res** 1995 Sep;30(3):419–31

The effect of afterload and angiotensin II on proto–oncogene mRNA levels in the isolated working rat heart. Roffe C, et al. **Cardiovasc Res** 1996 Jun;31(6):907–16

Angiotensin–II–induced increase in transcoronary protein clearance: role of hypertension vs. nitric oxide or cyclo–oxygenase products. Sigusch HH, et al. **Cardiovasc Res** 1995 Aug;30(2):291–8

The role of protein kinase C in activation and termination of mitogen–activated protein kinase activity in angiotensin II–stimulated rat aortic smooth–muscle cells. Malarkey K, et al. **Cell Signal** 1996 Feb;8(2):123–9

Altered ventricular and myocyte response to angiotensin II in pacing–induced heart failure. Cheng CP, et al. **Circ Res** 1996 May;78(5):880–92

Angiotensin II activates pp60c–src in vascular smooth muscle cells. Ishida M, et al. **Circ Res** 1995 Dec;77(6):1053–9

Passive load and angiotensin II evoke differential responses of gene expression and protein synthesis in cardiac myocytes. Kent RL, et al. **Circ Res** 1996 May;78(5):829–38

Angiotensin II decreases a resting K+ conductance in rat bulbospinal neurons of the C1 area. Li YW, et al. **Circ Res** 1996 Feb;78(2):274–82

Angiotensin II augments cytokine–stimulated nitric oxide synthesis in rat cardiac myocytes. Ikeda U, et al. **Circulation** 1995 Nov 1;92(9):2683–9

Angiotensin II induces the expression of c–fos mRNA in the central nervous system of the rat. Lebrun CJ, et al. **Clin Exp Hypertens** 1995 Aug;17(6):877–93

Impact of cyclo–oxygenase blockade on juxtamedullary microvascular responses to angiotensin II in rat kidney. Harrison–Bernard LM, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):732–8

Atrial natriuretic factor and angiotensin II stimulate nitric oxide release from human proximal tubular cells. McLay JS, et al. **Clin Sci (Colch)** 1995 Nov;89(5):527–31

Role of protein kinase C in glucose– and angiotensin II–induced plasminogen activator inhibitor expression. Feener EP, et al. **Contrib Nephrol** 1996;118:180–7

Effects of corticotropin–releasing hormone, lysine vasopressin, oxytocin, and angiotensin II on adrenocorticotropin secretion from porcine anterior pituitary cells. Abraham EJ, et al. **Domest Anim Endocrinol** 1996 May;13(3):259–68

Hormonal regulation of angiotensin II type 1 receptor expression and AT1–R mRNA levels in human adrenocortical cells. Bird IM, et al. **Endocr Res** 1995 Feb–May;21(1–2):169–82

Stimulation of cortisol production through angiotensin AT2 receptors in bovine fasciculata cells. Defaye G, et al. **Endocr Res** 1995 Feb–May;21(1–2):183–7

Aldosterone synthase gene regulation by angiotensin. Holland OB, et al. **Endocr Res** 1995 Feb–May; 21(1–2):455–62

Regulation of ACTH receptor mRNA and binding sites by ACTH and angiotensin II in cultured human and bovine adrenal fasciculata cells. Penhoat A, et al. **Endocr Res** 1995 Feb–May;21(1–2):157–68

Regulation of norepinephrine transport system by angiotensin II in neuronal cultures of normotensive and spontaneously hypertensive rat brains. Lu D, et al. **Endocrinology** 1996 Feb;137(2):763–72

Angiotensin II induces ovulation and oocyte maturation in rabbit ovaries via the AT2 receptor subtype. Yoshimura Y, et al. **Endocrinology** 1996 Apr;137(4):1204–11

Angiotensin II regulation of plasminogen activator inhibitor–1 gene expression in neurons of normotensive and spontaneously hypertensive rat brains. Yu K, et al.

Endocrinology 1996 Jun;137(6):2503–13

Endothelium–modulated proliferation of medial smooth muscle cells: influence of angiotensin II and converting enzyme inhibition. Hahn AW, et al. **Eur Heart J** 1995 May; 16 Suppl C:29–32

Angiotensin II modulates steroidogenesis in granulosa and theca in the rabbit ovary: its possible involvement in atresia. Féral C, et al. **Eur J Endocrinol** 1995 Dec;133(6):747–53

Interactions between angiotensin II and norepinephrine on renin release by juxtaglomerular cells [see comments] Ichihara A, et al. **Eur J Endocrinol** 1995 Nov;133(5):569–77 . Comment in: Eur J Endocrinol 1995 Nov;133(5):523.

Control of hepatic carbohydrate metabolism and haemodynamics in perfused rat liver by arterial and portal angiotensin II. Reisenleiter F, et al. **Eur J Gastroenterol Hepatol** 1996 Mar;8(3):279–86

Functional domains of the C–terminus of the rat angiotensin AT1A receptor. Balmforth AJ, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):135–41

Angiotensin II–induced responses in vascular smooth muscle cells: inhibition by non–peptide receptor antagonists. Catalioto RM, et al. **Eur J Pharmacol** 1995 Jul 14; 280(3):285–92

Angiotensin II–mediated renal vasoconstriction amenable to alpha 1–adrenoceptor blockade. Chen K, et al. **Eur J Pharmacol** 1995 Sep 25;284(3):281–8

Effects of irbesartan (SR47436/BMS–186295) on angiotensin II–induced pressor responses in the pithed rat: potential mechanisms of action. Christophe B, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):161–71

A long–term receptor stimulation is requisite for angiotensin II–dependent DNA synthesis in vascular smooth muscle cells from spontaneously hypertensive rats. Itazaki K, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):417–25

Endothelin–1 and angiotensin II act as progression but not competence growth factors in vascular smooth muscle cells. Jahan H, et al. **Eur J Pharmacol** 1996 Jan 11; 295(2–3):261–9

Responses to L–163,491, a nonpeptide angiotensin II mimic, in the pulmonary vascular bed of the cat. Kaye AD, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):163–8

Angiotensin II receptor subtypes and contractile responses in portal vein smooth muscle. Pelet C, et al. **Eur J Pharmacol** 1995 Jun 6;279(1):15–24

The selective angiotensin AT1 receptor antagonist LR–B/081 potently inhibits drinking induced by central injection of angiotensin II in rats. Polidori C, et al. **Eur J Pharmacol** 1995 Apr 24;277(2–3):223–8

Comparison of responses of canine pulmonary artery and vein to angiotensin II, bradykinin and vasopressin. Sai Y, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):235–41

Angiotensin II potentiates methacholine–induced bronchoconstriction in human airway both in vitro and in vivo. Millar EA, et al. **Eur Respir J** 1995 Nov; 8(11):1838–41

Activation of p70 S6 protein kinase is necessary for angiotensin II–induced hypertrophy in neonatal rat cardiac myocytes. Takano H, et al. **FEBS Lett** 1996 Feb 5; 379(3):255–9

Angiotensin II–induced hypertension: effects on central and peripheral atrial natriuretic peptide. Bahner U, et al. **Hypertens Res** 1995 Dec;18(4):279–84

Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin–(1–7). Benter IF, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1138–44

Endothelial AT1–mediated release of nitric oxide decreases angiotensin II contractions in rat carotid artery. Boulanger CM, et al. **Hypertension** 1995 Nov;26(5):752–7

Angiotensin–(1–7) dilates canine coronary arteries through kinins and nitric oxide. Brosnihan KB, et al. **Hypertension** 1996 Mar;27(3 Pt 2):523–8

Role of nitric oxide in short–term and prolonged effects of angiotensin II on renal hemodynamics. Deng X, et al. **Hypertension** 1996 May;27(5):1173–9

Basal and angiotensin II–induced cytosolic free calcium in adult rat cardiomyocytes and fibroblasts after volume overload. Fareh J, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1149–53

Angiotensin–(1–7) inhibits vascular smooth muscle cell growth. Freeman EJ, et al. **Hypertension** 1996 Jul; 28(1):104–8

Effects and interactions of endothelin–1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Gómez–Garre D, et al. **Hypertension** 1996 Apr;27(4):885–92

Myocardial contractility is modulated by angiotensin II via nitric oxide. Gomez Llambi H, et al. **Hypertension** 1996 Mar;27(3 Pt 2):704–8

Medullary neurons activated by angiotensin II in the conscious rabbit. Hirooka Y, et al. **Hypertension** 1996 Feb; 27(2):287–96

Effects of angiotensin II infusion and inhibition of nitric oxide synthase on the rat aorta. Kato H, et al. **Hypertension** 1996 Aug;28(2):153–8

Angiotensin–(1–7) potentiates the hypotensive effect of bradykinin in conscious rats. Paula RD, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1154–9

Influence of NaCl concentration at the macula densa on angiotensin II–induced constriction of the afferent arteriole. Ren YL, et al. **Hypertension** 1996 Mar;27(3 Pt 2):649–52

Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs. Susic D, et al. **Hypertension** 1996 Aug;28(2):265–8

Tyrosine kinase signaling pathways modulate angiotensin II–induced calcium ([Ca2+]i) transients in vascular smooth muscle cells. Touyz RM, et al. **Hypertension** 1996 May; 27(5):1097–103

Cytosolic calcium changes induced by angiotensin II in neonatal rat atrial and ventricular cardiomyocytes are mediated via angiotensin II subtype 1 receptors. Touyz RM, et al. **Hypertension** 1996 May;27(5):1090–6

Angiotensin II increases norepinephrine turnover in the anteroventral third ventricle of spontaneously hypertensive rats. Tsukashima A, et al. **Hypertension** 1996 Aug; 28(2):224–7

Angiotensin II is mitogenic for cultured rat glomerular endothelial cells. Wolf G, et al. **Hypertension** 1996 Apr; 27(4):897–905

Angiotensin II and angiotensin–(1–7) effects on free cytosolic sodium, intracellular pH, and the Na(+)–H+ antiporter in vascular smooth muscle. Ye M, et al. **Hypertension** 1996 Jan;27(1):72–8

Protein kinase C modulation of cardiomyocyte angiotensin II and vasopressin receptor desensitization. Zhang M, et al. **Hypertension** 1996 Feb;27(2):269–75

A comparative study of tumour blood flow modification in two rat tumour systems using endothelin–1 and angiotensin II: influence of tumour size on angiotensin II response. Bell KM, et al. **Int J Cancer** 1996 Sep 4;67(5):730–8

Spatial heterogeneity of tumour blood flow modification induced by angiotensin II: relationship to receptor distribution. Tozer GM, et al. **Int J Cancer** 1996 Mar 1; 65(5):658–63

Angiotensin II stimulates interleukin–6 release from cultured mouse mesangial cells. Moriyama T, et al. **J Am Soc Nephrol** 1995 Jul;6(1):95–101

Regulation of the renal Na–HCO3 cotransporter: IV. Mechanisms of the stimulatory effect of angiotensin II. Ruiz OS, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1202–8

Regulation of Na+/H+ exchange by diadenosine polyphosphates, angiotensin II, and vasopressin in rat cortical collecting duct. Schlatter E, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1223–9

Short exposure to endotoxin increases the constriction induced by angiotensin II in rat aorta. Rasetti C, et al. **J Appl Physiol** 1995 Dec;79(6):2094–100

Angiotensin II activates at least two tyrosine kinases in rat liver epithelial cells. Separation of the major calcium–regulated tyrosine kinase from p125FAK. Earp HS, et al. **J Biol Chem** 1995 Nov 24;270(47):28440–7

Identification of an essential signaling cascade for mitogen–activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells. Possible requirement of Gq–mediated p21ras activation coupled to a Ca2+/calmodulin–sensitive tyrosine kinase. Eguchi S, et al. **J Biol Chem** 1996 Jun 14;271(24):14169–75

Angiotensin II stimulates system y+ and cationic amino acid transporter gene expression in cultured vascular smooth muscle cells. Low BC, et al. **J Biol Chem** 1995 Nov 17; 270(46):27577–83

Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling. Reconstitution of the binding site by co–expression of two deficient mutants. Monnot C, et al. **J Biol Chem** 1996 Jan 19;271(3):1507–13

Regulation of angiotensin II–stimulated Ca2+ oscillations by Ca2+ influx mechanisms in adrenal glomerulosa cells. Rössig L, et al. **J Biol Chem** 1996 Sep 6;271(36):22063–9

Tissue– and subtype–specific modulation of angiotensin II receptors by chronic treatment with cyclosporin A, angiotensin–converting enzyme inhibitors and AT1 antagonists. Regitz–Zagrosek V, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):66–72

Growth–promoting effects of Ca(2+)–mobilizing agents in hepatocytes: lack of correlation between the acute activation of phosphoinositide–specific phospholipase C and the stimulation of DNA synthesis by angiotensin II, vasopressin, norepinephrine, and prostaglandin F2 alpha. Dajani OF, et al. **J Cell Physiol** 1996 Sep;168(3):608–17

Angiotensin II receptors and angiotensin II stimulation of ciliary activity in human fallopian tube. Saridogan E, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2719–25

Angiotensin II causes weight loss and decreases circulating insulin–like growth factor I in rats through a pressor–independent mechanism. Brink M, et al. **J Clin Invest** 1996 Jun 1;97(11):2509–16

Chronic blockade of AT2–subtype receptors prevents the effect of angiotensin II on the rat vascular structure. Levy BI, et al. **J Clin Invest** 1996 Jul 15;98(2):418–25

Angiotensin II–mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. Rajagopalan S, et al. **J Clin Invest** 1996 Apr 15;97(8):1916–23

The subtype–2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3', 5'–monophosphate and AT1 receptor–mediated prostaglandin E2 production in conscious rats [see comments] Siragy HM, et al. **J Clin Invest** 1996 Apr 15;97(8):1978–82. Comment in: J Clin Invest 1996 Apr 15;97(8):1787.

Pressor doses of angiotensin II increase hepatic glucose output and decrease insulin sensitivity in rats. Rao RH. **J Endocrinol** 1996 Feb;148(2):311–8

Angiotensin II induces cardiovascular hypertrophy in perindopril–treated rats. Black MJ, et al. **J Hypertens** 1995 Jun;13(6):683–92

Effect of angiotension II on the expression of the early growth response gene c–fos and DNA synthesis in human vascular smooth muscle cells. Patel MK, et al. **J Hypertens** 1996 Mar;14(3):341–7

Cyclosporin–induced renal vasoconstriction is augmented by frusemide and by angiotensin II in humans. Sturrock ND, et al. **J Hypertens** 1995 Sep;13(9):987–91

Angiotensin II induction of fibronectin biosynthesis in cultured human mesangial cells: association with CREB transcription factor activation. Nahman NS Jr, et al. **J Lab Clin Med** 1996 Jun;127(6):599–611

Stimulation of the Na+/Ca2+ exchanger by phenylephrine, angiotensin II and endothelin 1. Ballard C, et al. **J Mol Cell Cardiol** 1996 Jan;28(1):11–7

Tissue endothelin–1 levels in perfused rat heart following stimulation with agonists and in ischaemia and reperfusion. Brunner F. **J Mol Cell Cardiol** 1995 Sep;27(9):1953–63

Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. Campbell SE, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1545–60

Angiotensin II stimulates the autocrine production of transforming growth factor–beta 1 in adult rat cardiac fibroblasts. Lee AA, et al. **J Mol Cell Cardiol** 1995 Oct; 27(10):2347–57

The effects of endothelin–1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. Rizvi MA, et al. **J Mol Cell Cardiol** 1996 Feb;28(2):243–52

Angiotensin II stimulation of the basolateral located Na+/H+ antiporter in eel (Anguilla anguilla) enterocytes. Vilella S, et al. **J Mol Endocrinol** 1996 Feb;16(1):57–62

Angiotensin II regulation of intracellular calcium in astroglia cultured from rat hypothalamus and brainstem. Wang D, et al. **J Neurochem** 1996 Sep;67(3):996–1004

Nitric oxide mediates the inhibitory action of platelet–activating factor on angiotensin II–induced renal vasoconstriction, in vivo. Handa RK, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1486–91

Angiotensin II tachyphylaxis in the guinea pig ileum and its prevention: a pharmacological and biochemical study. Kanashiro CA, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1543–50

Angiotensin II–mediated activation of L–type calcium channels involves phosphatidylinositol hydrolysis–independent activation of protein kinase C in rat portal vein myocytes. Macrez–Leprêtre N, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):468–75

Inhibition of the slow pressor effect of angiotensin II contributes to the antihypertensive effect of angiotensin–converting enzyme inhibitors in renovascular hypertension. Melaragno MG, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):297–303

In vivo effects of angiotensin II on vascular smooth muscle contraction and blood pressure are mediated through a protein tyrosine–kinase–dependent mechanism. Sauro MD, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1744–50

Tachyphylaxis to angiotensin II and [Phe4]–angiotensin II in the rat mesentery in vivo. Tofovic SP, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):13–20

Effects of angiotensin II in fetal sheep and modification of its actions by indomethacin. Stevenson KM, et al. **J Physiol (Lond)** 1995 Aug 15;487 (Pt 1):147–58

Renal artery smooth muscle is refractory to contraction by angiotensin II. Whitney EG, et al. **J Surg Res** 1996 Mar; 61(2):307–10

Diadenosine polyphosphates increase cytosolic calcium and attenuate angiotensin–II–induced changes of calcium in vascular smooth muscle cells. Tepel M, et al. **J Vasc Res** 1996 Mar–Apr;33(2):132–8

Increase in vascular sensitivity to angiotensin II and norepinephrine after four–day infusion of 0.3 M sodium chloride in conscious kininogen–deficient brown Norway Katholiek rats. Majima M, et al. **Jpn J Pharmacol** 1995 Oct;69(2):149–58

Acute or chronic exercise alters angiotensin II–induced contraction of rat aorta. Izawa T, et al. **Jpn J Physiol** 1995; 45(6):1093–100

High glucose augments angiotensin II action by inhibiting NO synthesis in in vitro microperfused rabbit afferent arterioles. Arima S, et al. **Kidney Int** 1995 Sep;48(3):683–9

Nitric oxide antagonizes the actions of angiotensin II to enhance tubuloglomerular feedback responsiveness. Braam B, et al. **Kidney Int** 1995 Nov;48(5):1406–11

Sequential activation of MAP kinase cascade by angiotensin II in opossum kidney cells. Terada Y, et al. **Kidney Int** 1995 Dec;48(6):1801–9

Angiotensin II–stimulated expression of transforming growth factor beta in renal proximal tubular cells: attenuation after stable transfection with the c–mas oncogene. Wolf G, et al. **Kidney Int** 1995 Dec;48(6):1818–27

Angiotensin II receptor in human placental syncytiotrophoblast plasma membranes. Jiménez E, et al. **Life Sci** 1996;58(11):877–82

Angiotensin II stimulates production of nitric oxide in guinea pig airways via AT1 receptor activation. Kanazawa H, et al. **Life Sci** 1995 Mar 17;56(17):1427–31

Tyrosine kinase inhibition suppresses angiotensin contraction in hypertensive and normotensive small resistance arteries. Malloy LG, et al. **Life Sci** 1996;58(19):PL317–24

Cellular mechanism of angiotensin II–induced atrial natriuretic peptide release in rat right atrial tissue. Soualmia H, et al. **Life Sci** 1996;58(19):1621–9

Reduced renal microvascular reactivity to angiotensin II in diabetic rats. Inman SR, et al. **Microcirculation** 1994 Jul; 1(2):137–45

Differential contractile response of cultured microvascular pericytes to vasoactive agents. Murphy DD, et al. **Microcirculation** 1994 Jul;1(2):121–8

A role for cAMP in angiotensin II mediated inhibition of cell growth in AT1A receptor–transfected CHO–K1 cells. Thekkumkara TJ, et al. **Mol Cell Biochem** 1995 Nov 8; 152(1):77–86

Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Zhou G, et al. **Mol Cell Biochem** 1996 Jan 26;154(2):171–8

Angiotensin II stimulates calcium–dependent activation of c–Jun N–terminal kinase. Zohn IE, et al. **Mol Cell Biol** 1995 Nov;15(11):6160–8

Prolonged exposure to agonist results in a reduction in the levels of the Gq/G11 alpha subunits in cultured vascular smooth muscle cells. Kai H, et al. **Mol Pharmacol** 1996 Jan;49(1):96–104

Angiotensin II down–regulates the vascular smooth muscle AT1 receptor by transcriptional and post–transcriptional mechanisms: evidence for homologous and heterologous regulation. Lassègue B, et al. **Mol Pharmacol** 1995 Oct; 48(4):601–9

Involvement of a tyrosine kinase pathway in the growth–promoting effects of angiotensin II on aortic smooth muscle cells. Leduc I, et al. **Mol Pharmacol** 1995 Oct;48(4):582–92

Novel natriuretic peptide receptor/guanylyl cyclase A–selective agonist inhibits angiotensin II– and forskolin–evoked aldosterone synthesis in a human zona glomerulosa cell line. Olson LJ, et al. **Mol Pharmacol** 1996 Aug;50(2):430–5

Transforming growth factor beta mediates the angiotensin–II–induced stimulation of collagen type IV synthesis in cultured murine proximal tubular cells. Wolf G, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):263–9

Effects of angiotensin, vasopressin and atrial natriuretic peptide on intraocular pressure in anesthetized rats. Palm DE, et al. **Neuropeptides** 1995 Oct;29(4):193–203

AT1A, AT1B, and AT2 angiotensin II receptor subtype gene expression in rat brain. Johren O, et al. **Neuroreport** 1995 Dec 15;6(18):2549–52

Role of peripheral angiotensin in salt appetite of the sodium–deplete rat. Thunhorst RL. **Neurosci Biobehav Rev** 1996;20(1):101–6 (33 ref.)

Osmolality– and angiotensin–induced responses in the AV3V neurons are affected by estrogen in the ovariectomized rat. Akaishi T, et al. **Neurosci Lett** 1996 Jan 5;202(3):153–6

Acute administration of angiotensin II improves long–term habituation in the crab Chasmagnathus. Delorenzi A, et al. **Neurosci Lett** 1995 Aug 25;196(3):193–6

Role of alpha 1 and alpha 2–adrenoceptors of the lateral hypothalamic area on urinary excretion caused by centrally administered angiotensin II. Saad WA, et al. **Neurosci Lett** 1995 Jul 21;194(3):169–72

Regional suppression by lesions in the anterior third ventricle of c–fos expression induced by either angiotensin II or hypertonic saline. Xu Z, et al. **Neuroscience** 1995 Jul; 67(1):135–47

Preoptic recess ablation selectively increases baroreflex sensitivity to angiotensin II in conscious rats. Bealer SL. **Peptides** 1995;16(7):1197–201

Impaired retention by angiotensin II mediated by the AT1 receptor. Lee EH, et al. **Peptides** 1995;16(6):1069–71

Effects of diadenosine polyphosphates, ATP and angiotensin II on membrane voltage and membrane conductances of rat mesangial cells. Kleta R, et al. **Pflugers Arch** 1995 Sep; 430(5):713–20

Effects of diadenosine polyphosphates, ATP and angiotensin II on cytosolic Ca2+ activity and contraction of rat mesangial cells. Schlatter E, et al. **Pflugers Arch** 1995 Sep; 430(5):721–8

Characterization of contractile response to angiotensin in epididymal rat vas deferens. Sum CS, et al. **Pharmacology** 1995 Aug;51(2):105–11

Angiotensin II enhances responses to endothelin–1 in bovine bronchial smooth muscle. Nally JE, et al. **Pulm Pharmacol** 1994 Dec;7(6):409–13

Cyclosporine A enhances the vascular reactivity to angiotensin II in the renal microcirculation in rodents. Hodge EE, et al. **Transplant Proc** 1996 Apr;28(2):893–5

[Angiotensin II increasing the inhibitory effects of electroacupuncture on the nociceptive discharge of neurons in the spinal dorsal horn] Hu Q, et al. **Chen Tzu Yen Chiu** 1995;20(2):18–21 (Eng. Abstr.) **(Chi)**

[Effect of angiotensin II on vasopressin gene transcription in the hypothalamus of rats] Lu LM, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):373–80 (Eng. Abstr.) **(Chi)**

[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Korshak OL, et al. **Fiziol Zh** 1994 Sep–Dec;40(5–6):15–9 (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

Angiotensin and the brain. Andersson B, et al. **Acta Physiol Scand** 1995 Oct;155(2):117–25 (52 ref.)

Angiotensin II in cell growth and matrix production. Hsueh WA, et al. **Adv Exp Med Biol** 1995;377:217–23 (49 ref.)

The pathophysiology of ovarian hyperstimulation syndrome (OHSS). A proposal role of the ovarian derived prorenin to angiotensin cascade (ODPAC). Morris RS, et al. **Adv Exp Med Biol** 1995;377:391–8 (37 ref.)

Is estrogen–induced pituitary hyperplasia and hyperprolactinaemia mediated by angiotensin II? Pawlikowski M, et al. **Adv Exp Med Biol** 1995;377:371–8

AT1 receptors and angiotensin actions in the brain and neuronal cultures of normotensive and hypertensive rats. Raizada MK, et al. **Adv Exp Med Biol** 1995;377:331–48 (124 ref.)

The relationship between the adrenal tissue renin–angiotensin system, internalization of the type I angiotensin II receptor (AT1) and angiotensin II function in the rat adrenal zona glomerulosa cell. Vinson GP, et al. **Adv Exp Med Biol** 1995; 377:319–29

Angiotensin as a renal growth promoting factor. Wolf G. **Adv Exp Med Biol** 1995;377:225–36 (99 ref.)

Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Brilla CG, et al. **Am J Cardiol** 1995 Nov 2;76(13):8D–13D (42 ref.)

Effect of angiotensin II on the renal response to amino acid in rats. Garcia GE, et al. **Am J Kidney Dis** 1996 Jul; 28(1):115–23

Role of angiotensin II and catecholamines in blood pressure variability responses to stress in SHR. Gaudet E, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1265–72

Interactions between angiotensin and nitric oxide in the renal response to volume expansion. Llinás MT, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R504–10

Role of angiotensin–converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Morrell NW, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1186–94

Angiotensin II and cardiovascular regulation in a freshwater teleost, Anguilla rostrata LeSueur. Oudit GY, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R726–35

Neuroendocrine and cardiovascular effects of serotonin: selective role of brain angiotensin on vasopressin. Saydoff JA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E513–21

Spinal angiotensin II influences reflex cardiovascular responses to muscle contraction. Stebbins CL, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R864–8

Regulation of ANG II receptor in hypertension: role of ANG II. Wang DH, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H120–5

Decreased angiotensin II receptors mediate decreased vascular response in hepatocellular cancer. Wu Y, et al. **Ann Surg** 1996 Feb;223(2):225–31

Angiotensin receptors and their therapeutic implications. Griendling KK, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:281–306 (135 ref.)

Relationship of rostral ventrolateral medullary neurons and angiotensin in the central control of blood pressure. Chan YS, et al. **Biol Signals** 1995 May–Jun;4(3):133–41 (42 ref.)

Angiotensin II––an important stress hormone. Yang G, et al. **Biol Signals** 1996 Jan–Feb;5(1):1–8 (41 ref.)

Angiotensin II–mediated signal transduction events in vascular smooth muscle cells: kinases and phosphatases. Duff JL, et al. **Blood Press Suppl** 1995;2:55–60 (68 ref.)

Angiotensin II as a modulator of cardiovascular autonomic control. Townend JN. **Cardiologia** 1996 Mar;41(3):217–25 (83 ref.)

Angiotensin II signal transduction and the mitogen–activated protein kinase pathway. Duff JL, et al. **Cardiovasc Res** 1995 Oct;30(4):511–7 (102 ref.)

The role of tyrosine phosphorylation in angiotensin II–mediated intracellular signalling. Marrero MB, et al. **Cardiovasc Res** 1995 Oct;30(4):530–6 (54 ref.)

Angiotensin II: biosynthesis, molecular recognition, and signal transduction. Riordan JF. **Cell Mol Neurobiol** 1995 Dec;15(6):637–51 (62 ref.)

Angiotensin II signalling events mediated by tyrosine phosphorylation. Marrero MB, et al. **Cell Signal** 1996 Jan; 8(1):21–6 (30 ref.)

Upregulation of cardiac angiotensin II AT1 receptors in congenital cardiomyopathic hamsters. Lambert C, et al. **Circ Res** 1995 Nov;77(5):1001–7

Effects of subtype–selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis. Huckle WR, et al. **Circulation** 1996 Mar 1;93(5):1009–19

Augmentation of coronary blood flow by ACE inhibition: role of angiotensin and bradykinin. Ruocco NA, et al. **Clin Exp Hypertens** 1995 Oct;17(7):1059–72

Autocrine secretion of angiotensin II mediates stretch–induced hypertrophy of cardiac myocytes in vitro. Sadoshima J, et al. **Contrib Nephrol** 1996;118:214–21

The heterotrimeric G q protein–coupled angiotensin II receptor activates p21 ras via the tyrosine kinase–Shc–Grb2–Sos pathway in cardiac myocytes. Sadoshima J, et al. **EMBO J** 1996 Feb 15;15(4):775–87

Internalisation of the type I angiotensin II receptor (AT1) and angiotensin II function in the rat adrenal zona glomerulosa cell. Vinson GP, et al. **Endocr Res** 1995 Feb–May;21(1–2):211–7

Protein kinase cascade activated by mechanical stress in cardiocytes: possible involvement of angiotensin II. Komuro I, et al. **Eur Heart J** 1995 May;16 Suppl C:8–11

Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Weber KT, et al. **Eur Heart J** 1995 Dec;16 Suppl N:12–8 (83 ref.)

Characterisation of angiotensin II receptor mediated responses and inhibition of intimal hyperplasia in experimental vein grafts by the specific angiotensin II receptor inhibitor, L158,809. Davies MG, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):151–61

Differences in electrophysiological properties of angiotensinergic pathways from the subfornical organ to the median preoptic nucleus between normotensive Wistar–Kyoto and spontaneously hypertensive rats. Tanaka J, et al. **Exp Neurol** 1995 Aug;134(2):192–8

Multiple enhancer elements mediate induction of c–fos in vascular smooth muscle cells. Chen YQ, et al. **Hypertension** 1996 Jun;27(6):1224–33

Hypotensive response to losartan in normal rats. Role of Ang II and the area postrema. Collister JP, et al. **Hypertension** 1996 Mar;27(3 Pt 2):598–606

Renin–angiotensin system and cell communication in the failing heart. De Mello WC. **Hypertension** 1996 Jun; 27(6):1267–72

Evidence for a physiological role of angiotensin–(1–7) in the control of hydroelectrolyte balance. Santos RA, et al. **Hypertension** 1996 Apr;27(4):875–84

Role of nitric oxide in modulating the vasoconstrictor actions of angiotensin II in preglomerular and postglomerular vessels in dogs. Schnackenberg CG, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1024–9

Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. Pichler RH, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1186–96

During acute hypercapnia vasopressin inhibits an angiotensin drive to ventilation in conscious dogs. Walker JK, et al. **J Appl Physiol** 1995 Sep;79(3):786–94

Angiotensin II controls p21ras activity via pp60c–src. Schieffer B, et al. **J Biol Chem** 1996 Apr 26; 271(17):10329–33

Persistent inhibition of the pressor and aldosterone responses to angiotensin–II by TCV–116 in normotensive subjects. Ogihara T, et al. **J Cardiovasc Pharmacol** 1995 Sep; 26(3):490–4

Interactive control of renal function by alpha 2–adrenergic system and nitric oxide: role of angiotensin II. Vallon V, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):916–22

Cardiovascular hypertrophy: role of angiotensin II and bradykinin. Waeber B, et al. **J Cardiovasc Pharmacol** 1996; 27 Suppl 2:S36–40 (37 ref.)

Clinical review 79: Angiotensin II: an insulin–sensitizing vasoactive hormone? Morris AD, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1303–6 (40 ref.)

Role of angiotensin II in dietary modulation of rat late distal tubule bicarbonate flux in vivo. Levine DZ, et al. **J Clin Invest** 1996 Jan 1;97(1):120–5

Endogenous production of angiotensin II modulates rat proximal tubule transport. Quan A, et al. **J Clin Invest** 1996 Jun 15;97(12):2878–82

Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II. Devlin AM, et al. **J Hum Hypertens** 1995 Jun;9(6):497–500 (16 ref.)

Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. Fyhrquist F, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S19–24 (50 ref.)

Expression of cardiac angiotensin II AT1 receptor genes in rat hearts is regulated by steroids but not by angiotensin II. Della Bruna R, et al. **J Hypertens** 1995 Jul;13(7):763–9

Angiotensin II and glomerulonephritis. Jardine AG. **J Hypertens** 1995 May;13(5):487–93 (73 ref.)

Brain angiotensin II contributes to the development of hypertension in Dahl–Iwai salt–sensitive rats. Teruya H, et al. **J Hypertens** 1995 Aug;13(8):883–90

Angiotensin II receptor gene expression in hypertrophied left ventricles of rat hearts. Wolf K, et al. **J Hypertens** 1996 Mar;14(3):349–54

Angiotensin II and basic fibroblast growth factor induce neonatal bladder stromal cell mitogenesis. Cheng EY, et al. **J Urol** 1996 Aug;156(2 Pt 2):593–7

Role of angiotensin II in the expression and regulation of transforming growth factor–beta in obstructive nephropathy. Pimentel JL Jr, et al. **Kidney Int** 1995 Oct; 48(4):1233–46

Angiotensin II–mediated renal injury. Harris RC, et al. **Miner Electrolyte Metab** 1995;21(4–5):328–35 (83 ref.)

Angiotensin II signalling pathways in cardiac fibroblasts: conventional versus novel mechanisms in mediating cardiac growth and function. Dostal DE, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):15–21 (66 ref.)

Protein tyrosine phosphorylation in cardiovascular system. Srivastava AK. **Mol Cell Biochem** 1995 Aug–Sep; 149–150:87–94 (90 ref.)

Modulation of a Ca(2+)–activated K+ channel by angiotensin II in rat adrenal glomerulosa cells: involvement of a G protein. Payet MD, et al. **Mol Endocrinol** 1995 Aug; 9(8):935–47

Angiotensin–II–induced cell hypertrophy: potential role of impaired proteolytic activity in cultured LLC–PK1 cells. Ling H, et al. **Nephrol Dial Transplant** 1995;10(8):1305–12

Renal scarring: the role of angiotensin II. el Nahas AM. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:28–32 (53 ref.)

Ureteral obstruction in the neonatal guinea pig: interaction of sympathetic nerves and angiotensin. Chevalier RL, et

al. **Pediatr Nephrol** 1995 Aug;9(4):441-6

Angiotensin II regulates both adrenocortical and adrenomedullary function in isolated perfused pig adrenals. Breidert M, et al. **Peptides** 1996;17(2):287-92

Angiotensin II and its different receptor subtypes in placenta and fetal membranes. Kalenga MK, et al. **Placenta** 1996 Mar-Apr;17(2-3):103-110 (50 ref.)

Role of angiotensin in the regulation of renal response to proteins. Gabbai FB, et al. **Semin Nephrol** 1995 Sep; 15(5):396-404 (56 ref.)

Angiotensin II contributes to cerebral vasodilatation during hypoxia in the rabbit. Maktabi MA, et al. **Stroke** 1995 Oct; 26(10):1871-6

SECRETION

Acute effects of calcitonin gene related peptide on renal haemodynamics and renin and angiotensin II secretion in patients with renal disease. Palla R, et al.
Int J Tissue React 1995;17(1):43-9

Interactions between insulin-like growth factor-I (IGF-I) and the renin-angiotensin system in follicular growth and ovulation. Yoshimura Y, et al. **J Clin Invest** 1996 Jul 15; 98(2):308-16

THERAPEUTIC USE

Enalapril overdose and the corrective effect of intravenous angiotensin II [letter] Newby DE, et al.
Br J Clin Pharmacol 1995 Jul;40(1):103-4

Angiotensin-II-induced hypertension chemotherapy: evaluation of hepatic blood flow with oxygen-15 PET. Taniguchi H, et al. **J Nucl Med** 1996 Sep;37(9):1522-3

Treatment of hypotension in septic shock [letter; comment] Pastor CM, et al. **Lancet** 1996 Mar 2;347(9001):622; discussion 622-3. Comment on: Lancet 1995 Dec 16;346(8990):1604.

Treatment of hypotension in septic shock [letter; comment] Whiteley SM, et al. **Lancet** 1996 Mar 2;347(9001):622. Comment on: Lancet 1995 Dec 16;346(8990):1604.

Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging. Sato H, et al.
World J Surg 1995 Nov-Dec;19(6):836-42

TOXICITY

Angiotensin II-induced hypertrophy of rat vascular smooth muscle is associated with increased 18 S rRNA synthesis and phosphorylation of the rRNA transcription factor, upstream binding factor. Hershey JC, et al.
J Biol Chem 1995 Oct 20;270(42):25096-101

Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats. Morita O, et al.
J Cardiovasc Pharmacol 1995 Jun;25(6):880-7

ANGIOTENSIN III

METABOLISM

Effects of dietary salt on angiotensin peptides in kidney. Meng QC, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1209-15

PHARMACOLOGY

Effects of atrial natriuretic factor on norepinephrine release evoked by angiotensins II and III in the rat adrenal medulla. Papouchado ML, et al. **Arch Physiol Biochem** 1995 Apr; 103(1):55-8

Effects of angiotensin II antagonists on the contractile and hydrosmotic effect of AT II and AT III in the toad (Bufo arenarum). Peral de Bruno M, et al.
J Comp Physiol [B] 1996;165(7):565-70

PHYSIOLOGY

Neurobiology of central angiotensin III and dipsogenesis. Yang CC, et al. **Biol Signals** 1995 Mar-Apr;4(2):59-71 (70 ref.)

ANGIOTENSIN BINDING SITES see **RECEPTORS, ANGIOTENSIN**

ANGIOTENSIN CONVERTING ENZYME see **PEPTIDYL-DIPEPTIDASE A**

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Relational database for drug-use review of Tennessee Medicaid claims. Chyka PA, et al.
Am J Health Syst Pharm 1996 Jan 15;53(2):164-6

Calcium channel blockers as inhibitors of angiotensin I-converting enzyme. Casarini DE, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1145-8

ADMINISTRATION & DOSAGE

Evaluation of blood pressure response to the combination of enalapril (single dose) and diltiazem ER (four different doses) in systemic hypertension. Applegate WB, et al.
Am J Cardiol 1996 Jul 1;78(1):51-5

Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty. Freed M, et al. **Am J Cardiol** 1995 Dec 1; 76(16):1185-8

Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Trevisan R, et al. **Am J Hypertens** 1995 Sep; 8(9):876-83

Cilazapril reverses endothelium-dependent vasodilator response to acetylcholine in mesenteric artery from spontaneously hypertensive rats. Young RH, et al.
Am J Hypertens 1995 Sep;8(9):928-33

Conversions from captopril to lisinopril at a dosage ratio of 5:1 result in comparable control of hypertension. Gill TH, et al. **Ann Pharmacother** 1996 Jan;30(1):7-11

Cardiorespiratory effects of continuous i.v. administration of the ACE inhibitor enalaprilat in the critically ill. Boldt J, et al. **Br J Clin Pharmacol** 1995 Nov;40(5):415-22

Short-term effects of captopril on exercise tolerance in patients with chronic stable angina pectoris and normal left ventricular function. Steffensen R, et al. **Cardiology** 1995;86(6):445-50

Dose-dependent dissociation of ACE-inhibitor effects on blood pressure, cardiac hypertrophy, and beta-adrenergic signal transduction. Böhm M, et al. **Circulation** 1995 Nov 15;92(10):3006-13

Evaluation of antihypertensive effects of once-a-day isradipine and fosinopril: a double-blind crossover study by means of ambulatory blood pressure monitoring. Perticone F, et al. **Clin Cardiol** 1995 Jul;18(7):401-7

Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study. Sano T, et al. **Diabet Med** 1996 Feb;13(2):120-4

Left ventricular systolic function after marked reduction of ventricular hypertrophy induced by 5 years' enalapril treatment [see comments] González-Juanatey JR, et al.
Eur Heart J 1995 Dec;16(12):1981-7. Comment in: Eur Heart J 1995 Dec;16(12):1748-9.

Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure. Konstam MA. **Eur Heart J** 1995 Dec;16 Suppl N:59-64 (44 ref.)

Acute effect of captopril administration on baroreflex sensitivity in patients with acute myocardial infarction. Marakas SA, et al. **Eur Heart J** 1995 Jul;16(7):914-21

ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Pitt D. **Eur Heart J** 1995 Dec;16 Suppl N:107-10

Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Davidson NC, et al. **Heart** 1996 Jun;75(6):576-81

Nitric oxide release from kidneys of hypertensive rats treated with imidapril. Hirata Y, et al. **Hypertension** 1996 Mar;27(3 Pt 2):672-8

Effects of cilazapril on vascular structure and function in essential hypertension. Kiowski W, et al. **Hypertension** 1996 Mar;27(3 Pt 1):371-6

Effects of lisinopril on the structure of renal arterioles. Notoya M, et al. **Hypertension** 1996 Mar;27(3 Pt 1):364-70

Effects of ACE inhibitors on mortality when started in the early phase of myocardial infarction: evidence from the larger randomized controlled trials. Flather MD, et al.
J Cardiovasc Risk 1995 Oct;2(5):423-8 (27 ref.)

Clinical background to the use of ACE inhibitor therapy after myocardial infarction. Hall AS, et al.
J Cardiovasc Risk 1995 Oct;2(5):396-405 (66 ref.)

Anti-hypertensive effects of intravenous compared with oral captopril. Sramek JJ, et al. **J Hum Hypertens** 1995 Nov; 9(11):875-8

Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? Bakris GL, et al.
J Hypertens Suppl 1995 Aug;13(2):S95-101 (52 ref.)

The pharmacological basis for the combination of calcium channel antagonists and angiotensin converting enzyme inhibitors in the treatment of hypertension. Osswald H, et al. **J Hypertens Suppl** 1995 Aug;13(2):S21-8 (58 ref.)

Low-dose captopril and proteinuria [letter; comment] Boulton-Jones JM. **Nephrol Dial Transplant** 1995 Nov; 10(11):2157-8. Comment on: Nephrol Dial Transplant 1995;10(1):25-9.

Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? [letter] Hess E, et al.
Nephrol Dial Transplant 1996 Apr;11(4):749-751

ACE inhibitors in heart failure. What dose? [letter; comment] Jolobe OM. **Postgrad Med J** 1995 Aug;71(838):510. Comment on: Postgrad Med J 1995 Feb;71(832):65-6.

Effects of a single dose and short-term captopril treatment on some pressor and depressor humoral factors in healthy subjects. Zacharieva S, et al.
Prostaglandins Leukot Essent Fatty Acids 1995 Nov; 53(5):377-80

Multiple doses of trandolapril do not affect warfarin pharmacodynamics. Meyer BH, et al. **S Afr Med J** 1995 Aug;85(8):768-70

[Pharmacological prevention of late complications of diabetes] Jensen TJ, et al. **Ugeskr Laeger** 1996 Apr 22; 158(17):2402-3 **(Dan)**

[Renal function during treatment with angiotensin converting enzyme inhibitors] Rasmussen K, et al. **Ugeskr Laeger** 1995 Sep 25;157(39):5377-81 (17 ref.) (Eng. Abstr.) **(Dan)**

[Comparison of clinical and ambulatory measurements of blood pressure with benazepril alone or combined with hydrochlorothiazide in hypertension] Le Feuvre C, et al.
Therapie 1996 Jan-Feb;51(1):27-34 (Eng. Abstr.) **(Fre)**

[ACE inhibitor dosage in heart failure] Riegger G.
Dtsch Med Wochenschr 1995 Dec 8;120(49):1716-7 **(Ger)**

[Why is there no sustained-release form of captopril?] Thürmann P, et al. **Dtsch Med Wochenschr** 1996 Aug 23; 121(34-35):1072 **(Ger)**

[Interventional therapy of nonocclusive mesenteric ischemia with captopril: an experimental animal study] Jakschik J, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Jun;164(6):502-6 (Eng. Abstr.) **(Ger)**

[Cilazapril replacing captopril in the therapy of medium-severe essential hypertension] Kovács P, et al.
Orv Hetil 1995 Oct 15;136(42):2273-8 (Eng. Abstr.) **(Hun)**

[ACE inhibitors and early diabetic nephropathy] Bangstad HJ, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10; 115(24):3039-41 (25 ref.) (Eng. Abstr.) **(Nor)**

[ACE inhibitors, yes or no?] Jenssen TG.
Tidsskr Nor Laegeforen 1995 Oct 10;115(24):3014-5 **(Nor)**

[The antihypertensive activity of benazepril in the long-term treatment of hypertension patients and its effect on adrenal cortical function] Ol'binskaia LI, et al. **Ter Arkh** 1995; 67(9):56-8 (Eng. Abstr.) **(Rus)**

[The antihypertensive effect of lisinopril in a single daily dosage. A study of arterial pressure with ambulatory monitoring] González Romero S, et al.
Arch Inst Cardiol Mex 1995 Sep-Oct;65(5):435-43 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Kostis JB, et al. **Am Heart J** 1996 Feb;131(2):350-5

Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity. Casato M, et al.
Am J Med 1995 Oct;99(4):386-91

Granulocytopenia after combined therapy with interferon and angiotensin- converting enzyme inhibitors: evidence for a synergistic hematologic toxicity [letter] Jacquot C, et al. **Am J Med** 1996 Aug;101(2):235-6

Adverse effects of the angiotensin-converting enzyme inhibitors. Alderman CP. **Ann Pharmacother** 1996 Jan; 30(1):55-61 (61 ref.)

Lessons from low enrollment in ACE inhibitor cough study [letter] Cupp MJ, et al. **Ann Pharmacother** 1996 Apr; 30(4):413

Angio-oedema and ACE inhibitors [letter] Black PN, et al.
Aust N Z J Med 1995 Dec;25(6):746; discussion 747

Angio-oedema and ACE inhibitors [letter] Boyd IW.
Aust N Z J Med 1995 Dec;25(6):746-7

A QA perspective--report on ACE inhibitor angio-oedema [editorial; comment] Duggan JM. **Aust N Z J Med** 1995 Jun;25(3):189. Comment on: Aust N Z J Med 1995 Jun;25(3):241-2.

The effects of increasing doses of enalapril on insulin sensitivity in normotensive non-insulin dependent diabetic subjects. Walker RJ, et al. **Aust N Z J Med** 1995 Dec; 25(6):698-702

Failure to recognise the association of life-threatening angio-oedema and angiotensin-converting enzyme inhibitor therapy [see comments] Weiner JM.
Aust N Z J Med 1995 Jun;25(3):241-2. Comment in: Aust N Z J Med 1995 Jun;25(3):189.

Angiotensin converting enzyme inhibitor therapy and acute pancreatitis. Madsen JS, et al. **Blood Press** 1995 Nov; 4(6):369-71

Enalapril overdose and the corrective effect of intravenous angiotensin II [letter] Newby DE, et al.
Br J Clin Pharmacol 1995 Jul;40(1):103-4

High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Woo KS, et al.
Br J Clin Pharmacol 1995 Aug;40(2):141-4

Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P. Yeo WW, et al.
Br J Clin Pharmacol 1995 Nov;40(5):423-9

Self-reported depressive symptoms in association with medication exposures among medical inpatients: a cross-sectional study. Patten SB, et al.
Can J Psychiatry 1995 Jun;40(5):264-9

Brief treatment of SHR with an ACE inhibitor fails to cause long-term normotension but markedly increases mortality. Lan L, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S345-6

Acute renal failure following massive mannitol infusion and enalapril treatment. Nakhoul F, et al. **Clin Nephrol** 1995 Aug;44(2):118-20

Angiotensin converting enzyme inhibitors and the otolaryngologist [editorial] Cruickshank HE.
Clin Otolaryngol 1995 Jun;20(3):189-91

Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Brown NJ, et al. **Clin Pharmacol Ther** 1996 Jul;60(1):8-13

Generalized pustular eruption associated with converting

enzyme inhibitor therapy. Carroll J, et al. **Cutis** 1995 Nov; 56(5):276–8

Captopril–induced acute pancreatitis. Jeandidier N, et al. **Diabetes Care** 1995 Mar;18(3):410–1

ACE inhibitors and impotence: a case series from the Spanish drug monitoring system [letter] Carvajal A, et al. **Drug Saf** 1995 Aug;13(2):130–1

ACE inhibitors in elderly patients with hypertension. Special considerations. Ravid M, et al. **Drugs Aging** 1996 Jan; 8(1):29–37 (89 ref.)

ACE–inhibitor–induced cough, an adverse drug reaction unrecognised for several years: studies in prescription–event monitoring. Kubota K, et al. **Eur J Clin Pharmacol** 1996;49(6):431–7

European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort. Lawson DH, et al. **Eur J Clin Pharmacol** 1995;49(1–2):73–9

Effects of ACE inhibition on endurance exercise haemodynamics in trained subjects with mild hypertension. Palatini P, et al. **Eur J Clin Pharmacol** 1995;48(6):435–9

Cough due to ACE inhibitors: a case–control study using automated general practice data. Visser LE, et al. **Eur J Clin Pharmacol** 1996;49(6):439–44

Delayed renal revascularisation after enalapril induced renal failure in renal artery stenosis. Khaira HS, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):375–7 (17 ref.)

Captopril, an angiotensin–converting enzyme inhibitor, induced pulmonary infiltration with eosinophilia. Watanabe K, et al. **Intern Med** 1996 Feb;35(2):142–5

Pancytopenia associated with administration of captopril to a dog. Holland M, et al. **J Am Vet Med Assoc** 1996 May 15;208(10):1683–6

Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. Semple PF. **J Hypertens Suppl** 1995 Sep;13 Suppl 3:S17–21 (38 ref.)

Angio–oedema induced by ACE inhibitors [letter] Marinella MA. **J Intern Med** 1996 Apr;239(4):371–2

Methacholine inhalation challenge in patients with chronic cough induced by angiotensin–converting enzyme inhibitors. Wongtim S, et al. **J Med Assoc Thai** 1996 Mar; 79(3):166–70

Perioperative angioedema in a patient on long–term angiotensin–converting enzyme (ACE)–inhibitor therapy. Ogbureke KU, et al. **J Oral Maxillofac Surg** 1996 Jul; 54(7):917–20 (18 ref.)

Acute renal failure associated with use of angiotensin converting enzyme inhibitor—a report of two children with Down's syndrome. Krishna EV, et al. **J Tenn Med Assoc** 1996 Jan;89(1):5–7

Trumping the ACE [letter] Vane J. **Lancet** 1995 Sep 30; 346(8979):916

Cough induced by angiotensin–converting–enzyme inhibitors: Airway responses to inhalation of methacholine in patients who have essential hypertension. Kelleher JP, et al. **Mt Sinai J Med** 1995 Nov;62(6):445–52

Intensity of hemodialysis and response to erythropoietin [letter; comment] Kotanko P. **N Engl J Med** 1996 Jun 20; 334(25):1670; discussion 1670–1. Comment on: N Engl J Med 1996 Feb 15;334(7):420–5.

Bradykinin–evoked sensitization of airway sensory nerves: a mechanism for ACE–inhibitor cough. Fox AJ, et al. **Nat Med** 1996 Jul;2(7):814–7

Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: possible implications of angiotensin–converting enzyme inhibitors [letter] Ertürk S, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):396–7

No generation of bradykinin with a new polyacrylonitrile membrane (SPAN) in haemodialysis patients treated with ACE inhibitors. Mannstadt M, et al. **Nephrol Dial Transplant** 1995;10(9):1696–700

Kinin kinetics during different dialysis protocols with AN69 dialyser in ACEI–treated patients. Van der Niepen P, et al. **Nephrol Dial Transplant** 1995;10(9):1689–95

Severe reduction of renal function in hypertensives and/or diabetics induced by angiotensin–converting enzyme inhibitors [letter] Gotloib L, et al. **Nephron** 1995;71(2):230–1

Effect of angiotensin–converting enzyme inhibitors on anemia in hemodialyzed patients [letter] Teruel JL, et al. **Nephron** 1996;73(1):113

Glottic angioedema, ciprofloxacin, and ACE inhibitors [letter] Langauer Messmer S, et al. **Postgrad Med J** 1996 Jun;72(848):383

Acute renal failure induced by angiotensin converting enzyme inhibitor in a patient with polyarteritis nodosa. Wang AY, et al. **Ren Fail** 1996 Mar;18(2):293–8 (17 ref.)

Angiotensin converting enzyme (ACE) inhibitor–induced cough and substance P. Tomaki M, et al. **Thorax** 1996 Feb; 51(2):199–201

Angiotensin converting enzyme inhibitor induced anemia in a kidney transplant recipient. Kuriyama R, et al. **Transplant Proc** 1996 Jun;28(3):1635

[Significant teratogenicity of angiotensin converting enzyme inhibitors] Jirásek JE. **Ceska Gynekol** 1996 Feb;61(1):54 **(Cze)**

[Renal function during treatment of chronic renal failure with angiotensin converting enzyme inhibitors] Heitmann M, et al. **Ugeskr Laeger** 1995 Sep 25;157(39):5381–4 (Eng. Abstr.) **(Dan)**

[Schoenlein–Henoch purpura in a geriatric patient after captopril therapy] Jensen ON, et al. **Ugeskr Laeger** 1996 Aug 26;158(35):4926–7 (Eng. Abstr.) **(Dan)**

[Angioneurotic edema in relation to therapeutic use of angiotensin–converting enzyme inhibitor] Johansen EC, et al. **Ugeskr Laeger** 1996 Jan 1;158(1):59–60 (Eng. Abstr.) **(Dan)**

[ACE–inhibitors increase the risk of hypoglycemia in diabetics (letter)] Gansevoort RT, et al. **Ned Tijdschr Geneeskd** 1996 May 11;140(19):1042–4 **(Dut)**

[Psychotropic effects of angiotensin–converting enzyme inhibitors: what are the arguments?] Mesure G, et al. **Encephale** 1995 Sep–Oct;21(5):609–14 (59 ref.) (Eng. Abstr.) **(Fre)**

[Life–threatening postoperative angioedema following treatment with an angiotensin converting enzyme inhibitor] Maier C. **Anaesthesist** 1995 Dec;44(12):875–9 (Eng. Abstr.) **(Ger)**

[ACE inhibitor–associated interstitial lung infiltrates (see comments)] Obergassel L, et al. **Dtsch Med Wochenschr** 1995 Sep 22;120(38):1273–7 (22 ref.) (Eng. Abstr.). Comment in: Dtsch Med Wochenschr 1996 Jan 19;121(3):81. **(Ger)**

[Clinicopharmacological case report (3). Drug–induced angioedema] Kind B, et al. **Schweiz Rundsch Med Prax** 1996 Apr 23;85(17):567–9 (27 ref.) (Eng. Abstr.) **(Ger)**

[Cough as an adverse effect during angiotensin–converting enzyme inhibitor therapy] Adamek L, et al. **Pol Arch Med Wewn** 1996 Mar;95(3):254–60 (33 ref.) **(Pol)**

[ACE inhibitors may cause hypoglycemia in patients with diabetes] **Lakartidningen** 1995 Oct 18;92(42):3923 **(Swe)**

[Angioedema following treatment with ACE inhibitors] Ekborn A, et al. **Lakartidningen** 1996 Feb 7;93(6):468–70 **(Swe)**

AGONISTS

N–acetylcysteine potentiates the antihypertensive effect of angiotensin converting enzyme inhibitors [letter] Suárez C, et al. **Am J Hypertens** 1995 Aug;8(8):859

ANALYSIS

Simultaneous determination of enalapril maleate and hydrochlorothiazide by first–derivative ultraviolet spectrophotometry and high–performance liquid chromatography. el Walily AF, et al. **J Pharm Biomed Anal** 1995 Jun;13(7):851–6

BLOOD

Thrombomodulin and angiotensin–converting enzyme activity during pediatric open heart operations. Komai H, et al. **Ann Thorac Surg** 1996 Aug;62(2):553–8

Simultaneous determination of moexipril and moexiprilat, its active metabolite, in human plasma by gas chromatography–negative–ion chemical ionization mass spectrometry. Hammes W, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):81–9

Quantification of a dual angiotensin I–converting enzyme–neutral endopeptidase inhibitor and the active thiol metabolite in dog plasma by high–performance liquid chromatography with ultraviolet absorbance detection. Heath TG, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):91–101

[Inhibitors of renin–angiotensin system] Kawabe H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:994–7 (18 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Optimal recognition of neutral endopeptidase and angiotensin–converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors. Coric P, et al. **J Med Chem** 1996 Mar 15; 39(6):1210–9

Design of orally active dual inhibitors of neutral endopeptidase and angiotensin–converting enzyme with long duration of action. Fournie–Zaluski MC, et al. **J Med Chem** 1996 Jun 21;39(13):2594–608

CHEMISTRY

Stability of ramipril in water, apple juice, and applesauce. Allen LV Jr, et al. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2433–6

Structures of BAY o 6997 and BAY q 1313 microbial ACE inhibitors. Bauer K, et al. **Int J Pept Protein Res** 1995 Sep–Oct;46(3–4):302–5

The determination of palladium in fosinopril sodium (monopril) by ICP–MS. Lewen N, et al. **J Pharm Biomed Anal** 1995 Jun;13(7):879–83

CONTRAINDICATIONS

Current controversies with ACE inhibitor treatment in heart failure. Visser FC, et al. **Cardiology** 1996;87 Suppl 1:23–8 (21 ref.)

[Administration of beta–blockers and ACE inhibitors in this indication is frequently limited by hypotensive cardiovascular parameters] **Internist (Berl)** 1996 Jul; 37(7):739–40 **(Ger)**

[To what extent can prostaglandin synthesis inhibitors of the non–steroidal antirheumatic (NSAR) type modify the effect of ACE inhibitors?] Grote L. **Internist (Berl)** 1995 Dec; 36(12):1203–4 **(Ger)**

DIAGNOSTIC USE

Diagnosis of renovascular hypertension: feasibility of captopril–sensitized dynamic MR imaging and comparison with captopril scintigraphy. Grenier N, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):835–43

Angiotensin–converting enzyme inhibitor renography. Rehm PK. **AJR Am J Roentgenol** 1996 Feb;166(2):458–9

Role of captopril renography in the diagnosis of renovascular hypertension. Mittal BR, et al. **Am J Kidney Dis** 1996 Aug; 28(2):209–13

Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril. Schwartz D, et al. **Cardiovasc Drugs Ther** 1996 Mar;10(1):75–9

Superior imaging qualities of Tc–99m MAG–3 in captopril renal scintigraphy contributing to the detection of branch artery stenosis. Trepashko DW, et al. **Clin Nucl Med** 1996 May;21(5):393–4

'Captopril test', with blood pressure and peripheral renin as response variables in hypertensive patients with suspected renal artery stenosis. Schreij G, et al. **J Hum Hypertens** 1995 Sep;9(9):741–6

Radionuclide captopril renography in postpartum renal artery aneurysms. Turpin S, et al. **J Nucl Med** 1996 Aug; 37(8):1368–71

Acute blockage of the renin system and differential renal vein renin determinations in the diagnosis of renovascular hypertension. Kutkuhn B, et al. **Scand J Urol Nephrol** 1996 Feb;30(1):69–72

ECONOMICS

Cost–effectiveness analysis and clinical practice [editorial; comment] Rector TS, et al. **J Am Coll Cardiol** 1995 Oct; 26(4):920–1. Comment on: J Am Coll Cardiol 1995 Oct;26(4):914–9.

Cost–effectiveness of captopril therapy after myocardial infarction [see comments] Tsevat J, et al. **J Am Coll Cardiol** 1995 Oct;26(4):914–9. Comment in: J Am Coll Cardiol 1995 Oct;26(4):920–1.

HISTORY

[Angiotensin–converting enzyme inhibitors] Soyeur D. **Rev Med Liege** 1996 Jan;51(1):27–9 **(Fre)**

ISOLATION & PURIFICATION

Novel microbial inhibitors of ACE. Isolation and characterization. Bauer K, et al. **Int J Pept Protein Res** 1995 Sep–Oct;46(3–4):205–8

METABOLISM

Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. Verho M, et al. **Curr Med Res Opin** 1995;13(5):264–73

Distribution of the dipeptide transporter system along the gastrointestinal tract of rats based on absorption of a stable and specific probe, SQ–29852. Marino AM, et al. **J Pharm Sci** 1996 Mar;85(3):282–6

Reabsorption and metabolism of quinapril and quinaprilat in rat kidney: in vivo micropuncture studies. Smith DE, et al. **J Pharm Sci** 1995 Oct;84(10):1147–50

Mechanisms of transport of quinapril in Caco–2 cell monolayers: comparison with cephalexin. Hu M, et al. **Pharm Res** 1995 Aug;12(8):1120–5

PHARMACOKINETICS

Pharmacokinetic and fetal cardiovascular effects of enalaprilat administration to maternal rhesus macaques. Ducsay CA, et al. **Am J Obstet Gynecol** 1996 Jul; 175(1):50–5

Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin–converting enzyme activity after single and repeated administrations to dogs. King JN, et al. **Am J Vet Res** 1995 Dec;56(12):1620–8

Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure. Kostis JB, et al. **Clin Pharmacol Ther** 1995 Dec;58(6):660–5

A comparison of the pharmacokinetics and pharmacodynamics of cilazapril between Chinese and Caucasian healthy, normotensive volunteers. Anderson PJ, et al. **Eur J Clin Pharmacol** 1996;50(1–2):57–62

Chronopharmacology of enalapril in hypertensive patients. Sunaga K, et al. **Eur J Clin Pharmacol** 1995;48(6):441–5

Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function. Hersh AD, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):7–11

A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril. Breslin E, et al. **J Clin Pharmacol** 1996 May;36(5):414–21

Effects on the pharmacokinetics and pharmacodynamics in the elderly of coadministering ramipril with water, apple juice, and applesauce. Lee ID, et al. **Pharm Res** 1996 Apr; 13(4):639–42

PHARMACOLOGY

Biochemistry and cell biology of angiotensin–converting enzyme and converting enzyme inhibitors. Berecek KH, et al. **Adv Exp Med Biol** 1995;377:141–68 (256 ref.)

Renin inhibition: a novel therapy for cardiovascular disease.

Lin C, et al. **Am Heart J** 1996 May;131(5):1024–34 (115 ref.)

Influence of captopril on nitroglycerin–mediated vasodilation and development of nitrate tolerance in arterial and venous circulation. Pizzulli L, et al. **Am Heart J** 1996 Feb; 131(2):342–9

Effect of aging and chronic angiotensin I converting enzyme inhibition on the endothelial function of the mesenteric arterial bed of the rat. Atkinson J. **Am J Cardiol** 1995 Nov 24;76(15):19E–23E

Converting enzyme inhibition, heart rate variability, and myocardial infarction [letter] Bonaduce D, et al. **Am J Cardiol** 1996 Sep 1;78(5):609

Angiotensin–converting enzyme inhibitors reduce neointimal thickening and maintain endothelial nitric oxide function in rabbit carotid arteries. Dusting GJ, et al. **Am J Cardiol** 1995 Nov 24;76(15):24E–27E

Vascular and myocardial protective effects of converting enzyme inhibition in experimental heart failure. Mulder P, et al. **Am J Cardiol** 1995 Nov 24;76(15):28E–33E

Effects of enalapril on tissue factor in patients with uncomplicated acute myocardial infarction. Soejima H, et al. **Am J Cardiol** 1996 Aug 1;78(3):336–40

Endothelium–derived relaxing factors and converting enzyme inhibition. Vanhoutte PM, et al. **Am J Cardiol** 1995 Nov 24;76(15):3E–12E (83 ref.)

Influence of pressure overload and ACE inhibitor therapy on constitutive protein mRNA expression in the spontaneously hypertensive rat. Cipkala DA, et al. **Am J Hypertens** 1996 Apr;9(4 Pt 1):393–6

Reversal of the suppressed kidney renin level in the hypertensive transgenic rat TGR(mRen–2)27 by angiotensin converting enzyme inhibition. Tokita Y, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 1):1031–9

Enalapril attenuates the renal hemodynamic effect of acetazolamide in patients with diabetes mellitus: possible implications for tubuloglomerular feedback. Slomowitz LA, et al. **Am J Nephrol** 1996;16(4):315–9

Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure. Barbe F, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H1985–92

ACE inhibition prevents Na and water retention and MABP increase during reduction of renal perfusion pressure. Boemke W, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R481–9

Angiotensin–converting enzyme inhibitor and danazol increase sensitivity of cough reflex in female guinea pigs. Ebihara T, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):812–9

Long–term angiotensin–converting enzyme inhibitor treatment attenuates adrenergic responsiveness without altering hemodynamic control in patients undergoing cardiac surgery. Licker M, et al. **Anesthesiology** 1996 Apr; 84(4):789–800

Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases. Nakagawa T, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):1985–9

Pharmacokinetic interaction between cefdinir and two angiotensin–converting enzyme inhibitors in rats. Jacolot A, et al. **Antimicrob Agents Chemother** 1996 Apr; 40(4):979–82

Mechanism of inhibition of neointimal formation by the angiotensin–converting enzyme inhibitor cilazapril. A study in balloon catheter–injured rat carotid arteries. Fingerle J, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov; 15(11):1945–50

Antihypertensive properties of a new long–acting angiotensin converting enzyme inhibitor in renin–dependent and independent hypertensive models. Nagata S, et al. **Arzneimittelforschung** 1995 Aug;45(8):853–8

Abnormal taurocholate ileal transepithelial transport in atherosclerotic mini–pigs and effects of ACE inhibitors. Rahmani–Jourdheuil D, et al. **Atherosclerosis** 1995 Oct; 117(2):285–93

Angiotensin converting enzyme inhibitor normalizes vascular natriuretic peptide type A receptor gene expression via bradykinin–dependent mechanism in hypertensive rats. Yoshimoto T, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):50–3

Mercuric chloride effects on the kinetic parameters of human erythrocyte membrane bound acetylcholinesterase. Aijafari AA. **Biochem Mol Biol Int** 1995 Aug;36(6):1243–53

Inhibition and metal ion activation of pig kidney aminopeptidase P. Dependence on nature of substrate. Lloyd GS, et al. **Biochem Pharmacol** 1996 Jul 26; 52(2):229–36

Metabolism of angiotensin I in isolated rat hearts. Effect of angiotensin converting enzyme inhibitors. Neves LA, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1451–9

The role of the renin–angiotensin and natriuretic peptide systems in the pulmonary vasculature. Cargill RI, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):11–8 (68 ref.)

Effect of captopril, enalaprilat and mercaptopropionyl glycine (MPG) on the oxidative activity of human isolated neutrophils. Clapperton M, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):31–5

Ramipril–induced decrease in renal lithium excretion in the rat. Barthelmebs M, et al. **Br J Pharmacol** 1995 Oct; 116(4):2161–5

Lack of involvement of bradykinin in the vascular sympathoinhibitory effects of angiotensin converting enzyme inhibitors in spontaneously hypertensive rats. Chauvin B, et al. **Br J Pharmacol** 1995 Oct;116(4):2229–36

Effect of enalaprilat on bradykinin and des–Arg9–bradykinin release following reperfusion of the ischaemic rat heart. Lamontagne D, et al. **Br J Pharmacol** 1995 Jun; 115(3):476–8

Effects of dietary protein, angiotensin I converting enzyme inhibition and mesangial overload on the progression of adriamycin–induced nephropathy. Barretti P, et al. **Braz J Med Biol Res** 1995 Jan;28(1):39–50

Injection of ramipril into the lateral ventricle interferes with the drinking response induced by pharmacological and natural thirst stimuli. Saad WA, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2909–13

Effect of perindopril in pacing–induced canine models of acute and chronic heart failure. Ogilvie RI, et al. **Can J Cardiol** 1995 Nov;11(10):934–40

Comparative studies on differential inhibition of the renin – angiotensin system in the anesthetized guinea pig. Duan J, et al. **Can J Physiol Pharmacol** 1995 Oct;73(10):1512–8

Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. Zhu YC, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):827–31 (39 ref.)

Long–term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats. Traub O, et al. **Cardiovasc Drugs Ther** 1995 Jun;9(3):421–9

Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans. Cargill RI, et al. **Chest** 1996 Feb;109(2):424–9

Effect of angiotensin converting enzyme inhibitors on tolerance of nitroglycerin. Fang Z, et al. **Chin Med J (Engl)** 1995 Dec;108(12):919–22

Enhancement of left ventricular relaxation in the isolated heart by an angiotensin–converting enzyme inhibitor. Anning PB, et al. **Circulation** 1995 Nov 1;92(9):2660–5

C–type natriuretic peptide. An endogenous inhibitor of vascular angiotensin–converting enzyme activity. Davidson NC, et al. **Circulation** 1996 Mar 15;93(6):1155–9

Angiotensin–converting enzyme inhibition suppresses plasminogen activator inhibitor–1 expression in the neointima of balloon–injured rat aorta. Hamdan AD, et al. **Circulation** 1996 Mar 15;93(6):1073–8

Long–term angiotensin–converting enzyme inhibition with high–dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Münzel T, et al. **Circulation** 1996 Jun 1;93(11):2052–8

Evidence for load–dependent and load–independent determinants of cardiac natriuretic peptide production. Ogawa T, et al. **Circulation** 1996 Jun 1;93(11):2059–67

Angiotensin–converting enzyme inhibition preserves endothelium–dependent coronary microvascular responses during short–term ischemia–reperfusion. Piana RN, et al. **Circulation** 1996 Feb 1;93(3):544–51

Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload–induced cardiac hypertrophy in rats. Ruzicka M, et al. **Circulation** 1995 Dec 15;92(12):3568–73

Long–term treatment with angiotensin I–converting enzyme inhibitors attenuates the loss of cardiac beta–adrenoceptor responses in rats with chronic heart failure. Sanbe A, et al. **Circulation** 1995 Nov 1;92(9):2666–75

Coronary vasodilation induced by angiotensin–converting enzyme inhibition in vivo: differential contribution of nitric oxide and bradykinin in conductance and resistance arteries. Sudhir K, et al. **Circulation** 1996 May 1; 93(9):1734–9

Augmentation of coronary blood flow by ACE inhibition: role of angiotensin and bradykinin. Ruocco NA, et al. **Clin Exp Hypertens** 1995 Oct;17(7):1059–72

Angiotensin converting enzyme (ACE) inhibitors and kinin metabolism: evidence that ACE inhibitors may inhibit a kininase other than ACE. Campbell DJ. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):903–11 (99 ref.)

The role of angiotensin converting enzyme and nitric oxide in the enhanced systemic depressor responses to bradykinin in pregnant rats. Chu ZM, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):481–3

Antihypertensive effect of thermolysin digest of dried bonito in spontaneously hypertensive rat. Fujita H, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S304–5

Renin mRNA concentration in rat hypothalamus is decreased by enalapril. Lou YK, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):493–5

Effect of dose on trough peak ratio of antihypertensive drugs in elderly hypertensive males. Morgan TO, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):778–80

Renal medulla and bradykinin during the development of hypertension in SHR. O'Sullivan JB, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):463–5

Effects of captopril on [3H]–norepinephrine release in rat central nervous system. Tsuda K, et al. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):610–3

Plasma bradykinin levels during hemodialysis with PAN DX and polysulfone membranes with and without concurrent ACE inhibitor. Wakasa M, et al. **Clin Nephrol** 1995 Nov; 44 Suppl 1:S29–32

Local angiotensin–converting enzyme inhibition blunts endothelin–1–induced increase in forearm vascular resistance. Abernethy DR, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):328–34

Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men. Goldberg MR, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):72–82

Angiotensin converting enzyme inhibition and sympathetic activity in healthy subjects. Lang CC, et al. **Clin Pharmacol Ther** 1996 Jun;59(6):668–74

Direct angiotensin converting enzyme inhibitor–mediated venodilation. Zarnke KB, et al. **Clin Pharmacol Ther** 1996 May;59(5):559–68

Effect of angiotensin–converting enzyme inhibitors on resistance artery structure and endothelium–dependent relaxation in two–kidney, one–clip Goldblatt hypertensive and sham–operated rats. Bennett MA, et al. **Clin Sci (Colch)** 1996 Jan;90(1):21–9

Renal effects of angiotensin I–receptor blockade and angiotensin convertase inhibition in man. Schmitt F, et al. **Clin Sci (Colch)** 1996 Mar;90(3):205–13

Effects of lisinopril and bisoprolol on lipoprotein metabolism in patients with mild–to–moderate essential hypertension. Saku K, et al. **Clin Ther** 1995 Nov–Dec;17(6):1136–46

Effect of cilazapril therapy on glucose and lipid metabolism in patients with hypertension. Shionoiri H, et al. **Clin Ther** 1995 Nov–Dec;17(6):1126–35

Angiotensin–converting–enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Schindler R, et al. **Cytokine** 1995 Aug;7(6):526–33

Glucose transport activity in insulin–resistant rat muscle. Effects of angiotensin–converting enzyme inhibitors and bradykinin antagonism. Henriksen EJ, et al. **Diabetes** 1996 Jan;45 Suppl 1:S125–8

Effects of treatment of spontaneously hypertensive rats with the angiotensin–converting enzyme inhibitor trandolapril and the calcium antagonist verapamil on the sensitivity of glucose metabolism to insulin in rat soleus muscle in vitro. Leighton B, et al. **Diabetes** 1996 Jan;45 Suppl 1:S120–4

Renal enlargement and insulin–like growth factor–1 accumulation in the Wistar rat model of experimental diabetes is not prevented by angiotensin converting enzyme inhibition. New JP, et al. **Diabetologia** 1996 Feb; 39(2):166–71

The ACE–inhibitor captopril improves myocardial perfusion in spontaneously diabetic (BB) rats. Rösen R, et al. **Diabetologia** 1995 May;38(5):509–17

Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Plosker GL, et al. **Drugs Aging** 1995 Sep; 7(3):226–53 (171 ref.)

Carboxypeptidase A hydrolyses benzoylglycyl–histidyl–leucine but not furylacryloyl–phenylalanyl–glycyl–glycine, two usual substrates for angiotensin I–converting enzyme. Baudin B, et al. **Enzyme Protein** 1994–95;48(2):81–9

Endothelium–mediated vasodilation during ACE inhibition. Auch–Schwelk W, et al. **Eur Heart J** 1995 May;16 Suppl C:59–65

Endothelium–modulated proliferation of medial smooth muscle cells: influence of angiotensin II and converting enzyme inhibition. Hahn AW, et al. **Eur Heart J** 1995 May; 16 Suppl C:29–32

Does ACE inhibition limit structural changes in the heart following myocardial infarction? Smits JF, et al. **Eur Heart J** 1995 Dec;16 Suppl N:46–51 (48 ref.)

Effect of inhibitors on the coordination geometries of cadmium at the metal sites in angiotensin–I–converting enzyme. Carvalho E, et al. **Eur J Biochem** 1995 Dec 15; 234(3):780–5

Four week administration of an ACE inhibitor and a cardioselective beta–blocker in healthy volunteers: no influence on insulin sensitivity. Heinemann L, et al. **Eur J Clin Invest** 1995 Aug;25(8):595–600

A comparison of the pharmacokinetics and pharmacodynamics of cilazapril between Chinese and Caucasian healthy, normotensive volunteers. Anderson PJ, et al. **Eur J Clin Pharmacol** 1996;50(1–2):57–62

Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Antila S, et al. **Eur J Clin Pharmacol** 1996;49(6):451–8

Polymorphic inhibition of human angiotensin I–converting enzyme by enalaprilat. Lee EJ. **Eur J Clin Pharmacol** 1995; 49(3):173–5

Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients. Thürig C, et al. **Eur J Clin Pharmacol** 1995;49(1–2):21–6

Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors. Chow L, et al. **Eur J Pharmacol** 1995 Aug 25; 282(1–3):77–86

Effect of propionyl–l–carnitine and enalapril on cardiac function of pressure–overloaded rats during increase in load. Micheletti R, et al. **Eur J Pharmacol** 1995 Nov 14; 286(2):147–54

Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis. Moreno H Jr, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):93–6

Chronic angiotensin–converting enzyme inhibition and endothelial function of rat aorta. Berkenboom G, et al. **Hypertension** 1995 Nov;26(5):738–43

Role of kinins in the renal response to enalaprilat in normotensive and hypertensive rats. Fitzgibbon WR, et al.

Hypertension 1996 Feb;27(2):235–44

Renal circulation and blockade of the renin–angiotensin system. Is angiotensin–converting enzyme inhibition the last word? Hollenberg NK, et al. **Hypertension** 1995 Oct; 26(4):602–9 (108 ref.)

Chronic kinin blockade and effect of ramipril in renal adaptation to sodium restriction. Jover B, et al. **Hypertension** 1996 Jan;27(1):79–84

Comparison of effect of endothelin antagonism and angiotensin–converting enzyme inhibition on blood pressure and vascular structure in spontaneously hypertensive rats treated with N omega–nitro–L–arginine methyl ester. Correlation with topography of vascular endothelin–1 gene expression. Li JS, et al. **Hypertension** 1996 Aug;28(2):188–95

Paracrine systems in the cardioprotective effect of angiotensin–converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Liu YH, et al. **Hypertension** 1996 Jan;27(1):7–13

ACE inhibition prevents and reverses L–NAME–exacerbated nephrosclerosis in spontaneously hypertensive rats. Ono H, et al. **Hypertension** 1996 Feb;27(2):176–83

The effect of enalapril on tyramine induced changes in renal function in man. Rahman AR, et al. **Int J Clin Pharmacol Ther** 1995 Jul;33(7):404–9

Captopril ameliorates the decreased Na+,K(+)–ATPase activity in the retina of streptozotocin–induced diabetic rats. Ottlecz A, et al. **Invest Ophthalmol Vis Sci** 1996 Jul; 37(8):1633–41

Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure. Dibner–Dunlap ME, et al. **J Am Coll Cardiol** 1996 Feb;27(2):358–64

Angiotensin–converting enzyme inhibition limits dysfunction in adjacent noninfarcted regions during left ventricular remodeling. Kramer CM, et al. **J Am Coll Cardiol** 1996 Jan;27(1):211–7

Angiotensin converting enzyme inhibition of the gonadotropin–stimulated rabbit: effect on estradiol production. Morris RS, et al. **J Assist Reprod Genet** 1995 May;12(5):326–9

Effect of a calcium–sensitizing positive inotropic agent MCI–154 and its combined use with enalapril on postischemic contractile dysfunction of dog hearts. Abe Y, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):653–9

Effects of idrapril calcium on tissue angiotensin–converting enzyme in rats. Becagli P, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):27–32

Converting enzyme inhibition and its withdrawal in spontaneously hypertensive rats. Campbell DJ, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):426–36

Acute hemodynamic effects of ciprokiren, a novel renin inhibitor, in sodium–depleted dogs. Clozel JP, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):674–7

Effect of angiotensin–converting enzyme inhibition on intimal thickening in rabbit collared carotid artery. De Meyer GR, et al. **J Cardiovasc Pharmacol** 1995 Oct; 26(4):614–20

Comparison of the angiotensin II antagonist UP269–6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I. Inglesis N, et al. **J Cardiovasc Pharmacol** 1995 Jun; 25(6):986–93

Differential structure–activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin–converting enzyme, neutral endopeptidase, and angiotensin–converting enzyme. Kukkola PJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S65–8

Comparison between chronic converting enzyme inhibition and AT1 blockade in mRen2 transgenic rats. Lantelme P, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):476–81

Comparison of the oral angiotensin II receptor antagonist UP 269–6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt–deplete man. McIntyre M, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):994–1000

Renal responses to angiotensin receptor antagonist and angiotensin–converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. Okada H, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):564–9

Tissue– and subtype–specific modulation of angiotensin II receptors by chronic treatment with cyclosporin A, angiotensin–converting enzyme inhibitors and AT1 antagonists. Regitz–Zagrosek V, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):66–72

Influence of angiotensin–converting enzyme inhibition by fosinopril on myocardial perfusion in streptozotocin–diabetic rats. Rösen P, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):64–70

Effects of angiotensin–converting enzyme inhibition versus beta–adrenergic blockade on aortic stiffness in essential hypertension. Savolainen A, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):99–104

Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. Vaur L, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):127–31

Comparative effects of type 1 angiotensin II–receptor blockade with angiotensin–converting–enzyme inhibitor on left ventricular distensibility and collagen metabolism in spontaneously hypertensive rats. Yonezawa T, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):119–24

Alterations in cortisol metabolism in insulin–dependent diabetes mellitus: relationship with metabolic control and estimated blood volume and effect of angiotensin–converting enzyme inhibition. Dullaart RP, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3002–8

Acute angiotensin–converting enzyme inhibition increases the plasma level of the natural stem cell regulator N–acetyl–seryl–aspartyl–lysyl–proline [see comments] Azizi M, et al. **J Clin Invest** 1996 Feb 1;97(3):839–44. Comment in: J Clin Invest 1996 Feb 1;97(3):588.

Eotaxin: a VIC (very important chemokine) of allergic inflammation? [editorial] Baggiolini M. **J Clin Invest** 1996 Feb 1;97(3):587

Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. Clavell AL, et al. **J Clin Invest** 1996 Mar 1;97(5):1286–92

News about ACE, or, the separate lives of "Siamese twin" domains [editorial; comment] Erdös EG. **J Clin Invest** 1996 Feb 1;97(3):588. Comment on: J Clin Invest 1996 Feb 1;97(3):839–44.

The good side of side effects: captopril blocks vessel and tumor growth [editorial; comment] Kleinman HK, et al. **J Clin Invest** 1996 Aug 1;98(3):599. Comment on: J Clin Invest 1996 Aug 1;98(3):671–9.

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats [see comments] Volpert OV, et al. **J Clin Invest** 1996 Aug 1;98(3):671–9. Comment in: J Clin Invest 1996 Aug 1;98(3):599.

A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril. Breslin E, et al. **J Clin Pharmacol** 1996 May;36(5):414–21

Effect of angiotensin–converting enzyme inhibition on bronchial responsiveness. Dicpinigaitis PV, et al. **J Clin Pharmacol** 1996 Apr;36(4):361–4

Effect of losartan, an angiotensin II receptor antagonist, on response of cortisol and aldosterone to adrenocorticotrophic hormone. Sasaki M, et al. **J Clin Pharmacol** 1995 Aug;35(8):776–9

Long–term effects of antihypertensive treatment and good glycemic control on plasma lipids in diabetic rats. Reddi AS, et al. **J Diabetes Complications** 1995 Jul–Sep;9(3):163–9

Vascular changes in the diabetic kidney: effects of ACE inhibition. Vranes D, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):296–300

In vitro screening of traditional medicines for anti–hypertensive effect based on inhibition of the angiotensin converting enzyme (ACE). Hansen K, et al. **J Ethnopharmacol** 1995 Aug 11;48(1):43–51

Effects of ACE inhibition on the heart. Gavras I, et al. **J Hum Hypertens** 1995 Jun;9(6):455–8 (61 ref.)

Contrasting effects of nifedipine and captopril on natriuresis induced by isotonic saline infusion [letter] Lenz T, et al. **J Hum Hypertens** 1995 Aug;9(8):707

ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group. Ramsay LE, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S51–4

Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes–associated mesenteric vascular hypertrophy in the rat. Rumble JR, et al. **J Hypertens** 1996 May;14(5):601–7

Structural changes and cyclic GMP content of the aorta after calcium antagonism or angiotensin converting enzyme inhibition in renovascular hypertensive rats. Véniant M, et al. **J Hypertens** 1995 Jul;13(7):731–7

Acute administration of metoprolol and enalaprilat reduces insulin–stimulated thermogenesis and skin blood flow. Tuominen JA, et al. **J Intern Med** 1996 May;239(5):399–406

Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin–converting enzyme and neutral endopeptidase. Fink CA, et al. **J Med Chem** 1996 Aug 2;39(16):3158–68

New alpha–thiol dipeptide dual inhibitors of angiotensin–I converting enzyme and neutral endopeptidase EC 3.4.24.11. Fink CA, et al. **J Med Chem** 1995 Dec 22;38(26):5023–30

Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin–converting enzyme/neutral endopeptidase inhibitors. Robl JA, et al. **J Med Chem** 1996 Jan 19;39(2):494–502

Alterations of methionine fluxes and incorporation in intestines of miniature pigs fed a diet high in caseinate are restricted by angiotensin–converting enzyme inhibitor. Jourdheuil–Rahmani D, et al. **J Nutr** 1995 Dec; 125(12):3011–9

Effect of captopril on ocular irritative response to topical neutral formaldehyde and YAG–laser capsulotomy in the rabbit. Krootila K, et al. **J Ocul Pharmacol Ther** 1995 Fall; 11(3):243–52

Angiotensin converting enzyme inhibition prevents polyploidization of cardiomyocytes in spontaneously hypertensive rats with left ventricular hypertrophy. Panizo–Santos A, et al. **J Pathol** 1995 Dec;177(4):431–7

Moexipril, a new angiotensin–converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. Edling O, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):854–63

Inhibition of both angiotensin–converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction. Gonzalez W, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):573–81

Toxicodynamic analysis of cough and inflammatory reactions by angiotensin–converting enzyme inhibitors in guinea pig. Ito K, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):920–5

Angiotensin–converting enzyme inhibition attenuates arterial constrictor responses in experimental hypertension. Kähönen M, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1701–9

Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I–converting enzyme, in conscious rats with myocardial infarction. Marie C, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1324–31

Inhibition of the slow pressor effect of angiotensin II contributes to the antihypertensive effect of angiotensin–converting enzyme inhibitors in renovascular hypertension. Melaragno MG, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):297–303

Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors. Seymour AA, et al. **J Pharmacol Exp Ther** 1996 Feb; 276(2):708–13

Effects of enalapril on the collagen matrix in cardiomyopathic Syrian hamsters (Bio 14.6 and 53.58). Masutomo K, et al. **Jpn Circ J** 1996 Jan;60(1):50–61

Comparable effects of angiotensin II and converting enzyme blockade on hemodynamics and cardiac hypertrophy in spontaneously hypertensive rats. Mori T, et al. **Jpn Circ J** 1995 Sep;59(9):624–30

Angiotensin II type–1 receptor antagonist as well as angiotensin converying enzyme inhibitor attenuates the development of heart failure in aortocaval fistula rats. Nishikimi T, et al. **Jpn Circ J** 1995 Nov;59(11):754–61

Quantitative assessment of daily physical activity levels in patients with chronic heart failure by measuring energy expenditure––effects of converting enzyme inhibitor therapy. Sato H, et al. **Jpn Circ J** 1995 Oct;59(10):647–53

Difference among angiotensin–converting enzyme inhibitors in potentiating effects on bradykinin–induced microvascular leakage in guinea pig airways. Murata T, et al. **Jpn J Pharmacol** 1995 Oct;69(2):111–8

Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Ishidoya S, et al. **Kidney Int** 1996 Apr;49(4):1110–9

Effects of trandolapril and verapamil on glucose transport in insulin–resistant rat skeletal muscle. Jacob S, et al. **Metabolism** 1996 May;45(5):535–41

Effect of antihypertensive treatment with alacepril on insulin resistance in diabetic spontaneously hypertensive rats. Sato T, et al. **Metabolism** 1996 Apr;45(4):457–62

Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Linz W, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):89–97 (73 ref.)

Potentiation by enalaprilat of fenoldopam–evoked natriuresis is due to blockade of intrarenal production of angiotensin–II in rats. Chen C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug; 352(2):194–200

Long– versus short–term effects of two different ACE inhibitors on renal haemodynamics: preliminary results from an ongoing trial. Minetti EE, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:18–21

Effects of ACE inhibitors and calcium channel blockers on insulin sensitivity and other components of the syndrome. Sowers JR. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:52–5 (41 ref.)

Angiotensin–converting enzyme inhibition in experimental in–situ immune complex glomerulonephritis: influence on renal function, proteinuria, and morphology. Thaiss F, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):40–6

Angiotensin–converting enzyme (ACE) polymorphisms, angiotensin II, ACE inhibitors and glomerulosclerosis––a hypothesis [letter] Roy–Chaudhury P, et al. **Nephron** 1995; 71(3):359

Effect of chronic treatment with trandolapril or enalapril on brain ACE activity in spontaneously hypertensive rats. Jouquey S, et al. **Neuropharmacology** 1995 Dec; 34(12):1689–92

Effects of captopril on ischaemia–reperfusion–induced arrhythmias in an in vivo rat model. Olmez E, et al. **Pharmacol Res** 1995 Jul–Aug;32(1–2):37–41

The effect of long–term oral captopril treatment on mesenteric blood flow in spontaneously hypertensive rats. Rozsa Z, et al. **Pharmacol Res** 1995 Jul–Aug;32(1–2):21–5

Left ventricular hypertrophy in spontaneously hypertensive rat: effects of ACE–inhibition on myocardiocyte ultrastructure. Vulpis V, et al. **Pharmacol Res** 1995 Jun; 31(6):375–81

Evaluation of the effect of oral enalapril on neutrophil functions: comparison with the in vitro effect of enalapril and enalaprilat. Wysocki H, et al. **Pol J Pharmacol** 1995 Jan–Feb;47(1):53–8

Inhibitors of angiotensin–converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Reddy MK, et al. **Proc Soc Exp Biol Med** 1995 Dec; 210(3):221–6

Early genes induction in spontaneously hypertensive rats left ventricle with angiotensin–converting enzyme inhibitors but not hydralazine. Susic D, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):266–9

Effects of long–term treatment with angiotensin–converting enzyme inhibitor on angiotensin II and prostacyclin release from mesenteric arteries in spontaneously hypertensive rats. Ito M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov;53(5):359–63

Effect of angiotensin converting enzyme inhibition on airway

conductance during hypocapnic hyperventilation in normal subjects. Jamison JP, et al. **Pulm Pharmacol** 1995 Feb; 8(1):49–51

Equivalent effects of nicardipine and captopril on urinary albumin excretion of type 2, non-insulin-dependent diabetic subjects with mild to moderate hypertension. Bouhanick B. **Therapie** 1996 Jan–Feb;51(1):41–7

Angiotensin converting enzyme inhibitors—do they have an anti-ischemic action? Rutherford JD. **Trans Am Clin Climatol Assoc** 1995;107:57–66; discussion 66–7 (47 ref.)

[Restoration of normal coronary vasomotricity after intravenous infusion of angiotensin converting-enzyme inhibitor (perindoprilat) in hypertensive patients] Antony I, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88(8):1125–8 (Eng. Abstr.) **(Fre)**

[Effects of short-term treatment with trandolapril on vasodilatator responses mediated by receptors or on blood flow in the coronary arteries in SHR] Pourageaud F, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88(8):1089–93 (Eng. Abstr.) **(Fre)**

[Significance of therapy timing for the effects of systemic and local therapy with the ACE inhibitor captopril on intestinal microcirculation in manifest mesenteric ischemia. An animal experiment study in the swine] Jakschik J, et al. **Langenbecks Arch Chir** 1995;380(5):273–80 (Eng. Abstr.) **(Ger)**

[Anti-atherosclerotic action of ACE inhibitors. I. Inactivation of the renin-angiotensin system] Stajszczyk M, et al. **Postępy Hig Med Dosw** 1996;50(2):157–71 (80 ref.) (Eng. Abstr.) **(Pol)**

[Alternative pathways of angiotensin I. The glimpse of new possibilities in the treatment of hypertension and heart failure (editorial)] Francischetti EA. **Arq Bras Cardiol** 1995 Mar;64(3):191–4 (49 ref.) **(Por)**

[The ocular hypotonic effect induced by an angiotensin-converting enzyme inhibitor (captopril)] Chiseliță D, et al. **Oftalmologia** 1996 Jan–Mar;40(1):18–25 (Eng. Abstr.) **(Rum)**

[Effect of captopril and reserpine on the activity of certain neuropeptide metabolism enzymes] Gengin MT, et al. **Vopr Med Khim** 1995 Sep–Oct;41(5):37–9 (Eng. Abstr.) **(Rus)**

[Pharmacodynamics of angiotensin-converting enzyme inhibitors] Dzúrik R, et al. **Vnitr Lek** 1996 Feb;42(2):93–7 (Eng. Abstr.) **(Slo)**

POISONING

Poisoning with anti-hypertensive drugs: angiotensin converting enzyme inhibitors. Lip GY, et al. **J Hum Hypertens** 1995 Sep;9(9):711–5 (27 ref.)

THERAPEUTIC USE

Captopril in acute pulmonary edema: measuring the benefit [editorial; comment] Christenson JM. **Acad Emerg Med** 1996 Mar;3(3):192–3. Comment on: Acad Emerg Med 1996 Mar;3(3):205–12.

Rapid improvement of acute pulmonary edema with sublingual captopril [see comments] Hamilton RJ, et al. **Acad Emerg Med** 1996 Mar;3(3):205–12. Comment in: Acad Emerg Med 1996 Mar;3(3):192–3.

Diuretic effect of cilazapril and dopamine system in the spontaneously hypertensive rat. Watanabe H, et al. **Acta Med Okayama** 1995 Oct;49(5):247–52

Effect of angiotensin converting enzyme inhibitor on chronic ischemic patients. Kawakami N, et al. **Acta Neurol Scand Suppl** 1996;166:93–5

ACE inhibitors: myocardial infarction and congestive heart failure. Cody RJ. **Am Fam Physician** 1995 Nov 1; 52(6):1801–6 (18 ref.)

Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Awan NA, et al. **Am Heart J** 1996 Jan; 131(1):177–85 (81 ref.)

Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction? Ball SG, et al. **Am Heart J** 1996 Jul;132(1 Pt 2 Su):244–50 (22 ref.)

Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction. CONSENSUS II multiecho study group. Bonarjee VV, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):71–7

Assessment of hemodynamic effects of angiotensin-converting enzyme inhibitor therapy in chronic aortic regurgitation by using velocity-encoded cine magnetic resonance imaging. Globits S, et al. **Am Heart J** 1996 Feb;131(2):289–93

Successful heart failure therapy is effective antiarrhythmia therapy [editorial] Khosla S, et al. **Am Heart J** 1996 May; 131(5):1048–50 (23 ref.)

Angio-converting enzyme inhibition after myocardial infarction: the the Trandolapril Cardiac Evaluation Study. Torp-Pedersen C, et al. **Am Heart J** 1996 Jul;132(1 Pt 2 Su):235–43

Angiotensin-converting enzyme inhibition, autonomic activity, and hemodynamics in patients with heart failure who perform isometric exercise. Willenbrock R, et al. **Am Heart J** 1996 May;131(5):999–1006

The renin-angiotensin system in left ventricular remodeling. Blaufarb IS, et al. **Am J Cardiol** 1996 May 30; 77(13):8C–16C (121 ref.)

Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators. Boden WE, et al. **Am J Cardiol** 1996 May 15;77(12):1078–82

Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. The SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Borghi C, et al. **Am J Cardiol** 1996 Aug 1;78(3):317–22

Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure. de Vries RJ, et al. **Am J Cardiol** 1995 Dec 15;76(17):1253–8

Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Drexler H, et al. **Am J Cardiol** 1995 Nov 24; 76(15):13E–18E (35 ref.)

Chronic low-dose treatment with perindopril improves cardiac function in stroke-prone spontaneously hypertensive rats by potentiation of endogenous bradykinin. Gohlke P, et al. **Am J Cardiol** 1995 Nov 24; 76(15):41E–45E

Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction. Hansen JF, et al. **Am J Cardiol** 1996 Jun 20;77(16):16D–21D

Physical working capacity after acute myocardial infarction in patients with low ejection fraction and effect of captopril. Hartley LH, et al. **Am J Cardiol** 1995 Nov 1; 76(12):857–60

Angiotensin-converting enzyme inhibitors in adults with cyanotic congenital heart disease. Hopkins WE, et al. **Am J Cardiol** 1996 Feb 15;77(5):439–40

Microvascular angina in systemic hypertension: diagnosis and treatment with enalapril. Iriarte MM, et al. **Am J Cardiol** 1995 Nov 2;76(13):31D–34D (18 ref.)

Effect of long-term angiotensin-converting enzyme inhibition on vascular function in patients with chronic congestive heart failure. Jeserich M, et al. **Am J Cardiol** 1995 Nov 15;76(14):1079–82

Ventricular late potentials and left ventricular function after early enalapril treatment in acute myocardial infarction. Junker A, et al. **Am J Cardiol** 1995 Dec 15;76(17):1300–2

Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. Kontopoulos AG, et al. **Am J Cardiol** 1996 Feb 1;77(4):242–6

Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure. Lubsen J, et al. **Am J Cardiol** 1996 Jun 1;77(14):1191–6

Influence of digitalis on left ventricular functional response to exercise in congestive heart failure. Morisco C, et al. **Am J Cardiol** 1996 Mar 1;77(7):480–5

Effects of angiotensin-converting enzyme inhibitor alacepril in patients with stable effort angina during chronic isosorbide dinitrate treatment. Murohara T, et al. **Am J Cardiol** 1996 Jun 1;77(14):1159–63

Reduction in left ventricular mass in patients with systemic hypertension treated with enalapril, lisinopril, or fosenopril. Oren S, et al. **Am J Cardiol** 1996 Jan 1;77(1):93–6

Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Philbin EF, et al. **Am J Cardiol** 1996 Apr 15;77(10):832–8

Treatment of viral myocarditis with focus on captopril [editorial] Rezkalla SH, et al. **Am J Cardiol** 1996 Mar 15; 77(8):634–7 (41 ref.)

Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarction. Schulman SP, et al. **Am J Cardiol** 1995 Oct 15;76(11):764–70

Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor-based regimen in hypertensive patients. Sihm I, et al. **Am J Cardiol** 1995 Nov 24;76(15):38E–40E

Vascular wall thickness in hypertension: the Perindopril Regression of Vascular Thickening European Community Trial: PROTECT. Stumpe KO, et al. **Am J Cardiol** 1995 Nov 24;76(15):50E–54E

Effects of enalapril on heart rate variability in patients with congestive heart failure. Zhang YH, et al. **Am J Cardiol** 1995 Nov 15;76(14):1045–8

Appropriateness of therapy with angiotensin-converting-enzyme inhibitors in elderly outpatients. Scott MA, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):410–3

Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. Dominguez LJ, et al. **Am J Hypertens** 1995 Aug;8(8):808–14

The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Kostis JB. **Am J Hypertens** 1995 Sep;8(9):909–14

Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats. Panizo A, et al. **Am J Hypertens** 1995 Aug;8(8):815–22

Presence of cardiovascular structural changes in essential hypertensive patients with coronary microvascular disease and effects of long-term treatment [see comments] Virdis A, et al. **Am J Hypertens** 1996 Apr;9(4 Pt 1):361–9. Comment in: Am J Hypertens 1996 Apr;9(4 Pt 1):406–8.

Duration of action of angiotensin converting enzyme inhibitors. Zannad F. **Am J Hypertens** 1995 Oct;8(10 Pt 2):75S–81S (43 ref.)

In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progression. Cohen EP, et al. **Am J Kidney Dis** 1996 Feb; 27(2):199–203

Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Ihle BU, et al. **Am J Kidney Dis** 1996 Apr;27(4):489–95

Decrease of exercise-induced microalbuminuria in patients with type I diabetes by means of an angiotensin-converting enzyme inhibitor. Inserra F, et al. **Am J Kidney Dis** 1996 Jan;27(1):26–33

Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Kimmel PL, et al. **Am J Kidney Dis** 1996 Aug;28(2):202–8

Cilazapril delays progression of hypertension and uremia in rat polycystic kidney disease. Ogborn MR, et al. **Am J Kidney Dis** 1995 Dec;26(6):942–6

Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients. Sennesael JJ, et al. **Am J Kidney Dis** 1996 May;27(5):701–8

The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Laffel LM, et al. **Am J Med** 1995 Nov;99(5):497–504

Association of post-renal transplant erythrocytosis and microalbuminuria: response to angiotensin-converting enzyme inhibition. Mulhern JG, et al. **Am J Nephrol** 1995; 15(4):318–22

A management trial for Duchenne cardiomyopathy. Ishikawa Y, et al. **Am J Phys Med Rehabil** 1995 Sep-Oct; 74(5):345–50

Synergistic inhibitory effect of angiotensin-converting enzyme inhibitor and heparin on intimal hyperplasia after rat aorta injury. Park JS, et al. **Angiology** 1996 Jan; 47(1):9–14

ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapril in mild to moderate hypertension. Petersen JR, et al. **Angiology** 1996 Mar;47(3):233–40

Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Chrysant SG, et al. **Arch Fam Med** 1996 Jan;5(1):17–24; discussion 25

ACE inhibitors as a shield against diabetic nephropathy [editorial; comment] Materson BJ. **Arch Intern Med** 1996 Feb 12;156(3):239–40. Comment on: Arch Intern Med 1996 Feb 12;156(3):286–9.

Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study [see comments] Ravid M, et al. **Arch Intern Med** 1996 Feb 12;156(3):286–9. Comment in: Arch Intern Med 1996 Feb 12;156(3):239–40.

ACE inhibitors in cardiovascular disease. Which patient? Which drug? Which dose? Pellizzer AM, et al. **Aust Fam Physician** 1996 Jul;25(7):1067–9, 1072–3, 1076–7

Effects of cilazapril on renal haemodynamics and function in hypertensive patients: a randomised controlled study versus hydrochlorothiazide. Scaglione R, et al. **Blood Press** 1995 Nov;4(6):363–8

Effect of enalapril on erythrocytosis in hypertensive patients with renal disease. Shand BI, et al. **Blood Press** 1995 Jul; 4(4):238–40

Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. Sihm I, et al. **Blood Press** 1995 Jul;4(4):241–8

Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease. Epstein M. **Blood Press Suppl** 1995;2:108–12 (41 ref.)

Effect of cilazapril on hyperdipsia in hemodialyzed patients. Kuriyama S, et al. **Blood Purif** 1996;14(1):35–41

Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. Parving HH, et al. **BMJ** 1996 Sep 7;313(7057):591–4

Increasing prescription of drugs for secondary prevention of myocardial infarction. Authors' recommendations are too restrictive [letter; comment] Sapsford RJ, et al. **BMJ** 1996 Jan 27;312(7025):252. Comment on: BMJ 1995 Oct 7;311(7010):917–8.

Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function. Kakavas PW, et al. **Bone Marrow Transplant** 1995 Jun;15(6):859–61

Is aspirin safe for patients with heart failure? Cleland JG, et al. **Br Heart J** 1995 Sep;74(3):215–9 (53 ref.)

ACE inhibitors after myocardial infarction: patient selection or treatment for all? [letter; comment] Jolobe OM. **Br Heart J** 1995 Nov;74(5):573. Comment on: Br Heart J 1995 May;73(5):397–400.

Preoperative inhibition of angiotensin-converting enzyme improves systemic and renal haemodynamic changes during aortic abdominal surgery. Licker M, et al. **Br J Anaesth** 1996 May;76(5):632–9

The effect of tenidap on the anti-hypertensive efficacy of ACE inhibitors in patients treated for mild to moderate hypertension. Rapeport WG, et al. **Br J Clin Pharmacol**

1995;39 Suppl 1:57S–61S

ACE inhibitors after myocardial infarction [editorial; comment] Jackson G. **Br J Clin Pract** 1995 Jul–Aug; 49(4):171. Comment on: Br J Clin Pract 1995 Jul–Aug;49(4):173–6. Comment on: Br J Clin Pract 1995 Jul–Aug;49(4):195–9. Comment on: Br J Clin Pract 1995 Jul–Aug;49(4):200–4.

Improving outcome after acute myocardial infarction: what is the role of ACE inhibitors? [see comments] Purcell H, et al. **Br J Clin Pract** 1995 Jul–Aug;49(4):195–9 (59 ref.) . Comment in: Br J Clin Pract 1995 Jul–Aug;49(4):171.

Angiotensin-converting enzyme inhibitors [letter] Jolobe OM. **Br J Hosp Med** 1995 Jul 12–Aug 15;54(2–3):115

The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. **Can J Cardiol** 1996 Feb; 12(2):127–37

Angiotensin-converting enzyme inhibitors post-myocardial infarction. Young JB. **Cardiol Clin** 1995 Aug;13(3):379–90 (56 ref.)

Anti-ischemic properties of ACE-inhibitors. Deedwania PC. **Cardiologia** 1996 Mar;41(3):209–15 (30 ref.)

ACE Inhibitors in Heart Failure: Advancing Clinical Practice. Proceedings of a symposium. Geneva, Switzerland, May 21–25, 1995. **Cardiology** 1996;87 Suppl 1:1–44

Acute filling pattern changes of the failing left ventricle after captopril as related to ventricular structure. Barbier P, et al. **Cardiology** 1996 Mar–Apr;87(2):153–60

Interruption of the progression of heart failure: are ACE inhibitors the solution? Coats A. **Cardiology** 1996;87 Suppl 1:11–5 (7 ref.)

Successful treatment of hyponatremia with angiotensin-converting enzyme inhibitors in patients with congestive heart failure. Elisaf M, et al. **Cardiology** 1995; 86(6):477–80

The cost-effective way forward for the management of the patient with heart failure. Giles T. **Cardiology** 1996;87 Suppl 1:33–9 (15 ref.)

Myocardial infarction: when and how should we initiate treatment with ACE inhibitors? GISSI-3 Investigators. Latini R, et al. **Cardiology** 1996;87 Suppl 1:16–22 (22 ref.)

Tolerability and efficacy of antihypertensive treatment with cilazapril in general practice. Rosenthal JR, et al. **Cardiology** 1996 Jan–Feb;87(1):54–9

Lipoprotein(a) and oxygen free radicals in survivors of acute myocardial infarction: effects of captopril. Søgaard P, et al. **Cardiology** 1996 Jan–Feb;87(1):18–22

Identification, diagnosis and treatment of heart failure: could we do better? Struthers AD. **Cardiology** 1996;87 Suppl 1:29–32 (11 ref.)

Current controversies with ACE inhibitor treatment in heart failure. Visser FC, et al. **Cardiology** 1996;87 Suppl 1:23–8 (21 ref.)

Effects of an early treatment with lisinopril and isosorbide-5-mononitrate on hemodynamics and late ventricular remodelling in rats with 9-week myocardial infarction. Riva E, et al. **Cardioscience** 1995 Jun;6(2):139–46

Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril. Alcocer L, et al. **Cardiovasc Drugs Ther** 1995 Jun;9(3):431–6

Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. Breithaupt-Grögler K, et al. **Cardiovasc Drugs Ther** 1996 Mar;10(1):49–57

Coadministration of calcium antagonists and ACE inhibitors—is a skeptic convinced?: a personal view. Campbell RW. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:525–8 (33 ref.)

Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Ramipril Study Group. Gundersen T, et al. **Cardiovasc Drugs Ther** 1995 Aug; 9(4):589–94

ACE inhibitors and calcium antagonists in the treatment of congestive heart failure. Hansen JF. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:503–7 (30 ref.)

Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Lüscher TF, et al. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:509–23 (89 ref.)

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Pitt B, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):693–700 (80 ref.)

Functional activity and expression of the myocardial postreceptor adenylyl cyclase system in pressure overload hypertrophy in rat. Holmer SR, et al. **Cardiovasc Res** 1996 May;31(5):719–28

Left ventricular wall stress and sarcoplasmic reticulum Ca(2+)-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and AT1-receptor blockade. Zierhut W, et al. **Cardiovasc Res** 1996 May;31(5):758–68

Short-term and long-term effects of benazepril in mild to moderate hypertensives. Chen CH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Jul;56(1):12–22

Comparisons of long-term effects of lisinopril vs nifedipine vs conventional therapy in the treatment of mild-to-moderate hypertension in patients with chronic obstructive pulmonary disease. Lin M, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jun; 57(6):392–400

Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Benedict CR, et al. **Circulation** 1996 Aug 15;94(4):690–7

The 1995 European Society of Cardiology [news] Ferguson JJ 3rd. **Circulation** 1995 Nov 1;92(9):2359–63

Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Furukawa Y, et al. **Circulation** 1996 Jan 15;93(2):333–9

ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Latini R, et al. **Circulation** 1995 Nov 15;92(10):3132–7 (35 ref.)

Radionuclide monitoring of cardiac adaptations to volume loading in patients with dilated cardiomyopathy and mild heart failure. Effects of angiotensin-converting enzyme inhibition. Volpe M, et al. **Circulation** 1995 Nov 1; 92(9):2511–8

Captopril in acute myocardial infarction: beneficial effects on infarct size and arrhythmias. Bussmann WD, et al. **Clin Cardiol** 1995 Aug;18(8):465–70

Changes in red blood cell glutathione and glutathione-dependent enzymes on long-term treatment with captopril and enalapril. Golik A, et al. **Clin Chim Acta** 1995 Aug 31;240(1):89–94

Effect of angiotensin-converting enzyme inhibitors on fructose induced hypertension and hyperinsulinaemia in rats. Erlich Y, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22 Suppl 1:S347–9

Do kinins mediate cardioprotective and renoprotective effects of cilazapril in spontaneously hypertensive rats with renal ablation? Kohzuki M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S357–9

Long-term effects of treatment with enalapril on the structure of mesenteric resistance arteries in New Zealand genetically hypertensive rats. Ledingham JM, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S350–2

Long-term therapeutic effects of ACE inhibitor and calcium antagonists on hypertensive vascular lesions in M-SHRSP. Ohta Y, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S321–2

Enalapril improves glucose tolerance in two rat models: a new hypertensive diabetic strain and a fructose-induced hyperinsulinaemic rat. Rosenthal T, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S353–4

Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation. Grekas D, et al. **Clin Nephrol** 1995 Nov; 44(5):299–302

Angiotensin converting enzyme inhibitors and the otolaryngologist [editorial] Cruickshank HE. **Clin Otolaryngol** 1995 Jun;20(3):189–91

Ineffectiveness of angiotensin converting enzyme inhibition (enalapril) on overt and silent myocardial ischemia in vasospastic angina and comparison with verapamil. Guazzi M, et al. **Clin Pharmacol Ther** 1996 Apr;59(4):476–81

Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure. Mitrovic V, et al. **Clin Pharmacol Ther** 1996 Jun;59(6):686–98

Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Wapstra FH, et al. **Clin Sci (Colch)** 1996 May;90(5):393–401

Isradipine versus captopril in patients with essential hypertension. Manolis AJ, et al. **Clin Ther** 1995 Jul–Aug; 17(4):648–55

Effects of long-term cilazapril treatment on glucose and lipid metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus. Uchida K, et al. **Clin Ther** 1995 Jul–Aug;17(4):729–34

The use of angiotensin converting enzyme inhibitors in asymptomatic patients with left ventricular dysfunction after myocardial infarction. Bazunga M. **Conn Med** 1995 Nov;59(11):663–6 (39 ref.)

Angiotensin-converting enzyme inhibition in type I diabetic nephropathy. Lewis EJ. **Contrib Nephrol** 1996;118:206–13 (4 ref.)

Are angiotensin-converting enzyme inhibitors the renal protective antihypertensive drugs of choice? [editorial] Bauer JH. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):427–31 (23 ref.)

The management of hypertension in diabetes: with special reference to diabetic kidney disease. Leese GP, et al. **Diabet Med** 1996 May;13(5):401–10 (145 ref.)

Circulating catecholamines and metabolic effects of captopril in NIDDM patients. De Mattia G, et al. **Diabetes Care** 1996 Mar;19(3):226–30

Effect of ramipril on insulin sensitivity in obese patients. Time-course study of glucose infusion rate during euglycaemic hyperinsulinaemic clamp. Valensi P, et al. **Diabetes Metab** 1996 Jun;22(3):197–200

Renoprotective effect of enalapril in uninephrectomized spontaneously hypertensive rats with neonatal streptozotocin-induced diabetes. Sato Y, et al. **Diabetes Res Clin Pract** 1995 Sep;29(3):153–61

Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. **Diabetologia** 1996 May;39(5):587–93

Who needs nine ACE inhibitors? **Drug Ther Bull** 1995 Jan 19;33(1):1–3 (26 ref.)

Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life. Cooper ME, et al. **Drugs Aging** 1996 Jan;8(1):38–46 (90 ref.)

Quality of life in older patients with congestive heart failure. Effects of ACE inhibitors. Fergus I, et al. **Drugs Aging** 1996 Jan;8(1):23–8 (45 ref.)

ACE inhibitors. Differential use in elderly patients with hypertension. Israili ZH, et al. **Drugs Aging** 1995 Nov; 7(5):355–71 (225 ref.)

Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Plosker GL, et al. **Drugs Aging** 1995 Sep; 7(3):226–53 (171 ref.)

ACE inhibitors in elderly patients with hypertension. Special considerations. Ravid M, et al. **Drugs Aging** 1996 Jan; 8(1):29–37 (89 ref.)

Effects of delapril on stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Inada Y, et al. **Drugs Exp Clin Res** 1995;21(2):41–9

Heart Failure '95. Neurohormonal modulation of heart failure: ACE inhibition and beyond. Amsterdam, The Netherlands, 1–4 April 1995. Proceedings and abstracts. **Eur Heart J** 1995 Dec;16 Suppl N:1–130

ACE inhibitors in non-ischaemic heart failure: results from the MEGA trials. Cohn JN. **Eur Heart J** 1995 Dec;16 Suppl O:133–6 (31 ref.)

Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Erhardt L, et al. **Eur Heart J** 1995 Dec;16(12):1892–9

Converting enzyme inhibition and left ventricular hypertrophy [editorial; comment] Fagard R. **Eur Heart J** 1995 Dec;16(12):1748–9. Comment on: Eur Heart J 1995 Dec;16(12):1981–7.

Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. Fogari R, et al. **Eur Heart J** 1995 Aug;16(8):1120–5

Neurohormonal changes after acute myocardial infarction. Relationships with haemodynamic indices and effects of ACE inhibition. Foy SG, et al. **Eur Heart J** 1995 Jun; 16(6):770–8

Should ACE inhibitors be administered to all patients after acute myocardial infarction? A (cautious) negative response. Julian DG. **Eur Heart J** 1995 Jul;16 Suppl E:44–5 (7 ref.)

What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Narang R, et al. **Eur Heart J** 1996 Jan;17(1):120–34 (45 ref.)

Should ACE inhibitors be administered to all patients with acute myocardial infarction? Prashad R, et al. **Eur Heart J** 1995 Jul;16 Suppl E:41–3 (26 ref.)

Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects. Regitz-Zagrosek V, et al. **Eur Heart J** 1995 Dec;16 Suppl N:86–91 (19 ref.)

Neurohormonal modulation in heart failure: ACE inhibition and beyond. Remme WJ. **Eur Heart J** 1995 Dec;16 Suppl N:73–8 (36 ref.)

Anti-ischaemic effects of converting enzyme inhibitors: underlying mechanisms and future prospects. Remme WJ, et al. **Eur Heart J** 1995 Aug;16 Suppl I:87–95 (51 ref.)

Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use. Sigurdsson A, et al. **Eur Heart J** 1995 Dec;16 Suppl N:65–72 (53 ref.)

Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Struthers AD. **Eur Heart J** 1995 Dec;16 Suppl N:103–6 (26 ref.)

Platelet and leukocyte activation after myocardial infarction. Influence of enalapril. Sylvén C, et al. **Eur Heart J** 1995 Dec;16(12):1800–6

Effects of lisinopril on congestive heart failure in normotensive patients with diastolic dysfunction but intact systolic function. Lang CC, et al. **Eur J Clin Pharmacol** 1995;49(1–2):15–9

A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure. McElnay JC, et al. **Eur J Clin Pharmacol** 1996;49(6):471–6

Chronopharmacology of enalapril in hypertensive patients. Sunaga K, et al. **Eur J Clin Pharmacol** 1995;48(6):441–5

Humoral and haemodynamic effects of idrapril calcium, the prototype of a new class of ACE-inhibitors, in essential hypertensive patients. Taddei S, et al. **Eur J Clin Pharmacol** 1995;48(5):339–43

Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. Widimský J, et al. **Eur J Clin Pharmacol** 1995; 49(1–2):95–102

Polycythaemia vera: response to treatment with angiotensin-converting enzyme inhibitor [letter] Nomura S, et al. **Eur J Haematol** 1996 Jul;57(1):117–9

Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Remuzzi A, et al. **Exp Nephrol** 1996

Jan-Feb;4(1):19-25

ACE inhibitors for prophylaxis of migraine headaches. Bender WI. **Headache** 1995 Sep;35(8):470-1

Is aspirin safe in heart failure? more data [letter] Cleland JG, et al. **Heart** 1996 Apr;75(4):426

Investigation in general practice of patients with suspected heart failure [letter; comment] Signy M. **Heart** 1996 Jun; 75(6):642; discussion 643. Comment on: Br Heart J 1995 Oct;74(4):335-6.

Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Morris RS, et al. **Hum Reprod** 1995 Jun;10(6):1355-8

A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension--The GLANT Study. Study Group on Long-term Antihypertensive Therapy. **Hypertens Res** 1995 Sep; 18(3):235-44

Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Brilla CG, et al. **Hypertension** 1996 Aug;28(2):269-75

Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism. Burrell LM, et al. **Hypertension** 1995 Nov;26(5):828-34

Improvement of coronary flow reserve after long-term therapy with enalapril. Motz W, et al. **Hypertension** 1996 May;27(5):1031-8

Antihypertensive treatment efficacy in type II diabetes mellitus. Dissociation between casual and 24-hour ambulatory blood pressure. Spanish Multicenter Study Group. Puig JG, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1093-9

The trough-to-peak ratio as an instrument to evaluate antihypertensive drugs. The APTH Investigators. Ambulatory Blood Pressure and Treatment of Hypertension Trial. Staessen JA, et al. **Hypertension** 1995 Dec;26(6 Pt 1):942-9

Effects of the angiotensin converting enzyme inhibitor captopril on experimental autoimmune encephalomyelitis. Constantinescu CS, et al. **Immunopharmacol Immunotoxicol** 1995 Aug;17(3):471-91

Should angiotensin converting enzyme inhibitors be routinely used in patients with acute myocardial infarction? Chatterjee K. **Indian Heart J** 1995 May-Jun;47(3):275-8 (17 ref.)

Effect of angiotensin converting enzyme inhibitor (captopril) on gastric ulcer production in pylorus ligated rats. Rao SP, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):296-8

Is Ace inhibitor treatment a possible cause of better cardiovascular remodelling in well functioning kidney transplant? La Manna G, et al. **Int J Artif Organs** 1995 Jul;18(7):362-4

Left ventricular volume in thrombolysed patients with acute anterior myocardial infarction: the effect of captopril and xamoterol. Darasz KH, et al. **Int J Cardiol** 1995 Sep; 51(2):137-42

Captopril does not affect plasma endothelin-1 during thrombolysis and reperfusion. Di Pasquale P, et al. **Int J Cardiol** 1995 Sep;51(2):131-5

Enalaprilat controls postoperative hypertension while maintaining cardiac function and systemic oxygenation after neurosurgery. Tohmo H, et al. **Intensive Care Med** 1995 Aug;21(8):651-6

Evaluation of angiotensin-converting enzyme inhibitor in congestive heart failure. Matsuo H. **Intern Med** 1996 Jan; 35(1):65-7

Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. **J Am Coll Cardiol** 1996 Feb;27(2):337-44

Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). Berger PB, et al. **J Am Coll Cardiol** 1996 Jan;27(1):1-7

Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trail. Brozena SC, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1707-12

Long-term captopril treatment improves diastolic filling more than systolic performance in rats with large myocardial infarction. Litwin SE, et al. **J Am Coll Cardiol** 1996 Sep;28(3):773-81

Survival after myocardial infarction in rats: captopril versus losartan. Milavetz JJ, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):714-9

Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. Pepine CJ. **J Am Coll Cardiol** 1996 Apr;27(5):1048-52 (14 ref.)

Cost-effectiveness analysis and clinical practice [editorial; comment] Rector TS, et al. **J Am Coll Cardiol** 1995 Oct; 26(4):920-1. Comment on: J Am Coll Cardiol 1995 Oct;26(4):914-9.

Cost-effectiveness of captopril therapy after myocardial infarction [see comments] Tsevat J, et al. **J Am Coll Cardiol** 1995 Oct;26(4):914-9. Comment in: J Am Coll Cardiol 1995 Oct;26(4):920-1.

Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS). van Gilst WH, et al. **J Am Coll Cardiol** 1996 Jul;28(1):114-21

Long-term survival and use of antihypertensive medications in older persons [see comments] Pahor M, et al. **J Am Geriatr Soc** 1995 Nov;43(11):1191-7. Comment in: J Am Geriatr Soc 1995 Nov;43(11):1309-10. Comment in: J Am Geriatr Soc 1996 Jul;44(7):881-2.

Tolerability of enalapril in mild to moderate hypertension. Sharma S, et al. **J Assoc Physicians India** 1995 Jul; 43(7):475-6

Impact of advances in therapy for heart failure on secular trends in mortality [editorial] Rector TS. **J Card Fail** 1996 Mar;2(1):31-2 (7 ref.)

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. Struthers AD. **J Card Fail** 1996 Mar;2(1):47-54 (56 ref.)

New directions in the treatment of heart failure: some paradoxical observations. Merin RG. **J Card Surg** 1995 Jul; 10(4 Suppl):509-13

Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus. Araki M, et al. **J Cardiovasc Pharmacol** 1995 Jul; 26(1):61-5

Quality of life with ACE inhibitors in chronic heart failure. Bulpitt CJ. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S31-5 (35 ref.)

Chronic ACE-inhibitor treatment and adrenergic mechanisms in spontaneously hypertensive rats. Castellano M, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):381-7

Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. French JF, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):107-13

Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine. Grandi AM, et al. **J Cardiovasc Pharmacol** 1995 Nov;26(5):737-41

Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. Jin H, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):420-5

Clinical benefit of angiotensin-converting enzyme inhibitors in chronic heart failure. Kiowski W, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S19-24

Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. Morel Y, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):306-11

Improvement of vagal tone by ACE inhibition: a mechanism of cardioprotection in patients with mild-to-moderate heart failure. Osterziel KJ, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S25-30

Antihypertensive effects of moexipril, a new ACE inhibitor, as add-on therapy to nifedipine in patients with essential hypertension. Persson B, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):73-8

Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. Romero R, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):114-8

Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril. Scemama M, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 2:S34-9

Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I-converting enzyme inhibitor. Schiffrin EL. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S13-8

Comparative effects of diltiazem and lisinopril on left ventricular structure and filling in mild-to-moderate hypertension. van Leeuwen JT, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):983-9

Cardiovascular hypertrophy: role of angiotensin II and bradykinin. Waeber B, et al. **J Cardiovasc Pharmacol** 1996; 27 Suppl 2:S36-40 (37 ref.)

Pathophysiological aspects of the renin-angiotensin-aldosterone system in acute myocardial infarction. Dargie HJ, et al. **J Cardiovasc Risk** 1995 Oct; 2(5):389-95 (48 ref.)

Prevention of congestive heart failure by ACE inhibition in patients with acute myocardial infarction. Sigurdsson A, et al. **J Cardiovasc Risk** 1995 Oct;2(5):406-12 (44 ref.)

Practical issues for the use of ACE inhibitors in acute myocardial infarction. Testa M, et al. **J Cardiovasc Risk** 1995 Oct;2(5):429-33 (27 ref.)

Drug differences between ACE inhibitors in experimental settings and clinical practice. Voors AA, et al. **J Cardiovasc Risk** 1995 Oct;2(5):413-22 (105 ref.)

Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained-release verapamil. Abernethy DR, et al. **J Clin Pharmacol** 1995 Aug; 35(8):794-9

Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. Frishman WH, et al. **J Clin Pharmacol** 1995 Nov;35(11):1060-6

Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition. Allen TJ, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):318-22

Possible effect of angiotensin-converting enzyme inhibition on glomerular charge selectivity. Hansen PM, et al. **J Diabetes Complications** 1995 Jul-Sep;9(3):158-62

Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group. Jerums G, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):308-14 (47 ref.)

Longitudinal evaluation of renal function in non-insulin-dependent diabetic patients with early nephropathy: effects of angiotensin-converting enzyme inhibition. Vora JP, et al. **J Diabetes Complications** 1996 Mar-Apr;10(2):88-93

ACE inhibitors and renoprotection. Peterson K. **J Fam Pract** 1996 May;42(5):453

Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: from bench to bedside. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S246-9 (16 ref.)

Medical treatment of chronic valvular regurgitation. Schön HR. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S170-4 (26 ref.)

ACE inhibitors for the prevention and treatment of heart failure: why are they under-used? Cleland JG. **J Hum Hypertens** 1995 Jun;9(6):435-42 (47 ref.)

Comparison of amlodipine and quinapril on ambulatory blood pressure and platelet function in hypertension. Ding YA, et al. **J Hum Hypertens** 1995 Aug;9(8):637-41

Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension. White WB, et al. **J Hum Hypertens** 1995 Nov;9(11):879-84

Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. Favrat B, et al. **J Hypertens** 1995 Jul;13(7):797-804

Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. Ruff D, et al. **J Hypertens** 1996 Feb;14(2):263-70

A comparison of the effect of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism on the structural changes associated with hypertension in rat small arteries. Shaw LM, et al. **J Hypertens** 1995 Oct; 13(10):1135-43

Angiotensin converting enzyme inhibitors in hypertension: potential problems. Antonios TF, et al. **J Hypertens Suppl** 1995 Sep;13 Suppl 3:S11-6 (87 ref.)

Update on the use of angiotensin converting enzyme inhibitors and calcium antagonists in postinfarction patients. Persson S. **J Hypertens Suppl** 1995 Aug;13(2):S57-63 (33 ref.)

Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy. Ruilope LM. **J Hypertens Suppl** 1995 Aug;13(2):S91-3 (26 ref.)

Imidapril hydrochloride in essential hypertension: a double-blind comparative study using enalapril maleate as a control. Saruta T, et al. **J Hypertens Suppl** 1995 Sep;13 Suppl 3:523-30

Heart failure evaluation and treatment in Mississippi: results from a survey of the Mississippi Foundation for Medical Care. Heart Failure Study Group. O'Connell JB, et al. **J Miss State Med Assoc** 1996 Jul;37(7):648-52

Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. Sanbe A, et al. **J Mol Cell Cardiol** 1995 Oct; 27(10):2209-22

Plasma digoxin immunoreactivity and arterial potassium relaxation after quinapril therapy in hypertensive rats. Kähönen M, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):832-7

Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. Trippodo NC, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):745-52

Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. The IMPROVE Study Group. **J Vet Intern Med** 1995 Jul-Aug;9(4):234-42

Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. The COVE Study Group. **J Vet Intern Med** 1995 Jul-Aug;9(4):243-52

ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Ruiz-Ortega M, et al. **Kidney Int** 1995 Dec;48(6):1778-91

Criticism of Servier re perindopril [letter] Alliot LS. **Lancet** 1996 Mar 23;347(9004):832

Angiotensin-converting enzyme inhibitor for epirubicin-induced dilated cardiomyopathy [letter; comment] Hatake K, et al. **Lancet** 1996 May 25; 347(9013):1485. Comment on: Lancet 1996 Feb 3;347(8997):297-9.

Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy [see comments] Jensen BV, et al. **Lancet** 1996 Feb 3;347(8997):297-9. Comment in: Lancet 1996 May 25;347(9013):1485.

ACE inhibitors and diabetics with albuminuria. The

DIABHYCAR Study Group [letter; comment] Marre M, et al. **Lancet** 1995 Dec 16;346(8990):1638. Comment on: Lancet 1995 Oct 21;346(8982):1080-4.

Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. van Essen GG, et al. **Lancet** 1996 Jan 13;347(8994):94-5

Diabetes and hypertension. Australian Diabetes Society position statement [letter; comment] Mogyorosi A, et al. **Med J Aust** 1996 May 6;164(9):571-2. Comment on: Med J Aust 1995 Oct 2;163(7):372-5.

The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidemia in response to antiproteinuric treatment. Dullaart RP, et al. **Metabolism** 1996 Jun;45(6):723-30

Effectiveness of dietary protein augmentation associated with angiotensin-converting enzyme inhibition in the management of the nephrotic syndrome. Garini G, et al. **Miner Electrolyte Metab** 1996;22(1-3):123-7

Left ventricular performance after intravenous infusion of captopril in patients with congestive heart failure. Arcidiacono G, et al. **Minerva Cardioangiol** 1995 Nov-Dec; 43(11-12):481-4

Ventricular remodeling: insights from pharmacologic interventions with angiotensin-converting enzyme inhibitors. Goldstein S, et al. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):51-5

Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Schmitz W, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):251-8 (91 ref.)

Effect of benazepril in chronic renal insufficiency [letter; comment] Apperloo AJ, et al. **N Engl J Med** 1996 Aug 22;335(8):596-7; discussion 597. Comment on: N Engl J Med 1996 Apr 11;334(15):939-45.

Effect of benazepril in chronic renal insufficiency [letter; comment] Curren CG. **N Engl J Med** 1996 Aug 22; 335(8):597; discussion 597. Comment on: N Engl J Med 1996 Apr 11;334(15):939-45.

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group [see comments] Køber L, et al. **N Engl J Med** 1995 Dec 21; 333(25):1670-6. Comment in: N Engl J Med 1996 Jun 6;334(23):1546.

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group [see comments] Maschio G, et al. **N Engl J Med** 1996 Apr 11; 334(15):939-45. Comment in: N Engl J Med 1996 Aug 22;335(8):596-7; discussion 597. Comment in: N Engl J Med 1996 Aug 22;335(8):597.

Trandolapril in patients with left ventricular dysfunction after myocardial infarction [letter; comment] Neumayr G, et al. **N Engl J Med** 1996 Jun 6;334(23):1546. Comment on: N Engl J Med 1995 Dec 21;333(25):1670-6.

Effect of ACE inhibitors, calcium channel blockers and their combination on renal and extrarenal structures in renal failure. Amann K, et al. **Nephrol Dial Transplant** 1995 Oct; 10 Suppl 9:33-8

Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. Dhondt AW, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2107-9

Influence of ACE inhibition on glucose tolerance in patients with stable chronic renal failure. Fliser D, et al. **Nephrol Dial Transplant** 1995;10(5):643-7

Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Gansevoort RT, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):1963-74

Renal effects of captopril, indomethacin and nifedipine in nephrotic patients after an oral protein load. Garini G, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):628-34

Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes. Hannedouche TP, et al. **Nephrol Dial Transplant** 1996 Apr; 11(4):673-8

Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Lash JP, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:56-62 (52 ref.)

The effect of ACE inhibitors and other antihypertensive agents on insulin resistance [editorial] Lithell H. **Nephrol Dial Transplant** 1995;10(5):589-91

Effects of ACE inhibitors and calcium channel blockers on the development of glomerular sclerosis in models of renal damage. Raij L. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:23-7 (55 ref.)

ACE inhibitors do not decrease rHuEpo response in patients with end-stage renal failure [letter] Sánchez JA. **Nephrol Dial Transplant** 1995;10(8):1476-7

Influence of ACE inhibition on haemoglobin and haematocrit in essential hypertensive patients [letter] Spiering W, et al. **Nephrol Dial Transplant** 1995;10(7):1254

Anaphylactoid reactions during haemodialysis in sheep are mediated by bradykinin and can be prevented by bradykinin receptor antagonist [letter; comment] Van der Niepen P, et al. **Nephrol Dial Transplant** 1995 Nov; 10(11):2156-7. Comment on: Nephrol Dial Transplant 1995;10(4):509-13.

Comparison of the effects of ACE inhibitors and calcium channel blockers on the progression of renal failure. Zucchelli P, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:46-51

Inflammatory peptides at the beginning of hemodialysis in asymptomatic patients treated or not with angiotensin I-converting inhibitors [letter] Marceau F, et al. **Nephron** 1995;71(4):474-6

Is there any reason to lower proteinuria in a child with nephrotic-range proteinuria who is not clinically edematous? Kees-Folts D. **Pediatr Nephrol** 1996 Apr; 10(2):180 (17 ref.)

Angiotensin-converting enzyme inhibitors in left ventricular dysfunction. Linn WD. **Pharmacotherapy** 1996 Mar-Apr; 16(2 Pt 2):50S-58S (48 ref.)

Serum sodium stabilizing effect of enalapril after standard water load in a patient with a history of self-induced water intoxication. Sebastian CS, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):655-63

Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease. Kanno Y, et al. **QJM** 1996 Jan;89(1):65-70

Comparison of the effects of a low-protein diet with the effects of a converting enzyme inhibitor on the progression of renal insufficiency in hypertensive rats. Cervenka L, et al. **Ren Fail** 1996 Mar;18(2):173-80

Effects of enalapril treatment on gene expression of smooth muscle myosin heavy chain isoforms in glomeruli of diabetic rats. Nakamura T, et al. **Ren Physiol Biochem** 1995 Jul-Aug;18(4):183-90

Lisinopril and diltiazem reduce left ventricular mass without changing blood pressure in normotensive subjects with exaggerated blood pressure response to exercise. Polónia J, et al. **Rev Port Cardiol** 1996 Mar;15(3):185-93, 179

Progression of renal diseases--angiotensin-converting enzyme inhibitors versus calcium antagonists [news] **S Afr Med J** 1996 Apr;86 Suppl 2:C114

ACE inhibitors in pregnancy--how to avoid the sting in the tail [editorial] Opie LH. **S Afr Med J** 1996 Apr;86(4):326-7

Correction of post-renal transplant erythrocytosis by enalapril. Rostaing L, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):399-406

Fast and reproducible vascular neointima formation in the hamster carotid artery: effects of trapidil and captopril. Matsuno H, et al. **Thromb Haemost** 1995 Dec;74(6):1591-6

Treatment of post-renal-transplant erythrosis: ACE inhibitors or theophylline? Ben Hmida M, et al. **Transplant Proc** 1995 Oct;27(5):2720-1

Erythropoietin, interleukin-3, interleukin-11, and GM-CSF in posttransplant erythrocytosis treated with enalapril. Hu RH, et al. **Transplant Proc** 1996 Jun;28(3):1545-7

Preventive effect of enalapril on erythrocytosis after renal transplantation. Rhee SR, et al. **Transplant Proc** 1996 Jun; 28(3):1555-6

Effect of captopril in the treatment of erythrocytosis after renal transplantation. Suh BY, et al. **Transplant Proc** 1996 Jun;28(3):1557-8

Pharmacological inhibition of restenosis: learning from experience. Shaw LA, et al. **Trends Pharmacol Sci** 1995 Dec;16(12):401-4 (36 ref.)

Effect of angiotensin-converting enzyme inhibition on nephropathy in patients with a remnant kidney. Novick AC, et al. **Urology** 1995 Dec;46(6):785-9

[Comparison of the effects of a low protein diet and angiotensin converting enzyme inhibitors on renal insufficiency in hypertensive rats] Cervenka L, et al. **Cas Lek Cesk** 1996 May 15;135(10):305-7 (Eng. Abstr.) **(Cze)**

[Angiotensin-converting enzyme inhibitors in the treatment of arterial hypertension] Horký K. **Vnitr Lek** 1996 Feb; 42(2):110-3 **(Cze)**

[24-hour ambulatory monitoring of blood pressure in patients with essential hypertension: the effectiveness of enalapril therapy] Siegelová J, et al. **Vnitr Lek** 1996 Feb;42(2):98-101 (Eng. Abstr.) **(Cze)**

[24-hour effectiveness and tolerance of perindopril (Prestarium), an ACE inhibitor, in the treatment of mild to moderate hypertension. A 1-year Czech and Slovak study] Widimský J, et al. **Vnitr Lek** 1995 Jul;41(7):441-4 (Eng. Abstr.) **(Cze)**

[Spirapril in the therapy of mild and moderately severe hypertension. A Czech and Slovak multicenter study] Widimský J, et al. **Vnitr Lek** 1995 Nov;41(11):744-52 (Eng. Abstr.) **(Cze)**

[Angiotensin converting enzyme inhibitors in the treatment of arterial hypertension] Widimský J Jr. **Vnitr Lek** 1995 Aug;41(8):560-4 (16 ref.) (Eng. Abstr.) **(Cze)**

[Evaluation of trandolapril alone or in combination with a calcium channel blocker in hypertensive patients over 60 years of age] Gosse P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Nov;44(9):517-24 (Eng. Abstr.) **(Fre)**

[Behavior of patients with mild-to-moderate arterial hypertension in relation to their treatment. Contribution of an electronic pillbox] Mallion JM, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):597-605 (Eng. Abstr.) **(Fre)**

[Treatment of cardiac failure with angiotensin-converting enzyme inhibitors and diuretics] Deray G, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):735-40 (Eng. Abstr.) **(Fre)**

[Enzyme converting inhibitors. Current knowledge and perspectives] Pathé M. **Presse Med** 1995 Dec 9; 24(38):1852-6 (56 ref.) (Eng. Abstr.) **(Fre)**

[Pharmaclinics. Drug of the month. Captopril (Capoten) in diabetic nephropathies] Scheen AJ. **Rev Med Liege** 1995 Oct;50(10):445-6 **(Fre)**

[Angiotensin-converting enzyme inhibitors in liver function disorders?] Bönner G. **Dtsch Med Wochenschr** 1996 Feb 23;121(8):254 **(Ger)**

[ACE inhibitor after myocardial infarct: are there differences?] Jahrmärker H. **Herz** 1995 Aug;20(4):293-6 (15 ref.) **(Ger)**

[ACE inhibitors in the therapy of cardiac insufficiency. Post-symposium meeting to the 5th Mainz-Mayo-Symposium, Mainz, 21 October 1992] **Internist (Berl)** 1993 Jan;34(1 Suppl):1-8 **(Ger)**

[Therapy of heart failure. Digitalis, diuretic plus ACE inhibitor or more?] Becker H, et al. **Internist (Berl)** 1995 Dec;36(12):1117-23 (43 ref.) **(Ger)**

[ACE-inhibitors in acute heart infarct] Genoni M, et al. **Schweiz Rundsch Med Prax** 1996 Apr 23;85(17):548-53 (20 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of heart failure in dogs with ACe inhibitors: comparison of quinapril and captopril] Morisse B, et al. **Tierarztl Prax** 1995 Oct;23(5):489-96 (Eng. Abstr.) **(Ger)**

[Are ACE inhibitors nephroprotective? (letter)] Hörl WH. **Wien Klin Wochenschr** 1996;108(12):373-7 **(Ger)**

[Recent molecular and pharmacologic aspects of ACE inhibitors] Köppel H, et al. **Wien Med Wochenschr** 1995; 145(23):633-7 (20 ref.) (Eng. Abstr.) **(Ger)**

[A multicenter study of lisinopril in the treatment of mild to moderate hypertension] Yodfat Y. **Harefuah** 1995 Jul; 129(1-2):26-9, 78 (Eng. Abstr.) **(Heb)**

[ACE inhibitors in the treatment of patients with acute myocardial infarct] Borghi C, et al. **Ann Ital Med Int** 1995 Jul-Sep;10(3):175-87 (75 ref.) (Eng. Abstr.) **(Ita)**

[The coronary circulation, renin-angiotensin system and ACE inhibition] Campa PP. **Cardiologia** 1995 Sep; 40(9):635-41 (97 ref.) **(Ita)**

[Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity] Guazzi M, et al. **Cardiologia** 1996 Jun;41(6):527-33 (Eng. Abstr.) **(Ita)**

[Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension] Puddu P, et al. **Clin Ter** 1995 Dec; 146(12):801-10 (Eng. Abstr.) **(Ita)**

[Variations in microalbuminuria in essential hypertension treated with ACE inhibitors, calcium antagonists and their association] Abate D, et al. **Minerva Cardioangiol** 1995 Jul-Aug;43(7-8):303-7 (Eng. Abstr.) **(Ita)**

[Effect of cilazapril on exercise tolerance and neurohumoral factors in patients with asymptomatic chronic heart failure after myocardial infarction] Fujiwara M, et al. **J Cardiol** 1995 Nov;26(5):287-92 (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of ACE inhibitors for therapy of chronic congestive heart failure] Matsuo H. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1470-4 (17 ref.) **(Jpn)**

[Physiopathology of heart failure and new approach to the therapy] Yazaki Y. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1449-53 (10 ref.) **(Jpn)**

[Pathophysiologic and clinical aspects of usefulness regarding angiotensin converting enzyme inhibitors in diabetes] Jasik M. **Pol Arch Med Wewn** 1996 Mar;95(3):261-9 (29 ref.) **(Pol)**

[Comparison of treatment effects with an angiotensin converting enzyme inhibitor--lisinopril and a calcium blocker--nifedipine retard on urinary albumin excretion in patients with non-complicated essential hypertension] Widecka K, et al. **Pol Arch Med Wewn** 1995 Feb; 93(2):135-42 (Eng. Abstr.) **(Pol)**

[Acute hemodynamic effects of ibopamine, captopril, and placebo in patients with severe heart failure] Cantarelli MJ, et al. **Arq Bras Cardiol** 1995 Apr;64(4):335-9 (Eng. Abstr.) **(Por)**

[The clinical efficacy of the first Russian angiotensin-converting enzyme inhibitor methiopril in patients with heart failure] Glezer MG, et al. **Klin Med (Mosk)** 1995;73(3):49-51 (Eng. Abstr.) **(Rus)**

[Effectiveness and tolerance of benazepril versus captopril in patients with hypertension] Ol'binskaia LI, et al. **Klin Med (Mosk)** 1995;73(5):36-8 (Eng. Abstr.) **(Rus)**

[The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with arterial hypertension] Diadyk AI, et al. **Ter Arkh** 1995;67(8):65-8 (88 ref.) **(Rus)**

[The use of perindopril (prestarium) in arterial hypertension] Filatova NP. **Ter Arkh** 1995;67(9):81-3 (35 ref.) **(Rus)**

[Improving drug therapy in circulatory insufficiency: the role of renal kallikrein-kinin system] Komarov FI, et al. **Vestn Ross Akad Med Nauk** 1995;(10):3-7 (Eng. Abstr.) **(Rus)**

[Hemodynamic effects of captopril, an ACE inhibitor, in patients after aortocoronary bypass] Ivančan V, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:103-4 (Eng. Abstr.) **(Scr)**

[The effect of cilazapril and prazosin on insulin sensitivity in patients with essential hypertension] Cirić J, et al. **Med Pregl** 1995;48(9-10):326-8 (Eng. Abstr.) **(Scr)**

[A protein-restricted diet combined with ACE inhibitors does not improve insulin sensitivity in renal hypertension]

Spustová V, et al. **Vnitr Lek** 1996 Mar;42(3):157–61 (Eng. Abstr.) **(Slo)**

[Angiotensin converting enzyme inhibitors in ischemic heart disease] Takáč M, et al. **Vnitr Lek** 1996 Apr;42(4):290–6 (62 ref.) (Eng. Abstr.) **(Slo)**

[Historical perspective of renin–angiotensin system blocking in the treatment of arterial hypertension (editorial)] Coca A, et al. **Med Clin (Barc)** 1996 Mar 30;106(12):457–9 **(Spa)**

[Converting enzyme inhibitors in acute myocardial infarct and heart failure (editorial)] Martínez Martínez JA. **Medicina (B Aires)** 1995;55(1):81–3 **(Spa)**

[Controversies in the treatment of arterial hypertension: other drugs as the first step (calcium antagonists, ACE inhibitors and alpha-blockers)] Castro Beiras A, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:72–80 (31 ref.) (Eng. Abstr.) **(Spa)**

[A comparative study of the efficacy of lisinopril versus quinapril in controlling light to moderate arterial hypertension. A follow-up with ABPM] Motero Carrasco J. **Rev Esp Cardiol** 1995 Nov;48(11):746–53 (Eng. Abstr.) **(Spa)**

TOXICITY

Differential inhibition of rat brain acetylcholinesterase molecular forms by 7-methoxytacrine in vitro. Bajgar J, et al. **Toxicol Lett** 1995 Oct;80(1–3):109–14

Fosinopril treatment of pregnant rats: developmental toxicity, fetal angiotensin-converting enzyme inhibition, and fetal angiotensin II receptor regulation. Grove KL, et al. **Toxicol Lett** 1995 Oct;80(1–3):85–95

URINE

Determination of the angiotensin-converting enzyme inhibitor lisinopril in urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Wong YC, et al. **J Chromatogr B Biomed Appl** 1995 Nov 17;673(2):306–10

ANGIOTENSIN-FORMING ENZYME see RENIN

ANGIOTENSIN RECEPTORS see RECEPTORS, ANGIOTENSIN

ANGIOTENSINOGEN

BIOSYNTHESIS

Regulation of angiotensinogen gene expression in the rat forebrain by adrenal steroids and relation to salt appetite. Riftina F, et al. **Brain Res Mol Brain Res** 1995 Nov; 33(2):201–8

Permanent inhibition of angiotensinogen synthesis by antisense RNA expression. Schinke M, et al. **Hypertension** 1996 Mar;27(3 Pt 2):508–13

A cis-acting DNA element located between TATA box and transcription initiation site is critical in response to regulatory sequences in human angiotensinogen gene. Yanai K, et al. **J Biol Chem** 1996 Jul 5;271(27):15981–6

Alpha-adrenoceptors and angiotensinogen gene expression in opossum kidney cells. Wang TT, et al. **Kidney Int** 1995 Jul;48(1):139–45

BLOOD

Angiotensinogen and blood pressure among blacks: findings from a community survey in Jamaica. Forrester T, et al. **J Hypertens** 1996 Mar;14(3):315–21

Role of the kidney in the plasma clearance of angiotensinogen in the rat: plasma clearance and tissue distribution of 125I-angiotensinogen. Yayama K, et al. **Life Sci** 1995; 57(19):1791–801

[Angiotensinogen (renin substrate)] Tamura K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:692–4 (19 ref.) **(Jpn)**

DEFICIENCY

Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. Niimura F, et al. **J Clin Invest** 1995 Dec;96(6):2947–54

GENETICS

Coordinate regulation of renal expression of nitric oxide synthase, renin, and angiotensinogen mRNA by dietary salt. Singh I, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):F1027–37

Coronary atherosclerosis and the angiotensinogen gene [letter; comment] Keavney B, et al. **Circulation** 1995 Oct 15;92(8):2356–7. Comment on: Circulation 1995 Feb 15;91(4):951–4.

Departure from Hardy-Weinberg equilibrium should be systematically tested in studies of association between genetic markers and disease [letter; comment] Tiret L, et al. **Circulation** 1995 Dec 1;92(11):3364–5. Comment on: Circulation 1994 Nov;90(5):2199–202. Comment on: Circulation 1995 Feb;91(4):951–4.

Development of polyuria in Tsukuba hypertensive mice carrying human renin and angiotensinogen genes. Uehara S, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S12–4

Angiotensin-converting enzyme and angiotensinogen genes in patterns of left ventricular hypertrophy and in diastolic dysfunction. Wong KK, et al. **Clin Exp Pharmacol Physiol** 1995 Jun-Jul;22(6–7):438–40

A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Fogarty DG, et al. **Diabetes** 1996 Sep;45(9):1204–8

Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. Tarnow L, et al. **Diabetes** 1996 Mar;45(3):367–369

DNA polymorphisms and linkage disequilibrium in the angiotensinogen gene. Morgan L, et al. **Hum Genet** 1996 Aug;98(2):194–8

Recent advances in the study of renin and angiotensinogen genes: from molecules to the whole body. Tamura K, et al. **Hypertens Res** 1995 Mar;18(1):7–18 (134 ref.)

Human renin-dependent hypertension in rats transgenic for human angiotensinogen. Bohlender J, et al. **Hypertension** 1996 Mar;27(3 Pt 2):535–40

Mechanisms for inducible control of angiotensinogen gene transcription. Brasier AR, et al. **Hypertension** 1996 Mar; 27(3 Pt 2):465–75 (108 ref.)

Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Brasier AR, et al. **Hypertension** 1996 Apr;27(4):1009–17

Angiotensinogen polymorphism M235T, hypertension, and nephropathy in insulin-dependent diabetes. Doria A, et al. **Hypertension** 1996 May;27(5):1134–9

Role of transcriptional cis-elements, angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation. Morishita R, et al. **Hypertension** 1996 Mar;27(3 Pt 2):502–7

Polymorphisms of renin-angiotensin genes among Nigerians, Jamaicans, and African Americans. Rotimi C, et al. **Hypertension** 1996 Mar;27(3 Pt 2):558–63

Tissue-specific regulation of angiotensinogen gene expression in spontaneously hypertensive rats. Tamura K, et al. **Hypertension** 1996 Jun;27(6):1216–23

Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Wielbo D, et al. **Hypertension** 1996 Jul;28(1):147–51

The natural mutation Y248C of human angiotensinogen leads to abnormal glycosylation and altered immunological recognition of the protein. Gimenez-Roqueplo AP, et al. **J Biol Chem** 1996 Apr 19;271(16):9838–44

A cis-acting DNA element located between TATA box and transcription initiation site is critical in response to regulatory sequences in human angiotensinogen gene. Yanai K, et al. **J Biol Chem** 1996 Jul 5;271(27):15981–6

Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. Niimura F, et al. **J Clin Invest** 1995 Dec;96(6):2947–54

Lack of association between angiotensinogen polymorphism (M235T) and cerebrovascular disease and carotid atheroma. Barley J, et al. **J Hum Hypertens** 1995 Aug;9(8):681–3

Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. Dudley C, et al. **J Hypertens** 1996 Feb;14(2):259–62

Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. Hopkins PN, et al. **J Hypertens** 1996 Feb; 14(2):199–207

Effect of the angiotensinogen gene Met235-->Thr variant on blood pressure and other cardiovascular risk factors in two Japanese populations. Nishiuma S, et al. **J Hypertens** 1995 Jul;13(7):717–22

Effect of angiotensinogen gene T235 variant on the development of diabetic complications in type II diabetes mellitus [letter; comment] McLaughlin KJ, et al. **Lancet** 1995 Oct 28;346(8983):1160. Comment on: Lancet 1995 Jun 24;345(8965):1600–3.

Association analyses of the polymorphisms of angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics. Ohno T, et al. **Metabolism** 1996 Feb;45(2):218–22

Association of M235T variant of the angiotensinogen gene with familial hypertension of early onset. Schmidt S, et al. **Nephrol Dial Transplant** 1995;10(7):1145–8

[A case-control study of pregnancy-induced hypertension with a genetic predisposition: association of a molecular variant of angiotensinogen in the Japanese women] Kobashi G. **Hokkaido Igaku Zasshi** 1995 Jul;70(4):649–57 (Eng. Abstr.) **(Jpn)**

[DNA analysis in the determination of a predisposition for hypertension] Hudecová S, et al. **Bratisl Lek Listy** 1995 Jun;96(6):322–5 (Eng. Abstr.) **(Slo)**

METABOLISM

Human urinary kallikrein can generate angiotensin II from homologous renin substrates. Sasaguri M, et al. **Hypertens Res** 1995 Mar;18(1):33–7

The natural mutation Y248C of human angiotensinogen leads to abnormal glycosylation and altered immunological recognition of the protein. Gimenez-Roqueplo AP, et al. **J Biol Chem** 1996 Apr 19;271(16):9838–44

PHARMACOKINETICS

Role of the kidney in the plasma clearance of angiotensinogen in the rat: plasma clearance and tissue distribution of 125I-angiotensinogen. Yayama K, et al. **Life Sci** 1995; 57(19):1791–801

PHYSIOLOGY

Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. Merrill DC, et al. **J Clin Invest** 1996 Feb 15;97(4):1047–55

Role of angiotensinogen in the genetics of essential hypertension. Hata A. **Life Sci** 1995 Nov 17;57(26):2385–95 (73 ref.)

ANGIOTENSINOGENASE see RENIN

ANGIOTENSINS

see related
RECEPTORS, ANGIOTENSIN
RENIN-ANGIOTENSIN SYSTEM

[Histocytochemical and functional aspects on the "brain-vascular peptides"] Yamada H, et al. **Kaibogaku Zasshi** 1995 Oct;70(5):422–35 (108 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Angiotensin peptide research overlooked [letter] Chappell MC, et al. **Clin Chem** 1996 Sep;42(9):1500–1

BLOOD

Measurements of angiotensin peptides [letter; comment] Ferrario CM, et al. **Hypertension** 1995 Nov;26(5):843–5. Comment on: Hypertension 1995 May;25(5):928–34. Comment on: Hypertension 1995 May;25(5):1014–20.

METABOLISM

Metabolism of angiotensins by head membranes of the leech Theromyzon tessulatum. Laurent V, et al. **FEBS Lett** 1996 Apr 15;384(2):123–7

Angiotensin and bradykinin metabolism by peptidases identified in cultured human skeletal muscle myocytes and fibroblasts. Vaghy PL, et al. **Peptides** 1995;16(8):1367–73

Angiotensin and bradykinin metabolism by peptidases identified in skeletal muscle. Ward PE, et al. **Peptides** 1995; 16(6):1073–8

PHARMACOLOGY

A specific template-assembled peptidic agonist for the angiotensin II receptor subtype 2 (AT2) and its effect on inferior olivary neurones. Grouzmann E, et al. **Eur J Biochem** 1995 Nov 15;234(1):44–9

Characterization of a binding site for angiotensin IV on bovine aortic endothelial cells. Bernier SG, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):191–200

PHYSIOLOGY

The renin angiotensin system and the stress response. Aguilera G, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:173–86 (41 ref.)

Evidence for the role of angiotensin in the establishment and maintenance of renal morphology. Niimura F, et al. **Contrib Nephrol** 1996;118:234–7 (4 ref.)

Endogenous angiotensin within the rostral ventrolateral meoulla facilitates the somatosympathetic reflex. Hirooka Y, et al. **J Hypertens** 1995 Jul;13(7):747–54

Angiotensin receptors and their antagonists. Goodfriend TL, et al. **N Engl J Med** 1996 Jun 20;334(25):1649–54 (81 ref.)

ANGLE CLASS I see MALOCCLUSION, ANGLE CLASS I

ANGLE CLASS II see MALOCCLUSION, ANGLE CLASS II

ANGLE CLASS III see MALOCCLUSION, ANGLE CLASS III

ANGOR PECTORIS see ANGINA PECTORIS

ANGUILLA

ANATOMY & HISTOLOGY

Spinal and parachordal neurons in the eel leptocephali, Anguilla japonica revealed by labeling with a fluorescent dye. Yoshida M, et al. **Neurosci Lett** 1995 Aug 11; 195(3):206–8

GENETICS

The molecular basis for the green-blue sensitivity shift in the rod visual pigments of the European eel. Archer S, et al. **Proc R Soc Lond B Biol Sci** 1995 Dec 22; 262(1365):289–95

METABOLISM

Uptake and elimination of cadmium by Japanese eel, Anguilla japonica, at various temperatures. Yang HN, et al. **Bull Environ Contam Toxicol** 1996 Apr;56(4):670–6

Pesticide effects on eel metabolism pesticide; levels did not decline at any time when animals were exposed to 4.1

mg/liter. Gimeno L, et al. **Ecotoxicol Environ Saf** 1995 Jul;31(2):153–7

Development of a radioimmunoassay for European eel growth hormone and application to the study of silvering and experimental fasting. Marchelidon J, et al. **Gen Comp Endocrinol** 1996 Jun;102(3):360–9

[Effects of hydrostatic pressure on malondialdehyde (MDA) determination in brain from yellow freshwater eels] Sébert P, et al. **C R Acad Sci III** 1995 Jul;318(7):757–60 (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Aeromonas encheleia sp. nov., isolated from European eels. Esteve C, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):462–6

PARASITOLOGY

[Anguilluliasis of the European eel—a continuing problem] Wlasow T. **Wiad Parazytol** 1995;41(2):193–8 **(Pol)**

PHYSIOLOGY

Effect of HCO–3 and pH on ion transport in the posterior intestine of the freshwater–adapted teleost Anguilla anguilla. Baldisserotto B, et al. **Braz J Med Biol Res** 1995 Mar;28(3):327–30

Primary sequence, tissue specificity and expression of the Na+,K(+)–ATPase alpha 1 subunit in the European eel (Anguilla anguilla). Cutler CP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Aug; 111(4):567–73

Effects of serotonin on the cardio–circulatory system of the European eel (Anguilla anguilla) in vivo. Janvier JJ, et al. **J Comp Physiol [B]** 1996;166(2):131–7

Synergistic action of neuropeptide Y and adrenaline in the eel atrium. Uesaka T. **J Exp Biol** 1996 Aug;199 (Pt 8):1873–80

ANGUILLULIASIS see **STRONGYLOIDIASIS**

ANHIDROSIS see **HYPOHIDROSIS**

ANHIDROTIC ECTODERMAL DYSPLASIA see **ECTODERMAL DYSPLASIA**

ANHYDRIDES

Exposure to acid anhydrides in three resin and one cushioned flooring manufacturing plants. van Tongeren MJ, et al. **Ann Occup Hyg** 1995 Oct;39(5):559–71

ADVERSE EFFECTS

A clinical and immunological study on 92 workers occupationally exposed to anhydrides. Baur X, et al. **Int Arch Occup Environ Health** 1995;67(6):395–403

ANALYSIS

Assay for the dianhydride of diethylenetriaminepentaacetic acid and its major degradation products by capillary electrophoresis. Bullock J. **J Chromatogr B Biomed Appl** 1995 Jul 7;669(1):149–55

CHEMISTRY

The reduction of propionic anhydride by aldehyde dehydrogenase–NADH mixtures AT pH 7. Motion RL, et al. **Adv Exp Med Biol** 1995;372:53–60

Standard free energy change for the hydrolysis of the alpha, beta–phosphoanhydride bridge in ATP. Frey PA, et al. **Biochemistry** 1995 Sep 12;34(36):11307–10

Molecular heterogeneity of PAF in normal human mixed saliva: quantitative mass spectral analysis after direct derivatization of PAF with pentafluorobenzoic anhydride. Woodard DS, et al. **Biochim Biophys Acta** 1995 Nov 16; 1259(2):137–47

Urethane–protected alpha–amino acid N–carboxyanhydrides and peptide synthesis. Fuller WD, et al. **Biopolymers** 1996; 40(2):183–205 (56 ref.)

N,N–dialkoxycarbonylamino acids from the sodium hydride–mediated reaction of alkyl chloroformates with mixed anhydrides of N–alkoxycarbonylamino acids. Benoiton NL, et al. **Int J Pept Protein Res** 1995 May; 45(5):466–70

IMMUNOLOGY

Diagnostic validation of specific IgE antibody concentrations, skin prick testing, and challenge tests in chemical workers with symptoms of sensitivity to different anhydrides. Baur X, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):489–94

Structure–activity relationships of organic acid anhydrides as antigens in an animal model. Welinder H, et al. **Toxicology** 1995 Nov 30;103(2):127–36

PHARMACOLOGY

In vitro bone biocompatibility of poly (anhydride–co–imides) containing pyromellitylimidoalanine. Attawia MA, et al. **J Orthop Res** 1996 May;14(3):445–54

TOXICITY

Cytotoxicity testing of poly(anhydride–co–imides) for orthopedic applications. Attawia MA, et al. **J Biomed Mater Res** 1995 Oct;29(10):1233–40

ANHYDRO–ARA–C see **ANCITABINE**

ANHYDROGLUCOCHLORAL see **CHLORALOSE**

ANILIDES

ADMINISTRATION & DOSAGE

High–dose bicalutamide monotherapy for the treatment of prostate cancer. Blackledge GR. **Urology** 1996 Jan;47(1A Suppl):44–7; discussion 48–53

[Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer] Kotake T, et al. **Hinyokika Kiyo** 1996 Feb;42(2):157–68 (Eng. Abstr.) **(Jpn)**

[Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer] Kotake T, et al. **Hinyokika Kiyo** 1996 Feb;42(2):143–53 (Eng. Abstr.) **(Jpn)**

CHEMICAL SYNTHESIS

[Stereoselective synthesis and pharmacological properties of metabolites of new antiinflammatory agent. 4'–Acetyl–2'–(2,4–difluorophenoxy)methanesulfonanilide (FK3311)] Nakamura K, et al. **Yakugaku Zasshi** 1995 Nov; 115(11):928–36 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Substrates containing phosphorylated residues adjacent to proline decrease the cleavage by proline–specific peptidases. Kaspari A, et al. **Biochim Biophys Acta** 1996 Mar 7;1293(1):147–53

Bioisosterism in drug design: identification of and structure–activity relationships in a series of glycine anilide ACAT inhibitors. Roark WH, et al. **Bioorg Med Chem** 1995 Jan;3(1):29–39

METABOLISM

Enantioselective metabolism and pharmacokinetics of Casodex in the male rat. McKillop D, et al. **Xenobiotica** 1995 Jun;25(6):623–33

PHARMACOKINETICS

Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen. Denis L, et al. **Urology** 1996 Jan;47(1A Suppl):26–8; discussion 29–32

PHARMACOLOGY

Inhibition of peptidyl–prolyl cis/trans isomerase activity by substrate analog structures: thioxo tetrapeptide–4–nitroanilides. Schutkowski M, et al. **Biochemistry** 1995 Oct 10;34(40):13016–26

NS–49, a novel alpha 1a–adrenoceptor–selective agonist characterization using recombinant human alpha 1–adrenoceptors. Obika K, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):327–34

Effects of two non–steroidal antiandrogens on testicular function in prepubertal rats. Rulli SB, et al. **J Androl** 1995 May–Jun;16(3):225–32

Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC–781 and UC–82 as inhibitors of human immunodeficiency virus type 1 replication. Balzarini J, et al. **Mol Pharmacol** 1996 Aug;50(2):394–401

The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Furr BJ, et al. **Urology** 1996 Jan;47(1A Suppl):13–25; discussion 29–32

Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization. Kemppainen JA, et al. **Urology** 1996 Jul;48(1):157–63

[Stereoselective synthesis and pharmacological properties of metabolites of new antiinflammatory agent. 4'–Acetyl–2'–(2,4–difluorophenoxy)methanesulfonanilide (FK3311)] Nakamura K, et al. **Yakugaku Zasshi** 1995 Nov; 115(11):928–36 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group. Lunglmayr G. **Anticancer Drugs** 1995 Aug; 6(4):508–13

Clinical progress with a new antiandrogen, Casodex (bicalutamide). Blackledge GR. **Eur Urol** 1996;29 Suppl 2:96–104 (15 ref.)

The development of Casodex (bicalutamide): preclinical studies. Furr BJ. **Eur Urol** 1996;29 Suppl 2:83–95 (53 ref.)

A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group. Kaisary AV, et al. **Eur Urol** 1995;28(3):215–22

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone–releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:105–9

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long–term endocrine effects of monotherapy. Soloway MS, et al. **J Urol** 1995 Dec; 154(6):2110–4

Bicalutamide for prostate cancer. **Med Lett Drugs Ther** 1996 Jun 21;38(977):56–7

Bicalutamide (Casodex): The Critical Issues 1996. Proceedings of a meeting. Boston, Massachusetts, July 6–9, 1995. **Urology** 1996 Jan;47(1A Suppl):1–96

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Bales GT, et al. **Urology** 1996 Jan;47(1A Suppl):38–43; discussion 48–53

Single–agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Chodak G, et al. **Urology** 1995 Dec; 46(6):849–55

Worldwide activity and safety of bicalutamide: a summary review. Kolvenbag GJ, et al. **Urology** 1996 Jan;47(1A Suppl):70–9; discussion 80–4 (29 ref.)

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. Soloway MS, et al. **Urology** 1996 Jan;47(1A Suppl):33–7; discussion 48–53

TOXICITY

Fungicide methfuroxan administered chronically to rats did not affect serum thyroid hormone levels. Kita K, et al. **Cent Eur J Public Health** 1995 Aug;3(3):127–8

Interactions of cis–fatty acids and their anilides with formyl–methionyl–leucyl–phenylalanine, phorbol myristate acetate and dioctanoyl–s,n–glycerol in human leukocytes. Heiskanen K, et al. **Toxicology** 1995 Dec 15; 104(1–3):113–21

Formyl–methionyl–leucyl–phenylalanine and a calcium ionophore A23187 reverse the inhibition of phorbol myristate acetate–induced oxidative burst by linoleic and oleic acid anilides. Heiskanen KM, et al. **Toxicology** 1996 Jun 17;110(1–3):39–45

ANILINE COMPOUNDS

Interactions of aniline with soil and groundwater at an industrial spill site. Kosson DS, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:71–3 (13 ref.)

Evaluation of modified dichloran 18% glycerol (DG18) agar for enumerating fungi in wheat flour: a collaborative study. Beuchat LR, et al. **Int J Food Microbiol** 1996 Apr; 29(2–3):161–6

Fluorescent porphyrin counterstaining of chromatin DNA in conjunction with immunofluorescence methods using FITC–labelled antibodies. Juarranz A, et al. **J Microsc** 1996 Apr;182 (Pt 1):46–9

ANALYSIS

Residues of dicloran in clingstone peaches after pre– and postharvest application. Lentza–Rizos C, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):231–9

Metabolites beat adducts and monitors. Shuker D. **Hum Exp Toxicol** 1995 Aug;14(8):695–6

Optimization of a liquid chromatographic method for determination of malachite green and its metabolites in fish tissues. Plakas SM, et al. **J AOAC Int** 1995 Nov–Dec; 78(6):1388–94

Gas chromatographic/mass spectrometric confirmation of leucomalachite green in catfish (Ictalurus punctatus) tissue. Turnipseed SB, et al. **J AOAC Int** 1995 Jul–Aug; 78(4):971–7

Formation and elution of toxic compounds from sterilized medical products: methylenedianiline formation in polyurethane. Shintani H. **J Biomater Appl** 1995 Jul; 10(1):23–58

Monitoring of aromatic amine exposures in workers at a chemical plant with a known bladder cancer excess. Ward EM, et al. **J Natl Cancer Inst** 1996 Aug 7;88(15):1046–52

[A study on the simultaneous HPLC determination of chlorhexidine and its impurity 4–chloroaniline] Zhang D, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec; 26(4):447–51 (Eng. Abstr.) **(Chi)**

[Study of the level of aromatic amines in food products] Masłowska J, et al. **Rocz Panstw Zakl Hig** 1995; 46(4):357–61 (Eng. Abstr.) **(Pol)**

BLOOD

Simultaneous determination of malachite green and its metabolite leucomalachite green in eel plasma using post–column oxidation. Hajee CA, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):219–27

Blood distribution and single–dose pharmacokinetics of leflunomide. Lucien J, et al. **Ther Drug Monit** 1995 Oct; 17(5):454–9

CHEMICAL SYNTHESIS

Antitumor benzothiazoles. 3. Synthesis of 2–(4–aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. Shi DF, et al. **J Med Chem** 1996 Aug 16; 39(17):3375–84

Synthesis and evaluation of a new bifunctional chelating agent for the preparation of radioimmunoconjugates. Somayaji VV, et al. **Q J Nucl Med** 1995 Dec;39(4):300–10

CHEMISTRY

Design and synthesis of new mitochondrial cytotoxin N-thiadiazolylanilines that inhibit tumor cell growth. Hori H, et al. **Bioorg Med Chem** 1996 Feb;4(2):247-53

Model of interaction between a cardiotoxin and dimyristoylphosphatidic acid bilayers determined by solid-state 31P NMR spectroscopy. Picard F, et al. **Biophys J** 1996 Apr;70(4):1737-44

New surface-active comonomer for adhesive bonding. Bowen RL, et al. **J Dent Res** 1996 Jan;75(1):606-10

Palladium(II) complexes of dialkyl alpha-Anilinobenzylphosphonates. Synthesis, characterization, and cytostatic activity. Curić M, et al. **J Inorg Biochem** 1996 Aug 1;63(2):125-42

Quantitative relationships of structure-activity and volume fraction for selected nonpolar and polar narcotic chemicals. Jaworska JS, et al. **SAR QSAR Environ Res** 1993;1(1):3-19

METABOLISM

Elimination of nitrite from the explosive 2,4,6-trinitrophenylmethylnitramine (tetryl) catalyzed by ferredoxin NADP oxidoreductase from spinach. Shah MM, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):563-8

Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes. Yamazaki H, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):301-9

Structural basis for actomyosin chemomechanical transduction by non-nucleoside triphosphate analogues. Gopal D, et al. **Biochemistry** 1995 Sep 26;34(38):12178-84

Pseudomonas aeruginosa strain MA01 aerobically metabolizes the aminodinitrotoluenes produced by 2,4,6-trinitrotoluene nitro group reduction. Alvarez MA, et al. **Can J Microbiol** 1995 Nov;41(11):984-91

32P-postlabeling of a DNA adduct derived from 4,4'-methylenedianiline, in the olfactory epithelium of rats exposed by inhalation to 4,4'-methylenediphenyl diisocyanate. Vock EH, et al. **Carcinogenesis** 1996 May; 17(5):1069-73

Interaction between the substrate and the high-valent-iron-oxo porphyrin cofactor as a possible factor influencing the regioselectivity of cytochrome P450 catalysed aromatic ring hydroxylation of 3-fluoro(methyl)anilines. Koerts J, et al. **Chem Biol Interact** 1996 Jan 5;99(1-3):129-46

Comparative MO-QSAR studies in various species including man. Tyrakowska B, et al. **Chem Biol Interact** 1996 Mar 25;100(2):187-201

Subanesthetic concentrations of drugs inhibit cytochrome P450-mediated metabolism of aniline. LaBella FS, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):231-5

Effects of phenobarbital on aniline metabolism in primary liver cell culture of rats with ethionine-induced liver disorder. Noguchi M, et al. **Exp Anim** 1996 Apr; 45(2):161-70

Agromyces mediolanus sp. nov., nom. rev., comb. nov., a species for "Corynebacterium mediolanum" Mamoli 1939 and for some aniline-assimilating bacteria which contain 2,4-diaminobutyric acid in the cell wall peptidoglycan. Suzuki K, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):88-93

PHARMACOKINETICS

Biodegradability simulation studies in semicontinuous activated sludge reactors with low (microgram/L range) and standard (ppm range) chemical concentrations. Berg UT, et al. **Chemosphere** 1996 Aug;33(4):711-35

Estimation of kinetic rate constants for biodegradation of chemicals in activated sludge wastewater treatment plants using short term batch experiments and microgram/L range spiked concentrations. Nyholm N, et al. **Chemosphere** 1996 Sep;33(5):851-64

Flow cytometric functional analysis of multidrug resistance by Fluo-3: a comparison with rhodamine-123. Koizumi S, et al. **Eur J Cancer** 1995 Sep;31A(10):1682-8

PHARMACOLOGY

Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Zimmermann J, et al. **Arch Pharm (Weinheim)** 1996 Jul; 329(7):371-6

Effect of aniline on ethanol oxidation and carbohydrate metabolism in isolated hepatocytes. Efthivoulou MA, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):863-7

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Davis JP, et al. **Biochemistry** 1996 Jan 30;35(4):1270-3

2-Methoxy-4-nitroaniline is a selective inducer of cytochrome P450IA2 (CYP1A2) in rat liver. Degawa M, et al. **Cancer Lett** 1995 Sep 4;96(1):95-8

Serum iodothyronine concentrations in intestinally decontaminated rats treated with a 5'-deiodinase type I inhibitor 6-anilino-2-thiouracil. Veronikis IE, et al. **Eur J Endocrinol** 1996 Apr;134(4):519-23

Effects of trinitrotoluene (TNT) metabolites on chemiluminescence response of phagocytic cells. Thierfelder W, et al. **Int J Immunopharmacol** 1995 May; 17(5):453-6

Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. Cao WW, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 1):1016-30

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. Bridges AJ, et al. **J Med Chem** 1996 Jan 5; 39(1):267-76

[Collagenosis-like syndromes as the possible manifestations of poisoning by the components of a compound] Sichko ZhV, et al. **Med Tr Prom Ekol** 1995;(11):44-6 **(Rus)**

TOXICITY

Applications of frontier molecular orbital energies in QSAR studies. Huang Q, et al. **Bull Environ Contam Toxicol** 1996 May;56(5):758-65

Quantitative structure-activity relationships of organic acids and bases. Zhao YH, et al. **Bull Environ Contam Toxicol** 1996 Aug;57(2):242-9

Effects of the nitro-group on the mutagenicity and toxicity of some benzamines. Chung KT, et al. **Environ Mol Mutagen** 1996;27(1):67-74

The effect of p-chloroaniline on leucocytes of sheep peripheral blood under the migration-inhibition test conditions. Kačmár P, et al. **Immunopharmacol Immunotoxicol** 1995 Aug;17(3):577-84

Genotoxicity of the herbicide fluchloralin on human lymphocytes in vitro: chromosomal aberration and micronucleus tests. Panneerselvam N, et al. **Mutat Res** 1995 Aug;344(1-2):69-72

URINE

Determination of urinary 4,4'-methylenedianiline and its acetylated metabolites by solid-phase extraction and HPLC analysis with UV and electrochemical detection. Robert A, et al. **Int Arch Occup Environ Health** 1995;68(1):44-51

Determination of combined residues of metalaxyl and 2,6-dimethylaniline metabolites in urine by gas chromatography/mass spectrometry. Headley JV, et al. **J AOAC Int** 1996 Jan-Feb;79(1):117-23

ANILINE HYDROXYLASE

BLOOD

Stress response and drug metabolism in mice. Matamoros RA, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):255-63

METABOLISM

[Effect of heterochronic parabiosis on liver microsomal enzyme oxidation] Frol'kis VV, et al. **Dokl Akad Nauk** 1996 Apr;347(6):828-30 **(Rus)**

ANILINE MUSTARD

ANALOGS & DERIVATIVES

Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Blakey DC, et al. **Br J Cancer** 1995 Nov;72(5):1083-8

Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing. Wilson WR, et al. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):881-5

New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link. Dowell RI, et al. **J Med Chem** 1996 Mar 1;39(5):1100-5

Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. Palmer BD, et al. **J Med Chem** 1996 Jun 21;39(13):2518-28

Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing. Wentworth P, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):799-803

ANILINO NAPHTHALENESULFONATES

Effect of chaotropic denaturant on the binding of 1-anilino-8-naphthalene sulfonic acid to proteins. Kumar TK, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):103-5

CHEMISTRY

Effect of the concentration of 8-anilinonaphthalenesulfonic acid on the detection of folding intermediates in alpha-urease. Beauregard M. **Anal Biochem** 1996 Feb 15; 234(2):233-4

The structural elements of phospholipase A2 affecting the enhancement of 8-anilinonaphthalene-1-sulfonate fluorescence. Chang LS, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):617-23

Use of fluorescence decay times of 8-ANS-protein complexes to study the conformational transitions in proteins which unfold through the molten globule state. Uversky VN, et al. **Biophys Chem** 1996 Jun 11;60(3):79-88

The essentiality of His-47 and the N-terminal region for the binding of 8-anilinonaphthalene-1-sulfonate with Taiwan cobra phospholipase A2. Chang LS, et al. **J Protein Chem** 1996 Apr;15(3):255-60

Pressure-induced perturbation of ANS-apomyoglobin complex: frequency domain fluorescence studies on native and acidic compact states. Bismuto E, et al. **Protein Sci** 1996 Jan;5(1):121-6

METABOLISM

Characterization of the sources of protein-ligand affinity: 1-sulfonato-8-(1')anilinonaphthalene binding to intestinal fatty acid binding protein. Kirk WR, et al. **Biophys J** 1996 Jan;70(1):69-83

[Changes in binding parameters of fluorescent probes 1-anilinonaphthalene-8-sulfonate and 4-(n-dimethylaminostyryl)-1-methylpyridinium n-toluolsulfonate with liposomes upon radiation exposure] Gorbenko GP. **Biofizika** 1996 Mar-Apr;41(2):363-8 (Eng. Abstr.) **(Rus)**

ANIMAL CARE COMMITTEES see **ANIMAL WELFARE**

ANIMAL COMMUNICATION

see related
PHEROMONES
VOCALIZATION, ANIMAL

The evolution of understanding: a genetic algorithm model of the evolution of communication. Levin M. **Biosystems** 1995;36(3):167-78

What parameters can be used for individual acoustic recognition by the greater flamingo? Mathevon N. **C R Acad Sci III** 1996 Jan;319(1):29-32

Windows on animal minds. Griffin DR. **Conscious Cogn** 1995 Jun;4(2):194-204

Time and frequency domain characteristics of sperm whale clicks. Goold JC, et al. **J Acoust Soc Am** 1995 Sep; 98(3):1279-91

Modes of vocal variation in Sykes's monkey (Cercopithecus albogularis) squeals. Brown CH, et al. **J Comp Psychol** 1995 Dec;109(4):398-415

Representation of a species-specific vocalization in the primary auditory cortex of the common marmoset: temporal and spectral characteristics. Wang X, et al. **J Neurophysiol** 1995 Dec;74(6):2685-706

Repeated exposure to one song leads to a rapid and persistent decline in an immediate early gene's response to that song in zebra finch telencephalon. Mello C, et al. **J Neurosci** 1995 Oct;15(10):6919-25

Sexual selection enhances population extinction in a changing environment. Tanaka Y. **J Theor Biol** 1996 Jun 7; 180(3):197-206

Is there any intermediate stage between animal communication and language? Ujhelyi M. **J Theor Biol** 1996 May 7;180(1):71-6

An evolutionary perspective on signaling in behavior and immunology. McKean KA, et al. **Naturwissenschaften** 1995 Nov;82(11):509-16 (74 ref.)

Electrosensory optimization to conspecific phasic signals for mating. Tricas TC, et al. **Neurosci Lett** 1995 Dec 29; 202(1-2):129-32

The evolution of exploitation and honesty in animal communication: a model using artificial neural networks. Krakauer DC, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 May 30; 348(1325):355-61

Urine marking and maternal aggression of wild female mice in relation to anogenital distance at birth. Palanza P, et al. **Physiol Behav** 1995 Nov;58(5):827-35

An exaggerated preference for simple neural network models of signal evolution? Dawkins MS, et al. **Proc R Soc Lond B Biol Sci** 1995 Sep 22;261(1362):357-60

[The neurobiological bases of acoustical communication. A comparative physiological review of structures and mechanisms] Vartanian IA, et al. **Zh Evol Biokhim Fiziol** 1995 Sep-Dec;31(5-6):677-84 (33 ref.) **(Rus)**

ANIMAL DISEASES

The application of probabilistic scenario analysis for risk assessment of animal health in international trade. Ahl AS. **Ann N Y Acad Sci** 1996 Jul 23;791:255-68

Excessive impertinence or a missed diagnosis? Williams TM, et al. **BMJ** 1995 Dec 23-30;311(7021):1700-1

DIAGNOSIS

Use of Suratex for field diagnosis of patent and non-patent Trypanosoma evansi infections in camels. Olaho-Mukani W, et al. **Br Vet J** 1996 Jan;152(1):109-11

OIE workshop on veterinary diagnostics development of a common strategy for southern & eastern Africa. **J S Afr Vet Assoc** 1995 Sep;66(3):121-50

Developments in diagnosis: a review of the CVL's centenary year [news] **Vet Rec** 1995 Sep 9;137(11):254-5

Wildlife diseases [letter] Boardman SI, et al. **Vet Rec** 1996 Jan 13;138(2):48

[Diagnostic and pathophysiological aspects of the determination of kidney function in animals (corrected and republished with original paging, article originally printed

in Zentralbl Veterinarmed A 1994 May;41(4):253–67)] Reder S, et al. **Zentralbl Veterinarmed A** 1995 May; 42(3):253–67 (56 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Veterinary use of new quinolones in Japan. Nakamura S. **Drugs** 1995;49 Suppl 2:152–8 (41 ref.)

ECONOMICS

Impact and risk of foreign animal diseases. Brown CC, et al. **J Am Vet Med Assoc** 1996 Apr 1;208(7):1038–40 (16 ref.)

EPIDEMIOLOGY

Animal health monitoring and surveillance in Switzerland. Stärk KD. **Aust Vet J** 1996 Mar;73(3):96–7 (14 ref.)

Metabolic profiles and risks of diseases in camels in temperature conditions. Faye B, et al. **Comp Biochem Physiol A Physiol** 1995 Sep;112(1):67–73

Socio-economic aspects of animal diseases in southern Africa: research priorities in veterinary science. Krecek RC, et al. **J S Afr Vet Assoc** 1995 Sep;66(3):115–20

Surveillance of wild animal diseases in Europe. Leighton A. **Rev Sci Tech** 1995 Sep;14(3):819–30

International disease surveillance: January to March 1995. **Vet Rec** 1995 Aug 12;137(7):157

International disease surveillance: July to September 1995. **Vet Rec** 1995 Dec 9;137(24):604

[Reinforcement epidemiologic and economic expertise in health care for animals (news)] Verheijden JH. **Tijdschr Diergeneeskd** 1996 Jun 1;121(11):328 **(Dut)**

[Cause of diseases and death in New World camelids] Hänichen T, et al. **Tierarztl Prax** 1995 Oct;23(5):515–20 (Eng. Abstr.) **(Ger)**

GENETICS

Animal selection and breeding techniques that create diseased populations and compromise welfare. Ott RS. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1969–74 (48 ref.)

HISTORY

History and future perspectives of the use of disinfectants in animal health. King LJ. **Rev Sci Tech** 1995 Mar; 14(1):41–6

MORTALITY

Observations on neonatal mortality of the Chacoan peccary, Catagonus wagneri. Benirschke K, et al. **Vet Pathol** 1995 Sep;32(5):532–4

Clinical and clinical laboratory correlates in sea otters dying unexpectedly in rehabilitation centers following the Exxon Valdez oil spill. Rebar AH, et al. **Vet Pathol** 1995 Jul; 32(4):346–50

PHYSIOPATHOLOGY

[Diagnostic and pathophysiological aspects of the determination of kidney function in animals (corrected and republished with original paging, article originally printed in Zentralbl Veterinarmed A 1994 May;41(4):253–67)] Reder S, et al. **Zentralbl Veterinarmed A** 1995 May; 42(3):253–67 (56 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Application of risk assessment to international trade in animals and animal products. Metcalf HE, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:280–95

Production of veterinary vaccines in the Sudan. Babiker SH. **Berl Munch Tierarztl Wochenschr** 1996 Jan;109(1):8–9

The role of food animal practitioners in control and eradication of diseases. Herrick JB. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1966–7

Time to ban all antibiotics as animal growth-promoting agents? [letter] van den Bogaard AE, et al. **Lancet** 1996 Aug 31;348(9027):619

Future of biotechnology-based control of disease in marine invertebrates. Mialhe E, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):275–83

Environmental considerations of disinfectants used in agriculture. Bruins G, et al. **Rev Sci Tech** 1995 Mar; 14(1):81–94 (15 ref.)

Risks related to the introduction of exotic diseases: a European view. Janssen J, et al. **Rev Sci Tech** 1995 Dec; 14(4):957–61

General disinfection guidelines. Kahrs RF. **Rev Sci Tech** 1995 Mar;14(1):105–63 **(Eng, Fre, Spa)**

Disinfection of trucks and trailers. Mateost Poumian A. **Rev Sci Tech** 1995 Mar;14(1):165–76 (4 ref.) **(Eng, Spa)**

Risk of introducing exotic disease through importation of animals and animal products. Metcalf HE, et al. **Rev Sci Tech** 1995 Dec;14(4):951–6 (12 ref.)

[Farewell Andries van Foreest combined with Specialists' Day. Zoo-veterinarian relationship central in Ouwehand] Ubbink S. **Tijdschr Diergeneeskd** 1996 Jun 15;121(12):356–9 **(Dut)**

[The importance of tropical animal hygiene for indigenous animal production] Böhnel H. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):443–6 (6 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Socio-economic aspects of animal diseases in southern Africa: research priorities in veterinary science. Krecek RC, et al. **J S Afr Vet Assoc** 1995 Sep;66(3):115–20

TRANSMISSION

The role of dipterous insects in the mechanical transmission of animal viruses. Carn VM. **Br Vet J** 1996 Jul; 152(4):377–93 (55 ref.)

VIROLOGY

Special issue: Veterinary virology in Australia, the French connection. In honor of the 80th birthday of Dr. Eric French. Conference proceedings. Sidney, Australia, 9–11 July 1994. **Vet Microbiol** 1995 Sep;46(1–3):1–346

ANIMAL FEED

Effect of casein-based semi-synthetic food on renal acid excretion and acid-base state of blood in dogs. Zijlstra WG, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:179–83

Modifying the fatty acid profile of dairy products through feedlot technology lowers plasma cholesterol of humans consuming the products. Noakes M, et al. **Am J Clin Nutr** 1996 Jan;63(1):42–6

Bronchiolitis obliterans in an animal feed worker. Spain BA, et al. **Am J Ind Med** 1995 Sep;28(3):437–43

Galanin and the galanin antagonist M40 do not change fat intake in a fat-chow choice paradigm in rats. Corwin RL, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R511–8

Hepatic glycogen accurately reflected by acetaminophen glucuronide in dogs refed after fasting. Rother KI, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):E766–73

Influence of four diets on uric acid metabolism and endogenous acid production in healthy beagles. Bartges JW, et al. **Am J Vet Res** 1996 Mar;57(3):324–8

Effects of animal and soy fats and proteins in the diet on fatty acid concentrations in the serum and skin of dogs. Campbell KL, et al. **Am J Vet Res** 1995 Nov;56(11):1465–9

Evaluation of health and ruminal variables during adaptation to grain-based diets in beef cattle. Leedle JA, et al. **Am J Vet Res** 1995 Jul;56(7):885–92

Performance traits, hoof mineral composition, and hoof characteristics of bulls in a 112-day postweaning feedlot performance test. Sugg JL, et al. **Am J Vet Res** 1996 Mar; 57(3):291–5

The energy value for and nutritive value of para-rubber seed for rats. Fetuga BL, et al. **Arch Tierernahr** 1993;45(1):71–8

Influence of lasalocid, cationomycin and feeding frequency on the postprandial kinetics of some plasma parameters in the rumen vein, portal vein and mesenteric artery of sheep. Gomez L, et al. **Arch Tierernahr** 1995;48(4):357–66

The effect of dietary energy and protein concentration and feeding level on feed utilization and body composition of carp (Cyprinus carpio L.). Kim HH, et al. **Arch Tierernahr** 1995;48(1–2):221–9

Influence of grass source on net flux of nutrients across splanchnic tissues in sheep with restricted intake. Patil AR, et al. **Arch Tierernahr** 1995;48(3):257–69

Digestion characteristics by beef cattle consuming bermudagrass or bromegrass hay alone or with alfalfa and(or) corn. Sun W, et al. **Arch Tierernahr** 1993; 45(3):263–79

Effects of Fusarium moniliforme culture material containing known levels of fumonisin B1 in ducklings. Bermudez AJ, et al. **Avian Dis** 1995 Oct–Dec;39(4):879–86

Natural diets for Hermissenda crassicornis mariculture. Avila C, et al. **Biol Bull** 1995 Oct–Nov;189(2):237–8

Creutzfeldt–Jakob disease and bovine spongiform encephalopathy. Incidence of bovine spongiform encephalopathy is higher in cows born after feed ban [letter; comment] Bennett M. **BMJ** 1996 Mar 30;312(7034):843–4 . Comment on: BMJ 1996 Jan 20;312(7024):180–1.

Diet selection in sheep: the role of the rumen environment in the selection of a diet from two feeds that differ in their energy density. Cooper SD, et al. **Br J Nutr** 1995 Jul; 74(1):39–54

Digestive adaptations of rats given white bread and cooked haricot beans (Phaseolus vulgaris): large-bowel fermentation and digestion of complex carbohydrates. Key FB, et al. **Br J Nutr** 1995 Sep;74(3):393–406

The fate of absorbed and exogenous ammonia as influenced by forage or forage-concentrate diets in growing sheep. Lobley GE, et al. **Br J Nutr** 1996 Aug;76(2):231–48

Intake, digestion and small intestinal protein availability in sheep in relation to ammoniation of wheat straw with or without protein supplementation. Oosting SJ, et al. **Br J Nutr** 1995 Sep;74(3):347–68

The nutritive value of stackburned yellow maize for livestock: tests in vitro and in broiler chicks. Panigrahi S, et al. **Br J Nutr** 1996 Jul;76(1):97–108

Effects of three microbial probiotics on postprandial porto-arterial concentration differences of glucose, galactose and amino-nitrogen in the young pig. Rychen G, et al. **Br J Nutr** 1995 Jul;74(1):19–26

Effect of dried Bacillus subtilis culture on growth, body composition and hepatic lipogenic enzyme activity in female broiler chicks. Santoso U, et al. **Br J Nutr** 1995 Oct;74(4):523–9

Dietary factors affecting the maximum feed intake and the body composition of pre-ruminant kid goats of the Granadina breed. Sanz Sampelayo MR, et al. **Br J Nutr** 1995 Sep;74(3):335–45

Ability of mathematical models to predict faecal output with a pulse dose of indigestible marker. Susmel P, et al. **Br J Nutr** 1996 Apr;75(4):521–32

Screening tests of the protein quality of grain legumes for poultry production. Wiryawan KG, et al. **Br J Nutr** 1995 Nov;74(5):671–9

Nutritive activity of soluble rice brain arabinoxylans in broiler diets. Annison G, et al. **Br Poult Sci** 1995 Jul; 36(3):479–88

Irradiation-induced off-odour in chicken and its possible control. Patterson RL, et al. **Br Poult Sci** 1995 Jul; 36(3):425–41

Interaction between dietary 1,25-dihydroxycholecalciferol and calcium and effects of management on the occurrence of tibial dyschondroplasia, leg abnormalities and performance in broiler chickens. Rennie JS, et al. **Br Poult Sci** 1995 Jul;36(3):465–77

Food intake and growth in chickens given food in the wet form with and without access to drinking water. Yalda AY, et al. **Br Poult Sci** 1995 Jul;36(3):357–69

Effect of age and carcase composition on the onset of sexual maturity in quail under normal feeding regimens. Yannakopoulos AL, et al. **Br Poult Sci** 1995 Dec; 36(5):771–7

Pigs experimentally infected with Serpulina hyodysenteriae can be protected from developing swine dysentery by feeding them a highly digestible diet. Siba PM, et al. **Epidemiol Infect** 1996 Apr;116(2):207–16

Effect of diet on the excretion profile of ivermectin in cattle faeces. Cook DF, et al. **Int J Parasitol** 1996 Mar;26(3):291–5

Influence of diet type on the kinetic disposition of fenbendazole in cattle and buffalo. Sanyal PK, et al. **Int J Parasitol** 1995 Oct;25(10):1201–5

Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans? [letter; comment] Donnelly JP, et al. **J Antimicrob Chemother** 1996 Feb; 37(2):389–92. Comment on: J Antimicrob Chemother 1994 Oct;34(4):507–14.

Effect of roasted soybeans and corn on performance and ruminal and blood metabolites of dairy calves. Abdelgadir IE, et al. **J Dairy Sci** 1996 Mar;79(3):465–74

Effect of processing sorghum grain on dairy calf performance. Abdelgadir IE, et al. **J Dairy Sci** 1995 Sep; 78(9):2040–6

Effect of administration of bifidobacteria and lactic acid bacteria to newborn calves and piglets. Abe F, et al. **J Dairy Sci** 1995 Dec;78(12):2838–46

Responses in urea and true protein of milk to different protein feeding schemes for dairy cows. Baker LD, et al. **J Dairy Sci** 1995 Nov;78(11):2424–34

Influence of by-product feeds and tallow on lactation performance of Holstein cows during two seasons. Bateman HG 2nd, et al. **J Dairy Sci** 1996 Jan;79(1):114–20

Apparent digestibility of minerals by lactating cows from a total mixed ration supplemented with poultry litter. Ben-Ghedalia D, et al. **J Dairy Sci** 1996 Mar;79(3):454–8

Supplemental niacin and heat-treated whole soybeans for Jersey cows during early lactation. Bernard JK, et al. **J Dairy Sci** 1995 Sep;78(9):2016–23

Effect of enzyme treatment or steam-flaking of sorghum grain on lactation and digestion in dairy cows. Chen KH, et al. **J Dairy Sci** 1995 Aug;78(8):1721–7

Effect of Lactobacillus acidophilus supplementation of milk replacer on preweaning performance of calves. Cruywagen CW, et al. **J Dairy Sci** 1996 Mar;79(3):483–6

Influence of source and amount of dietary protein on milk yield by cows in early lactation. Cunningham KD, et al. **J Dairy Sci** 1996 Apr;79(4):620–30

The effects of changing ration ingredients on acid–base status, renal function, and macromineral metabolism. Delaquis AM, et al. **J Dairy Sci** 1995 Sep;78(9):2024–39

The lactational responses of dairy cows to amount of feed and to the source of carbohydrate energy. Friggens N, et al. **J Dairy Sci** 1995 Aug;78(8):1734–44

Milk fat depression, the glucogenic theory, and trans-C18:1 fatty acids. Gaynor PJ, et al. **J Dairy Sci** 1995 Sep; 78(9):2008–15

A study of the use of milk replacers for dairy calves in the United States. Heinrichs AJ, et al. **J Dairy Sci** 1995 Dec; 78(12):2831–7

Effects of forage percentage and canola seed on ruminal protein metabolism and duodenal flows of amino acids in steers. Hussein HS, et al. **J Dairy Sci** 1996 Jan;79(1):98–104

Effects of chemical treatment of whole canola seed on digestion of long-chain fatty acids by steers fed high or low forage diets. Hussein HS, et al. **J Dairy Sci** 1996 Jan; 79(1):87–97

Duodenal flow of microbial and feed nitrogen in sheep fed normal soybean meal or soybean meal treated with modified zein. Ivan M, et al. **J Dairy Sci** 1996 Jan; 79(1):121–6

Occurrence of conjugated cis-9,trans-11-octadecadienoic acid in bovine milk: effects of feed and dietary regimen. Jiang J, et al. **J Dairy Sci** 1996 Mar;79(3):438–45

Prediction of protein degradation of forages from solubility fractions. Kohn RA, et al. **J Dairy Sci** 1995 Aug; 78(8):1774–88

Effect of plant maturity and preservation method on in vitro protein degradation of forages. Kohn RA, et al.

J Dairy Sci 1995 Jul;78(7):1544–51

Effects of processing method on degradation characteristics of protein and carbohydrate sources in situ. Lykos T, et al. **J Dairy Sci** 1995 Aug;78(8):1789–801

Influence of moist heat treatment on ruminal and intestinal disappearance of amino acids from canola meal. Moshtaghi Nia SA, et al. **J Dairy Sci** 1995 Jul;78(7):1552–60

Ruminal fermentation and passage of nutrients to the duodenum of lactating cows fed mixtures of corn and barley. Overton TR, et al. **J Dairy Sci** 1995 Sep; 78(9):1981–98

Fatty acid digestion in lactating dairy cows fed fats varying in degree of saturation and different fiber sources. Pantoja J, et al. **J Dairy Sci** 1996 Apr;79(4):575–84

Validity of using accumulated gas pressure readings to measure forage digestion in vitro: a comparison involving three forages. Schofield P, et al. **J Dairy Sci** 1995 Oct; 78(10):2230–8

Influence of steam–flaked sorghum grain and supplemental fat on performance of dairy cows in early lactation. Simas JM, et al. **J Dairy Sci** 1995 Jul;78(7):1526–33

Full lactation response of cows fed diets with different sources and amounts of fiber and ruminal degradable protein. Weiss WP. **J Dairy Sci** 1995 Aug;78(8):1802–14

Effect of forage to concentrate ratio on disappearance of vitamins A and E during in vitro ruminal fermentation. Weiss WP, et al. **J Dairy Sci** 1995 Aug;78(8):1837–42

Responses of early lactation cows fed winter and summer annual forages and undegradable intake protein. Wheeler JG, et al. **J Dairy Sci** 1995 Dec;78(12):2767–81

Effects of inoculation and wilting on the preservation and utilization of wheat forage. Williams CC, et al. **J Dairy Sci** 1995 Aug;78(8):1755–65

Feeding enrichment and body weight in captive chimpanzees. Brent L. **J Med Primatol** 1995 Jan;24(1):12–6

A recipe for the preparation of a rodent food that eliminates chlorophyll–based tissue fluorescence [news] Holmes H, et al. **J Photochem Photobiol B** 1995 Aug;29(2–3):199

Type C botulism in sheep associated with the feeding of poultry litter [letter] van der Lugt JJ, et al. **J S Afr Vet Assoc** 1996 Mar;67(1):3–4

Serum vitamin A (retinol) reduction in broiler chicks on feed amended with Fusarium proliferatum culture material or fumonisin B1 and moniliformin. Hall JO, et al. **J Vet Diagn Invest** 1995 Jul;7(3):416–8

Serohematologic alterations in broiler chicks on feed amended with Fusarium proliferatum culture material on fumonisin B1 and moniliformin. Javed T, et al. **J Vet Diagn Invest** 1995 Oct;7(4):520–6

Pathology of experimentally induced chronic selenosis (alkali disease) in yearling cattle. O'Toole D, et al. **J Vet Diagn Invest** 1995 Jul;7(3):364–73

Medical management of right dorsal colitis in 5 horses: a retrospective study (1987–1993). Cohen ND, et al. **J Vet Intern Med** 1995 Jul–Aug;9(4):272–6

Effects of fasting and refeeding on some metabolic characteristics of rat brown adipose tissue. Nagashima Y, et al. **Jpn J Physiol** 1995;45(4):645–58

Failure to transmit bovine spongiform encephalopathy to marmosets with ruminant–derived meal [letter] Ridley RM, et al. **Lancet** 1996 Jul 6;348(9019):56

Avoparcin and animal feedstuff [letter] Wise R. **Lancet** 1996 Jun 29;347(9018):1835

The UK epidemic of BSE: slow virus or chronic pesticide–initiated modification of the prion protein? Part 2: An epidemiological perspective. Purdey M. **Med Hypotheses** 1996 May;46(5):445–54

A simple, sterile food source for rearing the larvae of Lucilia sericata (Diptera: Calliphoridae). Sherman RA, et al. **Med Vet Entomol** 1995 Oct;9(4):393–8

Did UK 'dump' contaminated feed after ban? [news] Butler D. **Nature** 1996 Jun 13;381(6583):544–5

The effect(s) of carbaryl–treated seed on body maintenance and survival of the multi–mammate mouse, Mastomys natalensis (sensu lato). Neluvhalani MJ, et al. **Onderstepoort J Vet Res** 1995 Dec;62(4):235–40

Feeding patterns of lactating cows of three different breeds fed hay, corn silage, and grass silage. Senn M, et al. **Physiol Behav** 1995 Aug;58(2):229–36

Effect of stress and food variety on food intake in male and female rats. Zylan KD, et al. **Physiol Behav** 1996 Jan; 59(1):165–9

Effects of strain and rearing dietary regimens on brown–egg pullet growth and strain, rearing dietary regimens, density, and feeder space effects on subsequent laying performance. Anderson KE, et al. **Poult Sci** 1995 Jul;74(7):1079–92

Yolk thiobarbituric acid reactive substances and n–3 fatty acids in response to whole and ground flaxseed. Aymond WM, et al. **Poult Sci** 1995 Aug;74(8):1388–94

The effect of enzyme predigestion on the quality of poultry by–product meal from whole turkey mortality. Barbour GW, et al. **Poult Sci** 1995 Jul;74(7):1180–90

Improving phosphorus availability in soybean meal for broilers by supplemental phytase. Denbow DM, et al. **Poult Sci** 1995 Nov;74(11):1831–42

Effect of feeding raw and treated common vetch seed (Vicia sativa) on the performance and egg quality parameters of laying hens. Farran MT, et al. **Poult Sci** 1995 Oct; 74(10):1630–5

Dietary formulation with cottonseed meal on a total amino acid versus a digestible amino acid basis. Fernandez SR, et al. **Poult Sci** 1995 Jul;74(7):1168–79

Removal of the alpha–galactosides of sucrose from soybean meal using either ethanol extraction or exogenous alpha–galactosidase and broiler performance. Irish GG, et al. **Poult Sci** 1995 Sep;74(9):1484–94

Effects of feeding fumonisin B1 present in Fusarium moniliforme culture material and aflatoxin singly and in combination to turkey poults. Kubena LF, et al. **Poult Sci** 1995 Aug;74(8):1295–303

Chemical and physical evaluations of commercial dicalcium phosphates as sources of phosphorus in animal nutrition. Lima FR, et al. **Poult Sci** 1995 Oct;74(10):1659–70

Tolerance of turkeys to diets high in trypsin inhibitor activity from undertoasted soybean meals. Mian MA, et al. **Poult Sci** 1995 Jul;74(7):1126–33

Response of turkey poults to tiered levels of Natuphos phytase added to soybean meal–based semi–purified diets containing three levels of nonphytate phosphorus. Ravindran V, et al. **Poult Sci** 1995 Nov;74(11):1843–54

Endogenous amylase levels and response to supplemental feed enzymes in male turkeys from hatch to eight weeks of age. Ritz CW, et al. **Poult Sci** 1995 Aug;74(8):1317–22

Effects of protein level and enzyme supplementation upon growth and rate of digesta passage of male turkeys. Ritz CW, et al. **Poult Sci** 1995 Aug;74(8):1323–8

Growth and intestinal morphology of male turkeys as influenced by dietary supplementation of amylase and xylanase. Ritz CW, et al. **Poult Sci** 1995 Aug;74(8):1329–34

Dates and date pits as ingredients in broiler starting and coturnix quail breeder diets. Vandepopuliere JM, et al. **Poult Sci** 1995 Jul;74(7):1134–42

Replacing protein in corn–soybean turkey diets with methionine and lysine. Waibel PE, et al. **Poult Sci** 1995 Jul;74(7):1143–58

Comparison of dietary 25–hydroxycholecalciferol and cholecalciferol in broiler chickens. Yarger JG, et al. **Poult Sci** 1995 Jul;74(7):1159–67

The use of an in vitro technique to predict the absorption of dietary radiocaesium by sheep. Beresford NA, et al. **Radiat Environ Biophys** 1995 Aug;34(3):191–4

Urinary iodine level as an intake indicator in dairy cows. Herzig I, et al. **Vet Med (Praha)** 1996 Apr;41(4):97–101

The contribution of lectins to the interaction between oral Newcastle disease vaccine and grains. Rehmani SF, et al. **Vet Microbiol** 1995 Sep;46(1–3):55–62

A 4–year study on the effectiveness of alternate grazing of cattle and sheep in the control of bovine parasitic gastro–enteritis. Bairden K, et al. **Vet Parasitol** 1995 Nov; 60(1–2):119–32

The combined effect of fenbendazole treatment and a move to aftermath 7 or 9 weeks after turnout on Dictyocaulus viviparus infections in calves. Eysker M, et al. **Vet Parasitol** 1995 Dec;60(3–4):339–48

Control of BSE: MAFF tightens up on feed production [news] **Vet Rec** 1995 Jul 29;137(5):107

Effect of hammer mill screen size and addition of fibre or S–methylmethionine–sulphonium chloride to the diet on the occurrence of oesophagogastric lesions in fattening pigs. Elbers AR, et al. **Vet Rec** 1995 Sep 16;137(12):290–3

Companion animal diets [letter] Gildersleeve J. **Vet Rec** 1996 Mar 9;138(10):239

Companion animal diets [letter] Sauvage JP. **Vet Rec** 1996 Mar 9;138(10):239

Longevity and diet [letter] Watson D. **Vet Rec** 1996 Jan 20; 138(3):71

Effect of dietary canola oil and its degree of oxidation on exocrine pancreatic secretions in growing pigs. Ozimek L, et al. **Z Ernahrungswiss** 1995 Sep;34(3):224–30

Effects of dietary soybean and cowpea on gut morphology and faecal composition in creep and noncreep–fed pigs. Makinde MO, et al. **Zentralbl Veterinarmed A** 1996 Apr; 43(2):75–85

[Effect of growth rate of lucerne on the degradability of crude protein in the rumen and on in vitro digestibility of non–degraded crude protein] Chrenková M, et al. **Arch Tierernahr** 1993;45(3):281–91 (Eng. Abstr.) **(Ger)**

[Hydrocarbon content in the fat of meat pigs after feeding "Fermosin"] Henk G, et al. **Arch Tierernahr** 1993; 45(1):35–47 (Eng. Abstr.) **(Ger)**

[Effect of feeding protected arginine on food intake, milk yield and growth hormone and amino acid levels in blood plasma of cows during the summer feeding period with grass] Kirchgessner M, et al. **Arch Tierernahr** 1993; 45(1):57–69 (Eng. Abstr.) **(Ger)**

[Methodical investigations on evaluation of lysine utilization in pigs after extreme changes of protein quantity and quality] Liebert F. **Arch Tierernahr** 1995;48(4):319–27 (Eng. Abstr.) **(Ger)**

[Use of microbial phytase at different phosphorus supply levels in broiler fattening. 1. Effect on fattening performance and tibia stability] Richter G. **Arch Tierernahr** 1993;45(3):235–44 (Eng. Abstr.) **(Ger)**

[Toasted rapeseed meal in broiler fattening diet] Schlöffel J, et al. **Arch Tierernahr** 1993;45(1):79–87 (Eng. Abstr.) **(Ger)**

[Significance of extruded feeds for trout nutrition and water protection] Steffens W. **Arch Tierernahr** 1993;45(3):189–210 (Eng. Abstr.) **(Ger)**

[Furazolidone resistance of E. coli from chicken intestines after prophylactic treatment with bioptivet GB in animal feed] Kobe A, et al. **Berl Munch Tierarztl Wochenschr** 1996 Jan;109(1):14–7 (Eng. Abstr.) **(Ger)**

[Pharmacological effects of hordenine] Hapke HJ, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Jun;102(6):228–32 (Eng. Abstr.) **(Ger)**

[Examination of feed and slurry additives for decrease of ammonia emissions in swine housing] Krieger R, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Aug;102(8):316–20 (Eng. Abstr.) **(Ger)**

[Reducing lipid peroxidation of stored frozen trout fillet by supplementing feed with vitamin E] Gessl H, et al. **Z Ernahrungswiss** 1995 Sep;34(3):198–205 (Eng. Abstr.) **(Ger)**

[B–vitamins (thiamine, vitamin b6, pantothenic acid) in lean muscle tissue of growing cattle of the German Simmental breed under different feeding intensities] Kirchgessner M, et al. **Z Lebensm Unters Forsch** 1995 Jul;201(1):20–4 (Eng. Abstr.) **(Ger)**

[The ipriflavone story] György L, et al. **Acta Pharm Hung** 1995 Nov;65(6):191–4 (20 ref.) (Eng. Abstr.) **(Hun)**

[Effects of feed and mating age on reproductive performance in Syrian hamsters] Satoh M, et al. **Exp Anim** 1995 Oct; 43(5):731–5 (Eng. Abstr.) **(Jpn)**

[Chemical composition of 6 unconventional plants from Oaxaca State, Mexico, as potential resources for animal feed] Arellano ML, et al. **Arch Latinoam Nutr** 1993 Sep; 43(3):264–8 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Laboratory chow–induced insulin resistance: a possible contributor to autoimmune type 1 diabetes in rodents [letter] Storlien LH, et al. **Diabetologia** 1996 May; 39(5):618–20

Responses of dogs with food allergies to single–ingredient dietary provocation. Jeffers JG, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):608–11

A chronic cardiomyopathy in feedlot cattle attributed to toxic levels of salinomycin in the feed. Bastianello SS, et al. **J S Afr Vet Assoc** 1996 Mar;67(1):38–41

Short–term effects of dietary cation:anion balance on bone mineral homeostasis in the bovine. Beighle DE, et al. **J S Afr Vet Assoc** 1995 Jun;66(2):56–60

Liver disease in cattle induced by consumption of moldy hay. Casteel SW, et al. **Vet Hum Toxicol** 1995 Jun; 37(3):248–51

Rape straw as a possible cause of neonatal goitre and weakly calves [letter] Barlow AM, et al. **Vet Rec** 1995 Nov 25; 137(22):572

Growth and oesophagogastric lesions in finishing pigs offered pelleted feed ad libitum. Elbers AR, et al. **Vet Rec** 1995 Jun 10;136(23):588–90

ANALYSIS

Structural responses of Japanese quail intestine to different diets. Starck JM, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Apr;102(4):146–50

Influence of altering ruminal degradation of soybean meal protein on in situ ruminal fiber disappearance of forages and fibrous byproducts. Hussein HS, et al. **J Anim Sci** 1995 Aug;73(8):2428–37

Influence of moisture content of forage on ruminal functional specific gravity and passage of digesta. Neel JP, et al. **J Anim Sci** 1995 Oct;73(10):3094–102

Effects of sodium sulfite on recovery and composition of detergent fiber and lignin. Hintz RW, et al. **J AOAC Int** 1996 Jan–Feb;79(1):16–22

Evaluation of a liquid chromatographic method for the determination of fumonisins in corn, poultry feed, and Fusarium culture material. Rice LG, et al. **J AOAC Int** 1995 Jul–Aug;78(4):1002–9

Determination of shell content in palm kernel cake. Siew WL. **J AOAC Int** 1996 Jan–Feb;79(1):80–2

Short–term effects of dietary cation:anion balance on bone mineral homeostasis in the bovine. Beighle DE, et al. **J S Afr Vet Assoc** 1995 Jun;66(2):56–60

Comparison of four methods for forage nitrate analysis. Bedwell CL, et al. **J Vet Diagn Invest** 1995 Oct;7(4):527–30

Natural co–occurrence of Fusarium toxins and aflatoxin B1 in corn for feed in north Vietnam. Wang DS, et al. **Nat Toxins** 1995;3(6):445–9

Determination of cobalt in vegetable animal foodstuffs by differential pulse adsorptive voltammetry using alpha–benzil dioxime. Giroussi S, et al. **Sci Total Environ** 1995 Dec 22;176(1–3):135–9

The determination of 129I in milk and vegetation using neutron activation analysis. Parry SJ, et al. **Sci Total Environ** 1995 Dec 1;173–174:351–60

Iodine in feeds [letter] Cooke BC. **Vet Rec** 1996 Jan 27; 138(4):96

Detection of beta 2–agonists in milk replacer. Caloni F, et al. **Vet Res Commun** 1995;19(4):285–93

Determination of biogenic amines by RP–HPLC of the dabsyl derivates. Bockhardt A, et al. **Z Lebensm Unters Forsch** 1996 Jul;203(1):65–70

Influence of soya antigen levels in milk replacers on the disruption of intestinal motility patterns in calves sensitive to soya. Lalles JP, et al. **Zentralbl Veterinarmed A** 1995 Sep;42(7):467–78

[The effect of enzyme supplements and high amounts of white lupins on concentrations of lipids in serum and meat in fattening chickens] Eder K, et al. **Arch Tierernahr** 1996; 49(3):221–8 (Eng. Abstr.) **(Ger)**

[Rapeseed and rapeseed meal as components in diets of laying

hens] Richter G, et al. **Arch Tierernahr** 1996;49(3):229–41 (Eng. Abstr.) **(Ger)**

[Glycerol as a feed ingredient for broiler chickens] Simon A, et al. **Arch Tierernahr** 1996;49(2):103–12 (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Effects of pelleting, lactose level, polyethylene glycol 4000, and guar gum compared to pectin on growth performances, energy values, and losses of lactose, lactic acid, and water in chickens. Carré B, et al. **Poult Sci** 1995 Nov; 74(11):1810–9

MICROBIOLOGY

Occurrence of Fusarium species and zearalenone in dairy cattle feeds in Vojvodina. Skrinjar M, et al. **Acta Vet Hung** 1995;43(2–3):259–67

Salmonella isolated from animals and feedstuffs in Sweden during 1988–1992. Malmqvist M, et al. **Acta Vet Scand** 1995; 36(1):21–39

Influence of aflatoxin and fumonisin B1–containing culture material on growing barrows. Harvey RB, et al. **Am J Vet Res** 1995 Dec;56(12):1668–72

Heat destruction of Salmonella in poultry feed: effect of time, temperature, and moisture. Himathongkham S, et al. **Avian Dis** 1996 Jan–Mar;40(1):72–7

Choice of the optimal method for the isolation of Salmonella from meat– and bone powder designed for industrial feed mixtures. Hoszowski A, et al. **Comp Immunol Microbiol Infect Dis** 1995 Sep;18(4):227–37

Occurrence of Fusarium sacchari var. subglutinans and its mycotoxin production ability in broiler feed. Styriak I, et al. **Folia Microbiol (Praha)** 1994;39(6):579–81

A survey of aflatoxins and aflatoxigenic Aspergillus flavus in corn–based products from the Spanish market. Sanchis V, et al. **Microbiol Res** 1995 Nov;150(4):437–40

Occurrence of mycotoxins in cereals and animal feedstuffs in Natal, South Africa 1994. Dutton MF, et al. **Mycopathologia** 1995 Jul;131(1):31–6

POISONING

[A case of sudden death among fattening pigs] Martens MR. **Tijdschr Diergeneeskd** 1995 Aug 15;120(16):466–7 (Eng. Abstr.) **(Dut)**

STANDARDS

Prediction of the net energy content of raw materials and compound feeds for ruminants by different laboratory methods. Aiple KP, et al. **Arch Tierernahr** 1996; 49(3):213–20

Studies on the biotin requirement of broilers fed sunflower seed meal based diets. Oloyo RA. **Arch Tierernahr** 1994; 45(4):345–53

Evaluation of potential sources of proteins in diets for rainbow trout (Oncorhynchus mykiss). Pfeffer E, et al. **Arch Tierernahr** 1994;45(4):371–7

Opinion on possible ban on ruminant by–products in ruminant feeds [letter] Scott GC. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1958

Effects of fill volume of diets on digestive tract kinetics and fattening pattern of growing Holstein–Friesian bull calves. Aharoni Y, et al. **J Anim Sci** 1995 Aug;73(8):2418–27

Forage systems for beef production from conception to slaughter: III. Finishing systems. Allen VG, et al. **J Anim Sci** 1996 Mar;74(3):625–38

Effect of intravenous glucose infusion on metabolism of portal–drained viscera in sheep fed a cereal/straw–based diet. Balcells J, et al. **J Anim Sci** 1995 Jul;73(7):2146–55

Performance, carcass yield, and carcass quality characteristics of steers finished on rhizoma peanut (Arachis glabrata)–tropical grass pasture or concentrate. Bennett LL, et al. **J Anim Sci** 1995 Jul;73(7):1881–7

In situ particle size reduction as affected by forage species and grinding mesh size. Bowman JG, et al. **J Anim Sci** 1996 Feb;74(2):439–46

Effects of barley variety and processing methods on feedlot steer performance and carcass characteristics. Bradshaw WL, et al. **J Anim Sci** 1996 Jan;74(1):18–24

Urea ammoniation effects on the feeding value of guineagrass (Panicum maximum) hay. Brown WF, et al. **J Anim Sci** 1995 Oct;73(10):3085–93

Persistence of the effects of early experience on consumption of low–quality roughage by sheep. Distel RA, et al. **J Anim Sci** 1996 May;74(5):965–8

Effects of previous grazing treatment and consumption of locoweed on liver mineral concentrations in beef steers. Galyean ML, et al. **J Anim Sci** 1996 Apr;74(4):827–33

Spent cellulose casings as potential feed ingredients for ruminants. Gentry JL, et al. **J Anim Sci** 1996 Mar; 74(3):663–71

Forage characteristics, steer performance, and water quality from bermudagrass pastures fertilized with two levels of nitrogen from swine lagoon effluent. Harvey RW, et al. **J Anim Sci** 1996 Feb;74(2):457–64

Supplemental cracked corn or wheat bran for steers grazing endophyte–free fescue pasture: effects on live weight gain, nutrient quality, forage intake, particulate and fluid kinetics, ruminal fermentation, and digestion. Hess BW, et al. **J Anim Sci** 1996 May;74(5):1116–25

Cattle grazing a riparian mountain meadow: effects of low and moderate stocking density on nutrition, behavior, diet selection, and plant growth response. Huber SA, et al. **J Anim Sci** 1995 Dec;73(12):3752–65

Effects of forage level and canola seed supplementation on site and extent of digestion of organic matter, carbohydrates, and energy by steers. Hussein HS, et al. **J Anim Sci** 1995 Aug;73(8):2458–68

Composition of ruminal bacteria harvested from steers as influenced by dietary forage level and fat supplementation. Hussein HS, et al. **J Anim Sci** 1995 Aug;73(8):2469–73

Feedlot performance and carcass characteristics of Holstein steers as affected by source of dietary protein and level of ruminally protected lysine and methionine. Hussein HS, et al. **J Anim Sci** 1995 Dec;73(12):3503–9

Characteristics of plant cell walls affecting intake and digestibility of forages by ruminants. Jung HG, et al. **J Anim Sci** 1995 Sep;73(9):2774–90 (147 ref.)

Influence of grain type, tallow level, and tallow feeding system on feedlot cattle performance. Krehbiel CR, et al. **J Anim Sci** 1995 Oct;73(10):2916–21

Nutrient digestibility and growth performance of pigs fed pearl millet as a replacement for corn. Lawrence BV, et al. **J Anim Sci** 1995 Jul;73(7):2026–32

Valine requirement of the finishing pig. Lewis AJ, et al. **J Anim Sci** 1995 Aug;73(8):2315–8

Animal performance and fleece characteristics of Angora goats maintained on western and southern Texas rangeland. Lupton CJ, et al. **J Anim Sci** 1996 Mar;74(3):545–50

Crystalline lysine and threonine supplementation of soft red winter wheat or triticale, low–protein diets for growing–finishing swine. Myer RO, et al. **J Anim Sci** 1996 Mar;74(3):577–83

Value of feather meal in a molasses–based liquid supplement fed to yearling cattle consuming a forage diet. Pate FM, et al. **J Anim Sci** 1995 Oct;73(10):2865–72

Influence of flake density on the feeding value of steam–processed corn in diets for lactating cows. Plascencia A, et al. **J Anim Sci** 1996 Feb;74(2):310–6

Application of nitrogen from swine lagoon effluent to bermudagrass pastures: seasonal changes in forage nitrogenous constituents and effects of energy and escape protein supplementation on beef cattle performance. Rogers JR, et al. **J Anim Sci** 1996 May;74(5):1126–33

Calf production by Angus–Hereford and Brahman–Hereford cows on two native rangeland forage systems. Sims PL, et al. **J Anim Sci** 1995 Oct;73(10):2893–902

Influence of energy or protein supplementation during midpregnancy on forage intake of ewes grazing Montana winter range. Soder KJ, et al. **J Anim Sci** 1995 Oct; 73(10):2853–9

Toxicity and growth–promoting potential of spermine when fed to chicks. Sousadias MG, et al. **J Anim Sci** 1995 Aug; 73(8):2375–81

Evaluation of the potential of supplements to substitute for low–quality, tallgrass–prairie forage. Stafford SD, et al. **J Anim Sci** 1996 Mar;74(3):639–47

Effect of protein level and source in molasses slurries on the performance of growing cattle fed hay during winter. Stateier DA, et al. **J Anim Sci** 1995 Oct;73(10):3078–84

Dietary fiber for cats: in vitro fermentation of selected fiber sources by cat fecal inoculum and in vivo utilization of diets containing selected fiber sources and their blends. Sunvold GD, et al. **J Anim Sci** 1995 Aug;73(8):2329–39

Influence of roughage and grain processing in high–concentrate diets on the performance of long–fed Holstein steers. Traxler MJ, et al. **J Anim Sci** 1995 Jul; 73(7):1888–900

Effects of feeding wash–water solids on health and performance of ewes and lambs. Williams JE, et al. **J Anim Sci** 1995 Dec;73(12):3552–61

Effects of mill type and particle size uniformity on growth performance, nutrient digestibility, and stomach morphology in finishing pigs. Wondra KJ, et al. **J Anim Sci** 1995 Sep;73(9):2564–73

Survival, body weights, feed efficiency, and carcass traits of 3/4 white composite and 1/4 Duroc, 1/4 Meishan, 1/4 Fengjing, or 1/4 Minzhu pigs. Young LD. **J Anim Sci** 1995 Dec;73(12):3534–42

A simple model for predicting the response of chicks to dietary enzyme supplementation. Zhang Z, et al. **J Anim Sci** 1996 Feb;74(2):394–402

The feeding value of soybeans fed to rats, chickens, catfish and dairy cattle is not altered by genetic incorporation of glyphosate tolerance. Hammond BG, et al. **J Nutr** 1996 Mar;126(3):717–27

Normal handling of diets--are all dogs created equal? Zentek J, et al. **J Small Anim Pract** 1995 Aug;36(8):354–9

Overview on community legislation in the field of official control of mycotoxins in feedingstuffs. Verardi G, et al. **Nat Toxins** 1995;3(4):248–56; discussion 280

The performance of commercial broilers when fed various levels of rendered whole–hen meal. Christmas RB, et al. **Poult Sci** 1996 Apr;75(4):536–9

Nutritional value for growing turkeys of corn of light test weight. Hsu LW, et al. **Poult Sci** 1995 Oct;74(10):1703–7

Effects of overprocessing on the nutritional quality of peanut meal. Zhang Y, et al. **Poult Sci** 1996 Apr;75(4):514–8

Whole–body fuel selection in ruminants: nutrient supply and utilization by major tissues. Ortigues I, et al. **Proc Nutr Soc** 1995 Mar;54(1):235–51 (55 ref.)

[Revision evaluation of feed for horses (news)] Hallebeek AJ. **Tijdschr Diergeneeskd** 1995 Sep 15;120(18):546 **(Dut)**

[Determination of the protein quality of food and animal feed] Bergner H. **Arch Tierernahr** 1994;45(4):293–332 (104 ref.) (Eng. Abstr.) **(Ger)**

[Fattening and slaughter values of pigs in relation to their genotype and to the protein source in their feed rations] Jacyno E, et al. **Arch Tierernahr** 1996;49(2):169–79 (Eng. Abstr.) **(Ger)**

TOXICITY

Fatty liver–hemorrhagic syndrome observed in commercial layers fed diets containing chelated minerals. Branton SL, et al. **Avian Dis** 1995 Jul–Sep;39(3):631–5

Apparent selenium toxicity in emus (Dromaius novaehollandiae). Kinder LL, et al. **Avian Dis** 1995 Jul–Sep;39(3):652–7

Physiological responses of rats fed loline and ergot alkaloids from endophyte–infected tall fescue. Jackson JA, et al. **Drug Chem Toxicol** 1996;19(1–2):85–96

Identity and pathogenesis of stomach tumors in Sprague–Dawley rats associated with the dietary administration of butachlor. Hard GC, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):95–105

Toxicity of PCB 77 (3,3',4,4'–tetrachlorobiphenyl) and PCB 118 (2,3',4,4'5–pentachlorobiphenyl) in the rat following subchronic dietary exposure. Chu I, et al. **Fundam Appl Toxicol** 1995 Jul;26(2):282–92

Toxicity and growth–promoting potential of spermine when fed to chicks. Sousadias MG, et al. **J Anim Sci** 1995 Aug; 73(8):2375–81

Safety evaluation of pullulanase enzyme preparation derived from Bacillus licheniformis containing the pullulanase gene from Bacillus deramificans. Modderman JP, et al. **Regul Toxicol Pharmacol** 1995 Jun;21(3):375–81

Response of Bovans chicks to low dietary levels of Linum usitatissimum seeds. Bakhiet AO, et al. **Vet Hum Toxicol** 1995 Dec;37(6):534–6

The effect of feeding dried tomato vines to beef cattle. Shlosberg A, et al. **Vet Hum Toxicol** 1996 Apr;38(2):135–6

ANIMAL HOSPITALS see **HOSPITALS, ANIMAL**

ANIMAL–HUMAN BONDING see **BONDING, HUMAN–PET**

ANIMAL HUSBANDRY

see related

VETERINARY MEDICINE

Onset of spermatogenesis in Corriedale ram lambs under extensive rearing conditions in Uruguay. Castrillejo A, et al. **Acta Vet Scand** 1995;36(2):161–73

Intervention research in agriculture: examples from the swine confinement and respiratory health project. Ferguson KJ, et al. **Am J Ind Med** 1996 Apr;29(4):386–91

Cross fostering between normal and sodium–restricted rats: effects on peripheral gustatory function. Phillips LM, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R603–7

Effects of giardiasis on production in a domestic ruminant (lamb) model. Olson ME, et al. **Am J Vet Res** 1995 Nov; 56(11):1470–4

Determinants of dust and endotoxin exposure of pig farmers: development of a control strategy using empirical modelling. Preller L, et al. **Ann Occup Hyg** 1995 Oct; 39(5):545–57

Bullous pemphigoid complicating human orf. Murphy JK, et al. **Br J Dermatol** 1996 May;134(5):929–30

Interaction between dietary 1,25–dihydroxycholecalciferol and calcium and effects of management on the occurrence of tibial dyschondroplasia, leg abnormalities and performance in broiler chickens. Rennie JS, et al. **Br Poult Sci** 1995 Jul;36(3):465–77

Risk factors associated with the incidence of foal mortality in an extensively managed mare herd. Haas SD, et al. **Can Vet J** 1996 Feb;37(2):91–5

An ethicist's commentary on whether veterinarians should prescribe medications that are neither therapeutic nor prophylactic to increase productivity. Rollin BE. **Can Vet J** 1995 Sep;36(9):535–6

Respiratory function in poultry workers and pharmacologic characterization of poultry dust extract. Zuskin E, et al. **Environ Res** 1995 Jul;70(1):11–9

Pig farmers have signs of bronchial inflammation and increased numbers of lymphocytes and neutrophils in BAL fluid. Pedersen B, et al. **Eur Respir J** 1996 Mar;9(3):524–30

AHI perspectives: flexible drug labeling and its impact on the drug development process. Practical aspects of flexible labeling in feedlots. Apley MD. **J Am Vet Med Assoc** 1995 Oct 1;207(7):901–2; discussion 902–4

More thoughts on animal rights and animal liberation [letter] Blackwell TE. **J Am Vet Med Assoc** 1996 Jan 1;208(1):22

Veterinary nutritional management of amphibians and reptiles. Donoghue S. **J Am Vet Med Assoc** 1996 Jun 1; 208(11):1816–20 (22 ref.)

Commingled grazing as a risk factor for trichomonosis in beef herds. Gay JM, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):643–6

Sources of information for livestock producers. Gehrke BC. **J Am Vet Med Assoc** 1995 Aug 15;207(4):432–3

Epidemiologic study of on–farm management practices associated with prevalence of Mycobacterium paratuberculosis infections in dairy cattle. Goodger WJ, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1877–81

Xenotransplantation and food animal practitioners [see comments] Herrick JB. **J Am Vet Med Assoc** 1996 Mar 15;208(6):826–7. Comment in: J Am Vet Med Assoc 1996 Jun 1;208(11):1788–9.

Opportunities for food animal practitioners to promote human and animal health. Humble JA. **J Am Vet Med Assoc** 1995 Dec 15;207(12):1554–5

American Society of Animal Science, Southern section. New Orleans, Louisiana, January 28–February 1, 1995. Abstracts. **J Anim Sci** 1995;73 Suppl 1:1–361

Environmental considerations of livestock producers. Morse D. **J Anim Sci** 1995 Sep;73(9):2733–40 (35 ref.)

Evaluation of animal welfare by the self–expression of an anxiety state. Carey MP, et al. **Lab Anim** 1995 Oct; 29(4):370–9

The commercial and agricultural applications of animal transgenesis. Ward KA, et al. **Mol Biotechnol** 1995 Oct; 4(2):167–78 (63 ref.)

Contention over growth promoters [news] Maddox J. **Nature** 1995 Dec 7;378(6557):553

When to help farm animals grow faster [news] Maddox J. **Nature** 1995 Oct 5;377(6548):381

Occupational exposure to poultry and prevalence of antibodies against Marek's disease virus and avian leukosis retroviruses. Choudat D, et al. **Occup Environ Med** 1996 Jun;53(6):403–10

The effect of chopped computer and bond paper mixed with wood shavings as a litter material on broiler performance. Martinez DF, et al. **Poult Sci** 1995 Aug;74(8):1395–9

Disinfectants: actions and applications. **Rev Sci Tech** 1995 Jun;14(2):257–477

Sarcoptic mange and production performance of swine: a review of the literature and studies of associations between mite infestation, growth rate and measures of mange severity in growing pigs. Davies PR. **Vet Parasitol** 1995 Dec;60(3–4):249–64 (51 ref.)

Handling of sheep at markets and the incidence of bruising. Jarvis AM, et al. **Vet Rec** 1995 Jun 10;136(23):582–5

[Occurrence of chlorinated pesticides and polychlorinated biphenyls in the stalls and outdoor environment in pig–fattening farms] Raszyk J, et al. **Vet Med (Praha)** 1996 Jun;41(6):165–71 (Eng. Abstr.) **(Cze)**

[Project 'Measuring is Knowledge' (letter)] **Tijdschr Diergeneeskd** 1996 Jun 1;121(11):328–30 **(Dut)**

[Certification (letter)] Beijer A. **Tijdschr Diergeneeskd** 1995 Nov 1;120(21):630 **(Dut)**

[Electric fences for cattle: danger for children? (letter)] Hébert JC. **Arch Pediatr** 1996 Jan;3(1):88 **(Fre)**

[The use of anabolic hormones and growth promoters in meat production and its consequences to man] Maghuin–Rogister G. **J Pharm Belg** 1995 Sep–Oct;50(5):455–60 **(Fre)**

[The importance of tropical animal hygiene for indigenous animal production] Böhnel H. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):443–6 (6 ref.) (Eng. Abstr.) **(Ger)**

[Promotion of Moroccan national agricultural research in the area of sheep production—a project of German development cooperation] Morkramer G. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):451–6 (Eng. Abstr.) **(Ger)**

[Prospects and limits of animal breeding from the physiological aspects] Breves G, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):42–3 (Eng. Abstr.) **(Ger)**

[Results of multi–gas analysis in the raising of fattening swine in composted stalls or on slatted floors] Müller K, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Nov;102(11):443–5 (Eng. Abstr.) **(Ger)**

[Animal welfare for animals kept for animal–supported therapy in homes and hospitals] von Wenzlawowicz C. **DTW Dtsch Tierarztl Wochenschr** 1995 Nov;102(11):425–6 (Eng. Abstr.) **(Ger)**

[Care of pregnancy and prevention of lamb diseases in goats] Elze K, et al. **Tierarztl Prax** 1995 Dec;23(6):559–64 (Eng. Abstr.) **(Ger)**

[Invention of a forced–air–ventilated micro–isolation cage and rack system—environment within cages: temperature and ammonia concentration] Yoshida K, et al. **Exp Anim** 1995 Oct;43(5):703–10 (Eng. Abstr.) **(Jpn)**

[Pulmonary function in Norwegian farmers keeping domestic animals] Varslot M, et al. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1077–80 (Eng. Abstr.) **(Nor)**

[Prevalence of allergic diseases in workers of industrial swine breeding] Fedotova EV, et al. **Med Tr Prom Ekol** 1995; (8):32–3 (Eng. Abstr.) **(Rus)**

[Increased resistance after administration of antibiotics to animals] Franklin A. **Lakartidningen** 1996 Apr 24; 93(17):1627–30 (21 ref.) **(Swe)**

ECONOMICS

Simulation of the economic impact of proliferative enteritis on pig production in Australia. Holyoake PK, et al. **Aust Vet J** 1996 Mar;73(3):89–92

Costs of major parasites to the Australian livestock industries. McLeod RS. **Int J Parasitol** 1995 Nov;25(11):1363–7 (25 ref.)

Use of performance ratios to calculate the economic impact of thin cows in a beef cattle herd. Wikse SE, et al. **J Am Vet Med Assoc** 1995 Nov 15;207(10):1292–7

Measuring financial performance: an overview of financial statements. Dalsted NL. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):293–311 (2 ref.)

SPA: marketing and financial performance measures for the cow–calf enterprise. Gutierrez PH. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):313–60 (3 ref.)

Farm Financial Standards. McGrann JM. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):279–91 (3 ref.)

Stocker/feeder cattle standardized performance analysis. McGrann JM, et al. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):361–73 (3 ref.)

EDUCATION

Instructing the animal physiology graduate student in human assisted reproductive technology. Boone WR, et al. **J Anim Sci** 1995 Aug;73(8):2503–6

Changing paradigms in animal agriculture: the role of academia and industry in technology transfer. Braund DG. **J Anim Sci** 1995 Oct;73(10):3173–7

Beef Quality Assurance education via satellite videoconference. Shulaw WP, et al. **J Anim Sci** 1995 Oct; 73(10):3182–8

HISTORY

The history of IRM and SPA. Corah LR. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):191–8 (8 ref.)

INSTRUMENTATION

[Testing of various drinking troughs in consideration of the physiological drinking behavior of rabbits] Drescher B, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Sep;102(9):365–9 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Food safety equation begins on farm [news] Reed CA. **J Am Vet Med Assoc** 1995 Nov 1;207(9):1153

[Value of the IBR–free certificate] Holman H. **Tijdschr Diergeneeskd** 1995 Sep 1;120(17):505 **(Dut)**

[Perspectives on fair legislation for the assurance of animal health in the countries of the European Union] Bätza HJ. **DTW Dtsch Tierarztl Wochenschr** 1995 Jul;102(7):288–93 (Eng. Abstr.) **(Ger)**

[Preventative tail amputation in fattening bulls] Busch B, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar; 102(3):127–9 (Eng. Abstr.) **(Ger)**

METHODS

Welfare in Danish dairy herds 3. Health management and general routines in 1983 and 1994. Agger JF, et al. **Acta Vet Scand** 1996;37(1):79–97

Examination of egg number and egg weight variables and their effects on daily management in aviary systems for laying hens. Lokhorst C, et al. **Br Poult Sci** 1995 Dec; 36(5):693–705

Bloodless castration of lambs: results of a questionnaire [see comments] Hosie BD, et al. **Br Vet J** 1996 Jan;152(1):47–55 . Comment in: Br Vet J 1996 Jan;152(1):7–9.

Deodorization of laboratory animal facilities by ozone. Pan TM, et al. **Exp Anim** 1995 Jul;44(3):255–9

Control charts and the value of statistical inference for food animal practitioners. Humble JA. **J Am Vet Med Assoc** 1996 Apr 15;208(8):1232–3

Forage systems for beef production from conception to slaughter: III. Finishing systems. Allen VG, et al. **J Anim Sci** 1996 Mar;74(3):625–38

An evaluation of estrus synchronization programs in reproductive management of dairy herds. Ryan DP, et al. **J Anim Sci** 1995 Dec;73(12):3687–95

An investigation into the effects of solid or grid cage flooring on the welfare of laboratory rats. Manser CE, et al. **Lab Anim** 1995 Oct;29(4):353–63

Behaviour of rats in their home cages: daytime variations and effects of routine husbandry procedures analysed by time sampling techniques. Saibaba P, et al. **Lab Anim** 1996 Jan;30(1):13–21

Exposure to sheep dip and the incidence of acute symptoms in a group of Welsh sheep farmers. Rees H. **Occup Environ Med** 1996 Apr;53(4):258–63

Successful application of deltamethrin pour on to cattle in a campaign against tsetse flies (Glossina spp.) in the pastoral zone of Samorogouan, Burkina Faso. Bauer B, et al. **Trop Med Parasitol** 1995 Sep;46(3):183–9

The prevalence of abnormal behaviours in dressage, eventing and endurance horses in relation to stabling. McGreevy PD, et al. **Vet Rec** 1995 Jul 8;137(2):36–7

[Comparative studies of the release and ability to survive of game pheasants (Phasianus colchicus sp.) from intensive and extensive husbandry] Sodeikat G, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):112–6 (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

[50–year anniversary Group Poultry Sciences. Poultry practice at the turn of the century] Ubbink S. **Tijdschr Diergeneeskd** 1996 May 15;121(10):292–5 **(Dut)**

[Veterinary medicine after 2002] Wentink GH. **Tijdschr Diergeneeskd** 1996 Jan 1;121(1):12–3 **(Dut)**

[Effect of structural changes in animal husbandry on the environment due to wastes and residues from animal production] Böhm R. **DTW Dtsch Tierarztl Wochenschr** 1995 Jul;102(7):278–83 (Eng. Abstr.) **(Ger)**

[Structural changes in the poultry production industry and in the tasks of veterinarians] Hafez HM. **DTW Dtsch Tierarztl Wochenschr** 1995 Jul;102(7):265–8 (Eng. Abstr.) **(Ger)**

[Inclusion of veterinarians in the structure of swine production] Ingwersen J. **DTW Dtsch Tierarztl Wochenschr** 1995 Jul;102(7):269–71 (Eng. Abstr.) **(Ger)**

STANDARDS

The application of probabilistic scenario analysis for risk assessment of animal health in international trade. Ahl AS. **Ann N Y Acad Sci** 1996 Jul 23;791:255–68

Application of risk assessment to international trade in animals and animal products. Metcalf HE, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:280–95

Implications of international trade agreements for global animal health. Sheesley DJ, et al. **Ann N Y Acad Sci** 1996 Jul 23;791: 296–302

Dry sow stalls—an animal welfare issue [letter] Baker FP. **Can Vet J** 1996 Feb;37(2):71–2

Food safety symposium: responding to the changing epidemiologic characteristics of foodborne diseases. **J Am Vet Med Assoc** 1996 May 1;208(9):1396–404

Entropy in food animal practice. Humble JA. **J Am Vet Med Assoc** 1995 Aug 15;207(4):412–3

Reducing pig mortality through supervision during the perinatal period. Holyoake PK, et al. **J Anim Sci** 1995 Dec; 73(12):3543–51

Animal care and use: an issue now and in the future. Kertz AF. **J Anim Sci** 1996 Jan;74(1):257–61 (16 ref.)

Behavioral and pituitary adrenal–axis responses of dairy cows to social isolation and deprivation of lying down. Munksgaard L, et al. **J Anim Sci** 1996 Apr;74(4):769–78

Bad ethics, good ethics and the genetic engineering of animals in agriculture. Rollin BE. **J Anim Sci** 1996 Mar; 74(3):535–41 (10 ref.)

Farm animal well–being and intensive production systems. Swanson JC. **J Anim Sci** 1995 Sep;73(9):2744–51 (60 ref.)

Institutional surgical practices for nonveterinarians. Banks RE. **J Invest Surg** 1995 Jul–Aug;8(4):211–22

Disinfecting equine facilities. Dwyer RM. **Rev Sci Tech** 1995 Jun;14(2):403–18 (4 ref.)

Disinfection procedures for personnel and vehicles entering and leaving contaminated premises. Ford WB. **Rev Sci Tech** 1995 Jun;14(2):393–401 (10 ref.)

Disinfection of livestock production premises. Fotheringham VJ. **Rev Sci Tech** 1995 Mar;14(1):191–205 (21 ref.)

Use of disinfectants in zoos and game parks. Heuschele WP. **Rev Sci Tech** 1995 Jun;14(2):447–54 (14 ref.)

Disinfecting poultry production premises. Meroz M, et al. **Rev Sci Tech** 1995 Jun;14(2):273–91 (27 ref.)

Application of disinfectants in poultry hatcheries. Samberg Y, et al. **Rev Sci Tech** 1995 Jun;14(2):365–80 (31 ref.)

SPA: marketing and financial performance measures for the cow–calf enterprise. Gutierrez PH. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):313–60 (3 ref.)

Standardized performance analysis. Hamilton ED. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):199–213 (2 ref.)

NCA–IRM desk record. Kniffen D. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):215–78 (0 ref.)

Farm Financial Standards. McGrann JM. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):279–91 (3 ref.)

Stocker/feeder cattle standardized performance analysis. McGrann JM, et al. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):361–73 (3 ref.)

Seedstock beef cattle: SPA. McGrann JM, et al. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):375–88 (2 ref.)

Health control policies in fish viral diseases. Michel C. **Vet Res** 1995;26(5–6):369–73

[Growth promotors in animal husbandry: between fancy and fact] Grommers FJ. **Tijdschr Diergeneeskd** 1996 Jun 15; 121(12):350–3 (Eng. Abstr.) **(Dut)**

[Veterinary herd health management in swine production] Blaha T. **DTW Dtsch Tierarztl Wochenschr** 1995 Jul; 102(7):273–5 (Eng. Abstr.) **(Ger)**

[Strategies for the assurance of health in swine production] Bollwahn W. **DTW Dtsch Tierarztl Wochenschr** 1995 Jul; 102(7):271–3 (Eng. Abstr.) **(Ger)**

[Performance of broiler chickens and quality of litter in various housing conditions (stocking density)] Coenen M, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Mar; 103(3):79–83 (Eng. Abstr.) **(Ger)**

[Requirements of raising game pheasants (Phasianus colchicus sp.) in respect to animal welfare laws] Fehlberg U, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):109–11 (Eng. Abstr.) **(Ger)**

[Gas and particle emissions from housing in animal production] Hartung J. **DTW Dtsch Tierarztl Wochenschr** 1995 Jul;102(7):283–8 (Eng. Abstr.) **(Ger)**

[Aspects of animal welfare relevant to poultry exhibitions]

ANIMAL HUSBANDRY

Mantel T. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar; 102(3):129–30 (Eng. Abstr.) **(Ger)**

[Feasibility for the influence of official veterinarians on the improvement of animal husbandry] Nowak D. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):120–3 (Eng. Abstr.) **(Ger)**

[Cattle flock service in small and middle sized Austrian dairy herds. 2. Udder health] Obritzhauser W. **DTW Dtsch Tierarztl Wochenschr** 1995 Jun;102(6):221–5 (Eng. Abstr.) **(Ger)**

[Applied animal welfare of slaughter houses] von Holleben K. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):55–8 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Welfare in Danish dairy herds 1. Disease management routines in 1983 and 1994. Alban L, et al. **Acta Vet Scand** 1996;37(1):49–63

Food animal practitioners and the numbers game. Herrick JB. **J Am Vet Med Assoc** 1996 Feb 15;208(4):478–9

Veterinary involvement in management practices of beef cow–calf producers. Sanderson MW, et al. **J Am Vet Med Assoc** 1996 Feb 15;208(4):488–91

NCA–IRM desk record. Kniffen D. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):215–78 (0 ref.)

TRENDS

Welfare in Danish dairy herds 2. Housing systems and grazing procedures in 1983 and 1994. Alban L, et al. **Acta Vet Scand** 1996;37(1):65–77

Exciting times for beef practitioners. Herrick JB. **J Am Vet Med Assoc** 1995 Oct 15;207(8):1031–2

Prospects for expanded mohair and cashmere production and processing in the United States of America. Lupton CJ. **J Anim Sci** 1996 May;74(5):1164–72 (18 ref.)

Changing paradigms in animal agriculture: addressing animal issues in Washington by a professional society. Zimbelman RG, et al. **J Anim Sci** 1995 Oct;73(10):3178–81

[The organization of veterinary services in African animal husbandry systems: chances for the exchange of interdisciplinary learning processes] Kirk M. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):447–50 (16 ref.) (Eng. Abstr.) **(Ger)**

[Development of animal production in Germany and in the European Union] Born H. **DTW Dtsch Tierarztl Wochenschr** 1995 Jul;102(7):262–4 (Eng. Abstr.) **(Ger)**

[Developmental trends in farm animal husbandry from an ethological point of view] Graf B. **Schweiz Arch Tierheilkd** 1995;137(9):423–31 (12 ref.) (Eng. Abstr.) **(Ger)**

ANIMAL IDENTIFICATION SYSTEMS

Tattoo identification eliminates possibility of initiating repeat spay/neuter surgery [news] Kahler SC. **J Am Vet Med Assoc** 1995 Nov 1;207(9):1149, 1154

INSTRUMENTATION

The efficacy of diazinon impregnated ear tags against buffalo fly and resulting weight gains and diazinon residues in meat and milk. Spradbery JP, et al. **Aust Vet J** 1996 Jan; 73(1):6–10

VETERINARY

Forensic identification of ungulate species using restriction digests of PCR-amplified mitochondrial DNA. Murray BW, et al. **J Forensic Sci** 1995 Nov;40(6):943–51

Microchip implant system used for animal identification in laboratory rabbits, guineapigs, woodchucks and in amphibians. Mrozek M, et al. **Lab Anim** 1995 Jul; 29(3):339–44

Electronic identification with injectable transponders in pig production: results of a field trail on commercial farms and slaughterhouses concerning injectability and retrievability. Lambooij E, et al. **Vet Q** 1995 Dec;17(4):118–23

Problems with the use of ear tags in sheep [letter] Hosie B. **Vet Rec** 1995 Nov 25;137(22):571

Effects of injecting electronic transponders into the auricle of pigs. Lammers GH, et al. **Vet Rec** 1995 Jun 17; 136(24):606–9

ANIMAL NUTRITION

Effect of avoparcin on rumen fermentation and duodenal nutrient flow in sheep. Fébel H, et al. **Acta Vet Hung** 1995; 43(2–3):229–46

Expression of MHC class II antigens and enzymatic activity in enterocytes of germ-free and conventional rats: dependence on nutritional factors during suckling. Stepánková R, et al. **Adv Exp Med Biol** 1995;371A:501–5

Ultrastructure of the liver of reindeer calves under different nutritional conditions. Soveri T, et al. **Anat Histol Embryol** 1995 Jun;24(2):91–5

Energy partitioning and modeling in animal nutrition. Baldwin RL, et al. **Annu Rev Nutr** 1995;15:191–211 (56 ref.)

Nutritional and hormonal regulation of thyroid hormone deiodinases. Larsen PR, et al. **Annu Rev Nutr** 1995; 15:323–52 (149 ref.)

The pattern of nutrient and energy utilization, retention and the chemical composition of the body in broilers from hatching to maturity. Burlacu G, et al. **Arch Tierernahr** 1996;49(2):125–49

The nutritional significance of endogenous N–losses along the gastro–intestinal tract of farm animals. Tamminga S, et al. **Arch Tierernahr** 1995;48(1–2):9–22 (44 ref.)

Prevention of preatheromatous lesions in sand rats by treatment with a nutritional supplement. Marquié G, et al. **Arzneimittelforschung** 1996 Jun;46(6):610–4

Maintenance of acquired immunity to Trichostrongylus colubriformis in Merino sheep that are losing weight. van Houtert MF, et al. **Aust Vet J** 1995 Aug;72(8):301–3

Interaction between nutrition and Eimeria acervulina infection in broiler chickens: diet compositions that improve fat digestion during Eimeria acervulina infection. Adams C, et al. **Br J Nutr** 1996 Jun;75(6):875–80

Interaction between nutrition and Eimeria acervulina infection in broiler chickens: development of an experimental infection model. Adams C, et al. **Br J Nutr** 1996 Jun;75(6):867–73

Do breeds of pig differ in the efficiency with which they use a limiting protein supply? Kyriazakis I, et al. **Br J Nutr** 1995 Aug;74(2):183–95

Effect of dietary protein quality on energy metabolism in growing chickens. Nieto R, et al. **Br J Nutr** 1995 Aug; 74(2):163–72

A survey of the selenium status of beef cows in Alberta. Campbell JR, et al. **Can Vet J** 1995 Nov;36(11):698–702

Effects of nutritional factors on reproduction, growth, preweaning reflex development and postweaning learning performance in SHRSP. Matsuo T, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S294–6

Stroke–prone SHR and arteriolipidosis–prone SHR as models for atherosclerosis: their mechanisms and application for nutritional and pharmacological studies. Yamori Y, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S244–5

Nutritional and physiological characteristics in germ–free chickens. Furuse M, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):547–56 (68 ref.)

Hormonal and nutritional modulation of hepatic arginase activity in growing cattle. Elsasser TH, et al. **Domest Anim Endocrinol** 1996 May;13(3):219–28

Islet acid glucan–1,4–alpha–glucosidase: a putative key enzyme in nutrient–stimulated insulin secretion. Lundquist I, et al. **Endocrinology** 1996 Apr;137(4):1219–25

Effects of season and nutrition on growth hormone and insulin–like growth factor–I in male red deer. Webster JR, et al. **Endocrinology** 1996 Feb;137(2):698–704

Proper nutrition a concern for ultimate athlete. Energy expenditure and nutrition top themes in proceedings available from the International Sled Dog VMA [news] **J Am Vet Med Assoc** 1996 Jun 15;208(12):1955–6

A survey of veterinarians' knowledge and attitudes about nutrition. Buffington CA, et al. **J Am Vet Med Assoc** 1996 Mar 1;208(5):674–5

Veterinary nutritional management of amphibians and reptiles. Donoghue S. **J Am Vet Med Assoc** 1996 Jun 1; 208(11):1816–20 (22 ref.)

Performance and body composition of finishing gilts (45 to 85 kilograms) as affected by energy intake and nutrition in earlier life: I. Growth of the body and body components. Bikker P, et al. **J Anim Sci** 1996 Apr;74(4):806–16

Performance and body composition of finishing gilts (45 to 85 kilograms) as affected by energy intake and nutrition in earlier life: II. Protein and lipid accretion in body components. Bikker P, et al. **J Anim Sci** 1996 Apr; 74(4):817–26

Impact of changes in organic nutrient metabolism on feeding the transition dairy cow. Grummer RR. **J Anim Sci** 1995 Sep;73(9):2820–33 (81 ref.)

Preweaning diet and stall weaning method influences on stress response in foals. Hoffman RM, et al. **J Anim Sci** 1995 Oct;73(10):2922–30

Cattle grazing a riparian mountain meadow: effects of low and moderate stocking density on nutrition, behavior, diet selection, and plant growth response. Huber SA, et al. **J Anim Sci** 1995 Dec;73(12):3752–65

Effect of nutrition on embryonal mortality in gilts: association with progesterone. Jindal R, et al. **J Anim Sci** 1996 Mar; 74(3):620–4

Valine requirement of the finishing pig. Lewis AJ, et al. **J Anim Sci** 1995 Aug;73(8):2315–8

Dietary fiber for cats: in vitro fermentation of selected fiber sources by cat fecal inoculum and in vivo utilization of diets containing selected fiber sources and their blends. Sunvold GD, et al. **J Anim Sci** 1995 Aug;73(8):2329–39

Mathematical analysis of the relationship between blood flow and uptake of nutrients in the mammary glands of a lactating cow. Cant JP, et al. **J Dairy Res** 1995 Aug; 62(3):405–22

Effect of processing sorghum grain on dairy calf performance. Abdelgadir IE, et al. **J Dairy Sci** 1995 Sep; 78(9):2040–6

Negative effects of a high level of nutrient intake on mammary gland development of prepubertal goats. Bowden CE, et al. **J Dairy Sci** 1995 Aug;78(8):1728–33

Effect of Lactobacillus acidophilus supplementation of milk replacer on preweaning performance of calves. Cruywagen CW, et al. **J Dairy Sci** 1996 Mar;79(3):483–6

The effects of changing ration ingredients on acid–base status, renal function, and macromineral metabolism. Delaquis AM, et al. **J Dairy Sci** 1995 Sep;78(9):2024–39

Utilization of supplemental fat by dairy cows fed diets varying in content of nonstructural carbohydrates. Elliott JP, et al. **J Dairy Sci** 1995 Jul;78(7):1512–25

Interactions between body condition at calving and cooling of dairy cows during lactation in summer. Flamenbaum I, et al. **J Dairy Sci** 1995 Oct;78(10):2221–9

The lactational responses of dairy cows to amount of feed and to the source of carbohydrate energy. Friggens N, et al. **J Dairy Sci** 1995 Aug;78(8):1734–44

Brown midrib sorghum silage for midlactation dairy cows. Grant RJ, et al. **J Dairy Sci** 1995 Sep;78(9):1970–80

Lasalocid and particle size of corn grain for dairy cows in early lactation. 1. Effect on performance, serum metabolites, and nutrient digestibility. Knowlton KF, et al. **J Dairy Sci** 1996 Apr;79(4):557–64

Juice–extracted grass pellets and sodium bicarbonate for cows fed timothy silage of two chop lengths. Orozco–Hernandez JR, et al. **J Dairy Sci** 1995 Nov; 78(11):2415–23

Ruminal fermentation and passage of nutrients to the duodenum of lactating cows fed mixtures of corn and barley. Overton TR, et al. **J Dairy Sci** 1995 Sep; 78(9):1981–98

Serum immunoglobulin concentrations and health of dairy calves in two management systems from birth to 12 weeks of age. Rajala P, et al. **J Dairy Sci** 1995 Dec;78(12):2737–44

Energy intake and gross efficiency comparisons from calorimetric and field data on the same lactating cows. Saama PM, et al. **J Dairy Sci** 1995 Sep;78(9):1945–53

Validity of using accumulated gas pressure readings to measure forage digestion in vitro: a comparison involving three forages. Schofield P, et al. **J Dairy Sci** 1995 Oct; 78(10):2230–8

Influence of steam–flaked sorghum grain and supplemental fat on performance of dairy cows in early lactation. Simas JM, et al. **J Dairy Sci** 1995 Jul;78(7):1526–33

The effect of nutrition on testicular growth in mature Merino rams involves mechanisms that are independent of changes in GnRH pulse frequency. Hötzel MJ, et al. **J Endocrinol** 1995 Oct;147(1):75–85

Differential regulation of plasma levels of insulin–like growth factors–I and –II by nutrition, age and growth hormone treatment in sheep. Hua KM, et al. **J Endocrinol** 1995 Dec; 147(3):507–16

Influence of nutrition on hepatic IGF–I mRNA levels and plasma concentrations of IGF–I and IGF–II in meat–type chickens. Kita K, et al. **J Endocrinol** 1996 Apr; 149(1):181–90

Impact of uraemia on food efficiency and the pulsatile mode of growth hormone secretion in rats. Krieg RJ Jr, et al. **J Endocrinol** 1995 Sep;146(3):509–17

The role of intracerebral insulin in the effect of nutrition on gonadotrophin secretion in mature male sheep. Miller DW, et al. **J Endocrinol** 1995 Nov;147(2):321–9

Selection for longevity favors stringent metabolic control in Drosophila melanogaster. Riha VF, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):B284–94

Nutritional modulation of guinea pig skin hyperproliferation by essential fatty acid deficiency is associated with selective down regulation of protein kinase C–beta. Cho Y, et al. **J Nutr** 1995 Nov;125(11):2741–50

The riboflavin requirement of adult dogs at maintenance is greater than previous estimates. Cline JL, et al. **J Nutr** 1996 Apr;126(4):984–8

Bone growth rather than myofibrillar protein turnover is strongly affected by nutritional restriction at early weaning of calves. Funaba M, et al. **J Nutr** 1996 Apr;126(4):898–905

Relationship of protein synthesis to mRNA levels in the liver of chicks under various nutritional conditions. Kita K, et al. **J Nutr** 1996 Jun;126(6):1610–7

Effect of infant formula zinc and iron level on zinc absorption, zinc status, and immune function in infant rhesus monkeys. Polberger S, et al. **J Pediatr Gastroenterol Nutr** 1996 Feb;22(2):134–43

Premating and gestational effects of maternal nutrition on secondary sex ratio in house mice. Meikle DB, et al. **J Reprod Fertil** 1995 Nov;105(2):193–6

Macromineral composition of kikuyu herbage relative to the requirements of ruminants. Miles N, et al. **J S Afr Vet Assoc** 1995 Dec;66(4):206–12

Growth hormone and nutrition interact to regulate expressions of kidney IGF–I and IGFBP mRNAs. Kobayashi S, et al. **Kidney Int** 1995 Jul;48(1):65–71

Nutritionally induced retinal degeneration in rats. el–Hifnawi el–S, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):705–7

Some nutritional aspects of ageing in dogs and cats. Taylor EJ, et al. **Proc Nutr Soc** 1996 Nov;54(3):645–56

Digestion of wheat gluten and potato protein by the preruminant calf: digestibility, amino acid composition and immunoreactive proteins in ileal digesta. Branco–Pardal P, et al. **Reprod Nutr Dev** 1995;35(6):639–54

Reassessing the manipulation of protein synthesis by rumen microbes. Broudiscou L, et al. **Reprod Nutr Dev** 1995; 35(5):517–35 (144 ref.)

Commentary. The uncontrolled variable in risk assessment: ad libitum overfed rodents--fat, facts and fiction. Keenan KP. **Toxicol Pathol** 1996 May–Jun;24(3):376–83 (57 ref.)

Nutrition and allorejection impact of lipids. Grimm H, et al. **Transpl Immunol** 1995 Mar;3(1):62–7

Longevity and diet [letter] Watson D. **Vet Rec** 1996 Jan 20;

138(3):71
[Behavior disorders in relation to food intake in African ostriches] Sambraus HH.
Berl Munch Tierarztl Wochenschr 1995 Sep;108(9):344–6 (Eng. Abstr.) **(Ger)**
[Report on the fifth symposium "Vitamins and Food Additives in the Nutrition of Man and Animals" on September 28–29, 1995 in Jena] **Z Ernahrungswiss** 1996 Mar;35(1):51–2 **(Ger)**
[A shift in types of nutrition and digestion in ontogeny] Arshavskiĭ IA, et al. **Usp Fiziol Nauk** 1996 Jan–Mar; 27(1):109–29 (95 ref.) (Eng. Abstr.) **(Rus)**
[The effect of neonatal nutrition on lipolysis and catecholamine binding in rat adipocytes] Macho L, et al. **Bratisl Lek Listy** 1995 Nov;96(11):581–5 (Eng. Abstr.) **(Slo)**

ANIMAL RIGHTS

It's a horse's life [letter; comment] Cary P.
Can Med Assoc J 1995 Oct 1;153(7):881, 884. Comment on: Can Med Assoc J 1995 Jun 1;152(11):1745. Comment on: Can Med Assoc J 1995 Jun 1;152(11):1745–6. Comment on: Can Med Assoc J 1995 Jun 1;152(11):1746–8.
The continuing debate over conjugated estrogens [letter] Nickel AK. **Can Med Assoc J** 1995 Oct 1;153(7):884
Forum article on nonhuman animal research elicits considerable dialogue [letter] Anderson BC.
J Am Vet Med Assoc 1996 Aug 1;209(3):543–4
More thoughts on animal rights and animal liberation [letter] Barghusen S. **J Am Vet Med Assoc** 1996 Jan 1;208(1):22–3
Forum article on nonhuman animal research elicits considerable dialogue [letter] Bennett BT.
J Am Vet Med Assoc 1996 Aug 1;209(3):544; discussion 550–2
Thoughts on animal rights and animal liberation [letter] Bischof NL. **J Am Vet Med Assoc** 1995 Dec 15; 207(12):1544
More thoughts on animal rights and animal liberation [letter] Blackwell TE. **J Am Vet Med Assoc** 1996 Jan 1;208(1):22
Article on animal rights/animal liberation still provoking thought [letter; comment] Bley J. **J Am Vet Med Assoc** 1996 Jan 15;208(2):184–5. Comment on: J Am Vet Med Assoc 1995 Oct 15;207(8):1023–30.
Forum article on nonhuman animal research elicits considerable dialogue [letter] Bley J.
J Am Vet Med Assoc 1996 Aug 1;209(3):544–5
Forum article on nonhuman animal research elicits considerable dialogue [letter] Boyce JR.
J Am Vet Med Assoc 1996 Aug 1;209(3):545–6
Forum article on nonhuman animal research elicits considerable dialogue [letter] Dennis J.
J Am Vet Med Assoc 1996 Aug 1;209(3):546
Forum article on nonhuman animal research elicits considerable dialogue [letter] DeTolla LJ Jr.
J Am Vet Med Assoc 1996 Aug 1;209(3):546
The immorality of nonhuman animal research. Feldmann BM. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1798–801
More thoughts on animal rights and animal liberation [letter] Fox MW. **J Am Vet Med Assoc** 1996 Jan 1;208(1):23
Forum article on nonhuman animal research elicits considerable dialogue [letter] Freeman A.
J Am Vet Med Assoc 1996 Aug 1;209(3):546–7
More thoughts on animal rights and animal liberation [letter] Hartwick JR. **J Am Vet Med Assoc** 1996 Jan 1;208(1):23–4
Forum article on nonhuman animal research elicits considerable dialogue [letter] Jackson RK.
J Am Vet Med Assoc 1996 Aug 1;209(3):547–8
Forum article on nonhuman animal research elicits considerable dialogue [letter] Jacobs FS.
J Am Vet Med Assoc 1996 Aug 1;209(3):548
Forum article on nonhuman animal research elicits considerable dialogue [letter] Mathey WJ.
J Am Vet Med Assoc 1996 Aug 1;209(3):548–9
Thoughts on animal rights and animal liberation [letter] Milani MM. **J Am Vet Med Assoc** 1995 Dec 15; 207(12):1544–5
Forum article on nonhuman animal research elicits considerable dialogue [letter] Nusbaum KE.
J Am Vet Med Assoc 1996 Aug 1;209(3):549–50
The natural wrongs about animal rights and animal liberation [see comments] Ott RS. **J Am Vet Med Assoc** 1995 Oct 15;207(8):1023–30. Comment in: J Am Vet Med Assoc 1996 Jan 15;208(2):184–5.
Forum article on nonhuman animal research elicits considerable dialogue [letter] Roen DT.
J Am Vet Med Assoc 1996 Aug 1;209(3):550
Forum article on nonhuman animal research elicits considerable dialogue [letter] Stabenow J.
J Am Vet Med Assoc 1996 Aug 1;209(3):550
Conference explores ethics of animal research with critical thinking and balanced argument [news] Phillips DF.
JAMA 1996 Jul 10;276(2):87–8
Animal rights and wrongs [letter; comment] Botting JH.
Nat Med 1995 Nov;1(11):1102. Comment on: Nat Med 1995 Sep;1(9):849.
Animal experimentation [letter] [see comments] Carlson P.
Nat Med 1995 Sep;1(9):849. Comment in: Nat Med 1995 Nov;1(11):1102.
Animal radical right [letter; comment] Martin PA.
Neurology 1996 Mar;46(3):884. Comment on: Neurology 1995 Apr;45(4):609–10.
Animal radical right [letter; comment] Newmark J.
Neurology 1996 Mar;46(3):883–4. Comment on: Neurology 1995 Apr;45(4):609–10.
Animal radical right [letter; comment] Nicely MC.
Neurology 1996 Mar;46(3):883; discussion 884. Comment on: Neurology 1995 Apr;45(4):609–10.
Animal radical right [letter; comment] White HH.
Neurology 1996 Mar;46(3):883–4; discussion 884. Comment on: Neurology 1995 Apr;45(4):609–10.
A dissection of the chapter "Tools for Research" in Peter Singer's Animal Liberation [see comments] Russell SM, et al. **Proc Soc Exp Biol Med** 1996 Feb;211(2):109–38. Comment in: Proc Natl Acad Sci U S A 1996 Feb;211(2):139–46.
Blind hostility: a response to Russell and Nicoll [comment] Singer P. **Proc Soc Exp Biol Med** 1996 Feb;211(2):139–46; discussion 147–54. Comment on: Proc Natl Acad Sci U S A 1996 Feb;211(2):109–38.
[Guide dogs—a partnership between man and beast. A German tragedy, that needs friends of animals and human beings] Rüggeberg A. **Tierarztl Prax** 1996 Jun;24(3):213–8 (Eng. Abstr.) **(Ger)**
[I National Meeting on Anesthesiology in experimental surgery. Conclusions (letter)] Cruz JI.
Rev Esp Anestesiol Reanim 1996 Apr;43(4):151 **(Spa)**

TRENDS

Animal care and use: an issue now and in the future. Kertz AF. **J Anim Sci** 1996 Jan;74(1):257–61 (16 ref.)
Neuroreality. I. Dedicated demolition of the decade of the brain:the genuine threat to neurologic research from the animal radical right American Academy of Neurology Animal Studies Subcommitte. [editorial] Landau WM, et al. **J Child Neurol** 1995 Sep;10(5):343–5

ANIMAL TECHNICIANS

Allergic sensitization is associated with increased bronchial responsiveness: a prospective study of allergy to laboratory animals. Renström A, et al. **Eur Respir J** 1995 Sep; 8(9):1514–9
Need training for application of insecticides [letter] Bukowski JA, et al. **J Am Vet Med Assoc** 1996 Apr 15;208(8):1227–8
Allergy to laboratory animals among animal handlers. Bryant DH, et al. **Med J Aust** 1995 Oct 16;163(8):415–8
Veterinary technicians: an important asset to the team. Decker CA, et al. **Semin Vet Med Surg (Small Anim)** 1996 Feb;11(1):51–3
How much are veterinary nurses worth? [news] **Vet Rec** 1995 Nov 4;137(19):477–8

EDUCATION

NVQs and investors in people [letter] Manning PR.
Vet Rec 1995 Jul 29;137(5):128
Veterinary nursing examinations [letter] Moses PA, et al.
Vet Rec 1995 Oct 21;137(17):444
Veterinary nursing examinations [letter] Scaife KJ.
Vet Rec 1995 Jul 29;137(5):128

ANIMAL TESTING ALTERNATIVES

The three Rs of Russell & Burch and the testing of biological products. Balls M, et al. **Dev Biol Stand** 1996;86:11–8 (13 ref.)
Evaluation of new approaches to poliovirus vaccine neurovirulence tests. Wood DJ. **Dev Biol Stand** 1996; 86:79–83 (16 ref.)
An alternative strategy to the use of guinea pigs for the identification of skin sensitization hazard. Basketter DA, et al. **Food Chem Toxicol** 1995 Dec;33(12):1051–6
Arachidonic acid release: an in vitro alternative for dermal irritancy testing. DeLeo VA, et al. **Food Chem Toxicol** 1996 Feb;34(2):167–76
The CTFA Evaluation of Alternatives Program: an evaluation of in vitro alternatives to the Draize primary eye irritation test. (Phase III) surfactant-based formulations. Gettings SD, et al. **Food Chem Toxicol** 1996 Jan;34(1):79–117
Development of alternative methods. Goldberg AM.
J Toxicol Sci 1995 Sep;20(4):443–9
A validation study of the COMPACT and HazardExpert techniques with 40 chemicals. Lewis DF, et al.
Mutat Res 1996 Aug 12;369(3–4):157–74
William James and vivisection [letter; comment] [see comments] White RJ. **Pharos** 1995 Fall;58(4):37. Comment on: Pharos 1995 Summer;58(3):46–7. Comment in: Pharos 1996 Spring;59(2):43.
The three Rs and biomedical research [editorial] Goldberg AM, et al. **Science** 1996 Jun 7;272(5267):1403
[Animal models in pharmacy—ethical problems and alternative methods] Kučová D, et al. **Ceska Slov Farm** 1995 Dec;44(6):287–92 (Eng. Abstr.) **(Cze)**
[Alternative methods to animal experimentation. Scientific and ethical problems] Adolphe M. **Bull Acad Natl Med** 1995 Jun;179(6):1009–16; discussion 1116–9 (16 ref.) (Eng. Abstr.) **(Fre)**
[Do we need animal trials for the improvement of the diagnosis and therapy of tumors? (letter)] Hartinger W. **Strahlenther Onkol** 1995 Oct;171(10):600–6 **(Ger)**
[Draize test and alternative methods for evaluating irritation from chemical substances] Moskalewski S, et al.
Rocz Panstw Zakl Hig 1995;46(2):163–8 (Eng. Abstr.) **(Pol)**

HISTORY

A short history of the use of animals in vaccine development and quality control. Hendriksen CF. **Dev Biol Stand** 1996; 86:3–10

LEGISLATION & JURISPRUDENCE

Animal ethics and welfare the Australian way. Derks A.
Dev Biol Stand 1996;86:330
USDA: progress toward in vitro tests and other trends. Goodman SA. **Dev Biol Stand** 1996;86:41–7
The five Rs: refinement, reduction, replacement. A regulatory revolution. Lucken RN. **Dev Biol Stand** 1996; 86:67–72

METHODS

Potency tests of diphtheria, tetanus and combined vaccines. Suggestion for a simplified potency assay. Aggerbeck H, et al. **Dev Biol Stand** 1996;86:297–301
Determination of protective erysipelas antibodies in pig and mouse sera as possible alternatives to the animal challenge models currently used for potency tests. Beckmann R, et al. **Dev Biol Stand** 1996;86:326
Rat immunogenicity assay of inactivated poliovirus. Bevilacqua JM, et al. **Dev Biol Stand** 1996;86:121–7
Detection of extraneous agents in vaccines using the polymerase chain reaction of Newcastle disease virus in poultry biologicals. Bruckner L, et al. **Dev Biol Stand** 1996; 86:175–82
Hepatitis B virus polymerase chain reaction--a possible alternative method to the in vivo assay using chimpanzees. Chudy M, et al. **Dev Biol Stand** 1996;86:328
Guidelines for the choice of an alternative to proposed animal experiments. Dawson M. **Dev Biol Stand** 1996;86:329
An in vitro assay for acute pathogenicity of immunodeficiency viruses. Dittmar MT, et al.
Dev Biol Stand 1996;86:167–73
Vero cell assay validation of an alternative to the Ph. Eur. diphtheria potency tests. Gommer AM. **Dev Biol Stand** 1996;86:217–24
Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines. Gupta RK, et al. **Dev Biol Stand** 1996;86:283–96
Use of in vitro Vero cell assay and ELISA in the United States potency test of vaccines containing adsorbed diphtheria and tetanus toxoids. Gupta RK, et al.
Dev Biol Stand 1996;86:207–15
Testing of immunomodulatory properties in vitro. Hartung T, et al. **Dev Biol Stand** 1996;86:85–96
Replacement of challenge procedures in the evaluation of poultry vaccines. Jungbäck C, et al. **Dev Biol Stand** 1996; 86:157–63
Opportunities to reduce the use of animals in the potency and toxicity testing of toxoid vaccines. Knight PA.
Dev Biol Stand 1996;86:185–97
Developments in pertussis vaccines leading to reduction and replacement of in vivo testing. Redhead K.
Dev Biol Stand 1996;86:263–70
Passive haemagglutination tests using purified antigens covalently coupled to turkey erythrocytes. Relyveld EH, et al. **Dev Biol Stand** 1996;86:225–41
Reducing the use of the target animal batch safety test for veterinary vaccines. Roberts B, et al. **Dev Biol Stand** 1996; 86:97–102
Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines. Rooijakkers E, et al. **Dev Biol Stand** 1996;86:137–45
Investigation of the product equivalence of monoclonal antibodies for therapeutic and in vivo diagnostic human use in case of change from ascitic to in vitro production. Schäffner G, et al. **Dev Biol Stand** 1996;86:319–20
Requirements for valid alternative assays for testing of biological therapeutic agents. Sesardic D.
Dev Biol Stand 1996;86:311–8
Comparison of in vivo and in vitro methods for determining unitage of diphtheria antitoxin in adsorbed diphtheria-tetanus (DT) and diphtheria-tetanus-pertussis (DTP) vaccines. Shinde YP, et al. **Dev Biol Stand** 1996; 86:245–60
Potency testing of diphtheria and tetanus toxoids. A reliable, pragmatic and economic approach. Stainer DW.
Dev Biol Stand 1996;86:303–8
Is the mouse weight gain test outdated as a model for the assessment of pertussis toxicity? Straaten-van der Kappelle IV, et al. **Dev Biol Stand** 1996;86:344
Importance of experiments in poliovirus-susceptible transgenic mice for evaluating current potency tests of inactivated polio vaccine (IPV). Taffs R, et al.
Dev Biol Stand 1996;86:345
Pertussis serological potency test as an alternatively to the intracerebral mouse protection test. van der Ark A, et al.
Dev Biol Stand 1996;86:271–81
Validation of the toxin-binding inhibition (ToBI) test for the estimation of the potency of the tetanus toxoïd component in vaccines. van der Gun J, et al. **Dev Biol Stand** 1996; 86:199–206

The reduction of the use of challenge testing to provide evidence of efficacy in tests of immunological veterinary medicinal products (IVMPs). Webster CJ. **Dev Biol Stand** 1996;86:103–9

Alternative method of assessing toxicity. Atterwill CK. **Methods Mol Biol** 1995;43:1–9 (8 ref.)

STANDARDS

Replacement, Reduction and Refinement of Animal Experiments in the Development and Control of Biological Products. Proceedings of a conference. Langen, Germany, November 2–4, 1994. **Dev Biol Stand** 1996;86:1–368

The views and policy of the Japanese control authorities on the three Rs. Chino F. **Dev Biol Stand** 1996;86:53–62

WHO activities towards the three Rs in the development and control of biological products. Milstien J, et al. **Dev Biol Stand** 1996;86:31–9

Replacement, reduction or refinement of animal use in the quality control of veterinary vaccines: development, validation and implementation. van der Kamp MD. **Dev Biol Stand** 1996;86:73–6

Alternatives to the use of animals in R & D and quality control of veterinary vaccines: an industry view. Verschueren C, et al. **Dev Biol Stand** 1996;86:49–51

A proposal for the development of a standardised programme for the calculation of probit analysis. Zott A, et al. **Dev Biol Stand** 1996;86:349

STATISTICS & NUMERICAL DATA

A proposal for the development of a standardised programme for the calculation of probit analysis. Zott A, et al. **Dev Biol Stand** 1996;86:349

TRENDS

Alternatives to animal testing: achievements and recent developments in the European Pharmacopoeia. Castle P. **Dev Biol Stand** 1996;86:21–9

USDA: progress toward in vitro tests and other trends. Goodman SA. **Dev Biol Stand** 1996;86:41–7

ANIMAL VIRUSES see VIRUSES

ANIMAL VOCALIZATION see VOCALIZATION, ANIMAL

ANIMAL WELFARE

see related
ANIMAL TESTING ALTERNATIVES

Housing of pregnant sows in loose and confined systems—a field study 1. Vulva and body lesions, culling reasons and production results. Gjein H, et al. **Acta Vet Scand** 1995; 36(2):185–200

Investigative approach to frog gastrocnemius laboratory: potential impact on animal use in teaching laboratories. Welsford IG, et al. **Am J Physiol** 1995 Dec;269(6 Pt 3):S42–9

The application of probabilistic scenario analysis for risk assessment of animal health in international trade. Ahl AS. **Ann N Y Acad Sci** 1996 Jul 23;791:255–68

Implications of international trade agreements for global animal health. Sheesley DJ, et al. **Ann N Y Acad Sci** 1996 Jul 23;791: 296–302

Eastern barred bandicoot recovery: the role of the veterinarian in the management of endangered species. Seebeck J, et al. **Aust Vet J** 1996 Mar;73(3):81–3 (21 ref.)

How to organize animal research in radiology. Hamm B, et al. **Eur Radiol** 1996;6(2):S19–22

Ethical principles and guidelines for experiments on animals. Swiss Academy of Medical Sciences. Swiss Academy of Sciences. **Experientia** 1996 Jan 16;52(1):1–3

Bioethical troubles. Animal individuals and human organisms. Donnelley S. **Hastings Cent Rep** 1995;25(7 Spec No):21–9

Animals in research: religious teachings. The 1995 symposium sponsored by the ARVO Animals in Research Committee. Stone RA, et al. **Invest Ophthalmol Vis Sci** 1996 Mar; 37(4):689–92

Vietnamese potbellied pigs: myths and misconceptions [news] **J Am Vet Med Assoc** 1995 Dec 15;207(12):1537–8

Forum article on nonhuman animal research elicits considerable dialogue [letter] Altrogge DM. **J Am Vet Med Assoc** 1996 Aug 1;209(3):543

Well-being of zoo and aquarium animals explored [news] Boyce J. **J Am Vet Med Assoc** 1995 Oct 1;207(7):832, 837

Forum article on nonhuman animal research elicits considerable dialogue [letter] Dennis J. **J Am Vet Med Assoc** 1996 Aug 1;209(3):546

Veterinary bioethics. Fox MW. **J Am Vet Med Assoc** 1996 May 15;208(10):1628–9

Wisconsin train derailment turns veterinarians into heroes [news] Grendahl LG, et al. **J Am Vet Med Assoc** 1996 May 15;208(10):1611–2

Welfare of cats depends on humankind [news] [see comments] Kahler SC. **J Am Vet Med Assoc** 1996 Jan 15;208(2):169–71 . Comment in: J Am Vet Med Assoc 1996 May 1;208(9):1380–1.

Feline behavior and welfare. Landsberg G. **J Am Vet Med Assoc** 1996 Feb 15;208(4):502–5 (9 ref.)

Animal shelter issues. Luke C. **J Am Vet Med Assoc** 1996 Feb 15;208(4):524–7 (1 ref.)

Opinion on ear cropping and tail docking [letter] Mathis G. **J Am Vet Med Assoc** 1995 Nov 1;207(9):1160

Animal selection and breeding techniques that create diseased populations and compromise welfare. Ott RS. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1969–74 (48 ref.)

Risk factors for relinquishment of dogs to an animal shelter. Patronek GJ, et al. **J Am Vet Med Assoc** 1996 Aug 1; 209(3):572–81

Risk factors for relinquishment of cats to an animal shelter. Patronek GJ, et al. **J Am Vet Med Assoc** 1996 Aug 1; 209(3):582–8

Advances in feline health research: impact of recent developments in vaccinology on feline welfare. Richards JR. **J Am Vet Med Assoc** 1996 Feb 15;208(4):505–10 (30 ref.)

Care of fish in biological research. Klontz GW. **J Anim Sci** 1995 Nov;73(11):3485–92 (24 ref.)

Behavioral and pituitary adrenal-axis responses of dairy cows to social isolation and deprivation of lying down. Munksgaard L, et al. **J Anim Sci** 1996 Apr;74(4):769–78

Bad ethics, good ethics and the genetic engineering of animals in agriculture. Rollin BE. **J Anim Sci** 1996 Mar; 74(3):535–41 (10 ref.)

Standardization of botulinum toxin: scientific progress enhances animal welfare [letter; comment] Morris TH. **J R Soc Med** 1995 Oct;88(10):604. Comment on: J R Soc Med 1995 Apr;88(4):239–40.

A humane killing trap for lynx (Felis lynx): the Conibear 330 with clamping bars. Proulx G, et al. **J Wildl Dis** 1995 Jan;31(1):57–61

Individual differences in macaques' responses to stressors based on social and physiological factors: implications for primate welfare and research outcomes. Boccia ML, et al. **Lab Anim** 1995 Jul;29(3):250–7

Provision for welfare of non-human primates used in biomedical research. Box HO, et al. **Lab Anim** 1995 Jul; 29(3):233–6

Evaluation of animal welfare by the self-expression of an anxiety state. Carey MP, et al. **Lab Anim** 1995 Oct; 29(4):370–9

Carbon dioxide euthanasia in rats: oxygen supplementation minimizes signs of agitation and asphyxia. Coenen AM, et al. **Lab Anim** 1995 Jul;29(3):262–8

An investigation into the effects of solid or grid cage flooring on the welfare of laboratory rats. Manser CE, et al. **Lab Anim** 1995 Oct;29(4):353–63

Guidelines and legal codes for the welfare of non-human primates in biomedical research. Poole TB. **Lab Anim** 1995 Jul;29(3):244–9

Animal experimentation [letter] [see comments] Carlson P. **Nat Med** 1995 Sep;1(9):849. Comment in: Nat Med 1995 Nov;1(11):1102.

Activists seek retirement home for chimps [news] Macilwain C. **Nature** 1996 Jun 27;381(6585):722

Albert Sabin's monkey experiments [letter; comment] Katz SL. **Pharos** 1996 Spring;59(2):43. Comment on: Pharos 1995 Fall;58(4):37.

Pretense and hidden feelings in the Humane Society environment: a source of stress. Hart LA, et al. **Psychol Rep** 1995 Oct;77(2):554

A proposed design for conducting target animal safety studies for developing new veterinary pharmaceuticals. Carakostas MC, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):49–54

The three Rs and biomedical research [editorial] Goldberg AM, et al. **Science** 1996 Jun 7;272(5267):1403

Animal activists target NASA mission [news] Lawler A. **Science** 1996 Apr 5;272(5258):26

More monkey business alleged at NYU [news] Stone R. **Science** 1996 Aug 23;273(5278):1040

CIWF calls for ban on genetic engineering of farm animals [news] **Vet Rec** 1995 Sep 2;137(10):231

Protests against live animal exports [letter] **Vet Rec** 1995 Oct 21;137(17):444

The science and sense behind behaviour counselling [news] **Vet Rec** 1995 Oct 21;137(17):416–7

Veterinarians and wildlife [news] **Vet Rec** 1995 Oct 21; 137(17):417–9

Live animal exports [letter] Allcock J. **Vet Rec** 1995 Jun 10;136(23):594

Wildlife rehabilitation [letter] Best JR. **Vet Rec** 1996 Mar 30;138(13):312

Docking of puppies' tails [letter] Chick S. **Vet Rec** 1995 Sep 30;137(14):356

Live animal exports [letter] Coffey DJ. **Vet Rec** 1995 Aug 26;137(9):228

Wildlife diseases [letter] Cork SC. **Vet Rec** 1995 Dec 2; 137(23):600

Live animal exports [letter] Day CE. **Vet Rec** 1995 Jun 10; 136(23):594

Protests against live animal exports [letter] D'Silva J. **Vet Rec** 1995 Dec 2;137(23):599

Ritual slaughter [letter] Gregory M. **Vet Rec** 1995 Sep 16; 137(12):299–300

Docking of puppies' tails [letter] Hoare C. **Vet Rec** 1995 Sep 30;137(14):355–6

Wildlife rehabilitation [letter; comment] [see comments] Hughes A. **Vet Rec** 1996 Feb 24;138(8):191–2. Comment on: Vet Rec 1996 Jan 27;138(4):95–6. Comment in: Vet Rec 1996 Mar 2;138(9):215.

Docking of puppies' tails [letter] Matthews JG. **Vet Rec** 1995 Sep 30;137(14):356

Welfare of caged birds [letter; comment] Meredith A, et al. **Vet Rec** 1995 Nov 25;137(22):571. Comment on: Vet Rec 1995 Oct 21;137(17):444.

Docking and other practices [letter; comment] Morton DB. **Vet Rec** 1995 Jul 22;137(4):103. Comment on: Vet Rec 1995 Jul 8;137(2):52.

Transport of animals [letter] [see comments] Notton G. **Vet Rec** 1995 Jul 15;137(3):76. Comment in: Vet Rec 1995 Jul 29;137(5):128.

Live animal exports [letter] Shepherd DA, et al. **Vet Rec** 1995 Jul 1;137(1):27

Docking of puppies' tails [letter] [see comments] Sinclair E. **Vet Rec** 1995 Sep 30;137(14):356. Comment in: Vet Rec 1995 Oct 14;137(16):411–2.

LVIs and BSE control measures [letter] Stevenson RM. **Vet Rec** 1996 May 18;138(20):503

Wildlife rehabilitation [letter; comment] Stocker L. **Vet Rec** 1996 Feb 24;138(8):191. Comment on: Vet Rec 1996 Jan 20;138(3):61–5.

Live animal exports [letter] Townsend T. **Vet Rec** 1995 Jun 10;136(23):594

Society of Greyhound Veterinarians [letter] Westaway AJ. **Vet Rec** 1996 Feb 24;138(8):192

[Use of laboratory animals for toxicologic testing of drugs and chemicals] Sýkora I. **Cas Lek Cesk** 1995 Aug 2; 134(15):467–70 (Eng. Abstr.) **(Cze)**

[Developments in cattle and swine health care and the existence of special outlook groups] **Tijdschr Diergeneeskd** 1996 Jul 1;121(13):390–2 **(Dut)**

[FIDIN theme afternoon on drugs and animal welfare. Welfare or non-existence?] Deleu S. **Tijdschr Diergeneeskd** 1996 Jul 1;121(13):405–6 **(Dut)**

[Sterin accreditation for the Inspection and Control activities of the Health Service. GD-IC: a new branch on the GD-tree! (Health Service)] Deleu S. **Tijdschr Diergeneeskd** 1995 Nov 1;120(21):624–5 **(Dut)**

[Annual congress 1995, its theme 'Animal and Art'. North Holland hold a mirror up to the veterinarian] Deleu S. **Tijdschr Diergeneeskd** 1995 Nov 15;120(22):660–72 **(Dut)**

[Minister van Aartsen visits the Royal Dutch Society for Veterinary Medicine. Udo on Aujeszky's disease: 'rid of it in 2 years time, unless....'] Deleu S. **Tijdschr Diergeneeskd** 1996 Jan 1;121(1):6–9 **(Dut)**

[Well-being—intrinsic value—integrity. Developments in the reevaluation of the domesticated animal] Grommers FJ, et al. **Tijdschr Diergeneeskd** 1995 Sep 1;120(17):490–4 (27 ref.) (Eng. Abstr.) **(Dut)**

[Growth promotors in animal husbandry: between fancy and fact] Grommers FJ. **Tijdschr Diergeneeskd** 1996 Jun 15; 121(12):350–3 (Eng. Abstr.) **(Dut)**

[Farewell Andries van Foreest combined with Specialists' Day. Zoo-veterinarian relationship central in Ouwehand] Ubbink S. **Tijdschr Diergeneeskd** 1996 Jun 15;121(12):356–9 **(Dut)**

[Reinforcement epidemiologic and economic expertise in health care for animals (news)] Verheijden JH. **Tijdschr Diergeneeskd** 1996 Jun 1;121(11):328 **(Dut)**

[Animal welfare laws concerning air transportation of lobsters and langostinos] Hildebrandt K. **Berl Munch Tierarztl Wochenschr** 1995 Apr;108(4):148–9 (Eng. Abstr.) **(Ger)**

["Breeding for distress" in fowl] Bartels T. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):117–9 (34 ref.) (Eng. Abstr.) **(Ger)**

[Animal welfare and profit motive in compatible pet shops] Bollhöfer H. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb; 103(2):65–6 (Eng. Abstr.) **(Ger)**

[Mobile slaughter facilities] Briese A. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):58–62 (Eng. Abstr.) **(Ger)**

[Ethological investigations in various housing of broiler chickens] Buchenauer D, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Mar;103(3):76–8 (Eng. Abstr.) **(Ger)**

[Activity of a veterinarian within the French fire departments (animal welfare, accidents, disasters)] Buecher M. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):44–6 (Eng. Abstr.) **(Ger)**

[Requirements of raising game pheasants (Phasianus colchicus sp.) in respect to animal welfare laws] Fehlberg U, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):109–11 (Eng. Abstr.) **(Ger)**

[Ten years of the Veterinary Association for Animal Welfare (TVT)] Goldhorn W. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):46–51 (Eng. Abstr.) **(Ger)**

[Ostrich farming from the perspective of veterinarians] Kösters J, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Mar;103(3):100–4 (Eng. Abstr.) **(Ger)**

[Aspects of animal welfare relevant to poultry exhibitions] Mantel T. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar; 102(3):129–30 (Eng. Abstr.) **(Ger)**

[Feasibility for the influence of official veterinarians on the improvement of animal husbandry] Nowak D. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):120–3 (Eng. Abstr.) **(Ger)**

[The total efficiency of stunning traps for the capture of stone martens and red foxes in hunting situations] Pohlmeyer K, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar; 102(3):133–7 (Eng. Abstr.) **(Ger)**

[Electrofishing from animal welfare aspects] Schulz U. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):125–7 (Eng. Abstr.) **(Ger)**

[Applied animal welfare of slaughter houses] von Holleben

K. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):55–8 (Eng. Abstr.) **(Ger)**

[Animal welfare for animals kept for animal-supported therapy in homes and hospitals] von Wenzlawowicz C. **DTW Dtsch Tierarztl Wochenschr** 1995 Nov;102(11):425–6 (Eng. Abstr.) **(Ger)**

[Animals as co-creatures--moral theological reflections on our responsibility to animals] Wolbert W. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):38–42 (Eng. Abstr.) **(Ger)**

[Boredom in zoo animals--an relevant animal welfare problem?] Wiesner H. **Tierarztl Prax** 1995 Aug; 23(4):328–35 (Eng. Abstr.) **(Ger)**

[The good use of experimental animals] Schumenann de Aluja A, et al. **Gac Med Mex** 1995 Jan-Feb;131(1):49–63 **(Spa)**

LEGISLATION & JURISPRUDENCE

The present state of national animal welfare policy. O'Flynn MA, et al. **Aust Vet J** 1996 Apr;73(4):121–4

An ethicist's commentary on the case of a veterinarian with a client who has illicitly imported boar semen. Rollin BE. **Can Vet J** 1995 Nov;36(11):674

Animal ethics and welfare the Australian way. Derks A. **Dev Biol Stand** 1996;86:330

William James and vivisection [letter; comment] [see comments] Cohen MJ. **Pharos** 1995 Summer;58(3):46–7. Comment on: Pharos 1995 Spring;58(2):14–9. Comment in: Pharos 1995 Fall;58(4):37.

Animal transport proposals 'less than satisfactory' [news] **Vet Rec** 1996 Jan 20;138(3):50–1

Wild Mammals (Protection) Act [letter] Bryant J. **Vet Rec** 1996 Mar 30;138(13):312

Live animal exports [letter] Houghton L. **Vet Rec** 1996 Jan 27;138(4):95

Wild Mammals (Protection) Act [letter] Radford M. **Vet Rec** 1996 Mar 23;138(12):287

Live animal exports [letter] [see comments] Taylor N. **Vet Rec** 1996 Jan 27;138(4):95. Comment in: Vet Rec 1996 Feb 24;138(8):192.

Illegal poisoning [letter] Thompson D. **Vet Rec** 1996 Feb 24;138(8):192

[Regulations animal transport further formulated. Transportation of impaired cattle] van Egmond S. **Tijdschr Diergeneeskd** 1995 Sep 1;120(17):517–9 **(Dut)**

[Health and welfare legislation for animals, what is its status?] van Egmond S. **Tijdschr Diergeneeskd** 1996 May 1; 121(9):260–5 **(Dut)**

[Development and actual status of animal welfare legislation] Baumgartner G. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):35–8 (Eng. Abstr.) **(Ger)**

[Preventative tail amputation in fattening bulls] Busch B, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar; 102(3):127–9 (Eng. Abstr.) **(Ger)**

[Feasibility for the influence of the animal welfare commissioner and cooperation with the responsible authorities] Cybik M. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):123–5 (Eng. Abstr.) **(Ger)**

[Supervision of animal welfare regulations in animal markets--an official veterinary stepchild?] Fröhlich T, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar; 102(3):131–3 (Eng. Abstr.) **(Ger)**

[Animal welfare slaughter regulation] Knierim U. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb;103(2):52–4 (Eng. Abstr.) **(Ger)**

[In vivo experimental research in vascular surgery. Methodology and current Italian law] Giardino R, et al. **Minerva Chir** 1995 Jun;50(6):613–9 (Eng. Abstr.) **(Ita)**

STANDARDS

Animal health monitoring and surveillance in Switzerland. Stärk KD. **Aust Vet J** 1996 Mar;73(3):96–7 (14 ref.)

Farm animal well-being and intensive production systems. Swanson JC. **J Anim Sci** 1995 Sep;73(9):2744–51 (60 ref.)

Animal Research. Care guide gives labs more freedom [news] Roush W. **Science** 1996 Mar 22;271(5256):1664

NFU sets out its position on farm animal welfare [news] **Vet Rec** 1995 Jul 8;137(2):30–1

Docking and other practices [letter; comment] [see comments] Cooper JE. **Vet Rec** 1995 Jul 8;137(2):52. Comment on: Vet Rec 1995 Mar 18;136(11):274. Comment in: Vet Rec 1995 Jul 22;137(4):103.

Transport of animals [letter; comment] Fearn AE. **Vet Rec** 1995 Jul 29;137(5):128. Comment on: Vet Rec 1995 Jul 15;137(3):76.

Attitudes to companion animals [letter] Houghton L. **Vet Rec** 1996 Jan 27;138(4):95

Live animal exports [letter; comment] Hovi ML. **Vet Rec** 1996 Feb 24;138(8):192. Comment on: Vet Rec 1996 Jan 27;138(4):95.

Welfare of caged birds [letter; comment] Lawton MP. **Vet Rec** 1995 Nov 11;137(20):523–4. Comment on: Vet Rec 1995 Sep 23;137(13):328. Comment on: Vet Rec 1995 Oct 21;137(17):444.

Veterinary treatment of reptiles [letter] Price H. **Vet Rec** 1996 Feb 17;138(7):168

Health and welfare of rehabilitated juvenile hedgehogs (Erinaceus europaeus) before and after release into the wild [see comments] Sainsbury AW, et al. **Vet Rec** 1996 Jan 20;138(3):61–5. Comment in: Vet Rec 1996 Jan 27;138(4):95–6. Comment in: Vet Rec 1996 Feb 10;138(6):143. Comment in: Vet Rec 1996 Feb 24;138(8):191.

TRENDS

Animal care and use: an issue now and in the future. Kertz AF. **J Anim Sci** 1996 Jan;74(1):257–61 (16 ref.)

Reviews of state veterinary services [letter; comment] Leslie NW. **Vet Rec** 1996 Mar 9;138(10):239. Comment on: Vet Rec 1996 Feb 3;138(5):118.

ANIMALS

Identification and quantitation of source from hemoglobin of blood and blood mixtures by high performance liquid chromatography. Espinoza EO, et al. **J Forensic Sci** 1996 Sep;41(5):804–11

Children's assignment of gender to animal characters in pictures. Arthur AG, et al. **J Genet Psychol** 1996 Sep; 157(3):297–301

LVIs and certification [editorial] **Vet Rec** 1995 Dec 16; 137(25):625

ANATOMY & HISTOLOGY

[The relationship of the lifespan of eukaryotes (animals and plants) to their physical characteristics] Metel'skii ST. **Zh Obshch Biol** 1995 Nov-Dec;56(6):723–35 (Eng. Abstr.) **(Rus)**

GENETICS

Patterns of nucleotide composition at fourfold degenerate sites of animal mitochondrial genomes. Perna NT, et al. **J Mol Evol** 1995 Sep;41(3):353–8

Phylogenetic analysis of the 90 kD heat shock family of protein sequences and an examination of the relationship among animals, plants, and fungi species. Gupta RS. **Mol Biol Evol** 1995 Nov;12(6):1063–73

GROWTH & DEVELOPMENT

Size control: the regulation of cell numbers in animal development. Raff MC. **Cell** 1996 Jul 26;86(2):173–5 (20 ref.)

METABOLISM

The form and bioavailability of non-ionic organic chemicals in sewage sludge-amended agricultural soils. Beck AJ, et al. **Sci Total Environ** 1996 Jun 21;185(1-3):125–49

PHYSIOLOGY

The lessons of middle-ear function in non-mammals: improving columellar prostheses [editorial] Manley GA. **J R Soc Med** 1995 Jul;88(7):367–8 (8 ref.)

ANIMALS, DOMESTIC

Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Asahina M, et al. **Acta Neurol Scand** 1995 Jun;91(6):437–43

Effect of spinal cord stimulation on myocardial blood flow assessed by positron emission tomography in patients with refractory angina pectoris. Hautvast RW, et al. **Am J Cardiol** 1996 Mar 1;77(7):462–7

The night of the Iguana. Flemmer M, et al. **Am J Gastroenterol** 1995 Dec;90(12):2243

A pet therapy intervention with geriatric psychiatry inpatients. Zisselman MH, et al. **Am J Occup Ther** 1996 Jan;50(1):47–51

Pet ownership among persons with AIDS in three Florida counties. Conti L, et al. **Am J Public Health** 1995 Nov; 85(11):1559–61

Central America Regional Screwworm Eradication Program (benefit/cost study). Wyss JH, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:241–7

Health hazards to humans associated with domestic pets. Plaut M, et al. **Annu Rev Public Health** 1996;17:221–45 (87 ref.)

The nutritional significance of endogenous N-losses along the gastro-intestinal tract of farm animals. Tamminga S, et al. **Arch Tierernahr** 1995;48(1-2):9–22 (44 ref.)

The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease. Kitching RP, et al. **Br Vet J** 1995 Jul-Aug; 151(4):379–89 (40 ref.)

Current perspectives in salmonellosis [see comments] Lax AJ, et al. **Br Vet J** 1995 Jul-Aug;151(4):351–77 (230 ref.). Comment in: Br Vet J 1995 Jul-Aug;151(4):339–41.

Rabies diagnosis in western canada, january 1 to june 30, 1995. Kush J, et al. **Can Vet J** 1995 Dec;36(12):776

Bartonella (Rochalimaea) antibodies, dementia, and cat ownership among men infected with human immunodeficiency virus. Schwartzman WA, et al. **Clin Infect Dis** 1995 Oct;21(4):954–9

Extrinsic regulation of domestic animal-derived satellite cells. Dodson MV, et al. **Domest Anim Endocrinol** 1996 Mar;13(2):107–26 (130 ref.)

Livestock legacy. Meadows R. **Environ Health Perspect** 1995 Dec;103(12):1096–1100

Acting against anthrax. US military veterinarian helps Haitians and their animals [news] **J Am Vet Med Assoc** 1995 Dec 15;207(12):1533, 1535

Compendium of animal rabies control, 1996: National Association of State Public Health Veterinarians, Inc. **J Am Vet Med Assoc** 1996 Jan 15;208(2):214–8

Unlicensed practice of veterinary medicine [letter] Allen JM. **J Am Vet Med Assoc** 1995 Nov 1;207(9):1161

AHI perspectives: flexible drug labeling and its impact on the drug development process. Practical aspects of flexible labeling in feedlots. Apley MD. **J Am Vet Med Assoc** 1995 Oct 1;207(7):901–2; discussion 902–4

More thoughts on animal rights and animal liberation [letter] Barghusen S. **J Am Vet Med Assoc** 1996 Jan 1;208(1):22–3

More thoughts on animal rights and animal liberation [letter] Blackwell TE. **J Am Vet Med Assoc** 1996 Jan 1;208(1):22

Forum article on nonhuman animal research elicits considerable dialogue [letter] Bley J. **J Am Vet Med Assoc** 1996 Aug 1;209(3):544–5

Impact and risk of foreign animal diseases. Brown CC, et al. **J Am Vet Med Assoc** 1996 Apr 1;208(7):1038–40 (16 ref.)

Reflections on the human-animal bond. Bustad LK. **J Am Vet Med Assoc** 1996 Jan 15;208(2):203–5

Postexposure rabies prophylaxis and preexposure rabies vaccination failure in domestic animals. Clark KA, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1827–30

Sources of information for livestock producers. Gehrke BC. **J Am Vet Med Assoc** 1995 Aug 15;207(4):432–3

Wisconsin train derailment turns veterinarians into heroes [news] Grendahl LG, et al. **J Am Vet Med Assoc** 1996 May 15;208(10):1611–2

What do food animal practitioners want to read? Herrick JB. **J Am Vet Med Assoc** 1996 Jan 15;208(2):196–7

The role of food animal practitioners in control and eradication of diseases. Herrick JB. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1966–7

Xenotransplantation and food animal practitioners [see comments] Herrick JB. **J Am Vet Med Assoc** 1996 Mar 15;208(6):826–7. Comment in: J Am Vet Med Assoc 1996 Jun 1;208(11):1788–9.

Breaking the human-companion animal bond. Houpt KA, et al. **J Am Vet Med Assoc** 1996 May 15;208(10):1653–9

Control charts and the value of statistical inference for food animal practitioners. Humble JA. **J Am Vet Med Assoc** 1996 Apr 15;208(8):1232–3

Opportunities for food animal practitioners to promote human and animal health. Humble JA. **J Am Vet Med Assoc** 1995 Dec 15;207(12):1554–5

Forum article on nonhuman animal research elicits considerable dialogue [letter] Jacobs FS. **J Am Vet Med Assoc** 1996 Aug 1;209(3):548

Equipping Pakistan for the future [news] Kathio IH. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1398

Rabies surveillance in the United States during 1994. Krebs JW, et al. **J Am Vet Med Assoc** 1995 Dec 15; 207(12):1562–75

Pets play role in child development [news] Meehan SK. **J Am Vet Med Assoc** 1995 Oct 15;207(8):1010–1

Clinical application of interferons in large animal medicine. Moore BR. **J Am Vet Med Assoc** 1996 May 15; 208(10):1711–5 (50 ref.)

Animal selection and breeding techniques that create diseased populations and compromise welfare. Ott RS. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1969–74 (48 ref.)

Right to pet ownership closer for seniors and disabled in federally assisted housing [news] Regula K. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1945, 1947

AVMA/Practice Group perspectives: use of drug labels in the prescription of antimicrobial therapy. Representing the American Animal Hospital Association (AAHA). Reid J. **J Am Vet Med Assoc** 1995 Oct 1;207(7):879–80; discussion 890–4

Forum article on nonhuman animal research elicits considerable dialogue [letter] Stabenow J. **J Am Vet Med Assoc** 1996 Aug 1;209(3):550

Animal care and use: an issue now and in the future. Kertz AF. **J Anim Sci** 1996 Jan;74(1):257–61 (16 ref.)

Pet ownership in the UAE: its effect on allergy and respiratory symptoms. Abdulrazzaq YM, et al. **J Asthma** 1995;32(2):117–24

Three cases of Pasteurella multocida skin infection from pet cats. Matsui T, et al. **J Dermatol** 1996 Jul;23(7):502–4

Prevalence of and potential risk factors for symptoms associated with insecticide use among animal groomers. Bukowski J, et al. **J Occup Environ Med** 1996 May; 38(5):528–34

Plant poisonings and mycotoxicoses as constraints in livestock production in east Africa: the southern African experience. Naudé TW, et al. **J S Afr Vet Assoc** 1996 Mar; 67(1):8–11 (18 ref.)

A taste of the exotic at Birmingham [news] **J Small Anim Pract** 1996 May;37(5):248–9

Population dynamics of feline immunodeficiency virus within cat populations. Courchamp F, et al. **J Theor Biol** 1995 Aug 21;175(4):553–60

The benefits of pet ownership. Anderson WP. **Med J Aust** 1996 Apr 1;164(7):441–2

Conservation biology. Dangerous liaisons and disease [news; comment] Macdonald DW. **Nature** 1996 Feb 1; 379(6564):400–1. Comment on: Nature 1996 Feb 1;379(6564):441–5.

Brain mechanisms in human classical conditioning: a PET blood flow study. Hugdahl K, et al. **Neuroreport** 1995 Sep 11;6(13):1723–8

Food preferences in farm animals: why don't they always

choose wisely? Forbes JM, et al. **Proc Nutr Soc** 1995 Jul; 54(2):429–40 (45 ref.)

Head motion during positron emission tomography: is it significant? Ruttimann UE, et al. **Psychiatry Res** 1995 May 31;61(1):43–51

Reproductive research on farm animals for Australia—some long-distance goals. Martin GB. **Reprod Fertil Dev** 1995; 7(5):967–82 (85 ref.)

Transgenic sheep and wool growth: possibilities and current status. Powell BC, et al. **Reprod Fertil Dev** 1994;6(5):615–23 (28 ref.)

Strategies for production of pharmaceutical proteins in milk. Wilmut I, et al. **Reprod Fertil Dev** 1994;6(5):625–30 (51 ref.)

Aircraft and ship disinfection. Cancellotti FM. **Rev Sci Tech** 1995 Mar;14(1):177–89 (20 ref.)

Epidemiology of Mycobacterium bovis infection in animals and humans, with particular reference to Africa. Cosivi O, et al. **Rev Sci Tech** 1995 Sep;14(3):733–46 (63 ref.)

Disinfection procedures for personnel and vehicles entering and leaving contaminated premises. Ford WB. **Rev Sci Tech** 1995 Jun;14(2):393–401 (10 ref.)

Disinfection of stockyards. Fotheringham VJ. **Rev Sci Tech** 1995 Jun;14(2):293–307 (21 ref.)

Disinfection of livestock production premises. Fotheringham VJ. **Rev Sci Tech** 1995 Mar;14(1):191–205 (21 ref.)

Disinfection of trucks and trailers. Mateost Poumian A. **Rev Sci Tech** 1995 Mar;14(1):165–76 (4 ref.) **(Eng, Spa)**

Risk of introducing exotic disease through importation of animals and animal products. Metcalf HE, et al. **Rev Sci Tech** 1995 Dec;14(4):951–6 (12 ref.)

Patients improve with pet therapy. Price CL. **Tex Med** 1996 Aug;92(8):12–3

Client counseling in orthopedic emergencies. Brackenridge SS, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1047–58 (7 ref.)

Intoxication due to Achyrantes aspera L. Sanchez Perere LM, et al. **Vet Hum Toxicol** 1995 Dec;37(6):582

Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs. Büttner M, et al. **Vet Immunol Immunopathol** 1995 Jun;46(3–4):237–50

NFU sets out its position on farm animal welfare [news] **Vet Rec** 1995 Jul 8;137(2):30–1

International disease surveillance: July to September 1995. **Vet Rec** 1995 Dec 9;137(24):604

CIWF calls for ban on genetic engineering of farm animals [news] **Vet Rec** 1995 Sep 2;137(10):231

International disease surveillance: January to March 1995. **Vet Rec** 1995 Aug 12;137(7):157

Practical applications of IAH research [news] **Vet Rec** 1995 Aug 12;137(7):154–5

Suspected adverse reactions, 1994 [news] **Vet Rec** 1996 Jan 13;138(2):26

Iodine in feeds [letter] Cooke BC. **Vet Rec** 1996 Jan 27; 138(4):96

Companion animal diets [letter] Gildersleeve J. **Vet Rec** 1996 Mar 9;138(10):239

A review of clinical conditions in pet rabbits associated with their teeth. Harcourt-Brown FM. **Vet Rec** 1995 Sep 30; 137(14):341–6

Attitudes to companion animals [letter] Houghton L. **Vet Rec** 1996 Jan 27;138(4):95

A survey of urban pet ownership in Bali. Margawani KR, et al. **Vet Rec** 1995 Nov 4;137(19):486–8

Embryonic stem cells in farm animals. Galli C, et al. **Zygote** 1994 Nov;2(4):385–9 (47 ref.)

[Electronic identification companion animals. 'Be sensible and wait!'] Deleu S. **Tijdschr Diergeneeskd** 1995 Dec 15; 120(24):734 **(Dut)**

[Dog endangered by emancipation] Graafsma C, et al. **Tijdschr Diergeneeskd** 1996 Jul 15–Aug 1; 121(14–15):429–32 **(Dut)**

[Well-being—intrinsic value—integrity. Developments in the reevaluation of the domesticated animal] Grommers FJ, et al. **Tijdschr Diergeneeskd** 1995 Sep 1;120(17):490–4 (27 ref.) (Eng. Abstr.) **(Dut)**

[Regulation indication contagious animal diseases (news)] van Egmond S. **Tijdschr Diergeneeskd** 1996 Jun 1;121(11):326–7 **(Dut)**

[Veterinary dentistry (12). Discoloration of teeth in companion animals] van Foreest AW. **Tijdschr Diergeneeskd** 1996 Jun 1;121(11):316–22 (18 ref.) (Eng. Abstr.) **(Dut)**

[What clients want from veterinarians following the death of their companion animal. Bobby died, what now?] Winius EE, et al. **Tijdschr Diergeneeskd** 1996 May 1;121(9):250–4 (Eng. Abstr.) **(Dut)**

[Domestic animals and pets as sources of infection] Vuento R. **Duodecim** 1994;110(6):555–66 (34 ref.) **(Fin)**

[The importance of tropical animal hygiene for indigenous animal production] Böhnel H. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):443–6 (6 ref.) (Eng. Abstr.) **(Ger)**

[Animal welfare and profit motive in compatible pet shops] Bollhöfer H. **DTW Dtsch Tierarztl Wochenschr** 1996 Feb; 103(2):65–6 (Eng. Abstr.) **(Ger)**

[Supervision of animal welfare regulations in animal markets—an official veterinary stepchild?] Fröhlich T, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar; 102(3):131–3 (Eng. Abstr.) **(Ger)**

[The African ostrich—a "useful animal" in Germany?] Hagen H, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Mar; 103(3):98–100 (Eng. Abstr.) **(Ger)**

[Ostrich farming from the perspective of veterinarians] Kösters J, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Mar;103(3):100–4 (Eng. Abstr.) **(Ger)**

[Animal welfare for animals kept for animal-supported therapy in homes and hospitals] von Wenzlawowicz C. **DTW Dtsch Tierarztl Wochenschr** 1995 Nov;102(11):425–6 (Eng. Abstr.) **(Ger)**

[Zoo, domestic and wild animal medicine—new veterinary problems] Isenbügel E. **Schweiz Arch Tierheilkd** 1996; 138(5):251–3 **(Ger)**

[New horizons in the human-animal relationship. Therapy and assistance by the use of animals (pet therapy) (news)] Bonofiglio T. **Ann Ig** 1995 Mar–Apr;7(2):137–40 **(Ita)**

[Epidemiology of Toxoplasma gondii infection in the municipality of Ribeirão das Neves, MG. I. Importance of domestic animals as sources of T. gondii infection in humans] de Camargo MC, et al. **Rev Soc Bras Med Trop** 1995 Jul–Sep;28(3):211–4 (Eng. Abstr.) **(Por)**

[Biodiversity and similarity between the nematode parasite communities of domestic and wild ruminants] Morales GA, et al. **Acta Cient Venez** 1993;44(5):285–91 (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Morphological investigations of the glandulae profundae plicae semilunares conjuctivae in the domestic swine (Sus scrofa domesticus) and the wild hog (Sus scrofa ferus). Hraste A, et al. **Anat Histol Embryol** 1995 Dec;24(4):223–6

Histomorphologic and histochemical characteristics of carpal glands (Glandulae carpeae) in domestic swine (Sus scrofa domesticus) and wild swine (Sus scrofa ferus). Hraste A, et al. **Anat Histol Embryol** 1995 Sep;24(3):209–11

Renal venous architectonics in domestic swine. Vodenicharov A, et al. **Anat Histol Embryol** 1995 Sep; 24(3):149–53

Morphological studies of the valves of the kidney vein in domestic swine. Vodenicharov A, et al. **Anat Histol Embryol** 1995 Sep;24(3):155–8

[All-Russian methodologic conference on pathology in agricultural animals] Shishkov VP, et al. **Arkh Patol** 1995 Nov–Dec;57(6):80 **(Rus)**

EMBRYOLOGY

The development of the genital peritoneum in domestic mammals. An analysis of the literature and nomenclature. Martin E. **Anat Histol Embryol** 1995 Dec;24(4):285–7 (18 ref.)

GENETICS

Genetic variation in domestic reindeer and wild caribou in Alaska. Cronin MA, et al. **Anim Genet** 1995 Dec; 26(6):427–34

Marker assisted selection for genetic improvement of animal populations when a single QTL is marked. Ruane J, et al. **Genet Res** 1995 Aug;66(1):71–83

Comparison of evaluation-selection systems for maximizing genetic response at the same level of inbreeding. Quinton M, et al. **J Anim Sci** 1995 Aug;73(8):2208–12

Progress and emerging problems in livestock transgenesis: a summary perspective. Seamark RF. **Reprod Fertil Dev** 1994;6(5):653–7 (36 ref.)

Livestock QTLs—bringing home the bacon? Haley CS. **Trends Genet** 1995 Dec;11(12):488–92 (27 ref.)

GROWTH & DEVELOPMENT

Farm animal well-being and intensive production systems. Swanson JC. **J Anim Sci** 1995 Sep;73(9):2744–51 (60 ref.)

IMMUNOLOGY

Effects of selenium and vitamin E on the immune responses of domestic animals. Finch JM, et al. **Res Vet Sci** 1996 Mar;60(2):97–106 (108 ref.)

Rheumatoid arthritis: are pets implicated in its etiology? Bond C, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):308–17

INJURIES

Gunshot injuries: pathophysiology and treatments. Bebchuk TN, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1111–26 (33 ref.)

Management of fracture-associated thoracic trauma. Cockshutt JR. **Vet Clin North Am Small Anim Pract** 1995 Sep;25(5):1031–46 (53 ref.)

Anesthetic management of the trauma patient. Cuvelliez S, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1073–92 (42 ref.)

Spinal fracture/luxation. Kirby BM. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1149–74 (49 ref.)

Management of penetrating joint injuries. Lewis DD. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1197–223 (107 ref.)

Traumatic joint luxations in small animals. McLaughlin RM Jr. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1175–96 (28 ref.)

General management considerations for the trauma patient. Payne JT. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1015–29 (6 ref.)

Fracture management decisions. Roush JK. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1059–72 (19 ref.)

Skull trauma and mandibular fractures. Smith MM, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1127–48 (47 ref.)

Open fracture management. Tillson DM. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1093–110 (55 ref.)

METABOLISM

Control of growth hormone synthesis. Tuggle CK, et al. **Domest Anim Endocrinol** 1996 Jan;13(1):1–33 (256 ref.)

[Proposal for the introduction of a metabolizable energy feed evaluation system based on unitary parameters and principles for all farm animals. 1. Energy feed evaluation for cattle] Hoffmann L. **Arch Tierernahr** 1993;45(3):245–61 (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Iguana-associated salmonellosis in a young adult. Weil BJ, et al. **J Adolesc Health** 1995 Aug;17(2):120–2

Ornamental fish: look but do not touch! [letter] Hay J, et al. **J R Soc Med** 1996 Jun;89(6):359

Escherichia coli O157 infection in a human linked to exposure to infected livestock [letter] Rice DH, et al. **Vet Rec** 1996 Mar 30;138(13):311

Vero cytotoxin-producing Escherichia coli O157 associated with companion animals [letter] Trevena WB, et al. **Vet Rec** 1996 Apr 20;138(16):400

[The resistance behavior of significant veterinary bacterial agents in the year 1992 (ranking in sequence)] Trolldenier H. **Berl Munch Tierarztl Wochenschr** 1995 Apr; 108(4):127–32 (Eng. Abstr.) **(Ger)**

[A new serovar of Salmonella: S. IIIb 35: l, z13: e, n, x, z15] Orlandella BM, et al. **G Batteriol Virol Immunol** 1992 Jan–1993 Dec;85(1–12):20–5 (Eng. Abstr.) **(Ita)**

PARASITOLOGY

Costs of major parasites to the Australian livestock industries. McLeod RS. **Int J Parasitol** 1995 Nov;25(11):1363–7 (25 ref.)

Current research on Sarcocystis species of domestic animals. Tenter AM. **Int J Parasitol** 1995 Nov;25(11):1311–30 (132 ref.)

Comparison of four murine Eimeria species in immunocompetent and immunodeficient mice. Schito ML, et al. **J Parasitol** 1996 Apr;82(2):255–62

Cyst wall ultrastructure of two Sarcocystis spp. from European mouflon (Ovis ammon musimon) in Germany compared with domestic sheep. Odening K, et al. **J Wildl Dis** 1995 Oct;31(4):550–4

The virtual absence of Culicoides imicola (Diptera: Ceratopogonidae) in a light-trap survey of the colder, high-lying area of the eastern Orange Free State, South Africa, and implications for the transmission of arboviruses. Venter GJ, et al. **Onderstepoort J Vet Res** 1994 Dec; 61(4):327–40

Propagation of the tick Amblyomma variegatum in the Caribbean. Barré N, et al. **Rev Sci Tech** 1995 Sep; 14(3):841–55

[Anthelmintics resistance in gastrointestinal nematodes in domestic animals] Geerts S. **Verh K Acad Geneeskd Belg** 1995;57(5):351–69; discussion 369–70 (45 ref.) (Eng. Abstr.) **(Dut)**

PHYSIOLOGY

The ovarian insulin and insulin-like growth factor system with an emphasis on domestic animals. Spicer LJ, et al. **Domest Anim Endocrinol** 1995 Jul;12(3):223–45 (182 ref.)

Environmental considerations of livestock producers. Morse D. **J Anim Sci** 1995 Sep;73(9):2733–40 (35 ref.)

Farm animal well-being and intensive production systems. Swanson JC. **J Anim Sci** 1995 Sep;73(9):2744–51 (60 ref.)

[Reproductive medicine in transition: new developments in embryo transfer] Binder H, et al. **Schweiz Arch Tierheilkd** 1996;138(5):245–50 (18 ref.) (Eng. Abstr.) **(Ger)**

[Developmental trends in farm animal husbandry from an ethological point of view] Graf B. **Schweiz Arch Tierheilkd** 1995;137(9):423–31 (12 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Pet ownership, social support, and one-year survival after acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial (CAST). Friedmann E, et al. **Am J Cardiol** 1995 Dec 15;76(17):1213–7

Emerging differentiation of folkbiology and folkpsychology: attributions of biological and psychological properties to living things. Coley JD. **Child Dev** 1995 Dec;66(6):1856–74

[The anatomy of consciousness in domestic animals. Opening address of the 20th Congress of the EVVA in Zürich in memory of Eugen Seiferle] Preuss F. **Anat Histol Embryol** 1996 Mar;25(1):71–4 (Eng. Abstr.) **(Ger)**

[Some theoretical aspects of behavior research in domestic animals] Puppe B. **Berl Munch Tierarztl Wochenschr** 1995 Apr;108(4):133–7 (60 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Questions effectiveness of Spay Day [letter] Buelke DL. **J Am Vet Med Assoc** 1996 Aug 1;209(3):538–9

ANIMALS, LABORATORY

see related
ANIMAL TESTING ALTERNATIVES
LABORATORY ANIMAL SCIENCE

The prevalence of spontaneous endometriosis in the baboon (Papio anubis, Papio cynocephalus) increases with the duration of captivity. D'Hooghe TM, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):98–101

Air quality in an animal facility: particulates, ammonia, and volatile organic compounds. Kacergis JB, et al. **Am Ind Hyg Assoc J** 1996 Jul;57(7):634–40

Epidemiologic assessment of laboratory animal allergy among university employees. Fuortes LJ, et al. **Am J Ind Med** 1996 Jan;29(1):67–74

Revealing animal experiments in general psychology texts: opening Pandora's box [comment] Cunningham PF. **Am Psychol** 1996 Jul;51(7):734–5. Comment on: Am Psychol 1995 Jul;50(7):496–503.

Teaching about animal research in psychology [comment] Domjan M, et al. **Am Psychol** 1996 Jul;51(7):736–7. Comment on: Am Psychol 1995 Jul;50(7):496–503.

Right, but for the wrong reasons [comment] Gosling SD. **Am Psychol** 1996 Jul;51(7):735–6. Comment on: Am Psychol 1995 Jul;50(7):496–503.

Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Karar|i TT. **Biopharm Drug Dispos** 1995 Jul; 16(5):351–80 (79 ref.)

Quantification of the hemolysis associated with use of T–61 as a euthanasia agent in rabbits—a comparison with Euthanyl (pentobarbital sodium) and the impact on serum hexosaminidase measurements. Doughty MJ, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1274–80

Precise control of the frequency and amount of food provided for small laboratory animals by a new electronic metering technique, used to evaluate the cariogenic potential of chocolate. Grenby TH, et al. **Caries Res** 1995;29(5):418–23

Laboratory reared Amblyomma hebraeum and Amblyomma variegatum ticks differ in their susceptibility to infection with Cowdria ruminantium. Mahan SM, et al. **Epidemiol Infect** 1995 Oct;115(2):345–53

Allergic rhinitis in laboratory workers caused by occupational exposure to guinea pigs: an immunological and clinical study. Hanada T, et al. **Eur Arch Otorhinolaryngol** 1995;252(5):304–7

Deodorization of laboratory animal facilities by ozone. Pan TM, et al. **Exp Anim** 1995 Jul;44(3):255–9

Ethical principles and guidelines for experiments on animals. Swiss Academy of Medical Sciences. Swiss Academy of Sciences. **Experientia** 1996 Jan 16;52(1):1–3

Impact of vitamin E supplement in standard laboratory animal diet on microvascular manifestation of ischemia/reperfusion injury. Willy C, et al. **Free Radic Biol Med** 1995 Dec;19(6):919–26

Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing. Weingand K, et al. **Fundam Appl Toxicol** 1996 Feb; 29(2):198–201 (26 ref.)

Forum article on nonhuman animal research elicits considerable dialogue [letter] Altrogge DM. **J Am Vet Med Assoc** 1996 Aug 1;209(3):543

Forum article on nonhuman animal research elicits considerable dialogue [letter] Bley J. **J Am Vet Med Assoc** 1996 Aug 1;209(3):544–5

Forum article on nonhuman animal research elicits considerable dialogue [letter] Dennis J. **J Am Vet Med Assoc** 1996 Aug 1;209(3):546

The immorality of nonhuman animal research. Feldmann BM. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1798–801

Forum article on nonhuman animal research elicits considerable dialogue [letter] Freeman A. **J Am Vet Med Assoc** 1996 Aug 1;209(3):546–7

Forum article on nonhuman animal research elicits considerable dialogue [letter] Jacobs FS. **J Am Vet Med Assoc** 1996 Aug 1;209(3):548

Forum article on nonhuman animal research elicits considerable dialogue [letter] Mathey WJ. **J Am Vet Med Assoc** 1996 Aug 1;209(3):548–9

Forum article on nonhuman animal research elicits considerable dialogue [letter] Nusbaum KE. **J Am Vet Med Assoc** 1996 Aug 1;209(3):549–50

Forum article on nonhuman animal research elicits considerable dialogue [letter] Stabenow J. **J Am Vet Med Assoc** 1996 Aug 1;209(3):550

Anaphylaxis after laboratory rat bite: an occupational hazard. Hesford JD, et al. **J Emerg Med** 1995 Nov–Dec;13(6):765–8

Ultra–high resolution SPECT system using four pinhole collimators for small animal studies [see comments] Ishizu K, et al. **J Nucl Med** 1995 Dec;36(12):2282–7. Comment in: J Nucl Med 1995 Dec;36(12):2287–9.

PET scanners for small animals [letter; comment] Lammertsma Aa, et al. **J Nucl Med** 1995 Dec;36(12):2391–2 . Comment on: J Nucl Med 1994 Aug;35(8):1396–7.

Provision for welfare of non–human primates used in biomedical research. Box HO, et al. **Lab Anim** 1995 Jul; 29(3):233–6

Black scorpion (Heterometrus longimanus) as a laboratory animal: maintenance of a colony of scorpion for milking of venom for research, using a restraining device. Gopalakrishnakone P, et al. **Lab Anim** 1995 Oct;29(4):456–8

An investigation into the effects of solid or grid cage flooring on the welfare of laboratory rats. Manser CE, et al. **Lab Anim** 1995 Oct;29(4):353–63

The use of a novel operant test to determine the strength of preference for flooring in laboratory rats. Manser CE, et al. **Lab Anim** 1996 Jan;30(1):1–6

Microchip implant system used for animal identification in laboratory rabbits, guineapigs, woodchucks and in amphibians. Mrozek M, et al. **Lab Anim** 1995 Jul; 29(3):339–44

Guidelines and legal codes for the welfare of non–human primates in biomedical research. Poole TB. **Lab Anim** 1995 Jul;29(3):244–9

Development of a laboratory colony of the musk shrew (Suncus murinus, insectivora) exhibiting a high incidence of spontaneous diabetes mellitus. Ohno T, et al. **Lab Anim Sci** 1996 Feb;46(1):107–8

Animal models of antisense oligonucleotides: lessons for use in humans. Plenat F. **Mol Med Today** 1996 Jun;2(6):250–7 (37 ref.)

Animal experimentation [letter] [see comments] Carlson P. **Nat Med** 1995 Sep;1(9):849. Comment in: Nat Med 1995 Nov;1(11):1102.

Activists seek retirement home for chimps [news] Macilwain C. **Nature** 1996 Jun 27;381(6585):722

The three Rs and biomedical research [editorial] Goldberg AM, et al. **Science** 1996 Jun 7;272(5267):1403

Animal Research. Care guide gives labs more freedom [news] Roush W. **Science** 1996 Mar 22;271(5256):1664

Registry of toxicologic pathology for animals [letter] Nold JB. **Toxicol Pathol** 1995 Sep–Oct;23(5):622–3

Percutaneous absorption of metal ions [letter] Lansdown AB. **Vet Rec** 1995 Sep 2;137(10):252

[Use of laboratory animals for toxicologic testing of drugs and chemicals] Sýkora I. **Cas Lek Cesk** 1995 Aug 2; 134(15):467–70 (Eng. Abstr.) (Cze)

[Feasibility for the influence of the animal welfare commissioner and cooperation with the responsible authorities] Cybik M. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):123–5 (Eng. Abstr.) (Ger)

[Feasibility for the influence of official veterinarians on the improvement of animal husbandry] Nowak D. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):120–3 (Eng. Abstr.) (Ger)

[Procedures for health monitoring in a breeding facility for specific pathogen free mice and rats] Wyss–Spillmann SK, et al. **Schweiz Arch Tierheilkd** 1995;137(11):505–14 (39 ref.) (Eng. Abstr.) (Ger)

[Application of the common marmoset to pharmacological studies] Nomoto M. **Nippon Yakurigaku Zasshi** 1995 Jul; 106(1):11–8 (23 ref.) (Eng. Abstr.) (Jpn)

[The dorsal flap in laboratory animals] Marcos M, et al. **An Otorrinolaringol Ibero Am** 1995;22(5):449–66 (Eng. Abstr.) (Spa)

[The good use of experimental animals] Schumenann de Aluja A, et al. **Gac Med Mex** 1995 Jan–Feb;131(1):49–63 (Spa)

[Anesthesia in experimental animals. Basic principles] Cruz JI. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):99–107 (54 ref.) (Eng. Abstr.) (Spa)

ANATOMY & HISTOLOGY

[Is the pig a good study model for lung preservation? (letter)] Torre W, et al. **Arch Bronconeumol** 1995 Dec;31(10):547 (Spa)

BLOOD

[A comparative analysis of the oxygen–binding and antioxidant properties of the blood of laboratory animals and the muskrat Ondatra zibethica] Korobov VN, et al. **Zh Evol Biokhim Fiziol** 1995 May–Jun;31(3):369–72 (Eng. Abstr.) (Rus)

GENETICS

Re: Inbred strains of laboratory animals: superior to outbred mice? [letter; comment] Festing MF, et al. **J Natl Cancer Inst** 1995 Nov 15;87(22):1715–6. Comment on: J Natl Cancer Inst 1995 Jun 21;87(12):933.

IMMUNOLOGY

Variation in rat urinary aeroallergen levels explained by differences in site, task and exposure group. Nieuwenhuijsen MJ, et al. **Ann Occup Hyg** 1995 Dec; 39(6):819–25

Allergic sensitization is associated with increased bronchial responsiveness: a prospective study of allergy to laboratory animals. Renström A, et al. **Eur Respir J** 1995 Sep; 8(9):1514–9

Development of allergy to laboratory animals is associated with particular Gm and HLA genes. Oxelius VA, et al. **Int Arch Allergy Immunol** 1996 May;110(1):73–8

Allergy to laboratory animals among animal handlers. Bryant DH, et al. **Med J Aust** 1995 Oct 16;163(8):415–8

MICROBIOLOGY

Survey of Pseudomonas aeruginosa contamination in human beings and laboratory animals. Urano T, et al. **Exp Anim** 1995 Jul;44(3):233–9

Identification of widespread Helicobacter hepaticus infection in feces in commercial mouse colonies by culture and PCR assay. Shames B, et al. **J Clin Microbiol** 1995 Nov; 33(11):2968–72

[The use of gnotobiological technology for producing and maintaining experimental, animals with different microbiological states of the intestines] Balnov NA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep–Oct;(5):80–4 (Eng. Abstr.) (Rus)

PHYSIOLOGY

Pentachlorophenol accumulation in the freshwater mussels Anodonta anatina and Pseudanodonta complanata, and some physiological consequences of laboratory maintenance. Mäkelä TP, et al. **Chemosphere** 1995 Oct; 31(7):3651–62

[A method for the multiple implantation of semimicroelectrodes into the brain of small animals for research in free behavior] Chebkasov SA, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Sep–Oct; 45(5):1051–6 (Rus)

PSYCHOLOGY

Effects of gentling on open–field behaviour of Wistar rats in fear–evoking test situation. Hirsjärvi P, et al. **Lab Anim** 1995 Oct;29(4):380–4

Hereditary compulsive self–mutillating behaviour in laboratory rabbits. Iglauer F, et al. **Lab Anim** 1995 Oct; 29(4):385–93

Acquisition of a conditioned reflex in New Zealand white rabbits from three sources. Kehoe EJ, et al. **Lab Anim** 1995 Oct;29(4):394–9

Exploration and predation models of anxiety: evidence from laboratory and wild species. Hendrie CA, et al. **Pharmacol Biochem Behav** 1996 May;54(1):13–20 (56 ref.)

SURGERY

Institutional surgical practices for nonveterinarians. Banks RE. **J Invest Surg** 1995 Jul–Aug;8(4):211–22

VIROLOGY

Equine morbillivirus pneumonia: susceptibility of laboratory animals to the virus [letter] Westbury HA, et al. **Aust Vet J** 1995 Jul;72(7):278–9

Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory [see comments] Jaax N, et al. **Lancet** 1995 Dec 23–30; 346(8991–8992):1669–71. Comment in: Lancet 1996 Mar 9;347(9002):691.

Research on Ebola virus [letter; comment] Kelly MJ. **Lancet** 1996 Mar 9;347(9002):691. Comment on: Lancet 1995 Dec 23–30;346(8991–8992):1669–71.

ANIMALS, NEWBORN

Abundance of endothelial nitric oxide synthase in newborn intrapulmonary arteries. Hislop AA, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F17–21

Perineuronal sulfated proteoglycans and dark neurons in the brain and spinal cord: a histochemical and electron microscopic study of newborn and adult mice. Murakami T, et al. **Arch Histol Cytol** 1995 Dec;58(5):557–65

Equine neonatal septicaemia: 24 cases. Raisis AL, et al. **Aust Vet J** 1996 Apr;73(4):137–40

Inhalation of nitric oxide: effect on cerebral hemodynamics and activity, and antioxidant status in the newborn lamb. Lopes Cardozo RH, et al. **Biol Neonate** 1996;69(4):284–92

Hypoxic–ischemic injury acutely disrupts microtubule–associated protein 2 immunostaining in neonatal rat brain. Malinak C, et al. **Biol Neonate** 1996; 69(4):257–67

Comparison of natural surfactant and brief liquid ventilation rescue treatment in very immature lambs. Clinical and physiological correlates. Valls–i–Soler A, et al. **Biol Neonate** 1996;69(4):275–83

Patterns of ovarian cell proliferation in rats during the embryonic period and the first three weeks postpartum. Hirshfield AN, et al. **Biol Reprod** 1995 Nov;53(5):1208–21

Effect of developmental age or time after transplantation on Sertoli cell number and testicular size in inbred Fischer rats. Johnson L, et al. **Biol Reprod** 1996 May;54(5):948–59

A case–control study of the congenital hypothyroidism and dysmaturity syndrome of foals. Allen AL, et al. **Can Vet J** 1996 Jun;37(6):349–51; 354–8

Risk factors associated with the incidence of foal mortality in an extensively managed mare herd. Haas SD, et al. **Can Vet J** 1996 Feb;37(2):91–5

Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Dennery PA, et al. **Free Radic Biol Med** 1995 Oct;19(4):395–404

Evaluation of liver function tests in neonatal calves. Pearson EG, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1466–9

A new model of transient cerebral ischemia in neonatal rats. Mitsufuji N, et al. **J Cereb Blood Flow Metab** 1996 Mar; 16(2):237–43

A study of the use of milk replacers for dairy calves in the United States. Heinrichs AJ, et al. **J Dairy Sci** 1995 Dec; 78(12):2831–7

Pharmacological evidence for the existence of different subtypes of muscarinic acetylcholine receptors for phosphoinositide hydrolysis in neonatal versus adult rat atria. Camusso JJ, et al. **J Lipid Mediat Cell Signal** 1995 Jul;12(1):1–10

Dietary restriction induces biochemical and morphometric changes in the small intestine of nursing piglets. Nuñez MC, et al. **J Nutr** 1996 Apr;126(4):933–44

The three-week-old piglet as a model animal for studying protein digestion in human infants. Darragh AJ, et al. **J Pediatr Gastroenterol Nutr** 1995 Nov;21(4):387–93

Effects of dietary supplementation with fructooligosaccharides on colonic microbiota populations and epithelial cell proliferation in neonatal pigs. Howard MD, et al. **J Pediatr Gastroenterol Nutr** 1995 Oct; 21(3):297–303

Cerebral tissue oxygenation during hypoxia and hyperoxia using artificial placentation in lamb. Schmidt S, et al. **J Perinat Med** 1996;24(1):61–8

Increased numbers of Sertoli and germ cells in adult rat testes induced by synergistic action of transient neonatal hypothyroidism and neonatal hemicastration. Simorangkir DR, et al. **J Reprod Fertil** 1995 Jul;104(2):207–13

Development of a swine animal model for the study of sudden infant death syndrome. Tong S, et al. **Lab Anim Sci** 1995 Aug;45(4):398–403

Neonatal methamphetamine-induced long-term acoustic startle facilitation in rats as a function of prepulse stimulus intensity. Vorhees CV, et al. **Neurotoxicol Teratol** 1996 Mar–Apr;18(2):135–9

PAF effects on eicosanoid release in neonatal rat cardiomyocytes. Becker K, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Sep; 53(3):197–200

Pre- versus post-ventilatory surfactant treatment in surfactant-deficient preterm lambs. Cummings JJ, et al. **Reprod Fertil Dev** 1995;7(5):1333–8

Ultrastructural demonstration of glucose-6-phosphatase activity and glycogen in skeletal muscles of newborn piglets with the splayleg syndrome. Antaliková L, et al. **Reprod Nutr Dev** 1996;36(2):205–12

Isolation of Leishmania from a newborn puppy. Mancianti F, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):402

Observations on neonatal mortality of the Chacoan peccary, Catagonus wagneri. Benirschke K, et al. **Vet Pathol** 1995 Sep;32(5):532–4

The interval between birth and sternal recumbency as an objective measure of the vitality of newborn calves. Schuijt G, et al. **Vet Rec** 1994 Jul 30;135(5):111–5

[Effect of housing of sows during parturition and the vitality of the piglets] Hoy S, et al. **Tierarztl Prax** 1995 Aug; 23(4):367–72 (Eng. Abstr.) **(Ger)**

[Experiences in diagnosis and therapy of puppy diseases in the fist days of life] Münnich A, et al. **Tierarztl Prax** 1995 Oct;23(5):497–501 (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Clarification on foal with cyanoses and intense murmur [letter; comment] Schott HC 2nd, et al. **J Am Vet Med Assoc** 1996 May 1;208(9):1381. Comment on: J Am Vet Med Assoc 1996 Mar 15;208(6):835–7; discussion 838–9.

Neonatal mouse hip joint and hindlimb anomalies induced by prenatal exposure to Ara-C. Chiba K, et al. **Reprod Toxicol** 1996 May–Jun;10(3):215–9

Persistent truncus arteriosus in a diprosopic newborn calf. Camón J, et al. **Zentralbl Veterinarmed A** 1995 Mar; 42(1):41–9

ANATOMY & HISTOLOGY

Density of myenteric plexuses and neurons in the large and transverse colon of one-day-old foals. Schusser GF, et al. **Equine Vet J** 1994 Jul;26(4):337–9

The kinocilium of auditory hair cells and evidence for its morphogenetic role during the regeneration of stereocilia and cuticular plates. Sobkowicz HM, et al. **J Neurocytol** 1995 Sep;24(9):633–53

Anterograde axonal tracing with the subunit B of cholera toxin: a highly sensitive immunohistochemical protocol for revealing fine axonal morphology in adult and neonatal brains. Angelucci A, et al. **J Neurosci Methods** 1996 Mar; 65(1):101–12

BLOOD

Newborn blood used as a source of donor cells in a murine model of transplantation across non-MHC antigens. de la Selle V, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:351–60

Antenatal glucocorticoid treatment attenuates immediate postnatal prostacyclin and thromboxane levels in plasma of very preterm lambs. Ibe BO, et al. **Biol Neonate** 1996; 69(3):153–64

Immunoreactive insulin-like growth factor I and insulin in blood plasma and milk of mares and in blood plasma of foals. Hess-Dudan F, et al. **Equine Vet J** 1994 Mar; 26(2):134–9

Preliminary studies of recombinant bovine granulocyte-colony stimulating factor on haematological values in normal neonatal foals. Madigan JE, et al. **Equine Vet J** 1994 Mar;26(2):159–61

Haematological, bone marrow and clinical chemical changes in neonatal foals given canine recombinant granulocyte-colony stimulating factor. Zinkl JG, et al. **Equine Vet J** 1994 Jul;26(4):313–8

Alterations in blood lymphocyte subpopulations and hematologic values in neonatal calves after administration of a combination of multiple-antigen vaccines. Allen LJ, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):638–42

A rapid method for determination of blood glucose concentration in cattle. Roeder BL, et al. **J Am Vet Med Assoc** 1996 Mar 1;208(5):707–10

Effects of continuous infusion fentanyl citrate on cerebrovascular and systemic prostanoids in postsurgical newborn piglets. Modanlou HD, et al. **J Investig Med** 1996 Aug;44(6):362–9

Oral bis(tri-n-butyltin) oxide in pregnant mice. II. Alterations in hematological parameters. Karrer D, et al. **J Toxicol Environ Health** 1995 Nov;46(3):369–77

Some characteristics of nutrition metabolism and hormone control during the first 24 hours in neonatal calves. Chen L, et al. **Nutr Hosp** 1996 Jan–Feb;11(1):43–6

A retrospective study of increased plasma progestagen concentrations in compromised neonatal foals. Rossdale PD, et al. **Reprod Fertil Dev** 1995;7(3):567–75

GENETICS

Vocalizations in newborn mice: genetic analysis. Roubertoux PL, et al. **Behav Genet** 1996 Jul;26(4):427–37

Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Ludwig T, et al. **Dev Biol** 1996 Aug 1; 177(2):517–35

Effects on neonatal growth of the Hba(th-j) deletion on mouse chromosome 11 are not due to genomic imprinting. Hendrey JA, et al. **Growth Regul** 1995 Sep;5(3):160–3

GROWTH & DEVELOPMENT

Determinants of postnatal weight in infant rhesus monkeys: implications for the study of interindividual differences in neonatal growth. Johnson RL, et al. **Am J Phys Anthropol** 1995 Nov;98(3):343–53

Enhanced growth of fetal and neonatal pulmonary artery adventitial fibroblasts is dependent on protein kinase C. Das M, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):L660–7

Trehalase gene expression during postnatal development of rabbit intestine and kidney: effects of glucocorticoids. Galand G, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G833–41

Ontogenetic development of gut function, growth, and metabolism in a wild bird, the Red Jungle Fowl. Jackson S, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1163–73

Fibroblast proliferation during myocardial development in rats is regulated by IGF-1 receptors. Reiss K, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H943–51

Abnormal postpartum renal development and cystogenesis in the bcl-2 (-/-) mouse. Sorenson CM, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F184–93

Quantitative histomorphology of liver growth in sheep at prenatal and postnatal stages. Liman N. **Anat Histol Embryol** 1996 Mar;25(1):43–8

Neurobehavioral development of CD-1 mice after combined gestational and postnatal exposure to ozone. Dell'Omo G, et al. **Arch Toxicol** 1995;69(9):608–16

Effect of carbohydrate source on lipid metabolism in lactating mice and on pup development. Ghusain-Choueiri AA, et al. **Br J Nutr** 1995 Dec;74(6):821–31

Protein utilization, growth and survival in essential-fatty-acid-deficient rats. Henry CJ, et al. **Br J Nutr** 1996 Feb;75(2):237–48

DSP-4 treatment influences olfactory preferences of developing rats. Cornwell CA, et al. **Brain Res** 1996 Mar 4;711(1-2):26–33

Oxidative enzyme activity in the rat soleus muscle and its motoneurons during postnatal maturation. Nakano H, et al. **Brain Res Bull** 1995;38(3):235–8

NMDA antagonism during development extends sparing of hindlimb function to older spinally transected rats. Maier DL, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):135–44

The effect of litter size on normal retinal vascular development in the neonatal rat. Holmes JM, et al. **Curr Eye Res** 1995 Aug;14(8):737–40

The effects of neonatal hypoxia on kindled seizure development and electroconvulsive shock profiles. Applegate CD, et al. **Epilepsia** 1996 Aug;37(8):723–7

Age-specific effects of baclofen on pentylenetetrazol-induced seizures in developing rats. Velíšková J, et al. **Epilepsia** 1996 Aug;37(8):718–22

Development of electrical membrane properties and discharge characteristics of superior olivary complex neurons in fetal and postnatal rats. Kandler K, et al. **Eur J Neurosci** 1995 Aug 1;7(8):1773–90

Development of locomotor behavior in the spinal kitten. Howland DR, et al. **Exp Neurol** 1995 Oct;135(2):108–22

The development of quadrupedal locomotion in the kitten. Howland DR, et al. **Exp Neurol** 1995 Oct;135(2):93–107

Transplants enhance locomotion in neonatal kittens whose spinal cords are transected: a behavioral and anatomical study. Howland DR, et al. **Exp Neurol** 1995 Oct; 135(2):123–45

Protective role of nerve growth factor against excitatory amino acid injury during neostriatal cholinergic neurons postnatal development. Pérez-Navarro E, et al. **Exp Neurol** 1995 Oct;135(2):146–52

Decreased birth weight and attainment of postnatal catch-up growth in offspring of rats exposed to cigarette smoke during gestation. Leichter J. **Growth Dev Aging** 1995 Spring-Summer;59(1-2):63–6

Effects of neonatal growth on adult blood pressures of borderline hypertensive rats. Myers MM, et al. **Hypertension** 1996 Jan;27(1):96–101

Recombinant bovine somatotropin increases milk yield and calf gain in diverse breeds of beef cattle: associated changes in hormones and indices of metabolism. Armstrong JD, et al. **J Anim Sci** 1995 Oct;73(10):3051–61

Effects of calcium soaps of fatty acids on postpartum reproductive activity in beef cows and growth of calves. Espinoza JL, et al. **J Anim Sci** 1995 Oct;73(10):2888–92

Development of the spinocerebellar projection in the prenatal mouse. Grishkat HL, et al. **J Comp Neurol** 1995 Dec 4; 363(1):93–108

Ruminal availabilities of protein and starch: effects on growth and ruminal and plasma metabolites of dairy calves. Abdelgadir IE, et al. **J Dairy Sci** 1996 Feb;79(2):283–90

Effect of administration of bifidobacteria and lactic acid bacteria to newborn calves and piglets. Abe F, et al. **J Dairy Sci** 1995 Dec;78(12):2838–46

Developmental regulation of the urea-cycle enzyme arginase in the direct developing frog Eleutherodactylus coqui. Callery EM, et al. **J Exp Zool** 1996 May 1;275(1):61–6

Decline in maximal oxygen uptake on work performance in rats during the developmental phase. Yano H, et al. **Jpn J Physiol** 1995;45(5):889–93

Effects of perinatal administration of haloperidol on GH pituitary contents and serum levels during the first postnatal month. Iñiguez C, et al. **Neuroendocrinology** 1995 Sep; 62(3):308–12

Prenatal testosterone differentially masculinizes tonic and surge modes of luteinizing hormone secretion in the developing sheep. Wood RI, et al. **Neuroendocrinology** 1995 Sep;62(3):238–47

The use of preserved colostrum for rearing replacement dairy calves: calf performance, economics and on-farm practicability in Kenya. Karioki DI, et al. **Onderstepoort J Vet Res** 1995 Sep;62(3):167–70

Long-term effects of gestational protein malnutrition on postnatal growth, insulin-like growth factor (IGF)-I, and IGF-binding proteins in rat progeny. Muaku SM, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):649–55

Quantitative cancer assessment for vinyl chloride: indications of early-life sensitivity. Cogliano VJ, et al. **Toxicology** 1996 Jul 17;111(1-3):21–8 (11 ref.)

Efficient tissue repair underlies the resiliency of postnatally developing rats to chlordecone + CCl4 hepatotoxicity. Dalu A, et al. **Toxicology** 1996 Jul 17;111(1-3):29–42 (41 ref.)

IMMUNOLOGY

Dietary antigen handling by mother and offspring in a two generation study. Telemo E, et al. **Adv Exp Med Biol** 1995; 371A:517–9

Influence of the perinatal period on bovine interferon production. Kandefer-Szerszeń M, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):307–11

Cytotoxicity towards neonatal versus adult BB rat pancreatic islet cells. Ekblond A, et al. **Autoimmunity** 1995;20(2):93–8

Prevention of adjuvant arthritis in Lewis rats by neonatal bacille Calmette-Guerin (BCG) infection. Esaguy N, et al. **Clin Exp Immunol** 1996 Apr;104(1):103–7

The identification of the neonatal NBXFO hybridoma cell and its mediator. Jadus MR, et al. **Dev Comp Immunol** 1995 May-Jun;19(3):261–77

Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Barrios C, et al. **Eur J Immunol** 1996 Jul;26(7):1489–96

Neonatally tolerant rats actively eliminate donor-specific lymphocytes despite persistent chimerism. Cutler AJ, et al. **Eur J Immunol** 1996 Feb;26(2):320–8

Restricted onset of T cell receptor alpha gene rearrangement in fetal and neonatal thymocytes. Rytkönen MA, et al. **Eur J Immunol** 1996 Aug;26(8):1892–6

Effect of testosterone administration, pre- and postnatally, on the immune system of rats. Konstadoulakis MM, et al. **Horm Metab Res** 1995 Jun;27(6):275–8

Late-term fetal thymectomy does not prevent the development of gut-homing T cells after birth. Cahill RN, et al. **Immunology** 1996 May;88(1):130–3

Ligation of CD40 with soluble CD40 ligand reverses anti-immunoglobulin-mediated negative signalling in murine B lymphoma cell lines but not in immature B cells from neonatal mice. Marshall-Clarke S, et al. **Immunology** 1996 Apr;87(4):624–32

Molecular characterization of VDJ transcripts from a newborn piglet. Sun J, et al. **Immunology** 1996 Jul; 88(3):331–9

The perinatal presence of antigen (p-azophenylarsonate) or anti-mu antibodies lead to the loss of the recurrent idiotype (CRIA) in A/J mice. Ryelandt M, et al. **Int Immunol** 1995 Apr;7(4):645–52

Effects of perinatal vaccination on humoral and cellular immune responses in cows and young calves [see comments] Ellis JA, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):393–400. Comment in: J Am Vet Med Assoc 1996 May 15;208(10):1625–7.

Influence of calf genotype on colostral immunoglobulins in Bos taurus and Bos indicus cows and serum immunoglobulins in their calves. Vann RC, et al. **J Anim Sci** 1995 Oct;73(10):3044–50

Immunoglobulin concentrations in serum in response to injectable immunoglobulin in neonatal dairy calves. Crawford ML, et al. **J Dairy Sci** 1995 Jul;78(7):1567–72

Effects of supplemental vitamins E and C on the immune responses of calves. Hidiroglou M, et al. **J Dairy Sci** 1995 Jul;78(7):1578–83

Serum immunoglobulin concentrations and health of dairy calves in two management systems from birth to 12 weeks of age. Rajala P, et al. **J Dairy Sci** 1995 Dec;78(12):2737–44

Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: implications for antibody vs. T cell–mediated autoimmunity [see comments] Singh RR, et al. **J Exp Med** 1996 Apr 1; 183(4):1613–21. Comment in: J Exp Med 1996 Apr 1;183(4):1297–301.

Naive murine neonatal T cells undergo apoptosis in response to primary stimulation. Adkins B, et al. **J Immunol** 1996 Aug 15;157(4):1343–9

IL-12 protects immunocompetent and immunodeficient neonatal mice against infection with Cryptosporidium parvum. Urban JF Jr, et al. **J Immunol** 1996 Jan 1; 156(1):263–8

Development of peripheral blood mononuclear cell response to mitogens in Japanese black newborn calves. Inokuma H, et al. **J Vet Med Sci** 1995 Oct;57(5):971–2

The effect of in ovo oocyst or sporocyst inoculation on response to subsequent coccidial challenge. Watkins KL, et al. **Poult Sci** 1995 Oct;74(10):1597–602

Induction of TH1 and TH2 immunity in neonatal mice [see comments] Forsthuber T, et al. **Science** 1996 Mar 22; 271(5256):1728–30. Comment in: Science 1996 Mar 22;271(5256):1665–7. Comment in: Science 1996 Jun 7;272(5267):1405–8. Comment in: Science 1996 Jun 7;272(5267):1408. Comment in: Science 1996 Aug 9;273(5276):722–3.

Neonatal tolerance revisited: turning on newborn T cells with dendritic cells [see comments] Ridge JP, et al. **Science** 1996 Mar 22;271(5256):1723–6. Comment in: Science 1996 Mar 22;271(5256):1665–7. Comment in: Science 1996 Jun 7;272(5267):1405–8. Comment in: Science 1996 Jun 7;272(5267):1408. Comment in: Science 1996 Aug 9;273(5276):722–3.

Induction of protective CTL responses in newborn mice by a murine retrovirus [see comments] Sarzotti M, et al. **Science** 1996 Mar 22;271(5256):1726–8. Comment in: Science 1996 Mar 22;271(5256):1665–7. Comment in: Science 1996 Jun 7;272(5267):1405–8. Comment in: Science 1996 Jun 7;272(5267):1408. Comment in: Science 1996 Aug 9;273(5276):722–3.

Attenuated retrovirus vaccines and AIDS [letter; comment] Shearer GM, et al. **Science** 1995 Nov 17;270(5239):1219; discussion 1220–2. Comment on: Science 1995 Mar 24;267(5205):1820–5.

Immunological tolerance [letter; comment] Silverstein AM. **Science** 1996 Jun 7;272(5267):1405–8. Comment on: Science 1996 Mar 22;271(5256):1665–7. Comment on: Science 1996 Mar 22;271(5256):1723–6. Comment on: Science 1996 Mar 22;271(5256):1726–8. Comment on: Science 1996 Mar 22;271(5256):1728–30.

Detection of donor-derived cells by polymerase chain reaction in neonatally tolerant mice. Microchimerism fails to predict tolerance. Alard P, et al. **Transplantation** 1995 Nov 27;60(10):1125–30

CD4 Th2 cells do not functionally suppress CTL generation in neonatal tolerant mice. Gao Q, et al. **Transplantation** 1995 Dec 15;60(11):1260–8

Passive immunotherapy in neonatal calves—II. The efficacy of a J5 Escherichia coli hyperimmune plasma as immunotherapy in neonatal calves. Selim SA, et al. **Vaccine** 1995;13(15):1454–9

Passive immunotherapy in neonatal calves—I. Safety and potency of a J5 Escherichia coli hyperimmune plasma in neonatal calves. Selim SA, et al. **Vaccine** 1995; 13(15):1449–53

METABOLISM

Nitric oxide synthase activity in the hippocampus, frontal cerebral cortex, and cerebellum of the guinea pig: ontogeny and in vitro ethanol exposure. Brien JF, et al. **Alcohol** 1995 Jul–Aug;12(4):329–33

Expression and localization of prostaglandin EP3 receptor mRNA in the immature rabbit kidney. Bonilla-Felix M, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F30–6

Expression of protein kinase C isoforms during cardiac ventricular development. Clerk A, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H1087–97

In situ localization of sodium–potassium ATPase mRNA in developing mouse lung epithelium. Crump RG, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):L299–308

Developmental regulation of chloride/formate exchange in guinea pig proximal tubules. Guillery EN, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):F686–95

Regulation of DNA synthesis of myocardial and epicardial cells in developing rat heart by [Met5]enkephalin. McLaughlin PJ. **Am J Physiol** 1996 Jul;271(1 Pt 2):R122–9

Effect of hypoxia on nitric oxide production in neonatal pig lung. Nelin LD, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H8–14

Expression of transforming growth factor-beta type II receptor in rat lung is regulated during development. Zhao Y, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):L419–26

Neonatal myocardial oxygen consumption during ventricular fibrillation, hypothermia, and potassium arrest. Jessen ME, et al. **Ann Thorac Surg** 1996 Jan;61(1):82–7

Effects of furosemide, captopril and indometacin on the renin–angiotensin system and the renal prostaglandins in anesthetized neonatal piglets. Joppich R, et al. **Arzneimittelforschung** 1995 Jul;45(7):822–5

Zinc and manganese bioavailability from human milk and infant formula used for very low birthweight infants, evaluated in a rat pup model. Knudsen E, et al. **Biol Trace Elem Res** 1995 Jul;49(1):53–65

Dietary factors affecting the maximum feed intake and the body composition of pre-ruminant kid goats of the Granadina breed. Sanz Sampelayo MR, et al. **Br J Nutr** 1995 Sep;74(3):335–45

The effect of post-asphyxial reoxygenation with 21% vs. 100% oxygen on Na+,K(+)-ATPase activity in striatum of newborn piglets. Goplerud JM, et al. **Brain Res** 1995 Oct 23;696(1–2):161–4

Suppression of presynaptic calcium influx by metabotropic glutamate receptor agonists in neonatal rat hippocampus. Yoshino M, et al. **Brain Res** 1995 Oct 16;695(2):179–85

Developmental profile of non-heme iron distribution in the rat brain during ontogenesis. Moos T. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):203–13

Regional cerebral metabolic consequences of bilirubin in rat depend upon post-gestational age at the time of hyperbilirubinemia. Roger C, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):194–202

Functional expression of voltage dependent sodium channels in Xenopus oocytes injected with mRNA from neonatal or adult rat brain. Virginio C, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):153–9

Neonatal capsaicin treatment (NCT) alters the metabolic activity of the rat somatosensory cortex in response to mechanical deflection of the mystacial vibrissae. Wu CC, et al. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):62–8

Organochlorine compounds in blubber, liver and brain in neonatal grey seal pups. Jenssen BM, et al. **Chemosphere** 1996 Jun;32(11):2115–25

Comparison of 5-hydroxyindole-acetic acid and para-amino hippurate clearances in newborn rabbits. Sulyok E, et al. **Clin Chim Acta** 1995 Sep 15;240(2):155–61

Effect of a corn diet during development on [3H]-spiperone binding in the brain of rats at the perinatal stage. Beas-Zárate C, et al. **Comp Biochem Physiol A Physiol** 1995 Sep;112(1):161–6

Carbachol-regulation of the expression of alpha i1-subunit of Gi and inositol-[1,4,5]-trisphosphate receptor in brain samples obtained from neonatal and adult rats. Singh AK. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):205–13

Expression of cell surface markers and myelin proteins in cultured oligodendrocytes from neonatal brain of rat and mouse: a comparative study. Duchala CS, et al. **Dev Neurosci** 1995;17(2):70–80

Developmental expression of a candidate müllerian inhibiting substance type II receptor. Teixeira J, et al. **Endocrinology** 1996 Jan;137(1):160–5

Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Zafra F, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1342–52

Neonatal rat cerebellar granule and Purkinje neurons in culture express different GABAA receptors. Zempel JM, et al. **Eur J Neurosci** 1995 Sep 1;7(9):1895–905

The entrance of surface active material to pulmonary capillaries in the lungs of newborn rats. Biczysko W, et al. **Folia Histochem Cytobiol** 1995;33(1):25–31

Sodium-dependent glutamate uptake as an activator of oxidative metabolism in primary astrocyte cultures from newborn rat. Eriksson G, et al. **Glia** 1995 Oct;15(2):152–6

Cytosolic calcium changes induced by angiotensin II in neonatal rat atrial and ventricular cardiomyocytes are mediated via angiotensin II subtype 1 receptors. Touyz RM, et al. **Hypertension** 1996 May;27(5):1090–6

The appearance of rod opsin during monkey retinal development. Dorn EM, et al. **Invest Ophthalmol Vis Sci** 1995 Dec;36(13):2634–51

11 beta-Hydroxysteroid dehydrogenase in developing rat intestine. Pácha J, et al. **J Endocrinol** 1996 Mar;148(3):561–6

Mechanisms of altered LH secretion in neonatally oestrogenized male rats. Pinilla L, et al. **J Endocrinol** 1995 Oct;147(1):43–50

The role of excitatory amino acid pathways in the control of pituitary function in neonatally oestrogenized male rats. Pinilla L, et al. **J Endocrinol** 1995 Oct;147(1):51–7

Regulation of alpha7 nicotinic acetylcholine receptors in the developing rat somatosensory cortex by thalamocortical afferents. Broide RS, et al. **J Neurosci** 1996 May 1; 16(9):2956–71

Stimulation of choline acetyl transferase activity by l- and d-carnitine in brain areas of neonate rats. Ayala CA. **J Neurosci Res** 1995 Jun 15;41(3):403–8

Neurons express ciliary neurotrophic factor mRNA in the early postnatal and adult rat brain. Seniuk-Tatton NA, et al. **J Neurosci Res** 1995 Aug 1;41(5):663–76

Milk carnitine affects organ carnitine concentration in newborn rats. Flores CA, et al. **J Nutr** 1996 Jun; 126(6):1673–82

Proline is synthesized from glutamate during intragastric infusion but not during intravenous infusion in neonatal piglets. Murphy JM, et al. **J Nutr** 1996 Apr;126(4):878–86

Carnitine palmitoyltransferase modulation of hepatic fatty acid metabolism and radio-HPLC evidence for low ketogenesis in neonatal pigs. Odle J, et al. **J Nutr** 1995 Oct;125(10):2541–9

Short-term metabolic responses do not differ between neonatal piglets fed formulas containing hydrolyzed or intact soy proteins. Zijlstra RT, et al. **J Nutr** 1996 Apr; 126(4):913–23

Cysteine supplementation increases glutathione, but not polyamine, concentrations of the small intestine and colon of parenterally fed newborn rabbits. Pollack PF, et al. **J Pediatr Gastroenterol Nutr** 1996 May;22(4):364–72

Inhibition of prostaglandin synthesis in newborn pigs increases cerebral microvessel prostaglandin F2 alpha and prostaglandin E2 receptors, their second messengers and vasoconstrictor response to adult levels. Li DY, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):370–7

Gentamicin pharmacokinetics in newborn and 42-day-old male piglets. Giroux D, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):407–12

Pharmacokinetics of oxytetracycline administered intravenously to 4 to 5-day-old foals. Papich MG, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):375–8

The temporal and spatial vascular endothelial growth factor expression in retinal vasculogenesis of rat neonates. Murata T, et al. **Lab Invest** 1996 Jan;74(1):68–77

Defects in liver and muscle glycogen metabolism in neonatal and adult New Zealand obese mice. Thorburn A, et al. **Metabolism** 1995 Oct;44(10):1298–302

A P2 purinoceptor activated by ADP in rat medullar neurons. Ikeuchi Y, et al. **Neurosci Lett** 1995 Sep 29; 198(2):71–4

Neonatal 6-hydroxydopamine lesions lead to opposing changes in the levels of dopamine receptors and their messenger RNAs. Frohna PA, et al. **Neuroscience** 1995 Sep; 68(2):505–18

Characteristics of substance P-evoked release of amino acids from neonatal rat spinal cord. Maehara T, et al. **Neuroscience** 1995 Sep;68(2):577–84

Physiological changes in antioxidant defences in fetal and neonatal rat liver. Gonzalez MM, et al. **Reprod Fertil Dev** 1995;7(5):1375–80

Acute hypoxia induces elevation of ornithine decarboxylase activity in neonatal rat brain slices. Longo LD, et al. **Reprod Fertil Dev** 1995;7(3):385–9

The developmental switch in ventricular myosin expression in vivo is not triggered by an increase in cyclic AMP. Schachat F, et al. **Reprod Fertil Dev** 1995;7(5):1361–7

Testicular toxicity of the transferrin binding radionuclide 114mIn in adult and neonatal rats. Hoyes KP, et al. **Reprod Toxicol** 1995 May–Jun;9(3):297–305

The ventilatory and metabolic response to hypercapnia in newborn mammalian species. Mortola JP, et al. **Respir Physiol** 1996 Mar;103(3):263–70

Expansion of memory Th2 cells over Th1 cells in neonatal primed mice. Chen N, et al. **Transplantation** 1995 Dec 15; 60(11):1187–93

[The content of Na, K, Ca, Mg, total P, Fe, Cu and Zn in different tissues and in the placenta of sheep fetuses and newborn lambs] Leo M, et al. **Berl Munch Tierarztl Wochenschr** 1995 May;108(5):179–84 (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Development of intestinal flora of human-flora-associated (HFA) mice in the intestine of their offspring. Hirayama K, et al. **Exp Anim** 1995 Jul;44(3):219–22

PARASITOLOGY

Protection of young rats from acute Trypanosoma cruzi infection by interferon-gamma given to their mothers during pregnancy. Davila HO, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):660–4

Systemic infection with an unidentified Toxoplasma-like protozoan in a neonatal Lichtenstein's hartebeest (Sigmoceros lichtensteinii). Jardine JE, et al. **J Parasitol** 1996 Jun;82(3):515–7

PHYSIOLOGY

Irregular breathing in young lambs and newborn infants during heat stress. Riesenfeld T, et al. **Acta Paediatr** 1996 Apr;85(4):467–70

The postnatal potentiation of chemoreceptor sensitivity to O2 and CO2 in the in vitro rat carotid body is blunted by chronic hypoxaemia. Development of chemosensitivity. Kumar P, et al. **Adv Exp Med Biol** 1995;393:317–22

Early handling can attenuate adverse effects of fetal ethanol exposure. Weinberg J, et al. **Alcohol** 1995 Jul–Aug; 12(4):317–27

Expression of sarcoplasmic reticulum Ca2+ transport proteins in cold-acclimating ducklings. Dumonteil E, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C955–60

Nitric oxide does not mediate autoregulation of retinal blood flow in newborn pig. Gidday JM, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H1065–72

Neonatal rat dietary carbohydrate affects pancreatic islet insulin secretion in adults and progeny. Laychock SG, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):E739–44

Perinatal cannabinoid exposure modifies the sociosexual approach behavior and the mesolimbic dopaminergic activity of adult male rats. Navarro M, et al. **Behav Brain Res** 1996 Feb;75(1–2):91–8

The isolation and companion comfort responses of 7- and 3-day-old rat pups are modulated by drugs active at the opioid receptor. Carden SE, et al. **Behav Neurosci** 1996 Apr;110(2):324–30

Interactive effects of thermal environment and energy intake on thyroid hormone metabolism in newborn pigs. Berthon D, et al. **Biol Neonate** 1996;69(1):51–9

Effects of chloral hydrate on the cardiorespiratory response to hypoxia in newborn piglets. Yu XQ, et al. **Biol Neonate** 1996;69(3):146–52

Free estradiol in serum and brain uptake of estradiol during fetal and neonatal sexual differentiation in female rats. Montano MM, et al. **Biol Reprod** 1995 Nov;53(5):1198–207

Preventive effects of dexamethasone on hypoxic-ischemic brain damage in the neonatal rat. Liu Y, et al. **Brain Dev** 1995 May–Jun;17(3):186–92

Intracellular alkalosis during hypoxia in newborn mouse brain in the presence of systemic acidosis: a phosphorus magnetic resonance spectroscopic study. Mitsufuji N, et al. **Brain Dev** 1995 Jul–Aug;17(4):256–60

Effects of neonatal hypoxia on brainstem cholinergic neurons–pedunculopontine nucleus and laterodorsal tegmental nucleus. Tanaka H, et al. **Brain Dev** 1995 Jul–Aug;17(4):264–70

Effects of ethanol on respiratory activity in the neonatal rat brainstem–spinal cord preparation. Di Pasquale E, et al. **Brain Res** 1995 Oct 16;695(2):271–4

Postnatal maturation of the blood–brain barrier for unbound bilirubin in newborn piglets. Lee C, et al. **Brain Res** 1995 Aug 21;689(2):233–8

Behavioral consequences of neonatal injury of the neocortex. Rosen GD, et al. **Brain Res** 1995 May 29;681(1–2):177–89

Paradoxical mitochondrial oxidation in perinatal hypoxic–ischemic brain damage. Yager JY, et al. **Brain Res** 1996 Mar 18;712(2):230–8

Transient functional connections between the developing corticospinal tract and cervical spinal interneurons as demonstrated by c-fos immunohistochemistry. Curfs MH, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):214–9

NMDA antagonism during development extends sparing of hindlimb function to older spinally transected rats. Maier DL, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):135–44

Isoflurane and halothane impair both systolic and diastolic function in the newborn pig. Graham MR, et al. **Can J Anaesth** 1996 May;43(5 Pt 1):495–502

Deterministic—chaotic and periodic properties of heart rate and arterial pressure fluctuations and their mediation in piglets. Zwiener U, et al. **Cardiovasc Res** 1996 Mar; 31(3):455–65

Ultrastructural localization of nitric oxide synthase and endothelin in rat pulmonary artery and vein during postnatal development and ageing. Loesch A, et al. **Cell Tissue Res** 1996 Mar;283(3):355–65

Physiological studies of gastro-oesophageal reflux and airway protective responses in the young animal and human infant. Jeffery HE, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):544–9 (51 ref.)

Repair and recovery following spinal cord injury in a neonatal marsupial (Monodelphis domestica). Saunders NR, et al. **Clin Exp Pharmacol Physiol** 1995 Aug; 22(8):518–26

Effects of altered olfactory experiences on the development of infant rats' responses to odors. Terry LM, et al. **Dev Psychobiol** 1996 May;29(4):353–77

Perinatal thermogenesis. Gunn TR, et al. **Early Hum Dev** 1995 Aug 18;42(3):169–83 (60 ref.)

The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Brown RW, et al. **Endocrinology** 1996 Feb;137(2):794–7

Effect of fibroblast growth factor-2 on Sertoli cells and gonocytes in coculture during the perinatal period. Van Dissel-Emiliani FM, et al. **Endocrinology** 1996 Feb; 137(2):647–54

Perinatal ontogeny of porcine growth hormone receptor gene expression is modulated by thyroid status. Duchamp C, et al. **Eur J Endocrinol** 1996 Apr;134(4):524–31

The unique characteristics of inflammatory responses in mouse brain are acquired during postnatal development. Lawson LJ, et al. **Eur J Neurosci** 1995 Jul 1;7(7):1584–95

Failure of axon regeneration in postnatal rat entorhinohippocampal slice coculture is due to maturation of the axon, not that of the pathway or target. Li D, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1164–71

Properties of K+ conductances in cat retinal ganglion cells during the period of activity-mediated refinements in retinofugal pathways. Skaliora I, et al. **Eur J Neurosci** 1995 Jul 1;7(7):1558–68

Involvement of AMPA receptors in maintenance of memory for a passive avoidance task in day-old domestic chicks (Gallus domesticus). Steele RJ, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1297–304

Relationship between arterial and end-tidal carbon dioxide pressure during controlled ventilation in porcine neonates. Sakamoto H, et al. **Exp Anim** 1996 Apr;45(2):195–8

Intrinsic burst generation of preinspiratory neurons in the medulla of brainstem–spinal cord preparations isolated from newborn rats. Onimaru H, et al. **Exp Brain Res** 1995; 106(1):57–68

Neonatal isolation enhances hippocampal dentate response to tetanization in freely moving juvenile male rats. Kehoe P, et al. **Exp Neurol** 1995 Dec;136(2):89–97

Cold-induced changes in circulating levels of catecholamines and thyroid hormones are modulated by energy intake in newborn pigs. Herpin P, et al. **Exp Physiol** 1995 Sep; 80(5):877–80

Environmental effects on thermoregulation and breathing patterns during early postnatal development in hand-reared lambs. Symonds ME, et al. **Exp Physiol** 1995 Sep; 80(5):779–92

Maternal responsiveness to infant distress calls in stumptail macaques. Maestripieri D. **Folia Primatol (Basel)** 1995; 64(4):201–6

Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Linseman DA, et al. **Fundam Appl Toxicol** 1995 Nov;28(1):59–64

Identification of sex in hatchling loggerhead turtles (Caretta caretta) by analysis of steroid concentrations in chorioallantoic/amniotic fluid. Gross TS, et al. **Gen Comp Endocrinol** 1995 Aug;99(2):204–10

Effects of melatonin, testosterone and the two hormones administered in parallel on ventral prostate of the rat treated with stilbestrol in the first day of life. Limanowski A, et al. **Histol Histopathol** 1995 Oct;10(4):869–74

Morphological changes of myoepithelial cells of mouse lacrimal glands during postnatal development. Wang YL, et al. **Histol Histopathol** 1995 Oct;10(4):821–7

Rhythm generation in organotypic medullary cultures of newborn rats. Baker RE, et al. **Int J Dev Neurosci** 1995 Dec;13(8):799–809

Reducing pig mortality through supervision during the perinatal period. Holyoake PK, et al. **J Anim Sci** 1995 Dec; 73(12):3543–51

Causes of reduced survival of neonatal pigs by medium-chain triglycerides: blood metabolite and behavioral activity approaches. Lin CL, et al. **J Anim Sci** 1995 Jul; 73(7):2019–25

The effect of ewe body condition at lambing on colostral immunoglobulin G concentration and lamb performance. al-Sabbagh TA, et al. **J Anim Sci** 1995 Oct;73(10):2860–4

Age-dependent vulnerability to carotid chemodenervation in piglets. Côté A, et al. **J Appl Physiol** 1996 Jan; 80(1):323–31

Effect of roasted soybeans and corn on performance and ruminal and blood metabolites of dairy calves. Abdelgadir IE, et al. **J Dairy Sci** 1996 Mar;79(3):465–74

Effect of Lactobacillus acidophilus supplementation of milk replacer on preweaning performance of calves. Cruywagen CW, et al. **J Dairy Sci** 1996 Mar;79(3):483–6

Effect of supplemental lactoferrin with ferrous iron on iron status of newborn calves. Kume S, et al. **J Dairy Sci** 1996 Mar;79(3):459–64

The neonatal period: a critical interval in male primate development. Mann DR, et al. **J Endocrinol** 1996 May; 149(2):191–7

At least two mechanisms are involved in the death of retinal ganglion cells following target ablation in neonatal rats. Cui Q, et al. **J Neurosci** 1995 Dec;15(12):8143–55

The divergent homeobox gene PBX1 is expressed in the postnatal subventricular zone and interneurons of the olfactory bulb. Redmond L, et al. **J Neurosci** 1996 May 1;16(9):2972–82

Inhibition of lipid peroxidation attenuates axotomy-induced apoptotic degeneration of facial motor neurons in neonatal rats. Hall ED, et al. **J Neurosci Res** 1996 May 1;44(3):293–9

Effect of infant formula zinc and iron level on zinc absorption, zinc status, and immune function in infant rhesus monkeys. Polberger S, et al. **J Pediatr Gastroenterol Nutr** 1996 Feb;22(2):134–43

Effect of lung liquid volume on respiratory performance after caesarean delivery in the lamb. Berger PJ, et al. **J Physiol (Lond)** 1996 May 1;492 (Pt 3):905–12

Calcium-dependent responses in neurons of the isolated respiratory network of newborn rats. Onimaru H, et al. **J Physiol (Lond)** 1996 Mar 15;491 (Pt 3):677–95

Postnatal changes in the mammalian respiratory network as revealed by the transverse brainstem slice of mice. Ramirez JM, et al. **J Physiol (Lond)** 1996 Mar 15;491 (Pt 3):799–812

Characterizations and comparisons of eupnoea and gasping in neonatal rats. Wang W, et al. **J Physiol (Lond)** 1996 Jan 1;490 (Pt 1):277–92

Effect of maturation on alpha-adrenoceptor activity in newborn piglet mesentery. Hoang TV, et al. **J Surg Res** 1996 Mar;61(2):330–8

Propranolol inhibits the spontaneous closure of the ductus arteriosus in newborn rats. Arishima K, et al. **J Vet Med Sci** 1995 Oct;57(5):943–4

The temporal and spatial vascular endothelial growth factor expression in retinal vasculogenesis of rat neonates. Murata T, et al. **Lab Invest** 1996 Jan;74(1):68–77

The actions of a range of excitatory amino acids at (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid–depolarizing receptors on neonatal rat motoneurones. Thompson GA, et al. **Neuropharmacology** 1995 Aug; 34(8):857–63

Sheath lengths of large motor axons in the ventral root L5 of neonatal and adult rats. Hildebrand C, et al. **Neurosci Lett** 1996 Jan 5;202(3):173–76

Lamina VII neurons are rhythmically active during locomotor-like activity in the neonatal rat spinal cord. MacLean JN, et al. **Neurosci Lett** 1995 Sep 1;197(1):9–12

Distribution of neuropeptide FF (FLFQPQRFamide) receptors in the adult rat spinal cord: effects of dorsal rhizotomy and neonatal capsaicin. Lombard MC, et al. **Neuroscience** 1995 Oct;68(4):1229–35

Neonatal exposure to anti-nerve growth factor antibodies affects exploratory behavior of developing mice in the hole board. Calamandrei G, et al. **Neurotoxicol Teratol** 1996 Mar–Apr;18(2):141–6

Effects of cyanide on the neural mechanisms controlling breathing in the neonatal rat in vitro. Greer JJ, et al. **Neurotoxicology** 1995 Summer;16(2):211–5

Ureteral obstruction in the neonatal rat: renal nerves modulate hemodynamic effects. Chevalier RL, et al. **Pediatr Nephrol** 1995 Aug;9(4):447–50

Adenosine 3':5'-cyclic monophosphate mediates a 5-hydroxytryptamine-induced response in neonatal rat motoneurones. Larkman PM, et al. **Pflugers Arch** 1995 Sep; 430(5):763–9

Involvement of the 5-HT1A subtype receptor in the neonatal organization of agonistic behaviour in the rat. Albonetti E, et al. **Pharmacol Biochem Behav** 1996 May;54(1):189–93

Problem solving following neonatal exposure to cocaine, ethanol, or cocaine/ethanol in combination in rats. Barron S, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):197–203

Neonatal organizational effects of the 5-HT2 and 5-HT1A subsystems on adult behavior in the rat. González MI, et al. **Pharmacol Biochem Behav** 1996 May;54(1):195–203

Impaired acquisition and operant responding after neonatal dopamine depletion in rats. Moy SS. **Pharmacol Biochem Behav** 1995 Oct;52(2):433–41

Protein kinase inhibitors disrupt memory formation in two chick brain regions. Serrano PA, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):547–54

Effects of neonatal dopamine depletion on sensory inhibition in the rat. Stevens KE, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):817–23

Dose-dependent decrements in adult male rat sexual behavior after neonatal clorimipramine treatment. Vogel G, et al. **Pharmacol Biochem Behav** 1996 Jul;54(3):605–9

Neonatal testosterone and handedness in yearling rhesus monkeys (Macaca mulatta). Drea CM, et al. **Physiol Behav** 1995 Dec;58(6):1257–62

Spatial learning ability of rats following acute exposure to alcohol during early postnatal life. Pauli J, et al. **Physiol Behav** 1995 Nov;58(5):1013–20

Simulated uterine contractions facilitate fetal and newborn respiratory behavior in rats. Ronca AE, et al. **Physiol Behav** 1995 Nov;58(5):1035–41

Ability of broilers to resist heat following neonatal exposure to high environmental temperature. May JD. **Poult Sci** 1995 Nov;74(11):1905–7

Posthatch changes in morphology and function of the small intestines in heavy- and light-strain chicks. Uni Z, et al. **Poult Sci** 1995 Oct;74(10):1622–9

Relationship between opioids and prostaglandins in hypoxia-induced vasodilation of pial arteries in the newborn pig. Armstead WM. **Proc Soc Exp Biol Med** 1996 Jun;212(2):135–41

Relationship between the fall in growth hormone secretion at birth and the onset of nonshivering thermogenesis is independent of beta adrenergic stimulation. Ball KT, et al. **Reprod Fertil Dev** 1995;7(5):1237–42

Postnatal renal adaptation in preterm and term lambs. Berry LM, et al. **Reprod Fertil Dev** 1995;7(3):491–8

Effect of neonatal allylestrenol treatment (hormonal imprinting) on the serum testosterone and progesterone concentration in adult rat. Pap E, et al. **Reprod Fertil Dev** 1995;7(5):1249–51

Stimulation of gastric proteases in the neonatal pig by a rise in adrenocortical secretion at parturition. Sangild PT. **Reprod Fertil Dev** 1995;7(5):1293–8

Effects of hypercarbia on autoregulation of brain blood flow and cerebral metabolism in newborn piglets. Stonestreet BS, et al. **Reprod Fertil Dev** 1995;7(5):1381–7

Neonatal exposures to technical methoxychlor alters ovaries in adult mice. Eroschenko VP, et al. **Reprod Toxicol** 1995 Jul–Aug;9(4):379–87

Effects of superior laryngeal nerve section on ventilation in neonatal guinea-pigs. Curran AK, et al. **Respir Physiol** 1995 Jul;101(1):23–9

The ventilatory and metabolic response to hypercapnia in newborn mammalian species. Mortola JP, et al. **Respir Physiol** 1996 Mar;103(3):263–70

Use of continuous electrical capacitance and transepidermal water loss measurements for assessing barrier function in neonatal rat skin. Wickett RR, et al. **Skin Pharmacol** 1995; 8(4):179–85

Automated scoring of sleep in the neonatal lamb. Grant DA, et al. **Sleep** 1995 Jul;18(6):439–45

PSYCHOLOGY

Effects of prenatal ethanol exposure and early experience on home-cage and open-field activity in mice. Mothes HK, et al. **Neurotoxicol Teratol** 1996 Jan–Feb;18(1):59–65

VIROLOGY

Comparison of detection methods for bovine viral diarrhea virus in bovine abortions and neonatal death. Ellis JA, et al. **J Vet Diagn Invest** 1995 Oct;7(4):433–6

Maintenance of high virus load even after seroconversion in newborn cats acutely infected with feline immunodeficiency virus. Tokunaga K, et al. **Vaccine** 1995; 13(15):1393–8

ANIMALS, NONDOMESTIC see **ANIMALS, WILD**

ANIMALS, POISONOUS

Poisonous snakebite in Utah. Plowman DM, et al. **West J Med** 1995 Dec;163(6):547–51

ANIMALS, SUCKLING

Pretranslational regulation of pyruvate dehydrogenase complex subunits in white adipose tissue during the suckling–weaning transition in the rat. Maury J, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):531–5

Morphometric analysis of liver and kidney peroxisomes in lactating rats and their pups after treatment with the peroxisomal proliferator di–(2–ethylhexyl)phthalate. Stefanini S, et al. **Biol Cell** 1995;85(2–3):167–76

Immunoglobulin A levels in southern elephant seal (Mirounga leonina) milk during the suckling period. Marquez ME, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Nov; 112(3):569–72

Preweanling administration of terazosin decreases blood pressure of hypertensive rats in adulthood. McCarty R, et al. **Hypertension** 1996 May;27(5):1115–20

Restricting calf presence without suckling compared with weaning prolongs postpartum anovulation in beef cattle. Hoffman DP, et al. **J Anim Sci** 1996 Jan;74(1):190–8

Necrotising enteritis in suckled calves. Caldow GL, et al. **Vet Rec** 1995 Sep 23;137(13):307–11

'Stupid calves' [letter; comment] Hugh–Jones M, et al. **Vet Rec** 1995 Sep 16;137(12):300. Comment on: Vet Rec 1995 Jul 8;137(2):52. Comment on: Vet Rec 1995 Aug 12;137(7):176.

'Stupid calves' [letter; comment] [see comments] Wilsmore AJ. **Vet Rec** 1995 Aug 12;137(7):176. Comment on: Vet Rec 1995 Jul 8;137(2):52. Comment in: Vet Rec 1995 Sep 16;137(12):300.

[Correlations between the vitality of newborn piglets, teat order, mortality, and live weight development up to weaning] Hoy S, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jun;108(6):224–8 (Eng. Abstr.) **(Ger)**

[Clinical chemical and hematological blood values and adaptation reactions in suckling calves in the first weeks of life] Steinhardt M, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Oct; 102(10):399–405 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Immunologic memory is established in nursling rats immunized with tetanus toxoid, but is not affected by concurrent supplementation with vitamin A. Gardner EM, et al. **Am J Clin Nutr** 1995 Nov;62(5):1007–12

Contribution of passive immunity to porcine respiratory coronavirus to protection against transmissible gastroenteritis virus challenge exposure in suckling pigs. Sestak K, et al. **Am J Vet Res** 1996 May;57(5):664–71

Reversible effects on B and T cells of the gut–associated lymphoid tissues in rats malnourished during suckling: impaired induction of the immune response to intra–Peyer patches immunization with cholera toxin. Fló J, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):147–54

Role of maternal antibody in the induction of virus specific and bystander IgA responses in Peyer's patches of suckling mice. Kramer DR, et al. **Int Immunol** 1995 Jun;7(6):911–8

METABOLISM

Reciprocal regulation of cardiac Na–K–ATPase and Na/Ca exchanger: hypertension, thyroid hormone, development. Magyar CE, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C675–82

Study on the energy and protein metabolism in horses. Burlacu GH, et al. **Arch Tierernahr** 1993;45(2):173–85

Placental and lactational transfer of lead in rats: a study on the lactational process and effects on offspring. Hallén IP, et al. **Arch Toxicol** 1995;69(9):596–602

Analysis of structural and biochemical events occurring in the small intestine after dietary polyamine ingestion in suckling rats. Kaouass M, et al. **Dig Dis Sci** 1996 Jul; 41(7):1434–44

Insulin–like growth factor I in suckling rat gastric contents. Olanrewaju HA, et al. **Dig Dis Sci** 1996 Jul;41(7):1392–7

[Energy and nitrogen metabolism of pregnant and lactating sows and suckling piglets. 3. Chemical composition and energy content of the animal body fractions as well as portions of the animal body fractions of empty body of nonpregnant, pregnant and lactating sows] Beyer M, et al. **Arch Tierernahr** 1993;45(1):13–34 (Eng. Abstr.) **(Ger)**

[The effect of neonatal nutrition on lipolysis and catecholamine binding in rat adipocytes] Macho L, et al. **Bratisl Lek Listy** 1995 Nov;96(11):581–5 (Eng. Abstr.) **(Slo)**

PHYSIOLOGY

The effect of diet composition on the development of rumen digestion in lambs. Zitňan R, et al. **Arch Tierernahr** 1993; 45(2):161–71

[The suckling behavior and development of biochemical parameters in piglets from conditions of group housing of suckling sows: preliminary results] Puppe B, et al. **Berl Munch Tierarztl Wochenschr** 1995 May;108(5):161–6 (Eng. Abstr.) **(Ger)**

[Thyroid hormones in cesarean–delivered suckling calves after birth and in the first days of life—maternofetal relations and early postnatal adaptation reactions] Steinhardt M, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Nov;102(11):430–4 (Eng. Abstr.) **(Ger)**

ANIMALS, TRANSGENIC

see related
CHIMERA

Transgenic animal models of renal development and pathogenesis. Kopp JB, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):F601–20 (216 ref.)

Transgenic animals in the study of blood pressure regulation and hypertension. Thompson MW, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E793–803 (101 ref.)

Gene–targeting and transgenic approaches to IGF and IGF binding protein function. Wood TL. **Am J Physiol** 1995 Oct;269(4 Pt 1):E613–22 (101 ref.)

Transgenic models and cancer treatment. Coletta PL, et al. **Cancer Treat Rev** 1996 Nov;21(6):565–76 (79 ref.)

Transgenic models to assess the neuropathogenic potential of HIV–1 proteins and cytokines. Mucke L, et al. **Curr Top Microbiol Immunol** 1995;202:187–205 (98 ref.)

New animals, new uses, and old issues. Zeiger E, et al. **Environ Mol Mutagen** 1996;28(1):3–4

Molecular medicine in genetically engineered animals: series introduction [editorial] Chien KR. **J Clin Invest** 1996 Jan 1;97(1):2

Targeted mutagenesis: analysis of phenotype without germ line transmission. Nagy A, et al. **J Clin Invest** 1996 Mar 15;97(6):1360–5 (38 ref.)

The commercial and agricultural applications of animal transgenesis. Ward KA, et al. **Mol Biotechnol** 1995 Oct; 4(2):167–78 (63 ref.)

Electroporation as an effective means of introducing DNA into abalone (Haliotis rufescens) embryos. Powers DA, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):369–75

Industrial Genotoxicology Group: transgenic animals in genotoxicity assays and the comet assay, Royal Society of Medicine, London, UK, May 1995. Jenkinson P. **Mutagenesis** 1996 Mar;11(2):217–8

Transgenic animals. Shuldiner AR. **N Engl J Med** 1996 Mar 7;334(10):653–5 (0 ref.)

The generation of transgenic pigs as potential organ donors for humans. Cozzi E, et al. **Nat Med** 1995 Sep;1(9):964–6 (30 ref.)

Papers from a symposium on embryonic stem cells and transgenic livestock. Melbourne, Australia, 12 January 1994. Symposium dedicated to Julian Wells. **Reprod Fertil Dev** 1994;6(5):541–657

Challenges and progress in the production of transgenic cattle. Eyestone WH. **Reprod Fertil Dev** 1994;6(5):647–52 (37 ref.)

Transgenic strategies to increase disease resistance in livestock. Müller M, et al. **Reprod Fertil Dev** 1994; 6(5):605–13 (83 ref.)

Transgenic sheep and wool growth: possibilities and current status. Powell BC, et al. **Reprod Fertil Dev** 1994;6(5):615–23 (28 ref.)

Progress and emerging problems in livestock transgenesis: a summary perspective. Seamark RF. **Reprod Fertil Dev** 1994;6(5):653–7 (36 ref.)

Site–specific transgene insertion: an approach. Wigley P, et al. **Reprod Fertil Dev** 1994;6(5):585–8 (21 ref.)

Strategies for production of pharmaceutical proteins in milk. Wilmut I, et al. **Reprod Fertil Dev** 1994;6(5):625–30 (51 ref.)

The production of pharmaceutical proteins from the milk of transgenic animals. Houdebine LM. **Reprod Nutr Dev** 1995;35(6):609–17 (64 ref.)

Pathobiology of transgenic and other induced mutant animals. A symposium held in conjunction with the XIV International Symposium of the Society of Toxicologic Pathologists, June 11, 1995, San Diego, California. Abstracts. **Toxicol Pathol** 1995 Nov–Dec;23(6):735–46

Transgenesis in rats: technical aspects and models. Charreau B, et al. **Transgenic Res** 1996 Jul;5(4):223–34 (75 ref.)

Development and analysis of transgenic pigs expressing the human complement regulatory protein CD59 and DAF. Byrne G, et al. **Transplant Proc** 1996 Apr;28(2):759

Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Diamond LE, et al. **Transplantation** 1996 Apr 27;61(8):1241–9

[Transgenic animals in medicine] Goetz P. **Cas Lek Cesk** 1996 Feb 14;135(4):102–5 (11 ref.) (Eng. Abstr.) **(Cze)**

[Matti Ayräpää Award. Production of drug proteins in bioreactors] Jänne J. **Duodecim** 1994;110(21):1979–86 **(Fin)**

[Transgenic swine as organ donors in heart transplantation?] Weismann H. **Dtsch Med Wochenschr** 1996 May 24; 121(21):A7 **(Ger)**

[A transgenic animal model: new possibilities for cardiovascular research] Franz WM, et al. **Z Kardiol** 1995; 84 Suppl 4:17–32 (105 ref.) (Eng. Abstr.) **(Ger)**

[Transgene expression and integration in the zebrafish, Danio rerio] Amanuma K, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2257–64 (19 ref.) **(Jpn)**

[Transgenic rabbit] Imai H, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2234–40 (16 ref.) **(Jpn)**

[Transgenic rat] Matsumoto K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2223–33 (49 ref.) **(Jpn)**

[Transgenic bird] Mochii M. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2265–73 (22 ref.) **(Jpn)**

[Current status and challenges in the production of transgenic pigs] Nagashima H. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2241–8 (16 ref.) **(Jpn)**

[Transgenesis and ES cell lines in Medaka] Ozato K, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2249–56 (19 ref.) **(Jpn)**

GENETICS

Transgenic animals: how they are made and their role in animal production and research. Dziadek M. **Aust Vet J** 1996 May;73(5):182–7 (67 ref.)

Transgenic manipulation of myocardial G protein–coupled receptors and receptor kinases. Koch WJ, et al. **Circ Res** 1996 Apr;78(4):511–6 (29 ref.)

Transgenic fish in aquaculture and developmental biology. Gong Z, et al. **Curr Top Dev Biol** 1995;30:177–214 (174 ref.)

Recent advances in gene mutagenesis by site–directed recombination. Marth JD. **J Clin Invest** 1996 May 1; 97(9):1999–2002 (29 ref.)

Transgenesis in the rat and larger mammals. Mullins LJ, et al. **J Clin Invest** 1996 Apr 1;97(7):1557–60 (33 ref.)

Use of transgenic animals in carcinogenesis studies. Gonzalez FJ. **Mol Carcinog** 1996 Jun;16(2):63–7

Treatment protocols for transgenic mutation assays in vivo. Heddle JA, et al. **Mutagenesis** 1995 Nov;10(6):467–70 (17 ref.)

Spontaneous mutants recovered from liver and germ cell tissue of low copy number lacI transgenic rats. de Boer JG, et al. **Mutat Res** 1996 Jun 10;352(1–2):73–8

APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Greenberg BD, et al. **Neurobiol Aging** 1996 Mar–Apr; 17(2):153–71 (323 ref.)

Fixing human factor IX (fIX): correction of a cryptic RNA splice enables the production of biologically active fIX in the mammary gland of transgenic mice. Yull F, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10899–903

Transgenic livestock as genetic models of human disease. Petters RM. **Reprod Fertil Dev** 1994;6(5):643–5 (24 ref.)

Regulation and expression of transgenes in fish — a review. Iyengar A, et al. **Transgenic Res** 1996 May;5(3):147–66 (101 ref.)

Germline transmission of exogenous genes in chickens using helper–free ecotropic avian leukosis virus–based vectors. Thoraval P, et al. **Transgenic Res** 1995 Nov;4(6):369–77

[Transgenic rats as a model for investigation of the pathogenesis of hypertension] Paul M. **Z Kardiol** 1995;84 Suppl 4:55–60 (32 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Production of proteins in the milk of transgenic livestock: problems, solutions, and successes. Colman A. **Am J Clin Nutr** 1996 Apr;63(4):639S–45S (30 ref.)

PHYSIOLOGY

The hypertensive Ren–2 transgenic rat TGR (mREN2)27 in hypertension research. Characteristics and functional aspects. Langheinrich M, et al. **Am J Hypertens** 1996 May; 9(5):506–12 (36 ref.)

Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Lee MA, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E919–29 (92 ref.)

Transgenic approaches to salivary gland research. Samuelson LC. **Annu Rev Physiol** 1996;58:209–29 (106 ref.)

Transgenic animals: how they are made and their role in animal production and research. Dziadek M. **Aust Vet J** 1996 May;73(5):182–7 (67 ref.)

The renin–angiotensin system in transgenic rats. Wagner J, et al. **Pediatr Nephrol** 1996 Feb;10(1):108–12 (20 ref.)

ANIMALS, WILD

The prevalence of spontaneous endometriosis in the baboon (Papio anubis, Papio cynocephalus) increases with the duration of captivity. D'Hooghe TM, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):98–101

Potential impact of wildlife on the tropical bont tick eradication program in the Caribbean. Corn JL, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:77–84

Rabies enzootic situation in animals on Lower Silesia in 1983–1992. Molenda J. **Arch Vet Pol** 1994;34(1–2):5–11

Age–specific prevalence of porcine parvovirus antibody in feral pigs from a site in the Northern Territory. Caley P, et al. **Aust Vet J** 1995 Jan;72(1):36–7

Pig sticking injuries are no joke [letter; comment] Garner P. **BMJ** 1995 Sep 30;311(7009):878. Comment on: BMJ 1995 Jul 22;311(6999):262.

Rabies diagnosis in western canada, january 1 to june 30, 1995. Kush J, et al. **Can Vet J** 1995 Dec;36(12):776

Environmental estrogens: health implications for humans and wildlife. Colborn T. **Environ Health Perspect** 1995 Oct;103 Suppl 7:135–6

Organization versus activation: the role of endocrine-disrupting contaminants (EDCs) during embryonic development in wildlife. Guillette LJ Jr, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:157–64 (81 ref.)

Compendium of animal rabies control, 1996: National Association of State Public Health Veterinarians, Inc. **J Am Vet Med Assoc** 1996 Jan 15;208(2):214–8

Impact and risk of foreign animal diseases. Brown CC, et al. **J Am Vet Med Assoc** 1996 Apr 1;208(7):1038–40 (16 ref.)

Rabies surveillance in the United States during 1994. Krebs JW, et al. **J Am Vet Med Assoc** 1995 Dec 15; 207(12):1562–75

Feral cats in the United Kingdom. Remfry J. **J Am Vet Med Assoc** 1996 Feb 15;208(4):520–3 (10 ref.)

Opposing view on elimination of brucellosis reservoir [letter] Rutberg AT, et al. **J Am Vet Med Assoc** 1996 May 1; 208(9):1380

Wildlife and zoo veterinarians take responsibility for ecosystem [news] Spencer LM. **J Am Vet Med Assoc** 1995 Oct 15;207(8):999–1002

Remotely delivered immunocontraception in free-roaming feral burros (Equus asinus). Turner JW Jr, et al. **J Reprod Fertil** 1996 May;107(1):31–5

Veterinary wildlife research and its role in community development. Meltzer DG. **J S Afr Vet Assoc** 1995 Dec; 66(4):187–9

Prevalence of antibodies to Toxoplasma gondii in wild mammals of Missouri and east central Kansas: biologic and ecologic considerations of transmission. Smith DD, et al. **J Wildl Dis** 1995 Jan;31(1):15–21

Tackling environmental endocrine disrupters. Ginsburg J. **Lancet** 1996 Jun 1;347(9014):1501–2

Adaptive optimization and the harvest of biological populations. Williams BK. **Math Biosci** 1996 Aug; 136(1):1–20

Maintenance of a microparasite infecting several host species: rabies in the Serengeti. Cleaveland S, et al. **Parasitology** 1995;111 Suppl:S33–47

Spermatology for understanding, managing and conserving rare species. Wildt D, et al. **Reprod Fertil Dev** 1995; 7(4):811–24

Disinfection and wildlife. Corn JL, et al. **Rev Sci Tech** 1995 Jun;14(2):455–68 (17 ref.)

Epidemiology of Mycobacterium bovis infection in animals and humans, with particular reference to Africa. Cosivi O, et al. **Rev Sci Tech** 1995 Sep;14(3):733–46 (63 ref.)

Surveillance of wild animal diseases in Europe. Leighton A. **Rev Sci Tech** 1995 Sep;14(3):819–30

Wild dogs in the Serengeti [letter; comment] East ML, et al. **Science** 1996 Jan 19;271(5247):275–6. Comment on: Science 1995 Nov 24;270(5240):1302–3.

Life at the top: animals pay the high price of dominance [news] Morell V. **Science** 1996 Jan 19;271(5247):292

Wildlife, people and development: veterinary contributions to wildlife health and resource management in Africa. Kock MD. **Trop Anim Health Prod** 1996 Feb;28(1):68–80 (28 ref.)

Veterinarians and wildlife [news] **Vet Rec** 1995 Oct 21; 137(17):417–9

Wildlife rehabilitation [letter] Best JR. **Vet Rec** 1996 Mar 30;138(13):312

Wildlife diseases [letter] Boardman SI, et al. **Vet Rec** 1996 Jan 13;138(2):48

Wildlife diseases [letter] Cork SC. **Vet Rec** 1995 Dec 2; 137(23):600

Wildlife rehabilitation [letter; comment] [see comments] Hughes A. **Vet Rec** 1996 Feb 24;138(8):191–2. Comment on: Vet Rec 1996 Jan 27;138(4):95–6. Comment in: Vet Rec 1996 Mar 2;138(9):215.

Wildlife rehabilitation [letter; comment] Stocker L. **Vet Rec** 1996 Feb 24;138(8):191. Comment on: Vet Rec 1996 Jan 20;138(3):61–5.

[Serologic investigations on the occurrence of Maedi-Visna antibodies in game ruminants] Starick E, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 May;102(5):202–3 (Eng. Abstr.) **(Ger)**

[Zoo, domestic and wild animal medicine—new veterinary problems] Isenbügel E. **Schweiz Arch Tierheilkd** 1996; 138(5):251–3 **(Ger)**

[Animal sources of rabies infection in Poland in 1985–1994. Epizootiological tendencies and dynamics of the focus before the introduction of mass wildlife oral antirabies vaccination] Seroka D. **Przegl Epidemiol** 1995;49(3):227–35 (Eng. Abstr.) **(Pol)**

[Biodiversity and similarity between the nematode parasite communities of domestic and wild ruminants] Morales GA, et al. **Acta Cient Venez** 1993;44(5):285–91 (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Morphometric abnormalities in brains of great blue heron hatchlings exposed in the wild to PCDDs. Henshel DS, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:61–6

ANATOMY & HISTOLOGY

Histomorphologic and histochemical characteristics of carpal glands (Glandulae carpeae) in domestic swine (Sus scrofa domesticus) and wild swine (Sus scrofa ferus). Hraste A, et al. **Anat Histol Embryol** 1995 Sep;24(3):209–11

Morphological investigations of the glandulae profundae plicae semilunares conjuctivae in the domestic swine (Sus scrofa domesticus) and the wild hog (Sus scrofa ferus). Hraste A, et al. **Anat Histol Embryol** 1995 Dec;24(4):223–6

Descriptive and comparative myology of the hindlimb of the babirusa (Babyrousa babyrussa L. 1758). Macdonald AA, et al. **Anat Histol Embryol** 1995 Sep;24(3):197–207

Quantitative skeletal muscle histochemistry of four east African ruminants. Spurway NC, et al. **J Anat** 1996 Apr; 188 (Pt 2):455–72

BLOOD

Variation in hematological and serum biochemical values of the mountain brushtail possum, Trichosurus caninus Ogilby (Marsupialia: Phalangeridae). Viggers KL, et al. **J Wildl Dis** 1996 Jan;32(1):142–6

EMBRYOLOGY

Environmentally Induced Alterations in Development: a Focus on Wildlife. Proceedings of a meeting. Racine, Wisconsin, December 10–12, 1993. **Environ Health Perspect** 1995 May;103 Suppl 4:1–100 (0 ref.)

GENETICS

Limited genetic differentiation among wild Oryctolagus cuniculus L. (rabbit) populations in arid eastern Australia. Fuller SJ, et al. **Heredity** 1996 Aug;77 (Pt 2):138–45

Microsatellite evolution in congeneric mammals: domestic and bighorn sheep. Forbes SH, et al. **Mol Biol Evol** 1995 Nov;12(6):1106–13

[DNA fingerprinting in wild equid and Poitou ass breeding] Werner P, et al. **Schweiz Arch Tierheilkd** 1995;137(8):395–7 (10 ref.) **(Ger)**

GROWTH & DEVELOPMENT

Ontogenetic development of gut function, growth, and metabolism in a wild bird, the Red Jungle Fowl. Jackson S, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1163–73

Environmentally Induced Alterations in Development: a Focus on Wildlife. Proceedings of a meeting. Racine, Wisconsin, December 10–12, 1993. **Environ Health Perspect** 1995 May;103 Suppl 4:1–100 (0 ref.)

IMMUNOLOGY

Serological survey for orthopoxvirus infection of wild mammals in areas where a recombinant rabies virus is used to vaccinate foxes. Boulanger D, et al. **Vet Rec** 1996 Mar 16;138(11):247–9

INJURIES

Wildlife rehabilitation [letter] Fletcher J. **Vet Rec** 1996 Mar 2;138(9):215

Wildlife rehabilitation [letter; comment] Stevens RD. **Vet Rec** 1996 Mar 2;138(9):215. Comment on: Vet Rec 1996 Feb 24;138(8):191–2.

MICROBIOLOGY

Pasteurella multocida isolated from wild birds of North America: a serotype and DNA fingerprint study of isolates from 1978 to 1993. Wilson MA, et al. **Avian Dis** 1995 Jul-Sep;39(3):587–93

A comparative study of three methods of detection of Borrelia crocidurae in wild rodents in Senegal. Diatta G, et al. **Trans R Soc Trop Med Hyg** 1994 Jul-Aug;88(4):423–4

PARASITOLOGY

The occurrence of antibodies to Naegleria species in wild mammals. Kollars TM Jr, et al. **J Parasitol** 1996 Feb; 82(1):73–7

Efficacy of praziquantel in natural populations of mallards infected with avian schistosomes. Reimink RL, et al. **J Parasitol** 1995 Dec;81(6):1027–9

Cyst wall ultrastructure of two Sarcocystis spp. from European mouflon (Ovis ammon musimon) in Germany compared with domestic sheep. Odening K, et al. **J Wildl Dis** 1995 Oct;31(4):550–4

Efficacy of ivermectin against nematodes infecting field populations of snowshoe hares (Lepus americanus) in Yukon, Canada. Sovell JR, et al. **J Wildl Dis** 1996 Jan; 32(1):23–30

Wildlife reservoir for human hydatidosis [letter] McManus DP. **Med J Aust** 1996 Jun 17;164(12):757

Morphology and cytology study of Foleyella agamae complex (Nematoda: Filarinae) infecting the agamid lizard Agama agama in Nigeria. Obiamiwe BA, et al. **Parasitol Res** 1995;81(6):527–30

Introduction: ecological impact of parasitism on wildlife host populations. Grenfell BT, et al. **Parasitology** 1995;111 Suppl:S3–14 (185 ref.)

Patterns of macroparasite abundance and aggregation in wildlife populations: a quantitative review. Shaw DJ, et al. **Parasitology** 1995;111 Suppl:S111–27

Parasites of wild brown rats (Rattus norvegicus) on UK farms. Webster JP, et al. **Parasitology** 1995 Sep;111 (Pt 3):247–55

Hydatid cyst development in an experimentally infected wild rabbit. Jenkins DJ, et al. **Vet Rec** 1995 Aug 5;137(6):148–9

PHYSIOLOGY

Defining the role of pollutants in the disruption of reproduction in wildlife. Hose JE, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:87–91 (44 ref.)

Effect of dominance status on sex hormone levels in laboratory and wild-spawning male trout. Cardwell JR, et al. **Gen Comp Endocrinol** 1996 Mar;101(3):333–41

Pregnancy detection in bighorn sheep (Ovis canadensis) using a fecal-based enzyme immunoassay. Borjesson DL, et al. **J Wildl Dis** 1996 Jan;32(1):67–74

Population dynamics, intervention and survival in African wild dogs (Lycaon pictus). Burrows R, et al. **Proc R Soc Lond B Biol Sci** 1995 Nov 22;262(1364):235–45

Local extinction in a small and declining population: wild dogs in the Serengeti. Ginsberg JR, et al. **Proc R Soc Lond B Biol Sci** 1995 Nov 22;262(1364):221–8

Wildlife rehabilitation [letter; comment] [see comments] Fletcher J. **Vet Rec** 1996 Jan 27;138(4):95–6. Comment on: Vet Rec 1996 Jan 20;138(3):61–5. Comment in: Vet Rec 1996 Feb 10;138(6):143. Comment in: Vet Rec 1996 Feb 24;138(8):191–2.

PSYCHOLOGY

Emerging differentiation of folkbiology and folkpsychology: attributions of biological and psychological properties to living things. Coley JD. **Child Dev** 1995 Dec;66(6):1856–74

Exploration and predation models of anxiety: evidence from laboratory and wild species. Hendrie CA, et al. **Pharmacol Biochem Behav** 1996 May;54(1):13–20 (56 ref.)

Handling-induced stress and mortalities in African wild dogs (Lycaon pictus). de Villiers MS, et al. **Proc R Soc Lond B Biol Sci** 1995 Nov 22;262(1364):215–20

VIROLOGY

Rabies and African wild dogs in Kenya. Kat PW, et al. **Proc R Soc Lond B Biol Sci** 1995 Nov 22;262(1364):229–33

ANIMALS, ZOO

Hypervariable genomic variation to reconstruct the natural history of populations: lessons from the big cats. Menotti-Raymond M, et al. **Electrophoresis** 1995 Sep; 16(9):1771–4

Compendium of animal rabies control, 1996: National Association of State Public Health Veterinarians, Inc. **J Am Vet Med Assoc** 1996 Jan 15;208(2):214–8

Well-being of zoo and aquarium animals explored [news] Boyce J. **J Am Vet Med Assoc** 1995 Oct 1;207(7):832, 837

Wildlife and zoo veterinarians take responsibility for ecosystem [news] Spencer LM. **J Am Vet Med Assoc** 1995 Oct 15;207(8):999–1002

Epizootic of Mycobacterium bovis in a zoologic park. Stetter MD, et al. **J Am Vet Med Assoc** 1995 Dec 15; 207(12):1618–21

Behavioural sleep in the giraffe (Giraffa camelopardalis) in a zoological garden. Tobler I, et al. **J Sleep Res** 1996 Mar; 5(1):21–32

Fulminant Streptococcus pneumoniae meningitis in a lion-tailed macaque (Macaca silenus) without detected signs. Graczyk TK, et al. **J Wildl Dis** 1995 Jan;31(1):75–8

Use of disinfectants in zoos and game parks. Heuschele WP. **Rev Sci Tech** 1995 Jun;14(2):447–54 (14 ref.)

[Farewell Andries van Foreest combined with Specialists' Day. Zoo-veterinarian relationship central in Ouwehand] Ubbink S. **Tijdschr Diergeneeskd** 1996 Jun 15;121(12):356–9 **(Dut)**

[Zoo animal medicine—once and now] Isenbügel E. **Schweiz Arch Tierheilkd** 1996;138(1):3–7 **(Ger)**

[Zoo, domestic and wild animal medicine—new veterinary problems] Isenbügel E. **Schweiz Arch Tierheilkd** 1996; 138(5):251–3 **(Ger)**

PARASITOLOGY

Sarcoptic mange in wild ruminants in zoological gardens in Israel. Yeruham I, et al. **J Wildl Dis** 1996 Jan;32(1):57–61

PHYSIOLOGY

[Result of a European-wide inquiry about the use of artificial UV radiation sources in zoo animal husbandry with special regard to the mammals (Primates/Simiae/monkeys)] Hofmann-Parisot M. **Berl Munch Tierarztl Wochenschr** 1995 May;108(5):185–91 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

[Boredom in zoo animals—an relevant animal welfare problem?] Wiesner H. **Tierarztl Prax** 1995 Aug; 23(4):328–35 (Eng. Abstr.) **(Ger)**

ANION EXCHANGE RESINS

CHEMISTRY

Purification of recombinant human basic fibroblast growth factor: stability of selective sorbents under cleaning in place conditions. Anspach FB, et al. **J Chromatogr A** 1995 Sep

8;711(1):129–39

THERAPEUTIC USE

The acceptability of resin therapy to patients attending a hospital lipid clinic. Iversen SA, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):92–4

ANION EXCHANGERS see ANTIPORTERS

ANION GAP see ACID–BASE EQUILIBRIUM

ANION PUMPS see ION PUMPS

ANION TRANSPORT PROTEIN, ERYTHROCYTE see BAND 3 PROTEIN

ANIONS

Strongly anionic sites in peripheral axons of the rat sciatic nerve: light and electron microscopic detection using cationic colloidal iron. Toda K, et al. **Arch Histol Cytol** 1995 Oct;58(4):485–92

Milk fever and dietary cation–anion balance effects on concentration of vitamin D receptor in tissue of periparturient dairy cows. Goff JP, et al. **J Dairy Sci** 1995 Nov;78(11):2388–94

ANALYSIS

Glomerular anionic charge in congenital nephrotic syndrome of the Finnish type [published erratum appears in Histochem J 1995 Sep;27(9):724] Ljungberg P, et al. **Histochem J** 1995 Jul;27(7):536–46

Analysis of anions in drinking water by capillary ion electrophoresis. Oehrle SA. **J Chromatogr A** 1996 May 10; 733(1–2):101–4

BLOOD

A new range for the anion gap [letter] Sadjadi SA. **Ann Intern Med** 1995 Nov 15;123(10):807

Effect of acute pH change on serum anion gap. Paulson WD. **J Am Soc Nephrol** 1996 Feb;7(2):357–63

Capillary electrophoresis as a clinical tool. Determination of organic anions in normal and uremic serum using photodiode–array detection. Petucci CJ, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23;668(2):241–51

CHEMISTRY

Structures of poly(dG–dC) and poly(dA–dT) stabilized by anions. Loprete DM, et al. **J Biomol Struct Dyn** 1995 Aug; 13(1):57–67

Confirmation of the Mukerjee term in an extended Corrin–Harkins relation using an anionic amphiphilic drug. Franchini MK, et al. **J Pharm Sci** 1996 Feb;85(2):220–7

METABOLISM

An oxonol dye is the most potent known inhibitor of band 3–mediated anion exchange. Knauf PA, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):C1073–7

Anion secretion drives fluid secretion by monolayers of cultured human polycystic cells. Mangoo–Karim R, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):F381–8

Impaired hepatocanalicular organic anion transport in endotoxemic rats. Roelofsen H, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):G427–34

Identification of efflux systems for large anions and anionic conjugates as the mediators of methotrexate efflux in L1210 Cells. Saxena M, et al. **Biochem Pharmacol** 1996 Apr 12; 51(7):974–82

Anion binding by transferrins: importance of second–shell effects revealed by the crystal structure of oxalate–substituted diferric lactoferrin. Baker HM, et al. **Biochemistry** 1996 Jul 16;35(28):9007–13

pH dependence of specific divalent anion binding to the N–lobe of recombinant human transferrin. Cheng Y, et al. **Biochemistry** 1995 Nov 14;34(45):14879–84

Cation and anion unitary ion channel currents in cultured bovine microglia. McLarnon JG, et al. **Brain Res** 1995 Sep 25;693(1–2):8–20

Effect of carbon dioxide on the temperature dependence of anion exchange in human red cells. Baker GF, et al. **Cytobios** 1995;82(330):189–200

pH regulation in mouse sperm: identification of Na(+)–, Cl(–)–, and HCO3(–)–dependent and arylaminobenzoate–dependent regulatory mechanisms and characterization of their roles in sperm capacitation. Zeng Y, et al. **Dev Biol** 1996 Feb 1;173(2):510–20

Unusual dehydrations in anaerobic bacteria: considering ketyls (radical anions) as reactive intermediates in enzymatic reactions. Buckel W. **FEBS Lett** 1996 Jun 24; 389(1):20–4 (43 ref.)

Temperature dependence of the mitochondrial inner membrane anion channel. The relationship between temperature and inhibition by protons. Liu G, et al. **J Biol Chem** 1996 Aug 16;271(33):19717–23

Separate control of anion and cation transport in malpighian tubules of Drosophila Melanogaster. O'Donnell MJ, et al. **J Exp Biol** 1996 May;199 (Pt 5):1163–75

Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. Ramos H, et al. **J Membr Biol** 1996 Jul;152(1):65–75

Diffusion through narrow pores: movement of ions, water and nonelectrolytes through track–etched PETP membranes. Rostovtseva TK, et al. **J Membr Biol** 1996 May;151(1):29–43

A Cl channel in Ascaris suum selectivity conducts dicarboxylic anion product of glucose fermentation and suggests a role in removal of waste organic anions. Valkanov MA, et al. **J Membr Biol** 1995 Nov;148(1):41–9

Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. Bossuyt X, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):891–6

Differential sensitivity of stilbenedisulfonates in their reaction with band 3 HT (Pro–868—>Leu). Salhany JM, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11844–8

Distribution of anionic sites on microvascular endothelium of the chick chorioallantoic membrane. Henry CB, et al. **Tissue Cell** 1996 Aug;28(4):449–54

PHARMACOLOGY

Distribution and analysis of surface charge on brain endothelium in vitro and in situ. dos Santos WL, et al. **Acta Neuropathol (Berl)** 1995;90(3):305–11

Centrally infused anions alter body temperature in conscious rats. Badgaiyan RD, et al. **Brain Res Bull** 1995;38(4):331–6

The influence of pH and various anions on the distribution of NH4+ in human blood. da Fonseca–Wollheim F. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):289–94

The effects of lyotropic anions on electric field–induced guidance of cultured frog nerves. Erskine L, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):229–36

ANIRIDIA

If the iris is absent? [letter] Gupte GL, et al. **Indian Pediatr** 1995 Jun;32(6):702–3

COMPLICATIONS

Retinal detachment and giant retinal tears in aniridia. Dowler JG, et al. **Eye** 1995;9 (Pt 3):268–70

DIAGNOSIS

Six signs in children with life–threatening implications. Tien DR. **R I Med** 1995 Dec;78(12):342–5 (6 ref.)

GENETICS

Genetics of aniridia and anterior segment dysgenesis. Churchill A, et al. **Br J Ophthalmol** 1996 Jul;80(7):669–73 (53 ref.)

Aniridia: recent achievements in paediatric practice. Ivanov I, et al. **Eur J Pediatr** 1995 Oct;154(10):795–800 (41 ref.)

A LINE element is present at the site of a 300–kb deletion starting in intron 10 of the PAX6 gene in a case of familial aniridia. Drechsler M, et al. **Hum Genet** 1996 Sep; 98(3):297–303

Three novel aniridia mutations in the human PAX6 gene. Martha A, et al. **Hum Mutat** 1995;6(1):44–9

Identification of a novel PAX6 gene mutation in an aniridia patient. Sahly I, et al. **Hum Mutat** 1996;7(4):377

Pax6: more than meets the eye. Hanson I, et al. **Trends Genet** 1995 Jul;11(7):268–72 (41 ref.)

PATHOLOGY

A nude mouse Wilms' tumor line (KCMC–WT–1) derived from an aniridia patient with monoalleleic partial deletion of chromosome 11p. Nagashima Y, et al. **Cancer** 1996 Feb 15;77(4):799–804

ANISAKIASIS

[2 cases of anisakiasis in the Del Río Hortega Hospital (Valladolid) (letter)] Acebes Rey JM, et al. **Rev Esp Enferm Dig** 1996 Jan;88(1):59–60 **(Spa)**

DIAGNOSIS

Laboratory determinations in Anisakis simplex allergy. del Pozo MD, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):977–84

EPIDEMIOLOGY

[Gastric anisakiasis cases in Cheju–do, Korea] Im KI, et al. **Korean J Parasitol** 1995 Sep;33(3):179–86 (Eng. Abstr.) **(Kor)**

ETIOLOGY

A very rare case of continuous ambulatory peritoneal dialysis peritonitis caused by Anisakis larva [letter] Ohta M, et al. **Am J Gastroenterol** 1995 Oct;90(10):1902–3

[Acute gastric anisakiasis caused by insufficient microwave cooking (letter)] Canut Blasco A, et al. **Med Clin (Barc)** 1996 Mar 2;106(8):317–8 **(Spa)**

IMMUNOLOGY

Laboratory determinations in Anisakis simplex allergy. del Pozo MD, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):977–84

Anisakis simplex: stage–specific antigens recognized by mice. Iglesias R, et al. **J Helminthol** 1995 Dec;69(4):319–24

Antigenic cross–reactivity in mice between third–stage larvae of Anisakis simplex and other nematodes. Iglesias R, et al. **Parasitol Res** 1996;82(4):378–81

PARASITOLOGY

Gastric anisakidosis due to Pseudoterranova decipiens larva [letter] Pinel C, et al. **Lancet** 1996 Jun 29;347(9018):1829

SURGERY

Anisakiasis of the tonsils. Bhargava D, et al. **J Laryngol Otol** 1996 Apr;110(4):387–8

TRANSMISSION

[Anisakiasis in the Nantes area. From fishmongers' stalls to medical offices] Chord–Auger S, et al. **Parasite** 1995 Dec; 2(4):395–400 (Eng. Abstr.) **(Fre)**

VETERINARY

[Contracaecum sp. larvae (Nematoda, Anisakidae) infection in Salminus maxillosus (Pisces, Characidae) in the dam of Termas de Río Hondo, Argentina] Ramallo G, et al. **Bol Chil Parasitol** 1995 Jan–Jun;50(1–2):21–3 (Eng. Abstr.) **(Spa)**

ANISAKIS

CLASSIFICATION

Micro–evolutionary implications of allozymic and morphometric variations in sealworms Pseudoterranova sp. (Ascaridoidea: Anisakidae) among sympatric hosts from the southeastern Pacific Ocean. George–Nascimento M, et al. **Int J Parasitol** 1995 Oct;25(10):1163–71

[Infection status of anisakid larvae in anchovies purchased from local fishery market near southern and eastern sea in Korea] Song SB, et al. **Korean J Parasitol** 1995 Jun; 33(2):95–9 (Eng. Abstr.) **(Kor)**

GROWTH & DEVELOPMENT

Anisakis simplex: stage–specific antigens recognized by mice. Iglesias R, et al. **J Helminthol** 1995 Dec;69(4):319–24

IMMUNOLOGY

Recurrent anaphylaxis caused by Anisakis simplex parasitizing fish. Audicana MT, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):558–60

Laboratory determinations in Anisakis simplex allergy. del Pozo MD, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):977–84

Antigenic cross–reactivity in mice between third–stage larvae of Anisakis simplex and other nematodes. Iglesias R, et al. **Parasitol Res** 1996;82(4):378–81

ISOLATION & PURIFICATION

Recovery of Pseudoterranova decipiens (Anisakidae) larvae from codfish of the Antarctic Ocean. Chai JY, et al. **Korean J Parasitol** 1995 Sep;33(3):231–4

Gastric anisakidosis due to Pseudoterranova decipiens larva [letter] Pinel C, et al. **Lancet** 1996 Jun 29;347(9018):1829

[Contracaecum sp. larvae (Nematoda, Anisakidae) infection in Salminus maxillosus (Pisces, Characidae) in the dam of Termas de Río Hondo, Argentina] Ramallo G, et al. **Bol Chil Parasitol** 1995 Jan–Jun;50(1–2):21–3 (Eng. Abstr.) **(Spa)**

ANISOCORIA

ETIOLOGY

Postoperative anisocoria: neurogenic or phenylephrine induced? A rapid diagnostic test. Sitzman BT, et al. **Anesth Analg** 1996 Sep;83(3):633–5

Prognosis and clinical relevance of anisocoria–craniotomy latency for epidural hematoma in comatose patients. Cohen JE, et al. **J Trauma** 1996 Jul;41(1):120–2

[Anisocoria disclosing malignant lymphoma] Fongione A, et al. **J Fr Ophtalmol** 1995;18(10):617–20 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Effect of light on the prevalence of simple anisocoria. Lam BL, et al. **Ophthalmology** 1996 May;103(5):790–3

ANISOLES

CHEMISTRY

Light–directed generation of the actin–activated ATPase activity of caged heavy meromyosin. Marriott G, et al. **Biochemistry** 1996 Mar 12;35(10):3170–4

Karalicin, a new biologically active compound from Pseudomonas fluorescens/putida. I. Production, isolation, physico–chemical properties and structure elucidation. Lampis G, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):260–2

METABOLISM

Oxidation of 1,2,4,5–tetramethoxybenzene by lignin peroxidase of Phanerochaete chrysosporium. Koduri RS, et al. **Arch Biochem Biophys** 1996 Feb 15;326(2):261–5

Metabolite predictions for para–substituted anisoles based on

ANISOLES

ab initio complete active space self-consistent field calculations. de Groot MJ, et al. **Chem Res Toxicol** 1995 Apr-May;8(3):437-43

Oxidation of dimethoxylated aromatic compounds by lignin peroxidase from Phanerochaete chrysosporium. Joshi DK, et al. **Eur J Biochem** 1996 Apr 1;237(1):45-57

Karalicin, a new biologically active compound from Pseudomonas fluorescens/putida. I. Production, isolation, physico-chemical properties and structure elucidation. Lampis G, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):260-2

Autoradiographic characterization of binding sites for [3H]NE-100 in guinea pig brain. Okuyama S, et al. **Life Sci** 1995;57(21):PL333-7

PHARMACOLOGY

Karalicin, a new biologically active compound from Pseudomonas fluorescens/putida. II. Biological properties. Lampis G, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):263-6

Effects of essential oil of Croton zehntneri, and of anethole and estragole on skeletal muscles. Albuquerque AA, et al. **J Ethnopharmacol** 1995 Nov 17;49(1):41-9

Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether. Hamann LG, et al. **J Med Chem** 1996 Apr 26;39(9):1778-89

THERAPEUTIC USE

Influence of anethole treatment on the tumour induced by Ehrlich ascites carcinoma cells in paw of Swiss albino mice. al-Harbi MM, et al. **Eur J Cancer Prev** 1995 Aug; 4(4):307-18

TOXICITY

o-Methoxy-4-alkylphenols that form quinone methides of intermediate reactivity are the most toxic in rat liver slices. Thompson DC, et al. **Chem Res Toxicol** 1995 Apr-May; 8(3):323-7

Lack of influence of modulators of epoxide metabolism on the genotoxicity of trans-anethole in freshly isolated rat hepatocytes assessed with the unscheduled DNA synthesis assay. Marshall AD, et al. **Food Chem Toxicol** 1996 Apr; 34(4):337-45

ANISOMETROPIA

PATHOLOGY

Computation of retinal contour in anisomyopia. Logan NS, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):363-6

PHYSIOPATHOLOGY

Anisometropia and binocularity. Brooks SE, et al. **Ophthalmology** 1996 Jul;103(7):1139-43

ANISOMYCIN

PHARMACOLOGY

Long-term increases in synaptic density in chick CNS after passive avoidance training are blocked by an inhibitor of protein synthesis. Sojka M, et al. **Brain Res** 1995 Jul 3; 684(2):209-14

Anisomycin induces phase shifts of circadian pacemaker in primary cultures of rat suprachiasmatic nucleus. Watanabe K, et al. **Brain Res** 1995 Jul 3;684(2):179-84

Cellular stresses and cytokines activate multiple mitogen-activated-protein kinase kinase homologues in PC12 and KB cells. Meier R, et al. **Eur J Biochem** 1996 Mar 15;236(3):796-805

Jun kinases are rapidly activated by cholecystokinin in rat pancreas both in vitro and in vivo. Dabrowski A, et al. **J Biol Chem** 1996 Mar 8;271(10):5686-90

Identification of anisomycin-activated kinases p45 and p55 in murine cells as MAPKAP kinase-2. Cano E, et al. **Oncogene** 1996 Feb 15;12(4):805-12

ANISOTROPY

Anisotropy of the transverse mode ultrasonic properties of fixed tendon and fixed myocardium. Hoffmeister BK, et al. **J Acoust Soc Am** 1996 Jun;99(6):3826-36

Anisotropy of the slope of ultrasonic attenuation in formalin fixed human myocardium. Verdonk ED, et al. **J Acoust Soc Am** 1996 Jun;99(6):3837-43

The contribution of stimulus attributes of three-dimensional solid forms and level of discrimination to the visual and haptic percept of balance. Locher P, et al. **Perception** 1995; 24(6):647-63

Edge computation in human vision: anisotropy in the combining of oriented filters. Meese TS, et al. **Perception** 1995;24(6):603-22

ANISOTROPY, FLUORESCENCE see **FLUORESCENCE POLARIZATION**

ANISOYLATED PLASMINOGEN-STREPTOKINASE ACTIVATOR COMPLEX see **ANISTREPLASE**

ANISTREPLASE

ADMINISTRATION & DOSAGE

The European Myocardial Infarction Project: an assessment of pre-hospital thrombolysis. Boissel JP. **Int J Cardiol** 1995 Aug;49 Suppl:S29-37

THERAPEUTIC USE

A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. O'Connor CM, et al. **Am J Cardiol** 1996 Apr 15;77(10):791-7

Comparison of mortality from acute myocardial infarction in patients receiving anistreplase with those not receiving thrombolysis. Ozbek C, et al. **Am J Cardiol** 1995 Dec 1; 76(16):1103-7

Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction. Zahger D, et al. **Am J Cardiol** 1995 Oct 15;76(11):749-52

Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT) [see comments] Rawles J. **BMJ** 1996 Jan 27;312(7025):212-5. Comment in: BMJ 1996 Jan 27;312(7025):215-6.

Changes in wall motion in patients treated for unstable angina. A suggestion of the stunned and hibernating myocardium in humans. UNASEM Collaborative Study Group. Unstable Angina Study Using Eminase. de Zwaan C, et al. **Chest** 1995 Oct;108(4):903-11

Ventricular fibrillation following administration of thrombolytic treatment. The EMIP experience. European Myocardial Infarction Project [see comments] Boissel JP, et al. **Eur Heart J** 1996 Feb;17(2):213-21. Comment in: Eur Heart J 1996 Feb;17(2):172-3.

Thrombolysis-associated ventricular fibrillation: is it reperfusion, the drug or what? [editorial; comment] Verheugt FW. **Eur Heart J** 1996 Feb;17(2):172-3. Comment on: Eur Heart J 1996 Feb;17(2):213-21.

ANKLE

MR imaging of posterior tibial tendon dysfunction. Khoury NJ, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):675-82

Exostosis presenting as solitary loose body in the ankle of two children. Low CK, et al. **Ann Acad Med Singapore** 1995 May;24(3):455-8

Ankle and foot pain in a 39-year-old man. Wilson SC, et al. **Clin Orthop** 1996 Jul;(328):304-7; 310-1

Giant cell tumor of bone in the foot and ankle. O'Keefe RJ, et al. **Foot Ankle Int** 1995 Oct;16(10):617-23

Paget's disease of bone presenting as chronic ankle pain. Neylon TA. **J Am Podiatr Med Assoc** 1995 Oct; 85(10):556-9

Myxoid liposarcoma of the ankle. Werd MB, et al. **J Foot Ankle Surg** 1995 Sep-Oct;34(5):465-74 (39 ref.)

Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Hesse S, et al. **Stroke** 1996 Mar; 27(3):455-60

ABNORMALITIES

Managing equinus in a child with cerebral palsy: merits of hinged ankle-foot orthoses. Carmick J. **Dev Med Child Neurol** 1995 Nov;37(11):1006-10

ANATOMY & HISTOLOGY

The long accessory flexor muscle: an anatomical study. Peterson DA, et al. **Foot Ankle Int** 1995 Oct;16(10):637-40

BLOOD SUPPLY

Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Fishbane S, et al. **Am J Kidney Dis** 1996 May;27(5):668-72

The relationship between arm-ankle pressure difference and peak systolic velocity in patients with stenotic lower extremity vein grafts. Papanicolaou G, et al. **Ann Vasc Surg** 1995 Nov;9(6):554-60

Ankle systolic blood pressure following sub-maximal and maximal exercises in healthy young men. Desvaux B, et al. **J Sports Med Phys Fitness** 1995 Jun;35(2):127-30

Ankle systolic blood pressure measurement and cuff application [letter] Wertheim D, et al. **Lancet** 1996 Jun 29; 347(9018):1845-6

Cannulation in an odd place [letter] Dearlove O, et al. **Paediatr Anaesth** 1996;6(3):244-5

EMBRYOLOGY

Prenatal development of the foot and ankle. Bareither D. **J Am Podiatr Med Assoc** 1995 Dec;85(12):753-64

INJURIES see ANKLE INJURIES

INNERVATION

The deep peroneal nerve in the foot and ankle: an anatomic study. Lawrence SJ, et al. **Foot Ankle Int** 1995 Nov; 16(11):724-8

PATHOLOGY

MRI of the foot and ankle: an overview for the referring physician. Scola AJ, et al. **Del Med J** 1995 Nov; 67(11):570-9

Accessory soleus presenting as a posterior ankle mass: a case report and literature review. Travis MT, et al. **Foot Ankle Int** 1995 Oct;16(10):651-4 (14 ref.)

Pruritic eruption on the ankle. What is the most likely cause of this recurrent reaction pattern? LEVINE N. **Geriatrics** 1996 Mar;51(3):20

Tumors of the ankle and foot. Shankman S, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):139-53 (57 ref.)

PHYSIOLOGY

Mechanical and electromyographic stretch responses in spastic and healthy subjects. Toft E. **Acta Neurol Scand Suppl** 1995;163:1-24 (103 ref.)

Electromyographic latency changes in the ankle musculature during inversion moments. Lynch SA, et al. **Am J Sports Med** 1996 May-Jun;24(3):362-9

The stretch reflex response in the normal and spastic ankle: effect of ankle position. Meinders M, et al. **Arch Phys Med Rehabil** 1996 May;77(5):487-92

A stable late soleus EMG response elicited by cortical stimulation during voluntary ankle dorsiflexion. Ertekin C, et al. **Electroencephalogr Clin Neurophysiol** 1995 Oct; 97(5):275-83

Endurance time characteristics of human ankle dorsiflexors and plantarflexors. Shahidi AV, et al. **Eur J Appl Physiol** 1995;71(2-3):124-30

Measurement of visco-elastic properties of muscles around the ankle during standing. Ishida A, et al. **Front Med Biol Eng** 1996;7(1):35-43

The significance of an absent ankle reflex. Bowditch MG, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):276-9

Mechanical and electromyographic analysis of reciprocal inhibition at the human ankle joint. Sinkjaer T, et al. **J Neurophysiol** 1995 Aug;74(2):849-55

Effect of running on volume of the foot and ankle. Cloughley WB, et al. **J Orthop Sports Phys Ther** 1995 Oct;22(4):151-4

[Activation of agonist and antagonist muscles during plantar flexion of the ankle] Amiridis IG, et al. **C R Seances Soc Biol Fil** 1995;189(6):1129-35 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Mechanical and electromyographic stretch responses in spastic and healthy subjects. Toft E. **Acta Neurol Scand Suppl** 1995;163:1-24 (103 ref.)

Reliability of isokinetic measurements of ankle dorsal and plantar flexors in normal subjects and in patients with peripheral neuropathy. Andersen H. **Arch Phys Med Rehabil** 1996 Mar;77(3):265-8

Corticospinal input onto motor neurons projecting to ankle muscles in individuals with cerebral palsy. Brouwer B, et al. **Dev Med Child Neurol** 1996 Sep;38(9):787-96

Hydrotherapy of patients with intermittent claudication: a novel approach to improve systolic ankle pressure and reduce symptoms. Elmståhl S, et al. **Int Angiol** 1995 Dec; 14(4):389-94

SURGERY

The lateral calcaneal artery adipofascial flap. Lin SD, et al. **Br J Plast Surg** 1996 Jan;49(1):52-7

Surgery to the ankle. Rowley DI. **Br J Rheumatol** 1995 Sep; 34(9):854-7 (31 ref.)

Musculoskeletal applications of hyaluronan and hylan. Potential uses in the foot and ankle. Weiss C, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):497-517 (44 ref.)

Failure rate of epidural anaesthesia for foot and ankle surgery. A comparison with other surgical procedures. Curatolo M, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):363-7

Late flexor digitorum longus tendon rupture after transfer for posterior tibial tendon insufficiency: a case report. Ouzounian TJ. **Foot Ankle Int** 1995 Aug;16(8):519-21

Release of the flexor hallucis longus tendon in ballet dancers. Kolettis GJ, et al. **J Bone Joint Surg Am** 1996 Sep; 78(9):1386-90

The Romano drill: a new surgical curved drill system. Dockery GL. **J Foot Ankle Surg** 1995 May-Jun;34(3):273-5

Appropriate methods for bone fixation [editorial] Reinherz RP. **J Foot Ankle Surg** 1996 Mar-Apr;35(2):93 (29 ref.)

[Neurocutaneous flap of the external saphenous nerve. A safe, easy and fast procedure for covering loss of substances of the ankle. A propos of 5 cases] de Soras X, et al. **Ann Chir Plast Esthet** 1996 Apr;41(2):121-6 (Eng. Abstr.) **(Fre)**

[Therapeutic possibilities of the lateral supra-malleolar flap and its variations. Apropos of 6 clinical cases] Le Nen D, et al. **Ann Chir Plast Esthet** 1996 Apr;41(2):127-35 (Eng. Abstr.) **(Fre)**

[Lateral calcaneal flap in the reconstruction of the calcaneal and malleolar region] Marconi F, et al. **Minerva Chir** 1995 May;50(5):527-30 (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Hypoechoic fat: another location [letter; comment] Norris MA, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):214-5. Comment on: AJR Am J Roentgenol 1995

May;164(5):1277–80.
Synovial fluid in the hindfoot and ankle: detection of amount and distribution with US. Nazarian LN, et al. **Radiology** 1995 Oct;197(1):275–8

ANKLE INJURIES

Evaluation of pediatric foot problems: Part II. The hindfoot and the ankle. Manusov EG, et al. **Am Fam Physician** 1996 Sep 1;54(3):1012–26, 1031 (21 ref.)
Gunshot wounds to the foot and ankle. Sergi AR, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):689–702 (41 ref.)
Diagnostic and therapeutic ankle arthroscopy. Harrington P, et al. **Ir J Med Sci** 1996 Apr–Jun;165(2):121–4

CLASSIFICATION

A computer tomographic classification system for the displaced intraarticular fracture of the os calcis. Corbett M, et al. **Orthopedics** 1995 Aug;18(8):705–10

COMPLICATIONS

Malleolar fractures in alcoholics treated with biodegradable internal fixation. 6/16 reoperations in a randomized study. Kankare J, et al. **Acta Orthop Scand** 1995 Dec;66(6):524–8
Musculoskeletal case of the day. Posttraumatic subchondral cyst. Kaplan PA, et al. **AJR Am J Roentgenol** 1996 Jul; 167(1):254–5, 258–9
Prolonged reaction time in patients with chronic lateral instability of the ankle. Löfvenberg R, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):414–7
Infection in diabetic patients with ankle fractures. Low CK, et al. **Ann Acad Med Singapore** 1995 May;24(3):353–5
Juvenile Tillaux fracture of the ankle associated with a tibial shaft fracture: a unique combination. Cox PJ, et al. **Injury** 1996 Apr;27(3):221–2
A mechanism for entrapment of the tibialis posterior tendon in lateral subtalar dislocation. Woodruff MJ, et al. **Injury** 1996 Apr;27(3):193–4
Distal tibiofibular synostosis after ankle fracture. A 14-year follow-up study. Albers GH, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):250–2
Reliability of the figure-of-eight method of ankle measurement. Tatro-Adams D, et al. **J Orthop Sports Phys Ther** 1995 Oct;22(4):161–3
Non-union of ankle fractures in patients with ipsilateral foot drop. Howell GE, et al. **J R Nav Med Serv** 1995 Winter; 81(3):207–9

DIAGNOSIS

Rupture of the anterior tibial tendon: diagnosis by MR imaging. Khoury NJ, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):351–4
Deltoid and syndesmosis ligament injury of the ankle without fracture. Miller CD, et al. **Am J Sports Med** 1995 Nov–Dec; 23(6):746–50
Current concepts in the diagnosis and treatment of ankle sprains. Kuwada GT. **Clin Podiatr Med Surg** 1995 Oct; 12(4):653–65 (39 ref.)
Evaluation and treatment of ankle sprains. Anderson SJ. **Compr Ther** 1996 Jan;22(1):30–8 (52 ref.)
Traumatic focal posterior tibialis muscle denervation. Rolle WA Jr, et al. **Foot Ankle Int** 1995 Jun;16(6):363–7
Medial ankle pain after lateral ligament rupture. van Dijk CN, et al. **J Bone Joint Surg Br** 1996 Jul;78(4):562–7
Extra-articular triplane fracture of the distal tibial epiphysis. Feldman DS, et al. **J Pediatr Orthop** 1995 Jul–Aug; 15(4):479–81
Magnetic resonance imaging of ankle ligaments. Emphasis on anatomy and injuries to lateral collateral ligaments. Mesgarzadeh M, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):39–58 (48 ref.)
[Ultra-short turbo-spin echo in comparison with turbo-spin echo. Possible applications in the musculoskeletal system] Breitenseher M, et al. **Radiologe** 1995 Dec;35(12):981–3 (Eng. Abstr.) **(Ger)**
[Injuries to the lateral ligaments of the ankle joint: study technic and demonstration by means of MRI] Breitenseher MJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):226–32 (Eng. Abstr.) **(Ger)**
[Rupture of lateral ligaments of the ankle joint: MR imaging before and after functional therapy] Grebe P, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Sep;163(3):225–9 (Eng. Abstr.) **(Ger)**
[Ankle sprain—a harmless injury? (editorial)] Hintermann B. **Schweiz Rundsch Med Prax** 1996 Mar 26;85(13):396–8 (17 ref.) **(Ger)**
[Orthopedic examination of the foot: refresher course] Dvořák J, et al. **Sportverletz Sportschaden** 1995 Sep; 9(3):A19–29 **(Ger)**
[Detection of the tendon of the musculus plantaris longus—diagnostic imaging and anatomic correlate] Wening JV, et al. **Unfallchirurgie** 1996 Feb;22(1):30–5 (Eng. Abstr.) **(Ger)**
[Reiter's disease as the source of errors in the diagnosis of traumatic arthritis] Il'in II, et al. **Vestn Khir Im I I Grek** 1995;154(2):74–6 **(Rus)**

EPIDEMIOLOGY

A prospective study of ankle injury risk factors. Baumhauer JF, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):564–70
Risk factors for ankle injury in college-aged athletes. Kumbhare DA. **Clin J Sport Med** 1996 Apr;6(2):136
Ankle injuries in basketball players. Leanderson J, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):200–2

ETIOLOGY

Test-retest reliability of ankle injury risk factors. Baumhauer JF, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):571–4
Fatigue fracture of the medial malleolus in a junior roller skater. Hitchen PR, et al. **Aust N Z J Surg** 1996 Apr; 66(4):265–6
Accessory calcaneus: a case report and literature review. Krause JO, et al. **Foot Ankle Int** 1995 Oct;16(10):646–50 (11 ref.)
Distal metaphyseal fractures of the tibia with minimal involvement of the ankle. Classification and treatment by locked intramedullary nailing. Robinson CM, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):781–7

PATHOLOGY

[Magnetic resonance imaging in tendon and ligament injuries of the ankle. Our personal experience] Carretta G, et al. **Radiol Med (Torino)** 1996 May;91(5):563–9 (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Practical methods of preventing ankle injuries. Rifat SF, et al. **Am Fam Physician** 1996 Jun;53(8):2491–8, 2501–3 (27 ref.)
Simulated lateral ankle ligamentous injury. Change in ankle stability. Hollis JM, et al. **Am J Sports Med** 1995 Nov–Dec; 23(6):672–7
Proprioception in classical ballet dancers. A prospective study of the influence of an ankle sprain on proprioception in the ankle joint. Leanderson J, et al. **Am J Sports Med** 1996 May–Jun;24(3):370–4
Ankle inversion injury and hypermobility: effect on hip and ankle muscle electromyography onset latency. Beckman SM, et al. **Arch Phys Med Rehabil** 1995 Dec;76(12):1138–43
Tibiotalar contact area. Contribution of posterior malleolus and deltoid ligament. Hartford JM, et al. **Clin Orthop** 1995 Nov;(320):182–7
An axially loaded model of the ankle after pronation external rotation injury. Michelson JD, et al. **Clin Orthop** 1996 Jul; (328):285–93
Traumatic focal posterior tibialis muscle denervation. Rolle WA Jr, et al. **Foot Ankle Int** 1995 Jun;16(6):363–7
Motion of the ankle in a simulated supination–external rotation fracture model. Michelsen JD, et al. **J Bone Joint Surg Am** 1996 Jul;78(7):1024–31
Case study: the painful os trigonum syndrome. Brown GP, et al. **J Orthop Sports Phys Ther** 1995 Jul;22(1):22–5
Ankle sprain and postural sway in basketball players. Leanderson J, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):203–5
Sensory changes associated with severe ankle sprain. Bullock-Saxton JE. **Scand J Rehabil Med** 1995 Sep; 27(3):161–7

PREVENTION & CONTROL

Practical methods of preventing ankle injuries. Rifat SF, et al. **Am Fam Physician** 1996 Jun;53(8):2491–8, 2501–3 (27 ref.)
Basketball shoe height and the maximal muscular resistance to applied ankle inversion and eversion moments. Ottaviani RA, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):418–23
Leuko and Nessa Ankle braces: effectiveness before and after exercise. Tweedy R, et al. **Aust J Sci Med Sport** 1994 Sep–Dec;26(3–4):62–6
The role of shoes in the prevention of ankle sprains. Barrett J, et al. **Sports Med** 1995 Oct;20(4):277–80
Effectiveness of prophylactic ankle stabilisers for prevention of ankle injuries. Sitler MR, et al. **Sports Med** 1995 Jul; 20(1):53–7 (24 ref.)
[Athletic shoes—wish and reality. Orthopedic considerations of athletic shoe construction and athletic shoe purchase] Segesser B. **Z Orthop Ihre Grenzgeb** 1996 Mar–Apr; 134(2):Oa7–14 **(Ger)**

RADIOGRAPHY

Cost-effectiveness analysis of the Ottawa Ankle Rules. Anis AH, et al. **Ann Emerg Med** 1995 Oct;26(4):422–8
Using tomography to diagnose occult ankle fractures. Ho K, et al. **Ann Emerg Med** 1996 May;27(5):600–5
The "real" Ottawa ankle rules [letter; comment] Stiell IG, et al. **Ann Emerg Med** 1996 Jan;27(1):103–4. Comment on: Ann Emerg Med 1995 Jul;26(1):1–5.
Ottawa ankle rules. Stiell I. **Can Fam Physician** 1996 Mar; 42:478–80
Retrospective evaluation of graded stress examination of the ankle. Martin DE, et al. **Clin Orthop** 1996 Jul;(328):165–70
Improving the detection of radiographically occult ankle fractures: positive predictive value of an ankle joint effusion. Clark TW, et al. **Clin Radiol** 1996 Sep;51(9):632–6
Economic analysis of roentgenogram use in the closed treatment of stable ankle fractures. Michelson JD, et al. **J Trauma** 1995 Dec;39(6):1119–22
A computer tomographic classification system for the displaced intraarticular fracture of the os calcis. Corbett M, et al. **Orthopedics** 1995 Aug;18(8):705–10
Can the Ottawa ankle decision rules be applied in the United States? [letter] Hale WR. **West J Med** 1996 Apr;164(4):363
Ottawa ankle decision rules. Milne L. **West J Med** 1996 Jan; 164(1):67
[Indication for radiological examination in acute ankle distorsion] Henriksen CW, et al. **Ugeskr Laeger** 1996 Apr 1;158(14):1981–3 (Eng. Abstr.) **(Dan)**

REHABILITATION

Monitoring recovery following syndesmosis sprain: a case report. Spaulding SJ. **Foot Ankle Int** 1995 Oct; 16(10):655–60
Comparison of two conservative methods of treating an isolated fracture of the lateral malleolus. Port AM, et al. **J Bone Joint Surg Br** 1996 Jul;78(4):568–72
Effect of orthotics on postural sway following inversion ankle sprain. Guskiewicz KM, et al. **J Orthop Sports Phys Ther** 1996 May;23(5):326–31
Wobble board training after partial sprains of the lateral ligaments of the ankle: a prospective randomized study. Wester JU, et al. **J Orthop Sports Phys Ther** 1996 May; 23(5):332–6

SURGERY

Metallic or absorbable implants for ankle fractures: a comparative study of infections in 3,111 cases. Sinisaari I, et al. **Acta Orthop Scand** 1996 Feb;67(1):16–8
Biomechanical comparison of reconstruction techniques in simulated lateral ankle ligament injury. Hollis JM, et al. **Am J Sports Med** 1995 Nov–Dec;23(6):678–82
The value of osteosynthesis in the treatment of bimalleolar fractures. Velkovski G. **Ann Chir Gynaecol** 1995; 84(4):403–16
Neurological complications of ankle arthroscopy. Ferkel RD, et al. **Arthroscopy** 1996 Apr;12(2):200–8
Metallic or absorbable fracture fixation devices. A cost minimization analysis. Böstman OM. **Clin Orthop** 1996 Aug; (329):233–9
Clinical biocompatibility and degradation of polylevolactide screws in the ankle. Böstman OM, et al. **Clin Orthop** 1995 Nov;(320):101–9
Separated ossicles of the lateral malleolus. Hasegawa A, et al. **Clin Orthop** 1996 Sep;(330):157–65
The internal fixation of ankle fracture repair. Savage TJ, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):603–31 (82 ref.)
Surgical revision after failed lateral ankle reconstruction. Sammarco GJ, et al. **Foot Ankle Int** 1995 Dec;16(12):748–53
Irreducible syndesmosis due to an entrapped posterior fragment. Chan D, et al. **Injury** 1995 Oct;26(8):569–71
The use of the Goodall Targetting Device for application of external fixators in the treatment of pilon fractures. Eastaugh-Waring SJ, et al. **Injury** 1995 Oct;26(8):567–8
Removing malleolar screws with ease. Middleton R, et al. **Injury** 1996 Mar;27(2):149–50
The repair of a ruptured deltoid ligament is not necessary in ankle fractures. Strömsöe K, et al. **J Bone Joint Surg Br** 1995 Nov;77(6):920–1
Postoperative treatment of internally fixed ankle fractures: a prospective randomised study. van Laarhoven CJ, et al. **J Bone Joint Surg Br** 1996 May;78(3):395–9
Transfibular osteotomy in the correction of ankle joint incongruity. Davis JL, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):389–99 (23 ref.)
The Maisonneuve fracture. Duchesneau S, et al. **J Foot Ankle Surg** 1995 Sep–Oct;34(5):422–8
The use of a transyndesmotic bolt in the treatment of tibiofibular diastasis: two case studies. Grady JF, et al. **J Foot Ankle Surg** 1995 Nov–Dec;34(6):571–6
Tibiofibular arthrodesis for malunion of the talocrural joint. Loder BG, et al. **J Foot Ankle Surg** 1995 May–Jun; 34(3):283–8 (8 ref.)
Internal fixation of distal fibula fractures: a case presentation demonstrating a unique technique for a severely comminuted fibula. Savage TJ, et al. **J Foot Ankle Surg** 1995 Nov–Dec;34(6):587–92; discussion 596
Talar fracture/dislocation in the adolescent patient [letter] Schuberth JM. **J Foot Ankle Surg** 1995 Nov–Dec; 34(6):597–8
Talar fracture/dislocation in the adolescent patient. Valentine BC 2nd, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):379–83 (11 ref.)
Major open injuries of the talus. Marsh JL, et al. **J Orthop Trauma** 1995;9(5):371–6
Traumatic dislocation of the tibialis posterior tendon: a new surgical procedure to obtain a strong reconstruction. Ballesteros R, et al. **J Trauma** 1995 Dec;39(6):1198–200
Expanding the use of the ankle distractor in the treatment of complex ankle fractures. Rupp RE, et al. **Orthopedics** 1995 Jul;18(7):639–41
Successful revascularization of a partially avulsed foot in a 6-year-old child. Simonich MP, et al. **Tex Med** 1996 Jul; 92(7):72–5
[Long-term results of total ankle replacement] Wang Y, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jun;33(6):359–61 (Eng. Abstr.) **(Chi)**
[Value of a direct approach to the calcaneum] Jarde O, et al. **Acta Orthop Belg** 1995;61(4):327–30 (Eng. Abstr.) **(Fre)**
[Traumatic luxation of the peroneal tendons. Report of 36

cases] Tourné Y, et al. **Int Orthop** 1995;19(4):197–203 (Eng. Abstr.) **(Fre)**

[Surgical treatment of ankle joint fractures with biodegradable screws and plates of poly-l-lactide] Eitenmüller J, et al. **Chirurg** 1996 Apr;67(4):413–8 (Eng. Abstr.) **(Ger)**

[Intermittent impulse compression. An alternative in therapy of post-traumatic and postoperative edema] Stöckle U, et al. **Chirurg** 1996 May;67(5):539–45 (Eng. Abstr.) **(Ger)**

[Use of laser in arthroscopy of the ankle. Indications, method, first results] Zangger P, et al. **Orthopade** 1996 Feb; 25(1):73–8 (Eng. Abstr.) **(Ger)**

[Various therapy concepts in severe fractures of the tibial pilon (type C injuries). A comparative study] Bastian L, et al. **Unfallchirurg** 1995 Nov;98(11):551–8 (Eng. Abstr.) **(Ger)**

[Current status of diagnosis and therapy of chronic collateral ligament instability of the ankle joint: results of a survey of 267 German clinics in 1994] Becker HP, et al. **Unfallchirurg** 1995 Sep;98(9):493–9 (Eng. Abstr.) **(Ger)**

[Experiences with using the soft cast in injuries of the fibular ligament of the upper ankle joint] Neugebauer H, et al. **Unfallchirurg** 1995 Sep;98(9):489–92 (Eng. Abstr.) **(Ger)**

[Treatment of fibular capsular ligament rupture. A multicenter study] Wülker N, et al. **Z Orthop Ihre Grenzgeb** 1996 Mar–Apr;134(2):149–54 (Eng. Abstr.) **(Ger)**

THERAPY

Treatment of acute ankle sprain. Comparison of a semi-rigid ankle brace and compression bandage in 73 patients. Leanderson J, et al. **Acta Orthop Scand** 1995 Dec; 66(6):529–31

Long-term outcome after ruptured lateral ankle ligaments. A prospective study of three different treatments in 79 patients with 11-year follow-up. Munk B, et al. **Acta Orthop Scand** 1995 Oct;66(5):452–4

Dynamic orthopaedic brace in the treatment of ankle sprains. Regis D, et al. **Foot Ankle Int** 1995 Jul;16(7):422–6

Ultrasound assessment and conservative management of inversion injuries of the ankle in children: plaster of Paris versus Tubigrip. Gleeson AP, et al. **J Bone Joint Surg Br** 1996 May;78(3):484–7

Extra-articular triplane fracture of the distal tibial epiphysis. Feldman DS, et al. **J Pediatr Orthop** 1995 Jul–Aug; 15(4):479–81

Tibial pilon fractures: a comparative clinical study of management techniques and results. Crutchfield EH, et al. **Orthopedics** 1995 Jul;18(7):613–7

Modified fracture brace for tibial fracture with varus angulation: a case report. Tang SF, et al. **Prosthet Orthot Int** 1995 Aug;19(2):115–9

[Rupture of lateral ligaments of the ankle joint: MR imaging before and after functional therapy] Grebe P, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Sep;163(3):225–9 (Eng. Abstr.) **(Ger)**

[Open total dislocation of the talus] Grabski RS, et al. **Chir Narzadow Ruchu Ortop Pol** 1992;57(4–6):368–71 (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Ultrasound assessment and conservative management of inversion injuries of the ankle in children: plaster of Paris versus Tubigrip. Gleeson AP, et al. **J Bone Joint Surg Br** 1996 May;78(3):484–7

ANKLE JOINT

Intraarticular foot and ankle injections to identify source of pain before arthrodesis. Khoury NJ, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):669–73

Biomechanical topography of human ankle cartilage. Athanasiou KA, et al. **Ann Biomed Eng** 1995 Sep–Oct; 23(5):697–704

Diabetic sensory neuropathy effect on ankle joint movement perception. Simoneau GG, et al. **Arch Phys Med Rehabil** 1996 May;77(5):453–60

Distraction for ankle arthroscopy. Casteleyn PP, et al. **Arthroscopy** 1995 Oct;11(5):633–4

Ankle pain and swelling in a 24-year-old woman [clinical conference] Chivers FS, et al. **Clin Orthop** 1996 Feb; (323):338–40, 343–4

Hemophilic ankle arthropathy. Ribbans WJ, et al. **Clin Orthop** 1996 Jul;(328):39–45 (10 ref.)

Volkmann's ischemic contracture of the foot and ankle: evaluation and treatment of established deformity. Santi MD, et al. **Foot Ankle Int** 1995 Jun;16(6):368–77 (72 ref.)

Periarticular ankle sarcoidosis: a variant of Löfgren's syndrome. Mañá J, et al. **J Rheumatol** 1996 May;23(5):874–7 (21 ref.)

Arthroscopic treatment of anterior synovitis of the ankle in athletes. Jerosch J, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(3):176–81

Joint distraction for osteoarthritis. Buckwalter JA. **Lancet** 1996 Feb 3;347(8997):279–80

[Ligamentoplasty using the peroneus tertius in the correction of lateral laxity of the ankle. Surgical technique] Mabit C, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(1):70–75 (Eng. Abstr.) **(Fre)**

[A case from practice (337). Psoriasis vulgaris, Hallopeau's continuous suppurative acrodermatitis. Psoriatic arthropathy. Chronic alcoholism with personality changes, polyneuropathy, hepatopathy. Cardiomyopathy with chronic atrial fibrillation, thrombocytopathy, macrocytosis] Widmer A. **Schweiz Rundsch Med Prax** 1995 Nov 28; 84(48):1435 **(Ger)**

[The combined use of cryogenic exposure and ultrasound in patients with arthrosis of the joints of the legs] Grigor'eva VD, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan–Feb; (1):18–21 (Eng. Abstr.) **(Rus)**

ABNORMALITIES

Evaluation of pediatric foot problems: Part II. The hindfoot and the ankle. Manusov EG, et al. **Am Fam Physician** 1996 Sep 1;54(3):1012–26, 1031 (21 ref.)

ANATOMY & HISTOLOGY

13 MHz high-frequency sonography of the lateral ankle joint ligaments and the tibiofibular syndesmosis in anatomic specimens. Milz P, et al. **J Ultrasound Med** 1996 Apr; 15(4):277–84

Normal magnetic resonance imaging anatomy of the ankle and foot. Kirsch MD, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):1–21 (24 ref.)

Technical considerations for magnetic resonance imaging of the ankle and foot. Kneeland JB. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):23–8 (7 ref.)

Magnetic resonance imaging of ankle ligaments. Emphasis on anatomy and injuries to lateral collateral ligaments. Mesgarzadeh M, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):39–58 (48 ref.)

Magnetic resonance imaging of the ankle and foot. Ho CP. **Semin Roentgenol** 1995 Jul;30(3):294–303

EMBRYOLOGY

[Development and biomechanics of the talocrural joint] Doskočil M. **Sb Lek** 1995;96(2):85–103 (Eng. Abstr.) **(Cze)**

ENZYMOLOGY

Chondrocyte matrix metalloproteinase-8: up-regulation of neutrophil collagenase by interleukin-1 beta in human cartilage from knee and ankle joints. Chubinskaya S, et al. **Lab Invest** 1996 Jan;74(1):232–40

INJURIES see ANKLE INJURIES

INNERVATION

Prolonged reaction time in patients with chronic lateral instability of the ankle. Löfvenberg R, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):414–7

Neurological complications of ankle arthroscopy. Ferkel RD, et al. **Arthroscopy** 1996 Apr;12(2):200–8

Reinnervation of post-arthritic joints in the rat. da Silva JA, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):43–51

Relationship between motoneuron pool excitability and parameters of timing and force in an isometric ankle-extension movement. Brunt D, et al. **Percept Mot Skills** 1996 Apr;82(2):448–50

PATHOLOGY

Painful ankle region in rheumatoid arthritis. Analysis of soft-tissue changes with ultrasonography and MR imaging. Lehtinen A, et al. **Acta Radiol** 1996 Jul;37(4):572–7

Magnetic resonance imaging of acute Maisonneuve fractures. Morris JR, et al. **Foot Ankle Int** 1996 May;17(5):259–63

Giant cell tumor of the tendon sheath in the ankle: MRI with pathologic correlation. Narra VR, et al. **J Magn Reson Imaging** 1995 Nov–Dec;5(6):781–3

Magnetic resonance imaging manifestations of synovial lesions of the ankle and foot. Bergman AG. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):131–8 (33 ref.)

Achilles tendon and miscellaneous tendon lesions. Chandnani VP, et al. **Magn Reson Imaging Clin N Am** 1994 Feb; 2(1):89–96 (21 ref.)

Clinical significance of magnetic resonance imaging of the ankle and foot. Jahss MH. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):29–38 (10 ref.)

Magnetic resonance imaging of pediatric disorders of the ankle and foot. Schoenberg NY, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):109–22 (51 ref.)

Reassessment of the MR criteria for stability of osteochondritis dissecans in the knee and ankle. De Smet AA, et al. **Skeletal Radiol** 1996 Feb;25(2):159–63

[Detection of the tendon of the musculus plantaris longus—diagnostic imaging and anatomic correlate] Wening JV, et al. **Unfallchirurgie** 1996 Feb;22(1):30–5 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Electromyographic latency changes in the ankle musculature during inversion moments. Lynch SA, et al. **Am J Sports Med** 1996 May–Jun;24(3):362–9

The effect of ankle stabilizers on athletic performance. A randomized prospective study. Pienkowski D, et al. **Am J Sports Med** 1995 Nov–Dec;23(6):757–62

Stability of the braced ankle. A biomechanical investigation. Thonnard JL, et al. **Am J Sports Med** 1996 May–Jun; 24(3):356–61

Parameter estimation for a prosthetic ankle. Singer E, et al. **Ann Biomed Eng** 1995 Sep–Oct;23(5):691–6

Biomechanical study on tibialis posterior tendon transfers. Goh JC, et al. **Clin Orthop** 1995 Oct;(319):297–302

Tibiotalar contact area. Contribution of posterior malleolus and deltoid ligament. Hartford JM, et al. **Clin Orthop** 1995 Nov;(320):182–7

Fibula and its ligaments in load transmission and ankle joint stability. Wang Q, et al. **Clin Orthop** 1996 Sep;(330):261–70

Influence of arthrodeses on kinematics of the axially loaded ankle complex during dorsiflexion/plantarflexion. Hintermann B, et al. **Foot Ankle Int** 1995 Oct;16(10):633–6

Influence of ligament transection on tibial and calcaneal rotation with loading and dorsi-plantarflexion. Hintermann B, et al. **Foot Ankle Int** 1995 Sep;16(9):567–71

In vitro kinematics of the axially loaded ankle complex in response to dorsiflexion and plantarflexion. Hintermann B, et al. **Foot Ankle Int** 1995 Aug;16(8):514–8

Kinematics of the normal arch of the foot and ankle under physiologic loading. Kitaoka HB, et al. **Foot Ankle Int** 1995 Aug;16(8):492–9

Kinematics of the axially loaded ankle. Michelson JD, et al. **Foot Ankle Int** 1995 Sep;16(9):577–82

Tibiotalar contact area and pressure distribution: the effect of mortise widening and syndesmosis fixation. Pereira DS, et al. **Foot Ankle Int** 1996 May;17(5):269–74

A system for the analysis of foot and ankle kinematics during gait. Kidder SM, et al. **IEEE Trans Rehabil Eng** 1996 Mar; 4(1):25–32

Evaluation of voluntary and elicited dorsiflexor torque-angle relationships. Koh TJ, et al. **J Appl Physiol** 1995 Dec; 79(6):2007–13

Stress in the Achilles tendon during a topple-over movement in the ankle joint. Wallenböck E, et al. **J Biomech** 1995 Sep;28(9):1091–101

A six-degree-of-freedom test system for the study of joint mechanics and ligament forces. Hollis JM. **J Biomech Eng** 1995 Nov;117(4):383–9

Effects of age on rapid ankle torque development. Thelen DG, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep; 51(5):M226–32

Alignment and joint motion in the normal foot. Aström M, et al. **J Orthop Sports Phys Ther** 1995 Nov;22(5):216–22

Relationship between three static angles of the rearfoot and the pattern of rearfoot motion during walking. McPoil TG, et al. **J Orthop Sports Phys Ther** 1996 Jun;23(6):370–5

The effects of semirigid Air-Stirrup bracing vs. adhesive ankle taping on motor performance. Verbrugge JD. **J Orthop Sports Phys Ther** 1996 May;23(5):320–5

The effect of an ankle orthosis on ankle range of motion and performance. Wiley JP, et al. **J Orthop Sports Phys Ther** 1996 Jun;23(6):362–9

Relationship of isokinetic peak torque with work and power for ankle plantar flexion and dorsiflexion. Woodson C, et al. **J Orthop Sports Phys Ther** 1995 Sep;22(3):113–5

Detection of movements imposed on human hip, knee, ankle and toe joints. Refshauge KM, et al. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):231–41

Perception of movement at the human ankle: effects of leg position. Refshauge KM, et al. **J Physiol (Lond)** 1995 Oct 1;488 (Pt 1):243–8

Range of motion, muscle torque and training habits in runners with and without Achilles tendon problems. Haglund-Akerlind Y, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):195–9

Ankle sprain and postural sway in basketball players. Leanderson J, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3–4):203–5

A method of measuring standing isokinetic plantar and dorsiflexion peak torques. Porter MM, et al. **Med Sci Sports Exerc** 1996 Apr;28(4):516–22

Is prophylactic bracing of the ankle cost effective? Jerosch J, et al. **Orthopedics** 1996 May;19(5):405–14 (47 ref.)

The effect of solid ankle-foot orthoses on movement patterns used in a supine-to-stand rising task. King LA, et al. **Phys Ther** 1995 Nov;75(11):952–64

A device for the measurement of malleoli diastasis. Torre M, et al. **Technol Health Care** 1996 Mar;3(4):241–9

[Development and biomechanics of the talocrural joint] Doskočil M. **Sb Lek** 1995;96(2):85–103 (Eng. Abstr.) **(Cze)**

PHYSIOPATHOLOGY

Peroneus longus and tibialis anterior muscle activity in the stance phase. A quantified electromyographic study of 10 controls and 25 patients with chronic ankle instability. Louwerens JW, et al. **Acta Orthop Scand** 1995 Dec; 66(6):517–23

Simulated lateral ankle ligamentous injury. Change in ankle stability. Hollis JM, et al. **Am J Sports Med** 1995 Nov–Dec; 23(6):672–7

Ankle inversion injury and hypermobility: effect on hip and ankle muscle electromyography onset latency. Beckman SM, et al. **Arch Phys Med Rehabil** 1995 Dec;76(12):1138–43

Chronic ankle instability: the value of talar tilt under general anaesthesia. McCaskie AW, et al. **Br J Sports Med** 1995 Jun;29(2):103–4

Lateral column lengthening with calcaneocuboid fusion:

range of motion in the triple joint complex. Deland JT, et al. **Foot Ankle Int** 1995 Nov;16(11):729–33
Case study: the painful os trigonum syndrome. Brown GP, et al. **J Orthop Sports Phys Ther** 1995 Jul;22(1):22–5
The effect of nontraumatic immobilization on ankle dorsiflexion stiffness in rats. Reynolds CA, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):27–33
Stress distribution in the ankle–foot orthosis used to correct pathological gait. Chu TM, et al. **J Rehabil Res Dev** 1995 Nov;32(4):349–60
Limited range of motion is a significant factor in venous ulceration. Back TL, et al. **J Vasc Surg** 1995 Nov; 22(5):519–23
Effects of functional electrical stimulation on the joints of adolescents with spinal cord injury. Betz R, et al. **Paraplegia** 1996 Mar;34(3):127–36
[Effects of fibular malunion on contact area and stress distribution at the ankle with six simulated loading conditions] Yoshimine F. **Nippon Seikeigeka Gakkai Zasshi** 1995 Jul;69(7):460–9 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

The os trigonum syndrome: imaging features. Karasick D, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):125–9
A mechanism for entrapment of the tibialis posterior tendon in lateral subtalar dislocation. Woodruff MJ, et al. **Injury** 1996 Apr;27(3):193–4
Distal tibial triplane fractures: long–term follow–up. Rapariz JM, et al. **J Pediatr Orthop** 1996 Jan–Feb;16(1):113–8
Can the Ottawa ankle decision rules be applied in the United States? [letter] Hale WR. **West J Med** 1996 Apr;164(4):363
[Demonstration of a communication between the ankle joint and the subchondral synovial cyst of the tibial medial malleolus. Contribution of noninvasive imaging] Battistelli JM, et al. **Ann Radiol (Paris)** 1995;38(3):145–9 (Eng. Abstr.) **(Fre)**

SURGERY

Technique and clinical evaluation of arthroscopic ankle arthrodesis. Corso SJ, et al. **Arthroscopy** 1995 Oct; 11(5):585–90
Arthroscopic debridement for the osteoarthritic ankle. Ogilvie–Harris DJ, et al. **Arthroscopy** 1995 Aug;11(4):433–6
The Ilizarov technique in ankle fusion: a preliminary report. Hawkins BJ, et al. **Bull Hosp Jt Dis** 1993–95;53(4):17–21
Separated ossicles of the lateral malleolus. Hasegawa A, et al. **Clin Orthop** 1996 Sep;(330):157–65
Arthroscopic ankle arthrodesis in rheumatoid arthritis. Turan I, et al. **Clin Orthop** 1995 Nov;(320):110–4
Calcification of the tibialis posterior tendon: a case report and literature review. Delmi M, et al. **Foot Ankle Int** 1995 Dec;16(12):792–5
Influence of arthrodeses on kinematics of the axially loaded ankle complex during dorsiflexion/plantarflexion. Hintermann B, et al. **Foot Ankle Int** 1995 Oct;16(10):633–6
Influence of ligament transection on tibial and calcaneal rotation with loading and dorsi–plantarflexion. Hintermann B, et al. **Foot Ankle Int** 1995 Sep;16(9):567–71
Cylindrical cemented ankle arthroplasty: a prospective series with long–term follow–up. Kofoed H. **Foot Ankle Int** 1995 Aug;16(8):474–9
Stress fracture of the tibia following extensive hindfoot and ankle arthrodesis: a report of three cases. Mitchell JR, et al. **Foot Ankle Int** 1995 Jul;16(7):445–8
Retrograde intramedullary nailing for ankle arthrodesis. Moore TJ, et al. **Foot Ankle Int** 1995 Jul;16(7):433–6
Ankle arthrodesis: results after the miniarthrotomy technique. Paremain GD, et al. **Foot Ankle Int** 1996 May;17(5):247–52
Tibiotalar contact area and pressure distribution: the effect of mortise widening and syndesmosis fixation. Pereira DS, et al. **Foot Ankle Int** 1996 May;17(5):269–74
Anatomic structures at risk: combined subtalar and ankle arthrodesis with a retrograde intramedullary rod. Pochatko DJ, et al. **Foot Ankle Int** 1995 Sep;16(9):542–7
Monitoring recovery following syndesmosis sprain: a case report. Spaulding SJ. **Foot Ankle Int** 1995 Oct; 16(10):655–60
New method for reconstruction in lateral ankle instability. Bauer GR. **J Am Podiatr Med Assoc** 1995 Sep;85(9):459–63 (32 ref.)
Arthrodesis of the ankle with a free vascularized autogenous bone graft. Reconstruction of segmental loss of bone secondary to osteomyelitis, tumor, or trauma. Bishop AT, et al. **J Bone Joint Surg Am** 1995 Dec;77(12):1867–75
Extensile posterior approach to the ankle. Hayes AG, et al. **J Bone Joint Surg Br** 1996 May;78(3):468–70
Can Ilizarov joint distraction delay the need for an arthrodesis of the ankle? A preliminary report. van Valburg AA, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):720–5
Ankle and subtalar fusion utilizing a tricortical bone graft, bone stimulator, and external fixator after avascular necrosis of the talus. Janis L, et al. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):120–6; discussion 188–9
Modified Elmslie lateral ankle stabilization procedure. Reed TM. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):162–5; discussion 191
Direct reduction with indirect fixation of distal tibial physeal fractures: a report of a technique. Lintecum N, et al. **J Pediatr Orthop** 1996 Jan–Feb;16(1):107–12
Late follow–up results of operative ankle arthroscopy in patients under local anaesthesia. Valentin A, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):250–4
The miniarthrotomy technique of ankle arthrodesis: a cadaver study of operative vascular compromise and early clinical results. Miller SD, et al. **Orthopedics** 1996 May; 19(5):425–30
Long–term results of the modified Evans repair for chronic ankle instability. Rosenbaum D, et al. **Orthopedics** 1996 May;19(5):451–5
A regional anesthetic technique for ankle arthroscopy [letter] Hannenberg AA. **Reg Anesth** 1995 Jul–Aug;20(4):357–8
[Long–term results of total ankle replacement] Wang Y, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jun;33(6):359–61 (Eng. Abstr.) **(Chi)**
[Arthrodesis of the ankle under arthroscopy. Apropos of 10 cases reviewed after a year] Bonnin M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(2):128–35 (Eng. Abstr.) **(Fre)**
[Arthrodesis of the ankle joint] Bauer G, et al. **Orthopade** 1996 Apr;25(2):158–65 (74 ref.) (Eng. Abstr.) **(Ger)**
[Screw arthrodesis of the ankle joint. Technique and outcome] Thermann H, et al. **Orthopade** 1996 Apr; 25(2):166–76 (55 ref.) (Eng. Abstr.) **(Ger)**
[Hindfoot arthrodesis] Wülker N, et al. **Orthopade** 1996 Apr; 25(2):177–86 (57 ref.) (Eng. Abstr.) **(Ger)**
[Biomechanical study of the initial stability of various arthrodesis methods for the upper ankle joint] Pommer A, et al. **Unfallchirurg** 1995 Oct;98(10):535–9 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Painful ankle region in rheumatoid arthritis. Analysis of soft–tissue changes with ultrasonography and MR imaging. Lehtinen A, et al. **Acta Radiol** 1996 Jul;37(4):572–7
13 MHz high–frequency sonography of the lateral ankle joint ligaments and the tibiofibular syndesmosis in anatomic specimens. Milz P, et al. **J Ultrasound Med** 1996 Apr; 15(4):277–84

ANKLE LATERAL LIGAMENT see **LATERAL LIGAMENT, ANKLE**

ANKYLOSIS

COMPLICATIONS

Bird face deformity secondary to bilateral temporomandibular joint ankylosis. el–Sheikh MM, et al. **J Craniomaxillofac Surg** 1996 Apr;24(2):96–103
[Hypoglossia–hypodactylia syndrome: apropos of a case with maxillo–mandibular synostosis, glossopalatine ankylosis and cleft palate] Casha P, et al. **Arch Pediatr** 1996 Mar; 3(3):241–4 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Do recently developed techniques for skull base surgery increase the risk of difficult airway management? Assessment of pseudoankylosis of the mandible following surgical manipulation of the temporalis muscle. Kawaguchi M, et al. **J Neurosurg Anesthesiol** 1995 Jul;7(3):183–6

ETIOLOGY

Elbow anchylosis due to postburn heterotopic ossification. Holguin PH, et al. **J Burn Care Rehabil** 1996 Mar–Apr; 17(2):150–4
A post–traumatic ankylosis of the lunate and scaphoid to the radius. Roolker W, et al. **J Hand Surg [Br]** 1996 Jun; 21(3):381–3
Concurrent osteochondroma of the mandibular condyle and ipsilateral cranial base resulting in temperomandibular joint ankylosis: report of a case and review of the literature. Karras SC, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):640–6 (27 ref.)
General case of the day. Enteropathic arthropathy secondary to Crohn disease. Hill SC, et al. **Radiographics** 1995 Jul; 15(4):1021–3

GENETICS

Localization of the gene (SYM1) for proximal symphalangism to human chromosome 17q21–q22. Polymeropoulos MH, et al. **Genomics** 1995 May 20;27(2):225–9

PATHOLOGY

Primary tooth ankylosis: report of case with histological analysis. Mancini G, et al. **ASDC J Dent Child** 1995 May–Jun;62(3):215–9

PHYSIOPATHOLOGY

Effect of spinal construct stiffness on short segment fusion mass incorporation. Johnston CE 2nd, et al. **Spine** 1995 Nov 15;20(22):2400–7

RADIOGRAPHY

General case of the day. Enteropathic arthropathy secondary to Crohn disease. Hill SC, et al. **Radiographics** 1995 Jul; 15(4):1021–3

SURGERY

Subtotal carbon dioxide laser arytenoidectomy by endoscopic approach for treatment of bilateral cord immobility in adduction. Remacle M, et al. **Ann Otol Rhinol Laryngol** 1996 Jun;105(6):438–45
Management of post–traumatic temporomandibular joint ankylosis in children: case report. Guthua SW, et al. **East Afr Med J** 1995 Jul;72(7):471–5
Modification of the temporalis muscle and fascia flap for the management of ankylosis of the temporomandibular joint. Omura S, et al. **J Oral Maxillofac Surg** 1996 Jun; 54(6):794–5
[Interposition of a full–thickness skin graft in the surgery of temporomandibular joint ankylosis. A study of 31 cases of which 20 had long–term follow–up] Guyot L, et al. **Rev Stomatol Chir Maxillofac** 1995;96(6):372–8 (Eng. Abstr.) **(Fre)**
[Mandibular micrognathism as a sequela of early childhood capitulum fractures and their treatment using distraction osteogenesis] Klein C, et al. **Fortschr Kiefer Gesichtschir** 1996;41:147–51 (Eng. Abstr.) **(Ger)**

THERAPY

Manuduction of adhesive ankylosis of the knee under anesthesia. Bai S, et al. **J Tradit Chin Med** 1996 Mar; 16(1):44–7

VETERINARY

Surgical management of digit disorders in cattle. Desrochers A, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):277–98 (45 ref.)

ANKYRIN REPEAT

GENETICS

A new Saccharomyces cerevisiae ankyrin repeat–encoding gene required for a normal rate of cell proliferation. Lycan DE, et al. **Gene** 1996 May 24;171(1):33–40

ANKYRINS

ANALYSIS

Immunoreactive analogues of erythrocyte ankyrin in human epidermal keratinocytes. Shimizu T, et al. **Arch Dermatol Res** 1996;288(1):19–23
A neuron–specific isoform of brain ankyrin, 440–kD ankyrinB, is targeted to the axons of rat cerebellar neurons. Kunimoto M. **J Cell Biol** 1995 Dec;131(6 Pt 2):1821–9

BIOSYNTHESIS

Molecular cloning, expression, and localization of E1, an Onchocerca volvulus antigen with similarity to brain ankyrin. Erttmann KD, et al. **J Biol Chem** 1996 Jan 19; 271(3):1645–50

CHEMISTRY

The ankyrin repeats but not the PEST–like sequences are required for signal–dependent degradation of IkappaBalpha. Aoki T, et al. **Oncogene** 1996 Mar 7; 12(5):1159–64

GENETICS

Ankyrin Napoli: a de novo deletional frameshift mutation in exon 16 of ankyrin gene (ANK1) associated with spherocytosis. del Giudice EM, et al. **Br J Haematol** 1996 Jun 2;93(4):828–34
Sequence of a gene encoding periplasmic Pseudomonas syringae ankyrin. Klotz MG, et al. **Gene** 1995 Oct 16; 164(1):187–8
Interactions between the ankyrin repeat–containing protein Akr1p and the pheromone response pathway in Saccharomyces cerevisiae. Kao LR, et al. **Mol Cell Biol** 1996 Jan;16(1):168–78
The Saccharomyces cerevisiae Start–specific transcription factor Swi4 interacts through the ankyrin repeats with the mitotic Clb2/Cdc28 kinase and through its conserved carboxy terminus with Swi6. Siegmund RF, et al. **Mol Cell Biol** 1996 Jun;16(6):2647–55
Ankyrin–1 mutations are a major cause of dominant and recessive hereditary spherocytosis. Eber SW, et al. **Nat Genet** 1996 Jun;13(2):214–8

METABOLISM

Association of hepatic system A amino acid transporter with the membrane–cytoskeletal proteins ankyrin and fodrin. Handlogten ME, et al. **Biochim Biophys Acta** 1996 Jun 13; 1282(1):107–14
Identification of a binding motif for ankyrin on the alpha–subunit of Na+,K(+)–ATPase. Jordan C, et al. **J Biol Chem** 1995 Dec 15;270(50):29971–5
Mechanism for binding site diversity on ankyrin. Comparison of binding sites on ankyrin for neurofascin and the Cl–/HCO3– anion exchanger. Michaely P, et al. **J Biol Chem** 1995 Dec 29;270(52):31298–302
High affinity binding of ankyrin induced by volume expansion in skate erythrocytes. Musch MW, et al. **J Biol Chem** 1996 Aug 30;271(35):21221–5
Identification of a small cytoplasmic ankyrin (AnkG119) in the kidney and muscle that binds beta I sigma spectrin and

associates with the Golgi apparatus. Devarajan P, et al. **J Cell Biol** 1996 May;133(4):819–30

Molecular basis of spectrin deficiency in beta spectrin Durham. A deletion within beta spectrin adjacent to the ankyrin–binding site precludes spectrin attachment to the membrane in hereditary spherocytosis. Hassoun H, et al. **J Clin Invest** 1995 Dec;96(6):2623–9

Overexpression of CD44 in pl85(neu)–transfected NIH3T3 cells promotes an up–regulation of hyaluronic acid–mediated membrane–cytoskeleton interaction and cell adhesion. Zhu D, et al. **Oncogene** 1996 Jun 6;12(11):2309–14

PHYSIOLOGY

Decreased content of protein 4.2 in ankyrin–deficient normoblastosis (nb/nb) mouse red blood cells: evidence for ankyrin enhancement of protein 4.2 membrane binding. Rybicki AC, et al. **Blood** 1995 Nov 1;86(9):3583–9

Involvement of CD44 and the cytoskeletal linker protein ankyrin in human neutrophil bacterial phagocytosis. Moffat FL Jr, et al. **J Cell Physiol** 1996 Sep;168(3):638–47

Selective down–regulation of 440 kDa ankyrinB associated with neurite retraction. Kunimoto M, et al. **Neuroreport** 1995 Dec 15;6(18):2545–8

ANLL see LEUKEMIA, NONLYMPHOCYTIC, ACUTE

ANNELIDA

CHEMISTRY

The role of the dodecamer subunit in the dissociation and reassembly of the hexagonal bilayer structure of Lumbricus terrestris hemoglobin. Sharma PK, et al. **J Biol Chem** 1996 Apr 12;271(15):8754–62

ENZYMOLOGY

A multifunctional Urechis caupo protein, PAPS synthetase, has both ATP sulfurylase and APS kinase activities. Rosenthal E, et al. **Gene** 1995 Nov 20;165(2):243–8

GENETICS

Localization of a vertebrate telomeric sequence in the chromosomes of two marine worms (phylum Annelida: class polychaeta). Jha AN, et al. **Chromosome Res** 1995 Dec;3(8):507–8

Isolation of a Pax–6 homolog from the ribbonworm Lineus sanguineus. Loosli F, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2658–63

IMMUNOLOGY

Protein contact dermatitis caused by Nereis diversicolor. Purello D'Ambrosio F, et al. **Allergy** 1995 Oct;50(10):830–2

PHYSIOLOGY

Propagated and nonpropagated calcium transients during egg activation in the annelid, Chaetopterus. Eckberg WR, et al. **Dev Biol** 1995 Dec;172(2):654–64

Bioluminescence in scale–worm photosomes: the photoprotein polynoidin is specific for the detection of superoxide radicals. Bassot JM, et al. **Histochem Cell Biol** 1995 Sep;104(3):199–210 (79 ref.)

ANNEXIN I

ANALYSIS

Distribution of annexin I during non–pathogen or pathogen phagocytosis by confocal imaging and immunogold electron microscopy. Harricane MC, et al. **Cell Biol Int** 1996 Mar;20(3):193–203

Distribution of annexins I, II, and IV in bovine mammary gland. Katoh N, et al. **J Dairy Sci** 1995 Nov;78(11):2382–7

Distribution of annexin I and II in term human fetal membranes, decidua and placenta. Sun M, et al. **Placenta** 1996 Mar–Apr;17(2–3):181–4

BIOSYNTHESIS

The concerted regulation of cPLA2, COX2, and lipocortin I expression by IL–1beta in A549 cells. Croxtal JD, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):491–5

Changes in the cellular distribution of lipocortin–1 (Annexin–1) in C6 glioma cells after exposure to dexamethasone. McLeod JD, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1103–7

Dexamethasone induces an increase in intracellular and membrane–associated lipocortin–1 (annexin–1) in rat astrocyte primary cultures. McLeod JD, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):193–205

Annexin 1 is overexpressed and specifically secreted during experimentally induced colitis in rats. Vergnolle N, et al. **Eur J Biochem** 1995 Sep 1;232(2):603–10

Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Masaki T, et al. **Hepatology** 1996 Jul;24(1):72–81

BLOOD

Translocation of annexin I to plasma membranes and phagosomes in human neutrophils upon stimulation with opsonized zymosan: possible role in phagosome function. Kaufman M, et al. **Biochem J** 1996 May 15;316 (Pt 1):35–42

CHEMISTRY

Folding properties of an annexin I domain: a 1H–15N NMR and CD study. Cordier–Ochsenbein F, et al. **Biochemistry** 1996 Aug 13;35(32):10347–57

Nonnative capping structure initiates helix folding in an annexin I fragment. A 1H NMR conformational study. Odaert B, et al. **Biochemistry** 1995 Oct 3;34(39):12820–9

Change in the N–terminal domain conformation of annexin I that correlates with liposome aggregation is impaired by Ser–27 to Glu mutation that mimics phosphorylation. Porte F, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):177–84

GENETICS

A BC200–derived element and Z–DNA as structural markers in annexin I genes: relevance to Alu evolution and annexin tetrad formation. Morgan RO, et al. **J Mol Evol** 1995 Dec; 41(6):979–85

IMMUNOLOGY

Lipocortin–1 autoantibody concentration in children with inflammatory bowel disease. Beattie RM, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):541–5

METABOLISM

Lipocortin I immunolocalization in normal and hydropic guinea pig ears. Reiber ME, et al. **Am J Otol** 1994 Jul; 15(4):506–14

Evidence for specific annexin I–binding proteins on human monocytes. Goulding NJ, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):593–7

Calcium–dependent binding of the plasma protein apolipoprotein A–I to two members of the annexin family. Brownawell AM, et al. **Biochemistry** 1996 May 28; 35(21):6839–45

Diverse effects of different neutrophil organelles on truncation and membrane–binding characteristics of annexin I. Sjölin C, et al. **Biochim Biophys Acta** 1996 Jun 11;1281(2):227–34

The role of lipocortin–1 in dexamethasone–induced suppression of PGE2 and TNF alpha release from human peripheral blood mononuclear cells. Sudlow AW, et al. **Br J Pharmacol** 1996 Apr;117(7):1449–56

Characterization of the interaction between annexin I and profilin. Alvarez–Martinez MT, et al. **Eur J Biochem** 1996 Jun 15;238(3):777–84

Topical glucocorticoids inhibit neurogenic inflammation: involvement of lipocortin 1. Ahluwalia A, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):193–8

Cyclic 3'–5'–adenosine monophosphate binds to annexin I and regulates calcium–dependent membrane aggregation and ion channel activity. Cohen BE, et al. **FEBS Lett** 1995 Dec 27;377(3):444–50

Lipocortin–1 distribution in bronchoalveolar lavage from healthy human lung: effect of prednisolone. Smith SF, et al. **J Appl Physiol** 1995 Jul;79(1):121–8

Calcium–dependent binding of S100C to the N–terminal domain of annexin I. Mailliard WS, et al. **J Biol Chem** 1996 Jan 12;271(2):719–25

PHARMACOLOGY

Modulation of cell death pathways to apoptosis and necrosis of H2O2–treated rat thymocytes by lipocortin I. Sakamoto T, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):643–7

Lipocortin 1 and the control of cPLA2 activity in A549 cells. Glucocorticoids block EGF stimulation of cPLA2 phosphorylation. Croxtall JD, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):351–6

Selective inhibition of neutrophil function by a peptide derived from lipocortin 1 N–terminus. Perretti M, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1037–42

Alteration of neutrophil trafficking by a lipocortin 1 N–terminus peptide. Harris JG, et al. **Eur J Pharmacol** 1995 Jun 12;279(2–3):149–57

Dexamethasone inhibits the release of TSH from the rat anterior pituitary gland in vitro by mechanisms dependent on de novo protein synthesis and lipocortin 1. Taylor AD, et al. **J Endocrinol** 1995 Dec;147(3):533–44

Immunoneutralization of lipocortin 1 reverses the acute inhibitory effects of dexamethasone on the hypothalamo–pituitary–adrenocortical responses to cytokines in the rat in vitro and in vivo. Taylor AD, et al. **Neuroendocrinology** 1995 Jul;62(1):19–31

Dexamethasone suppresses the release of prolactin from the rat anterior pituitary gland by lipocortin 1 dependent and independent mechanisms. Taylor AD, et al. **Neuroendocrinology** 1995 Nov;62(5):530–42

PHYSIOLOGY

Fifteenth Gaddum Memorial Lecture December 1994. Stress and the neuroendocrine–immune axis: the pivotal role of glucocorticoids and lipocortin 1. Buckingham JC. **Br J Pharmacol** 1996 May;118(1):1–19 (138 ref.)

SECRETION

Glucocorticoid–induced annexin 1 secretion by monocytes and peritoneal leukocytes. Coméra C, et al. **Br J Pharmacol** 1995 Jul;115(6):1043–7

Annexin 1 is overexpressed and specifically secreted during experimentally induced colitis in rats. Vergnolle N, et al. **Eur J Biochem** 1995 Sep 1;232(2):603–10

ANNEXIN II

ANALYSIS

Distribution of annexins I, II, and IV in bovine mammary gland. Katoh N, et al. **J Dairy Sci** 1995 Nov;78(11):2382–7

Detection of secreted and intracellular annexin II by a radioimmunoassay. Davis RG, et al. **J Immunol Methods** 1995 Dec 15;188(1):91–5

Distribution of annexin I and II in term human fetal membranes, decidua and placenta. Sun M, et al. **Placenta** 1996 Mar–Apr;17(2–3):181–4

CHEMISTRY

"In vitro" phosphorylation of annexin 2 heterotetramer by protein kinase C. Comparative properties of the unphosphorylated and phosphorylated annexin 2 on the aggregation and fusion of chromaffin granule membranes. Regnouf F, et al. **J Biol Chem** 1995 Nov 10; 270(45):27143–50

The crystal structure and ion channel activity of human annexin II, a peripheral membrane protein. Burger A, et al. **J Mol Biol** 1996 Apr 12;257(4):839–47

Annexin II tetramer: structure and function. Waisman DM. **Mol Cell Biochem** 1995 Aug–Sep;149–150:301–22 (215 ref.)

GENETICS

Complete structure of the murine p36 (annexin II) gene. Identification of mRNAs for both the murine and the human gene with alternatively spliced 5' noncoding exons. Fey MF, et al. **Biochim Biophys Acta** 1996 May 2; 1306(2–3):160–70

ISOLATION & PURIFICATION

Purification, microsequencing, and immunolocalization of p36, a new interferon–alpha–induced protein that is associated with human lupus inclusions. Rich SA, et al. **J Biol Chem** 1996 Jan 12;271(2):1118–26

METABOLISM

Annexin II up–regulates cellular levels of p11 protein by a post–translational mechanisms. Puisieux A, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):51–5

Modulation of annexin II tetramer by tyrosine phosphorylation. Hubaishy I, et al. **Biochemistry** 1995 Nov 7;34(44):14527–34

Phospholipase A2 activity and calpactin I levels in rat lymphokine–activated killer cells: correlation with the cytotoxic activity. Cifone MG, et al. **Cell Immunol** 1996 Jun 15;170(2):274–82

Interaction of calcyclin and its cyanogen bromide fragments with annexin II and glyceraldehyde 3–phosphate dehydrogenase. Filipek A, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1123–31

Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface. Essential role of endonexin repeat 2. Hajjar KA, et al. **J Biol Chem** 1996 Aug 30; 271(35):21652–9

Annexin II in exocytosis: catecholamine secretion requires the translocation of p36 to the subplasmalemmal region in chromaffin cells. Chasserot–Golaz S, et al. **J Cell Biol** 1996 Jun;133(6):1217–36

Annexins in the human neuroblastoma SH–SY5Y: demonstration of relocation of annexins II and V to membranes in response to elevation of intracellular calcium by membrane depolarisation and by the calcium ionophore A23187. Blanchard S, et al. **J Neurochem** 1996 Aug; 67(2):805–13

PHARMACOLOGY

Lung annexin II promotes fusion of isolated lamellar bodies with liposomes. Liu L, et al. **Biochim Biophys Acta** 1995 Nov 16;1259(2):166–72

PHYSIOLOGY

Studies on associations of glycolytic and glutaminolytic enzymes in MCF–7 cells: role of P36. Mazurek S, et al. **J Cell Physiol** 1996 May;167(2):238–50

SECRETION

Detection of secreted and intracellular annexin II by a radioimmunoassay. Davis RG, et al. **J Immunol Methods** 1995 Dec 15;188(1):91–5

ANNEXIN III

ANALYSIS

Distribution of annexins I, II, and IV in bovine mammary gland. Katoh N, et al. **J Dairy Sci** 1995 Nov;78(11):2382–7

CHEMISTRY

The high–resolution crystal structure of human annexin III shows subtle differences with annexin V. Favier–Perron

B, et al. **Biochemistry** 1996 Feb 13;35(6):1740–4

METABOLISM

Dissociation of cyclic inositol phosphohydrolase activity from annexin III. Sekar MC, et al. **J Biol Chem** 1996 Apr 5;271(14):8295–9

ANNEXIN IV

CHEMISTRY

Characterization of carbohydrate-binding protein p33/41: relation with annexin IV, molecular basis of the doublet forms (p33 and p41), and modulation of the carbohydrate binding activity by phospholipids. Kojima K, et al. **J Biol Chem** 1996 Mar 29;271(13):7679–85

METABOLISM

Ca(2+)-dependent binding of annexin IV to surfactant protein A and lamellar bodies in alveolar type II cells. Sohma H, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):175–81

A rise in nuclear calcium translocates annexins IV and V to the nuclear envelope. Raynal P, et al. **FEBS Lett** 1996 Sep 2;392(3):263–8

Changes in expression and subcellular localization of annexin IV in rabbit kidney proximal tubule cells during primary culture. Massey-Harroche D, et al. **J Cell Physiol** 1995 Nov;165(2):313–22

Calcium-induced relocation of annexins IV and V in the human osteosarcoma cell line MG-63. Mohiti J, et al. **Mol Membr Biol** 1995 Oct-Dec;12(4):321–9

ANNEXIN V

ANALYSIS

Annexin V is localized in association with Z-line of rat cardiac myocytes. Wang L, et al. **Cardiovasc Res** 1995 Sep; 30(3):363–71

BIOSYNTHESIS

Modulation of annexin V during chondrocytic differentiation in vitro. Bernier SM, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:212–4

BLOOD

[Annexin V in human platelets and its physiological role] Shidara Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov;47(11):1269–70 **(Jpn)**

CHEMISTRY

Structure and function of the ion channel model system annexin V. Voges D, et al. **Adv Enzymol Relat Areas Mol Biol** 1995;71:209–39 (144 ref.)

The high-resolution crystal structure of human annexin III shows subtle differences with annexin V. Favier-Perron B, et al. **Biochemistry** 1996 Feb 13;35(6):1740–4

Ca(2+)-bridging mechanism and phospholipid head group recognition in the membrane-binding protein annexin V. Swairjo MA, et al. **Nat Struct Biol** 1995 Nov;2(11):968–74

DIAGNOSTIC USE

Use of annexin V-ferrofluid to enumerate erythrocytes damaged in various pathologies or during storage in vitro. Sestier C, et al. **C R Acad Sci III** 1995 Nov;318(11):1141–6

Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi. Stratton JR, et al. **Circulation** 1995 Nov 15;92(10):3113–21

GENETICS

Structure of rat annexin V gene and molecular diversity of its transcripts. Imai Y, et al. **Eur J Biochem** 1995 Sep 1; 232(2):327–34

IMMUNOLOGY

High levels of antibodies to annexins V and VI in patients with rheumatoid arthritis. Dubois T, et al. **J Rheumatol** 1995 Jul;22(7):1230–4

METABOLISM

Mobilization of annexin V during the uptake of DNP-albumin by human dendritic cells. Larsson M, et al. **APMIS** 1995 Dec;103(12):855–61

Nuclear matrix localization of annexin V in chicken liver. Altieri F, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):448–54

Calcium involvement in aminophospholipid exposure and microparticle formation during platelet activation: a study using Ca2+-ATPase inhibitors. Dachary-Prigent J, et al. **Biochemistry** 1995 Sep 12;34(36):11625–34

Interactions of annexin V with phospholipid monolayers. Mukhopadhyay S, et al. **Biochim Biophys Acta** 1996 Feb 21;1279(1):58–62

Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Kuypers FA, et al. **Blood** 1996 Feb 1; 87(3):1179–87

Involvement of annexin V in the entry of influenza viruses and role of phospholipids in infection. Huang RT, et al. **FEBS Lett** 1996 Aug 19;392(1):59–62

A rise in nuclear calcium translocates annexins IV and V to the nuclear envelope. Raynal P, et al. **FEBS Lett** 1996 Sep 2;392(3):263–8

Species specificity for HBsAg binding protein endonexin II. de Bruin WC, et al. **J Hepatol** 1996 Mar;24(3):265–70

Structural and functional characterisation of the voltage sensor in the ion channel human annexin V. Liemann S, et al. **J Mol Biol** 1996 May 17;258(4):555–61

Annexins in the human neuroblastoma SH-SY5Y: demonstration of relocation of annexins II and V to membranes in response to elevation of intracellular calcium by membrane depolarisation and by the calcium ionophore A23187. Blanchard S, et al. **J Neurochem** 1996 Aug; 67(2):805–13

Molecular cloning and characterization of annexin V-binding proteins with highly hydrophilic peptide structure. Ohsawa K, et al. **J Neurochem** 1996 Jul;67(1):89–97

Calcium-induced relocation of annexins IV and V in the human osteosarcoma cell line MG-63. Mohiti J, et al. **Mol Membr Biol** 1995 Oct-Dec;12(4):321–9

PHARMACOLOGY

Preparation and characterization of a disulfide-linked bioconjugate of annexin V with the B-chain of urokinase: an improved fibrinolytic agent targeted to phospholipid-containing thrombi. Tanaka K, et al. **Biochemistry** 1996 Jan 23;35(3):922–9

Inhibitory effect of annexin V on protein kinase C activity in mesangial cell lysates. Rothhut B, et al. **Eur J Biochem** 1995 Sep 15;232(3):865–72

Inhibition of interleukin-1 beta-induced pyresis in the rabbit by peptide 204–212 of lipocortin 5. Palmi M, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):97–9

PHYSIOLOGY

Structure and function of the ion channel model system annexin V. Voges D, et al. **Adv Enzymol Relat Areas Mol Biol** 1995;71:209–39 (144 ref.)

ANNEXIN VI

ANALYSIS

Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression. Francia G, et al. **Cancer Res** 1996 Sep 1;56(17):3855–8

CHEMISTRY

The structure of recombinant human annexin VI in crystals and membrane-bound. Benz J, et al. **J Mol Biol** 1996 Aug 2;260(5):638–43

IMMUNOLOGY

High levels of antibodies to annexins V and VI in patients with rheumatoid arthritis. Dubois T, et al. **J Rheumatol** 1995 Jul;22(7):1230–4

PHYSIOLOGY

Functional and genetic analysis of annexin VI. Edwards HC, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:293–9 (75 ref.)

ANNEXIN VII

ANALYSIS

Annexin VII relocalization as a result of dystrophin deficiency. Selbert S, et al. **Exp Cell Res** 1996 Jan 10; 222(1):199–208

BIOSYNTHESIS

Novel isoforms of synexin in Xenopus laevis: multiple tandem PGQM repeats distinguish mRNAs in specific adult tissues and embryonic stages. Srivastava M, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):729–35

METABOLISM

Calcium-dependent binding of the plasma protein apolipoprotein A-I to two members of the annexin family. Brownawell AM, et al. **Biochemistry** 1996 May 28; 35(21):6839–45

ANNEXIN VIII see **ANNEXINS**

ANNEXIN IX see **ANNEXINS**

ANNEXIN X see **ANNEXINS**

ANNEXIN XI see **ANNEXINS**

ANNEXINS

ANALYSIS

Differential distribution of annexins-I, -II, -IV, and -VI in synovium. Goulding NJ, et al. **Ann Rheum Dis** 1995 Oct; 54(10):841–5

Identification, localization, and functional implications of an abundant nematode annexin. Creutz CE, et al. **J Cell Biol** 1996 Mar;132(6):1079–92

BIOSYNTHESIS

Isoform-specific intracellular vesicle formation by recombinant annexin XI-A in Sf9 cells. Sudo T, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):706–11

Differential expression of annexins I-VI in the rat dorsal root ganglia and spinal cord. Naciff JM, et al. **J Comp Neurol** 1996 May 6;368(3):356–70

CHEMISTRY

Isolation by calcium-dependent translation to neutrophil-specific granules of a 42-kD cytosolic protein, identified as being a fragment of annexin XI. Sjölin C, et al. **Blood** 1996 Jun 1;87(11):4817–23

Crystal structure of the annexin XII hexamer and implications for bilayer insertion [see comments] Luecke H, et al. **Nature** 1995 Nov 30;378(6556):512–5. Comment in: Nature 1995 Nov 30;378(6556):446–7.

GENETICS

Developmental regulation of various annexins in the embryonic palate of the mouse: dexamethasone affects expression of annexin-1. Chepenik KP, et al. **J Craniofac Genet Dev Biol** 1995 Oct-Dec;15(4):171–81

Molecular phylogeny of annexins and identification of a primitive homologue in Giardia lamblia. Morgan RO, et al. **Mol Biol Evol** 1995 Nov;12(6):967–79

METABOLISM

Annexin expression in human dendritic cells. Larsson M, et al. **Adv Exp Med Biol** 1995;378:191–3

Unique subcellular distribution of five annexins in resting and insulin-stimulated rat adipose cells. Raynal P, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):116–21

Tomato annexins p34 and p35 bind to F-actin and display nucleotide phosphodiesterase activity inhibited by phospholipid binding. Calvert CM, et al. **Plant Cell** 1996 Feb;8(2):333–42

PHYSIOLOGY

Ion channels. Annexins taken to task [news; comment] Moss SE. **Nature** 1995 Nov 30;378(6556):446–7. Comment on: Nature 1995 Nov 30;378(6556):512–5.

Annexins of plant cells. Clark GB, et al. **Plant Physiol** 1995 Dec;109(4):1133–9 (53 ref.)

Annexins in endocytosis. Jäckle S, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:81–2

ANNIVERSARIES AND SPECIAL EVENTS

Luau in Vermont. Peirce DM. **Am J Nurs** 1996 Jan;96(1):72

The conceptualisation and communication of clinical facts: a consideration of the 75th anniversary edition IJPA. Roiphe J. **Int J Psychoanal** 1995 Dec;76 (Pt 6):1179–90

The rites of spring [editorial] Haller KB. **J Obstet Gynecol Neonatal Nurs** 1996 Mar-Apr;25(3):203

Bibliographical note on behavioral aspects: on the margin of the 50th anniversary of the Minnesota Starvation-Nutritional Rehabilitation experiment. Brožek J. **Percept Mot Skills** 1995 Oct;81(2):395–400

-60-th anniversary of the Lodz section of the Polish Neurological Society- Niewodniczy A. **Neurol Neurochir Pol** 1995 Nov-Dec;29(6):827–34 **(Pol)**

ANNIVERSARY REACTION see **ADJUSTMENT DISORDERS**

ANNUAL IMPLEMENTATION PLANS see **REGIONAL HEALTH PLANNING**

ANNUAL REPORTS

The annual reports of Local Research Ethics Committees. Foster CG, et al. **J Med Ethics** 1995 Aug;21(4):214–9

ANNULAR GROOVES see **AMNIOTIC BAND SYNDROME**

ANODE see **ELECTRODES**

ANODONTIA

GAPO syndrome: report on the first case in Japan. Moriya N, et al. **Am J Med Genet** 1995 Sep 11;58(3):257–61

COMPLICATIONS

Congenitally missing permanent lateral incisors in conjunction with a supernumerary tooth: case report. Zhu JF, et al. **Pediatr Dent** 1996 Jan-Feb;18(1):64–6

ETIOLOGY

Dental agenesis in hemifacial microsomia. Silvestri A, et al. **Pediatr Dent** 1996 Jan-Feb;18(1):48–51

ANODONTIA

GENETICS

GAPO syndrome: a new case. Sandgren G.
Am J Med Genet 1995 Jul 31;58(1):87–90 (16 ref.)
Gene defect in hypodontia: exclusion of EGF, EGFR, and FGF-3 as candidate genes. Arte S, et al. **J Dent Res** 1996 Jun;75(6):1346–52
Two genes for missing teeth [news; comment] Thesleff I. **Nat Genet** 1996 Aug;13(4):379–80. Comment on: Nat Genet 1996 Aug;13(4):409–16. Comment on: Nat Genet 1996 Aug;13(4):417–21.
A human MSX1 homeodomain missense mutation causes selective tooth agenesis [see comments] Vastardis H, et al. **Nat Genet** 1996 Aug;13(4):417–21. Comment in: Nat Genet 1996 Aug;13(4):379–80.

HISTORY

Congenital absence of permanent second molars. Anderson T, et al. **Br Dent J** 1996 Jun 8;180(11):436–7

PATHOLOGY

Hypodontia of the permanent dentition. Case reports. Cameron J, et al. **Aust Dent J** 1996 Feb;41(1):1–5
Odontotrichodysplasia: a case report with a review of conditions combining ectodermal dysplasia (subgroup 1–2) with skin manifestations. Yadav TP, et al. **J Dermatol** 1995 Aug;22(8):606–10 (14 ref.)

PHYSIOPATHOLOGY

Craniofacial structure and soft tissue profile in patients with severe hypodontia. Ogaard B, et al.
Am J Orthod Dentofacial Orthop 1995 Nov;108(5):472–7

REHABILITATION

A multidisciplinary approach to oral rehabilitation with osseointegrated implants in children and adolescents with multiple aplasia. Bergendal B, et al. **Eur J Orthod** 1996 Apr;18(2):119–29

SURGERY

[Orthognathic surgery with missing teeth] Baralle MM, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):201–6 (Eng. Abstr.) **(Fre)**

THERAPY

Lateral thinking: the management of missing upper lateral incisors. Millar BJ, et al. **Br Dent J** 1995 Aug 5; 179(3):99–106 (16 ref.)
Complete dentures for a child with hypohidrotic epidermal dysplasia: a clinical report [letter] Alessini DJ.
J Prosthet Dent 1996 Jun;75(6):686
Complete dentures for a child with hypohidrotic ectodermal dysplasia: a clinical report. Ramos V, et al.
J Prosthet Dent 1995 Oct;74(4):329–31
[Treatment of a case of multiple tooth agenesis: an orthodontic and implant solution] Périsse J, et al.
Rev Stomatol Chir Maxillofac 1996;97(3):166–71 (Eng. Abstr.) **(Fre)**
[Hypodontia: considerations on orthodontic therapy in agenesis of the permanent upper lateral incisor] Villani S, et al. **Minerva Stomatol** 1995 May;44(5):211–22 (Eng. Abstr.) **(Ita)**

ANODYNES see **ANALGESICS**

ANOMIA

DIAGNOSIS

Levels of representation and units of access relevant to agrammatism. Kegl J. **Brain Lang** 1995 Aug;50(2):151–200
Anomic aphasia in childhood. Hynd GW, et al.
J Child Neurol 1995 Jul;10(4):289–93
Refractory semantics in global aphasia: on semantic organisation and the access-storage distinction in neuropsychology. Forde E, et al. **Memory** 1995 Sep–Dec; 3(3–4):265–307
Objects and properties: a study of the breakdown of semantic memory. Funnell E. **Memory** 1995 Sep–Dec;3(3–4):497–518
Autobiographical experience and word meaning. Snowden JS, et al. **Memory** 1995 Sep–Dec;3(3–4):225–46

ETIOLOGY

Cured of acute lymphoblastic leukaemia but lost for words. Winter E, et al. **Neuropediatries** 1995 Oct;26(5):267–9
[A case of biopsy-proven sarcoid meningoencephalitis presented with hallucination, nominal aphasia and dementia] Hayashi T, et al. **Rinsho Shinkeigaku** 1995 Sep; 35(9):1008–11 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Dysnomia following traumatic brain injury: an information-processing approach to assessment. Kerr C. **Brain Inj** 1995 Nov–Dec;9(8):777–96
Impaired naming and preserved reading: a complete dissociation. Breen K, et al. **Cortex** 1995 Sep;31(3):583–8
Selective impairment of the retrieval of people's names: a case of category specificity. Harris DM, et al. **Cortex** 1995 Sep;31(3):575–82
P300 in response to the subject's own name. Berlad I, et al. **Electroencephalogr Clin Neurophysiol** 1995 Sep; 96(5):472–4
Towards a unitary account of access dysphasia: a single case study. Cipolotti L, et al. **Memory** 1995 Sep–Dec; 3(3–4):309–32
The compositionality of lexical semantic representations: clues from semantic errors in object naming. Hillis AE, et al. **Memory** 1995 Sep–Dec;3(3–4):333–58
Charting the progression in semantic dementia: implications for the organisation of semantic memory. Hodges JR, et al. **Memory** 1995 Sep–Dec;3(3–4):463–95
An interactive activation approach to object processing: effects of structural similarity, name frequency, and task in normality and pathology. Humphreys GW, et al.
Memory 1995 Sep–Dec;3(3–4):535–86
Naming without knowing and appearance without associations: evidence for constructive processes in semantic memory? Laws KR, et al. **Memory** 1995 Sep–Dec; 3(3–4):409–33
Selective impairments of object knowledge in a case of acquired cortical blindness. Powell J, et al. **Memory** 1995 Sep–Dec;3(3–4):435–61

PSYCHOLOGY

[Comparison between anomia with word comprehension difficulty and Gogi aphasia due to lobar atrophy] Yamada N, et al. **No To Shinkei** 1995 Nov;47(11):1059–67 (Eng. Abstr.) **(Jpn)**

REHABILITATION

Team development and memory training in traumatic brain injury rehabilitation: two birds with one stone. Finset A, et al. **Brain Inj** 1995 Jul;9(5):495–507
Melodic intonation therapy in the verbal decoding of aphasics. Popovici M. **Rom J Neurol Psychiatry** 1995 Jan–Mar;33(1):57–97

ANOMIE

see related
PERSONALITY DISORDERS
SOCIAL BEHAVIOR DISORDERS

ANOPHELES

A field trial with Lambda-cyhalothrin (ICON) for the intradomiciliary control of malaria transmitted by Anopheles darlingi root in Rondonia, Brazil. Charlwood JD, et al. **Acta Trop** 1995 Sep;60(1):3–13
The potential for malaria control with the biological larvicide Bacillus thuringiensis israelensis (Bti) in Peru and Ecuador. Kroeger A, et al. **Acta Trop** 1995 Sep;60(1):47–57
Insecticide-impregnated bed nets for malaria control: varying experiences from Ecuador, Colombia, and Peru concerning acceptability and effectiveness. Kroeger A, et al.
Am J Trop Med Hyg 1995 Oct;53(4):313–23
Comparative effects of permethrin-impregnated bednets and DDT house spraying on survival rates and oviposition interval of Anopheles farauti No. 1 (Diptera:Culicidae) in Solomon Islands. Hii JL, et al. **Ann Trop Med Parasitol** 1995 Oct;89(5):521–9
Temporal and spatial distribution of anopheline mosquitos in an Ethiopian village: implications for malaria control strategies. Ribeiro JM, et al. **Bull World Health Organ** 1996; 74(3):299–305
An animal study on transmission of hepatitis B virus through mosquitoes. Zheng Y, et al. **Chin Med J (Engl)** 1995 Dec; 108(12):895–7
Permeability of intact and dechorionated eggs of the Anopheles mosquito to water vapor and liquid water: a comparison with Drosophila. Valencia MD, et al.
Cryobiology 1996 Feb;33(1):142–8
Permeabilization of eggs of the malaria mosquito Anopheles gambiae. Valencia MD, et al. **Cryobiology** 1996 Feb; 33(1):149–62
Some emerging issues on the malaria problem in Kenya. Oloo AJ, et al. **East Afr Med J** 1996 Jan;73(1):50–3 (48 ref.)
Insecticide susceptibility status of some anophelines in district Bikaner, Rajasthan. Bansal SK, et al. **Indian J Malariol** 1996 Mar;33(1):1–6
Larvicidal activity of a few plant extracts against Culex quinquefasciatus and Anopheles stephensi. Pushpalatha E, et al. **Indian J Malariol** 1995 Mar;32(1):14–23
Hut-scale trial of pyraclofos against malaria vectors in Malkangiri District of Orissa. Sahu SS.
Indian J Malariol 1996 Mar;33(1):16–20
Anopheline fauna of Ajodhya hills, district Purulia. West Bengal. Tandon N, et al. **Indian J Malariol** 1995 Jun; 32(2):54–8
Current status of Anopheles stephensi response to various insecticides in some areas of the Thar desert. Singh KV, et al. **Indian J Med Res** 1996 Jun;103:299–303
Rapid decomposition of permethrin in the outer fly of an experimental tent in Pakistan. Bouma MJ, et al.
J Am Mosq Control Assoc 1996 Mar;12(1):125–9
Effect of temperature on the wing length-body weight relationship in Anopheles quadrimaculatus. Lanciani CA, et al. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 1):241–3
Isolation of the insecticidal components of Tagetes minuta (Compositae) against mosquito larvae and adults. Perich MJ, et al. **J Am Mosq Control Assoc** 1995 Sep;11(3):307–10
Observations on nocturnal biting activity and host preference of anophelines collected in southern Thailand. Rattanarithikul R, et al. **J Am Mosq Control Assoc** 1996 Mar;12(1):52–7
Seasonal abundance and parity rates of Anopheles species in southern Thailand. Rattanarithikul R, et al.
J Am Mosq Control Assoc 1996 Mar;12(1):75–83
Evaluation of light traps combined with carbon dioxide and 1-octen-3-ol to collect anophelines in Venezuela. Rubio-Palis Y. **J Am Mosq Control Assoc** 1996 Mar; 12(1):91–6
Evaluation of controlled-release mosquito repellent formulations. Rutledge LC, et al.
J Am Mosq Control Assoc 1996 Mar;12(1):39–44
Proportionality between light trap catches and biting densities of malaria vectors [letter; comment] Smith T.
J Am Mosq Control Assoc 1995 Sep;11(3):377–8. Comment on: J Am Mosq Control Assoc 1993 Sep;9(3):260–3.
Impact of deltamethrin spraying on malaria transmission in Rameshwaram Island, Tamil Nadu State - India. Sharma DN, et al. **J Commun Dis** 1996 Mar;28(1):38–44
Distribution and ecology of the mosquito fauna in the southwestern Saudi Arabia. Abdullah MA, et al.
J Egypt Soc Parasitol 1995 Dec;25(3):815–37
Laboratory and field evaluation of deet, CIC-4, and AI3-37220 against Anopheles dirus (Diptera: Culicidae) in Thailand. Frances SP, et al. **J Med Entomol** 1996 Jul; 33(4):511–5
Spatial distribution of adult mosquitoes (Diptera:Culicidae) in habitats associated with the rice agroecosystem of northern California. Wekesa JW, et al. **J Med Entomol** 1996 May;33(3):344–50
Malaria transmission and climate change in Australia. Bryan JH, et al. **Med J Aust** 1996 Mar 18;164(6):345–7
Improved medium for Aedes aegypti tissue culture. Chalk R, et al. **Med Vet Entomol** 1995 Jul;9(3):339–40
Comparison of sampling anopheline mosquitoes by light-trap and human-bait collections indoors at Bagamoyo, Tanzania. Davis JR, et al. **Med Vet Entomol** 1995 Jul; 9(3):249–55
Efficacy of etofenprox against insecticide susceptible and resistant mosquito strains containing characterized resistance mechanisms. Hemingway J. **Med Vet Entomol** 1995 Oct;9(4):423–6
Malaria infection potential of anopheline mosquitoes sampled by light trapping indoors in coastal Tanzanian villages. Shiff CJ, et al. **Med Vet Entomol** 1995 Jul;9(3):256–62
Movement of Anopheles gambiae s.l. malaria vectors between villages in The Gambia. Thomson MC, et al.
Med Vet Entomol 1995 Oct;9(4):413–9
Urban malaria and its vectors Anopheles stephensi and Anopheles culicifacies (Diptera : Culicidae) in Gurgaon, India. Sharma RS.
Southeast Asian J Trop Med Public Health 1995 Mar; 26(1):172–6
[Entomological study on the malaria transmission in coastal and lagoon areas: the case of a village built on a brackish lake] Akogbeto M. **Ann Soc Belg Med Trop** 1995 Sep; 75(3):219–27 (Eng. Abstr.) **(Fre)**
[Malaria typology in tropical Africa (letter)] Coosemans M. **Med Trop (Mars)** 1995;55(4 Suppl):113 **(Fre)**
[Study of the impact of deltamethrin impregnated curtains on malaria morbidity in Ankazobe of the Madagascar highlands] Rabarison P, et al. **Med Trop (Mars)** 1995;55(4 Suppl):105–8 **(Fre)**
[Control of malaria re-emergence in Reunion] Girod R, et al. **Sante** 1995 Nov–Dec;5(6):397–401 (Eng. Abstr.) **(Fre)**
[Entomological surveillance in Mauritius] Gopaul R. **Sante** 1995 Nov–Dec;5(6):401–5 (Eng. Abstr.) **(Fre)**
[Malaria: research perspectives in medical entomology in Madagascar] Laventure S, et al. **Sante** 1995 Nov–Dec; 5(6):406–10 (Eng. Abstr.) **(Fre)**
[Vector control in the epidemics of the Madagascar highlands] Randriantsimaniry D. **Sante** 1995 Nov–Dec; 5(6):392–6 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Determination of the human blood index of some anopheline mosquitos by using ELISA. Adugna N, et al.
Ethiop Med J 1996 Jan;34(1):1–10

CLASSIFICATION

Short report: simultaneous detection by polymerase chain reaction of mosquito species and Plasmodium falciparum infection in Anopheles gambiae sensu lato. Bouare M, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):629–31
Misidentification of a Philippine malaria vector revealed by allozyme and ribosomal DNA markers. Foley DH, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):46–8
A review of the use of ribosomal DNA (rDNA) to differentiate among cryptic Anopheles species. Collins FH, et al. **Insect Mol Biol** 1996 Feb;5(1):1–9 (55 ref.)
Diagnosis by random amplified polymorphic DNA polymerase chain reaction of four cryptic species related to Anopheles (Nyssorhynchus) albitarsis (Diptera: Culicidae) from Paraguay, Argentina, and Brazil. Wilkerson RC, et al. **J Med Entomol** 1995 Sep; 32(5):697–704
PCR of the ribosomal DNA intergenic spacer regions as a

method for identifying mosquitoes in the Anopheles gambiae complex. Cornel AJ, et al. **Methods Mol Biol** 1996; 50:321–32

The use of synthetic DNA probes for the field identification of members of the Anopheles gambiae complex. Hill SM, et al. **Methods Mol Biol** 1996;50:305–20

DRUG EFFECTS

Tests for possible effects of selection by domestic pyrethroids for resistance in culicine and anopheline mosquitoes in Sichuan and Hubei, China. Kang W, et al.
Ann Trop Med Parasitol 1995 Dec;89(6):677–84

The impact of permethrin impregnated bednets on the malaria vector Anopheles maculatus (Diptera: Culicidae) in aboriginal villages of Pos Betau Pahang, Malaysia. Vythilingam I, et al.
Southeast Asian J Trop Med Public Health 1995 Jun; 26(2):354–8

ENZYMOLOGY

Isolation and characterization of three serine protease genes in the mosquito Anopheles gambiae. Sidén-Kiamos I, et al. **Insect Mol Biol** 1996 Feb;5(1):61–71

Enzyme polymorphisms in the Anopheles gambiae (Diptera:Culicidae) complex related to feeding and resting behavior in the Imbo Valley, Burundi. Smits A, et al.
J Med Entomol 1996 Jul;33(4):545–53

GENETICS

Discrimination of all members of the Anopheles punctulatus complex by polymerase chain reaction--restriction fragment length polymorphism analysis. Beebe NW, et al.
Am J Trop Med Hyg 1995 Nov;53(5):478–81

DNA probes for the Anopheles punctulatus complex. Beebe NW, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):395–8

Variation in ribosomal DNA intergenic spacers among populations of Anopheles albimanus in South and Central America. De Merida AM, et al. **Am J Trop Med Hyg** 1995 Nov;53(5):469–77

Biochemical systematics and population genetic structure of Anopheles pseudopunctipennis, vector of malaria in Central and South America. Manguin S, et al.
Am J Trop Med Hyg 1995 Oct;53(4):362–77

Distribution of T1, Q, Pegasus and mariner transposable elements on the polytene chromosomes of PEST, a standard strain of Anopheles gambiae. Mukabayire O, et al. **Chromosoma** 1996 Jun;104(8):585–95

Conserved function of anopheles gambiae midgut-specific promoters in the fruitfly. Skavdis G, et al. **EMBO J** 1996 Jan 15;15(2):344–50

Constitutive and blood meal-induced trypsin genes in Anopheles gambiae. Müller HM, et al. **Exp Parasitol** 1995 Nov;81(3):371–85

Two genes encoding midgut-specific maltase-like polypeptides from Anopheles gambiae. Zheng L, et al.
Exp Parasitol 1995 Nov;81(3):272–83

Genetic differentiation of Anopheles gambiae populations from East and west Africa: comparison of microsatellite and allozyme loci. Lehmann T, et al. **Heredity** 1996 Aug; 77 (Pt 2):192–200

The polyubiquitin gene of the mosquito Anopheles gambiae: structure and expression. Beard CB, et al.
Insect Mol Biol 1996 May;5(2):109–17

Precise limitation of concerted evolution to ORFs in mosquito Hsp82 genes. Benedict MQ, et al.
Insect Mol Biol 1996 Feb;5(1):73–9

Molecular characterization of the Anopheles gambiae 2L telomeric region via an integrated transgene. Biessmann H, et al. **Insect Mol Biol** 1996 Feb;5(1):11–20

Evolution of the mitochondrial DNA control region in the Anopheles gambiae complex. Caccone A, et al.
Insect Mol Biol 1996 Feb;5(1):51–9

Microsatellite DNA and isozyme variability in a west African population of Anopheles gambiae. Lanzaro GC, et al.
Insect Mol Biol 1995 May;4(2):105–12

Metaphase karyotypes of Anopheles of Thailand and Southeast Asia: V. The Myzomyia Series, subgenus Cellia (Diptera:Culicidae). Baimai V, et al.
J Am Mosq Control Assoc 1996 Mar;12(1):97–105

Metaphase karyotypes of Anopheles of Thailand and Southeast Asia: IV. The Barbirostris and Umbrosus species Groups, subgenus Anopheles (Diptera: Culicidae). Baimi V, et al. **J Am Mosq Control Assoc** 1995 Sep;11(3):323–8

Test for association of DDT resistance with inversion polymorphism in Anopheles arabiensis from Ethiopia. Nigatu W, et al. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 1):238–40

Eye pigments in wild-type and eye-color mutant strains of the African malaria vector Anopheles gambiae. Beard CB, et al. **J Hered** 1995 Sep-Oct;86(5):375–80

Genetic differentiation and diagnostic loci of Anopheles nuneztovari, An. trinkae, and An. rangeli (Diptera: Culicidae). Fritz GN, et al. **J Med Entomol** 1995 Sep; 32(5):663–72

Anopheles arabiensis and An. gambiae chromosomal inversion polymorphism, feeding and resting behaviour in relation to insecticide house-spraying in Tanzania. Mnzava AE, et al. **Med Vet Entomol** 1995 Jul;9(3):316–24

Differential screening for the isolation of species-specific sequences in the Anopheles farauti complex. Sriprakash KS. **Methods Mol Biol** 1996;50:367–79

Transfection and malaria. Wesson DM, et al. **Nat Med** 1995 Aug;1(8):745–7

Occurrence of an unusual polymerase chain reaction product during identification of Anopheles gambiae sibling species (Diptera: Culicidae). Kampen H, et al. **Parasitol Res** 1996; 82(3):261–3

Pantropic retroviral vectors integrate and express in cells of the malaria mosquito, Anopheles gambiae. Matsubara T, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11; 93(12):6181–5

IMMUNOLOGY

Antibodies to Anopheles midgut reduce vector competence for Plasmodium vivax malaria. Srikrishnaraj KA, et al.
Med Vet Entomol 1995 Oct;9(4):353–7

[Immunological factors blocking transmission (letter)] Mulder B. **Med Trop (Mars)** 1995;55(4 Suppl):116–8 **(Fre)**

METABOLISM

Subunit cleavage of mosquito pro-vitellogenin by a subtilisin-like convertase. Chen JS, et al.
Proc Natl Acad Sci U S A 1996 Jun 11;93(12):6186–90

[Studies on elements in Anopheles sinensis infected with Brugia malayi microfilariae] Li J, et al.
Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih 1995;13(3):218–21 (Eng. Abstr.) **(Chi)**

MICROBIOLOGY

Bacterial population dynamics in three anopheline species: the impact on Plasmodium sporogonic development. Pumpuni CB, et al. **Am J Trop Med Hyg** 1996 Feb; 54(2):214–8

PARASITOLOGY

Regulation of infectivity of Plasmodium to the mosquito vector. Sinden RE, et al. **Adv Parasitol** 1996;38:53–117 (314 ref.)

Transmission dynamics of Wuchereria bancrofti in East Sepik Province, Papua New Guinea. Bockarie M, et al.
Am J Trop Med Hyg 1996 Jun;54(6):577–81

Detection of Plasmodium vivax and Plasmodium falciparum circumsporozoite antigen in anopheline mosquitoes collected in southern Thailand. Rattanarithikul R, et al.
Am J Trop Med Hyg 1996 Feb;54(2):114–21

Effect of the sickle cell trait status of gametocyte carriers of Plasmodium falciparum on infectivity to anophelines. Robert V, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):111–3

Quantification of Plasmodium falciparum sporozoites by ribosomal RNA detection. Vernick KD, et al.
Am J Trop Med Hyg 1996 Apr;54(4):430–8

Anopheles minimus: its bionomics and role in the transmission of malaria in Assam, India. Dev V.
Bull World Health Organ 1996;74(1):61–6

Experimental and field studies on some biological characteristics of Plasmodium vivax isolated from tropical and temperate zones of China. Yang B.
Chin Med J (Engl) 1996 Apr;109(4):266–71

Malaria transmitted by mosquitoes in New York City.
Commun Dis Rep CDR Wkly 1995 Sep 22;5(38):179

Plasmodium gallinaceum: mosquito peritrophic matrix and the parasite-vector compatibility. Shahabuddin M, et al.
Exp Parasitol 1995 Nov;81(3):386–93

Lectin binding to extracellularly melanized microfilariae of Brugia malayi from the hemocoel of Anopheles quadrimaculatus. Nayar JK, et al. **J Invertebr Pathol** 1995 Nov;66(3):277–86

Proteolytic enzyme activity and Plasmodium falciparum sporogonic development in three species of Anopheles mosquitoes. Chege GM, et al. **J Parasitol** 1996 Feb; 82(1):11–6

Noninfectious sporozoites in the salivary glands of a minimally susceptible anopheline mosquito. Noden BH, et al. **J Parasitol** 1995 Dec;81(6):912–5

Detection of Plasmodium sporozoites in mosquitoes by polymerase chain reaction and oligonucleotide rDNA probe, without dissection of the salivary glands. Stoffels JA, et al. **Med Vet Entomol** 1995 Oct;9(4):433–7

Interactions between parasites and insects vectors. Hurd H.
Mem Inst Oswaldo Cruz 1994;89 Suppl 2:27–30 (20 ref.)

Early sporogonic development in local vectors of Plasmodium falciparum in rural Cameroon. Robert V, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:23–6 (10 ref.)

Development of sporogonic cycle of Plasmodium vivax in experimentally infected Anopheles albimanus mosquitoes. Salas ML, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:115–9

Plasmodium yoelii nigeriensis: the effect of high and low intensity of infection upon the egg production and bloodmeal size of Anopheles stephensi during three gonotrophic cycles. Hogg JC, et al. **Parasitology** 1995 Dec; 111 (Pt 5):555–62

Malaria parasites enhance blood-feeding of their naturally infected vector Anopheles punctulatus. Koella JC, et al.
Parasitology 1996 Aug;113 (Pt 2):105–9

The impact of variations in temperature on early Plasmodium falciparum development in Anopheles stephensi. Noden BH, et al. **Parasitology** 1995 Dec;111 (Pt 5):539–45

Vectorial capacity and entomological inoculation rates of Anopheles gambiae in a high rainfall forested area of southern Sierra Leone. Bockarie MJ, et al.
Trop Med Parasitol 1995 Sep;46(3):164–71

[Histochemical changes in Brugia malayi microfilariae-infected Anopheles sinensis] Li J, et al.
Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih 1995;13(2):123–5 (Eng. Abstr.) **(Chi)**

[Studies on elements in Anopheles sinensis infected with Brugia malayi microfilariae] Li J, et al.
Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih 1995;13(3):218–21 (Eng. Abstr.) **(Chi)**

[Effect of environmental temperature, cryopreservation and aging on Plasmodium vivax sporozoites developing into exoerythrocytic stages] Liu D, et al.
Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih 1995;13(3):165–9 (Eng. Abstr.) **(Chi)**

[Study of malaria vectors in the south-west of Madagascar] Rakotoson JD, et al. **Arch Inst Pasteur Madagascar** 1994; 61(2):70–2 (Eng. Abstr.) **(Fre)**

[Bred Anopheles gambiae infectivity of a population sample living in a malaria endemic zone] Boudin C, et al.
Med Trop (Mars) 1995;55(4 Suppl):109–10 **(Fre)**

[Vector control, perspectives and realities] Carnevale P.
Med Trop (Mars) 1995;55(4 Suppl):56–65 (89 ref.) (Eng. Abstr.) **(Fre)**

[The utilization of molecular biological tools in the study of malaria transmission: example of programs conducted in Senegal] Fontenille D, et al. **Med Trop (Mars)** 1995;55(4 Suppl):52–5 (15 ref.) (Eng. Abstr.) **(Fre)**

[Immunological factors blocking transmission (letter)] Mulder B. **Med Trop (Mars)** 1995;55(4 Suppl):116–8 **(Fre)**

[Experimental infections of Anopheles gambiae with Plasmodium falciparum gametocytes: epidemiology of malaria man-vector transmission in the urban milieu] Tchuinkam T, et al. **Med Trop (Mars)** 1995;55(4 Suppl):101–4 **(Fre)**

PHYSIOLOGY

Olfactory responses of host-seeking Anopheles gambiae s.s. Giles (Diptera: Culicidae). de Jong R, et al. **Acta Trop** 1995 Aug;59(4):333–5

Human blood-feeding rates among sympatric sibling species of Anopheles quadrimaculatus mosquitoes in northern Florida. Jensen T, et al. **Am J Trop Med Hyg** 1996 May; 54(5):523–5

Predictions of adult Anopheles albimanus densities in villages based on distances to remotely sensed larval habitats. Rejmankova E, et al. **Am J Trop Med Hyg** 1995 Nov; 53(5):482–8

Predictions of malaria vector distribution in Belize based on multispectral satellite data. Roberts DR, et al.
Am J Trop Med Hyg 1996 Mar;54(3):304–8

Blood-digestion kinetics of four Anopheles species from Trinidad, West Indies. Chadee DD, et al.
Ann Trop Med Parasitol 1995 Oct;89(5):531–40

Biting activity of the malaria vector, Anopheles culicifacies, on man and cattle in Doon valley, India. Singh S, et al.
Appl Parasitol 1995 Aug;36(3):185–91

Some observations on the biting behavior of Anopheles gambiae s.s., Anopheles arabiensis, and Anopheles funestus and their implications for malaria control. Githeko AK, et al. **Exp Parasitol** 1996 Apr;82(3):306–15

Distribution of indoor-resting Anopheles fluviatilis in human dwellings and its implication on indoor residual spray. Gunasekaran K, et al. **Indian J Malariol** 1995 Mar; 32(1):42–6

Studies on clasper movement of Anopheles species. Kang W, et al. **Indian J Malariol** 1995 Mar;32(1):37–41 (12 ref.)

Mosquito breeding in relation to aquatic vegetation and some physico-chemical parameters in rice fields of central Gujarat. Kant R, et al. **Indian J Malariol** 1996 Mar; 33(1):30–40

Indoor resting anophelines of north Bengal. Malakar P, et al. **Indian J Malariol** 1995 Mar;32(1):24–31

Probing and gorging responses of three mosquito species to a membrane feeding system at a range of temperatures. Cosgrove JB, et al. **J Am Mosq Control Assoc** 1995 Sep; 11(3):339–42

Anopheles fluviatilis complex: host feeding patterns of species S, T, and U. Nanda N, et al.
J Am Mosq Control Assoc 1996 Mar;12(1):147–9

Frequent blood-feeding and restrictive sugar-feeding behavior enhance the malaria vector potential of Anopheles gambiae s.l. and An. funestus (Diptera:Culicidae) in western Kenya. Beier JC. **J Med Entomol** 1996 Jul;33(4):613–8

Diel rhythms of oviposition and fecundity of Anopheles aquasalis (Diptera:Culicidae) under laboratory conditions. Chadee DD, et al. **J Med Entomol** 1996 Jul;33(4):686–8

Mosquitoes (Diptera:Culicidae) breeding in brackish water: female ovipositional preferences or larval survival? Roberts D. **J Med Entomol** 1996 Jul;33(4):525–30

Effects of sugar availability on the blood-feeding behavior of Anopheles gambiae (Diptera:Culicidae). Straif SC, et al. **J Med Entomol** 1996 Jul;33(4):608–12

Activation of Anopheles gambiae mosquitoes by carbon dioxide and human breath. Healy TP, et al.
Med Vet Entomol 1995 Jul;9(3):331–6

Development of a cyanobacterial biolarvicide. Murphy RC, et al. **Mem Inst Oswaldo Cruz** 1995 Jan-Feb;90(1):109–13

Studies on mosquitoes (Diptera: Culicidae) and anthropic environment. 7-behaviour of adults Nyssorhynchus anophelines with special reference to Anopheles albitarsis s.l. in south-eastern Brazil. Forattini OP, et al.
Rev Saude Publica 1995 Feb;29(1):20–6

ANOPHELES

A report of Anopheles (Diptera: Culicidae) attracted to cow bait in a malaria endemic village in Peninsular Malaysia near the Thailand border. Rahman WA, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):359–63

Anti-Pfs25 monoclonal antibody 32F81 blocks transmission from Plasmodium falciparum gametocyte carriers in Cameroon. Mulder B, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr;90(2):195

[Anopheles funestus and rice agriculture in the Madagascar highlands] Marrama L, et al. **Sante** 1995 Nov–Dec; 5(6):415–9 (Eng. Abstr.) **(Fre)**

VIROLOGY

Experimental evidence against replication or dissemination of hepatitis C virus in mosquitoes (Diptera:Culicidae) using detection by reverse transcriptase polymerase chain reaction. Silverman AL, et al. **J Med Entomol** 1996 May; 33(3):398–401

ANOPHTHALMOS

CHEMICALLY INDUCED

US court case starts over eyeless babies [news] Dyer C. **BMJ** 1996 May 18;312(7041):1247

COMPLICATIONS

Cryptorchidism, micropenis and clinical anophthalmia epilepsy in a retarded boy. Izumiya K, et al. **Int Urol Nephrol** 1996;28(1):103–8

DIAGNOSIS

Association of anophthalmia and esophageal atresia. Sandler D, et al. **Am J Med Genet** 1995 Dec 4;59(4):484–91

Complicated anophthalmos. Bajwa GS, et al. **Indian Pediatr** 1995 Apr;32(4):480–2 (5 ref.)

GENETICS

Apparently new "anophthalmia–plus" syndrome in sibs. Fryns JP, et al. **Am J Med Genet** 1995 Aug 28;58(2):113–4

Anophthalmia–Waardenburg syndrome: a report of three cases. Suyugül Z, et al. **Am J Med Genet** 1996 Apr 24; 62(4):391–7

Systemic anomalies in 77 patients with congenital anophthalmos or microphthalmos. Tucker S, et al. **Eye** 1996;10 (Pt 3):310–4

Anophthalmia with cleft palate and micrognathia: a new syndrome or an unusual presentation of Rubinstein–Taybi syndrome? [letter; comment] Fryns JP. **J Med Genet** 1995 Aug;32(8):668. Comment on: J Med Genet 1994 Dec;31(12):960–1.

METABOLISM

Diurnal variations in vasoactive intestinal polypeptide–like immunoreactivity in the suprachiasmatic nucleus of congenitally anophthalmic mice. Laemle LK, et al. **Brain Res** 1995 Aug 7;688(1–2):203–8

PATHOLOGY

Ophthalmo acromelic syndrome [letter] Quarrell OW. **Clin Dysmorphol** 1995 Jul;4(3):272–3

A case of lateral facial cleft, cleft lip and palate, anophthalmia, microtia, clavicular agenesis and asternia. Samson G, et al. **Clin Dysmorphol** 1995 Jul;4(3):251–4

[Cerebro–oculofacial dysplasia associated with vertebral changes] Munteanu G, et al. **Oftalmologia** 1995 Oct–Dec; 39(4):316–21 (10 ref.) (Eng. Abstr.) **(Rum)**

SURGERY

The superior auricular artery and retroauricular arterial island flaps. Song R, et al. **Plast Reconstr Surg** 1996 Sep; 98(4):657–67; discussion 668–70

ULTRASONOGRAPHY

[A case of congenital anophthalmos diagnosed antenatally] Kagiya A, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 May;48(5):347–50 **(Jpn)**

VETERINARY

Congenital anophthalmia with caudal vertebral anomalies in Japanese Brown cattle. Moritomo Y, et al. **J Vet Med Sci** 1995 Aug;57(4):693–6

ANOPLURA

Effects of the sucking louse (Linognathus vituli) on the grooming behaviour of housed calves. Weeks CA, et al. **Vet Rec** 1995 Jul 8;137(2):33–5

ANORECTICS see APPETITE DEPRESSANTS

ANOREXIA

Strategies for potential manipulation of anorexia during acute and chronic disease. Plata–Salamán CR. **Nutrition** 1995 Sep–Oct;11(5 Suppl):702–4 (39 ref.)

Anorexia during acute and chronic disease. Plata–Salamán CR. **Nutrition** 1996 Feb;12(2):69–78 (147 ref.)

Anorexia, cachexia, and dysphagia: the symptom experience. Grant MM, et al. **Semin Oncol Nurs** 1995 Nov;11(4):266–71 (32 ref.)

[Anorexic and pseudoanorexic child] Marranzini M, et al. **Pediatr Med Chir** 1995 Nov–Dec;17(6):545–58 (Eng. Abstr.) **(Ita)**

BLOOD

Zinc deficiency–induced anorexia influences the distribution of serum insulin–like growth factor–binding proteins in the rat. Clegg MS, et al. **Metabolism** 1995 Nov;44(11):1495–501

CEREBROSPINAL FLUID

Correlation between food intake and cerebrospinal fluid interleukin 1 alpha in anorectic tumor–bearing rats. Opara EI, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):678–9

CHEMICALLY INDUCED

Lesions of area postrema attenuate but do not prevent anorectic action of peripheral serotonin in rats. Adipudi V, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1314–20

Potency of naloxone's anorectic effect in rats is dependent on diet preference. Glass MJ, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R217–21

Interleukin–1 beta–induced anorexia and pyrexia in rat: relationship to hypothalamic neuropeptide Y. McCarthy HD, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E852–7

Anorexia induced by cytokine interactions at pathophysiological concentrations. Sonti G, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1394–402

Hepatic vagus does not mediate IL–1 alpha induced anorexia. Laviano A, et al. **Neuroreport** 1995 Jul 10;6(10):1394–6

Anorectic and neurochemical effects of pituitary adenylate cyclase activating polypeptide in rats. Chance WT, et al. **Peptides** 1995;16(8):1511–6

COMPLICATIONS

Case of ageusia from a variety of causes. Deguchi K, et al. **J Laryngol Otol** 1996 Jun;110(6):598–601

DRUG THERAPY

Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia–cachexia syndrome in patients with metastatic cancer. Gebbia V, et al. **Br J Cancer** 1996 Jun;73(12):1576–80

Hyperglycemia in an AIDS patient taking megestrol. Pimentel G, et al. **Hosp Pract (Off Ed)** 1996 Apr 15; 31(4):27–8

Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Mantovani G, et al. **Int J Clin Lab Res** 1995;25(3):135–41

Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double–blind, placebo–controlled trial. Goldberg RM, et al. **J Clin Oncol** 1995 Nov;13(11):2856–9

Effects of administration of oral branched–chain amino acids on anorexia and caloric intake in cancer patients. Cangiano C, et al. **J Natl Cancer Inst** 1996 Apr 17;88(8):550–2

North Central Cancer Treatment Group (NCCTG). Loprinzi CL. **J Natl Cancer Inst Monogr** 1996;(20):79–80

Relationship between interleukin–1 and cancer anorexia. Laviano A, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):680–3

ECONOMICS

Towards a political economy of anorexia? Fine B. **Appetite** 1995 Jun;24(3):231–42 (28 ref.)

ENZYMOLOGY

Refractory hypothalamic adenylate cyclase in anorectic tumor–bearing rats: implications for NPY–induced feeding. Chance WT, et al. **Brain Res** 1995 Sep 11;691(1–2):180–4

EPIDEMIOLOGY

Anorexia in older persons: epidemiology and optimal treatment. Morley JE. **Drugs Aging** 1996 Feb;8(2):134–55 (205 ref.)

ETIOLOGY

Anorexia and cachexia in advanced cancer patients. Vigano A, et al. **Cancer Surv** 1994;21:99–115 (76 ref.)

Family pathology and anorexia in the Indian context. Chandra PS, et al. **Int J Soc Psychiatry** 1995 Winter; 41(4):292–8

Mechanism of early tumor anorexia. Muscaritoli M, et al. **J Surg Res** 1996 Feb 1;60(2):389–97

Zinc deficiency–induced anorexia influences the distribution of serum insulin–like growth factor–binding proteins in the rat. Clegg MS, et al. **Metabolism** 1995 Nov;44(11):1495–501

Relationship between interleukin–1 and cancer anorexia. Laviano A, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):680–3

Anorexia in dialysis patients. Bergström J. **Semin Nephrol** 1996 May;16(3):222–9 (88 ref.)

GENETICS

NPY mRNA and peptide immunoreactivity in the arcuate nucleus are increased by osmotic stimuli: correlation with dehydration anorexia. O'Shea RD, et al. **Peptides** 1995; 16(6):1117–25

METABOLISM

NPY mRNA and peptide immunoreactivity in the arcuate nucleus are increased by osmotic stimuli: correlation with dehydration anorexia. O'Shea RD, et al. **Peptides** 1995; 16(6):1117–25

Contribution to characterization of anorectic protein similar to satietin from urine. Maletinská L, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):715–21

PARASITOLOGY

Anorexia induced by the parasitic nematode, Nippostrongylus brasiliensis: effects on NPY and CRF gene expression in the rat hypothalamus. Horbury SR, et al. **J Neuroendocrinol** 1995 Nov;7(11):867–73

PHYSIOPATHOLOGY

Role of cholecystokinin in the anorexia produced by duodenal delivery of oleic acid in rats. Woltman T, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1420–33

Dehydration anorexia in decerebrate rats. Flynn FW, et al. **Behav Neurosci** 1995 Oct;109(5):1009–12

Neutral mediation of food aversions and anorexia induced by tumor necrosis factor and tumors. Bernstein IL. **Neurosci Biobehav Rev** 1996;20(1):177–81 (27 ref.)

Tumor necrosis factor–alpha and total parenteral nutrition–induced anorexia. Opara EI, et al. **Surgery** 1995 Oct;118(4):756–60; discussion 760–2

PREVENTION & CONTROL

[A clinical trial Furlutal in the prevention of anorexia, weight loss and myelosuppression due to chemotherapy] Wang J, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):283–5 (Eng. Abstr.) **(Chi)**

PSYCHOLOGY

Towards a political economy of anorexia? Fine B. **Appetite** 1995 Jun;24(3):231–42 (28 ref.)

The hazards of using a child as an interpreter [see comments] Jacobs B, et al. **J R Soc Med** 1995 Aug;88(8):474P–475P . Comment in: J R Soc Med 1995 Aug;88(8):426–7.

THERAPY

Anorexia in older persons: epidemiology and optimal treatment. Morley JE. **Drugs Aging** 1996 Feb;8(2):134–55 (205 ref.)

VETERINARY

Diagnostic exercise: anorexia, wasting, and death in South African clawed frogs. Ruble G, et al. **Lab Anim Sci** 1995 Oct;45(5):592–4

Post–hibernation anorexia in tortoises [letter] Redrobe S. **Vet Rec** 1996 May 11;138(19):480

ANOREXIA NERVOSA

Anorexia nervosa: an overview. Hobbs WL, et al. **Am Fam Physician** 1996 Sep 15;54(4):1273–9, 1284–6 (16 ref.)

Anorexia nervosa: issues for the obstetrician and gynecologist. Hertweck SP. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):371–4 (26 ref.)

Anorexia nervosa—more than an eating disorder [letter] Russell JD, et al. **Nat Med** 1996 Apr;2(4):366–7

Anorexia nervosa and bulimia nervosa. When the pursuit of bodily 'perfection' becomes a killer. Zerbe KJ. **Postgrad Med** 1996 Jan;99(1):161–4, 167–9 (21 ref.)

[Bulimia and anorexia nervosa] Sakuramoto M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):345–7 (18 ref.) **(Jpn)**

[Anorexia nervosa] Mrass D, et al. **Lijec Vjesn** 1996 Jan–Feb; 118(1–2):34–8 (271 ref.) (Eng. Abstr.) **(Scr)**

[Insufficient knowledge about eating disorders in Russia. There is an anorexia clinic in Moscow] Heine SF. **Lakartidningen** 1996 Aug 28;93(35):2907–9 **(Swe)**

BLOOD

Serotonin–induced platelet calcium mobilization is enhanced in bulimia nervosa but not in anorexia nervosa. Okamoto Y, et al. **Biol Psychiatry** 1995 Aug 15;38(4):274–6

Total body potassium and serum potassium among eating disorder patients. Powers PS, et al. **Int J Eat Disord** 1995 Nov;18(3):269–76

Plasma concentrations of obese protein in anorexia nervosa [letter] Hebebrand J, et al. **Lancet** 1995 Dec 16; 346(8990):1624–5

Rebound hypoglycaemia after intravenous glucose in anorexia nervosa [letter] Inui A, et al. **Lancet** 1996 Feb 3;347(8997):323–4

T–lymphocyte cholecystokinin–8 and beta–endorphin concentrations in eating disorders: I. Anorexia nervosa. Brambilla F, et al. **Psychiatry Res** 1995 Nov 29; 59(1–2):43–50

COMPLICATIONS

Systemic pseudovasculitis from scurvy in anorexia nervosa. Mehta CL, et al. **Arthritis Rheum** 1996 Mar;39(3):532–3

Generalized pruritus in anorexia nervosa. Taniguchi S, et al. **Br J Dermatol** 1996 Mar;134(3):510–1
Anorexia nervosa and the heart. Cooke RA, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):313–7 (41 ref.)
Anorexia nervosa [letter] Cheng TO. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):16
Anorexia and bulimia nervosa (the eating disorders): conditions of interest to the dental practitioner. Robb ND, et al. **J Dent** 1996 Jan–Mar;24(1–2):7–16 (77 ref.)
Retropharyngeal abscess–an unusual complication of anorexia nervosa. Delap TG, et al. **J Laryngol Otol** 1996 May;110(5):483–4
Bulimia and anorexia nervosa in winter depression: lifetime rates in a clinical sample. Gruber NP, et al. **J Psychiatry Neurosci** 1996 Jan;21(1):9–12
Eating disorder and obsessive–compulsive disorder: neurochemical and phenomenological commonalities. Jarry JL, et al. **J Psychiatry Neurosci** 1996 Jan;21(1):36–48 (125 ref.)
Screening for eating disorders in diabetes mellitus. Cantwell R, et al. **J Psychosom Res** 1996 Jan;40(1):15–20
Anorexia nervosa and intussusception [letter] Inui A, et al. **Lancet** 1996 Feb 10;347(8998):399
Anorexia nervosa [letter] Cheng TO. **Postgrad Med J** 1996 Jun;72(848):383
Cor pulmonale due to untreated asthma in a young woman with coexistent anorexia nervosa. Wilson GE, et al. **Respir Med** 1995 Oct;89(9):631–3
Raynaud's phenomenon and anorexia nervosa [letter] Marinella MA. **South Med J** 1995 Dec;88(12):1279–80
[Severe hyponatremia associated with anorexia nervosa: role of inappropriate antidiuretic hormone secretion?] Challier P, et al. **Arch Pediatr** 1995 Oct;2(10):977–9 (Eng. Abstr.) **(Fre)**
[Acute gastric dilatation with superior mesenteric artery syndrome in a young girl with anorexia nervosa] Stheneur C, et al. **Arch Pediatr** 1995 Oct;2(10):973–6 (Eng. Abstr.) **(Fre)**
[Obsessive–compulsive disorder in girls with eating disorders] Rabe–Jabłońska J. **Psychiatr Pol** 1996 Mar–Apr; 30(2):187–200 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Magnetic resonance imaging of clival marrow in patients with anorexia nervosa. Kuwashima S, et al. **Acta Paediatr Jpn** 1996 Apr;38(2):114–7
Body size estimation in eating disorder patients: testing the video distortion method on a life–size screen. Probst M, et al. **Behav Res Ther** 1995 Nov;33(8):985–90
Should amenorrhoea be necessary for the diagnosis of anorexia nervosa? Evidence from a Canadian community sample. Garfinkel PE, et al. **Br J Psychiatry** 1996 Apr; 168(4):500–6
Eating disorders: 1. Anorexia nervosa. Mehler PS. **Hosp Pract (Off Ed)** 1996 Jan 15;31(1):109–13, 117
The reliability of bioelectrical impedance analysis for measuring changes in the body composition of patients with anorexia nervosa. Birmingham CL, et al. **Int J Eat Disord** 1996 Apr;19(3):311–5
Seasonality of symptoms in anorexia and bulimia nervosa. Lam RW, et al. **Int J Eat Disord** 1996 Jan;19(1):35–44
Obsessive–compulsive disorder, trichotillomania, and anorexia nervosa: a case report. Pryor TL, et al. **Int J Eat Disord** 1995 Dec;18(4):375–9
Vitamin status of eating disorder patients: relationship to clinical indices and effect of treatment. Rock CL, et al. **Int J Eat Disord** 1995 Nov;18(3):257–62
Case study: anorexia nervosa and autistic disorder in an adolescent girl. Fisman S, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):937–40
Obsessionality in eating–disorder patients: relationship to clinical presentation and two–year outcome. Zubieta JK, et al. **J Psychiatr Res** 1995 Jul–Aug;29(4):333–42
Screening for eating disorders in diabetes mellitus. Cantwell R, et al. **J Psychosom Res** 1996 Jan;40(1):15–20
Reversibility of brain tissue loss in anorexia nervosa assessed with a computerized Talairach 3–D proportional grid. Swayze VW 2nd, et al. **Psychol Med** 1996 Mar;26(2):381–90
[Anorexia nervosa. A frequent antecedent of obsessive compulsive disorder] Zribi S, et al. **Encephale** 1989 May–Jun;15(3):355–8 (19 ref.) (Eng. Abstr.) **(Fre)**
[Considerations on the diagnosis of infantile anorexia] Robin D, et al. **Psychiatr Enfant** 1995;38(1):365–401 (54 ref.) (Eng. Abstr.) **(Fre)**
[How I diagnose... anorexia nervosa] Scheen AJ. **Rev Med Liege** 1995 Dec;50(12):538–9 **(Fre)**
[Anorexia nervosa: a follow–up of nutritional, hormonal and psychiatric parameters] Foppiani L, et al. **Minerva Med** 1995 Dec;86(12):537–42 (Eng. Abstr.) **(Ita)**
[The anorexia nervosa syndrome] Preradović M, et al. **Vojnosanit Pregl** 1994 May–Jun;51(3):245–8 (Eng. Abstr.) **(Scr)**
[Clinical aspects of anorexia nervosa in males] de la Serna de Pedro I. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Mar–Apr;24(2):67–73 (Eng. Abstr.) **(Spa)**
[Anorexia nervosa—a severe somatic and psychiatric diagnosis! One does not die of anxiety but of caloric deficiency] Hjalmers I. **Lakartidningen** 1996 Jun 26; 93(26–27):2514–5 **(Swe)**

DIET THERAPY

Physical measures of recovery from anorexia nervosa during hospitalised re–feeding. Waller EG, et al. **Eur J Clin Nutr** 1996 Mar;50(3):165–70
Eating disorders: current nutrition therapy and perceived needs in dietetics education and research. Whisenant SL, et al. **J Am Diet Assoc** 1995 Oct;95(10):1109–12

DRUG THERAPY

Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Marrazzi MA, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):163–72
Reversibility of cerebral ventricular enlargement in anorexia nervosa, demonstrated by quantitative magnetic resonance imaging. Golden NH, et al. **J Pediatr** 1996 Feb; 128(2):296–301

ECONOMICS

The cost of the illness that defies [editorial] Howlett M, et al. **Postgrad Med J** 1995 Dec;71(842):705–6 (15 ref.)

EPIDEMIOLOGY

Eating disorders in female inpatients with versus without substance use disorders. Grilo CM, et al. **Addict Behav** 1995 Mar–Apr;20(2):255–60
Substance use and impulsive behaviors among adolescents with eating disorders. Wiederman MW, et al. **Addict Behav** 1996 Mar–Apr;21(2):269–72
Anorexia nervosa and bulimia nervosa in alcohol–dependent men and women and their relatives. Schuckit MA, et al. **Am J Psychiatry** 1996 Jan;153(1):74–82
Eating disturbances among American minority groups: a review. Crago M, et al. **Int J Eat Disord** 1996 Apr; 19(3):239–48 (59 ref.)
Season of birth and eating disorders. Rezaul I, et al. **Int J Eat Disord** 1996 Jan;19(1):53–61
The incidence and prevalence of anorexia nervosa in three suburban health districts in south west London, U.K. Rooney B, et al. **Int J Eat Disord** 1995 Dec;18(4):299–307
The relationship between eating disorders and depression. Willcox M, et al. **J Soc Psychol** 1996 Apr;136(2):269–71
[Comorbidity of bipolar and eating disorders. Epidemiologic and therapeutic aspects] Mury M, et al. **Encephale** 1995 Sep–Oct;21(5):545–53 (44 ref.) (Eng. Abstr.) **(Fre)**

ETHNOLOGY

An epidemiological study of eating disorders in a northern area of Japan. Nadaoka T, et al. **Acta Psychiatr Scand** 1996 Apr;93(4):305–10
Anorexia nervosa in 'non–white' populations. Soomro GM, et al. **Br J Psychiatry** 1995 Sep;167(3):385–9
Eating disorders: an Indian perspective. Khandelwal SK, et al. **Int J Soc Psychiatry** 1995 Summer;41(2):132–46

ETIOLOGY

Occult intracranial tumours masquerading as early onset anorexia nervosa. De Vile CJ, et al. **BMJ** 1995 Nov 18; 311(7016):1359–60
Anorexia nervosa—diagnosis, aetiology, and treatment. Hartman D. **Postgrad Med J** 1995 Dec;71(842):712–6 (30 ref.)
[Anorexia as the main symptom of gastroesophageal reflux: case study of a 13.5–year–old girl] Domagała Z, et al. **Pediatr Pol** 1996 May;71(5):473–5 (Eng. Abstr.) **(Pol)**

GENETICS

[2 sets of monozygotic twins concordant for anorexia nervosa] Schmid–Ott G, et al. **Z Psychosom Med Psychoanal** 1995;41(4):344–55 (Eng. Abstr.) **(Ger)**

HISTORY

Self–starvation through the ages: reflections on the pre–history of anorexia nervosa. Bemporad JR. **Int J Eat Disord** 1996 Apr;19(3):217–37

METABOLISM

Bone metabolism and osteopenia in eating disorders. Carmichael KA, et al. **Medicine (Baltimore)** 1995 Sep; 74(5):254–67 (132 ref.)

PATHOLOGY

Distribution of serouslike bone marrow changes in the lower limbs of patients with anorexia nervosa: predominant involvement of the distal extremities. Vande Berg BC, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):621–5
[Vaginal cytology in eating disorders in young girls] Nicoli JM, et al. **Rev Fr Gynecol Obstet** 1995 May–Jun; 90(5–6):291–6 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Micro– and macroanalyses of patterns within a meal in anorexia and bulimia nervosa. Sunday SR, et al. **Appetite** 1996 Feb;26(1):21–36
Food selection in anorectics and bulimics: food items, nutrient content and nutrient density. van der Ster Wallin G, et al. **J Am Coll Nutr** 1995 Jun;14(3):271–7
Gymnasts, distance runners, anorexics body composition and menstrual status. Bale P, et al. **J Sports Med Phys Fitness** 1996 Mar;36(1):49–53
Delayed gastric emptying in bulimic patients [letter] Inui A, et al. **Lancet** 1995 Nov 4;346(8984):1240
Serotonin activity in anorexia nervosa after long–term weight restoration: response to D–fenfluramine challenge. O'Dwyer AM, et al. **Psychol Med** 1996 Mar;26(2):353–9

PSYCHOLOGY

Eating disorder research in the past decade. Halmi KA. **Ann N Y Acad Sci** 1996 Jun 18;789:67–77 (56 ref.)
Family functioning in adolescent anorexia nervosa. North C, et al. **Br J Psychiatry** 1995 Nov;167(5):673–8
Sexual abuse in patients with eating disorder, patients with depression, and normal controls. A comparative study. Vize CM, et al. **Br J Psychiatry** 1995 Jul;167(1):80–5
Information–processing correlates of reported sexual abuse in eating–disordered and comparison women. Waller G, et al. **Child Abuse Negl** 1995 Jun;19(6):745–59
The cognitive profile of anorexia nervosa: a comparative study including a community–based sample. Gillberg IC, et al. **Compr Psychiatry** 1996 Jan–Feb;37(1):23–30
A clinical and phenomenological study of 185 Spanish adolescents with anorexia nervosa. Toro J, et al. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):165–74
Anorexia nervosa following gastroplasty in the male: two cases. Bonne OB, et al. **Int J Eat Disord** 1996 Jan; 19(1):105–8
The impact of stress, fear of fatness, and panic disorder with agoraphobia on eating disorder symptomatology: a case study. Chesler BE. **Int J Eat Disord** 1995 Sep;18(2):195–8
Cognitive style of patients with anorexia nervosa and bulimia nervosa. Kaye WH, et al. **Int J Eat Disord** 1995 Nov; 18(3):287–90
Issues and concerns associated with different risk models for eating disorders. Leung F, et al. **Int J Eat Disord** 1996 Apr;19(3):249–56
Stroop interference and food intake. Overduin J, et al. **Int J Eat Disord** 1995 Nov;18(3):277–85
Anorexia by proxy: are the children of anorexic mothers an at–risk group? Scourfield J. **Int J Eat Disord** 1995 Dec; 18(4):371–4
Food preferences and desire to eat in anorexia and bulimia nervosa. Stoner SA, et al. **Int J Eat Disord** 1996 Jan; 19(1):13–22
Feelings and fantasy in eating disorders: a factor analysis of the Toronto Alexithymia Scale. Troop NA, et al. **Int J Eat Disord** 1995 Sep;18(2):151–7
Defense mechanisms in severe adolescent anorexia nervosa. Gothelf D, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Dec;34(12):1648–54
Abnormal psychosocial situations and eating disorders in adolescence. Horesh N, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):921–7
The role of sensory and nonsensory factors in body size estimations of eating disorder subjects. Gardner RM, et al. **J Clin Psychol** 1996 Jan;52(1):3–15
Eating problems and interpersonal functioning among several groups of women. O'Mahony JF, et al. **J Clin Psychol** 1995 May;51(3):345–51
Body image distortion in anorexia and bulimia nervosa: the role of perceived and actual control. Waller G, et al. **J Nerv Ment Dis** 1996 Apr;184(4):213–9
Correlates of dissociative symptoms among women with eating disorders. Gleaves DH, et al. **J Psychiatr Res** 1995 Sep–Oct;29(5):417–26
New perspectives on the eating disorders [editorial] Kaplan AS. **J Psychiatry Neurosci** 1996 Jan;21(1):7–8
Perceived touch deprivation and body image: some observations among eating disordered and non–clinical subjects. Gupta MA, et al. **J Psychosom Res** 1995 May; 39(4):459–64
Eating disorders and substance abuse in women: a comparative study of MMPI patterns. Minnesota Multiphasic Personality Inventory. Shisslak CM, et al. **J Subst Abuse** 1988–89;1(2):209–19
Bone metabolism and osteopenia in eating disorders. Carmichael KA, et al. **Medicine (Baltimore)** 1995 Sep; 74(5):254–67 (132 ref.)
Anorexia nervosa, self–starvation and the reward of stress. Bergh C, et al. **Nat Med** 1996 Jan;2(1):21–2 (13 ref.)
Body–size estimation in anorexia nervosa. Molinari E. **Percept Mot Skills** 1995 Aug;81(1):23–31
Changes in taste responsiveness in patients with anorexia nervosa during behavior therapy. Nozoe S, et al. **Physiol Behav** 1996 Mar;59(3):549–53
The families of anorexia nervosa and cystic fibrosis patients. Blair C, et al. **Psychol Med** 1995 Sep;25(5):985–93
The relationship of partial syndrome eating disorders to anorexia nervosa and bulimia nervosa. Dancyger IF, et al. **Psychol Med** 1995 Sep;25(5):1019–25
Social, psychological and physical correlates of eating problems. A study of the general adolescent population in Norway. Wichstrøm L. **Psychol Med** 1995 May; 25(3):567–79
Perceived parental bonding in anorectic and bulimic patients. Sordelli A, et al. **Psychopathology** 1996;29(1):64–70
The relationship between eating disorders and running in women. Estok PJ, et al. **Res Nurs Health** 1996 Oct; 19(5):377–87
[Psychodynamic and psychotherapeutic outcomes in anorexia

nervosa during adolescence] Kocourková J, et al. **Ceska Slov Psychiatr** 1995 Feb;91(1):50–6 (Eng. Abstr.) **(Cze)**

[Eating disorders and suicide attempts in 2 dance students] Sanchez-Cardenas M, et al. **Arch Pediatr** 1996 Jan;3(1):51–4 (Eng. Abstr.) **(Fre)**

[A psychoanalytic approach to cases of anorexia nervosa] Matijaš B, et al. **Vojnosanit Pregl** 1995 Mar–Apr; 52(2):180–3 **(Scr)**

RADIOGRAPHY

Peculiar enlargement of the nasopharynx in patients with anorexia nervosa. Okamoto K, et al. **Neuroradiology** 1995 Nov;37(8):674–8

THERAPY

Persistent perfectionism, symmetry, and exactness after long-term recovery from anorexia nervosa. Srinivasagam NM, et al. **Am J Psychiatry** 1995 Nov;152(11):1630–4

Treating anorexia nervosa. Psychiatrists have mixed views on use of terminal care for anorexia nervosa [letter; comment] Ramsay R, et al. **BMJ** 1996 Jan 20;312(7024):182 . Comment on: BMJ 1995 Sep 2;311(7005):584.

Treating anorexia nervosa. Patients' beliefs hinder treatment [letter; comment] Sharkey J. **BMJ** 1996 Jan 20; 312(7024):182. Comment on: BMJ 1995 Sep 2;311(7005):584.

Conceptual models and integrative therapy: anorexia nervosa as a prototype. Greben DH, et al. **Can J Psychiatry** 1995 Dec;40(10):584–92 (65 ref.)

Treating bulimia nervosa in primary care: a pilot study. Waller D, et al. **Int J Eat Disord** 1996 Jan;19(1):99–103

A new treatment of anorexia nervosa [letter] Bergh C, et al. **Lancet** 1996 Aug 31;348(9027):611–2

Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa—restricted type. Brambilla F, et al. **Neuropsychobiology** 1995;32(2):59–63

Changes in taste responsiveness in patients with anorexia nervosa during behavior therapy. Nozoe S, et al. **Physiol Behav** 1996 Mar;59(3):549–53

Anorexia nervosa—diagnosis, aetiology, and treatment. Hartman D. **Postgrad Med J** 1995 Dec;71(842):712–6 (30 ref.)

Neuropsychological and structural brain changes in anorexia nervosa before and after refeeding. Kingston K, et al. **Psychol Med** 1996 Jan;26(1):15–28

[Effects of sexual abuse experiences on therapeutic outcome: study of eating disordered patients 2 years after inpatient psychotherapy] Köpp W, et al. **Psychother Psychosom Med Psychol** 1996 Mar–Apr; 46(3–4):131–8 (Eng. Abstr.) **(Ger)**

[Problems involving "target weight" in treatment of anorexia nervosa] Hebebrand J, et al. **Z Kinder Jugenpsychiatr** 1996 Jun;24(2):92–104 (60 ref.) **(Ger)**

[Family physician's role in anorexia nervosa (letter)] Pardo Alvarez J, et al. **Aten Primaria** 1995 Sep 15;16(4):234 **(Spa)**

ANOSMIA

COMPLICATIONS

Allergic rhinitis and olfactory loss. Apter AJ, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):311–6

Association between elevated body-mass index and impaired sense of smell in older people [letter] Hunter-Smith DG, et al. **J Am Geriatr Soc** 1996 Jan;44(1):100–1

CONGENITAL

MR evaluation of patients with congenital hyposmia or anosmia. Yousem DM, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):439–43

DIAGNOSIS

Olfaction and rhinitis [editorial] Druce HM. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):291–3

Prevalence and assessment of qualitative olfactory dysfunction in different age groups. Nordin S, et al. **Laryngoscope** 1996 Jun;106(6):739–44

[Diagnostic methods in the assessment of anosmia in neurologic diseases] Kobal G, et al. **Nervenarzt** 1995 Dec; 66(12):869–84 (54 ref.) (Eng. Abstr.) **(Ger)**

[Disorders of the sense of smell and taste] Hüttenbrink KB. **Ther Umsch** 1995 Nov;52(11):732–7 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

The treatment of hyposmia with intranasal steroids. Golding-Wood DG, et al. **J Laryngol Otol** 1996 Feb; 110(2):132–5

Efficacy of systemic corticosteroid treatment for anosmia with nasal and paranasal sinus disease. Ikeda K, et al. **Rhinology** 1995 Sep;33(3):162–5

ETIOLOGY

Long-term follow-up of olfactory loss secondary to head trauma and upper respiratory tract infection. Duncan HJ, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct; 121(10):1183–7

Dental, visual, auditory and olfactory complications in Paget's disease of bone. Wheeler TT, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1384–91

Anosmia and chronic sinus disease. Downey LL, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):24–8

[Expert evaluation of smell and taste disorders] Mrowinski D, et al. **HNO** 1996 Mar;44(3):157–63 **(Ger)**

[Zinc-deficient disorders of sense organs—dark adaptation, taste and smell disorders] Tomita H. **Nippon Rinsho** 1996 Jan;54(1):141–7 (40 ref.) (Eng. Abstr.) **(Jpn)**

[Disorders of olfactory function in penetrating head injuries sustained during war] Jović NS, et al. **Vojnosanit Pregl** 1995 May–Jun;52(3):225–32 (Eng. Abstr.) **(Scr)**

GENETICS

The genetic basis for specific anosmia to isovaleric acid in the mouse. Griff IC, et al. **Cell** 1995 Nov 3;83(3):407–14

PATHOLOGY

MR evaluation of patients with congenital hyposmia or anosmia. Yousem DM, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):439–43

PHYSIOPATHOLOGY

Bulbar morphology and expression of bulbar dopamine and parvalbumin in experimentally-induced anosmic rats. Tsukatani T, et al. **Acta Otolaryngol (Stockh)** 1995 Jul; 115(4):539–42

Case report: olfactory function in a fertile eunuch with Kallmann syndrome. Wortsman J, et al. **Am J Med Sci** 1996 Mar;311(3):135–8

Functionally mature olfactory neurons from two anosmic patients with Kallmann syndrome. Rawson NE, et al. **Brain Res** 1995 May 29;681(1–2):58–64

Taste and smell losses in HIV infected patients. Graham CS, et al. **Physiol Behav** 1995 Aug;58(2):287–93

Olfactory deficits in schizophrenia are not a function of task complexity. Kopala L, et al. **Schizophr Res** 1995 Oct; 17(2):195–9

[Pathophysiology of post-traumatic anosmia] Delank KW, et al. **Laryngorhinootologie** 1996 Mar;75(3):154–9 (Eng. Abstr.) **(Ger)**

[The behavioral reactions of anosmic rats to new complex stimuli] Makarchuk NE, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):176–8 **(Rus)**

PSYCHOLOGY

Recent advances in the neuropsychology of human olfaction and anosmia. Sullivan TE, et al. **Brain Inj** 1995 Aug–Sep; 9(6):641–6 (22 ref.)

RADIOTHERAPY

[Possibilities of helium-neon lasers in olfactory disorders] Morozova SV, et al. **Vestn Otorinolaringol** 1995 Sep–Oct; (5):35–6 (Eng. Abstr.) **(Rus)**

ANOVA see **ANALYSIS OF VARIANCE**

ANOVULATION

Functional life-span of the dominant follicle in pharmacologically induced anovulatory cycles. Faundes A, et al. **Hum Reprod** 1996 Jan;11(1):114–6

BLOOD

Circulating immunoreactive and bioactive follicle stimulating hormone concentrations in anovulatory infertile women and during gonadotrophin induction of ovulation using a decremental dose regimen. van Dessel HJ, et al. **Hum Reprod** 1996 Mar;11(3):478–85

Alternatives in plasma gonadotropin and sex steroid levels in obese ovulatory and chronically anovulatory women. Unzer SR, et al. **J Reprod Med** 1995 Jul;40(7):516–20

CHEMICALLY INDUCED

Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs. Smith G, et al. **Br J Rheumatol** 1996 May;35(5):458–62

DIAGNOSIS

Anovulatory infertility. The ESHRE Capri Workshop Group. **Hum Reprod** 1995 Jun;10(6):1549–53

DRUG THERAPY

Induction of multifollicular growth in patients non responding to clomiphene citrate and gonadotropins or gonadotropins only. Tartagni M, et al. **Clin Exp Obstet Gynecol** 1995;22(4):315–20

PHYSIOPATHOLOGY

Ovulation induction in clomiphene-resistant anovulatory women with normal dehydroepiandrosterone sulfate levels: beneficial effects of the addition of dexamethasone during the follicular phase. Trott EA, et al. **Fertil Steril** 1996 Sep; 66(3):484–6

Bone mass and subtle abnormalities in ovulatory function in healthy women. Waller K, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):663–8

Bone mineral density in premenopausal anovulatory women. Park KH, et al. **J Obstet Gynaecol** 1995 Feb;21(1):89–97

SURGERY

[Clinical and endocrine effects of laparoscopic ovarian surgery in patients with polycystic ovary syndrome] Rossmanith WG, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:103–7 (Eng. Abstr.) **(Ger)**

THERAPY

Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Clark AM, et al. **Hum Reprod** 1995 Oct;10(10):2705–12

URINE

Identification of anovulation and transient luteal function using a urinary pregnanediol-3-glucuronide ratio algorithm. Kassam A, et al. **Environ Health Perspect** 1996 Apr;104(4):408–13

ANOXEMIA

Effects of inhalation anesthetic agents on response of horses to three hours of hypoxemia. Whitehair KJ, et al. **Am J Vet Res** 1996 Mar;57(3):351–60

Levels of pro-opiomelanocortin and prolactin mRNA in the fetal sheep pituitary following hypoxaemia and glucocorticoid treatment in late gestation. Matthews SG, et al. **J Endocrinol** 1995 Oct;147(1):139–46

Oxygen terminology [letter; comment] Gilston A. **Lancet** 1996 Feb 10;347(8998):401. Comment on: Lancet 1996 Jan 6;347(8993):30.

BLOOD

Can prehospital personnel detect hypoxemia without the aid of pulse oximeters? Brown LH, et al. **Am J Emerg Med** 1996 Jan;14(1):43–4

Evaluation of pulse oximetry in sickle cell anemia patients presenting to the emergency department in acute vasoocclusive crisis. Comber JT, et al. **Am J Emerg Med** 1996 Jan;14(1):16–8

Plasma lactate as a predictor of early childhood neurodevelopmental outcome of neonates with severe hypoxaemia requiring extracorporeal membrane oxygenation. Cheung PY, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jan;74(1):F47–50

Hypoxaemia and release of endothelin-1. Cargill RI, et al. **Thorax** 1995 Dec;50(12):1308–10

CHEMICALLY INDUCED

Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Lavoie A, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1985–7

Hypoxemia and elevated tachykinins in rat monocrotaline pneumotoxicity. Lai YL, et al. **Lung** 1996;174(3):195–203

COMPLICATIONS

Transient bilateral cortical blindness due to hypoxemia [letter] Odeh M, et al. **Anaesth Intensive Care** 1996 Feb; 24(1):126

The effect on the heart of hypoxaemia in patients with severe coronary artery disease. Smith HL, et al. **Anaesthesia** 1996 Mar;51(3):211–8

Atrial septal aneurysm plus a patent foramen ovale. A predisposing factor for paradoxical embolism and refractory hypoxemia during pulmonary embolism. Estagnasié P, et al. **Chest** 1996 Sep;110(3):846–8

Sleep-disordered breathing in men with coronary artery disease. Mooe T, et al. **Chest** 1996 Mar;109(3):659–63

Ventilation-perfusion inequality in nocturnal hypoxaemia due to chronic obstructive lung disease (COLD). Sandek K, et al. **Clin Physiol** 1995 Sep;15(5):499–513

Respiratory and cardiac function in children after acute hypoxemic respiratory failure. Weiss I, et al. **Crit Care Med** 1996 Jan;24(1):148–54

Pulmonary arterial hypertension in nonagenarians [letter] Crausman RS, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1177

Psychological outcome of ECMO-eligible neonates with severe respiratory failure treated using conventional medical therapy. Mathias JL, et al. **J Paediatr Child Health** 1995 Oct;31(5):440–5

Studies of hypoxemic/reoxygenation injury: without aortic clamping. VI. Counteraction of oxidant damage by exogenous antioxidants: N-(2-mercaptopropionyl)-glycine and catalase. Ihnken K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1212–20

Studies of hypoxemic/reoxygenation injury with aortic clamping: XI. Cardiac advantages of normoxemic versus hyperoxemic management during qardiopulmonary bypass. Ihnken K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1255–64

Studies of hypoxemic/reoxygenation injury: with aortic clamping. XII. Delay of cardiac reoxygenation damage in the presence of cyanosis: a new concept of controlled cardiac reoxygenation. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1265–73

Studies of hypoxemic/reoxygenation injury: without aortic

clamping. VII. Counteraction of oxidant damage by exogenous antioxidants: coenzyme Q10. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1221–7

Studies of hypoxemic/reoxygenation injury: without aortic clamping. VIII. Counteraction of oxidant damage by exogenous glutamate and aspartate. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1228–34

Studies of hypoxemic/reoxygenation injury: without aortic clamping. IX. Importance of avoiding perioperative hyperoxemia in the setting of previous cyanosis. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1235–44

Determining the time before birth when ischemia and hypoxemia initiated cerebral palsy [see comments] Naeye RL, et al. **Obstet Gynecol** 1995 Nov;86(5):713–9. Comment in: Obstet Gynecol 1996 Mar;87(3):477–9. Comment in: Obstet Gynecol 1996 Mar;87(3):478–9.

More questions than answers [letter; comment] Raju TN. **Pediatrics** 1996 Apr;97(4):602–3. Comment on: Pediatrics 1995 Feb;95(2):238–43.

Nocturnal hypoxaemia in cystic fibrosis [letter; comment] Pond MN, et al. **Respir Med** 1995 Sep;89(8):585. Comment on: Respir Med 1994 Aug;88(7):537–9.

[Hypoxemic nosocomial pneumonia developing in excavation in a patient with Cushing disease] Mouas H, et al. **Rev Pneumol Clin** 1995;51(6):354–8 (Eng. Abstr.) **(Fre)**

[Hepatopulmonary syndrome] Akahane T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):505–8 (18 ref.) **(Jpn)**

DIAGNOSIS

The value of fetal arterial, cardiac and venous flows in predicting pH and blood gases measured in umbilical blood at cordocentesis in growth retarded fetuses. Rizzo G, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):963–9

Confirmation of spurious hypoxemia using continuous blood gas analysis in a patient with chronic myelogenous leukemia. Mizock BA, et al. **Leuk Res** 1995 Dec; 19(12):1001–4

[False signs of hypoxemia when using the dye Patent Blue V] Freudendal-Pedersen A, et al. **Ugeskr Laeger** 1996 Jan 15;158(3):284–5 (Eng. Abstr.) **(Dan)**

DRUG THERAPY

Inhaled aerosolized prostacyclin as a selective pulmonary vasodilator for the treatment of severe hypoxaemia. Van Heerden PV, et al. **Anaesth Intensive Care** 1996 Feb; 24(1):87–90

Methylene blue fails to improve hypoxaemia post orthotopic liver transplantation (OLT) [letter] Thomson A, et al. **Aust N Z J Med** 1995 Jun;25(3):262

Nitric oxide improves hypoxaemia following reperfusion oedema after pulmonary thromboendarterectomy. Gårdebäck M, et al. **Br J Anaesth** 1995 Dec;75(6):798–800

Beneficial effects of a novel anti-hypoxemic agent, TEI-7322, on bleomycin-induced experimental hypoxemia in rats. Horiuchi H, et al. **Eur J Pharmacol** 1995 Dec 4; 287(1):27–34

Transient effects of inhaled nitric oxide for prolonged postoperative treatment of hypoxemia after surgical correction of total anomalous pulmonary venous return. Morris GN, et al. **J Cardiothorac Vasc Anesth** 1995 Dec; 9(6):713–6

Inhaled nitric oxide in term infants with hypoxemic respiratory failure. Barefield ES, et al. **J Pediatr** 1996 Aug; 129(2):279–86

Studies of hypoxemic/reoxygenation injury: with aortic clamping. X. Exogenous antioxidants to avoid nullification of the cardioprotective effects of blood cardioplegia. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1245–54

Studies of hypoxemic/reoxygenation injury: without aortic clamping. IV. Role of the iron-catalyzed pathway: deferoxamine. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1190–9

Dose-response to inhaled nitric oxide in acute hypoxemic respiratory failure of newborn infants: a preliminary report. Bührer C, et al. **Pediatr Pulmonol** 1995 May;19(5):291–8

Effect of theophylline on metabolic and ventilatory response to hypoxemia during quiet sleep in piglets. Porras H, et al. **Pediatr Res** 1995 Dec;38(6):926–31

ENZYMOLOGY

Cardiac enzyme activities in fetal and adult pregnant and nonpregnant sheep exposed to high-altitude hypoxemia. Ohtsuka T, et al. **J Appl Physiol** 1995 Oct;79(4):1286–9

ETHNOLOGY

Arterial oxygen saturation in Tibetan and Han infants born in Lhasa, Tibet. Niermeyer S, et al. **N Engl J Med** 1995 Nov 9;333(19):1248–52

ETIOLOGY

Refractory hypoxemia during liver cirrhosis. Hepatopulmonary syndrome or "primary" pulmonary hypertension? Raffy O, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1169–71

Peri-operative hypoxaemia in children undergoing application of a plaster jacket for scoliosis. Lovell AT, et al. **Anaesthesia** 1996 Feb;51(2):119–22

The effect of passive smoking on the incidence of airway complications in children undergoing general anaesthesia. Lyons B, et al. **Anaesthesia** 1996 Apr;51(4):324–6

Combined use of spinal anesthesia and midazolam sedation increases the risk of hypoxemia [letter; comment] Muñoz HR, et al. **Anesth Analg** 1996 Jul;83(1):195–6. Comment on: Anesth Analg 1995 Sep;81(3):525–8.

Hypoxemia due to right-to-left shunt in the carcinoid syndrome; beneficial response to octreotide [letter] Hart D, et al. **Ann Oncol** 1995 Nov;6(9):952–4

Orthodeoxia-platypnea due to intracardiac shunting—relief with transcatheter double umbrella closure. Landzberg MJ, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):247–50

Refractory hypoxemia in a morbidly obese 28-year-old woman. Collop NA. **Chest** 1996 Apr;109(4):1101–2

Subacute tricuspid regurgitation with severe hypoxemia complicating blunt chest trauma. Ribichini F, et al. **Chest** 1996 Jan;109(1):289–91

A 37-year-old woman with end-stage cirrhosis, progressive dyspnea, platypnea, and hypoxemia. Lange PA, et al. **Cleve Clin J Med** 1996 Jan–Feb;63(1):8–11 (6 ref.)

Mechanisms of gas exchange impairment in patients with liver cirrhosis. Agusti AG, et al. **Clin Chest Med** 1996 Mar; 17(1):49–66 (159 ref.)

Hepatopulmonary syndrome. A pulmonary vascular complication of liver disease. Castro M, et al. **Clin Chest Med** 1996 Mar;17(1):35–48 (81 ref.)

Structural and pathologic changes in the lung vasculature in chronic liver disease. Schraufnagel DE, et al. **Clin Chest Med** 1996 Mar;17(1):1–15 (94 ref.)

Hypoxaemia and cardiorespiratory changes during epileptic seizures in young children. Hewertson J, et al. **Dev Med Child Neurol** 1996 Jun;38(6):511–22

Exercise-induced hypoxaemia in master athletes: effects of a polyunsaturated fatty acid diet. Aguilaniu B, et al. **Eur J Appl Physiol** 1995;72(1–2):44–50

Mechanisms for episodes of hypoxemia in preterm infants undergoing mechanical ventilation. Bolivar JM, et al. **J Pediatr** 1995 Nov;127(5):767–73

Hypoxemia and arterial hypotension at the accident scene in head injury. Stocchetti N, et al. **J Trauma** 1996 May; 40(5):764–7

Acute reversible hypoxemia in systemic lupus erythematosus: a new syndrome or an index of disease activity? Martinez-Taboada VM, et al. **Lupus** 1995 Aug;4(4):259–62

Nocturnal hypoxaemia in patients with chronic obstructive pulmonary disease: who should be treated and how? Heijdra YF, et al. **Neth J Med** 1995 Dec;47(6):296–301 (30 ref.)

Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia. Okubadejo AA, et al. **Thorax** 1996 Jan;51(1):44–7

[Treatment of refractory hypoxemia due to right-to-left interatrial shunt complicating right ventricular infarction: successful short-term percutaneous catheter closure of the patent foramen ovale] Matsuo R, et al. **J Cardiol** 1995 Oct; 26(4):243–8 (Eng. Abstr.) **(Jpn)**

[Hepatopulmonary syndrome in decompensated cirrhotic patients] Roblero JP, et al. **Rev Med Chil** 1995 Aug; 123(8):975–81 (Eng. Abstr.) **(Spa)**

METABOLISM

The influence of arterial carbon dioxide on cerebral oxygenation and haemodynamics during ECMO in normoxaemic and hypoxaemic piglets. Liem KD, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:157–64

Cerebral energy metabolism during hypoxaemia. A 31P and 1H magnetic resonance study. Garde K, et al. **Acta Physiol Scand** 1995 Jun;154(2):185–91

The effect of hypoxaemia on drug disposition in chronic respiratory failure. Rowett D, et al. **Eur J Clin Pharmacol** 1996;50(1–2):77–82

Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. Cremona G, et al. **Eur Respir J** 1995 Nov;8(11):1883–5

Studies of hypoxemic/reoxygenation injury: I. Linkage between cardiac function and oxidant damage. Buckberg GD. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1164–70 (47 ref.)

Studies of hypoxemic/reoxygenation injury: without aortic clamping. II. Evidence for reoxygenation damage. Ihnken K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1171–81

Studies of hypoxemic/reoxygenation injury: without aortic clamping. V. Role of the L-arginine-nitric oxide pathway: the nitric oxide paradox. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1200–11

Bile and bilirubin excretion in relation to hepatic energy status during hemorrhagic shock and hypoxemia in rabbits. Nakatani T, et al. **J Trauma** 1995 Oct;39(4):665–70

Long-term oxygen therapy may improve skeletal muscle metabolism in advanced chronic obstructive pulmonary disease patients with chronic hypoxaemia. Jakobsson P, et al. **Respir Med** 1995 Aug;89(7):471–6

Hypoxic stress alone does not modulate endothelial surface expression of bovine E-selectin and intercellular adhesion molecule-1 (ICAM-1). Zünd G, et al. **Swiss Surg Suppl** 1996;Suppl 1:41–5

Hormonal, renal, and autonomic nerve factors involved in the excretion of sodium and water during dynamic salt and water loading in hypoxaemic chronic obstructive pulmonary disease. Stewart AG, et al. **Thorax** 1995 Aug; 50(8):838–45

PHYSIOPATHOLOGY

Effect of hypoxaemia on water and sodium homeostatic hormones and renal function. Olsen NV. **Acta Anaesthesiol Scand Suppl** 1995;107:165–70 (55 ref.)

The postnatal potentiation of chemoreceptor sensitivity to O2 and CO2 in the in vitro rat carotid body is blunted by chronic hypoxaemia. Development of chemosensitivity. Kumar P, et al. **Adv Exp Med Biol** 1995;393:317–22

Chemoreflex and endocrine components of cardiovascular responses to acute hypoxemia in the llama fetus. Giussani DA, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R73–83

Nitric oxide is an important determinant of coronary flow at rest and during hypoxemic stress in fetal lambs. Reller MD, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):H2074–81

The effects of hypoxaemia and recommendations for postoperative oxygen therapy. Powell JF, et al. **Anaesthesia** 1996 Aug;51(8):769–72 (41 ref.)

Role of nitric oxide in the regulation of the cerebral circulation in the lamb fetus during normoxemia and hypoxemia. van Bel F, et al. **Biol Neonate** 1995;68(3):200–10

Nocturnal hypoxaemia in late pregnancy. Bourne T, et al. **Br J Anaesth** 1995 Dec;75(6):678–82

Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers. Kiely DG, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):313–8

Preflight evaluation. Patients and methods [letter; comment] Bhattacharyya P, et al. **Chest** 1996 Apr;109(4):1129. Comment on: Chest 1995 Feb;107(2):352–7.

Left ventricular systolic performance during acute hypoxemia [see comments] Cargill RI, et al. **Chest** 1995 Oct;108(4):899–902. Comment in: Chest 1995 Oct;108(4):889–91.

Angiotensin II receptor blockade and effects on pulmonary hemodynamics and hypoxic pulmonary vasoconstriction in humans [see comments] Kiely DG, et al. **Chest** 1996 Sep; 110(3):698–703. Comment in: Chest 1996 Sep;110(3):584–5.

Adverse effects of hypoxaemia on diastolic filling in humans. Cargill RI, et al. **Clin Sci (Colch)** 1995 Aug;89(2):165–9

Depression of stimulated erythropoietin production in mice with enhanced erythropoiesis. Lezón C, et al. **Haematologica** 1995 Nov-Dec;80(6):491–4

Low chemoresponsiveness and inadequate hyperventilation contribute to exercise-induced hypoxemia. Harms CA, et al. **J Appl Physiol** 1995 Aug;79(2):575–80

Role of hypoxemia in sleep apnea-induced sympathoexcitation. Smith ML, et al. **J Auton Nerv Syst** 1996 Jan 5;56(3):184–90

Myocardial metabolism and function in acutely ischemic and hypoxemic isolated rat hearts. Samaja M, et al. **J Mol Cell Cardiol** 1995 May;27(5):1213–8

Effect of hypoxemia and ethacrynic acid on ABR and distortion product emission thresholds. Freeman S, et al. **J Neurol Sci** 1995 Jul;131(1):21–9

Pulmonary gas exchange in athletes with exercise-induced hypoxaemia. Todaro A, et al. **J Sports Med Phys Fitness** 1995 Jun;35(2):114–23

Studies of hypoxemic/reoxygenation injury: without aortic clamping. III. Comparison of the magnitude of damage by hypoxemia/reoxygenation versus ischemia/reperfusion. Ihnken K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1182–9

Exercise-induced hypoxaemia in emphysematous type chronic obstructive pulmonary disease. Bellone A, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):117–9

Hypoxemia does not affect the strength of the inspiration-inhibiting Breuer-Hering reflex. Monier A, et al. **Neurosci Lett** 1995 Sep 8;197(2):129–32

Determining the time before birth when ischemia and hypoxemia initiated cerebral palsy [letter; comment] Goodlin RC. **Obstet Gynecol** 1996 Mar;87(3):477–9. Comment on: Obstet Gynecol 1995 Nov;86(5):713–9.

Determining the time before birth when ischemia and hypoxemia initiated cerebral palsy [letter; comment] Perkins RP. **Obstet Gynecol** 1996 Mar;87(3):478–9. Comment on: Obstet Gynecol 1995 Nov;86(5):713–9.

Role of nitric oxide in the hypoxemia-induced renal dysfunction of the newborn rabbit. Ballèvre L, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):725–30

Blood pressure and cardiovascular reflex development in fetal sheep. Relation to hypoxaemia, weight, and blood glucose. Crowe C, et al. **Reprod Fertil Dev** 1995;7(3):553–8

Cardiovascular responses to graded degrees of hypoxaemia in the llama fetus. Llanos AJ, et al. **Reprod Fertil Dev** 1995; 7(3):549–52

Hypoxemia/reoxygenation down-regulates interleukin-8-stimulated bactericidal activity of polymorphonuclear neutrophil by differential regulation of CD16 and CD35 mRNA expression. Knowles R, et al. **Surgery** 1996 Aug;120(2):382–7; discussion 388

[Is infection and septic shock caused by a global oxygen deficiency? An overview in 2 parts. 1: Infection and correlation between DO2 and VO2] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):132–42 (0 ref.) (Eng. Abstr.) **(Ger)**

[Acid-base balance in capillary blood of newborns with perinatal hypoxemia symptoms] Grudzińska M, et al. **Ginekol Pol** 1995 Mar;66(3):151–7 (Eng. Abstr.) **(Pol)**

ANOXEMIA

PREVENTION & CONTROL

Intraoperative ventilation with air and oxygen during laparoscopic cholecystectomy decreases the degree of postoperative hypoxaemia. Fujii Y, et al. **Anaesth Intensive Care** 1996 Feb;24(1):42–4

Avoiding hypoxemia during unifocalization. Mignosa C, et al. **Ann Thorac Surg** 1996 Feb;61(2):715–7

Exercise-induced hypoxaemia in master athletes: effects of a polyunsaturated fatty acid diet. Aguilaniu B, et al. **Eur J Appl Physiol** 1995;72(1–2):44–50

[Biochemical mechanisms of protective action of enomelanin during hemic hypoxia caused by carbon monoxide] Barinova IE, et al. **Ukr Biokhim Zh** 1995 Sep–Oct; 67(5):89–93 (Eng. Abstr.) **(Rus)**

[Relief of dyspnea, right-sided failure and hypoxemia] Larsen F, et al. **Lakartidningen** 1996 Apr 10;93(15):1422–4 **(Swe)**

THERAPY

Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia. McDonald CF, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1616–9

Noninvasive positive-pressure ventilation via face mask during bronchoscopy with BAL in high-risk hypoxemic patients. Antonelli M, et al. **Chest** 1996 Sep;110(3):724–8

Management of pediatric acute hypoxemic respiratory insufficiency with bilevel positive pressure nasal mask ventilation [editorial; comment] deLemos RA. **Chest** 1995 Oct;108(4):894–5. Comment on: Chest 1995 Oct;108(4):1059–64.

Management of pediatric acute hypoxemic respiratory insufficiency with bilevel positive pressure (BiPAP) nasal mask ventilation [see comments] Fortenberry JD, et al. **Chest** 1995 Oct;108(4):1059–64. Comment in: Chest 1995 Oct;108(4):894–5.

Noninvasive positive pressure ventilation via face mask. First-line intervention in patients with acute hypercapnic and hypoxemic respiratory failure. Meduri GU, et al. **Chest** 1996 Jan;109(1):179–93

The effectiveness of O2 administration for transient ischemic attacks in moyamoya disease in children. Fujiwara J, et al. **Childs Nerv Syst** 1996 Feb;12(2):69–75

Home oxygen therapy. O'Donohue WJ Jr. **Med Clin North Am** 1996 May;80(3):611–22 (38 ref.)

Nocturnal hypoxaemia in patients with chronic obstructive pulmonary disease: who should be treated and how? Heijdra YF, et al. **Neth J Med** 1995 Dec;47(6):296–301 (30 ref.)

Orthodeoxia and platypnoea after acute organophosphorus poisoning reversed by CPAP: a newly described cause and review of the literature. Bouros D, et al. **Respir Med** 1995 Oct;89(9):625–8 (33 ref.)

[Predictors of survival in patients with chronic obstructive pulmonary disease with moderate hypoxemia] Gorzelak K, et al. **Pol Arch Med Wewn** 1995 Jun;93(6):491–7 (Eng. Abstr.) **(Pol)**

VETERINARY

Evidence of a ventilation-perfusion mismatch during acute unilateral pulmonary artery occlusion in broilers. Wideman RF Jr, et al. **Poult Sci** 1995 Jul;74(7):1209–17

ANOXIA

Acute hypoxia modulates arachidonic acid metabolism in cat carotid bodies. Role of dopamine. Strosznajder RP. **Acta Neurobiol Exp (Warsz)** 1996;56(2):535–43

Hypoxic exercise does not elicit long-term modulation of the normoxic exercise ventilatory response in Goats. Turner DL, et al. **Adv Exp Med Biol** 1995;393:245–8

Effect of chronic hypoxia on myometrial responsiveness in the pregnant rat. Rhee JW, et al. **Am J Physiol** 1996 Mar; 270(3 Pt 1):E477–82

Neuroprotective effects of radical scavengers in an intact dorsal root ganglion hypoxia model. Bär PR. **Ann N Y Acad Sci** 1995 Sep 15;765:111–5; discussion 116–8

The impact of reversal of hypoxia by revascularization on the peripheral nerve function of diabetic patients. Veves A, et al. **Diabetologia** 1996 Mar;39(3):344–8

Methylcobalamin attenuates the hypoxia/hypoglycemia- or glutamate-induced reduction in hippocampal fiber spikes in vitro. Yamamoto Y, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):335–40

Responses to chronic hypoxia in embryonic alligators. Warburton SJ, et al. **J Exp Zool** 1995 Sep 1;273(1):44–50

Hypoxia preconditions rabbit myocardium via adenosine and catecholamine release. Cohen MV, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1527–34

Hypoxia, excitotoxicity, and neuroprotection in the hippocampal slice preparation. Schurr A, et al. **J Neurosci Methods** 1995 Jun;59(1):129–38

Oxygen terminology [letter; comment] Gilston A. **Lancet** 1996 Feb 10;347(8998):401. Comment on: Lancet 1996 Jan 6;347(8993):30.

Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: II. Double-blind, placebo-controlled EEG mapping and psychometric studies under hypoxia. Saletu B, et al. **Methods Find Exp Clin Pharmacol** 1996 Jan-Feb; 18(1):67–81

Reduced mitochondrial respiration in mouse cerebral cortex during chronic hypoxia. Chávez JC, et al. **Neurosci Lett** 1995 Jul 7;193(3):169–72

Transgenic AEQUORIN reveals organ-specific cytosolic Ca2+ responses to anoxia and Arabidopsis thaliana seedlings. Sedbrook JC, et al. **Plant Physiol** 1996 May; 111(1):243–57

Lidocaine reduces the hypoxia-induced release of an excitatory amino acid analog from rat striatal slices in superfusion. Díaz L, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):943–53

[Criteria for individual and population resistance to acute hypoxia] Agadzhanian NA, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):239–41 **(Rus)**

[Intraoperative hypoxic radiotherapy (IOHRT)—its first trial in world practice] Chernichenko AV, et al. **Vopr Onkol** 1995;41(2):68 **(Rus)**

[Acute altitude sickness and ventilatory function in subjects intermittently exposed to hypobaric hypoxia] Saldías F, et al. **Rev Med Chil** 1995 Jan;123(1):44–50 (Eng. Abstr.) **(Spa)**

BLOOD

Role of minor electrolytes when applied to Stewart's acid-base approach in an acidotic rabbit model. Waters JH, et al. **Anesth Analg** 1995 Nov;81(5):1043–51

Acute exposure to carbon monoxide does not affect plasma lipids, lipoproteins, and apolipoproteins. Leaf DA, et al. **Angiology** 1996 Apr;47(4):337–41

Dependence of pulmonary venous admixture on inspired oxygen fraction and time during regional hypoxia in the rabbit. O'Neill M, et al. **Br J Anaesth** 1995 Nov;75(5):603–9

Effect of hypoxia and beta 2-agonists on the activity of the renin-angiotensin system in normal subjects. Millar EA, et al. **Clin Sci (Colch)** 1995 Sep;89(3):273–6

Influence of hypoxic ventilatory response on arterial O2 saturation during maximal exercise in acute hypoxia. Benoit H, et al. **Eur J Appl Physiol** 1995;72(1–2):101–5

Increase of serum insulin and stable c-peptide concentrations with exhaustive incremental graded exercise during acute hypoxia in sedentary subjects. Kullmer T, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):156–61

Effect of dichloroacetate on PaCO2 responses to hypoxia in awake goats. Aaron EA, et al. **J Appl Physiol** 1996 Jan; 80(1):176–81

Signal changes in gradient echo images of human brain induced by hypo- and hyperoxia. Rostrup E, et al. **NMR Biomed** 1995 Feb;8(1):41–7

Monitoring of nocturnal oxygen desaturation using pulse oximeter and apnomonitor in patients with chronic pulmonary disease. Miyahara Y, et al. **Respiration** 1995; 62(6):348–52

[The relationship between respiratory system reactivity and neutrophil metabolism in hypoxia in persons subjected to ionizing radiation exposure] Serebrovskaia TV, et al. **Radiats Biol Radioecol** 1996 May-Jun;36(3):400–4 (Eng. Abstr.) **(Rus)**

[Chemiluminescence, blood lipid peroxidation and neutrophil activity during the hypoxic training of persons subjected to ionizing radiation exposure] Serebrovskaia ZA, et al. **Radiats Biol Radioecol** 1996 May-Jun;36(3):394–9 (Eng. Abstr.) **(Rus)**

[Dynamics of luminol-dependent chemiluminescence in rat whole blood at different oxygen concentrations] Prokof'ev VN, et al. **Vopr Med Khim** 1995 Sep–Oct;41(5):39–42 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Gas flames, closed spaces, and hypoxia. Balding LE, et al. **Am J Forensic Med Pathol** 1995 Sep;16(3):229–31

Gas kinetics during nitrous oxide analgesia for labour. Einarsson S, et al. **Anaesthesia** 1996 May;51(5):449–52

Effects of a continuous infusion of dopamine on the ventilatory and carotid body responses to hypoxia in cats. Ide T, et al. **Clin Exp Pharmacol Physiol** 1995 Sep; 22(9):658–64

Inhaled cigarette smoke selectively reverses human hypoxic vasoconstriction. Dupuy PM, et al. **Intensive Care Med** 1995 Nov;21(11):941–4

CLASSIFICATION

Classes of tissue hypoxia. Siggaard-Andersen O, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:137–42

COMPLICATIONS

Transplantation of the cadaver heart harvested one hour after hypoxic cardiac arrest using the core-cooling technique in dogs. Takagaki M, et al. **Acta Med Okayama** 1996 Feb; 50(1):17–24

Neurosensory hearing loss in neonates with severe hypoxemia [letter; comment] Cheung PY, et al. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):576. Comment on: Acta Otolaryngol Suppl (Stockh) 1994;514:81–4.

Retinal haemorrhage during sustained hypobaric hypoxia in rats. Osada H, et al. **Acta Physiol Scand** 1995 Dec; 155(4):463–74

ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. DiCarlo VS, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):L690–7

Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Morrell NW, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1186–94

Posthypoxic cooling of neonatal rats provides protection against brain injury. Thoresen M, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jan;74(1):F3–9

Reduction by beta-adrenoceptor blockade of hypoxia-induced right heart hypertrophy in the rat. Ostman-Smith I. **Br J Pharmacol** 1995 Nov; 116(6):2698–702

Stimulus-sensitive seizures in postanoxic coma. Van Cott AC, et al. **Epilepsia** 1996 Sep;37(9):868–74

Early cholestasis in premature infants receiving total parenteral nutrition: a possible consequence of shock and hypoxia. Jacquemin E, et al. **Eur J Pediatr Surg** 1995 Oct; 5(5):259–61

Combined hypoxia and hypercapnia evokes long-lasting sympathetic activation in humans. Morgan BJ, et al. **J Appl Physiol** 1995 Jul;79(1):205–13

Arterially misplaced Swan-Ganz catheter in a hypotensive and hypoxic COPD patient [see comments] Lee TS, et al. **J Clin Anesth** 1995 Jun;7(4):320–2. Comment in: J Clin Anesth 1996 Mar;8(2):171–2.

Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. Morrell NW, et al. **J Clin Invest** 1995 Oct;96(4):1823–33

Hypoxia-induced necrotizing enterocolitis in the immature rat: the role of lipid peroxidation and management by vitamin E. Okur H, et al. **J Pediatr Surg** 1995 Oct; 30(10):1416–9

Sustained systemic arterial hypertension induced by extended hypobaric hypoxia. Vaziri ND, et al. **Kidney Int** 1996 May; 49(5):1457–63

Non-ischemic hypoxia of the arterial wall is a primary cause of atherosclerosis. Simanonok JP. **Med Hypotheses** 1996 Feb;46(2):155–61 (80 ref.)

Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus. Matsumoto RR, et al. **Mov Disord** 1995 Sep;10(5):615–21

The predictive value of elevation in specific serum enzymes for subsequent development of hypoxic-ischemic encephalopathy or intraventricular hemorrhage in full-term and premature asphyxiated newborns. Lackmann GM, et al. **Neuropediatrics** 1995 Aug;26(4):192–8

Hypoxic ischaemic encephalopathy: early magnetic resonance imaging findings and their evolution. Rutherford MA, et al. **Neuropediatrics** 1995 Aug;26(4):183–91

Hypoxic pulmonary hypertension: haemodynamic changes after oxygen and various vasodilators in the same patient at different time periods. Král H, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl** 1993;36(4–5):317–24

[Effects of ginkgolide B on isobaric hypoxic pulmonary hypertension in rats] Cheng D, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):386–90 (Eng. Abstr.) **(Chi)**

[Contribution of oxidative stress to pulmonary hypertension induced by chronic hypoxia] Hoshikawa Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1168–73 (Eng. Abstr.) **(Jpn)**

[Angiotensin II receptors in a rat model of hypobaric hypoxic pulmonary hypertension] Mikami O, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):186–93 (Eng. Abstr.) **(Jpn)**

[Effects of thromboxane A2 on chronic hypoxic pulmonary hypertension in the rat] Saito M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):37–44 (Eng. Abstr.) **(Jpn)**

[Role of hypoxia factor in changes of ionic composition of blood and muscle tissue in experimental botulinum poisoning] Morrison VV. **Anesteziol Reanimatol** 1995 Sep–Oct;(5):27–9 (Eng. Abstr.) **(Rus)**

[The role of hypoxia in the development of bronchial asthma] Ialkut SI. **Ter Arkh** 1995;67(8):71–4 (40 ref.) **(Rus)**

[Cerebral ischemia and respiratory diseases] Castillo J, et al. **Rev Neurol** 1995;23 Suppl 1:S61–9 (81 ref.) **(Spa)**

DIAGNOSIS

Predicting hypoxia in children with acute lower respiratory infection: a study in the highlands of Papua New Guinea. Dyke T, et al. **J Trop Pediatr** 1995 Aug;41(4):196–201

Comparing techniques of measuring tumor hypoxia in different murine tumors: Eppendorf pO2 Histograph, [3H]misonidazole binding and paired survival assay. Kavanagh MC, et al. **Radiat Res** 1996 Apr;145(4):491–500

[Correct determination of blood base excess (BE, mmol/l)] Zander R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S36–8 **(Ger)**

[Nocturnal hypoxia index: a new pulse oxymetry index of nocturnal hypoventilation in neuromuscular disorders] Kawai M, et al. **Rinsho Shinkeigaku** 1995 Sep;35(9):1003–7 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Endothelin infusion reduces hypoxic pulmonary hypertension in pigs in vivo. Liska J, et al. **Acta Physiol Scand** 1995 Aug;154(4):489–98

Alkaloid delta agonist BW373U86 increases hypoxic

tolerance. Bofetiado DM, et al. **Anesth Analg** 1996 Jun; 82(6):1237–41

A new cognition–enhancing agent, (R)–(–)–1–(benzo[b]thiophen–5–yl)–2–[2–(N,N–diethylamino)ethoxy]ethanol hydrochloride. Effects on memory impairment in rats generated by cerebral embolization and basal forebrain lesions. Ono S, et al. **Biol Pharm Bull** 1995 Dec;18(12):1779–83

Preventive effects of dexamethasone on hypoxic–ischemic brain damage in the neonatal rat. Liu Y, et al. **Brain Dev** 1995 May–Jun;17(3):186–92

Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. Hjalmarsen A, et al. **Diabetes Metab** 1996 Feb;22(1):37–42

Exogenous glutathione attenuates stunning following intermittent hypoxia in isolated rat hearts. Seiler KS, et al. **Free Radic Res** 1996 Feb;24(2):115–22

Endothelin–receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. Chen SJ, et al. **J Appl Physiol** 1995 Dec;79(6):2122–31

Role of vasoconstrictors in the systemic hypertension of rats acclimatized to hypoxia. Moue Y, et al. **J Appl Physiol** 1995 Nov;79(5):1657–67

Protective effect of KBT–3022, a new cyclooxygenase inhibitor, in cerebral hypoxia and ischemia. Yamamoto N, et al. **Jpn J Pharmacol** 1995 Dec;69(4):421–8

Calcium blockage in pulmonary hypertension and hypoxic vasoconstriction. Neely CF, et al. **New Horiz** 1996 Feb; 4(1):99–106 (74 ref.)

Long–term aspirin therapy for hepatopulmonary syndrome. Song JY, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):917–20

The role of H1– and H2–receptors in the effect of compound 48/80 in the asphyxiation and body temperature of mice. Ulugöl A, et al. **Yonsei Med J** 1996 Apr;37(2):97–103

[Effect of efonidipine hydrochloride, a calcium channel blocker, on the experimental cerebral ischemia/anoxia] Matsumura T, et al. **Nippon Yakurigaku Zasshi** 1995 Jun; 105(6):437–46 (Eng. Abstr.) **(Jpn)**

[The protective action of limontar in pregnant animals with acute hypoxic hypoxia] Korneev AA, et al. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):34–6 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Hypoxia induces changes in phospholipase A2 in rat proximal tubules: evidence for multiple forms. Choi KH, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):F846–53

Regulation of xanthine dehydrogenase and xanthine oxidase activity by hypoxia. Poss WB, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):L941–6

Effect of endurance training under hypoxic condition on oxidative enzyme activity in rat skeletal muscle. Takahashi H, et al. **Appl Human Sci** 1996 May;15(3):111–4

Purification and characterization of a protein phosphatase that dephosphorylates pyruvate kinase in an anoxia tolerant animal. Brooks SP, et al. **Biochem Mol Biol Int** 1996 May; 38(6):1223–34

Multicatalytic proteinase activity in turtle liver: responses to anoxia stress and recovery. Willmore WG, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):445–51

Alteration of glutathione transferase subunits composition in the liver of young and aged rats submitted to hypoxic and hyperoxic conditions. Di Ilio C, et al. **Biochim Biophys Acta** 1996 Jun 13;1312(2):125–31

Enzymatic control of glycogenolysis during anoxic submergence in the freshwater turtle Trachemys scripta. Mehrani H, et al. **Int J Biochem Cell Biol** 1995 Aug; 27(8):821–30

Effects of hypobaric hypoxia on antioxidant enzymes in rats. Nakanishi K, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):869–76

Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Saugstad OD. **Pediatrics** 1996 Jul; 98(1):103–7 (83 ref.)

Induction and phosphorylation of protein kinase C–alpha and mitogen–activated protein kinase by hypoxia and by radiation in Chinese hamster V79 cells. Hasan NM, et al. **Radiat Res** 1996 Feb;145(2):128–33

Acute hypoxia induces elevation of ornithine decarboxylase activity in neonatal rat brain slices. Longo LD, et al. **Reprod Fertil Dev** 1995;7(3):385–9

[The effect of the 12–day combined exposure to hypobaric hypoxia and physical load on the structuro–metabolic characteristics of rat skeletal muscles] Nemirovskaia TL, et al. **Biull Eksp Biol Med** 1995 Jun;119(6):602–5 **(Rus)**

[The mono–oxygenase system as a target in the action of hypoxia in combination with hyperthermia] Luk'ianchuk VD, et al. **Lik Sprava** 1995 May–Jun;(5–6):100–2 **(Rus)**

EPIDEMIOLOGY

[Perinatal asphyxia, hypoxic–ischemic encephalopathy and neurological sequelae in full–term newborns: an epidemiological study (1)] Gónzalez de Dios J, et al. **Rev Neurol** 1996 Jul;24(131):812–9 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Oxygen saturation of patients recovering from electroconvulsive therapy. McCormick AS, et al. **Anaesthesia** 1996 Jul;51(7):702–4

Intermittent hypoxia due to right atrial compression by an ascending aortic aneurysm. Savage EB, et al. **Ann Thorac Surg** 1996 Aug;62(2):582–3

Cases from the aerospace medicine residents' teaching file. Case #62. Hypoxia. Parmet AJ. **Aviat Space Environ Med** 1995 Dec;66(12):1215–6

Hypoxia precedes the development of experimental preretinal neovascularization. Handa JT, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jan;234(1):43–6

Sustained pulmonary vasodilation after inhaled nitric oxide for hypoxic pulmonary hypertension in swine. Emil S, et al. **J Pediatr Surg** 1996 Mar;31(3):389–93

Does laminated intraluminal thrombus within abdominal aortic aneurysm cause anoxia of the aortic wall? [letter; comment] Vorp DA, et al. **J Vasc Surg** 1996 Mar; 23(3):540–1. Comment on: J Vasc Surg 1994 Oct;20(4):529–35; discussion 535–8.

Jet "leg", pulmonary embolism, and hypoxia [letter] James PB. **Lancet** 1996 Jun 15;347(9016):1697

[Perinatal asphyxia, hypoxic–ischemic encephalopathy and neurological sequelae in full–term newborns. II. Description and interrelation] González de Dios J, et al. **Rev Neurol** 1996 Aug;24(132):969–76 (Eng. Abstr.) **(Spa)**

GENETICS

Possible genomic mechanism involved in control systems responses to hypoxia. Cherniack NS, et al. **Adv Exp Med Biol** 1995;393:89–94 (26 ref.)

Role of reactive oxygen metabolites in DNA damage and cell death in chemical hypoxic injury to LLC–PK1 cells. Hagar H, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F209–15

Possible relationship between conditions associated with chronic hypoxia and brain mitochondrial DNA deletions. Merril CR, et al. **Arch Biochem Biophys** 1996 Feb 1; 326(1):172–7

Diphenylene iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia. Implications for the mechanism of oxygen sensing. Gleadle JM, et al. **Eur J Biochem** 1995 Nov 15;234(1):92–9

A hypoxia–responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. Melillo G, et al. **J Exp Med** 1995 Dec 1;182(6):1683–93

IMMUNOLOGY

Macrophage activation by culture in an anoxic environment. Albina JE, et al. **J Immunol** 1995 Nov 1;155(9):4391–6

METABOLISM

Lung uptake of lidocaine during hyperoxia and hypoxia in the dog. Hasegawa K, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):489–95

The effect of hypoxia and ouabain on the muscle resting potential of Periplaneta americana L. Grajpel B, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):103–6

Technetium 99m–Q12 kinetics in perfused rat myocardium: effects of hypoxia and low flow. Okada RD, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):108–15

Temporal alterations in basement membrane components in the pulmonary vasculature of the chronically hypoxic rat: impact of hypoxia and recovery. Vyas–Somani AC, et al. **Am J Med Sci** 1996 Aug;312(2):54–67

Hypoxia inhibits L–arginine uptake by pulmonary artery endothelial cells. Block ER, et al. **Am J Physiol** 1995 Nov; 269(5 Pt 1):L574–80

Differential regulation of G protein expression in rat hearts exposed to chronic hypoxia. Kacimi R, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):H1865–73

Electrophoretic analysis of contractile proteins of the diaphragm in chronically hypoxic rats. Mortola JP, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):L371–6

Effect of hypoxia on nitric oxide production in neonatal pig lung. Nelin LD, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H8–14

Mechanism of anoxia–induced atrial natriuretic peptide release in the isolated rat atria. Skvorak JP, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R237–43

Hypoxia inhibits L–arginine synthesis from L–citrulline in porcine pulmonary artery endothelial cells. Su Y, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):L581–7

Hyperpermeability and ATP depletion induced by chronic hypoxia or glycolytic inhibition in Caco–2BBe monolayers. Unno N, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):G1010–21

Propofol reduces neuronal transmission damage and attenuates the changes in calcium, potassium, and sodium during hyperthermic anoxia in the rat hippocampal slice. Amorim P, et al. **Anesthesiology** 1995 Dec;83(6):1254–65

Volatile and intravenous anesthetics decrease glutamate release from cortical brain slices during anoxia. Bickler PE, et al. **Anesthesiology** 1995 Dec;83(6):1233–40

Na(+)–Ca2+ exchange in anoxic/ischemic injury of CNS myelinated axons. Stys PK, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:366–78 (41 ref.)

Hypoxic regulation of vascular endothelial growth factor in retinal cells. Aiello LP, et al. **Arch Ophthalmol** 1995 Dec; 113(12):1538–44

Activation of protein kinase C increases adenosine production in the hypoxic canine coronary artery through the extracellular pathway. Minamino T, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2298–304

Hypoxic effects on the expression of mineralocorticoid and glucocorticoid receptors in human renal cortex epithelial cells. Jenq W, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):444–8

Involvement of protein kinase C in hypoxia–induced desensitization of the beta–adrenergic system in human endothelial cells. Resink T, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):753–8

Effect of acute and chronic intermittent hypoxia on DNA topoisomerase II alpha expression and mitomycin C–induced DNA damage and cytotoxicity in human colon cancer cells. Kang Y, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):669–76

Hypoxia, oxidative stress and rheumatoid arthritis. Mapp PI, et al. **Br Med Bull** 1995 Apr;51(2):419–36 (43 ref.)

Intracellular alkalosis during hypoxia in newborn mouse brain in the presence of systemic acidosis: a phosphorus magnetic resonance spectroscopic study. Mitsufuji N, et al. **Brain Dev** 1995 Jul–Aug;17(4):256–60

Determination of 8–hydroxydeoxyguanosine in human cells under oxygen–free conditions. Nakajima M, et al. **Carcinogenesis** 1996 Apr;17(4):787–91

Inhibitory effect of pyruvate on release of glutathione and swelling of rat heart mitochondria. Bindoli A, et al. **Cardiovasc Res** 1995 Nov;30(5):821–4

Cell–specificity and signaling pathway of endothelin–1 gene regulation by hypoxia. Bodi I, et al. **Cardiovasc Res** 1995 Dec;30(6):975–84

Ion channels, oxygen sensation and signal transduction in pulmonary arterial smooth muscle. Kozlowski RZ. **Cardiovasc Res** 1995 Sep;30(3):318–25 (73 ref.)

Evidence for the involvement of the ATP–sensitive potassium channel in a novel model of hypoxic preconditioning in dogs. Mei DA, et al. **Cardiovasc Res** 1995 Aug;30(2):222–30

Increased resistance to acute respiratory acidosis in isolated cardiac muscle following chronic hypoxia–induced hypertrophy. Neville E, et al. **Cardiovasc Res** 1996 May; 31(5):739–46

Prostaglandin–mediated inhibition of nitric oxide production by bovine aortic endothelium during hypoxia. Xu XP, et al. **Cardiovasc Res** 1995 Sep;30(3):345–50

Pre– and postnatal effects of chronic maternal hypoxia on substance–P immunoreactivity in rabbit brainstem regions. Gingras JL, et al. **Dev Neurosci** 1995;17(5–6):350–6

Decreased endothelium–dependent pulmonary vasodilator effect of calcitonin gene–related peptide in hypoxic rats contrasts with increased binding sites. Mannan MM, et al. **Eur Respir J** 1995 Dec;8(12):2029–37

Hypoxic and metabolic regulation of voltage–gated K+ channels in rat pulmonary artery smooth muscle cells. Yuan XJ, et al. **Exp Physiol** 1995 Sep;80(5):803–13 (24 ref.)

Brain peroxidative and glutathione status after moderate hypoxia in normal weight and intra–uterine growth–restricted newborn piglets. Barth A, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):139–47

Hypoxic preconditioning in isolated rat hearts: non–involvement of activation of adenosine A1 receptor, Gi protein, and ATP–sensitive K+ channel. Yabe K, et al. **Heart Vessels** 1995;10(6):294–303

Mechanisms of adaptation to hypoxia in energy metabolism in rats. Mimura Y, et al. **J Am Coll Surg** 1995 Nov; 181(5):437–43

Effects of hypoxia on carotid body dopamine content and release in developing rabbits. Bairam A, et al. **J Appl Physiol** 1996 Jan;80(1):20–4

Ventilatory and metabolic responses to hypoxia during moderate hypothermia in anesthetized rats. Frappell P, et al. **J Appl Physiol** 1995 Jul;79(1):256–60

Effects of hypoxia and vascular tone on endothelium–dependent and –independent responses in developing lungs. Gordon JB, et al. **J Appl Physiol** 1995 Sep;79(3):824–30

Brain glucose metabolism in hypobaric hypoxia. Harik SI, et al. **J Appl Physiol** 1995 Jul;79(1):136–40

The N–methyl–D–aspartate receptor pathway is involved in hypoxia–induced c–Fos protein expression in the rat nucleus of the solitary tract. Haxhiu MA, et al. **J Auton Nerv Syst** 1995 Oct 5;55(1–2):65–8

Influence of pentoxifylline on membrane thrombomodulin levels in endothelial cells submitted to hypoxic conditions. Seigneur M, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S85–7

Effect of hypoxia on hepatic DNA methylation and tRNA methyltransferase in rat: similarities to effects of methyl–deficient diets. Chawla RK, et al. **J Cell Biochem** 1996 Apr;61(1):72–80

Adaptive preservation of ATP and tolerance to hypoxia following carotid artery ligation in the immature rat. Hylton CM, et al. **J Cereb Blood Flow Metab** 1995 Nov; 15(6):1137–40

Regional alterations of ATP and heat–shock protein–72 mRNA following hypoxia–ischemia in neonatal rat brain. Kobayashi S, et al. **J Cereb Blood Flow Metab** 1995 Nov; 15(6):1047–56

Hypoxia–induced paracrine regulation of vascular endothelial growth factor receptor expression. Brogi E, et al. **J Clin Invest** 1996 Jan 15;97(2):469–76

Hypoxic encephalopathy after near–drowning studied by quantitative 1H–magnetic resonance spectroscopy. Kreis R, et al. **J Clin Invest** 1996 Mar 1;97(5):1142–54

Hypoxia–induced exocytosis of endothelial cell Weibel–Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. Pinsky DJ, et al. **J Clin Invest** 1996 Jan 15;97(2):493–500

Venous ulcer fibroblasts compared with normal fibroblasts

show differences in collagen but not fibronectin production under both normal and hypoxic conditions. Herrick SE, et al. **J Invest Dermatol** 1996 Jan;106(1):187–93

Adaptation to chronic hypoxia alters cardiac metabolic response to beta stimulation: novel face of phosphocreatine overshoot phenomenon. Novel-Chaté V, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1679–87

Hypoxia increases the susceptibility to oxidant stress and the permeability of the blood–brain barrier endothelial cell monolayer. Plateel M, et al. **J Neurochem** 1995 Nov; 65(5):2138–45

Dietary iron levels and hypoxia independently affect iron absorption in mice. Simpson RJ. **J Nutr** 1996 Jul; 126(7):1858–64

Hypoxia inhibits gastric emptying and gastric acid secretion in conscious rats. Yamaji R, et al. **J Nutr** 1996 Mar; 126(3):673–80

Localization of erythropoietin gene expression in proximal renal tubular cells detected by digoxigenin–labelled oligonucleotide probes. Shanks JH, et al. **J Pathol** 1996 Jul;179(3):283–7

Acute moderate hypoxia in conscious rabbits: effect on hepatic cytochrome P450 and on reactive oxygen species. Proulx M, et al. **J Pharm Pharmacol** 1995 May;47(5):392–7

Internal Ca2+ stores involved in anoxic responses of rat hippocampal neurons. Belousov AB, et al. **J Physiol (Lond)** 1995 Aug 1;486 (Pt 3):547–56

Adenosine mediates metabolic and cardiovascular responses to hypoxia in fetal sheep. Koos BJ, et al. **J Physiol (Lond)** 1995 Nov 1;488 (Pt 3):761–6

Chronic hypoxia induces adaptive metabolic changes in neonatal myocardium. Plunkett MD, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):8–13

The role of accumulation of sodium and calcium on contractile failure of the hypoxic/reoxygenated heart. Tanonaka K, et al. **Jpn Heart J** 1996 Jan;37(1):105–17

Hypoxia–induced amphiphiles inhibit renal Na+, K(+)–ATPase. Schonefeld M, et al. **Kidney Int** 1996 May; 49(5):1289–96

Nitric oxide kinetics during hypoxia in proximal tubules: effects of acidosis and glycine. Yaqoob M, et al. **Kidney Int** 1996 May;49(5):1314–9

Effects of glucose and oxygen deprivation on phosphoinositide hydrolysis in cerebral cortex slices from neonatal rats. Cristòfol RM, et al. **Life Sci** 1996; 59(7):587–97

The effect of anoxia on cardiomyocyte glucose transport does not involve an adenosine release or a change in energy state. Eblenkamp M, et al. **Life Sci** 1996;59(2):141–51

Virtually unaltered permeability–surface area products imply little capillary recruitment in brain with hypoxia. Chen JL, et al. **Microcirculation** 1994 Apr;1(1):35–47

Effects of hypoxia on the extracellular matrix production of cultured rat mesangial cells. Kim SB, et al. **Nephron** 1996;72(2):275–80

In utero hypoxic ischemia decreases the cholinergic agonist–stimulated poly–phosphoinositide turnover in the developing rat brain. Hersey K, et al. **Neurochem Res** 1995 Dec;20(12):1477–82

Potentiation by K+ of anoxic release of newly synthesized neuronal glutamate. Huang R, et al. **Neuroreport** 1995 Nov 27;6(17):2404–8

Phorbol ester alters rat hippocampal neuronal response to hypoxia. Liu ZW, et al. **Neuroreport** 1995 Oct 23; 6(15):2069–72

Opposite modulation of 4–aminopyridine and hypoxic hyperexcitability by A1 and A2 adenosine receptor ligands in rat hippocampal slices. Longo R, et al. **Neurosci Lett** 1995 Nov 10;200(1):21–4

Brief exposure to hypoxia induces bFGF mRNA and protein and protects rat cortical neurons from prolonged hypoxic stress. Sakaki T, et al. **Neurosci Res** 1995 Oct;23(3):289–96

Comparative response of rabbit bladder smooth muscle and mucosa to anoxia. Levin RM, et al. **Neurourol Urodyn** 1996; 15(1):79–84

Signal changes in gradient echo images of human brain induced by hypo– and hyperoxia. Rostrup E, et al. **NMR Biomed** 1995 Feb;8(1):41–7

Breathing pattern and cost of ventilation in the American alligator. Wang T, et al. **Respir Physiol** 1995 Oct; 102(1):29–37

Acute alveolar hypoxia increases endothelin–1 release but decreases release of calcitonin gene–related peptide in isolated perfused rat lungs. Helset E, et al. **Scand J Clin Lab Invest** 1995 Aug;55(5):369–76

Altered oxygen tension modulates cytokine–induced signal transduction in polymorphonuclear leukocytes: regulation of the GPLD pathway. Derevianko A, et al. **Shock** 1996 Feb;5(2):97–105

[Increased expression of platelet–derived growth factor beta receptor gene in hypoxic rat lungs] Lu Q, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Aug; 18(4):207–8, 254 (Eng. Abstr.) **(Chi)**

[Expression of endothelin–1 mRNA, endothelin receptor–A and nitric oxide synthase mRNA in pulmonary artery and right ventriculus cordis of rats exposed to hypoxia] Ran P, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Aug; 75(8):479–81, 511 (Eng. Abstr.) **(Chi)**

[8%–9% and 12%–13% hypoxic gas induced free radicals generation in rat's left and right myocardium] Han ZY, et al. **Sheng Li Hsueh Pao** 1995 Oct;47(5):453–62 (Eng. Abstr.) **(Chi)**

[Acute hypoxia induce free radicals generation in rat's cortex and hippocampus] Wang QH, et al. **Sheng Li Hsueh Pao** 1995 Oct;47(5):510–4 (Eng. Abstr.) **(Chi)**

[Comparison of the effect of isoflurane and that of sevoflurane on hepatic circulation and oxygen metabolism during acute hypoxia in dogs] Sugai M. **Masui** 1996 May; 45(5):608–16 (Eng. Abstr.) **(Jpn)**

[Effects of subacute hypoxia on alveolar epithelial ion transport in rats] Suzuki S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):52–6 (Eng. Abstr.) **(Jpn)**

[Level of 2,3–diphosphoglycerate and adenosine triphosphate in erythrocytes and acid–base status in adult and newborn rats in acute hypoxia] Alatyrtsev VV, et al. **Biull Eksp Biol Med** 1995 Jun;119(6):631–3 **(Rus)**

[The effect of season on lipid peroxidation indicators in the myocardium of animals with varying resistance to hypoxia] Khachatur'ian ML, et al. **Biull Eksp Biol Med** 1995 Jul; 120(7):87–90 **(Rus)**

[Indicators of lipid peroxidation in organs of rats with varying resistance to hypoxia] Khachatur'ian ML, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):26–9 **(Rus)**

[Value of several hormone indicators and cyclic nucleotides in the assessment and prognosis of resistance to acute hypoxia during operator activities] Bobrovnitskiĭ IP, et al. **Kosm Biol Aviakosm Med** 1991 Sep–Oct;25(5):43–6 (Eng. Abstr.) **(Rus)**

[Lipid composition and phospholipase A2 activity in rat placental cell membranes in hypoxic states] Pogorelova TN, et al. **Vopr Med Khim** 1995 Nov–Dec;41(6):30–3 (Eng. Abstr.) **(Rus)**

[Nucleotide metabolism in the lymph nodes of rats with hypoxic hypoxia] Lysenko OV. **Fiziol Zh** 1995 May–Aug; 41(3–4):97–102 (Eng. Abstr.) **(Ukr)**

PATHOLOGY

Indicators of histohypoxia. Willis N, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:45–8

Interacting effects of Ca2+ and hypoxia in the induction of sarcolemmal damage in mouse diaphragm in vitro. Bannister NJ, et al. **Acta Neuropathol (Berl)** 1995; 90(4):411–4

Influence of 12 weeks of hypobaric hypoxia on fibre type composition of the rat soleus muscle. Itoh K, et al. **Acta Physiol Scand** 1995 Jul;154(3):417–8

Role of reactive oxygen metabolites in DNA damage and cell death in chemical hypoxic injury to LLC–PK1 cells. Hagar H, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F209–15

Adhesion of flowing neutrophils to cultured endothelial cells after hypoxia and reoxygenation in vitro. Rainger GE, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1398–406

Identification of tissue hypoxia in the livers of ascitic and hypoxia–induced broilers using trypan blue. Maxwell MH, et al. **Br Poult Sci** 1995 Dec;36(5):791–8

Effects of neonatal hypoxia on brainstem cholinergic neurons–pedunculopontine nucleus and laterodorsal tegmental nucleus. Tanaka H, et al. **Brain Dev** 1995 Jul–Aug;17(4):264–70

Selective sparing of human nucleus accumbens in aging and anoxia. Huang KW, et al. **Can J Neurol Sci** 1995 Nov; 22(4):290–3

Use of fetal cortical grafts in hypoxic–ischemic brain injury in neonatal rats. Elsayed MH, et al. **Exp Neurol** 1996 Jan; 137(1):127–41

Acute hypoxic ventilation, carotid body cell division, and dopamine content during early hypoxia in rats. Bee D, et al. **J Appl Physiol** 1995 Nov;79(5):1504–11

Changes in dietary protein intake fail to prevent decrease in muscle growth induced by severe hypoxia in rats. Bigard AX, et al. **J Appl Physiol** 1996 Jan;80(1):208–15

Lung cytokinetics after exposure to hypobaria and/or hypoxia and undernutrition in growing rats. Sekhon HS, et al. **J Appl Physiol** 1995 Oct;79(4):1299–309

Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. Genbacev O, et al. **J Clin Invest** 1996 Jan 15;97(2):540–50

Glutamate and non–glutamate receptor mediated toxicity caused by oxygen and glucose deprivation in organotypic hippocampal cultures. Newell DW, et al. **J Neurosci** 1995 Nov;15(11):7702–11

Ultrastructure of rat pulmonary arterioles after neonatal exposure to hypoxia and subsequent relief and treatment with monocrotaline. King AP, et al. **J Pathol** 1995 Sep; 177(1):71–81

Apoptosis in substantia nigra following developmental hypoxic–ischemic injury. Oo TF, et al. **Neuroscience** 1995 Dec;69(3):893–901

Comparative studies on vascular endothelium in vitro. 2. Hypoxia: its influences on endothelial cell proliferation and expression of cell adhesion molecules. Klein CL, et al. **Pathobiology** 1995;63(1):1–8

Stereological evaluation of vascular adaptations in human placental villi to differing forms of hypoxic stress. Burton GJ, et al. **Placenta** 1996 Jan;17(1):49–55

[Unusual findings in death by hanging—reconstruction of capacity for action] Ortmann C, et al. **Arch Kriminol** 1996 Mar–Apr;197(3–4):104–10 (Eng. Abstr.) **(Ger)**

[Experimental studies of physiological and pathological effects induced by systemic hypoxia and the hypoxia–reoxygenation model in rats] Kagoshima M, et al. **Nippon Yakurigaku Zasshi** 1995 Aug;106(2):85–97 (Eng. Abstr.) **(Jpn)**

[The effect of the 12–day combined exposure to hypobaric hypoxia and physical load on the structuro–metabolic characteristics of rat skeletal muscles] Nemirovskaia TL, et al. **Biull Eksp Biol Med** 1995 Jun;119(6):602–5 **(Rus)**

[Changes in the endocrine pancreas of laboratory white rats with diabetes mellitus, adaptation to hypoxia and their combination (an immunohistochemical study)] Kolesnik IuM, et al. **Morfologiia** 1996;109(1):91–4 (Eng. Abstr.) **(Rus)**

[The structure of the stellate sympathetic ganglia under long–term hypoxia] Sosunov AA, et al. **Morfologiia** 1996; 109(1):12–7 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Epidural anesthesia modifies cardiovascular responses to severe hypoxia in dogs. Shibata K, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):748–53

Ventilatory responses to hypoxia and hypercapnia during inhalation anaesthesia and subparalytical muscle relaxation in humans [see comments] Lindahl SG. **Acta Anaesthesiol Sin** 1995 Dec;33(4):223–6 (13 ref.). Comment in: Acta Anaesthesiol Sin 1995 Dec;33(4):i–ii.

Ventilatory responses to hypoxia and hypercapnia in relation to anesthetic practice [editorial; comment] Wu RS. **Acta Anaesthesiol Sin** 1995 Dec;33(4):i–ii. Comment on: Acta Anaesthesiol Sin 1995 Dec;33(4):223–6.

Murine splenic proliferative response to human recombinant erythropoietin along hypoxia. Brandan NC, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(2):97–103

Body weight loss during acute hypoxia: effects of increased convective oxygen transport or previous acclimation. Leal TL, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995; 45(1):9–14

Effects of exercise–training on hypoxia and angiotensin II–induced pulmonary vasoconstrictions. Kashimura O, et al. **Acta Physiol Scand** 1995 Nov;155(3):291–5

Effect of BQ123 on vasoconstriction as a result of either hypoxia or endothelin–1 in perfused rat lungs. Takeoka M, et al. **Acta Physiol Scand** 1995 Sep;155(1):53–60

Respiratory responses to hypoxia peripheral and central effects. Chairman's introductory communication. Berkenbosch A, et al. **Adv Exp Med Biol** 1995;393:251–6

Hypoxic ventilatory response near normocapnia. Henson LC, et al. **Adv Exp Med Biol** 1995;393:271–5

Individual differences in ventilatory and HR responses to progressive hypoxia following 100% O2 exposure in humans. Honda Y, et al. **Adv Exp Med Biol** 1995;393:283–6

A comparison between the effects of 8 hours of isocapnic hypoxia and 8 hours of poikilocapnic hypoxia on respiratory control in humans. Howard LS, et al. **Adv Exp Med Biol** 1995;393:277–81

Central hypoxic chemoreceptors in the ventrolateral medulla and caudal hypothalamus. Nolan PC, et al. **Adv Exp Med Biol** 1995;393:261–6

Changes in blood flow in the middle cerebral artery in response to acute isocapnic hypoxia in humans. Poulin MJ, et al. **Adv Exp Med Biol** 1995;393:287–92

Hypoxic ventilatory depression may be due to central chemoreceptor cell hyperpolarization. Severinghaus JW. **Adv Exp Med Biol** 1995;393:257–60

Interactive ventilatory effects of carotid body hypoxia and hypocapnia in the unanesthetized dog. Smith CA, et al. **Adv Exp Med Biol** 1995;393:313–6

Ventilatory responses to isocapnic hypoxia in the eighth decade. Smith WD, et al. **Adv Exp Med Biol** 1995; 393:267–70

The effects of hypoxia and hyperoxia on the 1/F nature of breath–by–breath ventilatory variability. Tuck SA, et al. **Adv Exp Med Biol** 1995;393:297–302

Cross–linked hemoglobin increases fractional reabsorption and GFR in hypoxic isolated perfused rat kidneys. Baines AD, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):F628–36

Effects of indomethacin on brain blood flow, cerebral metabolism, and sagittal sinus prostanoids after hypoxia. Coyle MG, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1450–9

Hypoxia does not directly stimulate ischemically sensitive abdominal visceral afferents during ischemia. Fu LW, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H261–6

Hypoxic contraction of contractile interstitial cells isolated from bovine lung. Fukui M, et al. **Am J Physiol** 1996 Jun; 270(6 Pt 1):L962–72

Effects of swimming and environmental hypoxia on coronary blood flow in rainbow trout. Gamperl AK, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1258–66

Effect of stretch on contraction and the Ca2+ transient in ferret ventricular muscles during hypoxia and acidosis. Hongo K, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C690–7

Anoxic brain failure in an ectothermic vertebrate: release of amino acids and K+ in rainbow trout thalamus. Hylland P, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1077–84

Impaired ventilatory responses to hypoxia and hypercapnia in mutant mice deficient in endothelin–1. Kuwaki T, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1279–86

Lymphatic regulation of hematocrit during hypoxia in the toad Bufo woodhousei. Malvin GM, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R814–21

Effects of pulmonary denervation on renal sympathetic and heart rate responses to hypoxia. O'Hagan KP, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R923–9

Effect of L-NMMA, cromakalim, and glibenclamide on cerebral blood flow in hypercapnia and hypoxia. Reid JM, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H916-22

Role of endogenous opioids and serotonin in the hemodynamic response to hemorrhage during hypoxia. Resta TC, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1597-606

Opioids contribute to hypoxia-induced pial artery dilation through activation of ATP-sensitive K+ channels. Shankar V, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H997-1002

Changes in efferent pulmonary sympathetic nerve activity during systemic hypoxia in anesthetized cats. Shirai M, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1404-9

Mechanisms of hypoxic vasodilation in ferret pulmonary arteries. Wiener CM, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):L351-7

Alterations in pulmonary artery tone during repeated episodes of hypoxia. Yang BC, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):L293-8

Respiration and medullary blood flow during sinusoidal hypoxia in the peripherally chemodenervated cat. Yu QP, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R91-100

Arousal and cardiorespiratory responses to hypoxia in Prader-Willi syndrome. Arens R, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):283-7

Interaction between cold and hypoxia on pulmonary circulation in COPD. Bedu M, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1242-7

Is normobaric simulation of hypobaric hypoxia accurate in chronic airflow limitation? Naughton MT, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1956-60

Modulation of hypoxic pulmonary vasoconstriction by antioxidant enzymes in red blood cells. Yamaguchi K, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):211-7

Effect of the inhibitor of nitric oxide synthase, NG-nitro-L-arginine methyl ester, on cerebral and myocardial blood flows during hypoxia in the awake dog. Audibert G, et al. **Anesth Analg** 1995 Nov;81(5):945-51

The effect of thoracic epidural anesthesia on hypoxic pulmonary vasoconstriction in dogs: an analysis of the pressure-flow curve. Ishibe Y, et al. **Anesth Analg** 1996 May;82(5):1049-55

The effect of halothane on phrenic and chemoreceptor responses to hypoxia in anesthetized kittens. Morray JP, et al. **Anesth Analg** 1996 Aug;83(2):329-35

The effects of epidural anesthesia on ventilatory response to hypercapnia and hypoxia in elderly patients. Sakura S, et al. **Anesth Analg** 1996 Feb;82(2):306-11

Vecuronium-induced depression of phrenic nerve activity during hypoxia in the rabbit. Wyon N, et al. **Anesth Analg** 1996 Jun;82(6):1252-6

Ventilatory response to hypoxia in humans. Influences of subanesthetic desflurane. Dahan A, et al. **Anesthesiology** 1996 Jul;85(1):60-8

Attenuated hypoxic pulmonary vasoconstriction during isoflurane anesthesia is abolished by cyclooxygenase inhibition in chronically instrumented dogs. Lennon PF, et al. **Anesthesiology** 1996 Feb;84(2):404-14

Clonidine modulation of hemodynamic and catecholamine responses associated with hypoxia or hypercapnia in dogs. Nishikawa T, et al. **Anesthesiology** 1996 Mar;84(3):672-85

Acute pain and central nervous system arousal do not restore impaired hypoxic ventilatory response during sevoflurane sedation. Sarton E, et al. **Anesthesiology** 1996 Aug; 85(2):295-303

Circulatory effects of hypoxia, acute normovolemic hemodilution, and their combination in anesthetized pigs. Schou H, et al. **Anesthesiology** 1996 Jun;84(6):1443-54

Relaxation of the carotid artery to hypoxia is impaired in Watanabe heritable hyperlipidemic rabbits. Taguchi H, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1641-5

A comparison of visual and auditory reaction time and P300 latency thresholds to acute hypoxia. Fowler B, et al. **Aviat Space Environ Med** 1995 Jul;66(7):645-50

Inhibition of adenosine deaminase and administration of adenosine increase hypoxia induced ventricular ectopy. Leone RJ Jr, et al. **Basic Res Cardiol** 1995 May-Jun; 90(3):234-9

Effect of nordihydroguaiaretic acid on cerebral blood flow and metabolism during hypoxia in newborn piglets. Goplerud JM, et al. **Biol Neonate** 1995;67(6):425-31

Effects of chloral hydrate on the cardiorespiratory response to hypoxia in newborn piglets. Yu XQ, et al. **Biol Neonate** 1996;69(3):146-52

Increase in carotid body sensitivity during sustained hypoxia. Bisgard GE. **Biol Signals** 1995 Sep-Oct;4(5):292-7 (43 ref.)

Does catecholamine secretion mediate the hypoxia-induced increase in nerve activity? Donnelly DF. **Biol Signals** 1995 Sep-Oct;4(5):304-9

The cholinergic hypothesis revisited--an unfinished story. Fitzgerald RS, et al. **Biol Signals** 1995 Sep-Oct; 4(5):298-303

Heart rate and respiratory rhythm dynamics on ascent to high altitude. Lipsitz LA, et al. **Br Heart J** 1995 Oct; 74(4):390-6

Haemodynamic response to simulated haemorrhage in the rabbit: interaction of i.v. anaesthesia and hypoxia. Blake DW, et al. **Br J Anaesth** 1995 Nov;75(5):610-5

Slow ventilatory dynamics after isocapnic hypoxia and voluntary hyperventilation in humans: effects of isoflurane. Dahan A, et al. **Br J Anaesth** 1996 Mar;76(3):374-81

Influence of oral clonidine on the ventilatory response to acute and sustained isocapnic hypoxia in human males. Foo IT, et al. **Br J Anaesth** 1996 Feb;76(2):214-20

Comparison of the effects of sub-hypnotic concentrations of propofol and halothane on the acute ventilatory response to hypoxia. Nagyova B, et al. **Br J Anaesth** 1995 Dec; 75(6):713-8

beta-Adrenergic receptors contribute to hypoxaemia induced vasodilation in man. Blauw GJ, et al. **Br J Clin Pharmacol** 1995 Nov;40(5):453-8

Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans. Cargill RI, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):585-90

Action of adenosine receptor antagonists on hypoxia-induced effects in the rat hippocampus in vitro. Croning MD, et al. **Br J Pharmacol** 1995 Oct;116(3):2113-9

Poor ventilatory response to mild hypoxia may inhibit acclimatization at moderate altitude in elderly patients after carotid surgery. Roeggla G, et al. **Br J Sports Med** 1995 Jun;29(2):110-2

Sodium and potassium current in neonatal rat carotid body cells following chronic in vivo hypoxia. Hempleman SC. **Brain Res** 1995 Nov 13;699(1):42-50

Major differences in response to graded hypoxia between hypoglossal and neocortical neurons. O'Reilly JP, et al. **Brain Res** 1995 Jun 19;683(2):179-86

Chronic hypoxia in vivo renders neocortical neurons more vulnerable to subsequent acute hypoxic stress. O'Reilly JP, et al. **Brain Res** 1996 Mar 4;711(1-2):203-10

Stimulus interaction between CO and CO2 in the cat carotid body chemoreception. Osanai S, et al. **Brain Res** 1996 Mar 4;711(1-2):56-63

Ketamine antagonizes hypoxia-induced dopamine release in rat striatum. Wang Y, et al. **Brain Res** 1995 Sep 25; 693(1-2):233-45

Effects of almitrine on the ventilatory control, breathing pattern and maximal exercise tolerance in hypoxemic patients with chronic obstructive pulmonary disease. Ribeiro SA, et al. **Braz J Med Biol Res** 1995 Aug; 28(8):859-67

Hypoxia induces PMN adherence to umbilical vein endothelium. Arnould T, et al. **Cardiovasc Res** 1995 Dec; 30(6):1009-16

Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade. Kiely DG, et al. **Cardiovasc Res** 1995 Dec;30(6):875-80

Endothelin-1 does not mediate the endothelium-dependent hypoxic contractions of small pulmonary arteries in rats. Lazor R, et al. **Chest** 1996 Jul;110(1):189-97

Effects of aprotinin on renal function in chronic hypoxic rats. Chen CF, et al. **Chin J Physiol** 1995;38(1):23-6

Improved 4- and 6-hour myocardial preservation by hypoxic preconditioning. Engelman DT, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II417-22

Transverse limb deficiency, facial clefting and hypoxic renal damage: an association with treatment of maternal hypertension? Hurst JA, et al. **Clin Dysmorphol** 1995 Oct; 4(4):359-63

Cardiorespiratory responses to acute hypoxia and hyperoxia in adult and neonatal spontaneously hypertensive and normotensive rats. Grisk O, et al. **Clin Exp Hypertens** 1995 Oct;17(7):1025-47

Influence of body temperature on responses to hypoxia and hypercapnia: implications for SIDS. Maskrey M. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):527-32 (60 ref.)

Hypoxic inhibition of breathing and motor activity in the foetus and newborn. Walker DW. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):533-6 (30 ref.)

Ventilatory response to severe acute hypoxia in guinea-pigs and rats with high hemoglobin-oxygen affinity induced by cyanate. Rivera M, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):675-80

Effect of hypoxia on lung, heart, and liver insulin-like growth factor-I gene and receptor expression in the newborn rat. Moromisato DY, et al. **Crit Care Med** 1996 Jun; 24(6):919-24

The effects of neonatal hypoxia on kindled seizure development and electroconvulsive shock profiles. Applegate CD, et al. **Epilepsia** 1996 Aug;37(8):723-7

Effects of mild hypoxia on perceptual-motor performance: a signal-detection approach. McCarthy D, et al. **Ergonomics** 1995 Oct;38(10):1979-92

Sodium citrate ingestion and muscle performance in acute hypobaric hypoxia. Hausswirth C, et al. **Eur J Appl Physiol** 1995;71(4):362-8

Effects of exercise during normoxia and hypoxia on the growth hormone-insulin-like growth factor I axis. Schmidt W, et al. **Eur J Appl Physiol** 1995;71(5):424-30

Effects of low flow and hypoxia on myocardial retention of technetium-99m BMS181321. Okada RD, et al. **Eur J Nucl Med** 1996 Apr;23(4):443-7

Depolarization and hypoxia-induced cell damage in serum-free cultures of the rat cortex, and related extracellular glutamate changes. Uchiyama-Tsuyuki Y, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):245-50

Cardiovascular changes during acute episodic repetitive hypoxic and hypercapnic breathing in rats. Bakehe M, et al. **Eur Respir J** 1995 Oct;8(10):1675-80

Ventilatory and pulmonary vascular response to hypoxia and susceptibility to high altitude pulmonary oedema. Hohenhaus E, et al. **Eur Respir J** 1995 Nov;8(11):1825-33

Changes in open field behavior, spatial memory, and hippocampal parvalbumin immunoreactivity following enrichment in rats exposed to neonatal anoxia. Iuvone L, et al. **Exp Neurol** 1996 May;139(1):25-33

Clinical aspects of hypoxic pulmonary vasoconstriction. Leach RM, et al. **Exp Physiol** 1995 Sep;80(5):865-75 (29 ref.)

Redox agents as a link between hypoxia and the responses of ionic channels in rabbit pulmonary vascular smooth muscle. Park MK, et al. **Exp Physiol** 1995 Sep;80(5):835-42

The role of the endothelium in hypoxic pulmonary vasoconstriction. Ward JP, et al. **Exp Physiol** 1995 Sep; 80(5):793-801 (24 ref.)

Occurrence of lamellar bodies in the rat brain organotypic cultures in normal and pathological conditions. Matyja E, et al. **Folia Neuropathol** 1995;33(3):175-80

Hypoxia-induced vascular endothelial growth factor expression in normal rat astrocyte cultures. Ijichi A, et al. **Glia** 1995 Jun;14(2):87-93

Inhaled cigarette smoke selectively reverses human hypoxic vasoconstriction. Dupuy PM, et al. **Intensive Care Med** 1995 Nov;21(11):941-4

Systemic hypoxia dehydrates the space surrounding photoreceptors in the cat retina. Cao W, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):586-96

Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. Blitzer ML, et al. **J Am Coll Cardiol** 1996 Sep; 28(3):591-6

Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure. Chua TP, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):650-7

Changes in end-expiratory lung volume and diaphragmatic activity during hypoxia and hypercapnia in cats. Bonora M, et al. **J Appl Physiol** 1995 Dec;79(6):1900-7

Hypoxia, hypercapnia, and hypertension: their effects on pulsatile cerebral blood flow. Curran-Everett D, et al. **J Appl Physiol** 1995 Sep;79(3):870-8

Glibenclamide does not reverse attenuated vasoreactivity to acute or chronic hypoxia. Eichinger MR, et al. **J Appl Physiol** 1995 Oct;79(4):1173-80

Ventilatory and metabolic responses to hypoxia during moderate hypothermia in anesthetized rats. Frappell P, et al. **J Appl Physiol** 1995 Jul;79(1):256-60

Gas exchange, blood lactate, and plasma catecholamines during incremental exercise in hypoxia and normoxia. Hughson RL, et al. **J Appl Physiol** 1995 Oct;79(4):1134-41

Pulmonary vascular impedance response to hypoxia in dogs and minipigs: effects of inhaled nitric oxide. Maggiorini M, et al. **J Appl Physiol** 1995 Oct;79(4):1156-62

Neurochemical control of tissue resistance in piglets. Martin RJ, et al. **J Appl Physiol** 1995 Sep;79(3):812-7

Combined hypoxia and hypercapnia evokes long-lasting sympathetic activation in humans. Morgan BJ, et al. **J Appl Physiol** 1995 Jul;79(1):205-13

Pulmonary vascular adaptations to augmented polycythemia during chronic hypoxia. Petit RD, et al. **J Appl Physiol** 1995 Jul;79(1):229-35

Hypoxic ventilatory decline: site of action. Robbins PA. **J Appl Physiol** 1995 Aug;79(2):373-4

In vitro responses of lung arteries to acute hypoxia after NO synthase blockade or chronic hypoxia. Teng GQ, et al. **J Appl Physiol** 1995 Sep;79(3):763-70

Hypoxic respiratory responses attenuated by ablation of the cerebellum or fastigial nuclei. Xu F, et al. **J Appl Physiol** 1995 Oct;79(4):1181-9

Microdialyzed adenosine in nucleus tractus solitarii and ventilatory response to hypoxia in piglets. Yan S, et al. **J Appl Physiol** 1995 Aug;79(2):405-10

Renal neural response to ischemic renal failure in chronic hypoxic rats. Chien CT, et al. **J Auton Nerv Syst** 1996 Apr 20;58(1-2):11-7

Increased PVRI: due to hypoxia? [letter; comment] Setzer N. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):619. Comment on: J Cardiothorac Vasc Anesth 1994 Dec;8(6):636-41.

Hypoxia-induced arterial endothelin does not influence peripheral vascular tone. Blauw GJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S242-3

Differences between intracutaneous and transcutaneous skin oxygen tension in chronic venous insufficiency. Roszinski S, et al. **J Cardiovasc Surg (Torino)** 1995 Aug;36(4):407-13

Hypertonic environment prevents depolarization and improves functional recovery from hypoxia in hippocampal slices. Huang R, et al. **J Cereb Blood Flow Metab** 1996 May;16(3):462-7

Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. Cohen AH, et al. **J Clin Invest** 1996 Jan 1;97(1):172-9

Simultaneous measurement of pH and membrane potential in rat dorsal vagal motoneurons during normoxia and hypoxia: a comparison in bicarbonate and HEPES buffers. Cowan AI, et al. **J Neurophysiol** 1995 Dec;74(6):2713-21

In vitro ischemia promotes calcium influx and intracellular calcium release in hippocampal astrocytes. Duffy S, et al. **J Neurosci** 1996 Jan;16(1):71-81

Role of ventrolateral medulla catecholamine cells in hypothalamic neuroendocrine cell responses to systemic hypoxia. Smith DW, et al. **J Neurosci** 1995 Dec; 15(12):7979-88

Hypoxia inhibits gastric emptying and gastric acid secretion in conscious rats. Yamaji R, et al. **J Nutr** 1996 Mar; 126(3):673-80

Deficient hypoxia awakening response in infants of smoking mothers: possible relationship to sudden infant death syndrome. Lewis KW, et al. **J Pediatr** 1995 Nov; 127(5):691–9

Severity of hypoxia predicts response to nitric oxide in a porcine pulmonary hypertension model. Emil S, et al. **J Pediatr Surg** 1995 Jul;30(7):930–5; discussion 935–6

Endogenous nitric oxide and pulmonary vascular tone in the neonate. Lipsitz EC, et al. **J Pediatr Surg** 1996 Jan; 31(1):137–40

Hypoxic relaxation in functionally intact cattle coronary artery segments involves K+ ATP channels. Kalsner S. **J Pharmacol Exp Ther** 1995 Dec;275(3):1219–26

Reflex stimulation of aortic chemoreceptors through the stellate ganglion during hypoxia and hypotension in cats. Anand A. **J Physiol (Lond)** 1996 Mar 15;491 (Pt 3):853–8

Influence of hypoxic duration and posthypoxic inspired O2 concentration on short term potentiation of breathing in humans. Dahan A, et al. **J Physiol (Lond)** 1995 Nov 1;488 (Pt 3):803–13

The importance of sodium for anoxic transmission damage in rat hippocampal slices: mechanisms of protection by lidocaine. Fried E, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):557–65

The role of adenosine in mediating vasodilatation in mesenteric circulation of the rat in acute and chronic hypoxia. Mian R, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):225–34

The effects of systemic hypoxia on renal function in the anaesthetized rat. Neylon M, et al. **J Physiol (Lond)** 1995 Sep 1;487 (Pt 2):497–511

Nitric oxide as a retrograde messenger in the nucleus tractus solitarii of rats during hypoxia. Ogawa H, et al. **J Physiol (Lond)** 1995 Jul 15;486 (Pt 2):495–504

A study on rats of the effects of chronic hypoxia from birth on respiratory and cardiovascular responses evoked by acute hypoxia. Thomas T, et al. **J Physiol (Lond)** 1995 Sep 1;487 (Pt 2):513–25

The anoxic fibroblast response is an early-stage wound healing program. Anderson GR, et al. **J Surg Res** 1995 Dec;59(6):666–74

Fetal model of single ventricle physiology: hemodynamic effects of oxygen, nitric oxide, carbon dioxide, and hypoxia in the early postnatal period. Reddy VM, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):437–49

Altered contractility of rabbit penile corpus cavernosum smooth muscle by hypoxia. Kim NN, et al. **J Urol** 1996 Feb;155(2):772–8

Ventilatory depression during mild hypoxia in adult humans. Honda Y. **Jpn J Physiol** 1995;45(6):947–59 (41 ref.)

The effects of perinatal hypoxia on the behavioral, neurochemical, and neurohistological toxicity of the metabolic inhibitor 3-nitropropionic acid. Binienda Z, et al. **Metab Brain Dis** 1995 Dec;10(4):269–82

The predictive value of elevation in specific serum enzymes for subsequent development of hypoxic-ischemic encephalopathy or intraventricular hemorrhage in full-term and premature asphyxiated newborns. Lackmann GM, et al. **Neuropediatrics** 1995 Aug;26(4):192–8

Hypoxic ischaemic encephalopathy: early magnetic resonance imaging findings and their evolution. Rutherford MA, et al. **Neuropediatrics** 1995 Aug;26(4):183–91

Optical mapping of translucence changes in rat hippocampal slices during hypoxia. Turner DA, et al. **Neurosci Lett** 1995 Aug 11;195(3):209–13

Hypoxia-associated proteins. Graven KK, et al. **New Horiz** 1995 May;3(2):208–18 (58 ref.)

Calcium blockage in pulmonary hypertension and hypoxic vasoconstriction. Neely CF, et al. **New Horiz** 1996 Feb; 4(1):99–106 (74 ref.)

Time-dependent rundown of GABA response in mammalian cns neuron during experimental anoxia. Akaike N. **Obes Res** 1995 Dec;3 Suppl 5:769S–777S

Carotid bodies and ventilatory response to hypoxia in aminophylline-treated piglets. Cattarossi L, et al. **Pediatr Pulmonol** 1995 Aug;20(2):94–100

Aerobic capacity and skeletal muscle properties of normoxic and hypoxic rats in response to training. Abdelmalki A, et al. **Pflugers Arch** 1996 Mar;431(5):671–9

Influence of hypoxia on hepatic and renal endothelin gene expression. Ritthaler T, et al. **Pflugers Arch** 1996 Feb; 431(4):587–93

The effects of chronic hypoxia on the pharmacological responsiveness of the pulmonary artery. Karamsetty VS, et al. **Pharmacol Ther** 1995;68(2):233–46 (110 ref.)

Effect of prenatal hypoxia on contractile performance and responsiveness to Ca2+ in the isolated perinatal rat heart. Oštádalová I, et al. **Physiol Res** 1995;44(2):135–137

Oxygen sensing and molecular adaptation to hypoxia. Bunn HF, et al. **Physiol Rev** 1996 Jul;76(3):839–85 (388 ref.)

The response of umbilical vessels, with and without vascular endothelium, to local anesthesia in low PO2 and hypercarbia. Halevy S, et al. **Reg Anesth** 1995 Jul–Aug; 20(4):316–22

Hypoxic ventilatory responses in Tibetan residents of 4400 m compared with 3658 m. Curran LS, et al. **Respir Physiol** 1995 Jun;100(3):223–30

Estimation of hypoxic ventilatory dynamics using pseudorandom inputs. Dhawale P, et al. **Respir Physiol** 1995 Sep;101(3):267–78

Hypoxic helium breathing does not reduce alveolar–arterial PO2 difference in the horse. Erickson BK, et al. **Respir Physiol** 1995 Jun;100(3):253–60

Hypoxic ventilatory response predicts the extent of maximal breath-holds in man. Feiner JR, et al. **Respir Physiol** 1995 Jun;100(3):213–22

Medullary neuronal activities in gasping induced by pharyngeal stimulation and hypoxia. Fung ML, et al. **Respir Physiol** 1995 Jun;100(3):195–202

Nitric oxide and ventilatory response to hypoxia. Haxhiu MA, et al. **Respir Physiol** 1995 Sep;101(3):257–66

Circulatory and respiratory effects of an hypoxic stress in the Siberian sturgeon. Maxime V, et al. **Respir Physiol** 1995 Jun;100(3):203–12

Magnitude and time course of acute hypoxic pulmonary vasoconstriction in man. Morrell NW, et al. **Respir Physiol** 1995 Jun;100(3):271–81

A protocol for determining the shape of the ventilatory response to hypoxia in humans. Mou XB, et al. **Respir Physiol** 1995 Aug;101(2):139–43

Hypoxic response is inversely related to degree of exercise hyperventilation. Pianosi P, et al. **Respir Physiol** 1995 Jul; 101(1):71–8

Hypoxia sensitive neurons in the caudal hypothalamus project to the periaqueductal gray. Ryan JW, et al. **Respir Physiol** 1995 Jun;100(3):185–94

Decreased carotid body hypoxic sensitivity in chronic hypoxia: role of dopamine. Tatsumi K, et al. **Respir Physiol** 1995 Jul;101(1):47–57

Ventilatory and pulmonary vascular responses to acute hypoxia are nonuniform in healthy man. Naito T, et al. **Respiration** 1995;62(4):185–9

Hypobaric hypoxia: dual sympathetic control in the light of RR and QT spectra. Negoescu R, et al. **Rom J Physiol** 1994 Jan–Dec;31(1–4):47–53

Angiotensin II contributes to cerebral vasodilatation during hypoxia in the rabbit. Maktabi MA, et al. **Stroke** 1995 Oct; 26(10):1871–6

Effect of L-arginine on renal blood flow in normal subjects and patients with hypoxic chronic obstructive pulmonary disease. Howes TQ, et al. **Thorax** 1996 May;51(5):516–9

[Role of sensory neuropeptides in the responses of pulmonary and cerebral blood vessels to acute hypoxia in rats] Hu H, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):104–8 (Eng. Abstr.) **(Chi)**

[Effects of long-term hypoxia on intracellular pH and membrane potential of cultured rat carotid body glomus cells] He SF. **Sheng Li Hsueh Pao** 1995 Jun;47(3):225–30 (Eng. Abstr.) **(Chi)**

[The carotid bodies--mechanisms of hypoxia detection] Vízek M. **Cesk Fysiol** 1995 Jun;44(2):77–80 (Eng. Abstr.) **(Cze)**

[Redox fluorometry study of corneal flavoproteins following hypoxia. Preliminary results] Raynaud C, et al. **J Fr Ophtalmol** 1995;18(5):347–55 (Eng. Abstr.) **(Fre)**

[Hypoxic pulmonary vasoconstriction] Theissen IL, et al. **Anaesthesist** 1996 Jul;45(7):643–52 (137 ref.) (Eng. Abstr.) **(Ger)**

[Lung problems in acute to subacute exposure to medium altitudes] Marugg D. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1101–7 (41 ref.) (Eng. Abstr.) **(Ger)**

[Hypoxyradiotherapy: changes in the oxygen partial pressure distribution in the tumor and in the healthy tissue under acute respiratory hypoxia] Strnad V, et al. **Strahlenther Onkol** 1996 Aug;172(8):427–33 (Eng. Abstr.) **(Ger)**

[Hypothalamic-adenohypophysial function of corticotropin releasing hormone (CRH)-ACTH system in hypoxic coma] Nishioka H, et al. **No To Shinkei** 1996 Jan;48(1):53–7 (Eng. Abstr.) **(Jpn)**

[Cardiorespiratory evaluation of athletes for competitions at high altitudes] Costa RV. **Arq Bras Cardiol** 1995 Feb; 64(2):183–6 **(Por)**

[Effect of adapting to periodic hypoxia on kinetic parameters of respiratory chain enzymes in the rat brain] Dudchenko AM, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):252–5 **(Rus)**

[Adaptation to hypoxia, as opposed to adaptation to stress, does not protect the isolated heart from reperfusion after total ischemia. A nuclear magnetic resonance study] Golubeva LIu, et al. **Biull Eksp Biol Med** 1995 Nov; 120(11):481–4 **(Rus)**

[The effect of adaptation to interrupted normobaric hypoxia on the ultrastructure of pregnant rat cardiomyocytes] Lebkova NP, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):597–602 **(Rus)**

[Adaptation to high altitude hypoxia facilitates a limitation of lipid peroxidation activation in inflammation and stress] Malyshev VV, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):590–3 **(Rus)**

[Functional status of endothelium and production of nitric oxide in the rat, adapted to periodic hypoxia] Manukhina EB, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):495–8 **(Rus)**

[Mechanism of pulmonary hypertension in rats with high altitude hypoxia] Mazhbich BI, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):324–7 **(Rus)**

[Opposite effect of adaptation to short exposure to stressors and adaptation to periodic hypoxia on liver cell membrane Na,K-ATPase activity] Sazontova TG. **Biull Eksp Biol Med** 1996 Apr;121(4):383–6 **(Rus)**

[Adaptation to periodic hypoxia and diet with omega-3 polyunsaturated fatty acids increases the stability of myocardial sarcoplasmic reticulum Ca2+ transport to free radical oxidation] Sazontova TG, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):42–5 **(Rus)**

[Hypoxic training stimulates new growth of pancreatic beta cells and slows development of diabetes mellitus in rats] Kolesnik IuM, et al. **Dokl Akad Nauk** 1995 Jul;343(1):127–9 **(Rus)**

[Immunophysiologic mechanisms of adaptation to extreme conditions] Novikov VS. **Fiziol Cheloveka** 1996 Mar–Apr; 22(2):25–34 (44 ref.) **(Rus)**

[The effect of stimulation of the orbitofrontal cortex on the activity of the bulbar respiratory neurons and on respiration in normal rats and in hypoxia] Akopian NS, et al. **Fiziol Zh Im I M Sechenova** 1995 Mar;81(3):8–15 (Eng. Abstr.) **(Rus)**

[The use of phenylthiocarbamide for evaluating the degree of cAMP-dependent resistance to hypoxia in animals] Bolekhan EA, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug; 81(8):85–9 (Eng. Abstr.) **(Rus)**

[The dynamic impulse activity of the neocortical neurons in monkeys with the task of visual recognition after short-term oxygen starvation] Dudkin KN, et al. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):62–70 (Eng. Abstr.) **(Rus)**

[The microvascular permeability of the skin and mesentery in rats adapting to hypoxia] Gavrisheva NA, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):81–6 (Eng. Abstr.) **(Rus)**

[The reactions of rat respiratory neurons to a hypoxic stimulus] Sergeev OS. **Fiziol Zh Im I M Sechenova** 1995 Jan;81(1):48–55 (Eng. Abstr.) **(Rus)**

[The effect of acute hypoxia on the dynamic formation of unfused tetanus in the rat extensor digitorum longus] Zorova OV. **Fiziol Zh Im I M Sechenova** 1995 Sep; 81(9):79–82 (Eng. Abstr.) **(Rus)**

[The effect of acute hypoxia on the cytogenetic effect of cyclophosphamide in rat bone marrow cells, differing in resistance to oxygen deficiency] Bykovskaia NV, et al. **Genetika** 1995 Nov;31(11):1575–7 (Eng. Abstr.) **(Rus)**

[Glycemia as a risk factor of reduced tolerance of hypoxic hypoxia in flight personnel] Ivanchikov AP, et al. **Kosm Biol Aviakosm Med** 1991 Sep–Oct;25(5):10–2 (Eng. Abstr.) **(Rus)**

[The relationship between respiratory system reactivity and neutrophil metabolism in hypoxia in persons subjected to ionizing radiation exposure] Serebrovskaia TV, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):400–4 (Eng. Abstr.) **(Rus)**

[An initial trial of using pulsed hypoxia incorporating helium in the treatment of chronic obstructive bronchitis] Sil'vestrov VP, et al. **Ter Arkh** 1996;68(3):65–8 **(Rus)**

[Hypobaric hypoxia in the treatment of chronic anemia] Novikov VS, et al. **Voen Med Zh** 1995 Nov;(11):36–9, 80 (Eng. Abstr.) **(Rus)**

[The effect of adaptation to hypoxia on the results of the health resort treatment of children with bronchial asthma] Legkikh MV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec;(6):42 **(Rus)**

[Phosphoinositide response and changes in the supraoptic-neurohypophyseal system in individual resistance of rats to hypoxia] Vishnevskil AA, et al. **Vopr Med Khim** 1995 Jul–Aug;41(4):10–2 (Eng. Abstr.) **(Rus)**

[Perinatal asphyxia, hypoxic-ischemic encephalopathy and neurological sequelae in full-term newborns. II. Description and interrelation] González de Dios J, et al. **Rev Neurol** 1996 Aug;24(132):969–76 (Eng. Abstr.) **(Spa)**

[Perinatal asphyxia, hypoxic-ischemic encephalopathy and neurological sequelae in full-term newborns: an epidemiological study (1)] Gónzalez de Dios J, et al. **Rev Neurol** 1996 Jul;24(131):812–9 (Eng. Abstr.) **(Spa)**

[Molecular factors of cerebral hypoxia-ischemia] Macaya A, et al. **Rev Neurol** 1996 Jul;24(131):855–64 (84 ref.) (Eng. Abstr.) **(Spa)**

[Magnetic resonance in cerebral anoxia] Palacios G, et al. **Rev Neurol** 1996 Aug;24(132):1008–9 **(Spa)**

[The effect of intermittent hypoxic training on pancreatic endocrine function in animals with diabetes mellitus] Kolesnyk IUM, et al. **Fiziol Zh** 1994 Sep–Dec; 40(5–6):87–95 (Eng. Abstr.) **(Ukr)**

PREVENTION & CONTROL

Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. Chen SJ, et al. **J Appl Physiol** 1995 Dec;79(6):2122–31

Enhanced cardiac metabolism of plasma glucose in high-altitude natives: adaptation against chronic hypoxia. Holden JE, et al. **J Appl Physiol** 1995 Jul;79(1):222–8

Arachidonic acid protects against hypoxic injury in rat proximal tubules. Alkhunaizi AM, et al. **Kidney Int** 1996 Mar;49(3):620–5

Jet leg, pulmonary embolism, and hypoxia [letter] Simons R, et al. **Lancet** 1996 Aug 10;348(9024):416

Airway management and mechanical ventilation. Abrams KJ. **New Horiz** 1995 Aug;3(3):479–87 (65 ref.)

Avoid injury in confined spaces. Bove K, et al. **Occup Health Saf** 1995 Sep;64(9):42–6

The effect of high dose antenatal vitamin E on hypoxia-induced changes in newborn rats. Inan C, et al. **Pediatr Res** 1995 Nov;38(5):685–9

[Protective effects of vitamins C and E in hypoxia] Schreiber M, et al. **Sb Lek** 1995;96(2):163–6 **(Cze)**

[Problems and limits in noninvasive oxygen monitoring] Bardenheuer HJ, et al. **Anaesthesist** 1996 Jul;45(7):614–25 (86 ref.) (Eng. Abstr.) **(Ger)**

[Perioperative use of dobutamine (letter; comment)] Fiore T. **Minerva Anestesiol** 1995 Jun;61(6):283. Comment on: Minerva Anestesiol 1995 Jan–Feb;61(1–2):29–37. **(Ita)**

[Prevention of ventilation hypoxia in surgical interventions on the open trachea] Maslov VI, et al. **Anesteziol Reanimatol** 1995 Sep–Oct;(5):19–21 (Eng. Abstr.) **(Rus)**

[Transtracheal jet pulmonary ventilation as a measure for preventing hypoxia during reconstructive maxillofacial operations] Rovina AK, et al. **Stomatologiia (Mosk)** 1995; 74(2):55–7 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Tyrosine administration prevents hypoxia-induced decrements in learning and memory. Shukitt-Hale B, et al. **Physiol Behav** 1996 Apr–May;59(4–5):867–71

RADIONUCLIDE IMAGING

A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time–activity data. Casciari JJ, et al. **Med Phys** 1995 Jul;22(7):1127–39

THERAPY

Practical pulse oximetry. Saturation can be normal with dangerously high pCO2 [letter; comment] Robbins PM, et al. **BMJ** 1995 Nov 11;311(7015):1302. Comment on: BMJ 1995 Aug 5;311(7001):367–70.

Noninvasive nasal mask positive pressure ventilation in a pediatric patient with acute hypoxic respiratory failure. Padman R, et al. **Pediatr Emerg Care** 1996 Feb;12(1):44–7 (63 ref.)

The effect of prolonged modification of cerebral temperature on outcome after hypoxic–ischemic brain injury in the infant rat. Sirimanne ES, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):591–7

[Intermittent self-ventilation—burden or relief? (editorial)] Köhler D. **Med Klin** 1996 Apr 12;91 Suppl 2:1 **(Ger)**

[Intensive care of respiratory insufficiency and hypoxia] Zhdanov GG. **Anesteziol Reanimatol** 1995 Sep–Oct; (5):15–8 (Eng. Abstr.) **(Rus)**

[The correction of hypoxic damage to the pulmonary surfactant system of rats with extremely high-frequency electromagnetic fields] Alymkulov DA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan–Feb;(1):9–11 (Eng. Abstr.) **(Rus)**

URINE

Phosphate excretion during 24 h of hypoxia in conscious rats. Mimura Y. **Acta Physiol Scand** 1995 Nov;155(3):283–9

VETERINARY

Pulse oximetry for assessing oxygen status of neonatal calves [letter] Norton J, et al. **Vet Rec** 1996 Apr 6;138(14):340

[Evaluation of hypoxic conditions in calves using the erythrocyte density test (EDT) (corrected and republished with original paging, article originally printed in Zentralbl Veterinarmed A 1994 Apr;41(3):215–28)] Flegel T, et al. **Zentralbl Veterinarmed A** 1995 May;42(3):215–28 (Eng. Abstr.) **(Ger)**

ANOXIA, CELLULAR see **CELL HYPOXIA**

ANOXIA, FETAL see **FETAL ANOXIA**

ANP see **ATRIAL NATRIURETIC FACTOR**

ANP RECEPTORS see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

ANSERINE

METABOLISM

Histidine dipeptide levels in exercised and hypertensive rat muscles. Hong H, et al. **Biochem Soc Trans** 1995 Nov; 23(4):542S

Effect of a training session of endurance running on anserine and carnosine contents in fast and slow muscles of young rats. Tanaka M. **Jpn J Physiol** 1995;45(4):659–66

ANT VENOMS

ANALYSIS

Separation of jumper ant (Myrmecia pilosula) venom allergens: a novel group of highly basic proteins. Donovan GR, et al. **Electrophoresis** 1995 May;16(5):804–10

BIOSYNTHESIS

Production of a recombinant imported fire ant venom allergen, Sol i 2, in native and immunoreactive form. Schmidt M, et al. **J Allergy Clin Immunol** 1996 Jul; 98(1):82–8

CHEMISTRY

Separation of jumper ant (Myrmecia pilosula) venom allergens: a novel group of highly basic proteins. Donovan GR, et al. **Electrophoresis** 1995 May;16(5):804–10

[Protein composition of venoms from several species of tropical ants and their effect on mitochondrial H+-ATPase] Zaĭtseva LG, et al. **Bioorg Khim** 1995 Aug; 21(8):563–70 (Eng. Abstr.) **(Rus)**

GENETICS

Molecular cloning and characterization of the major allergen Myr p II from the venom of the jumper ant Myrmecia pilosula: Myr p I and Myr p II share a common protein leader sequence. Street MD, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1–2):87–97

Production of a recombinant imported fire ant venom allergen, Sol i 2, in native and immunoreactive form. Schmidt M, et al. **J Allergy Clin Immunol** 1996 Jul; 98(1):82–8

IMMUNOLOGY

Fire ant venom allergy. Hoffman DR. **Allergy** 1995 Jul; 50(7):535–44 (89 ref.)

Hypersensitivity to fire ant venom [see comments] Stafford CT. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):87–95; quiz 96–9 (50 ref.). Comment in: Ann Allergy Asthma Immunol 1996 Aug;77(2):85.

ANTACIDS

ADMINISTRATION & DOSAGE

Using the "GI cocktail": a descriptive study [see comments] Wrenn K, et al. **Ann Emerg Med** 1995 Dec;26(6):687–90. Comment in: Ann Emerg Med 1996 Jul;28(1):104–5.

Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Rauws EA, et al. **Drugs** 1995 Dec; 50(6):984–90

Topical treatments for hydrofluoric acid dermal burns. Further assessment of efficacy using an experimental pig model. Dunn BJ, et al. **J Occup Environ Med** 1996 May; 38(5):507–14

Formulation of controlled release drug preparations with antacid effect. Racz I, et al. **Pharmazie** 1996 May; 51(5):323–7

Treatment of Helicobacter pylori infection by topical administration of antimicrobial agents. Satoh K. **Scand J Gastroenterol Suppl** 1996;214:56; discussion 57–60

[Antacid activity of citrate–bicarbonate complex of effervescent formulations of ranitidine. In vitro analysis using 'artificial stomach–duodenum' model] Vatier J, et al. **Therapie** 1996 Mar–Apr;51(2):139–46 (Eng. Abstr.) **(Fre)**

[Therapy of candiduria by alkalinization of urine. Oral treatment with potassium–sodium–hydrogen citrate] Strassner C, et al. **Fortschr Med** 1995 Sep 10;113(25):359–62 (Eng. Abstr.) **(Ger)**

[New study results with lattice-layered antacids] **Internist (Berl)** 1993 Nov;34(11 Suppl):1–12 **(Ger)**

[Which factors influence the success of the classical triple therapy in the eradication of Helicobacter pylori?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1996 May;88(5):317–22 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Rolaids–yogurt syndrome: a 1990s version of milk–alkali syndrome. Muldowney WP, et al. **Am J Kidney Dis** 1996 Feb;27(2):270–2

[The milk-alkali syndrome—a rare differential diagnosis for hypercalcemia] Olschewski P, et al. **Dtsch Med Wochenschr** 1996 Aug 16;121(33):1015–8 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Is citrate an inhibitor of calcium oxalate crystal growth in high concentrations of urine? Bek-Jensen H, et al. **Urol Res** 1996;24(2):67–71

DIAGNOSTIC USE

Gastric emptying of two radiolabelled antacids with simultaneous monitoring of gastric pH. Monés J, et al. **Eur J Nucl Med** 1995 Oct;22(10):1123–8

PHARMACOKINETICS

Are calcitriol boli worth the return to aluminum hydroxide as a phosphate binder in severe secondary hyperparathyroidism? [letter] Calabrese G, et al. **Nephron** 1995;71(1):113–4

Can aluminium–containing antacid produce dementia? [letter] Jobst K, et al. **Nephron** 1995;71(4):473

PHARMACOLOGY

Effect of Rennie Liquid versus Maalox Liquid on intragastric pH in a double–blind, randomized, placebo–controlled, triple cross–over study in healthy volunteers. Hürlimann S, et al. **Am J Gastroenterol** 1996 Jun;91(6):1173–80

Comparison of the effects of ranitidine effervescent tablets and magnesium hydroxide–aluminium oxide on intragastric acidity. A single–centre, randomised, open cross–over study. Propst A, et al. **Arzneimittelforschung** 1996 Jun; 46(6):621–4

Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring. Stratford MR, et al. **Br J Cancer** 1996 Jul;74(1):16–21

Pharmacokinetics of tenidap sodium administered with food or antacid in healthy volunteers. Coates PE, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:17S–19S

Conventional dose of omeprazole alters gastric flora. Karmeli Y, et al. **Dig Dis Sci** 1995 Sep;40(9):2070–3

Effects of antacid on absorption and excretion of new quinolones. Shiba K, et al. **Drugs** 1995;49 Suppl 2:360–1

Effect of aluminum hydroxide/magnesium hydroxide antacid and bismuth subsalicylate on gastric pH in horses. Clark CK, et al. **J Am Vet Med Assoc** 1996 May 15; 208(10):1687–91

Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid. de Bony F, et al. **J Antimicrob Chemother** 1996 Feb;37(2):383–7

A new technique for continuous measurement and recording of gastric potential difference in the rat: evaluation of NSAID–induced gastric mucosal damage. Scarpignato C, et al. **J Pharmacol Toxicol Methods** 1995 Oct;34(2):63–72

Comparison of the effects of over–the–counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial. Feldman M. **JAMA** 1996 May 8;275(18):1428–31

Antiulcer and gastric secretory activity of N-octanoyl gamma–aminobutyric acid. Sen S, et al. **Life Sci** 1995; 57(20):1877–85

In vitro assessment of antacid efficacy using a computer–controlled 'artificial stomach–duodenum' model reproducing gastroduodenal flux regulation. Vatier J, et al. **Therapie** 1996 Mar–Apr;51(2):147–54

The history of acid inhibition. Baron JH. **Yale J Biol Med** 1994 May–Aug;67(3–4):97–106 (32 ref.)

THERAPEUTIC USE

Bismuth–based combination therapy for Helicobacter pylori–associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain). Tefera S, et al. **Am J Gastroenterol** 1996 May;91(5):935–41

The role of intragastric acidity and stress ulcus prophylaxis on colonization and infection in mechanically ventilated ICU patients. A stratified, randomized, double–blind study of sucralfate versus antacids. Bonten MJ, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1825–34

Acid aspiration prophylaxis for emergency Caesarean section. Stuart JC, et al. **Anaesthesia** 1996 May;51(5):415–21

GI cocktail [letter; comment] Rosenberg CA. **Ann Emerg Med** 1996 Jul;28(1):104–5. Comment on: Ann Emerg Med 1995 Dec;26(6):687–90.

Gastrointestinal tract complications of nonsteroidal anti–inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Singh G, et al. **Arch Intern Med** 1996 Jul 22;156(14):1530–6

Comparison of the effect of two dose schedules of oral omeprazole with oral ranitidine on gastric aspirate pH and volume in patients undergoing elective surgery. Levack ID, et al. **Br J Anaesth** 1996 Apr;76(4):567–9

A prospective randomized controlled trial comparing the use of merocel nasal tampons and BIPP in the control of acute epistaxis. Corbridge RJ, et al. **Clin Otolaryngol** 1995 Aug; 20(4):305–7

Healing of gastric body ulcer with gastroprotective versus antisecretory treatment. Jablonská M. **Dig Dis Sci** 1995 Sep; 40(9):2016–8

Colloid bismuth versus famotidine in the treatment and prevention of duodenal ulcer relapse: results of a double–blind, double dummy randomized study. Masci E, et al. **Fundam Clin Pharmacol** 1995;9(3):280–3

Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. McDougall NI, et al. **Gut** 1996 Apr;38(4):481–6

Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. Berstad A, et al. **J Physiol Pharmacol** 1996 Mar;47(1):31–49 (45 ref.)

Nosocomial pneumonia in ventilated trauma patients during stress ulcer prophylaxis with sucralfate, antacid, and ranitidine. Thomason MH, et al. **J Trauma** 1996 Sep; 41(3):503–8

Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta–analyses. Cook DJ, et al. **JAMA** 1996 Jan 24–31;275(4):308–14

Effects of famotidine vs antacid on gastric acidity: onset of action and symptom relief [letter] Decktor DL, et al. **JAMA** 1996 Sep 18;276(11):873–4

Calcitriol and calcium carbonate therapy in early chronic renal failure [letter; comment] Brown CB. **Nephrol Dial Transplant** 1995 Nov;10(11):2158–9. Comment on: Nephrol Dial Transplant 1995;10(4):577.

Cyclical etidronate and calcium carbonate (with citrate) supplementation for osteoporosis unmasking primary hyperparathyroidism. Forbes RB, et al. **Scott Med J** 1995 Dec;40(6):177–8

[Reinstatement of calcium–containing antacids] Tytgat GN. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2405–7 (14 ref.) **(Dut)**

[Antibacterial treatment of gastric ulcers associated with Helicobacter pylori without acid suppression] Folwaczny C. **Z Gastroenterol** 1995 Jul;33(7):416–7 **(Ger)**

[Evaluation of treatment for the prevention of acute gastric lesions in stress, in rats] Laudanno OM, et al.

ANTACIDS

Acta Gastroenterol Latinoam 1995;25(3):145–52 (Eng. Abstr.) **(Spa)**

ANTELOPES

Disseminated chlamydial infection in antelope. Mansell JL, et al. **J Vet Diagn Invest** 1995 Jul;7(3):397–9

Toxicologic evaluation of a high-selenium hay diet in captive pronghorn antelope (Antilocapra americana). Raisbeck MF, et al. **J Wildl Dis** 1996 Jan;32(1):9–16

New mammal data challenge evolutionary pulse theory [news] Kerr RA. **Science** 1996 Jul 26;273(5274):431–2

Cerebral coeneurosis in chamois (Rupicapra pyrenaica). Lavin S, et al. **Zentralbl Veterinarmed [B]** 1995 Jun; 42(4):205–8

ANATOMY & HISTOLOGY

Myoepithelial cells and innervation in the infraorbital gland of the Japanese serow (Capricornis crispus). Atoji Y, et al. **Eur J Morphol** 1995 Jul;33(3):237–46

Macroscopic observations of mammary glands and teats of Japanese serows, Capricornis crispus, with special reference to past gestation. Kita I, et al. **J Vet Med Sci** 1995 Jun; 57(3):447–51

[Ultrastructural organization of the hepatoid gland epithelium in Phillip's dik dik, Madoqua phillipsi, and Grant's gazelle (Artiodactyla, Bovidae] Sokolov VE, et al. **Dokl Akad Nauk** 1996 Apr;347(4):556–9 **(Rus)**

GENETICS

Allozyme divergence among four representatives of the subfamily Alcelaphinae (family: Bovidae). Grobler JP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):303–8

Chromosomal evolution in duiker antelope (Cephalophinae: Bovidae): karyotype comparisons, fluorescence in situ hybridization, and rampant X chromosome variation. Robinson TJ, et al. **Cytogenet Cell Genet** 1996; 73(1–2):116–22

Absence of geographic chromosomal variation in the roan and sable antelope and the cytogenetics of a naturally occurring hybrid. Robinson TJ, et al. **Cytogenet Cell Genet** 1995;71(4):363–9

Extreme genetic differences among populations of Gazella granti, Grant's gazelle in Kenya. Arctander P, et al. **Heredity** 1996 May;76 (Pt 5):465–75

Different rates of mitochondrial DNA sequence evolution in Kirk's dik-dik (Madoqua kirkii) populations. Zhang Y, et al. **Mol Phylogenet Evol** 1995 Sep;4(3):291–7

Mitochondrial DNA sequence relationships of the extinct blue antelope Hippotragus leucophaeus. Robinson TJ, et al. **Naturwissenschaften** 1996 Apr;83(4):178–82

PARASITOLOGY

Trypanosoma brucei rhodesiense: variation in human serum resistance after transmission between bushbuck and domestic ruminants by Glossina morsitans morsitans. Moloo SK, et al. **Acta Trop** 1995 Jun;59(3):255–8

The Mongolian gazelle (Procapra gutturosa, Bovidae) as an intermediate host of three Sarcocystis species in Mongolia. Odening K, et al. **Appl Parasitol** 1996 Jan;37(1):54–65

The efficiency of patch sampling for determination of relative tick burdens in comparison with total tick counts. Mooring MS, et al. **Exp Appl Acarol** 1995 Sep;19(9):533–47

Systemic infection with an unidentified Toxoplasma-like protozoan in a neonatal Lichtenstein's hartebeest (Sigmoceros lichtensteinii). Jardine JE, et al. **J Parasitol** 1996 Jun;82(3):515–7

Experimental infection of Arabian sand gazelles, Gazella subgutturosa marica with Eimeria rheemi. Mohammed OB, et al. **J Parasitol** 1996 Apr;82(2):356–7

A trypanosomatid organism on blood smears made from a waterbuck (Kobus ellipsiprymnus) carcass in the Kruger National Park [letter] Penzhorn BL, et al. **J S Afr Vet Assoc** 1996 Mar;67(1):4–5

Prevalence of hepatic helminths and associated pathology in impala (Aepyceros melampus) in Swaziland. Gallivan GJ, et al. **J Wildl Dis** 1996 Jan;32(1):137–41

Parasites of domestic and wild animals in South Africa. XXXIV. Arthropod parasites of nyalas in north-eastern KwaZulu-Natal. Horak IG, et al. **Onderstepoort J Vet Res** 1995 Sep;62(3):171–9

PHYSIOLOGY

Length of estrous cycle and gestation in the Arabian oryx (Oryx leucoryx) and the importance of the male presence for induction of postpartum estrus. Sempéré AJ, et al. **Gen Comp Endocrinol** 1996 Mar;101(3):235–41

Ovulatory cycles and anovulatory periods in the addax (Addax nasomaculatus). Asa CS, et al. **J Reprod Fertil** 1996 May;107(1):119–24

Grooming in impala: role of oral grooming in removal of ticks and effects of ticks in increasing grooming rate. Mooring MS, et al. **Physiol Behav** 1996 Apr–May; 59(4–5):965–71

Monogamy without biparental care in a dwarf antelope. Brotherton PN, et al. **Proc R Soc Lond B Biol Sci** 1996 Jan 22;263(1366):23–9

ANTELOPINES see **ANTELOPES**

ANTERIOR CHAMBER

Pupillary block, angle-closure glaucoma produced by an anterior chamber air bubble in a nanophthalmic eye [letter] Flowers CW Jr, et al. **Arch Ophthalmol** 1996 Sep; 114(9):1145–6

Transsclerally sulcus fixated anterior chamber lenses in eyes without posterior capsule support: three years follow up. Lodewijks H, et al. **Bull Soc Belge Ophtalmol** 1994;254:31–4

Ectopic retinal tacks [letter] Lehmann OJ, et al. **Eye** 1995; 9 (Pt 3):378–9

Use of the anterior chamber maintainer in anterior segment surgery. Chawla HB, et al. **J Cataract Refract Surg** 1996 Mar;22(2):172–7

Silicone sleeve defects [letter] Hunter LH. **J Cataract Refract Surg** 1996 Mar;22(2):158

Re-forming the flat anterior chamber with Healon. Osher RH, et al. **J Cataract Refract Surg** 1996 May;22(4):411–5

Anterior intraocular lens dislocation after combined cataract extraction trabeculectomy. Shammas HJ. **J Cataract Refract Surg** 1996 Apr;22(3):358–61

[The development of transplants of human embryonic neocortex in the anterior chamber of the rat eye] Smirnov EB, et al. **Morfologiia** 1994 Apr-Jun;106(4–6):75–82 (Eng. Abstr.) **(Rus)**

ANATOMY & HISTOLOGY

Refraction and anterior chamber depth before and after neodymium: YAG laser treatment for posterior capsule opacification in pseudophakic eyes: a prospective study. Thornval P, et al. **J Cataract Refract Surg** 1995 Jul; 21(4):457–60

Anterior chamber angle biometry: a comparison of Scheimpflug photography and ultrasound biomicroscopy. Böker T, et al. **Ophthalmic Res** 1995;27 Suppl 1:104–9

[Breed and age dependent structure of the eye chamber angle in cats] Köbnick M, et al. **Tierarztl Prax** 1995 Dec; 23(6):603–8 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Evaluation of albumin concentration in rabbit anterior chamber with laser flare-cell meter. Mori M, et al. **Curr Eye Res** 1995 Jul;14(7):593–9

DRUG EFFECTS

Postoperative hypopyon after intravitreal bovine thrombin for macular hole surgery. Olsen TW, et al. **Am J Ophthalmol** 1996 May;121(5):575–7

Effect of pilocarpine on anterior chamber angles. Hung L, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):221–6

GROWTH & DEVELOPMENT

[Breed and age dependent structure of the eye chamber angle in cats] Köbnick M, et al. **Tierarztl Prax** 1995 Dec; 23(6):603–8 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Influence of the anterior chamber of the eye on T-cell production of extracellular antigen-specific proteins. Cone RE, et al. **Adv Exp Med Biol** 1995;383:237–48 (31 ref.)

High-dose cyclophosphamide inhibits anterior chamber-associated immune deviation (ACAID) and the production of extracellular antigen-specific T cell proteins induced by trinitrophenylated (TNP) spleen cells. Wang Y, et al. **Cell Immunol** 1995 Oct 15;165(2):284–8

Role of splenic B cells in the immune privilege of the anterior chamber of the eye. Niederkorn JY, et al. **Eur J Immunol** 1995 Oct;25(10):2783–7

Regulators of immunological responses in the cornea and the anterior chamber of the eye. Jager MJ, et al. **Eye** 1995; 9 (Pt 2):241–6

Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Sano Y, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2176–85

Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. Streilein JW, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):413–24

Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. Apte RS, et al. **J Immunol** 1996 Apr 15;156(8):2667–73

Fas ligand-induced apoptosis as a mechanism of immune privilege [see comments] Griffith TS, et al. **Science** 1995 Nov 17;270(5239):1189–92. Comment in: Science 1995 Nov 17;270(5239):1158–9.

INJURIES

Trabeculectomy and manual clot evacuation in traumatic hyphaema with corneal blood staining. Verma N. **Aust N Z J Ophthalmol** 1996 Feb;24(1):33–8

METABOLISM

Localization and possible gene expression of proteoglycan decorin in the trabecular meshwork. Tanihara H, et al. **Curr Eye Res** 1995 Aug;14(8):727–30

Ocular adenovirus gene transfer varies in efficiency and inflammatory response. Borrás T, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1282–93

Contrast-enhanced magnetic resonance imaging confirmation of an anterior protein pathway in normal rabbit eyes. Kolodny NH, et al. **Invest Ophthalmol Vis Sci** 1996 Jul; 37(8):1602–7

MICROBIOLOGY

Anterior chamber aspirate cultures in small incision cataract surgery [see comments] Manners TD, et al. **Br J Ophthalmol** 1995 Oct;79(10):878–80. Comment in: Br J Ophthalmol 1995 Oct;79(10):873.

Anterior chamber fluid contamination after uncomplicated phacoemulsification. Assalian A, et al. **J Cataract Refract Surg** 1995 Sep;21(5):539–42

Anterior chamber fluid cultures following phacoemulsification and posterior chamber lens implantation. Gimbel HV, et al. **Ophthalmic Surg Lasers** 1996 Feb;27(2):121–6

PATHOLOGY

The effect of flat anterior chamber on the success of trabeculectomy. Kim YY, et al. **Acta Ophthalmol Scand** 1995 Jun;73(3):268–72

Corneal endothelial cell loss caused by detached opacified anterior lens capsule in the anterior chamber. Chiba K, et al. **J Cataract Refract Surg** 1995 Nov;21(6):701–5

Images in clinical medicine. Hypopyon. Soloway S, et al. **N Engl J Med** 1996 Jun 6;334(23):1512

Comparison of the configuration of the human anterior chamber angle, as determined by the Spaeth gonioscopic grading system and ultrasound biomicroscopy. Spaeth GL, et al. **Trans Am Ophthalmol Soc** 1995;93:337–47; discussion 347–51

[Comparison of simple methods to screen predisposing eye of primary angle-closure glaucoma] Ye T, et al. **Chung Hua Yen Ko Tsa Chih** 1995 Sep;31(5):341–4 (Eng. Abstr.) **(Chi)**

[Anterior chamber dimensions in patients with angle-closure glaucoma measured by an anterior eye segment analysis system] Sakai H, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jul;100(7):546–50 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Modeling the effects of anterior chamber fluid viscosities on intraocular pressure following glaucoma filtering surgery. Fankhauser F, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Nov;233(11):737–41

Serum effects on aqueous outflow during anterior chamber perfusion in monkeys. Kee C, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1840–8

SURGERY

Aqueous shunts: single-plate Molteno vs ACTSEB. Kim DM, et al. **Acta Ophthalmol Scand** 1995 Jun;73(3):277–80

Bacterial endophthalmitis after anterior chamber paracentesis [letter] Helbig H, et al. **Br J Ophthalmol** 1995 Sep;79(9):866

Experimental use of space-retaining substances with extended duration: functional and morphological results. Klemm M, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Sep;233(9):592–7

Secondary implantation of angle-supported anterior chamber and scleral-fixated posterior chamber intraocular lenses. Bellucci R, et al. **J Cataract Refract Surg** 1996 Mar; 22(2):247–52

Flexible open-loop anterior chamber intraocular lens implantation after posterior capsule complications in extracapsular cataract extraction. Rattigan SM, et al. **J Cataract Refract Surg** 1996 Mar;22(2):243–6 (10 ref.)

Anterior chamber paracentesis and carbogen treatment of acute CRAO [letter] Gombos GM. **Ophthalmology** 1996 Jun;103(6):865

Corneoscleral block excision of postoperative anterior chamber cysts. Forster RK. **Trans Am Ophthalmol Soc** 1995;93:83–97; discussion 97–104

ULTRASONOGRAPHY

Ultrasound Biomicroscopy of shallow anterior chamber in Vogt-Koyanagi-Harada syndrome. Gohdo T, et al. **Am J Ophthalmol** 1996 Jul;122(1):112–4

Ultrasound biomicroscopic analysis of transient shallow anterior chamber in Vogt-Koyanagi-Harada syndrome. Kawano Y, et al. **Am J Ophthalmol** 1996 Jun;121(6):720–3

Management of a patient with pseudophakic malignant glaucoma; role of ultrasound biomicroscopy [letter] Park M, et al. **Br J Ophthalmol** 1996 Jul;80(7):676–7

Anterior chamber angle biometry: a comparison of Scheimpflug photography and ultrasound biomicroscopy. Böker T, et al. **Ophthalmic Res** 1995;27 Suppl 1:104–9

Ultrasound biomicroscopy and corneal endothelium in Nd:YAG-laser iridotomy. Marraffa M, et al. **Ophthalmic Surg Lasers** 1995 Nov-Dec;26(6):519–23

ANTERIOR CHAMBER EPITHELIUM see **ENDOTHELIUM, CORNEAL**

ANTERIOR COMPARTMENT SYNDROME

DIAGNOSIS

Compartment syndrome in tibial shaft fracture missed because of a local nerve block. Hyder N, et al.

J Bone Joint Surg Br 1996 May;78(3):499–500

[MR imaging of a patient positioning–induced compartment syndrome of both lower legs after surgery in dorsal surgical position] Rominger MB, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Apr;164(4):338–40 **(Ger)**

ETIOLOGY

Compartment syndrome as complication of skin traction, in children with femoral fractures. Janzing H, et al.
Acta Chir Belg 1996 Jun;96(3):135–7

Compartment syndrome in tibial shaft fracture missed because of a local nerve block. Hyder N, et al.
J Bone Joint Surg Br 1996 May;78(3):499–500

Compartment–syndrome of the lower extremity after CABG. van den Wildenberg FA, et al.
J Cardiovasc Surg (Torino) 1996 Jun;37(3):237–41

Anterior dissection of popliteal cyst causing anterior compartment syndrome. Hammoudeh M, et al.
J Rheumatol 1995 Jul;22(7):1377–9

Compartment syndrome in a child occurring after femoral artery cannulation. Selby IR, et al. **Paediatr Anaesth** 1995; 5(6):393–5

PHYSIOPATHOLOGY

Influence of the running shoe sole on the pressure in the anterior tibial compartment. Jerosch J, et al.
Acta Orthop Belg 1995;61(3):190–8

RADIOGRAPHY

Case of the month: Calcified leg. Flinn J, et al.
Br J Radiol 1996 Apr;69(820):371–2

SURGERY

[Corrective osteotomies of the foot after compartment syndromes of the tibia] Dávid A, et al. **Chirurg** 1995 Nov; 66(11):1134–40 (Eng. Abstr.) **(Ger)**

ANTERIOR CRUCIATE LIGAMENT

see related
MEDIAL COLLATERAL LIGAMENT, KNEE
POSTERIOR CRUCIATE LIGAMENT

Ganglion of the anterior cruciate ligament presented as a mass [letter] Kaempffe FA. **Am J Orthop** 1996 Apr; 25(4):325

Ganglion of the anterior cruciate ligament presented as a knee mass. Sevilla CA. **Am J Orthop** 1996 Jan;25(1):46–8

Anterior cruciate reconstruction with the ABC carbon and polyester prosthetic ligament. Campbell AC, et al.
Ann R Coll Surg Engl 1995 Sep;77(5):349–50

Computed tomography—guided aspiration of a ganglion cyst of the anterior cruciate ligament: a case report. Campagnolo DI, et al. **Arch Phys Med Rehabil** 1996 Jul; 77(7):732–3 (22 ref.)

Symptomatic ganglion cyst within the substance of the anterior cruciate ligament. Kang CN, et al. **Arthroscopy** 1995 Oct;11(5):612–5

Examiner proficiency in performing the anterior drawer and Lachman tests. Draper DO, et al.
J Orthop Sports Phys Ther 1995 Dec;22(6):263–6

Review on tension in the natural and reconstructed anterior cruciate ligament. Andersen HN, et al.
Knee Surg Sports Traumatol Arthrosc 1994;2(4):192–202 (90 ref.)

Roentgenographic and magnetic resonance imaging of anterior cruciate reconstruction using a patellar tendon graft—correlations with physical findings. Djian P, et al.
Knee Surg Sports Traumatol Arthrosc 1994;2(4):207–13

Diagnosis of an ACL disruption with KT–1000 arthrometer measurements. Rangger C, et al.
Knee Surg Sports Traumatol Arthrosc 1993;1(1):60–6

ABNORMALITIES

[Agenesis of the anterior cruciate ligament. Report of a case and review of the literature] Barbuti D, et al.
Radiol Med (Torino) 1995 Jul–Aug;90(1–2):134–6 (20 ref.) **(Ita)**

ANATOMY & HISTOLOGY

Extrasynovial spaces of the cruciate ligaments: anatomy, MR imaging, and diagnostic implications. Lee SH, et al.
AJR Am J Roentgenol 1996 Jun;166(6):1433–7

The menisco–femoral ligaments. Wan AC, et al.
Clin Anat 1995;8(5):323–6

Characterisation of the neurosensory elements of the feline cranial cruciate ligament. Koch B, et al. **J Anat** 1995 Oct; 187 (Pt 2):353–9

The fibre bundle anatomy of human cruciate ligaments. Mommersteeg TJ, et al. **J Anat** 1995 Oct;187 (Pt 2):461–71

Tibial attachment area of the anterior cruciate ligament in the extended knee position. Anatomy and cryosections in vitro complemented by magnetic resonance arthrography in vivo. Stäubli HU, et al.
Knee Surg Sports Traumatol Arthrosc 1994;2(3):138–46

BLOOD SUPPLY

In vivo monitoring of circulation in the intact anterior cruciate ligament using the laser Doppler flowmeter. Passler JM, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):76–9

CHEMISTRY

Primary immunolocalization of estrogen and progesterone target cells in the human anterior cruciate ligament. Liu SH, et al. **J Orthop Res** 1996 Jul;14(4):526–33

CYTOLOGY

Proliferative and matrix synthesis response of canine anterior cruciate ligament fibroblasts submitted to combined growth factors. DesRosiers EA, et al. **J Orthop Res** 1996 Mar; 14(2):200–8

Patellar tendon and anterior cruciate ligament have different mitogenic responses to platelet–derived growth factor and transforming growth factor beta. Spindler KP, et al.
J Orthop Res 1996 Jul;14(4):542–6

INJURIES

Cryotherapy after cruciate knee surgery. Skin, subcutaneous and articular temperatures in 8 patients. Dahlstedt L, et al. **Acta Orthop Scand** 1996 Jun;67(3):255–7

MR imaging of anterior cruciate ligament injury: independent value of primary and secondary signs. Brandser EA, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):121–6

Subtle fractures about the knee: innocuous–appearing yet indicative of significant internal derangement. Delzell PB, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):699–703

MR imaging of the anterior cruciate ligament: frequency of discordant findings on sagittal–oblique images and correlation with arthroscopic findings. Smith DK, et al.
AJR Am J Roentgenol 1996 Feb;166(2):411–3

Revision ACL surgery. Etiology, indications, techniques, and results. Johnson DL, et al. **Am J Knee Surg** 1995 Fall; 8(4):155–67 (106 ref.)

Simultaneous bilateral anterior cruciate ligament tears. Maywood RM, et al. **Am J Knee Surg** 1995 Fall;8(4):134–6

Open versus closed chain kinetic exercises after anterior cruciate ligament reconstruction. A prospective randomized study [see comments] Bynum EB, et al.
Am J Sports Med 1995 Jul–Aug;23(4):401–6. Comment in: Am J Sports Med 1996 Jan–Feb;24(1):125.

A method to help reduce the risk of serious knee sprains incurred in alpine skiing. Ettlinger CF, et al.
Am J Sports Med 1995 Sep–Oct;23(5):531–7

Partial tears of the anterior cruciate ligament. Are they clinically detectable? [letter; comment] Hardy JR.
Am J Sports Med 1995 Jul–Aug;23(4):516. Comment on: Am J Sports Med 1995 Jan–Feb;23(1):111–8.

Effects of an accelerated rehabilitation program after anterior cruciate ligament reconstruction with combined semitendinosus–gracilis autograft and a ligament augmentation device. MacDonald PB, et al.
Am J Sports Med 1995 Sep–Oct;23(5):588–92

Early versus late reconstruction for anterior cruciate ligament rupture. Results after five years of followup. Marcacci M, et al. **Am J Sports Med** 1995 Nov–Dec;23(6):690–3

Immunohistologic analysis of synovium in infrapatellar fat pad after anterior cruciate ligament injury. Murakami S, et al. **Am J Sports Med** 1995 Nov–Dec;23(6):763–8

The long–term biomechanical and viscoelastic performance of repairing anterior cruciate ligament after hemitransection injury in a goat model. Ng GY, et al.
Am J Sports Med 1996 Jan–Feb;24(1):109–17

The treatment of acute combined ruptures of the anterior cruciate and medial ligaments of the knee. Noyes FR, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):380–9

Open versus closed chain kinetic exercises after anterior cruciate ligament reconstruction. A prospective randomized study [letter; comment] Rennison M.
Am J Sports Med 1996 Jan–Feb;24(1):125. Comment on: Am J Sports Med 1995 Jul–Aug;23(4):401–6.

Timing of surgery in acute anterior cruciate ligament tears on the return of quadriceps muscle strength after reconstruction using an autogenous patellar tendon graft. Shelbourne KD, et al. **Am J Sports Med** 1995 Nov–Dec; 23(6):686–9

Ligament stability two to six years after anterior cruciate ligament reconstruction with autogenous patellar tendon graft and participation in accelerated rehabilitation program. Shelbourne KD, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):575–9

Graft site morbidity with autogenous semitendinosus and gracilis tendons. Yasuda K, et al. **Am J Sports Med** 1995 Nov–Dec;23(6):706–14

Some clinical aspects of reconstruction for chronic anterior cruciate ligament deficiency [see comments] Dandy DJ.
Ann R Coll Surg Engl 1995 Jul;77(4):290–8. Comment in: Ann R Coll Surg Engl 1995 Nov;77(6):465–6.

Anterior cruciate ligament suture in comparison with plasty. A 5–year follow–up study. Träger D, et al.
Arch Orthop Trauma Surg 1995;114(5):278–80

Hamstring spasm in anterior cruciate ligament injuries. Frank CB, et al. **Arthroscopy** 1995 Aug;11(4):444–8 (19 ref.)

Cranial cruciate ligament rupture in the dog—a retrospective study comparing surgical techniques. Moore KW, et al.
Aust Vet J 1995 Aug;72(8):281–5

Evaluation of a neural net approach for assessing the rehabilitation status of ACL injuries. Patterson PE.
Biomed Sci Instrum 1996;32:275–7

Accuracy of direct signs of tears of the anterior cruciate ligament. Falchook FS, et al. **Can Assoc Radiol J** 1996 Apr;47(2):114–20

Natural history of untreated anterior cruciate tears. Frank C. **Clin J Sport Med** 1996 Apr;6(2):138

Allograft versus autograft anterior cruciate ligament reconstruction: 3– to 5–year outcome. Harner CD, et al.
Clin Orthop 1996 Mar;(324):134–44

Biologic incorporation of allograft anterior cruciate ligament replacements. Jackson DW, et al. **Clin Orthop** 1996 Mar; (324):126–33 (26 ref.)

Anterior instability of the knee despite an intensive rehabilitation program. Seitz H, et al. **Clin Orthop** 1996 Jul;(328):159–64

MRI diagnosis of partial tears of the anterior cruciate ligament. Lawrance JA, et al. **Injury** 1996 Apr;27(3):153–5

Anterior cruciate ligament: injuries and treatment. Larson RV, et al. **Instr Course Lect** 1996;45:235–43 (47 ref.)

Management of combined injuries of the anterior cruciate and medial collateral ligaments. Shelbourne KD, et al.
Instr Course Lect 1996;45:275–80

Isokinetic muscle performance after anterior cruciate ligament surgery. Long–term results and outcome predicting factors after primary surgery and late–phase reconstruction. Natri A, et al. **Int J Sports Med** 1996 Apr; 17(3):223–8

Popliteal cysts and associated disorders of the knee. Critical review with MR imaging. Sansone V, et al. **Int Orthop** 1995;19(5):275–9 (20 ref.)

Evaluation of fibular head transposition, lateral fabellar suture, and conservative treatment of cranial cruciate ligament rupture in large dogs: a retrospective study. Chauvet AE, et al. **J Am Anim Hosp Assoc** 1996 May–Jun; 32(3):247–55

A new load application system for in vitro study of ligamentous injuries to the human knee joint. Bach JM, et al. **J Biomech Eng** 1995 Nov;117(4):373–82

A prospective, randomized study of three operations for acute rupture of the anterior cruciate ligament. Five–year follow–up of one hundred and thirty–one patients. Grøntvedt T, et al. **J Bone Joint Surg Am** 1996 Feb; 78(2):159–68

Combined injuries of the anterior cruciate and medial collateral ligaments of the knee. Effect of treatment on stability and function of the joint. Hillard–Sembell D, et al. **J Bone Joint Surg Am** 1996 Feb;78(2):169–76

Brace–free rehabilitation, with early return to activity, for knees reconstructed with a double–looped semitendinosus and gracilis graft. Howell SM, et al.
J Bone Joint Surg Am 1996 Jun;78(6):814–25

Reconstruction of the anterior cruciate ligament with human allograft. Comparison of early and later results. Noyes FR, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):524–37

Conservative treatment of complete ACL tears [letter; comment] Callaghan MJ. **J Bone Joint Surg Br** 1996 Jul; 78(4):680–1. Comment on: J Bone Joint Surg Br 1995 Nov;77(6):890–4.

Non–operative management of anterior cruciate ligament injuries in the general population. Casteleyn PP, et al.
J Bone Joint Surg Br 1996 May;78(3):446–51

The conservative treatment of complete tears of the anterior cruciate ligament in skeletally immature patients [see comments] Mizuta H, et al. **J Bone Joint Surg Br** 1995 Nov;77(6):890–4. Comment in: J Bone Joint Surg Br 1996 Jul;78(4):680–1. Comment in: J Bone Joint Surg Br 1996 Jul;78(4):681.

Conservative treatment of complete ACL tears [letter; comment] Stanitski CL. **J Bone Joint Surg Br** 1996 Jul; 78(4):681. Comment on: J Bone Joint Surg Br 1995 Nov;77(6):890–4.

MRI of anterior cruciate ligament healing. Ihara H, et al.
J Comput Assist Tomogr 1996 Mar–Apr;20(2):317–21

Knee extension and flexion: MR delineation of normal and torn anterior cruciate ligaments. Niitsu M, et al.
J Comput Assist Tomogr 1996 Mar–Apr;20(2):322–7

Comparison of bone contusion seen by MRI in partial and complete tears of the anterior cruciate ligament. Zeiss J, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):773–6

MRI of meniscus and cruciate ligament tears correlated with arthroscopy. Chen MC, et al. **J Formos Med Assoc** 1995 Oct;94(10):605–11

SPECT bone scintigraphy of anterior cruciate ligament injury. Cook GJ, et al. **J Nucl Med** 1996 Aug;37(8):1353–6

Effect of tibial attachment location on the healing of the anterior cruciate ligament freeze model. Bush–Joseph CA, et al. **J Orthop Res** 1996 Jul;14(4):534–41

Subfailure injury of the rabbit anterior cruciate ligament. Panjabi MM, et al. **J Orthop Res** 1996 Mar;14(2):216–22

Medial collateral ligament healing one year after a concurrent medial collateral ligament and anterior cruciate ligament injury: an interdisciplinary study in rabbits. Yamaji T, et al. **J Orthop Res** 1996 Mar;14(2):223–7

Video views [letter] Merrick C.
J Orthop Sports Phys Ther 1995 Jul;22(1):39–40

Results of surgical treatment of arthrofibrosis after ACL reconstruction. Aglietti P, et al.
Knee Surg Sports Traumatol Arthrosc 1995;3(2):83–8

Post–operative problems following anterior cruciate ligament reconstruction. Almekinders LC, et al.
Knee Surg Sports Traumatol Arthrosc 1995;3(2):78–82

Proceedings of the ESSKA Scientific Workshop on Reconstruction of the Anterior and Posterior Cruciate Ligaments. Amis AA, et al.

Knee Surg Sports Traumatol Arthrosc 1994;2(3):124–32

The tendon defect after anterior cruciate ligament reconstruction using the midthird patellar tendon--a problem for the patellofemoral joint? Breitfuss H, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):194–8

Synovial fluid cytokine concentrations as possible prognostic indicators in the ACL-deficient knee. Cameron ML, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(1):38–44

Problems in regaining full extension of the knee after anterior cruciate ligament reconstruction: does arthrofibrosis exist? [see comments] Dandy DJ, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):76–9. Comment in: Knee Surg Sports Traumatol Arthrosc 1994;2(4):259–60.

Historical overview of operations for anterior cruciate ligament rupture. Dandy DJ. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):256–61

Long-term results of the Leeds-Keio anterior cruciate ligament reconstruction. Denti M, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(2):75–7

Palmer's "golden week" revisited [editorial] Eriksson E. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):193

Recurrent acute hemarthrosis after anterior cruciate ligament reconstruction. Report of an unusual complication and a review of the literature. Friederich NF, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):215–8

Anterior cruciate ligament reconstruction using cryopreserved irradiated bone-ACL-bone-allograft transplants. Goertzen MJ, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(3):150–7

Mechanisms of anterior cruciate ligament ruptures in skiing. Järvinen M, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):224–8

Which factors influence the progression of degenerative osteoarthritis after ACL surgery? Küllmer K, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):80–4

A comparative study of single- and double-bundle ACL reconstructions in sheep. Radford WJ, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):94–9

Medium-term results of 173 ligamentoplasties of the anterior cruciate ligament using the MacIntosh technique reinforced by the Kennedy ligament augmentation device (LAD). Saragaglia D, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(2):68–74

Combination of cold and compression after knee surgery. A prospective randomized study. Schröder D, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(3):158–65

Experience with the Leeds-Keio artificial ligament for anterior cruciate ligament reconstruction. Schroven IT, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):214–8

Untreated acute anterior cruciate ligament tears of the knee: progression and the influence of associated injuries. Shirakura K, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(2):62–7

Five-year results of anterior cruciate ligament reconstruction with the Stryker Dacron high-strength ligament. Wredmark T, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):71–5

MR imaging of anterior cruciate ligament injuries. Vahey TN, et al. **Magn Reson Imaging Clin N Am** 1994 Aug; 2(3):365–80 (58 ref.)

Can MRI distinguish between acute partial and complete anterior cruciate ligament tear? Yamato M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 May; 56(6):385–9

Electromyography and biomechanics of a dynamic knee brace for anterior cruciate ligament deficiency. Acierno SP, et al. **Orthopedics** 1995 Nov;18(11):1101–7 (33 ref.)

Cyclops lesion. Olson PN, et al. **Orthopedics** 1995 Oct; 18(10):1041, 1044–5

Osteoarthritis of the knee after injury to the anterior cruciate ligament or meniscus: the influence of time and age. Roos H, et al. **Osteoarthritis Cartilage** 1995 Dec;3(4):261–7

Magnetic resonance imaging of knee injuries in children. King SJ, et al. **Pediatr Radiol** 1996;26(4):287–90

Influence of examiner experience and gender on interrater reliability of KT-1000 arthrometer measurements. Ballantyne BT, et al. **Phys Ther** 1995 Oct;75(10):898–906

Anterior cruciate ligament tear: prospective evaluation of diagnostic accuracy of middle- and high-field-strength MR imaging at 1.5 and 0.5 T [see comments] Vellet AD, et al. **Radiology** 1995 Dec;197(3):826–30. Comment in: Radiology 1996 Jul;200(1):284–5.

Contraction of knee flexors and extensors in skiing related to the backward fall mechanism of injury to the anterior cruciate ligament. Aune AK, et al. **Scand J Med Sci Sports** 1995 Jun;5(3):165–9

Accuracy of MRI patterns in evaluating anterior cruciate ligament tears. Barry KP, et al. **Skeletal Radiol** 1996 May; 25(4):365–70

Anterior cruciate ligament injuries in young athletes. Recommendations for treatment and rehabilitation. McCarroll JR, et al. **Sports Med** 1995 Aug;20(2):117–27 (32 ref.)

Anterior cruciate ligament repair in children. Prietto C. **West J Med** 1995 Dec;163(6):567–8

Risk factors for anterior cruciate ligament injury. Goris JE, et al. **Wis Med J** 1996 Jun;95(6):367–9

[Experimental capsulo-ligamentar lesions of the knee during passive hyperextension. Biomechanical aspects. A lesional evaluation and consequences] Bizot P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(3):211–20 (Eng. Abstr.) **(Fre)**

[Sequelae in the knee extensor system following graft removal for the "Mac in Jones" type procedure] Lerat JL, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(5):404–9 (Eng. Abstr.) **(Fre)**

[The "gold standard" in cruciate ligament replacement] Benedetto KP. **Chirurg** 1995 Nov;66(11):1061–70 (57 ref.) (Eng. Abstr.) **(Ger)**

[Cruciate ligament allograft transplant: a reliable alternative?] Lobenhoffer P, et al. **Chirurg** 1995 Nov;66(11):1071–8 (69 ref.) (Eng. Abstr.) **(Ger)**

[Sense and nonsense of cruciate ligament prostheses] Neumann K, et al. **Chirurg** 1995 Nov;66(11):1079–84 (32 ref.) (Eng. Abstr.) **(Ger)**

[Proximal reinsertion in alloplastic replacement of the anterior cruciate ligament. Experimental studies of a modified over the top technique] Paar O, et al. **Chirurg** 1995 Nov;66(11):1115–9 (Eng. Abstr.) **(Ger)**

[Possibilities and limits of conservative management of cruciate ligament injuries] Paar O, et al. **Chirurg** 1995 Nov; 66(11):1050–60 (48 ref.) (Eng. Abstr.) **(Ger)**

[Open and closed kinetic chain in rehabilitation after athletic injuries] Banzer W, et al. **Sportverletz Sportschaden** 1995 Sep;9(3):98–100 **(Ger)**

[Arthroscopic approaches to reconstruction of the cruciate ligament: refresher course] Kohn D. **Sportverletz Sportschaden** 1995 Dec;9(4):A31–42 (0 ref.) **(Ger)**

[Backward fall in Alpine skiing. Case study of the effect of the back spoiler of the ski shoe on muscle activity and kinematics] Senner V, et al. **Sportverletz Sportschaden** 1995 Dec;9(4):109–17 (Eng. Abstr.) **(Ger)**

[Intraoperative and postoperative insertion control of anterior cruciate ligament-plasty. A radiologic measuring method (quadrant method)] Bernard M, et al. **Unfallchirurg** 1996 May;99(5):332–40 (Eng. Abstr.) **(Ger)**

[The pivot-shift test in relation to hip position and lower leg rotation. A clinical analysis] Petermann J, et al. **Unfallchirurg** 1996 Mar;99(3):191–5 (Eng. Abstr.) **(Ger)**

[Clinical relevance of tunnel position and interference screw location after replacement-plasty of the anterior cruciate ligament with a patellar ligament transplant] Rupp S, et al. **Unfallchirurg** 1995 Dec;98(12):650–4 (Eng. Abstr.) **(Ger)**

[Recurrent hemarthrosis after cruciate ligament refixation by wire suture. A case report] Berwarth H, et al. **Unfallchirurgie** 1996 Apr;22(2):88–90 (Eng. Abstr.) **(Ger)**

[Progression of arthrosis after alloplasty--what factors play a role?] Küllmer K, et al. **Unfallchirurgie** 1996 Jun; 22(3):130–8 (36 ref.) (Eng. Abstr.) **(Ger)**

[Complications in 283 cruciate ligament replacement operations with free patellar tendon transplantation. Modification by surgical technique and surgery timing] Passler JM, et al. **Unfallchirurgie** 1995 Oct;21(5):240–6 (Eng. Abstr.) **(Ger)**

[Injuries of the medial collateral ligament and anterior cruciate ligament of the knee joint and Lemaire surgical functional treatment. Long-term outcome] Schmid F. **Unfallchirurgie** 1996 Jun;22(3):124–9 (Eng. Abstr.) **(Ger)**

[Electromyography studies of surgically managed knee ligament ruptures. A retrospective analysis of defined injury patterns] Wening JV, et al. **Unfallchirurgie** 1996 Feb; 22(1):20–9 (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of cruciate ligament injuries in childhood. Clinical results] Wening JV, et al. **Unfallchirurgie** 1995 Dec;21(6):285–91 (Eng. Abstr.) **(Ger)**

[Isokinetic muscle training with high motion speeds in the rehabilitation following surgical treatment of fresh anterior cruciate rupture] Hehl G, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul-Aug;133(4):306–10 (Eng. Abstr.) **(Ger)**

[Proprioceptive deficit following cruciate lesions--afferent disorder or compensatory mechanism?] Hopf T, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul-Aug;133(4):347–51 (Eng. Abstr.) **(Ger)**

[Biomechanical correlations of lesions associated with traumatic diseases of the anterior cruciate ligament. Analysis with magnetic resonance] De Maria M, et al. **Radiol Med (Torino)** 1996 Jun;91(6):693–9 (Eng. Abstr.) **(Ita)**

[Arthroscopic diagnostics and treatment for cysts of the anterior cruciate ligament] Pawlas R, et al. **Chir Narzadow Ruchu Ortop Pol** 1994;59(3):227–30 (Eng. Abstr.) **(Pol)**

[Magnetic resonance imaging and arthroscopy in meniscal and ligamentous injuries of the knee] Ziemiański A, et al. **Chir Narzadow Ruchu Ortop Pol** 1994;59(1):45–50 (Eng. Abstr.) **(Pol)**

INNERVATION

Nerve supply of anterior cruciate ligaments and of cryopreserved anterior cruciate ligament allografts: a new method for the differentiation of the nervous tissues. Fromm B, et al. **Knee Surg Sports Traumatol Arthrosc** 1994; 2(2):118–22

[Loss of innervation of the anterior cruciate ligament in idiopathic gonarthrosis] Sparmann M, et al. **Z Orthop Ihre Grenzgeb** 1996 May-Jun;134(3):233–7 (Eng. Abstr.) **(Ger)**

METABOLISM

Biochemical properties of collagen from ligaments and periarticular tendons of the human knee. Fujii K, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):229–33

PATHOLOGY

MR imaging of anterior cruciate ligament injury: independent value of primary and secondary signs. Brandser EA, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):121–6

MR imaging of the anterior cruciate ligament: frequency of discordant findings on sagittal-oblique images and correlation with arthroscopic findings. Smith DK, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):411–3

Intraligamentous ganglion cysts of the anterior cruciate ligament: MR findings with clinical and arthroscopic correlations. Do-Dai DD, et al. **J Comput Assist Tomogr** 1996 Jan-Feb;20(1):80–4

Cryopreserved anterior cruciate ligament allografts in a canine model. Kirkpatrick JS, et al. **J South Orthop Assoc** 1996 Spring;5(1):20–9

Lateral-compartment bone contusions in adolescents with intact anterior cruciate ligaments. Snearly WN, et al. **Radiology** 1996 Jan;198(1):205–8

PHYSIOLOGY

Functional ACL bracing. A survey of current opinion and practice. Decoster LC, et al. **Am J Orthop** 1995 Nov; 24(11):838–43

Critical analysis of knee ligament rating systems. Sgaglione NA, et al. **Am J Sports Med** 1995 Nov-Dec;23(6):660–7

Determination of the in situ forces and force distribution within the human anterior cruciate ligament. Livesay GA, et al. **Ann Biomed Eng** 1995 Jul-Aug;23(4):467–74

Induction of osteoarthritis in guinea pigs by transection of the anterior cruciate ligament: radiographic and histopathological changes. Jimenez PA, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S129–30

Experimental and mathematical methods for representing relative surface elongation of the ACL. Pioletti DP, et al. **J Biomech** 1995 Sep;28(9):1123–6

A sagittal plane model of the knee and cruciate ligaments with application of a sensitivity analysis. Beynnon B, et al. **J Biomech Eng** 1996 May;118(2):227–39

MRI of anterior cruciate ligament healing. Ihara H, et al. **J Comput Assist Tomogr** 1996 Mar-Apr;20(2):317–21

Mechanical properties of the anterior cruciate ligament chronically relaxed by elevation of the tibial insertion. Keira M, et al. **J Orthop Res** 1996 Jan;14(1):157–66

Responses of mechanoreceptor neurons in the cat knee joint capsule before and after anterior cruciate ligament transection. Khalsa PS, et al. **J Orthop Res** 1996 Jan; 14(1):114–22

Combined knee loading states that generate high anterior cruciate ligament forces. Markolf KL, et al. **J Orthop Res** 1995 Nov;13(6):930–5

1994 Nicola Cerulli Young Researchers Award. Downhill walking: a stressful task for the anterior cruciate ligament? A biomechanical study with clinical implications. Kuster M, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(1):2–7

The bone-ligament junction: a comparison between biological and artificial ACL reconstruction. Schiavone Panni A, et al. **Knee Surg Sports Traumatol Arthrosc** 1993; 1(1):9–12

[Responses of ligamentous fibroblasts to mechanical stimulation] Desrosiers EA, et al. **Ann Chir** 1995; 49(8):768–74 (Eng. Abstr.) **(Fre)**

[Proprioceptive deficit following cruciate lesions--afferent disorder or compensatory mechanism?] Hopf T, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul-Aug;133(4):347–51 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Instrumented analysis of the pivot shift phenomenon after reconstruction of the anterior cruciate ligament. Gillquist J, et al. **Int J Sports Med** 1995 Oct;16(7):484–8

Equal effectiveness of electrical and volitional strength training for quadriceps femoris muscles after anterior cruciate ligament surgery. Lieber RL, et al. **J Orthop Res** 1996 Jan;14(1):131–8

Subfailure injury of the rabbit anterior cruciate ligament. Panjabi MM, et al. **J Orthop Res** 1996 Mar;14(2):216–22

The weight-bearing knee after anterior cruciate ligament rupture. An in vitro biomechanical study. Bonnin M, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):245–51

[Evaluation of laxity, rigidity and compliance of the normal and pathological knee. Application to survival curves of ligamentoplasties] Bercovy M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(2):114–27 (Eng. Abstr.) **(Fre)**

[Biomechanical correlations of lesions associated with traumatic diseases of the anterior cruciate ligament. Analysis with magnetic resonance] De Maria M, et al. **Radiol Med (Torino)** 1996 Jun;91(6):693–9 (Eng. Abstr.) **(Ita)**

[Biomechanical study on the optimal running route for anterior cruciate ligament reconstruction] Tsuchiya A. **Nippon Seikeigeka Gakkai Zasshi** 1995 Nov;69(11):1113–25 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Radiographic evaluation of native anterior cruciate ligament attachments and graft placement for reconstruction. A cadaveric study. Lintner DM, et al. **Am J Sports Med** 1996 Jan-Feb;24(1):72-8

RADIONUCLIDE IMAGING

SPECT bone scintigraphy of anterior cruciate ligament injury. Cook GJ, et al. **J Nucl Med** 1996 Aug;37(8):1353-6

SURGERY

Effect of graft position on laxity after anterior cruciate ligament reconstruction. Stress radiography in 90 knees 2 to 5 years after autograft. Boden B, et al. **Acta Orthop Belg** 1996 Mar;62(1):2-7

Complications after anterior cruciate ligament reconstruction: radiographic and MR findings. Recht MP, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):705-10

Posterior cortical violation of the femoral tunnel during endoscopic anterior cruciate ligament reconstruction. Bush-Joseph CA, et al. **Am J Knee Surg** 1995 Fall; 8(4):130-3

Revision ACL surgery. Etiology, indications, techniques, and results. Johnson DL, et al. **Am J Knee Surg** 1995 Fall; 8(4):155-67 (106 ref.)

Strategies for attachment site locations and twist of the intraarticular anterior cruciate ligament graft. Draganich LF, et al. **Am J Sports Med** 1996 May-Jun;24(3):342-9

Comparison between magnetic resonance imaging findings and knee stability: measurements after anterior cruciate ligament repair with and without augmentation. A five- to seven-year followup of 52 patients. Grøntvedt T, et al. **Am J Sports Med** 1995 Nov-Dec;23(6):729-35

The relationship between tunnel placement and clinical results after anterior cruciate ligament reconstruction. Khalfayan EE, et al. **Am J Sports Med** 1996 May-Jun; 24(3):335-41

Radiation exposure during fluoroarthroscopically assisted anterior cruciate reconstruction. Larson BJ, et al. **Am J Sports Med** 1995 Jul-Aug;23(4):462-4

Radiographic evaluation of native anterior cruciate ligament attachments and graft placement for reconstruction. A cadaveric study. Lintner DM, et al. **Am J Sports Med** 1996 Jan-Feb;24(1):72-8

Effects of an accelerated rehabilitation program after anterior cruciate ligament reconstruction with combined semitendinosus-gracilis autograft and a ligament augmentation device. MacDonald PB, et al. **Am J Sports Med** 1995 Sep-Oct;23(5):588-92

Achieving full range of motion after anterior cruciate ligament reconstruction. Majors RA, et al. **Am J Sports Med** 1996 May-Jun;24(3):350-5

Early versus late reconstruction for anterior cruciate ligament rupture. Results after five years of followup. Marcacci M, et al. **Am J Sports Med** 1995 Nov-Dec;23(6):690-3

Anterior cruciate ligament graft tensioning in full extension. Nabors ED, et al. **Am J Sports Med** 1995 Jul-Aug; 23(4):488-92

The treatment of acute combined ruptures of the anterior cruciate and medial ligaments of the knee. Noyes FR, et al. **Am J Sports Med** 1995 Jul-Aug;23(4):380-9

Comparison of failure strength between metallic and absorbable interference screws. Influence of insertion torque, tunnel-bone block gap, bone mineral density, and interference. Pena F, et al. **Am J Sports Med** 1996 May-Jun; 24(3):329-34

Long-term followup of anterior cruciate ligament reconstruction using freeze-dried fascia lata allografts. Pritchard JC, et al. **Am J Sports Med** 1995 Sep-Oct; 23(5):593-6

Anterior cruciate ligament graft rotation. Reproduction of normal graft rotation. Samuelson TS, et al. **Am J Sports Med** 1996 Jan-Feb;24(1):67-71

Allograft reconstruction of the anterior and posterior cruciate ligaments after traumatic knee dislocation. Shapiro MS, et al. **Am J Sports Med** 1995 Sep-Oct;23(5):580-7

Ligament stability two to six years after anterior cruciate ligament reconstruction with autogenous patellar tendon graft and participation in accelerated rehabilitation program. Shelbourne KD, et al. **Am J Sports Med** 1995 Sep-Oct;23(5):575-9

Timing of surgery in acute anterior cruciate ligament tears on the return of quadriceps muscle strength after reconstruction using an autogenous patellar tendon graft. Shelbourne KD, et al. **Am J Sports Med** 1995 Nov-Dec; 23(6):686-9

The effect of drilling and soft tissue grafting across open growth plates. A histologic study. Stadelmaier DM, et al. **Am J Sports Med** 1995 Jul-Aug;23(4):431-5

Anterior cruciate ligament reconstruction as an outpatient procedure. Tierney GS, et al. **Am J Sports Med** 1995 Nov-Dec;23(6):755-6

Arthroscopic findings associated with roof impingement of an anterior cruciate ligament graft. Watanabe BM, et al. **Am J Sports Med** 1995 Sep-Oct;23(5):616-25

Graft site morbidity with autogenous semitendinosus and gracilis tendons. Yasuda K, et al. **Am J Sports Med** 1995 Nov-Dec;23(6):706-14

Some clinical aspects of reconstruction for chronic anterior cruciate ligament deficiency [letter; comment] Nutton RW. **Ann R Coll Surg Engl** 1995 Nov;77(6):465-6. Comment on: Ann R Coll Surg Engl 1995 Jul;77(4):290-8.

Anterior cruciate ligament suture in comparison with plasty. A 5-year follow-up study. Träger D, et al. **Arch Orthop Trauma Surg** 1995;114(5):278-80

Preliminary results of an absorbable interference screw. Barber FA, et al. **Arthroscopy** 1995 Oct;11(5):537-48

Autograft bone-patella tendon-bone plug comminution with loss of ligament fixation and stability. Berg EE. **Arthroscopy** 1996 Apr;12(2):232-5

Tibial bone plug resorption with extra-articular cyst: a rare complication of anterior cruciate ligament reconstruction. Brettler D, et al. **Arthroscopy** 1995 Aug;11(4):478-81

Femoral nerve block as an alternative to parenteral narcotics for pain control after anterior cruciate ligament reconstruction. Edkin BS, et al. **Arthroscopy** 1995 Aug; 11(4):404-9

Positioning of the tibial tunnel for anterior cruciate ligament reconstruction. Goble EM, et al. **Arthroscopy** 1995 Dec; 11(6):688-95

Accuracy of femoral tunnel placement and resulting graft force using one- or two-incision drill guides. A cadaver study on ten paired knees. Grøntvedt T, et al. **Arthroscopy** 1996 Apr;12(2):187-92

Tourniquet-induced tibial nerve palsy complicating anterior cruciate ligament reconstruction. Guanche CA. **Arthroscopy** 1995 Oct;11(5):620-2

Anterior cruciate ligament reconstruction: endoscopic versus two-incision technique [letter; comment] Jenny JY. **Arthroscopy** 1995 Aug;11(4):513-5. Comment on: Arthroscopy 1994 Oct;10(5):502-12.

Effect of cold therapy following anterior cruciate ligament reconstructive surgery [letter; comment] Lindenbaum BL. **Arthroscopy** 1995 Aug;11(4):515-6. Comment on: Arthroscopy 1994 Oct;10(5):530-3.

Patellar tendon graft harvesting using horizontal incisions for anterior cruciate ligament reconstruction. Mishra AK, et al. **Arthroscopy** 1995 Dec;11(6):749-52

Isometry testing for anterior cruciate ligament reconstruction revisited. Morgan CD, et al. **Arthroscopy** 1995 Dec; 11(6):647-59

Cost containment: a charge comparison of anterior cruciate ligament reconstruction. Novak PJ, et al. **Arthroscopy** 1996 Apr;12(2):160-4

Endoscopic anterior cruciate ligament reconstruction: modified technique and radiographic review. O'Donnell JB, et al. **Arthroscopy** 1995 Oct;11(5):577-84

Periarticular heterotopic ossification: a complication of arthroscopic anterior cruciate ligament reconstruction using a two-incision technique. Ogilvie-Harris DJ, et al. **Arthroscopy** 1995 Dec;11(6):676-9

Endoscopic anterior cruciate ligament reconstruction: a modified technique for graft passage [letter; comment] Passler JM. **Arthroscopy** 1995 Aug;11(4):511. Comment on: Arthroscopy 1994 Aug;10(4):475-7.

Arthroscopic arthrolysis for flexion contracture following intraarticular reconstruction of the anterior cruciate ligament. Reider B, et al. **Arthroscopy** 1996 Apr; 12(2):165-73

Comparison of pullout strength for seven- and nine-millimeter diameter interference screw size as used in anterior cruciate ligament reconstruction. Shapiro JD, et al. **Arthroscopy** 1995 Oct;11(5):596-9

Simple and safe arthroscopic placement and removal of cannulated screw and washer for fixation of tibial avulsion fracture of the anterior cruciate ligament. Veselko M, et al. **Arthroscopy** 1996 Apr;12(2):259-62

Subcutaneous pretibial cyst formation associated with anterior cruciate ligament allografts: a report of four cases and literature review. Victoroff BN, et al. **Arthroscopy** 1995 Aug;11(4):486-94 (25 ref.)

Cranial cruciate ligament rupture in the dog--a retrospective study comparing surgical techniques. Moore KW, et al. **Aust Vet J** 1995 Aug;72(8):281-5

Comparative animal study of three ligament prostheses for the replacement of the anterior cruciate and medial collateral ligament. Dürselen L, et al. **Biomaterials** 1996 May;17(10):977-82

Use of the "blue dot" in femoral bone plug of bone-patellar tendon-bone graft in anterior cruciate ligament reconstruction. Lonner JH, et al. **Bull Hosp Jt Dis** 1993-95; 53(4):45-7

Review of outcome instruments for evaluation of anterior cruciate ligament reconstruction. Vangsness CT Jr, et al. **Bull Hosp Jt Dis** 1995;54(1):25-9 (29 ref.)

Meniscus repair: cases and review of the literature. Pellacci F, et al. **Chir Organi Mov** 1995 Jul-Aug;80(3):309-21 (80 ref.)

Allograft versus autograft anterior cruciate ligament reconstruction: 3- to 5-year outcome. Harner CD, et al. **Clin Orthop** 1996 Mar;(324):134-44

Biologic incorporation of allograft anterior cruciate ligament replacements. Jackson DW, et al. **Clin Orthop** 1996 Mar; (324):126-33 (26 ref.)

A comparison of isokinetics and muscle strength ratios following intra-articular and extra-articular reconstructions of the anterior cruciate ligament. Oni OO, et al. **Injury** 1996 Apr;27(3):195-7

Biology of ACL reconstructions: what happens to the graft? Arnoczky SP. **Instr Course Lect** 1996;45:229-33 (52 ref.)

Anterior cruciate ligament: injuries and treatment. Larson RV, et al. **Instr Course Lect** 1996;45:235-43 (47 ref.)

Outpatient ACL surgery: a review of safety, practicality, and economy. Malek MM, et al. **Instr Course Lect** 1996; 45:281-6

Arthroscopically assisted ACL reconstruction using central third patellar tendon autograft with press fit femoral fixation. Malek MM, et al. **Instr Course Lect** 1996;45:287-95

Intraoperative complications of arthroscopically assisted ACL reconstruction using patellar tendon autograft. Malek MM, et al. **Instr Course Lect** 1996;45:297-302

Prevention of complications after autogenous bone-patellar tendon-bone ACL reconstruction. Shelbourne KD, et al. **Instr Course Lect** 1996;45:253-62 (30 ref.)

Rehabilitation after autogenous bone-patellar tendon-bone ACL reconstruction. Shelbourne KD, et al. **Instr Course Lect** 1996;45:263-73

ACL reconstruction using the autogenous bone-patellar tendon-bone graft: open two-incision technique. Shelbourne KD, et al. **Instr Course Lect** 1996;45:245-52

Instrumented analysis of the pivot shift phenomenon after reconstruction of the anterior cruciate ligament. Gillquist J, et al. **Int J Sports Med** 1995 Oct;16(7):484-8

Isokinetic muscle performance after anterior cruciate ligament surgery. Long-term results and outcome predicting factors after primary surgery and late-phase reconstruction. Natri A, et al. **Int J Sports Med** 1996 Apr; 17(3):223-8

Evaluation of anterior cruciate reconstruction reinforced by the Kennedy ligament augmentation device. An arthroscopic and histological study. Asahina S, et al. **Int Orthop** 1995;19(4):229-33

Remarks on the complications following ACL reconstruction using synthetic ligaments. Savarese A, et al. **Ital J Orthop Traumatol** 1993;19(1):79-86

Anterior cruciate-retaining total knee arthroplasty. Pritchett JW. **J Arthroplasty** 1996 Feb;11(2):194-7

Development of fibroblast-seeded ligament analogs for ACL reconstruction. Dunn MG, et al. **J Biomed Mater Res** 1995 Nov;29(11):1363-71

A prospective, randomized study of three operations for acute rupture of the anterior cruciate ligament. Five-year follow-up of one hundred and thirty-one patients. Grøntvedt T, et al. **J Bone Joint Surg Am** 1996 Feb; 78(2):159-68

Brace-free rehabilitation, with early return to activity, for knees reconstructed with a double-looped semitendinosus and gracilis graft. Howell SM, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):814-25

Reconstruction of the anterior cruciate ligament with human allograft. Comparison of early and later results. Noyes FR, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):524-37

Arthroscopically assisted reconstruction of the anterior cruciate ligament. A prospective randomized analysis of three techniques. O'Neill DB. **J Bone Joint Surg Am** 1996 Jun;78(6):803-13

Fixation strength of a biodegradable screw in anterior cruciate ligament reconstruction. Kousa P, et al. **J Bone Joint Surg Br** 1995 Nov;77(6):901-5

Nerve regeneration during patellar tendon autograft remodelling after anterior cruciate ligament reconstruction: an experimental and clinical study. Aune AK, et al. **J Orthop Res** 1996 Mar;14(2):193-9

Equal effectiveness of electrical and volitional strength training for quadriceps femoris muscles after anterior cruciate ligament surgery. Lieber RL, et al. **J Orthop Res** 1996 Jan;14(1):131-8

Intraoperative force-setting did not improve the mechanical properties of an augmented bone-tendon-bone anterior cruciate ligament graft in a goat model. Smith JJ, et al. **J Orthop Res** 1996 Mar;14(2):209-15

Distribution of cellular repopulation and collagen synthesis in a canine anterior cruciate ligament autograft. Spindler KP, et al. **J Orthop Res** 1996 May;14(3):384-9

Medial collateral ligament healing one year after a concurrent medial collateral ligament and anterior cruciate ligament injury: an interdisciplinary study in rabbits. Yamaji T, et al. **J Orthop Res** 1996 Mar;14(2):223-7

Post-operative problems following anterior cruciate ligament reconstruction. Almekinders LC, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(2):78-82

Proceedings of the ESSKA Scientific Workshop on Reconstruction of the Anterior and Posterior Cruciate Ligaments. Amis AA, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(3):124-32

Arthroscopic osteochondral autograft transplantation in anterior cruciate ligament reconstruction: a preliminary clinical study. Bobić V. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):262-4

The weight-bearing knee after anterior cruciate ligament rupture. An in vitro biomechanical study. Bonnin M, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):245-51

The tendon defect after anterior cruciate ligament reconstruction using the midthird patellar tendon--a problem for the patellofemoral joint? Breitfuss H, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):194-8

Fixation strength of interference screw fixation in bovine, young human, and elderly human cadaver knees: influence of insertion torque, tunnel-bone block gap, and interference. Brown GA, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):238-44

Historical overview of operations for anterior cruciate ligament rupture. Dandy DJ. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):256-61

Problems in regaining full extension of the knee after anterior

cruciate ligament reconstruction: does arthrofibrosis exist? [see comments] Dandy DJ, et al.
Knee Surg Sports Traumatol Arthrosc 1994;2(2):76–9. Comment in: Knee Surg Sports Traumatol Arthrosc 1994;2(4):259–60.

Long-term results of the Leeds-Keio anterior cruciate ligament reconstruction. Denti M, et al.
Knee Surg Sports Traumatol Arthrosc 1995;3(2):75–7

Graft isometricity in unitunnel anterior cruciate ligament reconstruction: analysis of influential factors using a radiographic model. Feller JA, et al.
Knee Surg Sports Traumatol Arthrosc 1993;1(3–4):136–42

Recurrent acute hemarthrosis after anterior cruciate ligament reconstruction. Report of an unusual complication and a review of the literature. Friederich NF, et al.
Knee Surg Sports Traumatol Arthrosc 1996;3(4):215–8

Late results following proximal reinsertion of isolated ruptured ACL ligaments. Genelin F, et al.
Knee Surg Sports Traumatol Arthrosc 1993;1(1):17–9

Problems in regaining full extension of the knee after anterior cruciate ligament reconstruction [letter; comment] Jenny JY. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):259–60. Comment on: Knee Surg Sports Traumatol Arthrosc 1994;2(2):76–9.

Donor-site morbidity after harvest of a bone-tendon-bone patellar tendon autograft. Kohn D, et al.
Knee Surg Sports Traumatol Arthrosc 1994;2(4):219–23

Which factors influence the progression of degenerative osteoarthritis after ACL surgery? Küllmer K, et al.
Knee Surg Sports Traumatol Arthrosc 1994;2(2):80–4

A comparative study of single- and double-bundle ACL reconstructions in sheep. Radford WJ, et al.
Knee Surg Sports Traumatol Arthrosc 1994;2(2):94–9

Medium-term results of 173 ligamentoplasties of the anterior cruciate ligament using the MacIntosh technique reinforced by the Kennedy ligament augmentation device (LAD). Saragaglia D, et al.
Knee Surg Sports Traumatol Arthrosc 1995;3(2):68–74

Bone-ligament interaction in patellar tendon reconstruction of the ACL. Schiavone Panni A, et al.
Knee Surg Sports Traumatol Arthrosc 1993;1(1):4–8

The bone-ligament junction: a comparison between biological and artificial ACL reconstruction. Schiavone Panni A, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(1):9–12

Anterior cruciate and medial collateral ligament injury. ACL reconstruction and functional treatment of the MCL. Schierl M, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):203–6

Combination of cold and compression after knee surgery. A prospective randomized study. Schröder D, et al.
Knee Surg Sports Traumatol Arthrosc 1994;2(3):158–65

Experience with the Leeds-Keio artificial ligament for anterior cruciate ligament reconstruction. Schroven IT, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):214–8

Morphometry of the semitendinosus and gracilis tendons with application to anterior cruciate ligament reconstruction. Tohyama H, et al.
Knee Surg Sports Traumatol Arthrosc 1993;1(3–4):143–7

Effect of pretension in reconstructions of the anterior cruciate ligament with a Dacron prosthesis. A retrospective study. van Heerwaarden RJ, et al.
Knee Surg Sports Traumatol Arthrosc 1996;3(4):202–8

The use of continuous passive motion after arthroscopically assisted anterior cruciate ligament reconstruction: help or hindrance? Witherow GE, et al.
Knee Surg Sports Traumatol Arthrosc 1993;1(2):68–70

Five-year results of anterior cruciate ligament reconstruction with the Stryker Dacron high-strength ligament. Wredmark T, et al.
Knee Surg Sports Traumatol Arthrosc 1993;1(2):71–5

Cyclops lesion. Olson PN, et al. **Orthopedics** 1995 Oct; 18(10):1041, 1044–5

Assessment of patellar height after autogenous patellar tendon anterior cruciate ligament reconstruction. Shelbourne KD, et al. **Orthopedics** 1995 Nov;18(11):1073–7

Experimental osteoarthritis in dogs: a comparison of the Pond-Nuki and medial arthrotomy methods. Visco DM, et al. **Osteoarthritis Cartilage** 1996 Mar;4(1):9–22

Vascularised patellar tendon graft in anterior cruciate ligament reconstruction. Latosiewicz R, et al.
Rocz Akad Med Bialymst 1994;39:18–24

Comparison of intra-articular and epidural morphine for analgesia following stifle arthrotomy in dogs. Day TK, et al. **Vet Surg** 1995 Nov-Dec;24(6):522–30

Popliteal tendon transposition for stabilization of the cranial cruciate ligament deficient stifle joint in dogs: an experimental study. Monnet E, et al. **Vet Surg** 1995 Nov-Dec;24(6):465–75

The use of autografts and synthetic carbon fibers in reconstruction of the anterior cruciate ligament--an experimental study on dogs. Lešić A, et al.
Vojnosanit Pregl 1994 Nov-Dec;51(6):479–87 **(Eng, Ser)**

Histopathological evaluation of the carbon fibers application for the substitution of the anterior cruciate ligament--an experimental study on dogs. Lešić A, et al.
Vojnosanit Pregl 1995 May-Jun;52(3):215–20 **(Eng, Ser)**

Anterior cruciate ligament repair in children. Prietto C.
West J Med 1995 Dec;163(6):567–8

[Results of sutures of the internal meniscus associated with reconstruction of the anterior cruciate ligament in chronic knee joint instability. Apropos of 42 cases, 30 of them controlled by arthrography] Lerat JL, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(6):514–26 (Eng. Abstr.) **(Fre)**

[Influence of the tibial slope on tibial translation and mobility of non-constrained total knee prosthesis] Migaud H, et al.
Rev Chir Orthop Reparatrice Appar Mot 1996;82(1):7–13 (Eng. Abstr.) **(Fre)**

[Macroscopic, histologic and ultrastructural study of 89 prostheses of anterior cruciate ligament excised because of prosthesis failure] Poddevin N, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(5):410–8 (Eng. Abstr.) **(Fre)**

[Biocompatibility of polyethylene terephthalate--PET--(Trevira strong)--an in vivo study of the sheep knee] Seitz H, et al. **Biomed Tech (Berl)** 1996 Jun;41(6):178–82 (Eng. Abstr.) **(Ger)**

[Biomechanical study on the optimal running route for anterior cruciate ligament reconstruction] Tsuchiya A.
Nippon Seikeigeka Gakkai Zasshi 1995 Nov;69(11):1113–25 (Eng. Abstr.) **(Jpn)**

TRANSPLANTATION

Cryopreserved anterior cruciate ligament allografts in a canine model. Kirkpatrick JS, et al.
J South Orthop Assoc 1996 Spring;5(1):20–9

Nerve supply of anterior cruciate ligaments and of cryopreserved anterior cruciate ligament allografts: a new method for the differentiation of the nervous tissues. Fromm B, et al. **Knee Surg Sports Traumatol Arthrosc** 1994; 2(2):118–22

Anterior cruciate ligament reconstruction using cryopreserved irradiated bone-ACL-bone-allograft transplants. Goertzen MJ, et al.
Knee Surg Sports Traumatol Arthrosc 1994;2(3):150–7

ANTERIOR EYE SEGMENT

Anterior nodular scleritis secondary to syphilis [letter] Casey R, et al. **Arch Ophthalmol** 1996 Aug;114(8):1015–6

Total anterior capsule closure after silicone intraocular lens implantation. Martínez Toldos JJ, et al.
J Cataract Refract Surg 1996 Mar;22(2):269–71

Anterior proliferative vitreoretinopathy in the silicone study. Silicone Study Report Number 10. Diddie KR, et al.
Ophthalmology 1996 Jul;103(7):1092–9

ABNORMALITIES

Severe microcornea with anterior segment malformation in a mother and her son. Russell-Eggitt I, et al.
Acta Ophthalmol Scand Suppl 1996;(219):27–9

Genetics of aniridia and anterior segment dysgenesis. Churchill A, et al. **Br J Ophthalmol** 1996 Jul;80(7):669–73 (53 ref.)

ANATOMY & HISTOLOGY

The use of Scheimpflug photography in the documentation of clinical states and in the biometry of the anterior eye segment. Olbert D. **Ophthalmic Res** 1995;27 Suppl 1:20–4

BLOOD SUPPLY

Microvasculature of the ocular anterior segment. Morrison JC, et al. **Microsc Res Tech** 1996 Apr 15;33(6):480–9 (18 ref.)

Preservation and observation of anterior ciliary vessels in rectus muscles during strabismus surgery. Mai G, et al.
Yen Ko Hsueh Pao 1995 Mar;11(1):44–7

ENZYMOLOGY

The appearance of active plasminogen activator of urokinase type (u-PA) in the rabbit anterior eye segment irradiated by UVB rays. A histochemical and biochemical study. Cejková J, et al. **Acta Histochem** 1995 Jul;97(3):257–62

IMMUNOLOGY

The HNK-1 carbohydrate epitope in the anterior segment of the eye. The inner connective tissue layer of the human ciliary body as a distinct element. Uusitalo M.
Acta Ophthalmol Scand 1995 Aug;73(4):363

INJURIES

Anterior segment trauma and air bags [letter] McDermott ML, et al. **Arch Ophthalmol** 1995 Dec;113(12):1567–8

INNERVATION

Irritation of the anterior segment of the eye by ultraviolet radiation: influence of nerve blockade and calcium antagonists. Gallar J, et al. **Curr Eye Res** 1995 Sep; 14(9):827–35

METABOLISM

Corneal injury alters eicosanoid formation in the rabbit anterior segment in vivo. Bazan HE.
Invest Ophthalmol Vis Sci 1987 Feb;28(2):314–9

Retroperfusion studies of the aqueous outflow system. Part 2: Studies in human eyes. Ethier CR, et al.
Invest Ophthalmol Vis Sci 1995 Nov;36(12):2466–75

Localization of alpha 2-adrenergic receptor subtypes in the anterior segment of the human eye with selective antibodies. Huang Y, et al. **Invest Ophthalmol Vis Sci** 1995 Dec;36(13):2729–39

Free radicals and aging of anterior segment tissues of the eye: a hypothesis. Green K. **Ophthalmic Res** 1995;27 Suppl 1:143–9 (41 ref.)

PATHOLOGY

Complex choristoma. Lucarelli MJ, et al.
Arch Ophthalmol 1996 Apr;114(4):498–9

Alterations in anterior segment dimensions in eyes with retinitis pigmentosa. Horneber M, et al.
Graefes Arch Clin Exp Ophthalmol 1996 Feb;234(2):71–8

Free radical tissue damages in the anterior segment of the eye in experimental autoimmune uveitis. Ishimoto S, et al.
Invest Ophthalmol Vis Sci 1996 Mar;37(4):630–6

Scheimpflug anterior segment photography assessment of wound healing after myopic excimer laser photorefractive keratectomy. Binder PS, et al. **J Cataract Refract Surg** 1996 Mar;22(2):205–12

PHYSIOLOGY

Regulation of outflow rate and resistance in the perfused anterior segment of the bovine eye. Wiederholt M, et al.
Exp Eye Res 1995 Aug;61(2):223–34

Outflow characteristics of isolated anterior segments of human eyes. Dijkstra BG, et al.
Invest Ophthalmol Vis Sci 1996 Sep;37(10):2015–21

RADIATION EFFECTS

The appearance of active plasminogen activator of urokinase type (u-PA) in the rabbit anterior eye segment irradiated by UVB rays. A histochemical and biochemical study. Cejková J, et al. **Acta Histochem** 1995 Jul;97(3):257–62

Irritation of the anterior segment of the eye by ultraviolet radiation: influence of nerve blockade and calcium antagonists. Gallar J, et al. **Curr Eye Res** 1995 Sep; 14(9):827–35

SURGERY

Trabeculectomy at the inferior limbus. Caronia RM, et al.
Arch Ophthalmol 1996 Apr;114(4):387–91

Use of the anterior chamber maintainer in anterior segment surgery. Chawla HB, et al. **J Cataract Refract Surg** 1996 Mar;22(2):172–7

Drop, then decide approach to topical anesthesia [see comments] Dinsmore SC. **J Cataract Refract Surg** 1995 Nov;21(6):666–71. Comment in: J Cataract Refract Surg 1996 Mar;22(2):156–8.

Miyake analysis of anterior vitrectomy techniques. Eller AW, et al. **J Cataract Refract Surg** 1996 Mar;22(2):213–7

Treatment of anterior vitreous before suturing and intraocular lens to the ciliary sulcus. Tsunoda K, et al.
J Cataract Refract Surg 1996 Mar;22(2):222–6

Complications of anterior segment laser procedures. Carr LW 3rd, et al. **Optom Clin** 1995;4(4):33–49 (50 ref.)

Lasers and liability. Classé JG. **Optom Clin** 1995;4(4):113–23 (19 ref.)

Pars plana implant and vitrectomy for treatment of neovascular glaucoma. Luttrull JK, et al. **Retina** 1995; 15(5):379–87

[ProVisc--a new viscoelastic material for surgery of the anterior segment. A multicenter clinical study] Diblík P, et al. **Cesk Slov Oftalmol** 1995 Apr;51(2):88–93 (Eng. Abstr.) **(Cze)**

ULTRASONOGRAPHY

Personal computer-based 3-dimensional ultrasound biomicroscopy of the anterior segment. Iezzi R, et al.
Arch Ophthalmol 1996 May;114(5):520–4

Anterior-segment ultrasound biomicroscopy in a patient with AIDS and bilateral angle-closure glaucoma secondary to uveal effusions [letter] Krzystolik MG, et al.
Arch Ophthalmol 1996 Jul;114(7):878–9

Practical application of ultrasound biomicroscopy. Pavlin CJ.
Can J Ophthalmol 1995 Jun;30(4):225–9 (44 ref.)

Comparison of the configuration of the human anterior chamber angle, as determined by the Spaeth gonioscopic grading system and ultrasound biomicroscopy. Spaeth GL, et al. **Trans Am Ophthalmol Soc** 1995;93:337–47; discussion 347–51

[Ultrasound biomicroscopy for evaluation of space-occupying lesions of the anterior eye segment. Initial results] Bergmann U, et al. **Ophthalmologe** 1995 Dec; 92(6):844–8 (Eng. Abstr.) **(Ger)**

[Ultrasonic imaging of the anterior segment of the eye] Krásnik V, et al. **Cesk Oftalmol** 1995 Sep;51(4):231–4 (Eng. Abstr.) **(Slo)**

ANTERIOR HORN CELLS

Acute anterior horn cell disease resembling poliomyelitis as a manifestation of respiratory syncytial virus infection [letter] Tejada J, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):106–7

DRUG EFFECTS

A comparison of the effects of selective metabotropic glutamate receptor agonists on synaptically evoked whole cell currents of rat spinal ventral horn neurones in vitro. Cao CQ, et al. **Br J Pharmacol** 1995 Aug;115(8):1469–74

METABOLISM

Synaptophysin expression in the anterior horn of Werdnig-Hoffmann disease. Ikemoto A, et al. **J Neurol Sci** 1996 Mar;136(1-2):94-100

Neurofilament phosphorylation is increased in ventral horn neurons of neonatal rat spinal cord exposed to cerebrospinal fluid from patients with amyotrophic lateral sclerosis. Rao MS, et al. **Neurodegeneration** 1995 Dec;4(4):397-401

PATHOLOGY

Synaptic loss in the proximal axon of anterior horn neurons in motor neuron disease. Sasaki S, et al. **Acta Neuropathol (Berl)** 1995;90(2):170-5

Anterior horn cell degeneration in polymyositis associated with human T lymphotropic virus Type-I in patients from Barbados. Corbin DO, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):625-8

Dissociated motor loss syndrome with cavities in the anterior horns. Asaka T, et al. **Intern Med** 1995 Oct;34(10):1027-9

ANTERIOR HYPOTHALAMIC AREA see **HYPOTHALAMIC AREA, ANTERIOR**

ANTERIOR HYPOTHALAMIC NUCLEUS see **HYPOTHALAMIC AREA, ANTERIOR**

ANTERIOR LONGITUDINAL LIGAMENT see **LONGITUDINAL LIGAMENTS**

ANTERIOR PERFORATED SUBSTANCE see **OLFACTORY PATHWAYS**

ANTERIOR TIBIAL MUSCLE see **MUSCLE, SKELETAL**

ANTERIOR TIBIAL SYNDROME see **ANTERIOR COMPARTMENT SYNDROME**

ANTHELMINTICS

ADMINISTRATION & DOSAGE

The duration of anthelmintic effects of moxidectin and ivermectin in grazing sheep. Rendell D, et al. **Aust Vet J** 1996 Jan;73(1):35

Treatment of canine sarcoptic mange using milbemycin oxime: a correction [letter] de Jaham C. **Can Vet J** 1995 Aug;36(8):467

Development of an injectable formulation of albendazole and in vivo evaluation of its efficacy against Echinococcus multilocularis metacestode. Rodrigues JM Jr, et al. **Int J Parasitol** 1995 Dec;25(12):1437-41

Inoperable liver echinococcosis treated by oral antiparasitic drugs. Shalev I, et al. **J Clin Gastroenterol** 1996 Apr; 22(3):246-7

Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine. Wen H, et al. **Parasitology** 1996 Aug;113 (Pt 2):111-21

Low level ivermectin coverage and the transmission of onchocerciasis. Chavasse DC, et al. **Trans R Soc Trop Med Hyg** 1995 Sep-Oct;89(5):534-7

Control of gastrointestinal parasitism in calves with albendazole delivered via an intraruminal controlled-release device. Bell SL, et al. **Vet Parasitol** 1996 Apr;62(3-4):275-90

Development of immunity to lungworm in vaccinated calves treated with an ivermectin sustained release bolus or an oxfendazole pulse release bolus at turnout. Grimshaw WT, et al. **Vet Parasitol** 1996 Mar;62(1-2):119-24

Treatment of sarcoptic mite infestation and mite hypersensitivity in pigs with injectable doramectin. Cargill C, et al. **Vet Rec** 1996 May 11;138(19):468-71

Persistent activity of ivermectin topical and moxidectin injection against Ostertagia ostertagi and Dictyocaulus viviparus in calves. Hong C, et al. **Vet Rec** 1995 Dec 16; 137(25):640-1

The persistence of the efficacy of injectable or oral moxidectin against Teladorsagia, Haemonchus and Trichostrongylus species in experimentally infected sheep. Kerboeuf D, et al. **Vet Rec** 1995 Oct 14;137(16):399-401

Larval nematode infection and diarrhoea in lambs [letter; comment] Taylor SM, et al. **Vet Rec** 1995 Oct 14; 137(16):412. Comment on: Vet Rec 1995 Sep 23;137(13):311-6.

Ivermectin-moxidectin side resistance by Ostertagia species isolated from goats and passaged to sheep. Watson TG, et al. **Vet Rec** 1996 May 11;138(19):472-3

Maladministration of anthelmintic boluses [letter] West HJ, et al. **Vet Rec** 1995 Jul 15;137(3):76

The effects of early-season treatments with doramectin on set-stocked calves naturally exposed to trichostrongyles. Satrija F, et al. **Vet Res Commun** 1996;20(1):31-9

ADVERSE EFFECTS

Albendazole-induced pseudomembranous colitis. Shah V, et al. **Am J Gastroenterol** 1996 Jul;91(7):1453-4 (11 ref.)

Closantel intoxication in a dog. McEntee K, et al. **Vet Hum Toxicol** 1995 Jun;37(3):234-6

[Differential diagnosis of delayed encephalopathy induced by anthelmintic imidazoles] Zheng R. **Chung Hua Nei Ko Tsa Chih** 1995 Jul;34(7):468-71 (Eng. Abstr.) **(Chi)**

ANALYSIS

Dietary intake estimates as a means to the harmonization of maximum residue levels for veterinary drugs. I. Concept. Fitzpatrick SC, et al. **J Vet Pharmacol Ther** 1995 Oct; 18(5):325-7

ANTAGONISTS & INHIBITORS

Ophiobolin M and analogues, noncompetitive inhibitors of ivermectin binding with nematocidal activity. Tsipouras A, et al. **Bioorg Med Chem** 1996 Apr;4(4):531-6

CHEMICAL SYNTHESIS

Anthelmintic activity of 6,7-diaryl-pteridines. Ochoa C, et al. **Arzneimittelforschung** 1996 Jun;46(6):643-8

The pharmacology of FMRFamide-related neuropeptides in nematodes: new opportunities for rational anthelmintic discovery? Geary TG, et al. **Int J Parasitol** 1995 Nov; 25(11):1273-80 (42 ref.)

[The search for new antiparasitic agents. 14. The synthesis, acute toxicity and anthelmintic activity of N-(3,5-dibromobenzo-2,1,3-thiadiazolyl-4)-2-[(4-chlorophenylsulfonyl)amino]-5-bromobenzamide] Mikhallitsyn FS, et al. **Med Parazitol (Mosk)** 1995 Apr-Jun; (2):30-2 **(Rus)**

CHEMISTRY

Microbial conversion of milbemycins: oxidation of milbemycin A4 and related compounds at the C-25 ethyl group by Circinella umbellata and Absidia cylindrospora. Nakagawa K, et al. **J Antibiot (Tokyo)** 1995 Aug; 48(8):831-7

p-Azidosalicyl-5-amino-6-phenoxybenzimidazole photolabels the N-terminal 63-103 amino acids of Haemonchus contortus beta-tubulin 1. Nare B, et al. **J Biol Chem** 1996 Apr 12;271(15):8575-81

Structure and activity of avermectins and milbemycins in animal health. Shoop WL, et al. **Vet Parasitol** 1995 Sep; 59(2):139-56 (54 ref.)

[The effect of the dispersity of tegalid on its bioavailability] Lopatina NB, et al. **Med Parazitol (Mosk)** 1996 Jan-Mar; (1):23-5 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Cysticercosis mimicking brain tumor: the role of albendazole as a diagnostic tool. Del Brutto OH, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):256-8

METABOLISM

Further novel milbemycin antibiotics from Streptomyces sp. E225. Fermentation, isolation and structure elucidation. Baker GH, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):272-80

Inhibition of [3H]CGP 39653 binding to NMDA receptors by a P2 antagonist, suramin. Balcar VJ, et al. **Neuroreport** 1995 Dec 29;7(1):69-72

Hymenolepis diminuta and H. microstoma: uptake of cyclosporin A and drug binding to parasite cyclophilins. Roberts HC, et al. **Parasitology** 1995 Dec;111 (Pt 5):591-7

Small intestinal sulphoxidation of albendazole. Villaverde C, et al. **Xenobiotica** 1995 May;25(5):433-41

[Effect of nitrogen-containing compounds on the biosynthesis of avermectins] Sergeev AV, et al. **Antibiot Khimioter** 1995 Jul;40(7):3-7 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

The effect of a short-term reduction in feed on the pharmacokinetics and efficacy of albendazole in sheep. Hennessy DR, et al. **Aust Vet J** 1995 Jan;72(1):29-30

Transplacental transport of netobimin metabolites in ewes. Cristofol C, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul-Sep;20(3):167-71

Bioavailability comparison between albendazole and albendazole sulphoxide in rats and man. Dominguez L, et al. **Farmaco** 1995 Oct;50(10):697-702

The pharmacokinetics of albendazole metabolites following administration of albendazole, albendazole sulfoxide and netobimin to one-month- and eight-month-old sheep. McKellar QA, et al. **Int J Parasitol** 1995 Oct; 25(10):1207-12

Influence of diet type on the kinetic disposition of fenbendazole in cattle and buffalo. Sanyal PK, et al. **Int J Parasitol** 1995 Oct;25(10):1201-5

Pharmacokinetics and bioequivalence of parenterally administered doramectin in cattle. Nowakowski MA, et al. **J Vet Pharmacol Ther** 1995 Aug;18(4):290-8

Plasma disposition kinetics of albendazole metabolites in pigs fed different diets. Alvarez LI, et al. **Res Vet Sci** 1996 Mar; 60(2):152-6

An ivermectin tablet for sheep: efficacy against gastro-intestinal nematodes and a bioavailability comparison with a liquid ivermectin formulation. Gogolewski RP, et al. **Vet Parasitol** 1995 Dec; 60(3-4):297-302

Controlled efficacy study of the bioequivalence of Strongid C and generic pyrantel tartrate in horses. Valdez RA, et al. **Vet Parasitol** 1995 Nov;60(1-2):83-102

Bioavailability of different benzimidazole volume-dose formulations in sheep. Benchaoui HA, et al. **Vet Rec** 1995 Aug 12;137(7):171-2

The effect of diethylene glycol monoethyl ether as a vehicle for topical delivery of ivermectin. Yazdanian M, et al. **Vet Res Commun** 1995;19(4):309-19

Nutritional condition affects the disposition kinetics of albendazole in cattle. Sánchez SF, et al. **Xenobiotica** 1996 Mar;26(3):307-19

[Esophageal closure and the efficacy of febantel against Muellerius capillaris in goats] Chartier C, et al. **Can Vet J** 1995 Nov;36(11):714-6 **(Fre)**

[The effect of the dispersity of tegalid on its bioavailability] Lopatina NB, et al. **Med Parazitol (Mosk)** 1996 Jan-Mar; (1):23-5 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Anthelmintic activity of 6,7-diaryl-pteridines. Ochoa C, et al. **Arzneimittelforschung** 1996 Jun;46(6):643-8

Structural requirements for the induction of cytochromes P450 by benzimidazole anthelmintic derivatives in cultured rabbit hepatocytes. Rey-Grobellet X, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):789-94

Effects of mebendazole, albendazole and praziquantel on alanine aminotransferase and aspartate aminotransferase of Echinococcus granulosus cyst wall harbored in mice. Xiao S, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):107-10

Ascaris suum: ultrastructural effect of in vitro albendazole therapy. Magambo JK. **East Afr Med J** 1996 Feb; 73(2):140-2

The effect of intraoperative mebendazole-albendazole applications on the hepatobiliary system. Erzurumlu K, et al. **Eur Surg Res** 1995;27(5):340-5

In vitro cultivation of the human microsporidium Vittaforma corneae: development and effect of albendazole. Silveira H, et al. **Folia Parasitol (Praha)** 1995;42(4):241-50

Neuropharmacological effects of ivermectin in mice. Kanwar RS, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):421-2

Effects of ionophore feeding and anthelmintic administration on age and weight at puberty in spring-born beef heifers. Purvis HT 2nd, et al. **J Anim Sci** 1996 Apr;74(4):736-44

Anthelmintic usage of extracts of Embelia schimperi from Tanzania. Bøgh HO, et al. **J Ethnopharmacol** 1996 Jan; 50(1):35-42

The effects of ivermectin on the hydatid cyst of Echinococcus granulosus after direct injection at laparotomy. Ochieng'-Mitula PJ, et al. **J Parasitol** 1996 Feb;82(1):155-7

Lack of effect of ivermectin on antipyrine and erythromycin disposition in calves. Bohlen DM, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):476-8

Kinetic disposition of triclabendazole in buffalo compared to cattle. Sanyal PK. **J Vet Pharmacol Ther** 1995 Oct; 18(5):370-4

Flow-cytometry analysis of sheep-nematode egg populations. Kerboeuf D, et al. **Parasitol Res** 1996; 82(4):358-63

Effect of root-tuber extract of Flemingia vestita, a leguminous plant, on Artyfechinostomum sufrartyfex and Fasciolopsis buski: a scanning electron microscopy study. Roy B, et al. **Parasitol Res** 1996;82(3):248-52

World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) second edition of guidelines for evaluating the efficacy of anthelmintics in ruminants (bovine, ovine, caprine). Wood IB, et al. **Vet Parasitol** 1995 Jun;58(3):181-213

Reduced fecundity and egg viability in the pasture tick (Ixodes ricinus) exposed to closantel. Bates PG, et al. **Vet Rec** 1995 Oct 21;137(17):437-8

Comparison of the persistent activity of ivermectin, abamectin, doramectin and moxidectin in cattle. Entrocasso C, et al. **Vet Rec** 1996 Jan 27;138(4):91-2

Persistence of the effect of a moxidectin pour-on against naturally acquired cattle nematodes. Eysker M, et al. **Vet Rec** 1995 Oct 28;137(18):457-60

[Resistance to anthelmintics in nematodes in sheep and goats] Praslička J, et al. **Vet Med (Praha)** 1995 Aug;40(8):257-60 (Eng. Abstr.) **(Cze)**

[Structural disorders in the tissues of nematodes of the suborder Ascaridata after exposure to anthelmintics] Bogoiavlenskiĭ IuK, et al. **Med Parazitol (Mosk)** 1995 Apr-Jun;(2):19-27 (30 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Influence of early season moxidectin treatments on acquisition of immunity to Ostertagia ostertagi in calves. Satrija F, et al. **Acta Vet Scand** 1995;36(3):383-6

Anthelmintic therapy and iron supplementation of pregnant women [letter; comment] Pawlowski ZS. **Am J Clin Nutr** 1995 Nov;62(5):1023-4. Comment on: Am J Clin Nutr 1994 Aug;60(2):286-92.

Effective, single-dose treatment or porcine cysticercosis with oxfendazole. Gonzales AE, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):391-4

Treatment of porcine cysticercosis with albendazole. Gonzalez AE, et al. **Am J Trop Med Hyg** 1995 Nov; 53(5):571-4

Strategic effects of early season treatments with Moxidectin on trichostrongylosis in young calves. Yang X, et al.

Appl Parasitol 1996 Jan;37(1):8–16

Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Carpio A, et al. **Arch Intern Med** 1995 Oct 9;155(18):1982–8

The therapeutic efficacy and prophylactic activity of doramectin against Dictyocaulus viviparus in cattle. Barton NJ, et al. **Aust Vet J** 1995 Sep;72(9):349–51

Resistance of Fasciola hepatica to triclabendazole. Overend DJ, et al. **Aust Vet J** 1995 Jul;72(7):275–6

The effect of ivermectin treatment of late pregnant dairy cows in south–west Victoria on subsequent milk production and reproductive performance [published erratum appears in Aust Vet J 1995 Sep;72(9):360] Walsh A, et al. **Aust Vet J** 1995 Jun;72(6):201–7

Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial. Kelly P, et al. **BMJ** 1996 May 11; 312(7040):1187–91

Onchocerciasis in Ecuador: evolution of chorioretinopathy after amocarzine treatment. Cooper PJ, et al. **Br J Ophthalmol** 1996 Apr;80(4):337–42

The efficacy of three anthelmintic drugs given in a single dose. Sorensen E, et al. **Ceylon Med J** 1996 Jun;41(2):42–5

Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with the human immunodeficiency virus: response to therapy with albendazole. Dore GJ, et al. **Clin Infect Dis** 1995 Jul;21(1):70–6

Management of Syphacia muris infestation in rat colonies [letter; comment] Taylor J, et al. **Dig Dis Sci** 1995 Sep; 40(9):1890–1. Comment on: Dig Dis Sci 1992 Jan;37(1):60–4.

A comparative clinical trial of albendazole versus metronidazole in children with giardiasis. Misra PK, et al. **Indian Pediatr** 1995 Jul;32(7):779–82

A comparative clinical trial of albendazole versus metronidazole in giardiasis. Misra PK, et al. **Indian Pediatr** 1995 Mar;32(3):291–4

Cerebral and subcutaneous cysticercosis treated with albendazole. Schmidt DK, et al. **Int J Dermatol** 1995 Aug; 34(8):574–9

Effect of ivermectin prophylaxis on antibody responses to Onchocerca volvulus recombinant antigens in experimentally infected chimpanzees. Chandrashekar R, et al. **Int J Parasitol** 1995 Aug;25(8):983–8

Evaluation of the efficacy of albendazole against the larvae of Taenia solium in experimentally infected pigs, and kinetics of the immune response. Kaur M, et al. **Int J Parasitol** 1995 Dec;25(12):1443–50

A model for nematodiasis in New Zealand lambs: the effect of drenching regime and grazing management on the development of anthelmintic resistance. Leathwick DM, et al. **Int J Parasitol** 1995 Dec;25(12):1479–90

The efficacy of ivermectin against nodular worms of pigs: the response to treatment using three different dose levels against Oesophagostomum dentatum and Oesophagostomum quadrispinulatum. Várady M, et al. **Int J Parasitol** 1996 Apr;26(4):369–74

Clinical efficacy of increased dosages of milbemycin oxime for treatment of generalized demodicosis in adult dogs. Miller WH Jr, et al. **J Am Vet Med Assoc** 1995 Dec 15; 207(12):1581–4

Anthelmintic profile of the cyclodepsipeptide PF1022A in in vitro and in vivo models [published erratum appears in J Antibiot (Tokyo) 1995 Nov;48(11):C–2] Conder GA, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):820–3

Failure of albendazole therapy in two common types of parenchymal neurocysticercosis. Garg RK, et al. **J Assoc Physicians India** 1995 Oct;43(10):706–7

Pulmonary hydatidosis medical and surgical management. Maniar DR, et al. **J Assoc Physicians India** 1996 Jan; 44(1):63–4

Effect of mebendazole and ivermectin in experimental hepatic capillariasis: parasitological, scanning electron microscopy and immunological studies. El Gebaly MW, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):261–72

Studies of human fasciolosis in Egypt: some serum lipid parameters before and after treatment. Osman MM, et al. **J Egypt Soc Parasitol** 1995 Dec;25(3):769–72

Anthelmintic activity of papaya latex against patent Heligmosomoides polygyrus infections in mice. Satrija F, et al. **J Ethnopharmacol** 1995 Nov 3;48(3):161–4

Effects of the anthelmintics clorsulon, rafoxanide, mebendazole and arprinocid on Echinostoma caproni in ICR mice. Maurer K, et al. **J Helminthol** 1995 Dec; 69(4):373–4

Intestinal microsporidiosis with Septata intestinalis in a patient with AIDS—response to albendazole. Franzen C, et al. **J Infect** 1995 Nov;31(3):237–9

Neurocysticercosis: optimal dose treatment with albendazole. Cruz I, et al. **J Neurol Sci** 1995 Nov;133(1–2):152–4

Vitamin A status of Indonesian children infected with Ascaris lumbricoides after dosing with vitamin A supplements and albendazole. Tanumihardjo SA, et al. **J Nutr** 1996 Feb; 126(2):451–7

Infectivity of Hymenolepis diminuta for the jird, Meriones unguiculatus, and utility of this model for anthelmintic studies. Johnson SS, et al. **J Parasitol** 1996 Jun;82(3):492–5

Evaluation of anthelmintic efficacy of doramectin against gastrointestinal nematodes by fecal examination in cattle in Japan. Saeki H, et al. **J Vet Med Sci** 1995 Dec; 57(6):1057–61

Natural infection by gastrointestinal and bronchopulmonary nematodes in mouflons (Ovis musimon) and their response to netobimin treatment. Meana A, et al. **J Wildl Dis** 1996 Jan;32(1):39–43

Antiparasitic drugs. Liu LX, et al. **N Engl J Med** 1996 May 2;334(18):1178–84 (100 ref.)

Albendazole in neurocysticercosis. Padma MV, et al. **Natl Med J India** 1995 Nov–Dec;8(6):255–8

Two cases of giardiasis unsuccessfully treated by albendazole [letter] Brasseur P, et al. **Parasite** 1995 Dec;2(4):422

Effect of removing Ascaris on the growth of Guatemalan schoolchildren. Watkins WE, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):871–6

Anthelmintic properties of alpha–sanshool from Zanthoxylum liebmannianum. Navarrete A, et al. **Planta Med** 1996 Jun;62(3):250–1

Development of resistance to anthelmintic drugs [letter] Markus MB. **S Afr Med J** 1996 Jun;86(6):698

The effects of deworming on indicators of school performance in Guatemala. Watkins WE, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr;90(2):156–61

Reinfection patterns of Oesophagostomum bifurcum after anthelmintic treatment. Krepel HP, et al. **Trop Geogr Med** 1995;47(4):160–3

The chemotherapy of onchocerciasis. XIX: The clinical and laboratory tolerance of high dose ivermectin. Awadzi K, et al. **Trop Med Parasitol** 1995 Jun;46(2):131–7

Effect of chemoprophylaxis on immunity to gastrointestinal nematodes in cattle. Vercruysse J, et al. **Verh K Acad Geneeskd Belg** 1996;58(1):51–60 (18 ref.)

Efficacy of six anthelmintics against luminal stages of Baylisascaris procyonis in naturally infected raccoons (Procyon lotor). Bauer C, et al. **Vet Parasitol** 1995 Nov; 60(1–2):155–9

The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: Brazil. Echevarria F, et al. **Vet Parasitol** 1996 Apr;62(3–4):199–206

The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: Argentina. Eddi C, et al. **Vet Parasitol** 1996 Apr;62(3–4):189–97

Residual effect of injectable moxidectin against lungworm and gastrointestinal nematodes in calves exposed to high pasture infectivity levels in the Netherlands. Eysker M, et al. **Vet Parasitol** 1996 Jan;61(1–2):61–71

The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: Paraguay. Maciel S, et al. **Vet Parasitol** 1996 Apr;62(3–4):207–12

Dose titration of moxidectin oral gel against migrating Strongylus vulgaris and Parascaris equorum larvae in pony foals. Monahan CM, et al. **Vet Parasitol** 1995 Nov; 60(1–2):103–10

Dose titration of moxidectin oral gel against gastrointestinal parasites of ponies. Monahan CM, et al. **Vet Parasitol** 1995 Oct;59(3–4):241–8

Evidence for multiple anthelmintic resistance in sheep and goats reared under the same management in coastal Kenya. Mwamachi DM, et al. **Vet Parasitol** 1995 Dec; 60(3–4):303–13

The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: general overview. Waller PJ, et al. **Vet Parasitol** 1996 Apr; 62(3–4):181–7 (20 ref.)

Multiple anthelmintic resistance in Haemonchus contortus on a sheep farm in India. Yadav CL, et al. **Vet Parasitol** 1995 Dec;60(3–4):355–60

Use of moxidectin in goats in New Zealand [letter; comment] Cobb RM, et al. **Vet Rec** 1995 Nov 4;137(19):496. Comment on: Vet Rec 1995 Apr 29;136(17):443–4.

Evaluation of doramectin in a programme for season–long control of parasitic gastroenteritis in calves. Fisher MA, et al. **Vet Rec** 1995 Sep 16;137(12):281–4

Efficacy of moxidectin pour–on against nematode infections in cattle. Hubert J, et al. **Vet Rec** 1995 Jun 24;136(25):632–4

Equine cyathostome infection: suppression of faecal egg output with moxidectin. Jacobs DE, et al. **Vet Rec** 1995 Nov 18;137(21):545

Anthelmintic resistance in goats in southern Thailand. Kochapakdee S, et al. **Vet Rec** 1995 Jul 29;137(5):124–5

Effect of doramectin on the performance of cattle exposed to gastrointestinal worms and lungworms in Ireland. Parr SL, et al. **Vet Rec** 1995 Dec 9;137(24):617–8

Efficacy of pyrantel embonate and praziquantel against the equine tapeworm Anoplocephaloides mamillana. Proudman CJ, et al. **Vet Rec** 1995 Jul 8;137(2):45–6

A putative role for larval nematode infection in diarrhoeas of lambs which did not respond to anthelmintic drenches [see comments] Suttle N, et al. **Vet Rec** 1995 Sep 23; 137(13):311–6. Comment in: Vet Rec 1995 Oct 14;137(16):412. Comment in: Vet Rec 1995 Nov 25;137(22):572.

Comparison of moxidectin with ivermectin and pyrantel embonate for reduction of faecal egg counts in horses. Taylor SM, et al. **Vet Rec** 1995 Nov 11;137(20):516–8

Multiple resistance to ivermectin and oxfendazole in Cooperia species of cattle in New Zealand. Vermunt JJ, et al. **Vet Rec** 1995 Jul 8;137(2):43–5

Anthelmintic resistance of nematodes in sheep flocks in South America [letter] Waller PJ, et al. **Vet Rec** 1995 Jun 17; 136(24):620

[Anthelmintics resistance in gastrointestinal nematodes in domestic animals] Geerts S. **Verh K Acad Geneeskd Belg** 1995;57(5):351–69; discussion 369–70 (45 ref.) (Eng. Abstr.) **(Dut)**

[Antiparasitic therapeutics: the present] Magnaval JF. **Med Trop (Mars)** 1995;55(3 Suppl):10–2 (15 ref.) **(Fre)**

[Kidney reactivity in helminthiases and after anthelmintic treatment] Grishina EA, et al. **Med Parazitol (Mosk)** 1995 Apr–Jun;(2):27–30 (15 ref.) (Eng. Abstr.) **(Rus)**

[Evaluation of chemotherapeutic agents against cichlidogyriasis in tilapia (Oreochromis hornorum) in Mexico] Flores–Crespo J, et al. **Rev Latinoam Microbiol** 1995 Apr–Jun;37(2):179–87 (Eng. Abstr.) **(Spa)**

[Fasciolinip–1: experimental fasciolicidal activity in sheep] Ibarra–Velarde F, et al. **Rev Latinoam Microbiol** 1995 Apr–Jun;37(2):171–8 (Eng. Abstr.) **(Spa)**

TOXICITY

Effect of ivermectin on survival and fecundity of Culex pipiens the vector of Wuchereria bancrofti in Egypt. Nasr NT, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):161–8

Bacterial mutagenic evaluation of Luxabendazole, a new broad spectrum anthelmintic, with the Salmonella typhimurium His– and the Escherichia coli Tryp– reversion tests. Ortiz AI, et al. **Mutagenesis** 1996 Jan;11(1):27–31

Fasciola hepatica: disruption of the vitelline cells in vitro by the sulphoxide metabolite of triclabendazole. Stitt AW, et al. **Parasitol Res** 1996;82(4):333–9

In vitro screening of Haemonchus contortus third stage larvae for ivermectin resistance. d'Assonville JA, et al. **Vet Parasitol** 1996 Jan;61(1–2):73–80

ANTHOCYANINS

ANALYSIS

Anthocyanins in grapes and grape products. Mazza G. **Crit Rev Food Sci Nutr** 1995 Jul;35(4):341–71 (167 ref.)

BIOSYNTHESIS

Effects of biological factors on cell growth and anthocyanin formation by suspended cultures of Perilla frutescens cells. Zhong J, et al. **Chin J Biotechnol** 1995;11(2):143–7

Mutations throughout an Arabidopsis blue–light photoreceptor impair blue–light–responsive anthocyanin accumulation and inhibition of hypocotyl elongation. Ahmad M, et al. **Plant J** 1995 Nov;8(5):653–8

The maize GapC4 promoter confers anaerobic reporter gene expression and shows homology to the maize anthocyanin regulatory locus C1. Köhler U, et al. **Plant Mol Biol** 1995 Dec;29(6):1293–8

CHEMISTRY

Bleaching of the red anthocyanin induced by superoxide radical. Yamasaki H, et al. **Arch Biochem Biophys** 1996 Aug 1;332(1):183–6

Chemiluminescence of anthocyanins in the presence of acetaldehyde and tert–butyl hydroperoxide. Yoshiki Y, et al. **J Biolumin Chemilumin** 1995 Nov–Dec;10(6):335–8

GENETICS

The reduced expression of endogenous duplications (REED) in the maize R gene family is mediated by DNA methylation. Ronchi A, et al. **EMBO J** 1995 Nov 1; 14(21):5318–28

PHARMACOLOGY

Effects of proanthocyanidin on normal and reinnervated rat muscle. Ambrogini P, et al. **Boll Soc Ital Biol Sper** 1995 Jul–Aug;71(7–8):227–34

Suppression of tumor cell growth by anthocyanins in vitro. Kamei H, et al. **Cancer Invest** 1995;13(6):590–4

Anthocyanidines as inhibitors of xanthine oxidase. Costantino L, et al. **Pharmazie** 1995 Aug;50(8):573–4

[Effect of catechins and proanthocyanidins on the initial stage of protein biosynthesis] Arpentin GN, et al. **Ukr Biokhim Zh** 1995 Jul–Aug;67(4):104–7 (Eng. Abstr.) **(Rus)**

ANTHRACENEDIONES see **ANTHRAQUINONES**

ANTHRACENES

Liquid chromatographic determination of okadaic acid and dinophysistoxin–1 in shellfish after derivatization with 9–chloromethylanthracene. Lawrence JF, et al. **J Chromatogr A** 1996 Jan 19;721(2):359–64

ADVERSE EFFECTS

Allergic contact dermatitis from anthrarobin. Keller–Melchior R, et al. **Contact Dermatitis** 1995 Nov; 33(5):361

[Drug–induced and masked drug parkinsonism (comment)] Giménez–Roldán S, et al. **Rev Neurol** 1996 May; 24(129):584–5. Comment on: Rev Neurol 1995 Sep–Oct;23(123):961–3. Comment on: Rev Neurol 1995 Sep–Oct;23(123):964–8. Comment on: Rev Neurol 1995 Sep–Oct;23(123):983–5. **(Spa)**

CHEMICAL SYNTHESIS

2–Anthracenonyl acetic acids as 5–lipoxygenase inhibitors. Prinz H, et al. **Arch Pharm (Weinheim)** 1996 May; 329(5):262–6

CHEMISTRY

Anthracene-1,8-dicarboxylic acid. Fitzgerald LJ, et al. **Acta Crystallogr C** 1996 Jul 15;52 (Pt 7):1838-41

Laser desorption/ionization time-of-flight mass spectrometry of nitrated polycyclic aromatic hydrocarbons. Dotter RN, et al. **Anal Chem** 1996 Jul 15; 68(14):2319-24

Control of the depth of molecules within membranes by polar groups: determination of the location of anthracene-labeled probes in model membranes by parallax analysis of nitroxide-labeled phospholipid induced fluorescence quenching. Asuncion-Punzalan E, et al. **Biochemistry** 1995 Sep 12;34(36):11460-6

METABOLISM

Regio- and stereospecific oxidation of 9,10-dihydroanthracene and 9,10-dihydrophenanthrene by naphthalene dioxygenase: structure and absolute stereochemistry of metabolites. Resnick SM, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3355-9

Oxidation of 9-alkylanthracenes by cytochrome P450 2B1, horseradish peroxidase, and iron tetraphenylporphine/iodosylbenzene systems: anaerobic and aerobic mechanisms. Anzenbacher P, et al. **Biochemistry** 1996 Feb 27;35(8):2512-20

Microsomal aldehyde oxygenase (MALDO): purification and characterization of a cytochrome P450 isozyme responsible for oxidation of 9-anthraldehyde to 9-anthracenecarboxylic acid in monkey liver. Matsunaga T, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):617-25

PHARMACOLOGY

Antiviral activities of anthraquinones, bianthrones and hypericin derivatives from lichens. Cohen PA, et al. **Experientia** 1996 Feb 15;52(2):180-3

Effect of peroxisomicine and related anthracenones on catalase activity. Moreno-Sepúlveda M, et al. **Planta Med** 1995 Aug;61(4):337-40

TOXICITY

4-Ipomeanol and 2-aminoanthracene cytotoxicity in C3H/10T1/2 cells expressing rabbit cytochrome P450 4B1. Smith PB, et al. **Biochem Pharmacol** 1995 Nov 9; 50(10):1567-75

The effects of calcium antagonists on anthrone skin tumor promotion and promoter-related effects in SENCAR mice. Battalora MS, et al. **Cancer Lett** 1995 Nov 27;98(1):19-25

Potent tumorigenicity of 7-chlorobenz[a]anthracene and 7-bromobenz[a]anthracene in the neonatal B6C3F (1) male mouse. Fu PP, et al. **Cancer Lett** 1996 Mar 19;101(1):37-42

Regression and progression characteristics of papillomas induced by chrysarobin in SENCAR mice. Battalora MS, et al. **Carcinogenesis** 1996 May;17(5):955-60

Aflatoxin B1, 2-aminoanthracene, and 7,12-dimethylbenz[a]anthracene-induced frameshift mutations in human APRT. Zhu Y, et al. **Environ Mol Mutagen** 1995;26(3):234-9

Aminoanthracene is a mechanism-based inactivator of CYP1A in channel catfish hepatic tissue. Watson DE, et al. **Toxicol Appl Pharmacol** 1995 Dec;135(2):208-15

ANTHRACOSILICOSIS

[Comparative characteristics of intrathoracic lymph node coniotuberculosis of occupational and non-occupational etiology] Palerin VF, et al. **Probl Tuberk** 1995;(6):27-9 (Eng. Abstr.) **(Rus)**

ANTHRACYCLINE ANTIBIOTICS see **ANTIBIOTICS, ANTHRACYCLINE**

ANTHRACYCLINES

ADVERSE EFFECTS

Bradycardia due to mitoxantrone exacerbated by previous anthracycline therapy [letter] Umemoto M, et al. **Am J Hematol** 1996 Aug;52(4):327-8

Anthracycline-induced cardiotoxicity. Shan K, et al. **Ann Intern Med** 1996 Jul 1;125(1):47-58 (146 ref.)

Cytoprotective agents for anthracyclines. Dorr RT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):23-34 (122 ref.)

[Early detection of cardiotoxicity of anthracyclines. Value of isotopic method] Massing JL, et al. **Arch Mal Coeur Vaiss** 1996 Jan;89(1):57-62 (Eng. Abstr.) **(Fre)**

[Early and late anthracycline-induced cardiotoxicity in childhood: non-invasive evaluation of contractility in 116 patients] Agnoletti G, et al. **G Ital Cardiol** 1995 Oct; 25(10):1295-305 (Eng. Abstr.) **(Ita)**

[High-resolution electrocardiography in monitoring myocardial damage after therapy with anthracyclines in children] Mladosievičová B, et al. **Bratisl Lek Listy** 1996 May;97(5):289-97 (Eng. Abstr.) **(Slo)**

METABOLISM

Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells. Praet M, et al. **Biochem Pharmacol** 1996 May 17;51(10):1341-8

New anthracycline metabolites produced by the aklavinone 11-hydroxylase gene in Streptomyces galilaeus ATCC 31133. Kim HS, et al. **J Antibiot (Tokyo)** 1996 Apr; 49(4):355-60

A gene cluster involved in nogalamycin biosynthesis from Streptomyces nogalater: sequence analysis and complementation of early-block mutations in the anthracycline pathway. Ylihonko K, et al. **Mol Gen Genet** 1996 May 23;251(2):113-20

PHARMACOLOGY

Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells. Praet M, et al. **Biochem Pharmacol** 1996 May 17;51(10):1341-8

Sensitivity of vincristine-sensitive K562 and vincristine-resistant K562-Lucena 1 cells to anthracyclines and reversal of multidrug resistance. Maia RC, et al. **Braz J Med Biol Res** 1996 Apr;29(4):467-72

Heterogeneity of anthracycline retention and response to efflux blockers in human tumors. Krishan A. **Cytometry** 1995 Sep 1;21(1):72-5

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer [see comments] Ravdin PM, et al. **J Clin Oncol** 1995 Dec;13(12):2879-85. Comment in: J Clin Oncol 1995 Dec;13(12):2865-7.

Taxoids: effective agents in anthracycline-resistant breast cancer. Ravdin PM. **Semin Oncol** 1995 Dec;22(6 Suppl 13):29-34 (34 ref.)

THERAPEUTIC USE

The role of anthracyclines in adjuvant chemotherapy of breast cancer: a critical appraisal. Mouridsen HT. **Recent Results Cancer Res** 1996;140:191-9 (33 ref.)

[Control of the myocardial pump function during cytostatic treatment with anthracycline] Hesse B, et al. **Ugeskr Laeger** 1996 Aug 12;158(33):4628-30 **(Dan)**

TOXICITY

Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Pouna P, et al. **Br J Pharmacol** 1996 Apr; 117(7):1593-9

Assessing anthracycline cardiotoxicity in the 1990s [editorial] Carrió I, et al. **Eur J Nucl Med** 1996 Apr;23(4):359-64

ANTHRALIN

ADVERSE EFFECTS

Ultrasound description and quantification of irritant reactions induced by dithranol at different concentrations. A comparison with visual assessment and colorimetric measurements. Schiavi ME, et al. **Contact Dermatitis** 1996 Apr;34(4):272-7

ANALOGS & DERIVATIVES

Novel 10-substituted antipsoriatic anthrones as inhibitors of epidermal 12-lipoxygenase and lipid peroxidation in membranes. Müller K, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2077-83

Antipsoriatic anthrones with modulated redox properties. 3. 10-thio-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of keratinocyte growth, 5-lipoxygenase, and the formation of 12(S)-HETE in mouse epidermis. Müller K, et al. **J Med Chem** 1996 Aug 2;39(16):3132-8

PHARMACOLOGY

Inactivation of mouse epidermal 12-lipoxygenase by anthralin--implications for the role of oxygen radicals. Müller K, et al. **Biochem Pharmacol** 1996 May 3; 51(9):1173-9

Effects of anthralin and hypericin on growth factor signalling and cell proliferation in vitro. Richter A, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2039-45

Effects of dithranol on neutrophil superoxide generation in patients with psoriasis. Kavanagh GM, et al. **Br J Dermatol** 1996 Feb;134(2):234-7

Anti-psoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes. Schmidt KN, et al. **J Immunol** 1996 Jun 1;156(11):4514-9

THERAPEUTIC USE

Tars and anthralins. Silverman A, et al. **Dermatol Clin** 1995 Oct;13(4):817-33 (137 ref.)

ANTHRANILATE PHOSPHORIBOSYLTRANSFERASE

GENETICS

Mutations in the trpD gene of Corynebacterium glutamicum confer 5-methyltryptophan resistance by encoding a feedback-resistant anthranilate phosphoribosyltransferase. O'Gara JP, et al. **Appl Environ Microbiol** 1995 Dec; 61(12):4477-9

ANTHRANILATE SYNTHASE

GENETICS

The tryptophan biosynthetic pathway of aphid endosymbionts (Buchnera): genetics and evolution of plasmid-associated anthranilate synthase (trpEG) within the aphididae. Rouhbakhsh D, et al. **J Mol Evol** 1996 Apr; 42(4):414-21

Anthranilate synthase from Ruta graveolens. Duplicated AS alpha genes encode tryptophan-sensitive and tryptophan-insensitive isoenzymes specific to amino acid and alkaloid biosynthesis. Bohlmann J, et al. **Plant Physiol** 1996 Jun;111(2):507-14

The Arabidopsis thaliana trp5 mutant has a feedback-resistant anthranilate synthase and elevated soluble tryptophan. Li J, et al. **Plant Physiol** 1996 Jan;110(1):51-9

ANTHRANILATE SYNTHETASE see **ANTHRANILATE SYNTHASE**

ANTHRANILIC ACIDS

Determination of phosphodiesterase activity in rat mast cells using the fluorescent cAMP analogue anthraniloyl cAMP. Alfonso A, et al. **Cell Signal** 1995 Jul;7(5):513-8

ADMINISTRATION & DOSAGE

[A long-term clinical analysis of the rheumatoid patients treated by a combination of GST and CCA] Minami M, et al. **Ryumachi** 1995 Oct;35(5):780-91 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Nephrogenic diabetes insipidus induced by lobenzarit disodium treatment in patients with rheumatoid arthritis. Sakane N, et al. **Intern Med** 1996 Feb;35(2):119-22 (17 ref.)

METABOLISM

5'-(p-fluorosulfonylbenzoyl)-2'(or 3')-(methylanthraniloyl)adenosine, fluorescent affinity labels for adenine nucleotide binding sites: interaction with the kinase active site of the receptor for epidermal growth factor. Scoggins RM, et al. **Biochemistry** 1996 Jul 16; 35(28):9197-203

Factors affecting the metabolism of cinnamyl anthranilate in the rat and mouse. Keyhanfar F, et al. **Food Chem Toxicol** 1996 Mar;34(3):241-9

X-ray crystal structure analysis of the catalytic domain of the oncogene product p21H-ras complexed with caged GTP and mant dGppNHp. Scheidig AJ, et al. **J Mol Biol** 1995 Oct 13;253(1):132-50

Modified nucleotides as probes for dynein. Omoto CK. **Methods Cell Biol** 1995;47:507-10

PHARMACOLOGY

Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Miyazawa K, et al. **Atherosclerosis** 1995 Dec;118(2):213-21

Inhibition of interferon-gamma and interleukin-2 production from lymphocytes stimulated with food antigens by an anti-allergic drug, Tranilast, in patients with food-sensitive atopic dermatitis. Kondo N, et al. **Biotherapy** 1994; 8(1):19-22

Tranilast inhibits the effects of platelet-derived growth factor on cell proliferation and induction of nitric oxide. Hishikawa K, et al. **Eur J Pharmacol** 1995 Nov 30; 291(3):435-8

Inhibition of human neutrophil function by tolfenamic acid involves inhibition of Ca2+ influx. Kankaanranta H, et al. **Eur J Pharmacol** 1995 Sep 15;291(1):17-25

Tranilast suppresses intimal hyperplasia after photochemically induced endothelial injury in the rat. Kikuchi S, et al. **Eur J Pharmacol** 1996 Jan 11; 295(2-3):221-7

Mechanism of protection of lobenzarit against paracetamol-induced toxicity in rat hepatocytes. Remirez D, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):301-8

Inhibitory effects of azelastine and tranilast on leukotriene B4 and leukotriene C4 generation by rat colonic mucosa. Shimizu T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):355-8

Inhibition of iodide transport in rat thyroid cells using N-substituted anthranilic acid derivatives. Fanelli A, et al. **Thyroid** 1995 Jun;5(3):223-30

Comparative pharmacodynamics of flunixin, ketoprofen and tolfenamic acid in calves. Landoni MF, et al. **Vet Rec** 1995 Oct 21;137(17):428-31

THERAPEUTIC USE

New treatment of idiopathic severe oligozoospermia with mast cell blocker: results of a single-blind study. Yamamoto M, et al. **Fertil Steril** 1995 Dec;64(6):1221-3

Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: the regulation of lymph node cell populations and cytokine production. Haynes DR, et al.

ANTHRANILIC ACIDS

Inflamm Res 1996 Apr;45(4):159–65

Solitary mastocytoma treated with tranilast. Katoh N, et al. **J Dermatol** 1996 May;23(5):335–9

Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. Fukuyama J, et al. **Jpn J Pharmacol** 1996 Apr;70(4):321–7

TOXICITY

Differential cytotoxicity of iron chelators on malaria–infected cells versus mammalian cells. Glickstein H, et al. **Blood** 1996 Jun 1;87(11):4871–8

ANTHRAQUINONES

ADVERSE EFFECTS

[Severe diarrhea with hypokalemia attributed to diacetylrhein (letter)] Blondon H, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):851–2 **(Fre)**

ANALYSIS

[High performance liquid chromatographic determination of sennoside A in maren pills] Zhang Q, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Jul;20(7):413–5, 448 (Eng. Abstr.) **(Chi)**

ANTAGONISTS & INHIBITORS

Induction of apoptosis in human cancer cell lines by the novel anthracenyl–amino acid topoisomerase I inhibitor NU/ICRF 505. Meikle I, et al. **Br J Cancer** 1996 Aug; 74(3):374–9

CHEMICAL SYNTHESIS

Synthesis and cytostatic activity of some sulfamido–anthraquinones. Teijeira M, et al. **Farmaco** 1996 Jun;51(6):447–50

Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity. Gatto B, et al. **J Med Chem** 1996 Aug 2; 39(16):3114–22

Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity. Kim JY, et al. **J Med Chem** 1996 Jul 5;39(14):2812–8

CHEMISTRY

Transformations of Penicillium islandicum and Penicillium frequentans that produce anthraquinone–related compounds. Huang KX, et al. **Curr Genet** 1995 Nov; 28(6):580–4

EI–1507–1 and –2, novel interleukin–1 beta converting enzyme inhibitors produced by Streptomyces sp. E–1507. Tsukuda E, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):333–9

The interaction of antitumor–active anthraquinones with biologically important redox couples: I. Spectrophotometric investigation of the interaction of carminic acid and mitoxantrone with the iron (II, III) and copper (I, II) redox couples. Tütem E, et al. **J Inorg Biochem** 1996 Feb;61(2):79–96

ISOLATION & PURIFICATION

Identification of two pigments and a hydroxystilbene antibiotic from Photorhabdus luminescens. Li J, et al. **Appl Environ Microbiol** 1995 Dec;61(12):4329–33

Inhibition on platelet activation by shikonin derivatives isolated from Arnebia euchroma. Ko FN, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):329–34

METABOLISM

Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505. Cummings J, et al. **Anticancer Drug Des** 1996 Jul;11(5):367–82

The direct reduction of cytochrome c by some anthraquinone antitumor compounds. Tarasiuk J, et al. **Anticancer Drug Des** 1996 Apr;11(3):183–92

stcS, a putative P–450 monooxygenase, is required for the conversion of versicolorin A to sterigmatocystin in Aspergillus nidulans. Keller NP, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3628–32

Involvement of an extracellular H2O2–dependent ligninolytic activity of the white rot fungus Pleurotus ostreatus in the decolorization of Remazol brilliant blue R. Vyas BR, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3919–27

Engineered biosynthesis of novel polyketides: regiospecific methylation of an unnatural substrate by the tcmO O–methyltransferase. Fu H, et al. **Biochemistry** 1996 May 28;35(21):6527–32

Structural characterization of the 1:1 adduct formed between the antitumor antibiotic hedamycin and the oligonucleotide duplex d(CACGTG)2 by 2D NMR spectroscopy. Pavlopoulos S, et al. **Biochemistry** 1996 Jul 23; 35(29):9314–24

Transformations of Penicillium islandicum and Penicillium frequentans that produce anthraquinone–related compounds. Huang KX, et al. **Curr Genet** 1995 Nov; 28(6):580–4

Isolation and characterization of the versicolorin B synthase gene from Aspergillus parasiticus. Expansion of the aflatoxin b1 biosynthetic gene cluster. Silva JC, et al. **J Biol Chem** 1996 Jun 7;271(23):13600–8

PHARMACOKINETICS

A comparison of methods for limited–sampling strategy design using data from a phase I trial of the anthrapyrazole DuP–941. Jodrell DI, et al. **Cancer Chemother Pharmacol** 1996;37(4):356–62

PHARMACOLOGY

Anti–human cytomegalovirus activity and toxicity of sulfonated anthraquinones and anthraquinone derivatives. Barnard DL, et al. **Antiviral Res** 1995 Dec;28(4):317–29

Comparison of aza–anthracenedione–induced DNA damage and cytotoxicity in experimental tumor cells. Hazlehurst LA, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1087–94

Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity. Faltynek CR, et al. **Biochemistry** 1995 Sep 26;34(38):12404–10

Hydroxyquinones are competitive non–peptide inhibitors of HIV–1 proteinase. Brinkworth RI, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):5–8

DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Hejmadi MV, et al. **Br J Cancer** 1996 Feb;73(4):499–505

Induction of apoptosis in human cancer cell lines by the novel anthracenyl–amino acid topoisomerase I inhibitor NU/ICRF 505. Meikle I, et al. **Br J Cancer** 1996 Aug; 74(3):374–9

Discrimination between UTP– and P2–purinoceptor–mediated depolarization of rat superior cervical ganglia by 4,4'–diisothiocyanatostilbene–2,2'–disulphonate (DIDS) and uniblue A. Connolly GP, et al. **Br J Pharmacol** 1995 Jun;115(3):427–32

The mRNA overexpression of inflammatory enzymes, phospholipase A2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1–hydroxyanthraquinone. Yoshimi N, et al. **Cancer Lett** 1995 Oct 20;97(1):75–82

Antiviral activities of anthraquinones, bianthrones and hypericin derivatives from lichens. Cohen PA, et al. **Experientia** 1996 Feb 15;52(2):180–3

Protein tyrosine kinase and protein kinase C inhibition by fungal anthraquinones related to emodin. Fredenhagen A, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1355–8

Phase II trial of docetaxel in advanced anthracycline–resistant or anthracenedione–resistant breast cancer [see comments] Ravdin PM, et al. **J Clin Oncol** 1995 Dec;13(12):2879–85. Comment in: J Clin Oncol 1995 Dec;13(12):2865–7.

Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria: structure–activity relationship. Huang SS, et al. **J Nat Prod** 1995 Sep;58(9):1365–71

Angelmicin B, a new inhibitor of oncogenic signal transduction, inhibits growth and induces myelomonocytic differentiation of human myeloid leukemia HL–60 cells. Yokoyama A, et al. **Leuk Res** 1996 Jun;20(6):491–7

Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl–amino acid topoisomerase II catalytic inhibitor NU/ICRF 500. Cummings J, et al. **Mutat Res** 1995 Aug;344(1–2):55–62

[Effects of emodin, sennosides and rheum polysaccharides on free calcium in isolated rat liver cells] Lin XZ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jul; 15(7):419–21 (Eng. Abstr.) **(Chi)**

[The mechanism of action of sennosides] Lemli J. **Ann Gastroenterol Hepatol (Paris)** 1996 Mar–Apr; 32(2):109–12 (29 ref.) (Eng. Abstr.) **(Fre)**

[Mechanism of action of sennosides] Lemli J. **Bull Acad Natl Med** 1995 Nov;179(8):1605–11 (29 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study. Sosman JA, et al. **Invest New Drugs** 1995;13(1):83–7

TOXICITY

Chemoprevention of the naturally occurring carcinogen 1–hydroxyanthraquinone–induced carcinogenesis by the nonsteroidal anti–inflammatory drug indomethacin in rats. Tanaka T, et al. **Cancer Detect Prev** 1995;19(5):418–25

Evaluation of the potential carcinogenic activity of Senna and Cascara glycosides for the rat colon. Mereto E, et al. **Cancer Lett** 1996 Mar 19;101(1):79–83

Clastogenicity of anthraquinones in V79 and in three derived cell lines expressing P450 enzymes. Simi S, et al. **Mutat Res** 1995 Aug;347(3–4):151–6

URINE

Identification of two regioisomeric monocarboxylic acid metabolites of losoxantrone (DuP 941; Biantrazole) excreted in human urine. Richards LE, et al. **Drug Metab Dispos** 1995 May;23(5):600–2

ANTHRAX

BLOOD

A case of anthrax septicaemia in a London teaching hospital. **Commun Dis Rep CDR Wkly** 1995 Sep 8;5(36):169

DIAGNOSIS

Nasal anthrax in Boston [letter; comment] Katz AM. **Pharos** 1995 Summer;58(3):48–9. Comment on: Pharos 1995 Spring;58(2):35–8.

A case of cutaneous anthrax. Natori N. **Tohoku J Exp Med** 1995 Jul;176(3):187–90 (7 ref.)

[Errors in the diagnosis of anthrax] Skolubovich GV, et al. **Klin Med (Mosk)** 1995;73(3):54–5 **(Rus)**

EPIDEMIOLOGY

Acting against anthrax. US military veterinarian helps Haitians and their animals [news] **J Am Vet Med Assoc** 1995 Dec 15;207(12):1533, 1535

Anthrax in southern India [letter] Lalitha MK, et al. **Lancet** 1996 Aug 24;348(9026):553–4

IMMUNOLOGY

[The cellular mechanisms of antianthrax immunity] Solokhin EV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep–Oct;(5):72–6 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

A labourer with a spot on his chest. Breathnach AS, et al. **Lancet** 1996 Jan 13;347(8994):96

[The characteristics of the interaction of Bacillus anthracis with host phagocytes in relation to the plasmid spectrum of the causative agent] Popov SF, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr; (2):13–6 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Pathology of experimental inhalation anthrax in the rhesus monkey. Fritz DL, et al. **Lab Invest** 1995 Nov; 73(5):691–702

PREVENTION & CONTROL

[Technology of the production of antigens against soil–borne diseases in Madagascar] Fatou–Rakotobe, et al. **Berl Munch Tierarztl Wochenschr** 1996 Jan;109(1):6–7 (Eng. Abstr.) **(Ger)**

TRANSMISSION

Fulminant meningitis due to Bacillus anthracis in 11–year–old girl during Ramadan [letter] Berthier M, et al. **Lancet** 1996 Mar 23;347(9004):828

VETERINARY

Investigation, control and epizootiology of anthrax in a geographically isolated, free–roaming bison population in northern Canada. Gates CC, et al. **Can J Vet Res** 1995 Oct;59(4):256–64

Rapid bioassay for detection of Bacillus anthracis in mice. Shlyakhov E, et al. **Zentralbl Veterinarmed [B]** 1995 Aug; 42(6):361–8

ANTHROPOIDEA see **HAPLORHINI**

ANTHROPOLOGY

see related

HOMINIDAE

Anthropology's Hoodoo Museum. Fox K. **Cult Med Psychiatry** 1995 Sep;19(3):409–21

Commentary. On "Human pharmacology of hoasca": a medical anthropology perspective. Dobkin de Rios M. **J Nerv Ment Dis** 1996 Feb;184(2):95–98

Overview of the symposium on molecular anthropology. Wayne State University, March 13–14, 1995. Doolittle RF. **Mol Phylogenet Evol** 1996 Feb;5(1):266–8

[AIDS and AIDS: anthropological analysis of opinions relative to the death of AIDS patients in a district of Bangui (June 1994)] Epelboin A, et al. **Bull Soc Pathol Exot** 1996; 89(1):48–56 (Eng. Abstr.) **(Fre)**

[Anthropology and cardiology in Niamey (Niger)] Jaffré Y, et al. **Bull Soc Pathol Exot** 1996;89(1):68–75 (24 ref.) (Eng. Abstr.) **(Fre)**

LEGISLATION & JURISPRUDENCE

Anthropologist cleared in patent dispute [news] Lehrman S. **Nature** 1996 Apr 4;380(6573):374

TRENDS

Toward a more comprehensive medical anthropology: the case of adolescent psychopathology. Fabrega H Jr, et al. **Med Anthropol Q** 1995 Dec;9(4):431–61 (185 ref.)

ANTHROPOLOGY, CULTURAL

see related

ETHNOPSYCHOLOGY

Combining methods to identify new measures of women's drinking problems. Part I: The ethnographic stage. Ames G, et al. **Addiction** 1996 Jun;91(6):829–44

Antiscience trends in the rise of the "alternative medicine" movement. Sampson W. **Ann N Y Acad Sci** 1996 Jun 24; 775:188–97 (34 ref.)

Ethnography: a stepwise approach for primary care researchers. Ventres WB, et al. **Fam Med** 1996 Jan; 28(1):52–6 (25 ref.)
Proximate determinants of fertility in eastern Uttar Pradesh. Bhattacharya B, et al. **Hum Biol** 1995 Dec;67(6):867–86
Genetic affinities of Sri Lankan populations. Kshatriya GK. **Hum Biol** 1995 Dec;67(6):843–66
Anthropology and germ theory. Macqueen S. **J Hosp Infect** 1995 Jun;30 Suppl:116–26
Insult, aggression, and the southern culture of honor: an "experimental ethnography". Cohen D, et al. **J Pers Soc Psychol** 1996 May;70(5):945–59
Recasting the "ethno" in "epidemiology". Agar M. **Med Anthropol** 1996 Mar;16(4):391–403
Bioethnography: fieldwork in the lands of medical ethics. Crigger BJ. **Med Anthropol Q** 1995 Sep;9(3):400–17
Organ transplantation as a transformative experience: anthropological insights into the restructuring of the self. Sharp LA. **Med Anthropol Q** 1995 Sep;9(3):357–89
Abortion from a crosscultural perspective: an introduction. Rylko-Bauer B. **Soc Sci Med** 1996 Feb;42(4):479–82
[Anthropological medicine: myth and reality] Bataille M. **Acta Psychiatr Belg** 1995 Mar-Apr;95(2):57–69 (Eng. Abstr.) **(Fre)**
[Experiences from terminal care. Anthropological principles in human practice] Helle-Feldmann A. **Z Gerontol Geriatr** 1995 Jul-Aug;28(4):260–3 (Eng. Abstr.) **(Ger)**
[The significance of latent anthropology for psychotherapeutic treatment] Dührssen A. **Z Psychosom Med Psychoanal** 1995;41(3):279–83 **(Ger)**

HISTORY

[Academic eulogy of Professor Charles Mertens de Wilmars, titulary member] Hoet JJ. **Bull Mem Acad R Med Belg** 1995;150(7–9):304–12 **(Fre)**

ANTHROPOLOGY, FORENSIC see **FORENSIC ANTHROPOLOGY**

ANTHROPOLOGY, PHYSICAL

see related
ANTHROPOMETRY
BIOMETRY
GENETICS, MEDICAL

[Cranial morphology of modern kyongsangnam-do Koreans] Takenaka M. **Kaibogaku Zasshi** 1995 Oct;70(5):419–21 (12 ref.) **(Jpn)**

HISTORY

P.C. Mahalanobis and the symposium on frontiers of anthropology. Reddy BM, et al. **Hum Biol** 1995 Dec; 67(6):819–25

METHODS

Stereolithography: potential applications in anthropological studies. Hjalgrim H, et al. **Am J Phys Anthropol** 1995 Jul; 97(3):329–33
Allelic ladder characterization of the short tandem repeat polymorphism in intron 6 of the lipoprotein lipase gene and its application in an Austrian Caucasian population study. Glock B, et al. **J Forensic Sci** 1996 Jul;41(4):579–81
Validation of multiplex polymorphic STR amplification sets developed for personal identification applications. Micka KA, et al. **J Forensic Sci** 1996 Jul;41(4):582–90

STANDARDS

Anthropology and race [letter; comment] Marks J. **Nature** 1995 Oct 19;377(6550):570. Comment on: Nature 1995 Sep 21;377(6546):183–4.

ANTHROPOMETRY

Maternal smoking and body composition of the newborn. Zarén B, et al. **Acta Paediatr** 1996 Feb;85(2):213–9
Impact of hemodialysis on dual X-ray absorptiometry, bioelectrical impedance measurements, and anthropometry. Abrahamsen B, et al. **Am J Clin Nutr** 1996 Jan;63(1):80–6
Comparison of five body-composition methods in peritoneal dialysis patients. Stall SH, et al. **Am J Clin Nutr** 1996 Aug; 64(2):125–30
Sex-specific associations of magnetic resonance imaging-derived intra-abdominal and subcutaneous fat areas with conventional anthropometric indices. The Atherosclerosis Risk in Communities Study. Schreiner PJ, et al. **Am J Epidemiol** 1996 Aug 15;144(4):335–45
Informative morphogenetic and phenogenetic variants in children with cleft lip/cleft palate. Pelz L, et al. **Am J Med Genet** 1996 May 3;63(1):305–9
Anthropometry in adolescent girls in Kingston, Jamaica. Walker SP, et al. **Ann Hum Biol** 1996 Jan-Feb;23(1):23–9
Somatotypes of 14 to 19 years old urban boys and girls from Bilbao (Basque Country). Rebato E, et al. **Anthropol Anz** 1996 Jun;54(2):135–47
Ratio of waist circumference to height is strong predictor of intra-abdominal fat [letter] Ashwell M, et al. **BMJ** 1996 Aug 31;313(7056):559–60
The validity of predicted body composition in Chinese adults from anthropometry and bioelectrical impedance in comparison with densitometry. Wang J, et al. **Br J Nutr** 1996 Aug;76(2):175–82
The New Zealand rugby injury and performance project. IV. Anthropometric and physical performance comparisons between positional categories of senior A rugby players. Quarrie KL, et al. **Br J Sports Med** 1996 Mar;30(1):53–6
Maternal anthropometry and pregnancy outcomes. A WHO Collaborative Study. **Bull World Health Organ** 1995;73 Suppl:1–98
Anthropometric measures and metabolic rate in association with risk of breast cancer (United States). Freni SC, et al. **Cancer Causes Control** 1996 May;7(3):358–65
Anthropometric measurements and body proportions among Chinese children. Cheng JC, et al. **Clin Orthop** 1996 Feb; (323):22–30
Body measurements, bone mass, and fractures. Does the East differ from the West? Ho SC. **Clin Orthop** 1996 Feb; (323):75–80
External facial dimensions and minimum nasal cross-sectional area. Tomkinson A, et al. **Clin Otolaryngol** 1995 Dec; 20(6):557–60
Physical and laboratory measurements in the PEPI Trial Postmenopausal Estrogen/Progestin Interventions. Wood PD, et al. **Control Clin Trials** 1995 Aug;16(4 Suppl):36S–53S
Physical development in Estonian children with type 1 diabetes. Tillmann V, et al. **Diabet Med** 1996 Jan; 13(1):97–101
Anthropometric measurement in children aged 0–6 years in a Nigerian village. Oyedeji GA, et al. **East Afr Med J** 1995 Aug;72(8):523–6
School screening for scoliosis: the value of quantitative measurement. Pruijs JE, et al. **Eur Spine J** 1995;4(4):226–30
Superimposition and reconstruction in forensic facial identification: a survey. Aulsebrook WA, et al. **Forensic Sci Int** 1995 Oct 30;75(2–3):101–20 (230 ref.)
Are anthropometric changes in healthy adults caused by modifications in dietary habits or by aging? Ruiz-Torres A, et al. **Gerontology** 1995;41(5):243–51
Measurement of facial growth in the human fetus. Denis D, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Dec; 233(12):756–65
Role of anthropometric indexes and blood pressure as determinants of left ventricular mass and geometry in adolescents. The Rio de Janeiro Study. Brandão AA, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1190–4
Nutrient intake amongst adolescent girls belonging to poor socioeconomic group of rural area of Rajasthan. Chaturvedi S, et al. **Indian Pediatr** 1996 Mar;33(3):197–201
Anthropometric indices, cord length and placental weight in newborns. Jaya DS, et al. **Indian Pediatr** 1995 Nov; 32(11):1183–8
Nutritional status of children: validity of mid-upper arm circumference for screening undernutrition. Kumar R, et al. **Indian Pediatr** 1996 Mar;33(3):189–96
Use of anthropometric measurements in assessing risk for coronary heart disease: a useful tool in worksite health screening? Oshaug A, et al. **Int Arch Occup Environ Health** 1995;67(6):359–66
Fetal transverse cerebellar diameter/abdominal circumference ratio in assessing fetal size. Haller H, et al. **Int J Gynaecol Obstet** 1995 Aug;50(2):159–63
Dietary intake and anthropometric status of 7 to 9 year old children in economically disadvantaged communities in Ontario [see comments] Evers SE, et al. **J Am Coll Nutr** 1995 Dec;14(6):595–603. Comment in: J Am Coll Nutr 1995 Dec;14(6):561–2.
Simple anthropometric indices associated with ischemic heart disease. Kahn HS, et al. **J Clin Epidemiol** 1996 Sep; 49(9):1017–24
Circumferential measurement of thoracic wall using a standard respiratory belt. Rauvala E, et al. **J Digit Imaging** 1996 May;9(2):78–80
Body composition and its relationship with physical activity and anthropometric factors in Chinese adults. Chong CK, et al. **J Formos Med Assoc** 1995 Aug;94(8):481–6
Comparison of clinical judgment and anthropometric parameters for evaluating nutritional status in patients with alcoholic liver disease [letter] Naveau S, et al. **J Hepatol** 1995 Aug;23(2):234–5
Critical anthropometry for menarche. Gonzales GF, et al. **J Pediatr Adolesc Gynecol** 1996 Aug;9(3):139–43
A multivariate analysis of kinanthropometric profiles of elite female orienteers. Creagh U, et al. **J Sports Med Phys Fitness** 1995 Mar;35(1):59–66
Changes in the anthropometric status of rural African under-fives during a decade of primary health care. den Besten L, et al. **J Trop Med Hyg** 1995 Dec;98(6):361–6
Use of arm circumference (AC) measurement and maternal reporting of illness [letter] Ball TM, et al. **J Trop Pediatr** 1995 Aug;41(4):250–2
Head and chest circumferences as predictors of low birth weight in Indian babies. Verma SS, et al. **J Trop Pediatr** 1996 Jun;42(3):146–50
Using middle upper arm circumference to assess severe adult malnutrition during famine. Collins S. **JAMA** 1996 Aug 7;276(5):391–5
The waist-to-hip ratio as an index of central obesity [letter; comment] Kahn HS. **JAMA** 1996 Apr 17;275(15):1160. Comment on: JAMA 1995 Dec 27;274(24):1939–41.
Biochemical and anthropometric characterization of morbid obesity in a large Utah pedigree. Hunt SC, et al. **Obes Res** 1995 Sep;3 Suppl 2:165S–172S
Quantitation and localization of regional body fat distribution--a comparison between magnetic resonance imaging and somatometry. Sharma RC, et al. **Obes Res** 1996 Mar;4(2):167–78
Morphologic and anthropometric characteristics of high level Dutch korfball players. Godinho M, et al. **Percept Mot Skills** 1996 Feb;82(1):35–42
Application of a new method for anthropometric analysis of the nose. Mishima K, et al. **Plast Reconstr Surg** 1996 Sep;98(4):637–44
Anthropometric, vitamin A, iron and immunisation coverage status in children aged 6–71 months in South Africa, 1994. South African Vitamin A Consultative Group (SAVACG). **S Afr Med J** 1996 Apr;86(4):354–7
Simple anthropometric measurements--relation to body fat mass, visceral adipose tissue and risk factors of atherogenesis. Kunešová M, et al. **Sb Lek** 1995;96(3):257–67
Medical and anthropological study of a world and Olympic champion, long-distance runner, 35 years after the end his racing career. Novotný V, et al. **Sb Lek** 1994;95(2):139–55
Reference charts of foetal biometry in Asians. Lai FM, et al. **Singapore Med J** 1995 Dec;36(6):628–36
Multicenter German reference data base for peripheral quantitative computer tomography. Schneider P, et al. **Technol Health Care** 1995 Oct;3(2):69–73
Nutrition-related hair signs in Zairian preschool children and associations with anthropometry. van den Biggelaar I, et al. **Trop Geogr Med** 1995;47(6):248–51
Ultrasonographic organometry: liver and spleen dimensions among children in Zimbabwe. Friis H, et al. **Trop Med Int Health** 1996 Apr;1(2):183–90
Prospective study on fetal weight estimation using limb circumferences obtained by three-dimensional ultrasound. Favre R, et al. **Ultrasound Obstet Gynecol** 1995 Aug; 6(2):140–4
Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. **World Health Organ Tech Rep Ser** 1995;854:1–452
[Body proportions of Danish children. Curves for sitting height ratio, subischial length and arm span] Hertel NT, et al. **Ugeskr Laeger** 1995 Dec 4;157(49):6876–81 (Eng. Abstr.) **(Dan)**
[Body height, body mass and head circumference in children from birth to 3 years of age] Scheffler C. **Anthropol Anz** 1996 Jun;54(2):149–56 (Eng. Abstr.) **(Ger)**
[Development of selected physical measurements with reference to body height (relative measurements) in children from birth to the 3 years of age] Scheffler C. **Anthropol Anz** 1996 Jun;54(2):157–62 (Eng. Abstr.) **(Ger)**
[The heterosis effect in newborn infants] Schmidt HD, et al. **Anthropol Anz** 1996 Jun;54(2):125–34 (Eng. Abstr.) **(Ger)**
[Short term assessment of anthropometric indices and metabolic parameters in obese subjects treated with acarbose] Coli P, et al. **Minerva Med** 1996 Apr;87(4):161–70 (Eng. Abstr.) **(Ita)**
[Association between magnesium, calcium, phosphorous, copper and zinc in plasma and erythrocytes of umbilical cord blood and biometric parameters of newborns] Bażowska G, et al. **Ginekol Pol** 1995 Apr;66(4):205–10 (Eng. Abstr.) **(Pol)**

HISTORY

P.C. Mahalanobis and the symposium on frontiers of anthropology. Reddy BM, et al. **Hum Biol** 1995 Dec; 67(6):819–25

INSTRUMENTATION

A portable knemometer: a technique for assessment of short-term growth. Davies HA, et al. **Ann Hum Biol** 1996 Mar-Apr;23(2):149–57
Infant length measurements [letter; comment] Davies DP. **Arch Dis Child** 1996 Feb;74(2):184. Comment on: Arch Dis Child 1995 Jun;72(6):520–1.
A new approach to computer-aided comparison of skull and photograph. Bajnóczky I, et al. **Int J Legal Med** 1995; 108(3):157–61
Measurement of small tissue volumes using Holden's apparatus. Mason JD, et al. **J Laryngol Otol** 1995 Dec; 109(12):1181–3
The lennie test for measuring scapular position in healthy young adult females: a reliability and validity study. Sobush DC, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):39–50
Diagnosis of an ACL disruption with KT-1000 arthrometer measurements. Rangger C, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(1):60–6
Assessment of truncal edema following breast cancer treatment using modified Harpenden skinfold calipers. Roberts CC, et al. **Lymphology** 1995 Jun;28(2):78–88
Mikro-knemometry: an accurate technique of growth measurement in rats. Hermanussen M, et al. **Physiol Behav** 1995 Aug;58(2):347–52
Preoperative liposuction fat estimation [letter] Viggiano DA. **Plast Reconstr Surg** 1996 Jun;97(7):1515
[Determination of back shape in median sagittal plane using an inclination sensory] Haid C, et al. **Biomed Tech (Berl)** 1996 Jun;41(6):183–6 (Eng. Abstr.) **(Ger)**

ANTHROPOMETRY

METHODS

Predicting body composition by densitometry from simple anthropometric measurements. Lean ME, et al. **Am J Clin Nutr** 1996 Jan;63(1):4–14

Photoanthropometric study of craniofacial traits of individuals with Prader–Willi syndrome. Butler MG, et al. **Am J Med Genet** 1995 Jul 31;58(1):38–45

Postcranial estimates of body weight in Proconsul, with a note on a distal tibia of P. major from Napak, Uganda. Rafferty KL, et al. **Am J Phys Anthropol** 1995 Aug; 97(4):391–402

Knemometry in childhood: a study to compare the precision of two different techniques. Ahmed SF, et al. **Ann Hum Biol** 1995 May–Jun;22(3):247–52

Prediction of body composition in elderly men over 75 years of age. Fuller NJ, et al. **Ann Hum Biol** 1996 Mar–Apr; 23(2):127–47 (64 ref.)

Complex statistical characterization of women's body measurements. Kaarma H. **Anthropol Anz** 1995 Sep; 53(3):239–44

Ratio of waist circumference to height may be better indicator of need for weight management [letter] [see comments] Ashwell M, et al. **BMJ** 1996 Feb 10; 312(7027):377. Comment in: BMJ 1996 May 11;312(7040):1227–8.

Waist circumference remains useful predictor of coronary heart disease [letter; comment] Han TS, et al. **BMJ** 1996 May 11;312(7040):1227–8. Comment on: BMJ 1996 Feb 10;312(7027):377.

Evaluation of the laser scanner as a surface measuring tool and its accuracy compared with direct facial anthropometric measurements. Aung SC, et al. **Br J Plast Surg** 1995 Dec;48(8):551–8

The use of arch index to characterize arch height: a digital image processing approach. Chu WC, et al. **IEEE Trans Biomed Eng** 1995 Nov;42(11):1088–93

Weight–for–height indices of adiposity: relationships with height in childhood and early adult life. Freeman JV, et al. **Int J Epidemiol** 1995 Oct;24(5):970–6

Anthropometric tips [letter] Bassey EJ. **Int J Obes Relat Metab Disord** 1996 Apr;20(4):376

Reliability of near–infrared interactance body fat assessment relative to standard anthropometric techniques. Schreiner PJ, et al. **J Clin Epidemiol** 1995 Nov;48(11):1361–7

Characteristics in addition to size of the contralateral hand predict hand volume but are not clinically useful. Vasiliauskas R, et al. **J Hand Ther** 1995 Oct–Dec; 8(4):258–63

Comparison of leg length inequality measurement methods as estimators of the femur head height difference on standing X–ray. Rhodes DW, et al. **J Manipulative Physiol Ther** 1995 Sep;18(7):448–52

The validity of the prone leg check as an estimate of standing leg length inequality measured by X–ray. Rhodes DW, et al. **J Manipulative Physiol Ther** 1995 Jul–Aug;18(6):343–6

Can we measure growth? Voss LD. **J Med Screen** 1995; 2(3):164–7

Spherical assessment of the hip on standard AP radiographs: a simple method for the measurement of the contact area between acetabulum and femoral head and of acetabular orientation. Hefti F. **J Pediatr Orthop** 1995 Nov–Dec; 15(6):797–805

Limb circumference measurement for recording edema volume in patients with filarial lymphedema. Pani SP, et al. **Lymphology** 1995 Jun;28(2):57–63

Is it possible to derive a reliable estimate of human visceral and subcutaneous abdominal adipose tissue from simple anthropometric measurements? Bonora E, et al. **Metabolism** 1995 Dec;44(12):1617–25

Measurement of fat–free mass in infants. de Bruin NC, et al. **Pediatr Res** 1995 Sep;38(3):411–7

Intertester reliability of a modified version of McKenzie's lateral shift assessments obtained on patients with low back pain. Donahue MS, et al. **Phys Ther** 1996 Jul;76(7):706–16; discussion 717–26

Internal architecture of the thoracic pedicle. An anatomic study. Kothe R, et al. **Spine** 1996 Feb 1;21(3):264–70

[Sex difference of the facial profile: segments and angles, bony and cutaneous. A study using the discriminant function] Baillet R, et al. **Bull Assoc Anat (Nancy)** 1995 Sep;79(246):13–6 (Eng. Abstr.) **(Fre)**

[Comparative value of transverse abdominal diameter and fetal abdominal perimeter. 3844 biometric examinations] Grangé G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(8):843–9 (Eng. Abstr.) **(Fre)**

[Intraoperative assessment of leg length in alloplastic hip joint replacement] Küsswetter W, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep–Oct;133(5):453–5 (Eng. Abstr.) **(Ger)**

[The role and significance of sagittal abdominal diameter in the determination of adipose tissue distribution] Stokić E, et al. **Med Pregl** 1996;49(5–6):217–20 (Eng. Abstr.) **(Scr)**

ANTI–D–IMMUNOGLOBULIN see **RHO(D) IMMUNE GLOBULIN**

ANTI–INFLAMMATORY AGENTS, NON–STEROIDAL

PHARMACOLOGY

Inhibition of tumour necrosis factor–alpha (TNF–alpha) release from mast cells by the anti–inflammatory drugs, sodium cromoglycate and nedocromil sodium. Bissonnette EY, et al. **Clin Exp Immunol** 1995 Oct;102(1):78–84

Cytoprotective effects of CI–959 in the rat gastric mucosa: modulation of leukocyte adhesion. Low J, et al. **Gastroenterology** 1995 Oct;109(4):1224–33

ANTI–INFLAMMATORY AGENTS, STEROIDAL

ADMINISTRATION & DOSAGE

The effect of topical fluticasone propionate on intranasal histamine challenge in subjects with perennial allergic rhinitis. Birchall MA, et al. **Clin Otolaryngol** 1995 Jun; 20(3):204–10

PHARMACOLOGY

The effect of topical fluticasone propionate on intranasal histamine challenge in subjects with perennial allergic rhinitis. Birchall MA, et al. **Clin Otolaryngol** 1995 Jun; 20(3):204–10

ANTIADRENERGIC AGENTS see **ADRENERGIC ANTAGONISTS**

ANTIAGGREGANTS, PLATELET see **PLATELET AGGREGATION INHIBITORS**

ANTI–ALLERGIC AGENTS

see related
HISTAMINE H1 ANTAGONISTS

ADMINISTRATION & DOSAGE

The efficacy and tolerability of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis. Boner A, et al. **Allergy** 1995 Jun;50(6):498–505

Once daily fluticasone propionate aqueous nasal spray controls symptoms of most patients with seasonal allergic rhinitis. Pedersen B, et al. **Allergy** 1995 Oct;50(10):794–9

Dose–response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Pratt CM, et al. **Am Heart J** 1996 Mar;131(3):472–80

Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis. Jordana G, et al. **J Allergy Clin Immunol** 1996 Feb; 97(2):588–95

Evaluation of oral anti–allergic drugs in Japan [letter] Hayashi K, et al. **Lancet** 1996 Feb 17;347(8999):477

[Nedocromil sodium nasal spray in the treatment of seasonal allergic rhinitis] Pacor ML, et al. **Recenti Prog Med** 1996 May;87(5):213–4 (Eng. Abstr.) **(Ita)**

[Nedocromil sodium as a topical treatment of allergic conjunctivitis due to grasses] Pacor ML, et al. **Recenti Prog Med** 1996 May;87(5):215–7 (Eng. Abstr.) **(Ita)**

[Comparative assessment of astemizole–pseudoephedrine and loratadine–pseudoephedrine in children with allergic rhinitis] Paz Martinez D, et al. **Rev Alerg Mex** 1995 Nov–Dec;42(6):105–9 (Eng. Abstr.) **(Spa)**

[Important notice: normal dosage of Teldanex is halved (letter)] Wihl JA. **Lakartidningen** 1996 Jan 3;93(1–2):16–7 **(Swe)**

ADVERSE EFFECTS

Allergy injections at home? [letter] Michels MI. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):380

Probable terfenadine–fluoxetine–associated cardiac toxicity [letter] Marchiando RJ, et al. **Ann Pharmacother** 1995 Sep; 29(9):937–8

Lack of hypothalamic–pituitary–adrenal axis suppression with once–daily or twice–daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis. Brannan MD, et al. **Clin Ther** 1995 Jul–Aug;17(4):637–47

A case of iatrogenic growth retardation induced by a corticosteroid–containing anti–allergic drug. Nishikawa M, et al. **Horm Metab Res** 1995 Aug;27(8):376–8

CHEMICAL SYNTHESIS

Synthesis and antiplatelet, antiinflammatory and antiallergic activities of 2,3–disubstituted 1,4–naphthoquinones. Lien JC, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun;44(6):1181–7

CHEMISTRY

(2E,4E)–N–(4–(1H–indol–3–yl)piperidin–1–yl)alkyl–5–(substituted phenyl)–2,4–pentadienamides as antiallergic agents with antihistaminic and anti slow–reacting substance (SRS) activities. Shigenaga S, et al. **Arch Pharm (Weinheim)** 1996 Jan;329(1):3–10

[Biomimetic oxidation of clemastine hydrogen fumarate] Fröhlich L, et al. **Pharmazie** 1996 Jun;51(6):409–14 (Eng. Abstr.) **(Ger)**

ECONOMICS

Evaluation of oral anti–allergic drugs in Japan [letter] Hayashi K, et al. **Lancet** 1996 Feb 17;347(8999):477

IMMUNOLOGY

Role of very late activation antigen–4 in the antigen–induced accumulation of eosinophils and lymphocytes in the lungs and airway lumen of sensitized brown Norway rats. Richards IM, et al. **Am J Respir Cell Mol Biol** 1996 Aug; 15(2):172–83

ISOLATION & PURIFICATION

Potent antiplatelet, anti–inflammatory and antiallergic isoflavanquinones from the roots of Abrus precatorius. Kuo SC, et al. **Planta Med** 1995 Aug;61(4):307–12

METABOLISM

Cell adhesion via murine alpha4 human beta1 integrin chimera on transfected K562 cells to endothelial cells. Miyakawa Y, et al. **Exp Cell Res** 1996 Jul 10;226(1):75–9

The novel recognition site in the C–terminal heparin–binding domain of fibronectin by integrin alpha 4 beta 1 receptor on HL–60 cells. Mohri H, et al. **Exp Cell Res** 1996 Feb 1;222(2):326–32

PHARMACOKINETICS

Bioequivalence and pharmacokinetics of chlorpheneramine in healthy human volunteers. Najjar TA, et al. **Int J Clin Pharmacol Ther** 1995 Nov;33(11):619–22

Pharmacokinetics of cetirizine in 2– to 6–year–old children. Pariente–Khayat A, et al. **Int J Clin Pharmacol Ther** 1995 Jun;33(6):340–4

[Biomimetic oxidation of clemastine hydrogen fumarate] Fröhlich L, et al. **Pharmazie** 1996 Jun;51(6):409–14 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Clinical implications of the pharmacological profile of Tilarin. Davies RJ. **Allergy** 1996;51(28 Suppl):8–13 (26 ref.)

Nedocromil sodium reduces allergen–induced plasma extravasation in the guinea pig nasal mucosa by inhibition of tachykinin release. Javdan P, et al. **Allergy** 1995 Oct; 50(10):825–9

Effects of antiallergic drugs on the proliferation of estrogen–sensitive mouse Leydig cell line. Nishizawa Y, et al. **Anticancer Res** 1996 May–Jun;16(3A):1241–5

(2E,4E)–N–(4–(1H–indol–3–yl)piperidin–1–yl)alkyl–5–(substituted phenyl)–2,4–pentadienamides as antiallergic agents with antihistaminic and anti slow–reacting substance (SRS) activities. Shigenaga S, et al. **Arch Pharm (Weinheim)** 1996 Jan;329(1):3–10

Inhibitory effects of methanolic extract from corydalis tuber against types I–IV allergic models. Matsuda H, et al. **Biol Pharm Bull** 1995 Jul;18(7):963–7

Inhibition of interferon–gamma and interleukin–2 production from lymphocytes stimulated with food antigens by an anti–allergic drug, Tranilast, in patients with food–sensitive atopic dermatitis. Kondo N, et al. **Biotherapy** 1994; 8(1):19–22

Leukotriene B4 production by blood neutrophils in allergic rhinitis—effects of cetirizine. Cheria–Sammari S, et al. **Clin Exp Allergy** 1995 Aug;25(8):729–36

Terfenadine exerts antiallergic activity reducing ICAM–1 expression on nasal epithelial cells in patients with pollen allergy. Ciprandi G, et al. **Clin Exp Allergy** 1995 Sep; 25(9):871–8

LCB 2183 inhibits tracheal hyperreactivity and pulmonary inflammation in mouse airways. Buckley TL, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):103–9

Tranilast suppresses intimal hyperplasia after photochemically induced endothelial injury in the rat. Kikuchi S, et al. **Eur J Pharmacol** 1996 Jan 11; 295(2–3):221–7

The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A. Hartman DA, et al. **Inflamm Res** 1995 Jul;44(7):269–74

Pulmonary antiallergic and antiinflammatory effects of a novel, orally–active phosphodiesterase IV inhibitor (WAY–127093B) in guinea pigs and rats. Howell RE, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S172–3

Protective effect of heparin on immunologically induced tracheal smooth muscle contraction in vitro. Abraham WM, et al. **Int Arch Allergy Immunol** 1996 May; 110(1):79–84

Inhibition of leukotriene synthesis by honokiol in rat basophilic leukemia cells. Hamasaki Y, et al. **Int Arch Allergy Immunol** 1996 Jul;110(3):278–81

KW–4679, an antiallergic drug, inhibits the production of inflammatory lipids in human polymorphonuclear leukocytes and guinea pig eosinophils. Ikemura T, et al. **Int Arch Allergy Immunol** 1996 May;110(1):57–63

Effects of KW–4679, a new orally active antiallergic drug, on antigen–induced bronchial hyperresponsiveness, airway inflammation and immediate and late asthmatic responses in guinea pigs. Ohmori K, et al.

Int Arch Allergy Immunol 1996 May;110(1):64–72

Modulations of histamine release from mast cells by interleukin-2 is affected by nedocromil sodium. Rubinchik E, et al. **Int J Immunopharmacol** 1995 Jul;17(7):563–70

Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. Schwiebert LA, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):143–52 (105 ref.)

Inhibitory effect of epinastine on superoxide generation by rat neutrophils. Fukuishi N, et al. **Jpn J Pharmacol** 1995 Aug;68(4):449–52

Cetirizine--a new antihistamine. **Med Lett Drugs Ther** 1996 Mar 15;38(970):21–3

Pharmacological characteristics of Sho-seiryu-to, an antiallergic Kampo medicine without effects on histamine H1 receptors and muscarinic cholinergic system in the brain. Sakaguchi M, et al. **Methods Find Exp Clin Pharmacol** 1996 Jan–Feb;18(1):41–7

Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor. McDonnell JM, et al. **Nat Struct Biol** 1996 May;3(5):419–26

Inhibitory effects of azelastine and tranilast on leukotriene B4 and leukotriene C4 generation by rat colonic mucosa. Shimizu T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):355–8

[Inhibitory effects of saiboku-to and compornent herbs on the production of peptide leukotrienes (LTs) and LTB4] Kobayashi I, et al. **Arerugi** 1996 Jun;45(6):577–83 (Eng. Abstr.) **(Jpn)**

[Effect of KW-4679, an antiallergic drug, on antigen-induced airway microvascular leakage in rats passively sensitized with mouse monoclonal IgE antibody] Ohmori K, et al. **Arerugi** 1996 Apr;45(4):393–7 (Eng. Abstr.) **(Jpn)**

[Generation of tumor necrosis factor alpha by human nasal epithelial cells and inhibition by fluticasone propionate] Ohnishi M, et al. **Arerugi** 1995 Oct;44(10):1216–22 (Eng. Abstr.) **(Jpn)**

[Effect of mao-bushi-saishin-to (MBST), a formula of Chinese medicines, on 48 hr homologous passive cutaneous anaphylaxis in rats] Shibata H, et al. **Arerugi** 1995 Sep; 44(9):1167–75 (Eng. Abstr.) **(Jpn)**

[Role of adhesion molecules (VLA-4) in the asthmatic response to allergens] Tanimukai T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1240–9 (Eng. Abstr.) **(Jpn)**

[Pharmacological studies on KW-4679, an antiallergic drug. (1): Inhibitory effect on passive cutaneous anaphylaxis (PCA) and experimental asthma in rats and guinea pigs] Ishii H, et al. **Nippon Yakurigaku Zasshi** 1995 Oct; 106(4):289–98 (Eng. Abstr.) **(Jpn)**

[Effect of KW-4679, a novel antiallergic drug, on platelet-activating factor (PAF)-induced bronchoconstriction, airway hyperresponsiveness and pulmonary cell accumulation in guinea pigs] Sasaki Y, et al. **Nippon Yakurigaku Zasshi** 1995 Nov;106(5):347–57 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

The activity of recent anti-allergic drugs in the treatment of seasonal allergic rhinitis. Wang D, et al. **Acta Otorhinolaryngol Belg** 1996;50(1):25–32

Tilarin in combination with astemizole. Bukstein DA, et al. **Allergy** 1996;51(28 Suppl):20–7

Speed of onset of action of Tilarin. Donnelly A, et al. **Allergy** 1996;51(28 Suppl):14–9

A clinical overview of Tilarin. Knottnerus IG, et al. **Allergy** 1996;51(28 Suppl):28–34

Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge. Ciprandi G, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):446–52

Effect of (Z)-11-[3-(dimethylamino) propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride on experimental allergic conjunctivitis and rhinitis in rats and guinea pigs. Kamei C, et al. **Arzneimittelforschung** 1995 Sep;45(9):1005–8

Cold urticaria in Thai children: comparison between cyproheptadine and ketotifen in the treatment. Visitsunthorn N, et al. **Asian Pac J Allergy Immunol** 1995 Jun;13(1):29–35

Effects of certain antiallergic drugs on experimental conjunctivitis in guinea pigs. Kamei C, et al. **Biol Pharm Bull** 1995 Nov;18(11):1518–21

Controlled comparison of two fluorometholone formulations in the antigen challenge model of allergic conjunctivitis. Harper DG, et al. **CLAO J** 1995 Oct;21(4):256–60

Triamcinolone acetonide aqueous nasal spray for the treatment of patients with perennial allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled study. Kobayashi RH, et al. **Clin Ther** 1995 May-Jun; 17(3):503–13

Comparison of intranasal triamcinolone acetonide with oral loratadine for the treatment of patients with seasonal allergic rhinitis. Schoenwetter W, et al. **Clin Ther** 1995 May-Jun;17(3):479–92

Therapeutic options in ocular allergic disease. Hingorani M, et al. **Drugs** 1995 Aug;50(2):208–21 (167 ref.)

Three explorative studies on the efficacy of the antihistamine mebhydroline (Omeril). Waitzinger J, et al. **Int J Clin Pharmacol Ther** 1995 Jul;33(7):373–83

Successful prophylaxis of wheat-dependent exercise-induced anaphylaxis with terfenadine. Fujimoto S, et al. **Intern Med** 1995 Jul;34(7):654–6

Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. Bronsky EA, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):915–21

A new murine model of allergic conjunctivitis and effectiveness of nedocromil sodium. Merayo-Lloves J, et al. **J Allergy Clin Immunol** 1996 May;97(5):1129–40

A combination therapy of psychotropic drugs and antihistaminics or antiallergics in patients with chronic urticaria. Hashiro M, et al. **J Dermatol Sci** 1996 Mar; 11(3):209–13

Comparative study of terfenadine and cetirizine in hay fever: assessment of efficacy and central nervous system effects. Bonifazi F, et al. **J Investig Allergol Clin Immunol** 1995 Jan–Feb;5(1):40–6

Aftercare for participants in clinical research: ethical considerations in an asthma drug trial. Harth SC, et al. **J Med Ethics** 1995 Aug;21(4):225–8

Major basic protein and topical administration of ketotifen in pollinosis under natural allergen provocation. Kato M, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Sep-Oct; 57(5):269–72

Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Stefanini GF, et al. **Scand J Gastroenterol** 1995 Jun;30(6):535–41

[The effect of KW-4679, an antiallergic drug, on experimental allergic rhinitis] Kaise T, et al. **Arerugi** 1995 Oct;44(10):1229–33 (Eng. Abstr.) **(Jpn)**

[Anti-allergic agent therapy of asthma] Fujimura M. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):216–21 (5 ref.) **(Jpn)**

[Bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and the influence of loratadine and beclomethasone on this hyperresponsiveness] Kroczyńska-Bednarek J, et al. **Pneumonol Alergol Pol** 1996; 64(3-4):182–8 (Eng. Abstr.) **(Pol)**

ANTIANDROGENS see **ANDROGEN ANTAGONISTS**

ANTI-ANTIBODIES see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTI-ANXIETY AGENTS

see related

ADRENERGIC BETA-ANTAGONISTS

The efficacy of complaints management training in facilitating benzodiazepine withdrawal. Elsesser K, et al. **Behav Res Ther** 1996 Feb;34(2):149–56

Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Rascati K. **Clin Ther** 1995 Jul-Aug;17(4):786–90

[Hypnotics and anxiolytics: nominal daily delivery and development of their consumption at North University Hospital Center of Marseille (1991-1994)] Jentile B, et al. **J Pharm Belg** 1995 Nov-Dec;50(6):489–93 (Eng. Abstr.) **(Fre)**

[After the benzodiazepines] Cugurra F. **Clin Ter** 1995 Dec; 146(12):861–4 (Eng. Abstr.) **(Ita)**

[Assessment of anxiolytics (3)--biochemical approach] Ito Y. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):223–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Variation in prescribing of hypnotics, anxiolytics and antidepressants between 61 general practices. Pharoah PD, et al. **Br J Gen Pract** 1995 Nov;45(400):595–9

Acute administration of buspirone increases the escape of hypothalamic-pituitary-adrenal-axis hormones from suppression by dexamethasone in depression. Maes M, et al. **Psychoneuroendocrinology** 1996 Jan;21(1):67–81

[Treatment of delirium tremens with quick administration of diazepam] Wasilewski D, et al. **Psychiatr Pol** 1995 Sep-Oct;29(5):675–86 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Harth Y, et al. **Drug Saf** 1996 Apr;14(4):252–9 (47 ref.)

I have heard that buspirone regularly affects various blood tests. Is this so? Shader RI. **J Clin Psychopharmacol** 1996 Apr;16(2):194

Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Bourin M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):567–75

Beyond the brain-mind dichotomy and toward a common organizing principle of pharmacological and psychological treatments [editorial; comment] Biondi M. **Psychother Psychosom** 1995;64(1):1–8. Comment on: Psychother Psychosom 1994;61(3-4):125–31. Comment on: Psychother Psychosom 1995;63(3-4):137–41.

[The effect of nifedipine and chlordiazepoxide on alcohol withdrawal syndrome] Samochowiec J, et al. **Psychiatr Pol** 1996 Mar-Apr;30(2):307–20 (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS

Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Heilig M. **Regul Pept** 1995 Oct 20;59(2):201–5

BLOOD

Automated high-performance liquid chromatographic assay for lesopitron, a novel anxiolytic, in human plasma using on-line solid-phase extraction. García-Encina G, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):103–10

Inferring systemic exposure from a pharmacokinetic screen: model-free and model-based approaches. Nedelman JR, et al. **Stat Med** 1995 May 15-30;14(9-10):955–68; discussion 969–70

CHEMISTRY

Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Swart EL, et al. **Am J Health Syst Pharm** 1995 Sep 15; 52(18):2020–2

Stability of ondansetron hydrochloride injection in various beverages. Yamreudeewong W, et al. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2011–4

Molecular surface comparison. 2. Similarity of electrostatic vector fields in drug design. Blaney FE, et al. **J Mol Graph** 1995 Jun;13(3):165–74, 194–7

METABOLISM

6-Bromoflavone, a high affinity ligand for the central benzodiazepine receptors is a member of a family of active flavonoids. Marder M, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):384–9

In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N'-oxidation. Rodrigues AD, et al. **Drug Metab Dispos** 1995 Oct;23(10):1143–52

PHARMACOKINETICS

Enantioselective pharmacokinetics in animals of pazinaclone, a new isoindoline anxiolytic, and its active metabolite. Kondo T, et al. **Biopharm Drug Dispos** 1995 Dec; 16(9):755–73

Clinical pharmacokinetics in patients with burns. Jaehde U, et al. **Clin Pharmacokinet** 1995 Jul;29(1):15–28 (75 ref.)

Pharmacokinetics of abecarnil in patients with renal insufficiency. Karara AH, et al. **Clin Pharmacol Ther** 1996 May;59(5):520–8

Oral absorption of CGS-20625, an insoluble drug, in dogs and man. Hirschberg Y, et al. **J Pharmacokinet Biopharm** 1995 Feb;23(1):11–23

Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Buccafusco JJ, et al. **Psychopharmacology (Berl)** 1995 Aug;120(3):256–66

In vivo disposition and in vitro metabolism of an anxiolytic compound, BMS-184111, in rats. Yeleswaram K, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jul;89(1):27–44

Inferring systemic exposure from a pharmacokinetic screen: model-free and model-based approaches. Nedelman JR, et al. **Stat Med** 1995 May 15-30;14(9-10):955–68; discussion 969–70

PHARMACOLOGY

Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties. Arneric SP, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:50–61

Allopregnanolone acts as an inhibitory modulator on alpha1- and alpha6-containing GABA-A receptors. Hauser CA, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):531–6

Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Bradwejn J, et al. **Biol Psychiatry** 1995 Dec 1;38(11):742–6

The enantiomers of zacopride: an intra-species comparison of their potencies in functional and anxiolytic models. Bill DJ, et al. **Br J Pharmacol** 1995 Jul;115(5):775–80

Anxiolytic activity of adenosine receptor activation in mice. Jain N, et al. **Br J Pharmacol** 1995 Oct;116(3):2127–33

Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety. Kennett GA, et al. **Br J Pharmacol** 1996 Apr;117(7):1443–8

Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects. Semlitsch HV, et al. **Eur J Clin Pharmacol** 1995; 49(3):183–91

Potential anxiolytic properties of R-(+)-8-OSO2CF3-PAT, a 5-HT 1A receptor agonist. Barf T, et al. **Eur J Pharmacol** 1996 Feb 22;297(3):205–11

Presynaptic 5-HT1A receptors mediate the effect of ipsapirone on punished responding in rats. Cervo L, et al. **Eur J Pharmacol** 1995 Sep 25;284(3):249–55

Flumazenil blocks the anxiolytic action of allopregnanolone. Fernández-Guasti A, et al. **Eur J Pharmacol** 1995 Jul 25; 281(1):113–5

The anxiolytic effects of flesinoxan, a 5-HT1A receptor agonist, are not related to its neuroendocrine effects. Groenink L, et al. **Eur J Pharmacol** 1995 Jul 4; 280(2):185-93

Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists. Singh L, et al. **Eur J Pharmacol** 1995 Nov 14;286(2):185-91

Differential effect of buspirone and diazepam on negative contrast in one-way avoidance learning. Torres C, et al. **Eur J Pharmacol** 1995 Jul 14;280(3):277-84

Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain. Tanaka H, et al. **Gen Pharmacol** 1995 Dec;26(8):1765-72

Antistress activity of P-GABA in experimental animals. Pandit M, et al. **Indian J Exp Biol** 1996 Jan;34(1):37-40

Studies on psychomotor performance in healthy volunteers after diazepam, propranolol and alcohol given alone or in combination. Khajuria V, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):242-6

Diazepam blocks fear-potentiated startle in humans. Patrick CJ, et al. **J Abnorm Psychol** 1996 Feb;105(1):89-96

5-HT3 receptor-independent inhibition of the depolarization-induced 86Rb efflux from human neuroblastoma cells, TE671, by ondansetron. Toral J, et al. **J Pharm Pharmacol** 1995 Jul;47(7):618-22

Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT2A/2C antagonist anxiolytics. I. Antipunishment effects in the pigeon. Kleven MS, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):388-97

Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX). Swedberg MD, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1113-21

Comparison of the effects of typical and atypical anxiolytics on learning in monkeys and rats. Winsauer PJ, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1111-27

Behavioral and biochemical characterization of benzodiazepine receptor partial agonists in pigeons. Witkin JM, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):87-96

Neurosteroids: molecular mechanisms of action and psychopharmacological significance. Rupprecht R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):163-8 (50 ref.)

5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Ichimaru Y, et al. **Jpn J Pharmacol** 1995 May;68(1):65-70

Involvement of neurotransmitters in the 'anxiolytic-like' action of atrial natriuretic peptide in rats. Biró E, et al. **Neuropeptides** 1995 Oct;29(4):215-20

(+/-)-Kavain inhibits veratridine-activated voltage-dependent Na(+)-channels in synaptosomes prepared from rat cerebral cortex. Gleitz J, et al. **Neuropharmacology** 1995 Sep;34(9):1133-8

Pregnenolone sulfate antagonizes dizocilpine amnesia: role for allopregnanolone. Cheney DL, et al. **Neuroreport** 1995 Aug 21;6(12):1697-700

Inhibition of nitric oxide synthase causes anxiolytic-like behaviour in an elevated plus-maze. Volke V, et al. **Neuroreport** 1995 Jul 10;6(10):1413-6

Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Warpman U, et al. **Neuroreport** 1995 Nov 27;6(17):2419-23

Allopregnanolone potentiates a GABA-withdrawal syndrome in the rat cerebral cortex. Calixto E, et al. **Neurosci Lett** 1995 Aug 4;195(2):73-6

Stress-induced increase in brain neuroactive steroids: antagonism by abecarnil. Barbaccia ML, et al. **Pharmacol Biochem Behav** 1996 May;54(1):205-10

Effects of valproate and lorazepam on experimental anxiety: tolerance, withdrawal, and role of clonidine. de Angelis L. **Pharmacol Biochem Behav** 1995 Oct;52(2):329-33

Anxiolytic effects in the plus-maze of 5-HT1A-receptor ligands in dorsal raphé and ventral hippocampus. File SE, et al. **Pharmacol Biochem Behav** 1996 May;54(1):123-8

A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Hogg S. **Pharmacol Biochem Behav** 1996 May;54(1):21-30 (56 ref.)

The pituitary-adrenal axis and the different behavioral effects of buspirone and chlordiazepoxide. McNaughton N, et al. **Pharmacol Biochem Behav** 1996 May;54(1):51-6

Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors. Przegaliński E, et al. **Pharmacol Biochem Behav** 1996 May;54(1):73-7

"Anxiolytic" action of diazepam and abecarnil in a modified open field test. Rex A, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):1005-11

Plus-maze retest profile in mice: importance of initial stages of trail 1 and response to post-trail cholinergic receptor blockade. Rodgers RJ, et al. **Pharmacol Biochem Behav** 1996 May;54(1):41-50

Central noradrenergic neurones and stress. Stanford SC. **Pharmacol Ther** 1995;68(2):297-42 (360 ref.)

Anxiolytic-like action of intra-hippocampally administered NMDA antagonists in rats. Jessa M, et al. **Pol J Pharmacol** 1995 Jan-Feb;47(1):81-4

Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Jenck F, et al. **Psychiatry Res** 1995 Jul 28;57(2):181-91

ABT-418: discriminative stimulus properties and effect on ventral tegmental cell activity. Brioni JD, et al. **Psychopharmacology (Berl)** 1995 Jun;119(4):368-75

Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Buccafusco JJ, et al. **Psychopharmacology (Berl)** 1995 Aug;120(3):256-66

The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Cools AR, et al. **Psychopharmacology (Berl)** 1995 Jun; 119(4):428-39

Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist. Damaj MI, et al. **Psychopharmacology (Berl)** 1995 Aug;120(4):483-90

Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Dawson GR, et al. **Psychopharmacology (Berl)** 1995 Sep; 121(1):109-17

Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics. Miczek KA, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):38-56 (161 ref.)

The ambivalent behaviour "stretched approach posture" in the rat as a paradigm to characterize anxiolytic drugs. Molewijk HE, et al. **Psychopharmacology (Berl)** 1995 Sep; 121(1):81-90

A comparative study of the psychological effects of DN-2327, a partial benzodiazepine agonist, and alprazolam. Suzuki M, et al. **Psychopharmacology (Berl)** 1995 Oct; 121(4):442-50

Alcohol, anxiolytics and social stress in rats. Tornatzky W, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):135-44

The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Walsh DM, et al. **Psychopharmacology (Berl)** 1995 Sep;121(2):186-91

The road to tranquility: the search for selective anti-anxiety agents. Estes JW. **Synapse** 1995 Sep;21(1):10-20 (69 ref.)

[Assessment of anxiolytics (6)—A novel method in mice using psychological stress] Takahashi M, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Oct; 15(5):375-83 (Eng. Abstr.) **(Jpn)**

[Behavioral effects of penicillin in experimental anxiety in rats] Kaluev AV, et al. **Biull Eksp Biol Med** 1995 Oct; 120(10):352-4 **(Rus)**

[The characteristics of the anxiolytic action of taftsin and its analog TP-7 on behavior and serotonin metabolism in the brain of rats with chronic deprivation of serotoninergic system activity] Seredenin SB, et al. **Eksp Klin Farmakol** 1995 Nov-Dec;58(6):3-6 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Malec E, et al. **Alcohol Clin Exp Res** 1996 Apr;20(2):307-12

Azapirones: an alternative to benzodiazepines for anxiety. Cadieux RJ. **Am Fam Physician** 1996 May 15;53(7):2349-53 (23 ref.)

Management of delirium tremens on the head and neck service. Alvi A, et al. **Am J Otolaryngol** 1995 Jul-Aug; 16(4):224-31 (25 ref.)

Augmentation with buspirone: a review. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Sep;7(3):143-7 (32 ref.)

Relationship between the provision of counselling and the prescribing of antidepressants, hypnotics and anxiolytics in general practice. Fletcher J, et al. **Br J Gen Pract** 1995 Sep;45(398):467-9

A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Cottraux J, et al. **Br J Psychiatry** 1995 Nov;167(5):635-41

An imidazopyridine anxiolytic alters glucose tolerance in patients: a pilot investigation. Bottai T, et al. **Clin Neuropharmacol** 1995 Feb;18(1):79-82

Propranolol reduces the anxiety associated with day case surgery. Mealy K, et al. **Eur J Surg** 1996 Jan;162(1):11-4

Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder. Mandos LA, et al. **Int Clin Psychopharmacol** 1995 Nov;10(4):251-6

International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: II. Pharmacotherapy of anxiety disorders. Uhlenhuth EH, et al. **J Affect Disord** 1995 Dec 18; 35(4):153-62

Buspirone in ADHD with ODD [letter] Gross MD. **J Am Acad Child Adolesc Psychiatry** 1995 Oct;34(10):1260

Management of persistent anxiety and novel uses for anxiolytics. **J Clin Psychiatry** 1996;57 Suppl 7:3-95

Augmentation strategies: focus on anxiolytics. Joffe RT, et al. **J Clin Psychiatry** 1996;57 Suppl 7:25-31; discussion 32-3 (56 ref.)

A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. Adams JB, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):428-34

Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Bourin M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):567-75

Future directions in anxiolytic pharmacotherapy. Kunovac JL, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):895-909 (90 ref.)

Generalized anxiety disorder. Longitudinal course and pharmacologic treatment. Schweizer E. **Psychiatr Clin North Am** 1995 Dec;18(4):843-57 (76 ref.)

Hydroxyzine premedication--does it provide better anxiolysis than a placebo? Boon JH, et al. **S Afr Med J** 1996 Jun;86(6):661-4

The road to tranquility: the search for selective anti-anxiety agents. Estes JW. **Synapse** 1995 Sep;21(1):10-20 (69 ref.)

[Treatment of generalized anxiety: new pharmacologic approaches] Boulenger JP. **Encephale** 1995 Nov-Dec; 21(6):459-66 (51 ref.) (Eng. Abstr.) **(Fre)**

[Epidemiology of the use of anxiolytic and hypnotic drugs in France and in the world] Pélissolo A, et al. **Encephale** 1996 May-Jun;22(3):187-96 (68 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of essential tremor] Marchand L. **Union Med Can** 1995 Nov;124(3):32-4 **(Fre)**

[Panic disorder and agoraphobia: what is effective?] Bandelow B, et al. **Fortschr Neurol Psychiatr** 1995 Nov; 63(11):451-64 (120 ref.) (Eng. Abstr.) **(Ger)**

[The effect of nifedipine and chlordiazepoxide on alcohol withdrawal syndrome] Samochowiec J, et al. **Psychiatr Pol** 1996 Mar-Apr;30(2):307-20 (Eng. Abstr.) **(Pol)**

[Treatment of delirium tremens with quick administration of diazepam] Wasilewski D, et al. **Psychiatr Pol** 1995 Sep-Oct;29(5):675-86 (Eng. Abstr.) **(Pol)**

[Episodic depression in electroencephalography and midazolam] Abad-Alegría F, et al. **Rev Neurol** 1996 May; 24(129):585-6 **(Spa)**

TOXICITY

Potentiation of hypoxic injury in cultured rabbit hepatocytes by the quinoxalinone anxiolytic, panadiplon. Bacon JA, et al. **Toxicology** 1996 Apr 15;108(1-2):9-16

ANTI-ANXIETY AGENTS, BENZODIAZEPINE

The use of diazepam and ketamine for i.v. conscious sedation in outpatient surgery settings. Ringler JD. **AORN J** 1995 Oct;62(4):638-45

Addiction to benzodiazepines--how common? [letter; comment] Grad R. **Arch Fam Med** 1996 Jul-Aug;5(7):384 . Comment on: Arch Fam Med 1995 Nov;4(11):964-70.

Addiction to benzodiazepines--how common? [letter; comment] King SA. **Arch Fam Med** 1996 Jul-Aug; 5(7):383-4. Comment on: Arch Fam Med 1995 Nov;4(11):964-70.

Inappropriate guilt over benzodiazepine prescription [letter; comment] Reynolds RD. **Arch Fam Med** 1996 Jan;5(1):9 . Comment on: Arch Fam Med 1995 Jul;4(7):576.

Abuse of temazepam capsules [letter] Mansie DT. **Aust Fam Physician** 1995 Nov;24(11):2146

Use of benzodiazepines in the Italian general population: prevalence, pattern of use and risk factors for use. Magrini N, et al. **Eur J Clin Pharmacol** 1996;50(1-2):19-25

The management of opioid and benzodiazepine dependence in infants, children, and adolescents. Yaster M, et al. **Pediatrics** 1996 Jul;98(1):135-40 (41 ref.)

[Progresses in psychiatry in China, 1995] Zhang M, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):725-6 (0 ref.) **(Chi)**

[Anxiolysis, sedation, and stress reduction following oral premedication with midazolam in adults. A comparison with dipotassium clorazepate and placebo] Berendes E, et al. **Anaesthesist** 1996 Jun;45(6):506-11 (Eng. Abstr.) **(Ger)**

[Long-term administration of benzodiazepines--disease follow-up, sequelae, treatment. A retrospective clinical record evaluation of 194 patients] Luderer HJ, et al. **Psychiatr Prax** 1995 Nov;22(6):231-4 (Eng. Abstr.) **(Ger)**

[After the benzodiazepines] Cugurra F. **Clin Ter** 1995 Dec; 146(12):861-4 (Eng. Abstr.) **(Ita)**

ADMINISTRATION & DOSAGE

Postoperative medical management in single-stage laryngotracheoplasty. Rothschild MA, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct;121(10):1175-9

Response to intravenous midazolam sedation in general dental practice. Ellis S. **Br Dent J** 1996 Jun 8; 180(11):417-20

Long-term follow-up after a drug trial for panic disorder. Katschnig H, et al. **Br J Psychiatry** 1995 Oct;167(4):487-94

Safety and effectiveness of an oral premedication regimen before cardiac surgery. Böttiger BW, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):341-4

Benzodiazepine use during pregnancy: a prospective study [letter] Courtens W, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):181-2

Evaluation of oral midazolam as pre-medication in day care surgery in adult Pakistani patients. Ahmed N, et al. **JPMA J Pak Med Assoc** 1995 Sep;45(9):239-41

Sedation with benzodiazepines. Gempeler F, et al. **Middle East J Anesthesiol** 1995 Jun;13(2):117-45 (73 ref.)

Effects of intravenous diazepam pretreatment on lactate-induced panic. Liebowitz MR, et al. **Psychiatry Res** 1995 Sep 29;58(2):127-38

Maintaining schizophrenic patients on benzodiazepines. Kimhi R, et al. **Schizophr Res** 1995 Nov;17(3):283–5
[Use of intravenous midazolam in status epilepticus in children] Lemerle J, et al. **Arch Pediatr** 1995 Sep; 2(9):848–53 (Eng. Abstr.) **(Fre)**
[Comparison of the effectiveness of orally administered clorazepate dipotassium and nordiazepam on preoperative anxiety] Mielke L, et al. **Anaesthesiol Reanim** 1995; 20(6):144–8 (Eng. Abstr.) **(Ger)**
[The use of Dormicum in general anesthesia for oral surgery] Judit J, et al. **Fogorv Sz** 1995 Dec;88(12):399–403 (Eng. Abstr.) **(Hun)**
[Premedication in children: a comparison of oral midazolam and rectal bromazepam] Kambara N, et al. **Masui** 1995 Dec; 44(12):1707–11 (Eng. Abstr.) **(Jpn)**
[The use of low dose midazolam for the management of spinal anesthesia] Nagahama H, et al. **Masui** 1996 May;45(5):593–8 (Eng. Abstr.) **(Jpn)**
[Prescription for diazepam 5 mg tablets in Vestfold 1989 and 1995] Otterstad HK, et al. **Tidsskr Nor Laegeforen** 1996 Apr 30;116(11):1331–3 (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Late-onset seizures in alcohol withdrawal. Mayo-Smith MF, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):656–9
Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. Bashir K, et al. **Br J Gen Pract** 1994 Sep;44(386):408–12
A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. Tyrer P, et al. **Br J Psychiatry** 1996 Apr;168(4):457–61
Altered behavioral and neurochemical response to stress in benzodiazepine–withdrawn rats. Martijena ID, et al. **Brain Res** 1996 Mar 18;712(2):239–44
Benzodiazepine administration induces exogenic psychosis: a case of child abuse. Marcus A, et al. **Child Abuse Negl** 1995 Jul;19(7):833–6
Cross-reactive type IV hypersensitivity reactions to benzodiazepines revealed by patch testing. Kämpgen E, et al. **Contact Dermatitis** 1995 Nov;33(5):356–7
Delayed cell-mediated hypersensitivity to tetrazepam. Ortega NR, et al. **Contact Dermatitis** 1996 Feb;34(2):139
Maculopathy associated with diazepam [letter] Manners TD, et al. **Eye** 1995;9 (Pt 5):660–2
Acute confusion in a chronic benzodiazepine patient. Withdrawal-related nonconvulsive status epilepticus misdiagnosed as acute intoxication [letter] Primavera A, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):460–2
Withdrawal of routine psychiatric medications in a general medical ward [letter] Sloan D. **Ir Med J** 1996 May–Jun; 89(3):116
Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. Bond AJ, et al. **J Affect Disord** 1995 Dec 13;35(3):117–23
Fulminant hepatic failure associated with oral administration of diazepam in 11 cats. Center SA, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):618–25
Sedative-hypnotic drugs and the risk of hip fracture. Wysowski DK, et al. **J Clin Epidemiol** 1996 Jan;49(1):111–3
Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam. Greene DS, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):409–16
Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. Greene DS, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):399–408
Update to "Over-the-counter hypnotics and chronic insomnia in the elderly" (guest editorial, J Clin Psychopharmacol 1995;15:383–6) [letter; comment] Lasagna L. **J Clin Psychopharmacol** 1996 Apr;16(2):191. Comment on: J Clin Psychopharmacol 1995 Dec;15(6):383–6.
Benzodiazepine withdrawal syndrome seizures. Martínez-Cano H, et al. **Pharmacopsychiatry** 1995 Nov; 28(6):257–62
Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Bourin M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):567–75
Benzodiazepines on trial: a research strategy for their rehabilitation. Costa E, et al. **Trends Pharmacol Sci** 1996 May;17(5):192–200 (60 ref.)
["Depression and benzodiazepine dependence in the elderly" (letter; comment)] Kolitzus H. **Psychiatr Prax** 1995 Nov; 22(6):263. Comment on: Psychiatr Prax 1994 Jul;21(4):157–9. **(Ger)**

ANALYSIS

Nonisotopic receptor assay for benzodiazepine drugs using time-resolved fluorometry. Takeuchi T, et al. **Anal Chem** 1995 Aug 1;67(15):2655–8
Detection and quantification of lorazepam in human hair by GC-MS/NCI in a case of traffic accident. Cirimele V, et al. **Int J Legal Med** 1996;108(5):265–7
Hair analysis for nordiazepam and oxazepam by gas chromatography—negative-ion chemical ionization mass spectrometry. Kintz P, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):241–4
Sweat testing for benzodiazepines. Kintz P, et al. **J Forensic Sci** 1996 Sep;41(5):851–4

BLOOD

A specific immunoassay for the detection of flunitrazepam. West A, et al. **Int J Legal Med** 1995;108(2):105–9
Development of a fluorescence polarization immunoassay for lorazepam quantification. Agbuya PG, et al. **Ther Drug Monit** 1996 Apr;18(2):194–9
[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats] Liu JF, et al. **Yao Hsueh Hsueh Pao** 1995; 30(9):655–61 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Mantong ML, et al. **Am J Health Syst Pharm** 1995 Nov 15; 52(22):2567–8
[Characterization of lorazepam and oxazepam by the thermal behavior of their degradation product] Chauvet A. **Ann Pharm Fr** 1995;53(6):256–60 (Eng. Abstr.) **(Fre)**

METABOLISM

What changes drug metabolism in critically ill patients?—II Serum inhibits the metabolism of midazolam in human microsomes. Park GR, et al. **Anaesthesia** 1996 Jan; 51(1):11–5
Chronic administration of the antidepressants phenelzine, desipramine, clomipramine, or maprotiline decreases binding to 5-hydroxytryptamine2A receptors without affecting benzodiazepine binding sites in rat brain. Todd KG, et al. **Cell Mol Neurobiol** 1995 Jun;15(3):361–70
In vivo formation of diazepam-like 1,4-benzodiazepines by Penicillium verrucosum var. verrucosum after administration of 2-aminobenzophenones and glycine. Bringmann G, et al. **J Neural Transm Gen Sect** 1995; 101(1–3):169–81
Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. Zomorodi K, et al. **Pharm Res** 1995 Nov;12(11):1642–6
Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. Zomorodi K, et al. **Xenobiotica** 1995 Sep; 25(9):907–16

PHARMACOKINETICS

Hepatic drug clearance in patients with mild cystic fibrosis. Kearns GL, et al. **Clin Pharmacol Ther** 1996 May; 59(5):529–40
First-pass metabolism of midazolam by the human intestine. Paine MF, et al. **Clin Pharmacol Ther** 1996 Jul;60(1):14–24
A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Yasui N, et al. **Clin Pharmacol Ther** 1996 May;59(5):514–9
Flunitrazepam and nordiazepam slowly released from silastic capsules induce physical dependence in rat. Jing X, et al. **Drug Alcohol Depend** 1995 Jul;39(1):63–70
Oxidative biotransformation of oxazepam to reactive and nonreactive products in rat, mouse and human microsomes. Griffin RJ, et al. **Hum Exp Toxicol** 1995 Oct;14(10):779–86
Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. Barbhaiya RH, et al. **J Clin Psychopharmacol** 1995 Oct; 15(5):320–6
Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment. Kroboth PD, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):306–19
Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ahonen J, et al. **Ther Drug Monit** 1996 Apr;18(2):124–7

PHARMACOLOGY

Hemodynamic effects of medetomidine–midazolam–butorphanol and medetomidine–midazolam–buprenorphine combinations and reversibility by atipamezole in dogs. Pypendop B, et al. **Am J Vet Res** 1996 May;57(5):724–30
Semilinear canonical correlation applied to the measurement of the electroencephalographic effects of midazolam and flumazenil reversal. Schnider TW, et al. **Anesthesiology** 1996 Mar;84(3):510–9
Effects of midazolam on intracellular Ca2+ and tension in airway smooth muscles. Yoshimura H, et al. **Anesthesiology** 1995 Nov;83(5):1009–20
Social isolation increases aggressive behaviour and alters the effects of diazepam in the rat social interaction test. Wongwitdecha N, et al. **Behav Brain Res** 1996 Feb; 75(1–2):27–32
Genetic analysis of anxiety-related behaviors and responses to benzodiazepine-related drugs in AXB and BXA recombinant inbred mouse strains. Mathis C, et al. **Behav Genet** 1995 Nov;25(6):557–68
Stress controllability influences the ataxic properties of both ethanol and midazolam in the rat. Drugan RC, et al. **Behav Neurosci** 1996 Apr;110(2):360–7
The effect of ethanol and diazepam on the fatty acid composition of plasma and liver phospholipids in the rat. Ristić V, et al. **Biol Pharm Bull** 1995 Jun;18(6):842–5
Changes in benzodiazepine-GABA receptor coupling in an accumbens-habenula circuit after chronic diazepam treatment. Brett RR, et al. **Br J Pharmacol** 1995 Nov; 116(5):2375–84
Behavioral and pharmacological validation of the elevated plus maze constructed with transparent walls. Anseloni VZ, et al. **Braz J Med Biol Res** 1995 May;28(5):597–601
The effect of triazolam and flunitrazepam—two benzodiazepines with different half-lives—on breathing during sleep. Schneider H, et al. **Chest** 1996 Apr; 109(4):909–15
The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects. Hanks GW, et al. **Eur J Clin Pharmacol** 1995;48(6):455–60
The cognitive and psychomotor effects of opioid analgesics. I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects. O'Neill WM, et al. **Eur J Clin Pharmacol** 1995; 48(6):447–53
Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects. Semlitsch HV, et al. **Eur J Clin Pharmacol** 1995; 49(3):183–91
Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines. Benschop RJ, et al. **FASEB J** 1996 Mar;10(4):517–24
Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. Rush CR, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):146–57
Frequency domain source localization shows state-dependent diazepam effects in 47-channel EEG. Michel CM, et al. **J Neural Transm Gen Sect** 1995;99(1–3):157–71
Characterization of GABAA receptor function in human temporal cortical neurons. Gibbs JW 3rd, et al. **J Neurophysiol** 1996 Apr;75(4):1458–71
Diazepam pretreatment suppresses morphine withdrawal signs in the mouse. Suzuki T, et al. **Life Sci** 1995; 58(4):349–57
Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. Griebel G, et al. **Neuropharmacology** 1995 Dec;34(12):1625–33
Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Cole JC, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):473–8
Effects of valproate and lorazepam on experimental anxiety: tolerance, withdrawal, and role of clonidine. de Angelis L. **Pharmacol Biochem Behav** 1995 Oct;52(2):329–33
Effects of chlorpromazine and diazepam on time estimation behavior and motivation in rats. Ferguson SA, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):115–22
The pituitary-adrenal axis and the different behavioral effects of buspirone and chlordiazepoxide. McNaughton N, et al. **Pharmacol Biochem Behav** 1996 May;54(1):51–6
Effects of chlordiazepoxide on maternal aggression in mice depend on experience of resident and sex of intruder. Palanza P, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):175–82
Relationship between memory and fear: developmental and pharmacological studies. Pletnikov MV, et al. **Pharmacol Biochem Behav** 1996 May;54(1):93–8
"Anxiolytic" action of diazepam and abecarnil in a modified open field test. Rex A, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):1005–11
Serotonergic mechanisms involved in the exploratory behaviour of mice in a fully automated two-compartment black and white text box. Sánchez C. **Pharmacol Toxicol** 1995 Jul;77(1):71–8
Benzodiazepines and palatability: taste reactivity in normal ingestion. Gray RW, et al. **Physiol Behav** 1995 Nov; 58(5):853–9
Effects of several benzodiazepines, alone and in combination with flumazenil, in rhesus monkeys trained to discriminate pentobarbital from saline. Woolverton WL, et al. **Psychopharmacology (Berl)** 1995 Dec;122(3):230–6
The effect of lorazepam on memory and event-related potentials in heavy and light social drinkers. Nichols JM, et al. **Psychophysiology** 1996 Jul;33(4):446–56
[Electrophysiologic tests and benzodiazepine hypnosis] Hort-Legrand C, et al. **Neurophysiol Clin** 1995;25(3):167–73 (Eng. Abstr.) **(Fre)**
[Benzodiazepines] Ansseau M. **Rev Med Liege** 1996 Jan; 51(1):70–7 **(Fre)**
[Assessment of anxiolytics (5)—Vogel-type conflict task in mice] Umezu T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Aug; 15(4):305–14 (Eng. Abstr.) **(Jpn)**
[Assessment of anxiolytics (4)—Social interaction test] Yasumatsu H. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Aug;15(4):295–304 (Eng. Abstr.) **(Jpn)**
[The effect of diazepam on the activity of carboxypeptidase N and the angiotensin-converting enzyme in sections of the brain of rats with differing normal emotionality and in emotional stress] Nikishin NN, et al. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):108–13 (Eng. Abstr.) **(Rus)**
[Diazepam eliminates the anxious state induced by amputation of the vibrissae (a model for assessing anxious behavior)] Kozlovskiĭ VL, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Sep–Oct; 45(5):1057–61 (Eng. Abstr.) **(Rus)**

POISONING

Slow awakening after electroconvulsive therapy due to unrecognized attempted suicide. Surgenor SD, et al. **Anesth Analg** 1996 May;82(5):1105–6

Benzodiazepine poisoning in companion animals. Bertini S, et al. **Vet Hum Toxicol** 1995 Dec;37(6):559–62 (24 ref.)

THERAPEUTIC USE

Detoxification: the use of benzodiazepines. Shaw GK. **Alcohol Alcohol** 1995 Nov;30(6):765–70 (20 ref.)

Azapirones: an alternative to benzodiazepines for anxiety. Cadieux RJ. **Am Fam Physician** 1996 May 15;53(7):2349–53 (23 ref.)

Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Schenck CH, et al. **Am J Med** 1996 Mar;100(3):333–7

The Galway Study of Panic Disorder. III. Outcome at 5 to 6 years. O'Rourke D, et al. **Br J Psychiatry** 1996 Apr; 168(4):462–9

Debating benzodiazepine use [letter; comment] [see comments] Lexchin J. **Can Fam Physician** 1995 Aug; 41:1293, 1295. Comment on: Can Fam Physician 1995 May;41:760, 763–5, 772–6. Comment in: Can Fam Physician 1995 Nov;41:1848.

Setting the record straight [letter] Shandera R. **Can Fam Physician** 1996 May;42:852

Benzodiazepine debate continues [letter; comment] Shandera R. **Can Fam Physician** 1995 Nov;41:1848. Comment on: Can Fam Physician 1995 Aug;41:1293, 1295.

Effects of alprazolam on the development of Moloney sarcoma virus-induced tumors in stressed mice. Freire-Garabal M, et al. **Cancer Detect Prev** 1996; 20(2):160–5

Comparison of intranasal midazolam and sufentanil premedication in pediatric outpatients. Zedie N, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):341–8

Lorazepam and midazolam in the intensive care unit: a randomized, prospective, multicenter study of hemodynamics, oxygen transport, efficacy, and cost. Cernaianu AC, et al. **Crit Care Med** 1996 Feb;24(2):222–8

Effects of alprazolam on glucose regulation in diabetes. Results of double-blind, placebo-controlled trial. Lustman PJ, et al. **Diabetes Care** 1995 Aug;18(8):1133–9

International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: II. Pharmacotherapy of anxiety disorders. Uhlenhuth EH, et al. **J Affect Disord** 1995 Dec 18; 35(4):153–62

Benzodiazepines in alcoholics [letter] Hershberg PI. **J Fam Pract** 1996 Apr;42(4):342

How blood pressure in patients with non-insulin-dependent diabetes mellitus is influenced by stress. Okada S, et al. **J Int Med Res** 1995 Sep-Oct;23(5):377–80

Automatic analysis of sleep spindles—assessment in one case treated with a benzodiazepine anxiolytic drug. Kuwahara H, et al. **Kurume Med J** 1996;43(1):107–13

Premenstrual syndrome no progesterone; premenstrual dysphoric disorder no serotonin deficiency [see comments] van Leusden HA. **Lancet** 1995 Dec 2;346(8988):1443–4. Comment in: Lancet 1996 Jan 13;347(8994):122. Comment in: Lancet 1996 Feb 17;347(8999):470–1.

Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Peppers MP. **Pharmacotherapy** 1996 Jan-Feb;16(1):49–57 (49 ref.)

Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Bourin M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):567–75

Catatonia: short-term response to lorazepam and dopaminergic metabolism. Northoff G, et al. **Psychopharmacology (Berl)** 1995 Nov;122(2):182–6

A multiple imputation strategy for clinical trials with truncation of patient data. Lavori PW, et al. **Stat Med** 1995 Sep 15;14(17):1913–25

Benzodiazepines on trial: a research strategy for their rehabilitation. Costa E, et al. **Trends Pharmacol Sci** 1996 May;17(5):192–200 (60 ref.)

[Prevention of postoperative nausea and vomiting by lorazepam] Laraki M, et al. **Cah Anesthesiol** 1996; 44(2):159–62 (Eng. Abstr.) **(Fre)**

[New non-benzodiazepine hypnotics. Progress in therapy of sleep disorders?] Hajak G, et al. **Internist (Berl)** 1995 Nov; 36(11):1085–90; discussion 1090–1 (51 ref.) **(Ger)**

[Dependence of the strength of anxiolytic effect of tranquilizers on the level of anxiety in a conflict situation] Molodavkin GM, et al. **Biull Eksp Biol Med** 1996 Jan; 121(1):63–6 **(Rus)**

[The correlation of the electroencephalographic and clinical effects of benzodiazepine tranquilizers in patients with mental disorders at the neurotic level] Bochkarev VK, et al. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):18–22 **(Rus)**

[The efficacy of treatment with the tranquilizer tranxene in elderly persons with psychoemotional disorders against a background of initial and moderately pronounced atherosclerotic circulatory encephalopathy] Grebel'nik VI. **Lik Sprava** 1995 Jul-Aug;(7-8):29–32 (Eng. Abstr.) **(Rus)**

[The efficacy of alprazolam in the therapy of panic disorders] Diukova GM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):9–13 (Eng. Abstr.) **(Rus)**

[The stress-protective effect of fenazepam in rats with different capacities for escape in an acute aversive situation] Ostrovskiĭ OV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Sep-Oct; 45(5):1014–22 (Eng. Abstr.) **(Rus)**

TOXICITY

Chronic subarachnoid midazolam (Dormicum) in the rat. Morphologic evidence of spinal cord neurotoxicity. Svensson BA, et al. **Reg Anesth** 1995 Sep-Oct;20(5):426–34

[Voluntary drug poisoning cases admitted to an emergency care unit] Staikowsky F, et al. **Presse Med** 1995 Sep 30; 24(28):1296–300 (Eng. Abstr.) **(Fre)**

ANTI-ARRHYTHMIA AGENTS

see related
ADRENERGIC BETA-ANTAGONISTS
CALCIUM CHANNEL BLOCKERS

Dofetilide—medical and media information [news] **S Afr Med J** 1996 Apr;86 Suppl 2:C112–3

ADMINISTRATION & DOSAGE

Standard and higher doses of atropine in a canine model of pulseless electrical activity [see comments] DeBehnke DJ, et al. **Acad Emerg Med** 1995 Dec;2(12):1034–41. Comment in: Acad Emerg Med 1995 Dec;2(12):1023–4.

Effects of verapamil and magnesium sulfate on electrophysiologic changes during acute myocardial ischemia and following reperfusion in dogs: comparative effects of administration by intravenous and coronary sinus retroperfusion routes. Yamamoto K, et al. **Angiology** 1996 Jun;47(6):557–68

Intraosseous adenosine for the termination of supraventricular tachycardia in an infant. Friedman FD. **Ann Emerg Med** 1996 Sep;28(3):356–8

No interaction between dopamine and phenytoin [letter] Torres E, et al. **Ann Pharmacother** 1995 Dec;29(12):1300–1

Effect of low dose sotalol on the signal averaged P wave in patients with paroxysmal atrial fibrillation. Stafford PJ, et al. **Br Heart J** 1995 Dec;74(6):636–40

Should the routine use of atropine before succinylcholine in children be reconsidered? McAuliffe G, et al. **Can J Anaesth** 1995 Aug;42(8):724–9

Digoxin and increased mortality among patients recovering from acute myocardial infarction: importance of digoxin dose. The SPRINT Study Group. Leor J, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):723–9

Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group [see comments] Kowey PR, et al. **Circulation** 1995 Dec 1;92(11):3255–63. Comment in: Circulation 1995 Dec 1;92(11):3154–5.

Intravenous amiodarone. Another option in the acute management of sustained ventricular tachyarrhythmias [editorial; comment] Naccarelli GV, et al. **Circulation** 1995 Dec 1;92(11):3154–5. Comment on: Circulation 1995 Dec 1;92(11):3255–63. Comment on: Circulation 1995 Dec 1;92(11):3264–72.

Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group [see comments] Scheinman MM, et al. **Circulation** 1995 Dec 1;92(11):3264–72. Comment in: Circulation 1995 Dec 1;92(11):3154–5.

Novel delivery of antiarrhythmic agents. Labhasetwar V, et al. **Clin Pharmacokinet** 1995 Jul;29(1):1–5 (24 ref.)

Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. Di Biasi P, et al. **Eur J Cardiothorac Surg** 1995;9(10):587–91

Electrophysiologic effects and therapeutic efficacy of intravenous flecainide for termination of paroxysmal supraventricular tachycardia. Gambhir DS, et al. **Indian Heart J** 1995 May-Jun;47(3):237–43

Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. Bianconi L, et al. **J Am Coll Cardiol** 1996 Sep;28(3):700–6

Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. Ellenbogen KA, et al. **J Am Coll Cardiol** 1996 Jul; 28(1):130–6

Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. Galve E, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1079–82

Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. Guo GB, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1083–9

Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. Levine JH, et al. **J Am Coll Cardiol** 1996 Jan;27(1):67–75

Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. Perry JC, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1246–50

Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects. Stambler BS, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1679–84

A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. Echt DS, et al. **J Cardiovasc Electrophysiol** 1995 Sep;6(9):687–99

Use of intravenous dofetilide in atrial flutter with hemodynamic instability. Kuruma A, et al. **Jpn Circ J** 1996 Jan;60(1):67–9

Clinical characteristics and EPS-guided therapy in 142 cases of sustained ventricular tachycardia. Ebe K, et al. **Jpn Heart J** 1996 Jan;37(1):73–84

Dangers of European resuscitation guidelines [letter] O'Kane D, et al. **Lancet** 1996 Feb 10;347(8998):400–1

Amiodarone in congestive heart failure [letter] Colli A. **N Engl J Med** 1995 Dec 14;333(24):1640; discussion 1640–1

Model features of a cardiac iontophoretic drug delivery implant. Schwendeman SP, et al. **Pharm Res** 1995 May; 12(5):790–5

[Current clinical interest in monitoring digoxinemia] Salerno L, et al. **Clin Ter** 1995 Dec;146(12):775–9 (Eng. Abstr.) **(Ita)**

[A comparison between propafenone and hydroquinidine perorally in the treatment of recent-onset atrial fibrillation] Satullo G, et al. **Minerva Cardioangiol** 1996 Mar;44(3):141–4 (Eng. Abstr.) **(Ita)**

[Effectiveness of mexitil-depot in patients with chronic ventricular arrhythmia] Golikov AP, et al. **Klin Med (Mosk)** 1995;73(6):45–6 (Eng. Abstr.) **(Rus)**

[The action of intravenous flecainide in experimental ventricular arrhythmias] de Micheli A, et al. **Arch Inst Cardiol Mex** 1995 Sep-Oct;65(5):403–12 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Amiodarone and sexual dysfunction [letter] Ahmad S. **Am Heart J** 1995 Dec;130(6):1320–1

Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. Boriani G, et al. **Am Heart J** 1996 Jun;131(6):1214–6

Verapamil-induced acute right heart failure. Shimoni A, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):193–4

Danger of amiodarone therapy and elevated inspired oxygen concentrations in mice. Donica SK, et al. **Am J Cardiol** 1996 Jan 1;77(1):109–10

Adenosine-induced atrial fibrillation. Silverman AJ, et al. **Am J Emerg Med** 1996 May;14(3):300–1

Death associated with inappropriate ketorolac dosing [letter] Gales BJ, et al. **Ann Pharmacother** 1995 Dec;29(12):1299

Interference with anticoagulation monitoring by procainamide-induced lupus anticoagulant. Metzdorff MT, et al. **Ann Thorac Surg** 1996 Mar;61(3):994–5

Sotalol proarrhythmia: a report of five cases and an audit of the use of a sotalol in a teaching hospital [see comments] Basta MN, et al. **Aust N Z J Med** 1996 Apr;26(2):167–70 . Comment in: Aust N Z J Med 1996 Apr;26(2):147–9.

Proarrhythmic complications of sotalol [editorial; comment] Campbell TJ. **Aust N Z J Med** 1996 Apr;26(2):147–8. Comment on: Aust N Z J Med 1996 Apr;26(2):167–70.

Insidiously evolving, occult drug interaction involving warfarin and amiodarone. Cheung B, et al. **BMJ** 1996 Jan 13;312(7023):107–8

Monitoring may need to be prolonged in patients given warfarin and amiodarone [letter] Tomlinson B, et al. **BMJ** 1996 Aug 3;313(7052):301–2

Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Greenberg HM, et al. **Br Heart J** 1995 Dec;74(6):631–5

Lymphocytic pleural exudate in a patient receiving amiodarone. Carmichael LC, et al. **Br J Clin Pract** 1996 Jun;50(4):228–30

Adverse drug reactions and drug substitution in an arrhythmia clinic. Sadek I, et al. **Can J Cardiol** 1995 Dec; 11(11):1001–4

What have clinical trials taught us about proarrhythmia? Skanes AC, et al. **Can J Cardiol** 1996 Apr;12 Suppl B:20B–26B (39 ref.)

Amiodarone and reversible benign intracranial hypertension [letter] Ahmad S. **Cardiology** 1996 Jan-Feb;87(1):90

Dilantin hypersensitivity reaction. Conger LA Jr, et al. **Cutis** 1996 Apr;57(4):223–6 (32 ref.)

Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Chimienti M, et al. **Eur Heart J** 1995 Dec;16(12):1943–51

Torsade de pointes—the Achilles' heel of arrhythmia therapy with drugs that prolong the cardiac action potential [editorial; comment] Crijns HJ. **Eur Heart J** 1995 May; 16(5):580–1. Comment on: Eur Heart J 1995 MAY;16(5):667–73.

Physiological and pathological responses of TU waves to class Ia antiarrhythmic drugs [see comments] Maruyama T, et al. **Eur Heart J** 1995 May;16(5):667–73. Comment in: Eur Heart J 1995 May;16(5):580–1.

Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy. Macarri G, et al. **Ital J Gastroenterol** 1995 Oct-Nov;27(8):436–8 (18 ref.)

Non-sustained broad-complex tachycardia following intravenous adenosine. Hingorani AD, et al. **J Accid Emerg Med** 1995 Sep;12(3):208–9

Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison

of sotalol versus quinidine. Hohnloser SH, et al. **J Am Coll Cardiol** 1995 Oct;26(4):852–8

Efficacy and proarrhythmia of oral sotalol in pediatric patients. Pfammatter JP, et al. **J Am Coll Cardiol** 1995 Oct; 26(4):1002–7

Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. Hohnloser SH, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):920–36 (102 ref.)

Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis. Chay TR. **J Electrocardiol** 1995;28 Suppl:191–7

Ultrastructural evidence of thyroid damage in amiodarone-induced thyrotoxicosis. Cappiello E, et al. **J Endocrinol Invest** 1995 Dec;18(11):862–8

Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy. Mörike K, et al. **J Intern Med** 1995 Nov; 238(5):469–72

Treatment guidelines for hyperthyroidism and hypothyroidism [letter; comment] Ahmad S. **JAMA** 1995 Oct 4;274(13):1011; discussion 1011–2. Comment on: JAMA 1995 Mar 8;273(10):808–12.

A case of amiodarone-associated pulmonary toxicity. Kwon KH, et al. **Korean J Intern Med** 1995 Jul;10(2):155–9

European guidelines on resuscitation [letter] Dick W, et al. **Lancet** 1996 Jun 1;347(9014):1558

Amiodarone in congestive heart failure [letter] Sechi LA, et al. **N Engl J Med** 1995 Dec 14;333(24):1640–1

Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity. Low CL, et al. **Nephrol Dial Transplant** 1996 May;11(5):881–4

An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity. Reasor MJ, et al. **Proc Soc Exp Biol Med** 1996 Sep;212(4):297–304 (89 ref.)

Amiodarone-induced bronchiolitis obliterans organizing pneumonia (BOOP). Oren S, et al. **Respir Med** 1996 Mar; 90(3):167–9

Skin side-effects of amiodarone therapy. Ettler K, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl** 1993;36(4–5):305–15

Recurrent amiodarone pulmonary toxicity. Chendrasekhar A, et al. **South Med J** 1996 Jan;89(1):85–6

Antiarrhythmic drug-induced side effects: a prospective survey of 300 patients. Vigreux P, et al. **Therapie** 1995 Sep–Oct;50(5):413–8

[Torsade de Pointes tachycardia during sotalol treatment of a patient with normal potassium levels] Appel JM, et al. **Ugeskr Laeger** 1996 Jul 8;158(28):4093–4 (Eng. Abstr.) **(Dan)**

[Sotalol and torsades de pointes ventricular tachycardia] Petersen HH, et al. **Ugeskr Laeger** 1996 May 6; 158(19):2711–6 (Eng. Abstr.) **(Dan)**

[Early diagnosis of amiodarone-induced pulmonary toxicity: are repeated lung function tests of any value?] Ulrik CS, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3445–7 (17 ref.) (Eng. Abstr.) **(Dan)**

[Hyperthyroidism induced by amiodarone and hyperthyroidism induced by iodine. Histologic, immunohistochemical and ultrastructural aspects] Guyétant S, et al. **Ann Pathol** 1995;15(6):431–7 (Eng. Abstr.) **(Fre)**

[Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications] Aouate P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1869–74 (27 ref.) (Eng. Abstr.) **(Fre)**

[Value of thyroidectomy in amiodarone-induced hyperthyroidism. Apropos of 3 cases] Painvin I, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):445–9 (Eng. Abstr.) **(Fre)**

[Effects of amiodarone on thyroid function] Caron P. **Presse Med** 1995 Dec 2;24(37):1747–51 (25 ref.) (Eng. Abstr.) **(Fre)**

[Proarrhythmic effects of anti-arrhythmia agents] Scanu P, et al. **Rev Med Interne** 1995;16(8):602–7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Cardioversion in atrial fibrillation. Results and complications in 1,152 prospective patients. Study Group of the Working Society of Leading Cardiologic Hospital Physicians] Tebbe U, et al. **Med Klin** 1995 Dec 15;90(12):681–7 (Eng. Abstr.) **(Ger)**

["Arrhythmica" or: history, extent and practical consequences of pro-arrhythmia effects] Gertsch M. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):566–75 (13 ref.) (Eng. Abstr.) **(Ger)**

[Sotalol-induced torsade de pointes tachycardia in a 15-month-old infant] Sasse M, et al. **Z Kardiol** 1995 Oct; 84(10):863–6 (Eng. Abstr.) **(Ger)**

[Adverse reactions to amiodarone] Edoute Y, et al. **Harefuah** 1995 Jul;129(1–2):57–61 (28 ref.) **(Heb)**

[Main cardiotoxic drugs] Pettirossi G, et al. **Clin Ter** 1996 Jan–Feb;147(1–2):67–77 (34 ref.) (Eng. Abstr.) **(Ita)**

[A case of primary antiphospholipid antibody syndrome associated with procainamide induced systemic lupus erythematosus] Muramatsu M, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1736–8 **(Jpn)**

[Pancreatitis and inappropriate ADH secretion syndrome associated with amiodarone] Muñoz Ruiz AI, et al. **An Med Interna** 1996 Mar;13(3):125–6 (Eng. Abstr.) **(Spa)**

[Acute hepatitis caused by intravenous amiodarone] Paniagua Clusells J, et al. **Rev Esp Cardiol** 1996 May;49(5):384–5 (Eng. Abstr.) **(Spa)**

[Osteoporosis is a suspected adverse effect of amiodarone] Linde C, et al. **Lakartidningen** 1996 Sep 4;93(36):3050–2 **(Swe)**

ANALYSIS

The development and cross-validation of methods based on radioimmunoassay and LC/MS-MS for the quantification of the class III antiarrhythmic agent, MK-0499, in human plasma and urine. Gilbert JD, et al. **J Pharm Biomed Anal** 1995 Jul;13(8):937–50

A systematic review and critical comparison of internal standards for the routine liquid chromatographic assay of amiodarone and desethylamiodarone. Pollak PT. **Ther Drug Monit** 1996 Apr;18(2):168–78 (53 ref.)

BLOOD

Antiarrhythmic effect related to the plasma concentration of pentisomide in vivo and the antiarrhythmic–concentration relationship in vitro. Hachisu M, et al. **Drugs Exp Clin Res** 1995;21(4):145–51

Differences in amiodarone, digoxin, flecainide and sotalol concentrations between antemortem serum and femoral postmortem blood. O'Sullivan JJ, et al. **Hum Exp Toxicol** 1995 Jul;14(7):605–8

Measurement of serum amiodarone and desethylamiodarone by HPLC: its usefulness in the follow-up of arrhythmic patients treated with amiodarone. Manfredi C, et al. **Int J Clin Pharmacol Res** 1995;15(2):87–93

Assay of tocainide enantiomers in plasma by solid-phase extraction and indirect chiral high-performance liquid chromatography after derivatization with (–)-menthyl chloroformate. Christensen EB, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):243–9

The effect of age and everyday exercise on steady-state plasma digoxin concentrations. Teague AC, et al. **Pharmacotherapy** 1995 Jul–Aug;15(4):502–8

[HPLC method for determination of lorcainide hydrochloride in human serum] Luo X, et al. **Yao Hsueh Hsueh Pao** 1995;30(8):605–9 (Eng. Abstr.) **(Chi)**

[The plasma concentration measurement of local anesthetics, thiobarbiturates and mexiletine by HPLC with automatic pre-treatment system] Kakinohana O, et al. **Masui** 1995 Aug;44(8):1165–70 (Eng. Abstr.) **(Jpn)**

[Procainamide] Nishihara K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:954–6 (8 ref.) **(Jpn)**

[Lidocaine hydrochloride] Saito Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:983–5 (9 ref.) **(Jpn)**

[Disopyramide, mexiletine, aprindine] Suzuki M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:989–93 (25 ref.) **(Jpn)**

[Beta-blocking agents] Suzuki M. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:978–82 (16 ref.) **(Jpn)**

[Quinidine] Yamada K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:957–9 (8 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Preparation, local anaesthetic and antiarrhythmic activity of pyrrolidinomethylcyclohexyl esters of alkoxysubstituted phenylcarbamic acids. Búčiová L, et al. **Pharmazie** 1995 Aug;50(8):566–7

CHEMISTRY

7-Benzyl-3-thia-7-azabicyclo[3.3.1]nonane 3-oxide. Hossain MB, et al. **Acta Crystallogr C** 1996 Apr 15;52 (Pt 4):995–8

Incompatibility of amiodarone hydrochloride and sodium bicarbonate injections [letter] Korth-Bradley JM, et al. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2340

Incompatibility of amiodarone hydrochloride and evacuated glass bottles [letter] Strozyk WR, et al. **Am J Health Syst Pharm** 1996 Jan 15;53(2):184

Fluorenone 1,4-dihydropyridine derivatives with cardiodepressant activity: enantiomeric separation by chiral HPLC and conformational aspects. Caccamese S, et al. **Chirality** 1996;8(3):281–90

Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperchlorate. Garrison GL, et al. **J Med Chem** 1996 Jun 21;39(13):2559–70

The kinetics of alkaline hydrolysis of the new potential antiarrhythmic, substance H + B, in the presence of beta-cyclodextrin. Stankovičová M, et al. **Pharmazie** 1995 Oct;50(10):705

Molecular interactions of quinidine with phospholipid bilayers. Suwalsky M, et al. **Z Naturforsch [C]** 1995 Jul–Aug;50(7–8):527–34

[The anti-arrhythmic action of amidinohydrazone substituted benzophenones. 8. The separation and configuration of the (Z)- and (E)-isomers] Keckeis A, et al. **Pharmazie** 1995 Dec;50(12):824–5 **(Ger)**

CLASSIFICATION

Clinical pharmacology and classification of antiarrhythmic drugs. MacFadyen RJ, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):515–9 (16 ref.)

DIAGNOSTIC USE

Results of dipyridamole plus atropine echo stress test for the diagnosis of coronary artery disease. Lanzarini L, et al. **Int J Card Imaging** 1995 Dec;11(4):233–40

[Use of high doses of atropine during dipyridamole echocardiography: safety and efficacy of the combined test] Coletta C, et al. **G Ital Cardiol** 1995 Nov;25(11):1389–98 (Eng. Abstr.) **(Ita)**

METABOLISM

Tiracizine disposition in healthy volunteers with reference to the debrisoquine oxidation phenotype [letter] Berndt A, et al. **Br J Clin Pharmacol** 1995 Sep;40(3):287–8

Antiarrhythmic drug binding sites in cardiac K+ channels [editorial; comment] Colatsky TJ. **Circ Res** 1996 Jun; 78(6):1115–6. Comment on: Circ Res 1996 Jun;78(6):1105–14.

High- and low-affinity sites for [3H]dofetilide binding to guinea pig myocytes. Duff HJ, et al. **Circ Res** 1995 Oct; 77(4):718–25

Molecular analysis of a binding site for quinidine in a human cardiac delayed rectifier K+ channel. Role of S6 in antiarrhythmic drug binding [see comments] Yeola SW, et al. **Circ Res** 1996 Jun;78(6):1105–14. Comment in: Circ Res 1996 Jun;78(6):1115–6.

Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Walker DK, et al. **Drug Metab Dispos** 1996 Apr;24(4):447–55

In vitro inhibition of midazolam and quinidine metabolism by flavonoids. Ha HR, et al. **Eur J Clin Pharmacol** 1995; 48(5):367–71

Metabolism and metabolite pharmacokinetics of BRB-I-28, a class Ib antiarrhythmic agent. Chen CL, et al. **Eur J Drug Metab Pharmacokinet** 1995 Apr–Jun; 20(2):151–61

Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans. Tisdale JE, et al. **J Clin Pharmacol** 1995 Sep;35(9):902–10

Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy. Mörike K, et al. **J Intern Med** 1995 Nov; 238(5):469–72

Metabolism of amiodarone following intratracheal instillation in hamsters. Blake TL, et al. **Toxicol Lett** 1995 Nov 15; 81(2–3):223–8

Protein binding of acetylsalicylic acid and salicylic acid in porcine and human serum. Lee S, et al. **Vet Hum Toxicol** 1995 Jun;37(3):224–5

Metabolism of a novel antiarrhythmic agent, bidisomide, in man: use of high resolution mass spectrometry to distinguish desisopropyl bidisomide from desacetyl bidisomide. Cook CS, et al. **Xenobiotica** 1995 Sep; 25(9):981–91

PHARMACOKINETICS

Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? Cooke CE, et al. **Ann Pharmacother** 1996 Apr;30(4):364–6

Pharmacokinetics of the antiarrhythmic agent tiracizine: steady state kinetics in comparison with single-dose kinetics. Berndt A, et al. **Biopharm Drug Dispos** 1995 Jul; 16(5):427–41

Pharmacokinetics of HI-6 and atropine in anaesthetized pigs after administration by a new autoinjector. Nyberg AG, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):635–51

Tiracizine disposition in healthy volunteers with reference to the debrisoquine oxidation phenotype [letter] Berndt A, et al. **Br J Clin Pharmacol** 1995 Sep;40(3):287–8

Pharmacokinetics of ibutilide and its enantiomers in dogs. Hsu CY, et al. **Chirality** 1996;8(1):18–23

Day-night variations in the renal excretion of the antiarrhythmic agent tiracizine and its metabolites. Berndt A, et al. **Chronobiol Int** 1995 Apr;12(2):135–40

Novel delivery of antiarrhythmic agents. Labhasetwar V, et al. **Clin Pharmacokinet** 1995 Jul;29(1):1–5 (24 ref.)

Absence of a pharmacokinetic interaction between quinidine and diazepam. Rao BR, et al. **Drug Metabol Drug Interact** 1995;12(1):45–51

Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites. Fromm MF, et al. **Eur J Clin Pharmacol** 1995;48(3–4):279–83

Lack of a kinetic interaction between fluconazole and mexiletine. Ueno K, et al. **Eur J Clin Pharmacol** 1996; 50(1–2):129–31

Metabolism and metabolite pharmacokinetics of BRB-I-28, a class Ib antiarrhythmic agent. Chen CL, et al. **Eur J Drug Metab Pharmacokinet** 1995 Apr–Jun; 20(2):151–61

Effect of the aluminium ion on hepatic elimination of quinine and quinidine. Jakovljević V, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul–Sep; 20(3):185–90

Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral

administration of disopyramide to arrhythmic patients. Masuhara K, et al. **Int J Clin Pharmacol Res** 1995; 15(3):103–13

New and simple method for estimating metildigoxin dosing regimens by multiple trough screen analysis. Yukawa E. **Int J Clin Pharmacol Ther** 1995 Nov;33(11):605–11

Clinical effects and pharmacokinetics of a single oral dose of pirmenol hydrochloride. Atarashi H, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):556–62

Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. Min DI, et al. **J Clin Pharmacol** 1996 May;36(5):469–76

Pharmacokinetics of moricizine in young patients. Rice PJ, et al. **J Clin Pharmacol** 1995 Oct;35(10):1016–9

Impact of a four-day head-down tilt (-6 degrees) on lidocaine pharmacokinetics used as probe to evaluate hepatic blood flow. Saivin S, et al. **J Clin Pharmacol** 1995 Jul;35(7):697–704

Effect of aging on atenolol pharmacokinetics and pharmacodynamics. Sowinski KM, et al. **J Clin Pharmacol** 1995 Aug;35(8):807–14

Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. Kharidia J, et al. **J Pharm Sci** 1996 Jun;85(6):595–9

Susceptibility to amiodarone-induced pulmonary toxicity: relationship to the uptake of amiodarone by isolated lung cells. Wilson BD, et al. **Lung** 1996;174(1):31–41

Isolation and characterization of sulphoxidation metabolites of moricizine in rat and human biological fluids. Yang JM, et al. **Methods Find Exp Clin Pharmacol** 1995 Jul-Aug; 17(6):415–21

Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity. Low CL, et al. **Nephrol Dial Transplant** 1996 May;11(5):881–4

Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations. Bauer LA, et al. **Ther Drug Monit** 1996 Feb; 18(1):46–52

Kinetics and dynamics of sematilide. Shi J, et al. **Ther Drug Monit** 1995 Oct;17(5):437–44

Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. Kwok DW, et al. **Xenobiotica** 1995 Nov;25(10):1127–42

[Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals] Gaete LE, et al. **Rev Med Chil** 1995 Jun;123(6):713–9 (18 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Flecainide blocks the stimulatory effect of veratridine on slowly adapting pulmonary stretch receptors in anaesthetized rabbits without changing lung mechanics. Matsumoto S, et al. **Acta Physiol Scand** 1995 Nov; 155(3):297–302

Converting enzyme inhibition, heart rate variability, and myocardial infarction [letter] Bonaduce D, et al. **Am J Cardiol** 1996 Sep 1;78(5):609

Propafenone pharmacokinetics and pharmacodynamics in patients with sustained ventricular tachycardia. Gillis AM, et al. **Am J Cardiol** 1996 Sep 1;78(5):579–81

Influence of metoprolol on heart rate variability in survivors of remote myocardial infarction. Keeley EC, et al. **Am J Cardiol** 1996 Mar 15;77(8):557–60

Does sotalol have reverse-use dependence during tachyarrhythmias? Kovoor P, et al. **Am J Cardiol** 1996 Jul 15;78(2):247–50

Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates. Roden DM. **Am J Cardiol** 1996 Aug 29;78(4A):12–6

Reverse use dependence of human ventricular repolarization by chronic oral sotalol in monophasic action potential recordings. Shimizu W, et al. **Am J Cardiol** 1996 May 1; 77(11):1004–8

Proarrhythmic and antiarrhythmic actions of ion channel blockers on arrhythmias in the heart: model study. Chay TR. **Am J Physiol** 1996 Jul;271(1 Pt 2):H329–56

Effects of intravenous anesthetics on atrial wavelength and atrioventricular nodal conduction in guinea pig heart. Potential antidysrhythmic properties and clinical implications. Napolitano CA, et al. **Anesthesiology** 1996 Aug;85(2):393–402

Effects of gallium chloride on changes in action potentials and contraction in guinea pig ventricular muscle. Kantelip JP, et al. **Anticancer Res** 1996 Jan-Feb;16(1):327–32

Mechanisms and management of congenital and acquired long QT syndromes. Lazzara R. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:51–5 (34 ref.)

Is there a need for new antiarrhythmic drugs? Roden DM. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:13–8 (36 ref.)

Topical beta-adrenergic antagonists and quinidine. A risky interaction [editorial] Higginbotham EJ. **Arch Ophthalmol** 1996 Jun;114(6):745–6 (7 ref.)

Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. Ching MS, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):833–7

Clinical pharmacology and classification of antiarrhythmic drugs. MacFadyen RJ, et al. **Br J Hosp Med** 1995 Nov 15-Dec 12;54(10):515–9 (16 ref.)

Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Chatelain P, et al. **Br J Pharmacol** 1995 Oct;116(3):1949–56

Thapsigargin- and cyclopiazonic acid-induced endothelium-dependent hyperpolarization in rat mesenteric artery. Fukao M, et al. **Br J Pharmacol** 1995 Jul; 115(6):987–92

SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells. Hara Y, et al. **Br J Pharmacol** 1995 Nov;116(6):2750–6

Quinidine blockade of the carbachol-activated nonselective cationic current in guinea-pig gastric myocytes. Kim SJ, et al. **Br J Pharmacol** 1995 Aug;115(8):1407–14

Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Puisieux FL, et al. **Br J Pharmacol** 1996 Apr;117(7):1377–9

Increase in action potential duration and inhibition of the delayed rectifier outward current IK by berberine in cat ventricular myocytes. Sánchez-Chapula J. **Br J Pharmacol** 1996 Apr;117(7):1427–34

Mexiletine-induced shortening of the action potential duration of ventricular muscles by activation of ATP-sensitive K+ channels. Sato T, et al. **Br J Pharmacol** 1995 Jun;115(3):381–2

Electrophysiological basis for antiarrhyithmic efficacy, positive inotropy and low proarrhythmic potential of (-)-caryachine. Wu MH, et al. **Br J Pharmacol** 1995 Dec; 116(8):3211–8

The relationship between glutamate release and cerebral blood flow after focal cerebral ischaemia in the cat: effect of pretreatment with enadoline (a kappa receptor agonist). MacKay KB, et al. **Brain Res** 1996 Mar 18;712(2):329–34

Heterogeneous effect of quinidine on the ventricular depolarization process assessed by the spatial velocity electrocardiogram of the QRS complex. Preliminary report of a new investigative method. Fareh S, et al. **Cardiology** 1996 Mar-Apr;87(2):129–32

Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion. Aidonidis I, et al. **Cardiovasc Drugs Ther** 1995 Aug; 9(4):555–63

Effect of magnesium on ischemic and reperfusion arrhythmias in a canine model with diminished collateral blood flow. Euler DE. **Cardiovasc Drugs Ther** 1995 Aug;9(4):565–71

"Normal" response of the QT interval and QT dispersion following intravenous injection of the sodium channel blocker disopyramide: methodological aspects. Nowinski K, et al. **Cardiovasc Drugs Ther** 1995 Aug;9(4):573–80

R56865 is antifibrillatory in reperfused ischemic guinea-pig hearts, even when given only during reperfusion. Scheufler E, et al. **Cardiovasc Drugs Ther** 1995 Aug;9(4):545–53

Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes. Cheng J, et al. **Cardiovasc Res** 1996 Jun;31(6):963–74

Effects of propafenone on the median frequency of ventricular fibrillation in Langendorff perfused guinea-pig hearts. Eggenreich U, et al. **Cardiovasc Res** 1996 Jun; 31(6):926–31

KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide. Ferdinandy P, et al. **Cardiovasc Res** 1995 Nov;30(5):781–7

Negative dromotropic effects of class I antiarrhythmic drugs in anisotropic ventricular muscle. Iida M, et al. **Cardiovasc Res** 1996 Apr;31(4):640–50

Ventricular relaxation in the stage 24 chick embryo following changes in volume and blockade of Na+ and Ca2+ channels. Naheed ZJ, et al. **Cardiovasc Res** 1996 Feb;31 Spec No:E139–44

Effect of pH and lidocaine on beta-adrenergic receptor binding. Interaction during resuscitation? Modest VE, et al. **Chest** 1995 Nov;108(5):1373–9

Effects of prazosin on rat, guinea pig and human cardiac tissues. Su MJ, et al. **Chin J Physiol** 1995;38(3):159–69

Depressant effect of taurine on triggered activity induced by cesium chloride in rabbit hearts in vivo. Kang Y, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):464–7

Effects of Panax notoginseng saponin Rg1 on cardiac electrophysiological properties and ventricular fibrillation threshold in dogs. Wu W, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):459–63

Effects of toquipidine on ionic channels of cultured embryonic Xenopus laevis myoblasts and neurons. Zheng P, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep; 16(5):427–39

Two components of delayed rectifier current in canine atrium and ventricle. Does IKs play a role in the reverse rate dependence of class III agents? Gintant GA. **Circ Res** 1996 Jan;78(1):26–37

Cloned human inward rectifier K+ channel as a target for class III methanesulfonanilides. Kiehn J, et al. **Circ Res** 1995 Dec;77(6):1151–5

Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. Spector PS, et al. **Circ Res** 1996 Mar;78(3):499–503

Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions. Holubarsch C, et al. **Circulation** 1995 Nov 15;92(10):2904–10

Unique ionic mechanism of action of ibutilide on freshly isolated heart cells [letter; comment] Lee KS, et al. **Circulation** 1995 Nov 1;92(9):2755–7. Comment on: Circulation 1995 Mar 15;91(6):1799–806.

ATP-dependent potassium channel in rat cardiomyocytes is blocked by lidocaine. Possible impact on the antiarrhythmic action of lidocaine. Olschewski A, et al. **Circulation** 1996 Feb 15;93(4):656–9

Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy [see comments] Schwartz PJ, et al. **Circulation** 1995 Dec 15;92(12):3381–6 . Comment in: Circulation 1995 Dec 15;92(12):3373–5.

Antiarrhythmic activity of quinine in humans. Sheldon R, et al. **Circulation** 1995 Nov 15;92(10):2944–50

Electrophysiological effects of changrolin, an anti-arrhythmic agent derived from Dichroa febrifuga, on guinea-pig and rabbit heart cells. Lu LL, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):337–41

Interactions between antiarrhythmic drugs and implantable cardioverter-defibrillators. Dougherty AH. **Curr Opin Cardiol** 1996 Jan;11(1):2–8 (25 ref.)

Absence of a pharmacokinetic interaction between quinidine and diazepam. Rao BR, et al. **Drug Metabol Drug Interact** 1995;12(1):45–51

Antiarrhythmic effect related to the plasma concentration of pentisomide in vivo and the antiarrhythmic-concentration relationship in vitro. Hachisu M, et al. **Drugs Exp Clin Res** 1995;21(4):145–51

Effect of diprafenone on the pharmacokinetics of digoxin. Koytchev R, et al. **Eur J Clin Pharmacol** 1996; 50(1-2):97–100

Lack of selectivity for ventricular and ischaemic tissue limits the antiarrhythmic actions of lidocaine, quinidine and flecainide against ischaemia-induced arrhythmias. Barrett TD, et al. **Eur J Pharmacol** 1995 Oct 24;285(3):229–38

Effect of antiarrhythmics on the release of adenosine in rat hearts with coronary occlusion and reperfusion. Bernauer W. **Eur J Pharmacol** 1995 Sep 5;283(1-3):91–8

The KATP blocker sodium 5-hydroxydecanoate does not abolish preconditioning in isolated rat hearts. Grover GJ, et al. **Eur J Pharmacol** 1995 Apr 24;277(2-3):271–4

Effect of channel modulation and pH on IsK inhibition by the novel class III antiarrhythmic azimilide (NE-10064). Herzer T, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):205–8

SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Hodeige D, et al. **Eur J Pharmacol** 1995 Jun 6; 279(1):25–32

The electrophysiologic effects of ersentilide on canine hearts. Lee JH, et al. **Eur J Pharmacol** 1995 Oct 4;285(1):25–35

BN-063, a newly synthesized adenosine A1 receptor agonist, attenuates myocardial reperfusion injury in rats. Lee YM, et al. **Eur J Pharmacol** 1995 Jun 12;279(2-3):251–6

Antiarrhythmic and bradycardic drugs inhibit currents of cloned K+ channels, KV1.2 and KV1.4. Yamagishi T, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):151–9

Negative chronotropic and dromotropic effects of E-4031, an IKr blocker, on the atrioventricular node in anesthetized dog hearts. Yamazaki K, et al. **Eur J Pharmacol** 1996 Feb 22;297(3):233–9

The effect of exogenous adenosine on functional injury caused by hydrogen peroxide in the isolated rat heart. Valen G, et al. **Free Radic Res** 1996 Jan;24(1):31–38

Effects of diltiazem and its analogue siratiazem on contraction and 45Ca2+ uptake in sheep coronary artery rings. Hagerty M, et al. **Gen Pharmacol** 1995 Oct; 26(6):1349–54

Three distinct components of the negative inotropic action of lidocaine in dog Purkinje fiber. Pankucsi C, et al. **Gen Pharmacol** 1996 Jan;27(1):69–71

Sotalol facilitates spontaneous ventricular defibrillation by enhancing intercellular coupling. An entirely new mechanism for its antiarrhythmic action. Uchiyama H, et al. **Heart Vessels** 1995;10(4):185–9

Effects of disopyramide on the atrial fibrillation threshold in the human atrium. Ishibashi K, et al. **Int J Cardiol** 1995 Nov 24;52(2):177–84

QT prolongation and polymorphous ventricular tachycardia associated with trasodone-amiodarone combination. Mazur A, et al. **Int J Cardiol** 1995 Nov 10;52(1):27–9

Electrophysiologic characteristics, electropharmacologic responses and radiofrequency ablation in patients with decremental accessory pathway. Chen SA, et al. **J Am Coll Cardiol** 1996 Sep;28(3):732–7

Pharmacologic alterations in human type I atrial flutter cycle length and monophasic action potential duration. Evidence of a fully excitable gap in the reentrant circuit. Stambler BS, et al. **J Am Coll Cardiol** 1996 Feb;27(2):453–61

Mechanism of antiarrhythmic drug-induced changes in defibrillation threshold: role of potassium and sodium channel conductance. Ujhelyi MR, et al. **J Am Coll Cardiol** 1996 May;27(6):1534–42

Ethmozine and ethacizine—new antiarrhythmic drugs with defibrillating properties. Varon D, et al. **J Basic Clin Physiol Pharmacol** 1993 Oct-Dec;4(4):299–311

Membrane interactions of some catamphiphilic drugs and

relation to their multidrug-resistance-reversing ability. Pajeva IK, et al. **J Cancer Res Clin Oncol** 1996;122(1):27–40

Selective Ik blocker almokalant exhibits class III--specific effects on the repolarization and refractoriness of the human heart: a study of healthy volunteers using right ventricular monophasic action potential recordings [see comments] Darpö B, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):530–40. Comment in: J Cardiovasc Pharmacol 1995 Oct;26(4):524–7.

Amiodarone is a dose-dependent noncompetitive and competitive inhibitor of T3 binding to thyroid hormone receptor subtype beta 1, whereas disopyramide, lignocaine, propafenone, metoprolol, dl-sotalol, and verapamil have no inhibitory effect. Drvota V, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):222–6

The ethical issue--not only healthy volunteers! [editorial; comment] Edvardsson N, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):528–9. Comment on: J Cardiovasc Pharmacol 1995 Oct;26(4):524–7.

Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. Fermini B, et al. **J Cardiovasc Pharmacol** 1995 Aug; 26(2):259–71

Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration. Grover GJ, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):145–52

Protective effects of All-trans-retinoic acid against cardiac arrhythmias induced by isoproterenol, lysophosphatidylcholine or ischemia and reperfusion. Kang JX, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):943–8

Mechanisms of negative inotropic effects of class Ic antiarrhythmic agents: comparative study of the effects of flecainide and pilsicainide on intracellular calcium handling in dog ventricular myocardium. Kihara Y, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):42–51

Recording of transmembrane action potentials in chronic ischemic heart disease and dilated cardiomyopathy and the effects of the new class III antiarrhythmic agents D-sotalol and dofetilide. Montero M, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):571–7

Pharmacological analysis in rat of the role of the ATP-sensitive potassium channel as a potential target for antifibrillatory intervention in acute myocardial ischaemia. Rees SA, et al. **J Cardiovasc Pharmacol** 1995 Aug; 26(2):280–8

Kinetics of frequency-dependent conduction delay by class I antiarrhythmic drugs in human atrium. Sakai R, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):953–60

Rate-dependent effects of detajmium and propafenone on ventricular conduction and refractoriness in isolated guinea pig hearts. Stark U, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):125–31

Electrophysiological effects of SD-3212, a novel antiarrhythmic agent, on rabbit hearts in vivo and in vitro. Takahashi N, et al. **J Cardiovasc Pharmacol** 1995 Jun; 25(6):1006–11

K+ channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity. Vanoli E, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):847–54

Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig. Wiesfeld AC, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):594–600

Is the ECG measure RSh a promising technique for detecting class I antiarrhythmic drug action in men? Wolzt M, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):660–5

Comparison of direct negative chronotropic and positive inotropic effects of sematilide to those of E-4031 and MS-551 and the reverse frequency-dependent prolongation of cardiac refractoriness of sematilide. Yamada A, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):159–66

Single-dose interaction study of diprafenone HCl and propranolol HCl in healthy volunteers. Hinderling PH, et al. **J Clin Pharmacol** 1995 Jul;35(7):721–9

Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. Min DI, et al. **J Clin Pharmacol** 1996 May;36(5):469–76

Acid, basic and neutral soluble and membrane-bound aminopeptidase activities after lidocaine administration in discrete areas of the rat brain. de Gandarias JM, et al. **J Hirnforsch** 1995;36(3):349–52

Effects of stobadine on survival, histopathologic outcome and acid-base status after global brain ischemia in dogs. Pomfy M, et al. **J Hirnforsch** 1995;36(3):365–78

Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperchlorate. Garrison GL, et al. **J Med Chem** 1996 Jun 21;39(13):2559–70

Effects of cyclopiazonic acid on membrane currents, contraction and intracellular calcium transients in frog heart. Badaoui A, et al. **J Mol Cell Cardiol** 1995 Nov; 27(11):2495–505

Antiarrhythmic and electrophysiological effects in-vivo of the major metabolite of Org 7797 found in canine and rodent liver homogenate preparations. Winslow E, et al. **J Pharm Pharmacol** 1995 Jul;47(7):608–13

Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. Kharidia J, et al. **J Pharm Sci** 1996 Jun;85(6):595–9

Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. Bril A, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):637–46

Dual actions of the novel class III antiarrhythmic drug NE-10064 on delayed potassium channel currents in guinea pig ventricular and sinoatrial node cells. Davies MP, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1149–54

d-Sotalol terminates reentry by two mechanisms with different dependence on the duration of the excitable gap. Fei H, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):174–85

Selective inhibition by a class III antiarrhythmic agent, E-4031, of the negative chronotropic response to parasympathetic stimulation in anesthetized dogs. Imamura H, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):467–72

Acute amiodarone terminates ventricular fibrillation by modifying cellular Ca++ homeostasis in isolated perfused rat hearts. Kojima S, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):254–62

Actions of the benzopyran compound terikalant on macroscopic currents in rat ventricular myocytes. McLarnon JG, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):389–96

Intracellular [Mg++] determines specificity of K+ channel block by a class III antiarrhythmic drug. Sudo GZ, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):951–7

Saralasin suppresses arrhythmias in an isolated guinea pig ventricular free wall model of simulated ischemia and reperfusion. Thomas GP, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1379–86

Effect of captopril on membrane currents of ventricular myocytes. Wang YG, et al. **J Tongji Med Univ** 1995; 15(4):209–11

Transient prolongation of ventricular action potential duration after metabolic inhibition. Kasama M, et al. **Jpn Heart J** 1995 Nov;36(6):775–87

Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. Haruno A, et al. **Jpn J Pharmacol** 1995 May;68(1):95–102

Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias. Hashimoto K, et al. **Jpn J Pharmacol** 1995 May;68(1):1–9

Effects of sematilide, a novel class III antiarrhythmic agent, on action potential in guinea pig atrium. Ishii Y, et al. **Jpn J Pharmacol** 1995 Jun;68(2):175–82

Effects of dofetilide on membrane currents in sinoatrial node cells of rabbit. Tohse N, et al. **Jpn J Pharmacol** 1995 Dec; 69(4):303–9

Effects of halothane and isoflurane on rat ventricular action potentials recorded in situ. Hayes ES, et al. **Life Sci** 1996; 58(16):1375–85

Is cyclic AMP involved in the defibrillating effect of sotalol? Miyachi E, et al. **Life Sci** 1995 Nov 17;57(26):PL393–9

Mapping the block of a cloned human inward rectifier potassium channel by dofetilide. Kiehn J, et al. **Mol Pharmacol** 1996 Aug;50(2):380–7

High affinity open channel block by dofetilide of HERG expressed in a human cell line. Snyders DJ, et al. **Mol Pharmacol** 1996 Jun;49(6):949–55

Characterization of the sensitivity of cardiac outwardly-rectifying K+ channels to class III antiarrhythmics: the influence of inhibitory sulfonamide derivatives. Benz I, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):313–21

Effects of cromakalim or glibenclamide on arrhythmias and dispersion of refractoriness in chronically infarcted in anesthetized dogs. D'Alonzo AJ, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug; 352(2):222–8

Effects of the class III antiarrhythmic drug ambasilide on outward currents in human atrial myocytes. Koidl B, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jan; 353(2):226–32

Electrophysiological effects of dridocainide on isolated canine, guinea-pig and human cardiac tissues. Pankucsi C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Nov; 352(5):520–8

Effect of chronic oral moricizine and intravenous epinephrine on ventricular fibrillation and defibrillation thresholds. Pharand C, et al. **Pacing Clin Electrophysiol** 1996 Jan; 19(1):82–9

Effects of flecainide, encainide, and clofilium on ventricular refractory period extension by transcardiac shocks. Sweeney RJ, et al. **Pacing Clin Electrophysiol** 1996 Jan; 19(1):50–60

Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. Whalley DW, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1686–704 (119 ref.)

Interaction between external Na+ and mexiletine on Na+ channel in guinea-pig ventricular myocytes. Ono M, et al. **Pflugers Arch** 1995 Nov;431(1):101–9

Inhibition of ATP-sensitive potassium channels in cardiac myocytes by the novel class III antiarrhythmic agent MS-551. Martin DK, et al. **Pharmacol Toxicol** 1995 Jul; 77(1):65–70

Selective inhibition of human TNF-alpha action by flecainide acetate, an antiarrhythmic drug. Nojima S, et al. **Physiol Chem Phys Med NMR** 1995;27(2):77–89

The influence of selected antiarrhythmic drugs on the hemodynamic parameters in rabbits during anesthesia. Part I. Propofol anesthesia. Orszulak-Michalak D. **Pol J Pharmacol** 1995 Mar-Apr;47(2):143–52

The influence of selected antiarrhythmic drugs on the hemodynamic parameters in rabbits during anesthesia. Part II. Thiopental anesthesia. Orszulak-Michalak D, et al. **Pol J Pharmacol** 1995 Mar-Apr;47(2):153–62

Molecular determinants of drug access to the receptor site for antiarrhythmic drugs in the cardiac Na+ channel. Qu Y, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5; 92(25):11839–43

Can phenytoin lower plasma fibrinogen concentrations? Goerdt C, et al. **Thromb Res** 1995 Aug 1;79(3):231–6

The effects of atropine and glycopyrrolate on heart rates in conscious mature goats. Pablo LS, et al. **Vet Surg** 1995 Nov-Dec;24(6):531–4

[Effects of nicorandil on spontaneous beating and action potentials of cultured myocardial cells of neonatal rats] Wang HX, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep; 16(5):477–80 (Eng. Abstr.) **(Chi)**

[Flecainide acetate] Bordier P, et al. **Ann Cardiol Angeiol (Paris)** 1996 May;45(5):263–79 (135 ref.) (Eng. Abstr.) **(Fre)**

[Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation] Telichowski A, et al. **Pol Arch Med Wewn** 1995 Aug;94(2):132–43 (Eng. Abstr.) **(Pol)**

[Variability of antiarrhythmic drug action in prolonging action potential duration during various rates of heart action] Zakrzewski D, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):383–7 (20 ref.) **(Pol)**

[Sotalol interference in the determination of urinary metanephrine (letter)] Motjé Casas M, et al. **Med Clin (Barc)** 1995 Nov 25;105(18):716–7 **(Spa)**

POISONING

Role of the parasympathetic autonomic nervous system in digitalis intoxication: electrocardiographic and histological study. Princi T, et al. **Acta Med Croatica** 1996;50(2):81–5

Persistent electrocardiographic changes after flecainide overdose. Greig J, et al. **Br J Clin Pract** 1995 Jul-Aug; 49(4):218–9

Systemic inflammatory response syndrome caused by chronic salicylate intoxication. Chalasani N, et al. **South Med J** 1996 May;89(5):479–82

[Computerized tomography aspects of amiodarone poisoning] Pitton MB, et al. **Aktuelle Radiol** 1995 Jul;5(4):222–6 (Eng. Abstr.) **(Ger)**

[Cardiogenic shock and ventricular fibrillation induced by prajmalium and metoprolol poisoning] Almási R, et al. **Orv Hetil** 1996 Mar 31;137(13):695–700 (Eng. Abstr.) **(Hun)**

SUPPLY & DISTRIBUTION

Discontinuation of Sotazide [letter] Millar RS. **S Afr Med J** 1996 Apr;86(4):381

THERAPEUTIC USE

The principles and the PEA [editorial; comment] Christenson JM. **Acad Emerg Med** 1995 Dec;2(12):1023–4. Comment on: Acad Emerg Med 1995 Dec;2(12):1034–41.

Antiarrhythmic effects of magnesium sulphate. Report of three cases. Knudsen K, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):850–4

Suppression of ventricular tachycardia by sotalol in myotonic dystrophy. Cohen MB, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):446–9

Clinical spectrum, therapeutic management, and follow-up of ventricular tachycardia in infants and young children. Davis AM, et al. **Am Heart J** 1996 Jan;131(1):186–91

Effect of parenteral d-sotalol on transvenous atrial defibrillation threshold in a canine model of atrial fibrillation. Iskos D, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):116–9

Evolution of the management of malignant ventricular tachyarrhythmias: the roles of drug therapy and implantable defibrillators [editorial] Kim SG. **Am Heart J** 1995 Nov;130(5):1144–50 (59 ref.)

Drug therapy versus implantation of a cardiac defibrillator for the treatment of malignant arrhythmias in left ventricular dysfunction [editorial] Mannino MM, et al. **Am Heart J** 1996 Jun;131(6):1251–9 (44 ref.)

Holter-guided identification of premature ventricular contractions susceptible to suppression by beta-blockers. Pitzalis MV, et al. **Am Heart J** 1996 Mar;131(3):508–15

Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome. Tanel RE, et al. **Am Heart J** 1995 Oct;130(4):791–7

Efficacy and risks of medical therapy for supraventricular tachycardia in neonates and infants. Weindling SN, et al. **Am Heart J** 1996 Jan;131(1):66–72

A symposium: Supraventricular Arrhythmias: Update 1995. Boston, Massachusetts, May 6, 1995. **Am J Cardiol** 1996 Jan 25;77(3):1A–95A

Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Aliot E, et al. **Am J Cardiol** 1996

Jan 25;77(3):66A-71A

Maintaining sinus rhythm with antifibrillatory drugs in atrial fibrillation. Antman EM. **Am J Cardiol** 1996 Aug 29; 78(4A):67-72 (23 ref.)

Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. Bashir Y, et al. **Am J Cardiol** 1995 Nov 15;76(14):1040-4

Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. Chimienti M, et al. **Am J Cardiol** 1996 Jan 25;77(3):60A-75A

Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. Doni F, et al. **Am J Cardiol** 1995 Dec 15;76(17):1243-6

A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. The Flecainide Multicenter Investigators Group. Dorian P, et al. **Am J Cardiol** 1996 Jan 25;77(3):89A-95A

Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Falcone RA, et al. **Am J Cardiol** 1996 Aug 15;78(4):435-9

Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias. Foster MT, et al. **Am J Cardiol** 1996 Jul 1;78(1):47-50

Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia [see comments] Gorgels AP, et al. **Am J Cardiol** 1996 Jul 1; 78(1):43-6. Comment in: Am J Cardiol 1996 Jul 1;78(1):82-3.

Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy. Greene HL. **Am J Cardiol** 1996 Aug 29;78(4A):61-6 (49 ref.)

Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia. Hellestrand KJ. **Am J Cardiol** 1996 Jan 25;77(3):83A-88A

Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. Hopson JR, et al. **Am J Cardiol** 1996 Jan 25;77(3):72A-82A

Prospective trials of implantable cardioverter defibrillators versus drugs: are they addressing the right question? [editorial] Josephson M, et al. **Am J Cardiol** 1996 Apr 15; 77(10):859-63 (29 ref.)

Lidocaine and sustained monomorphic ventricular tachycardia: fact or fiction [editorial; comment] Josephson ME. **Am J Cardiol** 1996 Jul 1;78(1):82-3. Comment on: Am J Cardiol 1996 Jul 1;78(1):43-6.

From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Lazzara R. **Am J Cardiol** 1996 Aug 29;78(4A):28-33

Theoretical aspect of effective antiarrhythmic therapy: ventricular arrhythmia and drugs that prolong action potential duration (APD) [letter] Mkparu FO. **Am J Cardiol** 1995 Oct 15;76(11):856

Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Naccarelli GV, et al. **Am J Cardiol** 1996 Jan 25; 77(3):53A-59A

Evolving role of sotalol in the management of ventricular tachyarrhythmias. O'Callaghan PA, et al. **Am J Cardiol** 1996 Aug 29;78(4A):54-60 (40 ref.)

Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. Podrid PJ, et al. **Am J Cardiol** 1996 Aug 15;78(4):430-4

Implications of the Electrophysiologic Study versus Electrocardiographic Monitoring trial for controlling ventricular tachycardia and fibrillation. Reiffel JA. **Am J Cardiol** 1996 Aug 29;78(4A):34-40

Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Singh BN. **Am J Cardiol** 1996 Aug 29; 78(4A):41-53 (64 ref.)

The coming of age of the class III antiarrhythmic principle: retrospective and future trends. Singh BN. **Am J Cardiol** 1996 Aug 29;78(4A):17-27

Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Stambler BS, et al. **Am J Cardiol** 1996 May 1;77(11):960-6

Amiodarone for prevention of atrial fibrillation [letter; comment] van 't Hof AW, et al. **Am J Cardiol** 1996 Feb 1;77(4):327. Comment on: Am J Cardiol 1995 Jul 1;76(1):47-50.

Evaluation of end points of serial drug testing in patients with sustained ventricular tachycardia after healing of acute myocardial infarction. Wasilewski SJ, et al. **Am J Cardiol** 1995 Dec 15;76(17):1247-52

Effect of sotalol on RR interval variability during induced ventricular tachycardia. Yli-Mäyry S, et al. **Am J Cardiol** 1996 Aug 1;78(3):372-6

The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice. Kellen JC, et al. **Am J Crit Care** 1996 Jan;5(1):19-25

Intravenous calcium chloride in the conversion of paroxysmal supraventricular tachycardia to normal sinus rhythm. O'Brien JF, et al. **Am J Emerg Med** 1996 Jan; 14(1):50-2

Magnesium sulfate for conversion of supraventricular tachycardia refractory to intravenous adenosine. LeDuc TJ, et al. **Ann Emerg Med** 1996 Mar;27(3):375-8

Adenosine in acute theophylline intoxication. Blery JC, et al. **Ann Pharmacother** 1995 Dec;29(12):1285-7

Sotalol prophylaxis and treatment of atrial fibrillation. Pill MW, et al. **Ann Pharmacother** 1996 Apr;30(4):399-401

Amiodarone for ventricular tachycardia after coronary artery bypass grafting [letter] [see comments] Terada Y, et al. **Ann Thorac Surg** 1995 Oct;60(4):1155. Comment in: Ann Thorac Surg 1996 Jun;61(6):1874.

Verapamil as prophylactic treatment for atrial fibrillation after lung operations. Van Mieghem W, et al. **Ann Thorac Surg** 1996 Apr;61(4):1083-5; discussion 1086

Amiodarone for ventricular tachycardia after coronary artery bypass grafting [letter; comment] Wood MK. **Ann Thorac Surg** 1996 Jun;61(6):1874. Comment on: Ann Thorac Surg 1995 Oct;60(4):1155.

The cardiac ion channels: relevance to management of arrhythmias. Roden DM, et al. **Annu Rev Med** 1996; 47:135-48 (66 ref.)

The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. Kerin NZ, et al. **Arch Intern Med** 1996 Jan 8;156(1):49-53

Intravenous amiodarone for the conversion of atrial fibrillation [letter] Storch HD. **Arch Intern Med** 1996 Sep 9;156(16):1889

Post-infarction sustained ventricular tachycardias. The role of drugs and methods for assessing antiarrhythmic efficacy. Campbell RW. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:33-6

Nonsustained ventricular tachycardia in ischemic heart disease: when and which pharmacological treatment? El-Sherif N, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:29-32

Effects of dofetilide on electrical dispersion and arrhythmias in post-infarcted anesthetized dogs. D'Alonzo AJ, et al. **Basic Res Cardiol** 1995 Sep-Oct;90(5):424-34

Drugs for atrial fibrillation. Digoxin comes from Digitalis lanata [letter; comment] Hollman A. **BMJ** 1996 Apr 6; 312(7035):912. Comment on: BMJ 1995 Dec 16;311(7020):1631-4.

ABC of atrial fibrillation. Drugs for atrial fibrillation [see comments] Lip GY, et al. **BMJ** 1995 Dec 16; 311(7020):1631-4 (4 ref.). Comment in: BMJ 1996 Apr 6;312(7035):911-2. Comment in: BMJ 1996 Apr 6;312(7035):912.

Assessment of arrhythmias after myocardial infarction in the post-CAST era. Camm AJ, et al. **Can J Cardiol** 1996 Apr; 12 Suppl B:9B-19B; discussion 27B-28B (106 ref.)

Heart rate control in patients with atrial fibrillation. Gardner MJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:21A-23A (26 ref.)

An overview of antiarrhythmic drug management of electrical storm. Kowey PR. **Can J Cardiol** 1996 Apr;12 Suppl B:3B-8B; discussion 27B-28B (15 ref.)

Chronic drug therapy to prevent recurrence of atrial fibrillation. Newman D, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:24A-28A (43 ref.)

Restoration of sinus rhythm in patients with atrial fibrillation. Talajic M, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:29A-35A (83 ref.)

Antiarrhythmic effects of ceruloplasmin during reperfusion in the ischemic isolated rat heart. Atanasiu R, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1253-61

Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy. Hongo M, et al. **Cardiology** 1996 Jan-Feb;87(1):6-11

Electropharmacologic characteristics and radiofrequency catheter ablation of sustained ventricular tachycardia in patients without structural heart disease. Lee SH, et al. **Cardiology** 1996 Jan-Feb;87(1):33-41

Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction. Koch KT, et al. **Cardiovasc Drugs Ther** 1995 Jun; 9(3):437-43

Rate-dependent anisotropic conduction property in the epicardial border zone of canine myocardial infarcts and its modification by moricizine. Tsutsumi N, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):715-22

A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. **Circulation** 1995 Nov 1;92(9):2550-7

ESVEM tells us what we don't know [letter] Anderson KP, et al. **Circulation** 1995 Nov 15;92(10):3144

Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study. Bellandi F, et al. **Clin Cardiol** 1995 Nov;18(11):631-4

Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. Fresco C, et al. **Clin Cardiol** 1996 May;19(5):409-12

Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Moran JL, et al. **Crit Care Med** 1995 Nov;23(11):1816-24

The antiarrhythmic treatment of atrial fibrillation. **Drug Ther Bull** 1996 Jun;34(6):41-5 (34 ref.)

Guidelines for the use of propafenone in treating supraventricular arrhythmias. Kishore AG, et al. **Drugs** 1995 Aug;50(2):250-62 (73 ref.)

Narrow complex tachycardias. Collier WW, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):925-54 (99 ref.)

Atrial fibrillation: steering a management course between thromboembolism and proarrhythmic risk. Campbell RW. **Eur Heart J** 1995 Aug;16 Suppl G:28-31 (56 ref.)

Should post-infarction asymptomatic ventricular arrhythmias be treated? Campbell RW. **Eur Heart J** 1995 Jul;16 Suppl E:46-8 (37 ref.)

Studies on conversion of recent onset AF to sinus rhythm have to be controlled [letter; comment] Capucci A, et al. **Eur Heart J** 1995 May;16(5):719-20. Comment on: Eur Heart J 1994 Oct;15(10):1396-402.

Digitalis--friend or foe? Erdmann E. **Eur Heart J** 1995 Jul; 16 Suppl F:16-9 (18 ref.)

The Sicilian gambit: an opening move that loses the game? Garratt CJ, et al. **Eur Heart J** 1996 Mar;17(3):341-3

Future prospects of antiarrhythmic treatment based on experimental studies. Janse MJ. **Eur Heart J** 1995 Aug;16 Suppl G:2-6 (44 ref.)

Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms. Katritsis D, et al. **Eur Heart J** 1995 Dec; 16(12):1930-5

Complex frequency-dependent interaction of class-I antiarrhythmic drugs as they affect intraventricular conduction. Lee JK, et al. **Eur Heart J** 1995 Jun; 16(6):832-41

Consequences of the Sicilian Gambit. Rosen MR. **Eur Heart J** 1995 Aug;16 Suppl G:32-6

Should post-infarction asymptomatic ventricular arrhythmias be treated? The need for caution. Sleight P. **Eur Heart J** 1995 Jul;16 Suppl E:49 (29 ref.)

Continuation of antiarrhythmic drugs, or arrhythmia surgery after multiple drug failures. A randomized trial in the treatment of postinfarction ventricular tachycardia. van Hemel NM, et al. **Eur Heart J** 1996 Apr;17(4):564-73

Drug-induced narrowing of the width of the zone of entrainment as a predictor of the subsequent non-inducibility of reentrant ventricular tachycardia after an additional dose of an antiarrhythmic drug. Aizawa Y, et al. **Heart** 1996 Feb;75(2):165-70

Discrepant effects of mexiletine on cycle length of ventricular tachycardia and on the effective refractory period in the area of slow conduction. Aizawa Y, et al. **Heart** 1996 Mar; 75(3):281-6

Class III Antiarrhythmics: put to the SWORD? [editorial] Cobbe SM. **Heart** 1996 Feb;75(2):111-3

Amiodarone in congestive heart failure: unravelling the GESICA and CHF-STAT differences [editorial] Hammill SC, et al. **Heart** 1996 Jan;75(1):6-7

Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction. Rodríguez LM, et al. **Heart** 1996 Jan;75(1):23-8

Comparison of electrophysiologic effects and efficacy of single-dose intravenous and long-term oral amiodarone therapy in patients with AV nodal reentrant tachycardia. Gambhir DS, et al. **Indian Heart J** 1996 Mar-Apr; 48(2):133-7

Management of cardiac arrest survivors: drugs or devices. Madan N, et al. **Indian Heart J** 1995 Jul-Aug;47(4):387-93 (38 ref.)

Propranolol in supraventricular tachycardia [letter; comment] Gulati SK, et al. **Indian Pediatr** 1995 Feb; 32(2):244-6. Comment on: Indian Pediatr 1994 May;31(5):588-91.

Adjunctive magnesium infusion therapy in acute myocardial infarction. Bhargava B, et al. **Int J Cardiol** 1995 Nov 24; 52(2):95-9

Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients. Masuhara K, et al. **Int J Clin Pharmacol Res** 1995; 15(3):103-13

Treatment of fetal supraventricular tachycardia with maternal administration of digoxin [letter] Mozas J, et al. **Int J Gynaecol Obstet** 1995 Sep;50(3):293-4

Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Hohnloser SH, et al. **J Am Coll Cardiol** 1995 Oct;26(4):852-8

Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. Miyazaki T, et al. **J Am Coll Cardiol** 1996 Apr; 27(5):1061-70

Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography. Okada Y, et al. **J Am Coll Cardiol** 1996 Jan;27(1):84-9

Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants? O'Sullivan JJ, et al. **J Am Coll Cardiol** 1995 Oct;26(4):991-4

Efficacy and proarrhythmia of oral sotalol in pediatric patients. Pfammatter JP, et al. **J Am Coll Cardiol** 1995 Oct;

26(4):1002-7

Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. Shimizu W, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1299-309

Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators. Stevens SK, et al. **J Am Coll Cardiol** 1996 Aug;28(2):418-22

Mechanism of antiarrhythmic drug-induced changes in defibrillation threshold: role of potassium and sodium channel conductance. Ujhelyi MR, et al. **J Am Coll Cardiol** 1996 May;27(6):1534-42

Amiodarone and phenytoin: interaction [letter] Ahmad S. **J Am Geriatr Soc** 1995 Dec;43(12):1449-50

Efficacy of oral diltiazem and digoxin alone and in combination in chronic atrial fibrillation. Gupta RP, et al. **J Assoc Physicians India** 1995 Nov;43(11):781

Efficacy of intravenous magnesium sulphate in supraventricular tachyarrhythmias [see comments] Joshi PP, et al. **J Assoc Physicians India** 1995 Aug;43(8):529-31 . Comment in: J Assoc Physicians India 1995 Aug;43(8):527-8.

Chemical defibrillation in acute myocardial ischaemia: a hypothesis. Curtis MJ. **J Basic Clin Physiol Pharmacol** 1994 Jan-Mar;5(1):1-17

A new class of antiarrhythmic--defibrillatory compounds. Erez M, et al. **J Basic Clin Physiol Pharmacol** 1994 Jan-Mar;5(1):59-66

Changing Perspectives in Cardiac Arrhythmia Control: Agents, Techniques, Goals, and Outcomes. Symposium proceedings. Dallas, Texas, November 13, 1994. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):865-978

Effects of optical enantiomers CK-4000(S) and CK-4001(R) on defibrillation and enhancement of shock-induced extension of action potential duration. Beatch GN, et al. **J Cardiovasc Electrophysiol** 1995 Sep;6(9):716-28

Drugs versus devices: contemporary practice in light of contemporary trials. Epstein AE. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):937-41 (32 ref.)

Parenteral antiarrhythmics for life-threatening ventricular arrhythmias. Filart RA, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):901-13 (70 ref.)

Propafenone: an effective agent for the management of supraventricular arrhythmias. Grant AO. **J Cardiovasc Electrophysiol** 1996 Apr;7(4):353-64 (74 ref.)

Cardiac arrhythmias and antiarrhythmic drugs: recent advances in our understanding of mechanism. Rosen MR. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):868-79 (40 ref.)

Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents--focus on amiodarone. Scheinman MM. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):914-9 (34 ref.)

Expanding indications for the use of Class III agents in patients at high risk for sudden death. Singh BN. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):887-900 (47 ref.)

Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia. Antz M, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):627-35

Clinical effects and pharmacokinetics of a single oral dose of pirmenol hydrochloride. Atarashi H, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):556-62

Acute antiarrhythmic effects of intravenously administered amiodarone on canine ventricular arrhythmia. Awaji T, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):869-78

Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia. Almokalant PSVT Study Group. Darpö B, et al. **J Cardiovasc Pharmacol** 1995 Aug; 26(2):198-206

Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. Finance O, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):570-6

Antifibrillatory effects of BRL-32872 in anesthetized Yucatan minipigs with regional myocardial ischemia. Gout B, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):636-44

Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs. Lu HR, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):132-6

SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. Manning AS, et al. **J Cardiovasc Pharmacol** 1995 Sep; 26(3):453-61

Comparative effects of rilmenidine and atenolol on tests of autonomic function and mental and dynamic exercise in patients with essential hypertension. Panfilov V, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S44-7

Fractal dimension predicts arrhythmia recurrence in patients being treated for life-threatening ventricular arrhythmias. ESVEM Investigators. Karagounis LA, et al. **J Electrocardiol** 1995;28 Suppl:71-3

Polymorphous ventricular tachycardia following cardiopulmonary bypass. Thompson LD, et al. **J Natl Med Assoc** 1996 Jan;88(1):49-51

Differential efficacy of the class III agent MK-499 against programmed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction. Lynch JJ Jr, et al. **J Pharmacol Exp Ther** 1996 May;277(2):671-8

Rate-based management of fetal supraventricular tachycardia. Guntheroth WG, et al. **J Ultrasound Med** 1996 Jun;15(6):453-8

Idiopathic ventricular fibrillation initiated by a short-coupled ventricular premature beat. Nakazato Y, et al. **Jpn Heart J** 1996 Mar;37(2):265-9

The SWORD of Damocles. Sanderson J. **Lancet** 1996 Jul 6;348(9019):2-3

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Waldo AL, et al. **Lancet** 1996 Jul 6; 348(9019):7-12

The cardiac antiarrhythmic effects of polyunsaturated fatty acid. Kang JX, et al. **Lipids** 1996 Mar;31 Suppl:S41-4

Ibutilide. **Med Lett Drugs Ther** 1996 Apr 12;38(972):38

Drugs for cardiac arrhythmias. **Med Lett Drugs Ther** 1996 Aug 30;38(982):75-82

Intravenous amiodarone. **Med Lett Drugs Ther** 1995 Dec 8; 37(963):114-5

Differential effect of selected antiarrhythmic drugs on coronary artery ligation-induced ventricular arrhythmias on the right or left sides. Gautam CS, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun;17(5):327-31

Amiodarone in congestive heart failure [letter] Silver MJ, et al. **N Engl J Med** 1995 Dec 14;333(24):1639-40; discussion 1640-1

Antiarrhythmic and anti-ischemic properties of calcium-channel antagonists. Apostolakos MJ, et al. **New Horiz** 1996 Feb;4(1):45-57 (94 ref.)

Reproducibility of electrophysiological testing during antiarrhythmic therapy for ventricular arrhythmias unrelated to coronary artery disease. Ferrick KJ, et al. **Pacing Clin Electrophysiol** 1995 Jul;18(7):1395-400

Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent. Isomoto S, et al. **Pacing Clin Electrophysiol** 1995 Nov;18(11):2022-7

Reduction of antiarrhythmic drug use in patients receiving implantable cardioverter defibrillators. Sperry RE, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):61-4

Electrophysiological, rate dependent, and autonomic effects of the class III antiarrhythmic almokalant after myocardial infarction in the pig. Tuininga YS, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):802-10

Ventricular fibrillation following adenosine therapy for supraventricular tachycardia in a neonate with concealed Wolff-Parkinson-White syndrome treated with digoxin. Mulla N, et al. **Pediatr Emerg Care** 1995 Aug;11(4):238-9

Prevention of class III-induced proarrhythmias by flecainide in an animal model of the acquired long QT syndrome. Hallman K, et al. **Pharmacol Toxicol** 1995 Oct;77(4):250-4

Trilinolein reduces infarct size and suppresses ventricular arrhythmias in rats subjected to coronary ligation. Chan P, et al. **Pharmacology** 1995 Aug;51(2):118-26

Cardioversion of atrial fibrillation. Lip GY. **Postgrad Med J** 1995 Aug;71(838):457-65 (68 ref.)

The efficacy of flecainide versus digoxin in the management of fetal supraventricular tachycardia [see comments] Frohn-Mulder IM, et al. **Prenat Diagn** 1995 Dec; 15(13):1297-302. Comment in: Prenat Diagn 1995 Dec;15(13):1209-13.

Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia. Brooks RR, et al. **Proc Soc Exp Biol Med** 1996 May;212(1):84-93

Implantable defibrillators are preferable to pharmacologic therapy for patients with ventricular tachyarrhythmias: an antagonist's viewpoint. Anderson J. **Prog Cardiovasc Dis** 1996 Mar-Apr;38(5):393-400 (32 ref.)

Design and analysis of the ESVEM Trial. Anderson KP, et al. **Prog Cardiovasc Dis** 1996 May-Jun;38(6):489-502

A perspective on the ESVEM trial current knowledge: sotalol should not be the first-line agent in the management of ventricular arrhythmias. Garan H. **Prog Cardiovasc Dis** 1996 May-Jun;38(6):455-6

Implanted cardioverter-defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias. Saksena S, et al. **Prog Cardiovasc Dis** 1996 May-Jun;38(6):445-54 (51 ref.)

Management of patients with life-threatening sustained ventricular tachyarrhythmias--the role of guided antiarrhythmic drug therapy. Steinbeck G, et al. **Prog Cardiovasc Dis** 1996 May-Jun;38(6):419-28

Medical treatment of cardiac arrhythmias in Chagas' heart disease. de Paola AA, et al. **Rev Paul Med** 1995 Mar-Apr; 113(2):858-61 (29 ref.)

Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. Kumar A. **South Med J** 1996 Aug; 89(8):779-85

A simulation study used to design the sequential monitoring plan for a clinical trial. Brooks MM, et al. **Stat Med** 1995 Oct 30;14(20):2227-37

Atrial fibrillation pearls and perils of management. Kudenchuk PJ. **West J Med** 1996 May;164(5):425-34 (109 ref.)

[Effects of guan-fu base a on experimental cardiac arrhythmias and myocardial contractility] Dong YL, et al. **Yao Hsueh Hsueh Pao** 1995;30(8):577-82 (Eng. Abstr.) **(Chi)**

[Programmed esophageal stimulation of the atrium and the long-term effects of anti-arrhythmia therapy of atrial fibrillation and flutter] Novotný E, et al. **Vnitr Lek** 1995 Sep;41(9):586-9 (Eng. Abstr.) **(Cze)**

[Importance of programmed ventricular stimulation in the evaluation of proarrhythmic effects of orally administered anti-arrhythmia agents] Pleskot M, et al. **Vnitr Lek** 1995 Sep;41(9):581-5 (Eng. Abstr.) **(Cze)**

[The treatment of chronic atrial fibrillation] Gosselink AT. **Tijdschr Gerontol Geriatr** 1995 Dec;26(6):259-63 (20 ref.) (Eng. Abstr.) **(Dut)**

[The treatment of atrial fibrillation] Halinen MO. **Duodecim** 1995;111(8):705-13 (29 ref.) **(Fin)**

[Adenosine in the treatment of supraventricular arrhythmias] Lommi J, et al. **Duodecim** 1994;110(5):473-7 (27 ref.) **(Fin)**

[Combination of celiprolol and amiodarone in the treatment of recurrent ventricular tachycardia] Tonet J, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jan;45(1):18-23 (Eng. Abstr.) **(Fre)**

[Comparative effects of cibenzoline and hydroquinidine in the prevention of auricular fibrillation. A randomized double-blind study] Touboul P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Nov;44(9):525-31 (Eng. Abstr.) **(Fre)**

[International symposium on treatment of cardiac arrhythmia. Current trends. Lille, France, November 2-3, 1995] **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:11-154 **(Fre)**

[Anti-arrhythmic therapy and cardiac failure] Cosnay P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:35-41 (44 ref.) (Eng. Abstr.) **(Fre)**

[Hypertrophic cardiomyopathy: place and limitations of medical therapy] Desnos M, et al. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):573-5 (Eng. Abstr.) **(Fre)**

[Antiarrhythmia agents in heart failure] Duc P. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):595-8 (Eng. Abstr.) **(Fre)**

[Antiarrhythmic drugs in paroxysmal atrial fibrillation. When and how?] Lévy S, et al. **Arch Mal Coeur Vaiss** 1996 Feb; 89 Spec No 1:19-24 (Eng. Abstr.) **(Fre)**

[Value of calcium channel blockers in the prevention of ventricular fibrillation of ischemic etiology: experimental arguments] Timour Q, et al. **Bull Acad Natl Med** 1996 Jan; 180(1):215-26; discussion 226-7 (Eng. Abstr.) **(Fre)**

[Long term drug therapy for the prevention of recurrence in atrial fibrillation] Newman D, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:21A-26A (43 ref.) **(Fre)**

[Restoration of the sinus rhythm in atrial fibrillation] Talajic M, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:27A-34A (83 ref.) **(Fre)**

[Pharma-clinics. How I treat.... Ventricular tachycardia in children] Massin M. **Rev Med Liege** 1996 Feb;51(2):147-9 (28 ref.) **(Fre)**

[Pharma-clinics. How I treat... supraventricular tachycardia in children] Massin M. **Rev Med Liege** 1996 Mar; 51(3):210-3 (32 ref.) **(Fre)**

[Use of current anti-arrhythmia agents in pediatric cardiology] Massin M. **Rev Med Liege** 1995 Dec; 50(12):505-9 (40 ref.) **(Fre)**

[Pharma-clinics. How I treat... a patient with atrial fibrillation. 2] Soyeur D. **Rev Med Liege** 1995 Aug; 50(8):313-4 **(Fre)**

[Adenosine as an anti-arrhythmia agent] Scheininger MJ, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):139-40 **(Ger)**

[Paroxysmal supraventricular tachycardia in pregnancy. Value of adenosine and other anti-arrhythmia agents] Hösl P, et al. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):313-6 (Eng. Abstr.) **(Ger)**

["Sicilian gambit": basic principles and strategies of anti-arrhythmia therapy. Satellite symposium of the 15th Congress of the European Society for Cardiology, Barcelona, 30 August 1992] **Internist (Berl)** 1993 Jan;34(1 Suppl [sizilian]):1-20 **(Ger)**

[Therapy refractory continuous tachycardia of many years in a 40-year-old woman] Trappe HJ, et al. **Internist (Berl)** 1996 Apr;37(4):392-7 **(Ger)**

[Atrial fibrillation] Kappenberger L, et al. **Schweiz Rundsch Med Prax** 1996 Apr 30;85(18):600-3 (Eng. Abstr.) **(Ger)**

[Ventricular arrhythmias: diagnosis and drug therapy] Schüpfer C, et al. **Schweiz Rundsch Med Prax** 1996 May 14;85(20):647-54 (40 ref.) (Eng. Abstr.) **(Ger)**

[Effects of adenosine on the heart--therapeutic and diagnostic possibilities] Stark U, et al. **Wien Klin Wochenschr** 1996;108(12):343-51 (61 ref.) (Eng. Abstr.) **(Ger)**

[Calcium antagonists in treatment of ventricular tachycardia] Melichercik J, et al. **Z Kardiol** 1996 May;85(5):319-25 (31 ref.) (Eng. Abstr.) **(Ger)**

[How do you want to die? The therapeutic options in ventricular tachyarrhythmia at the end of the anti-arrhythmia drug era] Seipel L. **Z Kardiol** 1995 Oct; 84(10):787-90 (38 ref.) **(Ger)**

[Clinical use of intravenous amiodarone for supraventricular

arrhythmias] Assadi S, et al. **Harefuah** 1995 Dec 15; 129(12):583–6 (24 ref.) **(Heb)**

[Management of patients with sustained ventricular arrhythmia: anti-arrhythmia agents or defibrillator?] Cappato R, et al. **Cardiologia** 1996 Feb;41(2):95–105 (75 ref.) **(Ita)**

[Facilitating effect of propafenone pretreatment in the interruption of atrial flutter by transesophageal pacing] Doni F, et al. **Cardiologia** 1996 Feb;41(2):135–40 (Eng. Abstr.) **(Ita)**

[The pharmacological treatment of supraventricular atrioventricular nodal reentry or accessory pathway reentry tachycardias: the usefulness of transesophageal electrophysiological study in the selection of therapy] Sarubbi B, et al. **Cardiologia** 1996 Jun;41(6):543–9 (Eng. Abstr.) **(Ita)**

[Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine] Mondillo S, et al. **Clin Ter** 1995 Dec;146(12):769–74 (Eng. Abstr.) **(Ita)**

[Magnesium sulfate in acute myocardial infarction] Balli E, et al. **G Ital Cardiol** 1995 Nov;25(11):1425–32 (33 ref.) (Eng. Abstr.) **(Ita)**

[Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study] Bellandi F, et al. **G Ital Cardiol** 1996 Apr;26(4):379–90 (Eng. Abstr.) **(Ita)**

[Treatment of supraventricular tachyarrhythmias: drugs or ablation?] Chimienti M, et al. **G Ital Cardiol** 1996 Feb; 26(2):213–26 (80 ref.) **(Ita)**

[Role of a "bystander" concealed accessory pathway in the response to verapamil and flecainide treatment in a patient with nodal reentry tachycardia] Matteucci C, et al. **G Ital Cardiol** 1996 Apr;26(4):419–25 (Eng. Abstr.) **(Ita)**

[Therapy of arrhythmias in hypertrophic cardiomyopathy] Rapezzi C, et al. **G Ital Cardiol** 1995 Nov;25(11):1443–6 **(Ita)**

[Emergency drug therapy of arrhythmia] Mitamura H. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1804–9 (5 ref.) **(Jpn)**

[The effects of long-term treatment of sotalol hydrochloride on time and frequency domain parameters of signal averaged electrocardiogram in patients with ischemic heart disease] Bobak J, et al. **Pol Arch Med Wewn** 1996 Apr; 95(4):289–98 (Eng. Abstr.) **(Pol)**

[The effect of treatment with propafenone, metoprolol and amiodarone on lymphocyte sodium efflux and level of cAMP in serum] Kosmala W. **Pol Arch Med Wewn** 1995 Jul;94(1):14–20 (Eng. Abstr.) **(Pol)**

[Analysis of heart rhythm variability in evaluation of treatment for unstable angina pectoris] Petelenz T, et al. **Pol Arch Med Wewn** 1995 Jul;94(1):32–9 (Eng. Abstr.) **(Pol)**

[Magnesium or proajmaline (neogilurytmal) in treatment of recurrences of paroxysmal supraventricular tachyarrhythmias?] Dłużniewski M, et al. **Wiad Lek** 1994 Oct;47(19–20):721–4 (Eng. Abstr.) **(Pol)**

[Auricular fibrillation. Antiarrhythmic treatment revisited] Elvas L, et al. **Acta Med Port** 1995 Mar;8(3):173–9 (55 ref.) (Eng. Abstr.) **(Por)**

[Antiarrhythmic drug effectiveness. Proposal for a new approach based on pharmacological hourly effects] Maia IG, et al. **Arq Bras Cardiol** 1995 Jun;64(6):525–31 (Eng. Abstr.) **(Por)**

[Prophylactic use of lidocaine in the acute period of myocardial infarction] Fomichev VI, et al. **Klin Med (Mosk)** 1995;73(4):17–20 (26 ref.) **(Rus)**

[Use of bonnecor in the treatment of ventricular arrhythmia] Fomichev VI, et al. **Klin Med (Mosk)** 1995;73(4):44–6 (Eng. Abstr.) **(Rus)**

[Tactics of treatment of patients with arrhythmia] Glezer MG, et al. **Klin Med (Mosk)** 1995;73(4):13–7 (0 ref.) **(Rus)**

[Treatment of cardiac arrhythmias during pregnancy] Rodríguez Blanco VM, et al. **Med Clin (Barc)** 1996 Jun 1;107(1):29–36 (125 ref.) **(Spa)**

TOXICITY

Effect of folate supplementation on clinical chemistry and hematologic changes related to bidisomide administration in the rat. Vandenberghe Y, et al. **Drug Chem Toxicol** 1995 Nov;18(4):235–70

Effects of amiodarone-induced phospholipidosis on pulmonary host defense functions in rats. Reasor MJ, et al. **Proc Soc Exp Biol Med** 1996 Apr;211(4):346–52

Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Webster WS, et al. **Teratology** 1996 Mar;53(3):168–75

Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats. Reasor MJ, et al. **Toxicology** 1996 Jan 8;106(1–3):139–47

Amiodarone-induced pulmonary fibrosis in Fischer 344 rats. Reinhart PG, et al. **Toxicology** 1996 Jun 17;110(1–3):95–101

URINE

Determination of a cardiac antiarrhythmic, tricyclic antipsychotics and antidepressants in human and animal urine by micellar electrokinetic capillary chromatography using a bile salt. Aumatell A, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):331–44

ANTI-ASTHMATIC AGENTS

Regulation of airway wall remodeling: prospects for the development of novel antiasthma drugs. Stewart AG, et al. **Adv Pharmacol** 1995;33:209–53 (204 ref.)

Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Chung KF. **Eur Respir J** 1995 Jul;8(7):1203–13 (117 ref.)

Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses. Pizzichini MM, et al. **Eur Respir J** 1996 Mar;9(3):449–55

Biotech shares fall as company halts asthma drug trials [news] Ward M. **Nature** 1996 Feb 8;379(6565):480

Advances in the management of acute asthma in children. Murphy SJ, et al. **Pediatr Rev** 1996 Jul;17(7):227–34; quiz 235

[Corticoid resistance in asthma] Perrin-Fayolle M, et al. **Rev Pneumol Clin** 1996;52(2):150–8 (43 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Topical cromolyn can modify human allergic skin reactions. Phillips TJ, et al. **Allergy** 1996 Mar;51(3):198–9

Metered-dose inhaler technique of patients in an urban ED: prevalence of incorrect technique and attempt at education. Shrestha M, et al. **Am J Emerg Med** 1996 Jul;14(4):380–4

Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Kamada AK, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1739–48 (86 ref.)

Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Noonan M, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1467–73

Single, high-dose intramuscular triamcinolone acetonide versus weekly oral methotrexate in life-threatening asthma: a double-blind study [see comments] Ogirala RG, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1461–6 . Comment in: Am J Respir Crit Care Med 1996 Jun;153(6 Pt 1):1989–90.

Single, high dose intramuscular triamcinolone acetonide versus weekly oral methotrexate in life-threatening asthma: a double blind study [letter; comment] Vervloet D, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1989–90 . Comment on: Am J Respir Crit Care Med 1995 Nov;152(5 Pt 1):1461–6.

Comparison of volume output from two different continuous nebulizer systems. Reisner C, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):209–13

Babyhaler, hidden hazards [letter] Tseng RY. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):214

Patient perception of the diskus inhaler: a comparison with the turbuhaler inhaler. Schlaeppi M, et al. **Br J Clin Pract** 1996 Jan-Feb;50(1):14–9

Optimizing inhaled drug delivery in patients with asthma. Jackson C, et al. **Br J Gen Pract** 1995 Dec;45(401):683–7 (35 ref.)

Choose better device to treat asthma and put on a happy face [letter] Newhouse MT. **Can Med Assoc J** 1996 Aug 15;155(4):369

The change in the distribution of Tc-99m human serum albumin radioaerosols in asthma after a 1-week course of corticosteroid inhalation treatment. Changlai SP, et al. **Clin Nucl Med** 1995 Jul;20(7):626–9

Differences in output from corticosteroid inhalers used with a volumatic spacer. Miller MR, et al. **Eur Respir J** 1995 Oct;8(10):1637–8

Inflammatory bronchial polyps associated with asthma: resolution with inhaled corticosteroid. Niimi A, et al. **Eur Respir J** 1995 Jul;8(7):1237–9

MDIS and spacers in management of asthma. Bhadoria DP, et al. **Indian J Med Sci** 1995 May;49(5):123–6

Improving inhaler therapy compliance in asthmatics [letter] Bedi RS. **J Assoc Physicians India** 1995 Aug;43(8):585

A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. Wasserman SI, et al. **J Asthma** 1996;33(4):265–74

Self-management of asthma. Bramson R. **J Fam Pract** 1996 Jul;43(1):21–2

Design, synthesis, and pharmacokinetic evaluation of a chemical delivery system for drug targeting to lung tissue. Saah M, et al. **J Pharm Sci** 1996 May;85(5):496–504

External approach to the treatment of pediatric asthma. Sun Y. **J Tradit Chin Med** 1995 Dec;15(4):290–1

Evaluation of oral anti-allergic drugs in Japan [letter] Hayashi K, et al. **Lancet** 1996 Feb 17;347(8999):477

Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Todd G, et al. **Lancet** 1996 Jul 6;348(9019):27–9

Short term effect of methotrexate in severe steroid-dependent asthma. Kanzow G, et al. **Lung** 1995;173(4):223–31

Effects of corticosteroid inhalation therapy on the deposition pattern of Tc-99m human serum albumin radioaerosols in asthma. Kao CH, et al. **Lung** 1995;173(5):291–6

Effect of inhaled nedocromil sodium therapy on blood gas changes in children challenged with ultrasonically nebulized distilled water. A comparison of 8 mg versus 16 mg daily dose. Oggiano N, et al. **Minerva Pediatr** 1995 Oct;47(10):427–31

Update on spacer devices in childhood asthma. Leversha AM, et al. **N Z Med J** 1996 Mar 8;109(1017):76–8

Aerosolized furosemide in wheezy infants: a negative report. Van Bever HP, et al. **Pediatr Pulmonol** 1995 Jul;20(1):16–20

Aerosol delivery systems for bronchial asthma. Ariyananda PL, et al. **Postgrad Med J** 1996 Mar;72(845):151–6 (60 ref.)

Inhaled sodium cromoglycate. Holgate ST. **Respir Med** 1996 Aug;90(7):387–90 (45 ref.)

Patient education and guided self-management plans. Neville R. **Respir Med** 1996 Aug;90(7):385–6 (15 ref.)

Caution with inhaled corticosteroids in childhood asthma. Welch MJ. **West J Med** 1995 Oct;163(4):371–2

[Treating steroids dependent asthmatic patients with high dose beclomethasone dipropionate aerosol] Dong J, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Jun; 18(3):152–4, 190 (Eng. Abstr.) **(Chi)**

[Fluticasone propionate--a new inhalation steroid for the treatment of bronchial asthma] Lange P, et al. **Ugeskr Laeger** 1996 Jan 22;158(4):439–44 **(Dan)**

[Comparative study of the acceptability of Tilade Syncroner and Tilade Standard by mildly asthmatic patients. Syncroner Trial Research Group] Pujet JC, et al. **Allerg Immunol (Paris)** 1995 Dec;27(10):377–83 (Eng. Abstr.) **(Fre)**

[Nebulization for basic treatment of asthma in adults] Demoly P, et al. **Presse Med** 1996 May 25;25(18):857–62 (39 ref.) (Eng. Abstr.) **(Fre)**

[Inhaled corticotherapy in asthma: when should it be started and how to stop?] Aubier M. **Rev Pneumol Clin** 1996; 52(2):145–9 (19 ref.) (Eng. Abstr.) **(Fre)**

[Chronopharmacology of reversible airway obstruction] Haen E. **Wien Med Wochenschr** 1995;145(17–18):439–45 (38 ref.) (Eng. Abstr.) **(Ger)**

[Effect of dosing schedule on efficacy of corticosteroid inhalation in chronic asthma] Suzuki R, et al. **Arerugi** 1995 Jul;44(7):685–91 (Eng. Abstr.) **(Jpn)**

[The treatment of bronchial asthma with powdered salbutamol and powdered beclomethasone dipropionate] Basacopol A, et al. **Pneumoftiziologia** 1995 Jan-Jun; 44(1–2):25–8 (Eng. Abstr.) **(Rum)**

[Comparative study] of beclomethasone and budesonide, with same posology (400 micrograms every 12 hours), in the control of cortico-dependent intrinsic asthma] Hernández J, et al. **Allergol Immunopathol (Madr)** 1995 Sep-Oct; 23(5):193–201 (Eng. Abstr.) **(Spa)**

[The excretion of free cortisol in the urine in healthy children and in asthmatics treated with long-term inhaled glucocorticoids] González Pérez-Yarza E, et al. **An Esp Pediatr** 1996 Jun;44(6):531–6 (Eng. Abstr.) **(Spa)**

[Why is split the normal dose into half? (letter)] Wihl JA. **Lakartidningen** 1996 Jan 24;93(4):229 **(Swe)**

[Important notice: normal dosage of Teldanex is halved (letter)] Wihl JA. **Lakartidningen** 1996 Jan 3;93(1–2):16–7 **(Swe)**

ADVERSE EFFECTS

Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Kamada AK, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1739–48 (86 ref.)

Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma. Martinati LC, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):232–6

Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma. Fahy JV, et al. **Clin Chest Med** 1995 Dec;16(4):715–33 (145 ref.)

Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Todd G, et al. **Lancet** 1996 Jul 6;348(9019):27–9

Paradoxical bronchospasm and cutaneous rash after metered-dose inhaled bronchodilators. Facchini G, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):201–3

Caution with inhaled corticosteroids in childhood asthma. Welch MJ. **West J Med** 1995 Oct;163(4):371–2

[Hypersensitivity syndrome caused by dapsone. Transient circulating clone T] Bocquet H, et al. **Ann Dermatol Venereol** 1995;122(8):514–6 (14 ref.) (Eng. Abstr.) **(Fre)**

[Lipid pneumonia after aerosol therapy with gomenol in a 4-month-old child (letter)] Decocq G, et al. **Presse Med** 1996 Jun 15;25(21):994–5 **(Fre)**

[Primum non nocere: inhaled corticoids] Lacronique J. **Rev Pneumol Clin** 1996;52(2):137–43 (81 ref.) (Eng. Abstr.) **(Fre)**

[Effects of inhaled beclomethasone on height growth and bone metabolism in children with asthma] Inoue T, et al. **Arerugi** 1995 Jul;44(7):678–84 (Eng. Abstr.) **(Jpn)**

[Drug induced tetraparesis and loss of myosin. Mild types are probably overlooked] Larsson L, et al. **Lakartidningen** 1996 Jun 5;93(23):2249–54 **(Swe)**

BLOOD

Clinical application of the Biotrack 516 system for determination of theophylline by a turbidimetric latex agglutination inhibition reaction. Tsunekawa Y, et al. **Ther Drug Monit** 1996 Feb;18(1):86–91

CHEMICAL SYNTHESIS

Synthetic studies on condensed-azole derivatives. IV. Synthesis and anti-asthmatic activities of omega-sulfamoylalkyloxyimidazo[1,2-b]pyridazines. Kuwahara M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):122–31

Synthetic studies on condensed-azole derivatives. I. Synthesis and anti-asthmatic activities of omega-substituted alkylthioimidazo[1,2-b]pyridazines. Kuwahara M, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep; 43(9):1505-10

Synthetic studies on condensed-azole derivatives. III. Synthesis and anti-asthmatic activities of C-substituted alkyl side chain derivatives of omega-sulfamoylalkylthioimidazo[1,2-b]pyridazines and related compounds. Kuwahara M, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1516-22

Synthesis and thromboxane A2 antagonistic activity of [[1-aryl(or benzyl)-1-(benzenesulfonamido)methyl]phenyl]alkanoic acid derivatives. Sakurai S, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):765-77

Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity. Bundy GL, et al. **J Med Chem** 1995 Oct 13;38(21):4161-3

Synthesis and pharmacological activity of triazole derivatives inhibiting eosinophilia. Naito Y, et al. **J Med Chem** 1996 Jul 19;39(15):3019-29

ECONOMICS

Evaluation of oral anti-allergic drugs in Japan [letter] Hayashi K, et al. **Lancet** 1996 Feb 17;347(8999):477

HISTORY

Astute observers discover anti-asthma drugs. Persson CG. **Pharmacol Toxicol** 1995;77 Suppl 3:7-15

In vivo veritas: the continuing importance of discoveries in complex biosystems. Persson CG. **Thorax** 1996 Apr; 51(4):441-3

PHARMACOKINETICS

Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthma. Koopmans RP, et al. **Clin Pharmacokinet** 1995 Oct;29(4):213-20 (47 ref.)

PHARMACOLOGY

Asthma prophylaxis agents alter the function of an airway epithelial chloride channel. Alton EW, et al. **Am J Respir Cell Mol Biol** 1996 Apr;14(4):380-7

Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate. Birkebaek NH, et al. **Arch Dis Child** 1995 Dec;73(6):524-7

Augmentation of apoptosis in bronchial exuded rat eosinophils by cyclosporin A. Kitagaki K, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):71-7

In vivo effect of prednisolone on release of leukotriene C4 in eosinophils obtained from asthmatic patients. Shindo K, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):869-74

Inhibition of volume-activated chloride currents in endothelial cells by chromones. Heinke S, et al. **Br J Pharmacol** 1995 Aug;115(8):1393-8

Synthetic studies on condensed-azole derivatives. IV. Synthesis and anti-asthmatic activities of omega-sulfamoylalkyloxyimidazo[1,2-b]pyridazines. Kuwahara M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):122-31

An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Lönnebo A, et al. **Eur J Clin Pharmacol** 1996;49(6):459-63

PDE isoenzymes as targets for anti-asthma drugs. Schudt C, et al. **Eur Respir J** 1995 Jul;8(7):1179-83 (18 ref.)

Differential modulation by betamethasone of allergen-induced cell influx and cell peroxidase in guinea-pig lungs. Yeadon M, et al. **Inflamm Res** 1995 Aug; 44 Suppl 2:S177-8

Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. Holgate ST, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):1-13 (89 ref.)

Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. Feoktistov I, et al. **J Clin Invest** 1995 Oct;96(4):1979-86

Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans. Iwasaki T, et al. **J Med Chem** 1996 Jul 5;39(14):2696-704

Effect of M-711 on experimental asthma in rats. Shichinohe K, et al. **J Vet Med Sci** 1996 Jan;58(1):55-9

The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways. Banner KH, et al. **Pulm Pharmacol** 1995 Feb;8(1):37-42

Cromolyn increases strength in exercised mdx mice. Granchelli JA, et al. **Res Commun Mol Pathol Pharmacol** 1996 Mar;91(3):287-96

Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Hay DW, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):304-9 (54 ref.)

[Ginkgolides antagonizing some effects of platelet-activating factor in vitro] Dong JC, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):606-8 (Eng. Abstr.) **(Chi)**

[Pharmacological profiles of F-1322, a novel anti-asthmatic agent. (1). Mechanisms of action] Lee B, et al. **Nippon Yakurigaku Zasshi** 1995 Jul;106(1):31-40 (Eng. Abstr.) **(Jpn)**

[In vitro effect of disodium cromoglycate on phagocytic activity of polymorphonuclear cells of healthy asthmatic patients] Gómez Castillo CA, et al. **Rev Alerg Mex** 1995 Sep-Oct;42(5):89-95 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Asthma treatment in schoolchildren: lung function in different therapeutic groups. Korppi M, et al. **Acta Paediatr** 1996 Feb;85(2):190-4

Modern treatment of asthma in children. Zeffren BS, et al. **Adv Pediatr** 1996;43:423-68 (214 ref.)

Helping patients manage asthma. Brock P. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2662, 2666

Inadequate outpatient medical therapy for patients with asthma admitted to two urban hospitals [see comments] Hartert TV, et al. **Am J Med** 1996 Apr;100(4):386-94. Comment in: Am J Med 1996 Apr;100(4):381-2.

Comprehensive long-term management program for asthma: effect on outcomes in adult African-Americans. Kelso TM, et al. **Am J Med Sci** 1996 Jun;311(6):272-80

Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Bootsma GP, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):924-30

Time course of the protective effect of inhaled heparin on exercise-induced asthma. Garrigo J, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1702-7

The effect of nedocromil sodium on childhood asthma during the viral season. König P, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1879-86

Influence of inhaled steroids on recovery from occupational asthma after cessation of exposure: an 18-month double-blind crossover study. Malo JL, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):953-60

Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Meltzer SS, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):931-5

Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Pedersen B, et al. **Am J Respir Crit Care Med** 1996 May; 153(5):1519-29

Inhaled beclomethasone dipropionate and growth in children with mild asthma [letter; comment] Turpeinen M, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1726. Comment on: Am J Respir Crit Care Med 1995 Jun;151(6):1715-9.

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Woolcock A, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1481-8

Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Yates DH, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1170-4

Fluticasone propionate compared with theophylline for mild-to-moderate asthma. Galant SP, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):112-8

Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Scarfone RJ, et al. **Ann Emerg Med** 1995 Oct;26(4):480-6

Nedocromil in the outpatient management of asthma. Keenan JM, et al. **Arch Fam Med** 1995 Oct;4(10):835-42; discussion 843

Anti-inflammatory therapy reduces wheezing after bronchiolitis. Reijonen T, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):512-7

Are young adults with asthma treated sufficiently with inhaled steroids? A population-based study of prescription data from 1991 and 1994. Gaist D, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):285-9

Effects of IZP-94005 (contignasterol) on antigen-induced bronchial responsiveness in ovalbumin-sensitized guinea-pigs. Bramley AM, et al. **Br J Pharmacol** 1995 Aug; 115(8):1433-8

Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society. Beveridge RC, et al. **Can Med Assoc J** 1996 Jul 1;155(1):25-37 (167 ref.)

Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol [see comments] Kalra S, et al. **Chest** 1996 Apr;109(4):953-6. Comment in: Chest 1996 Apr;109(4):862-4.

A comparative study of the clinical efficacy of nedocromil sodium and placebo. How does cromolyn sodium compare as an active control treatment? Schwartz HJ, et al. **Chest** 1996 Apr;109(4):945-52

Long-acting beta-agonists, tachyphylaxis, and corticosteroids [editorial; comment] Sears MR. **Chest** 1996 Apr;109(4):862-4. Comment on: Chest 1996 Apr;109(4):953-6.

Asthma: current controversies and emerging therapies. Kavuru MS, et al. **Cleve Clin J Med** 1995 Sep-Oct; 62(5):293-304 (122 ref.)

Asthma mechanisms, determinants of severity and treatment: the role of nedocromil sodium. Report of a workshop held in Whistler, British Columbia, Canada, 18-19 May 1995. Barnes PJ, et al. **Clin Exp Allergy** 1995 Aug;25(8):771-87 (146 ref.)

Anti-inflammatory effects of long-acting beta-agonists in asthma [editorial] Bradding P. **Clin Exp Allergy** 1995 Oct; 25(10):912-4 (36 ref.)

Oral sodium cromoglycate: its use in the management of food allergy. Edwards AM. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:31-3 (30 ref.)

Effectiveness and safety of beclomethasone dipropionate, an intranasal corticosteroid, in the treatment of patients with allergic rhinitis. Edwards TB. **Clin Ther** 1995 Nov-Dec; 17(6):1032-41 (31 ref.)

Onset of action of aqueous beclomethasone dipropionate nasal spray in seasonal allergic rhinitis. Selner JC, et al. **Clin Ther** 1995 Nov-Dec;17(6):1099-109

Efficacy and safety of mepyramine-theophylline-acetate in the treatment of asthmatic crisis in children. Sienra-Monge JJ, et al. **Clin Ther** 1995 Jul-Aug;17(4):708-20

Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze. Freezer NJ, et al. **Eur Respir J** 1995 Sep;8(9):1488-93

Reversion and antihistamines [letter] Gupta SK. **J Assoc Physicians India** 1996 Jan;44(1):72-3

A computer-assisted telephone interview technique for assessment of asthma morbidity and drug use in adult asthma. Anie KA, et al. **J Clin Epidemiol** 1996 Jun; 49(6):653-6

Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group. Sheffer AL, et al. **J Fam Pract** 1996 Apr; 42(4):369-75

Differences in utilization of asthma drugs between two neighbouring Swedish provinces: relation to treatment in individuals with airway disease. Larsson L, et al. **J Intern Med** 1995 Oct;238(4):307-16

Action of nedocromil sodium in exercise-induced asthma in adolescents. Cavallo A, et al. **J Investig Allergol Clin Immunol** 1995 Sep-Oct;5(5):286-8

The protective effect of inhaled terbutaline, sodium cromoglycate and budesonide on exercise-induced asthma in children. Pichaipat V, et al. **J Med Assoc Thai** 1995 Oct;78(10):505-8

The effects on prescribing patterns and costs of having a special interest in asthma [see comments] Jones KP, et al. **J R Soc Med** 1995 Oct;88(10):570-5. Comment in: J R Soc Med 1996 Apr;89(4):238.

Inhaled steroids and psoriasis [letter] Harries M. **Lancet** 1995 Dec 9;346(8989):1567

Is it "urban" or is it "asthma"? Steigman DM. **Lancet** 1996 Jul 20;348(9021):143-4

Effect of fluticasone on growth in children with asthma [letter] Whitaker K, et al. **Lancet** 1996 Jul 6;348(9019):63-4

Is bronchial asthma a pancreatic disease? Casacó A. **Med Hypotheses** 1995 Jun;44(6):516-8

Pharmaceutical Benefits Advisory Committee: some questions answered [letter] Bandouvakis J. **Med J Aust** 1996 Jan 1;164(1):51-2

Fluticasone propionate for chronic asthma. **Med Lett Drugs Ther** 1996 Sep 13;38(983):83-4

Anti-inflammatory treatment of asthma in children. What strategy is appropriate? Frazier CA. **N C Med J** 1995 Dec; 56(12):616-8 (15 ref.)

A cornucopia of drug discovery? [letter; comment] Persson C. **Nat Med** 1996 Jan;2(1):5-6. Comment on: Nat Med 1995 Nov;1(11):1122-5.

Effectiveness of nedocromil sodium in preventing exercise-induced asthma in children. Verrotti A, et al. **Panminerva Med** 1995 Dec;37(4):210-3

beta-Adrenoceptor agonists in future asthma therapy. Ullman A. **Pharmacol Toxicol** 1995;77 Suppl 3:36-9

Asthma. Specific preventive strategies. Morris RJ. **Postgrad Med** 1996 Aug;100(2):105-6, 109-12, 118 passim (21 ref.)

Asthma. Calverley PM. **Postgrad Med J** 1996 Jan; 72(843):12-8 (34 ref.)

The efficacy and therapeutic position of nedocromil sodium. Holgate ST. **Respir Med** 1996 Aug;90(7):391-4 (32 ref.)

Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Bootsma GP, et al. **Thorax** 1995 Oct;50(10):1044-50

Long-acting beta 2-agonists and their role in asthma management. Galant SP. **West J Med** 1995 Oct;163(4):372

Steroid-resistant asthma. Leung DY. **West J Med** 1995 Oct; 163(4):367-8

[Beta-2 adrenergic receptor agonists in asthma treatment] Haahtela T, et al. **Duodecim** 1995;111(8):744-8 (28 ref.) **(Fin)**

[Pharma-clinics. Drug of the month. Fluticasone propionate (Flixotide)] Scheen AJ. **Rev Med Liege** 1996 Feb; 51(2):195-7 **(Fre)**

[Cyclosporin in severe steroid-requiring bronchial asthma] Klein RM, et al. **Dtsch Med Wochenschr** 1995 Oct 6; 120(40):1349-55 (Eng. Abstr.) **(Ger)**

[Limitations of current treatment of asthma: possibilities for new treatment forms] Wilkens H, et al. **Med Klin** 1996 May 15;91(5):302-7 (55 ref.) **(Ger)**

[Beta-2 agonists, exposure to allergens and bronchial hyperreactivity in children with allergic asthma] Piacentini GL, et al. **Pediatr Med Chir** 1995 Nov-Dec;17(6):515-7 (Eng. Abstr.) **(Ita)**

[Comparison of the effects of halothane, isoflurane and sevoflurane in the treatment of severe asthmatic attack: a case report] Ohyama A, et al. **Masui** 1996 Mar;45(3):362-6 (Eng. Abstr.) **(Jpn)**

[Chemotactic serum activity for neutrophils and eosinophils

and spontaneous production of histamine releasing factor in patients with seasonal bronchial asthma treated with nedocromil sodium] Grzelewska-Rzymowska I, et al. **Pneumonol Alergol Pol** 1996;64(3-4):132-40 (Eng. Abstr.) **(Pol)**

[Introductory clinical evaluation of fluticasone propionate efficacy for treatment of allergic rhinitis in children] Hofman J, et al. **Pneumonol Alergol Pol** 1995;63 Suppl 2:83-6 (Eng. Abstr.) **(Pol)**

[Lomuzol in the treatment of allergic rhinitis] Poliakova TS, et al. **Vestn Otorinolaringol** 1995 Sep-Oct;(5):47-50 (Eng. Abstr.) **(Rus)**

[Asthma symptoms and anti-asthma drugs in 4 Scandinavian countries] Janson C, et al. **Nord Med** 1996 May; 111(5):147-50 (Eng. Abstr.) **(Swe)**

ANTI-AUSTRALIA ANTIGENS see HEPATITIS B ANTIBODIES

ANTIBIOSIS

Role of bacterial interference and beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococcal pharyngotonsillitis. Brook I, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1405-9

Douglas-fir root-associated microorganisms with inhibitory activity towards fungal plant pathogens and human bacterial pathogens. Axelrood PE, et al. **Can J Microbiol** 1996 Jul;42(7):690-700

Lysis and biological control of Aspergillus niger by Bacillus subtilis AF 1. Podile AR, et al. **Can J Microbiol** 1996 Jun; 42(6):533-8

Anticarcinogenic, hypocholesterolemic, and antagonistic activities of Lactobacillus acidophilus. Mital BK, et al. **Crit Rev Microbiol** 1995;21(3):175-214 (371 ref.)

Effect of Lactobacillus rhamnosus strain GG (ATCC 53103) on the growth of Streptococcus sobrinus in vitro. Meurman JH, et al. **Eur J Oral Sci** 1995 Aug;103(4):253-8

Competition between Salmonella and Pseudomonas species growing in and on agar, as affected by pH, sodium chloride concentration and temperature. Thomas LV, et al. **Int J Food Microbiol** 1996 Apr;29(2-3):361-70

In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. Midolo PD, et al. **J Appl Bacteriol** 1995 Oct;79(4):475-9

Inverse correlation between the proportion of salivary bacteria inhibiting Streptococcus mutans and the percentage of untreated carious teeth. Goyette N, et al. **J Oral Pathol Med** 1995 Nov;24(10):462-7

Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections [see comments] Elmer GW, et al. **JAMA** 1996 Mar 20;275(11):870-6 (81 ref.). Comment in: JAMA 1996 Jul 3;276(1):29-30.

Probiotics: how microorganisms compete [letter; comment] Reid G. **JAMA** 1996 Jul 3;276(1):29-30. Comment on: JAMA 1996 Mar 20;275(11):870-6.

Inhibitory action of metabolites of Pseudomonas aeruginosa against gram-negative bacteria. Li Z, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):924-7

Presence of sterile hyphae in moulds: relationship with inhibitory activity. Calvo MA, et al. **Microbios** 1995; 84(339):79-85

Fermentation of radiolabeled carbohydrates by a reconstructed continuous-flow culture effective against Salmonella in broiler chicks. Hume ME, et al. **Poult Sci** 1995 Sep;74(9):1553-7

In vitro fructooligosaccharide utilization and inhibition of Salmonella spp. by selected bacteria. Oyarzabal OA, et al. **Poult Sci** 1995 Sep;74(9):1418-25

[The types of interaction of the microflora of the human oropharynx with the causative agent of meningococcal infection] Babich EM. **Mikrobiol Z** 1995 Sep-Oct; 57(5):57-63 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Effect of antibiotic treatment on competitive exclusion against Salmonella enteritidis PT4 in broilers. Bolder NM, et al. **Vet Rec** 1995 Sep 30;137(14):350-1

PHYSIOLOGY

Submerged bacterial colonies within food and model systems: their growth, distribution and interactions. Wimpenny JW, et al. **Int J Food Microbiol** 1995 Dec;28(2):299-315

ANTIBIOTIC-ASSOCIATED COLITIS see ENTEROCOLITIS, PSEUDOMEMBRANOUS

ANTIBIOTIC PROPHYLAXIS

A prospective, double-blind, placebo-controlled trial of i.v. immunoglobulin and trimethoprim-sulfamethoxazole in children with recurrent respiratory tract infections. Nydahl-Persson K, et al. **Acta Paediatr** 1995 Sep; 84(9):1007-9

Prophylax or perish? Flemmer M, et al. **Am J Gastroenterol** 1996 Sep;91(9):1867-8

Prenatal screening for group B Streptococcus. I. Impact of antepartum screening on antenatal prophylaxis and intrapartum care. Mercer BM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):837-41

Prenatal screening for group B Streptococcus. II. Impact of antepartum screening and prophylaxis on neonatal care. Mercer BM, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):842-6

Ampicillin/sulbactam versus ampicillin alone for cesarean section prophylaxis: a randomized double-blind trial. Rijhsinghani A, et al. **Am J Perinatol** 1995 Sep;12(5):322-4

Colonization in patients receiving and not receiving topical antimicrobial prophylaxis [letter; comment] Lipchik RJ. **Am J Respir Crit Care Med** 1996 Jan;153(1):463. Comment on: Am J Respir Crit Care Med 1994 Nov;150(5 Pt 1):1332-40.

Preincisional single-dose ceftriaxone for the prophylaxis of surgical wound infection. Chalkiadakis GE, et al. **Am J Surg** 1995 Oct;170(4):353-5

Surgical infections: prevention and treatment--1965 to 1995. Nichols RL. **Am J Surg** 1996 Jul;172(1):68-74 (54 ref.)

Do topical antibiotics provide improved prophylaxis against bacterial growth in the presence of polypropylene mesh? Troy MG, et al. **Am J Surg** 1996 Apr;171(4):391-3

One dose cefuroxime prophylaxis in hip fracture surgery. Kaukonen JP, et al. **Ann Chir Gynaecol** 1995;84(4):417-9

Piperacillin to prevent cholangitis after endoscopic retrograde cholangiopancreatography. A randomized, controlled trial. van den Hazel SJ, et al. **Ann Intern Med** 1996 Sep 15;125(6):442-7

Enrofloxacin to control Anaplasma marginale infections. Guglielmone AA, et al. **Ann N Y Acad Sci** 1996 Jul 23; 791:471-2

Earlier methods of antibiotics administered prophylactically perioperatively [letter; comment] Lord JW Jr. **Ann Surg** 1995 Nov;222(5):689-90. Comment on: Arch Surg 1994 Nov;129(11):1204-10.

Long term follow up to determine the prognostic value of imaging after urinary tract infections [letter; comment] Robson WL, et al. **Arch Dis Child** 1996 Jan;74(1):89. Comment on: Arch Dis Child 1995 May;72(5):388-92. Comment on: Arch Dis Child 1995 May;72(5):393-6.

Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Graham NM, et al. **Arch Intern Med** 1996 Apr 22;156(8):889-94

Prophylaxis with oral cefadroxil versus intravenous cefuroxime in trochanteric fracture surgery. A clinical multicentre study. Nungu KS, et al. **Arch Orthop Trauma Surg** 1995;114(6):303-7

Management of 168 neonates weighing more than 2000 g receiving intrapartum chemoprophylaxis for chorioamnionitis. Evaluation of an early discharge strategy. Singhal KK, et al. **Arch Pediatr Adolesc Med** 1996 Feb; 150(2):158-63

Prospective evaluation of antibiotic prophylaxis prior to cystometrogram and/or cystogram studies: oral versus intramuscular routes. Fried GW, et al. **Arch Phys Med Rehabil** 1996 Sep;77(9):900-2

Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. Zhang Y, et al. **Arthritis Rheum** 1996 Jul;39(7):1238-43

Australian Dental Research Fund Trebitsch Scholarship. Efficacy of antifungal prophylaxis in bone marrow transplantation. Quirk PC, et al. **Aust Dent J** 1995 Aug; 40(4):267-70

Managing patients with an absent or dysfunctional spleen. Is there evidence to show that daily antibiotic treatment is best? [letter; comment] Butler C, et al. **BMJ** 1996 May 25;312(7042):1360-1. Comment on: BMJ 1996 Feb 17;312(7028):430-4.

Managing patients with an absent or dysfunctional spleen. Under half of doctors know that antibiotic prophylaxis should be life long [letter; comment] Palejwala AA, et al. **BMJ** 1996 May 25;312(7042):1360; discussion 1361. Comment on: BMJ 1996 Feb 17;312(7028):430-4.

Children with an avulsed tooth may need antibiotic prophylaxis against bacterial endocarditis [letter; comment] Wallis D, et al. **BMJ** 1996 Jun 15;312(7045):1538. Comment on: BMJ 1996 Mar 2;312(7030):526.

Antibiotic prophylaxis in permanent pacemaker implantation [letter; comment] Mounsey JP, et al. **Br Heart J** 1995 Aug; 74(2):206. Comment on: Br Heart J 1995 Apr;73(4):392.

Prevention of infective endocarditis: enthusiasm tempered by realism. Prasad A, et al. **Br J Hosp Med** 1995 Oct 4-17; 54(7):341-7 (40 ref.)

Antibiotic prophylaxis in severe acute pancreatitis. Johnson CD. **Br J Surg** 1996 Jul;83(7):883-4

Antimicrobial prophylaxis for transrectal prostatic biopsy [letter] Anjum MI, et al. **Br J Urol** 1996 Apr;77(4):618-9

Urinary tract infections following laser prostatectomy: is there a need for antibiotic prophylaxis? te Slaa E, et al. **Br J Urol** 1996 Feb;77(2):228-32

Concentration of cephalosporins in tissues of the head and neck after parenteral infusion. Maier W, et al. **Chemotherapy** 1995 Nov-Dec;41(6):421-6

Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. DeRiso AJ 2nd, et al. **Chest** 1996 Jun;109(6):1556-61

Selective decontamination of the digestive tract in multiple trauma patients. A prospective double-blind, randomized, placebo-controlled study. Quinio B, et al. **Chest** 1996 Mar; 109(3):765-72

Antibiotic prophylaxis in patients undergoing radiological procedures who are at risk of infective endocarditis--do radiologists know what they are doing? Chakraverty S, et al. **Clin Radiol** 1996 Jan;51(1):39-41

Chemoprophylaxis fails to prevent a second case of meningococcal disease in a day nursery. Cartwright KA, et al. **Commun Dis Rep CDR Rev** 1995 Dec 8;5(13):R199

Management of asplenic patients in South Buckinghamshire: an audit of local practice. MacInnes J, et al. **Commun Dis Rep CDR Rev** 1995 Nov 10;5(12):R173-7

Antimicrobial prophylaxis in patients undergoing solid organ transplantation. Basgoz N, et al. **Curr Clin Top Infect Dis** 1995;15:344-64 (79 ref.)

Prophylaxis in bowel surgery. Nichols RL, et al. **Curr Clin Top Infect Dis** 1995;15:76-96 (89 ref.)

Antibiotics after laser skin resurfacing [letter] Wolfe SF. **Dermatol Surg** 1996 Aug;22(8):733-4

Single dose UTI prophylaxis in transurethral surgery. Oral ofloxacin vs parenteral cefotaxime. Madsen PO, et al. **Drugs** 1995;49 Suppl 2:480-2

Percutaneous endoscopic gastrostomy (PEG): comparison of push and pull methods and evaluation of antibiotic prophylaxis. Akkersdijk WL, et al. **Endoscopy** 1995 May; 27(4):313-6

Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation. Epstein JB, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):158-62

Prophylaxis in cardiac surgery. A controlled randomized comparison between cefazolin and cefuroxime. Wellens F, et al. **Eur J Cardiothorac Surg** 1995;9(6):325-9

Use of norfloxacin for prevention of symptomatic urinary tract infection in chronically catheterized patients. Rutschmann OT, et al. **Eur J Clin Microbiol Infect Dis** 1995 May;14(5):441-4

Antibiotic prophylaxis for ERCP: a randomized clinical trial comparing ciprofloxacin and cefuroxime in 200 patients at high risk of cholangitis. Mehal WZ, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):841-5

A prospective randomised study of the effects of prophylactic antibiotics on the incidence of bacteraemia following hysteroscopic surgery. Bhattacharya S, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):37-40

Prophylactic antibiotics in uncomplicated appendicitis during childhood--a prospective randomised study. Söderquist-Elinder C, et al. **Eur J Pediatr Surg** 1995 Oct; 5(5):282-5

Antibiotic prophylaxis for gastrointestinal endoscopy. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1995 Dec;42(6):630-5

Antibiotic prophylaxis of ERCP with ciprofloxacin [letter; comment] Mohandas KM, et al. **Gastrointest Endosc** 1996 Feb;43(2 Pt 1):175. Comment on: Gastrointest Endosc 1994 Nov-Dec;40(6):716-21.

Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Rolachon A, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1171-4

Routine antibiotic cover for newborns intubated for aspirating meconium: is it necessary? Krishnan L, et al. **Indian Pediatr** 1995 May;32(5):529-31

Antimicrobial prophylaxis of infection. Dickinson GM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):783-804 (83 ref.)

Preventing pelvic infection after abortion [editorial] Stevenson MM, et al. **Int J STD AIDS** 1995 Sep-Oct; 6(5):305-12 (61 ref.)

Efficacy of an intraperitoneal antibiotic to reduce the incidence of infection in the trauma patient: a prospective, randomized study. Yelon JA, et al. **J Am Coll Surg** 1996 Jun;182(6):509-14

Penetration of cefuroxime into the cerebrospinal fluid of patients with traumatic brain injury. Kossmann T, et al. **J Antimicrob Chemother** 1996 Jan;37(1):161-7

Antibiotic prophylaxis and infection control measures in minimally invasive surgery. Wilson AP. **J Antimicrob Chemother** 1995 Jul;36(1):1-5 (36 ref.)

Bacterial growth on antibiotic-loaded acrylic cement. A prospective in vivo retrieval study. Kendall RW, et al. **J Arthroplasty** 1995 Dec;10(6):817-22

Post-operative infection following hand surgery. Guidelines for antibiotic use. Platt AJ, et al. **J Hand Surg [Br]** 1995 Oct;20(5):685-90

Oral ciprofloxacin as prophylaxis in gastroduodenal surgery. McArdle CS, et al. **J Hosp Infect** 1995 Jul;30(3):211-6

Role of antibiotics in clean wounds. Hedawoo JB, et al. **J Indian Med Assoc** 1995 Aug;93(8):293-4, 290

Antibiotic prophylaxis for the prevention of donor-acquired Toxoplasma gondii infection in transplant patients [letter; comment] Wreghitt TG, et al. **J Infect** 1995 Nov; 31(3):253-4. Comment on: J Infect 1994 Nov;29(3):249-53.

An audit of prophylactic antibiotic treatment following tonsillectomy in children. Lee WC, et al. **J Laryngol Otol** 1996 Apr;110(4):357-9

Antibiotic prophylaxis for bacterial meningitis: overuse and uncertain efficacy. Pearson N, et al. **J Public Health Med** 1995 Dec;17(4):455-8

Antibiotic prophylaxis for infantile pyloromyotomy. Nour S, et al. **J R Coll Surg Edinb** 1996 Jun;41(3):178-80

A randomized prospective comparison of antibiotic tissue levels in the corpora cavernosa of patients undergoing penile prosthesis implantation using gentamicin plus cefazolin versus an oral fluoroquinolone for prophylaxis. Schwartz BF, et al. **J Urol** 1996 Sep;156(3):991-4

Hepatic chemoembolization: are prophylactic antibiotics necessary? [letter; comment] Tarazov PG.

J Vasc Interv Radiol 1995 Jul-Aug;6(4):658-9. Comment on: J Vasc Interv Radiol 1994 Mar-Apr;5(2):367-71.

Randomised controlled trial of single-dose antibiotic prophylaxis in surgical treatment of closed fractures: the Dutch Trauma Trial. Boxma H, et al. **Lancet** 1996 Apr 27;347(9009):1133-7

Managing HIV. Recommendations for antimicrobial prophylaxis in HIV. Mijch AM, et al. **Med J Aust** 1996 May 6;164(9):551

Prevention of perinatal group B streptococcal disease: a public health perspective. Centers for Disease Control and Prevention. **MMWR Morb Mortal Wkly Rep** 1996 May 31;45(RR-7):1-24

Perioperative normothermia and surgical-wound infection [letter] Schein M, et al. **N Engl J Med** 1996 Sep 5; 335(10):748-9; discussion 749-50

Prophylaxis against infective endocarditis in patients with cardiac disease. Hay KD. **N Z Dent J** 1995 Sep; 91(405):97-9

Antibiotic prophylaxis in cerebrospinal fluid shunting: a prospective randomized trial in 129 patients. Zentner J, et al. **Neurosurg Rev** 1995;18(3):169-72

Antibiotic penetration into cervical discs. Rhoten RL, et al. **Neurosurgery** 1995 Sep;37(3):418-21

Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Sawaya GF, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):884-90

Prophylaxis of endophthalmitis [letter; comment] Starr MB. **Ophthalmic Surg Lasers** 1996 Jan;27(1):81-3. Comment on: Ophthalmic Surg 1994 Nov-Dec;25(10):671-4.

Intravenous drug users: a consideration for infective endocarditis in dentistry? [editorial] Glick M. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Aug;80(2):125

The use of antibiotics for wound prophylaxis in spinal surgery. Rimoldi RL, et al. **Orthop Clin North Am** 1996 Jan;27(1):47-52 (33 ref.)

Epidemiology and prevention of meningococcal disease. Riedo FX, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):643-57 (163 ref.)

Prophylactic use of antibiotics and reduced case fatality in measles infection. Samb B, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):695-6

A prospective, double-blind, placebo-controlled trial of a single dose of azithromycin on postoperative wound infections in plastic surgery. Amland PF, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1378-83

Antibiotic prophylaxis for lower gastrointestinal endoscopy. Varma JR. **Prim Care** 1995 Sep;22(3):445-50 (6 ref.)

Failure of mass chemoprophylaxis to control hyperendemic meningococcal disease. Slater PE, et al. **Public Health Rev** 1995;23(4):367-9

Antibiotics before surgery. Kaatz B. **S D J Med** 1996 Jan; 49(1):27-8

Penetration of flomoxef into human maxillary and mandibular bones. Igawa HH, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Sep; 29(3):259-62

Vaginal scrub prophylaxis in abdominal hysterectomy. Vinkomin V. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):188-92

Prophylaxis of streptococcal bacteraemia with oral penicillin V in children undergoing bone marrow transplantation. Castagnola E, et al. **Support Care Cancer** 1995 Sep; 3(5):319-21

Postoperative infections in immunocompromised patients after oncological surgery. Ranchere JY, et al. **Support Care Cancer** 1995 Nov;3(6):409-13

Should antibiotic prophylaxis be used routinely in clean surgical procedures: a tentative yes. Lewis RT, et al. **Surgery** 1995 Oct;118(4):742-6; discussion 746-7

Antibiotic prophylaxis for patients undergoing transurethral resection of the prostate. Hall JC, et al. **Urology** 1996 Jun; 47(6):852-6

A word from WIPRO. Hospitals working on improving use of prophylactic antibiotics. Blustein J, et al. **Wis Med J** 1996 Jun;95(6):394-6

Comparison of cefotaxime plus metronidazole versus cefoxitin for prevention of wound infection after abdominal surgery. Kow L, et al. **World J Surg** 1995 Sep-Oct; 19(5):680-6; discussion 686

Subcuticular skin closure as a standard approach to emergency appendectomy in children: prospective clinical trial. Serour F, et al. **World J Surg** 1996 Jan;20(1):38-42

[Personal experience with use of Claforan in the form of a "protected coagulum" in patients after kidney transplantation] Janoušek L, et al. **Rozhl Chir** 1996 Feb; 75(2):106-8 (Eng. Abstr.) **(Cze)**

[Personal experience with Garamycin Schwamm in routine surgical practice] Vít P. **Rozhl Chir** 1996 Feb;75(2):81-2 (Eng. Abstr.) **(Cze)**

[Is antibiotic prophylaxis necessary in patients on chronic dialysis and with recurrent endocarditis?] Kopal V, et al. **Vnitr Lek** 1996 Mar;42(3):150-2 (Eng. Abstr.) **(Cze)**

[Cytoplasmic ribosomes of Plasmodium and prophylaxis of P. falciparum malaria by various antibiotics (editorial)] Charmot G. **Bull Soc Pathol Exot** 1995 Mar;88(4):147-8 **(Fre)**

[Search for bacterial contamination of the aqueous humor during cataract surgery with and without local antibiotic prophylaxis] Saint-Blancat P, et al. **J Fr Ophtalmol** 1995; 18(11):650-5 (Eng. Abstr.) **(Fre)**

[Antibiotic prophylaxis using cefuroxime in bile duct endoscopy] Lorenz R, et al. **Dtsch Med Wochenschr** 1996 Feb 23;121(8):223-30 (Eng. Abstr.) **(Ger)**

[Significance of Staphylococcus aureus in nose operations. Risk of toxic shock syndrome?] Pennekamp A, et al. **HNO** 1995 Nov;43(11):664-8 (Eng. Abstr.) **(Ger)**

[Fluconazole level in aqueous humor after oral drug administration in humans] Aust R, et al. **Ophthalmologe** 1995 Dec;92(6):829-32 (Eng. Abstr.) **(Ger)**

[Bite wounds and their characteristic position in trauma surgery management] Aigner N, et al. **Unfallchirurg** 1996 May;99(5):346-50 (Eng. Abstr.) **(Ger)**

[Routine antibiotic administration--consider risks and benefits! (editorial; comment)] Hansis M. **Unfallchirurg** 1996 May;99(5):315. Comment on: Unfallchirurg 1996 May;99(5):316-22. **(Ger)**

[Prophylactic and therapeutic use of antibiotics in trauma surgery (see comments] Hansis M, et al. **Unfallchirurg** 1996 May;99(5):316-22 (35 ref.) (Eng. Abstr.). Comment in: Unfallchirurg 1996 May;99(5):315. **(Ger)**

[Value of antibiotic prophylaxis in acute necrotizing pancreatitis] Rünzi M, et al. **Z Gastroenterol** 1996 Feb; 34(2):151-3 **(Ger)**

[Perioperative antibiotic prophylaxis in breast surgery: cefotiam versus clindamycin] Bier UW, et al. **Zentralbl Gynakol** 1996;118(5):279-82 (Eng. Abstr.) **(Ger)**

[Antibiotic prophylaxis with ++vancomycin in corrective surgery with alloplastic material] Massaioli N, et al. **Minerva Chir** 1995 Sep;50(9):827-9 (Eng. Abstr.) **(Ita)**

[Piperacillin in prevention and therapy in gynecological surgery] Giannone R, et al. **Minerva Ginecol** 1995 Jul-Aug; 47(7-8):335-9 (Eng. Abstr.) **(Ita)**

[Use of mini-septopal in trauma surgery of the hand. Experimental and clinical studies] Zimmer K. **Polim Med** 1996;26(1-2):3-57 (136 ref.) (Eng. Abstr.) **(Pol)**

[Assessment of gentamicin dosage in patients before planned surgical operation] Andrys I, et al. **Wiad Lek** 1994 Oct; 47(19-20):763-5 (Eng. Abstr.) **(Pol)**

[Endolymphatic therapy in the treatment of patients with acute appendicitis] Komarov NV, et al. **Klin Khir** 1996; (1):18-20 **(Rus)**

[Endolymphatic therapy in the treatment of patients with acute appendicitis] Komarov NV, et al. **Klin Khir** 1996; (1):53 **(Rus)**

[The use of antimicrobial preparations in preventing infectious wound complications after an operation on the kidney and upper urinary tract] Shirshov VA, et al. **Urol Nefrol (Mosk)** 1996 Mar-Apr;(2):11-3 (Eng. Abstr.) **(Rus)**

[A program of surveillance of surgical wounds (letter)] Figueroa Damián R. **Gac Med Mex** 1995 Mar-Apr; 131(2):259 **(Spa)**

[The importance of antibiotic prophylaxis in surgery (editorial)] Cainzos Fernández M. **Rev Clin Esp** 1995 Oct; 195(10):667-8 **(Spa)**

[The effect of surgical antibiotic prophylaxis and the timing of its administration on the risk of surgical wound infection] Muñoz Platón E, et al. **Rev Clin Esp** 1995 Oct; 195(10):669-73 (Eng. Abstr.) **(Spa)**

[Antibiotic prophylaxis suppurative infections of the foot in patients with diabetes mellitus] Shidlovs'kiĭ VO, et al. **Klin Khir** 1996;(1):20-2 **(Ukr)**

ADVERSE EFFECTS

Modification of cardiovascular response and histamine release by prophylactic antibiotic drugs in complicated surgery: a prospective randomized trial in a pig experimental model. Stinner B, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S78-9

Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV-infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis. Hennessy S, et al. **J Gen Intern Med** 1995 Jul;10(7):380-6

Resisting the routine [letter] Emmings FG. **N Y State Dent J** 1995 Oct;61(8):16

ECONOMICS

[Antibiotic strategy--an effective method in controlling pathogens and costs] Gutermuth L, et al. **Chirurg** 1996 May; 67(5):suppl 103-9 **(Ger)**

METHODS

Randomized study of antibiotic prophylaxis for general and gynaecological surgery from a single centre in rural Africa. Reggiori A, et al. **Br J Surg** 1996 Mar;83(3):356-9

Oral ciprofloxacin versus intravenous cefuroxime as prophylaxis against postoperative infection in vascular surgery: a randomised double-blind, prospective multicentre study. Risberg B, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):346-51

Meningococcal disease prevention and control strategies for practice-based physicians. Committee on Infectious Diseases, American Academy of Pediatrics. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. **Pediatrics** 1996 Mar;97(3):404-12

[Antibiotic prophylaxis and endoscopic retrograde cholangiopancreatography] Le Dreau G, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):55-63 (100 ref.) **(Fre)**

[Early antibiotic treatment in necrotizing acute pancreatitis] Sautereau D. **Gastroenterol Clin Biol** 1996;20(3):327-8 **(Fre)**

[Antibiotic prophylaxis in urology] Botto H. **Presse Med** 1995 Oct 28;24(32):1491-3 (Eng. Abstr.) **(Fre)**

STANDARDS

The American Society of Anesthesiologists physical status score and risk of perioperative infection [letter; comment] Rozner MA. **JAMA** 1996 May 22-29;275(20):1544. Comment on: JAMA 1996 Jan 17;275(3):234-40.

Improving the quality of antimicrobial drug use can result in cost containment. Gyssens IC, et al. **Pharm World Sci** 1995 Sep 22;17(5):163-7 (19 ref.)

UTILIZATION

Timeliness and use of antibiotic prophylaxis in selected inpatient surgical procedures. The Antibiotic Prophylaxis Study Group. Silver A, et al. **Am J Surg** 1996 Jun; 171(6):548-52

The use of antibiotic prophylaxis in radiology departments for patients at high-risk of infective endocarditis. Howlett DC, et al. **Clin Radiol** 1996 Sep;51(9):649-50

Antimicrobial prophylaxis in surgery in Belgian hospitals: room for improvement. Kurz X, et al. **Eur J Surg** 1996 Jan;162(1):15-21

Use of antibiotic-impregnated cement during hip and knee arthroplasty in the United States. Heck D, et al. **J Arthroplasty** 1995 Aug;10(4):470-5

Monitoring of antibiotic use in a primary and tertiary care hospital. Thomas M, et al. **J Clin Epidemiol** 1996 Feb; 49(2):251-4

Dentists' role in halting antimicrobial resistance [editorial] Slots J, et al. **J Dent Res** 1996 Jun;75(6):1338-41

ANTIBIOTIC RESISTANCE see **DRUG RESISTANCE, MICROBIAL**

ANTIBIOTICS

Filipin as a fluorescent probe of lipoprotein-derived sterols on thin-layer chromatograms. Smejkal GB, et al. **Anal Biochem** 1996 Jul 15;239(1):115-7

Survey of antibiotic control policies in university-affiliated teaching institutions. Lesar TS, et al. **Ann Pharmacother** 1996 Jan;30(1):31-4

False positive results for leucocytes in urine dipstick test with common antibiotics. Beer JH, et al. **BMJ** 1996 Jul 6; 313(7048):25

Antibiotic prophylaxis in patients undergoing radiological procedures who are at risk of infective endocarditis--do radiologists know what they are doing? Chakraverty S, et al. **Clin Radiol** 1996 Jan;51(1):39-41

The role of antibiotics in the evolution of microorganisms. Cavallo G. **G Batteriol Virol Immunol** 1992 Jan-1993 Dec; 85(1-12):3-11 (9 ref.)

Development of silastic polyurethane (Angioflex) materials with antibacterial agent. Rathinam K, et al. **J Biomater Appl** 1996 Jan;10(3):210-6

In vitro and in vivo antibiotic susceptibility of Lyme disease Borrelia isolated from the ixodid tick in Japan. Fujita H, et al. **J Dermatol** 1995 Dec;22(12):935-8

Labile antibiotic resistance in Staphylococcus aureus. Noble WC, et al. **J Hosp Infect** 1995 Oct;31(2):135-41

Icelandic researchers are showing the way to bring down rates of antibiotic-resistant bacteria [news] Stephenson J. **JAMA** 1996 Jan 17;275(3):175

New therapeutic agents marketed in 1995. Hussar DA. **Pa Med** 1996 Jun;99(6):35-6, 39-40

Antibiotic susceptibility of the sputum pathogens and throat swab pathogens isolated from the patients undergoing treatment in twenty-one private clinics in Japan. Watanabe A, et al. **Tohoku J Exp Med** 1995 Apr;175(4):235-47

[A study on antibiotic abuse in 750 children with acute respiratory infection in Tongxian County of Beijing] Li H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):331-4 (Eng. Abstr.) **(Chi)**

[The possibility for obtaining sorbents from the mycelial wastes of antibiotic production] Iakubova AR, et al. **Antibiot Khimioter** 1995 May;40(5):35-7 (Eng. Abstr.) **(Rus)**

[Microbial resistance: what is to be done? Information from the panel of experts] Mochales FB, et al. **Rev Esp Salud Publica** 1995 Nov-Dec;69(6):445-61 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Antibiotic prophylaxis in cesarean section. Pedersen TK, et al. **Acta Obstet Gynecol Scand** 1996 Jul;75(6):537-9

Failure of cefotaxime treatment in two children with meningitis caused by highly penicillin-resistant Streptococcus pneumoniae. Guibert M, et al. **Acta Paediatr** 1995 Jul;84(7):831-3

Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence. Porro GB, et al. **Am J Gastroenterol** 1996 Apr; 91(4):695-700

Home infusion of antimicrobials as an option for patients with AIDS [letter] Laing RB, et al. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2467-8

Continuous regional arterial infusion of protease inhibitor and

antibiotics in acute necrotizing pancreatitis. Takeda K, et al. **Am J Surg** 1996 Apr;171(4):394–8

Another use of the intravenous regional block technique [letter] Papakalou EP, et al. **Anesth Analg** 1996 Feb; 82(2):427

Dosing adjustment of 10 antimicrobials for patients with renal impairment. Preston SL, et al. **Ann Pharmacother** 1995 Dec; 29(12):1202–7

Meta-analysis of parenteral clindamycin dosing regimens. Rovers JP, et al. **Ann Pharmacother** 1995 Sep;29(9):852–8

Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Oh YK, et al.
Antimicrob Agents Chemother 1995 Sep;39(9):2104–11

Anti-infection treatment of a transcutaneous device by a collagen-rifampicine composite. Suh H, et al. **ASAIO J** 1994 Jul–Sep;40(3):M406–11

Oral versus intravenous antibiotics. Exclusion of sickest patients invalidates study [letter; comment] Tsang P.
BMJ 1995 Sep 9;311(7006):685. Comment on: BMJ 1995 May 27;310(6991):1360–2.

The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Symonds RP, et al. **Br J Cancer** 1996 Jul;74(2):312–7

Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. Benoit JL, et al. **Clin Infect Dis** 1995 Nov;21(5):1286–8

Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Cornelissen JJ, et al.
Clin Infect Dis 1995 Nov;21(5):1300–2

Evaluation of short-course therapy with cefixime or rifampin for eradication of pharyngeally carried group A streptococci. The Ontario GAS Study Group. Davies HD, et al. **Clin Infect Dis** 1995 Nov;21(5):1294–9

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Wenisch C, et al.
Clin Infect Dis 1996 May;22(5):813–8

A double-blind, multicenter comparative study of two regimens of clindamycin hydrochloride in the treatment of patients with acute streptococcal tonsillitis/pharyngitis. Gallegos B, et al. **Clin Ther** 1995 Jul–Aug;17(4):613–21

Pharmacist-managed intravenous to oral step-down program. Hunter KA, et al. **Clin Ther** 1995 May–Jun; 17(3):534–40; discussion 516

Long-term effects of selective decontamination on antimicrobial resistance [letter; comment] Kollef MH.
Crit Care Med 1996 Jan;24(1):177–8. Comment on: Crit Care Med 1995 Apr;23(4):637–45.

Ultrastructural study of the dermal microvasculature in patients undergoing retrograde intravenous pressure infusions. Langer K, et al. **Dermatology** 1996;192(2):103–9

Switch therapy in community-acquired pneumonia. Ramirez JA. **Diagn Microbiol Infect Dis** 1995 May–Jun; 22(1–2):219–23

Giving erythromycin by mouth. **Drug Ther Bull** 1995 Oct; 33(10):77–9

Inhalation of antibiotics in cystic fibrosis. Touw DJ, et al. **Eur Respir J** 1995 Sep;8(9):1594–604 (65 ref.)

An assessment of antibiotic therapy of urinary tract infection in elderly, hospitalised patients. McCaig DJ, et al.
Health Bull (Edinb) 1995 Nov;53(6):359–64

Treatment of Hickman catheter sepsis using antibiotic lock technique. Krzywda EA, et al.
Infect Control Hosp Epidemiol 1995 Oct;16(10):596–8

Biodegradable implants for potential use in bone infection. An in vitro study of antibiotic-loaded calcium sulphate. Mousset B, et al. **Int Orthop** 1995;19(3):157–61

A survey of current Israeli practices and approach to partially treated meningitis in children [see comments]
Meshulach-Netzer I, et al. **Isr J Med Sci** 1995 Oct; 31(10):611–5. Comment in: Isr J Med Sci 1995 Oct;31(10):638–9.

Home treatment of patients with cystic fibrosis using the 'Intermate': the first year's experience. Bramwell EC, et al. **J Adv Nurs** 1995 Dec;22(6):1063–7

Case against antibiotic prophylaxis for endocarditis and prosthesis infection in dermatologic procedures involving uninfected skin [letter; comment] George PM.
J Am Acad Dermatol 1996 Jan;34(1):153–4. Comment on: J Am Acad Dermatol 1995 Feb;32(2 Pt 1):155–76; quiz 177–80.

Use of antibiotic-impregnated cement during hip and knee arthroplasty in the United States. Heck D, et al.
J Arthroplasty 1995 Aug;10(4):470–5

Controlled release of antibiotics from coated orthopedic implants. Price JS, et al. **J Biomed Mater Res** 1996 Mar; 30(3):281–6

Assessment of in-line filters to prolong the life of intravenous cannulae in cystic fibrosis patients. Richards C, et al.
J Clin Pharm Ther 1995 Jun;20(3):165–6

Dentists' role in halting antimicrobial resistance [editorial] Slots J, et al. **J Dent Res** 1996 Jun;75(6):1338–41

Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. Ferris DG, et al. **J Fam Pract** 1995 Nov; 41(5):443–9

How far can the paediatric patient with a serious infection be managed as an outpatient? Dagan R. **J Hosp Infect** 1995 Jun;30 Suppl:172–8

Pyogenic infectious spondylitis in children: the convergence of discitis and vertebral osteomyelitis. Ring D, et al.
J Pediatr Orthop 1995 Sep–Oct;15(5):652–60

Scintigraphic assessment of the oropharyngeal and nasal depositions of fusafungine from a pressurized inhaler and from a novel pump spray device. Newman SP, et al.
J Pharm Pharmacol 1995 Oct;47(10):818–21

Rifampicin antibiotic impregnation of the St. Jude Medical mechanical valve sewing ring: a weapon against endocarditis. French BG, et al.
J Thorac Cardiovasc Surg 1996 Aug;112(2):248–52

In situ repair of mycotic abdominal aortic aneurysms with rifampin-bonded gelatin-impregnated Dacron grafts: a preliminary case report. Gupta AK, et al. **J Vasc Surg** 1996 Sep;24(3):472–6

Occurrence of Plesiomonas shigelloides in water environments of Rio de Janeiro city. de Mondino SS, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):1–4

Effect of intraperitoneally administered agents on human peritoneal mesothelial cell growth. Tsai TJ, et al.
Nephron 1995;71(1):23–8

Perioperative antimicrobial prophylaxis in neurosurgery: clinical trial of systemic flomoxef administration and saline containing gentamicin for irrigation. Yamamoto M, et al.
Neurol Med Chir (Tokyo) 1996 Jun;36(6):370–6

Modification by analgesics of the susceptibility to antibiotics in Serratia marcescens. Puig M, et al. **New Microbiol** 1995 Oct;18(4):385–90

The outpatient management of febrile neutropenia in cancer patients. Freifeld AG, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):599–606, 611–2; discussion 615–6 (31 ref.)

Nonsurgical treatment of patients with periodontal disease. Loesche WJ, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 May;81(5):533–43

Vaccine-associated paralytic poliomyelitis in the United States: no evidence of elevated risk after simultaneous intramuscular injections of vaccine. Izurieta HS, et al.
Pediatr Infect Dis J 1995 Oct;14(10):840–6

Aerosol administration of antibiotics. Smith AL, et al.
Pediatr Pulmonol Suppl 1995;11:68–9

Intraperitoneal antibiotics effectively treat
non-dialysis-related infections [letter] Gorman T, et al.
Perit Dial Int 1995 Jul–Sep;15(6):283–4

Audit of antibiotic usage in medium-sized general hospital over an 11-year period. The impact of antibiotic policies. McElnay JC, et al. **Pharm World Sci** 1995 Nov 24; 17(6):207–13

Community-acquired pneumonia. Cost-effective antimicrobial therapy [see comments] Cunha BA.
Postgrad Med 1996 Jan;99(1):109–10, 113–4, 117–9, passim (13 ref.). Comment in: Postgrad Med 1996 Apr;99(4):62–4.

Problems encountered using nebulized medications in hospitals [letter; comment] Beach JR, et al. **Respir Med** 1995 Nov;89(10):711–2. Comment on: Respir Med 1995 Jan;89(1):57–9.

Totally implantable venous access devices in adult patients with cystic fibrosis. Yung B, et al. **Respir Med** 1996 Jul; 90(6):353–6

Organism isolation and serum bactericidal titers in oral antibiotic therapy for pediatric osteomyelitis. Marshall GS, et al. **South Med J** 1996 Jan;89(1):68–70

Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Mukhopadhyay S, et al. **Thorax** 1996 Apr;51(4):364–8

Healing of muscle trauma after intramuscular injection of antibiotics in sheep: correlations between clinical, macroscopic and microscopic scores. Mikaelian I, et al.
Vet Res 1996;27(2):97–106

Pharmacoeconomics of intravenous antibictic use in serious infection. Levett PN, et al. **West Indian Med J** 1995 Sep; 44(3):81–4

[Rational use of antibiotics in general practice] Kolmos HJ.
Ugeskr Laeger 1996 Jan 15;158(3):258–60 **(Dan)**

[Rational use of antibiotics at hospitals] Kolmos HJ.
Ugeskr Laeger 1996 Jan 15;158(3):255–7 **(Dan)**

[Leading or misleading (letter)?] Lindegaard P, et al.
Ugeskr Laeger 1996 Feb 12;158(7):930 **(Dan)**

[A restrictive antibiotic policy in practice (letter; comment)] Nørgaard F. **Ugeskr Laeger** 1995 Sep 25;157(39):5404–5. Comment on: Ugeskr Laeger 1995 Jul 24;157(30):4260–2. **(Dan)**

[Fish diseases (letter)] Werkman PJ. **Tijdschr Diergeneeskd** 1996 Jan 15;121(2):40–2 **(Dut)**

[Antibiotic bonding on arterial prostheses: a necessity] Goeau-Brissonniere O. **J Mal Vasc** 1996;21 Suppl A:146–51 (42 ref.) (Eng. Abstr.) **(Fre)**

[Antibiotic-impregnated prostheses: eclectic indications] Melliere D, et al. **J Mal Vasc** 1996;21 Suppl A:139–45 (Eng. Abstr.) **(Fre)**

[Topical antibiotic therapy and skin infections] Henry F, et al. **Rev Med Liege** 1996 Feb;51(2):160–2 **(Fre)**

[Antibiotics in aerosols] Héritier F.
Rev Med Suisse Romande 1996 May;116(5):341–4 (30 ref.) **(Fre)**

[Respiratory tract infections: seven days antibiosis in general practice (interview)] Müller O. **Fortschr Med** 1996 Apr 10;114(10):45–6 **(Ger)**

[Modified triple therapy: what degree of acid inhibition is necessary? (letter)] Müller P, et al. **Leber Magen Darm** 1996 May;26(3):171–3 **(Ger)**

[Treatment of periprosthetic infection of the hip using one-stage exchange surgery] Steinbrink K, et al.
Orthopade 1995 Aug;24(4):335–43 (30 ref.) (Eng. Abstr.) **(Ger)**

[Effectiveness of triple therapy to eradicate H. pylori in patients after failed therapy with omeprazole/amoxicillin] Zala G, et al. **Schweiz Med Wochenschr** 1996 Feb 3; 126(5):153–8 (Eng. Abstr.) **(Ger)**

[Helicobacter pylori and peptic ulcer--1995 therapeutic indications and recommendations of a Munster Expert Group] Domschke W, et al. **Z Gastroenterol** 1995 Oct; 33(10):598–601 **(Ger)**

[Proper use of antibiotics--what is that?] Jensenius M, et al.
Tidsskr Nor Laegeforen 1995 Nov 20;115(28):3504–7 (23 ref.) (Eng. Abstr.) **(Nor)**

[Experience in the use of lymphatic infusion preparations in multimodal treatment of patients with giant lung abscess] Opanasenko NS. **Klin Khir** 1996;(1):25–7 **(Rus)**

[The efficacy of treating skin ulcers and burns with film dressings with antibiotics] Morozov VM, et al.
Voen Med Zh 1995 Aug;(8):31–3, 80 (Eng. Abstr.) **(Rus)**

[Restrictive prescription of antibiotics requires early follow-up] **Lakartidningen** 1996 Jul 10;93(28–29):2600 **(Swe)**

[New guidelines from the Medical Products Agency: the triple regime against Helicobacter pylori is necessary. Treat only if the ulcer is verified] Blomgren K, et al.
Lakartidningen 1996 Mar 13;93(11):1041–2, 1045 **(Swe)**

[Antibiotics in pneumonia may be changed without clinical examination (letter)] Braconier JH, et al. **Lakartidningen** 1995 Nov 22;92(47):4411–2 **(Swe)**

[Increased resistance after administration of antibiotics to animals] Franklin A. **Lakartidningen** 1996 Apr 24; 93(17):1627–30 (21 ref.) **(Swe)**

[Can lymphoma be cured by antibiotics?] Gunvén P, et al.
Lakartidningen 1996 Feb 28;93(9):767–8 (7 ref.) **(Swe)**

[Reconsider management of Helicobacter pylori infections. Time to go over to the triple therapy] Jaup BH.
Lakartidningen 1996 Feb 28;93(9):800–1 (12 ref.) **(Swe)**

[Physicians should keep a record of their own antibiotic prescriptions! Over-prescribing should be obvious] Wilhelmson B. **Lakartidningen** 1996 Feb 21;93(8):700–4 **(Swe)**

[The use of a low-frequency magnetic field and intraorganic electrophoresis in treating peritonitis in children] Tiktins'kyĭ VS, et al. **Klin Khir** 1995;(6):25–6 **(Ukr)**

ADVERSE EFFECTS

Renal and electrolyte complications associated with antibiotic therapy. Kasama R, et al. **Am Fam Physician** 1996 Jan; 53(1):227–32 (23 ref.)

Ototoxicity of ear drops: a clinical perspective. Linder TE, et al. **Am J Otol** 1995 Sep;16(5):653–7 (23 ref.)

Antibiotic patterns associated with fungal colonization in critically ill surgical patients. D'Amelio LF, et al.
Am Surg 1995 Dec;61(12):1049–53

Rifabutin-associated uveitis. Tseng AL, et al.
Ann Pharmacother 1995 Nov;29(11):1149–55 (45 ref.)

Action call to halt antibiotic-induced hearing loss [news] Abdulla S. **BMJ** 1996 Sep 14;313(7058):648

Fusidic acid induced acute immunologic thrombocytopenia. El-Kassar N, et al. **Br J Haematol** 1996 May;93(2):427–31

Widespread ocular use of topical chloramphenicol: is there justifiable concern regarding idiosyncratic aplastic anaemia? McGhee CN, et al. **Br J Ophthalmol** 1996 Feb; 80(2):182–4

Clindamycin-induced neuromuscular blockade. al Ahdal O, et al. **Can J Anaesth** 1995 Jul;42(7):614–7

Antibiotic-associated pseudomembranous enteritis due to Clostridium difficile [letter; comment] McBride M.
Clin Infect Dis 1995 Aug;21(2):455. Comment on: Clin Infect Dis 1994 Jun;18(6):982–4.

Mycobacterium avium complex infection, rifabutin, and uveitis--is there a connection? Nichols CW.
Clin Infect Dis 1996 Apr;22 Suppl 1:S43–7; discussion S47–9 (21 ref.)

Contact dermatitis from sodium fusidate. Giordano-Labadie F, et al. **Contact Dermatitis** 1996 Feb;34(2):159

Ultraviolet radiation-induced production of superoxide radicals by selected antibiotics. Ray RS, et al.
Drug Chem Toxicol 1996;19(1–2):121–30

Adverse reactions to antibiotics: is the patient really allergic? Boguniewicz M. **Drug Saf** 1995 Nov;13(5):273–80 (51 ref.)

Antibiotic-induced diarrhoea. **Drug Ther Bull** 1995 Mar; 33(3):23–4 (22 ref.)

Topical chloramphenicol: use or abuse? [editorial] Kirkness CM, et al. **Eye** 1995;9 (Pt 4):vii–viii

The Garrod Lecture. Selective toxicity and concordant pharmacodynamics of antibiotics and other drugs. Williams JD. **J Antimicrob Chemother** 1995 Jun;35(6):721–37 (63 ref.)

Pentoxifylline fails to prevent the Jarisch-Herxheimer reaction or associated cytokine release. Remick DG, et al.
J Infect Dis 1996 Sep;174(3):627–30

Acute interstitial nephritis associated with loracarbef therapy. Thieme RE, et al. **J Pediatr** 1995 Dec;127(6):997–1000

Severe neutropenia caused by recommended prophylactic doses of rifabutin [letter] Apseloff G, et al. **Lancet** 1996 Sep 7;348(9028):685

Amoxycillin-clavulanic acid prescribing remains high in the elderly despite warnings of drug-associated jaundice [letter] Parkes AJ. **Med J Aust** 1995 Oct 16;163(8):446

Peracute disseminated fatal Aspergillus fumigatus sepsis as

a complication of corticoid-treated systemic lupus erythematosus. Nenoff P, et al. **Mycoses** 1995 Nov-Dec; 38(11-12):467-71 (21 ref.)
Tumor necrosis factor and the Jarisch-Herxheimer reaction [editorial; comment] Beutler B, et al. **N Engl J Med** 1996 Aug 1;335(5):347-8. Comment on: N Engl J Med 1996 Aug 1;335(5):311-5.
Otitis media in children [letter] Mokry C. **N Engl J Med** 1995 Oct 26;333(17):1151; discussion 1152
Antibiotic associated nephropathy. Pospishil YO, et al. **Pol J Pathol** 1996;47(1):13-7
Medication errors result in costly claims for ophthalmologists. Brick DC. **Surv Ophthalmol** 1995 Nov-Dec;40(3):232-6
[Reversible tooth discoloration during oral use of antibiotics] Meyboom RH, et al. **Ned Tijdschr Geneeskd** 1996 Jan 27; 140(4):207-9 (Eng. Abstr.) **(Dut)**
[Anaphylaxis in cattle (news)] Kamphuis A. **Tijdschr Diergeneeskd** 1996 May 1;121(9):267 **(Dut)**
[Drug-induced acute pancreatitis] Grangé JD, et al. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B67-70 **(Fre)**
[Antibiotic-associated pseudomembranous colitis: retrospective study of 48 cases diagnosed by colonoscopy] Andrejak M, et al. **Therapie** 1996 Jan-Feb;51(1):81-6 (Eng. Abstr.) **(Fre)**
[Neutropenia during treatment with fusidic acid: analysis of 5 cases] Vial T, et al. **Therapie** 1995 Sep-Oct;50(5):447-50 (Eng. Abstr.) **(Fre)**
[Cholestatic jaundice after ingestion of amoxicillin and clavulanic acid] Friess G, et al. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1356-60 (Eng. Abstr.) **(Ger)**
[Side effects and consequences of frequently used antibiotics in clinical practice] Cerny A. **Schweiz Med Wochenschr** 1996 Mar 30;126(13):528-34 (38 ref.) (Eng. Abstr.) **(Ger)**
[Incidence of hypersensitivity to antibiotics and preservatives in eye drops] Rudzki E, et al. **Klin Oczna** 1995 Mar-Apr; 97(3-4):66-7 (Eng. Abstr.) **(Pol)**
[Intestinal microflora and antibiotic therapy (editorial)] Socha J. **Pediatr Pol** 1995 Jul;70(7):547-52 (Eng. Abstr.) **(Pol)**
[The effect of antibiotics on the body of those working in their manufacture] Tabakova TV, et al. **Ter Arkh** 1995; 67(10):31-3 (Eng. Abstr.) **(Rus)**
[Multicenter study comparing the efficacy and tolerance of topical ciprofloxacin (0.3%) versus topical gentamicin (0.3%) in the treatment of simple, non-cholesteatomaous chronic otitis media in the suppurative phase] Lorente J, et al. **An Otorrinolaringol Ibero Am** 1995;22(5):521-33 (Eng. Abstr.) **(Spa)**
[Diarrhea associated with antibiotics and disease caused by Clostridium difficile (letter)] Sánchez Muñoz LA, et al. **Aten Primaria** 1995 Sep 15;16(4):236 **(Spa)**
[Acute pancreatitis associated with hepatotoxicity induced by amoxicillin-clavulanic acid] Galindo C, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):597-600 (23 ref.) (Eng. Abstr.) **(Spa)**
[Recurrence of meningoencephalitis induced by cotrimoxazole] Carrillo F, et al. **Rev Neurol** 1995 Jan-Feb; 23(119):142-4 (Eng. Abstr.) **(Spa)**
[Clostridium difficile-associated diarrhea--an increasing problem. Reduce the administration of antibiotics and improve hygiene!] Svenungsson B. **Lakartidningen** 1996 Aug 28;93(35):2931-4 (67 ref.) **(Swe)**

ANALYSIS

Patterns of chemical residues detected in US beef carcasses between 1991 and 1993. Gibbons SN, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):589-93
Confirmation of chloramphenicol residues in egg by gas chromatography/high-resolution mass spectrometry and comparison of quantitation with gas chromatography-electron capture detection. Börner S, et al. **J AOAC Int** 1995 Sep-Oct;78(5):1153-60
Methods for determining concentrations of antimicrobial agents in human monocytes. Mor N, et al. **J Chemother** 1995 Jun;7(3):207-9
Liquid chromatographic determination of the antibiotic fumagillin in fish meat samples. Fekete J, et al. **J Chromatogr A** 1995 Oct 13;712(2):378-81
High-voltage electrophoretic identification of residual antibiotics in milk. Krčmář P, et al. **Vet Med (Praha)** 1996 Mar;41(3):93-5
[Residues of antibiotics and other inhibitory substances in milk] Rybińska K, et al. **Rocz Panstw Zakl Hig** 1995; 46(3):239-41 (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS

Inactivation of chloramphenicol by O-phosphorylation. A novel resistance mechanism in Streptomyces venezuelae ISP5230, a chloramphenicol producer. Mosher RH, et al. **J Biol Chem** 1995 Nov 10;270(45):27000-6
[The resistance to antibiotics and chemotherapeutic agents of Shigella strains isolated from HIV-seropositive children] Sfartz S, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Apr-Jun;40(2):145-8 **(Rum)**

BIOSYNTHESIS

Nutrient optimization for production of broad spectrum antibiotic by Streptomyces antibioticus SR15.4. Haque SF, et al. **Acta Microbiol Immunol Hung** 1995;42(2):155-62
Polyketide synthase gene manipulation: a structure-function approach in engineering novel antibiotics. Hutchinson CR, et al. **Annu Rev Microbiol** 1995;49:201-38 (144 ref.)
Production of kanosamine by Bacillus cereus UW85. Milner JL, et al. **Appl Environ Microbiol** 1996 Aug;62(8):3061-5
Tn5-directed cloning of pqq genes from Pseudomonas fluorescens CHA0: mutational inactivation of the genes results in overproduction of the antibiotic pyoluteorin. Schnider U, et al. **Appl Environ Microbiol** 1995 Nov; 61(11):3856-64
Genetics and biochemistry of antibiotic production. **Biotechnology** 1995;28:1-679
Isoprenoid antibiotics. Cane DE. **Biotechnology** 1995; 28:633-55 (99 ref.)
Rifamycin SV and related ansamycins. Chiao JS, et al. **Biotechnology** 1995;28:477-98 (110 ref.)
Agrocins. Clare BG. **Biotechnology** 1995;28:619-32 (53 ref.)
Global physiological controls. Doull JL, et al. **Biotechnology** 1995;28:9-63 (257 ref.)
Genetics of antibiotic production in Streptomyces coelicolor A3(2), a model streptomycete. Hopwood DA, et al. **Biotechnology** 1995;28:65-102 (132 ref.)
Aminoglycosides and aminocyclitols (other than streptomycin). Hotta K, et al. **Biotechnology** 1995;28:571-95 (82 ref.)
Microcins. Moreno F, et al. **Biotechnology** 1995;28:307-21 (58 ref.)
Bialaphos. Thompson CJ, et al. **Biotechnology** 1995; 28:197-222 (68 ref.)
Genetic and environmental control of antibiotic production. Vining LC. **Biotechnology** 1995;28:1-7 (26 ref.)
Chloramphenicol. Vining LC, et al. **Biotechnology** 1995; 28:505-30 (80 ref.)
Molecular analysis of genes encoding phenazine biosynthesis in the biological control bacterium. Pseudomonas aureofaciens 30-84. Pierson LS 3rd, et al. **FEMS Microbiol Lett** 1995 Dec 15;134(2-3):299-307
Identification of Streptomyces olivaceus Tü 2353 genes involved in the production of the polyketide elloramycin. Decker H, et al. **Gene** 1995 Dec 1;166(1):121-6
Clavulanic acid biosynthesis in Streptomyces clavuligerus: gene cloning and characterization. Hodgson JE, et al. **Gene** 1995 Dec 1;166(1):49-55
The phzI gene of Pseudomonas aureofaciens 30-84 is responsible for the production of a diffusible signal required for phenazine antibiotic production. Wood DW, et al. **Gene** 1996 Feb 2;168(1):49-53
Amicenomycins A and B, new antibiotics from Streptomyces sp. MJ384-46F6 [letter] Kawamura N, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1521-4
Biosynthetic study on the polyether carboxylic antibiotic, nigericin production and biohydroxylation of grisorixin by nigericin-producing Streptomyces hygroscopicus NRRL B-1865. Mouslim J, et al. **J Antibiot (Tokyo)** 1995 Sep; 48(9):1011-4
Hydranthomycin, a new agroactive antibiotic produced by Streptomyces sp. K93-5305 [letter] Tanaka Y, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1525-6
Global negative regulation of Streptomyces coelicolor antibiotic synthesis mediated by an absA-encoded putative signal transduction system. Brian P, et al. **J Bacteriol** 1996 Jun;178(11):3221-31
redD and actII-ORF4, pathway-specific regulatory genes for antibiotic production in Streptomyces coelicolor A3(2), are transcribed in vitro by an RNA polymerase holoenzyme containing sigma hrdD. Fujii T, et al. **J Bacteriol** 1996 Jun;178(11):3402-5
At least two separate gene clusters are involved in albicidin production by Xanthomonas albilineans. Rott PC, et al. **J Bacteriol** 1996 Aug;178(15):4590-6
A relA/spoT homologous gene from Streptomyces coelicolor A3(2) controls antibiotic biosynthetic genes. Martínez-Costa OH, et al. **J Biol Chem** 1996 May 3; 271(18):10627-34
1995 Colworth Prize Lecture. The regulation of antibiotic production in Streptomyces coelicolor A3(2). Bibb M. **Microbiology** 1996 Jun;142 (Pt 6):1335-44 (117 ref.)
A new Myxococcus xanthus gene cluster for the biosynthesis of the antibiotic saframycin Mx1 encoding a peptide synthetase. Pospiech A, et al. **Microbiology** 1995 Aug;141 (Pt 8):1793-803
Ecology of anti-microbials produced by bacterial associates of Steinernema carpocapsae and Heterorhabditis bacteriophora. Jarosz J. **Parasitology** 1996 Jun;112 (Pt 6):545-52
The sigma factor sigma s affects antibiotic production and biological control activity of Pseudomonas fluorescens Pf-5. Sarniguet A, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12255-9
[Conception and development of a universal scheme for sewage treatment in antibiotic production] Faingol'd ZL, et al. **Antibiot Khimioter** 1995 Oct;40(10):15-8 (Eng. Abstr.) **(Rus)**
[Induction of antibiotic production in inactive cultures of actinomycetes. Monensin production by a mutant strain 2608 EB-1] Malkina ND, et al. **Antibiot Khimioter** 1995 Oct;40(10):3-6 (Eng. Abstr.) **(Rus)**
[Electrocoagulation treatment of sewage in antibiotic production] Polunina EE, et al. **Antibiot Khimioter** 1995 Nov-Dec;40(11-12):10-5 (Eng. Abstr.) **(Rus)**
[Antibiotics, synthesized by Streptomyces chrysomallus subsp. macrotetrolidi in the early stages of growth] Sverdlova AN, et al. **Antibiot Khimioter** 1995 Nov-Dec; 40(11-12):3-9 (Eng. Abstr.) **(Rus)**
[Directed search for streptomycetes that are producers of ionophoric antibiotics] Sverdlova AN, et al. **Mol Gen Mikrobiol Virusol** 1995 Oct-Dec;(4):29-35 (Eng. Abstr.) **(Rus)**

BLOOD

Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Trapnell CB, et al. **Ann Intern Med** 1996 Mar 15;124(6):573-6
Comparative serum bactericidal activity against Pseudomonas aeruginosa of six antipseudomonal agents. Dan M, et al. **Chemotherapy** 1995 Sep-Oct;41(5):323-9
High-performance liquid chromatographic determination of spectinomycin in swine, calf and chicken plasma using post-column derivatization. Haagsma N, et al. **J Chromatogr B Biomed Appl** 1995 Oct 6;672(1):165-71
Determination of meropenem in plasma by high-performance liquid chromatography and a microbiological method. al-Meshal MA, et al. **J Clin Pharm Ther** 1995 Jun; 20(3):159-63

CEREBROSPINAL FLUID

Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Klugman KP, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1988-92

CHEMICAL SYNTHESIS

Synthesis of saframycins. X. Transformation of (-)-saframycin A to (-)-saframycin Mx type compound with the structure proposed for saframycin E. Saito N, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):777-82
Synthesis and chemistry of the ionophore antibiotic tetronasin. Ley SV, et al. **Farmaco** 1996 Mar;51(3):147-57 (27 ref.)
Total synthesis of (+/-)-phosphonothrixin, a novel herbicidal antibiotic containing C-P bond. Nakamura K, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1134-7
Derivatives of tetrodecamycin. Tsuchida T, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1330-5
[Synthesis of lactone ring-containing bioactive natural products. Cardiotonic steroids, naphthoquinone antibiotics, and tetronic acid ionophore antibiotics] Yoshii E. **Yakugaku Zasshi** 1996 Jan;116(1):1-20 (45 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Structures of quinoxaline antibiotics. Sheldrick GM, et al. **Acta Crystallogr B** 1995 Dec 1;51 (Pt 6):987-99
The interaction between "R/S domain" of rat 28S ribosomal RNA and ribosome-inactivating proteins investigated by fusidic acid. Li Q, et al. **Biochem Mol Biol Int** 1995 Nov; 37(5):877-83
Isoprenoid antibiotics. Cane DE. **Biotechnology** 1995; 28:633-55 (99 ref.)
Agrocins. Clare BG. **Biotechnology** 1995;28:619-32 (53 ref.)
Microcins. Moreno F, et al. **Biotechnology** 1995;28:307-21 (58 ref.)
Post-translational heterocyclic backbone modifications in the 43-peptide antibiotic microcin B17. Structure elucidation and NMR study of a 13C,15N-labelled gyrase inhibitor. Bayer A, et al. **Eur J Biochem** 1995 Dec 1;234(2):414-26
Nisin Z, mutant nisin Z and lacticin 481 interactions with anionic lipids correlate with antimicrobial activity. A monolayer study. Demel RA, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):267-74
The structure of the lantibiotic lacticin 481 produced by Lactococcus lactis: location of the thioether bridges. van den Hooven HW, et al. **FEBS Lett** 1996 Aug 12; 391(3):317-22
Degradation of citrinin using ammoniation. Castegnaro M, et al. **IARC Sci Publ** 1991;(113):17-22
Chemistry of pseudomonic acid. Part 16.Aryl and heteroaryl ketone derivatives of monic acid. Abson A, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):390-4
The chemistry of pseudomonic acid. Part 14. Synthesis and in vivo biological activity of heterocyclyl substituted oxazole derivatives. Broom NJ, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1336-44
Base-catalyzed isomerism in elfamycin antibiotics. Structures of ganefromycins epsilon and epsilon 1. Carter GT, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1312-9
Azalomycin F complex from Streptomyces hygroscopicus, MSU/MN-4-75B. Chandra A, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):896-8
Antibiotic GE37468 A: a novel inhibitor of bacterial protein synthesis. II. Structure elucidation. Ferrari P, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1304-11
Phosphonothrixin, a novel herbicidal antibiotic produced by Saccharothrix sp. ST-888. II. Structure determination. Kimura T, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1130-3
Components of the GE2270 complex produced by Planobispora rosea ATCC 53773. Selva E, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):1039-42
Biosynthesis of lactacystin. Takahashi S, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):1015-20
Macrosphelide, a novel inhibitor of cell-cell adhesion molecule. II. Physiochemical properties and structural elucidation. Takamatsu S, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):95-8

Kalimantacin A, B, and C, novel antibiotics produced by Alcaligenes sp. YL-02632S. II. Physico-chemical properties and structure elucidation. Tokunaga T, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):140–4

Epoxyquinomicins A and B, new antibiotics from Amycolatopsis [letter] Tsuchida T, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):326–8

Tetrodecamycin and dihydrotetrodecamycin, new antimicrobial antibiotics against Pasteurella piscicida produced by Streptomyces nashvillensis MJ885-mF8. II. Structure determination. Tsuchida T, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1110–4

Azicemicins A and B, new antimicrobial agents produced by Amycolatopsis. II. Structure determination. Tsuchida T, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1148–52

Covalent structure, synthesis, and structure-function studies of mesentericin Y 105(37), a defensive peptide from gram-positive bacteria Leuconostoc mesenteroides. Fleury Y, et al. **J Biol Chem** 1996 Jun 14;271(24):14421–9

Chemical structure and translation inhibition studies of the antibiotic microcin C7. Guijarro JI, et al. **J Biol Chem** 1995 Oct 6;270(40):23520–32

Randomized, double blind comparison of brand and generic antibiotic suspensions: II. A study of taste and compliance in children. El-Chaar GM, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):18–22

Randomized, double blind comparison of brand and generic antibiotic suspensions: I. A study of taste in adults. Samulak KM, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):14–17

Flavipucine and brunnescin, two antibiotics from cultures of the mycophilic fungus Cladobotryum rubrobrunnescens. Wagner C, et al. **Z Naturforsch [C]** 1995 May-Jun; 50(5–6):358–64

CLASSIFICATION

Impact of different classes antimicrobial agents on plasma endotoxin activity. Nitsche D, et al. **Arch Surg** 1996 Feb; 131(2):192–9

ECONOMICS

In-patient care for symptomatic, HIV-infected persons: a longitudinal study of hospitalizations, in-patient drug use, and related costs. Dijkgraaf MG, et al. **AIDS Care** 1995; 7(3):321–36

Cost management in community-acquired lower respiratory tract infection. Davey PG. **Am J Med** 1995 Dec 29; 99(6B):20S–23S

Tuberculosis in the United Kingdom. Treatment should be free for everyone [letter; comment] Davidson C, et al. **BMJ** 1996 Mar 23;312(7033):775. Comment on: BMJ 1995 Dec 2;311(7018):1483–5.

Pharmacoeconomics of appropriate antimicrobial use. Davey P. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1–2):225–9

Switch therapy in community-acquired pneumonia. Ramirez JA. **Diagn Microbiol Infect Dis** 1995 May-Jun; 22(1–2):219–23

Econotherapeutics. Roark MK, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1–2):209–17

Reassessment of frequency of occurrence of typhoid fever and cost efficacy analysis of antibiotic therapy. Sridhar CB, et al. **J Assoc Physicians India** 1995 Oct;43(10):679–84

Community-acquired pneumonia. Cost-effective antimicrobial therapy [see comments] Cunha BA. **Postgrad Med** 1996 Jan;99(1):109–10, 113–4, 117–9, passim (13 ref.). Comment in: Postgrad Med 1996 Apr;99(4):62–4.

Pharmacoeconomics of intravenous antibiotic use in serious infection. Levett PN, et al. **West Indian Med J** 1995 Sep; 44(3):81–4

[Health economics and antibiotic therapy] Leclercq P, et al. **Rev Med Brux** 1995 Jul-Aug;16(4):320–4 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

[Missing links in immunologic defense. Endogenous antibiotics are the primary protection] Wilhelmson B. **Lakartidningen** 1996 May 1;93(18):1728–33 **(Swe)**

ISOLATION & PURIFICATION

Cryptdins: endogenous antibiotic peptides of small intestinal Paneth cells. Harwig SS, et al. **Adv Exp Med Biol** 1995; 371A:251–5

Effect of micelles and mixed micelles on efficiency and selectivity of antibiotic-based capillary electrophoretic enantioseparations. Rundlett KL, et al. **Anal Chem** 1995 Jul 1;67(13):2088–95

Evaluation of a multiple bioassay technique for determination of antibiotic residues in meat with standard solutions of antimicrobials. Calderón V, et al. **Food Addit Contam** 1996 Jan;13(1):13–9

Developments and newer approaches in downstream processing of biopharmaceuticals. Chatterjee NR, et al. **Hindustan Antibiot Bull** 1994 Aug-Nov;36(3–4):78–97 (66 ref.)

Phencomycin, a new antibiotic from a Streptomyces species HIL Y-9031725. Chatterjee S, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1353–4

Isolation and structure determination of two novel phenazines from a Streptomyces with inhibitory activity against metallo-enzymes, including metallo-beta-lactamase. Gilpin ML, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1081–5

New albrassitriols from Aspergillus sp. (FH-A 6357). Grabley S, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):593–5

Hydroxymycotrienins A and B, new ansamycin group antibiotics. Hosokawa N, et al. **J Antibiot (Tokyo)** 1996 May;49(5):425–31

The ripostatins, novel inhibitors of eubacterial RNA polymerase isolated from myxobacteria. Irschik H, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):787–92

Bacillaene, a novel inhibitor of procaryotic protein synthesis produced by Bacillus subtilis: production, taxonomy, isolation, physico-chemical characterization and biological activity. Patel PS, et al. **J Antibiot (Tokyo)** 1995 Sep; 48(9):997–1003

Antibiotic GE37468 A: a new inhibitor of bacterial protein synthesis. I. Isolation and characterization [published erratum appears in J Antibiot (Tokyo) 1995 Dec;48(12):C-3] Stella S, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):780–6

Phosphonothrixin, a novel herbicidal antibiotic produced by Saccharothrix sp. ST-888. I. Taxonomy, fermentation, isolation and biological properties. Takahashi E, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1124–9

Tetrodecamycin and dihydrotetrodecamycin, new antimicrobial antibiotics against Pasteurella piscicida produced by Streptomyces nashvillensis MJ885-mF8. I. Taxonomy, fermentation, isolation, characterization and biological activities. Tsuchida T, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1104–9

AL072, a novel anti-Legionella antibiotic produced by Streptomyces sp. Yon C, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):773–9

Anguillosporal, a new antibacterial and antifungal metabolite from the freshwater fungus Anguillospora longissima. Harrigan GG, et al. **J Nat Prod** 1995 Sep;58(9):1467–9

Isolation and in vitro antibacterial screening of a tricarboxylic acid anhydride from Penicillium sp. Jabbar A, et al. **Pharmazie** 1995 Oct;50(10):706–7

Evaluation of acrodontiolamide, a chlorinated compound produced by Acrodontium salmoneum de Hoog for cytotoxicity and antimicrobial activity. Steiman R, et al. **Pharmazie** 1995 Oct;50(10):693–5

METABOLISM

Evidence for an efflux pump in multidrug-resistant Campylobacter jejuni. Charvalos E, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2019–22

Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Li XZ, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1948–53

A beta-lactamase from Serratia marcescens hydrolyzing the 2-carboxypenam T-5575. Matsumura N, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2132–4

A potential soft tissue filling material: chloramphenicol loaded poly(D,L-lactide) sponges. Kozluca A, et al. **Artif Organs** 1995 Sep;19(9):902–8

Chloramphenicol oxamylethanolamine as an end product of chloramphenicol metabolism in rat and humans: evidence for the formation of a phospholipid adduct. Cravedi JP, et al. **Chem Res Toxicol** 1995 Jul-Aug;8(5):642–8

Resistance to the polyether ionophore antibiotic pandavir (nigericin) in two producing strains of Streptomyces. Moncheva PA, et al. **J Antibiot (Tokyo)** 1995 Aug; 48(8):811–4

Production of actinorhodin-related "blue pigments" by Streptomyces coelicolor A3(2). Bystrykh LV, et al. **J Bacteriol** 1996 Apr;178(8):2238–44

Regulation of jadomycin B production in Streptomyces venezuelae ISP5230: involvement of a repressor gene, jadR2. Yang K, et al. **J Bacteriol** 1995 Nov;177(21):6111–7

From xenobiotic to antibiotic, formation of protoanemonin from 4-chlorocatechol by enzymes of the 3-oxoadipate pathway. Blasco R, et al. **J Biol Chem** 1995 Dec 8; 270(49):29229–35

The role of tryptophans 371 and 395 in the binding of antibiotics and the transport of sugars by the D-galactose-H+ symport protein (GalP) from Escherichia coli. McDonald TP, et al. **J Biol Chem** 1995 Dec 22; 270(51):30359–70

Inactivation of chloramphenicol by O-phosphorylation. A novel resistance mechanism in Streptomyces venezuelae ISP5230, a chloramphenicol producer. Mosher RH, et al. **J Biol Chem** 1995 Nov 10;270(45):27000–6

Fate and residues of 14C-chloramphenicol in laying chickens. Akhtar MH, et al. **J Environ Sci Health B** 1996 Sep; 31(5):1061–84

Accumulation of the angucycline antibiotic rabelomycin after disruption of an oxygenase gene in the jadomycin B biosynthetic gene cluster of Streptomyces venezuelae. Yang K, et al. **Microbiology** 1996 Jan;142 (Pt 1):123–32

[Penetration and intracellular activity of antimicrobial agents. A new pharmacologic parameter? (editorial)] Pascual A. **Med Clin (Barc)** 1995 Nov 18;105(17):652–3 **(Spa)**

PHARMACOKINETICS

Antibiotic pharmacokinetics following fluid resuscitation from traumatic shock. McKindley DS, et al. **Arch Surg** 1995 Dec;130(12):1321–8; discussion 1328–9

Comparative serum bactericidal activity against Pseudomonas aeruginosa of six antipseudomonal agents. Dan M, et al. **Chemotherapy** 1995 Sep-Oct;41(5):323–9

The clinical pharmacokinetics of rifabutin. Blaschke TF, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S15–21; discussion S21–2 (28 ref.)

Serum concentrations and tissue residues of spectinomycin in chickens. el-Sayed MG, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Nov;102(11):446–50

Application of saliva for drug monitoring. An in vivo model for transmembrane transport. Haeckel R, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):171–91 (179 ref.)

Residues of some veterinary drugs in animals and foods. Monographs prepared by the forty-third meeting of the Joint FAO/WHO Expert Committee on Food Additives. **FAO Food Nutr Pap** 1995;41(7):1–112

Comparative killing kinetics of methicillin-resistant Staphylococcus aureus by bacitracin or mupirocin. Chapnick EK, et al. **Infect Control Hosp Epidemiol** 1996 Mar;17(3):178–80

Absorption of clindamycin after intravaginal application of clindamycin phosphate 2% cream. Borin MT, et al. **J Antimicrob Chemother** 1995 Jun;35(6):833–41

Antimicrobial prescribing in patients on haemofiltration. Cotterill S. **J Antimicrob Chemother** 1995 Nov;36(5):773–80

An investigation of the pharmacokinetics and autoinduction of rifabutin metabolism in mice treated with 10 mg/kg/day six times a week for 8 weeks. Strolin Benedetti M, et al. **J Antimicrob Chemother** 1995 Jul;36(1):247–51

Use of ultrasound to facilitate antibiotic diffusion through Pseudomonas aeruginosa alginate. Williams KA, et al. **J Antimicrob Chemother** 1995 Sep;36(3):463–73

A new in-vitro model to investigate antibiotic penetration of the intervertebral disc. Thomas R de W, et al. **J Bone Joint Surg Br** 1995 Nov;77(6):967–70

Scintigraphic assessment of the oropharyngeal and nasal depositions of fusafungine from a pressurized inhaler and from a novel pump spray device. Newman SP, et al. **J Pharm Pharmacol** 1995 Oct;47(10):818–21

Florfenicol pharmacokinetics in lactating cows after intravenous, intramuscular and intramammary administration. Soback S, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):413–7

Modeling residue uptake by eggs. 1. Similar drug residue patterns in developing yolks following injection with ampicillin or oxytetracycline. Donoghue DJ, et al. **Poult Sci** 1996 Mar;75(3):321–8

[Tissue pharmacokinetics of antibiotics. Theoretical bases and new pharmacological approaches] Bergogne-Bérézin E. **Presse Med** 1996 Mar 2–9;25(8):399–406 (55 ref.) (Eng. Abstr.) **(Fre)**

[In vitro evaluation of antibiotic diffusion from antibiotic impregnated xenografts] Günal I, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(1):59–62 (Eng. Abstr.) **(Fre)**

[Pharmacokinetics of antibiotics in burn patients] Lesne-Hulin A, et al. **Therapie** 1995 Nov-Dec;50(6):575–86 (74 ref.) (Eng. Abstr.) **(Fre)**

[Excretion of erythromycin, clindamycin and lincomycin into the saliva] Kelentey BA, et al. **Fogorv Sz** 1995 Jul; 88(7):219–24 (Eng. Abstr.) **(Hun)**

[Active transport of fosfomycin into cells of Escherichia coli, multidrug-resistant Pseudomonas aeruginosa and Staphylococcus aureus] Tsuruoka T, et al. **Jpn J Antibiot** 1995 Dec;48(12):1935–8 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

A model for testing drug susceptibility of Pseudomonas aeruginosa and Staphylococcus aureus grown in biofilms on medical devices [see comments] Kétyi I. **Acta Microbiol Immunol Hung** 1995;42(2):215–9. Comment in: Acta Microbiol Immunol Hung 1995;42(2):221.

Interaction between tricyclic psychopharmacons and some antibiotics. Molnár J, et al. **Acta Microbiol Immunol Hung** 1995;42(3):277–85

Antimicrobial susceptibility and rRNA gene restriction patterns among Staphylococcus intermedius from healthy dogs and from dogs suffering from pyoderma or otitis externa. Pedersen K, et al. **Acta Vet Scand** 1995; 36(3):335–42

Newer antibiotics: a dermatologist's guide. Webster GF. **Adv Dermatol** 1996;11:105–15; discussion 116 (60 ref.)

Comparative susceptibilities of Klebsiella species, Enterobacter species, and Pseudomonas aeruginosa to 11 antimicrobial agents in a tertiary-care university hospital. Fekete T, et al. **Am J Med** 1996 Jun 24;100(6A):20S–25S

Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods. Thornsberry C, et al. **Am J Med** 1996 Jun 24;100(6A):26S–38S

Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Han DP, et al. **Am J Ophthalmol** 1996 Jul;122(1):1–17

Rickettsia tsutsugamushi infection in cell culture: antibiotic susceptibility determined by flow cytometry. Kelly DJ, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):602–6

Rifampin-fluconazole interaction in critically ill patients. Nicolau DP, et al. **Ann Pharmacother** 1995 Oct; 29(10):994–6

In vitro activities of ciprofloxacin, cefotaxime, ceftriaxone, chloramphenicol, and rifampin against fully susceptible and moderately penicillin-resistant Neisseria meningitidis. Blondeau JM, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2577–9

Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria. Brown BA, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):874–8

Activities of oral antibiotics on Providencia strains isolated from institutionalized elderly patients with urinary tract infections. Cornaglia G, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2819–21

Antibacterial activity of WY-49605 compared with those of six other oral agents and selection of disk content for disk diffusion susceptibility testing. Fuchs PC, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1472–9

In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin. Giron KP, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2798–800

Different patterns of bacterial DNA synthesis during postantibiotic effect. Gottfredsson M, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1314–9

In vitro antibiotic susceptibility testing of clinical isolates of Mycoplasma penetrans from patients with AIDS. Hayes MM, et al. **Antimicrob Agents Chemother** 1995 Jun; 39(6):1386–7

MICs of 28 antibiotic compounds for 14 Bartonella (formerly Rochalimaea) isolates. Maurin M, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2387–91

Antibiotics and prevention of microbial colonization of catheters. Raad I, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2397–400

In vitro and in vivo antibiotic susceptibilities of ELB rickettsiae. Radulovic S, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2564–6

GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin. Stieger M, et al. **Antimicrob Agents Chemother** 1996 Apr; 40(4):1060–2

Characterization of antimicrobial resistance in enterococci of animal origin. Thal LA, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2112–5

Effects of free and liposome-encapsulated antibiotics on adherence of Pseudomonas aeruginosa to collagen type I. Trafny EA, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2645–9

Susceptibilities of nontuberculosis mycobacterial species to amoxicillin-clavulanic acid alone and in combination with antimycobacterial agents. Utrup LJ, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1454–7

Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: evaluation of current treatment. Walsh AL, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2356–8

In vitro antibacterial properties of T-5575 and T-5578 novel parenteral 2-carboxypenams. Watanabe Y, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2787–91

Comparison of antimicrobial susceptibilities of Corynebacterium species by broth microdilution and disk diffusion methods. Weiss K, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):930–3

In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods. Arpi M, et al. **APMIS** 1996 Feb;104(2):108–14

The effect of antibiotics on nitrification processes. Batch assays. Gomez J, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:869–76

Infection and male infertility: effect of different antibiotic regimens on semen quality. Merino G, et al. **Arch Androl** 1995 Nov-Dec;35(3):209–12

Bicyclomycin and dihydrobicyclomycin inhibition kinetics of Escherichia coli rho-dependent transcription termination factor ATPase activity. Park HG, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):447–54

Pentalenolactone-insensitive glyceraldehyde-3-phosphate dehydrogenase from Streptomyces arenae is closely related to GAPDH from thermostable eubacteria and plant chloroplasts. Fröhlich KU, et al. **Arch Microbiol** 1996 Mar; 165(3):179–86

Emerging antibiotic resistance: real and relative [editorial] Jones DB. **Arch Ophthalmol** 1996 Jan;114(1):91–2 (12 ref.)

Influence of lasalocid, cationomycin and feeding frequency on the postprandial kinetics of some plasma parameters in the rumen vein, portal vein and mesenteric artery of sheep. Gomez L, et al. **Arch Tierernahr** 1995;48(4):357–66

Comparison of fosfomycin and teicoplanin in serum bactericidal activity against staphylococci. Vogt K, et al. **Arzneimittelforschung** 1995 Aug;45(8):894–7

An assay to measure antibiotic efficacy against Staphylococcus epidermidis biofilms on implant surfaces. Richards GK, et al. **ASAIO J** 1994 Jul-Sep;40(3):M570–5

Antibiotics and contraceptives [letter; comment] Riddoch G. **Aust Fam Physician** 1995 Oct;24(10):1969–70. Comment on: Aust Fam Physician 1995 May;24(5):928–9.

Tiamulin inhibits human CYP3A4 activity in an NIH/3T3 cell line stably expressing CYP3A4 cDNA. De Groene EM, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):771–3

Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins. Levy D, et al. **Biochem Pharmacol** 1995 Dec 22; 50(12):2105–7

The interaction of coumarin antibiotics with fragments of DNA gyrase B protein. Gormley NA, et al. **Biochemistry** 1996 Apr 16;35(15):5083–92

Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. Kim DH, et al. **Biochemistry** 1996 Apr 16; 35(15):4923–8

Molecular mechanisms of drug inhibition of DNA gyrase. Lewis RJ, et al. **Bioessays** 1996 Aug;18(8):661–71 (73 ref.)

Quantitative relation between surface active properties and antibiotic activity of 1-alkyl-3-alkylthiomethylimidazolium chlorides. Pernak J, et al. **Chem Pharm Bull (Tokyo)** 1995 Nov;43(11):2019–20

Comparative evaluation of orally active antibiotics against community-acquired pathogens: results of eight European countries. Cullmann W. **Chemotherapy** 1996 Jan-Feb; 42(1):11–20

Comparison of imipenem and five other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa. Gerçeker AA, et al. **Chemotherapy** 1995 Sep-Oct;41(5):334–6

Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca. Traub WH, et al. **Chemotherapy** 1995 Sep-Oct;41(5):345–52

Serotype epidemiology and patterns of antibiotic susceptibilities of salmonellae isolated in Hong Kong 1983–93. Kam KM. **Chin Med J (Engl)** 1996 Apr; 109(4):276–81

Differentiation of borreliacidal activity caused by immune serum or antimicrobial agents by flow cytometry. Liu YF, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):145–9

Activity of ampicillin/sulbactam, ticarcillin/clavulanate, clarithromycin, and eleven other antimicrobial agents against anaerobic bacteria isolated from infections in children. Citron DM, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S356–60

Evaluation of the Etest for determinations of antimicrobial spectrum and potency against anaerobes associated with bacterial vaginosis and peritonitis. Croco JL, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S339–41

Rifabutin in the treatment of Mycobacterium avium complex infection: experience in Europe. Dautzenberg B. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S33–6 (22 ref.)

Susceptibility results for the Bacteroides fragilis group: comparison of the broth microdilution and agar dilution methods. Hecht DW, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S342–5

Effect of choice of medium on the results of in vitro susceptibility testing of eight antibiotics against the Bacteroides fragilis group. Hecht DW, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S346–9

Antimicrobial susceptibility tests for anaerobic bacteria with use of the disk diffusion method. Johnson MJ, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S334–6

Antimicrobial activity of rifabutin. Kunin CM. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S3–13; discussion S13–4 (124 ref.)

Evaluation of susceptibility of anaerobic organisms by the Etest and the reference agar dilution method. Schieven BC, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S337–8

Rifabutin prophylaxis for Mycobacterium avium complex infection in patients with AIDS. Siegal FP. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S23–30; discussion S30–2 (38 ref.)

Antibiotic effects on bacterial viability, toxin production, and host response. Stevens DL, et al. **Clin Infect Dis** 1995 Jun; 20 Suppl 2:S154–7

Antibiotic susceptibility profiles of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan from 1990 to 1992. Tanaka-Bandoh K, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S352–5

Rapid detection of antimicrobial activity using flow cytometry. Durodie J, et al. **Cytometry** 1995 Dec 1; 21(4):374–7

The intrinsic antimicrobial activity of selected sclerosing agents in sclerotherapy. Sadick NS, et al. **Dermatol Surg** 1996 Apr;22(4):369–71

Bactericidal activity of cefotaxime, desacetylcefotaxime, rifampin, and various combinations tested at cerebrospinal fluid levels against penicillin-resistant Streptococcus pneumoniae. Cormican MG, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1–2):119–23

Minimum bactericidal concentrations of Propionibacterium acnes isolates from cases of chronic endophthalmitis. Hall GS, et al. **Diagn Microbiol Infect Dis** 1995 Apr;21(4):187–90

Evaluation of the Etest for susceptibility testing of anaerobic bacteria. Rosenblatt JE, et al. **Diagn Microbiol Infect Dis** 1995 Jul;22(3):279–84

The antibiotic tiamulin is a potent inducer and inhibitor of cytochrome P4503A via the formation of a stable metabolic intermediate complex. Studies in primary hepatocyte cultures and liver microsomes of the pig. Witkamp RF, et al. **Drug Metab Dispos** 1995 May;23(5):542–7

Characteristics of gonococci isolated from men with urethritis in Dubai. Al-Hattawi K, et al. **Epidemiol Infect** 1996 Feb;116(1):15–20

Antibiotic susceptibility of campylobacter isolates from sewage and poultry abattoir drain water. Koenraad PM, et al. **Epidemiol Infect** 1995 Dec;115(3):475–83

Biotype traits and antibiotic susceptibility of Vibrio cholerae serogroup O1 before, during and after the emergence of the O139 serogroup. Mukhopadhyay AK, et al. **Epidemiol Infect** 1995 Dec;115(3):427–34

UDP-N-acetylglucosamine:dolichyl-phosphate N-acetylglucosamine-1-phosphate transferase is amplified in tunicamycin-resistant soybean cells. Zeng Y, et al. **Eur J Biochem** 1995 Oct 15;233(2):458–66

Novobiocin-Salmonella-shigella agar for isolation of Salmonella spp. [letter] Núñez ML, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jan;15(1):96–7

Modulation of ICAM-1 expression in human alveolar macrophages in vitro. Fattal-German M, et al. **Eur Respir J** 1996 Mar;9(3):463–71

Induction of vancomycin resistance in Enterococcus faecium by non-glycopeptide antibiotics. Allen NE, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1–2):107–14

Antibacterial effect of substituted 4-quinazolyl-hydrazines and their arylhydrazones determined by a modified microdilution method. Jantová S, et al. **Folia Microbiol (Praha)** 1995;40(6):611–4

A growth-defective kirromycin-resistant EF-Tu Escherichia coli mutant and a spontaneously evolved suppression of the defect. Zeef LA, et al. **Gene** 1995 Nov 7;165(1):39–43

Antibiotic sensitivity pattern of various Lactobacillus acidophilus strains. Gupta PK, et al. **Indian J Exp Biol** 1995 Aug;33(8):620–1

Antibiotics change contractility of guinea pig aorta and trachea to histamine after a short exposure to LPS. Künneke M, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S100–1

The impact of environment and antimicrobial agents on the growth response of early-weaned pigs to spray-dried porcine plasma. Coffey RD, et al. **J Anim Sci** 1995 Sep; 73(9):2532–9

Chemistry of pseudomonic acid. Part 16.Aryl and heteroaryl ketone derivatives of monic acid. Abson A, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):390–4

Isolation and structure determination of two novel phenazines from a Streptomyces with inhibitory activity against metallo-enzymes, including metallo-beta-lactamase. Gilpin ML, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1081–5

Macrosphelide, a novel inhibitor of cell-cell adhesion molecule. I. Taxonomy, fermentation, isolation and biological activities. Hayashi M, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1435–9

Hydroxymycotrienins A and B, new ansamycin group antibiotics. Hosokawa N, et al. **J Antibiot (Tokyo)** 1996 May;49(5):425–31

PCR inhibition assay for DNA-targeted antibiotics. Hotta K, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1267–72

4'-Deacetyl-(-)-griseusins A and B, new naphthoquinone antibiotics from an actinomycete. Igarashi M, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1502–5

Sorangiolid A, a new antibiotic isolated from the myxobacterium Sorangium cellulosum So ce 12. Irschik H, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):886–7

Kalimantacins A, B and C, novel antibiotics from Alcaligenes sp. YL-02632S. I. Taxonomy, fermentation, isolation and biological properties. Kamigiri K, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):136–9

Leustroduscin B, a new cytokine inducer derived from an actinomycetes, induces thrombocytosis in mice. Kohama T, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):91–4

BE-24566B, a new antibiotic produced by Streptomyces violaceusniger. Kojiri K, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1506–8

Phenopyrrozin, a new radical scavenger produced by Penicillium sp. FO-2047. Shiomi K, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1413–8

Epoxyquinomicins A and B, new antibiotics from Amycolatopsis [letter] Tsuchida T, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):326–8

Antimicrobial susceptibility of penicillin-sensitive and penicillin-resistant meningococci. Abadi FJ, et al. **J Antimicrob Chemother** 1995 May;35(5):687–90

Speculations on the influence of infecting phenotype on virulence and antibiotic susceptibility of Legionella pneumophila. Barker J, et al. **J Antimicrob Chemother** 1995 Jul;36(1):7–21 (131 ref.)

Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans? [letter; comment] Donnelly JP, et al. **J Antimicrob Chemother** 1996 Feb; 37(2):389–92. Comment on: J Antimicrob Chemother 1994 Oct;34(4):507–14.

In-vitro susceptibility to thirteen antibiotics of Pasteurella spp. and related bacteria isolated from humans [letter] Gaillot O, et al. **J Antimicrob Chemother** 1995 Nov; 36(5):878–80

In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. Gerçeker AA, et al. **J Antimicrob Chemother** 1995 Oct;36(4):707–11

The in-vitro susceptibilities of vaginal lactobacilli to four broad-spectrum antibiotics, as determined by the agar dilution and E test methods. Herra CM, et al. **J Antimicrob Chemother** 1995 Jun;35(6):775–83

The effect of antibiotics on bacteria under hyperbaric conditions. Hind J, et al. **J Antimicrob Chemother** 1996 Feb;37(2):253–63

In-vitro antimicrobial susceptibility of the "Streptococcus milleri' group (Streptococcus anginosus, Streptococcus

constellatus and Streptococcus intermedius). Jacobs JA, et al. **J Antimicrob Chemother** 1996 Feb;37(2):371–5

The issue of the true postantibiotic effect [letter; comment] Majcherczyk PA. **J Antimicrob Chemother** 1996 Jan; 37(1):188–90. Comment on: J Antimicrob Chemother 1995 Apr;35(4):551–2.

Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics. Marchese A, et al. **J Antimicrob Chemother** 1995 Nov;36(5):833–7

Lack of bactericidal effect of antibiotics except aminoglycosides on Bartonella (Rochalimaea) henselae. Musso D, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):101–8

Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of Mycobacterium avium complex. Piersimoni C, et al. **J Antimicrob Chemother** 1995 Sep;36(3):497–502

Growth temperature-dependent variation of cell envelope lipids and antibiotic susceptibility in Stenotrophomonas (Xanthomonas) maltophilia. Rahmati-Bahram A, et al. **J Antimicrob Chemother** 1995 Aug;36(2):317–26

Comparative in-vitro activity of sparfloxacin and eight other antimicrobial agents against clinical isolates of non-tuberculous mycobacteria. Sánchez-Carrillo C, et al. **J Antimicrob Chemother** 1996 Jan;37(1):151–4

An 8 year Microbe Base survey of the epidemiology, frequency and antibiotic susceptibility of Pseudomonas aeruginosa hospital isolates in the United Kingdom. Spencer RC. **J Antimicrob Chemother** 1996 Feb; 37(2):295–301

In-vitro antimicrobial susceptibility of Yersinia enterocolitica isolates from stools of patients in The Netherlands from 1982–1991. Stolk-Engelaar VM, et al. **J Antimicrob Chemother** 1995 Nov;36(5):839–43

The effects of low concentrations of antibiotics on epithelial damage caused by non-typable Haemophilus influenzae and bacterial morphology. Tsang KW, et al. **J Antimicrob Chemother** 1995 Sep;36(3):545–9

The Garrod Lecture. Selective toxicity and concordant pharmacodynamics of antibiotics and other drugs. Williams JD. **J Antimicrob Chemother** 1995 Jun;35(6):721–37 (63 ref.)

Cryopreservation of bacterial vegetative cells used in antibiotic assay. Reamer R, et al. **J AOAC Int** 1995 Jul–Aug;78(4):997–1001

The effect of cryptolepine on the morphology and survival of Escherichia coli, Candida albicans and Saccharomyces cerevisiae. Sawer IK, et al. **J Appl Bacteriol** 1995 Sep; 79(3):314–21

Bacteriolytic effect of membrane vesicles from Pseudomonas aeruginosa on other bacteria including pathogens: conceptually new antibiotics. Kadurugamuwa JL, et al. **J Bacteriol** 1996 May;178(10):2767–74

Differential antibiotic sensitivity determined by the large ribosomal subunit in thermophilic archaea. Ruggero D, et al. **J Bacteriol** 1996 Jun;178(11):3396–8

Chloramphenicol causes fusion of separated nucleoids in Escherichia coli K-12 cells and filaments. van Helvoort JM, et al. **J Bacteriol** 1996 Jul;178(14):4289–93

The in vitro activity of trospectomycin against anaerobic bacteria. Chisari G, et al. **J Chemother** 1995 Dec;7(6):515–8

In vitro and in vivo antimicrobial action of fluphenazine. Dastidar SG, et al. **J Chemother** 1995 Jun;7(3):201–6

Determination of the in vitro susceptibility of 220 Mycobacterium fortuitum isolates to ten antimicrobial agents. Hernández AM, et al. **J Chemother** 1995 Dec; 7(6):503–8

Susceptibility of Capnocytophaga to antimicrobial agents. Kolokotronis A. **J Chemother** 1995 Oct;7(5):414–6

Effects of sub-minimal inhibitory concentrations of antimicrobial agents on the cell surface of Klebsiella pneumoniae and phagocytic killing activity. Nomura S, et al. **J Chemother** 1995 Oct;7(5):406–13

Update on mupirocin resistance. Poupard JA. **J Chemother** 1995 Jul;7 Suppl 3:71–4 (14 ref.)

Effect of antibiotics contained in two Brucella selective media on growth of Brucella abortus, B. melitensis, and B. ovis. Marín CM, et al. **J Clin Microbiol** 1996 Feb; 34(2):426–8

Evaluation of mupirocin E-test for determination of isolate susceptibility: comparison with standard agar dilution techniques. Simpson IN, et al. **J Clin Microbiol** 1995 Sep; 33(9):2254–9

Mastitis-causing Escherichia coli: serum sensitivity and susceptibility to selected antibacterials in milk. Fang W, et al. **J Dairy Sci** 1996 Jan;79(1):76–82

Lipolysis and biohydrogenation of soybean oil in the rumen in vitro: inhibition by antimicrobials. Van Nevel C, et al. **J Dairy Sci** 1995 Dec;78(12):2797–806

Antimicrobial susceptibility of microorganisms isolated from the mammary glands of dairy heifers. Watts JL, et al. **J Dairy Sci** 1995 Jul;78(7):1637–48

Relationship between enterotoxicity and multiple drug resistance in Aeromonas spp. Singh DV, et al. **J Diarrhoeal Dis Res** 1995 Sep;13(3):172–5

Anti-microbial activity and anti-complement activity of extracts obtained from selected Hawaiian medicinal plants. Locher CP, et al. **J Ethnopharmacol** 1995 Nov 17; 49(1):23–32

Screening of selected medicinal plants of Nepal for antimicrobial activities. Taylor RS, et al. **J Ethnopharmacol** 1995 Jun;46(3):153–9

Antimicrobial susceptibility and beta-lactamase production of Moraxella catarrhalis isolates in Taiwan. Fung CP, et al. **J Formos Med Assoc** 1995 Sep;94(9):548–54

Mupirocin resistance in coagulase-negative staphylococci, after topical prophylaxis for the reduction of colonization of central venous catheters. Zakrzewska-Bode A, et al. **J Hosp Infect** 1995 Nov;31(3):189–93

Differential activation of a calcium-dependent endonuclease in human B lymphocytes. Role in ionomycin-induced apoptosis. Aagaard-Tillery KM, et al. **J Immunol** 1995 Oct 1;155(7):3297–307

Effect of biofilm culture on antibiotic susceptibility of lactobacilli causing endocarditis [letter] Jones JW, et al. **J Infect** 1995 Jul;31(1):80–1

Serotypes and antibiotic susceptibilities of Streptococcus pneumoniae in Nairobi, Kenya. Paul J, et al. **J Infect** 1996 Mar;32(2):139–42

The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. Raad I, et al. **J Infect Dis** 1996 Feb;173(2):418–24

Sensitivity of Staphylococcus aureus, isolated from skin infections in 1994, to 19 antimicrobial agents. Nishijima S, et al. **J Int Med Res** 1995 Sep-Oct;23(5):328–34

Inhibition of glycosylation decreases Na+/H+ exchange activity, blocks NHE-3 transport to the membrane, and increases NHE-3 mRNA expression in LLC-PK1 cells. Soleimani M, et al. **J Lab Clin Med** 1996 Jun;127(6):565–73

The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity. Broom NJ, et al. **J Med Chem** 1996 Aug 30;39(18):3596–600

Chemistry and antimicrobial activity of caryoynencins analogs. Yamaguchi M, et al. **J Med Chem** 1995 Dec 22; 38(26):5015–22

Effects of seven antibiotics on the growth and development of Phaenicia sericata (Diptera: Calliphoridae) larvae. Sherman RA, et al. **J Med Entomol** 1995 Sep;32(5):646–9

Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant. Sjöström JE, et al. **J Med Microbiol** 1996 Jun;44(6):425–33

Inhibition of Na(+)-pump expression by impairment of protein glycosylation is independent of the reduced sodium entry into the cell. Pedemonte CH. **J Membr Biol** 1995 Oct;147(3):223–31

(all trans)-2,4,6,8,10,12-tetradecahexene-1,14-dial, a new pigment from Conidiobolus paulus. Vesonder RF. **J Nat Prod** 1996 Apr;59(4):441–2

Dietary antibiotics decrease taurine loss in cats fed a canned heat-processed diet. Kim SW, et al. **J Nutr** 1996 Feb; 126(2):509–15

Maillard reaction products in purified diets induce taurine depletion in cats which is reversed by antibiotics. Kim SW, et al. **J Nutr** 1996 Jan;126(1):195–201

Pharmacologic treatment of neonatal sepsis: antimicrobial agents and immunotherapy. Cavaliere TA. **J Obstet Gynecol Neonatal Nurs** 1995 Sep;24(7):647–58 (77 ref.)

Prevention of attachment of phosphorylcholine to a major excretory-secretory product of Acanthocheilonema viteae using tunicamycin. Houston KM, et al. **J Parasitol** 1996 Apr;82(2):320–4

In vitro activity of tetracyclines, macrolides, quinolones, clindamycin and metronidazole against periodontopathic bacteria. Miyake Y, et al. **J Periodontal Res** 1995 Jul; 30(4):290–3

Bacteriological profile of neonatal septicemia cases (for the year 1990–91). Mathur M, et al. **J Postgrad Med** 1994 Jan-Mar;40(1):18–20

Antibiotic efficacy against Staphylococcus epidermidis adherent to vascular grafts. Bergamini TM, et al. **J Surg Res** 1996 Jan;60(1):3–6

Allograft heart valve sterilization: a six-year in-depth analysis of a twenty-five-year experience with low-dose antibiotics. Gall K, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):680–7

Influence of the antibiotics lincomycin and tylosin on aflatoxicosis when added to aflatoxin-contaminated diets of growing swine. Harvey RB, et al. **J Vet Diagn Invest** 1995 Jul;7(3):374–9

Serotypes and antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolated from piglets with pleuropneumonia. Asawa T, et al. **J Vet Med Sci** 1995 Aug; 57(4):757–9

Antimicrobial activity of lasalocid against Selenomonas ruminantium--effect of changes in pH induced by changing glucose concentration. Nakamura I, et al. **J Vet Med Sci** 1995 Aug;57(4):611–6

In vitro antibacterial activity of florfenicol against Actinobacillus pleuropneumoniae. Ueda Y, et al. **J Vet Med Sci** 1995 Apr;57(2):363–4

Inostamycin, an inhibitor of P-glycoprotein function, interacts specifically with phosphatidylethanolamine. Kawada M, et al. **Jpn J Cancer Res** 1995 Sep;86(9):873–8

Antibiotics, free radicals, and acute pancreatitis [letter; comment] Banerjee A. **Lancet** 1995 Oct 7;346(8980):972. Comment on: Lancet 1995 Sep 9;346(8976):652. Comment on: Lancet 1995 Sep 9;346(8976):663–7.

Proton-pump inhibitors or H2-receptor antagonists for Helicobacter pylori eradication-a meta-analysis [letter] [see comments] Holtmann G, et al. **Lancet** 1996 Mar 16; 347(9003):763. Comment in: Lancet 1996 Apr 27;347(9009):1193–4. Comment in: Lancet 1996 Apr 27;347(9009):1194.

Drug-resistant Streptococcus pneumoniae: the beginning of the end for many antibiotics? [letter] Gottlieb T. **Med J Aust** 1996 Aug 19;165(4):233–4

Use of antibiotics to select auxotrophic mutants of Neisseria meningitidis. Erwin AL, et al. **Microb Pathog** 1995 Apr; 18(4):289–96

Effects of tunicamycin on glycoprotein antigens of Aspergillus fumigatus. Hearn VM, et al. **Microbios** 1996; 85(345):239–50

Antibiotic activity of marine algae against multi-antibiotic resistant bacteria. Mahasneh I, et al. **Microbios** 1995; 83(334):23–6

Isolation and in vitro antibacterial screening of a tricarboxylic acid anhydride from Penicillium sp. Jabbar A, et al. **Pharmazie** 1995 Oct;50(10):706–7

Oxadin: a new chemotherapeuticum with antistaphylococcus effect. Michajlov Y, et al. **Pharmazie** 1995 Dec;50(12):832–3

Influence of Trichoderma viride enzyme complex on nutrient utilization and performance of laying hens in diets with and without antibiotic supplementation. Vukic Vranjes M, et al. **Poult Sci** 1996 Apr;75(4):551–5

Salmonella typhimurium TnphoA mutants with increased sensitivity to biological and chemical detergents. Lacroix FJ, et al. **Res Microbiol** 1995 Oct;146(8):659–70

Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents. Slomiany BL, et al. **Scand J Gastroenterol Suppl** 1995;210:82–4

Antibiotics that resist resistance [news] Service RF. **Science** 1995 Nov 3;270(5237):724–7

The effect of treatment regimens for vaginitis and cervicitis on vaginal colonization by lactobacilli. Agnew KJ, et al. **Sex Transm Dis** 1995 Sep-Oct;22(5):269–73

Antimicrobial resistance pattern of bacteria isolated from patients seen by private practitioners in the Klang Valley. Cheong YM, et al. **Singapore Med J** 1995 Feb;36(1):43–6

Chloramphenicol-dependent antibody: a case report. Fried MR, et al. **Transfusion** 1996 Feb;36(2):187–90

Plasmid-mediated multidrug resistance in Salmonella typhi in Kuwait. Panigrahi D, et al. **Trop Med Int Health** 1996 Aug;1(4):439–42

Antimicrobial resistance of Escherichia coli isolates from the faecal flora of veterinarians with different professional specialties. Bongers JH, et al. **Vet Q** 1995 Dec;17(4):146–9

Sensitivity of Serpulina hyodysenteriae to tiamulin in the UK [letter; comment] Dalziel RW. **Vet Rec** 1996 Mar 23; 138(12):288. Comment on: Vet Rec 1996 Feb 17;138(7):158–60.

In vitro antibiotic sensitivity of Ornithobacterium rhinotracheale strains from poultry and wild birds. Devriese LA, et al. **Vet Rec** 1995 Oct 21;137(17):435–6

The antimicrobial susceptibility of Staphylococcus species isolated from canine dermatitis. Kruse H, et al. **Vet Res Commun** 1996;20(3):205–14

Frequency, clonal heterogeneity and antibiotic resistance of methicillin-resistant Staphylococcus aureus (MRSA) isolated in 1992–1994. Schneider C, et al. **Zentralbl Bakteriol** 1996 Apr;283(4):529–42

Susceptibility of poultry lactobacilli to ionophore antibiotics. Marounek M, et al. **Zentralbl Veterinarmed [B]** 1995 Jun; 42(4):193–6

[The sensitivity to antibacterial preparations of enterococcal strains isolated from gynecological patients, pregnant women, puerperae and newborn infants] Shopova E. **Akush Ginekol (Sofiia)** 1995;34(3):32–4 (Eng. Abstr.) **(Bul)**

[Bacteria isolated in 1994–1995 in female upper genitalia infections and in male urethritis. Distribution and sensitivity to antibiotics] Joly-Guillou ML, et al. **Presse Med** 1996 Mar 2-9;25(8):342–8 (Eng. Abstr.) **(Fre)**

[Effect of avilamycin and tylosin on the metabolizable energy in growing and finishing pigs] Kirchgessner M, et al. **Arch Tierernahr** 1995;48(1-2):63–70 (Eng. Abstr.) **(Ger)**

[The resistance behavior of significant veterinary bacterial agents in the year 1992 (ranking in sequence)] Trolldenier H. **Berl Munch Tierarztl Wochenschr** 1995 Apr; 108(4):127–32 (Eng. Abstr.) **(Ger)**

[Polymer-containing eyedrops. IV. Microbiological study of eyedrops containing antibiotics] Koczka-Kiss C, et al. **Acta Pharm Hung** 1995 Sep;65(5):157–62 (Eng. Abstr.) **(Hun)**

[Urinary infection. II. Comparative in vitro activities of several antibiotic drugs against Gram-positive bacteria] Allocco A, et al. **G Batteriol Virol Immunol** 1992 Jan-1993 Dec;85(1-12):68–78 (Eng. Abstr.) **(Ita)**

[In vitro activity of several antibiotics on pathogenic micro-organisms isolated from the lower respiratory tract] Allocco A, et al. **G Batteriol Virol Immunol** 1994 Jan-Dec; 86(1-12):15–28 (Eng. Abstr.) **(Ita)**

[Urinary infection. I. Comparative in vitro activities of several antibiotic drugs against Gram-negative bacteria] Giachino F, et al. **G Batteriol Virol Immunol** 1992 Jan-1993 Dec;85(1-12):55–67 (Eng. Abstr.) **(Ita)**

[Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)] Ikemoto H, et al. **Jpn J Antibiot** 1996 May;49(5):419–55 (Eng. Abstr.) **(Jpn)**

[Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1991)] Ikemoto H, et al. **Jpn J Antibiot** 1995 Aug;48(8):965–98 (Eng. Abstr.) **(Jpn)**

[Susceptibilities of bacteria isolated from patients with

respiratory infectious diseases to antibiotics (1990)] Ikemoto H, et al. **Jpn J Antibiot** 1995 Jul;48(7):887–920 (Eng. Abstr.) **(Jpn)**

[Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1993)] Ikemoto H, et al. **Jpn J Antibiot** 1996 Feb;49(2):107–43 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Nov;48(11):1627–57 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). III. Secular changes in susceptibility] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Nov; 48(11):1671–756 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Nov;48(11):1757–87 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). III. Secular changes in susceptibility] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Dec; 48(12):1803–90 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Sep;48(9):1131–60 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). III. Secular changes in susceptibility] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Sep;48(9):1174–263 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1990). I. Susceptibility distribution] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Oct;48(10):1295–316 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1990). III. Secular changes in susceptibility] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Oct;48(10):1329–93 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1991). I. Susceptibility distribution] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Oct;48(10):1394–421 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1991). III. Secular changes in susceptibility] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Oct; 48(10):1436–580 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution] Kumamoto Y, et al. **Jpn J Antibiot** 1996 May;49(5):465–93 (Eng. Abstr.) **(Jpn)**

[Isolation rate of E. coli from surgical infections and their susceptibilities] Shinagawa N, et al. **Jpn J Antibiot** 1996 May;49(5):456–64 (Eng. Abstr.) **(Jpn)**

[Frequency of clinical isolation of glucose non-fermentative gram-negative rods and their susceptibilities to antibacterial agents] Suzuki Y, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1264–73 (Eng. Abstr.) **(Jpn)**

[Prevalence of pertussis in Fukuoka: incidence and MICs of antibiotics for Bordetella pertussis isolate] Horikawa K, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):878–83 (Eng. Abstr.) **(Jpn)**

[Comparative susceptibility of 10 antimicrobials against Pseudomonas aeruginosa isolated from complicated urinary tract infection on 1992 & 1993 vs. 1994 & 1995] Ishikawa K, et al. **Kansenshogaku Zasshi** 1996 Jun;70(6):584–90 (Eng. Abstr.) **(Jpn)**

[A nation-wide surveillance of pathogen in elderly patients with urinary tract infections. 2nd Report: Sensitivities of pathogen for oral antibacterial agents] Kumazawa J, et al. **Kansenshogaku Zasshi** 1995 Jul;69(7):797–810 (Eng. Abstr.) **(Jpn)**

[Species and serovar-distribution, and drug-resistance of Shigella strains isolated from imported and domestic cases from 1990 through 1994 in Tokyo] Matsushita S, et al. **Kansenshogaku Zasshi** 1995 Dec;69(12):1336–41 (Eng. Abstr.) **(Jpn)**

[Drug sensitivity and expression of beta-lactamase in enterococci isolated at Okayama University Hospital] Nasu Y, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):919–23 (Eng. Abstr.) **(Jpn)**

[Antibiotic resistance of clinical isolates Streptococcus pneumoniae] Komori T, et al. **Rinsho Byori** 1996 May; 44(5):465–70 (Eng. Abstr.) **(Jpn)**

[Overcoming tumor multiple drug resistance. MDR modulators] Dudnik IuV, et al. **Antibiot Khimioter** 1995 Oct;40(10):48–54 (81 ref.) **(Rus)**

[Effect of antibiotics on glucocorticoid receptor function] Golikov PP. **Antibiot Khimioter** 1995 Jul;40(7):25–9 (Eng. Abstr.) **(Rus)**

[Antimicrobial peptides and resistance in animals] Kharchenko EP. **Antibiot Khimioter** 1995 Jul;40(7):45–53 (33 ref.) **(Rus)**

[Features of oral cavity microflora in congenital cleft lip and palate] Vadachkoriia ZO, et al. **Antibiot Khimioter** 1995 Sep;40(9):26–9 (Eng. Abstr.) **(Rus)**

[Sensitivity of bacteria of the genus Proteus to antibiotics] Vereshchagin IA, et al. **Antibiot Khimioter** 1995 Sep; 40(9):35–7 (Eng. Abstr.) **(Rus)**

[Effects of antibiotics on the gastric mucosa and Helicobacter pylori in prolonged therapy] Aruin LI, et al. **Klin Med (Mosk)** 1995;73(5):78 **(Rus)**

[The antibiotic resistance of strains of Campylobacter of different origins] Kirik DL, et al. **Mikrobiol Z** 1995 Jul-Aug;57(4):49–54 (Eng. Abstr.) **(Rus)**

[The antibiotic properties of the phytotoxic metabolites of Botrytis cinerea Pers.] Rubezhniak IG, et al. **Mikrobiol Z** 1995 Nov-Dec;57(6):46–51 (Eng. Abstr.) **(Rus)**

[The repair of DNA single-stranded breaks and degradation under the action of novobiocin in gamma-irradiated HeLa cells] Seregina TB, et al. **Tsitologiia** 1996;38(1):57–65 (Eng. Abstr.) **(Rus)**

[Modern methods and means for the rapid determination of the sensitivity of the causative agents of dangerous infectious diseases to antibiotics and chemical preparations] D'iakov SI, et al. **Voen Med Zh** 1996 Mar;317(3):44–7 (17 ref.) **(Rus)**

[Antibiotic resistance to erythromycin, clindamycin and tetracycline of 573 strains of Streptococcus pyogenes (1992-1994)] Orden B, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):86–9 (Eng. Abstr.) **(Spa)**

[Penetration and intracellular activity of antimicrobial agents. A new pharmacologic parameter? (editorial)] Pascual A. **Med Clin (Barc)** 1995 Nov 18;105(17):652–3 **(Spa)**

POISONING

A chronic cardiomyopathy in feedlot cattle attributed to toxic levels of salinomycin in the feed. Bastianello SS, et al. **J S Afr Vet Assoc** 1996 Mar;67(1):38–41

Cardiomyopathy of ruminants induced by the litter of poultry fed on rations containing the ionophore antibiotic, maduramicin. II. Macropathology and histopathology. Bastianello SS, et al. **Onderstepoort J Vet Res** 1995 Mar; 62(1):5–18

RADIATION EFFECTS

Ultraviolet radiation-induced production of superoxide radicals by selected antibiotics. Ray RS, et al. **Drug Chem Toxicol** 1996;19(1-2):121–30

The sterilization of honey with cobalt 60 gamma radiation: a study of honey spiked with spores of Clostridium botulinum and Bacillus subtilis. Postmes T, et al. **Experientia** 1995 Sep 29;51(9-10):986–9

SUPPLY & DISTRIBUTION

Antibiotic use in a periurban community in Mexico: a household and drugstore survey. Calva J. **Soc Sci Med** 1996 Apr;42(8):1121–8

Drug prescribing practices of general practitioners and paediatricians for childhood diarrhoea in Karachi, Pakistan. Nizami SQ, et al. **Soc Sci Med** 1996 Apr;42(8):1133–9

Factors influencing physicians' prescribing behaviour in the treatment of childhood diarrhoea: knowledge may not be the clue. Paredes P, et al. **Soc Sci Med** 1996 Apr; 42(8):1141–53

Improving physician prescribing patterns to treat rhinopharyngitis. Intervention strategies in two health systems of Mexico. Pérez-Cuevas R, et al. **Soc Sci Med** 1996 Apr;42(8):1185–94

Small group intervention vs formal seminar for improving appropriate drug use. Santoso B. **Soc Sci Med** 1996 Apr; 42(8):1163–8

THERAPEUTIC USE

Short-course intravenous antibiotics with oral quinolone prophylaxis in the treatment of neutropenic fever in autologous bone marrow or peripheral blood progenitor cell transplant recipients. Mahendra P, et al. **Acta Haematol** 1996;96(2):64–7

The menace of beta-lactamase production on antibiotic prescription in community acquired-infections in Nigeria. Oyelese AO, et al. **Afr J Med Med Sci** 1995 Jun; 24(2):125–30

Increase of antimicrobial resistance of faecal aerobic gram-negative bacteria in a geriatric hospital. Leistevuo T, et al. **Age Ageing** 1996 May;25(3):197–200

Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Reilly TG, et al. **Aliment Pharmacol Ther** 1995 Oct; 9(5):483–90

No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease. Tytgat GN. **Aliment Pharmacol Ther** 1995;9 Suppl 1:39–42 (15 ref.)

Resistant respiratory pathogens and extended-spectrum antibiotics. Pichichero ME. **Am Fam Physician** 1995 Nov 1;52(6):1739–46 (30 ref.)

An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Prantera C, et al. **Am J Gastroenterol** 1996 Feb;91(2):328–32

What is the meaning of ranitidine in successful triple-therapy against Helicobacter pylori infection? [letter; comment] Savarino V, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2262–3. Comment on: Am J Gastroenterol 1995 Jan;90(1):168–9.

Pylephlebitis: a case report and review of outcome in the antibiotic era. Saxena R, et al. **Am J Gastroenterol** 1996 Jun;91(6):1251–3 (17 ref.)

Pharmacist's impact on antimicrobial drug therapy. Cadle RM, et al. **Am J Health Syst Pharm** 1995 Jul 15; 52(14):1544–6

Enforcing antimicrobial restrictions [letter; comment] White AC Jr, et al. **Am J Health Syst Pharm** 1996 Apr 1; 53(7):796–7. Comment on: Am J Health Syst Pharm 1995 Jul 1;52(13):1433–5.

Mupirocin ointment with and without chlorhexidine baths in the eradication of Staphylococcus aureus nasal carriage in nursing home residents. Watanakunakorn C, et al. **Am J Infect Control** 1995 Oct;23(5):306–9

A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Bernardini J, et al. **Am J Kidney Dis** 1996 May; 27(5):695–700

Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis. Bloom BS, et al. **Am J Kidney Dis** 1996 May;27(5):687–94

Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia [see comments] Anaissie EJ, et al. **Am J Med** 1996 Jan;100(1):17–23. Comment in: Am J Med 1996 Jan;100(1):15–6.

Cost management in community-acquired lower respiratory tract infection. Davey PG. **Am J Med** 1995 Dec 29; 99(6B):20S–23S

The use of growth factors with antibiotics in the setting of neutropenic fever [editorial; comment] Hussein AM, et al. **Am J Med** 1996 Jan;100(1):15–6. Comment on: Am J Med 1996 Jan;100(1):17–23.

Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Jones RN. **Am J Med** 1996 Jun 24;100(6A):3S–12S (53 ref.)

Sequential therapy in the hospital management of lower respiratory infections. Vogel F. **Am J Med** 1995 Dec 29; 99(6B):14S–19S (27 ref.)

Reasons for the emergence of antibiotic resistance. Tenover FC, et al. **Am J Med Sci** 1996 Jan;311(1):9–16 (82 ref.)

Randomized investigation of antimicrobials for the prevention of preterm birth. Cox SM, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):206–10

Antibiotic treatment in preterm premature rupture of membranes and neonatal morbidity: a metaanalysis. Egarter C, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):589–97

Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. Joesoef MR, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1527–31

Comparative treatment of experimental Staphylococcus aureus endophthalmitis. Aguilar HE, et al. **Am J Ophthalmol** 1996 Mar;121(3):310–7

Prevalence of Serpulina species in relation to diarrhea and feed medication in pig-rearing herds in Sweden. Fellström C, et al. **Am J Vet Res** 1996 Jun;57(6):807–11

Efficacy dose determination study of tilmicosin phosphate in feed for control of pneumonia caused by Actinobacillus pleuropneumoniae in swine. Moore GM, et al. **Am J Vet Res** 1996 Feb;57(2):220–3

Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine. Moore GM, et al. **Am J Vet Res** 1996 Feb;57(2):224–8

Efficacy of florfenicol for treatment of clinical and subclinical bovine mastitis. Wilson DJ, et al. **Am J Vet Res** 1996 Apr; 57(4):526–8

Haptoglobin response to clinical respiratory tract disease in feedlot cattle. Wittum TE, et al. **Am J Vet Res** 1996 May; 57(5):646–9

The clinical spectrum of Clostridium difficile colitis in immunocompromised patients. Schweitzer MA, et al. **Am Surg** 1996 Jul;62(7):603–7; discussion 607–8

Antibiotic strategy after the empiric phase in patients treated for a hematological malignancy. De Pauw BE, et al. **Ann Hematol** 1996 Apr;72(4):273–9

Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Pestotnik SL, et al. **Ann Intern Med** 1996 May 15;124(10):884–90

Comment: clindamycin meta-analysis [letter] Gill MA. **Ann Pharmacother** 1996 May;30(5):548–9

Antibiotic use in children with febrile seizures [letter] James C, et al. **Ann Pharmacother** 1996 Jan;30(1):85

Antimicrobial-resistant pathogens in the 1990s. Jacoby GA. **Annu Rev Med** 1996;47:169–79 (62 ref.)

Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. Atkinson BA, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2316–9

Evaluation of antibiotic therapies for eradication of

Helicobacter hepaticus. Foltz CJ, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1292–4

Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Oh YK, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2104–11

Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Paris MM, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2171–5 (64 ref.)

Fox-Fordyce disease treated with topical clindamycin solution. Miller ML, et al. **Arch Dermatol** 1995 Oct; 131(10):1112–3

Current management of acute bronchitis in ambulatory care [letter] Benz D. **Arch Fam Med** 1996 Sep;5(9):440

Bronchodilators and antibiotics in the treatment of acute bronchitis [editorial; comment] King DE. **Arch Fam Med** 1996 Feb;5(2):86. Comment on: Arch Fam Med 1996 Feb;5(2):79–83.

Current management of acute bronchitis in ambulatory care: The use of antibiotics and bronchodilators [see comments] Mainous AG 3rd, et al. **Arch Fam Med** 1996 Feb;5(2):79–83. Comment in: Arch Fam Med 1996 Feb;5(2):84–5. Comment in: Arch Fam Med 1996 Feb;5(2):86.

Treatment of acute bronchitis: there's much work to be done [editorial; comment] Williamson HA Jr. **Arch Fam Med** 1996 Feb;5(2):84–5. Comment on: Arch Fam Med 1996 Feb;5(2):79–83.

The Endophthalmitis Vitrectomy Study [letter; comment] Baker A, et al. **Arch Ophthalmol** 1996 Aug;114(8):1025–6; discussion 1026–7. Comment on: Arch Ophthalmol 1995 Dec;113(12):1479–96.

Comparative intravitreal antibiotic therapy for experimental Enterococcus faecalis endophthalmitis. Choi S, et al. **Arch Ophthalmol** 1996 Jan;114(1):61–5

The Endophthalmitis Vitrectomy Study [letter; comment] Flynn HW Jr, et al. **Arch Ophthalmol** 1996 Aug; 114(8):1027–8; discussion 1028–9. Comment on: Arch Ophthalmol 1995 Dec;113(12):1479–96.

The endophthalmitis vitrectomy study [editorial; comment] [see comments] Forster RK. **Arch Ophthalmol** 1995 Dec; 113(12):1555–7 (6 ref.). Comment on: Arch Ophthalmol 1995 Dec;113(12):1479–96. Comment in: Arch Ophthalmol 1996 Aug;114(8):1025; discussion 1026–7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1029–30; discussion 1028–9.

The Endophthalmitis Vitrectomy Study [letter; comment] Hanscom T. **Arch Ophthalmol** 1996 Aug;114(8):1029–30; discussion 1028–9. Comment on: Arch Ophthalmol 1995 Dec;113(12):1479–96. Comment on: Arch Ophthalmol 1995 Dec;113(12):1555–7.

The Endophthalmitis Vitrectomy Study [letter; comment] LeClaire JE. **Arch Ophthalmol** 1996 Aug;114(8):1029; discussion 1028–9, 1030. Comment on: Arch Ophthalmol 1995 Dec;113(12):1479–96.

Rifabutin use in inflammatory bowel disease [letter; comment] To KW, et al. **Arch Ophthalmol** 1995 Nov;113(11):1354. Comment on: Arch Ophthalmol 1994 Sep;112(9):1159–65.

A cost-effectiveness evaluation of 3 antimicrobial regimens for the prevention of infective complications after abdominal surgery. Anderson G, et al. **Arch Surg** 1996 Jul; 131(7):744–8

Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Mock CN, et al. **Arch Surg** 1995 Nov;130(11):1234–40; discussion 1240–1

Impact of different classes antimicrobial agents on plasma endotoxin activity. Nitsche D, et al. **Arch Surg** 1996 Feb; 131(2):192–9

Treatment of urinary tract infections. Korman TM, et al. **Aust Fam Physician** 1995 Dec;24(12):2205–11 (5 ref.)

Vaginitis. Murtagh J. **Aust Fam Physician** 1995 Sep; 24(9):1697–8

Prevention of preterm birth. Owen P, et al. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):465–79 (96 ref.)

Antimicrobial therapy for rheumatoid arthritis. Kloppenburg M, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):759–69 (89 ref.)

Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. Arason VA, et al. **BMJ** 1996 Aug 17; 313(7054):387–91

Growth in the use of antibiotics in the community in England and Scotland in 1980–93. Davey PG, et al. **BMJ** 1996 Mar 9;312(7031):613

Prevalence of antibiotic resistance and serotypes in pneumococci in England and Wales: results of observational surveys in 1990 and 1995. Johnson AP, et al. **BMJ** 1996 Jun 8;312(7044):1454–6

Use of antibiotics after complex open hand injury. Drew PJ, et al. **Br J Clin Pract** 1995 Nov–Dec;49(6):297–300

Current aspects in the management of pneumonia. Woodhead M. **Br J Clin Pract** 1995 Jul–Aug;49(4):205–10 (83 ref.)

Randomized controlled trial of appendicectomy versus antibiotic therapy for acute appendicitis [letter; comment] Ozgüc H, et al. **Br J Surg** 1995 Sep;82(9):1284. Comment on: Br J Surg 1995 Feb;82(2):166–9.

Prescription of antibiotics for mild acute respiratory infections in children. González Ochoa E, et al. **Bull Pan Am Health Organ** 1996 Jun;30(2):106–17

Bacterial pericarditis after heart transplantation: successful management of two cases with catheter drainage and antibiotics. Davies RA, et al. **Can J Cardiol** 1996 Jul; 12(7):641–4

Rational antimicrobial therapy. Dowling PM. **Can Vet J** 1996 Apr;37(4):246–9

Empiric therapy for bacterial infections in neutropenic patients. Klastersky J. **Cancer Treat Res** 1995;79:101–12 (34 ref.)

Bacteriological epidemiology and treatment of bacterial vaginosis. Mikamo H, et al. **Chemotherapy** 1996 Jan–Feb; 42(1):78–84

Effect of previous antimicrobial therapy on the accuracy of the main procedures used to diagnose nosocomial pneumonia in patients who are using ventilation. Timsit JF, et al. **Chest** 1995 Oct;108(4):1036–40

Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Condon RE, et al. **Clin Infect Dis** 1995 Sep;21(3):544–50

Treatment of erythema migrans in pregnancy. Maraspin V, et al. **Clin Infect Dis** 1996 May;22(5):788–93

Comparison of the activity of meropenem with that of other agents in the treatment of intraabdominal, obstetric/gynecologic, and skin and soft tissue. Pitkin D, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S372–5

Rifabutin therapy for disseminated Mycobacterium avium complex infection. Sullam PM. **Clin Infect Dis** 1996 Apr; 22 Suppl 1:S37–41; discussion S41–2 (41 ref.)

Adjunctive care of preterm labor—the use of antibiotics. Lewis R, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):755–70 (69 ref.)

Antibiotic prophylaxis and head and neck surgery—what about pulmonary complications? [editorial] Morton RP. **Clin Otolaryngol** 1996 Apr;21(2):97–8

The microbiology and antibiotic treatment of peritonsillar abscesses. Prior A, et al. **Clin Otolaryngol** 1995 Jun; 20(3):219–23

Management of otitis media. A review. Liston TE. **Clin Pediatr (Phila)** 1995 Oct;34(10):542–8 (53 ref.)

A double-blind, multicenter comparative study of two regimens of clindamycin hydrochloride in the treatment of patients with acute streptococcal tonsillitis/pharyngitis. Gallegos B, et al. **Clin Ther** 1995 Jul–Aug;17(4):613–21

Does selective decontamination of the digestive tract reduce mortality for severely ill patients? Sun X, et al. **Crit Care Med** 1996 May;24(5):753–5

Rifaximin in the treatment of chronic hepatic encephalopathy. Puxeddu A, et al. **Curr Med Res Opin** 1995;13(5):274–81

Antibiotic resistance in acne patients under antibiotic treatment in comparison to an untreated control group with retrospective assessment of therapy. Forssman T. **Curr Probl Dermatol** 1995;22:91–7

The treatment of acne. Part III: antibacterials. Kligman AM. **Cutis** 1995 Dec;56(6):315–6

Antibiotic therapy in diabetic foot infection. van der Meer JW, et al. **Diabet Med** 1996;13 Suppl 1:S48–51 (19 ref.)

A team approach to hospital formulary replacement. Lee J, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun; 22(1–2):239–42

Diagnosis and treatment of streptococcal sore throat. **Drug Ther Bull** 1995 Feb;33(2):9–12 (28 ref.)

The thrombocytopenic purpuras. Recognition and management. Gillis S. **Drugs** 1996 Jun;51(6):942–53 (104 ref.)

Streptococcal pharyngitis: alternative treatments. Kieserman SP, et al. **Ear Nose Throat J** 1995 Nov;74(11):777–80

Outcome-oriented managed care comparing efficacies of cefaclor and amoxicillin in acute and recurrent acute otitis media. Perry BP, et al. **Ear Nose Throat J** 1995 Dec; 74(12):840–4

Cavernous sinus thrombosis: a report of eight consecutive comatose patients. Kalangu KK. **East Afr Med J** 1995 Dec; 72(12):791–5

Triadic nose drops in the treatment of chronic sinusitis. Zhu FG. **East Afr Med J** 1995 Dec;72(12):816–7

Percutaneous endoscopic gastrostomy (PEG): comparison of push and pull methods and evaluation of antibiotic prophylaxis. Akkersdijk WL, et al. **Endoscopy** 1995 May; 27(4):313–6

Antibiotic prescribing during an outbreak of meningococcal disease. Stuart JM, et al. **Epidemiol Infect** 1996 Aug; 117(1):103–5

Treatment with various antibiotics of experimental endocarditis caused by penicillin-resistant Streptococcus sanguis. Martínez F, et al. **Eur Heart J** 1995 May; 16(5):687–91

An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Viscoli C, et al. **Eur J Cancer** 1995 Nov;31A(12):2013–22 (60 ref.)

Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Craig WA. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):636–42 (27 ref.)

Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Tice AD. **Eur J Clin Microbiol Infect Dis** 1995 Jul; 14(7):655–61 (8 ref.)

Changes in the use of antibacterial drugs in the countries of central and eastern Europe. Kiivet RA, et al. **Eur J Clin Pharmacol** 1995;48(3–4):299–304

Timing of antibiotic treatment in non-perforated gangrenous appendicitis. Almqvist P, et al. **Eur J Surg** 1995 Jun; 161(6):431–3

Infection, the gut and the development of the multiple organ dysfunction syndrome. Nieuwenhuijzen GA, et al. **Eur J Surg** 1996 Apr;162(4):259–73 (185 ref.)

Empirical treatment of nonsevere community-acquired pneumonia: still a difficult issue [editorial; comment] Torres A, et al. **Eur Respir J** 1995 Dec;8(12):1996–8. Comment on: Eur Respir J 1996 Dec;8(12):1999–2007.

Antibiotic use in upper respiratory tract infections in New Zealand. McGregor A, et al. **Fam Pract** 1995 Jun; 12(2):166–70

Evolving therapies for peptic ulcer disease: Helicobacter pylori treatment. Cohen JC. **Gastroenterologist** 1995 Dec; 3(4):289–300 (129 ref.)

Antibiotic treatment improves survival in experimental acute necrotizing pancreatitis. Mithöfer K, et al. **Gastroenterology** 1996 Jan;110(1):232–40

Antibiotic treatment based on seminal cultures from asymptomatic male partners in in-vitro fertilization is unnecessary and may be detrimental. Liversedge NH, et al. **Hum Reprod** 1996 Jun;11(6):1227–31

Chloramphenicol-furazolidone combination in enteric fever [letter] Bairwa A, et al. **Indian Pediatr** 1995 Jan;32(1):109

An outbreak of multidrug resistant. Salmonella typhimurium in a nursery. Kumar A, et al. **Indian Pediatr** 1995 Aug; 32(8):881–5

Antibiotic concerns in the elderly. A clinician's perspective. Gleckman RA. **Infect Dis Clin North Am** 1995 Sep; 9(3):575–90 (60 ref.)

Antibacterial agents in pediatrics. LiPuma JJ, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):561–74 (55 ref.)

Rational use of oral antibiotics for pediatric infections. Sunakawa K, et al. **Infection** 1995;23 Suppl 2:S74–8

Choice of antibiotics by the site of infection in a community hospital. Chung SJ, et al. **Int J Biomed Comput** 1995 Sep; 40(1):31–9

Treatment of acne vulgaris: combination of 3% erythromycin and 5% benzoyl peroxide in a gel compared to clindamycin phosphate lotion. Packman AM, et al. **Int J Dermatol** 1996 Mar;35(3):209–11

Bacteria and antimicrobial agents in the treatment of acne. Parry EJ, et al. **Int J Dermatol** 1996 Apr;35(4):249–51 (15 ref.)

Treatment of aspiration or tracheostomy-associated pneumonia in neurologically impaired children: effect of antimicrobials effective against anaerobic bacteria. Brook I. **Int J Pediatr Otorhinolaryngol** 1996 Apr;35(2):171–7

Acute haematogenous osteomyelitis—evaluation of management in the 1990s. Lane-O'Kelly A, et al. **Ir J Med Sci** 1995 Oct–Dec;164(4):285–8

Partially treated meningitis in children—room for clinical judgement [editorial; comment] Ashkenazi S, et al. **Isr J Med Sci** 1995 Oct;31(10):638–9 (20 ref.). Comment on: Isr J Med Sci 1995 Oct;31(10):611–5.

Polypharmacy in nursing homes [letter; comment] Spoelhof GD. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):430; discussion 430–1. Comment on: J Am Board Fam Pract 1995 May–Jun;8(3):195–205.

Antibiotic prophylaxis against infective endocarditis in mitral valve prolapse [letter; comment] Guntheroth W. **J Am Coll Cardiol** 1996 Feb;27(2):515. Comment on: J Am Coll Cardiol 1995 Mar;25(3):693–9. Comment on: J Am Coll Cardiol 1995 Sep;26(3):839.

Researchers use antibiotics to fight periodontal disease [news] **J Am Dent Assoc** 1996 Aug;127(8):1158

Effectiveness of oral antibiotic treatment in nursing-home acquired pneumonia [letter; comment] Buehrens PE. **J Am Geriatr Soc** 1995 Dec;43(12):1443; discussion 1443–4. Comment on: J Am Geriatr Soc 1995 Mar;43(3):245–51.

Confounding issues of bacteremic older adults [letter; comment] Mathis DE. **J Am Geriatr Soc** 1995 Oct; 43(10):1179. Comment on: J Am Geriatr Soc 1995 Mar;43(3):230–5.

The potential effect on Neisseria gonorrhoeae of the use of clindamycin vaginal cream in the empirical treatment of vaginal discharge. Adu-Sarkodie YA, et al. **J Antimicrob Chemother** 1995 Sep;36(3):557–60

Efficacy of azithromycin and rifabutin in preventing infection by Mycobacterium avium complex in beige mice. Bermudez LE, et al. **J Antimicrob Chemother** 1995 Oct; 36(4):641–6

Anti-infective strategies in neutropenia. Boogaerts MA. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:167–78 (54 ref.)

Evaluation of an antibiotic prescribing protocol for treatment of acute exacerbations of chronic obstructive airways disease in a hospital respiratory unit. Boyter AC, et al. **J Antimicrob Chemother** 1995 Aug;36(2):403–9

Comparative activity of azithromycin and doxycycline against Brucella spp. infection in mice. Domingo S, et al. **J Antimicrob Chemother** 1995 Oct;36(4):647–56

Antibiotics and the expression of staphylococcal virulence. Gemmell CG. **J Antimicrob Chemother** 1995 Aug; 36(2):283–91 (54 ref.)

Neutropenic infections: strategies for empirical therapy. Kibbler CC. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:107–17 (65 ref.)

Empiric antibiotic therapy for acute infective diarrhoea in the developed world. Moss PJ, et al. **J Antimicrob Chemother** 1995 Jun;35(6):903–13 (74 ref.)

Access to antibiotics: a case for a change in category. Pringle

M. **J Antimicrob Chemother** 1995 Sep;36(3):577–9
A novel drug delivery system for osteomyelitis using porous hydroxyapatite blocks loaded by centrifugation. Itokazu M, et al. **J Appl Biomater** 1995 Fall;6(3):167–9
Antibiotic irrigation of the capsular bag to resolve low-grade endophthalmitis. Busin M. **J Cataract Refract Surg** 1996 Apr;22(3):385–9
Staphylococcus aureus infections in haemodialysis patients: pathophysiology and use of nasal mupirocin for prevention. Boelaert JR, et al. **J Chemother** 1995 Jul;7 Suppl 3:49–53
Infection of the pancreatic duct following pancreas transplantation with bladder drainage. Bonatti H, et al. **J Chemother** 1995 Oct;7(5):442–5
Antibiotic therapy and the anesthesiologist. Cheng EY, et al. **J Clin Anesth** 1995 Aug;7(5):425–39 (97 ref.)
Monitoring of antibiotic use in a primary and tertiary care hospital. Thomas M, et al. **J Clin Epidemiol** 1996 Feb; 49(2):251–4
Incidence of diarrhea and Clostridium difficile toxin in stools from hospitalized patients receiving clindamycin, beta-lactams, or nonantibiotic medications. Thamlikitkul V, et al. **J Clin Gastroenterol** 1996 Mar;22(2):161–3
Clinical and microbiological changes associated with the use of 4 adjunctive systemically administered agents in the treatment of periodontal infections. Haffajee AD, et al. **J Clin Periodontol** 1995 Aug;22(8):618–27
Financial analysis of alternative treatments for clinical mastitis associated with environmental pathogens. Van Eenennaam AL, et al. **J Dairy Sci** 1995 Sep;78(9):2086–95
Adjunctive dexamethasone therapy for pediatric bacterial meningitis. Bonadio WA. **J Emerg Med** 1996 Mar–Apr; 14(2):165–72 (40 ref.)
Introduction to the series, "Antibiotic use in the emergency department". Pollack CV Jr. **J Emerg Med** 1996 Mar–Apr; 14(2):209–11
C pneumoniae in adult asthma [comment] Ebell MH. **J Fam Pract** 1995 Oct;41(4):405–6. Comment on: J Fam Pract 1995 Oct;41(4):345–51.
Treatment of Helicobacter pylori infection. Ebell MH. **J Fam Pract** 1996 Jun;42(6):568
Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial [see comments] Hahn DL. **J Fam Pract** 1995 Oct;41(4):345–51. Comment in: J Fam Pract 1995 Oct;41(4):405–6. Comment in: J Fam Pract 1996 Mar;42(3):307–8.
Antibiotics and respiratory infections: are patients more satisfied when expectations are met? Hamm RM, et al. **J Fam Pract** 1996 Jul;43(1):56–62
Antibiotics and upper respiratory infection: do some folks think there is a cure for the common cold? Mainous AG 3rd, et al. **J Fam Pract** 1996 Apr;42(4):357–61
Minocycline vs tetracycline [letter] Shubin JA. **J Fam Pract** 1995 Dec;41(6):538
Antibiotic treatment of asthma [letter; comment] Thom D. **J Fam Pract** 1996 Mar;42(3):307–8. Comment on: J Fam Pract 1995 Oct;41(4):345–51.
Post-operative infection following hand surgery. Guidelines for antibiotic use. Platt AJ, et al. **J Hand Surg [Br]** 1995 Oct;20(5):685–90
Statistical analysis of results [letter; comment] Cheesbrough A. **J Hosp Infect** 1995 Sep;31(1):75–6. Comment on: J Hosp Infect 1994 Apr;26(4):287–92.
Infections in liver transplantation: risk factors and strategies for prevention. Kibbler CC. **J Hosp Infect** 1995 Jun;30 Suppl:209–17 (40 ref.)
Blanket use of intranasal mupirocin for outbreak control and long-term prophylaxis of endemic methicillin-resistant Staphylococcus aureus in an open ward. Mayall B, et al. **J Hosp Infect** 1996 Apr;32(4):257–66
The prevention of orthopaedic implant and vascular graft infections. Strachan CJ. **J Hosp Infect** 1995 Jun;30 Suppl:54–63
Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of gram-negative sepsis. Bucklin SE, et al. **J Infect Dis** 1995 Dec;172(6):1519–27
Systemic prophylaxis of experimental staphylococcal endophthalmitis: comparative efficacy of sparfloxacin, pefloxacin, imipenem, vancomycin, and amikacin. Marrakchi-Benjaafar S, et al. **J Infect Dis** 1995 Nov; 172(5):1312–6
Antimicrobial management of chronic sinusitis in children. Brook I, et al. **J Laryngol Otol** 1995 Dec;109(12):1159–62
Knowledge, beliefs, and use of prescribed antibiotic medications among low-socioeconomic African Americans. Kandakai TL, et al. **J Natl Med Assoc** 1996 May;88(5):289–94
Pharmacologic treatment of neonatal sepsis: antimicrobial agents and immunotherapy. Cavaliere TA. **J Obstet Gynecol Neonatal Nurs** 1995 Sep;24(7):647–58 (77 ref.)
Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee [see comments] Arnold KE, et al. **J Pediatr** 1996 Jun; 128(6):757–64. Comment in: J Pediatr 1996 Jun;128(6):729–30.
Benzathine as a cause for a false-positive test result for amphetamines [letter; comment] Berthier M, et al. **J Pediatr** 1995 Oct;127(4):669–70. Comment on: J Pediatr 1995 Jan;126(1):135–40.
Penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae causing sepsis and meningitis in children with sickle cell disease [see comments] Chesney PJ, et al. **J Pediatr** 1995 Oct;127(4):526–32. Comment in: J Pediatr 1996 Jun;128(6):862–3.
Resisting the urge to prescribe [editorial; comment] Edwards KM. **J Pediatr** 1996 Jun;128(6):729–30. Comment on: J Pediatr 1996 Jun;128(6):757–64.
Successful medical treatment of severely decompensated Wilson disease. Santos Silva EE, et al. **J Pediatr** 1996 Feb; 128(2):285–7
Acute interstitial nephritis associated with loracarbef therapy. Thieme RE, et al. **J Pediatr** 1995 Dec;127(6):997–1000
Streptococcus pneumoniae colonization in the young child: association with otitis media and resistance to penicillin. Zenni MK, et al. **J Pediatr** 1995 Oct;127(4):533–7
Cessation of antibiotics regardless of ANC is safe in children with febrile neutropenia. A preliminary prospective trial. Cohen KJ, et al. **J Pediatr Hematol Oncol** 1995 Nov; 17(4):325–30
Subacute hematogenous osteomyelitis: are biopsy and surgery always indicated? Hamdy RC, et al. **J Pediatr Orthop** 1996 Mar–Apr;16(2):220–3
Compliance with short-term antibiotic therapy among patients attending primary health centres in Riyadh, Saudi Arabia. al-Shammari SA, et al. **J R Soc Health** 1995 Aug; 115(4):231–4
Efficacy of florfenicol on experimental Actinobacillus pleuropneumonia in pigs. Ueda Y, et al. **J Vet Med Sci** 1995 Apr;57(2):261–5
Antibiotic treatment for exacerbations of chronic obstructive pulmonary disease [letter; comment] Gilkey EA. **JAMA** 1995 Oct 11;274(14):1131–2. Comment on: JAMA 1995 Mar 22–29;273(12):957–60.
Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. Plouffe JF, et al. **JAMA** 1996 Jan 17;275(3):194–8
Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology [published erratum appears in JAMA 1996 May 1;275(17):1314] Soll AH. **JAMA** 1996 Feb 28;275(8):622–9 (99 ref.)
Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association [see comments] Wilson WR, et al. **JAMA** 1995 Dec 6; 274(21):1706–13. Comment in: JAMA 1996 Mar 27;275(12):911.
Prevention and treatment of cilia-associated respiratory bacillus in mice by use of antibiotics. Matsushita S, et al. **Lab Anim Sci** 1995 Oct;45(5):503–7
Use of antibiotics to prevent hepatitis and typhlitis in male scid mice spontaneously infected with Helicobacter hepaticus. Russell RJ, et al. **Lab Anim Sci** 1995 Aug; 45(4):373–8
Early antibiotic treatment in acute necrotising pancreatitis [letter; comment] [see comments] Baudin F, et al. **Lancet** 1995 Nov 18;346(8986):1374–5. Comment on: Lancet 1995 Sep 9;346(8976):663–7. Comment in: Lancet 1996 Feb 17;347(8999):480–1.
How to treat bacteraemic Mycobacterium avium complex disease. Chin DP, et al. **Lancet** 1995 Oct 7;346(8980):920–1
Management of acute bacterial meningitis [letter; comment] Enting R, et al. **Lancet** 1996 Feb 24;347(9000):536–7. Comment on: Lancet 1995 Dec 23–30;346(8991–8992):1675–80.
Preterm premature rupture of membranes [letter; comment] Hay PE, et al. **Lancet** 1996 Jan 20;347(8995):203. Comment on: Lancet 1995 Nov 11;346(8985):1271–9.
Preterm premature rupture of membranes [letter; comment] McGregor JA, et al. **Lancet** 1996 Jan 20;347(8995):203–4. Comment on: Lancet 1995 Nov 11;346(8985):1271–9.
Management of acute bacterial meningitis [letter; comment] Maggs AF. **Lancet** 1996 Feb 24;347(9000):536; discussion 538–9. Comment on: Lancet 1995 Dec 23–30;346(8991–8992):1675–80.
Antibiotics for the common cold [letter] Mainous AG 3rd, et al. **Lancet** 1996 Sep 14;348(9029):754
Antimicrobial therapy in expectant management of preterm premature rupture of the membranes [see comments] [published erratum appears in Lancet 1996 Feb 10;347(8998):410] Mercer BM, et al. **Lancet** 1995 Nov 11; 346(8985):1271–9 (46 ref.). Comment in: Lancet 1996 Jan 20;347(8995):203. Comment in: Lancet 1996 Jan 20;347(8995):203–4. Comment in: Lancet 1996 Jan 20;347(8995):204. Comment in: Lancet 1996 Mar 23;347(9004):837–8.
Management of acute bacterial meningitis [letter; comment] Obaro SK. **Lancet** 1996 Feb 24;347(9000):538. Comment on: Lancet 1995 Dec 23–30;346(8991–8992):1675–80.
Antimicrobial treatment in expectant management of preterm premature rupture of membranes [letter; comment] Ohlsson A, et al. **Lancet** 1996 Mar 23;347(9004):837–8. Comment on: Lancet 1995 Nov 11;346(8985):1271–9.
Management of acute bacterial meningitis [letter; comment] Tamburlini G, et al. **Lancet** 1996 Feb 24;347(9000):537–8; discussion 538–9. Comment on: Lancet 1995 Dec 23–30;346(8991–8992):1675–80.
Preterm premature rupture of membranes [letter; comment] Taylor D, et al. **Lancet** 1996 Jan 20;347(8995):204. Comment on: Lancet 1995 Nov 11;346(8985):1271–9.
Antibiotics for the common cold [letter] Tyrrell DA. **Lancet** 1996 Sep 14;348(9029):754–5
Time to ban all antibiotics as animal growth-promoting agents? [letter] van den Bogaard AE, et al. **Lancet** 1996 Aug 31;348(9027):619
Antibiotics for the uncommon cold [comment] Wise R. **Lancet** 1996 Jun 1;347(9014):1499. Comment on: Lancet 1996 Jun 1;347(9014):1507–10.
Managing HIV. Part 5: Treating secondary outcomes. 5.16 HIV and bacterial infections. Allworth AM, et al. **Med J Aust** 1996 May 6;164(9):546–8 (5 ref.)
Drug-resistant Streptococcus pneumoniae: the beginning of the end for many antibiotics? Australian Group on Antimicrobial Resistance (AGAR). Collignon PJ, et al. **Med J Aust** 1996 Jan 15;164(2):64–7
Adaptive control of therapeutic drug regimens relations between clinical situations: outcomes and simulations using nonlinear dynamic models. Maire PH, et al. **Medinfo** 1995; 8 Pt 2:1111–5
Adaptation and abstraction as steps towards case-based reasoning in the real medical world: case-based selection strategies for antibiotics therapy. Schmidt R, et al. **Medinfo** 1995;8 Pt 2:947–51
Community-acquired pneumonia [letter; comment] Halm EA, et al. **N Engl J Med** 1996 Mar 28;334(13):862; discussion 862–3. Comment on: N Engl J Med 1995 Dec 14;333(24):1618–24.
Advances in the prevention and treatment of Mycobacterium avium disease [editorial; comment] Horsburgh CR Jr. **N Engl J Med** 1996 Aug 8;335(6):428–30. Comment on: N Engl J Med 1996 Aug 8;335(6):377–83. Comment on: N Engl J Med 1996 Aug 8;335(6):384–91. Comment on: N Engl J Med 1996 Aug 8;335(6):392–8.
Bacterial vaginosis and preterm birth [letter; comment] McGregor JA, et al. **N Engl J Med** 1996 May 16; 334(20):1337–8; discussion 1338–9. Comment on: N Engl J Med 1995 Dec 28;333(26):1732–6. Comment on: N Engl J Med 1995 Dec 28;333(26):1737–42.
Community-acquired pneumonia [letter; comment] Mandell LA, et al. **N Engl J Med** 1996 Mar 28;334(13):861; discussion 862–3. Comment on: N Engl J Med 1995 Dec 14;333(24):1618–24.
Drug-resistant Streptococcus pneumoniae [letter; comment] Redondo E. **N Engl J Med** 1996 Jan 4;334(1):53; discussion 54. Comment on: N Engl J Med 1995 Aug 24;333(8):481–6.
A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group [see comments] Shafran SD, et al. **N Engl J Med** 1996 Aug 8;335(6):377–83. Comment in: N Engl J Med 1996 Aug 8;335(6):428–30.
Otitis media in children [letter] van Buchem FL, et al. **N Engl J Med** 1995 Oct 26;333(17):1151; discussion 1152
Otitis media with effusion [letter; comment] Roydhouse N. **N Z Med J** 1996 Jul 12;109(1025):263. Comment on: N Z Med J 1996 May 24;109(1022):182–4.
Value of antibiotic therapy in tuberculin-positive children with parenchymal lung lesions. Somu N, et al. **Natl Med J India** 1995 Nov–Dec;8(6):261–2
Cervical discitis associated with spinal epidural abscess caused by methicillin-resistant staphylococcus aureus. Sawada M, et al. **Neurol Med Chir (Tokyo)** 1996 Jan; 36(1):40–4
Adjunctive antibiotic treatment in preterm labor and neonatal morbidity: a meta-analysis. Egarter C, et al. **Obstet Gynecol** 1996 Aug;88(2):303–9
Utility of antibiotic therapy in preterm premature rupture of membranes: a meta-analysis. Ananth CV, et al. **Obstet Gynecol Surv** 1996 May;51(5):324–8
Using metronidazole (Flagyl) for odor control. Melious N. **Oncol Nurs Forum** 1995 Jul:22(6):987–8
The role of smears, cultures, and antibiotic sensitivity testing in the management of suspected infectious keratitis. McLeod SD, et al. **Ophthalmology** 1996 Jan;103(1):23–8
Infected pancreatic necrosis and peripancreatic fluid collections: serendipitous response to antibiotics and medical therapy in three patients. Dubner H, et al. **Pancreas** 1996 Apr;12(3):298–302
Pediatric bone and joint infections. Diagnosis and antimicrobial management. Sonnen GM, et al. **Pediatr Clin North Am** 1996 Aug;43(4):933–47 (30 ref.)
Prospective study of Yersinia enterocolitica infection in thalassemic patients. Cherchi GB, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):579–84
Treatment of persistent otitis media [letter; comment] Giebink GS. **Pediatr Infect Dis J** 1995 Oct;14(10):922–3. Comment on: Pediatr Infect Dis J 1995 Mar;14(3):183–8.
Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children. Girgis NI, et al. **Pediatr Infect Dis J** 1995 Jul; 14(7):603–5
Effect of antibiotic therapy on the outcome of outpatients with unsuspected bacteremia. Harper MB, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):760–7
Rational selection of antimicrobials for pediatric upper respiratory infections. Harrison CJ. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S121–9 (28 ref.)
Determining etiology of pneumonia [letter; comment] Shann F. **Pediatr Infect Dis J** 1995 Oct;14(10):920–1. Comment on: Pediatr Infect Dis J 1994 Nov;13(11):975–82.
Antibiotic drug levels. Rosenberg MG. **Pediatr Rev** 1995 Oct; 16(10):397–8
Treatment of acute streptococcal pharyngitis and prevention

of rheumatic fever: a statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Dajani A, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):758–64

Managing otitis media: a time for change. Paradise JL. **Pediatrics** 1995 Oct;96(4 Pt 1):712–5

Reinsertion of PD catheters during PD-related infections performed either simultaneously or after an intervening period. Fredensborg BB, et al. **Perit Dial Int** 1995 Oct–Dec; 15(8):374–8

Practical strategies for the appropriate use of antimicrobials. Guglielmo BJ. **Pharm World Sci** 1995 Jul 28;17(4):96–102 (29 ref.)

Improving the quality of antimicrobial drug use can result in cost containment. Gyssens IC, et al. **Pharm World Sci** 1995 Sep 22;17(5):163–7 (19 ref.)

The best of times, the worst of times. The global challenge of antimicrobial resistance. Tenover FC. **Pharm World Sci** 1995 Sep 22;17(5):149–51 (40 ref.)

Common bacterial pyodermas. Taking aim against the most likely pathogens. Carroll JA. **Postgrad Med** 1996 Sep; 100(3):311–3, 317–22 (22 ref.)

Choosing an antibiotic for pneumonia [letter; comment] Rashada SC. **Postgrad Med** 1996 Apr;99(4):62–4. Comment on: Postgrad Med 1996 Jan;99(1):109–10, 113–4, 117–9, passim.

Recurrent streptococcal pharyngitis. Using practical treatment options to interrupt the cycle. Ruoff GE. **Postgrad Med** 1996 Feb;99(2):211–4, 219–22 (19 ref.)

Infectious arthritis: tailoring initial treatment to clinical findings. Stimmler MM. **Postgrad Med** 1996 Apr; 99(4):127–31, 135–9

Overview of the newer antibiotics. Lea AS. **Proc Annu Meet Med Sect Am Counc Life Insur** 1995; :109–17 (0 ref.)

A decision support tool for antibiotic therapy. Evans RS, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:651–5

How long is too long? Determining the early management of meningococcal disease in Birmingham. Wood AL, et al. **Public Health** 1996 Jul;110(4):237–9

Management of acute asthma attacks associated with respiratory tract infection: a postal survey of general practitioners in the U.K. Jones K, et al. **Respir Med** 1996 Aug;90(7):419–25

Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals. Trentham DE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):817–34 (58 ref.)

Helicobacter pylori eradication: unravelling the facts. Dixon JS. **Scand J Gastroenterol Suppl** 1995;212:48–62 (244 ref.)

Helicobacter pylori eradication: a critical appraisal and current concerns. Hunt RH. **Scand J Gastroenterol Suppl** 1995;210:73–6 (18 ref.)

Helicobacter pylori and peptic ulcer. Korman MG, et al. **Scand J Gastroenterol Suppl** 1995;210:92–6 (61 ref.)

Sucralfate in Helicobacter pylori eradication strategies. Lam SK, et al. **Scand J Gastroenterol Suppl** 1995;210:89–91 (19 ref.)

Peptic ulcer and Helicobacter pylori: eradication and relapse. Tytgat GN. **Scand J Gastroenterol Suppl** 1995;210:70–2 (13 ref.)

Efficacy of maduramicin against turkey coccidiosis in battery: a clinical and pathological study. Cerruti Sola S, et al. **Schweiz Arch Tierheilkd** 1996;138(4):201–6

Lyme disease research [letter; comment] [see comments] McFadden P. **Science** 1995 Dec 1;270(5241):1419. Comment on: Science 1995 Oct 13;270(5234):228–9. Comment in: Science 1996 Mar 1;271(5253):1216–8.

Lyme disease. NIH gears up to test a hotly disputed theory [news] [see comments] Marshall E. **Science** 1995 Oct 13; 270(5234):228–9. Comment in: Science 1995 Nov 17;270(5239):1103. Comment in: Science 1995 Dec 1;270(5241):1419. Comment in: Science 1996 Mar 1;271(5253):1216–8.

Treatment of chronic Lyme disease [letter; comment] Steere AC. **Science** 1996 Mar 1;271(5253):1216–8. Comment on: Science 1995 Oct 13;270(5234):228–9. Comment on: Science 1995 Dec 1;270(5241):1419.

A selective inhibitor of inducible in nitric oxide synthase prolongs survival in a rat model of bacterial peritonitis: comparison with two nonselective strategies. Aranow JS, et al. **Shock** 1996 Feb;5(2):116–21

Antimicrobial therapy in Plesiomonas shigelloides-associated diarrhea in Thai children. Visitsunthorn N, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):86–90

Initial empirical antibiotic therapy for neutropenic fever: analysis of the causes of death. Rossi C, et al. **Support Care Cancer** 1996 May;4(3):207–12

Preoperative administration of antibiotics in patients with suspected acute appendicitis. Murao Y, et al. **Surg Today** 1996;26(5):314–22

Is an initial small-spectrum antibiotic regimen safe in fulminant hepatic failure? Clemmesen J, et al. **Transplant Proc** 1995 Dec;27(6):3505

About Salmonella typhi infections [letter] Ozsoylu S. **Turk J Pediatr** 1996 Apr–Jun;38(2):281, 283

General management considerations for the trauma patient. Payne JT. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1015–29 (6 ref.)

Effect of salinomycin in the control of Clostridium perfringens type C infections in sucklings pigs. Kyriakis SC, et al. **Vet Rec** 1996 Mar 23;138(12):281–3

Assessment of the effect of three treatments to remove intrauterine fluid on pregnancy rate in the mare. Pycock JF, et al. **Vet Rec** 1996 Apr 6;138(14):320–3

The effect of salinomycin on the control of Clostridium perfringens type-A infection in growing pigs. Kyriakis SC, et al. **Zentralbl Veterinarmed [B]** 1995 Aug;42(6):355–9

[The basic principles of the antibiotic therapy of burn patients] Leseva M, et al. **Khirurgiia (Sofiia)** 1995;48(3):8–11 (Eng. Abstr.) **(Bul)**

[Empirical antimicrobial therapy of respiratory infections] Musilová J. **Vnitr Lek** 1996 Feb;42(2):133–5 (Eng. Abstr.) **(Cze)**

[Antibiotics in the treatment of acute pancreatitis] Spičák J. **Vnitr Lek** 1996 Feb;42(2):115–6 **(Cze)**

[Peritonitis in continuous ambulatory peritoneal dialysis. An evaluation of the empiric initial antibiotic treatment] Hagelskjaer LH, et al. **Ugeskr Laeger** 1996 Apr 29; 158(18):2532–7 (Eng. Abstr.) **(Dan)**

[Prescribing antibiotics in children with exacerbations of airway symptoms?] Brand PL, et al. **Ned Tijdschr Geneeskd** 1996 Apr 27;140(17):913–6 **(Dut)**

[Rational use of antibiotics in the neutropenic patient with fever] de Pauw BE, et al. **Ned Tijdschr Geneeskd** 1995 Aug 26;139(34):1725–9 (26 ref.) **(Dut)**

[Dog bites: publications on risk factors, infections, antibiotics and primary wound closure (letter; comment)] Hemmes JH. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1202–3. Comment on: Ned Tijdschr Geneeskd 1996 Mar 30;140(13):709–13. **(Dut)**

[Guidelines for endocarditis prophylaxis; revision 1996. Commission Endocarditis Prophylaxis of the Netherland Heart Foundation] Thompson J. **Ned Tijdschr Geneeskd** 1996 May 11;140(19):1017–8 **(Dut)**

[Veterinary antibiotic policy: responsible and effective? A viewpoint from industry (news)] **Tijdschr Diergeneeskd** 1996 Feb 1;121(3):78–9 **(Dut)**

[Are antibiotics necessary for a child with the flu? (editorial)] Mäkelä M, et al. **Duodecim** 1995;111(7):583–4 (12 ref.) **(Fin)**

[What should be done for diarrhea during antibiotic therapy?] de Parades V, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 Mar–Apr;32(2):59–62 **(Fre)**

[Survey on the practice of antibiotic prophylaxis of infective endocarditis by dentists] Bennis A, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):713–8 (Eng. Abstr.) **(Fre)**

[Example of common pathology: antibiotic prescription in current pediatric practice] Beley G. **Arch Pediatr** 1996;3 Suppl 1:272s–274s **(Fre)**

[Antibiotics in gynecology. Treatment of acute infections] Judlin P. **Contracept Fertil Sex** 1996 May;24(5):353–8 (0 ref.) **(Fre)**

[Can the incidence of infectious complications in digestive surgery be reduced? Role of antibiotic prophylaxis (1100) cases (editorial)] Champault G. **G Chir** 1995 Oct; 16(10):401–6 **(Fre)**

[Therapeutic management of duodenal ulcer except in emergency: eradication of Helicobacter pylori] Lamouliatte H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S58–S63 (63 ref.) **(Fre)**

[Corneal abscess: therapeutic attitude based on microbiological testing] Briat B, et al. **J Fr Ophtalmol** 1996; 19(5):375–9 (Eng. Abstr.) **(Fre)**

[Account of the Roussel-Diamant symposium] **Nouv Rev Fr Hematol** 1995;37(3):211–3 **(Fre)**

[Bacteria, multiresistant to antibiotics, in intensive care units: epidemiological context and strategies of control] Régnier B. **Pathol Biol (Paris)** 1996 Feb;44(2):113–23 (Eng. Abstr.) **(Fre)**

[Therapeutic applications of tissue pharmacokinetics of antibiotics] Bergogne-Bérézin E. **Presse Med** 1996 Mar 2–9; 25(8):408–10, 412–4, 416–8 (41 ref.) (Eng. Abstr.) **(Fre)**

[Community-acquired pneumonia in children: importance of Mycoplasma pneumoniae infections and efficacy of antibiotics] Gendrel D, et al. **Presse Med** 1996 May 18; 25(17):793–7 (Eng. Abstr.) **(Fre)**

[Treatment of non-tuberculous mycobacterial infections] Dautzenberg B. **Rev Mal Respir** 1996;13(1):81–3 (17 ref.) **(Fre)**

[Diagnostic and therapeutic strategies in exacerbations of chronic bronchitis in city practice] Taytard A, et al. **Rev Mal Respir** 1995;12(4):371–6 (Eng. Abstr.) **(Fre)**

[Current therapies 1990–1995 in infectious diseases] Scheen AJ. **Rev Med Liege** 1995 Oct;50(10):413–7 **(Fre)**

[Antibiotic resistance in pneumococci] Moreillon P, et al. **Schweiz Med Wochenschr** 1996 Feb 17;126(7):255–63 (30 ref.) (Eng. Abstr.) **(Fre)**

[Occurrence of anterior uveitis in a HIV patient treated with rifabutin, ethambutol, clarithromycin (letter)] Pinzani V, et al. **Therapie** 1995 Sep–Oct;50(5):482–3 **(Fre)**

[Comparison of the use of a vaccine and sequential antibiotic treatment in a herd infected with Mycoplasma hyopneumoniae] Le Grand A, et al. **Vet Res** 1996; 27(3):241–53 (Eng. Abstr.) **(Fre)**

[Management of E. coli dependent factorial diseases in weaning piglets] Bölcskei A, et al. **Berl Munch Tierarztl Wochenschr** 1996 Mar;109(3):108–11 (Eng. Abstr.) **(Ger)**

[Effectiveness of oral rifampicin against mycobacteriosis in tropical fish] Boos S, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jul;108(7):253–5 (Eng. Abstr.) **(Ger)**

[Resistance pattern of bovine Pasteurella] Hörmansdorfer S, et al. **Berl Munch Tierarztl Wochenschr** 1996 May; 109(5):168–71 (Eng. Abstr.) **(Ger)**

[Antibiotic therapy for pneumonias acquired outside the hospital] Achermann E, et al. **Dtsch Med Wochenschr** 1996 Aug 23;121(34–35):1057–9 (14 ref.) **(Ger)**

[Current aspects of patients with life-threatening diseases. Symposium, Berlin, 19–20 March 1993] **Internist (Berl)** 1993 May;34(5 Suppl [aktuelle]):1–12 **(Ger)**

[New advancements in the study of infection (news)] **Pharm Unserer Zeit** 1995 Nov;24(6):339 **(Ger)**

[Antibacterial treatment of gastric ulcers associated with Helicobacter pylori without acid suppression] Folwaczny C. **Z Gastroenterol** 1995 Jul;33(7):416–7 **(Ger)**

[Current trends in antibiotic therapy in dentistry] Gáspár L, et al. **Fogorv Sz** 1995 Nov;88(11):355–64 (Eng. Abstr.) **(Hun)**

[A possible therapeutic improvement of the antibacterial effect by monitoring the production of leukocyte free oxygen radicals during antibiotic treatment of infertile patients with chronic bacterial prostatitis] Vicari E, et al. **Arch Ital Urol Androl** 1996 Apr;68(2):91–7 (Eng. Abstr.) **(Ita)**

[Acute pelvic inflammatory disease: comparison of therapeutic protocols] Balbi G, et al. **Minerva Ginecol** 1996 Jan–Feb;48(1–2):19–23 (Eng. Abstr.) **(Ita)**

[Management of MRSA-harboring patients: focused on mupirocin] Inoue M. **Jpn J Antibiot** 1996 May;49(5):403–18 **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). II. Background of patients] Kumamoto Y, et al. **Jpn J Antibiot** 1996 May;49(5):494–508 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). II. Background of patients] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Sep;48(9):1161–73 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). II. Background of patients] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Nov;48(11):1788–801 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). II. Background of patients] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Nov;48(11):1658–70 (Eng. Abstr.) **(Jpn)**

[Emergency drug therapy of meningoencephalitis] Kuzuhara S. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1837–42 (5 ref.) **(Jpn)**

[May the choice of antibiotics against gonorrhea be guided by anamnesis?] Aavitsland P. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):837–40 (Eng. Abstr.) **(Nor)**

[Roxithromycin (Rulid) in treatment of Chlamydia trachomatis genital infections in women] Radowicki S, et al. **Ginekol Pol** 1995 Jun;66(6):354–6 (Eng. Abstr.) **(Pol)**

[Treatment of bacterial infections in patients with AIDS] Lewi DS. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:22–6 **(Por)**

[Sulacillin (a combination of ampicillin and sulbactam)—a new combined drug form for treatment of bacterial infections] Bogomolova NS, et al. **Antibiot Khimioter** 1995 Jun;40(6):43–8 (Eng. Abstr.) **(Rus)**

[Correction of the immunomodulating action of antibiotics in health and in staphylococcal infection] Prokopenko LG, et al. **Antibiot Khimioter** 1995 Nov–Dec;40(11–12):50–4 (Eng. Abstr.) **(Rus)**

[Methods for rapid evaluation of the effectiveness of drugs showing promise for urgent prevention and treatment of plague] Romanov VE, et al. **Antibiot Khimioter** 1995 Jun; 40(6):31–6 (Eng. Abstr.) **(Rus)**

[Standardization of conditions for the evaluation of effectiveness of antibacterial drugs in pneumonic plague in sacred baboons] Romanov VE, et al. **Antibiot Khimioter** 1995 Jun;40(6):23–30 (Eng. Abstr.) **(Rus)**

[Immunomodulating action of antibiotics in health and in staphylococcal infection] Siplivaia LE, et al. **Antibiot Khimioter** 1995 Nov–Dec;40(11–12):45–9 (Eng. Abstr.) **(Rus)**

[Microflora of purulent necrotic leisions of the foot in patients with diabetes mellitus] Svetukhin AM, et al. **Antibiot Khimioter** 1995 Aug;40(8):40–2 (Eng. Abstr.) **(Rus)**

[Current approaches to the treatment and prevention of subacute infectious endocarditis] Belokrinitskaia OA, et al. **Klin Med (Mosk)** 1995;73(5):23–8 (50 ref.) **(Rus)**

[The antibiotic therapy of patients with hemorrhagic fever with renal syndrome] Sidel'nikov IuN. **Klin Med (Mosk)** 1995;73(3):47–8 (Eng. Abstr.) **(Rus)**

[The treatment of periodontal diseases with the preparation Linco-HAP] Dmitrieva LA, et al. **Stomatologiia (Mosk)** 1995;74(3):25–8 (Eng. Abstr.) **(Rus)**

[Antibacterial therapy in the combined treatment of periodontitis] Romanov AE, et al. **Stomatologiia (Mosk)** 1996;75(1):23–5 (Eng. Abstr.) **(Rus)**

[Effectiveness of bioparox treatment in acute inflammatory diseases of the upper airways] Luchikhin LA, et al. **Vestn Otorinolaringol** 1996 Mar–Apr;(2):38–42 (Eng.

Abstr.) **(Rus)**

[Optimization of the etiological diagnosis and adequate antibacterial therapy in acute disseminated pneumonias] Sinopal'nikov AI, et al. **Voen Med Zh** 1996 Feb;317(2):30–3, 79 (Eng. Abstr.) **(Rus)**

[Critical approach to antibiotic therapy in Lyme disease] Bojić I. **Vojnosanit Pregl** 1994 May–Jun;51(3):233–6 (30 ref.) **(Scr)**

[Antibiotic prophylaxis in surgery of uncomplicated cholesteatoma: review of 150 patients] López Amado M, et al. **Acta Otorrinolaringol Esp** 1995 Nov–Dec;46(6):421–6 (Eng. Abstr.) **(Spa)**

[Splenic abscess following gynecologic infection with complete response to antibiotic treatment] Fombuena Moreno M, et al. **An Med Interna** 1995 Jul;12(7):340–2 (Eng. Abstr.) **(Spa)**

[Multicenter study comparing the efficacy and tolerance of topical ciprofloxacin (0.3%) versus topical gentamicin (0.3%) in the treatment of simple, non-cholesteatomaous chronic otitis media in the suppurative phase] Lorente J, et al. **An Otorrinolaringol Ibero Am** 1995;22(5):521–33 (Eng. Abstr.) **(Spa)**

[Analysis of prescriptions of antibiotics for acute respiratory infections at a health center (see comments)] Formento Tirado JA, et al. **Aten Primaria** 1995 Sep 30;16(5):281–4 (Eng. Abstr.). Comment in: Aten Primaria 1996 Apr 15;17(6):425–6. **(Spa)**

[Prescription of antibiotics in acute respiratory infections (letter; comment)] Pérez Caballero MC, et al. **Aten Primaria** 1996 Apr 15;17(6):425–6. Comment on: Aten Primaria 1995 Sep 30;16(5):281–4. **(Spa)**

[Use of antibiotics in primary care: treatment of urinary infection] Rodríguez Moreno C, et al. **Aten Primaria** 1996 Mar 31;17(5):309–16 (Eng. Abstr.) **(Spa)**

[Current clinical problems in evaluating microbiological and pharmacological data] Aguado JM. **Enferm Infecc Microbiol Clin** 1995 Oct;13(8):477–81 (11 ref.) **(Spa)**

[Complications of intravenous therapy. Influence of parenteral nutrition, central venous pressure and antibiotics] Armero M, et al. **Nutr Hosp** 1991 May–Jun; 6(3):186–93 (Eng. Abstr.) **(Spa)**

[Pneumococcus resistance. Reconsiderations on its empirical treatment] Pallarés M. **Rev Med Univ Navarra** 1995 Apr–Jun;40(2):90–2 (13 ref.) **(Spa)**

[Microbiology, penetrating deeply into the world of microbes. Basic changes in the treatment of infections] Wilhelmson B. **Lakartidningen** 1996 Jan 3;93(1–2):49–51 **(Swe)**

TOXICITY

Hepatotoxicity of antibiotics. Hautekeete ML. **Acta Gastroenterol Belg** 1995 May–Aug;58(3–4):290–6 (64 ref.)

Experimental evidence of ototoxicity of ear drops. A review of the literature. Kuhweide R. **Acta Otorhinolaryngol Belg** 1995;49(3):293–8 (28 ref.)

Toxicological studies on potentiated ionophores in chickens. I. Tolerance study. Lehel J, et al. **Acta Vet Hung** 1995; 43(2–3):321–33

Toxicological studies on potentiated ionophores in chickens. II. Compatibility study. Lehel J, et al. **Acta Vet Hung** 1995; 43(2–3):335–45

Toxicological studies on potentiated ionophores in chickens. III. Electrotoxicological investigations. Lehel J, et al. **Acta Vet Hung** 1995;43(2–3):347–54

Toxic effects of wound irrigation solutions on cultured tibiae and osteoblasts. Kaysinger KK, et al. **J Orthop Trauma** 1995;9(4):303–11

Genotoxicity of dihydroabikoviromycin, a secondary metabolite of Streptomyces anulatus. Holmalahti J, et al. **Mutat Res** 1996 Jul 5;368(3–4):157–63

Citrinin produces acute adverse changes in renal function and ultrastructure in pentobarbital-anesthetized dogs without concomitant reductions in [potassium]plasma. Krejci ME, et al. **Toxicology** 1996 Jan 8;106(1–3):167–77

ANTIBIOTICS, AMINOGLYCOSIDE

An outbreak of gentamicin-resistant Klebsiella pneumoniae in a neonatal ward. Shamseldin el Shafie S, et al. **Cent Eur J Public Health** 1995 Aug;3(3):129–31

ADMINISTRATION & DOSAGE

Effect of intratympanically administered gentamicin on hearing and tinnitus in Menière's disease. Kaasinen S, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:184–5

A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis. Lye WC, et al. **Adv Perit Dial** 1995;11:179–81

The evolution of aminoglycoside therapy: a single daily dose [see comments] Deamer RL, et al. **Am Fam Physician** 1996 Apr;53(5):1782–6 (24 ref.). Comment in: Am Fam Physician 1996 Apr;53(5):1512–4.

Aminoglycosides: once-daily dosing regimen [editorial; comment] Sloan RW. **Am Fam Physician** 1996 Apr; 53(5):1512–4. Comment on: Am Fam Physician 1996 Apr;53(5):1782–6.

Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Koo J, et al. **Am J Med** 1996 Aug;101(2):177–83

A model for long-term intracochlear administration of pharmacologic agents. Davies E, et al. **Am J Otol** 1994 Nov;15(6):757–61

Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Hatala R, et al. **Ann Intern Med** 1996 Apr 15;124(8):717–25

Lipid-based slow-release formulation of amikacin sulfate reduces foreign body-associated infections in mice. Roehrborn AA, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1752–5

Treatment of chronic ear disease. Topical ciprofloxacin vs topical gentamicin. Tutkun A, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1414–6

Magnetic field enhancement of antibiotic activity in biofilm forming Pseudomonas aeruginosa. Benson DE, et al. **ASAIO J** 1994 Jul–Sep;40(3):M371–6

Single or multiple daily doses of aminoglycosides: a meta-analysis. Barza M, et al. **BMJ** 1996 Feb 10; 312(7027):338–45

Single or multiple daily doses of aminoglycosides. Exposure to aminoglycosides should be monitored during treatment [letter] Begg EJ, et al. **BMJ** 1996 Aug 24;313(7055):491

Single or multiple daily doses of aminoglycosides. More details needed of treatment in neonates and young children [letter] Campbell H. **BMJ** 1996 Aug 24;313(7055):490; discussion 490–1

Single or multiple daily doses of aminoglycosides. Giving gentamicin once daily for neutropenic fever has proved to be simple [letter] Cooke RP, et al. **BMJ** 1996 Aug 24; 313(7055):490; discussion 490–1

The administration regimen of isepamicin in patients with chronic respiratory tract infection. Hara K, et al. **Chemotherapy** 1995 Nov–Dec;41(6):462–9

Persistence of bacteria on antibiotic loaded acrylic depots. A reason for caution. Kendall RW, et al. **Clin Orthop** 1996 Aug;(329):273–80

Mycobacterium chelonae keratitis: resolution after debridement and presoaked collagen shields. Lois N, et al. **Cornea** 1995 Sep;14(5):536–9

Once-daily dosing of aminoglycosides. Blaser J, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec;14(12):1029–38

Easier monitoring of aminoglycoside therapy with once-daily dosing schedules. Prins JM, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):531–5

The treatment of bacterial vaginosis with a 3 day course of 2% clindamycin cream: results of a multicentre, double blind, placebo controlled trial. B V Investigators Group. Ahmed-Jushuf IH, et al. **Genitourin Med** 1995 Aug; 71(4):254–6

Influence of intraperitoneal gentamicin on peritoneal transport in IPD patients. Janicka L, et al. **Int Urol Nephrol** 1995;27(2):215–21

Efficacy of an intraperitoneal antibiotic to reduce the incidence of infection in the trauma patient: a prospective, randomized study. Yelon JA, et al. **J Am Coll Surg** 1996 Jun;182(6):509–14

Use of antibiotic-impregnated polymethyl methacrylate for treatment of an open radial fracture in a horse. Schneider RK, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1454–7

A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. Munckhof WJ, et al. **J Antimicrob Chemother** 1996 Apr;37(4):645–63

Once-daily versus multiple-daily dosing of aminoglycosides. Craig WA. **J Chemother** 1995 Jun;7 Suppl 2:47–52 (22 ref.)

Once-daily tobramycin therapy in lower respiratory tract infections. Grassi C, et al. **J Chemother** 1995 Aug;7(4):371–9

Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections. Paradisi F, et al. **J Chemother** 1995 Aug;7(4):338–43 (54 ref.)

Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy. Periti P. **J Chemother** 1995 Aug;7(4):311–37 (184 ref.)

Hematogenous osteomyelitis of the calcaneus in children: surgical treatment and use of implanted antibiotic beads. Kelsey R, et al. **J Foot Ankle Surg** 1995 Nov–Dec; 34(6):547–55; discussion 594 (26 ref.)

Per-operative antibiotic/steroid prophylaxis of tympanostomy tube otorrhoea: chemical or mechanical effect? Shinkwin CA, et al. **J Laryngol Otol** 1996 Jun; 110(6):531–3

Antibiotic treatment for infective endocarditis [letter; comment] Schwartz SN. **JAMA** 1996 Mar 27;275(12):911 . Comment on: JAMA 1995 Dec 6;274(21):1706–13.

Meta-analysis: the final answer, or even more confusion? [letter] Prins JM, et al. **Lancet** 1996 Jul 20;348(9021):199

Aminoglycoside dosing: one, two or three times a day? [see comments] McLean AJ, et al. **Med J Aust** 1996 Jan 1; 164(1):39–42 (54 ref.). Comment in: Med J Aust 1996 May 20;164(10):636–7.

Once-daily aminoglycoside dosing [letter; comment] Millar JA. **Med J Aust** 1996 May 20;164(10):636–7. Comment on: Med J Aust 1996 Jan 1;164(1):39–42.

A comparison of once-daily and 8-hour gentamicin dosing in the treatment of postpartum endometritis. Del Priore G, et al. **Obstet Gynecol** 1996 Jun;87(6):994–1000

Amikacin administration in open heart surgery. Oto O, et al. **Panminerva Med** 1995 Jun;37(2):65–7

Effects of streptozotocin-induced diabetes on postpneumonectomy lung growth and connective tissue levels. Ofulue AF, et al. **Pediatr Pulmonol** 1995 Jun; 19(6):365–70 (29 ref.)

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Wood PJ, et al. **Thorax** 1996 Apr; 51(4):369–73

Treatment of intrasynovial infection with gentamicin-impregnated polymethylmethacrylate beads. Butson RJ, et al. **Vet Rec** 1996 May 11;138(19):460–4

[Gentamicin skin ointment: 200 kilos too much (published erratum appears in Ned Tijdschr Geneeskd 1995 Dec 30;139(52):2768)] Renders NH, et al. **Ned Tijdschr Geneeskd** 1995 Nov 11;139(45):2314–6 (Eng. Abstr.) **(Dut)**

[27 years experiences with transtympanic aminoglycoside treatment of Menière's disease] Lange G. **Laryngorhinootologie** 1995 Dec;74(12):720–3 (Eng. Abstr.) **(Ger)**

[Dosing aminoglycosides once a day] Blaser J. **Schweiz Med Wochenschr Suppl** 1996;76:39S–48S (61 ref.) (Eng. Abstr.) **(Ger)**

[Use of selective intestinal decontamination with non-absorbable antibiotics] Müller C, et al. **Z Gastroenterol** 1995 Nov;33(11):685–6 **(Ger)**

[Assessment of gentamicin dosage in patients before planned surgical operation] Andrys I, et al. **Wiad Lek** 1994 Oct; 47(19–20):763–5 (Eng. Abstr.) **(Pol)**

[Prevention and treatment of acute suppurative infection in emergency abdominal surgery] Ashrafov AA, et al. **Klin Khir** 1995;(4):29–31 **(Rus)**

[Endolymphatic therapy in the treatment of patients with acute appendicitis] Komarov NV, et al. **Klin Khir** 1996; (1):18–20 **(Rus)**

[Endolymphatic therapy in the treatment of patients with acute appendicitis] Komarov NV, et al. **Klin Khir** 1996; (1):53 **(Rus)**

[The use of antimicrobial preparations in preventing infectious wound complications after an operation on the kidney and upper urinary tract] Shirshov VA, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):11–3 (Eng. Abstr.) **(Rus)**

[Gentamycin-polymethylmethacrylate in the treatment of osteoarticular panaritium] Mladenović D, et al. **Acta Chir Iugosl** 1991;38(1):113–9 (Eng. Abstr.) **(Scc)**

ADVERSE EFFECTS

Predictive monitoring of high-frequency vestibulo-ocular reflex rehabilitation following gentamicin ototoxicity. O'Leary DP, et al. **Acta Otolaryngol Suppl (Stockh)** 1995; 520 Pt 1:202–4

Aminoglycoside toxicity after sternal wound irrigations [letter] Hernandez JE, et al. **Ann Thorac Surg** 1996 Feb; 61(2):772

Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Sherertz EF. **Arch Dermatol** 1996 Apr;132(4):461, 464 (11 ref.)

N-acetyl-beta-D-glucosaminidase enzymuria as an indicator in monitoring the therapy of some rheumatic diseases with potentially nephrotoxic drugs. Wiland P, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):331–6

Aminoglycoside macular infarction in association with gentamicin-soaked collagen corneal shield [letter] Kanter ED, et al. **Arch Ophthalmol** 1995 Nov;113(11):1359–60

Audiovestibular findings in patients with deafness caused by a mitochondrial susceptibility mutation and precipitated by an inherited nuclear mutation or aminoglycosides. Braverman I, et al. **Arch Otolaryngol Head Neck Surg** 1996 Sep;122(9):1001–4

Neomycin-induced perception deafness following bladder irrigation in patients with end-stage renal disease. Gerharz EW, et al. **Br J Urol** 1995 Oct;76(4):479–81

Toxic effects and drug interactions of antimycobacterial therapy. Chan-Tompkins NH. **Clin Dermatol** 1995 May–Jun;13(3):223–33 (99 ref.)

Effects of two non-steroidal anti-inflammatory drugs (NSAIDs) and gentamicin on renal function [comment] **Clin Sci (Colch)** 1996 Aug;91(2):119. Comment on: Clin Sci (Colch) 1996 Aug;91(2):187–91.

Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium [see comments] Farag MM, et al. **Clin Sci (Colch)** 1996 Aug;91(2):187–91. Comment in: Clin Sci (Colch) 1996 Aug;91(2):119.

Streptozotocin: inherent but not expressed skin sensitizing activity. Ashby J, et al. **Contact Dermatitis** 1995 Sep; 33(3):165–7

Gentamicin nephrotoxicity in humans and animals: some recent research. Ali BH. **Gen Pharmacol** 1995 Nov; 26(7):1477–87 (119 ref.)

Severe anaphylactic reaction to topical administration of framycetin. Proebstle TM, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):429–30

An overview of the safety of isepamicin in adults. Blum D. **J Chemother** 1995 Jun;7 Suppl 2:87–93

Hypermagnesiuria and hypercalciuria in childhood leukemia: an effect of amikacin therapy. Wu B, et al. **J Pediatr Hematol Oncol** 1996 Feb;18(1):86–9

Urinary trehalase activity is a useful marker of renal proximal tubular damage in newborn infants. Sasai-Takedatsu M, et al. **Nephron** 1995;70(4):443–8

Urinary excretion of adenosine deaminase binding protein in neonates treated with tobramycin. Gordjani N, et al. **Pediatr Nephrol** 1995 Aug;9(4):419–22

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Wood PJ, et al. **Thorax** 1996 Apr; 51(4):369–73

[Treatment of ototoxic auditory damage caused by kanamycin with electroacupuncture at different acupoints] Sun D, et al. **Chen Tzu Yen Chiu** 1995;20(3):62–6 (Eng. Abstr.) **(Chi)**

[Toxic retinopathy caused by intravitreal injection of amikacin and vancomycin] Piguet B, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):358–9 (Eng. Abstr.) **(Fre)**

[Aminoglycoside nephrotoxicity and obstructive jaundice (editorial)] Lucena MI, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):457–60 (55 ref.) **(Spa)**

ANALYSIS

Determination of neomycin sulfate by liquid chromatography with pulsed electrochemical detection. Adams E, et al. **J Chromatogr A** 1996 Aug 16;741(2):233–40

The analysis of aminoglycoside antibiotics by capillary electrophoresis. Flurer CL. **J Pharm Biomed Anal** 1995 Jun;13(7):809–16

ANTAGONISTS & INHIBITORS

The influence of proline analogs on bleomycin–induced lung injury in rats. Ledwożyw A. **Acta Physiol Hung** 1995; 83(2):195–202

The effect of betaine accumulation by Escherichia coli K–12 on aminoglycoside activity [letter] Peddie BA, et al. **J Antimicrob Chemother** 1996 Feb;37(2):396–7

BIOSYNTHESIS

Aminoglycosides and aminocyclitols (other than streptomycin). Hotta K, et al. **Biotechnology** 1995;28:571–95 (82 ref.)

Streptomycin and related aminoglycosides. Piepersberg W. **Biotechnology** 1995;28:531–70 (179 ref.)

Production and isolation of two novel esperamicins in a chemically defined medium. Lam KS, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1497–501

Cloning and heterologous expression of the entire set of structural genes for nikkomycin synthesis from Streptomyces tendae Tü901 in Streptomyces lividans. Bormann C, et al. **J Bacteriol** 1996 Feb;178(4):1216–8

The biosynthetic pathway of the aminonucleoside antibiotic puromycin, as deduced from the molecular analysis of the pur cluster of Streptomyces alboniger. Tercero JA, et al. **J Biol Chem** 1996 Jan 19;271(3):1579–90

BLOOD

Comment: fluorescein as a circulation determinant [letter] Toler SM. **Ann Pharmacother** 1995 Oct;29(10):1052

Evaluation of plasmapheresis on the removal of tobramycin. Kale–Pradhan PB, et al. **Pharmacotherapy** 1995 Sep–Oct; 15(5):673–6

Prospective evaluation of a dose prediction algorithm for intravenous tobramycin in adolescent and adult patients with cystic fibrosis. Touw DJ, et al. **Ther Drug Monit** 1996 Apr;18(2):118–23

Evaluation of a fluorescence polarographic immunoassay with increased sensitivity for measurement of low concentrations of tobramycin in serum. Touw DJ, et al. **Ther Drug Monit** 1996 Apr;18(2):189–93

[Aminoglycosides] Kubo H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:998–1001 (11 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Synthesis of N–acetylglucosaminyl asparagine–substituted puromycin analogues. Kirsch P, et al. **Bioorg Med Chem** 1995 Dec;3(12):1631–6

Novel aminocyclitol antibiotics derived from natural carbohydrates. Pelyvás IF, et al. **Carbohydr Res** 1995 Aug 11;272(2):C5–9

Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. Kotretsou S, et al. **J Med Chem** 1995 Nov 10; 38(23):4710–9

CHEMISTRY

Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Priuska EM, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1749–52

Structural distortions induced by integration host factor (IHF) at the H' site of phage lambda probed by (+)–CC–1065, pluramycin, and KMnO4 and by DNA cyclization studies. Sun D, et al. **Biochemistry** 1996 Aug 20;35(33):10815–27

Streptomycin and related aminoglycosides. Piepersberg W. **Biotechnology** 1995;28:531–70 (179 ref.)

Synthesis of 5–deoxy–5–epifluoro derivatives of arbekacin, amikacin, and 1–N–[(S)–4–amino–2–hydroxybutanoyl]tobramycin (study on structure—toxicity relationships). Shitara T, et al. **Carbohydr Res** 1995 Oct 16;276(1):75–89

The enediyne antibiotics. Smith AL, et al. **J Med Chem** 1996 May 24;39(11):2103–17 (130 ref.)

A comparative study of the visible light photochemistry of gilvocarcins V and M. Alegría AE, et al. **Photochem Photobiol** 1995 Sep;62(3):409–15

Calicheamicin–DNA complexes: warhead alignment and saccharide recognition of the minor groove. Ikemoto N, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10506–10

Sequence–selective carbohydrate–DNA interaction: dimeric and monomeric forms of the calicheamicin oligosaccharide interfere with transcription factor function. Liu C, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):940–4

ECONOMICS

Pharmacoeconomic evaluation of once–daily aminoglycoside treatment. Periti P. **J Chemother** 1995 Aug;7(4):380–94 (137 ref.)

[New modalities of administration of amikacin: economic point of view of a hospital pharmacist] Charpiat B, et al. **Pathol Biol (Paris)** 1996 Feb;44(2):141–4 (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

Enzymatic 2'–N–acetylation of arbekacin and antibiotic activity of its product. Hotta K, et al. **J Antibiot (Tokyo)** 1996 May;49(5):458–64

BE–29602, a new member of the Papulacandin family. Okada H, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):103–6

METABOLISM

In vitro selection analysis of neomycin binding RNAs with a mutagenized pool of variants of the 16S rRNA decoding region. Famulok M, et al. **Biochemistry** 1996 Apr 9; 35(14):4265–70

Structural investigation of the antibiotic and ATP–binding sites in kanamycin nucleotidyltransferase. Pedersen LC, et al. **Biochemistry** 1995 Oct 17;34(41):13305–11

PHARMACOKINETICS

Aminoglycoside pharmacokinetics in Alaskan natives. McAndrews KL Jr, et al. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2015–8

Comparison of once–daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Koo J, et al. **Am J Med** 1996 Aug;101(2):177–83

Comment: pharmacokinetic variability of aminoglycosides [letter; comment] Colucci RD, et al. **Ann Pharmacother** 1995 Sep;29(9):939–40. Comment on: Ann Pharmacother 1995 Feb;29(2):117–9.

Pharmacokinetics of amikacin in children with kwashiorkor. Hendricks MK, et al. **Ann Trop Paediatr** 1995 Dec; 15(4):295–8

Pharmacokinetics and metabolism of 14C–isepamicin in humans following intravenous administration. Lin C, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2201–3

Population pharmacokinetic study of isepamicin with intensive care unit patients. Tod M, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):983–7

Pharmacokinetics of gentamicin following single–dose parenteral administration to goats. Garg SK, et al. **Br Vet J** 1995 Jul–Aug;151(4):453–8

Tissue and serum concentrations of amikacin after intramuscular and intrauterine administration to mares in estrus. Orsini JA, et al. **Can Vet J** 1996 Mar;37(3):157–60

Disposition kinetics of dibekacin in patients with renal failure and in patients undergoing hemodialysis. Arancibia A, et al. **Int J Clin Pharmacol Ther** 1995 Nov;33(11):623–7

Aminoglycoside pharmacokinetics and –dynamics: a nonlinear approach. Czock D, et al. **Int J Clin Pharmacol Ther** 1995 Oct;33(10):537–9

Pharmacokinetics of isepamicin. Barr WH, et al. **J Chemother** 1995 Jun;7 Suppl 2:53–61 (46 ref.)

Tissue penetration and pulmonary disposition of tobramycin. Mazzei T, et al. **J Chemother** 1995 Aug;7(4):363–70

Preclinical and clinical evaluation of once–daily aminoglycoside chemotherapy. Periti P. **J Chemother** 1995 Aug;7(4):311–37 (184 ref.)

Pharmacokinetics of isepamicin in paediatric patients. Scaglione F, et al. **J Chemother** 1995 Jun;7 Suppl 2:63–9

Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. Ronchera–Oms CL, et al. **J Clin Pharm Ther** 1995 Oct; 20(5):253–8

Single and multiple dose pharmacokinetics of gentamicin administered intravenously and intramuscularly in adult conditioned thoroughbred mares. Swan GE, et al. **J S Afr Vet Assoc** 1995 Sep;66(3):151–6

A randomized prospective comparison of antibiotic tissue levels in the corpora cavernosa of patients undergoing penile prosthesis implantation using gentamicin plus cefazolin versus an oral fluoroquinolone for prophylaxis. Schwartz BF, et al. **J Urol** 1996 Sep;156(3):991–4

Gentamicin pharmacokinetics in newborn and 42–day–old male piglets. Giroux D, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):407–12

Depletion of gentamicin in the milk of Holstein cows after single and repeated intramammary and parenteral treatments. Pedersoli WM, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):457–63

Serum and milk concentrations of apramycin in lactating cows, ewes and goats. Ziv G, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):346–51

Ocular availability of gentamicin in small animals after topical administration of a conventional eye drop solution and a novel long acting bioadhesive ophthalmic drug insert. Gurtler F, et al. **Pharm Res** 1995 Nov;12(11):1791–5

The effects of age and chemotherapy on gentamicin pharmacokinetics and dosing in pediatric oncology patients. Ho KK, et al. **Pharmacotherapy** 1995 Nov–Dec; 15(6):754–64

[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis] Cotera A, et al. **Rev Med Chil** 1995 Jun;123(6):742–8 (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Application of exponential smoothing for nosocomial infection surveillance. Ngo L, et al. **Am J Epidemiol** 1996 Mar 15;143(6):637–47

The effect of neomycin on organotypic cultures of the adult guinea–pig utricle. Quint E, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:683–5

Use of decimal assay for additivity to demonstrate synergy in pair combinations of econazole, nikkomycin Z, and ibuprofen against Candida albicans in vitro. Tariq VN, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2615–9

Inhibition of PDGF–induced phosphoinositide–turnover by glucopiericidin A. Ahn SC, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):125–32

High–ionic strength interference of ribosomal inhibition produced by aminoglycoside antibiotics. Marín I, et al. **Biochemistry** 1995 Dec 19;34(50):16519–23

Influence of elsamicin A on the activity of mammalian topoisomerase I. Rodríguez–Campos A, et al. **Biochemistry** 1996 Aug 27;35(34):11177–82

New insights into calicheamicin–DNA interactions derived from a model nucleosome system. Yu L, et al. **Bioorg Med Chem** 1995 Jun;3(6):729–41

Morphological indications of hair cell neodifferentiation in the organ of Corti of amikacin treated rat pups. Lenoir M, et al. **C R Acad Sci III** 1996 Apr;319(4):269–76

Aminoglycoside antibiotics prevent the formation of non–bilayer structures in negatively–charged membranes. Comparative studies using fusogenic (bis(beta–diethylaminoethylether)hexestrol) and aggregating (spermine) agents. van Bambeke F, et al. **Chem Phys Lipids** 1996 Mar 29;79(2):123–35

Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa. Gerçeker AA, et al. **Chemotherapy** 1995 Nov–Dec;41(6):433–6

Gentamicin– and methicillin–resistant Staphylococcus aureus: phenotypic and genotypic characterization of three putative nosocomial outbreak strains. Traub WH, et al. **Chemotherapy** 1996 Jan–Feb;42(1):21–36

High–level gentamicin resistance among enterococci. Sahm DF, et al. **Dev Biol Stand** 1995;85:99–105

Mechanism of amikacin resistance in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Hurley JC, et al. **Diagn Microbiol Infect Dis** 1995 Aug; 22(4):331–6

Interaction of gentamycin and atracurium in anaesthetised horses. Hildebrand SV, et al. **Equine Vet J** 1994 May; 26(3):209–11

Detection of aminoglycoside–penicillin synergy against Enterococcus faecium using high–content aminoglycoside disks. Torres C, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):878–82

Brain enzyme activities after intracerebroventricular injection of streptozotocin in rats receiving acetyl–L–carnitine. Terwel D, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):65–71

Induction of p53–independent apoptosis by hygromycin B: suppression by Bcl–2 and adenovirus E1B 19–kDa protein. Chen G, et al. **Exp Cell Res** 1995 Nov;221(1):55–9

Sensitivity of fungi to nikkomycin Z. Tariq VN, et al. **Fungal Genet Biol** 1996 Mar;20(1):4–11

Determination of high level resistance to aminoglycosides among enterococci. Cherian BP, et al. **Indian J Med Res** 1995 Dec;102:255–7

Incidence and mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa serotype O11 isolates. Kettner M, et al. **Infection** 1995 Nov–Dec;23(6):380–3

In vitro effects of aminoglycosides and fluoroquinolones on keratocytes. Seitz B, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):656–65

Enzymatic 2'–N–acetylation of arbekacin and antibiotic activity of its product. Hotta K, et al. **J Antibiot (Tokyo)** 1996 May;49(5):458–64

Characterization of a cinodine–resistant mutant of Escherichia coli. Osburne MS. **J Antibiot (Tokyo)** 1995 Nov;48(11):1359–61

Bactericidal in–vitro activity of beta–lactams and beta–lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. Joly–Guillou ML, et al. **J Antimicrob Chemother** 1995 Oct;36(4):619–29

Detection of high– and moderately high–level resistance to gentamicin and streptomycin in Enterococcus faecium by a disc diffusion method. Lopardo H, et al. **J Antimicrob Chemother** 1995 Jul;36(1):237–40

Lack of bactericidal effect of antibiotics except aminoglycosides on Bartonella (Rochalimaea) henselae. Musso D, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):101–8

Incorporation, release and in–vitro antibacterial activity of liposomal aminoglycosides against Pseudomonas aeruginosa. Omri A, et al. **J Antimicrob Chemother** 1995 Oct;36(4):631–9

Temperature–dependent aminoglycoside resistance in

Stenotrophomonas (Xanthomonas) maltophilia; alterations in protein and lipopolysaccharide with growth temperature. Rahmati-Bahram A, et al. **J Antimicrob Chemother** 1996 Apr;37(4):665-76

The role of oxygen limitation in the resistance of agar-entrapped, sessile-like Escherichia coli to aminoglycosides and beta-lactam antibiotics. Tresse O, et al. **J Antimicrob Chemother** 1995 Sep;36(3):521-6

Unorthodox antibiotic combinations including ciprofloxacin against high-level gentamicin resistant enterococci. Tripodi MF, et al. **J Antimicrob Chemother** 1996 Apr;37(4):727-36

Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin. Urban C, et al. **J Antimicrob Chemother** 1996 Feb;37(2):361-4

Minimum inhibitory concentrations of intestinal Escherichia coli from broiler chickens after oral administration of apramycin. Kobe A, et al. **J Appl Bacteriol** 1996 Jan; 80(1):26-30

Sensitivity of ribosomes of the hyperthermophilic bacterium Aquifex pyrophilus to aminoglycoside antibiotics. Bocchetta M, et al. **J Bacteriol** 1996 Mar;178(6):1762-5

Papulacandin B resistance in budding and fission yeasts: isolation and characterization of a gene involved in (1,3)beta-D-glucan synthesis in Saccharomyces cerevisiae. Castro C, et al. **J Bacteriol** 1995 Oct;177(20):5732-9

Phosphatidylinositol phospholipase C is activated allosterically by the aminoglycoside G418. 2-deoxy-2-fluoro-scyllo-inositol-1-O-dodecylphosphonate and its analogs inhibit glycosylphosphatidylinositol phospholipase C. Morris JC, et al. **J Biol Chem** 1996 Jun 28;271(26):15468-77

Streptolydigin-resistant mutants in an evolutionarily conserved region of the beta' subunit of Escherichia coli RNA polymerase. Severinov K, et al. **J Biol Chem** 1995 Oct 13;270(41):23926-9

Streptolydigin resistance can be conferred by alterations to either the beta or beta' subunits of Bacillus subtilis RNA polymerase. Yang X, et al. **J Biol Chem** 1995 Oct 13; 270(41):23930-3

The most frequently occurring aminoglycoside resistance mechanisms--combined results of surveys in eight regions of the world. The Aminoglycoside Resistance Study Groups. **J Chemother** 1995 Jun;7 Suppl 2:17-30

Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. Jones RN. **J Chemother** 1995 Jun;7 Suppl 2:7-16 (39 ref.)

The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin--a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups. Miller GH, et al. **J Chemother** 1995 Jun;7 Suppl 2:31-44

In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin. Novelli A, et al. **J Chemother** 1995 Aug;7(4):355-62

Multilaboratory evaluation of screening methods for detection of high-level aminoglycoside resistance in enterococci. National Committee for Clinical Laboratory Standards Study Group on Enterococci. Swenson JM, et al. **J Clin Microbiol** 1995 Nov;33(11):3008-18

Molecular characterization and multilaboratory evaluation of Enterococcus faecalis ATCC 51299 for quality control of screening tests for vancomycin and high-level aminoglycoside resistance in enterococci. Swenson JM, et al. **J Clin Microbiol** 1995 Nov;33(11):3019-21

Colonization of streptomycin-treated mice by Aeromonas species. Sanderson K, et al. **J Diarrhoeal Dis Res** 1996 Mar; 14(1):27-32

A novel plasmid from Staphylococcus epidermidis specifying resistance to kanamycin, neomycin and tetracycline. Schwarz S, et al. **J Med Microbiol** 1996 Jul;45(1):57-63

Inhibition of the self-cleavage reaction of the human hepatitis delta virus ribozyme by antibiotics. Rogers J, et al. **J Mol Biol** 1996 Jun 28;259(5):916-25

Bone toxicity of locally applied aminoglycosides. Miclau T, et al. **J Orthop Trauma** 1995;9(5):401-6

Neomycin selectively inhibits 5-hydroxytryptamine-induced contraction in the guinea pig trachea. Cox DA, et al. **J Pharmacol Exp Ther** 1996 May;277(2):954-9

Effect of repeated administrations of neomycin on the neuromuscular functions and the enhancement of d-tubocurarine action in mice. Tsusaki H, et al. **J Toxicol Sci** 1995 Sep;20(4):395-400

In vitro activity of imipenem and six other beta-lactam antibiotics against aminoglycoside resistant gram-negative bacilli. Bujdáková H, et al. **Microbios** 1995;84(339):87-90

Transformation of the cultivated mushroom, Agaricus bisporus, to hygromycin B resistance. van de Rhee MD, et al. **Mol Gen Genet** 1996 Feb 25;250(3):252-8

Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations [see comments] Howard M, et al. **Nat Med** 1996 Apr;2(4):467-9. Comment in: Nat Med 1996 Apr;2(4):392-3. Comment in: Nat Med 1996 Jun;2(6):608-9.

Ultrastructural changes in water-clear cells of the golden hamster parathyroid gland after streptozotocin treatment. Emura S, et al. **Okajimas Folia Anat Jpn** 1996 May; 73(1):7-13

Antibiotic supplementation of intraocular irrigating solutions. An in vitro model of antibacterial action. Gritz DC, et al. **Ophthalmology** 1996 Aug;103(8):1204-8; discussion 1208-9

Antibacterial activity of liposomal amikacin against Pseudomonas aeruginosa in vitro. Antos M, et al. **Pharmacol Res** 1995 Jul-Aug;32(1-2):85-7

Isolation and in vitro antibacterial screening of a tricarboxylic acid anhydride from Penicillium sp. Jabbar A, et al. **Pharmazie** 1995 Oct;50(10):706-7

Aminoglycosides and polyamines: targets and effects in the mammalian organism of two important groups of natural aliphatic polycations. Seiler N, et al. **Prog Drug Res** 1996; 46:183-241 (610 ref.)

Antimicrobial susceptibility patterns and high-level gentamicin resistance among enterococci isolated in a Mexican tertiary care center. Sifuentes-Osornio J, et al. **Rev Invest Clin** 1996 Mar-Apr;48(2):91-6

[Gentamicin skin ointment: 200 kilos too much (letter)] Smit F. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):279 **(Dut)**

[Staphylococcus aureus resistant to methicillin. Survey of prevalence in Yvelines hospitals] Bérardi-Grassias L, et al. **Pathol Biol (Paris)** 1996 May;44(5):411-5 (Eng. Abstr.) **(Fre)**

[Comparative susceptibility of Ochrobactrum anthropi, Agrobacterium tumefaciens, Alcaligenes faecalis, Alcaligenes denitrificans subsp. denitrificans, Alcaligenes denitrificans subsp. xylosidans and Bordetella bronchiseptica against 35 antibiotics including 17 beta-lactams] Bizet C, et al. **Pathol Biol (Paris)** 1995 Apr; 43(4):258-63 (Eng. Abstr.) **(Fre)**

[Kinetics of bactericidal activity of cefepime and cefpirome alone or combined with gentamicin, amikacin or ciprofloxacin against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae hyperproductive in cephalosporinase] Elkhaïli H, et al. **Pathol Biol (Paris)** 1996 May;44(5):367-73 (Eng. Abstr.) **(Fre)**

[Evaluation of hearing loss by means of inner ear acoustic emission in neonates treated with aminoglycoside] Révai K, et al. **Orv Hetil** 1995 Nov 26;136(48):2615-8 (Eng. Abstr.) **(Hun)**

[Formation of clone cells resistant to G418 and not containing human chromosomes as a result of somatic hybridization of cell line A9 with human fibroblasts transfected with pSV2neo] Lupatov AIu, et al. **Dokl Akad Nauk** 1996 Mar; 347(2):264-7 **(Rus)**

[Enzymatic mechanisms of resistance to aminoglycoside antibiotics in gram negative bacilli from Chilean hospitals] Del Solar E, et al. **Rev Med Chil** 1995 Mar;123(3):293-7 (Eng. Abstr.) **(Spa)**

[Pattern of antimicrobial susceptibility of enterococci strains] Hoyos A, et al. **Rev Med Chil** 1995 Apr;123(4):473-8 (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

A comparative study of the visible light photochemistry of gilvocarcins V and M. Alegría AE, et al. **Photochem Photobiol** 1995 Sep;62(3):409-15

THERAPEUTIC USE

Prospective trial of paromomycin for cryptosporidiosis in AIDS. Flanigan TP, et al. **Am J Med** 1996 Mar; 100(3):370-2

In vitro susceptibility of aural isolates of Pseudomonas aeruginosa to commonly used ototopical antibiotics. Dohar JE, et al. **Am J Otol** 1996 Mar;17(2):207-9

Long-term results of low dose intramuscular streptomycin for Menière's disease. Shea JJ, et al. **Am J Otol** 1994 Jul; 15(4):540-4

A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Asilian A, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):648-51

Effect of phenylbutazone and flunixin meglumine on acute toxic mastitis in dairy cows. Dascanio JJ, et al. **Am J Vet Res** 1995 Sep;56(9):1213-8

Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Perdikaris G, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2289-94

Lipid-based slow-release formulation of amikacin sulfate reduces foreign body-associated infections in mice. Roehrborn AA, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1752-5

Evaluation of high-dose regimen of paromomycin against cryptosporidiosis in the dexamethasone-treated rat model. Verdon R, et al. **Antimicrob Agents Chemother** 1995 Sep; 39(9):2155-7

Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group [see comments] **Arch Ophthalmol** 1995 Dec; 113(12):1479-96. Comment in: Arch Ophthalmol 1995 Dec;113(12):1555-7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1025; discussion 1026-7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1025-6; discussion 1026-7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1027-8; discussion 1028-9. Comment in: Arch Ophthalmol 1996 Aug;114(8):1029; discussion 1028-9, 1030. Comment in: Arch Ophthalmol 1996 Aug;114(8):1029-30; discussion 1028-9.

Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis [letter] Baker RS, et al. **Arch Ophthalmol** 1996 May;114(5):632-3

Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. O'Brien TP, et al. **Arch Ophthalmol** 1995 Oct;113(10):1257-65

Diagnosis and treatment of nosocomial pneumonia. Bonten MJ, et al. **Br J Hosp Med** 1995 Oct 4-17;54(7):335-40 (25 ref.)

Renal effect of gentamicin in diabetic rats. Martinez BB, et al. **Braz J Med Biol Res** 1995 Jul;28(7):801-4

Treating patients who have Klebsiella pneumoniae pneumonia [letter; comment] Feldman C, et al. **Chest** 1996 Feb;109(2):587-8. Comment on: Chest 1995 Jan;107(1):214-7.

Efficacy of topical gentamicin treatment after 193-nm photorefractive keratectomy in an experimental Pseudomonas keratitis model. Frucht-Pery J, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Aug;233(8):532-4

Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. Berne TV, et al. **J Am Coll Surg** 1996 May; 182(5):403-7

Prospective audit of costs and outcome of aminoglycoside treatment and of therapy for gram-negative bacteraemia. Davey PG, et al. **J Antimicrob Chemother** 1995 Sep; 36(3):561-75

Elimination of bacteraemia after dental extraction: comparison of erythromycin and clindamycin for prophylaxis of infective endocarditis. Hall G, et al. **J Antimicrob Chemother** 1996 Apr;37(4):783-95

A prospective laboratory-based audit of gentamicin use and therapeutic monitoring. Saunders NJ, et al. **J Antimicrob Chemother** 1995 Oct;36(4):729-36

Isepamicin Once a Day--Enhancing Traditional Aminoglycoside Therapy. Proceedings of a meeting. Rotherwick, England, September 24-25, 1994. **J Chemother** 1995 Jun;7 Suppl 2:1-173

The role of aminoglycosides in modern therapy. Beaucaire G. **J Chemother** 1995 Jun;7 Suppl 2:111-23 (58 ref.)

Overview of the efficacy of isepamicin in the adult core clinical trial programme. Carbon C. **J Chemother** 1995 Jun; 7 Suppl 2:79-85

The place of tobramycin in lower respiratory tract infections (LRTI). Gialdroni Grassi G. **J Chemother** 1995 Aug; 7(4):344-54 (80 ref.)

The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections. Leal del Rosal P. **J Chemother** 1995 Jun;7 Suppl 2:143-8

Evaluation of the efficacy and safety of isepamicin in the treatment of various bacterial infections. Petrikkos G, et al. **J Chemother** 1995 Jun;7 Suppl 2:161-4

Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections. Rodriguez-Noriega E, et al. **J Chemother** 1995 Jun;7 Suppl 2:155-60

Isepamicin versus amikacin in the treatment of urinary tract infection. Sturm W. **J Chemother** 1995 Jun;7 Suppl 2:149-54

A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients. Viganò A, et al. **J Chemother** 1995 Jun;7 Suppl 2:95-101

A new breakthrough in treatment of visceral leishmaniasis in children. Hassan M, et al. **JPMA J Pak Med Assoc** 1995 Jun;45(6):155-7

Effectiveness of once-weekly vancomycin and once-daily gentamicin, intraperitoneally, for CAPD peritonitis [see comments] Bailie GR, et al. **Perit Dial Int** 1995 Jul-Sep; 15(6):269-71. Comment in: Perit Dial Int 1995 Jul-Sep;15(6):201-2.

Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective. Benson CA. **Res Microbiol** 1996 Jan-Feb;147(1-2):16-24 (43 ref.)

Treatment of infections caused by rapidly growing mycobacteria in the era of the newer macrolides. Wallace RJ Jr. **Res Microbiol** 1996 Jan-Feb;147(1-2):30-5 (34 ref.)

Use of aminoglycosides: the Swiss consensus. Swiss Society of Infectious Diseases. **Schweiz Med Wochenschr Suppl** 1996;76:5S-52S (0 ref.)

The use of aminoglycosides in neutropenic patients. Cometta A, et al. **Schweiz Med Wochenschr Suppl** 1996;76:21S-27S (10 ref.)

[Personal experience with Garamycin Schwamm in routine surgical practice] Vít P. **Rozhl Chir** 1996 Feb;75(2):81-2 (Eng. Abstr.) **(Cze)**

[Replacement of infected total hip prosthesis in two stages] Lenoble E, et al. **Int Orthop** 1995;19(3):151-6 (Eng. Abstr.) **(Fre)**

[Antibiotic prophylaxis in urology] Botto H. **Presse Med** 1995 Oct 28;24(32):1491-3 (Eng. Abstr.) **(Fre)**

[Treatment of severe infections: should one always administer an aminoglycoside?] Cometta A, et al. **Schweiz Med Wochenschr Suppl** 1996;76:28S-33S (30 ref.) (Eng. Abstr.) **(Fre)**

[The use of aminoglycosides in Swiss university hospitals] Sudre P, et al. **Schweiz Med Wochenschr Suppl** 1996; 76:9S-13S (Eng. Abstr.) **(Fre)**

[Intestinal cryptosporidiosis in HIV infection: clinical features, course and therapy] Günthard M, et al. **Dtsch Med Wochenschr** 1996 May 24;121(21):686-92 (Eng. Abstr.) **(Ger)**

[Aminoglycosides in the treatment of infectious endocarditis] Malinverni R. **Schweiz Med Wochenschr Suppl** 1996; 76:14S-20S (41 ref.) (Eng. Abstr.) **(Ger)**

ANTIBIOTICS, AMINOGLYCOSIDE

[The role of aminoglycosides in HIV-infected patients] Opravil M. **Schweiz Med Wochenschr Suppl** 1996; 76:49S-53S (27 ref.) (Eng. Abstr.) **(Ger)**

[Aminoglycosides in pediatrics] Schaad UB. **Schweiz Med Wochenschr Suppl** 1996;76:34S-38S (23 ref.) (Eng. Abstr.) **(Ger)**

[Retrospective study of sputum culture after esophagectomy] Minamiya Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1138-44 (Eng. Abstr.) **(Jpn)**

[The treatment of cryptosporidiosis in AIDS patients using paromomycin] Stefani HN, et al. **Rev Soc Bras Med Trop** 1996 Jul-Aug;29(4):355-7 (Eng. Abstr.) **(Por)**

[Effect of drugs of various groups on the course of experimental local pyo-inflammatory processes] Men'shikov DD, et al. **Antibiot Khimioter** 1995 Oct; 40(10):30-5 (Eng. Abstr.) **(Rus)**

[Amikacin in single daily doses in children with fever] Solórzano-Santos F, et al. **Rev Invest Clin** 1996 Jan-Feb; 48(1):13-8 (Eng. Abstr.) **(Spa)**

[Antibiotic prophylaxis suppurative infections of the foot in patients with diabetes mellitus] Shidlovs'kiĭ VO, et al. **Klin Khir** 1996;(1):20-2 **(Ukr)**

TOXICITY

Comparison of gentamicin nephrotoxicity between rats and mice. Suzuki S, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Sep;112(1):15-28

Effects of kanamycin ototoxicity and hair cell regeneration on the DC endocochlear potential in adult chickens. Chen L, et al. **Hear Res** 1995 Sep;89(1-2):28-34

Base-to-apex gradient of cell proliferation in the chick cochlea following kanamycin-induced hair cell loss. Hashino E, et al. **Hear Res** 1995 Aug;88(1-2):156-68

Avian cochlear hair cell regeneration: stereological analyses of damage and recovery from a single high dose of gentamicin. Janas JD, et al. **Hear Res** 1995 Dec; 92(1-2):17-29

Glutathione protection against gentamicin ototoxicity depends on nutritional status. Lautermann J, et al. **Hear Res** 1995 Jun;86(1-2):15-24

Onset of ototoxicity in the cat is related to onset of auditory function. Shepherd RK, et al. **Hear Res** 1995 Dec; 92(1-2):131-42

Damage and recovery of hair cells in fish canal (but not superficial) neuromasts after gentamicin exposure. Song J, et al. **Hear Res** 1995 Nov;91(1-2):63-71

Histological evidence for hair cell regeneration after ototoxic cell destruction with local application of gentamicin in the chinchilla crista ampullaris. Tanyeri H, et al. **Hear Res** 1995 Sep;89(1-2):194-202

Effects of fish oil and sunflower oil supplementations on gentamicin-induced nephrotoxicity in rat. Abdel-Gayoum AA, et al. **Hum Exp Toxicol** 1995 Nov;14(11):884-8

Gentamicin nephrotoxicity in the rat: influence of age and diabetes mellitus. Ali BH, et al. **Hum Exp Toxicol** 1996 Jan;15(1):51-55

Basic fibroblast growth factor (FGF-2) protects rat cochlear hair cells in organotypical culture from aminoglycoside injury. Low W, et al. **J Cell Physiol** 1996 Jun;167(3):443-50

Auditory impairment in guinea pigs treated with isepamicin. Fredelius L, et al. **J Chemother** 1995 Jun;7 Suppl 2:71-6

Pharmacodynamics of subconjunctival gentamicin after experimental cataract operations and traumatic lacerations. Yoshizumi MO, et al. **J Ocul Pharmacol Ther** 1995 Winter; 11(4):519-25

Quantitative study of vestibulotoxicity induced by gentamicin or cisplatin in the guinea pig. Nakayama M, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):162-7

Scanning electron microscopic observation of dark cells after streptomycin perfusion of the vestibule in guinea pigs. Ge X, et al. **Scanning Microsc** 1995 Mar;9(1):283-8

Ototoxicity of tobramycin in young adult and old rats. Dormans JA, et al. **Toxicol Appl Pharmacol** 1996 Jan; 136(1):179-85

Extent and persistence of streptozotocin-induced DNA damage and cell proliferation in rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays. Kraynak AR, et al. **Toxicol Appl Pharmacol** 1995 Dec; 135(2):279-86

Guanidinoacetic acid (GAA) synthesis in rat tubular suspension as a system for evaluating gentamicin (GM) nephrotoxicity. Takeda M, et al. **Toxicol Lett** 1995 Nov 15;81(2-3):85-9

[Glutathione-SH as protection from cytotoxic side-effects of gentamycin. Studies with isolated outer hair cells] Keiner S, et al. **HNO** 1995 Aug;43(8):492-7 (Eng. Abstr.) **(Ger)**

[Reduced nutritional status enhances ototoxicity] Lautermann J, et al. **Laryngorhinootologie** 1995 Dec;74(12):724-7 (Eng. Abstr.) **(Ger)**

[Membrane-active preparations as correctors of the nephrotoxicity of gentamicin] Veshkurtseva IM, et al. **Eksp Klin Farmakol** 1995 Nov-Dec;58(6):36-9 (Eng. Abstr.) **(Rus)**

[A model for the study of the ototoxic effects of drugs in an experiment] Fisenko VP, et al. **Vestn Otorinolaringol** 1996 Jan-Feb;(1):25-8 (Eng. Abstr.) **(Rus)**

ANTIBIOTICS, ANTHRACYCLINE

Reversal of adriamycin resistance with chimeric anti-ganglioside GM2 antibody. Fukumoto H, et al. **Int J Cancer** 1996 Sep 4;67(5):676-80

Expression of MRP and mdr1 in human gastrointestinal cancer cell lines: a correlation with resistance against doxorubicin. Murase M, et al. **J Surg Oncol** 1996 Mar; 61(3):223-9

ADMINISTRATION & DOSAGE

Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study. Andersson H, et al. **Acta Oncol** 1995;34(6):821-7

Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma. Uthayakumar S, et al. **AIDS** 1996 May; 10(5):515-9

A combination of vinblastine and doxorubicin with interferon alpha. Jekunen A, et al. **Am J Clin Oncol** 1996 Aug; 19(4):384-5

Chemotherapy of Mediterranean abdominal lymphoma. Retrospective comparison of chemotherapy protocols in Iranian patients. Salimi M, et al. **Am J Clin Oncol** 1996 Feb;19(1):18-22

Doxorubicin liposome formulation gains marketing approval [news] **Am J Health Syst Pharm** 1996 Jan 15;53(2):116, 119

Epirubicin + G-CSF as peripheral blood progenitor cells (PBPC) mobilising agents in breast cancer patients. Rosti G, et al. **Ann Oncol** 1995 Dec;6(10):1045-7

Isolated lung perfusion with doxorubicin reduces cardiac and host toxicities associated with systemic administration. Ng B, et al. **Ann Thorac Surg** 1996 Mar;61(3):969-72

Endoluminal instillation of epidoxorubicin as adjuvant treatment for upper urinary tract urothelial tumours. Ponchietti R, et al. **Anticancer Res** 1996 Jan-Feb; 16(1):537-9

Antitumor activity of doxorubicin encapsulated in poly(ethylene glycol)-coated liposomes. Hosoda J, et al. **Biol Pharm Bull** 1995 Sep;18(9):1234-7

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Goebel FD, et al. **Br J Cancer** 1996 Apr;73(8):989-94

An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation. Gokhale PC, et al. **Br J Cancer** 1996 Jul; 74(1):43-8

Intravesical instillation of epirubicin: effect on tumour recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour. Igawa M, et al. **Br J Urol** 1996 Mar;77(3):358-62

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [letter; comment] Anand A, et al. **Cancer** 1996 May 1; 77(9):1959-60. Comment on: Cancer 1995 Dec 1;76(11):2230-6.

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [see comments] Shin DM, et al. **Cancer** 1995 Dec 1; 76(11):2230-6. Comment in: Cancer 1996 May 1;77(9):1959-60.

On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Hu YP, et al. **Cancer Chemother Pharmacol** 1996;37(6):556-60

Penetration of intravesical doxorubicin in human bladders. Wientjes MG, et al. **Cancer Chemother Pharmacol** 1996; 37(6):539-46

Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Peterson CM, et al. **Cancer Res** 1996 Sep 1;56(17):3980-5

Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Sakakibara T, et al. **Cancer Res** 1996 Aug 15;56(16):3743-6

Intensification of the conditioning regimen by the addition of anthracyclines results in a higher incidence of sustained molecular remissions after allogeneic bone marrow transplantation for chronic myeloid leukaemia with marrow depleted of lymphocytes by counterflow centrifugation. Schattenberg A, et al. **Cas Lek Cesk** 1996 Apr 17; 135(8):239-43

Pharmacokinetics, targeting and delivery systems in anthracycline-resistant cancers. Cassidy J. **Eur J Cancer** 1995;31A Suppl 7:S18-20 (23 ref.)

Intra-arterial liposomal adriamycin for metastatic adenocarcinoma of the liver. Konno H, et al. **Eur Surg Res** 1995;27(5):301-6

Circumvention of multidrug resistance in neoplastic cells through scavenger receptor mediated drug delivery. Mukhopadhyay A, et al. **FEBS Lett** 1995 Nov 27; 376(1-2):95-8

Liposomal doxorubicin (Doxil). Porche DJ. **J Assoc Nurses AIDS Care** 1996 Mar-Apr;7(2):55-9 (6 ref.)

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. Bastholt L, et al. **J Clin Oncol** 1996 Apr; 14(4):1146-55

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. Gill PS, et al. **J Clin Oncol** 1996 Aug; 14(8):2353-64

Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. Sonneveld P, et al. **J Clin Oncol** 1995 Oct; 13(10):2530-9

Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. Siegal T, et al. **J Neurosurg** 1995 Dec;83(6):1029-37

Pre-, peri-, and postoperative chemotherapy for breast cancer: is one better than the other? Murthy MS, et al. **J Surg Oncol** 1996 Apr;61(4):273-7

Improvement of pharmacokinetics and antitumor activity against human hepatoma cell line by using adriamycin-entrapped stealth liposomes. Shimizu H, et al. **J Surg Oncol** 1996 Jul;62(3):186-93

Response to liposome-encapsulated doxorubicin (TLC D-99) in a dog with myeloma. Kisseberth WC, et al. **J Vet Intern Med** 1995 Nov-Dec;9(6):425-8

Treatment of childhood Hodgkin's disease with ABVD without radiotherapy. Behrendt H, et al. **Med Pediatr Oncol** 1996 Apr;26(4):244-8

Doxorubicin in sterically stabilized liposomes. Lasic DD. **Nature** 1996 Apr 11;380(6574):561-2

The use of bioerodible polymers and daunorubicin in glaucoma filtration surgery. Rabowsky JH, et al. **Ophthalmology** 1996 May;103(5):800-7

Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Dombernowsky P, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):13-7 (14 ref.)

Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Hudis CA, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):18-23

Pharmacokinetic evaluation of percutaneous hepatic venous isolation for administration of regional chemotherapy. August DA, et al. **Surg Oncol** 1995 Aug;4(4):205-16

Percutaneous hepatic venous isolation and extracorporeal charcoal hemoperfusion for high-dose intraarterial chemotherapy in patients with colorectal hepatic metastases. Ku Y, et al. **Surg Today** 1996;26(5):305-13

[Preparation of 125I-F(ab')2-DNR-liposomes and radioimmunoassay of their specific conjugating ability] Liu J, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):383-6 (Eng. Abstr.) **(Chi)**

[A randomized controlled study of maintenance therapy with (2"R)-4'-O-tetrahydropyranyladriamycin for advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in Japan] Enomoto K, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):871-80 (Eng. Abstr.) **(Jpn)**

[Trial of a treatment for lymph node metastases in patients with breast cancer using aclarubicin bound to activated carbon particles] Imanishi T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1635-7 (Eng. Abstr.) **(Jpn)**

[A course of pirarubicin vesical irrigation at thirty mg effectively prevents post-TUR recurrence of superficial bladder cancer] Kawamura S, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):465-70 (Eng. Abstr.) **(Jpn)**

[Preoperative intra-arterial chemotherapy with THP-ADR for locally advanced breast cancer] Mukai S, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1542-5 (Eng. Abstr.) **(Jpn)**

[Efficacy of treatment with frequent and low-dose epirubicin in two cases of pulmonary metastases after surgery of liver cancer] Nakao A, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1831-4 (Eng. Abstr.) **(Jpn)**

[Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma] Ohmori H, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):601-6 (Eng. Abstr.) **(Jpn)**

[Investigation of retention time of intravesical instillation therapy with pirarubicin (THP)] Sugano O, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1169-74 (Eng. Abstr.) **(Jpn)**

[A case of hepatocellular carcinoma treated by intra-arterial infusion chemotherapy using THP-adriamycin] Sunahara M, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1201-4 (Eng. Abstr.) **(Jpn)**

[Neoadjuvant intraarterial chemotherapy with dose intensification in locally advanced breast cancer] Takatsuka Y, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1546-8 (Eng. Abstr.) **(Jpn)**

[A case of multiple liver metastases of breast cancer treated successfully with high-dose intraarterial chemotherapy under hepatic venous isolation and charcoal hemoperfusion (HVI-CHP)] Tominaga M, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1715-8 (Eng. Abstr.) **(Jpn)**

[Effectiveness of liposomal forms of cytostatics] Dranov AL, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):85-8 **(Rus)**

[Functionally sparing surgery in locally spread malignant maxillary tumors and the use of local chemotherapy]

Ol'shanskii VO, et al. **Vestn Otorinolaringol** 1995 Nov-Dec; (6):23-5 (Eng. Abstr.) **(Rus)**

[Effectiveness of free and liposomal forms of platinum and anthracycline antibiotics for hepatic metastasis of GA-1 and P-388 tumors in mice] Kaledin VI, et al. **Vopr Onkol** 1996;42(3):64-6 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Prevention of anthracycline cardiotoxicity by iron chelation. Hershko C, et al. **Acta Haematol** 1996;95(1):87-92 (68 ref.)

Acute myelomonocytic leukaemia with 11q23 abnormality during multiple myeloma: is this related to anthracycline? Matano S, et al. **Acta Haematol** 1996;95(2):144-7

New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy [news] **Am J Health Syst Pharm** 1995 Oct 1;52(19):2076

Effects of dietary protein, angiotensin I converting enzyme inhibition and mesangial overload on the progression of adriamycin-induced nephropathy. Barretti P, et al. **Braz J Med Biol Res** 1995 Jan;28(1):39-50

Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Pihkala J, et al. **Eur J Cancer** 1996 Jan;32A(1):97-103

Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women. Cottin Y, et al. **Eur J Nucl Med** 1996 May;23(5):511-6

Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity. Minotti G, et al. **J Clin Invest** 1996 Aug 1;98(3):650-61

Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. Anderlini P, et al. **J Clin Oncol** 1995 Nov;13(11):2827-34

Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier—sharpens antitumor profile and therapeutic index [editorial] Hellmann K. **J Clin Oncol** 1996 Feb;14(2):332-3

Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children [editorial] Lipshultz SE. **J Clin Oncol** 1996 Feb;14(2):328-31

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. Wexler LH, et al. **J Clin Oncol** 1996 Feb;14(2):362-72

Doxorubicin-induced cardiac neurotoxicity: study with iodine 123-labeled metaiodobenzylguanidine scintigraphy. Lekakis J, et al. **J Nucl Cardiol** 1996 Jan-Feb;3(1):37-41

Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. Carrió I, et al. **J Nucl Med** 1995 Nov;36(11):2044-9

Atrophic nerve fibers in regions of reduced MIBG uptake in doxorubicin cardiomyopathy. Takano H, et al. **J Nucl Med** 1995 Nov;36(11):2060-1

Late echocardiographic findings following childhood chemotherapy with normal serial cardiac monitoring. Johnson GL, et al. **J Pediatr Hematol Oncol** 1996 Feb; 18(1):72-5

Angiotensin-converting enzyme inhibitor for epirubicin-induced dilated cardiomyopathy [letter; comment] Hatake K, et al. **Lancet** 1996 May 25; 347(9013):1485. Comment on: Lancet 1996 Feb 3;347(8997):297-9.

Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy [see comments] Jensen BV, et al. **Lancet** 1996 Feb 3;347(8997):297-9. Comment in: Lancet 1996 May 25;347(9013):1485.

Late cardiotoxicity after treatment for a malignant bone tumor. Postma A, et al. **Med Pediatr Oncol** 1996 Apr; 26(4):230-7

The protective effect of probucol on adriamycin nephrosis in the rat. Futenma A, et al. **Nippon Jinzo Gakkai Shi** 1995 Nov;37(11):616-21

[Evaluation of the cardioprotective effect of bispiperazinedione ICRF-187 (Cardioxane) in patients treated with anthracyclines—an echocardiographic study] Elbl L, et al. **Vnitr Lek** 1996 Apr;42(4):268-73 (Eng. Abstr.) **(Cze)**

[Pediatric aspects of anthracycline cardiotoxicity and practical implications for prevention] Pein F, et al. **Arch Pediatr** 1995 Oct;2(10):988-99 (75 ref.) (Eng. Abstr.) **(Fre)**

[Long-term selective beta 1-blockade therapy for a patient with anthracycline-induced cardiomyopathy] Okamoto M, et al. **Rinsho Ketsueki** 1995 Nov;36(11):1305-10 (Eng. Abstr.) **(Jpn)**

[Acute myocardial infarction after cytostatic therapy] Stolt CM. **Lakartidningen** 1995 Nov 22;92(47):4421-2 **(Swe)**

ANTAGONISTS & INHIBITORS

Effect of H2O2 on adriamycin-induced cytotoxicity in vitro. Anuszewska EL. **Arch Immunol Ther Exp (Warsz)** 1994; 42(4):281-5

Inhibition of doxorubicin-induced cell death in vitro and in vivo by cycloheximide. Furusawa S, et al. **Biol Pharm Bull** 1995 Oct;18(10):1367-72

Protection by selective amino acid solutions against doxorubicin induced growth inhibition of Escherichia coli. Amash HS, et al. **Gen Pharmacol** 1995 Sep;26(5):983-7

BIOSYNTHESIS

Anthracyclines. Hutchinson CR. **Biotechnology** 1995; 28:331-57 (118 ref.)

Cloning, sequencing, and analysis of aklaviketone reductase from Streptomyces sp. strain C5. Dickens ML, et al. **J Bacteriol** 1996 Jun;178(11):3384-8

Production of hybrid anthracycline antibiotics by heterologous expression of Streptomyces nogalater nogalamycin biosynthesis genes. Ylihonko K, et al. **Microbiology** 1996 Aug;142 (Pt 8):1965-72

BLOOD

Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. Mayer LD, et al. **Anal Biochem** 1995 Dec 10;232(2):149-57

CHEMICAL SYNTHESIS

New anthracycline antibiotics 10-epi-oxaunomycin and 10-epi-11-deoxyoxaunomycin. Johdo O, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1153-8

Synthesis and antiproliferative effects of a 4'-morpholino-9-methyl anthracycline. Nafziger J, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1185-7

[14-O-hemiesters and 13-hydrazones of anthracyline antibiotics of the daunorubicin series. Synthesis and cytostatic activity with respect to tumor cells sensitive or resistant to doxorubicin] Povarov LS, et al. **Bioorg Khim** 1995 Dec;21(12):925-32 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Prodrugs of anthracycline antibiotics suited for tumor-specific activation. Azoulay M, et al. **Anticancer Drug Des** 1995 Sep;10(6):441-50

Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains. Shelton CJ, et al. **Biochemistry** 1996 Jun 18;35(24):7974-82

Theoretical study of anthracycline antibiotic analogues—III. Conformational analysis on different 2, 6-dideoxy-2-halo-alpha-l-hexopyranoses by molecular mechanics and semiempirical methods. el Bergmi R, et al. **Bioorg Med Chem** 1996 Feb;4(2):151-63

A proton nuclear magnetic resonance investigation of the conformation of daunomycin. Barthwal R, et al. **Chem Biol Interact** 1996 Mar 25;100(2):125-39

Spectral shape modifications of anthracyclines bound to cell nuclei: a microspectrofluorometric study. Laigle A, et al. **Chem Biol Interact** 1996 Jun;101(1):49-58

Melting profile and temperature dependent binding constant of an anticancer drug daunomycin-DNA complex. Chen YZ, et al. **Eur Biophys J** 1996;24(4):203-12

Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG). Berger I, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4488-94

High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Nagy A, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19; 93(6):2464-9

DIAGNOSTIC USE

Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. Elsinga PH, et al. **J Nucl Med** 1996 Sep;37(9):1571-5

HISTORY

Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry. Takeuchi T. **J Cancer Res Clin Oncol** 1995;121(9-10):505-10 (52 ref.)

IMMUNOLOGY

Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Morelli D, et al. **Cancer Res** 1996 May 1;56(9):2082-5

METABOLISM

Sequence-specific DNA interactions by novel alkylating anthracycline derivatives. Marchini S, et al. **Anticancer Drug Des** 1995 Dec;10(8):641-53

Influence of cell membrane potential, and selectivity of the Na+/H+ exchanger and Cl-/HCO3- exchanger on the intracellular accumulation of adriamycin. Asaumi JI, et al. **Anticancer Res** 1996 Mar-Apr;16(2):725-8

Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells. Bogush T, et al. **Anticancer Res** 1996 Jan-Feb;16(1):365-8

Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms. Urasaki Y, et al. **Anticancer Res** 1996 Mar-Apr; 16(2):709-14

The effect of crown ethers, tetraalkylammonium salts, and polyoxyethylene amphiphiles on pirarubicin incorporation in K562 resistant cells. Borrel MN, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2069-76

The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity. Mülder HS, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):967-74

Parsing the free energy of anthracycline antibiotic binding to DNA. Chaires JB, et al. **Biochemistry** 1996 Feb 20; 35(7):2047-53

Binding of biologically important molecules to DNA, probed using electro-fluorescence polarization spectroscopy. Windsor SA, et al. **Biophys Chem** 1996 Jan 16; 58(1-2):141-50

Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model. Duffy PM, et al. **Br J Urol** 1996 Jun;77(6):819-23

Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study. Duffy PM, et al. **Br J Urol** 1996 Jun;77(6):824-9

Comparison of DNA sequence selectivity of anthracycline antibiotics and their 3'-hydroxylated analogs. Jollès B, et al. **Chem Biol Interact** 1996 Mar 25;100(2):165-76

Spectral shape modifications of anthracyclines bound to cell nuclei: a microspectrofluorometric study. Laigle A, et al. **Chem Biol Interact** 1996 Jun;101(1):49-58

Binding of benanomicin A to fungal cells in reference to its fungicidal action. Watanabe M, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):366-73

Isolation and characterization of a gene from Streptomyces sp. strain C5 that confers the ability to convert daunomycin to doxorubicin on Streptomyces lividans TK24. Dickens ML, et al. **J Bacteriol** 1996 Jun;178(11):3389-95

Re: How does the MRP/GS-X pump export doxorubicin? [letter] Broxterman HJ, et al. **J Natl Cancer Inst** 1996 Apr 3;88(7):466-8

[New anti-HIV drug which binds the oligosaccharides of HIV envelope glycoprotein] Mizuochi T, et al. **Nippon Rinsho** 1995 Sep;53(9):2340-9 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Pulmonary artery perfusion of doxorubicin with blood flow occlusion: pharmacokinetics and treatment in a metastatic sarcoma model. Wang HY, et al. **Ann Thorac Surg** 1995 Nov;60(5):1390-4

FK506 completely inhibits adriamycin efflux in the adriamycin-resistant strain of Ehrlich ascites tumor cells. Asaumi J, et al. **Anticancer Res** 1996 Jan-Feb;16(1):247-50

Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Ross DD, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1673-83

Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Colombo T, et al. **Br J Cancer** 1996 Apr;73(7):866-71

Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. Verovski VN, et al. **Br J Cancer** 1996 Mar;73(5):596-602

Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Webster LK, et al. **Br J Cancer** 1996 Feb;73(4):522-4

Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Dobbs NA, et al. **Cancer Chemother Pharmacol** 1995;36(6):473-6

Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer. Mader RM, et al. **Cancer Chemother Pharmacol** 1995;37(1-2):91-6

Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells. Nagasawa K, et al. **Cancer Chemother Pharmacol** 1996;37(4):297-304

Effects of lipophilicity and protein binding on the hepatocellular uptake and hepatic disposition of two anthracyclines, doxorubicin and iododoxorubicin. Rivory LP, et al. **Cancer Chemother Pharmacol** 1996;38(5):439-45

Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice. Shinkai H, et al. **Cancer Chemother Pharmacol** 1996;38(5):417-24

Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells. Tidefelt U, et al. **Cancer Chemother Pharmacol** 1996;38(5):476-80

Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Baldini N, et al. **Eur J Cell Biol** 1995 Nov;68(3):226-39

Improvement of pharmacokinetics and antitumor activity against human hepatoma cell line by using adriamycin-entrapped stealth liposomes. Shimizu H, et al. **J Surg Oncol** 1996 Jul;62(3):186-93

P170-related multidrug resistance. Enhancement of idarubicin content in leukemic cells with cyclosporin in vivo: a report of two cases [letter] Damiani D, et al. **Leukemia** 1995 Oct;9(10):1792-5

Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Schleyer E, et al. **Leukemia** 1996 Apr;10(4):707-12

Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mankhetkorn S, et al. **Mol Pharmacol** 1996 Mar;49(3):532-9

Kinetic transport analysis of daunorubicin by LoVo and

LoVo/DX cells. Andreoni A, et al. **Photochem Photobiol** 1996 Jul;64(1):159–62

Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to alloxan-induced diabetes mellitus rats. Lee HJ, et al. **Res Commun Mol Pathol Pharmacol** 1995 Aug;89(2):165–78

Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. Czejka M, et al. **Z Naturforsch [C]** 1995 Jul–Aug;50(7–8):565–70

[Lifetime quantitative assessment of intracellular distribution of doxorubicin in tumor cells] Bogush TA, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):518–21 **(Rus)**

PHARMACOLOGY

Doxorubicin inhibits Tat-dependent transactivation of HIV type 1 LTR. Jeyaseelan R, et al. **AIDS Res Hum Retroviruses** 1996 May 1;12(7):569–76

Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells. Kurosawa M, et al. **Ann Hematol** 1996 Jan;72(1):17–21

Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle. Yamamoto M, et al. **Anticancer Drugs** 1995 Aug;6(4):570–7

Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin. Decorti G, et al. **Anticancer Res** 1996 Jan–Feb;16(1):317–20

Immunohistochemical characterisation of immunological changes at the tumour site after chemo–immunotherapy with doxorubicin, interleukin-2 and interferon-gamma. Lumsden AJ, et al. **Anticancer Res** 1996 May–Jun; 16(3A):1145–54

Development of human leukemia U-937 cell sublines resistant to doxorubicin: induction of differentiation and altered sensitivities to topoisomerase-directed drugs. Pantazis P, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):1873–81

Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Volm M, et al. **Anticancer Res** 1996 Jan–Feb;16(1):213–7

Induction of cell death by Doxorubicin in multicellular spheroids as studied by confocal laser scanning microscopy. Wartenberg M, et al. **Anticancer Res** 1996 Mar–Apr; 16(2):573–9

In vitro antitumor activity of 4'-O-tetrahydropyranyladriamycin on human gastric cancer cells. Yamaue H, et al. **Anticancer Res** 1996 Jan–Feb; 16(1):243–6

Antitumor activity of menogaril alone, and in combination against human mammary cancer models in mice and rats. Yoshida M, et al. **Anticancer Res** 1996 May–Jun; 16(3A):1155–9

Comparative evaluation of toxicity and antitumor activity of original and reproduced anthracycline drugs. Kuśnierczyk H, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):51–62

Evidence for distinct regulation processes in the aclacinomycin- and doxorubicin-mediated differentiation of human erythroleukemic cells. Morceau F, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):839–45

Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Ross DD, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1673–83

The influence of antioxidants and cycloheximide on the level of nitric oxide in the livers of mice in vivo. Mikoyan VD, et al. **Biochim Biophys Acta** 1995 Oct 19;1269(1):19–24

Immunoselective cell growth inhibition by antibody–adriamycin conjugates targeting c-erbB-2 product on human cancer cells. Suzuki S, et al. **Biol Pharm Bull** 1995 Sep;18(9):1279–82

Pharmaceutical and biological properties of doxorubicin encapsulated in liposomes (L-ADM): the effect of repeated administration on the systemic phagocytic activity and pharmacokinetics. Yachi K, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):653–67

Activation of erythroid-specific promoters during anthracycline-induced differentiation of K562 cells. Aries A, et al. **Blood** 1996 Apr 1;87(7):2885–90

Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Colombo T, et al. **Br J Cancer** 1996 Apr;73(7):866–71

Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas. Kaaijk P, et al. **Br J Cancer** 1996 Jul; 74(2):187–93

Selenium (Se) cytotoxicity in drug sensitive and drug resistant murine tumour. Shallom J, et al. **Cancer Biother** 1995 Fall; 10(3):243–8

Glutathione S-transferase and glutathione peroxidase are essential in the early stage of adriamycin resistance before P-glycoprotein overexpression in HOB1 lymphoma cells. Lee WP, et al. **Cancer Chemother Pharmacol** 1996; 38(1):45–51

Acquisition of doxorubicin resistance in human leukemia HL-60 cells is reproducibly associated with 7q21 chromosomal anomalies. Ganapathi R, et al. **Cancer Genet Cytogenet** 1996 Feb;86(2):116–9

Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells. Froesch BA, et al. **Cancer Immunol Immunother** 1996 Jan;42(1):55–63

The effects of 5-fluorouracil and doxorubicin on expression of human immunodeficiency virus type 1 long terminal repeat. Panozzo J, et al. **Cancer Lett** 1996 Aug 2; 105(2):217–23

Activity of creatine kinase MB-isoenzyme in rat serum after heart irradiation and/or farmorubicin (4'-epidoxorubicin) treatment. Przybyszewski WM, et al. **Cancer Lett** 1996 Feb 27;100(1–2):145–50

Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal agents. Quesada AR, et al. **Cancer Lett** 1996 Jan 19;99(1):109–14

The effects of theanine, as a novel biochemical modulator, on the antitumor activity of adriamycin. Sadzuka Y, et al. **Cancer Lett** 1996 Aug 2;105(2):203–9

Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line. Le Moyec L, et al. **Cancer Res** 1996 Aug 1;56(15):3461–7

Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Venne A, et al. **Cancer Res** 1996 Aug 15;56(16):3626–9

Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Broxterman HJ, et al. **Curr Opin Oncol** 1995 Nov; 7(6):532–40 (78 ref.)

Ambroxol inhibits doxorubicin-induced lipid peroxidation in heart of mice. Nowak D, et al. **Free Radic Biol Med** 1995 Nov;19(5):659–63

Effects of pirarubicin in comparison with epirubicin and doxorubicin on the contractile function in rat isolated cardiac muscles. Hirano S, et al. **Gen Pharmacol** 1995 Oct; 26(6):1339–47

Synthesis and antiproliferative effects of a 4'-morpholino-9-methyl anthracycline. Nafziger J, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1185–7

The Streptomyces peucetius drrC gene encodes a UvrA-like protein involved in daunorubicin resistance and production. Lomovskaya N, et al. **J Bacteriol** 1996 Jun;178(11):3238–45

Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. Cutts SM, et al. **J Biol Chem** 1996 Mar 8;271(10):5422–9

The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. Figueiredo-Pereira ME, et al. **J Biol Chem** 1996 Jul 12;271(28):16455–9

Acute presynaptic inhibition by doxorubicin of negative chrono- and inotropic responses to parasympathetic nerve stimulation in isolated, blood-perfused dog atrium. Hoyano Y, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):37–41

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. Jones S, et al. **J Clin Oncol** 1995 Oct;13(10):2567–74

Bacterial lipopolysaccharide confers resistance to G418, doxorubicin, and taxol in the murine macrophage cell line, RAW264. Sweet MJ, et al. **J Leukoc Biol** 1996 Feb; 59(2):280–6

Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833 [see comments] Beketic-Oreskovic L, et al. **J Natl Cancer Inst** 1995 Nov 1;87(21):1593–602. Comment in: J Natl Cancer Inst 1995 Nov 1;87(21):1573–5.

Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance. Chen G, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1271–7

Effect of intraperitoneal chemotherapy and fibrinolytic therapy on tumor implantation in wound sites. Jacquet P, et al. **J Surg Oncol** 1996 Jun;62(2):128–34

Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon carcinoma 26 Iigo M, et al. **Jpn J Cancer Res** 1995 Sep;86(9):867–72

Enhanced topoisomerase II-induced DNA breaks and free radical production by a new anthracycline with potent antileukemic activity. Andrivon W, et al. **Leuk Res** 1996 Feb;20(2):119–26

Treatment of leukemia with fibroblast-mediated interferon-alpha gene therapy alone or in combination with doxorubicin. Wang J, et al. **Leuk Res** 1996 May; 20(5):379–84

Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Gieseler F, et al. **Leukemia** 1996 Jul; 10(7):1177–80

Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Gieseler F, et al. **Leukemia** 1996 Jul; 10 Suppl 3:S46–S49

MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Hegewisch-Becker S. **Leukemia** 1996 Jul;10 Suppl 3:S32–S38 (53 ref.)

Protection of human myeloid leukemic cells against doxorubicin-induced apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin 3. Kaplinsky C, et al. **Leukemia** 1996 Mar; 10(3):460–5

Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Quillet-Mary A, et al. **Leukemia** 1996 Mar;10(3):417–25

Doxorubicin-induced Id2A gene transcription is targeted at an activating transcription factor/cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A. Kurabayashi M, et al. **Mol Cell Biol** 1995 Nov; 15(11):6386–97

Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Friesen C, et al. **Nat Med** 1996 May;2(5):574–7

Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Dong J, et al. **Oncol Res** 1995;7(5):245–52

Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells. Kisara S, et al. **Oncol Res** 1995; 7(3–4):191–200

Energy metabolism of adriamycin-sensitive and -resistant Ehrlich ascites tumor cells. Miccadei S, et al. **Oncol Res** 1996;8(1):27–35

Qualitatively different mechanisms of resistance to doxorubicin, both involving altered glutathione pools, in two myeloid cell lines in vitro. Dajani LK, et al. **Pediatr Hematol Oncol** 1995 Nov–Dec;12(6):531–44

Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Gartenhaus RB, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):265–8

Daunomycin inhibits insulin-like growth factor I-dependent protein tyrosine phosphorylation. Vig PJ, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jul;89(1):3–15

Changes of some biochemical and hematological parameters following administration of daunorubicin in rabbits. Geršl V, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl** 1995;38(2):79–84

[Comparison of the cytostatic effect of epirubicin and mitoxantrone on native breast carcinoma cells using the ATP tumor chemosensitivity assay] Kurbacher CM, et al. **Zentralbl Gynakol** 1996;118(5):271–8 (Eng. Abstr.) **(Ger)**

[Relationship of intracellular concentration and duration of contamination of pirarubicin and adriamycin in human bladder cancer cell lines and human bladder normal mucosa cell line] Saika T, et al. **Gan To Kagaku Ryoho** 1996 Jun; 23(7):905–9 (Eng. Abstr.) **(Jpn)**

[Studies on reversing effect of multidrug resistance by dipyridamole. I. modulation of epirubicin-induced effects on cell proliferation and cell cycle by dipyridamole] Hayashi A, et al. **Yakugaku Zasshi** 1996 Mar;116(3):217–27 (Eng. Abstr.) **(Jpn)**

[Studies on reversing effect of multidrug resistance by dipyridamole. II. Inhibition of epirubicin efflux from resistant cells by dipyridamole and its pharmacological effect] Hayashi A, et al. **Yakugaku Zasshi** 1996 Mar; 116(3):228–37 (Eng. Abstr.) **(Jpn)**

[Use of modifiers of multiple drug resistance to overcome tumor resistance to cytostatics in an in vivo system] Sitdikova SM, et al. **Biull Eksp Biol Med** 1996 Apr; 121(4):459–61 **(Rus)**

[The effect of adriamycin and ethidium bromide on the Ca2(+)-dependent K channel of human erythrocytes] Davtian TK, et al. **Tsitologiia** 1996;38(2):135–44 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro. Behnam Motlagh P, et al. **Acta Oncol** 1995;34(6):871–5

Treatment of Kaposi's sarcoma with liposomal doxorubicin. Bergin C, et al. **Am J Health Syst Pharm** 1995 Sep 15; 52(18):2001–4

Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Huizing MT, et al. **Ann Oncol** 1995 Sep;6(7):699–704

Pulmonary artery perfusion of doxorubicin with blood flow occlusion: pharmacokinetics and treatment in a metastatic sarcoma model. Wang HY, et al. **Ann Thorac Surg** 1995 Nov;60(5):1390–4

Mitomycin C, methotrexate, and vincristine with medroxyprogesterone acetate or prednisolone for doxorubicin resistant advanced breast cancer—a randomized control study. Tashiro H, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2229–37

Phase II trial of mitoxantrone, doxifluridine and medroxyprogesterone acetate as second-line treatment for anthracycline-resistant metastatic breast cancer. Yokoe T, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2303–5

Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Ibrahim NK, et al. **Arch Intern Med** 1996 Apr 22;156(8):882–8

Treatment of acute myelogenous leukaemia in patients aged 50–65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group. Pignon B, et al. **Br J Haematol** 1996 Aug; 94(2):333–41

P-glycoprotein immunostaining correlates with ER and with

high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Seymour L, et al. **Breast Cancer Res Treat** 1995;36(1):61–9

Epirubicin–Lipiodol chemotherapy versus 131iodine–Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Bhattacharya S, et al. **Cancer** 1995 Dec 1;76(11):2202–10

Intravesical idarubicin: a dose–finding study. Boccardo F, et al. **Cancer Chemother Pharmacol** 1996;38(1):102–5

High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group [see comments] Brausi M, et al. **Eur J Cancer** 1995 Sep;31A(10):1622–6. Comment in: Eur J Cancer 1995 Sep;31A(10):1565–6.

Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Piccart MJ, et al. **Eur J Cancer** 1995;31A Suppl 7:S1–10 (117 ref.)

Anthracycline resistance in breast cancer: clinical applications of current knowledge. Ravdin PM. **Eur J Cancer** 1995;31A Suppl 7:S11–4 (47 ref.)

Phase II trial of docetaxel in advanced anthracycline–resistant or anthracenedione–resistant breast cancer [see comments] Ravdin PM, et al. **J Clin Oncol** 1995 Dec;13(12):2879–85. Comment in: J Clin Oncol 1995 Dec;13(12):2865–7.

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline–resistant metastatic breast cancer [see comments] Valero V, et al. **J Clin Oncol** 1995 Dec; 13(12):2886–94. Comment in: J Clin Oncol 1995 Dec;13(12):2865–7.

Paclitaxel in doxorubicin–resistant metastatic breast cancer patients [letter; comment] Anand A, et al. **J Natl Cancer Inst** 1995 Nov 1;87(21):1642. Comment on: J Natl Cancer Inst 1995 Aug 2;87(15):1169–75.

Laser photochemotherapy with anthracyclines on cultured human squamous carcinoma cells. Paiva MB, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):257–62

Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte–macrophage colony–stimulating factor. (GM–CSF). Economopoulos T, et al. **Leuk Res** 1996 May; 20(5):385–90

The role of anthracyclines in adult acute lymphoblastic leukaemia. Bassan R, et al. **Leukemia** 1996 Jun;10 Suppl 2:s58–61 (11 ref.)

Cardiorespiratory status after treatment for acute lymphoblastic leukemia. Turner–Gomes SO, et al. **Med Pediatr Oncol** 1996 Mar;26(3):160–5

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Aas T, et al. **Nat Med** 1996 Jul;2(7):811–4

Intravesical bacillus Calmette–Guérin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours. Melekos MD, et al. **Oncology** 1996 Jul–Aug; 53(4):281–8

Immunoliposomes as enzyme–carriers (immuno–enzymosomes) for antibody–directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Vingerhoeds MH, et al. **Pharm Res** 1996 Apr;13(4):604–10

[Experimental study on targeting therapy of human hepatocellular carcinoma in nude mice using adriamycin–anti–transferrin receptor conjugate] Wang F, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep;17(5):354–7 (Eng. Abstr.) **(Chi)**

TOXICITY

Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A. Bellamy WT, et al. **Anticancer Drugs** 1995 Dec;6(6):736–43

Relationship between doxorubicin cell sensitivity, drug–induced DNA double–strand breaks, glutathione content and P–glycoprotein in mammalian tumor cells. Valenzuela MT, et al. **Anticancer Drugs** 1995 Dec; 6(6):749–57

Reduction of adriamycin cardiotoxicity by enoximone. Bossa R, et al. **Anticancer Res** 1996 Jan–Feb;16(1):141–3

CG5/Dx human breast cancer cell line: characterization of a new doxorubicin–resistant variant. Gibelli N, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1675–81

Effects of hemin on apoptosis, suppression of cytochrome c oxidase gene expression, and bone–marrow toxicity induced by doxorubicin (adriamycin). Papadopoulou LC, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):713–22

Novel doxorubicin–monoclonal anti–carcinoembryonic antigen antibody immunoconjugate activity in vitro. Lau A, et al. **Bioorg Med Chem** 1995 Oct;3(10):1305–12

Monohydroxyethylrutoside as protector against chronic doxorubicin–induced cardiotoxicity. van Acker SA, et al. **Br J Pharmacol** 1995 Aug;115(7):1260–4

Differential single– versus double–strand DNA breakage produced by doxorubicin and its morpholinyl analogues. Duran GE, et al. **Cancer Chemother Pharmacol** 1996; 38(3):210–6

Prevention of doxorubicin induced cardiotoxicity by catechin. Kozluca O, et al. **Cancer Lett** 1996 Jan 19; 99(1):1–6

Flow injection analysis quantifies multidrug resistance phenotype. Venkatesan PV, et al. **Cancer Lett** 1995 Oct 20;97(1):93–8

Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Gonzalez B, et al. **Cancer Res** 1995 Oct 15;55(20):4646–50

Attenuation of cardiotoxicity of daunomycin using a complex with heparin. Mizuno Y, et al. **Int J Hematol** 1996 Jan; 63(1):25–31

Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. Kang YJ, et al. **J Biol Chem** 1996 May 24;271(21):12610–6

Effect of doxorubicin on postrest contraction in isolated rat hearts. Asayama J, et al. **J Cardiovasc Pharmacol** 1995 Nov; 26(5):693–7

Aging increases the cardiotoxicity of daunorubicin and daunorubicinol in the rat. Cusack BJ, et al. **J Gerontol A Biol Sci Med Sci** 1996 Sep;51(5):B376–84

Doxorubicin–induced disturbance of the energy metabolism after hepatectomy. Akaza K, et al. **J Surg Res** 1996 Mar; 61(2):454–8

Effects of adriamycin, an anticancer drug showing testicular toxicity, on fertility in male rats. Imahie H, et al. **J Toxicol Sci** 1995 Aug;20(3):183–93

A new anthracycline with potent antileukemic activity exhibits reduced mutagenicity. Andrivon W, et al. **Mutat Res** 1995 Oct;344(3–4):135–40

Evidence for the involvement of vasopressin in the pathophysiology of adriamycin–induced nephropathy in rats. Okada H, et al. **Nephron** 1996;72(4):667–72

Oral selenium supplementation in rats reduces cardiac toxicity of adriamycin during ischemia and reperfusion. Boucher F, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):708–11

Cytotoxic analogs of luteinizing hormone–releasing hormone containing doxorubicin or 2–pyrrolinodoxorubicin, a derivative 500–1000 times more potent. Nagy A, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7269–73

High yield conversion of doxorubicin to 2–pyrrolinodoxorubicin, an analog 500–1000 times more potent: structure–activity relationship of daunosamine–modified derivatives of doxorubicin. Nagy A, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19; 93(6):2464–9

In vitro action of continuous–wave ultrasound combined with adriamycin, X rays or hyperthermia. Harrison GH, et al. **Radiat Res** 1996 Jan;145(1):98–101

[Long–term effects of the harmful action of anthracycline antibiotics on the rat reproductive system] Gol'dberg ED, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):55–8 **(Rus)**

[Genotoxic and mutagenic activity of antineoplastic anthracyclines and their aglycones: study in two test–systems] Vasil'eva SV, et al. **Genetika** 1996 Feb; 32(2):233–9 (Eng. Abstr.) **(Rus)**

ANTIBIOTICS, ANTIFUNGAL

Chondramides A approximately D, new antifungal and cytostatic depsipeptides from Chondromyces crocatus (myxobacteria). Production, physico–chemical and biological properties. Kunze B, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1262–6

Natamycin as a selective antifungal agent in media for growth of Legionella spp. Edelstein PH, et al. **J Clin Microbiol** 1996 Jan;34(1):185–7

ADMINISTRATION & DOSAGE

Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Behre GF, et al. **Ann Hematol** 1995 Dec;71(6):287–91

Administration of lipid–emulsion versus conventional amphotericin B in patients with neutropenia. Pascual B, et al. **Ann Pharmacother** 1995 Dec;29(12):1197–201

Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. van Etten EW, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1954–8

Comments concerning 'The penetration of amphotericin B from an Intralipid formulation into fibrin loci in a rabbit model of candidiasis' [letter; comment] Washington C, et al. **Biopharm Drug Dispos** 1995 Aug;16(6):529–31. Comment on: Biopharm Drug Dispos 1994 Aug;15(6):485–92.

Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. Oravcová E, et al. **Chemotherapy** 1995 Nov–Dec;41(6):473–6

The use of collagen shields impregnated with amphotericin B to treat Aspergillus keratomycosis. Mendicute J, et al. **CLAO J** 1995 Oct;21(4):252–5

Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses over a relatively short period [letter; comment] Churchill D, et al. **Clin Infect Dis** 1995 Nov;21(5):1352–3. Comment on: Clin Infect Dis 1995 Feb;20(2):263–6.

Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Fan–Havard P, et al. **Clin Infect Dis** 1995 Oct;21(4):960–5

Lipid formulations of amphotericin B: recent progress and future directions. Hiemenz JW, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S133–44 (83 ref.)

Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Kline S, et al. **Clin Infect Dis** 1995 Nov;21(5):1154–8

Intrathecal amphotericin B therapy for cerebral mucormycosis [letter; comment] McCormack JG. **Clin Infect Dis** 1995 Nov;21(5):1352. Comment on: Clin Infect Dis 1994 Dec;19(6):1133–7.

Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Rex JH, et al. **Clin Infect Dis** 1995 Oct;21(4):994–6

Deposition of amphotericin B aerosols in pulmonary aspergilloma. Diot P, et al. **Eur Respir J** 1995 Aug; 8(8):1263–8

PCR monitoring of response to liposomal amphotericin B treatment of systemic candidiasis in neutropenic mice. van Deventer AJ, et al. **J Clin Microbiol** 1996 Jan;34(1):25–8

Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. Bowden RA, et al. **J Infect Dis** 1996 May; 173(5):1208–15

Continuous versus intermittent bladder irrigation of amphotericin B for the treatment of candiduria [see comments] Trinh T, et al. **J Urol** 1995 Dec;154(6):2032–4 . Comment in: J Urol 1996 Aug;156(2 Pt 1):485.

Re: Continuous versus intermittent bladder irrigation of amphotericin B for the treatment of candiduria [letter; comment] Wise GJ. **J Urol** 1996 Aug;156(2 Pt 1):485. Comment on: J Urol 1995 Dec;154(6):2032–4.

The use of lipid formulations of amphotericin B for systemic fungal infections. Leenders AC, et al. **Leukemia** 1996 Oct; 10(10):1570–5 (55 ref.)

Something new in coping with invasive fungal infections? Nardini S. **Monaldi Arch Chest Dis** 1995 Oct;50(5):405–6

Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony–stimulating factor, and surgery: report of five cases. Dornbusch HJ, et al. **Pediatr Hematol Oncol** 1995 Nov–Dec;12(6):577–86

Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Purcell IF, et al. **Thorax** 1995 Dec;50(12):1321–3

Treatment of pulmonary aspergilloma in cystic fibrosis by percutaneous instillation of amphotericin B via indwelling catheter [see comments] Ryan PJ, et al. **Thorax** 1995 Jul; 50(7):809–10. Comment in: Thorax 1995 Jul;50(7):812–3.

[Chronic necrotizing pulmonary aspergillosis treated with itraconazole and inhaled amphotericin B] Sato A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1141–5 (Eng. Abstr.) **(Jpn)**

[Multiple candida liver abscesses successfully treated by continuous intrahepatic arterial infusion of amphotericin B using a reservoir in a case with acute myelocytic leukemia (M2)] Miyata A, et al. **Rinsho Ketsueki** 1995 Oct; 36(10):1217–22 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Myositis associated with griseofulvin therapy [letter] Davidson BK. **Am Fam Physician** 1995 Oct;52(5):1277

Amphotericin B infusion–related toxicity: comparison of two– and four–hour infusions. Nicholl TA, et al. **Ann Pharmacother** 1995 Nov;29(11):1081–7

Population pharmacokinetics and renal function–sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Amantea MA, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2042–7

Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Kline S, et al. **Clin Infect Dis** 1995 Nov;21(5):1154–8

Amphotericin–induced heart–rate decrease in children. Levy M, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):358–64

Bullous drug eruption to griseofulvin in a man with Hailey–Hailey disease. Meffert JJ, et al. **Cutis** 1995 Nov; 56(5):279–80

Anaphylaxis due to liposomal amphotericin (AmBisome) [letter] Bates CM, et al. **Genitourin Med** 1995 Dec;71(6):414

Amphotericin B–induced leukoencephalopathy in a patient with cryptococcal meningitis. Liu JS, et al. **J Formos Med Assoc** 1995 Jul;94(7):432–4

Potassium depletion potentiates amphotericin–B–induced toxicity to renal tubules. Bernardo JF, et al. **Nephron** 1995; 70(2):235–41

Nephrotic syndrome related to systemic lupus erythematosus after griseofulvin therapy. Bonilla–Felix M, et al. **Pediatr Nephrol** 1995 Aug;9(4):478–9

[Lipoid pneumonia combined with pulmonary nocardiosis caused by inhalation of amphotericin–B after renal transplantation] Abe M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun; 34(6):737–40 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Effects of some heavy metals on growth, pigment and antibiotic production by Streptomyces galbus. Raytapadar S, et al. **Acta Microbiol Immunol Hung** 1995;42(2):171–7

Conservation of the 2,4–diacetylphloroglucinol biosynthesis locus among fluorescent Pseudomonas strains from diverse geographic locations. Keel C, et al. **Appl Environ Microbiol** 1996 Feb;62(2):552–63

The molecular basis for the natural resistance of the cytochrome bc1 complex from strobilurin–producing basidiomycetes to center Qp inhibitors. Kraiczy P, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):54–63

The jerangolids: A family of new antifungal compounds from

Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties of jerangolid A. Gerth K, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):71-5

Mutants of Streptomyces akiyoshiensis blocked in 5-hydroxy-4-oxonorvaline production. Le Y, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):107-9

Cloning and heterologous expression of the entire set of structural genes for nikkomycin synthesis from Streptomyces tendae Tü901 in Streptomyces lividans. Bormann C, et al. **J Bacteriol** 1996 Feb;178(4):1216-8

CEREBROSPINAL FLUID

Determination of amphotericin B in cerebrospinal fluid by solid-phase extraction and liquid chromatography. Liu H, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1395-400

CHEMISTRY

Amphotericin B formulated in a lipid emulsion [editorial] Cleary JD. **Ann Pharmacother** 1996 Apr;30(4):409-12

Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Tollemar J, et al. **Drug Saf** 1995 Oct; 13(4):207-18 (86 ref.)

Discovery of saricandin, a novel papulacandin, from a Fusarium species. Chen RH, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):596-8

Chrysospermins, new peptaibol antibiotics from Apiocrea chrysosperma Ap101. Dornberger K, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):977-89

Digestion of rhizocticins to (Z)-L-2-amino-5-phosphono-3-pentenoic acid: revision of the absolute configuration of plumbemycins A and B. Fredenhagen A, et al. **J Antibiot (Tokyo)** 1995 Sep; 48(9):1043-5

Bacillopeptins, new cyclic lipopeptide antibiotics from Bacillus subtilis FR-2. Kajimura Y, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1095-103

Structure of furanocandin, a new antifungal antibiotic from Tricothecium sp. Magome E, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):599-602

On an unstable antifungal metabolite from Trichoderma koningii. Isolation and structure elucidation of a new cyclopentenone derivative (3-Dimethylamino-5-hydroxy-5-vinyl-2-cyclopenten-1-one). Mukhopadhyay T, et al. **J Antibiot (Tokyo)** 1996 Feb; 49(2):210-1

Structure-activity relationship of pamamycins: effects of alkyl substituents. Natsume M, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1159-64

Stereostructure of perimycin A. Pawlak J, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):1034-8

YM-47522, a novel antifungal antibiotic produced by Bacillus sp. I. Taxonomy, fermentation, isolation and biological properties. Shibazaki M, et al. **J Antibiot (Tokyo)** 1996 Apr; 49(4):340-4

Stereostructure of Rimocidin. Sowiński P, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1288-91

YM-47522, a novel antifungal antibiotic produced by Bacillus sp. II. Structure and relative stereochemistry. Sugawara T, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):345-8

Carbazate as a glycine bioisostere in restricticin [letter] VanMiddlesworth F, et al. **J Antibiot (Tokyo)** 1996 Mar; 49(3):329-31

Structure and toxicity of amphotericin B/triglyceride emulsion formulations. Lance MR, et al. **J Antimicrob Chemother** 1995 Jul;36(1):119-28

Liposomal and lipid-based formulations of amphotericin B. de Marie S. **Leukemia** 1996 Jun;10 Suppl 2:s93-6 (34 ref.)

AH17, a new non-polyenic antifungal antibiotic produced by a strain of Spirillospora. Hacène H, et al. **Microbios** 1995;83(336):199-205

On the synthesis of pyridazomycin congeners. Part 2: L-alpha-Amino acids bearing a terminal azinium or diazinium system. Easmon J, et al. **Pharmazie** 1996 Feb; 51(2):76-83

[Amphotericin B into parenteral lipid emulsions. Galenic stability of mixtures. Preliminary results] Blancard A, et al. **Pathol Biol (Paris)** 1996 May;44(5):384-8 (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

Identification of two pigments and a hydroxystilbene antibiotic from Photorhabdus luminescens. Li J, et al. **Appl Environ Microbiol** 1995 Dec;61(12):4329-33

Antimicrobial activity of calprotectin isolated from human empyema fluid supernatants. Santhanagopalan V, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):285-90

Discovery of saricandin, a novel papulacandin, from a Fusarium species. Chen RH, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):596-8

SCH57404, an antifungal agent possessing the rare sodaricin skeleton and a tricyclic sugar moiety. Coval SJ, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1171-2

Chrysospermins, new peptaibol antibiotics from Apiocrea chrysosperma Ap101. Dornberger K, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):977-89

Hydroxystrobilurin A, a new antifungal E-beta-methoxyacrylate from a Pterula species. Engler M, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):884-5

Bacillomycin Lc, a new antibiotic of the iturin group: isolations, structures, and antifungal activities of the congeners. Eshita SM, et al. **J Antibiot (Tokyo)** 1995 Nov; 48(11):1240-7

Ratjadon: a new antifungal compound from Sorangium cellulosum (myxobacteria) production, physio-chemical and biological properties. Gerth K, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):973-6

Chivosazol A, a new inhibitor of eukaryotic organisms isolated from myxobacteria. Irschik H, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):962-6

Liposidolide A, a new antifungal macrolide antibiotic [letter] Kihara T, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1385-7

TMC-34, a new macrolide antifungal antibiotic. Kohno J, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1173-5

Structure of furanocandin, a new antifungal antibiotic from Tricothecium sp. Magome E, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):599-602

On an unstable antifungal metabolite from Trichoderma koningii. Isolation and structure elucidation of a new cyclopentenone derivative (3-Dimethylamino-5-hydroxy-5-vinyl-2-cyclopenten-1-one). Mukhopadhyay T, et al. **J Antibiot (Tokyo)** 1996 Feb; 49(2):210-1

2-Demethylazalomycins F4a and F5a, two new antifungal metabolites from Actinomycete sp. HIL Y-9120362. Mukhopadhyay T, et al. **J Antibiot (Tokyo)** 1995 Nov; 48(11):1350-2

BE-29602, a new member of the Papulacandin family. Okada H, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):103-6

Polytolypin, a new antifungal triterpenoid from the coprophilous fungus Polytolypa hystricis. Gamble WR, et al. **J Nat Prod** 1995 Dec;58(12):1983-6

Antimicrobial metabolites from a bacterial symbiont. Li J, et al. **J Nat Prod** 1995 Jul;58(7):1081-6

AH17, a new non-polyenic antifungal antibiotic produced by a strain of Spirillospora. Hacène H, et al. **Microbios** 1995;83(336):199-205

METABOLISM

Virtual kinetics: using statistical experimental design for rapid analysis of enzyme inhibitor mechanisms. Bronson DD, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):823-31

Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Pizer ES, et al. **Cancer Res** 1996 Mar 15;56(6):1189-93

Binding of benanomicin A to fungal cells in reference to its fungicidal action. Watanabe M, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):366-73

TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. Lorenz MC, et al. **J Biol Chem** 1995 Nov 17;270(46):27531-7

[New anti-HIV drug which binds the oligosaccharides of HIV envelope glycoprotein] Mizuochi T, et al. **Nippon Rinsho** 1995 Sep;53(9):2340-9 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Amantea MA, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2042-7

Clinical and pharmacokinetic evaluation of a new lipid-based delivery system of amphotericin B in AIDS patients. Villani P, et al. **Arzneimittelforschung** 1996 Apr;46(4):445-9

Pharmacokinetics of amphotericin B in rats as a function of dose following constant-rate intravenous infusion. Chow HH, et al. **Biopharm Drug Dispos** 1995 Aug;16(6):461-73

Deposition of amphotericin B aerosols in pulmonary aspergilloma. Diot P, et al. **Eur Respir J** 1995 Aug; 8(8):1263-8

Elimination of liposomal amphotericin by hemodiafiltration [letter] Tomlin M, et al. **Intensive Care Med** 1995 Aug; 21(8):699-700

[Amphotericin B—bioavailability in the cornea. Studies with local administration of liposome incorporated amphotericin B] Pleyer U, et al. **Ophthalmologe** 1995 Aug;92(4):469-75 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Currie B, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1934-7

The AUR1 gene in Saccharomyces cerevisiae encodes dominant resistance to the antifungal agent aureobasidin A (LY295337). Heidler SA, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2765-9

Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Scheven M, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1779-83

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907-12 (46 ref.)

In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species. Vazquez JA, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2689-91

Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Wanger A, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2520-2

Inhibition of mitogen-induced DNA synthesis by bafilomycin A1 in Swiss 3T3 fibroblasts. Saurin AJ, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):65-70

Fluorescence studies on the molecular action of amphotericin B on susceptible and resistant fungal cells. Haynes MP, et al. **Biochemistry** 1996 Jun 18;35(24):7983-92

Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. Sampol E, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):83-6

Accumulation of Golgi-specific mannosyltransferases in Candida albicans cells grown in the presence of brefeldin A. Kossaczká Z, et al. **Can J Microbiol** 1995 Nov; 41(11):971-7

Effects of amphotericin B on glucose metabolism in Candida albicans blastospores evidenced by 13C NMR. Rabaste F, et al. **Can J Microbiol** 1996 Jul;42(7):705-710

Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Pizer ES, et al. **Cancer Res** 1996 Jun 15;56(12):2745-7

Amphotericin B susceptibility of Candida species assessed by rapid flow cytometric membrane potential assay. Ordóñez JV, et al. **Cytometry** 1995 Jun 15;22(2):154-7

The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. Pearson RB, et al. **EMBO J** 1995 Nov 1;14(21):5279-87

Sensitivity of fungi to nikkomycin Z. Tariq VN, et al. **Fungal Genet Biol** 1996 Mar;20(1):4-11

Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Kurtz MB, et al. **Infect Immun** 1996 Aug; 64(8):3244-51

Eulicin inhibits human immunodeficiency virus infection and replication. Nakamura M, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1362-3

Relationship between structure and biological activity of novel R106 analogs. Rodriguez MJ, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):386-9

YM-47522, a novel antifungal antibiotic produced by Bacillus sp. I. Taxonomy, fermentation, isolation and biological properties. Shibazaki M, et al. **J Antibiot (Tokyo)** 1996 Apr; 49(4):340-4

Induction of differentiation of HL-60 cells by the anti-fungal antibiotic, radicicol. Shimada Y, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):824-30

The effects of amphotericin B, fluconazole and miconazole on neutrophil and lymphocyte function in a guinea pig model. Drummond DC, et al. **J Antimicrob Chemother** 1995 Aug;36(2):375-84

Cytotoxicity of hamycin for Trichomonas vaginalis, HeLa and BHK-21. Lushbaugh WB, et al. **J Antimicrob Chemother** 1995 Nov;36(5):795-802

Papulacandin B resistance in budding and fission yeasts: isolation and characterization of a gene involved in (1,3)beta-D-glucan synthesis in Saccharomyces cerevisiae. Castro C, et al. **J Bacteriol** 1995 Oct;177(20):5732-9

Characterization of a nuclear protein conferring brefeldin A resistance in Schizosaccharomyces pombe. Turi TG, et al. **J Biol Chem** 1996 Apr 12;271(15):9166-71

Polytolypin, a new antifungal triterpenoid from the coprophilous fungus Polytolypa hystricis. Gamble WR, et al. **J Nat Prod** 1995 Dec;58(12):1983-6

Influence of free or liposomal amphotericin B on killing of Candida species by human peritoneal macrophages. Allwinn R, et al. **Methods Find Exp Clin Pharmacol** 1995 Apr;17(3):163-7

AUR1, a novel gene conferring aureobasidin resistance on Saccharomyces cerevisiae: a study of defective morphologies in Aur1p-depleted cells. Hashida-Okado T, et al. **Mol Gen Genet** 1996 May 23;251(2):236-44

Dose-response study and threshold estimation of griseofulvin-induced aneuploidy during female mouse meiosis I and II. Marchetti F, et al. **Mutagenesis** 1996 Mar; 11(2):195-200

New systematically active antimycotics from the beta-blocker category. Hänel H, et al. **Mycoses** 1995 Jul-Aug;38(7-8):251-64

Amphotericin B. Abadi J. **Pediatr Rev** 1995 Oct;16(10):363-4

On the synthesis of pyridazomycin congeners. Part 2: L-alpha-Amino acids bearing a terminal azinium or diazinium system. Easmon J, et al. **Pharmazie** 1996 Feb; 51(2):76-83

Use of amphotericin B to clear fungal contamination of islet tissue isolated from contaminated source pancreas. Fraga DW, et al. **Transplant Proc** 1995 Dec;27(6):3279

[Studies on microtiter broth dilution method for antifungal susceptibility testing of yeast isolates from blood and cerebrospinal fluid] Fujita S. **Rinsho Byori** 1996 Apr; 44(4):373-8 (Eng. Abstr.) **(Jpn)**

[A complex antibiotic preparation obtained from a medicinal plant from the family Asteraceae] Smirnov VV, et al. **Mikrobiol Z** 1995 Jul-Aug;57(4):73-82 (29 ref.) (Eng. Abstr.) **(Rus)**

POISONING

Clinical experience in poisonings following exposure to blasticidin S, a curiously strong fungicide. Yang CC, et al. **Vet Hum Toxicol** 1996 Apr;38(2):107-12

THERAPEUTIC USE

Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Anaissie EJ, et al. **Am J Med** 1996 Aug;101(2):170–6

Continuous ambulatory peritoneal dialysis complicated by Aureobasidium pullulans peritonitis. Clark EC, et al. **Am J Nephrol** 1995;15(4):353–5

Cryptococcal meningitis in pregnancy. Chen CP, et al. **Am J Perinatol** 1996 Jan;13(1):35–6

Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Denning DW, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1809–14

Liposomal amphotericin B therapy of murine histoplasmosis. Graybill JR, et al. **Antimicrob Agents Chemother** 1995 Aug; 39(8):1885–7

Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Kurtz MB, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1784–9

New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Schmatz DM, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1320–3

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907–12 (46 ref.)

Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Valero G, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2588–90

Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Nguyen MH, et al. **Arch Intern Med** 1995 Dec 11–25; 155(22):2429–35

Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Strasser MD, et al. **Arch Intern Med** 1996 Feb 12;156(3):337–9 (21 ref.)

Amphotericin B: an update. Abu-Salah KM. **Br J Biomed Sci** 1996 Jun;53(2):122–33 (148 ref.)

Experience with liposomal Amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation. Krüger W, et al. **Br J Haematol** 1995 Nov;91(3):684–90

Breakthrough fungemia due to Hansenula anomala in a leukemic patient successfully treated with amphotericin B [letter] Kunová A, et al. **Chemotherapy** 1996 Mar–Apr; 42(2):157–8

Zygomycotic lung abscess: a case report. Chen JS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Aug; 56(2):129–33

Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Dromer F, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S154–60

Old and new therapies for sporotrichosis. Kauffman CA. **Clin Infect Dis** 1995 Oct;21(4):981–5 (63 ref.)

Management of scalp ringworm. **Drug Ther Bull** 1996 Jan; 34(1):5–6 (15 ref.)

The yeast connection and the woman [letter] Crook WG. **Ear Nose Throat J** 1995 Sep;74(9):658

Successful treatment of catheter-related fusarial infection in immunocompromised children. Velasco E, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):697–9

Breakthrough fungemia caused by Candida stellatoidea in a patient with lymphoma associated with shock, successfully treated with amphotericin B lipid complex [letter] Sufliarsky J, et al. **Infection** 1995 Jul–Aug; 23(4):246–7

Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. MacPhail LA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):470–6

Clinical trials of the new antifungal drug therapies [letter; comment] Rand S. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):863. Comment on: J Am Acad Dermatol 1995 May;32(5 Pt 1):750–3.

Nasopharyngeal conidiobolomycosis in a horse. Zamos DT, et al. **J Am Vet Med Assoc** 1996 Jan 1;208(1):100–1

Amphotericin B responsive Scedosporium apiospermum infection in a patient with acute myeloid leukaemia. Cunningham R, et al. **J Clin Pathol** 1996 Jan;49(1):93–4

Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. Lumbreras C, et al. **J Infect Dis** 1996 Sep; 174(3):583–8

Management of postoperative Acremonium endophthalmitis. Weissgold DJ, et al. **Ophthalmology** 1996 May; 103(5):749–56

Successful treatment of cryptococcosis in a premature neonate. Gavai M, et al. **Pediatr Infect Dis J** 1995 Nov; 14(11):1009–10

Blood culture as a parameter of treatment effectiveness in experimental histoplasmosis of the hamster. Finquelievich J, et al. **Rev Inst Med Trop Sao Paulo** 1995 Mar–Apr; 37(2):99–102

Candida albicans meningitis in a 27 weeks premature infant treated with liposomal amphotericin-B (AmBisome) Jarløv JO, et al. **Scand J Infect Dis** 1995;27(4):419–20

Treatment of cryptococcal meningitis with triple combination of amphotericin B, flucytosine and itraconazole. Chotmongkol V, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):381–3

Amphotericin B in the treatment of candida meningitis in three neonates. Aydin M, et al. **Turk J Pediatr** 1995 Jul–Sep;37(3):247–52

The management of renal candidiasis in the newborn. Uçsel R, et al. **Turk J Pediatr** 1996 Apr–Jun;38(2):239–43

[New antifungal agents] Dupont B. **Arch Pediatr** 1996;3 Suppl 1:306s–308s **(Fre)**

[Palliative percutaneous treatment under x-ray computed tomographic control of inoperable pulmonary aspergilloma. Apropos of 30 cases] Giron J, et al. **Rev Mal Respir** 1995;12(6):593–9 (Eng. Abstr.) **(Fre)**

[Rational use of antimycotics against yeast infections] Hof H, et al. **Immun Infekt** 1995 Dec;23(6):209–15 (29 ref.) (Eng. Abstr.) **(Ger)**

[Procedures for Candida albicans systemic infections in premature infants] Lauterbach R. **Ginekol Pol** 1995 May; 66(5):289–93 (13 ref.) (Eng. Abstr.) **(Pol)**

[Features of the course of the candida infection process during combined effect of medications] Khmel'nitskii OK, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):506–10 **(Rus)**

TOXICITY

Toxicological profile of aureofungin: a potent plant antifungal antibiotic. Dhuley JN, et al. **Indian J Exp Biol** 1995 Nov; 33(11):857–60

Structure and toxicity of amphotericin B/triglyceride emulsion formulations. Lance MR, et al. **J Antimicrob Chemother** 1995 Jul;36(1):119–28

URINE

HPLC method for the quantitation of cispentacin enantiomers in rat urine. Zanol M, et al. **Boll Chim Farm** 1995 Jul–Aug;134(7):390–3

ANTIBIOTICS, ANTINEOPLASTIC

Generation of small fusion genes carrying phleomycin resistance and Drosophila alcohol dehydrogenase reporter properties: their application in retroviral vectors. Gautier R, et al. **Exp Cell Res** 1996 May 1;224(2):291–301

Chondramides A approximately D, new antifungal and cytostatic depsipeptides from Chondromyces crocatus (myxobacteria). Production, physico-chemical and biological properties. Kunze B, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1262–6

Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Higginbotham EJ, et al. **Ophthalmology** 1996 Apr;103(4):650–6

ADMINISTRATION & DOSAGE

Is the MVP regimen less active than previously described? Results of a phase II study in advanced non-small cell lung cancer. Ferrigno D, et al. **Acta Oncol** 1996;35(4):435–9

Systemic mitomycin C as second-line treatment for metastatic urothelial cancer. Sengeløv L, et al. **Acta Oncol** 1995;34(7):978–9

Salvage chemotherapy with mitomycin, vindesine, and cisplatin (MiViP) in recurrent carcinoma of the cervix. Delaloye JF, et al. **Am J Clin Oncol** 1996 Apr;19(2):204–6

Needle elevation of the scleral flap for failing filtration blebs after trabeculectomy with mitomycin C. Greenfield DS, et al. **Am J Ophthalmol** 1996 Aug;122(2):195–204

Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Schneebaum S, et al. **Ann Surg Oncol** 1996 Jan;3(1):44–50

Endophthalmitis after filtering surgery with mitomycin. Greenfield DS, et al. **Arch Ophthalmol** 1996 Aug; 114(8):943–9

Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer. Levi JA, et al. **Aust N Z J Med** 1995 Oct;25(5):474–8

Properties of water-insoluble mitomycin C-albumin conjugate as a sustained release drug delivery system in mice inoculated with Sarcoma 180. Tanaka T, et al. **Biol Pharm Bull** 1995 Dec;18(12):1724–8

Morphometric study of wound healing in a model of filtering surgery with mitomycin-C. Pablo LE, et al. **Eur J Ophthalmol** 1995 Jul–Sep;5(3):168–71

Circumvention of multidrug resistance in neoplastic cells through scavenger receptor mediated drug delivery. Mukhopadhyay A, et al. **FEBS Lett** 1995 Nov 27; 376(1–2):95–8

Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer. Denehy TR, et al. **Gynecol Oncol** 1996 Jan;60(1):64–71 (21 ref.)

Bleomycin-mediated electrochemotherapy of basal cell carcinoma. Glass LF, et al. **J Am Acad Dermatol** 1996 Jan; 34(1):82–6

A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma [see comments] Lundholm C, et al. **J Urol** 1996 Aug;156(2 Pt 1):372–6. Comment in: J Urol 1996 Aug;156(2 Pt 1):389–90.

Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group [see comments] Rintala E, et al. **J Urol** 1996 Jul;156(1):56–9; discussion 59–60. Comment in: J Urol 1996 Jul;156(1):61–2.

Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. Rintala E, et al. **J Urol** 1995 Dec; 154(6):2050–3

The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. Tolley DA, et al. **J Urol** 1996 Apr;155(4):1233–8

Effects of postoperative mitomycin C eyedrop on trabeculectomy in refractory glaucoma patients. Choi MY, et al. **Korean J Ophthalmol** 1996 Jun;10(1):34–41

The effect of low-and high-dose adjunctive mitomycin C in trabeculectomy. Lee JJ, et al. **Korean J Ophthalmol** 1996 Jun;10(1):42–7

Treatment of childhood Hodgkin's disease with ABVD without radiotherapy. Behrendt H, et al. **Med Pediatr Oncol** 1996 Apr;26(4):244–8

Intraoperative application of topical mitomycin C for pterygium surgery. Frucht-Pery J, et al. **Ophthalmology** 1996 Apr;103(4):674–7

Combined cataract extraction with intraocular lens implant and mitomycin-augmented trabeculectomy. Lederer CM Jr. **Ophthalmology** 1996 Jul;103(7):1025–34

Formula revealed [letter] Schmidt CM, et al. **Ophthalmology** 1996 May;103(5):700

Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin. Wasan KM, et al. **Pharm Res** 1996 Mar; 13(3):462–8

Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma. Yanai S, et al. **Pharm Res** 1995 May;12(5):653–7

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Liu C, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8618–23

[Incidence of recurrence after primary pterygium excision, phototherapeutic keratectomy with the ArF:Excimer laser and local mitomycin C administration] Walkow T, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):406–9 (Eng. Abstr.) **(Ger)**

[Effect of mitomycin C on aqueous humor flow after trabeculectomy] Diestelhorst M, et al. **Ophthalmologe** 1995 Aug;92(4):542–5 (Eng. Abstr.) **(Ger)**

[Pterygium excision with intra-operative administration of low dosage mitomycin C] Heiligenhaus A, et al. **Ophthalmologe** 1995 Aug;92(4):458–62 (Eng. Abstr.) **(Ger)**

[Progress in laser sclerotomy ab externo] Enlarging the sclerostomy channel and local mitomycin administration] Schmidt-Erfurth U, et al. **Ophthalmologe** 1995 Aug; 92(4):536–41 (Eng. Abstr.) **(Ger)**

[Therapy of carcinomatous peritonitis by the angiogenesis inhibitor TNP-470 in mice: analysis of timing and doses for intraperitoneal administration] Tsujimoto H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1527–30 (Eng. Abstr.) **(Jpn)**

[Antitumor effect of MMC mixed in Beriplast P] Yano K, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1629–31 (Eng. Abstr.) **(Jpn)**

[Anti-tumor effects of an angiogenesis inhibitor, TNP-470 (AGM-1470) alone and in combination with cisplatinum, and changes in serum copper levels in liver cancer bearing rats] Matsuoka S. **Hokkaido Igaku Zasshi** 1996 Jan; 71(1):69–80 (Eng. Abstr.) **(Jpn)**

[Effectiveness of local in vivo application of bleomycetin (bleomycin), chemosorbed on ion exchange medical gauze] Tikhomirov GA, et al. **Antibiot Khimioter** 1995 Jun; 40(6):19–22 (Eng. Abstr.) **(Rus)**

[Functionally sparing surgery in locally spread malignant maxillary tumors and the use of local chemotherapy] Ol'shanskiĭ VO, et al. **Vestn Otorinolaringol** 1995 Nov–Dec; (6):23–5 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Phase I trial of elactocin. Newlands ES, et al. **Br J Cancer** 1996 Aug;74(4):648–9

Generalized dermatitis due to mitomycin C patch test. Echechipía S, et al. **Contact Dermatitis** 1995 Dec;33(6):432

Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Sleijfer S, et al. **Eur J Cancer** 1996 Mar; 32A(3):550–2

Beneficial effects of a novel anti-hypoxemic agent, TEI-7322, on bleomycin-induced experimental hypoxemia in rats. Horiuchi H, et al. **Eur J Pharmacol** 1995 Dec 4; 287(1):27–34

Cell proliferation in lung fibrosis-associated hyperplastic lesions. Nishikawa A, et al. **Hum Exp Toxicol** 1995 Sep; 14(9):701–5

Effect of short-term dietary administration of eugenol in humans. Rompelberg CJ, et al. **Hum Exp Toxicol** 1996 Feb; 15(2):129–35

Scleral changes due to mitomycin C after pterygium excision: a report of two cases. Saifuddin S, et al. **Indian J Ophthalmol** 1995 Jun;43(2):75–6

MMC in ONS decompression [letter] Kersten RC, et al. **Ophthalmology** 1996 Jun;103(6):864–5

Bladder wall fibrosis following intravesical mitomycin treatment for superficial bladder cancer. Katz G, et al.

Urology 1996 Jun;47(6):928–9

[Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports] Pouya M, et al. **Acta Urol Belg** 1996 Mar;64(1):47–53 (24 ref.) (Eng. Abstr.) **(Fre)**

[Chemotherapy–induced hemolytic uremic syndrome. A complication to mitomycin treatment of breast carcinoma] Schjølseth SA, et al. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3371–3 (Eng. Abstr.) **(Nor)**

ANTAGONISTS & INHIBITORS

Inhibition of puromycin–induced renal injury by a superoxide dismutase derivative with prolonged in vivo half–life. Nishimura Y, et al. **Nephron** 1995;70(4):460–5

BIOSYNTHESIS

Characterization of Streptomyces argillaceus genes encoding a polyketide synthase involved in the biosynthesis of the antitumor mithramycin. Lombó F, et al. **Gene** 1996 Jun 12;172(1):87–91

Production and isolation of two novel esperamicins in a chemically defined medium. Lam KS, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1497–501

Improved production of phenomycin by a genetically engineered Escherichia coli. Nagano Y, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):81–5

Studies on cochleamycins, novel antitumor antibiotics. III. Biosyntheses of cochleamycins: incorporation of 13C– and 2H–labeled compounds into cochleamycins. Shindo K, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):249–52

[Induction of antibiotic formation by inactive cultures of actinomycetes. A mutant strain of Streptomyces helvaticus, a new producer of bruneomycin] Malkina ND, et al. **Antibiot Khimioter** 1995 Jun;40(6):3–6 (Eng. Abstr.) **(Rus)**

BLOOD

Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin. Wasan KM, et al. **Pharm Res** 1996 Mar; 13(3):462–8

Mycophenolic acid: measurement and relationship to pharmacologic effects. Shaw LM, et al. **Ther Drug Monit** 1995 Dec;17(6):685–9 (22 ref.)

CHEMICAL SYNTHESIS

Polymeric prodrugs of mitomycin C designed for tumour tropism and sustained activation. Seymour LW, et al. **Anticancer Drug Des** 1996 Jul;11(5):351–65

Design, synthesis, cytotoxic properties and preliminary DNA sequencing evaluation of CPI—N–methylpyrrole hybrids. Enhancing effect of a trans double bond linker and role of the terminal amide functionality on cytotoxic potency. Wang Y, et al. **Anticancer Drug Des** 1996 Jan;11(1):15–34

Key analogs of the tetrapeptide subunit of RA–VII and deoxybouvardin. Boger DL, et al. **Bioorg Med Chem** 1995 Dec;3(12):1579–93

1,2,9,9a–Tetrahydrocyclopropa[c]benz[e]indol–4–one (CBI) analogs of CC–1065 and the duocarmycins: synthesis and evaluation. Boger DL, et al. **Bioorg Med Chem** 1995 Nov; 3(11):1429–53

Diastereoselective Dieckmann condensation suitable for introduction of the duocarmycin A C6 center: development of a divergent strategy for the total synthesis of duocarmycins A and SA. Boger DL, et al. **Bioorg Med Chem** 1995 Jan;3(1):67–77

Study on surfactin, a cyclic depsipeptide. II. Synthesis of surfactin B2 produced by Bacillus natto KMD 2311. Nagai S, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):5–10

Synthesis and antitumor activity of duocarmycin derivatives. Nagamura S, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep; 43(9):1530–5

Synthesis of saframycins. X. Transformation of (–)–saframycin A to (–)–saframycin Mx type compound with the structure proposed for saframycin E. Saito N, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):777–82

Synthesis and modeling studies with monocyclic analogues of mycophenolic acid. Anderson WK, et al. **J Med Chem** 1996 Jan 5;39(1):46–55

Synthesis and antiproliferative and antiviral activity of 2'–deoxy–2'–fluoroarabinofuranosyl analogs of the nucleoside antibiotics toyocamycin and sangivamycin. Krawczyk SH, et al. **J Med Chem** 1995 Sep 29; 38(20):4106–14

Synthesis and evaluation of certain thiosangivamycin analogs as potential inhibitors of cell proliferation and human cytomegalovirus. Krawczyk SH, et al. **J Med Chem** 1995 Sep 29;38(20):4115–9

erbB–2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure–activity relationships. Schnur RC, et al. **J Med Chem** 1995 Sep 15; 38(19):3813–20

CHEMISTRY

Structures of quinoxaline antibiotics. Sheldrick GM, et al. **Acta Crystallogr B** 1995 Dec 1;51 (Pt 6):987–99

Structural studies of mitomycins. VII. Mitomycin G. Hirayama N, et al. **Acta Crystallogr C** 1996 Jul 15;52 (Pt 7):1806–8

A noncovalent binding–translocation mechanism for site–specific CC–1065–DNA recognition. Gunz D, et al. **Biochem Pharmacol** 1996 Aug 9;52(3):447–53

1,2–Dithiolan–3–one 1–oxides: a class of thiol–activated DNA–cleaving agents that are structurally related to the natural product leinamycin. Behroozi SJ, et al. **Biochemistry** 1996 Feb 13;35(6):1768–74

Metal coordination environment and dynamics in 113cadmium bleomycin: relationship to zinc bleomycin. Otvos JD, et al. **Biochemistry** 1996 Feb 6;35(5):1458–65

A single binding mode of activated enediyne C1027 generates two types of double–strand DNA lesions: deuterium isotope–induced shuttling between adjacent nucleotide target sites. Xu YJ, et al. **Biochemistry** 1995 Sep 26; 34(38):12451–60

CBI–CDPBO1 and CBI–CDPBI1: CC–1065 analogs containing deep–seated modifications in the DNA binding subunit. Boger DL, et al. **Bioorg Med Chem** 1995 Jun; 3(6):761–7

CC–1065 CBI analogs: an example of enhancement of DNA alkylation efficiency through introduction of stabilizing electrostatic interactions. Boger DL, et al. **Bioorg Med Chem** 1995 Jun;3(6):611–21

NMR studies of the post–activated neocarzinostatin chromophore–DNA complex. Conformational changes induced in drug and DNA. Gao X, et al. **Bioorg Med Chem** 1995 Jun;3(6):795–809

On the conformation of Phe78 of a chromoprotein antibiotic, neocarzinostatin. Imajo S, et al. **Bioorg Med Chem** 1995 Apr;3(4):429–36

Selective recognition of the m5CpG dinucleotide sequence in DNA by mitomycin C for alkylation and cross–linking. Johnson WS, et al. **Bioorg Med Chem** 1995 Jun;3(6):851–60

Binding and cleavage characteristics of the complexes formed between the neocarzinostatin chromophore and single site containing oligonucleotides. Stassinopoulos A, et al. **Bioorg Med Chem** 1995 Jun;3(6):713–21

Time–resolved fluorescence studies of tomaymycin bonding to synthetic DNAs. Barkley MD, et al. **Biophys J** 1996 Apr;70(4):1923–32

Acylfulvenes, a new class of potent antitumor agents. McMorris TC, et al. **Experientia** 1996 Jan 16;52(1):75–80

Himastatin, a new antitumor antibiotic from Streptomyces hygroscopicus. III. Structural elucidation. Leet JE, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):299–311

Thiazoline analogues of epiderstatin, new inhibitors of cell cycle of tsFT–210 cells. Rani B, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1179–81

Structure–antitumor activity relationship of semi–synthetic Spicamycin derivatives. Sakai T, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1467–80

Absolute configuration of spicamycin, an antitumor antibiotic produced by Streptomyces alanosinicus. Sakai T, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):899–900

Isolation of novel saquayamycins as inhibitors of farnesyl–protein transferase. Sekizawa R, et al. **J Antibiot (Tokyo)** 1996 May;49(5):487–90

Studies on cochleamycins, novel antitumor antibiotics. II. Physico–chemical properties and structure determination. Shindo K, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):244–8

Preparation of optically active epiderstatin and its stereoisomers—epiderstatin is not a real inhibitor of the mitogenic activity induced by epidermal growth factor. Ubukata M, et al. **J Antibiot (Tokyo)** 1995 Oct; 48(10):1176–8

Crystal structures of four morpholino–doxorubicin anticancer drugs complexed with d(CGTACG) and d(CGATCG): implications in drug–DNA crosslink. Gao YG, et al. **J Biomol Struct Dyn** 1995 Aug;13(1):103–17

Inhibition of the oncogene product p185erbB–2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. Schnur RC, et al. **J Med Chem** 1995 Sep 15; 38(19):3806–12

The enediyne antibiotics. Smith AL, et al. **J Med Chem** 1996 May 24;39(11):2103–17 (130 ref.)

A comparative study of the visible light photochemistry of gilvocarcins V and M. Alegría AE, et al. **Photochem Photobiol** 1995 Sep;62(3):409–15

Calicheamicin–DNA complexes: warhead alignment and saccharide recognition of the minor groove. Ikemoto N, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10506–10

High yield conversion of doxorubicin to 2–pyrrolinodoxorubicin, an analog 500–1000 times more potent: structure–activity relationship of daunosamine–modified derivatives of doxorubicin. Nagy A, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19; 93(6):2464–9

1D and 2D 1H NMR studies on bisantrene complexes with short DNA oligomers. Yao S, et al. **Sci China B** 1995 Dec; 38(12):1462–72

[Reaction of acylation of the antineoplastic antibiotic bleomycetin] Usol'tseva SV, et al. **Antibiot Khimioter** 1995 Aug;40(8):7–11 (Eng. Abstr.) **(Rus)**

HISTORY

Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry. Takeuchi T. **J Cancer Res Clin Oncol** 1995;121(9–10):505–10 (52 ref.)

ISOLATION & PURIFICATION

The clecarmycins, new antitumor antibiotics produced by Streptomyces: fermentation, isolation and biological properties. Fujii N, et al. **J Antibiot (Tokyo)** 1995 Aug; 48(8):768–72

Anguinomycins C and D, new antitumor antibiotics with selective cytotoxicity against transformed cells. Hayakawa Y, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):954–61

Medelamines, novel anticancer agents which cancel RAS2val19 induced heat shock sensitivity of yeast [letter] Morino T, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):904–6

Isolation of novel saquayamycins as inhibitors of farnesyl–protein transferase. Sekizawa R, et al. **J Antibiot (Tokyo)** 1996 May;49(5):487–90

Sparoxomycins A1 and A2, new inducers of the flat reversion of NRK cells transformed by temperature sensitive Rous sarcoma virus. II. Isolation, physico–chemical properties and structure elucidation. Ubukata M, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):65–70

Evaluation of acrodontiolamide, a chlorinated compound produced by Acrodontium salmoneum de Hoog for cytotoxicity and antimicrobial activity. Steiman R, et al. **Pharmazie** 1995 Oct;50(10):693–5

METABOLISM

Cooperativity in the binding of echinomycin to DNA fragments containing closely spaced CpG sites. Bailly C, et al. **Biochemistry** 1996 Jan 30;35(4):1150–61

Binding of the antitumor drug nogalamycin to bulged DNA structures. Caceres–Cortes J, et al. **Biochemistry** 1996 Jan 16;35(2):616–25

Dissociation kinetics of echinomycin from CpG binding sites in different sequence environments. Fletcher MC, et al. **Biochemistry** 1996 Jan 23;35(3):1064–75

Sequence–specific hydrolysis of yeast tRNA(Phe) mediated by metal–free bleomycin. Keck MV, et al. **Biochemistry** 1995 Sep 19;34(37):12029–37

Madoropeptin: an antitumor chromoprotein with selective protease activity and DNA cleaving properties. Zein N, et al. **Biochemistry** 1995 Sep 12;34(36):11591–7

Pharmacokinetics and metabolism of O–(chloroacetyl–carbamoyl) fumagillol (TNP–470, AGM–1470) in rhesus monkeys. Cretton–Scott E, et al. **Cancer Chemother Pharmacol** 1996;38(2):117–22

Binding of distamycin and chromomycin to human immunodeficiency type 1 virus DNA: a non–radioactive automated footprinting study. Feriotto G, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):85–93

DT–diaphorase as a target enzyme for biochemical modulation of mitomycin C. Saeki S, et al. **Hiroshima J Med Sci** 1995 Sep;44(3):55–63

Cloning and characterization of a polyketide synthase gene from Streptomyces fradiae Tü2717, which carries the genes for biosynthesis of the angucycline antibiotic urdamycin A and a gene probably involved in its oxygenation. Decker H, et al. **J Bacteriol** 1995 Nov;177(21):6126–36

Different conformations and site selectivity of HO–2–Co(III)–bleomycin A2 and Co (III)–bleomycin A2 bound to DNA oligmers. Mao Q, et al. **J Biol Chem** 1996 Mar 15;271(11):6185–91

PHARMACOKINETICS

Intraaortic stop–flow infusion: pharmacokinetic feasibility study of regional chemotherapy for unresectable gastrointestinal cancers. Averbach AM, et al. **Ann Surg Oncol** 1995 Jul;2(4):325–31

Mitomycin–C concentration in human ocular aqueous humor after topical administration during trabeculectomy. Rump AF, et al. **Arzneimittelforschung** 1995 Dec;45(12):1329–30

Lipid emulsions of palmitoylrhizoxin: effects of composition on lipolysis and biodistribution. Kurihara A, et al. **Biopharm Drug Dispos** 1996 May;17(4):331–42

Lipid emulsions of palmitoylrhizoxin: effects of particle size on blood dispositions of emulsion lipid and incorporated compound in rats. Kurihara A, et al. **Biopharm Drug Dispos** 1996 May;17(4):343–53

Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co–administration with doxorubicin. Desrues B, et al. **Br J Cancer** 1995 Nov; 72(5):1076–82

Antitumor electrochemotherapy: new advances in the clinical protocol. Domenge C, et al. **Cancer** 1996 Mar 1; 77(5):956–63

Pharmacology of N,N–di(n–butyl)adriamycin–14–valerate in the rat. Han G, et al. **Cancer Chemother Pharmacol** 1996; 37(5):472–8

Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor–bearing mice. Shinkai H, et al. **Cancer Chemother Pharmacol** 1996;38(5):417–24

Ocular concentrations of mitomycin C after extraocular application in rabbits. Mietz H, et al. **J Ocul Pharmacol Ther** 1995 Spring;11(1):49–55

Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein. Wasan KM, et al. **J Pharm Sci** 1995 Sep;84(9):1094–100

PHARMACOLOGY

Glucuronidation by human colorectal adenocarcinoma cells as a mechanism of resistance to mycophenolic acid. Franklin TJ, et al. **Adv Enzyme Regul** 1995;35:91–100

Preferential kill of hypoxic EMT6 mammary tumor cells by the bioreductive alkylating agent porfiromycin. Sartorelli

AC, et al. **Adv Enzyme Regul** 1995;35:117-30

In vitro and in vivo stimulation of the murine immune system by AGM-1470, a potent angiogenesis inhibitor. Antoine N, et al. **Am J Pathol** 1996 Feb;148(2):393-8

Bleomycin induces apoptosis in human alveolar macrophages. Hamilton RF Jr, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):L318-25

Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle. Yamamoto M, et al. **Anticancer Drugs** 1995 Aug;6(4):570-7

Antitumor effect of TNP-470 on glial tumors transplanted in rats. Isobe N, et al. **Anticancer Res** 1996 Jan-Feb; 16(1):71-6

Helix-stabilizing agent, CC-1065, enhances suppression of translation by an antisense oligodeoxynucleotide. Kim DY, et al. **Antisense Res Dev** 1995 Summer;5(2):149-54

On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Basak J. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):509-14

The angiogenesis inhibitor AGM-1470 selectively increases E-selectin. Budson AE, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):141-5

Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Beall HD, et al. **Biochem Pharmacol** 1996 Mar 8;51(5):645-52

Rapamycin-resistant human lymphoid cell lines. Kay JE, et al. **Biochem Soc Trans** 1996 Feb;24(1):89S

1,2-Dithiolan-3-one 1-oxides: a class of thiol-activated DNA-cleaving agents that are structurally related to the natural product leinamycin. Behroozi SJ, et al. **Biochemistry** 1996 Feb 13;35(6):1768-74

Specific cleavage of a DNA triple helix by FeII.bleomycin. Kane SA, et al. **Biochemistry** 1995 Dec 26;34(51):16715-24

Double-stranded damage of DNA.RNA hybrids by neocarzinostatin chromophore: selective C-1' chemistry on the RNA strand. Zeng X, et al. **Biochemistry** 1995 Sep 26;34(38):12435-44

19-Allylaminoherbimycin A, an analog of herbimycin A that is stable against treatment with thiol compounds or granulocyte-macrophage colony-stimulating factor in human leukemia cells. Makishima M, et al. **Biochim Biophys Acta** 1995 Dec 12;1272(3):199-205

Enediyne-mediated cleavage of RNA. Battigello JM, et al. **Bioorg Med Chem** 1995 Jun;3(6):839-49

Design, synthesis and sequence selective DNA cleavage of functional models of bleomycin--II. 1,2-trans-disubstituted cyclopropane units as novel linkers. Huang L, et al. **Bioorg Med Chem** 1995 Jun;3(6):647-57

New insights into calicheamicin-DNA interactions derived from a model nucleosome system. Yu L, et al. **Bioorg Med Chem** 1995 Jun;3(6):729-41

The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Consoli U, et al. **Blood** 1996 Jul 15;88(2):633-44

Bleomycin-induced DNA damage and repair in wild-type and thymidine kinase-deficient Friend mouse erythroleukaemia cells. Sweetman SF, et al. **Br J Biomed Sci** 1995 Dec;52(4):257-65

Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. McLeskey SW, et al. **Br J Cancer** 1996 May; 73(9):1053-62

Streptococcal glycoprotein-induced tumour cell growth inhibition involves the modulation of a pertussis toxin-sensitive G protein. Yoshida J, et al. **Br J Cancer** 1996 Apr;73(8):917-23

Sensitivity of cell lines to mitomycin C. Watts PL, et al. **Br J Urol** 1996 Mar;77(3):363-6

Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Teicher BA, et al. **Breast Cancer Res Treat** 1995; 36(2):227-36

Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Konno H, et al. **Cancer** 1996 Apr 15; 77(8 Suppl):1736-40

Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. Han G, et al. **Cancer Chemother Pharmacol** 1996; 37(5):472-8

The activity of deoxyspergualin in multidrug-resistant cells. Holmes JA, et al. **Cancer Chemother Pharmacol** 1995; 36(6):499-505

Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells. McIlwrath AJ, et al. **Cancer Chemother Pharmacol** 1996;37(5):423-8

Flavone acetic acid increases the cytotoxicity of mitomycin C when combined with hyperthermia. Takeuchi H, et al. **Cancer Chemother Pharmacol** 1996;38(1):1-8

Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor beta by treatment with bleomycin. Yuan L, et al. **Cancer Immunol Immunother** 1995 Dec;41(6):355-62

Potentiation of enediyne-induced apoptosis and differentiation by Bcl-2. Cortazzo M, et al. **Cancer Res** 1996 Mar 15;56(6):1199-203

Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Devineni D, et al. **Cancer Res** 1996 May 1;56(9):1983-7

Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells. Franklin TJ, et al. **Cancer Res** 1996 Mar 1;56(5):984-7

Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. Kelner MJ, et al. **Cancer Res** 1995 Nov 1;55(21):4936-40

Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Seufferlein T, et al. **Cancer Res** 1996 Sep 1; 56(17):3895-7

Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Taniguchi K, et al. **Cancer Res** 1996 May 15;56(10):2348-54

Alternative splicing and differential expression of DT-diaphorase transcripts in human colon tumors and in peripheral mononuclear cells in response to mitomycin C treatment. Yao KS, et al. **Cancer Res** 1996 Apr 15; 56(8):1731-6

Influence of the antioxidant N-acetylcysteine and its metabolites on damage induced by bleomycin in PM2 bacteriophage DNA. Cloos J, et al. **Carcinogenesis** 1996 Feb;17(2):327-31

The antitumor drug fostriecin induces vimentin hyperphosphorylation and intermediate filament reorganization. Ho DT, et al. **Carcinogenesis** 1996 May; 17(5):967-72

Status of new anthrapyrazole and pyrazoloacridine derivatives. Berg SL. **Crit Rev Oncol Hematol** 1996 Mar; 22(2):79-87 (57 ref.)

Re-evaluation of the molecular pharmacology of mitomycin C. Cummings J, et al. **Eur J Cancer** 1995 Nov; 31A(12):1928-33 (61 ref.)

Analogue versus digital recognition of DNA by bleomycin: an effect of the carbohydrate moiety. Bailly C, et al. **FEBS Lett** 1995 Sep 25;372(2-3):144-7

DT-diaphorase as a target enzyme for biochemical modulation of mitomycin C. Saeki S, et al. **Hiroshima J Med Sci** 1995 Sep;44(3):55-63

Sirolimus (rapamycin) inhibits mitogen-induced stimulation of protein synthesis in primary lymphocytes. Bansbach CC, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S179-80

Differentiation of U-937 promonocytic cells with mitomycin C or cis-diamminedichloroplatinum II. Ballester A, et al. **Int J Cancer** 1996 Mar 15;65(6):791-5

Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line. Singh SV, et al. **Int J Cancer** 1996 Mar 15;65(6):852-7

Isolation and characterization of a novel Deinococcus radiodurans mutant abnormally susceptible to mutation induction by UV, gamma-ray, and mitomycin C. Lin CL, et al. **Int J Radiat Biol** 1996 Apr;69(4):493-502

Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro. Ebrahim el-Zayat AA, et al. **Invest New Drugs** 1995;13(2):125-131

Inhibition of c-fos proto-oncogene induction by Sch 52900 and Sch 52901, novel diketopiperazine produced by Gliocladium sp. Chu M, et al. **J Antibiot (Tokyo)** 1995 Dec; 48(12):1440-5

Rakicidins, new cytotoxic lipopeptides from Micromonospora sp. fermentation, isolation and characterization. McBrien KD, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1446-52

Structure-antitumor activity relationship of semi-synthetic Spicamycin derivatives. Sakai T, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1467-80

Studies on cochleamycins, novel antitumor antibiotics. I. Taxonomy, production, isolation and biological activities. Shindo K, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):241-3

Inhibition of mouse tumor metastasis with nojirimycin-related compounds. Tsuruoka T, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):155-61

Inhibition of the association with nuclear matrix of pRB, p70 and p40 proteins along with the specific suppression of c-MYC expression by geldanamycin, an inhibitor of Src tyrosine kinase. Yamaki H, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):1021-6

Screening for apoptosis inducers in microbial products and induction of apoptosis by cytostatin. Yamazaki K, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1138-40

Morphology of ras-transformed cells becomes apparently normal again with tyrosine kinase inhibitors without a decrease in the ras-GTP complex. Kwon HJ, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):221-8

Sensitivity to the parvovirus minute virus of mice as a probe for azatyrosine-mediated phenotypic reversion of spontaneously transformed cells. Koering CE, et al. **J Gen Virol** 1996 May;77 (Pt 5):913-7

Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. Schnur RC, et al. **J Med Chem** 1995 Sep 15; 38(19):3806-12

Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833 [see comments] Beketic-Oreskovic L, et al. **J Natl Cancer Inst** 1995 Nov 1;87(21):1593-602. Comment in: J Natl Cancer Inst 1995 Nov 1;87(21):1573-5.

Re: Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and E09 [letter] Pritsos C. **J Natl Cancer Inst** 1996 Aug 21;88(16):1161-3

Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. Ikemoto H, et al. **J Neurosurg** 1995 Dec;83(6):1008-16

Induction of apoptosis in murine and human neuroblastoma cell lines by the enediyne natural product neocarzinostatin. Hartsell TL, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):479-85

Antitumor effects of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma. Fujioka T, et al. **J Urol** 1996 May;155(5):1775-8

Angelmicin B, a new inhibitor of oncogenic signal transduction, inhibits growth and induces myelomonocytic differentiation of human myeloid leukemia HL-60 cells. Yokoyama A, et al. **Leuk Res** 1996 Jun;20(6):491-7

An ABC transporter is essential for resistance to the antitumor agent mithramycin in the producer Streptomyces argillaceus. Fernández E, et al. **Mol Gen Genet** 1996 Jul 26;251(6):692-8

Sparsomycin and its analogues: a new approach for evaluating their potency as inhibitors of peptide bond formation. Kallia-Raftopoulos S, et al. **Mol Pharmacol** 1996 Jun;49(6):1085-91

DNA strand cleavage by tumor-inhibiting antibiotic 6-diazo-5-oxo-L-norleucine. Hiramoto K, et al. **Mutat Res** 1996 Jun 10;360(2):95-100

The antitumor effect of MX2, a new morpholino anthracycline, against malignant glioma cell lines and its subcellular distribution. Kabuto M, et al. **Neurosurgery** 1995 Sep;37(3):471-6; discussion 476-7

Effect of herbimycin A on renal cancer cell growth. Tsuji A, et al. **Nippon Jinzo Gakkai Shi** 1996 May;38(5):198-201

In vitro detection of endonuclease IV-specific DNA damage formed by bleomycin in vivo. Levin JD, et al. **Nucleic Acids Res** 1996 Mar 1;24(5):885-9

Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild-type and repair-deficient cell lines [corrected and republished with original paging, article originally printed in Oncol Res 1995;7(1):39-47] Kim SY, et al. **Oncol Res** 1995;7(5):39-47

Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild-type and repair-deficient cell lines [corrected and republished in Oncol Res 1995;7(5):39-47] Rockwell S, et al. **Oncol Res** 1995;7(1):39-47

Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. Uchegbu IF, et al. **Pharm Res** 1995 Jul;12(7):1019-24

Human cDNA clones that modify radiomimetic sensitivity of ataxia-telangiectasia (group A) cells. Ziv Y, et al. **Somat Cell Mol Genet** 1995 Mar;21(2):99-111

Mycophenolic acid: measurement and relationship to pharmacologic effects. Shaw LM, et al. **Ther Drug Monit** 1995 Dec;17(6):685-9 (22 ref.)

Mechanism of action of rapamycin (Sirolimus, Rapamune). Molnar-Kimber KL. **Transplant Proc** 1996 Apr;28(2):964-9 (127 ref.)

The potent angioinhibin AGM-1470 stimulates normal but not human tumoral lymphocytes. Antoine N, et al. **Tumori** 1996 Jan-Feb;82(1):27-30

[Mechanism of resistance to mitomycin C in a human bladder cancer cell line] Xu B, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep;17(5):343-6 (Eng. Abstr.) **(Chi)**

[Antitumor effect of MX2, a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro] Kabuto M, et al. **No To Shinkei** 1995 Oct;47(10):969-73 (Eng. Abstr.) **(Jpn)**

[Studies on reversing effect of multidrug resistance by dipyridamole. II. Inhibition of epirubicin efflux from resistant cells by dipyridamole and its pharmacological effect] Hayashi A, et al. **Yakugaku Zasshi** 1996 Mar; 116(3):228-37 (Eng. Abstr.) **(Jpn)**

[Increase in the effectiveness of site-specific cleavage of target DNA by tetranucleotide bleomycin derivatives using oligonucleotide-effectors] Vorob'ev PE, et al. **Bioorg Khim** 1996 Feb;22(2):111-6 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

A comparative study of the visible light photochemistry of gilvocarcins V and M. Alegría AE, et al. **Photochem Photobiol** 1995 Sep;62(3):409-15

THERAPEUTIC USE

Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia. Bassan R, et al. **Acta Haematol** 1996;95(3-4):188-92 (22 ref.)

A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium [letter; comment] Sanchez-Thorin JC. **Am J Ophthalmol** 1996 Mar;121(3):333-4. Comment on: Am J Ophthalmol 1995 Aug;120(2):151-60.

Activity of N-benzyl-adriamycin-14-valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines. Harstrick A, et al. **Anticancer Drugs** 1995 Oct;6(5):681-5

A clinical nude mouse metastatic model for highly malignant human pancreatic cancer. An Z, et al. **Anticancer Res** 1996 Mar-Apr;16(2):627-31

Aminopeptidase inhibitor ubenimex (bestatin) inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity. Inoi K, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2081-7

Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study. Baas P, et al. **Br J Cancer** 1996 Apr;73(8):945-51

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group. Hanauske AR, et al. **Br J Cancer** 1996 Feb;73(3):397-9

Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group. Kaplan S, et al. **Br J Cancer** 1996 Feb;73(3):403-5

Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia. Nishimura Y, et al. **Br J Cancer** 1996 Feb; 73(3):270-4

Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group. Verweij J, et al. **Br J Cancer** 1996 Feb;73(3):400-2

Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group. Pignon B, et al. **Br J Haematol** 1996 Aug; 94(2):333-41

Long term results of intraoperative mitomycin C in the treatment of recurrent pterygium. Mastropasqua L, et al. **Br J Ophthalmol** 1996 Apr;80(4):288-91

Antitumor electrochemotherapy: new advances in the clinical protocol. Domenge C, et al. **Cancer** 1996 Mar 1; 77(5):956-63

Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Heller R, et al. **Cancer** 1996 Mar 1;77(5):964-71

Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancer. Sella A, et al. **Cancer Biother** 1995 Fall;10(3):225-35

Mitomycins. Verweij J. **Cancer Chemother Biol Response Modif** 1996;16:48-56 (43 ref.)

An indicator quantitatively comparing two treatment effect sizes on responder and non-responder groups--exponential of estimated interaction parameter. Sugita M, et al. **Cancer Immunol Immunother** 1995 Oct;41(4):251-6

DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Mikami K, et al. **Cancer Res** 1996 Jun 15; 56(12):2823-6

A prospective study of pulmonary function in patients receiving mitomycin. Castro M, et al. **Chest** 1996 Apr; 109(4):939-44

Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Van der Meijden AP, et al. **Eur Urol** 1996;29(2):199-203

Success rate and complications of intraoperative 0.2 mg/ml mitomycin C in trabeculectomy surgery. Singh J, et al. **Eye** 1995;9 (Pt 4):460-6

Histopathology of episcleral fibrosis after trabeculectomy with and without mitomycin C. Mietz H, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jun;234(6):364-8

Regional chemotherapy with hemofiltration: a rationale for a different treatment approach to advanced pancreatic cancer. Muchmore JH, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):346-55

Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes. Davies SL, et al. **Int J Cancer** 1996 Jan 3; 65(1):63-6

Short-term clinical results and complications of trabeculectomies performed with mitomycin C using different concentrations. Mietz H, et al. **Int Ophthalmol** 1995;19(1):51-6

A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study. Gradishar WJ, et al. **Invest New Drugs** 1995;13(2):171-4

Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Tetef M, et al. **Invest New Drugs** 1995;13(2):157-62

A new aromatase inhibitor, FR901537. II. Pharmacological and antitumor effects. Oohata N, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):763-7

Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. Stępień H, et al. **J Endocrinol** 1996 Jul;150(1):99-106

Paclitaxel in doxorubicin-resistant metastatic breast cancer patients [letter; comment] Anand A, et al. **J Natl Cancer Inst** 1995 Nov 1;87(21):1642. Comment on: J Natl Cancer Inst 1995 Aug 2;87(15):1169-75.

Preoperative mitomycin-C subconjunctival injection and glaucoma filtering surgery. Hung PT, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):233-41

Successful treatment of two children with Langerhans' cell histiocytosis with 2'-deoxycoformycin. McCowage GB, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):154-8

Applicability of monoclonal antibody Fab fragments as a carrier of neocarzinostatin in targeting chemotherapy. Otsuji E, et al. **J Surg Oncol** 1996 Feb;61(2):149-54

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics [see comments] Krege S, et al. **J Urol** 1996 Sep;156(3):962-6. Comment in: J Urol 1996 Sep;156(3):972-4.

Experimentally designed glaucoma implant surgery with mitomycin C in rabbit. Kee C, et al. **Korean J Ophthalmol** 1995 Dec;9(2):89-95

A phase II study of menogaril (7R-O-methylnogarol) in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group. Dutcher JP, et al. **Leukemia** 1995 Oct;9(10):1638-42

Laser suture lysis after mitomycin C trabeculectomy. Morinelli EN, et al. **Ophthalmology** 1996 Feb;103(2):306-14

Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Parangi S, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2002-7

Recurrent breast cancer treated successfully with mitomycin-C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel--a case report. Sekine I, et al. **Tohoku J Exp Med** 1996 Mar; 178(3):331-7

Short schedule intravesical mitomycin preceding transurethral resection for recurrent Ta-T1, G1-G2 bladder cancer. Maffezzini M, et al. **Tumori** 1995 May-Jun; 81(3):191-3

[Minocycline potentiates the antimetastatic effect of boanmycin] Liu JG, et al. **Yao Hsueh Hsueh Pao** 1995; 30(9):668-73 (Eng. Abstr.) **(Chi)**

[Effect of the conjugate composed of a human monoclonal antibody and pingyangmycin on mammary cancer] Wang WG, et al. **Yao Hsueh Hsueh Pao** 1995;30(8):583-7 (Eng. Abstr.) **(Chi)**

[Bleomycin in Kaposi disease in a patient with heart transplantation] Modiano P, et al. **Ann Dermatol Venereol** 1996;123(3):174-6 (Eng. Abstr.) **(Fre)**

[A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder] Iavarone C, et al. **G Chir** 1996 May;17(5):289-91 (Eng. Abstr.) **(Ita)**

[Effects of angiogenesis inhibitor TNP-470 to suppress the recurrence in the liver remnant after partial hepatectomy for liver metastases in rabbits] Mugitani T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1477-9 (Eng. Abstr.) **(Jpn)**

[Effects of IgG-Fc-mitomycin C conjugate on cancer cells] Baba E. **Hokkaido Igaku Zasshi** 1996 Mar;71(2):271-81 (Eng. Abstr.) **(Jpn)**

[Hematological stability under ubenimex monotherapy in a patient with acute myelogenous leukemia developing marrow karyotypic changes during the course] Shimosegawa K, et al. **Rinsho Ketsueki** 1995 Nov; 36(11):1289-94 (Eng. Abstr.) **(Jpn)**

[Mitomycin C for the treatment of superficial tumors of the bladder (Tis-Ta-T1) with one or more risk factors. Argentinian Cooperative Group of Oncourology (GCAO)] Villaronga A, et al. **Arch Esp Urol** 1996 Mar;49(2):133-8 (Eng. Abstr.) **(Spa)**

TOXICITY

Histopathological effects of illudin S, a toxic substance of poisonous mushroom, in rat. Tanaka K, et al. **Hum Exp Toxicol** 1996 Apr;15(4):289-93

Effects of bleomycin and Staphylococcus protein-A on lungs of mice. Sahu AP, et al. **Indian J Exp Biol** 1995 Oct; 33(10):734-8

Paradoxical effects of bleomycin and heavy water (D2O) in mice. Gaeng DP, et al. **Int J Cancer** 1995 Sep 15; 62(6):784-90

Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results. Lasek W, et al. **Int J Cancer** 1996 May 3;66(3):374-9

Selective cytotoxicity of mycophenolic acid against transformed cells. Hayakawa Y, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1182-4

Hepatotoxins and liver transplantation decrease pulmonary metastases in rats with hepatoma. Freise CE, et al. **J Surg Res** 1996 Aug;64(2):198-202

DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Povirk LF. **Mutat Res** 1996 Aug 17; 355(1-2):71-89 (125 ref.)

Low mutagenic effects of mitomycin C in undifferentiated embryonic P19 cells are correlated with efficient cell cycle control. Sehlmeyer U, et al. **Mutat Res** 1996 Jul 5; 354(1):103-12

Enhancement of chromosome aberrations by the combination of DNA substitution with halogenated deoxyuridine and streptonigrin treatments. Testoni MI, et al. **Mutat Res** 1996 Jan 16;359(1):31-7

Effects of trichothecene structure on cytokine secretion and gene expression in murine CD4+ T-cells. Ouyang YL, et al. **Toxicology** 1995 Dec 15;104(1-3):187-202

URINE

Metabolism of illudin S, a toxic substance of Lampteromyces japonicus: urinary excretion of mercapturic acids in rat. Tanaka K, et al. **Xenobiotica** 1996 Mar;26(3):347-54

ANTIBIOTICS, ANTITUBERCULAR

Structure determination of ribosylated rifampicin and its derivative: new inactivated metabolites of rifampicin by mycobacterial strains. Morisaki N, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1299-303

ADMINISTRATION & DOSAGE

Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. China Tuberculosis Control Collaboration [see comments] **Lancet** 1996 Feb 10;347(8998):358-62. Comment in: Lancet 1996 Mar 23;347(9004):835. Comment in: Lancet 1996 Mar 23;347(9004):835-6.

ADVERSE EFFECTS

Adverse reaction to rifampin mimicking symptoms of pulmonary tuberculosis [letter] Hogenauer AF, et al. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2339-40

Tuberculosis in the elderly. Epidemiology and optimal management. Davies PD. **Drugs Aging** 1996 Jun;8(6):436-44 (31 ref.)

Streptomycin induced myaesthenic syndrome. Asotra S, et al. **J Assoc Physicians India** 1995 Sep;43(9):650

Redman syndrome [letter] Dayavathi, et al. **J Assoc Physicians India** 1995 Oct;43(10):724

Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol. Lowe SH, et al. **Neth J Med** 1996 Jun;48(6):211-5

[Monitoring ototoxic side effects in streptomycin therapy of tuberculosis patients with transitory evoked otoacoustic emissions TEOAE] Fürst G, et al. **Pneumologie** 1995 Nov; 49(11):590-5 (Eng. Abstr.) **(Ger)**

[Fulminant, rapidly reversible hepatitis and life-threatening anaphylaxis following rifampicin in an HIV-positive female patient with latent adrenal cortex insufficiency] Canova CR, et al. **Schweiz Med Wochenschr** 1996 Mar 9; 126(10):392-7 (Eng. Abstr.) **(Ger)**

[Two cases of therapy-related myelodysplastic syndrome] Takahashi A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):53-9 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Fatal anaphylactic shock caused by rifampicin in a patient with HIV infection (letter)] Inmaculada Rubio M, et al. **Enferm Infecc Microbiol Clin** 1996 Mar;14(3):200-1 **(Spa)**

[Desensitization to rifampicin. Apropos of a case (letter)] Alonso MD, et al. **Med Clin (Barc)** 1996 Mar 2;106(8):319 **(Spa)**

BLOOD

A comparison of disc and cartridge solid-phase extraction for the LC determination of rifampin and 25-desacetylrifampin in human serum. Ye L, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1185-8

PHARMACOKINETICS

Isoniazid elimination kinetics in children with protein-energy malnutrition treated for tuberculous meningitis with a four-component antimicrobial regimen. Seifart HI, et al. **Ann Trop Paediatr** 1995 Sep;15(3):249-54

[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs] Kaltenbach G, et al. **Pathol Biol (Paris)** 1996 May;44(5):379-83 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Fujii K, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1489-92

In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Hirata T, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2295-303

Antituberculosis activity of clarithromycin. Luna-Herrera J, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2692-5

Antimycobacterial activity of a new rifamycin derivative, 3-(4-cinnamylpiperazinyl iminomethyl) rifamycin SV (T9). Reddy VM, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2320-4

Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide. Speirs RJ, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1269-71

Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Sreevatsan S, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1024-6

Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Musser JM. **Clin Microbiol Rev** 1995 Oct; 8(4):496-514 (181 ref.)

Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Backman JT, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):7-13

In-vitro and intracellular activity of rifabutin on drug-susceptible and multiple drug-resistant (MDR)

tubercle bacilli. Luna-Herrera J, et al. **J Antimicrob Chemother** 1995 Aug;36(2):355-63

In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. Moneib NA. **J Chemother** 1995 Dec; 7(6):525-9

An entomopoxvirus homologue of the vaccinia virus D13L-encoded 'rifampicin resistance' protein. Osborne RJ, et al. **J Gen Virol** 1996 May;77 (Pt 5):839-46

Evaluation of cycloserine in the treatment of Alzheimer's disease. Fakouhi TD, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8(4):226-30

Semipreparative chromatographic separation of cyclosporin G metabolites generated by microsomes from rabbits treated with rifampicin. Liu WT, et al. **J Pharmacol Toxicol Methods** 1996 Jun;35(3):121-9

A new genetic assay for rifampicin susceptibility of Mycobacterium tuberculosis. Kusunoki S, et al. **Kansenshogaku Zasshi** 1995 Dec;69(12):1342-7

Rifampicin-resistant tuberculosis [letter; comment] Wynne BA, et al. **Lancet** 1995 Oct 7;346(8980):971-2. Comment on: Lancet 1995 Jun 10;345(8963):1513.

Rapid measurement of antimycobacterial drug activity. Gordon S, et al. **Res Microbiol** 1996 Jan-Feb; 147(1-2):79-86 (31 ref.)

The genetics of multiple drug resistance in Mycobacterium tuberculosis and the Mycobacterium avium complex. Morris SL, et al. **Res Microbiol** 1996 Jan-Feb; 147(1-2):68-73 (40 ref.)

Ribosomal drug resistance in mycobacteria. Sander P, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):59-67 (73 ref.)

Novel strategies for the detection of drug resistance in Mycobacterium tuberculosis. Telenti A, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):73-9 (34 ref.)

Rifampicin resistance in Mycobacterium tuberculosis--rapid detection and implications in chemotherapy. Pretorius GS, et al. **S Afr Med J** 1996 Jan;86(1):50-5

Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog. Hosoe K, et al. **Xenobiotica** 1996 Mar;26(3):321-32

[A complex antibiotic preparation obtained from a medicinal plant from the family Asteraceae] Smirnov VV, et al. **Mikrobiol Z** 1995 Jul-Aug;57(4):73-82 (29 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. Kassim S, et al. **AIDS** 1995 Oct;9(10):1185-91

Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. Moore RD, et al. **AIDS** 1995 Dec;9(12):1337-42

Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Lutfey M, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):837-40

Potential role of rifabutin in prophylaxis for tuberculosis and infections due to multiple opportunistic pathogens. Chaisson RE. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S61-6; discussion S66-9 (51 ref.)

Use of rifabutin in the treatment of pulmonary tuberculosis. Grassi C, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S50-4 (21 ref.)

Risk factors associated with drug-resistant Mycobacterium tuberculosis in Castilla-la-Mancha (Spain). Arévalo M, et al. **Eur Respir J** 1996 Feb;9(2):274-8

Alternatives to INH chemoprophylaxis [letter; comment] Sane SV, et al. **Indian Pediatr** 1995 Aug;32(8):935-7. Comment on: Indian Pediatr 1995 Jan;32(1):105.

Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. Lundstrom TS, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):747-67 (91 ref.)

Rifabutin as salvage therapy for cases of chronic multidrug-resistant pulmonary tuberculosis in Taiwan. Lee CN, et al. **J Chemother** 1996 Apr;8(2):137-43

Evaluation of cycloserine in the treatment of Alzheimer's disease. Fakouhi TD, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8(4):226-30

Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi. Harries AD, et al. **Lancet** 1996 Mar 23; 347(9004):807-9

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group [see comments] Havlir DV, et al. **N Engl J Med** 1996 Aug 8;335(6):392-8 . Comment in: N Engl J Med 1996 Aug 8;335(6):428-30.

Effect of rifampin on Staphylococcus aureus colonization in children on chronic peritoneal dialysis. Hanevold CD, et al. **Pediatr Nephrol** 1995 Oct;9(5):609-11

Evaluating the quality of life associated with rifabutin prophylaxis for Mycobacterium avium complex in persons with AIDS: combining Q-TWiST and multiattribute utility techniques. Revicki DA, et al. **Qual Life Res** 1995 Aug; 4(4):309-18

Clinical and epidemiologic implications of polyclonal infection due to Mycobacterium avium complex. von Reyn CF, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):24-30 (46 ref.)

Rifampicin for ulcerative colitis [letter] Schoonees R, et al. **S Afr Med J** 1996 Jan;86(1):97-8

Rifabutin-containing regimens for pulmonary tuberculosis: early assessment of treatment effectiveness [letter] Gonzales Montanler J, et al. **Tuber Lung Dis** 1996 Feb;77(1):100

Pattern of utilization of rifabutin for prophylaxis of Mycobacterium avium complex among patients with advanced human immunodeficiency virus disease in a community setting. Mandigo K, et al. **Tuber Lung Dis** 1996 Jun;77(3):233-8

Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. Reddy MV, et al. **Tuber Lung Dis** 1996 Apr;77(2):154-9

[Comparison of routine therapeutic protocols used in Madagascar for the treatment of smear-positive pulmonary tuberculosis (preliminary results)] Boisier P, et al. **Arch Inst Pasteur Madagascar** 1995;62(1):72-6 (Eng. Abstr.) **(Fre)**

[Mechanism of bacterial regrowth at the sites of infection in Mycobacterium avium complex-infected mice during treatment with chemotherapeutic agents] Sato K, et al. **Kekkaku** 1995 Dec;70(12):673-8 (Eng. Abstr.) **(Jpn)**

[Oxidative metabolism changes in respiratory tract cells of guinea pigs during natural development of experimental tuberculosis and under specific chemotherapy] Kaminskaia GO, et al. **Probl Tuberk** 1996;(2):33-6 (Eng. Abstr.) **(Rus)**

TOXICITY

Cytogenetic effects of rifampicin in somatic and germinal cells of the mouse. Aboul-Ela EI. **J Appl Toxicol** 1995 Jul-Aug;15(4):325-6

URINE

Presence of rifampicin in urine causes cross-reactivity with opiates using the KIMS method [letter] Herrera Trevilla P, et al. **J Anal Toxicol** 1995 May-Jun;19(3):200

Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog. Hosoe K, et al. **Xenobiotica** 1996 Mar;26(3):321-32

ANTIBIOTICS, BETA-LACTAM see **ANTIBIOTICS, LACTAM**

ANTIBIOTICS, CARBAPENEM see **CARBAPENEMS**

ANTIBIOTICS, CEPHALOSPORIN see **CEPHALOSPORINS**

ANTIBIOTICS, CEPHAMYCIN see **CEPHAMYCINS**

ANTIBIOTICS, COMBINATION see **ANTIBIOTICS, COMBINED**

ANTIBIOTICS, COMBINED

[Study of the usefulness of a kit containing imipenem/cilastatin powder with diluent for injection: convenience of use and preparation] Hirayama T, et al. **Jpn J Antibiot** 1996 Feb;49(2):203-10 (Eng. Abstr.) **(Jpn)**

[Study of the usefulness of a kit containing imipenem/cilastatin powder with diluent for injection: accuracy of reconstitution] Hirayama T, et al. **Jpn J Antibiot** 1996 Feb;49(2):211-7 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

The efficacy of intraperitoneally administered gentamicin and rifampin as initial treatment of peritoneal dialysis-related peritonitis. Brulez HF, et al. **Adv Perit Dial** 1995;11:182-6

Treatment of peritoneal dialysis-associated peritonitis with continuous versus intermittent vancomycin/teicoplanin and ceftazidime in children: preliminary results of a prospective randomized trial. Members of APN Arbeitsgemeinschaft Paidiatrische Nephrologie. Klaus G, et al. **Adv Perit Dial** 1995;11:296-301

Effect of gentamicin dosing interval on therapy of viridans streptococcal experimental endocarditis with gentamicin plus penicillin. Gavaldà J, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2098-103

Efficacy of twice-daily amoxycillin/clavulanate ('Augmentin-Duo' 400/57) in mild to moderate lower respiratory tract infection in children. Cook RC, et al. **Br J Clin Pract** 1996 Apr-May;50(3):125-8

Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective randomized trial of cefuroxime versus piperacillin/tazobactam. Brewster SF, et al. **Br J Urol** 1995 Sep;76(3):351-4

Discoid lupus erythematosus. Poirier N. **Can Vet J** 1995 Aug; 36(8):493

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Griffith DE, et al. **Clin Infect Dis** 1995 Sep;21(3):594-8

A randomized trial of pefloxacin plus klindamicin and cefoxitin in hepatobiliary and pancreatic surgery. Fried M, et al. **Hepatogastroenterology** 1996 Jan-Feb;43(7):306-8

Intramuscular administration of ceftiofur sodium versus intramammary infusion of penicillin/novobiocin for treatment of Streptococcus agalactiae mastitis in dairy cows. Erskine RJ, et al. **J Am Vet Med Assoc** 1996 Jan 15;208(2):258-60

Comparison of intravenous and oral antibiotic therapy in the treatment of fractures caused by low-velocity gunshots. A prospective, randomized study of infection rates. Knapp TP, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1167-71 (35 ref.)

Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections. Paradisi F, et al. **J Chemother** 1995 Aug;7(4):338-43 (54 ref.)

Metronidazole resistance: a predictor of failure of Helicobacter pylori eradication by triple therapy. Midolo PD, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):290-2

Combination therapy involving ciprofloxacin for peritonitis. Guest SS, et al. **Perit Dial Int** 1996 May-Jun;16(3):316-8

Ampicillin plus mecillinam vs. cefotaxime/cefadroxil treatment of patients with severe pneumonia or pyelonephritis: a double-blind multicentre study evaluated by intention-to-treat analysis. Cronberg S, et al. **Scand J Infect Dis** 1995;27(5):463-8

Combined use of fluconazole and selective digestive decontamination in the prevention of fungal infection after adult liver transplantation. Decruyenaere J, et al. **Transplant Proc** 1995 Dec;27(6):3515-6

A controlled clinical trial of short-course chemotherapy for tuberculoma of the brain. Rajeswari R, et al. **Tuber Lung Dis** 1995 Aug;76(4):311-7

[Antibiotic and anti-cancer pasting for putrefactive cancers] Okuyama S, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1851-3 **(Jpn)**

[Clinical efficacy of sulbactam/cefoperazone for the treatment of geriatric patients with respiratory tract infections] Takaki K, et al. **Jpn J Antibiot** 1995 Jul; 48(7):942-8 (Eng. Abstr.) **(Jpn)**

[Combination therapy with arbekacin and fosfomycin against postoperative severe mixed-pneumonia of MRSA in primary lung cancer patients] Harada R, et al. **Kyobu Geka** 1995 Sep;48(10):836-40 (Eng. Abstr.) **(Jpn)**

[Interesting case of pulmonary alveolar proteinosis] Nakamura Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1909-11 **(Jpn)**

[The efficacy of sulbactam-ampicillin in a urinary infection due to Acinetobacter calcoaceticus var. anitratus (letter)] Telenti Asensio M, et al. **Med Clin (Barc)** 1995 Oct 7; 105(11):438-9 **(Spa)**

ADVERSE EFFECTS

Hypersensitivity reaction during prolonged use of piperacillin/tazobactam in treatment of osteomyelitis [letter] Behbahani R, et al. **Ann Pharmacother** 1995 Sep; 29(9):936-7

Co-trimoxazole induced aseptic meningitis. Pashankar D, et al. **Arch Dis Child** 1995 Sep;73(3):257-8

Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. García Rodríguez LA, et al. **Arch Intern Med** 1996 Jun 24;156(12):1327-32

Chorioamnionitis due to pseudomonas aeruginosa: a complication of prolonged antibiotic therapy for premature rupture of membranes. Kyle P, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):181-3

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease [letter] Berning SE, et al. **Clin Infect Dis** 1996 May;22(5):885

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Griffith DE, et al. **Clin Infect Dis** 1995 Sep;21(3):594-8

Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol. Lowe SH, et al. **Neth J Med** 1996 Jun;48(6):211-5

[Cholestatic hepatitis and amoxicillin-clavulanic acid combination. Personnel case report and literature review] Watteeuw G, et al. **Rev Med Brux** 1995 Dec;16(6):391-3 (11 ref.) (Eng. Abstr.) **(Fre)**

[Spektramox and liver damage] **Lakartidningen** 1996 Feb 7; 93(6):490 **(Swe)**

CHEMISTRY

Stability of metronidazole and ceftizoxime sodium in ready-to-use metronidazole bags stored at 4 and 25 degrees C. Nahata MC, et al. **Am J Health Syst Pharm** 1996 May 1;53(9):1046-8

Stability of amoxicillin-clavulanate in BACTEC medium determined by high-performance liquid chromatography and bioassay. Moore TD, et al. **J Clin Microbiol** 1996 May; 34(5):1321-2

ECONOMICS

A cost-benefit analysis of the post-operative use of antibiotic ear drops following grommet insertion. Pearson CR, et al. **J Laryngol Otol** 1996 Jun;110(6):527-30

PHARMACOKINETICS

Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Cappelletty DM, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1797-801

Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics. Nix DE, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):71-6

Pharmacokinetic-based ticarcillin/clavulanic acid dose recommendations for infants and children. Reed MD, et al. **J Clin Pharmacol** 1995 Jul;35(7):658-65

Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. Jhee SS, et al. **Pharmacotherapy** 1995 Jul-Aug;15(4):472-8

Clearance of ticarcillin-clavulanic acid by continuous venovenous hemofiltration in three critically ill children, two with and one without concomitant extracorporeal membrane oxygenation. Lindsay CA, et al. **Pharmacotherapy** 1996 May-Jun;16(3):458-62

Comparative pharmacokinetics of an ampicillin/sulbactam combination administered intramuscularly in lactating sheep and goats. Escudero E, et al. **Vet Res** 1996; 27(3):201-8

[Demonstration of activity of two potentiated sulfonamides in feces of horses after oral or intravenous administration] Fey K, et al. **Tierarztl Prax** 1996 Jun;24(3):261-9 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

In vitro activity of amoxycillin/clavulanate and ticarcillin/clavulanate compared with that of other antibiotics against anaerobic bacteria: comparison with the results of the 1987 survey. Pierard D, et al. **Acta Clin Belg** 1996;51(2):70-9

Comment: piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination [letter] Wang F, et al. **Ann Pharmacother** 1995 Oct;29(10):1051-2

Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Baltch AL, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1661-6

Enhanced activity of the combination of penicillin G and gentamicin against penicillin-resistant viridans group streptococci. Cercenado E, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2816-8

Use of time-kill methodology to assess antimicrobial combinations against metronidazole-susceptible and metronidazole-resistant strains of Helicobacter pylori. Coudron PE, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2641-4

In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae. Dhople AM, et al. **Antimicrob Agents Chemother** 1995 Sep; 39(9):2116-9

In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Hyatt JM, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1711-6

Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo. Jagannath C, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1349-54

Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model. Kang SL, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1505-11

Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. Klepser ME, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2503-10

Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci. Pankuch GA, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1499-504

In vitro interactions between different beta-lactam antibiotics and fosfomycin against bloodstream isolates of enterococci. Pes:el M, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2341-4

Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Stapleton P, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2478-83

Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Walsh TJ, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1361-4

Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Weiss K, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2411-4

Role of gut-derived endotoxaemia and bacterial translocation in rats after thermal injury: effects of selective decontamination of the digestive tract. Yao YM, et al. **Burns** 1995 Dec;21(8):580-5

High-level gentamicin-resistant enterococci: in vitro activity of double and triple combinations of antimicrobial drugs. Ferrara A, et al. **Chemotherapy** 1996 Jan-Feb;42(1):37-46

Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa. Gerçeker AA, et al. **Chemotherapy** 1995 Nov-Dec;41(6):433-6

Bactericidal kinetics of an in vitro infection model of once-daily ceftriaxone plus amikacin against gram-positive and gram-negative bacteria. Scaglione F, et al. **Chemotherapy** 1995 Jul-Aug;41(4):239-46

Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review. Jones RN. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):19-33 (79 ref.)

Susceptibility of bacterial isolates from complicated skin and skin structure infections to cefazolin, imipenem-cilastatin, ciprofloxacin and ofloxacin. Liu HH, et al. **Drugs** 1995;49 Suppl 2:215-8

Activity of new 4-quinolones in combination with erythromycin or tetracycline against S. pneumoniae. Morrissey I, et al. **Drugs** 1995;49 Suppl 2:226-7

In vitro activity of ofloxacin, ciprofloxacin, and cefoperazone alone and in combination against Xanthomonas maltophilia. Ristow TA, et al. **Drugs** 1995;49 Suppl 2:246-9

Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. Vanjak D, et al. **Eur J Clin Microbiol Infect Dis** 1995 Nov;14(11):972-8

Newer penicillins and beta-lactamase inhibitors. Bush LM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):653-86 (154 ref.)

Analysis of beta-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin-clavulanic acid. The CERIB Study Group [letter] Chardon H, et al. **J Antimicrob Chemother** 1995 Jul;36(1):267-9

In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. Gerçeker AA, et al. **J Antimicrob Chemother** 1995 Oct;36(4):707-11

Bactericidal in-vitro activity of beta-lactams and beta-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. Joly-Guillou ML, et al. **J Antimicrob Chemother** 1995 Oct;36(4):619-29

Comparative activity of ampicillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. Pankuch GA, et al. **J Antimicrob Chemother** 1995 Jun;35(6):883-8

Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of Mycobacterium avium complex. Piersimoni C, et al. **J Antimicrob Chemother** 1995 Sep;36(3):497-502

Bactericidal effect of beta-lactams and amikacin alone or in association against Klebsiella pneumoniae producing extended spectrum beta-lactamase. Roussel-Delvallez M, et al. **J Antimicrob Chemother** 1995 Jul;36(1):241-6

Unorthodox antibiotic combinations including ciprofloxacin against high-level gentamicin resistant enterococci. Tripodi MF, et al. **J Antimicrob Chemother** 1996 Apr;37(4):727-36

In vitro activity of metronidazole alone and in combination with clotrimazole against clinical isolates of Trichomonas vaginalis. Debbia EA, et al. **J Chemother** 1996 Apr; 8(2):96-101

In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. Moneib NA. **J Chemother** 1995 Dec; 7(6):525-9

Ticarcillin/clavulanic acid: determination of minimal inhibitory concentrations against bacterial strains isolated from patients in intensive care units. Comparison with other agents. Pasargiklian I, et al. **J Chemother** 1996 Apr; 8(2):113-21

Effect of PANTA on growth of Mycobacterium kansasii in BACTEC 12B medium. Conville PS, et al. **J Clin Microbiol** 1995 Aug;33(8):2012-5

Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy. Rice LB, et al. **J Infect Dis** 1996 Jan;173(1):151-8

Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam. Sullivan MC, et al. **Pharmacotherapy** 1995 Jul-Aug;15(4):479-86

The effects of experimental splenic autotransplantation and imipenem-cilastatin treatment in postsplenectomy Pseudomonas aeruginosa sepsis. Eskitürk A, et al. **Res Exp Med (Berl)** 1995;195(3):163-9

Sensitivity to augmentin and cephalosporines of some bacterial strains isolated from hospitalized patients. Debeleac L, et al. **Rom J Intern Med** 1995 Jul-Dec; 33(3-4):227-35

[Demonstration of activity of two potentiated sulfonamides in feces of horses after oral or intravenous administration] Fey K, et al. **Tierarztl Prax** 1996 Jun;24(3):261-9 (Eng. Abstr.) **(Ger)**

[Antibacterial activities of combination uses of isepamicin and beta-lactams in vitro against clinically isolated strains. Part 3. The results against Pseudomonas aeruginosa] Deguchi K, et al. **Jpn J Antibiot** 1996 May;49(5):509-16 (Eng. Abstr.) **(Jpn)**

[Antibacterial activities of combination uses of isepamicin and beta-lactams in vitro against clinically isolated strains. Part 1. Activities against Staphylococcus aureus] Deguchi K, et al. **Jpn J Antibiot** 1996 Feb;49(2):194-202 (Eng. Abstr.) **(Jpn)**

[Antimicrobial activities of clavulanic acid/ticarcillin against clinical isolates] Koguchi M, et al. **Jpn J Antibiot** 1995 Dec;48(12):1899-905 (Eng. Abstr.) **(Jpn)**

[Antimicrobial activities of clavulanic acid/amoxicillin against freshly isolated clinical strains from outpatients] Koguchi M, et al. **Jpn J Antibiot** 1995 Dec;48(12):1920-34 (Eng. Abstr.) **(Jpn)**

[Comparative in vitro activity of ampicillin, cefoperazone, their combinations with sulbactam and other antibiotics with respect to staphylococci and pneumococci] Sidorenko SV, et al. **Antibiot Khimioter** 1995 Mar;40(3):22-7 (Eng. Abstr.) **(Rus)**

[The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro] Blahová J, et al. **Cas Lek Cesk** 1995 Sep 6;134(17):558-61 (Eng. Abstr.) **(Slo)**

[Detection of resistance to the amoxicillin-clavulamic acid combination in Salmonella and Shigella] Miró E, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):31-3 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. Dalla Libera M, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):203-6

Gastric mucosal infiltration by Helicobacter pylori favours bacterial survival after treatment. Neri M, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):181-5

Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. Parente F, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):211-3

Eradication of Helicobacter pylori in general practice. Penston JG, et al. **Aliment Pharmacol Ther** 1996 Apr; 10(2):139-45

Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. Velasco E, et al. **Am J Clin Oncol** 1995 Oct;18(5):429-35

Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication [letter] Tursi A, et al. **Am J Gastroenterol** 1996 Aug;91(8):1668-70

Gastroenterological associations recognize three antimicrobial combinations for ulcer therapy [news] **Am J Health Syst Pharm** 1996 Apr 15;53(8):832, 835

Current management of cytomegalovirus infection: treatment and prophylaxis. Hardy D. **Am J Health Syst Pharm** 1996 Apr 15;53(8 Suppl 2):S12-6; discussion S17

Ticarcillin-clavulanate as an alternative to imipenem-cilastatin [letter] Sesin GP, et al. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2468-9

Ofloxacin eardrop treatment for active chronic suppurative otitis media: prospective randomized study. Yuen PW, et al. **Am J Otol** 1994 Sep;15(5):670-3

An outbreak of antibiotic multiresistant Klebsiella at the Neonatal Intensive Care Unit, Kaplan Hospital, Rehovot, Israel, November 1991 to April 1992. Flidel-Rimon O, et al. **Am J Perinatol** 1996 Feb;13(2):99-102

Ampicillin/sulbactam versus ampicillin alone for cesarean section prophylaxis: a randomized double-blind trial. Rijhsinghani A, et al. **Am J Perinatol** 1995 Sep;12(5):322-4

Recurrent methicillin-resistant Staphylococcus aureus osteomyelitis: combination antibiotic therapy with evaluation by serum bactericidal titers. Aspinall SL, et al. **Ann Pharmacother** 1995 Jul-Aug;29(7-8):694-7

Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Solomkin JS, et al. **Ann Surg** 1996 Mar;223(3):303-15

Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. Atkinson BA, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2316-9

Effective treatment of cephalosporin-rifampin combinations against cryptic methicillin-resistant beta-lactamase-producing coagulase-negative staphylococcal experimental endocarditis. Brandt CM, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1815-9

Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Brouqui P, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2423-5

In vivo activity and pharmacodynamics of cefotaxime or ceftriaxone in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae. Chavanet P, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1736-43

Effect of gentamicin dosing interval on therapy of viridans streptococcal experimental endocarditis with gentamicin plus penicillin. Gavaldà J, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2098-103

Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Perdikaris G, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2289-94

Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. Solera J, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2061-7

Lymphadenopathy [letter; comment] Clark JE, et al. **Arch Dis Child** 1996 Apr;74(4):368. Comment on: Arch Dis Child 1995 Nov;73(5):476-9.

Water precautions in children with tympanostomy tubes. Salata JA, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):276-80

Treatment of ovine dermatophilosis with long-acting oxytetracycline or a lincomycin-spectinomycin combination. Jordan D, et al. **Aust Vet J** 1995 Jun; 72(6):234–6

Randomized study of antibiotic prophylaxis for general and gynaecological surgery from a single centre in rural Africa. Reggiori A, et al. **Br J Surg** 1996 Mar;83(3):356–9

A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients. Raad II, et al. **Cancer** 1996 Apr 1; 77(7):1386–94

Initial treatment of sepsis in non-neutropenic patients: ceftazidime alone versus 'best guess' combined antibiotic therapy. Extermann M, et al. **Chemotherapy** 1995 Jul-Aug; 41(4):306–15

Vancomycin plus imipenem ceftazidime or ciprofloxacin in second line therapy in patients with febrile neutropenia not responding to first line therapy. Lacka J, et al. **Chemotherapy** 1996 Mar-Apr;42(2):146–9

Clinical experience with ceftriaxone treatment in the neonate. Van Reempts PJ, et al. **Chemotherapy** 1995 Jul-Aug; 41(4):316–22

Effect of previous antimicrobial therapy on the accuracy of the main procedures used to diagnose nosocomial pneumonia in patients who are using ventilation. Timsit JF, et al. **Chest** 1995 Oct;108(4):1036–40

Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections. Shyr YM, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Aug;56(2):102–8

Antimicrobial activity of glycerine-ichthammol in otitis externa. Ahmed K, et al. **Clin Otolaryngol** 1995 Jun; 20(3):201–3

Clinical comparison of cefuroxime axetil suspension and amoxicillin/clavulanate suspension in the treatment of pediatric patients with acute otitis media with effusion. Gooch WM 3rd, et al. **Clin Ther** 1995 Sep-Oct;17(5):838–51

Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with secondary bacterial infections of acute bronchitis. Henry D, et al. **Clin Ther** 1995 Sep-Oct;17(5):861–74

Results of a survey of children with acute bacterial conjunctivitis treated with trimethoprim-polymyxin B ophthalmic solution. Wagner RS. **Clin Ther** 1995 Sep-Oct; 17(5):875–81

Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Chantelau E, et al. **Diabet Med** 1996 Feb;13(2):156–9

Cefotaxime and metronidazole in severe intra-abdominal infection. Aprahamian C, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):183–8

Cephalosporin-metronidazole combinations in the management of intra-abdominal infections. Nicolau DP, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun; 22(1-2):189–94 (28 ref.)

Additive effect of continuous low dose ofloxacin on erythromycin therapy for sinobronchial syndrome. Fujimura M, et al. **Drugs** 1995;49 Suppl 2:409–11

Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin. Snydman D, et al. **Drugs** 1995; 49 Suppl 2:439–41

Once-daily pefloxacin + teicoplanin vs netilmicin + teicoplanin in empirical therapy for fever and neutropenia. Studená M, et al. **Drugs** 1995;49 Suppl 2:483–5

Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Principi N. **Eur J Clin Microbiol Infect Dis** 1995 Aug; 14(8):669–76

Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. Deltenre M, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S39–44

Rationale for the choice of antibiotics for the eradication of Helicobacter pylori. Mégraud F. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S49–54 (46 ref.)

Pharmacology of the gastric mucosa: a rational approach to Helicobacter polytherapy [editorial; comment] Lambert JR. **Gastroenterology** 1996 Aug;111(2):521–3. Comment on: Gastroenterology 1996 Aug;111(2):358–67.

Antibiotic therapy of cholangitis [letter; comment] Henry MJ. **Gastrointest Endosc** 1995 Sep;42(3):276–7. Comment on: Gastrointest Endosc 1994 Nov-Dec;40(6):716–21.

Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Borody TJ, et al. **Gut** 1995 Oct; 37(4):477–81

Pelvic inflammatory disease: an ongoing epidemic. Augenbraun MH, et al. **Hosp Pract (Off Ed)** 1995 Sep 15; 30(9):61–6 (6 ref.)

Acute otitis media in children: a study of nasopharyngeal carriage of potential pathogens and therapeutic efficacy of cefixime and amoxicillin-clavulanate. Boulesteix J, et al. **Infection** 1995;23 Suppl 2:S79–82

Selective decontamination of the digestive tract: indications and problems [editorial] Lode H, et al. **Infection** 1995 May-Jun;23(3):129–32 (31 ref.)

Adult-onset Still's disease. Lugo-Somolinos A, et al. **Int J Dermatol** 1995 Jul;34(7):490–2

Imipenem/cilastin dosage during acute renal failure and hemofiltration [letter] Dehne MG, et al. **Intensive Care Med** 1995 Oct;21(10):863

A comparative trial of short term therapy with omeprazole plus either amoxycillin or azithromycin for Helicobacter pylori eradication [letter] Caselli M, et al. **J Antimicrob Chemother** 1996 Apr;37(4):849–50

Phenoxymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of beta-lactamase activity in saliva. Dykhuizen RS, et al. **J Antimicrob Chemother** 1996 Jan;37(1):133–8

Ampicillin plus ciprofloxacin therapy of experimental endocarditis caused by multidrug-resistant Enterococcus faecium. Landman D, et al. **J Antimicrob Chemother** 1995 Jul;36(1):253–8

Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group. Portier H, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:83–91

Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. Schuler D. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:99–108

Combined therapy with co-amoxiclav and erythromycin against intracellular Legionella pneumophila in cell culture and in an experimental respiratory infection in neutropenic rats. Smith GM, et al. **J Antimicrob Chemother** 1995 Jun; 35(6):889–93

Treatment of experimental endocarditis due to multidrug-resistant Enterococcus faecium with clinafloxacin and penicillin. Zaman MM, et al. **J Antimicrob Chemother** 1996 Jan;37(1):127–32

An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections. Arguedas A, et al. **J Chemother** 1996 Apr; 8(2):130–6

Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. Beaucaire G. **J Chemother** 1995 Jun;7 Suppl 2:165–73

Amoxicillin/clavulanic acid vs cefetamet pivoxil in the treatment of acute exacerbation of chronic bronchitis (AECB) in adults. Behler PG, et al. **J Chemother** 1995 May; 7 Suppl 1:16–20

The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection. Colardyn F. **J Chemother** 1995 Jun;7 Suppl 2:129–35

Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms. Covi M, et al. **J Chemother** 1995 Jun;7 Suppl 2:137–42

Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients. Herbrecht R, et al. **J Chemother** 1995 Jun;7 Suppl 2:103–10

Report of Arcanobacterium haemolyticum meningitis in a cancer patient [letter] Minarik T, et al. **J Chemother** 1996 Apr;8(2):165

Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tract infections: an open non-comparative and multicentered trial. Sifuentes-Osornio J, et al. **J Chemother** 1996 Apr; 8(2):122–9

Problems in the management of penicillin-resistant pneumococci [letter] Boswell TC, et al. **J Hosp Infect** 1995 Jul;30(3):233–5

Open randomized study comparing doxycycline and co-amoxiclav in the treatment of acute suppurative tracheobronchitis in adults. The Collaborative Group of the Centre Universitaire de Medécine Générale de L'Université Libre de Bruxelles (CUMG-ULB) Investigators. Sternon J. **J Int Med Res** 1995 Sep-Oct; 23(5):369–76

A cost-benefit analysis of the post-operative use of antibiotic ear drops following grommet insertion. Pearson CR, et al. **J Laryngol Otol** 1996 Jun;110(6):527–30

Nonsurgical management of surgical otitis media with effusion. Rosenfeld RM. **J Laryngol Otol** 1995 Sep; 109(9):811–6

Antibiotic-resistant pneumococci [letter; comment] Friedland IR. **J Pediatr** 1996 Jun;128(6):862–3. Comment on: J Pediatr 1995 Oct;127(4):526–32.

Pyomyositis during induction chemotherapy for acute lymphocytic leukemia. Corden TE, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):323–6

Outpatient therapy with ceftriaxone and oral cefixime for selected febrile children with sickle cell disease. Williams LL, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):257–61

Comparative study of marbofloxacin and amoxicillin-clavulanic acid in the treatment of urinary tract infections in dogs. Cotard JP, et al. **J Small Anim Pract** 1995 Aug;36(8):349–53

Antibiotics for the common cold [letter] Buntinx F, et al. **Lancet** 1996 Sep 14;348(9029):754

Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions [see comments] Kaiser L, et al. **Lancet** 1996 Jun 1; 347(9014):1507–10. Comment in: Lancet 1996 Jun 1;347(9014):1499.

Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. van Balen FA, et al. **Lancet** 1996 Sep 14; 348(9029):713–6

Safety of ototopical antibiotics [letter; comment] Masaki M. **Laryngoscope** 1996 Mar;106(3 Pt 1):370. Comment on: Laryngoscope 1995 May;105(5 Pt 1):472–4.

Prevention of indwelling central venous catheter sepsis. Daghistani D, et al. **Med Pediatr Oncol** 1996 Jun; 26(6):405–8

Continuing problems with the use of Augmentin for urinary tract infections [letter] Bailey RR. **N Z Med J** 1995 Nov 10;108(1011):465

Group B streptococcus and treatment of CAPD peritonitis [letter] Pagniez D, et al. **Nephron** 1995;71(4):480

Cure of a solitary brainstem abscess with antibiotic therapy: case report. Fulgham JR, et al. **Neurology** 1996 May; 46(5):1451–4 (10 ref.)

Meningitis caused by Streptococcus pneumoniae showing high level resistance to penicillin. Wise KA, et al. **Pathology** 1995 Apr;27(2):165–7 (35 ref.)

Lateral sinus thrombosis associated with otitis media and mastoiditis in children. Garcia RD, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):617–23 (35 ref.)

Multicenter controlled trial comparing ceftibuten with amoxicillin/clavulanate in the empiric treatment of acute otitis media. Members of the Ceftibuten Otitis Media United States Study Group. Mclinn SE, et al. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S108–14

Brucellosis presenting with cough. Rowen JI, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):721–2

Successful combination vancomycin and rifampin therapy in a newborn with community-acquired Flavobacterium meningosepticum neonatal meningitis. Tizer KB, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):916–7

Effectiveness of once-weekly vancomycin and once-daily gentamicin, intraperitoneally, for CAPD peritonitis [see comments] Bailie GR, et al. **Perit Dial Int** 1995 Jul-Sep; 15(6):269–71. Comment in: Perit Dial Int 1995 Jul-Sep;15(6):201–2.

Spontaneous closure of a large emphysematous bulla [letter] Millar EA, et al. **Respir Med** 1996 Feb;90(2):120–1

Bacterial endocarditis revealed by infectious discitis. Pascaretti C, et al. **Rev Rhum Engl Ed** 1996 Feb; 63(2):119–23

Control of Brucella melitensis infection in a large camel herd in Saudi Arabia using antibiotherapy and vaccination with Rev. 1 vaccine. Radwan AI, et al. **Rev Sci Tech** 1995 Sep; 14(3):719–32

Increased bactericidal activity as documented by serum bactericidal titers for a triple combination of cell wall active agents against gentamicin-resistant enterococci. Antony SJ, et al. **Scand J Infect Dis** 1995;27(4):401–3

The use of aminoglycosides in neutropenic patients. Cometta A, et al. **Schweiz Med Wochenschr Suppl** 1996;76:21S–27S (10 ref.)

Treatment of cryptococcal meningitis with triple combination of amphotericin B, flucytosine and itraconazole. Chotmongkol V, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):381–3

Prevention of infection in children with acute leukaemia. No major difference between total and selective bowel decontamination. Muis N, et al. **Support Care Cancer** 1996 May;4(3):200–6

Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Burnett RJ, et al. **Surgery** 1995 Oct;118(4):716–21; discussion 721–3

Nutritional status and weight gain in patients with pulmonary tuberculosis in Tanzania. Kennedy N, et al. **Trans R Soc Trop Med Hyg** 1996 Mar-Apr;90(2):162–6

A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis. Rajchanuvong A, et al. **Trans R Soc Trop Med Hyg** 1995 Sep-Oct;89(5):546–9

An animal model of pulmonary infection after single lung transplantation. Kim HK, et al. **Transplant Proc** 1996 Jun; 28(3):1816–7

Intravenous chloramphenicol plus penicillin versus intramuscular ceftriaxone for the treatment of pyogenic meningitis in Nepalese children [letter] Sharma PR, et al. **Trop Doct** 1996 Apr;26(2):84–5

An uncontrolled trial of pefloxacin in the retreatment of patients with pulmonary tuberculosis. Rao S. **Tuber Lung Dis** 1995 Jun;76(3):219–22

A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Schwander S, et al. **Tuber Lung Dis** 1995 Jun;76(3):210–8

[Prevention and therapy of airway infections in patients with cystic fibrosis] Möller AV, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2350–3 (26 ref.) **(Dut)**

[Antibiotic prophylaxis in biliary surgery] Gondret R, et al. **Ann Chir** 1995;49(6):493–9 (52 ref.) (Eng. Abstr.) **(Fre)**

[What antibiotic combinations for pneumococcal meningitis in children in 1996? (editorial)] Bégué P. **Arch Pediatr** 1996 May;3(5):411–3 (16 ref.) **(Fre)**

[Pneumococcal meningitis in children: should probabilistic antibiotherapy of infectious meningitis be modified?] Le Masne A, et al. **Arch Pediatr** 1996 May;3(5):419–26 (Eng. Abstr.) **(Fre)**

ANTIBIOTICS, COMBINED

[Non-surgical treatment of perforations of the thoracic esophagus] Slim K, et al. **Presse Med** 1996 Feb 3; 25(4):154–6 (Eng. Abstr.) **(Fre)**

[Importance of ranitidine in the eradication of Helicobacter pylori] Beglinger C. **Rev Med Suisse Romande** 1995 Oct; 115(10):795–7 **(Fre)**

[Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose] Chaulet P, et al. **Tuber Lung Dis** 1995 Oct;76(5):407–12 (Eng. Abstr.) **(Fre)**

[Recommendations of the DGPI and PEG for antibiotic treatment of meningitis in newborn infants] Noack R, et al. **Klin Padiatr** 1995 Nov–Dec;207(6):359–60 **(Ger)**

[Role of antibiotics in the treatment of infected joint prosthesis] Zimmerli W. **Orthopade** 1995 Aug;24(4):308–13 (22 ref.) (Eng. Abstr.) **(Ger)**

[The problem of resistance in the treatment of Mycobacterium infections: new experimental results and combinations for the treatment of tuberculosis and leprosy] Seydel JK, et al. **Pharm Unserer Zeit** 1995 Nov; 24(6):313–23 (14 ref.) **(Ger)**

[Treatment of osteomyelitis with oral bactericidal antibiotics— description of 9 cases] Major S, et al. **Schweiz Med Wochenschr** 1996 Jan 27;126(4):124–7 (Eng. Abstr.) **(Ger)**

[Two cases of gram-positive sepsis successfully treated with vancomycin in combination with imipenem or cilastatin] Sakamoto M, et al. **Kansenshogaku Zasshi** 1996 May; 70(5):490–5 (Eng. Abstr.) **(Jpn)**

[Retrospective study of sputum culture after esophagectomy] Minamiya Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1138–44 (Eng. Abstr.) **(Jpn)**

[Use of antibiotic thienam in critical care patients] Mariutin PV, et al. **Anesteziol Reanimatol** 1995 Jul–Aug;(4):67–8 **(Rus)**

[A trial of using sulperazone (cefoperazone/sulbactam) in the combined treatment of patients with a burn infection] Iakovlev VP, et al. **Antibiot Khimioter** 1995 May; 40(5):38–41 (Eng. Abstr.) **(Rus)**

[Use of rovamycin and amox-clav in patients with infectious-inflammatory pathology of the ORL organs] Kriukov AI, et al. **Vestn Otorinolaringol** 1996 Mar–Apr; (2):42–5 (Eng. Abstr.) **(Rus)**

[Triple combination antimicrobial therapy of Helicobacter pylori and basal levels of serum gastrin] Jurgoš L, et al. **Bratisl Lek Listy** 1996 Mar;97(3):131–3 (Eng. Abstr.) **(Slo)**

[Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients] Pérez C, et al. **Rev Med Chil** 1995 Mar;123(3):312–20 (Eng. Abstr.) **(Spa)**

TOXICITY

Noncytotoxic combinations of topical antimicrobial agents for use with cultured skin substitutes. Boyce ST, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1324–8

[Nephrotoxicity and drug interaction of vancomycin (2)] Toyoguchi T, et al. **Nippon Yakurigaku Zasshi** 1996 May; 107(5):225–35 (Eng. Abstr.) **(Jpn)**

ANTIBIOTICS, GLYCOPEPTIDE

Current perspectives on glycopeptide resistance. Woodford N, et al. **Clin Microbiol Rev** 1995 Oct;8(4):585–615 (429 ref.)

Stable DNA transformation of Toxoplasma gondii using phleomycin selection. Messina M, et al. **Gene** 1995 Nov 20;165(2):213–7

Control of endemic glycopeptide-resistant enterococci. Dembry LM, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):286–92

ADMINISTRATION & DOSAGE

Efficacy of femoral intra-arterial administration of teicoplanin in gram-positive diabetic foot infections. Dorigo B, et al. **Angiology** 1995 Dec;46(12):1115–22

Comment: dilution of vancomycin for intrathecal or intraventricular administration. Aalfs RL, et al. **Ann Pharmacother** 1996 Apr;30(4):415

Persistence of bacteria on antibiotic loaded acrylic depots. A reason for caution. Kendall RW, et al. **Clin Orthop** 1996 Aug;(329):273–80

Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. Brandt CM, et al. **J Infect Dis** 1996 Apr;173(4):909–13

Relative importance of oral versus intravenous vancomycin exposure in the development of vancomycin-resistant enterococci [letter] Luber AD, et al. **J Infect Dis** 1996 May; 173(5):1292–4

Avoparcin and animal feedstuff [letter] Wise R. **Lancet** 1996 Jun 29;347(9018):1835

ADVERSE EFFECTS

A bullous eruption in an elderly woman. Vancomycin-associated linear IgA dermatosis (LAD). Richards SS, et al. **Arch Dermatol** 1995 Dec;131(12):1447–8, 1450–1

Vancomycin-induced linear IgA bullous dermatosis (LABD). Whitworth JM, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):890–1

[Toxic retinopathy caused by intravitreal injection of amikacin and vancomycin] Piguet B, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):358–9 (Eng. Abstr.) **(Fre)**

[Vancomycin-induced thrombocytopenia for MRSA pneumonia] Kishimoto T. **Rinsho Ketsueki** 1995 Aug; 36(8):768–73 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Comparison and modeling study of vancomycin, ristocetin A, and teicoplanin for CE enantioseparations. Gasper MP, et al. **Anal Chem** 1996 Aug 1;68(15):2501–14

ANTAGONISTS & INHIBITORS

The effect of Ambroxol on bleomycin-induced changes in phospholipid composition of rat lung surfactant. Stettner S, et al. **Acta Physiol Hung** 1995;83(2):181–7

BLOOD

Comparison of high-performance liquid chromatography with fluorescence polarization immunoassay for the analysis of vancomycin in patients with chronic renal failure. Najjar TA, et al. **J Chromatogr B Biomed Appl** 1995 Oct 20;672(2):295–9

[Vancomycin] Furuta I, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1028–30 (6 ref.) **(Jpn)**

[Determination of serum vancomycin using capillary isotachophoresis] Sádecká J, et al. **Ceska Slov Farm** 1995 Dec;44(6):322–6 (Eng. Abstr.) **(Slo)**

CHEMICAL SYNTHESIS

Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. Cooper RD, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):575–81

CHEMISTRY

Compatibility and stability of aztreonam and vancomycin hydrochloride. Trissel LA, et al. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2560–4

Deacylation of the glycopeptide antibiotic A40926 by Actinoplanes teichomyceticus ATCC 31121 [letter] Borghi A, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):607–9

Dimerization of A82846B, vancomycin and ristocetin: influence on antibiotic complexation with cell wall model peptides. Linsdell H, et al. **J Antibiot (Tokyo)** 1996 Feb; 49(2):181–93

Carboxamides and hydrazide of glycopeptide antibiotic eremomycin. Synthesis and antibacterial activity. Pavlov AY, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):194–8

Two conformers of the glycopeptide antibiotic teicoplanin with distinct ligand binding sites. Westwell MS, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1292–8

ISOLATION & PURIFICATION

New 4-oxovancosamine-containing glycopeptide antibiotics from Amycolatopsis sp. Y-86,21022. Vértesy L, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):115–8

PHARMACOKINETICS

Changes in vancomycin pharmacokinetics in critically ill infants. Gous AG, et al. **Anaesth Intensive Care** 1995 Dec; 23(6):678–82

Comment: cyclosporine and vancomycin disposition during continuous venovenous hemodiafiltration [letter; comment] Seay R. **Ann Pharmacother** 1995 Sep;29(9):941. Comment on: Ann Pharmacother 1995 Apr;29(4):374–7.

Pharmacokinetics of MDL 63,246, a new semisynthetic glycopeptide antibiotic, in the rat. Borgonovi M, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2176–82

Influence of arterio-venous haemofiltration on teicoplanin elimination. Hillaire-Buys D, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):95–7

A Bayesian approach to drug disposition evaluation: application to teicoplanin. Ferrante L, et al. **Int J Clin Pharmacol Ther** 1995 Jul;33(7):410–4

Population pharmacokinetics of teicoplanin in patients with endocarditis. Yu DK, et al. **J Pharmacokinet Biopharm** 1995 Feb;23(1):25–39

Vancomycin pharmacokinetics in spinal cord injured patients: a comparison with age-matched, able-bodied controls. Lavezo LA, et al. **J Spinal Cord Med** 1995 Oct;18(4):233–5

Antibiotic treatment for infective endocarditis [letter; comment] Johns TE, et al. **JAMA** 1996 Mar 27;275(12):911 . Comment on: JAMA 1995 Dec 6;274(21):1706–13.

Vancomycin levels after intravitreal injection. Effects of inflammation and surgery. Aguilar HE, et al. **Retina** 1995; 15(5):428–32

Influence of pharmacokinetic model on vancomycin peak concentration targets. Fernandez de Gatta MM, et al. **Ther Drug Monit** 1996 Apr;18(2):145–8

Vancomycin pharmacokinetics and dosing in premature neonates. McDougal A, et al. **Ther Drug Monit** 1995 Aug; 17(4):319–26

Changes in vancomycin pharmacokinetics during treatment. Pou L, et al. **Ther Drug Monit** 1996 Apr;18(2):149–53

PHARMACOLOGY

Effect of avoparcin on rumen fermentation and duodenal nutrient flow in sheep. Fébel H, et al. **Acta Vet Hung** 1995; 43(2–3):229–46

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615–22 (46 ref.)

A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Slaughter S, et al. **Ann Intern Med** 1996 Sep 15;125(6):448–56

Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Dykhuizen RS, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1842–7

Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic. Goldstein BP, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1580–8

Identification of chromosomal mobile element conferring high-level vancomycin resistance in Enterococcus faecium. Handwerger S, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2446–53

Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots. Kang SL, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2832–4

In vitro activity of the semisynthetic glycopeptide amide MDL 63,246. Kenny MT, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1589–90

Use of primers selective for vancomycin resistance genes to determine van genotype in enterococci and to study gene organization in VanA isolates. Miele A, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1772–8

Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria. Nicas TI, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2585–7

Bloodstream infections with vancomycin-resistant enterococci. Montecalvo MA, et al. **Arch Intern Med** 1996 Jul 8;156(13):1458–62

Influence of Avotan on the microflora and concentrations of ammonia and volatile fatty acids in the rumen. Sommer A, et al. **Arch Tierernahr** 1993;45(1):49–55

Comparison of fosfomycin and teicoplanin in serum bactericidal activity against staphylococci. Vogt K, et al. **Arzneimittelforschung** 1995 Aug;45(8):894–7

Clinical and molecular epidemiology of vancomycin-resistant Enterococcus faecium during its emergence in a city in southern Texas. Moreno F, et al. **Clin Infect Dis** 1995 Nov; 21(5):1234–7

Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Wells CL, et al. **Clin Infect Dis** 1995 Jul;21(1):45–50

Vancomycin resistant enterococci in hospitals in the United Kingdom. **Commun Dis Rep CDR Wkly** 1995 Dec 15; 5(50):281, 284

Antibiotic resistance in Enterococcus species: an update. Eliopoulos GM. **Curr Clin Top Infect Dis** 1996;16:21–51 (231 ref.)

Comparison of the in vitro activity of levofloxacin and other antimicrobial agents against vancomycin-susceptible and vancomycin-resistant Enterococcus species. Hayden MK, et al. **Diagn Microbiol Infect Dis** 1995 Aug;22(4):349–52

In vitro conjugative transfer of VanA vancomycin resistance between Enterococci and Listeriae of different species. Biavasco F, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jan;15(1):50–9

Susceptibility of nosocomial gram-positive cocci to teicoplanin and other antibiotics. Multicenter Study Group [letter] Cavallo JD, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):923–5

Selective medium for screening for vancomycin-resistant enterococci in faeces. Rao GG, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):175–7

Bleomycin-induced beta-lactamase overexpression in Escherichia coli carrying a bleomycin-resistance gene from Streptomyces verticillus and its application to screen bleomycin analogues. Yuasa K, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1–2):61–6

Mobilization of vancomycin resistance by transposon-mediated fusion of a VanA plasmid with an Enterococcus faecium sex pheromone-response plasmid. Heaton MP, et al. **Gene** 1996 May 24;171(1):9–17

Controlling vancomycin-resistant enterococci. Boyce JM, et al. **Infect Control Hosp Epidemiol** 1995 Nov;16(11):634–7

Vancomycin-resistant enterococci: pervasive and persistent pathogens [editorial; comment] Boyce JM. **Infect Control Hosp Epidemiol** 1995 Dec;16(12):676–9. Comment on: Infect Control Hosp Epidemiol 1995 Dec;16(12):680–5.

Natural history of colonization with vancomycin-resistant Enterococcus faecium [see comments] Montecalvo MA, et al. **Infect Control Hosp Epidemiol** 1995 Dec;16(12):680–5 . Comment in: Infect Control Hosp Epidemiol 1995 Dec;16(12):676–9.

New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci. Malabarba A, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):869–83

Characterization of vancomycin resistance in Enterococcus durans. Cercenado E, et al. **J Antimicrob Chemother** 1995 Nov;36(5):821–5

Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans? [letter; comment] Donnelly JP, et al. **J Antimicrob Chemother** 1996 Feb; 37(2):389–92. Comment on: J Antimicrob Chemother 1994 Oct;34(4):507–14.

Bleomycin resistance in Staphylococcus aureus clinical isolates. Gennimata D, et al. **J Antimicrob Chemother** 1996 Jan;37(1):65–75

Evaluation of the Epsilometer test (E test) for testing the susceptibility of coagulase-negative staphylococci to teicoplanin. Martin E, et al. **J Antimicrob Chemother** 1995 Jul;36(1):83–91

vanA genes in vancomycin-resistant clinical isolates of Oerskovia turbata and Arcanobacterium (Corynebacterium) haemolyticum. Power EG, et al. **J Antimicrob Chemother** 1995 Oct;36(4):595–606

The effect of burn wound surgery and teicoplanin on the bactericidal activity of polymorphonuclear leucocytes against Staphylococcus aureus. Steer JA, et al. **J Antimicrob Chemother** 1995 Nov;36(5):851–5

Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin. Urban C, et al. **J Antimicrob Chemother** 1996 Feb;37(2):361–4

Regulation of VanB-type vancomycin resistance gene expression by the VanS(B)-VanR (B) two-component regulatory system in Enterococcus faecalis V583. Evers S, et al. **J Bacteriol** 1996 Mar;178(5):1302–9

Amplification of a novel gene, sanA, abolishes a vancomycin-sensitive defect in Escherichia coli. Rida S, et al. **J Bacteriol** 1996 Jan;178(1):94–102

Vancomycin-resistant enterococci [letter] Hyman GF. **J Cataract Refract Surg** 1995 Nov;21(6):599–600

Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients. Gordts B, et al. **J Clin Microbiol** 1995 Nov;33(11):2842–6

Molecular characterization and multilaboratory evaluation of Enterococcus faecalis ATCC 51299 for quality control of screening tests for vancomycin and high-level aminoglycoside resistance in enterococci. Swenson JM, et al. **J Clin Microbiol** 1995 Nov;33(11):3019–21

Selective isolation of vancomycin-resistant enterococci. van Horn KG, et al. **J Clin Microbiol** 1996 Apr;34(4):924–7

Comparison of rectal and perirectal swabs for detection of colonization with vancomycin-resistant enterococci. Weinstein JW, et al. **J Clin Microbiol** 1996 Jan;34(1):210–2

In-vitro activity of a catheter loaded with silver and teicoplanin to prevent bacterial and fungal colonization [letter] Jansen B, et al. **J Hosp Infect** 1995 Nov;31(3):238–41

The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents—a preliminary report. Wade JJ. **J Hosp Infect** 1995 Jun;30 Suppl:483–93

Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. Shay DK, et al. **J Infect Dis** 1995 Oct;172(4):993–1000

Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. Van der Auwera P, et al. **J Infect Dis** 1996 May;173(5):1129–36

From the Centers for Disease Control and Prevention. Assessment of testing for and completeness of reporting of vancomycin-resistant enterococci—Connecticut, 1994. **JAMA** 1996 May 8;275(18):1397

Vancomycin resistance and avoparcin [letter] Mudd A. **Lancet** 1996 May 18;347(9012):1412

Emerging resistance in Enterococcus spp. Heath CH, et al. **Med J Aust** 1996 Jan 15;164(2):116–20 (44 ref.)

Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). **MMWR Morb Mortal Wkly Rep** 1995 Sep 22; 44(RR-12):1–13

Assessment of testing for and completeness of reporting of vancomycin-resistant enterococci—Connecticut, 1994. **MMWR Morb Mortal Wkly Rep** 1996 Apr 12; 45(14):289–91

Complementation of a Toxoplasma gondii ROP1 knock-out mutant using phleomycin selection. Soldati D, et al. **Mol Biochem Parasitol** 1995 Oct;74(1):87–97

In vitro effects of novel glycopeptide antibiotics on the reactivity of the lipopolysaccharide (LPS) of S. minnesota R595. Matera G, et al. **New Microbiol** 1995 Jul;18(3):325–9

Resistance to aminoglycosides and other antibiotics among clinical isolates of Enterococcus spp. Tripodi MF, et al. **New Microbiol** 1995 Jul;18(3):319–23

Antibiotic supplementation of intraocular irrigating solutions. An in vitro model of antibacterial action. Gritz DC, et al. **Ophthalmology** 1996 Aug;103(8):1204–8; discussion 1208–9

Vancomycin prescribing in the era of vancomycin-resistant enterococci [editorial; comment] Polk R. **Pharmacotherapy** 1995 Sep-Oct;15(5):682–3. Comment on: Pharmacotherapy 1995 Sep-Oct;15(5):579–85.

Vancomycin-resistant enterococci [editorial; comment] Rybak MJ, et al. **Pharmacotherapy** 1995 Sep-Oct; 15(5):684–5. Comment on: Pharmacotherapy 1995 Sep-Oct;15(5):579–85.

Vancomycin-resistant enterococci. The 'superbug' scourge that's coming your way. Hagman HM, et al. **Postgrad Med** 1996 May;99(5):60–5, 69–71

[A study on antimicrobial resistance of coagulase negative staphylococci] Huang J, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):620–2 (Eng. Abstr.) **(Chi)**

[Staphylococci causing nosocomial infections in pediatric units. Sensitivity to glycopeptides and primary antibiotics (letter)] Fabre R, et al. **Presse Med** 1996 Feb 10;25(5):214 **(Fre)**

POISONING

Multiple-dose activated charcoal in an accidental vancomycin overdose. Kucukguclu S, et al. **J Toxicol Clin Toxicol** 1996;34(1):83–6

THERAPEUTIC USE

Intralesional bleomycin for the treatment of non-genital warts in HIV-infected patients [letter] Shah M, et al. **Acta Derm Venereol** 1996 Jan;76(1):81–2

New hemodialysis membranes and vancomycin clearance. Meyer CC, et al. **Am J Health Syst Pharm** 1995 Dec 15; 52(24):2794–6

Coagulase-negative Staphylococcus endophthalmitis after cataract surgery with intraocular vancomycin. Townsend-Pico WA, et al. **Am J Ophthalmol** 1996 Mar; 121(3):318–9

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615–22 (46 ref.)

Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. Cabellos C, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2158–60

Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Perdikaris G, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2289–94

Controversies in endophthalmitis prevention. The risk for emerging resistance to vancomycin [editorial; comment] Alfonso EC, et al. **Arch Ophthalmol** 1995 Nov; 113(11):1369–70 (15 ref.). Comment on: Arch Ophthalmol 1995 Nov;113(11):1353–4.

Vancomycin use in ophthalmology [letter] [see comments] Fiscella RG. **Arch Ophthalmol** 1995 Nov;113(11):1353–4. Comment in: Arch Ophthalmol 1995 Nov;113(11):1369–70.

Effect of intravitreal dexamethasone in treatment of pneumococcal endophthalmitis in rabbits. Park SS, et al. **Arch Ophthalmol** 1995 Oct;113(10):1324–9

Use of vancomycin for the treatment of Corynebacterium xerosis pneumonia [letter; comment] Bayston R. **Clin Infect Dis** 1995 Jul;21(1):223. Comment on: Clin Infect Dis 1994 May;18(5):845–6.

Treatment of Peptostreptococcus micros endocarditis with teicoplanin [letter] Wenisch C, et al. **Clin Infect Dis** 1995 Aug;21(2):446–7

Successful treatment of chylothorax by bleomycin for Gorham's disease. Aoki M, et al. **Clin Orthop** 1996 Sep; (330):193–7

Antimicrobial resistance patterns in long term geriatric care. Implications for drug therapy. Mao CA, et al. **Drugs Aging** 1996 Mar;8(3):162–70 (66 ref.)

Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Graninger W, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):643–7

Epidemiologic analysis of glycopeptide-resistant Enterococcus strains in neutropenic patients receiving prolonged vancomycin administration. Plessis P, et al. **Eur J Clin Microbiol Infect Dis** 1995 Nov;14(11):959–63

Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. Lundstrom TS, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):747–67 (91 ref.)

Treatment of experimental endocarditis caused by multidrug resistant Enterococcus faecium with ramoplanin and penicillin. Landman D, et al. **J Antimicrob Chemother** 1996 Feb;37(2):323–9

Efficacy and safety of teicoplanin in infections caused by methicillin-resistant Staphylococcus aureus [letter] Pachon J, et al. **J Antimicrob Chemother** 1996 Jan;37(1):197–200

Vancomycin administration and monitoring reappraisal. Saunders NJ. **J Antimicrob Chemother** 1995 Aug; 36(2):279–82 (32 ref.)

The comparative efficacy and safety of teicoplanin and vancomycin. Wood MJ. **J Antimicrob Chemother** 1996 Feb; 37(2):209–22 (27 ref.)

Oral care with vancomycin paste for alpha-hemolytic streptococcal sepsis [letter] Jenson HB. **J Pediatr Hematol Oncol** 1996 Aug;18(3):334–5

Oral care with vancomycin paste for alpha-hemolytic streptococcal sepsis [letter] Schreiber J, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):334

Vancomycin-resistant Enterococcus faecalis [letter] Branley J, et al. **Med J Aust** 1996 Sep 2;165(5):292

Vancomycin-resistant Enterococcus faecium colonisations [letter] Ferguson J, et al. **Med J Aust** 1996 Sep 2; 165(5):292–3

Effectiveness of once-weekly vancomycin and once-daily gentamicin, intraperitoneally, for CAPD peritonitis [see comments] Bailie GR, et al. **Perit Dial Int** 1995 Jul-Sep; 15(6):269–71. Comment in: Perit Dial Int 1995 Jul-Sep;15(6):201–2.

Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention [see comments] Johnson SV, et al. **Pharmacotherapy** 1995 Sep-Oct;15(5):579–85. Comment in: Pharmacotherapy 1995 Sep-Oct;15(5):682–3. Comment in: Pharmacotherapy 1995 Sep-Oct;15(5):684–5.

Protracted and recurrent methicillin-resistant Staphylococcus aureus bacteremia despite defervescence with vancomycin therapy. Khatib R, et al. **Scand J Infect Dis** 1995;27(5):529–32

Vancomycin pharmacokinetics and dosing in premature neonates. McDougal A, et al. **Ther Drug Monit** 1995 Aug; 17(4):319–26

[Adequate intrathecal diffusion of teicoplanin after failure of vancomycin, administered in continuous infusion in three cases of shunt associated meningitis] Jourdan C, et al. **Pathol Biol (Paris)** 1996 May;44(5):389–92 (Eng. Abstr.) **(Fre)**

[Antibiotic prophylaxis with ++vancomycin in corrective surgery with alloplastic material] Massaioli N, et al. **Minerva Chir** 1995 Sep;50(9):827–9 (Eng. Abstr.) **(Ita)**

[Effect of inhaled vancomycin hydrochloride on elimination of methicillin-resistant Staphylococcus aureus] Shirai M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1233–9 (Eng. Abstr.) **(Jpn)**

[Staphylococcus aureus septicemia in children: bacterial tolerance to vancomycin and serum bactericidal activity] Reis AG, et al. **Rev Assoc Med Bras** 1995 Jan-Feb; 41(1):47–52 (Eng. Abstr.) **(Por)**

TOXICITY

Alterations in surfactant neutral lipid composition during the development of bleomycin-induced pulmonary fibrosis. Swendsen CL, et al. **Biochim Biophys Acta** 1996 May 31; 1301(1-2):90–6

Decreased sensitivity to the cytogenetic effects of bleomycin in individuals occupationally exposed to ionizing radiation. Barquinero JF, et al. **Mutat Res** 1996 Jul 5;354(1):81–6

Do human lymphocytes exposed to the fallout of the Chernobyl accident exhibit an adaptive response? III. Challenge with bleomycin in lymphocytes from children hit by the initial acute dose of ionizing radiation. Tedeschi B, et al. **Mutat Res** 1996 Jul 5;354(1):77–80

[Nephrotoxicity and drug interaction of vancomycin] Toyoguchi T, et al. **Nippon Yakurigaku Zasshi** 1996 Feb; 107(2):53–66 (Eng. Abstr.) **(Jpn)**

ANTIBIOTICS, GLYCOSIDE see **ANTIBIOTICS, AMINOGLYCOSIDE**

ANTIBIOTICS, LACTAM

ADMINISTRATION & DOSAGE

Therapy for acute otitis media. Preference of parents for oral or parenteral antibiotic. Bauchner H, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):396–9

Continuous infusion of beta-lactam antibiotics: a rational dosing approach. Patel KB, et al. **Conn Med** 1995 Aug; 59(8):471–4 (26 ref.)

Once-daily tobramycin therapy in lower respiratory tract infections. Grassi C, et al. **J Chemother** 1995 Aug;7(4):371–9

Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections. Paradisi F, et al. **J Chemother** 1995 Aug;7(4):338–43 (54 ref.)

Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever? Currie BJ. **Pediatrics** 1996 Jun;97(6 Pt 2):989–91 (21 ref.)

Rheumatic fever prophylaxis using benzathine penicillin G (BPG): two- week versus four-week regimens: comparison of two brands of BPG. Kassem AS, et al. **Pediatrics** 1996 Jun;97(6 Pt 2):992–5

ADVERSE EFFECTS

Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. García Rodríguez LA, et al. **Arch Intern Med** 1996 Jun 24;156(12):1327–32

Transient reduction of human left ventricular mass in carnitine depletion induced by antibiotics containing pivalic acid. Abrahamsson K, et al. **Br Heart J** 1995 Dec; 74(6):656–9

Independent anaphylaxis to cefazolin without allergy to other beta-lactam antibiotics. Warrington RJ, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):460–2

Allergic reactions in rheumatic fever patients on long-term benzathine penicillin G: the role of skin testing for penicillin allergy. Markowitz M, et al. **Pediatrics** 1996 Jun;97(6 Pt 2):981–3

[Cholestatic jaundice induced by amoxicillin and clavulanic acid (letter)] Kurowski V. **Dtsch Med Wochenschr** 1996 Mar 22;121(12):390–1 **(Ger)**

[Myoclonic jerks secondary to imipemen] Ortega JJ, et al. **Rev Neurol** 1995 Nov-Dec;23(124):1323 **(Spa)**

ANALYSIS

Electrochemiluminescence-based detection of beta-lactam antibiotics and beta-lactamases. Liang P, et al. **Anal Chem** 1996 Jul 15;68(14):2426–31

Identification and measurement of beta-lactam antibiotic residues in milk: integration of screening kits with liquid chromatography. Harik-Khan R, et al. **J AOAC Int** 1995 Jul-Aug;78(4):978–86

ANTIBIOTICS, LACTAM

ANTAGONISTS & INHIBITORS

In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin. Giron KP, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2798-800

Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Cheng K, et al. **Lancet** 1996 Sep 7;348(9028):639-42

BIOSYNTHESIS

Beta-lactams. Jensen SE, et al. **Biotechnology** 1995;28:239-68 (208 ref.)

Giant linear plasmids of beta-lactam antibiotic producing Streptomyces. Netolitzky DJ, et al. **FEMS Microbiol Lett** 1995 Aug 15;131(1):27-34

CHEMICAL SYNTHESIS

Chemical synthesis of allysine ethylene acetal and conversion in situ into 1-piperideine-6-carboxylic acid: key intermediate of the alpha-aminoadipic acid for beta-lactam antibiotics biosynthesis. Rumbero A, et al. **Bioorg Med Chem** 1995 Sep;3(9):1237-40

Synthesis and modification of a novel 1 beta-methyl carbapenem antibiotic, S-4661. Iso Y, et al. **J Antibiot (Tokyo)** 1996 May;49(5):478-84

A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems. Iso Y, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):199-209

2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics. Altamura M, et al. **J Med Chem** 1995 Oct 13;38(21):4244-56

Versatile approach to encoding combinatorial organic syntheses using chemically robust secondary amine tags. Ni ZJ, et al. **J Med Chem** 1996 Apr 12;39(8):1601-8

CHEMISTRY

Stability of ceftazidime (with arginine) in an elastomeric infusion device. Bednar DA, et al. **Am J Health Syst Pharm** 1995 Sep 1;52(17):1912-4

Ciprofloxacin-ampicillin sulbactam incompatibility [letter] Melonakos TK. **Ann Pharmacother** 1996 Jan;30(1):87

Structure-activity relationship of new 2-substituted penem antibiotics. Fontana R, et al. **J Antibiot (Tokyo)** 1995 Dec; 48(12):1488-93

Novel spirodihydrobenzofuranlactams as antagonists of endothelin and as inhibitors of HIV-1 protease produced by Stachybotrys sp. II. Structure determination. Roggo BE, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):374-9

IMMUNOLOGY

Cross-reactivity of T cell lines and clones to beta-lactam antibiotics. Mauri-Hellweg D, et al. **J Immunol** 1996 Aug 1;157(3):1071-9

ISOLATION & PURIFICATION

Thiomarinols B and C, new antimicrobial antibiotics produced by a marine bacterium [letter] Shiozawa H, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):907-9

Evaluation of liquid chromatography methods for the separation of ampicillin and its related substances. Zhu Y, et al. **J Pharm Biomed Anal** 1996 Mar;14(5):631-9

METABOLISM

Interactions of Yersinia pestis penicillin-binding proteins with beta-lactam antibiotics. Ferreira RC, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1853-5

Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. Ganapathy ME, et al. **J Biol Chem** 1995 Oct 27; 270(43):25672-7

Saturation of penicillin-binding protein 1 by beta-lactam antibiotics in growing cells of Bacillus licheniformis. Lepage S, et al. **Mol Microbiol** 1995 Apr;16(2):365-72

[Beta-lactamase and its molecular evolution] Sawai T, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1887-99 (34 ref.) **(Jpn)**

PHARMACOKINETICS

Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs. Marcellin-Little DJ, et al. **Am J Vet Res** 1996 May;57(5):720-3

Effect of protein binding on penetration of beta-lactams into rabbit peripheral lymph. Woodnutt G, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2678-83

Immunolocalization and pharmacological relevance of oligopeptide transporter PepT1 in intestinal absorption of beta-lactam antibiotics. Sai Y, et al. **FEBS Lett** 1996 Aug 19;392(1):25-9

Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney. Saito H, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1631-7

The secretory intestinal transport of some beta-lactam antibiotics and anionic compounds: a mechanism contributing to poor oral absorption. Saitoh H, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):205-11

Characterization of plasma and lung concentrations after ceftiofur sodium and tilmicosin phosphate administered subcutaneously to mice. Brown SA, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):385-7

Intraocular injection of ceftazidime. Effects of inflammation and surgery. Shaarawy A, et al. **Retina** 1995;15(5):433-8

Sequential changes in the prostatic fluid level of latamoxef in patients with acute bacterial prostatitis. Itoh M, et al. **Urol Int** 1995;55(2):101-4

Comparative pharmacokinetics of an ampicillin/sulbactam combination administered intramuscularly in lactating sheep and goats. Escudero E, et al. **Vet Res** 1996; 27(3):201-8

PHARMACOLOGY

Resistance to beta-lactam antibiotics and beta-lactamase production of Bacteroides, Porphyromonas and Prevotella strains. Nagy E, et al. **Acta Microbiol Immunol Hung** 1995; 42(3):287-99

Hypersensitivity to cefuroxime with good tolerance to other betalactams. Marcos Bravo C, et al. **Allergy** 1995 Apr; 50(4):359-61

Susceptibility of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over a 5-year period. Kessler RE, et al. **Am J Med** 1996 Jun 24;100(6A):13S-19S

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615-22 (46 ref.)

In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Alcaide F, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2243-7

Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Chambers HF, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2620-4

Resistance to ceftriaxone and other beta-lactams in bacteria isolated in the community. The Vigil Roc Study Group. Goldstein FW, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2516-9

Staphylococcus aureus penicillin-binding protein 4 and intrinsic beta-lactam resistance. Henze UU, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2415-22

In vitro interactions between different beta-lactam antibiotics and fosfomycin against bloodstream isolates of enterococci. Pestel M, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2341-4

In vitro antibacterial properties of T-5575 and T-5578 novel parenteral 2-carboxypenams. Watanabe Y, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2787-91

Target-mediated resistance to beta-lactam antibiotics. Hakenbeck R. **Biochem Pharmacol** 1995 Oct 12; 50(8):1121-7

Penems as research tools to investigate the activity of E.coli leader peptidase. Perry CR, et al. **Biochem Soc Trans** 1995 Nov;23(4):548S

Dual mechanisms of GABAA response inhibition by beta-lactam antibiotics in the pyramidal neurones of the rat cerebral cortex. Fujimoto M, et al. **Br J Pharmacol** 1995 Dec;116(7):3014-20

Stereoselective uptake of beta-lactam antibiotics by the intestinal peptide transporter. Wenzel U, et al. **Br J Pharmacol** 1995 Dec;116(7):3021-7

Antibiotic resistance in Enterococcus species: an update. Eliopoulos GM. **Curr Clin Top Infect Dis** 1996;16:21-51 (231 ref.)

Genetic competence and susceptibility to beta-lactam antibiotics in Streptococcus pneumoniae R6 are linked via a two-component signal-transducing system cia. Guenzi E, et al. **Dev Biol Stand** 1995;85:125-8

Comparison of susceptibility to extended-spectrum beta-lactam antibiotics and ciprofloxacin among gram-negative bacilli isolated from intensive care units. Liu PY, et al. **Diagn Microbiol Infect Dis** 1995 Jul; 22(3):285-91

Transfer of ceftazidime and aztreonam resistance from nosocomial strains of Xanthomonas (Stenotrophomonas) maltophilia to a recipient strain of Pseudomonas aeruginosa ML-1008 [letter] Babálová M, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):925-7

Emergence of resistance to beta-lactam agents in Pseudomonas aeruginosa with group I beta-lactamases in Spain. Colom K, et al. **Eur J Clin Microbiol Infect Dis** 1995 Nov;14(11):964-71

Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents in Pseudomonas aeruginosa. Dib C, et al. **Eur J Clin Microbiol Infect Dis** 1995 Nov;14(11):979-86

Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. Vanjak D, et al. **Eur J Clin Microbiol Infect Dis** 1995 Nov;14(11):972-8

Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications. Sutherland R. **Infection** 1995 Jul-Aug; 23(4):191-200 (49 ref.)

Structure-activity relationship of new 2-substituted penem antibiotics. Fontana R, et al. **J Antibiot (Tokyo)** 1995 Dec; 48(12):1488-93

Effects of a beta-lactamase inhibitor, sulbactam, on the activity of carbapenems against Pseudomonas aeruginosa. Hazumi N, et al. **J Antibiot (Tokyo)** 1995 Nov; 48(11):1364-7

A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems. Iso Y, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):199-209

Synthesis and modification of a novel 1 beta-methyl carbapenem antibiotic, S-4661. Iso Y, et al. **J Antibiot (Tokyo)** 1996 May;49(5):478-84

In-vitro activity of cephalosporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles. Aubert G, et al. **J Antimicrob Chemother** 1996 Jan; 37(1):155-60

In-vitro development of resistance to beta-lactam antibiotics in Streptococcus pneumoniae. Carsenti-Etesse H, et al. **J Antimicrob Chemother** 1995 Aug;36(2):417-23

Escherichia hermannii: susceptibility pattern to beta-lactams and production of beta-lactamase. Fitoussi F, et al. **J Antimicrob Chemother** 1995 Sep;36(3):537-43

Bactericidal in-vitro activity of beta-lactams and beta-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. Joly-Guillou ML, et al. **J Antimicrob Chemother** 1995 Oct;36(4):619-29

Effect of pO2 and pH on synergy of tazobactam and beta-lactam antibiotics against beta-lactamase producing Enterobacteriaceae. König C, et al. **J Antimicrob Chemother** 1995 Sep;36(3):513-9

Klebsiella oxytoca revealing decreased susceptibility to extended spectrum beta-lactams [letter] Smith JM, et al. **J Antimicrob Chemother** 1995 Jul;36(1):265-7

In-vitro evaluation of beta-lactamase inhibition by latamoxef and imipenem. Sotto A, et al. **J Antimicrob Chemother** 1996 Apr;37(4):697-701

The ability of beta-lactam antibiotics to select mutants with derepressed beta-lactamase synthesis from Citrobacter freundii. Stapleton P, et al. **J Antimicrob Chemother** 1995 Sep;36(3):483-96

The role of oxygen limitation in the resistance of agar-entrapped, sessile-like Escherichia coli to aminoglycoside and beta-lactam antibiotics. Tresse O, et al. **J Antimicrob Chemother** 1995 Sep;36(3):521-6

In vitro activity of levofloxacin and FK-037 against aerobic isolates from spontaneous bacterial peritonitis. Cormican MG, et al. **J Chemother** 1995 Jun;7(3):197-200

Antimicrobial resistance and prevalence of extended spectrum beta-lactamase among clinical isolates of gram-negative bacteria in Riyadh. El-Karsh T, et al. **J Chemother** 1995 Dec;7(6):509-14

The beta-lactamase problem: new therapeutic options. Schito GC, et al. **J Chemother** 1995 May;7 Suppl 1:5-8 (29 ref.)

Effect of beta-lactamase inhibitors on normal immune capabilities and their interactions with staphylococcal pathogenicity. Tawfik AF, et al. **J Chemother** 1996 Apr; 8(2):102-6

Variable degree of slime production is linked to different levels of beta-lactam susceptibility in Staphylococcus epidermidis phase variants. Mempel M, et al. **Med Microbiol Immunol (Berl)** 1995 Oct;184(3):109-13

In vitro activity of imipenem and six other beta-lactam antibiotics against aminoglycoside resistant gram-negative bacilli. Bujdáková H, et al. **Microbios** 1995;84(339):87-90

Beta-lactamases and bacterial resistance to antibiotics. Frère JM. **Mol Microbiol** 1995 May;16(3):385-95 (51 ref.)

Resistance to aminoglycosides and other antibiotics among clinical isolates of Enterococcus spp. Tripodi MF, et al. **New Microbiol** 1995 Jul;18(3):319-23

Drug-resistant pneumococci increasingly common in elderly, study suggests [news] **Oncology (Huntingt)** 1996 Apr; 10(4):592-3

Quantitative variations in beta-lactam antibiotic released endotoxin from Pseudomonas aeruginosa: in-vivo relevance. Jackson JJ, et al. **Prog Clin Biol Res** 1995; 392:235-51

Anionic properties of beta-lactam-enhancing factor on methicillin-resistant Staphylococcus aureus. Tajima Y, et al. **Res Microbiol** 1996 May;147(4):279-86

Evaluation of an expert system linked to a rapid antibiotic susceptibility testing system for the detection of beta-lactam resistance phenotypes. Vedel G, et al. **Res Microbiol** 1996 May;147(4):297-309

In vitro efficacy of cefquinome (INN) and other anti-infective drugs against bovine bacterial isolates from Belgium, France, Germany, The Netherlands, and the United Kingdom. Böttner A, et al. **Zentralbl Veterinarmed [B]** 1995 Aug;42(6):377-83

[In vitro antibacterial activity of sulperazone on multi-resistant strains of bacteria from burn wounds] Xu W, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul;33(7):390-2 (Eng. Abstr.) **(Chi)**

[Comparison of the activity of beta-lactams against Pseudomonas aeruginosa according to phenotypes of resistance] Bert F, et al. **Pathol Biol (Paris)** 1996 May; 44(5):329-32 (Eng. Abstr.) **(Fre)**

[Comparative susceptibility of Ochrobactrum anthropi, Agrobacterium tumefaciens, Alcaligenes faecalis, Alcaligenes denitrificans subsp. denitrificans, Alcaligenes denitrificans subsp. xylosidans and Bordetella bronchiseptica against 35 antibiotics including 17 beta-lactams] Bizet C, et al. **Pathol Biol (Paris)** 1995 Apr; 43(4):258-63 (Eng. Abstr.) **(Fre)**

[Comparative activity of azithromycin against 100 strains of

Neisseria gonorrhoeae] Chevalier B, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):281-3 (Eng. Abstr.) **(Fre)**

[Identification of a cephalosporinase susceptible to clavulanic acid in a clinical strain of Serratia fonticola] Farzaneh S, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):315-9 (Eng. Abstr.) **(Fre)**

[Outbreak of infections of Klebsiella pneumoniae with extended spectrum beta-lactamase in a hospital unit with a long and medium stay] Mangeney N, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):336-42 (Eng. Abstr.) **(Fre)**

[Detection of beta-lactamases resistant to inhibitors (IRT) by the disk diffusion method] Romaszko JP, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):306-9 (Eng. Abstr.) **(Fre)**

[Detection of pneumococci with reduced susceptibility to penicillin G using the ATB+ +STREP strip] Romaszko JP, et al. **Pathol Biol (Paris)** 1996 May;44(5):355-7 (Eng. Abstr.) **(Fre)**

[beta-Lactamases of Branhamella catarrhalis and their phenotypic implications] Chaïbi EB, et al. **Res Microbiol** 1995 Nov-Dec;146(9):761-71 (40 ref.) (Eng. Abstr.) **(Fre)**

[Antibacterial activity of sulopenem, a new parenteral penem antibiotic] Inoue E, et al. **Jpn J Antibiot** 1996 Apr; 49(4):338-51 (Eng. Abstr.) **(Jpn)**

[In vitro and in vivo antibacterial activities of sulopenem, a new penem antibiotic] Komoto A, et al. **Jpn J Antibiot** 1996 Apr;49(4):352-66 (Eng. Abstr.) **(Jpn)**

[In vitro and in vivo activities of sulopenem compared with those of imipenem and cephalosporins] Nagashima M, et al. **Jpn J Antibiot** 1996 Apr;49(4):303-23 (Eng. Abstr.) **(Jpn)**

[In vitro activities of sulopenem, a new parenteral penem, against anaerobes] Watanabe K, et al. **Jpn J Antibiot** 1996 Apr;49(4):367-76 (Eng. Abstr.) **(Jpn)**

[In vitro antibacterial activity of a new parenteral penem, sulopenem] Yoshida T, et al. **Jpn J Antibiot** 1996 Apr; 49(4):324-37 (Eng. Abstr.) **(Jpn)**

[Clinical and laboratory significance of inducible beta-lactamases] Bedenić B, et al. **Lijec Vjesn** 1995 Sep-Oct;117(9-10):249-53 (41 ref.) (Eng. Abstr.) **(Scr)**

THERAPEUTIC USE

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615-22 (46 ref.)

Evaluation and management of hemoptysis in infants and children. A report of nine cases. Thompson JW, et al. **Ann Otol Rhinol Laryngol** 1996 Jul;105(7):516-20

Diagnosis and treatment of nosocomial pneumonia. Bonten MJ, et al. **Br J Hosp Med** 1995 Oct 4-17;54(7):335-40 (25 ref.)

Treating patients who have Klebsiella pneumoniae pneumonia [letter; comment] Feldman C, et al. **Chest** 1996 Feb;109(2):587-8. Comment on: Chest 1995 Jan;107(1):214-7.

Comparison of cefoxitin, cefotetan, and ampicillin/sulbactam as prophylaxis for polymicrobial infection in mice. Brook I. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S376-7

The perioperative use of ceftriaxone as infection prophylaxis in neurosurgery. Zhao JZ, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):285-9

Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics. Thomson KS, et al. **Curr Clin Top Infect Dis** 1996;16:151-63 (46 ref.)

Meropenem--an advantageous antibiotic? **Drug Ther Bull** 1996 Jul;34(7):53-5 (23 ref.)

Unresolved Issues in Beta-Lactam Therapy. Proceedings of the satellite symposium from the 9th Mediterranean Congress of Chemotherapy. Milan, Italy, 13-17 June 1994. **J Chemother** 1995 May;7 Suppl 1:1-35

Nonsurgical management of surgical otitis media with effusion. Rosenfeld RM. **J Laryngol Otol** 1995 Sep; 109(9):811-6

Microbial dynamics of persistent purulent otitis media in children. Brook I, et al. **J Pediatr** 1996 Feb;128(2):237-40

Meconium-stained amniotic fluid-associated infectious morbidity: a randomized, double-blind trial of ampicillin-sulbactam prophylaxis. Adair CD, et al. **Obstet Gynecol** 1996 Aug;88(2):216-20

A review of the rationale and advantages of various mixtures of benzathine penicillin G. Bass JW. **Pediatrics** 1996 Jun; 97(6 Pt 2):960-3

Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever? Currie BJ. **Pediatrics** 1996 Jun;97(6 Pt 2):989-91 (21 ref.)

Antibiotic resistance: relationship to persistence of group A streptococci in the upper respiratory tract. Gerber MA. **Pediatrics** 1996 Jun;97(6 Pt 2):971-5 (59 ref.)

Rheumatic fever prophylaxis using benzathine penicillin G (BPG): two- week versus four-week regimens: comparison of two brands of BPG. Kassem AS, et al. **Pediatrics** 1996 Jun;97(6 Pt 2):992-5

Three- versus four-week administration of benzathine penicillin G: effects on incidence of streptococcal infections and recurrences of rheumatic fever. Lue HC, et al. **Pediatrics** 1996 Jun;97(6 Pt 2):984-8

Allergic reactions in rheumatic fever patients on long-term benzathine penicillin G: the role of skin testing for penicillin allergy. Markowitz M, et al. **Pediatrics** 1996 Jun;97(6 Pt 2):981-3

Evaluation of penicillins, cephalosporins, and macrolides for therapy of streptococcal pharyngitis. Shulman ST. **Pediatrics** 1996 Jun;97(6 Pt 2):955-9 (34 ref.)

Comparative in vitro activity of 11 beta-lactam antibiotics against 91 Staphylococcus intermedius strains isolated from staphylococcal dermatitis in dogs. Piriz S, et al. **Zentralbl Veterinarmed [B]** 1995 Jul;42(5):293-300

[Bacterial resistance and management of nosocomial infections: relations to hematology] Ladeb S, et al. **Pathol Biol (Paris)** 1996 Feb;44(2):107-12 (Eng. Abstr.) **(Fre)**

TOXICITY

Species specificity of 2-aryl carbapenem-induced immune-mediated hemolytic anemia in primates. Lankas GR, et al. **Toxicology** 1996 Apr 30;108(3):207-15

URINE

Direct quantitative determination of optically active absorbing drugs in human urine by circular dichroism. Simultaneous direct determination of beta-lactam antibiotics and proteins. Gortázar P, et al. **J Pharm Sci** 1995 Nov;84(11):1316-21

ANTIBIOTICS, MACROLIDE

[Clarithromycin] Schouenborg P. **Ugeskr Laeger** 1996 May 13;158(20):2870-3 (31 ref.) **(Dan)**

[New macrolides in pediatrics or new perspectives for an old classification of antibiotics] Bourrillon A. **Arch Pediatr** 1996;3 Suppl 1:302s-305s (16 ref.) **(Fre)**

[Special issue devoted to azithromycin] **Pathol Biol (Paris)** 1995 Jun;43(6):481-572 **(Fre)**

ADMINISTRATION & DOSAGE

Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Bertoni G, et al. **Am J Gastroenterol** 1996 Feb;91(2):258-63

The use of azithromycin in short-term low-dose triple therapies for Helicobacter pylori infection [letter] Tursi A, et al. **Am J Gastroenterol** 1996 Apr;91(4):817-8

Combination chemotherapy of canine and feline cryptococcosis using subcutaneously administered amphotericin B. Malik R, et al. **Aust Vet J** 1996 Apr; 73(4):124-8

Treatment of canine sarcoptic mange using milbemycin oxime: a correction [letter] de Jaham C. **Can Vet J** 1995 Aug;36(8):467

Treatment of canine scabies with milbemycin oxime. Miller WH Jr, et al. **Can Vet J** 1996 Apr;37(4):219-21

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Griffith DE, et al. **Clin Infect Dis** 1995 Sep;21(3):594-8

Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Seaman J, et al. **Clin Infect Dis** 1995 Jul;21(1):188-93

Effect of oral erythromycin on colonic transit in patients with idiopathic constipation. A pilot study. Sharma SS, et al. **Dig Dis Sci** 1995 Nov;40(11):2446-9

Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori. Takimoto T, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S63-6

Effect of Helicobacter pylori eradication on the healing and recurrence of peptic ulcer: combination therapy with low-dose omeprazole and clarithromycin. Uemura N, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S67-9

Comparison of regimens of amphotericin B deoxycholate in kala-azar. Thakur CP, et al. **Indian J Med Res** 1996 May; 103:259-63

Treatment of chancroid with azithromycin. Ballard RC, et al. **Int J STD AIDS** 1996;7 Suppl 1:9-12 (16 ref.)

Treatment of syphilis with azithromycin. Mashkilleyson AL, et al. **Int J STD AIDS** 1996;7 Suppl 1:13-5

Azithromycin in gonorrhoea. Waugh MA. **Int J STD AIDS** 1996;7 Suppl 1:2-4 (11 ref.)

Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. Shimoyama T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S125-7

Clarithromycin and omeprazole for Helicobacter pylori. **Med Lett Drugs Ther** 1996 Jun 7;38(976):51-2

A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis. Rodriguez LV, et al. **Mem Inst Oswaldo Cruz** 1995 Jul-Aug;90(4):525-8

Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases. Dornbusch HJ, et al. **Pediatr Hematol Oncol** 1995 Nov-Dec;12(6):577-86

Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. Schütze K, et al. **Z Gastroenterol** 1995 Nov;33(11):651-3

[Combined therapy with azithromycin and omeprazole for the eradication of Helicobacter pylori (letter)] Bokemeyer B. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1339 **(Ger)**

[One week triple therapy for eradication of Helicobacter pylori infection: simple and effective (letter)] Diehl HG. **Leber Magen Darm** 1995 Dec;25(6):283 **(Ger)**

[Use of selective intestinal decontamination with non-absorbable antibiotics] Müller C, et al. **Z Gastroenterol** 1995 Nov;33(11):685-6 **(Ger)**

[Omeprazole + clarithromycin + metronidazole--a new standard for eradication of Helicobacter pylori] Schepp W. **Z Gastroenterol** 1995 Oct;33(10):621-3 **(Ger)**

[Mepartricin 150.000 (40 mg) vs mepartricin 50.000 U (13 mg) in the treatment of BIP. Double blind clinical trial] Mirone V, et al. **Minerva Med** 1996 Apr;87(4):147-54 (Eng. Abstr.) **(Ita)**

[A case of Legionella pneumonia successfully treated with roxithromycin] Heki U, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):775-9 (Eng. Abstr.) **(Jpn)**

[A case of cystic fibrosis in a Japanese student] Nakanishi N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul; 33(7):771-4 (Eng. Abstr.) **(Jpn)**

[Clarithromycin combined with pyrimethamine in cerebral toxoplasmosis--a report of 2 cases] Dalston MO, et al. **Rev Soc Bras Med Trop** 1995 Oct-Dec;28(4):409-13 (11 ref.) (Eng. Abstr.) **(Por)**

ADVERSE EFFECTS

Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval. Chennareddy SB, et al. **Am Heart J** 1996 Sep;132(3):691-4 (11 ref.)

Fulminant hepatic failure associated with clarithromycin. Shaheen N, et al. **Am J Gastroenterol** 1996 Feb;91(2):394-5

Stevens-Johnson syndrome following erythromycin administration. Lestico MR, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1805-7

Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis. Steinman MA, et al. **Am J Kidney Dis** 1996 Jan;27(1):143-6

Pancreatitis induced by clarithromycin [letter] Liviu L, et al. **Ann Intern Med** 1996 Oct 15;125(8):701

Macrolides versus azalides: a drug interaction update. Amsden GW. **Ann Pharmacother** 1995 Sep;29(9):906-17 (109 ref.)

Erythromycin-induced hypotension [letter] Brown GR. **Ann Pharmacother** 1995 Sep;29(9):934-5

Erythromycin monotherapy associated with torsade de pointes. Granberry MC, et al. **Ann Pharmacother** 1996 Jan; 30(1):77-8

Erythromycin-induced clozapine toxic reaction. Cohen LG, et al. **Arch Intern Med** 1996 Mar 25;156(6):675-7

A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Wilton LV, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):277-84

Toxic effects and drug interactions of antimycobacterial therapy. Chan-Tompkins NH. **Clin Dermatol** 1995 May-Jun;13(3):223-33 (99 ref.)

Clarithromycin-induced digoxin toxicity in a patient with AIDS. Ford A, et al. **Clin Infect Dis** 1995 Oct;21(4):1051-2

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Griffith DE, et al. **Clin Infect Dis** 1995 Sep;21(3):594-8

Allergic contact dermatitis from erythromycin. Martins C, et al. **Contact Dermatitis** 1995 Nov;33(5):360

Contact allergy to tylosin and cobalt in a pig-farmer. Tuomi ML, et al. **Contact Dermatitis** 1995 Oct;33(4):285

Nail pigmentation due to roxithromycin [letter] Dawn G, et al. **Dermatology** 1995;191(4):342-3

Macrolide antibacterials. Drug interactions of clinical significance. von Rosensteil NA, et al. **Drug Saf** 1995 Aug; 13(2):105-22 (237 ref.)

Severe carbamazepine toxicity induced by concurrent erythromycin therapy [letter] Mota CR, et al. **Eur J Pediatr** 1996 Apr;155(4):345

Erythromycin-induced acute pancreatitis. Fang CC, et al. **J Toxicol Clin Toxicol** 1996;34(1):93-5 (13 ref.)

Acute interstitial nephritis and acute renal failure following erythromycin treatment: case report. Ding SL, et al. **N Z Med J** 1996 Aug 23;109(1028):322

[Pseudo-cholangitis, a form of erythromycin-induced hepatitis (letter)] Ducloux D, et al. **Presse Med** 1995 Nov 18;24(35):1663 **(Fre)**

[Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)] Cadisch R, et al. **Schweiz Med Wochenschr** 1996 Feb 24;126(8):308-10 (Eng. Abstr.) **(Ger)**

[Antibiotic-associated diarrhea in light of personal observations] Ellert-Zygadłowska J, et al. **Pol Tyg Lek** 1995 Sep;50(36-39):45-9 (Eng. Abstr.) **(Pol)**

[Acute pancreatitis and erythromycin (letter)] González Carro P, et al. **Rev Esp Enferm Dig** 1995 Oct;87(10):757-8 **(Spa)**

ANALYSIS

Determination of tilmicosin in bovine milk by liquid chromatography with ultraviolet detection. Ngoh MA. **J AOAC Int** 1996 May-Jun;79(3):652-5

Influence of methodological aspects on tissue drug concentration estimation. Petitjean O, et al. **J Pharm Biomed Anal** 1995 Jun;13(7):817–22

Analysis of tilmicosin in swine liver extracts by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Kiehl DE, et al. **Rapid Commun Mass Spectrom** 1995;9(13):1297–301

BIOSYNTHESIS

Purification and initial characterization of proline 4-hydroxylase from Streptomyces griseoviridus P8648: a 2-oxoacid, ferrous-dependent dioxygenase involved in etamycin biosynthesis. Lawrence CC, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):185–91

Macrolides. Katz L, et al. **Biotechnology** 1995;28:385–420 (136 ref.)

Regulation of valine catabolism by ammonium in Streptomyces ambofaciens, producer of spiramycin. Lounès A, et al. **Can J Microbiol** 1995 Sep;41(9):800–8

Direct fermentative production of acyltylosins by genetically-engineered strains of Streptomyces fradiae. Arisawa A, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):349–54

Further novel milbemycin antibiotics from Streptomyces sp. E225. Fermentation, isolation and structure elucidation. Baker GH, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):272–80

[Effect of some cations on activity of macrotetralide synthase during development of Streptomyces chrysomallus subsp. Macrotetralidi] Sverdlova AN, et al. **Mol Gen Mikrobiol Virusol** 1996 Jan-Mar;(1):16–23 (Eng. Abstr.) **(Rus)**

BLOOD

Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. Bohte R, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2801–2

[Macrolide] Watanabe H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1024–7 (9 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Design, synthesis, and biological evaluation of isocyanurate-based antifungal and macrolide antibiotic conjugates: iron transport-mediated drug delivery. Ghosh M, et al. **Bioorg Med Chem** 1995 Nov;3(11):1519–25

Synthesis and antibacterial activity of 6-deoxysporeamicin A. Faghih R, et al. **J Antibiot (Tokyo)** 1996 May; 49(5):493–5

3-Keto-11,12-carbazate derivatives of 6-O-methylerythromycin A synthesis and in vitro activity. Griesgraber G, et al. **J Antibiot (Tokyo)** 1996 May; 49(5):465–77

Cladinose analogues of sixteen-membered macrolide antibiotics. I. Synthesis of 4-O-alkyl-L-cladinose analogues via glycosylation. Kurihara K, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):582–92

CHEMISTRY

Theoretical study of the self-association of amphotericin B. Caillet J, et al. **Biochim Biophys Acta** 1995 Dec 13; 1240(2):179–95

Identification of the structural elements of amphotericin B and other polyene macrolide antibiotics of the hepteane group influencing the ionic selectivity of the permeability pathways formed in the red cell membrane. Cybulska B, et al. **Biochim Biophys Acta** 1995 Dec 13;1240(2):167–78

Molecular dynamics of amphotericin B. II. Dimer in water. Mazerski J, et al. **Biophys Chem** 1996 Jan;57(2-3):205–17

Self-association of the polyene antibiotic nystatin in dipalmitoylphosphatidylcholine vesicles: a time-resolved fluorescence study. Coutinho A, et al. **Biophys J** 1995 Dec; 69(6):2541–57

Base decomposition of erythromycin A methoxime. Huang XM, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):318–20

Structure of the new spiroketal-macrolide A82548A. Kirst HA, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):990–6

Structural elucidation of aculeximycin. III. Planar structure of aculeximycin, belonging to a new class of macrolide antibiotics. Murata H, et al. **J Antibiot (Tokyo)** 1995 Aug; 48(8):838–49

Structural elucidation of aculeximycin. IV. Absolute structure of aculeximycin, belonging to a new class of macrolide antibiotics. Murata H, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):850–62

A new inhibitor of melanogenesis, albocycline K3, produced by Streptomyces sp. OH-3984. Takamatsu S, et al. **J Antibiot (Tokyo)** 1996 May;49(5):485–6

Enantiomeric resolution using the macrocyclic antibiotics rifamycin B and rifamycin SV as chiral selectors for capillary electrophoresis. Ward TJ, et al. **J Chromatogr A** 1995 Nov 3;715(2):337–44

Study of the stability of tylosin A in aqueous solutions. Paesen J, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1153–9

[Macrolides, the attractive antibiotics—from a structural and functional aspect] Nakajima Y. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):717–36 (120 ref.) **(Jpn)**

CONTRAINDICATIONS

Use of terfenadine and contraindicated drugs. Thompson D, et al. **JAMA** 1996 May 1;275(17):1339–41

ECONOMICS

Cost-effectiveness of H. pylori eradication. Roesch W. **J Physiol Pharmacol** 1996 Mar;47(1):71–7 (20 ref.)

The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Haddix AC, et al. **Sex Transm Dis** 1995 Sep-Oct;22(5):274–80

ISOLATION & PURIFICATION

Isolation of brefeldin A. Kim HL, et al. **Gen Pharmacol** 1995 Mar;26(2):363–4

Liposidolide A, a new antifungal macrolide antibiotic [letter] Kihara T, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1385–7

Structure of the new spiroketal-macrolide A82548A. Kirst HA, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):990–6

TMC-34, a new macrolide antifungal antibiotic. Kohno J, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1173–5

A new inhibitor of melanogenesis, albocycline K3, produced by Streptomyces sp. OH-3984. Takamatsu S, et al. **J Antibiot (Tokyo)** 1996 May;49(5):485–6

METABOLISM

Role of extracellular calcium in in vitro uptake and intraphagocytic location of macrolides. Mtairag EM, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1676–82

Nucleotide sequence and characterization of erythromycin resistance determinant that encodes macrolide 2'-phosphotransferase I in Escherichia coli. Noguchi N, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2359–63

Reaction of roxithromycin and clarithromycin with macrolide-inactivating enzymes from highly erythromycin-resistant Escherichia coli. O'Hara K, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1036–8

Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. Wondrack L, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):992–8

[3H]Bafilomycin as a probe for the transmembrane proton channel of the osteoclast vacuolar H(+)-ATPase. Mattsson JP, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):98–106

PHARMACOKINETICS

Levels of flurithromycin in female genital tissue. Furneri PM, et al. **Antimicrob Agents Chemother** 1995 Aug; 39(8):1899–901

Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Gustavson LE, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2078–83

Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Nahata MC, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1875–7

Haemophilus influenzae type b exoproducts induce chemotaxis and macrolide antibiotic release by human polymorphonuclear leukocytes. Fontán PA, et al. **Chemotherapy** 1996 Jan-Feb;42(1):71–77

Effect of clarithromycin on the pharmacokinetics of 2',3'-dideoxyinosine in patients who are seropositive for human immunodeficiency virus. Gillum JG, et al. **Clin Infect Dis** 1996 Apr;22(4):716–8

The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Harris RZ, et al. **Clin Pharmacol Ther** 1996 Apr; 59(4):429–35

Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice [see comments] Goddard AF, et al. **Gastroenterology** 1996 Aug; 111(2):358–67. Comment in: Gastroenterology 1996 Aug;111(2):521–3.

Azithromycin levels in cervical mucus and plasma after a single 1.0g oral dose for chlamydial cervicitis. Worm AM, et al. **Genitourin Med** 1995 Aug;71(4):244–6

Pharmacokinetics of azithromycin in normal and impaired renal function. Höffler D, et al. **Infection** 1995 Nov-Dec; 23(6):356–61

Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers. Kees F, et al. **Infection** 1995 May-Jun;23(3):168–72

Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis. Lam YW, et al. **J Antimicrob Chemother** 1995 Jul;36(1):157–63

Lack of effect of ivermectin on antipyrine and erythromycin disposition in calves. Bohlen DM, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):476–8

Characterization of plasma and lung concentrations after ceftiofur sodium and tilmicosin phosphate administered subcutaneously to mice. Brown SA, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):385–7

Minimal inhibitory concentrations for canine isolates and oral absorption of roxythromycin in fed and fasted dogs. Lavy E, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):382–4

Tilmicosin antibacterial activity and pharmacokinetics in cows. Ziv G, et al. **J Vet Pharmacol Ther** 1995 Oct; 18(5):340–5

Disposition kinetics of tylosin tartrate administered intravenously and intramuscularly to normal and water-deprived camels. Ziv G, et al. **J Vet Pharmacol Ther** 1995 Aug;18(4):299–305

Dental anxiety and the absorption of orally administered erythromycin stearate. Coulter WA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):660–5

Optimization of topical erythromycin formulations by ion pairing. Matschiner S, et al. **Skin Pharmacol** 1995; 8(6):319–25

Evaluation of the effect of zinc acetate on the stratum corneum penetration kinetics of erythromycin in healthy male volunteers. van Hoogdalem EJ, et al. **Skin Pharmacol** 1996;9(2):104–10

PHARMACOLOGY

Erythromycin shortens orocaecal transit time in diabetic male subjects: a double-blind placebo-controlled study. Minocha A, et al. **Aliment Pharmacol Ther** 1995 Oct; 9(5):529–33

Inhibition of acetylcholine-evoked Cl- currents by 14-membered macrolide antibiotics in isolated acinar cells of the guinea pig nasal gland. Ikeda K, et al. **Am J Respir Cell Mol Biol** 1995 Oct;13(4):449–54

The effect of intravenous erythromycin on esophageal motility in healthy subjects. Tzovaras G, et al. **Am J Surg** 1996 Mar;171(3):316–9

Erythromycin as a prokinetic agent in children [letter] Hall JE, et al. **Anaesthesia** 1996 May;51(5):503–4

Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Champney WS, et al. **Antimicrob Agents Chemother** 1995 Sep; 39(9):2141–4

Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex. Ellis LC, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2803–6

Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan. Hsueh PR, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2239–42

Macrolide susceptibility of Mycoplasma hyorhinis isolated from piglets. Kobayashi H, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1030–2

Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Lucier TS, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2770–3

Antituberculosis activity of clarithromycin. Luna-Herrera J, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2692–5

Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Nash KA, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2625–30

Nucleotide sequence and characterization of erythromycin resistance determinant that encodes macrolide 2'-phosphotransferase I in Escherichia coli. Noguchi N, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2359–63

In vitro effectiveness of azithromycin against doxycycline-resistant and -susceptible strains of Rickettsia tsutsugamushi, etiologic agent of scrub typhus. Strickman D, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2406–10

Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Tamaoki J, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1688–90

Ex vivo effect of azithromycin in human leukocyte bactericidal functions [letter] Tomažič J, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1906

Clarithromycin is inactive against Mycobacterium tuberculosis. Truffot-Pernot C, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2827–8

Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells. Ochiai H, et al. **Antiviral Res** 1995 Aug;27(4):425–30

In vitro activity of six macrolides, clindamycin and tetracycline on Streptococcus pneumoniae with different penicillin susceptibilities. Poulsen RL, et al. **APMIS** 1996 Mar;104(3):227–33

Erythromycin-resistant Staphylococcus aureus in Denmark. Westh H. **APMIS Suppl** 1996;57:1–37 (126 ref.)

Vanadate and bafilomycin A1 are potent inhibitors of the ATPase activity of the reconstituted bacterial ATP-binding cassette transporter for maltose (MalFGK2). Hunke S, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):589–94

Inhibition of mitogen-induced DNA synthesis by bafilomycin A1 in Swiss 3T3 fibroblasts. Saurin AJ, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):65–70

Characteristics of 45Ca2+ release induced by quinolidomicin A1, a 60-membered macrolide from skeletal muscle sarcoplasmic reticulum. Ohkura M, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):177–82

Effects of roxithromycin on proliferation of peripheral blood mononuclear cells and production of lipopolysaccharide-induced cytokines. Yoshimura T, et al. **Biol Pharm Bull** 1995 Jun;18(6):876–81

Antibacterial activity of azithromycin against Brucella melitensis. Qadri SM, et al. **Chemotherapy** 1995 Jul-Aug; 41(4):253–6

Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Sadoshima J, et al. **Circ Res** 1995 Dec;77(6):1040–52

Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Bailey DG, et al.

Clin Pharmacol Ther 1996 Jul;60(1):25–33

Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Brannan MD, et al. **Clin Pharmacol Ther** 1995 Sep; 58(3):269–78

Azithromycin and terfenadine: lack of drug interaction. Harris S, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):310–5

Altering tooth eruption by blocking bone resorption—the local delivery of bafilomycin A1. Sundquist K, et al. **Connect Tissue Res** 1995;32(1–4):159–63

Antral axial forces postprandially and after erythromycin in organic and functional dysmotilities. Surrenti E, et al. **Dig Dis Sci** 1996 Apr;41(4):697–704

Inhibition of the vacuolar H(+)-ATPase with bafilomycin reduces delivery of internalized molecules from mature multivesicular endosomes to lysosomes in HEp-2 cells. van Deurs B, et al. **Eur J Cell Biol** 1996 Apr;69(4):343–50

Effects of erythromycin on gastric emptying, duodeno-caecal transit time, gastric and biliopancreatic secretion during continuous gastric infusion of a liquid diet in healthy volunteers. Landry C, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):797–802

Bafilomycin A1 in bone resorption and tooth eruption in dogs. Marks SC Jr, et al. **Eur J Oral Sci** 1995 Aug; 103(4):231–5

Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Khair OA, et al. **Eur Respir J** 1995 Sep;8(9):1451–7

Inhibitory mechanisms of H(+)-ATPase inhibitor bafilomycin A1 and carbonic anhydrase II inhibitor acetazolamide on experimental bone resorption. Ohba Y, et al. **FEBS Lett** 1996 Jun 3;387(2–3):175–8

Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. Debets-Ossenkopp YJ, et al. **FEMS Microbiol Lett** 1996 Aug 15;142(1):37–42

Stimulatory mechanism of EM523-induced contractions in postprandial stomach of conscious dogs. Shiba Y, et al. **Gastroenterology** 1995 Nov;109(5):1513–21

Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Bauernfeind A, et al. **Infection** 1995 Sep-Oct;23(5):316–21

Azithromycin does not increase plasma concentrations of oral midazolam. Backman JT, et al. **Int J Clin Pharmacol Ther** 1995 Jun;33(6):356–9

Synthesis and antibacterial activity of 6-deoxysporeamicin A. Faghih R, et al. **J Antibiot (Tokyo)** 1996 May; 49(5):493–5

3-Keto-11,12-carbazate derivatives of 6-O-methylerythromycin A synthesis and in vitro activity. Griesgraber G, et al. **J Antibiot (Tokyo)** 1996 May; 49(5):465–77

Reassessment of methods for testing the susceptibility of Haemophilus influenzae to clarithromycin [letter] Barry AL, et al. **J Antimicrob Chemother** 1996 Apr;37(4):845–7

Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. Doucet-Populaire F, et al. **J Antimicrob Chemother** 1995 Jul;36(1):129–36

In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii. Romand S, et al. **J Antimicrob Chemother** 1995 Jun;35(6):821–32

Intra-Golgi transport inhibition by megalomicin. Bonay P, et al. **J Biol Chem** 1996 Feb 16;271(7):3719–26

Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods. Mehaffey PC, et al. **J Clin Microbiol** 1996 Feb;34(2):479–81

The effect of roxithromycin on the generation of reactive oxygen species in vitro. Akamatsu H, et al. **J Int Med Res** 1996 Jan-Feb;24(1):27–32

Enhanced effect of clarithromycin on neutrophil function in vitro. Akamatsu H, et al. **J Int Med Res** 1996 Mar-Apr; 24(2):185–9

Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro. Van Asselt GJ, et al. **J Med Microbiol** 1995 Nov; 43(5):386–91

Inhibition of Nef- and phorbol ester-induced CD4 degradation by macrolide antibiotics. Luo T, et al. **J Virol** 1996 Mar;70(3):1527–34

Characterization of tetracycline and erythromycin resistance in Actinobacillus pleuropneumoniae. Wasteson Y, et al. **Vet Microbiol** 1996 Jan;48(1–2):41–50

[The effect of subinhibitory concentrations of quinolone and macrolide antibiotics on production of thermolabile hemolysins in Pseudomonas aeruginosa] Hybenová D, et al. **Epidemiol Mikrobiol Imunol** 1995 Dec;44(4):169–70 (Eng. Abstr.) **(Cze)**

[Possible potentiation of phenprocoumon by clarithromycin and roxithromycin] Meyboom RH, et al. **Ned Tijdschr Geneeskd** 1996 Feb 17;140(7):375–7 (Eng. Abstr.) **(Dut)**

[Effect of desertomycin on the synthesis of cell wall polymers in Saccharomyces uvarum] Benallaoua S, et al. **Can J Microbiol** 1995 Aug;41(8):722–9 (Eng. Abstr.) **(Fre)**

[In vitro susceptibility of Pasteurella and related bacteria to five orally administered antibiotics] Lion C, et al. **Pathol Biol (Paris)** 1996 May;44(5):341–6 (13 ref.) (Eng. Abstr.) **(Fre)**

[Effect of the molecular structure of azithromycin on pharmacokinetics and the antimicrobial activity] Pechère JC. **Pathol Biol (Paris)** 1995 Jun;43(6):483–7 (8 ref.) (Eng. Abstr.) **(Fre)**

[Effect of avilamycin and tylosin on the metabolizable energy in growing and finishing pigs] Kirchgessner M, et al. **Arch Tierernahr** 1995;48(1–2):63–70 (Eng. Abstr.) **(Ger)**

[Efficacy and tolerance of azithromycin in respiratory tract infections in children] Toscano MA, et al. **Minerva Pediatr** 1995 Jun;47(6):249–60 (Eng. Abstr.) **(Ita)**

[Effects of azithromycin on fecal flora of healthy adult volunteers] Uchino U, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1119–30 (Eng. Abstr.) **(Jpn)**

[Effect of prolonged administration of erythromycin on the drug sensitivity and the biological properties of Streptococcus pneumoniae] Koizumi A, et al. **Kansenshogaku Zasshi** 1996 May;70(5):441–8 (Eng. Abstr.) **(Jpn)**

[Effect of macrolide antibiotics on airway goblet hypersecretion in guinea pigs] Tamaoki J, et al. **Kansenshogaku Zasshi** 1996 Jun;70(6):591–6 (Eng. Abstr.) **(Jpn)**

[Effect of clarithromycin on macrophage functions] Xu G, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):864–72 (Eng. Abstr.) **(Jpn)**

[The effect of subinhibitory concentrations of norfloxacin, erythromycin and roxithromycin on Pseudomonas aeruginosa virulence factors] Hoštacká A. **Epidemiol Mikrobiol Imunol** 1995 Sep;44(3):115–7 (Eng. Abstr.) **(Slo)**

THERAPEUTIC USE

High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. Dalla Libera M, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):203–6

One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. Labenz J, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):207–10

Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Kobayashi H. **Am J Med** 1995 Dec 29;99(6A):26S–30S

Mycobacterium avium disease: progress at last [editorial; comment] Bates JH. **Am J Respir Crit Care Med** 1996 Jun; 153(6 Pt 1):1737–8. Comment on: Am J Respir Crit Care Med 1996 Jun;153(6 Pt 1):1766–72.

Clarithromycin treatment for Mycobacterium avium-intracellulare complex lung disease [letter; comment] Frothingham R. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1990–1. Comment on: Am J Respir Crit Care Med 1994 May;149(5):1335–41.

Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients [see comments] Wallace RJ Jr, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1766–72. Comment in: Am J Respir Crit Care Med 1996 Jun;153(6 Pt 1):1737–8.

An open non-comparative pilot study with azithromycin in the treatment of non-gonococcal urethritis in the sexually transmitted disease clinics in Hong Kong. Lo KK, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):547–9

Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Anderson SL, et al. **Ann Intern Med** 1995 Nov 15;123(10):771–3

A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. Genç M, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):1–7

Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Luft BJ, et al. **Ann Intern Med** 1996 May 1;124(9):785–91

Treatment of non-HIV cryptosporidial diarrhea with azithromycin. Bessette RE, et al. **Ann Pharmacother** 1995 Oct;29(10):991–3

Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice. Bermudez LE, et al. **Antimicrob Agents Chemother** 1996 Apr; 40(4):1033–5

In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G. Tissi L, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1938–47

Use of tilmicosin in a severe outbreak of respiratory disease in weaned beef calves. Scott PR, et al. **Aust Vet J** 1996 Feb;73(2):62–4

New drugs—reports of new drugs recently approved by the FDA. Dirithromycin. Shinkai I, et al. **Bioorg Med Chem** 1996 Apr;4(4):521–2

Efficacy of nizatidine, clarithromycin and bismuth subcitrate therapy for Helicobacter pylori eradication in duodenal ulcer patients—a preliminary report. Papp J, et al. **Br J Clin Pract** 1996 Jul-Aug;50(5):249–53

The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Eady EA, et al. **Br J Dermatol** 1996 Jan;134(1):107–13

Chlamydial infection in women [letter] Higgins SP. **Br J Gen Pract** 1996 Apr;46(405):255–6

Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Kuschner RA, et al. **Clin Infect Dis** 1995 Sep;21(3):536–41

Comparison of azithromycin and ceftriaxone for the treatment of chancroid. Martin DH, et al. **Clin Infect Dis** 1995 Aug;21(2):409–14

An open-label, noncomparative study to evaluate the efficacy, safety, and tolerability of azithromycin in the treatment of patients with acute sinusitis. Amin NM, et al. **Clin Ther** 1995 Jul-Aug;17(4):701–7

Azithromycin. Johnson RB. **Curr Probl Dermatol** 1996; 24:184–93 (30 ref.)

Gonorrhoea: single-dose oral treatment. Kohl PK, et al. **Curr Probl Dermatol** 1996;24:82–9 (29 ref.)

Therapy with omeprazole and clarithromycin increases serum carbamazepine levels in patients with H. pylori gastritis [letter; comment] Dammann HG. **Dig Dis Sci** 1996 Mar;41(3):519–20. Comment on: Dig Dis Sci 1995 Apr;40(4):912–5.

Benzamycin gel for acne. **Drug Ther Bull** 1995 Aug; 33(8):62–4 (13 ref.)

Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Bojar RA, et al. **Drugs** 1995;49 Suppl 2:164–7

Macrolide antibiotics in paediatric infectious diseases. Guay DR. **Drugs** 1996 Apr;51(4):515–36 (205 ref.)

Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin. Kawahara S, et al. **Drugs** 1995;49 Suppl 2:414–5

A guide to the treatment of lower respiratory tract infections. Vogel F. **Drugs** 1995 Jul;50(1):62–72 (56 ref.)

Studies on the efficacy of combined immunostimulant-antibiotic therapy against experimental Mycoplasma gallisepticum infection in chickens. Hanafy MS, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Oct; 102(10):408–9

Streptococcal pharyngitis: alternative treatments. Kieserman SP, et al. **Ear Nose Throat J** 1995 Nov;74(11):777–80

Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Principi N. **Eur J Clin Microbiol Infect Dis** 1995 Aug; 14(8):669–76

A double-blind controlled evaluation of the sebosuppressive activity of topical erythromycin-zinc complex. Piérard-Franchimont C, et al. **Eur J Clin Pharmacol** 1995; 49(1–2):57–60

Clarithromycin for treatment of Helicobacter pylori infections. Graham DY. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S55–8 (46 ref.)

Pilot study of azithromycin in the treatment of genital donovanosis. Bowden FJ, et al. **Genitourin Med** 1996 Feb; 72(1):17–9

Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises. Thorpe EM Jr, et al. **Genitourin Med** 1996 Apr;72(2):93–7

The newer macrolides. Azithromycin and clarithromycin. Zuckerman JM, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):731–45 (66 ref.)

The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis. Chang HR. **Int J STD AIDS** 1996;7 Suppl 1:18–22 (34 ref.)

Azithromycin in the prophylaxis of opportunistic infections in AIDS. McCutchan JA. **Int J STD AIDS** 1996;7 Suppl 1:34–7

Azithromycin in sexually transmitted diseases. Ridgway GL. **Int J STD AIDS** 1996;7 Suppl 1:1

Azithromycin in the management of Chlamydia trachomatis infections. Ridgway GL. **Int J STD AIDS** 1996;7 Suppl 1:5–8

Treatment and prophylaxis of Mycobacterium avium complex. Young LS. **Int J STD AIDS** 1996;7 Suppl 1:23–7 (15 ref.)

Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity. Shirai T, et al. **Intern Med** 1995 Jun; 34(6):469–74

The value of tilmicosin in production medicine [letter; comment] Day FG. **J Am Vet Med Assoc** 1996 Mar 1; 208(5):655–6. Comment on: J Am Vet Med Assoc 1996 Jan 1;208(1):102–6.

Clinical efficacy of increased dosages of milbemycin oxime for treatment of generalized demodicosis in adult dogs. Miller WH Jr, et al. **J Am Vet Med Assoc** 1995 Dec 15; 207(12):1581–4

Comparison of tilmicosin with long-acting oxytetracycline for treatment of respiratory tract disease in calves [see comments] Musser J, et al. **J Am Vet Med Assoc** 1996 Jan 1;208(1):102–6. Comment in: J Am Vet Med Assoc 1996 Mar 1;208(5):655–6.

In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin. Gill CJ, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1141–7

Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. Doucet-Populaire F, et al. **J Antimicrob Chemother** 1995 Jul;36(1):129–36

Elimination of bacteraemia after dental extraction:

comparison of erythromycin and clindamycin for prophylaxis of infective endocarditis. Hall G, et al. **J Antimicrob Chemother** 1996 Apr;37(4):783–95

A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis. Hosie J, et al. **J Antimicrob Chemother** 1995 Jul;36(1):173–83

In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii. Romand S, et al. **J Antimicrob Chemother** 1995 Jun;35(6):821–32

Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. Wilcox MH, et al. **J Antimicrob Chemother** 1995 Oct;36(4):673–9

Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B [letter] Mishra M. **J Assoc Physicians India** 1995 Apr;43(4):306

Effectiveness of erythromycin in the treatment of acute bronchitis. King DE, et al. **J Fam Pract** 1996 Jun; 42(6):601–5

Antibiotic treatment of ophthalmic infection: new developments. Andrews V. **J Hosp Infect** 1995 Jun;30 Suppl:268–74

Clinical evaluation of roxithromycin in patients with acne. Akamatsu H, et al. **J Int Med Res** 1996 Jan–Feb; 24(1):109–14

The treatment of non-gonococcal urethritis with single dose oral azithromycin. Erdogru T, et al. **J Int Med Res** 1995 Sep–Oct;23(5):386–93

Clarithromycin prophylaxis against Cryptosporidium enteritis in patients with AIDS. Jordan WC. **J Natl Med Assoc** 1996 Jul;88(7):425–7

Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. Hicks P, et al. **J Pediatr** 1996 Aug;129(2):297–300

Treatment of cyclic vomiting in childhood with erythromycin. Vanderhoof JA, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S60–2

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59–69 (66 ref.)

One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients. Sito E, et al. **J Physiol Pharmacol** 1996 Mar; 47(1):221–8

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 May 22–29;275(20):1534

Use of terfenadine and contraindicated drugs. Thompson D, et al. **JAMA** 1996 May 1;275(17):1339–41

An HIV-1–positive child with fever and a scalp nodule. Malane MS, et al. **Lancet** 1995 Dec 2;346(8988):1466

Effects of azithromycin on malariometric indices in The Gambia. Sadiq ST, et al. **Lancet** 1995 Sep 30; 346(8979):881–2

Dirithromycin. **Med Lett Drugs Ther** 1995 Nov 24; 37(962):109–10

Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis [see comments] Hauth JC, et al. **N Engl J Med** 1995 Dec 28; 333(26):1732–6. Comment in: N Engl J Med 1995 Dec 28;333(26):1772–4. Comment in: N Engl J Med 1996 May 16;334(20):1337–8; discussion 1338–9.

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group [see comments] Havlir DV, et al. **N Engl J Med** 1996 Aug 8;335(6):392–8 . Comment in: N Engl J Med 1996 Aug 8;335(6):428–30.

A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome [see comments] Pierce M, et al. **N Engl J Med** 1996 Aug 8;335(6):384–91. Comment in: N Engl J Med 1996 Aug 8;335(6):428–30.

Amoxicillin or erythromycin for the treatment of antenatal chlamydial infection: a meta-analysis. Turrentine MA, et al. **Obstet Gynecol** 1995 Dec;86(6):1021–5

Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Tabbara KF, et al. **Ophthalmology** 1996 May;103(5):842–6

Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. De Serres G, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):969–75

Treatment of Mycobacterium marinum facial abscess using clarithromycin. Kuhn SM, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):631–2

Pneumococcal meningitis during therapy of otitis media with clarithromycin. Reid R Jr, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1104–5

The role of clarithromycin in the prophylaxis of disseminated Mycobacterium avium-intracellulare infection in patients with AIDS. Mertl SL. **Pharmacotherapy** 1996 May–Jun; 16(3):393–400

A preliminary study of clarithromycin versus doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis. Stein GE, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):727–31

A prospective, double-blind, placebo-controlled trial of a single dose of azithromycin on postoperative wound infections in plastic surgery. Amland PF, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1378–83

Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective. Benson CA. **Res Microbiol** 1996 Jan–Feb;147(1–2):16–24 (43 ref.)

Clinical and epidemiologic implications of polyclonal infection due to Mycobacterium avium complex. von Reyn CF, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):24–30 (46 ref.)

Treatment of infections caused by rapidly growing mycobacteria in the era of the newer macrolides. Wallace RJ Jr. **Res Microbiol** 1996 Jan–Feb;147(1–2):30–5 (34 ref.)

Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori. Götz JM, et al. **Scand J Gastroenterol Suppl** 1995;212:34–7

Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect. Portincasa P, et al. **Scand J Gastroenterol Suppl** 1995;212:63–78 (294 ref.)

Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study. Kuzman I, et al. **Scand J Infect Dis** 1995;27(5):503–5

Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Fujii T, et al. **Thorax** 1995 Dec;50(12):1246–52

Improvement in cyclosporine A associated gingival hyperplasia with azithromycin therapy. Boran M, et al. **Transplant Proc** 1996 Aug;28(4):2316

Clarithromycin against Mycobacterium avium complex infections. Heifets LB. **Tuber Lung Dis** 1996 Feb; 77(1):19–26 (105 ref.)

Open clinical trial of roxithromycin amongst patients of Jos University Teaching Hospital with lower and upper respiratory tract infections. Idoko JA, et al. **West Afr J Med** 1995 Jul–Sep;14(3):127–33

Open clinical trial of roxithromycin in patients of Plateau Hospitals, Jos in upper and lower respiratory tract infections. Okeke EN, et al. **West Afr J Med** 1995 Oct–Dec; 14(4):238–41

[Surgical treatment of lymphadenitis caused by non-tuberculous mycobacteria in children (letter)] Weits J, et al. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2452 **(Dut)**

[Role of macrolides in the treatment of respiratory tract infections in children] Floret D. **Arch Pediatr** 1995 Dec; 2(12):1184–91 (41 ref.) (Eng. Abstr.) **(Fre)**

[Azithromycin: from macrolides to azalides] Carbon C. **Pathol Biol (Paris)** 1995 Jun;43(6):481–2 **(Fre)**

[Maintenance treatment of cerebral toxoplasmosis in AIDS: role of clarithromycin-minocycline combination (letter)] Sellal A, et al. **Presse Med** 1996 Mar 23;25(10):509 **(Fre)**

[Pharma-clinics. Drug of the month. Azithromycin (Zitromax)] Scheen AJ. **Rev Med Liege** 1995 Sep; 50(9):398–9 **(Fre)**

[New clinical perspectives in the management of pediatric respiratory tract infections. Studies substantiate the effectiveness of josamycin. Symposium, 30 October 1992] **HNO** 1993 Sep;41(9 Suppl):1–4 **(Ger)**

[Efficacy and tolerance of azithromycin in respiratory tract infections in children] Toscano MA, et al. **Minerva Pediatr** 1995 Jun;47(6):249–60 (Eng. Abstr.) **(Ita)**

[Pharmacokinetic and clinical studies with azithromycin (capsule) in the pediatric field. Pediatric Study Group of Azithromycin] Fujii R, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1074–92 (Eng. Abstr.) **(Jpn)**

[Comparative clinical study of azithromycin with tosufloxacin tosilate in the treatment of acute odontogenic infection] Sasaki J, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1093–118 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetic and clinical studies with azithromycin (fine granule) in the pediatric field. Pediatric Study Group of Azithromycin] Tajima T, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1051–73 (Eng. Abstr.) **(Jpn)**

[Dirithromycin in the treatment of infections of the lower respiratory tract] Belousov IuB, et al. **Antibiot Khimioter** 1995 Jul;40(7):35–8 (Eng. Abstr.) **(Rus)**

[Contemporary macrolides--characterization of the action, importance in the treatment of bacterial infections] Fomina IP. **Antibiot Khimioter** 1995 Sep;40(9):47–56 (35 ref.) **(Rus)**

[Dirithromycin, a new antibiotic in the treatment of pharyngeal inflammation] Riazantsev SV, et al. **Vestn Otorinolaringol** 1995 Sep–Oct;(5):40–3 (Eng. Abstr.) **(Rus)**

[Visceral leishmaniasis refractory to treatment: the efficacy of amphotericin B] Pérez Brea A, et al. **An Esp Pediatr** 1996 Feb;44(2):161–3 (8 ref.) **(Spa)**

[Macrolides and Helicobacter pylori (editorial)] Piqué JM. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):503–5 **(Spa)**

[Erythromycin: an alternative in conservative management of Ogilvie syndrome (letter)] Acea Nebril B, et al. **Rev Esp Enferm Dig** 1995 Sep;87(9):685–6 **(Spa)**

TOXICITY

Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. Kataoka T, et al. **J Immunol** 1996 May 15;156(10):3678–86

[A 13-week subchronic toxicity study of josamycin in F344 rats] Ikezaki S, et al. **Eisei Shikenjo Hokoku** 1995; (113):44–50 (Eng. Abstr.) **(Jpn)**

ANTIBIOTICS, MONOBACTAM see **MONOBACTAMS**

ANTIBIOTICS, PENICILLIN see **PENICILLINS**

ANTIBIOTICS, PEPTIDE

Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. Chant C, et al. **Ann Pharmacother** 1995 Oct; 29(10):1022–7 (30 ref.)

A gene replacement strategy for engineering nisin. Dodd HM, et al. **Microbiology** 1996 Jan;142 (Pt 1):47–55

Peptide antibiotics: holy or heretic grails of innate immunity? Boman HG. **Scand J Immunol** 1996 May;43(5):475–82 (51 ref.)

ADMINISTRATION & DOSAGE

Do topical antibiotics provide improved prophylaxis against bacterial growth in the presence of polypropylene mesh? Troy MG, et al. **Am J Surg** 1996 Apr;171(4):391–3

Failure of topical polymyxin B to improve mild plaque psoriasis [letter] Stutz JA, et al. **Arch Dermatol** 1996 Feb; 132(2):231

[Pulmonary deposition of colistin aerosols in cystic fibrosis. Comparison of an ultrasonic nebulizer and a pneumatic nebulizer] Gagnadoux F, et al. **Rev Mal Respir** 1996; 13(1):55–60 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Sherertz EF. **Arch Dermatol** 1996 Apr;132(4):461, 464 (11 ref.)

Allergic contact dermatitis from colistin. Inoue A, et al. **Contact Dermatitis** 1995 Sep;33(3):200

Eczematous-like drug eruption induced by synergistins. Michel M, et al. **Contact Dermatitis** 1996 Feb;34(2):86–7

[Acute hemorrhagic diarrhea caused by Klebsiella oxytoca: associated with virginiamycin? (letter)] Terrier F, et al. **Presse Med** 1995 Oct 21;24(31):1446 **(Fre)**

ANALYSIS

Lack of magainin-like activity in human cervical tissue. Hansen KA, et al. **Am J Reprod Immunol** 1995 Jun; 33(6):481–4

Generation of polyclonal antibodies against nisin: immunization strategies and immunoassay development. Suárez AM, et al. **Appl Environ Microbiol** 1996 Jun; 62(6):2117–21

Analytical characterization of peptide contaminants of L-tryptophan. Barnhart ER, et al. **Arch Environ Contam Toxicol** 1996 Jan;30(1):142–8

Beauvericin and fumonisin B1 in preharvest Fusarium moniliforme maize ear rot in Sardinia. Bottalico A, et al. **Food Addit Contam** 1995 Jul–Aug;12(4):599–607

Absolute structural determination of stevastelin B. Shimada K, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):569–74

Development and validation of chromatographic methods (HPLC and GC) for the determination of the active components (benzocaine, tyrothricin and menthol) of a pharmaceutical preparation. Ortiz-Boyer F, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1297–303

BIOSYNTHESIS

Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5. Bierbaum G, et al. **Appl Environ Microbiol** 1996 Feb;62(2):385–92

Isolation of a gene essential for biosynthesis of the lipopeptide antibiotics plipastatin B1 and surfactin in Bacillus subtilis YB8. Tsuge K, et al. **Arch Microbiol** 1996 Apr; 165(4):243–51

Purification and characterization of two haloperoxidases from the glycopeptide antibiotic producer Streptomyces toyocaensis NRRL 15009. Marshall GC, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):580–3

Purification and initial characterization of proline 4-hydroxylase from Streptomyces griseoviridus P8648: a 2-oxoacid, ferrous-dependent dioxygenase involved in etamycin biosynthesis. Lawrence CC, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):185–91

Engineered biosynthesis of peptide antibiotics. Stachelhaus T, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):177–86 (64 ref.)

The genetics of lantibiotic biosynthesis. Jack R, et al. **Bioessays** 1995 Sep;17(9):793–802 (69 ref.)

Lantibiotics. Gasson MJ. **Biotechnology** 1995;28:283–306 (78 ref.)

Peptidolactones. Keller U. **Biotechnology** 1995;28:173–96 (74 ref.)

Thiopeptides. Strohl WR, et al. **Biotechnology** 1995;28:223–38 (50 ref.)

Peptide and peptide-derived antibiotics. Vining LC, et al. **Biotechnology** 1995;28:121–7 (12 ref.)

Peptides. von Döhren H. **Biotechnology** 1995;28:129–71 (256 ref.)

Glycopeptides. Zmijewski MJ Jr, et al. **Biotechnology** 1995; 28:269–81 (49 ref.)

A response regulator gene controls production of the

lantibiotic streptococcin A-FF22. Hynes WL, et al. **Dev Biol Stand** 1995;85:635-7

Lactococcal expression systems for protein engineering of nisin. Kuipers OP, et al. **Dev Biol Stand** 1995;85:605-13

A lantibiotic gene family widely distributed in Streptococcus salivarius and Streptococcus pyogenes. Simpson WJ, et al. **Dev Biol Stand** 1995;85:639-43

Nucleotide sequence of the lantibiotic Pep5 biosynthetic gene cluster and functional analysis of PepP and PepC. Evidence for a role of PepC in thioether formation. Meyer C, et al. **Eur J Biochem** 1995 Sep 1;232(2):478-89

Trichorzins HA and MA, antibiotic peptides from Trichoderma harzianum. I. Fermentation, isolation and biological properties. Goulard C, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1248-53

Improved production of phenomycin by a genetically engineered Escherichia coli. Nagano Y, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):81-5

A newly discovered gene, tfuA, involved in the production of the ribosomally synthesized peptide antibiotic trifolitoxin. Breil B, et al. **J Bacteriol** 1996 Jul; 178(14):4150-6

Serine protease EpiP from Staphylococcus epidermidis catalyzes the processing of the epidermin precursor peptide. Geissler S, et al. **J Bacteriol** 1996 Jan;178(1):284-8

Expression, purification, and characterization of EpiC, an enzyme involved in the biosynthesis of the lantibiotic epidermin, and sequence analysis of Staphylococcus epidermidis epiC mutants. Kupke T, et al. **J Bacteriol** 1996 Mar;178(5):1335-40

Characterization of a chimeric proU operon in a subtilin-producing mutant of Bacillus subtilis 168. Lin Y, et al. **J Bacteriol** 1995 Dec;177(23):6874-80

Analysis of the Staphylococcus epidermidis genes epiF, -E, and -G involved in epidermin immunity. Peschel A, et al. **J Bacteriol** 1996 Jan;178(2):531-6

Molecular characterization and transcriptional analysis of a multidrug resistance gene cloned from the pristinamycin-producing organism, Streptomyces pristinaespiralis. Blanc V, et al. **Mol Microbiol** 1995 Sep; 17(5):989-99

Production of type A trichothecenes and enniatin B by Fusarium sambucinum Fuckel sensu lato. Altomare C, et al. **Mycopathologia** 1995;129(3):177-81

Inducible expression of an antibiotic peptide gene in lipopolysaccharide-challenged tracheal epithelial cells. Diamond G, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5156-60

CHEMICAL SYNTHESIS

Conformation of polymyxin B analogs in DMSO from NMR spectra and molecular modeling. Liao SY, et al. **Biochim Biophys Acta** 1995 Oct 25;1252(2):312-20

CHEMISTRY

Structures of quinoxaline antibiotics. Sheldrick GM, et al. **Acta Crystallogr B** 1995 Dec 1;51 (Pt 6):987-99

Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5. Bierbaum G, et al. **Appl Environ Microbiol** 1996 Feb;62(2):385-92

Physiochemical characterization of the nisin-membrane interaction with liposomes derived from Listeria monocytogenes. Winkowski K, et al. **Appl Environ Microbiol** 1996 Feb;62(2):323-7

Antimicrobial peptide pores in membranes detected by neutron in-plane scattering. He K, et al. **Biochemistry** 1995 Dec 5;34(48):15614-8

A single binding mode of activated enediyne C1027 generates two types of double-strand DNA lesions: deuterium isotope-induced shuttling between adjacent nucleotide target sites. Xu YJ, et al. **Biochemistry** 1995 Sep 26; 34(38):12451-60

Role of proline residue in the channel-forming and catecholamine-releasing activities of the peptaibol, trichosporin-B-VIa. Nagaoka Y, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):31-6

A convergent solid-phase synthesis of actinomycin analogues--towards implementation of double-combinatorial chemistry. Tong G, et al. **Bioorg Med Chem** 1996 May;4(5):693-8

Hydrogen bond stabilities in membrane-reconstituted alamethicin from amide-resolved hydrogen-exchange measurements. Dempsey CE, et al. **Biophys J** 1996 Apr; 70(4):1777-88

Molecular structure and mechanisms of action of cyclic and linear ion transport antibiotics. Duax WL, et al. **Biopolymers** 1996;40(1):141-55 (44 ref.)

Lantibiotics. Gasson MJ. **Biotechnology** 1995;28:283-306 (78 ref.)

Glycopeptides. Zmijewski MJ Jr, et al. **Biotechnology** 1995; 28:269-81 (49 ref.)

Fungal metabolites. XX. Effect of proline residue on the structure of ion-channel-forming peptide, trichosporin B-VIa. Nagaoka Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1119-24

The Enterococcus faecalis cytolysin determinant and its relationship to those encoding lantibiotics. Bogie CP, et al. **Dev Biol Stand** 1995;85:627-34

The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Gudmundsson GH, et al. **Eur J Biochem** 1996 Jun 1;238(2):325-32

Interaction of the lantibiotic nisin with membranes revealed by fluorescence quenching of an introduced tryptophan. Martin I, et al. **Eur J Biochem** 1996 Jul 1;239(1):156-64

Three-dimensional structure of the lantibiotic nisin in the presence of membrane-mimetic micelles of dodecylphosphocholine and of sodium dodecylsulphate. Van Den Hooven HW, et al. **Eur J Biochem** 1996 Jan 15; 235(1-2):382-93

Surface location and orientation of the lantibiotic nisin bound to membrane-mimicking micelles of dodecylphosphocholine and of sodium dodecylsulphate. Van Den Hooven HW, et al. **Eur J Biochem** 1996 Jan 15; 235(1-2):394-403

Structure-activity relationships in the peptide antibiotic nisin: antibacterial activity of fragments of nisin. Chan WC, et al. **FEBS Lett** 1996 Jul 22;390(2):129-32

Antibacterial activity of secretolytin, a chromogranin B-derived peptide (614-626), is correlated with peptide structure. Strub JM, et al. **FEBS Lett** 1996 Feb 5; 379(3):273-8

Drastic reduction in antimicrobial activity by replacement of Orn residues with Lys in cyclized amphiphilic beta-structural model peptides. Ando S, et al. **Int J Pept Protein Res** 1995 Aug;46(2):97-105

Structural and charge requirements for antimicrobial and hemolytic activity in the peptide PKLLETFLSKWIG, corresponding to the hydrophobic region of the antimicrobial protein bovine seminalplasmin. Sitaram N, et al. **Int J Pept Protein Res** 1995 Aug;46(2):166-73

Siamycins I and II, new anti-HIV-1 peptides: II. Sequence analysis and structure determination of siamycin I. Detlefsen DJ, et al. **J Antibiot (Tokyo)** 1995 Dec; 48(12):1515-7

Chrysospermins, new peptaibol antibiotics from Apiocrea chrysosperma Ap101. Dornberger K, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):977-89

Antibiotics A21459 A and B, new inhibitors of bacterial protein synthesis. II. Structure elucidation. Ferrari P, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):150-4

Structure of new cyclic depsipeptides, Bu-2841-08 and -10. Fukai T, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1115-23

Trichorzins HA and MA, antibiotic peptides from Trichoderma harzianum. II. Sequence determination. Hlimi S, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1254-61

Structural determination of stevastelins, novel depsipeptides from Penicillium sp. Morino T, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):564-8

Relationship between structure and biological activity of novel R106 analogs. Rodriguez MJ, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):386-9

Absolute structural determination of stevastelin B. Shimada K, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):569-74

Role of the leader and structural regions of prelantibiotic peptides as assessed by expressing nisin-subtilin chimeras in Bacillus subtilis 168, and characterization of their physical, chemical, and antimicrobial properties. Chakicherla A, et al. **J Biol Chem** 1995 Oct 6; 270(40):23533-9

Competition between netropsin and restriction nuclease EcoRI for DNA binding. Sidorova NYu, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):367-85

Liquid chromatographic determination of D- and L-amino acids by derivatization with o-phthaldialdehyde and N-isobutyryl-L-cysteine. Applications with reference to the analysis of peptidic antibiotics, toxins, drugs and pharmaceutically used amino acids. Brückner H, et al. **J Chromatogr A** 1995 Sep 8;711(1):201-15

Fungal metabolites. XXI. Characteristics of low energy collision induced dissociation of [M + 2H]2+, [M + H + Na]2+ and [M + 2Na]2+ of peptaibols using electrospray ionization mass spectrometry. Kanai M, et al. **J Mass Spectrom** 1996 Feb;31(2):177-83

Structure and orientation of the mammalian antibacterial peptide cecropin P1 within phospholipid membranes. Gazit E, et al. **J Mol Biol** 1996 May 24;258(5):860-70

Paracelsin E, a new peptaibol from Trichoderma saturnisporum. Ritieni A, et al. **J Nat Prod** 1995 Nov; 58(11):1745-8

Comparison of the effects of hydrophobicity, amphiphilicity, and alpha-helicity on the activities of antimicrobial peptides. Pathak N, et al. **Proteins** 1995 Jun;22(2):182-6

IMMUNOLOGY

Generation of polyclonal antibodies against nisin: immunization strategies and immunoassay development. Suárez AM, et al. **Appl Environ Microbiol** 1996 Jun; 62(6):2117-21

ISOLATION & PURIFICATION

Isolation and characterization of genetically engineered gallidermin and epidermin analogs. Ottenwälder B, et al. **Appl Environ Microbiol** 1995 Nov;61(11):3894-903

Gavaserin and saltavalin, new peptide antibiotics produced by Bacillus polymyxa. Pichard B, et al. **FEMS Microbiol Lett** 1995 Nov 15;133(3):215-8

Chrysospermins, new peptaibol antibiotics from Apiocrea chrysosperma Ap101. Dornberger K, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):977-89

[Antibacterial components of rat uterus] Xu L, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Sep;26(3):261-5 (Eng. Abstr.) **(Chi)**

METABOLISM

Diversity among the gram-positive acetyltransferases inactivating streptogramin A and structurally related compounds and characterization of a new staphylococcal determinant, vatB. Allignet J, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2027-36

Characterization of the covalent binding of thiostrepton to a thiostrepton-induced protein from Streptomyces lividans. Chiu ML, et al. **Biochemistry** 1996 Feb 20;35(7):2332-41

Interaction of the mammalian antibacterial peptide cecropin P1 with phospholipid vesicles. Gazit E, et al. **Biochemistry** 1995 Sep 12;34(36):11479-88

Kinetics of pore formation by an antimicrobial peptide, magainin 2, in phospholipid bilayers. Matsuzaki K, et al. **Biochemistry** 1995 Oct 3;34(39):12553-9

Cooperative interactions of RNA and thiostrepton antibiotic with two domains of ribosomal protein L11. Xing Y, et al. **Biochemistry** 1996 Feb 6;35(5):1581-8

Maduropeptin: an antitumor chromoprotein with selective protease activity and DNA cleaving properties. Zein N, et al. **Biochemistry** 1995 Sep 12;34(36):11591-7

Maturation pathway of nisin and other lantibiotics: post-translationally modified antimicrobial peptides exported by gram-positive bacteria. de Vos WM, et al. **Mol Microbiol** 1995 Aug;17(3):427-37 (73 ref.)

The structure of bovine F1-ATPase complexed with the peptide antibiotic efrapeptin. Abrahams JP, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9420-4

PHARMACOKINETICS

Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Chang D. **Pediatr Infect Dis J** 1995 Aug;14(8):667-73

Depletion of the residues of colistin and amoxicillin in turkeys following simultaneous subcutaneous administration. Tomasi L, et al. **Vet Res Commun** 1996;20(2):175-82

[Bactericidal effect of colistin on Escherichia coli. Model and simulation or the pharmacokinetic-pharmacodynamic relation for prediction of efficacy in veterinary antibiotic therapy] Renard L, et al. **Vet Res** 1996;27(1):23-32 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Peptides as weapons against microorganisms in the chemical defense system of vertebrates. Nicolas P, et al. **Annu Rev Microbiol** 1995;49:277-304 (116 ref.)

Identification of daptomycin-binding proteins in the membrane of Enterococcus hirae. Boaretti M, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2068-72

The AUR1 gene in Saccharomyces cerevisiae encodes dominant resistance to the antifungal agent aureobasidin A (LY295337). Heidler SA, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2765-9

Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium. Herrera-Insúa I, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):886-90

In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species. Vazquez JA, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2689-91

Structure-activity relationships in the peptide antibiotic nisin: role of dehydroalanine 5. Chan WC, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2966-9

Investigation of the effect of combined variations in temperature, pH, and NaCl concentration on nisin inhibition of Listeria monocytogenes and Staphylococcus aureus. Thomas LV, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2006-12

Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins. Levy D, et al. **Biochem Pharmacol** 1995 Dec 22; 50(12):2105-7

Membrane thinning caused by magainin 2. Ludtke S, et al. **Biochemistry** 1995 Dec 26;34(51):16764-9

Pathway for Ca2+ influx into cells by trichosporin-B-VIa, an alpha-aminoisobutyric acid-containing peptide, from the fungus Trichoderma polysporum. Tachikawa E, et al. **Biochim Biophys Acta** 1996 Jun 13;1282(1):140-8

A mechanism of resistance to partial macrolide and streptogramin B antibiotics in Staphylococcus aureus clinically isolated in Hungary. Matsuoka M, et al. **Biol Pharm Bull** 1995 Nov;18(11):1482-6

Properties of trichosporin-B-VIa-induced catecholamine secretion from bovine adrenal chromaffin cells. Tachikawa E, et al. **Biol Pharm Bull** 1995 Aug;18(8):1165-7

Semi-synthesis of polymyxin-B conjugated ovalbumin: evaluation of lipopolysaccharide binding avidity and neutralization of induced tnf-alpha synthesis. Coyne CP, et al. **Biotherapy** 1994;8(1):69-83

Antifungal activity of LY295337 in vitro against clinical isolates of Candida spp. Aller AI, et al. **Chemotherapy** 1995 Jul-Aug;41(4):276-80

Structure-activity relationships in the peptide antibiotic nisin: antibacterial activity of fragments of nisin. Chan WC, et al. **FEBS Lett** 1996 Jul 22;390(2):129-32

Cell wall changes in nisin-resistant variants of Listeria innocua grown in the presence of high nisin concentrations. Maisnier-Patin S, et al. **FEMS Microbiol Lett** 1996 Jun

15;140(1):29–35
The thiostrepton-resistance-encoding gene in Streptomyces laurentii is located within a cluster of ribosomal protein operons. Smith TM, et al. **Gene** 1995 Oct 16;164(1):137–42
In vitro antimalarial activity of monoterpenic fragment analogues of aplasmomycin. Biswas S, et al. **Indian J Exp Biol** 1995 Jul;33(7):521–3
Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Kurtz MB, et al. **Infect Immun** 1996 Aug; 64(8):3244–51
Drastic reduction in antimicrobial activity by replacement of Orn residues with Lys in cyclized amphiphilic beta-structural model peptides. Ando S, et al. **Int J Pept Protein Res** 1995 Aug;46(2):97–105
Fusaricidin A, a new depsipeptide antibiotic produced by Bacillus polymyxa KT-8. Taxonomy, fermentation, isolation, structure elucidation and biological activity. Kajimura Y, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):129–35
Relationship between structure and biological activity of novel R106 analogs. Rodriguez MJ, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):386–9
Antibiotics A21459 A and B, new inhibitors of bacterial protein synthesis. I. Taxonomy, isolation and characterization. Selva E, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):145–9
Starvation- and Stationary-phase-induced resistance to the antimicrobial peptide polymyxin B in Salmonella typhimurium is RpoS (sigma(S)) independent and occurs through both phoP-dependent and -independent pathways. McLeod GI, et al. **J Bacteriol** 1996 Jul;178(13):3683–8
Zwittermicin A resistance gene from Bacillus cereus. Milner JL, et al. **J Bacteriol** 1996 Jul;178(14):4266–72
Mode of action of an antibacterial peptide, KLKLLLLLKLK-NH2. Alvarez-Bravo J, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1312–6
In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. Moneib NA. **J Chemother** 1995 Dec; 7(6):525–9
RP 59500, a streptogramin derivative, is effective in murine listeriosis. Nichterlein T, et al. **J Chemother** 1996 Apr; 8(2):107–12
Interaction of nisin with planar lipid bilayers monitored by fluorescence recovery after photobleaching. Giffard CJ, et al. **J Membr Biol** 1996 Jun;151(3):293–300
DNA bending and unwinding associated with actinomycin D antibiotics bound to partially overlapping sites on DNA. Chen H, et al. **J Mol Biol** 1996 May 10;258(3):457–79
Antibiotic-induced oligomerisation of group I intron RNA. Wank H, et al. **J Mol Biol** 1996 Apr 26;258(1):53–61
Effects of a subtherapeutic dose of polymyxin B on gut origin endotoxin/bacterial translocation [letter; comment] Freund HR, et al. **J Trauma** 1996 Jan;40(1):171. Comment on: J Trauma 1995 Jun;38(6):924–30.
Bacillus licheniformis bacitracin-resistance ABC transporter: relationship to mammalian multidrug resistance. Podlesek Z, et al. **Mol Microbiol** 1995 Jun;16(5):969–76
Stress-activated expression of a Streptomyces pristinaespiralis multidrug resistance gene (ptr) in various Streptomyces spp. and Escherichia coli. Salah-Bey K, et al. **Mol Microbiol** 1995 Sep;17(5):1001–12
Distamycin-induced inhibition of formation of a nucleoprotein complex between the terminase small subunit G1P and the non-encapsidated end (pacL site) of Bacillus subtilis bacteriophage SPP1. Chai S, et al. **Nucleic Acids Res** 1996 Jan 15;24(2):282–8
Generation of analogs having potent antimicrobial and hemolytic activities with minimal changes from an inactive 16-residue peptide corresponding to the helical region of Staphylococcus aureus delta-toxin. Dhople VM, et al. **Protein Eng** 1995 Mar;8(3):315–8
Bacterial responses to host-defense peptides. Groisman EA. **Trends Microbiol** 1996 Apr;4(4):127–8; discussion 128–9 (17 ref.)
Antimicrobial activity of chicken and turkey heterophil peptides CHP1, CHP2, THP1, and THP3. Evans EW, et al. **Vet Microbiol** 1995 Dec;47(3–4):295–303
In-vitro activity of RP 59500, a new semisynthetic injectable pristinamycin against staphylococci. von Eiff C, et al. **Zentralbl Bakteriol** 1996 Apr;283(4):497–501
[In vitro susceptibility of Pasteurella and related bacteria to five orally administered antibiotics] Lion C, et al. **Pathol Biol (Paris)** 1996 May;44(5):341–6 (13 ref.) (Eng. Abstr.) **(Fre)**
[Bactericidal effect of colistin on Escherichia coli. Model and simulation or the pharmacokinetic-pharmacodynamic relation for prediction of efficacy in veterinary antibiotic therapy] Renard L, et al. **Vet Res** 1996;27(1):23–32 (Eng. Abstr.) **(Fre)**
[Nisin, a potential preservative for topical preparations] Valenta C, et al. **Pharmazie** 1996 Feb;51(2):119–22 (Eng. Abstr.) **(Ger)**
[Man's own antibiotics—an innate immune system] Boman HG. **Nord Med** 1996 Jun;111(6):176–9 (Eng. Abstr.) **(Swe)**

THERAPEUTIC USE

Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Kurtz MB, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1784–9
Treatment of methicillin-resistant Staphylococcus aureus infection with quinupristin/dalfopristin [letter] Torralba MD, et al. **Clin Infect Dis** 1995 Aug;21(2):460–1
Reduction of endotoxin-induced inflammation of the middle ear by polymyxin B. Darrow DH, et al. **Laryngoscope** 1996 Aug;106(8):1028–33
Clinical evaluation of in-feed zinc bacitracin for the control of porcine intestinal adenomatosis in growing/fattening pigs. Kyriakis SC, et al. **Vet Rec** 1996 May 18; 138(20):489–92
Field trial evaluation of two teat dips containing nisin or polyvinylpyrrolidone iodophor designed for use before and after milking. Sérieys F, et al. **Vet Res** 1996;27(3):295–303
[Pristinamycin in the treatment of acute bacterial dermohypodermitis in adults. An open study of 42 patients] Bernard P, et al. **Ann Dermatol Venereol** 1996;123(1):16–20 (Eng. Abstr.) **(Fre)**

ANTIBIOTICS, TETRACYCLINE

In vivo tetracycline labelling as a measure of rearing-system influence on chicken-bone dynamics. Vitorovic D, et al. **Anat Histol Embryol** 1995 Jun;24(2):85–6

ADMINISTRATION & DOSAGE

Randomized controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated Plasmodium falciparum malaria in Brazil. Duarte EC, et al. **Am J Trop Med Hyg** 1996 Feb; 54(2):197–202
Dual therapy with doxycycline and ketoprofen compared to doxycycline in the treatment of uncomplicated non-gonococcal urethritis. Tay YK, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):519–22
Triple drug therapy with quinine, cotrimoxazole and tetracycline in the management of cerebral malaria—A review of 254 cases. Waiz A, et al. **Bangladesh Med Res Counc Bull** 1995 Aug;21(2):77–80
Response to intracrevicular controlled delivery of 25% tetracycline from poly(lactide/glycolide) film strips in SPT patients. Maze GI, et al. **J Clin Periodontol** 1995 Nov; 22(11):860–7
The "cyclic" regimen of low-dose doxycycline for adult periodontitis: a preliminary study. Crout RJ, et al. **J Periodontol** 1996 May;67(5):506–14
Slow release of tetracycline hydrochloride from a cellulose membrane used in guided tissue regeneration. Markman C, et al. **J Periodontol** 1995 Nov;66(11):978–83
[Papillomatosis confluens et reticularis. Successful therapy with minocycline] Kretzschmar L, et al. **Hautarzt** 1996 Mar;47(3):209–13 (Eng. Abstr.) **(Ger)**
[Which factors influence the success of the classical triple therapy in the eradication of Helicobacter pylori?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1996 May;88(5):317–22 (Eng. Abstr.) **(Spa)**
[Alternative drugs against Chlamydia urethritis. Tetracycline offers the most cost-effective cure] Lindemalm-Lundstam B, et al. **Lakartidningen** 1996 Jan 31;93(5):369–71 **(Swe)**

ADVERSE EFFECTS

Minocycline-induced liver injury. Malcolm A, et al. **Am J Gastroenterol** 1996 Aug;91(8):1641–3
Short report: severe hiccups secondary to doxycycline-induced esophagitis during treatment of malaria. Tzianetas I, et al. **Am J Trop Med Hyg** 1996 Feb; 54(2):203–4
Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Knowles SR, et al. **Arch Dermatol** 1996 Aug;132(8):934–9 (38 ref.)
Hyperpigmented patches on the dorsa of the feet. Minocycline pigmentation. Meyer AJ, et al. **Arch Dermatol** 1995 Dec;131(12):1447, 1450
Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome [see comments] Gough A, et al. **BMJ** 1996 Jan 20;312(7024):169–72. Comment in: BMJ 1996 Jan 20;312(7024):138. Comment in: BMJ 1996 Apr 27;312(7038):1101.
Gynaecomastia in association with minocycline [letter] Davies JP, et al. **Br J Clin Pract** 1995 Jul-Aug;49(4):179
Minocycline-induced hyperpigmentation in leprosy. Fleming CJ, et al. **Br J Dermatol** 1996 Apr;134(4):784–7
Safety of long-term high-dose minocycline in the treatment of acne. Goulden V, et al. **Br J Dermatol** 1996 Apr; 134(4):693–5
Black breast milk due to minocycline therapy. Hunt MJ, et al. **Br J Dermatol** 1996 May;134(5):943–4
Severe, long-lasting symptoms from doxycycline-induced esophageal injury. Tankurt IE, et al. **Endoscopy** 1995 Oct; 27(8):626
Bronchiolitis obliterans organizing pneumonia associated with minocycline therapy: a possible cause. Piperno D, et al. **Eur Respir J** 1995 Jun;8(6):1018–20
A clinical study of minocycline-induced pneumonitis. Toyoshima M, et al. **Intern Med** 1996 Mar;35(3):176–9
Minocycline-induced chronic interstitial nephritis? Fletcher S, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):540–1
[Acute hepatitis induced by minocycline (letter)] Castex F, et al. **Gastroenterol Clin Biol** 1995 Jun-Jul;19(6-7):640–1 **(Fre)**

ANALYSIS

The effect of cooking on veterinary drug residues in food: 4. Oxytetracycline. Rose MD, et al. **Food Addit Contam** 1996 Apr;13(3):275–86
Determination of tetracycline residues in bovine milk, serum, and urine by capillary electrophoresis. Chen CL, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1369–77
Application of reversed-phase liquid chromatography and prepacked C18 cartridges for the analysis of oxytetracycline and related compounds. Fedeniuk RW, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):291–7

CHEMISTRY

Shelf life [letter] McCrory P. **Br Dent J** 1996 May 25; 180(10):366

ISOLATION & PURIFICATION

Assay and purity control of minocycline by thin-layer chromatography using UV and fluorescence densitometry—a comparison with liquid chromatography. Naidong W, et al. **J Pharm Biomed Anal** 1995 Jun; 13(7):905–10

METABOLISM

Tet(M)-promoted release of tetracycline from ribosomes is GTP dependent. Burdett V. **J Bacteriol** 1996 Jun; 178(11):3246–51
[Chelating and oxidizing properties of tetracycline metabolites forming during its peroxidase or photoinduced oxidation] Petrenko IuM, et al. **Antibiot Khimioter** 1995 Oct;40(10):7–14 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Selective adherence of a sucralfate-tetracycline complex to gastric ulcers: implications for the treatment of Helicobacter pylori. Yokel RA, et al. **Biopharm Drug Dispos** 1995 Aug;16(6):475–9
Pharmacokinetics of oxytetracycline administered intravenously to 4 to 5-day-old foals. Papich MG, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):375–8
Some pharmacokinetic parameters of doxycycline in east African goats after intramuscular administration of a long-acting formulation. Ole-Mapenay IM, et al. **Vet Res Commun** 1995;19(5):425–32
Species specific pharmacokinetics of rolitetracycline. Lashev L, et al. **Zentralbl Veterinarmed A** 1995 May;42(3):201–8

PHARMACOLOGY

In vitro modulation of bovine blood neutrophils and mononuclear cells by oxytetracycline. Myers MJ, et al. **Am J Vet Res** 1995 Aug;56(8):1007–11
Tetracyclines and calcified tissues. van der Bijl P, et al. **Ann Dent** 1995 Summer-Fall;54(1-2):69–72 (46 ref.)
The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Kloppenburg M, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):934–40
In vitro effectiveness of azithromycin against doxycycline-resistant and -susceptible strains of Rickettsia tsutsugamushi, etiologic agent of scrub typhus. Strickman D, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2406–10
Doxycycline activity against Streptococcus pneumoniae [letter] Shea KW, et al. **Chest** 1995 Dec;108(6):1775–6
The influence of tetracyclines on T cell activation. Kloppenburg M, et al. **Clin Exp Immunol** 1995 Dec; 102(3):635–41
Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae to the glycylcyclines. Weiss WJ, et al. **J Antimicrob Chemother** 1995 Jul;36(1):225–30
Minocycline impairment of both osteoid tissue removal and osteoclastic resorption in a synchronized model of remodeling in the rat. Klapisz-Wolikow M, et al. **J Cell Physiol** 1996 May;167(2):359–68
Effect of tetracycline HCl on periodontally-affected human root surfaces. Trombelli L, et al. **J Periodontol** 1995 Aug; 66(8):685–91
The effect of vitamin E and doxycycline on the development of intimal hyperplasia. Petrik PV, et al. **J Surg Res** 1996 Feb 1;60(2):279–83
Tetracycline-regulated reporter gene expression in the moss Physcomitrella patens. Zeidler M, et al. **Plant Mol Biol** 1996 Jan;30(1):199–205
A novel tetracycline-resistant determinant, tet(U), is encoded on the plasmid pKq10 in Enterococcus faecium. Ridenhour MB, et al. **Plasmid** 1996 Mar;35(2):71–80
[Comparative study of minimal inhibiting concentrations of doxycycline, ofloxacin and erythromycin against 18 recent isolates from Chlamydia trachomatis (1994–1995)] Bianchi A, et al. **Pathol Biol (Paris)** 1996 May;44(5):347–50 (Eng. Abstr.) **(Fre)**
[Resistance to tetracycline of E. coli of chicken intestines after prophylactic treatment of animal feed with bioptivet GB] Kobe A, et al. **Berl Munch Tierarztl Wochenschr** 1995 Nov;108(11):412–7 (Eng. Abstr.) **(Ger)**
[Subgingival distribution of periodontopathic bacteria in periodontic patients and susceptibility of these bacteria to minocycline-HCl] Hagiwara S, et al. **Kokubyo Gakkai Zasshi** 1995 Dec;62(4):495–505 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects. Thijs JC, et al. **Am J Gastroenterol** 1996 Jan;91(1):93–7

Evaluation of injections of collagenase and oxytetracycline via the umbilical artery as treatment for retained placenta in cattle. Fecteau KA, et al. **Am J Vet Res** 1996 Apr; 57(4):522–5

A cost–effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. Genç M, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):1–7

Treatment of ovine dermatophilosis with long–acting oxytetracycline or a lincomycin–spectinomycin combination. Jordan D, et al. **Aust Vet J** 1995 Jun; 72(6):234–6

Minocycline is a useful adjuvant therapy for pemphigus. Gaspar ZS, et al. **Australas J Dermatol** 1996 May;37(2):93–5

Minocycline for acne. Doctors should not change the way they prescribe for acne [letter; comment] Cunliffe WJ. **BMJ** 1996 Apr 27;312(7038):1101. Comment on: BMJ 1996 Jan 20;312(7024):138. Comment on: BMJ 1996 Jan 20;312(7024):169–72.

Minocycline for acne [editorial; comment] [see comments] Ferner RE, et al. **BMJ** 1996 Jan 20;312(7024):138. Comment on: BMJ 1996 Jan 20;312(7024):169–72. Comment in: BMJ 1996 Apr 27;312(7038):1101.

Minocycline for acne. Food reduces minocycline's bioavailability [letter; comment] Meyer FP. **BMJ** 1996 Apr 27;312(7038):1101. Comment on: BMJ 1996 Jan 20;312(7024):138.

Effects of doxycycline in patients with acute cough and purulent sputum: a double blind placebo controlled trial. Verheij TJ, et al. **Br J Gen Pract** 1994 Sep;44(386):400–4

Aspiration sclerotherapy for hydroceles in the tropics. Musa MT, et al. **Br J Urol** 1995 Oct;76(4):488–90

Milia en plaque—a new site and novel treatment. Keohane SG, et al. **Clin Exp Dermatol** 1996 Jan;21(1):58–60

Importation into the UK of a strain of Neisseria gonorrhoeae resistant to penicillin, ciprofloxacin and tetracycline [letter] Turner A, et al. **Genitourin Med** 1995 Oct;71(5):331–2

Protection against endotoxic shock and lipopolysaccharide–induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Shapira L, et al. **Infect Immun** 1996 Mar; 64(3):825–8

Large symptomatic müllerian duct cyst treated by tetracycline sclerotherapy. Ahmed M, et al. **Int Urol Nephrol** 1995;27(2):193–7

Minocycline in rheumatoid arthritis. Langevitz P, et al. **Isr J Med Sci** 1996 May;32(5):327–30 (33 ref.)

Confluent and reticulated papillomatosis: response to minocycline. Montemarano AD, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):253–6

Treatment of localized Mycobacterium avium complex infection with clofazimine and doxycycline in a cat. Kaufman AC, et al. **J Am Vet Med Assoc** 1995 Aug 15; 207(4):457–9

Comparison of tilmicosin with long–acting oxytetracycline for treatment of respiratory tract disease in calves [see comments] Musser J, et al. **J Am Vet Med Assoc** 1996 Jan 1;208(1):102–6. Comment in: J Am Vet Med Assoc 1996 Mar 1;208(5):655–6.

Evaluation of the use of intrauterine infusions of oxytetracycline, subcutaneous injections of fenprostalene, or a combination of both, for the treatment of retained fetal membranes in dairy cows. Stevens RD, et al. **J Am Vet Med Assoc** 1995 Dec 15;207(12):1612–5

A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of non–gonococcal urethritis in men. Phillips I, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:123–34

Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice. Russell P, et al. **J Antimicrob Chemother** 1996 Apr; 37(4):769–74

Open randomized study comparing doxycycline and co–amoxiclav in the treatment of acute suppurative tracheobronchitis in adults. The Collaborative Group of the Centre Universitaire de Medécine Générale de L'Université Libre de Bruxelles (CUMG–ULB) Investigators. Sternon J. **J Int Med Res** 1995 Sep–Oct; 23(5):369–76

The effect of non–surgical periodontal and adjunctive minocycline–HCL treatments on the activity of salivary proteases. Atilla G, et al. **J Periodontol** 1996 Jan;67(1):1–6

Evaluation of periodontal treatments using controlled–release tetracycline fibers: clinical response. Drisko CL, et al. **J Periodontol** 1995 Aug;66(8):692–9

Clinical significance of bacterial resistance to tetracyclines in the treatment of periodontal diseases. Greenstein G. **J Periodontol** 1995 Nov;66(11):925–32 (72 ref.)

Evaluation of periodontal treatments using controlled–release tetracycline fibers: microbiological response. Lowenguth RA, et al. **J Periodontol** 1995 Aug;66(8):700–7

Evaluation of periodontal treatments using controlled–release tetracycline fibers: maintenance response. Michalowicz BS, et al. **J Periodontol** 1995 Aug;66(8):708–15

Microbial flora in the acute phase of periodontitis and the effect of local administration of minocycline. Umeda M, et al. **J Periodontol** 1996 Apr;67(4):422–7

Doxycycline inhibition of aneurysmal degeneration in an elastase–induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. Petrinec D, et al. **J Vasc Surg** 1996 Feb;23(2):336–46

Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions in Somalia and Cambodia. Shanks GD, et al. **Mil Med** 1995 Sep; 160(9):443–5

A preliminary study of clarithromycin versus doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis. Stein GE, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):727–31

Local and systemic factors in periodontal disease increase matrix–degrading enzyme activities in rat gingiva: effect of micocycline therapy. Chang KM, et al. **Res Commun Mol Pathol Pharmacol** 1996 Mar;91(3):303–18

Treatment of infections caused by rapidly growing mycobacteria in the era of the newer macrolides. Wallace RJ Jr. **Res Microbiol** 1996 Jan–Feb;147(1–2):30–5 (34 ref.)

Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals. Trentham DE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):817–34 (58 ref.)

Verification of decreased basal and stimulated serum pepsinogen–I levels is a useful non–invasive method for determining the success of eradication therapy for Helicobacter pylori. Gisbert JP, et al. **Scand J Gastroenterol** 1996 Feb;31(2):103–10

Severe psittacosis during pregnancy and suppression of antibody response with early therapy. Khatib R, et al. **Scand J Infect Dis** 1995;27(5):519–21

[Maintenance treatment of cerebral toxoplasmosis in AIDS: role of clarithromycin–minocycline combination (letter)] Sellal A, et al. **Presse Med** 1996 Mar 23;25(10):509 **(Fre)**

[Comparison of the use of a vaccine and sequential antibiotic treatment in a herd infected with Mycoplasma hyopneumoniae] Le Grand A, et al. **Vet Res** 1996; 27(3):241–53 (Eng. Abstr.) **(Fre)**

[Effect of doxycycline in the treatment of progressive periodontal disease] Bokor M. **Med Pregl** 1995; 48(1–2):48–50 (Eng. Abstr.) **(Scr)**

ANTIBIOTICS, THIENAMYCIN see THIENAMYCINS

ANTIBODIES

see related

ANTIGEN–ANTIBODY REACTIONS

Follow–up of antibodies to growth hormone in 210 growth hormone–deficient children treated with different commercial preparations. Pirazzoli P, et al. **Acta Paediatr** 1995 Nov;84(11):1233–6

Antigen—antibody interactions in the reverse micellar system: quenching of the fluorescence of fluorescein–labeled atrazine by antibodies against atrazine. Matveeva EG, et al. **Anal Biochem** 1996 Feb 1;234(1):13–8

Immunoaffinity chromatography on antibodies immobilized on nitrocellulose powder. Petrescu S, et al. **Anal Biochem** 1995 Aug 10;229(2):299–303

Oriented immobilization of antibodies and its applications in immunoassays and immunosensors. Lu B, et al. **Analyst** 1996 Mar;121(3):29R–32R (47 ref.)

The use of antibodies for characterization and quantification of a recombinant protein. Sabater M, et al. **Ann N Y Acad Sci** 1996 May 15;782:462–77

Search for antibodies for immunoenzymatic assay of human lutropin. Szewczuk A, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(5–6):453–8

Clinical correlations with HLA type in Japanese patients with connective tissue disease and anti–U1 small nuclear RNP antibodies. Kuwana M, et al. **Arthritis Rheum** 1996 Jun; 39(6):938–42

Significance and immunoassay of 9– and 13–hydroxyoctadecadienoic acids. Spindler SA, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):187–91

Cloning and production of antisera to human placental 11 beta–hydroxysteroid dehydrogenase type 2. Brown RW, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):1007–17

Recognition of 5–HT transporter by antipeptide antibodies. Lawrence JA, et al. **Biochem Soc Trans** 1995 Aug; 23(3):473S

Binding of phenylphosphocholine–carrier conjugates to the combining site of antibodies maintains a conformation of the hapten. Barbar E, et al. **Biochemistry** 1996 Mar 5; 35(9):2958–67

Extended length heterobifunctional coupling agents for protein conjugations. Bieniarz C, et al. **Bioconjug Chem** 1996 Jan–Feb;7(1):88–95

Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Erhardtsen E, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):388–94

Towards artificial antibodies prepared by molecular imprinting. Ansell RJ, et al. **Clin Chem** 1996 Sep; 42(9):1506–12

Characterization of commercial antibodies for use in high resolution apo(a) phenotyping by immunoblot analysis. Gaw A, et al. **Clin Chim Acta** 1995 Aug 31;240(1):75–81

Anti–head and anti–tail antibodies against distinct epitopes in the catalytic subunit of protein kinase A. Use in the study of the kinase splitting membranal proteinase KSMP. Chestukhin A, et al. **FEBS Lett** 1996 Mar 18;382(3):265–70

A model phage display subtraction method with potential for analysis of differential gene expression. Stausbøl–Grøn B, et al. **FEBS Lett** 1996 Aug 5;391(1–2):71–5

Immunohistochemical testing of a new anti–EGF antibody. Seiwerth S, et al. **Folia Histochem Cytobiol** 1996;34(1):27–9

A strategy for identifying candidate sperm antigens for immunocontraception: isolation of human testis cDNA clones using polyclonal antisera directed against hamster acrosomal membrane preparation. Adoyo PA, et al. **Int J Androl** 1995 Jun;18 Suppl 1:32–8

Measuring the lifetime of bonds made between surface–linked molecules. Pierres A, et al. **J Biol Chem** 1995 Nov 3; 270(44):26586–92

Topological mimicry of cross–reacting enantiomeric peptide antigens. Verdoliva A, et al. **J Biol Chem** 1995 Dec 22; 270(51):30422–7

Monoclonal and polyclonal antibodies detect a new type of post–translational modification of axonemal tubulin. Levilliers N, et al. **J Cell Sci** 1995 Sep;108 (Pt 9):3013–28

A new method for double immunolabelling with primary antibodies from identical species. Eichmüller S, et al. **J Immunol Methods** 1996 Apr 19;190(2):255–65

Comparison of antibodies raised against the peptide 10–24 of chicken riboflavin carrier protein (cRCP) by classical and multiple antigen peptide (MAP) approaches. Mahale SD, et al. **J Immunol Methods** 1996 Apr 19;190(2):215–9

Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti–cytokine antibodies. Prussin C, et al. **J Immunol Methods** 1995 Dec 15;188(1):117–28

Microtubule minus ends can be labelled with a phage display antibody specific to alpha–tubulin. Fan J, et al. **J Mol Biol** 1996 Jun 14;259(3):325–30

Identification of gliadin presence in pharmaceutical products: appropriateness of polyclonal antibodies for detection of gliadin and other toxic prolamins [letter; comment] Miletic ID, et al. **J Pediatr Gastroenterol Nutr** 1995 Nov; 21(4):482–3. Comment on: J Pediatr Gastroenterol Nutr 1994 Jul;19(1):27–33.

Production and characterization of polyclonal anti–canine interleukin–8 antibodies. Mohamed A, et al. **J Vet Med Sci** 1996 Mar;58(3):219–224

Characterization of site–directed antibodies to the LH receptor in functionally active gonadal cells and their differential effects on LH–stimulated signal transduction in Leydig tumour (MA10) cells. Pallikaros Z, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):57–68

Brain GABAA receptors studied with subunit–specific antibodies. De Blas AL. **Mol Neurobiol** 1996 Feb; 12(1):55–71 (139 ref.)

Synthetic human antibodies. Barbas CF 3rd. **Nat Med** 1995 Aug;1(8):837–9 (32 ref.)

Determining the safety of the silicone envelope: in search of a silicone antibody. Rohrich RJ, et al. **Plast Reconstr Surg** 1996 Sep;98(3):455–8

A general assay for antibody catalysis using acridone as a fluorescent tag. Reymond JL, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4251–6

A sensitive enzyme immunoassay for cyclosporin A using antibodies generated against a novel hapten. Chen P, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jun; 88(3):317–26

[Anti–gangliosides antibodies in neuromuscular's pathology] Illa I. **Rev Neurol** 1995 Jul–Aug;23(122):885–8 (48 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Effects on complement activation and cytokine (TNF–alpha and IL–8) release of infusion of anti–TNF–antibodies or a xanthine derivative (HWA 138) in septic baboons. Bengtsson A, et al. **Acta Anaesthesiol Scand** 1996 Feb; 40(2):244–9

Attachment of antibody to biotinylated red blood cells: immuno–red blood cells display high affinity to immobilized antigen and normal biodistribution in rats. Muzykantov VR, et al. **Biotechnol Appl Biochem** 1996 Aug; 24 (Pt 1):41–5

Anti–Mac–1 antibodies and early pregnancy loss in mice. Savion S, et al. **J Reprod Fertil** 1996 May;107(1):7–10

From pseudocholinesterase to human immunodeficiency virus. Madhavankutty K, et al. **Med Hypotheses** 1995 Sep; 45(3):225–6

Microinjection of antibodies. Kovary K. **Methods Enzymol** 1995;254:445–58

Electroporation of antibodies into mammalian cells. Campbell PL, et al. **Methods Mol Biol** 1995;48:83–92

Different mediator systems in biphasic heterologous phase of anti–GBM nephritis in mice. Feith GW, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):599–607

Antibodies to tumor necrosis factor–alpha: use as adjunctive therapy in established group B streptococcal disease in newborn rats. Givner LB, et al. **Pediatr Res** 1995 Oct; 38(4):551–4

Administration of rabbit anti–asialo GM1 antiserum facilitates the development of human Epstein–Barr virus–induced lymphoproliferations in xenografted C.B–17 scid/scid mice. Lacerda JF, et al. **Transplantation** 1996 Feb 15;61(3):492–7

[A comparative analysis of the effects of the systemic and intraventricular administration of serotonin antibodies on the behavioral reactions and nociceptive sensitivity in animals] Evseev VA, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):129–36 (Eng. Abstr.) **(Rus)**

ANTIBODIES

ADVERSE EFFECTS

Antibodies to streptokinase [editorial] Jennings K. **BMJ** 1996 Feb 17;312(7028):393–4

Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. De Vos AF, et al. **Exp Eye Res** 1995 Dec;61(6):667–75

ANALYSIS

Antibodies to the 90 kDa heat shock protein in chronic plaque psoriasis [letter] al-Masaud AS, et al. **Acta Derm Venereol** 1995 Jul;75(4):317–9

The effects of islet cell surface antibodies on the metabolic function of mouse islet B cells in vitro. Dronfield DM, et al. **Acta Diabetol** 1995 Oct;32(3):153–7

Anti-verocytotoxin (VT)1, VT2 and VT2c antibodies in commercial intravenous immune globulins in Japan. Morooka T, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):294–5

Prevalence of CagA-bearing Helicobacter pylori strains detected by the anti-CagA assay in patients with peptic ulcer disease and in controls. Ching CK, et al. **Am J Gastroenterol** 1996 May;91(5):949–53

Bispecific multivalent antibody studied by real-time interaction analysis for the development of an antigen-inhibition enzyme-linked immunosorbent assay. Reinartz HW, et al. **Analyst** 1996 Jun;121(6):767–71

Anti-GD1a ganglioside antibodies in peripheral motor syndromes. Carpo M, et al. **Ann Neurol** 1996 Apr; 39(4):539–43

Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Jacobs BC, et al. **Ann Neurol** 1996 Aug;40(2):181–7

Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. Vázquez-Abad D, et al. **Arthritis Rheum** 1996 Feb;39(2):292–6

One framework, two systems: flexible abductive methods in the problem-space paradigm applied to antibody identification and biopsy interpretation. Smith JW Jr, et al. **Artif Intell Med** 1995 Jun;7(3):201–25

Antigen topography is critical for interaction of IgG2 anti-red-cell antibodies with Fc gamma receptors. Kumpel BM, et al. **Br J Haematol** 1996 Jul;94(1):175–83

Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha. Russo D, et al. **Br J Haematol** 1996 Aug;94(2):300–5

Re: Characterization of a novel human antibody xenoreactive with fibronectin [letter] Atta MS, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):336–7

Absence of antisteroid antibodies in oral contraceptive users presenting with vascular events. van den Brûle FA, et al. **Contraception** 1995 Oct;52(4):237–40

Statistical correlation between increased TSH and increased gliadin antibodies in Down syndrome [letter] Storm W. **Eur J Pediatr** 1996 May;155(5):426

Evaluation for antisperm antibodies after storage of sperm in TEST-yolk buffer. Hensleigh HC, et al. **Fertil Steril** 1996 Sep;66(3):454–8

Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. Milella M, et al. **Hepatogastroenterology** 1995 Jul;42(3):201–4

A rapid radioimmunoassay for the measurement of antibodies to glutamic acid decarboxylase in human serum. Aguilar-Diosdado M, et al. **Horm Metab Res** 1995 Jun; 27(6):293–5

Longitudinal study of serum and cerebrospinal fluid (CSF) class-specific antibodies against Campylobacter jejuni and GM1 ganglioside in Guillain-Barré syndrome. Kimura F, et al. **Intern Med** 1995 Oct;34(10):1009–14

IFL- and ELISA-antigliadin antibodies recognize different antigenic reactivities from those of R1-antireticulin and antiendomysial antibodies. Volta U, et al. **Ital J Gastroenterol** 1995 Mar;27(2):64–8

IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. Sakaguchi M, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):563–5

Residual antigenicity of hypoallergenic infant formulas and the occurrence of milk-specific IgE antibodies in patients with clinical allergy. van Beresteijn EC, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):365–74

Raised streptokinase neutralization titers following a single use of topical streptokinase in an older patient [letter] Trescoli-Serrano C. **J Am Geriatr Soc** 1996 May;44(5):614

Immunization of heifers against gonadotropin-releasing hormone: antibody titers, ovarian function, body growth, and carcass characteristics. Prendiville DJ, et al. **J Anim Sci** 1995 Aug;73(8):2382–9

Capillary isoelectric focusing as a tool in the examination of antibodies, peptides and proteins of pharmaceutical interest. Liu X, et al. **J Chromatogr A** 1996 May 31; 735(1-2):165–90 (72 ref.)

Immunoglobulin A class fibroblast antibodies in patients with Graves' disease and pretibial myxedema [see comments] Arnold K, et al. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3430–7. Comment in: J Clin Endocrinol Metab 1995 Dec;80(12):3427–9.

Maternal thyroid peroxidase antibodies during pregnancy: a marker of impaired child development? Pop VJ, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3561–6

Frequency and significance of antibodies to histones in autoimmune hepatitis. Czaja AJ, et al. **J Hepatol** 1995 Jul; 23(1):32–8

Evaluation of six anti-gliadin antibody assays. Berger R, et al. **J Immunol Methods** 1996 May 10;191(1):77–86

Anti-Thomsen-Friedenreich (T) antibody-based ELISA and its application to human breast carcinoma detection [see comments] Desai PR, et al. **J Immunol Methods** 1995 Dec 27;188(2):175–85. Comment in: J Immunol Methods 1995 Dec 27;188(2):171–3.

Determination of active single chain antibody concentrations in crude periplasmic fractions. Kazemier B, et al. **J Immunol Methods** 1996 Aug 14;194(2):201–9

Fluorescence resonance energy transfer as a new method for the epitope-specific characterization of anti-platelet antibodies. Koksch M, et al. **J Immunol Methods** 1995 Nov 16;187(1):53–67

Anti-Thomsen-Friedenreich (T) antibody and its application to human breast carcinoma: where are we after 20 years? [editorial; comment] McCarty KS Jr. **J Immunol Methods** 1995 Dec 27;188(2):171–3 (7 ref.). Comment on: J Immunol Methods 1995 Dec 27;188(2):175–85.

Characterization of antibodies to nerve growth factor: assay-dependent variability in the cross-reactivity with other neurotrophins. Conner JM, et al. **J Neurosci Methods** 1996 Mar;65(1):93–9

Prevalence of antikeratin antibodies in Greek patients with rheumatoid arthritis. A clinical, serologic, and immunogenetic study. Boki KA, et al. **J Rheumatol** 1995 Nov;22(11):2046–8

Methods of measuring antibodies in sera/plasma, ascites, and tissue-culture media. Rudbach JA, et al. **Methods Mol Biol** 1995;45:79–82

New assays for the measurement of serum antibodies reactive with eye muscle membrane antigens confirm their significance in thyroid-associated ophthalmopathy. Barsouk A, et al. **Thyroid** 1995 Jun;5(3):195–200

[Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a] Corbillet V, et al. **Ann Med Interne (Paris)** 1995; 146(6):399–403 (Eng. Abstr.) **(Fre)**

[Joint and systemic manifestations related to type 2 anti-mitochondrial antibodies] Dhôte R, et al. **Ann Med Interne (Paris)** 1995;146(8):536–40 (31 ref.) (Eng. Abstr.) **(Fre)**

[Circulating antigliadin antibodies. Prevalence in a diabetic (type 1 or 2) and non diabetic adult population] Tourniaire J, et al. **Presse Med** 1995 Oct 21;24(31):1425–7 (Eng. Abstr.) **(Fre)**

[Relations between vasculotensional disease, sudden deafness and benign paroxysmal postural vertigo: value of anticochlear antibodies] Maisin JP, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(3):179–82 (Eng. Abstr.) **(Fre)**

[Factor IX inhibitor] Higasa S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:98–9 (6 ref.) **(Jpn)**

[Factor VIII inhibitors] Takamatsu J. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:94–7 (11 ref.) **(Jpn)**

[Neurologic paraneoplastic syndromes and anti-neuronal antibodies] Mygland A. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):361–5 (44 ref.) (Eng. Abstr.) **(Nor)**

[Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia] Windyga J, et al. **Acta Haematol Pol** 1996;27(1):27–31 (Eng. Abstr.) **(Pol)**

[Level of antifibrinogen antibodies in newborns and women during the postpartum period] Kondera-Anasz Z. **Ginekol Pol** 1995 Dec;66(12):674–80 (Eng. Abstr.) **(Pol)**

[The value of IgA endomysium antibodies in diagnosis of coeliac disease among short children] Czerwionka-Szaflarska M, et al. **Pediatr Pol** 1995 Jul; 70(7):575–8 (Eng. Abstr.) **(Pol)**

[Evaluation of thyroid anti-membrane and anti-thyroglobulin antibody determination in patients with thyroid cysts treated with external drainage under ultrasonographic control] Chorąży M, et al. **Pol Arch Med Wewn** 1995 Jan; 93(1):19–24 (Eng. Abstr.) **(Pol)**

[Antibodies to alpha-2A interferon in children with juvenile respiratory papillomatosis] Kol'tsov VD, et al. **Vestn Otorinolaringol** 1995 Sep-Oct;(5):24–6 (Eng. Abstr.) **(Rus)**

[The effect of interferon alfa-2b therapy on titers of isohemagglutinins and anti-Forssman antibodies in patients with malignant melanoma] Kovčiń V, et al. **Glas Srp Akad Nauka [Med]** 1994;(44):109–16 (Eng. Abstr.) **(Scc)**

BIOSYNTHESIS see ANTIBODY FORMATION

BLOOD

Antibodies made against a formaldehyde-protein adduct cross react with an acetaldehyde-protein adduct. Implications for the origin of antibodies in human serum which recognize acetaldehyde-protein adducts. Pietrzak ER, et al. **Alcohol Alcohol** 1995 May;30(3):373–8

Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia [see comments] Arepally G, et al. **Am J Clin Pathol** 1995 Dec;104(6):648–54 . Comment in: Am J Clin Pathol 1995 Dec;104(6):611–3.

Hemolytic transfusion reaction due to Rh antibodies detectable only by manual polybrene and polyethylene glycol technique. Lin CK, et al. **Am J Clin Pathol** 1995 Dec;104(6):660–2

Antibodies to collagens in sera from patients receiving bovine cartilage graft [letter] Sittinger M, et al. **Ann Rheum Dis** 1996 May;55(5):333–4

Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. Lavieille JP, et al. **Anticancer Res** 1996 Jul-Aug;16(4C):2385–8

Selective induction of mucosal immune responses to 2-acetylaminofluorene. Silbart LK, et al. **Anticancer Res** 1996 Mar-Apr;16(2):651–60

A simple direct enzyme immunoassay of antibodies based on the differences in diffusion rates in a gel of a synthetic antigen and of its complex with antibodies. Semenov AN, et al. **Appl Biochem Biotechnol** 1996 Jan;56(1):73–8

Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Chabre H, et al. **Arthritis Rheum** 1995 Oct;38(10):1485–91

Use of enzyme-linked immunoassays for antibody to types C and D botulinum toxins for investigations of botulism in cattle. Gregory AR, et al. **Aust Vet J** 1996 Feb; 73(2):55–61

Presentation of peptide antigens as albumin conjugates for use in detection of serum antibodies by enzyme-linked immunosorbent assay. Yu Z, et al. **Bioconjug Chem** 1996 May-Jun;7(3):338–42

Antibodies against retinal S-antigen in patients with juvenile chronic arthritis-associated uveitis [letter] Edelsten C, et al. **Br J Rheumatol** 1996 Jan;35(1):101–2

Interference by IgM rheumatoid factor on ELISA for antibodies to mycobacterial 65 kDa heat shock protein in rheumatoid arthritis [letter; comment] Lim KK, et al. **Br J Rheumatol** 1996 Mar;35(3):300–1. Comment on: Br J Rheumatol 1995 Jul;34(7):610–5.

Anti-ganglioside antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy. Salih AM, et al. **Br J Rheumatol** 1996 Aug;35(8):725–31

Anti-tyrosinase antibodies in malignant melanoma. Merimsky O, et al. **Cancer Immunol Immunother** 1996 Jun; 42(5):297–302

Autoimmunity to collagen in human lung cancer. Fernandez-Madrid F, et al. **Cancer Res** 1996 Jan 1; 56(1):121–6

Effect of malnutrition on serum and milk antibodies in Zairian women. Brüssow H, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):37–41

Antineurofilament and antiretinal antibodies in AIDS patients with cytomegalovirus retinitis. Rosberger DF, et al. **Clin Diagn Lab Immunol** 1994 Jul;1(4):445–9

Characterization of a novel human antibody xenoreactive with fibronectin. Girard D, et al. **Clin Immunol Immunopathol** 1995 Nov;77(2):149–61

The development of an ELISA method for the detection of "antibodies" to silicone. Rosenau B, et al. **Curr Top Microbiol Immunol** 1996;210:69–74

Antibodies to bovine serum albumin in Brazilian children and young adults with IDDM. Pardini VC, et al. **Diabetes Care** 1996 Feb;19(2):126–9

Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Czaja AJ, et al. **Dig Dis Sci** 1996 Sep;41(9):1733–40

Treatment of systemic mastocytosis with interferon-gamma: failure after appearance of anti-IFN-gamma antibodies. Fiehn C, et al. **Eur J Clin Invest** 1995 Aug;25(8):615–8

Potential of endogenous peptides to induce immunological reactions as observed in type I diabetes, a study in mice. Petersen KG, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(3):162–7

Frequency of sperm antibodies in different populations of infertile persons. Gateva I, et al. **Folia Med (Plovdiv)** 1995; 37(4A Suppl):22

Natural antibodies to dietary proteins: the existence of natural antibodies to alliinase (Alliin lyase) and mannose-specific lectin from garlic (Allium sativum) in human serum. Tchernychev B, et al. **Immunol Lett** 1995 Jul-Aug; 47(1-2):53–7

Sequential study of IgG antibody response in immunized rabbit and development of immunization protocol for raising monospecific antibody. Chande C, et al. **Indian J Pathol Microbiol** 1996 Jan;39(1):27–32

The relationship between RAST and skin test results in patients with asthma or rhinitis: a quantitative study with purified major allergens. Witteman AM, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):16–25

Self-reported signs and symptoms in breast implant patients with novel antibodies to silicone surface associated antigens [anti-SSAA(x)] [published erratum appears in J Appl Biomater 1995 Winter;6(4):305] Kossovsky N, et al. **J Appl Biomater** 1995 Fall;6(3):153–60

Impaired pancreatic function in patients with Crohn's disease with and without pancreatic autoantibodies. Seibold F, et al. **J Clin Gastroenterol** 1996 Apr;22(3):202–6

Durable elimination of high affinity, T cell-dependent antibodies by low molecular weight antigen arrays in vivo. Symer DE, et al. **J Immunol** 1995 Dec 15;155(12):5608–16

Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis. Kisand KE, et al. **J Mol Med** 1996 May;74(5):269–72

Anti-beta-tubulin antibodies have no diagnostic value in patients with chronic inflammatory demyelinating polyneuropathy. van Schaik IN, et al. **J Neurol** 1995 Sep;

242(9):599–603
Detection and quantification of Ornithodoros-specific anti-tick antibody by competitive inhibition ELISA. Wozniak EJ, et al. **J Parasitol** 1996 Feb;82(1):88–93
Neonatal thrombocytopenia caused by passive transfer of anti-PLA1 antibody by blood transfusion. Marzich C, et al. **J Pediatr** 1996 Jan;128(1):137–9
Facilitation of the growth promoting effect of growth hormone (GH) by an antibody to methionyl-GH. Suh BK, et al. **J Pediatr Endocrinol Metab** 1995 Apr–Jun;8(2):97–102
Seroprevalence of Psoroptes sp. mites in free-ranging elk (Cervus elaphus) as determined by kinetic ELISA. Ziccardi MH, et al. **J Wildl Dis** 1996 Jan;32(1):51–6
Do serum antibodies to heat-shock protein 65 relate to age or stroke? [letter] Mantle R, et al. **Lancet** 1995 Dec 23–30; 346(8991–8992):1715
Assessment of serum antibodies in patients with rapidly progressive sensorineural hearing loss and Menière's disease. Gottschlich S, et al. **Laryngoscope** 1995 Dec;105(12 Pt 1):1347–52
Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients. Greene PE, et al. **Mov Disord** 1996 Mar;11(2):181–4
Do dietary antibodies still play a role in the diagnosis and follow-up of coeliac disease? A comparison among different serological tests. Ferfoglia G, et al. **Panminerva Med** 1995 Jun;37(2):55–9
Elevated levels of serum antibodies to the lectin wheat germ agglutinin in celiac children lend support to the gluten–lectin theory of celiac disease. Fälth-Magnusson K, et al. **Pediatr Allergy Immunol** 1995 May;6(2):98–102
Sheep red blood cell and Brucella abortus antibody responses in chickens selected for multitrait immunocompetence. Nelson NA, et al. **Poult Sci** 1995 Oct;74(10):1603–9
Antibodies to heat shock proteins in patients with pulmonary sarcoidosis. Hrycaj P, et al. **Sarcoidosis** 1995 Sep; 12(2):124–30
Five-year follow-up of human anti-mouse antibody in multitransfused HIV negative haemophilics treated with a monoclonal purified plasma derived factor VIII concentrate [letter] Smid WM, et al. **Thromb Haemost** 1995 Oct;74(4):1203
Attack on prewarmed tests--too much hot air? [letter; comment] Garratty G. **Transfusion** 1996 Feb;36(2):192. Comment on: Transfusion 1995 Mar;35(3):271–5.
Anti-skeletal muscle glycolipid antibodies in human heart transplantation as markers of acute rejection.Correlation with endomyocardial biopsy. Laguens RP, et al. **Transplantation** 1996 Jul 27;62(2):211–6
Rhesus immunization after renal transplantation. Quan VA, et al. **Transplantation** 1996 Jan 15;61(1):149–50
Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Reed EF, et al. **Transplantation** 1996 Feb 27;61(4):566–72
Evaluation of HLA antibodies with the PRA-STAT test. An ELISA test using soluble HLA class I molecules. Zachary AA, et al. **Transplantation** 1995 Dec 27; 60(12):1600–6
Functional bovine immunoglobulins in Boophilus microplus hemolymph. Vaz Júnior I da S, et al. **Vet Parasitol** 1996 Mar;62(1–2):155–60
Reliability of a screening assay for the simultaneous detection of antibodies to HIV-1/2 and HTLV-I/II [letter] Gómez-Hernando C, et al. **Vox Sang** 1996;70(2):119–20
[Assessment of various immunologic parameters in silicone implant carriers] Granchi D, et al. **G Chir** 1995 Nov–Dec; 16(11–12):479–85 (Eng. Abstr.) **(Ita)**
[Study on reverse transcriptase inhibiting antibody in plasma of HIV-1 seropositive subjects] Saito T, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):851–7 (Eng. Abstr.) **(Jpn)**
[Complement-binding antibodies to alpha-amylase in the diagnosis of chronic pancreatitis] Amosova EN, et al. **Lik Sprava** 1995 May–Jun;(5–6):91–3 (Eng. Abstr.) **(Rus)**
[Antibodies to skeletal muscle myofibrillar proteins in the diagnosis of rheumatoid arthritis] Zborovskiĭ AB, et al. **Ter Arkh** 1995;67(8):54–6 (Eng. Abstr.) **(Rus)**
[Antibodies to organ-nonspecific and organ-specific antigens in the blood sera of persons with bronchopulmonary diseases] Iastrebova NE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec; (6):67–8 **(Rus)**

CEREBROSPINAL FLUID

Cerebrospinal fluid antiganglioside antibodies in patients with AIDS. Sorice M, et al. **Infection** 1995 Sep–Oct;23(5):288–91

CHEMISTRY

Antibody-mimicking polymers as chiral stationary phases in HPLC. Kempe M. **Anal Chem** 1996 Jun 1;68(11):1948–53
Patterning and regeneration of surfaces with antibodies. Pritchard DJ, et al. **Anal Chem** 1995 Oct 1;67(19):3605–7
Strategy for fractionating high-affinity antibodies to steroid hormones by affinity chromatography. Giraudi G, et al. **Analyst** 1996 Jul;121(7):939–44
Development of a simple and selective separation of 67Cu from irradiated zinc for use in antibody labelling: a comparison of methods. Schwarzbach R, et al. **Appl Radiat Isot** 1995 May;46(5):329–36
A mutational analysis of the binding of two different proteins to the same antibody. Dall'Acqua W, et al. **Biochemistry** 1996 Jul 30;35(30):9667–76
Folding nuclei of the scFv fragment of an antibody. Freund C, et al. **Biochemistry** 1996 Jun 25;35(25):8457–64
Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Hansen CB, et al. **Biochim Biophys Acta** 1995 Nov 1;1239(2):133–44
A laser assisted deposition technique suitable for the fabrication of biosensors and molecular electronic devices. Morales P, et al. **Biosens Bioelectron** 1995;10(9–10):847–52
Linkage of silver to antibodies through 2-imino thiolane. Hazra DK, et al. **Cell Biophys** 1995 Jun;26(3):183–6
Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105–14 (65 ref.)
Antibody engineering. Nilsson B. **Curr Opin Struct Biol** 1995 Aug;5(4):450–6 (77 ref.)
Immunohistological staining of lymphoid tissue in four Australian marsupial species using species cross-reactive antibodies. Hemsley SW, et al. **Immunol Cell Biol** 1995 Aug; 73(4):321–5
Stability of polypeptide immunoreactants and polyvinyl alcohol as a blocking agent on polyester cloth during dry storage. Boyd S, et al. **Immunol Invest** 1995 Aug; 24(5):795–803
Influence of the antibody-peroxidase coupling methods on the conjugate stability and on the methodologies for the preservation of the activity in time. Presentini R, et al. **J Immunoassay** 1995 Aug;16(3):309–24
Optimization of the covalent conjugating procedure (NaIO4) of horseradish peroxidase to antibodies for use in enzyme-linked immunosorbent assay. Tsang VC, et al. **J Immunoassay** 1995 Nov;16(4):395–418
Scanning tunnelling microscopy and dynamic contact angle studies of the effects of partial denaturation on immunoassay solid phase antibody. Davies J, et al. **J Immunol Methods** 1995 Oct 12;186(1):111–23
Comparative properties of polyclonal and monoclonal antibodies. Rodkey LS. **Methods Mol Biol** 1995;51:139–50
Molecular modeling of antibody-combining sites. Webster DM, et al. **Methods Mol Biol** 1995;51:17–49
Development and use of a receptor antibody to characterize the interaction between somatostatin receptor subtype 1 and G proteins. Gu YZ, et al. **Mol Pharmacol** 1995 Dec; 48(6):1004–14
Properties of a single-chain antibody containing different linker peptides. Alfthan K, et al. **Protein Eng** 1995 Jul; 8(7):725–31
Linker modification introduces useful molecular instability in a single chain antibody. Solar I, et al. **Protein Eng** 1995 Jul;8(7):717–23
Model building of antibody combining sites. Bajorath J, et al. **Ther Immunol** 1995 Apr;2(2):95–103 (104 ref.)

DEFICIENCY see IMMUNOLOGIC DEFICIENCY SYNDROMES

DIAGNOSTIC USE

A polyclonal antibody against mammalian FOS can be used as a cytoplasmic neuronal activity marker in a teleost fish. Bosch TJ, et al. **J Neurosci Methods** 1995 May; 58(1–2):173–9
[Preparation of specific antiserum of secretin and its use in time-resolved fluoroimmunoassay] Ito K, et al. **Yakugaku Zasshi** 1995 Dec;115(12):985–91 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Effect of dietary fatty acids on antibody production and fatty acid composition of lymphoid organs in broiler chicks. Friedman A, et al. **Poult Sci** 1995 Sep;74(9):1463–9

GENETICS

Specificity and binding affinity of an anti-crotoxin combinatorial antibody selected from a phage-displayed library. Meng J, et al. **Biochem Pharmacol** 1995 Dec 22; 50(12):1969–77
Repair and recombination. How to make ends meet. Roth DB, et al. **Curr Biol** 1995 May 1;5(5):496–9
Molecular studies on thyrotropin (TSH) receptor and anti-TSH receptor antibodies. Akamizu T, et al. **Endocr J** 1995 Oct;42(5):617–27 (46 ref.)
Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Chu TH, et al. **Gene Ther** 1994 Sep;1(5):292–9
A genetically engineered single-gene-encoded anti-TAG72 chimeric antibody secreted from myeloma cells. Qi Y, et al. **Hum Antibodies Hybridomas** 1995;6(4):161–6
Construction and evolution of antibody-phage libraries by DNA shuffling. Crameri A, et al. **Nat Med** 1996 Jan; 2(1):100–2
Molecular basis for a geographic variation of varicella-zoster virus recognized by a peptide antibody. Kinchington PR, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S13–4 (7 ref.)
Expression of a single-chain Fv antibody against abscisic acid creates a wilty phenotype in transgenic tobacco. Artsaenko O, et al. **Plant J** 1995 Nov;8(5):745–50
Protein evolution on partially correlated landscapes. Perelson AS, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9657–61

IMMUNOLOGY

Antibodies of type II collagen and immune complexes in Menière's disease. Yoshino K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:79–85
Cross-reacting IgE antibodies recognizing latex allergens, including Hev b 1, as well as papain. Baur X, et al. **Allergy** 1995 Jul;50(7):604–9
IgG1 and IgG4 antibody responses to the dust mite Lepidoglyphus destructor in a naturally exposed farming population. Johansson E, et al. **Allergy** 1995 Jun;50(6):473–7
Characterization of the antibody response to a Haemophilus influenzae type b conjugate vaccine in children with recurrent lower respiratory tract infection. Kristensen K, et al. **Allergy** 1995 Jun;50(6):528–31
Chemokine gene expression in anti-glomerular basement membrane antibody glomerulonephritis. Tang WW, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):F323–30
T-cell-targeted immunofusion proteins from E. coli. Better M. **Ann N Y Acad Sci** 1996 May 15;782:544–54
Uptake of vWF-anti-vWF complexes by platelets in suspension. White JG, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):868–77
Antibodies to synovial antigens in recent-onset rheumatoid arthritis. McColl GJ, et al. **Arthritis Rheum** 1995 Oct; 38(10):1418–28
Preparation and characterization of a D-myo-inositol 1,4,5-trisphosphate-specific antibody. Shieh WR, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):1009–14
Antibodies raised against guanosine bind to double-stranded DNA. Kala KC, et al. **Biochem Mol Biol Int** 1995 Oct; 37(2):305–12
Structural basis of antibody cross-reactivity: solution conformation of an immunogenic peptide fragment containing both T and B epitopes. Cuniasse P, et al. **Biochemistry** 1995 Oct 3;34(39):12782–9
Antibodies specific for proteolyzed forms of protein kinase C alpha. Kikuchi H, et al. **Biochim Biophys Acta** 1995 Nov 30;1269(3):253–9
High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Dazzi F, et al. **Br J Haematol** 1996 Jun 1;93(3):688–93
Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Deshane J, et al. **Cancer Gene Ther** 1996 Mar–Apr;3(2):89–98
Designing human consensus antibodies with minimal positional templates. Couto JR, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5973s–5977s
Size heterogeneity of amyloid fibril proteins of beta 2-microglobulin origin in hemodialysis and disease-specific antibodies. Linke RP, et al. **Contrib Nephrol** 1995;112:65–76
CD43 and CD5 antibodies define four normal and neoplastic B-cell subsets: a three-color flow cytometric study. Lynch EF, et al. **Cytometry** 1995 Sep 15;22(3):223–31
Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken. Magdolen V, et al. **Electrophoresis** 1995 May;16(5):813–6
A conformational change in the beta-subunit of the insulin-like growth factor I receptor identified by antipeptide antibodies. Gual P, et al. **Endocrinology** 1995 Dec;136(12):5298–304
Bovine granulosa cell culture for assessment of potency and specificity of antibodies to pregnant mares' serum gonadotrophin. Kuran M, et al. **Eur J Endocrinol** 1996 Apr; 134(4):497–500
Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2. Nolte KU, et al. **Eur J Immunol** 1996 Sep;26(9):2155–9
5'-nucleotidase activates and an inhibitory antibody prevents neuritic differentiation of PC12 cells. Heilbronn A, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1172–9
Clinical significance of antibodies against calcitonin. Grauer A, et al. **Exp Clin Endocrinol Diabetes** 1995;103(6):345–51 (37 ref.)
The functional affinity and specificity of autoantibodies in animal models of anti-glomerular basement membrane disease. Marriott JB, et al. **Exp Nephrol** 1995 Jul–Aug; 3(4):257–64
Screening for in vitro haemolysing antibodies [letter] Kenéz E, et al. **Haematologia (Budap)** 1995;26(4):221–4
Nitric oxide synthase isozymes antibodies. Pollock JS, et al. **Histochem J** 1995 Oct;27(10):738–44 (61 ref.)
Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: strategies for evading the humoral immune response. Rollins SA, et al. **Hum Gene Ther** 1996 Mar 20;7(5):619–26
Pulmonary immune memory: localized production of antibody in the lung after antigen challenge. Bice DE, et al. **Immunology** 1996 Jun;88(2):191–7
Immunogenicity of peptides coupled with multiple T-cell epitopes of a surface protein antigen of Streptococcus mutans. Senpuku H, et al. **Immunology** 1996 Jun; 88(2):275–83
Antibody-mediated inhibition of Aedes aegypti midgut trypsins blocks sporogonic development of Plasmodium

gallinaceum. Shahabuddin M, et al. **Infect Immun** 1996 Mar; 64(3):739–43

Antibodies to quail erythrocytes in quail–chicken spinal cord chimeras. Saito K, et al. **Int Arch Allergy Immunol** 1996 Feb;109(2):127–32

Characterization of development-specific, cell type-specific mouse testicular antigens using testis-specific polyclonal antibodies. Tsuchida J, et al. **Int J Androl** 1995 Aug; 18(4):208–12

Temporary anti-CD25/CsA therapy induces a CD4+ T-cell–mediated tolerance in BB/OK rats. Kuttler B, et al. **J Autoimmun** 1996 Jun;9(3):321–9

Anti-metatype antibody stabilization of Fv 4-4-20 variable domain dynamics. Carrero J, et al. **J Biol Chem** 1996 May 10;271(19):11247–52

Regulation and immunolocalization of acyl–coenzyme A: cholesterol acyltransferase in mammalian cells as studied with specific antibodies. Chang CC, et al. **J Biol Chem** 1995 Dec 8;270(49):29532–40

S-antigen antibody partially blocks entrainment and the effects of constant light on the circadian rhythm of locomotor activity in the adult blow fly, Calliphora vicina. Cymborowski B, et al. **J Biol Rhythms** 1996 Mar; 11(1):68–74

Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary electrophoresis. Hoffmann T, et al. **J Chromatogr A** 1995 Nov 17;716(1-2):355–62

Anesthesia with antiphospholipid antibodies: anesthetic management of a parturient with lupus anticoagulant and anticardiolipin antibody. Fahy BG, et al. **J Clin Anesth** 1996 Feb;8(1):49–53

Discrete characteristics of antibodies raised against thyrotropin receptor–related peptides whose sequences are not conserved in the luteinizing hormone/chorionic gonadotropin receptor. Murakami M, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1747–52

Relationships between antibodies against human soluble complement receptor 1 (hsCR1) from various species. Ruggieri EV, et al. **J Clin Immunol** 1996 Mar;16(2):97–106

Targeted tumor killing via an intracellular antibody against erbB–2. Deshane J, et al. **J Clin Invest** 1995 Dec; 96(6):2980–9

Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist [editorial] Pascual V, et al. **J Clin Invest** 1996 Mar 15;97(6):1357–8

Noradrenergic system in the chicken brain: immunocytochemical study with antibodies to noradrenaline and dopamine–beta–hydroxylase. Moons L, et al. **J Comp Neurol** 1995 Sep 18;360(2):331–48

Hybrid antibody mediated veto of cytotoxic T lymphocyte responses. Qi Y, et al. **J Exp Med** 1996 May 1; 183(5):1973–80

Study of the acrosome reaction and the fertilizing ability of hamster epididymal cauda spermatozoa treated with antibodies against phospholipase A2 and/or lysophosphatidylcholine. Riffo MS, et al. **J Exp Zool** 1996 Aug 15;275(6):459–68

Production of polyclonal antibody specific for human natriuretic peptide receptor B. Kitano K, et al. **J Immunol Methods** 1996 Aug 14;194(2):147–53

Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. Alving CR, et al. **J Lab Clin Med** 1996 Jan;127(1):40–9

Salivary gland changes and host antibody responses associated with feeding of male lone star ticks (Acari:Ixodidae). Sanders ML, et al. **J Med Entomol** 1996 Jul;33(4):628–34

Antibody recognition of calcium-binding proteins depends on their calcium-binding status. Winsky L, et al. **J Neurochem** 1996 Feb;66(2):764–71

Distribution of androgen receptor–like immunoreactivity in the brains of cynomolgus monkeys. Michael RP, et al. **J Neuroendocrinol** 1995 Sep;7(9):713–9

A technique for sorting rat gonadotropes using anti-LH or anti-FSH antibodies covalently attached to magnetic beads. Valenti S, et al. **J Neuroendocrinol** 1995 Sep;7(9):673–9

Antineutrophil cytoplasmic antibodies and the optic-spinal form of multiple sclerosis in Japan [letter] Fukazawa T, et al. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):203–4

Gerstmann–Sträussler–Scheinker disease (PRNP P102L): amyloid deposits are best recognized by antibodies directed to epitopes in PrP region 90–165. Piccardo P, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):790–801

Intra–vitreal injection of substance P antibodies as an antagonist in the vertebrate (fish) retina. Djamgoz MB, et al. **J Neurosci Methods** 1996 Feb;64(2):237–43

Immune recognition of Ornithodoros tick (Acari: Argasidae) salivary antigens by anti-Psoroptes cuniculi antibodies. Wozniak EJ, et al. **J Parasitol** 1996 Apr;82(2):375–8

Inhibition of calcium currents and exocytosis by Lambert–Eaton syndrome antibodies in human lung cancer cells. Viglione MP, et al. **J Physiol (Lond)** 1995 Oct 15; 488 (Pt 2):303–17

Epitope identification by polyclonal antibody from phage-displayed random peptide library. Yao ZJ, et al. **J Protein Chem** 1995 Apr;14(3):161–6

Antibodies directed to restricted sequences of the c-Erb A alpha hinge domain interfere with hormone or DNA binding to recombinant alpha-type triiodothyronine receptor (c-Erb A alpha1) and detect structural changes. Daadi M, et al. **J Recept Signal Transduct Res** 1995 Apr; 15(5):715–35

Generation of antibodies against a human lipoprotein lipase fusion protein. Singh-Bist A, et al. **Life Sci** 1995; 57(18):1709–15

Antibodies to Anopheles midgut reduce vector competence for Plasmodium vivax malaria. Srikrishnaraj KA, et al. **Med Vet Entomol** 1995 Oct;9(4):353–7

Evaluation of antibody clonality. Rodkey LS. **Methods Mol Biol** 1995;51:151–63

Comparative properties of polyclonal and monoclonal antibodies. Rodkey LS. **Methods Mol Biol** 1995;51:139–50

Modelling antibody-antigen interactions: ferritin as a case study. Helmer–Citterich M, et al. **Mol Immunol** 1995 Sep; 32(13):1001–10

Effects of secondary forces on the primary antibody–ligand interaction. Mummert ME, et al. **Mol Immunol** 1995 Nov; 32(16):1225–33

IgM M-protein with antibody activity against gangliosides with disialosyl residue in sensory neuropathy binds to sensory neurons. Oka N, et al. **Muscle Nerve** 1996 Apr; 19(4):528–0

Antiglomerular basement membrane disease with cANCA positivity without pulmonary involvement. Neary P, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):693–5

Cyclosporin A reduces albuminuria in experimental anti–GBM nephritis independently from changes in GFR. Schrijver G, et al. **Nephrol Dial Transplant** 1995; 10(7):1149–54

Generation and characterization of an antiserum reactive with a proteolytic processing site within rat procorticotrophin–releasing hormone. Castro MG, et al. **Neuropeptides** 1995 Oct;29(4):183–92

Chemically defined neuron groups and their subpopulations in the glomerular layer of the rat main olfactory bulb. Kosaka K, et al. **Neurosci Res** 1995 Aug;23(1):73–88

Testing NF–kappa B1–p50 antibody specificity using knockout mice. Pereira DS, et al. **Oncogene** 1996 Jul 18; 13(2):445–6

Antibody dependent, complement mediated liver uptake of liposomes containing GM1. Liu D, et al. **Pharm Res** 1995 Nov;12(11):1775–80

Anti-activin A antibody (IgY) specifically neutralizes various activin A activities. Murata T, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):100–7

The effect of leucotrofina and BSA (bovine serum albumin) antigen on the ontogenetical capacity of antibody generation in chicken. Roman J, et al. **Rom J Physiol** 1993 Jul–Dec;30(3-4):193–7

Antibodies against oxidised low-density lipoprotein in juvenile chronic arthritis. Savolainen A, et al. **Scand J Rheumatol** 1995;24(4):209–11

Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Chen SY, et al. **Semin Oncol** 1996 Feb; 23(1):148–53 (55 ref.)

Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype. Jarvis MA, et al. **Thromb Haemost** 1996 Feb; 75(2):318–25

Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies. Belloc C, et al. **Toxicology** 1996 Jan 8;106(1-3):207–19

Antibody-mediated neutralization and binding–reversal studies on alpha-neurotoxins from Micrurus nigrocinctus nigrocinctus (coral snake) venom. Alape-Giron A, et al. **Toxicon** 1996 Mar;34(3):369–80

The reducing end of alpha Gal oligosaccharides contributes to their efficiency in blocking natural antibodies of human and baboon sera. Neethling FA, et al. **Transpl Int** 1996; 9(2):98–101

Different action of xenoreactive natural and immune antibodies on functioning cardiomyocytes. Autenrieth A, et al. **Transplant Proc** 1996 Apr;28(2):576–7

Anti-carbohydrate antibodies associated with hyperacute rejection in a vascularized mouse heart-to-rat xenotransplantation model. Gustavsson ML, et al. **Transplantation** 1996 Mar 27;61(6):957–63

Early renal graft dysfunction. The role of preformed antibodies to DR-typed lymphoblastoid cell lines. Lederer SR, et al. **Transplantation** 1996 Jan 27;61(2):313–9

Antigenic determinants at the carboxy terminus of chicken egg white riboflavin carrier protein (RCP): epitope mapping and antibody–mediated pregnancy curtailment in rodents. Koshy BT, et al. **Vaccine** 1996 Mar;14(4):307–12

Antibodies to canine granulocyte colony–stimulating factor induce persistent neutropenia. Reagan WJ, et al. **Vet Pathol** 1995 Jul;32(4):374–8

Anti–peptide antibodies to the P4502D subfamily in rat, dog and man. Nakamura A, et al. **Xenobiotica** 1995 Nov; 25(10):1103–9

[Study of an anti-serum against phenytoin with two organometallic tracers] Mfouara JC, et al. **Ann Pharm Fr** 1996;54(1):34–9 (Eng. Abstr.) **(Fre)**

[Crohn disease, hemorrhagic rectocolitis: antibodies and humans (editorial)] Duclos B. **Gastroenterol Clin Biol** 1995 Nov;19(11):865–6 (21 ref.) **(Fre)**

[Blocking antibodies in Dermatophagoides allergy] Sánchez Armengol A, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec;23(6):271–6 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Synthesis of 17 beta–hydroxyandrost–4–en–3–one–7 alpha–(biotinyl–6–N–hexylamide), a conjugate useful for affinity chromatography and for testosterone immunoassays. Luppa P, et al. **Bioconjug Chem** 1996 May–Jun;7(3):332–7

Use of insoluble fusion proteins to purify antibodies. Luo J, et al. **Biotechniques** 1995 Oct;19(4):544–6, 548, 550

Polystyrene as an affinity chromatography matrix for the purification of antibodies. Staak C, et al. **J Immunol Methods** 1996 Aug 14;194(2):141–6

An improved method to create nitrocellulose particles suitable for the immobilization of antigen and antibody. Steinitz M, et al. **J Immunol Methods** 1995 Nov 16; 187(1):171–7

Laboratory management of antibodies to blood–group antigens in pregnancy [letter; comment] Judd WJ. **Lancet** 1996 May 18;347(9012):1412–3. Comment on: Lancet 1996 Feb 24;347(9000):485–6.

Affinity immunoblotting. Knisley KA, et al. **Methods Mol Biol** 1995;51:165–70

Functional activities of antibodies directed against surface lipoproteins of Borrelia hermsii. Sambri V, et al. **Microbiol Immunol** 1995;39(8):623–7

A novel and efficient route for the isolation of antibodies that recognise T cell receptor V alpha(s). Popov S, et al. **Mol Immunol** 1996 Apr;33(6):493–502

Production and characterization of an antibody directed against the mouse 5HT1B receptor. Grimaldi B, et al. **Neurosci Res** 1995 Dec;24(1):97–101

Elimination of acquired factor VIII antibodies by extracorporal antibody–based immunoadsorption (Ig–Therasorb). Knöbl P, et al. **Thromb Haemost** 1995 Oct; 74(4):1035–8

Cytophilic antibodies in cats with miliary dermatitis and eosinophilic plaques: passive transfer of immediate–type hypersensitivity. Roosje PJ, et al. **Vet Q** 1995 Jun; 17(2):66–9

[Serum smooth muscle antibodies with anti–actin specificity appeared during treatment with interferon alpha (letter)] Grimbert S, et al. **Gastroenterol Clin Biol** 1996;20(4):404–5 **(Fre)**

METABOLISM

Jejunal fluid antibodies and mucosal gamma/delta IEL in latent and potential coeliac disease. Arranz E, et al. **Adv Exp Med Biol** 1995;371B:1345–8

Local antibodies and cytokine responses in crevicular fluid of patients with juvenile periodontitis. Bártová J, et al. **Adv Exp Med Biol** 1995;371B:1109–12

Oral immunization with attenuated Salmonella expressing human sperm antigen induces antibodies in serum and the reproductive tract. Srinivasan J, et al. **Biol Reprod** 1995 Aug;53(2):462–71

An analysis of antigen–antibody binding kinetics for biosensor applications utilized as a model system: influence of non–specific binding. Chen Z, et al. **Biophys Chem** 1996 Jan;57(2–3):177–87

Neutralising antibodies after streptokinase treatment for myocardial infarction: a persisting puzzle. McGrath K, et al. **Br Heart J** 1995 Aug;74(2):122–3

Pharmacokinetic analysis of the microscopic distribution of enzyme–conjugated antibodies and prodrugs: comparison with experimental data. Baxter LT, et al. **Br J Cancer** 1996 Feb;73(4):447–56

Characterisation of a sperm coating auto–antigen reacting with antisperm antibodies of infertile males using monoclonal antibodies. Poulton TA, et al. **Br J Obstet Gynaecol** 1996 May;103(5):463–7

Antibody penetration of tumor GS–7 xenografts in nude mice: a model for mucinous adenocarcinoma of the colon. Blumenthal RD, et al. **Cancer Res** 1996 Aug 1; 56(15):3508–15

Effect of malnutrition on serum and milk antibodies in Zairian women. Brüssow H, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):37–41

Receptor–mediated gene transfer into human T lymphocytes via binding of DNA/CD3 antibody particles to the CD3 T cell receptor complex. Buschle M, et al. **Hum Gene Ther** 1995 Jun;6(6):753–61

Beta–galactosidase enzymatic activity as a molecular probe to detect specific antibodies. Benito A, et al. **J Biol Chem** 1996 Aug 30;271(35):21251–6

Corticotrophin–releasing hormone (CRH)–binding protein interference with CRH antibody binding: implications for direct CRH immunoassay. Linton EA, et al. **J Endocrinol** 1995 Jul;146(1):45–53

Catalytic antibodies. Structure and possible applications. Amital H, et al. **Methods Mol Biol** 1995;51:203–10 (29 ref.)

Assay of radiolabeled VIP binding and hydrolysis by antibodies. Huang H, et al. **Methods Mol Biol** 1995; 51:409–15

Characterisation of antibody–binding RNAs selected from structurally constrained libraries. Hamm J. **Nucleic Acids Res** 1996 Jun 15;24(12):2220–7

The C–terminal KDEL sequence increases the expression level of a single–chain antibody designed to be targeted to both the cytosol and the secretory pathway in transgenic tobacco. Schouten A, et al. **Plant Mol Biol** 1996 Feb; 30(4):781–93

Antibody response to sheep red blood cells in major

histocompatibility (B) complex aneuploid line of chickens. LePage KT, et al. **Poult Sci** 1996 Mar;75(3):346–50

Xenogeneic discordant islet transplantation: natural antibodies and complement in a human-to-rat model. Schachner RD, et al. **Transplant Proc** 1995 Dec;27(6):3318

Can semen analysis predict the presence of antisperm antibodies in patients with primary infertility? Cookson MS, et al. **World J Urol** 1995;13(5):318–22

PHARMACOLOGY

Hepatic portal insulin antibody infusion increases, but insulin does not alter, spontaneous meal size in rats. Surina-Baumgartner DM, et al. **Am J Physiol** 1995 Nov; 269(5 Pt 2):R978–82

Inhibition of TNF alpha improves survival in an experimental model of acute pancreatitis. Hughes CB, et al. **Am Surg** 1996 Jan;62(1):8–13

Effects of interleukin-6 and its neutralizing antibodies on peritoneal adhesion formation and wound healing. Saba AA, et al. **Am Surg** 1996 Jul;62(7):569–72

Production of a form-specific, inhibitory antibody against rat cytochrome P450 2B1 using a synthetic peptide antigen against a putative substrate binding site. Charnecki J, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):1024–33

Neutralizing antibodies to nucleoside diphosphate kinase inhibit the enzyme in vitro and in vivo: evidence for two distinct mechanisms of activation of atrial currents by ATPgammaS. Yi XB, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):334–42

Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Pancook JD, et al. **Cancer Immunol Immunother** 1996 Feb;42(2):88–92

Generation of polyclonal catalytic antibodies against cocaine using transition state analogs of cocaine conjugated to diphtheria toxoid. Basmadjian GP, et al. **Chem Pharm Bull (Tokyo)** 1995 Nov;43(11):1902–11

Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule-1 (VCAM-1). Mayet WJ, et al. **Clin Exp Immunol** 1996 Feb;103(2):259–67

The evolution of ocular toxoplasmosis in anti-interferon gamma treated mice. Olle P, et al. **Curr Eye Res** 1996 Jul; 15(7):701–7

Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6. Cribb A, et al. **Drug Metab Dispos** 1995 Jul;23(7):671–5

Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Crippes BA, et al. **Endocrinology** 1996 Mar;137(3):918–24

Effect of interleukin-1a, IL-1b and IL-1 receptor antibody on the proliferation and steroidogenesis of regenerating rat adrenal cortex. Zieleniewski W, et al. **Exp Clin Endocrinol Diabetes** 1995;103(6):373–7

Inhibition of the catalytic activity of human transaldolase by antibodies and site-directed mutagenesis. Banki K, et al. **FEBS Lett** 1996 Jan 8;378(2):161–5

An explanation on the limited efficacy of detoxication against VX toxicity by purified specific antibodies. Liao WG, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):90–4

Immunogenicity of tissue plasminogen activators in rhesus monkeys: antibody formation and effects on blood level and enzymatic activity. Zwickl CM, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):243–54

Modulation of the endothelial procoagulant response to lipopolysaccharide and tumour necrosis factor-alpha in-vitro: the effects of dexamethasone, pentoxifylline, iloprost and a polyclonal anti-human IL-1 alpha antibody. Heyderman RS, et al. **Inflamm Res** 1995 Jul;44(7):275–80

In vitro and in vivo inactivation of transcobalamin II receptor by its antiserum. Bose S, et al. **J Biol Chem** 1996 Feb 23; 271(8):4195–200

Anti-Ig-induced calcium influx in rat B lymphocytes mediated by cGMP through a dihydropyridine-sensitive channel. Sadighi Akha AA, et al. **J Biol Chem** 1996 Mar 29;271(13):7297–300

Activation and inhibition of phosphorylase kinase by monospecific antibodies raised against peptides from the regulatory domain of the gamma-subunit. Wangsgard WP, et al. **J Biol Chem** 1996 Aug 30;271(35):21126–33

Production of polyclonal antibody specific for human natriuretic peptide receptor B. Kitano K, et al. **J Immunol Methods** 1996 Aug 14;194(2):147–53

Expression of low density lipoprotein receptors in lymphoblasts induced by anti-CD3 antibody in patients with hypercholesterolemia. Shin BM, et al. **J Korean Med Sci** 1995 Oct;10(5):318–23

Antibodies directed against the mu-opioid receptor alleviated multiple signs of morphine withdrawal in mice. Sánchez-Blázquez P, et al. **Life Sci** 1996;59(8):PL87–92

The stimulatory effect on human erythrocyte rubidium-86 uptake by anti-cardiac-glycoside antibodies. Balzan S, et al. **Q J Nucl Med** 1995 Jun;39(2):134–9

Expression and inducibility of antigens in severe combined immunodeficient mice recognized by human anti-P450 antibodies. Rajasenan RS, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):89–99

Protective properties of anti-IFN alpha/beta antibodies in normothermic hepatic ischaemia in the rat. Cursio R, et al. **Transplant Proc** 1996 Feb;28(1):73–4

[The effect of antibodies to S-100 proteins on synaptogenesis processes and learning in rats] Babichenko II, et al. **Fiziol Zh Im I M Sechenova** 1996 Jan;82(1):79–84 (Eng. Abstr.) **(Rus)**

[The membrane mechanism of the development of tonic stress in the heart muscle of rats under the action of antimembrane antibodies] Bidzilia IuP, et al. **Fiziol Zh** 1995 May-Aug; 41(3–4):67–75 (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

Immunoinfertility: a case study with implications for immunocontraception. Clarke GN, et al. **Arch Androl** 1995 Jul-Aug;35(1):21–7

Structure and function of natural antibodies. Casali P, et al. **Curr Top Microbiol Immunol** 1996;210:167–79 (74 ref.)

Immunity to viruses in B cell-deficient mice: influence of antibodies on virus persistence and on T cell memory. Bründler MA, et al. **Eur J Immunol** 1996 Sep;26(9):2257–62

Neonatal exposure to anti-nerve growth factor antibodies affects exploratory behavior of developing mice in the hole board. Calamandrei G, et al. **Neurotoxicol Teratol** 1996 Mar-Apr;18(2):141–6

Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Jannot CB, et al. **Oncogene** 1996 Jul 18;13(2):275–82

Strange-male-induced pregnancy disruption in mice: reduction of vulnerability by 17 beta-estradiol antibodies. de Catanzaro D, et al. **Physiol Behav** 1995 Aug;58(2):401–4

Functional activity of anti-C6 antibodies elicited in C6-deficient rats reconstituted by liver allografts. Ability to inhibit hyperacute rejection of discordant cardiac xenografts. Brauer RB, et al. **Transplantation** 1996 Feb 27; 61(4):588–94

RADIATION EFFECTS

Light activatable antibodies: models for remotely activatable proteins. Self CH, et al. **Nat Med** 1996 Jul;2(7):817–20

THERAPEUTIC USE

Immunoconjugates and immunotoxins for therapy of carcinomas. Hellström I, et al. **Adv Pharmacol** 1995; 33:349–88 (159 ref.)

Use of specific anti-HLA antibodies in clinical nephrology. Buglova SE, et al. **Arch Immunol Ther Exp (Warsz)** 1995; 43(2):145–8

Sepsis-induced acute lung injury is attenuated by selectin blockade following the onset of sepsis. Ridings PC, et al. **Arch Surg** 1995 Nov;130(11):1199–208

Antibodies proposed as therapeutic agents. Bismuth C, et al. **Arch Toxicol Suppl** 1996;18:321–32 (39 ref.)

Biological effect of active anti-IFN alpha immunization in HIV-infected patients. Fall LS, et al. **Biomed Pharmacother** 1995;49(9):422–8

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Hale G, et al. **Bone Marrow Transplant** 1996 Mar;17(3):305–8

Evidence of involvement of cytotoxic antibodies directed against patients's HLA class II produced by transfused donor-derived B cells in post-transfusion graft-versus-host disease. Nishimura M, et al. **Br J Haematol** 1996 Mar; 92(4):1011–3

Engineering recombinant antibodies for immunotherapy. Neri D, et al. **Cell Biophys** 1995 Aug;27(1):47–61 (62 ref.)

Return to the past: the case for antibody-based therapies in infectious diseases. Casadevall A, et al. **Clin Infect Dis** 1995 Jul;21(1):150–61 (181 ref.)

Anti-interleukin-6 antibody treatment improves survival during gut-derived sepsis in a time-dependent manner by enhancing host defense. Gennari R, et al. **Crit Care Med** 1995 Dec;23(12):1945–53

Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Ofei F, et al. **Diabetes** 1996 Jul; 45(7):881–5

A possible role for antibodies to tumour necrosis factor alpha and to endotoxin in the treatment of Reye's syndrome. Odeh M. **Gut** 1995 Sep;37(3):441–3

Intracellular single-chain Fv antibodies--a knockout punch for neoplastic cells? [editorial; comment] Adams GP, et al. **Gynecol Oncol** 1995 Oct;59(1):6–7. Comment on: Gynecol Oncol 1995 Oct;59(1):8–14.

Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody [see comments] Deshane J, et al. **Gynecol Oncol** 1995 Oct;59(1):8–14. Comment in: Gynecol Oncol 1995 Oct;59(1):6–7.

Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis. Uslu R, et al. **Gynecol Oncol** 1996 Aug; 62(2):282–91

Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies. Villunger A, et al. **Int J Cancer** 1996 Feb 8;65(4):498–505

An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. Arai M, et al. **J Am Coll Cardiol** 1996 Apr; 27(5):1278–85

Lack of effect of ET antibody or SB 209670 on endotoxin-induced renal failure. Wellings RP, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S476–8

Modulation of T cell responses to recall antigens presented by Langerhans cells in HIV-discordant identical twins by anti-interleukin (IL)-10 antibodies and IL-12. Blauvelt A, et al. **J Clin Invest** 1996 Mar 15;97(6):1550–5

Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. Walker RE, et al. **J Infect Dis** 1996 Jul;174(1):63–8

Tumor necrosis factor-alpha gene transfer augments anti-Fas antibody-mediated apoptosis in human glioma cells. Mizuno M, et al. **Jpn J Cancer Res** 1996 May;87(5):543–7

Induction of long-term rat renal allograft survival by pretransplant T cell receptor-alpha/beta-targeted therapy. Heidecke CD, et al. **Transplantation** 1996 Jan 27; 61(2):336–9

[Antibodies as medication] Kurki P, et al. **Duodecim** 1995; 111(8):788–96 (29 ref.) **(Fin)**

[Prophylactic effect of specific egg yolk antibodies in diarrhea caused by Escherichia coli K88 (F4) in weaned piglets] Erhard MH, et al. **Zentralbl Veterinarmed A** 1996 Jun;43(4):217–23 (Eng. Abstr.) **(Ger)**

TOXICITY

Activation of the renin-angiotensin system in anti-glomerular basement membrane antibody-induced glomerulonephritis. Yayama K, et al. **Biol Pharm Bull** 1995 Mar;18(3):411–5

A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. Rodriguez I, et al. **J Exp Med** 1996 Mar 1;183(3):1031–6

IFN-gamma receptor-deficient mice are hypersensitive to the anti-CD3-induced cytokine release syndrome and thymocyte apoptosis. Protective role of endogenous nitric oxide. Matthys P, et al. **J Immunol** 1995 Oct 15; 155(8):3823–9

Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Lacronique V, et al. **Nat Med** 1996 Jan;2(1):80–6

ULTRASTRUCTURE

Imaging of single antigens, antibodies, and specific immunocomplex formation by scanning force microscopy. Quist AP, et al. **Scanning Microsc** 1995 Jun;9(2):395–400

ANTIBODIES, ALLOTYPIC see IMMUNOGLOBULIN ALLOTYPES

ANTIBODIES, ANTICARDIOLIPIN

Thrombolysis of right atrial thrombus with pulmonary embolism in anticardiolipin antibody syndrome. Ryan J, et al. **Am Heart J** 1995 Oct;130(4):905–7

ANALYSIS

Diagnostic and prognostic significance of anticardiolipin antibodies in patients with recurrent spontaneous abortions. Melk A, et al. **Am J Reprod Immunol** 1995 Mar; 33(3):228–33

The use of an anti-beta 2-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. McNally T, et al. **Br J Haematol** 1995 Oct;91(2):471–3

Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome. Gattorno M, et al. **Br J Rheumatol** 1995 Sep;34(9):873–81

Anticardiolipin antibodies and antiphospholipid syndrome in chronic discoid lupus erythematosus. Ruffatti A, et al. **Clin Rheumatol** 1995 Jul;14(4):402–4

Antibodies to oxidized low-density lipoprotein and to cardiolipin in nonpregnant and pregnant women with habitual abortion. Tulppala M, et al. **Fertil Steril** 1995 Nov; 64(5):947–50

Lupoid sclerosis with raised anticardiolipin antibodies. Dabadghao S, et al. **J Assoc Physicians India** 1995 Apr; 43(4):298

Fetal calf serum in growth medium obscures the detection of early anticardiolipin antibody secreting clones. Menon S, et al. **J Immunol Methods** 1995 Oct 12;186(1):65–70

Lipoproteins, anticardiolipin autoantibodies and artherosclerosis [letter] Cheng HM. **J Intern Med** 1996 Jul; 240(1):44–5

Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. Nityanand S, et al. **J Intern Med** 1995 Nov;238(5):437–43

Anticardiolipin antibodies and cardiovascular disease [letter; comment] Nelson-Piercy C, et al. **J R Soc Med** 1996 Feb; 89(2):119. Comment on: J R Soc Med 1995 Aug;88(8):433–6.

Anticardiolipin antibodies and acute alcoholic intoxication. Biron C, et al. **Lupus** 1995 Dec;4(6):486–90

[Anti-beta 2 glycoprotein 1 antibodies in idiopathic livedo reticularis] Aubry F, et al. **Ann Dermatol Venereol** 1995; 122(10):667–70 (Eng. Abstr.) **(Fre)**

[Anticardiolipin antibodies and thrombosis (letter; comment)] Bentolila S, et al. **Presse Med** 1995 Nov 4;24(33):1580. Comment on: Presse Med 1995 Feb 4;24(5):267–70. **(Fre)**

[Anticardiolipin antibodies in patients with ischemic brain disease] Ivanišević V, et al. **Vojnosanit Pregl** 1994 Sep-Oct; 51(5):402–6 (Eng. Abstr.) **(Ser)**

ANTIBODIES, ANTICARDIOLIPIN

BIOSYNTHESIS

Induction of high levels of anticardiolipin antibodies in mice by immunization with beta 2-glycoprotein I does not cause fetal death. Silver RM, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1410-5

BLOOD

Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Camerlingo M, et al. **Acta Neurol Scand** 1995 Jul;92(1):69-71

Anticardiolipin antibodies (aCL) in patients following acute stroke [letter; comment] Muir KW, et al. **Acta Neurol Scand** 1995 Jun;91(6):514-5. Comment on: Acta Neurol Scand 1994 Aug;90(2):86-90.

Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Abu-Shakra M, et al. **Am J Med** 1995 Dec;99(6):624-8

A family study of anticardiolipin antibodies and associated clinical conditions. Goldberg SN, et al. **Am J Med** 1995 Nov;99(5):473-9

Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro. Tsakiris DA, et al. **Ann Hematol** 1995 Oct;71(4):195-8

Familial primary antiphospholipid antibody syndrome. Bansal AS, et al. **Arthritis Rheum** 1996 Apr;39(4):705-6

Monoclonal anticardiolipin autoantibodies established from the (New Zealand white x BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Mizutani H, et al. **Arthritis Rheum** 1995 Oct;38(10):1382-8

Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis. Picillo U, et al. **Autoimmunity** 1995; 20(1):1-7

Novel homogeneous liposomal immunoassay for colorimetric estimation of serum IgG anticardiolipin antibodies. Frost SJ, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):874-9

Antibodies against beta2-glycoprotein I in anti-cardiolipin calibrators. Wei TQ, et al. **Clin Chem** 1996 Apr;42(4):642-3

Evaluation of two enzymatic immunoassays for anticardiolipin antibody measurements [letter] Nava A, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):408-9

Lipid profile and anticardiolipin antibodies in rheumatoid arthritis [letter] Seriolo B, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):406-7

Anti beta 2-glycoprotein I antibodies in a patient with catastrophic antiphospholipid syndrome. Pengo V, et al. **Clin Rheumatol** 1995 Nov;14(6):646-9

Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Yetman DL, et al. **Fertil Steril** 1996 Oct;66(4):540-6

Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Prieto J, et al. **Hepatology** 1996 Feb; 23(2):199-204

beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Katano K, et al. **Hum Reprod** 1996 Mar; 11(3):509-12

IgA class anticardiolipin antibodies in cutaneous leukocytoclastic vasculitis. Burden AD, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):411-5

Clinical analysis of anti-cardiolipin.beta 2 glycoprotein 1 antibody positive patients in anti-phospholipid syndrome. Katayama I, et al. **J Dermatol Sci** 1995 May;9(3):215-20

The pathophysiology of alveolar osteonecrosis of the jaw: anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. Gruppo R, et al. **J Lab Clin Med** 1996 May;127(5):481-8

Anticardiolipin antibodies and cardiovascular disease [see comments] Muir KW. **J R Soc Med** 1995 Aug;88(8):433-6 (53 ref.). Comment in: J R Soc Med 1996 Feb;89(2):119.

A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant cell arteritis. Chakravarty K, et al. **J Rheumatol** 1995 Sep;22(9):1694-7

The significance of anticardiolipin antibodies in patients with lupus nephritis. Abu-Shakra M, et al. **Lupus** 1996 Feb; 5(1):70-3

Anticardiolipin antibodies and beta 2-glycoprotein I. Koike T, et al. **Lupus** 1996 Apr;5(2):156-7 (13 ref.)

Longitudinal measurement of anticardiolipin antibodies during normal pregnancy: a prospective study. Lynch AM, et al. **Lupus** 1995 Oct;4(5):365-9

Measuring of cardiolipin antibodies and plasma lipids in different stages of coronary disease. Rebić R, et al. **Med Pregl** 1993;46 Suppl 1:20-2

Increased prevalence of anticardiolipin antibodies in renal transplant recipients [letter] Oymak O, et al. **Nephron** 1995; 71(4):469-70

Anticardiolipin antibodies: clinical consequences of "low titers". Silver RM, et al. **Obstet Gynecol** 1996 Apr; 87(4):494-500

Prevalence and clinical significance of anticardiolipin antibodies in pregnancies complicated by parvovirus B19 infection. Gratacós E, et al. **Prenat Diagn** 1995 Dec; 15(12):1109-13

Screening psychiatric admissions for anticardiolipin antibody. Oomen HA, et al. **Psychiatry Res** 1995 Sep 8;58(1):83-8

Anticardiolipin-antibodies in stroke and in other neurological disorders. Perju-Dumbrava L, et al. **Rom J Neurol Psychiatry** 1995 Apr-Jun;33(2):137-43

Catastrophic anti-phospholipid syndrome in the absence of IgG anti-cardiolipin antibodies. Kennedy M, et al. **Scand J Rheumatol** 1995;24(6):389-91

Natural beta 2-glycoprotein I-independent anticardiolipin autoantibodies are not age-related [letter; comment] Cheng HM, et al. **Stroke** 1996 May;27(5):1007-8. Comment on: Stroke 1995 May;26(5):749-54.

Lipoprotein (a) and anticardiolipin antibodies as risk factors for vascular disease in rheumatoid arthritis [letter; comment] Seriolo B, et al. **Thromb Haemost** 1995 Aug; 74(2):799-800. Comment on: Thromb Haemost 1994 Apr;71(4):424-7. Comment on: Thromb Haemost 1994 Oct;72(4):563-6.

Systemic lupus erythematosus presenting with thrombocytopenia. Report of a child with positive anticardiolipin antibodies. Kanra G, et al. **Turk J Pediatr** 1996 Apr-Jun;38(2):231-4

[A case showing recurrence of myelopathy and optic nerve disturbance accompanied by pusturosis palmaris et plantaris and positive anticardiolipin antibody] Mochizuki Y, et al. **No To Shinkei** 1996 Jan;48(1):65-8 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Vaarala O, et al. **Clin Exp Immunol** 1996 May; 104(2):269-74

CLASSIFICATION

Anticardiolipin and anti-beta 2-GPI are two distinct populations of autoantibodies. Sorice M, et al. **Thromb Haemost** 1996 Feb;75(2):303-8

DRUG EFFECTS

Tween 20 selectively enhances naturally occurring anticardiolipin antibody binding in ELISA procedures [letter; comment] Cheng HM. **J Immunol Methods** 1996 May 10;191(1):87-91. Comment on: J Immunol Methods 1994 Sep 30;175(1):107-14.

GENETICS

Analysis of variable region genes encoding anti-Sm and anti-cardiolipin antibodies from a systemic lupus erythematosus patient. Demaison C, et al. **Immunology** 1995 Nov;86(3):487-94

IMMUNOLOGY

Anticardiolipin antibodies in patients with angioimmunoblastic lymphadenopathy with dysproteinaemia [letter] Ramakrishna R, et al. **Am J Hematol** 1995 Nov;50(3):225-6

Cerebral and vein thrombosis, transient protein S deficiency, and anticardiolipin antibodies [letter] Ricchieri GL, et al. **Am J Hematol** 1996 May;52(1):69-70

Anticardiolipin antibodies from syphilis and systemic lupus erythematosus induce leakage in cardiolipin vesicles. Gremião MP, et al. **Braz J Med Biol Res** 1996 Apr; 29(4):489-94

Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations. Tikly M, et al. **Clin Rheumatol** 1996 Mar;15(2):143-7

Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes. Arfors L, et al. **Eur J Haematol** 1996 Apr;56(4):230-4

Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. Hörkkö S, et al. **J Clin Invest** 1996 Aug 1; 98(3):815-25

Role of beta 2-glycoprotein I in the anticardiolipin antibody affinity for phospholipid in autoimmune disease. Dueymes M, et al. **Lupus** 1995 Dec;4(6):477-81

Anticardiolipin antibodies in two elderly subpopulations. Juby A, et al. **Lupus** 1995 Dec;4(6):482-5

A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Olee T, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8606-11

Renal allograft thrombosis associated with the antiphospholipid antibody syndrome. Knight RJ, et al. **Transplantation** 1995 Sep 27;60(6):614-5

[Anticardiolipin antibodies and Horton disease] Liozon F, et al. **Ann Med Interne (Paris)** 1995;146(8):541-7 (Eng. Abstr.) **(Fre)**

[Anticardiolipin antibodies, cerebral ischemia and adrenal hemorrhage in a newborn infant] Teyssier G, et al. **Arch Pediatr** 1995 Nov;2(11):1086-8 (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Vaarala O, et al. **Clin Exp Immunol** 1996 May; 104(2):269-74

METABOLISM

Human immunodeficiency virus rather than hepatitis C virus infection is relevant to the development of an anti-cardiolipin antibody. Gotoh M, et al. **Am J Hematol** 1995 Nov;50(3):220-2

Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Igarashi M, et al. **Blood** 1996 Apr 15;87(8):3262-70

Monoclonal antibodies from NZW x BXSB F1 mice to beta2 glycoprotein I and cardiolipin. Species specificity and charge-dependent binding. Monestier M, et al. **J Immunol** 1996 Apr 1;156(7):2631-41

PHARMACOLOGY

Inducible platelet adherence to human umbilical vein endothelium by anticardiolipin antibody-positive sera. Silver RK, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):702-7

Increased expression of inducible cyclooxygenase-2 in human endothelial cells by antiphospholipid antibodies. Habib A, et al. **Thromb Haemost** 1995 Aug;74(2):770-7

PHYSIOLOGY

Anticardiolipin antibodies in patients with pregnancy loss induce factor Xa production in the presence of beta 2-glycoprotein I. Ogasawara M, et al. **Am J Reprod Immunol** 1995 Nov;34(5):269-73

ANTIBODIES, ANTI-DNA see ANTIBODIES, ANTINUCLEAR

ANTIBODIES, ANTI-IDIOTYPIC

see related
IMMUNOGLOBULIN IDIOTYPES
MOLECULAR MIMICRY

Surface plasmon resonance studies of immunoreactions utilizing disposable diffraction gratings. Lawrence CR, et al. **Biosens Bioelectron** 1996;11(4):389-400

Kabuki make-up syndrome associated with an acquired hypogammaglobulinemia and anti-IgA antibodies. Hostoffer RW, et al. **Clin Pediatr (Phila)** 1996 May; 35(5):273-6

Syngeneic anti-idiotypic monoclonal antibodies against an anti-human chorionic gonadotrophin antibody. Stamenova M, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1117-22

The measurement of oestrone-3-glucuronide in urine by non-competitive idiometric assay. Barnard G, et al. **J Steroid Biochem Mol Biol** 1995 Oct;55(1):107-14

Evidence that two distinct populations of rabbit anti-idiotypic antibodies are induced by three monoclonal antibodies specific for bluetongue virus core protein VP7. Lin M, et al. **Microbiol Immunol** 1996;40(4):295-302

ADMINISTRATION & DOSAGE

Fetal lambs are depleted of IgM+ cells following a single injection of an anti-IgM antibody early in gestation. Press CM, et al. **Immunology** 1996 May;88(1):28-34

ANALYSIS

Analysis of anti-U1 RNA antibodies in patients with connective tissue diseases: comment on the article by Hoffman et al [letter] van den Hoogen FH, et al. **Arthritis Rheum** 1996 Jul;39(7):1265-6

Absence of anti-idiotypic antibodies in IVIG preparations to autoantibodies of rare autoimmune diseases. Krause I, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):229-35

Detection and side-chain specificity of IgE antibodies to flucloxacillin in allergic subjects. Baldo BA, et al. **J Mol Recognit** 1995 May-Jun;8(3):171-7

Dot-ELISA-IgM in saliva for the diagnosis of human leptospirosis using polyester fabric-resin as support (preliminary report). da Silva MV, et al. **Rev Inst Med Trop Sao Paulo** 1994 Sep-Oct;36(5):475-8

Detection of anti-idiotypic antibodies after OKT3 treatment by flow cytometry [letter; comment] Hesse CJ, et al. **Transplantation** 1996 Jan 15;61(1):169. Comment on: Transplantation 1995 Jun 15;59(11):1507-8.

BIOSYNTHESIS

In vitro suppression of anti-TSH receptor antibody by autologous anti-idiotypic antibody in patients with Graves' disease. Balázs C, et al. **Acta Microbiol Immunol Hung** 1995; 42(2):163-9

Induction of a protective immune response to murine coronavirus with non-internal image anti-idiotypic antibodies. Yu M, et al. **Adv Exp Med Biol** 1995;380:165-72

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212-26 (23 ref.)

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Fagerberg J, et al. **Cancer Immunol Immunother** 1996 Feb;42(2):81-7

Immune response to bovine viral diarrhea virus induced by anti-idiotypic antibodies. Xue W, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):95-8

Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Madiyalakan R, et al. **Hybridoma** 1995 Apr;14(2):199-203

Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.

Mittelman A, et al. **Hybridoma** 1995 Apr;14(2):175–81 (31 ref.)

Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3. Schmolling J, et al. **Hybridoma** 1995 Apr;14(2):183–6

Generation of monoclonal antibodies utilizing the host anti-idiotypic network. Hatzistilianou MN, et al. **In Vivo** 1995 Mar–Apr;9(2):139–44

Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1. De Nardo GL, et al. **Int J Biol Markers** 1995 Apr–Jun;10(2):67–74

Induction and characterization of monoclonal anti-idiotypic antibodies to tick-borne encephalitis virus neutralizing antibody. Kopecký J, et al. **J Immunoassay** 1995 Nov; 16(4):437–65

Human CD4-internal antigen anti-idiotypic monoclonal antibody: induction of a CD4-specific response in humans. Perosa F, et al. **J Immunol** 1996 May 1;156(9):3563–9

Human natural yeast killer toxin-like candidacidal antibodies. Polonelli L, et al. **J Immunol** 1996 Mar 1;156(5):1880–5

Antibody production in rabbits and chickens immunized with human IgG. A comparison of titre and avidity development in rabbit serum, chicken serum and egg yolk using three different adjuvants. Svendsen Bollen L, et al. **J Immunol Methods** 1996 May 27;191(2):113–20

Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients. Tibben JG, et al. **Nucl Med Commun** 1995 Oct;16(10):853–9

The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Kimball JA, et al. **Transpl Immunol** 1995 Sep;3(3):212–21

Comparison of Freund's adjuvant and TiterMax in inducing anti-idiotype to idiotypic antibodies against pseudorabies virus antigens. Zhou EM, et al. **Vet Immunol Immunopathol** 1995 Sep;48(1–2):113–22

[Preparation and study of properties of anti-idiotypic antibodies, carrying hemagglutinating paratopes of tick-borne encephalitis virus on their surface] Protopopova EV, et al. **Vopr Virusol** 1996 Mar–Apr;41(2):50–3 (Eng. Abstr.) **(Rus)**

BLOOD

Effect of vaccination of ponies with A4 anti-idiotypic antibody on serum idiotype (1C9) and antilipid A concentration. BonenClark GD, et al. **Am J Vet Res** 1996 May;57(5):655–8

Motor neuron disease: a paraneoplastic process associated with anti-hu antibody and small-cell lung carcinoma. Verma A, et al. **Ann Neurol** 1996 Jul;40(1):112–6

Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. Gelpí C, et al. **Arthritis Rheum** 1996 Apr;39(4):692–7

Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Press J, et al. **Arthritis Rheum** 1996 Apr;39(4):671–6

Detection of antiribosomal P protein antibodies in patients with systemic sclerosis. Fujimoto M, et al. **Br J Rheumatol** 1995 Oct;34(10):908–11

CA 125 determined by three methods in samples from patients with human anti-mouse antibodies (HAMA). Turpeinen U, et al. **Clin Chem** 1995 Nov;41(11):1667–9

A patient with autoimmune thrombocytopenic purpura demonstrating serum antibodies reactive with mouse cross-reactive idiotypes. Clofent-Sanchez G, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):271–81

Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies. Tosi E, et al. **Eur J Cancer** 1996 Mar;32A(3):498–505

A simple and sensitive assay for determination of human anti-idiotypic anti-B72.3 antibodies, which is not affected by the presence of tumour-associated glycoprotein 72. Reinsberg J, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):237–44

IgE and IgG4 antibodies from patients with mite allergy recognize different epitopes of Dermatophagoides pteronyssinus group II antigen (Der p2). Kobayashi I, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):638–45

Long-term follow-up of anti-IgA antibodies in healthy IgA-deficient adults. Koskinen S, et al. **J Clin Immunol** 1995 Jul;15(4):194–8

Antibody production in rabbits and chickens immunized with human IgG. A comparison of titre and avidity development in rabbit serum, chicken serum and egg yolk using three different adjuvants. Svendsen Bollen L, et al. **J Immunol Methods** 1996 May 27;191(2):113–20

Quantification of antiribosomal P0 protein antibodies by ELISA with recombinant P0 fusion protein and their association with central nervous system disease in systemic lupus erythematosus. Yoshio T, et al. **J Rheumatol** 1995 Sep;22(9):1681–7

An audit of ANCA in routine clinical practice. Edgar JD, et al. **Postgrad Med J** 1995 Oct;71(840):605–12

Finger skin temperature in patients affected by Raynaud's phenomenon with or without anticentromere antibody positivity. Caramaschi P, et al. **Rheumatol Int** 1996; 15(5):217–20

Normal human cord blood B cells can produce high affinity IgG antibodies to dsDNA that are recognized by cord blood-derived anti-idiotypic antibodies. Warrington RJ, et al. **Scand J Immunol** 1995 Oct;42(4):397–406

Low immunogenicity of therapeutic rat CD45 antibodies when used for pre-treatment of donor organs for transplantation. Watts MJ, et al. **Ther Immunol** 1995 Feb; 2(1):23–9

[Antibodies of IgM type against small cell lung carcinoma and 29 kD neuronal antigen of rat in a patient with paraneoplastic sensory neuropathy] Azuma A, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr;18(2):241–6 (Eng. Abstr.) **(Jpn)**

[Prospective study with infants whose mothers had dengue during pregnancy] Figueiredo LT, et al. **Rev Inst Med Trop Sao Paulo** 1994 Sep–Oct;36(5):417–21 (Eng. Abstr.) **(Por)**

[Is there any clinical significance to anti-IgA antibodies which appear in patients with immunodeficiencies treated with intravenous gamma globulin? (editorial)] Ferreira A, et al. **Sangre (Barc)** 1995 Jun;40(3):171–3 **(Spa)**

CEREBROSPINAL FLUID

Association of polyclonal anti-GM1 IgM and anti-neurofilament antibodies with CSF oligoclonal bands in a young with amyotrophic lateral sclerosis. Annunziata P, et al. **Acta Neurol Scand** 1995 Nov;92(5):387–93

CHEMISTRY

Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. Cacia J, et al. **Biochemistry** 1996 Feb 13; 35(6):1897–903

Development of ulcerative colitis-associated anti-idiotype antibody using a novel monoclonal antibody against a colonic autoantigen. Shah U, et al. **Cell Immunol** 1995 Nov; 166(1):154–7

Molecular localization of human IgG anti-F(ab')2 reactivity with variable- and constant-region lambda light-chain epitopes. Williams RC Jr, et al. **J Clin Immunol** 1995 Nov; 15(6):349–62

An alternative ELISA for T4 determination based on idiotype anti-idiotype interaction and a latex method for anti-idiotype monoclonal antibody selection. Becker MI, et al. **J Immunol Methods** 1996 Jun 10;192(1–2):73–85

Crystal structure of an anti-anti-idiotype shows it to be self-complementary. Ban N, et al. **J Mol Biol** 1996 Feb 2;255(4):617–27

Primary structures of three Armenian hamster monoclonal antibodies specific for idiotopes and metatopes of the monoclonal anti-fluorescein antibody 4-4-20. Mallender WD, et al. **Mol Immunol** 1995 Oct;32(14–15):1093–103

The three C-terminal residues of human respiratory syncytial virus G glycoprotein (Long strain) are essential for integrity of multiple epitopes distinguishable by antiidiotypic antibodies. Rueda P, et al. **Viral Immunol** 1995; 8(1):37–46

DIAGNOSTIC USE

Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumor:nontumor ratio in experimental radioimmunolocalization. Ullén A, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5868s–5873s

Syngeneic anti-idiotypic antibodies eliminate excess radiolabeled idiotypes at experimental radioimmunolocalization. Ullén A, et al. **Cell Biophys** 1995 Aug;27(1):31–45

[Anti-idiotypic antibodies as vaccinal and diagnostic preparations in viral infections] Tarasishin LA. **Mikrobiol Z** 1996 Jan–Feb;58(1):97–105 (30 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes. Lustgarten J, et al. **Eur J Immunol** 1995 Oct;25(10):2985–91

Cloned antigens and antiidiotypes. Herlyn D, et al. **Hybridoma** 1995 Apr;14(2):159–66

Vl-linker-Vh orientation-dependent expression of single chain Fv-containing an engineered disulfide-stabilized bond in the framework regions. Luo D, et al. **J Biochem (Tokyo)** 1995 Oct;118(4):825–31

A recurrent clonotype in the spontaneous anti-IgG2a rheumatoid factor response of lpr/lpr mice. Hande S, et al. **J Immunol** 1996 Mar 1;156(5):1856–64

Immunoglobulin-like domain of HIV-1 envelope glycoprotein gp120 encodes putative internal image of some common human proteins. Metlaš R, et al. **Viral Immunol** 1994;7(4):215–9

IMMUNOLOGY

Association of polyclonal anti-GM1 IgM and anti-neurofilament antibodies with CSF oligoclonal bands in a young with amyotrophic lateral sclerosis. Annunziata P, et al. **Acta Neurol Scand** 1995 Nov;92(5):387–93

Minimal signal requirements for superantigen-specific T cell-driven B cell proliferation. Wetzel GD. **Adv Exp Med Biol** 1995;371A:137–40

Effects of loratadine on anti-IgE-induced inflammation, histamine release, and leukocyte recruitment in skin of atopics. Roquet A, et al. **Allergy** 1995 May;50(5):414–20

Anti-idiotypic immunization against progesterone [letter] Wang MW, et al. **Am J Reprod Immunol** 1995 Dec; 34(6):386–8

Acute paresis of extraocular muscles associated with IgG anti-GQ1b antibody. Yuki N. **Ann Neurol** 1996 May; 39(5):668–72

Monoclonal anti-idiotypic antibodies as probes for common idiotopes shared by anti-"benzo(a)pyrene-like" IgA of cancer patients and rabbit anti-conjugated benzo(a)pyrene antibodies. Chagnaud JL, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2161–8

Some autoantibodies to Ro/SS-A and La/SS-B are antiidiotypes to anti-double-stranded DNA. Zhang W, et al. **Arthritis Rheum** 1996 Mar;39(3):522–31

Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Kuus-Reichel K, et al. **Clin Diagn Lab Immunol** 1994 Jul; 1(4):365–72 (82 ref.)

Lupus-derived autoantibodies with dual autoactivity: anti-DNA and anti-Fc. I. Comparison of IgG autoreactivities with single-chain Fv derivatives. Rumbley CA, et al. **Clin Exp Immunol** 1995 Nov;102(2):341–8

Lupus-derived autoantibodies with dual autoactivity: anti-DNA and anti-Fc. II. Fine specificity of anti-self autoreactivity. Rumbley CA, et al. **Clin Exp Immunol** 1995 Nov;102(2):349–53

Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Bogen B, et al. **Eur J Immunol** 1995 Nov;25(11):3079–86

Correlation between immune maturation and idiotypic network recognition. Lange H, et al. **Eur J Immunol** 1996 Sep;26(9):2234–42

Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses. Buckley DT, et al. **Hum Antibodies Hybridomas** 1995;6(2):68–72

Immunogenicity of immunoliposomes: reactivity against species-specific IgG and liposomal phospholipids. Phillips NC, et al. **Immunol Lett** 1995 Mar;45(3):149–52

Regulation and targeting of T-cell immune responses by IgE and IgG antibodies. Bheekha Escura R, et al. **Immunology** 1995 Nov;86(3):343–50

Primary structure of the variable region of monoclonal antibody 2B10, capable of inducing anti-idiotypic antibodies that recognize the C-terminal region of MSA-1 of Plasmodium falciparum. Su S, et al. **Infect Immun** 1996 Jan;64(1):326–31

The perinatal presence of antigen (p-azophenylarsonate) or anti-mu antibodies lead to the loss of the recurrent idiotype (CRIA) in A/J mice. Ryelandt M, et al. **Int Immunol** 1995 Apr;7(4):645–52

Auto-anti-idiotypy, autoimmunity and some thoughts on the structure of internal images. Erlanger BF. **Int Rev Immunol** 1989;5(2):131–7 (29 ref.)

Anti-idiotypes against autoantibodies to procoagulant factor VIII (VIII:C) in intravenous immunoglobulins. Kazatchkine MD, et al. **Int Rev Immunol** 1989;5(2):157–63

A novel phosphatidylserine-binding peptide motif defined by an anti-idiotypic monoclonal antibody. Localization of phosphatidylserine-specific binding sites on protein kinase C and phosphatidylserine decarboxylase. Igarashi K, et al. **J Biol Chem** 1995 Dec 8;270(49):29075–8

Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. Gilles JG, et al. **J Clin Invest** 1996 Mar 15;97(6):1382–8

A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death. Lens SM, et al. **J Immunol** 1996 Jan 15;156(2):507–14

Detection and side-chain specificity of IgE antibodies to flucloxacillin in allergic subjects. Baldo BA, et al. **J Mol Recognit** 1995 May–Jun;8(3):171–7

Anti-idiotypic antibodies: a useful alternative for studying the biochemical expression of mu/delta opioid binding sites in mammalian brain. Cucumel K, et al. **J Neuroimmunol** 1995 Nov;62(2):183–95

Determination of the immunoreactivity of radiolabelled monoclonal antibody fragments by binding to immobilised anti-idiotypic antibodies. Pimm MV, et al. **Life Sci** 1995 Mar 17;56(17):1401–6

Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen. Baharav E, et al. **Melanoma Res** 1995 Oct;5(5):337–43

Anti-idiotypic antibodies that mimic opioids. Glasel JA, et al. **Methods Mol Biol** 1995;51:183–201

Role of cyclin A and p27 in anti-IgM induced G1 growth arrest of murine B-cell lymphomas. Ezhevsky SA, et al. **Mol Biol Cell** 1996 Apr;7(4):553–64

Schistosoma mansoni in the baboon: modulation of pathology after vaccination with polyclonal anti-idiotypic antibodies. Nyindo M, et al. **Scand J Immunol** 1995 Dec;42(6):637–43

Disputed results now just a footnote [news] Marshall E. **Science** 1996 Jul 12;273(5272):174–5

Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies. Isaacs JD, et al. **Ther Immunol** 1994 Dec;1(6):303–12

Processing of IgM/Anti-IgM immune complexes by the liver of rats treated with anti-IgM monoclonal antibodies. Havaux XB, et al. **Transplant Proc** 1996 Apr;28(2):574

Review and preview of anti-T-cell antibodies. Helderman JH. **Transplant Proc** 1995 Oct;27(5 Suppl 1):8–9 (7 ref.)

Detection of IGA anti-OKT3 antibodies in OKT3-treated transplant recipients. McIntyre JA, et al.

Transplantation 1996 May 27;61(10):1465-9

Immunological evaluation of three generations of anti-idiotype vaccine: study of B and T cell responses following priming with anti-idiotype, anti-idiotype peptide and its MAP structure. Rajadhyaksha M, et al. **Vaccine** 1995;13(15):1421-6

Comparison of Freund's adjuvant and TiterMax in inducing anti-idiotype to idiotypic antibodies against pseudorabies virus antigens. Zhou EM, et al.
Vet Immunol Immunopathol 1995 Sep;48(1-2):113-22

Production and characterization of rabbit anti-idiotypic antibodies directed against a murine monoclonal anti-B. abortus antibody. Adone R, et al. **Vet Res Commun** 1995; 19(6):457-61

Induction of antibodies to the bluetongue virus core polypeptide VP7 in sheep by internal image rabbit antiidiotypic antibodies. Lin M, et al. **Viral Immunol** 1996; 9(1):35-43

[A case of Guillain-Barré syndrome associated with anti-GM2 antibody due to cytomegalovirus infection--special reference to the effect of ganciclovir] Niwa K, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):652-6 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Anti-idiotypic antibodies as vaccinal and diagnostic preparations in viral infections] Tarasishin LA. **Mikrobiol Z** 1996 Jan-Feb;58(1):97-105 (30 ref.) (Eng. Abstr.) **(Rus)**

[Preparation and study of properties of anti-idiotypic antibodies, carrying hemagglutinating paratopes of tick-borne encephalitis virus on their surface] Protopopova EV, et al. **Vopr Virusol** 1996 Mar-Apr;41(2):50-3 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Development and evaluation of the specificity of a rat monoclonal anti-idiotype antibody, WN, to an anti-B-cell lymphoma monoclonal antibody, LL2. Losman MJ, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5978s-5982s

METABOLISM

Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells. Manetti C, et al. **Int J Cancer** 1995 Oct 9;63(2):250-6

Anti-IgM-mediated regulation of c-myc and its possible relationship to apoptosis. Kaptein JS, et al.
J Biol Chem 1996 Aug 2;271(31):18875-84

Modulation of anti-IgM-induced B cell apoptosis by Bcl-xL and CD40 in WEHI-231 cells. Dissociation from cell cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction. Merino R, et al. **J Immunol** 1995 Oct 15;155(8):3830-8

Fate of human IgG from lupus erythematosus antinuclear antibody positive sera passively transfered to mice. Herrera-Esparza R, et al. **Rev Rhum Engl Ed** 1996 Feb; 63(2):111-8

Production and characterization of rabbit anti-idiotypic antibodies directed against a murine monoclonal anti-B. abortus antibody. Adone R, et al. **Vet Res Commun** 1995; 19(6):457-61

PHARMACOLOGY

IgE-anti-IgE-induced prostaglandin D2 release from cultured human mast cells. Obata T, et al.
Biochem Biophys Res Commun 1996 Aug 23;225(3):1015-20

Transforming growth factor-beta 1 cooperates with anti-immunoglobulin for the induction of apoptosis in group I (biopsy-like) Burkitt lymphoma cell lines. MacDonald I, et al. **Blood** 1996 Feb 1;87(3):1147-54

Human auto-anti-idiotypic antibodies to mite-specific IgE can degranulate human basophils in vitro. Weyer A, et al. **Clin Exp Allergy** 1995 Oct;25(10):935-41

Calcitonin gene-related peptide as an endogenous vasodilator: immunoblockade studies in vivo with an anti-calcitonin gene-related peptide monoclonal antibody and its Fab' fragment. Tan KK, et al. **Clin Sci (Colch)** 1995 Dec;89(6):565-73

Anti-CD5 extends the proliferative response of human CD5+ B cells activated with anti-IgM and interleukin-2. Jamin C, et al. **Eur J Immunol** 1996 Jan;26(1):57-62

Blimp-1 overcomes the block in IgM secretion in lipopolysaccharide/anti-mu F(ab')2-co-stimulated B lymphocytes. Schliephake DE, et al. **Eur J Immunol** 1996 Jan;26(1):268-71

Basophil histamine release and leukotriene production in response to anti-IgE and anti-IgE receptor antibodies. Comparison of normal subjects and patients with urticaria, atopic dermatitis or bronchial asthma. Bischoff SC, et al. **Int Arch Allergy Immunol** 1996 Jul;110(3):261-71

Comparative ultrastructural morphology of human basophils stimulated to release histamine by anti-IgE, recombinant IgE-dependent histamine-releasing factor, or monocyte chemotactic protein-1. Dvorak AM, et al.
J Allergy Clin Immunol 1996 Aug;98(2):355-70

Role of LFA-1/ICAM-1-dependent cell adhesion in CD40-mediated inhibition of anti-IgM antibody-induced B-cell death. Mayumi M, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1136-44

Anti-IgE-induced accumulation of leukocytes, mediators, and albumin in skin chamber fluid from healthy and atopic subjects. Raud J, et al. **J Allergy Clin Immunol** 1996 May; 97(5):1151-63

Anti-idiotypic antibody as an oestrogen mimetic in vivo: stimulation of creatine kinase specific activity in rat animal models. Sömjen D, et al. **J Endocrinol** 1996 May; 149(2):305-12

Modulation of rat B cell differentiation in vivo by the administration of an anti-mu monoclonal antibody. Soares M, et al. **J Immunol** 1996 Jan 1;156(1):108-18

[Modulation of the tumoral progression by anti-idiotypic antibodies of angiogenesis factors] Ortéga N, et al.
C R Acad Sci III 1996 May;319(5):411-5 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Influence of anti-IgG antibodies on graft outcome in live related donor renal transplantation. Tahir MT, et al.
Transpl Immunol 1995 Sep;3(3):240-4

THERAPEUTIC USE

Anti-TNFalpha therapy improves survival and ameliorates the pathophysiologic sequelae in acute pancreatitis in the rat. Hughes CB, et al. **Am J Surg** 1996 Feb;171(2):274-80

Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Demanet C, et al. **Blood** 1996 May 15;87(10):4390-8

Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. White CA, et al. **Blood** 1996 May 1;87(9):3640-9

Controlling allergy with anti-idiotypic antibodies [editorial] Shakib F. **Clin Exp Allergy** 1995 Oct;25(10):908-9 (18 ref.)

Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. Silvestris F, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:91-7

Anti-IgE therapy. Jardieu P. **Curr Opin Immunol** 1995 Dec; 7(6):779-82 (36 ref.)

A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer. Schlebusch H, et al. **Hybridoma** 1995 Apr;14(2):167-74

In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma. Demanet C, et al. **J Hematother** 1995 Oct;4(5):363-8

CD4-imitating human antibodies in HIV infection and anti-idiotypic vaccination. Deckert PM, et al.
J Immunol 1996 Jan 15;156(2):826-33

Prolonged inhibition of IgE production in mice following treatment with an IgE-specific immunotoxin. Lustgarten J, et al. **Mol Immunol** 1996 Feb;33(3):245-51

TOXICITY

Preclinical evaluation in nonhuman primates of an anti-idiotypic antibody that mimicks the carcinoembryonic antigen. Chakraborty M, et al.
J Immunother Emphasis Tumor Immunol 1995 Aug; 18(2):95-103

ANTIBODIES, ANTINUCLEAR

see related
COLLAGEN DISEASES

Anti-La monoclonal antibodies recognizing epitopes within the RNA-binding domain of the La protein show differential capacities to immunoprecipitate RNA-associated La protein. Pruijn GJ, et al.
Eur J Biochem 1995 Sep 1;232(2):611-9

Enhancement of oxidative cleavage of DNA by the binding sites of two anti-double-stranded DNA antibodies. Kubota T, et al. **J Biol Chem** 1996 Mar 15;271(11):6555-61

ANALYSIS

Cytoplasmic staining, ANA negative status, and ENA testing in rheumatic diseases [letter; comment] Lems WF, et al. **Ann Rheum Dis** 1995 Sep;54(9):779. Comment on: Ann Rheum Dis 1995 Apr;54(4):269-73.

Significance of anti-nuclear matrix antibodies in patients with in vivo speckled antinuclear antibody staining. Deng JS, et al. **Arthritis Rheum** 1996 Aug;39(8):1300-7

Specificity of antiperinuclear factor for rheumatoid arthritis in rheumatoid factor-positive sera. Berthelot JM, et al.
Br J Rheumatol 1995 Aug;34(8):716-20

A computer program that periodically monitors the ability to interpret the antinuclear antibody test. Astion ML, et al. **Clin Chem** 1996 May;42(5):836-40

Antiperinuclear factor isotypes in rheumatoid arthritis [letter; comment] Borg AA. **Clin Exp Rheumatol** 1995 Jul-Aug; 13(4):529-31. Comment on: Clin Exp Rheumatol 1994 Nov-Dec;12(6):615-9.

Antiperinuclear factor isotypes in rheumatoid arthritis [letter; comment] Muñoz-Fernández S, et al.
Clin Exp Rheumatol 1995 Jul-Aug;13(4):529; discussion 530-1. Comment on: Clin Exp Rheumatol 1994 Nov-Dec;12(6):615-9.

Rheumatoid factor, anti-heat shock protein (65 kDa) antibodies and anti-nuclear antibodies in equine joint diseases. Carter SD, et al. **Equine Vet J** 1995 Jul; 27(4):288-95

Significance of the anti-Ro (SS-A) antibody in evaluation of patients with cutaneous manifestations of a connective tissue disease. Provost TT, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):147-69; quiz 170-2 (213 ref.)

Sjögren's antibodies identified in saliva [news]
J Am Dent Assoc 1996 Jul;127(7):854

Non-specific autoantibodies in cardiomyopathies and myocardial infarction. Syrigou EI, et al.
J Clin Lab Immunol 1995;46(4):155-62

Frequency and significance of antibodies to histones in autoimmune hepatitis. Czaja AJ, et al. **J Hepatol** 1995 Jul; 23(1):32-8

Occurrence of antineutrophil cytoplasmic and antineutrophil (peri)nuclear antibodies in rheumatoid arthritis. Bosch X, et al. **J Rheumatol** 1995 Nov;22(11):2038-45

Are antinuclear antibodies predictive of recurrent miscarriage? [letter] Ogasawara M, et al. **Lancet** 1996 Apr 27;347(9009):1183-4

Antinuclear antibodies in multiple sclerosis [letter] Aisen ML, et al. **Neurology** 1995 Dec;45(12):2299-300;discussion 2300-1

Antinuclear antibodies in multiple sclerosis [letter] Heinzlef O, et al. **Neurology** 1995 Dec;45(12):2299-300; discussion 2300-1

Reevaluation of enzyme-linked immunosorbent assay with ultraviolet-treated polystyrene microtiter plates for measurement of antibodies to dsDNA. Kaburaki J, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr;19(2):163-7

[Recurrent annular erythema--cutaneous manifestation of Sjögren syndrome with anti SS-A (Ro) and anti SS-B (La) antibodies] Usuda T. **Nippon Rinsho** 1995 Oct; 53(10):2557-62 (Eng. Abstr.) **(Jpn)**

[Studies on anti-DNA antibodies associated with renal involvement by enzyme-linked immunosorbent assay in patients with systemic lupus erythematosus] Taman J, et al. **Ryumachi** 1996 Feb;36(1):8-15 (Eng. Abstr.) **(Jpn)**

[Study on correlation between chest X-P course findings and change in antinuclear antibody in asbestos plant employees] Tamura M, et al. **Sangyo Eiseigaku Zasshi** 1996 May; 38(3):138-41 (Eng. Abstr.) **(Jpn)**

[Occurrence of antinuclear antibodies in women with endometriosis and unexplained infertility] Malinowski A, et al. **Ginekol Pol** 1995 Jul;66(7):420-4 (Eng. Abstr.) **(Pol)**

[Analysis of response to interferon alpha-2b and the significance of antinuclear antibodies in hairy cell leukemia] Ríos R, et al. **Med Clin (Barc)** 1996 Apr 20;106(15):583-5 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Effect of histone and histone-RNA complexes on the disease process of murine systemic lupus erythematosus. Ravirajan CT, et al. **Autoimmunity** 1995;21(2):117-22

Detection of nucleosome-IgG immune complexes in ascites from mice transplanted with anti-DNA antibody-secreting hybridomas and in plasma from MRL-lpr/lpr mice. Fournié GJ. **Clin Exp Immunol** 1996 May;104(2):236-40

V gene sequences of human anti-ssDNA antibodies secreted by lupus-derived CD5-negative B cell hybridomas. Mitamura K, et al. **Clin Immunol Immunopathol** 1996 Feb; 78(2):152-60

Two kappa immunoglobulin light chains are secreted by an anti-DNA hybridoma: implications for isotypic exclusion. Zack DJ, et al. **Mol Immunol** 1995 Dec;32(17-18):1345-53

Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Satoh M, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21; 92(24):10934-8

BLOOD

Screening for antinuclear antibodies by enzyme immunoassay. Jaskowski TD, et al. **Am J Clin Pathol** 1996 Apr;105(4):468-73

Autoimmune phenomena in bronchial asthma with special reference to aspirin intolerance. Szczeklik A, et al.
Am J Respir Crit Care Med 1995 Dec;152(6 Pt 1):1753-6

Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Chabre H, et al.
Arthritis Rheum 1995 Oct;38(10):1485-91

Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Clawson K, et al.
Arthritis Rheum 1995 Oct;38(10):1519-23

Development of complete heart block in an adult patient with Sjögren's syndrome and anti-Ro/SS-A autoantibodies. Lee LA, et al. **Arthritis Rheum** 1996 Aug; 39(8):1427-9

Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Sánchez-Guerrero J, et al. **Arthritis Rheum** 1996 Jun;39(6):1055-61

Clinical associations of anti-lamin autoantibodies [see comments] Hill C, et al. **Aust N Z J Med** 1996 Apr; 26(2):162-6. Comment in: Aust N Z J Med 1996 Apr;26(2):145-6.

IgA antihistone antibodies in isoniazid-treated tuberculosis patients. Vázquez-Del Mercado M, et al. **Autoimmunity** 1995;20(2):105-11

Triplex-DNA stabilization by hydralazine and the presence of anti-(triplex DNA) antibodies in patients treated with hydralazine. Thomas TJ, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):183-8

Autoantibodies to DNA in schizophrenia. Patel R, et al.
Biochem Soc Trans 1995 Aug;23(3):480S

Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. Bell SA, et al. **Br J Dermatol** 1996 May;134(5):848-54

Hypergammaglobulinaemic purpura of Waldenström and Ro/SSA autoantibodies. Miyagawa S, et al. **Br J Dermatol** 1996 May;134(5):919-23

Maternal HLA antigens and antibodies to SS-A/Ro and SS-B/La. Comparison with systemic lupus erythematosus and primary Sjögren's syndrome. Julkunen H, et al. **Br J Rheumatol** 1995 Oct;34(10):901-7

The antiperinuclear factor in spondylarthropathies [letter] Muñoz-Fernández S, et al. **Br J Rheumatol** 1996 Aug; 35(8):804-5

'Seronegative' Sjögren's syndrome manifested as a subset of chronic fatigue syndrome. Nishikai M, et al. **Br J Rheumatol** 1996 May;35(5):471-4

The antiperinuclear factor in spondylarthropathies. Saraux A, et al. **Br J Rheumatol** 1995 Oct;34(10):912-4

Predominance of IgM anti-U1RNP antibodies in patients with systemic lupus erythematosus. Vlachoyiannopoulos PG, et al. **Br J Rheumatol** 1996 Jun;35(6):534-41

Frequency of biochemical hypothyroidism in sera referred for autoantibody testing. Reyes H, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):351-2

Significance of anti-nuclear and anti-extracellular matrix autoantibodies for albuminuria in murine lupus nephritis; a longitudinal study on plasma and glomerular eluates in MRL/l mice. van Bruggen MC, et al. **Clin Exp Immunol** 1996 Jul;105(1):132-9

Prolonged elevation of antinuclear antibodies in a patient with atrial myxoma after tumor extirpation [letter] Wang HT, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):676-7

Autoantibodies in patients with silicone implants. Bridges AJ, et al. **Curr Top Microbiol Immunol** 1996;210:277-82

Antinuclear antibodies in apparently healthy women with breast implants. Claman HN, et al. **Curr Top Microbiol Immunol** 1996;210:265-8

Laboratory studies in breast implant patients: ANA positivity, gammaglobulin levels, and other autoantibodies. Lewy RI, et al. **Curr Top Microbiol Immunol** 1996;210:337-53

The prevalence of autoantibodies in symptomatic and asymptomatic patients with breast implants and patients with fibromyalgia. Silverman S, et al. **Curr Top Microbiol Immunol** 1996;210:317-22

Re-evaluation of autoantibodies and clinical overview of silicone-related disorders. Tan EM, et al. **Curr Top Microbiol Immunol** 1996;210:291-8

Binding of anti-double stranded (ds) DNA-positive sera to denatured (d) DNA and synthetic poly[dA-dT] x poly[dA-dT] double stranded copolymer in an ELISA format. Batinić D, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):343-7

Systemic lupus erythematosus as a cause of the pulmonary renal syndrome [letter] Sewell WA, et al. **J Intern Med** 1996 Jul;240(1):43

Elevated serum prolactin levels in children with juvenile rheumatoid arthritis and antinuclear antibody seropositivity. McMurray RW, et al. **J Rheumatol** 1995 Aug;22(8):1577-80

Antinuclear antibodies and thyroid function in sexually abused girls. De Bellis MD, et al. **J Trauma Stress** 1996 Apr;9(2):369-78

Prolactin levels and antinuclear antibody profiles in women tested for connective tissue disease. Allen SH, et al. **Lupus** 1996 Feb;5(1):30-7

Clinical evaluation of various selected ELISA kits for the detection of anti-DNA antibodies. Aviña-Zubieta JA, et al. **Lupus** 1995 Oct;4(5):370-4

Autoantibodies to topoisomerase I in a patient with systemic lupus erythematosus without features of scleroderma. Stojanov L, et al. **Lupus** 1995 Aug;4(4):314-7

The role of circulating immune complexes; antinuclear and rheumatoid factor autoantibodies in aging in Nigerians. Oyeyinka GO, et al. **Mech Ageing Dev** 1995 Nov 24; 85(2-3):73-81

Variation in ANA titres in Auckland [see comments] Green G, et al. **N Z Med J** 1995 Dec 8;108(1013):512-4. Comment in: N Z Med J 1996 Feb 9;109(1015):38.

Pearson's correlation coefficient [letter; comment] Williams S. **N Z Med J** 1996 Feb 9;109(1015):38. Comment on: N Z Med J 1995 Dec 8;108(1013):512-4.

Immunosuppressive treatment prevents behavioral deficit in autoimmune MRL-lpr mice. Sakić B, et al. **Physiol Behav** 1995 Oct;58(4):797-802

Antinuclear antibodies in dogs with leishmaniasis. Lucena R, et al. **Zentralbl Veterinarmed A** 1996 Jun;43(4):255-9

[Subacute paraneoplastic cerebellar degeneration with anti-neuronal antibodies and gynecological cancers. A case report of a bilateral ovarian cancer where the classic "anti-YO" antibody is associated with another antineuronal antibody] Tremouilhac C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):253-6 (Eng. Abstr.) **(Fre)**

[Anti-Jo-1-positive polymyositis with interstitial alveolitis and pericardial effusion. Overview of 3 years treatment] Krajnc I. **Wien Klin Wochenschr** 1995;107(19):590-2 (Eng. Abstr.) **(Ger)**

[Optimal fixation for the detection of anti-neuronal antibody by immunohistochemistry in the paraneoplastic syndrome] Kanazawa N, et al. **Rinsho Byori** 1996 Jul;44(7):640-6 (Eng. Abstr.) **(Jpn)**

[Detection of anti small nuclear ribonucleoprotein antibody in patients with collagen disease--a comparison of sensitivities of four methods] Akashi Y, et al. **Ryumachi** 1995 Jun;35(3):552-8 (Eng. Abstr.) **(Jpn)**

[Antibodies to DNA in immunoglobulin preparations and healthy human blood serum are found in free and bound states] Lekakh IV, et al. **Mol Biol (Mosk)** 1996 May-Jun; 30(3):707-13 **(Rus)**

[Antinuclear antibodies and juvenile chronic rheumatoid arthritis (editorial)] Modesto Caballero C. **An Esp Pediatr** 1996 Apr;44(4):305-9 (33 ref.) **(Spa)**

CHEMISTRY

The importance of the diversity region YYGS motif in anti-DNA antibody binding to DNA. Mahmoudi M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:424-6

Structural properties and mutation patterns of anti-nucleosome monoclonal antibodies are similar to those of anti-DNA antibodies. Brard F, et al. **Eur J Immunol** 1996 Jul;26(7):1587-94

Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. Iakoubov L, et al. **Immunol Lett** 1995 Jul-Aug;47(1-2):147-9

Structural elements controlling anti-DNA antibody affinity and their relationship to anti-phosphorylcholine activity. Pewzner-Jung Y, et al. **J Immunol** 1996 Apr 15; 156(8):3065-73

CLASSIFICATION

Subclass distribution of maternal and neonatal anti-Ro(SSA) and La(SSB) antibodies in congenital heart block. Tseng CE, et al. **J Rheumatol** 1996 May;23(5):925-32

[Isotypes and subtypes of anti-SS-A and/or SS-B antibodies in different subgroups of Sjögren's syndrome] Takaya M, et al. **Nippon Rinsho** 1995 Oct;53(10):2429-33 (17 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Use of a phage expression system to produce Fabs from human autoanti-DNA antibodies encoded by the VH4-21 gene segment. Chapman CJ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:576-9

B-1 cellular origin and VH segment structure of IgG, IgA, and IgM anti-DNA autoantibodies in patients with systemic lupus erythematosus. Kasaian MT, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:410-23 (52 ref.)

Analysis of V kappa I and V lambda II light chain genes in the expressed B-cell repertoire. Manheimer-Lory A, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:301-11

Origins of anti-DNA antibodies and their implications for B-cell tolerance. Radic MZ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:384-96 (13 ref.)

Repertoire cloning of human lupus autoantibodies. Silverman GJ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:565-6

VH and VL gene elements that encode human antibodies to DNA. Hoch S, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):88-95

Structural properties and mutation patterns of anti-nucleosome monoclonal antibodies are similar to those of anti-DNA antibodies. Brard F, et al. **Eur J Immunol** 1996 Jul;26(7):1587-94

Differences in V kappa gene utilization and VH CDR3 sequence among anti-DNA from C3H-lpr mice and lupus mice with nephritis. Wloch MK, et al. **Eur J Immunol** 1996 Sep;26(9):2225-33

The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Waisman A, et al. **Int Immunol** 1995 Apr;7(4):689-96

Ligand recognition by murine anti-DNA autoantibodies. II. Genetic analysis and pathogenicity. Swanson PC, et al. **J Clin Invest** 1996 Apr 1;97(7):1748-60

Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Morel L, et al. **Mamm Genome** 1996 May;7(5):335-9

IMMUNOLOGY

Antinuclear autoantibodies in chronic schizophrenia. Spivak B, et al. **Acta Psychiatr Scand** 1995 Oct;92(4):266-9

The importance of the diversity region YYGS motif in anti-DNA antibody binding to DNA. Mahmoudi M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:424-6

Immunological properties of bacterial DNA. Pisetsky DS, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:152-63 (33 ref.)

Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene. A possible link between infection and lupus. Spellerberg M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:427-32

Human pathogenic autoantibodies and their escape from deletion. Zouali M. **Ann N Y Acad Sci** 1995 Sep 29; 764:436-9

Increased release of von Willebrand factor antigen from endothelial cells by anti-DNA autoantibodies. Lai KN, et al. **Ann Rheum Dis** 1996 Jan;55(1):57-62

Some autoantibodies to Ro/SS-A and La/SS-B are antiidiotypes to anti-double-stranded DNA. Zhang W, et al. **Arthritis Rheum** 1996 Mar;39(3):522-31

Ligand recognition by anti-DNA autoantibodies. Affinity, specificity, and mode of binding. Swanson PC, et al. **Biochemistry** 1996 Feb 6;35(5):1624-33

Immunofluorescent artifacts due to the pH of antifading mounting media. Swartz DJ, et al. **Biotechniques** 1996 Mar; 20(3):398-400

Significance of extractable nuclear antigens in childhood autoimmune liver disease. Gregorio GV, et al. **Clin Exp Immunol** 1995 Nov;102(2):308-13

Anti-DNA antibody derived from a systemic lupus erythematosus (SLE) patient forms histone-DNA-anti-DNA complexes that bind to rat glomeruli in vivo. Morioka T, et al. **Clin Exp Immunol** 1996 Apr;104(1):92-6

Lupus-derived autoantibodies with dual autoactivity: anti-DNA and anti-Fc. II. Fine specificity of anti-self autoreactivity. Rumbley CA, et al. **Clin Exp Immunol** 1995 Nov;102(2):349-53

Lupus-derived autoantibodies with dual autoactivity: anti-DNA and anti-Fc. I. Comparison of IgG autoreactivities with single-chain Fv derivatives. Rumbley CA, et al. **Clin Exp Immunol** 1995 Nov;102(2):341-8

Nonprecipitating anti-La(SS-B) autoantibodies in primary Sjögren's syndrome. Beer RG, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):314-8

Genetic susceptibility to silver-induced anti-fibrillarin autoantibodies in mice. Hultman P, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):291-7

Detection of anti-DNA topoisomerase I antibody by an enzyme-linked immunosorbent assay using overlapping recombinant polypeptides. Kuwana M, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):266-78

Shared V-region antigens and cross-reacting specificities of human IgG anti-F(ab')2 and anti-DNA antibodies. Williams RC Jr, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):194-203

Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations. Tikly M, et al. **Clin Rheumatol** 1996 Mar;15(2):143-7

Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene: a possible link between infection and lupus. Spellerberg MB, et al. **Hum Antibodies Hybridomas** 1995;6(2):52-6

Hydralazine-induced lupus: yet another autoantibody! Pirmohamed M. **Hum Exp Toxicol** 1996 Apr;15(4):361-2

Immunoglobulin heavy chain gene replacement: a mechanism of receptor editing. Chen C, et al. **Immunity** 1995 Dec; 3(6):747-55

The expression of acidic ribosomal phosphoproteins on the surface membrane of different tissues in autoimmune and normal mice which are the target molecules for anti-double-stranded DNA antibodies. Sun KH, et al. **Immunology** 1996 Mar;87(3):362-71

Chronic ulcerative stomatitis with stratified epithelium-specific antinuclear antibodies. Lewis JE, et al. **Int J Dermatol** 1996 Apr;35(4):272-5 (7 ref.)

Properties of a system of public idiotypes of lupus autoantibodies. Schwartz RS. **Int Rev Immunol** 1989; 5(2):153-5 (13 ref.)

Pathogenic aspects of systemic lupus erythematosus. Kalden JR. **Isr J Med Sci** 1996 Jan;32(1):3-6 (28 ref.)

Heparan sulfate staining of the glomerular basement membrane in relation to circulating anti-DNA and anti-heparan sulfate reactivity: a longitudinal study in NZB/W F1 mice. Hylkema MN, et al. **J Autoimmun** 1996 Feb;9(1):41-50

Dual reactivity of several monoclonal anti-nucleosome autoantibodies for double-stranded DNA and a short segment of histone H3. Stemmer C, et al. **J Biol Chem** 1996 Aug 30;271(35):21257-61

The double edged sword of the immune response: mutational analysis of a murine anti-pneumococcal, anti-DNA antibody. Putterman C, et al. **J Clin Invest** 1996 May 15; 97(10):2251-9

Ligand recognition by murine anti-DNA autoantibodies. II. Genetic analysis and pathogenicity. Swanson PC, et al. **J Clin Invest** 1996 Apr 1;97(7):1748-60

Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. Calleja JL, et al. **J Hepatol** 1996 Mar;24(3):308-12

The immunologic properties of DNA. Pisetsky DS. **J Immunol** 1996 Jan 15;156(2):421-3 (37 ref.)

Lupus autoantibodies to double-stranded DNA cross-react with ribosomal protein S1. Tsuzaka K, et al. **J Immunol** 1996 Feb 15;156(4):1668-75

Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells. Neng Lai K, et al. **J Pathol** 1996 Apr;178(4):451-7

Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Ehrenstein MR, et al. **Kidney Int** 1995 Sep;48(3):705-11

Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. Kalsi JK, et al. **Mol Immunol** 1996 Mar-Apr;33(4-5):471-83

Specificities and genetic characteristics of nucleosome-reactive antibodies from autoimmune mice. Monestier M, et al. **Mol Immunol** 1996 Jan;33(1):89-99

Normal human cord blood B cells can produce high affinity IgG antibodies to dsDNA that are recognized by cord blood-derived anti-idiotypic antibodies. Warrington RJ, et al. **Scand J Immunol** 1995 Oct;42(4):397-406

[Appearance of anti-DNA antibodies after treatment with interferon in a patient with chronic type C viral hepatitis] Ballardini P, et al. **Riv Eur Sci Med Farmacol** 1995 Jul-Aug;

ANTIBODIES, ANTINUCLEAR

17(4):131–2 (Eng. Abstr.) **(Ita)**

[Epitopes of the target proteins of anti–SS–A/Ro and anti–SS–B/La autoantibodies] Kato T. **Nippon Rinsho** 1995 Oct;53(10):2434–9 (26 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Antibodies specific for the DNA quadruplex [d(CGC G4 GCG)4] isolated from autoimmune mice. Brown BA 2nd, et al. **Nucleic Acids Symp Ser** 1995;(33):134–6

[Therapeutic (im)possibilities in Raynaud's phenomenon (letter)] Jager J. **Ned Tijdschr Geneeskd** 1996 May 11; 140(19):1044 **(Dut)**

METABOLISM

Co–localisation of autoimmune antibodies specific for double stranded DNA with procorticotrophin–releasing hormone within the nucleus of stably transfected CHO–K1 cells. Castro MG, et al. **Cell Tissue Res** 1995 Dec;282(3):367–76

Selective accumulation of anti–histone antibodies in glomeruli of lupus–prone lpr mice. Minota S, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):82–7

Binding of nucleosomes to a cell surface receptor: redistribution and endocytosis in the presence of lupus antibodies. Koutouzov S, et al. **Eur J Immunol** 1996 Feb; 26(2):472–86

Heavy chain dominance in the binding of DNA by a lupus mouse monoclonal autoantibody. Jang YJ, et al. **Mol Immunol** 1996 Feb;33(2):197–210

Impact of using stored cells for immunofluorescence detection of antiperinuclear factor on sensitivity of the method for the diagnosis of rheumatoid arthritis. Berthelot JM, et al. **Rev Rhum Engl Ed** 1995 Jul–Sep;62(7–8):507–12

Fate of human IgG from lupus erythematosus antinuclear antibody positive sera passively transfered to mice. Herrera–Esparza R, et al. **Rev Rhum Engl Ed** 1996 Feb; 63(2):111–8

PHYSIOLOGY

Structure–function relationships of anti–DNA antibodies [editorial] Kalsi JK, et al. **Lupus** 1995 Aug;4(4):245–8

[Interview with Moncef Zouali: What is going to happen tomorrow in the field of lupus anti–DNA antibodies? (interview)] Zouali M. **Ann Med Interne (Paris)** 1995; 146(5):316–8 **(Fre)**

THERAPEUTIC USE

Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti–DNA–reactive IgG. Silvestris F, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:91–7

ANTIBODIES, ANTIPHOSPHOLIPID

see related

ANTIPHOSPHOLIPID SYNDROME

Spontaneous adrenal gland haematoma in a patient with antiphospholipid antibodies [letter] Luppi M, et al. **Eur J Haematol** 1995 Nov;55(5):335–8

ADMINISTRATION & DOSAGE

The pathogenic role of anti–phosphatidylserine antibodies: active immunization with the antibodies leads to the induction of antiphospholipid syndrome. Yodfat O, et al. **Clin Immunol Immunopathol** 1996 Jan;78(1):14–20

ANALYSIS

Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four–year prospective study from the Italian Registry. Finazzi G, et al. **Am J Med** 1996 May;100(5):530–6

Takayasu's arteritis associated with antiphospholipid antibodies. Report of two cases. Yokoi K, et al. **Angiology** 1996 Mar;47(3):315–9

Myocardial infarction as the presenting manifestation of systemic lupus erythematosus with antiphosphatidylserine antibodies. Jansen NL, et al. **Ann Allergy Asthma Immunol** 1996 Mar;76(3):266–8

Presence of multiple anti–phospholipid antibody specificities in a pediatric population. Beaman KD, et al. **Autoimmunity** 1995;21(2):99–106

Antiphospholipid antibodies and venous thromboembolism. Ginsberg JS, et al. **Blood** 1995 Nov 15;86(10):3685–91

Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high–titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome. Gattorno M, et al. **Br J Rheumatol** 1995 Sep;34(9):873–81

Antiphospholipid antibodies in heart transplant recipients. McIntyre JA, et al. **Clin Cardiol** 1995 Oct;18(10):575–80

Detection of bilayer phospholipid–binding antibodies using flow cytometry. Eschwège V, et al. **Clin Exp Immunol** 1996 Jan;103(1):171–5

Mesangioproliferative glomerulonephritis and antibodies to phospholipids in a patient with acute Q fever: case report. Tolosa–Vilella C, et al. **Clin Infect Dis** 1995 Jul;21(1):196–8

Antiphospholipid antibodies in women having in–vitro fertilization. Birdsall MA, et al. **Hum Reprod** 1996 Jun; 11(6):1185–9

Absence of antiphospholipid and anti–endothelial cell antibodies in malignant atrophic papulosis: a study of 15 cases. Assier H, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):831–3

Measurement of mouse anti–phospholipid antibodies to solid–phase microspheres by both flow cytofluorometry and Alcian blue–pretreated microtitre plates in an ELISA. Laakel M, et al. **J Immunol Methods** 1996 Apr 19; 190(2):267–73

Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Brunet P, et al. **Kidney Int** 1995 Sep;48(3):794–800

Antiphospholipid antibodies, haemostatic variables and thrombosis—a survey of 144 patients. Ames PR, et al. **Thromb Haemost** 1995 May;73(5):768–73

[ELISA in the determination of antiphosphatidylserine antibodies] Fialová L, et al. **Epidemiol Mikrobiol Imunol** 1996 May;45(2):52–5 (Eng. Abstr.) **(Cze)**

[Relapsing polychondritis, thrombosis and antiphospholipid antibodies] Grasland A, et al. **Rev Med Interne** 1996; 17(3):231–3 (Eng. Abstr.) **(Fre)**

[Progressive lupus dementia. 2 cases with or without antiphospholipid antibodies] Robin C, et al. **Rev Neurol (Paris)** 1995 Dec;151(12):699–707 (48 ref.) (Eng. Abstr.) **(Fre)**

[Multiple osseous avascular necrosis in a patient with systemic lupus erythematosus with antiphospholipid antibody positivity] Biasi D, et al. **Recenti Prog Med** 1995 Nov;86(11):449–50 **(Ita)**

[Antiphospholipid antibodies in women with habitual abortions. Treatment with prednisone and acetylsalicylic acid during pregnancy] Marco P, et al. **Sangre (Barc)** 1995 Oct;40(5):389–92 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Clinical significance of anti–GM3 antibodies in recurrent pregnancy loss with elevated level of antiphospholipid antibodies. Ozaki Y, et al. **Am J Reprod Immunol** 1995 Mar; 33(3):234–42

Antiphospholipid antibody production during Mediterranean spotted fever. Sotto A, et al. **Autoimmunity** 1995; 21(2):123–6

Soluble products of inflammatory reactions are not induced in children with asymptomatic Plasmodium falciparum infections. Jakobsen PH, et al. **Clin Exp Immunol** 1996 Jul; 105(1):69–73

BLOOD

Anti–phospholipid antibodies and cerebral vasospasm following subarachnoid haemorrhage. Hirashima Y, et al. **Acta Neurochir (Wien)** 1995;135(3–4):191–7

Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Toubi E, et al. **Am J Med** 1995 Oct;99(4):397–401

Increased antiphospholipid antibody activity in in–vitro fertilization patients is not treatment–dependent but rather an inherent characteristic of the infertile state. Fisch B, et al. **Am J Reprod Immunol** 1995 Dec;34(6):370–4

The relationship of anti–endothelial cell antibodies to anti–phospholipid antibodies in patients with giant cell arteritis and/or polymyalgia rheumatica. Le Tonquèze M, et al. **Autoimmunity** 1995;20(1):59–66

Phospholipid antibodies and resistance to activated protein C in women with thrombophilia. Bokarewa MI, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):417–22

Refractory thrombocytopenia due to anti–PLA1 antibodies following autologous peripheral blood stem cell transplantation: case report and review of literature. Roy V, et al. **Bone Marrow Transplant** 1996 Jan;17(1):115–7

Antibodies to phospholipid–binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Puurunen M, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):16–22

Antiphospholipid antibodies and anetoderma: are they associated? Stephansson EA, et al. **Dermatology** 1995; 191(3):204–9

Antiphospholipid syndrome in a patient with type I diabetes presenting as retinal artery occlusion [letter] Manzanares JM, et al. **Diabetes Care** 1996 Jan;19(1):92–4

Migrainous stroke: are antiphospholipid antibodies pathogenetic, a biological epiphenomenon, or an incidental laboratory aberration? [see comments] Gupta VK. **Eur Neurol** 1996;36(2):110–1. Comment in: Eur Neurol 1996;36(2):114.

Migrainous stroke and antiphospholipid antibodies: are they pathogenetically linked? [letter; comment] Silvestrini M. **Eur Neurol** 1996;36(2):114. Comment on: Eur Neurol 1996;36(2):110–1.

Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Yetman DL, et al. **Fertil Steril** 1996 Oct;66(4):540–6

Antiphospholipid antibodies, low–dose aspirin and pregnancy losses [letter] Balasch J, et al. **Hum Reprod** 1996 May; 11(5):1140–1

Antiphospholipid antibodies and beta 2–glycoprotein–I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Rai RS, et al. **Hum Reprod** 1995 Aug;10(8):2001–5

Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: lack of correlation with antiphospholipid antibodies. Gabrielli F, et al. **Int J Cardiol** 1995 Sep;51(2):117–26

Anti–oxidized LDL antibodies and antiphospholipid antibodies in healthy subjects: relationship with lipoprotein– and oxidation–related analytes. Craig WY, et al. **J Autoimmun** 1995 Oct;8(5):713–26

Clinical analysis of anti–cardiolipin.beta 2 glycoprotein 1 antibody positive patients in anti–phospholipid syndrome. Katayama I, et al. **J Dermatol Sci** 1995 May;9(3):215–20

Low–dose aspirin and prednisone treatment of pregnancy loss caused by lupus anticoagulants. Harger JH, et al. **J Perinatol** 1995 Nov–Dec;15(6):463–9

The presence of antiphospholipid antibodies in acute myocardial infarction. Adler Y, et al. **Lupus** 1995 Aug; 4(4):309–13

Clinical manifestations and management of the antiphospholipid syndrome. Derksen RH. **Lupus** 1996 Apr; 5(2):167–9 (18 ref.)

Laboratory detection of antiphospholipid antibodies. Kandiah DA, et al. **Lupus** 1996 Apr;5(2):160–2 (10 ref.)

Immunology of antiphospholipid antibodies and their interaction with plasma proteins. Kandiah DA, et al. **Lupus** 1996 Apr;5(2):153–5 (31 ref.)

Antiphospholipid antibodies and thrombosis: assessment of the potential risk for thrombosis. Salem HH. **Lupus** 1996 Apr;5(2):163–6 (24 ref.)

Potential role for antiphospholipid antibodies in renal thrombotic microangiopathy induced by interferon–alpha [letter; comment] Piette JC, et al. **Nephrol Dial Transplant** 1995;10(9):1781. Comment on: Nephrol Dial Transplant 1995;10(1):111–3.

Antiphospholipid antibodies and fetal death. Oshiro BT, et al. **Obstet Gynecol** 1996 Apr;87(4):489–93

Antiphospholipid antibodies in pediatric systemic lupus erythematosus. Seaman DE, et al. **Pediatrics** 1995 Dec; 96(6):1040–5

Cutaneous polyarteritis nodosa in a child with positive antiphospholipid and P–ANCA. Pereira BA, et al. **Scand J Rheumatol** 1995;24(6):386–8 (14 ref.)

False positive activated protein C resistance test due to anti–phospholipid antibodies is corrected by platelet extract [letter; comment] Martorell JR, et al. **Thromb Haemost** 1995 Aug;74(2):796–7. Comment on: Thromb Haemost 1994 Oct;72(4):645–6.

[The Budd–Chiari syndrome and the antiphospholipid antibody in childhood] Pérez Payarols J, et al. **An Esp Pediatr** 1996 Jul;45(1):79–81 (12 ref.) **(Spa)**

[Antiphospholipid antibodies and Q fever (letter; comment)] Selva A, et al. **Med Clin (Barc)** 1995 Sep 23;105(9):359. Comment on: Med Clin (Barc) 1994 Nov 19;103(17):667–75. **(Spa)**

CHEMISTRY

Structural elements controlling anti–DNA antibody affinity and their relationship to anti–phosphorylcholine activity. Pewzner–Jung Y, et al. **J Immunol** 1996 Apr 15; 156(8):3065–73

IMMUNOLOGY

Functional specificity of anticoagulant autoantibodies defined by protein cofactors and Tween 20 [letter; comment] Cheng HM. **Am J Hematol** 1995 Nov;50(3):224–5. Comment on: Am J Hematol 1993 Nov;44(3):187–91.

Monoclonal antiphospholipid antibodies and germline VH genes: comment on the article by Harmer et al [letter; comment] Rahman A, et al. **Arthritis Rheum** 1996 Mar; 39(3):537–8. Comment on: Arthritis Rheum 1995 Aug;38(8):1068–76.

Antiphosphatidylserine antibodies in human immunodeficiency virus–1 patients with evidence of T–cell apoptosis and mediate antibody–dependent cellular cytotoxicity. Silvestris F, et al. **Blood** 1996 Jun 15; 87(12):5185–95

Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen–PE complex. Sugi T, et al. **Blood** 1995 Oct 15;86(8):3083–9

The Michael Mason Prize Essay (1994). Antiphospholipid antibodies and disease. Mackworth–Young CG. **Br J Rheumatol** 1995 Nov;34(11):1009–30 (160 ref.)

Amantadine, livedo reticularis, and antiphospholipid antibodies [letter] Paulson GW, et al. **Clin Neuropharmacol** 1995 Oct;18(5):466–7

Antiphospholipid antibodies and antiphospholipid syndrome. Khamashta MA, et al. **Curr Opin Rheumatol** 1995 Sep; 7(5):389–94 (69 ref.)

The antiphospholipid–protein syndrome. Cines DB, et al. **J Clin Immunol** 1995 Nov;15(6 Suppl):86S–100S (186 ref.)

Activation of cultured vascular endothelial cells by antiphospholipid antibodies. Simantov R, et al. **J Clin Invest** 1995 Nov;96(5):2211–9

The role of antiphospholipid antibodies in coronary artery disease in juvenile systemic lupus erythematosus [letter; comment] Falcini F, et al. **J Rheumatol** 1995 Jul; 22(7):1438–9. Comment on: J Rheumatol 1994 Nov;21(11):2147–56.

Clinical significance of phospholipid–dependent anti–beta 2–glycoprotein I (beta 2–GPI) antibodies in systemic lupus erythematosus. Kaburaki J, et al. **Lupus** 1995 Dec; 4(6):472–6

Renal infarction in a severely hypertensive patient with lupus erythematosus and antiphospholipid antibodies. Hernández

D, et al. **Nephron** 1996;72(2):298–301

The role of antiphospholipid antibodies in lupus nephropathy. Perdiguero M, et al. **Nephron** 1995;71(1):35–9

Antiphospholipid antibodies and Binswanger's disease [letter; comment] Grotta J, et al. **Neurology** 1996 Jan;46(1):292. Comment on: Neurology 1995 Apr;45(4):626–33.

Antiphospholipid antibodies and Binswanger's disease [letter; comment] Serra-Mestres J. **Neurology** 1996 Jan;46(1):291–2 . Comment on: Neurology 1995 Apr;45(4):626–33.

Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Casciola-Rosen L, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1624–9

Antiphospholipid and anticentromere antibodies occurring together in a patient with pulmonary hypertension. Tilley S, et al. **Tenn Med** 1996 May;89(5):166, 168

Characterization of serum anti-phospholipid antibodies in patients with multiple sclerosis. Sugiyama Y, et al. **Tohoku J Exp Med** 1996 Mar;178(3):203–15

[Recent findings on antigens reactive to antiphospholipid antibodies] Matsuda S. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):27–38 (66 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Specific antiphospholipid antibodies (aPL) eluted from placentae of pregnant women with aPL-positive sera. Katano K, et al. **Lupus** 1995 Aug;4(4):304–8

Demonstration of antiphospholipid antibody heterogeneity by phospholipid column chromatography and salt gradient elution techniques. Walton SP, et al. **Lupus** 1995 Aug; 4(4):263–71

METABOLISM

Complement activation and tissue factor expression on the feto-placental allograft [letter] Cheng HM. **Thromb Haemost** 1995 Oct;74(4):1204

PHARMACOLOGY

Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. Adler RR, et al. **Biol Reprod** 1995 Oct;53(4):905–10

PHYSIOLOGY

[The heart and antiphospholipid antibodies. Personal experience and review of the literature] Laraki R, et al. **Rev Med Interne** 1996;17(1):46–57 (78 ref.) (Eng. Abstr.) **(Fre)**

[Meningoradiculitis in systemic lupus: role of antiphospholipid antibodies? (letter)] Marguerie L, et al. **Rev Med Interne** 1996;17(3):264–5 **(Fre)**

ANTIBODIES, BACTERIAL

Lack of cross-reaction of antibodies against cell-associated glucosyltransferase from Streptococcus mutans with human heart tissue. Iwase T, et al. **Adv Exp Med Biol** 1995; 371B:1161–5

Strategies to interrupt the development of Anaplasma marginale in its tick vector. The effect of bovine-derived antibodies. Kocan KM, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:157–65 (57 ref.)

Polyclonal antibodies to chlorosome proteins as probes for green sulfur bacteria. Cahill AD, et al. **Appl Environ Microbiol** 1995 Feb;61(2):784–7

Application of antisera raised against sulfate-reducing bacteria for indirect immunofluorescent detection of immunoreactive bacteria in sediment from the German Baltic Sea. Lillebaek R. **Appl Environ Microbiol** 1995 Sep; 61(9):3436–42

Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. Murray LJ, et al. **Br Heart J** 1995 Nov;74(5):497–501

An Eikenella corrodens toxin detected by plaque toxin-neutralizing monoclonal antibodies. Levine M, et al. **Infect Immun** 1996 May;64(5):1672–8

Evaluation of commercial antisera for Shigella serogrouping. Lefebvre J, et al. **J Clin Microbiol** 1995 Aug; 33(8):1997–2001

Production and characterization of monoclonal antibodies specific for lipooligosaccharide of Serpulina hyodysenteriae. Westerman RB, et al. **J Clin Microbiol** 1995 Aug;33(8):2145–9

Congenital streptococcal toxic shock syndrome with absence of antibodies against streptococcal pyrogenic exotoxins. Mahieu LM, et al. **J Pediatr** 1995 Dec;127(6):987–9

Colostrum from dams living in a heartwater-endemic area influences calfhood immunity to Cowdria ruminantium. Deem SL, et al. **Vet Parasitol** 1996 Jan;61(1–2):133–44

ADMINISTRATION & DOSAGE

A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Fattom AI, et al. **Infect Immun** 1996 May;64(5):1659–65

Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Menzies BE, et al. **Infect Immun** 1996 May;64(5):1839–41

ANALYSIS

Indirect hemagglutination assay for antibodies to Escherichia coli lipopolysaccharides O157, O111 and O26 in patients with hemolytic uremic syndrome. Morooka T, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):469–73

The colon and rectum as inductor sites for local and distant mucosal immunity. Haneberg B, et al. **Adv Exp Med Biol** 1995;371A:107–9

Titration of inhibiting antibodies to bacterial IgA1 proteases in human sera and secretions. Reinholdt J, et al. **Adv Exp Med Biol** 1995;371A:605–8

Detection of Helicobacter pylori infection by saliva IgG testing. Fallone CA, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1145–9

A chemiluminescent immunoassay for the identification of functional single-chain antibodies. Lee I, et al. **Anal Biochem** 1995 Sep 1;230(1):62–7

Antibody titres in Helicobacter pylori infection: implications in the follow-up of antimicrobial therapy. Kosunen TU. **Ann Med** 1995 Oct;27(5):605–7

Helicobacter pylori antibodies in patients with psoriasis [letter] Halasz CL. **Arch Dermatol** 1996 Jan;132(1):95–6

Use of proZZ-obelin fusion protein in bioluminescent immunoassay. Frank LA, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):475–9

Synovial fluid and serum antibodies against Chlamydia in different forms of arthritis: intra-articular IgA production in Chlamydia sexually acquired reactive arthritis. Bas S, et al. **Br J Rheumatol** 1996 Jun;35(6):548–52

Comparative analysis of antibodies to Francisella tularensis antigens during the acute phase of tularemia and eight years later. Bevanger L, et al. **Clin Diagn Lab Immunol** 1994 Mar; 1(2):238–40

Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay. Madore DV, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):84–8

Measurement of sputum antibodies in the diagnosis of acute and chronic respiratory infections associated with Chlamydia pneumoniae. von Hertzen L, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):454–7

Steps towards the development of a replacement in vitro test for quantification of antibodies to tetanus toxin during potency testing of vaccine. Southern J, et al. **Dev Biol Stand** 1996;86:343

Comparison of rocket immuno-electrophoresis (RIE) and ELISA for determination of tetanus antibodies in tetanus immunoglobulins. Zott A. **Dev Biol Stand** 1996;86:348

Detection of anti-cord factor antibodies in intestinal tuberculosis for its differential diagnosis from Crohn's disease and ulcerative colitis. Kashima K, et al. **Dig Dis Sci** 1995 Dec;40(12):2630–4

High seroprevalence of IgG against Helicobacter pylori among endoscopists in Taiwan. Su YC, et al. **Dig Dis Sci** 1996 Aug;41(8):1571–6

Three-year study of antibody to Borrelia burgdorferi in southern Spain. Gutierrez J, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):542–6

Serologic response to rickettsial antigens in patients with Astrakhan fever. Eremeeva ME, et al. **Eur J Epidemiol** 1995 Aug;11(4):383–7

Prevalence of Legionella pneumophila serogroup 1 antibodies in blood donors. Franzin L, et al. **Eur J Epidemiol** 1995 Aug;11(4):475–8

Pityriasis rosea Gibert: detection of Legionella micdadei antibodies in patients. Gjenero-Margan I, et al. **Eur J Epidemiol** 1995 Aug;11(4):459–62

Seroepidemiology of Q fever in Nova Scotia: evidence for age dependent cohorts and geographical distribution. Marrie TJ, et al. **Eur J Epidemiol** 1995 Feb;11(1):47–54

Antibodies to spotted fever group rickettsiae in dogs in Croatia. Punda-Polić V, et al. **Eur J Epidemiol** 1995 Aug; 11(4):389–92

Evaluation of a western blot serum test for the diagnosis of Mycobacterium tuberculosis infection. Rovatti E, et al. **Eur Respir J** 1996 Feb;9(2):288–92

Diagnostic efficacy of chlamydial antibodies in cervical secretions from pregnant women and adolescent girls. Thejls H, et al. **Genitourin Med** 1995 Dec;71(6):370–4

Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Macpherson A, et al. **Gut** 1996 Mar;38(3):365–75

Local immune response in Helicobacter pylori-infected cats and identification of H. pylori in saliva, gastric fluid and faeces. Fox JG, et al. **Immunology** 1996 Jul;88(3):400–6

Antibody response in bronchoalveolar lavage and serum of rats after aerosol immunization of the airways with a well-adhering and a poorly adhering strain of Streptococcus pneumoniae. Arvá E, et al. **Int Arch Allergy Immunol** 1996 Jan;109(1):35–43

Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease. von Hertzen L, et al. **Int J Epidemiol** 1996 Jun;25(3):658–64

Immunoglobulin A antibodies against Pseudomonas aeruginosa in the tear fluid of contact lens wearers. Cheng KH, et al. **Invest Ophthalmol Vis Sci** 1996 Sep; 37(10):2081–8

The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. Mine T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S75–8

Diagnosis of Helicobacter pylori infection by specific gastric mucosal IgA and IgG pylori antibodies. Veenendaal RA, et al. **J Clin Pathol** 1995 Nov;48(11):990–3

An ospA frame shift, identified from DNA in Lyme arthritis synovial fluid, results in an outer surface protein A that does not bind protective antibodies. Fikrig E, et al. **J Immunol** 1995 Dec 15;155(12):5700–4

Simultaneous quantitation of diphtheria and tetanus antibodies by double antigen, time-resolved fluorescence immunoassay. Aggerbeck H, et al. **J Immunol Methods** 1996 Apr 19;190(2):171–83

A quantitative ELISA for antigen-specific IgG subclasses using equivalence dilutions of anti-kappa and anti-subclass specific secondary reagents. Application to the study of the murine immune response against the capsular polysaccharide of Neisseria meningitidis serogroup B. Colino J, et al. **J Immunol Methods** 1996 Apr 19; 190(2):221–34

Simple determination of polysaccharide specific antibodies by means of chemically modified ELISA plates. Zielen S, et al. **J Immunol Methods** 1996 Jun 14;193(1):1–7

Quantitative determination of antibodies to type III group B streptococcal polysaccharide. Guttormsen HK, et al. **J Infect Dis** 1996 Jan;173(1):142–50

Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents. Mitchell LA, et al. **J Infect Dis** 1996 Apr;173(4):1009–13

A modified Farr assay is more specific than ELISA for measuring antibodies to Streptococcus pneumoniae capsular polysaccharides. Nahm MH, et al. **J Infect Dis** 1996 Jan;173(1):113–8

Analysis of naturally occurring antibodies to mucoid Pseudomonas aeruginosa in cystic fibrosis patients [letter; comment] Pier GB. **J Infect Dis** 1996 Feb;173(2):513–5. Comment on: J Infect Dis 1995 Aug;172(2):453–61.

Nasopharyngeal antibodies to pneumococcal capsular polysaccharides in children with acute otitis media. Virolainen A, et al. **J Infect Dis** 1995 Oct;172(4):1115–8

Development and evaluation of an ELISA to detect Escherichia coli K88 (F4) fimbrial antibody levels. Vazquez F, et al. **J Med Microbiol** 1996 Jun;44(6):453–63

Electrophysiological studies in Guillain-Barré syndrome: correlation with antibodies to GM1, GD1B and Campylobacter jejuni. Vriesendorp FJ, et al. **J Neurol** 1995 Jul;242(7):460–5

Occurrence of Actinobacillus actinomycetemcomitans and anti-leukotoxin antibodies in some members of an extended family affected by Papillon-Lefèvre syndrome. Stabholz A, et al. **J Periodontol** 1995 Jul;66(7):653–7

IgG ELISA antibodies and detection of Helicobacter pylori in elderly patients [letter; comment] Liston R, et al. **Lancet** 1996 Jan 27;347(8996):269. Comment on: Lancet 1995 Nov 18;346(8986):1315–8.

Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine [letter; comment] Obaro SK. **Lancet** 1996 Jan 20;347(8995):192–3 . Comment on: Lancet 1995 Nov 11;346(8985):1252–7.

Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine [see comments] Shahid NS, et al. **Lancet** 1995 Nov 11;346(8985):1252–7. Comment in: Lancet 1996 Jan 20;347(8995):192–3.

IgG ELISA antibodies and detection of Helicobacter pylori in elderly patients. Italian Helicobacter pylori Study Group [letter; comment] Vaira D, et al. **Lancet** 1996 Jan 27; 347(8996):269–70. Comment on: Lancet 1995 Nov 18;346(8986):1315–8.

Prevalence of antibodies to Borrelia spirochetes among wild small rodents in central and western Japan. Ishiguro F, et al. **Microbiol Immunol** 1995;39(6):419–24

Tick bites, clinical symptoms of Lyme borreliosis, and Borrelia antibody responses in Finnish army recruits training in an endemic region during summer. Oksi J, et al. **Mil Med** 1995 Sep;160(9):453–6

Helicobacter pylori antibodies in patients on chronic hemodialysis [letter] Seyrek N, et al. **Nephron** 1996; 72(4):725–6

The use of surface immunofluorescence assay (SIFA) in the microbiological diagnosis of Lyme borreliosis: a case report. Sambri V, et al. **New Microbiol** 1995 Jul; 18(3):307–10

Cluster of five children with acute encephalopathy associated with cat-scratch disease in south Florida. Noah DL, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):866–9

Shigella lipopolysaccharide antibodies in pediatric populations. Passwell JH, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):859–65

Distribution of antibody titres against phenolic glycolipids from Mycobacterium tuberculosis in the sera from tuberculosis patients and healthy controls. Watanabe M, et al. **Res Microbiol** 1995 Nov-Dec;146(9):791–7

Detection of antibodies to Staphylococcus aureus in water buffalo milk by flow cytometry. D'Apice L, et al. **Res Vet Sci** 1996 Mar;60(2):179–81

Presence of antigen and antibodies in serum and genital discharges of cows from dairy herds naturally infected with Leptospira interrogans serovar hardjo. Dhaliwal GS, et al. **Res Vet Sci** 1996 Mar;60(2):163–7

Is Helicobacter pylori infection a real risk factor for gastric carcinoma? Muszyński J, et al. **Scand J Gastroenterol** 1995 Jul;30(7):647–51

Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. Isacson J, et al. **Scand J Infect Dis** 1995;

27(3):273–7

Development and preliminary evaluation of an IgM dot–immunobinding assay (IgM–DIA) for rapid serodiagnosis of scrub typhus infection. Koay AS, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):350–3

Sensitivity of SL–IV and PPD for sero–diagnosis of tuberculosis in HIV seronegative and HIV–infected persons [letter] Fonseca LS, et al. **Tuber Lung Dis** 1995 Oct; 76(5):471–2

Diagnostic utility of the estimation of mycobacterial Antigen A60 specific immunoglobulins IgM, IgA and IgG in the sera of cases of adult human tuberculosis. Gupta S, et al. **Tuber Lung Dis** 1995 Oct;76(5):418–24

Comparative performance of the enzyme–linked immunosorbent assay (ELISA) and conventional assays in the diagnosis of bovine brucellosis in Argentina. Saravi MA, et al. **Vet Immunol Immunopathol** 1995 Jul; 47(1–2):93–9

Evaluation of SEF14 fimbrial dot blot and flagellar western blot tests as indicators of Salmonella enteritidis infection in chickens. Cooper GL, et al. **Vet Rec** 1996 Feb 17; 138(7):149–53

Detection of antibodies to Salmonella enteritidis in sera and yolks from experimentally and naturally infected chickens. Desmidt M, et al. **Vet Rec** 1996 Mar 9;138(10):223–6

Diagnosis of Brucella ovis infection of rams with an ELISA using protein G as conjugate. Ficapal A, et al. **Vet Rec** 1995 Aug 5;137(6):145–7

Evaluation of an O–antigen ELISA for screening cattle herds for Salmonella typhimurium. Hoorfar J, et al. **Vet Rec** 1995 Oct 7;137(15):374–9

Copro–antibody in calves from dams vaccinated against Salmonella typhimurium. Staak C, et al. **Zentralbl Veterinarmed [B]** 1995 Oct;42(8):493–502

[Development of a sandwich ELISA for detection of specific antibodies against fimbrial antigens K88, K99 and 987p of Escherichia coli] Jäkel C. **Berl Munch Tierarztl Wochenschr** 1995 Jun;108(6):221–3 (Eng. Abstr.) **(Ger)**

[Detection of chlamydial antibodies by immunoblotting technique—in comparison of three commercially available test kits and micro–IF] Komoda T, et al. **Kansenshogaku Zasshi** 1996 Mar;70(3):232–8 (Eng. Abstr.) **(Jpn)**

[Axonal Guillain–Barré syndrome associated with anti–GalNAc–GD1a antibody subsequent to Campylobacter jejuni (PEN 43) enteritis] Ihara Y, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):901–3 (Eng. Abstr.) **(Jpn)**

[Evaluation of conventional and new generation tests for testing the humeral response to Mycoplasma pneumoniae antigens in natural infection in humans. III Use of ELISA, complement fixation and immunoelectroprecipitation tests in diagnosis of Mycoplasma pneumoniae infections—comparative analysis] Rastawicki W. **Med Dosw Mikrobiol** 1995;47(1–2):77–88 (Eng. Abstr.) **(Pol)**

[Diagnostic value of the latex test (Pyloriset) for detection of Helicobacter pylori antibodies in adult patients with upper digestive tract diseases] Zaremba M, et al. **Med Dosw Mikrobiol** 1995;47(1–2):11–6 (Eng. Abstr.) **(Pol)**

[Monoclonal antibodies in the differentiation of Pseudomonas mallei and Pseudomonas pseudomallei] Iakovleva IV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec; (6):14–5 **(Rus)**

[Determination of antibody kinetics in Mediterranean spotted fever using the Weil–Felix agglutination test, complement fixation and indirect immunofluorescence] Punda–Polić V, et al. **Lijec Vjesn** 1995 Mar–Apr;117(3–4):73–6 (Eng. Abstr.) **(Scr)**

[IgG antibodies to Borrelia in dogs in the area of Kolice] Štefančíková A, et al. **Vet Med (Praha)** 1996 Mar;41(3):83–6 (Eng. Abstr.) **(Slo)**

BIOSYNTHESIS

Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin. Kimura M, et al. **Acta Paediatr Jpn** 1995 Oct;37(5):562–74

Humoral immune response against Salmonella typhimurium antigen fractions and protection. Calderon GM, et al. **Adv Exp Med Biol** 1995;371B:1659–62

Oral immunization induces humoral and cell–mediated immunity and protects germ–free mice against infection from Helicobacter felis. Czinn SJ, et al. **Adv Exp Med Biol** 1995;371B:1645–8

Development of IgE antibodies and T cell reactivity against intestinal bacterial antigens in rats and the influence of feeding. Dahlman A, et al. **Adv Exp Med Biol** 1995; 371A:497–500

A comparative study of the immune response to poly–[alpha(2—>8)–N–acetyl neuraminic acid] Diaz Romero J, et al. **Adv Exp Med Biol** 1995;371A:543–8

Factors influencing the fate of Escherichia coli and Salmonella typhimurium in germ–free piglets and rats. Diabac V, et al. **Adv Exp Med Biol** 1995;371A:473–7

Alterations of GALT due to malnutrition and decrease in the secretory immune response to cholera toxin. Fló J, et al. **Adv Exp Med Biol** 1995;371A:513–5

The antibody response in infants after oral administration of inactivated and living E. coli vaccines and their protective effect against nosocomial infections. Lodinová–Zádníková R, et al. **Adv Exp Med Biol** 1995; 371B:1431–8

Development of mucosal humoral immune responses in germ–free (GF) mice. Shroff KE, et al. **Adv Exp Med Biol** 1995;371A:441–6

Specific immune responses of dairy cattle after primary inoculation with recombinant bovine interferon–gamma as an adjuvant when vaccinating against mastitis. Pighetti GM, et al. **Am J Vet Res** 1996 Jun;57(6):819–24

Preimmunization and postimmunization pneumococcal antibody titers in children with recurrent infections. Hidalgo H, et al. **Ann Allergy Asthma Immunol** 1996 Apr; 76(4):341–6

Isotype–specific antibody responses to acute Mycoplasma pneumoniae infection. Seggev JS, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):67–73

Induction of antibodies against Salmonella typhi OmpC porin by naked DNA immunization. López–Macías C, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:285–8

The antibody response after immunization with pneumococcal polysaccharide vaccine in splenectomized mice: the effect of re–immunization with pneumococcal antigens. Aaberge IS, et al. **APMIS** 1996 Apr;104(4):307–17

Antibody response to polyribosyl–ribitol phosphate antigen of Haemophilus influenzae in Ecuadorian and German children. Brüssow H, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):21–5

Q fever serology: cutoff determination for microimmunofluorescence. Dupont HT, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):189–96

Age–dependent humoral responses of children to mycobacterial antigens. Fairchok MP, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):443–7

Lack of antibody response to invasin in humans with yersiniosis. Fortineau N, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):235–7

Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease. Granoff DM, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):574–82

Serum antibody responses of divers to waterborne pathogens. Losonsky GA, et al. **Clin Diagn Lab Immunol** 1994 Mar; 1(2):182–5

Immune response in the lungs following oral immunization with bacterial lysates of respiratory pathogens. Ruedl C, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):150–4

Human antibody response to a pneumococcal vaccine in SCID–PBL–hu mice and simultaneously vaccinated human cell donors. Aaberge IS, et al. **Clin Exp Immunol** 1996 Jul; 105(1):12–7

Autoantibodies to human heat shock protein (hsp)60 may be induced by Escherichia coli groEL. Handley HH, et al. **Clin Exp Immunol** 1996 Mar;103(3):429–35

Are polysaccharide antibody responses independent: the T cell enigma? Lane P. **Clin Exp Immunol** 1996 Jul; 105(1):10–1 (16 ref.)

Immune responsiveness in Mycobacterium avium–infected mice: changes in the proportion of T cell subsets and antibody production during the course of infection. Xu DL, et al. **Clin Exp Immunol** 1995 Dec;102(3):523–8

Vitamin A deficiency and retinoid repletion regulate the antibody response to bacterial antigens and the maintenance of natural killer cells. Ross AC. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S63–72

Immune responses to the capsular polysaccharide of Mycoplasma dispar in calves and mice. Bansal P, et al. **Comp Immunol Microbiol Infect Dis** 1995 Sep;18(4):259–68

Immune response to Chlamydia trachomatis heat–shock protein in infertile female patients and influence of Chlamydia pneumoniae antibodies. Freidank HM, et al. **Eur J Clin Microbiol Infect Dis** 1995 Dec;14(12):1063–9

Modulation of immunity to Borrelia burgdorferi by ultraviolet irradiation: differential effect on Th1 and Th2 immune responses. Brown EL, et al. **Eur J Immunol** 1995 Nov;25(11):3017–22

Deficient antipneumococcal polysaccharide responses in HIV–seropositive patients. Loeliger AE, et al. **FEMS Immunol Med Microbiol** 1995 Sep;12(1):33–41

Effect of Brucella abortus transfer factor in preventing murine brucellosis. Stevens MG, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):279–84

Polyclonal activation of human lymphocytes by Bacillus firmus and its constituents. Prokešová L, et al. **Folia Microbiol (Praha)** 1995;40(6):647–51

Expression and functional characterisation of the clpC gene of Mycobacterium leprae: ClpC protein elicits human antibody response. Misra N, et al. **Gene** 1996 Jun 12; 172(1):99–104

In vivo treatment with anti–interleukin–13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice. Bost KL, et al. **Immunology** 1996 Apr;87(4):633–41

Induction of immune responses to functional determinants of a cell surface streptococcal antigen. Todryk SM, et al. **Immunology** 1996 Jan;87(1):55–63

Effects of ethyl carbamate and its metabolites on the antibody response in splenocyte cultures from female Balb/C mice. Jeong TC, et al. **Immunopharmacol Immunotoxicol** 1996 Feb;18(1):91–103

Induction of antigen–specific antibodies in vaginal secretions by using a nontoxic mutant of heat–labile enterotoxin as a mucosal adjuvant. Di Tommaso A, et al. **Infect Immun** 1996 Mar;64(3):974–9

P55, an immunogenic but nonprotective 55–kilodalton Borrelia burgdorferi protein in murine Lyme disease. Feng S, et al. **Infect Immun** 1996 Jan;64(1):363–5

Experimental immunization with Borrelia burgdorferi induces development of antibodies to gangliosides. Garcia–Monco JC, et al. **Infect Immun** 1995 Oct; 63(10):4130–7

Persistence of serum and salivary antibody responses after oral immunization with a bacterial protein antigen genetically linked to the A2/B subunits of cholera toxin. Hajishengallis G, et al. **Infect Immun** 1996 Feb;64(2):665–7

Colonization in the rectum and uterine cervix with group B streptococci may induce specific antibody responses in cervical secretions of pregnant women. Hordnes K, et al. **Infect Immun** 1996 May;64(5):1643–52

Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Rosenqvist E, et al. **Infect Immun** 1995 Dec;63(12):4642–52

Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit. Russell MW, et al. **Infect Immun** 1996 Apr;64(4):1272–83

An antigenic peptide inducing cross–reacting antibodies inhibiting the interaction of Streptococcus mutans PAc with human salivary components. Senpuku H, et al. **Infect Immun** 1995 Dec;63(12):4695–703

Commensal enteric bacteria engender a self–limiting humoral mucosal immune response while permanently colonizing the gut. Shroff KE, et al. **Infect Immun** 1995 Oct; 63(10):3904–13

Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. van der Voort ER, et al. **Infect Immun** 1996 Jul;64(7):2745–51

Increased antibody titers against mycobacterial heat–shock protein 65 in patients with vasculitis and arteriosclerosis. Gruber R, et al. **Int Arch Allergy Immunol** 1996 May; 110(1):95–8

In vivo and in vitro study of the primary and secondary antibody response to a bacterial antigen in aged mice. Borghesi C, et al. **Int J Exp Pathol** 1995 Dec;76(6):419–24

Anti–pneumococcal antibody response in normal subjects: a meta–analysis. Go ES, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):205–15

Antibody response to unconjugated Haemophilus influenzae b and pneumococcal polysaccharide vaccines in children with recurrent infections. Raby R, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):451–9

Serologic responses of dogs naturally exposed to or vaccinated against Borrelia burgdorferi infection. Barthold SW, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1435–40

Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. Avanzini MA, et al. **J Clin Immunol** 1995 May;15(3):137–44

Staphylococcus aureus Cowan I–induced human immunoglobulin responses: preferential IgM rheumatoid factor production and VH3 mRNA expression by protein A–binding B cells. Kozlowski LM, et al. **J Clin Immunol** 1995 May;15(3):145–51

Direct demonstration of antigenic substitution of Borrelia burgdorferi ex vivo: exploration of the paradox of the early immune response to outer surface proteins A and C in Lyme disease. Montgomery RR, et al. **J Exp Med** 1996 Jan 1;183(1):261–9

Protective antibodies in murine Lyme disease arise independently of CD40 ligand. Fikrig E, et al. **J Immunol** 1996 Jul 1;157(1):1–3

Production of a monoclonal antibody against the 128 kDa (CagA) protein of Helicobacter pylori. Stephens JC, et al. **J Immunol Methods** 1996 Apr 19;190(2):163–9

Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. Ahmed F, et al. **J Infect Dis** 1996 Jan;173(1):83–90

Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. Sankilampi U, et al. **J Infect Dis** 1996 Feb;173(2):387–93

Antibodies to meningococcal class 1 outer–membrane protein and its variable regions in patients with systemic meningococcal disease. Idänpään–Heikkilä I, et al. **J Med Microbiol** 1995 Nov;43(5):335–43

Antibody response in rabbits to serotype–specific determinants in lipopolysaccharides from Moraxella catarrhalis. Rahman M, et al. **J Med Microbiol** 1996 May; 44(5):348–54

Antibody response to Staphylococcus aureus collagen binding protein in patients with S. aureus septicaemia and collagen binding properties of corresponding strains. Ryding U, et al. **J Med Microbiol** 1995 Nov;43(5):328–34

Antigenicity of amino–acid sequences from Clostridium difficile toxin B. Torres JF, et al. **J Med Microbiol** 1996 Jun;44(6):464–74

Systemic and mucosal antibody responses to group B streptococci following immunization of the colonic–rectal mucosa. Hordnes K, et al. **J Reprod Immunol** 1995 Mar; 28(3):247–62

Immediate burn wound excision restores antibody synthesis

to bacterial antigen. Yamamoto H, et al. **J Surg Res** 1996 Jun;63(1):157–62

Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response. Murphy TF. **Microbiol Rev** 1996 Jun;60(2):267–79 (186 ref.)

Immune reactions to Bacteroides fragilis populations with three different types of capsule in a model of infection. Patrick S, et al. **Microbiology** 1995 Aug;141 (Pt 8):1969–76

The antimeningococcal vaccine VAMENGOC B–C induced poor serum and salivary antibody response in young Brazilian children. Carbonare SB, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):797–803

Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Halperin SA, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):792–7

Mechanism of UVB-induced suppression of the immune response to Mycobacterium bovis bacillus Calmette-Guerin: role of cytokines on macrophage function. Jeevan A, et al. **Photochem Photobiol** 1996 Aug; 64(2):259–66

Induction of humoral immune response to Salmonella typhimurium in mouse Peyer's patches. Camacho Villarreal NG, et al. **Rev Latinoam Microbiol** 1995 Apr–Jun; 37(2):153–60

Antibody response to Mycobacterium tuberculosis antigens in children with pulmonary tuberculosis and in BCG vaccinated non tuberculous pediatric patients. López de Arcila C, et al. **Rev Latinoam Microbiol** 1995 Apr–Jun; 37(2):161–9

Rates of seroconversion in the progeny of Brucella abortus seropositive and seronegative cattle and buffalo. Akhtar S, et al. **Rev Sci Tech** 1995 Sep;14(3):711–8

The antibody response to secondary immunization with pneumococcal polysaccharides in mice. Aaberge IS, et al. **Scand J Immunol** 1995 Dec;42(6):617–25

Humoral immune responses against particulate bacterial antigens are dependent on marginal metallophilic macrophages in the spleen. Buiting AM, et al. **Scand J Immunol** 1996 Apr;43(4):398–405

Intranasal inoculation of Bordetella bronchiseptica in mice induces long-lasting antibody and T-cell mediated immune responses. Gueirard P, et al. **Scand J Immunol** 1996 Feb; 43(2):181–92

Humoral immune response in infants after Bacillus Calmette-Guerin (BCG) vaccination [letter] Grange JM, et al. **Tuber Lung Dis** 1996 Feb;77(1):98

Effective antibody response in newborn babies living in Maldives to simultaneous vaccination against hepatitis B, poliomyelitis, diphtheria and tetanus. Da Villa G, et al. **Vaccine** 1995 Jun;13(9):795–8

Human antibody response to meningococcal transferrin binding proteins: evidence for vaccine potential. Gorringe AR, et al. **Vaccine** 1995 Sep;13(13):1207–12

The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis. Idänpään-Heikkilä I, et al. **Vaccine** 1995 Nov;13(16):1501–8

Immunoregulatory role of H-2 and intra-H-2 alleles on antibody responses to recombinant preparations of B-subunits of Escherichia coli heat-labile enterotoxin (rEtxB) and cholera toxin (rCtxB). Nashar TO, et al. **Vaccine** 1995 Jun;13(9):803–10

Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone. Samore MH, et al. **Vaccine** 1996 Mar;14(4):290–7

Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection. Su H, et al. **Vaccine** 1995 Aug;13(11):1023–32

Serum antibody responses of cattle to iron-regulated outer membrane proteins of Pasteurella haemolytica A1. Confer AW, et al. **Vet Immunol Immunopathol** 1995 Jul; 47(1–2):101–10

Study of the humoral response of Atlantic salmon (Salmo salar L.), naturally infected with Aeromonas salmonicida ssp. achromogenes. Magnadóttir B, et al. **Vet Immunol Immunopathol** 1995 Nov;49(1–2):127–42

Production and characterization of monoclonal antibodies against Actinobacillus pleuropneumoniae serotype 1. Lairini K, et al. **Vet Microbiol** 1995 Oct;46(4):369–81

Vaccination of grasscutters with a multicomponent clostridial vaccine. Younan M, et al. **Zentralbl Veterinarmed [B]** 1995 Aug;42(6):369–75

[Development of humoral precipitating antibodies to Campylobacter spp. in chickens] Glünder G. **Zentralbl Veterinarmed [B]** 1995 Apr;42(2):89–99 (Eng. Abstr.) **(Ger)**

[Antibody to Bacillus megaterium H. glycoprotein in pregnant women with a pathological course of pregnancy] Autenshlius AI, et al. **Biull Eksp Biol Med** 1995 Aug; 120(8):203–5 **(Rus)**

BLOOD

Antibodies to spotted fever group rickettsiae and Coxiella burnetii among domestic animals in southern Croatia. Punda-Polić V, et al. **Acta Microbiol Immunol Hung** 1995; 42(4):339–44

Differences in secretory IgA and serum antibodies to Streptococcus mutans isolates from caries-resistant and caries-susceptible subjects. Gregory RL, et al. **Adv Exp Med Biol** 1995;371B:1149–52

An assessment of a new diagnostic indirect enzyme immunoassay for the detection of anti-Mycoplasma pneumoniae IgM. Cimolai N, et al. **Am J Clin Pathol** 1996 Feb;105(2):205–9

Seroprevalence of immunoglobulin G, M, and A antibodies to Helicobacter pylori in an unselected Danish population. Andersen LP, et al. **Am J Epidemiol** 1996 Jun 1; 143(11):1157–64

Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Aromaa A, et al. **Am J Epidemiol** 1996 Jul 15;144(2):142–9

Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines. Clemens J, et al. **Am J Epidemiol** 1995 Oct 1; 142(7):759–64

Biologic sex as a risk factor for Helicobacter pylori infection in healthy young adults. Replogle ML, et al. **Am J Epidemiol** 1995 Oct 15;142(8):856–63

Long-term follow-up of Helicobacter pylori serology after successful eradication. Cutler AF, et al. **Am J Gastroenterol** 1996 Jan;91(1):85–8

Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country. Mitchell HM, et al. **Am J Gastroenterol** 1996 Sep;91(9):1785–8

Experimental recurrent otitis media induced by Haemophilus influenzae: protection and serum antibodies. Melhus A, et al. **Am J Otolaryngol** 1995 Nov–Dec;16(6):383–90

Autoimmunity in chronic active Helicobacter hepatitis of mice. Serum antibodies and expression of heat shock protein 70 in liver. Ward JM, et al. **Am J Pathol** 1996 Feb; 148(2):509–17

Unrecognized spotted fever group rickettsiosis masquerading as dengue fever in Mexico. Zavala-Velazquez JE, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):157–9

Serum neutralizing antibody response and protection against experimentally induced liver abscesses in steers vaccinated with Fusobacterium necrophorum. Saginala S, et al. **Am J Vet Res** 1996 Apr;57(4):483–8

Preimmunization and postimmunization pneumococcal antibody titers in children with recurrent infections. Hidalgo H, et al. **Ann Allergy Asthma Immunol** 1996 Apr; 76(4):341–6

Seroprevalence of tetanus antibodies among adults older than 65 years. Alagappan K, et al. **Ann Emerg Med** 1996 Jul; 28(1):18–21

Role of enteric bacteria in the pathogenesis of rheumatoid arthritis: evidence for antibodies to enterobacterial common antigens in rheumatoid sera and synovial fluids. Aoki S, et al. **Ann Rheum Dis** 1996 Jun;55(6):363–9

Increased levels of serum IgM antibody to staphylococcal enterotoxin B in patients with rheumatoid arthritis. Origuchi T, et al. **Ann Rheum Dis** 1995 Sep;54(9):713–20

Chlamydia trachomatis antibodies in serum and ejaculate of male patients without acute urethritis. Ludwig M, et al. **Ann Urol (Paris)** 1996;30(3):139–46

Thermophilic actinomycetes in cane sugar mills: an aeromicrobiologic and seroepidemiologic study. Khan ZU, et al. **Antonie Van Leeuwenhoek** 1995;67(4):339–44

Antibodies to Helicobacter pylori in dyspeptic patients, asymptomatic adults, and children from Costa Rica. Bartels G, et al. **APMIS** 1995 Jun;103(6):428–32

Seroepidemiological study of Helicobacter pylori infection in infancy. Ashorn M, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar;74(2):F141–2

Meningococcal antibody titres in infants of women immunised with meningococcal polysaccharide vaccine during pregnancy. O'Dempsey TJ, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jan;74(1):F43–6

Proficiency testing program for Lyme disease [letter; comment] Seder RH, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):323–5. Comment on: Arch Pathol Lab Med 1994 May;118(5):501–5.

Response of human immunodeficiency virus-exposed and -infected infants to Haemophilus influenzae type b conjugate vaccine. Rutstein RM, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):838–41

Comparison of enzyme-linked immunosorbent assay and hemagglutination-inhibition for detection of antibody to Mycoplasma gallisepticum in commercial broiler, fair and exhibition, and experimentally infected birds. Ewing ML, et al. **Avian Dis** 1996 Jan–Mar;40(1):13–22

The value of isotype determination of serum antibodies against Chlamydia for the diagnosis of Chlamydia reactive arthritis. Bas S, et al. **Br J Rheumatol** 1996 Jun;35(6):542–7

Similarly increased serum IgA1 and IgA2 subclass antibody levels against Klebsiella pneumoniae bacteria in ankylosing spondylitis patients with/without extra-articular features. Mäki-Ikola O, et al. **Br J Rheumatol** 1996 Feb;35(2):125–8

Antibodies to four gram-negative bacteria in rheumatoid arthritis which share sequences with the rheumatoid arthritis susceptibility motif. Tiwana H, et al. **Br J Rheumatol** 1996 Jun;35(6):592–4

Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia. Concha A, et al. **Bull Pan Am Health Organ** 1995 Dec;29(4):312–21

Tissue reaction and immunity in swine immunized with Actinobacillus pleuropneumoniae vaccines. Willson PJ, et al. **Can J Vet Res** 1995 Oct;59(4):299–305

Evaluation of dogs as sero-indicators of the geographic distribution of Lyme borreliosis in British Columbia. Banerjee S, et al. **Can Vet J** 1996 Mar;37(3):168–9

Serum antibody response to the superficial and released components of Helicobacter pylori. Bazillou M, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):310–7

Maternal antibodies and acquired serological response to Moraxella catarrhalis in children determined by an enzyme-linked immunosorbent assay. Ejlertsen T, et al. **Clin Diagn Lab Immunol** 1994 Jul;1(4):464–8

Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Grimprel E, et al. **Clin Diagn Lab Immunol** 1996 Jan; 3(1):93–7

Antibody response to Prevotella spp. in patients with ventilator-associated pneumonia. Grollier G, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):61–5

Enzyme-linked immunosorbent assay using a recombinant baculovirus-expressed Bacillus anthracis protective antigen (PA): measurement of human anti-PA antibodies. Iacono-Connors LC, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):78–82

Detection of borreliacidal antibody by using acridine orange and flow cytometry. Lim LC, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):44–50

Differentiation of borreliacidal activity caused by immune serum or antimicrobial agents by flow cytometry. Liu YF, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):145–9

Correlation between serological and mucosal inflammatory responses to Helicobacter pylori. Pérez-Pérez GI, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):325–9

Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Quataert SA, et al. **Clin Diagn Lab Immunol** 1995 Sep; 2(5):590–7

Cattle serologically positive for Brucella abortus have antibodies to B. abortus Cu-Zn superoxide dismutase. Tabatabai LB, et al. **Clin Diagn Lab Immunol** 1994 Sep; 1(5):506–10

Nasopharyngeal antibodies to pneumococcal pneumolysin in children with acute otitis media. Virolainen A, et al. **Clin Diagn Lab Immunol** 1995 Nov;2(6):704–7

Helicobacter pylori infections in IgA deficiency: lack of role for the secretory immune system. Bogstedt AK, et al. **Clin Exp Immunol** 1996 Aug;105(2):202–4

Pneumococcal antibody responses in elite swimmers. Gleeson M, et al. **Clin Exp Immunol** 1996 Aug;105(2):238–44

Circulating IgA, IgG, and IgM class antibody against Haemophilus parainfluenzae antigens in patients with IgA nephropathy. Suzuki S, et al. **Clin Exp Immunol** 1996 May; 104(2):306–11

Prevalence of antibodies to Coxiella burnetti, Rickettsia conorii, and Rickettsia typhi in seven African countries. Dupont HT, et al. **Clin Infect Dis** 1995 Nov;21(5):1126–33

Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Konradsen HB. **Clin Infect Dis** 1995 Sep; 21(3):616–20

Serum responses of cats with periodontal/gingival disease to members of the genus Porphyromonas. Norris JM, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S314–6

Bartonella (Rochalimaea) antibodies, dementia, and cat ownership among men infected with human immunodeficiency virus. Schwartzman WA, et al. **Clin Infect Dis** 1995 Oct;21(4):954–9

Evaluation of the response of human humoral antibodies to Salmonella typhi lipopolysaccharide in an area of endemic typhoid fever. Shaheen HI, et al. **Clin Infect Dis** 1995 Oct; 21(4):1012–3

Evaluation of different serological tests for detection of antibodies against Serpulina hyodysenteriae in pig sera. Diarra AT, et al. **Comp Immunol Microbiol Infect Dis** 1995 Jun;18(3):215–21

Determination of protective erysipelas antibodies in pig and mouse sera as possible alternatives to the animal challenge models currently used for potency tests. Beckmann R, et al. **Dev Biol Stand** 1996;86:326

Antibodies that react with the capsular polysaccharide of Vibrio vulnificus are detectable in infected patients, and in persons without known exposure to the organism. Fiore A, et al. **Diagn Microbiol Infect Dis** 1996 Mar;24(3):165–7

New noninvasive tests for Helicobacter pylori gastritis. Comparison with tissue-based gold standard. Faigel DO, et al. **Dig Dis Sci** 1996 Apr;41(4):740–8

High seroprevalence of Helicobacter pylori in diabetes mellitus patients. Oldenburg B, et al. **Dig Dis Sci** 1996 Mar; 41(3):458–61

Prevalence of Helicobacter pylori infection and chronic dyspeptic symptoms among immigrants from developing countries and people born in industrialized countries. Verdú EF, et al. **Digestion** 1996;57(3):180–5

Salmonella typhi and Salmonella paratyphi antibodies in Kenya [see comments] Jumba MM, et al. **East Afr Med J** 1995 Dec;72(12):755–7. Comment in: East Afr Med J 1995 Dec;72(12):753–4.

Diagnosis and over diagnosis of typhoid fever [editorial; comment] Mirza NB. **East Afr Med J** 1995 Dec; 72(12):753–4. Comment on: East Afr Med J 1995 Dec;72(12):755–7.

Differing antibody responses to Haemophilus influenzae type b after meningitis or epiglottitis. Johnson PD, et al. **Epidemiol Infect** 1996 Feb;116(1):21–6

Borrelia burgdorferi infection in UK horses [see comments] Carter SD, et al. **Equine Vet J** 1994 May;26(3):187–90. Comment in: Equine Vet J 1994 May;26(3):175–7.

Enzyme immunoassay for detection of antibodies against isolated flagella of Legionella pneumophila. Neumeister B, et al. **Eur J Clin Microbiol Infect Dis** 1995 Sep;14(9):764–7

Analysis of the immunological humoral response to Mycobacterium tuberculosis glycolipid antigens (DAT, PGLTb1) for diagnosis of tuberculosis in HIV-seropositive and -seronegative patients. Simonney N, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):883–91

Serology to Bartonella (Rochalimaea) henselae may replace traditional diagnostic criteria for cat-scratch disease. Nadal D, et al. **Eur J Pediatr** 1995 Nov;154(11):906–8

Serological diagnosis of tuberculosis. Bothamley GH. **Eur Respir J Suppl** 1995 Sep;20:676s–688s (114 ref.)

Concentration and avidity of anti-tetanus antibodies in mother-infant pairs: relation to immunization time. Abacioğlu YH, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):273–7

Antibiotic treatment induces an increase of the specific antibody levels in Brucella melitensis infected mice. Domingo S, et al. **FEMS Immunol Med Microbiol** 1995 Oct;12(2):91–5

Production and identification of recombinant proteins of Salmonella typhimurium and their use in detection of antibodies in experimentally challenged animals. Kwang J, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):25–30

Does serologic evidence of remote Chlamydia trachomatis infection and its heat shock protein (CHSP 60) affect in vitro fertilization-embryo transfer outcome? [see comments] Claman P, et al. **Fertil Steril** 1996 Jan; 65(1):146–9. Comment in: Fertil Steril 1996 Jun;65(6):1263–5.

Prospective screening of dyspeptic patients by Helicobacter pylori serology. Tham TC, et al. **Gastrointest Endosc** 1996 May;43(5):532–4

Effect of intestinal resection on serum antibodies to the mycobacterial 45/48 kilodalton doublet antigen in Crohn's disease. Kreuzpaintner G, et al. **Gut** 1995 Sep;37(3):361–6

The occurrence of natural antibodies to minimal component of bacterial cell wall (N-acetylglucosaminyl-N-acetylmuramyl dipeptide) in sera from healthy humans. Pinegin BV, et al. **Immunol Lett** 1995 Jul-Aug;47(1–2):33–7

Fractionation, analysis and diagnostic utility of Mycobacterium tuberculosis H37Ra excretory-secretory antigen in pulmonary tuberculosis. Lodam AN, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):66–71

Antibody response to outer membrane proteins in Shigella dysenteriae type 1 infection with special reference to appearance of murine antibodies. Chakrabarti S, et al. **Indian J Med Res** 1996 Jul;104:142–7

Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier. Barzu S, et al. **Infect Immun** 1996 Apr;64(4):1190–6

Defining antibody targets in Streptococcus oralis infection. Burnie JP, et al. **Infect Immun** 1996 May;64(5):1600–8

Chronic respiratory mycoplasmosis in C3H/HeN and C57BL/6N mice: lesion severity and antibody response. Cartner SC, et al. **Infect Immun** 1995 Oct;63(10):4138–42

Evaluation of humoral and cell-mediated inducible immunity to Haemophilus ducreyi in an animal model of chancroid. Desjardins M, et al. **Infect Immun** 1996 May;64(5):1778–88

In vivo induction of apoptosis and immune responses in mice by administration of lipopolysaccharide from Porphyromonas gingivalis. Isogai E, et al. **Infect Immun** 1996 Apr;64(4):1461–6

Serum antibody responses of cattle following experimental infection with Escherichia coli O157:H7. Johnson RP, et al. **Infect Immun** 1996 May;64(5):1879–83

Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Losonsky GA, et al. **Infect Immun** 1996 Jan;64(1):10–5

Characterization of the murine antibody response to peptides representing the variable domains of the major outer membrane protein of Chlamydia pneumoniae. Peterson EM, et al. **Infect Immun** 1996 Aug;64(8):3354–9

Antibody responses to Brucella abortus 2308 in cattle vaccinated with B. abortus RB51. Stevens MG, et al. **Infect Immun** 1996 Mar;64(3):1030–4

Serum antibodies to the components of diphtheria-tetanus-pertussis vaccine in Polish children related to vaccination status. Torbicka E, et al. **Infection** 1995 Jul-Aug;23(4):212–5

Specific serum IgA titres as realistic indicators of treatment prognoses. Landry RG. **Int Dent J** 1995 Aug;45(4):267–74

IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting. Klaamas K, et al. **Int J Cancer** 1996 Jul 3;67(1):1–5

Enhancement of antigen-specific antibody production by extracellular slime products from slime-forming Lactococcus lactis subspecies cremoris SBT 0495 in mice. Nakajima H, et al. **Int J Food Microbiol** 1995 Apr; 25(2):153–8

Analysis of T-cell and B-cell responses to recombinant M. leprae antigens in leprosy patients and in healthy contacts: significant T-cell responses to antigens in M. leprae nonresponders. Thole JE, et al. **Int J Lepr Other Mycobact Dis** 1995 Sep;63(3):369–80

The clinical usefulness of serum pepsinogens, specific IgG anti-HP antibodies and gastrin for monitoring Helicobacter pylori treatment in older people. Pilotto A, et al. **J Am Geriatr Soc** 1996 Jun;44(6):665–70

Evaluation of an agar gel immunodiffusion test kit for detection of antibodies to Mycobacterium paratuberculosis in sheep. Dubash K, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):401–3

Evidence for a high rate of false-positive results with the indirect fluorescent antibody test for Ehrlichia risticii antibody in horses. Madigan JE, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1448–53

An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. Thompson J, et al. **J Biol Chem** 1995 Nov 24;270(47):28037–41

Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing. Nakata H, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S118–20

Helicobacter pylori serology in chronic gastritis with antral atrophy and negative histology for Helicobacter-like organisms. Testoni PA, et al. **J Clin Gastroenterol** 1996 Apr;22(3):182–5

Myelin- and microbe-specific antibodies in Guillain-Barré syndrome. Terryberry J, et al. **J Clin Lab Anal** 1995; 9(5):308–19

Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. Aguero-Rosenfeld ME, et al. **J Clin Microbiol** 1996 Jan;34(1):1–9

Performance of Meridian ImmunoCard Mycoplasma test in a multicenter clinical trial. Alexander TS, et al. **J Clin Microbiol** 1996 May;34(5):1180–3

Characterization of a 17-kilodalton antigen of Bartonella henselae reactive with sera from patients with cat scratch disease. Anderson B, et al. **J Clin Microbiol** 1995 Sep; 33(9):2358–65

Nocardia species as an etiologic agent in Parkinson's disease: serological testing in a case-control study. Hubble JP, et al. **J Clin Microbiol** 1995 Oct;33(10):2768–9

Coexistence of antibodies to tick-borne pathogens of babesiosis, ehrlichiosis, and Lyme borreliosis in human sera. Magnarelli LA, et al. **J Clin Microbiol** 1995 Nov; 33(11):3054–7

Antibodies against whole sonicated Borrelia burgdorferi spirochetes, 41-kilodalton flagellin, and P39 protein in patients with PCR- or culture-proven late Lyme borreliosis. Oksi J, et al. **J Clin Microbiol** 1995 Sep; 33(9):2260–4

Sera from OspA-vaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi. Straubinger RK, et al. **J Clin Microbiol** 1995 Oct;33(10):2745–51

Development and application of enzyme-linked immunosorbent assay for specific detection of Salmonella enteritidis infections in chickens based on antibodies to SEF14 fimbrial antigen. Thorns CJ, et al. **J Clin Microbiol** 1996 Apr;34(4):792–7

Comparison of three commercially available enzyme-linked immunosorbent assays and biopsy-dependent diagnosis for detecting Helicobacter pylori infection. van de Wouw BA, et al. **J Clin Microbiol** 1996 Jan;34(1):94–7

Spectrotypic analysis of antibodies to Helicobacter pylori in patients with antral gastritis and duodenal ulcer. Biselli R, et al. **J Clin Pathol** 1995 Dec;48(12):1117–21

A practical single sample dry latex agglutination test for Helicobacter pylori antibody detection. Midolo PD, et al. **J Clin Pathol** 1995 Oct;48(10):969–71

Inverse relation of serum Helicobacter pylori antibody titres and extent of intestinal metaplasia. Osawa H, et al. **J Clin Pathol** 1996 Feb;49(2):112–5

Effect of periodontal treatments on serum IgG antibody titers against periodontopathic bacteria. Horibe M, et al. **J Clin Periodontol** 1995 Jul;22(7):510–5

Antibody responses to suspected periodontal pathogens in elderly subjects with periodontal disease. McArthur WP, et al. **J Clin Periodontol** 1995 Nov;22(11):842–9

Some suspected periodontopathogens and serum antibody response in adult long-duration insulin-dependent diabetics. Thorstensson H, et al. **J Clin Periodontol** 1995 Jun;22(6):449–58

Anti-Plesiomonas shigelloides agglutinating and complement-fixing antibody titres in normal individuals and diarrhoeal patients in Edo State, Nigeria. Ndip RN, et al. **J Diarrhoeal Dis Res** 1996 Mar;14(1):41–3

The pathogenic role of Bacteroides vulgatus in patients with ulcerative colitis. Bamba T, et al. **J Gastroenterol** 1995 Nov; 30 Suppl 8:45–7

The application of epitope mapping in the development of a new serological test for Helicobacter pylori infection. Burnie JP, et al. **J Immunol Methods** 1996 Jul 17; 194(1):85–94

Production of a monoclonal antibody against the 128 kDa (CagA) protein of Helicobacter pylori. Stephens JC, et al. **J Immunol Methods** 1996 Apr 19;190(2):163–9

The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1–65 years. Cattaneo LA, et al. **J Infect Dis** 1996 May;173(5):1256–9

Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. Dillner J, et al. **J Infect Dis** 1996 Jun; 173(6):1394–8

phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. Hohmann EL, et al. **J Infect Dis** 1996 Jun; 173(6):1408–14

Western blot analysis of anti-Escherichia coli serum immunoglobulins in women susceptible to recurrent urinary tract infections. Hopkins WJ, et al. **J Infect Dis** 1995 Dec; 172(6):1612–6

Prevalence of Bartonella henselae antibodies in pet cats throughout regions of North America. Jameson P, et al. **J Infect Dis** 1995 Oct;172(4):1145–9

Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. Käyhty H, et al. **J Infect Dis** 1995 Nov;172(5):1273–8

Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. Mascart-Lemone F, et al. **J Infect Dis** 1995 Nov;172(5):1253–60

Antibody-secreting cells and their relation to humoral antibodies in serum and in nasopharyngeal aspirates in children with pneumococcal acute otitis media. Nieminen T, et al. **J Infect Dis** 1996 Jan;173(1):136–41

IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. Rodriguez-Barradas MC, et al. **J Infect Dis** 1996 Jun;173(6):1347–53

Recall of original serologic response after challenge with homologous and heterologous Chlamydia trachomatis serovars. Zhao Q, et al. **J Infect Dis** 1996 Mar;173(3):609–18

The value of Helicobacter pylori IgG antibody in estimating the severity of gastritis in children. Sim JG, et al. **J Korean Med Sci** 1995 Oct;10(5):329–33

Immune response to Fusobacterium nucleatum and Prevotella intermedia in patients with infectious mononucleosis. Brook I, et al. **J Med Microbiol** 1996 Feb; 44(2):131–4

Serum antibody response to Staphylococcus aureus enterotoxins and TSST-1 in patients with septicaemia. Kanclerski K, et al. **J Med Microbiol** 1996 Mar;44(3):171–7

Helicobacter pylori seroprevalence and colorectal neoplasia: evidence against an association. Moss SF, et al. **J Natl Cancer Inst** 1995 May 17;87(10):762–3

Re: Helicobacter pylori and atrophic gastritis: importance of the cagA status [letter; comment] Ponzetto A, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):1000. Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):465–6.

Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration. Furth SL, et al. **J Pediatr** 1996 Jan; 128(1):99–101

Anti-pneumococcal antibody levels three to seven years after first booster immunization in children with sickle cell disease, and after a second booster. Rao SP, et al. **J Pediatr** 1995 Oct;127(4):590–2

Helicobacter pylori-specific IgM antibodies in children born to infected mothers [letter] Blecker U, et al. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):337–8

Reactive antibodies in sera from pubertal and adult gingivitis patients against various Porphyromonas gingivalis antigens. Nakagawa T, et al. **J Periodontal Res** 1995 Nov; 30(6):396–403

Evaluation of a commercial enzyme-linked immunosorbent assay for the diagnosis of paratuberculosis in dairy cattle. Sweeney RW, et al. **J Vet Diagn Invest** 1995 Oct; 7(4):488–93

Temporal association of Amblyomma americanum with the presence of Ehrlichia chaffeensis reactive antibodies in white-tailed deer. Lockhart JM, et al. **J Wildl Dis** 1995 Apr;31(2):119–24

Reactivity of white-footed mouse and raccoon sera to whole cell and recombinant antigens of Borrelia burgdorferi. Magnarelli LA, et al. **J Wildl Dis** 1995 Jul;31(3):339–44

Immunofluorescent titers in H. pylori [letter] Arain GM, et al. **JPMA J Pak Med Assoc** 1995 Sep;45(9):255

Induction of IgE antibody production in mice with different DPT-vaccine preparations. Naito S, et al. **Jpn J Med Sci Biol** 1995 Apr;48(2):117–22

Serological studies of Corynebacterium kutscheri and coryneform bacteria using an enzyme-linked immunosorbent assay (ELISA). Boot R, et al. **Lab Anim** 1995 Jul;29(3):294–9

An enzyme-linked immunosorbent assay (ELISA) for monitoring rodent colonies for Pasteurella pneumotropica antibodies. Boot R, et al. **Lab Anim** 1995 Jul;29(3):307–13

Protective immunity to Pasteurella multocida heat-labile toxin by intranasal immunization in rabbits. Suckow MA, et al. **Lab Anim Sci** 1995 Oct;45(5):526–32

Pseudomonas aeruginosa exotoxin A antibodies in rapidly deteriorating chronic leg ulcers [letter] Danielsen L, et al. **Lancet** 1996 Jan 27;347(8996):265

Melioidosis in India [letter] Kang G, et al. **Lancet** 1996 Jun 1;347(9014):1565–6

Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine [see comments] Shahid NS, et al. **Lancet** 1995 Nov 11;346(8985):1252–7.

Comment in: Lancet 1996 Jan 20;347(8995):192-3.
Human ehrlichiosis in the UK [letter] Sumption KJ, et al. **Lancet** 1995 Dec 2;346(8988):1487-8
Antisphingolipid antibodies in the sera of leprosy patients. Vemuri N, et al. **Lepr Rev** 1996 Jun;67(2):95-103
Seroepidemiological survey of Bartonella (Rochalimaea) henselae in domestic cats in Japan. Ueno H, et al. **Microbiol Immunol** 1995;39(5):339-41
Campylobacter jejuni infection and Guillain-Barre syndrome [letter; comment] Aguago JM, et al. **N Engl J Med** 1996 Mar 21;334(12):802. Comment on: N Engl J Med 1995 Nov 23;333(21):1374-9.
Diphtheria disaster relief [letter] Arya SC. **Nat Med** 1995 Sep;1(9):851-2
Antibodies to Borrelia burgdorferi in sheep and goats. Alto Adige-South Tyrol, Italy. Ciceroni L, et al. **New Microbiol** 1996 Apr;19(2):171-4
Serological prevalence of leptospiral antibodies in pigs in South Africa. Potts AD, et al. **Onderstepoort J Vet Res** 1995 Dec;62(4):281-4
Endogenous endotoxin-core antibody (EndoCAb) as a marker of endotoxin exposure and a prognostic indicator: a review. Barclay GR. **Prog Clin Biol Res** 1995;392:263-72 (20 ref.)
Antibodies against Mycobacterium paratuberculosis in Crohn's disease. Walmsley RS, et al. **QJM** 1996 Mar; 89(3):217-21
Presence of antigen and antibodies in serum and genital discharges of heifers after experimental intrauterine inoculation with Leptospira interrogans serovar hardjo. Dhaliwal GS, et al. **Res Vet Sci** 1996 Mar;60(2):157-62
Uses of serology for the diagnosis of contagious bovine pleuropneumonia. Rurangirwa FR. **Rev Sci Tech** 1995 Sep; 14(3):603-9 (30 ref.)
The specificity of the anti-Proteus antibody response in tissue-typed rheumatoid arthritis (RA) patients from Brest. Fielder M, et al. **Rheumatol Int** 1995;15(2):79-82
Seasonal prevalence of antibodies against Borrelia burgdorferi in Białowieża inhabitants. Flisiak R, et al. **Rocz Akad Med Bialymst** 1996;41(1):96-102
Prevalence of antibodies to Borrelia burgdorferi in European bison (bison bonasus) from Białowieża Primeval Forest. Siński E, et al. **Rocz Akad Med Bialymst** 1996;41(1):111-6
Cross-reactivity between Borrelia burgdorferi and "arthrogenic" bacteria in sera from patients with reactive arthritis. Sobieszczańska B, et al. **Rocz Akad Med Bialymst** 1996;41(1):90-5
Serum values of pepsinogens and antibodies to Helicobacter pylori in relation to a history of peptic ulcer disease and NSAID use. Janssen M, et al. **Scand J Rheumatol** 1995; 24(4):204-8
Association of antibodies to heat-shock protein-65 with percutaneous transluminal coronary angioplasty and subsequent restenosis. Mukherjee M, et al. **Thromb Haemost** 1996 Feb;75(2):258-60
Raised levels of agalactosyl IgG in childhood tuberculosis. Pilkington C, et al. **Trans R Soc Trop Med Hyg** 1996 Mar-Apr;90(2):167-8
A simple, quantitative, reproducible avidin-biotin ELISA for the evaluation of group B streptococcus type-specific antibodies in humans. Basham LE, et al. **Vaccine** 1996 Apr; 14(5):439-45
Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2. Johnson BJ, et al. **Vaccine** 1995 Aug; 13(12):1086-94
Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Klugman KP, et al. **Vaccine** 1996 Apr;14(5):435-8
Development of an alternative method for testing the immunogenicity of diphtheria vaccines. Manghi MA, et al. **Vaccine** 1995 Apr;13(6):597-601
Induction of pneumococcal polysaccharide-specific mucosal immune responses by oral immunization. VanCott JL, et al. **Vaccine** 1996 Apr;14(5):392-8
Susceptibility to Actinobacillus pleuropneumoniae infection in pigs from an endemically infected herd is related to the presence of toxin-neutralizing antibodies. Cruijsen T, et al. **Vet Microbiol** 1995 Dec;47(3-4):219-28
Cross-protection experiments in pigs vaccinated with Actinobacillus pleuropneumoniae subtypes 1A and 1B. Jolie RA, et al. **Vet Microbiol** 1995 Aug;45(4):383-91
Serological crossreactivity between Brucella abortus and Yersinia enterocolitica 0:9 I immunoblot analysis of the antibody response to Brucella protein antigens in bovine brucellosis. Kittelberger R, et al. **Vet Microbiol** 1995 Dec; 47(3-4):257-70
Serological crossreactivity between Brucella abortus and Yersinia enterocolitica 0:9 II the use of Yersinia outer proteins for the specific detection of Yersinia enterocolitica infections in ruminants. Kittelberger R, et al. **Vet Microbiol** 1995 Dec;47(3-4):271-80
The humoral immune response of turbot to recently isolated pathogenic Enterococcus strains. Cross-reactivity with other Gram-positive bacteria. Leiro J, et al. **Vet Microbiol** 1996 Jan;48(1-2):29-39
Serological response of cattle to Brucella allergen after repeated intradermal applications of this allergen. Muskens JA, et al. **Vet Microbiol** 1996 Jan;48(1-2):174-8
The serological response to Salmonella serovars typhimurium and infantis in experimentally infected pigs. The time course followed with an indirect anti-LPS ELISA and bacteriological examinations. Nielsen B, et al. **Vet Microbiol** 1995 Dec;47(3-4):205-18
Comparative evaluation of antibodies induced by commercial Pasteurella haemolytica vaccines using solid phase immunoassays. Srinand S, et al. **Vet Microbiol** 1996 Apr; 49(3-4):181-95
Infection of cattle with Yersinia enterocolitica O:9 a cause of the false positive serological reactions in bovine brucellosis diagnostic tests. Weynants V, et al. **Vet Microbiol** 1996 Jan;48(1-2):101-12
Prevalence and development of antibodies neutralizing the haemolysin and cytotoxin of Actinobacillus pleuropneumoniae in three infected pig herds. Cruijsen T, et al. **Vet Q** 1995 Sep;17(3):96-100
Residual anti-Brucella abortus strain 19 antibodies detected in adult cattle by two indirect-ELISA tests. Abalos P, et al. **Vet Rec** 1996 Feb 10;138(6):140
Survey of Ehrlichia canis antibodies among dogs in Israel. Baneth G, et al. **Vet Rec** 1996 Mar 16;138(11):257-9
Serum sensitivity and apathogenicity for chickens and chick embryos of Escherichia coli J5 strain. Abdul-Aziz TA, et al. **Vet Res** 1996;27(3):267-71
Enzyme-linked immunosorbent assay, complement fixation test and immunoelectroprecipitation test in the diagnosis of Mycoplasma pneumoniae infections--comparative analysis. Rastawicki W, et al. **Zentralbl Bakteriol** 1996 Apr; 283(4):477-84
Borrelia in pigeons: no serological evidence of Borrelia burgdorferi infection. Fabbi M, et al. **Zentralbl Veterinarmed [B]** 1995 Oct;42(8):503-7
[Relationship between Helicobacter pylori infection other factors and diffuse-and intestinal type stomach carcinomas] Li DG, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1995 Oct; 16(5):299-302 (Eng. Abstr.) (Chi)
[A new zoonosis--investigation of Gardnerella vaginalis disease of fox. IV. Study of dot-ELISA for the detection of serum antibody of Gardnerella vaginalis disease of fox] Yan X, et al. **Wei Sheng Wu Hsueh Pao** 1995 Aug; 35(4):287-91 (Eng. Abstr.) (Chi)
[Seroprevalence of Chlamydia trachomatis infection in STD consultants in Morocco] Takourt B, et al. **Bull Soc Pathol Exot** 1995 Mar;88(4):194-8 (Eng. Abstr.) (Fre)
[Cat scratch disease. Bartonella henselae antibodies and DNA detection in regional lymphadenopathy] Heizmann WR, et al. **Dtsch Med Wochenschr** 1996 May 10;121(19):622-6 (33 ref.) (Eng. Abstr.) (Ger)
[Effect of administration of blood products on the course of tetanus antibody concentration in immuno-incompetent patients] Pietsch M, et al. **Infusionsther Transfusionsmed** 1996 Feb;23(1):25-8 (Eng. Abstr.) (Ger)
[The microagglutination test--a simple and sensitive procedure for serodiagnosis of pertussis infections] Heininger U, et al. **Klin Padiatr** 1995 Sep-Oct; 207(5):277-80 (Eng. Abstr.) (Ger)
[Current status and diagnostic value of nucleic acid amplification and conventional methods in laboratory diagnosis of tuberculosis] Küchler R. **Pneumologie** 1996 Apr;50(4):323-6 (19 ref.) (Ger)
[The status in wild and zoo birds of antibodies to selected agents relevant to domestic animals] Ziedler K, et al. **Zentralbl Veterinarmed [B]** 1995 Aug;42(6):321-30 (Eng. Abstr.) (Ger)
[Eight cases of infection caused by the Streptococcus milleri group--significance of serum antibody titer and a comparative investigation of the backgrounds and factors of infections caused by Streptococcus milleri and Streptococcus pneumoniae] Kimura M, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):884-9 (Eng. Abstr.) (Jpn)
[Correlation between serum anti CagA antibody and gastric disease] Akimoto M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):69 (Jpn)
[Evaluation of conventional and new generation tests for testing the humeral response to Mycoplasma pneumoniae antigens in natural infection in humans. I. Occurrence and level of mycoplasma antibodies in clinically healthy subjects] Rastawicki W. **Med Dosw Mikrobiol** 1995; 47(1-2):35-53 (Eng. Abstr.) (Pol)
[Evaluation of conventional and new generation tests for testing the humeral response to Mycoplasma pneumoniae antigens in natural infections in humans. II. Occurrence and level of mycoplasma antibodies in patients with respiratory tract infections] Rastawicki W. **Med Dosw Mikrobiol** 1995;47(1-2):55-76 (Eng. Abstr.) (Pol)
[Seasonal prevalence of antibodies against Borrelia burgdorferi in Białowiez inhabitants] Flisiak R, et al. **Przegl Epidemiol** 1995;49(3):251-6 (Eng. Abstr.) (Pol)
[Clinical significance of detecting discrete antigens of group A Streptococcus and their antibodies in the blood of erysipelas patients] Cherkasov VL, et al. **Klin Med (Mosk)** 1995;73(4):97-8 (Rus)
[The diagnostic importance of determining tuberculosis antibodies by immunoenzyme analysis in exudative pleurisy] Uklistaia TA, et al. **Ter Arkh** 1996;68(3):71-3 (Eng. Abstr.) (Rus)
[The indices of interleukin 1, 2 and 4 production and the specific antibody titers in mice with an opposite sensitivity to staphylococcal infection] Averbakh MM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):79-81 (Eng. Abstr.) (Rus)
[The antibody spectrum after the inoculation of sensitive animals with Yersinia pestis and Yersinia pseudotuberculosis bacteria] Drobkov VI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):81-5 (Eng. Abstr.) (Rus)
[A comparative study by immunoblotting of the serological response in white mice and guinea pigs inoculated against plague] Nekliaev VN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):75-6 (Rus)
[An immunoenzyme method for detecting Brucella antibodies and antigen in the blood serum of animal breeders from farms with an unfavorable brucellosis situation] Podoliako MP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec;(6):53-4 (Rus)
[Chlamydia pneumoniae infection associated with autoimmune hemolytic anemia due to warm antibodies] Belda J, et al. **Arch Bronconeumol** 1996 May;32(5):251-2 (7 ref.) (Eng. Abstr.) (Spa)
[Significance of human leptospirosis in Mexico. Detection of Leptospira antibodies in a blood donor population] Gavaldón DG, et al. **Gac Med Mex** 1995 May-Jun; 131(3):289-92 (Eng. Abstr.) (Spa)

CEREBROSPINAL FLUID

Borreliosis as a cause of sudden deafness and vestibular neuritis in Sweden. Hydén D, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:320-2
Cognitive change after treatment for neurosyphilis. Correlation with CSF laboratory measures. Roberts MC, et al. **Gen Hosp Psychiatry** 1995 Jul;17(4):305-9
Value of clinical symptoms, intrathecal specific antibody production and PCR in CSF in the diagnosis of childhood Lyme neuroborreliosis. Issakainen J, et al. **Klin Padiatr** 1996 May-Jun;208(3):106-9
Detection of Borrelia burgdorferi-specific antigen in antibody-negative cerebrospinal fluid in neurologic Lyme disease. Coyle PK, et al. **Neurology** 1995 Nov;45(11):2010-5
Significance of mycobacterial immune complexes (IgG) in the diagnosis of tuberculous meningitis. Patil SA, et al. **Tuber Lung Dis** 1996 Apr;77(2):164-7
[The value of clinical and chemical laboratory follow-up parameters in neuroborreliosis] Koch J, et al. **Fortschr Neurol Psychiatr** 1995 Sep;63(9):358-62 (Eng. Abstr.) (Ger)

CHEMISTRY

Salmonella-specific monoclonal antibodies against recombinant Salmonella typhi 36-kilodalton porin. Kissel V, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):250-2
Blocking antibody assay for confirmation of urogenital Chlamydia infection. Nachamkin I, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):634-5
Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Quataert SA, et al. **Clin Diagn Lab Immunol** 1995 Sep; 2(5):590-7
Monoclonal antibodies to Coxiella burnetii that cross-react with strain Nine Mile. Sekeyová Z, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):531-4
Occurrence, in Crohn's disease, of antibodies directed against a species-specific recombinant polypeptide of Mycobacterium paratuberculosis. Vannuffel P, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):241-3
Farmer's lung: patients' IgG2 antibodies specifically recognize Saccharopolyspora rectivirgula proteins and carbohydrate structures. Mundt C, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):441-50
The pentameric structure of IgM is necessary to enhance opsonization of Bacteroides thetaiotaomicron and Bacteroides fragilis via the alternative complement pathway. Bjornson AB, et al. **Microb Pathog** 1995 Aug; 19(2):117-28
Molecular characterization of a monoclonal antibody produced in response to a group C meningococcal polysaccharide peptide mimic. Hutchins WA, et al. **Mol Immunol** 1996 Apr;33(6):503-10

DIAGNOSTIC USE

ELISA inhibition test using monoclonal antibody specific for Treponema pallidum as the serologic test for syphilis. Whang KK, et al. **Acta Derm Venereol** 1995 Sep;75(5):397-9
Development and testing of monoclonal antibody-based rapid immunodiagnostic test kits for direct detection of Vibrio cholerae O139 synonym Bengal. Hasan JA, et al. **J Clin Microbiol** 1995 Nov;33(11):2935-9
Evaluation and validation of a monoclonal immunofluorescent reagent for direct detection of Bordetella pertussis. McNicol P, et al. **J Clin Microbiol** 1995 Nov;33(11):2868-71
Monoclonal antibodies to detect capsular diversity among Bacteroides fragilis isolates. Pantosti A, et al. **J Clin Microbiol** 1995 Oct;33(10):2647-52

GENETICS

The immunoglobulin gene repertoire to Haemophilus

influenzae type b. Carroll WL, et al.
Ann N Y Acad Sci 1995 Sep 29;764:374–7

Patterns of V-region gene segment association in the human antibody response to Haemophilus influenzae type B capsular polysaccharide. Pinchuk GV, et al.
Ann N Y Acad Sci 1995 Sep 29;764:378–80

A defective Vkappa A2 allele in Navajos which may play a role in increased susceptibility to haemophilus influenzae type b disease. Feeney AJ, et al. **J Clin Invest** 1996 May 15;97(10):2277–82

Diverse VH and V kappa genes encode antibodies to Pseudomonas aeruginosa LPS. Emara MG, et al.
J Immunol 1995 Oct 15;155(8):3912–21

IMMUNOLOGY

Inhibition of enteropathogenic Escherichia coli (EPEC) adherence to HeLa cells by human colostrum. Detection of specific sIgA related to EPEC outer-membrane proteins. Cãmara LM, et al. **Adv Exp Med Biol** 1995;371A:673–6

Biological properties of yolk immunoglobulins. Janson AK, et al. **Adv Exp Med Biol** 1995;371A:685–90

Salivary specific antibodies in relation to adhesion of Streptococcus pyogenes to pharyngeal cells of patients with rheumatic fever and rheumatic heart disease. Kumar KS, et al. **Adv Exp Med Biol** 1995;371A:677–9

Intraperitoneal administration of tetanus toxoid elicits a specific response of antibody-secreting cells in the peritoneal cavity. Lue C, et al. **Adv Exp Med Biol** 1995; 371A:103–6

Structure-function studies of human monoclonal antibodies to pneumococcus type 3 polysaccharide. Shaw DR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:370–3

Bactericidal properties of Campylobacter jejuni-specific immunoglobulin M antibodies in commercial immunoglobulin preparations. Autenrieth IB, et al.
Antimicrob Agents Chemother 1995 Sep;39(9):1965–9

Production and characterization of monoclonal antibodies against the O-5 antigen of Salmonella typhimurium lipopolysaccharide. Jaradat ZW, et al.
Appl Environ Microbiol 1996 Jan;62(1):1–5

Chlamydial antibodies in women who suffer miscarriage. Osser S, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):137–41

Helicobacter pylori infection and serum IgG avidity [letter] Basso D, et al. **Clin Chim Acta** 1996 Feb 9;245(1):129–32

Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies. Verheul AF, et al. **Clin Diagn Lab Immunol** 1994 Nov;1(6):729–36

Anti-endotoxin human monoclonal antibody A6H4C5 (HA-1A) utilizes the VH4.21 gene. Bieber MM, et al.
Clin Infect Dis 1995 Oct;21 Suppl 2:S186–9

Cat-scratch disease, Bartonella henselae, and the usefulness of routine serological testing for Afipia felis [letter; comment] Patnaik M, et al. **Clin Infect Dis** 1995 Oct; 21(4):1064. Comment on: Clin Infect Dis 1994 Aug;19(2):355.

Preliminary studies on the effect of Anaplasma marginale antibodies ingested by Dermacentor andersoni ticks (Acari:Ixodidae) with their blood meal on infections in salivary glands. Kocan KM, et al. **Exp Appl Acarol** 1996 Jun;20(6):297–311

Antibody protection in aging: influence of idiotypic repertoire and antibody binding activity to a bacterial antigen. Nicoletti C. **Exp Mol Pathol** 1995 Apr;62(2):99–108

Deficient antipneumococcal polysaccharide responses in HIV-seropositive patients. Loeliger AE, et al.
FEMS Immunol Med Microbiol 1995 Sep;12(1):33–41

Passive immunization with monoclonal antibodies against Porphyromonas gingivalis in patients with periodontitis. Booth V, et al. **Infect Immun** 1996 Feb;64(2):422–7

The V-region repertoire of Haemophilus influenzae type b polysaccharide antibodies induced by immunization of infants. Chung GH, et al. **Infect Immun** 1995 Nov; 63(11):4219–23

Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Cotter TW, et al. **Infect Immun** 1995 Dec; 63(12):4704–14

Assembly and antigenicity of the Neisseria gonorrhoeae pilus mapped with antibodies. Forest KT, et al.
Infect Immun 1996 Feb;64(2):644–52

Monoclonal antibodies specific for the bundle-forming pilus of enteropathogenic Escherichia coli. Girón JA, et al.
Infect Immun 1995 Dec;63(12):4949–52

Monoclonal antibodies that recognize a common pneumococcal protein with similarities to streptococcal group A surface glyceraldehyde-3-phosphate dehydrogenase. Kolberg J, et al. **Infect Immun** 1996 Sep; 64(9):3544–7

Helicobacter pylori cytotoxin: importance of native conformation for induction of neutralizing antibodies. Manetti R, et al. **Infect Immun** 1995 Nov;63(11):4476–80

Identification of surface-exposed linear B-cell epitopes of the nonfimbrial adhesin CS31A of Escherichia coli by using overlapping peptides and antipeptide antibodies. Méchin MC, et al. **Infect Immun** 1996 Sep;64(9):3555–64

Immune response to Shigella sonnei in U.S. Marines. Mikhail MM, et al. **Infect Immun** 1996 Sep;64(9):3942–5

The galactosyl-(alpha 1-4)-galactose-binding adhesin of Streptococcus suis: occurrence in strains of different hemagglutination activities and induction of opsonic antibodies. Tikkanen K, et al. **Infect Immun** 1996 Sep; 64(9):3659–65

Antibodies to Haemophilus influenzae type b polysaccharide affect bacterial adherence and multiplication. van Alphen L, et al. **Infect Immun** 1996 Mar;64(3):995–1001

The nature of the immunogen determines the specificity of antibodies and T cells to selected peptides of the 38 kDa mycobacterial antigen. Vordermeier HM, et al.
Int Immunol 1995 Apr;7(4):559–66

IgG subclass recognition pattern in leprosy: recognition of M. leprae antigens by IgG1 and IgG3 antibodies is distinct across the disease spectrum. Kifayet A, et al.
Int J Lepr Other Mycobact Dis 1996 Mar;64(1):69–78

Intrathecal immune response in neuroborreliosis: importance of cross-reactive antibodies. Kaiser R.
Int J Med Microbiol Virol Parasitol Infect Dis 1995 Apr; 282(3):303–14

Antibodies against proteins of streptococcal hyaluronate synthase bind to human fibroblasts and are present in patients with rheumatic fever. Prehm S, et al. **J Anat** 1995 Oct;187 (Pt 2):271–7

Cross-reactivity of antibodies raised to Pseudomonas fluorescens protease with extracellular proteins produced by meat-spoiling pseudomonads. Lundy FT, et al.
J Appl Bacteriol 1996 Jul;81(1):1–6

Isolation of monoclonal antibodies reacting with the core component of lipopolysaccharide from Rhizobium leguminosarum strain 3841 and mutant derivatives. Lucas MM, et al. **J Bacteriol** 1996 May;178(10):2727–33

The double edged sword of the immune response: mutational analysis of a murine anti-pneumococcal, anti-DNA antibody. Putterman C, et al. **J Clin Invest** 1996 May 15; 97(10):2251–9

Host response assessment in recurring periodontitis. Ebersole JL, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):258–62 (22 ref.)

Longitudinal changes in antibody avidity to Actinobacillus actinomycetemcomitans in periodontitis. O'Dell DS, et al.
J Clin Periodontol 1996 Mar;23(3 Pt 1):203–11

Comparison of protocols for depleting anti-E. coli antibody in immunoblotting of recombinant antigens. Covini G, et al. **J Immunol Methods** 1996 Mar 28;190(1):143–5

Antibodies to lipopolysaccharide. Poxton IR.
J Immunol Methods 1995 Oct 12;186(1):1–15 (85 ref.)

Technical problems arising from the use of the immunoblot for determination of the reactivity of natural antibodies with different lipopolysaccharides (LPS). Schoenherr G, et al. **J Immunol Methods** 1996 Apr 19;190(2):185–8

Antibodies to Campylobacter jejuni react with myelin proteins of the central nervous system [letter; comment] Polt RJ, et al. **J Infect** 1995 Nov;31(3):249–50. Comment on: J Infect 1994 Jan;28(1):99–100.

Complement-mediated bactericidal activity of human antibodies to poly alpha 2-->8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. Mandrell RE, et al. **J Infect Dis** 1995 Nov; 172(5):1279–89

Compensatory levels of salivary IgM anti-Streptococcus mutans antibodies in IgA-deficient patients. Fernandes FR, et al. **J Investig Allergol Clin Immunol** 1995 May-Jun; 5(3):151–5

Molecular mimicry by Mycoplasma pneumoniae to evade the induction of adherence inhibiting antibodies. Jacobs E, et al. **J Med Microbiol** 1995 Dec;43(6):422–9

Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lang AB, et al. **J Pediatr** 1995 Nov; 127(5):711–7

Crystallization and preliminary X-ray analysis of Borrelia burgdorferi outer surface protein A (OspA) complexed with a murine monoclonal antibody Fab fragment. Li H, et al. **J Struct Biol** 1995 Nov-Dec;115(3):335–7

Binding specificity for four monoclonal antibodies recognizing terminal Gal alpha 1-->4Gal residues in Haemophilus influenzae lipopolysaccharide. Borrelli S, et al. **Microb Pathog** 1995 Sep;19(3):139–57

Specificity of the immune response to Haemophilus ducreyi. Brown TJ, et al. **Microb Pathog** 1995 Jul;19(1):31–8

The Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes. Muttilainen S, et al. **Microb Pathog** 1995 Jun; 18(6):423–36

An immunochemical study of serological cross-reaction between lipopolysaccharides from Vibrio cholerae O22 and O139. Isshiki Y, et al. **Microbiology** 1996 Jun;142 (Pt 6):1499–504

Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: implications for serological typing and vaccine design. Suker J, et al.
Microbiology 1996 Jan;142 (Pt 1):63–9

Infection by Mycoplasma pneumoniae induces serum antibody against Gal-C [letter] Kusunoki S, et al.
Muscle Nerve 1996 Feb;19(2):257–8

Immune responses in chickens against lipopolysaccharide of Escherichia coli and Salmonella typhimurium. Sunwoo HH, et al. **Poult Sci** 1996 Mar;75(3):342–5

The serological response to heartwater immunization in cattle is an indicator of protective immunity. Lawrence JA, et al. **Rev Elev Med Vet Pays Trop** 1995;48(1):63–5

Human T-cell epitopes on the Mycobacterium tuberculosis secreted protein MPT64. Roche PW, et al.
Scand J Immunol 1996 Jun;43(6):662–70

Antibodies in cat sera from southern Africa react with antigens of Ehrlichia canis. Matthewman LA, et al.
Vet Rec 1996 Apr 13;138(15):364–5

Production and characterization of rabbit anti-idiotypic antibodies directed against a murine monoclonal anti-B. abortus antibody. Adone R, et al. **Vet Res Commun** 1995; 19(6):457–61

[Direct suppression of bacteria viability in vitro by antibodies] Pal'tsyn AA, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):662–4 **(Rus)**

[Relationship between the duration of the clinical course of human brucellosis and the avidity of specific IgG antibodies] Gutiérrez J, et al. **Rev Med Chil** 1995 Jul; 123(7):819–22 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

High prevalence of Helicobacter pylori antibodies in an institutionalized population: evidence for person-to-person transmission. Lambert JR, et al. **Am J Gastroenterol** 1995 Dec;90(12):2167–71

Validation of the combined toxin-binding inhibition test for determination of neutralizing antibodies against tetanus and diphtheria toxins in a vaccine field study in Viet Nam. Hong HA, et al. **Bull World Health Organ** 1996; 74(3):275–82

Development and characterization of monoclonal antibodies specific for the genus Listeria. Loiseau O, et al.
FEMS Immunol Med Microbiol 1995 Jun;11(3):219–30

Anti-purified protein derivative cell-enzyme-linked immunosorbent assay, a sensitive method for early diagnosis of tuberculous meningitis. Baig SM. **J Clin Microbiol** 1995 Nov;33(11):3040–1

An immunofluorescence assay in microwell plate (IFA) for detecting serum antibodies to Chlamydia pneumoniae. Rumpianesi F, et al. **New Microbiol** 1995 Jul;18(3):311–4

Evaluation of a potassium chloride extract of Brucella abortus in an ELISA for detecting Brucella antibodies in bulk tank milk samples from cows. Thoen CO, et al.
Vet Microbiol 1995 Jul;45(2-3):185–9

METABOLISM

Dental caries and salivary anti-Streptococcus mutans antibodies in IgA deficient children. Fernandes FR, et al.
Adv Exp Med Biol 1995;371B:1145–8

Characterization of bovine pulmonary and serum antibody responses after parenteral or intrapulmonary vaccination with live Pasteurella haemolytica. McBride JW, et al.
Comp Immunol Microbiol Infect Dis 1996 Feb;19(2):99–115

Vaccine strategies for prevention of Helicobacter pylori infection. Sellman S, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S1–6

Secretory monoclonal IgA class-switch variants against bacterial enteric pathogens in bile and intestinal secretions. Steinmetz I, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):329–36

Relationship between an asymptomatic male genital tract exposure to Chlamydia trachomatis and an autoimmune response to spermatozoa. Witkin SS, et al. **Hum Reprod** 1995 Nov;10(11):2952–5

Transplacental IgG anti-Haemophilus influenzae type b transfer in Mexican mothers of a low socioeconomic level [letter] Paéz A, et al. **J Infect Dis** 1996 Apr;173(4):1047–8

The repertoire of human antibodies to the carbohydrate capsule of Streptococcus pneumoniae 6B. Park MK, et al.
J Infect Dis 1996 Jul;174(1):75–82

Tracking the in vivo localization of streptococcal cell membrane (SCM) monoclonal antibodies: potential model for post-streptococcal sequelae. Lange CF.
Res Commun Mol Pathol Pharmacol 1995 Aug;89(2):241–55

PHARMACOLOGY

A method for titration of inhibiting antibodies to bacterial immunoglobulin A1 proteases in human serum and secretions. Reinholdt J. **J Immunol Methods** 1996 May 10; 191(1):39–48

PHYSIOLOGY

Contradictory roles for antibody and complement in the interaction of Brucella abortus with its host. Hoffmann EM, et al. **Crit Rev Microbiol** 1995;21(3):153–63 (50 ref.)

Protection against non-typable Haemophilus influenzae following sensitization of gut associated lymphoid tissue: role of specific antibody and phagocytes. Wallace FJ, et al. **Immunol Cell Biol** 1995 Jun;73(3):258–65

THERAPEUTIC USE

Beneficial effect of Salmonella typhimurium infection and of immunoglobulins from S. typhimurium-infected mice on the autoimmune disease of (NZB x NZW) F1 mice. Matsiota-Bernard P, et al. **Clin Exp Immunol** 1996 May; 104(2):228–35

Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice. Frasa H, et al. **Infect Immun** 1996 Mar;64(3):775–81

Antibody against the capsule of Vibrio cholerae O139 protects against experimental challenge. Sengupta DK, et al. **Infect Immun** 1996 Jan;64(1):343–5

Pre-antibiotic treatments spur modern fungal infection research [news] **Oncology (Huntingt)** 1995 Apr;9(4):299

[Prophylactic effect of specific egg yolk antibodies in diarrhea caused by Escherichia coli K88 (F4) in weaned piglets] Erhard MH, et al. **Zentralbl Veterinarmed A** 1996 Jun;43(4):217-23 (Eng. Abstr.) **(Ger)**

ANTIBODIES, BISPECIFIC

see related
IMMUNOTOXINS
RADIOIMMUNOTHERAPY

Bispecific antibody modification of nicotinic acetylcholine receptors for biosensing. Reiken SR, et al. **Biosens Bioelectron** 1996;11(1-2):91-102

Murine bispecific antibody 1A10 directed to human transferrin receptor and a 42-kDa tumor-associated glycoprotein. Shi T, et al. **Clin Immunol Immunopathol** 1996 Feb;78(2):188-95

Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line. Flavell DJ, et al. **Hematol Oncol** 1995 Jul-Aug; 13(4):185-200

Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. de Kruif J, et al. **J Biol Chem** 1996 Mar 29; 271(13):7630-4

Proceedings of the 4th International Conference on Bispecific Antibodies. Duck Key, Florida, March 1-5, 1995. **J Hematother** 1995 Oct;4(5):345-483

Comments on the Fourth International Conference on Bispecific Antibodies and Cellular Cytotoxicity, Duck Key, Florida, March 1-5, 1995 [editorial] Fanger MW, et al. **J Hematother** 1995 Oct;4(5):345-9

ADMINISTRATION & DOSAGE

Bifunctional antibody retargeting in vivo-activated T lymphocytes: simplifying clinical application. Chapoval AI, et al. **J Hematother** 1995 Dec;4(6):571-7

BIOSYNTHESIS

Solid phase synthesis of bifunctional antibodies. DeSilva BS, et al. **J Immunol Methods** 1995 Dec 15;188(1):9-19

Production and characterization of bispecific single-chain antibody fragments. De Jonge J, et al. **Mol Immunol** 1995 Dec;32(17-18):1405-12

CHEMISTRY

A genetically engineered fusion protein M4/TNF with increased bifunctional activity refolded in the presence of protein disulfide isomerase. Yang J, et al. **Hum Antibodies Hybridomas** 1995;6(4):129-36

Production and characterization of bispecific single-chain antibody fragments. De Jonge J, et al. **Mol Immunol** 1995 Dec;32(17-18):1405-12

GENETICS

A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL. Jost CR, et al. **Mol Immunol** 1996 Feb;33(2):211-9

Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Hayden MS, et al. **Ther Immunol** 1994 Jan;1(1):3-15

IMMUNOLOGY

Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. Ely P, et al. **Blood** 1996 May 1;87(9):3813-21

Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors. Sahin U, et al. **Cancer Immunol Immunother** 1996 Jan;42(1):9-14

Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor. Amoroso AR, et al. **Cancer Res** 1996 Jan 1; 56(1):113-20

Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma. Kranenborg MH, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5864s-5867s

Redirection of cellular cytotoxicity. A two-step approach using recombinant single-chain Fv molecules. George AJ, et al. **Cell Biophys** 1995 Jun;26(3):153-65 (39 ref.)

Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen. Kipriyanov SM, et al. **Hum Antibodies Hybridomas** 1995;6(3):93-101

A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. Chamow SM, et al. **J Hematother** 1995 Oct;4(5):439-46

Properties of bispecific single chain antibodies expressed in Escherichia coli. Kranz DM, et al. **J Hematother** 1995 Oct; 4(5):403-8

Functional consequences of macrophage infection by human immunodeficiency virus: bispecific antibody targeting of HIV-1-infected cells to Fc gamma RI expressing effector cells. Mabondzo A, et al. **J Hematother** 1995 Dec; 4(6):579-85

Targeting lipoproteins to Fc gamma receptors with bispecific antibodies. Morganelli PM. **J Hematother** 1995 Oct; 4(5):457-61 (19 ref.)

Alternative triggering molecules and single chain bispecific antibodies. Segal DM, et al. **J Hematother** 1995 Oct; 4(5):377-82 (31 ref.)

Anti-CD3:anti-IL-2 receptor-bispecific mAb-mediated immunomodulation. Low systemic toxicity, differential effect on lymphoid tissue, and inhibition of cell-mediated hypersensitivity. MacLean JA, et al. **J Immunol** 1995 Oct 1;155(7):3674-82

A rapid non-selective method to generate quadromas by microelectrofusion. Cao Y, et al. **J Immunol Methods** 1995 Nov 16;187(1):1-7

Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha. Yoshida J, et al. **J Surg Oncol** 1996 Jul;62(3):177-82

A bispecific antibody recognizing influenza A virus M2 protein redirects effector cells to inhibit virus replication in vitro. Fernandez-Sesma A, et al. **J Virol** 1996 Jul; 70(7):4800-4

The molecular recognition theory applied to bispecific antibodies... [letter; comment] Ruf J, et al. **Nat Med** 1995 Dec;1(12):1222. Comment on: Nat Med 1995 Sep;1(9):876-8. Comment on: Nat Med 1995 Sep;1(9):894-901.

Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains. Haagen IA, et al. **Ther Immunol** 1994 Oct;1(5):279-87

[Anti-tumor effects of bispecific monoclonal antibody targeted human monocytes-macrophages on hepatoma cells] Wang Q, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):96-9 (Eng. Abstr.) **(Chi)**

ISOLATION & PURIFICATION

Toward the production of bispecific antibody fragments for clinical applications. Carter P, et al. **J Hematother** 1995 Oct;4(5):463-70 (63 ref.)

[Bispecific monoclonal antibodies: the isolation and study of their antigen-binding properties] Dmitriev AD, et al. **Vestn Ross Akad Med Nauk** 1996;(4):46-51 (Eng. Abstr.) **(Rus)**

METABOLISM

Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII. Weiner LM, et al. **Cancer Immunol Immunother** 1996 Mar; 42(3):141-50

Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells. Manetti C, et al. **Int J Cancer** 1995 Oct 9;63(2):250-6

Primate erythrocyte (E) complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulation. Taylor RP, et al. **J Hematother** 1995 Oct;4(5):357-62

PHARMACOKINETICS

Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer. Boerman OC, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):2169-74

In vivo targeting of human neuroblastoma xenograft by anti-GD2/anti-Fc gamma RI (CD64) bispecific antibody. Michon J, et al. **Eur J Cancer** 1995;31A(4):631-6

Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Tibben JG, et al. **Int J Cancer** 1996 May 16;66(4):477-83

PHARMACOLOGY

T-lymphocyte proliferation stimulated by alpha beta TCR/CD2 bispecific antibody is dependent on LFA-1/ICAM-1 recognition of accessory cells. Di Mauro ME, et al. **Adv Exp Med Biol** 1995;378:381-3

The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity. Kroesen BJ, et al. **Br J Cancer** 1996 Mar; 73(6):721-7

In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine. Hsieh-Ma ST, et al. **Clin Immunol Immunopathol** 1996 Aug; 80(2):185-93

Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies. Thibault C, et al. **Int J Cancer** 1996 Jul 17;67(2):232-7

T cell activation and cytokine production in anti-CD3 bispecific antibody therapy. Belani R, et al. **J Hematother** 1995 Oct;4(5):395-402

Lysis of small cell carcinoma of the lung (SCCL) cells by cytokine-activated monocytes and natural killer cells in the presence of bispecific immunoconjugates containing a gastrin-releasing peptide (GRP) analog or a GRP antagonist. Chen J, et al. **J Hematother** 1995 Oct; 4(5):369-76

THERAPEUTIC USE

Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Demanet C, et al. **Blood** 1996 May 15;87(10):4390-8

Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Renner C, et al. **Blood** 1996 Apr 1;87(7):2930-7

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Negri DR, et al. **Br J Cancer** 1995 Oct; 72(4):928-33

MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Katayose Y, et al. **Cancer Res** 1996 Sep 15;56(18):4205-12

Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Weiner LM, et al. **Cancer Res** 1995 Oct 15;55(20):4586-93

Bifunctional antibodies for radioimmunotherapy. Chatal JF, et al. **Hybridoma** 1995 Apr;14(2):125-8 (9 ref.)

Tumor therapy by immune recruitment with bispecific antibodies. Renner C, et al. **Immunol Rev** 1995 Jun; 145:179-209 (153 ref.)

A bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma. Bakács T, et al. **Int Immunol** 1995 Jun;7(6):947-55

Pulmonary metastases neutralization and tumor rejection by in vivo administration of beta glucan and bispecific antibody. Penna C, et al. **Int J Cancer** 1996 Jan 26; 65(3):377-82

A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor. Schmidt M, et al. **Int J Cancer** 1996 Feb 8;65(4):538-46

Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. Canevari S, et al. **J Hematother** 1995 Oct;4(5):423-7

Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies. De Gast GC, et al. **J Hematother** 1995 Oct;4(5):433-7

In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma. Demanet C, et al. **J Hematother** 1995 Oct;4(5):363-8

A human Fc gamma RI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeutics. Heijnen IA, et al. **J Hematother** 1995 Oct;4(5):351-6

Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects. Kroesen BJ, et al. **J Hematother** 1995 Oct;4(5):409-14

Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. Liu L, et al. **J Hematother** 1995 Oct;4(5):477-83

Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies. Renner C, et al. **J Hematother** 1995 Oct;4(5):447-51

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). Repp R, et al. **J Hematother** 1995 Oct;4(5):415-21 (26 ref.)

Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. Valone FH, et al. **J Hematother** 1995 Oct; 4(5):471-5

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Weiner LM, et al. **J Hematother** 1995 Oct;4(5):453-6

Bispecific antibodies: the new magic bullets [news] Featherstone C. **Lancet** 1996 Aug 24;348(9026):536

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5-6):381-93 (160 ref.)

Response of B-cell lymphoma to a combination of bispecific antibodies and saporin. French RR, et al. **Leuk Res** 1996 Jul;20(7):607-17

Antibody with two targets may boost immunotherapy benefit [news] **Oncology (Huntingt)** 1996 Apr;10(4):620

Immunotherapy with bispecific antibodies. Thielemans KM. **Verh K Acad Geneeskd Belg** 1995;57(3):229-47; discussion 247-8

ANTIBODIES, BLOCKING

Different efficacy of various blocking reagents to eliminate interferences by human antimouse antibodies with a two-site immunoassay. Reinsberg J. **Clin Biochem** 1996 Apr;29(2):145-8

BIOSYNTHESIS

A progesterone-induced protein increases the synthesis of asymmetric antibodies. Kelemen K, et al. **Cell Immunol** 1996 Jan 10;167(1):129-34

BLOOD

Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies. Vitti P, et al. **Acta Med Austriaca** 1996;23(1-2):52-6

Fel d 1-specific IgG antibodies induced by natural exposure

have blocking activity in skin tests. Witteman AM, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):369–75

IMMUNOLOGY

Glycoprotein IIb/IIIa autoantigenic repertoire in chronic idiopathic thrombocytopenic purpura. Hou M, et al. **Br J Haematol** 1995 Dec;91(4):971–5

[Hypothyroidism and blocking antibodies] Ducornet B, et al. **Ann Med Interne (Paris)** 1995;146(8):559–74 (129 ref.) **(Fre)**

PHARMACOLOGY

Treatment of IFN-gamma transgenic mice with anti-IFN-gamma reveals the remodeling capacity of the adult pancreas. Gu D, et al. **Diabetes** 1995 Oct; 44(10):1161–4

THERAPEUTIC USE

Therapeutic potential for blockade of the CD40 ligand, gp39. Buhlmann JE, et al. **J Clin Immunol** 1996 Mar;16(2):83–9 (56 ref.)

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Wang Y, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8563–8

ANTIBODIES, CATALYTIC

Evolving catalysts in real time [comment] Davis MM. **Science** 1996 Feb 23;271(5252):1078–9. Comment on: Science 1996 Feb 23;271(5252):1086–91.

BIOSYNTHESIS

Low level formation of potent catalytic IgG fragments mediated by disulfide bond instability. Li L, et al. **Mol Immunol** 1996 May-Jun;33(7-8):593–600

Expression studies of catalytic antibodies. Ulrich HD, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11907–11

CHEMISTRY

Antibody catalysis via strategic use of haptenic charge. Kikuchi K, et al. **Acta Chem Scand** 1996 Apr;50(4):333–6 (34 ref.)

Localization of protease activity in antibody subunits. Sun M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:573–5

Low level formation of potent catalytic IgG fragments mediated by disulfide bond instability. Li L, et al. **Mol Immunol** 1996 May-Jun;33(7-8):593–600

Using antibodies to perturb the coordination sphere of a transition metal complex. Ghosh P, et al. **Nature** 1996 Jul 25;382(6589):339–41

Cationic cyclopropanation by antibody catalysis. Li T, et al. **Nature** 1996 Jan 25;379(6563):326–7

Crystal structure of the complex of a catalytic antibody Fab fragment with a transition state analog: structural similarities in esterase-like catalytic antibodies. Charbonnier JB, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11721–5

From molecular diversity to catalysis: lessons from the immune system. Schultz PG, et al. **Science** 1995 Sep 29; 269(5232):1835–42 (74 ref.)

Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes [see comments] Wagner J, et al. **Science** 1995 Dec 15;270(5243):1797–800. Comment in: Science 1995 Dec 15;270(5243):1775–82.

Reactive immunization [comment] Wirsching P, et al. **Science** 1995 Dec 15;270(5243):1775–82. Comment on: Science 1995 Dec 15;270(5243):1797–800.

GENETICS

Selection of linkers for a catalytic single-chain antibody using phage display technology. Tang Y, et al. **J Biol Chem** 1996 Jun 28;271(26):15682–6

Site-directed mutagenesis of proteolytic antibody light chain. Gao QS, et al. **J Mol Biol** 1995 Nov 10;253(5):658–64

IMMUNOLOGY

The immunological evolution of catalysis [see comments] Patten PA, et al. **Science** 1996 Feb 23;271(5252):1086–91. Comment in: Science 1996 Feb 23;271(5252):1078–9.

METABOLISM

Antibody catalysis via strategic use of haptenic charge. Kikuchi K, et al. **Acta Chem Scand** 1996 Apr;50(4):333–6 (34 ref.)

Antibody catalysis of pericyclic reactions. Ulrich HD, et al. **Acta Chem Scand** 1996 Apr;50(4):328–32

Substrate-driven formation of a proteolytic antibody light chain. Gao QS, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:567–9

Catalytic activity of anti-thyroglobulin antibodies. Li L, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:570–2

Specific orientation of porphyrin at the binding site of catalytic antibody. Kawamura-Konishi Y, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):537–44

Efficient vasoactive intestinal polypeptide hydrolyzing autoantibody light chains selected by phage display. Tyutyulkova S, et al. **Biochim Biophys Acta** 1996 Aug 23; 1316(3):217–23

Enzymes: chemistry and biochemistry. Jeffery J. **EXS** 1995; 73:79–104 (181 ref.)

Catalytic antibodies: evolution of protein function in real time. Lerner RA, et al. **EXS** 1995;73:121–38 (36 ref.)

Antibody catalysis. The key is in the pocket [news; comment] Benkovic SJ. **Nature** 1996 Sep 5;383(6595):23–4. Comment on: Nature 1996 Sep 5;383(6595):60–2.

Off-the-shelf proteins that rival tailor-made antibodies as catalysts [see comments] Hollfelder F, et al. **Nature** 1996 Sep 5;383(6595):60–2. Comment in: Nature 1996 Sep 5;383(6595):23–4.

From molecular diversity to catalysis: lessons from the immune system. Schultz PG, et al. **Science** 1995 Sep 29; 269(5232):1835–42 (74 ref.)

[Do catalytically active antibodies exist in healthy people? (Protein kinase activity of sIgA antibodies from human milk)] Kit Iula, et al. **Mol Biol (Mosk)** 1995 Jul-Aug; 29(4):893–906 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing. Wentworth P, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):799–803

ANTIBODIES, ENHANCING see **ANTIBODIES, BLOCKING**

ANTIBODIES, FUNGAL

ANALYSIS

Improved diagnosis of allergic bronchopulmonary aspergillosis with gp66 (formerly antigen 7) of Aspergillus fumigatus for specific IgE detection. Little SA, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):55–63

Automated reading and processing of quantitative IgG, IgM, IgA, and IgE isotypic agglutination results in microplates. Development and application in parasitology-mycology. Aubert D, et al. **J Immunol Methods** 1995 Oct 26; 186(2):323–8

[Experimental and clinical study on pneumocystosis. IV. Use of a 4D7 monoclonal antibody to detect Pneumocystis carinii by immunoperoxidase staining] Mei Q, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):130–3 (Eng. Abstr.) **(Chi)**

[Relationship between histoplasmin skin test and antibody levels detectable by ELISA and immunodiffusion (letter; comment)] Velásquez A. **Rev Inst Med Trop Sao Paulo** 1994 Nov-Dec;36(6):557. Comment on: Rev Inst Med Trop Sao Paulo 1994 Jan-Feb;36(1):83–7. **(Spa)**

BIOSYNTHESIS

Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D. Ikeda R, et al. **Clin Diagn Lab Immunol** 1996 Jan; 3(1):89–92

Human natural yeast killer toxin-like candidacidal antibodies. Polonelli L, et al. **J Immunol** 1996 Mar 1;156(5):1880–5

BLOOD

Candida antigen and antibody assays [letter; comment] Klingspor L. **Acta Paediatr** 1995 Aug;84(8):964. Comment on: Acta Paediatr 1995 Feb;84(2):183–7.

Chronic mucocutaneous candidiasis. II. Class and subclass of specific antibody responses in vivo and in vitro. Lilic D, et al. **Clin Exp Immunol** 1996 Aug;105(2):213–9

Serum IgG antibody response to Pneumocystis carinii among immunosuppressed, malnourished and healthy rats. El Gebaly WM, et al. **J Egypt Soc Parasitol** 1996 Apr; 26(1):63–71

Oral immunization of mice against candidiasis. Jensen J, et al. **J Infect Dis** 1996 Jul;174(1):133–40

Detection of coccidioidal antibodies by 33-kDa spherule antigen, Coccidioides EIA, and standard serologic tests in sera from patients evaluated for coccidioidomycosis. Wieden MA, et al. **J Infect Dis** 1996 May;173(5):1273–7

Detection of antibodies and delayed hypersensitivity with Rotofor preparative IEF fractions of Blastomyces dermatitidis yeast phase lysate antigen. Bono JL, et al. **J Med Vet Mycol** 1995 Jul-Aug;33(4):209–14

Immunoblot analysis for serum antibodies to Pneumocystis carinii by age and intensity of infection in rats. Hong ST, et al. **Korean J Parasitol** 1995 Sep;33(3):187–94

Aspergillus fumigatus antigens. López-Medrano R, et al. **Microbiology** 1995 Oct;141 (Pt 10):2699–704

Aspergillus spp. seropositivity in New Zealand penguins. Graczyk TK, et al. **Mycopathologia** 1995 Sep;131(3):179–84

Sensitivity and specificity of an isoelectric focusing fraction of Blastomyces dermatitidis yeast lysate antigen for the detection of canine blastomycosis. Fisher MA, et al. **Mycoses** 1995 May-Jun;38(5-6):177–82

Evaluation of eight antibody tests and one antigen test for the diagnosis of invasive aspergillosis. Kappe R, et al. **Mycoses** 1996 Jan-Feb;39(1-2):13–23

CEREBROSPINAL FLUID

Cerebrospinal fluid antibodies detected by ELISA against a 33-kDa antigen from spherules of Coccidioides immitis in patients with coccidioidal meningitis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Galgiani JN, et al. **J Infect Dis** 1996 Feb; 173(2):499–502

CHEMISTRY

Monoclonal antibodies against a 97-kilodalton antigen from Aspergillus flavus. Hetherington SV, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):63–7

Antibodies from patients with psoriasis recognize N-acetylglucosamine terminals in glycoproteins from Pityrosporum ovale. Mathov I, et al. **Clin Exp Immunol** 1996 Jul;105(1):79–83

IMMUNOLOGY

Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies. Cleare W, et al. **Clin Diagn Lab Immunol** 1994 Nov;1(6):737–40

Antibody immunity and invasive fungal infections. Casadevall A. **Infect Immun** 1995 Nov;63(11):4211–8 (133 ref.)

Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies. Zhong Z, et al. **Infect Immun** 1996 Sep;64(9):3446–50

Humoral and cell-mediated autoimmunity in allergy to Aspergillus fumigatus. Crameri R, et al. **J Exp Med** 1996 Jul 1;184(1):265–70

Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans. Nussbaum G, et al. **J Exp Med** 1996 Apr 1;183(4):1905–9

Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. Valadon P, et al. **J Mol Biol** 1996 Aug 9; 261(1):11–22

Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody. Lee SC, et al. **J Neuroimmunol** 1995 Oct;62(1):43–52

Dynamic expression of cell-surface antigens probed with Candida albicans-specific monoclonal antibodies. Deslauriers N, et al. **Microbiology** 1996 May;142 (Pt 5):1239–48

ISOLATION & PURIFICATION

Detection of specific antibodies in human blastomycosis by enzyme immunoassay. Bradsher RW, et al. **South Med J** 1995 Dec;88(12):1256–9

PHARMACOLOGY

Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Mukherjee J, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1398–405

Cross-reactivity between Aspergillus fumigatus and Penicillium. Brouwer J. **Int Arch Allergy Immunol** 1996 Jun;110(2):166–73

THERAPEUTIC USE

Antibody therapy appears promising for cryptococcal infections [news] **Oncology (Huntingt)** 1995 Apr;9(4):299

ANTIBODIES, HELMINTH

Use of a monoclonal antibody against the antigen B of Echinococcus granulosus for purification and detection of antigen B. Ortona E, et al. **Appl Parasitol** 1995 Aug; 36(3):220–5

Lacto-N-fucopentaose III (Lewis x), a target of the antibody response in mice vaccinated with irradiated cercariae of Schistosoma mansoni. Richter D, et al. **Infect Immun** 1996 May;64(5):1826–31

Schistosomiasis: beware delayed seroconversion [letter] Golledge CL. **Med J Aust** 1995 Oct 16;163(8):446–7

ANALYSIS

Stage-specific and species cross-reactive antibody responses in experimental Onchocerca infections of cattle. Kuo YM, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):624–32

Detection of antibodies to surface antigens of Angiostrongylus cantonensis by ELISA. Chang JH, et al. **Ann Trop Med Parasitol** 1995 Oct;89(5):569–72

Filarial antibody detection in suspected occult filariasis in children in an endemic area. Chaturvedi P, et al. **J Trop Pediatr** 1995 Aug;41(4):243–5

Detection of anti-Schistosoma antibodies in oral fluids. Garcia MM, et al. **Mem Inst Oswaldo Cruz** 1995 Jul-Aug; 90(4):513

The sheath of the microfilaria of Brugia malayi from human infections has IgG on its surface. Shenoy RK, et al. **Parasitol Res** 1996;82(4):382–4

Antibodies in serum of patients with clonorchiasis before and after treatment. Lin YL, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):114–9

Serodiagnosis of cysticercosis: specificity of different antigens and enzyme-linked immunosorbent assays. Ng TF, et al. **Trans R Soc Trop Med Hyg** 1994 Jul-Aug;88(4):421–2

Syndrome resembling tropical pulmonary eosinophilia but of non-filarial aetiology: serological findings with filarial antigens. Rocha A, et al. **Trans R Soc Trop Med Hyg** 1995

Sep–Oct;89(5):573–5
Humoral and cellular responses following local immunization with a surface antigen of the gastrointestinal parasite Haemonchus contortus. Jacobs HJ, et al.
Vet Immunol Immunopathol 1995 Oct;48(3–4):323–32
[Indirect biological examinations in parasitic digestive pathology] Dutoit E, et al. **Gastroenterol Clin Biol** 1995; 19(5 Pt 2):B104–9 **(Fre)**
[Immunodiagnosis of schistosomiasis mansoni with a low parasitic load] Lima DM, et al.
Rev Soc Bras Med Trop 1996 Mar–Apr;29(2):145–52 (Eng. Abstr.) **(Por)**

BIOSYNTHESIS

Cysteine protease of the nematode Nippostrongylus brasiliensis preferentially evokes an IgE/IgG1 antibody response in rats. Kamata I, et al. **Clin Exp Immunol** 1995 Oct;102(1):71–7
Schistosoma mansoni infection in humans and primates induces cytolytic antibodies to surface Le(x) determinants on myeloid cells. Nyame AK, et al. **Exp Parasitol** 1996 Mar;82(2):191–200
Parasite-specific isotype and subclass antibody profiles during acute prepatent human schistosomiasis. Shaheen H, et al. **Exp Parasitol** 1996 Mar;82(2):222–4
Acceleration of IgE responses by treatment with recombinant interleukin-3 prior to infection with Trichinella spiralis in mice. Korenaga M, et al. **Immunology** 1996 Apr;87(4):642–6
Immunoglobulin A response in murine schistosomiasis: stimulatory role of egg antigens. Poulain-Godefroy O, et al. **Infect Immun** 1996 Mar;64(3):763–8
Differential antibody isotype reactivity to specific antigens in human lymphatic filariasis: gp15/400 preferentially induces immunoglobulin E (IgE), IgG4, and IgG2. Yazdanbakhsh M, et al. **Infect Immun** 1995 Oct; 63(10):3772–9
Production of a monoclonal dinitrophenyl-specific rat IgE and establishment of an IgE capture ELISA for estimating the concentration of rat IgE antibodies to dinitrophenyl–Ascaris suum. Hanashiro K, et al.
Int Arch Allergy Immunol 1996 Aug;110(4):371–9
Genetic factors affecting antibody responses to four species of nematode parasite in Romney ewe lambs. Douch PG, et al. **Int J Parasitol** 1995 Jul;25(7):823–8
Antibody responses of grazing alpacas (Lama pacos) in New Zealand to intestinal nematodes. Green RS, et al.
Int J Parasitol 1996 Apr;26(4):429–35
The immune response of sheep surgically modified with intestinal loops to challenge with Trichostrongylus colubriformis. Pernthaner A, et al. **Int J Parasitol** 1996 Apr;26(4):415–22
Neutralizing antibody responses elicited in mice immunized with recombinant bacillus Calmette–Guérin producing the Schistosoma mansoni glutathione S-transferase. Kremer L, et al. **J Immunol** 1996 Jun 1;156(11):4309–17
CD40-mediated stimulation contributes to lymphocyte proliferation, antibody production, eosinophilia, and mastocytosis during an in vivo type 2 response, but is not required for T cell IL-4 production. Lu P, et al.
J Immunol 1996 May 1;156(9):3327–33
Production and characterization of a monoclonal antibody against Schistosoma japonicum glutathione S-transferase. Campbell MJ, et al. **J Immunol Methods** 1995 Dec 15; 188(1):73–8
Toxocariasis: a cause of hyper IgE and eosinophilia. Arias Irigoyen J, et al. **J Investig Allergol Clin Immunol** 1995 Jul–Aug;5(4):232–4
Humoral immune response of children with chronic schistosomiasis. Isotype recognition of adult worm antigens. Noya O, et al. **Parasite Immunol** 1995 Jun; 17(6):319–28
Immunoepidemiology of human necatoriasis: correlations between antibody responses and parasite burdens. Quinnell RJ, et al. **Parasite Immunol** 1995 Jun;17(6):313–8
Nutritional status and the IgE response against Ascaris lumbricoides in children from a tropical slum. Hagel I, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct;89(5):562–5
Involvement of excretion–secretion products from Fasciola hepatica inducing suppression of the cellular immune responses. Cervi L, et al. **Vet Parasitol** 1996 Jan; 61(1–2):97–111
Experimental Taenia solium cysticercosis in pigs: characteristics of the infection and antibody response. de Aluja AS, et al. **Vet Parasitol** 1996 Jan;61(1–2):49–59
Local and plasma antibody responses to the parasitic larval stages of the abomasal nematode Ostertagia circumcincta. Sinski E, et al. **Vet Parasitol** 1995 Sep;59(2):107–18

BLOOD

Egg-negative residents of an Opisthorchiasis-endemic area possess high levels of anti-Opisthorchis antibodies. Akai PS, et al. **Adv Exp Med Biol** 1995;371B:983–6
Immunodiagnosis of polycystic hydatid disease/polycystic echinococcosis due to Echinococcus vogeli. Gottstein B, et al. **Am J Trop Med Hyg** 1995 Nov;53(5):558–63
Immunoglobulin G subclass antibodies against excretory/secretory antigens of Ancylostoma caninum in human enteric infections. Loukas A, et al.
Am J Trop Med Hyg 1996 Jun;54(6):672–6
Human onchocerciasis in Nigeria: isotypic responses and antigen recognition in individuals with defined cutaneous pathology. Murdoch ME, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):600–12
Bancroftian filariasis: the patterns of filarial-specific immunoglobulin G1 (IgG1), IgG4, and circulating antigens in an endemic community of northeastern Tanzania. Simonsen PE, et al. **Am J Trop Med Hyg** 1996 Jul; 55(1):69–75
Evaluation of a recombinant antigen-based antibody assay for diagnosis of bancroftian filariasis in Egypt. Ramzy RM, et al. **Ann Trop Med Parasitol** 1995 Aug;89(4):443–6
Immunoglobulin G subclass responses of children during infection with Onchocerca volvulus. Gbakima AA, et al.
Clin Diagn Lab Immunol 1996 Jan;3(1):98–104
Humoral immune responses in acute schistosomiasis mansoni: relation to morbidity. Rabello AL, et al.
Clin Infect Dis 1995 Sep;21(3):608–15
Bancroftian filariasis: profile of serum antifilarial antibody and circulating parasite antigen. Wamae CN, et al.
East Afr Med J 1995 Aug;72(8):492–4
A serosurvey of water-borne pathogens amongst canoeists in South Africa. Taylor MB, et al. **Epidemiol Infect** 1995 Oct;115(2):299–307
Dot immunobinding assay as a new diagnostic test for human hydatid disease. Mistrello G, et al. **Immunol Lett** 1995 Jul–Aug;47(1–2):79–85
Antibody-independent effector mechanisms in resistance to the intestinal nematode parasite Trichuris muris. Else KJ, et al. **Infect Immun** 1996 Aug;64(8):2950–4
Serum antibody responses in opisthorchiasis. Akai PS, et al.
Int J Parasitol 1995 Aug;25(8):971–3
Humoral and cellular immune responses to Fasciola hepatica experimental primary and secondary infection in sheep. Chauvin A, et al. **Int J Parasitol** 1995 Oct;25(10):1227–41
Immune response of lambs to vaccination with Ostertagia circumcincta surface antigens eliciting bile antibody responses. Wedrychowicz H, et al. **Int J Parasitol** 1995 Sep;25(9):1111–21
Immunoglobulin kappa chain allotypes (KM) in onchocerciasis. Pandey JP, et al. **J Clin Invest** 1995 Dec; 96(6):2732–4
Immunodiagnosis of early dracunculiasis. Bapna S, et al.
J Commun Dis 1996 Mar;28(1):33–7
Evaluation of IHA test for fascioliasis in cases of hepatitis C virus infection. el Abdel Aaty H, et al.
J Egypt Soc Parasitol 1996 Aug;26(2):475–80
Observations on possible immunity to reinfection among school children after schistosomiasis treatment. Nagaty IM, et al. **J Egypt Soc Parasitol** 1996 Aug;26(2):443–52
Allergic reactivity and IgG subclasses to a proteinase fraction of Setaria digitata in filariasis. Beuria MK, et al.
J Helminthol 1995 Sep;69(3):181–5
Effects of free and liposomized praziquantel on worm burden and antibody response in mice infected with Mesocestoides corti tetrathyridia. Hrčkova G, et al. **J Helminthol** 1995 Sep;69(3):213–21
Differential decline in filaria-specific IgG1, IgG4, and IgE antibodies in Brugia malayi-infected patients after diethylcarbamazine chemotherapy. Atmadja AK, et al.
J Infect Dis 1995 Dec;172(6):1567–72
Antischistosome IgG4 and IgE responses are affected differentially by chemotherapy in children versus adults. Grogan JL, et al. **J Infect Dis** 1996 May;173(5):1242–7
Reduced antifilarial IgG4 responsiveness in a subpopulation of microfilaremic persons. Marley SE, et al.
J Infect Dis 1995 Dec;172(6):1630–3
Antibody response patterns against Schistosoma mansoni in a recently exposed community in Senegal. van Dam GJ, et al. **J Infect Dis** 1996 May;173(5):1232–41
Immunopurification and measurement of IgE in serum samples from bancroftian filariasis patients. Marley SE, et al. **J Parasitol** 1996 Feb;82(1):178–81
Antibody isotypes, including IgG subclasses, in Ecuadorian patients with pulmonary paragonimiasis. Guevara A, et al.
Mem Inst Oswaldo Cruz 1995 Jul–Aug;90(4):497–502
Temporal changes in the humoral immune response of cattle during experimental infections with Onchocerca lienalis. Kuo YM, et al. **Parasite Immunol** 1995 Aug;17(8):393–404
Antibody response to a protease secreted by Trichinella spiralis muscle larvae. de Armas-Serra C, et al.
Parasitol Res 1995;81(6):540–2
An enzyme-linked immunosorbent assay for detecting anti-Echinostoma trivolvis (trematoda) IgG in experimentally infected ICR mice. Cross-reactivity with E. caproni. Graczyk TK, et al. **Parasitol Res** 1995; 81(8):710–2
Antibody isotype responses to antigens of Ascaris lumbricoides in a case-control study of persistently heavily infected Bangladeshi children. Palmer DR, et al.
Parasitology 1995 Sep;111 (Pt 3):385–93
Experimental single and trickle infections of cattle with Taenia saginata: studies of immunodiagnosis. Bøgh HO, et al. **Res Vet Sci** 1996 Jan;60(1):64–8
Persistence of specific antibody response in different experimental infections of mice with Toxocara canis larvae. Chieffi PP, et al. **Rev Inst Med Trop Sao Paulo** 1995 May–Jun;37(3):187–90
Dot-ELISA for the detection of IgM and IgG antibodies to Schistosoma mansoni worm and egg antigens, associated with egg excretion by patients. Pinto PL, et al.
Rev Inst Med Trop Sao Paulo 1995 Mar–Apr;37(2):109–15
Serum antibody response to Opisthorchis viverrini antigen as a marker for opisthorchiasis-associated cholangiocarcinoma. Akai PS, et al.
Trans R Soc Trop Med Hyg 1994 Jul–Aug;88(4):471–4
Markers of Loa loa infection in permanent residents of a loiasis endemic area of Gabon. Akue JP, et al.
Trans R Soc Trop Med Hyg 1996 Mar–Apr;90(2):115–8
A filter paper technique for the detection of anti-filarial IgG4 in lymphatic filariasis. Terhell AJ, et al.
Trans R Soc Trop Med Hyg 1996 Mar–Apr;90(2):196–8
Analysis of immunoglobulin G subclass in the serum antibody responses of alveolar echinococcosis patients after surgical treatment and chemotherapy as an aid to assessing the outcome. Wen H, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):692–7
Pathogenetic factors of acute schistosomiasis mansoni: correlation of worm burden, IgE, blood eosinophilia and intensity of clinical manifestations. Rocha MO, et al.
Trop Med Int Health 1996 Apr;1(2):213–20
Evaluation of Fasciola excretory-secretory (E/S) product in diagnosis of acute human fasciolosis by IgM ELISA. Osman MM, et al. **Trop Med Parasitol** 1995 Jun;46(2):115–8
Nematode burdens and immunological responses following natural challenge in Romney lambs selectively bred for low or high faecal worm egg count. Bisset SA, et al.
Vet Parasitol 1996 Feb;61(3–4):249–63
Immune responses of chronically infected adult cattle to Fasciola hepatica. Clery D, et al. **Vet Parasitol** 1996 Mar; 62(1–2):71–82
Comparison of single and trickle infections of pigs with eggs of the Asian Taenia. Fall EH, et al. **Vet Parasitol** 1996 Feb;61(3–4):231–7
Prevalence of IgG antibodies to Trichinella spiralis in dogs in Macedonia, northern Greece. Frydas SI, et al.
Vet Parasitol 1995 Aug;59(1):81–5
Time-course analysis of antibody response by EITB and ELISA before and after chemotherapy in sheep infected with Fasciola gigantica. Guobadia EE, et al.
Vet Parasitol 1995 Jun;58(3):247–53
Herd evaluation by enzyme-linked immunosorbent assay for the determination of Fasciola hepatica infection in sheep and cattle from the Altiplano of Bolivia. Hillyer GV, et al. **Vet Parasitol** 1996 Feb;61(3–4):211–20
Enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to Anoplocephala perfoliata in horse sera. Höglund J, et al. **Vet Parasitol** 1995 Sep;59(2):97–106
Dietary protein influences upon immunity to Nematodirus battus infection in lambs. Israf DA, et al. **Vet Parasitol** 1996 Feb;61(3–4):273–86
Isotype-specific antibody responses to the surface-exposed antigens of adult and larval stages of Dictyocaulus viviparus in infected and vaccinated calves. McKeand JB, et al. **Vet Parasitol** 1996 Feb;61(3–4):287–95
Detection of antibodies of Fasciola hepatica excretory—secretory antigens in experimentally infected goats by enzyme immunosorbent assay. Martínez A, et al.
Vet Parasitol 1996 Apr;62(3–4):247–52
Systemic antibody responses of calves to low molecular weight Cooperia oncophora antigens. Nieuwland MG, et al. **Vet Parasitol** 1995 Oct;59(3–4):231–9
Diagnosis of Taenia saginata cysticercosis in Kenyan cattle by antibody and antigen ELISA. Onyango-Abuje JA, et al. **Vet Parasitol** 1996 Feb;61(3–4):221–30
Low molecular weight Cooperia oncophora antigens: characterization and humoral immune responses in calves mono-infected with 100,000 infective larvae. Parmentier HK, et al. **Vet Parasitol** 1995 Oct;59(3–4):219–30
Use of excretory/secretory antigens for the serodiagnosis of Anoplocephala perfoliata cestodosis. Proudman CJ, et al.
Vet Parasitol 1996 Feb;61(3–4):239–47
Immunization of pigs against Taenia solium cysticercosis: factors related to effective protection. Sciutto E, et al.
Vet Parasitol 1995 Nov;60(1–2):53–67
Evaluation of mebendazole activity on experimental murine toxocariasis by immune complexes determination. Bardon R, et al. **Zentralbl Veterinarmed [B]** 1995 Jun;42(4):235–46
[The influence of infected mothers on their children's immune response to filariasis] Shen J, et al.
Chung Hua I Hsueh Tsa Chih 1996 Mar;76(3):211–3 (Eng. Abstr.) **(Chi)**
[A ten-year follow-up observation on serum antibody level in schistosomiasis patients treated with praziquantel] Xu S, et al.
Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih 1995;13(2):142–4 (Eng. Abstr.) **(Chi)**
[Seroprevalence of cysticercosis in the lacustrian community of Vekky, Atlantic district (Benin)] Adjidé CC, et al.
Bull Soc Pathol Exot 1996;89(1):24–9 (Eng. Abstr.) **(Fre)**
[Diagnosis of trichinellosis in living pigs using indirect ELISA] Nöckler K, et al.
Berl Munch Tierarztl Wochenschr 1995 May;108(5):167–74 (Eng. Abstr.) **(Ger)**
[Immunoenzyme analysis in the diagnosis of opisthorchiasis. I. The development of an immunoenzyme method for determining IgM antibodies to the Opisthorchis antigen] Meniavtseva TA, et al. **Med Parazitol (Mosk)** 1996 Jan–Mar;(1):41–3 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Differences between ventricular and lumbar cerebrospinal fluid in hydrocephalus secondary to cysticercosis. Rubalcava MA, et al. **Neurosurgery** 1995 Oct;37(4):668–71; discussion 671–2

ANTIBODIES, HELMINTH

CHEMISTRY

Early development and progression of lymphocyte-stimulatory cross-reactive idiotypes expressed on antibodies to soluble egg antigens during Schistosoma mansoni infection of mice. Bosshardt SC, et al. **Eur J Immunol** 1996 Jan;26(1):272-5

DIAGNOSTIC USE

Em18 and Em16, new serologic marker epitopes for alveolar echinococcosis in western blot analysis, are the only two epitopes recognized by commercially available weak positive (cut off) sera for Em2plus-ELISA. Ito A, et al. **J Helminthol** 1995 Dec;69(4):369-71

GENETICS

Genetic factors affecting antibody responses to four species of nematode parasite in Romney ewe lambs. Douch PG, et al. **Int J Parasitol** 1995 Jul;25(7):823-8

IMMUNOLOGY

Vaccination of mice against Taenia taeniaeformis using antigen fractions partitioned with Triton X-114. Schnieder T, et al. **Appl Parasitol** 1996 Jan;37(1):1-7

Strongyloides stercoralis: role of antibody and complement in immunity to the third stage of larvae in BALB/cByJ mice. Brigandi RA, et al. **Exp Parasitol** 1996 Apr; 82(3):279-89

Shedding of surface-bound antibody by adult Dictyocaulus viviparus. McKeand JB, et al. **Int J Parasitol** 1995 Oct; 25(10):1255-8

Anisakis simplex: stage-specific antigens recognized by mice. Iglesias R, et al. **J Helminthol** 1995 Dec;69(4):319-24

Secretory granule proteins from the subventral esophageal glands of the potato cyst nematode identified by monoclonal antibodies to a protein fraction from second-stage juveniles. de Boer JM, et al. **Mol Plant Microbe Interact** 1996 Jan;9(1):39-46

Isotype-specific characterization of antibody responses to Onchocerca volvulus in putatively immune individuals. Stewart GR, et al. **Parasite Immunol** 1995 Jul;17(7):371-80

Comparison of antibody isotype responses to Schistosoma mansoni antigens by infected and putative resistant individuals living in an endemic area. Viana IR, et al. **Parasite Immunol** 1995 Jun;17(6):297-304

Further characterization of the 38 kDa antigen from Echinococcus granulosus (hydatid disease) cyst fluid: evidence for antigenic heterogeneity and reactivity with anti-P1 antibodies. Zhang LH, et al. **Parasite Immunol** 1995 Jun;17(6):287-96

Immunoelectron microscopical localization of a circulating antigen in the excretory system of Schistosoma mansoni. Ultrastructural localization studies of the excretory system of S. mansoni. Bogers JJ, et al. **Parasitol Res** 1995; 81(5):375-81

Ultrastructural colocalization of phosphorylcholine and a phosphorylcholine-associated epitope in first-stage larvae of Trichinella spiralis. Hernández S, et al. **Parasitol Res** 1995;81(8):643-50

Antigenic cross-reactivity in mice between third-stage larvae of Anisakis simplex and other nematodes. Iglesias R, et al. **Parasitol Res** 1996;82(4):378-81

Schistosoma: analysis of monoclonal antibodies reactive with the circulating antigens CAA and CCA. Deelder AM, et al. **Parasitology** 1996 Jan;112 (Pt 1):21-35

Temporal differences in praziquantel- and oxamniquine-induced tegumental damage to adult Schistosoma mansoni: implications for drug-antibody synergy. Fallon PG, et al. **Parasitology** 1996 Jan;112 (Pt 1):47-58

The effect of ivermectin treatment on the antibody response to antigens of Onchocerca volvulus. Gillespie AJ, et al. **Trans R Soc Trop Med Hyg** 1994 Jul-Aug;88(4):456-60

[Anti-embryonation immunity and cultivation of schistosoma japonicum eggs in vitro] Wang S, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Mar;76(3):218-21 (Eng. Abstr.) **(Chi)**

ANTIBODIES, HEPATITIS see **HEPATITIS ANTIBODIES**

ANTIBODIES, HETEROGENETIC see **ANTIBODIES, HETEROPHILE**

ANTIBODIES, HETEROPHILE

Germline VH gene usage in xenoreactive monoclonal antibody. Cramer DV, et al. **Transplant Proc** 1996 Apr; 28(2):541-2

Expression of newborn pig endothelial cell xenoantigens recognized by baboon natural xenoantibody. Xu H, et al. **Transplant Proc** 1996 Apr;28(2):627

ANALYSIS

Failure of human immunoresponse to N-glycolylneuraminic acid epitope contained in recombinant human erythropoietin. Noguchi A, et al. **Nephron** 1996; 72(4):599-603

Newborn discordant cardiac xenotransplantation in primates: a model of natural antibody depletion. Michler RE, et al. **Transplant Proc** 1996 Apr;28(2):651-2

BIOSYNTHESIS

Production of human sperm-immobilizing antibodies in severe combined immunodeficient (SCID) mice reconstituted with human peripheral blood lymphocytes from infertile women. Shibahara H, et al. **Am J Reprod Immunol** 1996 Jan;35(1):57-60

Age-related development of human anti-pig xenoantibody. Xu H, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1023-9

Xenogeneic study of the isolated liver perfusion. Adham M, et al. **Transplant Proc** 1996 Apr;28(2):851-2

The humoral immune response in humans following ex vivo perfusion of porcine livers. Cotterell AH, et al. **Transplant Proc** 1996 Apr;28(2):546

Effect of leflunomide on T-independent xenoantibody formation in rats receiving hamster heart xenografts. Lin Y, et al. **Transplant Proc** 1996 Apr;28(2):952

Human xenoreactive natural antibodies against Gal alpha (1-3) pig terminal residues are not produced by CD5+ B-lymphocytes. Pitre J, et al. **Transplant Proc** 1996 Apr; 28(2):545

Sequential morphological, functional and xenoreactive antibody analysis of hamster kidneys transplanted into unmodified rats. Salomon S, et al. **Transplant Proc** 1996 Apr;28(2):687-8

alpha 1,3-Galactosyltransferase-deficient mice produce naturally occurring cytotoxic anti-Gal antibodies. Thall AD, et al. **Transplant Proc** 1996 Apr;28(2):556-7

BLOOD

Different efficacy of various blocking reagents to eliminate interferences by human antimouse antibodies with a two-site immunoassay. Reinsberg J. **Clin Biochem** 1996 Apr;29(2):145-8

Falsely elevated steroidal assay levels related to heterophile antibodies against various animal species. Check JH, et al. **Gynecol Obstet Invest** 1995;40(2):139-40

Thomsen-Friedenreich and PK antigens in pig-to-human xenotransplantation. Cairns T, et al. **Transplant Proc** 1996 Apr;28(2):795-6

Videomicroscopic analysis of the renal microcirculation during xenograft hyperacute rejection in the rat. Flechner SM, et al. **Transplant Proc** 1996 Apr;28(2):713-4

Increased anti-Gal activity in diabetic patients transplanted with porcine islet cells. Galili U, et al. **Transplant Proc** 1996 Apr;28(2):564-6

New World monkeys as a primate model for xenografts in the absence of anti-Gal. Galili U, et al. **Transplant Proc** 1996 Apr;28(2):567-8

The effect of plasmapheresis and deoxyspergualin or cyclophosphamide treatment on anti-porcine Gal-alpha (1,3)-Gal antibody titres in humans. Gannedahl G, et al. **Transplant Proc** 1996 Apr;28(2):551

Loss of antigenicity at one month after liver transplantation and change of serum antibody titer to donor antigens. Gu W, et al. **Transplant Proc** 1996 Apr;28(2):1084-5

Difference in tolerization of T-independent and T-dependent xenoantibody formation after cardiac xenotransplantation in rats. Lin Y, et al. **Transplant Proc** 1996 Apr;28(2):741

Efficacy of leflunomide to reduce xenoantibody titers in vivo: an evaluation of the prolongation of discordant xenograft survival. Lucien J, et al. **Transplant Proc** 1996 Apr; 28(2):704-7

Extracorporeal immunoadsorption of xenoreactive natural antibodies in the pig/rhesus model: comparison of three methods. Meyer C, et al. **Transplant Proc** 1996 Apr; 28(2):799-800

Xenoreactivity in the pig islet to human combination: feasibility of adenovirus-mediated gene transfer into pig islets. Mirenda V, et al. **Transplant Proc** 1996 Apr; 28(2):808-10

In vitro and in vivo studies to prevent hyperacute rejection. Miyagawa S, et al. **Transplant Proc** 1996 Apr;28(2):1031-3

Characterization of xenoreactive natural antibodies: interactions with carbohydrate determinants. Parker W, et al. **Transplant Proc** 1996 Apr;28(2):548

CLASSIFICATION

Xenoreactive natural antibodies and isohemagglutinins: a distinct class of antibodies. Lin SS, et al. **Transplant Proc** 1996 Apr;28(2):573

GENETICS

Polymorphism within the human anti-pig repertoire. Goldberg LC, et al. **Transplant Proc** 1996 Apr;28(2):549-50

IMMUNOLOGY

Characterization of porcine platelet glycoproteins recognized by human natural "anti-gal" antibodies. Thibaudeau K, et al. **Blood** 1996 Jun 1;87(11):4636-42

Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies. Helfand SC, et al. **Cell Immunol** 1996 Jan 10;167(1):99-107

Production of monoclonal antibodies directed to Hanganutziu-Deicher active gangliosides, N-glycolylneuraminic acid-containing gangliosides. Watarai S, et al. **J Biochem (Tokyo)** 1995 May;117(5):1062-9

Natural antipig xenoantibody is absent in neonatal human serum. Xu H, et al. **J Heart Lung Transplant** 1995 Jul-Aug; 14(4):749-54

Variation in expression of biologically reactive xenoantigen does not correlate with expression of Gal alpha (1-3)Gal. Alvarado CG, et al. **Transplant Proc** 1996 Apr;28(2):555

Different action of xenoreactive natural and immune antibodies on functioning cardiomyocytes. Autenrieth A, et al. **Transplant Proc** 1996 Apr;28(2):576-7

Identification and characterization of a peptide mimeotope of galactose alpha 1,3 galactose. Kooyman DL, et al. **Transplant Proc** 1996 Apr;28(2):554

Porcine islet cell antigens are recognized by xenoreactive natural human antibodies of both IgG and IgM subtypes. Korbutt GS, et al. **Transplant Proc** 1996 Apr;28(2):837-8

Porcine endothelial cell membrane antigens recognized by human and baboon xenoreactive antibodies during organ perfusion. Lin SS, et al. **Transplant Proc** 1996 Apr;28(2):607

Efficiency of different synthetic oligosaccharides for blocking the natural anti-g Gal antibodies found in human and baboon sera. Oriol R, et al. **Transplant Proc** 1996 Apr; 28(2):562

The mechanism of xenogeneic cell-mediated lympholysis between human and pig cells. Yamada K, et al. **Transplant Proc** 1996 Apr;28(2):757

The humoral immune response in humans following cross-perfusion of porcine organs. Cotterell AH, et al. **Transplantation** 1995 Oct 27;60(8):861-8

PHARMACOLOGY

Murine monoclonal anti-idiotypic antibodies directed against human anti-alpha Gal antibodies prevent rejection of pig cells in culture: implications for pig-to-human organ xenotransplantation. Koren E, et al. **Transplant Proc** 1996 Apr;28(2):559

Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody. Galili U, et al. **Vaccine** 1996 Mar;14(4):321-8

PHYSIOLOGY

Biochemical and functional characterization of xenoreactive natural antibodies in hu-PBL-SCID mice. Naziruddin B, et al. **J Clin Invest** 1996 Mar 1;97(5):1267-75

ANTIBODIES, HETEROTYPIC see **ANTIBODIES, HETEROPHILE**

ANTIBODIES, INTERNAL IMAGE see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTIBODIES, MONOCLONAL

see related
HYBRIDOMAS

The monoclonal antibody FDC-M1 recognizes possible follicular dendritic cell precursors in the blood and bone marrow. Haley ST, et al. **Adv Exp Med Biol** 1995; 378:289-91

A monoclonal antibody to Shigella dysenteriae serotype 13 cross-reacting with Shiga toxin. Qadri F, et al. **Adv Exp Med Biol** 1995;371B:923-6

Neurovirulence for rats of the JHMV variants escaped from neutralization with the S1-specific monoclonal antibodies. Taguchi F, et al. **Adv Exp Med Biol** 1995;380:185-7

4D5.4, a monoclonal antibody which recognizes cells in inflamed human intestine. Taylor J, et al. **Adv Exp Med Biol** 1995;371B:1331-2

Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. D'Souza MP, et al. **AIDS** 1995 Aug; 9(8):867-74

Comparative study between cytology and dot-ELISA for early detection of bladder cancer. Attallah AM, et al. **Am J Clin Pathol** 1996 Jan;105(1):109-14

A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice. Vogt E, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):700-7

Growth of vestibular schwannomas: in situ model employing the monoclonal antibody Ki-67 and DNA flow cytometry. Charabi S, et al. **Am J Otol** 1996 Mar;17(2):301-6

Immunohistochemical detection of active transforming growth factor-beta in situ using engineered tissue. Barcellos-Hoff MH, et al. **Am J Pathol** 1995 Nov; 147(5):1228-37

Recognition of consensus CHO structure in ligands for selectins by novel antibody against sialyl Lewis X. Tamatani T, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1282-7

Pro-vs-anti-CD45 [letter] Neiman RS, et al. **Am J Surg Pathol** 1996 Apr;20(4):507-9

Analysis and ultrastructural localization of Ehrlichia chaffeensis proteins with monoclonal antibodies. Chen SM, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):405-12

A monoclonal antibody to swine erythrocytes recognizes the B blood group on the major glycophorin. González A, et al. **Anim Genet** 1995 Oct;26(5):351-3

Pore-forming activity of Coxiella burnetii outer membrane protein oligomer comprised of 29.5- and 31-kDa polypeptides. Inhibition of porin activity by monoclonal antibodies 4E8 and 4D6. Banerjee-Bhatnagar N, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:378-401

Development of murine (OC-147) and human (H-106) monoclonal antibodies reactive with a 53-kDa ovarian

tumor-associated antigen. Mruthinti S, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:264-8

The use of antibodies for characterization and quantification of a recombinant protein. Sabater M, et al. **Ann N Y Acad Sci** 1996 May 15;782:462-77

Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy. Bodey B, et al. **Anticancer Res** 1996 Jan-Feb;16(1):517-31

Identification with monoclonal antibody 140.240 of a structural variant of melanotransferrin shed by human melanoma cell lines in vitro. Liao SK. **Anticancer Res** 1996 Jan-Feb;16(1):171-6

Monoclonal antibodies recognizing nitrite oxidoreductase of Nitrobacter hamburgensis, N. winogradskyi, and N. vulgaris. Aamand J, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2352-5

Selective enumeration of Bacteroides vulgatus and B. distasonis organisms in the predominant human fecal flora by using monoclonal antibodies. Corthier G, et al. **Appl Environ Microbiol** 1996 Feb;62(2):735-8

Rapid purification of the oxygenase component of toluene dioxygenase from a polyol-responsive monoclonal antibody. Lynch NA, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2133-7

Use of a monoclonal antibody against the antigen B of Echinococcus granulosus for purification and detection of antigen B. Ortona E, et al. **Appl Parasitol** 1995 Aug; 36(3):220-5

Quantitation of reduced disulfide groups in monoclonal antibodies using 5-iodoacetamidofluorescein: a novel size exclusion-HPLC technique. Muddukrishna SN, et al. **Appl Radiat Isot** 1995 Oct;46(10):1015-26

Reactivity of monoclonal antibodies OK-CLL (anti-CD5) with peripheral blood cells of patients with B cell lymphoproliferative disorders. Milošević D, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(1):23-9

Expression of the fibroblast growth factor receptor-1 in human normal tissues and tumors determined by a new monoclonal antibody. Morikawa Y, et al. **Arch Pathol Lab Med** 1996 May;120(5):490-6

Characterization of Bangor virus proteins by using monoclonal antibodies. Mao X, et al. **Avian Dis** 1996 Jan-Mar;40(1):150-7

Recognition of human recombinant myelin associated glycoprotein by anti-carbohydrate antibodies of the L2/HNK-1 family. Bigliardi-Qi M, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):171-8

A novel monoclonal antibody to N-myristoyl glycine moiety found a new N-myristoylated HIV-1 p28gag protein in HIV-1-infected cells. Furuishi K, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):344-51

Monoclonal antibody against the polymorphic site distinguishes apolipoprotein E4 from other isoforms. Nukina N, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):467-72

Sandwich enzyme immunoassay for endothelin with monoclonal antibodies and its application. Shima H, et al. **Biochem Mol Med** 1995 Jun;55(1):61-5

Human and humanized monoclonal antibodies: preclinical studies and clinical experience. Ostberg L, et al. **Biochem Soc Trans** 1995 Nov;23(4):1038-43

Transferred nuclear Overhauser enhancement experiments show that the monoclonal antibody strep 9 selects a local minimum conformation of a Streptococcus group A trisaccharide-hapten. Weimar T, et al. **Biochemistry** 1995 Oct 17;34(41):13672-81

Preliminary study of the metal binding site of an anti-DTPA-indium antibody by equilibrium binding immunoassays and immobilized metal ion affinity chromatography. Boden V, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):373-9

Criteria for investigation of the product equivalence of monoclonal antibodies for therapeutic and in vivo-diagnostic use in case of introduction of changes in the manufacturing process. Schäffner G, et al. **Biologicals** 1995 Sep;23(3):253-9 (32 ref.)

Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein. Ravon DM, et al. **Blood** 1995 Dec 1; 86(11):4134-43

Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor. Okamoto S, et al. **Br J Cancer** 1996 Jun;73(11):1366-72

Two novel mast cell phenotypic markers, monoclonal antibodies Ki-MC1 and Ki-M1P, identify distinct mast cell subtypes. Hamann K, et al. **Br J Dermatol** 1995 Oct; 133(4):547-52

The use of filter paper monoclonal antibodies in a Dot-blot test for typing Neisseria meningitidis B. De-Gaspari EN, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2889-93

A rapid and efficient purification method for horse IgG(T) using a rat monoclonal antibody. Fernandes I, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2599-606

The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract. Chowdhury GM, et al. **Cancer** 1996 Aug 15;78(4):827-33

MIB-1 staining index and peritumoral brain edema of meningiomas. Ide M, et al. **Cancer** 1996 Jul 1;78(1):133-43

A new approach to fecal occult blood testing based on the detection of haptoglobin. Xing PX, et al. **Cancer** 1996 Jul 1;78(1):48-56

p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer. Brotherick I, et al. **Cancer Immunol Immunother** 1995 Sep;41(3):146-50

Rhodamine 123-efflux from hematopoietic subpopulations and leukaemic blast populations marked by PerCP-conjugated monoclonal antibodies. Beck J, et al. **Cancer Lett** 1996 Feb 6;99(2):197-207

Specific monoclonal antibodies against leukocyte-restricted cell surface molecule CD43 react with nonhematopoietic tumor cells. Santamaría M, et al. **Cancer Res** 1996 Aug 1;56(15):3526-9

Production of a novel monoclonal antibody, JT-95, which can detect antigen of thyroid carcinoma. Takeyama H, et al. **Cancer Res** 1996 Apr 15;56(8):1817-22

Characterization of a new antigen expressed by B and myeloid lineage cells identified by the monoclonal antibody LIP-6. Holmes KL, et al. **Cell Immunol** 1995 Nov; 166(1):131-40

Antibody against phosphorylated proteins (MPM-2) recognizes mitotic microtubules in endosperm cells of higher plant Haemanthus. Smirnova EA, et al. **Cell Motil Cytoskeleton** 1995;31(1):34-44

Cold-treated centrosome: isolation of centrosomes from mitotic sea urchin eggs, production of an anticentrosomal antibody, and novel ultrastructural imaging. Thompson-Coffe C, et al. **Cell Motil Cytoskeleton** 1996; 33(3):197-207

2A3 and 3F9. Novel lung epithelial antigens with early upregulation in hyperoxic and radiation lung injury models. Girod CE, et al. **Chest** 1996 Mar;109(3 Suppl):33S

A monoclonal antibody against DNA topoisomerase II labels the axial granules of Pleurodeles lampbrush chromosomes. Hock R, et al. **Chromosoma** 1996;104(5):358-66

Monoclonal antibody assay for free urinary pyridinium cross-links. Gomez B Jr, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1168-75

Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum [see comments] Gomez B Jr, et al. **Clin Chem** 1995 Nov;41(11):1560-6. Comment in: Clin Chem 1995 Nov;41(11):1551-3.

Diagnosis of premature rupture of membranes with an improved alpha-fetoprotein monoclonal antibody kit. Kishida T, et al. **Clin Chem** 1995 Oct;41(10):1500-3

Monoclonal immunoglobulin interferences in measurement of serum inorganic phosphate with a new modified reagent [letter] Poupon-Fleuret C, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1298-300

Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Rosenquist C, et al. **Clin Chem** 1995 Oct;41(10):1439-45

Characterization of the house dust mite allergen Der p 7 by monoclonal antibodies. Shen HD, et al. **Clin Exp Allergy** 1995 May;25(5):416-22

Characterization of a monoclonal antibody for in vitro potency testing of erysipelas bacterins. Henderson LM, et al. **Dev Biol Stand** 1996;86:334

Ontogeny and thymus-dependence of T cell surface antigens in Xenopus: flow cytometric studies on monoclonal antibody-stained thymus and spleen. Gravenor I, et al. **Dev Comp Immunol** 1995 Nov-Dec;19(6):507-23

Estimation of estrogen receptor content in fine-needle aspirates from breast cancer using the monoclonal antibody 1D5 and microwave oven processing: correlation with paraffin embedded and frozen sections determinations. Schmitt FC, et al. **Diagn Cytopathol** 1995 Nov;13(4):347-51

Anti-La monoclonal antibodies recognizing epitopes within the RNA-binding domain of the La protein show differential capacities to immunoprecipitate RNA-associated La protein. Pruijn GJ, et al. **Eur J Biochem** 1995 Sep 1;232(2):611-9

Immunostaining of human melanomas by a monoclonal antibody to B700 mouse melanoma antigen. Xu X, et al. **Eur J Cancer** 1996 Jan;32A(1):168-73

Two strategies to prepare neural cortical cytoskeleton components for the generation of monoclonal antibodies. Mack TG, et al. **Eur J Cell Biol** 1995 Jul;67(3):218-26

Monoclonal antibody-based methods for quantitation of hemoglobins: application to evaluating patients with sickle cell anemia treated with hydroxyurea. Epstein N, et al. **Eur J Haematol** 1996 Jul;57(1):17-24

Monoclonal antibody to single-stranded DNA is a specific and sensitive cellular marker of apoptosis. Frankfurt OS, et al. **Exp Cell Res** 1996 Aug 1;226(2):387-97

Cell type- and differentiation stage-dependent expression of PML domains in rat, detected by monoclonal antibody HIS55. Lam YW, et al. **Exp Cell Res** 1995 Dec; 221(2):344-56

A keratin antibody recognizing a heterotypic complex: epitope mapping to complementary locations on both components of the complex. Waseem A, et al. **Exp Cell Res** 1996 Mar 15;223(2):203-14

Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice. de Kroon JF, et al. **Exp Hematol** 1996 Jul;24(8):919-26

The novel monoclonal antibody By114 helps detect the early emergence of a paroxysmal nocturnal hemoglobinuria clone in aplastic anemia. Tooze JA, et al. **Exp Hematol** 1995 Dec; 23(14):1484-91

Monoclonal antibodies to surfactant protein D: evaluation of immunoreactivity in normal rat lung and in a radiation-induced fibrosis model. Kasper M, et al. **Exp Lung Res** 1995 Jul-Aug;21(4):577-88

Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. Hasegawa M, et al. **FEBS Lett** 1996 Apr 8; 384(1):25-30

Antigen binding of antiganglioside antibodies in vitro is strongly influenced by the ganglioside composition of the sample. Hildebrandt H. **FEBS Lett** 1996 Jun 10; 388(1):29-33

A monoclonal antibody reacting with the cell envelope of spirochaetes isolated from cases of intestinal spirochaetosis in pigs and humans. Lee BJ, et al. **FEMS Microbiol Lett** 1995 Sep 1;131(2):179-84

Monoclonal antibodies recognized bovine leukocyte antigens used in immuno-scanning electron microscopy. Levkut M, et al. **Folia Histochem Cytobiol** 1995;33(3):179-81

Recognition of the blood group H type 2 trisaccharide epitope by 28 monoclonal antibodies and three lectins. Mollicone R, et al. **Glycoconj J** 1996 Apr;13(2):263-71

The value of PE-10, a monoclonal antibody against pulmonary surfactant, in distinguishing primary and metastatic lung tumours. Nicholson AG, et al. **Histopathology** 1995 Jul;27(1):57-60

A human monoclonal antibody to carbohydrate moiety of carcinoembryonic antigen. Tsukazaki K, et al. **Hum Antibodies Hybridomas** 1995;6(4):145-52

Orosomucoid phenotyping with monoclonal antibodies:polymorphic occurrence of ORM1*Q0 in aboriginal Taiwanese populations. Umetsu K, et al. **Hum Hered** 1995 Jul-Aug;45(4):181-5

The use of GDA-J/F3 monoclonal antibody for the detection of dead spermatozoa (necrosperm) during semen analysis. Jassim A, et al. **Hum Reprod** 1995 Sep;10(9):2301-4

Epitopic analysis and quantification of bovine myoglobin with monoclonal antibodies. Levieux D, et al. **Hybridoma** 1995 Oct;14(5):435-42

Membrane-associated and cytosolic species-specific antigens of Mycoplasma bovis recognized by monoclonal antibodies. Rasberry U, et al. **Hybridoma** 1995 Oct;14(5):481-5

Studies on natural ST2 gene products in the human leukemic cell line UT-7 using monoclonal antihuman ST2 antibodies. Yoshida K, et al. **Hybridoma** 1995 Oct;14(5):419-27

An Eikenella corrodens toxin detected by plaque toxin-neutralizing monoclonal antibodies. Levine M, et al. **Infect Immun** 1996 May;64(5):1672-8

Mapping of the linear site on the Fas/APO-1 molecule targeted by the prototypic anti-Fas mAb. Fadeel B, et al. **Int Immunol** 1995 Dec;7(12):1967-75

Syngeneic anti-idiotypic monoclonal antibodies against an anti-human chorionic gonadotrophin antibody. Stamenova M, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1117-22

Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study. Howell LP, et al. **Int J Biol Markers** 1995 Jul-Sep;10(3):129-35

Immunoglobulin Inhibiting Reagent: evaluation of a new method for eliminating spurious elevations in CA125 caused by HAMA. Nicholson S, et al. **Int J Biol Markers** 1996 Jan-Mar;11(1):46-9

Development of a new Prolifigen TPA IRMA assay using monoclonal anti-cytokeratin antibodies. Sundström BE, et al. **Int J Biol Markers** 1995 Jul-Sep;10(3):166-73

Monoclonal antibodies against recombinant-MAGE-1 protein identify a cross-reacting 72-kDa antigen which is co-expressed with MAGE-1 protein in melanoma cells. Carrel S, et al. **Int J Cancer** 1996 Jul 29;67(3):417-22

Characterisation of the tumour-associated carbohydrate epitope recognised by monoclonal antibody 4D3. Pinczower GD, et al. **Int J Cancer** 1996 May 29; 66(5):636-44

Characterization of monoclonal antibodies against stromelysin-3 and their use to evaluate stromelysin-3 levels in breast carcinoma by semi-quantitative immunohistochemistry. Santavicca M, et al. **Int J Cancer** 1995 Oct 20;64(5):336-41

A monoclonal antibody KIS-1 recognizing a new membrane antigen on human squamous-cell carcinoma. Toh U, et al. **Int J Cancer** 1996 May 29;66(5):600-6

Evaluation of MHS-5 in detecting seminal fluid in vaginal swabs. Keil W, et al. **Int J Legal Med** 1996;108(4):186-90

Use of a monoclonal antibody to ovine IgE for fly strike studies in sheep. MacDiarmid JA, et al. **Int J Parasitol** 1995 Dec;25(12):1505-7

Production and characterization of murine monoclonal antibodies to Blastocystis hominis. Tan SW, et al. **Int J Parasitol** 1996 Apr;26(4):375-81

An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. Chen X, et al. **J Biol Chem** 1996 Mar 29; 271(13):7620-9

A new monoclonal antibody which selectively recognizes the active form of Src tyrosine kinase. Kawakatsu H, et al. **J Biol Chem** 1996 Mar 8;271(10):5680-5

7-O-acetyl-GD3 in human T-lymphocytes is detected by a specific T-cell-activating monoclonal antibody. Kniep B, et al. **J Biol Chem** 1995 Dec 15;270(50):30173-80

Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1

chain. Luque A, et al. **J Biol Chem** 1996 May 10; 271(19):11067–75

Structural analysis of bovine somatotropin using monoclonal antibodies and the conformation–sensitive immunoassay. Pfund WP, et al. **J Biol Chem** 1996 Jun 14;271(24):14055–61

Measuring the lifetime of bonds made between surface–linked molecules. Pierres A, et al. **J Biol Chem** 1995 Nov 3; 270(44):26586–92

Individually distinct Ig homology domains in PECAM–1 regulate homophilic binding and modulate receptor affinity. Sun QH, et al. **J Biol Chem** 1996 May 10;271(19):11090–8

Immunochemical analysis of the structure of diphtheria toxin shows all three domains undergo structural changes at low pH. Tortorella D, et al. **J Biol Chem** 1995 Nov 17; 270(46):27439–45

Production of monoclonal antibodies to study corrosion products of CO–CR biomaterials. Yang J, et al. **J Biomed Mater Res** 1996 May;31(1):71–80

Monoclonal and polyclonal antibodies detect a new type of post–translational modification of axonemal tubulin. Levilliers N, et al. **J Cell Sci** 1995 Sep;108 (Pt 9):3013–28

Interactions of macromolecules with the mammalian cell surface. Wall J, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2673–82

Monoclonal, human autoantibodies to the TSH receptor—the Holy Grail and why are we looking for it? [editorial] McLachlan SM, et al. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3152–4 (29 ref.)

Production and characterization of monoclonal antibodies specific for lipooligosaccharide of Serpulina hyodysenteriae. Westerman RB, et al. **J Clin Microbiol** 1995 Aug;33(8):2145–9

Identification of parietal cells in gastric body mucosa with HMFG–2 monoclonal antibody. Walker MM, et al. **J Clin Pathol** 1995 Sep;48(9):832–4

Undetectable luteinizing hormone levels using a monoclonal immunometric assay. Barbé F, et al. **J Endocrinol Invest** 1995 Nov;18(10):806–8

Conformational changes between human immunodeficiency virus type 1 nucleocapsid protein NCp7 and its precursor NCp15 as detected by anti–NCp7 monoclonal antibodies. Tanchou V, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2457–66

CD5–mediated specific delivery of DNA to T lymphocytes: compartmentalization augmented by adenovirus. Merwin JR, et al. **J Immunol Methods** 1995 Oct 26;186(2):257–66

Molecular characterization of two monoclonal antibodies specific for the LDL receptor–binding site of human apolipoprotein E. Raffai R, et al. **J Lipid Res** 1995 Sep; 36(9):1905–18

The detection of verocytotoxins in bacterial cultures from human diarrhoeal samples with monoclonal antibody–based ELISAs. Ball HJ, et al. **J Med Microbiol** 1996 Apr; 44(4):273–6

Generation of monoclonal antibodies to Macaca mulatta (rhesus) IgA. Ward DC, et al. **J Med Primatol** 1995 Feb; 24(2):74–80

Affinity maturation of a high–affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. Thompson J, et al. **J Mol Biol** 1996 Feb 16;256(1):77–88

Monoclonal antibody markers for early development of the stereociliary bundles of mammalian hair cells. Holley MC, et al. **J Neurocytol** 1995 Nov;24(11):853–64

Alz–50 recognizes epitopes in primary sensory fibres and in neurons of the substantia gelatinosa of the spinal cord. An ultrastructural study in the rat. Liberini P, et al. **J Neurocytol** 1995 Aug;24(8):559–67

Monoclonal autoantibody SCH94.03, which promotes central nervous system remyelination, recognizes an antigen on the surface of oligodendrocytes. Asakura K, et al. **J Neurosci Res** 1996 Feb 1;43(3):273–281

Bone marrow scintigraphy using technetium–99m–antigranulocyte antibody in hematologic disorders [see comments] Chung JK, et al. **J Nucl Med** 1996 Jun;37(6):978–82. Comment in: J Nucl Med 1996 Jun;37(6):982–4.

Potential false–positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. Baas IO, et al. **J Pathol** 1996 Mar; 178(3):264–7

MIB1, a promising marker for the classification of cervical intraepithelial neoplasia. Bulten J, et al. **J Pathol** 1996 Mar; 178(3):268–73

Identification of the antigen recognized by the monoclonal antibody BU31 as lamins A and C [see comments] Coates PJ, et al. **J Pathol** 1996 Jan;178(1):21–9. Comment in: J Pathol 1996 Jan;178(1):3–4.

A cautionary note regarding the application of Ki–67 antibodies to paraffin–embedded breast cancers. Gee JM, et al. **J Pathol** 1995 Nov;177(3):285–93

Differential reactivity of anti–E–selectin monoclonal antibodies in human gingival tissue. Pietrzak ER, et al. **J Periodontal Res** 1995 Nov;30(6):375–81

Application of anti–bovine CD2 monoclonal antibody to the rosette inhibition test for detection of early pregnancy factor in cattle. Yoshioka K, et al. **J Vet Med Sci** 1995 Aug;57(4):721–5

The positive nuclear staining observed with monoclonal antibody against PRAD1/cyclin D1 correlates with mRNA expression in mantle cell lymphoma. Kuroda H, et al. **Jpn J Cancer Res** 1995 Sep;86(9):890–8

Effect of circulating antigen on immunoscintigraphy of ovarian cancer patients using anti–CA125 monoclonal antibody. Sakahara H, et al. **Jpn J Cancer Res** 1996 Jun; 87(6):655–61

Organization of Wolbachia pipientis in the Drosophila fertilized egg and embryo revealed by an anti–Wolbachia monoclonal antibody. Kose H, et al. **Mech Dev** 1995 Jun; 51(2–3):275–88

Monoclonal antibodies to oncoproteins. Chang JH, et al. **Methods Enzymol** 1995;254:430–45

Preparation and use of immunoaffinity columns with monoclonal antibodies without purification from ascites and tissue–culture medium. Bøg–Hansen TC, et al. **Methods Mol Biol** 1995;45:189–93

Antigen purification by monoclonal antibody immunoaffinity chromatography. Brassfield AL. **Methods Mol Biol** 1995; 45:195–203

Use of monoclonal antibodies and flow cytometry to cluster and analyze leukocyte differentiation molecules. Davis WC, et al. **Methods Mol Biol** 1995;45:149–67

Use of monoclonal antibodies for western blotting with enhanced chemiluminescent detection. Fowler SJ. **Methods Mol Biol** 1995;45:115–27

Coupling of monoclonal antibodies with enzymes. Haugland RP. **Methods Mol Biol** 1995;45:235–43

Coupling of monoclonal antibodies with fluorophores. Haugland RP. **Methods Mol Biol** 1995;45:205–21

Coupling of monoclonal antibodies with biotin. Haugland RP, et al. **Methods Mol Biol** 1995;45:223–33

Epitope and idiotope mapping using monoclonal antibodies. Kaveri S. **Methods Mol Biol** 1995;51:171–81

Use of monoclonal antibodies in immunohistochemistry. Shi SR, et al. **Methods Mol Biol** 1995;45:89–108

The use of directly and indirectly labeled monoclonal antibodies in flow cytometry. Stewart CC, et al. **Methods Mol Biol** 1995;45:129–47

Use of monoclonal antibodies in immunoelectron microscopy. Suarez CE, et al. **Methods Mol Biol** 1995; 45:109–14

Use of monoclonal antibodies with magnetic particles to separate cell subpopulations by negative selection. Vaccaro DE, et al. **Methods Mol Biol** 1995;45:245–52

Use of monoclonal antibodies with magnetic particles to separate cell subpopulations by positive selection. Vaccaro DE, et al. **Methods Mol Biol** 1995;45:253–9

Establishment of immunological probes to study human gonadotropin–releasing hormone receptors. Karande AA, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):51–6

Localization of epitopes for monoclonal antibodies at the N–terminus of the porcine zona pellucida glycoprotein pZPC. Gupta SK, et al. **Mol Reprod Dev** 1995 Oct; 42(2):220–5

Complement–specific antibodies: designing novel anti–inflammatories. Matis LA, et al. **Nat Med** 1995 Aug; 1(8):839–42 (18 ref.)

Species–specificity of glial vimentin as revealed by immunocytochemical studies with the Vim 3B4 and V9 monoclonal antibodies. Gereben B, et al. **Neurobiology (Bp)** 1995;3(2):151–64

Immunohistochemical study of medulloblastoma with a monoclonal antibody against human copper and zinc–superoxide dismutase. Kurisaka M, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):220–3

Monoclonal antibodies against antigens exposed on the surface of vegetative forms and spores of Myxococcus virescens. Martinelli F, et al. **New Microbiol** 1995 Oct; 18(4):399–407

Labelling small quantities of monoclonal antibodies and their F(ab')2 fragments with technetium–99m. Tesic M, et al. **Nucl Med Biol** 1995 May;22(4):451–7

Preventing renal uptake of 111In from labelled monoclonal antibody fragments [letter; comment] Pimm MV. **Nucl Med Commun** 1995 Aug;16(8):710–1. Comment on: Nucl Med Commun 1995 Apr;16(4):299–305.

Radiochemical and radioimmunological data of 99Tcm–anti–CEA labelled by two diverse methods. Varvarigou AD, et al. **Nucl Med Commun** 1996 Jan; 17(1):80–8

Members of a family of proteins (the RD family) detected by a U1 70K monoclonal antibody are present in spliceosomal complexes. Staknis D, et al. **Nucleic Acids Res** 1995 Oct 25;23(20):4081–6

O6–methylguanine–DNA methyltransferase in human brain tumors detected by activity assay and monoclonal antibodies. Citron M, et al. **Oncol Res** 1995;7(1):49–55

Rapid analysis of small samples containing forskolin using monoclonal antibodies. Yanagihara H, et al. **Planta Med** 1996 Apr;62(2):169–72

Detection of membrane–bound HLA–G translated products with a specific monoclonal antibody. Bensussan A, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10292–6

Monoclonal antibodies: the promise and the reality. Coons T. **Radiol Technol** 1995 Sep–Oct;67(1):39–60; quiz 61–4 (75 ref.)

Characterisation of murine monoclonal antibodies recognising opsonic, mouse–protective, chaining and mucosally relevant epitopes on the M protein of Streptococcus equi subspecies equi. Timoney JF, et al. **Res Vet Sci** 1996 Jan;60(1):76–81

Identification of structurally altered estrogen receptors in human breast cancer by site–directed monoclonal antibodies. Traish AM, et al. **Steroids** 1995 Jul;60(7):467–74

Characterisation of the chains of human fibrinogen isolated by perfusion chromatography using fibrin specific monoclonal antibodies. Raut S, et al. **Thromb Res** 1995 Aug 15;79(4):405–13

Application of monoclonal antibodies to histologic diagnosis of gastric cancers. Otsuji E, et al. **Tohoku J Exp Med** 1995 Aug;176(4):213–8

Rejection of cartilage formed by transplanted allogeneic chondrocytes: evaluation with monoclonal antibodies. Romaniuk A, et al. **Transpl Immunol** 1995 Sep;3(3):251–7

Characterization of a murine monoclonal antibody reactive with a leukocyte common antigen and its application to bone marrow transplantation. Amirghofran Z, et al. **Transplant Proc** 1995 Oct;27(5):2657–8

Perfusion of pig hearts with anti–CD45 monoclonal antibody to label interstitial dendritic cells before xenotransplantation. Casey JJ, et al. **Transplant Proc** 1996 Apr;28(2):801–2

Cross Species Interaction of xenogeneic interleukins. Hammer C, et al. **Transplant Proc** 1996 Apr;28(2):858–9

Antigenic analysis of Japanese encephalitis viruses in Asia by using monoclonal antibodies. Hasegawa H, et al. **Vaccine** 1995 Dec;13(17):1713–21

Identification of a cellular receptor for fish rhabdoviruses. Béarzotti M, et al. **Vet Res** 1995;26(5–6):544–5

A fairly conserved epitope on the hemagglutinin of influenza A (H3N2) virus with variable accessibility to neutralizing antibody. Vanlandschoot P, et al. **Virology** 1995 Oct 1; 212(2):526–34

[Monoclonal antibodies and immune marking] Kleine HD, et al. **Infusionsther Transfusionsmed** 1996 Apr;23(2):109–10 **(Ger)**

[Monoclonal antibodies: George Kohler] Danon YL. **Harefuah** 1996 Jan 15;130(2):108–9 (14 ref.) **(Heb)**

[Immunohistological evaluation of esophageal cancer with antikeratin monoclonal antibodies] Tanimura S. **Nippon Geka Gakkai Zasshi** 1995 Nov;96(11):741–52 (Eng. Abstr.) **(Jpn)**

[Construction and clinical application of chimeric antibodies] Kuroki M, et al. **Nippon Rinsho** 1995 Dec;53(12):3122–31 (23 ref.) (Eng. Abstr.) **(Jpn)**

[General properties and kinds of antibodies for enzyme immunoassay—characteristics and advantages of polyclonal and monoclonal antibodies] Miyanishi S. **Nippon Rinsho** 1995 Sep;53(9):2149–53 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Monoclonal antibody mNI–58 inducing morphological changes in a human monocyte–like cell line, U937, stimulated with phorbol myristate acetate (PMA)] Ikewaki N. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):1033–7 (Eng. Abstr.) **(Jpn)**

[Detection of small cell lung cancer metastases in the bone marrow in vitro using monoclonal antibodies] Goncharskaia MA, et al. **Biull Eksp Biol Med** 1996 Apr; 121(4):456–8 **(Rus)**

[Characteristics of monoclonal antibodies to RS virus in immunoenzyme and immunofluorescence techniques] Sominina AA, et al. **Vestn Ross Akad Med Nauk** 1995; (9):49–54 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Intralesional administration of I–131 labelled monoclonal antibodies in the treatment of malignant gliomas. Arista A, et al. **Acta Neurochir (Wien)** 1995;135(3–4):159–62

CAMPATH–1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose–escalation study. Weinblatt ME, et al. **Arthritis Rheum** 1995 Nov;38(11):1589–94

Anti–tumour effects of an antibody–carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Blakey DC, et al. **Br J Cancer** 1995 Nov;72(5):1083–8

CAMPATH–1H in rheumatoid arthritis—an intravenous dose–ranging study. Isaacs JD, et al. **Br J Rheumatol** 1996 Mar;35(3):231–40

Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Riva P, et al. **Cancer Res** 1995 Dec 1; 55(23 Suppl):5952s–5956s

Differential dose–response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Kereiakes DJ, et al. **Circulation** 1996 Sep 1;94(5):906–10

Administration of anti–CD3 monoclonal antibody during experimental Chagas' disease induces CD8+ cell–dependent lethal shock. Jacobs F, et al. **Clin Exp Immunol** 1996 Feb;103(2):233–8

Administration of an antibody to E–selectin in patients with septic shock. Friedman G, et al. **Crit Care Med** 1996 Feb; 24(2):229–33

Administration of anti–interleukin–2 receptor alpha antibody in vivo induces localized autoimmune disease. Taguchi O, et al. **Eur J Immunol** 1996 Jul;26(7):1608–12

Delay in corneal allograft rejection due to anti–CD4 antibody given alone and in combination with cyclosporin A and leflunomide. Coupland SE, et al. **Ger J Ophthalmol** 1995 Sep;4(5):294–301

Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro. Moradpour D, et al. **Hepatology** 1995 Nov;22(5):1527–37

Anti–T cell receptor monoclonal antibody prolongs transgene expression following adenovirus–mediated in vivo gene transfer to mouse synovium. Sawchuk SJ, et

al. **Hum Gene Ther** 1996 Mar 1;7(4):499–506

Transfer of type II collagen–induced arthritis from DBA/1 to severe combined immunodeficiency mice can be prevented by blockade of Mac–1. Taylor PC, et al. **Immunology** 1996 Jun;88(2):315–21

Anti–progesterone effects on maternal recognition and behaviour imprinted during first pregnancy in mice. Crombie DL, et al. **J Endocrinol** 1995 Nov;147(2):331–7

Targeting of type 1 ribosome–inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies. Sforzini S, et al. **J Hematother** 1995 Oct; 4(5):429–32

Unresponsiveness to 2,4–dinitro–1–fluoro–benzene after treatment with monoclonal antibodies to leukocyte function–associated molecule–1 and intercellular adhesion molecule–1 during sensitization. Scheynius A, et al. **J Immunol** 1996 Mar 1;156(5):1804–9

Enhanced uptake of rsCD4 across the rodent and primate blood–brain barrier after conjugation to anti–transferrin receptor antibodies. Walus LR, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1067–75

Intratumoral injection of an adriamycin immunoconjugate against human pancreatic cancer xenografts. Kondo Y, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1072–9

Differential permeability of the blood–tumour barrier in intracerebral tumour–bearing rats: antidrug antibody to achieve systemic drug rescue. Kroll RA, et al. **Ther Immunol** 1994 Dec;1(6):333–41

Antibodies directed at mouse IL–2–R alpha and beta chains act in synergy to abolish T–cell proliferation in vitro and delayed type hypersensitivity reaction in vivo. François C, et al. **Transpl Int** 1996;9(1):46–50

Effect of monoclonal anti–CD4 and anti–CD8 on skin allograft survival in mice treated with donor bone marrow cells. De Fazio SR, et al. **Transplantation** 1996 Jan 15; 61(1):104–10

The F(ab')2 fragment of an anti–ICAM–1 monoclonal antibody attenuates liver injury after orthotopic liver transplantation. Nishimura Y, et al. **Transplantation** 1996 Jan 15;61(1):99–104

Mechanism by which additional monoclonal antibody (mAB) injections overcome the requirement for thymic irradiation to achieve mixed chimerism in mice receiving bone marrow transplantation after conditioning with anti–T cell mABs and 3–Gy whole body irradiation. Tomita Y, et al. **Transplantation** 1996 Feb 15;61(3):477–85

Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti–T cell mABs and 3–Gy whole body irradiation. Tomita Y, et al. **Transplantation** 1996 Feb 15;61(3):469–77

Donor–specific prolongation of rat skin graft survival induced by rat–donor cells and cyclophosphamide under coadministration of monoclonal antibodies against T cell receptor alpha beta and natural killer cells in mice. Umesue M, et al. **Transplantation** 1996 Jan 15;61(1):116–24

Beneficial effect of graft perfusion with anti–T cell receptor monoclonal antibodies on survival of small bowel allografts in rat recipients treated with brequinar alone or in combination with cyclosporine and sirolimus. Wang M, et al. **Transplantation** 1996 Feb 15;61(3):458–64

[Prolongation of allogenic rat renal graft survival after perfusion the organ with anti–MHC class II antibody] Oko A, et al. **Przegl Lek** 1996;53(5):420–2 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

A monoclonal antibody to an early pregnancy factor–induced suppressor factor (EPF–S1) disrupts implantation in mice. Athanasas–Platsis S, et al. **Am J Reprod Immunol** 1995 Mar; 33(3):259–66

Severe migratory polyarthritis following in vivo CAMPATH–1G. Varadi G, et al. **Bone Marrow Transplant** 1995 Dec;16(6):843–5

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Moreau T, et al. **Brain** 1996 Feb;119 (Pt 1):225–37

Administration of anti–interleukin–2 receptor alpha antibody in vivo induces localized autoimmune disease. Taguchi O, et al. **Eur J Immunol** 1996 Jul;26(7):1608–12

Interference by human antibodies with tumor marker assays. Reinsberg J. **Hybridoma** 1995 Apr;14(2):205–8 (30 ref.)

Prevention of anti–T–cell receptor alpha beta monoclonal antibody–induced side–effects by treatment with cyclosporin A without interference of monoclonal antibody–induced immunosuppression in mice. Murakami Y, et al. **Immunology** 1995 Oct;86(2):238–43

Reversible bronchial hyperresponsiveness induced by OK–T3/IL–2 administration in a patient with multiple myeloma. Rolla G, et al. **Respiration** 1995;62(4):228–31

Low immunogenicity of therapeutic rat CD45 antibodies when used for pre–treatment of donor organs for transplantation. Watts MJ, et al. **Ther Immunol** 1995 Feb; 2(1):23–9

The repetitive histologic pattern of vascular cardiac allograft rejection.Increased incidence associated with longer exposure to prophylactic murine monoclonal anti–CD3 antibody (OKT3). Ma H, et al. **Transplantation** 1996 Jul 27;62(2):205–10

ANALYSIS

Abundant tyrosine residues in the antigen binding site in anti–osteosarcoma monoclonal antibodies TP–1 and TP–3: Application to radiolabeling. Olafsen T, et al. **Acta Oncol** 1996;35(3):297–301

Diagnostic approach to and follow–up of difficult cases of AL amyloidosis. Perfetti V, et al. **Haematologica** 1995 Sep–Oct;80(5):409–15

Monoclonal antibody detection of heparin–binding proteins on sperm corresponds to increased fertility of bulls. Bellin ME, et al. **J Anim Sci** 1996 Jan;74(1):173–82

Quantitation of monoclonal antibodies by perfusion chromatography–immunodetection. Gadowski L, et al. **J Chromatogr A** 1995 Nov 3;715(2):241–5

Analysis of monoclonal antibody and immunoconjugate digests by capillary electrophoresis and capillary liquid chromatography. Liu J, et al. **J Chromatogr A** 1996 May 31;735(1–2):357–66

Rapid profiling of carbohydrate glycoforms in monoclonal antibodies using MALDI/TOF mass spectrometry. Kroon DJ, et al. **J Pharm Biomed Anal** 1995 Jul;13(8):1049–54

High–performance liquid chromatographic mapping of the oligosaccharides released from the humanised immunoglobulin, CAMPATH 1H. Lines AC. **J Pharm Biomed Anal** 1996 Mar;14(5):601–8

A monoclonal antibody identifies vimentin filaments in Sertoli cells and in a subset of epithelial cells in the rat epididymis, urinary bladder, and prostate. Danahey DG, et al. **J Urol** 1995 Dec;154(6):2190–6

Nuclear morphometry and the MIB–1 index in rhabdomyosarcoma. Noguchi S, et al. **Mod Pathol** 1996 Mar;9(3):253–60

Determination of Ki–67 defined growth fraction by monoclonal antibody MIB–1 in formalin–fixed, paraffin–embedded prostatic cancer tissues. Noordzij MA, et al. **Prostate** 1995 Sep;27(3):154–9

Immunocytochemical analysis of a monoclonal antibody specific for rainbow trout (Oncorhynchus mykiss) granulocytes and thrombocytes. Slierendrecht WJ, et al. **Vet Immunol Immunopathol** 1995 Jun;46(3–4):349–60

[Determination of antibodies to HLA class I antigens by an immunoenzyme method] Borozdenkova SD, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):315–7 **(Rus)**

[Monoclonal antibodies in the differentiation of Pseudomonas mallei and Pseudomonas pseudomallei] Iakovleva IV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec; (6):14–5 **(Rus)**

BIOSYNTHESIS

Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer. Alfonso M, et al. **Acta Oncol** 1996; 35(3):287–95 (67 ref.)

Specific anti–E. histolytica IgA monoclonal antibodies. Ximenez C, et al. **Adv Exp Med Biol** 1995;371B:963–6

Direct production of the Fab fragment derived from the sperm immobilizing antibody using polymerase chain reaction and cDNA expression vectors. Sawai H, et al. **Am J Reprod Immunol** 1995 Jul;34(1):26–34

Generation and characterization of monoclonal antibodies specific to surface antigens of human trophoblast cells. Yoshiki T, et al. **Am J Reprod Immunol** 1995 Sep; 34(3):148–55

Identification of low molecular weight allergens of American cockroach and production of monoclonal antibodies. Wu CH, et al. **Ann Allergy Asthma Immunol** 1996 Feb; 76(2):195–203

Model–based monitoring and control of a monoclonal antibody production process. Biener RK, et al. **Ann N Y Acad Sci** 1996 May 15;782:272–85

Metabolic engineering of animal cells. Häggström L, et al. **Ann N Y Acad Sci** 1996 May 15;782:40–52

Production and characterization of a monoclonal antibody specific for Trypanosoma simiae. Bosompem KM, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):611–20

Purification of a 54–kilodalton protein (OprJ) produced in NfxB mutants of Pseudomonas aeruginosa and production of a monoclonal antibody specific to OprJ. Hosaka M, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1731–5

The effect of alternative carbohydrates on the growth and antibody production of a murine hybridoma. Petch D, et al. **Appl Biochem Biotechnol** 1996 Apr;59(1):93–104

Production, characterization and application of monoclonal antibodies against the organophosphorus nerve agent Vx. Ci YX, et al. **Arch Toxicol** 1995;69(8):565–7

Production of humanized monoclonal antibodies for in vivo imaging and therapy. Harris WJ. **Biochem Soc Trans** 1995 Nov;23(4):1035–8 (21 ref.)

Production and characterization of a monoclonal antibody against sterigmatocystin. Lou JL, et al. **Biomed Environ Sci** 1996 Mar;9(1):17–25

Generation of chimeric bispecific G250/anti–CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Luiten RM, et al. **Br J Cancer** 1996 Sep; 74(5):735–44

Production and characterization of monoclonal antibodies to Actinobacillus pleuropneumoniae serotype 5b. Altman E, et al. **Can J Vet Res** 1995 Oct;59(4):279–84

Induction of muscle protein degradation and weight loss by a tumor product. Todorov PT, et al. **Cancer Res** 1996 Mar 15;56(6):1256–61

Generation and characterization of monoclonal antibodies to human type–5 tartrate–resistant acid phosphatase: development of a specific immunoassay of the isoenzyme in serum. Chamberlain P, et al. **Clin Chem** 1995 Oct; 41(10):1495–9

Development of monoclonal antibodies against Hantaan virus nucleocapsid protein. Ha IS, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):439–42

Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D. Ikeda R, et al. **Clin Diagn Lab Immunol** 1996 Jan; 3(1):89–92

Production, characterization, and application of monoclonal antibodies to Vibrio cholerae O139 synonym Bengal. Qadri F, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):51–4

Immune response to bovine viral diarrhea virus induced by anti–idiotypic antibodies. Xue W, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):95–8

Production of fully human antibodies by transgenic mice. Jakobovits A. **Curr Opin Biotechnol** 1995 Oct;6(5):561–6 (24 ref.)

Production of monoclonal antibodies in COS and CHO cells. Trill JJ, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):553–60 (53 ref.)

Development of a monoclonal antibody to immuno–cytochemical analysis of the cellular localization of the peripheral benzodiazepine receptor. Dussossoy D, et al. **Cytometry** 1996 May 1;24(1):39–48

Investigation of the product equivalence of monoclonal antibodies for therapeutic and in vivo diagnostic human use in case of change from ascitic to in vitro production. Schäffner G, et al. **Dev Biol Stand** 1996;86:319–20

Human monoclonal antibodies to cytomegalovirus. Characterization and recombinant expression of a glycoprotein–B–specific antibody. Böldicke T, et al. **Eur J Biochem** 1995 Dec 1;234(2):397–405

Co–expression of human protein disulphide isomerase (PDI) can increase the yield of an antibody Fab' fragment expressed in Escherichia coli. Humphreys DP, et al. **FEBS Lett** 1996 Feb 12;380(1–2):194–7

A human antibody specific for hepatitis C virus core protein: synthesis in a bacterial system and characterization. Esposito G, et al. **Gene** 1995 Oct 27;164(2):203–9

A new monoclonal antibody (3D3) generated with human respiratory mucins and directed against Lewis determinants. Emery N, et al. **Glycobiology** 1995 Sep; 5(6):563–70

Monoclonal antibody against the glutaraldehyde–conjugated polyamine, spermine. Fujiwara K, et al. **Histochem Cell Biol** 1995 Oct;104(4):309–16

Production of monoclonal antibody against the C1 component of rat estramustine–binding protein: immunohistochemical study of rat prostate. Tamura Y, et al. **Histochem Cell Biol** 1995 Dec;104(6):429–33

T cell–independent B cell response to self–monosialoganglíosides: primary response monoclonal antibodies. Alfonso M, et al. **Hybridoma** 1995 Jun; 14(3):209–16

Generation of murine monoclonal antihuman milk fat globule membrane antibodies using immunoprecipitation and BIAcore analyses. Bynum J, et al. **Hybridoma** 1995 Dec; 14(6):587–91

Development of monoclonal antibodies for the selective isolation of human plasma apolipoprotein A–containing particles. Calvo C, et al. **Hybridoma** 1995 Dec;14(6):603–8

Development of highly specific monoclonal antibodies for the diagnosis of Vibrio cholerae 01. Castillo L, et al. **Hybridoma** 1995 Jun;14(3):271–8

Production and characterization of monoclonal antibodies against the ribosome–inactivating protein PAP from Phytolacca americana. Desvoyes B, et al. **Hybridoma** 1995 Dec;14(6):571–5

Production of CEA–reactive monoclonal antibody (4E7) and its applications in immunochemistry. Devine PL, et al. **Hybridoma** 1995 Aug;14(4):397–9

Monoclonal antibodies against acetylcholinesterase of Schistosoma mansoni: production and characterization. Espinoza B, et al. **Hybridoma** 1995 Dec;14(6):577–86

Generation and characterization of monoclonal antibodies specific for members of the mammalian 70–kDa heat shock protein family. Green JM, et al. **Hybridoma** 1995 Aug; 14(4):347–54

Monoclonal antibodies against noxiustoxin. Hérion P, et al. **Hybridoma** 1995 Jun;14(3):247–51

Development and characterization of murine monoclonal antibodies to the latency–associated peptide of transforming growth factor beta 1. Hongo JA, et al. **Hybridoma** 1995 Jun;14(3):253–60

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Kashmiri SV, et al. **Hybridoma** 1995 Oct;14(5):461–73

The production and characterization of murine monoclonal antibodies to human Gadd45 raised against a recombinant protein. Kilpatrick KE, et al. **Hybridoma** 1995 Aug; 14(4):355–9

Production and characterization of monoclonal and polyclonal antibodies against thyrotropin–releasing hormone. Klootwijk W, et al. **Hybridoma** 1995 Jun; 14(3):285–90

A method for monoclonal antibody isotype switching: anti–CD60 VH expression in a heavy chain–deficient hybridoma variant. Kozarsky KF, et al. **Hybridoma** 1995

Dec;14(6):597–601
Production and characterization of monoclonal antibodies against the recombinant p50csk protein tyrosine kinase: a tool for signal transduction research. Li S, et al. **Hybridoma** 1995 Aug;14(4):341–6
Anti-peptide monoclonal antibodies to the beta-adrenergic receptor: use in purification of beta receptor. Luxembourg A. **Hybridoma** 1995 Jun;14(3):261–4
Production and characterization of a monoclonal antibody against epirubicin. Papadopoulos NG, et al. **Hybridoma** 1995 Dec;14(6):593–6
Production and characterization of monoclonal antibodies directed against the Ah receptor. Perdew GH, et al. **Hybridoma** 1995 Jun;14(3):279–83
Optimizing production of human monoclonal IgG antibodies by in vitro-primed human PBMC: influence of CD56+ NK cell depletion. Puhlmann CM, et al. **Hybridoma** 1995 Aug;14(4):391–6
Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates. Reeves JP, et al. **Hybridoma** 1995 Jun;14(3):235–42
Production of monoclonal antibodies to Bruton's tyrosine kinase. Stewart DM, et al. **Hybridoma** 1995 Jun;14(3):243–6
Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Vázquez AM, et al. **Hybridoma** 1995 Dec;14(6):551–6
Production of a rat pancreatic polypeptide-specific monoclonal antibody and its influence on glucose homeostasis by in vivo immunoneutralization. Wong HC, et al. **Hybridoma** 1995 Aug;14(4):369–76
Production of a monoclonal antibody to an antigen present on both trophoblasts and leukocytes. Yu KJ, et al. **Hybridoma** 1995 Oct;14(5):487–93
Generation and characterization of monoclonal antibodies against the ERGB/FLI-1 transcription factor. Zhang XK, et al. **Hybridoma** 1995 Dec;14(6):563–9
Production of human monoclonal antibodies to i blood group by EBV-induced transformation: possible presence of a new glycolipid in cord red cell membranes and human hematopoietic cell lines. Nagatsuka Y, et al. **Immunol Lett** 1995 May;46(1–2):93–100
A new and efficient method to generate human IgG monoclonal antibodies reactive to cancer cells using SCID-hu mice. Satoh N, et al. **Immunol Lett** 1995 Jul–Aug; 47(1–2):113–9
Hybridoma cells producing antibodies against A-chain of mistletoe lectin I are resistant to this toxin. Tonevitsky AG, et al. **Immunol Lett** 1995 May;46(1–2):5–8
Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Alving CR, et al. **Immunol Rev** 1995 Jun;145:5–31 (104 ref.)
Canine IgE monoclonal antibody specific for a filarial antigen: production by a canine x murine heterohybridoma using B cells from a clinically affected lymph node. Gebhard D, et al. **Immunology** 1995 Jul;85(3):429–34
Generation of monoclonal antibodies utilizing the host anti-idiotypic network. Hatzistilianou MN, et al. **In Vivo** 1995 Mar–Apr;9(2):139–44
Production of a monoclonal dinitrophenyl-specific rat IgE and establishment of an IgE capture ELISA for estimating the concentration of rat IgE antibodies to dinitrophenyl-Ascaris suum. Hanashiro K, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):371–9
Establishment and structural analysis of human mAb to the E2 component of the 2-oxoglutarate dehydrogenase complex generated from a patient with primary biliary cirrhosis. Fukushima N, et al. **Int Immunol** 1995 Jul; 7(7):1047–55
Production and application of monoclonal antibodies specific to pyrroloquinoline quinone. Narita H, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):830–5
Production of monoclonal antibodies directed to Hanganutziu-Deicher active gangliosides, N-glycolylneuraminic acid-containing gangliosides. Watarai S, et al. **J Biochem (Tokyo)** 1995 May;117(5):1062–9
Production and characterisation of an antimelanoma monoclonal antibody KBA.62 using a new melanoma cell line reactive on paraffin wax embedded sections. Cohen-Knafo E, et al. **J Clin Pathol** 1995 Sep;48(9):826–31
Induction and characterization of monoclonal anti-idiotypic antibodies to tick-borne encephalitis virus neutralizing antibody. Kopecký J, et al. **J Immunoassay** 1995 Nov; 16(4):437–65
Generation of a new gamma delta T cell-specific monoclonal antibody (GD3.5). Biochemical comparisons of GD3.5 antigen with the previously described Workshop Cluster 1 (WC1) family. Jones WM, et al. **J Immunol** 1996 May 15;156(10):3772–9
Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein. Bei R, et al. **J Immunol Methods** 1995 Oct 26;186(2):245–55
Production and characterization of a monoclonal antibody against Schistosoma japonicum glutathione S-transferase. Campbell MJ, et al. **J Immunol Methods** 1995 Dec 15; 188(1):73–8
Influence of antigen presentation and exogenous cytokine activity during in vitro primary immunizations employed for the generation of monoclonal antibodies. Halabi G, et al. **J Immunol Methods** 1995 Oct 26;186(2):205–16
Evaluation of hollow fiber bioreactors as an alternative to murine ascites production for small scale monoclonal antibody production. Jackson LR, et al. **J Immunol Methods** 1996 Feb 5;189(2):217–31
Structural analysis of gamma delta TCR using a novel set of TCR gamma and delta chain-specific monoclonal antibodies generated against soluble gamma delta TCR. Evidence for a specific conformation adopted by the J delta 2 region and for a V delta 1 polymorphism. Romagné F, et al. **J Immunol Methods** 1996 Jan 16;189(1):25–36
Production of a monoclonal antibody against the 128 kDa (CagA) protein of Helicobacter pylori. Stephens JC, et al. **J Immunol Methods** 1996 Apr 19;190(2):163–9
Long-term production of human monoclonal antibodies by human-mouse heterohybridomas. Yoshinari K, et al. **J Immunol Methods** 1995 Oct 12;186(1):17–25
Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies. Peterson NC. **Lab Anim Sci** 1996 Feb;46(1):8–14 (69 ref.)
Production of stable heterohybridomas producing human monoclonal antibodies. Cooper MD, et al. **Methods Mol Biol** 1995;45:29–39
Measurement of immunoglobulin synthesis using the ELISPOT assay. Cooper MD, et al. **Methods Mol Biol** 1995;45:83–7
Preparation and assay of acetylcholinesterase antibody. Friboulet A, et al. **Methods Mol Biol** 1995;51:211–22
Murine monoclonal antibody development. Johnson DR. **Methods Mol Biol** 1995;51:123–37
Production of monoclonal antibodies in swine. Lumanglas AL, et al. **Methods Mol Biol** 1995;45:49–54
In vivo and in vitro production of monoclonal antibodies. Bioreactors vs immune ascites. Marx U, et al. **Methods Mol Biol** 1995;45:169–76
Production of monoclonal antibodies in horses. Perryman LE, et al. **Methods Mol Biol** 1995;45:55–60
Methods of immunization to enhance the immune response to specific antigens in vivo in preparation for fusions yielding monoclonal antibodies. Rudbach JA, et al. **Methods Mol Biol** 1995;45:1–8
Use of electric-field-mediated cell fusion to produce hybridomas secreting monoclonal antibodies. Zhao X. **Methods Mol Biol** 1995;45:61–7
Antibody networks and imaging: elicitation of anti-fluorescein antibodies in response to the metatypic state of fluorescein-specific monoclonal antibodies. Cedergren AM, et al. **Mol Immunol** 1996 May-Jun; 33(7–8):711–23
Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor. Garrone P, et al. **Mol Immunol** 1996 May-Jun;33(7–8):649–58
Characteristics of human antibody repertoires following active immune responses in vivo. Ohlin M, et al. **Mol Immunol** 1996 May-Jun;33(7–8):583–92 (79 ref.)
Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling. Olafsen T, et al. **Nucl Med Biol** 1995 Aug;22(6):765–71
Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Spieker-Polet H, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9348–52
Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. Williamson RA, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7279–82
Production and properties of mouse monoclonal anti-adriamycin antibody. Watanabe T, et al. **Tokai J Exp Clin Med** 1994 Dec;19(3–6):103–7
Preparation and characterization of monoclonal antibodies against bovine myeloperoxidase. Cooray R, et al. **Vet Immunol Immunopathol** 1995 Jun;46(3–4):211–21
Monoclonal antibodies for the measurement of class-specific antibody responses in the green turtle, Chelonia mydas. Herbst LH, et al. **Vet Immunol Immunopathol** 1995 Jun; 46(3–4):317–35
Monoclonal equine IgM and IgG immunoglobulins. Wagner B, et al. **Vet Immunol Immunopathol** 1995 Jul;47(1–2):1–12
Production and characterization of monoclonal antibodies against Actinobacillus pleuropneumoniae serotype 1. Lairini K, et al. **Vet Microbiol** 1995 Oct;46(4):369–81
Production and use of monoclonal antibodies to Microsporum canis. Pinter L, et al. **Vet Microbiol** 1995 Oct;46(4):435–44
[Preparation of monoclonal antibodies against 185-SA of Streptococcus mutans] Xie L, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 May; 30(3):178–80 **(Chi)**
[Production and characterization of monoclonal antibody against aflatoxin B1] Wang G, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Sep;26(3):275–8 (Eng. Abstr.) **(Chi)**
[The production of high sensitive anti-myeloperoxidase monoclonal antibodies and their sensitivity and specificity] Okano K, et al. **Rinsho Byori** 1996 Jul;44(7):687–91 (Eng. Abstr.) **(Jpn)**
[The production of hybridomas producing monoclonal antibodies to the causative agent of melioidosis by using antigen-stimulated lymphocytes in an in-vitro system] Titova NG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec;(6):82–3 **(Rus)**

BLOOD

Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method. Garkavij M, et al. **Acta Oncol** 1996;35(3):309–12
Effect of vaccination of ponies with A4 anti-idiotypic antibody on serum idiotype (1C9) and antilipid A concentration. BonenClark GD, et al. **Am J Vet Res** 1996 May;57(5):655–8
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Witzig TE, et al. **Blood** 1996 Sep 1;88(5):1780–7
Transport of anti-sperm monoclonal IgA and IgG into murine male and female genital tracts from blood. Effect of sex hormones. Wang Y, et al. **J Immunol** 1996 Feb 1; 156(3):1014–9
Gammopathy with two M-components in a dog with IgA-type multiple myeloma. Kato H, et al. **Vet Immunol Immunopathol** 1995 Nov;49(1–2):161–8
[Mixed IgM kappa-IgM lambda cryoglobulinemia with a double monoclonal serum component. A case report] Napoli P, et al. **Minerva Med** 1995 May;86(5):223–6 (Eng. Abstr.) **(Ita)**

CHEMISTRY

A monoclonal antibody that recognizes a carbohydrate epitope of human protoplasmic astrocytes. Yokoo H, et al. **Acta Neuropathol (Berl)** 1996;91(1):23–30
99mTc-dextran-antibody conjugates. Labelling procedures. Márquez M, et al. **Acta Oncol** 1996;35(4):489–92
Monitoring of IgG antibody thermal stability by micellar electrokinetic capillary chromatography and matrix-assisted laser desorption/ionization mass spectrometry. Alexander AJ, et al. **Anal Chem** 1995 Oct 15;67(20):3626–32
Conformational diversity and conformational transitions of a monoclonal antibody monitored by circular dichroism and capillary electrophoresis. Kats M, et al. **Anal Chem** 1995 Sep 1;67(17):2943–8
Determination of the binding of ligands containing the N-2,4-dinitrophenyl group to bivalent monoclonal rat anti-DNP antibody using affinity capillary electrophoresis. Mammen M, et al. **Anal Chem** 1995 Oct 1;67(19):3526–35
An integrated strategy for structural characterization of the protein and carbohydrate components of monoclonal antibodies: application to anti-respiratory syncytial virus MAb. Roberts GD, et al. **Anal Chem** 1995 Oct 15; 67(20):3613–25
Imaging of immobilized antibody layers with scanning electrochemical microscopy. Wittstock G, et al. **Anal Chem** 1995 Oct 1;67(19):3578–82
Localization of protease activity in antibody subunits. Sun M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:573–5
Improved synthesis and characterisation of a hydrazide derivative of diethylenetriaminepentaacetic acid for site-specific labelling of monoclonal antibodies with 111In. Jolley C, et al. **Appl Radiat Isot** 1996 Jul;47(7):623–6
Mouse monoclonal IgA antibodies lack interchain disulfide bonds. Krotkiewski H, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(3–4):167–72
Developmental regulation of the human beta-globin cluster. Jane SM, et al. **Aust N Z J Med** 1995 Dec;25(6):865–9 (30 ref.)
A stable phage-display system using a phagemid vector: phage display of hen egg-white lysozyme (HEL), Escherichia coli alkaline, phosphatase, and anti-HEL monoclonal antibody, HyHEL10. Maenaka K, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):682–7
Confocal fluorescence microscopy for antibodies against a highly conserved sequence in SH2 domains. Okabe T, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):245–9
Primary structure of light and heavy chain variable regions of antibodies recognizing phosphorylated vimentins. Tsujino S, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):633–7
Domain swap chimeras to study the binding of IgG by Fc gamma RI, the high affinity receptor for IgG. Harrison PT, et al. **Biochem Soc Trans** 1996 Feb;24(1):144S
A mutational analysis of the binding of two different proteins to the same antibody. Dall'Acqua W, et al. **Biochemistry** 1996 Jul 30;35(30):9667–76
Rapid characterization of chemically-modified proteins by electrospray mass spectrometry. Bennett KL, et al. **Bioconjug Chem** 1996 Jan–Feb;7(1):18–22
Conjugation of doxorubicin to monoclonal anti-carcinoembryonic antigen antibody via novel thiol-directed cross-linking reagents. Lau A, et al. **Bioorg Med Chem** 1995 Oct;3(10):1299–304
Structural predictions of the binding site architecture for monoclonal antibody NC6.8 using computer-aided molecular modeling, ligand binding, and spectroscopy. Viswanathan M, et al. **Biophys J** 1995 Sep;69(3):741–53
Two-dimensional NMR studies of the interactions between a peptide of cholera toxin and monoclonal antibodies. Anglister J, et al. **Biopolymers** 1995;37(6):383–9
Modeling the structure of the combining site of an antisweet taste ligand monoclonal antibody NC10.14. Viswanathan M, et al. **Biopolymers** 1996 Sep;39(3):395–406
Use of thermal fluctuations to study the length and flexibility of ligand-receptor bonds. Pierres A, et al. **C R Acad Sci III** 1995 Dec;318(12):1191–6
Labeling of polypeptides with technetium-99m using a

dextran spacer. Holmberg A, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5710s-5713s

Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy. Li M, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5726s-5728s

Development of ulcerative colitis-associated anti-idiotype antibody using a novel monoclonal antibody against a colonic autoantigen. Shah U, et al. **Cell Immunol** 1995 Nov; 166(1):154-7

Evaluation of antibody- and antigen-coated enzymeimmunoassays for measuring oestrone-3-glucuronide concentrations in urine. Henderson KM, et al. **Clin Chim Acta** 1995 Dec 29;243(2):191-203

Monoclonal antibodies that distinguish between encephalitogenic bovine herpesvirus type 1.3 and respiratory bovine herpesvirus type 1.1. Chung CS, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):83-8

Monoclonal rat antibodies directed against Toxoplasma gondii suitable for studying tachyzoite-bradyzoite interconversion in vivo. Gross U, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):542-8

Monoclonal antibodies against a 97-kilodalton antigen from Aspergillus flavus. Hetherington SV, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):63-7

Salmonella-specific monoclonal antibodies against recombinant Salmonella typhi 36-kilodalton porin. Kissel V, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):250-2

Evidence obtained with monoclonal antibodies that O antigen is the major antigen responsible for the cross-reactivities between serotypes 4 and 7 of Actinobacillus (Haemophilus) pleuropneumoniae. Rodriguez Barbosa JI, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):563-8

Monoclonal antibodies to Coxiella burnetii that cross-react with strain Nine Mile. Sekeyová Z, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):531-4

USAN Council. List No. 375. New Names. Dacliximab. **Clin Pharmacol Ther** 1995 Sep;58(3):363-4

Molecular inactivation. Spatially and temporally defined molecular knockouts. Müller BK, et al. **Curr Biol** 1995 Nov 1;5(11):1255-6 (9 ref.)

Serologic crossreactions among primate immunoglobulins. Shearer MH, et al. **Dev Comp Immunol** 1995 Nov-Dec; 19(6):547-57

Identification of koala T lymphocytes using an anti-human CD3 antibody. Wilkinson R, et al. **Dev Comp Immunol** 1995 Nov-Dec;19(6):537-45

Monoclonal antibodies against Manduca sexta hemocytes bind Aedes aegypti hemocytes: characterization of six monoclonal antibodies that bind hemocytes from both species. Willott E, et al. **Dev Comp Immunol** 1995 Nov-Dec;19(6):451-61

Monoclonal antibody BLT-1, specific for the bovine homologue of CD5, reacts with the majority of mature T cells, a subpopulation of B cells and stimulates T cell proliferation. Yang TJ, et al. **Dev Comp Immunol** 1995 Jul-Aug;19(4):337-46

A monoclonal antibody, 3/22, to rabbit CD11c which induces homotypic T cell aggregation: evidence that ICAM-1 is a ligand for CD11c/CD18. Blackford J, et al. **Eur J Immunol** 1996 Mar;26(3):525-31

A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex-specific monoclonal antibody. Eastman S, et al. **Eur J Immunol** 1996 Feb;26(2):385-93

Relative location of epitopes involved in synergistic antibody binding using human chorionic gonadotropin as a model. Klonisch T, et al. **Eur J Immunol** 1996 Aug;26(8):1897-905

Permissive residues within the minimal epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV-1. Laisney IL, et al. **Eur J Immunol** 1996 Jul; 26(7):1634-40

Use of monoclonal antibodies to study interleukin-1 beta-converting enzyme expression: only precursor forms are detected in interleukin-1 beta-secreting cells. Miossec C, et al. **Eur J Immunol** 1996 May;26(5):1032-42

Detection of a 67-kD glycoprotein in human tumor cell lines by a monoclonal antibody established against a recombinant human endogenous retrovirus-K envelope-gene-encoded protein. Vogetseder W, et al. **Exp Clin Immunogenet** 1995; 12(2):96-102

Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Lifely MR, et al. **Glycobiology** 1995 Dec;5(8):813-22

Influence on antibody recognition of amino acid substitutions in the cleft of HLA-DQ2 molecules. Suggestive evidence of peptide-dependent epitopes. Viken HD, et al. **Hum Immunol** 1995 Oct;44(2):63-9

Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor121 (VEGF/VPF121). Asano M, et al. **Hybridoma** 1995 Oct;14(5):475-80

Effect of valency on binding properties of the antihuman IgM monoclonal antibody 202. Ćirić B, et al. **Hybridoma** 1995 Dec;14(6):537-44

Molecular characterization of mouse monoclonal antibody BIII.136 and the epitope recognized by the antibody in human band 3 protein. Czerwiński M, et al. **Hybridoma** 1995 Jun;14(3):217-23

Production and characterization of monoclonal antibodies against the ribosome-inactivating protein PAP from Phytolacca americana. Desvoyes B, et al. **Hybridoma** 1995 Dec;14(6):571-5

Production of CEA-reactive monoclonal antibody (4E7) and its applications in immunochemistry. Devine PL, et al. **Hybridoma** 1995 Aug;14(4):397-9

Monoclonal antibodies against acetylcholinesterase of Schistosoma mansoni: production and characterization. Espinoza B, et al. **Hybridoma** 1995 Dec;14(6):577-86

A monoclonal antibody against human beta-glucuronidase for application in antibody-directed enzyme prodrug therapy. Haisma HJ, et al. **Hybridoma** 1995 Aug; 14(4):377-82

Development and characterization of murine monoclonal antibodies to the latency-associated peptide of transforming growth factor beta 1. Hongo JA, et al. **Hybridoma** 1995 Jun;14(3):253-60

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Kashmiri SV, et al. **Hybridoma** 1995 Oct;14(5):461-73

cDNA sequence analysis and characterization of a cytokine-inducing monoclonal antibody derived from autoimmune MRL/MP-lpr/lpr mouse. Kimura N, et al. **Hybridoma** 1995 Dec;14(6):523-8

Monoclonal antibodies directed against unique and common determinants on the lipopolysaccharide molecule of Salmonella serogroups A, B, and D. Merkulova TI, et al. **Hybridoma** 1995 Dec;14(6):557-62

Production and characterization of a monoclonal antibody against epirubicin. Papadopoulos NG, et al. **Hybridoma** 1995 Dec;14(6):593-6

Precise epitope mapping of three monoclonal antibodies raised against tms1 protein of fission yeast. Schneider E, et al. **Hybridoma** 1995 Aug;14(4):329-33

Characterization of monoclonal antibodies against integrin alpha V beta 5. Stuiver I, et al. **Hybridoma** 1995 Dec; 14(6):545-50

Monoclonal antibodies against human collagenase and stromelysin. Su JL, et al. **Hybridoma** 1995 Aug;14(4):383-90

Novel monoclonal antibody reactive with thrombin-sensitive 74-kDa glycoproteins present on platelets and megakaryocytes both from mouse and rat. Takada K, et al. **Hybridoma** 1995 Aug;14(4):361-7

A human monoclonal antibody to a human self-antigen, CD2 derived from human peripheral blood lymphocytes engrafted in SCID mice. Uchibayashi N, et al. **Hybridoma** 1995 Aug;14(4):313-21

Generation and characterization of monoclonal antibodies against the ERGB/FLI-1 transcription factor. Zhang XK, et al. **Hybridoma** 1995 Dec;14(6):563-9

Variable domain sequences of mAb with high affinity for a linear oligopeptide. Hanke T, et al. **Immunogenetics** 1995; 42(5):442-3

Characterization of an anti-CD44 single-chain FV antibody that stimulates natural killer cell activity and induces TNF alpha release. Tan PH, et al. **Immunol Invest** 1995 Nov; 24(6):907-26

Molecular characterization of human monoclonal antibodies specific for several HIV proteins: analysis of the VH3 family expression. David D, et al. **Immunol Lett** 1995 Jul-Aug;47(1-2):107-12

Epitope mapping of monoclonal antibodies to tumor necrosis factor-alpha by synthetic peptide approach. Nagahira K, et al. **Immunol Lett** 1995 May;46(1-2):135-41

Characterization of the epitope recognized by a mAb that reacts differentially with murine suppressor T cells. Kapp JA, et al. **Int Immunol** 1995 Aug;7(8):1319-30

C-1-inhibitor binding monoclonal immunoglobins in three patients with acquired angioneurotic edema. Chevailler A, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):998-1008

Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3. Benhar I, et al. **J Biol Chem** 1995 Oct 6;270(40):23373-80

Temperature and pH dependence of fluorescein binding within the monoclonal antibody 9-40 active site as monitored by hydrostatic pressure. Carrero J, et al. **J Biol Chem** 1996 Mar 8;271(10):5332-7

Comparative properties of the single chain antibody and Fv derivatives of mAb 4-4-20. Relationship between interdomain interactions and the high affinity for fluorescein ligand. Mallender WD, et al. **J Biol Chem** 1996 Mar 8;271(10):5338-46

Platelet and monoclonal antibody binding to fibrinogen adsorbed on glow-discharge-deposited polymers. Kiaei D, et al. **J Biomed Mater Res** 1995 Jun;29(6):729-39

The influence of surface morphology and wettability on the inflammatory response against poly(L-lactic acid): a semi-quantitative study with monoclonal antibodies. Lam KH, et al. **J Biomed Mater Res** 1995 Aug;29(8):929-42

Monoclonal antibodies recognize antigen expressed by osteoblasts. Benayahu D, et al. **J Bone Miner Res** 1995 Oct;10(10):1496-503

An enzyme linked immunosorbent assay (ELISA) for detection of seminal fluid using a monoclonal antibody to prostatic acid phosphatase. Allen SM. **J Immunoassay** 1995 Aug;16(3):297-308

Binding kinetics of monoclonal antibody using antigen-beta-galactosidase hybrid protein: application to measurement of peptide antigenicity. Cho EW, et al. **J Immunoassay** 1995 Nov;16(4):349-63

A common epitope on platelet integrin alpha IIb beta 3 (glycoprotein IIbIIIa; CD41b/CD61) and alpha M beta 2 (Mac-1; CDIIb/CD18) detected by a monoclonal antibody. De Nichilo MO, et al. **J Immunol** 1996 Jan 1;156(1):284-8

Generation of a new gamma delta T cell-specific monoclonal antibody (GD3.5). Biochemical comparisons of GD3.5 antigen with the previously described Workshop Cluster 1 (WC1) family. Jones WM, et al. **J Immunol** 1996 May 15;156(10):3772-9

Epitope mapping by mass spectrometry: determination of an epitope on HIV-1 IIIB p26 recognized by a monoclonal antibody. Parker CE, et al. **J Immunol** 1996 Jul 1; 157(1):198-206

Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. Pulito VL, et al. **J Immunol** 1996 Apr 15;156(8):2840-50

Haptoglobin phenotyping by newly developed monoclonal antibodies. Demonstration of haptoglobin uptake into peripheral blood neutrophils and monocytes. Wagner L, et al. **J Immunol** 1996 Mar 1;156(5):1989-96

An alternative ELISA for T4 determination based on idiotype anti-idiotype interaction and a latex method for anti-idiotype monoclonal antibody selection. Becker MI, et al. **J Immunol Methods** 1996 Jun 10;192(1-2):73-85

Acid hydrolysis of monoclonal antibodies. Davagnino J, et al. **J Immunol Methods** 1995 Sep 25;185(2):177-80

Binding of autoreactive mouse anti-type II collagen antibodies derived from the primary and the secondary immune response investigated with the biosensor technique. Karlsson R, et al. **J Immunol Methods** 1995 Dec 15; 188(1):63-71

Modification of monoclonal and polyclonal IgG with palladium (II) coproporphyrin I: stimulatory and inhibitory functional effects induced by two different methods. Martsev SP, et al. **J Immunol Methods** 1995 Oct 26; 186(2):293-304

Evaluation of monoclonal antibodies with specificity for human IgA, IgA subclasses and allotypes and secretory component. Results of an IUIS/WHO collaborative study. Mestecky J, et al. **J Immunol Methods** 1996 Jun 21; 193(2):103-48

Assessment of variation in trypsin-sensitive neutralizable antigenic site of type O foot-and-mouth disease virus (FMDV) isolates using a Mab-binding inhibition assay [letter] Pattnaik B, et al. **J Immunol Methods** 1996 Jun 10; 192(1-2):191-3

Structural analysis of gamma delta TCR using a novel set of TCR gamma and delta chain-specific monoclonal antibodies generated against soluble gamma delta TCR. Evidence for a specific conformation adopted by the J delta 2 region and for a V delta 1 polymorphism. Romagné F, et al. **J Immunol Methods** 1996 Jan 16;189(1):25-36

Novel monoclonal antibody, SO-MU1, against human gastric MUC5AC apomucin. Sotozono M, et al. **J Immunol Methods** 1996 Jun 10;192(1-2):87-96

An improved cell-ELISA for the differential screening of antibodies against cell surface molecules of viable adherent Schwann cells. Wewetzer K, et al. **J Immunol Methods** 1996 May 27;191(2):171-8

Characterization of anti-mouse IL-12 monoclonal antibodies and measurement of mouse IL-12 by ELISA. Wilkinson VL, et al. **J Immunol Methods** 1996 Jan 16;189(1):15-24

The crystal structure of the antibody N10-staphylococcal nuclease complex at 2.9 A resolution. Bossart-Whitaker P, et al. **J Mol Biol** 1995 Nov 3;253(4):559-75

Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops. Xiang J, et al. **J Mol Biol** 1995 Oct 27;253(3):385-90

Conservation of water molecules in an antibody-antigen interaction. Braden BC, et al. **J Mol Recognit** 1995 Sep-Oct;8(5):317-25

Drug-protein conjugates: haptenation of 1-methyl-10 alpha-methoxydihydrolysergol and 5-bromonicotinic acid to albumin for the production of epitope-specific monoclonal antibodies against nicergoline. Gabor F, et al. **J Pharm Sci** 1995 Sep;84(9):1120-5

Solution properties of Escherichia coli-expressed VH domain of anti-neuraminidase antibody NC41. Kortt AA, et al. **J Protein Chem** 1995 Apr;14(3):167-78

Comparative properties of polyclonal and monoclonal antibodies. Rodkey LS. **Methods Mol Biol** 1995;51:139-50

Screening strategies for catalytic antitransition-state analog antibodies. Tramontano A. **Methods Mol Biol** 1995; 51:237-50

Three antigenic regions in p17 of human immunodeficiency virus type 1 (HIV-1) revealed by mouse monoclonal antibodies and human antibodies in HIV-1 carrier sera. Liu X, et al. **Microbiol Immunol** 1995;39(10):775-85

Ber-EP4 immunoreactivity in normal skin and cutaneous neoplasms. Jimenez FJ, et al. **Mod Pathol** 1995 Oct; 8(8):854-8

Reactivity and epitope mapping of single-chain T cell receptors with monoclonal antibodies. Brodnicki TC, et al. **Mol Immunol** 1996 Feb;33(3):253-63

Metal-binding properties of a calcium-dependent monoclonal antibody. Hopp TP, et al. **Mol Immunol** 1996 May-Jun;33(7-8):601-8

Molecular characterization of a monoclonal antibody produced in response to a group C meningococcal polysaccharide peptide mimic. Hutchins WA, et al. **Mol Immunol** 1996 Apr;33(6):503-10

Specificity of monoclonal antibodies produced against

phosphorothioate and ribo modified DNAs. Latimer LJ, et al. **Mol Immunol** 1995 Oct;32(14–15):1057–64

Primary structures of three Armenian hamster monoclonal antibodies specific for idiotopes and metatopes of the monoclonal anti-fluorescein antibody 4-4-20. Mallender WD, et al. **Mol Immunol** 1995 Oct;32(14–15):1093–103

N-glycanase treatment of F(ab')2 derived from asymmetric murine IgG3 mAb determines the acquisition of precipitating activity. Mathov I, et al. **Mol Immunol** 1995 Oct;32(14–15):1123–30

Characterization of a monoclonal antibody directed against the NH2 terminal area of interleukin-2 (IL-2) and inhibiting specifically the binding of IL-2 to IL-2 receptor beta chain (IL-2R beta). Moreau JL, et al. **Mol Immunol** 1995 Oct;32(14–15):1047–56

Analysis of the interaction between a synthetic peptide of influenza virus hemagglutinin and monoclonal antibodies using an optical biosensor. Nice EC, et al. **Mol Immunol** 1996 May-Jun;33(7–8):659–70

Characteristics of human antibody repertoires following active immune responses in vivo. Ohlin M, et al. **Mol Immunol** 1996 May-Jun;33(7–8):583–92 (79 ref.)

Heteroligation of a mouse monoclonal IgE antibody (La2) with small molecules, analysed by computer-aided automated docking. Sotriffer CA, et al. **Mol Immunol** 1996 Feb;33(2):129–44

Structural analysis of affinity maturation: the three-dimensional structures of complexes of an anti-nitrophenol antibody. Yuhasz SC, et al. **Mol Immunol** 1995 Oct;32(14–15):1143–55

Solid phase labeling of monoclonal antibodies with 99mTc using two bifunctional photocleavable reagents. Ranadive GN, et al. **Nucl Med Biol** 1995 Jul;22(5):607–12

Preservation of immunoreactivity in the photolabeling of the B72.3 human antibody. Pandurangl RS, et al. **Photochem Photobiol** 1996 Jul;64(1):100–5

Photochemical linkage of antibodies to silicon chips. Sundarababu G, et al. **Photochem Photobiol** 1995 Jun; 61(6):540–4

Interactions of protein antigens with antibodies. Davies DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):7–12 (69 ref.)

Insights into antibody catalysis: structure of an oxygenation catalyst at 1.9-angstrom resolution. Hsieh-Wilson LC, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5363–7

Mapping protein-protein interactions by affinity-directed mass spectrometry. Zhao Y, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4020–4

Identifying a putative common binding site shared by substance P receptor and an anti-substance P monoclonal antibody. Amati V, et al. **Protein Eng** 1995 Apr;8(4):403–8

Determination of the pKa values of titratable groups of an antigen-antibody complex, HyHEL-5-hen egg lysozyme. McDonald SM, et al. **Protein Eng** 1995 Sep;8(9):915–24

1.85 A structure of anti-fluorescein 4-4-20 Fab. Whitlow M, et al. **Protein Eng** 1995 Aug;8(8):749–61

Crystallization and preliminary X-ray diffraction studies of complexes between an influenza hemagglutinin and Fab fragments of two different monoclonal antibodies. Gigant B, et al. **Proteins** 1995 Sep;23(1):115–7

Crystallization of intact monoclonal antibodies. Harris LJ, et al. **Proteins** 1995 Oct;23(2):285–9

Conformation of the T-cell antigen receptor-beta chain C-domain contributes to V beta 3 epitope recognition by monoclonal antibody KJ25. Li ZG, et al. **Scand J Immunol** 1996 Feb;43(2):140–5

Expression and characterization of a divalent chimeric anti-human CD3 single chain antibody. Ma S, et al. **Scand J Immunol** 1996 Feb;43(2):134–9

Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis. Greenwood J, et al. **Ther Immunol** 1994 Oct;1(5):247–55

Considerations in the design and production of small anti-receptor antibody forms: optimizing gains while reducing size. Peterson NC, et al. **Ther Immunol** 1994 Oct; 1(5):289–95 (58 ref.)

Immunohistological reaction mechanism of anti-monosialoganglioside monoclonal antibody, MAb 202, showing predominant cytotoxicity for malignant melanoma. Ota T, et al. **Tohoku J Exp Med** 1995 Sep; 177(1):1–12

Intestinal immunization of mice with antigen conjugated to anti-MHC class II antibodies. Estrada A, et al. **Vaccine** 1995 Jul;13(10):901–7

Expression of the monoclonal antibody HECA-452 defined E-selectin ligands in Langerhans cell histiocytosis. Simonitsch I, et al. **Virchows Arch** 1996 Feb;427(5):477–81

CLASSIFICATION

Evaluation of monoclonal antibodies with specificity for human IgA, IgA subclasses and allotypes and secretory component. Results of an IUIS/WHO collaborative study. Mestecky J, et al. **J Immunol Methods** 1996 Jun 21; 193(2):103–48

Rapid isotyping of mouse monoclonal antibodies. Pouletty P. **Methods Mol Biol** 1995;45:69–78

Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Nustad K, et al. **Tumour Biol** 1996; 17(4):196–219

DIAGNOSTIC USE

ELISA inhibition test using monoclonal antibody specific for Treponema pallidum as the serologic test for syphilis. Whang KK, et al. **Acta Derm Venereol** 1995 Sep;75(5):397–9

A putative mechanism for the non-specific uptake of intact radiolabelled monoclonal antibodies in the testes and prostate. Ahlström KE, et al. **Acta Oncol** 1996;35(3):303–7

Radiolabeled monoclonal antibodies in diagnosis and therapy of cancer. Summary and perspectives. Britton KE. **Acta Oncol** 1996;35(3):385–90

Breast cancer 99mTc SM3 radioimmunoscintigraphy. Granowska M, et al. **Acta Oncol** 1996;35(3):319–21

Aggressive hepatic leiomyosarcoma--an immunohistochemical evaluation of malignant potential using monoclonal antibody MIB-1. Higuchi T, et al. **Acta Oncol** 1995;34(7):970–1

Double-tracer dosimetry of organs in assessment of bone marrow involvement by two monoclonal antibodies. Korppi-Tommola ET, et al. **Acta Oncol** 1996;35(3):357–65

The pattern of HMB-45 antibody staining in compound Spitz nevi. Bergman R, et al. **Am J Dermatopathol** 1995 Dec; 17(6):542–6

Rapid diagnosis of major variants of congenital epidermolysis bullosa using a monoclonal antibody against collagen type IV. Bolte C, et al. **Am J Dermatopathol** 1995 Dec; 17(6):580–3

Patterns of cell proliferation in actinic keratoacanthomas and squamous cell carcinomas of the skin. Immunohistochemical study using the MIB 1 antibody in formalin-fixed paraffin sections [see comments] Skálová A, et al. **Am J Dermatopathol** 1995 Aug;17(4):332–4. Comment in: Am J Dermatopathol 1995 Aug;17(4):319–20.

Monoclonal antibodies in the management of acute leukemia. Wang JC, et al. **Am J Hematol** 1995 Nov;50(3):188–99 (159 ref.)

Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. Ioachim HL, et al. **Am J Surg Pathol** 1996 Jan;20(1):64–71

Utility of a paraffin section-reactive CD56 antibody (123C3) for characterization and diagnosis of lymphomas. Tsang WY, et al. **Am J Surg Pathol** 1996 Feb;20(2):202–10

Production of monoclonal and polyclonal antibodies against various haemoglobins for the detection of thalassaemias. Gan YY, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):75–8 (20 ref.)

Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Askanas V, et al. **Ann Neurol** 1996 Mar;39(3):389–91

Immunocytochemistry of cytological specimens as a diagnostic and prognostic tool. Giovagnoli MR, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2225–32 (56 ref.)

Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine. Greiner JW, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2129–33 (23 ref.)

Tumor markers as targets for selective diagnostic and therapeutic procedures. Roselli M, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2187–92 (59 ref.)

Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab')2 (FO23C5) in CEA serum-negative colorectal cancer patients. Roselli M, et al. **Anticancer Res** 1996 Mar-Apr;16(2):883–9

Radiolabeled monoclonal antibodies. Brumley CL, et al. **AORN J** 1995 Sep;62(3):343–50, 353–5; quiz 356–8, 361–2 (12 ref.)

A novel human monoclonal antibody against cervical cancer: its immunoreactivity with normal tube and ovary and with ovarian tumor tissue. Nakanishi T, et al. **Arch Gynecol Obstet** 1995;256(4):177–84

Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Müller W, et al. **Br J Cancer** 1996 Sep;74(5):759–65

Improved flow cytometric identification of myelopoiesis by the simultaneous labelling with CD13, CD14 and CD66 monoclonal antibodies. Bonde J, et al. **Br J Haematol** 1996 Feb;92(2):269–79

Prostatic radioimmunoscintigraphy: preliminary results using technetium-labelled monoclonal antibody, CYT-351. Feneley MR, et al. **Br J Urol** 1996 Mar;77(3):373–81

Differential distributions of HNK-1 and tenascin immunoreactivity during innervation of myotomal muscle in Xenopus. Somasekhar T, et al. **Brain Res Dev Brain Res** 1995 Aug 28;88(1):53–67

The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report. Method MW, et al. **Cancer** 1996 Jun 1;77(11):2286–93

Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Muto MG, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2016–27 (100 ref.)

99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphoma. Vervoordeldonk SF, et al. **Cancer Immunol Immunother** 1996 Jun;42(5):291–6

Breakthroughs and slow progress: tumor targeting with antibodies [editorial; comment] Beatty JD. **Cancer Invest** 1996;14(3):287. Comment on: Cancer Invest 1996;14(3):211–7.

Diagnosis of breast carcinoma with radiolabeled monoclonal antibodies (MoAbs) to carcinoembryonic antigen (CEA) and human milk fat globulin (HMFG). Rosner D, et al. **Cancer Invest** 1995;13(6):573–82

Improved staging of B-cell non-Hodgkin's lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment. Blend MJ, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5764s–5770s

Enhanced radioimmunotargeting of 125I-labeled L6-biotin monoclonal antibody (MAb) by combining preload of cold L6 MAb and subsequent immunoadsorption in rats. Garkavij M, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5874s–5880s

Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2. Gulec SA, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5774s–5776s

Syngeneic anti-idiotypic antibodies eliminate excess radiolabeled idiotypes at experimental radioimmunolocalization. Ullén A, et al. **Cell Biophys** 1995 Aug;27(1):31–45

RT97: a marker for capsaicin-insensitive sensory endings in the rat skin. Sann H, et al. **Cell Tissue Res** 1995 Oct; 282(1):155–61

Significance of urinary fibrin/fibrinogen degradation products (FDP) D-dimer measured by a highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases. Shibata T, et al. **Clin Nephrol** 1995 Aug;44(2):91–5

False-positive imaging of In-111 labeled monoclonal antibody conjugate CYT-103 in a patient with metastatic colorectal carcinoma. Bhatia M, et al. **Clin Nucl Med** 1995 Nov;20(11):979–80

Intense uptake of In-111 satumomab pendetide in an inflammatory mass. Silberstein EB, et al. **Clin Nucl Med** 1996 Jan;21(1):53–5

Rapid imaging of infections with a monoclonal antibody fragment (LeukoScan). Becker W, et al. **Clin Orthop** 1996 Aug;(329):263–72

Pharmacokinetics and dosimetry of [111In] F(ab')2 fragments against prostatic acid phosphatase after intraprostatic injection for immunoscintigraphy in prostate cancer. Nielsen JT, et al. **Clin Physiol** 1995 Sep;15(5):467–81

Use of monoclonal antibodies for identification of growth-controlling neuropeptides in the mussel Mytilus edulis (Mollusca:Bivalvia). Kellner-Cousin K, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):689–98

Recent progress in the use of monoclonal antibodies for imaging and therapy. Monson JR. **Curr Opin Gen Surg** 1993;:334–9 (24 ref.)

Micrometastasis detection and treatment with monoclonal antibodies. Pantel K, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):1–18 (88 ref.)

Comparison of monoclonal antibodies for flow cytometric analysis of HLA-B27 antigen. Ward AM, et al. **Cytometry** 1995 Mar 15;22(1):65–9

Anti-melanoma monoclonal antibody 225.28S immunoscintigraphy in metastatic melanoma. Böni R, et al. **Dermatology** 1995;191(2):119–23

111In-CYT-103 scanning in recurrent colorectal cancer--does it affect standard management? Dominguez JM, et al. **Dis Colon Rectum** 1996 May;39(5):514–9

Active myocardial damage in hyperthyroidism. A concurrent mechanism of heart failure reversed by treatment. Marti V, et al. **Eur Heart J** 1995 Jul;16(7):1014–6

Flow cytometry and monoclonal antibodies identify normal liver cell populations antigenically related to oval cells. Agelli M, et al. **Eur J Histochem** 1995;39(3):175–82

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences. Alexander C, et al. **Eur J Nucl Med** 1995 Jul;22(7):645–51

Experience with the iodine-123 and technetium-99m labelled anti-granulocyte antibody MAb47: a comparison of labelling methods. Bläuenstein P, et al. **Eur J Nucl Med** 1995 Jul;22(7):690–8

Immunoscintigraphy for ocular melanoma: a reliable diagnostic technique? Loeffler KU, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Feb;234(2):100–4

Immunodetection of squamous cell carcinoma-associated variant of nuclear protein. Rakowicz-Szulczynska EM, et al. **Gynecol Oncol** 1996 Feb;60(2):255–63

Immunocytochemical detection of lung cancer cells with monoclonal antibodies to 14-3-3 proteins. Setoguchi Y, et al. **Hum Antibodies Hybridomas** 1995;6(4):137–44

Natural evolution of antimyosin scan and cardiac function in patients with acute myocarditis. Lekakis J, et al. **Int J Cardiol** 1995 Nov 10;52(1):53–8

Radioimmunodetection of human cervical carcinoma xenograft by 111In-labeled monoclonal antibody MAb Cx-99. Yuan CC, et al. **Int J Gynaecol Obstet** 1995 Jul; 49 Suppl:S33–8

Monoclonal antibody MIB1 in the assessment of cervical squamous intraepithelial lesions. McCluggage WG, et al. **Int J Gynecol Pathol** 1996 Apr;15(2):131–6

Uterine adenomatoid tumors: immunohistochemical characteristics with emphasis on Ber-EP4 immunoreactivity and distinction from adenocarcinoma. Otis CN. **Int J Gynecol Pathol** 1996 Apr;15(2):146–51

Encephalocytozoon intestinalis-specific monoclonal antibodies for laboratory diagnosis of microsporidiosis. Beckers PJ, et al. **J Clin Microbiol** 1996 Feb;34(2):282–5

Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. Moffat FL Jr, et al.

J Clin Oncol 1996 Aug;14(8):2295–305

OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material. Edwards C, et al. **J Clin Pathol** 1995 Jul;48(7):626–30

VS38 immunostaining in melanocytic lesions. Shanks JH, et al. **J Clin Pathol** 1996 Mar;49(3):205–7

Detection of Haemophilus ducreyi lipooligosaccharide by means of an immunolimulus assay. Hansen EJ, et al. **J Immunol Methods** 1995 Sep 25;185(2):225–35

Taxane–specific monoclonal antibodies: measurement of taxol, baccatin III, and "total taxanes" in Taxus brevifolia extracts by enzyme immunoassay. Grothaus PG, et al. **J Nat Prod** 1995 Jul;58(7):1003–14

Preclinical evaluation of SPECT imaging with 131I–labeled monoclonal antibody SZ39 in nude mice bearing human glioma xenografts. Lan Q, et al. **J Neuroimaging** 1996 Apr; 6(2):131–5

Indium–111–antimyosin and iodine–123–MIBG studies in early assessment of doxorubicin cardiotoxicity. Carrió I, et al. **J Nucl Med** 1995 Nov;36(11):2044–9

Dosimetry of copper–64–labeled monoclonal antibody 1A3 as determined by PET imaging of the torso. Cutler PD, et al. **J Nucl Med** 1995 Dec;36(12):2363–71

Pharmacokinetics and scintigraphy of indium–111–DTPA–MOC–31 in small–cell lung carcinoma. Kosterink JG, et al. **J Nucl Med** 1995 Dec; 36(12):2356–62

Monoclonal antibody scan holds promise for prostate cancer staging [news] Kotz D. **J Nucl Med** 1996 Apr; 37(4):11N–12N, 15N

Difference analysis of antifibrin images in the detection of deep venous thrombosis. Line BR, et al. **J Nucl Med** 1995 Dec;36(12):2326–32

Comparison of iodine–123–vasoactive intestinal peptide receptor scintigraphy and indium–111–CYT–103 immunoscintigraphy. Raderer M, et al. **J Nucl Med** 1996 Sep;37(9):1480–7

Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. Reubi JC. **J Nucl Med** 1995 Oct; 36(10):1825–35 (61 ref.)

Biodistribution of indium–111–labeled antibody directed against intercellular adhesion molecule–1. Sasso DE, et al. **J Nucl Med** 1996 Apr;37(4):656–61

Galactose–modified streptavidin–GC4 antifibrin monoclonal antibody conjugates: application for two–step thrombus/embolus imaging. Rosebrough SF, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):770–5

Analysis of proliferative activity using antiproliferating cell nuclear antigen antibody in colorectal cancer. Nakae S, et al. **J Surg Oncol** 1995 Nov;60(3):149–53

Therapy and imaging of pancreatic carcinoma xenografts with radioiodine–labeled chimeric monoclonal antibody A10 and its Fab fragment. Kamigaki T, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1216–23

Diagnosis of bovine cryptosporidiosis by indirect immunofluorescence assay using monoclonal antibody. Wee SH, et al. **Korean J Parasitol** 1995 Jun;33(2):107–15

Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies. Williams LE, et al. **Med Phys** 1995 Dec;22(12):2025–7

Utility of a proliferation marker in distinguishing between benign naevocellular naevi and naevocellular naevus–like lesions with malignant properties. Kanter L, et al. **Melanoma Res** 1995 Oct;5(5):345–50

Microparticle immunoenzymatic assay for detection of prostate specific antigen: characterization of the technique and comparative analysis with a monoclonal immunoradiometric assay. Sánchez de la Muela P, et al. **Mil Med** 1995 Aug;160(8):416–9

Carboxyl end–specific monoclonal antibodies to amyloid beta protein (A beta) subtypes (A beta 40 and A beta 42(43)) differentiate A beta in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys. Nakamura S, et al. **Neurosci Lett** 1995 Dec 8;201(2):151–4

Analysis of choline acetyltransferase protein in temperature sensitive mutant flies using newly generated monoclonal antibody. Takagawa K, et al. **Neurosci Res** 1996 Feb; 24(3):237–43

Immunoscintigraphy with a 99Tcm–labelled anti–granulocyte monoclonal antibody in patients with human immunodeficiency virus infection and AIDS. Prvulovich EM, et al. **Nucl Med Commun** 1995 Oct; 16(10):838–45

Falsely negative 99mTc–antigranulocyte immunoscintigraphy and positive 99mTc–HMPAO–labelled leukocyte scan in active Crohn's disease. Possible effects of immunosuppressive therapy? Ivančević V, et al. **Nuklearmedizin** 1995 Dec;34(6):248–51

Plasmodium vivax: detection of blood parasites using fluorochrome labelled monoclonal antibodies. Perez HA, et al. **Parasite Immunol** 1995 Jun;17(6):305–12

A new monoclonal antibody (IE8) reactive with dendritically shaped cells in the human tonsil. Nagasaki M, et al. **Pathol Int** 1995 Apr;45(4):266–74

Flow sorting of fetal erythroblasts using intracytoplasmic anti–fetal haemoglobin: preliminary observations on maternal samples. Zheng YL, et al. **Prenat Diagn** 1995 Oct; 15(10):897–905

Detection of pelvic recurrence of colorectal carcinoma: prospective, blinded comparison of Tc–99m–IMMU–4 monoclonal antibody scanning and CT. Stomper PC, et al. **Radiology** 1995 Dec;197(3):688–92

Monoclonal antibodies: innovations in diagnosis and therapy. Baquiran DC, et al. **Semin Oncol Nurs** 1996 May; 12(2):130–41 (71 ref.)

Evaluation of WHO monoclonal antibody kit for diagnosis of acute respiratory viral infections. Khairullah NS, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):263–7

Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Bertsch DJ, et al. **Surgery** 1995 Oct;118(4):634–8; discussion 638–9 (9 ref.)

Scintigraphy and biodistribution of monoclonal adrenocortical antibody in mice grafted with human adrenocortical carcinoma. Ohrvall U, et al. **Surgery** 1995 Nov;118(5):893–900

Anti–CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer. Buccheri G, et al. **Thorax** 1996 Apr;51(4):359–63

Comparison of serum and urinary levels of modified nucleoside, 1–methyladenosine, in cancer patients using a monoclonal antibody–based inhibition ELISA. Ishiwata S, et al. **Tohoku J Exp Med** 1995 May;176(1):61–8

Use of a directly conjugated monoclonal anti–D (BRAD–3) for quantification of fetomaternal hemorrhage by flow cytometry [see comments] Lloyd–Evans P, et al. **Transfusion** 1996 May;36(5):432–7. Comment in: Transfusion 1996 May;36(5):392–3.

Enzyme linked immunosorbent assay for identification of whole Mycobacterium bovis isolates with the monoclonal antibodies. Androsova MV, et al. **Tuber Lung Dis** 1996 Aug;77(4):348–52

Radioimmunoguided surgery: clinical experience with different monoclonal antibodies and methods. Di Carlo V, et al. **Tumori** 1995 May–Jun;81(3 Suppl):98–102

Clinical utility of radioimmunoscintigraphy of non–Hodgkin's lymphoma with radiolabelled LL2 monoclonal antibody, LymphoSCAN: preliminary results. Gasparini M, et al. **Tumori** 1995 May–Jun;81(3):173–8

Peroperative radioimmunodetection, PROD, of colorectal cancer using 99m–Tc PR1A3 monoclonal antibody. Howell R, et al. **Tumori** 1995 May–Jun;81(3 Suppl):107–8

Dual–parameter immunoflow cytometry—a new technique in the noninvasive diagnosis of bladder cancer. Jankevicius F, et al. **Urol Int** 1995;55(2):68–73

Immunohistochemical detection of canine leucocyte antigens by specific monoclonal antibodies in canine normal tissues. Rabanal RM, et al. **Vet Immunol Immunopathol** 1995 Jul; 47(1–2):13–23

Detection of tumor–associated antigens in sera of canine cancer patients by monoclonal antibodies generated against canine mammary carcinoma cells. Wang J, et al. **Vet Immunol Immunopathol** 1995 Oct;48(3–4):193–207

Immunohistochemical diagnosis of systemic bovine zygomycosis by murine monoclonal antibodies. Jensen HE, et al. **Vet Pathol** 1996 Mar;33(2):176–83

Use of a single anti–nucleocapsid monoclonal antibody to detect rabies antigen in formalin–fixed, paraffin–embedded tissues. Hamir AN, et al. **Vet Rec** 1996 Feb 3;138(5):114–5

[Monoclonal antibodies for diagnosis and therapy in oncological patients] Boven E, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2552–8 (31 ref.) **(Dut)**

[Monoclonal antibodies for diagnosis and therapy in oncological patients (letter)] van Duijnhoven JL. **Ned Tijdschr Geneeskd** 1996 Feb 24;140(8):453 **(Dut)**

[Indium III monoclonal antimyosin antibody scintigraphy for the detection of chronic myocardial infarction apart from the acute phase] Adrie C, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1863–8 (33 ref.) (Eng. Abstr.) **(Fre)**

[Suitability of monoclonal reagents for antigen determination in T–antigen activation] Strobel E. **Infusionsther Transfusionsmed** 1995 Aug;22(4):249–57 (Eng. Abstr.) **(Ger)**

[Evaluation of a new method for determining glycated hemoglobin with monoclonal antibodies (DCA 2000)] Kopp HP, et al. **Wien Klin Wochenschr** 1996;108(1):16–9 (Eng. Abstr.) **(Ger)**

[Simultaneous double nucleotide scintigraphy with indium 111 antimyosin Fab and technetium sestamibi for evaluation of myocardial viability after experimental and clinical infarct] Morguet AJ, et al. **Z Kardiol** 1996 Jun;85(6):388–94 (Eng. Abstr.) **(Ger)**

[Diagnosis and targeting therapy of colorectal cancer using antibody] Yamaguchi T, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):549–53 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Image diagnosis of heart diseases using new radioisotope compounds] Nishimural T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1564–8 (8 ref.) **(Jpn)**

[Analysis of the proliferative potential of meningiomas with MIB–1 monoclonal antibodies] Miyagami M, et al. **No To Shinkei** 1996 Jan;48(1):39–43 (Eng. Abstr.) **(Jpn)**

[Monoclonal antibodies in diagnosis of acute leukemias] Krawczyńska A, et al. **Przegl Lek** 1996;53(1):20–5 (41 ref.) (Eng. Abstr.) **(Pol)**

[Anti–macrophage monoclonal antibody D–11 in the diagnosis of histiocytic tumors] Petrovichev NN, et al. **Arkh Patol** 1995 Jul–Aug;57(4):25–30 (Eng. Abstr.) **(Rus)**

[Use of a new antimacrophage monoclonal antibody D11 in diagnosis of hemoblastosis] Frenkel' MA, et al. **Gematol Transfuziol** 1995 Jul–Aug;40(4):13–6 (Eng. Abstr.) **(Rus)**

[Comparative analysis of causes of error in determining blood groups of the ABO system with isohemagglutinating sera and monoclonal antibodies] Zavgorodnii GN, et al. **Gematol Transfuziol** 1995 Jul–Aug;40(4):42–4 **(Rus)**

[The comparative results of determining the rhesus classification of donors using anti–D monoclonal antibodies on the plate and a universal reagent in the test tube without heating] Zavgorodnii GN, et al. **Gematol Transfuziol** 1995 Nov–Dec;40(6):40–1 **(Rus)**

[The use of the immunoperoxidase test with monoclonal antibodies for detecting influenza A viruses] Bakova AA, et al. **Mikrobiol Z** 1995 Jul–Aug;57(4):54–9 (Eng. Abstr.) **(Rus)**

[The evaluation of a monoclonal antibody panel for Lyssavirus typing in Mexico] Loza–Rubio E, et al. **Bol Oficina Sanit Panam** 1995 Nov;119(5):391–5 (Eng. Abstr.) **(Spa)**

[Pneumocystis carinii pneumonia. Diagnosis using immunofluorescence with monoclonal antibodies (letter)] Cruz Villuendas M, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):64–5 **(Spa)**

[The use of FD–6 monoclonal antibody in diagnosing and detecting the carriers of familial amyloidotic polyneuropathy type I] López Domínguez JM, et al. **Neurologia** 1996 Mar;11(3):93–8 (Eng. Abstr.) **(Spa)**

[The diagnosis of rejection activity in the heart transplant by monoclonal antimyosin antibodies] Obrador D, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:92–5 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Effect of MUC1 mucin, an anti–adhesion molecule, on tumor cell growth. Makiguchi Y, et al. **Jpn J Cancer Res** 1996 May;87(5):505–11

GENETICS

Structure of the VH–D–JH segments of human natural polyreactive IgM and IgG antibodies. Use of germline or somatically mutated forms of commonly expressed VH genes. Ikematsu H, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:362–9

Structural correspondences between mouse and human immunoglobulin VH genes. Application to the humanization of mouse monoclonal antibodies. Poul MA, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:359–61

Cellular origin, antigen reactivity, and VH segment structure of IgM mAbs from AIDS lymphomas. Riboldi P, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:509–18

Immunoglobulin gene usage in diabetes–associated human monoclonal antibodies recognizing glutamate decarboxylase. Richter W, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:457–60

Repertoire cloning of human lupus autoantibodies. Silverman GJ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:565–6

Expression and regulation of clonally ignorant B cells. Thomas JW, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:461–2

Genetic and functional characterization of human autoantibodies using combinatorial phage display libraries. Zeidel M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:559–64

Molecular characterization of monoclonal IgM derived from human B cell lines expressing the 4C9 rheumatoid factor associated idiotype. Davidson A, et al. **Autoimmunity** 1995; 20(3):171–83

Rapid cytotoxicity of human B lymphocytes induced by VH4–34 (VH4.21) gene–encoded monoclonal antibodies. Bhat NM, et al. **Clin Exp Immunol** 1996 Jul;105(1):183–90

Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes. Lustgarten J, et al. **Eur J Immunol** 1995 Oct;25(10):2985–91

Sequences of the cDNAs encoding the heavy– and light–chain Fab region of an antibody to the phenylurea herbicide diuron. Bell CW, et al. **Gene** 1995 Nov 20; 165(2):323–4

Cloning and characterization of cDNAs coding for heavy and light chains of a monoclonal antibody (MabB23) specific for human plasma apolipoprotein B–100. Kwak JW, et al. **Gene** 1996 Mar 9;169(2):237–9

cDNA sequence analysis and characterization of a cytokine–inducing monoclonal antibody derived from autoimmune MRL/MP–lpr/lpr mouse. Kimura N, et al. **Hybridoma** 1995 Dec;14(6):523–8

PCR cloning and sequencing of a CD3–specific monoclonal antibody. Thirion S, et al. **Immunogenetics** 1996;43(3):167–8

Analysis of immunoglobulin variable region genes of a human IgM anti–myeloperoxidase antibody derived from a patient with vasculitis. Longhurst C, et al. **Immunology** 1996 Feb; 87(2):334–8

Monoclonal immunoglobulin A derived from peritoneal B cells is encoded by both germ line and somatically mutated VH genes and is reactive with commensal bacteria. Bos NA, et al. **Infect Immun** 1996 Feb;64(2):616–23

The pathogenic human monoclonal anti–DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Waisman A, et al. **Int Immunol** 1995 Apr;7(4):689–96

Human antibodies from transgenic mice. Lonberg N, et al. **Int Rev Immunol** 1995;13(1):65–93 (102 ref.)

Vl–linker–Vh orientation–dependent expression of single chain Fv–containing an engineered disulfide–stabilized bond in the framework regions. Luo D, et al.

ANTIBODIES, MONOCLONAL

J Biochem (Tokyo) 1995 Oct;118(4):825–31

An improved phage display antibody cloning system using newly designed PCR primers optimized for Pfu DNA polymerase. Yamanaka HI, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1218–27

Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E–deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. Palinski W, et al. **J Clin Invest** 1996 Aug 1;98(3):800–14

Ligand recognition by murine anti–DNA autoantibodies. II. Genetic analysis and pathogenicity. Swanson PC, et al. **J Clin Invest** 1996 Apr 1;97(7):1748–60

Humanization and molecular modeling of the anti–CD4 monoclonal antibody, OKT4A. Pulito VL, et al. **J Immunol** 1996 Apr 15;156(8):2840–50

Enhancing the avidity of a human recombinant anti–HIV–1 monoclonal antibody through oligomerization. Tsai PK, et al. **J Pharm Sci** 1995 Jul;84(7):866–70

Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single–chain variable fragments to inhibit early stages of the viral life cycle. Shaheen F, et al. **J Virol** 1996 Jun;70(6):3392–400

Principles and applications of recombinant antibody phage display technology to plant biology. Crosby WL, et al. **Methods Cell Biol** 1995;50:85–99

Variable region cDNA sequences and characterization of murine anti–human interferon gamma receptor monoclonal antibodies that inhibit receptor binding by interferon gamma. Bridges A, et al. **Mol Immunol** 1995 Dec; 32(17–18):1329–38

Engineering disulfide–linked single–chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti–digoxin 26–10 (sFv')2 and anti–c–erbB–2 741F8 (sFv')2 made by protein folding and bonded through C–terminal cysteinyl peptides. McCartney JE, et al. **Protein Eng** 1995 Mar;8(3):301–14

Expression and characterization of a divalent chimeric anti–human CD3 single chain antibody. Ma S, et al. **Scand J Immunol** 1996 Feb;43(2):134–9

A quasi–monoclonal mouse [see comments] Cascalho M, et al. **Science** 1996 Jun 14;272(5268):1649–52. Comment in: Science 1996 Jun 14;272(5268):1585.

Single–chain mono– and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Hayden MS, et al. **Ther Immunol** 1994 Jan;1(1):3–15

Bacterial expression of neutralizing mouse monoclonal antibody Fab fragments to Hantaan virus. Liang M, et al. **Virology** 1996 Mar 1;217(1):262–71

[Cloning and sequencing of VH and VL genes of an anti–human lung adenocarcinoma monoclonal antibody] Wang Y, et al. **J Chuan Hsueh Pao** 1996;23(2):91–5 (Eng. Abstr.) **(Chi)**

HISTORY

A little bit of CD history [editorial; comment] LeBien TW. **Transfusion** 1996 Mar;36(3):197–9. Comment on: Transfusion 1996 Mar;36(3):268–85.

IMMUNOLOGY

Multiple myeloma with monoclonal surface immunoglobulin expression: a case report. Dunphy CH, et al. **Acta Cytol** 1996 Mar–Apr;40(2):358–62

Adhesion of human hematopoietic progenitor cells to bone–marrow–derived stromal cells is enhanced by antibodies to CD44. Oostendorp RA, et al. **Acta Haematol** 1996;95(3–4):243–7

Immunostaining with monoclonal antibodies to eosinophil cationic protein (EG1 and EG2) does not distinguish between resting and activated eosinophils in formalin–fixed tissue specimens. Jahnsen F, et al. **Adv Exp Med Biol** 1995; 371A:283–6

Intracellular neutralization of Sendai and influenza viruses by IgA monoclonal antibodies. Mazanec MB, et al. **Adv Exp Med Biol** 1995;371A:651–4

Multifaceted consequences of anti–gp41 monoclonal antibody 2F5 binding to HIV type 1 virions. Neurath AR, et al. **AIDS Res Hum Retroviruses** 1995 Jun;11(6):687–96

Expression and purification of the HIV type 1 Rev protein produced in Escherichia coli and its use in the generation of monoclonal antibodies. Orsini MJ, et al. **AIDS Res Hum Retroviruses** 1995 Aug;11(8):945–53

Inhibition of HIV type 1 infection of mononuclear phagocytes by anti–CD44 antibodies. Rivadeneira ED, et al. **AIDS Res Hum Retroviruses** 1995 May;11(5):541–6

A monoclonal antibody defines a novel HIV type 1 Tat domain involved in trans–cellular trans–activation. Valvatne H, et al. **AIDS Res Hum Retroviruses** 1996 May 1;12(7):611–9

Monoclonal antibody against a major latex allergen reacts with latex products and ammoniated natural latex. Lu LJ, et al. **Allergy** 1995 Jul;50(7):545–50

Monoclonal antibodies PG–B6a and PG–B6p recognize, respectively, a highly conserved and a formol–resistant epitope on the human BCL–6 protein amino–terminal region. Flenghi L, et al. **Am J Pathol** 1996 May; 148(5):1543–55

The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors. Chan JK, et al. **Am J Surg Pathol** 1995 Oct;19(10):1115–23

Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. Ioachim HL, et al. **Am J Surg Pathol** 1996 Jan;20(1):64–71

A monoclonal immunoassay for the coplanar polychlorinated biphenyls. Chiu YW, et al. **Anal Chem** 1995 Nov 1; 67(21):3829–39

Comparative activity of peroxidase–antibody conjugates with periodate and glutaraldehyde coupling according to an enzyme immunoassay. Tresca JP, et al. **Ann Biol Clin (Paris)** 1995;53(4):227–31

Development and characterization of a monoclonal antibody 369.2B specific for the carboxyl–terminus of the beta A4 peptide. König G, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:344–55

Structure–function studies of human monoclonal antibodies to pneumococcus type 3 polysaccharide. Shaw DR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:370–3

Monoclonal anti–idiotypic antibodies as probes for common idiotopes shared by anti–"benzo(a)pyrene–like" IgA of cancer patients and rabbit anti–conjugated benzo(a)pyrene antibodies. Chagnaud JL, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2161–8

Human monoclonal antibody developed against a metastasizing paraganglioma: preparation and preclinical studies. Freiberg B, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2489–93

Monoclonal antibodies for detection of the H7 antigen of Escherichia coli. He Y, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3325–32

Production and characterization of monoclonal antibodies against the O–5 antigen of Salmonella typhimurium lipopolysaccharide. Jaradat ZW, et al. **Appl Environ Microbiol** 1996 Jan;62(1):1–5

Cell migration between graft and host—an analysis with monoclonal antibodies after allogeneic rat kidney transplantation. Krzymański M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(3–4):229–36

Influence of a rat kidney perfusion using the anti–MHC class II monoclonal antibody and reduced dose of 15–deoxyspergualine on the allogeneic graft survival. Oko A, et al. **Arch Immunol Ther Exp (Warsz)** 1995; 43(5–6):293–7

Antigenic relationships of hantavirus strains analysed by monoclonal antibodies. Dzagurova T, et al. **Arch Virol** 1995;140(10):1763–73

Identification of cell membrane proteins linked to susceptibility to bovine viral diarrhoea virus infection. Schelp C, et al. **Arch Virol** 1995;140(11):1997–2009

A monoclonal antibody that recognizes the GPIIb/IIIa antagonist DMP 728. Reversal of the effects of DMP 728 on platelet aggregation and bleeding time in the dog. Reilly TM, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec; 15(12):2195–9

Monoclonal antiphospholipid antibodies and germline VH genes: comment on the article by Harmer et al [letter; comment] Rahman A, et al. **Arthritis Rheum** 1996 Mar; 39(3):537–8. Comment on: Arthritis Rheum 1995 Aug;38(8):1068–76.

CAMPATH–1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose–escalation study. Weinblatt ME, et al. **Arthritis Rheum** 1995 Nov;38(11):1589–94

Characterization of monoclonal antibodies against infections laryngotracheitis virus. Abbas F, et al. **Avian Dis** 1996 Jan–Mar;40(1):49–55

ErbB receptor activation, cell morphology changes, and apoptosis induced by anti–Her2 monoclonal antibodies. Kita Y, et al. **Biochem Biophys Res Commun** 1996 Sep 4; 226(1):59–69

Characterization of a specific monoclonal antibody 9F5–3a and the development of assay system for oxidized HDL. Nakajima T, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):407–11

Characterization of monoclonal antibodies to epitopes of human transcobalamin II. Quadros EV, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):149–54

Triplex DNA in the nucleus: direct binding of triplex–specific antibodies and their effect on transcription, replication and cell growth. Agazie YM, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):461–6

Modulation of CD4 lateral mobility in intact cells by an intracellularly applied antibody. Grebenkämper K, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):251–9

Binding sites of monoclonal antibodies and dihydropyridine receptor alpha 1 subunit cytoplasmic II–III loop on skeletal muscle triadin fusion peptides. Fan H, et al. **Biochemistry** 1995 Nov 14;34(45):14893–901

4–4–20 anti–fluorescyl IgG Fab' recognition of membrane bound hapten: direct evidence for the role of protein and interfacial structure. Leckband DE, et al. **Biochemistry** 1995 Sep 12;34(36):11467–78

Identification of the epitope for monoclonal antibody 4B1 which uncouples lactose and proton translocation in the lactose permease of Escherichia coli. Sun J, et al. **Biochemistry** 1996 Jan 23;35(3):990–8

Effects of antibody binding on structural transitions of the nicotinic acetylcholine receptor. Tamamizu S, et al. **Biochemistry** 1996 Sep 10;35(36):11773–81

Human interleukin 4 receptor complex: neutralization effect of two monoclonal antibodies. Taremi SS, et al. **Biochemistry** 1996 Feb 20;35(7):2322–31

Purification and characterization of N–acetylmuramyl–L–alanine amidase from human plasma using monoclonal antibodies. Hoijer MA, et al. **Biochim Biophys Acta** 1996 Feb 9;1289(1):57–64

Molecular characterization of Euglena ascorbate peroxidase using monoclonal antibody. Ishikawa T, et al. **Biochim Biophys Acta** 1996 May 21;1290(1):69–75

Identification of monoclonal antibodies that recognize different disulfide bonded forms of thrombospondin 1. Matthias LJ, et al. **Biochim Biophys Acta** 1996 Sep 5; 1296(2):138–44

Subunit specific monoclonal antibodies show different steady–state levels of various cytochrome–c oxidase subunits in chronic progressive external ophthalmoplegia. Taanman JW, et al. **Biochim Biophys Acta** 1996 Apr 12; 1315(3):199–207

Epitope of 24G7 anti–bilirubin monoclonal antibody. Yamaguchi T, et al. **Biochim Biophys Acta** 1996 Feb 9; 1289(1):110–4

Heterogeneous localization of epitopes along axonemes of mammalian cilia. Mencarelli C, et al. **Biol Cell** 1995; 83(2–3):179–84

Use of monoclonal antibodies in the standardization of Parietaria judaica allergenic extracts. Afferni C, et al. **Biologicals** 1995 Sep;23(3):239–47

A monoclonal antibody recognizing CD43 (leukosialin) initiates apoptosis of human hematopoietic progenitor cells but not stem cells. Bažil V, et al. **Blood** 1996 Feb 15; 87(4):1272–81

Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Behm FG, et al. **Blood** 1996 Feb 1; 87(3):1134–9

A human monoclonal antibody specific for the leucine–33 (P1A1, HPA–1a) form of platelet glycoprotein IIIa from a V gene phage display library. Griffin HM, et al. **Blood** 1995 Dec 15;86(12):4430–6

The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Hall SE, et al. **Blood** 1996 Jun 15;87(12):5332–40

Intracellular calcium and calcineurin regulate neutrophil motility on vitronectin through a receptor identified by antibodies to integrins alphav and beta3. Hendey B, et al. **Blood** 1996 Mar 1;87(5):2038–48

Anti–erythropoietin receptor monoclonal antibody: epitope mapping, quantification of the soluble receptor, and detection of the solubilized transmembrane receptor and the receptor–expressing cells. Morishita E, et al. **Blood** 1996 Jul 15;88(2):465–71

Distribution of ligand–occupied alpha IIb beta 3 in resting and activated human platelets determined by expression of a novel class of ligand–induced binding site recognized by monoclonal antibody AP6. Nurden P, et al. **Blood** 1996 Aug 1;88(3):887–99

A monoclonal antibody that recognizes a neo–antigen exposed in the E domain of fibrin monomer complexed with fibrinogen or its derivatives: its application to the measurement of soluble fibrin in plasma. Soe G, et al. **Blood** 1996 Sep 15;88(6):2109–17

Monoclonal antibody 7G3 recognizes the N–terminal domain of the human interleukin–3 (IL–3) receptor alpha–chain and functions as a specific IL–3 receptor antagonist. Sun Q, et al. **Blood** 1996 Jan 1;87(1):83–92

Monoclonal antibody directed to a fibrinogen A alpha #529–539 epitope inhibits alpha–chain crosslinking by transglutaminases. Mitkevich OV, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):85–92

Rapid engraftment of peripheral blood progenitor cell grafts purged with B cell–specific monoclonal antibodies and immunomagnetic beads. Dreger P, et al. **Bone Marrow Transplant** 1995 Oct;16(4):627–9

Comparison of MIB–1 proliferation index with S–phase fraction in human breast carcinomas. Ellis PA, et al. **Br J Cancer** 1996 Mar;73(5):640–3

Comparison of monoclonal antibodies 17–1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. Kievit E, et al. **Br J Cancer** 1996 Feb; 73(4):457–64

Generation of human monoclonal antibodies recognising membranous antigens of the lung adenocarcinoma cell line A549 using an AMeX immunohistostaining method. Yoshinari K, et al. **Br J Cancer** 1996 Aug;74(3):359–67

Heterogenous inhibition of platelet aggregation by monoclonal antibodies binding to multiple sites on GPIIIa. Liu LX, et al. **Br J Haematol** 1995 Dec;91(4):976–82

Inhibition of platelet adhesion to collagen by monoclonal anti–CD36 antibodies. Matsuno K, et al. **Br J Haematol** 1996 Mar;92(4):960–7

A plasmocyte selective monoclonal antibody (B–B4) recognizes syndecan–1. Wijdenes J, et al. **Br J Haematol** 1996 Aug;94(2):318–23

Lack of effect of TNF antibodies on the cardiovascular sequelae of lipopolysaccharide infusion in conscious rats. Waller J, et al. **Br J Pharmacol** 1995 Nov;116(5):2487–95

Characterization of murine brain–reactive monoclonal IgG autoantibodies. Crimando J, et al. **Brain Behav Immun** 1995 Sep;9(3):165–81

Binding of Alz 50 depends on Phe8 in tau synthetic peptides and varies between native and denatured tau proteins. Ksiezak–Reding H, et al. **Brain Res** 1995 Oct 30;

697(1-2):63-75
The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer. Devine PL, et al. **Cancer Biochem Biophys** 1993 Sep;13(4):221-38
Positive reaction of monoclonal antibody (TO73) with resistant leukemic cells. Kakihara T, et al. **Cancer Detect Prev** 1996;20(3):180-4
Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: identification of its antigen as a neutral glycolipid. Kingsley EA, et al. **Cancer Immunol Immunother** 1995 Dec;41(6):348-54
Human monoclonal antibody against colon cancer [see comments] Yao CZ, et al. **Cancer Invest** 1996;14(3):211-7 . Comment in: Cancer Invest 1996;14(3):287.
Biological activity of two humanized antibodies against two different breast cancer antigens and comparison to their original murine forms. Ceriani RL, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5852s-5856s
Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys. Co MS, et al. **Cancer Res** 1996 Mar 1;56(5):1118-25
Location of a protease-hypersensitive region in the multidrug resistance protein (MRP) by mapping of the epitope of MRP-specific monoclonal antibody QCRL-1. Hipfner DR, et al. **Cancer Res** 1996 Jul 15;56(14):3307-14
Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma. Kranenborg MH, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5864s-5867s
Development and evaluation of the specificity of a rat monoclonal anti-idiotype antibody, WN, to an anti-B-cell lymphoma monoclonal antibody, LL2. Losman MJ, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5978s-5982s
Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Peng D, et al. **Cancer Res** 1996 Aug 15;56(16):3666-9
Characterization of a monoclonal antibody that recognizes an arabinosylated (1-->6)-beta-D-galactan epitope in plant complex carbohydrates. Steffan W, et al. **Carbohydr Res** 1995 Oct 2;275(2):295-307
Antibodies to the food mutagens, 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine and 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline: useful for immunoassay and immunoaffinity chromatography of biological samples. Dragsted LO, et al. **Carcinogenesis** 1995 Nov;16(11):2795-806
KIM127, an antibody that promotes adhesion, maps to a region of CD18 that includes cysteine-rich repeats. Stephens P, et al. **Cell Adhes Commun** 1995 Dec;3(5):375-84
Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies. Helfand SC, et al. **Cell Immunol** 1996 Jan 10;167(1):99-107
IL-2-resistant hyporesponsiveness induced by CD4 mAbs in OKT3-activated human T cells is reversed by CD45RA triggering. Robinet E, et al. **Cell Immunol** 1996 Jan 10; 167(1):1-7
Effect of injection of anti-CD4 and anti-CD8 monoclonal antibodies on the development of experimental systemic lupus erythematosus in mice. Ruiz PJ, et al. **Cell Immunol** 1996 Jan 10;167(1):30-7
DEC-205, a 205-kDa protein abundant on mouse dendritic cells and thymic epithelium that is detected by the monoclonal antibody NLDC-145: purification, characterization, and N-terminal amino acid sequence. Swiggard WJ, et al. **Cell Immunol** 1995 Oct 15; 165(2):302-11
The CD45RB-associated epitope defined by monoclonal antibody CZ-1 is an activation and memory marker for mouse CD4 T cells. Varga SM, et al. **Cell Immunol** 1996 Jan 10;167(1):56-62
Signaling by a new anti-Thy 1 monoclonal antibody inhibits T cell proliferation and interferes with T-cell-mediated induction of costimulatory molecule B7-2. Wu Y, et al. **Cell Immunol** 1995 Oct 15;165(2):266-77
The characterization of the monoclonal antibody Th-10a, specific for a nuclear protein appearing in the S phase of the cell cycle in normal thymocytes and its unregulated expression in lymphoma cell lines. Muto M, et al. **Cell Prolif** 1995 Dec;28(12):645-57
A monoclonal anticarbohydrate antibody detecting superfast myosin in the masseter muscle. Kirkeby S. **Cell Tissue Res** 1996 Jan;283(1):85-92
Monoclonal antibody raised against murine IL-1 alpha peptide cross-reacts with a 60-kDa antigen in early Drosophila melanogaster embryo. Riparbelli MG, et al. **Cell Tissue Res** 1995 Nov;282(2):269-75
Immunochemiluminometric assay with two monoclonal antibodies against the N-terminal sequence of human parathyroid hormone. Gao P, et al. **Clin Chim Acta** 1996 Feb 9;245(1):39-59
Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies. Verheul AF, et al. **Clin Diagn Lab Immunol** 1994 Nov;1(6):729-36
Characterization of a monoclonal antibody specific for Brucella smooth lipopolysaccharide and development of a competitive enzyme-linked immunosorbent assay to improve the serological diagnosis of brucellosis. Weynants V, et al. **Clin Diagn Lab Immunol** 1996 May;3(3):309-14
Progressive renal lesions induced by administration of monoclonal antibody 1-22-3 to unilaterally nephrectomized rats. Cheng QL, et al. **Clin Exp Immunol** 1995 Oct;102(1):181-5
Diverse antigen specificity of erythrocyte-reactive monoclonal autoantibodies from NZB mice. de Sá Oliveira GG, et al. **Clin Exp Immunol** 1996 Aug;105(2):313-20
Preparation of a monoclonal antibody against mouse brain natriuretic peptide (BNP) and tissue distribution of BNP in mice. Nakagawa M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S186-7
Anti-endotoxin human monoclonal antibody A6H4C5 (HA-1A) utilizes the VH4.21 gene. Bieber MM, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S186-9
The use of neutralizing antibodies to demonstrate the role of transforming growth factor-beta and Amadori-glycated albumin as mediators of experimental diabetic kidney disease. Ziyadeh FN, et al. **Contrib Nephrol** 1996; 118:188-94 (39 ref.)
Humoral immune response in a marsupial Monodelphis domestica: anti-isotypic and anti-idiotypic responses detected by species-specific monoclonal anti-immunoglobulin reagents. Shearer MH, et al. **Dev Comp Immunol** 1995 May-Jun;19(3):237-46
Monoclonal antibodies recognising sialyl-Tn: production and application to immunochemistry. Devine PL, et al. **Dis Markers** 1995 Aug;12(3):175-86
Production and characterisation of anti-cardiac troponin-I monoclonal antibodies. Haider KH, et al. **Dis Markers** 1995 Aug;12(3):187-97
Characterization of neutrophil NADPH oxidase activity reconstituted in a cell-free assay using specific monoclonal antibodies raised against cytochrome b558. Batot G, et al. **Eur J Biochem** 1995 Nov 15;234(1):208-15
Monoclonal antibodies against two electron reduced riboflavin and a quantification of affinity constants for this oxygen-sensitive molecule. Bruggeman YE, et al. **Eur J Biochem** 1995 Nov 15;234(1):245-50
T-cell membrane-associated serine protease, tryptase TL2, binds human immunodeficiency virus type 1 gp120 and cleaves the third-variable-domain loop of gp120. Neutralizing antibodies of human immunodeficiency virus type 1 inhibit cleavage of gp120. Niwa Y, et al. **Eur J Biochem** 1996 Apr 1;237(1):64-70
Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Paemen L, et al. **Eur J Biochem** 1995 Dec 15;234(3):759-65
Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies. Tosi E, et al. **Eur J Cancer** 1996 Mar;32A(3):498-505
Detection improvement of cytomegalovirus antigen in human peripheral blood using monoclonal antibodies and automated reading of cell preparations. Boland GJ, et al. **Eur J Clin Invest** 1995 Sep;25(9):639-46
Monoclonal antibodies against Haemophilus ducreyi lipooligosaccharide and their diagnostic usefulness. Ahmed HJ, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct; 14(10):892-8
Inhibition of NK binding to K562 cells induced by MAb saturation of adhesion molecules on target membrane. Papa S, et al. **Eur J Histochem** 1994;38 Suppl 1:83-90
The blockage of the human transferrin receptor by a monoclonal antibody, EA.3, induces growth inhibition in leukemia cell lines. Valentini M, et al. **Eur J Histochem** 1994;38 Suppl 1:61-8
R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy. Boussiotis VA, et al. **Eur J Immunol** 1996 Sep;26(9):2149-54
Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction. Starling GC, et al. **Eur J Immunol** 1996 Apr; 26(4):738-46
Introduction: workshop summary of the CD15 monoclonal antibody panel from the Fifth International Workshop on Leukocyte Antigens. Ball ED. **Eur J Morphol** 1995 Apr; 33(2):95-100
Diagnosis of pulmonary lymphangioleiomyomatosis by HMB45 in surgically treated spontaneous pneumothorax. Tanaka H, et al. **Eur Respir J** 1995 Nov;8(11):1879-82
Identification of the antigen recognized by the monoclonal antibody 31D8. Spiekermann K, et al. **Exp Hematol** 1996 Feb;24(3):453-8
Characterization of monoclonal antibodies to proteinase-3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies. Sommarin Y, et al. **Exp Nephrol** 1995 Jul-Aug;3(4):249-56
Entamoeba histolytica: localization of a 30-kDa cysteine proteinase using a monoclonal antibody. Becker I, et al. **Exp Parasitol** 1996 Mar;82(2):171-81
Immunochemical characterization of antibody-coated nanoparticles. Velge-Roussel F, et al. **Experientia** 1996 Aug 15;52(8):803-6
Molecular recognition of lysozyme by monoclonal antibodies. Smith-Gill SJ. **EXS** 1996;75:277-300 (59 ref.)
Modulation of cardiac physiology by an anti-Trypanosoma cruzi monoclonal antibody after interaction with myocardium. Cremaschi G, et al. **FASEB J** 1995 Nov; 9(14):1482-8
Monoclonal antibody LU-BCRU-G7 against a breast tumour-associated glycoprotein recognizes the disaccharide Gal beta 1-3GlcNAc. Rye PD, et al. **Glycobiology** 1995 Jun;5(4):385-9
Characterization of carbohydrate structural features recognized by anti-arabinogalactan-protein monoclonal antibodies. Yates EA, et al. **Glycobiology** 1996 Mar; 6(2):131-9
Anti-hepatitis B virus activity of a mixture of two monoclonal antibodies in an "inhibition in solution" assay. Heijtink RA, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1078-83
Establishment by the rat lymph node method of epitope-defined monoclonal antibodies recognizing the six different alpha chains of human type IV collagen. Sado Y, et al. **Histochem Cell Biol** 1995 Oct;104(4):267-75
Production of monoclonal antibody against the C1 component of rat estramustine-binding protein: immunohistochemical study of rat prostate. Tamura Y, et al. **Histochem Cell Biol** 1995 Dec;104(6):429-33
Antigen-specific primary immune response of human B-lymphocytes after in vitro immunization with GM3 ganglioside. Alfonso M, et al. **Hum Antibodies Hybridomas** 1995;6(3):102-12
A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hu P, et al. **Hum Antibodies Hybridomas** 1995;6(2):57-67
Phage displayed antibodies specific for a cytoskeletal antigen. Selection by competitive elution with a monoclonal antibody. Meulemans EV, et al. **Hum Antibodies Hybridomas** 1995;6(3):113-8
A subset of HLA-DR9 molecules is detected by a polymorphic monoclonal antibody on lymphoblastoid cell lines but not on peripheral blood lymphocytes. Cayrol C, et al. **Hum Immunol** 1995 Sep;44(1):19-27
Identification of the epitope recognized by the human V beta 5-specific monoclonal antibody 42/1C1. Potential implications for disease therapy. Henwood J, et al. **Hum Immunol** 1995 Apr;42(4):301-6
Characterization of an HLA-DQ2-specific monoclonal antibody. Influence of amino acid substitutions in DQ beta 1*0202. Viken HD, et al. **Hum Immunol** 1995 Apr; 42(4):319-27
The cytotoxic HLA-DQ3 reactive human hybridoma antibody 4166 that may distinguish DQ7 + 8 from DQ9. Viken HD, et al. **Hum Immunol** 1995 Apr;42(4):281-8
Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Mittelman A, et al. **Hybridoma** 1995 Apr;14(2):175-81 (31 ref.)
Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3. Schmolling J, et al. **Hybridoma** 1995 Apr;14(2):183-6
Idiotypic restriction of murine monoclonal antibodies to a defined antigenic region of human thyroglobulin. Del Rio M, et al. **Immunol Invest** 1995 Aug;24(5):655-67
Binding reactivity of monoclonal anti-carcinoembryonic antigen (CEA) antibodies with cell membrane-bound CEA and with free CEA in solution. Murakami M, et al. **Immunol Invest** 1996 Jan-Mar;25(1-2):23-35
Reactivity of monoclonal antibodies established against a recombinant human endogenous retrovirus-K (HERV-K) envelope protein. Vogetseder W, et al. **Immunol Lett** 1995 May;46(1-2):129-34
Genetically determined CD45 variant of value in leucocyte tracing in vivo in the pig. Binns RM, et al. **Immunology** 1995 Sep;86(1):25-33
Recognition of CD52 allelic gene products by CAMPATH-1H antibodies. Hale C, et al. **Immunology** 1996 Jun;88(2):183-90
Chimaeric monoclonal antibodies encoded by the human VH26 gene from naïve transgenic mice display a wide range of antigen-binding specificities. Harmer IJ, et al. **Immunology** 1996 Jun;88(2):174-82
Human capillary endothelial cells from abdominal wall adipose tissue: isolation using an anti-pecam antibody. Springhorn JP, et al. **In Vitro Cell Dev Biol Anim** 1995 Jun;31(6):473-81
Comparison of the sensitivity & specificity of a polyclonal versus monoclonal capture antibody based Bead ELISA for direct detection of cholera toxin from stool specimens. Ramamurthy T, et al. **Indian J Med Res** 1996 Jul;104:125-8
Passive immunization with monoclonal antibodies against Porphyromonas gingivalis in patients with periodontitis. Booth V, et al. **Infect Immun** 1996 Feb;64(2):422-7
A novel 95-kilodalton antigen of Wuchereria bancrofti infective larvae identified by species-specific monoclonal antibodies. Burkot TR, et al. **Infect Immun** 1996 Feb; 64(2):485-8
Neutralizing monoclonal antibodies against listeriolysin: mapping of epitopes involved in pore formation. Darji A, et al. **Infect Immun** 1996 Jun;64(6):2356-8
Functional analysis of pneumolysin by use of monoclonal antibodies. de los Toyos JR, et al. **Infect Immun** 1996 Feb; 64(2):480-4
An oligomer of the major outer membrane protein of Chlamydia psittaci is recognized by monoclonal antibodies which protect mice from abortion. de Sa C, et al. **Infect Immun** 1995 Dec;63(12):4912-6
Differential effects of monoclonal antibody blockade of adhesion molecules on in vivo susceptibility to soft tissue infection. Garcia N, et al. **Infect Immun** 1995 Oct;

63(10):3816–9
Antibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumonia. Gigliotti F, et al. **Infect Immun** 1996 Jun;64(6):1892–9
Monoclonal antibodies specific for the bundle-forming pilus of enteropathogenic Escherichia coli. Girón JA, et al. **Infect Immun** 1995 Dec;63(12):4949–52
Characterization and immunoprotective properties of a monoclonal antibody against the major oocyst wall protein of Eimeria tenella. Karim MJ, et al. **Infect Immun** 1996 Apr;64(4):1227–32
Monoclonal antibodies that recognize a common pneumococcal protein with similarities to streptococcal group A surface glyceraldehyde-3-phosphate dehydrogenase. Kolberg J, et al. **Infect Immun** 1996 Sep; 64(9):3544–7
Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi. Liao J, et al. **Infect Immun** 1995 Nov;63(11):4429–32
Anti-Hsp65 antibodies recognize M proteins of group A streptococci. Quinn A, et al. **Infect Immun** 1996 Mar; 64(3):818–24
Delineation by use of specific monoclonal antibodies of the T-cell receptor and major histocompatibility complex interaction sites on the superantigen toxic shock syndrome toxin 1. Shimonkevitz R, et al. **Infect Immun** 1996 Apr; 64(4):1133–9
A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide. Barouch D, et al. **Int Immunol** 1995 Oct;7(10):1599–605
Identification and functional characterization of mouse CD29 with a mAb. Noto K, et al. **Int Immunol** 1995 May; 7(5):835–42
Activation of natural killer cells by the mAb YTA-1 that recognizes leukocyte function-associated antigen-1. Sugie K, et al. **Int Immunol** 1995 May;7(5):763–9
Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1. De Nardo GL, et al. **Int J Biol Markers** 1995 Apr-Jun;10(2):67–74
A novel anti-Thy-1 (CD90) monoclonal antibody induces apoptosis in mouse malignant T-lymphoma cells in spite of inducing bcl-2 expression. Fujita N, et al. **Int J Cancer** 1996 May 16;66(4):544–50
Monoclonal anti-idiotypic antibody functionally mimics the human gastrointestinal carcinoma epitope GA733. Maruyama H, et al. **Int J Cancer** 1996 Feb 8;65(4):547–53
Site-directed mutagenesis of hamster complement C1S: characterization with an active form-specific antibody and possible involvement of C1S in tumorigenicity. Sakiyama H, et al. **Int J Cancer** 1996 Jun 11;66(6):768–71
Characterization and epitope mapping of several new anti-P-glycoprotein monoclonal antibodies. Shapiro AB, et al. **Int J Cancer** 1996 Jul 17;67(2):256–63
Distinct sub-populations of carcinoma-associated MUC1 mucins as detected by the monoclonal antibody 9H8 and antibodies against the sialyl-Lewis a and sialyl-Lewis x epitopes in the circulation of breast-cancer patients. Sikut R, et al. **Int J Cancer** 1996 May 29;66(5):617–23
Suppression of humoral immunity by monoclonal antibody to CD79b, an invariant component of antigen receptors on B lymphocytes. Nakamura T, et al. **Int J Hematol** 1996 Jul;64(1):39–46
A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates. Cotropia J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jul; 12(3):221–32
The CDw65 monoclonal antibodies VIM-8 and VIM-11 bind to the neutral glycolipid V3FucnLc8Cer. Kniep B, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):456–62
Production and application of monoclonal antibodies specific to pyrroloquinoline quinone. Narita H, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):830–5
Anti-metatype antibody stabilization of Fv 4-4-20 variable domain dynamics. Carrero J, et al. **J Biol Chem** 1996 May 10;271(19):11247–52
A novel phosphatidylserine-binding peptide motif defined by an anti-idiotypic monoclonal antibody. Localization of phosphatidylserine-specific binding sites on protein kinase C and phosphatidylserine decarboxylase. Igarashi K, et al. **J Biol Chem** 1995 Dec 8;270(49):29075–8
Antigen binding properties of purified immunoglobulin A and reconstituted secretory immunoglobulin A antibodies. Lüllau E, et al. **J Biol Chem** 1996 Jul 5;271(27):16300–9
The inhibitory anti-beta1 integrin monoclonal antibody 13 recognizes an epitope that is attenuated by ligand occupancy. Evidence for allosteric inhibition of integrin function. Mould AP, et al. **J Biol Chem** 1996 Aug 23; 271(34):20365–74
Comparative structural and functional features of the human fibrinogen alpha C domain and the isolated alpha C fragment. Characterization using monoclonal antibodies to defined COOH-terminal A alpha chain regions. Rudchenko S, et al. **J Biol Chem** 1996 Feb 2;271(5):2523–30
Dual reactivity of several monoclonal anti-nucleosome autoantibodies for double-stranded DNA and a short segment of histone H3. Stemmer C, et al. **J Biol Chem** 1996 Aug 30;271(35):21257–61
Presence of N-unsubstituted glucosamine units in native heparan sulfate revealed by a monoclonal antibody. van den Born J, et al. **J Biol Chem** 1995 Dec 29;270(52):31303–9
Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4. Zhou J, et al. **J Biol Chem** 1996 May 3;271(18):10760–6
A cell-surface epitope associated with liver-preferential metastasis detected by the new monoclonal antibody 3H4 in the murine tumor model ER 15-P. Wulf GG, et al. **J Cancer Res Clin Oncol** 1996;122(8):476–82
Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. Hörkkö S, et al. **J Clin Invest** 1996 Aug 1; 98(3):815–25
Role of the intercellular adhesion molecule-1(ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. Kumasaka T, et al. **J Clin Invest** 1996 May 15;97(10):2362–9
Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement. Nomura A, et al. **J Clin Invest** 1995 Nov; 96(5):2348–56
Ligand recognition by murine anti-DNA autoantibodies. II. Genetic analysis and pathogenicity. Swanson PC, et al. **J Clin Invest** 1996 Apr 1;97(7):1748–60
Characterization of a monoclonal antibody specific for H type 2 structure of ABO blood group, and its use for measuring H type 2 on human red blood cells. Liu Y, et al. **J Clin Lab Anal** 1996;10(3):144–8
Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy. Reisfeld RA, et al. **J Clin Lab Anal** 1996; 10(3):160–6 (34 ref.)
Antisporozoite antibodies with protective and nonprotective activities: in vitro and in vivo correlations using Plasmodium gallinaceum, an avian model. Ramirez AD, et al. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):705–8
Monoclonal antibodies to rabbit hepatocyte myosin that cross-react with human liver myosin. Ueno T, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):223–9
A protective anti-peptide antibody against the immunodominant site of the A24 Cruzeiro strain of foot-and-mouth disease virus and its reactivity with other subtype viruses containing the same minimum binding sequence. Barnett PV, et al. **J Gen Virol** 1996 May;77 (Pt 5):1011–8
Comparison of equine arteritis virus isolates using neutralizing monoclonal antibodies and identification of sequence changes in GL associated with neutralization resistance. Glaser AL, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2223–33
Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. Schønning K, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):753–8
Conformational and linear epitopes on virus-like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2. Volpers C, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2661–7
Characterization of the nucleocapsid protein of Hantaan virus strain 76-118 using monoclonal antibodies. Yoshimatsu K, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):695–704
Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. Liu L, et al. **J Hematother** 1995 Oct;4(5):477–83
Immobilized antibodies to CD45 induce rapid morphologic changes and increased tyrosine phosphorylation of p56lck-associated proteins in T cells. Arendt CW, et al. **J Immunol** 1995 Dec 1;155(11):5095–103
Murine glomerulotropic monoclonal antibodies are highly oligoclonal and exhibit distinctive molecular features. Lefkowith JB, et al. **J Immunol** 1996 Aug 1;157(3):1297–305
Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2. Mnich SJ, et al. **J Immunol** 1995 Nov 1;155(9):4437–44
Human CD4-internal antigen anti-idiotypic monoclonal antibody: induction of a CD4-specific response in humans. Perosa F, et al. **J Immunol** 1996 May 1;156(9):3563–9
The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding. Tamm A, et al. **J Immunol** 1996 Aug 15;157(4):1576–81
CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human skin. Werfel T, et al. **J Immunol** 1996 Aug 15;157(4):1729–35
A rapid non-selective method to generate quadromas by microelectrofusion. Cao Y, et al. **J Immunol Methods** 1995 Nov 16;187(1):1–7
Determination of tissue inhibitor of metalloproteinases-2 (TIMP-2) in experimental animals using monoclonal antibodies against TIMP-2-specific oligopeptides. Fujimoto N, et al. **J Immunol Methods** 1995 Nov 16; 187(1):33–9
Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M. Gu ZJ, et al. **J Immunol Methods** 1996 Mar 28;190(1):21–7
Specific detection of the precursor of ras p21 with a mouse monoclonal anti-C-terminal peptide antibody, SARA-K1. Ishihara H, et al. **J Immunol Methods** 1995 Sep 25; 185(2):217–23
Comparison of three methods for competitive binding of monoclonal antibodies. The localization of antigenic sites for monoclonal antibodies on Panulirus interruptus hemocyanin. Perton FG, et al. **J Immunol Methods** 1996 Mar 28;190(1):117–25
TCRBV23 specificity of two monoclonal antibodies revealed by a panel of human V beta chains expressed in mouse cells. Romagné F, et al. **J Immunol Methods** 1995 Oct 26; 186(2):313–22
Neutralization of human cytomegalovirus by human CD13-specific antibodies. Giugni TD, et al. **J Infect Dis** 1996 May;173(5):1062–71
A monoclonal antibody to the NH2-terminal region of human interferon-gamma inhibits its antiproliferative activity without affecting its internalization. Folghera S, et al. **J Interferon Cytokine Res** 1995 Mar;15(3):197–204
Specificity of B.C1 for TGK after renaturation prior to transfer of proteins [letter; comment] Hohl D, et al. **J Invest Dermatol** 1996 Apr;106(4):801–3. Comment on: J Invest Dermatol 1995 Feb;104(2):211–7.
MAT-1, a monoclonal antibody that specifically recognizes human tyrosinase. Takimoto H, et al. **J Invest Dermatol** 1995 Dec;105(6):764–8
A monoclonal antibody to human macrophage gangliosides inhibits macrophage migration. Berenson CS, et al. **J Leukoc Biol** 1996 Mar;59(3):371–9
Development and characterization of a novel monoclonal antibody (mNI-11) that induces cell adhesion of the LPS-stimulated human monocyte-like cell line U937. Ikewaki N, et al. **J Leukoc Biol** 1996 May;59(5):697–708
Cardiac accumulation of 125I-labeled monoclonal antibody to atrial natriuretic peptide in a rat model of myocardial infarction. Kanda T, et al. **J Med** 1995;26(1-2):53–64
Outer-membrane protein- and rough lipopolysaccharide-specific monoclonal antibodies protect mice against Brucella ovis. Bowden RA, et al. **J Med Microbiol** 1995 Nov;43(5):344–7
Further characterisation of a monoclonal antibody reactive with Escherichia coli O157:H7. Clark CG, et al. **J Med Microbiol** 1995 Oct;43(4):262–9
Protective activity of a murine monoclonal antibody against acute and chronic experimental infection with type IV group B streptococcus. Ricci ML, et al. **J Med Microbiol** 1996 Jun;44(6):475–81
Characterization of three novel monoclonal antibodies against hepatitis C virus core protein. Moradpour D, et al. **J Med Virol** 1996 Mar;48(3):234–41
Comparison of monoclonal antibodies for immunostaining in the cytomegalovirus shell vial assay on 4,388 specimens. St. George K, et al. **J Med Virol** 1995 Nov;47(3):269–71
Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. Bonnycastle LL, et al. **J Mol Biol** 1996 May 24; 258(5):747–62
Anti-cruciform monoclonal antibody and cruciform DNA interaction. Steinmetzer K, et al. **J Mol Biol** 1995 Nov 17;254(1):29–37
Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. Valadon P, et al. **J Mol Biol** 1996 Aug 9; 261(1):11–22
The Le(x) carbohydrate sequence is recognized by antibody to L5, a functional antigen in early neural development. Streit A, et al. **J Neurochem** 1996 Feb;66(2):834–44
A monoclonal autoantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens. Asakura K, et al. **J Neuroimmunol** 1996 Mar;65(1):11–9
Systemic passive transfer studies using IgM monoclonal antibodies to sulfatide. Nardelli E, et al. **J Neuroimmunol** 1995 Dec;63(1):29–37
An antineuronal monoclonal antibody that reverses neurite growth inhibition by central nervous system myelin. Lozano AM, et al. **J Neurosci Res** 1995 Oct 15;42(3):306–13
Characterization of a chicken monoclonal antibody that recognizes the apical complex of Eimeria acervulina sporozoites and partially inhibits sporozoite invasion of CD8+ T lymphocytes in vitro. Sasai K, et al. **J Parasitol** 1996 Feb;82(1):82–7
AM-3K, a novel monoclonal antibody specific for tissue macrophages and its application to pathological investigation. Zeng L, et al. **J Pathol** 1996 Feb; 178(2):207–14
Lowered norepinephrine turnover as a sign of impaired ganglionic transmission after preganglionic lesioning by acetylcholinesterase antibodies. McKinzie S, et al. **J Pharmacol Exp Ther** 1996 May;277(2):817–22
Analysis of an epitope sequence recognized by a monoclonal antibody MAb-5H4 against a porcine zona pellucida glycoprotein (pZP4) that blocks fertilization. Hasegawa A, et al. **J Reprod Fertil** 1995 Nov;105(2):295–302
Thymosin alpha-1 and FA-1 monoclonal antibody affect murine preimplantation embryo development by modulating protein phosphorylation. Ahmad K, et al. **J Reprod Immunol** 1995 Oct;29(3):239–63
Reduction of ovulation rate in the rat by administration of a neutrophil-depleting monoclonal antibody. Brännström M, et al. **J Reprod Immunol** 1995 Oct;29(3):265–70
Epitope analysis of a sperm acrosomal antigen defined by HSA-5 monoclonal antibody. Lee CYG, et al. **J Reprod Immunol** 1995 Oct;29(3):223–38

Purification and characterization of a sperm antigen recognized by HSA-5 monoclonal antibody. Yoshiki T, et al. **J Reprod Immunol** 1995 Oct;29(3):209–22

Three-dimensional reconstruction of Androctonus australis hemocyanin labeled with a monoclonal Fab fragment. Boisset N, et al. **J Struct Biol** 1995 Jul–Aug;115(1):16–29

Crystallization and preliminary X-ray analysis of Borrelia burgdorferi outer surface protein A (OspA) complexed with a murine monoclonal antibody Fab fragment. Li H, et al. **J Struct Biol** 1995 Nov–Dec;115(3):335–7

Inhibition of human immunodeficiency virus type 1 integrase by the Fab fragment of a specific monoclonal antibody suggests that different multimerization states are required for different enzymatic functions. Barsov EV, et al. **J Virol** 1996 Jul;70(7):4484–94

Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules. Gaudin MC, et al. **J Virol** 1996 Apr; 70(4):2586–92

Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively. Gu Z, et al. **J Virol** 1996 Apr;70(4):2620–6

Monoclonal antibodies to reovirus sigma 1 and mu 1 proteins inhibit chromium release from mouse L cells. Hooper JW, et al. **J Virol** 1996 Jan;70(1):672–7

Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. Klasse PJ, et al. **J Virol** 1996 Jun;70(6):3668–77

Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. Moore JP, et al. **J Virol** 1996 Mar; 70(3):1863–72

Monoclonal antibodies against human immunodeficiency virus type 1 integrase: epitope mapping and differential effects on integrase activities in vitro. Nilsen BM, et al. **J Virol** 1996 Mar;70(3):1580–7

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Trkola A, et al. **J Virol** 1996 Feb;70(2):1100–8

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. Trkola A, et al. **J Virol** 1995 Nov;69(11):6609–17

Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. Vijh-Warrier S, et al. **J Virol** 1996 Jul;70(7):4466–73

Application of a monoclonal antibody recognizing protein p30 to detect African swine fever virus-infected cells in peripheral blood. Ramiro-Ibáñez F, et al. **J Virol Methods** 1995 Nov;55(3):339–45

Monoclonal antibody based competitive ELISA for the detection of antibodies against epizootic haemorrhagic disease of deer virus. Thevasagayam JA, et al. **J Virol Methods** 1996 Apr 5;57(2):117–26

A novel monoclonal antibody specific for sialylated MUC1 mucin. Yamamoto M, et al. **Jpn J Cancer Res** 1996 May; 87(5):488–96

Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Ehrenstein MR, et al. **Kidney Int** 1995 Sep;48(3):705–11

Murine monoclonal antibodies (MCS-1 and MCS-2) reactive with human myeloid leukemia cells. Sagawa K, et al. **Kurume Med J** 1995;42(3):177–85

Monoclonal antibodies (NU-T1 and NU-T2) recognizing antigens expressed on human T cells. Sagawa K, et al. **Kurume Med J** 1996;43(1):25–31

CD34+ leukemic cells assessed by different CD34 monoclonal antibodies. Lanza F, et al. **Leuk Lymphoma** 1995;18 Suppl 1:25–30

Immunocytochemical studies of an antigen in a human T-cell lymphoma line (Jurkat) recognized by certain monoclonal antibodies to CD-13 (aminopeptidase-N). Murray H, et al. **Leuk Lymphoma** 1995 May;17(5–6):501–8

The adhesion molecule E-cadherin and a surface antigen recognized by the antibody 9C4 are selectively expressed on erythroid cells of defined maturational stages. Bühring HJ, et al. **Leukemia** 1996 Jan;10(1):106–16

Cross-reactivity of antihuman monoclonal antibodies with cell surface receptors in the common marmoset. Neubert R, et al. **Life Sci** 1995;58(4):317–24

Determination of the immunoreactivity of radiolabelled monoclonal antibody fragments by binding to immobilised anti-idiotypic antibodies. Pimm MV, et al. **Life Sci** 1995 Mar 17;56(17):1401–6

Analysis of three new idiotypes on human monoclonal autoantibodies. Kalsi JK, et al. **Lupus** 1995 Oct;4(5):375–89

Generation and selection of monoclonal antibodies, single-chain Fv and antibody fusion phage specific for human melanoma-associated antigens. Kupsch JM, et al. **Melanoma Res** 1995 Dec;5(6):403–11

Monoclonal antibodies to cell-specific cell surface carbohydrates in plant cell biology and development. Pennell RI, et al. **Methods Cell Biol** 1995;49:123–41 (61 ref.)

Anti-idiotypic antibodies that mimic opioids. Glasel JA, et al. **Methods Mol Biol** 1995;51:183–201

Comparative properties of polyclonal and monoclonal antibodies. Rodkey LS. **Methods Mol Biol** 1995;51:139–50

Binding specificity for four monoclonal antibodies recognizing terminal Gal alpha 1-->4Gal residues in Haemophilus influenzae lipopolysaccharide. Borrelli S, et al. **Microb Pathog** 1995 Sep;19(3):139–57

Evidence that two distinct populations of rabbit anti-idiotypic antibodies are induced by three monoclonal antibodies specific for bluetongue virus core protein VP7. Lin M, et al. **Microbiol Immunol** 1996;40(4):295–302

Monoclonal antibody developed against a hemolysin of Bacillus thuringiensis. Matsuyama J, et al. **Microbiol Immunol** 1995;39(8):619–22

Mapping and characterization of a sequential epitope on the rabies virus glycoprotein which is recognized by a neutralizing monoclonal antibody, RG719. Ni Y, et al. **Microbiol Immunol** 1995;39(9):693–702

Further characterization of Chlamydia pneumoniae specific monoclonal antibodies. Puolakkainen M, et al. **Microbiol Immunol** 1995;39(8):551–4

Dynamic expression of cell-surface antigens probed with Candida albicans-specific monoclonal antibodies. Deslauriers N, et al. **Microbiology** 1996 May;142 (Pt 5):1239–48

Monoclonal antibodies as tools for studying the osteoblast lineage. Aubin JE, et al. **Microsc Res Tech** 1996 Feb 1; 33(2):128–40 (119 ref.)

Mapping of linear epitopes recognized by monoclonal antibodies with gene-fragment phage display libraries. Petersen G, et al. **Mol Gen Genet** 1995 Dec 10; 249(4):425–31

Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. Kalsi JK, et al. **Mol Immunol** 1996 Mar–Apr;33(4–5):471–83

The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Knight DM, et al. **Mol Immunol** 1995 Nov; 32(16):1271–81

Immunodominant RNA recognition motifs of human nucleolin/C23. Valdez BC, et al. **Mol Immunol** 1995 Nov; 32(16):1207–13

LL95 monoclonal antibody mimics functional effects of ZP3 on mouse sperm: evidence that the antigen recognized is not hexokinase. Leyton L, et al. **Mol Reprod Dev** 1995 Nov; 42(3):347–58

Intra-acrosomal 155,000 dalton protein increases the antigenicity during mouse sperm maturation in the epididymis: a study using a monoclonal antibody MC101. Toshimori K, et al. **Mol Reprod Dev** 1995 Sep;42(1):72–9

Use of monoclonal antibodies for the analysis of mycotoxins. Dietrich R, et al. **Nat Toxins** 1995;3(4):288–93; discussion 317

In vivo immunosuppression by targeting a novel protease receptor [see comments] Duchosal MA, et al. **Nature** 1996 Mar 28;380(6572):352–6. Comment in: Nature 1996 Mar 28;380(6572):284–5.

Transplantation biology. Educating effector T cells [news; comment] Trucco M, et al. **Nature** 1996 Mar 28; 380(6572):284–5. Comment on: Nature 1996 Mar 28;380(6572):352–6.

SMI-32 antibody against non-phosphorylated neurofilaments identifies a subpopulation of cultured cortical neurons hypersensitive to kainate toxicity. Gottron F, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):1–4

Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients. Tibben JG, et al. **Nucl Med Commun** 1995 Oct;16(10):853–9

Epitope analysis of the murine p53 tumour suppressor protein. Lane DP, et al. **Oncogene** 1996 Jun 6;12(11):2461–6

Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Wu X, et al. **Oncogene** 1996 Apr 4;12(7):1397–403

LFA-1 (CD11a/CD18) and ICAM-1 (CD54) antibodies attenuate superoxide anion release from polymorphonuclear leukocytes in rats with experimental acute pancreatitis. Inoue S, et al. **Pancreas** 1996 Mar; 12(2):183–8

Immunoelectron microscopical localization of a circulating antigen in the excretory system of Schistosoma mansoni. Ultrastructural localization studies of the excretory system of S. mansoni. Bogers JJ, et al. **Parasitol Res** 1995; 81(5):375–81

Electron microscopical investigation of surface alterations on Giardia lamblia trophozoites after exposure to a cytotoxic monoclonal antibody. Hemphill A, et al. **Parasitol Res** 1996;82(3):206–10

Ultrastructural colocalization of phosphorylcholine and a phosphorylcholine-associated epitope in first-stage larvae of Trichinella spiralis. Hernández S, et al. **Parasitol Res** 1995;81(8):643–50

Schistosoma: analysis of monoclonal antibodies reactive with the circulating antigens CAA and CCA. Deelder AM, et al. **Parasitology** 1996 Jan;112 (Pt 1):21–35

Elucidation of monoclonal antibody polyspecificity using a synthetic combinatorial library. Pinilla C, et al. **Pept Res** 1995 Sep–Oct;8(5):250–7

Monoclonal digoxin-specific antibodies induce dose- and affinity-dependent plasma digoxin redistribution in rats. Cano NJ, et al. **Pharm Res** 1995 May;12(5):709–14

Diffusion of an anti-transferrin receptor antibody in cultured murine melanoma cell layers. Vijaykumar V, et al. **Pharm Res** 1995 Dec;12(12):1907–16

Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Walker I, et al. **Pharm Res** 1995 Oct; 12(10):1548–53

Surface antigen cross-linking triggers forced exit of a protozoan parasite from its host. Clark TG, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6825–9

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Solomon B, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):452–5

Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Spieker-Polet H, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9348–52

Measurement of prostate-specific membrane antigen in the serum with a new antibody. Murphy GP, et al. **Prostate** 1996 Apr;28(4):266–71

Bacterial secretion of the Fab fragment of a mouse monoclonal IgM that reacts with IgG variable regions. Adib-Conquy M, et al. **Protein Eng** 1995 Sep;8(9):859–63

A highly specific and sensitive monoclonal antibody detecting histidine-tagged recombinant proteins. Pogge von Strandmann E, et al. **Protein Eng** 1995 Jul;8(7):733–5

Purification and antigenic analysis of the major 25-kilodalton outer membrane protein of Brucella abortus. Cloeckaert A, et al. **Res Microbiol** 1996 May;147(4):225–35

Analysis of the expression and secretion of isotypes of sheep B cell immunoglobulins with a panel of isotype-specific monoclonal antibodies. Bird P, et al. **Res Vet Sci** 1995 Nov; 59(3):189–94

Monoclonal antibody to serotype 17 of Neisseria meningitidis and their prevalence in Brazilian states. Sacchi CT, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jan–Feb;37(1):1–5

IFN-gamma restores HIV- and non-HIV-specific cell mediated immune response in vitro and its activity is neutralized by antibodies from patients with AIDS. De Francesco MA, et al. **Scand J Immunol** 1996 Jan; 43(1):94–100

Characterization of monoclonal antibodies to the alpha IIb beta 3 integrin on bovine platelets. Nthale JM, et al. **Scand J Immunol** 1995 Nov;42(5):524–8

Enhanced in vivo immunogenicity induced by an antibody to the IL-4 receptor-associated gp200-MR6 molecule. Sivolapenko GB, et al. **Scand J Immunol** 1996 Aug; 44(2):135–42

Short-term administration of selected anti-T-cell receptor V beta chain specific MoAb reduces sialadenitis in MRL/lpr mice. Skarstein K, et al. **Scand J Immunol** 1995 Nov;42(5):529–34

In situ hybridization and monoclonal antibody analysis of plasma membrane Ca-pump mRNA and protein in submandibular glands of rabbit, rat and man. Borke JL, et al. **Scanning Microsc** 1995 Sep;9(3):817–23; discussion 723–4

Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity [see comments] Burns JW, et al. **Science** 1996 Apr 5;272(5258):104–7. Comment in: Science 1996 Apr 5;272(5258):46–8.

Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Dreyfus M, et al. **Semin Thromb Hemost** 1995;21(4):371–81 (26 ref.)

Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies. Isaacs JD, et al. **Ther Immunol** 1994 Dec;1(6):303–12

Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterization, and application to fibrinogen purification. Takebe M, et al. **Thromb Haemost** 1995 Apr;73(4):662–7

Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. White GC 2nd, et al. **Thromb Haemost** 1995 May; 73(5):779–84

A cytotoxic human monoclonal antibody that can discriminate HLA-A*3002 from HLA-A*3001 subtypes. Pistillo MP, et al. **Tissue Antigens** 1995 Oct;46(4):327–9

Characterization of two human IgM monoclonal antibodies reactive with HLA-B27. Wölpl A, et al. **Tissue Antigens** 1995 Oct;46(4):305–12

Isolation and characterization of two monoclonal antibodies that recognize different epitopes of the human c-kit receptor. Morita S, et al. **Tohoku J Exp Med** 1996 Feb; 178(2):187–98

Anti-Pfs25 monoclonal antibody 32F81 blocks transmission from Plasmodium falciparum gametocyte carriers in Cameroon. Mulder B, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr;90(2):195

Monoclonal anti-D specificity and Rh D structure: criteria for selection of monoclonal anti-D reagents for routine typing of patients and donors [see comments] Jones J, et al. **Transfus Med** 1995 Sep;5(3):171–84 (59 ref.). Comment in: Transfus Med 1995 Dec;5(4):304–5.

Analysis of the expression of NB1 antigen using two monoclonal antibodies. Stroncek DF, et al. **Transfusion** 1996 Feb;36(2):168–74

Antibody to CD18 reduces neutrophil and T lymphocyte infiltration and vascular cell adhesion molecule-1 expression in cardiac rejection. Akimoto H, et al. **Transplantation** 1996 Jun 15;61(11):1610–7

Genetic control of the humoral immune response to

xenografts. II. Monoclonal antibodies that cause rejection of heart xenografts are encoded by germline immunoglobulin genes. Borie DC, et al. **Transplantation** 1995 Dec 27;60(12):1504–10

Complement inhibition with an anti–C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig–to–human xenotransplantation. Kroshus TJ, et al. **Transplantation** 1995 Dec 15;60(11):1194–202

The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Routledge EG, et al. **Transplantation** 1995 Oct 27; 60(8):847–53

Kinetics of induction of transplantation tolerance with a nondepleting anti–Cd4 monoclonal antibody and donor–specific transfusion before transplantation. A critical period of time is required for development of immunological unresponsiveness. Saitovitch D, et al. **Transplantation** 1996 Jun 15;61(11):1642–7

In vivo administration of anti–murine CD3 monoclonal antibody induces selective, long–term anergy in CD8+ T cells. Woodle ES, et al. **Transplantation** 1996 Mar 15; 61(5):798–803

Quantification of whole virus particles (146S) of foot–and–mouth disease virus in the presence of virus subunits (12S), using monoclonal antibodies in a sandwich ELISA. Crowther JR, et al. **Vaccine** 1995 Aug; 13(12):1064–75

The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Ibsen PH. **Vaccine** 1996 Apr;14(5):359–68

Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA–2. Johnson BJ, et al. **Vaccine** 1995 Aug; 13(12):1086–94

The behaviour of monoclonal antibodies in the First International Pig CD Workshop reacting with gamma delta/Null T lymphocytes in the blood of SLAb/b line pigs. Licence ST, et al. **Vet Immunol Immunopathol** 1995 Aug;47(3–4):253–71

Monoclonal antibodies specific for equine IgG sub–isotypes including an antibody which recognizes B lymphocytes. Lunn DP, et al. **Vet Immunol Immunopathol** 1995 Aug; 47(3–4):239–51

Homotypic aggregation of ovine leucocyte induced by anti–leucosialin (CD43) monoclonal antibodies. Pintado CO, et al. **Vet Immunol Immunopathol** 1995 Aug; 47(3–4):333–40

Identification of a dog IgD–like molecule by a monoclonal antibody. Yang M, et al. **Vet Immunol Immunopathol** 1995 Aug;47(3–4):215–24

Differentiation of classical swine fever virus (CSFV) strains using monoclonal antibodies against structural glycoproteins. Kosmidou A, et al. **Vet Microbiol** 1995 Nov; 47(1–2):111–8

Comparison of isolates of canine parvovirus by monoclonal antibody and restriction enzyme analysis. Greenwood NM, et al. **Vet Rec** 1996 May 18;138(20):495–6

Activity of a monoclonal antibody against Besnoitia besnoiti endozoites. Shkap V, et al. **Vet Res** 1995;26(4):328–34

Production and characterization of rabbit anti–idiotypic antibodies directed against a murine monoclonal anti–B. abortus antibody. Adone R, et al. **Vet Res Commun** 1995; 19(6):457–61

Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly. Hughey PG, et al. **Virology** 1995 Oct 1;212(2):411–21

An anti–HIV–1 gag protein rat monoclonal antibody library. Bodéus M, et al. **Virus Res** 1995 Nov;39(1):35–46

Antigenicity of the rabbit hemorrhagic disease virus studied by its reactivity with monoclonal antibodies. Capucci L, et al. **Virus Res** 1995 Aug;37(3):221–38

Characterization of monoclonal antibodies recognizing neurotropic Friend murine leukemia virus. Ikeda T, et al. **Virus Res** 1995 Oct;38(2–3):297–304

Epitope mapping of cross–reactive monoclonal antibodies specific for the influenza A virus PA and PB2 polypeptides. Ochoa M, et al. **Virus Res** 1995 Aug;37(3):305–15

Preparation of monoclonal antibodies against Marek's disease virus serotype 1 glycoprotein D expressed by a recombinant baculovirus. Ono M, et al. **Virus Res** 1995 Oct;38(2–3):219–30

Characterization of monoclonal antibodies recognizing amino– and carboxy–terminal epitopes of the herpes simplex virus UL42 protein. Sheaffer AK, et al. **Virus Res** 1995 Oct;38(2–3):305–14

[Anti–tumor effects of bispecific monoclonal antibody targeted human monocytes–macrophages on hepatoma cells] Wang Q, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):96–9 (Eng. Abstr.) **(Chi)**

[Antiplatelet glycoprotein monoclonal antibodies: properties and practical value] Saffroy R, et al. **Ann Biol Clin (Paris)** 1995;53(3):97–105 (119 ref.) (Eng. Abstr.) **(Fre)**

[Airborne Japanese cedar allergens studied by immunoblotting technique using anti–Cry j 1 monoclonal antibody—comparison with actual pollen counts and effect of wind speed and directions] Iwaya M, et al. **Arerugi** 1995 Jul;44(7):670–7 (Eng. Abstr.) **(Jpn)**

[Effect of KW–4679, an antiallergic drug, on antigen–induced airway microvascular leakage in rats passively sensitized with mouse monoclonal IgE antibody] Ohmori K, et al. **Arerugi** 1996 Apr;45(4):393–7 (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of TPA–assay kit using monoclonal antibodies] Saga T, et al. **Gan To Kagaku Ryoho** 1996 Apr; 23(5):615–21 (Eng. Abstr.) **(Jpn)**

[Expression of a proliferation associated–nuclear antigen defined by Ki–67 monoclonal antibody in childhood acute leukemia] Ito M, et al. **Rinsho Ketsueki** 1995 Aug; 36(8):713–9 (Eng. Abstr.) **(Jpn)**

[Interaction of a monoclonal antibody to P–selectin with activated platelets and endothelial cells. Heterogeneity of expressing P–selectin in human aorta endothelial cells] Byzova TV, et al. **Biokhimiia** 1995 Aug;60(8):1292–301 (Eng. Abstr.) **(Rus)**

[Conformational changes of the platelet membrane glycoprotein IIb–IIIa complex stimulated by a monoclonal antibody to the N–terminal segment of glycoprotein IIIa] Khaspekova SG, et al. **Biokhimiia** 1996 Mar;61(3):412–28 (Eng. Abstr.) **(Rus)**

[Use of an immunotoxin against the human T–lymphocyte CD5 antigen for removing "passenger" lymphocytes from kidney transplants] Shumakov VI, et al. **Dokl Akad Nauk** 1995 May;342(1):138–40 **(Rus)**

[Functional activity of monoclonal antibodies against the CDw50 antigen (ICAM–3)] Zemskov VM, et al. **Dokl Akad Nauk** 1995 Aug;343(5):708–10 **(Rus)**

[Study of plant lectins from Viscum album using monoclonal antibodies] Tonevitskil AG, et al. **Mol Biol (Mosk)** 1995 May–Jun;29(3):619–26 (Eng. Abstr.) **(Rus)**

[Preparation of monoclonal antibodies to super early human cytomegalovirus proteins and their use for detecting infected cells] Makarova NE, et al. **Vopr Virusol** 1996 Jan–Feb;41(1):28–32 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Production of monoclonal antibody specific to Campylobacter jejuni and its potential in diagnosis of Campylobacter enteritis. Chaiyaroj SC, et al. **Asian Pac J Allergy Immunol** 1995 Jun;13(1):55–61

Monoclonal antibodies against protein antigens of salmonellae causing paratyphoid fever and their diagnostic application. Ekpo P, et al. **Asian Pac J Allergy Immunol** 1995 Jun; 13(1):63–70

Establishment of OVS1 and OVS2 monoclonal antibodies recognizing human ovarian mucinous cystadenocarcinoma. Neungton N, et al. **Asian Pac J Allergy Immunol** 1995 Jun; 13(1):47–53

Isolation and characterization of conformation sensitive antierythropoietin monoclonal antibodies: effect of disulfide bonds and carbohydrate on recombinant human erythropoietin structure. Elliott S, et al. **Blood** 1996 Apr 1;87(7):2714–22

A human monoclonal antibody obtained from EBV–transformed B cells with specificity for myosin. Laroche–Traineau J, et al. **Br J Haematol** 1995 Dec; 91(4):951–62

Monoclonal antibodies against Vi antigen production and characterization. Pieńkowska D, et al. **Bull Inst Marit Trop Med Gdynia** 1993–94;44–45(1–4):89–93

Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virus. Crowe JE Jr, et al. **Clin Diagn Lab Immunol** 1994 Nov;1(6):701–6

Purification, characterisation and production of a monoclonal antibody to Cl. novyi type B alpha toxin. Whitworth K. **Dev Biol Stand** 1996;86:347

Development and characterization of monoclonal antibodies specific for the genus Listeria. Loiseau O, et al. **FEMS Immunol Med Microbiol** 1995 Jun;11(3):219–30

Characterization of human, mouse and rabbit anti–gliadin antibodies by ELISA and western blotting. Vančíková Z, et al. **Folia Microbiol (Praha)** 1995;40(6):659–64

Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor121 (VEGF/VPF121). Asano M, et al. **Hybridoma** 1995 Oct;14(5):475–80

Isolation and characterization of a monoclonal anti–protein kinase CK2 beta–subunit antibody of the IgG class for the direct detection of CK2 beta–subunit in tissue cultures of various mammalian species and human tumors. Nastainczyk W, et al. **Hybridoma** 1995 Aug;14(4):335–9

Isolation and characterization of a monoclonal antibody binding to the extracellular domain of the flk–2 tyrosine kinase receptor. Rose C, et al. **Hybridoma** 1995 Oct; 14(5):453–9

Interphase phosphorylation of the Drosophila nuclear lamin: site–mapping using a monoclonal antibody. Stuurman N, et al. **J Cell Sci** 1995 Sep;108 (Pt 9):3137–44

Purification of monoclonal antibodies on dextran–coated silica support grafted by thiophilic ligand. Serres A, et al. **J Chromatogr A** 1995 Sep 8;711(1):151–7

Recombinant proteins L and LG: efficient tools for purification of murine immunoglobulin G fragments. Vola R, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23; 668(2):209–18

Production and characterization of monoclonal antibodies against Serpulina hyodysenteriae and S. innocens and their use in serotyping. Achacha M, et al. **J Clin Microbiol** 1995 Sep;33(9):2519–21

Construction and characterization of a humanized anti–gamma–Ig receptor type I (Fc gamma RI) monoclonal antibody. Graziano RF, et al. **J Immunol** 1995 Nov 15; 155(10):4996–5002

Four IgG anti–islet human monoclonal antibodies isolated from a type 1 diabetes patient recognize distinct epitopes of glutamic acid decarboxylase 65 and are somatically mutated. Madec AM, et al. **J Immunol** 1996 May 1; 156(9):3541–9

Chicken monoclonal antibody isolated by a phage display system. Yamanaka HI, et al. **J Immunol** 1996 Aug 1; 157(3):1156–62

A monoclonal antibody that specifically recognizes a novel mitochondrial protein of human astrocytes. Yokoo H, et al. **J Neuropathol Exp Neurol** 1996 Jun;55(6):716–21

Analysis of the globose basal cell compartment in rat olfactory epithelium using GBC–1, a new monoclonal antibody against globose basal cells. Goldstein BJ, et al. **J Neurosci** 1996 Jun 15;16(12):4005–16

Development and application of a modified monoclonal hybridoma technique for isolating monoclonal antibodies to human brain regions. Fukuyama R, et al. **J Neurosci Methods** 1995 Jul;59(2):199–204

Separation of monoclonal antibodies from cell–culture supernatants and ascites fluid using thiophilic agarose. Bøg–Hansen TC. **Methods Mol Biol** 1995;45:177–81

Murine monoclonal antibody development. Johnson DR. **Methods Mol Biol** 1995;51:123–37

Methods of immunization to enhance the immune response to specific antigens in vitro. Schelling ME. **Methods Mol Biol** 1995;45:9–15

Purification of reduced and alkylated antibody subunits. Sun M, et al. **Methods Mol Biol** 1995;51:111–22

Detection, purification, and utilization of murine monoclonal IgM antibodies. Walker ID. **Methods Mol Biol** 1995; 45:183–8

Expression of 18.6/CD23 antigen on human lymphoid progenitor cell lines and phorbol 12–myristate 13–acetate (PMA)–induced microglia–shaped cells. Okumura A, et al. **Microbiol Immunol** 1995;39(11):879–90

In vitro and in vivo inhibition of complement activity by a single–chain Fv fragment recognizing human C5. Evans MJ, et al. **Mol Immunol** 1995 Nov;32(16):1183–95

Characterization of the variable regions of a chimpanzee monoclonal antibody with potent neutralizing activity against HIV–1. Vijh–Warrier S, et al. **Mol Immunol** 1995 Oct;32(14–15):1081–92

[Cloning of anti–breast cancer monoclonal antibodies from phage antibody libraries] Zhang G, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):258–62 (Eng. Abstr.) **(Chi)**

[Cryofibrinogenemia caused by monoclonal anti–fibrinogen antibodies] Zeuner RA, et al. **Dtsch Med Wochenschr** 1996 Sep 6;121(36):1084–9 (Eng. Abstr.) **(Ger)**

[The outlook for improving the immunoglobulin preparations for the detection and identification of the causative agents of glanders and melioidosis] Khrapova NP, et al. **Med Parazitol (Mosk)** 1995 Oct–Dec;(4):49–53 (Eng. Abstr.) **(Rus)**

METABOLISM

Penetration and binding of monoclonal antibody in human osteosarcoma multicell spheroids. Comparison of confocal laser scanning microscopy and autoradiography. Hjelstuen MH, et al. **Acta Oncol** 1996;35(3):273–9

Construction, expression and characterisation of a single chain anti–tumour antibody (scFv)–IL–2 fusion protein. Boleti E, et al. **Ann Oncol** 1995 Nov;6(9):945–7

Domain swap chimeras to study the binding of IgG by Fc gamma RI, the high affinity receptor for IgG. Harrison PT, et al. **Biochem Soc Trans** 1996 Feb;24(1):144S

Modulation of functional properties of galectin–3 by monoclonal antibodies binding to the non–lectin domains. Liu FT, et al. **Biochemistry** 1996 May 14;35(19):6073–9

Thiolations, 99mTc labelings, and animal in vivo biodistributions of divalent monoclonal antibody fragments. Govindan SV, et al. **Bioconjug Chem** 1996 May–Jun; 7(3):290–7

Phorbol ester enhances integrin alpha IIb beta 3–dependent adhesion of human erythroleukemic cells to activation–dependent monoclonal antibodies. Boudignon–Proudhon C, et al. **Blood** 1996 Feb 1; 87(3):968–76

Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Wagner CL, et al. **Blood** 1996 Aug 1;88(3):907–14

Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti–tumour antibody. Marshall D, et al. **Br J Cancer** 1996 Mar;73(5):565–72

Use of thermal fluctuations to study the length and flexibility of ligand–receptor bonds. Pierres A, et al. **C R Acad Sci III** 1995 Dec;318(12):1191–6

Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN–14 F(ab)2. Juweid M, et al. **Cancer** 1996 Jul 1;78(1):157–68

In vivo evaluation of epidermal growth factor (EGF) receptor density on human tumor xenografts using radiolabeled EGF and anti–(EGF receptor) mAb 425. Senekowitsch–Schmidtke R, et al. **Cancer Immunol Immunother** 1996 Feb;42(2):108–14

Degradation of radioiodinated B cell monoclonal antibodies: inhibition via a FCgamma–receptor–II–mediated mechanism and by drugs. Vervoordeldonk SF, et al.

Cancer Immunol Immunother 1996 Jan;42(1):24-30

Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII. Weiner LM, et al. **Cancer Immunol Immunother** 1996 Mar; 42(3):141-50

Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies. Spencer DI, et al. **Cancer Lett** 1996 Feb 27; 100(1-2):11-5

Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. Hanna R, et al. **Cancer Res** 1996 Jul 1;56(13):3062-8

L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. Kobayashi H, et al. **Cancer Res** 1996 Aug 15;56(16):3788-95

Construction of phosphorylatable monoclonal antibody to a tumor-associated antigen. Lin L, et al. **Cancer Res** 1996 Sep 15;56(18):4250-4

Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Press OW, et al. **Cancer Res** 1996 May 1; 56(9):2123-9

Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Xu XC, et al. **Cancer Res** 1995 Dec 1; 55(23):5507-11

Monoclonal antibody binding to a receptor on nonspecific cytotoxic cells (NCC) increases the expression of proto-oncogene kinases and protein kinase C. Jaso-Friedmann L, et al. **Cell Signal** 1995 Jul;7(5):463-70

Engagement of CD20 suppresses apoptosis in germinal center B cells. Holder M, et al. **Eur J Immunol** 1995 Nov; 25(11):3160-4

Determination of binding site of anti-tumour necrosis factor-alpha monoclonal antibody using hybrid and mutant proteins. Shingarova LN, et al. **FEBS Lett** 1996 May 13; 386(1):72-4

Thermostable peroxidase activity with a recombinant antibody L chain-porphyrin Fe(III) complex. Takagi M, et al. **FEBS Lett** 1995 Nov 20;375(3):273-6

Binding specificity of a monoclonal antibody to human Hb A. Rosenthal MA, et al. **Hemoglobin** 1995 May-Jul; 19(3-4):191-6

Comparison of three human-murine heteromyeloma cell lines for formation of human hybridomas after electrofusion with human peripheral blood lymphocytes from meningococcal cases and carriers. Delvig AA, et al. **Hum Antibodies Hybridomas** 1995;6(2):42-6

Epitope in cytochrome c from Candida krusei cross-reacts lung cancer-specific human monoclonal antibody HB4C5 [letter] Kawamoto S, et al. **In Vitro Cell Dev Biol Anim** 1995 Jun;31(6):424-6

CD44 plays a co-stimulatory role in murine T cell activation: ligation of CD44 selectively co-stimulates IL-2 production, but not proliferation in TCR-stimulated murine Th1 cells. Sommer F, et al. **Int Immunol** 1995 Nov;7(11):1779-86

Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody. Hills D, et al. **Int J Cancer** 1995 Nov 15;63(4):537-43

Analysis of monoclonal antibody and immunoconjugate digests by capillary electrophoresis and capillary liquid chromatography. Liu J, et al. **J Chromatogr A** 1996 May 31;735(1-2):357-66

CD45 ligation induces programmed cell death in T and B lymphocytes. Klaus SJ, et al. **J Immunol** 1996 Apr 15; 156(8):2743-53

Monoclonal antibodies from NZW x BXSB F1 mice to beta2 glycoprotein I and cardiolipin. Species specificity and charge-dependent binding. Monestier M, et al. **J Immunol** 1996 Apr 1;156(7):2631-41

Differential recognition of free and covalently bound polyamines by the monoclonal anti-spermine antibody SPM8-2. Delcros JG, et al. **J Immunol Methods** 1995 Sep 25;185(2):191-8

Direct calibration ELISA: a rapid method for the simplified determination of association constants of unlabeled biological molecules. Fuchs H, et al. **J Immunol Methods** 1995 Dec 27;188(2):197-208

Cardiac accumulation of 125I-labeled monoclonal antibody to atrial natriuretic peptide in a rat model of myocardial infarction. Kanda T, et al. **J Med** 1995;26(1-2):53-64

High-affinity rat anti-fluorescein monoclonal antibody with unique fine specificity properties including differential recognition of dynamic ligand analogues. Miklasz SD, et al. **J Mol Recognit** 1995 Jul-Aug;8(4):258-69

Rapid internalization and degradation of surface-bound antibodies by Tritrichomonas foetus. Granger BL, et al. **J Parasitol** 1996 Aug;82(4):539-49

In vitro bioactivity of gonadotrophin surge attenuating factor is not affected by an antibody to human inhibin. Balen AH, et al. **J Reprod Fertil** 1995 Jul;104(2):285-9

Screening strategies for catalytic antitransition-state analog antibodies. Tramontano A. **Methods Mol Biol** 1995; 51:237-50

The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Boyd PN, et al. **Mol Immunol** 1995 Dec;32(17-18):1311-8

Activation of human complement by totally human monoclonal antibodies. Dillman SL, et al. **Mol Immunol** 1995 Sep;32(13):957-64

Heavy chain dominance in the binding of DNA by a lupus mouse monoclonal autoantibody. Jang YJ, et al. **Mol Immunol** 1996 Feb;33(2):197-210

Heteroligation of a mouse monoclonal IgE antibody (La2) with small molecules, analysed by computer-aided automated docking. Sotriffer CA, et al. **Mol Immunol** 1996 Feb;33(2):129-44

Insights into antibody catalysis: structure of an oxygenation catalyst at 1.9-angstrom resolution. Hsieh-Wilson LC, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5363-7

Diversity in lipid A binding ligands: comparison of lipid A monoclonal antibodies with rBPI23. Appelmelk BJ, et al. **Prog Clin Biol Res** 1995;392:453-63

Tracking the in vivo localization of streptococcal cell membrane (SCM) monoclonal antibodies: potential model for post-streptococcal sequelae. Lange CF. **Res Commun Mol Pathol Pharmacol** 1995 Aug;89(2):241-55

Similar binding properties for a neutralizing anti-tetanus toxoid human monoclonal antibody and its bacterially expressed Fab. Lafaye P, et al. **Res Immunol** 1995 Jul-Aug; 146(6):373-82

Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Amlot PL, et al. **Transplantation** 1995 Oct 15;60(7):748-56

[Certain features of monoclonal rheumatoid immunoglobulin M fragmentation by "hot" trypsin] Lapuk VA, et al. **Biokhimiia** 1996 Jan;61(1):85-8 (Eng. Abstr.) **(Rus)**

[Activation of phagocytes with anti-ICAM-3 monoclonal antibodies] Zemskov VM, et al. **Biul Eksp Biol Med** 1996 Apr;121(4):447-9 **(Rus)**

PHARMACOKINETICS

Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer. Boerman OC, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):2169-74

Affinity and dose-dependent digoxin Na+K+ATPase dissociation by monoclonal digoxin-specific antibodies. Cano NJ, et al. **Biochem Pharmacol** 1995 Nov 27; 50(11):1867-72

Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. Garg PK, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):493-501

Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Delgado C, et al. **Br J Cancer** 1996 Jan; 73(2):175-82

Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin. Desrues B, et al. **Br J Cancer** 1995 Nov; 72(5):1076-82

Different biodistribution of 99mTc-labelled chimeric mouse-human monoclonal antibody between athymic mice model and human. Oriuchi N, et al. **Br J Cancer** 1996 Jun; 73(12):1466-72

Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Uttenreuther-Fischer MM, et al. **Cancer Immunol Immunother** 1995 Dec;41(6):331-8

Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Baxter LT, et al. **Cancer Res** 1995 Oct 15;55(20):4611-22

Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts. Choi CW, et al. **Cancer Res** 1995 Nov 15;55(22):5323-9

Lysine reduces renal accumulation of radioactivity associated with injection of the [177Lu]alpha-[2-(4-aminophenyl) ethyl]-1,4,7,10-tetraaza-cyclodecane-1,4,7,10-tetraacetic acid-CC49 Fab radioimmunoconjugate. DePalatis LR, et al. **Cancer Res** 1995 Nov 15;55(22):5288-95

Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Mariani G, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5911s-5915s

Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. Murray JL, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5925s-5928s

Preparation of a trivalent antigen-binding construct using polyoxime chemistry: improved biodistribution and potential for therapeutic application. Werlen RC, et al. **Cancer Res** 1996 Feb 15;56(4):809-15

Pharmacokinetics of reshaped MAb 425 in three animal species. Haunschild J, et al. **Cell Biophys** 1995 Jun; 26(3):167-82

Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1. Wolfe EJ, et al. **Clin Pharmacol Ther** 1996 Jun; 59(6):662-7

Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Davis CB, et al. **Drug Metab Dispos** 1995 Oct;23(10):1028-36

Repeating the avidin "chase" markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity. Kobayashi H, et al. **Eur J Cancer** 1995 Sep; 31A(10):1689-96

Pharmacokinetics of an indium-labeled IgG monoclonal antibody over a prolonged period. Halpern SE, et al. **Eur J Nucl Med** 1995 Nov;22(11):1323-5

Secretory monoclonal IgA class-switch variants against bacterial enteric pathogens in bile and intestinal secretions. Steinmetz I, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):329-36

Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Stephens S, et al. **Immunology** 1995 Aug;85(4):668-74

Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay. Fayer BE, et al. **J Immunol Methods** 1995 Oct 12;186(1):47-54

Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization. Pardridge WM, et al. **J Pharm Sci** 1995 Aug;84(8):943-8

A human/mouse chimeric monoclonal antibody against intercellular adhesion molecule-1 for tumor radioimmunoimaging. Yamamura M, et al. **Jpn J Cancer Res** 1996 Apr;87(4):405-11

On the correction for radioactive decay in pharmacokinetic modeling. Williams LE, et al. **Med Phys** 1995 Oct; 22(10):1619-26

Specific deposition of passively transferred monoclonal antibodies against herpes simplex virus type 1 in rat brain infected with the virus. Tamada K, et al. **Microbiol Immunol** 1995;39(11):861-71

Production and characterization of a monoclonal antibody against medulloblastoma-derived cell line. Tatsumi S, et al. **Neurol Med Chir (Tokyo)** 1996 May;36(5):277-85

Biodistribution and radioimmunopharmacokinetics of 131I-Ama monoclonal antibody in atherosclerotic rabbits. Chakrabarti M, et al. **Nucl Med Biol** 1995 Aug;22(6):693-7

Biodistribution of monoclonal antibody Po66 in a human lung tumour-bearing mouse model: effect of blood exchange on tumour antibody uptake. Desrues B, et al. **Nucl Med Biol** 1995 Jul;22(5):569-72

In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody. Scott AM, et al. **Nucl Med Biol** 1995 May;22(4):497-504

Tumor targeting and pharmacokinetics of unmodified and modified F(ab)2 fragments of an anti-CEA murine monoclonal antibody (Immu-14). Siddiqui A, et al. **Nucl Med Biol** 1995 May;22(4):425-35

Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H. Hutchins JT, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11980-4

PHARMACOLOGY

Entamoeba histolytica adherence: inhibition by IgA monoclonal antibodies. Leyva O, et al. **Adv Exp Med Biol** 1995;371A:681-3

Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies. Forthal DN, et al. **AIDS Res Hum Retroviruses** 1995 Sep; 11(9):1095-9

The effect of an anti-CD3 monoclonal antibody on bleomycin-induced lymphokine production and lung injury. Sharma SK, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):193-200

Effects of tumor necrosis factor blockade on interleukin 6, lactate, thromboxane, and prostacyclin responses in miniature horses given endotoxin. Cargile JL, et al. **Am J Vet Res** 1995 Nov;56(11):1445-50

Effect of treatment with a monoclonal antibody against equine tumor necrosis factor (TNF) on clinical, hematologic, and circulating TNF responses of miniature horses given endotoxin. Cargile JL, et al. **Am J Vet Res** 1995 Nov;56(11):1451-9

Neutralization of stem cell factor in vitro and in vivo: dose-dependent inhibition of stromal cells and induction of granulocyte/monocyte differentiation. Huss R, et al. **Ann Hematol** 1996 Apr;72(4):253-9

Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines. Kopreski MS, et al. **Anticancer Res** 1996 Jan-Feb; 16(1):433-6

Growth regulation of multidrug resistant ovarian cancer cells by 1D7 monoclonal antibody. Yang X, et al. **Anticancer Res** 1996 Jan-Feb;16(1):273-6

Evidence for involvement of equine herpesvirus 1 glycoprotein B in cell-cell fusion. Wellington JE, et al. **Arch Virol** 1996;141(1):167-75

Antibodies to CD36 (GPIV) inhibit platelet adhesion to subendothelial surfaces under flow conditions. Diaz-Ricart M, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):883-8

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Paleolog EM, et al. **Arthritis Rheum** 1996 Jul; 39(7):1082-91

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Tak PP, et al. **Arthritis Rheum** 1996 Jul;39(7):1077-81

Tumor necrosis factor monoclonal antibody prevents alterations in leukocyte populations during cardiopulmonary bypass. Vertrees RA, et al. **ASAIO J** 1994 Jul-Sep;40(3):M554-9

Selective immunotoxic lesions of basal forebrain cholinergic cells: effects on learning and memory in rats. Baxter MG, et al. **Behav Neurosci** 1995 Aug;109(4):714–22

Induction of CD38/NADase and its monoclonal antibody–induced tyrosine phosphorylation in human leukemia cell lines. Kontani K, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):466–71

Monoclonal antibodies to the EGF receptor act as betacellulin antagonists. Modjtahedi H, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):625–30

Inhibition of protein synthesis in frog (Xenopus laevis) egg extracts by an antibody against phosphatidylinositol 4,5–bisphosphate. Keating TJ, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):643–6

Identification of a heparin–binding protein using monoclonal antibodies that block heparin binding to porcine aortic endothelial cells. Patton WA 2nd, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):461–9

Stimulatory antibody–induced activation and selective translocation of protein kinase C isoenzymes in human platelets. Wang F, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):401–6

Activation of human beta–glucuronidase by murine monoclonal antibodies and bovine serum albumin in an uncompetitive fashion. Ho KJ. **Biochem Mol Biol Int** 1995 Aug;36(6):1277–86

Application of anti–E1 monoclonal antibodies to the study of the pyruvate dehydrogenase complex. Stafejeva OA, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):167–73

Inhibitory and non–inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Gelboin HV, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1841–50

Functional uncoupling between flavin and heme domains in flavocytochrome b2 by a monoclonal antibody. Lé KH, et al. **Biochem Soc Trans** 1996 Feb;24(1):16S

Anti–platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor. Weisman HF, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1051–7 (25 ref.)

Monoclonal antibody 4B1 alters the pKa of a carboxylic acid at position 325 (helix X) of the lactose permease of Escherichia coli. Frillingos S, et al. **Biochemistry** 1996 Aug 6;35(31):10166–71

Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. Adler RR, et al. **Biol Reprod** 1995 Oct;53(4):905–10

Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation. Katzav–Gozansky T, et al. **Biotechnol Appl Biochem** 1996 Jun;23 (Pt 3):227–30

Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin–6 and neutrophil elastase. Jansen PM, et al. **Blood** 1996 Mar 15;87(6):2337–44

Immobilized anti–KIT monoclonal antibody induces ligand–independent dimerization and activation of Steel factor receptor: biologic similarity with membrane–bound form of Steel factor rather than its soluble form. Kurosawa K, et al. **Blood** 1996 Mar 15;87(6):2235–43

Antibody ligation of CD9 modifies production of myeloid cells in long–term cultures. Oritani K, et al. **Blood** 1996 Mar 15;87(6):2252–61

Monoclonal Lym–1 antibody–dependent lysis of B–lymphoblastoid tumor targets by human complement and cytokinine–exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Ottonello L, et al. **Blood** 1996 Jun 15;87(12):5171–8

Single human T cells stimulated in the absence of feeder cells transcribe interleukin–2 and undergo long–term clonal growth in response to defined monoclonal antibodies and cytokine stimulation. Sunder–Plassmann R, et al. **Blood** 1996 Jun 15;87(12):5179–84

Suppression of normal and neoplastic human T cells with unconjugated monoclonal antibodies in SCID mouse chimeras. Zengerle U, et al. **Bone Marrow Transplant** 1995 Sep;16(3):337–41

The role of apoptosis in bispecific antibody–mediated T–cell cytotoxicity. Kroesen BJ, et al. **Br J Cancer** 1996 Mar; 73(6):721–7

In vitro and in vivo anti–tumour effects of a humanised monoclonal antibody against c–erbB–2 product. Tokuda Y, et al. **Br J Cancer** 1996 Jun;73(11):1362–5

A monoclonal antibody directed against a granule membrane glycoprotein (GMP–140/PADGEM, P–selectin, CD62P) inhibits ristocetin–induced platelet aggregation. Boukerche H, et al. **Br J Haematol** 1996 Feb;92(2):442–51

Inhibitory effect of anti–epidermal growth factor receptor antibody on a human gastric cancer. Teramoto T, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1639–45

Complete inhibition of angiogenesis and growth of microtumors by anti–vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Borgström P, et al. **Cancer Res** 1996 Sep 1;56(17):4032–9

Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): potent dose–dependent inhibition of platelet function. Bhattacharya S, et al. **Cardiovasc Drugs Ther** 1995 Oct; 9(5):665–75

In vitro T cell unresponsiveness following low–dose injection of anti–CD3 MoAb. Ben–Amor A, et al. **Clin Exp Immunol** 1996 Mar;103(3):491–8

Anti–leukocyte function–1 antibody treatment prevents the rejection of intraocular regressor tumors and their metastases. Li XY, et al. **Curr Eye Res** 1995 Aug; 14(8):719–26

Rapid and selective induction of blood eosinophilia in guinea pigs by recombinant human interleukin 5. Portanova JP, et al. **Cytokine** 1995 Nov;7(8):775–83

A peroxovanadium compound induces Xenopus oocyte maturation: inhibition by a neutralizing anti–insulin receptor antibody. Cummings C, et al. **Dev Biol** 1996 May 1;175(2):338–46

Monoclonal antibody BLT–1, specific for the bovine homologue of CD5, reacts with the majority of mature T cells, a subpopulation of B cells and stimulates T cell proliferation. Yang TJ, et al. **Dev Comp Immunol** 1995 Jul–Aug;19(4):337–46

Neutralization of TGF–beta by anti–TGF–beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ–induced diabetic mice. Sharma K, et al. **Diabetes** 1996 Apr; 45(4):522–30

Role of syntaxin in mouse pancreatic beta cells. Martín F, et al. **Diabetologia** 1995 Jul;38(7):860–3

Induction of T cell unresponsiveness by anti–CD3 antibodies occurs independently of co–stimulatory functions. Andris F, et al. **Eur J Immunol** 1996 May;26(5):1187–95

Nerve growth–factor and anti–CD40 provide opposite signals for the production of IgE in interleukin–4–treated lymphocytes. Brodie C, et al. **Eur J Immunol** 1996 Jan; 26(1):171–8

Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti–C5a receptor (CD88) antibodies. Elsner J, et al. **Eur J Immunol** 1996 Jul;26(7):1560–4

Inhibition of interleukin–6 synthesis in an animal model of septic shock by anti–C5a monoclonal antibodies. Höpken U, et al. **Eur J Immunol** 1996 May;26(5):1103–9

B cell–B cell interaction through intercellular adhesion molecule–1 and lymphocyte functional antigen–1 regulates immunoglobulin E synthesis by B cells stimulated with interleukin–4 and anti–CD40 antibody. Katada Y, et al. **Eur J Immunol** 1996 Jan;26(1):192–200

Down–regulation of class II major histocompatibility complex molecules on antigen–presenting cells by antibody fragments. Vidović D, et al. **Eur J Immunol** 1995 Dec; 25(12):3349–55

Interleukin–6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti–gp130 monoclonal antibodies. Wijdenes J, et al. **Eur J Immunol** 1995 Dec;25(12):3474–81

Antithrombotic effect of a humanized anti–GPIIb/IIIa monoclonal antibody, YM207, in a photochemically induced thrombosis model in monkeys. Kaku S, et al. **Eur J Pharmacol** 1995 Jun 12;279(2–3):115–21

Behavioral studies on the putative gamma–type endorphin receptor using different antibodies. Van Ree JM, et al. **Eur J Pharmacol** 1995 Jun 12;279(2–3):187–96

Monoclonal antibodies against P–glycoprotein, an MDR1 gene product, inhibit interleukin–2 release from PHA–activated lymphocytes. Raghu G, et al. **Exp Hematol** 1996 Aug;24(10):1258–64

An antibody to CD44 enhances hematopoiesis in long–term marrow cultures. Rossbach HC, et al. **Exp Hematol** 1996 Feb;24(2):221–7

Paradoxical stimulation of normal and leukemic rat hematopoiesis by monoclonal antibody to CSF–1 receptor. Shadduck RK, et al. **Exp Hematol** 1996 Feb;24(2):314–7

Stimulation of platelet glycoprotein IIb–IIIa (alpha IIb beta 3–integrin) functional activity by a monoclonal antibody to the N–terminal region of glycoprotein IIIa. Mazurov AV, et al. **FEBS Lett** 1996 Aug 5;391(1–2):84–8

A monoclonal antibody against T–cell receptor alpha beta induces endogenous cytokines and prevents mice from a lethal infection with Listeria monocytogenes. Nakane A, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):321–7

Purification of circulating liver plasma membrane fragments using a monoclonal antileucine aminopeptidase antibody. Deng JT, et al. **Hepatology** 1996 Mar;23(3):445–54

Differential activation through the TCR–CD3 complex affects the requirement for costimulation of human T cells. Kawaguchi M, et al. **Hum Immunol** 1995 Jun;43(2):136–48

An anti–interleukin 8 monoclonal antibody that interferes with the binding of interleukin 8 to cellular receptors and the activation of human blood neutrophils. Kurdowska A, et al. **Hybridoma** 1995 Jun;14(3):225–33

Inhibition of staphylococcal enterotoxin–driven lymphocyte proliferation by anti–MHC class II monoclonal antibody. Loh MT, et al. **Hybridoma** 1995 Oct;14(5):429–33

Homotypic cell aggregation via conformational change of CD44 molecule induced by anti–CD44 monoclonal antibodies. Cao L, et al. **Immunobiology** 1995 Jun; 193(1):1–14

The induction of skin xenograft tolerance in rat–to–mouse combination could be affected by DFR mediating cells and antibodies against rat bone marrow cells as well as NK cells in the cyclophosphamide–induced tolerance system. Nishimura Y, et al. **Immunobiology** 1995 Aug;193(5):420–38

The effect of WSEWS pentapeptide and WSEWS–specific monoclonal antibodies on constitutive and IL–6 induced acute–phase protein production by a human hepatoma cell line, HEPG–2. Biró J, et al. **Immunol Lett** 1995 May; 46(1–2):183–7

Enhancement and inhibition of cellular responsiveness mediated by the anti–leucocyte monoclonal antibody NDS 71. Higgins RM, et al. **Immunol Lett** 1995 May; 46(1–2):37–42

Anti–gamma delta T cell antibody blocks the induction and maintenance of oral tolerance to ovalbumin in mice. Mengel J, et al. **Immunol Lett** 1995 Dec;48(2):97–102

Anti–CD40 monoclonal antibody induces the proliferation of murine B cells as a B–cell mitogen through a distinct pathway from receptors for antigens or lipopolysaccharide. Nomura J, et al. **Immunol Lett** 1995 Mar;45(3):195–203

Physical interaction with monocytes rescues human mature CD4+ T–cell lines from anti–CD3–induced apoptosis. Yamauchi Y, et al. **Immunol Lett** 1995 May;46(1–2):85–92

High–level IL–10 production by monoclonal antibody–stimulated human T cells. Schwarz M, et al. **Immunology** 1995 Nov;86(3):364–71

Parallel pattern of expression of CD43 and of LFA–1 on the CD45RA+ (naive) and CD45RO+ (memory) subsets of human CD4+ and CD8+ cells. Correlation with the aggregative response of the cells to CD43 monoclonal antibodies. Youseffi–Etemad R, et al. **Immunology** 1996 Mar;87(3):439–46

Basophil histamine release and leukotriene production in response to anti–IgE and anti–IgE receptor antibodies. Comparison of normal subjects and patients with urticaria, atopic dermatitis or bronchial asthma. Bischoff SC, et al. **Int Arch Allergy Immunol** 1996 Jul;110(3):261–71

Emergence of CD52–, glycosylphosphatidylinositol–anchor–deficient lymphocytes in rheumatoid arthritis patients following Campath–1H treatment. Brett SJ, et al. **Int Immunol** 1996 Mar;8(3):325–34

Potentiation of the reversal activity of SDZ PSC833 on multi–drug resistance by an anti–P–glycoprotein monoclonal antibody MRK–16. Naito M, et al. **Int J Cancer** 1996 Jul 29;67(3):435–40

Anti–L–selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. Rosato A, et al. **Int J Cancer** 1996 Mar 15;65(6):847–51

Effect of antibody to HIV–1 Tat protein on viral replication in vitro and progression of HIV–1 disease in vivo. Re MC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):408–16

Activation of a recombinant petunia glutamate decarboxylase by calcium/calmodulin or by a monoclonal antibody which recognizes the calmodulin binding domain. Snedden WA, et al. **J Biol Chem** 1996 Feb 23;271(8):4148–53

A monoclonal antibody enhances ligand binding of fibronectin MSCRAMM (adhesin) from Streptococcus dysgalactiae. Speziale P, et al. **J Biol Chem** 1996 Jan 19; 271(3):1371–8

Anti–CD18 attenuates deleterious effects of cardiopulmonary bypass and hypothermic circulatory arrest in piglets. Aoki M, et al. **J Card Surg** 1995 Jul;10(4 Suppl):407–17

An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. Drake CJ, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2655–61

An anti–alpha v–integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. Mitjans F, et al. **J Cell Sci** 1995 Aug;108 (Pt 8):2825–38

Anti–CD3–induced changes in protein kinase C isozymes expression in human CD4+ and CD8+ T lymphocytes. Harris W, et al. **J Clin Immunol** 1995 Sep;15(5):232–41

Monoclonal antibodies specific for the binding site on the LH receptor alter progesterone production in cultured granulosa cells. Nau EA, et al. **J Endocrinol** 1996 Jul; 150(1):9–16

Immuno–enhancement and –inhibition of GH–releasing factor by site–directed anti peptide antibodies in vivo and in vitro. Pell JM, et al. **J Endocrinol** 1995 Sep;146(3):535–41

A critical role for transforming growth factor–beta but not interleukin 4 in the suppression of T helper type 1–mediated colitis by CD45RB(low) CD4+ T cells. Powrie F, et al. **J Exp Med** 1996 Jun 1;183(6):2669–74

CTLA–4 ligation blocks CD28–dependent T cell activation. Walunas TL, et al. **J Exp Med** 1996 Jun 1;183(6):2541–50

Alloantigen–induced human lymphocytes rendered nonresponsive by a combination of anti–CD80 monoclonal antibodies and cyclosporin–A suppress mixed lymphocyte reaction in vitro. Comoli P, et al. **J Immunol** 1995 Dec 15;155(12):5506–11

CD45 ligation induces programmed cell death in T and B lymphocytes. Klaus SJ, et al. **J Immunol** 1996 Apr 15; 156(8):2743–53

Fc gamma II receptor–mediated platelet activation induced by anti–CD9 monoclonal antibody opens Ca2+ channels which are distinct from those associated with Ca2+ store depletion. Kuroda K, et al. **J Immunol** 1995 Nov 1; 155(9):4427–36

An antibody that binds domain 1 of CD4 inhibits replication of HIV–1, but not HTLV–I, in a CD4–positive/p56lck–negative HTLV–I–transformed cell line. Lemasson I, et al. **J Immunol** 1996 Jan 15; 156(2):859–65

Local inflammation caused by a monoclonal antibody that blocks the function of the rat membrane inhibitor of C3 convertase. Nishikawa K, et al. **J Immunol** 1996 Feb 1; 156(3):1182–8

CTLA–4 blockade enhances clinical disease and cytokine

production during experimental allergic encephalomyelitis. Perrin PJ, et al. **J Immunol** 1996 Aug 15;157(4):1333–6
Proteolytic cleavage of alpha–actinin by calpain in T cells stimulated with anti–CD3 monoclonal antibody. Selliah N, et al. **J Immunol** 1996 May 1;156(9):3215–21
CD45 monoclonal antibodies inhibit TCR–mediated calcium signals, calmodulin–kinase IV/Gr activation, and oncoprotein 18 phosphorylation. Shivnan E, et al. **J Immunol** 1996 Jul 1;157(1):101–9
Modulation of rat B cell differentiation in vivo by the administration of an anti–mu monoclonal antibody. Soares M, et al. **J Immunol** 1996 Jan 1;156(1):108–18
Internalization of human macrophage surface antigens induced by monoclonal antibodies. Audran R, et al. **J Immunol Methods** 1995 Dec 15;188(1):147–54
A convenient method for epitope competition analysis of two monoclonal antibodies for their antigen binding. Kwak JW, et al. **J Immunol Methods** 1996 May 10;191(1):49–54
Establishment of dengue virus–specific human CD4+ T lymphocyte clones from Percoll–purified T lymphoblasts by stimulation with monoclonal antibody to CD3 [letter] Zivny J, et al. **J Immunol Methods** 1995 Dec 15; 188(1):165–7
Potentiation of antiproliferative effects of monoclonal antibody Lym–1 and immunoconjugate Lym–1–gelonin on human Burkitt's lymphoma cells with gamma–interferon and tumor necrosis factor. O'Boyle KP, et al. **J Immunother Emphasis Tumor Immunol** 1995 Nov; 18(4):221–30
The pharmacokinetics, antigenicity, and fusion–inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. Everitt DE, et al. **J Infect Dis** 1996 Sep;174(3):463–9
Biphasic granulocytopenia after administration of the first dose of OKT3. Bemelman FJ, et al. **J Lab Clin Med** 1995 Dec;126(6):571–9
Anti–CD69 antibodies enhance phorbol–dependent glucose metabolism and Ca2+ levels in human thymocytes. Antagonist effect of cyclosporin A. Conde M, et al. **J Leukoc Biol** 1996 Aug;60(2):278–84
A monoclonal antibody to alpha 4–integrin reverses the MR–detectable signs of experimental allergic encephalomyelitis in the guinea pig. Kent SJ, et al. **J Magn Reson Imaging** 1995 Sep–Oct;5(5):535–40
Neurotrophin–3 antibodies disrupt the normal development of the chick retina. Bovolenta P, et al. **J Neurosci** 1996 Jul 15;16(14):4402–10
Potent human p140–TrkA agonists derived from an anti–receptor monoclonal antibody. LeSauteur L, et al. **J Neurosci** 1996 Feb 15;16(4):1308–16
Thymosin alpha–1 and FA–1 monoclonal antibody affect fertilizing capacity of human sperm by modulating protein phosphorylation pattern. Ahmad K, et al. **J Reprod Immunol** 1995 May;29(1):1–17
CD18 antibody treatment limits early myocardial reperfusion injury after initial leukocyte deposition. McDonagh PF, et al. **J Surg Res** 1996 Aug;64(2):139–49
Autoimmune destruction of islet grafts in the NOD mouse is resistant to 15–deoxyspergualin but sensitive to anti–CD4 antibody. Stegall MD, et al. **J Surg Res** 1996 Aug; 64(2):156–60
Enhanced isolated lung function after ischemia with anti–intercellular adhesion molecule antibody. Buchanan SA, et al. **J Thorac Cardiovasc Surg** 1996 May;111(5):941–7
Functional epitope analysis of the human CD4 molecule: antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3–like region of CD4. Benkirane M, et al. **J Virol** 1995 Nov; 69(11):6898–903
The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3–like region in domain 1 of CD4. Benkirane M, et al. **J Virol** 1995 Nov;69(11):6904–10
Effects of anti–E2 monoclonal antibody on sindbis virus replication in AT3 cells expressing bcl–2. Després P, et al. **J Virol** 1995 Nov;69(11):7006–14
Antiviral activity of alpha interferon in Sindbis virus–infected cells is restored by anti–E2 monoclonal antibody treatment. Després P, et al. **J Virol** 1995 Nov;69(11):7345–8
Gamma interferon is critical for resistance to Theiler's virus–induced demyelination. Rodriguez M, et al. **J Virol** 1995 Nov;69(11):7286–90
Role of T–lymphocyte subsets in recovery from respiratory syncytial virus infection in calves. Taylor G, et al. **J Virol** 1995 Nov;69(11):6658–64
Lesions of the cholinergic nuclei in the rat basal forebrain: excitotoxins vs. an immunotoxin. Waite JJ, et al. **Life Sci** 1996;58(22):1947–53
Preparation and assay of acetylcholinesterase antibody. Friboulet A, et al. **Methods Mol Biol** 1995;51:211–22
Effect of monoclonal antibodies directed against Candida albicans cell wall antigens on the adhesion of the fungus to polystyrene. San Millan R, et al. **Microbiology** 1996 Aug; 142 (Pt 8):2271–7
Immunosuppressive effect of monoclonal antibodies to ICAM–1 and LFA–1 on peripheral nerve allograft in mice. Nakao Y, et al. **Microsurgery** 1995;16(9):612–20
Promotion of animal growth with a monoclonal antibody specific to growth hormone receptor. Wang BS, et al. **Mol Cell Endocrinol** 1996 Feb 5;116(2):223–6
Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin–1 alpha specific inhibitor. Garrone P, et al. **Mol Immunol** 1996 May–Jun;33(7–8):649–58
Antibodies against human CD63 activate transfected rat basophilic leukemia (RBL–2H3) cells. Smith DA, et al. **Mol Immunol** 1995 Dec;32(17–18):1339–44
Production of tissue inhibitor of metalloproteinases–1 (TIMP–1) by human astrocytic tumors. Nakagawa T, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):728–31
A monoclonal antibody extends the half–life of an anti–HIV oligodeoxynucleotide and targets it to CD4+ cells. Morelli D, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4603–7
Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Wyde PR, et al. **Pediatr Res** 1995 Oct; 38(4):543–50
Monoclonal digoxin–specific antibodies induce dose– and affinity–dependent plasma digoxin redistribution in rats. Cano NJ, et al. **Pharm Res** 1995 May;12(5):709–14
Conjugates of folate and anti–T–cell–receptor antibodies specifically target folate–receptor–positive tumor cells for lysis. Kranz DM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9057–61
Inhibition of chemomigration of a human prostatic carcinoma cell (TSU–pr1) line by inhibition of epidermal growth factor receptor function. Zolfaghari A, et al. **Prostate** 1996 Apr;28(4):232–8
Production and characterization of anti–human interferon gamma receptor antibody fragments that inhibit cytokine binding to the receptor. Bridges A, et al. **Protein Eng** 1996 Apr;9(4):365–70
Triggering of target of an antiproliferative antibody–1 (TAPA–1/CD81) up–regulates the release of tumour necrosis factor–alpha by the EBV–B lymphoblastoid cell line JY. Altomonte M, et al. **Scand J Immunol** 1996 Apr; 43(4):367–73
Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti–Lewis Y antibody and antibodies to complement regulatory proteins [letter] Brasoveanu LI, et al. **Scand J Immunol** 1996 Mar; 43(3):351–3
Altered allogeneic response in neonatally anti–MHC class I–treated mice. Marušić–Galešić S, et al. **Scand J Immunol** 1996 Mar;43(3):321–8
A non–competitive P55 TNF receptor antibody enhances the specific activity of lymphotoxin–alpha. Medvedev AE, et al. **Scand J Immunol** 1996 Apr;43(4):439–48
Role of platelet–endothelial cell adhesion molecule (PECAM) in platelet adhesion/aggregation over injured but not denuded endothelium in vivo and ex vivo. Rosenblum WI, et al. **Stroke** 1996 Apr;27(4):709–11
Mechanisms of action and overview of OKT3. Norman DJ. **Ther Drug Monit** 1995 Dec;17(6):615–20 (72 ref.)
A single–chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity. Moosmayer D, et al. **Ther Immunol** 1995 Feb;2(1):31–40
Generation and mechanism of action of a potent inhibitor of factor XIII function. Reed GL, et al. **Thromb Haemost** 1995 Aug;74(2):680–5
Differential effects of T cell receptor ligation of TCR gamma delta thymocyte development in fetal thymic organ culture. Tatsumi Y, et al. **Thymus** 1994–95;23(3–4):131–53
Effects of monoclonal antibody against CD45RB on peripheral blood mononuclear cell proliferation and on HLA–DR and adhesion molecule expression on thyrocytes of patients with autoimmune thyroid disease. Nishikawa M, et al. **Thyroid** 1995 Aug;5(4):265–72
Immunohistological reaction mechanism of anti–monosialoganglioside monoclonal antibody, MAb 202, showing predominant cytotoxicity for malignant melanoma. Ota T, et al. **Tohoku J Exp Med** 1995 Sep; 177(1):1–12
Blocking effect of anti–mouse interleukin–6 monoclonal antibody and glucocorticoid receptor antagonist, RU38486, on metallothionein–inducing activity of serum from lipopolysaccharide–treated mice. Itoh N, et al. **Toxicology** 1996 Aug 1;112(1):29–36
In vivo neutralization of tetrodotoxin by a monoclonal antibody. Matsumura K. **Toxicon** 1995 Sep;33(9):1239–41
The effect of a depleting anti–CD4 monoclonal antibody on T cells and fetal pig islet xenograft survival in various strains of mice. Mandel TE, et al. **Transpl Immunol** 1995 Sep;3(3):265–72
Immunological effects of the anti–IL–2 receptor monoclonal antibody BT 563 in liver allografted patients. Nashan B, et al. **Transpl Immunol** 1995 Sep;3(3):203–11
Blocking of ICAM–1 and LFA–1 in rat liver transplantation. Degawa H, et al. **Transplant Proc** 1996 Jun;28(3):1362–3
Dose dependent immunosuppressive effects of antibodies to ICAM–1 and LFA–1 on hepatic allografts. Harihara Y, et al. **Transplant Proc** 1996 Jun;28(3):1794–5
Processing of IgM/Anti–IgM immune complexes by the liver of rats treated with anti–IgM monoclonal antibodies. Havaux XB, et al. **Transplant Proc** 1996 Apr;28(2):574
Effects of exogenous IL–2 on tolerance induction by anti–ICAM–1 and anti–LFA–1 monoclonal antibodies. Isobe M, et al. **Transplant Proc** 1996 Apr;28(2):1045–6
Murine monoclonal anti–idiotypic antibodies directed against human anti–alpha Gal antibodies prevent rejection of pig cells in culture: implications for pig–to–human organ xenotransplantation. Koren E, et al. **Transplant Proc** 1996 Apr;28(2):559
The effect of a depleting anti–CD4 monoclonal antibody on T cells and fetal pig islet xenograft survival in various strains of mice. Mandel T, et al. **Transplant Proc** 1995 Dec; 27(6):3569
An anti–CD2 monoclonal antibody that elicits alloantigen–specific hyporesponsiveness. Schad V, et al. **Transplant Proc** 1996 Aug;28(4):2051–3 (17 ref.)
Effect of LFA–1 inhibition on immediate organ function in concordant ex–vivo hemoperfusion of primate kidneys. Storck M, et al. **Transplant Proc** 1996 Apr;28(2):765–6
Transmembrane signaling requirements of T cells: implications for regulation of alloimmunity. Suthanthiran M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):5–7 (25 ref.)
Reduction of ischemia–reperfusion injury by monoclonal antibody to intercellular adhesion molecule–1. Tosa Y, et al. **Transplant Proc** 1996 Jun;28(3):1210–1
Expression of granzyme A and perforin in mouse heart transplants immunosuppressed with donor–specific transfusion and anti–CD4 monoclonal antibody. Chen RH, et al. **Transplantation** 1996 Feb 27;61(4):625–9
In vivo anti–CD3–driven cell activation. Cellular source of induced tumor necrosis factor, interleukin–1 beta, and interleukin–6. Goumy L, et al. **Transplantation** 1996 Jan 15;61(1):83–7
CD2 antigen targeting reduces intragraft expression of mRNA–encoding granzyme B and IL–10 and induces tolerance. Kapur S, et al. **Transplantation** 1996 Jul 27; 62(2):249–55
HIV–1 candidate vaccines can induce antibodies which share specificity with human monoclonal antibodies capable of neutralizing primary isolates [letter] Davis D. **Vaccine** 1996 Mar;14(4):353–4
[Characterization of platelet activation induced by CD9 McAbs] Peng L, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):365–70 (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

The biological activity of human monoclonal IgG anti–D is reduced by beta–galactosidase treatment. Kumpel BM, et al. **Hum Antibodies Hybridomas** 1995;6(3):82–8
Production of a rat pancreatic polypeptide–specific monoclonal antibody and its influence on glucose homeostasis by in vivo immunoneutralization. Wong HC, et al. **Hybridoma** 1995 Aug;14(4):369–76
Novel mAbs reveal potent co–stimulatory activity of murine CD27. Gravestein LA, et al. **Int Immunol** 1995 Apr; 7(4):551–7
The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath–1H. Boyd PN, et al. **Mol Immunol** 1995 Dec;32(17–18):1311–8

RADIATION EFFECTS

Effects of proton irradiation on radiolabeled monoclonal antibody uptake in human colon tumor xenografts. Gridley DS, et al. **J Immunother Emphasis Tumor Immunol** 1995 May;17(4):229–37
Prevention of radiolysis of monoclonal antibody during labeling. Chakrabarti MC, et al. **J Nucl Med** 1996 Aug; 37(8):1384–8

THERAPEUTIC USE

Radiolabeled monoclonal antibodies in diagnosis and therapy of cancer. Summary and perspectives. Britton KE. **Acta Oncol** 1996;35(3):385–90
Monoclonal antibody therapy of leukemia and lymphoma. Jurcic JG, et al. **Adv Pharmacol** 1995;33:287–314 (104 ref.)
Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six–month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Lefkovits J, et al. **Am J Cardiol** 1996 May 15;77(12):1045–51
Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE. **Am J Cardiol** 1996 Aug 14; 78(3A):35–40 (27 ref.)
Clearance of PCR–detectable lymphoma cells from the peripheral blood, but not bone marrow after therapy with campath–1H [letter] DelleKarth G, et al. **Am J Hematol** 1995 Oct;50(2):146–7
Monoclonal antibodies in the management of acute leukemia. Wang JC, et al. **Am J Hematol** 1995 Nov;50(3):188–99 (159 ref.)
Do monoclonal antibodies and anticytokines still have a future in infectious diseases? Cohen J, et al. **Am J Med** 1995 Dec 29;99(6A):45S–52S; discussion 52S–53S (36 ref.)
Effects of CD11b/18 monoclonal antibody on rats with permanent middle cerebral artery occlusion. Garcia JH, et al. **Am J Pathol** 1996 Jan;148(1):241–8
Anti–CD18 antibody does not block ileal injury induced by phorbol myristate acetate. Overdahl MC, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1331–6
Treatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two children. Horneff G, et al. **Ann Rheum Dis** 1995 Oct;54(10):846–9
Anti–CD11b monoclonal antibody improves myocardial function after six hours of hypothermic storage. Forbess JM, et al. **Ann Thorac Surg** 1995 Nov;60(5):1238–44
Human cancer detection and immunotherapy with conjugated and non–conjugated monoclonal antibodies.

Bodey B, et al. **Anticancer Res** 1996 Mar-Apr;16(2):661-74 (172 ref.)

Effect of imipenem on monoclonal antibody-mediated protection against Escherichia coli O18K5. Frasa H, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):999-1004

CMV retinitis: ganciclovir/monoclonal antibody. Pollard RB. **Antiviral Res** 1996 Jan;29(1):73-5

Production, characterization and application of monoclonal antibodies against the organophosphorus nerve agent Vx. Ci YX, et al. **Arch Toxicol** 1995;69(8):565-7

Antibodies proposed as therapeutic agents. Bismuth C, et al. **Arch Toxicol Suppl** 1996;18:321-32 (39 ref.)

Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Choy EH, et al. **Arthritis Rheum** 1996 Jan;39(1):52-6

Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Moreland LW, et al. **Arthritis Rheum** 1995 Nov;38(11):1581-8

Synovial tissue responses following treatment of rheumatoid arthritis with the humanized monoclonal antibody CAMPATH-1H [letter; comment] Soriano ER, et al. **Arthritis Rheum** 1996 Jan;39(1):181-2. Comment on: Arthritis Rheum 1995 Feb;38(2):254-8.

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Tak PP, et al. **Arthritis Rheum** 1995 Oct; 38(10):1457-65

Therapeutic monoclonals. Boleti E, et al. **Biochem Soc Trans** 1995 Nov;23(4):1044-7 (49 ref.)

Clinical trials with CAMPATH-1 and other monoclonal antibodies. Hale G, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1057-63 (49 ref.)

Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Taylor G, et al. **Biochem Soc Trans** 1995 Nov;23(4):1063-7 (24 ref.)

Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts. Drobyski WR, et al. **Blood** 1996 Jun 15;87(12):5355-69

Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Knox S, et al. **Blood** 1996 Feb 1;87(3):893-9

Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Lu ZY, et al. **Blood** 1995 Oct 15;86(8):3123-31

Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Martin PJ, et al. **Blood** 1996 Aug 1; 88(3):824-30

Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Renner C, et al. **Blood** 1996 Apr 1;87(7):2930-7

Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. White CA, et al. **Blood** 1996 May 1;87(9):3640-9

Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1. Ferrant A, et al. **Bone Marrow Transplant** 1995 Oct;16(4):577-81

Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Hebart H, et al. **Bone Marrow Transplant** 1995 Jun;15(6):891-4

Management of pre-eclampsia [letter; comment] Ward JE, et al. **Br J Anaesth** 1996 Jun;76(6):889-90. Comment on: Br J Anaesth 1996 Jan;76(1):133-48.

Perturbations of triglycerides but not of cholesterol metabolism are prevented by anti-tumour necrosis factor treatment in rats bearing an ascites hepatoma (Yoshida AH-130). Dessi S, et al. **Br J Cancer** 1995 Nov; 72(5):1138-43

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Modjtahedi H, et al. **Br J Cancer** 1996 Jan; 73(2):228-35

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Negri DR, et al. **Br J Cancer** 1995 Oct; 72(4):928-33

Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro. Perron MJ, et al. **Br J Cancer** 1996 Feb;73(3):281-7

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Tokuda Y, et al. **Br J Cancer** 1996 Jun;73(11):1362-5

Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. Ericson SG, et al. **Br J Haematol** 1996 Mar; 92(3):718-24

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H [letter] Isaacs JD, et al. **Br J Ophthalmol** 1995 Nov;79(11):1054-5

Effects of low dose intra-arterial monoclonal antibodies to ICAM-1 and CD11/CD18 on local and systemic consequences of ischaemia-reperfusion injury in skeletal muscle. Breidahl AF, et al. **Br J Plast Surg** 1996 Jun; 49(4):202-9

Therapeutic monoclonal antibodies. Choy EH, et al. **Br J Rheumatol** 1995 Aug;34(8):707-15 (64 ref.)

Monoclonal antibody therapy of inflammatory rheumatic diseases. Breedveld FC, et al. **Br Med Bull** 1995 Apr; 51(2):493-502 (47 ref.)

Postischemic treatment (2-4 h) with anti-CD11b and anti-CD18 monoclonal antibodies are neuroprotective after transient (2 h) focal cerebral ischemia in the rat. Zhang ZG, et al. **Brain Res** 1995 Nov 6;698(1-2):79-85

Experimental gut-derived endotoxaemia and bacteraemia are reduced by systemic administration of monoclonal anti-LPS antibodies. Gianotti L, et al. **Burns** 1996 Mar; 22(2):120-4

Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Muto MG, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2016-27 (100 ref.)

Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays [see comments] Pertschuk LP, et al. **Cancer** 1996 Jun 15; 77(12):2514-9. Comment in: Cancer 1996 Jun 15;77(12):2419-22.

Whither magic bullets and guided missiles: monoclonal antibodies 20 years later [editorial] Dillman RO. **Cancer Biother** 1995 Fall;10(3):177-80

Monoclonal antibody therapy of cancer. Jurcic JG, et al. **Cancer Chemother Biol Response Modif** 1996;16:168-88 (124 ref.)

Immunoconjugates and immunotoxins for therapy of solid tumors. Hellström I, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S35-6 (13 ref.)

Immunogene approach toward cancer therapy using erythrocyte growth factor receptor-mediated gene delivery. Shimizu N, et al. **Cancer Gene Ther** 1996 Mar-Apr;3(2):113-20

Immunotherapy of human colon cancer by antibody-targeted superantigens. Dohlsten M, et al. **Cancer Immunol Immunother** 1995 Sep;41(3):162-8

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Fagerberg J, et al. **Cancer Immunol Immunother** 1996 Feb;42(2):81-7

Anti-(transforming growth factor beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice. Hoefer M, et al. **Cancer Immunol Immunother** 1995 Nov; 41(5):302-8

Radioimmunotherapy of small-cell lung cancer xenografts using 131I-labelled anti-NCAM monoclonal antibody 123C3. Kwa HB, et al. **Cancer Immunol Immunother** 1995 Sep;41(3):169-74

Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer. Alisauskus R, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5743s-5748s

Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Asano M, et al. **Cancer Res** 1995 Nov 15; 55(22):5296-301

Radiation-absorbed dose estimates to normal organs following intraperitoneal 186Re-labeled monoclonal antibody: methods and results. Breitz HB, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5817s-5822s

Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression. DeNardo SJ, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5837s-5841s

A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach. Juhl H, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5749s-5755s

Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Jurcic JG, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5908s-5910s

Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Juweid M, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5899s-5907s

Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen. Juweid M, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5946s-5951s

MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Katayose Y, et al. **Cancer Res** 1996 Sep 15;56(18):4205-12

Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Morelli D, et al. **Cancer Res** 1996 May 1;56(9):2082-5

Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Sharkey RM, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5935s-5945s

In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Tian ZG, et al. **Cancer Res** 1995 Nov 15; 55(22):5335-41

Protection of ischemic/reperfused canine myocardium by CL18/6, a monoclonal antibody to adhesion molecule ICAM-1. Hartman JC, et al. **Cardiovasc Res** 1995 Jul; 30(1):47-54

Administration of a nondepleting anti-CD4 monoclonal antibody (W3/25) prevents adjuvant arthritis, even upon rechallenge: parallel administration of a depleting anti-CD8 monoclonal antibody (OX8) does not modify the effect of W3/25. Pelegri C, et al. **Cell Immunol** 1995 Oct 15; 165(2):177-82

Administration of monoclonal antibodies against vascular cell adhesion molecule-1/very late antigen-4 abrogates predisposing autoimmune diabetes in NOD mice. Tsukamoto K, et al. **Cell Immunol** 1995 Oct 15; 165(2):193-201

Anti-CD4 monoclonal antibodies suppress murine collagen-induced arthritis only at the time of primary immunisation. Williams RO, et al. **Cell Immunol** 1996 Jun 15;170(2):291-5

Induction of immunological tolerance to islet allografts. Rossini AA, et al. **Cell Transplant** 1996 Jan-Feb;5(1):49-52

The integrin alpha 4 beta 1 (VLA-4) as a therapeutic target. Elices MJ. **Ciba Found Symp** 1995;189:79-85; discussion 85-90, 174-6 (56 ref.)

Treatment of inflammatory diseases with a monoclonal antibody to intercellular adhesion molecule 1. Rothlein R, et al. **Ciba Found Symp** 1995;189:200-8; discussion 208-11 (41 ref.)

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Mark DB, et al. **Circulation** 1996 Aug 15;94(4):629-35

Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Ragni M, et al. **Circulation** 1996 May 15;93(10):1913-8

The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al. **Cleve Clin J Med** 1996 May-Jun;63(3):181-9 (32 ref.)

Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Kuus-Reichel K, et al. **Clin Diagn Lab Immunol** 1994 Jul; 1(4):365-72 (82 ref.)

Selective CD4+ T cell deletion after specific activation in HIV-infected individuals; protection by anti-CD28 monoclonal antibodies. Cottrez F, et al. **Clin Exp Immunol** 1996 Jul;105(1):31-8

Immunotherapy with monoclonal antibodies directed against the immunosuppressive domain of p15E inhibits tumour growth. Lang MS, et al. **Clin Exp Immunol** 1995 Dec; 102(3):468-75

Treatment with an anti-CD4 monoclonal antibody strongly ameliorates established rat adjuvant arthritis. Pelegri C, et al. **Clin Exp Immunol** 1996 Feb;103(2):273-8

Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Wadhwa M, et al. **Clin Exp Immunol** 1996 May; 104(2):351-8

Treatment of arthritis in Lewis rats by a monoclonal antibody against alpha beta T cell receptor: differential sensitivity of Yersinia-induced arthritis versus adjuvant arthritis. Gaede K, et al. **Clin Immunol Immunopathol** 1995 Dec; 77(3):339-48

Adhesion molecules as therapeutic targets in the treatment of allergic and immunologically mediated diseases. Kavanaugh A. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S15-22 (37 ref.)

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Cohen J, et al. **Crit Care Med** 1996 Sep;24(9):1431-40

Post hoc analyses in sepsis trials: a formula for disappointment? [editorial; comment] Dellinger RP. **Crit Care Med** 1996 May;24(5):727-9. Comment on: Crit Care Med 1996 May;24(5):733-42.

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study [see comments] Reinhart K, et al. **Crit Care Med** 1996 May; 24(5):733-42. Comment in: Crit Care Med 1996 May;24(5):727-9.

International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Sprung CL, et al. **Crit Care Med** 1996 Sep;24(9):1441-7

Monoclonal antibody to tumor necrosis factor-alpha attenuates hemodynamic dysfunction secondary to intestinal ischemia/reperfusion in rats. Yao YM, et al. **Crit Care Med** 1996 Sep;24(9):1547-53

Micrometastasis detection and treatment with monoclonal antibodies. Pantel K, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):1-18 (88 ref.)

Endotoxin-based molecular strategies for the prevention and treatment of gram-negative sepsis and septic shock. Pollack M, et al. **Curr Top Microbiol Immunol** 1996;216:275-97 (185 ref.)

Lymphocyte function associated antigen-1, integrin alpha 4,

and L-selectin mediate T-cell homing to the pancreas in the model of adoptive transfer of diabetes in NOD mice. Fabien N, et al. **Diabetes** 1996 Sep;45(9):1181-6

Prevention of decline in renal function in the diabetic db/db mouse. Cohen MP, et al. **Diabetologia** 1996 Mar;39(3):270-4

Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma. Bier H, et al. **Eur Arch Otorhinolaryngol** 1995; 252(7):433-9

More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials [editorial] van de Werf F. **Eur Heart J** 1996 Mar;17(3):325-6

Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Schlimok G, et al. **Eur J Cancer** 1995 Oct; 31A(11):1799-803

Prevention of manifest metastasis with monoclonal antibodies: a novel approach to immunotherapy of solid tumours. Schneider-Gädicke E, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1326-30 (51 ref.)

Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Stragliotto G, et al. **Eur J Cancer** 1996 Apr;32A(4):636-40

Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Nakajima A, et al. **Eur J Immunol** 1995 Nov;25(11):3060-9

Role of the VLA-4 integrin in leucocyte recruitment and bronchial hyperresponsiveness in the guinea-pig. Milne AA, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):243-9

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. Newman DK, et al. **Eye** 1995;9 (Pt 5):564-9

Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice. Qi Y, et al. **Gastroenterology** 1995 Dec;109(6):1950-7

Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses. Buckley DT, et al. **Hum Antibodies Hybridomas** 1995;6(2):68-72

Enhancement of monoclonal antibody efficacy: the effect of external beam radiation. Bender H, et al. **Hybridoma** 1995 Apr;14(2):129-34

Radioimmunotherapy of lymphoma: a UC Davis experience. Lewis JP, et al. **Hybridoma** 1995 Apr;14(2):115-20

Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Madiyalakan R, et al. **Hybridoma** 1995 Apr;14(2):199-203

A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer. Schlebusch H, et al. **Hybridoma** 1995 Apr;14(2):167-74

Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3. Schmolling J, et al. **Hybridoma** 1995 Apr;14(2):183-6

Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Snelling L, et al. **Hybridoma** 1995 Apr;14(2):111-4

Prevention of mortality by in vivo depletion of alpha beta T cells in murine lethal listeriosis and involvement of gamma delta T cells in bacterial elimination. Matsutake T, et al. **Immunobiology** 1995 Jun;193(1):71-83

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Maini RN, et al. **Immunol Rev** 1995 Apr;144:195-223 (112 ref.)

Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Brett S, et al. **Immunology** 1996 May;88(1):13-9

Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies. Harada M, et al. **Immunology** 1996 Mar;87(3):447-53

Pharmacodynamics of prophylactic antirejection therapy with an anti interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation. Hesse CJ, et al. **Immunopharmacology** 1995 Sep;30(3):237-46

Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice. Frasa H, et al. **Infect Immun** 1996 Mar;64(3):775-81

Prevention of endotoxin shock by an antibody against leukocyte integrin beta 2 through inhibiting production and action of TNF. Watanabe S, et al. **Int Immunol** 1995 Jul; 7(7):1037-46

Radioimmunotherapy of prostatic adenocarcinomas: effects of 131I-labelled E4 antibodies on cells at different depth in DU 145 spheroids. Essand M, et al. **Int J Cancer** 1995 Nov 3;63(3):387-94

Reversal of adriamycin resistance with chimeric anti-ganglioside GM2 antibody. Fukumoto H, et al. **Int J Cancer** 1996 Sep 4;67(5):676-80

Prevention of reovirus type 2-induced diabetes-like syndrome in DBA/1 suckling mice by treatment with antibodies against intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1. Hayashi T, et al. **Int J Exp Pathol** 1995 Dec;76(6):403-9

New therapeutic approaches in sepsis: a critical review. Eidelman LA, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S269-72 (18 ref.)

Paradoxic effect of anti-CD4 therapy on lacrimal gland disease in MRL/Mp-lpr/lpr mice. Jabs DA, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):246-50

Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. Prinz JC, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):244-52

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. Kleiman NS, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1665-71

A new therapeutic monoclonal antibody. Freeman PR. **J Am Pharm Assoc (Wash)** 1996 Feb;NS36(2):90-1

The monoclonal antibody, 7E3 and treatment of coronary artery disease. Talley JD. **J Ark Med Soc** 1996 Feb; 92(9):453-4

Monoclonal antibody [7E3 F(ab')2] prevents arterial but not venous rethrombosis. Sudo Y, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):241-50

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin [see comments] Brooks PC, et al. **J Clin Invest** 1995 Oct;96(4):1815-22. Comment in: J Clin Invest 1995 Oct;96(4):1696-7.

Starve a tumor: therapeutic advice for breast cancer? [editorial; comment] Damsky CH. **J Clin Invest** 1995 Oct; 96(4):1696-7. Comment on: J Clin Invest 1995 Oct;96(4):1815-22.

Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice. Fujisawa K, et al. **J Clin Invest** 1996 Jul 15;98(2):271-8

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". Reverter JC, et al. **J Clin Invest** 1996 Aug 1;98(3):863-74

Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. Tsujinaka T, et al. **J Clin Invest** 1996 Jan 1; 97(1):244-9

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer [see comments] Baselga J, et al. **J Clin Oncol** 1996 Mar; 14(3):737-44. Comment in: J Clin Oncol 1996 Mar;14(3):697-9.

Should we treat HER, too? [editorial; comment] Hayes DF. **J Clin Oncol** 1996 Mar;14(3):697-9. Comment on: J Clin Oncol 1996 Mar;14(3):737-44.

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. Hara I, et al. **J Exp Med** 1995 Nov 1; 182(5):1609-14

Antibodies to interleukin 12 abrogate established experimental colitis in mice. Neurath MF, et al. **J Exp Med** 1995 Nov 1;182(5):1281-90

Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects. Kroesen BJ, et al. **J Hematother** 1995 Oct;4(5):409-14

A combination of CD34 selection and complement-mediated immunopurging (anti-CD15 monoclonal antibody) eliminates tumor cells while sparing normal progenitor cells. Nimgaonkar M, et al. **J Hematother** 1996 Feb; 5(1):39-48

Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies. Renner C, et al. **J Hematother** 1995 Oct;4(5):447-51

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). Repp R, et al. **J Hematother** 1995 Oct;4(5):415-21 (26 ref.)

Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. Valone FH, et al. **J Hematother** 1995 Oct; 4(5):471-5

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Weiner LM, et al. **J Hematother** 1995 Oct;4(5):453-6

Adhesion molecules and liver transplantation: new strategies for therapeutic intervention. Adams DH. **J Hepatol** 1995 Aug;23(2):225-31 (58 ref.)

Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors. Araga S, et al. **J Immunol** 1996 Jul 1; 157(1):386-92

CD4-imitating human antibodies in HIV infection and anti-idiotypic vaccination. Deckert PM, et al. **J Immunol** 1996 Jan 15;156(2):826-33

Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. Edwards CK 3rd, et al. **J Immunol** 1996 Aug 15;157(4):1758-72

In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. Lorenz HM, et al. **J Immunol** 1996 Feb 15;156(4):1646-53

Blockade of platelet endothelial cell adhesion molecule-1 protects against myocardial ischemia and reperfusion injury in cats. Murohara T, et al. **J Immunol** 1996 May 1; 156(9):3550-7

Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration. Conry RM, et al. **J Immunother Emphasis Tumor Immunol** 1995 Nov; 18(4):231-41

Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. Walker RE, et al. **J Infect Dis** 1996 Jul;174(1):63-8

Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. Weltzin R, et al. **J Infect Dis** 1996 Aug;174(2):256-61

HER-2/neu gene bumped into the limelight [news] Holzman D. **J Natl Cancer Inst** 1996 Feb 21;88(3-4):147-8

Monoclonal antibodies progress to the next generation [news] McNeil C. **J Natl Cancer Inst** 1995 Dec 6;87(23):1738-9

A new generation of monoclonal antibodies arrives at the clinic [news] McNeil C. **J Natl Cancer Inst** 1995 Nov 15; 87(22):1658-60

Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. Roy DC, et al. **J Natl Cancer Inst** 1996 Aug 21; 88(16):1136-45

Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. Gordon EJ, et al. **J Neuroimmunol** 1995 Nov;62(2):153-60

Anti ICAM-1 (CD 54) monoclonal antibody reduces inflammatory changes in experimental bacterial meningitis. Weber JR, et al. **J Neuroimmunol** 1995 Dec;63(1):63-8

Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. Bigner DD, et al. **J Neurooncol** 1995;24(1):109-22

Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. Juweid M, et al. **J Nucl Med** 1996 Jun;37(6):905-11

Prevention of fetal bowel allograft rejection by combined treatment with anti-ICAM-1 and anti-LFA-1 antibodies. Kato Y, et al. **J Pediatr Surg** 1995 Jul;30(7):1093-7

Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. Valentine JL, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):717-24

Inhibition of selectin- and integrin-mediated inflammatory response after burn injury. Nwariaku F, et al. **J Surg Res** 1996 Jun;63(1):355-8

Combination therapy of Pseudomonas aeruginosa pyelonephritis in neutropenic mice with human antilipopolysaccharide monoclonal antibody and cefsulodin. Ishibashi K, et al. **J Urol** 1996 Jun;155(6):2094-7

Anti-CD 18 monoclonal antibody slows experimental aortic aneurysm expansion. Ricci MA, et al. **J Vasc Surg** 1996 Feb;23(2):301-7

Antibody to the ligand for CD40 (gp39) inhibits murine AIDS-associated splenomegaly, hypergammaglobulinemia, and immunodeficiency in disease-susceptible C57BL/6 mice. Green KA, et al. **J Virol** 1996 Apr;70(4):2569-75

Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. Pincus SH, et al. **J Virol** 1995 Nov;69(11):7152-8

Reengineered monoclonal antibodies step up to the plate in cancer studies [news] Stephenson J. **JAMA** 1995 Dec 20; 274(23):1821-2

Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes. Hanibuchi M, et al. **Jpn J Cancer Res** 1996 May;87(5):497-504

Therapy and imaging of pancreatic carcinoma xenografts with radioiodine-labeled chimeric monoclonal antibody A10 and its Fab fragment. Kamigaki T, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1216-23

Transduction of the macrophage colony-stimulating factor gene into human multidrug resistant cancer cells: enhanced therapeutic efficacy of monoclonal anti-P-glycoprotein antibody in nude mice. Sone S, et al. **Jpn J Cancer Res** 1996 Jul;87(7):757-64

CMV retinitis monoclonal antibody trial halted [news] McCarthy M. **Lancet** 1996 Aug 31;348(9027):603

Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2. Borrione P, et al. **Leuk Lymphoma** 1996 Apr;21(3-4):325-30

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5-6):381-93 (160 ref.)

Evaluation of monoclonal antibody-mediated anti-acute myeloid leukemia immunotherapy in a SCID/hu model. Zhong RK, et al. **Leuk Res** 1996 Jul;20(7):581-9

Leukocyte adhesion molecules as a cofactor in AIDS: basic science and pilot study. Allen AD, et al. **Med Hypotheses** 1995 Aug;45(2):164-8

Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies. Williams LE, et al. **Med Phys** 1995

Dec;22(12):2025-7

Prolonged inhibition of IgE production in mice following treatment with an IgE-specific immunotoxin. Lustgarten J, et al. **Mol Immunol** 1996 Feb;33(3):245-51

A target for tumour-directed therapy [comment] Hynes NE, et al. **Nat Med** 1995 Jul;1(7):631. Comment on: Nat Med 1995 Jul;1(7):644-8.

Prevention of breast tumour development in vivo by downregulation of the p185neu receptor [see comments] Katsumata M, et al. **Nat Med** 1995 Jul;1(7):644-8. Comment in: Nat Med 1995 Jul;1(7):631-2.

Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Mikecz K, et al. **Nat Med** 1995 Jun;1(6):558-63

Prevention and reversal of renal allograft rejection by antibody against CD45RB. Lazarovits AI, et al. **Nature** 1996 Apr 25;380(6576):717-20

Therapeutic effect of combined treatment with monoclonal antibodies against intercellular adhesion molecule 1 and lymphocyte-function-associated antigen 1 in Masugi nephritis of WKY rats [letter] Kawasaki K, et al. **Nephron** 1995;71(1):101-2

MoAb to block growth signals plus chemo may act synergistically to kill tumor cells [news] **Oncology (Huntingt)** 1996 Apr;10(4):591-2

Monoclonal antibodies may help locate and treat occult metastases [news] **Oncology (Huntingt)** 1996 Apr;10(4):552

MoAb A33 shows promise in targeting colon cancer for radioimmunotherapy [news] **Oncology (Huntingt)** 1996 Apr; 10(4):553

Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro. Kovar J, et al. **Pathobiology** 1995;63(2):65-70

Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection. Jabado N, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):420-8

Preventing the infiltration of leukocytes by monoclonal antibody blocks the development of progressive ischemia in rat burns. Choi M, et al. **Plast Reconstr Surg** 1995 Oct; 96(5):1177-85; discussion 1186-7

New immunotherapies for sepsis. Young LS, et al. **Proc Assoc Am Physicians** 1995 Oct;107(3):361-4 (19 ref.)

Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu. Connett JM, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6814-8

Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Wang Y, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8955-9

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Wang Y, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8563-8

Higher efficiency of 131I-labeled anti-carcinoembryonic antigen-monoclonal antibody F(ab')2 as compared to intact antibodies in radioimmunotherapy of established human colon carcinoma grafted in nude mice. Buchegger F, et al. **Recent Results Cancer Res** 1996;141:19-35

Monoclonal antibodies in tumor therapy. Matzku S. **Recent Results Cancer Res** 1996;141:1-8 (31 ref.)

The use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of patients with high grade gliomas of the brain. Miyamoto CT, et al. **Recent Results Cancer Res** 1996; 141:183-92

Can preirradiation enhance tumor uptake of radiolabeled pharmaceuticals? Experimental data in a mouse neuroblastoma xenograft system. Sautter-Bihl ML, et al. **Recent Results Cancer Res** 1996;141:123-35

Minimal residual disease: a target for radioimmunotherapy with 131I-labeled monoclonal antibodies? Some dosimetric considerations. Sautter-Bihl ML, et al. **Recent Results Cancer Res** 1996;141:67-75

Biologic interventions in rheumatoid arthritis. Cush JJ, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):797-816 (74 ref.)

Monoclonal antibodies at age 20: promise at last? [news] Hall SS. **Science** 1995 Nov 10;270(5238):915-6

Monoclonal antibodies: innovations in diagnosis and therapy. Baquiran DC, et al. **Semin Oncol Nurs** 1996 May; 12(2):130-41 (71 ref.)

Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-alpha 4 antibody in adjuvant arthritis. Barbadillo C, et al. **Springer Semin Immunopathol** 1995;16(4):427-36 (59 ref.)

Therapeutic efficacy of an antineutrophil monoclonal antibody, Urge-8, against acute necrotizing pancreatitis in rats. Han SL, et al. **Surgery** 1996 May;119(5):585-91

Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation. Przepiorka D, et al. **Ther Immunol** 1994 Apr;1(2):77-82

Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti-platelet glycoprotein IIb/IIIa antibody in a baboon model. Kotzé HF, et al. **Thromb Haemost** 1995 Aug;74(2):751-7

Prophylaxis and treatment with a monoclonal antibody of tetrodotoxin poisoning in mice. Rivera VR, et al. **Toxicon** 1995 Sep;33(9):1231-7

The introduction of human monoclonal anti-D for therapeutic use. Fletcher A, et al. **Transfus Med Rev** 1995 Oct;9(4):314-26 (87 ref.)

Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D. Godeau B, et al. **Transfusion** 1996 Apr;36(4):328-30

Manipulation of skin graft rejection in alloimmune mice by anti-VCAM-1:VLA-4 but not anti-ICAM-1:LFA-1 monoclonal antibodies. Gorcyznski RM, et al. **Transpl Immunol** 1995 Mar;3(1):55-61

Tissue-specific effects of anti-CD4 therapy in induction of allograft unresponsiveness in high and low responder rats. Yin D, et al. **Transpl Immunol** 1995 Sep;3(3):258-64

Leukocyte CD18 receptors may be a better target than ICAM-1 ligands for reducing histologic evidence of cellular and vascular rejection in the rabbit. Sadahiro M, et al. **Transpl Int** 1995;8(6):452-8

Specific acceptance of cardiac allografts after treatment with antibodies to CD80 and CD86 in mice. Bashuda H, et al. **Transplant Proc** 1996 Apr;28(2):1039-41

Microchimerism and graft acceptance: cardiac allograft acceptance following antiadhesion molecules antibody therapy. Hara MH, et al. **Transplant Proc** 1996 Jun; 28(3):1370-1

Difference in immunosuppressive effects of antibodies to ICAM-1 and LFA-1 between hepatic and cardiac allografts. Harihara Y, et al. **Transplant Proc** 1996 Jun; 28(3):1368-9

Effect of monoclonal antibody to VLA-4 on corneal allograft survival in mice. Hori J, et al. **Transplant Proc** 1996 Jun; 28(3):1990-1

Anti-adhesion (anti-ICAM-1 and anti-LFA-1) therapy in a rat pancreas transplantation model. Kawabe A, et al. **Transplant Proc** 1996 Jun;28(3):1808-11

Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Kovarik JM, et al. **Transplant Proc** 1996 Apr;28(2):913-4

Tolerance to islet xenografts induced by dual manipulation of antigen presentation and co-stimulation. Markees TG, et al. **Transplant Proc** 1996 Apr;28(2):814-5

Combined CTLA4Ig and anti-CD4/DC8 monoclonal antibody treatment prolongs survival of rat-to-mouse heterotopic cardiac xenografts. Rehman A, et al. **Transplant Proc** 1996 Apr;28(2):660-1

In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients. Stock PG, et al. **Transplant Proc** 1996 Apr; 28(2):915-6

Microchimerism and graft acceptance: IV. Cardiac allograft acceptance following anti-adhesion molecule antibody therapy. Suzuki H, et al. **Transplant Proc** 1996 Aug; 28(4):2058-60

Synergistic effects of mycophenolate mofetil (MMF, RS-61443) and anti-LFA-1/ICAM-1 monoclonal antibodies on the prolongation of heart allograft survival in rats. Takazawa K, et al. **Transplant Proc** 1996 Jun; 28(3):1980-1

Expression of ICAM-1 is involved in the mechanism of liver injury during liver transplantation: therapeutic usefulness of the F(ab')2 fragment of an anti-ICAM-1 monoclonal antibody. Takei Y, et al. **Transplant Proc** 1996 Apr; 28(2):1103-5

Prolongation of rat to mouse skin and heart xenograft survival by combined CTLA4Ig and anti-CD4/CD8 antibody. Tu Y, et al. **Transplant Proc** 1996 Aug; 28(4):2061-2

Factors affecting therapeutic effect of anti-CD3 and CD4 monoclonal antibody in acute renal allograft rejection. Wang XH, et al. **Transplant Proc** 1996 Jun;28(3):1306-8

Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Amlot PL, et al. **Transplantation** 1995 Oct 15;60(7):748-56

Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. Bashuda H, et al. **Transplantation** 1996 Jul 15;62(1):117-22

The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. Binder J, et al. **Transplantation** 1996 Mar 15;61(5):804-11

Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Cahn JY, et al. **Transplantation** 1995 Nov 15;60(9):939-42

alpha/beta-T cell receptor-directed therapy in rat allograft recipients. Long-term survival of cardiac allografts after pretreatment with R73 mAb is associated with upregulation of Th2-type cytokines. Heidecke CD, et al. **Transplantation** 1996 Mar 27;61(6):948-56

Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11). Henrickson M, et al. **Transplantation** 1995 Oct 27;60(8):828-35

Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Henslee-Downey PJ, et al. **Transplantation** 1996 Mar 15;61(5):738-45

Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Lenschow DJ, et al. **Transplantation** 1995 Nov 27;60(10):1171-8

The repetitive histologic pattern of vascular cardiac allograft rejection.Increased incidence associated with longer exposure to prophylactic murine monoclonal anti-CD3 antibody (OKT3). Ma H, et al. **Transplantation** 1996 Jul 27;62(2):205-10

Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients. Nashan B, et al. **Transplantation** 1996 Feb 27;61(4):546-54

Prophylactic immunosuppression with anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 versus OKT3 in liver allografting. A two-year follow-up study. Reding R, et al. **Transplantation** 1996 May 15;61(9):1406-9

Coronary atherosclerosis in transplanted mouse hearts. IV Effects of treatment with monoclonal antibodies to intercellular adhesion molecule-1 and leukocyte function-associated antigen-1. Russell PS, et al. **Transplantation** 1995 Oct 15;60(7):724-9

A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. van Gelder T, et al. **Transplantation** 1996 Jul 15;62(1):51-5

Radiolabeled monoclonal antibody G250 in renal-cell carcinoma. Oosterwijk E, et al. **World J Urol** 1995; 13(3):186-90

Prevention of spontaneous autoimmune thyroiditis in the obese strain (OS) chickens by treatment with a monoclonal anti-CD4 antibody. Cihak J, et al. **Zentralbl Veterinarmed A** 1996 Jun;43(4):211-6

[Monoclonal antibodies for diagnosis and therapy in oncological patients] Boven E, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2552-8 (31 ref.) **(Dut)**

[Monoclonal antibodies for diagnosis and therapy in oncological patients (letter)] van Duijnhoven JL. **Ned Tijdschr Geneeskd** 1996 Feb 24;140(8):453 **(Dut)**

[Immunotherapy of colorectal cancers] Bécouarn Y, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):20-32 (106 ref.) **(Fre)**

[Immunological factors blocking transmission (letter)] Mulder B. **Med Trop (Mars)** 1995;55(4 Suppl):116-8 **(Fre)**

[Can monoclonal antibodies to a carcinoma-specific cell surface molecule prevent liver metastasis of human colorectal carcinoma and effectively treat already existing micrometastases?] Burkart C, et al. **Z Gastroenterol** 1996 Jan;34(1):41-2 **(Ger)**

[Use of monoclonal antibodies to lipopolysaccharide with the purpose of correction of cytokine activity in endotoxic shock in an acute experiment] Dubrovina ES, et al. **Gematol Transfuziol** 1995 Sep-Oct;40(5):36-8 **(Rus)**

TOXICITY

Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro. Lau A, et al. **Bioorg Med Chem** 1995 Oct;3(10):1305-12

192IgG-saporin-induced immunotoxic lesions of cholinergic basal forebrain system differentially affect glutamatergic and GABAergic markers in cortical rat brain regions. Rossner S, et al. **Brain Res** 1995 Oct 23;696(1-2):165-76

192IGG-saporin-induced selective lesion of cholinergic basal forebrain system: neurochemical effects on cholinergic neurotransmission in rat cerebral cortex and hippocampus. Rossner S, et al. **Brain Res Bull** 1995;38(4):371-81

Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies. Bhat NM, et al. **Clin Exp Immunol** 1996 Jul;105(1):183-90

Preclinical evaluation in nonhuman primates of an anti-idiotypic antibody that mimicks the carcinoembryonic antigen. Chakraborty M, et al. **J Immunother Emphasis Tumor Immunol** 1995 Aug; 18(2):95-103

ANTIBODIES, NEOPLASM

ADMINISTRATION & DOSAGE

Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy. Ullén A, et al. **Acta Oncol** 1996;35(3):281-5 (37 ref.)

Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Blakey DC, et al. **Br J Cancer** 1995 Nov;72(5):1083-8

CAMPATH-1H in rheumatoid arthritis—an intravenous dose-ranging study. Isaacs JD, et al. **Br J Rheumatol** 1996 Mar;35(3):231-40

Intratumoral injection of an adriamycin immunoconjugate against human pancreatic cancer xenografts. Kondo Y, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1072-9

ADVERSE EFFECTS

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Moreau T, et al. **Brain** 1996 Feb;119 (Pt 1):225-37

ANALYSIS

Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling. Olafsen T, et al. **Acta Oncol** 1996;35(3):297-301

Re: Problems related to immunohistochemical detection of monotypic immunoglobulin light chain expression on B cells [letter; comment] Brandtzaeg P. **J Pathol** 1995 Dec; 177(4):439–40. Comment on: J Pathol 1993 Jul;170(3):257–64.

High-performance liquid chromatographic mapping of the oligosaccharides released from the humanised immunoglobulin, CAMPATH 1H. Lines AC. **J Pharm Biomed Anal** 1996 Mar;14(5):601–8

BIOSYNTHESIS

A role for antigen in the evolution of gastrointestinal MALT-type B cell lymphoma. Hussell T, et al. **Adv Exp Med Biol** 1995;371A:145–7

Nucleic acid vaccination against virally induced tumors. Bright RK, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:241–51

Production, purification and characterization of an anti-(carcinoembryonic antigen) recombinant single-chain Fv antibody fragment. Pérez L, et al. **Biotechnol Appl Biochem** 1996 Aug;24 (Pt 1):79–82

Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Litton MJ, et al. **Eur J Immunol** 1996 Jan;26(1):1–9

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Kashmiri SV, et al. **Hybridoma** 1995 Oct;14(5):461–73

A new and efficient method to generate human IgG monoclonal antibodies reactive to cancer cells using SCID-hu mice. Satoh N, et al. **Immunol Lett** 1995 Jul–Aug; 47(1–2):113–9

Autologous human B-cell immune response to pulmonary adenocarcinomatous polymorphic epithelial mucin. Xiang J, et al. **J Clin Immunol** 1995 Mar;15(2):74–9

Engraftment of human tumor-infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. Williams SS, et al. **J Immunol** 1996 Mar 1;156(5):1908–15

Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein. Bei R, et al. **J Immunol Methods** 1995 Oct 26;186(2):245–55

Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Leung SO, et al. **Mol Immunol** 1995 Dec; 32(17–18):1413–27

BLOOD

Malignant melanoma of the head and neck. Clinical and immunological considerations. Merimsky O, et al. **Am J Clin Oncol** 1996 Aug;19(4):363–7

The significance of p53 autoantibodies in the serum of patients with breast cancer. Willsher PC, et al. **Anticancer Res** 1996 Mar-Apr;16(2):927–30

Serological response to Helicobacter pylori in gastric and non-gastric cancer. Menegatti M, et al. **Clin Sci (Colch)** 1996 Aug;91(2):219–23

Immunologic status of the cancer patient and the effects of blood transfusion on antitumor responses. Browell DA, et al. **Curr Opin Gen Surg** 1993;:325–33 (110 ref.)

Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. Ryder SD, et al. **J Clin Pathol** 1996 Apr; 49(4):295–9

Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. Bourhis J, et al. **J Natl Cancer Inst** 1996 Sep 4;88(17):1228–33

Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen. Baharav E, et al. **Melanoma Res** 1995 Oct;5(5):337–43

Serum p53 antibodies as early markers of lung cancer. Lubin R, et al. **Nat Med** 1995 Jul;1(7):701–2

Human neoplasms elicit multiple specific immune responses in the autologous host. Sahin U, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11810–3

Detection of antibodies to human melanoma cell in vitiligo by western blot analysis. Hann SK, et al. **Yonsei Med J** 1995 Nov;36(5):457–61

[Immune response to p53 protein in patients with squamous epithelial carcinoma of the upper aerodigestive tract is independent of p53 point mutation] Gottschlich S, et al. **Laryngorhinootologie** 1996 May;75(5):301–5 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Site-specific modifications of light chain glycosylated antilymphoma (LL2) and anti-carcinoembryonic antigen (hImmu-14-N) antibody divalent flagments. Govindan SV, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5721s–5725s

Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy. Li M, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5726s–5728s

Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Lifely MR, et al. **Glycobiology** 1995 Dec;5(8):813–22

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Kashmiri SV, et al. **Hybridoma** 1995 Oct;14(5):461–73

Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. Iakoubov L, et al. **Immunol Lett** 1995 Jul–Aug;47(1–2):147–9

X-ray structure of the uncomplexed anti-tumor antibody BR96 and comparison with its antigen-bound form. Sheriff S, et al. **J Mol Biol** 1996 Jun 28;259(5):938–46

Ber-EP4 immunoreactivity in normal skin and cutaneous neoplasms. Jimenez FJ, et al. **Mod Pathol** 1995 Oct; 8(8):854–8

DIAGNOSTIC USE

Use of a polyclonal antibody for the determination of the prognostic value of c-erbB-2 protein over-expression in human breast cancer. Terrier P, et al. **Acta Oncol** 1996; 35(1):23–30

Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies. Ballou B, et al. **Cancer Immunol Immunother** 1995 Oct;41(4):257–63

Anti-melanoma monoclonal antibody 225.28S immunoscintigraphy in metastatic melanoma. Böni R, et al. **Dermatology** 1995;191(2):119–23

Therapy and imaging of pancreatic carcinoma xenografts with radioiodine-labeled chimeric monoclonal antibody A10 and its Fab fragment. Kamigaki T, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1216–23

Clinical evaluation of metastases of malignant melanoma imaging with 99Tcm-glutathione and 99Tcm-anti-melanoma antibody: a comparative study. Duman Y, et al. **Nucl Med Commun** 1995 Nov; 16(11):927–35

Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients. Tibben JG, et al. **Nucl Med Commun** 1995 Oct;16(10):853–9

A new monoclonal antibody (IE8) reactive with dendritically shaped cells in the human tonsil. Nagasaki M, et al. **Pathol Int** 1995 Apr;45(4):266–74

GENETICS

In vivo isotype class switching in CD5+ chronic lymphocytic leukemia B cells. Dono M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:478–81

Hodgkin's disease: clonal Ig gene rearrangements in Hodgkin and Reed-Sternberg cells picked from histological sections. Küppers R, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:523–4

VH gene use by CD5+ AIDS-associated B-cell lymphoproliferations. Ng VL, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:507–8

Cellular origin, antigen reactivity, and VH segment structure of IgM mAbs from AIDS lymphomas. Riboldi P, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:509–18

Clonal analysis of IgM+ CD5+ CLL B cells. Schettino EW, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:485–91

Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma. Hsu FJ, et al. **Blood** 1995 Oct 15; 86(8):3072–82

Expression of a tumor-reactive antibody-interleukin 2 fusion protein after in vivo particle-mediated gene delivery. Nicolet CM, et al. **Cancer Gene Ther** 1995 Sep;2(3):161–70

Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Slavin-Chiorini DC, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5957s–5967s

Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides. McCartney JE, et al. **Protein Eng** 1995 Mar;8(3):301–14

The production and preclinical characterization of a chimeric anti-breast-cancer antibody, cBC2. Sutton VR, et al. **Ther Immunol** 1994 Apr;1(2):83–93

IMMUNOLOGY

Multiple myeloma with monoclonal surface immunoglobulin expression: a case report. Dunphy CH, et al. **Acta Cytol** 1996 Mar-Apr;40(2):358–62

A basement membrane molecule preferentially associated with mucosal post-capillary venules. Hussell T, et al. **Adv Exp Med Biol** 1995;371A:111–5

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212–26 (23 ref.)

Monoclonal anti-idiotypic antibodies as probes for common idiotopes shared by anti-"benzo(a)pyrene-like" IgA of cancer patients and rabbit anti-conjugated benzo(a)pyrene antibodies. Chagnaud JL, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2161–8

Human monoclonal antibody developed against a metastasizing paraganglioma: preparation and preclinical studies. Freiberg B, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2489–93

Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Yi Q, et al. **Blood** 1995 Oct 15;86(8):3043–9

Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: identification of its antigen as a neutral glycolipid. Kingsley EA, et al. **Cancer Immunol Immunother** 1995 Dec;41(6):348–54

Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Slavin-Chiorini DC, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5957s–5967s

A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hu P, et al. **Hum Antibodies Hybridomas** 1995;6(2):57–67

Recognition of CD52 allelic gene products by CAMPATH-1H antibodies. Hale C, et al. **Immunology** 1996 Jun;88(2):183–90

Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1. De Nardo GL, et al. **Int J Biol Markers** 1995 Apr-Jun;10(2):67–74

IgG anti-50 kd lymphocyte membrane peptide antibody in patients with Sézary syndrome. D'Ambra-Cabry K, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):777–80

Novel colorectal adenocarcinoma-associated 40- and 47-kDa protein antigens recognized by anti-60-kDa heat shock protein antibody. Otaka M, et al. **J Clin Gastroenterol** 1995 Oct;21(3):224–9

TCRBV23 specificity of two monoclonal antibodies revealed by a panel of human V beta chains expressed in mouse cells. Romagné F, et al. **J Immunol Methods** 1995 Oct 26; 186(2):313–22

The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. Buckanovich RJ, et al. **J Neurosci** 1996 Feb 1;16(3):1114–22

Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha. Yoshida J, et al. **J Surg Oncol** 1996 Jul;62(3):177–82

Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody. Sivolapenko GB, et al. **Lancet** 1995 Dec 23-30; 346(8991-8992):1662–6

Generation and selection of monoclonal antibodies, single-chain Fv and antibody fusion phage specific for human melanoma-associated antigens. Kupsch JM, et al. **Melanoma Res** 1995 Dec;5(6):403–11

A melanoma-specific VH antibody cloned from a fusion phage library of a vaccinated melanoma patient. Cai X, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6280–5

Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Hayden MS, et al. **Ther Immunol** 1994 Jan;1(1):3–15

METABOLISM

Construction, expression and characterisation of a single chain anti-tumour antibody (scFv)-IL-2 fusion protein. Boleti E, et al. **Ann Oncol** 1995 Nov;6(9):945–7

Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Delgado C, et al. **Br J Cancer** 1996 Jan; 73(2):175–82

Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Marshall D, et al. **Br J Cancer** 1996 Mar;73(5):565–72

Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Adluri S, et al. **Cancer Immunol Immunother** 1995 Sep;41(3):185–92

Construction of phosphorylatable monoclonal antibody to a tumor-associated antigen. Lin L, et al. **Cancer Res** 1996 Sep 15;56(18):4250–4

Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Rogers BE, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5714s–5720s

Epitope in cytochrome c from Candida krusei cross-reacts lung cancer-specific human monoclonal antibody HB4C5 [letter] Kawamoto S, et al. **In Vitro Cell Dev Biol Anim** 1995 Jun;31(6):424–6

Spontaneous antibody-secreting cells in the stomach of gastric cancer patients. Kunori T, et al. **J Gastroenterol** 1996 Apr;31(2):161–6

The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Boyd PN, et al. **Mol Immunol** 1995 Dec;32(17–18):1311–8

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Begent RH, et al. **Nat Med** 1996 Sep;2(9):979–84

PHARMACOLOGY

Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokinine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Ottonello L, et al. **Blood** 1996 Jun 15;87(12):5171–8

Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment. Brett SJ, et al. **Int Immunol** 1996 Mar;8(3):325–34

PHYSIOLOGY

The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Boyd PN, et al. **Mol Immunol** 1995 Dec;32(17–18):1311–8

ANTIBODIES, NEOPLASM

THERAPEUTIC USE

Clinical trials with CAMPATH-1 and other monoclonal antibodies. Hale G, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1057–63 (49 ref.)

Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin. Desrues B, et al. **Br J Cancer** 1995 Nov; 72(5):1076–82

Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro. Perron MJ, et al. **Br J Cancer** 1996 Feb;73(3):281–7

Preclinical analysis of intraperitoneal administration of 111In-labeled human tumor reactive monoclonal IgM AC6C3-2B12. Quadri SM, et al. **Cancer Res** 1995 Dec 1; 55(23 Suppl):5736s–5742s

Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model. Roberson PL, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5811s–5816s

In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Shih LB, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5857s–5863s

Recombinant antibody fusion proteins for cancer immunotherapy. Reisfeld RA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):27–53 (67 ref.)

Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Wels W, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):113–28 (47 ref.)

Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice. Qi Y, et al. **Gastroenterology** 1995 Dec;109(6):1950–7

Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects. Kroesen BJ, et al. **J Hematother** 1995 Oct;4(5):409–14

Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. Valone FH, et al. **J Hematother** 1995 Oct; 4(5):471–5

Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. Meredith RF, et al. **J Nucl Med** 1996 Sep;37(9):1491–6

Therapy and imaging of pancreatic carcinoma xenografts with radioiodine-labeled chimeric monoclonal antibody A10 and its Fab fragment. Kamigaki T, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1216–23

A target for tumour-directed therapy [comment] Hynes NE, et al. **Nat Med** 1995 Jul;1(7):631. Comment on: Nat Med 1995 Jul;1(7):644–8.

Prevention of breast tumour development in vivo by downregulation of the p185neu receptor [see comments] Katsumata M, et al. **Nat Med** 1995 Jul;1(7):644–8. Comment in: Nat Med 1995 Jul;1(7):631–2.

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Liu C, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8618–23

Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Saga T, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8999–9003

ANTIBODIES, PROTOZOAN

Recognition of acidic proteins of Giardia muris by anti-trophozoite antibodies. Heyworth MF, et al. **Adv Exp Med Biol** 1995;371B:939–43

Production and characterization of murine monoclonal antibodies to Blastocystis hominis. Tan SW, et al. **Int J Parasitol** 1996 Apr;26(4):375–81

Serological reactivity against cyst and tachyzoite antigens of Toxoplasma gondii determined by FAST-ELISA. Zhang YW, et al. **J Clin Pathol** 1995 Oct;48(10):908–11

ANALYSIS

Malaria and pregnancy in Cameroonian primigravidae: humoral and cellular immune responses to Plasmodium falciparum blood-stage antigens. Fievet N, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):612–7

Comparison of methods for estimation of Toxoplasma gondii-specific antibody production in the aqueous humor of cats. Hill SL, et al. **Am J Vet Res** 1995 Sep;56(9):1181–7

Prevalence of antibodies to the repeat epitope of the circumsporozoite protein of Plasmodium vivax in San Luis Potosi, Mexico. Mota J, et al. **Arch Med Res** 1996 Summer; 27(2):233–6

The Vitek immunodiagnostic assay for detection of immunoglobulin M toxoplasma antibodies. Candolfi E, et al. **Clin Diagn Lab Immunol** 1994 Jul;1(4):401–5

Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease. Martins-Filho OA, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):569–73

Evaluation of an enzyme-linked immunoassay for the detection in serum of antibodies to Entamoeba histolytica. Rosenblatt JE, et al. **Diagn Microbiol Infect Dis** 1995 Jul; 22(3):275–8

Prevalence of antibodies against Entamoeba histolytica in Mexico measured by ELISA. González CR, et al. **Epidemiol Infect** 1995 Dec;115(3):535–43

Automated reading and processing of quantitative IgG, IgM, IgA, and IgE isotypic agglutination results in microplates. Development and application in parasitology-mycology. Aubert D, et al. **J Immunol Methods** 1995 Oct 26; 186(2):323–8

Serum antibody detected by fluorescent antibody test in patients with symptomatic Blastocystis hominis infection. Garavelli PL, et al. **Recenti Prog Med** 1995 Oct; 86(10):398–400

Detection by enzyme immunosorbent assay of Toxoplasma gondii IgG antibodies in dried blood spots on PKU-filter paper from newborns. Lebech M, et al. **Scand J Infect Dis** 1995;27(3):259–63

Acquired antibody levels to Plasmodium falciparum merozoite surface antigen 1 in residents of a highly endemic area of Papua New Guinea. al-Yaman F, et al. **Trans R Soc Trop Med Hyg** 1995 Sep-Oct;89(5):555–9

Effect of the microsporidian Enterocytozoon salmonis on the immune response of chinook salmon. Wongtavatchai J, et al. **Vet Immunol Immunopathol** 1995 Oct;48(3–4):367–74

Prevalence of agglutinating antibodies to Toxoplasma gondii in small ruminants of the Madrid region, Spain, and identification of factors influencing seropositivity by multivariate analysis. Mainar RC, et al. **Vet Res Commun** 1996;20(2):153–9

[Exploration on experimental conditions of dot-ELISA for Trichomonas vaginalis using intact parasite antigen-monoclonal antibody detecting system] Yu C, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):138–41 (Eng. Abstr.) **(Chi)**

[Diagnosis of acquired toxoplasmosis using simultaneous determination of specific immunoglobulins M, A and E] Valkoun A, et al. **Epidemiol Mikrobiol Imunol** 1995 Sep; 44(3):107–10 (Eng. Abstr.) **(Cze)**

[Occurrence of toxoplasmosis in pregnant women in Denmark. A study of 5.402 pregnant women] Lebech M, et al. **Ugeskr Laeger** 1995 Sep 18;157(38):5242–5 (Eng. Abstr.) **(Dan)**

[Indirect biological examinations in parasitic digestive pathology] Dutoit E, et al. **Gastroenterol Clin Biol** 1995; 19(5 Pt 2):B104–9 **(Fre)**

[Comparative study on serological diagnosis of entamoebiasis histolytica] Ono K, et al. **Rinsho Byori** 1996 Apr; 44(4):362–6 (Eng. Abstr.) **(Jpn)**

[Detection of Toxoplasma antigens and antibodies in mice infected with different strains of Toxoplasma gondii] Lee YH, et al. **Korean J Parasitol** 1995 Sep;33(3):201–10 (Eng. Abstr.) **(Kor)**

[Prevalence of Toxoplasma gondii antibodies in a population of pregnant women in Cuba] González-Morales T, et al. **Gac Med Mex** 1995 Sep-Dec;131(5–6):499–503 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Specific anti-E. histolytica IgA monoclonal antibodies. Ximenez C, et al. **Adv Exp Med Biol** 1995;371B:963–6

Evidence of HLA class II association with antibody response against the malaria vaccine SPF66 in a naturally exposed population. Beck HP, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):284–8

Studies on cryopreservation of Toxoplasma gondii and its antigenicity in mice. Lin DB, et al. **Am J Trop Med Hyg** 1995 Oct;53(4):392–6

Production and characterization of a monoclonal antibody specific for Trypanosoma simiae. Bosompem KM, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):611–20

Evaluation of antibody responses in Indian kala-azar by immunoblot. Tiwari V, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):959–64

Anti-malaria antibody-producing B cell frequencies in adults after a Plasmodium falciparum outbreak in Madagascar. Migot F, et al. **Clin Exp Immunol** 1995 Dec;102(3):529–34

The presence of the HLA class II allele DPB1*0501 in ethnic Thais correlates with an enhanced vaccine-induced antibody response to a malaria sporozoite antigen. Stephens HA, et al. **Eur J Immunol** 1995 Nov;25(11):3142–7

Antibody response in dogs experimentally infected with Leishmania infantum: infection course antigen markers. Carrera L, et al. **Exp Parasitol** 1996 Mar;82(2):139–46

Oral immunization with a recombinant cysteine-rich section of the Entamoeba histolytica galactose-inhibitable lectin elicits an intestinal secretory immunoglobulin A response that has in vitro adherence inhibition activity. Beving DE, et al. **Infect Immun** 1996 Apr;64(4):1473–6

Immunoglobulin E elevation in Plasmodium chabaudi malaria. Helmby H, et al. **Infect Immun** 1996 Apr; 64(4):1432–3

A recombinant protein based on the Trypanosoma cruzi metacyclic trypomastigote 82-kilodalton antigen that induces and effective immune response to acute infection. Santori F R, et al. **Infect Immun** 1996 Apr;64(4):1093–9

Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects. Barral A, et al. **Int J Dermatol** 1995 Jul;34(7):474–9

Induction of Plasmodium falciparum sporozoite-neutralizing antibodies upon vaccination with recombinant Pfs16 vaccinia virus and/or recombinant Pfs16 protein produced in yeast. Moelans II, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):179–92

Cellular and humoral immune responses to recombinant antigens in sheep infected with Toxoplasma gondii. Coughlan SN, et al. **Parasite Immunol** 1995 Sep;17(9):465–8

Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Deplazes P, et al. **Parasite Immunol** 1995 Sep;17(9):451–8

Interferon-gamma and the induction of protective IgG2a antibodies in non-lethal Plasmodium berghei infections of mice. Waki S, et al. **Parasite Immunol** 1995 Oct; 17(10):503–8

Ig-isotype patterns of primary and secondary B cell responses to Plasmodium chabaudi chabaudi correlate with IFN-gamma and IL-4 cytokine production with CD45RB expression by CD4+ spleen cells. D'Império Lima MR, et al. **Scand J Immunol** 1996 Mar;43(3):263–70

Immunoparasitological studies of Trypanosoma cruzi low virulence clones from Panama: humoral immune responses and antigenic cross-reactions with Trypanosoma rangeli in experimentally infected mice. Saldaña A, et al. **Scand J Immunol** 1995 Dec;42(6):644–50

Fine specificity of immune responses to epitopic sequences in synthetic peptides containing B and T epitopes from the conserved Plasmodium falciparum blood-stage antigens. Chatterjee S, et al. **Vaccine** 1995;13(15):1474–81

Serum and colostrum antibody responses induced by jet-injection of sheep with DNA encoding a Cryptosporidium parvum antigen. Jenkins M, et al. **Vaccine** 1995 Dec;13(17):1658–64

Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis. Martínez-Moreno A, et al. **Vet Immunol Immunopathol** 1995 Oct;48(3–4):209–20

BLOOD

Serum antibodies to Trypanosoma cruzi antigens in Atacameños patients from highland of northern Chile. González J, et al. **Acta Trop** 1996 Feb;60(4):225–36

Specific antiamebic serum antibodies in Mexican puerperae and their newborns. Aguirre-Cruz L, et al. **Adv Exp Med Biol** 1995;371B:949–52

Testing and management of Toxoplasma serology in HIV-seropositive patients [letter] Aarons E, et al. **AIDS** 1996 Apr;10(4):443–4

Trypanosoma cruzi and Leishmania spp. human mixed infection. Chiaramonte MG, et al. **Am J Trop Med Hyg** 1996 Mar;54(3):271–3

Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States. Gordon DM, et al. **Am J Trop Med Hyg** 1996 Jul;55(1):63–8

Acute-phase proteins and serologic profiles of chagasic children from an endemic area in Bolivia. Medrano-Mercado N, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):154–61

Acquired transmission-blocking immunity to Plasmodium vivax in a population of southern coastal Mexico. Ramsey JM, et al. **Am J Trop Med Hyg** 1996 May;54(5):458–63

Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. al-Yaman F, et al. **Am J Trop Med Hyg** 1996 May;54(5):443–8

Asymptomatic malaria parasitaemia and seroreactivities to Plasmodium falciparum antigens in blood donors from Ibadan, south-western Nigeria. Achidi EA, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):601–10

Detection of anti-Plasmodium falciparum antibodies directed against a repetitive peptide of the gametocyte antigen Pfs2400 in malaria patients in Brazil. Marrelli MT, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):593–99

Trypanosoma equiperdum: detection of trypanosomal antibodies and antigen by enzyme-linked immunosorbent assay. Bishop S, et al. **Br Vet J** 1995 Nov-Dec; 151(6):715–20

Serological evidence of toxoplasma infection in cougars on Vancouver Island, British Columbia. Stephen C, et al. **Can Vet J** 1996 Apr;37(4):241

Serological response of patients suffering from primary and recrudescent typhus: comparison of complement fixation reaction, Weil-Felix test, microimmunofluorescence, and immunoblotting. Eremeeva ME, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):318–24

A prognostic role for anti-phosphatidyl choline antibodies in human cerebral malaria. Das BK, et al. **Clin Exp Immunol** 1996 Mar;103(3):442–5

Value of specific immunoglobulin A detection by two immunocapture assays in the diagnosis of toxoplasmosis. Foudrinier F, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):585–90

Multicenter evaluation of a new commercial assay for detection of immunoglobulin M antibodies to Toxoplasma gondii. Multicenter Study Group. Luyasu V, et al. **Eur J Clin Microbiol Infect Dis** 1995 Sep;14(9):787–93

Performance of European laboratories testing serum samples for Toxoplasma gondii. Petithory JC, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jan;15(1):45–9

Prevalence of anti-Toxoplasma gondii antibodies in the population of the area of Parma (Italy). Valcavi PP, et al. **Eur J Epidemiol** 1995 Jun;11(3):333–7

Serum antibodies to Trichomonas vaginalis in invasive cervical cancer patients. Yap EH, et al. **Genitourin Med** 1995 Dec;71(6):402–4

Relationship between maternally derived anti-Plasmodium falciparum antibodies and risk of infection and disease in

infants living in an area of Liberia, west Africa, in which malaria is highly endemic. Høgh B, et al. **Infect Immun** 1995 Oct;63(10):4034–8

Serological analysis of antigenic heterogeneity of Giardia lamblia variant surface proteins. Müller N, et al. **Infect Immun** 1996 Apr;64(4):1385–90

Neospora species infection in a herd of dairy cattle. Björkman C, et al. **J Am Vet Med Assoc** 1996 May 1;208(9):1441–4

Detection of anti-toxoplasma immunoglobulin A antibodies by Platelia-Toxo IgA directed against P30 and by IMx Toxo IgA for diagnosis of acquired and congenital toxoplasmosis. Decoster A, et al. **J Clin Microbiol** 1995 Aug;33(8):2206–8

Coexistence of antibodies to tick-borne pathogens of babesiosis, ehrlichiosis, and Lyme borreliosis in human sera. Magnarelli LA, et al. **J Clin Microbiol** 1995 Nov; 33(11):3054–7

The value of Toxoplasma specific IgA in diagnosis [letter; comment] Ashburn D, et al. **J Clin Pathol** 1995 Jul; 48(7):689. Comment on: J Clin Pathol 1994 Dec;47(12):1101–4.

Enzyme immunoassays for IgG and IgM antibodies to Toxoplasma gondii based on enhanced chemiluminescence. Crouch CF. **J Clin Pathol** 1995 Jul;48(7):652–7

Toxoplasma IgG. & IgM. antibodies. A case control study. Attia RA, et al. **J Egypt Soc Parasitol** 1995 Dec; 25(3):877–82

Seropositivity of toxoplasmosis among reproductive-age women in Malatya, Turkey. Durmaz R, et al. **J Egypt Soc Parasitol** 1995 Dec;25(3):693–8

Assessment of latex indirect agglutination test (Toxolatex Fumouze) for the detection of Toxoplasma specific antibodies in human sera in Turkey. Gürüz AY, et al. **J Egypt Soc Parasitol** 1996 Aug;26(2):367–74

Incidence of Toxoplasma and Toxocara antibodies among out-patients in the Ophthalmic Research Institute, Egypt. Safar EH, et al. **J Egypt Soc Parasitol** 1995 Dec; 25(3):839–52

Encephalitozoon-like organisms in patients with alveolar hydatid disease: cell culture, ultrastructure, histoimmunochemical localization and seroprevalence. Furuya K, et al. **J Eukaryot Microbiol** 1995 Sep–Oct; 42(5):518–25

rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. Badaró R, et al. **J Infect Dis** 1996 Mar;173(3):758–61

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1 Egan AF, et al. **J Infect Dis** 1996 Mar;173(3):765–9

Long-term antibody responses of cats fed toxoplasma gondii tissue cysts. Dubey JP, et al. **J Parasitol** 1995 Dec; 81(6):887–93

Sources and reservoirs of Toxoplasma gondii infection on 47 swine farms in Illinois. Dubey JP, et al. **J Parasitol** 1995 Oct;81(5):723–9

Avian malaria seroprevalence in Jackass penguins (Spheniscus demersus) in South Africa. Graczyk TK, et al. **J Parasitol** 1995 Oct;81(5):703–7

The occurrence of antibodies to Naegleria species in wild mammals. Kollars TM Jr, et al. **J Parasitol** 1996 Feb; 82(1):73–7

Prevalence of Neospora caninum and Toxoplasma gondii antibodies in coyotes (Canis latrans) and experimental infections of coyotes with Neospora caninum. Lindsay DS, et al. **J Parasitol** 1996 Aug;82(4):657–9

Prevalence of Toxoplasma gondii antibodies in hunter-killed white-tailed deer (Odocoileus virginianus) in four regions of Minnesota. Vanek JA, et al. **J Parasitol** 1996 Feb; 82(1):41–4

An enzyme-linked immunosorbent assay (ELISA) for serological diagnosis of Neospora sp. infection in cattle. Paré J, et al. **J Vet Diagn Invest** 1995 Jul;7(3):352–9

Role of sodium azide in reducing nonspecific color development in enzyme immunoassays. Saini PK, et al. **J Vet Diagn Invest** 1995 Oct;7(4):509–14

Serologic survey of Toxoplasma gondii in grizzly bears (Ursus arctos) and black bears (Ursus americanus), from Alaska, 1988 to 1991. Chomel BB, et al. **J Wildl Dis** 1995 Oct;31(4):472–9

Seroprevalence of two Babesia spp. isolates in selected bighorn sheep (Ovis canadensis) and mule deer (Odocoileus hemionus) populations in California. Kjemtrup AM, et al. **J Wildl Dis** 1995 Oct;31(4):467–71

Toxoplasmosis in wild turkeys: a case report and serologic survey. Quist CF, et al. **J Wildl Dis** 1995 Apr;31(2):255–8

Prevalence of antibodies to Toxoplasma gondii in wild mammals of Missouri and east central Kansas: biologic and ecologic considerations of transmission. Smith DD, et al. **J Wildl Dis** 1995 Jan;31(1):15–21

A serological antibody survey for Toxoplasma gondii in twin cities of Rawalpindi and Islamabad. Pal RA, et al. **JPMA J Pak Med Assoc** 1995 Jul;45(7):188–9

Electrocardiographic alteration among first degree relatives with serologic evidence of Trypanosoma cruzi infection. A sibship study. Morini JC, et al. **Mem Inst Oswaldo Cruz** 1994 Jul–Sep;89(3):371–5

Seroprevalence of human toxoplasmosis. Gutiérrez J, et al. **Microbios** 1996;85(343):73–5

The detection of antibodies cross-reacting with Cowdria ruminantium in the sera of domestic ruminants in regions of South Africa where Amblyomma hebraeum does not occur. Du Plessis JL, et al. **Onderstepoort J Vet Res** 1994 Dec;61(4):277–81

Antibodies to Pf155/RESA and circumsporozoite protein of Plasmodium falciparum in paired maternal-cord sera from Nigeria. Achidi EA, et al. **Parasite Immunol** 1995 Oct; 17(10):535–40

Circulating trans-sialidase activity and trans-sialidase-inhibiting antibodies in Trypanosoma cruzi-infected mice. Alcântara-Neves NM, et al. **Parasitol Res** 1995;81(7):560–4

An enzyme-linked immunosorbent assay with whole trophozoites of Toxoplasma gondii from serum-free tissue culture for detection of specific antibodies. Obwaller A, et al. **Parasitol Res** 1995;81(5):361–4

Improved specificity of Trypanosoma cruzi identification by polymerase chain reaction using an oligonucleotide derived from the amino-terminal sequence of a Tc24 protein. Taibi A, et al. **Parasitology** 1995 Dec;111 (Pt 5):581–90

Seroepidemiology of Toxoplasma gondii (Apicomplexa) in meat producing animals in Costa Rica. Arias ML, et al. **Rev Biol Trop** 1994 Apr–Aug;42(1–2):15–20

Diagnosis of human toxoplasmosis by a Dot enzyme-linked immunosorbent assay. Elsaid MM, et al. **Rev Inst Med Trop Sao Paulo** 1995 Mar–Apr;37(2):117–22

Incidence of anti-Toxoplasma antibodies in women with high-risk pregnancy and habitual abortions. Galván Ramírez M de la L, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):333–7

The role of dogs in the epidemiology of human visceral leishmaniasis in northern Pakistan. Rab MA, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):612–5

Visceral leishmaniasis in Somalia. Circulating antibodies as measured by DAT, immunofluorescence and ELISA. Shiddo SA, et al. **Trop Geogr Med** 1995;47(2):68–73

Evaluation of circumsporozoite antibody testing as a sero-epidemiological tool for the detection of Plasmodium falciparum infection in non-immune travelers. Jelinek T, et al. **Trop Med Parasitol** 1995 Sep;46(3):154–7

Evaluation of three serological tests for the detection of antiamebic antibodies applied to sera of patients from an area endemic for amebiasis. Lotter H, et al. **Trop Med Parasitol** 1995 Sep;46(3):180–2

Relationship of antibodies to soluble Plasmodium falciparum antigen (Pf70) and protection against malaria in a human population living under intense transmission in Kinshasa, Zaire. Tshefu K, et al. **Trop Med Parasitol** 1995 Jun; 46(2):72–6

Serum and colostrum antibody responses induced by jet-injection of sheep with DNA encoding a Cryptosporidium parvum antigen. Jenkins M, et al. **Vaccine** 1995 Dec;13(17):1658–64

Prevalence of Toxoplasma gondii antibodies in cats in the western part of Great Buenos Aires, Argentina, 1993. Fernández F, et al. **Vet Parasitol** 1995 Aug;59(1):75–9

Observations on the use of ELISA for detection of Babesia bigemina specific antibodies. el-Ghaysh A, et al. **Vet Parasitol** 1996 Mar;62(1–2):51–61

Seroprevalence of Toxoplasma gondii in cattle, sheep and goats in Iran. Hashemi-Fesharki R. **Vet Parasitol** 1996 Jan; 61(1–2):1–3

Cryptosporidium parvum oocyst antigens recognized by sera from infected asymptomatic adult cattle. Lorenzo MJ, et al. **Vet Parasitol** 1995 Nov;60(1–2):17–25

Comparison between an enzyme-linked immunosorbent assay using a detergent-soluble Leishmania infantum antigen and indirect immunofluorescence for the diagnosis of canine leishmaniosis. Mancianti F, et al. **Vet Parasitol** 1995 Aug; 59(1):13–21

Prevalence of specific anti-Cryptosporidium IgG, IgM and IgA antibodies in cat sera using an indirect immunofluorescence antibody test. Mtambo MM, et al. **Vet Parasitol** 1995 Nov;60(1–2):37–43

Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63). Olobo JO, et al. **Vet Parasitol** 1995 Dec;60(3–4):199–212

Ovine toxoplasmosis: seroconversion during pregnancy and lamb birth rate in Uruguayan sheep flocks. Savio E, et al. **Vet Parasitol** 1995 Dec;60(3–4):241–7

Prevalence of antibodies to Toxoplasma gondii in cattle and swine in The Netherlands: towards an integrated control of livestock production. van Knapen F, et al. **Vet Q** 1995 Sep;17(3):87–91

Hepatozoon canis: the prevalence of antibodies and gametocytes in dogs in Israel. Baneth G, et al. **Vet Res Commun** 1996;20(1):41–6

[Identification of specific serologic markers in visceral leishmaniasis: anti-p32 antibody response] Tebourski F, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):447–51 (Fre)

[Immune response against Plasmodium falciparum merozoite antigens and HLA restriction] Dieye A, et al. **Med Trop (Mars)** 1995;55(4 Suppl):69–70 (Fre)

[Seroepidemiology of toxoplasmosis in Niamey, Niger] Julvez J, et al. **Med Trop (Mars)** 1996;56(1):48–50 (Eng. Abstr.) (Fre)

[Decision analysis of congenital toxoplasmosis in the absence of exact knowledge of the treatment benefits and secondary effects] Ecochard R, et al. **Rev Epidemiol Sante Publique** 1996 Apr;44(2):145–54 (Eng. Abstr.) (Fre)

[Seroprevalence of toxoplasmosis in Dakar (Senegal) in 1993: study of women in their reproductive years] Diallo S, et al. **Sante** 1996 Mar–Apr;6(2):102–6 (Eng. Abstr.) (Fre)

[Levels of anti-Gal antibodies in persons infected and non-infected with Trypanosoma cruzi. Probably induced by bacteria and by the parasite] González J, et al. **Bol Chil Parasitol** 1995 Jan–Jun;50(1–2):3–9 (Eng. Abstr.) (Spa)

CHEMISTRY

Monoclonal rat antibodies directed against Toxoplasma gondii suitable for studying tachyzoite-bradyzoite interconversion in vivo. Gross U, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):542–8

Evidence for anti-Plasmodium falciparum antibodies that cross-react with human T-lymphotropic virus type I proteins in a population in Irian Jaya, Indonesia. Porter KR, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):11–5

DIAGNOSTIC USE

Encephalocytozoon intestinalis-specific monoclonal antibodies for laboratory diagnosis of microsporidiosis. Beckers PJ, et al. **J Clin Microbiol** 1996 Feb;34(2):282–5

Diagnosis of bovine cryptosporidiosis by indirect immunofluorescence assay using monoclonal antibody. Wee SH, et al. **Korean J Parasitol** 1995 Jun;33(2):107–15

Plasmodium vivax: detection of blood parasites using fluorochrome labelled monoclonal antibodies. Perez HA, et al. **Parasite Immunol** 1995 Jun;17(6):305–12

GENETICS

Primary structure of the variable region of monoclonal antibody 2B10, capable of inducing anti-idiotypic antibodies that recognize the C-terminal region of MSA-1 of Plasmodium falciparum. Su S, et al. **Infect Immun** 1996 Jan;64(1):326–31

IMMUNOLOGY

Carbohydrate epitopes of Entamoeba histolytica cell surface glycoproteins are major targets of the human humoral response. de la Torre P, et al. **Acta Trop** 1995 Sep; 60(1):59–71

Plasmodium falciparum: differential parasite growth inhibition mediated by antibodies to the antigens Pf332 and Pf155/RESA. Ahlborg N, et al. **Exp Parasitol** 1996 Mar; 82(2):155–63

Plasmodium gallinaceum: sporozoite invasion of Aedes aegypti salivary glands is inhibited by anti-gland antibodies and by lectins. Barreau C, et al. **Exp Parasitol** 1995 Nov; 81(3):332–43

Toxoplasma gondii: characterization of a monoclonal antibody recognizing antigens of 36 and 38 kDa with acid phosphatase activity located in dense granules and rhoptries. Metsis A, et al. **Exp Parasitol** 1995 Dec; 81(4):472–9

Modulation of cardiac physiology by an anti-Trypanosoma cruzi monoclonal antibody after interaction with myocardium. Cremaschi G, et al. **FASEB J** 1995 Nov; 9(14):1482–8

Myosin II is involved in capping and uroid formation in the human pathogen Entamoeba histolytica. Arhets P, et al. **Infect Immun** 1995 Nov;63(11):4358–67

Inhibition of Giardia lamblia excystation by antibodies against cyst walls and by wheat germ agglutinin. Meng TC, et al. **Infect Immun** 1996 Jun;64(6):2151–7

Antibodies to a conserved-motif peptide sequence of the Plasmodium falciparum thrombospondin-related anonymous protein and circumsporozoite protein recognize a 78-kilodalton protein in the asexual blood stages of the parasite and inhibit merozoite invasion in vitro. Sharma P, et al. **Infect Immun** 1996 Jun;64(6):2172–9

Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Taylor RR, et al. **Infect Immun** 1995 Nov;63(11):4382–8

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Tine JA, et al. **Infect Immun** 1996 Sep;64(9):3833–44

Seroprevalence and specificity of human responses to the Plasmodium falciparum rhoptry protein Rhop-3 determined by using a C-terminal recombinant protein. Yang JC, et al. **Infect Immun** 1996 Sep;64(9):3584–91

Coexistence of anti-salmonella agglutinins in falciparum malaria [letter] Khubnani H, et al. **J Assoc Physicians India** 1995 Aug;43(8):585–6

Antisporozoite antibodies with protective and nonprotective activities: in vitro and in vivo correlations using Plasmodium gallinaceum, an avian model. Ramirez AD, et al. **J Eukaryot Microbiol** 1995 Nov–Dec;42(6):705–8

Trypanosoma rangeli: epimastigote immunogenicity and cross-reaction with Trypanosoma cruzi. Saldaña A, et al. **J Parasitol** 1996 Apr;82(2):363–6

Prevalence of antibodies to potential malaria vaccine antigens in an endemic area of the State of Rondônia (Brazil). Balthazar-Guedes HC, et al. **Mem Inst Oswaldo Cruz** 1995 Jul–Aug;90(4):511–2

Immune mechanisms underlying the premunition against Plasmodium falciparum malaria. Pérignon JL, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:51–3 (13 ref.)

Transmission blocking immunity as observed in a feeder system and serological reactivity to Pfs 48/45 and Pfs230

in field sera. Roeffen W, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:13–5

Naturally acquired antibodies against the major merozoite surface coat protein (MSP-1) of Plasmodium falciparum acquired by residents in an endemic area of Colombia. Terrientes ZI, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:55–61

Epitope tagging of flagellar proteins. Diener DR. **Methods Cell Biol** 1995;47:545–50

Immunogens containing sequences from antigen Pf332 induce Plasmodium falciparum–reactive antibodies which inhibit parasite growth but not cytoadherence. Ahlborg N, et al. **Parasite Immunol** 1995 Jul;17(7):341–52

Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. al-Yaman F, et al. **Parasite Immunol** 1995 Sep;17(9):493–501

Detection of an "epimastigote-like" intracellular stage of Trypanosoma cruzi. Faucher JF, et al. **Parasitol Res** 1995; 81(5):441–3

Electron microscopical investigation of surface alterations on Giardia lamblia trophozoites after exposure to a cytotoxic monoclonal antibody. Hemphill A, et al. **Parasitol Res** 1996;82(3):206–10

Differentiation between culture-derived insect stages of T. brucei, T. vivax, T. congolense and T. simiae using a monoclonal antibody-based dot-ELISA. Bosompem KM, et al. **Parasitology** 1996 Jan;112 (Pt 1):59–66

Entamoeba histolytica: detection of coproantigens by purified antibody in the capture sandwich ELISA. Urdaneta H, et al. **Rev Inst Med Trop Sao Paulo** 1994 Nov–Dec; 36(6):539–45

Antibodies reactive to Trypanosoma cruzi epimastigotes or amastigotes express different idiotypic patterns if from patients with different clinical forms of Chagas' disease. Ribeiro-Rodrigues R, et al. **Scand J Immunol** 1996 Jun; 43(6):671–9

Recognition of a 170 kD protein in mammalian Golgi complexes by an antibody against malarial intraerythrocytic lamellae. Li W, et al. **Tissue Cell** 1995 Aug;27(4):355–67

Activity of a monoclonal antibody against Besnoitia besnoiti endozoites. Shkap V, et al. **Vet Res** 1995;26(4):328–34

ISOLATION & PURIFICATION

Humoral and mucosal IgA antibody response to a recombinant 52-kDa cysteine-rich portion of the Entamoeba histolytica galactose-inhibitable lectin correlates with detection of native 170-kDa lectin antigen in serum of patients with amebic colitis. Abou-el-Magd I, et al. **J Infect Dis** 1996 Jul;174(1):157–62

METABOLISM

Rapid internalization and degradation of surface-bound antibodies by Tritrichomonas foetus. Granger BL, et al. **J Parasitol** 1996 Aug;82(4):539–49

PHARMACOLOGY

Entamoeba histolytica adherence: inhibition by IgA monoclonal antibodies. Leyva O, et al. **Adv Exp Med Biol** 1995;371A:681–3

THERAPEUTIC USE

[Immunological factors blocking transmission (letter)] Mulder B. **Med Trop (Mars)** 1995;55(4 Suppl):116–8 **(Fre)**

TOXICITY

Maternal Trypanosoma cruzi–specific antibodies and worsening of acute infection in mouse offspring. Marques de Araujo S, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):13–7

ANTIBODIES, THYROID-STIMULATING see **IMMUNOGLOBULINS, THYROID-STIMULATING**

ANTIBODIES, VIRAL

Determination of optimum formulation of a novel infectious bursal disease virus (IBDV) vaccine constructed by mixing bursal disease antibody with IBDV. Whitfill CE, et al. **Avian Dis** 1995 Oct–Dec;39(4):687–99

Epitopes exposed on hepatitis delta virus ribonucleoproteins. Bichko VV, et al. **J Virol** 1996 Sep;70(9):5807–11

Autoantigens interact with cis-acting elements of rubella virus RNA. Pogue GP, et al. **J Virol** 1996 Sep; 70(9):6269–77

The neuraminidase of Newcastle disease virus inhibited in the elution-inhibition reaction. Graves IL. **Vet Res** 1996; 27(1):45–54

A fairly conserved epitope on the hemagglutinin of influenza A (H3N2) virus with variable accessibility to neutralizing antibody. Vanlandschoot P, et al. **Virology** 1995 Oct 1; 212(2):526–34

ADMINISTRATION & DOSAGE

Combinations of ganciclovir and antibody for experimental CMV infections. Stals FS, et al. **Antiviral Res** 1996 Jan; 29(1):61–4

Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. Bratcher DF, et al. **J Infect Dis** 1995 Oct;172(4):944–50

Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. Prince GA, et al. **J Infect Dis** 1996 Mar;173(3):598–608

Protective antibody therapy is associated with reduced chemokine transcripts in herpes simplex virus type 1 corneal infection. Su YH, et al. **J Virol** 1996 Feb; 70(2):1277–81

Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Crowe JE Jr, et al. **Vaccine** 1995 Jun; 13(9):847–55

ANALYSIS

Virus-specific antibody production and polyclonal B-cell activation in the intestinal mucosa of HIV-infected individuals. Eriksson K, et al. **AIDS** 1995 Jul;9(7):695–700

Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Elfgren K, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):937–42

Field trial to evaluate immunogenicity of a glycoprotein I (gE)-deleted pseudorabies virus vaccine after its administration in the presence of maternal antibodies. Weigel RM, et al. **Am J Vet Res** 1995 Sep;56(9):1155–62

Undetectable IgE responses after respiratory syncytial virus infection. Toms GL, et al. **Arch Dis Child** 1996 Feb; 74(2):126–30

Detection of respiratory syncytial virus (RSV) antigen in the lungs of guinea pigs 6 weeks after experimental infection and despite of the production of neutralizing antibodies. Streckert HJ, et al. **Arch Virol** 1996; 141(3–4):401–10

Bovine respiratory syncytial virus antibodies in non-bovine species. Van der Poel WH, et al. **Arch Virol** 1995; 140(9):1549–55

Seroprevalence of human herpesvirus 6 and 7 infections in the Thai population. Kositanont U, et al. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):151–7

Infection of cattle in Queensland with bluetongue viruses: I. Prevalence of antibodies. II. Distribution of antibodies [letter; comment] St George TD, et al. **Aust Vet J** 1995 Sep;72(9):358–60. Comment on: Aust Vet J 1995 May;72(5):182–6. Comment on: Aust Vet J 1995 Jun;72(6):217–20.

Salivary immunoglobulins in recipients of bone marrow grafts. III. A longitudinal follow-up of CMV specific antibodies. Chaushu G, et al. **Bone Marrow Transplant** 1996 Feb;17(2):237–41

In vitro induced antibody production for the diagnosis of herpes simplex virus infection in immunosuppressed patients. Bellei NC, et al. **Braz J Med Biol Res** 1996 Apr; 29(4):485–7

Assessment of seropositivity to porcine reproductive and respiratory syndrome (PRRS) virus in swine herds in Ontario—1978 to 1982. Carman S, et al. **Can Vet J** 1995 Dec;36(12):776–7

Evaluation of immunoassays for detection of antibodies to human herpesvirus 7. Black JB, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):79–83

Comparison of three commercially available assays for detection of varicella-zoster virus antibody. Martins TB, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):186–8

Subclasses of IgA antibodies in serum and saliva samples of newborns and infants immunized against rotavirus. Friedman MG, et al. **Clin Exp Immunol** 1996 Feb; 103(2):206–11

Measles immunity and response to revaccination among secondary school children in Cumbria. Calvert N, et al. **Epidemiol Infect** 1996 Feb;116(1):65–70

A school outbreak of parvovirus B19 infection investigated using salivary antibody assays. Rice PS, et al. **Epidemiol Infect** 1996 Jun;116(3):331–8

Seroprevalence of rubella among women of childbearing age in Switzerland. Zufferey J, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):691–6

Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. Sairenji T, et al. **Intervirology** 1995;38(5):269–73

Diagnosis of parvovirus B19 infection by detection of specific immunoglobulin M antibody in saliva. Cubel RC, et al. **J Clin Microbiol** 1996 Jan;34(1):205–7

Expression of recombinant parvovirus NS1 protein by a baculovirus and application to serologic testing of rodents. Riley LK, et al. **J Clin Microbiol** 1996 Feb;34(2):440–4

Characterization of mouse nasal lymphocytes isolated by enzymatic extraction with collagenase. Asanuma H, et al. **J Immunol Methods** 1995 Nov 16;187(1):41–51

Serum, fecal, and breast milk rotavirus antibodies as indices of infection in mother-infant pairs. Bishop RF, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S22–9

Relationship between antibodies to herpes simplex virus (HSV) and symptoms of HSV infection. Cowan FM, et al. **J Infect Dis** 1996 Sep;174(3):470–5

The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. Everitt DE, et al. **J Infect Dis** 1996 Sep;174(3):463–9

Comparative detection of measles-specific IgM in oral fluid and serum from children by an antibody-capture IgM EIA. Helfand RF, et al. **J Infect Dis** 1996 Jun;173(6):1470–4

Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. Wang JB, et al. **J Infect Dis** 1996 Aug;174(2):387–92

Comparison of monoclonal antibodies for immunostaining in the cytomegalovirus shell vial assay on 4,388 specimens. St. George K, et al. **J Med Virol** 1995 Nov;47(3):269–71

HTLV tax-rex DNA and antibodies in idiopathic amyotrophic lateral sclerosis. Ferrante P, et al. **J Neurol Sci** 1995 May;129 Suppl:140–4

Development and evaluation of an ELISA using recombinant fusion protein to detect the presence of host antibody to equine arteritis virus. Chirnside ED, et al. **J Virol Methods** 1995 Jul;54(1):1–13

A diagnostic immunoassay for Newcastle disease virus based on the nucleocapsid protein expressed by a recombinant baculovirus. Errington W, et al. **J Virol Methods** 1995 Nov; 55(3):357–65

Automated microneutralization: method and comparison with western blot for type-specific detection of herpes simplex antibodies in two pregnant populations. Garland SM, et al. **J Virol Methods** 1995 Nov;55(3):285–94

Monoclonal antibody based competitive ELISA for the detection of antibodies against epizootic haemorrhagic disease of deer virus. Thevasagayam JA, et al. **J Virol Methods** 1996 Apr 5;57(2):117–26

Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States [see comments] Chen RT, et al. **JAMA** 1996 Jun 5;275(21):1639–45. Comment in: JAMA 1996 Jun 5;275(21):1682–3.

Rubella in mothers [letter] [see comments] Rushworth RL, et al. **Lancet** 1996 May 4;347(9010):1262. Comment in: Lancet 1996 Jul 27;348(9022):267–8.

Prevalence of antibody to hepatitis E virus among healthy individuals in southern Taiwan. Peng CF, et al. **Microbiol Immunol** 1995;39(9):733–6

KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma [see comments] Gao SJ, et al. **Nat Med** 1996 Aug;2(8):925–8. Comment in: Nat Med 1996 Aug;2(8):862–3.

Is isolation needed for anti-HCV-positive hemodialysis patients? [letter; comment] Beccari M, et al. **Nephron** 1996; 72(2):372. Comment on: Nephron 1994;68(4):514.

Anti-hepatitis E virus markers in hemodialysis patients [letter] Wang CH, et al. **Nephron** 1996;72(2):343–5

Mild hantaviral disease caused by sin Nombre virus in a four-year-old child. Armstrong LR, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1108–10

High incidence of congenital rubella syndrome after a rubella outbreak. Mellinger AK, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):573–8

Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Arpadi SM, et al. **Pediatrics** 1996 May;97(5):653–7

Detection of IgM antibodies specific for measles virus by capture and indirect enzyme immunoassays. Arista S, et al. **Res Virol** 1995 May-Jun;146(3):225–32

Interpretation of intraocular and serum antibody levels in necrotizing retinitis. Davis JL, et al. **Retina** 1995; 15(3):233–40

Vaccination against tick-borne encephalitis—distant evaluation. Bobrowska E, et al. **Rocz Akad Med Bialymst** 1996;41(1):44–50

Prevalence of antibodies to herpes simplex virus types 1 and 2, Epstein-Barr virus and cytomegalovirus in teenage girls. Andersson-Ellström A, et al. **Scand J Infect Dis** 1995; 27(4):315–8

Parvovirus B19 infection—persistence and genetic variation. Kerr JR, et al. **Scand J Infect Dis** 1995;27(6):551–7

Decline of herpes simplex virus type 2 and Chlamydia trachomatis infections from 1970 to 1993 indicated by a similar change in antibody pattern. Persson K, et al. **Scand J Infect Dis** 1995;27(3):195–9

Searching for antibodies specific for human cytomegalovirus: is it diagnostically useful? When and how. Landini MP, et al. **Scand J Infect Dis Suppl** 1995;99:18–23 (43 ref.)

Prevalence of hemagglutination-inhibition and neutralizing antibodies to arboviruses in horses of java. Widjaja S, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):109–13

Single radial haemolysis for the detection of goat pox virus antigen and antibody. Tiwari AK, et al. **Trop Anim Health Prod** 1996 Feb;28(1):117–20

Isotype-specific antibody responses in sera and mucosal secretions of calves experimentally infected with bovine herpesvirus 1. Madic J, et al. **Vet Immunol Immunopathol** 1995 Jun;46(3–4):267–83

Isotype-specific antibody responses to bovine herpesvirus 1 in sera and mucosal secretions of calves after experimental reinfection and after reactivation. Madic J, et al. **Vet Immunol Immunopathol** 1995 Jul;47(1–2):81–92

Persistence of bovine herpesvirus-1-specific antibodies in cattle after intranasal vaccination with a live virus vaccine. Van der Poel WH, et al. **Vet Rec** 1995 Sep 30;137(14):347–8

[Seroprevalence of IgG antibodies against parvovirus B19 in the population of the Czech Republic] Sodja I, et al. **Epidemiol Mikrobiol Imunol** 1995 Dec;44(4):171–4 (Eng. Abstr.) **(Cze)**

[Cytomegalovirus antibodies: review of results of repeated examinations in 208 hemodialyzed patients] Korčáková L. **Vnitr Lek** 1995 Jul;41(7):454–7 (Eng. Abstr.) **(Cze)**

[Poliomyelitis immunity status in the centro-meridional Italy] Ribera G, et al. **Ann Ig** 1995 Nov-Dec;7(6):421–9 (Eng. Abstr.) **(Ita)**

[Type-specificity of serum antibodies from genital herpes patients as determined by an enzyme-linked immunosorbent assay using HSV-infected cells as antigens] Hashido M, et al. **Kansenshogaku Zasshi** 1995 Jul; 69(7):785–9 (Eng. Abstr.) **(Jpn)**

[Glomerular lesion in patients with type II mixed cryoglobulinemia having antibodies to hepatitis C virus] Yumura W, et al. **Nippon Jinzo Gakkai Shi** 1995 Oct; 37(10):587–94 (Eng. Abstr.) **(Jpn)**

[Viral tumor markers] Ohtsuru A, et al. **Nippon Rinsho** 1996 Jun;54(6):1529–35 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Virological diagnostics in acute encephalitis. Experience with nucleic acid detection and ratio examination during the period 1991–94] Bruu AL. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):721–5 (Eng. Abstr.) **(Nor)**

[Use of a latex-agglutination test for determining anti-measles antibody titer] Aleksander SK, et al. **Vopr Virusol** 1995 Sep-Oct;40(5):231–4 (Eng. Abstr.) **(Rus)**

[Herpes simplex virus and ovarian malignancies] Cokić-Damjanović J, et al. **Med Pregl** 1995;48(9–10):311–4 (Eng. Abstr.) **(Ser)**

[Titration of rabies antibodies with the rapid fluorescence focus inhibition test] Závadová J, et al. **Vet Med (Praha)** 1996 Jul;41(7):225–30 (Eng. Abstr.) **(Slo)**

BIOSYNTHESIS

Altered humoral immunity against cytomegalovirus and Epstein-Barr virus without detectable virus antigens and virus-DNA in the glomeruli of patients with IGA nephropathy in remission phase. Nagy J, et al. **Acta Microbiol Immunol Hung** 1995;42(2):179–87

Different kinetics of antibody responses between IgA and IgG classes in nasopharyngeal secretion in infants and children during primary respiratory syncytial virus infection. Tsutsumi H, et al. **Acta Paediatr Jpn** 1995 Aug; 37(4):464–8

Nasopharyngeal and systemic humoral responses induced by trivalent attenuated poliomyelitis vaccine in newborns. Padilla-Ramos JC, et al. **Adv Exp Med Biol** 1995; 371B:1601–4

Clonal antibody dominance after influenza vaccination in IgA nephropathy patients and controls. Radl J, et al. **Adv Exp Med Biol** 1995;371B:829–34

Viral status and antibody response in cattle inoculated with recombinant bovine leukemia virus-vaccinia virus vaccines after challenge exposure with bovine leukemia virus-infected lymphocytes. Cherney TM, et al. **Am J Vet Res** 1996 Jun;57(6):812–8

Nucleic acid vaccination against virally induced tumors. Bright RK, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:241–51

Protective efficacy of intramuscular immunization with naked DNA. Donnelly JJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:40–6 (26 ref.)

Plasmid vectors as anti-viral vaccines. Ertl HC, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:77–87

Simian immunodeficiency virus DNA vaccine trial in macaques. Robinson HL, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:209–11

Cell-mediated and humoral immunity in bulls infected with IBR/IPV virus (BHV 1). Deptula W. **Arch Vet Pol** 1994; 34(1–2):13–23

Kinetics of humoral immune response to the major structural proteins of the porcine reproductive and respiratory syndrome virus. Loemba HD, et al. **Arch Virol** 1996; 141(3–4):751–61

In vitro synthesis of foot-and-mouth disease virus specific antibodies by porcine leukocytes. Rodríguez A, et al. **Arch Virol** 1995;140(9):1645–52

Antiviral immune responses of mice lacking MHC class II or its associated invariant chain. Battegay M, et al. **Cell Immunol** 1996 Jan 10;167(1):115–21

Elevated levels of total and Puumala virus-specific immunoglobulin E in the Scandinavian type of hemorrhagic fever with renal syndrome. Alexeyev OA, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):269–72

Neutralizing antibody immune response in children with primary and secondary rotavirus infections. Arias CF, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):89–94

Immune response to bovine viral diarrhea virus induced by anti-idiotypic antibodies. Xue W, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):95–8

Augmentation of anti-influenza virus hemagglutinin antibody production by Peyer's patch cells with Bifidobacterium breve YIT4064. Yasui H, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):244–6

The restricted IgG1 antibody response to maedi visna virus is seen following infection but not following immunization with recombinant gag protein. Bird P, et al. **Clin Exp Immunol** 1995 Nov;102(2):274–80

Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Juillard V, et al. **Eur J Immunol** 1995 Dec;25(12):3467–73

IgD-receptor up-regulation on human peripheral blood T cells in response to IgD in vitro or antigen in vivo correlates with the antibody response to influenza vaccination. Swenson CD, et al. **Eur J Immunol** 1996 Feb; 26(2):340–4

Lipid vesicle-entrapped influenza A antigen modulates the influenza A-specific human antibody response in immune reconstituted SCID-human mice. Walker W, et al. **Eur J Immunol** 1996 Jul;26(7):1664–7

Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Van Ginkel FW, et al. **Hum Gene Ther** 1995 Jul;6(7):895–903

Definition of cotton rat immunoglobulins: sigmodon species differ in expression of IgG isotypes and production of respiratory syncytial virus antibody. Coe JE, et al. **Immunology** 1996 Jul;88(3):323–30

CD40 cross-linking inhibits specific antibody production by human B cells. Callard RE, et al. **Int Immunol** 1995 Nov; 7(11):1809–15

Role of maternal antibody in the induction of virus specific and bystander IgA responses in Peyer's patches of suckling mice. Kramer DR, et al. **Int Immunol** 1995 Jun;7(6):911–8

Adjuvant effect of polyadenylic.polyuridylic acid on antibody production of recombinant hepatitis B surface antigen in mice. Park SJ, et al. **Int J Immunopharmacol** 1995 Jun;17(6):513–6

Abnormalities of measles antibody response in human immunodeficiency virus type 1 (HIV-1) infection. Brunell PA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 15;10(5):540–8

Effects of perinatal vaccination on humoral and cellular immune responses in cows and young calves [see comments] Ellis JA, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):393–400. Comment in: J Am Vet Med Assoc 1996 May 15;208(10):1625–7.

T cell-independent antibody-mediated clearance of polyoma virus in T cell-deficient mice. Szomolanyi-Tsuda E, et al. **J Exp Med** 1996 Feb 1;183(2):403–11

Replication-defective adenovirus type 5 as an in vitro and in vivo gene transfer vector in chickens. Adam M, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3153–7

Vaccinia virus-expressed bovine ephemeral fever virus G but not G(NS) glycoprotein induces neutralizing antibodies and protects against experimental infection. Hertig C, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):631–40

Immunological response to recombinant VP8* subunit protein of bovine roravirus in pregnant cattle. Lee J, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2477–83

Induction of varicella-zoster virus-neutralizing antibodies in mice by co-infection with recombinant vaccinia viruses expressing the gH or gL gene. Němečková S, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):211–5

Induction and characterization of monoclonal anti-idiotypic antibodies to tick-borne encephalitis virus neutralizing antibody. Kopecký J, et al. **J Immunoassay** 1995 Nov; 16(4):437–65

Influence of antigen presentation and exogenous cytokine activity during in vitro primary immunizations employed for the generation of monoclonal antibodies. Halabi G, et al. **J Immunol Methods** 1995 Oct 26;186(2):205–16

Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. Chan CY, et al. **J Infect Dis** 1996 Jan;173(1):256–8

Virus-like particles as a rotavirus subunit vaccine. Conner ME, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S88–92

Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. Gorse GJ, et al. **J Infect Dis** 1996 Feb; 173(2):285–90

Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. The US Rotavirus Vaccine Efficacy Group. Rennels MB, et al. **J Infect Dis** 1996 Feb;173(2):306–13

Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. Rennels MB. **J Infect Dis** 1996 Sep;174 Suppl 1:S107–11 (35 ref.)

Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. Ward BJ, et al. **J Infect Dis** 1995 Dec; 172(6):1591–5

Simian varicella virus antibody response in experimental infection of African green monkeys. Gray WL, et al. **J Med Primatol** 1995 Dec;24(4):246–51

Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection. Wikström A, et al. **J Med Virol** 1995 Aug;46(4):368–74

Characterization of the humoral immune response to porcine reproductive and respiratory syndrome (PRRS) virus infection. Yoon KJ, et al. **J Vet Diagn Invest** 1995 Jul; 7(3):305–12

Antibody response to rabbit viral hemorrhagic disease virus in red foxes (Vulpes vulpes) consuming livers of infected rabbits (Oryctolagus cuniculus). Leighton FA, et al. **J Wildl Dis** 1995 Oct;31(4):541–4

Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. King GE, et al. **JAMA** 1996 Mar 6;275(9):704–7

Stabilizing antibody secretion of human Epstein Barr virus-activated B-lymphocytes with hybridoma formation by electrofusion. Perkins S, et al. **Methods Mol Biol** 1995; 48:295–307

Class-specific antibody response in acyclovir-treated and adenine arabinoside-treated patients with primary genital herpes simplex virus infection. Kawana T, et al. **Microbiol Immunol** 1995;39(10):795–9

Variable response to a candidate cancer vaccine antigen: MHC control of the antibody response in the rat to avian erythroblastosis virus (AEV)-encoded epithelial growth factor receptor but not AEV-encoded thyroid hormones receptor. Nardi N, et al. **Mol Med** 1995 Jul;1(5):563–7

Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus [see comments] Donnelly JJ, et al. **Nat Med** 1995 Jun;1(6):583–7 . Comment in: Nat Med 1995 Jun;1(6):521–2.

Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung [see comments] Yang Y, et al. **Nat Med** 1995 Sep;1(9):890–3. Comment in: Nat Med 1995 Sep;1(9):887–9.

Specific cytotoxic T cells eliminate cells producing neutralizing antibodies [letter] Planz O, et al. **Nature** 1996 Aug 22;382(6593):726–9

Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins. Sjölander A, et al. **Scand J Immunol** 1996 Feb;43(2):164–72

Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type B conjugate vaccines given for primary immunisation by separate or mixed injection. Begg NT, et al. **Vaccine** 1995 Nov;13(16):1547–50

Effective antibody response in newborn babies living in Maldives to simultaneous vaccination against hepatitis B, poliomyelitis, diphtheria and tetanus. Da Villa G, et al. **Vaccine** 1995 Jun;13(9):795–8

Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. de Haan A, et al. **Vaccine** 1995 Oct;13(14):1320–4

Antibody responses by cattle after vaccination with commercial viral vaccines containing bovine herpesvirus-1, bovine viral diarrhea virus, parainfluenza-3 virus, and bovine respiratory syncytial virus immunogens and subsequent revaccination at day 140. Fulton RW, et al. **Vaccine** 1995;13(8):725–33

Enhancement of protective immune responses to Venezuelan equine encephalitis (VEE) virus with microencapsulated vaccine. Greenway TE, et al. **Vaccine** 1995;13(15):1411–20

Induction of systemic immune responses to measles virus synthetic peptides administered intranasally. Hathaway LJ, et al. **Vaccine** 1995 Nov;13(16):1495–500

Myxoma virus as a vaccine vector for rabbits: antibody levels to influenza virus haemagglutinin presented by a recombinant myxoma virus. Kerr PJ, et al. **Vaccine** 1995 Dec;13(17):1722–6

Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins. Moldoveanu Z, et al. **Vaccine** 1995 Aug; 13(11):1013–22

Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Moldoveanu Z, et al. **Vaccine** 1995 Aug;13(11):1006–12

In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant. Powers DC, et al. **Vaccine** 1995 Oct;13(14):1330–5

Immune response to a booster dose of enhanced potency inactivated polio vaccine administered in association with HBV vaccine in adolescents. Pregliasco F, et al. **Vaccine** 1996 Mar;14(4):267–9

A new epitope presenting system displays a HIV-1 V3 loop sequence and induces neutralizing antibodies. Scodeller EA, et al. **Vaccine** 1995 Sep;13(13):1233–9

Immune response of calves to foot-and-mouth disease virus vaccine emulsified with oil adjuvant. Strategies of vaccination. Späth EJ, et al. **Vaccine** 1995 Jul;13(10):909–14

Immune response and protection against influenza A infection in mice immunised with subunit influenza A vaccine in combination with whole cell or acellular DTP vaccine. Tamizifar H, et al. **Vaccine** 1995 Nov;13(16):1539–46

Maintenance of high virus load even after seroconversion in newborn cats acutely infected with feline immunodeficiency virus. Tokunaga K, et al. **Vaccine** 1995; 13(15):1393–8

Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine. Vafai A. **Vaccine** 1995 Oct;13(14):1336–8

Immunogenicity of infectious bovine rhinotracheitis virus (BHV-1) proteins integrated into ISCOMs or liposomes. Franz J, et al. **Vet Med (Praha)** 1996 Jul;41(7):213–8

Antibody response of sheep following administration of louping-ill virus vaccine. Reid HW, et al. **Vet Rec** 1995 Jun 24;136(25):638–9

Induction of antibodies to the bluetongue virus core polypeptide VP7 in sheep by internal image rabbit antiidiotypic antibodies. Lin M, et al. **Viral Immunol** 1996; 9(1):35–43

Prior infection by respiratory syncytial virus or parainfluenza

viruses augments virus-specific IgG responses induced by the measles/mumps/rubella vaccine. Ziola B, et al. **Viral Immunol** 1994;7(4):205–14

A transmissible gastroenteritis coronavirus nucleoprotein epitope elicits T helper cells that collaborate in the in vitro antibody synthesis to the three major structural viral proteins. Antón IM, et al. **Virology** 1995 Oct 1; 212(2):746–51

Rapid generation of antibodies against the HTLV-II external envelope protein by growth of mouse plasmacytomas in SCID mice. Li QX, et al. **Virology** 1995 Dec 20; 214(2):680–4

Induction of antibodies protecting against transmissible gastroenteritis coronavirus (TGEV) by recombinant adenovirus expressing TGEV spike protein. Torres JM, et al. **Virology** 1995 Nov 10;213(2):503–16

[Immune reactions and mechanisms in classical swine fever] Kolontsov AA, et al. **Mol Gen Mikrobiol Virusol** 1995 Apr–Jun;(2):18–21 (46 ref.) (Eng. Abstr.) **(Rus)**

[Humoral antiviral immunity in children with hematologic neoplasms] Nisevich LL, et al. **Vopr Virusol** 1995 Jul–Aug; 40(4):177–81 (Eng. Abstr.) **(Rus)**

[Mechanisms involved in the prolonged humoral immune response: behavior of aphthous fever virus] Wigdorovitz A, et al. **Rev Argent Microbiol** 1996 Jan–Mar;28(1):45–54 (45 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Rabies antibodies in vaccinated dogs. Sihvonen L, et al. **Acta Vet Scand** 1995;36(1):87–91

R-subtype of early antigen of the Epstein–Barr virus in the diagnostics of the chronic form of infectious mononucleosis [letter] Kotuliak J. **Acta Virol** 1995 Jun;39(3):183–4

Passive immunization of rhesus macaques against SIV infection and disease. Gardner M, et al. **AIDS Res Hum Retroviruses** 1995 Jul;11(7):843–54

Evidence for the existence of Puumula-related virus among Clethrionomys rufocanus in Hokkaido, Japan. Kariwa H, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):222–7

Prevalence of antibodies to arenaviruses in rodents from the southern and western United States: evidence for an arenavirus associated with the genus Neotoma. Kosoy MY, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):570–6

Antibodies to hemorrhagic fever viruses in domestic livestock in Niger: Rift Valley fever and Crimean–Congo hemorrhagic fever. Mariner JC, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):217–21

Differential reactivity of immune sera from human vaccinees with field strains of eastern equine encephalitis virus. Strizki JM, et al. **Am J Trop Med Hyg** 1995 Nov;53(5):564–70

Seroepidemiology of La Crosse virus infection in humans in western North Carolina. Szumlas DE, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):332–7

Liquid-phase blocking sandwich enzyme-linked immunosorbent assay for detection of antibodies against foot-and-mouth disease virus in water buffalo sera. Araújo JP, et al. **Am J Vet Res** 1996 Jun;57(6):840–3

Comparison of the abilities of serologic tests to detect pseudorabies-infected pigs during the latent phase of infection. White AK, et al. **Am J Vet Res** 1996 May; 57(5):608–11

Comparison of HHV-6 antibody titers in West Africa and the Caribbean. Cleghorn FR, et al. **Ann Epidemiol** 1995 Nov;5(6):497–500

Serum antibody to Rift Valley fever virus in African carnivores. House C, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:345–9

A blocking ELISA for detection of antibody to a subgroup-reactive epitope of African horsesickness viral protein 7 (VP7) using a novel gamma-irradiated antigen. House JA, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:333–44

Malignant catarrhal fever virus. Characterization of a United States isolate and development of diagnostic assays. Li H, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:198–210

High prevalence of arthropathy in HTLV-I carriers on a Japanese island. Motokawa S, et al. **Ann Rheum Dis** 1996 Mar;55(3):193–5

A simple direct enzyme immunoassay of antibodies based on the differences in diffusion rates in a gel of a synthetic antigen and of its complex with antibodies. Semenov AN, et al. **Appl Biochem Biotechnol** 1996 Jan;56(1):73–8

Anti-EBNA1/anti-EBNA2 ratio decreases significantly in patients with progression of HIV infection. Winkelspecht B, et al. **Arch Virol** 1996;141(5):857–64

Age-specific prevalence of porcine parvovirus antibody in feral pigs from a site in the Northern Territory. Caley P, et al. **Aust Vet J** 1995 Jan;72(1):36–7

Antibodies to bluetongue and related orbiviruses in sheep and goats in bluetongue virus-endemic areas of northern and central Queensland. Flanagan M, et al. **Aust Vet J** 1995 Jan;72(1):31–2

Infection of cattle in Queensland with bluetongue viruses: II. Distribution of antibodies [see comments] Ward MP, et al. **Aust Vet J** 1995 Jun;72(6):217–20. Comment in: Aust Vet J 1995 Sep;72(9):358–60.

Failure of maternally derived yolk IgG to reach detectable concentrations in the sera of nestling budgerigars (Melopsittacus undulatus). Phalen DN, et al. **Avian Dis** 1995 Oct–Dec;39(4):700–8

An enzyme immunoassay based micro-neutralization test for titration of antibodies to human cytomegalovirus (CMV) and its correlation with direct ELISA measuring CMV IgG antibodies. Gupta CK, et al. **Biologicals** 1996 Mar; 24(1):41–9

A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant [see comments] Bowden RA, et al. **Blood** 1995 Nov 1;86(9):3598–603. Comment in: Blood 1996 Jun 1;87(11):4910. Comment in: Blood 1996 Aug 15;88(4):1515.

Competitive ELISA to evaluate the immunogenicity of double-virus-inactivated factor VIII in rabbits. Verdier F, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S62–4

Serum p53 accumulation and altered antibody responses to Epstein–Barr virus proteins precede diagnosis of haemopoietic malignancies of lymphoid origin. Lehtinen T, et al. **Br J Haematol** 1996 Apr;93(1):104–10

Measles immunization strategy: measles antibody response following MMR II vaccination of children at one year of age. Ratnam S, et al. **Can J Public Health** 1996 Mar–Apr; 87(2):97–100

An ELISA for porcine reproductive and respiratory syndrome: production of antigen of high quality. Cho HJ, et al. **Can J Vet Res** 1996 Apr;60(2):89–93

A serological survey of bovine syncytial virus in Ontario: associations with bovine leukemia and immunodeficiency-like viruses, production records, and management practices. Jacobs RM, et al. **Can J Vet Res** 1995 Oct;59(4):271–8

Study of immune function in inbred miniature pigs vaccinated and challenged with suid herpesvirus 1. Williams PP. **Can J Vet Res** 1995 Oct;59(4):285–93

Association of serum antibodies against defined epitopes of human papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident cervical cancer. Dillner L, et al. **Cancer Detect Prev** 1995;19(5):381–93

Detection of antibodies to avian leukosis/sarcoma viruses (ALSV) and reticuloendotheliosis viruses (REV) in humans by ELISA. Johnson ES, et al. **Cancer Detect Prev** 1995; 19(5):394–404

Measles virus haemagglutination-inhibition antibodies among pregnant and non-pregnant women in the vaccine era in Harare, Zimbabwe. Obi CL, et al. **Cent Afr J Med** 1996 May;42(5):135–8

Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids. Kubiet MA, et al. **Chest** 1996 Aug;110(2):367–70

Early appearance of antibodies to simian immunodeficiency virus in saliva and serum of infected macaques. Meiller TF, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):489–91

Evaluation of two recombinant Maedi-visna virus proteins for use in an enzyme-linked immunosorbent assay for the detection of serum antibodies to ovine lentiviruses. Power C, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):631–3

Complement-dependent cytotoxic antibodies to human T lymphotropic virus type I (HTLV-I)-infected cells in the sera of HTLV-I-infected individuals. Plotnicky-Gilquin H, et al. **Clin Exp Immunol** 1996 Jul;105(1):39–45

High correlations of anti-CMV titers with lymphocyte activation status and CD57 antibody-binding capacity as estimated with three-color, quantitative flow cytometry in blood donors. Lenkei R, et al. **Clin Immunol Immunopathol** 1995 Nov;77(2):131–8

Viral antibodies in chronic fatigue syndrome [letter; comment] Swanink CM, et al. **Clin Infect Dis** 1995 Sep; 21(3):708–9. Comment on: Clin Infect Dis 1994 Sep;19(3):448–53.

Automatic image analysis of antibody assays to measles virus. Jordan MM, et al. **Comput Methods Programs Biomed** 1996 Jan;49(1):85–94

Serological responses in calves to vaccines against bovine respiratory syncytial, infectious bovine rhinotracheitis, bovine viral diarrhoea and parainfluenza-3 viruses. Tollis M, et al. **Dev Biol Stand** 1996;86:147–56

IgG avidity in the diagnosis of acute Ross River virus infection. Kapeleris J, et al. **Dis Markers** 1996 Mar; 12(4):279–82

Investigation of tick-borne viruses as pathogens of humans in South Africa and evidence of Dugbe virus infection in a patient with prolonged thrombocytopenia. Burt FJ, et al. **Epidemiol Infect** 1996 Jun;116(3):353–61

Seroprevalence of astrovirus types 1 and 6 in London, determined using recombinant virus antigen. Kriston S, et al. **Epidemiol Infect** 1996 Aug;117(1):159–64

A serosurvey of water-borne pathogens amongst canoeists in South Africa. Taylor MB, et al. **Epidemiol Infect** 1995 Oct;115(2):299–307

Antibodies to LMP2A/2B in EBV-carrying malignancies. Lennette ET, et al. **Eur J Cancer** 1995 Oct;31A(11):1875–8

Longitudinal study of cytomegalovirus antibodies in individuals infected with the human immunodeficiency virus. Flø RW, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):504–11

Epstein–Barr virus serology in patients with autoimmune thyroiditis. Vrbikova J, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):89–92

The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer. Fisher SG, et al. **Gynecol Oncol** 1996 Apr;61(1):73–8

Antibodies against tick-borne encephalitis virus (TBEV) non-structural and structural proteins in human sera and spinal fluid. Matveeva VA, et al. **Immunol Lett** 1995 May; 46(1–2):1–4

Relative superiority of c-ELISA for detection of bluetongue virus antibodies. Naresh A, et al. **Indian J Exp Biol** 1995 Nov;33(11):880–2

Rapid Dot enzyme immuno assay for the quantitation of rabies antibodies. Jayakumar R, et al. **Indian J Public Health** 1995 Jan–Mar;39(1):8–11

Serum respiratory virus antibodies: predictor of reduced one-second forced expiratory volume (FEV1) in Norwegian adults. Omenaas E, et al. **Int J Epidemiol** 1996 Feb;25(1):134–41

Prevalence of serum antibodies to Norwalk virus among Norwegian military recruits. Myrmel M, et al. **Int J Food Microbiol** 1996 Apr;29(2–3):233–40

Myelin- and microbe-specific antibodies in Guillain–Barré syndrome. Terryberry J, et al. **J Clin Lab Anal** 1995; 9(5):308–19

Enzyme-linked immunosorbent assay-based inhibition test for neutralizing antibodies to polioviruses as an alternative to the neutralization test in tissue culture. Edevåg G, et al. **J Clin Microbiol** 1995 Nov;33(11):2927–30

Evaluation of Cobas Core Rubella IgG EIA recomb, a new enzyme immunoassay based on recombinant rubella-like particles. Grangeot-Keros L, et al. **J Clin Microbiol** 1995 Sep;33(9):2392–4

Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay. Landini MP, et al. **J Clin Microbiol** 1995 Oct;33(10):2535–42

Immunoglobulin A-specific serodiagnosis of acute human cytomegalovirus infection by using recombinant viral antigens. Vornhagen R, et al. **J Clin Microbiol** 1996 Apr; 34(4):1020–3

Serum rotavirus neutralizing-antibody titers compared by plaque reduction and enzyme-linked immunosorbent assay-based neutralization assays. Ward RL, et al. **J Clin Microbiol** 1996 Apr;34(4):983–5

Comparison of two methods for detecting varicella-zoster virus antibody with varicella-zoster virus cell-mediated immunity. Weinberg A, et al. **J Clin Microbiol** 1996 Feb; 34(2):445–6

Serological evidence of DEN-2 activity in Assam and Nagaland. Barua HC, et al. **J Commun Dis** 1996 Mar; 28(1):56–8

Seroepidemiology of herpes virus infections among dental personnel. Herbert AM, et al. **J Dent** 1995 Dec; 23(6):339–42

A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. Rother RP, et al. **J Exp Med** 1995 Nov 1;182(5):1345–55

Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groups. Eisemann C, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1799–803

Low prevalence of antibodies to hepatitis C virus in patients with Hashimoto's thyroiditis [letter] Bisot-Locard S, et al. **J Hepatol** 1995 Aug;23(2):233–4

Hantavirus serologies in patients hospitalized with community-acquired pneumonia. Auwaerter PG, et al. **J Infect Dis** 1996 Jan;173(1):237–9

Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. Dillner J, et al. **J Infect Dis** 1996 Jun; 173(6):1394–8

Age, sex, and household exposure are associated with the acute measles-specific antibody-dependent cellular cytotoxicity antibody response. Forthal DN, et al. **J Infect Dis** 1995 Dec;172(6):1587–91

The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. Hussey GD, et al. **J Infect Dis** 1996 Jun;173(6):1320–6

Immunologic properties of Epstein–Barr virus-seronegative adults. Jabs WJ, et al. **J Infect Dis** 1996 May;173(5):1248–51

Prevalence of IgM antibodies to human herpesvirus 6 early antigen (p41/38) in patients with chronic fatigue syndrome [published erratum appears in J Infect Dis 1995 Dec;172(6):1643] Patnaik M, et al. **J Infect Dis** 1995 Nov; 172(5):1364–7

Detection of human serum antibodies to the BFRF3 Epstein–Barr virus capsid component by means of a DNA-binding assay. Shedd D, et al. **J Infect Dis** 1995 Nov;172(5):1367–70

Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19. Söderlund M, et al. **J Infect Dis** 1995 Dec;172(6):1431–6

Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. Treanor JJ, et al. **J Infect Dis** 1996 Jun; 173(6):1467–70

Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. von Poblotzki A, et al. **J Infect Dis** 1995 Nov;172(5):1356–9

Role of maternally derived circulating antibodies in protection of neonatal swine against porcine group A rotavirus. Ward LA, et al. **J Infect Dis** 1996 Aug; 174(2):276–82

Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia [see comments] Wideroff L, et al. **J Infect Dis** 1995 Dec;172(6):1425–30. Comment in: J Infect Dis 1996 Jul;174(1):237–9.

Antibody responses to two encephalomyocarditis virus

vaccines in rhesus macaques (Macaca mulatta). Emerson CL, et al. **J Med Primatol** 1996 Jan;25(1):42–5

Analysis of the human serological immune response to a variable region of the attachment (G) protein of respiratory syncytial virus during primary infection. Cane PA, et al. **J Med Virol** 1996 Mar;48(3):253–61

Antibody prevalence and immunoglobulin IgG subclass pattern to Norwalk virus in Sweden. Hinkula J, et al. **J Med Virol** 1995 Sep;47(1):52–7

Comparison of two immunoassay procedures for detecting enterovirus IgM. Hodgson J, et al. **J Med Virol** 1995 Sep; 47(1):29–34

Seroepidemiology of Inoue-Melnick virus in the general population of Buffalo, New York. Ito M. **J Med Virol** 1995 Sep;47(1):83–6

Study of Norwalk-related viruses in Mexican children. Jiang X, et al. **J Med Virol** 1995 Dec;47(4):309–16

IgM antibody detection of ppUL80A and ppUL32 by immunoblotting: an early parameter for recurrent cytomegalovirus infection in renal transplant recipients. Kraat YJ, et al. **J Med Virol** 1996 Mar;48(3):289–94

Comparison of coxsackie B neutralisation and enteroviral PCR in chronic fatigue patients. Nairn C, et al. **J Med Virol** 1995 Aug;46(4):310–3

"Cytomegalovirus disease" in renal allograft recipients: is human herpesvirus 7 a co-factor for disease progression? Osman HK, et al. **J Med Virol** 1996 Apr;48(4):295–301

Enzyme immunoassay using baculovirus-expressed human calicivirus (Mexico) for the measurement of IgG responses and determining its seroprevalence in London, UK. Parker SP, et al. **J Med Virol** 1995 Jul;46(3):194–200

Homotypic immune response to primary infection with rotavirus serotype G1. Rojas AM, et al. **J Med Virol** 1995 Dec;47(4):404–9

Absence of serological evidence for foamy virus infection in patients with amyotrophic lateral sclerosis. Rösener M, et al. **J Med Virol** 1996 Mar;48(3):222–6

Antibodies prevalence against HPV-6b and -16 recombinant fusion proteins in Korean patients with cervical neoplasia. Park SN, et al. **J Obstet Gynaecol** 1995 Dec;21(6):609–17

Immunity to hepatitis B, poliomyelitis and measles in fully vaccinated aboriginal and Torres Strait Island children. Hanna JN, et al. **J Paediatr Child Health** 1995 Aug; 31(4):345–9

Complement fixing antibodies to respiratory viruses in children in Jos, Nigeria. Karaivanova G, et al. **J Trop Pediatr** 1995 Dec;41(6):325–7

Prevalence of cattle persistently infected with bovine viral diarrhea virus in 20 dairy herds in two counties in central Michigan and comparison of prevalence of antibody-positive cattle among herds with different infection and vaccination status. Houe H, et al. **J Vet Diagn Invest** 1995 Jul;7(3):321–6

Application of antibody titers against bovine viral diarrhea virus (BVDV) as a measure to detect herds with cattle persistently infected with BVDV. Houe H, et al. **J Vet Diagn Invest** 1995 Jul;7(3):327–32

Low prevalence of antibodies to bluetongue and epizootic hemorrhagic disease viruses in dogs from southern Georgia. Howerth EW, et al. **J Vet Diagn Invest** 1995 Jul;7(3):393–4

Evaluation of an indirect fluorescent IgM antibody test for the detection of pigs with recent infection of porcine reproductive and respiratory syndrome virus. Park BK, et al. **J Vet Diagn Invest** 1995 Oct;7(4):544–6

Failure to consider the antigenic diversity of porcine reproductive and respiratory syndrome (PRRS) virus isolates may lead to misdiagnosis. Yoon KJ, et al. **J Vet Diagn Invest** 1995 Jul;7(3):386–7

A serological study on infection patterns, control and persistence of classical swine fever in infected farms in the Philippines. Geerts P, et al. **J Vet Med Sci** 1995 Oct; 57(5):917–20

Serological survey of canine distemper virus infection using enzyme-linked immunosorbent assay. Gemma T, et al. **J Vet Med Sci** 1995 Aug;57(4):761–3

Quantification of feline immunodeficiency virus (FIV) proviral DNA in peripheral blood mononuclear cells of cats infected with Japanese strains of FIV. Inoshima Y, et al. **J Vet Med Sci** 1995 Jun;57(3):487–92

Biphasic immune responses of cats under controlled infection with a feline enteric coronavirus-79-1683 strain. Kai K, et al. **J Vet Med Sci** 1995 Aug;57(4):781–3

Prevalence of antibodies to type A influenza viruses in swine sera 1990–1994. Katsuda K, et al. **J Vet Med Sci** 1995 Aug; 57(4):773–5

Efficacy of subcutaneous application of live infectious bursal disease vaccine in young chickens with maternally derived antibody. Komine KI, et al. **J Vet Med Sci** 1995 Aug; 57(4):647–53

A retrospective serological survey of the encephalomyocarditis virus among pigs in Chiba prefecture, Japan. Kudo H, et al. **J Vet Med Sci** 1995 Aug; 57(4):793–5

Distribution of antibodies to influenza A virus in chickens in Japan. Otsuki K, et al. **J Vet Med Sci** 1995 Dec; 57(6):1063–6

Detection of sheep-associated malignant catarrhal fever virus antibodies by complement fixation tests. Sentsui H, et al. **J Vet Med Sci** 1996 Jan;58(1):1–5

Antibodies against hepatitis E virus in Old World monkeys. Arankalle VA, et al. **J Viral Hepat** 1994;1(2):125–9

Raised levels of antibodies to human viruses at the clinical onset of autoimmune chronic active hepatitis. Kalvenes MB, et al. **J Viral Hepat** 1995;2(3):159–64

Locations of herpes simplex virus type 2 glycoprotein B epitopes recognized by human serum immunoglobulin G antibodies. Goade DE, et al. **J Virol** 1996 May;70(5):2950–6

Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies. Matteucci D, et al. **J Virol** 1996 Jan;70(1):617–22

Evaluation of 4 commercial test kits for parvovirus B19-specific IgM. Cohen BJ, et al. **J Virol Methods** 1995 Sep;55(1):11–25

Determination of the concentration of influenza virus antihaemagglutinin antibody molecules of the IgG class and of the equilibrium constant by use of enzyme immunoassay titres determined for graded epitope concentrations. Drescher J, et al. **J Virol Methods** 1995 Oct;55(2):257–70

A synthetic parvovirus B19 capsid protein can replace viral antigen in antibody-capture enzyme immunoassays. Kock WC. **J Virol Methods** 1995 Sep;55(1):67–82

Detection of human coronavirus 229E-specific antibodies using recombinant fusion proteins. Pohl-Koppe A, et al. **J Virol Methods** 1995 Oct;55(2):175–83

Competitive ELISA for the detection of antibodies against epizootic haemorrhagic disease of deer virus. Thevasagayam JA, et al. **J Virol Methods** 1995 Nov; 55(3):417–25

Application of a competitive ELISA for the detection of bluetongue virus antibodies in llamas and wild ruminants. Afshar A, et al. **J Wildl Dis** 1995 Jul;31(3):327–30

Antibodies to St. Louis encephalitis virus in armadillos from southern Florida. Day JF, et al. **J Wildl Dis** 1995 Jan; 31(1):10–4

Bovine virus diarrhea and mucosal disease in free-ranging and captive deer (Cervidae) in Germany. Frölich K. **J Wildl Dis** 1995 Apr;31(2):247–50

Ockelbo virus (Togaviridae: Alphavirus) neutralizing antibodies in experimentally infected Swedish birds. Lundström JO, et al. **J Wildl Dis** 1996 Jan;32(1):87–93

Serological survey for avian paramyxoviruses from wildfowl in aquatic habitats in Andalusia. Maldonado A, et al. **J Wildl Dis** 1995 Jan;31(1):66–9

Lyssavirus in Eptesicus serotinus (Chiroptera: Vespertilionidae). Pérez-Jordá JL, et al. **J Wildl Dis** 1995 Jul;31(3):372–7

Serologic survey of neotropical bats in Guatemala for virus antibodies. Ubico SR, et al. **J Wildl Dis** 1995 Jan;31(1):1–9

Enzyme-linked immunosorbent assay for detection of antibody to lymphocytic choriomeningitis virus in mouse sera, with recombinant nucleoprotein as antigen. Homberger FR, et al. **Lab Anim Sci** 1995 Oct;45(5):493–6

Detection of Ebola-Reston (Filoviridae) virus antibody by dot-immunobinding assay. Kalter SS, et al. **Lab Anim Sci** 1995 Oct;45(5):523–5

Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs. Robuccio JA, et al. **Lab Anim Sci** 1995 Aug;45(4):420–6

Hantaan and Puumala virus antibodies in blood donors in Samara, an HFRS-endemic region in European Russia [letter] Alexeyev OA, et al. **Lancet** 1996 May 25; 347(9013):1483

IgM-specific measles-virus antibody in families with a high frequency of Crohn's disease [letter] Touze I, et al. **Lancet** 1995 Oct 7;346(8980):967

Vaccine-associated paralytic poliomyelitis [letter; comment] Catton M, et al. **Med J Aust** 1996 Feb 19;164(4):255–6. Comment on: Med J Aust 1995 Oct 16;163(8):423–4.

Absence of antibody-dependent enhancement (ADE) of viral infectivity in the epidemic neuropathy in Cuba. Guzmán MG, et al. **Mem Inst Oswaldo Cruz** 1995 Jul–Aug; 90(4):523–4

Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. Gao SJ, et al. **N Engl J Med** 1996 Jul 25;335(4):233–41

Testing for antibodies in Kaposi's sarcoma [letter] Martin JN, et al. **N Engl J Med** 1996 Sep 12;335(11):819; discussion 819–20

Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. Miller G, et al. **N Engl J Med** 1996 May 16; 334(20):1292–7

IgM antibody response to hepatitis C virus in end-stage renal disease. Fabrizi F, et al. **Nephrol Dial Transplant** 1996 Feb; 11(2):314–8

Prevalence of antibodies to human herpesviruses 6 and 7 in early infancy and age at primary infection. Cermelli C, et al. **New Microbiol** 1996 Jan;19(1):1–8

Detection of immunoglobulin G to a Sindbis-related virus by a membrane antigen enzyme immunoassay. Scalia G, et al. **New Microbiol** 1996 Jan;19(1):91–6

Anti-HCMV serologic response in patients with acute viral hepatitis. Stivala A, et al. **New Microbiol** 1995 Oct; 18(4):423–6

Occupational exposure to poultry and prevalence of antibodies against Marek's disease virus and avian leukosis retroviruses. Choudat D, et al. **Occup Environ Med** 1996 Jun;53(6):403–10

Epidemiology of African horsesickness: antibodies in free-living elephants (Loxodonta africans) and their response to experimental infection. Barnard BJ, et al. **Onderstepoort J Vet Res** 1995 Dec;62(4):271–5

Detection of bovine-virus-diarrhoea-virus antibodies in cattle with an enzyme-linked immunosorbent assay. Muvavarirwa P, et al. **Onderstepoort J Vet Res** 1995 Dec; 62(4):241–4

The use of sucrose-acetone-extracted Rift Valley fever virus antigen derived from cell culture in an indirect enzyme-linked immunosorbent assay and haemagglutination-inhibition test. Paweska JT, et al. **Onderstepoort J Vet Res** 1995 Dec;62(4):227–33

Influence of high titers of maternal antibody on the serologic response of infants to diphtheria vaccination at three, five and twelve months of age. Björkholm B, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):846–50

Decay of maternally derived measles antibody in a highly vaccinated population in southern Israel. Dagan R, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):965–9

Symptomatic hepatitis A virus infection during the first year of life. Linder N, et al. **Pediatr Infect Dis J** 1995 Jul; 14(7):628–9

Detection of IgM antibodies to human herpesvirus 6 in Romanian children with nonprogressive human immunodeficiency virus disease. Nigro G, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):891–4

Immune response to influenza vaccination in children with renal disease. Furth SL, et al. **Pediatr Nephrol** 1995 Oct; 9(5):566–8

Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Markowitz LE, et al. **Pediatrics** 1996 Jan;97(1):53–8

Enzyme linked immunosorbent assay for rubella antibodies: a simple method of antigen production. A preliminary report. de Souza VA, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jul–Aug;37(4):357–9

Studies on human anti-rabies immunization in Brazil. II—Preliminary evaluation of the 2-1-1 schedule for human pre-exposure anti-rabies immunization, employing suckling mouse brain vaccine. Zanetti CR, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jul–Aug;37(4):353–6

Serological study of pigs for antibody against African swine fever virus in two areas of southern Malawi. Allaway EC, et al. **Rev Sci Tech** 1995 Sep;14(3):667–76

Antibodies to HCV and HTLV-I in a group of HIV-seropositive STD patients [letter] van der Ryst E, et al. **S Afr Med J** 1995 Aug;85(8):792

Reports bolster viral cause of KS [news] Cohen J. **Science** 1996 Aug 2;273(5275):573

Serum hepatitis C virus (HCV) RNA: a reliable tool for evaluating HCV-related liver disease in anti-HCV-positive blood donors with persistently normal alanine aminotransferase values. Nalpas B, et al. **Transfusion** 1995 Sep;35(9):750–3

Definitions of cytomegalovirus disease after heart transplantation: antigenemia as a marker for antiviral therapy. Iberer F, et al. **Transpl Int** 1996;9(3):236–42

Increased late rejection in cytomegalovirus-immunoglobulin-M-positive heart transplantation patients. Bunke M, et al. **Transplant Proc** 1995 Oct;27(5 Suppl 1):44–5

Early diagnosis of CMV syndrome after kidney transplantation: comparison between CMV antigenemia and PCR assay. Tanabe K, et al. **Transplant Proc** 1996 Jun; 28(3):1508–10

Varicella vaccine in children requiring renal or hepatic transplantation. Giacchino R, et al. **Transplantation** 1995 Nov 15;60(9):1055–6

Occurrence of haemagglutination-inhibition antibodies against egg drop syndrome 1976 virus in broilers. Singh JK, et al. **Trop Anim Health Prod** 1995 Aug;27(3):167–70

Reducing the cost of HIV-testing through use of the IgG antibody captured particle adherence test (GACPAT) in district hospitals. Klokke AH, et al. **Trop Geogr Med** 1995; 47(6):296–9

Susceptibility to rubella infection in females at high risk. Immune protection associated to population density. Yamamoto L, et al. **Trop Geogr Med** 1995;47(6):235–8

Measles, mumps, and rubella antibodies in children 5–6 years after immunization: effect of vaccine type and age at vaccination. Boulianne N, et al. **Vaccine** 1995 Nov; 13(16):1611–6

Cross-reaction but no avidity change of the serum antibody response after influenza vaccination. Brokstad KA, et al. **Vaccine** 1995 Nov;13(16):1522–8

Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Davidkin I, et al. **Vaccine** 1995 Nov;13(16):1617–22

Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Miller E, et al. **Vaccine** 1995 Jun;13(9):799–802

Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Piedra PA, et al. **Vaccine** 1995 Aug; 13(12):1095–101

Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Pittman PR, et al. **Vaccine** 1996 Mar;14(4):337–43

Maintenance of high virus load even after seroconversion in newborn cats acutely infected with feline immunodeficiency virus. Tokunaga K, et al. **Vaccine** 1995;

13(15):1393–8
Vaccination against tick-borne encephalitis (TBE): influence of simultaneous application of TBE immunoglobulin on seroconversion and rate of adverse events. von Hedenström M, et al. **Vaccine** 1995;13(8):759–62
Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. US Rotavirus Vaccine Efficacy Group. Ward RL, et al. **Vaccine** 1995 Sep;13(13):1226–32
African horse sickness and African carnivores. Alexander KA, et al. **Vet Microbiol** 1995 Nov;47(1–2):133–40
Immune responses of the camel (Camelus dromedarius) to contagious ecthyma (Orf) virus infection. Azwai SM, et al. **Vet Microbiol** 1995 Nov;47(1–2):119–31
Comparison of native and subunit antigens as ELISA reagents for the detection of antibodies against scabby mouth virus. Chin JC, et al. **Vet Microbiol** 1995 Sep; 46(1–3):327–34
Prevalence of neutralizing antibodies to 9 rotavirus strains representing 7 G-serotypes in sheep sera. Muñoz M, et al. **Vet Microbiol** 1995 Aug;45(4):351–61
Comparison of a commercial ELISA and an immunoperoxidase monolayer assay to detect antibodies directed against porcine respiratory and reproductive syndrome virus. Nodelijk G, et al. **Vet Microbiol** 1996 Apr; 49(3–4):285–95
Selective humoral immune response of Balb/C mice to Brucella abortus proteins expressed by vaccinia virus recombinants. Toth TE, et al. **Vet Microbiol** 1995 Jul; 45(2–3):171–83
High molecular weight polypeptide bands specific for equine herpesvirus 4. Zheng M, et al. **Vet Microbiol** 1995 Sep; 46(1–3):203–11
Estimating sample sizes for a two-stage sampling survey of seroprevalence of pseudorabies virus (PRV)-infected swine at a regional level in The Netherlands. Elbers AR, et al. **Vet Q** 1995 Sep;17(3):92–5
Serological survey for orthopoxvirus infection of wild mammals in areas where a recombinant rabies virus is used to vaccinate foxes. Boulanger D, et al. **Vet Rec** 1996 Mar 16;138(11):247–9
Serological evidence for the presence of A/equine-1 influenza virus in unvaccinated horses in Croatia. Madić J, et al. **Vet Rec** 1996 Jan 20;138(3):68
Newcastle disease viruses in birds in the Atlantic flyway: isolations, haemagglutination-inhibition and elution-inhibition antibody profiles. Graves IL. **Vet Res** 1996;27(3):209–18
Neutralization enzyme-linked immunosorbent assay for evaluation of immunity to measles virus. Nates SV, et al. **Viral Immunol** 1995;8(1):47–52
Serum antibodies to HPV 16 virus-like particles are not associated with penile cancer in Chinese males. Wideroff L, et al. **Viral Immunol** 1996;9(1):23–5
Pattern of infection with the porcine reproductive and respiratory syndrome virus on swine farms in Belgium. Houben S, et al. **Zentralbl Veterinarmed [B]** 1995 Jun; 42(4):209–15
Detection of antibodies to rabbit haemorrhagic disease virus: an immunoblotting method using virus-coated human erythrocyte membranes. Ruvoen-Clouet N, et al. **Zentralbl Veterinarmed [B]** 1995 Jun;42(4):197–204
[Comparison between the plaque reduction neutralization test and the hemagglutination inhibition test in determination of human anti-measles antibodies] Kong J, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Apr; 17(2):105–7 (Eng. Abstr.) **(Chi)**
[A study on the level of antibody against measles through maternal-fetal transfer and the immuno-response to measles vaccine among 4 to 7 month olds] Liu BY, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1995 Oct; 16(5):263–5 (Eng. Abstr.) **(Chi)**
[Surveillance of levels of neutralizing antibodies against poliovirus among children aged 0–3 in rural areas of Anhui Province] Shen Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):335–8 (Eng. Abstr.) **(Chi)**
[Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx] Mazeron MC. **Bull Cancer Radiother** 1996;83(1):3–7 (29 ref.) (Eng. Abstr.) **(Fre)**
[Post-vaccination anti-poliomyelitis seroprevalence in an urban setting in Abidjan] Akoua-Koffi G, et al. **Bull Soc Pathol Exot** 1995;88(3):117–20 (Eng. Abstr.) **(Fre)**
[Residual risks of viral transmission by transfusions and projected yields of additional screening tests. Retrovirus Epidemiology Donors Study (REDS)] Busch MP. **Transfus Clin Biol** 1996;3(1):7–11 (Eng. Abstr.) **(Fre)**
[Estimation of risk of virus transmission in hepatitis B and C and human retrovirus via transfusion of labile blood derivatives] Couroucé AM, et al. **Transfus Clin Biol** 1996; 3(1):13–8 (Eng. Abstr.) **(Fre)**
[Comparative studies of maedi-visna diagnosis: immunodiffusion test, enzyme immunoassay, immunoblot] Starick E, et al. **Berl Munch Tierarztl Wochenschr** 1995 Apr;108(4):138–42 (Eng. Abstr.) **(Ger)**
[Serologic investigations on the occurrence of Maedi-Visna antibodies in game ruminants] Starick E, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 May;102(5):202–3 (Eng. Abstr.) **(Ger)**
[Specific serologic studies with a novel authentic HPV antigen (virus-like particles) for HPV-6 antibodies in gynecologic patient samples] Heim K, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:25–31 (Eng. Abstr.) **(Ger)**
[Detection of serum IgA antibodies to varicella zoster virus (VZV)—differential etiology of peripheral facial paralysis. A case report] May G, et al. **Laryngorhinootologie** 1995 Sep;74(9):553–4 (Eng. Abstr.) **(Ger)**
[The status in wild and zoo birds of antibodies to selected agents relevant to domestic animals] Ziedler K, et al. **Zentralbl Veterinarmed [B]** 1995 Aug;42(6):321–30 (Eng. Abstr.) **(Ger)**
[Poliomyelitis surveillance: seroepidemiologic study on a Piedmont population sample] Maiello A, et al. **Ann Ist Super Sanita** 1995;31(3):317–22 (Eng. Abstr.) **(Ita)**
[Immunological determinants and the spread of viral infection in facial nerve paralysis induced by herpes simplex virus in mice] Hato N. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Apr;99(4):544–51 (Eng. Abstr.) **(Jpn)**
[False-positive ELISA reactions for the hepatitis C virus and the human immunodeficiency virus after anti-influenzal vaccination] Ioniță E, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul-Dec; 40(3–4):249–52 (Eng. Abstr.) **(Rum)**
[The circulation of the California encephalitis complex and Batai viruses in the Lake Baikal region (serological research data)] Chaporgina EA, et al. **Med Parazitol (Mosk)** 1995 Oct-Dec;(4):56–60 (Eng. Abstr.) **(Rus)**
[Correlation of MMTV antibody expression and risk factors of human breast cancer] Riabykh TP, et al. **Vopr Onkol** 1996;42(2):40–5 (Eng. Abstr.) **(Rus)**
[Measles seroprevalence in the schoolchildren of Valencia. The Measles Study Group] Diez Domingo J, et al. **Med Clin (Barc)** 1995 Oct 21;105(13):487–90 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Intrathecal synthesis of antibodies to human herpesvirus 6 early antigen in patients with meningitis/encephalitis [letter] Patnaik M, et al. **Clin Infect Dis** 1995 Sep; 21(3):715–6
Antibodies against tick-borne encephalitis virus (TBEV) non-structural and structural proteins in human sera and spinal fluid. Matveeva VA, et al. **Immunol Lett** 1995 May; 46(1–2):1–4

CHEMISTRY

Monoclonal antibodies that distinguish between encephalitogenic bovine herpesvirus type 1.3 and respiratory bovine herpesvirus type 1.1. Chung CS, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):83–8
Peptide sequences of glycoprotein G-2 discriminate between herpes simplex virus type 2 (HSV-2) and HSV-1 antibodies. Levi M, et al. **Clin Diagn Lab Immunol** 1996 May;3(3):265–9
Structure of a neutralizing antibody bound bivalently to human rhinovirus 2. Hewat EA, et al. **EMBO J** 1996 Apr 1;15(7):1515–23
Variable domain sequences of mAb with high affinity for a linear oligopeptide. Hanke T, et al. **Immunogenetics** 1995; 42(5):442–3
Assessment of variation in trypsin-sensitive neutralizable antigenic site of type O foot-and-mouth disease virus (FMDV) isolates using a Mab-binding inhibition assay [letter] Pattnaik B, et al. **J Immunol Methods** 1996 Jun 10; 192(1–2):191–3
Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence. Rasmussen M, et al. **J Immunol Methods** 1996 Jan 16; 189(1):47–58
Induced pocket to accommodate the cell attachment Arg-Gly-Asp motif in a neutralizing antibody against foot-and-mouth-disease virus. Verdaguer N, et al. **J Mol Biol** 1996 Feb 23;256(2):364–76
Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon. Smith TJ, et al. **Nature** 1996 Sep 26;383(6598):350–4
Docking of a human rhinovirus neutralizing antibody onto the viral capsid. Tormo J, et al. **Proteins** 1995 Dec; 23(4):491–501
Loss of Gag-specific antibody reactivity in cattle experimentally infected with bovine immunodeficiency-like virus. Isaacson JA, et al. **Viral Immunol** 1995;8(1):27–36

DIAGNOSTIC USE

[Anti-idiotypic antibodies as vaccinal and diagnostic preparations in viral infections] Tarasishin LA. **Mikrobiol Z** 1996 Jan-Feb;58(1):97–105 (30 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Vaccine immune response and side effects with the use of acetaminophen with influenza vaccine. Gross PA, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):134–8

GENETICS

Generation of diversity in a human anti-viral response. Rioux JD, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:381–3
Nucleocapsid protein N of Lelystad virus: expression by recombinant baculovirus, immunological properties, and suitability for detection of serum antibodies. Meulenberg JJ, et al. **Clin Diagn Lab Immunol** 1995 Nov;2(6):652–6
Bacterial expression of neutralizing mouse monoclonal antibody Fab fragments to Hantaan virus. Liang M, et al. **Virology** 1996 Mar 1;217(1):262–71

IMMUNOLOGY

A prospective study of antibodies against parvovirus B19 in pregnancy. Skjöldebrand-Sparre L, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):336–9
New functions for mucosal IgA. Lamm ME, et al. **Adv Exp Med Biol** 1995;371A:647–50
Intracellular neutralization of Sendai and influenza viruses by IgA monoclonal antibodies. Mazanec MB, et al. **Adv Exp Med Biol** 1995;371A:651–4
Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. Montefiori DC, et al. **AIDS Res Hum Retroviruses** 1995 Aug;11(8):963–70
Rubella immunity. Defining the level of protective antibody. Skendzel LP. **Am J Clin Pathol** 1996 Aug;106(2):170–4 (39 ref.)
Hantavirus antigen detection using human serum immunoglobulin M as the capturing antibody in an enzyme-linked immunosorbent assay. Alexeyev OA, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):367–71
Cross-reactive, serotype- and monotype-specific neutralization epitopes on VP7 of serotype G3 and G5 porcine rotavirus strains. Ciarlet M, et al. **Arch Virol** 1996; 141(3–4):601–14
Antigenic relationships of hantavirus strains analysed by monoclonal antibodies. Dzagurova T, et al. **Arch Virol** 1995;140(10):1763–73
Induction of protective antibody responses against pseudorabies virus by intranasal vaccination with glycoprotein B in mice. Takada A, et al. **Arch Virol** 1995; 140(9):1629–35
Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Jahrling PB, et al. **Arch Virol Suppl** 1996;11:135–40
The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease. Kitching RP, et al. **Br Vet J** 1995 Jul-Aug; 151(4):379–89 (40 ref.)
Evidence for an antiviral effect and interferon neutralizing capacity in human sera; variability and implications for HIV infection. Fall LS, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):409–16
Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies. Gimenez HB, et al. **Clin Diagn Lab Immunol** 1996 May;3(3):280–6
Determination of varicella-zoster virus (VZV) immune status with the VIDAS VZV immunoglobulin G automated immunoassay and the VZVScan latex agglutination assay. Gleaves CA, et al. **Clin Diagn Lab Immunol** 1996 May; 3(3):365–7
Epitope-specific antibody response against glycoprotein E of pseudorabies virus. Jacobs L, et al. **Clin Diagn Lab Immunol** 1994 Sep;1(5):500–5
Respiratory syncytial virus group-specific antibody response in nasopharyngeal secretions from infants and children after primary infection. Yamazaki H, et al. **Clin Diagn Lab Immunol** 1994 Jul;1(4):469–72
Measles vaccination policy. Williams BG, et al. **Epidemiol Infect** 1995 Dec;115(3):603–21
Failure of vaccination to prevent outbreaks of foot-and-mouth disease. Woolhouse ME, et al. **Epidemiol Infect** 1996 Jun;116(3):363–71
Generation of a human monoclonal antibody to hepatitis C virus, JRA1 by activation of peripheral blood lymphocytes and hypo-osmolar electrofusion. Zimmermann U, et al. **Hum Antibodies Hybridomas** 1995;6(2):77–80
Serological response to HPV16 in CIN-III and cervical cancer patients. Case-control studies in Spain and Colombia. De Sanjosé S, et al. **Int J Cancer** 1996 Mar 28; 66(1):70–4
Failure of immune sera to neutralize dengue-2 virus in intrathoracically inoculated Aedes aegypti. Putnam JL, et al. **J Am Mosq Control Assoc** 1995 Sep;11(3):372–4
Evaluation of an enterovirus group-specific anti-VP1 monoclonal antibody, 5-D8/1, in comparison with neutralization and PCR for rapid identification of enteroviruses in cell culture. Trabelsi A, et al. **J Clin Microbiol** 1995 Sep;33(9):2454–7
A protective anti-peptide antibody against the immunodominant site of the A24 Cruzeiro strain of foot-and-mouth disease virus and its reactivity with other subtype viruses containing the same minimum binding sequence. Barnett PV, et al. **J Gen Virol** 1996 May;77 (Pt 5):1011–8
Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. Gaukroger JM, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1577–83
Comparison of equine arteritis virus isolates using neutralizing monoclonal antibodies and identification of sequence changes in GL associated with neutralization resistance. Glaser AL, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2223–33

Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies. Grund CH, et al. **J Gen Virol** 1996 Mar; 77 (Pt 3):435–42

Antibody and host cell recognition of foot-and-mouth disease virus (serotype C) cleaved at the Arg-Gly-Asp (RGD) motif: a structural interpretation. Hernández J, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):257–64

Monoclonal antibodies raised against infectious haematopoietic necrosis virus (IHNV) G protein and a cellular 90 kDa protein neutralize IHNV infection in vitro. Lee JY, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1731–7

Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. Urban M, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1537–47

Characterization of the nucleocapsid protein of Hantaan virus strain 76–118 using monoclonal antibodies. Yoshimatsu K, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):695–704

Neutralization of human cytomegalovirus by human CD13-specific antibodies. Giugni TD, et al. **J Infect Dis** 1996 May;173(5):1062–71

Evaluation of subgroup-specific peptides of the G protein of respiratory syncytial virus for characterization of the immune response. Akerlind-Stopner B, et al. **J Med Virol** 1995 Oct;47(2):120–5

Synthetic peptides deduced from the amino acid sequence of Epstein-Barr virus nuclear antigen 6 (EBNA 6): antigenic properties, production of monoreactive reagents, and analysis of antibody responses in man. Falk K, et al. **J Med Virol** 1995 Aug;46(4):349–57

Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: evidence for primary or secondary humoral responses depending on donor immune status. Lutz E, et al. **J Med Virol** 1996 May;49(1):61–5

Virus-specific, antibody-secreting cells during upper respiratory infections. Mäkelä MJ, et al. **J Med Virol** 1995 Dec;47(4):416–20

Circulating immunoglobulin G can play a critical role in clearance of intestinal reovirus infection. Barkon ML, et al. **J Virol** 1996 Feb;70(2):1109–16

In vivo blockade of gamma interferon affects the influenza virus-induced humoral and the local cellular immune response in lung tissue. Baumgarth N, et al. **J Virol** 1996 Jul;70(7):4411–8

A bispecific antibody recognizing influenza A virus M2 protein redirects effector cells to inhibit virus replication in vitro. Fernandez-Sesma A, et al. **J Virol** 1996 Jul; 70(7):4800–4

Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. Ludmerer SW, et al. **J Virol** 1996 Jul;70(7):4791–4

Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. Moore JP, et al. **J Virol** 1996 Mar; 70(3):1863–72

Application of a monoclonal antibody recognizing protein p30 to detect African swine fever virus-infected cells in peripheral blood. Ramiro-Ibáñez F, et al. **J Virol Methods** 1995 Nov;55(3):339–45

Monoclonal antibody blocking tests for the detection of HSV-1- and HSV-2-specific humoral responses: comparison with western blot assay. Slomka MJ, et al. **J Virol Methods** 1995 Sep;55(1):27–35

The humoral immune response of children and infants to an RSV infection: its maturation and association with illness. Forster J, et al. **Klin Padiatr** 1995 Nov-Dec; 207(6):313–6

Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Ohlin M, et al. **Mol Immunol** 1996 Jan;33(1):47–56

Examination of variables affecting syncytium formation by, and serum neutralization of, feline immunodeficiency virus on CrFK cells. Bandecchi P, et al. **New Microbiol** 1995 Jul;18(3):241–52

A cotton rat model of effectors of immunity to respiratory syncytial virus other than serum antibody. Piazza FM, et al. **Pediatr Pulmonol** 1995 Jun;19(6):355–9

Role of T-cells, virus neutralising antibodies and complement-mediated antibody lysis in the immune response against equine herpesvirus type-1 (EHV-1) infection of C3H (H-2k) and BALB/c (H-2d) mice. Alber DG, et al. **Res Vet Sci** 1995 Nov;59(3):205–13

Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity [see comments] Burns JW, et al. **Science** 1996 Apr 5;272(5258):104–7. Comment in: Science 1996 Apr 5;272(5258):46–8.

Cross-reaction but no avidity change of the serum antibody response after influenza vaccination. Brokstad KA, et al. **Vaccine** 1995 Nov;13(16):1522–8

Serologic comparison of four isolates of rabbit hemorrhagic disease virus. Berninger ML, et al. **Vet Microbiol** 1995 Nov; 47(1-2):157–65

Antibodies specific for channel catfish virus cross-react with Pacific oyster, Crassostrea gigas, herpes-like virus. Le Deuff RM, et al. **Vet Res** 1995;26(5-6):526–9

Antibody-dependent enhancement (ADE) of porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs. Yoon KJ, et al. **Viral Immunol** 1996; 9(1):51–63

Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly. Hughey PG, et al. **Virology** 1995 Oct 1;212(2):411–21

Effector functions of antibody and CD8+ cells in resolution of rotavirus infection and protection against reinfection in mice. McNeal MM, et al. **Virology** 1995 Dec 20; 214(2):387–97

Variability of herpes simplex virus 1 gL and anti-gL antibodies that inhibit cell fusion but not viral infectivity. Novotny MJ, et al. **Virology** 1996 Jul 1;221(1):1–13

Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV. Sanna PP, et al. **Virology** 1996 Jan 1; 215(1):101–6

Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Schoppel K, et al. **Virology** 1996 Feb 1; 216(1):133–45

Cucumber mosaic cucumovirus antibodies from a synthetic phage display library. Ziegler A, et al. **Virology** 1995 Dec 1;214(1):235–8

Antigenicity of the rabbit hemorrhagic disease virus studied by its reactivity with monoclonal antibodies. Capucci L, et al. **Virus Res** 1995 Aug;37(3):221–38

Characterization of monoclonal antibodies recognizing neurotropic Friend murine leukemia virus. Ikeda T, et al. **Virus Res** 1995 Oct;38(2-3):297–304

Antibody recognition of picornaviruses and escape from neutralization: a structural view. Mateu MG. **Virus Res** 1995 Sep;38(1):1–24 (161 ref.)

Epitope mapping of cross-reactive monoclonal antibodies specific for the influenza A virus PA and PB2 polypeptides. Ochoa M, et al. **Virus Res** 1995 Aug;37(3):305–15

Preparation of monoclonal antibodies against Marek's disease virus serotype 1 glycoprotein D expressed by a recombinant baculovirus. Ono M, et al. **Virus Res** 1995 Oct;38(2-3):219–30

Characterization of monoclonal antibodies recognizing amino- and carboxy-terminal epitopes of the herpes simplex virus UL42 protein. Sheaffer AK, et al. **Virus Res** 1995 Oct;38(2-3):305–14

Virus-neutralization domains on the oligomeric (230 kDa) forms of antigen B of herpesvirus of turkeys and Marek's disease virus differ in cross-serotypic activity. Davidson I, et al. **Zentralbl Veterinarmed [B]** 1995 Apr;42(2):100–9

[Antibody activity before polio vaccination] Müller HE. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):539 (Ger)

[Anti-idiotypic antibodies as vaccinal and diagnostic preparations in viral infections] Tarasishin LA. **Mikrobiol Z** 1996 Jan-Feb;58(1):97-105 (30 ref.) (Eng. Abstr.) (Rus)

[Cellular and humoral immunity in measles] Iuminova NV. **Vopr Virusol** 1996 Mar-Apr;41(2):81–4 (Rus)

[Prevalence of rubella virus antibodies in pregnant women in two zones of Valle de Mexico] Bustamante-Calvillo ME, et al. **Ginecol Obstet Mex** 1996 Mar;64:114–6 (Eng. Abstr.) (Spa)

ISOLATION & PURIFICATION

A long term study of goats naturally infected with caprine arthritis-encephalitis virus. Hanson J, et al. **Acta Vet Scand** 1996;37(1):31–9

Distribution of age-specific rotavirus antibody in human: a hospital-based study in Calcutta. Saha MR, et al. **J Indian Med Assoc** 1995 Aug;93(8):295–6, 290

Is HIV the cause of AIDS? [letter] Duesberg PH. **Lancet** 1995 Nov 18;346(8986):1371–2

Preparation of serotype specific antiserum against porcine adenoviruses in mice. Kadoi K. **New Microbiol** 1996 Apr; 19(2):179–82

METABOLISM

Long-term sequential changes of antibody to p40tax in HTLV-I carrier mothers and children. Kusuhara K, et al. **Acta Paediatr Jpn** 1995 Oct;37(5):651–3

Docking of a human rhinovirus neutralizing antibody onto the viral capsid. Tormo J, et al. **Proteins** 1995 Dec; 23(4):491–501

Antibody-enhanced binding of dengue-2 virus to human platelets. Wang S, et al. **Virology** 1995 Oct 20;213(1):254–7

PHARMACOLOGY

Selective cytotoxicity towards cytomegalovirus-infected cells by immunotoxins consisting of gelonin linked to anti-cytomegalovirus antibody. Barnett BB, et al. **Antiviral Res** 1995 Sep;28(1):93–100

Neutrophil deactivation by influenza A viruses: mechanisms of protection after viral opsonization with collectins and hemagglutination-inhibiting antibodies. Hartshorn KL, et al. **Blood** 1996 Apr 15;87(8):3450–61

Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. Poignard P, et al. **J Exp Med** 1996 Feb 1; 183(2):473–84

PHYSIOLOGY

[Significance of the functional activity of antibodies in influenza immunity] Naĭkhin AN, et al. **Vestn Ross Akad Med Nauk** 1995;(9):32–6 (Eng. Abstr.) (Rus)

THERAPEUTIC USE

Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Aguado JM, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1643–5

Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Taylor G, et al. **Biochem Soc Trans** 1995 Nov;23(4):1063–7 (24 ref.)

Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection. Pope M, et al. **J Immunol** 1996 May 1;156(9):3342–9

Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs. Bravo FJ, et al. **J Infect Dis** 1996 Jan;173(1):1–6

IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. Ishizaka ST, et al. **J Infect Dis** 1995 Oct;172(4):1108–11

The role of antibody in the treatment of acute herpes simplex virus disease and in the pathogenesis of latency in newborn guinea pigs [letter] Tenser RB. **J Infect Dis** 1996 Sep; 174(3):667–8

Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. Weltzin R, et al. **J Infect Dis** 1996 Aug;174(2):256–61

Antiviral antibodies in transplantation. Snydman DR. **Transplant Proc** 1995 Oct;27(5 Suppl 1):10–2 (22 ref.)

Cytomegalovirus hyperimmune globulin for CMV disease refractory to ganciclovir in renal transplantation. Waid TH, et al. **Transplant Proc** 1995 Oct;27(5 Suppl 1):46

URINE

Evaluation of antigen and antibody detection in urine specimens from children with congenital human cytomegalovirus infection. Koopmans M, et al. **J Med Virol** 1995 Aug;46(4):321–8

ANTIBODIES, XENOGENEIC see ANTIBODIES, HETEROPHILE

ANTIBODY AFFINITY

Lectin-affinity electrophoresis for the detection of AFP microheterogeneities in patients with hepatocellular carcinoma. Zaninotto M, et al. **Anticancer Res** 1996 Jan-Feb;16(1):305–9

A subgroup of human VH3 germline genes that encode a high-avidity synovial rheumatoid factor. Wong A, et al. **Autoimmunity** 1995;20(3):191–9

The affinity of binding of digoxin to ovine anti-digoxin Fab (DIGIBIND) preparations. Allen G. **Biologicals** 1996 Mar; 24(1):19–24

Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. Kievit E, et al. **Br J Cancer** 1996 Feb; 73(4):457–64

On the validity of "functional affinity" determination for antibodies binding to cell surface antigens or other polyvalent antigens. Mattes MJ. **Cancer Res** 1995 Dec 1; 55(23 Suppl):5733s-5735s

Helicobacter pylori infection and serum IgG avidity [letter] Basso D, et al. **Clin Chim Acta** 1996 Feb 9;245(1):129–32

Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Vaarala O, et al. **Clin Exp Immunol** 1996 May; 104(2):269–74

Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Wu R, et al. **Clin Exp Immunol** 1995 Oct;102(1):174–80

Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105–14 (65 ref.)

Monoclonal antibodies against Manduca sexta hemocytes bind Aedes aegypti hemocytes: characterization of six monoclonal antibodies that bind hemocytes from both species. Willott E, et al. **Dev Comp Immunol** 1995 Nov-Dec;19(6):451–61

Quantitative determination of antibody binding capacity (ABC) by flow cytometry. Schwartz A, et al. **Eur J Histochem** 1994;38 Suppl 1:13–20 (14 ref.)

Affinity maturation and hypermutation in a simulation of the humoral immune response. Celada F, et al. **Eur J Immunol** 1996 Jun;26(6):1350–8

Bacterial and plant-produced scFv proteins have similar antigen-binding properties. Bruyns AM, et al. **FEBS Lett** 1996 May 13;386(1):5–10

Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Schier R, et al. **Gene** 1996 Mar 9;169(2):147–55

Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen. Kipriyanov SM, et al.

Hum Antibodies Hybridomas 1995;6(3):93–101

C-1-inhibitor binding monoclonal immunoglobins in three patients with acquired angioneurotic edema. Chevailler A, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):998–1008

Observations on the binding of four anti-carbohydrate monoclonal antibodies to their homologous ligands. Nashed EM, et al. **J Biol Chem** 1996 Apr 5;271(14):8209–14

Longitudinal changes in antibody avidity to Actinobacillus actinomycetemcomitans in periodontitis. O'Dell DS, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):203–11

Binding kinetics of monoclonal antibody using antigen-beta-galactosidase hybrid protein: application to measurement of peptide antigenicity. Cho EW, et al. **J Immunoassay** 1995 Nov;16(4):349–63

Identification, molecular cloning, biologic properties, and tissue distribution of a novel isoform of murine low-affinity IgG receptor homologous to human Fc gamma RIIB1. Latour S, et al. **J Immunol** 1996 Jul 1;157(1):189–97

Structural elements controlling anti-DNA antibody affinity and their relationship to anti-phosphorylcholine activity. Pewzner-Jung Y, et al. **J Immunol** 1996 Apr 15; 156(8):3065–73

Human monocytes are unable to bind to or phagocytize IgA and IgG immune complexes formed with influenza virus in vitro. Scott CB, et al. **J Immunol** 1996 Jul 1;157(1):351–9

Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen. Yan X, et al. **J Immunol** 1996 Aug 15;157(4):1582–8

The assessment of antibody affinity distribution by thiocyanate elution: a simple dose-response approach. Ferreira MU, et al. **J Immunol Methods** 1995 Dec 1; 187(2):297–305

Binding kinetics of an antibody against HIV p24 core protein measured with real-time biomolecular interaction analysis suggest a slow conformational change in antigen p24. Glaser RW, et al. **J Immunol Methods** 1996 Jan 16; 189(1):1–14

Antibody production in rabbits and chickens immunized with human IgG. A comparison of titre and avidity development in rabbit serum, chicken serum and egg yolk using three different adjuvants. Svendsen Bollen L, et al. **J Immunol Methods** 1996 May 27;191(2):113–20

Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: evidence for primary or secondary humoral responses depending on donor immune status. Lutz E, et al. **J Med Virol** 1996 May;49(1):61–5

Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. Schier R, et al. **J Mol Biol** 1996 Jan 12;255(1):28–43

High-affinity rat anti-fluorescein monoclonal antibody with unique fine specificity properties including differential recognition of dynamic ligand analogues. Miklasz SD, et al. **J Mol Recognit** 1995 Jul-Aug;8(4):258–69

Synthetic antibody gene libraries for in vitro affinity maturation. Deng SJ, et al. **Methods Mol Biol** 1995; 51:329–42

Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor. Garrone P, et al. **Mol Immunol** 1996 May-Jun;33(7–8):649–58

Metal-binding properties of a calcium-dependent monoclonal antibody. Hopp TP, et al. **Mol Immunol** 1996 May-Jun;33(7–8):601–8

Use of a novel mutagenesis strategy, optimized residue substitution, to decrease the off-rate of an anti-gp120 antibody. Lewis CM, et al. **Mol Immunol** 1995 Oct; 32(14–15):1065–72

Binding of cynomolgus monkey IgE to a humanized anti-human IgE antibody and human high affinity IgE receptor. Meng YG, et al. **Mol Immunol** 1996 May-Jun; 33(7–8):635–42

Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Ohlin M, et al. **Mol Immunol** 1996 Jan;33(1):47–56

Structural analysis of affinity maturation: the three-dimensional structures of complexes of an anti-nitrophenol antibody. Yuhasz SC, et al. **Mol Immunol** 1995 Oct;32(14–15):1143–55

Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Nustad K, et al. **Tumour Biol** 1996; 17(4):196–219

[Antibody avidity in immune response and in the diagnosis of infectious diseases] Seppälä I, et al. **Duodecim** 1994; 110(2):178–84 (34 ref.) **(Fin)**

[Relationship between the duration of the clinical course of human brucellosis and the avidity of specific IgG antibodies] Gutiérrez J, et al. **Rev Med Chil** 1995 Jul; 123(7):819–22 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Durable elimination of high affinity, T cell-dependent antibodies by low molecular weight antigen arrays in vivo. Symer DE, et al. **J Immunol** 1995 Dec 15;155(12):5608–16

High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. Wiegand TW, et al. **J Immunol** 1996 Jul 1;157(1):221–30

GENETICS

Evaluation of loss and change of specificity resulting from random mutagenesis of an antibody VH region. Casson LP, et al. **J Immunol** 1995 Dec 15;155(12):5647–54

CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. Yang WP, et al. **J Mol Biol** 1995 Dec 1; 254(3):392–403

IMMUNOLOGY

Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses. McCloskey N, et al. **Immunology** 1996 Jun;88(2):169–73

Relationships between antibodies against human soluble complement receptor 1 (hsCR1) from various species. Ruggieri EV, et al. **J Clin Immunol** 1996 Mar;16(2):97–106

The use of dedicated peptide libraries permits the discovery of high affinity binding peptides. de Koster HS, et al. **J Immunol Methods** 1995 Nov 16;187(1):179–88

Avidity distribution of antibodies against peripheral nerve myelin in patients with polyneuropathy associated with IgM monoclonal gammopathy and in healthy controls. Vrethem M, et al. **J Neurol Sci** 1995 Aug;131(2):190–9

Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lang AB, et al. **J Pediatr** 1995 Nov; 127(5):711–7

Affinity maturation without germinal centres in lymphotoxin-alpha-deficient mice. Matsumoto M, et al. **Nature** 1996 Aug 1;382(6590):462–6

Cross-reaction but no avidity change of the serum antibody response after influenza vaccination. Brokstad KA, et al. **Vaccine** 1995 Nov;13(16):1522–8

ANTIBODY AVIDITY see **ANTIBODY AFFINITY**

ANTIBODY BINDING SITES see **BINDING SITES, ANTIBODY**

ANTIBODY DEFICIENCY SYNDROME see **IMMUNOLOGIC DEFICIENCY SYNDROMES**

ANTIBODY-DEPENDENT CELL CYTOTOXICITY

Antibody-dependent cellular cytotoxicity, ingestion and digestion in Dermatophagoides pteronyssinus-sensitive asthmatic children. Barić I, et al. **Acta Med Croatica** 1995; 49(4–5):177–80

Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokinine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Ottonello L, et al. **Blood** 1996 Jun 15;87(12):5171–8

Antiphosphatidylserine antibodies in human immunodeficiency virus-1 patients with evidence of T-cell apoptosis and mediate antibody-dependent cellular cytotoxicity. Silvestris F, et al. **Blood** 1996 Jun 15; 87(12):5185–95

Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Mori S, et al. **Cancer Res** 1996 Apr 15;56(8):1874–9

Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies. Bhat NM, et al. **Clin Exp Immunol** 1996 Jul;105(1):183–90

Complement-dependent cytotoxic antibodies to human T lymphotropic virus type I (HTLV-I)-infected cells in the sera of HTLV-I-infected individuals. Plotnicky-Gilquin H, et al. **Clin Exp Immunol** 1996 Jul;105(1):39–45

Complement activation by HIV-1-infected target cells enhances IL-2-stimulated but not unstimulated ADCC activity mediated by peripheral blood mononuclear cells. Sereti I, et al. **Clin Immunol Immunopathol** 1996 Jan; 78(1):77–82

Fully and long-term xenogeneic hematopoietic chimeras created in poorly concordant rat-mouse combinations: expression of hereditary donor characteristics. Spach C, et al. **Exp Hematol** 1995 Oct;23(11):1192–203

Antibody-dependent cellular cytotoxicity in HIV infections. Ahmad A, et al. **FASEB J** 1996 Feb;10(2):258–66 (57 ref.)

Protective effects of interferon-gamma on squamous-cell carcinoma of head and neck targets in antibody-dependent cellular cytotoxicity mediated by human natural killer cells. Sung MW, et al. **Int J Cancer** 1996 May 3;66(3):393–9

Antibody-dependent cell-mediated cytotoxicity in autoimmune thyroid disease: relationship to antithyroperoxidase antibodies. Rodien P, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2595–600

The multidrug resistance phenotype confers immunological resistance. Weisburg JH, et al. **J Exp Med** 1996 Jun 1; 183(6):2699–704

Comments on the Fourth International Conference on Bispecific Antibodies and Cellular Cytotoxicity, Duck Key, Florida, March 1–5, 1995 [editorial] Fanger MW, et al. **J Hematother** 1995 Oct;4(5):345–9

Age, sex, and household exposure are associated with the acute measles-specific antibody-dependent cellular cytotoxicity antibody response. Forthal DN, et al. **J Infect Dis** 1995 Dec;172(6):1587–91

Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H. Hutchins JT, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11980–4

Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins [letter] Brasoveanu LI, et al. **Scand J Immunol** 1996 Mar; 43(3):351–3

[The activity of natural and antibody-dependent leukocyte cytotoxicity in lympholeukemia and multiple myeloma] Vozniuk VP, et al. **Lik Sprava** 1995 May-Jun;(5–6):103–4 (Eng. Abstr.) **(Rus)**

[Study of spontaneous cytotoxic activity in laryngeal carcinoma: prognostic value] González FM, et al. **Acta Otorrinolaringol Esp** 1995 Nov-Dec;46(6):431–6 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Immunomodulating activities on cellular cytotoxicity and the blast transformation of human lymphocytes by 10-[n-(phthalimido)alkyl-2-substituted-10H-phenothiazines and 1-(2-chloroethyl)-3-(2-substituted-10 H-phenothiazin-10-yl)alkyl-1-ureas. Petri IB, et al. **Anticancer Res** 1996 May-Jun;16(3A):1247–50

IL-8 enhances antibody-dependent cellular cytotoxicity in human neutrophils. Reali E, et al. **Immunol Cell Biol** 1995 Jun;73(3):234–8

Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells. Qi CF, et al. **Immunol Lett** 1995 Jul-Aug;47(1-2):15–24

Tumor necrosis factor and interferon-gamma augment anticolon antibody- dependent cellular cytotoxicity in ulcerative colitis. Watanabe N, et al. **Immunopharmacol Immunotoxicol** 1996 Feb;18(1):15–26

N-acetylcysteine enhances antibody-dependent cellular cytotoxicity in neutrophils and mononuclear cells from healthy adults and human immunodeficiency virus-infected patients. Roberts RL, et al. **J Infect Dis** 1995 Dec; 172(6):1492–502

[The effect of sodium nucleinate on the precursors of antigen-dependent suppressors following irradiation] Surinov BP, et al. **Radiats Biol Radioecol** 1996 May-Jun; 36(3):355–8 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity. Kroesen BJ, et al. **Br J Cancer** 1996 Mar; 73(6):721–7

Positive correlation between the natural killer and gp 120/41-specific antibody-dependent cellular cytotoxic effector functions in HIV-infected individuals. Ahmad A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):115–9

Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes. Hanibuchi M, et al. **Jpn J Cancer Res** 1996 May;87(5):497–504

Antibody-dependent cellular cytotoxic activity of cells in the rat metrial gland in pregnancy. Peel S, et al. **Scand J Immunol** 1996 Jan;43(1):16–22

ANTIBODY-DEPENDENT ENHANCEMENT

Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis. Linn ML, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):407–11

ANTIBODY DIVERSITY

Human IgH-V gene repertoire in neonatal cord blood, adult peripheral blood, and EBV-transformed cells. Choi Y, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:261–4

Anomalous diversification of the antibody repertoire following bone marrow transplantation. Glas AM, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:312–4

A complete preimmune human VH3 repertoire. Hufnagle WO, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:293–5

Development of the antibody repertoire as revealed by single-cell PCR of FACS-sorted B-cell subsets. Kantor AB, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:224–7

Development of the antibody repertoire in rabbits. Knight KL, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:198–206 (23 ref.)

Development of the mouse B-cell repertoire. Martin F, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:207–21 (56 ref.)

Contribution of the V lambda light chain to the development of the primary antibody repertoire. Nangpal A, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:296–300

Analysis of immunoglobulin VH gene repertoire by an anchored PCR-ELISA. Rassenti LZ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:463–73

Generation of diversity in a human anti-viral response. Rioux JD, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:381–3

Unconventional B-cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342–55 (42 ref.)

Development of the immunoglobulin repertoire. Fanning LJ, et al. **Clin Immunol Immunopathol** 1996 Apr;79(1):1–14 (129 ref.)

Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product

P-glycoprotein. Lehne G, et al. **Cytometry** 1995 Jul 1; 20(3):228–37

B-cell superantigens: implications for selection of the human antibody repertoire. Zouali M. **Immunol Today** 1995 Aug; 16(8):399–405 (73 ref.)

T cell recognition and tolerance of antibody diversity. Eyerman MC, et al. **J Immunol** 1996 Aug 1;157(3):1037–46

B cells selected for apoptosis in the sheep ileal Peyer's patch have enhanced mutational diversity in the Ig V lambda light chain. Maybaum TA, et al. **J Immunol** 1996 Aug 15; 157(4):1474–84

The imprint of somatic hypermutation on the repertoire of human germline V genes. Tomlinson IM, et al. **J Mol Biol** 1996 Mar 15;256(5):813–17

Failure to consider the antigenic diversity of porcine reproductive and respiratory syndrome (PRRS) virus isolates may lead to misdiagnosis. Yoon KJ, et al. **J Vet Diagn Invest** 1995 Jul;7(3):386–7

Non-stochastic utilization of Ig V region genes in unselected human peripheral B cells. Huang SC, et al. **Mol Immunol** 1996 Apr;33(6):553–60

GENETICS

Mechanistic properties of immunoglobulin somatic mutation. Ford JE, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:187–8

Developmental regulation of the human antibody repertoire. Schroeder HW Jr, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:242–60 (60 ref.)

The generation of antibody diversity in the turtle. Turchin A, et al. **J Immunol** 1996 May 15;156(10):3797–805

Mechanistic constraints on diversity in human V(D)J recombination. Gauss GH, et al. **Mol Cell Biol** 1996 Jan; 16(1):258–69

PHYSIOLOGY

Somatic hypermutation: how many mechanisms diversify V region sequences? Maizels N. **Cell** 1995 Oct 6;83(1):9–12 (26 ref.)

ANTIBODY ENZYME TECHNIQUE, UNLABELED see **IMMUNOENZYME TECHNIQUES**

ANTIBODY FORMATION

Regulation of the humoral response by the antigen-presenting cells in vivo. De Becker G, et al. **Adv Exp Med Biol** 1995;378:183–5

Use of gut lavage fluid to measure intestinal humoral immunity, GI bleeding and protein losses in Sierra Leonean children. Hodges M, et al. **Adv Exp Med Biol** 1995; 371B:813–5

Antibody production to secretory component (SC) using recombinant SC fragment. Kamei M, et al. **Adv Exp Med Biol** 1995;371A:633–5

Induction of specific antibody responses in the human nasopharyngeal mucosa. Quiding M, et al. **Adv Exp Med Biol** 1995;371B:1445–50

Cow's milk allergy: the humoral immune response to eight purified allergens. Wal JM, et al. **Adv Exp Med Biol** 1995; 371B:879–81

Iccosomes and induction of specific antibody production in vitro. Wu J, et al. **Adv Exp Med Biol** 1995;378:309–11

Induction of a protective immune response to murine coronavirus with non-internal image anti-idiotypic antibodies. Yu M, et al. **Adv Exp Med Biol** 1995;380:165–72

Humoral and cellular immune responses in asthmatic isocyanate workers: report of two cases. Baur X, et al. **Am J Ind Med** 1996 May;29(5):467–73

Long-term antibody production in canine lung allografts: implications in pulmonary immunity and asthma. Bice DE, et al. **Am J Respir Cell Mol Biol** 1996 Apr;14(4):341–7

Comparison of methods for estimation of Toxoplasma gondii-specific antibody production in the aqueous humor of cats. Hill SL, et al. **Am J Vet Res** 1995 Sep;56(9):1181–7

Newborn baboon immunity: lessons in cross-species transplantation. Michler RE, et al. **Ann Thorac Surg** 1995 Dec;60(6 Suppl):S582–4

Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma. Jurincic-Winkler CD, et al. **Anticancer Res** 1996 Jul–Aug; 16(4A):2105–10

Characterization of the non-specific humoral and cellular antiviral immunity stimulated by the chloroform-methanol residue (CMR) fraction of Coxiella burnetii. Zvilich M, et al. **Antiviral Res** 1995 Aug;27(4):389–404

A comparison of the immunogenicity of the native and denatured forms of a protein. Koch C, et al. **APMIS** 1996 Feb;104(2):115–25

Generation of polyclonal antibodies against nisin: immunization strategies and immunoassay development. Suárez AM, et al. **Appl Environ Microbiol** 1996 Jun; 62(6):2117–21

CD4+ T cells from mice primed for humoral immunity to sheep erythrocytes (SRBC) specifically inhibit cell-mediated immunity and vice versa. Zimecki M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(5–6):259–64

The human intestinal immune system: basic cellular and humoral mechanisms. Brandtzaeg P. **Baillieres Clin Rheumatol** 1996 Feb;10(1):1–24 (91 ref.)

A mixture model with detection limits for regression analyses of antibody response to vaccine. Moulton LH, et al. **Biometrics** 1995 Dec;51(4):1570–8

Immunoglobulin heavy chain variable region gene usage in bone marrow transplant recipients: lack of somatic mutation indicates a maturational arrest. Suzuki I, et al. **Blood** 1996 Mar 1;87(5):1873–80

Human immunoglobulins produced in hu-PBL-SCID mice are polyclonal early after xenotransplantation. Tissot JD, et al. **Cell Immunol** 1996 Feb 1;167(2):241–8

Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction. Collen D, et al. **Circulation** 1996 Jul 15;94(2):207–16

Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Wadhwa M, et al. **Clin Exp Immunol** 1996 May; 104(2):351–8

Humoral immune response and natural killer activity in patients with mixed cryoglobulinemia. Gabrielli A, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S95–9 (21 ref.)

The humoral response to vascular and nonvascular allografts of bone. Stevenson S, et al. **Clin Orthop** 1996 May; (326):86–95

Monitoring of allograft recipients for the development of HLA-specific antibodies: elimination of OKT3 as a complicating factor. Mulligan D, et al. **Clin Transplant** 1995 Dec;9(6):438–41

Immunoregulation in fish II: intermolecular-induced suppression of antibody responses studied by haptenated antigens in atlantic salmon (Salmo salar L). Angell Killie JE, et al. **Dev Comp Immunol** 1995 Sep–Oct;19(5):389–404

Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Barrios C, et al. **Eur J Immunol** 1996 Jul;26(7):1489–96

Altered Th1/Th2 balance associated with the immunosuppressive/protective effect of the H-2Ab allele on the response to allo-4-hydroxyphenylpyruvate dioxygenase. Brunner M, et al. **Eur J Immunol** 1995 Dec; 25(12):3285–9

Role of vascular endothelial cells in the allograft response. Brindle NP. **Eye** 1995;9 (Pt 2):167–72 (63 ref.)

The humoral response to an allograft. Hutchinson IV, et al. **Eye** 1995;9 (Pt 2):155–60

From the forehead of Zeus: the ontogeny of the immune response. Silverstein AM. **Eye** 1995;9 (Pt 2):147–51 (36 ref.)

T-cell mediated immunosuppression and its implications for the development of protective immunity. Baker PJ, et al. **Folia Biol (Praha)** 1994;40(6):349–58 (50 ref.)

Polyclonal immunoglobulin response of thymic, hepatic and splenic lymphocytes from fetal, germ-free and conventionally reared pigs to different B-cell activators. Cukrowska B, et al. **Folia Microbiol (Praha)** 1995; 40(4):421–30

Humoral immune response to the chlamydial heat shock proteins hsp60 and hsp70 in Chlamydia-associated chronic salpingitis with tubal occlusion. Dieterle S, et al. **Hum Reprod** 1996 Jun;11(6):1352–6

Pulmonary immunity to Pseudomonas aeruginosa. Cripps AW, et al. **Immunol Cell Biol** 1995 Oct;73(5):418–24 (84 ref.)

Humoral and cellular immunity rates in chemical plant workers employed in the production of liquid pesticides. Kluciński P, et al. **Int J Occup Med Environ Health** 1996; 9(2):103–10

The lack of immunogenicity of iotrolan. Krause W, et al. **Invest Radiol** 1995 Sep;30(9):548–51

Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. Heijnen IA, et al. **J Clin Invest** 1996 Jan 15;97(2):331–8

Antibody response to a T-dependent antigen requires B cell expression of complement receptors. Croix DA, et al. **J Exp Med** 1996 Apr 1;183(4):1857–64

Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. Le Hir M, et al. **J Exp Med** 1996 May 1; 183(5):2367–72

Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. Toellner KM, et al. **J Exp Med** 1996 May 1;183(5):2303–12

Relative contribution of T and B cells to hypermutation and selection of the antibody repertoire in germinal centers of aged mice. Yang X, et al. **J Exp Med** 1996 Mar 1; 183(3):959–70

Reduced immune responses in rhesus monkeys subjected to dietary restriction. Roecker EB, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):B276–9

Role of antibody and indirect antigen presentation in transplant-associated coronary artery vasculopathy. Rose ML. **J Heart Lung Transplant** 1996 Apr;15(4):342–9 (75 ref.)

Luminometry: a novel bioluminescent immunoassay enhances the quantitation of mucosal and systemic antibody responses. Jackson RJ, et al. **J Immunol Methods** 1996 Apr 19;190(2):189–97

Antibody responses in cattle infested with Haematobia irritans irritans (Diptera: Muscidae). Baron RW, et al. **J Med Entomol** 1995 Sep;32(5):630–5

Anti-human gonadotropin antibodies generated during in vitro fertilization (IVF)-related cycles: effect on fertility of rhesus macaques. Iliff SA, et al. **J Med Primatol** 1995 Jan;24(1):7–11

An orally supplemented mononucleotide mixture prevents the decrease in T cell-dependent humoral immunity in C57BL/6 mice fed a nucleotide-free diet. Jyonouchi H, et al. **J Nutr** 1996 Jun;126(6):1586–93

Antibody response of pediatric solid organ transplant recipients to immunization against influenza virus. Mauch TJ, et al. **J Pediatr** 1995 Dec;127(6):957–60

Peptide vaccine against canine parvovirus: identification of two neutralization subsites in the N terminus of VP2 and optimization of the amino acid sequence. Casal JI, et al. **J Virol** 1995 Nov;69(11):7274–7

A mimotope from a solid-phase peptide library induces a measles virus-neutralizing and protective antibody response. Steward MW, et al. **J Virol** 1995 Dec; 69(12):7668–73

Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Kay MA, et al. **Nat Genet** 1995 Oct;11(2):191–7

Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Takai T, et al. **Nature** 1996 Jan 25;379(6563):346–9

The BALB/c mouse B-cell response to pigeon cytochrome c initiates as a heteroclitic response specific for the self antigen mouse cytochrome c. Minnerath JM, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12379–83

Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Molina H, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3357–61

Indirect effects are independent of the way of tolerance induction. Carvalho CR, et al. **Scand J Immunol** 1996 Jun; 43(6):613–8

Engraftment and humoral immunity in SCID and RAG-2-deficient mice transplanted with human peripheral blood lymphocytes. Steinsvik TE, et al. **Scand J Immunol** 1995 Dec;42(6):607–16

C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Dempsey PW, et al. **Science** 1996 Jan 19;271(5247):348–50

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Sato Y, et al. **Science** 1996 Jul 19;273(5273):352–4

Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Abou-Elella AA, et al. **Transfusion** 1995 Nov-Dec;35(11):931–5

Differences in distribution of lymphocyte antigens in chicken lines divergently selected for antibody responses to sheep red blood cells. Parmentier HK, et al. **Vet Immunol Immunopathol** 1995 Sep;48(1–2):155–68

Enhancement of antibody response to bovine herpesvirus 1 with non-specific immunostimulants. Hampl J, et al. **Vet Med (Praha)** 1996 May;41(5):143–7

The effects of continuous and intermittent delivery of antigens of Boophilus microplus on the development of murine antibodies. Ehrenhofer C, et al. **Vet Parasitol** 1995 Oct;59(3–4):263–73

Immunogenicity of bovine herpesvirus 1 glycoprotein D in mice: effect of antigen form on the induction of cellular and humoral immune responses. Baca-Estrada ME, et al. **Viral Immunol** 1996;9(1):11–22

[Analysis of regulatory mechanism for humoral immunity using transgenic mice of rearranged immunoglobulin genes] Shimizu A. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2107–17 (21 ref.) **(Jpn)**

[The presence of antibodies against Francisella tularensis among inhabitants of North-Eastern Poland] Hermanowska-Szpakowicz T, et al. **Przegl Epidemiol** 1996; 50(1–2):55–9 (Eng. Abstr.) **(Pol)**

[Humoral response in hepatitis C infections: types of anti-HCV and reactivity evaluated using BLOT-index] Migdalski P, et al. **Przegl Epidemiol** 1996;50(1–2):15–22 (Eng. Abstr.) **(Pol)**

[Modification of immune response by implanting a suspension and antigen-stimulated lymphoid organs in an allogeneic system] Kovalevskil GV. **Dokl Akad Nauk** 1995 Jun; 342(6):843–5 **(Rus)**

[Specific features of humoral immunity and nonspecific resistance in pilots] Bochenkov AA, et al. **Kosm Biol Aviakosm Med** 1991 Sep–Oct;25(5):8–10 (Eng. Abstr.) **(Rus)**

[Study of cyclic kinetics of immunity by mathematical modeling methods] Smirnova OA. **Kosm Biol Aviakosm Med** 1991 Sep–Oct;25(5):53–6 (Eng. Abstr.) **(Rus)**

[Missing links in immunologic defense. Endogenous antibiotics are the primary protection] Wilhelmson B. **Lakartidningen** 1996 May 1;93(18):1728–33 **(Swe)**

DRUG EFFECTS

Oxygen tension-associated changes on secondary immune response in halothane or isoflurane anesthetized mice. Puig NR, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):945–8

Intestinal and systemic immune responses in rats to dietary lectins. Gómez E, et al. **Adv Exp Med Biol** 1995;371A:533–6

Comparison of the effects of sulphasalazine, 5-aminosalicylic acid and sulphapyridine on the humoral response to antigen in vivo. Sheldon P, et al. **Adv Exp Med Biol** 1995; 371B:905–8

Development and characterization of a binge drinking model

in mice for evaluation of the immunological effects of ethanol. Carson EJ, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):132–8

Effect of saponin from Quillaja saponaria (molina) on antibody, tumour necrosis factor and interferon–gamma production. Gebara VC, et al. **Biotechnol Appl Biochem** 1995 Aug;22 (Pt 1):31–7

Granulocyte–macrophage colony–stimulating factor: an effective adjuvant for protein and peptide–based vaccines. Disis ML, et al. **Blood** 1996 Jul 1;88(1):202–10

Induction of humoral immunity toward 2–acetylaminofluorene in mice: modulation of DNA binding after 4 weeks dietary exposure to the carcinogen. Verdina A, et al. **Carcinogenesis** 1996 Aug;17(8):1705–9

IL–10 stimulates murine antigen–driven antibody responses in vitro by regulating helper cell subset participation. Marcelletti JF, et al. **Cell Immunol** 1996 Jan 10;167(1):86–98

Zidovudine as an immunomodulatory agent. Urso P, et al. **Cell Mol Biol (Noisy–le–grand)** 1995;41 Suppl 1:S103–12

Regulation of anti–SRBC antibody production by opioids and their mechanisms. Wang H, et al. **Chin Med Sci J** 1995 Sep;10(3):125–30

Neuropeptides accentuate interleukin–4 induced human immunoglobuline E synthesis in vitro. Aebischer I, et al. **Exp Dermatol** 1996 Feb;5(1):38–44

Effects of ochratoxin A on the mouse immune system after subchronic exposure. Thuvander A, et al. **Food Chem Toxicol** 1995 Dec;33(12):1005–11

Evidence for a dual effect of acebutolol, a beta blocker, on the mouse humoral immune response. In S, et al. **Immunopharmacol Immunotoxicol** 1995 Aug;17(3):529–50

Effect of mechlorethamine on SRBC–induced secondary antibody response in mice. Obmińska–Domoradzka B, et al. **Immunopharmacol Immunotoxicol** 1995 Aug; 17(3):585–93

Modulation of primary antibody response by protein A in tumor bearing mice. Zaidi SI, et al. **Immunopharmacol Immunotoxicol** 1995 Nov;17(4):759–73

In vivo interleukin–4 regulation of antibody responses in euthymic and athymic mice to a T–independent antigen (hydroxyethyl starch). Macedo–Soares F, et al. **Int Arch Allergy Immunol** 1996 Jun;110(2):174–81

Interleukin 12 alters the isotype–restricted antibody response of mice to hen eggwhite lysozyme. Buchanan JM, et al. **Int Immunol** 1995 Sep;7(9):1519–28

Suppression of immune response in lambs during treatment with the beta–adrenergic agonist clenbuterol. Spencer GS, et al. **J Anim Sci** 1996 Jan;74(1):151–3

Influence of air pollution on humoral immune response. Stiller–Winkler R, et al. **J Clin Epidemiol** 1996 May; 49(5):527–34

A transforming growth factor beta–like immunosuppressive factor in immunoglobulin G–binding factor. Bouchard C, et al. **J Exp Med** 1995 Dec 1;182(6):1717–26

Long–term production of human monoclonal antibodies by human–mouse heterohybridomas. Yoshinari K, et al. **J Immunol Methods** 1995 Oct 12;186(1):17–25

Effects of putative cannabinoid receptor ligands, anandamide and 2–arachidonyl–glycerol, on immune function in B6C3F1 mouse splenocytes. Lee M, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):529–36

Effects of 6–Hydroxydopamine on the antibody response to the hapten dinitrophenyl in the chicken. Yasuda M, et al. **J Vet Med Sci** 1995 Dec;57(6):1073–5

Role of hormonal–cytokine interactions in the formation of the humoral immune response. Shirshev SV. **Neurosci Behav Physiol** 1995 Sep–Oct;25(5):345–7

Modulatory effects of hen egg–white lysozyme on immune response in mice. Valisena S, et al. **New Microbiol** 1996 Jan;19(1):15–24

Lysozyme inhibitors enhance immune response in mice. Valisena S, et al. **New Microbiol** 1996 Jan;19(1):25–30

Dietary fatty acid modulates actions of nucleotides on humoral immune responses. Jyonouchi H, et al. **Nutrition** 1995 Sep–Oct;11(5):437–43

Effect of oral administration of a pectic polysaccharide fraction from a kampo (Japanese herbal) medicine "juzen–taiho–to" on antibody response of mice. Kiyohara H, et al. **Planta Med** 1995 Oct;61(5):429–34

Use of Mishell–Dutton culture for the detection of the immunosuppressive effect of iron–containing compounds. Ban M, et al. **Toxicol Lett** 1995 Nov 15;81(2–3):183–8

Inhibition of tumor necrosis factor activity fails to restore 2,3,7,8–tetrachlorodibenzo–p–dioxin (TCDD)–induced suppression of the antibody response to sheep red blood cells. Moos AB, et al. **Toxicol Lett** 1995 Nov 15; 81(2–3):175–81

Effects of 2,3,7,8–tetrachlorodibenzo–p–dioxin on humoral and cell–mediated immunity in Sprague–Dawley rats. Fan F, et al. **Toxicology** 1996 Jan 8;106(1–3):221–8

Repeated high dose oral exposure or continuous subcutaneous infusion of 2–methoxyacetic acid does not suppress humoral immunity in the mouse. Riddle MM, et al. **Toxicology** 1996 May 3;109(1):67–74

[Immune status studies after one–time alcohol consumption in healthy subjects] Mohadjer C, et al. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1577–81 (Eng. Abstr.) **(Ger)**

[The effect of short–term erythropoietin therapy on selected parameters of cell mediated and humoral immunity in hemodialyzed uremic patients] Więcek A, et al. **Pol Arch Med Wewn** 1995 Jan;93(1):41–7 (Eng. Abstr.) **(Pol)**

[Effect of fluoroquinolones on the interaction of phagocytic cells with pathogens, lymphocyte function and immune response] Iordanova AI, et al. **Antibiot Khimioter** 1995 Aug; 40(8):50–6 **(Rus)**

[Stimulating effect of a polypeptide substance (Cuban stimulator) on hemopoiesis and formation of humoral immunity to murine thymus–dependent antigen] Shurygin AIa, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):511–4 **(Rus)**

GENETICS

Production of antigen–specific human antibodies from mice engineered with human heavy and light chain YACs. Jakobovits A, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:525–35

Reduced humoral immunity in uremic mice genetically selected for high antibody response. Prado EB, et al. **Braz J Med Biol Res** 1995 Oct;28(10):1081–7

Regulation by non–major histocompatibility complex genes of the allo–4–hydroxy–phenylpyruvate dioxygenase (F liver protein) response. Brunner MC, et al. **Immunology** 1996 Jul;88(3):452–5

Investigations into the ubiquitous nature of high or low immune responsiveness after divergent selection for antibody production in common carp (Cyprinus carpio L.). Wiegertjes GF, et al. **Vet Immunol Immunopathol** 1995 Oct; 48(3–4):355–66

IMMUNOLOGY

Induction of potent humoral and cell–mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. Okuda K, et al. **AIDS Res Hum Retroviruses** 1995 Aug;11(8):933–43

The humoral immune system in coeliac disease. Mäki M. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):231–49 (115 ref.)

Immunoglobulin gene usage in the human anti–pathogen response. Newkirk MM, et al. **Infect Agents Dis** 1995 Sep; 4(3):153–60 (59 ref.)

Disclosure of trauma and immune response to a hepatitis B vaccination program. Petrie KJ, et al. **J Consult Clin Psychol** 1995 Oct;63(5):787–92

Electric myocardial impedance registration in humoral rejection after heart transplantation. Grauhan O, et al. **J Heart Lung Transplant** 1996 Feb;15(2):136–43

Cellular and humoral immunity to vascular endothelium and the development of cardiac allograft vasculopathy. Hosenpud JD, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S185–7

Interference between Neisseria meningitidis and PC–KLH induced anti–phosphorylcholine PFC responses in NZB/W autoimmune mice. Seoane R, et al. **Microbiol Immunol** 1995;39(7):491–7

Affinity maturation without germinal centres in lymphotoxin–alpha–deficient mice. Matsumoto M, et al. **Nature** 1996 Aug 1;382(6590):462–6

Expression and immunogenicity of an 18–residue epitope of HIV1 gp41 inserted in the flagellar protein of a Salmonella live vaccine. Newton SM, et al. **Res Microbiol** 1995 Mar–Apr;146(3):203–16

Systemic and local gut–specific antibody responses in preruminant calves sensitive to soya. Lallès JP, et al. **Res Vet Sci** 1995 Jul;59(1):56–60

[The function of antigen presentation of dendritic cells] Péguet–Navarro J. **Pathol Biol (Paris)** 1995 Dec; 43(10):863–70 (54 ref.) (Eng. Abstr.) **(Fre)**

[Effect of menstrual cycle on the immune response to surgical stress] Lazzaretti MG, et al. **Minerva Ginecol** 1995 May; 47(5):197–205 (48 ref.) (Eng. Abstr.) **(Ita)**

[Humoral immune response to tissue injury, characterized by a rise in serum immunoglobulin E] Szczeklik A, et al. **Pol Arch Med Wewn** 1995 Dec;94(6):495–505 (Eng. Abstr.) **(Pol)**

[Biologic effects of immunotherapy] Dávila González I, et al. **Allergol Immunopathol (Madr)** 1996;24 Suppl 1:60–8 (85 ref.) **(Spa)**

PHYSIOLOGY

A subpopulation of Menière's patients produce antibodies that bind to endolymphatic sac antigens. Soliman AM. **Am J Otol** 1996 Jan;17(1):76–80

Alterations in cytokine and antibody production following chemical sympathectomy in two strains of mice. Kruszewska B, et al. **J Immunol** 1995 Nov 15; 155(10):4613–20

Characterization of humoral and cellular immunity in the central nervous system of HAM/TSP. Matsui M, et al. **J Neurol Sci** 1995 Jun;130(2):183–9

Clonal selection and learning in the antibody system. Rajewsky K. **Nature** 1996 Jun 27;381(6585):751–8 (182 ref.)

Enhancement of antibody production by a learning paradigm. Alvarez–Borda B, et al. **Neurobiol Learn Mem** 1995 Sep; 64(2):103–5

Production and characterization of an antibody directed against the mouse 5HT1B receptor. Grimaldi B, et al. **Neurosci Res** 1995 Dec;24(1):97–101

RADIATION EFFECTS

[The combined action of ionizing radiation and stress on antibody formation in mice] Surinov BP, et al. **Radiats Biol Radioecol** 1996 May–Jun;36(3):359–64 (Eng. Abstr.) **(Rus)**

ANTIBODY FRAGMENTS see **IMMUNOGLOBULIN FRAGMENTS**

ANTIBODY–PRODUCING CELLS

see related
HEMOLYTIC PLAQUE TECHNIQUE

FAS is highly expressed in the germinal center but is not required for regulation of the B–cell response to antigen. Smith KG, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11628–32

CHEMISTRY

Influence of fluorescent antibody probe specificity on flow cytometric analysis of antibody–producing cells. Bae SW, et al. **J Immunol Methods** 1996 Jan 16;189(1):83–8

CLASSIFICATION

The phenotype and fate of the antibody–forming cells of the splenic foci. Smith KG, et al. **Eur J Immunol** 1996 Feb; 26(2):444–8

CYTOLOGY

The differentiation of human memory B cells into specific antibody–secreting cells is CD40 independent. Silvy A, et al. **Eur J Immunol** 1996 Mar;26(3):517–24

DRUG EFFECTS

Fumonisin B1 alters sphingolipid metabolism and immune function in BALB/c mice: immunological responses to fumonisin B1. Martinova EA, et al. **Mycopathologia** 1995 Jun;130(3):163–70

IMMUNOLOGY

Immunoglobulin subclass distribution of anti–LPS antibody–secreting cells of colonic mucosa from patients with inflammatory bowel disease. Arashi M, et al. **Adv Exp Med Biol** 1995;371B:1277–80

Specific antibody–producing cells in humans after oral immunization with a ribosomal vaccine Ribomunyl. Bene MC, et al. **Adv Exp Med Biol** 1995;371B:1563–6

Generation and distribution of antibody secreting cells in salivary glands of mice immunized with Porphyromonas gingivalis fimbriae. Hamada S, et al. **Adv Exp Med Biol** 1995;371B:1113–7

Decreased IgA–producing cells in the gut of SIV–infected rhesus monkeys. Jackson S, et al. **Adv Exp Med Biol** 1995; 371B:1035–8

Antibody secreting cells in upper urinary tract infection: comparison of the response in children and adults. Kantele A, et al. **Adv Exp Med Biol** 1995;371B:991–4

Phenotypic characterization of circulating antibody–secreting cells after mucosal and systemic immunizations in humans. Lakew M, et al. **Adv Exp Med Biol** 1995;371B:1451–3

Intraperitoneal administration of tetanus toxoid elicits a specific response of antibody–secreting cells in the peritoneal cavity. Lue C, et al. **Adv Exp Med Biol** 1995; 371A:103–6

Ig–secreting and interferon–gamma–producing cells in mice mucosally immunized with influenza virus. Novak M, et al. **Adv Exp Med Biol** 1995;371B:1587–90

Virus–specific antibody production and polyclonal B–cell activation in the intestinal mucosa of HIV–infected individuals. Eriksson K, et al. **AIDS** 1995 Jul;9(7):695–700

Expansion of the humoral effector cell compartment of both systemic and mucosal immune systems in a weanling murine model which duplicates critical features of human protein–energy malnutrition. Ha CL, et al. **Br J Nutr** 1996 Mar;75(3):445–60

In vitro enhancement of antibody responses by T delta cells expressing IgD receptors. Yang YJ, et al. **Cell Immunol** 1996 Feb 25;168(1):107–16

The phenotype and fate of the antibody–forming cells of the splenic foci. Smith KG, et al. **Eur J Immunol** 1996 Feb; 26(2):444–8

Immunoregulatory activities of eicosanoids in the rainbow trout (Oncorhynchus mykiss). Knight J, et al. **Immunology** 1995 Jul;85(3):389–93

Activation and negative selection of functionally distinct subsets of antibody–secreting cells by influenza hemagglutinin as a viral and a neo–self antigen. Caton AJ, et al. **J Exp Med** 1996 Jan 1;183(1):13–26

Antibody–secreting cells and their relation to humoral antibodies in serum and in nasopharyngeal aspirates in children with pneumococcal acute otitis media. Nieminen T, et al. **J Infect Dis** 1996 Jan;173(1):136–41

Systematic and intestinal antibody–secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. Yuan L, et al. **J Virol** 1996 May;70(5):3075–83

Kinetics and isotype profile of rheumatoid factor production during viral infection: organ distribution of antibody secreting cells. Fazekas G, et al. **Scand J Immunol** 1996 Sep;44(3):273–84

METABOLISM

In vitro enhancement of antibody responses by T delta cells expressing IgD receptors. Yang YJ, et al. **Cell Immunol** 1996 Feb 25;168(1):107–16

Spontaneous antibody–secreting cells in the stomach of gastric cancer patients. Kunori T, et al. **J Gastroenterol** 1996 Apr;31(2):161–6

Quantification of natural antibody producing B cells in rats by an improved ELISPOT technique using the polyvinylidene difluoride membrane as the solid support. Schielen P, et al. **J Immunol Methods** 1995 Dec 15; 188(1):33–41

Changes in the concentration and distribution of immunoglobulin–producing cells in SIDS palatine tonsils. Stoltenberg L, et al. **Pediatr Allergy Immunol** 1995 Feb; 6(1):48–55

PATHOLOGY

Number of specific antibody–secreting cells in the peripheral blood among children with mycoplasma pneumonia. Iseki M, et al. **Infect Immun** 1996 Jul;64(7):2799–803

SECRETION

The differentiation of human memory B cells into specific antibody–secreting cells is CD40 independent. Silvy A, et al. **Eur J Immunol** 1996 Mar;26(3):517–24

ANTIBODY-SECRETING CELLS see **ANTIBODY-PRODUCING CELLS**

ANTIBODY SPECIFICITY

see related
ANTIBODIES, BISPECIFIC

Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection. Langedijk JP, et al. **AIDS Res Hum Retroviruses** 1995 Oct;11(10):1153–62

Generation and characterization of monoclonal antibodies specific to surface antigens of human trophoblast cells. Yoshiki T, et al. **Am J Reprod Immunol** 1995 Sep; 34(3):148–55

Latex–specific IgE in patients evaluated for allergy [letter; comment] Niggemann B, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):370–1. Comment on: Ann Allergy Asthma Immunol 1995 Feb;74(2):184–7.

Isotype–specific antibody responses to acute Mycoplasma pneumoniae infection. Seggev JS, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):67–73

Production and characterization of a monoclonal antibody specific for Trypanosoma simiae. Bosompem KM, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):611–20

Characterization of epitopes recognized by 4–hydroxy–2–nonenal specific antibodies. Uchida K, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):241–8

Cell–type specificity of anti–CD45 autoantibodies in systemic lupus erythematosus. Czyzyk J, et al. **Arthritis Rheum** 1996 Apr;39(4):592–9

Spectroscopic, calorimetric, and kinetic demonstration of conformational adaptation in peptide–antibody recognition. Leder L, et al. **Biochemistry** 1995 Dec 19;34(50):16509–18

Complete inhibition of angiogenesis and growth of microtumors by anti–vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Borgström P, et al. **Cancer Res** 1996 Sep 1;56(17):4032–9

Specific monoclonal antibodies against leukocyte–restricted cell surface molecule CD43 react with nonhematopoietic tumor cells. Santamaría M, et al. **Cancer Res** 1996 Aug 1;56(15):3526–9

Effect of antibody specificity on results of selected digoxin immunoassays among various clinical groups. Datta P, et al. **Clin Chem** 1996 Mar;42(3):373–9

Elevated levels of total and Puumala virus–specific immunoglobulin E in the Scandinavian type of hemorrhagic fever with renal syndrome. Alexeyev OA, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):269–72

Lipopolysaccharide–reactive immunoglobulin E is associated with lower mortality and organ failure in traumatically injured patients. DiPiro JT, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):295–8

Characteristics and clinical significance of a stabilization assay to detect specific antibodies to reverse transcriptase of human immunodeficiency virus. Morita M, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):583–9

Detection of allergen–specific IgE in tears of grass pollen–allergic patients with allergic rhinoconjunctivitis. Hoffmann–Sommergruber K, et al. **Clin Exp Allergy** 1996 Jan;26(1):79–87

The association of age, gender and smoking with total IgE and specific IgE. Jarvis D, et al. **Clin Exp Allergy** 1995 Nov;25(11):1083–91

Cholesterol sulphate–reactive autoantibodies are specifically increased in chronic chagasic human patients. Avila JL, et al. **Clin Exp Immunol** 1996 Jan;103(1):40–6

Peptide phage libraries can be an efficient tool for identifying antibody ligands for polyclonal antisera. Dybwad A, et al. **Clin Exp Immunol** 1995 Nov;102(2):438–42

Shared V–region antigens and cross–reacting specificities of human IgG anti–F(ab')2 and anti–DNA antibodies. Williams RC Jr, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):194–203

Monoclonal antibody BLT–1, specific for the bovine homologue of CD5, reacts with the majority of mature T cells, a subpopulation of B cells and stimulates T cell proliferation. Yang TJ, et al. **Dev Comp Immunol** 1995 Jul–Aug;19(4):337–46

Bovine granulosa cell culture for assessment of potency and specificity of antibodies to pregnant mares' serum gonadotrophin. Kuran M, et al. **Eur J Endocrinol** 1996 Apr; 134(4):497–500

A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex–specific monoclonal antibody. Eastman S, et al. **Eur J Immunol** 1996 Feb;26(2):385–93

A keratin antibody recognizing a heterotypic complex: epitope mapping to complementary locations on both components of the complex. Waseem A, et al. **Exp Cell Res** 1996 Mar 15;223(2):203–14

From the forehead of Zeus: the ontogeny of the immune response. Silverstein AM. **Eye** 1995;9 (Pt 2):147–51 (36 ref.)

Falsely elevated steroidal assay levels related to heterophile antibodies against various animal species. Check JH, et al. **Gynecol Obstet Invest** 1995;40(2):139–40

Cloning and expression of a single–chain antibody fragment specific for a monomorphic determinant of class I molecules of the human major histocompatibility complex. Marin M, et al. **Hybridoma** 1995 Oct;14(5):443–51

Membrane–associated and cytosolic species–specific antigens of Mycoplasma bovis recognized by monoclonal antibodies. Rasberry U, et al. **Hybridoma** 1995 Oct;14(5):481–5

Generation of a murine monoclonal antibody specific for N–glycolylneuraminic acid–containing gangliosides that also recognizes sulfated glycolipids. Vázquez AM, et al. **Hybridoma** 1995 Dec;14(6):551–6

Sequence of two cattle MHC class I cDNAs associated with BoLA A10 specificity. Pichowski JS, et al. **Immunogenetics** 1996;43(4):253–4

A patient–derived cytotoxic T–lymphocyte clone and two peptide–dependent monoclonal antibodies recognize HLA–B27–peptide complexes with low stringency for peptide sequences. Huang F, et al. **Infect Immun** 1996 Jan; 64(1):120–7

Production of a monoclonal dinitrophenyl–specific rat IgE and establishment of an IgE capture ELISA for estimating the concentration of rat IgE antibodies to dinitrophenyl–Ascaris suum. Hanashiro K, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):371–9

Disproportional distribution of isotype and non–isotype–specific IgG subclass anti–IgE autoantibodies in human cord serum. Magnusson CG, et al. **Int Arch Allergy Immunol** 1996 May;110(1):31–40

CD40 cross–linking inhibits specific antibody production by human B cells. Callard RE, et al. **Int Immunol** 1995 Nov; 7(11):1809–15

Association of skin test reactivity, specific IgE, total IgE, and eosinophils with nasal symptoms in a community–based population study. The Dutch ECRHS Group. Droste JH, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):922–32

Assessment of skin prick test and serum specific IgE detection in the diagnosis of Cupressaceae pollinosis. Mari A, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):21–31

Single doses of intravenous protamine result in the formation of protamine–specific IgE and IgG antibodies. Nyhan DP, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):991–7

Fine specificity of equine infectious anaemia virus gp90–specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies. Grund CH, et al. **J Gen Virol** 1996 Mar; 77 (Pt 3):435–42

Interspecies reactivities of anti–human macrophage monoclonal antibodies to various animal species. Zeng L, et al. **J Histochem Cytochem** 1996 Aug;44(8):845–53

Evidence for distinct contributions of heavy and light chains to restriction of antibody recognition of the HIV–1 principal neutralization determinant. Watkins BA, et al. **J Immunol** 1996 Feb 15;156(4):1676–83

The role of NK cells during in vivo antigen–specific antibody responses. Wilder JA, et al. **J Immunol** 1996 Jan 1; 156(1):146–52

Influence of fluorescent antibody probe specificity on flow cytometric analysis of antibody–producing cells. Bae SW, et al. **J Immunol Methods** 1996 Jan 16;189(1):83–8

Generation of type VIII collagen–specific antibodies. Korsching E, et al. **J Immunol Methods** 1995 Dec 15; 188(1):51–62

Antibodies to p24 antigen do not specifically detect HIV–infected lymphocytes in AIDS patients. Kux A, et al. **J Immunol Methods** 1996 May 27;191(2):179–86

Evaluation of monoclonal antibodies with specificity for human IgA, IgA subclasses and allotypes and secretory component. Results of an IUIS/WHO collaborative study. Mestecky J, et al. **J Immunol Methods** 1996 Jun 21; 193(2):103–48

Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence. Rasmussen M, et al. **J Immunol Methods** 1996 Jan 16; 189(1):47–58

Structural analysis of gamma delta TCR using a novel set of TCR gamma and delta chain–specific monoclonal antibodies generated against soluble gamma delta TCR. Evidence for a specific conformation adopted by the J delta 2 region and for a V delta 1 polymorphism. Romagné F, et al. **J Immunol Methods** 1996 Jan 16;189(1):25–36

Specificity of B.C1 for TGK after renaturation prior to transfer of proteins [letter; comment] Hohl D, et al. **J Invest Dermatol** 1996 Apr;106(4):801–3. Comment on: J Invest Dermatol 1995 Feb;104(2):211–7.

Detection of specific antibodies in immune complexes of farmer's lung patients. Rottoli P, et al. **J Investig Allergol Clin Immunol** 1995 Jul–Aug;5(4):191–7

Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. Bonnycastle LL, et al. **J Mol Biol** 1996 May 24; 258(5):747–62

Peptide libraries define the fine specificity of anti–polysaccharide antibodies to Cryptococcus neoformans. Valadon P, et al. **J Mol Biol** 1996 Aug 9; 261(1):11–22

Canonical structure repertoire of the antigen–binding site of immunoglobulins suggests strong geometrical restrictions associated to the mechanism of immune recognition. Vargas–Madrazo E, et al. **J Mol Biol** 1995 Dec 1; 254(3):497–504

Inhibition of neurite outgrowth following intracellular delivery of anti–GAP–43 antibodies depends upon culture conditions and method of neurite induction. Shea TB, et al. **J Neurosci Res** 1995 Jun 15;41(3):347–54

Differential reactivity of anti–E–selectin monoclonal antibodies in human gingival tissue. Pietrzak ER, et al. **J Periodontal Res** 1995 Nov;30(6):375–81

A novel monoclonal antibody specific for sialylated MUC1 mucin. Yamamoto M, et al. **Jpn J Cancer Res** 1996 May; 87(5):488–96

Antigen–specific humoral immune responses to a hapten–carrier conjugate in SCID mice engrafted with bovine fetal hematopoietic tissues. Denny SL, et al. **Lab Anim Sci** 1996 Feb;46(1):48–55

Affinity immunoblotting. Knisley KA, et al. **Methods Mol Biol** 1995;51:165–70

Evaluation of antibody clonality. Rodkey LS. **Methods Mol Biol** 1995;51:151–63

Class–specific antibody response in acyclovir–treated and adenine arabinoside–treated patients with primary genital herpes simplex virus infection. Kawana T, et al. **Microbiol Immunol** 1995;39(10):795–9

Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: implications for serological typing and vaccine design. Suker J, et al. **Microbiology** 1996 Jan;142 (Pt 1):63–9

Antibody networks and imaging: elicitation of anti–fluorescein antibodies in response to the metatypic state of fluorescein–specific monoclonal antibodies. Cedergren AM, et al. **Mol Immunol** 1996 May–Jun; 33(7–8):711–23

Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin–1 alpha specific inhibitor. Garrone P, et al. **Mol Immunol** 1996 May–Jun;33(7–8):649–58

Primary structures of three Armenian hamster monoclonal antibodies specific for idiotopes and metatopes of the monoclonal anti–fluorescein antibody 4–4–20. Mallender WD, et al. **Mol Immunol** 1995 Oct;32(14–15):1093–103

Characterization of a monoclonal antibody directed against the NH2 terminal area of interleukin–2 (IL–2) and inhibiting specifically the binding of IL–2 to IL–2 receptor beta chain (IL–2R beta). Moreau JL, et al. **Mol Immunol** 1995 Oct;32(14–15):1047–56

BRCA1 protein products: antibody specificity... [letter; comment] Wilson CA, et al. **Nat Genet** 1996 Jul;13(3):264–5 . Comment on: Nat Genet 1996 Mar;12(3):303–8.

Testing NF–kappa B1–p50 antibody specificity using knockout mice. Pereira DS, et al. **Oncogene** 1996 Jul 18; 13(2):445–6

Elucidation of monoclonal antibody polyspecificity using a synthetic combinatorial library. Pinilla C, et al. **Pept Res** 1995 Sep–Oct;8(5):250–7

Monoclonal anti–D specificity and Rh D structure: criteria for selection of monoclonal anti–D reagents for routine typing of patients and donors [see comments] Jones J, et al. **Transfus Med** 1995 Sep;5(3):171–84 (59 ref.). Comment in: Transfus Med 1995 Dec;5(4):304–5.

Anti–epithelial (anti–A549) antibodies: their nature, specificity and relevance to transplantation. Abdul–Karim AB, et al. **Transpl Immunol** 1995 Sep;3(3):192–202

Xenoreactive natural antibodies in the world of natural antibodies: typical or unique? Parker W, et al. **Transpl Immunol** 1995 Sep;3(3):181–91 (88 ref.)

Feasibility of radioimmunoguided surgery of colorectal carcinoma using indium 111 CEA specific antibody and simulation with a phantom using 2 steps targetting with bispecific antibody. Hamy A, et al. **Tumori** 1995 May–Jun; 81(3 Suppl):103–6

Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD–1 workshop. International Society for Oncodevelopmental Biology and Medicine. Nustad K, et al. **Tumour Biol** 1996; 17(4):196–219

HIV–1 candidate vaccines can induce antibodies which share specificity with human monoclonal antibodies capable of neutralizing primary isolates [letter] Davis D. **Vaccine** 1996 Mar;14(4):353–4

Characterization of a murine–human chimeric antibody with

specificity for the pre-S2 surface antigen of hepatitis B virus expressed in baculovirus-infected insect cells. Jin BR, et al. **Virus Res** 1995 Oct;38(2-3):269-77

Specificities of rabbit antisera to multiple antigen (MAP) peptides. Chersi A, et al. **Z Naturforsch [C]** 1995 Sep-Oct; 50(9-10):735-8

[Diagnosis of acquired toxoplasmosis using simultaneous determination of specific immunoglobulins M, A and E] Valkoun A, et al. **Epidemiol Mikrobiol Imunol** 1995 Sep; 44(3):107-10 (Eng. Abstr.) **(Cze)**

[Type-specificity of serum antibodies from genital herpes patients as determined by an enzyme-linked immunosorbent assay using HSV-infected cells as antigens] Hashido M, et al. **Kansenshogaku Zasshi** 1995 Jul; 69(7):785-9 (Eng. Abstr.) **(Jpn)**

[Antibodies to organ-nonspecific and organ-specific antigens in the blood sera of persons with bronchopulmonary diseases] Iastrebova NE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):67-8 **(Rus)**

DRUG EFFECTS

Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Delgado C, et al. **Br J Cancer** 1996 Jan; 73(2):175-82

Induction of antigen-specific IgE response in murine lymphocytes by IL-10. Ohmori H, et al. **Immunol Lett** 1995 Jul-Aug;47(1-2):127-32

GENETICS

Cell cluster formation during up-scaling of a human-mouse heterohybridoma producing a polyspecific human IgM antibody. Roggenbuck D, et al. **Hybridoma** 1995 Oct; 14(5):495-500

Expression of monovalent fragments derived from a human IgM autoantibody in E. coli. The input of the somatically mutated CDR1/CDR2 and of the CDR3 into antigen binding specificity. Jahn S, et al. **Immunobiology** 1995 Aug; 193(5):400-19

Molecular characterization of human monoclonal antibodies specific for several HIV proteins: analysis of the VH3 family expression. David D, et al. **Immunol Lett** 1995 Jul-Aug;47(1-2):107-12

IMMUNOLOGY

Specificity of intrathecal IgG synthesis for HTLV-1 core and envelope proteins in HAM/TSP. Kitze B, et al. **Acta Neurol Scand** 1995 Sep;92(3):213-7

Organ-specific cardiac autoantibodies in dilated cardiomyopathy. Frequency and clinical correlates in Polish patients. Bilińska ZT, et al. **Eur Heart J** 1995 Dec; 16(12):1907-11

Organ-specific cardiac autoantibodies in dilated cardiomyopathy--an update. Caforio AL, et al. **Eur Heart J** 1995 Dec;16 Suppl O:68-70

The contribution of specific immunoglobulin M antibodies to the diagnosis of Helicobacter pylori infection in children. Blecker U, et al. **Eur J Gastroenterol Hepatol** 1995 Oct; 7(10):979-83

Early detection of specific IgE antibody against house dust mite in children at risk of allergic disease. Sasai K, et al. **J Pediatr** 1996 Jun;128(6):834-40

Value of clinical symptoms, intrathecal specific antibody production and PCR in CSF in the diagnosis of childhood Lyme neuroborreliosis. Issakainen J, et al. **Klin Padiatr** 1996 May-Jun;208(3):106-9

Monoclonal antibodies for the measurement of class-specific antibody responses in the green turtle, Chelonia mydas. Herbst LH, et al. **Vet Immunol Immunopathol** 1995 Jun; 46(3-4):317-35

Monoclonal antibodies specific for equine IgG sub-isotypes including an antibody which recognizes B lymphocytes. Lunn DP, et al. **Vet Immunol Immunopathol** 1995 Aug; 47(3-4):239-51

Immunocytochemical analysis of a monoclonal antibody specific for rainbow trout (Oncorhynchus mykiss) granulocytes and thrombocytes. Slierendrecht WJ, et al. **Vet Immunol Immunopathol** 1995 Jun;46(3-4):349-60

[The indices of interleukin 1, 2 and 4 production and the specific antibody titers in mice with an opposite sensitivity to staphylococcal infection] Averbakh MM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):79-81 (Eng. Abstr.) **(Rus)**

ANTIBODY-TOXIN CONJUGATES see **IMMUNOTOXINS**

ANTIBODY-TOXIN HYBRIDS see **IMMUNOTOXINS**

ANTICANCER DRUG COMBINATIONS see **ANTINEOPLASTIC AGENTS, COMBINED**

ANTICANCER DRUG SENSITIVITY TESTS see **DRUG SCREENING ASSAYS, ANTITUMOR**

ANTICARCINOGENIC AGENTS

see related
ANTIMUTAGENIC AGENTS
ANTINEOPLASTIC AGENTS

Daidzein and genistein concentrations in human milk after soy consumption [see comments] Franke AA, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):955-64. Comment in: Clin Chem 1996 Jun;42(6 Pt 1):841-2.

Capsaicin in hot chili pepper: carcinogen, co-carcinogen or anticarcinogen? Surh YJ, et al. **Food Chem Toxicol** 1996 Mar;34(3):313-6 (48 ref.)

Ascorbic acid and gastrointestinal cancer. Cohen M, et al. **J Am Coll Nutr** 1995 Dec;14(6):565-78 (136 ref.)

Cancer Chemopreventive Agents: Drug Development Status and Future Prospects. Conference proceedings. Princeton, New Jersey, October 18-22, 1994. **J Cell Biochem Suppl** 1995;22:1-262

Learning how phytochemicals help fight disease [news] Marwick C. **JAMA** 1995 Nov 1;274(17):1328-30

Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Narisawa T, et al. **Jpn J Cancer Res** 1996 Aug;87(8):798-804

Tea consumption and lung cancer risk: a case-control study in Okinawa, Japan. Ohno Y, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1027-34

The 4th International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis. Banff, Canada, 4-9 September 1994. **Mutat Res** 1996 Feb 19;350(1):1-294

The 4th International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis: a summary. Liviero L, et al. **Mutat Res** 1996 Feb 19;350(1):287-93

Dietary antioxidants in disease prevention. Gordon M. **Nat Prod Rep** 1996 Aug;13(4):265-73 (130 ref.)

Special issue: Proceedings of the American Health Foundation's 25th Anniversary Symposium. Toward optimal health: examining goals for nutrition and the environment. Tarrytown, New York, November 16-17, 1994. **Prev Med** 1996 Jan-Feb;25(1):1-67

[Calcium and colon cancer] Liberman-Insel V, et al. **Harefuah** 1996 Jan 15;130(2):129-31 (20 ref.) **(Heb)**

ADMINISTRATION & DOSAGE

Interactions in indices of vitamin A, zinc and copper status when these nutrients are fed to rats at adequate and increased levels. Sundaresan PR, et al. **Br J Nutr** 1996 Jun; 75(6):915-28

Efficacy of cancer prevention by high-selenium garlic is primarily dependent on the action of selenium. Ip C, et al. **Carcinogenesis** 1995 Nov;16(11):2649-52

Chemoprevention by melatonin and combined melatonin-tamoxifen therapy of second generation nitroso-methylurea-induced mammary tumours in rats. Kothari A, et al. **Eur J Cancer Prev** 1995 Dec;4(6):497-500

Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. The Australian Polyp Prevention Project [see comments] MacLennan R, et al. **J Natl Cancer Inst** 1995 Dec 6;87(23):1760-6. Comment in: J Natl Cancer Inst 1995 Dec 6;87(23):1733-5. Comment in: J Natl Cancer Inst 1996 Mar 20;88(6):377-8.

A pilot study for a randomized controlled trial to prevent gastric cancer in high-risk Japanese population: study design and feasibility evaluation. Tsugane S, et al. **Jpn J Cancer Res** 1996 Jul;87(7):676-9

Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Reddy BS. **Prev Med** 1996 Jan-Feb;25(1):48-50 (13 ref.)

ADVERSE EFFECTS

-Tamoxifen and the endometrium: monitoring and evaluation of endometrial changes- Rageth JC, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S122-7 (24 ref.) **(Ger)**

ANALYSIS

Quantification of genistein and genistin in soybeans and soybean products. Fukutake M, et al. **Food Chem Toxicol** 1996 May;34(5):457-61

High-performance liquid chromatographic assay for Melanotan-1 ([Nle4-DPhe7]alpha-melanocyte-stimulating hormone) in biological matrices. Surendran N, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):235-42

Survey of the conjugated linoleic acid contents of dairy products. Lin H, et al. **J Dairy Sci** 1995 Nov;78(11):2358-65

CHEMISTRY

Steroidal saponins from the underground parts of Hosta longipes and their inhibitory activity on tumor promoter-induced phospholipid metabolism. Mimaki Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1190-6

How to see characteristics of structural parameters in QSAR analysis: descriptor mapping using neural networks. Ichikawa H, et al. **SAR QSAR Environ Res** 1993; 1(2-3):115-30

ECONOMICS

Is chemoprevention overrated or underfunded? [news] Nelson NJ. **J Natl Cancer Inst** 1996 Jul 17;88(14):947-9

METABOLISM

N-(4-hydroxyphenyl)retinamide: interactions with retinoid-binding proteins/receptors. Sani BP, et al. **Carcinogenesis** 1995 Oct;16(10):2531-4

The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: potential importance to its proposed anti-carcinogenic/carcinogenic actions. Wiseman H, et al. **Carcinogenesis** 1996 Jun;17(6):1357-60

Toxicity and metabolism in mice of 2,6-dithiopurine, a potential chemopreventive agent. Qing WG, et al. **Drug Metab Dispos** 1995 Aug;23(8):854-60

Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and oltipraz. Buetler TM, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):45-57

PHARMACOKINETICS

Contrasting patterns of selenium excretion by female CD rats treated with chemically related chemopreventive organic selenocyanate compounds. Sohni OS, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):1849-56

Mechanisms of tumor modulation by indole-3-carbinol. Disposition and excretion in male Fischer 344 rats. Stresser DM, et al. **Drug Metab Dispos** 1995 Sep;23(9):965-75

PHARMACOLOGY

Growth retardation in human cervical dysplasia-derived cell lines by beta-carotene through down-regulation of epidermal growth factor receptor. Muto Y, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1535S-1540S

Chemoprevention of mammary preneoplasia. In vitro effects of a green tea polyphenol. Araki R, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:215-22

Activity of maitake D-fraction to inhibit carcinogenesis and metastasis. Nanba H. **Ann N Y Acad Sci** 1995 Sep 30; 768:243-5

Inhibition of steroid 5 alpha-reductase activity by aliphatic fatty acids. Candidates for chemoprevention of prostate cancer. Niederprüm HJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:227-30

Effect of retinoic acid (RA) in MNU-induced rat mammary tumors. Okamoto T, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:223-6

Inhibition of DNA adduct formation of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) by dietary indole-3-carbinol (I3C) in the mammary gland, colon, and liver of the female F-344 rat. Schut HA, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:210-4

Molecular markers in chemoprevention of colon cancer. Inhibition of expression of ras-p21 and p53 by sulindac during azoxymethane-induced colon carcinogenesis. Singh J, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:205-9

How can carcinogenesis be inhibited? Smith TJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:82-90 (67 ref.)

Inhibitory effects of chlorophyllin on chemically induced mutagenesis and carcinogenesis. Surh YJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:246-9

Inhibition of the development of rat liver preneoplastic lesions by verapamil and dexverapamil. Ghia M, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1739-41

Relative efficacy of the opioid antagonist, naltrexone, on the initiation and promotion phases of rat mammary carcinogenesis. Koo KL, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1893-8

Deoxycholic acid as an endogenous risk factor for hepatocarcinogenesis and effects of gomisin A, a lignan component of Schizandra fruits. Ohmki Y, et al. **Anticancer Res** 1996 Mar-Apr;16(2):751-5

Novel anti-carcinogenic activity of an organosulfide from garlic: inhibition of H-RAS oncogene transformed tumor growth in vivo by diallyl disulfide is associated with inhibition of p21H-ras processing. Singh SV, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):660-5

Effects of gomisin A on the promotor action and serum bile acid concentration in hepatocarcinogenesis induced by 3'-methyl-4-dimethylamino-azobenzene. Miyamoto K, et al. **Biol Pharm Bull** 1995 Oct;18(10):1443-5

Effect of selenium on malignant tumor cells of brain. Zhu Z, et al. **Biol Trace Elem Res** 1995 Jul;49(1):1-7

Beta-carotene prevents lipid peroxidation and red blood cell membrane protein damage in experimental hepatocarcinogenesis. Sarkar A, et al. **Cancer Biochem Biophys** 1995 Nov;15(2):111-25

Saffron chemoprevention in biology and medicine: a review. Nair SC, et al. **Cancer Biother** 1995 Winter;10(4):257-64 (41 ref.)

Ipomeanol analogs as chemopreventive agents: effect on the in vitro metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Desai D, et al. **Cancer Lett** 1995 Nov 6;97(2):155-62

Suppression of the tumorigenicity of human hepatoma hep3B cells by long-term retinoic acid treatment. Hsu SL, et al. **Cancer Lett** 1996 Jan 19;99(1):79-85

Native cellular fluorescence identifies terminal squamous differentiation of normal oral epithelial cells in culture: a potential chemoprevention biomarker. Sacks PG, et al. **Cancer Lett** 1996 Jul 12;104(2):171-81

Rosemary extract and carnosol stimulate rat liver glutathione-S-transferase and quinone reductase activities. Singletary KW. **Cancer Lett** 1996 Feb 27;100(1-2):139-44

Induction by carcinogens and chemoprevention by N-acetylcysteine of adducts to mitochondrial DNA in rat organs. Balansky R, et al. **Cancer Res** 1996 Apr 1;

56(7):1642–7
Oltipraz–mediated changes in aflatoxin B(1) biotransformation in rat liver: implications for human chemointervention. Buetler TM, et al. **Cancer Res** 1996 May 15;56(10):2306–13
Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole–3–carbinol. Christensen JG, et al. **Cancer Res** 1996 Feb 1;56(3):574–81
Biomarker alterations produced in rat lung by intratracheal instillations of air particulate extracts and chemoprevention with oral N–acetylcysteine. Izzotti A, et al. **Cancer Res** 1996 Apr 1;56(7):1533–8
Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti–inflammatory drug piroxicam. Jacoby RF, et al. **Cancer Res** 1996 Feb 15;56(4):710–4
Suppression of carcinogenesis in the intestines of min mice by the soybean–derived Bowman–Birk inhibitor. Kennedy AR, et al. **Cancer Res** 1996 Feb 15;56(4):679–82
SCH 51344 inhibits ras transformation by a novel mechanism. Kumar CC, et al. **Cancer Res** 1995 Nov 1;55(21):5106–17
Inhibition of CYP1A2 and CYP3A4 by oltipraz results in reduction of aflatoxin B1 metabolism in human hepatocytes in primary culture. Langouët S, et al. **Cancer Res** 1995 Dec 1;55(23):5574–9
Inhibition of tumor promoter–induced transformation by retinoids that transrepress AP–1 without transactivating retinoic acid response element. Li JJ, et al. **Cancer Res** 1996 Feb 1;56(3):483–9
Effects of phenethyl isothiocyanate on the tissue distribution of 4–(methylnitrosamino)–1–(3–pyridyl)–1–butanone and metabolites in F344 rats. Staretz ME, et al. **Cancer Res** 1995 Dec 1;55(23):5580–8
A new process of cancer prevention mediated through inhibition of tumor necrosis factor alpha expression. Suganuma M, et al. **Cancer Res** 1996 Aug 15;56(16):3711–5
Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C–alpha, –beta II, and –zeta. Wali RK, et al. **Cancer Res** 1995 Nov 15; 55(22):5257–64
Phenethyl isothiocyanate, a natural chemopreventive agent, activates c–Jun N–terminal kinase 1. Yu R, et al. **Cancer Res** 1996 Jul 1;56(13):2954–9
In vitro exposure to cadmium in rat L6 myoblasts can result in both enhancement and suppression of malignant progression in vivo. Abshire MK, et al. **Carcinogenesis** 1996 Jun;17(6):1349–56
Effects of dietary beta–carotene and selenium on initiation and promotion of pancreatic carcinogenesis in azaserine–treated rats. Appel MJ, et al. **Carcinogenesis** 1996 Jul;17(7):1411–6
Inhibitory effect of dietary flavonol quercetin on 7,12–dimethylbenz[a]anthracene–induced hamster buccal pouch carcinogenesis. Balasubramanian S, et al. **Carcinogenesis** 1996 Apr;17(4):877–9
CYP2E1–mediated mechanism of anti–genotoxicity of the broccoli constituent sulforaphane. Barcelo S, et al. **Carcinogenesis** 1996 Feb;17(2):277–82
Structure–function relationships of the dietary anticarcinogen ellagic acid. Barch DH, et al. **Carcinogenesis** 1996 Feb; 17(2):265–9
Sulindac suppresses tumorigenesis in the Min mouse. Beazer–Barclay Y, et al. **Carcinogenesis** 1996 Aug; 17(8):1757–60
Inhibition of aflatoxin MI excretion in rat urine during dietary intervention with oltipraz. Chung FL, et al. **Carcinogenesis** 1996 Jun;17(6):1385–8
Re: Pereira, M.A., Barnes, L.H., Rassman, V.L., Kelloff, G.V. and Steele, V.E. (1994). Use of azoxymethane–induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis, 15, 1049–1054 [letter] Hardman WE, et al. **Carcinogenesis** 1996 Jul;17(7):1539–40
Chemopreventive effect of S–allylcysteine and its relationship to the detoxification enzyme glutathione S–transferase. Hatono S, et al. **Carcinogenesis** 1996 May;17(5):1041–4
Inhibitory effects of 1–O–hexyl–2,3,5–trimethylhydroquinone (HTHQ), green tea catechins and other antioxidants on 2–amino–6–methyldipyrido[1,2–a:3',2'–d]imidazole (Glu–P–1)–induced rat hepatocarcinogenesis and dose–dependent inhibition by HTHQ of lesion induction by Glu–P–1 or 2–amino–3,8–dimethylimidazo[4,5–f]quinoxaline (MeIQx). Hirose M, et al. **Carcinogenesis** 1995 Dec;16(12):3049–55
The efficacy of conjugated linoleic acid in mammary cancer prevention is independent of the level or type of fat in the diet. Ip C, et al. **Carcinogenesis** 1996 May;17(5):1045–50
Inhibitory effects of d–limonene on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats. Kawamori T, et al. **Carcinogenesis** 1996 Feb; 17(2):369–72
Genistein suppresses mammary cancer in rats. Lamartiniere CA, et al. **Carcinogenesis** 1995 Nov;16(11):2833–40
The effects of cycloheximide and WR–1065 on radiation–induced repair processes: a mechanism for chemoprevention. Murley JS, et al. **Carcinogenesis** 1995 Nov;16(11):2699–705
Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Murrill WB, et al. **Carcinogenesis** 1996 Jul;17(7):1451–7
Effects of docosahexaenoic acid (DHA) on intestinal polyp development in Apc delta 716 knockout mice. Oshima M, et al. **Carcinogenesis** 1995 Nov;16(11):2605–7
Effects of dietary 1,4–phenylenebis(methylene)selenocyanate on 4–(methylnitrosamino)–1–(3–pyridyl)–1–butanone–induced DNA adduct formation in lung and liver of A/J mice and F344 rats. Prokopczyk B, et al. **Carcinogenesis** 1996 Apr; 17(4):749–53
Inhibitory effect of probucol on nephrotoxicity induced by ferric nitrilotriacetate (Fe–NTA) in rats. Qin X, et al. **Carcinogenesis** 1995 Oct;16(10):2549–52
Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Rao KV, et al. **Carcinogenesis** 1996 Jul; 17(7):1435–8
N–(4–hydroxyphenyl)retinamide (4–HPR)–mediated biological actions involve retinoid receptor–independent pathways in human breast carcinoma. Sheikh MS, et al. **Carcinogenesis** 1995 Oct;16(10):2477–86
Persistent chemopreventive effect of S–adenosyl–L–methionine on the development of liver putative preneoplastic lesions induced by thiobenzamide in diethylnitrosamine–initiated rats. Simile MM, et al. **Carcinogenesis** 1996 Jul;17(7):1533–7
Modulatory influence of chlorophyllin on the mouse skin papillomagenesis and xenobiotic detoxication system. Singh A, et al. **Carcinogenesis** 1996 Jul;17(7):1459–63
Use of a microsome–mediated test system to assess efficacy and mechanisms of cancer chemopreventive agents. Smith WA, et al. **Carcinogenesis** 1996 Jun;17(6):1285–90
Diallyl disulfide induces apoptosis of human colon tumor cells. Sundaram SG, et al. **Carcinogenesis** 1996 Apr; 17(4):669–73
The model Ah–receptor agonist beta–naphthoflavone inhibits aflatoxin B1–DNA binding in vivo in rainbow trout at dietary levels that do not induce CYP1A enzymes. Takahashi N, et al. **Carcinogenesis** 1996 Jan;17(1):79–87
Effect of oltipraz, alpha–tocopherol, beta–carotene and phenethylisothiocyanate on rat oesophageal, gastric, colonic and hepatic glutathione, glutathione S–transferase and peroxidase. van Lieshout EM, et al. **Carcinogenesis** 1996 Jul;17(7):1439–45
Molecular effects of genistein on estrogen receptor mediated pathways. Wang TT, et al. **Carcinogenesis** 1996 Feb; 17(2):271–5
Inhibition of UV light– and Fenton reaction–induced oxidative DNA damage by the soybean isoflavone genistein. Wei H, et al. **Carcinogenesis** 1996 Jan;17(1):73–7
The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme–substrate interactions: potential importance to its proposed anti–carcinogenic/carcinogenic actions. Wiseman H, et al. **Carcinogenesis** 1996 Jun;17(6):1357–60
Antioxidants inhibit the enhancement of malignant cell transformation induced by 2,3,7,8–tetrachlorodibenzo–p–dioxin. Wölfle D, et al. **Carcinogenesis** 1996 Jun;17(6):1273–8
Protection by green tea, black tea, and indole–3–carbinol against 2–amino–3–methylimidazo[4,5–f]quinoline–induced DNA adducts and colonic aberrant crypts in the F344 rat. Xu M, et al. **Carcinogenesis** 1996 Jul;17(7):1429–34
Inhibition of the tumor promoting action of 12–O–tetradecanoylphorbol–13–acetate by tubeimoside III isolated from Bolbostemma paniculatum. Yu L, et al. **Carcinogenesis** 1995 Dec;16(12):3045–8
Inhibitory effect of probucol on benzo[alpha]pyrene induced lung tumorigenesis. Zarkovic M, et al. **Carcinogenesis** 1995 Oct;16(10):2599–601
Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N–(4–hydroxyphenyl) retinamide. Pellegrini R, et al. **Cell Growth Differ** 1995 Jul; 6(7):863–9
Differential effects of nitrogen mustard in vivo on the cancer and host cells in MCa–11 tumours. Bose KK, et al. **Cell Prolif** 1995 Jul;28(7):403–14
Cell cycle perturbation by sodium butyrate in tumorigenic and non–tumorigenic human urothelial cell lines assessed by flow cytometric bromodeoxyuridine/DNA analysis. Larsen JK, et al. **Cell Prolif** 1995 Jul;28(7):359–71
Steroidal saponins from the underground parts of Hosta longipes and their inhibitory activity on tumor promoter–induced phospholipid metabolism. Mimaki Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1190–6
Antitumor–promoting activities of various synthetic 1–O–acyl–3–O–(6'–O–acyl–beta–D–galactopyranosyl)–sn–glycerols related to natural product from freshwater cyanobacterium Anabaena flos–aquae f. flos–aquae. Shirahashi H, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul; 44(7):1404–6
Screening of tissue cultures and thalli of lichens and some of their active constituents for inhibition of tumor promoter–induced Epstein–Barr virus activation. Yamamoto Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Aug; 43(8):1388–90
Mechanisms of tumor modulation by indole–3–carbinol. Disposition and excretion in male Fischer 344 rats. Stresser DM, et al. **Drug Metab Dispos** 1995 Sep;23(9):965–75
Phytoestrogens: epidemiology and a possible role in cancer protection. Adlercreutz H. **Environ Health Perspect** 1995 Oct;103 Suppl 7:103–12 (133 ref.)
Dietary modifiers of carcinogenesis. Kohlmeier L, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:177–84 (78 ref.)
Phytoestrogens are partial estrogen agonists in the adult male mouse. Mäkelä S, et al. **Environ Health Perspect** 1995 Oct; 103 Suppl 7:123–7
Effects of 22–oxacalcitriol on bone metabolism in vitro: comparison with calcitriol—effects of 22–oxacalcitriol on osteoclast–like cell formation and bone–resorbing activity. Kanatani M, et al. **Eur J Endocrinol** 1995 Nov; 133(5):618–25
Protein kinase C isoforms in the chemopreventive effects of a novel vitamin D3 analogue in rat colonic tumorigenesis. Wali RK, et al. **Gastroenterology** 1996 Jul;111(1):118–26
Suppression by amiloride of bombesin–enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Iishi H, et al. **Int J Cancer** 1995 Nov 27; 63(5):716–9
Effect of prepubertal retinyl palmitate treatment on uterine development and subsequent uterine capacity in swine. Vallet JL, et al. **J Anim Sci** 1996 Mar;74(3):603–9
The anticarcinogen 3,3'–diindolylmethane is an inhibitor of cytochrome P–450. Stresser DM, et al. **J Biochem Toxicol** 1995 Aug;10(4):191–201
Nutrient antioxidants in the pathogenesis and prevention of cervical dysplasias and cancer. Romney SL, et al. **J Cell Biochem Suppl** 1995;23:96–103 (45 ref.)
Growth inhibition and induction of apoptosis by fenretinide in small–cell lung cancer cell lines [see comments] Kalemkerian GP, et al. **J Natl Cancer Inst** 1995 Nov 15; 87(22):1674–80. Comment in: J Natl Cancer Inst 1995 Nov 15;87(22):1655–7.
Phenethyl isothiocyanate, a new dietary liver aldehyde dehydrogenase inhibitor. Lindros KO, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):79–83
Effect of herba artemisiae scopariae on cytogenetic damage induced by aflatoxin B1. Hong Z, et al. **J Tradit Chin Med** 1996 Mar;16(1):51–4
Inhibition of 1,2–dimethylhydrazine–induced oxidative DNA damage by green tea extract in rat. Inagake M, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1106–11
Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti–c–myc DNA phosphorothioate. Huang Y, et al. **Mol Med** 1995 Sep; 1(6):647–58
Antioxidant defences against reactive oxygen species causing genetic and other damage. Anderson D. **Mutat Res** 1996 Feb 19;350(1):103–8 (46 ref.)
Analysis of National Toxicology Program rodent bioassay data for anticarcinogenic effects. Haseman JK, et al. **Mutat Res** 1996 Feb 19;350(1):131–41
Dietary garlic extract in modifying clastogenic effects of inorganic arsenic in mice: two–generation studies. RoyChoudhury A, et al. **Mutat Res** 1996 Apr 4; 359(3):165–70
Natural toxins and protective factors in brassica species, including rapeseed. Heaney RK, et al. **Nat Toxins** 1995; 3(4):233–7; discussion 242 (16 ref.)
Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha–carotene or beta–carotene. Levy J, et al. **Nutr Cancer** 1995;24(3):257–66
Selective toxicity of compounds naturally present in food toward the transformed phenotype of human colorectal cell line HT29. Musk SR, et al. **Nutr Cancer** 1995; 24(3):289–98
Inhibitory effect of taraxastane–type triterpenes on tumor promotion by 12–O–tetradecanoylphorbol–13–acetate in two–stage carcinogenesis in mouse skin. Yasukawa K, et al. **Oncology** 1996 Jul–Aug;53(4):341–4
Bombesin antagonist prevents CO2 laser–induced promotion of oral cancer. Kozacko MF, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2953–7
Transforming growth factor–beta s in mammary tumorigenesis: promoters or antipromoters? Wakefield LM, et al. **Prog Clin Biol Res** 1995;391:133–48 (56 ref.)
The role of lactic acid bacteria in colon cancer prevention. Rafter JJ. **Scand J Gastroenterol** 1995 Jun;30(6):497–502 (56 ref.)
Effect of fumaric acid, its dimethylester, and topical antipsoriatic drugs on epidermal differentiation in the mouse tail model. Sebök B, et al. **Skin Pharmacol** 1996; 9(2):99–103
Mechanisms in tumor promotion: guidance for risk assessment and cancer chemoprevention. Marks F, et al. **Toxicol Lett** 1995 Dec;82–83:907–17
Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Smith LL, et al. **Toxicol Lett** 1995 Dec; 82–83:181–6 (18 ref.)
Chemoprotection against cancer by phase 2 enzyme induction. Talalay P, et al. **Toxicol Lett** 1995 Dec; 82–83:173–9 (36 ref.)
Effect of methimazole on rat renal carcinogenesis induced by N–ethyl–N–hydroxyethylnitrosamine. Konishi N, et al. **Toxicol Pathol** 1995 Sep–Oct;23(5):606–11
Antioxidant agents and colorectal carcinogenesis: role of beta–carotene, vitamin E and vitamin C. Pappalardo G, et al. **Tumori** 1996 Jan–Feb;82(1):6–11 (88 ref.)
[Induction of differentiation by all–trans–retinoic acid in a human lung adenocarcinoma cell line] Li B, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Nov;75(11):683–5, 711 (Eng. Abstr.) **(Chi)**
[Inhibition of colorectal carcinoma induced by 1, 2–dimethylhydrazine in mice with tea polyphenols] Pan H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov;

29(6):356–9 (Eng. Abstr.) **(Chi)**

[Inhibition of ornithine decarboxylase activity and epidermal papilloma in mice by beta-carotene] Tan A, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):360–2 (Eng. Abstr.) **(Chi)**

[Anti-promoting and anti-mutagenic actions of G9315] Fu N, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):349–52 (Eng. Abstr.) **(Chi)**

[Anticarcinogenic effect of beta-carotene on the development of rat kidney tumors induced by 3-(alpha-L-arabinopyranosyl-1)methyl-1-nitrosourea (AMNU)] Sherenesheva NI, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):453-5 **(Rus)**

[Melatonin and epithalamin inhibit the process of free radical oxidation in rats] Anisimov VN, et al. **Dokl Akad Nauk** 1995 Aug;343(4):557-9 **(Rus)**

THERAPEUTIC USE

Tamoxifen for the prevention of breast cancer [letter; comment] Greenspan EM. **Am J Med** 1996 Jun;100(6):665 . Comment on: Am J Med 1995 Aug;99(2):180–9.

Indole-3-carbinol. A novel approach to breast cancer prevention. Bradlow HL, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:180–200 (22 ref.)

Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. Costa A, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:148–62 (49 ref.)

The potential application of finasteride for chemoprevention of prostate cancer. Gormley GJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:163–9 (22 ref.)

Preventive clinical trials. An overview. Greenwald P. **Ann N Y Acad Sci** 1995 Sep 30;768:129–40 (41 ref.)

An overview of considerations for the testing of tamoxifen as a preventive for breast cancer. Jordan VC. **Ann N Y Acad Sci** 1995 Sep 30;768:141–7 (47 ref.)

Strategies for colon cancer prevention. Lipkin M. **Ann N Y Acad Sci** 1995 Sep 30;768:170–9 (10 ref.)

Chemoprevention of colon cancer by dietary curcumin. Rao CV, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:201–4

Behavioral and social factors that predict participation in the Breast Cancer Prevention Trial. Vernon SW, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:300

What are the critical attributes for cancer chemopreventive agents? Wattenberg LW. **Ann N Y Acad Sci** 1995 Sep 30; 768:73–81 (35 ref.)

Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth. Curley RW Jr, et al. **Anticancer Res** 1996 Mar-Apr;16(2):757–63

Expression of retinoic acid receptors in squamous cell carcinomas and their possible implication for chemoprevention. Issing WJ, et al. **Anticancer Res** 1996 Jul-Aug;16(4C):2373–7

The development of an anchorage-independence assay using human lung tumor cells to screen potential chemopreventive agents. Korytynski EA, et al. **Anticancer Res** 1996 May-Jun;16(3A):1091–4

Chemoprevention of diethylnitrosamine-induced liver foci and hepatocellular adenomas in C3H mice. Pereira MA. **Anticancer Res** 1995 Sep-Oct;15(5B):1953–6

Evaluation of organoselenium compounds for potential chemopreventive properties in colon cancer. Reddy BS, et al. **Anticancer Res** 1996 May-Jun;16(3A):1123–7

Transient blockage of proliferative signalling: a novel strategy for protective chemotherapy. Weyman CM, et al. **Anticancer Res** 1996 Jan-Feb;16(1):493–8

Evaluating the role of niacin in human carcinogenesis. Jacobson EL, et al. **Biochimie** 1995;77(5):394–8 (22 ref.)

Suppressive effect of molybdenum on hepatotoxicity of N-nitrosodiethylamine in rats. Koizumi T, et al. **Biol Pharm Bull** 1995 Mar;18(3):460–2

Anti-tumor-promoting activities of euglobals from Eucalyptus plants. Takasaki M, et al. **Biol Pharm Bull** 1995 Mar;18(3):435–8

Anxiety in women "at risk' of developing breast cancer. Thirlaway K, et al. **Br J Cancer** 1996 Jun;73(11):1422–4

Chemoprevention trials and surrogate end point biomarkers in the cervix. Mitchell MF, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1956–77 (227 ref.)

Inhibitory effects and toxicity of green tea polyphenols for gastrointestinal carcinogenesis. Yamane T, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1662–7

Chemoprevention of the naturally occurring carcinogen 1-hydroxyanthraquinone-induced carcinogenesis by the nonsteroidal anti-inflammatory drug indomethacin in rats. Tanaka T, et al. **Cancer Detect Prev** 1995;19(5):418–25

Effects of watercress consumption on metabolism of a tobacco-specific lung carcinogen in smokers. Hecht SS, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Dec; 4(8):877–84

Design and recruitment for retinoid skin cancer prevention (SKICAP) trials. The Southwest Skin Cancer Prevention Study Group. Moon TE, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):661–9

Decreased incidence of spontaneous mammary gland neoplasms in female F344 rats treated with amphetamine, methylphenidate, or codeine. Dunnick JK, et al. **Cancer Lett** 1996 Apr 19;102(1–2):77–83

Inhibitory effect of iridoids on Epstein-Barr virus activation by a short-term in vitro assay for anti-tumor promoters. Kapadia GJ, et al. **Cancer Lett** 1996 Apr 19;102(1–2):223–6

Chemoprevention of lung and skin cancer by Beta vulgaris (beet) root extract. Kapadia GJ, et al. **Cancer Lett** 1996 Feb 27;100(1–2):211–4

Chemopreventive activity of chlorophyllin against mouse skin carcinogenesis by benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide. Park KK, et al. **Cancer Lett** 1996 Apr 19;102(1–2):143–9

Effect of free fatty acids on two-stage skin carcinogenesis in mice. Ramesh G, et al. **Cancer Lett** 1996 Feb 27; 100(1–2):199–209

Garlic and associated allyl sulfur components inhibit N-methyl-N-nitrosourea induced rat mammary carcinogenesis. Schaffer EM, et al. **Cancer Lett** 1996 Apr 19;102(1–2):199–204

A rapid dual organ rat carcinogenesis bioassay for evaluating the chemoprevention of breast and colon cancer. Shivapurkar N, et al. **Cancer Lett** 1996 Feb 27; 100(1–2):169–79

Antitumour activity of protein A in a mouse skin model of two-stage carcinogenesis. Shukla Y, et al. **Cancer Lett** 1996 May 15;103(1):41–7

Inhibition by rosemary and carnosol of 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary tumorigenesis and in vivo DMBA-DNA adduct formation. Singletary K, et al. **Cancer Lett** 1996 Jun 24; 104(1):43–8

Inhibition of 12-O-tetradecanoylphorbol-13-acetate promoted mouse skin papilloma by digalactosyl diacylglycerols from the fresh water cyanobacterium Phormidium tenue. Tokuda H, et al. **Cancer Lett** 1996 Jun 24;104(1):91–5

Inhibition of the hepatocarcinogenicity of aflatoxin B1 in rats by low levels of the phenolic antioxidants butylated hydroxyanisole and butylated hydroxytoluene. Williams GM, et al. **Cancer Lett** 1996 Jun 24;104(1):49–53

Cholesterol sulfate, a second messenger for the eta isoform of protein kinase C, inhibits promotional phase in mouse skin carcinogenesis. Chida K, et al. **Cancer Res** 1995 Nov 1;55(21):4865–9

Chemopreventive efficacy of arylalkyl isothiocyanates and N-acetylcysteine for lung tumorigenesis in Fischer rats. Chung FL, et al. **Cancer Res** 1996 Feb 15;56(4):772–8

G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. DuBois RN, et al. **Cancer Res** 1996 Feb 15; 56(4):733–7

Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Joseph IB, et al. **Cancer Res** 1996 Aug 1; 56(15):3404–8

Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Lucia MS, et al. **Cancer Res** 1995 Dec 1;55(23):5621–7

Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland. McCormick DL, et al. **Cancer Res** 1996 Apr 15; 56(8):1724–6

Inhibition of 2-Amino-1-methyl-6-phenylimidazo[4,5]pyridine-induced lymphoma formation by oltipraz. Rao CV, et al. **Cancer Res** 1996 Aug 1;56(15):3395–8

Chemoprevention by dehydroepiandrosterone and indomethacin in a rat multiorgan carcinogenesis model. Shibata M, et al. **Cancer Res** 1995 Nov 1;55(21):4870–4

Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and beta-carotene in 10T1/2 cells. Acevedo P, et al. **Carcinogenesis** 1995 Sep;16(9):2215–22

Chemopreventive activity of Oltipraz against N-nitrosobis(2-oxopropyl)amine (BOP)-induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters. Clapper ML, et al. **Carcinogenesis** 1995 Sep;16(9):2159–65

Protection by chlorophyllin and indole-3-carbinol against 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced DNA adducts and colonic aberrant crypts in the F344 rat. Guo D, et al. **Carcinogenesis** 1995 Dec; 16(12):2931–7

Inhibitory effect of chlorophyllin on PhIP-induced mammary carcinogenesis in female F344 rats. Hasegawa R, et al. **Carcinogenesis** 1995 Sep;16(9):2243–6

Chemoprevention of urinary bladder carcinogenesis by the natural phenolic compound protocatechuic acid in rats. Hirose Y, et al. **Carcinogenesis** 1995 Oct;16(10):2337–42

Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. Huang MT, et al. **Carcinogenesis** 1995 Oct; 16(10):2493–7

The influence of flaxseed and lignans on colon carcinogenesis and beta-glucuronidase activity. Jenab M, et al. **Carcinogenesis** 1996 Jun;17(6):1343–8

Lack of effect of retinoic acid and fluocinolone acetonide on mirex tumor promotion indicates a novel mirex mechanism. Kim TW, et al. **Carcinogenesis** 1995 Sep; 16(9):2199–204

Protection of conjugated linoleic acids against 2-amino-3-methylimidazo[4,5-f]quinoline-induced colon carcinogenesis in the F344 rat: a study of inhibitory mechanisms. Liew C, et al. **Carcinogenesis** 1995 Dec; 16(12):3037–43

Inhibition of 4-nitroquinoline-1-oxide-induced rat oral carcinogenesis by dietary exposure of a new retinoidal butenolide, KYN-54, during the initiation and post-initiation phases. Makita H, et al. **Carcinogenesis** 1995 Sep;16(9):2171–6

K-ras mutations in lung tumors from A/J and A/J x TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. Matzinger SA, et al. **Carcinogenesis** 1995 Oct;16(10):2487–92

Chemopreventive effects of phenethyl isothiocyanate on lung and pancreatic tumorigenesis in N-nitrosobis(2-oxopropyl)amine-treated hamsters. Nishikawa A, et al. **Carcinogenesis** 1996 Jun;17(6):1381–4

Rosemary components inhibit benzo[a]pyrene-induced genotoxicity in human bronchial cells. Offord EA, et al. **Carcinogenesis** 1995 Sep;16(9):2057–62

Evaluation of chemopreventive effect of dietary selenium-rich egg on mouse skin tumor induced by 2'-(4-nitrophenoxy)oxirane and 12-O-tetradecanoylphorbol-13-acetate. Oh SH, et al. **Carcinogenesis** 1995 Dec;16(12):2995–8

Suppressing effect of perilla oil on azoxymethane-induced foci of colonic aberrant crypts in rats. Onogi N, et al. **Carcinogenesis** 1996 Jun;17(6):1291–6

Inhibition of intestinal tumor development in rat multi-organ carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22-oxa-calcitriol, a synthetic analogue of 1 alpha, 25-dihydroxyvitamin D3. Otoshi T, et al. **Carcinogenesis** 1995 Sep;16(9):2091–7

Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Pereira MA, et al. **Carcinogenesis** 1996 Jun; 17(6):1305–11

Chemoprotective effects of capsaicin and diallyl sulfide against mutagenesis or tumorigenesis by vinyl carbamate and N-nitrosodimethylamine. Surh YJ, et al. **Carcinogenesis** 1995 Oct;16(10):2467–71

Inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats by green and black tea. Wang ZY, et al. **Carcinogenesis** 1995 Sep;16(9):2143–8

Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study. Recchia F, et al. **Clin Ter** 1995 Oct;146(10):603–10

Healthcare resources should be targeted to chemoprevention in prostate cancer: the argument for. Denis LJ. **Eur Urol** 1996;29 Suppl 2:13–6 (13 ref.)

Healthcare resources should be targeted to chemoprevention: the argument against. Trachtenberg J. **Eur Urol** 1996;29 Suppl 2:17–8 (1 ref.)

Retinoids in cancer chemoprevention. Lotan R. **FASEB J** 1996 Jul;10(9):1031–9 (47 ref.)

Regional chemoprevention of carcinogen-induced tumors in rat colon. Liu T, et al. **Gastroenterology** 1995 Oct; 109(4):1167–72

Strategies for intervention with chemopreventive agents. Lipkin M. **Int J Cancer** 1996 Feb 20;69(1):64–7 (10 ref.)

Effects of sandostatin, alone and in combination with surgical castration, on pancreatic carcinogenesis in rats and hamsters. Visser CJ, et al. **Int J Cancer** 1996 Mar 15; 65(6):827–32

Hyperthermia, radiation carcinogenesis and the protective potential of vitamin A and N-acetylcysteine. Sminia P, et al. **J Cancer Res Clin Oncol** 1996;122(6):343–50

Prospects for Chemoprevention of Cancers of the Cervix, Endometrium and Ovary: Surrogate Endpoints and Design of Clinical Trials. Conference proceedings. Oxnard, California, February 1-5, 1995. **J Cell Biochem Suppl** 1995; 23:1–250

Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? Alberts DS, et al. **J Cell Biochem Suppl** 1995; 22:18–23

Effects of oltipraz and related chemoprevention compounds on gene expression in rat liver. Anderson L, et al. **J Cell Biochem Suppl** 1995;22:108–16 (20 ref.)

Potential criteria for cohort selection in chemoprevention trials of uterine adenocarcinoma. Baker VV. **J Cell Biochem Suppl** 1995;23:184–8 (32 ref.)

Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. Barnes S, et al. **J Cell Biochem Suppl** 1995;22:181–7

Chemoprevention of cancer by organoselenium compounds. el-Bayoumy K, et al. **J Cell Biochem Suppl** 1995;22:92–100 (34 ref.)

beta-carotene and cancer chemoprevention. Buring JE, et al. **J Cell Biochem Suppl** 1995;22:226–30 (37 ref.)

Chemopreventive properties and mechanisms of N-Acetylcysteine. The experimental background. De Flora S, et al. **J Cell Biochem Suppl** 1995;22:33–41 (37 ref.)

Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. De Palo G, et al. **J Cell Biochem Suppl** 1995;22:11–7 (16 ref.)

A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer. Dhingra K. **J Cell Biochem Suppl** 1995;23:19–24 (27 ref.)

Probing the molecular program of apoptosis by cancer chemopreventive agents. Fésüs L, et al. **J Cell Biochem Suppl** 1995;22:151–61 (49 ref.)

Prevention and therapy of mammary cancer by

monoterpenes. Gould MN. **J Cell Biochem Suppl** 1995; 22:139–44

Chemoprevention by isothiocyanates. Hecht SS. **J Cell Biochem Suppl** 1995;22:195–209 (33 ref.)

Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. Kelloff GJ, et al. **J Cell Biochem Suppl** 1995;23:1–9 (51 ref.)

Effects of protease inhibitors on levels of proteolytic activity in normal and premalignant cells and tissues. Kennedy AR, et al. **J Cell Biochem Suppl** 1995;22:188–94 (22 ref.)

Oltipraz: clinical opportunities for cancer chemoprevention. p Kensler TW, et al. **J Cell Biochem Suppl** 1995;22:101–7 (38 ref.)

Lutein, lycopene, and their oxidative metabolites in chemoprevention of cancer. Khachik F, et al. **J Cell Biochem Suppl** 1995;22:236–46

Calcium and the prevention of colon cancer. Lipkin M, et al. **J Cell Biochem Suppl** 1995;22:65–73 (54 ref.)

Retinoids and chemoprevention: clinical and basic studies. Lippman SM, et al. **J Cell Biochem Suppl** 1995;22:1–10 (66 ref.)

Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer. Meyskens FL Jr, et al. **J Cell Biochem Suppl** 1995; 22:126–31

Chemoprevention trials in the cervix: design, feasibility, and recruitment. Mitchell MF, et al. **J Cell Biochem Suppl** 1995; 23:104–12 (43 ref.)

Fostering chemopreventive agent development: how to proceed? Mulshine JL. **J Cell Biochem Suppl** 1995;22:254–9 (16 ref.)

Tamoxifen's role in chemoprevention of breast cancer: an update. Nayfield SG. **J Cell Biochem Suppl** 1995;22:42–50 (63 ref.)

Cancer chemoprevention by natural carotenoids and their related compounds. Nishino H. **J Cell Biochem Suppl** 1995; 22:231–5

The vitamin D Endocrine system: manipulation of structure–function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. Norman AW. **J Cell Biochem Suppl** 1995;22:218–25 (39 ref.)

Ornithine decarboxylase as a target for chemoprevention. Pegg AE, et al. **J Cell Biochem Suppl** 1995;22:132–8 (41 ref.)

Surrogate endpoint biomarkers for cervical cancer chemopreventive trials. Ruffin MT 4th, et al. **J Cell Biochem Suppl** 1995;23:113–24 (98 ref.)

Cancer prevention with dehydroepiandrosterone and non–androgenic structural analogs. Schwartz AG, et al. **J Cell Biochem Suppl** 1995;22:210–7 (58 ref.)

Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. Sherman ME, et al. **J Cell Biochem Suppl** 1995;23:160–4 (27 ref.)

Polyphenols as cancer chemopreventive agents. Stoner GD, et al. **J Cell Biochem Suppl** 1995;22:169–80 (87 ref.)

N–acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. van Zandwijk N. **J Cell Biochem Suppl** 1995; 22:24–32 (48 ref.)

Chalcones, myo–inositol and other novel inhibitors of pulmonary carcinogenesis. Wattenberg L. **J Cell Biochem Suppl** 1995;22:162–8 (40 ref.)

Calcium–cell cycle regulator, differentiator, killer, chemopreventor, and maybe, tumor promoter. Whitfield JF, et al. **J Cell Biochem Suppl** 1995;22:74–91 (38 ref.)

Chemoprevention of head and neck cancer. Voravud N. **J Med Assoc Thai** 1996 Mar;79(3):185–93 (65 ref.)

Alkane–6,8–diol: inhibitor of tumor promotion in two–stage carcinogenesis in mouse skin. Motohashi S, et al. **J Med Chem** 1995 Oct 13;38(21):4155–6

Prospective study of regular aspirin use and the risk of breast cancer [see comments] Egan KM, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):988–93. Comment in: J Natl Cancer Inst 1996 Jul 17;88(14):941–2.

Is chemoprevention overrated or underfunded? [news] Nelson NJ. **J Natl Cancer Inst** 1996 Jul 17;88(14):947–9

Trials reveal no benefit, possible harm of beta carotene and vitamin A for lung cancer prevention [news] Marwick C. **JAMA** 1996 Feb 14;275(6):422–3

Chemoprevention of breast cancer [clinical conference] O'Shaughnessy JA. **JAMA** 1996 May 1;275(17):1349–53

Suppressing effects of 6–(2,5–dichlorophenyl)–2,4–diamino–1,3,5–triazine and related synthetic compounds on azoxymethane–induced aberrant crypt foci in rat colon. Hirose Y, et al. **Jpn J Cancer Res** 1996 Jun;87(6):549–54

Lack of chemoprevention effects of the monoterpene d–limonene in a rat multi–organ carcinogenesis model. Kimura J, et al. **Jpn J Cancer Res** 1996 Jun;87(6):589–94

Inhibitory effects of medroxyprogesterone acetate on mouse endometrial carcinogenesis. Niwa K, et al. **Jpn J Cancer Res** 1995 Aug;86(8):724–9

Chemopreventive effect of a xanthine oxidase inhibitor, 1'–acetoxychavicol acetate, on rat oral carcinogenesis. Ohnishi M, et al. **Jpn J Cancer Res** 1996 Apr;87(4):349–56

Chemopreventive effects of taurine on diethylnitrosamine and phenobarbital–induced hepatocarcinogenesis in male F344 rats. Okamoto K, et al. **Jpn J Cancer Res** 1996 Jan; 87(1):30–6

Evaluation of melanotan–II, a superpotent cyclic melanotropic peptide in a pilot phase–I clinical study. Dorr RT, et al. **Life Sci** 1996;58(20):1777–84

Folic acid as a cancer–preventing agent. Jennings E. **Med Hypotheses** 1995 Sep;45(3):297–303 (60 ref.)

Inhibitory effects of lanostane–type triterpene acids, the components of Poria cocos, on tumor promotion by 12–O–tetradecanoylphorbol–13–acetate in two–stage carcinogenesis in mouse skin. Kaminaga T, et al. **Oncology** 1996 Sep–Oct;53(5):382–5

Intravesical bacillus Calmette–Guérin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours. Melekos MD, et al. **Oncology** 1996 Jul–Aug; 53(4):281–8

1'–Acetoxychavicol acetate, a superoxide anion generation inhibitor, potently inhibits tumor promotion by 12–O–tetradecanoylphorbol–13–acetate in ICR mouse skin. Murakami A, et al. **Oncology** 1996 Sep–Oct;53(5):386–91

Breast cancer chemoprevention: clinical trials and research. Noguchi M, et al. **Oncology** 1996 May–Jun;53(3):175–81 (111 ref.)

Inhibitory effect of oral administration of Monascus pigment on tumor promotion in two–stage carcinogenesis in mouse skin. Yasukawa K, et al. **Oncology** 1996 May–Jun; 53(3):247–9

Chemoprevention of cancer. Wattenberg LW. **Prev Med** 1996 Jan–Feb;25(1):44–5 (11 ref.)

The tumor promoter receptor protein kinase C: a novel target for chemoprevention and therapy of human colon cancer. O'Brian CA, et al. **Prog Clin Biol Res** 1995;391:117–20 (20 ref.)

Skin carcinogenesis: characteristics, mechanisms, and prevention. Slaga TJ, et al. **Prog Clin Biol Res** 1995; 391:1–20 (43 ref.)

Effects of dietary n–3, n–6 and n–9 polyunsaturated fatty acids on benzo(a)pyrene–induced forestomach tumorigenesis in C57BL6J mice. Silva RA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):273–7

"Natural" cancer prevention [letter; comment] Lachance PA. **Science** 1996 Jun 28;272(5270):1860–1. Comment on: Science 1996 Jan 26;271(5248):441.

Tamoxifen's trials and tribulations [news] Marshall E. **Science** 1995 Nov 10;270(5238):910

'Natural' cancer prevention trial halted [news] [see comments] Peterson K. **Science** 1996 Jan 26;271(5248):441 . Comment in: Science 1996 Jun 28;272(5270):1860–1.

[Chemoprevention of cancers] Espie M. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:181s–185s (Eng. Abstr.) (Fre)

–Results of ongoing breast cancer prevention studies– Jungi WF. **Arch Gynecol Obstet** 1995;256 Suppl:S116–21 (18 ref.) (Ger)

[Chemoprevention of cancer. Prevention of cancer in groups with increased risk] Sanner T, et al. **Tidsskr Nor Laegeforen** 1996 Aug 20;116(19):2329–33 (Eng. Abstr.) (Nor)

[A new way of preventing urinary bladder tumors] Pliss GB, et al. **Vopr Onkol** 1996;42(2):68–73 (Eng. Abstr.) (Rus)

TOXICITY

Dietary fish oil (MaxEPA) enhances pancreatic carcinogenesis in azaserine–treated rats. Appel MJ, et al. **Br J Cancer** 1996 Jan;73(1):36–43

The effect of tamoxifen and two of its non–isomerizable fixed–ring analogs on multistage rat hepatocarcinogenesis. Dragan YP, et al. **Carcinogenesis** 1996 Mar;17(3):585–94

Toxicity and metabolism in mice of 2,6–dithiopurine, a potential chemopreventive agent. Qing WG, et al. **Drug Metab Dispos** 1995 Aug;23(8):854–60

ANTICARDIOLIPIN ANTIBODIES see **ANTIBODIES, ANTICARDIOLIPIN**

ANTICESTODAL AGENTS

ADMINISTRATION & DOSAGE

Perioperative benzimidazole therapy in human hydatid liver disease. Tsimoyiannis EC, et al. **Int Surg** 1995 Apr–Jun; 80(2):131–3

Effects of free and liposomized praziquantel on worm burden and antibody response in mice infected with Mesocestoides corti tetrathyridia. Hrčkova G, et al. **J Helminthol** 1995 Sep;69(3):213–21

ANALYSIS

Environmental impact of two molluscicides: niclosamide and metaldehyde in a rice paddy ecosystem. Calumpang SM, et al. **Bull Environ Contam Toxicol** 1995 Oct;55(4):494–501

CHEMICAL SYNTHESIS

[The technology for manufacturing antiparasitic preparations. 5. The development of a technology for producing the anthelmintic triclonate and the evaluation of its therapeutic efficacy in monieziasis] Mikhallitsyn FS, et al. **Med Parazitol (Mosk)** 1996 Jan–Mar;(1):27–9 (Eng. Abstr.) (Rus)

PHARMACOLOGY

Effect of antihydatid drugs on carbohydrate metabolism of metacestode of echinococcus granulosus. Xiao S, et al. **Chin Med J (Engl)** 1995 Sep;108(9):682–8

THERAPEUTIC USE

[Observation on dynamics of circulating antigen from patients with cysticercosis before and after treatment] Zhang Y, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):222–4 (Eng. Abstr.) (Chi)

[The technology for manufacturing antiparasitic preparations. 5. The development of a technology for producing the anthelmintic triclonate and the evaluation of its therapeutic efficacy in monieziasis] Mikhallitsyn FS, et al. **Med Parazitol (Mosk)** 1996 Jan–Mar;(1):27–9 (Eng. Abstr.) (Rus)

TOXICITY

Genotoxicity of potential metabolites of nitroscanate—an antischistosomal drug. Gupta RL, et al. **Mutat Res** 1995 Dec;335(3):235–43

ANTICHOLESTEREMIC AGENTS

Squalene synthase inhibitors: their potential as hypocholesterolaemic agents. Watson NS, et al. **Prog Med Chem** 1996;33:331–78 (83 ref.)

ADMINISTRATION & DOSAGE

Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty. Freed M, et al. **Am J Cardiol** 1995 Dec 1; 76(16):1185–8

A diet moderately enriched in phytosterols lowers plasma cholesterol concentrations in normocholesterolemic humans. Pelletier X, et al. **Ann Nutr Metab** 1995; 39(5):291–5

Evidence for a synergistic effect of calcium channel blockers with lipid–lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Jukema JW, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):425–30

Fat substitution and food intake: effect of replacing fat with sucrose polyester at lunch or evening meals. Cotton JR, et al. **Br J Nutr** 1996 Apr;75(4):545–56

Short–term satiating effect of the fat replacer sucrose polyester (SPE) in man. Hulshof T, et al. **Br J Nutr** 1995 Oct;74(4):569–85

Statins and coronary heart disease [letter; comment] Thompson GR. **Lancet** 1996 Jul 6;348(9019):57. Comment on: Lancet 1996 May 18;347(9012):1389–90.

Treating hypercholesterolemia aggressively [editorial] Wilson CS. **Nebr Med J** 1996 Jan;81(1):3–4

Simvastatin added to ursodeoxycholic acid does not enhance disappearance of gallstone fragments after shock wave therapy. Sackmann M, et al. **Z Gastroenterol** 1995 Oct; 33(10):585–9

[Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia] Lechleitner M, et al. **Wien Med Wochenschr** 1995;145(21):577–83 (Eng. Abstr.) (Ger)

[The efficacy, safety and tolerance of fluvastatin sodium 40 mg in patients with hyperlipidemia type IIA] Fanghänel Salmón G, et al. **Arch Inst Cardiol Mex** 1996 Mar–Apr; 66(2):151–6 (Eng. Abstr.) (Spa)

[Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia] Jover E, et al. **Med Clin (Barc)** 1996 May 25;106(20):776–9 (Eng. Abstr.) (Spa)

ADVERSE EFFECTS

Lovastatin and peripheral neuropathy [letter] Ahmad S. **Am Heart J** 1995 Dec;130(6):1321

Probucol–associated tachyarrhythmic events and QT prolongation: importance of gender. Reinoehl J, et al. **Am Heart J** 1996 Jun;131(6):1184–91

The prevalence of side effects with regular and sustained–release nicotinic acid. Gibbons LW, et al. **Am J Med** 1995 Oct;99(4):378–85

The cholesterol controversy [see comments] Geurian KL. **Ann Pharmacother** 1996 May;30(5):495–500 (60 ref.). Comment in: Ann Pharmacother 1996 May;30(5):539–42.

Cholesterol–lowering therapy: is there really a controversy? [comment] Jungnickel PW. **Ann Pharmacother** 1996 May; 30(5):539–42 (33 ref.). Comment on: Ann Pharmacother 1996 May;30(5):495–500.

Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients. Jensen RA, et al. **ASAIO J** 1995 Jul–Sep;41(3):M704–6

Long–term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. Kajinami K, et al. **Atherosclerosis** 1996 Feb;120(1–2):181–7

Dermatomyositis with lung involvement in a patient treated with simvastatin [letter] Hill C, et al. **Aust N Z J Med** 1995 Dec;25(6):745–6

Brain serotonin (5–HT) neuroendocrine function in patients

taking cholesterol-lowering drugs. Delva NJ, et al. **Biol Psychiatry** 1996 Jan 15;39(2):100–6

Pravastatin: interaction with oral anticoagulant? Trenque T, et al. **BMJ** 1996 Apr 6;312(7035):886

Safety profile of fluvastatin. Peters TK. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:20–3 (4 ref.)

Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Harris ML, et al. **Br J Ophthalmol** 1995 Nov;79(11):996–1002

Radiation reaction recall following simvastatin therapy: a new observation. Abadir R, et al. **Clin Oncol (R Coll Radiol)** 1995;7(5):325–6

Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Azzarito C, et al. **Horm Metab Res** 1996 Apr;28(4):193–8

Effectiveness and safety of low-dose pravastatin and squalene, alone and in combination, in elderly patients with hypercholesterolemia. Chan P, et al. **J Clin Pharmacol** 1996 May;36(5):422–7

Interstitial lung disease with pleural effusion caused by simvastin. De Groot RE, et al. **J Intern Med** 1996 Apr; 239(4):361–3

Statin therapy and CHD [letter; comment] Tobert JA. **Lancet** 1996 Jan 13;347(8994):128. Comment on: Lancet 1995 Dec 2;346(8988):1440–2.

Lovastatin during warfarin therapy resulting in bleeding. Iliadis EA, et al. **Pa Med** 1995 Dec;98(12):31

Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol. Murphy MJ, et al. **Postgrad Med J** 1995 Aug;71(838):498–500

[Clinically manifest liver lesions during use of simvastatin] Koornstra JJ, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13; 140(15):846–8 (Eng. Abstr.) **(Dut)**

[Terminal myoglobinuric renal failure in lovastatin therapy with pre-existing chronic renal insufficiency] Biesenbach G, et al. **Wien Klin Wochenschr** 1996;108(11):334–7 (Eng. Abstr.) **(Ger)**

[Do cholesterol-lowering drugs cause cancer? (letter)] Ravnskov U. **Lakartidningen** 1996 May 22;93(21):2040 **(Swe)**

BLOOD

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Neuvonen PJ, et al. **Clin Pharmacol Ther** 1996 Jul;60(1):54–61

CHEMICAL SYNTHESIS

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: oxime ether analogs of pravastatin. Turabi N, et al. **Bioorg Med Chem** 1995 Nov;3(11):1479–84

Inhibitors of acyl-CoA: cholesterol acyltransferase. II. Preparation and hypocholesterolemic activity of optically active dibenz[b,e]oxepin-11-carboxanilides. Kumazawa T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):222–5

Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. Brown GR, et al. **J Med Chem** 1996 Jul 19;39(15):2971–9

CHEMISTRY

Bioisosterism in drug design: identification of and structure–activity relationships in a series of glycine anilide ACAT inhibitors. Roark WH, et al. **Bioorg Med Chem** 1995 Jan;3(1):29–39

Structural and stereoelectronic requirements for the inhibition of mammalian 2,3-oxidosqualene cyclase by substituted isoquinoline derivatives. Barth MM, et al. **J Med Chem** 1996 Jun 7;39(12):2302–12

Phenoxypropylamines: a new series of squalene synthase inhibitors. Brown GR, et al. **J Med Chem** 1995 Oct 13; 38(21):4157–60

Substituted 2-azaspiro[5.3]nonan-1-ones as potent cholesterol absorption inhibitors: defining a binding conformation for SCH 48461. Dugar S, et al. **J Med Chem** 1995 Dec 8;38(25):4875–7

ECONOMICS

Costs of coronary restenosis (Lovastatin Restenosis Trial). Gilbert SP, et al. **Am J Cardiol** 1996 Jan 15;77(2):196–9

Cost of lipid-lowering statin drugs [letter] Gotto AM Jr, et al. **Am J Cardiol** 1996 Jan 15;77(2):225–6

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. Pharoah PD, et al. **BMJ** 1996 Jun 8; 312(7044):1443–8

Cost-effectiveness of prescription recommendations for cholesterol-lowering drugs: a survey of a representative sample of American cardiologists. Gaspoz JM, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1232–7

Cost effectiveness of cholesterol-lowering drugs: a review of the evidence. Thorvik E, et al. **Wien Klin Wochenschr** 1996;108(8):234–43 (23 ref.)

[Cost-effectiveness of pharmacologic treatments for the reduction of blood lipids (see comments)] Plans Rubió P, et al. **Med Clin (Barc)** 1995 Sep 23;105(9):327–33 (Eng. Abstr.). Comment in: Med Clin (Barc) 1995 Sep 23;105(9):338–40. **(Spa)**

PHARMACOKINETICS

Development and pharmacology of fluvastatin. Jokubaitis LA. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:11–5 (4 ref.)

Biotransformation of lifibrol (U-83860) to mixed glyceride metabolites by rat and human hepatocytes in primary culture. Sun EL, et al. **Drug Metab Dispos** 1996 Feb; 24(2):221–31

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Plosker GL, et al. **Drugs** 1995 Aug;50(2):334–63 (239 ref.)

Effect of age and gender on pharmacokinetics of atorvastatin in humans. Gibson DM, et al. **J Clin Pharmacol** 1996 Mar; 36(3):242–6

Explaining variable absorption of a hypolipidemic agent (CGP 43371) in healthy subjects by gamma scintigraphy and pharmacokinetics. Sun JX, et al. **J Clin Pharmacol** 1996 Mar;36(3):230–7

Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes. Ishigami M, et al. **Pharm Res** 1995 Nov;12(11):1741–5

Proton-cotransport of pravastatin across intestinal brush-border membrane. Tamai I, et al. **Pharm Res** 1995 Nov;12(11):1727–32

PHARMACOLOGY

The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Laaksonen R, et al. **Am J Cardiol** 1996 Apr 15;77(10):851–4

Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Vogel RA, et al. **Am J Cardiol** 1996 Jan 1;77(1):37–40

Replacement of dietary fat with sucrose polyester: effects on energy intake and appetite control in nonobese males. Cotton JR, et al. **Am J Clin Nutr** 1996 Jun;63(6):891–6

Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. Bergstrom JD, et al. **Annu Rev Microbiol** 1995;49:607–39 (80 ref.)

Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Ness GC, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):242–8

Probucol downregulates E-selectin expression on cultured human vascular endothelial cells. Kaneko M, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1047–51

Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Shiomi M, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1938–44

Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia. Feillet C, et al. **Atherosclerosis** 1995 Dec;118(2):251–8

The effect of cholesterol absorption inhibition on low density lipoprotein cholesterol level. Gylling H, et al. **Atherosclerosis** 1995 Oct;117(2):305–8

Inhibitory effect of a single local probucol administration on neointimal formation in balloon-injured rat carotid artery. Ishizaka N, et al. **Atherosclerosis** 1995 Nov; 118(1):53–6

Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Krause BR, et al. **Atherosclerosis** 1995 Oct;117(2):237–44

Enhanced efficacy of sitostanol-containing versus sitostanol-free phytosterol mixtures in altering lipoprotein cholesterol levels and synthesis in rats. Ling WH, et al. **Atherosclerosis** 1995 Dec;118(2):319–31

TMP-153, a novel ACAT inhibitor, lowers plasma cholesterol through its hepatic action in golden hamsters. Sugiyama Y, et al. **Atherosclerosis** 1995 Nov;118(1):145–53

Probucol, but not MaxEPA fish oil, inhibits mononuclear cell adhesion to the aortic intima in the rat model of atherosclerosis. Barbeau ML, et al. **Biochem Cell Biol** 1995 May-Jun;73(5–6):283–8

Thyronines and probucol inhibition of human capillary endothelial cell-induced low density lipoprotein oxidation. Hanna AN, et al. **Biochem Pharmacol** 1995 Nov 9; 50(10):1627–33

Fermentable carbohydrates exert a more potent cholesterol-lowering effect than cholestyramine. Favier ML, et al. **Biochim Biophys Acta** 1995 Sep 14; 1258(2):115–21

Cholesterol biosynthesis from lanosterol: regulation and purification of rat hepatic sterol 14-reductase. Kim CK, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):39–48

High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits. Kurokawa J, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):99–104

Hypoglycemic and hypolipidemic effect of chitosan in normal and neonatal streptozotocin-induced diabetic mice. Miura T, et al. **Biol Pharm Bull** 1995 Nov;18(11):1623–5

Species specificity in the blood cholesterol-lowering effect of YM-16638. Goto S, et al. **Br J Pharmacol** 1996 May; 118(1):174–8

Preservation of endothelium-dependent relaxation in cholesterol-fed and streptozotocin-induced diabetic mice by the chronic administration of cholestyramine. Kamata K, et al. **Br J Pharmacol** 1996 May;118(2):385–91

Arylnaphthalene lignans as novel series of hypolipidemic agents raising high-density lipoprotein level. Iwasaki T, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1701–5

Inhibitors of acyl-CoA: cholesterol acyltransferase. II. Preparation and hypocholesterolemic activity of optically active dibenz[b,e]oxepin-11-carboxanilides. Kumazawa T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):222–5

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Transon C, et al. **Clin Pharmacol Ther** 1995 Oct;58(4):412–7

Effect of probucol, an oral hypocholesterolaemic agent, on acute tobacco smoke inhalation in rats. Ishizaki T, et al. **Clin Sci (Colch)** 1996 Jun;90(6):517–23

Fatty acids and fibrates are potent inducers of transcription of the phosphenolpyruvate carboxykinase gene in adipocytes. Antras-Ferry J, et al. **Eur J Biochem** 1995 Dec 1;234(2):390–6

Does the HMG-CoA reductase inhibitor pravastatin influence nucleation of cholesterol crystals in supersaturated model bile? Smit JW, et al. **Eur J Gastroenterol Hepatol** 1996 Mar;8(3):197–200

Crilvastatin, a new 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, inhibits cholesterol absorption in genetically hypercholesterolemic rats. Hajri T, et al. **Eur J Pharmacol** 1995 Nov 14;286(2):131–6

Regulation of bile acid synthesis by estradiol and progesterone in primary cultures of rat hepatocytes. Chico Y, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):137–44

Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia. Smit JW, et al. **Gut** 1995 Nov; 37(5):654–9

Regulation of the last two enzymatic reactions in cholesterol biosynthesis in rats: effects of BM 15.766, cholesterol, cholic acid, lovastatin, and their combinations. Honda A, et al. **Hepatology** 1996 Aug;24(2):435–9

Blocking late cholesterol biosynthesis inhibits the growth of transplanted Morris hepatomas (7288CTC) in rats. Xu G, et al. **Hepatology** 1996 Aug;24(2):440–5

Effects of S-allyl cysteine sulfoxide isolated from Allium sativum Linn and gugulipid on some enzymes and fecal excretions of bile acids and sterols in cholesterol fed rats. Sheela CG, et al. **Indian J Exp Biol** 1995 Oct;33(10):749–51

Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients. Branchi A, et al. **Int J Clin Pharmacol Ther** 1995 Jun;33(6):345–50

alpha-Tocopherol enhances the hypocholesterolemic action of sesamin in rats. Nakabayashi A, et al. **Int J Vitam Nutr Res** 1995;65(3):162–8

Soluble fiber enhances the hypocholesterolemic effect of the step I diet in childhood. Williams CL, et al. **J Am Coll Nutr** 1995 Jun;14(3):251–7

The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Berkhout TA, et al. **J Biol Chem** 1996 Jun 14; 271(24):14376–82

Progesterone inhibits cholesterol biosynthesis in cultured cells. Accumulation of cholesterol precursors. Metherall JE, et al. **J Biol Chem** 1996 Feb 2;271(5):2627–33

Effect of feeding psyllium and cholestyramine in combination on low density lipoprotein metabolism and fecal bile acid excretion in hamsters with dietary-induced hypercholesterolemia. Turley SD, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):71–9

Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets. Himber J, et al. **J Lipid Res** 1995 Jul;36(7):1567–85

The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors. Chan C, et al. **J Med Chem** 1996 Jan 5;39(1):207–16

Inhibitors of acyl-CoA:cholesterol O-acyltransferase. synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5- acetamide and structurally related tetrazole amide derivatives. O'Brien PM, et al. **J Med Chem** 1996 Jun 7;39(12):2354–66

The squalestatins: inhibitors of squalene synthase. Enzyme inhibitory activities and in vivo evaluation of C3-modified analogues. Procopiou PA, et al. **J Med Chem** 1996 Mar 29;39(7):1413–22

Increased intestinal contents viscosity reduces cholesterol absorption efficiency in hamsters fed hydroxypropyl methylcellulose. Carr TP, et al. **J Nutr** 1996 May; 126(5):1463–9

Effects of spinach leaf protein concentrate on the serum cholesterol and amino acid concentrations in rats fed a cholesterol-free diet. Satoh A, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Oct;41(5):563–73

Antihypercholesterolemic effect of undigested fraction of soybean protein in young female volunteers. Wang MF, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Apr;41(2):187–95

Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors. Tsai JC, et al. **J Pharm Sci** 1996 Jun;85(6):643–8

The mechanism of comparable serum cholesterol lowering effects of pravastatin sodium, a

3-hydroxy-3-methylglutaryl coenzyme A inhibitor, between once- and twice-daily treatment regimens in beagle dogs and rabbits. Fujioka T, et al. **Jpn J Pharmacol** 1996 Apr;70(4):329-35

Effects of probucol on hypercholesterolemia-induced changes in antioxidant enzymes. Mantha SV, et al. **Life Sci** 1996;58(6):503-9

Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin. Del Puppo M, et al. **Lipids** 1995 Nov;30(11):1057-61

Cholestyramine alters the lipid and energy metabolism of chicks fed dietary medium- or long-chain triacylglycerol. Mabayo RT, et al. **Lipids** 1995 Sep;30(9):839-45

Fats for the food industry: implications for cholesterol-lowering. Nestel P, et al. **Lipids** 1996 Mar;31 Suppl:S65-9 (10 ref.)

Resistant starch is more effective than cholestyramine as a lipid-lowering agent in the rat. Younes H, et al. **Lipids** 1995 Sep;30(9):847-53

Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition. Bard JM, et al. **Metabolism** 1995 Nov;44(11):1447-54

Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia. Tazuma S, et al. **Metabolism** 1995 Nov;44(11):1410-2

Influence of cholesterol-lowering on plasma membrane lipids and function. Lijnen P, et al. **Methods Find Exp Clin Pharmacol** 1996 Mar;18(2):123-36

Expression of a 24 kDa GTP-binding protein (Gn24) is increased in lovastatin treated human erythroleukemia cells. Bhullar RP. **Mol Cell Biochem** 1996 Mar 9;156(1):59-67

A study on the antihypercholesterolemic and antihyperlipidemic effects of cabbage extracts and their phytochemical evaluation. Jahodář L, et al. **Pharmazie** 1995 Dec;50(12):833-4

Paradoxical increase in peroxisomal cyanide-insensitive respiration following dietary exposure to WY-14,643 in the perfused liver. Bojes HK, et al. **Toxicol Appl Pharmacol** 1996 Apr;137(2):202-9

[The effect of lovastatin on the development of adriamycin nephropathy in rats] Tesař V, et al. **Sb Lek** 1995;96(1):35-42 (Eng. Abstr.) **(Cze)**

[Statins. From LDL receptor to cardiovascular protection] Scheen AJ. **Rev Med Liege** 1996 Jan;51(1):97-101 **(Fre)**

[Simvastatin] Burgmer U, et al. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):769-70 **(Ger)**

[Action of lovastatin--an inhibitor of cholesterol biosynthesis on bacterial bioluminescence] Baranova NA, et al. **Antibiot Khimioter** 1995 Aug;40(8):12-6 (Eng. Abstr.) **(Rus)**

[Cholesterol turnover in triglyceride transport and effect of probucol] Titov VN. **Vopr Med Khim** 1995 Sep-Oct; 41(5):2-8 (80 ref.) **(Rus)**

STANDARDS

Nutritional significance of rice bran oil. Raghuram TC, et al. **Indian J Med Res** 1995 Nov;102:241-4

THERAPEUTIC USE

Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Levy D, et al. **Am Heart J** 1996 May; 131(5):966-73

Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Watanabe K, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):23-9

Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). **Am J Cardiol** 1995 Nov 1;76(12):899-905

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Ashraf T, et al. **Am J Cardiol** 1996 Aug 15;78(4):409-14

Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Ballantyne CM, et al. **Am J Cardiol** 1996 Sep 1;78(5):532-5 (34 ref.)

What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? Brown G, et al. **Am J Cardiol** 1995 Sep 28; 76(9):93C-97C (20 ref.)

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Byington RP, et al. **Am J Cardiol** 1995 Sep 28;76(9):54C-59C

Fluvastatin versus pravastatin [letter] Chilton R. **Am J Cardiol** 1996 Jul 1;78(1):127

Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. de Groot E, et al. **Am J Cardiol** 1995 Sep 28;76(9):40C-46C

Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries. Furberg CD, et al. **Am J Cardiol** 1995 Sep 28; 76(9):60C-63C

The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160 mg/dl. Glasser SP, et al. **Am J Cardiol** 1996 Jan 1; 77(1):83-5

Cholesterol reduction and its impact on coronary artery disease and total mortality. Holme I. **Am J Cardiol** 1995 Sep 28;76(9):10C-17C

Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Kjekshus J, et al. **Am J Cardiol** 1995 Sep 28;76(9):64C-68C

Unresolved issues in early trials of cholesterol lowering. LaRosa JC. **Am J Cardiol** 1995 Sep 28;76(9):5C-9C (28 ref.)

Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. O'Keefe JH Jr, et al. **Am J Cardiol** 1996 Mar 15;77(8):649-52

Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Pfeffer MA, et al. **Am J Cardiol** 1995 Sep 28; 76(9):98C-106C

Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia. Prisant LM, et al. **Am J Cardiol** 1996 Aug 15;78(4):420-4

Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. Probstfield JL, et al. **Am J Cardiol** 1995 Sep 28; 76(9):47C-53C

The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group. Sacks FM, et al. **Am J Cardiol** 1995 Sep 28;76(9):78C-85C (30 ref.)

The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Salonen R, et al. **Am J Cardiol** 1995 Sep 28;76(9):34C-39C

The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Shepherd J. **Am J Cardiol** 1995 Sep 28;76(9):113C-117C

Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. Simes RJ. **Am J Cardiol** 1995 Sep 28;76(9):122C-126C

Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Tonkin AM. **Am J Cardiol** 1995 Sep 28;76(9):107C-112C

Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group. Weir MR, et al. **Am J Cardiol** 1996 Mar 1;77(7):475-9

Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study. Espeland MA, et al. **Am J Epidemiol** 1995 Nov 15; 142(10):1011-9

Should we treat cholestatic liver disease with cholesterol synthesis inhibitors? [letter; comment] Schmidt HH, et al. **Am J Gastroenterol** 1996 Feb;91(2):406-7. Comment on: Am J Gastroenterol 1995 Jul;90(7):1187-8.

The inhibitory effects of dai-chai-hu-tang (dai-saiko-to) extract on supersaturated bile formation in cholesterol gallstone disease [letter] Shoda J, et al. **Am J Gastroenterol** 1996 Apr;91(4):828-30

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Garnett WR. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1639-45 (44 ref.)

The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy. Chan P, et al. **Am J Hypertens** 1995 Nov;8(11):1099-104

Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Marcelino JJ, et al. **Am J Med** 1996 Jun;100(6):605-10

Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. Raskin P, et al. **Am J Med** 1995 Oct; 99(4):362-9

The influence of angiographic endpoints on the outcome of lipid intervention studies. A proposal for standardization. REGRESS study group. Jukema JW, et al. **Angiology** 1996 Jul;47(7):633-42

Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Hodis HN, et al. **Ann Intern Med** 1996 Mar 15; 124(6):548-56

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia [see comments] Hsu I, et al. **Ann Pharmacother** 1995 Jul-Aug; 29(7-8):743-59 (114 ref.). Comment in: Ann Pharmacother 1995 Dec;29(12):1304.

Cholesterol lowering and the risk of stroke [letter; comment] Boop BS, et al. **Arch Intern Med** 1996 Jan 22;156(2):214-5 . Comment on: Arch Intern Med 1995 Jan 9;155(1):50-5.

Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Oster G, et al. **Arch Intern Med** 1996 Apr 8; 156(7):731-9

Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. Chang MY, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1631-40

Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia. Tomochika Y, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):955-62

Morphological aspects of the effects of orotic acid and magnesium orotate on hypercholesterolaemia in rabbits. Jellinek H, et al. **Arzneimittelforschung** 1995 Aug; 45(8):836-42

Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients. Lansberg PJ, et al. **Atherosclerosis** 1995 Aug;116(2):153-62

Case studies in lipid management. Tallis GA, et al. **Aust Fam Physician** 1995 Sep;24(9):1627-31, 1634-5, 1637

Sugar and fat, a recipe for disaster. New guidelines for the pharmacological management of diabetic dyslipidaemia. Tallis GA, et al. **Aust Fam Physician** 1995 Sep;24(9):1638-9, 1642-7, 1649

Combined treatment with captopril, hydrochlorothiazide and pravastatin in dyslipidemic hypertensive patients. Waeber B, et al. **Blood Press** 1995 Nov;4(6):358-62

Lowering patients' cholesterol. Extrapolating results of trial of simvastatin gives room for doubt [letter; comment] Hippisley-Cox J. **BMJ** 1995 Sep 9;311(7006):690-1. Comment on: BMJ 1995 May 20;310(6990):1280-1.

Lowering patients' cholesterol. Excluding patients from trials increases uncertainty [letter; comment] Jay RH. **BMJ** 1995 Sep 9;311(7006):690. Comment on: BMJ 1995 May 20;310(6990):1280-1.

Beneficial effects of simvastatin may be due to non-lipid actions [letter; comment] Ravnskov U. **BMJ** 1995 Nov 25; 311(7017):1436-7. Comment on: BMJ 1995 May 20;310(6990):1280-1.

Lowering patients' cholesterol. Few eligible patients currently receive treatment [letter; comment] Tuominen S, et al. **BMJ** 1995 Sep 9;311(7006):690. Comment on: BMJ 1995 May 20;310(6990):1280-1.

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group. Wardle J, et al. **BMJ** 1996 Jul 13; 313(7049):75-8

The acceptability of resin therapy to patients attending a hospital lipid clinic. Iversen SA, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):92-4

Fluvastatin in combination with other lipid-lowering agents. Jokubaitis LA. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:28-32 (4 ref.)

Treatment of dyslipidaemias with fluvastatin. Peters TK. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:16-9 (7 ref.)

Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs. Dobs AS, et al. **Cardiovasc Drugs Ther** 1995 Oct; 9(5):677-84

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Byington RP, et al. **Circulation** 1995 Nov 1;92(9):2419-25

LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Kroon AA, et al. **Circulation** 1996 May 15;93(10):1826-35

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Lacoste L, et al. **Circulation** 1995 Dec 1; 92(11):3172-7

Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study [see comments] Pedersen TR, et al. **Circulation** 1996 May 15;93(10):1796-802. Comment in: Circulation 1996 May 15;93(10):1774-6.

Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Waters D, et al. **Circulation** 1995 Nov 1;92(9):2404-10

Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group [see comments] Waters D, et al. **Circulation** 1996 Aug 15;94(4):614-21. Comment in: Circulation 1996 Aug 15;94(4):596-8.

Cost of prevention. The case of lipid lowering [editorial; comment] Yusuf S, et al. **Circulation** 1996 May 15; 93(10):1774-6. Comment on: Circulation 1996 May 15;93(10):1796-802.

Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Bruckert E, et al. **Clin Cardiol** 1995 Nov;18(11):621-9

High-performance capillary electrophoresis-pure creatine monohydrate reduces blood lipids in men and women. Earnest CP, et al. **Clin Sci (Colch)** 1996 Jul;91(1):113-8

Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: a pilot study. Yoshida H, et al. **Clin Ther** 1995 May-Jun;17(3):379-89

Relationship between total mortality and cholesterol

reduction as found by meta-regression analysis of randomized cholesterol-lowering trials. Holme I. **Control Clin Trials** 1996 Feb;17(1):13–22

Profiling a landmark clinical trial: Scandinavian Simvastatin Survival Study. Guptha S. **Curr Opin Lipidol** 1995 Oct; 6(5):251–3

Statin therapy in clinical practice: new developments. Shepherd J. **Curr Opin Lipidol** 1995 Oct;6(5):254–5 (13 ref.)

Probucol normalizes cholesteryl ester transfer in IDDM. Bagdade JD, et al. **Diabetes Care** 1995 Oct;18(10):1341–6

Treatment of hypercholesterolemia in NIDDM with policosanol. Torres O, et al. **Diabetes Care** 1995 Mar; 18(3):393–7

The effect of cholesterol-lowering therapy on the progression of diabetic nephropathy is unproved.–letter–Bender R. **Diabetologia** 1996 Mar;39(3):368–70

Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Lam KS, et al. **Diabetologia** 1995 May;38(5):604–9

Cholesterol-lowering therapy may retard the progression of diabetic nephropathy [letter] Parving HH. **Diabetologia** 1996 Mar;39(3):367–8

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Plosker GL, et al. **Drugs** 1995 Aug;50(2):334–63 (239 ref.)

The 4S study. Implications for prescribing. van Boven AJ, et al. **Drugs** 1996 Apr;51(4):507–14 (55 ref.)

Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene? Leren TP, et al. **Eur J Clin Invest** 1995 Dec; 25(12):967–73

Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Watts GF, et al. **Eur J Clin Invest** 1995 Aug;25(8):559–67

Effect of a synthetic prostaglandin E2 analogue, RS-86505-007, on plasma lipids and lipoproteins in patients with moderate hypercholesterolaemia: efficacy and tolerance of treatment and response in different apolipoprotein polymorphism groups. Korhonen T, et al. **Eur J Clin Pharmacol** 1995;48(2):97–102

Probucol prevents the progression of fatty liver in MSG obese mice. Yoshida T, et al. **Exp Clin Endocrinol Diabetes** 1995;103(2):119–22

Hypolipidemic and antiatherosclerotic effects of a novel ACAT inhibitor, HL-004, in stroke-prone spontaneously hypertensive rats. Murakami S, et al. **Exp Mol Pathol** 1995 Aug;63(1):23–32

Hypocholesterolemic and immunostimulatory effects of orally applied Enterococcus faecium M-74 in man. Mikeš A, et al. **Folia Microbiol (Praha)** 1995;40(6):639–46

Hypocholesterolemic activity of nut shell extract of Semecarpus anacardium (Bhilawa) in cholesterol fed rabbits. Sharma A, et al. **Indian J Exp Biol** 1995 Jun; 33(6):444–8

Prevention of hypercholesterolemia and atherosclerosis in rabbits after supplementation of Myristica fragrans seed extract. Sharma A, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):407–10

Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study. Batista J, et al. **Int J Clin Pharmacol Ther** 1996 Mar; 34(3):134–7

Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients. Sasaki J, et al. **Int J Clin Pharmacol Ther** 1995 Jul;33(7):420–6

Secondary prevention in coronary heart disease. Fact: lowering cholesterol saves lives [editorial] McKenna CJ, et al. **Ir Med J** 1995 Nov–Dec;88(6):191

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. Pitt B, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1133–9

Osteopathic medicine: an inherently natural approach to cholesterol reduction [editorial] Rogers FJ. **J Am Osteopath Assoc** 1996 Jan;96(1):28–9

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. Steinmetz A, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):563–70

Effectiveness and safety of low-dose pravastatin and squalene, alone and in combination, in elderly patients with hypercholesterolemia. Chan P, et al. **J Clin Pharmacol** 1996 May;36(5):422–7

Treating elevated cholesterol levels: the great Satan in perspective. Gibaldi M, et al. **J Clin Pharmacol** 1996 Mar; 36(3):189–97 (45 ref.)

Cholesterol-lowering agent in men without CHD. Millard P, et al. **J Fam Pract** 1996 Mar;42(3):223–4

Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients [letter] de Lorgeril M, et al. **J Heart Lung Transplant** 1996 May;15(5):539–40

Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. Pflugfelder PW, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):613–22

Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the C.3LL Study. Lindholm LH, et al. **J Intern Med** 1996 Jul;240(1):13–22

Sterol absorption and sterol balance in phytosterolemia evaluated by deuterium-labeled sterols: effect of sitostanol treatment. Lütjohann D, et al. **J Lipid Res** 1995 Aug; 36(8):1763–73

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Bakker-Arkema RG, et al. **JAMA** 1996 Jan 10; 275(2):128–33

Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Lee YJ, et al. **Jpn Heart J** 1996 May;37(3):327–32

Simvastatin-oral anticoagulant interaction [letter] Grau E, et al. **Lancet** 1996 Feb 10;347(8998):405–6

Statins and coronary heart disease [letter; comment] Grimes DS. **Lancet** 1996 Jul 6;348(9019):57. Comment on: Lancet 1995 Nov 25;346(8987):1378–9. Comment on: Lancet 1996 May 18;347(9012):1389–90.

Statins, cholesterol, and mevalonate pathways? [letter; comment] Lewis LS. **Lancet** 1996 Feb 24;347(9000):551. Comment on: Lancet 1994 Nov 19;344(8934):1383–9. Comment on: Lancet 1996 Jan 13;347(8994):102–3.

Implementation of the 4S study in first myocardial infarction [letter; comment] MacFadyen RJ, et al. **Lancet** 1996 Feb 24;347(9000):551–2. Comment on: Lancet 1995 Dec 2;346(8988):1440–2.

Statins and coronary heart disease [letter; comment] Oliver MF. **Lancet** 1996 Jul 6;348(9019):57. Comment on: Lancet 1996 May 18;347(9012):1389–90.

Statins prevent coronary heart disease [see comments] Oliver MF. **Lancet** 1995 Nov 25;346(8987):1378–9. Comment in: Lancet 1996 Jul 6;348(9019):57.

Are the effects of cholesterol lowering drugs always equal? [letter] Vandenbroucke JP, et al. **Lancet** 1996 May 4; 347(9010):1267–8

Sitosterolemia: opposing effects of cholestyramine and lovastatin on plasma sterol levels in a homozygous girl and her heterozygous father. Cobb MM, et al. **Metabolism** 1996 Jun;45(6):673–9

Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Guijarro C, et al. **Miner Electrolyte Metab** 1996; 22(1–3):147–52 (45 ref.)

Drugs in cardiac transplantation [letter; comment] Ballantyne CM. **N Engl J Med** 1996 Feb 8;334(6):400–1; discussion 401–2. Comment on: N Engl J Med 1995 Sep 7;333(10):621–7. Comment on: N Engl J Med 1995 Sep 7;333(10):628–33.

Prevention of coronary heart disease with pravastatin [letter; comment] Davis DR. **N Engl J Med** 1996 May 16; 334(20):1334; discussion 1335. Comment on: N Engl J Med 1995 Nov 16;333(20):1301–7. Comment on: N Engl J Med 1995 Nov 16;333(20):1350–1.

Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population [see comments] Miettinen TA, et al. **N Engl J Med** 1995 Nov 16;333(20):1308–12. Comment in: N Engl J Med 1995 Nov 16;333(20):1350–1.

Lowering cholesterol with drugs and diet [editorial; comment] [see comments] Pedersen TR. **N Engl J Med** 1995 Nov 16;333(20):1350–1. Comment on: N Engl J Med 1995 Nov 16;333(20):1301–7. Comment on: N Engl J Med 1995 Nov 16;333(20):1308–12. Comment in: N Engl J Med 1996 May 16;334(20):1334; discussion 1335.

Prevention of coronary heart disease with pravastatin [letter; comment] Rogers S. **N Engl J Med** 1996 May 16; 334(20):1333; discussion 1334–5. Comment on: N Engl J Med 1995 Nov 16;333(20):1301–7.

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. Sacks FM, et al. **N Engl J Med** 1996 Oct 3;335(14):1001–9

Prevention of coronary heart disease with pravastatin [letter; comment] Samani NJ, et al. **N Engl J Med** 1996 May 16; 334(20):1333–4; discussion 1334–5. Comment on: N Engl J Med 1995 Nov 16;333(20):1301–7.

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group [see comments] Shepherd J, et al. **N Engl J Med** 1995 Nov 16;333(20):1301–7. Comment in: N Engl J Med 1995 Nov 16;333(20):1350–1. Comment in: N Engl J Med 1996 May 16;334(20):1333; discussion 1334–5. Comment in: N Engl J Med 1996 May 16;334(20):1334; discussion 1334–5. Comment in: N Engl J Med 1996 May 16;334(20):1334; discussion 1334–5.

Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia. Morris R, et al. **N Z Med J** 1996 Aug 23;109(1028):319–22

Modulation of coronary endothelial function by lovastatin. Misra A. **Natl Med J India** 1995 Nov–Dec;8(6):271–2

Decrease of urine protein after treatment with probucol in patients with mild glomerulonephritis and arteriolosclerosis [letter] Ogawa M, et al. **Nephron** 1995;70(3):376–7

The protective effect of probucol on adriamycin nephrosis in the rat. Futenma A, et al. **Nippon Jinzo Gakkai Shi** 1995 Nov;37(11):616–21

Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Kaul N, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):551–4

Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Lambert M, et al. **Pediatrics** 1996 May;97(5):619–28

New targets for lipid lowering and atherosclerosis prevention. Sirtori CR. **Pharmacol Ther** 1995;67(3):433–47 (108 ref.)

Cerebrotendinous xanthomatosis: a family study of sterol 27-hydroxylase mutations and pharmacotherapy. Watts GF, et al. **QJM** 1996 Jan;89(1):55–63

Pravastatin improves outcome for heart transplant recipients [news] **S Afr Med J** 1996 Apr;86 Suppl 2:C113–4

Heart attacks: gone with the century? [editorial] [see comments] Brown MS, et al. **Science** 1996 May 3; 272(5262):629. Comment in: Science 1996 Jul 5;273(5271):15. Comment in: Science 1996 Jul 5;273(5271):15–6.

Vestibular vertigo and lovastatin therapy [letter] Ahmad S. **South Med J** 1996 Feb;89(2):257–8

The efficacy and safety of fluvastatin in hypercholesterolemia in renal transplant recipients. Ghods AJ, et al. **Transplant Proc** 1995 Oct;27(5):2579–80

The effect of pravastatin on acute rejection after kidney transplantation—a pilot study. Katznelson S, et al. **Transplantation** 1996 May 27;61(10):1469–74

Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia. Li PK, et al. **Transplantation** 1995 Oct 15;60(7):652–6

[Zocor lobby? (letter)] Kruse P. **Ugeskr Laeger** 1996 Apr 29;158(18):2557–8 **(Dan)**

[Cholesterol synthesis inhibitors: lowering of cholesterol for everybody?] Westendorp RG, et al. **Ned Tijdschr Geneeskd** 1996 Feb 24;140(8):411–4 (14 ref.) **(Dut)**

[The cholesterol hypothesis has been proved true at last (editorial)] Huttunen J. **Duodecim** 1995;111(5):385–6 **(Fin)**

[The drug therapy of hypercholesterolemia] Berthold HK, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):729–34 (30 ref.) **(Ger)**

[Effect of lowered cholesterol on the course of coronary heart disease. An analysis of the results of controlled, angiographically documented intervention studies] Stierle U, et al. **Dtsch Med Wochenschr** 1995 Dec 1;120(48):1652–9 (Eng. Abstr.) **(Ger)**

[Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program] Byington RP, et al. **Fortschr Med** 1996 Mar 20;114(8):91–8 (Eng. Abstr.) **(Ger)**

[Victory in primary prevention—or? Can we afford to translate results from the West-of-Scotland Study into general practice?] Klose G. **Fortschr Med** 1996 Jun 20; 114(17):231–2 **(Ger)**

[Disorders of lipid metabolism—diagnosis and therapy in general practice. 5: Hypercholesterolemia—drug therapy] Richter WO. **Fortschr Med** 1996 May 30;114(15):193–5 **(Ger)**

[Disorders of lipid metabolism—diagnosis and therapy in general practice. 4: Therapy of hypercholesterolemia—drug treatment] Richter WO. **Fortschr Med** 1996 May 20;114(14):177–8 **(Ger)**

[Prevention and treatment of coronary heart disease: lowering LDL, increasing HDL or monitoring both?] Windler E. **Internist (Berl)** 1996 Jun;37(6):643–6 **(Ger)**

[The 4-S study—a turning point in the cholesterol debate. Work Group Lipids and Atherosclerosis of the Swiss Society for Cardiology] Nigg C. **Schweiz Rundsch Med Prax** 1995 Dec 19;84(51–52):1514–6 **(Ger)**

[Drug therapy of hypercholesterolemia] Schwandt P, et al. **Wien Klin Wochenschr** 1995;107(18):544–8 (64 ref.) (Eng. Abstr.) **(Ger)**

[An update on the use of fluvastatin in primary hypercholesterolemia] Baggio G. **Ann Ital Med Int** 1995 Oct;10 Suppl:43S (5 ref.) **(Ita)**

[Comparison of pravastatin and diet in the treatment of hypercholesterolemia] Palazzuoli V, et al. **Clin Ter** 1995 Oct;146(10):587–93 (Eng. Abstr.) **(Ita)**

[Effects of simvastatin on blood levels of lipoprotein (a)] Galetta F, et al. **Minerva Med** 1995 Jul–Aug; 86(7–8):299–303 (Eng. Abstr.) **(Ita)**

[Statin therapy of individuals with high risk for coronary disease] Holme I. **Tidsskr Nor Laegeforen** 1996 May 10; 116(12):1479–81 (Eng. Abstr.) **(Nor)**

[Pharmacologic treatment of mild proliferation of prostatic cancer (editorial)] Dutkiewicz S. **Pol Tyg Lek** 1996 Feb; 51(6–9):67–72 (Eng. Abstr.) **(Pol)**

[Comparative study of gemfibrozil versus pravastatin in the treatment of patients with coronary artery disease and low HDL cholesterol levels] Santos RD, et al. **Arq Bras Cardiol** 1995 Aug;65(2):181–3 (Eng. Abstr.) **(Por)**

[Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia (letter; comment)] Martínez-Castelao A. **Med Clin (Barc)** 1995 Nov 25;105(18):719. Comment on: Med Clin (Barc) 1994 Feb 5;102(4):139–41. **(Spa)**

[The Scandinavian Simvastatin Survival Study: the clinical consequences] Larsen ML. **Rev Esp Cardiol** 1995;48 Suppl 5:39–42 (Eng. Abstr.) **(Spa)**

[Limitation of atherosclerosis in coronary arteries with pravastatin (PLAC 1)] Mancini GB. **Rev Esp Cardiol** 1995; 48 Suppl 2:11–3 (Eng. Abstr.) **(Spa)**

[The pharmacological treatment of hypercholesterolemia] Pérez Jiménez F. **Rev Esp Cardiol** 1995;48 Suppl 5:31–8 (53 ref.) (Eng. Abstr.) **(Spa)**

[A new study on hypercholesterolemia. Statin is effective against heart disease] Olsson AG. **Lakartidningen** 1996 May 29;93(22):2131–3 **(Swe)**

TOXICITY

Differential sensitivity of C2–C12 striated muscle cells to lovastatin and pravastatin. Gadbut AP, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2397–402

The effects of peroxisome proliferators on protein abundances in mouse liver. Anderson NL, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):75–89

ANTICHOLINERGIC AGENTS see **CHOLINERGIC ANTAGONISTS**

ANTICHOLINESTERASE AGENTS see **CHOLINESTERASE INHIBITORS**

ANTICIPATORY VOMITING see **VOMITING, ANTICIPATORY**

ANTICOAGULANTS

Disparity in blood activation by two different heparin–coated cardiopulmonary bypass systems. Moen O, et al. **Ann Thorac Surg** 1995 Nov;60(5):1317–23

cDNA cloning of IX/X–BP, a heterogeneous two–chain anticoagulan: protein from snake venom. Matsuzaki R, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):382–7

4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Tucson, Arizona, April 1995. Proceedings. **Chest** 1995 Oct;108(4 Suppl):225S–522S (0 ref.)

Protein C, protein S, and antithrombin III in acute ocular occlusive diseases. Bertram B, et al. **Ger J Ophthalmol** 1995 Nov;4(6):332–5

Veno–venous ELS with heparin bonded circuits. Marcolin R, et al. **Int J Artif Organs** 1995 Oct;18(10):624–6

Primary stent implantation without coumadin in acute myocardial infarction. Saito S, et al. **J Am Coll Cardiol** 1996 Jul;28(1):74–81

The role of international normalized ratio (INR) in clinical practice. Chen M, et al. **J Ark Med Soc** 1995 Sep; 92(4):178–80

Effects of storage on in vitro platelet responses: comparison of ACD and Na citrate anticoagulated samples. Pignatelli P, et al. **J Clin Lab Anal** 1996;10(3):134–9

Multidimensional outcomes in intravenous access device maintenance: a pilot study. Reineck C, et al. **J Nurs Care Qual** 1996 Jul;10(4):10–7

Discard volumes necessary for clinically useful coagulation studies from heparinized Hickman catheters. Mayo DJ, et al. **Oncol Nurs Forum** 1996 May;23(4):671–5

Comparison of two anticoagulants for production of antigens of Cowdria ruminantium in neutrophils. Awa DN, et al. **Rev Elev Med Vet Pays Trop** 1995;48(1):41–3

New anticoagulant prompts bad blood between partners [news] [see comments] Friedly J. **Science** 1996 Mar 29; 271(5257):1800–1. Comment in: Science 1996 May 24;272(5265):1085. Comment in: Science 1996 May 24;272(5265):1086.

[Oral anticoagulation from the primary care perspective (letter; comment)] Alonso M, et al. **Aten Primaria** 1995 Nov 30;16(9):574. Comment on: Aten Primaria 1995 May 31;15(9):555–60. **(Spa)**

[Control of anticoagulation in primary care (letter; comment)] Caballero Martinez F, et al. **Aten Primaria** 1995 Nov 30; 16(9):574–5. Comment on: Aten Primaria 1995 May 31;15(9):555–60. **(Spa)**

ADMINISTRATION & DOSAGE

Anticoagulant therapy in pregnancy. Report of 54 cases. Lecuru f, et al. **Acta Obstet Gynecol Scand** 1996 Mar; 75(3):217–21

Heparinization for routine hemodialysis. Ward RA. **Adv Ren Replace Ther** 1995 Oct;2(4):362–70

Shortened hospitalization by means of adjusted–dose subcutaneous heparin for deep venous thrombosis. Hirsch DR, et al. **Am Heart J** 1996 Feb;131(2):276–80

Heparin delivery at the site of angioplasty with a novel drug delivery sleeve. Kaplan AV, et al. **Am J Cardiol** 1996 Feb 1;77(4):307–10

Oral anticoagulant therapy—an algorithm to facilitate control [letter] Wenger NK. **Am J Cardiol** 1996 Feb 1;77(4):325–6

Reinstituting warfarin in patients who develop warfarin skin necrosis. Jillella AP, et al. **Am J Hematol** 1996 Jun; 52(2):117–9

Regional hemodialysis anticoagulation: hypertonic tri–sodium citrate or anticoagulant citrate dextrose–A. Flanigan MJ, et al. **Am J Kidney Dis** 1996 Apr;27(4):519–24

Severe calciphylaxis in a renal patient on long–term oral anticoagulant therapy. Rudwaleit M, et al. **Am J Nephrol** 1996;16(4):344–8

Are you up to date on weight–based heparin dosing? Sparks KS. **Am J Nurs** 1996 Apr;96(4):33–6; quiz 37 (6 ref.)

The effect of the anticoagulation regimen on endothelial–related coagulation in cardiac surgery patients. Boldt J, et al. **Anaesthesia** 1995 Nov;50(11):954–60

The effect of low molecular weight heparin (fragmin) on myocardial neutrophil accumulation and infarct size in a rat model of myocardial infarction. Hasdai D, et al. **Angiology** 1996 May;47(5):491–9

Prevention of venous thromboembolism after knee arthroplasty. A randomized, double–blind trial comparing enoxaparin with warfarin. Leclerc JR, et al. **Ann Intern Med** 1996 Apr 1;124(7):619–26

Warfarin and nonsteroidal antiinflammatory drugs: why not? [editorial; comment] Frazee LA, et al. **Ann Pharmacother** 1995 Dec;29(12):1289–91. Comment on: Ann Pharmacother 1995 Dec;29(12):1274–83.

Heparin–bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Aldea GS, et al. **Ann Thorac Surg** 1996 Aug; 62(2):410–7; discussion 417–8

Use of centrifugal pumps for postcardiotomy ventricular failure: technique and anticoagulation. Curtis JJ, et al. **Ann Thorac Surg** 1996 Jan;61(1):296–300; discussion 311–3

Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses [see comments] Despotis GJ, et al. **Ann Thorac Surg** 1996 Mar;61(3):795–9 . Comment in: Ann Thorac Surg 1996 Mar;61(3):781–2.

High and low heparin dose with heparin–coated cardiopulmonary bypass: activation of complement and granulocytes. Ovrum E, et al. **Ann Thorac Surg** 1995 Dec; 60(6):1755–61

Transgraft infusion of heparin to prevent early thrombosis of expanded PTFE grafts in canine femoral veins. Chen C, et al. **Ann Vasc Surg** 1996 Mar;10(2):147–55

Oral anticoagulation in paediatric patients: dose requirements and complications. Tait RC, et al. **Arch Dis Child** 1996 Mar;74(3):228–31

Long–term patient self–management of oral anticoagulation. Ansell JE, et al. **Arch Intern Med** 1995 Nov 13; 155(20):2185–9

The successful application of a heparin nomogram in a community hospital. Hollingsworth JA, et al. **Arch Intern Med** 1995 Oct 23;155(19):2095–100

Ideal anticoagulation for use with a left ventricular assist device. Takahama T, et al. **ASAIO J** 1995 Jul–Sep; 41(3):M779–82

Warfarin should be available as 0.5 mg tablet [letter] Rouse G, et al. **BMJ** 1996 Jul 6;313(7048):50

Rheumatoid arthritis and heparin [letter] Gaffney A, et al. **Br J Rheumatol** 1996 Aug;35(8):808–9

Predictors of the effect of heparin during cardiac catheterization. Laslett L, et al. **Cardiology** 1995; 86(5):380–3

Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin [see comments] Sankardas MA, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):355–9. Comment in: Cathet Cardiovasc Diagn 1996 Apr;47(4):360–1.

Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Hirsh J, et al. **Chest** 1995 Oct;108(4 Suppl):231S–246S (160 ref.)

Intracoronary heparin delivery in humans. Acute feasibility and long–term results. Camenzind E, et al. **Circulation** 1995 Nov 1;92(9):2463–72

Low–molecular–weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Gent M, et al. **Circulation** 1996 Jan 1;93(1):80–4

Intramural delivery of agent via a novel drug–delivery sleeve. Histological and functional evaluation. Moura A, et al. **Circulation** 1995 Oct 15;92(8):2299–305

Validation of an algorithm for oral anticoagulant dosing and appointment scheduling. Vadher BD, et al. **Clin Lab Haematol** 1995 Dec;17(4):339–45

Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients. Low CL, et al. **Clin Nephrol** 1996 Feb;45(2):120–4

Effects of short–term, high dose, heparin therapy on biochemical markers of bone metabolism. Cantini F, et al. **Clin Rheumatol** 1995 Nov;14(6):663–6

Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Gohlke–Bärwolf C, et al. **Eur Heart J** 1995 Oct;16(10):1320–30 (165 ref.)

Low molecular weight heparin for anticoagulation during haemodialysis in children—a preliminary study [letter] Van Biljon I, et al. **Eur J Pediatr** 1996 Jan;155(1):70

How should clinicians choose treatment for preventing stroke when therapeutic trials are not available to guide the situation? **Eur Neurol** 1995;35(5):293–305; discussion 305–8

Post–stent management with a pneumatic groin compression device and self injected low molecular weight heparin. Stables RH, et al. **Heart** 1996 Jun;75(6):588–90

Optimal intensity of oral anticoagulant therapy after myocardial infarction. Azar AJ, et al. **J Am Coll Cardiol** 1996 May;27(6):1349–55

Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses [see comments] Salazar E, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1698–703 . Comment in: J Am Coll Cardiol 1996 Jun;27(7):1704–6.

Altering anticoagulation therapy: a survey of physicians. Wahl MJ, et al. **J Am Dent Assoc** 1996 May;127(5):625–6, 629–30, 633–4 passim

Modifications to increase accuracy and consistency of anticoagulant delivery using the Fenwal CS3000 plus. Burgstaler EA, et al. **J Clin Apheresis** 1995;10(4):203–9

Introduction of computer assisted control of oral anticoagulation in general practice. Galloway MJ, et al. **J Clin Pathol** 1995 Dec;48(12):1144–6

Review of the initiation of anticoagulant therapy. Corbett NE, et al. **J Clin Pharm Ther** 1995 Aug;20(4):221–4

Oral anticoagulation. Alexander C, et al. **J Fam Pract** 1996 Jan;42(1):21

New method to predict patients' intravenous heparin dose requirements. Reilly BM, et al. **J Gen Intern Med** 1996 Mar;11(3):168–73

Surgical management of patients on warfarin sodium. Beirne OR, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1115–8 (18 ref.)

Periadventitial delivery of heparin in the prevention of microvenous thrombosis. Hirigoyen MB, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1097–102

Tranexamic acid rinses in anticoagulated patients [letter; comment] Lieblich S. **J Oral Maxillofac Surg** 1996 May; 54(5):657. Comment on: J Oral Maxillofac Surg 1996 Jan;54(1):27–32; discussion 323.

Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study [see comments] Souto JC, et al. **J Oral Maxillofac Surg** 1996 Jan;54(1):27–32; discussion 323. Comment in: J Oral Maxillofac Surg 1996 May;54(5):657.

Thrombin generation with heparin–bonded cardiopulmonary bypass circuits [letter] Bannan S, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):849

Recurrent thrombosis of biventricular–support devices associated with accelerated intravascular coagulation and increased heparin requirements. Despotis GJ, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):538–40

Individualized patient heparinization and protamine reversal [letter; comment] Martin P, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):493–4. Comment on: J Thorac Cardiovasc Surg 1995 Jul;110(1):46–54.

The benefit of heparin–bound circuits [letter] Moulijn AC, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):557–8

Biocompatibility of heparin–coated extracorporeal bypass circuits: a randomized, masked clinical trial. Muehrcke DD, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):472–83

Adjusted–dose warfarin versus low–intensity, fixed–dose warfarin plus aspirin for high–risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. **Lancet** 1996 Sep 7; 348(9028):633–8

Eliminating errors with intravenous heparin [letter] Vasanthakumar V. **Lancet** 1996 Sep 7;348(9028):694

Reversal of thrombocytopenia following oral anticoagulation in two patients with primary antiphospholipid syndrome. Ames PR, et al. **Lupus** 1995 Dec;4(6):491–3

Low–molecular–weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. Bergovist D, et al. **N Engl J Med** 1996 Sep 5;335(10):696–700

An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation [see comments] Hylek EM, et al. **N Engl J Med** 1996 Aug 22;335(8):540–6. Comment in: N Engl J Med 1996 Aug 22;335(8):587–9.

Unfractionated versus low–molecular–weight heparin for deep venous thrombosis [letter; comment] Penner J. **N Engl J Med** 1996 Aug 29;335(9):671; discussion 671–2 . Comment on: N Engl J Med 1996 Mar 14;334(11):677–81. Comment on: N Engl J Med 1996 Mar 14;334(11):682–7.

The Scylla and Charybdis of oral anticoagulant treatment [editorial; comment] Rosendaal FR. **N Engl J Med** 1996 Aug 22;335(8):587–9. Comment on: N Engl J Med 1996 Aug 22;335(8):540–6.

Duration of anticoagulant therapy for venous thrombosis [letter; comment] Safavi K. **N Engl J Med** 1995 Nov 9; 333(19):1288; discussion 1289. Comment on: N Engl J Med 1995 Jun 22;332(25):1661–5.

Duration of anticoagulant therapy for venous thrombosis [letter; comment] Shojania AM. **N Engl J Med** 1995 Nov 9;333(19):1288–9. Comment on: N Engl J Med 1995 Jun 22;332(25):1661–5.

Optimal oral anticoagulation for patients with nonrheumatic atrial fibrillation and recent cerebral ischemia [letter; comment] Singer DE, et al. **N Engl J Med** 1995 Nov 30; 333(22):1504. Comment on: N Engl J Med 1995 Jul 6;333(1):5–10. Comment on: N Engl J Med 1995 Jul 6;333(1):11–7.

Unfractionated versus low–molecular–weight heparin for deep venous thrombosis [letter; comment] Strandness DE Jr. **N Engl J Med** 1996 Aug 29;335(9):670–1; discussion 671–2. Comment on: N Engl J Med 1996 Mar 14;334(11):677–81. Comment on: N Engl J Med 1996 Mar 14;334(11):682–7.

Optimal oral anticoagulation for patients with mechanical heart valves [letter; comment] von Schacky C. **N Engl J Med** 1995 Nov 30;333(22):1504–5. Comment on: N Engl J Med 1995 Jul 6;333(1):11–7.

Warfarin therapy at 6 pm [letter] Dunckley C. **N Z Med J** 1995 Nov 10;108(1011):466

Low molecular weight heparin ('fragmin') in haemodialysis: is laboratory monitoring worthwhile? [letter] Sigüenza F, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2163–4

International Normalized Ratio (INR): an improved way to

monitor oral anticoagulant therapy. Oertel LB. **Nurse Pract** 1995 Sep;20(9):15–6, 21–2 (12 ref.)

Influence of a single HELP application on hemorheology and retinal hemodynamics. Haas A, et al. **Ophthalmologica** 1996;210(3):171–4

INR and PTR anticoagulation values [letter] Wahl MJ. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):377–8

Lovastatin during warfarin therapy resulting in bleeding. Iliadis EA, et al. **Pa Med** 1995 Dec;98(12):31

Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Furuya H, et al. **Pharmacogenetics** 1995 Dec;5(6):389–92

Prevention of microvascular thrombosis by topical application of recombinant tissue factor pathway inhibitor. Lantieri LA, et al. **Plast Reconstr Surg** 1996 Mar; 97(3):587–94

Effect of vitamin K on oral anticoagulation [letter; comment] Booth S, et al. **Postgrad Med** 1995 Dec;98(6):27–8. Comment on: Postgrad Med 1995 Sep;98(3):153–4, 159–62, 164–5, passim.

Maintenance doses of warfarin in Chinese patients [letter] Cheng TO. **QJM** 1996 Jul;89(7):557

Heparin dosing. Farnsworth TL. **S D J Med** 1995 Nov; 48(11):386–7 (13 ref.)

Preoperative disseminated intravascular coagulation (DIC) associated with aortic aneurysm—does it need to be corrected before surgery? Oba J, et al. **Surg Today** 1995; 25(12):1011–4

A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis. Diquélou A, et al. **Thromb Haemost** 1995 Nov;74(5):1286–92

A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement. Horbach T, et al. **Thromb Haemost** 1996 Feb;75(2):246–50

Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Levine MN, et al. **Thromb Haemost** 1995 Aug;74(2):606–11

Treatment of a patient with an undefined hypercoagulable state with long-term low-molecular-weight heparin. Dobie SA, et al. **West J Med** 1996 Apr;164(4):350–3 (6 ref.)

Warfarin encouraged for stroke prevention in atrial fibrillation. Gold JA. **Wis Med J** 1996 Jan;95(1):42–3

[Optimal treatment with oral anticoagulants (letter)] Breukink-Engbers WG. **Ned Tijdschr Geneeskd** 1996 Jul 20;140(29):1518–9 **(Dut)**

[Duration of antivitamin K therapy in venous thromboembolic disease] Ferrari E, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1891–4 (24 ref.) (Eng. Abstr.) **(Fre)**

[Thrombolytic therapy for myocardial infarction in oral anticoagulation] Pizzulli L, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):424 **(Ger)**

[Prevention of thrombosis with fraxiparin 0.3 after ambulatory surgery] Schain FH. **Fortschr Med** 1996 Apr 30;114(12):149–52 (Eng. Abstr.) **(Ger)**

[Prevention and treatment of thrombosis in pregnancy] Winkler UH, et al. **Geburtshilfe Frauenheilkd** 1996 Jun; 56(6):301–12 (83 ref.) (Eng. Abstr.) **(Ger)**

[Risk and prevention of thromboembolism complications in gynecologic malignancies] Graf AH, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):37–9 (Eng. Abstr.) **(Ger)**

-Anticoagulation after intracoronary stent implantation- Bode C, et al. **Herz** 1996 Feb;21(1):60–3 (21 ref.) (Eng. Abstr.) **(Ger)**

[Before administering oral anticoagulant therapy with vitamin K antagonists, should heparin be administered, even when therapy is purely of preventive intent without an acute clinical manifestation?] Seitz R. **Internist (Berl)** 1995 Nov;36(11):1099–100 **(Ger)**

[Recommendations for prevention of thromboembolism in heart valve diseases. Working Group on Valvular Heart Disease, European Society of Cardiology] Gohlke-Bärwolf C, et al. **Z Kardiol** 1995 Dec;84(12):1018–32 (168 ref.) (Eng. Abstr.) **(Ger)**

[Local drug administration systems, preclinical and clinical use: perspectives and limitations] Gonschior P, et al. **Z Kardiol** 1996 Mar;85(3):155–65 (59 ref.) (Eng. Abstr.) **(Ger)**

[General perioperative prevention of thromboembolism in gynecology with low-molecular weight heparin: clinical experiences with enoxaparin over 7 years] Slunsky R. **Zentralbl Gynakol** 1995;117(11):598–601 (Eng. Abstr.) **(Ger)**

[The effect of prolonged acenocoumarol therapy on bone density] Kiss J, et al. **Orv Hetil** 1995 Sep 24;136(39):2113–5 (Eng. Abstr.) **(Hun)**

[Significance of combined use of anticoagulants and antiplatelet agents in the early stage after prosthetic valve replacement] Toyohira H, et al. **Kyobu Geka** 1995 Aug; 48(9):749–55 (Eng. Abstr.) **(Jpn)**

[Oral anticoagulants treatment of thrombosis] Matsuda T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1523–7 (2 ref.) **(Jpn)**

[Plasma activity of diamine oxidase after heparin in patients with diabetic enteropathy] Loba J, et al. **Pol Arch Med Wewn** 1995 Feb;93(2):114–21 (Eng. Abstr.) **(Pol)**

[Anticoagulants in hemodialysis therapy] Małyszko J, et al. **Przegl Lek** 1996;53(5):454–8 (49 ref.) **(Pol)**

[Anticoagulation in hemodialysis with a single dose of low molecular weight heparin] Vukusich A, et al. **Rev Med Chil** 1995 Jun;123(6):735–41 (Eng. Abstr.) **(Spa)**

[Low-molecular weight heparins in dental extractions of patients receiving oral anticoagulant treatment (letter)] Guerra L, et al. **Sangre (Barc)** 1995 Aug;40(4):336–7 **(Spa)**

ADVERSE EFFECTS

Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Smith AJ, et al. **Am Heart J** 1996 Mar;131(3):434–9

The risk of withdrawing chronic anticoagulation because of acute GI bleeding. Kuwada SK, et al. **Am J Gastroenterol** 1996 Jun;91(6):1116–9

Heparin-induced thrombocytopenia. Borkowski DA, et al. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2528, 2535–6

Additional anticoagulant strategies for managing heparin-induced thrombocytopenia [letter] Nawarskas JJ, et al. **Am J Health Syst Pharm** 1996 Apr 15;53(8):945

Reinstituting warfarin in patients who develop warfarin skin necrosis. Jillella AP, et al. **Am J Hematol** 1996 Jun; 52(2):117–9

Heparin-induced thrombocytopenia in hemodialysis patients. Yamamoto S, et al. **Am J Kidney Dis** 1996 Jul;28(1):82–5

Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: a preliminary report. Auger WR, et al. **Am J Med** 1995 Oct;99(4):392–6

Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease [see comments] Greenberg PD, et al. **Am J Med** 1996 Jun; 100(6):598–604. Comment in: Am J Med 1996 Jun;100(6):596–7.

Spinal epidural hematoma associated with warfarin therapy. Lederle FA, et al. **Am J Med** 1996 Feb;100(2):237–8

Spermatic cord hematoma: case report and literature review. McKenney MG, et al. **Am Surg** 1996 Sep;62(9):768–9 (13 ref.)

Epidural hematoma associated with enoxaparin. Hynson JM, et al. **Anesth Analg** 1996 May;82(5):1072–5

Enoxaparin and epidural analgesia [letter] Weitz SR, et al. **Anesthesiology** 1996 Aug;85(2):432–4

Heparin-induced thrombocytopenia with multiple cerebral infarctions simulating thrombotic thrombocytopenic purpura. A case report. Boon DM, et al. **Angiology** 1996 Apr;47(4):407–11

Coumarin-induced skin necrosis following heparin-induced thrombocytopenia and thrombosis. A case report. Shahak A, et al. **Angiology** 1996 Jul;47(7):725–7

The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation. Fihn SD, et al. **Ann Intern Med** 1996 Jun 1;124(11):970–9

Enoxaparin-induced skin necrosis [letter] Fried M, et al. **Ann Intern Med** 1996 Sep 15;125(6):521–2

Thrombocytosis associated with low-molecular-weight heparin [letter] Rizzieri DA, et al. **Ann Intern Med** 1996 Jul 15;125(2):157

Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance [see comments] Chan TY. **Ann Pharmacother** 1995 Dec;29(12):1274–83 (89 ref.). Comment in: Ann Pharmacother 1995 Dec;29(12):1289–91.

Warfarin and nonsteroidal antiinflammatory drugs: why not? [editorial; comment] Frazee LA, et al. **Ann Pharmacother** 1995 Dec;29(12):1289–91. Comment on: Ann Pharmacother 1995 Dec;29(12):1274–83.

Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass [see comments] Khuri SF, et al. **Ann Thorac Surg** 1995 Oct;60(4):1008–14. Comment in: Ann Thorac Surg 1996 May;61(5):1590–1.

Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Wilhelm MJ, et al. **Ann Thorac Surg** 1996 Mar;61(3):920–4

Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. **Arch Intern Med** 1996 Feb 26;156(4):409–16

Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapy. Blackshear JL, et al. **Arch Intern Med** 1996 Mar 25;156(6):658–60

Aging and heparin-related bleeding. Campbell NR, et al. **Arch Intern Med** 1996 Apr 22;156(8):857–60

Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics. White RH, et al. **Arch Intern Med** 1996 Jun 10;156(11):1197–201

Danger of urokinase as an anticoagulant with left ventricular assist devices. Takahama T, et al. **ASAIO J** 1995 Jul-Sep; 41(3):M787–90

Abdominal wall haematoma in anti-coagulated patients: the role of imaging in diagnosis. Davies RS, et al. **Australas Radiol** 1996 May;40(2):109–12

Warfarin-induced changes in procoagulant and anticoagulant proteins. Stirling Y. **Blood Coagul Fibrinolysis** 1995 Jul; 6(5):361–73 (115 ref.)

Insidiously evolving, occult drug interaction involving warfarin and amiodarone. Cheung B, et al. **BMJ** 1996 Jan 13;312(7023):107–8

Quality of service provision for anticoagulation in atrial fibrillation. Difficulties of routine treatment are exaggerated [letter; comment] Marshall T. **BMJ** 1996 Jan 6;312(7022):52 . Comment on: BMJ 1995 Aug 26;311(7004):558–60.

Monitoring may need to be prolonged in patients given warfarin and amiodarone [letter] Tomlinson B, et al. **BMJ** 1996 Aug 3;313(7052):301–2

Pravastatin: interaction with oral anticoagulant? Trenque T, et al. **BMJ** 1996 Apr 6;312(7035):886

Deaths associated with warfarin in elderly patients. Reardon M, et al. **Br J Clin Pract** 1995 Nov-Dec;49(6):322–3

Heparin-induced thrombocytopenia: an improved method of detection based on lumi-aggregometry. Stewart MW, et al. **Br J Haematol** 1995 Sep;91(1):173–7

Life threatening secondary haemorrhage following endoscopic laser ablation of the prostate in an anti-coagulated patient. Bellringer JF, et al. **Br J Urol** 1996 Mar;77(3):463–4

Successful embolization of a large superior gluteal artery pseudoaneurysm emerging during anticoagulant therapy. Gabata T, et al. **Cardiovasc Intervent Radiol** 1995 Sep–Oct; 18(5):327–9

Hapten resistant dextran induced ARDS reaction following intracoronary stent deployment. Gossman DE, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):56–61

Not too conservative treatment of over anticoagulated patients [letter; comment] Fernandez BB Jr. **Chest** 1996 Apr;109(4):1132. Comment on: Chest 1995 Oct;108(4):987–90.

Conservative treatment of overanticoagulated patients [see comments] Glover JJ, et al. **Chest** 1995 Oct;108(4):987–90 . Comment in: Chest 1996 Apr;109(4):1132.

Hemorrhagic complications of anticoagulant treatment. Levine MN, et al. **Chest** 1995 Oct;108(4 Suppl):276S–290S (118 ref.)

Late intracapsular hemorrhage in an anticoagulated patient with a breast implant [letter] Willens HJ, et al. **Chest** 1996 Jul;110(1):304–5

Hemopericardium with cardiac tamponade after intravenous thrombolysis for acute myocardial infarction. Mohammad S, et al. **Clin Cardiol** 1996 May;19(5):432–4

Retroperitoneal haematoma in a patient treated with acenocoumarol, phenytoin and paroxetine. Abad-Santos F, et al. **Clin Lab Haematol** 1995 Jun;17(2):195–7

A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole. Wehbe TW, et al. **Clin Pharmacol Ther** 1996 Mar; 59(3):360–2

Delayed allergic skin reactions due to subcutaneous heparin-calcium, enoxaparin-sodium, pentosan polysulfate and acute skin lesions from systemic sodium-heparin. Koch P, et al. **Contact Dermatitis** 1996 Feb;34(2):156–8

Anticoagulation and pregnancy. Oakley CM. **Eur Heart J** 1995 Oct;16(10):1317–9 (22 ref.)

Bone density studies in pregnant women receiving heparin. Shefras J, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):171–4

Acute renal failure in an elderly man taking warfarin. Larry JA, et al. **Hosp Pract (Off Ed)** 1996 May 15;31(5):119, 123–4

Heparin-induced thrombocytopenia type II: successful use of Orgaran (ORG 10172) in intensive care patients [letter] Burkhard-Meier U, et al. **Intensive Care Med** 1995 Jun; 21(6):542–3

Warfarin-induced eosinophilic pleurisy. Kuwahara T, et al. **Intern Med** 1995 Aug;34(8):794–6

Phase I trial of pentosan polysulfate. Swain SM, et al. **Invest New Drugs** 1995;13(1):55–62

Effect of ketorolac tromethamine on bleeding and on requirements for analgesia after total knee arthroplasty [letter; comment] Linville D. **J Bone Joint Surg Am** 1996 Jun;78(6):967–8. Comment on: J Bone Joint Surg Am 1995 Jul;77(7):998–1002.

Perioperative low-molecular-weight heparin. Is it effective and safe? Warwick D, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):715–9

Spinal epidural hematoma during anticoagulant therapy. A case report and review of the literature. Rodriguez y Baena R, et al. **J Neurosurg Sci** 1995 Mar;39(1):87–94 (90 ref.)

Minimally invasive therapies in the treatment of erectile dysfunction in anticoagulated cases: a study of satisfaction and safety. Limoge JP, et al. **J Urol** 1996 Apr;155(4):1276–9

Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome. Slocum MM, et al. **J Vasc Surg** 1996 May;23(5):839–43

Severe thrombocytopenia in a man with prostatic cancer. Hamid S, et al. **JPMA J Pak Med Assoc** 1995 Sep; 45(9):252–4

Complications of intravenous heparin therapy for treatment of thromboembolic disease in joint arthroplasty patients. Pence CD, et al. **Kans Med** 1996 Spring;97(1):16–8

Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis [letter] Greinacher A, et al. **Lancet** 1996 Sep 14;348(9029):764

Treatment of warfarin-induced hair loss with ubidecarenone [letter] Nagao T, et al. **Lancet** 1995 Oct 21;346(8982):1104–5

Bleeding complications of oral anticoagulant treatment: an

inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Palareti G, et al. **Lancet** 1996 Aug 17;348(9025):423–8

Anticoagulants during pregnancy. Corbett JV, et al. **MCN Am J Matern Child Nurs** 1995 Jan–Feb;20(1):56

Fatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug [letter] Gabb GM. **Med J Aust** 1996 Jun 3;164(11):700–1

Case 11–1996: atheroembolism of the kidneys and lungs [letter] Mallory R, et al. **N Engl J Med** 1996 Sep 12; 335(11):821

Complement activation by LDL-apheresis using dextran sulphate [letter] Pascual M, et al. **Nephrol Dial Transplant** 1995;10(8):1475–6

Thrombosis resulting from heparin therapy. Gottschling LL, et al. **Pharmacotherapy** 1996 May–Jun;16(3):469–72

Epidural hematoma after epidural pain control and concomitant postoperative anticoagulation [letter] Badenhorst CH. **Reg Anesth** 1996 May–Jun;21(3):272–3

Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)

Management of intracranial hemorrhage associated with anticoagulant therapy. Kawamata T, et al. **Surg Neurol** 1995 Nov;44(5):438–42; discussion 443

The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Douketis JD, et al. **Thromb Haemost** 1996 Feb;75(2):254–7

Warfarin induced skin necrosis associated with activated protein C resistance [letter] Makris M, et al. **Thromb Haemost** 1996 Mar;75(3):523–4

Transfusion medicine issues in the practice of anesthesiology [letter; comment] Alparin JB. **Transfus Med Rev** 1995 Oct; 9(4):339. Comment on: Transfus Med Rev 1995 Jan;9(1):60–78.

Coagulopathy induced by overuse of heparin containing FLUH solution in orthotopic liver transplantation. Jawan B, et al. **Transplant Proc** 1996 Jun;28(3):1719–20

Washington's experience and recommendations Re: Anticoagulant rodenticides. Morrissey B, et al. **Vet Hum Toxicol** 1995 Aug;37(4):362–3 (4 ref.)

[Interaction between warfarin and nalidic acid] Gulløv AL, et al. **Ugeskr Laeger** 1996 Sep 9;158(37):5174–5 (Eng. Abstr.) **(Dan)**

[Hemorrhagic risk from antivitamins K: importance of the surveillance and information of patients (letter)] Laurent M, et al. **Presse Med** 1995 Nov 11;24(34):1621 **(Fre)**

[Spinal extradural hematoma after anticoagulants. 5 cases (letter)] Rizk T, et al. **Presse Med** 1996 May 25;25(18):864 **(Fre)**

[Diffuse alveolar hemorrhage secondary to oral anticoagulant use] Léna H, et al. **Rev Mal Respir** 1995;12(5):496–8 (Eng. Abstr.) **(Fre)**

[Prolonged fever induced by fluindione (letter)] Grunenberger F, et al. **Rev Med Interne** 1995;16(12):973–4 **(Fre)**

[Prolonged fever following treatment with acenocoumarol (letter)] Renou C, et al. **Rev Med Interne** 1996;17(1):93–4 **(Fre)**

[Phenprocoumon-induced necrotizing hepatitis (letter)] Ehrenforth S, et al. **Dtsch Med Wochenschr** 1995 Nov 3; 120(44):1529–30 **(Ger)**

[Pronounced phenprocoumon overdosage as a consequence of an unclear physician's order (letter)] Schaer B. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):887 **(Ger)**

[Phenprocoumon-induced cholestatic hepatitis] Woolley S, et al. **Dtsch Med Wochenschr** 1995 Nov 3;120(44):1507–10 (Eng. Abstr.) **(Ger)**

[Tooth extraction in patients undergoing anticoagulant therapy] Pácz Z, et al. **Fogorv Sz** 1995 Sep;88(9):289–92 (Eng. Abstr.) **(Hun)**

[Anticoagulant related hemorrhage and thromboembolism after valvular surgery] Okada K, et al. **Kyobu Geka** 1996 Mar;49(3):190–3 (Eng. Abstr.) **(Jpn)**

[Heparin as the cause of severe thrombosis] Abildgaard U, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):757–8 (Eng. Abstr.) **(Nor)**

[A false incisional hernia during coumarin anticoagulation] Gabriel HM, et al. **Acta Med Port** 1995 Oct;8(10):589–90 (Eng. Abstr.) **(Por)**

[Upper airway obstruction. An unusual and life-threatening complication of Waran therapy] Engborg L, et al. **Lakartidningen** 1995 Oct 25;92(43):3997, 3999 **(Swe)**

ANALYSIS

Adaptation of a functional assay for protein S to a Cobas Fara II centrifugal analyzer. Solomon HM, et al. **Am J Clin Pathol** 1995 Dec;104(6):655–9

Anticoagulant poisoning in animals: a simple new high-performance thin-layer chromatographic (HPTLC) method for the simultaneous determination of eight anticoagulant rodenticides in liver samples. Berny PJ, et al. **J Anal Toxicol** 1995 Nov–Dec;19(7):576–80

Salivary gland anticoagulants in culicine and anopheline mosquitoes (Diptera:Culicidae). Stark KR, et al. **J Med Entomol** 1996 Jul;33(4):645–50

[Tissue factor pathway inhibitor (TFPI)] Matsuo T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:157–61 (10 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Oral vitamin K1: an option to reduce warfarin's activity. Harrell CC, et al. **Ann Pharmacother** 1995 Dec; 29(12):1228–32 (26 ref.)

Intravenous vitamin K1 injections: dangerous prophylaxis [letter; comment] O'Reilly RA, et al. **Arch Intern Med** 1995 Oct 23;155(19):2127–8. Comment on: Arch Intern Med 1995 Jan 23;155(2):149–61.

Endotoxin negates anticoagulant effect of cyclosporine. Spillert CR, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S197

A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation. Wakefield TW, et al. **J Surg Res** 1996 Jun;63(1):280–6

Effects of differing rates of protamine reversal of heparin anticoagulation. Wakefield TW, et al. **Surgery** 1996 Feb; 119(2):123–8

[Warfarin therapy and chlorella] Ohkawa S, et al. **Rinsho Shinkeigaku** 1995 Jul;35(7):806–7 (Eng. Abstr.) **(Jpn)**

[Thrombophilia characterized by resistance to anticoagulants with indirect action] Barkagan ZS, et al. **Ter Arkh** 1995; 67(7):50–2 (8 ref.) (Eng. Abstr.) **(Rus)**

BLOOD

Differences in the stability of intact osteocalcin in serum, lithium heparin plasma and EDTA plasma. Durham BH, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):422–3

Anticoagulant effects of antioxidant capacity [letter] Rea CA, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):174

Determination of a depolymerized holothurian glycosaminoglycan in plasma after intravenous administration by postcolumn HPLC. Huang Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2182–6

Changes in plasma warfarin levels and variations in steady-state prothrombin times. White RH, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):588–93

The anticoagulant effect of the human secretory phospholipase A2 on blood plasma and on a cell-free system is due to a phospholipid-independent mechanism of action involving the inhibition of factor Va. Mounier C, et al. **Eur J Biochem** 1996 May 1;237(3):778–85

Dilution of citrated plasma [letter; comment] Lammers M. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):369. Comment on: Eur J Clin Chem Clin Biochem 1995 Nov;33(11):805–12.

Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393). Thürmann P, et al. **Eur J Clin Pharmacol** 1995;48(3–4):241–6

A method for the simultaneous identification and quantitation of five superwarfarin rodenticides in human serum. Kuijpers EA, et al. **J Anal Toxicol** 1995 Nov–Dec; 19(7):557–62

Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. Kitchen S, et al. **J Clin Pathol** 1996 Jan;49(1):10–4

Hemostasis, fibrinolysis, and natural anticoagulation in transplant vascular sclerosis. Faulk WP, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S158–64

International Normalized Ratio (INR): an improved way to monitor oral anticoagulant therapy. Oertel LB. **Nurse Pract** 1995 Sep;20(9):15–6, 21–2 (12 ref.)

High-performance liquid chromatographic determination of free ferulic acid in serum of rabbits with blood stasis. Wen AD, et al. **Yao Hsueh Hsueh Pao** 1995;30(10):762–7

[A case of hemolytic uremic syndrome associated with circulating anticoagulant] Arakawa M, et al. **Nippon Jinzo Gakkai Shi** 1995 Sep;37(9):523–8 (Eng. Abstr.) **(Jpn)**

[Laboratory control of oral anticoagulation] Lourenço DM, et al. **Rev Assoc Med Bras** 1995 Mar–Apr;41(2):103–8 (Eng. Abstr.) **(Por)**

CHEMICAL SYNTHESIS

Platelet aggregation inhibiting and anticoagulant effects of oligoamines, Part 33. From tetradecane- to octacosanediamines. Rehse K, et al. **Arch Pharm (Weinheim)** 1996 Apr;329(4):191–6

Active site-directed thrombin inhibitors: alpha-hydroxyacyl-prolyl-arginals. New orally active stable analogs of D-Phe-Pro-Arg-H. Bajusz S, et al. **Bioorg Med Chem** 1995 Aug;3(8):1079–89

Synthesis and comparison of tripeptidylfluoroalkane thrombin inhibitors. Neises B, et al. **Bioorg Med Chem** 1995 Aug;3(8):1049–61

CHEMISTRY

Compatibility and activity of enoxaparin sodium in 0.9% sodium chloride injection for 48 hours. Mewborn AL, et al. **Am J Health Syst Pharm** 1996 Jan 15;53(2):167–9

Thrombin active site inhibitors. Das J, et al. **Bioorg Med Chem** 1995 Aug;3(8):999–1007 (57 ref.)

A unique dermatan sulfate-like glycosaminoglycan from ascidian. Its structure and the effect of its unusual sulfation pattern on anticoagulant activity. Pavão MS, et al. **J Biol Chem** 1995 Dec 29;270(52):31027–36

Heparin release from thermosensitive polymer coatings: in vivo studies. Gutowska A, et al. **J Biomed Mater Res** 1995 Jul;29(7):811–21

Synthetic low-molecular weight thrombin inhibitors: the ideal antithrombotic drug? An introduction. Stürzebecher J, et al. **J Enzym Inhib** 1995;9(1):1–2

Determination of the disulfide bond pairings in human tissue factor pathway inhibitor purified from Escherichia coli. Violand BN, et al. **J Protein Chem** 1995 Jul;14(5):341–7

Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity [letter] Grootenhuis PD, et al. **Nat Struct Biol** 1995 Sep;2(9):736–9

Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Greinacher A, et al. **Thromb Haemost** 1995 Sep;74(3):886–92

ECONOMICS

Antithrombotic strategy after total hip replacement. A cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis. Sarasin FP, et al. **Arch Intern Med** 1996 Aug 12–26; 156(15):1661–8

Costs of oral anticoagulation treatment after myocardial infarction [letter; comment] Bussey HI, et al. **JAMA** 1995 Nov 22–29;274(20):1588–9. Comment on: JAMA 1995 Mar 22–29;273(12):925–8. Comment on: JAMA 1995 Mar 22–29;273(12):965–7.

[Socioeconomic studies of hemostaseologic therapy and anticoagulation] Schramm W, et al. **Zentralbl Chir** 1995; 120(8):593–7 (Eng. Abstr.) **(Ger)**

HISTORY

The discovery of heparin revisited: the peptone connection. Marcum JA. **Perspect Biol Med** 1996 Summer;39(4):610–25

Salicylates and dicoumarol revisited—anything new under the sun? [letter; comment] Stormorken H, et al. **Thromb Haemost** 1995 Aug;74(2):809. Comment on: Thromb Haemost 1994 Dec;72(6):988–9.

[From the history of thrombosis prevention and treatment] Mahler F. **Ther Umsch** 1996 Apr;53(4):254–7 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Functional specificity of anticoagulant autoantibodies defined by protein cofactors and Tween 20 [letter; comment] Cheng HM. **Am J Hematol** 1995 Nov;50(3):224–5. Comment on: Am J Hematol 1993 Nov;44(3):187–91.

ISOLATION & PURIFICATION

Reversal of anticoagulation without protamine using a heparin removal device after cardiopulmonary bypass. Vertress RA, et al. **ASAIO J** 1994 Jul–Sep;40(3):M560–4

METABOLISM

Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Kunze KL, et al. **Drug Metab Dispos** 1996 Apr;24(4):414–21

Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions. Hoppensteadt DA, et al. **Int Angiol** 1996 Mar;15(1):39–46

Characterization and hormonal modulation of anticoagulant heparan sulfate proteoglycans synthesized by rat ovarian granulosa cells. Hosseini G, et al. **J Biol Chem** 1996 Sep 6;271(36):22090–9

The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. Regan LM, et al. **J Biol Chem** 1996 Jul 19;271(29):17499–503

The affinity of troxerutin for the venous wall measured by laser scanning microscopy. Patwardhan A, et al. **J Cardiovasc Surg (Torino)** 1995 Aug;36(4):381–5

Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Furuya H, et al. **Pharmacogenetics** 1995 Dec;5(6):389–92

NSAIDs and anticoagulant therapy [letter; comment] Cohen RB. **Postgrad Med** 1996 Jan;99(1):44, 47. Comment on: Postgrad Med 1995 Sep;98(3):153–4, 159–62, 164–5, passim.

Multiple doses of trandolapril do not affect warfarin pharmacodynamics. Meyer BH, et al. **S Afr Med J** 1995 Aug;85(8):768–70

[Resistance to activated protein C: a new cause of hypercoagulability] Fouéré S, et al. **Ann Dermatol Venereol** 1996;123(1):37–9 **(Fre)**

[Interaction between prostaglandin E and oral anticoagulants (letter)] Thijssen HW. **Presse Med** 1995 Nov 18;24(35):1665 **(Fre)**

PHARMACOKINETICS

Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Brancazio LR, et al. **Am J Obstet Gynecol** Oct; 173(4):1240–5

Distribution behaviour of 131-iodine labelled trans-N,N'-bis-(ethoxy-carbonyl)-N-[4-(3-iodo-4-methoxyphenyl)butyl]-N' -5-phenylpentyl)-1,4-cyclohexanedimethanamine. Rehse K,

et al. **Arch Pharm (Weinheim)** 1995 Oct;328(10):731–6
Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. Azizi M, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):577–84
Prolonged antithrombin activity of low–molecular–weight heparins. Clinical implications for the treatment of thromboembolic diseases. Agnelli G, et al. **Circulation** 1995 Nov 15;92(10):2819–24
Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Awni WM, et al. **Clin Pharmacokinet** 1995;29 Suppl 2:67–76
Warfarin–fluconazole. II. A metabolically based drug interaction: in vivo studies. Black DJ, et al. **Drug Metab Dispos** 1996 Apr;24(4):422–8
Warfarin–fluconazole. III. A rational approach to management of a metabolically based drug interaction. Kunze KL, et al. **Drug Metab Dispos** 1996 Apr;24(4):429–35
Coumarin 7–hydroxylation in long–term adherents of a strict uncooked vegan diet. Rauma AL, et al. **Eur J Clin Pharmacol** 1996;50(1–2):133–7
Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. Narita M, et al. **J Biol Chem** 1995 Oct 20;270(42):24800–4
Pharmacokinetic study of the low–molecular–weight heparin fraxiparin in patients with nephrotic syndrome. Albenc–Gelas M, et al. **Nephron** 1995;71(2):149–52

PHARMACOLOGY

Concentrations of progesterone during storage of whole blood from llama (Lama glama): effects of anticoagulants, storage time and temperature. Abal MA, et al. **Acta Vet Scand** 1996;37(1):123–5
Inhibition of mesothelial cell growth and protein synthesis by heparin. Manalaysay MT, et al. **Adv Perit Dial** 1995; 11:239–42
Low anticoagulant heparin retains anti–HIV type 1 activity in vitro. Coombe DR, et al. **AIDS Res Hum Retroviruses** 1995 Nov;11(11):1393–6
Effect of vitamin E on the anticoagulant response to warfarin. Kim JM, et al. **Am J Cardiol** 1996 Mar 1;77(7):545–6
Heparin–induced increase in the International Normalized Ratio [letter; comment] Carroll JJ. **Am J Clin Pathol** 1996 Feb;105(2):253–4. Comment on: Am J Clin Pathol 1995 Jun;103(6):735–9.
Compatibility and activity of enoxaparin sodium in 0.9% sodium chloride injection for 48 hours. Mewborn AL, et al. **Am J Health Syst Pharm** 1996 Jan 15;53(2):167–9
The effects of supraceliac aortic clamping on the anticoagulant effects of heparin. Money SR, et al. **Am J Surg** 1996 Aug;172(2):155–7
An investigation of the effects of heparin, low molecular weight heparin, protamine, and fentanyl on the balance of pro– and anti–inflammatory cytokines in in–vitro monocyte cultures. McBride WT, et al. **Anaesthesia** 1996 Jul;51(7):634–40
Procoagulant action of aprotinin [letter; comment] Alston TA. **Anesth Analg** 1996 Jun;82(6):1305–6. Comment on: Anesth Analg 1995 Nov;81(5):919–24.
Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro. Despotis GJ, et al. **Anesth Analg** 1996 Jun;82(6):1126–31
Effects of a single heparin bolus on neointimal growth after arterial injury in intact rabbits. Janiszewski M, et al. **Angiology** 1996 Jun;47(6):549–56
The effect of anticoagulant choice on apparent total antioxidant capacity using three different methods. Goode HF, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):413–6
Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Dahlbäck B, et al. **Ann Hematol** 1996 Apr;72(4):166–76 (152 ref.)
Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. van der Bom JG, et al. **Ann Intern Med** 1996 Aug 15;125(4):265–9
Eosinophil granulocyte activation and heparin–coated cardiopulmonary bypass [letter; comment] Ovrum E. **Ann Thorac Surg** 1996 Mar;61(3):1038–9. Comment on: Ann Thorac Surg 1995 Mar;59(3):713–6.
Platelet aggregation inhibiting and anticoagulant effects of oligoamines, Part 33. From tetradecane– to octacosanediamines. Rehse K, et al. **Arch Pharm (Weinheim)** 1996 Apr;329(4):191–6
Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig. André P, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):56–63
Oversulfated fucoidan and heparin suppress endotoxin induction of plasminogen activator inhibitor–1 in cultured human endothelial cells: their possible mechanism of action. Soeda S, et al. **Biochim Biophys Acta** 1995 Oct 19; 1269(1):85–90
In vitro contact phase activation with haemodialysis membranes: role of pharmaceutical agents. Matata BM, et al. **Biomaterials** 1995 Nov;16(17):1305–12
Heparin effect on red blood cell aggregation. Kameneva MV, et al. **Biorheology** 1994 May–Jun;31(3):297–304
Anticoagulant effects of retinoic acids on leukemia cells. Saito T, et al. **Blood** 1996 Jan 15;87(2):657–65
Effects of low–molecular–weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. Harenberg J, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):49–56
Inhibition of thrombin generation by heparin and LMW heparins: a comparison of chromogenic and clotting methods. Houbouyan L, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):24–30
Dextran sulfate promotes the rapid aggregation of porcine bone–marrow stromal cells. Noble BS, et al. **Bone** 1995 Oct;17(4):375–82
Potent and long–lasting anticonvulsant effects of 1–naphthylacetyl spermine, an analogue of Joro spider toxin, against amygdaloid kindled seizures in rats. Takazawa A, et al. **Brain Res** 1996 Jan 8;706(1):173–6
Effect of heparin anticoagulation on neutrophil adhesion molecules and release of IL8: C3 is not essential. El Habbal MH, et al. **Cardiovasc Res** 1995 Nov;30(5):676–81
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Hirsh J, et al. **Chest** 1995 Oct;108(4 Suppl):258S–275S (268 ref.)
Prolonged antithrombin activity of low–molecular–weight heparins. Clinical implications for the treatment of thromboembolic diseases. Agnelli G, et al. **Circulation** 1995 Nov 15;92(10):2819–24
Effect of thrombin inhibition with desulfatohirudin on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits. Ragosta M, et al. **Circulation** 1996 Mar 15;93(6):1194–200
Heparins designed to specifically inhibit platelet interactions with von Willebrand factor. Sobel M, et al. **Circulation** 1996 Mar 1;93(5):992–9
Promotion of nitric oxide formation by heparin in cultured aortic endothelial cells from spontaneously hypertensive rats. Minami M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S146–7
LPS induced release of IL–1 beta, IL–6, IL–8 and TNF–alpha in EDTA or heparin anticoagulated whole blood from persons with high or low levels of serum HDL. Eggesbø JB, et al. **Cytokine** 1996 Feb;8(2):152–60
Anticoagulant pretreatment attenuates production of cytokine–induced neutrophil chemoattractant following ischemia–reperfusion of rat liver. Hisama N, et al. **Dig Dis Sci** 1996 Jul;41(7):1481–6
Effects of anticoagulants on lipoprotein(a) measurements with four commercial assays. Lippi G, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):251–5
Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393). Thürmann P, et al. **Eur J Clin Pharmacol** 1995;48(3–4):241–6
A novel inhibitor of factor X activation from the salivary glands of the bed bug Cimex lectularius. Valenzuela JG, et al. **Exp Parasitol** 1996 Jul;83(2):184–90
Benzalkonium chloride inhibited the histamine release from rat peritoneal mast cells induced by bradykinin and GlcNAc oligomer–specific lectin Datura stramonium agglutinin, but heparin did not. Niitsuma A, et al. **Gen Pharmacol** 1996 Jan;27(1):123–8
Sulfatide prolongs blood–coagulation time and bleeding time by forming a complex with fibrinogen. Hara A, et al. **Glycoconj J** 1996 Apr;13(2):187–94
Pharmacological activities of heparin chains: should our past knowledge be revised? Agnelli G. **Haemostasis** 1996;26 Suppl 2:2–9
Influence of heparin, protamine and polybrene on the time integral of thrombin generation (endogenous thrombin potential). Rotteveel RC, et al. **Haemostasis** 1996 Jan–Feb; 26(1):1–10
The effect of protein adsorption on the anticoagulant activity of surface immobilized heparin. van Delden CJ, et al. **J Biomater Sci Polym Ed** 1996;7(8):727–40
Mechanism of thrombin inactivation by immobilized heparin. Byun Y, et al. **J Biomed Mater Res** 1996 Apr;30(4):423–7
Degradation of subcutaneous implants of bone particles from normal and warfarin–treated rats. Serre CM, et al. **J Bone Miner Res** 1995 Aug;10(8):1158–67
Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits. Erlich JH, et al. **J Clin Invest** 1996 Jul 15; 98(2):325–35
Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. Kong AN, et al. **J Clin Pharmacol** 1995 Oct;35(10):1008–15
Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. Salazar DE, et al. **J Clin Pharmacol** 1995 Jul; 35(7):730–8
Thrombin inhibitors based on ketone derivatives of arginine and lysine. Jones DM, et al. **J Enzym Inhib** 1995;9(1):43–60
Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. Stone SR, et al. **J Enzym Inhib** 1995; 9(1):3–15 (56 ref.)
Influence of specimen age and anticoagulant on flow cytometric evaluation of granulocyte oxidative burst generation. Prince HE, et al. **J Immunol Methods** 1995 Dec 15;188(1):129–38
Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau–tau interaction. Pérez M, et al. **J Neurochem** 1996 Sep; 67(3):1183–90
DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. Herbert JM, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1030–8
Inhibition of zeta–crystallin by Coumarins: a structure–activity study. Duhaiman AS. **J Protein Chem** 1996 Apr;15(3):261–4
Surface–bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. Gorman RC, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):1–11; discussion 11–2
The effects of Carmeda Bioactive Surface on human blood components during simulated extracorporeal circulation. Korn RL, et al. **J Thorac Cardiovasc Surg** 1996 May; 111(5):1073–84
Conversion of thrombin into an anticoagulant by protein engineering [see comments] Gibbs CS, et al. **Nature** 1995 Nov 23;378(6555):413–6. Comment in: Nat Med 1995 Nov 23;378(6555):337–8.
Variations in prothrombin time and international normalized ratio over 24 hours in warfarin–treated patients. Bleske BE, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):709–12
Decreased axial and peripheral bone density in patients taking long–term warfarin. Philip WJ, et al. **QJM** 1995 Sep; 88(9):635–40
Vascular endothelial growth factor and heparin in a biologic glue promotes human aortic endothelial cell proliferation with aortic smooth muscle cell inhibition. Weatherford DA, et al. **Surgery** 1996 Aug;120(2):433–9
Low molecular weight heparin is responsible for the anti–Xa activity of Desmin 370. Brieger D, et al. **Thromb Haemost** 1996 Feb;75(2):286–91
Diagnosis of APC resistance in patients on standard or low molecular weight heparin [letter] Gilmore G, et al. **Thromb Haemost** 1996 Feb;75(2):372–3
A collaborative study of proposed European Pharmacopoeia reference preparations of low molecular mass heparin. Gray E, et al. **Thromb Haemost** 1995 Sep;74(3):893–9
DX–9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Hara T, et al. **Thromb Haemost** 1995 Aug;74(2):635–9
Sulfated polysaccharide anticoagulants suppress natural killer cell activity in vitro. Johann S, et al. **Thromb Haemost** 1995 Oct;74(4):998–1002
Kinetics of the inhibition of tissue factor–factor VIIa by tissue factor pathway inhibitor. Lindhout T, et al. **Thromb Haemost** 1995 Sep;74(3):910–5
Antithrombotic action of endogenous porcine protein C activated with a latent porcine thrombin preparation. McBane RD, et al. **Thromb Haemost** 1995 Sep;74(3):879–85
Venous antithrombotic and anticoagulant activities of a fucoïdan fraction. Mauray S, et al. **Thromb Haemost** 1995 Nov;74(5):1280–5
Generation and mechanism of action of a potent inhibitor of factor XIII function. Reed GL, et al. **Thromb Haemost** 1995 Aug;74(2):680–5
Characterisation of a novel series of aprotinin–derived anticoagulants. I. In vitro and pharmacological properties. Stassen JM, et al. **Thromb Haemost** 1995 Aug;74(2):646–54
Soluble thrombomodulin purified from human urine exhibits a potent anticoagulant effect in vitro and in vivo. Takahashi Y, et al. **Thromb Haemost** 1995 May;73(5):805–11
Effect of fucoidan during activation of human plasminogen. Doctor VM, et al. **Thromb Res** 1995 Aug 1;79(3):237–47
Full–length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin. Hamamoto T, et al. **Thromb Res** 1995 Nov 15;80(4):291–7
Species differences in anticoagulant and anti–Xa activity of DX–9065a, a highly selective factor Xa inhibitor. Hara T, et al. **Thromb Res** 1995 Oct 1;80(1):99–104
Heparin suppresses lipopolysaccharide–induced monocyte production of several cytokines, but simultaneously stimulates C3 production. Högåsen AK, et al. **Thromb Res** 1995 Oct 15;80(2):179–84
N' alkylamine low molecular mass heparins (LMM–heparin–tyramine and LMM–heparin–tyramine–fitc) exhibit long lasting anticoagulant effects. Malsch R, et al. **Thromb Res** 1995 Nov 1;80(3):235–46
Extremely low doses of heparin release lipase activity into the plasma and can thereby cause artifactual elevations in the serum–free thyroxine concentration as measured by equilibrium dialysis. Jaume JC, et al. **Thyroid** 1996 Apr; 6(2):79–83
Anticoagulant effects of Pseudechis australis (Australian king brown snake) venom on human blood: a computerized thromboelastography study. Dambisya YM, et al. **Toxicon** 1995 Oct;33(10):1378–82 (16 ref.)
Unpurified islet cell transplantation in diabetic rats. Nomura Y, et al. **Transplant Proc** 1996 Jun;28(3):1849–50
The anticoagulant effect of antithrombin III on hyperacute xenograft rejection. Takeshita K, et al. **Transplant Proc** 1996 Apr;28(2):631–2
Effect of heparin on hemagglutination by Akabane and Aino viruses belonging to the Simbu group of bunyaviruses. Jusa ER, et al. **Vet Microbiol** 1995 Jul;45(2–3):251–8
[The effects of Salvia miltiorrhiza and polysaccharide sulphate on the adhesion of erythrocytes of the patients with cerebral thrombosis to cultured endothelial cells] Wang L, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):381–5 (Eng. Abstr.) **(Chi)**
[Effects of substituted dextran on reinnervation of a skeletal muscle in adult rats during regeneration] Aamiri A, et al. **C R Acad Sci III** 1995 Oct;318(10):1037–43 (Eng. Abstr.) **(Fre)**
[Comment on the article by E. Czestochowska and B.L. Imielinski in Neurologia and Neurochirurgia Polska, No. 2:95 (comment)] Bidziński J. **Neurol Neurochir Pol** 1995

Jul-Aug;29(4):633-4. Comment on: Neurol Neurochir Pol 1995 Mar-Apr;29(2):241-8. **(Pol)**

[The effect of the joint administration of heparin and chitosan sulfate ether on hemostatic function] Drozd NN, et al. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):30-3 (Eng. Abstr.) **(Rus)**

[The pharmacological properties of a direct-action anticoagulant from the herb Nonea poulla (L.) D. C.] Gubaev AG, et al. **Eksp Klin Farmakol** 1996 Jan-Feb; 59(1):40-2 (Eng. Abstr.) **(Rus)**

STANDARDS

Selection of anticoagulant-preservatives for canine and feline blood storage. Wardrop KJ. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1263-76 (50 ref.)

[Analysis of the individual quality of an oral anticoagulant using the ratio F1+2/INR] Bruhn HD, et al. **Dtsch Med Wochenschr** 1995 Oct 20;120(42):1441-4 (10 ref.) **(Ger)**

THERAPEUTIC USE

Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass. Yamada H, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):311-7

Prevention of thromboembolic events in valvular heart disease. Gohlke-Bärwolf C, et al. **Acta Cardiol** 1996; 51(2):129-42 (37 ref.)

Osteitis pubis. A case of successful treatment with anticoagulants. Watkin NA, et al. **Acta Orthop Scand** 1995 Dec;66(6):569-70

Aortic thrombosis in a neonate with hereditary antithrombin III deficiency: successful outcome with thrombolytic and replacement treatment. Sánchez J, et al. **Acta Paediatr** 1996 Feb;85(2):245-7

Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Becker RC, et al. **Am Heart J** 1996 Mar;131(3):421-33 (66 ref.)

Bolus recombinant urokinase versus heparin in deep venous thrombosis: a randomized controlled trial. Goldhaber SZ, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):314-8

Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Glick A, et al. **Am J Cardiol** 1996 Jun 1;77(14):1145-8

Interaction of intravenous heparin and organic nitrates in acute ischemic syndromes. Koh KK, et al. **Am J Cardiol** 1995 Oct 1;76(10):706-9

Atrial fibrillation, anticoagulation, and stroke. Morley J, et al. **Am J Cardiol** 1996 Jan 25;77(3):38A-44A (29 ref.)

Adjunctive intracoronary urokinase therapy during percutaneous transluminal coronary angioplasty. Schächinger V, et al. **Am J Cardiol** 1996 Jun 1; 77(14):1174-8

Markers of in vivo activation of coagulation. Interrelationships change with intensity of oral anticoagulation. Solymoss S, et al. **Am J Clin Pathol** 1996 Mar;105(3):293-7

Lack of prophylactic anticoagulant therapy is not associated with clinical thrombotic complications in patients with hemophilia who undergo orthopedic surgical procedures [letter] Djulbegovic B. **Am J Hematol** 1995 Nov; 50(3):229-30

Diatrizoate and dextran treatment of sudden sensorineural hearing loss. Redleaf MI, et al. **Am J Otol** 1995 May; 16(3):295-303

Blunt carotid injury: reassessing the role of anticoagulation. Colella JJ, et al. **Am Surg** 1996 Mar;62(3):212-7

Extrinsic pathway--associated activated clotting time for anticoagulation monitoring during cardiopulmonary bypass [letter; comment] Gu YJ, et al. **Anesth Analg** 1996 Aug; 83(2):433. Comment on: Anesth Analg 1995 Nov;81(5):919-24.

Synergistic inhibitory effect of angiotensin-converting enzyme inhibitor and heparin on intimal hyperplasia after rat aorta injury. Park JS, et al. **Angiology** 1996 Jan; 47(1):9-14

Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Golzari H, et al. **Ann Intern Med** 1996 Aug 15;125(4):311-23 (205 ref.)

Recurrence of venous thromboembolism after treatment with unfractionated heparin [letter; comment] Sutton SK. **Ann Intern Med** 1996 Mar 1;124(5):532. Comment on: Ann Intern Med 1995 Jul 1;123(1):1-9.

Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction. Azar AJ, et al. **Ann Neurol** 1996 Mar;39(3):301-7

Prevention of cardioembolic stroke with anticoagulant therapy [editorial] Yanagihara T, et al. **Ann Neurol** 1996 Mar;39(3):281-2

Continuous subcutaneous heparin infusion for treatment of Trousseau's syndrome. Alderman CP, et al. **Ann Pharmacother** 1995 Jul-Aug;29(7-8):710-3

Another perspective on monitoring anticoagulation therapy [editorial; comment] Burnakis TG. **Ann Pharmacother** 1995 Oct;29(10):1045-6. Comment on: Ann Pharmacother 1995 Oct;29(10):1015-21.

Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin [see comments] Simko RJ, et al. **Ann Pharmacother** 1995 Oct;29(10):1015-21; quiz 1061 (36 ref.). Comment in: Ann Pharmacother 1995 Oct;29(10):1045-6.

Enoxaparin for unstable angina and ancrod for cardiac surgery following heparin allergy. Smith RE, et al. **Ann Pharmacother** 1996 May;30(5):476-80

Blunt carotid injury. Importance of early diagnosis and anticoagulant therapy. Fabian TC, et al. **Ann Surg** 1996 May;223(5):513-22; discussion 522-5

Monitoring of systemic anticoagulation during cardiopulmonary bypass [editorial; comment] Bidstrup BP. **Ann Thorac Surg** 1996 Mar;61(3):781-2. Comment on: Ann Thorac Surg 1996 Mar;61(3):795-9.

Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting. Jansen PG, et al. **Ann Thorac Surg** 1996 May;61(5):1363-6

Interaction of thyroid hormone and heparin in postischemic myocardial recovery. Katz MG, et al. **Ann Thorac Surg** 1995 Nov;60(5):1215-8

Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass. Terrell MR, et al. **Ann Thorac Surg** 1996 Aug;62(2):506-11

Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Wilhelm MJ, et al. **Ann Thorac Surg** 1996 Mar;61(3):920-4

Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study. Enoxart Study Group. Samama CM, et al. **Ann Vasc Surg** 1995;9 Suppl:S45-53

New knowledge, old patients [editorial; comment] Brechtelsbauer DA. **Arch Fam Med** 1995 Dec;4(12):1014-6 . Comment on: Arch Fam Med 1995 Dec;4(12):1017-26.

Use of warfarin for nonvalvular atrial fibrillation in nursing home patients [see comments] Lackner TE, et al. **Arch Fam Med** 1995 Dec;4(12):1017-26. Comment in: Arch Fam Med 1995 Dec;4(12):1014-6.

Anticoagulation for cardioversion of atrial fibrillation [letter] Carlsson J, et al. **Arch Intern Med** 1996 Sep 9;156(16):1889, 1894-5

The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Gage BF, et al. **Arch Intern Med** 1996 Sep 9;156(16):1829-36

Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. Levine MN, et al. **Arch Intern Med** 1996 Apr 22;156(8):851-6

Anticoagulation for atrial fibrillation [letter] Liron M. **Arch Intern Med** 1996 Sep 9;156(16):1895, 1899

Warfarin for atrial fibrillation. The patient's perspective. Man-Son-Hing M, et al. **Arch Intern Med** 1996 Sep 9; 156(16):1841-8

Physician practices regarding anticoagulation and cardioversion of atrial fibrillation. Schlicht JR, et al. **Arch Intern Med** 1996 Feb 12;156(3):290-4

Influenza immunization is a safe procedure in patients undergoing long-term anticoagulation [letter; comment] Souto JC, et al. **Arch Intern Med** 1996 Jul 22;156(14):1589, 1592. Comment on: Arch Intern Med 1995 Jul 24;155(14):1529-31.

Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery. Sarasin FP, et al. **Arch Surg** 1996 Jul;131(7):694-7; discussion 698

Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. Palevsky PM, et al. **ASAIO J** 1995 Oct-Dec;41(4):847-9

Maintenance of adequate hemodialysis access. Prevention of neointimal hyperplasia. Taber TE, et al. **ASAIO J** 1995 Oct-Dec;41(4):842-6

Anticoagulation. Chong BH. **Aust Fam Physician** 1996 Jan; 25(1):74-8 (8 ref.)

Idiopathic chronic DIC controlled with low-molecular-weight heparin. Majumdar G. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):97-8

Occlusive thrombosis in the femoral artery of the rabbit: a pharmacological model for evaluating antiplatelet and anticoagulant agents. Sugidachi A, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):57-64

Evaluation of a primary care anticoagulant clinic. Issue of quality control was not addressed [letter; comment] Adlakha S, et al. **BMJ** 1996 Jun 22;312(7046):1609; discussion 1610. Comment on: BMJ 1996 Mar 2;312(7030):560.

After a first episode of venous thromboembolism [editorial] Chesterman CN. **BMJ** 1995 Sep 16;311(7007):700-1

Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Collins R, et al. **BMJ** 1996 Sep 14;313(7058):652-9

Quality of service provision for anticoagulation in atrial fibrillation. Bridges from evidence to practice are fragile [letter; comment] Edwards A, et al. **BMJ** 1996 Jan 6; 312(7022):51. Comment on: BMJ 1995 Aug 26;311(7004):558-60.

Quality of service provision for anticoagulation in atrial fibrillation. In Finland anticoagulant treatment is monitored by general practitioners [letter; comment] Eskola K, et al. **BMJ** 1996 Jan 6;312(7022):52-3. Comment on: BMJ 1995 Aug 26;311(7004):558-60.

Monitoring oral anticoagulation in primary care [editorial] Fitzmaurice DA, et al. **BMJ** 1996 Jun 8;312(7044):1431-2

Evaluation of a primary care anticoagulant clinic. Reporting of results should be standardised [letter; comment] Fitzmaurice DA, et al. **BMJ** 1996 Jun 22; 312(7046):1609-10; discussion 1610. Comment on: BMJ 1996 Mar 2;312(7030):560.

Evaluation of a primary care anticoagulant clinic. Authors did not present enough data [letter; comment] Fowlie PW. **BMJ** 1996 Jun 22;312(7046):1609. Comment on: BMJ 1996 Mar 2;312(7030):560.

ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. Lip GY, et al. **BMJ** 1996 Jan 6;312(7022):45-9 (0 ref.)

Quality of service provision for anticoagulation in atrial fibrillation. Many patients are ineligible [letter; comment] Lip GY. **BMJ** 1996 Jan 6;312(7022):51. Comment on: BMJ 1995 Aug 26;311(7004):558-60.

Evaluation of a primary care anticoagulant clinic managed by a pharmacist [see comments] Macgregor SH, et al. **BMJ** 1996 Mar 2;312(7030):560. Comment in: BMJ 1996 Jun 22;312(7046):1609. Comment in: BMJ 1996 Jun 22;312(7046):1609; discussion 1610. Comment in: BMJ 1996 Jun 22;312(7046):1609-10; discussion 1610.

Quality of service provision for anticoagulation in atrial fibrillation. Patients and doctors play it safe [letter; comment] Scott ME, et al. **BMJ** 1996 Jan 6;312(7022):51-2 . Comment on: BMJ 1995 Aug 26;311(7004):558-60.

Anticoagulants in pregnancy. Oakley CM. **Br Heart J** 1995 Aug;74(2):107-11 (54 ref.)

Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction. van Bergen PF, et al. **Br Heart J** 1995 Aug;74(2):117-21

Venous thromboembolism and cardiovascular surgery [letter] McDonald DS. **Br J Anaesth** 1996 Mar;76(3):473

Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. Lip GY, et al. **Br J Clin Pharmacol** 1996 May; 41(5):369-79 (83 ref.)

Warfarin in stroke prevention [letter] Fitzmaurice DA. **Br J Gen Pract** 1995 Aug;45(397):444

Warfarin for elderly patients [letter] Frame AC. **Br J Gen Pract** 1996 Jan;46(402):49-50

Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Genewein U, et al. **Br J Haematol** 1996 Feb;92(2):479-85

Reduction of urinary basic fibroblast growth factor using pentosan polysulphate sodium. Barrington JW, et al. **Br J Urol** 1996 Jul;78(1):54-6

Contact laser prostatectomy in anti-coagulated patients: mixed results. Keoghane SR, et al. **Br J Urol** 1996 Apr; 77(4):613-4

Anticoagulant therapy in ischaemic heart disease in seafarers. Częstochowska E. **Bull Inst Marit Trop Med Gdynia** 1993-94;44-45(1-4):13-5 (10 ref.)

Antithrombotic therapy in atrial fibrillation. Turpie AG, et al. **Can Fam Physician** 1996 Jul;42:1341-5 (16 ref.)

Modified Blalock-Taussig shunts: to heparinize or not to heparinize? Mullen JC, et al. **Can J Cardiol** 1996 Jul; 12(7):645-7

Thrombin inhibitors in acute myocardial infarction. Cannon CP. **Cardiol Clin** 1995 Aug;13(3):421-33 (73 ref.)

Disappearance of the Dressler syndrome [letter; comment] Cheng TO. **Cardiology** 1995;86(5):444. Comment on: Cardiology 1994;85(3-4):255-8.

Antithrombotic therapy in atrial fibrillation [letter] Manning WJ, et al. **Chest** 1996 Jun;109(6):1663-4

Thrombolytic therapy for acute cerebral vascular occlusion. Zhu T, et al. **Chin Med J (Engl)** 1995 Dec;108(12):930-1

Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Ezekowitz MD, et al. **Circulation** 1995 Oct 15;92(8):2178-82

Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zürich study). Franzeck UK, et al. **Circulation** 1996 Jan 1;93(1):74-9

Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Jang Y, et al. **Circulation** 1995 Nov 15;92(10):3041-50

Antiplatelet and anticoagulant use after myocardial infarction. Almony GT, et al. **Clin Cardiol** 1996 May; 19(5):357-65 (109 ref.)

Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Colwell CW Jr, et al. **Clin Orthop** 1995 Dec; (321):19-27

Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Colwell CW Jr, et al. **Clin Orthop** 1995 Oct;(319):215-22

Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Lotke PA, et al. **Clin Orthop** 1996 Mar; (324):251-8

Low-dose heparinization for anticoagulation in intensive care patients on continuous hemofiltration. Gretz N, et al. **Contrib Nephrol** 1995;116:130-5

Effectiveness of combined anticoagulant therapy for extending portal vein thrombosis in Crohn's disease. Report of a case. Tsujikawa T, et al. **Dis Colon Rectum** 1996 Jul; 39(7):823-5

Low molecular mass heparin instead of unfractionated heparin during infrainguinal bypass surgery. Swedenborg

J, et al. **Eur J Vasc Endovasc Surg** 1996 Jan;11(1):59–64

Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: a Joint Vascular Research Group study. Thompson JF, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):86–90

The long-term outcome of proximal vein thrombosis during pregnancy is not improved by the addition of surgical thrombectomy to anticoagulant treatment. Törngren S, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):31–6

Clinical results from the treatment of erysipelas with heparin. Iankova R, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):49

Anticoagulation: risks and benefits in atrial fibrillation. Fiore LD. **Geriatrics** 1996 Jun;51(6):22–4, 27–8, 31 (37 ref.)

Comparison of a recombinant thromboplastin with Thrombotest for oral anticoagulant control. Baele G, et al. **Haemostasis** 1996 Jan–Feb;26(1):11–5

Are low-molecular-weight heparins useful for the prophylaxis and treatment of arterial thrombi? Samama CM, et al. **Haemostasis** 1996;26 Suppl 2:57–64

Reduction of migrainous headaches during the use of acenocoumarol. van Puijenbroek EP, et al. **Headache** 1996 Jan;36(1):48

Physician variation in the management of patients with atrial fibrillation. Lip GY, et al. **Heart** 1996 Feb;75(2):200–5

New directions in anticoagulant and antiplatelet treatment [letter] O'Brien JR. **Heart** 1996 Apr;75(4):426

Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation [letter] Stables RH, et al. **Heart** 1996 Apr; 75(4):426

Effects of modified positioning and mobilization of back pain and delayed bleeding in patients who had received heparin and undergone angiography: a pilot study. Pooler-Lunse C, et al. **Heart Lung** 1996 Mar–Apr;25(2):117–23

Inhibition of intimal hyperplasia and occlusion in Dacron graft with heparin and low molecular weight heparin. Taylor A, et al. **Int Angiol** 1995 Dec;14(4):375–80

Low molecular weight heparins in the initial treatment of deep vein thrombosis. Volteas SK, et al. **Int Angiol** 1996 Mar;15(1):67–74 (46 ref.)

Combined drug therapy with diltiazem, dextran, and hydrocortisone (DDH therapy) for late cerebral vasospasm after aneurysmal subarachnoid hemorrhage: assessment of efficacy and safety in an open clinical study. Kawano T, et al. **Int J Clin Pharmacol Ther** 1995 Sep;33(9):513–7

Heparin-induced thrombocytopenia type II: successful use of Orgaran (ORG 10172) in intensive care patients [letter] Burkhard-Meier U, et al. **Intensive Care Med** 1995 Jun; 21(6):542–3

Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation. Webb AR, et al. **Intensive Care Med** 1995 Jan;21(1):84–93 (77 ref.)

Anticoagulation in pregnant women with prosthetic heart valves: a double jeopardy [editorial; comment] Elkayam UR. **J Am Coll Cardiol** 1996 Jun;27(7):1704–6. Comment on: J Am Coll Cardiol 1996 Jun;27(7):1698–703.

Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen. Fernández-Avilés F, et al. **J Am Coll Cardiol** 1996 Jan;27(1):22–9

Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. Unterberg C, et al. **J Am Coll Cardiol** 1995 Dec; 26(7):1747–54

The use of oral anticoagulants (warfarin) in older people. AGS Clinical Practice Committee [see comments] **J Am Geriatr Soc** 1996 Sep;44(9):1112–3. Comment in: J Am Geriatr Soc 1996 Sep;44(9):1114–3.

The utilization of antithrombotic prophylaxis for atrial fibrillation in a geriatric rehabilitation hospital. Lawson F, et al. **J Am Geriatr Soc** 1996 Jun;44(6):708–11

Combined use of aprotinin and a heparin-bonded cardiopulmonary bypass system for aortic aneurysm repair. Gallagher JM, et al. **J Cardiothorac Vasc Anesth** 1995 Dec; 9(6):728–30

Acute thrombogenicity of arterial prostheses exposed to reduced blood flow in dogs: effects of heparin, aspirin, and prostacyclin. Merhi Y, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):1–5

Fibrinolysis and hemorheology in chronic venous insufficiency: a double blind study of troxerutin efficiency. Boisseau MR, et al. **J Cardiovasc Surg (Torino)** 1995 Aug; 36(4):369–74

Evaluation of laboratory coagulation and lytic parameters resulting from autologous whole blood transfusion during primary aortocoronary artery bypass grafting. Whitten CW, et al. **J Clin Anesth** 1996 May;8(3):229–35

Audit of anticoagulant therapy. Rose PE. **J Clin Pathol** 1996 Jan;49(1):5–9

Contemporary use of and future roles for heparin in antithrombotic therapy. Gibaldi M, et al. **J Clin Pharmacol** 1995 Nov;35(11):1031–45 (67 ref.)

Home treatment of deep venous thrombosis. Force RW. **J Fam Pract** 1996 Jun;42(6):566–7

Heparin and thrombolysis in acute MI. Millard PS, et al. **J Fam Pract** 1996 Jul;43(1):20–1

Venous thromboembolism. Spaulding C. **J Fam Pract** 1995 Dec;41(6):604–5

The use of prothrombin fragment F1+2 to monitor the effect of oral anticoagulation. Bruhn HD, et al. **J Heart Valve Dis** 1995 Mar;4(2):138–40

Optimization of oral anticoagulation for patients with mechanical heart valve prostheses. Piper C, et al. **J Heart Valve Dis** 1995 Mar;4(2):127–37 (83 ref.)

Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):371–6

Thrombocytopenia corrected by warfarin in antiphospholipid syndrome. Wisbey HL, et al. **J Rheumatol** 1996 Apr; 23(4):769–71

Use of low molecular weight heparin in preventing thromboembolism in trauma patients. Knudson MM, et al. **J Trauma** 1996 Sep;41(3):446–59

Ultrasound-guided compression closure of postcatheterization pseudoaneurysms during concurrent anticoagulation: a review of seventy-seven patients. Dean SM, et al. **J Vasc Surg** 1996 Jan;23(1):28–34, discussion 34–5

Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation [see comments] Gage BF, et al. **JAMA** 1995 Dec 20; 274(23):1839–45. Comment in: JAMA 1996 Mar 27;275(12):909; discussion 910.

Cost-effectiveness of stroke prophylaxis for nonvalvular atrial fibrillation [letter; comment] Kan BD, et al. **JAMA** 1996 Mar 27;275(12):909; discussion 910. Comment on: JAMA 1995 Dec 20;274(23):1839–45.

Guidelines for anticoagulation therapy in pregnancy. Ryan K, et al. **JPMA J Pak Med Assoc** 1995 May;45(5):133–6 (4 ref.)

Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. Janssen MJ, et al. **Kidney Int** 1996 Mar;49(3):806–13

Follow-up observation of a patient with left ventricular thrombus by echocardiography. Kawata M, et al. **Kobe J Med Sci** 1995 Jun;41(3):63–70

Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group [see comments] **Lancet** 1996 Mar 2;347(9001):561–8. Comment in: Lancet 1996 Apr 27;347(9009):1191. Comment in: Lancet 1996 May 4;347(9010):1263.

Heparin prophylaxis in bedridden patients [letter; comment] Bergmann JF, et al. **Lancet** 1996 Jul 20;348(9021):205–6. Comment on: Lancet 1996 May 18;347(9012):1357–61.

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393 [see comments] Eriksson BI, et al. **Lancet** 1996 Mar 9;347(9002):635–9. Comment in: Lancet 1996 Mar 9;347(9002):632–3. Comment in: Lancet 1996 Jun 1;347(9014):1561–2.

Simvastatin-oral anticoagulant interaction [letter] Grau E, et al. **Lancet** 1996 Feb 10;347(8998):405–6

Low-molecular-weight heparin during instability in coronary artery disease [letter; comment] Mikhailidis DP, et al. **Lancet** 1996 Apr 27;347(9009):1191. Comment on: Lancet 1996 Mar 2;347(9001):561–8.

Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo [see comments] Planes A, et al. **Lancet** 1996 Jul 27;348(9022):224–8. Comment in: Lancet 1996 Jul 27;348(9022):209–10.

Hirudin and thrombosis prophylaxis [comment] Turpie AG. **Lancet** 1996 Mar 9;347(9002):632–3. Comment on: Lancet 1996 Mar 9;347(9002):635–9.

Hirudin CGP 39393 as thromboprophylaxis [letter; comment] Williams DJ, et al. **Lancet** 1996 Jun 1;347(9014):1561–2. Comment on: Lancet 1996 Mar 9;347(9002):635–9.

Outpatient anticoagulation issues for the primary care physician. Spandorfer JM, et al. **Med Clin North Am** 1996 Mar;80(2):475–91 (79 ref.)

Dalteparin--another low-molecular-weight heparin. **Med Lett Drugs Ther** 1995 Dec 8;37(963):115–6

A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. Geerts WH, et al. **N Engl J Med** 1996 Sep 5;335(10):701–7

Platelets and coronary artery disease [editorial; comment] Handin RI. **N Engl J Med** 1996 Apr 25;334(17):1126–7. Comment on: N Engl J Med 1996 Apr 25;334(17):1084–9. Comment on: N Engl J Med 1996 Apr 25;334(17):1090–4.

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared wtih subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group [see comments] Koopman MM, et al. **N Engl J Med** 1996 Mar 14;334(11):682–7. Comment in: N Engl J Med 1996 Mar 14;334(11):724–5. Comment in: N Engl J Med 1996 Aug 29;335(9):670–1; discussion 671–2. Comment in: N Engl J Med 1996 Aug 29;335(9):671; discussion 671–2.

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis [see comments] Levine M, et al. **N Engl J Med** 1996 Mar 14;334(11):677–81. Comment in: N Engl J Med 1996 Mar 14;334(11):724–5. Comment in: N Engl J Med 1996 Aug 29;335(9):670–1; discussion 671–2. Comment in: N Engl J Med 1996 Aug 29;335(9):671; discussion 671–2.

Low-molecular-weight heparin--an opportunity for home treatment of venous thrombosis [editorial; comment] Schafer AI. **N Engl J Med** 1996 Mar 14;334(11):724–5. Comment on: N Engl J Med 1996 Mar 14;334(11):677–81. Comment on: N Engl J Med 1996 Mar 14;334(11):682–7.

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents [see comments] Schömig a, et al. **N Engl J Med** 1996 Apr 25; 334(17):1084–9. Comment in: N Engl J Med 1996 Apr 25;334(17):1126–8.

Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Koide M, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2137–40

Association of membranous nephropathy with familial resistance to activated protein C. Montinaro V, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2133–6

Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Tamsma JT, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):182–5

Monitoring heparin treatment with the APTT: the effect of methodological changes on the APTT. Krulder JW, et al. **Neth J Med** 1996 Jul;49(1):13–8

Warfarin in Sneddon's syndrome [letter; comment] Dupont S, et al. **Neurology** 1996 Jun;46(6):1781–2. Comment on: Neurology 1995 Mar;45(3 Pt 1):557–60.

Safety of heparin in acute ischemic stroke [letter] Hart RG, et al. **Neurology** 1996 Feb;46(2):589; discussion 589–91

Radiation damage [letter; comment] Landau K, et al. **Neurology** 1996 Mar;46(3):889. Comment on: Neurology 1994 Nov;44(11):2020–7.

Safety of heparin in acute ischemic stroke [letter] Lee N. **Neurology** 1996 Feb;46(2):589; discussion 589–91

Safety of heparin in acute ischemic stroke [letter] Lodder J. **Neurology** 1996 Feb;46(2):589; discussion 589–91

Use of INR to assess degree of anticoagulation in patients who have dental procedures. Steinberg MJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Aug;80(2):175–7

Treatment of established deep vein thrombosis: a review of the therapeutic armamentarium. Berkowitz SD. **Orthopedics** 1995 Jul;18 Suppl:18–20

Consortium data: comparative efficacy of low molecular weight heparin and warfarin following total hip replacement. Colwell CW Jr. **Orthopedics** 1995 Jul;18 Suppl:21–3

Preventing DVT following total knee replacement: a review of recent clinical trials. Fitzgerald RH Jr. **Orthopedics** 1995 Jul;18 Suppl:10–1

Thromboembolic complications following trauma surgery: incidence and outcomes. Paiement GD. **Orthopedics** 1995 Jul;18 Suppl:12–4

Deep vein thrombosis prophylaxis in the outpatient setting: preventing complications following hospital discharge. Turpie AG. **Orthopedics** 1995 Jul;18 Suppl:15–7

KePRO project sheds light on anticoagulation in atrial fibrillation. Whittle J. **Pa Med** 1995 Dec;98(12):30–1

Evaluation of low molecular weight heparin during and after aortic and carotid surgery: dose finding study. Alimi YS, et al. **Panminerva Med** 1996 Mar;38(1):15–21

Outcome analysis of a pharmacist-managed anticoagulation service. Wilt VM, et al. **Pharmacotherapy** 1995 Nov–Dec; 15(6):732–9

Heparin monitoring in acute thrombosis associated with antiphospholipid antibody syndrome. Wittkowsky AK, et al. **Pharmacotherapy** 1995 Jul–Aug;15(4):517–21

Heparin therapy: current regimens and principles of monitoring. Berry BR, et al. **Postgrad Med** 1996 Jun; 99(6):64–6, 69–76 (19 ref.)

Oral anticoagulant therapy: practical aspects of management. Brigden ML. **Postgrad Med** 1996 Jun;99(6):81–4, 87–9, 93–4 passim (22 ref.)

New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon? Carter CJ. **Postgrad Med** 1996 Jun;99(6):129–36 (22 ref.)

Cardioversion of atrial fibrillation. Lip GY. **Postgrad Med J** 1995 Aug;71(838):457–65 (68 ref.)

Outcomes research using the electronic patient record: Beth Israel Hospital's experience with anticoagulation. Einbinder JS, et al. **Proc Annu Symp Comput Appl Med Care** 1995; :819–23

Current recommendations for the anticoagulation of patients with atrial fibrillation. Orsinelli DA. **Prog Cardiovasc Dis** 1996 Jul–Aug;39(1):1–20 (52 ref.)

Oral anticoagulant treatment in a medical care district--a descriptive study. Jansson JH, et al. **Scand J Prim Health Care** 1995 Dec;13(4):268–74

Antithrombotic therapy prescribed for patients with non-rheumatic atrial fibrillation. Hendry A, et al. **Scott Med J** 1994 Aug;39(4):110–1

Anti-thrombotic therapy prescribed for patients with non-rheumatic atrial fibrillation (Scot Med J 1994: 39; 110–111) [letter] Jolobe OM. **Scott Med J** 1994 Oct; 39(5):139–40

Anti-thrombotic therapy prescribed for patients with non-rheumatic atrial fibrillation (Scot Med J 1994:39;110–111) [letter] Oldroyd KG. **Scott Med J** 1994 Oct;39(5):140

Anticoagulant therapy for deep vein thrombosis: its proper application. Rohrer MJ, et al. **Semin Vasc Surg** 1996 Mar; 9(1):13–20 (38 ref.)

Equal effectiveness of very-low-intensity anticoagulation and standard low-intensity anticoagulation: a pilot study. Klein KL, et al. **South Med J** 1995 Nov;88(11):1136–9

The morbidity of heparin therapy after development of pulmonary embolus in patients undergoing thoracolumbar

or lumbar spinal fusion. Cain JE Jr, et al. **Spine** 1995 Jul 15;20(14):1600–3

Heparin reduces neurological impairment after cerebral arterial air embolism in the rabbit. Ryu KH, et al. **Stroke** 1996 Feb;27(2):303–9; discussion 310

Anticoagulation for prevention of cerebral infarcts following subarachnoid hemorrhage. Wang DZ, et al. **Surg Neurol** 1995 Sep;44(3):270–4 (22 ref.)

Prevention of spinal cord injury after transient aortic clamping with tissue factor pathway inhibitor. Koudsi B, et al. **Surgery** 1996 Mar;119(3):269–74

Current status of anticoagulation and thrombosis–related issues in mechanical valves. Gray RJ. **Tex Heart Inst J** 1996;23(1):36–41 (34 ref.)

Ancrod for coronary angioplasty. Pothoulakis AJ, et al. **Tex Heart Inst J** 1995;22(4):342–6

Aortic bioprosthesis without early anticoagulation—risk of thromboembolism. Babin–Ebell J, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):212–4

Oral anticoagulant treatment with and without aspirin. Altman R, et al. **Thromb Haemost** 1995 Jul;74(1):506–10 (37 ref.)

Clinical coagulation laboratory and oral anticoagulant therapy treatment. Instrumentation and methodology. Barbui T, et al. **Thromb Haemost** 1995 Jul;74(1):511–4

Comparison between recombinant and rabbit thromboplastin in the management of patients on oral anticoagulant therapy. Barcellona D, et al. **Thromb Haemost** 1996 Mar; 75(3):488–90

The efficacy and safety of oral anticoagulation in patients with cancer. Bona RD, et al. **Thromb Haemost** 1995 Oct; 74(4):1055–8

Endothelial haemostatic factors may be associated with mortality in patients on long–term anticoagulant treatment. Brännström M, et al. **Thromb Haemost** 1995 Aug; 74(2):612–5

Thrombotic risk during pregnancy and puerperium in women with APC–resistance—effective subcutaneous heparin prophylaxis in a pregnant patient [letter] De Stefano V, et al. **Thromb Haemost** 1995 Aug;74(2):793–4

Subcutaneous low–molecular weight heparin or oral anticoagulants for the prevention of deep–vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Hamulyák K, et al. **Thromb Haemost** 1995 Dec;74(6):1428–31

Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Hirsh J, et al. **Thromb Haemost** 1995 Jul;74(1):360–3

Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE). Kakkar VV. **Thromb Haemost** 1995 Jul;74(1):364–8

Influence of various heparin preparations on lipoproteins in hemodialysis patients: a multicentre study. Kronenberg F, et al. **Thromb Haemost** 1995 Oct;74(4):1025–8

Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Lynch JJ Jr, et al. **Thromb Haemost** 1995 Aug; 74(2):640–5

Subcutaneous low–molecular–weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Meyer G, et al. **Thromb Haemost** 1995 Dec;74(6):1432–5

Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Mitusch R, et al. **Thromb Haemost** 1996 Feb;75(2):219–23

Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin). Monreal M, et al. **Thromb Haemost** 1996 Feb;75(2):251–3

Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Nurmohamed MT, et al. **Thromb Haemost** 1996 Feb;75(2):233–8

Factor VIII: C levels during oral anticoagulation and after its withdrawal [letter] Palareti G, et al. **Thromb Haemost** 1995 Dec;74(6):1609–10

Quality control and oral anticoagulation. Preston FE. **Thromb Haemost** 1995 Jul;74(1):515–20

Characterisation of a novel series of aprotinin–derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo. Stassen JM, et al. **Thromb Haemost** 1995 Aug;74(2):655–9

The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant [letter] Trossaërt M, et al. **Thromb Haemost** 1996 Mar;75(3):521–2

Effects of low molecular weight heparin on a severely antithrombin III–decreased disseminated intravascular coagulation model in rabbits. Tazawa S, et al. **Thromb Res** 1995 Dec 1;80(5):391–8

Endotoxin–induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats. Uchiba M, et al. **Thromb Res** 1995 Apr 15;78(2):117–25

Atrial fibrillation pearls and perils of management. Kudenchuk PJ. **West J Med** 1996 May;164(5):425–34 (109 ref.)

Warfarin sodium or aspirin therapy to prevent stroke in nonrheumatic atrial fibrillation. Answered and unanswered questions [editorial; comment] Stratton JR. **West J Med** 1995 Aug;163(2):177–9. Comment on: West J Med 1995 Aug;163(2):145–57.

Anticoagulation and atrial fibrillation. Putting the results of clinical trials into practice [clinical conference] [see comments] Wipf JE. **West J Med** 1995 Aug;163(2):145–52 . Comment in: West J Med 1995 Aug;163(2):177–9.

[Analysis for 13 term deliveries after cardiac valve replacement and percutaneous transluminal mitral commissuroplasty] Wang Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan;31(1):12–4 (Eng. Abstr.) (Chi)

[The effect of hirudo on proteinuria, lipid metabolism and coagulation system in the patients with chronic glomerulonephritis] Dong K, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Apr;34(4):250–2 (Eng. Abstr.) (Chi)

[Anticoagulation therapy in patients with valve defects] Chlumský J, et al. **Vnitr Lek** 1996 Feb;42(2):78–81 (Eng. Abstr.) (Cze)

[Optimal treatment with oral anticoagulants] Prins MH, et al. **Ned Tijdschr Geneeskd** 1996 May 18;140(20):1059–61 (Dut)

[Treatments of ischemic cardiopathies (IC) and modalities of prescription of aspirin in the three French MONICA centers in 1990] Cambou JP, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):578–86 (Eng. Abstr.) (Fre)

[Anticoagulation in cardiology] Meier B. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):567–77 (53 ref.) (Eng. Abstr.) (Fre)

[Anticoagulant therapy in pulmonary embolism] Charbonnier B, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1755–61 (Eng. Abstr.) (Fre)

[Anticoagulant treatment and dilated cardiomyopathy] Gibelin P. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):617–21 (Eng. Abstr.) (Fre)

[Severe parvovirus B19 infection in an immunocompetent child with hemophilia A] Coumau E, et al. **Arch Pediatr** 1996 Jan;3(1):35–9 (Eng. Abstr.) (Fre)

[Breast–feeding is possible in case of maternal treatment with enoxaparin (letter)] Guillonneau M, et al. **Arch Pediatr** 1996 May;3(5):513–4 (Fre)

[Antithrombotic treatment of atrial fibrillation] Connelly SJ, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:14A–18A (13 ref.) (Fre)

[Post–traumatic thrombosis of the portal vein] Beaufort P, et al. **Presse Med** 1996 Feb 17;25(6):247–8 (Eng. Abstr.) (Fre)

[Thrombopenia induced by heparin: treatment with Org 10172. Tolerability and efficacy] Tardy–Poncet B, et al. **Presse Med** 1996 May 4–11;25(16):751–5 (Eng. Abstr.) (Fre)

[Therapeutic role of coagulation in small cell lung cancers] LeBeau B. **Rev Mal Respir** 1996;13(1):21–6 (41 ref.) (Eng. Abstr.) (Fre)

[The treatment of deep venous thrombosis with low–molecular–weight heparin] Samama MM, et al. **Rev Med Brux** 1995 Jul–Aug;16(4):304–9 (30 ref.) (Eng. Abstr.) (Fre)

[Classical anticoagulant treatment of venous thromboembolic disease in cancer patients. Apropos of a retrospective study of 71 patients] Debourdeau P, et al. **Rev Med Interne** 1996; 17(3):207–12 (Eng. Abstr.) (Fre)

[Ambulatory follow–up in oral anticoagulation: recommendations for clinical practice] Christen Y, et al. **Schweiz Med Wochenschr** 1996 Mar 23;126(12):471–6 (Eng. Abstr.) (Fre)

–Anticoagulant drugs– Gulba DC. **Herz** 1996 Feb; 21(1):12–27 (164 ref.) (Eng. Abstr.) (Ger)

–New perspectives in therapy of unstable angina– Hamm CW. **Herz** 1996 Feb;21(1):37–43 (69 ref.) (Eng. Abstr.) (Ger)

[Anticoagulation in patients with atrial fibrillation] Mügge A. **Herz** 1996 Feb;21(1):28–36 (60 ref.) (Eng. Abstr.) (Ger)

[Drug therapy of deep venous thrombosis] Bounameaux H. **Ther Umsch** 1996 Apr;53(4):272–6 (16 ref.) (Eng. Abstr.) (Ger)

[Common basic knowledge (interview by Klaus Reinhardt)] Mahler F. **Ther Umsch** 1996 Apr;53(4):252–3 (Ger)

[Blood thinning in heart patients] Meier B. **Ther Umsch** 1995 Oct;52(10):661–71 (55 ref.) (Eng. Abstr.) (Ger)

[New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)] Schächinger V, et al. **Z Kardiol** 1995 Sep;84(9):651–67 (152 ref.) (Eng. Abstr.) (Ger)

[Idiopathic atrial fibrillation: clinical–instrumental characterization and thromboembolic risk] Boriani G, et al. **Cardiologia** 1995 Jan;40(1):23–30 (Eng. Abstr.) (Ita)

[Emergency therapy of disseminated intravascular coagulation] Yawata Y. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1858–64 (5 ref.) (Jpn)

[Significance of heparin elimination from plasma in the assessment of coagulogram and antithrombin III activity] Momot AP, et al. **Klin Lab Diagn** 1995 Sep–Oct;(5):31–4 (Eng. Abstr.) (Rus)

[A clinico–morphological analysis of the efficacy of therapy in chronic glomerulonephritis using prednisone, a cytostatic, an anticoagulant and an antiaggregant] Ratner MIa, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):32–5 (Eng. Abstr.) (Rus)

[Atrial fibrillation due to non–valvular causes: indications for antithrombotic therapy] Codinach Huix P. **Med Clin (Barc)** 1996 Apr 20;106(15):586–9 (25 ref.) (Spa)

[Anticoagulation in auricular fibrillation (letter; comment)] Rojo Sebastián A, et al. **Med Clin (Barc)** 1995 Nov 11; 105(16):638. Comment on: Med Clin (Barc) 1994 Sep 10;103(7):267–70. (Spa)

[Heparin therapy in acute ischemic infarction of the vertebrobasilar area (comment)] Arias M, et al. **Neurologia** 1995 Aug–Sep;10(7):311–2. Comment on: Neurologia 1995 Feb;10(2):87–91. (Spa)

[Guidelines for the management of acute cerebrovascular disease in patients] Alonso de Leciñana M, et al. **Rev Neurol** 1995 Mar–Apr;23(120):363–9 (54 ref.) (Eng. Abstr.) (Spa)

[Management of intracranial hemorrhage] Kase CS. **Rev Neurol** 1996 Jun;24(130):661–3 (Spa)

[Comparative study of the stability of oral anticoagulant treatments (warfarin vs acenocoumarol)] Amián A, et al. **Sangre (Barc)** 1996 Feb;41(1):9–11 (Eng. Abstr.) (Spa)

TOXICITY

Heparin–protamine complexes cause pulmonary hypertension in goats. Horiguchi T, et al. **Anesthesiology** 1995 Oct; 83(4):786–91

ANTICOCCIDIAL AGENTS see COCCIDIOSTATS

ANTICODON

Effects of modifying the tRNA(3Lys) anticodon on the initiation of human immunodeficiency virus type 1 reverse transcription. Huang Y, et al. **J Virol** 1996 Jul;70(7):4700–6

CHEMISTRY

Characterization of a B. subtilis minor isoleucine tRNA deduced from tDNA having a methionine anticodon CAT. Matsugi J, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):811–6

The presence of codon–anticodon pairs in the acceptor stem of tRNAs. Rodin S, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4537–42

GENETICS

The nature of the nucleotide at the 5' side of the tRNA Su9 anticodon affects UGA suppression in Escherichia coli. Goldman–Levi R, et al. **DNA Res** 1994;1(3):123–7

Design, biological activity and NMR–solution structure of a DNA analogue of yeast tRNA(Phe) anticodon domain. Basti MM, et al. **Nat Struct Biol** 1996 Jan;3(1):38–44

The presence of codon–anticodon pairs in the acceptor stem of tRNAs. Rodin S, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4537–42

METABOLISM

A mechanism for reducing entropic cost of induced fit in protein—RNA recognition. Ribas de Pouplana L, et al. **Biochemistry** 1996 Jun 25;35(25):8095–102

A tRNA identity switch mediated by the binding interaction between a tRNA anticodon and the accessory domain of a class II aminoacyl–tRNA synthetase. Yan W, et al. **Biochemistry** 1996 May 28;35(21):6559–68

Solution structure of the anticodon–binding domain of Escherichia coli lysyl–tRNA synthetase and studies of its interaction with tRNA(Lys). Commans S, et al. **J Mol Biol** 1995 Oct 13;253(1):100–13

ANTICONVULSANTS

New Developments in Antiepileptic Drug Therapy. Proceedings. New Orleans, Louisiana, December 1994. **Epilepsia** 1995;36 Suppl 2:S1–118

Appropriateness of antiepileptic drug level monitoring [letter; comment] Gambino R. **JAMA** 1996 Mar 13;275(10):757; discussion 758. Comment on: JAMA 1995 Nov 22–29;274(20):1622–6.

New antiepileptic drugs. Dichter MA, et al. **N Engl J Med** 1996 Jun 13;334(24):1583–90 (101 ref.)

[Drug–resistant epilepsy in adults] Loiseau P, et al. **Rev Neurol (Paris)** 1995 May;151(5):295–306 (96 ref.) (Eng. Abstr.) (Fre)

ADMINISTRATION & DOSAGE

Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Mattson RH, et al. **Acta Neurol Scand Suppl** 1995;162:27–30 (16 ref.)

Long–term efficacy and cognitive effects of vigabatrin. Ylinen A, et al. **Acta Neurol Scand Suppl** 1995;162:47–50

Established role of magnesium sulfate as prophylactic anticonvulsive agent in preeclampsia/eclampsia. Skajaa K. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):313–5 (18 ref.)

Late–onset pyridoxine–dependent seizures: report of two cases. Chou ML, et al. **Acta Paediatr Sin** 1995 Nov–Dec; 36(6):434–7

Comment: lamotrigine dosing [letter; comment] Manasco PK. **Ann Pharmacother** 1995 Nov;29(11):1173. Comment on: Ann Pharmacother 1995 Feb;29(2):144–51.

Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study [see comments] Kälviäinen R, et al. **Arch Neurol** 1995 Oct; 52(10):989–96. Comment in: Arch Neurol 1996 Jun;53(6):477–8.

Vigabatrin and carbamazepine monotherapy for newly diagnosed epilepsy [letter; comment] Walker MC, et al.

Arch Neurol 1996 Jun;53(6):477–8. Comment on: Arch Neurol 1995 Oct;52(10):989–96.

Analysis of anticonvulsant and neurotoxic responses to combination therapy with carbamazepine, felbamate and phenytoin by response-surface modeling. Gennings C, et al. **Arzneimittelforschung** 1995 Jul;45(7):739–48

Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Fresta M, et al. **Biomaterials** 1996 Apr; 17(8):751–8

How long to treat childhood onset absence epilepsy. Amit R, et al. **Clin Electroencephalogr** 1995 Jul;26(3):163–5

Quantitative pharmaco-EEG of carbamazepine in volunteers and epileptics. Wu X, et al. **Clin Electroencephalogr** 1996 Jan;27(1):40–5

Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study. Matsuo F, et al. **Epilepsia** 1996 Sep;37(9):857–62

Monotherapy or polytherapy for epilepsy revisited: a quantitative assesament [letter] Ng PW. **Epilepsia** 1996 Jan; 37(1):108

Safety of topiramate: adverse events and relationships to dosing. Shorvon SD. **Epilepsia** 1996;37 Suppl 2:S18–S22

Seizure occurrence during long-term monitoring. Swick CT, et al. **Epilepsia** 1996 Oct;37(10):927–30

Rising dose study of safety and tolerance of flunarizine. Handforth A, et al. **Eur J Clin Pharmacol** 1995;49(1–2):91–4

Vigabatrin and posttraumatic stress disorder [letter] Macleod AD. **J Clin Psychopharmacol** 1996 Apr;16(2):190–1

Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses. Puryear LJ, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8(4):234–7

Protocol for ACTH administration in refractory childhood seizures: educational strategies. O'Dell C, et al. **J Neurosci Nurs** 1995 Dec;27(6):363–9

Anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. Comparison of diazepam, bretazenil and abecarnil. Rundfeldt C, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):693–702

Appropriateness of antiepileptic drug level monitoring [see comments] Schoenenberger RA, et al. **JAMA** 1995 Nov 22–29;274(20):1622–6. Comment in: JAMA 1996 Mar 13;275(10):757; discussion 758. Comment in: JAMA 1996 Mar 13;275(10):757–8.

Position statement on the use of rectal diazepam in epilepsy. Epilepsy Society of Australia, the Child Neurology Study Group, the Australian Association of Neurologists, and the National Epilepsy Association of Australia [see comments] Somerville ER, et al. **Med J Aust** 1995 Sep 4;163(5):268–9 . Comment in: Med J Aust 1995 Oct 16;163(8):445–6.

Pharmacokinetic considerations in phenytoin pharmacotherapy: preventing overdoses and underdoses. Profeta LM, et al. **Mt Sinai J Med** 1995 Sep;62(4):312–4

Short-term perioperative anticonvulsant prophylaxis for the surgical treatment of low-risk patients with intracranial aneurysms. Baker CJ, et al. **Neurosurgery** 1995 Nov; 37(5):863–70; discussion 870–1

Flunarizine of limited value in children with intractable epilepsy. Hoppu K, et al. **Pediatr Neurol** 1995 Sep; 13(2):143–7

Pentobarbital therapy for status epilepticus in children: timing of tapering. Kinoshita H, et al. **Pediatr Neurol** 1995 Sep; 13(2):164–8

Neither dosage nor serum levels of antiepileptic drugs are predictive for efficacy and adverse effects. Lammers MW, et al. **Pharm World Sci** 1995 Nov 24;17(6):201–6

Habituation of orienting reaction in therapy-resistant partial epilepsy. Rogozea R, et al. **Rom J Neurol Psychiatry** 1995 Jan-Mar;33(1):7–27

Rational polypharmacy. Richens A. **Seizure** 1995 Sep; 4(3):211–4

An audit of therapeutic drug monitoring of anticonvulsants. Sharpe PC, et al. **Ulster Med J** 1995 Oct;64(2):151–6

[Discontinuation of epilepsy drug therapy] Keränen T. **Duodecim** 1994;110(18):1725–9 (26 ref.) **(Fin)**

[Effectiveness of intravenous midazolam for the treatment of status epilepticus in a child with severe myoclonic epilepsy in infancy] Minakawa K. **No To Hattatsu** 1995 Nov;27(6):498–500 **(Jpn)**

[Administration of a single oral high-dose of diazepam at bedtime as therapy for intractable seizures] Tojo M. **No To Hattatsu** 1995 Sep;27(5):355–62 (Eng. Abstr.) **(Jpn)**

[Treatment with antiepileptics of mentally retarded patients. Experiences from the 1980s a challenge in the 1990s] Brodtkorb E. **Tidsskr Nor Laegeforen** 1996 Jan 30; 116(3):387–91 (Eng. Abstr.) **(Nor)**

[Lamiktal in the treatment of epilepsy patients] Bakunts GO, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(3):41–4 (Eng. Abstr.) **(Rus)**

[Therapeutic drug monitoring and the pharmacokinetics of carbamazepine in children with a convulsive syndrome] Kholodov LE, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):35–40 (Eng. Abstr.) **(Rus)**

[Epilepsy is difficult to treat during an attack of porphyria] Bylesjö EI, et al. **Lakartidningen** 1996 Jun 26; 93(26–27):2506–8 (15 ref.) **(Swe)**

ADVERSE EFFECTS

Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Sabers A, et al. **Acta Neurol Scand** 1995 Jul;92(1):19–27

Short-term withdrawal of antiepileptic medication: effects on attention and memory. Tuunainen A, et al. **Acta Neurol Scand** 1995 Sep;92(3):198–205

Behavioural abnormalities and retention rates of anti-epilepsy drugs during long-term treatment of epilepsy: a clinical perspective. Schmidt D. **Acta Neurol Scand Suppl** 1995; 162:7–10 (28 ref.)

The effect of carnitine supplementation in valproate-induced hyperammonaemia. Böhles H, et al. **Acta Paediatr** 1996 Apr;85(4):446–9

Stevens-Johnson syndrome resulting from whole-brain radiation and phenytoin [see comments] Cockey GH, et al. **Am J Clin Oncol** 1996 Feb;19(1):32–4. Comment in: Am J Clin Oncol 1996 Aug;19(4):431.

Stevens-Johnson syndrome resulting from whole-brain irradiation and phenytoin [letter; comment] Weltman E, et al. **Am J Clin Oncol** 1996 Aug;19(4):431. Comment on: Am J Clin Oncol 1996 Feb;19(1):32–4.

Association of intravenous phenytoin toxicity with demographic, clinical, and dosing parameters. Binder L, et al. **Am J Emerg Med** 1996 Jul;14(4):398–401

Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Howe AM, et al. **Am J Med Genet** 1995 Sep 11;58(3):238–44 (52 ref.)

Hand anomalies in fetal-hydantoin syndrome: from nail/phalangeal hypoplasia to unilateral acheiria [letter] Sabry MA, et al. **Am J Med Genet** 1996 Apr 24;62(4):410–2 (34 ref.)

Effects of magnesium sulphate on suxamethonium-induced complications during rapid-sequence induction of anaesthesia. Stacey MR, et al. **Anaesthesia** 1995 Nov; 50(11):933–6

Vigabatrin-associated reversible acute psychosis in a child. Cánovas Martínez A, et al. **Ann Pharmacother** 1995 Nov; 29(11):1115–7 (10 ref.)

Lymphopenic effect of carbamazepine in a patient with chronic lymphocytic leukemia. Silverman DA, et al. **Ann Pharmacother** 1995 Sep;29(9):865–7

Comment: leucovorin-phenytoin: a drug-drug interaction? [letter; comment] Tidwell BH, et al. **Ann Pharmacother** 1995 Dec;29(12):1303–4. Comment on: Ann Pharmacother 1995 Jul-Aug;29(7–8):726–35. Comment on: Ann Pharmacother 1995 Jul-Aug;29(7–8):760–8.

Anticonvulsant hypersensitivity syndrome. Vittorio CC, et al. **Arch Intern Med** 1995 Nov 27;155(21):2285–90

Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Wilder BJ, et al. **Arch Neurol** 1996 Aug; 53(8):764–8

Low serum concentration of all-trans and 13-cis retinoic acids in patients treated with phenytoin, carbamazepine and valproate. Possible relation to teratogenicity. Fex G, et al. **Arch Toxicol** 1995;69(8):572–4

Kinetic parameters of lymphocyte microsomal epoxide hydrolase in carbamazepine hypersensitive patients. Assessment by radiometric HPLC. Davis CD, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1361–6

Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Green VJ, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1353–9

Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Chopra S, et al. **Br J Dermatol** 1996 Jun; 134(6):1109–12 (19 ref.)

Toxic epidermal necrolysis induced by terbinafine in a patient on long-term anti-epileptics [letter] White SI, et al. **Br J Dermatol** 1996 Jan;134(1):188–9

Hypomania induced by gabapentin [letter] Hauck A, et al. **Br J Psychiatry** 1995 Oct;167(4):549

Mania precipitated by carbamazepine withdrawal [letter] Scull DA, et al. **Br J Psychiatry** 1995 Nov;167(5):698

Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects. Kennebäck G, et al. **Cardiovasc Drugs Ther** 1995 Oct; 9(5):709–14

Phenytoin-induced toxic epidermal necrolysis: a case report. Creamer JD, et al. **Clin Exp Dermatol** 1996 Mar; 21(2):116–20

Retroperitoneal haematoma in a patient treated with acenocoumarol, phenytoin and paroxetine. Abad-Santos F, et al. **Clin Lab Haematol** 1995 Jun;17(2):195–7

Treatment of complex partial status epilepticus unmasking acute intermittent porphyria in a patient with resected anaplastic glioma. Yandel ML, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):261–3

Gabapentin: pharmacokinetics, efficacy, and safety. Beydoun A, et al. **Clin Neuropharmacol** 1995 Dec;18(6):469–81 (61 ref.)

Folate deficiency, anticonvulsant drugs, and psychiatric morbidity. Fröscher W, et al. **Clin Neuropharmacol** 1995 Apr;18(2):165–82

Vigabatrin and multifocal myoclonus in adults with partial seizures. Neufeld MY, et al. **Clin Neuropharmacol** 1995 Jun; 18(3):280–3

Urinary retention related to phenytoin therapy. Nussinovitch M, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):382–3

Anticonvulsant hypersensitivity syndrome. Licata AL, et al. **Compr Ther** 1996 Mar;22(3):152–5 (22 ref.)

Update in the treatment of epilepsy. Schachter SC. **Compr Ther** 1995 Sep;21(9):473–9 (7 ref.)

Exfoliative dermatitis caused by carbamazepine in a patient with isolated IgA deficiency. Corazza M, et al. **Contact Dermatitis** 1995 Dec;33(6):447

Dilantin hypersensitivity reaction. Conger LA Jr, et al. **Cutis** 1996 Apr;57(4):223–6 (32 ref.)

Oropharyngeal dysphagia due to iatrogenic neurological dysfunction. Buchholz DW. **Dysphagia** 1995 Fall; 10(4):248–54 (51 ref.)

Cognitive and behavioral effects of antiepileptic drugs. Devinsky O. **Epilepsia** 1995;36 Suppl 2:S46–65 (106 ref.)

Felbamate-induced headache. Ettinger AB, et al. **Epilepsia** 1996 May;37(5):503–5

Remacemide hydrochloride and ARL 15896AR lack abuse potential: additional differences from other uncompetitive NMDA antagonists. Hudzik TJ, et al. **Epilepsia** 1996 Jun; 37(6):544–50

Menstrual disorders in women with epilepsy receiving carbamazepine. Isojärvi JI, et al. **Epilepsia** 1995 Jul; 36(7):676–81

Behavioral side effects of gabapentin in children. Lee DO, et al. **Epilepsia** 1996 Jan;37(1):87–90

Tiagabine: the safety landscape. Leppik IE. **Epilepsia** 1995; 36 Suppl 6:S10–S13

Efficacy and adverse effects of established and new antiepileptic drugs. Mattson RH. **Epilepsia** 1995;36 Suppl 2:S13–26 (108 ref.)

Movement disorders associated with the use of gabapentin. Reeves AL, et al. **Epilepsia** 1996 Oct;37(10):988–90

Assessment of drowsiness in epilepsy patients receiving chronic antiepileptic drug therapy. Salinsky MC, et al. **Epilepsia** 1996 Feb;37(2):181–7

Safety of topiramate: adverse events and relationships to dosing. Shorvon SD. **Epilepsia** 1996;37 Suppl 2:S18–S22

Gabapentin associated with aggressive behavior in pediatric patients with seizures. Tallian KB, et al. **Epilepsia** 1996 May;37(5):501–2

Preoperative valproate administration does not increase blood loss during temporal lobectomy. Ward MW, et al. **Epilepsia** 1996 Jan;37(1):98–101

Gabapentin toxicity in children manifesting as behavioral changes. Wolf SM, et al. **Epilepsia** 1995 Dec;36(12):1203–5

Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Vermeulen J, et al. **Epilepsy Res** 1995 Oct;22(2):65–95 (130 ref.)

Retrospective study of vigabatrin and psychiatric behavioural disturbances. Wong IC. **Epilepsy Res** 1995 Jul;21(3):227–30

Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic-gingival hyperplasia: in vivo and in vitro study. Ieiri I, et al. **Eur J Clin Pharmacol** 1995; 49(1–2):51–6

An acardiac acephalic monster following in-utero anti-epileptic drug exposure. Kutlay B, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):245–8

Severe carbamazepine toxicity induced by concurrent erythromycin therapy [letter] Mota CR, et al. **Eur J Pediatr** 1996 Apr;155(4):345

Activities of antioxidant enzymes and formation of the glutathione adduct of hemoglobin (Hb ASSG) in epileptic patients with long-term antiepileptic therapy. Niketić V, et al. **Farmaco** 1995 Nov;50(11):811–3

The ethosuximide-induced hyperpolarization of smooth muscle tissues—a cause of functional changes in the gastrointestinal tract of rats—is provoked by CA(2+)-dependent K(+)-efflux. Kristev A, et al. **Folia Med (Plovdiv)** 1994;36(4):13–22

Tolerance, drug dependence and withdrawal syndrome in antiepileptic drugs. Toreva D, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):29

Hepatic functions in epileptics on sodium valproate monotherapy [letter] Jha S, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):305–6

Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Sterker M, et al. **Int J Clin Pharmacol Ther** 1995 Nov;33(11):595–7

Carnitine deficiency during valproic acid treatment. Van Wouwe JP. **Int J Vitam Nutr Res** 1995;65(3):211–4

Carbamazepine hypersensitivity [letter] Bellman B, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1405–6

Porphyria cutanea tarda in a patient on chronic ambulatory peritoneal dialysis. Ruggian JC, et al. **J Am Soc Nephrol** 1996 Mar;7(3):397–402

Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults. Buzan RD, et al. **J Clin Psychiatry** 1995 Nov;56(11):529–32

Psychosis associated with felbamate treatment [letter] Knable MB, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):292–3

A case of eosinophilic pustular folliculitis (Ofuji's disease) induced by patch and challenge tests with indeloxazine hydrochloride. Kimura K, et al. **J Dermatol** 1996 Jul; 23(7):479–83

Carbamazepine induced erythroderma with systemic lymphadenopathy. Okuyama R, et al. **J Dermatol** 1996 Jul; 23(7):489–94

Fetal valproate syndrome. Clayton-Smith J, et al. **J Med Genet** 1995 Sep;32(9):724–7

Valproate induced encephalopathy treated with carnitine in an adult [letter] Beversdorf D, et al. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):211

Hypogammaglobulinaemia with absent B lymphocytes and agranulocytosis after carbamazepine treatment [letter] Spickett GP, et al. **J Neurol Neurosurg Psychiatry** 1996

Apr;60(4):459

Effect of plasma anticonvulsant level on pipecuronium-induced neuromuscular blockade: preliminary results. Hans P, et al. **J Neurosurg Anesthesiol** 1995 Oct;7(4):254–8

Hydroxyproline and total protein levels in gingiva from patients treated with phenytoin and cyclosporine–A. Akalin FA, et al. **J Nihon Univ Sch Dent** 1996 Mar;38(1):21–30

Methionine reduces the valproic acid–induced spina bifida rate in mice without altering valproic acid kinetics. Ehlers K, et al. **J Nutr** 1996 Jan;126(1):67–75

Lymphoblastic lymphoma following prenatal exposure to phenytoin. Murray JC, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):241–3 (23 ref.)

In utero exposure to phenobarbital and intelligence deficits in adult men. Reinisch JM, et al. **JAMA** 1995 Nov 15; 274(19):1518–25

Lamotrigine encephalopathy [letter] Hennessy MJ, et al. **Lancet** 1996 Apr 6;347(9006):974–5

Antiepileptic drug behavioral side effects in individuals with mental retardation and the use of behavioral measurement techniques. Kalachnik JE, et al. **Ment Retard** 1995 Dec; 33(6):374–82

Phenytoin–induced focal chorea [letter] Shulman LM, et al. **Mov Disord** 1996 Jan;11(1):111–4

Phenytoin–associated vasculitis and ANCA positivity: a case report. Parry RG, et al. **Nephrol Dial Transplant** 1996 Feb; 11(2):357–9

Immunologically mediated chronic tubulo–interstitial nephritis caused by valproate therapy [letter] Fukuda Y, et al. **Nephron** 1996;72(2):328–9

Valproic acid hepatic fatalities. III. U.S. experience since 1986. Bryant AE 3rd, et al. **Neurology** 1996 Feb;46(2):465–9

Vigabatrin edema [letter] Cocito L, et al. **Neurology** 1995 Nov;45(11):2115–6

Lamotrigine–induced rash in children. Dooley J, et al. **Neurology** 1996 Jan;46(1):240–2

Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Krauss GL, et al. **Neurology** 1996 Jun;46(6):1534–9

Felbamate–associated fatal acute hepatic necrosis. O'Neil MG, et al. **Neurology** 1996 May;46(5):1457–9

Effects of ACTH on brain midline structures in infants with infantile spasms. Konishi Y, et al. **Pediatr Neurol** 1995 Sep; 13(2):134–6

Discontinuation of phenobarbital in children: effects on neurocognitive behavior. Riva D, et al. **Pediatr Neurol** 1996 Jan;14(1):36–40

A slow acetylator genotype is a risk factor for sulphonamide–induced toxic epidermal necrolysis and Stevens–Johnson syndrome. Wolkenstein P, et al. **Pharmacogenetics** 1995 Aug;5(4):255–8

Adverse effects of established and new antiepileptic drugs: an attempted comparison. Rogvi–Hansen B, et al. **Pharmacol Ther** 1995;68(3):425–34 (98 ref.)

Paralytic ileus in a fetus–neonate after maternal intake of benzodiazepine. Haeusler MC, et al. **Prenat Diagn** 1995 Dec;15(12):1165–7

Recurrence of seizures in childhood epilepsy after discontinuation of antiepileptic drugs. Hirokawa H, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S262–3

The effect of 5–(p–hydroxyphenyl)–5–phenylhydantoin (p–HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic side effects: in vivo and in vitro studies. Ieiri I, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S247–51

Carbamazepine–exacerbated epilepsy with multifocal shifting independent epileptiform discharges on electroencephalogram: a case report. Kimura M, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):65–7

Carbamazepine–induced thrombocytopenia and carbamazepine–10,11–epoxide: a case report. Kimura M, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):69–70

Prognosis of epilepsy withdrawn from antiepileptic drugs. Nakazawa Y, et al. **Psychiatry Clin Neurosci** 1995 Jun; 49(3):163–8

Orofacial clefts and maternal anticonvulsant use [letter] Shaw GM, et al. **Reprod Toxicol** 1995 Jan–Feb;9(1):97–8

Generic prescribing for epilepsy. Is it safe? Crawford P, et al. **Seizure** 1996 Mar;5(1):1–5

Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)

A potentially fatal drug reaction. Patel D, et al. **Tenn Med** 1996 Aug;89(8):294–5

Holoprosencephaly and antiepileptic exposures [letter; comment] Rosa F. **Teratology** 1995 Apr;51(4):230. Comment on: Teratology 1993 Jul;48(1):15–9.

Phenytoin as a risk factor in gingival hyperplasia. Perlik F, et al. **Ther Drug Monit** 1995 Oct;17(5):445–8

A case of phenytoin–alcohol interaction [letter] Bellibas SE, et al. **Therapie** 1995 Sep–Oct;50(5):487–8

[Acute porphyria and multiple organ failure during treatment with lamotrigine] Gregersen H, et al. **Ugeskr Laeger** 1996 Jul 8;158(28):4091–2 (Eng. Abstr.) **(Dan)**

[Caution rules when prescribing valproate] Jensen K. **Ugeskr Laeger** 1995 Oct 16;157(42):5875–6 **(Dan)**

[Generalized side effects with the use of carbamazepine] Tijhuis GJ, et al. **Ned Tijdschr Geneeskd** 1995 Nov 4; 139(44):2265–8 (Eng. Abstr.) **(Dut)**

[Side effects of phenytoin and carbamazepine on cognitive functioning] Pulliainen V, et al. **Duodecim** 1994; 110(14):1320–8 (44 ref.) **(Fin)**

[Uncontrolled retrospective study of 75 pregnancies in women treated for epilepsy] Lainé–Cessac P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):537–42 (Eng. Abstr.) **(Fre)**

[Drug hypersensitivity syndrome during treatment with valproic acid (letter)] Plantin P, et al. **Presse Med** 1995 Nov 11;24(34):1624 **(Fre)**

[Metabolic acidosis caused by injectable sodium valproate. 6 postoperative cases in neurosurgery (letter)] Riche H, et al. **Presse Med** 1996 Apr 13;25(13):642 **(Fre)**

[Systemic lupus erythematosus, caused by carbamazepine. Apropos of a case (letter)] Ghorayeb I, et al. **Rev Med Interne** 1996;17(6):503–4 **(Fre)**

[The effect of valproic acid monotherapy on behavior and cognitive performance of children with idiopathic generalized epilepsy] Schmidt A, et al. **Z Kinder Jugenpsychiatr** 1995 Sep;23(3):161–70 (Eng. Abstr.) **(Ger)**

[Interference of anticonvulsants in the rehabilitation treatment] Pisaturo C, et al. **Minerva Pediatr** 1996 Apr; 48(4):135–41 (Eng. Abstr.) **(Ita)**

[Exacerbation of complex partial seizures by carbamazepine in a child with frontal lobe epilepsy] Enoki H, et al. **No To Hattatsu** 1995 Sep;27(5):403–5 **(Jpn)**

[Oligohidrosis caused by zonisamide] Okumura A, et al. **No To Hattatsu** 1996 Jan;28(1):44–7 (Eng. Abstr.) **(Jpn)**

[A case of behavior disorder with gait and sleep disturbances induced by zonisamide] Ozawa H, et al. **No To Hattatsu** 1995 Nov;27(6):496–8 **(Jpn)**

[Multiple myeloma associated with phenytoin (diphenylhydantoin) therapy] Kanoh T, et al. **Rinsho Ketsueki** 1996 Mar;37(3):239–43 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Oligospermia improved by switching an anticonvulsant from phenytoin to valproate] Niwa K, et al. **Rinsho Shinkeigaku** 1996 Mar;36(3):492–4 (Eng. Abstr.) **(Jpn)**

[Hemorrhagic shock and fulminant hepatic failure associated with valproate] Fernandez–Fernandez FJ, et al. **An Med Interna** 1995 Dec;12(12):606–8 (Eng. Abstr.) **(Spa)**

[The anticonvulsant hypersensitivity syndrome caused by phenobarbital (letter)] Gorraiz A, et al. **An Med Interna** 1995 Dec;12(12):617 **(Spa)**

[Acute pancreatitis caused by valproic acid: apropos a case] Bahamonde Carrasco A, et al. **Gastroenterol Hepatol** 1996 May;19(5):253–4 (21 ref.) (Eng. Abstr.) **(Spa)**

[Parkinsonism induced by sodium valproate] del Real Francia MA, et al. **Neurologia** 1995 Nov;10(9):381–3 (Eng. Abstr.) **(Spa)**

[Stevens–Johnson syndrome after lamotrigine treatment] Campistol J, et al. **Rev Neurol** 1995 Nov–Dec; 23(124):1236–8 (Eng. Abstr.) **(Spa)**

[Reversible neuropsychological deterioration associated with valproate] Vaquerizo J, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):148–50 (Eng. Abstr.) **(Spa)**

ANALYSIS

Testing human hair for carbamazepine in epileptic patients: is hair investigation suitable for drug monitoring? Kintz P, et al. **Hum Exp Toxicol** 1995 Oct;14(10):812–5

Liquid chromatographic assay using a microcolumn coupled to a U–shaped optical cell for high–sensitivity ultraviolet absorbance detection of oxcarbazepine and its major metabolite in microdialysates. Van Belle K, et al. **J Chromatogr B Biomed Appl** 1995 Oct 6;672(1):97–102

Production of specific antibodies and development of a non–isotopic immunoassay for carbamazepine by the carbonyl metallo–immunoassay (CMIA) method. Varenne A, et al. **J Immunol Methods** 1995 Oct 26;186(2):195–204

A comparison of the OPUS and TDx analysers for antiepileptic drug monitoring. O'Connell MT, et al. **Ther Drug Monit** 1995 Oct;17(5):549–55

ANTAGONISTS & INHIBITORS

Low level hyperbaric antagonism of diazepam's locomotor depressant and anticonvulsant properties in mice. Davies DL, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):667–75

BLOOD

Diminished protein binding capacity of uremic sera for valproate following hemodialysis: role of free fatty acids and uremic compounds. Dasgupta A, et al. **Am J Nephrol** 1996;16(4):327–33

Routine therapeutic monitoring of lamotrigine in epileptic patients using a simple and rapid high performance liquid chromatographic technique. George S, et al. **Ann Clin Biochem** 1995 Nov;32 (Pt 6):584–8

Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state. Cardot JM, et al. **Biopharm Drug Dispos** 1995 Oct;16(7):603–14

The drug–drug interaction effects of haloperidol on plasma carbamazepine levels. Iwahashi K, et al. **Clin Neuropharmacol** 1995 Jun;18(3):233–6

Felbamate levels in patients with epilepsy. Harden CL, et al. **Epilepsia** 1996 Mar;37(3):280–3

Determination of gabapentin in serum by capillary electrophoresis. Garcia LL, et al. **J Chromatogr B Biomed Appl** 1995 Jul 7;669(1):157–62

Phenytoin free fraction determination: comparison of an improved direct serum injection high–performance liquid chromatographic method to ultrafiltration coupled with fluorescence polarization immunoassay. Gurley BJ, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):358–64

Automated analysis of free and total concentrations of three antiepileptic drugs in plasma with on–line dialysis and high–performance liquid chromatography. Johansen K, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):281–8

Simple and rapid analysis of lamotrigine, a novel antiepileptic, in human serum by high–performance liquid chromatography using a solid–phase extraction technique. Yamashita S, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):354–7

Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high–performance liquid chromatography. Matar KM, et al. **J Clin Pharm Ther** 1995 Aug;20(4):229–34

Comparison of equations for predicting bound serum concentrations of carbamazepine and carbamazepine–10, 11–epoxide after polytherapy in patients with epilepsy. Kodama Y, et al. **J Clin Pharmacol** 1995 Oct; 35(10):995–1002

Effect of plasma anticonvulsant level on pipecuronium–induced neuromuscular blockade: preliminary results. Hans P, et al. **J Neurosurg Anesthesiol** 1995 Oct;7(4):254–8

Neither dosage nor serum levels of antiepileptic drugs are predictive for efficacy and adverse effects. Lammers MW, et al. **Pharm World Sci** 1995 Nov 24;17(6):201–6

A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography. Ratnaraj N, et al. **Ther Drug Monit** 1996 Apr;18(2):154–7

Monitoring free extracellular valproic acid by microdialysis in epileptic patients. Ståhle L, et al. **Ther Drug Monit** 1996 Feb;18(1):14–8

Determination of valproic acid in human plasma by capillary gas chromatography. Yu HY, et al. **Ther Drug Monit** 1996 Feb;18(1):107–8

[Phenytoin] Furuno K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:924–7 (21 ref.) **(Jpn)**

[Primidone] Furuno K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:928–30 (21 ref.) **(Jpn)**

[Carbamazepine] Gomita Y, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:907–10 (8 ref.) **(Jpn)**

[Ethosuximide] Ichiba M, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:915–7 (8 ref.) **(Jpn)**

[Phenobarbital] Kawasaki H, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:921–3 (12 ref.) **(Jpn)**

[Valproic acid] Kohda Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:918–20 (10 ref.) **(Jpn)**

[Zonisamide] Shuto H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:931–3 (6 ref.) **(Jpn)**

[Clonazepam, nitrazepam, diazepam] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:911–4 (19 ref.) **(Jpn)**

CEREBROSPINAL FLUID

Seizure frequency and CSF parameters in a double–blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. Ben–Menachem E, et al. **Epilepsy Res** 1995 Jul;21(3):231–6

CHEMICAL SYNTHESIS

Studies on cerebral protective agents. X. Synthesis and evaluation of anticonvulsant activities for novel 4,5,6,7–tetrahydrothieno[3,3–c]pyridines and related compounds. Ohkubo M, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):778–84

Some 3–hydrazono–2–indolinones and N–Mannich bases as potential anticonvulsants. Gürsoy A, et al. **Farmaco** 1996 Jun;51(6):437–42

Synthesis and anticonvulsant activity of new acylthiosemicarbazides and thiazolidones. Gürsoy A, et al. **Farmaco** 1995 Dec;50(12):857–66

Synthesis of 1,4,7,8,9,10–hexahydro–9–methyl–6–nitropyrido[3,4–f]–quinoxaline–2,3–dione and related quinoxalinediones: characterization of alpha–amino–3–hydroxy–5–methyl–4–isoxazolepropionic acid (and N–methyl–D–aspartate) receptor and anticonvulsant activity. Bigge CF, et al. **J Med Chem** 1995 Sep 15;38(19):3720–40

Synthesis and anticonvulsant activities of N–Benzyl–2–acetamidopropionamide derivatives. Choi D, et al. **J Med Chem** 1996 Apr 26;39(9):1907–16

Synthesis and evaluation of N–(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents. Flaherty PT, et al. **J Med Chem** 1996 Mar 29;39(7):1509–13

1–(Fluorobenzyl)–4–amino–1H–1,2,3–triazolo[4,5–c]pyridines: synthesis and anticonvulsant activity. Kelley JL, et al. **J Med Chem** 1995 Sep 29;38(20):4131–4

Synthesis and anticonvulsant activity of N–benzylpyrrolo[2,3–d]–, –pyrazolo[3,4–d]–, and –triazolo[4,5–d]pyrimidines: imidazole ring–modified analogues of 9–(2–fluorobenzyl)–6–(methylamino)–9H–purine. Kelley JL, et al. **J Med Chem** 1995 Sep 15;38(19):3884–8

Novel

alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonists: synthesis and structure-activity relationships of 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-pyrido[2,3-b]pyrazinedione and related compounds. Ohmori J, et al. **J Med Chem** 1996 Mar 15;39(6):1331–8

Synthesis and anticonvulsant activity of enaminones. 3. Investigations on 4'-, 3'-, and 2'-substituted and polysubstituted anilino compounds, sodium channel binding studies, and toxicity evaluations. Scott KR, et al. **J Med Chem** 1995 Sep 29;38(20):4033–43

Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. Takada S, et al. **J Med Chem** 1996 Jul 5; 39(14):2844–51

Synthesis and pharmacological evaluation of spiro-analogues of 5-benzyl-5-ethyl barbituric acid. King SB, et al. **Pharm Res** 1995 Aug;12(8):1240–3

Anticonvulsant activity of aryl and hetarylsulfonylhydrazones. Darias V, et al. **Pharmazie** 1995 Nov;50(11):756–8

Anticonvulsant semicarbazones: are aryl groups necessary for activity? Dimmock JR, et al. **Pharmazie** 1995 Dec; 50(12):823–4

Structural modifications of the primary amino group of anticonvulsant aryl semicarbazones. Dimmock JR, et al. **Pharmazie** 1996 Feb;51(2):83–8

Search for new anticonvulsant compounds. Part 1: Synthesis, physicochemical and anticonvulsant properties of new derivatives of alpha-amino-gamma-phthalimidobutyric acid. Malawska B, et al. **Pharmazie** 1995 Nov;50(11):722–5

Synthesis and anticonvulsant activity of some amino acid derivatives. Part 2: Derivatives of Gly, Ala, Leu, Pro, Trp, Phe(4 Cl), Ala(alpha-Me). Paruszewski R, et al. **Pharmazie** 1996 Apr;51(4):212–5

CHEMISTRY

Triazolines. 34. Structure and stability relationships of novel delta 2-1,2,3-triazoline anticonvulsants. Chow AH, et al. **Pharm Res** 1996 Jan;13(1):179–82

Use of molecular electrostatic potentials for analysis of anticonvulsant activities of phenylsuccinimides. Kwiatkowski W, et al. **SAR QSAR Environ Res** 1993; 1(2–3):233–44

CLASSIFICATION

[New antiepileptic drugs (letter)] Deonna T. **Arch Pediatr** 1996;3 Suppl 1:358s–359s **(Fre)**

DIAGNOSTIC USE

Treatment of electrical status epilepticus by short diazepam (DZP) cycles after DZP rectal bolus test. De Negri M, et al. **Brain Dev** 1995 Sep–Oct;17(5):330–3

ECONOMICS

Costing of antiepileptic drugs [letter] Kochen S. **Lancet** 1996 Jan 27;347(8996):266

IMMUNOLOGY

Expression and inducibility of antigens in severe combined immunodeficient mice recognized by human anti-P450 antibodies. Rajasenan RS, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):89–99

METABOLISM

Bupropion and anticonvulsant drug interactions. Popli AP, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):99–101

Altered aromatic amine metabolism in epileptic patients treated with phenobarbital. Wallin H, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov; 4(7):771–3

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Eap CB, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):322–31

S-mephenytoin hydroxylation phenotypes in a Jordanian population. Hadidi HF, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):542–7

Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Sugihara K, et al. **Drug Metab Dispos** 1996 Feb;24(2):199–202

Distribution of felbamate in brain. Cornford EM, et al. **Epilepsia** 1996 Jan;37(1):15–8

Mechanism of valproic acid uptake by isolated rat brain microvessels. Naora K, et al. **Epilepsy Res** 1995 Oct; 22(2):97–106

The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Noyer M, et al. **Eur J Pharmacol** 1995 Nov 14; 286(2):137–46

In the hippocampus in vivo, nitric oxide does not appear to function as an endogenous antiepileptic agent. Stringer JL, et al. **Exp Brain Res** 1995;105(3):391–401

Binding of a valproate metabolite to the trifunctional protein of fatty acid oxidation. Baldwin GS, et al. **FEBS Lett** 1996 Apr 8;384(1):58–60

The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. Gee NS, et al. **J Biol Chem** 1996 Mar 8;271(10):5768–76

Metabolism of beclamide after a single oral dose in man: quantitative studies. Ahmadi M, et al. **J Pharm Pharmacol** 1995 Oct;47(10):876–8

beta-Carboline gamma-aminobutyric acidA receptor inverse agonists modulate gamma-aminobutyric acid via the loreclezole binding site as well as the benzodiazepine site. Stevenson A, et al. **Mol Pharmacol** 1995 Dec;48(6):965–9

Reconversion of fosphenytoin in the presence of intestinal alkaline phosphatase. TenHoor CN, et al. **Pharm Res** 1995 Nov;12(11):1806–9

Influence of partial hepatectomy in dogs on trimethadione metabolism and microsomal monooxygenases. Tanaka E, et al. **Xenobiotica** 1995 Dec;25(12):1301–10

PHARMACOKINETICS

Effect of pregnancy on plasma phenobarbital concentrations in rats. Moriyama M, et al. **Acta Med Okayama** 1995 Oct; 49(5):237–40

Pharmacokinetics of dextromethorphan and dextrorphan in epileptic patients. Kazis A, et al. **Acta Neurol Scand** 1996 Feb–Mar;93(2–3):94–8

Pharmacokinetic and pharmacodynamic drug interactions during treatment with vigabatrin. Richens A. **Acta Neurol Scand Suppl** 1995;162:43–6 (16 ref.)

Absorption of diazepam after its rectal administration in dogs. Papich MG, et al. **Am J Vet Res** 1995 Dec;56(12):1629–36

Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. Alloul K, et al. **Anesthesiology** 1996 Feb; 84(2):330–9

Carbamazepine pharmacokinetics in obese and lean subjects. Caraco Y, et al. **Ann Pharmacother** 1995 Sep;29(9):843–7

Effect of dexamethasone on the decrease of serum phenytoin concentrations [letter] Recuenco I, et al. **Ann Pharmacother** 1995 Sep;29(9):935

Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Wilder BJ, et al. **Arch Neurol** 1996 Aug; 53(8):764–8

Effects of ingesta on systemic availability of phenobarbitone in dogs. Watson AD, et al. **Aust Vet J** 1996 Mar;73(3):108–9

Pharmaceutical evaluation of carbamazepine suppositories in rats. Shinoda M, et al. **Biol Pharm Bull** 1995 Sep; 18(9):1289–91

Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state. Cardot JM, et al. **Biopharm Drug Dispos** 1995 Oct;16(7):603–14

Pharmacokinetic interaction studies between felbamate and vigabatrin. Reidenberg P, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):157–60

Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. Vauzelle-Kervroëdan F, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):325–30

Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Battino D, et al. **Clin Pharmacokinet** 1995 Nov;29(5):341–69 (126 ref.)

Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Battino D, et al. **Clin Pharmacokinet** 1995 Oct;29(4):257–86 (136 ref.)

Lack of pharmacokinetic interaction between zileuton and phenytoin in humans. Samara E, et al. **Clin Pharmacokinet** 1995;29 Suppl 2:84–91

Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. Hulsman JA, et al. **Clin Pharmacol Ther** 1995 Oct; 58(4):383–9

Effects of felbamate on the pharmacokinetics of phenobarbital. Reidenberg P, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):279–87

The pharmacokinetics of valproic acid in pregnant sheep after maternal and fetal intravenous bolus administration. Gordon JD, et al. **Drug Metab Dispos** 1995 Dec; 23(12):1383–9

Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Edeki TI, et al. **Drug Metab Rev** 1995;27(3):449–69 (89 ref.)

Pharmacokinetic optimisation of drug therapy in elderly patients. Parker BM, et al. **Drugs Aging** 1995 Jul;7(1):10–8 (38 ref.)

Important pharmacokinetic properties of antiepileptic drugs. Bourgeois BF. **Epilepsia** 1995;36 Suppl 5:S1–7 (17 ref.)

Drug interaction profile of topiramate. Bourgeois BF. **Epilepsia** 1996;37 Suppl 2:S14–S17 (23 ref.)

Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Eriksson AS, et al. **Epilepsia** 1996 Aug;37(8):769–73

Neuropharmacology and drug interactions in clinical practice. Graves NM. **Epilepsia** 1995;36 Suppl 2:S27–33 (20 ref.)

Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation. Hooper WD, et al. **Epilepsia** 1996 Jan;37(1):91–7

Antiepileptic drug monitoring: a reappraisal. Mattson RH. **Epilepsia** 1995;36 Suppl 5:S22–9

Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Perucca E. **Epilepsia** 1996; 37 Suppl 2:S8–S13 (55 ref.)

Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Sachdeo RC, et al. **Epilepsia** 1996 Aug;37(8):774–80

The effect of age on pharmacokinetics of antiepileptic drugs. Willmore LJ. **Epilepsia** 1995;36 Suppl 5:S14–21 (72 ref.)

Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. Bareggi SR, et al. **Eur J Clin Pharmacol** 1995;48(3–4):265–8

Determination of phenobarbitone population clearance values for South African children. Botha JH, et al. **Eur J Clin Pharmacol** 1995;48(5):381–3

Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. Booth CL, et al. **Hepatology** 1996 Apr; 23(4):771–80

Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. Biber A, et al. **Int J Clin Pharmacol Ther** 1996 Jan;34(1):6–11

Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. Gidal BE, et al. **J Clin Pharm Ther** 1995 Aug;20(4):215–9

A model for estimating individualized valproate clearance values in children. Botha JH, et al. **J Clin Pharmacol** 1995 Oct;35(10):1020–4

Methionine reduces the valproic acid-induced spina bifida rate in mice without altering valproic acid kinetics. Ehlers K, et al. **J Nutr** 1996 Jan;126(1):67–75

Bioavailability of phenytoin following oral administration of phenytoin-lipid conjugates to rats. Scriba GK, et al. **J Pharm Pharmacol** 1995 Nov;47(11):945–8

Placental transfer of valproic acid after liposome encapsulation during in vitro human placenta perfusion. Barzago MM, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):79–86

Pharmacokinetic considerations in phenytoin pharmacotherapy: preventing overdoses and underdoses. Profeta LM, et al. **Mt Sinai J Med** 1995 Sep;62(4):312–4

Pharmacology and pharmacokinetics of fosphenytoin. Browne TR, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S3–7 (48 ref.)

Influence of vehicle composition variations on the in vitro and ex vivo clonazepam diffusion from hydrophilic ointment bases. Mura P, et al. **Pharm Acta Helv** 1996 Jul; 71(2):147–54

Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Cheung WK, et al. **Pharm Res** 1995 Dec;12(12):1878–82

Age-related changes in pharmacokinetic parameters of phenytoin after liver resection in rats. Nakashima E, et al. **Pharm Res** 1995 Oct;12(10):1530–4

The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. Wang Y, et al. **Pharm Res** 1996 Mar;13(3):398–403

Clinical pharmacokinetics of new antiepileptic drugs. Walker MC, et al. **Pharmacol Ther** 1995;67(3):351–84 (164 ref.)

Pharmacokinetic study of trimethadione and its metabolite in blood, liver and brain by microdialysis in conscious, unrestrained rats. Kurata N, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jul;89(1):45–56

The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. Banfield CR, et al. **Ther Drug Monit** 1996 Feb; 18(1):19–29

Validation of a quick modeling program generating clearance estimates at steady state for routine therapeutic drug monitoring. el Battah A, et al. **Ther Drug Monit** 1995 Aug; 17(4):348–55

Clonazepam disposition in pediatric patients. Walson PD, et al. **Ther Drug Monit** 1996 Feb;18(1):1–5

[Population pharmacokinetics/pharmacodynamics of magnesium sulfate in pregnancy induced hypertensive gravidas treated with the drug] Rui JZ, et al. **Yao Hsueh Hsueh Pao** 1996;31(2):81–5 (Eng. Abstr.) **(Chi)**

[Therapeutic drug monitoring and the pharmacokinetics of carbamazepine in children with a convulsive syndrome] Kholodov LE, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):35–40 (Eng. Abstr.) **(Rus)**

[Epilepsy and cerebral aging. Pharmacokinetics of antiepileptic treatment in adult age] Oller Ferrer-Vidal L. **Rev Neurol** 1995 Nov–Dec;23(124):1318–9 **(Spa)**

PHARMACOLOGY

Prevention of neuronal cell death by anticonvulsants in experimental epilepsy (extended abstract). Pitkänen A, et al. **Acta Neurol Scand Suppl** 1995;162:22–3

Mechanism of action of antiepileptic and antimyoclonic drugs. Pranzatelli MR, et al. **Adv Neurol** 1995;67:329–60 (251 ref.)

Inhibition of a fast inwardly rectifying potassium conductance by barbiturates. Gibbons SJ, et al. **Anesth Analg** 1996 Jun;82(6):1242–6

Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Palmer GC, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:236–47;

discussion 248 (38 ref.)
The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Petroff OA, et al. **Ann Neurol** 1996 Jan;39(1):95-9
Phenytoin-folic acid interaction [see comments] Lewis DP, et al. **Ann Pharmacother** 1995 Jul-Aug;29(7-8):726-35 (65 ref.). Comment in: Ann Pharmacother 1995 Dec;29(12):1303-4.
The comparison of anticonvulsant properties of commercial diphenylhydantoin (DPH) and its 3-amino-derivative (3-amino-DPH). Kozicka M.
Ann Univ Mariae Curie Sklodowska [Med] 1993;48:57-60
Induction of the male-specific cytochrome P450 3A2 in female rats by phenytoin. Ghosal A, et al.
Arch Biochem Biophys 1996 Aug 1;332(1):153-62
Anticonvulsant activity of piperine on seizures induced by excitatory amino acid receptor agonists. D'Hooge R, et al. **Arzneimittelforschung** 1996 Jun;46(6):557-60
Stereoselective anticonvulsant activity of the enantiomers of (+/-)-2-hydroxy-2-phenylbutyramide. Meza-Toledo SE, et al. **Arzneimittelforschung** 1995 Jul;45(7):756-9
Effect of the GABA-transaminase inhibitor vigabatrin on exploratory behaviour in socially isolated rats. Sherif F, et al. **Behav Brain Res** 1995 Dec 14;72(1-2):135-40
Platelet-derived growth factor B-chain homodimer suppressing a convulsion of epilepsy model mouse El. Masuda Y, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):60-3
Biochemical evaluations of the effects of loreclezole and propofol on the GABAA receptor in rat brain. Ghiani CA, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1527-34
A comparison of the ability of myo-inositol and epi-inositol to attenuate lithium-pilocarpine seizures in rats. Patishi Y, et al. **Biol Psychiatry** 1996 May 1;39(9):829-32
Triazolines 31--anticonvulsant properties of three triazoline--and aziridinedicarboximide derivatives [letter] Kadaba PK, et al. **Biomed Pharmacother** 1995;49(7-8):381
Triazolines--XXVII. delta2-1,2,3-triazoline anticonvulsants: novel 'built-in' heterocyclic prodrugs with a unique 'dual-action' mechanism for impairing excitatory amino acid L-glutamate neurotransmission. Kadaba PK, et al. **Bioorg Med Chem** 1996 Feb;4(2):165-78
Dose-response relationship and time-course of the effect of inhaled magnesium sulphate on airflow in normal and asthmatic subjects. Hill J, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):539-44
Electrophysiological actions of felbamate on rat striatal neurones. Pisani A, et al. **Br J Pharmacol** 1995 Oct; 116(3):2053-61
The effect of the desglycinyl metabolite of remacemide hydrochloride (FPL 12495AA) and dizocilpine (MK-801) on endogenous amino acid release from mouse cortex. Srinivasan J, et al. **Br J Pharmacol** 1995 Dec;116(8):3087-92
Lack of anticonvulsant tolerance and benzodiazepine receptor down regulation with imidazenil in rats. Zanotti A, et al. **Br J Pharmacol** 1996 Feb;117(4):647-52
The effect of anti-epileptic drugs on visual perception in patients with epilepsy. Paulus W, et al. **Brain** 1996 Apr;119 (Pt 2):539-49
Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding. Tasaki K, et al. **Brain Dev** 1995 May-Jun;17(3):182-5
The neurosteroid 3 alpha, 5 apha-THP has antiseizure and possible neuroprotective effects in an animal model of epilepsy. Frye CA. **Brain Res** 1995 Oct 23;696(1-2):113-20
The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Honmou O, et al. **Brain Res** 1995 Sep 18;692(1-2):273-7
Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study. Shuaib A, et al. **Brain Res** 1995 Dec 8; 702(1-2):199-206
The effects of anticonvulsant drugs on long-term potentiation (LTP) in the rat hippocampus. Lee GY, et al.
Brain Res Bull 1996;39(1):39-42
Amphetamine and vigabatrin down regulate aromatic L-amino acid decarboxylase mRNA levels. Buckland PR, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1-2):69-76
Effects of propofol and thiopentone on picrotoxin convulsive threshold in the rabbit. Hasan Z, et al.
Can J Physiol Pharmacol 1995 Jun;73(6):714-7
Weight loss in patients taking felbamate. Bergen DC, et al. **Clin Neuropharmacol** 1995 Feb;18(1):23-7
Gabapentin: pharmacokinetics, efficacy, and safety. Beydoun A, et al. **Clin Neuropharmacol** 1995 Dec;18(6):469-81 (61 ref.)
The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Iwahashi K, et al.
Clin Neuropharmacol 1995 Jun;18(3):233-6
Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Ducharme MP, et al. **Clin Pharmacol Ther** 1995 Dec;58(6):617-24
Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. Hulsman JA, et al. **Clin Pharmacol Ther** 1995 Oct; 58(4):383-9
Effects of felbamate on the pharmacokinetics of phenobarbital. Reidenberg P, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):279-87
Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Saano V, et al.
Clin Pharmacol Ther 1995 Nov;58(5):523-31
Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Wong SL, et al.
Clin Pharmacol Ther 1996 Jul;60(1):48-53
Induction of rodent hepatic drug-metabolizing enzyme activities by the novel anticonvulsant remacemide hydrochloride. Riley RJ, et al. **Drug Metab Dispos** 1995 Sep;23(9):922-8
Comparative anticonvulsant activity and neurotoxicity of 4-amino-N-(2,6-dimethylphenyl)phthalimide and prototype antiepileptic drugs in mice and rats. Bailleux V, et al. **Epilepsia** 1995 Jun;36(6):559-65
Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice. Borowicz KK, et al. **Epilepsia** 1996 Jul; 37(7):618-24
Tiagabine pharmacology in profile. Brodie MJ. **Epilepsia** 1995;36 Suppl 6:S7-S9 (18 ref.)
Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Calabresi P, et al. **Epilepsia** 1995 Oct;36(10):990-6
Comparison of antiepileptic drugs on cognitive function in newly diagnosed epileptic children: a psychometric and neurophysiological study. Chen YJ, et al. **Epilepsia** 1996 Jan;37(1):81-6
Effects of the anticonvulsant losigamone and its isomers on the GABAA receptor system. Dimpfel W, et al.
Epilepsia 1995 Oct;36(10):983-9
Anticonvulsant activity of phenobarbital and valproate against maximal electroshock in mice during chronic treatment with caffeine and caffeine discontinuation. Gasior M, et al. **Epilepsia** 1996 Mar;37(3):262-8
Pharmacology of cortical epileptic afterdischarges in rats. Kubova H, et al. **Epilepsia** 1996 Apr;37(4):336-41
Antiepileptic drug mechanisms of action. Macdonald RL, et al. **Epilepsia** 1995;36 Suppl 2:S2-12 (112 ref.)
Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Nakamura F, et al. **Epilepsia** 1996 Aug; 37(8):728-35
Anticonvulsant efficacy of ADCI (5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine) after acute and chronic dosing in mice. Rogawski MA, et al. **Epilepsia** 1995 Jun;36(6):566-71
Failure of chronic treatment with abecarnil to induce contigent and noncontingent tolerance in pentylenetetrazol-kindled rats. Serra M, et al. **Epilepsia** 1996 Apr;37(4):332-5
Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Stefani A, et al. **Epilepsia** 1995 Oct;36(10):997-1002
Comparative effects of valproate and the new experimental anticonvulsant drug alpha-ethyl-alpha-methyl-thiobutyrolactone on selected metabolite levels in the plasma, livers, and brains of infant mice. Thurston JH, et al. **Epilepsia** 1996 Jan;37(1):2-5
Influence of D-cycloserine on the anticonvulsant activity of phenytoin and carbamazepine against electroconvulsions in mice. Wlaź P, et al. **Epilepsia** 1996 Jul;37(7):610-7
Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. Ben-Menachem E, et al. **Epilepsy Res** 1995 Jul;21(3):231-6
Selective suppression of in vitro electrographic seizures by low-dose tetrodotoxin: a novel anticonvulsant effect. Burack MA, et al. **Epilepsy Res** 1995 Oct;22(2):115-26
Effects of the GABA-uptake inhibitor tiagabine on electroencephalogram, spike-wave discharges and behaviour of rats. Coenen AM, et al. **Epilepsy Res** 1995 Jun;21(2):89-94
Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Goldlust A, et al. **Epilepsy Res** 1995 Sep;22(1):1-11
Effects of anticonvulsants in a novel operant learning paradigm in rats: comparison of remacemide hydrochloride and FPL 15896AR to other anticonvulsant agents. Hudzik TJ, et al. **Epilepsy Res** 1995 Jul;21(3):183-93
Effects of chronic tiagabine treatment on [3H]GABAA, [3H]GABAB and [3H]tiagabine binding to sections from mice brain. Thomsen C, et al. **Epilepsy Res** 1995 Jun; 21(2):79-88
Effect of sodium valproate on renal cell brush-border enzymes in rats. Cepelak I, et al.
Eur J Clin Chem Clin Biochem 1995 Oct;33(10):673-7
Effects of 5, 5'-diphenylhydantoin on the thyroid status in rats. Schröder-van der Elst JP, et al. **Eur J Endocrinol** 1996 Feb;134(2):221-4
Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Adami M, et al.
Eur J Pharmacol 1995 Dec 29;294(2-3):383-9
Differentiation of in vivo effects of AMPA and NMDA receptor ligands using drug discrimination methods and convulsant/anticonvulsant activity. Arnt J, et al.
Eur J Pharmacol 1995 Oct 24;285(3):289-97
The non-competitive AMPA/kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics. Borowicz KK, et al.
Eur J Pharmacol 1995 Aug 15;281(3):319-26
GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice. de Sarro G, et al.
Eur J Pharmacol 1995 Dec 29;294(2-3):411-22
Antimyoclonic effect of gabapentin in a posthypoxic animal model of myoclonus. Kanthasamy AG, et al.
Eur J Pharmacol 1996 Feb 22;297(3):219-24
ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo. Margineanu DG, et al. **Eur J Pharmacol** 1995 Nov 24;286(3):321-5
Differential effects of phenytoin and sodium valproate on seizure-induced changes in gamma-aminobutyric acid and glutamate release in vivo. Rowley HL, et al.
Eur J Pharmacol 1995 Dec 29;294(2-3):541-6
Felbamate neuroprotection against CA1 traumatic neuronal injury. Wallis RA, et al. **Eur J Pharmacol** 1995 Dec 29; 294(2-3):475-82
Loreclezole modulates [35S]t-butylbicyclophosphorothionate and [3H]flunitrazepam binding via a distinct site on the GABAA receptor complex. Xue BG, et al.
Eur J Pharmacol 1996 Apr 4;300(1-2):125-30
YM90K, an AMPA antagonist, has no neurotoxic effects on cerebrocortical neurons in rats. Izumisawa N, et al.
Exp Neurol 1995 Aug;134(2):199-204
Effect of sodium valproate on the spontaneous contractile and bioelectric activity of smooth muscle fibres isolated from experimental animals. Kristev A, et al.
Folia Med (Plovdiv) 1994;36(3):11-9
Phenytoin-induced glutathione depletion in rat peripheral nerve. Raya A, et al. **Free Radic Biol Med** 1995 Nov; 19(5):665-7
Comparative evaluation of anticonvulsant activity of calcium channel blockers in experimental animals. Desai CK, et al. **Indian J Exp Biol** 1995 Dec;33(12):931-4
Anticonvulsant activity of Albizzia lebbeck leaves. Kasture VS, et al. **Indian J Exp Biol** 1996 Jan;34(1):78-80
Pentylenetetrazol-induced kindling in animals: protective effect of BR-16A. Kulkarni SK, et al.
Indian J Exp Biol 1995 Jun;33(6):424-7
Antiepileptic drugs and mechanisms of epileptogenesis. A review. Mutani R, et al. **Ital J Neurol Sci** 1995 May; 16(4):217-22 (51 ref.)
Ethnopharmacology of bear gall bladder: I. Li YW, et al.
J Ethnopharmacol 1995 Jun 23;47(1):27-31
Effects of an ethanolic extract of Desmodium adscendens on central nervous system in rodents. N'gouemo P, et al.
J Ethnopharmacol 1996 Jun;52(2):77-83
Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives. Choi D, et al. **J Med Chem** 1996 Apr 26;39(9):1907-16
Synthesis and anticonvulsant activity of N-benzylpyrrolo[2,3-d]-, -pyrazolo[3,4-d]-, and -triazolo[4,5-d]pyrimidines: imidazole ring-modified analogues of 9-(2-fluorobenzyl)-6-(methylamino)-9H-purine. Kelley JL, et al. **J Med Chem** 1995 Sep 15;38(19):3884-8
3,3-Dialkyl- and 3-alkyl-3-benzyl-substituted 2-pyrrolidinones: a new class of anticonvulsant agents. Reddy PA, et al. **J Med Chem** 1996 Apr 26;39(9):1898-906
Recovery from mivacurium-induced neuromuscular blockade is not affected by anticonvulsant therapy. Jellish WS, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):4-8
Modulation of seizure activity in mice by metabotropic glutamate receptor ligands. Dalby NO, et al.
J Pharmacol Exp Ther 1996 Feb;276(2):516-22
Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells. Hough CJ, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):143-9
Felbamate relieves several abnormal pain sensations in rats with an experimental peripheral neuropathy. Imamura Y, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):177-82
Felbamate inhibits [3H]t-butylbicycloorthobenzoate (TBOB) binding and enhances Cl- current at the gamma-aminobutyric AcidA (GABAA) receptor. Kume A, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1784-92
Effects of felbamate on muscarinic and metabotropic-glutamate agonist-mediated responses and magnesium-free or 4-aminopyridine-induced epileptiform activity in guinea pig olfactory cortex neurons in vitro. Libri V, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1759-69
YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist. Shimizu-Sasamata M, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):84-92
Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. Stefani A, et al.
J Pharmacol Exp Ther 1996 Apr;277(1):121-7
Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. Subramaniam S, et al.
J Pharmacol Exp Ther 1996 Jan;276(1):161-8
Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX). Swedberg MD, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1113-21
Studies of Qingyangshen (II): modulatory effect of co-treatment with qingyangshen and diphenylhydantoin sodium on rat hippocampal c-fos expression during seizures. Guo Q, et al. **J Tradit Chin Med** 1996 Mar; 16(1):48-50

Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine. A paradox resolved. Surks MI, et al. **JAMA** 1996 May 15; 275(19):1495–8

Actions of nipecotic acid and SKF89976A on GABA transporter in cone-driven horizontal cells dissociated from the catfish retina. Takahashi K, et al. **Jpn J Physiol** 1995; 45(3):457–73

Neurochemical correlates of antiepileptic drugs in the genetically epilepsy-prone rat (GEPR). Dailey JW, et al. **Life Sci** 1995;58(4):259–66 (49 ref.)

Effects of felbamate, kynurenic acid derivatives and NMDA antagonists on in vitro kainate-induced epileptiform activity. Domenici MR, et al. **Life Sci** 1996 May 24; 58(26):PL391–6

Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. Edmonds HL Jr, et al. **Life Sci** 1996;59(10):PL127–31

Diazepam pretreatment suppresses morphine withdrawal signs in the mouse. Suzuki T, et al. **Life Sci** 1995; 58(4):349–57

AQ-0145, a newly developed histamine H3 antagonist, decreased seizure susceptibility of electrically induced convulsions in mice. Murakami K, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:70–3

Motor alterations and neuronal damage induced by intracerebral administration of Ruthenium red: effect of NMDA receptor antagonists and other anticonvulsant drugs. Belmar E, et al. **Mol Chem Neuropathol** 1995 Dec; 26(3):285–99

Inhibition by carbamazepine of various ion channels-mediated catecholamine secretion in cultured bovine adrenal medullary cells. Yoshimura R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):297–303

L-lysine is a barbiturate-like anticonvulsant and modulator of the benzodiazepine receptor. Chang YF, et al. **Neurochem Res** 1995 Aug;20(8):931–7

Effect of chronic administration of phenytoin on regional monoamine levels in rat brain. Meshkibaf MH, et al. **Neurochem Res** 1995 Jul;20(7):773–8

Pharmacology and pharmacokinetics of fosphenytoin. Browne TR, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S3–7 (48 ref.)

Cognitive effects of vigabatrin: a review. Monaco F. **Neurology** 1996 Jul;47(1 Suppl 1):S6–11 (71 ref.)

Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Waldmeier PC, et al. **Neurology** 1995 Oct;45(10):1907–13

Effect of anticonvulsant drugs on peripheral benzodiazepine receptors of human lymphocytes. Ferrarese C, et al. **Neuropharmacology** 1995 Apr;34(4):427–31

Influence of BAY k-8644, a calcium channel agonist, on the anticonvulsant activity of conventional anti-epileptics against electroconvulsions in mice. Gasior M, et al. **Neuropharmacology** 1995 Apr;34(4):433–8

Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Parsons CG, et al. **Neuropharmacology** 1995 Oct; 34(10):1239–58

Effect of lamotrigine on the electrically-evoked release of endogenous amino acids from slices of dorsal horn of the rat spinal cord. Teoh H, et al. **Neuropharmacology** 1995 Oct;34(10):1273–8

Effects of remacemide and its metabolite FPL 12495 on spike-wave discharges, electroencephalogram and behaviour in rats with absence epilepsy. van Luijtelaar EL, et al. **Neuropharmacology** 1995 Apr;34(4):419–25

The severity of naloxone-precipitated opiate withdrawal is attenuated by felbamate, a possible glycine antagonist. Kosten TA, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):323–33

Effects of phenytoin on the persistent Na+ current of mammalian CNS neurones. Chao TI, et al. **Neuroreport** 1995 Sep 11;6(13):1778–80

Benzodiazepine antagonist flumazenil reduces hippocampal epileptiform activity. Polc P, et al. **Neuroreport** 1995 Jul 31;6(11):1549–52

Influence of dilantin on the reactions of neurons of the sensorimotor cortex and hippocampus during learning. Shul'gina GI. **Neurosci Behav Physiol** 1995 Sep–Oct; 25(5):413–8

Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response. Dailey JW, et al. **Neurosci Lett** 1995 Aug 4;195(2):77–80

Vigabatrin protects against kainic acid-induced neuronal damage in the rat hippocampus. Halonen T, et al. **Neurosci Lett** 1995 Jul 28;195(1):13–6

Effects of losigamone on synaptic potentials and spike frequency habituation in rat entorhinal cortex and hippocampal CA1 neurones. Schmitz D, et al. **Neurosci Lett** 1995 Nov 17;200(2):141–3

Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones. Xie X, et al. **Pflugers Arch** 1995 Jul;430(3):437–46

Pharmacokinetics and anticonvulsant effect of a new hypnotic, CL 284,846, in rats. Gaudreault J, et al. **Pharm Res** 1995 Nov;12(11):1592–7

Tolerance to the anticonvulsant and ataxic effects of pentobarbital: effect of an ascending-dose regimen. Kim CK, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):825–9

Contingent drug tolerance: differential tolerance to the anticonvulsant, hypothermic, and ataxic effects of ethanol. Kim CK, et al. **Pharmacol Biochem Behav** 1995 Nov; 52(3):531–9

Suppression of cortical epileptic afterdischarges by ketamine is not stable during ontogenesis in rats. Kubová H, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):489–92

Antagonism of isoniazid-induced convulsions by abecarnil in mice tolerant to diazepam. Serra M, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):249–54

Antiabsence seizure activity of specific GABAB and gamma-Hydroxybutyric acid receptor antagonists. Snead OC 3rd. **Pharmacol Biochem Behav** 1996 Jan;53(1):73–9

Phenobarbital in the anticonvulsant dose range does not impair learning and memory or alter brain AChE activity or monoamine levels. Sudha S, et al. **Pharmacol Biochem Behav** 1996 Jul;54(3):633–8

Age-dependent anticonvulsant action of clonazepam in the N-methyl-D-aspartate model of seizures. Velišek L, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):291–6

NMDA antagonists: antiepileptic-neuroprotective drugs with diversified neuropharmacological profiles. Sagratella S. **Pharmacol Res** 1995 Jul–Aug;32(1–2):1–13 (124 ref.)

Anticonvulsant activity of aryl and hetarylsulfonylhydrazones. Darias V, et al. **Pharmazie** 1995 Nov;50(11):756–8

Search for new anticonvulsant compounds. Part 1: Synthesis, physicochemical and anticonvulsant properties of new derivatives of alpha-amino-gamma-phthalimidobutyric acid. Malawska B, et al. **Pharmazie** 1995 Nov;50(11):722–5

Blockade of the discriminative stimulus effects of gamma-hydroxybutyric acid (GHB) by the GHB receptor antagonist NCS-382. Colombo G, et al. **Physiol Behav** 1995 Sep;58(3):587–90

Excitatory amino acid antagonists and the anticonvulsive activity of conventional antiepileptic drugs. Kleinrok Z, et al. **Pol J Pharmacol** 1995 May–Jun;47(3):247–52 (47 ref.)

Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain. Strolin Benedetti M, et al. **Prog Brain Res** 1995; 106:123–34

Enhancement of acetylcholine release by flumazenil in the hippocampus of rats chronically treated with diazepam but not with imidazenil or abecarnil. Dazzi L, et al. **Psychopharmacology (Berl)** 1995 Sep;121(2):180–5

Bretazenil modulates sleep EEG and nocturnal hormone secretion in normal men. Guldner J, et al. **Psychopharmacology (Berl)** 1995 Nov;122(2):115–21

Discriminative stimulus effects of midazolam and abecarnil in rats treated chronically with diazepam or abecarnil. Lytle DA, et al. **Psychopharmacology (Berl)** 1995 Oct; 121(3):339–46

Convulsive properties of N-(3,5-dimethoxy-4-propoxyphenyl-ethyl) aziridine and their influencing by diazepam and triazolam. Herink J. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(2):85–8

Dissociation of synchronization and excitability in furosemide blockade of epileptiform activity. Hochman DW, et al. **Science** 1995 Oct 6;270(5233):99–102

Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Finnell RH, et al. **Teratology** 1995 Dec;52(6):324–32

Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Otani K, et al. **Ther Drug Monit** 1996 Apr;18(2):164–7

Phenobarbital induces the 2-hydroxylation of desipramine. Spina E, et al. **Ther Drug Monit** 1996 Feb;18(1):60–4

[Effect of DL-butylphthalide (NBP) on mouse brain energy metabolism in complete brain ischemia induced by decapitation] Feng YP, et al. **Yao Hsueh Hsueh Pao** 1995; 30(10):741–4 (Eng. Abstr.) **(Chi)**

[The role of adrenergic mechanisms in the anticonvulsive action of the new preparation acetylaminoazaleptin] Tregubov AL. **Eksp Klin Farmakol** 1996 Jan–Feb; 59(1):19–20 (Eng. Abstr.) **(Rus)**

[The mechanism of the anticonvulsive effect of the delta sleep-inducing peptide under conditions of elevated oxygen pressure] Mendzheritskiĭ AM, et al. **Fiziol Zh Im I M Sechenova** 1996 Jan;82(1):59–64 (Eng. Abstr.) **(Rus)**

[The effect of the intranigral use of the delta sleep-inducing peptide and its analogs on the motor and seizure activities of rats] Shandra AA, et al. **Fiziol Zh Im I M Sechenova** 1995 Feb;81(2):1–6 (Eng. Abstr.) **(Rus)**

[Increase of human resistance to the effects of high ambient temperatures by using drugs] Pastushenkov VA, et al. **Med Tr Prom Ekol** 1995;(9):39–42 **(Rus)**

[The effects of phenobarbital, valproic acid and carbamazepine on the serum lipids and lipoproteins in a pediatric population] de Juan Frigola J, et al. **An Esp Pediatr** 1996 Feb;44(2):133–8 (Eng. Abstr.) **(Spa)**

[Study of the influence of anticonvulsant treatment on thyroid function] Gonzalez IG, et al. **An Med Interna** 1995 Dec;12(12):593–6 (Eng. Abstr.) **(Spa)**

[Vecuronium resistance induced by chronic phenobarbital treatment (letter)] Herrero E, et al. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):113–4 **(Spa)**

[Interaction of sleep, epilepsy and antiepileptic drugs in an adult] Salas Puig J. **Rev Neurol** 1995 Nov–Dec; 23(124):1287–9 (10 ref.) **(Spa)**

POISONING

Treatment of acute carbamazepine poisoning by hemoperfusion [letter] Low CL, et al. **Am J Emerg Med** 1996 Sep;14(5):540–1

Amiodarone and phenytoin: interaction [letter] Ahmad S. **J Am Geriatr Soc** 1995 Dec;43(12):1449–50

Bromide toxicosis secondary to renal insufficiency in an epileptic dog. Nichols ES, et al. **J Am Vet Med Assoc** 1996 Jan 15;208(2):231–3

Iatrogenic magnesium overdose: two case reports. Vissers RJ, et al. **J Emerg Med** 1996 Mar–Apr;14(2):187–91

Gabapentin, valproic acid, and ethanol intoxication: elevated blood levels with mild clinical effects. Fernández MC, et al. **J Toxicol Clin Toxicol** 1996;34(4):437–9

Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion. Graudins A, et al. **J Toxicol Clin Toxicol** 1996;34(3):335–41

Hypoglycemia associated with phenytoin intoxication. Manto M, et al. **J Toxicol Clin Toxicol** 1996;34(2):205–8

Felbamate overdose: a case report and discussion of a new antiepileptic drug. Nagel TR, et al. **Pediatr Emerg Care** 1995 Dec;11(6):369–71

Phenytoin toxicity due to concomitant antituberculosis therapy. Walubo A, et al. **S Afr Med J** 1995 Nov; 85(11):1175–6

THERAPEUTIC USE

Sodium valproate in severe migraine and tension-type headache: an open study of long-term efficacy and correlation with blood levels. Lenaerts M, et al. **Acta Neurol Belg** 1996 Jun;96(2):126–9

Effectiveness and tolerance of clobazam in temporal lobe epilepsy. Barcs G, et al. **Acta Neurol Scand** 1996 Feb–Mar; 93(2–3):88–93

Lamotrigine in the treatment of absence seizures [letter] Buchanan N. **Acta Neurol Scand** 1995 Oct;92(4):348

Lamotrigine: clinical experience in 93 patients with epilepsy. Buchanan N. **Acta Neurol Scand** 1995 Jul;92(1):28–32

Gabapentin in refractory partial epilepsy--a trial in India. Dixit SN, et al. **Acta Neurol Scand** 1996 Feb–Mar; 93(2–3):85–7

Rationalized polytherapy for epilepsy. Goldsmith P, et al. **Acta Neurol Scand Suppl** 1995;162:35–9 (27 ref.)

Vigabatrin as first add-on treatment in carbamazepine-resistant epilepsy patients. Murri L, et al. **Acta Neurol Scand Suppl** 1995;162:40–2

Pharmacological principles as a basis for polytherapy. Perucca E. **Acta Neurol Scand Suppl** 1995;162:31–4 (16 ref.)

A case of West syndrome with atypical massive gray matter heterotopia that is well controlled by ACTH therapy. Kuwahara M, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):274–7

Clinical use of drugs useful in the treatment of atonic seizures. Bourgeois B. **Adv Neurol** 1995;67:361–7 (42 ref.)

Clinical physiological study of the therapeutic effects of phenytoin in acute alcohol withdrawal and the asthenic-autonomic syndrome in patients with chronic alcoholism. Ilyuchina VA, et al. **Alcohol** 1995 Nov–Dec; 12(6):511–7

Second-line and 'alternative' treatments for alcohol withdrawal: alpha-agonists, beta-blockers, anticonvulsants, acupuncture and neuro-electric therapy. Brewer C. **Alcohol Alcohol** 1995 Nov;30(6):799–803 (25 ref.)

The management of alcohol withdrawal using chlormethiazole. Morgan MY. **Alcohol Alcohol** 1995 Nov; 30(6):771–4 (21 ref.)

The irreversible gamma-aminobutyrate transaminase inhibitor vigabatrin in the treatment of the alcohol withdrawal syndrome [letter] Stuppaeck CH, et al. **Alcohol Alcohol** 1996 Jan;31(1):109–11

Does magnesium sulfate affect the length of labor induction in women with pregnancy-associated hypertension? Atkinson MW, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1219–22

The feasibility of a control population for a randomized control trial of seizure prophylaxis in the hypertensive disorders of pregnancy [see comments] Burrows RF, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):929–35. Comment in: Am J Obstet Gynecol 1996 Feb;174(2):800–1.

Antidepressant effects of lamotrigine in rapid cycling bipolar disorder [letter] Calabrese JR, et al. **Am J Psychiatry** 1996 Sep;153(9):1236

Practical considerations in anticonvulsant therapy—Part 2. Meyer MC, et al. **Am Pharm** 1995 Sep;NS35(9):31–6, 40

Drugs in status epilepticus [letter; comment] Dimpel HL. **Anaesthesia** 1995 Sep;50(9):824–6. Comment on: Anaesthesia 1995 Feb;50(2):130–5.

Drugs in status epilepticus [letter] James MF. **Anaesthesia** 1996 Mar;51(3):290

Propofol in the management of myoclonus syndrome induced by chloralose poisoning [letter] Quinio P, et al. **Anesthesiology** 1995 Oct;83(4):875

Divalproex sodium as a treatment for borderline personality disorder. Wilcox JA. **Ann Clin Psychiatry** 1995 Mar;

7(1):33–7
Potential use of gabapentin and lamotrigine. Cory PR, et al. **Ann Pharmacother** 1995 Nov;29(11):1160–1 (10 ref.)
Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Gattis WA, et al. **Ann Pharmacother** 1996 May;30(5):520–6 (20 ref.)
Weight gain and gabapentin therapy [letter] Gidal BE, et al. **Ann Pharmacother** 1995 Oct;29(10):1048
Valproate in status epilepticus. Holle LM, et al. **Ann Pharmacother** 1995 Oct;29(10):1042–4
Acetazolamide in the treatment of seizures. Reiss WG, et al. **Ann Pharmacother** 1996 May;30(5):514–9 (68 ref.)
Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis. Welty DF, et al. **Ann Pharmacother** 1995 Nov;29(11):1164–7
Long term outcome of prophylaxis for febrile convulsions. Knudsen FU, et al. **Arch Dis Child** 1996 Jan;74(1):13–8
Reduction of fasciculations in patients with amyotrophic lateral sclerosis with the use of gabapentin [letter] Romano JG. **Arch Neurol** 1996 Aug;53(8):716
Eclamptic seizures, magnesium, and semantics [letter] Sheth RD, et al. **Arch Neurol** 1996 Feb;53(2):122
Magnesium sulphate should be used for eclamptic fits [letter; comment] [see comments] Duley L. **BMJ** 1996 Mar 9; 312(7031):639. Comment on: BMJ 1995 Nov 25;311(7017):1433. Comment in: BMJ 1996 Jun 29;312(7047):1669–70.
Diazepam is more useful than magnesium for immediate control of eclampsia [letter; comment] Fox R, et al. **BMJ** 1996 Jun 29;312(7047):1669–70. Comment on: BMJ 1996 Mar 9;312(7031):639.
Prefer diazepam for initial control of pre–eclamptic fits [letter; comment] [see comments] Fox R, et al. **BMJ** 1995 Nov 25;311(7017):1433. Comment on: BMJ 1995 Sep 16;311(7007):702–3. Comment in: BMJ 1996 Mar 9;312(7013):639.
Anticonvulsant drugs for management of pain: a systematic review. McQuay H, et al. **BMJ** 1995 Oct 21; 311(7012):1047–52 (53 ref.)
Magnesium sulphate: the drug of choice in eclampsia [editorial] [see comments] Neilson JP. **BMJ** 1995 Sep 16; 311(7007):702–3. Comment in: BMJ 1995 Nov 25;311(7017):1433.
Management of epilepsy in pregnancy: therapeutic aspects. Rutherford JM, et al. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):620–2
Magnesium sulphate regimens for women with eclampsia: messages from the Collaborative Eclampsia Trial. Duley L. **Br J Obstet Gynaecol** 1996 Feb;103(2):103–5
The magnesium sulphate story [editorial; comment] Grant JM. **Br J Obstet Gynaecol** 1996 Feb;103(2):vii–viii. Comment on: Br J Obstet Gynaecol 1996 Feb;103(2):99–102.
Randomised study assessing the effect of phenytoin and magnesium sulphate on maternal cerebral circulation in eclampsia using transcranial Doppler ultrasound. Naidu S, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):111–6
Magnesium sulphate: the time of reckoning [see comments] Robson SC. **Br J Obstet Gynaecol** 1996 Feb;103(2):99–102 (30 ref.). Comment in: Br J Obstet Gynaecol 1996 Feb;103(2):vii–viii.
Successful treatment of tardive dystonia with clozapine and clonazepam. Shapleske J, et al. **Br J Psychiatry** 1996 Apr; 168(4):516–8
Treatment of electrical status epilepticus by short diazepam (DZP) cycles after DZP rectal bolus test. De Negri M, et al. **Brain Dev** 1995 Sep–Oct;17(5):330–3
Reduction of seizure frequency with clomipramine in patients with complex partial seizures. Sakakihara Y, et al. **Brain Dev** 1995 Jul–Aug;17(4):291–3
Open label trial with vigabatrin in children with intractable epilepsy. Wong V. **Brain Dev** 1995 Jul–Aug;17(4):249–52
Effects of carbamazepine and valproate on brainstem auditory evoked potentials in epileptic children. Yuksel A, et al. **Childs Nerv Syst** 1995 Aug;11(8):474–7
New drugs for the treatment of epilepsy. Fraser AD. **Clin Biochem** 1996 Apr;29(2):97–110 (114 ref.)
The use of felbamate in patients with periodic lateralized epileptiform discharges (PLEDs). Hughes JR, et al. **Clin Electroencephalogr** 1995 Jul;26(3):180–3
Routine use of lamotrigine, a new anti–epileptic medication, and the value of measuring its blood levels. Beran RG, et al. **Clin Exp Neurol** 1994;31:61–7
Gabapentin for the treatment of hemifacial spasm. Patel J, et al. **Clin Neuropharmacol** 1996 Apr;19(2):185–8
Midazolam in the treatment of refractory neonatal seizures. Sheth RD, et al. **Clin Neuropharmacol** 1996 Apr; 19(2):165–70
The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Eadie MJ. **Clin Pharmacokinet** 1995 Jul;29(1):29–35 (26 ref.)
Phenytoin in the treatment of cocaine abuse: a double–blind study. Crosby RD, et al. **Clin Pharmacol Ther** 1996 Apr; 59(4):458–68
Efficacy and tolerability of gabapentin in clinical practice. Morris GL 3rd. **Clin Ther** 1995 Sep–Oct;17(5):891–900
Update in the treatment of epilepsy. Schachter SC. **Compr Ther** 1995 Sep;21(9):473–9 (7 ref.)
The treatment of infantile spasms by paediatric neurologists in the UK and Ireland [letter] Appleton RE. **Dev Med Child Neurol** 1996 Mar;38(3):278–9
Carbamazepine treatment for cocaine dependence [see comments] Cornish JW, et al. **Drug Alcohol Depend** 1995 Jun;38(3):221–7. Comment in: Drug Alcohol Depend 1995 Jun;38(3):201–2.
Why publish three negative articles on carbamazepine as a medication for the treatment of cocaine dependence? [editorial; comment] Johanson CE. **Drug Alcohol Depend** 1995 Jun;38(3):201–2. Comment on: Drug Alcohol Depend 1995 Jun;38(3):203–11. Comment on: Drug Alcohol Depend 1995 Jun;38(3):213–9. Comment on: Drug Alcohol Depend 1995 Jun;38(3):221–7.
Carbamazepine treatment of cocaine dependence: a placebo–controlled trial [see comments] Kranzler HR, et al. **Drug Alcohol Depend** 1995 Jun;38(3):203–11. Comment in: Drug Alcohol Depend 1995 Jun;38(3):201–2.
Double–blind comparison of carbamazepine and placebo for treatment of cocaine dependence [see comments] Montoya ID, et al. **Drug Alcohol Depend** 1995 Jun;38(3):213–9. Comment in: Drug Alcohol Depend 1995 Jun;38(3):201–2.
Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Fitton A, et al. **Drugs** 1995 Oct; 50(4):691–713 (175 ref.)
Tiagabine: The Art of Epilepsy Care. Proceedings of a satellite symposium to the 21st International Epilepsy Congress. Syndney, Australia, September 2, 1995. **Epilepsia** 1995;36 Suppl 6:S1–26
Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Aicardi J, et al. **Epilepsia** 1996 Jul; 37(7):638–42
International experience with tiagabine add–on therapy. Ben–Menachem E. **Epilepsia** 1995;36 Suppl 6:S14–S21
Expanding antiepileptic drug options: clinical efficacy of new therapeutic agents. Ben–Menachem E. **Epilepsia** 1996;37 Suppl 2:S4–S7
Double–blind, placebo–controlled trial of topiramate as add–on therapy in patients with refractory partial seizures. Ben–Menachem E, et al. **Epilepsia** 1996 Jun;37(6):539–43
Vigabatrin. Ben–Menachem E. **Epilepsia** 1995;36 Suppl 2:S95–104 (70 ref.)
Antiepileptic drugs in pediatric practice. Bourgeois BF. **Epilepsia** 1995;36 Suppl 2:S34–45 (100 ref.)
Comparison between one and three years of treatment in uncomplicated childhood epilepsy: a prospective study. I. Outcome in different seizure types. Braathen G, et al. **Epilepsia** 1996 Sep;37(9):822–32
Antiepileptic drug therapy: when is epilepsy truly intractable? Camfield PR, et al. **Epilepsia** 1996;37 Suppl 1:S60–5 (18 ref.)
Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Cramer J, et al. **Epilepsia** 1995 Nov;36(11):1111–7
Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single–blind dose–increasing study. Dalla Bernardina B, et al. **Epilepsia** 1995 Jul; 36(7):687–91
Rational polypharmacy. Ferrendelli JA. **Epilepsia** 1995;36 Suppl 2:S115–8 (11 ref.)
Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs. Fisher R, et al. **Epilepsia** 1995;36 Suppl 2:S105–14 (113 ref.)
Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs. French JA. **Epilepsia** 1996;37 Suppl 2:S23–S26
Families are content to discontinue antiepileptic drugs at different risks than their physicians. Gordon K, et al. **Epilepsia** 1996 Jun;37(6):557–62
Epilepsy care: image of the future. Gram L. **Epilepsia** 1995; 36 Suppl 6:S22–S24
Neuropharmacology and drug interactions in clinical practice. Graves NM. **Epilepsia** 1995;36 Suppl 2:S27–33 (20 ref.)
Systematic testing of medical intractability for carbamazepine, phenytoin, and phenobarbital or primidone in monotherapy for patients considered for epilepsy surgery. Hermanns G, et al. **Epilepsia** 1996 Jul;37(7):675–9
Concentration–-effect and concentration–-toxicity relations with lamotrigine: a prospective study. Kilpatrick ES, et al. **Epilepsia** 1996 Jun;37(6):534–8
Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving antiepileptic drug therapy. Kürekçi AE, et al. **Epilepsia** 1995 Jun;36(6):600–4
Felbamate. Leppik IE. **Epilepsia** 1995;36 Suppl 2:S66–72 (55 ref.)
Gabapentin. McLean MJ. **Epilepsia** 1995;36 Suppl 2:S73–86 (70 ref.)
Efficacy and adverse effects of established and new antiepileptic drugs. Mattson RH. **Epilepsia** 1995;36 Suppl 2:S13–26 (108 ref.)
Lamotrigine. Messenheimer JA. **Epilepsia** 1995;36 Suppl 2:S87–94 (64 ref.)
Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. Mitchell WG. **Epilepsia** 1996;37 Suppl 1:S74–80 (53 ref.)
Utilization of new antiepileptic drugs in children. Pellock JM. **Epilepsia** 1996;37 Suppl 1:S66–73 (40 ref.)
Tiagabine monotherapy in the treatment of partial epilepsy. Schachter SC. **Epilepsia** 1995;36 Suppl 6:S2–S6
Chemical kindling: implications for antiepileptic drugs – sensitive and resistant epilepsy models. Shandra AA, et al. **Epilepsia** 1996 Mar;37(3):269–74
Does antiepileptic drug therapy prevent the development of "chronic" epilepsy? Shinnar S, et al. **Epilepsia** 1996 Aug; 37(8):701–8 (92 ref.)
The epidemiology and treatment of chronic and refractory epilepsy. Shorvon SD. **Epilepsia** 1996;37 Suppl 2:S1–S3 (6 ref.)
Zonisamide: electrophysiological and metabolic changes in kainic acid–induced limbic seizures in rats. Takano K, et al. **Epilepsia** 1995 Jul;36(7):644–8
Double–blind, placebo–controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Tassinari CA, et al. **Epilepsia** 1996 Aug;37(8):763–8
Felbamate monotherapy: implications for antiepileptic drug development. Theodore WH, et al. **Epilepsia** 1995 Nov; 36(11):1105–10
Thyroid status of patients receiving long–term anticonvulsant therapy assessed by peripheral parameters: a placebo–controlled thyroxine therapy trial. Tiihonen M, et al. **Epilepsia** 1995 Nov;36(11):1118–25
Treatment with vigabatrin may mimic alpha–aminoadipic aciduria. Vallat C, et al. **Epilepsia** 1996 Aug;37(8):803–5
Age–dependent effects of gamma–aminobutyric acid agents on flurothyl seizures. Velíšek L, et al. **Epilepsia** 1995 Jul; 36(7):636–43
Anticonvulsant therapy in the elderly–-a need for placebo controlled trials. Cameron H, et al. **Epilepsy Res** 1995 Jun; 21(2):149–57
Retrospective study of vigabatrin and psychiatric behavioural disturbances. Wong IC. **Epilepsy Res** 1995 Jul;21(3):227–30
Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. Bareggi SR, et al. **Eur J Clin Pharmacol** 1995;48(3–4):265–8
Factors predicting the risk of relapse after antiepileptic drug discontinuation in children with partial seizures. Donati F, et al. **Eur J Pediatr** 1995;154(9 Suppl 4):S44–7
Prophylaxis of epilepsy. Minchev D. **Folia Med (Plovdiv)** 1995;37(4A Suppl):82
Clonazepam prophylaxis and busulfan–related myoclonic epilepsy in autografted acute leukemia patients. Meloni G, et al. **Haematologica** 1995 Nov–Dec;80(6):532–4
Divalproex sodium and other medications for headache following craniotomy for acoustic neuroma. Hendler N, et al. **Headache** 1995 Sep;35(8):490–3
Carbamazepine augmentation therapy in three patients with trazodone–resistant unipolar depression. Otani K, et al. **Int Clin Psychopharmacol** 1996 Mar;11(1):55–7
Medical options in the treatment of generalised seizures in adults [editorial] Callaghan N. **Ir Med J** 1995 Nov–Dec; 88(6):193, 195
The new anti–epileptic drugs [editorial] Murphy R. **Ir Med J** 1995 Nov–Dec;88(6):198–9
The management of partial seizures [editorial] Redmond J. **Ir Med J** 1996 Mar–Apr;89(2):54
The use of sodium valproate in the treatment of alcoholism. Minuk GY, et al. **J Addict Dis** 1995;14(2):67–74
Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. Aman MG, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1672–81
Carbamazepine hypersensitivity [letter] Bellman B, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1405–6
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1262–72 (138 ref.)
Managing patients who have seizure disorders: dental and medical issues. Sanders BJ, et al. **J Am Dent Assoc** 1995 Dec;126(12):1641–7 (18 ref.)
High dietary chloride content associated with loss of therapeutic serum bromide concentrations in an epileptic dog. Shaw N, et al. **J Am Vet Med Assoc** 1996 Jan 15; 208(2):234–6
Withdrawal of antiepileptic drugs in epileptics [letter] Garg R. **J Assoc Physicians India** 1995 Jul;43(7):518
Nitrazepam for refractory infantile spasms and the Lennox–Gastaut syndrome. Chamberlain MC. **J Child Neurol** 1996 Jan;11(1):31–4
Valproic acid treatment of learning disorder and severely epileptiform EEG without clinical seizures. Gordon K, et al. **J Child Neurol** 1996 Jan;11(1):41–3
Combination therapy of infantile spasms with high–dose pyridoxal phosphate and low–dose corticotropin. Takuma Y, et al. **J Child Neurol** 1996 Jan;11(1):35–40
Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. Gidal BE, et al. **J Clin Pharm Ther** 1995 Aug;20(4):215–9
Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses. Puryear LJ, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8(4):234–7
Anticonvulsant and other non–neuroleptic treatment of agitation in dementia. Tariot PN, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S28–39 (103 ref.)
Gabapentin for seizure control in organ transplant recipients [letter] Warner EG. **J Heart Lung Transplant** 1995 Sep–Oct;14(5):1011
Folinic acid responsive seizures: a new syndrome? Hyland K, et al. **J Inherit Metab Dis** 1995;18(2):177–81
Riboflavin–responsive epilepsy in a patient with SER209 variant form of short–chain acyl–CoA dehydrogenase.

Kmoch S, et al. **J Inherit Metab Dis** 1995;18(2):227–9
Noncompliance [letter] Hargrave R, et al.
J Natl Med Assoc 1996 Jan;88(1):7, 11
Withdrawal of antiepileptic drug treatment in childhood epilepsy: factors related to age. Murakami M, et al.
J Neurol Neurosurg Psychiatry 1995 Nov;59(5):477–81
Simple partial status epilepticus: causes, treatment, and outcome in 47 patients. Scholtes FB, et al.
J Neurol Neurosurg Psychiatry 1996 Jul;61(1):90–2
Non-convulsive status epilepticus: causes, treatment, and outcome in 65 patients. Scholtes FB, et al.
J Neurol Neurosurg Psychiatry 1996 Jul;61(1):93–5
Lamotrigine for the treatment of epilepsy in childhood. Besag FM, et al. **J Pediatr** 1995 Dec;127(6):991–7
Efficacy of gabapentin therapy in children with refractory partial seizures. Khurana DS, et al. **J Pediatr** 1996 Jun; 128(6):829–33
Diazepam to reduce recurrences of febrile seizures [letter; comment] Rosman NP. **J Pediatr** 1996 Feb;128(2):303–4. Comment on: J Pediatr 1995 Jun;126(6):929–30.
Therapy-resistant seizures in pseudohypoparathyroidism. A case report. Pollak L, et al.
J Pediatr Endocrinol Metab 1995 Jul–Sep;8(3):209–11
Characterization of the antiabsence effects of SCH 50911, a GABA-B receptor antagonist, in the lethargic mouse, gamma-hydroxybutyrate, and pentylenetetrazole models. Hosford DA, et al. **J Pharmacol Exp Ther** 1995 Sep; 274(3):1399–403
Increasing-current electroshock seizure test: a new method for assessment of anti- and pro-convulsant activities of drugs in mice. Kitano Y, et al.
J Pharmacol Toxicol Methods 1996 Feb;35(1):25–9
Acute and chronic effects of melatonin as an anticonvulsant in male gerbils. Champney TH, et al. **J Pineal Res** 1996 Mar;20(2):79–83
Does early anti-epileptic drug treatment alter the prognosis for remission of the epilepsies? O'Donoghue M, et al.
J R Soc Med 1996 May;89(5):245–8 (38 ref.)
Studies of qingyangshen (I): Differential expression of hippocampal c-fos proto-oncogene during kainic acid induced acute and chronic seizures. Guo Q, et al.
J Tradit Chin Med 1995 Dec;15(4):292–6
Shortcomings in the pharmacotherapy of epileptic children in Bombay, India. Karande SC, et al. **J Trop Pediatr** 1995 Aug;41(4):247–9
Restless legs syndrome [letter] Cochran JW, et al. **JAMA** 1996 Jan 17;275(3):187
Antiepileptic drugs, clinical trials, and the marketplace. Brodie MJ. **Lancet** 1996 Mar 23;347(9004):777–9
Taming the brain storms: felbamate updated. Brodie MJ, et al. **Lancet** 1995 Oct 7;346(8980):918–9
Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. de Silva M, et al. **Lancet** 1996 Mar 16;347(9003):709–13
Magnesium and eclampsia [letter] Duley L. **Lancet** 1995 Nov 18;346(8986):1365
Clobazam for seizure prophylaxis during busulfan chemotherapy [letter] Schwarer AP, et al. **Lancet** 1995 Nov 4;346(8984):1238
Improvement of stiff-man syndrome with vigabatrin [letter] Vermeij FH, et al. **Lancet** 1996 Aug 31;348(9027):612
Outcomes in 248 patients who had diagnostic evaluations for epilepsy surgery. Vickrey BG, et al. **Lancet** 1995 Dec 2;346(8988):1445–9
Selection of antiepileptic drugs: a practical approach. Britton JW, et al. **Mayo Clin Proc** 1996 Aug;71(8):778–86 (76 ref.)
Extending the indications of registered drugs: rectal diazepam in epilepsy [letter; comment] Wright M. **Med J Aust** 1995 Oct 16;163(8):445–6. Comment on: Med J Aust 1995 Sep 4;163(5):268–9.
Antiepileptic drugs [published erratum appears in N Engl J Med 1996 Feb 15;334(7):479] Brodie MJ, et al.
N Engl J Med 1996 Jan 18;334(3):168–75 (83 ref.)
Magnesium sulfate versus phenytoin for the prevention of eclampsia [letter] Duggan K, et al. **N Engl J Med** 1995 Dec 14;333(24):1638–9
Magnesium sulfate versus phenytoin for the prevention of eclampsia [letter] Friedman MN. **N Engl J Med** 1995 Dec 14;333(24):1638; discussion 1639
Magnesium sulfate versus phenytoin for the prevention of eclampsia [letter] Sankar R, et al. **N Engl J Med** 1995 Dec 14;333(24):1638; discussion 1639
Anticonvulsants in eclampsia: is this the final answer? George K, et al. **Natl Med J India** 1996 May-Jun;9(3):125–6
Felbamate and tremor [letter; comment] Edwards KR. **Neurology** 1995 Oct;45(10):1951. Comment on: Neurology 1995 Jan;45(1):185–7.
Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Faught E, et al. **Neurology** 1996 Jun;46(6):1684–90
Anticonvulsant effect of fluoxetine in humans [see comments] Favale E, et al. **Neurology** 1995 Oct;45(10):1926–7. Comment in: Neurology 1996 Jul;47(1):303.
Newer antiepileptic drugs as monotherapy: data on vigabatrin. Fisher R, et al. **Neurology** 1996 Jul;47(1 Suppl 1):S2–5
A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. French JA, et al. **Neurology** 1996 Jan;46(1):54–61
Use of antiepileptic drugs in a community-dwelling Dutch population. Lammers MW, et al. **Neurology** 1996 Jan; 46(1):62–7
Examining the role of vigabatrin. Mackenzie RA.
Neurology 1996 Jul;47(1 Suppl 1):S1
Parenteral antiepileptic/anticonvulsant drugs. Mattson RH.
Neurology 1996 Jun;46(6 Suppl 1):S8–13 (42 ref.)
Cognitive effects of vigabatrin: a review. Monaco F.
Neurology 1996 Jul;47(1 Suppl 1):S6–11 (71 ref.)
Fosphenytoin use in children. Pellock JM. **Neurology** 1996 Jun;46(6 Suppl 1):S14–6 (8 ref.)
Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Petroff OA, et al. **Neurology** 1996 May;46(5):1459–63
Treatment with antiepileptic drugs: possible neuroprotective effects. Pitkänen A. **Neurology** 1996 Jul;47(1 Suppl 1):S12–6
Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Privitera M, et al. **Neurology** 1996 Jun;46(6):1678–83
Intravenous administration of fosphenytoin: options for the management of seizures. Ramsay RE, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S17–9 (12 ref.)
Epilepsy in porphyria [letter; comment] Reynolds NC Jr. **Neurology** 1996 May;46(5):1497–8. Comment on: Neurology 1995 Mar;45(3 Pt 1):594–5. Comment on: Neurology 1995 Jun;45(6):1216–7.
Emergency treatment of status epilepticus. Runge JW, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S20–3 (25 ref.)
Intramuscular use of fosphenytoin: an overview. Uthman BM, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S24–8 (28 ref.)
Use of parenteral antiepileptic drugs and the role for fosphenytoin. Wilder BJ. **Neurology** 1996 Jun;46(6 Suppl 1):S1–2
Efficacy and safety of add-on divalproex sodium in the treatment of complex partial seizures. The M88-194 Study Group. Willmore LJ, et al. **Neurology** 1996 Jan;46(1):49–53
Vigabatrin in childhood epilepsy: a 5-year follow-up study. Uldall P, et al. **Neuropediatrics** 1995 Oct;26(5):253–6
Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE2 and in the chronic hyperalgesia in rats with streptozotocin-induced diabetes. Nakamura-Craig M, et al. **Pain** 1995 Oct;63(1):33–7
The use of clobazam in uncontrolled epilepsy [letter] Salt SD, et al. **Palliat Med** 1995 Oct;9(4):342
Efficacy of low-dose dextromethorphan in the treatment of nonketotic hyperglycinemia. Alemzadeh R, et al.
Pediatrics 1996 Jun;97(6 Pt 1):924–6
Discontinuation of antiepileptic drug treatment after two seizure-free years in children with cerebral palsy. Delgado MR, et al. **Pediatrics** 1996 Feb;97(2):192–7
Antenatal phenobarbital therapy and neonatal outcome. I: Effect on intracranial hemorrhage. Shankaran S, et al.
Pediatrics 1996 May;97(5):644–8
Antenatal phenobarbital therapy and neonatal outcome. II: Neurodevelopmental outcome at 36 months. Shankaran S, et al. **Pediatrics** 1996 May;97(5):649–52
Epidemiological study of epilepsy by monitoring prescriptions of antiepileptic drugs. Banfi R, et al.
Pharm World Sci 1995 Jul 28;17(4):138–40
Antiepileptic drugs--their effects on kindled seizures and kindling-induced learning impairments. Becker A, et al.
Pharmacol Biochem Behav 1995 Nov;52(3):453–9
Treatment of childhood epilepsy. Appleton RE.
Pharmacol Ther 1995;67(3):419–31 (72 ref.)
Interactions involving new antiepileptic drugs. Mawer GE, et al. **Pharmacol Ther** 1995;68(2):209–31 (110 ref.)
Effects of long-term antiepileptic therapy on the catabolism of testosterone. Brunet M, et al. **Pharmacol Toxicol** 1995 Jun;76(6):371–5
Carbamazepine clinical pharmacology: a review. Albani F, et al. **Pharmacopsychiatry** 1995 Nov;28(6):235–44 (189 ref.)
Carbamazepine-induced thrombocytopenia and carbamazepine-10,11-epoxide: a case report. Kimura M, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):69–70
Carbamazepine-exacerbated epilepsy with multifocal shifting independent epileptiform discharges on electroencephalogram: a case report. Kimura M, et al.
Psychiatry Clin Neurosci 1995 Mar;49(1):65–7
Effective anticonvulsant therapy in a patient with limb shaking: a case report. Shimoda M, et al.
Psychiatry Clin Neurosci 1995 Mar;49(1):71–2
Pharmacokinetics of slow-release preparations of sodium valproate. Yamatogi Y, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S245–7
Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). Gay PE, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1208–10
Concurrent use of phenytoin and furosemide: problems in a patient with congestive cardiac failure, chronic renal failure, liver cirrhosis and fluid overload. Bissoli F, et al.
Recenti Prog Med 1996 May;87(5):227–8
The eclampsia trial--implications for South Africa [editorial] Moodley J, et al. **S Afr Med J** 1995 Aug;85(8):746–7
Anticonvulsant action of carbonic anhydrase inhibition. Velišek L, et al. **Sb Lek** 1994;95(3):161–71
Vigabatrin in unsatisfactory controlled epilepsies. Swiss Vigabatrin Study Group. Russ W.
Schweiz Arch Neurol Psychiatr 1995;146(2):55–9
Design of clinical antiepileptic drug trials. Binnie CD.
Seizure 1995 Sep;4(3):187–92 (14 ref.)
The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability. Buchanan N. **Seizure** 1995 Sep;4(3):233–6
Methsuximide therapy of juvenile myoclonic epilepsy. Hurst DL. **Seizure** 1996 Mar;5(1):47–50
An audit of treated epilepsy in Glasgow. West of Scotland Epilepsy Research Group. Muir TM, et al. **Seizure** 1996 Mar;5(1):41–6
Combination vigabatrin and lamotrigine therapy for intractable epilepsy. Schapel GJ, et al. **Seizure** 1996 Mar; 5(1):51–6
Management issues in severe childhood epilepsies. Wallace SJ. **Seizure** 1995 Sep;4(3):215–20 (46 ref.)
Clonazepam-sensitive intermittent dystonic tremor. Davis TL, et al. **South Med J** 1995 Oct;88(10):1069–71 (16 ref.)
Plasma concentrations of praziquantel during the therapy of neurocysticerosis with praziquantel, in the presence of antiepileptics and dexamethasone. Na-Bangchang K, et al.
Southeast Asian J Trop Med Public Health 1995 Mar; 26(1):120–3
Chronic subdural hematomas and seizures: the role of prophylactic anticonvulsive medication. Sabo RA, et al.
Surg Neurol 1995 Jun;43(6):579–82
Validation of a quick modeling program generating clearance estimates at steady state for routine therapeutic drug monitoring. el Battah A, et al. **Ther Drug Monit** 1995 Aug; 17(4):348–55
Treatment of acute isoniazid overdose in dogs. Villar D, et al. **Vet Hum Toxicol** 1995 Oct;37(5):473–7 (50 ref.)
New antiepileptic medications. Lee EK. **West J Med** 1995 Nov;163(5):475–6
[Withdrawal of antiepileptic treatment] Balslev T.
Ugeskr Laeger 1996 Apr 1;158(14):1961–4 (24 ref.) (Eng. Abstr.) **(Dan)**
[Epilepsy (editorial)] Gram L. **Ugeskr Laeger** 1996 Apr 1; 158(14):1951 **(Dan)**
[Antiepileptic drug therapy--current aspects] Gram L.
Ugeskr Laeger 1996 Apr 1;158(14):1953–4 **(Dan)**
[Lamotrigine treatment of 92 patients with intractable epilepsy] Karlsborg M, et al. **Ugeskr Laeger** 1996 Apr 1; 158(14):1969–72 (Eng. Abstr.) **(Dan)**
[Lamotrigine. A new possibility in the treament of epilepsy] Mai J. **Ugeskr Laeger** 1996 Apr 1;158(14):1994–7 **(Dan)**
[Treatment of childhood epilepsy with lamotrigine. An evaluation of efficacy in different types of epilepsy] Uldall PV, et al. **Ugeskr Laeger** 1996 Apr 1;158(14):1973–6 (Eng. Abstr.) **(Dan)**
[Drug therapy of children with epilepsy] Uldall PV.
Ugeskr Laeger 1996 Apr 1;158(14):1959–60 **(Dan)**
[Treatment of convulsions in newborn infants] Fischer K, et al. **Ned Tijdschr Geneeskd** 1996 Jul 27;140(30):1557–60 (Eng. Abstr.) **(Dut)**
[Pyridoxine-dependent epilepsy in an infant] van Waarde WM, et al. **Ned Tijdschr Geneeskd** 1995 Aug 19; 139(33):1694–7 (Eng. Abstr.) **(Dut)**
[Vigabatrin in the treatment of infantile spasms] Backström M, et al. **Duodecim** 1995;111(9):853–5 **(Fin)**
[Current anti-epilepsy drugs] Iivanainen M, et al.
Duodecim 1995;111(8):751–8 (30 ref.) **(Fin)**
[XIV Consensus Conference on Intensive care and emergency medicine. Management of status epilepticus (children-adults). 23 June 1995, Le Kremlin-Bicêtre]
Ann Fr Anesth Reanim 1996;15(1):106–9 (0 ref.) **(Fre)**
[New medical treatment of epilepsy (editorial)] Loiseau P.
Presse Med 1996 Mar 23;25(10):481–3 (Eng. Abstr.) **(Fre)**
[Antiepileptic drugs] Franck G. **Rev Med Liege** 1996 Jan; 51(1):53–60 **(Fre)**
[Current viewpoints in the treatment of epilepsies: role of new antiepileptics?] Despland PA.
Schweiz Rundsch Med Prax 1995 Sep 19;84(38):1036–41 (51 ref.) (Eng. Abstr.) **(Fre)**
[Value of old and new anticonvulsants in treatment of psychiatric diseases] Walden J, et al.
Fortschr Neurol Psychiatr 1995 Aug;63(8):320–35 (185 ref.) (Eng. Abstr.) **(Ger)**
[Lamotrigin--a new anticonvulsant for epilepsy. Conference, 25 June 1993, Frankfurt] **Nervenarzt** 1993 Oct;64(10 Suppl [lamotri]):1–8 **(Ger)**
[Vigabatrin symposium within the congress "Epilepsy Europe", 3 September 1992, Glasgow] **Nervenarzt** 1992 Dec;63(12 Suppl):1–12 **(Ger)**
[Therapy of epilepsy: trends and effectiveness of new anticonvulsants] Scollo-Lavizzari G, et al.
Schweiz Arch Neurol Psychiatr 1995;146(4):168–73 (27 ref.) (Eng. Abstr.) **(Ger)**
[Current role of novel antiepileptics in the treatment of epilepsies] Despland PA. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):80–3 (Eng. Abstr.) **(Ger)**
[Gabapentin (Neurontin): a new possibility in the add-on therapy of partial epilepsies] Krämer G.
Schweiz Rundsch Med Prax 1996 Jan 23;85(4):84–93 (106 ref.) (Eng. Abstr.) **(Ger)**
[Recommendations on clinical epilepsy treatment using gabapentin] Krämer G, et al.
Schweiz Rundsch Med Prax 1996 Jan 23;85(4):99–101 (Eng. Abstr.) **(Ger)**
[Clinical studies on gabapentin in Switzerland] Shokry A.
Schweiz Rundsch Med Prax 1996 Jan 23;85(4):94–8 (Eng. Abstr.) **(Ger)**
[Gabapentin--a new add-on antiepileptic drug (editorial)] Vassella F. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):73 **(Ger)**

[Treatment of epilepsy: where are we today?] Wieser HG. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):74–9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Future perspectives in epilepsy treatment] Wieser HG. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):102–5 (Eng. Abstr.) **(Ger)**

[Drug treatment after a first unprovoked epileptic seizure] Gilad R, et al. **Harefuah** 1995 Jun 15;128(12):806–8 (19 ref.) **(Heb)**

[Cardiac effects of carbamazepine therapy] Checchini M, et al. **Minerva Cardioangiol** 1995 Sep;43(9):379–81 (Eng. Abstr.) **(Ita)**

[Interference of anticonvulsants in the rehabilitation treatment] Pisaturo C, et al. **Minerva Pediatr** 1996 Apr; 48(4):135–41 (Eng. Abstr.) **(Ita)**

[Computerized stabilometry in the monitoring of antiepileptic therapy in children] Franzoni E, et al. **Pediatr Med Chir** 1995 Sep–Oct;17(5):407–9 (Eng. Abstr.) **(Ita)**

[Acetazolamide treatment of a newborn infant with posthemorrhagic cerebral ventricular dilatation] Rubetti P, et al. **Pediatr Med Chir** 1995 Jul–Aug;17(4):359–63 (Eng. Abstr.) **(Ita)**

[The effect of zonisamide in West syndrome] Yanagihara K, et al. **No To Hattatsu** 1995 Nov;27(6):500–2 **(Jpn)**

[The comparison of sodium valproate and ergotamine titrate plus caffeine in the abortive treatment of migraine attacks] Kozubski W, et al. **Neurol Neurochir Pol** 1995 Nov–Dec; 29(6):929–35 (Eng. Abstr.) **(Pol)**

[Sodium valproate versus propranolol in the prophylactic treatment of migraine] Kozubski W, et al. **Neurol Neurochir Pol** 1995 Nov–Dec;29(6):937–47 (Eng. Abstr.) **(Pol)**

[Changes in the activity of an epileptogenic focus in the rat hippocampus under the influence of bemitil] Mikhailov IB, et al. **Eksp Klin Farmakol** 1995 Jul–Aug;58(4):12–3 (Eng. Abstr.) **(Rus)**

[A positive effect from a combination of gonadotropin with antiepileptic preparations in patients with hypogonadism and epileptic seizures] Karlov VA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):73 (Eng. Abstr.) **(Rus)**

[The function of the kallikrein-kinin system of the blood serum in epilepsy patients during therapy] Kovalenko VS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(3):32–4 (Eng. Abstr.) **(Rus)**

[A change in the thyroid status of children with epilepsy being treated with diphenylhydantoin] Temin PA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):25–9 **(Rus)**

[Diagnosis and treatment of drug-resistant epilepsy] Arroyo S. **Neurologia** 1996 Feb;11(2):56–68 (137 ref.) (Eng. Abstr.) **(Spa)**

[Refractory epilepsy in adults and the new antiepileptic drugs: the role of gabapentin] Galdames D, et al. **Rev Med Chil** 1995 Apr;123(4):500–8 (34 ref.) (Eng. Abstr.) **(Spa)**

[Prevention of neurological disorders of high altitude disease] Carod FJ, et al. **Rev Neurol** 1995 Nov–Dec;23(124):1324 **(Spa)**

[What should be first considered in the treatment of epileptic patients: control of seizures or increase of quality of life?] Forcadas I. **Rev Neurol** 1995 Nov–Dec;23(124):1327–8 **(Spa)**

[Pharmacological treatment of migraine: other treatments] Gómez Aranda F, et al. **Rev Neurol** 1995;23 Suppl 2:S198–200 (43 ref.) **(Spa)**

[The concept and treatment of drug-resistant intractable epilepsy] Iváñez V. **Rev Neurol** 1995 Nov–Dec; 23(124):1214–9 (85 ref.) (Eng. Abstr.) **(Spa)**

[Advances in the diagnostic and treatment of infantile epilepsy] Legido A. **Rev Neurol** 1996 Jun;24(130):688–93 (25 ref.) **(Spa)**

[Neonatal seizures: diagnostic and therapeutic controversies] Legido A. **Rev Neurol** 1996 Jun;24(130):694–700 (40 ref.) **(Spa)**

[Treatment of the partial epilepsy in the first two years of life. Experience in 26 cases] Martínez Bermejo A, et al. **Rev Neurol** 1995 Mar–Apr;23(120):290–2 (Eng. Abstr.) **(Spa)**

[Callosotomy in the treatment of drug-resistant epilepsy] Mínguez-Castellanos A, et al. **Rev Neurol** 1996 May; 24(129):539–48 (Eng. Abstr.) **(Spa)**

[Epilepsy and cerebral aging. Pharmacokinetics of antiepileptic treatment in adult age] Oller Ferrer-Vidal L. **Rev Neurol** 1995 Nov–Dec;23(124):1318–9 **(Spa)**

[What should be first considered in the treatment of epileptic patients: control of seizures or increase of quality of life?] Palao A. **Rev Neurol** 1995 Nov–Dec;23(124):1327 **(Spa)**

[Felbamate: perspectives for new antiepileptic treatment] Pérez-Miranda J, et al. **Rev Neurol** 1995 Nov–Dec; 23(124):1220–5 (46 ref.) (Eng. Abstr.) **(Spa)**

[Interaction of sleep, epilepsy and antiepileptic drugs in an adult] Salas Puig J. **Rev Neurol** 1995 Nov–Dec; 23(124):1287–9 (10 ref.) **(Spa)**

[What should be first considered in the treatment of epileptic patients: control of seizures or increase of quality of life?] Salas Puig J. **Rev Neurol** 1995 Nov–Dec;23(124):1328–9 **(Spa)**

[Adding lamotrigine to the treatment of epilepsy which is difficult to control] Suárez P, et al. **Rev Neurol** 1995 Nov–Dec;23(124):1190–2 (Eng. Abstr.) **(Spa)**

[Treatment of an epileptic patient: a global concept] Suárez Gil P. **Rev Neurol** 1995 Nov–Dec;23(124):1329–30 **(Spa)**

[Reversible neuropsychological deterioration associated with valproate] Vaquerizo J, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):148–50 (Eng. Abstr.) **(Spa)**

TOXICITY

Phenytoin covalent binding and embryopathy in mouse embryos co-cultured with maternal hepatocytes from mouse, rat, and rabbit. Ozolins TR, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1831–40

Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Tang W, et al. **Chem Res Toxicol** 1995 Jul–Aug;8(5):671–82

Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Edeki TI, et al. **Drug Metab Rev** 1995;27(3):449–69 (89 ref.)

Comparative anticonvulsant activity and neurotoxicity of 4-amino-N-(2,6-dimethylphenyl)phthalimide and prototype antiepileptic drugs in mice and rats. Bailleux V, et al. **Epilepsia** 1995 Jun;36(6):559–65

Infant monkey hyperexcitability after prenatal exposure to antiepileptic compounds. Phillips NK, et al. **Epilepsia** 1996 Oct;37(10):991–9

Circadian rhythm of embryotoxicity induced by sodium valproate in mice. Ohdo S, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):281–5

Perspective on the carcinogenic potential of phenytoin based on rodent tumor bioassays and human epidemiological data. Dethloff LA, et al. **Hum Exp Toxicol** 1996 Apr; 15(4):335–48

Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. Nishikawa S, et al. **J Periodontol** 1996 May;67(5):463–71 (94 ref.)

Modulation of embryonic glutathione peroxidase activity and phenytoin teratogenicity by dietary deprivation of selenium in CD-1 mice. Ozolins TR, et al. **J Pharmacol Exp Ther** 1996 May;277(2):945–53

In vitro neuroteratogenicity of valproic acid and 4-en-VPA. Gofflot F, et al. **Neurotoxicol Teratol** 1995 Jul–Aug; 17(4):425–35

Effect of doxorubicin and phenytoin on sea urchin development. Sconzo G, et al. **Pharmazie** 1995 Sep; 50(9):616–9

Ethanol potentiates valproic acid–induced neural tube defects (NTDs) in mice due to toxicokinetic interactions. Elmazar MM, et al. **Reprod Toxicol** 1995 Sep–Oct;9(5):427–33

Cytotoxicity of unsaturated metabolites of valproic acid and protection by vitamins C and E in glutathione-depleted rat hepatocytes. Jurima-Romet M, et al. **Toxicology** 1996 Aug 1;112(1):69–85

Toxic effect of valproic acid on tryptophan binding to rat hepatic nuclei. Sidransky H, et al. **Toxicology** 1996 May 3;109(1):39–47

[Voluntary drug poisoning cases admitted to an emergency care unit] Staikowsky F, et al. **Presse Med** 1995 Sep 30; 24(28):1296–300 (Eng. Abstr.) **(Fre)**

URINE

Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Skjelbo E, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):304–11

ANTIDEPRESSANTS see **ANTIDEPRESSIVE AGENTS**

ANTIDEPRESSANTS, ATYPICAL see **ANTIDEPRESSIVE AGENTS, SECOND-GENERATION**

ANTIDEPRESSANTS, TRICYCLIC see **ANTIDEPRESSIVE AGENTS, TRICYCLIC**

ANTIDEPRESSIVE AGENTS

see related

MONOAMINE OXIDASE INHIBITORS

Prospects for improved antidepressants. Broekkamp CL, et al. **J Med Chem** 1995 Nov 10;38(23):4615–33 (196 ref.)

Phosphodiesterase type IV inhibitors. Palfreyman MN, et al. **Prog Med Chem** 1996;33:1–52 (306 ref.)

Managing diazepam abuse in an AIDS-related psychiatric clinic with a high percentage of substance abusers. Freedman JB, et al. **Psychosomatics** 1996 Jan–Feb; 37(1):43–7

[Peripeteia in the development of new antidepressive agents in the early 1990s] Svestka J. **Ceska Slov Psychiatr** 1995 Nov;91(5):282–90 (88 ref.) **(Cze)**

[New antidepressive agents] LaBranche S. **Union Med Can** 1995 Nov;124(3):8–13 (23 ref.) **(Fre)**

[When your needs are most urgent, you will be denied help. Indistinct borderlines between advertisment, campaigns and information] Waal H. **Tidsskr Nor Laegeforen** 1996 Apr 30;116(11):1370–1 **(Nor)**

ADMINISTRATION & DOSAGE

Low-dose antidepressant therapy for early depression [letter] Grove VE Jr. **Am Fam Physician** 1995 Oct;52(5):1278

Low-dose antidepressant therapy for mild depression [letter] Rathbun ED. **Am Fam Physician** 1996 Apr;53(5):1536–7

Effect of recommended dosage range on the prescribing of antidepressants. Little JD. **Aust N Z J Psychiatry** 1995 Jun; 29(2):304–8

Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Fabre LF, et al. **Biol Psychiatry** 1995 Nov 1;38(9):592–602

Variation in prescribing of hypnotics, anxiolytics and antidepressants between 61 general practices. Pharoah PD, et al. **Br J Gen Pract** 1995 Nov;45(400):595–9

Augmentation of antidepressant therapy by buspirone: three geriatric case histories [letter] Robillard M Lieff S, et al. **Can J Psychiatry** 1995 Dec;40(10):639–40

Maintenance therapies for late-life recurrent major depression: research and review circa 1995. Reynolds CF 3rd, et al. **Int Psychogeriatr** 1995;7 Suppl:27–39 (27 ref.)

Why can low doses of sulpiride counteract depression? [letter] Okada F. **J Clin Psychopharmacol** 1995 Dec; 15(6):442–3

Depression, guidelines, and reality [editorial; comment] Siegler EL. **J Gen Intern Med** 1995 Dec;10(12):699–700. Comment on: J Gen Intern Med 1995 Dec;10(2):663–70.

Outcomes of "inadequate" antidepressant treatment [see comments] Simon GE, et al. **J Gen Intern Med** 1995 Dec; 10(12):663–70. Comment in: J Gen Intern Med 1996 Dec;10(12):699–700.

Prescription pattern of antidepressants in out-patient psychiatric practice. Munizza C, et al. **Psychol Med** 1995 Jul;25(4):771–8

Sertraline with methylphenidate in an ICU patient [letter] McGlohn SE, et al. **Psychosomatics** 1995 Nov–Dec; 36(6):584–5

[Delay in the effect of antidepressive agents: pharmacologic approach] Allain H, et al. **Encephale** 1995 Mar;21 Spec No 2:9–15 (39 ref.) (Eng. Abstr.) **(Fre)**

[Practical considerations in initial treatment] Allilaire JF. **Encephale** 1995 Mar;21 Spec No 2:23–9 (0 ref.) (Eng. Abstr.) **(Fre)**

[The long-term course of depression (epidemiology and clinical aspects)] Cardot H, et al. **Encephale** 1995 Mar;21 Spec No 2:51–9 (77 ref.) (Eng. Abstr.) **(Fre)**

[Practical modalities of consolidation treatment] Dalery J, et al. **Encephale** 1995 Mar;21 Spec No 2:43–5 (Eng. Abstr.) **(Fre)**

[Delay of the antidepressant effect: clinical studies] Escande M, et al. **Encephale** 1995 Mar;21 Spec No 2:3–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Consolidation treatment. The status in dysthymia] Hardy P. **Encephale** 1995 Mar;21 Spec No 2:39–42 (15 ref.) (Eng. Abstr.) **(Fre)**

[Initiating thymoregulator treatment] Olié JP, et al. **Encephale** 1995 Mar;21 Spec No 2:71–8 (86 ref.) (Eng. Abstr.) **(Fre)**

[Efficacy of antidepressants and thymoregulators in the long-term evolution of depression] Pringuey D, et al. **Encephale** 1995 Mar;21 Spec No 2:61–70 (18 ref.) (Eng. Abstr.) **(Fre)**

[Long-term clinical effects of antidepressive agents] Sechter D. **Encephale** 1995 Mar;21 Spec No 2:35–8 (14 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of depressive symptoms with a high concentration hypericum preparation. A multicenter placebo-controlled double-blind study] Witte B, et al. **Fortschr Med** 1995 Oct 10;113(28):404–8 (Eng. Abstr.) **(Ger)**

[Depressing data on depression (editorial)] Heinzl S. **Med Monatsschr Pharm** 1995 Dec;18(12):343 **(Ger)**

[Save us from idiocy (letter)] Bramness JG. **Tidsskr Nor Laegeforen** 1996 Jun 30;116(17):2083 **(Nor)**

[When the need is great, patients should receive help (letter)] Dahl AA, et al. **Tidsskr Nor Laegeforen** 1996 Aug 10; 116(18):2213–4 **(Nor)**

ADVERSE EFFECTS

Antidepressant-induced cycle acceleration in bipolar disorder [letter] Simpson HB, et al. **Am J Psychiatry** 1996 Sep;153(9):1239

Do antidepressants promote tumor growth? [letter] Storch DD. **Am J Psychiatry** 1996 Mar;153(3):446

Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189–201 (107 ref.)

SIADH in a patient receiving sertraline [letter] Bluff DD, et al. **Ann Intern Med** 1995 Nov 15;123(10):811

Phenelzine-induced fulminant hepatic failure [letter] Gómez-Gil E, et al. **Ann Intern Med** 1996 Apr 1; 124(7):692–3

Serotonin syndrome induced by administration of venlafaxine and phenelzine [letter] Heisler MA, et al. **Ann Pharmacother** 1996 Jan;30(1):84

Antidepressants and side effects [letter; comment] Carter G. **Aust N Z J Psychiatry** 1995 Jun;29(2):337. Comment on: Aust N Z J Psychiatry 1995 Mar;29(1):156–7.

Discontinuation reactions following sertraline. Leiter FL, et al. **Biol Psychiatry** 1995 Nov 15;38(10):694–5 (7 ref.)

Depression, antidepressants, and accidents [letter; comment] Diamond PA. **BMJ** 1995 Dec 9;311(7019):1570. Comment on: BMJ 1995 Oct 7;311(7010):887–8.

Depression, antidepressants, and accidents [editorial] [see comments] Edwards JG. **BMJ** 1995 Oct 7;311(7010):887–8 . Comment in: BMJ 1995 Dec 9;311(7019):1570.

Repeat prescription antidepressants and residential care [letter] Farmer A. **Br J Psychiatry** 1995 Sep;167(3):408–9

Suspected congenital sertraline dependence [letter] Kent LS,

et al. **Br J Psychiatry** 1995 Sep;167(3):412–3
Antidepressants in pregnancy and breastfeeding [letter] Ratan DA, et al. **Br J Psychiatry** 1995 Dec;167(6):824
Extreme suicidality following serotonin syndrome [letter; comment] Serfaty MA, et al. **Br J Psychiatry** 1995 Sep; 167(3):410. Comment on: Br J Psychiatry 1995 Mar;166(3):401–2.
Paresthesia as a side effect of the new antidepressant, nefazodone [letter] Ghaemi SN, et al. **Can J Psychiatry** 1995 Oct;40(8):499–500
Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Harth Y, et al. **Drug Saf** 1996 Apr;14(4):252–9 (47 ref.)
Antidepressant-induced hyponatraemia in the aged. Avoidance and management strategies. Sharma H, et al. **Drugs Aging** 1996 Jun;8(6):430–5 (26 ref.)
The safety and tolerability of citalopram. Muldoon C. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:35–40 (17 ref.)
Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Hsu JH, et al. **Int J Psychiatry Med** 1995;25(2):191–201
Do antidepressants cause, promote, or inhibit cancers? Steingart AB, et al. **J Clin Epidemiol** 1995 Nov; 48(11):1407–12 (43 ref.)
Adverse effects of medications on urinary symptoms and flow rate: a community-based study. Su L, et al. **J Clin Epidemiol** 1996 Apr;49(4):483–7
Tolerability and safety: essentials in antidepressant pharmacotherapy. Lader MH. **J Clin Psychiatry** 1996;57 Suppl 2:39–44 (26 ref.)
Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. Greene DS, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):399–408
Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam. Greene DS, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):409–16
Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. Guentert TW, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):84S–94S
Moclobemide safety: monitoring a newly developed product in the 1990s. Hilton S, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):76S–83S (28 ref.)
Prolonged neurological sequelae after combination treatment with lithium and antipsychotic drugs [letter] Mani J, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):350–1
Antidepressant-induced orgasm disorder. Segraves RT. **J Sex Marital Ther** 1995 Fall;21(3):192–201 (81 ref.)
A 61-year-old man with Parkinson's disease [letter; comment] Hayes HD. **JAMA** 1996 Jul 10;276(2):103–4; discussion 104. Comment on: JAMA 1996 Mar 6;275(9):716–22.
A depressed workman with heatstroke. Albukrek D, et al. **Lancet** 1996 Apr 13;347(9007):1016
Hypertension with moclobemide [letter] [see comments] Coulter DM, et al. **Lancet** 1995 Oct 14;346(8981):1032. Comment in: Lancet 1995 Dec 2;346(8988):1498.
Dental caries with longterm use of antidepressants [letter] deVries MW, et al. **Lancet** 1995 Dec 16;346(8990):1640
Antidepressant-associated fatal intrahepatic cholestasis [letter; comment] Dollow S. **Lancet** 1996 May 4; 347(9010):1268–9. Comment on: Lancet 1996 Mar 16;347(9003):762–3.
Toxic interaction of venlafaxine and isocarboxazide [letter] Klysner R, et al. **Lancet** 1995 Nov 11;346(8985):1298–9
Hypertension with moclobemide [letter] Laux G, et al. **Lancet** 1996 May 11;347(9011):1330
Severe adverse reaction to moclobemide [letter] O'Kane GM, et al. **Lancet** 1996 May 11;347(9011):1329–30
Intrahepatic cholestasis associated with moclobemide leading to death [letter] [see comments] Timmings P, et al. **Lancet** 1996 Mar 16;347(9003):762–3. Comment in: Lancet 1996 May 4;347(9010):1268–9.
Serotonin syndrome—a potentially fatal complication of antidepressant therapy. Corkeron MA. **Med J Aust** 1995 Nov 6;163(9):481–2
Suicide and antidepressant medication [letter] Moore CS. **N Z Med J** 1996 Feb 9;109(1015):39
Effect of previous antidepressant therapy on the growth hormone response to apomorphine. Pitchot W, et al. **Neuropsychobiology** 1995;32(1):19–22
A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder. Trabert W, et al. **Pharmacopsychiatry** 1995 May;28(3):95–7
Antidepressant-induced tardive dyskinesia: review and case report. Clayton AH. **Psychopharmacol Bull** 1995; 31(2):259–64
Decreased bone mineral density in medicated psychiatric patients. Halbreich U, et al. **Psychosom Med** 1995 Sep–Oct; 57(5):485–91
Beyond the brain-mind dichotomy and toward a common organizing principle of pharmacological and psychological treatments [editorial; comment] Biondi M. **Psychother Psychosom** 1995;64(1):1–8. Comment on: Psychother Psychosom 1994;61(3–4):125–31. Comment on: Psychother Psychosom 1995;63(3–4):137–41.
Holding on: depression, sensitization by antidepressant drugs, and the prodigal experts [editorial; comment] Fava GA. **Psychother Psychosom** 1995;64(2):57–61. Comment on: Psychother Psychosom 1994;61(3–4):125–31.
[Extrapyramidal disorders following sertraline use; experiences with a new selective antidepressant] Kölling P, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1467–8 (Eng. Abstr.) **(Dut)**
[Inhibition of saliva secretion caused by antidepressive drugs; a risk for oral health] Peeters FP, et al. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):533–6 (25 ref.) **(Dut)**
[The serotonin syndrome; a misdiagnosed complication of antidepressive agents] Verhoeven WM, et al. **Ned Tijdschr Geneeskd** 1995 Oct 14;139(41):2073–5 **(Dut)**
[Adverse effects: priapism caused by paroxetine] Bertholon F, et al. **Ann Med Psychol (Paris)** 1996 May;154(2):145–6; discussion 146–7 (Eng. Abstr.) **(Fre)**
[Fever caused by medifoxamine (letter)] Guy C, et al. **Presse Med** 1996 Jan 27;25(3):127 **(Fre)**
[Sleep, depression and antidepressive treatments (2)] Arriaga F. **Acta Med Port** 1995 Mar;8(3):181–6 (73 ref.) (Eng. Abstr.) **(Por)**
[Parkinsonism secondary to the use of sertraline (letter)] Cano A, et al. **Med Clin (Barc)** 1995 Dec 8;105(20):797–8 **(Spa)**
[Acute dystonia induced by fluoxetine] Vaamonde J, et al. **Neurologia** 1996 May;11(5):197 **(Spa)**
[Drug-induced extrapyramidal disorders (see comments)] Horga JF, et al. **Rev Neurol** 1995 Sep–Oct;23(123):961–3 (Eng. Abstr.). Comment in: Rev Neurol 1996 May;24(129):584–5. **(Spa)**

ANTAGONISTS & INHIBITORS

[Thrombocytic serotoninergic markers in therapy-resistant patients with endogenous depression undergoing alpha-tocopherol treatment] Brusov OS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):72–6 (Eng. Abstr.) **(Rus)**

BLOOD

Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. Rochat B, et al. **Chirality** 1995; 7(6):389–95
[Lithium carbonate] Higuchi S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:942–4 (9 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Novel pyrimidinediones and thiazolidinones as anti depressants. Misra U, et al. **Boll Chim Farm** 1995 Oct; 134(9):492–6

CHEMISTRY

Structure-activity relationship studies of CNS agents, Part 22. A search for new trazodone-like antidepressants: synthesis and preliminary receptor binding studies. Mokrosz JL, et al. **Arch Pharm (Weinheim)** 1995 Jul–Aug; 328(7–8):623–5
Chromatographic modelling of interactions between melanin and phenothiazine and dibenzazepine drugs. Radwańska A, et al. **Biomed Chromatogr** 1995 Sep–Oct;9(5):233–7
NMR spectroscopic characterization of adinazolam mesylate: pH-dependent structure change in aqueous solution and active methylene. Ogata M, et al. **J Pharm Sci** 1995 Jun; 84(6):786–90

CLASSIFICATION

The future of antidepressants. Bourin M, et al. **Biomed Pharmacother** 1996;50(1):7–12 (53 ref.)
Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. Duncan GE, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1076–89
[Criteria for choosing antidepressants] Olié JP, et al. **Therapie** 1995 Nov–Dec;50(6):523–9 (Eng. Abstr.) **(Fre)**

DIAGNOSTIC USE

Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)

ECONOMICS

Meta-analysis of antidepressant prescribing. Drop out rates presented in a misleading manner [letter; comment] Freemantle N, et al. **BMJ** 1995 Sep 16;311(7007):751. Comment on: BMJ 1995 Jun 3;310(6992):1433–8.
Economics of treatment of depression [letter; comment] Thompson C. **Br J Psychiatry** 1995 Jul;167(1):112. Comment on: Br J Psychiatry 1995 Mar;166(3):397–9.
Pharmacoeconomic issues in the treatment of depression. Saklad SR. **Pharmacotherapy** 1995 Nov–Dec;15(6 Pt 2):76S–83S (24 ref.)
The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone. Anton SF, et al. **Psychopharmacol Bull** 1995; 31(2):249–58

ISOLATION & PURIFICATION

Simultaneous quantification of fluoxetine, norfluoxetine, and desipramine using gas chromatography with nitrogen-phosphorus detection. Goodnough DB, et al. **J Pharmacol Toxicol Methods** 1995 Nov;34(3):143–7

METABOLISM

Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1. Schloss P, et al. **Biochemistry** 1995 Oct 3;34(39):12590–5
Relationships between in vitro and in vivo biotransformation of drugs in humans and animals: pharmaco-toxicological consequences. de Sousa G, et al. **Cell Biol Toxicol** 1995 Aug;11(3–4):147–53
Gradient high performance liquid chromatographic assay for degradation products of adinazolam mesylate in a sustained release tablet formulation. Stemm NL, et al. **Pharm Res** 1995 May;12(5):738–45

PHARMACOKINETICS

Antidepressants and drug-metabolizing enzymes—expert group report. Meyer UA, et al. **Acta Psychiatr Scand** 1996 Feb;93(2):71–9 (45 ref.)
Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Edwards DM, et al. **Biopharm Drug Dispos** 1995 Aug;16(6):443–60
Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans. Barbhaiya RH, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):161–5
Hemodialyzability of sertraline. Schwenk MH, et al. **Clin Nephrol** 1995 Aug;44(2):121–4
Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Barbhaiya RH, et al. **Clin Pharmacol Ther** 1995 Oct;58(4):390–8
Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Barbhaiya RH, et al. **Eur J Clin Pharmacol** 1995;49(3):221–8
Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function. Barbhaiya RH, et al. **Eur J Clin Pharmacol** 1995;49(3):229–35
Principles to optimize drug treatment in the depressed elderly: practical pharmacokinetics and drug interactions. Cohen LJ. **Geriatrics** 1995 Oct;50 Suppl 1:S32–40 (33 ref.)
Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. Kaul S, et al. **J Clin Pharmacol** 1995 Aug;35(8):830–9
Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. Barbhaiya RH, et al. **J Clin Psychopharmacol** 1995 Oct; 15(5):320–6
Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. Guentert TW, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):84S–94S
Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment. Kroboth PD, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):306–19
Effects of the putative antidepressant, ABT 200, on the clearance of exogenous norepinephrine in rat cerebellum. Cass WA, et al. **Synapse** 1995 Sep;21(1):77–84

PHARMACOLOGY

Newer antidepressants and the cytochrome P450 system. Nemeroff CB, et al. **Am J Psychiatry** 1996 Mar; 153(3):311–20 (101 ref.)
Bupropion and anticonvulsant drug interactions. Popli AP, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):99–101
The P-450 system. Definition and relevance to the use of antidepressants in medical practice. Goldberg RJ. **Arch Fam Med** 1996 Jul–Aug;5(7):406–12 (104 ref.)
Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Miller HL, et al. **Arch Gen Psychiatry** 1996 Feb;53(2):117–28
The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Hunter KD, et al. **Arch Oral Biol** 1995 Nov; 40(11):983–9
Structure-activity relationship studies of CNS agents, Part 22. A search for new trazodone-like antidepressants: synthesis and preliminary receptor binding studies. Mokrosz JL, et al. **Arch Pharm (Weinheim)** 1995 Jul–Aug; 328(7–8):623–5
Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. Dockens RC, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):598–601
Protein kinase C in rat brain cortex and hippocampus: effect of repeated administration of fluoxetine and desipramine. Mann CD, et al. **Br J Pharmacol** 1995 Jun;115(4):595–600
Chronic administration of the antidepressants phenelzine, desipramine, clomipramine, or maprotiline decreases binding to 5-hydroxytryptamine2A receptors without affecting benzodiazepine binding sites in rat brain. Todd KG, et al. **Cell Mol Neurobiol** 1995 Jun;15(3):361–70
Managing selective serotonin reuptake inhibitor-drug interactions in clinical practice. Rosenbaum JR. **Clin Pharmacokinet** 1995;29 Suppl 1:53–9 (17 ref.)
Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. von Moltke LL, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:33–43; discussion 43–4 (66 ref.)
Effect of antidepressants on ATP content, 3H-valine incorporation and cell morphometry of astrocytes cultured

from rat brain. Trzeciak HI, et al. **Dev Neurosci** 1995; 17(5–6):292–9

Effects of bifemelane hydrochloride on plasma neuropeptide Y, 3–methoxy–4–hydroxyphenylethylene glycol and 5–hydroxy–indole acetic acid concentrations in patients with cerebral infarction. Koide S, et al. **Drugs Exp Clin Res** 1995;21(5):175–80

Antidepressants and hypothalamic–pituitary–adrenocortical regulation. Holsboer F, et al. **Endocr Rev** 1996 Apr; 17(2):187–205 (237 ref.)

Behavioural response to SKF 38393 and quinpirole following chronic antidepressant treatment. Allison K, et al. **Eur J Pharmacol** 1995 Apr 24;277(2–3):139–44

Long–term antidepressant treatments alter 5–HT2A and 5–HT2C receptor–mediated hyperthermia in Fawn–Hooded rats. Aulakh CS, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):65–70

Prolyl–leucyl–glycinamide, thyrotropin–releasing hormone and beta–endorphin–(10–16), like antidepressants, antagonize melatonin–induced behavioural changes in rats. Hatta K, et al. **Eur J Pharmacol** 1995 Sep 25;284(3):327–30

Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Ichikawa J, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):255–61

Antidepressant–like effect by postsynaptic 5–HT1A receptor activation in mice. Matsuda T, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):235–8

Effects of chlomipramine and fluoxetine on subcutaneous carrageenin–induced inflammation in the rat. Bianchi M, et al. **Inflamm Res** 1995 Nov;44(11):466–9

Are pharmacokinetic drug interactions with the SSRIs an issue? Brøsen K. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:23–7 (9 ref.)

Does selectivity matter? Deakin JFW. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:13–7 (12 ref.)

Serotonin: current understanding and the way forward. Dinan TG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:19–21 (10 ref.)

Autoradiographic studies on the uptake of 3H–noradrenaline and 3H–serotonin by neurones and astrocytes in explant and primary cultures of rat CNS: effects of antidepressants. Hösli E, et al. **Int J Dev Neurosci** 1995 Dec;13(8):897–908

GABA–elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (–)–deprenyl and clorgyline. Todd KG, et al. **J Affect Disord** 1995 Dec 13;35(3):125–9

The defibrillating effect of catecholamine reuptake inhibitors. Falkin L, et al. **J Basic Clin Physiol Pharmacol** 1993 Oct–Dec;4(4):291–7

Do antidepressants cause, promote, or inhibit cancers? Steingart AB, et al. **J Clin Epidemiol** 1995 Nov; 48(11):1407–12 (43 ref.)

Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. Salazar DE, et al. **J Clin Pharmacol** 1995 Jul; 35(7):730–8

Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. Potter WZ. **J Clin Psychiatry** 1996;57 Suppl 4:4–8 (45 ref.)

Sodium–dependent norepinephrine–induced currents in norepinephrine–transporter–transfected HEK–293 cells blocked by cocaine and antidepressants. Galli A, et al. **J Exp Biol** 1995 Oct;198 (Pt 10):2197–212

(2S,3S,5R)–2–(3,5–difluorophenyl)–3,5–dimethyl–2–morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake. Kelley JL, et al. **J Med Chem** 1996 Jan 19;39(2):347–9

D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function. Cheetham SC, et al. **J Neural Transm Gen Sect** 1995;102(1):35–46

Long–term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. Montkowski A, et al. **J Neuroendocrinol** 1995 Nov;7(11):841–5

Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. Nibuya M, et al. **J Neurosci** 1995 Nov; 15(11):7539–47

Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. Nibuya M, et al. **J Neurosci** 1996 Apr 1;16(7):2365–72

Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content. Chen J, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):509–17

Effect of the alpha–2 adrenoceptor antagonist mirtazapine on the 5–hydroxytryptamine system in the rat brain. Haddjeri N, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):861–71

Regulation of 5–hydroxytryptamine release from rat midbrain raphe nuclei by 5–hydroxytryptamine1D receptors: effect of tetrodotoxin, G protein inactivation and long–term antidepressant administration. Piñeyro G, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):697–707

Influence of antidepressant drugs administration on the morphine inhibitory effect in mice vasa deferentia. Moreno–Brea MR, et al. **Life Sci** 1995;57(21):PL339–45

The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Owens MJ, et al. **Life Sci** 1995;57(24):PL373–80

Simultaneous brain and blood microdialysis study with a new removable venous probe. Serotonin and 5–hydroxyindolacetic acid changes after D–norfenfluramine or fluoxetine. Páez X, et al. **Life Sci** 1996;58(15):1209–21

Prenatal stress prevents the desensitization of the corticosterone response to TFMPP by desmethylimipramine, but not by phenelzine, in adult male offspring. Poland RE, et al. **Life Sci** 1995;57(23):2163–70

Test–dependent relationship of the antidepressant and analgesic effects of amitriptyline. Casas J, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):583–8

Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Buck KJ, et al. **Mol Pharmacol** 1995 Dec;48(6):1030–7

The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis [see comments] Sommer N, et al. **Nat Med** 1995 Mar;1(3):244–8 . Comment in: Nat Med 1995 Mar;1(3):211–4.

BIMT 17, a 5–HT2A receptor antagonist and 5–HT1A receptor full agonist in rat cerebral cortex. Borsini F, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):276–82

BIMT 17, a 5–HT1A receptor agonist/5–HT2A receptor antagonist, directly activates postsynaptic 5–HT inhibitory responses in the rat cerebral cortex. Borsini F, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):283–90

Aged rats are still responsive to the antidepressant and memory–improving effects of oxytocin. Arletti R, et al. **Neuropeptides** 1995 Sep;29(3):177–82

[3H]nisoxetine––a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP–4 lesioning and antidepressant treatments. Cheetham SC, et al. **Neuropharmacology** 1996 Jan;35(1):63–70

Effects of antidepressants on cognitive functions: a review. Amado–Boccara I, et al. **Neurosci Biobehav Rev** 1995 Fall; 19(3):479–93 (68 ref.)

Long–lasting inhibition of 5–HT uptake of platelets in subjects treated by duloxetine, a potential antidepressant. Kasahara T, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Feb; 16(1):25–31

Placebo washout is not a meaningful part of antidepressant drug trials. Greenberg RP, et al. **Percept Mot Skills** 1995 Oct;81(2):688–90

Antidepressant–like actions of the polyamine site NMDA antagonist, eliprodil (SL–82.0715). Layer RT, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):621–7

Central noradrenergic neurones and stress. Stanford SC. **Pharmacol Ther** 1995;68(2):297–42 (360 ref.)

Effect of p–chlorophenylalanine and alpha–methyltyrosine on the antinociceptive effect of antidepressant drugs. Sierralta F, et al. **Pharmacol Toxicol** 1995 Oct;77(4):276–80

Recent advances in the GABA–A–benzodiazepine receptor pharmacology. Kostowski W. **Pol J Pharmacol** 1995 May–Jun;47(3):237–46 (57 ref.)

Antidepressant treatment influences cyclic AMP accumulation induced by excitatory amino acids in rat brain. Pilc A, et al. **Pol J Pharmacol** 1995 Jul–Aug; 47(4):359–61

Stress and antidepressants differentially regulate neurotrophin 3 mRNA expression in the locus coeruleus. Smith MA, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8788–92

The combination of several antidepressants is not synergistic on the firing of lateral septal neurons in the rat. Contreras CM, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Nov;19(7):1157–62

TJS–010, a new prescription of oriental medicine, antagonizes tetrabenazine–induced suppression of spontaneous locomotor activity in rats. Tanra AJ, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):963–71

A comparison of the behavioral effects of minaprine, amphetamine and stress. Cabib S, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):73–80

Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Detke MJ, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):66–72

Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects. Fleishaker JC, et al. **Psychopharmacology (Berl)** 1995 Jul;120(2):169–76

The additive effects of quinine on antidepressant drugs in the forced swimming test in mice. Guo WY, et al. **Psychopharmacology (Berl)** 1995 Sep;121(2):173–9

Effects of Antidepressants and antipsychotics on the 5HT2 receptor–mediated signal transducing system in human platelets. Ohsuka N, et al. **Psychopharmacology (Berl)** 1995 Oct;121(4):428–32

Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Overstreet DH, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):27–37 (62 ref.)

Decreased bone mineral density in medicated psychiatric patients. Halbreich U, et al. **Psychosom Med** 1995 Sep–Oct; 57(5):485–91

Effects of the putative antidepressant, ABT 200, on the clearance of exogenous norepinephrine in rat cerebellum. Cass WA, et al. **Synapse** 1995 Sep;21(1):77–84

[Antidepressive agents, the dorsal horn and pain] Eschalier A. **Cah Anesthesiol** 1995;43(4):357–61 **(Fre)**

[Effects of chronic administration of antidepressants on microtubule assembly in rat cerebral cortex] Miyamoto S, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Oct; 15(5):385–95 (Eng. Abstr.) **(Jpn)**

[The effect of amitriptyline on the pathological crying and other pseudobulbar signs] Szczudlik A, et al. **Neurol Neurochir Pol** 1995 Sep–Oct;29(5):663–74 (Eng. Abstr.) **(Pol)**

[Biphosphonic acid derivatives as antidepressants] Tolstikova TG, et al. **Dokl Akad Nauk** 1995 Oct;344(4):565–7 **(Rus)**

[The effect of antidepressants on the catecholamine content of the rat hypothalamus and adrenals] Arushanian EB, et al. **Eksp Klin Farmakol** 1995 Nov–Dec;58(6):14–6 (Eng. Abstr.) **(Rus)**

[Antidepressants and migraine] Legarda I. **Rev Neurol** 1995; 23 Suppl 2:S193–7 (47 ref.) **(Spa)**

POISONING

In–vivo binding of lithium using the cation exchange resin sodium polystyrene sulfonate. Gehrke JC, et al. **Am J Emerg Med** 1996 Jan;14(1):37–8

Analysis of sertraline–only overdoses. Klein–Schwartz W, et al. **Am J Emerg Med** 1996 Sep;14(5):456–8

Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine. Power BM, et al. **Anaesth Intensive Care** 1995 Aug;23(4):499–502

Self–poisonings with antidepressants and other psychotropics in an urban area of Sweden. Isacsson G, et al. **Ann Clin Psychiatry** 1995 Sep;7(3):113–8

Multiple delayed peak lithium concentrations following acute intoxication with an extended–release product. Dupuis RE, et al. **Ann Pharmacother** 1996 Apr;30(4):356–60

The cost of antidepressant overdose. D'Mello DA, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):454–5

Two fatalities involving phenelzine. Lichtenwalner MR, et al. **J Anal Toxicol** 1995 Jul–Aug;19(4):265–6

"Ping–pong" gaze in severe monoamine oxidase inhibitor toxicity. Erich JL, et al. **J Emerg Med** 1995 Sep–Oct; 13(5):653–5

THERAPEUTIC USE

Medication response to ECT–resistant melancholic patients. Lykouras L, et al. **Acta Psychiatr Belg** 1995 May–Jun; 95(3):113–21

Moclobemide and sertraline in the treatment of depressive disorders: a comparative study. Orsel Donbak S, et al. **Acta Psychiatr Belg** 1995 May–Jun;95(3):139–51

Use and misuse of antidepressant drugs in a random sample of the population of Rome, Italy. Arpino C, et al. **Acta Psychiatr Scand** 1995 Jul;92(1):7–9

A double–blind comparison of moclobemide and doxepin in depressed general practice patients. Lingjaerde O, et al. **Acta Psychiatr Scand** 1995 Aug;92(2):125–31

Interactions with drugs used in the treatment of depressive illness. D'Arcy PF, et al. **Adverse Drug React Toxicol Rev** 1995 Winter;14(4):211–31 (160 ref.)

Panic disorder [see comments] Weinstein RS. **Am Fam Physician** 1995 Nov 15;52(7):2055–63, 2067–8 (35 ref.). Comment in: Am Fam Physician 1995 Nov 15;52(7):1999–2000.

Possible antidepressant effect of minocycline [letter] Levine J, et al. **Am J Psychiatry** 1996 Apr;153(4):582

Resistance to antidepressant medications and short–term clinical response to ECT. Prudic J, et al. **Am J Psychiatry** 1996 Aug;153(8):985–92

Antidepressant treatment during breast–feeding. Wisner KL, et al. **Am J Psychiatry** 1996 Sep;153(9):1132–7 (52 ref.)

Acute treatment response in outpatients with panic disorder: high versus low depressive symptoms. Black DW, et al. **Ann Clin Psychiatry** 1995 Dec;7(4):181–8

Medication treatment in first–admission patients with psychotic affective disorders: preliminary findings on research–facility diagnostic agreement and rehospitalization. Fennig S, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):87–90

Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189–201 (107 ref.)

Bupropion and anticonvulsant drug interactions. Popli AP, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):99–101

Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Gold PW, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:716–29 (53 ref.)

Sertraline in the treatment of neurotic excoriations and related disorders [letter] Kalivas J, et al. **Arch Dermatol** 1996 May;132(5):589–90

Nocturnal enuresis: a placebo controlled trial of two antidepressant drugs. Smellie JM, et al. **Arch Dis Child** 1996 Jul;75(1):62–6

Pindolol, 5–hydroxytryptamine, and antidepressant augmentation [letter; comment] Artigas F. **Arch Gen Psychiatry** 1995 Nov;52(11):969–71. Comment

on: Arch Gen Psychiatry 1995 Feb;52(2):156.
Effect of antidepressant medication on morning and evening thyroid function tests during a major depressive episode. Duval F, et al. **Arch Gen Psychiatry** 1996 Sep;53(9):833–40
Chronological milestones to guide drug change. When should clinicians switch antidepressants? Quitkin FM, et al. **Arch Gen Psychiatry** 1996 Sep;53(9):785–92
The role of pterins in depression and the effects of antidepressive therapy. Abou-Saleh MT, et al. **Biol Psychiatry** 1995 Oct 1;38(7):458–63
All-night EEG spectral analysis as a tool for the prediction of clinical response to antidepressant treatment. Luthringer R, et al. **Biol Psychiatry** 1995 Jul 15;38(2):98–104
Benzodiazepines as antidepressants: does GABA play a role in depression? Petty F, et al. **Biol Psychiatry** 1995 Nov 1;38(9):578–91
Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. Pitts AF, et al. **Biol Psychiatry** 1995 Sep 1;38(5):330–5
St John's wort as an antidepressant [editorial; comment] De Smet PA, et al. **BMJ** 1996 Aug 3;313(7052):241–2. Comment on: BMJ 1996 Aug 3;313(7052):253–8.
St John's wort for depression—an overview and meta-analysis of randomised clinical trials [see comments] Linde K, et al. **BMJ** 1996 Aug 3;313(7052):253–8. Comment in: BMJ 1996 Aug 3;313(7052):241–2.
Treatment of major depression in general practice: a double-blind comparison of paroxetine and lofepramine. Moon CA, et al. **Br J Clin Pract** 1996 Jul-Aug;50(5):240–4
Relationship between the provision of counselling and the prescribing of antidepressants, hypnotics and anxiolytics in general practice. Fletcher J, et al. **Br J Gen Pract** 1995 Sep;45(398):467–9
Practical management of treatment-resistant affective disorders. Bridges PK, et al. **Br J Hosp Med** 1995 Nov 15-Dec 12;54(10):501–6 (58 ref.)
Recent advances in the treatment of depression. Hale AS. **Br J Hosp Med** 1996 Feb 21-Mar 5;55(4):183–6 (23 ref.)
Publication bias and meta-analysis [letter; comment] Gilbody S, et al. **Br J Psychiatry** 1995 Aug;167(2):266. Comment on: Br J Psychiatry 1995 Apr;166(4):424–43.
The Galway Study of Panic Disorder. III. Outcome at 5 to 6 years. O'Rourke D, et al. **Br J Psychiatry** 1996 Apr; 168(4):462–9
Placebo effects and antidepressant medication: implications for research and clinical care. Lurie SN. **Bull Menninger Clin** 1996 Winter;60(1):94–101
Anaesthetic management of labour and delivery in a woman taking long-term MAOI. Pavy TJ, et al. **Can J Anaesth** 1995 Jul;42(7):618–20
Treatment of late-onset agoraphobia secondary to depression [letter] Flint AJ. **Can J Psychiatry** 1995 Nov;40(9):568
The loss of the therapeutic effect of antidepressant medication [letter] Persad E, et al. **Can J Psychiatry** 1995 Aug; 40(6):361–2
A comparison of comorbid patterns in treatment-resistant unipolar and bipolar depression. Sharma V, et al. **Can J Psychiatry** 1995 Jun;40(5):270–4
Treatment of acute bipolar depression: a review of the literature. Srisurapanont M, et al. **Can J Psychiatry** 1995 Nov;40(9):533–44 (89 ref.)
Pharmacology of neuropathic pain. Ollat H, et al. **Clin Neuropharmacol** 1995 Oct;18(5):391–404 (62 ref.)
Chronic idiopathic urticaria associated with panic disorder: a syndrome responsive to selective serotonin reuptake inhibitor antidepressants? Gupta MA, et al. **Cutis** 1995 Jul; 56(1):53–4
Adjunctive therapy in patients with Alzheimer's disease. A practical approach. Corey-Bloom J, et al. **Drugs Aging** 1995 Aug;7(2):79–87 (46 ref.)
Burning mouth syndrome. Successful treatment with combined psychotherapy and psychopharmacotherapy. Van Houdenhove B, et al. **Gen Hosp Psychiatry** 1995 Sep; 17(5):385–8
Rational antidepressant selection in the elderly. Christensen DD. **Geriatrics** 1995 Oct;50 Suppl 1:S41–50 (41 ref.)
Structural validity of MADRS during antidepressant treatment. Galinowski A, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):157–61
Scandinavian experience with citalopram in the elderly. Gottfries CG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:41–4 (14 ref.)
The antidepressant efficacy of citalopram. Montgomery SA, et al. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:29–33 (9 ref.)
Effective management of depression today: report from an interactive workshop. Thompson C, et al. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:45–50
The effects of bifemelane hydrochloride on depressive illness of the elderly. Yamagami S, et al. **Int J Clin Pharmacol Res** 1995;15(1):1–7
Antidepressants in geriatric depression: what difference have they made? Baldwin RC. **Int Psychogeriatr** 1995;7 Suppl:55–68 (65 ref.)
Treatment-resistant depression in the elderly. Bonner D, et al. **Int Psychogeriatr** 1995;7 Suppl:83–94 (70 ref.)
Research directions for treatment of depression. Finkel SI. **Int Psychogeriatr** 1995;7 Suppl:139–42
Late-life delusional depression: acute and long-term treatment. Meyers BS. **Int Psychogeriatr** 1995;7 Suppl:113–24 (73 ref.)
Efficacy of acute treatment for geriatric depression. Schneider LS, et al. **Int Psychogeriatr** 1995;7 Suppl:7–25 (75 ref.)
Therapeutic efficacy of antidepressants in agitated anxious depression—a meta-analysis of moclobemide studies. Delini-Stula A, et al. **J Affect Disord** 1995 Oct 9; 35(1-2):21–30
The tridimensional personality questionnaire as a predictor of response to nefazodone treatment of depression [comment] Nelson EC, et al. **J Affect Disord** 1995 Oct 9; 35(1-2):51–7. Comment on: J Affect Disord 1994 Jan;30(1):35–46.
Fluoxetine for ADHD in a young child [letter] Campbell NB, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1259–60
More on SSRI-induced mania [letter] Kat H. **J Am Acad Child Adolesc Psychiatry** 1996 Aug;35(8):975
Efficacy and tolerability of antidepressant therapy in the old-old. Finkel SI. **J Clin Psychiatry** 1996;57 Suppl 5:23–8 (47 ref.)
Antidepressant treatment of binge-eating disorder: research findings and clinical guidelines. Hudson JI, et al. **J Clin Psychiatry** 1996;57 Suppl 8:73–9 (37 ref.)
Augmentation strategies: focus on anxiolytics. Joffe RT, et al. **J Clin Psychiatry** 1996;57 Suppl 7:25–31; discussion 32–3 (56 ref.)
New developments in the pharmacologic treatment of schizoaffective disorder. Keck PE Jr, et al. **J Clin Psychiatry** 1996;57 Suppl 9:41–8 (78 ref.)
The experts converse. Special considerations in switching antidepressants. Keller MB, et al. **J Clin Psychiatry** 1995 Oct;56(10):suppl 1–12
Tolerability and safety: essentials in antidepressant pharmacotherapy. Lader MH. **J Clin Psychiatry** 1996;57 Suppl 2:39–44 (26 ref.)
Efficacy in long-term treatment of depression. Montgomery SA. **J Clin Psychiatry** 1996;57 Suppl 2:24–30 (28 ref.)
Antidepressants and cognitive impairment in the elderly. Oxman TE. **J Clin Psychiatry** 1996;57 Suppl 5:38–44 (59 ref.)
The diagnosis and treatment of late-life depression. Rothschild AJ. **J Clin Psychiatry** 1996;57 Suppl 5:5–11 (80 ref.)
A meta-analysis of antidepressant outcome studies that involved children and adolescents. Thurber S, et al. **J Clin Psychol** 1995 May;51(3):340–5
Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. Angst J, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):16S–23S
Moclobemide in continuation treatment of major depressive episodes: an open follow-up study over six months. Gagiano CA, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):46S–50S
Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three times daily dosage schedules. Gagiano CA, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):4S–9S
Moclobemide versus fluoxetine in the treatment of inpatients with major depression. Gattaz WF, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):35S–40S
Carbamazepine but not valproate induces bupropion metabolism. Ketter TA, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):327–33
Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study. Kragh-Sørensen P, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):24S–30S
A comparison of the efficacy and tolerability of moclobemide given as a single daily dose or in three divided doses per day for the treatment of patients with a major depressive episode (DSM-III-R). Newburn G, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):10S–15S
Recent clinical development with reversible and selective amine oxidase inhibitors: a valuable addition to the armamentarium. Chairman's introduction. Priest RG. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):1S–3S (18 ref.)
A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression. Stabl M, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):41S–45S
Moclobemide for depression: an Australian psychiatric practice study. Tiller JW, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):31S–34S
Health-related quality of life in patients with major depression who are treated with moclobemide. Walker V, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):60S–67S
Nefazodone and venlafaxine: two new agents for the treatment of depression. Goldberg RJ. **J Fam Pract** 1995 Dec;41(6):591–4 (19 ref.)
Usefulness of the SF-36 Health Survey in measuring health outcomes in the depressed elderly. Beusterien KM, et al. **J Geriatr Psychiatry Neurol** 1996 Jan;9(1):13–21
The depressions of Alzheimer's disease: sorting, pharmacotherapy, and clinical advice. Knesper DJ. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S40–51 (147 ref.)
Commentary. What should doctors do in the face of negative evidence? Eisenberg L. **J Nerv Ment Dis** 1996 Feb; 184(2):103–5
Antidepressants for children. Is scientific support necessary? Fisher RL, et al. **J Nerv Ment Dis** 1996 Feb;184(2):99–102 (31 ref.)
Commentary. Clinical judgment, scientific data, and ethics: antidepressant therapy in adolescents and children. Pellegrino ED. **J Nerv Ment Dis** 1996 Feb;184(2):106–8
Treatment of depression in Parkinson's disease: a meta-analysis. Klaassen T, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):281–6
A 47-year-old man with chronic depression, 1 year later. Delbanco TL, et al. **JAMA** 1996 Sep 11;276(10):822
Transdermal oestrogen for treatment of severe postnatal depression [see comments] Gregoire AJ, et al. **Lancet** 1996 Apr 6;347(9006):930–3. Comment in: Lancet 1996 Apr 6;347(9006):918–9.
Oestrogen and postnatal depression [comment] Murray D. **Lancet** 1996 Apr 6;347(9006):918–9. Comment on: Lancet 1996 Apr 6;347(9006):930–3.
Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Scott TF, et al. **Neurol Res** 1995 Dec;17(6):421–2
New antidepressants. Kupecz D. **Nurse Pract** 1995 Sep; 20(9):64–7 (18 ref.)
A double-blind randomized placebo-controlled trial of sibutramine. Bray GA, et al. **Obes Res** 1996 May; 4(3):263–70
A randomized controlled trial of citalopram in the treatment of fibromyalgia. Nørregaard J, et al. **Pain** 1995 Jun; 61(3):445–9
Paroxetine in the elderly: a comparative meta-analysis against standard antidepressant pharmacotherapy. Dunbar GC. **Pharmacology** 1995 Sep;51(3):137–44
How to assess the onset of antidepressant effect: comparison of global ratings and findings based on depression scales. Möller HJ, et al. **Pharmacopsychiatry** 1996 Mar;29(2):57–62
The morality of using antidepressants [letter; comment] Rifkin A. **Pharos** 1995 Fall;58(4):36. Comment on: Pharos 1995 Summer;58(3):2–7.
Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)
Treatment algorithms in treatment-resistant depression. Amsterdam JD, et al. **Psychiatr Clin North Am** 1996 Jun; 19(2):371–86 (72 ref.)
Definition and epidemiology of treatment-resistant depression. Fava M, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):179–200 (104 ref.)
The management of treatment-resistant depression in the medically ill. Franco-Bronson K. **Psychiatr Clin North Am** 1996 Jun;19(2):329–50 (154 ref.)
Pharmacotherapy for chronic depression. Friedman RA, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):121–32 (31 ref.)
Treatment-resistant depression in children and adolescents. Geller B, et al. **Psychiatr Clin North Am** 1996 Jun; 19(2):253–67 (89 ref.)
The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder. Gruber AJ, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):351–69 (79 ref.)
Novel strategies for treatment-resistant depression. Hornig-Rohan M, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):387–405 (133 ref.)
Management of treatment resistance in the depressed geriatric patient. Kamholz BA, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):269–86 (147 ref.)
Combined medication and psychotherapy in the treatment of chronic mood disorders. Miller IW, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):151–71 (70 ref.)
The management of treatment resistance in depressed patients with substance use disorders. Nunes EV, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):311–27 (92 ref.)
Management of treatment-resistant unipolar and chronically depressed patients. Reus VI. **Psychiatr Clin North Am** 1996 Jun;19(2):201–13 (134 ref.)
Treatment-resistant bipolar depression. Sachs GS. **Psychiatr Clin North Am** 1996 Jun;19(2):215–36 (78 ref.)
The role of Axis II comorbidity in the management of patients with treatment-resistant depression. Thase ME. **Psychiatr Clin North Am** 1996 Jun;19(2):287–309 (97 ref.)
Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Fava M, et al. **Psychiatry Res** 1995 Apr 28;56(3):295–7
Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Maes M, et al. **Psychiatry Res** 1995 Oct 16;58(3):217–25
Novel French antidepressants not available in the United States. Mitchell PB. **Psychopharmacol Bull** 1995; 31(3):509–19
Clinical trials of antidepressants: the hidden face: where locus of control appears to play a key role in depression outcome. Reynaert C, et al. **Psychopharmacology (Berl)** 1995 Jun; 119(4):449–54
Onset and time course of antidepressant action: psychopharmacological implications of a controlled trial of electroconvulsive therapy. Segman RH, et al. **Psychopharmacology (Berl)** 1995 Jun;119(4):440–8
Rapid synergistic effects of lithium and antidepressants [letter] Terao T. **Psychopharmacology (Berl)** 1995 Nov;

122(2):206-7
The efficacy of amitriptyline and acetaminophen in the management of acute low back pain. Stein D, et al. **Psychosomatics** 1996 Jan-Feb;37(1):63-70
Benzodiazepine use in the elderly prior to psychiatric hospitalization. Zisselman MH, et al. **Psychosomatics** 1996 Jan-Feb;37(1):38-42
Antidepressant treatment in general practice--an interview study. Rosholm JU, et al. **Scand J Prim Health Care** 1995 Dec;13(4):281-6
A controlled double-blind trial of moclobemide and imipramine in the treatment of depression. Kok LP, et al. **Singapore Med J** 1995 Feb;36(1):38-40
Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Staner L, et al. **Sleep** 1995 Jul;18(6):470-7
[Effectiveness of clonazepam in depressive disorders] Svestka J, et al. **Ceska Slov Psychiatr** 1995 Aug;91(4):199-207 (Eng. Abstr.) **(Cze)**
[The concept of depression and evaluation of the effect of antidepressive agents (letter; comment)] Licht RW. **Ugeskr Laeger** 1996 Jun 3;158(23):3332-3. Comment on: Ugeskr Laeger 1996 Mar 11;158(11):1508-12. **(Dan)**
[Citalopram and desmethylcitalopram for psychiatric patients] Linnet K, et al. **Ugeskr Laeger** 1996 Aug 26; 158(35):4920-3 (Eng. Abstr.) **(Dan)**
[Effect of adjuvant drug therapy following successful electroconvulsive therapy for therapy-resistant depression is still disappointing] Leentjens AF, et al. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):241-3 (31 ref.) **(Dut)**
[Electroconvulsive therapy in therapy-resistant depression (letter)] Verwey B. **Ned Tijdschr Geneeskd** 1996 May 11; 140(19):1042 **(Dut)**
[Citalopram in the treatment of panic disorders and school phobia in children and adolescents] Lepola U, et al. **Duodecim** 1994;110(1):60-2 **(Fin)**
[Adverse effects: priapism caused by paroxetine] Bertholon F, et al. **Ann Med Psychol (Paris)** 1996 May;154(2):145-6; discussion 146-7 (Eng. Abstr.) **(Fre)**
[Duration of treatment for depression. IVth Marseille colloquium. Marseille, France, 28-29 January 1994] **Encephale** 1995 Mar;21 Spec No 2:1-78 **(Fre)**
[Pathologic personality, temperament and treatment] Akiskal HS. **Encephale** 1995 Mar;21 Spec No 2:47-9 (Eng. Abstr.) **(Fre)**
[Pharmacologic treatment of bulimia] Corcos M, et al. **Encephale** 1996 Mar-Apr;22(2):133-42 (37 ref.) (Eng. Abstr.) **(Fre)**
[Biological factors and resistance to antidepressive agents] Puech AJ, et al. **Encephale** 1995 Mar;21 Spec No 2:17-21 (25 ref.) (Eng. Abstr.) **(Fre)**
[Pharmaco-epidemiologic study of the use of antidepressant drugs in the general population] Rouillon F, et al. **Encephale** 1996 May;22 Spec No 1:39-48 (Eng. Abstr.) **(Fre)**
[The concept of depression (editorial)] Scotto JC. **Encephale** 1996 May;22 Spec No 1:1-2 **(Fre)**
[Status of thymoleptics in the treatment of bipolar disorders] Sechter D. **Encephale** 1996 Jan-Feb;22(1):65-8 (24 ref.) (Eng. Abstr.) **(Fre)**
[Antidepressive agents] Ansseau M. **Rev Med Liege** 1996 Jan; 51(1):78-84 **(Fre)**
[Evolution of benefit-risk ratio of antidepressants] Corruble E, et al. **Therapie** 1995 Nov-Dec;50(6):515-21 (46 ref.) (Eng. Abstr.) **(Fre)**
[Follow-up of antidepressive therapy in psychiatric clinical practice] Vandel B, et al. **Therapie** 1995 Nov-Dec; 50(6):511-3 (Eng. Abstr.) **(Fre)**
[St. John's wort as antidepressive therapy] Ernst E. **Fortschr Med** 1995 Sep 10;113(25):354-5 (13 ref.) (Eng. Abstr.) **(Ger)**
[Correlation between symptoms and diagnosis in pharmacotherapeutic decision process] Adelhard K, et al. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):123-31 (Eng. Abstr.) **(Ger)**
[Panic disorder and agoraphobia: what is effective?] Bandelow B, et al. **Fortschr Neurol Psychiatr** 1995 Nov; 63(11):451-64 (120 ref.) (Eng. Abstr.) **(Ger)**
[Drug therapy and affective disorders: state of the art] Cugurra F. **Clin Ter** 1995 Oct;146(10):577-85 (32 ref.) (Eng. Abstr.) **(Ita)**
[The effect of amitriptyline on the pathological crying and other pseudobulbar signs] Szczudlik A, et al. **Neurol Neurochir Pol** 1995 Sep-Oct;29(5):663-74 (Eng. Abstr.) **(Pol)**
[Depression in schizophrenia. Comments on possibilities to use fluoxetine] Jarema M. **Psychiatr Pol** 1996 Jan-Feb; 30(1):75-86 (Eng. Abstr.) **(Pol)**
[A case of serotonin syndrome] Loza B. **Psychiatr Pol** 1995 Jul-Aug;29(4):529-38 (Eng. Abstr.) **(Pol)**
[Mianserin efficacy in the treatment of depression] Ostapowicz A, et al. **Psychiatr Pol** 1996 Jan-Feb; 30(1):127-36 (Eng. Abstr.) **(Pol)**
[Depression, antidepressants and the biological clock] Arushanian EB, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):85-9 (71 ref.) **(Rus)**
[The use of a decoction of the rhizome of Leuzea carthamoides for the treatment of alcoholics with depressive states] Ibatov AN. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):78-9 (Eng. Abstr.) **(Rus)**
[Usefulness of lithium in neutropenia associated with AIDS (letter)] Martinez Ruiz M, et al. **An Med Interna** 1996 Jan; 13(1):49 **(Spa)**
[Antidepressants and migraine] Legarda I. **Rev Neurol** 1995; 23 Suppl 2:S193-7 (47 ref.) **(Spa)**
[Pharmacotherapeutic recommendation for depression. Newer preparations are recommended, especially in primary health care. Läkemedelsverket (Swedish Drug Authority)] **Lakartidningen** 1996 Jan 3;93(1-2):65-8 **(Swe)**

TOXICITY

Antidepressant toxicity and the need for identification and concentration monitoring in overdose. Power BM, et al. **Clin Pharmacokinet** 1995 Sep;29(3):154-71 (137 ref.)
The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: a study of healthy male and female volunteers. Davis C, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):347-52
Enhancement of tumor growth by drugs with some common molecular actions. LaBella FS, et al. **Mol Carcinog** 1996 Jun;16(2):68-76 (91 ref.)

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION

Frankenstein in the age of Prozac. Goodson AC. **Lit Med** 1996 Spring;15(1):16-32

ADMINISTRATION & DOSAGE

Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. Covi L, et al. **Am J Drug Alcohol Abuse** 1995 Aug;21(3):327-44
Therapeutic dose range of nefazodone in the treatment of major depression. Robinson DS, et al. **J Clin Psychiatry** 1996;57 Suppl 2:6-9
Sertraline in stuttering [letter] Costa AD, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):443-4
Nefazodone: a novel antidepressant. Goldberg RJ. **Psychiatr Serv** 1995 Nov;46(11):1113-4
[Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate] Viala A, et al. **Therapie** 1996 Jan-Feb;51(1):19-25 (Eng. Abstr.) **(Fre)**
[Adolescents manage their crises without "happy pills" (letter)] Berggren I. **Lakartidningen** 1996 Jan 17;93(3):123 **(Swe)**

ADVERSE EFFECTS

Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants. Devulder J, et al. **Acta Clin Belg** 1996;51(3):184-6
Bupropion and nightmares [letter] Balon R. **Am J Psychiatry** 1996 Apr;153(4):579-80
Hair loss associated with fluvoxamine use [letter] Parameshwar E. **Am J Psychiatry** 1996 Apr;153(4):581-2
Development of obsessive symptoms during nefazodone treatment [letter] Sofuoglu M, et al. **Am J Psychiatry** 1996 Apr;153(4):577-8
Apparent interaction between nefazodone and cyclosporine [letter] Helms-Smith KM, et al. **Ann Intern Med** 1996 Sep 1;125(5):424
Eosinophilia associated with bupropion. Malesker MA, et al. **Ann Pharmacother** 1995 Sep;29(9):867-9
Probable terfenadine-fluoxetine-associated cardiac toxicity [letter] Marchiando RJ, et al. **Ann Pharmacother** 1995 Sep; 29(9):937-8
Severe hyponatremia during therapy with fluoxetine. ten Holt WL, et al. **Arch Intern Med** 1996 Mar 25;156(6):681-2
Suicidality and the use of serotonin reuptake inhibitors [letter; comment] Arya DK. **Aust N Z J Psychiatry** 1995 Sep; 29(3):517-8. Comment on: Aust N Z J Psychiatry 1995 Mar;29(1):156-7.
Exacerbation of extrapyramidal symptoms with paroxetine [letter] Arya DK, et al. **Aust N Z J Psychiatry** 1995 Sep; 29(3):521-2
Vulnerability to fluoxetine-induced indifference syndrome among opiate addicts: a case report. Bertschy G, et al. **Biol Psychiatry** 1995 Sep 15;38(6):404-6
Possible serotonin syndrome with trazodone addition to fluoxetine [letter] George TP, et al. **Biol Psychiatry** 1996 Mar 1;39(5):384-5
Fluoxetine and visual hallucinations in dementia. Omar SJ, et al. **Biol Psychiatry** 1995 Oct 15;38(8):556-8
A clinical dilemma [letter] Divinsky M. **Can Fam Physician** 1996 Mar;42:406
Involuntary sperm emission with fluoxetine [letter] Benazzi F. **Can J Psychiatry** 1995 Sep;40(7):431
Antidepressant-induced mania [letter] Shammi C. **Can J Psychiatry** 1995 Dec;40(10):635-6
Retroperitoneal haematoma in a patient treated with acenocoumarol, phenytoin and paroxetine. Abad-Santos F, et al. **Clin Lab Haematol** 1995 Jun;17(2):195-7
Akathisia: a review and case report following paroxetine treatment. Baldassano CF, et al. **Compr Psychiatry** 1996 Mar-Apr;37(2):122-4 (40 ref.)
Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Hewer W, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;246(1):1-6
Fluoxetin-induced pulmonary granulomatosis. de Kerviler E, et al. **Eur Respir J** 1996 Mar;9(3):615-7
Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Shen WW, et al. **Int J Psychiatry Med** 1995; 25(3):239-48
Pseudo-mycosis fungoides in a patient taking clonazepam and fluoxetine. Gordon KB, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):304-6
The safety profile of nefazodone. Robinson DS, et al. **J Clin Psychiatry** 1996;57 Suppl 2:31-8 (20 ref.)
Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. Bauer M, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):130-4
A toxic reaction from combining fluoxetine and phentermine [letter] Bostwick JM, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):189-90
Withdrawal syndromes after paroxetine and sertraline discontinuation [letter] Fava GA, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):374-5
Serotonin syndrome in the elderly after antidepressive monotherapy [letter] Fischer P. **J Clin Psychopharmacol** 1995 Dec;15(6):440-2
Effects of third trimester fluoxetine exposure on the newborn. Goldstein DJ. **J Clin Psychopharmacol** 1995 Dec; 15(6):417-20
Trazodone and spontaneous orgasms in an elderly postmenopausal woman: a case report [letter] Purcell P, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):293-5
A depressed workman with heatstroke. Albukrek D, et al. **Lancet** 1996 Apr 13;347(9007):1016
Toxic interaction of venlafaxine and isocarboxazide [letter] Klysner R, et al. **Lancet** 1995 Nov 11;346(8985):1298-9
Paroxetine-induced SIADH [letter] Ayonrinde OT, et al. **Med J Aust** 1995 Oct 2;163(7):390
Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring. Gründer G, et al. **Pharmacopsychiatry** 1996 Mar;29(2):72-8
Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience. Hochberg HM, et al. **Pharmacopsychiatry** 1995 Nov; 28(6):253-6
Adverse events after the abrupt discontinuation of paroxetine. Dominguez RA, et al. **Pharmacotherapy** 1995 Nov-Dec; 15(6):778-80
[Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration] Bonin B, et al. **Encephale** 1996 May-Jun;22(3):221-7 (Eng. Abstr.) **(Fre)**
[Fluvoxamine and serotonin syndrome in a patient with Parkinson disease (letter)] Le Cavorzin P, et al. **Therapie** 1996 Mar-Apr;51(2):195-6 **(Fre)**
[Extrapyramidal disorders induced by veralipride (Agreal). Apropos of 5 cases] Masmoudi K, et al. **Therapie** 1995 Sep-Oct;50(5):451-4 (Eng. Abstr.) **(Fre)**
[Toxic tricyclic drug plasma level caused by fluoxetine] Hambrecht M. **Psychiatr Prax** 1995 Nov;22(6):252-3 (Eng. Abstr.) **(Ger)**
[SSRI-induced akathesia] Hofmann M, et al. **Psychiatr Prax** 1996 May;23(3):143-4 **(Ger)**
[Pollakiuria and micturition syndrome related to fluoxetine (letter)] Sancho A, et al. **Med Clin (Barc)** 1995 Nov 4; 105(15):598-9 **(Spa)**

ANALYSIS

Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. Miner CM, et al. **Biol Psychiatry** 1995 Nov 15;38(10):696-8

ANTAGONISTS & INHIBITORS

Inhibition of trazodone metabolism by thioridazine in humans. Yasui N, et al. **Ther Drug Monit** 1995 Aug; 17(4):333-5

BLOOD

Determination of maprotiline in plasma by high-performance liquid chromatography with chemiluminescence detection. Ishida J, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21; 669(2):390-6
Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Otani K, et al. **Ther Drug Monit** 1996 Apr;18(2):164-7
Enantioselective determination of mianserin and its desmethyl metabolite in plasma during treatment of depressed Japanese patients. Tybring G, et al. **Ther Drug Monit** 1995 Oct;17(5):516-21

ECONOMICS

Meta-analysis of antidepressant prescribing. Important differences exist between second generation antidepressants [letter; comment] Ferguson JJ, et al. **BMJ** 1995 Sep 16; 311(7007):751. Comment on: BMJ 1995 Jun 3;310(6992):1433-8.
Economics of treatment of depression [letter; comment] Owens DW. **Br J Psychiatry** 1995 Jul;167(1):112. Comment on: Br J Psychiatry 1994 May;164(5):665-73.
Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Lapierre Y, et

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION

al. **Can J Psychiatry** 1995 Sep;40(7):370–7

[New antidepressive agents—expenses and incomes (letter)] Hovind OB. **Tidsskr Nor Laegeforen** 1996 Apr 30; 116(11):1383 **(Nor)**

METABOLISM

Further evidence that fluoxetine interacts with a 5-HT2C receptor in glial cells. Chen Y, et al. **Brain Res Bull** 1995; 38(2):153–9

Lack of an interaction between sumatriptan and selective serotonin reuptake inhibitors. Leung M, et al. **Headache** 1995 Sep;35(8):488–9

PHARMACOKINETICS

Pharmacokinetics of the newer antidepressants [letter; comment] Burke MJ, et al. **Am J Med** 1996 Jan; 100(1):119–21. Comment on: Am J Med 1994 Dec 19;97(6A):13S–23S.

Overview of the pharmacokinetics of fluvoxamine. van Harten J. **Clin Pharmacokinet** 1995;29 Suppl 1:1–9 (49 ref.)

Nefazodone pharmacokinetics: assessment of nonlinearity, intra–subject variability and time to attain steady–state plasma concentrations after dose escalation and de–escalation. Barbhaiya RH, et al. **Eur J Clin Pharmacol** 1996;50(1–2):101–7

Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Levy NB, et al. **Gen Hosp Psychiatry** 1996 Jan;18(1):8–13

Pharmacokinetic interactions between lithium and fluoxetine after single and repeated fluoxetine administration in young healthy volunteers. Breuel HP, et al. **Int J Clin Pharmacol Ther** 1995 Jul;33(7):415–9

Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double–blind, phase I study. Barbhaiya RH, et al. **J Clin Pharmacol** 1995 Oct;35(10):974–84

Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men. Salazar DE, et al. **J Clin Pharmacol** 1995 Nov; 35(11):1109–18

Pharmacokinetics of single– and multiple–dose bupropion in elderly patients with depression. Sweet RA, et al. **J Clin Pharmacol** 1995 Sep;35(9):876–84

Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans. Marathe PH, et al. **Pharm Res** 1995 Nov; 12(11):1716–21

Inhibition of trazodone metabolism by thioridazine in humans. Yasui N, et al. **Ther Drug Monit** 1995 Aug; 17(4):333–5

PHARMACOLOGY

Single–dose ritanserin and alcohol in healthy volunteers: a placebo–controlled trial. Estevez F, et al. **Alcohol** 1995 Nov–Dec;12(6):541–5

Clarification of venlafaxine chemistry, pharmacology, and pharmacokinetics [letter; comment] Albano D, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1573–4. Comment on: Am J Hosp Pharm 1994 Dec 15;51(24):3033–46.

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Brøsen K. **Clin Pharmacokinet** 1995;29 Suppl 1:20–5 (20 ref.)

Fluvoxamine. A review of global drug–drug interaction data. Wagner W, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:26–31; discussion 31–2 (23 ref.)

Platelet 5–hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5–hydroxytryptamine re–uptake inhibiting drug fluoxetine. Menys VC, et al. **Clin Sci (Colch)** 1996 Jul;91(1):87–92

Modulation of ionic currents in isolated canine and human jejunal circular smooth muscle cells by fluoxetine. Farrugia G. **Gastroenterology** 1996 May;110(5):1438–45

Changes in histamine and serotonin secretion from rat peritoneal mast cells caused by antidepressants. Ferjan I, et al. **Inflamm Res** 1996 Mar;45(3):141–4

QT prolongation and polymorphous ventricular tachycardia associated with trasodone–amiodarone combination. Mazur A, et al. **Int J Cardiol** 1995 Nov 10;52(1):27–9

New approaches to the treatment of depression. Leonard BE. **J Clin Psychiatry** 1996;57 Suppl 4:26–33 (67 ref.)

Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Riesenman C. **Pharmacotherapy** 1995 Nov–Dec;15(6 Pt 2):84S–99S (78 ref.)

Male reproductive systems under chronic fluoxetine or trimipramine treatment. Taylor G, et al. **Physiol Behav** 1996 Mar;59(3):479–85

Interaction of opioids with antidepressant–induced antinociception. Sierralta F, et al. **Psychopharmacology (Berl)** 1995 Dec;122(4):374–8

POISONING

Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine. Power BM, et al. **Anaesth Intensive Care** 1995 Aug;23(4):499–502

Trazodone for the treatment of depression in alcoholics [letter] Hershberg PI. **J Subst Abuse Treat** 1995 Jul–Aug; 12(4):297

THERAPEUTIC USE

Nefazodone: a new antidepressant. Ellingrod VL, et al. **Am J Health Syst Pharm** 1995 Dec 15;52(24):2799–812 (54 ref.)

Multicenter, placebo–controlled study of fluoxetine in seasonal affective disorder. Lam RW, et al. **Am J Psychiatry** 1995 Dec;152(12):1765–70

Venlafaxine for the treatment of chronic pain [letter] Songer DA, et al. **Am J Psychiatry** 1996 May;153(5):737

Treatment of dysphoric mania with nefazodone [letter] Worthington JJ 3rd, et al. **Am J Psychiatry** 1996 May; 153(5):732–3

An evaluation of antidepressants in rheumatic pain conditions. Rani PU, et al. **Anesth Analg** 1996 Aug; 83(2):371–5

Fluoxetine treatment of depressed patients with HIV infection. Judd FK, et al. **Aust N Z J Psychiatry** 1995 Sep; 29(3):433–6

Yohimbine augmentation of fluvoxamine in refractory depression: a single–blind study. Cappiello A, et al. **Biol Psychiatry** 1995 Dec 1;38(11):765–7

Deciding which selective serotonin reuptake inhibitor to prescribe [letter; comment] Cleare AJ. **BMJ** 1995 Dec 16; 311(7020):1641. Comment on: BMJ 1993 Mar 13;306(6879):683–7. Comment on: BMJ 1995 Jun 3;310(6992):1433–8.

Paroxetine in the treatment of premature ejaculation. Ludovico GM, et al. **Br J Urol** 1996 Jun;77(6):881–2

Paroxetine in the treatment of Chinese patients with depressive episode: a double–blind randomized comparison with imipramine. Chiu HJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jun; 57(6):418–23

Lack of an interaction between sumatriptan and selective serotonin reuptake inhibitors. Leung M, et al. **Headache** 1995 Sep;35(8):488–9

Out of the dumps by blocking the serotonin pump [editorial] **Indian J Physiol Pharmacol** 1995 Oct;39(4):313

Acute effects of fluoxetine versus placebo on functional health and well–being in late–life depression. Heiligenstein JH, et al. **Int Psychogeriatr** 1995;7 Suppl:125–37

Clinical response predictors in a double–blind, placebo–controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group. Small GW, et al. **Int Psychogeriatr** 1995;7 Suppl:41–53

Predictors of response to amine–specific antidepressants. Burns RA, et al. **J Affect Disord** 1995 Dec 13;35(3):97–106

Changes in EEG power density of non–REM sleep in depressed patients during treatment with trazodone. Van Bemmel AL, et al. **J Affect Disord** 1995 Oct 9;35(1–2):11–9

New perspectives in the management of depression. Symposium highlights from ECNP, Venice, September 1995. **J Clin Psychiatry** 1996 Aug;57(8):377–84

A multicenter double–blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate–to–severe depression. Baldwin DS, et al. **J Clin Psychiatry** 1996;57 Suppl 2:46–52

Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. Cohn CK, et al. **J Clin Psychiatry** 1996;57 Suppl 2:15–8

An open–label trial of nefazodone in high comorbidity panic disorder. DeMartinis NA, et al. **J Clin Psychiatry** 1996 Jun; 57(6):245–8

Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. Feiger A, et al. **J Clin Psychiatry** 1996;57 Suppl 2:53–62

Venlafaxine in adults with attention–deficit/hyperactivity disorder: an open clinical trial. Findling RL, et al. **J Clin Psychiatry** 1996 May;57(5):184–9

Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition [letter] Ketter TA, et al. **J Clin Psychiatry** 1996 Jul;57(7):307

Nefazodone in the treatment of severe, melancholic, and recurrent depression. Marcus RN, et al. **J Clin Psychiatry** 1996;57 Suppl 2:19–23

The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. Zajecka JM. **J Clin Psychiatry** 1996;57 Suppl 2:10–4

Fluvoxamine maleate in the treatment of depression: a single–center, double–blind, placebo–controlled comparison with imipramine in outpatients. Claghorn JL, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):113–20

Predicting response to fluoxetine in geriatric patients with major depression. Koran LM, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):421–7

Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. Simon GE, et al. **JAMA** 1996 Jun 26;275(24):1897–902

Fluoxetine and chronic fatigue syndrome [letter] Cleare AJ, et al. **Lancet** 1996 Jun 22;347(9017):1770; discussion 1771–2

Fluoxetine and chronic fatigue syndrome [letter] Lynch S, et al. **Lancet** 1996 Jun 22;347(9017):1771; discussion 1171–2

Randomised, double–blind, placebo–controlled study of fluoxetine in chronic fatigue syndrome. Vercoulen JH, et al. **Lancet** 1996 Mar 30;347(9005):858–61

New antidepressants. Kupecz D. **Nurse Pract** 1995 Sep; 20(9):64–7 (18 ref.)

Paroxetine in the elderly: a comparative meta–analysis against standard antidepressant pharmacotherapy. Dunbar GC. **Pharmacology** 1995 Sep;51(3):137–44

Notes on the use of fluvoxamine as treatment of depression in HIV–1–infected subjects. Grassi B, et al. **Pharmacopsychiatry** 1995 May;28(3):93–4

Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience. Hochberg HM, et al. **Pharmacopsychiatry** 1995 Nov; 28(6):253–6

A controlled study of the efficacy and safety of mianserin and amitriptyline in depressive inpatients. Möller HJ, et al. **Pharmacopsychiatry** 1995 Nov;28(6):249–52

Therapeutic options for treating major depression, and the role of venlafaxine. Scott MA, et al. **Pharmacotherapy** 1996 May–Jun;16(3):352–65 (91 ref.)

Recent developments in antidepressant agents. Claghorn J, et al. **Prog Drug Res** 1996;46:243–62 (72 ref.)

A new pharmacologic treatment of functional gastrointestinal disorder. A double–blind placebo–controlled study with mianserin. Tanum L, et al. **Scand J Gastroenterol** 1996 Apr; 31(4):318–25

Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Dam M, et al. **Stroke** 1996 Jul;27(7):1211–4

[Paroxetine in the treatment of depressive disorders (pilot study)] Svestka J, et al. **Cesk Psychiatr** 1995 Jul; 91(3):135–42 (Eng. Abstr.) **(Cze)**

[Major depressive episodes in patients over 70 years of age. Evaluation of the efficiency and acceptability of tianeptine and mianserin] Brion S, et al. **Presse Med** 1996 Mar 16; 25(9):461–8 (Eng. Abstr.) **(Fre)**

[Is there a new trend in antidepressive therapy? Bonn, 2 July 1993] **Nervenarzt** 1993 Oct;64(10 Suppl):1–8 **(Ger)**

[Therapy of post–stroke depression with fluoxetine. A pilot project] Stamenkovic M, et al. **Nervenarzt** 1996 Jan; 67(1):62–7 (Eng. Abstr.) **(Ger)**

[The effect of fluoxetine on insulin resistance in non diabetic obese patients] Araya V, et al. **Rev Med Chil** 1995 Aug; 123(8):943–7 (Eng. Abstr.) **(Spa)**

ANTIDEPRESSIVE AGENTS, TRICYCLIC

ADMINISTRATION & DOSAGE

Long–term follow–up after a drug trial for panic disorder. Katschnig H, et al. **Br J Psychiatry** 1995 Oct;167(4):487–94

Drugs to treat the tissue complications of diabetes: peripheral neuropathy. Emanuele NV, et al. **Compr Ther** 1995 Oct; 21(10):579–82 (30 ref.)

Life stress and treatment course of recurrent depression: II. Postrecovery associations with attrition, symptom course, and recurrence over 3 years. Monroe SM, et al. **J Abnorm Psychol** 1996 Aug;105(3):313–28

Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. Kuhs H, et al. **J Affect Disord** 1996 Feb 12;37(1):31–41

Dosing of antidepressants—the unknown art. Jerling M. **J Clin Psychopharmacol** 1995 Dec;15(6):435–9

[Treatment of depression with a neuro–thymoleptic combination in general practice] Schirmer G. **Psychiatr Prax** 1996 Mar;23(2):99–100 **(Ger)**

[Spare us the idiocy (letter)] Terland O. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2214 **(Nor)**

ADVERSE EFFECTS

Nightmares and hallucinations after long–term intake of tramadol combined with antidepressants. Devulder J, et al. **Acta Clin Belg** 1996;51(3):184–6

Pilocarpine for anticholinergic adverse effects associated with desipramine treatment [letter] Salah RS, et al. **Am J Psychiatry** 1996 Apr;153(4):579

Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189–201 (107 ref.)

Allergic contact dermatitis from doxepin cream. One–year patch test clinic experience. Taylor JS, et al. **Arch Dermatol** 1996 May;132(5):515–8

Psychotropic drugs [letter] Lambe J. **Aust N Z J Psychiatry** 1995 Sep;29(3):522–3

Tricyclic–induced musical hallucinations and states of relative sensory deprivation. Terao T. **Biol Psychiatry** 1995 Aug 1;38(3):192–3

Meta–analysis of antidepressant prescribing. Acceptability of side effects as reason for stopping may bias results [letter; comment] Ramchandani P, et al. **BMJ** 1995 Sep 16; 311(7007):751. Comment on: BMJ 1995 Jun 3;310(6992):1433–8.

Effect of exposure to dothiepin and northiaden in breast milk on child development. Buist A, et al. **Br J Psychiatry** 1995 Sep;167(3):370–3

Behavioural toxicities of antidepressants [letter; comment] Kerr JS, et al. **Br J Psychiatry** 1995 Sep;167(3):413–4. Comment on: Br J Psychiatry 1995 Apr;166(4):421–3.

Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. Taylor D. **Br J Psychiatry** 1995 Nov; 167(5):575–80 (38 ref.)

Tricyclic medication in children and the QT interval: case report and discussion. Alderton HR. **Can J Psychiatry** 1995 Aug;40(6):325–9 (30 ref.)

ECG changes in pediatric patients on tricyclic antidepressants, desipramine, and imipramine. Johnson A, et al. **Can J Psychiatry** 1996 Mar;41(2):102–6

Development of mania in close association with tricyclic antidepressant administration in children. A report of two cases. Briscoe JJ, et al. **Eur Child Adolesc Psychiatry** 1995 Oct;4(4):280–3

Withdrawal of routine psychiatric medications in a general medical ward [letter] Sloan D. **Ir Med J** 1996 May–Jun; 89(3):116

Another cause for acute carpal tunnel syndrome: tricyclic overdose. Hargreaves DG, et al. **J Accid Emerg Med** 1995 Jun;12(2):158–9

Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents [see comments] Leonard HL, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1460–8. Comment in: J Am Acad Child Adolesc Psychiatry 1996 Jun;35(6):701–2.

Polypharmacy side effects [letter] Markowitz J, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):842

TCA cardiotoxicity: the latest [letter; comment] Oesterheld J. **J Am Acad Child Adolesc Psychiatry** 1996 Jun; 35(6):701–2. Comment on: J Am Acad Child Adolesc Psychiatry 1995 Nov;34(11):1460–8.

Resolved: cardiac arrhythmias make desipramine an unacceptable choice in children. Werry JS, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1239–45; discussion 1245–8

Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study. Kragh-Sørensen P, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):24S–30S

Case 7: the addled nonagenarian. Shader RI, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):378

Five-year multicenter retrospective review of cyclobenzaprine toxicity. Spiller HA, et al. **J Emerg Med** 1995 Nov–Dec;13(6):781–5 (14 ref.)

Amaurosis fugax on standing and angle-closure glaucoma with clomipramine [letter] Schlingemann RO, et al. **Lancet** 1996 Feb 17;347(8999):465

Drugs that cause weight gain. Fernstrom MH. **Obes Res** 1995 Nov;3 Suppl 4:435S–439S (18 ref.)

The use of anti-depressants and benzodiazepines in the perpetrators and victims of accidents. Currie D, et al. **Occup Med (Oxf)** 1995 Dec;45(6):323–5

Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring. Gründer G, et al. **Pharmacopsychiatry** 1996 Mar;29(2):72–8

Hepatic failure associated with imipramine therapy. Ilan Y, et al. **Pharmacopsychiatry** 1996 Mar;29(2):79–80

Regional cerebral blood flow changes following chronic administration of antidepressant drugs. Passero S, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):627–36

The prophylaxis of depressive episodes in recurrent depression following discontinuation of drug therapy: integrating psychological and biological factors. Spanier C, et al. **Psychol Med** 1996 May;26(3):461–75

Extreme values of the concentration/dose ratio as a risk factor of obtaining suboptimal nortriptyline serum concentrations. Linnet K. **Ther Drug Monit** 1996 Feb; 18(1):53–9

Nortriptyline-induced hepatic failure. Pedersen AM, et al. **Ther Drug Monit** 1996 Feb;18(1):100–2

[Prolonged pseudodementia after treatment with tricyclic antidepressive agents and electroconvulsive therapy] Bennedsen BE, et al. **Ugeskr Laeger** 1996 Apr 8; 158(15):2134–5 (Eng. Abstr.) **(Dan)**

[Torsades de pointes in a patient under long-term maprotiline therapy. Apropos of a case] Rialan A, et al. **Ann Cardiol Angeiol (Paris)** 1996 Mar;45(3):123–5 (Eng. Abstr.) **(Fre)**

[Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration] Bonin B, et al. **Encephale** 1996 May–Jun;22(3):221–7 (Eng. Abstr.) **(Fre)**

[Electrocardiographic changes that wrongly indicate severe myocardial ischemia in patients treated with antidepressive drugs] Minutiello L. **Minerva Cardioangiol** 1996 Jan–Feb; 44(1–2):59–65 (Eng. Abstr.) **(Ita)**

[Drug-induced and masked drug parkinsonism (comment)] Giménez-Roldán S, et al. **Rev Neurol** 1996 May; 24(129):584–5. Comment on: Rev Neurol 1995 Sep–Oct;23(123):961–3. Comment on: Rev Neurol 1995 Sep–Oct;23(123):964–8. Comment on: Rev Neurol 1995 Sep–Oct;23(123):983–5. **(Spa)**

ANALYSIS

A fatal dothiepin overdose. Cirimele V, et al. **Forensic Sci Int** 1995 Dec 29;76(3):205–9

Rapid microsample analysis of imipramine and desipramine by reversed-phase high-performance liquid chromatography with ultraviolet detection. Yoo SD, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23;668(2):338–42

ANTAGONISTS & INHIBITORS

Antagonism of behavioral effects of electroconvulsive shock but not those of desipramine by the selective 5-HT-3 receptor antagonist, ondansetron. Kostowski W, et al. **Pol J Pharmacol** 1995 Mar–Apr;47(2):193–5

Minaprine, but not oxiracetam, prevents desipramine-induced impairment of avoidance learning in mice. Sansone M, et al. **Pol J Pharmacol** 1995 Jan–Feb;47(1):69–73

BLOOD

Is platelet imipramine binding reduced in depression? A meta-analysis by Ellis and Salmond [letter; comment] Schneider LS, et al. **Biol Psychiatry** 1995 Dec 1; 38(11):775–6. Comment on: Biol Psychiatry 1994 Sep 1;36(5):292–9.

Differential effect of cancer on the serum protein binding to mianserin and imipramine. Torres I, et al. **Eur J Drug Metab Pharmacokinet** 1995 Apr–Jun; 20(2):107–11

Improved clean-up procedure for the high-performance liquid chromatographic assay of clomipramine and its demethylated metabolite in human plasma. Altieri I, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):416–7

Determination of maprotiline in plasma by high-performance liquid chromatography with chemiluminescence detection. Ishida J, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21; 669(2):390–6

Quantitative determination of E- and Z-doxepin and E- and Z-desmethyldoxepin by high-performance liquid chromatography. Adamczyk M, et al. **Ther Drug Monit** 1995 Aug;17(4):371–6

Extreme values of the concentration/dose ratio as a risk factor of obtaining suboptimal nortriptyline serum concentrations. Linnet K. **Ther Drug Monit** 1996 Feb; 18(1):53–9

[Tricyclic antidepressants (imipramine, desipramine, amitriptyline, nortriptyline)] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:934–7 (20 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Synthesis and antidepressant evaluation of new hetero[2,1]benzothiazepine derivatives. Díaz JA, et al. **Arch Pharm (Weinheim)** 1996 Jul;329(7):352–60

CHEMISTRY

Synthesis, pharmacological investigation and computational studies on a tricyclic ergoline analog with selective dopamine autoreceptor activity. Gmeiner P, et al. **Arch Pharm (Weinheim)** 1995 Jul–Aug;328(7–8):609–14

ECONOMICS

Are SSRIs a cost-effective alternative to tricyclics? Hotopf M, et al. **Br J Psychiatry** 1996 Apr;168(4):404–9

Economics of treatment of depression [letter; comment] Owens DW. **Br J Psychiatry** 1995 Jul;167(1):112. Comment on: Br J Psychiatry 1994 May;164(5):665–73.

Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Lapierre Y, et al. **Can J Psychiatry** 1995 Sep;40(7):370–7

Comparing the cost effectiveness of psychiatric treatments: bulimia nervosa. Koran LM, et al. **Psychiatry Res** 1995 Sep 8;58(1):13–21

METABOLISM

Further characterization of rat brain flavin-containing monooxygenase. Metabolism of imipramine to its N-oxide. Bhagwat SV, et al. **Biochem Pharmacol** 1996 Jun 14; 51(11):1469–75

[Ca(2+)-channel blockers and binding of tricyclic antidepressive agents] Krulík R, et al. **Cesk Psychiatr** 1995 Jul;91(3):143–51 (Eng. Abstr.) **(Cze)**

PHARMACOKINETICS

Effects of recombinant drug-specific single chain antibody Fv fragment on [3H]-desipramine distribution in rats. Shelver WL, et al. **Biochem Pharmacol** 1996 Feb 23; 51(4):531–7

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Ereshefsky L, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:10–8; discussion 18–9 (38 ref.)

Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Wong SL, et al. **Clin Pharmacol Ther** 1996 Jul;60(1):48–53

Biotransformation of amitriptyline by Cunninghamella elegans. Zhang D, et al. **Drug Metab Dispos** 1995 Dec; 23(12):1417–25

Amitriptyline metabolism in elderly depressed patients and normal controls in relation to hypothalamic-pituitary-adrenal system function. Schmider J, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):250–8

Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds. Sgaragli GP, et al. **J Pharm Pharmacol** 1995 Sep;47(9):782–90

Stereoselectivity in bioequivalence studies of nortriptyline [letter] Midha KK, et al. **J Pharm Sci** 1995 Oct; 84(10):1265–6

The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats—a comparison with the pharmacokinetics of imipramine. Daniel W, et al. **Pol J Pharmacol** 1995 Mar–Apr;47(2):127–36

Phenobarbital induces the 2-hydroxylation of desipramine. Spina E, et al. **Ther Drug Monit** 1996 Feb;18(1):60–4

Analysis of plasma metabolites during human PET-studies with three receptor ligands, [11C]YM-09151-2, [11C]doxepin and [11C]pyrilamine. Ishiwata K, et al. **Tohoku J Exp Med** 1996 Feb;178(2):129–36

PHARMACOLOGY

The effects of imipramine, amitriptyline and clonidine administered by iontophoresis on the pain threshold. Taniguchi K, et al. **Acta Anaesthesiol Belg** 1995; 46(3–4):121–5

Interaction between tricyclic psychopharmacons and some antibiotics. Molnár J, et al. **Acta Microbiol Immunol Hung** 1995;42(3):277–85

Reversal of multidrug resistance by amitriptyline in vitro. Varga A, et al. **Anticancer Res** 1996 Jan–Feb;16(1):209–11

Synthesis and antidepressant evaluation of new hetero[2,1]benzothiazepine derivatives. Díaz JA, et al. **Arch Pharm (Weinheim)** 1996 Jul;329(7):352–60

Synthesis, pharmacological investigation and computational studies on a tricyclic ergoline analog with selective dopamine autoreceptor activity. Gmeiner P, et al. **Arch Pharm (Weinheim)** 1995 Jul–Aug;328(7–8):609–14

Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites. McNeil CM, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):15–20

Desipramine administration in the olfactory bulbectomized rat: changes in brain beta-adrenoceptor and 5-HT2A binding sites and their relationship to behaviour. Mudunkotuwa NT, et al. **Br J Pharmacol** 1996 Apr; 117(7):1481–6

Potent block of potassium currents in rat isolated sympathetic neurones by the uncharged form of amitriptyline and related tricyclic compounds. Wooltorton JR, et al. **Br J Pharmacol** 1995 Oct;116(4):2191–200

Tianeptine treatment induces regionally specific changes in monoamines. Frankfurt M, et al. **Brain Res** 1995 Oct 23; 696(1–2):1–6

Effects of different types of stress on histamine-H3 receptors in the rat cortex. Ghi P, et al. **Brain Res** 1995 Aug 28; 690(1):104–7

Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Rossby SP, et al. **Brain Res** 1995 Jul 31;687(1–2):79–82

Differential effect of desipramine and 2-hydroxydesipramine on depolarization-induced calcium uptake in synaptosomes from rat limbic sites. Beauchamp G, et al. **Can J Physiol Pharmacol** 1995 May;73(5):619–23

Inhibition and induction of cytochrome P450 isozymes after repetitive administration of imipramine in rats. Masubuchi Y, et al. **Drug Metab Dispos** 1995 Sep;23(9):999–1003

Chronic fluoxetine or desmethylimipramine treatment alters 5-HT2 receptor mediated c-fos gene expression. Tilakaratne N, et al. **Eur J Pharmacol** 1995 Aug 15; 290(3):263–6

Changes in the regulation of 5-hydroxytryptamine release by alpha2-adrenoceptors in the rat hippocampus after long-term desipramine treatment. Yoshioka M, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):565–70

The effect of chronic treatment with imipramine on the immunoreactivity of animals subjected to a chronic mild stress model of depression. Kubera M, et al. **Immunopharmacology** 1995 Sep;30(3):225–30

Reversal of doxorubicin-resistance in solid tumors by clomipramine. Pommerenke EW, et al. **In Vivo** 1995 Mar–Apr;9(2):99–101

Effect of amitriptyline on blood glucose level in rabbits. Gupta B, et al. **Indian J Physiol Pharmacol** 1995 Jul; 39(3):279–82

Changes in histamine and serotonin secretion from rat peritoneal mast cells caused by antidepressants. Ferjan I, et al. **Inflamm Res** 1996 Mar;45(3):141–4

Characteristics of the inhibitory effect of tricyclic antidepressants on histamine release from rat peritoneal mast cells. Ferjan I, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S17–8

Isoniazid, tricyclics and the "cheese reaction". DiMartini A. **Int Clin Psychopharmacol** 1995 Sep;10(3):197–8

Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants. Souêtre E, et al. **Int Clin Psychopharmacol** 1996 Mar;11(1):45–52

The pharmacologic profile of mirtazapine. de Boer T. **J Clin Psychiatry** 1996;57 Suppl 4:19–25 (48 ref.)

Chronic imipramine treatment induces downregulation of alpha-2 receptors in rat's locus coeruleus and A2 region of the tractus solitarius. Jiménez-Rivera CA, et al. **Life Sci** 1995;58(4):287–94

Cerebral metabolic responses to clomipramine are greatly reduced following pretreatment with the specific serotonin neurotoxin para-chloroamphetamine (PCA). A 2-deoxyglucose study in rats. Freo U, et al. **Neuropsychopharmacology** 1995 Nov;13(3):215–22

The influence of prolonged antidepressant treatment on the changes in cyclic AMP accumulation induced by excitatory amino acids in rat cerebral cortical slices. Pilc A, et al. **Neuroreport** 1995 Dec 29;7(1):85–8

Dose-dependent decrements in adult male rat sexual behavior after neonatal clorimipramine treatment. Vogel G, et al. **Pharmacol Biochem Behav** 1996 Jul;54(3):605–9

Male reproductive systems under chronic fluoxetine or trimipramine treatment. Taylor G, et al. **Physiol Behav** 1996 Mar;59(3):479–85

The effect of amitriptyline on the cell-mediated immunity of stressed rats. Kubera M, et al. **Pol J Pharmacol** 1995 Mar-Apr;47(2):137-42

Interaction of opioids with antidepressant-induced antinociception. Sierralta F, et al. **Psychopharmacology (Berl)** 1995 Dec;122(4):374-8

Fluoxetine and cyclosporine in organ transplantation. Failure to detect significant drug interactions or adverse clinical events in depressed organ recipients. Strouse TB, et al. **Psychosomatics** 1996 Jan-Feb;37(1):23-30

Tricyclic antidepressants inhibit human natural killer cells. Xiao L, et al. **Toxicol Appl Pharmacol** 1996 Apr; 137(2):157-62

[Effects of desipramine and clomipramine on alpha 2-adrenergic receptor function in nucleus accumbens: studies with intracerebral dialysis in freely moving rats] Sekiya Y, et al. **Seishin Shinkeigaku Zasshi** 1995; 97(8):605-22 (Eng. Abstr.) **(Jpn)**

[Effect of melipramine on the development of an experimental depressive syndrome in rats, caused by systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)] Krupina NA, et al. **Biull Eksp Biol Med** 1995 Aug; 120(8):160-3 **(Rus)**

[Prodigiozan modulation of the specific activity of antidepressants] Sibiriak SV, et al. **Eksp Klin Farmakol** 1995 Sep-Oct;58(5):9-12 (Eng. Abstr.) **(Rus)**

POISONING

Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine. Power BM, et al. **Anaesth Intensive Care** 1995 Aug;23(4):499-502

A fatal dothiepin overdose. Cirimele V, et al. **Forensic Sci Int** 1995 Dec 29;76(3):205-9

Decreased R-R variation: a criterium for overdosage of tricyclic psychotropic drugs. Rechlin T. **Intensive Care Med** 1995 Jul;21(7):598-601

Amoxapine overdose in a young man: a transient mitochondrial abnormality? Mancias P, et al. **Pharmacotherapy** 1995 Jul-Aug;15(4):528-32

Drug-specific antibodies as antidotes for tricyclic antidepressant overdose. Pentel PR, et al. **Toxicol Lett** 1995 Dec;82-83:801-6 (20 ref.)

[Toxic tricyclic drug plasma level caused by fluoxetine] Hambrecht M. **Psychiatr Prax** 1995 Nov;22(6):252-3 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

A double-blind comparison of moclobemide and doxepin in depressed general practice patients. Lingjaerde O, et al. **Acta Psychiatr Scand** 1995 Aug;92(2):125-31

An evaluation of antidepressants in rheumatic pain conditions. Rani PU, et al. **Anesth Analg** 1996 Aug; 83(2):371-5

Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189-201 (107 ref.)

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Aronson R, et al. **Arch Gen Psychiatry** 1996 Sep;53(9):842-8

A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Godfrey RG. **Arch Intern Med** 1996 May 27;156(10):1047-52 (44 ref.)

Improved arousal and initiation following tricyclic antidepressant use in severe brain injury. Reinhard DL, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):80-3

Clomipramine efficacy for Tourette syndrome and major depression: a case study. Iancu I, et al. **Biol Psychiatry** 1995 Sep 15;38(6):407-9

Effect of nortriptyline on yohimbine-induced changes in heart rate variability [letter] Yeragani VK. **Biol Psychiatry** 1996 Mar 1;39(5):385-6

Prior antidepressant treatment does not have an impact on response to desipramine treatment in major depression. Young LT, et al. **Biol Psychiatry** 1995 Sep 15;38(6):410-2

A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. Tyrer P, et al. **Br J Psychiatry** 1996 Apr;168(4):457-61

Paroxetine in the treatment of Chinese patients with depressive episode: a double-blind randomized comparison with imipramine. Chiu HJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jun; 57(6):418-23

Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Nunes EV, et al. **Drug Alcohol Depend** 1995 Oct;39(3):185-95

Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Bryson HM, et al. **Drugs Aging** 1996 Jun;8(6):459-76 (111 ref.)

Obsessive-compulsive disorder in elderly patients. Jackson CW. **Drugs Aging** 1995 Dec;7(6):438-48 (108 ref.)

Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study. Ottevanger EA. **Encephale** 1995 Jul-Aug;21(4):317-21

Treatments for postherpetic neuralgia--a systematic review of randomized controlled trials. Volmink J, et al. **Fam Pract** 1996 Feb;13(1):84-91

A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. Berlanga C, et al. **J Affect Disord** 1995 Jun 8;34(3):187-92

Predictors of response to amine-specific antidepressants. Burns RA, et al. **J Affect Disord** 1995 Dec 13;35(3):97-106

A double-blind placebo-controlled study of Org 3770 in depressed outpatients. Claghorn JL, et al. **J Affect Disord** 1995 Jun 8;34(3):165-71

Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents [see comments] Leonard HL, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1460-8. Comment in: J Am Acad Child Adolesc Psychiatry 1996 Jun;35(6):701-2.

Resolved: cardiac arrhythmias make desipramine an unacceptable choice in children. Werry JS, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1239-45; discussion 1245-8

Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. Engel PA. **J Am Geriatr Soc** 1996 Sep;44(9):1072-4

A new class of antiarrhythmic--defibrillatory compounds. Erez M, et al. **J Basic Clin Physiol Pharmacol** 1994 Jan-Mar;5(1):59-66

A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. Bremner JD. **J Clin Psychiatry** 1995 Nov;56(11):519-25

Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. Szegedi A, et al. **J Clin Psychiatry** 1996 Jun;57(6):257-64

Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. Angst J, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):16S-23S

Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. Claghorn JL, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):113-20

Predictors of response to desipramine in dysthymia. Friedman RA, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):280-3

Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study. Kragh-Sørensen P, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):24S-30S

One foot on the bandwagon? [editorial] Pies R. **J Clin Psychopharmacol** 1995 Oct;15(5):303-5 (16 ref.)

Case 6: a free solution. Shader RI, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):297

Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine (Org 3770). Tulen JH, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):135-45

The role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: findings in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Krupnick JL, et al. **J Consult Clin Psychol** 1996 Jun;64(3):532-9

Treating depression in alcoholics. Douglas MB, et al. **J Fam Pract** 1996 Jun;42(6):565-6

SSRIs vs tricyclic antidepressants. Griffin GH. **J Fam Pract** 1996 Feb;42(2):110

Comparison of TCAs and SSRIs in the treatment of major depression in hospitalized geriatric patients. Miller FT, et al. **J Geriatr Psychiatry Neurol** 1995 Jul;8(3):173-6

A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. Bendtsen L, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep; 61(3):285-90

A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression [see comments] Mason BJ, et al. **JAMA** 1996 Mar 13;275(10):761-7. Comment in: JAMA 1996 Mar 13;275(10):803-4.

Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. Simon GE, et al. **JAMA** 1996 Jun 26;275(24):1897-902

Starting SSRI antidepressant therapy: its effect on tricyclic antidepressant and benzodiazepine prescribing [letter] Parkes AJ. **Med J Aust** 1996 Apr 15;164(8):509

Are there any differences in the safety and efficacy of brofaromine and imipramine between non-elderly and elderly patients with major depression? Volz HP, et al. **Neuropsychobiology** 1995;32(1):23-30

Emergency pharmacotherapy: the evolving role of medications in the emergency department. Ellison JM, et al. **New Dir Ment Health Serv** 1995 Fall;(67):87-98 (64 ref.)

A comparison of amitriptyline, vasopressin and amitriptyline with vasopressin in nocturnal enuresis. Burke JR, et al. **Pediatr Nephrol** 1995 Aug;9(4):438-40

Medication for children with attentional disorders. American Academy of Pediatrics Committee on Children With Disabilities and Committee on Drugs. **Pediatrics** 1996 Aug; 98(2 Pt 1):301-4

Mirtazapine as treatment for serotonin syndrome [letter] Hoes MJ, et al. **Pharmacopsychiatry** 1996 Mar;29(2):81

A controlled study of the efficacy and safety of mianserin and amitriptyline in depressive inpatients. Möller HJ, et al. **Pharmacopsychiatry** 1995 Nov;28(6):249-52

Ethnicity and psychopharmacology. Bridging the gap. Lin KM, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):635-47 (56 ref.)

Identifying delirious states and autonomic cardiovascular dysfunction associated with amitriptyline treatment by standardized analysis of heart rate. Rechlin T, et al. **Psychiatry Res** 1995 Apr 28;56(3):279-87

Effect of initial treatment with antidepressants as a predictor of outcome after 8 weeks. Volz HP, et al. **Psychiatry Res** 1995 Sep 29;58(2):107-15

Cognitive behavior therapy, relaxation training, and tricyclic antidepressant medication in the treatment of depression. Murphy GE, et al. **Psychol Rep** 1995 Oct;77(2):403-20

Fluctuation of symptoms and social functioning in panic disorder with or without concomitant depression. A 5-year prospective follow-up. Albus M, et al. **Psychopathology** 1995;28(5):229-34

Stability of remission during tricyclic antidepressant continuation therapy for dysthymia. Kocsis JH, et al. **Psychopharmacol Bull** 1995;31(2):213-6

Fluoxetine and cyclosporine in organ transplantation. Failure to detect significant drug interactions or adverse clinical events in depressed organ recipients. Strouse TB, et al. **Psychosomatics** 1996 Jan-Feb;37(1):23-30

Polyuric and non-polyuric bedwetting--pathogenic differences in nocturnal enuresis. Hunsballe JM, et al. **Scand J Urol Nephrol Suppl** 1995;173:77-8; discussion 79

A multiple imputation strategy for clinical trials with truncation of patient data. Lavori PW, et al. **Stat Med** 1995 Sep 15;14(17):1913-25

[Drug therapy and other biological therapies in mood disorders] Syvälahti E, et al. **Duodecim** 1994;110(3):295-304 (26 ref.) **(Fin)**

[Prediction of therapeutic response in depressive states] Radat F, et al. **Ann Med Psychol (Paris)** 1996 May;154(2):89-102 (53 ref.) (Eng. Abstr.) **(Fre)**

[Major depressive episodes in patients over 70 years of age. Evaluation of the efficiency and acceptability of tianeptine and mianserin] Brion S, et al. **Presse Med** 1996 Mar 16; 25(9):461-8 (Eng. Abstr.) **(Fre)**

[Multiple sclerosis and major depression resistant to treatment. Case of a patient with antidepressive therapy-induced mood disorder, associated with manic features] Pariante CM, et al. **Clin Ter** 1995 Jun-Jul; 146(6-7):449-52 (Eng. Abstr.) **(Ita)**

[Pharmacotherapy in depression during conversion from depression to mania in patients with bipolar affective disorder] Koszewska I. **Psychiatr Pol** 1996 Jan-Feb; 30(1):113-25 (Eng. Abstr.) **(Pol)**

[Pharmacotherapy of depression in patients with and without conversion from depression to mania in the course of bipolar affective disorder] Koszewska I. **Psychiatr Pol** 1996 Jan-Feb;30(1):99-111 (Eng. Abstr.) **(Pol)**

[Cost analysis of treating depression. Comparison of tricyclic antidepressants and selective serotonine re-uptake inhibitors] Mazurek J, et al. **Psychiatr Pol** 1996 Jan-Feb; 30(1):87-98 (Eng. Abstr.) **(Pol)**

[Combined therapy with tricyclic and MAOI antidepressants in the treatment of resistant major depression] Rosan TA, et al. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):314-20 (Eng. Abstr.) **(Spa)**

[Therapeutic strategies in mixed or combined headache] Morales F. **Rev Neurol** 1995;23 Suppl 2:S238-9 (7 ref.) **(Spa)**

TOXICITY

Ovine desipramine antibody fragments reverse desipramine cardiovascular toxicity in the rat. Dart RC, et al. **Ann Emerg Med** 1996 Mar;27(3):309-15

Antidepressant toxicity and the need for identification and concentration monitoring in overdose. Power BM, et al. **Clin Pharmacokinet** 1995 Sep;29(3):154-71 (137 ref.)

Nitric oxide contributes to desipramine-induced hypotension in rats. Pentel PR, et al. **Hum Exp Toxicol** 1996 Apr; 15(4):320-8

Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats. Wananukul W, et al. **J Toxicol Clin Toxicol** 1996;34(5):499-506

URINE

Determination of a cardiac antiarrhythmic, tricyclic antipsychotics and antidepressants in human and animal urine by micellar electrokinetic capillary chromatography using a bile salt. Aumatell A, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):331-44

ANTIDIABETICS see **HYPOGLYCEMIC AGENTS**

ANTIDIARRHEALS

ADMINISTRATION & DOSAGE

Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. Geller RB, et al. **Am J Hematol** 1995 Nov;50(3):167-72

High dose loperamide suppositories: a novel approach for improving clinical function after restorative proctocolectomy. Levitt MD, et al. **Aust N Z J Surg** 1995 Dec;65(12):881-3

Treatment of travellers' diarrhoea: zaldaride compared with loperamide and placebo. Silberschmidt G, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):871-5

Loperamide for treatment of acute diarrhoea in infants and young children. A double-blind placebo-controlled trial. Bowie MD, et al. **S Afr Med J** 1995 Sep;85(9):885-7

[Sandostatin in the treatment of diarrhea of different origins] Belousova EA, et al. **Ter Arkh** 1995;67(7):62-5 (Eng.

Abstr.) (Rus)

ADVERSE EFFECTS

Antidiarrhoeal drugs for acute diarrhoea in children: non work, and many may be dangerous [news]
Indian J Med Sci 1995 Jan;49(1):22

Regulatory actions to enhance appropriate drug use: the case of antidiarrhoeal drugs. Haak H, et al. **Soc Sci Med** 1996 Apr;42(7):1011-9

ANALYSIS

[High pressure liquid chromatographic determination of baicalin in lung-cleaning and diarrhoea-relieving infusion] Qi Y. **Chung Kuo Chung Yao Tsa Chih** 1995 Oct; 20(10):607-8, 639 (Eng. Abstr.) (Chi)

CHEMICAL SYNTHESIS

Metabolically programmed polyamine analogue antidiarrheals. Bergeron RJ, et al. **J Med Chem** 1996 Jun 21;39(13):2461-71

PHARMACOKINETICS

Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules). Doser K, et al. **Int J Clin Pharmacol Ther** 1995 Aug;33(8):431-6

Pharmacokinetic, metabolic, and antidiarrheal properties of (D and L) heptapeptides of sorbin in rodent. Nicol P, et al. **Peptides** 1995;16(8):1343-50

[Clinical pharmacokinetics of fluorazole] Firsov AA, et al. **Antibiot Khimioter** 1995 Sep;40(9):42-6 (Eng. Abstr.) (Rus)

PHARMACOLOGY

Effect of quercitrin on acute and chronic experimental colitis in the rat. Sánchez de Medina F, et al.
J Pharmacol Exp Ther 1996 Aug;278(2):771-9

Effect of quercitrin on lactose-induced chronic diarrhoea in rats. Gálvez J, et al. **Planta Med** 1995 Aug;61(4):302-6

[The effect of pectin on the viability of Vibrio cholerae] Potievskiĭ EG, et al.
Zh Mikrobiol Epidemiol Immunobiol 1995 Nov-Dec; (6):22-3 (Rus)

POISONING

Poisoning by antidiarrhoeals [letter] Kulkarni ML, et al. **Natl Med J India** 1995 Sep-Oct;8(5):244

SUPPLY & DISTRIBUTION

Assessing the impact of a regulatory intervention in Pakistan. Bhutta TI, et al. **Soc Sci Med** 1996 Apr;42(8):1195-202

Drug prescribing practices of general practitioners and paediatricians for childhood diarrhoea in Karachi, Pakistan. Nizami SQ, et al. **Soc Sci Med** 1996 Apr;42(8):1133-9

Factors influencing physicians' prescribing behaviour in the treatment of childhood diarrhoea: knowledge may not be the clue. Paredes P, et al. **Soc Sci Med** 1996 Apr; 42(8):1141-53

Small group intervention vs formal seminar for improving appropriate drug use. Santoso B. **Soc Sci Med** 1996 Apr; 42(8):1163-8

THERAPEUTIC USE

Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Halpern GM, et al. **Am J Gastroenterol** 1996 Aug;91(8):1579-85

First-line treatment in acute non-dysenteric diarrhoea: clinical comparison of loperamide oxide, loperamide and placebo. UK Janssen Research Group of General Practitioners. Hughes IW. **Br J Clin Pract** 1995 Jul-Aug; 49(4):181-5

Zaldaride maleate (a new calmodulin antagonist) versus loperamide in the treatment of traveler's diarrhea: randomized, placebo-controlled trial. Okhuysen PC, et al. **Clin Infect Dis** 1995 Aug;21(2):341-4

Efficacy and tolerance of insoluble carob fraction in the treatment of travellers' diarrhoea. Hostettler M, et al.
J Diarrhoeal Dis Res 1995 Sep;13(3):155-8

Loperamide oxide for the treatment of chronic diarrhoea in Crohn's disease. van Outryve M, et al. **J Int Med Res** 1995 Sep-Oct;23(5):335-41

Application of xiang cheng san in treatment of chronic protracted diarrhea in children. Yang S.
J Tradit Chin Med 1995 Sep;15(3):214-9

A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Efskind PS, et al.
Scand J Gastroenterol 1996 May;31(5):463-8

TOXICITY

Study of genotoxic effects of antidiarrheal medicinal herbs on human cells in vitro. Settheetham W, et al.
Southeast Asian J Trop Med Public Health 1995;26 Suppl 1:306-10

ANTIDIURETIC HORMONE, INAPPROPRIATE SECRETION see **INAPPROPRIATE ADH SYNDROME**

ANTIDIURETIC HORMONES see **VASOPRESSINS**

ANTI-DNA ANTIBODIES see **ANTIBODIES, ANTINUCLEAR**

ANTIDOTES

see related
CHELATING AGENTS
CHOLINESTERASE REACTIVATORS

ADMINISTRATION & DOSAGE

Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer. Alba E, et al. **Am J Clin Oncol** 1996 Apr;19(2):140-3

Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association. Atkins JN, et al. **Am J Clin Oncol** 1996 Feb; 19(1):23-5

Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma. Bensmaine M el-A, et al. **Am J Clin Oncol** 1996 Aug;19(4):356-62

A phase II trial of 5-fluorouracil and l-leucovorin in patients with metastatic colorectal cancer. Erlichman C, et al.
Am J Clin Oncol 1996 Feb;19(1):26-31

Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma. Kim YH, et al. **Am J Clin Oncol** 1996 Apr; 19(2):212-6

Acetaminophen overdose: need to consider intravenous preparation of N-acetylcysteine in the United States [letter] Dhawan A, et al. **Am J Gastroenterol** 1996 Jul;91(7):1476

Rectal flumazenil to reverse midazolam sedation in children [letter] Carbajal R, et al. **Anesth Analg** 1996 Apr;82(4):895

Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study. Berenberg JL, et al. **Cancer** 1995 Sep 1;76(5):715-9

Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma [see comments] Chi KH, et al. **Cancer** 1995 Dec 1;76(11):2186-92. Comment in: Cancer 1996 Aug 1;78(3):566-7.

Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. Feliu J, et al. **Cancer** 1996 Jul 15;78(2):211-6

5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer [letter; comment] Vermeulen PB, et al. **Cancer** 1995 Aug 1;76(3):528-30. Comment on: Cancer 1995 Mar 1;75(5):1072-6.

A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer [letter] Parnis FX, et al.
Eur J Cancer 1995 Sep;31A(10):1721

Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. Petrioli R, et al. **Eur J Cancer** 1995 Nov; 31A(12):2105-8

Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study. Garufi C, et al.
J Infus Chemother 1995;5(3 Suppl 1):134-7

CS sprays: antidote and decontaminant [letter] Jones GR.
Lancet 1996 Apr 6;347(9006):968-9

Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Barata JD, et al.
Nephrol Dial Transplant 1996 Jan;11(1):125-32

A retrospective study of sodium nitroprusside use and assessment of the potential risk of cyanide poisoning. Johanning RJ, et al. **Pharmacotherapy** 1995 Nov-Dec; 15(6):773-7

[Comparison of the effect of selected cholinesterase reactivators combined with atropine on the toxicity of soman and fosdrin in mice] Kassa J.
Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 1995;38(1 Suppl):63-6 (Eng. Abstr.) (Cze)

[Digoxin poisoning treated with Digibind] Andersen JB, et al. **Ugeskr Laeger** 1996 Apr 15;158(16):2262-4 (Eng. Abstr.) (Dan)

[Antagonist or antidote? (editorial)] Saint-Maurice C.
Cah Anesthesiol 1995;43(4):341-2 (Fre)

[Clinical-toxicological case (1). Dosage of N-acetylcysteine in acute paracetamol poisoning] Kind B, et al.
Schweiz Rundsch Med Prax 1996 Aug 2;85(31-32):935-8 (33 ref.) (Eng. Abstr.) (Ger)

[Treatment of acute poisoning caused by carbamazepine, digoxin, and acetylsalicylic acid, with repeated doses of activated charcoal] Montoya-Cabrera MA, et al.
Gac Med Mex 1995 May-Jun;131(3):349-54 (Eng. Abstr.) (Spa)

ADVERSE EFFECTS

Fatal Aeromonas hydrophila bacteremia in a hemodialysis patient treated with deferoxamine. Lin SH, et al.
Am J Kidney Dis 1996 May;27(5):733-5

Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. De Sanctis V, et al. **Eur J Pediatr** 1996 May;155(5):368-72

A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer. Haas NB, et al.
Invest New Drugs 1995;13(3):229-33

Pleural effusion associated with D-penicillamine therapy: a case report. Karkos C, et al. **J Clin Pharm Ther** 1996 Feb; 21(1):15-7

Antidotes: benefits and risks. Proudfoot AT. **Toxicol Lett** 1995 Dec;82-83:779-83 (20 ref.)

CHEMISTRY

Minimal water requirements for suspending powdered antidotal charcoals. Cooney DO. **Vet Hum Toxicol** 1995 Dec;37(6):542-3

DIAGNOSTIC USE

Use of flumazenil in the treatment of drug overdose: a double-blind and open clinical study in 110 patients. Weinbroum A, et al. **Crit Care Med** 1996 Feb;24(2):199-206

HISTORY

The snakestone experiments. An early modern medical debate. Baldwin M. **Isis** 1995 Sep;86(3):394-418

ISOLATION & PURIFICATION

Cloning, expression, and purification of an anti-desipramine single chain antibody in NS/O myeloma cells. Kitchin K, et al. **J Pharm Sci** 1995 Oct;84(10):1184-9

METABOLISM

Cloning, expression, and purification of an anti-desipramine single chain antibody in NS/O myeloma cells. Kitchin K, et al. **J Pharm Sci** 1995 Oct;84(10):1184-9

PHARMACOKINETICS

Pharmacokinetics of HI-6 and atropine in anaesthetized pigs after administration by a new autoinjector. Nyberg AG, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):635-51

4-methylpyrazole monitoring during haemodialysis of ethylene glycol intoxicated patients. Faessel H, et al.
Eur J Clin Pharmacol 1995;49(3):211-3

A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. Meropol NJ, et al. **Invest New Drugs** 1995;13(2):149-55

Measurement of the oxime HI-6 after peripheral administration in tandem with neurotransmitter levels in striatal dialysates: effects of soman intoxication. Cassel GE, et al. **J Pharmacol Toxicol Methods** 1996 Jun;35(3):159-66

Pharmacokinetics of hydroxocobalamin in smoke inhalation victims. Houeto P, et al. **J Toxicol Clin Toxicol** 1996; 34(4):397-404

Pharmacokinetics following a loading plus a continuous infusion of pralidoxime compared with the traditional short infusion regimen in human volunteers. Medicis JJ, et al.
J Toxicol Clin Toxicol 1996;34(3):289-95

Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients. Andriani M, et al.
Nephron 1996;72(2):218-24

PHARMACOLOGY

Flumazenil: an unreliable antagonist in baclofen overdose. Byrnes SM, et al. **Anaesthesia** 1996 May;51(5):481-2

Penicillamine produces changes in the acute blood elimination and tissue accumulation of thallium. Careaga-Olivares J, et al. **Arch Med Res** 1995 Winter; 26(4):427-30

Effect of DMPS and various adsorbents on the arsenic excretion in guinea-pigs after injection with As2O3. Reichl FX, et al. **Arch Toxicol** 1995;69(10):712-7

5-methyltetrahydrofolate or 5-formyltetrahydrofolic acid to modulate 5-fluorouracil's cytotoxic activity in vivo. A phase II study in patients with advanced colon cancer. Porta C, et al. **Cancer Chemother Pharmacol** 1996; 38(2):195-7

The effects of flumazenil in neuropsychiatric disorders. Malizia AL, et al. **Clin Neuropharmacol** 1995 Jun; 18(3):215-32 (134 ref.)

Effect of folate supplementation on clinical chemistry and hematologic changes related to bidisomide administration in the rat. Vandenberghe Y, et al. **Drug Chem Toxicol** 1995 Nov;18(4):235-70

An increase in the blood thyroxine level after methylene blue in rats: the interaction with carbimazole. Nedvidková J, et al. **Endocr Res** 1995 Nov;21(4):709-17

The role of interferon-alpha as a modulator of fluorouracil and leucovorin. Grem JL, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1316-20 (29 ref.)

Role of leucovorin dosing and administration schedule. Jolivet J. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1311-5 (52 ref.)

Evidence for potential application of zinc as an antidote to acetaminophen-induced hepatotoxicity. Woo PC, et al.
Eur J Pharmacol 1995 Oct 6;293(3):217-24

Antidotal efficacy of newly synthesized dimercaptosuccinic acid (DMSA) monoesters in experimental arsenic poisoning in mice. Kreppel H, et al. **Fundam Appl Toxicol** 1995 Jul; 26(2):239-45

The comparative effects of sodium thiosulfate,

diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Church MW, et al. **Hear Res** 1995 Jun;86(1-2):195-203

Cyanide toxicity in mice pretreated with diethylamine nitric oxide complex. Baskin SI, et al. **Hum Exp Toxicol** 1996 Jan;15(1):13-18

Reduced glutathione esters--antidotes to toxicity. Cytotoxicity induced by hydrogen peroxide, 1-chloro-2,4-dinitrobenzene, and menadione in murine P388D1 macrophages in vitro. Minhas HS, et al. **J Biochem Toxicol** 1995 Oct;10(5):245-250

Pharmacologic mechanism of antidotes in cyanide and nitrile poisoning [letter] Borak J. **J Occup Environ Med** 1995 Jul; 37(7):793-4

A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro. Day BJ, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1227-32

Dose-related efficiency of mono-n-hexyl meso-2,3-dimercaptosuccinate in decreasing 203Hg retention in rats. Kostial K, et al. **Pharmacol Toxicol** 1995 Jul;77(1):79-80

Prolonged oral treatment with two monoesters of meso-2,3-dimercaptosuccinic acid for depleting inorganic mercury retention in suckling rats. Kostial K, et al. **Pharmacol Toxicol** 1995;77:216-8

Effects of antidotes to cocaine on the deregulation of the baroreflex by the alkaloid. Trouvé R, et al. **Proc Soc Exp Biol Med** 1996 Jul;212(3):239-42

Cadmium and glutathione: effect on human placental thromboxane and prostacyclin production. Eisenmann CJ, et al. **Reprod Toxicol** 1995 Jan-Feb;9(1):41-8

The influence of "selenium organicum" upon the hepatic function of carbon tetrachloride poisoned rats. Ianăş O, et al. **Rom J Intern Med** 1995 Jan-Jun;33(1-2):113-20

The effect of reduced glutathione (TAD-600) on the behavior of rats neonatally intoxicated with ethanol. Lupu V, et al. **Rom J Physiol** 1994 Jan-Dec;31(1-4):59-67

Antidotal effect of dihydroxyacetone against cyanide toxicity in vivo. Niknahad H, et al. **Toxicol Appl Pharmacol** 1996 May;138(1):186-91

Modifying toxicokinetics with antidotes. Baud FJ, et al. **Toxicol Lett** 1995 Dec;82-83:785-93 (20 ref.)

Modification of cyanide toxicodynamics: mechanistic based antidote development. Isom GE, et al. **Toxicol Lett** 1995 Dec;82-83:795-9 (14 ref.)

Antagonism of cyanide toxicity by isosorbide dinitrate: possible role of nitric oxide. Sun P, et al. **Toxicology** 1995 Dec 15;104(1-3):105-11

[An experimental study of the effect of an artichoke preparation on the activity of the sympathetic-adrenal system in carbon disulfide exposure] Khalkova Zh, et al. **Probl Khig** 1995;20:162-71 (Eng. Abstr.) **(Bul)**

[Glutathione-SH as protection from cytotoxic side-effects of gentamycin. Studies with isolated outer hair cells] Keiner S, et al. **HNO** 1995 Aug;43(8):492-7 (Eng. Abstr.) **(Ger)**

[Effect of biological membrane stabilizing drugs (coenzyme Q10, dextran sulfate and reduced glutathione) on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice] Shinozawa S, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):93-8 (Eng. Abstr.) **(Jpn)**

[The antagonism of phosphorus-containing heterocyclics with the anticholinesterase agent Phosphacol (paraoxon)] Garaev RS. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):68-70 (Eng. Abstr.) **(Rus)**

[Anti-edematous action of EDTA, its effect on lipid peroxidation intensity and various components of the antioxidant system of the lungs in rats exposed to NO2] Galkin BN, et al. **Ukr Biokhim Zh** 1995 Jul-Aug;67(4):92-5 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Efficacy of the association of folinic acid and 5-fluorouracil alone versus folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma. Colucci G, et al. **Am J Clin Oncol** 1995 Dec; 18(6):519-24

Comparison of N-acetylcysteine and methylene blue, alone or in combination, for treatment of acetaminophen toxicosis in cats. Rumbeiha WK, et al. **Am J Vet Res** 1995 Nov; 56(11):1529-33

Reversal of a paradoxical reaction to midazolam with flumazenil. Thurston TA, et al. **Anesth Analg** 1996 Jul; 83(1):192

Activated charcoal and salicylate [letter; comment] Cienki J, et al. **Ann Emerg Med** 1996 May;27(5):672-3. Comment on: Ann Emerg Med 1995 Nov;26(5):569-74.

Empiric use of flumazenil in comatose patients: limited applicability of criteria to define low risk. Gueye PN, et al. **Ann Emerg Med** 1996 Jun;27(6):730-5

Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model [see comments] Johnson D, et al. **Ann Emerg Med** 1995 Nov; 26(5):569-74. Comment in: Ann Emerg Med 1996 May;27(5):672-3.

Arrhythmias in organophosphate poisoning: effect of atropine and bispyridinium oximes. Worek F, et al. **Arch Int Pharmacodyn Ther** 1995 May-Jun;329(3):418-35

Treatment of organophosphate poisoning in pigs: antidote administration by a new binary autoinjector. Göransson-Nyberg A, et al. **Arch Toxicol** 1995;70(1):20-7

A comparison of trimedoxime, obidoxime, pralidoxime and HI-6 in the treatment of oral organophosphorus insecticide poisoning in the rat. Jokanović M, et al. **Arch Toxicol** 1995; 70(2):119-23

Use of flumazenil in the treatment of drug overdose: a double-blind and open clinical study in 110 patients. Weinbroum A, et al. **Crit Care Med** 1996 Feb;24(2):199-206

Dose-response effects of atropine and HI-6 treatment of organophosphorus poisoning in guinea pigs. Koplovitz I, et al. **Drug Chem Toxicol** 1995 May-Aug;18(2-3):119-36

Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer [letter] Colleoni M, et al. **Eur J Cancer** 1995 Dec;31A(13-14):2426-7

Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. González-Barón M, et al. **Eur J Cancer** 1995 Dec; 31A(13-14):2215-9

Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma. Scheithauer W, et al. **Eur J Cancer** 1995 Nov; 31A(12):1981-6

Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin. Préfontaine M, et al. **Gynecol Oncol** 1996 May;61(2):249-52

Prussian Blue decorporation of 137Cs in beagles of different ages. Melo DR, et al. **Health Phys** 1996 Aug;71(2):190-7

Conservative management options for cervical pregnancy; case reports and literature review. Creinin MD, et al. **Int J Fertil Menopausal Stud** 1995 Jul-Aug;40(4):175-86 (67 ref.)

A phase I study of combined radiation therapy with 5-fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma. Hsue V, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):445-50

Long-term intravenous and oral flumazenil treatment of acute diazepam overdose in an older patient [letter] Weinbroum A, et al. **J Am Geriatr Soc** 1996 Jun;44(6):737-8

Activated charcoal--an antidote to methyl alcohol poisoning. Mathangi DC, et al. **J Indian Med Assoc** 1995 Apr; 93(4):136-7

Risks of parenteral deferoxamine for acute iron poisoning. Howland MA. **J Toxicol Clin Toxicol** 1996;34(5):491-7 (50 ref.)

Antidotal efficacy of alpha-ketoglutaric acid and sodium thiosulfate in cyanide poisoning. Hume AS, et al. **J Toxicol Clin Toxicol** 1995;33(6):721-4

The relative efficacy of antidotes. Jacobsen D. **J Toxicol Clin Toxicol** 1995;33(6):705-8

4-Methylpyrazole--present status [editorial; comment] Jacobsen D, et al. **J Toxicol Clin Toxicol** 1996;34(4):379-81 . Comment on: J Toxicol Clin Toxicol 1996;34(4):373-7.

4-Methylpyrazole and hemodialysis in ethylene glycol poisoning [see comments] Jobard E, et al. **J Toxicol Clin Toxicol** 1996;34(4):373-7. Comment in: J Toxicol Clin Toxicol 1996;34(4):379-80.

Benefits of parenteral deferoxamine for acute iron poisoning. Tenenbein M. **J Toxicol Clin Toxicol** 1996;34(5):485-9 (36 ref.)

Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs. Yokel RA, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):667-83 (90 ref.)

Antidotal action of atropine sulfate against insecticide benfuracarb poisoning in rats. Ichikawa S, et al. **J Toxicol Sci** 1995 May;20(2):143-8

Lead poisoning and toxicokinetics in a heifer and fetus treated with CaNa2 EDTA and thiamine. O'Hara TM, et al. **J Vet Diagn Invest** 1995 Oct;7(4):531-7

A money-saving approach to antidote immunotherapy for digoxin toxicity [letter] Zoppi F, et al. **Lancet** 1996 May 18;347(9012):1405-6

Release of osteocalcin fragments in the serum of dialyzed patients during desferrioxamine treatment [letter] Gerakis A, et al. **Nephron** 1995;71(1):124

Oral activated charcoal in patients with uremic pruritus. Giovannetti S, et al. **Nephron** 1995;70(2):193-6

Influence of hydroxypyridones and desferrioxamine on the mobilization of aluminium from tissues of aluminium-loaded rats. Florence AL, et al. **Neurodegeneration** 1995 Dec;4(4):449-55

Short-term efficacy of oral dimercaptosuccinic acid in children with low to moderate lead intoxication. Besunder JB, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):683-7

Effect of oxygen and sodium thiosulfate during combined carbon monoxide and cyanide poisoning. Breen PH, et al. **Toxicol Appl Pharmacol** 1995 Oct;134(2):229-34

Drug-specific antibodies as antidotes for tricyclic antidepressant overdose. Pentel PR, et al. **Toxicol Lett** 1995 Dec;82-83:801-6 (20 ref.)

Antagonistic effect of melatonin against cyanide-induced seizures and acute lethality in mice. Yamamoto H, et al. **Toxicol Lett** 1996 Sep;87(1):19-24

Failure of 3,4-diaminopyridine and edrophonium to produce significant clinical benefit in neurotoxicity following the bite of Papuan taipan (Oxyuranus scutellatus canni). Trevett AJ, et al. **Trans R Soc Trop Med Hyg** 1995 Jul-Aug; 89(4):444-6

Iron complexation with oral deferoxamine in a swine model. Dean BS, et al. **Vet Hum Toxicol** 1996 Apr;38(2):96-8

High dose methotrexate infusion with leucovorin rescue for treatment of ectopic pregnancy [see comments] Larson DM, et al. **Wis Med J** 1995 Dec;94(12):664-7. Comment in: Wis Med J 1995 Dec;94(12):668-9.

[Emergency treatment of respiratory failure induced by acute organophosphorus (editorial)] Wang H, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jun;34(6):365-6 **(Chi)**

[Comparison of the effect of HI-6 oxime and its derivatives in combination with benactyzine on cholinergic and stress effects of soman in rats] Kassa J. **Ceska Slov Farm** 1996 May;45(3):149-53 (Eng. Abstr.) **(Cze)**

[Flumazenil in zolpidem poisoning in children (letter)] Carbajal R, et al. **Arch Pediatr** 1996 Feb;3(2):191-2 **(Fre)**

[Successful treatment with methylene blue of ifosfamide-induced central nervous system effects (letter)] Demandt M, et al. **Dtsch Med Wochenschr** 1996 Apr 26; 121(17):575 **(Ger)**

[The comparative clinico-experimental characteristics of aminostigmine and galanthamine used for treating poisonings by choline-blocking substances] Prozorovskiĭ VB, et al. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):64-7 (Eng. Abstr.) **(Rus)**

[Anticyan--a new highly effective antidote in cyanide poisoning] Trinus FP, et al. **Lik Sprava** 1995 May-Jun; (5-6):175-6 (Eng. Abstr.) **(Rus)**

TOXICITY

Toxicity evaluation of two treatment regimens for cyanide poisoning. Bhattacharya R, et al. **J Appl Toxicol** 1995 Nov-Dec;15(6):439-41

Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Vaccari A, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):102-8

HI-6 therapy and the acute phase response in the rat. Ivanović-Matić S, et al. **Toxicology** 1996 Jan 8; 106(1-3):11-7

ANTIDROMIC POTENTIALS see **EVOKED POTENTIALS**

ANTI-DYSKINESIA AGENTS

ADMINISTRATION & DOSAGE

Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. Schurch B, et al. **J Urol** 1996 Mar;155(3):1023-9

Botulinum toxin type A injection for hyperfunctional facial lines. Keen MS, et al. **Laryngoscope** 1995 Oct; 105(10):1134-7

ADVERSE EFFECTS

Prolonged neurological sequelae after combination treatment with lithium and antipsychotic drugs [letter] Mani J, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):350-1

Tetrabenazine as a cause of neuroleptic malignant syndrome [letter] Ossemann M, et al. **Mov Disord** 1996 Jan;11(1):95

ANTAGONISTS & INHIBITORS

Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate. Egan MF, et al. **Brain Res Bull** 1995;38(4):355-63

PHARMACOLOGY

The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Cichon JV Jr, et al. **Laryngoscope** 1995 Feb;105(2):144-8

Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Sloop RR, et al. **Neurology** 1996 May;46(5):1382-6

THERAPEUTIC USE

Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter. Fishman VM, et al. **Am J Gastroenterol** 1996 Sep;91(9):1724-30

Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Pierson SH, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):717-21

Management of strabismus due to orbital myositis. Bessant DA, et al. **Eye** 1995;9 (Pt 5):558-63

Botulinum toxin for achalasia: to be or not to be? [editorial; comment] Castell DO, et al. **Gastroenterology** 1996 May; 110(5):1650-2. Comment on: Gastroenterology 1996 May;110(5):1410-5.

Botulinum toxin for achalasia: long-term outcome and predictors of response [see comments] Pasricha PJ, et al. **Gastroenterology** 1996 May;110(5):1410-5. Comment in: Gastroenterology 1996 May;110(5):1650-2.

Successful treatment of tardive oculogyric spasms with vitamin E [letter] Coupland N, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):285-6

Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A. Sheean GL, et al. **J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):601-7

Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Simpson DM, et al. **Neurology** 1996 May; 46(5):1306-10

Botulinum toxin in the treatment of cerebral palsy. Denišlič M, et al. **Neuropediatrics** 1995 Oct;26(5):249-52

Short-term electrical stimulation enhances the effectiveness

of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Hesse S, et al. **Neurosci Lett** 1995 Dec 1;201(1):37–40

The use of botulinum A toxin to ameliorate facial kinetic frown lines. Foster JA, et al. **Ophthalmology** 1996 Apr; 103(4):618–22

Palatal myoclonus: treatment with Clostridium botulinum toxin injection. Varney SM, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):317–20

The effect of botulinum toxin A on the function if a person with poststroke quadriplegia. Cromwell SJ, et al. **Phys Ther** 1996 Apr;76(4):395–402

Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Hesse S, et al. **Stroke** 1996 Mar; 27(3):455–60

[Clinical and psychological factors influencing the efficacy of botulinum toxin in the treatment of hemifacial spasm and blepharospasm] Burbaud P, et al. **J Fr Ophtalmol** 1995; 18(12):751–7 (Eng. Abstr.) **(Fre)**

[Dose–response relationship in the treatment of cervical dystonia with botulinum toxin type A (AGN 191622)—a phase II study] Mezaki T, et al. **No To Shinkei** 1995 Sep; 47(9):857–62 (Eng. Abstr.) **(Jpn)**

[The clinical usefulness of botulinum toxin type A for spasmodic torticollis and facial spasm] Mezaki T, et al. **No To Shinkei** 1995 Aug;47(8):749–54 (Eng. Abstr.) **(Jpn)**

[Botulinum toxin—from threat to cure] Odergren T, et al. **Lakartidningen** 1996 Apr 24;93(17):1619–24 (40 ref.) **(Swe)**

ANTIEMETICS

Granisetron: the second serotonin–receptor antagonist. Adams VR, et al. **Ann Pharmacother** 1995 Dec; 29(12):1240–51 (72 ref.)

Ondansetron. Thavaraj V, et al. **Indian Pediatr** 1995 Aug; 32(8):898–901 (12 ref.)

ADMINISTRATION & DOSAGE

Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. Tarkkila P, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):983–6

Single–dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol. Paech MJ, et al. **Anaesth Intensive Care** 1995 Oct;23(5):548–54

How much droperidol in combination with PCA morphine? [letter] Morrow BC, et al. **Anaesthesia** 1996 Jan;51(1):92

Ondansetron and morphine sulphate: are they compatible? [letter] Paes M, et al. **Anaesthesia** 1996 Aug;51(8):795

Improved outcome with chronic subcutaneous infusion of odansetron for intractable nausea and vomiting [letter] Macario A, et al. **Anesth Analg** 1996 Jul;83(1):194–5

Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting. Pueyo FJ, et al. **Anesth Analg** 1996 Jul;83(1):117–22

Intravenous ondansetron in established postoperative emesis in children. S3A–381 Study Group. Khalil S, et al. **Anesthesiology** 1996 Aug;85(2):270–6

Efficacy of two oral dose regimens of granisetron. Maisano R, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2287–90

Granisetron–dexamethasone combination for multiple day cisplatin. Pronzato P, et al. **Anticancer Res** 1995 Sep–Oct; 15(5B):2261–3

Rectal administration of ondansetron in uncontrolled emesis induced by chemotherapy [letter] al–Moundhri M, et al. **Aust N Z J Med** 1995 Oct;25(5):538

Single dose i.v. tropisetron in the prevention of postoperative nausea and vomiting after gynaecological surgery. Capouet V, et al. **Br J Anaesth** 1996 Jan;76(1):54–60

Effect of transdermal hyoscine on nausea and vomiting [letter; comment] Foster RN. **Br J Anaesth** 1996 May; 76(5):749–50. Comment on: Br J Anaesth 1996 Jan;76(1):49–53.

Effect of transdermal hyoscine on nausea and vomiting during and after middle ear surgery under local anaesthesia [see comments] Honkavaara P. **Br J Anaesth** 1996 Jan; 76(1):49–53. Comment in: Br J Anaesth 1996 May;76(5):749–50.

Single–dose i.v. granisetron in the prevention of postoperative nausea and vomiting. Wilson AJ, et al. **Br J Anaesth** 1996 Apr;76(4):515–8

Pharmacokinetic profile and clinical efficacy of a once–daily ondansetron suppository in cyclophosphamide–induced emesis: a double blind comparative study with ondansetron tablets. de Wit R, et al. **Br J Cancer** 1996 Jul;74(2):323–6

An N–of–1 trial for treatment of hyperemesis gravidarum. Magee LA, et al. **Br J Obstet Gynaecol** 1996 May; 103(5):478–80

Comparative effects of three doses of intravenous ketorolac or morphine on emesis and analgesia for restorative dental surgery in children. Purday JP, et al. **Can J Anaesth** 1996 Mar;43(3):221–5

Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin. Cleri LB, et al. **Cancer** 1995 Sep 1;76(5):774–8

A double–blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Ettinger DS, et al. **Cancer** 1996 Jul 1;78(1):144–51

Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin–based chemotherapy. A prospective randomized trial. Gebbia V, et al. **Cancer** 1995 Nov 15;76(10):1821–8

Chemotherapy–induced emesis: management of early and delayed emesis in milder emetogenic regimens. Barrenetxea G, et al. **Cancer Chemother Pharmacol** 1996;38(5):471–5

A randomized, double–blind comparison of single–dose and divided multiple–dose dolasetron for cisplatin–induced emesis. Harman GS, et al. **Cancer Chemother Pharmacol** 1996;38(4):323–8

Adrenal function following high–dose steroids in ovarian cancer patients. Del Priore G, et al. **Gynecol Oncol** 1995 Oct;59(1):102–4

National survey of drug use in palliative care. Drummond SH, et al. **Palliat Med** 1996 Apr;10(2):119–24

A randomized study of ondansetron syrup in children: evaluation of taste acceptability and tolerance. Stevens R, et al. **Pediatr Hematol Oncol** 1996 Mar–Apr;13(2):199–202

[Postoperative vomiting after pars plana vitrectomy] Heinke W, et al. **Anaesthesiol Reanim** 1996;21(2):47–50 (Eng. Abstr.) **(Ger)**

[Prevention and treatment of postoperative nausea and vomiting with 5–HT3–receptor blockers] Alon E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):200–4 (47 ref.) (Eng. Abstr.) **(Ger)**

[Paracetamol and metoclopramide in fixed combination?] Chrubasik S, et al. **Med Monatsschr Pharm** 1996 Apr; 19(4):110 **(Ger)**

[Granisetron, a antiemetic for treatment of cytostatic drug–induced vomiting: results of a practice–oriented study] Golaszewski T, et al. **Wien Klin Wochenschr** 1995; 107(20):613–21 (Eng. Abstr.) **(Ger)**

[Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy] Hisano C, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1175–81 (Eng. Abstr.) **(Jpn)**

[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP] Kimura E, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):477–81 (Eng. Abstr.) **(Jpn)**

[A comparative study of the effect of granisetron and a combination of granisetron plus steroids on cancer chemotherapy induced emesis] Nukariya N, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1821–9 (Eng. Abstr.) **(Jpn)**

[Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy—comparative study by the cross–over trial. University of Tsukuba Antiemetics Study Group] Uchida K, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):81–6 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Akathisia following low–dose droperidol for antiemesis in day–case patients. Foster PN, et al. **Anaesthesia** 1996 May; 51(5):491–4

Metoclopramide exaggerates stress–induced tachycardia in pregnant sheep. Eisenach JC, et al. **Anesth Analg** 1996 Mar; 82(3):607–11

Angioedema associated with droperidol administration. Palombaro JF, et al. **Ann Emerg Med** 1996 Mar; 27(3):379–81

An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Carmichael J, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):134–8

Metoclopramide–induced impotence and akathisia: a case report. Tsai SJ. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jun;57(6):443–6

Fixed drug eruption secondary to ondansetron [letter] [see comments] Iglesias ME, et al. **Dermatology** 1995; 191(3):270–1. Comment in: Dermatology 1995;191(3):185–7.

Massive tissue necrosis after hydroxyzine injection. Tokodi G Jr, et al. **J Am Osteopath Assoc** 1995 Oct;95(10):609–12

Granisetron–induced acute pancreatitis [letter] Rodier JM, et al. **J Cancer Res Clin Oncol** 1996;122(2):132–3

A double–blind, placebo–controlled, dose–ranging safety evaluation of single–dose intravenous dolasetron in healthy male volunteers. Hunt TL, et al. **J Clin Pharmacol** 1995 Jul;35(7):705–12

Ondansetron: reasons to be restrictive [letter; comment] Frigerio C, et al. **Lancet** 1996 May 25;347(9013):1484–5. Comment on: Lancet 1996 Mar 2;347(9001):584–5.

Hypersensitivity reactions associated with 5–hydroxytryptamine(3)–receptor antagonists: a class effect? [see comments] Kataja V, et al. **Lancet** 1996 Mar 2; 347(9001):584–5. Comment in: Lancet 1996 May 25;347(9013):1484–5.

Familial acute dystonic–dyskinetic syndrome with dominant inheritance after use of antidopaminergic antiemetic drugs [letter; comment] Macucci M, et al. **Mov Disord** 1995 Jul; 10(4):528–9. Comment on: Mov Disord 1992 Oct;7(4):385–6.

Pressor effect of metoclopramide in phaeochromocytoma [letter] Freestone S, et al. **Postgrad Med J** 1996 Mar; 72(845):188–9

Bendectin/diclectin for morning sickness: a Canadian follow–up of an American tragedy [editorial] Ornstein M, et al. **Reprod Toxicol** 1995 Jan–Feb;9(1):1–6

ANALYSIS

Retention behaviour of anti–emetic serotonin antagonists in reversed phase high performance liquid chromatography. Barbato F, et al. **Farmaco** 1995 Dec;50(12):875–80

BLOOD

High–performance liquid chromatographic determination of granisetron in human plasma. Pinguet F, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):99–105

CHEMISTRY

Stability of granisetron hydrochloride in a disposable elastomeric infusion device. Chung KC, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1541–3

Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. Henry DW, et al. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2570–3

Stability of ondansetron hydrochloride in a total parenteral nutrient admixture. Kirkham JC, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1557–8

Stability and compatibility of granisetron hydrochloride in i.v. solutions and oral liquids and during simulated Y–site injection with selected drugs. Mayron D, et al. **Am J Health Syst Pharm** 1996 Feb 1;53(3):294–304

ECONOMICS

Cost–effectiveness analysis of antiemetic therapy for ambulatory surgery [letter; comment] Lake AP, et al. **J Clin Anesth** 1995 Sep;7(6):551–3. Comment on: J Clin Anesth 1994 Sep–Oct;6(5):370–7.

Cost–effectiveness analysis of antiemetic therapy for ambulatory surgery [letter; comment] Parasuraman TV, et al. **J Clin Anesth** 1995 Aug;7(5):440–3. Comment on: J Clin Anesth 1994 Sep–Oct;6(5):370–7.

Economic impact of antiemesis. Grunberg SM. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):155–60 (16 ref.)

PHARMACOKINETICS

Pharmacokinetic profile and clinical efficacy of a once–daily ondansetron suppository in cyclophosphamide–induced emesis: a double blind comparative study with ondansetron tablets. de Wit R, et al. **Br J Cancer** 1996 Jul;74(2):323–6

PHARMACOLOGY

Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro. Behnam Motlagh P, et al. **Acta Oncol** 1995;34(6):871–5

Metoclopramide and prochlorperazine do not decrease propofol hypnotic requirements. Ali PB, et al. **Anaesthesia** 1995 Nov;50(11):990–1

Effect of domperidone–induced hyperprolactinemia on selected immune parameters in healthy women. Rovenský J, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(3–4):221–7

Ocular effects of hyoscine in double dose transdermal administration and its reversal by low dose pyridostigmine. Alhalel A, et al. **Aviat Space Environ Med** 1995 Nov; 66(11):1037–40

Influence of granisetron on thermoregulation during exercise in the heat. McLellan TM, et al. **Aviat Space Environ Med** 1996 May;67(5):453–7

The broad–spectrum anti–emetic activity of the novel non–peptide tachykinin NK1 receptor antagonist GR203040. Gardner CJ, et al. **Br J Pharmacol** 1995 Dec; 116(8):3158–63

An interaction of ondansetron and dexamethasone antagonizing cisplatin–induced acute and delayed emesis in the ferret. Rudd JA, et al. **Br J Pharmacol** 1996 May; 118(2):209–14

Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Jantunen IT, et al. **Cancer Chemother Pharmacol** 1996;37(5):502–4

The effect of ondansetron on pyridostigmine–induced blood acetylcholinesterase inhibition in the guinea pig. Capacio BR, et al. **Drug Chem Toxicol** 1996;19(1–2):1–19

Influence of residual C–peptide secretion on the arginine vasopressin response to hypoglycaemia and metoclopramide in insulin–dependent diabetes. Chiodera P, et al. **Eur J Clin Invest** 1995 Aug;25(8):568–73

The anti–emetic activity of GK–128 in Suncus murinus. Ito C, et al. **Eur J Pharmacol** 1995 Oct 4;285(1):37–43

Antinociceptive effects of clebopride in the mouse. Bittencourt SC, et al. **Gen Pharmacol** 1995 Sep;26(5):1083–7

Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)–(2–methoxy–5–tetrazol–1–ylbenzyl)(2–phenylpiperidin–3–yl)amine (GR203040), with potent antiemetic activity. Ward P, et al. **J Med Chem** 1995 Dec 22;38(26):4985–92

Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion– and apomorphine–induced pica in rats. Takeda N, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):589–90

Enantiospecific inhibition of emesis induced by nicotine in

the house musk shrew (Suncus murinus) by the neurokinin1 (NK1) receptor antagonist CP-99,994. Tattersall FD, et al. **Neuropharmacology** 1995 Dec;34(12):1697-9

Blockade of lithium chloride-induced conditioned place aversion as a test for antiemetic agents: comparison of metoclopramide with combined extracts of Zingiber officinale and Ginkgo biloba. Frisch C, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):321-7

Comparison of the antiemetic effects of a 5-HT1A agonist, LY228729, and 5-HT3 antagonists in the pigeon. Wolff MC, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):571-5

Instrumental outcome devaluation is attenuated by the anti-emetic ondansetron. Balleine B, et al. **Q J Exp Psychol B** 1995 Aug;48(3):235-51

A new trend in the therapy of orthostatic arterial hypotension: prevention by propranolol or metoclopramide of the excessive adrenaline release of brainstem infarct patients with postural hypotension. Stoica E, et al. **Rom J Neurol Psychiatry** 1995 Jul-Dec;33(3-4):203-14

A pharmacologic profile of oral granisetron (Kytril tablets). Blower P. **Semin Oncol** 1995 Aug;22(4 Suppl 10):3-5 (13 ref.)

[Antimotion-sickness effect of nooglutil and its neuronal mechanism] Iasentsov VV, et al. **Biull Eksp Biol Med** 1995 May;119(5):515-6 **(Rus)**

POISONING

Promethazine toxicity in a seven-month-old Doberman pinscher. Staley EC, et al. **Vet Hum Toxicol** 1995 Jun; 37(3):243-4

THERAPEUTIC USE

Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences. Moerman I, et al. **Acta Anaesthesiol Belg** 1995;46(3-4):127-32

Sustained-release metoclopramide plus methylprednisolone versus placebo plus methylprednisolone as antiemetic prophylaxis during non-cisplatin chemotherapy. A randomized double-blind cross-over trial. Hansen O, et al. **Acta Oncol** 1996;35(1):57-61

Development of antiemetic therapy in cancer patients. Herrstedt J. **Acta Oncol** 1995;34(5):637-40 (42 ref.)

Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. Jørgensen M, et al. **Acta Oncol** 1996;35(2):159-63

Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Jones J, et al. **Am J Emerg Med** 1996 May; 14(3):262-4

Metoclopramide in trauma CT scanning: preventing emesis of oral radiographic contrast. Page B, et al. **Am J Emerg Med** 1996 Jul;14(4):373-6

Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. Vutyavanich T, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):881-4

A double-blind randomized controlled trial of ginger for the prevention of postoperative nausea and vomiting. Arfeen Z, et al. **Anaesth Intensive Care** 1995 Aug;23(4):449-52

Ondansetron and minor oral surgery [letter; comment] Campbell RC, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):516. Comment on: Anaesth Intensive Care 1995 Feb;23(1):122.

A double-blind randomized prospective study comparing ondansetron with droperidol in the prevention of emesis following strabismus surgery. Davis A, et al. **Anaesth Intensive Care** 1995 Aug;23(4):438-43

Comparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia. Alexander R, et al. **Anaesthesia** 1995 Dec;50(12):1086-8

Tropisetron and metoclopramide in the prevention of postoperative nausea and vomiting. A comparative, placebo controlled study in patients undergoing ophthalmic surgery. Ali-Melkkilä T, et al. **Anaesthesia** 1996 Mar; 51(3):232-5

Antiemetic efficacy of prophylactic ondansetron in laparoscopic cholecystectomy. A randomised, double-blind, placebo-controlled trial. Koivuranta MK, et al. **Anaesthesia** 1996 Jan;51(1):52-55

Infusions of subhypnotic doses of propofol for the prevention of postoperative nausea and vomiting. Montgomery JE, et al. **Anaesthesia** 1996 Jun;51(6):554-7

Postoperative emesis following otoplasty in children. Paxton D, et al. **Anaesthesia** 1995 Dec;50(12):1083-5

The prevention of postoperative nausea and vomiting using a combination of ondansetron and droperidol. Wrench IJ, et al. **Anaesthesia** 1996 Aug;51(8):776-8

Tropisetron for the prevention of postoperative nausea and vomiting in women undergoing gynecologic surgery. Alon E, et al. **Anesth Analg** 1996 Feb;82(2):338-41

Effects of ondansetron on emesis in the first 24 hours after craniotomy in children. Furst SR, et al. **Anesth Analg** 1996 Aug;83(2):325-8

The effects of the menstrual cycle on the incidence of emesis and efficacy of ondansetron. Gratz I, et al. **Anesth Analg** 1996 Sep;83(3):565-9

Preoperative oral ondansetron for pediatric tonsillectomy. Rose JB, et al. **Anesth Analg** 1996 Mar;82(3):558-62

A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures. Tang J, et al. **Anesth Analg** 1996 Aug;83(2):304-13

Dimenhydrinate decreases vomiting after strabismus surgery in children. Vener DF, et al. **Anesth Analg** 1996 Apr; 82(4):728-31

Effect of antiemetic therapy on recovery and hospital discharge time. A double-blind assessment of ondansetron, droperidol, and placebo in pediatric patients undergoing ambulatory surgery. Davis PJ, et al. **Anesthesiology** 1995 Nov;83(5):956-60

Prochlorperazine or metoclopramide? [letter; comment] Ducharme J, et al. **Ann Emerg Med** 1996 Apr;27(4):529-30 . Comment on: Ann Emerg Med 1995 Nov;26(5):541-6.

Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. **Ann Oncol** 1995 Oct;6(8):805-10

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Griffin AM, et al. **Ann Oncol** 1996 Feb;7(2):189-95

Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial. Adams M, et al. **Anticancer Drugs** 1995 Aug;6(4):514-21

A comparison of the antiemetic efficacy and safety of intramuscular and intravenous formulations of granisetron in patients receiving moderately emetogenic chemotherapy. Contu A, et al. **Anticancer Drugs** 1995 Oct;6(5):652-6

Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Dick GS, et al. **Arch Dis Child** 1995 Sep;73(3):243-5

The effect of intravenous dexamethasone in pediatric adenotonsillectomy. April MM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):117-20

Assessing the comparative clinical value of tropisetron. Olver IN. **Aust N Z J Med** 1995 Oct;25(5):523-7 (31 ref.)

Interim analyses in 2 x 2 crossover trials. Cook RJ. **Biometrics** 1995 Sep;51(3):932-45

Placebo controlled trials of ondansetron for postoperative nausea and vomiting [letter; comment] Palmer JB, et al. **BMJ** 1996 Jan 20;312(7024):183. Comment on: BMJ 1995 Sep 30;311(7009):844-6.

Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant. Agura ED, et al. **Bone Marrow Transplant** 1995 Aug;16(2):213-22

Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia. Honkavaara P. **Br J Anaesth** 1996 Feb;76(2):316-8

Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting. López-Olaondo L, et al. **Br J Anaesth** 1996 Jun; 76(6):835-40

Prevention of vomiting after paediatric strabismus surgery: a systematic review using the numbers-needed-to-treat method. Tramèr M, et al. **Br J Anaesth** 1995 Nov; 75(5):556-61 (48 ref.)

Comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after adenotonsillectomy. van den Berg AA. **Br J Anaesth** 1996 Mar;76(3):449-51

Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients. Alfieri AB, et al. **Br J Cancer** 1995 Oct; 72(4):1013-5

Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Matsui K, et al. **Br J Cancer** 1996 Jan;73(2):217-21

The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial. Chua DT, et al. **Br J Clin Pharmacol** 1996 May; 41(5):403-8

Dimenhydrinate pretreatment in patients receiving intra-arterial ioxaglate: effect on nausea and vomiting. Smith DC, et al. **Can Assoc Radiol J** 1995 Dec;46(6):449-53

Prevention of postoperative nausea and vomiting with granisetron: a randomized, double-blind comparison with droperidol. Fujii Y, et al. **Can J Anaesth** 1995 Oct; 42(10):852-6

Granisetron reduces vomiting after strabismus surgery and tonsillectomy in children. Fujii Y, et al. **Can J Anaesth** 1996 Jan;43(1):35-8

Propofol and chemotherapy-induced emesis [letter; comment] Jones P, et al. **Can J Anaesth** 1995 Jul;42(7):659 . Comment on: Can J Anaesth 1994 Nov;41(11):1117-9.

Oral clonidine premedication reduces vomiting in children after strabismus surgery. Mikawa K, et al. **Can J Anaesth** 1995 Nov;42(11):977-81

Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. Naguib M, et al. **Can J Anaesth** 1996 Mar;43(3):226-31

Ondansetron is a better prophylactic antiemetic than droperidol for tonsillectomy in children. Splinter WM, et al. **Can J Anaesth** 1995 Oct;42(10):848-51

Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting [letter; comment] Fedele P, et al. **Cancer** 1995 Aug 1;76(3):535-6 . Comment on: Cancer 1994 Oct 1;74(7):1945-52.

Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. Gilbert CJ, et al. **Cancer** 1995 Dec 1;76(11):2330-7

Issues in antiemetic therapy [editorial; comment] Goldspiel BR, et al. **Cancer** 1996 Mar 1;77(5):823-6. Comment on: Cancer 1996 Mar 1;77(5):941-8.

Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial [see comments] Mantovani G, et al. **Cancer** 1996 Mar 1;77(5):941-8. Comment in: Cancer 1996 Mar 1;77(5):823-33.

Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Morrow GR, et al. **Cancer** 1995 Aug 1; 76(3):343-57 (121 ref.)

Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. Chang TC, et al. **Cancer Chemother Pharmacol** 1996;37(3):279-85

Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron. Schröder CP, et al. **Cancer Chemother Pharmacol** 1995;36(6):477-82

Emesis and anti-emesis. Naylor RJ, et al. **Cancer Surv** 1994; 21:117-35 (138 ref.)

Comparison of intravenous granisetron with metoclopramide in the treatment of chemotherapy-induced emesis. Chiou TJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Jul; 56(1):23-30

Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients. Koriech OM. **Clin Oncol (R Coll Radiol)** 1995;7(6):371-2

Does dexamethasone leucocytosis facilitate full dosage adjuvant chemotherapy for breast cancer? Rees GJ. **Clin Oncol (R Coll Radiol)** 1995;7(4):257-8

The pharmacological treatment of Menière's disease. Brookes GB. **Clin Otolaryngol** 1996 Feb;21(1):3-11 (78 ref.)

Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. DiBenedetto J Jr, et al. **Clin Ther** 1995 Nov-Dec;17(6):1091-8

Ondansetron for the control of dacarbazine-induced emesis [letter] Campora E, et al. **Eur J Cancer** 1995 Sep; 31A(10):1720-1

An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. Martoni A, et al. **Eur J Cancer** 1996 Jan;32A(1):82-5

Nausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide. Miralbell R, et al. **Eur J Cancer** 1995;31A(9):1461-4

Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloride for prophylactic treatment of emesis induced by cisplatin chemotherapy. Tsukuda M, et al. **Eur J Cancer** 1995 Sep;31A(10):1647-9

Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. Meden H, et al. **Eur J Gynaecol Oncol** 1996;17(2):114-22

A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis. Sabbatini R, et al. **Haematologica** 1995 Sep-Oct;80(5):416-20

Management of acute emesis. Singhal S, et al. **J Assoc Physicians India** 1995 Aug;43(8):560-2 (6 ref.)

Epidural scopolamine administration in preventing nausea after epidural morphine. Moscovici R, et al. **J Clin Anesth** 1995 Sep;7(6):474-6

Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery [letter; comment] Parasuraman TV, et al. **J Clin Anesth** 1995 Aug;7(5):440-3. Comment on: J Clin Anesth 1994 Sep-Oct;6(5):370-7.

Changing physicians' practice patterns [news] **J Clin Monit** 1995 Nov;11(6):412-3

Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. de Wit R, et al. **J Clin Oncol** 1996 Feb;14(2):644-51

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. Hesketh P, et al. **J Clin Oncol** 1996 Aug;14(8):2242-9

Is oral ondansetron really efficacious in the control of cisplatin-induced delayed emesis? [letter; comment] Martin M. **J Clin Oncol** 1996 Apr;14(4):1401-2. Comment on: J Clin Oncol 1995 Sep;13(9):2408-16.

Reduction of nausea and vomiting from epidural opioids by adding droperidol to the infusate in home-bound patients. Aldrete JA. **J Pain Symptom Manage** 1995 Oct;10(7):544-7

Effectiveness of levosulpiride versus metoclopramide for nausea and vomiting in advanced cancer patients: a double-blind, randomized, crossover study. Corli O, et al. **J Pain Symptom Manage** 1995 Oct;10(7):521-6

Successful management of intractable nausea with ondansetron: a case study. Pereira J, et al.

J Palliat Care 1996 Summer;12(2):47–50

The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning. Clark RF, et al. **J Toxicol Clin Toxicol** 1996;34(2):163–7

Marijuana as medicine [letter; comment] Nahas GG, et al. **JAMA** 1995 Dec 20;274(23):1837–8. Comment on: JAMA 1995 Jun 21;273(23):1875–6.

A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis. Sekine I, et al. **Jpn J Clin Oncol** 1996 Jun; 26(3):164–8

Minimising the side effects of cancer chemotherapy [editorial; comment] Green M. **Med J Aust** 1996 Mar 18;164(6):326 . Comment on: Med J Aust 1996 Mar 18;164(6):337–40.

An open multicentre study of tropisetron for cisplatin-induced nausea and vomiting [see comments] Olver IN, et al. **Med J Aust** 1996 Mar 18;164(6):337–40. Comment in: Med J Aust 1996 Mar 18;164(6):326.

Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy. Benoit Y, et al. **Med Pediatr Oncol** 1995 Dec;25(6):457–62

Compliance with guidelines results in appropriate ondansetron prescribing at Christchurch Hospital. Busch AF, et al. **N Z Med J** 1996 Apr 26;109(1020):142–4

Nurses' perceptions of antiemetic effectiveness. Rhodes VA, et al. **Oncol Nurs Forum** 1995 Sep;22(8):1243–52

Mechanisms and Management of Nausea and Emesis Associated with Cancer Therapy. Symposium proceedings. Marlow, United Kingdom, October 13–14, 1994. **Oncology** 1996 Jun;53 Suppl 1:1–110

Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Bountra C, et al. **Oncology** 1996 Jun;53 Suppl 1:102–9 (17 ref.)

Mechanisms and management of nausea and emesis [editorial] Dicato M. **Oncology** 1996 Jun;53 Suppl 1:1–3 (16 ref.)

Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-induced emesis. A phase II trial in women. Franchi M, et al. **Oncology** 1995 Nov–Dec; 52(6):509–12

Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin. Gralla RJ, et al. **Oncology** 1996 Jun;53 Suppl 1:86–91

Management of cisplatin-induced delayed emesis. Hesketh P. **Oncology** 1996 Jun;53 Suppl 1:73–7 (14 ref.)

Antiemetic study methodology: recommendations for future studies. Olver IN. **Oncology** 1996 Jun;53 Suppl 1:96–101 (32 ref.)

5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. Ossi M, et al. **Oncology** 1996 Jun;53 Suppl 1:78–85

Control of acute cisplatin-induced emesis over repeat courses of chemotherapy. Italian Group for Antiemetic Research. Roila F. **Oncology** 1996 Jun;53 Suppl 1:65–72

Management of other non-cisplatin-induced emesis. Schmoll HJ, et al. **Oncology** 1996 Jun;53 Suppl 1:51–5 (24 ref.)

Management of cyclophosphamide-induced emesis over repeat courses. Soukop M. **Oncology** 1996 Jun;53 Suppl 1:39–45

Optimal control of cyclophosphamide-induced emesis. Stewart A. **Oncology** 1996 Jun;53 Suppl 1:32–8 (38 ref.)

Optimal control of acute cisplatin-induced emesis. Verweij J, et al. **Oncology** 1996 Jun;53 Suppl 1:56–64 (80 ref.)

Clinical trials referral resource. Cancer chemoprevention and control trials. Brawley OW, et al. **Oncology (Huntingt)** 1996 Apr;10(4):499–500

Economic impact of antiemesis. Grunberg SM. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):155–60 (16 ref.)

Anticholinergic prophylaxis does not prevent emesis following strabismus surgery in children. Chisakuta AM, et al. **Paediatr Anaesth** 1995;5(2):97–100

Rapid intravenous administration of ondansetron or metoclopramide is not associated with cardiovascular compromise in children. Rose JB, et al. **Paediatr Anaesth** 1995;5(2):121–4

Prevention of emesis by tropisetron in children receiving combined chemotherapy with cisplatin. Berberoglu S. **Pediatr Hematol Oncol** 1995 Sep–Oct;12(5):479–83

Ondansetron in radiation therapy of brain tumor in children. Lippens RJ, et al. **Pediatr Hematol Oncol** 1996 May–Jun; 13(3):247–52

A new trend in the therapy of orthostatic arterial hypotension: prevention by propranolol or metoclopramide of the excessive adrenaline release of brainstem infarct patients with postural hypotension. Stoica E, et al. **Rom J Neurol Psychiatry** 1995 Jul–Dec;33(3–4):203–14

Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Ettinger DS. **Semin Oncol** 1995 Aug;22(4 Suppl 10):6–18 (109 ref.)

Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Hesketh P. **Semin Oncol** 1995 Aug;22(4 Suppl 10):19–23 (23 ref.)

Overview: oral granisetron (Kytril tablets) prophylaxis for chemotherapy-induced nausea and vomiting. Perez EA. **Semin Oncol** 1995 Aug;22(4 Suppl 10):1–2

A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. Barbounis V, et al. **Support Care Cancer** 1995 Sep;3(5):301–6

Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Hesketh PJ, et al. **Support Care Cancer** 1996 Mar;4(2):141–6

Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Latreille J, et al. **Support Care Cancer** 1995 Sep;3(5):307–12

Granisetron (Kytril): a survey of use in clinical practice in Switzerland. Terrey JP, et al. **Support Care Cancer** 1995 Nov;3(6):435–8

Prevention of highly emetogenic chemotherapy-induced vomiting: a double blind, randomized crossover study to compare pancopride (LAS 30451) and pancopride plus dexamethasone. Aranda E, et al. **Tumori** 1995 Nov–Dec; 81(6):432–4

[The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial] Zeng W, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):294–7 (Eng. Abstr.) **(Chi)**

[Methodology of the evaluation of antiemetics] Bergmann JF. **Bull Cancer (Paris)** 1995 Dec;82(12):1062–6 (18 ref.) (Eng. Abstr.) **(Fre)**

[Future trends in chemotherapy and impact on the management of emesis] Catimel G, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):1067–71 (Eng. Abstr.) **(Fre)**

[Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin] Harousseau JL. **Bull Cancer (Paris)** 1996 Jan;83(1):71–76 (27 ref.) (Eng. Abstr.) **(Fre)**

[Colonic preparation with sodium phosphate. Prospective, randomized, placebo-controlled double blind study with various antiemetics] Güller R, et al. **Schweiz Med Wochenschr** 1996 Aug 6;126(31–32):1352–7 (Eng. Abstr.) **(Ger)**

[The development of a new QOL Questionnaire on chemotherapy – induced emesis and vomiting—investigation of reliability and validity. Group for Investigation of QOL Questionnaire for Anti-Emetics Used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative study] Ishihara Y, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):745–55 (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors] Kitada M, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):87–91 (Eng. Abstr.) **(Jpn)**

[Effects of an anti-emetic tropisetron capsule on QOL of patients with delayed nausea and vomiting induced by cancer chemotherapy. Group for Investigation of QOL Questionnaire for Anti-Emetics used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative Study] Nukariya N, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):757–71 (Eng. Abstr.) **(Jpn)**

[Efficacy of granisetron rescue therapy for nausea and vomiting induced by cancer chemotherapies in urogenital malignant tumor] Takigawa H, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):899–903 (Eng. Abstr.) **(Jpn)**

[A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin] Tsukuda M, et al. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1959–67 (Eng. Abstr.) **(Jpn)**

[Estimation of effectiveness of antiemetic treatment with Zofran given in one dose to children with neoplasms] Kurylak A, et al. **Pediatr Pol** 1995 Nov;70(11):925–8 (Eng. Abstr.) **(Pol)**

[Anti-5-HT-3: a new group of antiemetics] Galindo JR. **Rev Clin Esp** 1996 Feb;196(2):119–24 (73 ref.) **(Spa)**

[Ondansetron in the prevention of postoperative nausea and vomiting in ambulatory surgery] Bustos-Molina F, et al. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):138–41 (Eng. Abstr.) **(Spa)**

[5HT3 antagonists: ondansetron] López de Ocariz A, et al. **Rev Med Univ Navarra** 1993 Jan–Mar;38(1):43–9 **(Spa)**

TOXICITY

Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Brent RL. **Reprod Toxicol** 1995 Jul–Aug;9(4):337–49 (178 ref.)

ANTIEPILEPTIC AGENTS see ANTICONVULSANTS

ANTIESTROGENS see ESTROGEN ANTAGONISTS

ANTIFIBRILLATORY AGENTS see ANTI-ARRHYTHMIA AGENTS

ANTIFIBRINOLYSINS see ANTIFIBRINOLYTIC AGENTS

ANTIFIBRINOLYTIC AGENTS

ADMINISTRATION & DOSAGE

Oral vitamin K1: an option to reduce warfarin's activity. Harrell CC, et al. **Ann Pharmacother** 1995 Dec; 29(12):1228–32 (26 ref.)

Intravenous vitamin K1 injections: dangerous prophylaxis [letter; comment] O'Reilly RA, et al. **Arch Intern Med** 1995 Oct 23;155(19):2127–8. Comment on: Arch Intern Med 1995 Jan 23;155(2):149–61.

Changes of K vitamins in portal and femoral venous plasma of rats after oral administration of phylloquinone and menaquinone-4. Sakamoto N, et al. **Int J Vitam Nutr Res** 1995;65(2):105–10

Antifibrinolytic therapy in cardiac surgery. Chen RH, et al. **Tex Heart Inst J** 1995;22(3):211–5 (73 ref.)

Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. Penta de Peppo A, et al. **Tex Heart Inst J** 1995; 22(3):231–6

ADVERSE EFFECTS

Intravenous vitamin K1 injections: dangerous prophylaxis [letter; comment] O'Reilly RA, et al. **Arch Intern Med** 1995 Oct 23;155(19):2127–8. Comment on: Arch Intern Med 1995 Jan 23;155(2):149–61.

[Cutaneous hypersensitivity at the site of injection of vitamin K1] Moreau-Cabarrot A, et al. **Ann Dermatol Venereol** 1996;123(3):177–9 (22 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Diagnosis of pulmonary embolism by a decision analysis-based strategy including clinical probability, D-dimer levels, and ultrasonography: a management study. Perrier A, et al. **Arch Intern Med** 1996 Mar 11;156(5):531–6

The role of plasma D-dimers concentration in the exclusion of pulmonary embolism. van Beek EJ, et al. **Br J Haematol** 1996 Mar;92(3):725–32

Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Lip GY, et al. **Int J Cardiol** 1995 Oct;51(3):245–51

D-dimer test for HELLP syndrome [letter; comment] McClincy MS, et al. **South Med J** 1995 Nov;88(11):1182–3 . Comment on: South Med J 1995 Apr;88(4):416–9.

Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Lee AJ, et al. **Thromb Haemost** 1995 Sep; 74(3):828–32

[alpha 2-Plasmin inhibitor-plasmin complex (PIC)] Yoshikawa Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:55–8 (13 ref.) **(Jpn)**

CHEMISTRY

Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands epsilon-aminocaproic acid and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid. Mathews II, et al. **Biochemistry** 1996 Feb 27;35(8):2567–76

[Fibrin fragment beta 15–118. Inhibitory and complex-forming properties] Lugovskoĭ EV, et al. **Ukr Biokhim Zh** 1995 Jul–Aug;67(4):57–64 (Eng. Abstr.) **(Rus)**

METABOLISM

Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Lip GY, et al. **Am Heart J** 1996 Apr;131(4):724–30

Haemostatic markers of procoagulant imbalance in Behçet's disease [letter] Haznedaroğlu IC, et al. **Eur J Haematol** 1996 Jul;57(1):107–8

PHARMACOLOGY

Inhibitors for the in vitro assembly of Lp(a). Frank S, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1774–80

Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis. Lijnen HR, et al. **Thromb Haemost** 1995 May;73(5):845–9

THERAPEUTIC USE

Concomitant treatment with factor IX concentrates and antifibrinolytics in hemophilia B. Djulbegovic B, et al. **Acta Haematol** 1995;94 Suppl 1:43–7; discussion 48

Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. Djulbegovic B, et al. **Am J Hematol** 1996 Feb; 51(2):168–70

Does tranexamic acid reduce blood loss in knee arthroplasty? Benoni G, et al. **Am J Knee Surg** 1995 Summer;8(3):88–92

Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. Shore-Lesserson L, et al. **Anesth Analg** 1996 Jul;83(1):18–26

Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients. Katsaros D, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1131–5

Tranexamic acid use during coronary artery bypass grafting [letter; comment] Rubens F, et al. **Ann Thorac Surg** 1996 Feb;61(2):774–5. Comment on: Ann Thorac Surg 1995 Mar;59(3):671–5.

Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. Bonnar J, et al. **BMJ** 1996 Sep 7; 313(7057):579–82

Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Edlund M, et al. **Br J Obstet Gynaecol** 1995

Nov;102(11):913-7
Reduction of haemorrhagic complications during mechanically assisted circulation with the use of a multi-system anticoagulation protocol. Glauber M, et al. **Int J Artif Organs** 1995 Oct;18(10):649-55
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. Barbash GI, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1222-9
Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. Benoni G, et al. **J Bone Joint Surg Br** 1996 May; 78(3):434-40
Antifibrinolytic therapy: treat whom and with what? [letter] Horrow JC. **J Clin Anesth** 1995 Dec;7(8):690
Tranexamic acid rinses in anticoagulated patients [letter; comment] Liebiich S. **J Oral Maxillofac Surg** 1996 May; 54(5):657. Comment on: J Oral Maxillofac Surg 1996 Jan;54(1):27-32; discussion 323.
The effect of preoperative tranexamic acid on blood loss after cardiac operations in children. Zonis Z, et al. **J Thorac Cardiovasc Surg** 1996 May;111(5):982-7
A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. Shpilberg O, et al. **Leuk Lymphoma** 1995 Sep; 19(1-2):141-4
Effect of antiproteolytic drugs: epsilon-aminocaproic acid (EACA) and aprotinin on experimental anti-GBM nephritis. Hruby Z, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):32-9
The effects of gynaecological surgery on coagulation activation, fibrinolysis and fibrinolytic inhibitor in patients with and without ketorolac infusion. Koh SC, et al. **Thromb Res** 1995 Sep 15;79(5-6):501-14
Does tranexamic acid decrease bleeding in patients undergoing cardiopulmonary bypass? Connelly NR, et al. **Yale J Biol Med** 1994 Sep-Dec;67(5-6):265-8
[Fibrinolytic inhibitors and prevention of bleeding in cardiac valve surgery. Comparison of tranexamic acid and high dose aprotinin] Boughenou F, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):363-70 (Eng. Abstr.) **(Fre)**
[Prophylaxis of late hemorrhagic disease in newborn infants with vitamin K1 at birth (letter)] Besson-Leaud M, et al. **Arch Pediatr** 1996 Jan;3(1):89-90 discussion 90 **(Fre)**

ANTIFLATULENTS see **ANTIFOAMING AGENTS**

ANTIFOAMING AGENTS

DIAGNOSTIC USE

The effectiveness of simethicone in improving visibility during colonoscopy when given with a sodium phosphate solution: a double-bind randomized study. Sudduth RH, et al. **Gastrointest Endosc** 1995 Nov;42(5):413-5

PHARMACOLOGY

Susceptibility of Helicobacter pylori to simethicone and other non-antibiotic drugs. Ansorg R, et al. **J Antimicrob Chemother** 1996 Jan;37(1):45-52

ANTIFOLATES see **FOLIC ACID ANTAGONISTS**

ANTIFUNGAL AGENTS

see related
FUNGICIDES, INDUSTRIAL

Discoloration of the nail plate due to the misuse of amorolfine 5% nail lacquer [letter] Rigopoulos D, et al. **Acta Derm Venereol** 1996 Jan;76(1):83-4
Cloning, structural organization and regulation of expression of the Penicillium chrysogenum paf gene encoding an abundantly secreted protein with antifungal activity. Marx F, et al. **Gene** 1995 Dec 29;167(1-2):167-71
Fungistatic and fungicidal activity of east African medicinal plants. Fabry W, et al. **Mycoses** 1996 Jan-Feb;39(1-2):67-70
Membrane fluidization by animycotic bifonazole. Albertini G, et al. **Physiol Chem Phys Med NMR** 1995;27(2):91-109
Structure and function of a virally encoded fungal toxin from Ustilago maydis: a fungal and mammalian Ca2+ channel inhibitor. Gu F, et al. **Structure** 1995 Aug 15;3(8):805-14

ADMINISTRATION & DOSAGE

Effect of treatment of palatal inflammatory papillary hyperplasia with local and systemic antifungal agents accompanied by renewal of complete dentures. Salonen MA, et al. **Acta Odontol Scand** 1996 Apr;54(2):87-91
Successful treatment of fungal peritonitis with intracatheter antifungal retention. Lee SH, et al. **Adv Perit Dial** 1995; 11:172-5
Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact on the incidence of disseminated cryptococcal infection [letter] Newton JA Jr, et al. **AIDS** 1995 Nov;9(11):1286-7
Oral fluconazole for vaginal candidiasis. Desai PC, et al. **Am Fam Physician** 1996 Sep 15;54(4):1337-40, 1345-6 (11 ref.)
Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Dewsnup DH, et al. **Ann Intern Med** 1996 Feb 1;124(3):305-10
Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. De Doncker P, et al. **Arch Dermatol** 1996 Jan;132(1):34-41
A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day--a double-blind comparative trial. De Backer M, et al. **Br J Dermatol** 1996 Jun;134 Suppl 46:16-7: discussion 38
Long-term evaluation of terbinafine 250 and 500 mg daily in a 16-week oral treatment for toenail onychomycosis [letter] De Cuyper C. **Br J Dermatol** 1996 Jul;135(1):156-7
A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Haroon TS, et al. **Br J Dermatol** 1996 Jul;135(1):86-8
Very short duration therapy with oral terbinafine for fingernail onychomycosis [letter] Wong CK, et al. **Br J Dermatol** 1995 Aug;133(2):329-31
Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. Benoit JL, et al. **Clin Infect Dis** 1995 Nov;21(5):1286-8
Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Fan-Havard P, et al. **Clin Infect Dis** 1995 Oct;21(4):960-5
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Menichetti F, et al. **Clin Infect Dis** 1996 May;22(5):838-40
Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Rex JH, et al. **Clin Infect Dis** 1995 Oct;21(4):994-6
Comparison of the efficacy and safety of oral fluconazole and topical clotrimazole in patients with candida balanitis. Stary A, et al. **Genitourin Med** 1996 Apr;72(2):98-102
Oil of bitter orange: new topical antifungal agent. Ramadan W, et al. **Int J Dermatol** 1996 Jun;35(6):448-9
Long-term administration of aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia in infants and children with symptomatic human immunodeficiency virus infection. The Italian Pediatric Collaborative Study Group on Pentamidine. Principi N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):158-63
Fluconazole infused via a nephrostomy tube: a novel and effective route of delivery. Oliver SE, et al. **J Clin Pharm Ther** 1995 Dec;20(6):317-8
Better efficacy of twice-monthly than monthly aerosolised pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. An Italian multicentric randomised controlled trial. The Italian PCP Study Group. Rizzardi GP, et al. **J Infect** 1995 Sep; 31(2):99-105
Treatment of experimental cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome. Kartalija M, et al. **J Infect Dis** 1996 May;173(5):1216-21
Efficacy of oral saperconazole in systemic murine aspergillosis. Hanson LH, et al. **J Med Vet Mycol** 1995 Sep-Oct;33(5):311-7
Systemic candidiasis in Sprague-Dawley rats. Schmidt A. **J Med Vet Mycol** 1996 Mar-Apr;34(2):99-104
Endoscopic instillation of fungicide to treat aspergilloma [letter] Guleria R, et al. **Lancet** 1996 Aug 31;348(9027):621
Comparative study of fluconazole and clotrimazole for the treatment of vulvovaginal candidiasis. O-Prasertsawat P, et al. **Sex Transm Dis** 1995 Jul-Aug;22(4):228-30
Combined use of fluconazole and selective digestive decontamination in the prevention of fungal infection after adult liver transplantation. Decruyenaere J, et al. **Transplant Proc** 1995 Dec;27(6):3515-6
Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Osowski CL, et al. **Transplantation** 1996 Apr 27;61(8):1268-72
Comparison of single-dose and 7-day fluconazole treatment of fungal esophagitis in alcoholic liver disease. Péter Z, et al. **Z Gastroenterol** 1996 Jun;34(6):361-4
[Treatment and prevention of generalized mycoses (letter; comment)] Prooy E. **Ned Tijdschr Geneeskd** 1995 Dec 2; 139(48):2514. Comment on: Ned Tijdschr Geneeskd 1995 Jul 15;139(28):1436-41. **(Dut)**
[HIV-associated Pneumocystis carinii pneumonia, primary pentamidine inhalation prophylaxis notwithstanding. Are there differences with Pneumocystis carinii pneumonia without prophylaxis?] Ewig S, et al. **Dtsch Med Wochenschr** 1996 Jan 26;121(4):83-9 (Eng. Abstr.) **(Ger)**
[Dermatomycoses. 13: Mycoses of the genital region--therapy and follow-up] Meinhof W. **Fortschr Med** 1995 Nov 10;113(31):444-5 **(Ger)**
[Dermatomycoses. 17: Topical therapy of skin and mucous membrane mycoses] Meinhof W. **Fortschr Med** 1996 Jan 20;114(1-2):35-6 **(Ger)**
[Dermatomycoses. 16: Topical therapy of skin and mucous membrane mycoses] Meinhof W. **Fortschr Med** 1995 Dec 10;113(34):495-7 **(Ger)**
[Chronic necrotizing pulmonary aspergillosis treated with itraconazole and inhaled amphotericin B] Sato A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1141-5 (Eng. Abstr.) **(Jpn)**
[Pulmonary aspergillosis and itraconazole (letter)] Serrano-Heranz R, et al. **Arch Bronconeumol** 1995 Aug-Sep;31(7):372-3 **(Spa)**

ADVERSE EFFECTS

Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration. Guillaume MP, et al. **Am J Gastroenterol** 1996 Jan;91(1):165-8 (14 ref.)
Suspected vein irritation from i.v. pentamidine isethionate [letter] Andersen JM. **Am J Health Syst Pharm** 1996 Jan 15;53(2):185
Vortex keratopathy associated with atovaquone. Shah GK, et al. **Am J Ophthalmol** 1995 Nov;120(5):669-71
Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Böhme A, et al. **Ann Hematol** 1995 Dec;71(6):311-2
Alopecia associated with fluconazole therapy [letter; comment] Goldsmith LA. **Ann Intern Med** 1996 Jul 15; 125(2):153; discussion 153-4. Comment on: Ann Intern Med 1995 Sep 1;123(5):354-7.
Thrombocytopenia and leukopenia associated with itraconazole [letter] Horst HA, et al. **Ann Intern Med** 1996 Jul 15;125(2):156-7
Probable interaction between fluoxetine and itraconazole [letter] Black PN. **Ann Pharmacother** 1995 Oct; 29(10):1048-9
The development of green vision in association with terbinafine therapy [letter] Gupta AK, et al. **Arch Dermatol** 1996 Jul;132(7):845-6
Peripheral edema due to nifedipine-itraconazole interaction: a case report [letter] Tailor SA, et al. **Arch Dermatol** 1996 Mar;132(3):350-2
A study of 72 patients with contact allergy to tioconazole. Heikkilä H, et al. **Br J Dermatol** 1996 Apr;134(4):678-80
Renal impairment associated with oral terbinafine [letter] Lee MS, et al. **Br J Dermatol** 1996 Feb;134(2):374-5
Terbinafine and fixed drug eruption [letter] Munn SE, et al. **Br J Dermatol** 1995 Nov;133(5):815-6
Toxic epidermal necrolysis induced by terbinafine in a patient on long-term anti-epileptics [letter] White SI, et al. **Br J Dermatol** 1996 Jan;134(1):188-9
Hallucinations associated with itraconazole therapy [letter] Cleveland KO, et al. **Clin Infect Dis** 1995 Aug;21(2):456
Contact allergy to imidazoles used as antimycotic agents. Dooms-Goossens A, et al. **Contact Dermatitis** 1995 Aug; 33(2):73-7 (54 ref.)
Allergic contact dermatitis from sertaconazole with cross-sensitivity to miconazole and econazole. Goday JJ, et al. **Contact Dermatitis** 1995 Jun;32(6):370-1
Allergic contact dermatitis from cyclopiroxolamine? Jager SU, et al. **Contact Dermatitis** 1995 Nov;33(5):349-50
Contact dermatitis from amorolfine-containing cream and nail lacquer. Kramer K, et al. **Contact Dermatitis** 1996 Feb; 34(2):145
Allergic contact dermatitis from naftifine. Willa-Craps C, et al. **Contact Dermatitis** 1995 Jun;32(6):369-70
Ethylenebisdithiocarbamates and ethylenethiourea: possible human health hazards. Houeto P, et al. **Environ Health Perspect** 1995 Jun;103(6):568-73 (102 ref.)
Hepatotoxicity associated with itraconazole [letter] Gallardo-Quesada S, et al. **Int J Dermatol** 1995 Aug; 34(8):589
Thrombocytopenia caused by fluconazole [letter] Kalivas J. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):284
Systemic antifungal drugs. **Med Lett Drugs Ther** 1996 Feb 2;38(967):10-2
Megaloblastic cytopenia in an AIDS patient treated with trimethoprim-sulfamethoxazole. Shami PJ, et al. **N C Med J** 1995 Dec;56(12):602-4
Pentamidine-induced hyperglycemia and ketosis in acquired immunodeficiency syndrome [letter] Lu CP, et al. **Pancreas** 1995 Oct;11(3):315-6
HIV medicine: drug side effects and interactions. Bates CM. **Postgrad Med J** 1996 Jan;72(843):30-6 (27 ref.)
Acute severe autonomic insufficiency during pentamidine therapy [letter] Siddiqui MA, et al. **South Med J** 1995 Oct; 88(10):1087-8
[Hepatitis attributed to the use of terbinafine] Boldewijn OY, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23;140(12):669-72 (Eng. Abstr.) **(Dut)**
[Acute hepatitis related to the ingestion of terbinafine (letter)] Vantaux P, et al. **Gastroenterol Clin Biol** 1996;20(4):402-3 **(Fre)**
[Severe erythema multiforme during terbinafine therapy (letter)] Tramaloni S, et al. **Therapie** 1995 Nov-Dec; 50(6):594-5 **(Fre)**
[A case of itraconazole-induced hypokalemia with pulmonary aspergilloma] Yamamoto T, et al. **Kansenshogaku Zasshi** 1995 Dec;69(12):1413-7 (Eng. Abstr.) **(Jpn)**
[An AIDS case of probable pentamidine-induced diabetic ketoacidosis and severe acute pancreatitis] Pae Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):226-30 **(Jpn)**
[Hypocalcemia and hypomagnesemia associated with the treatment with pentamidine in 2 patients with HIV infection (letter)] Cortés E, et al. **Med Clin (Barc)** 1996 May 11;106(18):717 **(Spa)**
[Ageusia caused by terbinafine (letter)] Martínez Yélamos S, et al. **Med Clin (Barc)** 1995 Sep 9;105(7):276 **(Spa)**

ANALYSIS

Stability of flucytosine in an extemporaneously compounded oral liquid. Wintermeyer SM, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):407-9

Rapid identification and quantitation of clotrimazole, miconazole, and ketokonazole in pharmaceutical creams and ointments by thin-layer chromatography-densitometry. Roychowdhury U, et al. **J AOAC Int** 1996 May-Jun;79(3):656-9

[A high concentration of itraconazole in an aspergilloma] Niwa H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):67-70 (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Cholesterol sulfate protects Candida albicans from inhibition by sphingosine in vitro. Payne CD, et al. **J Invest Dermatol** 1996 Mar;106(3):549-52

BLOOD

Simultaneous determination of itraconazole, hydroxy-itraconazole and amphotericin B in human plasma by HPLC with photodiode array detection. Lacroix C, et al. **Ann Biol Clin (Paris)** 1995;53(5):293-7

Itraconazole does not interfere with fluorescence polarization immunoassay of serum digoxin [letter] McClure AF, et al. **Ann Pharmacother** 1995 Sep;29(9):938-9

Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia. Merali S, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2023-6

Protein binding of itraconazole and fluconazole in patients with cancer. Arredondo G, et al. **Int J Clin Pharmacol Ther** 1995 Aug;33(8):449-52

Rapid high-performance liquid chromatographic assay for atovaquone. Hansson AG, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):180-2

A chiral liquid chromatographic method for the determination of the enantiomers of the racemic triazole antifungal drug (SCH 39304) in human plasma. Kim H, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1415-9

A robotics-based liquid chromatographic assay for the measurement of atovaquone in plasma. Studenberg SD, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1383-93

Determination of itraconazole and its metabolite in plasma using SPE-HPLC. Brandšteterová E, et al. **Pharmazie** 1995 Sep;50(9):597-9

The development and validation of a high performance liquid chromatography (HPLC)/tandem mass spectrometry assay for fenticonazole in human plasma and comparison with an HPLC-UV method. Speed W, et al. **Rapid Commun Mass Spectrom** 1995;9(14):1452-6

A high-performance liquid chromatographic assay for the determination of itraconazole concentration using solid-phase extraction and small sample volume. Rifai N, et al. **Ther Drug Monit** 1995 Oct;17(5):522-5

Serum level determination of fluconazole by high-performance liquid chromatography and bioassay. Hülsewede JW, et al. **Zentralbl Bakteriol** 1996 Apr; 283(4):492-6

[Antifungal drugs] Murase S, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:1006-9 (15 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Sulfogriseofulvin derivatives. synthesis by [4 + 2]cycloaddition, structure, properties, crystal structure analysis, and antifungal activity of spiro[1,3-benzoxathiole-2,1'-cyclohex-2'-en]-4'-one 3,3-dioxides. Friedrich M, et al. **Arch Pharm (Weinheim)** 1996 Jul;329(7):361-70

Antifungal agents, Part 11. Biphenyl analogues of naftifine: synthesis and antifungal activities. Porretta GC, et al. **Arch Pharm (Weinheim)** 1995 Sep;328(9):667-72

Design, synthesis, and biological evaluation of isocyanurate-based antifungal and macrolide antibiotic conjugates: iron transport-mediated drug delivery. Ghosh M, et al. **Bioorg Med Chem** 1995 Nov;3(11):1519-25

Synthesis and antifungal activity of alkylthio and alkylsulfonyl derivatives of SM-8668. Miyauchi H, et al. **Bioorg Med Chem** 1996 Feb;4(2):263-73

Design, synthesis and in vitro evaluation of pyridinium ion based cyclase inhibitors and antifungal agents. Rose IC, et al. **Bioorg Med Chem** 1996 Jan;4(1):97-103

Structure-activity relationships of 3-methyl and 3,3-dimethyl analogs of 2-(2,4-difluorophenyl)-3-(omega-substituted alkyl)sulfonyl-1-(1H-1,2,4-triazol-1-yl)-2-propanols. Miyauchi H, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr; 44(4):785-92

Molecular modelling of known non-steroidal inhibitors of 17 alpha-hydroxylase/17,20-lyase using antimycotic compounds. Ahmed S. **Drug Des Discov** 1994 Jul; 12(1):77-88

Synthesis of 3-methyl-4-[(2,4-dihydro-4-substituted-3H-1,2,4-triazole-3-thione-5-yl) phenylhydrazono]-5-isoxazolone and evaluation of their antimicrobial activities. Kömürcü SG, et al. **Drug Metabol Drug Interact** 1995;12(2):161-9

Synthesis and characterization of certain thiourea derivatives starting from 1,2,4-triazoline-3-thiones as potential antibacterial and antifungal agents. Küçükgüzel I, et al. **Drug Metabol Drug Interact** 1995;12(2):151-60

Some new 3-methoxy-5-methyl-1,4-substituted pyrazoles. Garuti L, et al. **Farmaco** 1995 Nov;50(11):815-8

Research on antibacterial and antifungal agents. XII--Synthesis and antimicrobial activity of some Mannich bases of diarylpyrroles. Porretta GC, et al. **Farmaco** 1995 Sep;50(9):617-23

Antifungal agents. 9. 3-Aryl-4-[alpha-(1H-imidazol-1-yl)arylmethyl]pyrroles: a new class of potent anti-Candida agents. Artico M, et al. **J Med Chem** 1995 Oct 13;38(21):4223-33

Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring. Bartroli J, et al. **J Med Chem** 1995 Sep 29;38(20):3918-32

Synthetic antimicrobial peptide design. Powell WA, et al. **Mol Plant Microbe Interact** 1995 Sep-Oct;8(5):792-4

Thiophene congeners of morpholine and allylamine type antifungals--syntheses and biological activities. Bracher F, et al. **Pharmazie** 1995 Aug;50(8):525-7

Synthesis of some pyrido- and pyrazino-benzimidazole derivatives and their antifungal activity. Demirayak S, et al. **Pharmazie** 1995 Aug;50(8):527-9

Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Abad-Zapatero C, et al. **Protein Sci** 1996 Apr;5(4):640-52

CHEMISTRY

A crystallographic and spectroscopic study of the complex between d(CGCGAATTCGCG)2 and 2,5-bis(4-guanylphenyl)furan, an analogue of berenil. Structural origins of enhanced DNA-binding affinity. Laughton CA, et al. **Biochemistry** 1996 May 7; 35(18):5655-61

Delineation of an active fragment and poly(L-proline) II conformation for candidacidal activity of bactenecin 5. Raj PA, et al. **Biochemistry** 1996 Apr 9;35(14):4314-25

Small changes in cationic substituents of diphenylfuran derivatives have major effects on the binding affinity and the binding mode with RNA helical duplexes. Zhao M, et al. **Bioorg Med Chem** 1995 Jun;3(6):785-94

Structural determination of a glucuronide conjugate of flucytosine in humans. Chouini-Lalanne N, et al. **Drug Metab Dispos** 1995 Aug;23(8):813-7

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. Gerth K, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):560-3

Ascosteroside, a new antifungal agent from Ascotricha amphitricha. II. Isolation and structure elucidation. Leet JE, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):553-9

Molecular modeling of azole antifungal agents active against Candida albicans. 1. A comparative molecular field analysis study. Tafi A, et al. **J Med Chem** 1996 Mar 15;39(6):1227-35

H NMR study of the solution structure of Ac-AMP2, a sugar binding antimicrobial protein isolated from Amaranthus caudatus. Martins JC, et al. **J Mol Biol** 1996 May 3; 258(2):322-33

Stability, compatibility and plasticizer extraction of miconazole injection added to infusion solutions and stored in PVC containers. Faouzi M el-A, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1363-72

The crystal structure of the antifungal protein zeamatin, a member of the thaumatin-like, PR-5 protein family [letter] Batalia MA, et al. **Nat Struct Biol** 1996 Jan;3(1):19-23

New antifungal proteins from sugar beet (Beta vulgaris L.) showing homology to non-specific lipid transfer proteins. Nielsen KK, et al. **Plant Mol Biol** 1996 Jun;31(3):539-52

The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Cutfield SM, et al. **Structure** 1995 Nov 15;3(11):1261-71

CLASSIFICATION

[New antifungal agents] Dupont B. **Arch Pediatr** 1996;3 Suppl 1:306s-308s **(Fre)**

CONTRAINDICATIONS

Use of terfenadine and contraindicated drugs. Thompson D, et al. **JAMA** 1996 May 1;275(17):1339-41

IMMUNOLOGY

Autoantibodies to calprotectin are not found in patients with systemic lupus erythematosus or other inflammatory rheumatic diseases [letter] Wahren M, et al. **Lupus** 1995 Dec;4(6):498

ISOLATION & PURIFICATION

Isolation and characterization of a 30 kDa protein with antifungal activity from leaves of Engelmannia pinnatifida. Huynh QK, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):723-7

Purification and cDNA cloning of an antifungal protein from the hemolymph of Holotrichia diomphalia larvae. Lee SY, et al. **Biol Pharm Bull** 1995 Aug;18(8):1049-52

Metchnikowin, a novel immune-inducible proline-rich peptide from Drosophila with antibacterial and antifungal properties. Levashina EA, et al. **Eur J Biochem** 1995 Oct 15;233(2):694-700

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. Gerth K, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):560-3

Ascosteroside, a new antifungal agent from Ascotricha amphitricha. I. Taxonomy, fermentation and biological activities. Gorman JA, et al. **J Antibiot (Tokyo)** 1996 Jun; 49(6):547-52

Ascosteroside, a new antifungal agent from Ascotricha amphitricha. II. Isolation and structure elucidation. Leet JE, et al. **J Antibiot (Tokyo)** 1996 Jun;49(6):553-9

Innate immunity. Isolation of several cysteine-rich antimicrobial peptides from the blood of a mollusc, Mytilus edulis. Charlet M, et al. **J Biol Chem** 1996 Sep 6; 271(36):21808-13

New antifungal bithienylacetylenes from Blumea obliqua. Ahmad VU, et al. **J Nat Prod** 1995 Sep;58(9):1426-9

Anguillosporal, a new antibacterial and antifungal metabolite from the freshwater fungus Anguillospora longissima. Harrigan GG, et al. **J Nat Prod** 1995 Sep;58(9):1467-9

C-geranyl compounds from Mimulus clevelandii. Phillips WR, et al. **J Nat Prod** 1996 May;59(5):495-7

Antibacterial and antifungal polyine compounds from Glehnia littoralis ssp. leiocarpa. Matsuura H, et al. **Planta Med** 1996 Jun;62(3):256-9

An antifungal naphthoquinone, xanthones and secoiridoids from Swertia calycina [letter] Rodriguez S, et al. **Planta Med** 1995 Aug;61(4):362-4

METABOLISM

Characterization of streptomyces lydicus WYEC108 as a potential biocontrol agent against fungal root and seed rots. Yuan WM, et al. **Appl Environ Microbiol** 1995 Aug; 61(8):3119-28

The L1 adhesion molecule is a cellular ligand for VLA-5. Ruppert M, et al. **J Cell Biol** 1995 Dec;131(6 Pt 2):1881-91

Synthesis and DNA interactions of benzimidazole dications which have activity against opportunistic infections. Lombardy RL, et al. **J Med Chem** 1996 Mar 29; 39(7):1452-62

Antifungal compounds induced in the dual culture with Phytolacca americana callus and Botrytis fabae. Kobayashi A, et al. **Z Naturforsch [C]** 1995 May-Jun;50(5-6):398-402

PHARMACOKINETICS

Intracutaneous transport of orally administered fluconazole to the stratum corneum. Faergemann J, et al. **Acta Derm Venereol** 1995 Sep;75(5):361-3

Bioavailability of itraconazole from oral liquids in question [letter] Villarreal JD, et al. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1707-8

Elimination of flucytosine by continuous hemofiltration. Lau AH, et al. **Am J Nephrol** 1995;15(4):327-31

Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Kovarik JM, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2738-41

Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, following a single oral dose in healthy subjects. Humbert H, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):685-94

Pharmacokinetics of fluconazole in people with HIV infection: a population analysis. McLachlan AJ, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):291-8

Nail incorporation kinetics of terbinafine in onychomycosis patients. Schatz F, et al. **Clin Exp Dermatol** 1995 Sep; 20(5):377-83

Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Ducharme MP, et al. **Clin Pharmacol Ther** 1995 Dec;58(6):617-24

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Goa KL, et al. **Drugs** 1995 Oct;50(4):658-90 (204 ref.)

Lack of a kinetic interaction between fluconazole and mexiletine. Ueno K, et al. **Eur J Clin Pharmacol** 1996; 50(1-2):129-31

Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. Venkateswarlu K, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):337-41

Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. Nicolau DP, et al. **J Antimicrob Chemother** 1995 Aug;36(2):395-401

Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. Prentice AG, et al. **J Antimicrob Chemother** 1995 Oct;36(4):657-63

Pharmacokinetics and pharmacodynamics of multiple-dose terbinafine. Nedelman JR, et al. **J Clin Pharmacol** 1996 May;36(5):452-61

The release of isoconazole nitrate from different suppository bases: in-vitro dissolution, physicochemical and microbiological studies. Asikoglu M, et al. **J Pharm Pharmacol** 1995 Sep;47(9):713-6

The release of isoconazole nitrate from different suppository bases: in-vivo release of drug labelled with 99mTc in rabbits. Asikoglu M, et al. **J Pharm Pharmacol** 1995 Sep; 47(9):717-20

Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium. Matsumoto T, et al. **Mycoses** 1995 Mar-Apr;38(3-4):135-44

Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Van de Velde VJ, et al. **Pharmacotherapy**

1996 May-Jun;16(3):424-8

Distribution of topical agents in the frontal sinuses and nasal cavity of dogs: comparison between current protocols for treatment of nasal aspergillosis and a new noninvasive technique. Richardson EF, et al. **Vet Surg** 1995 Nov-Dec; 24(6):476-83

[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs] Kaltenbach G, et al. **Pathol Biol (Paris)** 1996 May;44(5):379-83 (Eng. Abstr.) **(Fre)**

[Fluconazole level in aqueous humor after oral drug administration in humans] Aust R, et al. **Ophthalmologe** 1995 Dec;92(6):829-32 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Olkkola KT, et al. **Anesth Analg** 1996 Mar;82(3):511-6

Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells. Kurosawa M, et al. **Ann Hematol** 1996 Jan;72(1):17-21

Rifampin-fluconazole interaction in critically ill patients. Nicolau DP, et al. **Ann Pharmacother** 1995 Oct; 29(10):994-6

Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. Bergstrom JD, et al. **Annu Rev Microbiol** 1995;49:607-39 (80 ref.)

Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Geber A, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2708-17

In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Ghannoum MA, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2459-65

Inhibition of 2,3-oxidosqualene-lanosterol cyclase in Candida albicans by pyridinium ion-based inhibitors. Goldman RC, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1044-7

Resistance of Candida albicans biofilms to antifungal agents in vitro. Hawser SP, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2128-31

Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Joseph-Horne T, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1526-9

Inhibition of sterol 4-demethylation in Candida albicans by 6-amino-2-n-pentylthiobenzothiazole, a novel mechanism of action for an antifungal agent. Kuchta T, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1538-41

Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Martinez-Suarez JV, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1512-6

In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Nakajima R, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1517-21

In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Nguyen MH, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1691-5

Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Odds FC, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2051-60

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Sanglard D, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2378-86

Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Scheven M, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1779-83

Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Scott EM, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2610-4

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907-12 (46 ref.)

Use of decimal assay for additivity to demonstrate synergy in pair combinations of econazole, nikkomycin Z, and ibuprofen against Candida albicans in vitro. Tariq VN, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2615-9

Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Walsh TJ, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1361-4

Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Wanger A, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2520-2

Mechanism of pyrithione-induced membrane depolarization in Neurospora crassa. Ermolayeva E, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3385-90

Antifungal activity of new compounds from Nepeta leucophylla and Nepeta clarkei. Saxena J, et al. **Appl Environ Microbiol** 1996 Feb;62(2):702-4

The use of short-term cultures of Pneumocystis for drug testing. Sahm M, et al. **Appl Parasitol** 1996 Jan;37(1):45-53

Enhanced efficacy of a liposomal pentamidine preparation in Pneumocystis carinii in an ex vivo/in vitro culture model without feederlayer cells. Sahm M, et al. **Appl Parasitol** 1996 Jun;37(2):137-45

Sulfogriseofulvin derivatives. synthesis by [4 + 2]cycloaddition, structure, properties, crystal structure analysis, and antifungal activity of spiro[1,3-benzoxathiole-2,1'-cyclohex-2'-en]-4'-one 3,3-dioxides. Friedrich M, et al. **Arch Pharm (Weinheim)** 1996 Jul;329(7):361-70

Antifungal agents, Part 11. Biphenyl analogues of naftifine: synthesis and antifungal activities. Porretta GC, et al. **Arch Pharm (Weinheim)** 1995 Sep;328(9):667-72

In vitro activity of clotrimazole for Candida strains isolated from recent patient samples. Schmidt A. **Arzneimittelforschung** 1995 Dec;45(12):1338-40

In vitro susceptibility of Malassezia furfur. Schmidt A, et al. **Arzneimittelforschung** 1996 Apr;46(4):442-4

Stabilization of helix by side-chain interactions in histatin-derived peptides: role in candidacidal activity. Ramalingam K, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):47-53

Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Schwartz EL, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):923-8

Delineation of an active fragment and poly(L-proline) II conformation for candidacidal activity of bactenecin 5. Raj PA, et al. **Biochemistry** 1996 Apr 9;35(14):4314-25

Design of an antifungal methionine inhibitor not antagonized by methionine. Aoki Y, et al. **Biol Pharm Bull** 1995 Sep; 18(9):1267-71

Bioactivity of nickel(II) complex containing N-glycosides derived from D-glucosamine and ethylenediamine against pathogenic yeast, Candida albicans. Yano S, et al. **Biol Pharm Bull** 1995 Jun;18(6):923-5

Design, synthesis and in vitro evaluation of pyridinium ion based cyclase inhibitors and antifungal agents. Rose IC, et al. **Bioorg Med Chem** 1996 Jan;4(1):97-103

N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Gill HJ, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):531-8

Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Varhe A, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):319-23

Antifungal activity of LY295337 in vitro against clinical isolates of Candida spp. Aller AI, et al. **Chemotherapy** 1995 Jul-Aug;41(4):276-80

Candida glabrata: in vitro susceptibility of 84 isolates to eight antifungal agents. Arias A, et al. **Chemotherapy** 1996 Mar-Apr;42(2):107-11

Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp.. Martin-Mazuelos E, et al. **Chemotherapy** 1996 Mar-Apr;42(2):112-7

Is antifungal susceptibility testing useful in guiding fluconazole therapy? Ghannoum MA. **Clin Infect Dis** 1996 May;22 Suppl 2:S161-5 (25 ref.)

Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Mitra AK, et al. **Clin Pharmacol Ther** 1996 Mar; 59(3):332-40

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Neuvonen PJ, et al. **Clin Pharmacol Ther** 1996 Jul;60(1):54-61

Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Robbins B, et al. **Clin Pharmacol Ther** 1996 Mar; 59(3):275-83

The antifungal activity of a coal tar gel on Malassezia furfur in vitro. Nenoff P, et al. **Dermatology** 1995;191(4):311-4

Molecular modelling of known non-steroidal inhibitors of 17 alpha-hydroxylase/17,20-lyase using antimycotic compounds. Ahmed S. **Drug Des Discov** 1994 Jul; 12(1):77-88

Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Black DJ, et al. **Drug Metab Dispos** 1996 Apr;24(4):422-8

Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. Ervine CM, et al. **Drug Metab Dispos** 1996 Feb;24(2):211-5

Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Kunze KL, et al. **Drug Metab Dispos** 1996 Apr;24(4):414-21

Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction. Kunze KL, et al. **Drug Metab Dispos** 1996 Apr;24(4):429-35

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Goa KL, et al. **Drugs** 1995 Oct;50(4):658-90 (204 ref.)

Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Spencer CM, et al. **Drugs** 1995 Jul;50(1):176-96 (64 ref.)

Pathogenicity and antifungal susceptibility of Chaetomium species. Guarro J, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):613-8

Differential and enrichment media for selective culture and recognition of yeast species from clinical material. Louwagie B, et al. **Eur J Clin Microbiol Infect Dis** 1995 May;14(5):406-11

Unusual antimicrobial compounds from Aeollanthus buchnerianus. Dellar JE, et al. **Experientia** 1996 Feb 15; 52(2):175-9

Site-directed mutagenesis of Saccharomyces cerevisiae beta-tubulin: interaction between residue 167 and benzimidazole compounds. Li J, et al. **FEBS Lett** 1996 Apr 29;385(1-2):7-10

In vitro antifungal susceptibility of Candida. Chakrabarti A, et al. **Indian J Med Res** 1995 Jul;102:13-9

Antimycotic susceptibility testing of mould-fungi with allylamines by disk diffusion. Venugopal PV, et al. **Indian J Med Sci** 1995 May;49(5):109-13

Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis. Goldman RC, et al. **Infect Agents Dis** 1995 Dec;4(4):228-47 (120 ref.)

Peroxynitrite contributes to the candidacidal activity of nitric oxide-producing macrophages. Vazquez-Torres A, et al. **Infect Immun** 1996 Aug;64(8):3127-33

Influence of serum protein binding on the in vitro activity of anti-fungal agents. Schäfer-Korting M, et al. **Infection** 1995 Sep-Oct;23(5):292-7

150 mg fluconazole does not substantially increase the effects of 10 mg midazolam or the plasma midazolam concentrations in healthy subjects. Vanakoski J, et al. **Int J Clin Pharmacol Ther** 1995 Sep;33(9):518-23

Karyotyping of fluconazole-resistant yeasts with phenotype reported as Candida krusei or Candida inconspicua. Essayag SM, et al. **Int J Syst Bacteriol** 1996 Jan;46(1):35-40

Inhibitory effect of terbinafine on the invasion of nails by Trichophyton mentagrophytes. Rashid A, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):718-23

Susceptibility of Helicobacter pylori to simethicone and other non-antibiotic drugs. Ansorg R, et al. **J Antimicrob Chemother** 1996 Jan;37(1):45-52

Drug protonation and pH in relation to the lethal action of tamoxifen on Candida albicans [letter] Beggs WH. **J Antimicrob Chemother** 1996 Apr;37(4):841-2

Action of clotrimazole on Candida albicans [letter] Beggs WH. **J Antimicrob Chemother** 1995 Oct;36(4):742-3

In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp. Carrillo-Muñoz AJ, et al. **J Antimicrob Chemother** 1995 Oct;36(4):713-6

In-vitro antifungal activity of sertaconazole, bifonazole, ketoconazole, and miconazole against yeasts of the Candida genus. Carrillo-Muñoz AJ, et al. **J Antimicrob Chemother** 1996 Apr;37(4):815-9

Relative growth measurement of Candida species in a single concentration of fluconazole predicts the clinical response to fluconazole in HIV infected patients with oral candidosis. Cartledge JD, et al. **J Antimicrob Chemother** 1996 Feb;37(2):275-83

Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique. Chen SC, et al. **J Antimicrob Chemother** 1996 Feb;37(2):265-73

In-vitro activity of terbinafine, atovaquone and co-trimoxazole against Pneumocystis carinii [letter] Cirioni O, et al. **J Antimicrob Chemother** 1995 Oct;36(4):740-2

Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole. Colombo AL, et al. **J Antimicrob Chemother** 1995 Jul;36(1):93-100

The effects of amphotericin B, fluconazole and miconazole on neutrophil and lymphocyte function in a guinea pig model. Drummond DC, et al. **J Antimicrob Chemother** 1995 Aug;36(2):375-84

Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species. Johnson EM, et al. **J Antimicrob Chemother** 1995 Nov;36(5):787-93

Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria. Rodriguez-Tudela JL, et al. **J Antimicrob Chemother** 1995 Jun;35(6):739-49

Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. Rodríguez-Tudela JL, et al. **J Antimicrob Chemother** 1995 Jun;35(6):793-804

Dyes as fungal inhibitors: effect on colony enumeration. Bragulat MR, et al. **J Appl Bacteriol** 1995 Nov;79(5):578-82

The multidrug resistance-associated protein (MRP) subfamily (Yrs1/Yor1) of Saccharomyces cerevisiae is important for the tolerance to a broad range of organic anions. Cui Z, et al. **J Biol Chem** 1996 Jun 21; 271(25):14712-6

Fungal membrane responses induced by plant defensins and thionins. Thevissen K, et al. **J Biol Chem** 1996 Jun 21; 271(25):15018-25

Surface-modified poly(methyl methacrylate) enhances adsorption and retains anticandidal activities of salivary histatin 5. Edgerton M, et al. **J Biomed Mater Res** 1995 Oct;29(10):1277-86

Alterations in surface morphology of Candida albicans produced by rilopirox: a scanning electron microscopy study. Braga PC, et al. **J Chemother** 1995 Dec;7(6):519-24

In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. Moneib NA. **J Chemother** 1995 Dec; 7(6):525-9

Gel electrophoretic analysis of cellular and secreted proteins from resting and activated rat alveolar macrophages treated

with pentamidine isethionate. Selkirk JK, et al. **J Chromatogr A** 1995 Sep 22;711(2):331–7

Contribution of molecular typing methods and antifungal susceptibility testing to the study of a candidemia cluster in a burn care unit. Bart–Delabesse E, et al. **J Clin Microbiol** 1995 Dec;33(12):3278–83

Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27–P for in vitro testing of fluconazole–resistant and –susceptible isolates of Candida albicans. Espinel–Ingroff A, et al. **J Clin Microbiol** 1995 Dec;33(12):3154–8

Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. Espinel–Ingroff A, et al. **J Clin Microbiol** 1996 Apr;34(4):848–52

Fluconazole– and itraconazole–resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. Le Guennec R, et al. **J Clin Microbiol** 1995 Oct;33(10):2732–7

Quality control guidelines for National Committee for Clinical Laboratory Standards—recommended broth macrodilution testing of ketoconazole and itraconazole. Rex JH, et al. **J Clin Microbiol** 1996 Apr;34(4):816–7

Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. Sanati H, et al. **J Clin Microbiol** 1996 May; 34(5):1280–2

Torulopsis glabrata: azole susceptibilities by microdilution colorimetric and macrodilution broth assays. Tiballi RN, et al. **J Clin Microbiol** 1995 Oct;33(10):2612–5

Comparative evaluation of macrodilution and alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates. To WK, et al. **J Clin Microbiol** 1995 Oct;33(10):2660–4

Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E–test and semiautomated broth microdilution test. van Eldere J, et al. **J Clin Microbiol** 1996 Apr;34(4):842–7

Pharmacokinetics and pharmacodynamics of multiple–dose terbinafine. Nedelman JR, et al. **J Clin Pharmacol** 1996 May;36(5):452–61

Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo [see comments] von Moltke LL, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):104–12. Comment in: J Clin Psychopharmacol 1996 Apr;16(2):101–3.

Functional comparison of native and recombinant human salivary histatin 1. Driscoll J, et al. **J Dent Res** 1995 Dec; 74(12):1837–44

Screening of hundred Rwandese medicinal plants for antimicrobial and antiviral properties. Vlietinck AJ, et al. **J Ethnopharmacol** 1995 Apr;46(1):31–47

Identification of a glucan–associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics. Angiolella L, et al. **J Infect Dis** 1996 Mar;173(3):684–90

Effect of azoles on the glucuronidation of zidovudine by human liver UDP–glucuronosyltransferase [letter; comment] Asgari M, et al. **J Infect Dis** 1995 Dec; 172(6):1634–6. Comment on: J Infect Dis 1994 May;169(5):1103–7.

Synergy of fluconazole with human monocytes or monocyte–derived macrophages for killing of Candida species. Garcha UK, et al. **J Infect Dis** 1995 Dec; 172(6):1620–3

Risk factors for fluconazole–resistant candidiasis in human immunodeficiency virus–infected patients. Maenza JR, et al. **J Infect Dis** 1996 Jan;173(1):219–25

Cholesterol sulfate protects Candida albicans from inhibition by sphingosine in vitro. Payne CD, et al. **J Invest Dermatol** 1996 Mar;106(3):549–52

Chemistry and antimicrobial activity of caryoynencins analogs. Yamaguchi M, et al. **J Med Chem** 1995 Dec 22; 38(26):5015–22

In–vitro proteinase production by oral Candida albicans isolates from individuals with and without HIV infection and its attenuation by antimycotic agents. Wu T, et al. **J Med Microbiol** 1996 Apr;44(4):311–6

Evaluation of the susceptibility of dermatophytes to antifungal drugs: a new technique. Butty P, et al. **J Med Vet Mycol** 1995 Nov–Dec;33(6):403–9

Ultrastructural alterations produced by sertaconazole on several opportunistic pathogenic fungi. Figueras MJ, et al. **J Med Vet Mycol** 1995 Nov–Dec;33(6):395–401

Comparisons of the susceptibilities of planktonic and adherent Candida albicans to antifungal agents: a modified XTT tetrazolium assay using synchronised C. albicans cells. Hawser S. **J Med Vet Mycol** 1996 Mar–Apr;34(2):149–52

Sex hormone effects on Phialophora verrucosa in vitro and characterization of progesterone receptors. Hernández–Hernández F, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):235–9

A comparison of miconazole, ketoconazole and fluconazole in their effects on temperature–dependent growth and thermal death in Candida albicans. Madeira–Lopes A, et al. **J Med Vet Mycol** 1995 Nov–Dec;33(6):375–8

Activity of terbinafine on Trichophyton mentagrophytes in a human living skin equivalent model. Rashid A, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):229–33

Effect of components of resilient denture–lining materials on the growth, acid production and colonization of Candida albicans. Nikawa H, et al. **J Oral Rehabil** 1995 Nov; 22(11):817–24

Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. von Moltke LL, et al. **J Pharmacol Exp Ther** 1996 Feb; 276(2):370–9

Fluconazole increases bactericidal activity of neutrophils. Zervos EE, et al. **J Trauma** 1996 Jul;41(1):10–4

Fluconazole increases bactericidal activity of neutrophils through non–cytokine–mediated pathway. Zervos EE, et al. **J Trauma** 1996 Sep;41(3):465–70

Anti–Candida activity of a novel killer toxin from the yeast Williopsis mrakii. Hodgson VJ, et al. **Microbiology** 1995 Aug;141 (Pt 8):2003–12

A study of the structural basis of the ability of chlorinated alkanes and alkenes to induce aneuploidy and toxicity in the mold Aspergillus nidulans. Rosenkranz HS, et al. **Mutat Res** 1996 Jul 22;354(2):183–93

Efficacy of 6–amino–2–n–pentylthiobenzothiazole on Trichophyton in vitro and in vivo. Bujdáková H, et al. **Mycopathologia** 1995 Jun;130(3):141–5

Synergy of fluconazole with macrophages for antifungal activity against Candida albicans. Garcha UK, et al. **Mycopathologia** 1995–96;132(3):123–8

Study of the role of iron in the anticryptococcal activity of human serum and fluconazole. Grover DD, et al. **Mycopathologia** 1996;133(2):71–7

In vitro susceptibility of fungi to acyclic inhibitors of 2,3–oxidosqualene cyclases. Airaudi D, et al. **Mycoses** 1996 Jan–Feb;39(1–2):51–6

Further studies on the in vitro antifungal activity of amorolfine. De Vroey C, et al. **Mycoses** 1996 Jan–Feb; 39(1–2):41–4

Effects of three azole derivatives on the lipids of different strains of Cryptococcus neoformans. Franzot SP, et al. **Mycoses** 1995 May–Jun;38(5–6):183–9

Fungicidal activity of latex sap from Carica papaya and antifungal effect of D(+)–glucosamine on Candida albicans growth. Giordani R, et al. **Mycoses** 1996 Mar–Apr; 39(3–4):103–10

Fungicidal effect of tyrothricin on Candida albicans. Kretschmar M, et al. **Mycoses** 1996 Jan–Feb;39(1–2):45–50

Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Marichal P, et al. **Mycoses** 1995 Mar–Apr;38(3–4):111–7

Preliminary studies of the antifungal activities of some medicinal plants against Basidiobolus and some other pathogenic fungi. Nwosu MO, et al. **Mycoses** 1995 May–Jun;38(5–6):191–5

Quantitative screening for fluconazole–amphotericin B antagonism in several Candida albicans strains by a comparative agar diffusion assay. Scheven M, et al. **Mycoses** 1996 Mar–Apr;39(3–4):111–4

Post–antibiotic effect and post–expositional polyene antagonism of azole antifungal agents in Candida albicans: dependence on substance lipophilia. Scheven M, et al. **Mycoses** 1995 Nov–Dec;38(11–12):435–42

An evaluation of seven methods of testing in vitro susceptibility of clinical yeast isolates to fluconazole. Schmalreck AF, et al. **Mycoses** 1995 Sep–Oct; 38(9–10):359–68

Testing susceptibility of Candida species to fluconazole and itraconazole using the microdilution assay. Seibold M, et al. **Mycoses** 1995 Nov–Dec;38(11–12):443–8

Susceptibility of clinical isolates of Fusarium to antifungal drugs. Speeleveld E, et al. **Mycoses** 1996 Jan–Feb; 39(1–2):37–40

In vitro antifungal activity of Polyporaceae against yeasts and dermatophytes. Steinmetz MD, et al. **Mycoses** 1995 Jul–Aug;38(7–8):305–9

The anti–Malassezia furfur activity in vitro and in experimental dermatitis of six imidazole antifungal agents: bifonazole, clotrimazole, flutrimazole, ketoconazole, miconazole and sertaconazole. Van Gerven F, et al. **Mycoses** 1995 Sep–Oct;38(9–10):389–93

P450 inhibitors of use in medical treatment: focus on mechanisms of action. Vanden Bossche H, et al. **Pharmacol Ther** 1995;67(1):79–100 (155 ref.)

Novel osmotically induced antifungal chitinases and bacterial expression of an active recombinant isoform. Yun DJ, et al. **Plant Physiol** 1996 Aug;111(4):1219–25

Biological activities of cyanobacteria: evaluation of extracts and pure compounds. Falch BS, et al. **Planta Med** 1995 Aug;61(4):321–8

Antifungal and antibacterial chalcones from Myrica serrata. Gafner S, et al. **Planta Med** 1996 Feb;62(1):67–9

Screening for in vitro antifungal activities of some indole alkaloids [letter] Quetin–Leclercq J, et al. **Planta Med** 1995 Oct;61(5):475–7

Antifungal principles of Baccharis pedunculata [letter] Rahalison L, et al. **Planta Med** 1995 Aug;61(4):360–2

Calprotectin–mediated zinc chelation as a biostatic mechanism in host defence. Clohessy PA, et al. **Scand J Immunol** 1995 Nov;42(5):551–6

Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV–infected patients. Chryssanthou E, et al. **Scand J Infect Dis** 1995;27(4):391–5

Biocides: mechanisms of antifungal action and fungal resistance. Russell AD, et al. **Sci Prog** 1996;79 (Pt 1):27–48 (102 ref.)

Croconazole: an inhibitor of eicosanoid synthesis in A23187–stimulated human polymorphonuclear leukocytes and human whole blood. Lehmann B, et al. **Skin Pharmacol** 1995;8(6):326–33

Anti–inflammatory activity of croconazole, a broad–spectrum antimycotic agent, in the arachidonic acid–induced mouse ear swelling test. Steinmann D, et al. **Skin Pharmacol** 1995;8(4):211–4

Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ahonen J, et al. **Ther Drug Monit** 1996 Apr;18(2):124–7

Bifonazole, but not the structurally–related clotrimazole, induces both peroxisome proliferation and members of the cytochrome P4504A sub–family in rat liver. Sabzevari O, et al. **Toxicology** 1996 Jan 8;106(1–3):19–26

Antimicrobial activity of chicken and turkey heterophil peptides CHP1, CHP2, THP1, and THP3. Evans EW, et al. **Vet Microbiol** 1995 Dec;47(3–4):295–303

[Comparison of the effects of fenticonazole and econazole on the aspartic proteinase secreted by Candida albicans] De Bernardis F, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):163–5 (Eng. Abstr.) **(Fre)**

[Comparison of in vitro action of cetylpyridinium chloride containing preparations] Deckers C, et al. **Arzneimittelforschung** 1995 Dec;45(12):1335–7 (Eng. Abstr.) **(Ger)**

[Modification of phagocytic microbicide function by antifungal agents—measuring luminol enhanced chemoluminescence in full blood] Wilhelm L, et al. **Langenbecks Arch Chir** 1996;381(2):88–94 (Eng. Abstr.) **(Ger)**

[Significant role of azole antifungal agents: focused on itraconazole] Nishikawa T, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1033–50 **(Jpn)**

[Studies on microtiter broth dilution method for antifungal susceptibility testing of yeast isolates from blood and cerebrospinal fluid] Fujita S. **Rinsho Byori** 1996 Apr; 44(4):373–8 (Eng. Abstr.) **(Jpn)**

[Colorimetric broth microdilution for antifungal susceptibility testing] Yamane N, et al. **Rinsho Byori** 1996 Jan;44(1):67–75 (Eng. Abstr.) **(Jpn)**

[Antimicrobial and anti–inflammatory actions of tea–leaf saponin] Sagesaka YM, et al. **Yakugaku Zasshi** 1996 Mar; 116(3):238–43 (Eng. Abstr.) **(Jpn)**

[Ultrastructural study of the action of cyclosporine on cells of the fungus Aspergillus niger] Sazykin IuO, et al. **Antibiot Khimioter** 1995 Nov–Dec;40(11–12):34–9 (Eng. Abstr.) **(Rus)**

[Sensitivity tests to antifungal agents for yeasts based on the standards proposed by the NCCLS in 1992] Rodríguez–Tudela JL, et al. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):559–68 **(Spa)**

[In vitro sensitivity tests for yeasts: evaluation of a micromethod] Rodero LL, et al. **Rev Argent Microbiol** 1995 Apr–Jun;27(2):81–9 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals [letter] Baran R, et al. **Acta Derm Venereol** 1996 Jan; 76(1):82–3

Immunological features of chronic adult paracoccidioidomycosis: report of a case treated with fluconazole [letter] Pereiro M Jr, et al. **Acta Derm Venereol** 1996 Jan;76(1):84–5

Fluconazole–resistant oral candidosis in HIV–infected patients [letter; comment] Diz Dios P, et al. **AIDS** 1995 Jul;9(7):809–10. Comment on: AIDS 1994 Jun;8(6):787–92. Comment on: AIDS 1994 Jul;8(7):945–50.

Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS. Laine L, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):553–6

Criteria for use of atovaquone oral suspension in adult inpatients and outpatients. Goodwin SD, et al. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2460–2

Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Anaissie EJ, et al. **Am J Med** 1996 Aug;101(2):170–6

The changing face of candidemia: emergence of non–Candida albicans species and antifungal resistance. Nguyen MH, et al. **Am J Med** 1996 Jun;100(6):617–23

Peritoneal dialysis complicated by Bipolaris hawaiiensis peritonitis: successful therapy with catheter removal and oral itraconazol without the use of amphotericin–B. Gadallah MF, et al. **Am J Nephrol** 1995;15(4):348–52 (19 ref.)

Coadministration of ketoconazole to cyclosporin–treated kidney transplant recipients: a prospective randomized study. Sobh M, et al. **Am J Nephrol** 1995;15(6):493–9

Cryptococcal meningitis in pregnancy. Chen CP, et al. **Am J Perinatol** 1996 Jan;13(1):35–6

Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV–infected patients. Trapnell CB, et al. **Ann Intern Med** 1996 Mar 15;124(6):573–6

Antifungal prophylaxis in bone marrow transplant. Lam HH, et al. **Ann Pharmacother** 1995 Sep;29(9):921–4 (12 ref.)

Nystatin prophylaxis in immunocompromised children. Taylor TL. **Ann Pharmacother** 1996 May;30(5):534–5 (8 ref.)

Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Buggia I, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2083–8

Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis. Allendoerfer R, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1345–8

Antipneumocystis activity of 17C91, a prodrug of atovaquone. Comley JC, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2217–9

Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Denning DW, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1809–14

Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response? Graybill JR, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2197–200

Monitoring of co-trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia. Joos B, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2661–6

Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Kurtz MB, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1784–9

Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia. Merali S, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2023–6

Short-term topical therapy of experimental tinea pedis in guinea pigs with lanoconazole, a new imidazole antimycotic agent. Niwano Y, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2353–5

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907–12 (46 ref.)

Antifungal agents in neonatal systemic candidiasis. van den Anker JN, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1391–7 (66 ref.)

Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study. Momeni AZ, et al. **Arch Dermatol** 1996 Jul;132(7):784–6

Pseudallescheria boydii in an immunocompromised host. Successful treatment with debridement and itraconazole. Ruxin TA, et al. **Arch Dermatol** 1996 Apr;132(4):382–4 (23 ref.)

Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Nguyen MH, et al. **Arch Intern Med** 1995 Dec 11–25; 155(22):2429–35

Laryngeal cryptococcus. Treatment with oral fluconazole. Kerschner JE, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct;121(10):1193–5

Fungal infections in left ventricular assist device recipients. Incidence, prophylaxis, and treatment. Goldstein DJ, et al. **ASAIO J** 1995 Oct–Dec;41(4):873–5

Australian Dental Research Fund Trebitsch Scholarship. Efficacy of antifungal prophylaxis in bone marrow transplantation. Quirk PC, et al. **Aust Dent J** 1995 Aug; 40(4):267–70

Vaginitis. Murtagh J. **Aust Fam Physician** 1995 Sep; 24(9):1697–8

Long-term survival of four dogs with disseminated Aspergillus terreus infection treated with itraconazole. Kelly SE, et al. **Aust Vet J** 1995 Aug;72(8):311–3

Efficacy of miconazole nitrate against favus in oriental breed chickens. Bradley FA, et al. **Avian Dis** 1995 Oct–Dec; 39(4):900–1

Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group [see comments] [published erratum appears in BMJ 1995 Nov 18;311(7016):1350] Bräutigam M, et al. **BMJ** 1995 Oct 7; 311(7010):919–22. Comment in: BMJ 1996 Feb 3;312(7026):312–3.

Treatment of toenail tinea infection. True cure seems unlikely [letter; comment] Buck DS. **BMJ** 1996 Feb 3; 312(7026):312–3. Comment on: BMJ 1995 Oct 7;311(7010):919–22.

German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. Bräutigam M, et al. **Br J Dermatol** 1996 Jun;134 Suppl 46:18–21: discussion 38

Employment of terbinafine against Pneumocystis carinii infection in rat models. Contini C, et al. **Br J Dermatol** 1996 Jun;134 Suppl 46:30–2; discussion 40

Cutaneous mycoses in children. Elewski BE. **Br J Dermatol** 1996 Jun;134 Suppl 46:7–11: discussion 37–8 (34 ref.)

Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Esterre P, et al. **Br J Dermatol** 1996 Jun;134 Suppl 46:33–6; discussion 40

Pityrosporum ovale (Malassezia furfur) as the causative agent of seborrhoeic dermatitis: new treatment options. Faergemann J, et al. **Br J Dermatol** 1996 Jun;134 Suppl 46:12–5: discussion 38

Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. Nandwani R, et al. **Br J Dermatol** 1996 Jun;134 Suppl 46:22–4: discussion 39

New mechanisms of action with fungicidal antifungals. Rashid A. **Br J Dermatol** 1996 Jun;134 Suppl 46:1–6

Refractory pulmonary aspergillosis: compassionate trial with terbinafine. Schiraldi GF, et al. **Br J Dermatol** 1996 Jun; 134 Suppl 46:25–9: discussion 39–40

A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours. Finlay PM, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):23–5

Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Walsh TJ, et al. **Cancer** 1995 Dec 1;76(11):2357–62

New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases. Walsh TJ, et al. **Cancer Treat Res** 1995;79:113–48 (268 ref.)

The effect of prophylaxis on the outcome of HIV-associated Pneumocystis carinii pneumonia [letter; comment] Ewig S. **Chest** 1996 Feb;109(2):586–7. Comment on: Chest 1995 Apr;107(4):1018–23.

New antifungal drugs for pulmonary mycoses. Klein NC, et al. **Chest** 1996 Aug;110(2):525–32 (100 ref.)

Pityrosporum (Malassezia) folliculitis in Saudi Arabia—diagnosis and therapeutic trials. Abdel-Razek M, et al. **Clin Exp Dermatol** 1995 Sep;20(5):406–9

Topical sphingolipids in antisepsis and antifungal therapy. Bibel DJ, et al. **Clin Exp Dermatol** 1995 Sep;20(5):395–400

Kerion—a case report. Urbanek M, et al. **Clin Exp Dermatol** 1995 Sep;20(5):413–4

Focus on Fungal Infections 5. Symposium proceedings. San Francisco, California, 9–10 March 1995. **Clin Infect Dis** 1996 May;22 Suppl 2:S71–184

Use of itraconazole for treatment of sporotrichosis involving a knee prosthesis [letter] DeHart DJ. **Clin Infect Dis** 1995 Aug;21(2):450

Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Dromer F, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S154–60

Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Gallis HA. **Clin Infect Dis** 1996 May;22 Suppl 2:S145–7 (18 ref.)

The future of antifungal therapy. Graybill JR. **Clin Infect Dis** 1996 May;22 Suppl 2:S166–78 (147 ref.)

Role of azoles in antifungal therapy. Kauffman CA. **Clin Infect Dis** 1996 May;22 Suppl 2:S148–53 (72 ref.)

Old and new therapies for sporotrichosis. Kauffman CA. **Clin Infect Dis** 1995 Oct;21(4):981–5 (63 ref.)

Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species [letter] Kunová A, et al. **Clin Infect Dis** 1995 Jul;21(1):226–7

Recent advances in the management of cryptococcal meningitis in patients with AIDS. Powderly WG. **Clin Infect Dis** 1996 May;22 Suppl 2:S119–23 (32 ref.)

Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Sobel JD, et al. **Clin Infect Dis** 1996 Apr;22(4):726–7

Problems and controversies in the management of hematogenous candidiasis. Uzun O, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S95–101 (62 ref.)

Fluconazole treatment of candida peritonitis with delayed removal of the peritoneal dialysis catheter. Montenegro J, et al. **Clin Nephrol** 1995 Jul;44(1):60–3

Therapy of fungal meningitis. Slavoski LA, et al. **Clin Neuropharmacol** 1995 Apr;18(2):95–112 (81 ref.)

Amphotericin B lipid complex treatment of a leukemic child with disseminated Fusarium solani infection. Patterson TS, et al. **Clin Pediatr (Phila)** 1996 May;35(5):257–60

When and how to treat serious candidal infections: concepts and controversies. Filler SG, et al. **Curr Clin Top Infect Dis** 1995;15:1–18 (122 ref.)

Fluconazole: its properties and efficacy in vaginal candidiasis. Troke PF. **Curr Probl Dermatol** 1996;24:203–8 (19 ref.)

Itraconazole and therapy of fungal infections. Van Cutsem J. **Curr Probl Dermatol** 1996;24:194–202 (29 ref.)

Oral candidiasis in HIV-infected patients. Brawner DL, et al. **Curr Top Med Mycol** 1995;6:113–25 (68 ref.)

Dematiaceous fungal infections in China. Li R, et al. **Curr Top Med Mycol** 1995;6:283–305 (48 ref.)

Treatment of eumycetoma and actinomycetoma. Welsh O, et al. **Curr Top Med Mycol** 1995;6:47–71 (105 ref.)

Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. De Doncker P, et al. **Cutis** 1995 Sep;56(3):180–3

Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Haria M, et al. **Drugs** 1996 Apr;51(4):585–620 (245 ref.)

Fungal urinary tract infections in the elderly: treatment guidelines. Jacobs LG. **Drugs Aging** 1996 Feb;8(2):89–96 (32 ref.)

Current drug therapy of systemic mycoses: a review. Yonga G. **East Afr Med J** 1995 Jun;72(6):394–8 (59 ref.)

Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study. Barbaro G, et al. **Endoscopy** 1995 Jun;27(5):377–83

Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Graybill JR, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):700–3

Fluconazole in the treatment of three cases of mucormycosis [letter] Koçak R, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):559–61

Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Quereda C, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jan;15(1):30–7

Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Lister J. **Eur J Haematol Suppl** 1996;57:18–23

Small intestinal histoplasmosis: successful treatment with itraconazole in an immunocompetent host. Bodily K, et al. **Gastrointest Endosc** 1996 May;43(5):518–21

Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Annaloro C, et al. **Haematologica** 1995 Nov–Dec;80(6):512–7

The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products. Gurwitz JH, et al. **Health Serv Res** 1995 Dec;30(5):672–85

Therapy for opportunistic fungal infections: past, present and future. Stevens DA. **Indian J Cancer** 1995 Mar;32(1):1–9 (15 ref.)

Peritonitis caused by Monilia sitophila in a patient undergoing peritoneal dialysis. Radix AE, et al. **Int J Artif Organs** 1996 Apr;19(4):218–20

Ketoconazole in the treatment of cutaneous leishmaniasis in Kuwait. Alsaleh QA, et al. **Int J Dermatol** 1995 Jul; 34(7):495–7

Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis. Bonifaz A, et al. **Int J Dermatol** 1995 Jul;34(7):500–3

Subcutaneous phaeohyphomycosis caused by Exophiala jeanselmei: successful treatment with itraconazole. Chuan MT, et al. **Int J Dermatol** 1995 Aug;34(8):563–6

Onychomycosis treated with a short course of oral terbinafine. Galimberti R, et al. **Int J Dermatol** 1996 May; 35(5):374–5

Terbinafine in the treatment of Majocchi's granuloma. Gupta AK, et al. **Int J Dermatol** 1995 Jul;34(7):489

Fluconazole versus itraconazole in the treatment of tinea versicolor. Köse O. **Int J Dermatol** 1995 Jul;34(7):498–9

Successful treatment of chromoblastomycosis due to Fonsecaea pedrosoi by the combination of itraconazole and cryotherapy. Kullavanijaya P, et al. **Int J Dermatol** 1995 Nov;34(11):804–7

Systemic ketoconazole in the treatment of tinea versicolor. Sadeque JB, et al. **Int J Dermatol** 1995 Jul;34(7):504–5

Hyperkeratotic chronic tinea pedis treated with neticonazole cream. Neticonazole Study Group. Tsuboi R, et al. **Int J Dermatol** 1996 May;35(5):371–3

Treatment of vaginitis. Kükner S, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):43–7

Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Birley HD, et al. **Int J STD AIDS** 1995 Sep–Oct;6(5):353–5

Comparison of therapeutic activity of fluconazole and itraconazole in the treatment of oesophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Barbaro G, et al. **Ital J Gastroenterol** 1995 May;27(4):175–80

Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. Assaf RR, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):216–9

Therapeutic efficacy of terbinafine in the treatment of three children with tinea tonsurans. Desgarennes MD, et al. **J Am Acad Dermatol** 1996 Jul;35(1):114–6

International summit on cutaneous antifungal therapy. Boston, Massachusetts, Nov. 11–13, 1994. Elewski B, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):816–22

A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. Hickman JG. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):785–7

Systemic antifungal drugs and drug interactions [letter; comment] Kahn G. **J Am Acad Dermatol** 1996 Jul; 35(1):134–5. Comment on: J Am Acad Dermatol 1995 Aug;33(2 Pt 1):259–60.

A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. Odom R, et al. **J Am Acad Dermatol** 1996 Jul;35(1):110–1

New therapies for onychomycosis. Odom RB. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 2):S26–30

Clinical trials of the new antifungal drug therapies [letter; comment] Rand S. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):863. Comment on: J Am Acad Dermatol 1995 May;32(5 Pt 1):750–3.

Improvement of eumycetoma with itraconazole. Resnik BI, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):917–9

Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. Tosti A, et al. **J Am Acad Dermatol** 1996 Apr;34(4):595–600

Terbinafine in onychomycosis of the toenail: a novel treatment protocol. Watson A, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):775–9

Efficacy of griseofulvin and itraconazole in the treatment of experimentally induced dermatophytosis in cats. Moriello KA, et al. **J Am Vet Med Assoc** 1995 Aug 15; 207(4):439–44

An audit of the use of antifungal agents. Gutiérrez F, et al. **J Antimicrob Chemother** 1996 Jan;37(1):175–85

Azole drug resistance in yeasts. Johnson EM, et al. **J Antimicrob Chemother** 1995 Nov;36(5):751–5

Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. Rodríguez-Tudela JL, et al. **J Antimicrob Chemother** 1995 Jun;35(6):793–804

Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV. St-Germain G, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):109–18

Fluconazole therapy for candiduria [letter] Castiglia M, et al. **J Fam Pract** 1995 Dec;41(6):536

Women's use of over-the-counter antifungal medications for gynecologic symptoms. Ferris DG, et al. **J Fam Pract** 1996 Jun;42(6):595–600

Diagnosis and treatment of tinea versicolor. Savin R. **J Fam Pract** 1996 Aug;43(2):127–32 (25 ref.)

Antifungal pulse therapy for onychomycosis. Smith GN. **J Fam Pract** 1996 Apr;42(4):348

Diagnosing and treating onychomycosis. Zaias N, et al. **J Fam Pract** 1996 May;42(5):513–8 (20 ref.)

An analysis of the trends in the use of antifungal drugs and fungal isolates in a UK University Hospital [letter] Gutiérrez F, et al. **J Hosp Infect** 1995 Oct;31(2):149–52

Treatment of native valve Candida endocarditis with fluconazole. Wells CJ, et al. **J Infect** 1995 Nov;31(3):233–5

Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. Lumbreras C, et al. **J Infect Dis** 1996 Sep; 174(3):583–8

Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. Schaffner A, et al. **J Infect Dis** 1995 Oct;172(4):1035–41

Comparison of D0870 and fluconazole in the treatment of murine cryptococcal meningitis. Correa AL, et al. **J Med Vet Mycol** 1995 Nov-Dec;33(6):367–74

Molecular karyotyping of multiple yeast species isolated from nine patients with AIDS during prolonged fluconazole therapy. Espinel-Ingroff A, et al. **J Med Vet Mycol** 1996 Mar-Apr;34(2):111–6

Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole. Goldani LZ, et al. **J Med Vet Mycol** 1995 Jul-Aug;33(4):267–70 (22 ref.)

Aspergillus flavus mycetoma and epidural abscess successfully treated with itraconazole. Witzig RS, et al. **J Med Vet Mycol** 1996 Mar-Apr;34(2):133–7

Candiduria as an early marker of disseminated infection in critically ill surgical patients [letter; comment] Huang CT, et al. **J Trauma** 1995 Sep;39(3):616. Comment on: J Trauma 1993 Aug;35(2):290–4; discussion 294–5.

Re: Fluconazole treatment in Torulopsis glabrata upper urinary tract infection causing ureteral obstruction [letter; comment] Ansari SH, et al. **J Urol** 1995 Nov;154(5):1870 . Comment on: J Urol 1992 Apr;147(4):1116–7.

New drugs for the nail fungus prevalent in elderly [news] Phillips P. **JAMA** 1996 Jul 3;276(1):12–3

Use of terfenadine and contraindicated drugs. Thompson D, et al. **JAMA** 1996 May 1;275(17):1339–41

Quandary about treatment of aspergillomas persists. Kauffman CA. **Lancet** 1996 Jun 15;347(9016):1640

Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Caras WE, et al. **Mayo Clin Proc** 1996 Jan;71(1):25–30

Tinea of the skin, hair and nails. Wargon O. **Med J Aust** 1996 May 6;164(9):552–6 (23 ref.)

Itraconazole for onychomycosis. **Med Lett Drugs Ther** 1996 Jan 19;38(966):5–6

Terbinafine for onychomycosis. **Med Lett Drugs Ther** 1996 Aug 16;38(981):72–4

Systemic antifungal drugs. **Med Lett Drugs Ther** 1996 Feb 2;38(967):10–2

Efficacy of 6-amino-2-n-pentylthiobenzothiazole on Trichophyton in vitro and in vivo. Bujdáková H, et al. **Mycopathologia** 1995 Jun;130(3):141–5

Cryptococcal prostatitis in a patient with Behçet's disease treated with fluconazole. Fuse H, et al. **Mycopathologia** 1995 Jun;130(3):147–50

Short therapy for tinea unguium with terbinafine: four different courses of treatment. Albanese G, et al. **Mycoses** 1995 May-Jun;38(5–6):211–4

Croconazole in the treatment of tinea pedis. Beierdörffer H, et al. **Mycoses** 1995 Nov-Dec;38(11–12):501–7

Treatment of chronic disseminated Geotrichum capitatum infection with high cumulative dose of colloidal amphotericin B and itraconazole in a leukaemia patient. Cofrancesco E, et al. **Mycoses** 1995 Sep-Oct; 38(9–10):377–84

A double-blind, randomized comparative trial: flutrimazole 1% solution versus bifonazole 1% solution once daily in dermatomycoses. del Palacio, et al. **Mycoses** 1995 Sep-Oct; 38(9–10):395–403

Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: a phase II dose-finding pilot study. del Palacio A, et al. **Mycoses** 1995 Jul-Aug;38(7–8):317–24

Phialophora verrucosa infection in an AIDS patient. Duggan JM, et al. **Mycoses** 1995 May-Jun;38(5–6):215–8

Port-a-cath-related Fusarium oxysporum infection in an HIV-infected patient: treatment with liposomal amphotericin B. Eljaschewitsch J, et al. **Mycoses** 1996 Mar-Apr;39(3–4):115–9

Fluconazole in the therapy of tropical deep mycoses. Gugnani HC, et al. **Mycoses** 1995 Nov-Dec; 38(11–12):485–8

Itraconazole and flucytosine+itraconazole combination in the treatment of experimental cryptococcosis in hamsters. Iovannitti C, et al. **Mycoses** 1995 Nov-Dec; 38(11–12):449–52

Fluconazole in the treatment of pulmonary zygomycosis. Koszyca B, et al. **Mycoses** 1995 Jul-Aug;38(7–8):277–80

Systemic Fusarium nygamai infection in a patient with lymphoblastic non-Hodgkin's lymphoma. Krulder JW, et al. **Mycoses** 1996 Mar-Apr;39(3–4):121–3

Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium. Matsumoto T, et al. **Mycoses** 1995 Mar-Apr;38(3–4):135–44

Sporothrix schenckii isolated from a cat in Japan. Nakamura Y, et al. **Mycoses** 1996 Mar-Apr;39(3–4):125–8

Terbinafine in the treatment of non-immunocompromised compassionate cases of bronchopulmonary aspergillosis. Schiraldi GF, et al. **Mycoses** 1996 Jan-Feb;39(1–2):5–12

The anti-Malassezia furfur activity in vitro and in experimental dermatitis of six imidazole antifungal agents: bifonazole, clotrimazole, flutrimazole, ketoconazole, miconazole and sertaconazole. Van Gerven F, et al. **Mycoses** 1995 Sep-Oct;38(9–10):389–93

Drugs in cardiac transplantation [letter; comment] Ballantyne CM. **N Engl J Med** 1996 Feb 8;334(6):400–1; discussion 401–2. Comment on: N Engl J Med 1995 Sep 7;333(10):621–7. Comment on: N Engl J Med 1995 Sep 7;333(10):628–33.

Considerable ferment over antifungal agents [news] Fox JL. **Nat Med** 1995 May;1(5):398

The role of surgery and itraconazole in Aspergillus peritonitis in CAPD [letter] Kitiyakara C, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1498

Effect of Candida albicans infection and clotrimazole treatment on vaginal microflora in vitro. Ross RA, et al. **Obstet Gynecol** 1995 Dec;86(6):925–30

Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants. Epstein JB, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Mar;81(3):291–6

Successful outpatient treatment of Trichosporon beigelii peritonitis with oral fluconazole. Melez KA, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1110–3

Opportunistic fungal infections in patients with HIV disease: combating cryptococcosis and histoplasmosis. Kirchner JT. **Postgrad Med** 1996 Jun;99(6):209–16 (34 ref.)

Antifungal drugs [editorial] Hay RJ. **QJM** 1995 Oct; 88(10):681–4

Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: a case-control study. Ammassari A, et al. **Scand J Infect Dis** 1995;27(3):235–7

Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Barbaro G, et al. **Scand J Infect Dis** 1995;27(6):613–7

Fluconazole failure in two cases of disseminated candidosis. Jahnson L, et al. **Scand J Infect Dis** 1995;27(4):421–4

Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. Nielsen TL, et al. **Scand J Infect Dis** 1995;27(3):217–20

Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. Korraa H, et al. **South Med J** 1996 Mar;89(3):272–7 (38 ref.)

An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. Smith SW, et al. **South Med J** 1995 Dec;88(12):1217–20

Prevention and therapy of fungal infections in cancer patients. A review of recently published information [see comments] Klastersky J. **Support Care Cancer** 1995 Nov; 3(6):393–401 (42 ref.). Comment in: Support Care Cancer 1995 Nov;3(6):385–6.

New challenges to the therapy of systemic fungal infections. Medoff G. **Trans Am Clin Climatol Assoc** 1995;107:146–57; discussion 157–8 (24 ref.)

Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala-azar dermal leishmaniasis. Khalil EA, et al. **Trans R Soc Trop Med Hyg** 1996 Mar-Apr;90(2):187–8

Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients. Lee KH, et al. **Transplant Proc** 1996 Jun;28(3):1488–9

Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Marks WH, et al. **Transplantation** 1996 Jun 27; 61(12):1771–4 (8 ref.)

New strategies in the management of onychomycosis. Gupta AK. **West J Med** 1996 Jun;164(6):521–2

[Failure of terbinafine treatment in 2 children with tinea capitis (letter)] Strobos MA, et al. **Ned Tijdschr Geneeskd** 1996 Aug 3;140(31):1611–2 (Dut)

[Terbinafine versus miconazole in patients with tinea pedis] Vermeer BJ, et al. **Ned Tijdschr Geneeskd** 1996 Aug 3; 140(31):1605–8 (Eng. Abstr.) (Dut)

[Oral antifungal drugs] Ruutu P, et al. **Duodecim** 1995; 111(8):687–94 (27 ref.) (Fin)

[Oropharyngeal candidiasis resistant to fluconazole in patients infected by HIV] Drobacheff C, et al. **Ann Dermatol Venereol** 1996;123(2):85–9 (Eng. Abstr.) (Fre)

[Subcutaneous phycomycosis successfully treated with itraconazole] Mahé A, et al. **Ann Dermatol Venereol** 1996; 123(3):182–4 (Eng. Abstr.) (Fre)

[Extra-pulmonary pneumocystosis in the course of AIDS. Report of a case] Terris B, et al. **Ann Pathol** 1996;16(1):41–4 (Eng. Abstr.) (Fre)

[Evaluation of the time response of a single dose administration of fenticonazole nitrate] Balaïsch J. **Contracept Fertil Sex** 1996 May;24(5):417–22 (Eng. Abstr.) (Fre)

[Recurrent vulvovaginal mycoses] Salvat J, et al. **Rev Fr Gynecol Obstet** 1995 Nov;90(11):494–501 (17 ref.) (Eng. Abstr.) (Fre)

[Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole] Béchade D, et al. **Rev Med Interne** 1996; 17(3):234–7 (20 ref.) (Eng. Abstr.) (Fre)

[Pharma-clinics. Drug of the month. Terbinafine (Lamisil)] Piérard GE. **Rev Med Liege** 1995 Aug;50(8):352–3 (Fre)

[Curative antifungal treatment of invasive pulmonary aspergillosis] Andrès E, et al. **Rev Pneumol Clin** 1995; 51(4):228–31 (31 ref.) (Eng. Abstr.) (Fre)

[Entomophthoramycosis: a case report of a Congolese child with rapid regression using ketoconazole] Carme B, et al. **Sante** 1995 Nov-Dec;5(6):346–7 (Eng. Abstr.) (Fre)

[Terbinafine (Lamisil)] Breton MC. **Union Med Can** 1995 Nov;124(3):20–5 (Fre)

[The Candida infected hen's egg. An alternative test system for systemic anticandida activity] Härtl A, et al. **Arzneimittelforschung** 1995 Aug;45(8):926–8 (Eng. Abstr.) (Ger)

[Dermatomycoses. 8: Mycoses of the trunk, neck and face—therapy and follow-up] Meinhof W. **Fortschr Med** 1995 Sep 20;113(26):372–3 (Ger)

[Dermatomycoses—new attempts at systemic therapy] **Hautarzt** 1993 Apr;44(4 Suppl):1–4 (Ger)

[Rational use of antimycotics against yeast infections] Hof H, et al. **Immun Infekt** 1995 Dec;23(6):209–15 (29 ref.) (Eng. Abstr.) (Ger)

[Therapy and prevention of pneumocystis carinii pneumonia] Goebel FD, et al. **Internist (Berl)** 1995 Dec;36(12):1150–5 (31 ref.) (Ger)

[Candidiasis of the liver following successful chemotherapy of acute myeloid leukemia (Fab type 6) and recovery with oral fluconazole therapy] Keiser G, et al. **Schweiz Med Wochenschr** 1996 Apr 27;126(17):713–7 (Eng. Abstr.) (Ger)

[Clinical efficacy of fluconazole against fungal infections in hematological diseases] Morioka E, et al. **Jpn J Antibiot** 1996 Apr;49(4):399–402 (Eng. Abstr.) (Jpn)

[Clinical studies of fluconazole in patients with deep-seated fungal infection in intravenous hyperalimentation (IVH)] Takeda S, et al. **Kansenshogaku Zasshi** 1996 May; 70(5):437–40 (Eng. Abstr.) (Jpn)

[Emergency drug therapy of meningoencephalitis] Kuzuhara S. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1837–42 (5 ref.) (Jpn)

[Prophylaxis of puerperal infections using the Gyno-Pevaryl 150 preparation] Południewski G, et al. **Ginekol Pol** 1995 Feb;66(2):117–20 (Eng. Abstr.) (Pol)

[Treatment of patients with pulmonary aspergilloma with itraconazole] Wierzbicka M, et al. **Pneumonol Alergol Pol** 1996;64(1–2):59–63 (Eng. Abstr.) (Pol)

[Treatment of fungal infections in patients with AIDS] Boulos M. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:28–31 (Por)

[Metamphocin in the treatment of ocular mycoses] Maichuk IuF, et al. **Antibiot Khimioter** 1995 Nov-Dec; 40(11–12):55–6 (Eng. Abstr.) (Rus)

[Induction of oral aphthae after anesthesia in a patient with Behcet's disease] Seoane J, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):167–8 (Spa)

[Current status of antifungal prophylaxis in opportunistic mycoses] Torres-Rodríguez JM. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):44–53 (73 ref.) (Spa)

TOXICITY

Antifungal and molluscicidal saponins from Serjania salzmanniana. Ekabo OA, et al. **J Nat Prod** 1996 Apr; 59(4):431–5

Ocular tolerance of sertaconazole gel. Romero A, et al. **Mycoses** 1996 Jan-Feb;39(1–2):57–60

[Twenty-eight days repeated dose toxicity test of N-(fluorodichloromethylthio)phthalimide in rats] Matsushima Y, et al. **Eisei Shikenjo Hokoku** 1995; (113):19–30 (Eng. Abstr.) (Jpn)

ANTIGAMMA GLOBULIN ANTIBODIES see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTIGEN-ANTIBODY COMPLEX

see related

IMMUNE COMPLEX DISEASES

Immune complex transfer enzyme immunoassay that is more sensitive and specific than western blotting for detection of antibody immunoglobulin G to human immunodeficiency virus type 1 in serum with recombinant pol and gag proteins as antigens. Hashida S, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):535–41

Diagnostic utility of immune-complex-dissociated p24 antigen detection in perinatally acquired HIV-1 infection in Rwanda. Bulterys M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):186–91

[Dynamics of antigen-antibody interaction--an introduction] Sakurabayashi I. **Nippon Rinsho** 1995 Sep;53(9):2126–33 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical assessment of autoimmune and immunocomplex reactions in patients with leptospirosis] Frolov VM, et al. **Klin Med (Mosk)** 1996;74(1):68 **(Rus)**

ADMINISTRATION & DOSAGE

Specific down-regulation of anti-allergen IgE and IgG antibodies in humans associated with injections of allergen-specific antibody complexes. Jacquemin MG, et al. **Ther Immunol** 1995 Feb;2(1):41–52

ANALYSIS

A biosensor concept based on imaging ellipsometry for visualization of biomolecular interactions. Jin G, et al. **Anal Biochem** 1995 Nov 20;232(1):69–72

Calibration of biosensor response using simultaneous evanescent wave excitation of cyanine-labeled capture antibodies and antigens. Wadkins RM, et al. **Anal Biochem** 1995 Nov 20;232(1):73–8

Intravenous immunoglobulin therapy: modification of the immunofluorescence pattern in the skin of six patients with systemic lupus erythematosus. Puddu P, et al. **Arthritis Rheum** 1996 Apr;39(4):704–5

Identification of acute-phase proteins (APP) in circulating immune complexes (CIC) in esophageal cancer patients' sera. Croce MV, et al. **Cancer Invest** 1996;14(5):421–6

Immune complex kinase assays for mitogen-activated protein kinase and MEK. Reuter CW, et al. **Methods Enzymol** 1995; 255:245–56

The kinetics of the pathogenic pronase-digested renal proximal tubular antigen and antibody in rat active Heymann nephritis. Maezawa A, et al. **Nephron** 1995; 71(4):448–53

Fetal alkaline phosphatase/maternal IgG immune complexes in trisomy 21 pregnancies [letter] Grozdea J, et al. **Prenat Diagn** 1995 Nov;15(11):1084–5

Fibronectin and circulating immune complexes in Behçet's disease. Ozoran K, et al. **Rheumatol Int** 1996;15(6):221–4

[HCV-RNA in the circulating immune complexes] Hada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:143–9 (24 ref.) **(Jpn)**

[Isolation of soluble immune complex in biopsied tissues] Beletskaia LV, et al. **Biull Eksp Biol Med** 1995 Nov; 120(11):545–7 **(Rus)**

[A method of detecting soluble immune complexes in tissue biopsies] Beletskaia LV, et al. **Klin Lab Diagn** 1996 Mar-Apr;(2):40–2 (Eng. Abstr.) **(Rus)**

[Determination of circulating immune complexes by immunoenzyme method] Kuznetsov SI, et al. **Klin Lab Diagn** 1996 Mar-Apr;(2):39–40 (Eng. Abstr.) **(Rus)**

BLOOD

Circulating immune complexes in intracranial neoplasms. Manjula S, et al. **Acta Neurochir (Wien)** 1995; 133(3-4):164–8

Uptake of vWF-anti-vWF complexes by platelets in suspension. White JG, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):868–77

Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Gourevitch MM, et al. **Br J Cancer** 1995 Oct;72(4):934–8

Circulating immune complexes in patients with advanced tuberculosis and their association with autoantibodies and reduced CD4+ lymphocytes. Dlugovitzky D, et al. **Braz J Med Biol Res** 1995 Mar;28(3):331–5

Cholesterol content of circulating immune complexes in patients with coronary stenosis and subjects without evidence of atherosclerosis. Lecomte E, et al. **Clin Chem** 1995 Oct;41(10):1526–31

A case of immunoglobulin A-lambda conjugated with lactate dehydrogenase-3 isoenzyme, causing an extremely high enzyme activity in serum. Tozuka M, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1288–90

Immunoglobulin and complement complexes in blood following infection with human immunodeficiency virus type 1. Peng XX, et al. **Clin Diagn Lab Immunol** 1996 Jan; 3(1):128–31

Detection of nucleosome-IgG immune complexes in ascites from mice transplanted with anti-DNA antibody-secreting hybridomas and in plasma from MRL-lpr/lpr mice. Fournié GJ. **Clin Exp Immunol** 1996 May;104(2):236–40

Immune complexes from sera of patients with juvenile rheumatoid arthritis reveal novel 40 and 60 kd bands. Moore TL, et al. **Clin Exp Rheumatol** 1995 Sep-Oct; 13(5):667–72

Increased IgM class circulating immune complexes in acute hepatitis A virus infection. Tsai JF, et al. **Clin Immunol Immunopathol** 1996 Mar;78(3):291–5

Hepatitis B surface antigen- and immunoglobulin-specific circulating immune complexes in acute hepatitis B virus infection. Tsai JF, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):278–82

Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes. Arfors L, et al. **Eur J Haematol** 1996 Apr;56(4):230–4

Identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable PRL-IgG complex. Bonhoff A, et al. **Exp Clin Endocrinol Diabetes** 1995;103(4):252–5

Polyethylene glycol precipitates of serum contain a large proportion of uncomplexed immunoglobulins and C3. Crowley-Nowick PA, et al. **Immunol Invest** 1996 Jan-Mar; 25(1-2):91–101

Sequential occurrence of IgM, IgM/IgG, and gp120-IgM/IgG complement complexes on CD4+ lymphocytes in relation to CD4+ blood lymphocyte depletion in HIV+ hemophilia patients: results of a 10-year study. Daniel V, et al. **Immunol Lett** 1995 Jul-Aug; 47(1-2):97–102

Circulating immune complexes in various forms of Behçet's disease. Abdallah MA, et al. **Int J Dermatol** 1995 Dec; 34(12):841–5

CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. Wolbink GJ, et al. **J Immunol** 1996 Jul 1; 157(1):473–9

Relationship between immune complex-dissociated p24 antigen and human immunodeficiency virus type 1 RNA titers in plasma [letter; comment] Lafeuillade A, et al. **J Infect Dis** 1996 Jun;173(6):1522–4. Comment on: J Infect Dis 1995 Oct;172(4):1091–5.

Detection of specific antibodies in immune complexes of farmer's lung patients. Rottoli P, et al. **J Investig Allergol Clin Immunol** 1995 Jul-Aug;5(4):191–7

Enhancement of renal disease in BXSB lupus prone mice after prior exposure to bacterial lipopolysaccharide [see comments] Granholm NA, et al. **Lupus** 1995 Oct; 4(5):339–47. Comment in: Lupus 1995 Oct;4(5):333–5.

The role of circulating immune complexes; antinuclear and rheumatoid factor autoantibodies in aging in Nigerians. Oyeyinka GO, et al. **Mech Ageing Dev** 1995 Nov 24; 85(2-3):73–81

Correlation of IgG Fc receptors on granulocytes with serum immune complex level in systemic lupus erythematosus. Szücs G, et al. **Scand J Immunol** 1995 Nov;42(5):577–80

Novel thyrotropin (TSH)-TSH antibody complex in a healthy woman and her neonates. Tamaki H, et al. **Thyroid** 1995 Aug;5(4):299–303

Evaluation of mebendazole activity on experimental murine toxocariasis by immune complexes determination. Bardon R, et al. **Zentralbl Veterinarmed [B]** 1995 Jun;42(4):235–46

[Effect of praziquantel treatment on serum circulating soluble egg antigen-antibody complex (SEAIC) level in mice infected with Schistosoma japonicum] Shi G, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):189–92 (Eng. Abstr.) **(Chi)**

[Circulating immune complexes in airborne allergy--a protective role?] Jarząb J, et al. **Przegl Lek** 1995; 52(8):375–81 (Eng. Abstr.) **(Pol)**

[Induction of human platelet aggregation by nerve tissue antigens and immune complexes] Matusevich LI, et al. **Gematol Transfuziol** 1995 Jul-Aug;40(4):29–31 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Detection of immune complexes in the CSF of Japanese encephalitis patients: correlation of findings with outcome. Desai A, et al. **Intervirology** 1994;37(6):352–5

Diagnosis of tuberculous meningitis: a comparative analysis of 3 immunoassays, an immune complex assay and the polymerase chain reaction. Miörner H, et al. **Tuber Lung Dis** 1995 Oct;76(5):381–6

Significance of mycobacterial immune complexes (IgG) in the diagnosis of tuberculous meningitis. Patil SA, et al. **Tuber Lung Dis** 1996 Apr;77(2):164–7

CHEMISTRY

Transition-state theory and secondary forces in antigen--antibody complexes. Mummert ME, et al. **Biochemistry** 1996 Jun 25;35(25):8187–92

A systematic analysis of average molecular weights and gelation conditions for branched immune complexes: the interaction between a multivalent antigen with distinct epitopes and many different types of bivalent antibodies. Shiau LD. **Biopolymers** 1996 Sep;39(3):445–54

The crystal structures of complexes formed between lysozyme and antibody fragments. Bentley GA. **EXS** 1996; 75:301–19 (42 ref.)

Analysis by surface plasmon resonance of the influence of valence on the ligand binding affinity and kinetics of an anti-carbohydrate antibody. MacKenzie CR, et al. **J Biol Chem** 1996 Jan 19;271(3):1527–33

Scanning tunnelling microscopy and dynamic contact angle studies of the effects of partial denaturation on immunoassay solid phase antibody. Davies J, et al. **J Immunol Methods** 1995 Oct 12;186(1):111–23

Enzyme-labelled antibody-avidin conjugates: new flexible and sensitive immunochemical reagents. van Gijlswijk RP, et al. **J Immunol Methods** 1996 Jan 16;189(1):117–27

Neutrophil functional responses depend on immune complex valency. Strohmeier GR, et al. **J Leukoc Biol** 1995 Oct; 58(4):403–14

Role of the Fc gamma R subclasses Fc gamma RII and Fc gamma RIII in the activation of human neutrophils by low and high valency immune complexes. Strohmeier GR, et al. **J Leukoc Biol** 1995 Oct;58(4):415–22

The crystal structure of the antibody N10-staphylococcal nuclease complex at 2.9 A resolution. Bossart-Whitaker P, et al. **J Mol Biol** 1995 Nov 3;253(4):559–75

Crystal structure of the complex of the variable domain of antibody D1.3 and turkey egg white lysozyme: a novel conformational change in antibody CDR-L3 selects for antigen. Braden BC, et al. **J Mol Biol** 1996 Apr 19; 257(5):889–94

Three-dimensional structures of the Fab fragment of murine N1G9 antibody from the primary immune response and of its complex with (4-hydroxy-3-nitrophenyl)acetate. Mizutani R, et al. **J Mol Biol** 1995 Nov 24;254(2):208–22

Global changes in amide hydrogen exchange rates for a protein antigen in complex with three different antibodies. Williams DC Jr, et al. **J Mol Biol** 1996 Apr 12; 257(4):866–76

Conservation of water molecules in an antibody-antigen interaction. Braden BC, et al. **J Mol Recognit** 1995 Sep-Oct;8(5):317–25

Crystallization and preliminary X-ray analysis of Borrelia burgdorferi outer surface protein A (OspA) complexed with a murine monoclonal antibody Fab fragment. Li H, et al. **J Struct Biol** 1995 Nov-Dec;115(3):335–7

Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon. Smith TJ, et al. **Nature** 1996 Sep 26;383(6598):350–4

Determination of the pKa values of titratable groups of an antigen-antibody complex, HyHEL-5-hen egg lysozyme. McDonald SM, et al. **Protein Eng** 1995 Sep;8(9):915–24

Free energy simulations of the HyHEL-10/HEL antibody-antigen complex. Pomès R, et al. **Protein Eng** 1995 Jul;8(7):663–75

The use of antibody fragments for crystallization and structure determinations. Kovari LC, et al. **Structure** 1995 Dec 15;3(12):1291–3 (34 ref.)

[Effect of degree of aerosol OT reverse micelle hydration on the catalytic activity of peroxidase, its conjugate with cortisol and their immune complexes] Karaseva EI, et al. **Biokhimiia** 1996 Feb;61(2):322–35 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Inhibitory and disruptive effects of some antirheumatics on antigen-antibody complexes. Kallee E, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):711–4

The effect of various forms of heparin on the release of immune complexes from the surface of cultured mesangial cells. Drakeley SJ, et al. **J Pathol** 1996 Apr;178(4):458–61

Morphine enhances deposition of ferritin-antiferritin complexes in the glomerular mesangium. Singhal PC, et al. **Nephron** 1995;70(2):229–34

Modulation of antigen-antibody complexations by immunoglobulins. Andersson K, et al. **Scand J Immunol** 1995 Oct;42(4):407–17

IMMUNOLOGY

High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Lutz HU, et al. **Blood** 1996 Jul 1;88(1):184–93

Characterisation of the endo-polygalacturonase-resistant region of the pectin from Bupleurum falcatum L.--a polysaccharide with an active function in clearance of immune complexes. Matsumoto T, et al. **Carbohydr Res** 1995 Apr 30;270(2):221–9

A 56,000 Mr phosphoseryl protein in PC12 cell lysates strongly associates with protein-A sepharose beads and was observed in immune complex kinase assays for PP60c-src. Buensuceso C, et al. **Cell Signal** 1995 Nov;7(8):765–71

Recombinant soluble Fc gamma RII inhibits immune complex precipitation. Gavin AL, et al. **Clin Exp Immunol** 1995 Dec;102(3):620–5

Rabbit polymorphonuclear granulocyte function during ethanol administration--migration and oxidative responses in a joint with immune complex synovitis. Nilsson E, et al. **Clin Exp Immunol** 1995 Oct;102(1):137–43

Immune complex-induced interleukin-6, interleukin-10 and prostaglandin secretion by human monocytes: a network of pro- and anti-inflammatory cytokines dependent on the antigen:antibody ratio. Berger S, et al. **Eur J Immunol** 1996 Jun;26(6):1297–301

Co-selection of cognate antibody-antigen pairs by selectively-infective phages. Krebber C, et al. **FEBS Lett** 1995 Dec 18;377(2):227–31

Effect of nitric oxide donors on neutrophil responses induced by immune complexes. Andonegui G, et al. **Immunology** 1995 Dec;86(4):646–50

T-cell dependent response to immune complexes abrogates B-cell unresponsiveness to pneumococcal cell wall polysaccharide. Caulfield MJ, et al. **Immunology** 1995 Nov;

86(3):331-5
A novel pathway for Ca2+ signalling in neutrophils by immune complexes. Davies EV, et al. **Immunology** 1995 Aug;85(4):538-43
Cross-linking of Fc gamma receptors activates HIV-1 long terminal repeat-driven transcription in human monocytes. Tsitsikov EN, et al. **Int Immunol** 1995 Oct;7(10):1665-70
Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. Miletic VD, et al. **J Immunol** 1996 Jan 15;156(2):749-57
Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited. Berg PA, et al. **Liver** 1995 Dec; 15(6):281-92 (73 ref.)
Evolution of renal injury in a chronic model of IgA immune-complex-associated nephropathy. Montinaro V, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2035-42
Neurogenic amplification of immune complex inflammation. Bozic CR, et al. **Science** 1996 Sep 20;273(5282):1722-5
Use of peroxidase:anti-peroxidase immune complexes as markers for Fc gamma receptors in vitro. Kreisle RA, et al. **Vet Immunol Immunopathol** 1995 Aug;47(3-4):283-93
[Hypervariable region specific formation of immune complexes in a plasma with quasispecies of hepatitis C virus] Hijikata M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:150-5 (19 ref.) **(Jpn)**
[Some patterns in formation of antibody-antigen-antibody complexes on a solid phase: experimental study and mathematical modeling] Zherdev AV, et al. **Prikl Biokhim Mikrobiol** 1996 Mar-Apr;32(2):194-202 (Eng. Abstr.) **(Rus)**
[Detection of human immunodeficiency virus antigen both free and in immune complexes] Banfi NH, et al. **Rev Argent Microbiol** 1995 Jul-Sep;27(3):123-9 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Immune-complex trapping in the splenic ellipsoids of rainbow trout (Oncorhynchus mykiss). Espenes A, et al. **Cell Tissue Res** 1995 Oct;282(1):41-8
Polyethylene glycol-modified avidin: a novel agent for the selective extraction of biotinylated immune-complex in an aqueous two-phase system. Nishimura H, et al. **J Biomater Sci Polym Ed** 1995;7(3):289-96

METABOLISM

An immunohistochemical study on isotypes of the immune complexes trapped by follicular dendritic cells (FDC) in various human lymphoid tissues. Degawa N, et al. **Adv Exp Med Biol** 1995;378:281-3
Hepatic elimination of circulating IgA immune complexes: a comparison between rats and guinea pigs. Johansson A, et al. **Adv Exp Med Biol** 1995;371B:1049-52
Oral mercuric chloride leads to intestinal basement membrane (IBM) immune complex deposition and fecal protein loss. Knoflach P, et al. **Adv Exp Med Biol** 1995;371B:1399-401
In vitro immune complex binding assay to examine the mechanism of immune complex trapping by human follicular dendritic cells (FDC). Maeda K, et al. **Adv Exp Med Biol** 1995;378:317-9
The effects of altered glycosylation of IgG on rheumatoid factor-binding and immune complex formation. Soltys AJ, et al. **Adv Exp Med Biol** 1995;376:155-60 (12 ref.)
Iccosomes and induction of specific antibody production in vitro. Wu J, et al. **Adv Exp Med Biol** 1995;378:309-11
Michael Mason Prize Essay 1995. Complement, immune complexes and systemic lupus erythematosus. Davies KA. **Br J Rheumatol** 1996 Jan;35(1):5-23 (69 ref.)
Presence of covalent bonds between immune deposits and other macromolecules in murine renal glomeruli. Mannik M. **Clin Exp Immunol** 1996 Feb;103(2):285-8
Mechanism of immune complex trapping by follicular dendritic cells. Van den Berg TK, et al. **Curr Top Microbiol Immunol** 1995;201:49-67 (110 ref.)
Effect of iC3b binding to immune complexes upon the phagocytic response of human neutrophils: synergistic functions between Fc gamma R and CR3. Ohkuro M, et al. **FEBS Lett** 1995 Oct 16;373(3):189-92
Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Johansson AG, et al. **Hepatology** 1996 Jul;24(1):169-75
Targeting lipoproteins to Fc gamma receptors with bispecific antibodies. Morganelli PM. **J Hematother** 1995 Oct; 4(5):457-61 (19 ref.)
Primate erythrocyte (E) complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulation. Taylor RP, et al. **J Hematother** 1995 Oct;4(5):357-62
Binding of HIV-1 virions or gp120-anti-gp120 immune complexes to HIV-1-infected quiescent peripherai blood mononuclear cells reveals latent infection. Briant L, et al. **J Immunol** 1996 May 15;156(10):3994-4004
Clearance pathways of soluble immune complexes in the pig. Insights into the adaptive nature of antigen clearance in humans. Davies KA, et al. **J Immunol** 1995 Dec 15; 155(12):5760-8
Binding of model soluble immune complexes to modified C-reactive protein. Motie M, et al. **J Immunol** 1996 Jun 1;156(11):4435-41
Human monocytes are unable to bind to or phagocytize IgA and IgG immune complexes formed with influenza virus in vitro. Scott CB, et al. **J Immunol** 1996 Jul 1;157(1):351-9
Neutrophil lactoferrin release induced by IgA immune complexes can be mediated either by Fc alpha receptors or by complement receptors through different pathways. Zhang W, et al. **J Immunol** 1996 Apr 1;156(7):2599-606
Monomeric immunoglobulin A protects glomerulus against polymeric immunoglobulin A immune complex in experimental immunoglobulin A nephropathy. Chen A, et al. **Lab Invest** 1996 Apr;74(4):737-46
Binding to erythrocyte complement receptor type 1 of BSA/anti-BSA complexes opsonized by C4A3 or C4B1 in the presence of serum. Klint C, et al. **Scand J Immunol** 1995 Oct;42(4):425-32
Processing of IgM/Anti-IgM immune complexes by the liver of rats treated with anti-IgM monoclonal antibodies. Havaux XB, et al. **Transplant Proc** 1996 Apr;28(2):574

PHARMACOLOGY

Role of the Fc gamma R subclasses Fc gamma RII and Fc gamma RIII in the activation of human neutrophils by low and high valency immune complexes. Strohmeier GR, et al. **J Leukoc Biol** 1995 Oct;58(4):415-22

PHYSIOLOGY

Study of complement-mediated anaphylaxis in humans. The role of IgG subclasses (IgG1 and/or IgG4) in the complement-activating capacity of immune complexes. Bergamaschini L, et al. **J Immunol** 1996 Feb 1; 156(3):1256-61
Neutrophil functional responses depend on immune complex valency. Strohmeier GR, et al. **J Leukoc Biol** 1995 Oct; 58(4):403-14
Activation of human neutrophils induced by immune complexes prepared with cationic and anionic fractions of normal IgG antibodies. Trevani AS, et al. **Scand J Immunol** 1996 Mar;43(3):341-4

ULTRASTRUCTURE

Estimation of variance distribution in three-dimensional reconstruction. II. Applications. Liu W, et al. **J Opt Soc Am A** 1995 Dec;12(12):2628-35
Three-dimensional reconstruction of Androctonus australis hemocyanin labeled with a monoclonal Fab fragment. Boisset N, et al. **J Struct Biol** 1995 Jul-Aug;115(1):16-29
Imaging of single antigens, antibodies, and specific immunocomplex formation by scanning force microscopy. Quist AP, et al. **Scanning Microsc** 1995 Jun;9(2):395-400

ANTIGEN-ANTIBODY REACTIONS

see related
BINDING SITES, ANTIBODY
HYPERSENSITIVITY, IMMEDIATE

Structure and thermodynamics of antigen recognition by antibodies. Braden BC, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:315-27
Analysis of the structural correlates for self-antigen binding by natural and disease-related autoantibodies. In vitro expression of recombinant and/or mutagenized human IgG. Ichiyoshi Y, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:328-41 (35 ref.)
The importance of the diversity region YYGS motif in anti-DNA antibody binding to DNA. Mahmoudi M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:424-6
Structure-function studies of human monoclonal antibodies to pneumococcus type 3 polysaccharide. Shaw DR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:370-3
Antigen-antibody diffusion-limited binding kinetics for biosensors. A fractal analysis. Sadana A, et al. **Appl Biochem Biotechnol** 1996 Jun;59(3):259-82
Antibody binding to a peptide but not the whole protein by recognition of the C-terminal carboxy group. Liang TC, et al. **Arch Biochem Biophys** 1996 May 15; 329(2):208-14
Rheumatoid arthritis in a United States Public Health Service Hospital in Oklahoma: serologic manifestations in rheumatoid arthritis vary among tribal groups. Scofield RH, et al. **Arthritis Rheum** 1996 Feb;39(2):283-6
Force field development and conformational search strategy in the simulation of biomolecular recognition processes. Tenette C, et al. **Biochem Soc Trans** 1996 Feb;24(1):268-74 (43 ref.)
An analysis of antigen-antibody binding kinetics for biosensor applications utilized as a model system: influence of non-specific binding. Chen Z, et al. **Biophys Chem** 1996 Jan;57(2-3):177-87
Impedance based sensing of the specific binding reaction between Staphylococcus enterotoxin B and its antibody on an ultra-thin platinum film. DeSilva MS, et al. **Biosens Bioelectron** 1995 Fall;10(8):675-82
Chemiluminescent immunoenzyme biosensor with a thin-layer flow-through cell. Application for study of a real-time bimolecular antigen-antibody interaction. Osipov AP, et al. **Biosens Bioelectron** 1996;11(9):881-7
A 'mixed' self-assembled monolayer for an impedimetric immunosensor. Rickert J, et al. **Biosens Bioelectron** 1996; 11(8):757-68
A fractal analysis of the influence of non-specific binding on antigen-antibody binding kinetics for biosensor applications. Sadana A, et al. **Biosens Bioelectron** 1996; 11(8):769-82
The critical sensor: a new type of evanescent wave immunosensor. Schipper EF, et al. **Biosens Bioelectron** 1996;11(3):295-304
Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Igarashi M, et al. **Blood** 1996 Apr 15;87(8):3262-70
Oligodendrocyte-reactive O1, O4, and HNK-1 monoclonal antibodies are encoded by germline immunoglobulin genes. Asakura K, et al. **Brain Res Mol Brain Res** 1995 Dec 28; 34(2):283-93
Structural differences between the human and mouse 52-kD Ro autoantigens associated with poorly conserved autoantibody activity across species. Keech CL, et al. **Clin Exp Immunol** 1996 May;104(2):255-63
Antigen binding of antiganglioside antibodies in vitro is strongly influenced by the ganglioside composition of the sample. Hildebrandt H. **FEBS Lett** 1996 Jun 10; 388(1):29-33
FAB CID-MS/MS characterization of tetrasaccharide tri- and tetrasulfate derived from the antigenic determinant recognized by the anti-chondroitin sulfate monoclonal antibody MO-225. Ii T, et al. **Glycoconj J** 1995 Jun; 12(3):282-9
Effect of hyperbaric oxygen on the immunoreactivity to substance P in the nasal mucosa of cluster headache patients. Di Sabato F, et al. **Headache** 1996 Apr;36(4):221-3
HLA-B*1303: a new example of poor correlation between serology and structure. Balas A, et al. **Hum Immunol** 1996 Jan;45(1):32-6
Binding reactivity of monoclonal anti-carcinoembryonic antigen (CEA) antibodies with cell membrane-bound CEA and with free CEA in solution. Murakami M, et al. **Immunol Invest** 1996 Jan-Mar;25(1-2):23-35
Recognition of CD52 allelic gene products by CAMPATH-1H antibodies. Hale C, et al. **Immunology** 1996 Jun;88(2):183-90
Biochemical alterations in macrophages by interaction with immune complexes. Anand V, et al. **Indian J Exp Biol** 1996 Apr;34(4):307-10
Characterization of the epitope recognized by a mAb that reacts differentially with murine suppressor T cells. Kapp JA, et al. **Int Immunol** 1995 Aug;7(8):1319-30
Comparison of reactivity of monoclonal antibody (3F2) to trimeric tumor necrosis factor (TNF-alpha) with that to monomeric TNF-alpha. Saijo S, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):28-32
Observations on the binding of four anti-carbohydrate monoclonal antibodies to their homologous ligands. Nashed EM, et al. **J Biol Chem** 1996 Apr 5;271(14):8209-14
Monoclonal antibodies recognize antigen expressed by osteoblasts. Benayahu D, et al. **J Bone Miner Res** 1995 Oct;10(10):1496-503
Multiple interactive residues of recognition: elucidation of discontinuous epitopes with linear peptides. Gao B, et al. **J Immunol** 1996 Jul 1;157(1):183-8
Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. Bonnycastle LL, et al. **J Mol Biol** 1996 May 24; 258(5):747-62
Intra-vitreal injection of substance P antibodies as an antagonist in the vertebrate (fish) retina. Djamgoz MB, et al. **J Neurosci Methods** 1996 Feb;64(2):237-43
Reactivity and epitope mapping of single-chain T cell receptors with monoclonal antibodies. Brodnicki TC, et al. **Mol Immunol** 1996 Feb;33(3):253-63
Modelling antibody-antigen interactions: ferritin as a case study. Helmer-Citterich M, et al. **Mol Immunol** 1995 Sep; 32(13):1001-10
Effects of secondary forces on the primary antibody-ligand interaction. Mummert ME, et al. **Mol Immunol** 1995 Nov; 32(16):1225-33
Interactions of protein antigens with antibodies. Davies DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):7-12 (69 ref.)
Detection and localization of individual antibody-antigen recognition events by atomic force microscopy. Hinterdorfer P, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3477-81
Conformation of the T-cell antigen receptor-beta chain C-domain contributes to V beta 3 epitope recognition by monoclonal antibody KJ25. Li ZG, et al. **Scand J Immunol** 1996 Feb;43(2):140-5
Mapping of two overlapping linear epitopes in Pfg27 recognized by Plasmodium falciparum transmission-blocking monoclonal antibodies. Ploton IN, et al. **Vaccine** 1995 Sep;13(13):1161-9
[Specificity of antibodies formed in people with Rh-negative blood in response to administration to antigens C(rh', Rh2) and Cw(rhwf, Rh8)] Morokov VA. **Gematol Transfuziol** 1995 Sep-Oct;40(5):15-7 (Eng. Abstr.) **(Rus)**
[The immune reactivity of patients with chronic bronchitis on vaccinal therapy] Sukhovskaia OA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):68-71 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Complex gangliosides affect GD3 accessibility to antibody in developing neuronal cells. Allende ML, et al. **Brain Res Dev Brain Res** 1995 Dec 21;90(1-2):102-10
A putative enzyme from various secretions specifically inhibits antibody-antigen interactions. Poethke R, et al.

J Immunol Methods 1996 May 27;191(2):149-57

IMMUNOLOGY

Chimaeric monoclonal antibodies encoded by the human VH26 gene from naïve transgenic mice display a wide range of antigen-binding specificities. Harmer IJ, et al. **Immunology** 1996 Jun;88(2):174-82

Novel colorectal adenocarcinoma-associated 40- and 47-kDa protein antigens recognized by anti-60-kDa heat shock protein antibody. Otaka M, et al. **J Clin Gastroenterol** 1995 Oct;21(3):224-9

Incidence, target antigens, and clinical implications of antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Braun MG, et al. **J Rheumatol** 1996 May; 23(5):826-30

Further characterization of the 38 kDa antigen from Echinococcus granulosus (hydatid disease) cyst fluid: evidence for antigenic heterogeneity and reactivity with anti-P1 antibodies. Zhang LH, et al. **Parasite Immunol** 1995 Jun;17(6):287-96

Chorionic villus sampling and materno-fetal transfusions: an immunological pathogenesis of vascular disruptive syndromes? Los FJ, et al. **Prenat Diagn** 1996 Mar; 16(3):193-8

PHYSIOLOGY

[Role of antigen-antibody reaction in pulmonary hypertensive reaction after antigen challenge] Shoji K, et al. **Masui** 1995 Aug;44(8):1091-6 (Eng. Abstr.) **(Jpn)**

ANTIGEN, B7 see **ANTIGENS, CD80**

ANTIGEN BRONCHIAL PROVOCATION TESTS see **BRONCHIAL PROVOCATION TESTS**

ANTIGEN CA-15-3 see **CA-15-3 ANTIGEN**

ANTIGEN CA-19-9 see **CA-19-9 ANTIGEN**

ANTIGEN CA-125 see **CA-125 ANTIGEN**

ANTIGEN, LYT-1 see **ANTIGENS, LY**

ANTIGEN P150,95

ANALYSIS

Phenotypic and functional characterization of CD11c+ dendritic cell population in mouse Peyer's patches. Ruedl C, et al. **Eur J Immunol** 1996 Aug;26(8):1801-6

GENETICS

Granulocyte-macrophage colony-stimulating factor, phorbol ester, and sodium butyrate induce the CD11c integrin gene promoter activity during myeloid cell differentiation. Rubio MA, et al. **Blood** 1995 Nov 15;86(10):3715-24

Identification of Sp1-binding sites in the CD11c (p150,95 alpha) and CD11a (LFA-1 alpha) integrin subunit promoters and their involvement in the tissue-specific expression of CD11c. López-Rodríguez C, et al. **Eur J Immunol** 1995 Dec;25(12):3496-503

Regulation of expression of the LFA-1 and p150,95 leukocyte integrins: involvement of the CD11a and CD11c gene promoters. López-Rodríguez C, et al. **Immunobiology** 1995 Jul;193(2-4):315-21

AP-1 regulates the basal and developmentally induced transcription of the CD11c leukocyte integrin gene. López-Rodríguez C, et al. **J Immunol** 1996 May 15; 156(10):3780-7

Sp1 binds two sites in the CD11c promoter in vivo specifically in myeloid cells and cooperates with AP1 to activate transcription. Noti JD, et al. **Mol Cell Biol** 1996 Jun;16(6):2940-50

Regulation of the leukocyte integrin gene CD11c is mediated by AP1 and Ets transcription factors. Noti JD, et al. **Mol Immunol** 1996 Feb;33(2):115-27

IMMUNOLOGY

A monoclonal antibody, 3/22, to rabbit CD11c which induces homotypic T cell aggregation: evidence that ICAM-1 is a ligand for CD11c/CD18. Blackford J, et al. **Eur J Immunol** 1996 Mar;26(3):525-31

METABOLISM

The beta 2 integrin Mac-1 but not p150,95 associates with Fc gamma RIIA. Annenkov A, et al. **Eur J Immunol** 1996 Jan;26(1):207-12

A monoclonal antibody, 3/22, to rabbit CD11c which induces homotypic T cell aggregation: evidence that ICAM-1 is a ligand for CD11c/CD18. Blackford J, et al. **Eur J Immunol** 1996 Mar;26(3):525-31

ANTIGEN PRESENTATION

Cholera toxin enhances antigen presentation. Bromander AK, et al. **Adv Exp Med Biol** 1995;371B:1501-6

Antigen presenting and primary in vitro sensitizing capacity of CD1a+ dendritic cells generated from human blood. Degwert J, et al. **Adv Exp Med Biol** 1995;378:187-9

Human epidermal Langerhans cells efficiently present HIV-1 antigens to specific T cell lines. Girolomoni G, et al. **Adv Exp Med Biol** 1995;378:473-5

Microdissected domes from gut-associated lymphoid tissues: a model of M cell transepithelial transport in vitro. Kabok Z, et al. **Adv Exp Med Biol** 1995;371A:235-8

Antigen processing capacity of dendritic cells from mice of different MHC backgrounds: down-regulation upon culture and evidence for heterogeneity of dendritic cell populations. Koch F, et al. **Adv Exp Med Biol** 1995; 378:203-6

Dendritic cells "in vivo": their role in the initiation of intestinal immune responses. Liu L, et al. **Adv Exp Med Biol** 1995;371A:271-4 (5 ref.)

Analysis of invariant chain processing in 3 day cultured rat Langerhans cells. Neiss U, et al. **Adv Exp Med Biol** 1995; 378:223-5

Uptake of bead-adsorbed versus soluble antigen by bone marrow derived dendritic cells triggers their activation and increases their antigen presentation capacity. Scheicher C, et al. **Adv Exp Med Biol** 1995;378:253-5

The fate of protein antigen in annelids--in vivo and in vitro studies. Tucková L, et al. **Adv Exp Med Biol** 1995; 371A:335-9

Antigen presentation by a mouse duodenal epithelial cell line (MODE-K). Vidal K, et al. **Adv Exp Med Biol** 1995; 371A:225-8

Umbilical cord blood contains normal frequencies of cytotoxic T-lymphocyte precursors (ctlp) and helper T-lymphocyte precursors against noninherited maternal antigens and noninherited paternal antigens. Falkenburg JH, et al. **Ann Hematol** 1996 Apr;72(4):260-4

The role of dendritic cells in antigen processing in the Peyer's patch. Kelsall BL, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:47-54

The dendritic cell lineage: a ubiquitous antigen-presenting organization. Massard G, et al. **Ann Thorac Surg** 1996 Jan; 61(1):252-8 (67 ref.)

Surface engineering: optimization of antigen presentation in self-assembled monolayers. Duschl C, et al. **Biophys J** 1996 Apr;70(4):1985-95

Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Cardoso AA, et al. **Blood** 1996 Jul 1;88(1):41-8

Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins. Harris PE, et al. **Blood** 1996 Jun 15; 87(12):5104-12

The ICAM-3/LFA-1 interaction is critical for epidermal Langerhans cell alloantigen presentation to CD4+ T cells. Griffiths CE, et al. **Br J Dermatol** 1995 Dec;133(6):823-9

A subset of splenic macrophages process and present native antigen to naive antigen-specific CD4+ T-cells from mice transgenic for an alpha beta T-cell receptor. Askew D, et al. **Cell Immunol** 1995 Nov;166(1):62-70

Lack of MMTV superantigen presentation in MHC class II-deficient mice. Beutner U, et al. **Cell Immunol** 1996 Mar 15;168(2):141-7

Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Gabrilovich DI, et al. **Cell Immunol** 1996 May 25;170(1):101-10

Polymorphism in the beta chain of IAq versus IAp influences presentation of protein but not peptide antigens. Lambert LE, et al. **Cell Immunol** 1995 Oct 15;165(2):202-10

High-density presentation of an immunodominant nanimal peptide on B cells is MHC-linked to Th1-like immunity. Murray JS, et al. **Cell Immunol** 1995 Nov;166(1):9-15

Human natural killer (NK) cells present staphylococcal enterotoxin B (SEB) to T lymphocytes. D'Orazio JA, et al. **Clin Exp Immunol** 1996 May;104(2):366-73

Defective antigen processing associated with familial disseminated mycobacteriosis. D'Souza S, et al. **Clin Exp Immunol** 1996 Jan;103(1):35-9

Antigen processing and presentation by a murine myoblast cell line. Garlepp MJ, et al. **Clin Exp Immunol** 1995 Dec; 102(3):614-9

Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes. Villacres-Eriksson M. **Clin Exp Immunol** 1995 Oct;102(1):46-52

Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules. Yi Q, et al. **Clin Exp Immunol** 1996 May;104(2):359-65

LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes. Sibille C, et al. **Curr Biol** 1995 Aug 1;5(8):923-30

Follicular dendritic cells: antigen retention, B cell activation, and cytokine production. Kosco-Vilbois MH, et al. **Curr Top Microbiol Immunol** 1995;201:69-82 (30 ref.)

Murine follicular dendritic cells: accessory activities in vitro. Tew JG, et al. **Curr Top Microbiol Immunol** 1995; 201:93-104 (50 ref.)

A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Brichard VG, et al. **Eur J Immunol** 1996 Jan;26(1):224-30

Glycosylphosphatidylinositol-anchored H-2Db molecules are defective in antigen processing and presentation to cytotoxic T lymphocytes. Cariappa A, et al. **Eur J Immunol** 1996 Sep;26(9):2215-24

A third interferon-gamma-induced subunit exchange in the 20S proteasome. Groettrup M, et al. **Eur J Immunol** 1996 Apr;26(4):863-9

Difference in antigen presentation pathways between cortical and medullary thymic epithelial cells. Kasai M, et al. **Eur J Immunol** 1996 Sep;26(9):2101-7

Translocation of long peptides by transporters associated with antigen processing (TAP). Koopmann JO, et al. **Eur J Immunol** 1996 Aug;26(8):1720-8

Expression levels of stress protein gp96 are not limiting for major histocompatibility complex class I-restricted antigen presentation. Lammert E, et al. **Eur J Immunol** 1996 Apr; 26(4):875-9

Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2. Lee SP, et al. **Eur J Immunol** 1996 Aug;26(8):1875-83

Processing and presentation of type II collagen, a fibrillar autoantigen, by H-2q antigen-presenting cells. Manoury-Schwartz B, et al. **Eur J Immunol** 1995 Dec; 25(12):3235-42

Antigen processing and presentation of a naturally glycosylated protein elicits major histocompatibility complex class II-restricted, carbohydrate-specific T cells. Michaëlsson E, et al. **Eur J Immunol** 1996 Aug; 26(8):1906-10

Characterization of processing requirements and metal cross-reactivities in T cell clones from patients with allergic contact dermatitis to nickel. Moulon C, et al. **Eur J Immunol** 1995 Dec;25(12):3308-15

Recognition of altered self major histocompatibility complex molecules modulated by specific peptide interactions. Nepom GT, et al. **Eur J Immunol** 1996 Apr;26(4):949-52

Role of splenic B cells in the immune privilege of the anterior chamber of the eye. Niederkorn JY, et al. **Eur J Immunol** 1995 Oct;25(10):2783-7

One cause for the apparent inability of human T cell clones to function as professional superantigen-presenting cells is autoactivation. Nisini R, et al. **Eur J Immunol** 1996 Apr; 26(4):797-803

Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system. Oxenius A, et al. **Eur J Immunol** 1995 Dec;25(12):3402-11

Cell type-specific processing of the I-Ed-restricted hen egg lysozyme determinant 107-116. Robadey C, et al. **Eur J Immunol** 1996 Jul;26(7):1656-9

Ligation of either CD2 or CD28 rescues CD4+ T cells from HIV-gp120-induced apoptosis. Tuosto L, et al. **Eur J Immunol** 1995 Oct;25(10):2917-22

Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1. von Bonin A, et al. **Eur J Immunol** 1995 Oct;25(10):2894-8

Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay. Drijfhout JW, et al. **Hum Immunol** 1995 May; 43(1):1-12

How selective is the transporter associated with antigen processing? Androlewicz MJ, et al. **Immunity** 1996 Jul; 5(1):1-5 (41 ref.)

Role of B cell receptor Ig alpha and Ig beta subunits in MHC class II-restricted antigen presentation. Bonnerot C, et al. **Immunity** 1995 Sep;3(3):335-47

A Listeria monocytogenes pentapeptide is presented to cytolytic T lymphocytes by the H2-M3 MHC class Ib molecule. Gulden PH, et al. **Immunity** 1996 Jul;5(1):73-9

In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Huang AY, et al. **Immunity** 1996 Apr;4(4):349-55

Identification of an H2-M3-restricted Listeria epitope: implications for antigen presentation by M3. Lenz LL, et al. **Immunity** 1996 Jul;5(1):63-72

Single-cell PCR analysis of TCR repertoires selected by antigen in vivo: a high magnitude CD8 response is comprised of very few clones. Maryanski JL, et al. **Immunity** 1996 Jan;4(1):47-55

Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Morita CT, et al. **Immunity** 1995 Oct;3(4):495-507

Polarity of T cell shape, motility, and sensitivity to antigen. Negulescu PA, et al. **Immunity** 1996 May;4(5):421-30

Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Norbury CC, et al. **Immunity** 1995 Dec;3(6):783-91

HLA-DM: an in vivo facilitator of MHC class II peptide loading. Roche PA. **Immunity** 1995 Sep;3(3):259-62 (31 ref.)

Major histocompatibility class II peptide occupancy, antigen presentation, and CD4+ T cell function in mice lacking the p41 isoform of invariant chain. Takaesu NT, et al. **Immunity** 1995 Sep;3(3):385-96

The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Van Parijs L, et al. **Immunity** 1996 Mar;4(3):321-8

Differential sensitivity to antigenic competition in antigen-specific and -nonspecific antigen presentation by B cells. Kakiuchi T, et al. **Immunobiology** 1995 Jun; 193(1):84-97

Role of newly synthesized MHC class II molecules in antigen-specific antigen presentation by B cells. Kokuho T, et al. **Immunobiology** 1995 Jun;193(1):42-58

Alloreactive cytotoxic T-lymphocyte-defined HLA-B7

subtypes differ in peptide antigen presentation. Smith KD, et al. **Immunogenetics** 1996;43(1-2):27-37

The immune response to cytochrome c in BALB/c mice is delayed due to inability of their non-specific antigen-presenting cells to provide its immunodominant epitope. Skok MV, et al. **Immunol Lett** 1995 Jul-Aug; 47(1-2):87-92

Single-cell observation of calcium signals in T cells and antigen-presenting cells during antigen presentation. Torigoe C, et al. **Immunol Lett** 1995 May;46(1-2):75-9

Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation. Ehrlich R. **Immunol Res** 1995;14(2):77-97 (165 ref.)

Antigen-presenting function of the TL antigen and mouse CD1 molecules. Cheroutre H, et al. **Immunol Rev** 1995 Oct;147:31-52 (73 ref.)

Synthesis and assembly of MHC-peptide complexes. Benham A, et al. **Immunol Today** 1995 Jul;16(7):359-62 (20 ref.)

Issues concerning the nature of antigen recognition by alpha beta and gamma delta T-cell receptors. Davis MM, et al. **Immunol Today** 1995 Jul;16(7):316-8 (21 ref.)

Consequences of IgE/CD23-mediated antigen presentation in allergy. Mudde GC, et al. **Immunol Today** 1995 Aug; 16(8):380-3 (41 ref.)

Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Sakihama T, et al. **Immunol Today** 1995 Dec;16(12):581-7 (43 ref.)

Cultured human Langerhans' cells are superior to fresh cells at presenting native HIV-1 protein antigens to specific CD4+ T-cell lines. Girolomoni G, et al. **Immunology** 1996 Feb;87(2):310-6

Interferon-gamma differentially regulates antigen-processing functions in distinct endocytic compartments of macrophages with constitutive expression of class II major histocompatibility complex molecules. Hockett RD, et al. **Immunology** 1996 May;88(1):68-75

Cell-invasive activity of epitope-tagged adenylate cyclase of Bordetella pertussis allows in vitro presentation of a foreign epitope to CD8+ cytotoxic T cells. Sebo P, et al. **Infect Immun** 1995 Oct;63(10):3851-7

Peptide epitopes from noncytosolic Listeria monocytogenes can be presented by major histocompatibility complex class I molecules. Zwickey HL, et al. **Infect Immun** 1996 May; 64(5):1870-2

Antigen presentation--recent developments. Rammensee HG. **Int Arch Allergy Immunol** 1996 Aug;110(4):299-307 (63 ref.)

Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules. Bangia N, et al. **Int Immunol** 1995 Oct;7(10):1585-91

A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide. Barouch D, et al. **Int Immunol** 1995 Oct;7(10):1599-605

Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro. Gagliardi MC, et al. **Int Immunol** 1995 Nov;7(11):1741-52

H2-M3wt-restricted, Listeria monocytogenes-specific CD8 T cells recognize a novel, hydrophobic, protease-resistant, periodate-sensitive antigen. Nataraj C, et al. **Int Immunol** 1996 Mar;8(3):367-78

Interactions among polymorphic and conserved residues in MHC class II proteins affect MHC-peptide conformation and T cell recognition. Tate KM, et al. **Int Immunol** 1995 May;7(5):747-61

Isolation of a human allo-peptide presented by HLA-B51 molecules. Tomiyama H, et al. **Int Immunol** 1995 Jun; 7(6):905-9

On the issue of inappropriate HLA class II expression on endocrine cells: an answer to a sceptic. Todd I, et al. **J Autoimmun** 1995 Jun;8(3):313-22 (48 ref.)

Antigen presentation in the pathogenesis of autoimmune endocrine disease. Weetman AP. **J Autoimmun** 1995 Jun; 8(3):305-12 (38 ref.)

MHC class II presentation of human acetylcholine receptor in Myasthenia gravis: binding of synthetic gamma subunit sequences to DR molecules. Yuen MH, et al. **J Autoimmun** 1996 Feb;9(1):67-77

Isoforms of the invariant chain regulate transport of MHC class II molecules to antigen processing compartments. Warmerdam PA, et al. **J Cell Biol** 1996 Apr;133(2):281-91

Intracellular location of cysteine transport activity correlates with productive processing of antigen disulfide. Gainey D, et al. **J Cell Physiol** 1996 Aug;168(2):248-54

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity [see comments] Celluzzi CM, et al. **J Exp Med** 1996 Jan 1;183(1):283-7. Comment in: J Exp Med 1996 Jan 1;183(1):7-11.

The presentation of a hepatitis C viral peptide by distinct major histocompatibility complex class I allotypes from two chimpanzee species. Cooper S, et al. **J Exp Med** 1996 Feb 1;183(2):663-8

Successful T cell priming in B cell-deficient mice. Epstein MM, et al. **J Exp Med** 1995 Oct 1;182(4):915-22

Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus. Fedoseyeva EV, et al. **J Exp Med** 1995 Nov 1;182(5):1481-91

Strictly transporter of antigen presentation (TAP)-dependent presentation of an immunodominant cytotoxic T lymphocyte epitope in the signal sequence of a virus protein. Hombach J, et al. **J Exp Med** 1995 Nov 1; 182(5):1615-9

Patr-A and B, the orthologues of HLA-A and B, present hepatitis C virus epitopes to CD8+ cytotoxic T cells from two chronically infected chimpanzees. Kowalski H, et al. **J Exp Med** 1996 Apr 1;183(4):1761-75

The extracellular domain of CD45 controls association with the CD4-T cell receptor complex and the response to antigen-specific stimulation. Leitenberg D, et al. **J Exp Med** 1996 Jan 1;183(1):249-59

Major histocompatibility complex class II-expressing endothelial cells induce allospecific nonresponsiveness in naive T cells. Marelli-Berg FM, et al. **J Exp Med** 1996 Apr 1;183(4):1603-12

T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates. Morkowski S, et al. **J Exp Med** 1995 Nov 1;182(5):1403-13

CD4+ T cell activation and tolerance induction in B cell knockout mice. Phillips JA, et al. **J Exp Med** 1996 Apr 1;183(4):1339-44

LMP-associated proteolytic activities and TAP-dependent peptide transport for class I MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. Rotem-Yehudar R, et al. **J Exp Med** 1996 Feb 1;183(2):499-514

Endogenous altered peptide ligands can affect peripheral T cell responses. Vidal K, et al. **J Exp Med** 1996 Apr 1; 183(4):1311-21

Vaccinia virus serpins B13R and B22R do not inhibit antigen presentation to class I-restricted cytotoxic T lymphocytes. Blake NW, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2393-8

Immunogenicity of poliovirus B and T cell epitopes presented by hybrid porcine parvovirus particles. Sedlik C, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2361-8

Role of antibody and indirect antigen presentation in transplant-associated coronary artery vasculopathy. Rose ML. **J Heart Lung Transplant** 1996 Apr;15(4):342-9 (75 ref.)

Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo. Böhm W, et al. **J Immunol** 1995 Oct 1;155(7):3313-21

The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. Carrasco-Marin E, et al. **J Immunol** 1996 Jan 15;156(2):450-8

Class I-restricted presentation of an HIV-1 gp41 epitope containing an N-linked glycosylation site. Implications for the mechanism of processing of viral envelope proteins. Ferris RL, et al. **J Immunol** 1996 Jan 15;156(2):834-40

Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. Finkelman FD, et al. **J Immunol** 1996 Aug 15;157(4):1406-14

The presentation of class I and class II epitopes of listeriolysin O is regulated by intracellular localization and by intercellular spread of Listeria monocytogenes. Hiltbold EM, et al. **J Immunol** 1996 Aug 1;157(3):1163-75

Antigen presentation by T cells inhibits IL-2 production and induces IL-4 release due to altered cognate signals. Lombardi G, et al. **J Immunol** 1996 Apr 15;156(8):2769-75

Identification of a contact region for peptide on the TAP1 chain of the transporter associated with antigen processing. Nijenhuis M, et al. **J Immunol** 1996 Mar 15;156(6):2186-95

Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages. Prina E, et al. **J Immunol** 1996 Jun 1;156(11):4318-27

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. Rivoltini L, et al. **J Immunol** 1996 May 15;156(10):3882-91

Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. Rock KL, et al. **J Immunol** 1996 May 15;156(10):3721-6

Processing of exogenous heat-aggregated (denatured) and particulate (native) hepatitis B surface antigen for class I-restricted epitope presentation. Schirmbeck R, et al. **J Immunol** 1995 Nov 15;155(10):4676-84

Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. Shastri N, et al. **J Immunol** 1995 Nov 1; 155(9):4339-46

Relationship between beta cell injury and antigen presentation in NOD mice. Shimizu J, et al. **J Immunol** 1995 Oct 15;155(8):4095-9

Two Listeria monocytogenes CTL epitopes are processed from the same antigen with different efficiencies. Sijts AJ, et al. **J Immunol** 1996 Jan 15;156(2):683-92

Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. Song R, et al. **J Immunol** 1996 Jun 1;156(11):4182-90

Analysis of MHC class II presentation of particulate antigens of B lymphocytes. Vidard L, et al. **J Immunol** 1996 Apr 15;156(8):2809-18

Listeriolysin is processed efficiently into an MHC class I-associated epitope in Listeria monocytogenes-infected cells. Villanueva MS, et al. **J Immunol** 1995 Dec 1; 155(11):5227-33

Selection and binding of peptides to human transporters associated with antigen processing and rat cim-a and -b. Wang P, et al. **J Immunol** 1996 Jul 1;157(1):213-20

MHC class I-dependent presentation of exoerythrocytic antigens to CD8+ T lymphocytes is required for protective immunity against Plasmodium berghei. White KL, et al. **J Immunol** 1996 May 1;156(9):3374-81

Characteristics of ATP-dependent peptide transport in isolated microsomes. Yang B, et al. **J Immunol** 1995 Oct 15;155(8):3889-96

Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide. Zechel MA, et al. **J Immunol** 1996 Jun 1;156(11):4232-9

Influence of antigen presentation and exogenous cytokine activity during in vitro primary immunizations employed for the generation of monoclonal antibodies. Halabi G, et al. **J Immunol Methods** 1995 Oct 26;186(2):205-16

Differential regulation of Ia expression and antigen presentation by listeriolysin-producing versus non-producing strains of Listeria monocytogenes. Vazquez MA, et al. **J Leukoc Biol** 1996 May;59(5):683-90

The 1995 Albert Lasker Medical Research Award. The concept of antigen processing and presentation. Unanue ER. **JAMA** 1995 Oct 4;274(13):1071-3

Intact antigen presentation for Epstein-Barr virus (EBV)-specific CTL by a lymphoblastoid cell line established from a patient with severe chronic active EBV infection. Kimura H, et al. **Med Microbiol Immunol (Berl)** 1995 Aug;184(2):63-8

Processing of DR1-restricted determinants from the fusion protein of measles virus following two distinct pathways. Demotz S, et al. **Mol Immunol** 1996 Mar-Apr; 33(4-5):387-97

Fine chemical modifications at N- and C-termini enhance peptide presentation to T cells by increasing the lifespan of both free and MHC-complexed peptides. Maillère B, et al. **Mol Immunol** 1995 Dec;32(17-18):1377-85

Immune responses to self peptides naturally presented by murine class II major histocompatibility complex molecules. Rider BJ, et al. **Mol Immunol** 1996 May-Jun; 33(7-8):625-33

The phoP locus influences processing and presentation of Salmonella typhimurium antigens by activated macrophages. Wick MJ, et al. **Mol Microbiol** 1995 May; 16(3):465-76

Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Falo LD Jr, et al. **Nat Med** 1995 Jul;1(7):649-53

Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells. Pulaski BA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3669-74

Biosynthesis of major histocompatibility complex molecules and generation of T cells in Ii TAP1 double-mutant mice. Tourne S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20; 93(4):1464-9

Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Wucherpfennig KW, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11935-9

Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes. Wucherpfennig KW, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8896-900

Functional differences in the specific B-cell compartment in high or low antibody responder mice. de Franco M, et al. **Scand J Immunol** 1996 Aug;44(2):129-34

Antigen presentation and T cell development in H2-M-deficient mice. Fung-Leung WP, et al. **Science** 1996 Mar 1;271(5253):1278-81

Population biology of antigen presentation by MHC class I molecules [see comments] Parham P, et al. **Science** 1996 Apr 5;272(5258):67-74 (71 ref.). Comment in: Science 1996 Aug 9;273(5276):723-5.

High frequency of alloreactive T cells is a consequence of the presentation of many peptides by allogeneic MHC molecules. Salom R, et al. **Transplant Proc** 1995 Dec; 27(6):3579

Restricted TCR V beta repertoire in the human mixed lymphocyte reaction is determined by the TCR on the responder cell and not by the stimulating antigen on the stimulator cell. Barth C, et al. **Transplantation** 1996 Jan 15;61(1):133-9

CNS antigen presentation. Hart MN, et al. **Trends Neurosci** 1995 Nov;18(11):475-81 (56 ref.)

Presentation of soluble and bacterial antigens by milk-derived cells to unprimed bovine T cells in vitro. Fitzpatrick JL, et al. **Vet Immunol Immunopathol** 1995 Jun;46(3-4):251-66

DRUG EFFECTS

TNF alpha interrupts antigen-presenting function of Langerhans cells by two mechanisms: loss of immunogenic peptides and impairment of antigen-independent T cell clustering. Koch F, et al. **Adv Exp Med Biol** 1995;378:207-9

Inhibitory effect of IL-10 on human Langerhans cell antigen presenting function. Péguet-Navarro J, et al. **Adv Exp Med Biol** 1995;378:359-61

Dendritic cells migrating from carcinogen-treated skin have reduced antigen-presenting function. Ragg SJ, et al.

Adv Exp Med Biol 1995;378:237–41
Presentation of antigen by B cell subsets. V. Effect of interleukin 7 (IL-7) and interleukin 10 (IL-10) on phenotype and antigen presenting function of immature B cells. Zimecki M, et al.
Arch Immunol Ther Exp (Warsz) 1995;43(5–6):253–7
Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Gribben JG, et al. **Blood** 1996 Jun 1; 87(11):4887–93
Listeriolysin generates a route for the presentation of exogenous antigens by major histocompatibility complex class I. Darji A, et al. **Eur J Immunol** 1995 Oct; 25(10):2967–71
CD40–CD40 ligand interactions stimulate B cell antigen processing. Faassen AE, et al. **Eur J Immunol** 1995 Dec; 25(12):3249–55
Different cytokines regulate antigen uptake and presentation of a precursor dendritic cell line. Lutz MB, et al.
Eur J Immunol 1996 Mar;26(3):586–94
Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Moser M, et al. **Eur J Immunol** 1995 Oct;25(10):2818–24
Interferon-gamma and interleukin-10 inhibit antigen presentation by Langerhans cells for T helper type 1 cells by suppressing their CD80 (B7-1) expression. Ozawa H, et al. **Eur J Immunol** 1996 Mar;26(3):648–52
Distinct effects of recombinant cholera toxin B subunit and holotoxin on different stages of class II MHC antigen processing and presentation by macrophages. Matousek MP, et al. **J Immunol** 1996 Jun 1;156(11):4137–45
Sex hormone and IL-6 regulation of antigen presentation in the female reproductive tract mucosal tissues. Prabhala RH, et al. **J Immunol** 1995 Dec 15;155(12):5566–73
Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction. Fisk B, et al. **J Immunother Emphasis Tumor Immunol** 1995 Nov; 18(4):197–209
Alpha-melanocyte-stimulating hormone suppresses antigen-stimulated T cell production of gamma-interferon. Taylor AW, et al. **Neuroimmunomodulation** 1994 May–Jun; 1(3):188–94
Calcitonin gene-related peptide modulates Langerhans cell antigen-presenting function. Asahina A, et al.
Proc Assoc Am Physicians 1995 Jul;107(2):242–4 (18 ref.)
Augmented antigen presentation by mouse Ia + T clone cells BK-BI-2.6.O4.1 mediated by transferrin receptors. Tschoetschel U, et al. **Scand J Immunol** 1996 May; 43(5):500–6
Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody. Galili U, et al. **Vaccine** 1996 Mar;14(4):321–8

GENETICS

The CD1 family: a third lineage of antigen-presenting molecules. Porcelli SA. **Adv Immunol** 1995;59:1–98 (179 ref.)
Antigen presentation by class I major histocompatibility complex molecules: a context for thinking about HLA-G. Parham P. **Am J Reprod Immunol** 1995 Jul;34(1):10–9 (48 ref.)
Regulation of the immune response—lessons from transgenic models. Fazekas de St Groth B. **Aust N Z J Med** 1995 Dec;25(6):761–7
A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity. Armandola EA, et al. **Eur J Immunol** 1996 Aug; 26(8):1748–55
A point mutation in HLA-A*0201 results in failure to bind the TAP complex and to present virus-derived peptides to CTL. Peace-Brewer AL, et al. **Immunity** 1996 May; 4(5):505–14
Transgenic mice expressing MHC class II molecules with truncated A beta cytoplasmic domains reveal signaling-independent defects in antigen presentation. Smiley ST, et al. **Int Immunol** 1995 Apr;7(4):665–77
Sequence analysis and antigen binding characteristics of Ig SCID Ig+ mice. Young D, et al. **Int Immunol** 1995 May; 7(5):807–19
Persistence of V beta 6+ T cells in Mls-1a mice. A role for the third complementarity-determining region (CDR3) of the T cell receptor beta chain in superantigen recognition. Chies JA, et al. **J Immunol** 1995 Nov 1; 155(9):4171–8
Isolation of low molecular mass polypeptide complementary DNA clones from primitive vertebrates. Implications for the origin of MHC class I-restricted antigen presentation. Kandil E, et al. **J Immunol** 1996 Jun 1;156(11):4245–53
The COI mitochondrial gene encodes a minor histocompatibility antigen presented by H2-M3. Morse MC, et al. **J Immunol** 1996 May 1;156(9):3301–7
Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. Neisig A, et al. **J Immunol** 1996 May 1; 156(9):3196–206
Peptide-dependent expression of HLA-B7 on antigen processing-deficient T2 cells. Smith KD, et al.
J Immunol 1996 May 15;156(10):3755–64
A phage display system for detection of T cell receptor-antigen interactions. Onda T, et al.
Mol Immunol 1995 Dec;32(17–18):1387–97
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Wu TC, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5; 92(25):11671–5
Myxoma virus as a vaccine vector for rabbits: antibody levels to influenza virus haemagglutinin presented by a recombinant myxoma virus. Kerr PJ, et al. **Vaccine** 1995 Dec;13(17):1722–6

IMMUNOLOGY

B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines. Iezzi G, et al. **Cancer Res** 1996 Jan 1;56(1):11–5
H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Martin WD, et al. **Cell** 1996 Feb 23; 84(4):543–50
Antigen-presenting cells. Professionals and amateurs. Sprent J. **Curr Biol** 1995 Oct 1;5(10):1095–7 (18 ref.)
Absorption and presentation of antigens by epithelial cells of the small intestine: hypotheses and predictions relating to the pathogenesis of coeliac disease. Mayrhofer G.
Immunol Cell Biol 1995 Oct;73(5):433–9 (63 ref.)
Regulation and targeting of T-cell immune responses by IgE and IgG antibodies. Bheekha Escura R, et al.
Immunology 1995 Nov;86(3):343–50
Effects of antigen presentation on superantigen-induced apoptosis mediated by Fas/Fas ligand interactions in human T cells. Boshell M, et al. **Immunology** 1996 Apr; 87(4):586–92
Major histocompatibility complex class I presentation of exogenous and endogenous protein-derived peptides by a transfected human monocyte cell line. Harris PE, et al. **Immunology** 1995 Dec;86(4):606–11
Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway. Martinez-Kinader B, et al. **Immunology** 1995 Oct;86(2):287–95
Defective 'gut processing' of gliadin in mice with graft-versus-host enteropathy. Troncone R, et al.
Int Arch Allergy Immunol 1996 Jan;109(1):44–9
Class I MHC presentation of exogenous antigens. Harding CV. **J Clin Immunol** 1996 Mar;16(2):90–6 (50 ref.)
The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen. Yang B, et al.
J Exp Med 1996 Apr 1;183(4):1545–52
Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells. Hengel H, et al.
J Gen Virol 1995 Dec;76 (Pt 12):2987–97
Alloantigen processing and presentation. Tambur AR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 1):1031–7 (49 ref.)
Human dendritic Langerhans cells generated in vitro from CD34+ progenitors can prime naive CD4+ T cells and process soluble antigen. Caux C, et al. **J Immunol** 1995 Dec 1;155(11):5427–35
Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. Grant EP, et al. **J Immunol** 1995 Oct 15;155(8):3750–8
Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles.
Kirschmann DA, et al. **J Immunol** 1995 Dec 15; 155(12):5655–62
Mouse microglial cell lines differing in constitutive and interferon-gamma-inducible antigen-presenting activities for naive and memory CD4+ and CD8+ T cells. Walker WS, et al. **J Neuroimmunol** 1995 Dec 31;63(2):163–74
Requirement of CD80 and CD86 molecules for antigen presentation by eosinophils. Tamura N, et al.
Scand J Immunol 1996 Sep;44(3):229–38
Trauma-induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes [editorial] Ayala A, et al. **Shock** 1996 Feb;5(2):79–90 (140 ref.)
A new epitope presenting system displays a HIV-1 V3 loop sequence and induces neutralizing antibodies. Scodeller EA, et al. **Vaccine** 1995 Sep;13(13):1233–9
[Expression of HLA molecules on the surface of hepatocytes and antigen presentation] Manabe K, et al.
Nippon Rinsho 1995 Oct;53 Suppl:166–72 (20 ref.) **(Jpn)**
[HLA types and their ability to present the HBV peptides] Yokosuka O, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:173–9 **(Jpn)**

PHYSIOLOGY

Antigen processing by rat lymph-borne dendritic cells. Liu LM, et al. **Adv Exp Med Biol** 1995;378:215–7
Functional and ultrastructural aspects of antigen processing by dendritic cells. Ossevoort MA, et al.
Adv Exp Med Biol 1995;378:227–31 (24 ref.)
Processing and presentation of protein and parasite-derived antigens by 4F7+ dendritic cells. Pavlidou A, et al.
Adv Exp Med Biol 1995;378:233–5
Endogenous pathway of class II presentation. Aichinger G, et al. **Biochem Soc Trans** 1995 Aug;23(3):657–60 (48 ref.)
Antigen processing by the class I pathway. Benham AM, et al. **Biochem Soc Trans** 1995 Aug;23(3):664–9 (45 ref.)
Presentation of N-formylated peptides by H2-M3. Lindahl KF, et al. **Biochem Soc Trans** 1995 Aug;23(3):669–74 (34 ref.)
A role for microfilaments but not microtubules in processing soluble antigens. Soreng KM, et al. **Cell Immunol** 1995 Nov; 166(1):25–34
Impaired protein catabolism in Trypanosoma cruzi-infected macrophages: possible involvement in antigen presentation. Plasman N, et al. **Immunology** 1995 Dec;86(4):636–45
Alloantigen presentation by B cells: analysis of the requirement for B-cell activation. Wilson JL, et al.
Immunology 1995 Nov;86(3):325–30
The immune response and the eye. TCR alpha-chain related molecules regulate the systemic immunity to antigen presented in the eye. Griffith TS, et al. **Int Immunol** 1995 Oct;7(10):1617–25
Modelling thymic functions in a cellular automaton. Morpurgo D, et al. **Int Immunol** 1995 Apr;7(4):505–16
Anergy-associated T cell antigen presentation. A mechanism of infectious tolerance in experimental autoimmune encephalomyelitis. Mannie MD, et al. **J Immunol** 1996 Aug 1;157(3):1062–70
pH dependence of MHC class I-restricted peptide presentation. Stryhn A, et al. **J Immunol** 1996 Jun 1; 156(11):4191–7
Proteasome and class I antigen processing and presentation. Belich MP, et al. **Mol Biol Rep** 1995;21(1):53–6 (39 ref.)
A role for the proteasome regulator PA28alpha in antigen presentation. Groettrup M, et al. **Nature** 1996 May 9; 381(6578):166–8

RADIATION EFFECTS

Inhibitory effects of ultraviolet B on human Langerhans cell antigen presenting function. Rattis FM, et al.
Adv Exp Med Biol 1995;378:243–5
Low-dose UVB radiation perturbs the functional expression of B7.1 and B7.2 co-stimulatory molecules on human Langerhans cells. Weiss JM, et al. **Eur J Immunol** 1995 Oct;25(10):2858–62
A radiosensitive APC activity dissociates IL-2 secretion and activation-induced cell death by autoreactive T cell hybridomas. Prasad SA, et al. **Int Immunol** 1995 Nov; 7(11):1787–98

ANTIGEN-PRESENTING CELLS

see related
ANTIGEN PRESENTATION
HISTOCOMPATIBILITY ANTIGENS CLASS II
LYMPHOCYTE TRANSFORMATION

Antigen-presenting cell engineering. The molecular toolbox. Tykocinski ML, et al. **Am J Pathol** 1996 Jan;148(1):1–16 (180 ref.)

CHEMISTRY

Characterization of a novel co-stimulatory molecule: a 155–160kD B cell surface protein provides accessory help to CD4+ T cells to proliferate and differentiate. Vinay DS, et al. **Mol Immunol** 1996 Jan;33(1):1–14

CYTOLOGY

Establishment and characterization of antigen-presenting cell lines (XS series) derived from newborn mouse epidermis. Takashima A, et al. **Adv Exp Med Biol** 1995;378:159–62
Immunohistochemical characterization and localization of MHC class II antigen-presenting cells in the periodontal ligament of rat incisors. Kawahara I, et al.
Connect Tissue Res 1995;33(1–3):47–56

DRUG EFFECTS

Evaluation of cross-sensitization among dye-intermediate agents using a modified lymphocyte transformation test. Li Q, et al. **Arch Toxicol** 1996;70(7):414–9
Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Disis ML, et al. **Blood** 1996 Jul 1;88(1):202–10
Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Zissel G, et al. **Cancer Immunol Immunother** 1996 Feb; 42(2):122–6
In vitro activation of antigen-presenting cells (APC) by defined composition of Quillaja saponaria Molina triterpenoids. Behboudi S, et al. **Clin Exp Immunol** 1996 Jul;105(1):26–30
Effects of cyclosporin A on some accessory cells of rat thymus. Rezzani R, et al. **Int J Exp Pathol** 1995 Aug; 76(4):247–54
A tumor-derived protein which provides T-cell costimulation through accessory cell activation. Powell TJ, et al. **J Immunother Emphasis Tumor Immunol** 1995 May; 17(4):209–21
Staphylococcal enterotoxin B upregulates expression of ICAM-1 molecules on IFN-gamma-treated keratinocytes and keratinocyte cell lines. Wakita H, et al.
J Invest Dermatol 1995 Oct;105(4):536–42

ENZYMOLOGY

T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility

complex class II-bound peptides. Larsen SL, et al. **J Exp Med** 1996 Jul 1;184(1):183-9

IMMUNOLOGY

Regulation of the humoral response by the antigen-presenting cells in vivo. De Becker G, et al. **Adv Exp Med Biol** 1995;378:183-5

T-lymphocyte proliferation stimulated by alpha beta TCR/CD2 bispecific antibody is dependent on LFA-1/ICAM-1 recognition of accessory cells. Di Mauro ME, et al. **Adv Exp Med Biol** 1995;378:381-3

Mixed epidermal cell lymphocyte reaction: HLA-DR+ cells exhibit a greater immunostimulatory activity than CD1a+ cells. Dobmeyer TS, et al. **Adv Exp Med Biol** 1995; 378:393-6

Spleen accessory cell antigen processing and in vitro induction of specific lymphocyte proliferation in BALB/c mice infested with nymphal Ixodes ricinus ticks. Ganapamo F, et al. **Adv Exp Med Biol** 1995;378:195-7

Pilot study of oral tolerance to keyhole limpet hemocyanin in humans: down-regulation of KLH-reactive precursor-cell frequency. Matsui M, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:398-404

Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis. Thomas R, et al. **Arthritis Rheum** 1996 Feb;39(2):183-90 (85 ref.)

Receptor-linked antigen delivery system. Importance of autologous alpha 2-macroglobulin in the development of peptide vaccine. Mitsuda S, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):399-405

Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Cardoso AA, et al. **Blood** 1996 Jul 1;88(1):41-8

Role of antigen presenting cells in rheumatoid arthritis. Viner NJ. **Br Med Bull** 1995 Apr;51(2):359-67 (40 ref.)

Cells involved in the regulation of the autoimmune response to rat male accessory glands. Rivero VE, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2579-89

Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Zissel G, et al. **Cancer Immunol Immunother** 1996 Feb; 42(2):122-6

A subset of splenic macrophages process and present native antigen to naive antigen-specific CD4+ T-cells from mice transgenic for an alpha beta T-cell receptor. Askew D, et al. **Cell Immunol** 1995 Nov;166(1):62-70

Macrophage presentation of endogenous self-protein: the MHC class II presentation pathway is not accessible to intracellular C5 or alpha 1-antitrypsin. Grant CF, et al. **Cell Immunol** 1996 Feb 1;167(2):230-40

Fc gamma RII on human B cells can mediate enhanced antigen presentation. Liu C, et al. **Cell Immunol** 1996 Feb 1;167(2):188-94

The two faces of interleukin 12: a pro-inflammatory cytokine and a key immunoregulatory molecule produced by antigen-presenting cells. Trinchieri G. **Ciba Found Symp** 1995;195:203-14; discussion 214-20 (59 ref.)

Use of fixed autologous stimulator cells to correctly present human immunodeficiency virus type 1 viral peptides to nonhuman primate lymphocytes in proliferation and cytotoxic T-lymphocyte assays. Munroe KJ, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):283-9

Epstein-Barr virus-transformed B cells, a potentially convenient source of autologous antigen-presenting cells for the propagation of certain human cytotoxic T lymphocytes. Purner MB, et al. **Clin Diagn Lab Immunol** 1994 Nov;1(6):696-700

In vitro activation of antigen-presenting cells (APC) by defined composition of Quillaja saponaria Molina triterpenoids. Behboudi S, et al. **Clin Exp Immunol** 1996 Jul;105(1):26-30

Human natural killer (NK) cells present staphylococcal enterotoxin B (SEB) to T lymphocytes. D'Orazio JA, et al. **Clin Exp Immunol** 1996 May;104(2):366-73

Antigen-presenting cells. Professionals and amateurs. Sprent J. **Curr Biol** 1995 Oct 1;5(10):1095-7 (18 ref.)

Antigen-specific B cells are required for the secondary response of T cells but not for their priming. Chowdhury MG, et al. **Eur J Immunol** 1996 Jul;26(7):1628-33

Generation of antigen-presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients. Fisch P, et al. **Eur J Immunol** 1996 Mar;26(3):595-600

Negative feedback mechanism suppresses interleukin-12 production by antigen-presenting cells interacting with T helper 2 cells. Hino A, et al. **Eur J Immunol** 1996 Mar; 26(3):623-8

Bacterial superantigens induce T cell unresponsiveness in B cell-deficient mice. Miethke T, et al. **Eur J Immunol** 1995 Nov;25(11):3187-90

Cell type-specific processing of the I-Ed-restricted hen egg lysozyme determinant 107-116. Robadey C, et al. **Eur J Immunol** 1996 Jul;26(7):1656-9

Down-regulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragments. Vidović D, et al. **Eur J Immunol** 1995 Dec; 25(12):3349-55

The mechanisms of corneal graft failure in the rat. Katami M. **Eye** 1995;9 (Pt 2):197-207 (38 ref.)

I-J revisited: is the I-J genetic restriction in downregulation due to an endogenous superantigen analogous to mammary tumour virus (Mtv)-encoded endogenous superantigen? Asherson GL, et al. **Folia Biol (Praha)** 1994;40(6):341-7

Presentation of antigen and MHC-restricted unresponsiveness. Říhová B. **Folia Biol (Praha)** 1995; 41(3-4):140-62 (28 ref.)

Antigen-presenting function and B7 expression of murine sinusoidal endothelial cells and Kupffer cells. Lohse AW, et al. **Gastroenterology** 1996 Apr;110(4):1175-81

Dual function of Drosophila cells as APCs for naive CD8+ T cells: implications for tumor immunotherapy. Sun S, et al. **Immunity** 1996 Jun;4(6):555-64

Deficiency in T cell responses of human fetal lymph node cells: a lack of accessory cells. von Hoegen P, et al. **Immunol Cell Biol** 1995 Aug;73(4):353-61

Monocyte-mediated regulation of antigen-driven IFN gamma production by T cells. The role of endogenously produced TNF. Mytar B, et al. **Immunol Invest** 1995 Nov; 24(6):897-906

Lectin-activated CD4+CD45RA+ T-lymphocytes have no ability to kill monocytes. Pryjma J, et al. **Immunol Invest** 1996 Jan-Mar;25(1-2):1-11

The immune response to cytochrome c in BALB/c mice is delayed due to inability of their non-specific antigen-presenting cells to provide its immunodominant epitope. Skok MV, et al. **Immunol Lett** 1995 Jul-Aug; 47(1-2):87-92

Induction of T-cell hyporesponsiveness by intrahepatic modulation of donor antigen-presenting cells. Chung SW, et al. **Immunology** 1995 Aug;85(4):582-90

Synovial fibroblasts as accessory cells for staphylococcal enterotoxin-mediated T-cell activation. Kraft M, et al. **Immunology** 1995 Jul;85(3):461-6

Role of F4/80+ cells during induction of hapten-specific contact hypersensitivity. Kurimoto I, et al. **Immunology** 1995 Aug;85(4):621-9

Functional activation of encephalitogenic T cells in the absence of antigen-presenting cells. Reizis B, et al. **Int Immunol** 1995 Aug;7(8):1375-9

An MHC class II-expressing T cell clone presenting conventional antigen lacks the ability to present bacterial superantigen. Sun D, et al. **Int Immunol** 1995 Jul; 7(7):1079-85

Immunocytochemical study of the ontogeny of the marsupial Didelphis albiventris immune system. Coutinho HB, et al. **J Anat** 1995 Aug;187 (Pt 1):37-46

Conformation of human leukocyte antigen class II molecules. Evidence for superdimers and empty molecules on human antigen presenting cells. Roucard C, et al. **J Biol Chem** 1996 Jun 14;271(24):13993-4000

Class I MHC presentation of exogenous antigens. Harding CV. **J Clin Immunol** 1996 Mar;16(2):90-6 (50 ref.)

Antigen targeting to myeloid-specific human Fc gamma R1/CD64 triggers enhanced antibody responses in transgenic mice. Heijnen IA, et al. **J Clin Invest** 1996 Jan 15;97(2):331-8

Early biochemical signals arise from low affinity TCR-ligand reactions at the cell-cell interface. Beeson C, et al. **J Exp Med** 1996 Aug 1;184(2):777-82

A pathway of costimulation that prevents anergy in CD28- T cells: B7-independent costimulation of CD1-restricted T cells. Behar SM, et al. **J Exp Med** 1995 Dec 1; 182(6):2007-18

Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. Bender A, et al. **J Exp Med** 1995 Dec 1;182(6):1663-71

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. Cella M, et al. **J Exp Med** 1996 Aug 1;184(2):747-52

Myocarditis-inducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart. Donermeyer DL, et al. **J Exp Med** 1995 Nov 1; 182(5):1291-300

T cell receptor (TCR) recognition of MHC class I variants: intermolecular second-site reversion provides evidence for peptide/MHC conformational variation. Dyall R, et al. **J Exp Med** 1996 Jul 1;184(1):253-8

Successful T cell priming in B cell-deficient mice. Epstein MM, et al. **J Exp Med** 1995 Oct 1;182(4):915-22

Dendritic cells but not B cells present antigenic complexes to class II-restricted T cells after administration of protein in adjuvant. Guéry JC, et al. **J Exp Med** 1996 Mar 1; 183(3):751-7

A rare cryptic translation product is presented by Kb major histocompatibility complex class I molecule to alloreactive T cells. Malarkannan S, et al. **J Exp Med** 1995 Dec 1; 182(6):1739-50

A novel antigen-processing-defective phenotype in major histocompatibility complex class II-positive CIITA transfectants is corrected by interferon-gamma. Siegrist CA, et al. **J Exp Med** 1995 Dec 1;182(6):1793-9

B cells solicit their own help from T cells [see comments] Stockinger B, et al. **J Exp Med** 1996 Mar 1;183(3):891-9 . Comment in: J Hyg Epidemiol Microbiol Immunol 1996 Mar 1;183(3):717-9.

Localization of DNA damage and its role in altered antigen-presenting cell function in ultraviolet-irradiated mice. Vink AA, et al. **J Exp Med** 1996 Apr 1; 183(4):1491-500

B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. Constant S, et al. **J Immunol** 1995 Oct 15;155(8):3734-41

Activated B cells express CD28/B7-independent costimulatory activity. Ding L, et al. **J Immunol** 1996 Aug 15;157(4):1389-96

Quantitative thresholds of MHC class II I-E expressed on hemopoietically derived antigen-presenting cells in transgenic NOD/Lt mice determine level of diabetes resistance and indicate mechanism of protection. Hanson MS, et al. **J Immunol** 1996 Aug 1;157(3):1279-87

Antigen presentation by T cells inhibits IL-2 production and induces IL-4 release due to altered cognate signals. Lombardi G, et al. **J Immunol** 1996 Apr 15;156(8):2769-75

Relationship between beta cell injury and antigen presentation in NOD mice. Shimizu J, et al. **J Immunol** 1995 Oct 15;155(8):4095-9

Peptide-dependent expression of HLA-B7 on antigen processing-deficient T2 cells. Smith KD, et al. **J Immunol** 1996 May 15;156(10):3755-64

Analysis of MHC class II presentation of particulate antigens of B lymphocytes. Vidard L, et al. **J Immunol** 1996 Apr 15;156(8):2809-18

Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells. Jiang H, et al. **J Neuroimmunol** 1995 Aug;61(1):17-25

Antigen presentation by rat brain and retinal endothelial cells. Wang Y, et al. **J Neuroimmunol** 1995 Sep;61(2):231-9

Antigen binding differences between secreted and cell surface expressed rheumatoid factor derived from inflamed synovium. Kenny TP, et al. **J Rheumatol** 1996 May; 23(5):819-25

Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Chaux P, et al. **Lab Invest** 1996 May;74(5):975-83

Electroporation of antigen-presenting cells for T-cell recognition and cytotoxic T-lymphocyte priming. Chen W, et al. **Methods Mol Biol** 1995;48:73-81

Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Kay MA, et al. **Nat Genet** 1995 Oct;11(2):191-7

Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Doe B, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8578-83

Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells. Pulaski BA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3669-74

Antigen presentation and T cell development in H2-M-deficient mice. Fung-Leung WP, et al. **Science** 1996 Mar 1;271(5253):1278-81

Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Grewal IS, et al. **Science** 1996 Sep 27;273(5283):1864-7

HLA-DR expression on arachnoid cells. A role in the fibrotic inflammation surrounding nerve roots in spondylotic cervical myelopathy. Frank E. **Spine** 1995 Oct 1; 20(19):2093-6

Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts. Sundstrom JB, et al. **Transpl Immunol** 1995 Dec;3(4):273-89 (147 ref.)

Human T-cell activation is mediate predominantly by direct recognition of porcine SLA and involves accessory molecule interaction of ICAM1/LFA 1 and CD2/LFA3. Herrlinger KR, et al. **Transplant Proc** 1996 Apr;28(2):650

T-cell restriction patterns in pig bone marrow chimera. Nakajima K, et al. **Transplant Proc** 1996 Jun;28(3):1244-5

Presentation of soluble and bacterial antigens by milk-derived cells to unprimed bovine T cells in vitro. Fitzpatrick JL, et al. **Vet Immunol Immunopathol** 1995 Jun;46(3-4):251-66

METABOLISM

Producton of tumor necrosis factor and granulocyte colony stimulating factor by bone marrow accessory cells in myelodysplastic patients. Mencoboni M, et al. **Eur J Haematol** 1996 Mar;56(3):148-52

Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Creery WD, et al. **Eur J Immunol** 1996 Jun;26(6):1273-7

Negative feedback mechanism suppresses interleukin-12 production by antigen-presenting cells interacting with T helper 2 cells. Hino A, et al. **Eur J Immunol** 1996 Mar; 26(3):623-8

Single-cell observation of calcium signals in T cells and antigen-presenting cells during antigen presentation. Torigoe C, et al. **Immunol Lett** 1995 May;46(1-2):75-9

HLA-A2 subtypes are functionally distinct in peptide binding and presentation. Barouch D, et al. **J Exp Med** 1995 Dec 1;182(6):1847-56

The cleavage preference of the proteasome governs the yield of antigenic peptides. Eggers M, et al. **J Exp Med** 1995 Dec 1;182(6):1865-70

Accessory cell-derived IL-12 and prostaglandin E2 determine the IFN-gamma level of activated human CD4+ T cells. Hilkens CM, et al. **J Immunol** 1996 Mar 1;156(5):1722-27

Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. Malaviya R, et al. **J Immunol** 1996 Feb 15;156(4):1490-6

IL-12 produced by antigen-presenting cells induces

IL-2-independent proliferation of T helper cell clones. Maruo S, et al. **J Immunol** 1996 Mar 1;156(5):1748-55
Peptide-dependent expression of HLA-B7 on antigen processing-deficient T2 cells. Smith KD, et al. **J Immunol** 1996 May 15;156(10):3755-64

PATHOLOGY

Immunohistochemical analysis of proliferating and antigen-presenting cells in rheumatoid synovial tissue. Krenn V, et al. **Rheumatol Int** 1996;15(6):239-47

PHYSIOLOGY

Defective antigen-presenting cell function in patients with systemic lupus erythematosus. Tsokos GC, et al. **Arthritis Rheum** 1996 Apr;39(4):600-9
Calcium response of helper T lymphocytes to antigen-presenting cells in a single-cell assay. Agrawal NG, et al. **Biophys J** 1995 Sep;69(3):1178-90
Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-beta 1 and independent accessory cell-derived contact and soluble factors. Pierson BA, et al. **Blood** 1996 Jan 1;87(1):180-9
Signal extinction and T cell repolarization in T helper cell-antigen-presenting cell conjugates. Valitutti S, et al. **Eur J Immunol** 1996 Sep;26(9):2012-6
Antigen presentation in the murine oral epithelium. Eriksson K, et al. **Immunology** 1996 May;88(1):147-52
Activation of a myelin basic protein-specific human T cell clone by antigen-presenting cells from rhesus monkeys. Meinl E, et al. **Int Immunol** 1995 Sep;7(9):1489-95
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. Boczkowski D, et al. **J Exp Med** 1996 Aug 1;184(2):465-72
Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo. Nair SK, et al. **J Immunol** 1996 Mar 1;156(5):1772-80
Antigen-presenting cells for naive transgenic gamma delta T cells. Potent activation by activated alpha beta T cells. Spaner D, et al. **J Immunol** 1995 Oct 15;155(8):3866-76
Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. Blackstock R. **J Med Vet Mycol** 1996 Jan-Feb; 34(1):19-30
Patterns of lymphokine production by Semliki Forest virus-specific T-cell hybridomas stimulated with different antigen-presenting cells. Watari E, et al. **Jpn J Med Sci Biol** 1995 Jun;48(3):131-43
The antigen-presenting cell function of Reed-Sternberg cells. Delabie J, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):35-40 (55 ref.)
Truncation of the class II beta-chain cytoplasmic domain influences the level of class II/invariant chain-derived peptide complexes. Smiley ST, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):241-4
Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes. Toshitani K, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):236-40
Donor antigen-presenting cell-independent rejection of islet xenografts. Wolf LA, et al. **Transplantation** 1995 Nov 27; 60(10):1164-70

RADIATION EFFECTS

Decreased inducible expression of CD80 and CD86 in human monocytes after ultraviolet-B irradiation: its involvement in inactivation of allogenecity. Fujihara M, et al. **Blood** 1996 Mar 15;87(6):2386-93
Ultraviolet B-exposed major histocompatibility complex class ii positive keratinocytes and antigen-presenting cells demonstrate a differential capacity to activate T cells in the presence of staphylococcal superantigens. Skov L, et al. **Br J Dermatol** 1996 May;134(5):824-30
A radioesensitive APC activity dissociates IL-2 secretion and activation-induced cell death by autoreactive T cell hybridomas. Prasad SA, et al. **Int Immunol** 1995 Nov; 7(11):1787-98

VIROLOGY

Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation. Ehrlich R. **Immunol Res** 1995;14(2):77-97 (165 ref.)

ANTIGEN PROCESSING see **ANTIGEN PRESENTATION**

ANTIGEN, PROLIFERATING CELL NUCLEAR see **PROLIFERATING CELL NUCLEAR ANTIGEN**

ANTIGEN RECEPTORS see **RECEPTORS, ANTIGEN**

ANTIGEN RECEPTORS, B-CELL see **RECEPTORS, ANTIGEN, B-CELL**

ANTIGEN RECEPTORS, T-CELL see **RECEPTORS, ANTIGEN, T-CELL**

ANTIGEN RECEPTORS, T-CELL, ALPHA-BETA see **RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA**

ANTIGEN RECEPTORS, T-CELL, GAMMA-DELTA see **RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA**

ANTIGEN S 100 see **NERVE TISSUE PROTEIN S 100**

ANTIGEN SWITCHING see **ANTIGENIC VARIATION**

ANTIGENIC DETERMINANTS see **EPITOPES**

ANTIGENIC DETERMINANTS, IMMUNODOMINANT see **IMMUNODOMINANT EPITOPES**

ANTIGENIC MIMICRY see **MOLECULAR MIMICRY**

ANTIGENIC MODULATION

Peptide modulation of allergen-specific immune responses. Hoyne GF, et al. **Curr Opin Immunol** 1995 Dec;7(6):757-61 (41 ref.)

DRUG EFFECTS

Alteration of a model antigen by Au(III) leads to T cell sensitization to cryptic peptides. Griem P, et al. **Eur J Immunol** 1996 Feb;26(2):279-87

ANTIGENIC SPECIFICITY see **EPITOPES**

ANTIGENIC VARIATION

DNA fingerprint analysis of standard, intermediate, and variant antigenic types of Salmonella enterica subspecies enterica serovar Gallinarum biovar pullorum. Wilson MA, et al. **Avian Dis** 1995 Jul-Sep;39(3):594-8
Occurrence and antigenic heterogeneity of L-2,4-diaminobutyrate decarboxylase in Acinetobacter species. Yamamoto S, et al. **Biol Pharm Bull** 1995 Mar; 18(3):454-6
Alterations of T-cell receptor variable region expression in human immunodeficiency virus disease. McCoy JP Jr, et al. **Cytometry** 1995 Mar 15;22(1):1-9
HLA antigens in five Amerindian groups (Yuko, Bari, Tunebo, Guane and Paez) of Colombia: results of 'Expedición Humana'. Bernal JE, et al. **Hum Hered** 1995 Jul-Aug;45(4):186-91
HLA-DRB1 molecules and antigenic experience shape the repertoire of CD4 T cells. Walser-Kuntz DR, et al. **Hum Immunol** 1995 Dec;44(4):203-9
Molecular basis of size and antigenic variation of a Mycoplasma hominis adhesin encoded by divergent vaa genes. Zhang Q, et al. **Infect Immun** 1996 Jul;64(7):2737-44
Monoclonal antibodies to detect capsular diversity among Bacteroides fragilis isolates. Pantosti A, et al. **J Clin Microbiol** 1995 Oct;33(10):2647-52
Antigenic differences between a field isolate and vaccine strains of bovine viral diarrhea virus. Reddy JR, et al. **J Clin Microbiol** 1995 Aug;33(8):2159-61
Variant colony surface antigenic phenotypes within mycoplasma strain populations: implications for species identification and strain standardization. Rosengarten R, et al. **J Clin Microbiol** 1996 Jan;34(1):149-58
Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. Lukashov VV, et al. **J Virol** 1995 Nov;69(11):6911-6
Sequence identification of antigenic variants in plaque isolates of foot-and-mouth disease virus. Meyer RF, et al. **J Virol Methods** 1995 Oct;55(2):281-3
Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: implications for serological typing and vaccine design. Suker J, et al. **Microbiology** 1996 Jan;142 (Pt 1):63-9
Sequence variations in the non-repetitive regions of the liver stage-specific antigen-1 (LSA-1) of Plasmodium falciparum from field isolates. Yang C, et al. **Mol Biochem Parasitol** 1995 May;71(2):291-4
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection [see comments] Wolinsky SM, et al. **Science** 1996 Apr 26;272(5261):537-42 . Comment in: Science 1996 Apr 26;272(5261):505-6. Comment in: Science 1996 Jun 28;272(5270):1962.
In vivo variation of Mycoplasma gallisepticum antigen expression in experimentally infected chickens. Levisohn S, et al. **Vet Microbiol** 1995 Jul;45(2-3):219-31
Molecular basis of antigenic variation between the glycoproteins C of respiratory bovine herpesvirus 1 (BHV-1) and neurovirulent BHV-5. Chowdhury SI. **Virology** 1995 Nov 10;213(2):558-68
Antigenic variation of SIV: mutations in V4 alter the neutralization profile. Kinsey NE, et al. **Virology** 1996 Jul 1;221(1):14-21
[Genetic variation in the cleavage site of the precore region of hepatitis B virus in Chinese patients with fulminant hepatitis] Hou J, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Nov;34(11):735-8 (Eng. Abstr.) **(Chi)**
[Antigenic variation and the problem of vaccines against African trypanosomes] Pays E. **Bull Mem Acad R Med Belg** 1995;150(1-2):123-31; discussion 131-5 (Eng. Abstr.) **(Fre)**
[Measles virus proteins, their function and antigenic variability] Khaider AM. **Vopr Virusol** 1996 Mar-Apr; 41(2):72-4 **(Rus)**
[Mathematical model of the cyclic variability of the influenza virus] Kolesin ID. **Vopr Virusol** 1996 Jan-Feb;41(1):12-3 (Eng. Abstr.) **(Rus)**

GENETICS

Distribution of linear antigenic epitopes on GP120 encoded in sibling clones of novel New York HIV-1 subtype B isolates. Riley JP, et al. **Cell Mol Biol (Noisy-le-grand)** 1995;41 Suppl 1:S83-91
Variation in HLA-associated risks of childhood insulin-dependent diabetes in the Finnish population: II. Haplotype effects. DiMe Study Group. Childhood Diabetes in Finland. Thomas D, et al. **Genet Epidemiol** 1995; 12(5):455-66
Increased structural and combinatorial diversity in an extended family of genes encoding Vlp surface proteins of Mycoplasma hyorhinis. Yogev D, et al. **J Bacteriol** 1995 Oct;177(19):5636-43
Sequence divergence in a family of variant surface glycoprotein genes from trypanosomes: coding region hypervariability and downstream recombinogenic repeats. Field MC, et al. **J Mol Evol** 1996 May;42(5):500-11
The putative promoter for a metacyclic VSG gene in African trypanosomes. Nagoshi YL, et al. **Mol Biochem Parasitol** 1995 Jun;72(1-2):33-45
Selection of diversity at putative glycosylation sites in the immunodominant merozoite/piroplasm surface antigen of Theileria parasites. Shiels BR, et al. **Mol Biochem Parasitol** 1995 Jun;72(1-2):149-62
A multiple site-specific DNA-inversion model for the control of Omp1 phase and antigenic variation in Dichelobacter nodosus. Moses EK, et al. **Mol Microbiol** 1995 Jul;17(1):183-96
Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus [see comments] Donnelly JJ, et al. **Nat Med** 1995 Jun;1(6):583-7 . Comment in: Nat Med 1995 Jun;1(6):521-2.
Characterization of repetitive DNA in the Mycoplasma genitalium genome: possible role in the generation of antigenic variation. Peterson SN, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11829-33
A highly divergent antigenic site of foot-and-mouth disease virus retains its immunodominance. Borrego B, et al. **Viral Immunol** 1995;8(1):11-8
Large deletions in antigenic variants of the chlorella virus PBCV-1. Landstein D, et al. **Virology** 1995 Dec 20; 214(2):413-20
Identification of two new D variants, DHMi and DHMii using monoclonal anti-D. Jones J. **Vox Sang** 1995; 69(3):236-41

IMMUNOLOGY

Heterogeneity of pollen proteins within individual Betula pendula trees. Hjelmroos M, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):368-76
Assessment of variation in trypsin-sensitive neutralizable antigenic site of type O foot-and-mouth disease virus (FMDV) isolates using a Mab-binding inhibition assay [letter] Pattnaik B, et al. **J Immunol Methods** 1996 Jun 10; 192(1-2):191-3
Antigenic variants in a plaque-isolate of foot-and-mouth disease virus: implications for vaccine production. Piatti P, et al. **Vaccine** 1995;13(8):781-4 (23 ref.)

PHYSIOLOGY

Mechanism of antigenic variation in Shigella flexneri bacilli. III. Complement sensitivity of S. flexneri 1b strains and their 3b variants selected either as Lac+ recombinants or phage F2 resistant mutants. Doroszkiewicz W, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(1):67-72

ANTIGENS

see related
ANTIGEN-ANTIBODY REACTIONS
RECEPTORS, ANTIGEN

Oral tolerance in humans: T cell but not B cell tolerance to a soluble protein antigen. Husby S, et al. **Adv Exp Med Biol** 1995;371B:1225-8
A subpopulation of Menière's patients produce antibodies that bind to endolymphatic sac antigens. Soliman AM. **Am J Otol** 1996 Jan;17(1):76-80
A simple direct enzyme immunoassay of antibodies based on the differences in diffusion rates in a gel of a synthetic antigen and of its complex with antibodies. Semenov AN, et al. **Appl Biochem Biotechnol** 1996 Jan;56(1):73-8
Attachment of antibody to biotinylated red blood cells: immuno-red blood cells display high affinity to immobilized antigen and normal biodistribution in rats. Muzykantov VR, et al. **Biotechnol Appl Biochem** 1996 Aug; 24 (Pt 1):41-5
Detection on immunoblot of new proteins from the microsomal fraction recognized by anti-liver-kidney microsome antibodies type 1. Ballot E, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):255-65
Passive haemagglutination tests using purified antigens covalently coupled to turkey erythrocytes. Relyveld EH, et al. **Dev Biol Stand** 1996;86:225-41
Antigenic regions of human chromogranin A and their topographic relationships with structural/functional domains. Corti A, et al. **Eur J Biochem** 1996 Jan 15; 235(1-2):275-80
In susceptible mice, Leishmania major induce very rapid

interleukin-4 production by CD4+ T cells which are NK1.1-. Launois P, et al. **Eur J Immunol** 1995 Dec; 25(12):3298-307

A strategy for identifying candidate sperm antigens for immunocontraception: isolation of human testis cDNA clones using polyclonal antisera directed against hamster acrosomal membrane preparation. Adoyo PA, et al. **Int J Androl** 1995 Jun;18 Suppl 1:32-8

Enhancement of Antigen-specific functional responses by neutrophils from allergic patients. Monteseirin J, et al. **J Exp Med** 1996 Jun 1;183(6):2571-9

Stress-induced enhancement of antigen-specific cell-mediated immunity. Dhabhar FS, et al. **J Immunol** 1996 Apr 1;156(7):2608-15

Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. Baas IO, et al. **J Pathol** 1996 Mar; 178(3):264-7

ADMINISTRATION & DOSAGE

The effect of immune sera from hamsters immunized with sandfly gut and whole body extract antigens on the fecundity and mortality of Phlebotomus duboscqi (Diptera: Psychodidae). Ingonga P, et al. **Acta Trop** 1996 Feb; 60(4):269-79

Do CD5 B cells respond to oral antigens? Beagley KW, et al. **Adv Exp Med Biol** 1995;371B:1439-44

Induction of CTL by oral immunization. Enders GA. **Adv Exp Med Biol** 1995;371B:1455-8

Evidence of a direct role for mucosal immune cells in the induction of oral tolerance. Furrie E, et al. **Adv Exp Med Biol** 1995;371B:1235-8

The absence of gut flora has no effect on the induction of oral tolerance to ovalbumin. Furrie E, et al. **Adv Exp Med Biol** 1995;371B:1239-41

Cholera toxin increases T lymphocyte responses to unrelated antigens. Hornquist E, et al. **Adv Exp Med Biol** 1995; 371B:1507-12

The influence of antigen digestion on orally induced immunity and tolerance. Jain SL, et al. **Adv Exp Med Biol** 1995;371B:1245-50

Specific immunological non-responsiveness induced by antigens via mucosal surfaces. Metzler B, et al. **Adv Exp Med Biol** 1995;371B:1243-4

Oral tolerance to ovalbumin in mice: effect of some parameters on the induction and persistence of the suppression of systemic IgE and IgG antibody responses. Moreau MC, et al. **Adv Exp Med Biol** 1995;371B:1229-34

Lactobacilli: vehicles for antigen delivery to the female urogenital tract. Rush CM, et al. **Adv Exp Med Biol** 1995; 371B:1547-52

Cholera and pertussis toxins, but not forskolin or LT-B, adjuvant IgA antibody responses to orally administered antigen. Wilson AD, et al. **Adv Exp Med Biol** 1995; 371B:1523-6

Effect of chronic antigen and beta 2 agonist exposure on airway remodeling in guinea pigs. Wang ZL, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2097-104

Oral Tolerance: Mechanisms and Applications. Proceedings of a conference. New York City, New York, March 30-April 2, 1995. **Ann N Y Acad Sci** 1996 Feb 13; 778:xiii-xviii, 1-453

Dose-dependent activation and deletion of antigen-specific T cells following oral tolerance. Chen YH, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:111-21 (60 ref.)

Cholera toxin B subunit as transmucosal carrier-delivery and immunomodulating system for induction of antiinfectious and antipathological immunity. Czerkinsky C, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:185-93 (32 ref.)

Oral-antigen delivery by way of a multiple emulsion system enhances oral tolerance. Elson CO, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:156-62

Induction of anergy in Th1 lymphocytes by oral tolerance. Importance of antigen dosage and frequency of feeding. Friedman A. **Ann N Y Acad Sci** 1996 Feb 13;778:103-10 (47 ref.)

Multiple emulsions oral vaccine vehicles for inducing immunity or tolerance. Hearn TL, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:388-9

Effects of oral antigen in T-cell receptor transgenic mice. Hurst SD, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:163-73 (20 ref.)

Immune deviation during the induction of tolerance by way of nasal installation: nasal installation itself can induce Th-2 responses and exacerbation of disease. Melo ME, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:408-11

Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Nussenblatt RB, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:325-37 (23 ref.)

Oral tolerance: mechanisms and possible role in inflammatory joint diseases. Kagnoff MF. **Baillieres Clin Rheumatol** 1996 Feb;10(1):41-54 (71 ref.)

In vitro immunization of murine lymphocytes using immobilized immunogens. Geeta NS, et al. **Biotechnol Appl Biochem** 1996 Aug;24 (Pt 1):61-4

Activation patterns of murine T cells after oral administration of an enterocoated soluble antigen. Jain SL, et al. **Cell Immunol** 1996 Feb 1;167(2):170-5

Pulmonary immune memory: localized production of antibody in the lung after antigen challenge. Bice DE, et al. **Immunology** 1996 Jun;88(2):191-7

Antigen-induced anaphylactic death in mice. Lei HY, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):407-12

Delivery of protein antigen to the major histocompatibility complex class I-restricted antigen presentation pathway. Zhou F, et al. **J Drug Target** 1995;3(2):91-109 (177 ref.)

Epicutaneous exposure of protein antigen induces a predominant Th2-like response with high IgE production in mice. Wang LF, et al. **J Immunol** 1996 Jun 1; 156(11):4077-82

Mouse ear spleen grafts: a model for intrasplenic immunization with minute amounts of antigen. Cardillo F, et al. **J Immunol Methods** 1995 Dec 15;188(1):43-9

Methods of immunization to enhance the immune response to specific antigens in vivo in preparation for fusions yielding monoclonal antibodies. Rudbach JA, et al. **Methods Mol Biol** 1995;45:1-8

Methods of immunization to enhance the immune response to specific antigens in vitro. Schelling ME. **Methods Mol Biol** 1995;45:9-15

Particle-mediated delivery of recombinant expression vectors to rabbit skin induces high-titered polyclonal antisera (and circumvents purification of a protein immunogen). Sundaram P, et al. **Nucleic Acids Res** 1996 Apr 1; 24(7):1375-7

Food antigen activates intraepithelial and lamina propria lymphocytes in food-sensitive enteropathy in mice. Ohtsuka Y, et al. **Pediatr Res** 1996 May;39(5):862-6

Liposomal presentation of antigens for human vaccines. Glück R. **Pharm Biotechnol** 1995;6:325-45 (142 ref.)

Indirect effects are independent of the way of tolerance induction. Carvalho CR, et al. **Scand J Immunol** 1996 Jun; 43(6):613-8

Inhibition of pulmonary hypertensive response after antigen challenge. Enzan K, et al. **Shock** 1995 Oct;4(4):294-7

Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP). Hornung RL, et al. **Ther Immunol** 1995 Feb; 2(1):7-14

[The effect of fractionated introduction of an antigen on rosette formation in mice] Eliseeva LS. **Biull Eksp Biol Med** 1995 Jul;120(7):71-4 **(Rus)**

ADVERSE EFFECTS

Effects of NIP-502 on antigen-induced bronchial responses and allergic reactions in animal models. Yamamoto A, et al. **Jpn J Pharmacol** 1995 May;68(1):47-55

[Allergic rhinitis due to cockroach antigenic components. An emerging pathology?] Liccardi G, et al. **Recenti Prog Med** 1996 May;87(5):208-12 (Eng. Abstr.) **(Ita)**

ANALYSIS

An analysis of beta-lactam-derived antigens on spleen cell and serum proteins by ELISA and Western blotting. Warbrick EV, et al. **Allergy** 1995 Nov;50(11):910-7

Antigen retrieval in immunofluorescent testing of bullous pemphigoid. D'Ambra-Cabry K, et al. **Am J Dermatopathol** 1995 Dec;17(6):560-3

Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Billing P, et al. **Am J Pathol** 1995 Oct; 147(4):979-87

An immunofiltration apparatus for accelerating the visualization of antigen on membrane supports. Clark CR, et al. **Anal Biochem** 1995 Jul 1;228(2):232-7

Expression immunoassay. Antigen quantitation using antibodies labeled with enzyme-coding DNA fragments. Christopoulos TK, et al. **Anal Chem** 1995 Dec 1; 67(23):4290-4

Cytoplasmic staining, ANA negative status, and ENA testing in rheumatic diseases [letter; comment] Lems WF, et al. **Ann Rheum Dis** 1995 Sep;54(9):779. Comment on: Ann Rheum Dis 1995 Apr;54(4):269-73.

The identification of an 18,000-molecular-weight antigen specific to big liver and spleen disease. McAlinden VA, et al. **Avian Dis** 1995 Oct-Dec;39(4):788-95

Antigenic proteins in latex glove extracts: sources of variability. Zehr BD, et al. **Biomed Instrum Technol** 1995 Sep-Oct;29(5):434-8

Immunohistochemical staining of fixed tissue using antigen retrieval and a thermal cycler. Baker-Cairns B, et al. **Biotechniques** 1996 Apr;20(4):641-50

Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Behm FG, et al. **Blood** 1996 Feb 1; 87(3):1134-9

Respirable tire fragments contain specific IgE-binding and bridging latex antigens. Williams PB, et al. **Chest** 1996 Mar; 109(3 Suppl):13S

Evaluation by SDS-PAGE and immunoblotting of residual antigenicity in hydrolysed protein formulas. Restani P, et al. **Clin Exp Allergy** 1995 Jul;25(7):651-8

Characterization of the house dust mite allergen Der p 7 by monoclonal antibodies. Shen HD, et al. **Clin Exp Allergy** 1995 May;25(5):416-22

Sea urchin egg tropomyosin isoforms with muscle-type and nonmuscle-type antigenicities. Ishimoda-Takagi T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Nov; 112(3):415-27

Optimal preservation of the J1-31 antigen in astroglia examined by immunogold labelling. Bhatnagar R, et al. **Cytobios** 1995;82(331):239-49

Evaluation of red blood cell lysing solutions for the detection of intracellular antigens by flow cytometry. Tiirikainen MI. **Cytometry** 1995 Aug 1;20(4):341-8

Mouse gamma delta TCR+NK1.1+ thymocytes specifically produce interleukin-4, are major histocompatibility complex class I independent, and are developmentally related to alpha beta TCR+NK1.1+ thymocytes. Vicari AP, et al. **Eur J Immunol** 1996 Jul;26(7):1424-9

Distribution of Dermatophagoides mite (Acari: Pyroglyphidae) antigens in homes of allergic patients in Japan. Konishi E, et al. **Exp Appl Acarol** 1995 May; 19(5):275-86

The immunolocalization of nuclear antigens during the pollen developmental program and the induction of pollen embryogenesis. Testillano PS, et al. **Exp Cell Res** 1995 Nov; 221(1):41-54

Coexpression of a novel glomerular basement membrane matrix material in mesangial cell culture and glomerulosclerosis. Yang AH, et al. **Exp Mol Pathol** 1995 Apr;62(2):83-98

A model phage display subtraction method with potential for analysis of differential gene expression. Stausbøl-Grøn B, et al. **FEBS Lett** 1996 Aug 5;391(1-2):71-5

Comparative study of zona pellucida in vertebrate animals. Kalaidzhiev S, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):25

Forensic application of organ-specific antigens. Takahama K. **Forensic Sci Int** 1996 Jun 28;80(1-2):63-9

The importance of tissue fixation for light microscopic immunohistochemical localization of peroxisomal proteins: the superiority of Carnoy's fixative over Baker's formalin and Bouin's solution. Lehmann T, et al. **Histochem Cell Biol** 1995 Mar;103(3):187-95

Carbohydrate and peptide antigens in macrophage populations derived from human bone marrow and milk: an immunomorphological and immunochemical analysis. Baldus SE, et al. **Histochem J** 1995 Aug;27(8):630-8

Residual antigenicity of hypoallergenic infant formulas and the occurrence of milk-specific IgE antibodies in patients with clinical allergy. van Beresteijn EC, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):365-74

Functional characterization of the primate sperm acrosomal antigen (PSA-63). Archibong AE, et al. **J Androl** 1995 Jul-Aug;16(4):318-26

Comparison of seven bio- and chemiluminescent reagents for in situ detection of antigens and nucleic acids. Lamarcq L, et al. **J Biolumin Chemilumin** 1995 Jul-Aug;10(4):247-56

Should superheating be used for immunohistochemistry? [letter] Lambkin HA, et al. **J Clin Pathol** 1995 Sep;48(9):883

Efficient immunodetection of various protein antigens in glutaraldehyde-fixed brain tissue. Mrini A, et al. **J Histochem Cytochem** 1995 Dec;43(12):1285-91

A novel method of microwave treatment for detection of cytoplasmic and nuclear antigens by flow cytometry. Lan HY, et al. **J Immunol Methods** 1996 Mar 28;190(1):1-10

Demonstration of interleukin-3 receptor-associated antigen in the central nervous system. Konishi Y, et al. **J Neurosci Res** 1995 Aug 1;41(5):572-82

Identification of a marker antigen for the endocytic stage of intestinal development in rat, sheep, and human. Trahair JF, et al. **J Pediatr Gastroenterol Nutr** 1995 Oct; 21(3):277-87

Murine asialo GM1+CD8+ T cells as novel interleukin-12-responsive killer T cell precursors. Lee U, et al. **Jpn J Cancer Res** 1996 May;87(5):429-32

Guinea pig inner ear antigens: extraction and application to the study of human autoimmune inner ear disease. Cao MY, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):207-12

Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes. Groeneveld K, et al. **Leukemia** 1996 Aug;10(8):1383-9

Mechanism for antigen detection on deplasticized epoxy sections. Brorson SH, et al. **Micron** 1995;26(4):301-10

Microwave oven heating enhances the ultrastructural detection of antigens in bioacryl-embedded tissue sections. Preda P, et al. **Microsc Res Tech** 1995 Sep 1;32(1):75-6

Brief report: detection of high-molecular-weight cytokeratins in neoplastic and non-neoplastic thyroid tumors using microwave antigen retrieval. Raphael SJ, et al. **Mod Pathol** 1995 Oct;8(8):870-2

Odorant receptors and desensitization proteins colocalize in mammalian sperm. Walensky LD, et al. **Mol Med** 1995 Jan;1(2):130-41

Membranous nephropathy, interstitial nephritis, and Fanconi syndrome-- glomerular antigen. Makker SP, et al. **Pediatr Nephrol** 1996 Feb;10(1):7-13

Widespread appearance of Alz-50 immunoreactive neurons in the human brain with cerebral infarction. Uchihara T, et al. **Stroke** 1995 Nov;26(11):2145-8

Dietary fat intake and plasma factor VII antigen concentration [letter] Miller GJ, et al. **Thromb Haemost** 1995 May;73(5):893

Immunohistochemical localization and biological significance of the phylogenically conserved thymus-brain antigen (UB-13 antigen) in skate, rat and human. Kuniki H, et al. **Vet Immunol Immunopathol** 1995 Aug;47(3-4):341-9

Western blot analysis of tick antigens from a Rhipicephalus sanguineus unfed larval extract and identification of

antigenic sites in tick sections using immunohistochemistry. A comparative study between resistant and susceptible host species. Ferreira BR, et al. **Vet Parasitol** 1996 Mar; 62(1-2):161-74

A study of immunoactivity of retinal S-antigen in retinoblastoma. Song Y, et al. **Yen Ko Hsueh Pao** 1995 Mar;11(1):22-5

Influence of soya antigen levels in milk replacers on the disruption of intestinal motility patterns in calves sensitive to soya. Lalles JP, et al. **Zentralbl Veterinarmed A** 1995 Sep;42(7):467-78

[Ultrastructural localisation of pemphigus vulgaris and pemphigus foliaceus antigens by indirect immunoelectron microscopy. Apropos of 7 cases] Boulinguez S, et al. **Ann Dermatol Venereol** 1995;122(6-7):417-21 (25 ref.) (Eng. Abstr.) **(Fre)**

[Retinal antigens in eye diseases--clinical value of diagnostic tests] Misiuk-Hojło M, et al. **Klin Oczna** 1995 Mar-Apr; 97(3-4):86-9 (26 ref.) (Eng. Abstr.) **(Pol)**

[New methods of immunoenzyme analysis, based on the use of interpolyelectrolyte reactions] Dzantiev BB, et al. **Dokl Akad Nauk** 1995 Jun;342(4):549-52 **(Rus)**

BIOSYNTHESIS

The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Smith FO, et al. **Blood** 1996 Feb 1;87(3):1123-33

Tissue distribution and quantitation of a gene expressing a 64-kDa antigen associated with thyroid-associated ophthalmopathy. Zhang ZG, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):236-44

O-2A progenitors of the mouse optic nerve exhibit a developmental pattern of antigen expression different from the rat. Fanarraga ML, et al. **Glia** 1995 Oct;15(2):95-104

Expression of A, B, and H blood group antigens in epithelial ovarian cancer: relationship to tumor grade and patient survival. Welshinger M, et al. **Gynecol Oncol** 1996 Jul; 62(1):106-12

Stringent V beta requirement for the development of NK1.1+ T cell receptor-alpha/beta+ cells in mouse liver. Ohteki T, et al. **J Exp Med** 1996 Mar 1;183(3):1277-82

Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. Nishiyama A, et al. **J Neurosci Res** 1996 Feb 1;43(3):299-314

MP 48 expression in red blood cells of renal transplant recipients. Mukhtar A. **Minerva Urol Nefrol** 1996 Jun; 48(2):87-8

Generation of truncated forms of the NG2 proteoglycan by cell surface proteolysis. Nishiyama A, et al. **Mol Biol Cell** 1995 Dec;6(12):1819-32

Expression and inducibility of antigens in severe combined immunodeficient mice recognized by human anti-P450 antibodies. Rajasenan RS, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):89-99

BLOOD

Red blood cells expressing fetal antigens: their presence in adults with certain forms of anemia. Lunghi M, et al. **Acta Haematol** 1996;96(1):29-35

Biphasic response of complement to heparin: fluid-phase generation of neoantigens in human serum and in a reconstituted alternative pathway amplification cycle. Keil LB, et al. **Am J Hematol** 1995 Dec;50(4):254-62

Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Kobayashi J, et al. **Chest** 1996 May; 109(5):1276-82

Acetaminophen toxicity in children: diagnostic confirmation using a specific antigenic biomarker. Webster PA, et al. **J Clin Pharmacol** 1996 May;36(5):397-402

Characterization of endothelial antigens associated with transplant-associated coronary artery disease. Wheeler CH, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S188-97

Paraformaldehyde fixation of neutrophils for immunolabeling of granule antigens in cryoultrasections. Elliott E, et al. **J Histochem Cytochem** 1995 Oct;43(10):1019-25

Standardization of an enzyme linked immunosorbent assay (ELISA) for detecting circulating toxic venom antigens in patients stung by the scorpion Tityus serrulatus. de Rezende NA, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jan-Feb;37(1):71-4

von Willebrand factor antigen and fibronectin in essential hypertension. Kloczko J, et al. **Thromb Res** 1995 Aug 1; 79(3):331-6

Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis. Inoue Y, et al. **Tuber Lung Dis** 1995 Jun; 76(3):230-3

No detectable alterations in immunogenicity following terminal severe dry-heat treatment of high-purity factor VIII (Liberate) and factor IX (HP9) concentrates. MacGregor IR, et al. **Vox Sang** 1995;69(4):319-27

[Use of the the ED046 kit to analyze serum KL-6 in patients with pneumonitis] Kitamura S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun; 34(6):639-45 (Eng. Abstr.) **(Jpn)**

[Establishment of reference intervals and cut-off value by an enzyme immunoassay for KL-6 antigen, a new marker for interstitial pneumonia] Kobayashi J, et al. **Rinsho Byori** 1996 Jul;44(7):653-8 (Eng. Abstr.) **(Jpn)**

[Induction of human platelet aggregation by nerve tissue antigens and immune complexes] Matusevich LI, et al. **Gematol Transfuziol** 1995 Jul-Aug;40(4):29-31 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Changes in a CSF antigen associated with dementia. Carretero MT, et al. **Dementia** 1995 Sep-Oct;6(5):281-5

CHEMISTRY

Immunohistochemical localization of C9 neoantigen and the terminal complement inhibitory protein CD59 in human endometrium. Ratnoff WD, et al. **Am J Reprod Immunol** 1995 Aug;34(2):72-9

Trout red blood cell arrestin (TRCarr), a novel member of the arrestin family: cloning, immunoprecipitation and expression of recombinant TRCarr. Jahns R, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):497-506

Modulation of arrestin release in the light-driven regeneration of Rh1 Drosophila rhodopsin. Kiselev A, et al. **Biochemistry** 1996 Feb 13;35(6):1848-55

Evaluation of antibody- and antigen-coated enzymeimmunoassays for measuring oestrone-3-glucuronide concentrations in urine. Henderson KM, et al. **Clin Chim Acta** 1995 Dec 29;243(2):191-203

Molecular inactivation. Spatially and temporally defined molecular knockouts. Müller BK, et al. **Curr Biol** 1995 Nov 1;5(11):1255-6 (9 ref.)

The sequence of arrestins from rod and cone photoreceptors in the frogs Rana catesbeiana and Rana pipiens. Localization of gene transcripts by reverse-transcription polymerase chain reaction on isolated photoreceptors. Abdulaeva G, et al. **Eur J Biochem** 1995 Dec 1; 234(2):437-42

Identification of factor-XIIIa-reactive glutaminyl residues in the propolypeptide of bovine von Willebrand factor. Takagi J, et al. **Eur J Biochem** 1995 Sep 15;232(3):773-7

Porcine S-antigen: cDNA sequence and expression in retina, ciliary epithelium and iris. Singh AK, et al. **Exp Eye Res** 1996 Mar;62(3):299-308

Passive adsorption of immunologically active and inactive synthetic peptides to polystyrene is influenced by the proportion of non-polar residues in the peptide. Sällberg M, et al. **Immunol Lett** 1995 May;46(1-2):25-30

Occupational asthma caused by roasted coffee: immunologic evidence that roasted coffee contains the same antigens as green coffee, but at a lower concentration. Lemière C, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):464-6

Selective proteolysis of arrestin by calpain. Molecular characteristics and its effect on rhodopsin dephosphorylation. Azarian SM, et al. **J Biol Chem** 1995 Oct 13;270(41):24375-84

Molecular weights and isoelectric points of sperm antigens relevant to autoimmune infertility in men. Pillai S, et al. **J Urol** 1996 Jun;155(6):1928-33

Structures of an MHC class II molecule with covalently bound single peptides [see comments] Fremont DH, et al. **Science** 1996 May 17;272(5264):1001-4. Comment in: Nature 1996 May 17;272(5264):973-4.

Reactive immunization [comment] Wirsching P, et al. **Science** 1995 Dec 15;270(5243):1775-82. Comment on: Science 1995 Dec 15;270(5243):1797-800.

The use of antibody fragments for crystallization and structure determinations. Kovari LC, et al. **Structure** 1995 Dec 15;3(12):1291-3 (34 ref.)

DRUG EFFECTS

Tannic acid's effect on bird antigen. Craig TJ, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):348-50

Antigen and functional expression of tissue factor in endotoxin stimulated U937 cells: regulation of activity by calcium ionophore A23187. Consonni R, et al. **Thromb Haemost** 1995 Sep;74(3):904-9

GENETICS

The N-terminal amino acid sequence of the psoriasis-associated antigen, pso p27. Iversen OJ, et al. **Arch Dermatol Res** 1995;287(8):761-3

Trout red blood cell arrestin (TRCarr), a novel member of the arrestin family: cloning, immunoprecipitation and expression of recombinant TRCarr. Jahns R, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):497-506

Complementary deoxyribonucleic acid cloning and characterization of mSP-10: the mouse homologue of human acrosomal protein SP-10. Reddi PB, et al. **Biol Reprod** 1995 Oct;53(4):873-81

Oral immunization with attenuated Salmonella expressing human sperm antigen induces antibodies in serum and the reproductive tract. Srinivasan J, et al. **Biol Reprod** 1995 Aug;53(2):462-71

Expression of RHD and RHCE gene products using retroviral transduction of K562 cells establishes the molecular basis of Rh blood group antigens. Smythe JS, et al. **Blood** 1996 Apr 1;87(7):2968-73

Reported sequence homology between Alzheimer amyloid770 and the MRC OX-2 antigen does not predict function [letter] Richards SJ, et al. **Brain Res Bull** 1995; 38(3):305-6

Antigenic regions of human chromogranin A and their topographic relationships with structural/functional domains. Corti A, et al. **Eur J Biochem** 1996 Jan 15; 235(1-2):275-80

Epitope mapping of recombinant antigens by transposon mutagenesis. Morris GE, et al. **Mol Biotechnol** 1995 Aug; 4(1):45-54

Virus-vectored immunocontraception for control of wild rabbits: identification of target antigens and construction of recombinant viruses. Holland MK, et al. **Reprod Fertil Dev** 1994;6(5):631-42 (61 ref.)

A new form of particulate single and multiple immunogen delivery system based on recombinant bluetongue virus-derived tubules. Mikhailov M, et al. **Virology** 1996 Mar 1;217(1):323-31

IMMUNOLOGY

Testicular morphology and testosterone levels in dogs immunized with antibodies generated against an androgen binding antigen in the epididymal cauda. Wango EO. **Acta Biol Hung** 1995;46(1):107-17

Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer. Alfonso M, et al. **Acta Oncol** 1996; 35(3):287-95 (67 ref.)

Immunology of chondroitin/dermatan sulfate. Hascall VC, et al. **Adv Exp Med Biol** 1995;376:205-16 (34 ref.)

Amelioration of autoimmune reactions by antigen-induced apoptosis of T cells. McFarland HI, et al. **Adv Exp Med Biol** 1995;383:157-66

Quantification of salivary, urinary and fecal secretory IgA, as well as in saliva titers and avidities of IgA antibodies in children living at different levels of antigenic exposure and undernutrition. Nagao AT, et al. **Adv Exp Med Biol** 1995;371A:507-11

Dietary antigen handling by mother and offspring in a two generation study. Telemo E, et al. **Adv Exp Med Biol** 1995; 371A:517-9

The fate of protein antigen in annelids--in vivo and in vitro studies. Tucková L, et al. **Adv Exp Med Biol** 1995; 371A:335-9

The regulation of pulmonary immunity. Lipscomb MF, et al. **Adv Immunol** 1995;59:369-455 (534 ref.)

The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases. Nardin EH, et al. **Adv Immunol** 1995;60:105-49 (135 ref.)

Peak expiratory flow variation and bronchial hyperresponsiveness in asthmatic children during periods of antigen avoidance and reexposure. Valletta EA, et al. **Allergy** 1995 Apr;50(4):366-9

Contralateral differences among biomarkers determined by a modified nasal lavage technique after unilateral antigen challenge. Wihl JA, et al. **Allergy** 1995 Apr;50(4):308-15

Antigen phenotype and cytotoxic activity of natural killer cells in hemodialysis patients. Gascon A, et al. **Am J Kidney Dis** 1996 Mar;27(3):373-9

Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Billing P, et al. **Am J Pathol** 1995 Oct; 147(4):979-87

Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice. Kips JC, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):535-9

Oriented immobilization of antibodies and its applications in immunoassays and immunosensors. Lu B, et al. **Analyst** 1996 Mar;121(3):29R-32R (47 ref.)

MHC class II restriction for T cell proliferative response to mite antigen. Matsuoka H, et al. **Ann Allergy Asthma Immunol** 1996 Sep;77(3):191-6

Characterization of latex and chestnut antigens by immunoblotting. Moneo I, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):440-4

T-cell recognition of antigen. A process controlled by transient intermolecular interactions. Boniface JJ, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:62-9 (34 ref.)

Active immunity or tolerance to foods in patients with celiac disease or inflammatory bowel disease. Ferguson A, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:202-16 (25 ref.)

Breaking of oral tolerance by an encapsulated antigen. Flanagan M, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:373-5

Role of gamma delta T cells in the regulation of mucosal IgA response and oral tolerance. Fujihashi K, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:55-63 (42 ref.)

Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis. Fukaura H, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:251-7

Effects of cyclosporin A on the induction of oral tolerance. Fukushima A, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:376-8

The role of chemokines in oral tolerance. Abrogation of nonresponsiveness by treatment with antimonocyte chemotactic protein-1. Karpus WJ, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:133-44

Studying immunological tolerance by physically monitoring antigen-specific T cells in vivo. Khoruts A, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:72-9 (43 ref.)

Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-gamma-expressing Th1-like cells and up-regulation of TGF-beta mRNA in mononuclear cells. Ma CG, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:273-87

Pilot study of oral tolerance to keyhole limpet hemocyanin in humans: down-regulation of KLH-reactive precursor-cell frequency. Matsui M, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:398-404

Antigen trafficking in the intestine. Mayer L, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:28-35 (16 ref.)

Oral tolerance in myelin basic protein TCR transgenic mice. Meyer A, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:412-3

Effect of oral beta interferon on subsequent immune responsiveness. Nelson PA, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:145-55

IL-4 is not involved in the early MLN T-cell response to antigen given orally with cholera toxin, but those cells can express IL-4R. Snider DP, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:427-8

Neonatal oral tolerance. Strobel S. **Ann N Y Acad Sci** 1996 Feb 13;778:88-102 (92 ref.)

Oral tolerance: mechanisms and applications. Introduction. Weiner HL, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:xiii-xviii

Altered expression of a new antigen of the dermal-epidermal junction (NU-T2 DEJ Ag) in junctional epidermolysis bullosa. Tadini G, et al. **Arch Dermatol Res** 1995; 287(8):699-704

Effect of benzodiazepine on antigen-induced eosinophil infiltration into guinea pig conjunctiva. Kawata E, et al. **Arerugi** 1996 May;45(5):478-84

Oral tolerance: mechanisms and possible role in inflammatory joint diseases. Kagnoff MF. **Baillieres Clin Rheumatol** 1996 Feb;10(1):41-54 (71 ref.)

Production of a form-specific, inhibitory antibody against rat cytochrome P450 2B1 using a synthetic peptide antigen against a putative substrate binding site. Charnecki J, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):1024-33

Spectroscopic, calorimetric, and kinetic demonstration of conformational adaptation in peptide-antibody recognition. Leder L, et al. **Biochemistry** 1995 Dec 19;34(50):16509-18

Antigen-mediated phospholipase D activation in rat basophilic leukemia (RBL-2H3) cells: possible involvement of calcium/calmodulin. Kumada T, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):107-14

Antigenicity of topochemically related peptides. Verdoliva A, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):57-62

Oral immunization with attenuated Salmonella expressing human sperm antigen induces antibodies in serum and the reproductive tract. Srinivasan J, et al. **Biol Reprod** 1995 Aug;53(2):462-71

Improved technique for the preparation of water-in-oil emulsions containing protein antigens. Vulliet R. **Biotechniques** 1996 May;20(5):797-800

Cockroaches linked with asthma [news] Roberts J. **BMJ** 1996 Jun 29;312(7047):1630

An acquired bullous dermatosis due to an autoimmune reaction against uncein. Horiguchi Y, et al. **Br J Dermatol** 1996 May;134(5):934-8

NA-phenotype-dependent differences in neutrophil Fc gamma RIIIb expression cause differences in plasma levels of soluble Fc gamma RIII. Koene HR, et al. **Br J Haematol** 1996 Apr;93(1):235-41

The promotion of patent airways and inhibition of antigen-induced bronchial obstruction by endogenous nitric oxide. Persson MG, et al. **Br J Pharmacol** 1995 Dec; 116(7):2957-62

Antibodies against retinal S-antigen in patients with juvenile chronic arthritis-associated uveitis [letter] Edelsten C, et al. **Br J Rheumatol** 1996 Jan;35(1):101-2

Antigen presentation by astrocytes primes rat T lymphocytes for apoptotic cell death. A model for T-cell apoptosis in vivo. Gold R, et al. **Brain** 1996 Apr;119 (Pt 2):651-9

Binding of Alz 50 depends on Phe8 in tau synthetic peptides and varies between native and denatured tau proteins. Ksiezak-Reding H, et al. **Brain Res** 1995 Oct 30; 697(1-2):63-75

Immunochemical characterization of carbohydrate antigens from fungi, protozoa and mammals by monoclonal antibodies directed to glycan epitopes. Straus AH, et al. **Braz J Med Biol Res** 1995 Aug;28(8):919-23

Lung cancer-related changing profile of B-cell epitopes recognized on mucosal antigens: the Der p1 model. Michils A, et al. **Cancer** 1995 Oct 1;76(7):1166-75

Human lymphocyte responses against epitopes of a self antigen: a follow-up at different time points. Fukushima A, et al. **Cell Immunol** 1996 Jan 10;167(1):150-3

IL-10 stimulates murine antigen-driven antibody responses in vitro by regulating helper cell subset participation. Marcelletti JF, et al. **Cell Immunol** 1996 Jan 10;167(1):86-98

Effect of interferon-gamma on antigen-induced eosinophil infiltration into the mouse airway. Shi H, et al. **Chin Med J (Engl)** 1996 Mar;109(3):215-8

Lymphatics and the processing of antigen. Ryan TJ, et al. **Clin Dermatol** 1995 Sep-Oct;13(5):485-92 (34 ref.)

IgG and IgA antibodies to dietary antigens in food allergy and intolerance. Barnes RM. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:7-9 (39 ref.)

Raising the pH of the pepsin-catalysed hydrolysis of bovine whey proteins increases the antigenicity of the hydrolysates. Schmidt DG, et al. **Clin Exp Allergy** 1995 Oct;25(10):1007-17

Azurocidin is a novel antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis. Zhao MH, et al. **Clin Exp Immunol** 1996 Mar;103(3):397-402

Identification of antigenic epitopes of 1D antigen recognized by antibodies in the serum of patients with thyroid-associated ophthalmopathy. Zhang ZG, et al. **Clin Immunol Immunopathol** 1995 Nov;77(2):193-200

Immunohistochemical studies on melanin associated antigen (MAA) induced experimental autoimmune anterior uveitis (EAAU). Kim MC, et al. **Curr Eye Res** 1995 Aug; 14(8):703-10

Interleukin-4-producing CD4+ NK1.1+ TCR alpha/beta intermediate liver lymphocytes are down-regulated by Listeria monocytogenes. Emoto M, et al. **Eur J Immunol** 1995 Dec;25(12):3321-5

Carrier-reactive hapten-specific cytotoxic T lymphocyte clones originate from a highly preselected T cell repertoire: implications for chemical-induced self-reactivity. Martin S, et al. **Eur J Immunol** 1995 Oct;25(10):2788-96

The fate of adoptively transferred antigen-specific T cells in vivo. Zhang L. **Eur J Immunol** 1996 Sep;26(9):2208-14

Peritoneal mast cell hyperplasia in rats after IgE antibody-antigen interaction. Inagaki N, et al. **Exp Anim** 1995 Oct;44(4):337-40

Response to mucosal antigen challenge in IgA nephropathy. Layward L, et al. **Exp Nephrol** 1995 Sep-Oct;3(5):300-7

Production of a monoclonal antibody to an antigen present on both trophoblasts and leukocytes. Yu KJ, et al. **Hybridoma** 1995 Oct;14(5):487-93

Peripheral immune response in albino rats following cerebroventricular and intraperitoneal antigen challenge. Devi RS, et al. **Indian J Physiol Pharmacol** 1995 Oct; 39(4):354-60

Effects of KW-4679, a new orally active antiallergic drug, on antigen-induced bronchial hyperresponsiveness, airway inflammation and immediate and late asthmatic responses in guinea pigs. Ohmori K, et al. **Int Arch Allergy Immunol** 1996 May;110(1):64-72

Autocrine feedback death and the regulation of mature T lymphocyte antigen responses. Lenardo MJ, et al. **Int Rev Immunol** 1995;13(2):115-34 (76 ref.)

A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. Kane GC, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):646-54

Endogenous nitric oxide modifies antigen-induced microvascular leakage in sensitized guinea pig airways. Miura M, et al. **J Allergy Clin Immunol** 1996 Jul; 98(1):144-51

Topological mimicry of cross-reacting enantiomeric peptide antigens. Verdoliva A, et al. **J Biol Chem** 1995 Dec 22; 270(51):30422-7

S-antigen antibody partially blocks entrainment and the effects of constant light on the circadian rhythm of locomotor activity in the adult blow fly, Calliphora vicina. Cymborowski B, et al. **J Biol Rhythms** 1996 Mar; 11(1):68-74

Human immunoglobulin G autoantibodies to the thyrotropin receptor from Epstein-Barr virus-transformed B lymphocytes: characterization by immunoprecipitation with recombinant antigen and biological activity. Morgenthaler NG, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3155-61

Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. Alexander-Miller MA, et al. **J Exp Med** 1996 Aug 1;184(2):485-92

Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. Constant S, et al. **J Exp Med** 1995 Nov 1;182(5):1591-6

Binding kinetics of monoclonal antibody using antigen-beta-galactosidase hybrid protein: application to measurement of peptide antigenicity. Cho EW, et al. **J Immunoassay** 1995 Nov;16(4):349-63

Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). Cambier JC. **J Immunol** 1995 Oct 1;155(7):3281-5 (65 ref.)

B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. Constant S, et al. **J Immunol** 1995 Oct 15;155(8):3734-41

Role of environmental antigen in the development of IgG+ cells in the bursa of fabricius. Ekino S, et al. **J Immunol** 1995 Nov 15;155(10):4551-8

Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. Mackall CL, et al. **J Immunol** 1996 Jun 15; 156(12):4609-16

Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. Takeda K, et al. **J Immunol** 1996 May 1; 156(9):3366-73

Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen. Yan X, et al. **J Immunol** 1996 Aug 15;157(4):1582-8

Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes. Boeckler C, et al. **J Immunol Methods** 1996 May 10;191(1):1-10

Cellular immune response to fractionated avian antigens by peripheral blood mononuclear cells from patients with pigeon breeder's disease [see comments] Mendoza F, et al. **J Lab Clin Med** 1996 Jan;127(1):23-8. Comment in: J Lab Clin Med 1996 Jan;127(1):10-2.

Soluble extracellular antigen-specific T cell immunoproteins. Cone RE. **J Leukoc Biol** 1996 May;59(5):605-12 (65 ref.)

Calcium influx into human neuroblastoma cells induces ALZ-50 immunoreactivity: involvement of calpain-mediated hydrolysis of protein kinase C. Shea TB, et al. **J Neurochem** 1996 Apr;66(4):1539-49

Astaxanthin, a carotenoid without vitamin A activity, augments antibody responses in cultures including T-helper cell clones and suboptimal doses of antigen. Jyonouchi H, et al. **J Nutr** 1995 Oct;125(10):2483-92

Immune recognition of Ornithodoros tick (Acari: Argasidae) salivary antigens by anti-Psoroptes cuniculi antibodies. Wozniak EJ, et al. **J Parasitol** 1996 Apr;82(2):375-8

Epitope analysis of a sperm acrosomal antigen defined by HSA-5 monoclonal antibody. Lee CYG, et al. **J Reprod Immunol** 1995 Oct;29(3):223-38

Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion. Du M, et al. **Leukemia** 1996 Jul; 10(7):1190-7

Another step towards xenotransplantation [comment] Platt JL, et al. **Nat Med** 1995 Dec;1(12):1248-50. Comment on: Nat Med 1995 Dec;1(12):1261-7.

Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Grewal IS, et al. **Nature** 1995 Dec 7;378(6557):617-20

Essential flexibility in the T-cell recognition of antigen. Kersh GJ, et al. **Nature** 1996 Apr 11;380(6574):495-8 (69 ref.)

The kinetics of the pathogenic pronase-digested renal proximal tubular antigen and antibody in rat active Heymann nephritis. Maezawa A, et al. **Nephron** 1995; 71(4):448-53

Expression of T cell receptor gamma delta antigens in human brain tissue. Frenzel KH, et al. **Neuroimmunomodulation** 1995 Mar-Apr;2(2):115-20

Muscarinic cholinergic receptors of rat lymphocytes: effect of antigen stimulation and local brain lesion. Gushchin GV, et al. **Neuroimmunomodulation** 1994 Jul-Aug;1(4):259-64

Diversity in localisation of nitric oxide synthase antigen and NADPH-diaphorase histochemical staining in sacral somatic motor neurones of the cat. Pullen AH, et al. **Neurosci Lett** 1995 Aug 18;196(1-2):33-6

Antigenic variation and the within-host dynamics of parasites. Antia R, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):985-9

Eosinophil recruitment into the respiratory epithelium following antigenic challenge in hyper-IgE mice is accompanied by interleukin 5-dependent bronchial hyperresponsiveness. Eum SY, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12290-4

On the role of antigen in maintaining cytotoxic T-cell memory. Kündig TM, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9716-23

The law of mass action governs antigen-stimulated cytolytic activity of CD8+ cytotoxic T lymphocytes. Sykulev Y, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11990-2

Effect of a novel leukotoriene synthesis inhibitor, BAY x1005, on the antigen-and LPS-induced airway hyperresponsiveness in guinea pigs. Nagai H, et al. **Prostaglandins** 1996 Feb;51(2):139-48

Hyperresponsiveness to non-adrenergic, non-cholinergic vagal stimulation following multiple antigen challenge in guinea-pigs. Perretti F, et al. **Pulm Pharmacol** 1995 Feb; 8(1):21-30

Immunological cross-reaction between sperm dynein heavy chains from different species. Gatti JL, et al. **Reprod Nutr Dev** 1996;36(2):213-20

Giant cell arteritis as an antigen-driven disease. Weyand CM, et al. **Rheum Dis Clin North Am** 1995 Nov;21(4):1027-39 (43 ref.)

New assays for the measurement of serum antibodies reactive with eye muscle membrane antigens confirm their significance in thyroid-associated ophthalmopathy. Barsouk A, et al. **Thyroid** 1995 Jun;5(3):195-200

Structure-activity relationships of organic acid anhydrides as antigens in an animal model. Welinder H, et al. **Toxicology** 1995 Nov 30;103(2):127-36

Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response. Fitchen J, et al. **Vaccine** 1995 Aug;13(12):1051-7

Effect of vaccination with a recombinant Bm86 antigen preparation on natural infestations of Boophilus microplus in grazing dairy and beef pure and cross-bred cattle in Brazil. Rodríguez M, et al. **Vaccine** 1995 Dec;13(18):1804-8

Presentation of soluble and bacterial antigens by milk-derived cells to unprimed bovine T cells in vitro. Fitzpatrick JL, et al. **Vet Immunol Immunopathol** 1995 Jun;46(3-4):251-66

Larval salivary gland proteins of the sheep nasal bot fly, (Oestrus ovis L.), are major immunogens in infested sheep. Innocenti L, et al. **Vet Parasitol** 1995 Dec;60(3-4):273-82

Lymphocyte proliferation response to S antigen in patients with uveitis and optic neuritis. Ren P, et al. **Yen Ko Hsueh Pao** 1995 Sep;11(3):120-3

Specificities of rabbit antisera to multiple antigen (MAP) peptides. Chersi A, et al. **Z Naturforsch [C]** 1995 Sep-Oct; 50(9-10):735-8

[The DEC-205 receptor expressed by dendritic cells and thymic epithelial cells is implicated in antigen processing (news)] Haymann JP. **Nephrologie** 1995;16(5):381 (Fre)

[Inhibitory effect of Kanpo-medicines: saiboku-to, syouseryu-to, sairei-to on Dermatophagoides farinae

antigen-induced IL2 responsiveness in lymphocytes from patients with bronchial asthma and their comparison] Noma T, et al. **Arerugi** 1996 May;45(5):494–502 (Eng. Abstr.) **(Jpn)**

[Effect of KW-4679, an antiallergic drug, on antigen-induced airway microvascular leakage in rats passively sensitized with mouse monoclonal IgE antibody] Ohmori K, et al. **Arerugi** 1996 Apr;45(4):393–7 (Eng. Abstr.) **(Jpn)**

[An antigenicity study of calcipotriol (MC903)] Suzuki T, et al. **J Toxicol Sci** 1996 Jul;21 Suppl 2:457–63 (Eng. Abstr.) **(Jpn)**

[Antigenicity studies of prulifloxacin (NM441)] Tateda C, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:231–9 (Eng. Abstr.) **(Jpn)**

[Effect of IL-10 on the mite antigen-induced IFN-gamma production by peripheral blood lymphocytes from individuals with bronchial asthma] Kawano Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Oct;18(5):538–44 (Eng. Abstr.) **(Jpn)**

[Structure and function of major tissue histocompatibility complex (MHC) class I antigens] Falkiewicz B, et al. **Postepy Biochem** 1996;42(1):41–8 (64 ref.) **(Pol)**

[Studies on diversification and restriction of immune response against glycopeptide antigens] Czerwiński M. **Postepy Hig Med Dosw** 1995;49(1):23–31 (47 ref.) (Eng. Abstr.) **(Pol)**

[Modification of immune response by implanting a suspension and antigen-stimulated lymphoid organs in an allogeneic system] Kovalevskiĭ GV. **Dokl Akad Nauk** 1995 Jun; 342(6):843–5 **(Rus)**

[Centrosome morphogenesis in the early development of mice: an immunofluorescence study using antibodies to the centriole antigen] Abumuslimov SS, et al. **Tsitologiia** 1996; 38(1):5–13 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Antibodies to synovial antigens in recent-onset rheumatoid arthritis. McColl GJ, et al. **Arthritis Rheum** 1995 Oct; 38(10):1418–28

Azurocidin is a novel antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis. Zhao MH, et al. **Clin Exp Immunol** 1996 Mar;103(3):397–402

An improved method to create nitrocellulose particles suitable for the immobilization of antigen and antibody. Steinitz M, et al. **J Immunol Methods** 1995 Nov 16; 187(1):171–7

Purification and characterization of a sperm antigen recognized by HSA-5 monoclonal antibody. Yoshiki T, et al. **J Reprod Immunol** 1995 Oct;29(3):209–22

Antigen purification by monoclonal antibody immunoaffinity chromatography. Brassfield AL. **Methods Mol Biol** 1995; 45:195–203

[The purification and analysis of S-antigen in rabbit retina] Sun X, et al. **Chung Hua Yen Ko Tsa Chih** 1996 Jan; 32(1):45–8 (Eng. Abstr.) **(Chi)**

METABOLISM

The influence of antigen digestion on orally induced immunity and tolerance. Jain SL, et al. **Adv Exp Med Biol** 1995;371B:1245–50

Microdissected domes from gut-associated lymphoid tissues: a model of M cell transepithelial transport in vitro. Kabok Z, et al. **Adv Exp Med Biol** 1995;371A:235–8

A confocal microscopical analysis of Peyer's patch membranous (M) cell and lymphocyte interactions in the scid mouse. Savidge TC, et al. **Adv Exp Med Biol** 1995; 371A:243–5

Uptake of bead-adsorbed versus soluble antigen by bone marrow derived dendritic cells triggers their activation and increases their antigen presentation capacity. Scheicher C, et al. **Adv Exp Med Biol** 1995;378:253–5

Procoagulant activity after exposure of monocyte-derived macrophages to minimally oxidized low density lipoprotein. Co-localization of tissue factor antigen and nascent fibrin fibers at the cell surface. Lewis JC, et al. **Am J Pathol** 1995 Oct;147(4):1029–40

Calibration of biosensor response using simultaneous evanescent wave excitation of cyanine-labeled capture antibodies and antigens. Wadkins RM, et al. **Anal Biochem** 1995 Nov 20;232(1):73–8

Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Zitoun D, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):77–81

Racial variation of factor VII activity and antigen levels and their correlates in healthy Chinese and Indians at low and high risk for coronary artery disease. Saha N, et al. **Atherosclerosis** 1995 Sep;117(1):33–42

Predicting major histocompatibility complex-binding sequences within protein antigens. Sinigaglia F, et al. **Biochem Soc Trans** 1995 Aug;23(3):675–7 (18 ref.)

Constitutive activation of opsin: interaction of mutants with rhodopsin kinase and arrestin. Rim J, et al. **Biochemistry** 1995 Sep 19;34(37):11938–45

Differential biodistribution of encapsulated and surface-linked liposomal antigens. Thérien HM, et al. **Biochim Biophys Acta** 1996 Apr 3;1280(1):91–7

An analysis of antigen-antibody binding kinetics for biosensor applications utilized as a model system: influence of non-specific binding. Chen Z, et al. **Biophys Chem** 1996 Jan;57(2–3):177–87

2A3 and 3F9. Novel lung epithelial antigens with early upregulation in hyperoxic and radiation lung injury models. Girod CE, et al. **Chest** 1996 Mar;109(3 Suppl):33S

Immunodetection of an arrestin-like protein in human retinal pigment epithelium. Reising CA, et al. **Curr Eye Res** 1996 Jan;15(1):9–15

Binding of purified recombinant beta-arrestin to guanine-nucleotide-binding-protein-coupled receptors. Söhlemann P, et al. **Eur J Biochem** 1995 Sep 1; 232(2):464–72

The distribution of TM-316-associated surface antigen on polymorphonuclear leucocytes: an immunoelectron microscopic study. Mato TK, et al. **Experientia** 1995 Sep 29;51(9–10):947–52

Immunoblot analysis of IgE and IgG binding antigens in extracts of mosquitos Aedes vexans, Culex tarsalis and Culiseta inornata. Peng Z, et al. **Int Arch Allergy Immunol** 1996 May;110(1):46–51

Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules. Bangia N, et al. **Int Immunol** 1995 Oct;7(10):1585–91

TPS cytosolic levels in non-malignant breast diseases [letter] Alvarez A, et al. **Int J Biol Markers** 1995 Jul-Sep; 10(3):183–5

Selective proteolysis of arrestin by calpain. Molecular characteristics and its effect on rhodopsin dephosphorylation. Azarian SM, et al. **J Biol Chem** 1995 Oct 13;270(41):24375–84

In vivo assembly of the proteasomal complexes, implications for antigen processing. Yang Y, et al. **J Biol Chem** 1995 Nov 17;270(46):27687–94

The peptide-binding motif for the human transporter associated with antigen processing. van Endert PM, et al. **J Exp Med** 1995 Dec 1;182(6):1883–95

Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. Viner NJ, et al. **J Immunol** 1996 Apr 1;156(7):2365–8

DOPA-negative melanocytes in the outer root sheath of human hair follicles express premelanosomal antigens but not a melanosomal antigen or the melanosome-associated glycoproteins tyrosinase, TRP-1, and TRP-2. Horikawa T, et al. **J Invest Dermatol** 1996 Jan;106(1):28–35

Stabilization of tetanus toxoid in poly(DL-lactic-co-glycolic acid) microspheres for the controlled release of antigen. Chang AC, et al. **J Pharm Sci** 1996 Feb;85(2):129–32

Antigenic peptides containing large PEG loops designed to extend out of the HLA-A2 binding site form stable complexes with class I major histocompatibility complex molecules. Bouvier M, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4583–8

Another twist to MHC-peptide recognition [comment] Wilson IA. **Science** 1996 May 17;272(5264):973–4 (20 ref.) . Comment on: Nature 1996 May 17;272(5264):1001–4.

[Bispecific monoclonal antibodies: the isolation and study of their antigen-binding properties] Dmitriev AD, et al. **Vestn Ross Akad Med Nauk** 1996;(4):46–51 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Effect of Ca2+ influx on intracellular free Ca2+ responses in antigen-stimulated RBL-2H3 cells. Smith GD, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C939–52

Immobilization of the type I receptor for IgE initiates signal transduction in mast cells. Tamir I, et al. **Biochemistry** 1996 May 28;35(21):6872–83

Challenge of mast cells with increasing amounts of antigen induces desensitization. Shalit M, et al. **Clin Exp Allergy** 1995 Sep;25(9):896–902

A similarity and a difference between two models of late eosinophil accumulation into the airway induced by antigen exposure in actively sensitized brown Norway (BN) rats. Tominaga T, et al. **Gen Pharmacol** 1995 Mar;26(2):353–6

Chemical carcinogens and antigens induce immune suppression via Langerhans' cell depletion. Woods GM, et al. **Immunology** 1996 May;88(1):134–9

Effects of KW-4679, a new orally active antiallergic drug, on antigen-induced bronchial hyperresponsiveness, airway inflammation and immediate and late asthmatic responses in guinea pigs. Ohmori K, et al. **Int Arch Allergy Immunol** 1996 May;110(1):64–72

Detection of allergen-induced genes in peripheral blood mononuclear cells of patients with allergic asthma using subtractive hybridization. Fukuda T, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1076–82

Tachykinins mediate the potentiation of antigen-induced bronchoconstriction by cold air in guinea pigs. Yoshihara S, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):756–60

Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. Toellner KM, et al. **J Exp Med** 1996 May 1;183(5):2303–12

Durable elimination of high affinity, T cell-dependent antibodies by low molecular weight antigen arrays in vivo. Symer DE, et al. **J Immunol** 1995 Dec 15;155(12):5608–16

Modulation by IL-10 of antigen-induced IL-5 generation, and CD4+ T lymphocyte and eosinophil infiltration into the mouse peritoneal cavity. Zuany-Amorim C, et al. **J Immunol** 1996 Jul 1;157(1):377–84

PHYSIOLOGY

The perinuclear microtubule-organizing center and the synaptonemal complex of higher plants share a common antigen: its putative transfer and role in meiotic chromosomal ordering. Schmit AC, et al. **Chromosoma** 1996 Mar;104(6):405–13

Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. Grako KA, et al. **Exp Cell Res** 1995 Nov;221(1):231–40

The O:34-antigen lipopolysaccharide as an adhesin in Aeromonas hydrophila. Merino S, et al. **FEMS Microbiol Lett** 1996 Jun 1;139(2–3):97–101

IL-4 producing CD4+ TCR alpha beta int liver lymphocytes: influence of thymus, beta 2-microglobulin and NK1.1 expression. Emoto M, et al. **Int Immunol** 1995 Nov;7(11):1729–39

Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. Nishiyama A, et al. **J Neurosci Res** 1996 Feb 1;43(3):315–30

Thymosin alpha-1 and FA-1 monoclonal antibody affect fertilizing capacity of human sperm by modulating protein phosphorylation pattern. Ahmad K, et al. **J Reprod Immunol** 1995 May;29(1):1–17

Thymosin alpha-1 and FA-1 monoclonal antibody affect murine preimplantation embryo development by modulating protein phosphorylation. Ahmad K, et al. **J Reprod Immunol** 1995 Oct;29(3):239–63

Fertilization antigen (FA-1) completely blocks human sperm binding to human zona pellucida: FA-1 antigen may be a sperm receptor for zona pellucida in humans. Kadam AL, et al. **J Reprod Immunol** 1995 May;29(1):19–30

Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Ferguson SS, et al. **Science** 1996 Jan 19;271(5247):363–6

Regulation of G protein-coupled receptors by receptor kinases and arrestins. Sterne-Marr R, et al. **Vitam Horm** 1995;51:193–234 (121 ref.)

RADIATION EFFECTS

Modulation of arrestin release in the light-driven regeneration of Rh1 Drosophila rhodopsin. Kiselev A, et al. **Biochemistry** 1996 Feb 13;35(6):1848–55

THERAPEUTIC USE

Antigen-specific immunotherapy of autoimmune disease: a commentary [editorial] Wraith DC. **Clin Exp Immunol** 1996 Mar;103(3):349–52 (38 ref.)

From epitopes to peptides to immunotherapy. Hoyne G, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S23–30 (90 ref.)

Antigen based therapies to prevent diabetes in NOD mice. Ramiya VK, et al. **J Autoimmun** 1996 Jun;9(3):349–56

Antigen-specific therapy for autoimmune disease: prospects for the prevention of insulin-dependent diabetes. Harrison LC. **Mol Med** 1995 Nov;1(7):722–7 (34 ref.)

TOXICITY

Characteristics of muscarinic cholinoceptors in airways of antigen-induced airway hyperresponsive rats. Chiba Y, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jul;111(3):351–7

Leukocyte-derived neutrophil chemotactic factor-2 produced by infiltrated leukocytes in allergic inflammation model in rats is macrophage inflammatory protein-2. Tanabe J, et al. **Immunol Invest** 1995 Aug;24(5):757–64

Pathogenic effects of the human chemical biofield. Rumyantsev SN, et al. **Med Hypotheses** 1995 Jul;45(1):94–8

ULTRASTRUCTURE

Immunohistochemical observations of antigen presenting cells and follicular dendritic cells in the tonsil. Torigoe T, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:74–8

Imaging of single antigens, antibodies, and specific immunocomplex formation by scanning force microscopy. Quist AP, et al. **Scanning Microsc** 1995 Jun;9(2):395–400

ANTIGENS, BACTERIAL

Development of salivary IgA antibody to oral streptococcal antigens associated with virulence. Smith DJ, et al. **Adv Exp Med Biol** 1995;371B:1141–3

Serotype 2-specific antigens from ruminant strains of Chlamydia pecorum detected by monoclonal antibodies. Salinas J, et al. **Comp Immunol Microbiol Infect Dis** 1996 Feb;19(2):155–61

Fractionation, analysis and diagnostic utility of Mycobacterium tuberculosis H37Ra excretory-secretory antigen in pulmonary tuberculosis. Lodam AN, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):66–71

Defining antibody targets in Streptococcus oralis infection. Burnie JP, et al. **Infect Immun** 1996 May;64(5):1600–8

Invasion of primary nasopharyngeal epithelial cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens. de Vries FP, et al. **Infect Immun** 1996 Aug;64(8):2998–3006

Actinobacillus actinomycetemcomitans serotype b-specific polysaccharide antigen stimulates production of chemotactic factors and inflammatory cytokines by human monocytes. Yamaguchi N, et al. **Infect Immun** 1996 Jul; 64(7):2563–70

H2-M3wt-restricted, Listeria monocytogenes-specific CD8 T cells recognize a novel, hydrophobic, protease-resistant, periodate-sensitive antigen. Nataraj C, et al. **Int Immunol** 1996 Mar;8(3):367-78

Characterization of Aeromonas trota strains that cross-react with Vibrio cholerae O139 Bengal. Albert MJ, et al. **J Clin Microbiol** 1995 Dec;33(12):3119-23

Variant colony surface antigenic phenotypes within mycoplasma strain populations: implications for species identification and strain standardization. Rosengarten R, et al. **J Clin Microbiol** 1996 Jan;34(1):149-58

Protective effect of the combined vaccine prepared from cell-free-antigen of Actinobacillus pleuropneumoniae serotypes 1, 2 and 5 in pigs. Oishi E, et al. **J Vet Med Sci** 1995 Dec;57(6):1125-8

Reduction of endotoxin-induced inflammation of the middle ear by polymyxin B. Darrow DH, et al. **Laryngoscope** 1996 Aug;106(8):1028-33

Correlation of the polysaccharide antigens of Francisella tularensis with virulence in experimental mice. Fujita H, et al. **Microbiol Immunol** 1995;39(12):1007-9

Major membrane proteins and lipoproteins as highly variable immunogenic surface components and strain-specific antigenic markers of Mycoplasma arthritidis. Droesse M, et al. **Microbiology** 1995 Dec;141 (Pt 12):3207-19

Monoclonal antibodies against antigens exposed on the surface of vegetative forms and spores of Myxococcus virescens. Martinelli F, et al. **New Microbiol** 1995 Oct; 18(4):399-407

Comparison of two anticoagulants for production of antigens of Cowdria ruminantium in neutrophils. Awa DN, et al. **Rev Elev Med Vet Pays Trop** 1995;48(1):41-3

Evaluation of a potassium chloride extract of Brucella abortus in an ELISA for detecting Brucella antibodies in bulk tank milk samples from cows. Thoen CO, et al. **Vet Microbiol** 1995 Jul;45(2-3):185-9

[Technology of the production of antigens against soil-borne diseases in Madagascar] Fatou-Rakotobe, et al. **Berl Munch Tierarztl Wochenschr** 1996 Jan;109(1):6-7 (Eng. Abstr.) **(Ger)**

[The role of some cellular components of bacterial parasites in determining the incidence of tuberculosis: studies on mycobacterial antigens, with special reference to mycobacterial immunoreactive ribosomal and secreted proteins] Yamada T, et al. **Kekkaku** 1995 Nov; 70(11):639-44 (40 ref.) (Eng. Abstr.) **(Jpn)**

[K-antigen as a marker of Klebsiella pneumoniae and its use in clinical and epidemiological analysis (literature review)] Priamukhina NS, et al. **Klin Lab Diagn** 1996 Mar-Apr; (2):47-9 (29 ref.) **(Rus)**

ADMINISTRATION & DOSAGE

Specific antibody-producing cells in humans after oral immunization with a ribosomal vaccine Ribomunyl. Bene MC, et al. **Adv Exp Med Biol** 1995;371B:1563-6

Assessment of attenuated Salmonella typhimurium strains designed as potential carriers of foreign antigens for mucosal localization and immuno-genicity in a rabbit model. Boedeker EC, et al. **Adv Exp Med Biol** 1995; 371B:1653-7

Humoral immune response against Salmonella typhimurium antigen fractions and protection. Calderon GM, et al. **Adv Exp Med Biol** 1995;371B:1659-62

Oral immunization induces humoral and cell-mediated immunity and protects germ-free mice against infection from Helicobacter felis. Czinn SJ, et al. **Adv Exp Med Biol** 1995;371B:1645-8

Induction of salivary IgA responses to Streptococcus mutans antigen I/II after intranasal immunization. Katz J, et al. **Adv Exp Med Biol** 1995;371B:1153-6

Immune reaction of pigs following intra-gastric or ileal inoculation of attenuated Salmonella typhi. Loftager MK, et al. **Adv Exp Med Biol** 1995;371B:913-7

Intraduodenal immunization with microencapsulated CFA/II induces a delayed, anti-CFA/II, IgG antibody-secreting spleen cell response. Sau K, et al. **Adv Exp Med Biol** 1995; 371B:1469-74

Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery. Phalipon A, et al. **Biologicals** 1995 Jun; 23(2):125-34 (54 ref.)

Sheep red blood cell and Brucella abortus antibody responses in chickens selected for multitrait immunocompetence. Nelson NA, et al. **Poult Sci** 1995 Oct;74(10):1603-9

ANALYSIS

Enhancement in the histological diagnosis of indeterminate leprosy by demonstration of mycobacterial antigens. Natrajan M, et al. **Acta Leprol** 1995;9(4):201-7

Evaluation of suprapubic bladder aspiration for detection of group B streptococcal antigen by latex agglutination in neonatal urine. Palmer AL, et al. **Am J Perinatol** 1996 May; 13(4):235-9

Monoclonal antibodies for detection of the H7 antigen of Escherichia coli. He Y, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3325-32

Chemiluminescence immunosorbent assay (CLISA) and a possibility of the specific detection of soluble antigens of Clostridium botulinum type A. Ligięza J, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(2):129-33

Immune response to Streptococcus pyogenes and the susceptibility to psoriasis. Muto M, et al. **Australas J Dermatol** 1996 May;37 Suppl 1:S54-5

Presence of bacterial flora-derived antigen in synovial tissue macrophages and dendritic cells. Melief MJ, et al. **Br J Rheumatol** 1995 Dec;34(12):1112-6

A Bordetella pertussis acellular vaccine candidate: antigenic characterization and antibody induction. Dias WO, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2607-11

Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery [see comments] Grayston JT, et al. **Circulation** 1995 Dec 15;92(12):3397-400. Comment in: Circulation 1995 Dec 15;92(12):3376.

Significance of Chlamydia pneumoniae (TWAR) in atherosclerotic lesions [editorial; comment] Wissler RW. **Circulation** 1995 Dec 15;92(12):3376. Comment on: Circulation 1995 Dec 15;92(12):3397-400.

Detection and identification of cagA of Helicobacter pylori by polymerase chain reaction. Awakawa T, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S75-8

Bacterial superantigen specificities of mouse T cell receptor V beta 20. Bravo de Alba Y, et al. **Eur J Immunol** 1995 Dec;25(12):3425-30

Detection of chlamydia trachomatis antigen using the direct immunofluorescence technique: a four year survey in Northwestern Greece. Kostoula AG, et al. **G Batteriol Virol Immunol** 1994 Jan-Dec;86(1-12):11-4

Lipooligosaccharidic antigens from Mycobacterium kansasii and Mycobacterium gastri. Gilleron M, et al. **Glycoconj J** 1995 Jun;12(3):298-308

Mycobacterium tuberculosis antigen, interleukin 2 and interleukin 2 inhibitor in patients with rheumatoid arthritis. Wu CH, et al. **Immunol Invest** 1995 Nov;24(6):957-64

Development of an antigen capture enzyme immuno assay using genus specific monoclonal antibodies for detection of Chlamydia in clinical specimens. Mohanty S, et al. **Indian J Med Res** 1996 Feb;103:77-83

Rapid identification of colonization factor antigens I & II of enterotoxigenic Escherichia coli by coagglutination test. Ram S, et al. **Indian J Med Res** 1995 Oct;102:156-8

Changes in Helicobacter pylori ultrastructure and antigens during conversion from the bacillary to the coccoid form. Benaissa M, et al. **Infect Immun** 1996 Jun;64(6):2331-5

Experimental Yersinia infection of human synovial cells: persistence of live bacteria and generation of bacterial antigen deposits including "ghosts," nucleic acid-free bacterial rods. Huppertz HI, et al. **Infect Immun** 1996 Apr; 64(4):1484-7

Regarding analysis of vaccines [letter; comment] Convit J. **Int J Lepr Other Mycobact Dis** 1995 Dec;63(4):576-7. Comment on: Int J Lepr Other Mycobact Dis 1995 Mar;63(1):48-55.

Rapid antigen detection testing [letter; comment] Schafer S. **J Am Board Fam Pract** 1995 Sep-Oct;8(5):428-30. Comment on: J Am Board Fam Pract 1995 May-Jun;8(3):177-82.

Role of the C terminus in antigen P1 surface localization in Streptococcus mutans and two related cocci. Homonylo-McGavin MK, et al. **J Bacteriol** 1996 Feb; 178(3):801-7

Chemiluminescent immunoassay (CLIA) for the detection of brucellosis and tularaemia antigens. Vidžiunaitė R, et al. **J Biolumin Chemilumin** 1995 Jul-Aug;10(4):199-203

Rapid antigen detection assay for identification of Burkholderia (Pseudomonas) pseudomallei infection. Anuntagool A, et al. **J Clin Microbiol** 1996 Apr;34(4):975-6

Streptococcus pneumoniae types 19A and 19F and Streptococcus suis capsular type 8 share common capsular epitopes. Gottschalk M, et al. **J Clin Microbiol** 1995 Sep; 33(9):2492-5

Evaluation of commercial latex reagents for identification of O157 and H7 antigens of Escherichia coli. Sowers EG, et al. **J Clin Microbiol** 1996 May;34(5):1286-9

Protection against mortality due to Vibrio cholerae infection in infant rabbits caused by immunization of mothers with cholera protective antigen. Sciortino CV. **J Diarrhoeal Dis Res** 1996 Mar;14(1):16-26

Detection of Haemophilus ducreyi lipooligosaccharide by means of an immunolimulus assay. Hansen EJ, et al. **J Immunol Methods** 1995 Sep 25;185(2):225-35

Enhancing immunoelectrochemiluminescence (IECL) for sensitive bacterial detection. Yu H. **J Immunol Methods** 1996 Jun 10;192(1-2):63-71

Further characterisation of a monoclonal antibody reactive with Escherichia coli O157:H7. Clark CG, et al. **J Med Microbiol** 1995 Oct;43(4):262-9

Potential of exocellular carbohydrate antigens of Staphylococcus epidermidis in the serodiagnosis of orthopaedic prosthetic infection. Lambert PA, et al. **J Med Microbiol** 1996 May;44(5):355-61

Comparison of the Gimenez staining method and antigen detection ELISA with culture for detecting chlamydiae in birds. Arizmendi F, et al. **J Vet Diagn Invest** 1995 Jul; 7(3):400-1

Biochemical and antigenical characterization of tannin-protein complex degrading enterobacteria isolated from koalas, Phascolarctos cinereus. Nakai Y, et al. **J Vet Med Sci** 1995 Jun;57(3):559-61

Colonization factors of enterotoxigenic E. coli (ETEC) from residents of northern Egypt. Oyofo BA, et al. **Microbiol Res** 1995 Nov;150(4):429-36

Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response. Murphy TF. **Microbiol Rev** 1996 Jun;60(2):267-79 (186 ref.)

Multiple phase variation in haemolytic, adhesive and antigenic properties of Streptococcus gordonii. Jones GW, et al. **Microbiology** 1996 Jan;142 (Pt 1):181-9

Identification of mycobacterial peptide epitopes recognized by CD4+ T cells in association with multiple major histocompatibility complex class II molecules. Mustafa AS. **Nutrition** 1995 Sep-Oct;11(5 Suppl):657-60

Detection of Brucella abortus antigens by immunoperoxidase histochemical staining of lochia smears. Alberts JN, et al. **Onderstepoort J Vet Res** 1995 Jun;62(2):147-50

Comparison of antigen detection, polymerase chain reaction and culture for detection of Chlamydia trachomatis in genital infection. Hallsworth PG, et al. **Pathology** 1995 Apr; 27(2):168-71

Comparison of M and T type antigen testing to field inversion gel electrophoresis in the differentiation of strains of group A streptococcus. Shah R, et al. **Pediatr Res** 1995 Dec; 38(6):988-92

Presence of antigen and antibodies in serum and genital discharges of cows from dairy herds naturally infected with Leptospira interrogans serovar hardjo. Dhaliwal GS, et al. **Res Vet Sci** 1996 Mar;60(2):163-7

Pattern of mycobacterial antigen detection in leprosy. Pagliari C, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jan-Feb;37(1):7-12

Dot-enzyme-linked immunosorbent assay (Dot-ELISA) for detection of pneumococcal polysaccharide antigens in pleural fluid effusion samples. Comparison with bacterial culture, counterimmunoelectrophoresis and latex agglutination. Requejo HI, et al. **Rev Inst Med Trop Sao Paulo** 1994 Nov-Dec;36(6):531-7

Clinical evaluation of a rapid immunochromatographic assay based on the 38 kDa antigen of Mycobacterium tuberculosis on patients with pulmonary tuberculosis in China. Cole RA, et al. **Tuber Lung Dis** 1996 Aug;77(4):363-8

Immunohistochemical detection of virulence-associated antigens of Rhodococcus equi in pulmonary lesions of foals. Madarame H, et al. **Vet Pathol** 1996 May;33(3):341-3

Immortalized B-lymphocytes from rheumatoid synovial tissue show specificity for bacterial HSP 60. Krenn V, et al. **Virchows Arch** 1996 Feb;427(5):511-8

[Distribution of Chlamydia trachomatis (CT) antigen on the area surrounding the cervix in patients with CT cervicitis] Kojima H. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 May; 48(5):343-6 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Serogroup conversion of Vibrio cholerae non-O1 to Vibrio cholerae O1: effect of growth state of cells, temperature, and salinity. Montilla R, et al. **Can J Microbiol** 1996 Jan; 42(1):87-93

Prevalence of gca, a gene involved in synthesis of A-band common antigen polysaccharide in Pseudomonas aeruginosa. Currie HL, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):554-62

De novo synthesis of Legionella pneumophila antigens during intracellular growth in phagocytic cells. Susa M, et al. **Infect Immun** 1996 May;64(5):1679-84

Positive autoregulation of vipR expression in ViaB region-encoded Vi antigen of Salmonella typhi. Hashimoto Y, et al. **J Bacteriol** 1996 Mar;178(5):1430-6

Genetic analysis of the dTDP-rhamnose biosynthesis region of the Escherichia coli VW187 (O7:K1) rfb gene cluster: identification of functional homologs of rfbB and rfbA in the rff cluster and correct location of the rffE gene. Marolda CL, et al. **J Bacteriol** 1995 Oct;177(19):5539-46

Identification and functional differentiation of two type I fatty acid synthases in Brevibacterium ammoniagenes. Stuible HP, et al. **J Bacteriol** 1996 Aug;178(16):4787-93

Characterization of the rcsA and rcsB genes from Salmonella typhi: rcsB through tviA is involved in regulation of Vi antigen synthesis. Virlogeux I, et al. **J Bacteriol** 1996 Mar; 178(6):1691-8

Role of the viaB locus in synthesis, transport and expression of Salmonella typhi Vi antigen. Virlogeux I, et al. **Microbiology** 1995 Dec;141 (Pt 12):3039-47

Lack of production of the 19-kDa glycolipoprotein in certain strains of Mycobacterium tuberculosis. Lathigra R, et al. **Res Microbiol** 1996 May;147(4):237-49

[Homology of the recombinant DNA of plasmid pDJH2 with the recombinant DNA probe of L. alstoni and analysis of its expression in Escherichia coli] Jiang N, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Sep;26(3):241-7 (Eng. Abstr.) **(Chi)**

BLOOD

Recombinant expression and use in serology of a specific fragment from the Cowdria ruminantium MAP1 protein. van Vliet AH, et al. **Ann N Y Acad Sci** 1996 Jul 23; 791:35-45

Diagnosis of bacterial meningitis and septicemia by serum counterimmunoelectrophoresis. Alkmin MG, et al. **Braz J Med Biol Res** 1995 Oct;28(10):1065-8

Analysis of tuberculous meningitis cases by an immunoblotting assay based on a mycobacterial antigen complex. Zou YL, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):353-6

Agglutinins for brucellae antigens in blood sera of an urban and rural population in Kenya. Jumba MM, et al. **East Afr Med J** 1996 Mar;73(3):204-6

Serological diagnosis of tuberculosis. Bothamley GH. **Eur Respir J Suppl** 1995 Sep;20:676s-688s (114 ref.)

Detection of C-polysaccharide in serum of patients with Streptococcus pneumoniae bacteraemia. Gillespie SH, et al. **J Clin Pathol** 1995 Sep;48(9):803-6

Re: Helicobacter pylori and atrophic gastritis: importance of the cagA status [letter; comment] Ponzetto A, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):1000. Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):465-6.

Ehrlichiosis in Belgium [letter] Pierard D, et al. **Lancet** 1995 Nov 4;346(8984):1233-4

Detection of IgA anti-PGL-I specific antigen to Mycobacterium leprae in mangabey monkeys inoculated with M. leprae. Saad MH, et al. **Lepr Rev** 1995 Dec; 66(4):296-306

Presence of antigen and antibodies in serum and genital discharges of heifers after experimental intrauterine inoculation with Leptospira interrogans serovar hardjo. Dhaliwal GS, et al. **Res Vet Sci** 1996 Mar;60(2):157-62

Uses of serology for the diagnosis of contagious bovine pleuropneumonia. Rurangirwa FR. **Rev Sci Tech** 1995 Sep; 14(3):603-9 (30 ref.)

Preliminary evaluation of a Mycobacterium tuberculosis lipooligosaccharide (LOS) antigen in the serological diagnosis of tuberculosis in HIV seropositive and seronegative patients. Daleine G, et al. **Tuber Lung Dis** 1995 Jun;76(3):234-9

[Clinical significance of detecting discrete antigens of group A Streptococcus and their antibodies in the blood of erysipelas patients] Cherkasov VL, et al. **Klin Med (Mosk)** 1995;73(4):97-8 **(Rus)**

[An immunoenzyme method for detecting Brucella antibodies and antigen in the blood serum of animal breeders from farms with an unfavorable brucellosis situation] Podoliako MP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec;(6):53-4 **(Rus)**

CEREBROSPINAL FLUID

Analysis of tuberculous meningitis cases by an immunoblotting assay based on a mycobacterial antigen complex. Zou YL, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):353-6

Effect of pH changes in cerebrospinal fluid specimens on bacterial survival and antigen test results. Cunniffe JG, et al. **J Clin Pathol** 1996 Mar;49(3):249-53

Detection of Borrelia burgdorferi-specific antigen in antibody-negative cerebrospinal fluid in neurologic Lyme disease. Coyle PK, et al. **Neurology** 1995 Nov;45(11):2010-5

Bacterial antigen detection in cerebrospinal fluid by the latex agglutination test. Landgraf IM, et al. **Rev Inst Med Trop Sao Paulo** 1995 May-Jun;37(3):257-60

CHEMISTRY

The variable surface glycolipids of mycobacteria: structures, synthesis of epitopes, and biological properties. Aspinall GO, et al. **Adv Carbohydr Chem Biochem** 1995;51:169-242 (226 ref.)

Purification and characterization of Porphyromonas gingivalis outer membrane antigens. Polak B, et al. **Arch Oral Biol** 1995 Oct;40(10):905-12

Structural analysis of invasion plasmid antigen D (IpaD) from Shigella flexneri. Marquart ME, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):963-70

Comparison of NMR solution structures of the receptor binding domains of Pseudomonas aeruginosa pili strains PAO, KB7, and PAK: implications for receptor binding and synthetic vaccine design. Campbell AP, et al. **Biochemistry** 1995 Dec 19;34(50):16255-68

Determination by NMR spectroscopy of the structure and conformational features of the enterobacterial common antigen isolated from Escherichia coli. Bruix M, et al. **Carbohydr Res** 1995 Aug 25;273(2):157-70

Synthesis of the tetrasaccharide repeating unit of the antigen from Klebsiella type 2. Misra AK, et al. **Carbohydr Res** 1995 Nov 30;278(1):103-11

Structural studies of the saccharide part of the cell envelope lipooligosaccharide from Haemophilus influenzae strain galEgalK. Schweda EK, et al. **Carbohydr Res** 1995 Aug 11;272(2):213-24

Immunological analysis of the components of the antigen complex A60 of Mycobacterium bovis BCG. Coetsier C, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):139-44

Structures of the glycolipid antigens of members of the third biovariant complex of Mycobacterium fortuitum. Lanĕelle MA, et al. **Eur J Biochem** 1996 May 15;238(1):270-9

Enteroaggregative strains of Escherichia coli belonging to serotypes O126:H27 and O44:H18 express antigenically similar 18 kDa outer membrane-associated proteins. Chart H, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1-2):17-22

Immunochemical studies of streptococcal cell membrane antigens immunologically related to glomerular basement membrane. Zelman ME, et al. **Hybridoma** 1995 Dec; 14(6):529-36

Purification and characterization of the staphylococcal slime-associated antigen and its occurrence among Staphylococcus epidermis clinical isolates. Baldassarri L, et al. **Infect Immun** 1996 Aug;64(8):3410-5

Mapping of a surface-exposed, conformational epitope of the P6 protein of Haemophilus influenzae. Bogdan JA Jr, et al. **Infect Immun** 1995 Nov;63(11):4395-401

Variation in repeat number within the alpha C protein of group B streptococci alters antigenicity and protective epitopes. Gravekamp C, et al. **Infect Immun** 1996 Sep; 64(9):3576-83

Structure of the core oligosaccharide in the serotype O8 lipopolysaccharide from Klebsiella pneumoniae. Severn WB, et al. **J Bacteriol** 1996 Mar;178(6):1731-41

Structural and immunochemical characterization of the type VIII group B Streptococcus capsular polysaccharide. Kogan G, et al. **J Biol Chem** 1996 Apr 12;271(15):8786-90

Preparation and characterization of poly-(D,L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres with entrapped pneumotropic bacterial antigens. Kofler N, et al. **J Immunol Methods** 1996 Jun 10;192(1-2):25-35

Phosphorylcholine-containing antigens in bacteria from the mouth and respiratory tract. Gillespie SH, et al. **J Med Microbiol** 1996 Jan;44(1):35-40

Detection of antigenic proteins in Porphyromonas gingivalis using two-dimensional electrophoresis and western blots. Tani M, et al. **J Periodontal Res** 1995 May;30(3):172-80

Cell wall antigens in Vibrio cholerae O139 Bengal, a causative agent of new epidemics. Weintraub A, et al. **Prog Clin Biol Res** 1995;392:141-50

Nucleotide sequence and characterization of peb4A encoding an antigenic protein in Campylobacter jejuni. Burucoa C, et al. **Res Microbiol** 1995 Jul-Aug;146(6):467-76

Molecular characterization of MPT83: a seroreactive antigen of Mycobacterium tuberculosis with homology to MPT70. Hewinson RG, et al. **Scand J Immunol** 1996 May; 43(5):490-9

Heterogenous expression of the related MPB70 and MPB83 proteins distinguish various substrains of Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv. Wiker HG, et al. **Scand J Immunol** 1996 Apr;43(4):374-80

[The chemical and immunochemical characteristics of the antigens of Shigella dysenteriae 1 isolated by using hydroxylamine hydrochloride] Vaneeva NP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):45-6 **(Rus)**

CLASSIFICATION

Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. Poccia F, et al. **J Immunol** 1996 Jul 1;157(1):449-61

DIAGNOSTIC USE

Evaluation of Anaplasma marginale major surface protein 3 (MSP3) as a diagnostic test antigen. Alleman AR, et al. **J Clin Microbiol** 1996 Feb;34(2):270-76

Characterization of a 17-kilodalton antigen of Bartonella henselae reactive with sera from patients with cat scratch disease. Anderson B, et al. **J Clin Microbiol** 1995 Sep; 33(9):2358-65

Use of recombinant antigens of Borrelia burgdorferi in serologic tests for diagnosis of lyme borreliosis. Magnarelli LA, et al. **J Clin Microbiol** 1996 Feb;34(2):237-40

Establishment of enzyme-linked immunosorbent assay using purified recombinant 83-kilodalton antigen of Borrelia burgdorferi sensu stricto and Borrelia afzelii for serodiagnosis of Lyme disease. Rauer S, et al. **J Clin Microbiol** 1995 Oct;33(10):2596-600

Serodiagnosis of Lyme disease: accuracy of a two-step approach using a flagella-based ELISA and immunoblotting. Johnson BJ, et al. **J Infect Dis** 1996 Aug; 174(2):346-53

Clinical evaluation of MPT-64 and MPT-59, two proteins secreted from Mycobacterium tuberculosis, for skin test reagents. Wilcke JT, et al. **Tuber Lung Dis** 1996 Jun; 77(3):250-6

[A comparison of Clearview Chlamydia diagnostic tests and direct immunofluorescence (Chlamyset Antigen) in inflammatory gynecological diseases due to Chlamydia trachomatis] Borisov I, et al. **Akush Ginekol (Sofiia)** 1995; 34(2):35-7 (Eng. Abstr.) **(Bul)**

[Non-specific tuberculin reactivity due to sensitization to non-tuberculous mycobacteria (NTM) in children not vaccinated with BCG. Diagnostic value of a comparison of intradermal tests with tuberculin and NTM antigens] Albertini M, et al. **Rev Mal Respir** 1996 Jul;13(3):273-9 (Eng. Abstr.) **(Fre)**

[The development and evaluation of a leptospiral polyvalent antigenic erythrocytic diagnostic agent] Mel'nitskaia EV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):79-80 **(Rus)**

GENETICS

Antigenic and genetic heterogeneity among Haemophilus influenzae and Neisseria IgA1 proteases. Lomholt H, et al. **Adv Exp Med Biol** 1995;371A:599-603 (18 ref.)

Role of vacA and the cagA locus of Helicobacter pylori in human disease. Blaser MJ. **Aliment Pharmacol Ther** 1996 Apr;10 Suppl 1:73-7

DNA fingerprint analysis of standard, intermediate, and variant antigenic types of Salmonella enterica subspecies enterica serovar Gallinarum biovar pullorum. Wilson MA, et al. **Avian Dis** 1995 Jul-Sep;39(3):594-8

Distribution, gene sequence and expression in vivo of the plasmid encoded fimbrial antigen of Salmonella serotype Enteritidis. Woodward MJ, et al. **Epidemiol Infect** 1996 Aug;117(1):17-28

Use of a new oligonucleotide probe for detection of colonization factor antigen III gene in enterotoxigenic Escherichia coli. Taniguchi T, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):713-6

Conservation and variability in Archaea: protein antigens with tandem repeats encoded by a cluster of genes with common motifs in Methanosarcina mazei S-6. Mayerhofer LE, et al. **Gene** 1995 Nov 7;165(1):87-91

Sequence of a novel virulence-mediating gene, virC, from Vibrio anguillarum. Milton DL, et al. **Gene** 1995 Oct 16; 164(1):95-100

Characterization, genetic analysis, and expression of a protease antigen (PrpRI) of Porphyromonas gingivalis W50. Aduse-Opoku J, et al. **Infect Immun** 1995 Dec; 63(12):4744-54

Analysis of a genomic DNA expression library of Mycobacterium tuberculosis using tuberculosis patient sera: evidence for modulation of host immune response. Amara RR, et al. **Infect Immun** 1996 Sep;64(9):3765-71

Epitope mapping of B-cell determinants on the 15-kilodalton lipoproteinof Treponema pallidum (Tpp15) with synthetic peptides. Baughn RE, et al. **Infect Immun** 1996 Jul; 64(7):2457-66

Molecular characterization of a common 48-kilodalton outer membrane protein of Actinobacillus pleuropneumoniae. Cruz WT, et al. **Infect Immun** 1996 Jan;64(1):83-90

Characterization of an adherence and antigenic determinant of the ArgI protease of Porphyromonas gingivalis which is present on multiple gene products. Curtis MA, et al. **Infect Immun** 1996 Jul;64(7):2532-9

Expression of major surface protein 2 antigenic variants during acute Anaplasma marginale rickettsemia. Eid G, et al. **Infect Immun** 1996 Mar;64(3):836-41

Genes for CS2 pili of enterotoxigenic Escherichia coli and their interchangeability with those for CS1 pili. Froehlich BJ, et al. **Infect Immun** 1995 Dec;63(12):4849-56

Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Harboe M, et al. **Infect Immun** 1996 Jan;64(1):16-22

Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis. Harth G, et al. **Infect Immun** 1996 Aug;64(8):3038-47

Differential induction of carrier antigen-specific immunity by Salmonella typhimurium live-vaccine strains after single mucosal or intravenous immunization of BALB/c mice. Karem KL, et al. **Infect Immun** 1995 Dec;63(12):4557-63

Cloning, sequencing, and expression of the apa gene coding for the Mycobacterium tuberculosis 45/47-kilodalton secreted antigen complex. Laqueyrerie A, et al. **Infect Immun** 1995 Oct;63(10):4003-10

Cloning of a Brucella melitensis group 3 antigen gene encoding Omp28, a protein recognized by the humoral immune response during human brucellosis. Lindler LE, et al. **Infect Immun** 1996 Jul;64(7):2490-9

Sequence analysis of the chromosomal region around and within the V-1-encoding gene of Mycoplasma pulmonis: evidence for DNA inversion as a mechanism for V-1 variation. Simmons WL, et al. **Infect Immun** 1996 Feb; 64(2):472-9

Antigenic topology of the P29 surface lipoprotein of Mycoplasma fermentans: differential display of epitopes results in high-frequency phase variation. Theiss P, et al. **Infect Immun** 1996 May;64(5):1800-9

Molecular characterization, occurrence, and immunogenicity in infected sheep and cattle of two minor outer membrane proteins of Brucella abortus. Tibor A, et al. **Infect Immun** 1996 Jan;64(1):100-7

The structural gene encoding human enterotoxigenic Escherichia coli PCFO20 is homologous to that for porcine 987P. Viboud GI, et al. **Infect Immun** 1996 Apr; 64(4):1233-9

Cloning, nucleotide sequence, and expression of the Brucella melitensis omp31 gene coding for an immunogenic major outer membrane protein. Vizcaíno N, et al. **Infect Immun** 1996 Sep;64(9):3744-51

Genetic basis of Neisseria gonorrhoeae lipooligosaccharide antigenic variation. Danaher RJ, et al. **J Bacteriol** 1995 Dec;177(24):7275-9

Distribution of the rol gene encoding the regulator of lipopolysaccharide O-chain length in Escherichia coli and its influence on the expression of group I capsular K antigens. Dodgson C, et al. **J Bacteriol** 1996 Apr; 178(7):1895-902

Identification of two targets of the type III protein secretion system encoded by the inv and spa loci of Salmonella typhimurium that have homology to the Shigella IpaD and IpaA proteins. Kaniga K, et al. **J Bacteriol** 1995 Dec; 177(24):7078-85

Transcriptional analysis of the Yersinia pestis pH 6 antigen gene. Price SB, et al. **J Bacteriol** 1995 Oct; 177(20):5997-6000

A family of genes located on four separate 32-kilobase circular plasmids in Borrelia burgdorferi B31. Stevenson B, et al. **J Bacteriol** 1996 Jun;178(12):3508-16

Identification and characterization of an immunogenic outer membrane protein of Campylobacter jejuni. Burnens A, et al. **J Clin Microbiol** 1995 Nov;33(11):2826-32

Development of nested PCR based on the ViaB sequence to detect Salmonella typhi. Hashimoto Y, et al. **J Clin Microbiol** 1995 Nov;33(11):3082

Geographical heterogeneity between Far East and Europe in prevalence of ypm gene encoding the novel superantigen among Yersinia pseudotuberculosis strains. Yoshino K, et al. **J Clin Microbiol** 1995 Dec;33(12):3356–8

Identification of a CD4+ T cell–stimulating antigen of pathogenic bacteria by expression cloning. Sanderson S, et al. **J Exp Med** 1995 Dec 1;182(6):1751–7

Helicobacter pylori and atrophic gastritis: importance of the cagA status [see comments] Kuipers EJ, et al. **J Natl Cancer Inst** 1995 Dec 6;87(23):1777–80. Comment in: J Natl Cancer Inst 1995 Dec 6;87(23):1731–2. Comment in: J Natl Cancer Inst 1996 Jun 5;88(11):762–3.

Role of the viaB locus in synthesis, transport and expression of Salmonella typhi Vi antigen. Virlogeux I, et al. **Microbiology** 1995 Dec;141 (Pt 12):3039–47

Opa-typing: a high-resolution tool for studying the epidemiology of gonorrhoea. O'Rourke M, et al. **Mol Microbiol** 1995 Sep;17(5):865–75

Characterization of the gene encoding the immunodominant 35 kDa protein of Mycobacterium leprae. Winter N, et al. **Mol Microbiol** 1995 Jun;16(5):865–76

Immunogenicity and protective efficacy of a tuberculosis DNA vaccine [see comments] Huygen K, et al. **Nat Med** 1996 Aug;2(8):893–8. Comment in: Nat Med 1996 Aug;2(8):857–9.

Vaccination against tuberculosis by DNA injection. Tascon RE, et al. **Nat Med** 1996 Aug;2(8):888–92

An internal control for the rapid detection of mycobacteria by amplification of a segment of the gene encoding alpha antigen. Kitaura H, et al. **New Microbiol** 1995 Oct; 18(4):429–33

Isolation and characterization of the genes of pathogenic mycobacteria that express antigens for T cell reactivity. Mustafa AS. **Nutrition** 1995 Sep–Oct;11(5 Suppl):653–6

Studies of the anaerobically induced promoter pnirB and the improved expression of bacterial antigens. Newton SM, et al. **Res Microbiol** 1995 Mar–Apr;146(3):193–202

Secretion of MPB64 antigen by a recombinant clone of Mycobacterium smegmatis: characterization and application for the diagnosis of tuberculosis. Tasaka H, et al. **Scand J Immunol** 1995 Oct;42(4):487–92

Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by delta aroC, delta aroD Salmonella typhi vaccine strain CVD 908. Girón JA, et al. **Vaccine** 1995 Jul;13(10):939–46

In vivo variation of Mycoplasma gallisepticum antigen expression in experimentally infected chickens. Levisohn S, et al. **Vet Microbiol** 1995 Jul;45(2–3):219–31

[Cloning of a cluster of genes encoding coli-surface antigen 6(CS6) of human enterotoxigenic E. coli] Yang X, et al. **Wei Sheng Wu Hsueh Pao** 1995 Oct;35(5):390–3 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Development of IgE antibodies and T cell reactivity against intestinal bacterial antigens in rats and the influence of feeding. Dahlman A, et al. **Adv Exp Med Biol** 1995; 371A:497–500

A comparative study of the immune response to poly-[alpha(2-->8)-N-acetyl neuraminic acid] Diaz Romero J, et al. **Adv Exp Med Biol** 1995;371A:543–8

The regulation of IL-6 secretion from IEC-6 intestinal epithelial cells by cytokines and mucosally important antigens. McGee DW, et al. **Adv Exp Med Biol** 1995; 371A:229–32

In vivo activation of extrathymic T cells in mice by staphylococcal enterotoxin B. Ohtsuka K, et al. **Adv Exp Med Biol** 1995;371A:549–52

Bacterial antigen priming of marine fish larvae. Olafsen JA. **Adv Exp Med Biol** 1995;371A:349–52 (36 ref.)

Titration of inhibiting antibodies to bacterial IgA1 proteases in human sera and secretions. Reinholdt J, et al. **Adv Exp Med Biol** 1995;371A:605–8

Effect of bacterial antigens on local immunity. Ruedl C, et al. **Adv Exp Med Biol** 1995;371A:529–32

Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country. Mitchell HM, et al. **Am J Gastroenterol** 1996 Sep;91(9):1785–8

Sequestration of inhaled particulate antigens by lung phagocytes. A mechanism for the effective inhibition of pulmonary cell-mediated immunity. MacLean JA, et al. **Am J Pathol** 1996 Feb;148(2):657–66

Effect of a putative B cell superantigen on complement. Kozlowski LM, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:356–8

Induction of antibodies against Salmonella typhi OmpC porin by naked DNA immunization. López-Macías C, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:285–8

Patterns of V-region gene segment association in the human antibody response to Haemophilus influenzae type B capsular polysaccharide. Pinchuk GV, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:378–80

Tolerance to an arthritogenic T-cell epitope of HSP65 and the regulation of experimental arthritis. Prakken BJ, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:425–6

Structure-function studies of human monoclonal antibodies to pneumococcus type 3 polysaccharide. Shaw DR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:370–3

Unconventional B-cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342–55 (42 ref.)

Increased serum and synovial fluid antibodies to immunoselected peptides in patients with rheumatoid arthritis. Dybwad A, et al. **Ann Rheum Dis** 1996 Jul; 55(7):437–41

Characterization of the non-specific humoral and cellular antiviral immunity stimulated by the chloroform-methanol residue (CMR) fraction of Coxiella burnetii. Zvilich M, et al. **Antiviral Res** 1995 Aug;27(4):389–404

Effect of outer membrane proteins (OMP) of Shigella on interleukin 2 (IL-2) production by spleen cells of mice. Czarny A, et al. **Arch Immunol Ther Exp (Warsz)** 1994; 42(3):159–61

A new typhoid vaccine composed of the Vi capsular polysaccharide. Plotkin SA, et al. **Arch Intern Med** 1995 Nov 27;155(21):2293–9 (70 ref.)

Optical immunoassay for rapid detection of group A beta-hemolytic streptococci. Should culture be replaced? Schlager TA, et al. **Arch Pediatr Adolesc Med** 1996 Mar; 150(3):245–8

Proper evaluation of rapid antigen detection methods for diagnosing streptococcal pharyngitis [editorial] Wegner DL. **Arch Pediatr Adolesc Med** 1996 Mar;150(3):241, 245–8

Monoclonal antibodies against protein antigens of salmonellae causing paratyphoid fever and their diagnostic application. Ekpo P, et al. **Asian Pac J Allergy Immunol** 1995 Jun; 13(1):63–70

Identification of Mycoplasma synoviae immunogenic surface proteins and their potential use as antigens in the enzyme-linked immunosorbent assay. Gurevich VA, et al. **Avian Dis** 1995 Jul–Sep;39(3):465–74

Lymphoproliferative responses to Borrelia burgdorferi in circumscribed scleroderma. Breier P, et al. **Br J Dermatol** 1996 Feb;134(2):285–91

Monoclonal antibodies against Vi antigen production and characterization. Pieńkowska D, et al. **Bull Inst Marit Trop Med Gdynia** 1993–94;44–45(1–4):89–93

Size variation of the major immunodominant protein of Cowdria ruminantium. Barbet AF, et al. **Clin Diagn Lab Immunol** 1994 Nov;1(6):744–6

Serum antibody response to the superficial and released components of Helicobacter pylori. Bazillou M, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):310–7

Age-dependent humoral responses of children to mycobacterial antigens. Fairchok MP, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):443–7

Immune responses to the R4 protein antigen of group B streptococci and its relationship to other streptococcal R4 proteins. Fasola EL, et al. **Clin Diagn Lab Immunol** 1996 May;3(3):321–5

Enzyme-linked immunosorbent assay using a recombinant baculovirus-expressed Bacillus anthracis protective antigen (PA): measurement of human anti-PA antibodies. Iacono-Connors LC, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):78–82

Immunoblot analysis of humoral immune responses to Mycobacterium bovis in experimentally infected cattle: early recognition of a 26-kilodalton antigen. O'Loan CJ, et al. **Clin Diagn Lab Immunol** 1994 Sep;1(5):608–11

Occurrence, in Crohn's disease, of antibodies directed against a species-specific recombinant polypeptide of Mycobacterium paratuberculosis. Vannuffel P, et al. **Clin Diagn Lab Immunol** 1994 Mar;1(2):241–3

Detection of pulmonary and extrapulmonary tuberculosis patients with the 38-kilodalton antigen from Mycobacterium tuberculosis in a rapid membrane-based assay. Zhou AT, et al. **Clin Diagn Lab Immunol** 1996 May; 3(3):337–41

Human T cell responses to peptide epitopes of the 16-kD antigen in tuberculosis. Friscia G, et al. **Clin Exp Immunol** 1995 Oct;102(1):53–7

Serological distinction of integral plasma membrane proteins as a class of mycobacterial antigens and their relevance for human T cell activation. Mehrotra J, et al. **Clin Exp Immunol** 1995 Dec;102(3):626–34

Peripheral cell-mediated immune response to mycobacterial antigens in inflammatory bowel disease. Rowbotham DS, et al. **Clin Exp Immunol** 1995 Dec;102(3):456–61

Circulating IgA, IgG, and IgM class antibody against Haemophilus parainfluenzae antigens in patients with IgA nephropathy. Suzuki S, et al. **Clin Exp Immunol** 1996 May; 104(2):306–11

Divergence of human and nonhuman primate lymphocyte responses to bacterial superantigens. Bavari S, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):248–54

Definition of a discontinuous immunodominant epitope of intestinal alkaline phosphatase, an autoantigen in acute bacterial infections. Kolbus N, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):298–306

Evaluation of a Lyme disease enzyme immunoassay using the 41-G fragment of flagellin. Cretella S, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):609–13

Analysis of the immunological humoral response to Mycobacterium tuberculosis glycolipid antigens (DAT, PGLTb1) for diagnosis of tuberculosis in HIV-seropositive and -seronegative patients. Simonney N, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):883–91

Seroepidemiology of Q fever in Nova Scotia: evidence for age dependent cohorts and geographical distribution. Marrie TJ, et al. **Eur J Epidemiol** 1995 Feb;11(1):47–54

Cross-recognition by T cells of an epitope shared by two unrelated mycobacterial antigens. Harris DP, et al. **Eur J Immunol** 1995 Nov;25(11):3173–9

Analysis of the natural human IgG antibody repertoire: life-long stability of reactivities towards self antigens contrasts with age-dependent diversification of reactivities against bacterial antigens. Lacroix-Desmazes S, et al. **Eur J Immunol** 1995 Sep;25(9):2598–604

Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand-dependent mechanism: CTLA4-Ig protects V beta 8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B. Lane P, et al. **Eur J Immunol** 1996 Apr;26(4):858–62

One cause for the apparent inability of human T cell clones to function as professional superantigen-presenting cells is autoactivation. Nisini R, et al. **Eur J Immunol** 1996 Apr; 26(4):797–803

Abundance of H-2 promiscuous T cells specific for mycobacterial determinants in H-2b/d F1 hybrid mice. Vordermeier HM, et al. **Eur J Immunol** 1995 Oct; 25(10):2770–4

Evaluation of a novel tuberculosis complex-specific 34 kDa protein in the serological diagnosis of tuberculosis. Amicosante M, et al. **Eur Respir J** 1995 Dec;8(12):2008–14

T-cell recognition of mycobacterial antigens. Vordermeier HM. **Eur Respir J Suppl** 1995 Sep;20:657s–667s (121 ref.)

Antibody protection in aging: influence of idiotypic repertoire and antibody binding activity to a bacterial antigen. Nicoletti C. **Exp Mol Pathol** 1995 Apr;62(2):99–108

Investigation into the origin of the antigens of Mycoplasma arthritidis cross-reacting with host tissue antigens. Tangen G, et al. **FEMS Immunol Med Microbiol** 1995 Sep; 12(1):9–15

Production and identification of recombinant proteins of Salmonella typhimurium and their use in detection of antibodies in experimentally challenged animals. Kwang J, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):25–30

Effect of intestinal resection on serum antibodies to the mycobacterial 45/48 kilodalton doublet antigen in Crohn's disease. Kreuzpaintner G, et al. **Gut** 1995 Sep;37(3):361–6

Cross-reactive and species specific Mycobacterium tuberculosis antigens in the immunoprofile of Schaumann bodies: a major clue to the etiology of sarcoidosis. Ang SC, et al. **Histol Histopathol** 1996 Jan;11(1):125–34

Characterization of human T-cell responses to Yersinia enterocolitica superantigen. Stuart PM, et al. **Hum Immunol** 1995 Aug;43(4):269–75

Membrane-associated and cytosolic species-specific antigens of Mycoplasma bovis recognized by monoclonal antibodies. Rasberry U, et al. **Hybridoma** 1995 Oct;14(5):481–5

A Listeria monocytogenes pentapeptide is presented to cytolytic T lymphocytes by the H2-M3 MHC class Ib molecule. Gulden PH, et al. **Immunity** 1996 Jul;5(1):73–9

Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Morita CT, et al. **Immunity** 1995 Oct;3(4):495–507

Bacterial superantigens induce the proliferation of resting gamma/delta receptor bearing T cells. Ramesh N, et al. **Immunol Invest** 1995 Aug;24(5):713–24

Staphylococcal enterotoxin is a bovine T cell superantigen. Schmaltz R, et al. **Immunol Invest** 1995 Aug;24(5):805–18

T-cell dependent response to immune complexes abrogates B-cell unresponsiveness to pneumococcal cell wall polysaccharide. Caulfield MJ, et al. **Immunology** 1995 Nov; 86(3):331–5

T-cell lung granulomas induced by sepharose-coupled Mycobacterium tuberculosis protein antigens: immunosuppressive phenomena reversed with cyclophosphamide and indomethacin. Hernández-Pando R, et al. **Immunology** 1995 Dec;86(4):506–11

Conversion of Salmonella typhimurium to L-forms contributes to the maintenance of acquired immunity against murine typhoid. Kita E, et al. **Immunology** 1995 Oct;86(2):206–11

Cytokine profile of circulating T cells of leprosy patients reflects both indiscriminate and polarized T-helper subsets: T-helper phenotype is stable and uninfluenced by related antigens of Mycobacterium leprae. Misra N, et al. **Immunology** 1995 Sep;86(1):97–103

Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Roberts AD, et al. **Immunology** 1995 Jul;85(3):502–8

H-2-associated effects of flanking residues on the recognition of a permissive mycobacterial T-cell epitope. Román E, et al. **Immunology** 1995 Oct;86(2):183–9

Sequential production of Th1 and Th2 cytokines in response to live bacillus Calmette-Guérin. Sander B, et al. **Immunology** 1995 Dec;86(4):512–8

Immunogenicity of peptides coupled with multiple T-cell epitopes of a surface protein antigen of Streptococcus mutans. Senpuku H, et al. **Immunology** 1996 Jun; 88(2):275–83

Protection against tuberculosis by bone marrow cells expressing mycobacterial hsp65. Silva CL, et al. **Immunology** 1995 Dec;86(4):519–24

Induction of immune responses to functional determinants of a cell surface streptococcal antigen. Todryk SM, et al. **Immunology** 1996 Jan;87(1):55–63

New approaches to identification of antigens of Mycobacterium tuberculosis. Wallis RS. **Infect Agents Dis** 1996 Mar;5(2):119–25 (70 ref.)

Identification of surface-exposed B-cell epitopes on high molecular-weight adhesion proteins of nontypeable Haemophilus influenzae. Barenkam SJ, et al.

Infect Immun 1996 Aug;64(8):3032–7

Induction of a local anti–IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier. Barzu S, et al. **Infect Immun** 1996 Apr;64(4):1190–6

Identification and characterization of epitopes on the 120–kilodalton surface protein antigen of Rickettsia prowazekii with synthetic peptides. Ching WM, et al. **Infect Immun** 1996 Apr;64(4):1413–9

Induction of antigen–specific antibodies in vaginal secretions by using a nontoxic mutant of heat–labile enterotoxin as a mucosal adjuvant. Di Tommaso A, et al. **Infect Immun** 1996 Mar;64(3):974–9

P55, an immunogenic but nonprotective 55–kilodalton Borrelia burgdorferi protein in murine Lyme disease. Feng S, et al. **Infect Immun** 1996 Jan;64(1):363–5

Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick–transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Gilmore RD Jr, et al. **Infect Immun** 1996 Jun; 64(6):2234–9

Immune mechanisms and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development. Jonson G, et al. **Infect Immun** 1996 Sep; 64(9):3778–85

Monoclonal antibodies that recognize a common pneumococcal protein with similarities to streptococcal group A surface glyceraldehyde–3–phosphate dehydrogenase. Kolberg J, et al. **Infect Immun** 1996 Sep; 64(9):3544–7

Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha. Larsson C, et al. **Infect Immun** 1996 Sep;64(9):3518–23

Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi. Liao J, et al. **Infect Immun** 1995 Nov;63(11):4429–32

Immune response to Shigella sonnei in U.S. Marines. Mikhail MM, et al. **Infect Immun** 1996 Sep;64(9):3942–5

Antigen recognition during progression from acute to chronic infection with a cagA–positive strain of Helicobacter pylori. Mitchell HM, et al. **Infect Immun** 1996 Apr;64(4):1166–72

Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live–vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Noriega FR, et al. **Infect Immun** 1996 Jan;64(1):23–7

Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Rosenqvist E, et al. **Infect Immun** 1995 Dec;63(12):4642–52

Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit. Russell MW, et al. **Infect Immun** 1996 Apr;64(4):1272–83

An antigenic peptide inducing cross–reacting antibodies inhibiting the interaction of Streptococcus mutans PAc with human salivary components. Senpuku H, et al. **Infect Immun** 1995 Dec;63(12):4695–703

Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a. Turbyfill KR, et al. **Infect Immun** 1995 Oct;63(10):3927–35

Molecular characterization and T–cell–stimulatory capacity of Mycobacterium leprae antigen T5. Wieles B, et al. **Infect Immun** 1995 Dec;63(12):4682–5

Role of the capsular polysaccharide–like serotype–specific antigen in resistance of Actinobacillus actinomycetemcomitans to phagocytosis by human polymorphonuclear leukocytes. Yamaguchi N, et al. **Infect Immun** 1995 Dec;63(12):4589–94

Salicylate–enhanced exposure of Klebsiella pneumoniae subcapsular components. Salo RJ, et al. **Infection** 1995 Nov–Dec;23(6):371–7

ICAM–1 is required for T cell proliferation but not for anergy or apoptosis induced by Staphylococcus aureus enterotoxin B in vivo. Gonzalo JA, et al. **Int Immunol** 1995 Oct;7(10):1691–8

An MHC class II–expressing T cell clone presenting conventional antigen lacks the ability to present bacterial superantigen. Sun D, et al. **Int Immunol** 1995 Jul; 7(7):1079–85

The nature of the immunogen determines the specificity of antibodies and T cells to selected peptides of the 38 kDa mycobacterial antigen. Vordermeier HM, et al. **Int Immunol** 1995 Apr;7(4):559–66

IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting. Klaamas K, et al. **Int J Cancer** 1996 Jul 3;67(1):1–5

In vivo and in vitro study of the primary and secondary antibody response to a bacterial antigen in aged mice. Borghesi C, et al. **Int J Exp Pathol** 1995 Dec;76(6):419–24

Enhancement of antigen–specific antibody production by extracellular slime products from slime–forming Lactococcus lactis subspecies cremoris SBT 0495 in mice. Nakajima H, et al. **Int J Food Microbiol** 1995 Apr; 25(2):153–8

Immunological profiles of leprosy patients and healthy family contacts toward M. leprae antigens. Ilangumaran S, et al. **Int J Lepr Other Mycobact Dis** 1996 Mar;64(1):6–14

IgG subclass recognition pattern in leprosy: recognition of M. leprae antigens by IgG1 and IgG3 antibodies is distinct across the disease spectrum. Kifayet A, et al. **Int J Lepr Other Mycobact Dis** 1996 Mar;64(1):69–78

CD4+ T–cell responses to recombinant hsp65 and hsp18 of M. leprae and their trypsin–digested fragments in leprosy: diversity in HLA–DR restriction. Mitra DK, et al. **Int J Lepr Other Mycobact Dis** 1995 Dec;63(4):518–28

Analysis of T–cell and B–cell responses to recombinant M. leprae antigens in leprosy patients and in healthy contacts: significant T–cell responses to antigens in M. leprae nonresponders. Thole JE, et al. **Int J Lepr Other Mycobact Dis** 1995 Sep;63(3):369–80

Bacterial stimulators of macrophages. Hauschildt S, et al. **Int Rev Cytol** 1995;161:263–331 (341 ref.)

Coexistence of anti–salmonella agglutinins in falciparum malaria [letter] Khubnani H, et al. **J Assoc Physicians India** 1995 Aug;43(8):585–6

Antigenic specificity of lymphocytes isolated from valvular specimens of rheumatic fever patients. Yoshinaga M, et al. **J Autoimmun** 1995 Aug;8(4):601–13

Immunochemical features of a macromolecule of Treponema denticola. Yotis WW, et al. **J Basic Microbiol** 1995; 35(4):255–68

Comparison between bacillus Calmette–Guérin and the A60 mycobacterial antigen complex used as cancer–preventive immunotherapies. Maes H, et al. **J Cancer Res Clin Oncol** 1996;122(5):296–300

Antibodies in patients with inflammatory bowel disease and the apparent influence of medications. Song CH, et al. **J Clin Lab Immunol** 1995;46(4):143–54

Six newly recognized types of Streptococcus pneumoniae. Henrichsen J. **J Clin Microbiol** 1995 Oct;33(10):2759–62

Usefulness of ELISA using antigen A60 in serodiagnosis of neurotuberculosis. Thakur A, et al. **J Commun Dis** 1996 Mar;28(1):8–14

Immune system stimulation by probiotics. Perdigon G, et al. **J Dairy Sci** 1995 Jul;78(7):1597–606 (18 ref.)

Antigenic crossreactivity and lipopolysaccharide neutralization properties of bovine immunoglobulin G. Tomita GM, et al. **J Dairy Sci** 1995 Dec;78(12):2745–52

Induction of lymphocytes cytotoxic to oral epithelial cells by Streptococcus mitis superantigen. Matsushita K, et al. **J Dent Res** 1996 Mar;75(3):927–34

Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses. Kusunoki T, et al. **J Exp Med** 1995 Dec 1;182(6):1673–82

Cross–linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. Mehindate K, et al. **J Exp Med** 1995 Nov 1;182(5):1573–7

Inhibition of superantigen–induced proinflammatory cytokine production and inflammatory arthritis in MRL–lpr/lpr mice by a transcriptional inhibitor of TNF–alpha. Edwards CK 3rd, et al. **J Immunol** 1996 Aug 15;157(4):1758–72

Implantation of IL–2–containing osmotic pump prolongs the survival of superantigen–reactive T cells expanded in mice injected with bacterial superantigen. Kuroda K, et al. **J Immunol** 1996 Aug 15;157(4):1422–31

Nonviable bacterial antigens administered with IL–12 generate antigen–specific T cell responses and protective immunity against Listeria monocytogenes. Miller MA, et al. **J Immunol** 1995 Nov 15;155(10):4817–28

Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV–1–infected persons. Poccia F, et al. **J Immunol** 1996 Jul 1;157(1):449–61

CTL epitope generation is tightly linked to cellular proteolysis of a Listeria monocytogenes antigen. Sijts AJ, et al. **J Immunol** 1996 Feb 15;156(4):1497–503

Two Listeria monocytogenes CTL epitopes are processed from the same antigen with different efficiencies. Sijts AJ, et al. **J Immunol** 1996 Jan 15;156(2):683–92

Bacterial lipoproteins may substitute for cytokines in the humoral immune response to T cell–independent type II antigens. Snapper CM, et al. **J Immunol** 1995 Dec 15; 155(12):5582–9

Adjuvant–free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV–1 p24. Suzue K, et al. **J Immunol** 1996 Jan 15;156(2):873–9

Directing antigen specificity towards botulinum neurotoxin with combinatorial phage display libraries. Emanuel P, et al. **J Immunol Methods** 1996 Jun 21;193(2):189–97

Antibodies to lipopolysaccharide. Poxton IR. **J Immunol Methods** 1995 Oct 12;186(1):1–15 (85 ref.)

Development of a mucosal challenge test for leprosy using leprosin A. Ramaprasad P, et al. **J Immunol Methods** 1995 Dec 27;188(2):239–46

The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1–65 years. Cattaneo LA, et al. **J Infect Dis** 1996 May;173(5):1256–9

Pathogen antigen– and superantigen–reactive synovial fluid T cells in reactive arthritis. Lahesmaa R, et al. **J Infect Dis** 1995 Nov;172(5):1290–7

Immune response to recombinant mycobacterial proteins in patients with tuberculosis infection and disease. Mehra V, et al. **J Infect Dis** 1996 Aug;174(2):431–4

Antigenicity of amino–acid sequences from Clostridium difficile toxin B. Torres JF, et al. **J Med Microbiol** 1996 Jun;44(6):464–74

Development and evaluation of an ELISA to detect Escherichia coli K88 (F4) fimbrial antibody levels. Vazquez F, et al. **J Med Microbiol** 1996 Jun;44(6):453–63

New perspectives on inflammation in atopic dermatitis. Kemp AS, et al. **J Paediatr Child Health** 1996 Feb;32(1):4–6

Lymphomas of mucosa–associated lymphoid tissue and antigen drive [editorial; comment] Wright DH. **J Pathol** 1996 Feb;178(2):111–2 (14 ref.). Comment on: J Pathol 1996 Feb;178(2):122–7.

Reactive antibodies in sera from pubertal and adult gingivitis patients against various Porphyromonas gingivalis antigens. Nakagawa T, et al. **J Periodontal Res** 1995 Nov; 30(6):396–403

Immunoblot analysis of immune response to cell surface antigens of different Helicobacter pylori strains. Karczewska E, et al. **J Physiol Pharmacol** 1996 Mar; 47(1):115–20

Dot–ELISA for human leptospirosis employing immunodominant antigen. Ribeiro MA, et al. **J Trop Med Hyg** 1995 Dec;98(6):452–6

Reactivity of white–footed mouse and raccoon sera to whole cell and recombinant antigens of Borrelia burgdorferi. Magnarelli LA, et al. **J Wildl Dis** 1995 Jul;31(3):339–44

Role of gamma delta T cells in pathogenesis and diagnosis of Behcet's disease [see comments] Hasan A, et al. **Lancet** 1996 Mar 23;347(9004):789–94. Comment in: Lancet 1996 Jun 8;347(9015):1631–2.

Do serum antibodies to heat–shock protein 65 relate to age or stroke? [letter] Mantle R, et al. **Lancet** 1995 Dec 23–30; 346(8991–8992):1715

Aetiopathogenesis of Takayasu's arteritis and BCG vaccination: the missing link? Kothari SS. **Med Hypotheses** 1995 Sep;45(3):227–30

Comparative cutaneous testing with purified protein derivative and the antigen complex A60 in vaccinated subjects and tuberculosis patients. Zou YL, et al. **Med Microbiol Immunol (Berl)** 1995 May;184(1):9–15

The Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes. Muttilainen S, et al. **Microb Pathog** 1995 Jun; 18(6):423–36

Further characterization of Chlamydia pneumoniae specific monoclonal antibodies. Puolakkainen M, et al. **Microbiol Immunol** 1995;39(8):551–4

A highly immunogenic putative Mycobacterium kansasii lipoprotein. Armoa GR, et al. **Microbiology** 1995 Oct;141 (Pt 10):2705–12

A major T–cell–inducing cytosolic 23 kDa protein antigen of the vaccine candidate Mycobacterium habana is superoxide dismutase. Bisht D, et al. **Microbiology** 1996 Jun;142 (Pt 6):1375–83

Antigenic variability of Shigella flexneri serovars 1–5. Petrovskaya VG, et al. **Mol Gen Mikrobiol Virusol** 1995 Apr–Jun;(2):15–7

Molecular characterization of a monoclonal antibody produced in response to a group C meningococcal polysaccharide peptide mimic. Hutchins WA, et al. **Mol Immunol** 1996 Apr;33(6):503–10

The phoP locus influences processing and presentation of Salmonella typhimurium antigens by activated macrophages. Wick MJ, et al. **Mol Microbiol** 1995 May; 16(3):465–76

Isolation and characterization of the genes of pathogenic mycobacteria that express antigens for T cell reactivity. Mustafa AS. **Nutrition** 1995 Sep–Oct;11(5 Suppl):653–6

Identification of mycobacterial peptide epitopes recognized by CD4+ T cells in association with multiple major histocompatibility complex class II molecules. Mustafa AS. **Nutrition** 1995 Sep–Oct;11(5 Suppl):657–60

Recognition of mycobacterial HSP65 in association with HLA–DR4 is not sufficient for autoreactivity. Mustafa AS. **Nutrition** 1995 Sep–Oct;11(5 Suppl):661–4

High levels of complement–activation capacity in sera from patients with cystic fibrosis correlate with high levels of IgG3 antibodies to Pseudomonas aeruginosa antigens and poor lung function. Pressler T, et al. **Pediatr Pulmonol** 1995 Aug;20(2):71–7

Serologic responses to Bartonella and Afipia antigens in patients with cat scratch disease. Szelc–Kelly CM, et al. **Pediatrics** 1995 Dec;96(6):1137–42

Lyme vaccine enhancement. N–terminal acylation of a protein antigen and inclusion of a saponin adjuvant. Coughlin RT, et al. **Pharm Biotechnol** 1995;6:719–35 (126 ref.)

Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Hess J, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1458–63

Immunological response in mice after long–term stimulation with cell wall antigens from Brucella melitensis. Galdiero M, et al. **Res Microbiol** 1995 Jul–Aug;146(6):507–15

Characterisation of murine monoclonal antibodies recognising opsonic, mouse–protective, chaining and mucosally relevant epitopes on the M protein of Streptococcus equi subspecies equi. Timoney JF, et al. **Res Vet Sci** 1996 Jan;60(1):76–81

Antibody response to Mycobacterium tuberculosis antigens in children with pulmonary tuberculosis and in BCG vaccinated non tuberculous pediatric patients. López de Arcila C, et al. **Rev Latinoam Microbiol** 1995 Apr–Jun; 37(2):161–9

Humoral immune responses against particulate bacterial

antigens are dependent on marginal metallophilic macrophages in the spleen. Buiting AM, et al. **Scand J Immunol** 1996 Apr;43(4):398–405

Recognition of B-cell epitopes of the 65 kDa HSP in Behçet's disease. Direskeneli H, et al. **Scand J Immunol** 1996 Apr; 43(4):464–71

Cancer prevention by adoptive transfer of antigen 60-activated immunocompetent cells. Maes H, et al. **Scand J Immunol** 1996 Mar;43(3):283–8

Human T-cell epitopes on the Mycobacterium tuberculosis secreted protein MPT64. Roche PW, et al. **Scand J Immunol** 1996 Jun;43(6):662–70

Association of antibodies to heat-shock protein-65 with percutaneous transluminal coronary angioplasty and subsequent restenosis. Mukherjee M, et al. **Thromb Haemost** 1996 Feb;75(2):258–60

Phenotypic variation of carbohydrate surface antigens and the pathogenesis of Haemophilus influenzae infections. Roche RJ, et al. **Trends Microbiol** 1995 Aug;3(8):304–9 (60 ref.)

Bacterial superantigens in human disease: structure, function and diversity. Ulrich RG, et al. **Trends Microbiol** 1995 Dec; 3(12):463–8 (51 ref.)

Diagnostic utility of bacille Calmette-Guerin test in tuberculosis in adults [letter] Arya SC. **Tuber Lung Dis** 1996 Apr;77(2):195

Candidate antigens for improved serodiagnosis of tuberculosis. Bassey EO, et al. **Tuber Lung Dis** 1996 Apr; 77(2):136–45

T-cell response to mycobacterial proteins: a comparative study of tuberculous and control immunoblots of Mycobacterium tuberculosis and M. bovis BCG. Bassey EO, et al. **Tuber Lung Dis** 1996 Apr;77(2):146–53

Diagnostic utility of the estimation of mycobacterial Antigen A60 specific immunoglobulins IgM, IgA and IgG in the sera of cases of adult human tuberculosis. Gupta S, et al. **Tuber Lung Dis** 1995 Oct;76(5):418–24

Human antibody response to meningococcal transferrin binding proteins: evidence for vaccine potential. Gorringe AR, et al. **Vaccine** 1995 Sep;13(13):1207–12

Protection against oral challenge three months after i.v. immunization of BALB/c mice with live Aro Salmonella typhimurium and Salmonella enteritidis vaccines is serotype (species)-dependent and only partially determined by the main LPS O antigen. Hormaeche CE, et al. **Vaccine** 1996 Mar;14(4):251–9

Immunological parameters associated with antigenic competition in a multivalent footrot vaccine. Hunt JD, et al. **Vaccine** 1995 Dec;13(17):1649–57

Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Ivins B, et al. **Vaccine** 1995 Dec;13(18):1779–84

Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vordermeier HM, et al. **Vaccine** 1995 Nov;13(16):1576–82

Responses of bovine T cells to fractionated lysate and culture filtrate proteins of Mycobacterium bovis BCG. Gulle H, et al. **Vet Immunol Immunopathol** 1995 Sep;48(1–2):183–90

Serological crossreactivity between Brucella abortus and Yersinia enterocolitica 0:9 II the use of Yersinia outer proteins for the specific detection of Yersinia enterocolitica infections in ruminants. Kittelberger R, et al. **Vet Microbiol** 1995 Dec;47(3–4):271–80

Serological crossreactivity between Brucella abortus and Yersinia enterocolitica 0:9 I immunoblot analysis of the antibody response to Brucella protein antigens in bovine brucellosis. Kittelberger R, et al. **Vet Microbiol** 1995 Dec; 47(3–4):257–70

The protective efficacy of cloned Moraxella bovis pili in monovalent and multivalent vaccine formulations against experimentally induced infectious bovine keratoconjunctivitis (IBK). Lepper AW, et al. **Vet Microbiol** 1995 Jul;45(2–3):129–38

Serological response of cattle to Brucella allergen after repeated intradermal applications of this allergen. Muskens JA, et al. **Vet Microbiol** 1996 Jan;48(1–2):174–8

Comparative evaluation of antibodies induced by commercial Pasteurella haemolytica vaccines using solid phase immunoassays. Srinand S, et al. **Vet Microbiol** 1996 Apr; 49(3–4):181–95

Selective humoral immune response of Balb/C mice to Brucella abortus proteins expressed by vaccinia virus recombinants. Toth TE, et al. **Vet Microbiol** 1995 Jul; 45(2–3):171–83

Evaluation of SEF14 fimbrial dot blot and flagellar western blot tests as indicators of Salmonella enteritidis infection in chickens. Cooper GL, et al. **Vet Rec** 1996 Feb 17; 138(7):149–53

Antibodies in cat sera from southern Africa react with antigens of Ehrlichia canis. Matthewman LA, et al. **Vet Rec** 1996 Apr 13;138(15):364–5

Local cellular immune response in Helicobacter pylori associated type B gastritis--selective increase of CD4+ but not gamma delta T-cells in the immune response to H. pylori antigens. Seifarth C, et al. **Z Gastroenterol** 1996 Apr;34(4):215–24

[Preparation of monoclonal antibodies against 185-SA of Streptococcus mutans] Xie L, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 May; 30(3):178–80 **(Chi)**

[Evaluation of conventional and new generation tests for testing the humeral response to Mycoplasma pneumoniae antigens in natural infections in humans. II. Occurrence and level of mycoplasma antibodies in patients with respiratory tract infections] Rastawicki W. **Med Dosw Mikrobiol** 1995;47(1–2):55–76 (Eng. Abstr.) **(Pol)**

[Evaluation of conventional and new generation tests for testing the humeral response to Mycoplasma pneumoniae antigens in natural infection in humans. I. Occurrence and level of mycoplasma antibodies in clinically healthy subjects] Rastawicki W. **Med Dosw Mikrobiol** 1995; 47(1–2):35–53 (Eng. Abstr.) **(Pol)**

[Antigenic structure of the Bordetella pertussis pertactin Pro-rich segment 536–566. I. Preparation and analysis of antisera to synthetic peptides] Kavun EM, et al. **Biokhimiia** 1995 Jul;60(7):1023–31 (Eng. Abstr.) **(Rus)**

[The diagnostic and prognostic significance of the indices of the immune response to streptococcal group A antigens in rheumatism] Miasoedova SE, et al. **Ter Arkh** 1995; 67(11):69–71 (Eng. Abstr.) **(Rus)**

[The antigenic and immunogenic properties of the bivalent strain Shigella flexneri-Shigella sonnei 1 No. 200] Bondarenko VM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):47–8 **(Rus)**

[The effect of the antigens and strains of Yersinia pestis with the expression of different immunogenicity and virulence determinants on the level of lymphocyte blast transformation] Ledvanov MIu, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec;(6):4–5 **(Rus)**

[The accumulation in immune lymphocytes of the RNA sequences complementary to the gene controlling the synthesis of the corresponding heterologous antigen] Nikolaeva AI. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec;(6):63–4 **(Rus)**

[The production of hybridomas producing monoclonal antibodies to the causative agent of melioidosis by using antigen-stimulated lymphocytes in an in-vitro system] Titova NG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec;(6):82–3 **(Rus)**

[The use of inbred mice for studying the protective properties of Yersinia pestis antigens] Zadumina SIu, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):69–70 **(Rus)**

ISOLATION & PURIFICATION

Secretion of the mycobacterial 19-kilodalton protein by Escherichia coli, a novel method for the purification of recombinant mycobacterial antigens. Hewinson RG, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):23–9

Macrophage nitric oxide synthase (NOS) activation by Nocardia opaca fractions and 15- and 56-kD isolated antigens. Tučková L, et al. **Clin Exp Immunol** 1996 May; 104(2):215–20

Identifying and purifying protective immunogens from cultures of Clostridium chauvoei. Hauer PJ, et al. **Dev Biol Stand** 1996;86:332

Rapid detection of group B streptococcal antigen from vaginal specimens using a new Optical ImmunoAssay technique. Park CH, et al. **Diagn Microbiol Infect Dis** 1996 Mar;24(3):125–8

Localization of viable bacteria and bacterial antigens in arthritic joints of Erysipelothrix rhusiopathiae-infected pigs. Franz B, et al. **FEMS Immunol Med Microbiol** 1995 Oct;12(2):137–42

Purification and partial immunochemical characterization of proteins of fimbriae F107 from Escherichia coli isolated from edema disease of pigs. Rosocha J, et al. **Folia Microbiol (Praha)** 1995;40(5):541–6

Production of the 19-kDa antigen of Mycobacterium tuberculosis in Escherichia coli and its purification. Prestidge RL, et al. **Gene** 1995 Oct 16;164(1):129–32

Identification of an H2-M3-restricted Listeria epitope: implications for antigen presentation by M3. Lenz LL, et al. **Immunity** 1996 Jul;5(1):63–72

Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Andrews GP, et al. **Infect Immun** 1996 Jun;64(6):2180–7

Evaluation of two rapid antigen assays, BioStar Strep A OIA and Pacific Biotech CARDS O.S., and culture for detection of group A streptococci in throat swabs [letter; comment] Harbeck RJ. **J Clin Microbiol** 1995 Dec;33(12):3365–7. Comment on: J Clin Microbiol 1994 Nov;32(11):2698–701.

PCR and direct fluorescent-antibody staining confirm Chlamydia trachomatis antigens in swabs and urine below the detection threshold of Chlamydiazyme enzyme immunoassay. Krepel J, et al. **J Clin Microbiol** 1995 Nov; 33(11):2847–9

Comparison of commercial diagnostic tests for identification of serogroup antigens of Neisseria meningitidis. van der Ende A, et al. **J Clin Microbiol** 1995 Dec;33(12):3326–7

Protective efficacy of cell-free-antigen of Actinobacillus pleuropneumoniae in mice. Oishi E, et al. **J Vet Med Sci** 1995 Aug;57(4):727–31

Isolation of K88 antigen variants (ab, ac, ad) from porcine enterotoxigenic Escherichia coli belonging to different serotypes. González EA, et al. **Microbiol Immunol** 1995; 39(12):937–42

Purification of meningococcal lipo-oligosaccharide by FPLC techniques. Evans JS, et al. **Microbiology** 1996 Jan;142 (Pt 1):57–62

Identification and characterization of genus-specific epitopes of Serpulina species using monoclonal antibodies. Achacha M, et al. **Vet Microbiol** 1996 Jan;48(1–2):73–85

[Purification of serotype d-- and e--specific antigens from Actinobacillus actinomycetemcomitans and seroclassification of clinical isolates from periodontal patients] Yamamoto M. **Kokubyo Gakkai Zasshi** 1996 Mar; 63(1):174–87 (Eng. Abstr.) **(Jpn)**

METABOLISM

Identification of an immunoglobulin A binding motif located in the beta-antigen of the c protein complex of group B streptococci. Jerlström PG, et al. **Infect Immun** 1996 Jul; 64(7):2787–93

Porcine 987P glycolipid receptors on intestinal brush borders and their cognate bacterial ligands. Khan AS, et al. **Infect Immun** 1996 Sep;64(9):3688–93

Temperature-related differential expression of antigens in the Lyme disease spirochete, Borrelia burgdorferi. Stevenson B, et al. **Infect Immun** 1995 Nov;63(11):4535–9

Peptide epitopes from noncytosolic Listeria monocytogenes can be presented by major histocompatibility complex class I molecules. Zwickey HL, et al. **Infect Immun** 1996 May; 64(5):1870–2

Identification of major and minor chaperone proteins involved in the export of 987P fimbriae. Edwards RA, et al. **J Bacteriol** 1996 Jun;178(12):3426–33

Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. Malaviya R, et al. **J Immunol** 1996 Feb 15;156(4):1490–6

PHARMACOLOGY

Salmonella typhimurium infection in mice: lymphoproliferative responses to fractionated protein antigens. Melendro EI, et al. **Arch Med Res** 1995 Winter; 26(4):355–60

Lymphocyte reactivity to Clostridium perfringens antigens and toxoid in patients with arthritis [letter] Ström H, et al. **Br J Rheumatol** 1995 Nov;34(11):1095–6

Autoantibodies to human heat shock protein (hsp)60 may be induced by Escherichia coli groEL. Handley HH, et al. **Clin Exp Immunol** 1996 Mar;103(3):429–35

Vitamin A deficiency and retinoid repletion regulate the antibody response to bacterial antigens and the maintenance of natural killer cells. Ross AC. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S63–72

K1 and K3 capsular antigens of Klebsiella induce tumor necrosis factor activities. Choy YM, et al. **Life Sci** 1996; 58(9):PL153–8

A 38-kDa antigen of Mycobacterium tuberculosis predominantly induces the secretion of interleukin-2, interferon-gamma and IgG2a antibodies. Agrewala JN, et al. **Microbiol Immunol** 1995;39(10):801–8

Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Chang JC, et al. **Thorax** 1996 Mar; 51(3):306–11

PHYSIOLOGY

Gonococcal opacity protein promotes bacterial entry-associated rearrangements of the epithelial cell actin cytoskeleton. Grassmé HU, et al. **Infect Immun** 1996 May; 64(5):1621–30

Studies into the role of the SEF14 fimbrial antigen in the pathogenesis of Salmonella enteritidis. Thorns CJ, et al. **Microb Pathog** 1996 Apr;20(4):235–46

The EH-domain-containing protein Pan1 is required for normal organization of the actin cytoskeleton in Saccharomyces cerevisiae. Tang HY, et al. **Mol Cell Biol** 1996 Sep;16(9):4897–914

The secreted Ipa complex of Shigella flexneri promotes entry into mammalian cells. Ménard R, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1254–8

THERAPEUTIC USE

Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Litton MJ, et al. **Eur J Immunol** 1996 Jan;26(1):1–9

[Effect of Ribomunyl therapy on production of selected cytokines by mononuclear peripheral blood cells in nonatopic bronchial asthma] Moniuszko T, et al. **Pneumonol Alergol Pol** 1995;63 Suppl 2:71–5 (Eng. Abstr.) **(Pol)**

ULTRASTRUCTURE

Crystallization and preliminary X-ray analysis of Borrelia burgdorferi outer surface protein A (OspA) complexed with a murine monoclonal antibody Fab fragment. Li H, et al. **J Struct Biol** 1995 Nov-Dec;115(3):335–7

URINE

Failure of the urinary group B streptococcal antigen test as a screen for neonatal sepsis. Williamson M, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Sep;73(2):F109–11

Ultrasound-enhanced latex agglutination for the detection of bacterial antigens in urine. Gualano MP, et al.

ANTIGENS, BACTERIAL

Br J Biomed Sci 1995 Sep;52(3):178–83

Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy. Kashuba AD, et al. **Diagn Microbiol Infect Dis** 1996 Mar;24(3):129–39 (31 ref.)

ANTIGENS, CARBOHYDRATE, TUMOR-ASSOCIATED
see **ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE**

ANTIGENS, CD

Inhibition of Sephadex-induced lung injury in the rat by Ro 45-2081, a tumor necrosis factor receptor fusion protein. Gater PR, et al. **Am J Respir Cell Mol Biol** 1996 May; 14(5):454–60

CD98: a type II transmembrane glycoprotein expressed from the beginning of primitive and definitive hematopoiesis may play a critical role in the development of hematopoietic cells. Warren AP, et al. **Blood** 1996 May 1;87(9):3676–87

Characterization of eosinophils generated in vitro from CD34+ peripheral blood progenitor cells. Rosenberg HF, et al. **Exp Hematol** 1996 Jul;24(8):888–93

Tumor necrosis factor alpha is a potent synergistic factor for the proliferation of primitive human hematopoietic progenitor cells and induces resistance to transforming growth factor beta but not to interferon gamma. Snoeck HW, et al. **J Exp Med** 1996 Feb 1;183(2):705–10

CD34+ progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing. Colter M, et al. **J Hematother** 1996 Apr;5(2):179–84 (22 ref.)

Does CD34+ cell selection enrich malignant stem cells in B cell (and other) malignancies? [letter] Reading CL. **J Hematother** 1996 Apr;5(2):97–8

Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. Van Zee KJ, et al. **J Immunol** 1996 Mar 15;156(6):2221–30

CD34+/CD33+ blast cells: correlation with FAB subtypes. Rigolin GM, et al. **Leuk Lymphoma** 1995;18 Suppl 1:43–8

Human CNTF and related cytokines: effects on DRG neurone survival. Simon R, et al. **Neuroreport** 1995 Dec 29;7(1):153–7

1995 directory for the human leukocyte clusters of differentiation [see comments] Stockinger H, et al. **Transfusion** 1996 Mar;36(3):268–85. Comment in: Transfusion 1996 Mar;36(3):197–9.

[CD22: a cell adhesion molecule that displays alpha 2-6-linked sialic acid-binding lectin activity] Hanasaki K. **Seikagaku** 1995 Aug;67(8):1040–7 (15 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Matteson EL, et al. **Arthritis Rheum** 1995 Sep;38(9):1187–93

Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Osterborg A, et al. **Br J Haematol** 1996 Apr;93(1):151–3

ANALYSIS

Fine needle aspiration cytology, histology and immunohistochemistry of anaplastic large cell Ki-1-positive lymphoma. A report of three cases. McCluggage WG, et al. **Acta Cytol** 1996 Jul–Aug; 40(4):779–85

Interleukin-6 and soluble interleukin-6 receptor in cord blood in the diagnosis of early onset sepsis in neonates. Lehrnbecher T, et al. **Acta Paediatr** 1995 Jul;84(7):806–8

Phenotype of HML-1-positive and HML-1-negative T lymphocytes in the human intestinal lamina propria. Schieferdecker HL, et al. **Adv Exp Med Biol** 1995; 371A:77–9

Diagnostic significance of CD40, CD40L, and CD26 expression in Hodgkin's disease and other lymphomas [letter] Carbone A, et al. **Am J Clin Pathol** 1996 Apr; 105(4):522–3

Distributions of melanoma growth stimulatory activity of growth-regulated gene and the interleukin-8 receptor B in human wound repair. Nanney LB, et al. **Am J Pathol** 1995 Nov;147(5):1248–60

Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Niehans GA, et al. **Am J Pathol** 1996 Jul;149(1):129–42

Increased expression of interleukin-4 receptors on psoriatic epidermal cells. Prens E, et al. **Am J Pathol** 1996 May; 148(5):1493–502

In situ analysis of B7-2 costimulatory, major histocompatibility complex class II, and adhesion molecule expression in schistosomal egg granulomas. Rathore A, et al. **Am J Pathol** 1996 Jul;149(1):187–94

Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Skubitz AP, et al. **Am J Pathol** 1996 May;148(5):1445–61

Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Gattorno M, et al. **Ann Rheum Dis** 1996 Apr;55(4):243–7

Intracellular and surface distribution of CD9 in human eosinophils. Fernvik E, et al. **APMIS** 1995 Oct; 103(10):699–706

A histological and immunohistological study of malarial placentas. Moshi EZ, et al. **APMIS** 1995 Oct; 103(10):737–43

The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Liu MF, et al. **Arthritis Rheum** 1996 Jan;39(1):110–4

Responsiveness of human T lymphocytes to bacterial superantigens presented by cultured rheumatoid arthritis synoviocytes. Tsai C, et al. **Arthritis Rheum** 1996 Jan; 39(1):125–36

Soluble form of Lamp II in purified rat liver lysosomes. Jadot M, et al. **Biochem Biophys Res Commun** 1996 Jun 14; 223(2):353–9

A porcine homolog of human integrin alpha 6 is a differentiation antigen of granulosa cells. Fujiwara H, et al. **Biol Reprod** 1995 Aug;53(2):407–17

Azure B-eosin APAAP staining: a method for simultaneous hematological and immunological cell analysis. Koch B, et al. **Biotech Histochem** 1995 Sep;70(5):267–70

Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Creutzig U, et al. **Blood** 1995 Oct 15; 86(8):3097–108

CDW60, which identifies the acetylated form of GD3 gangliosides, is strongly expressed in human basal cell carcinoma. Heidenheim M, et al. **Br J Dermatol** 1995 Sep; 133(3):392–7

Improved flow cytometric identification of myelopoiesis by the simultaneous labelling with CD13, CD14 and CD66 monoclonal antibodies. Bonde J, et al. **Br J Haematol** 1996 Feb;92(2):269–79

Expression of lymphoid-associated antigens in mast cells: report of a case of systemic mast cell disease. Escribano L, et al. **Br J Haematol** 1995 Dec;91(4):941–3

Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Garcia-Sanz R, et al. **Br J Haematol** 1996 Apr;93(1):81–8

Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies. Lavabre-Bertrand T, et al. **Br J Haematol** 1995 Dec;91(4):871–7

Quantitation of soluble and membrane-bound Fc gamma RIIA (CD32A) mRNA in platelets and megakaryoblastic cell line (Meg-01). Markovic B, et al. **Br J Haematol** 1995 Sep;91(1):37–42

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Reddish MA, et al. **Cancer Immunol Immunother** 1996 Jun;42(5):303–9

Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Miyake M, et al. **Cancer Res** 1996 Mar 15;56(6):1244–9

Quantitative evaluation of lysozyme- and CD68-positive Kupffer cells in diethylnitrosamine-induced hepatocellular carcinomas in monkeys. Lapis K, et al. **Carcinogenesis** 1995 Dec;16(12):3083–5

Immunological abnormality in C3H/HeJ mice with heritable inflammatory bowel disease. Ni J, et al. **Cell Immunol** 1996 Apr 10;169(1):7–15

Plasma inhibitory activity against tumour necrosis factor in fulminant hepatic failure. Keane HM, et al. **Clin Sci (Colch)** 1996 Jan;90(1):77–80

Early prediction of outcome in score-identified, postcardiac surgical patients at high risk for sepsis, using soluble tumor necrosis factor receptor-p55 concentrations. Pilz G, et al. **Crit Care Med** 1996 Apr;24(4):596–600

Identification of a soluble, high affinity human interleukin 4 binding protein in normal human urine. Christie G, et al. **Cytokine** 1995 May;7(4):305–10

Near-IR dyes in three-color volumetric capillary cytometry: cell analysis with 633- and 785-nm laser excitation. Lee LG, et al. **Cytometry** 1995 Oct 1;21(2):120–8

Heterogeneous calcium flux in peripheral T cell subsets revealed by five-color flow cytometry using log-ratio circuitry. Roederer M, et al. **Cytometry** 1995 Oct 1; 21(2):187–96

Localization of alpha 4m integrin at sites of mesenchyme condensation during embryonic mouse development. Jaspers M, et al. **Differentiation** 1995 Sep;59(2):79–86

Relationship between bone metabolism and plasma cytokine levels in patients at risk of post-transplantation bone disease after bone marrow transplantation. Withold W, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):295–9

A sensitive assay for detecting low-affinity interactions at the cell surface reveals no additional ligands for the adhesion pair rat CD2 and CD48. Brown MH, et al. **Eur J Immunol** 1995 Dec;25(12):3222–8

Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti-C5a receptor (CD88) antibodies. Elsner J, et al. **Eur J Immunol** 1996 Jul;26(7):1560–4

Lineage commitment of CD34+ human hematopoietic progenitor cells. Tjønnfjord GE, et al. **Exp Hematol** 1996 Jul;24(8):875–82

Effect of 4-Hydroxynonenal on cell cycle progression and expression of differentiation-associated antigens in HL-60 cells. Barrera G, et al. **Free Radic Biol Med** 1996; 20(3):455–62

Immunohistochemical staining of ovarian granulosa cell tumours with MIC2 antibody. Loo KT, et al. **Histopathology** 1995 Oct;27(4):388–90

Granular cell epulis [letter; comment] Charles A. **Hum Pathol** 1996 Jan;27(1):96. Comment on: Hum Pathol 1994 Nov;25(11):1172–8.

What does CD68 in activated lymphocyte mean? [letter] Hameed A. **Hum Pathol** 1995 Nov;26(11):1285–6

Cell surface determinants on typhoid-specific B cells isolated from peripheral blood after oral Ty21a typhoid vaccination in humans. Penttila IA, et al. **Immunol Cell Biol** 1995 Jun; 73(3):198–204

Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Agis H, et al. **Immunology** 1996 Apr;87(4):535–43

The immunodiagnosis of Hodgkin's disease [editorial] Carbone A, et al. **Int J Biol Markers** 1996 Jan–Mar; 11(1):1–5 (36 ref.)

Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas. Goslings WR, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1884–91

Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection. Frissen PH, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):482–8

Alpha v and alpha 3 integrin subunits are associated with myofibrils during myofibrillogenesis. McDonald KA, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2573–81

Integrin alpha 6 is a differentiation antigen of human granulosa cells. Honda T, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2899–905

Soluble interleukin-6 (IL-6) receptor in the sera of pregnant women forms a complex with IL-6 and augments human chorionic gonadotropin production by normal human trophoblasts through binding to the IL-6 signal transducer. Matsuzaki N, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):2912–7

Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia. Cordone I, et al. **J Clin Pathol** 1995 Oct;48(10):955–60

Use of buffered formaldehyde in the enzymatic digestion of inflamed mucosa. Meenan J, et al. **J Clin Pathol** 1996 Feb; 49(2):177–9

Colocalization of scavenger receptor in CD68 positive foam cells in verruciform xanthoma. Furue M, et al. **J Dermatol Sci** 1995 Nov;10(3):213–9

CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. Prall F, et al. **J Histochem Cytochem** 1996 Jan;44(1):35–41

Identification of a mouse protein homologous to the human CD6 T cell surface protein and sequence of the corresponding cDNA. Robinson WH, et al. **J Immunol** 1995 Nov 15;155(10):4739–48

Tissue digestion with dispase substantially reduces lymphocyte and macrophage cell-surface antigen expression. Ford AL, et al. **J Immunol Methods** 1996 Jul 17;194(1):71–5

Interleukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis. Kornelisse RF, et al. **J Infect Dis** 1996 Jun;173(6):1498–502

In human dermis, ultraviolet radiation induces expansion of a CD36+ CD11b+ CD1- macrophage subset by infiltration and proliferation; CD1+ Langerhans-like dendritic antigen-presenting cells are concomitantly depleted. Meunier L, et al. **J Invest Dermatol** 1995 Dec; 105(6):782–8

Lack of increased serum interleukin-6 and soluble IL-6 receptor concentrations in patients with thyroid diseases following recombinant human interferon alpha therapy. Minelli R, et al. **J Investig Med** 1996 Aug;44(6):370–4

The inflammatory response in pediatric biliary disease: macrophage phenotype and distribution. Tracy TF Jr, et al. **J Pediatr Surg** 1996 Jan;31(1):121–5; discussion 125–6

Characterization of interleukin-13 receptor in carcinoma cell lines and human blood cells and comparison with the interleukin-4 receptor. Feng N, et al. **J Recept Signal Transduct Res** 1995 Sep–Dec; 15(7–8):931–49

Cellular localization and steroid hormone regulation of mRNA encoding tumour necrosis factor receptor I in mouse uterus. Roby KF, et al. **J Reprod Fertil** 1996 Mar; 106(2):285–90

Soluble tumor necrosis factor receptors and soluble interleukin-6 receptor in fetal and maternal sera, coelomic and amniotic fluids in normal and pre-eclamptic pregnancies. Opsjøn SL, et al. **J Reprod Immunol** 1995 Jul; 29(2):119–34

High levels of soluble p55-TNF receptors in seminal and prostatic fluids of normal and infertile men. Tur-Kaspa I, et al. **J Urol** 1996 Apr;155(4):1436–8

Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Chaux P, et al. **Lab Invest** 1996 May;74(5):975–83

Levels of CAF7 (CD98) expression correlate with the complete remission duration in childhood acute leukemia. Taskov H, et al. **Leuk Res** 1996 Jan;20(1):75–9

Phenotype and progeny of primitive adherent human hematopoietic progenitors. Gordon MY, et al. **Leukemia**

1996 Aug;10(8):1347–53
High prevalence of T cell receptor D delta 2(D delta)J delta rearrangement in CD7-positive early T cell acute lymphoblastic leukemia. Kimura N, et al. **Leukemia** 1996 Apr;10(4):650–7
Acute undifferentiated leukemia with an unusual CD7+ CD56+ CD33+ immunophenotype of NK progenitors [letter] Reuss-Borst MA, et al. **Leukemia** 1996 May; 10(5):923–4
Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Rothe G, et al. **Leukemia** 1996 May;10(5):877–95
Immune phenotype and some enzyme patterns in phorbol ester-induced chronic lymphocytic leukemia cells. Babušíková O, et al. **Neoplasma** 1995;42(5):221–6
Evaluation of different fixation-permeabilization methods for simultaneous detection of surface, cytoplasmic markers and DNA analysis by flow cytometry in some human hematopoietic cell lines. Glasová M, et al. **Neoplasma** 1995; 42(6):337–46
Phorbol ester (TPA)-induced differential modulation of cell surface antigens in human pluripotential leukemia (K-562) cell line: effects of protein kinase inhibitors with broad- and PKC selective inhibitory activity. Hunáková L, et al. **Neoplasma** 1995;42(5):249–53
A comparison of some leucocyte differentiation markers and the adenosine deaminase and purine nucleoside phosphorylase values in B and T cell leukemias and lymphomas. Mesárošová A, et al. **Neoplasma** 1995; 42(6):307–12
Integrin distribution in gastric carcinoma: association of beta 3 and beta 5 integrins with tumor invasiveness. Kawahara E, et al. **Pathol Int** 1995 Jul;45(7):493–500
CD68+ reactive histiocytosis complicating early gastric cancer [letter] Ogawa Y, et al. **Pathol Int** 1995 Sep; 45(9):698–701
Distribution of interferon-gamma receptors in normal and psoriatic skin. van den Oord JJ, et al. **Pathol Res Pract** 1995 Jul;191(6):530–4
Clinical significance of childhood acute myeloid leukemias expressing lymphoid-associated antigens. Kawai S, et al. **Pediatr Hematol Oncol** 1995 Sep-Oct;12(5):463–9
Childhood acute myeloid leukemias expressing lymphoid-associated antigens [editorial] Schaison GS. **Pediatr Hematol Oncol** 1995 Sep-Oct;12(5):413–5
Soluble interleukin-6 receptor levels in pleural effusions. Yokoyama A, et al. **Respir Med** 1996 Jul;90(6):329–32
Identification and characterization of specific receptor for interleukin-8 from the surface of human monocytes. Bishayi B, et al. **Scand J Immunol** 1996 May;43(5):531–6
CD3-4-8- thymocyte precursors with interleukin-2 receptors differentiate phenotypically in coculture with thymic stromal cells. Small M, et al. **Scand J Immunol** 1996 Aug;44(2):115–21
The red cell chemokine receptor is distinct from the Fy6 epitope. Hausman E, et al. **Transfusion** 1996 May; 36(5):421–5
CD45 isoforms and lymphocyte activation antigens in acute renal allograft rejection. Battochio A, et al. **Transplant Proc** 1996 Feb;28(1):482–3
Molecular activation markers in rejection diagnosis. von Willebrand E, et al. **Transplant Proc** 1996 Feb;28(1):484–5
Canine lymphoma: immunocytochemical analysis of fine-needle aspiration biopsy. Caniatti M, et al. **Vet Pathol** 1996 Mar;33(2):204–12
Distribution of thrombospondin and integrin alpha V in DCIS, invasive ductal and lobular human breast carcinomas. Analysis by electron microscopy. Serre CM, et al. **Virchows Arch** 1995;427(4):365–72
[Importance of the expression of the C6 molecule on cells in chronic lymphatic leukemia] Krejsek J, et al. **Vnitr Lek** 1996 Apr;42(4):274–7 (Eng. Abstr.) **(Cze)**
[Predicting recurrent pterygium based on morphologic and immunohistologic parameters] Rohrbach IM, et al. **Ophthalmologe** 1995 Aug;92(4):463–8 (Eng. Abstr.) **(Ger)**
[Detection of minimal residual disease in acute leukemias by immunophenotyping of bone marrow cells] Deptała A, et al. **Acta Haematol Pol** 1995;26(4):403–11 (Eng. Abstr.) **(Pol)**
[Clinical significance and prognostic detection of minimal residual disease in acute leukemias] Deptała A, et al. **Acta Haematol Pol** 1995;26(4):413–20 (Eng. Abstr.) **(Pol)**
[Chronic lymphatic leukemia from B CD5+ cells: characteristics, clinical and laboratory features, and immunophenotyping] Dwilewicz-Trojaczek J. **Pol Tyg Lek** 1995 Oct;50(40–44):12–4 (Eng. Abstr.) **(Pol)**
[Cellular and intracellular markers of lymphocyte activation in patients with infiltrative pulmonary tuberculosis] Mishin VIu, et al. **Probl Tuberk** 1995;(4):45–8 (Eng. Abstr.) **(Rus)**
[Expression of primitive stem cell antigens on the blast cells of patients with chronic myeloid leukemia] Baryshnikov AIu. **Vestn Ross Akad Med Nauk** 1996;(3):9–13 (53 ref.) (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Expression of VLA-4 and L-selectin in human gut-associated lymphoid tissue (GALT). Farstad IN, et al. **Adv Exp Med Biol** 1995;371A:91–6
Lymphoid-associated antigen expression by acute myeloid leukemia. Launder TM, et al. **Am J Clin Pathol** 1996 Aug; 106(2):185–91
CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Gruss HJ, et al. **Am J Pathol** 1996 Aug;149(2):469–81
Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Mäenpää A, et al. **Am J Pathol** 1996 Apr;148(4):1139–52
Expression and distribution of CD9 in myelin of the central and peripheral nervous systems. Nakamura Y, et al. **Am J Pathol** 1996 Aug;149(2):575–83
Interleukin 6-receptor expression on human bronchial epithelial cells: regulation by IL-1 and IL-6. Takizawa H, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):L346–52
IL-4 is not involved in the early MLN T-cell response to antigen given orally with cholera toxin, but those cells can express IL-4R. Snider DP, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:427–8
Effects of TNF-alpha and retinoic acid on the proliferation of the clear cell and chromophilic types of human renal cell carcinoma in vitro. Gerharz CD, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1633–41
Absence of detectable alpha 6 integrin in pyloric atresia-junctional epidermolysis bullosa syndrome. Application for prenatal diagnosis in a family at risk for recurrence. Shimizu H, et al. **Arch Dermatol** 1996 Aug; 132(8):919–25
Surface expression of CD63 antigen (AD1 antigen) in P815 mastocytoma cells by transfected IgE receptors. Furuno T, et al. **Biochem Biophys Res Commun** 1996 Feb 27; 219(3):740–4
An alternatively spliced form of the human lysosome-associated membrane protein-2 gene is expressed in a tissue-specific manner. Konecki DS, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):757–67
Human leukocyte integrin CD18 promoter directs low levels of expression of a mutated human CD4 reporter gene in leukocytes of transgenic mice. Kwiatkowski BA, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):601–6
Inhibition of sphingolipid synthesis down-modulates CD4 expression by peripheral blood T lymphocytes and T lymphoma cells. Tamma SL, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):916–21
Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines. Hatanaka M, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):969–76
Interleukin-1 alpha upregulates tumor necrosis factor receptors expressed by a human bone marrow stromal cell strain: implications for cytokine redundancy and synergy. Caldwell J, et al. **Blood** 1995 Nov 1;86(9):3364–72
Rapid and efficient selection of human hematopoietic cells expressing murine heat-stable antigen as an indicator of retroviral-mediated gene transfer. Conneally E, et al. **Blood** 1996 Jan 15;87(2):456–64
Decreased inducible expression of CD80 and CD86 in human monocytes after ultraviolet-B irradiation: its involvement in inactivation of allogenecity. Fujihara M, et al. **Blood** 1996 Mar 15;87(6):2386–93
Deficient expression of adhesion molecules by human CD5-B lymphocytes both after bone marrow transplantation and during normal ontogeny. Parra C, et al. **Blood** 1996 Sep 1;88(5):1733–40
Regulation of alpha 2 integrin gene expression in cells with megakaryocytic features: a common theme of three necessary elements. Zutter MM, et al. **Blood** 1995 Oct 15; 86(8):3006–14
Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin. Chiang HS, et al. **Br J Cancer** 1996 Apr;73(7):902–8
Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Adachi M, et al. **Cancer Res** 1996 Apr 15;56(8):1751–5
Gradient of integrin alpha 6A distribution in the myocardium during early heart development. Collo G, et al. **Cell Adhes Commun** 1995 May;3(2):101–13
An alternatively spliced exon in the extracellular domain of the human alpha 6 integrin subunit--functional analysis of the alpha 6 integrin variants. Delwel GO, et al. **Cell Adhes Commun** 1995 May;3(2):143–61
Selective induction of CD11a,b,c/CD18 and CD54 expression at the cell surface of human leukocytes by muramyl peptides. Darcissac EC, et al. **Cell Immunol** 1996 May 1;169(2):294–301
Signaling by a new anti-Thy 1 monoclonal antibody inhibits T cell proliferation and interferes with T-cell-mediated induction of costimulatory molecule B7-2. Wu Y, et al. **Cell Immunol** 1995 Oct 15;165(2):266–77
Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Liaw L, et al. **Circ Res** 1995 Oct;77(4):665–72
Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in IDDM. Giordano C, et al. **Diabetologia** 1995 Dec;38(12):1449–54
Characterization and regulation of interleukin-4 receptor in adult T-cell leukemia cells. Mori N, et al. **Eur J Haematol** 1996 Apr;56(4):241–7
Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Buelens C, et al. **Eur J Immunol** 1995 Sep; 25(9):2668–72
Expression of an avian CD6 candidate is restricted to alpha beta T cells, splenic CD8+ gamma delta T cells and embryonic natural killer cells. Göbel TW, et al. **Eur J Immunol** 1996 Aug;26(8):1743–7
Identification of a novel subpopulation of germinal center B cells characterized by expression of IgD and CD70. Lens SM, et al. **Eur J Immunol** 1996 May;26(5):1007–11
Expression of monocyte chemoattractant protein-1 and interleukin-8 receptors on subsets of T cells: correlation with transendothelial chemotactic potential. Oin S, et al. **Eur J Immunol** 1996 Mar;26(3):640–7
Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells. Rattis FM, et al. **Eur J Immunol** 1996 Feb;26(2):449–53
Raf-1 provides a dominant but not exclusive signal for the induction of CD69 expression on T cells. Taylor-Fishwick DA, et al. **Eur J Immunol** 1995 Dec;25(12):3215–21
Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue. Vyth-Dreese FA, et al. **Eur J Immunol** 1995 Nov; 25(11):3023–9
Low-dose UVB radiation perturbs the functional expression of B7.1 and B7.2 co-stimulatory molecules on human Langerhans cells. Weiss JM, et al. **Eur J Immunol** 1995 Oct;25(10):2858–62
Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: regulation by CD4+ T cells. Wolthers KC, et al. **Eur J Immunol** 1996 Aug;26(8):1700–6
Expression of the integrin alpha 5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation. O'Brien V, et al. **Exp Cell Res** 1996 Apr 10; 224(1):208–13
Natural human interferon-alpha enhances the expression of intracellular adhesion molecule-1, integrin alpha 2 and beta 1 by a mucosal epithelial cell line. Dao T, et al. **Folia Biol (Praha)** 1995;41(5):213–25
Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Carreiras F, et al. **Gynecol Oncol** 1996 Aug;62(2):260–7
Differential display and integrin alpha 6 messenger RNA overexpression in hepatocellular carcinoma. Begum NA, et al. **Hepatology** 1995 Nov;22(5):1447–55
Heterogeneity of antigen expression among human umbilical cord vascular endothelial cells: identification of cell subsets by co-expression of haemopoietic antigens. Vermot-Desroches C, et al. **Immunol Lett** 1995 Nov; 48(1):1–9
Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment. Brett SJ, et al. **Int Immunol** 1996 Mar;8(3):325–34
Expression of CD69 after in vitro stimulation: a rapid method for quantitating impaired lymphocyte responses in HIV-infected individuals. Krowka JF, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):95–104
Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS. Sippy BD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 15;10(5):511–21
Upregulated expression of IL-4 receptors and increased levels of IL-4 in rheumatoid arthritis patients. Rivas D, et al. **J Autoimmun** 1995 Aug;8(4):587–600
Structural and functional characterization of the human CD36 gene promoter: identification of a proximal PEBP2/CBF site. Armesilla AL, et al. **J Biol Chem** 1996 Mar 29;271(13):7781–7
Granulocyte-colony stimulating factor and lipopolysaccharide regulate the expression of interleukin 8 receptors on polymorphonuclear leukocytes. Lloyd AR, et al. **J Biol Chem** 1995 Nov 24;270(47):28188–92
Post-translational modification of CD38 protein into a high molecular weight form alters its catalytic properties. Umar S, et al. **J Biol Chem** 1996 Jul 5;271(27):15922–7
Extracellular matrix alters PDGF regulation of fibroblast integrins. Xu J, et al. **J Cell Biol** 1996 Jan;132(1–2):239–49
Transcriptional activation of endothelial cell integrin alpha v by protein kinase C activator 12(S)-HETE. Tang DG, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2629–44
Accelerated Nerve Regeneration in Mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma [see comments] Hirota H, et al. **J Exp Med** 1996 Jun 1;183(6):2627–34. Comment in: J Exp Med 1996 Jun 1;183(6):2417–9.
Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia [see comments] Simon HU, et al. **J Exp Med** 1996 Mar 1;183(3):1071–82. Comment in: J Exp Med 1996 Mar 1;183(3):721–4.
Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate. Wetzler LW, et al. **J Exp Med** 1996 Mar 1;183(3):1151–9
Enhanced interferon-gamma production and B7-2 expression in isolated intestinal mononuclear cells from patients with Crohn's disease. Noguchi M, et al. **J Gastroenterol** 1995

Nov;30 Suppl 8:52–5
Rejection of MHC class II–transfected tumor cells requires induction of tumor–encoded B7–1 and/or B7–2 costimulatory molecules. Baskar S, et al. **J Immunol** 1996 May 15;156(10):3821–7
Differential expression of alternate mB7–2 transcripts. Borriello F, et al. **J Immunol** 1995 Dec 15;155(12):5490–7
Reduction of early B lymphocyte precursors in transgenic mice overexpressing the murine heat–stable antigen. Hough MR, et al. **J Immunol** 1996 Jan 15;156(2):479–88
Activation of human eosinophils by IL–13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. Luttmann W, et al. **J Immunol** 1996 Aug 15;157(4):1678–83
Heat shock protein 65 induces CD62e, CD106, and CD54 on cultured human endothelial cells and increases their adhesiveness for monocytes and granulocytes. Verdegaal ME, et al. **J Immunol** 1996 Jul 1;157(1):369–76
Effects of ex vivo manipulation on the expression of cell adhesion molecules on neutrophils. Youssef PP, et al. **J Immunol Methods** 1995 Oct 26;186(2):217–24
Polymorphonuclear leukocyte opsonic receptor expression after hypoxia/reoxygenation. Simms H, et al. **J Lab Clin Med** 1996 Apr;127(4):364–81
Desmopressin stimulates the expression of P–selectin on human platelets in vitro. Wun T, et al. **J Lab Clin Med** 1995 Oct;126(4):401–9
Control of the production of soluble interleukin–4 receptors: implications in immunoregulation. Fernandez–Botran R, et al. **J Leukoc Biol** 1996 Apr;59(4):499–504 (35 ref.)
Beta3 integrin expression in melanoma predicts subsequent metastasis. Hieken TJ, et al. **J Surg Res** 1996 Jun; 63(1):169–73
High expression of a CD38–like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. Kramer G, et al. **J Urol** 1995 Nov;154(5):1636–41
CD4 down–modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. Chen BK, et al. **J Virol** 1996 Sep;70(9):6044–53
Differential downregulation of CD46 by measles virus strains. Schneider–Schaulies J, et al. **J Virol** 1995 Nov; 69(11):7257–9
Expression of CD60 on multiple cell lineages in inflammatory synovitis. Carr K, et al. **Lab Invest** 1995 Sep;73(3):332–8
Human nasal epithelium adsorbs complement C3–related fragments and expresses cell membrane complement regulatory proteins. Varsano S, et al. **Laryngoscope** 1996 May;106(5 Pt 1):599–604
TCR delta gene rearrangements in acute myeloid leukemia with T–lymphoid antigen expression. Schmidt CA, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):45–9 (57 ref.)
Differential expression of B29 (CD79b) and mb–1 (CD79a) proteins in acute lymphoblastic leukaemia. Astsaturov IA, et al. **Leukemia** 1996 May;10(5):769–73
CD49f (alpha 6 integrin) and CD66a (BGP) are specifically induced by retinoids during human monocytic differentiation. Botling J, et al. **Leukemia** 1995 Dec; 9(12):2034–41
Intercellular adhesion molecules (ICAMs) 2 and 3 are frequently expressed in B cell chronic lymphocytic leukemia. Molica S, et al. **Leukemia** 1996 May;10(5):907–8
Assembly and function of integrin receptors is dependent on opposing alpha and beta cytoplasmic domains. Briesewitz R, et al. **Mol Biol Cell** 1995 Aug;6(8):997–1010
Transcriptional regulation of the human CD9 gene: characterization of the 5'–flanking region. Le Naour F, et al. **Oncogene** 1996 Aug 1;13(3):481–6
Interleukin 2 (IL–2) and interleukin 7 (IL–7) reciprocally induce IL–7 and IL–2 receptors on gamma delta T–cell receptor–positive intraepithelial lymphocytes. Fujihashi K, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3613–8
Role of monocytes in the up–regulation of the early activation marker CD69 on B and T murine lymphocytes induced by microbial mitogens. Vilanova M, et al. **Scand J Immunol** 1996 Feb;43(2):155–63
The human mast cell line HMC–1 expresses C5a receptors and responds to C5a but not to C5a(desArg). Werfel T, et al. **Scand J Immunol** 1996 Jul;44(1):30–6
Ligand–induced autoregulation of IFN–gamma receptor beta chain expression in T helper cell subsets. Bach EA, et al. **Science** 1995 Nov 17;270(5239):1215–8
Expression of intercellular adhesion molecule–1 and CD4/CD8 lymphocyte markers in perioperative liver allograft biopsies. Bhargava A, et al. **Transplant Proc** 1995 Oct;27(5):2814–5
In vivo evaluation of human membrane cofactor protein in transgenic mice. IJzermans JN, et al. **Transplant Proc** 1996 Apr;28(2):671–2
Production of pigs transgenic for human regulators of complement activation using YAC technology. Langford GA, et al. **Transplant Proc** 1996 Apr;28(2):862–3
Difference of expression levels between gene technological product delta CYT–MCP(CD46) and intact MCP(CD46) in transgenic mice. Miyagawa S, et al. **Transplant Proc** 1996 Apr;28(2):585–6
Human MCP and DHF double transgenic mice are protected from human complement attack in an in vivo model. Mulder LC, et al. **Transplant Proc** 1996 Apr;28(2):589
Characterization of complement–mediated liver damage and protection in control and transgenic mice for human complement blockers MCP and DAF. Mulder LC, et al. **Transplant Proc** 1996 Feb;28(1):127–9
High–level tissue specific expression of human CD59, MCP, and DAF proteins from genomic clones in transgenic mice. Oldham ER, et al. **Transplant Proc** 1996 Apr;28(2):693
Targeting gene expression to endothelial cells in transgenic mice using the human intercellular adhesion molecule 2 promoter. Cowan PJ, et al. **Transplantation** 1996 Jul 27; 62(2):155–60
Selective expression of a subset of measles virus receptor–competent CD46 isoforms in human brain. Buchholz CJ, et al. **Virology** 1996 Mar 1;217(1):349–55

BLOOD

Up–regulated expression of CD56+, CD56+/CD16+, and CD19+ cells in peripheral blood lymphocytes in pregnant women with recurrent pregnancy losses. Kwak JY, et al. **Am J Reprod Immunol** 1995 Aug;34(2):93–9
Expression of complement regulatory proteins on fetal blood cells in utero. Jarvis JN, et al. **Biol Neonate** 1996; 69(4):225–9
Identification of eosinophils by flow cytometry. Thurau AM, et al. **Cytometry** 1996 Feb 1;23(2):150–8
Expression of the T antigen on a T–lymphoid cell line, supT1. Nakada H, et al. **Glycoconj J** 1995 Jun;12(3):356–9
CD66b, CD66c and carcinoembryonic antigen (CEA) are independently regulated markers in sera of tumor patients. Grunert F, et al. **Int J Cancer** 1995 Nov 3;63(3):349–55
Inhibitory effects of interleukin 12 on retroviral gene transduction into CD34 cord blood myeloid progenitors mediated by induction of tumor necrosis factor–alpha. Xiao M, et al. **J Hematother** 1996 Apr;5(2):171–7
Blood cell flow cytometry in paroxysmal nocturnal hemoglobinuria: a tool for measuring the extent of the PNH clone. Alfinito F, et al. **Leukemia** 1996 Aug;10(8):1326–30
Variable expression of CD49d antigen in B cell chronic lymphocytic leukemia is related to disease stages. Eksioğlu–Demiralp E, et al. **Leukemia** 1996 Aug; 10(8):1331–9
Functional role of PECAM–1/CD31 molecule expressed on human cord blood progenitors. El–Marsafy S, et al. **Leukemia** 1996 Aug;10(8):1340–6
Immunophenotypic features and configuration of immunoglobulin genes in hairy cell leukemia–Japanese variant. Yamaguchi M, et al. **Leukemia** 1996 Aug; 10(8):1390–4
Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells. Abouna GM, et al. **Transplant Proc** 1995 Oct;27(5):2676–8
Investigation of the biochemical relationship between the blood group antigens Xga and CD99 (12E7 antigen) on red cells. Petty AC, et al. **Vox Sang** 1995;69(3):231–5
[Assessment of various immunologic parameters in silicone implant carriers] Granchi D, et al. **G Chir** 1995 Nov–Dec; 16(11–12):479–85 (Eng. Abstr.) **(Ita)**
[Immunophenotypic heterogeneity of CD7+CD4–CD8–acute leukemia] Abramenko IV, et al. **Gematol Transfuziol** 1995 Jul–Aug;40(4):10–3 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Biology of natural and recombinant soluble interleukin–4 receptor. Enssle K, et al. **Behring Inst Mitt** 1995 Jun; (96):103–17 (78 ref.)
Monomeric and dimeric forms of soluble receptors can differ in their neutralization potential. Lauffer L, et al. **Behring Inst Mitt** 1995 Jun;(96):21–31
Integrin alpha 4 cysteines 278 and 717 modulate VLA–4 ligand binding and also contribute to alpha 4/180 formation. Pujades C, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):899–908
NMR analysis of interacting soluble forms of the cell–cell recognition molecules CD2 and CD48. McAlister MS, et al. **Biochemistry** 1996 May 14;35(19):5982–91
Human interleukin–6 receptor super–antagonists with high potency and wide spectrum on multiple myeloma cells. Sporeno E, et al. **Blood** 1996 Jun 1;87(11):4510–9
Invariant chain structure and MHC class II function. Cresswell P. **Cell** 1996 Feb 23;84(4):505–7 (17 ref.)
Dimerization of chimeric erythropoietin/75 kDa tumour necrosis factor (TNF) receptors transduces TNF signals: necessity for the 75 kDa–TNF receptor transmembrane domain. Declercq W, et al. **Cytokine** 1995 Oct;7(7):701–9
Functional distinction of two regions of human interleukin 6 important for signal transduction via gp130. de Hon FD, et al. **Cytokine** 1995 Jul;7(5):398–407
Osteopontin activation of c–src in human melanoma cells requires the cytoplasmic domain of the integrin alpha v–subunit. Chellaiah M, et al. **Endocrinology** 1996 Jun; 137(6):2432–40
Participation of two Ser–Ser–Phe–Tyr repeats in interleukin–6 (IL–6)–binding sites of the human IL–6 receptor. Kalai M, et al. **Eur J Biochem** 1996 Jun 15; 238(3):714–23
Translation is enhanced after silent nucleotide substitutions in A+T– rich sequences of the coding region of CD46 cDNA. Milland J, et al. **Eur J Biochem** 1996 May 15; 238(1):221–30
Site–directed mutagenesis of conserved charged residues in the helical region of the human C5a receptor. Arg2O6 determines high–affinity binding sites of C5a receptor. Raffetseder U, et al. **Eur J Biochem** 1996 Jan 15; 235(1–2):82–90
Human CD6 possesses a large, alternatively spliced cytoplasmic domain. Robinson WH, et al. **Eur J Immunol** 1995 Oct;25(10):2765–9
A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR–I and Fas. Chapman BS. **FEBS Lett** 1995 Oct 30;374(2):216–20
Use of immobilized synthetic peptides for the identification of contact sites between human interleukin–6 and its receptor. Weiergräber O, et al. **FEBS Lett** 1996 Jan 29; 379(2):122–6
Receptor recognition and specificity of interleukin–8 is determined by residues that cluster near a surface–accessible hydrophobic pocket. Hammond ME, et al. **J Biol Chem** 1996 Apr 5;271(14):8228–35
Two different cytoplasmic tails direct isoforms of the membrane cofactor protein (CD46) to the basolateral surface of Madin–Darby canine kidney cells. Maisner A, et al. **J Biol Chem** 1996 Aug 2;271(31):18853–8
The amino–terminal immunoglobulin–like domain of sialoadhesin contains the sialic acid binding site. Comparison with CD22. Nath D, et al. **J Biol Chem** 1995 Nov 3;270(44):26184–91
Characterization of an interleukin 6 cytokine family antagonist protein from a marine sponge, Callyspongia sp. Peppard JV, et al. **J Biol Chem** 1996 Mar 29;271(13):7281–4
A single N–linked glycosylation site is implicated in the regulation of ligand recognition by the I–type lectins CD22 and CD33. Sgroi D, et al. **J Biol Chem** 1996 Aug 2; 271(31):18803–9
The ligand recognition specificity of beta3 integrins. Suehiro K, et al. **J Biol Chem** 1996 Apr 26;271(17):10365–71
Localization of the putative sialic acid–binding site on the immunoglobulin superfamily cell–surface molecule CD22. van der Merwe PA, et al. **J Biol Chem** 1996 Apr 19; 271(16):9273–80
Influence of interleukin–6 (IL–6) dimerization on formation of the high affinity hexameric IL–6.receptor complex. Ward LD, et al. **J Biol Chem** 1996 Aug 16;271(33):20138–44
Divalent cations regulate the organization of integrins alpha v beta 3 and alpha v beta 5 on the cell surface. Stuiver I, et al. **J Cell Physiol** 1996 Sep;168(3):521–31
IL–4 induces human B cell maturation and IgE synthesis in SCID–hu mice. Inhibition of ongoing IgE production by in vivo treatment with an IL–4/IL–13 receptor antagonist. Carballido JM, et al. **J Immunol** 1995 Nov 1; 155(9):4162–70
Differential effects of CTLA–4 substitutions on the binding of human CD80 (B7–1) and CD86 (B7–2). Morton PA, et al. **J Immunol** 1996 Feb 1;156(3):1047–54
Molecular characterization of fusion regulatory protein–1 (FRP–1) that induces multinucleated giant cell formation of monocytes and HIV gp160–mediated cell fusion. FRP–1 and 4F2/CD98 are identical molecules. Ohgimoto S, et al. **J Immunol** 1995 Oct 1;155(7):3585–92
Characterization of murine intercellular adhesion molecule–2. Xu H, et al. **J Immunol** 1996 Jun 15;156(12):4909–14
Identification of two forms (31–33 and 48 kD) of the urinary soluble p55 tumor necrosis factor receptor that are differentially N– and O–glycosylated. Corti A, et al. **J Interferon Cytokine Res** 1995 Feb;15(2):143–52
Identification of two variants of the human integrin alpha 4 subunit. Szabo M, et al. **Mol Immunol** 1995 Dec; 32(17–18):1453–4
Structural basis for IL–4 receptor phosphopeptide recognition by the IRS–1 PTB domain. Zhou MM, et al. **Nat Struct Biol** 1996 Apr;3(4):388–93
Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Hilton DJ, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):497–501
The 94– to 97–kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine–rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Ramprasad MP, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9580–4
Crystallization of the complex of human IFN–gamma and the extracellular domain of the IFN–gamma receptor. Chène C, et al. **Proteins** 1995 Dec;23(4):591–4

CLASSIFICATION

Human lymphocytes are more susceptible to measles virus than granulocytes, which is attributable to the phenotypic differences of their membrane cofactor protein (CD46). Kurita M, et al. **Immunol Lett** 1995 Dec;48(2):91–5

DRUG EFFECTS

Glucocorticoid–dependent induction of interleukin–6 receptor expression in human hepatocytes facilitates interleukin–6 stimulation of amino acid transport. Fischer CP, et al. **Ann Surg** 1996 May;223(5):610–8; discussion 618–9
Direct synergistic effects of leukemia inhibitory factor on hematopoietic progenitor cell growth: comparison with other hematopoietins that use the gp130 receptor subunit. Keller JR, et al. **Blood** 1996 Aug 1;88(3):863–9
Tumor necrosis factor–alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. van der Poll T, et

al. **Blood** 1996 Aug 1;88(3):922–7

Raf-1 provides a dominant but not exclusive signal for the induction of CD69 expression on T cells. Taylor-Fishwick DA, et al. **Eur J Immunol** 1995 Dec;25(12):3215–21

Evidence for the promotion of positive selection of thymocytes by Ah receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin. Kremer J, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):413–27

Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. Russell ME, et al. **J Clin Invest** 1996 Feb 1;97(3):833–8

IFN-gamma up-regulates the human C5a receptor (CD88) in myeloblastic U937 cells and related cell lines. Burg M, et al. **J Immunol** 1995 Nov 1;155(9):4419–26

Heat shock protein 65 induces CD62e, CD106, and CD54 on cultured human endothelial cells and increases their adhesiveness for monocytes and granulocytes. Verdegaal ME, et al. **J Immunol** 1996 Jul 1;157(1):369–76

Tumor necrosis factor alpha and interleukin-1 alpha stimulate late shedding of p75 TNF receptors but not p55 TNF receptors from human monocytes. Joyce DA, et al. **J Interferon Cytokine Res** 1995 Nov;15(11):947–54

GENETICS

1,25(OH)2D3 and cAMP synergistically induce complement 5a receptor messenger RNA. Rubin J, et al. **Am J Med Sci** 1996 Feb;311(2):73–9

Surface phenotype and immunoglobulin heavy chain gene usage in chronic B-cell leukemias. Ikematsu W, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:492–5

A DNA motif present in alpha V integrin promoter exhibits dual binding preference to distinct transcription factors. Sharma HW, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):1857–67

Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Duits AJ, et al. **Arthritis Rheum** 1995 Dec;38(12):1832–6

Expression and function of CD80 and CD86 costimulator molecules on synovial dendritic cells in chronic arthritis. Summers KL, et al. **Arthritis Rheum** 1996 Aug; 39(8):1287–91

Integrin beta 3 cDNA transfection into a highly metastatic alpha v beta 3-negative human melanoma cell line inhibits invasion and experimental metastasis. Danen EH, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):75–81

The promoter and 5' flanking sequences controlling human B29 gene expression. Thompson AA, et al. **Blood** 1996 Jan 15;87(2):666–73

Expression of interleukin-6 receptor (IL-6R) and gp130 mRNA in PC12 cells and sympathetic neurons: modulation by tumor necrosis factor alpha (TNF-alpha). März P, et al. **Brain Res** 1996 Jan 8;706(1):71–9

Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. La Motte RN, et al. **Cancer Immunol Immunother** 1996 Mar;42(3):161–9

Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Higashiyama M, et al. **Cancer Res** 1995 Dec 15;55(24):6040–4

Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Huang LR, et al. **Cancer Res** 1995 Oct 15; 55(20):4717–21

An alternatively spliced exon in the extracellular domain of the human alpha 6 integrin subunit—functional analysis of the alpha 6 integrin variants. Delwel GO, et al. **Cell Adhes Commun** 1995 May;3(2):143–61

Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130). Geisterfer M, et al. **Cytokine** 1995 Aug;7(6):503–9

Cytotoxicity in L929 murine fibrosarcoma cells after triggering of transfected human p75 tumour necrosis factor (TNF) receptor is mediated by endogenous murine TNF. Vercammen D, et al. **Cytokine** 1995 Jul;7(5):463–70

Deletion of integrin alpha 1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. Gardner H, et al. **Dev Biol** 1996 May 1;175(2):301–13

Insulin-like growth factor-I stimulates neurogenesis in chick retina by regulating expression of the alpha 6 integrin subunit. Frade JM, et al. **Development** 1996 Aug; 122(8):2497–506

The genomic structure of the murine alpha 4 integrin gene. De Meirsman C, et al. **DNA Cell Biol** 1996 Jul; 15(7):595–603

The family of LAMP-2 proteins arises by alternative splicing from a single gene: characterization of the avian LAMP-2 gene and identification of mammalian homologs of LAMP-2b and LAMP-2c. Gough NR, et al. **DNA Cell Biol** 1995 Oct;14(10):863–7

Cloning and chromosomal localization of a pseudogene corresponding to a mRNA for a soluble IL-6 receptor. Snyers L, et al. **DNA Seq** 1995;5(5):311–4

Translation is enhanced after silent nucleotide substitutions in A+T- rich sequences of the coding region of CD46 cDNA. Milland J, et al. **Eur J Biochem** 1996 May 15; 238(1):221–30

Site-directed mutagenesis of conserved charged residues in the helical region of the human C5a receptor. Arg2O6 determines high-affinity binding sites of C5a receptor. Raffetseder U, et al. **Eur J Biochem** 1996 Jan 15; 235(1–2):82–90

Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily. Chang C, et al. **Eur J Immunol** 1995 Sep; 25(9):2433–7

Embryonic lineage of vascular smooth muscle cells determines responses to collagen matrices and integrin receptor expression. Thieszen SL, et al. **Exp Cell Res** 1996 Aug 25;227(1):135–45

Cloning of the cDNA encoding the porcine p55 tumor necrosis factor receptor. Suter B, et al. **Gene** 1995 Oct 3; 163(2):263–6

Physical mapping and genomic structure of the human TNFR2 gene. Beltinger CP, et al. **Genomics** 1996 Jul 1; 35(1):94–100

Genetic localization of Cd63, a member of the transmembrane 4 superfamily, reveals two distinct loci in the mouse genome. Gwynn B, et al. **Genomics** 1996 Jul 15; 35(2):389–91

Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Marchese A, et al. **Genomics** 1995 Sep 20; 29(2):335–44

High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. Chiorini JA, et al. **Hum Gene Ther** 1995 Dec;6(12):1531–41

Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Mackiewicz A, et al. **Hum Gene Ther** 1995 Jun;6(6):805–11

Molecular defects in beta-thalassaemias in the population of Saudi Arabia. el-Hazmi MA, et al. **Hum Hered** 1995 Sep-Oct;45(5):278–85

Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor. Ryan JJ, et al. **Immunity** 1996 Feb;4(2):123–32

Promoter analysis of the human interleukin-8 receptor genes, IL-8RA and IL-8RB. Sprenger H, et al. **Immunobiology** 1995 Jul;193(2–4):334–40

Characterization of interleukin-8 receptors in non-human primates. Alvarez V, et al. **Immunogenetics** 1996; 43(5):261–7

Molecular linkage of the mouse CD5 and CD6 genes. Lecomte O, et al. **Immunogenetics** 1996;44(5):385–90

Alternatively spliced forms of the human myeloid Fc alpha receptor (CD89) in neutrophils. Morton HC, et al. **Immunogenetics** 1996;43(4):246–7

Mapping of the genes for four members of the transmembrane 4 superfamily: mouse Cd9, Cd63, Cd81, and Cd82. Seldin MF, et al. **Immunogenetics** 1995;42(5):422–5

Recognition of CD52 allelic gene products by CAMPATH-1H antibodies. Hale C, et al. **Immunology** 1996 Jun;88(2):183–90

Structural and functional characterization of the human CD36 gene promoter: identification of a proximal PEBP2/CBF site. Armesilla AL, et al. **J Biol Chem** 1996 Mar 29;271(13):7781–7

Competition for a unique response element mediates retinoic acid inhibition of vitamin D3-stimulated transcription. Cao X, et al. **J Biol Chem** 1996 Aug 23;271(34):20650–4

Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. Caput D, et al. **J Biol Chem** 1996 Jul 12; 271(28):16921–6

Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. Santee SM, et al. **J Biol Chem** 1996 Aug 30;271(35):21151–9

Cloning of mouse integrin alphaV cDNA and role of the alphaV-related matrix receptors in metanephric development. Wada J, et al. **J Cell Biol** 1996 Mar; 132(6):1161–76

PDGF induction of alpha 2 integrin gene expression is mediated by protein kinase C-zeta. Xu J, et al. **J Cell Biol** 1996 Sep;134(5):1301–11

In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). Reinhold MI, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3419–25

Differential expression of alternate mB7-2 transcripts. Borriello F, et al. **J Immunol** 1995 Dec 15;155(12):5490–7

Mice lacking the IFN-gamma receptor have impaired ability to resolve a lung eosinophilic inflammatory response associated with a prolonged capacity of T cells to exhibit a Th2 cytokine profile. Coyle AJ, et al. **J Immunol** 1996 Apr 15;156(8):2680–5

Effect of gene-targeted mutation in TNF receptor (p55) on contact hypersensitivity and ultraviolet B-induced immunosuppression. Kondo S, et al. **J Immunol** 1995 Oct 15;155(8):3801–5

Identification of Fc alpha receptor (CD89) isoforms generated by alternative splicing that are differentially expressed between blood monocytes and alveolar macrophages. Patry C, et al. **J Immunol** 1996 Jun 1; 156(11):4442–8

IL-4 induces germ-line IgE heavy chain gene transcription in human fetal pre-B cells. Evidence for differential expression of functional IL-4 and IL-13 receptors during B cell ontogeny. Punnonen J, et al. **J Immunol** 1995 Nov 1;155(9):4248–54

Modulation of the expression of the IFN-gamma receptor beta-chain controls responsiveness to IFN-gamma in human peripheral blood T cells. Sakatsume M, et al. **J Immunol** 1996 Jun 1;156(11):4160–6

Upregulation of NF-kappa B-dependent gene expression mediated by the p75 tumor necrosis factor receptor. Rao P, et al. **J Interferon Cytokine Res** 1995 Feb;15(2):171–7

Relationship between Fc receptor IIA polymorphism and infection in children with sickle cell disease. Norris CF, et al. **J Pediatr** 1996 Jun;128(6):813–9

Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3' sulfo-galactosyl ceramide-positive cell line. Harouse JM, et al. **J Virol** 1995 Dec;69(12):7383–90

Genetic mapping of the gene for the mouse interferon-gamma receptor signaling subunit to the distal end of chromosome 16. Mariano TM, et al. **Mamm Genome** 1996 Apr;7(4):321–2

Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Leung SO, et al. **Mol Immunol** 1995 Dec; 32(17–18):1413–27

Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis. Truneh A, et al. **Mol Immunol** 1996 Feb;33(3):321–34

Absence of integrin alpha 6 leads to epidermolysis bullosa and neonatal death in mice. Georges-Labouesse E, et al. **Nat Genet** 1996 Jul;13(3):370–3

Epithelial detachment due to absence of hemidesmosomes in integrin beta 4 null mice. van der Neut R, et al. **Nat Genet** 1996 Jul;13(3):366–9

Metastases suppressors and prostate cancer. Petrylak DP. **Nat Med** 1995 Aug;1(8):739–40

Transcriptional regulation of the human CD9 gene: characterization of the 5'-flanking region. Le Naour F, et al. **Oncogene** 1996 Aug 1;13(3):481–6

Mapping functional chicken genes: an alternative approach. Smith EJ, et al. **Poult Sci** 1996 May;75(5):642–7

Interleukin 7 receptor-deficient mice lack gammadelta T cells. Maki K, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7172–7

Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors. Migita M, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12075–9

High expression of membrane cofactor protein of complement (CD46) in human leukaemia cell lines: implication of an alternatively spliced form containing the STA domain in CD46 up-regulation. Hara T, et al. **Scand J Immunol** 1995 Dec;42(6):581–90

Localization of the human homolog of the yeast cell division control 27 gene (CDC27) proximal to ITGB3 on human chromosome 17q21.3. Ho PP, et al. **Somat Cell Mol Genet** 1995 Sep;21(5):351–5

Role of Fc gamma RIIA gene polymorphism in human platelet activation by monoclonal antibodies. Bachelot C, et al. **Thromb Haemost** 1995 Dec;74(6):1557–63

On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia. Brandt JT, et al. **Thromb Haemost** 1995 Dec;74(6):1564–72

Targeting gene expression to endothelial cells in transgenic mice using the human intercellular adhesion molecule 2 promoter. Cowan PJ, et al. **Transplantation** 1996 Jul 27; 62(2):155–60

[Production of smallpox proteins, homologous to the human gamma-interferon receptor, in E. coli] Seregin SV, et al. **Mol Biol (Mosk)** 1996 May-Jun;30(3):692–700 **(Rus)**

HISTORY

A little bit of CD history [editorial; comment] LeBien TW. **Transfusion** 1996 Mar;36(3):197–9. Comment on: Transfusion 1996 Mar;36(3):268–85.

IMMUNOLOGY

The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors. Chan JK, et al. **Am J Surg Pathol** 1995 Oct;19(10):1115–23

Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Nasert S, et al. **Behring Inst Mitt** 1995 Jun;(96):118–30 (55 ref.)

A human monoclonal antibody specific for the leucine-33 (P1A1, HPA-1a) form of platelet glycoprotein IIIa from a V gene phage display library. Griffin HM, et al. **Blood** 1995 Dec 15;86(12):4430–6

Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte-macrophage colony-stimulating factor. Walsh GM, et al. **Blood** 1996 Apr 1;87(7):2815–21

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Hale G, et al. **Bone Marrow Transplant** 1996 Mar;17(3):305–8

T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture. Satoh J, et al. **Brain Res** 1995 Dec 15;704(1):92–6

Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens. Kirkin AF, et al. **Cancer Immunol Immunother** 1996 May;42(4):203–12

Cell surface antigens in leukemias and lymphomas. Freedman AS. **Cancer Invest** 1996;14(3):252–76 (354 ref.)

Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Chamberlain RS, et al. **Cancer Res** 1996 Jun 15;56(12):2832–6

Differential requirements for alpha4 integrins during fetal and adult hematopoiesis. Arroyo AG, et al. **Cell** 1996 Jun 28; 85(7):997–1008

The repertoire of T cells shaped by a single MHC/peptide ligand. Ignatowicz L, et al. **Cell** 1996 Feb 23;84(4):521–9

Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura. Bettaieb A, et al. **Clin Exp Immunol** 1996 Jan; 103(1):19–23

Lymphocyte function associated antigen-1, integrin alpha 4, and L-selectin mediate T-cell homing to the pancreas in the model of adoptive transfer of diabetes in NOD mice. Fabien N, et al. **Diabetes** 1996 Sep;45(9):1181–6

Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti-C5a receptor (CD88) antibodies. Elsner J, et al. **Eur J Immunol** 1996 Jul;26(7):1560–4

Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Nakajima A, et al. **Eur J Immunol** 1995 Nov;25(11):3060–9

Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction. Starling GC, et al. **Eur J Immunol** 1996 Apr; 26(4):738–46

A CD44 monoclonal antibody differentially regulates CD11a/CD18 binding to intercellular adhesion molecules CD54, CD102 and CD50. Vermot-Desroches C, et al. **Eur J Immunol** 1995 Sep;25(9):2460–4

Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Wijdenes J, et al. **Eur J Immunol** 1995 Dec;25(12):3474–81

Heat-stable antigen is expressed by murine keratinocytes and delivers costimulatory signals in T-cell activation. Erdmann G, et al. **Exp Dermatol** 1995 Oct;4(5):291–6

Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice. de Kroon JF, et al. **Exp Hematol** 1996 Jul;24(8):919–26

Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Lifely MR, et al. **Glycobiology** 1995 Dec;5(8):813–22

A method for monoclonal antibody isotype switching: anti-CD60 VH expression in a heavy chain-deficient hybridoma variant. Kozarsky KF, et al. **Hybridoma** 1995 Dec;14(6):597–601

An anti-interleukin 8 monoclonal antibody that interferes with the binding of interleukin 8 to cellular receptors and the activation of human blood neutrophils. Kurdowska A, et al. **Hybridoma** 1995 Jun;14(3):225–33

Selective CD28pYMNM mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation. Cai YC, et al. **Immunity** 1995 Oct; 3(4):417–26

The critical region in the cytoplasmic domain of human IL-4 receptor for induction of IgE synthesis. Schultz C, et al. **Immunol Lett** 1995 Jun;46(3):215–9

Role of B7 signaling in the differentiation of naive CD4+ T cells to effector interleukin-4-producing T helper cells. Gause WC, et al. **Immunol Res** 1995;14(3):176–88 (84 ref.)

B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. Perrin PJ, et al. **Immunol Res** 1995; 14(3):189–99 (47 ref.)

Engineering of recombinant soluble CD46: an inhibitor of complement activation. Christiansen D, et al. **Immunology** 1996 Mar;87(3):348–54

Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells. Fagnoni FF, et al. **Immunology** 1995 Jul;85(3):467–74

Signal transduction by B7/BB1 expressed on activated T lymphocytes: cross-linking of B7/BB1 induces protein tyrosine phosphorylation and synergizes with signalling through T-cell receptor/CD3. Hirokawa M, et al. **Immunology** 1995 Oct;86(2):155–61

Modulation of cell-bound and soluble CD23, spontaneous and ongoing IgE synthesis of human peripheral blood mononuclear cells by soluble IL-4 receptors and the partial antagonistic IL-4 mutant protein IL-4 (Y124D). König B, et al. **Immunology** 1995 Aug;85(4):604–10

Differentiation between MHC-restricted and non-MHC-restricted porcine cytolytic T lymphocytes. Pauly T, et al. **Immunology** 1996 Jun;88(2):238–46

Involvement of LFA-1/ICAM-2 adhesive interactions and PKC in activation-induced cell death following SEB rechallenge. Tchilian EZ, et al. **Immunology** 1996 Apr; 87(4):566–72

Impaired immunity and altered pulmonary responses in mice with a disrupted interferon-gamma receptor gene exposed to the irradiated Schistosoma mansoni vaccine. Wilson RA, et al. **Immunology** 1996 Feb;87(2):275–82

Suppression of humoral immunity by monoclonal antibody to CD79b, an invariant component of antigen receptors on B lymphocytes. Nakamura T, et al. **Int J Hematol** 1996 Jul;64(1):39–46

Characterization of distribution of T lymphocyte subsets and activated T lymphocytes infiltrating into sarcoid lesions [see comments] Kita S, et al. **Intern Med** 1995 Sep; 34(9):847–55. Comment in: Intern Med 1995 Sep;34(9):819.

The CDw65 monoclonal antibodies VIM-8 and VIM-11 bind to the neutral glycolipid V3FucnLc8Cer. Kniep B, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):456–52

Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. Racke MK, et al. **J Clin Invest** 1995 Nov;96(5):2195–203

Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. Tsujinaka T, et al. **J Clin Invest** 1996 Jan 1; 97(1):244–9

Negative selection of human germinal center B cells by prolonged BCR cross-linking. Galibert L, et al. **J Exp Med** 1996 May 1;183(5):2075–85

Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. Malisan F, et al. **J Exp Med** 1996 Mar 1; 183(3):937–47

Interspecies reactivities of anti-human macrophage monoclonal antibodies to various animal species. Zeng L, et al. **J Histochem Cytochem** 1996 Aug;44(8):845–53

Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. Gajewski TF, et al. **J Immunol** 1996 Apr 15;156(8):2909–17

Fc gamma II receptor-mediated platelet activation induced by anti-CD9 monoclonal antibody opens Ca2+ channels which are distinct from those associated with Ca2+ store depletion. Kuroda K, et al. **J Immunol** 1995 Nov 1; 155(9):4427–36

Costimulatory effects of T cell proliferation during infection with human T lymphotropic virus types I and II are mediated through CD80 and CD86 ligands. Lal RB, et al. **J Immunol** 1996 Aug 1;157(3):1288–96

Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells. Law CL, et al. **J Immunol** 1995 Oct 1;155(7):3368–76

CD59 and CD48 expressed by rat retinal pigment epithelial cells are major ligands for the CD2-mediated alternative pathway of T cell activation. Liversidge J, et al. **J Immunol** 1996 May 15;156(10):3696–703

Suppression of the antibody response to a polymorphic peptide from the platelet alloantigen integrin beta3 with low molecular weight antigen arrays. Watson DC, et al. **J Immunol** 1996 Apr 1;156(7):2443–50

CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human skin. Werfel T, et al. **J Immunol** 1996 Aug 15;157(4):1729–35

Intercellular adhesion molecule-2 (CD102) binds to the leukocyte integrin CD11b/CD18 through the A domain. Xie J, et al. **J Immunol** 1995 Oct 1;155(7):3619–28

Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M. Gu ZJ, et al. **J Immunol Methods** 1996 Mar 28;190(1):21–7

Anti-CD69 antibodies enhance phorbol-dependent glucose metabolism and Ca2+ levels in human thymocytes. Antagonist effect of cyclosporin A. Conde M, et al. **J Leukoc Biol** 1996 Aug;60(2):278–84

Control of the production of soluble interleukin-4 receptors: implications in immunoregulation. Fernandez-Botran R, et al. **J Leukoc Biol** 1996 Apr;59(4):499–504 (35 ref.)

A CD66a-specific, activation-dependent epitope detected by recombinant human single chain fragments (scFvs) on CHO transfectants and activated granulocytes. Jantscheff P, et al. **J Leukoc Biol** 1996 Jun;59(6):891–901

A monoclonal antibody to alpha 4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig. Kent SJ, et al. **J Magn Reson Imaging** 1995 Sep-Oct;5(5):535–40

Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis. Perrin PJ, et al. **J Neuroimmunol** 1996 Mar;65(1):31–9

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. Trkola A, et al. **J Virol** 1995 Nov;69(11):6609–17

Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor. Karkar AM, et al. **Kidney Int** 1995 Dec; 48(6):1738–46

An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia. Myers DE, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):119–22

Variable region cDNA sequences and characterization of murine anti-human interferon gamma receptor monoclonal antibodies that inhibit receptor binding by interferon gamma. Bridges A, et al. **Mol Immunol** 1995 Dec; 32(17-18):1329–38

Antibodies against human CD63 activate transfected rat basophilic leukemia (RBL-2H3) cells. Smith DA, et al. **Mol Immunol** 1995 Dec;32(17-18):1339–44

Anti-CD4 therapy for AIDS suggested by mathematical models. De Boer RJ, et al. **Proc R Soc Lond B Biol Sci** 1996 Jul 22;263(1372):899–905

Production and characterization of anti-human interferon gamma receptor antibody fragments that inhibit cytokine binding to the receptor. Bridges A, et al. **Protein Eng** 1996 Apr;9(4):365–70

Triggering of target of an antiproliferative antibody-1 (TAPA-1/CD81) up-regulates the release of tumour necrosis factor-alpha by the EBV-B lymphoblastoid cell line JY. Altomonte M, et al. **Scand J Immunol** 1996 Apr; 43(4):367–73

Enhanced in vivo immunogenicity induced by an antibody to the IL-4 receptor-associated gp200-MR6 molecule. Sivolapenko GB, et al. **Scand J Immunol** 1996 Aug; 44(2):135–42

Requirement of CD80 and CD86 molecules for antigen presentation by eosinophils. Tamura N, et al. **Scand J Immunol** 1996 Sep;44(3):229–38

Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-alpha 4 antibody in adjuvant arthritis. Barbadillo C, et al. **Springer Semin Immunopathol** 1995;16(4):427–36 (59 ref.)

Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis. Greenwood J, et al. **Ther Immunol** 1994 Oct;1(5):247–55

Specific acceptance of cardiac allografts after treatment with antibodies to CD80 and CD86 in mice. Bashuda H, et al. **Transplant Proc** 1996 Apr;28(2):1039–41

Transmembrane signaling requirements of T cells: implications for regulation of alloimmunity. Suthanthiran M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):5–7 (25 ref.)

The mechanism of xenogeneic cell-mediated lympholysis between human and pig cells. Yamada K, et al. **Transplant Proc** 1996 Apr;28(2):757

The behaviour of monoclonal antibodies in the First International Pig CD Workshop reacting with gamma delta/Null T lymphocytes in the blood of SLAb/b line pigs. Licence ST, et al. **Vet Immunol Immunopathol** 1995 Aug;47(3-4):253–71

[Characterization of platelet activation induced by CD9 McAbs] Peng L, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):365–70 (Eng. Abstr.) **(Chi)**

[CD23/sCD23—receptor/cytokine in IgE-dependent reactions] Rogala B, et al. **Postepy Hig Med Dosw** 1995; 49(3):425–32 (35 ref.) (Eng. Abstr.) **(Pol)**

ISOLATION & PURIFICATION

Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing. Müller-Newen G, et al. **Eur J Biochem** 1996 Mar 15; 236(3):837–42

Immunochemical analysis of carcinoembryonic antigen (CEA)-related antigens differentially localized in intracellular granules of human neutrophils. Kuroki M, et al. **Immunol Invest** 1995 Aug;24(5):829–43

Purification and functional properties of soluble forms of membrane cofactor protein (CD46) of complement: identification of forms increased in cancer patients' sera. Seya T, et al. **Int Immunol** 1995 May;7(5):727–36

Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. Gasque P, et al. **J Immunol** 1995 Nov 15;155(10):4882–9

Identification of two variants of the human integrin alpha 4 subunit. Szabo M, et al. **Mol Immunol** 1995 Dec; 32(17-18):1453–4

METABOLISM

Distribution of alpha 6 and beta 4 integrins following epithelial abrasion in the rabbit cornea. Latvala T, et al. **Acta Ophthalmol Scand** 1996 Feb;74(1):21–5

Expression of B7 costimulator molecules on mouse dendritic cells. Inaba K, et al. **Adv Exp Med Biol** 1995;378:65–70

Crypt epithelial cells express the 4F2 antigen in untreated coeliac mucosa. Maiuri L, et al. **Adv Exp Med Biol** 1995; 371B:1363–5

Architectural and antigenic features of follicular dendritic cells as a clue to the histogenesis of primary cutaneous B-cell lymphoma. Mori M, et al. **Adv Exp Med Biol** 1995; 378:277–9

Activation of the TNF alpha-p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in cultured human tracheal smooth muscle cells. Amrani Y, et al. **Am J Respir Cell Mol Biol** 1996 Jul; 15(1):55–63

Tumor necrosis factor soluble receptor 75: the principal receptor form released by human alveolar macrophages and monocytes in the presence of interferon(gamma). Galve-de Rochemonteix B, et al. **Am J Respir Cell Mol Biol** 1996 Mar;14(3):279–87

Protein kinase C, interleukin-1 beta, and corticosteroids regulate shedding of the type I, 55 kDa TNF receptor from human airway epithelial cells. Levine SJ, et al. **Am J Respir Cell Mol Biol** 1996 Mar;14(3):254–61

Cytokine signal transduction through a homo- or heterodimer of gp130. Kishimoto T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:224–34 (22 ref.)

Glucocorticoid-dependent induction of interleukin-6 receptor expression in human hepatocytes facilitates

interleukin-6 stimulation of amino acid transport. Fischer CP, et al. **Ann Surg** 1996 May;223(5):610-8; discussion 618-9

Murine epidermal Langerhans cells express CD48, which is a counter-receptor for mouse CD2. Ozawa H, et al. **Arch Dermatol Res** 1995;287(6):524-8

Tumor necrosis factor receptor p75 correlates better than p55 with disease activity in juvenile rheumatoid arthritis: comment on the article by Mangge et al [letter; comment] Gattorno M, et al. **Arthritis Rheum** 1996 May;39(5):883-4 . Comment on: Arthritis Rheum 1995 Feb;38(2):211-20.

Antagonistic mutant proteins of interleukin-4. Duschl A, et al. **Behring Inst Mitt** 1995 Jun;(96):87-94 (27 ref.)

Biology of natural and recombinant soluble interleukin-4 receptor. Enssle K, et al. **Behring Inst Mitt** 1995 Jun; (96):103-17 (78 ref.)

Monomeric and dimeric forms of soluble receptors can differ in their neutralization potential. Lauffer L, et al. **Behring Inst Mitt** 1995 Jun;(96):21-31

Identification of the proteolytic enzyme which cleaves human p75 TNF receptor in vitro. Katsura K, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):298-302

Direct binding of F actin to the cytoplasmic domain of the alpha 2 integrin chain in vitro. Kieffer JD, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):466-74

CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta 1 integrins in human melanoma. Radford KJ, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):13-8

Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line. Zarn JA, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):384-91

Submicromolar La3+ concentrations block the calcium release-activated channel, and impair CD69 and CD25 expression in CD3- or thapsigargin-activated Jurkat cells. Aussel C, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):909-13

The lysosomal membrane glycoproteins Lamp-1 and Lamp-2 are present in mobilizable organelles, but are absent from the azurophil granules of human neutrophils. Dahlgren C, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):667-74

Integrin alpha 4 cysteines 278 and 717 modulate VLA-4 ligand binding and also contribute to alpha 4/180 formation. Pujades C, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):899-908

Growth inhibition signalled through the interleukin-4/interleukin-13 receptor complex is associated with tyrosine phosphorylation of insulin receptor substrate-1. Schnyder B, et al. **Biochem J** 1996 May 1;315 (Pt 3):767-74

Estimation of the dissociation constant of the cell adhesion molecules srCD2 and srCD48 using analytical ultracentrifugation. Silkowski H, et al. **Biochem Soc Trans** 1995 Aug;23(3):435S

Regulation of human interleukin-8 receptor A: identification of a phosphorylation site involved in modulating receptor functions. Richardson RM, et al. **Biochemistry** 1995 Oct 31;34(43):14193-201

Melanoma growth stimulatory activity signaling through the class II interleukin-8 receptor enhances the tyrosine phosphorylation of Crk-associated substrate, p130, and a 70-kilodalton protein. Schraw W, et al. **Biochemistry** 1995 Oct 24;34(42):13760-7

Human interleukin 4 receptor complex: neutralization effect of two monoclonal antibodies. Taremi SS, et al. **Biochemistry** 1996 Feb 20;35(7):2322-31

Association of TM4SF proteins with integrins: relevance to cancer. Hemler ME, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2-3):67-71 (58 ref.)

Intracellular trafficking of lysosomal membrane proteins. Hunziker W, et al. **Bioessays** 1996 May;18(5):379-89 (88 ref.)

Cytokines that use gp130 as a signal transducer stimulate mouse placental lactogen-I (mPL-I) but inhibit mPL-II production in vitro. Yamaguchi M, et al. **Biol Reprod** 1995 Aug;53(2):399-406

Signal transduction and glycophosphatidylinositol-linked proteins (lyn, lck, CD4, CD45, G proteins, and CD55) selectively localize in Triton-insoluble plasma membrane domains of human leukemic cell lines and normal granulocytes. Parolini I, et al. **Blood** 1996 May 1; 87(9):3783-94

Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain. Schnyder B, et al. **Blood** 1996 May 15;87(10):4286-95

Tumor necrosis factor (TNF) is a physiologic regulator of hematopoietic progenitor cells: increase of early hematopoietic progenitor cells in TNF receptor p55-deficient mice in vivo and potent inhibition of progenitor cell proliferation by TNF alpha in vitro. Zhang Y, et al. **Blood** 1995 Oct 15;86(8):2930-7

The P1A alloantigen system is a sensitive indicator of the structural integrity of the amino-terminal domain of the human integrin beta 3 subunit. Kunicki TJ, et al. **Blood Cells Mol Dis** 1995;21(2):131-41

Multiplicity of fibronectin-binding alpha V integrin receptors in colorectal cancer. Agrez MV, et al. **Br J Cancer** 1996 Apr;73(7):887-92

Correlation between integrin alpha 5 expression and the malignant phenotype of transitional cell carcinoma. Saito T, et al. **Br J Cancer** 1996 Feb;73(3):327-31

Bladder carcinomas and normal urothelium universally express gp200-MR6, a molecule functionally associated with the interleukin 4 receptor (CD 124). Tungekar MF, et al. **Br J Cancer** 1996 Feb;73(4):429-32

Expression of the antigen recognized by mAb GB36 in normal skin and in skin tumours. Hofman P, et al. **Br J Dermatol** 1995 Dec;133(6):874-83

Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Kyrtsonis MC, et al. **Br J Haematol** 1996 May;93(2):398-400

Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias [see comments] Ohtani K, et al. **Br J Haematol** 1995 Sep;91(1):116-20. Comment in: Br J Haematol 1996 Mar;92(3):767-8.

Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group. Pulkki K, et al. **Br J Haematol** 1996 Feb;92(2):370-4

Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Salles G, et al. **Br J Haematol** 1996 May;93(2):352-9

Clinical significance of elevated soluble interleukin 6 receptor levels in patients with plasma cell disorders [letter; comment] Smith SR, et al. **Br J Haematol** 1996 Mar; 92(3):767-8. Comment on: Br J Haematol 1995 Sep;91(1):116-20.

Differential expression of the costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid synovial tissue. Balsa A, et al. **Br J Rheumatol** 1996 Jan;35(1):33-7

Increased expression of interferon (IFN)-gamma together with IFN-gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis. Dolhain RJ, et al. **Br J Rheumatol** 1996 Jan; 35(1):24-32

CD69 on synovial T cells in rheumatoid arthritis correlates with disease activity [letter] Iannone F, et al. **Br J Rheumatol** 1996 Apr;35(4):397

Trifluoperazine reduces the expression of CD69 in phytohemagglutinin-activated lymphocytes. Pires V, et al. **Braz J Med Biol Res** 1996 Apr;29(4):479-83

Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Bjørge L, et al. **Cancer Immunol Immunother** 1996 Mar;42(3):185-92

Peripheral natural killer cell activity and intraperitoneal soluble p55 tumor necrosis factor receptor in patients with malignant ascites: two possible indicators for response to intraperitoneal combined tumor necrosis factor alpha and interferon gamma treatment. Ott MG, et al. **Cancer Immunol Immunother** 1996 Jan;42(1):31-7

Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Oka M, et al. **Cancer Res** 1996 Jun 15;56(12):2776-80

A direct binding assay for the vascular cell adhesion molecule-1 (VCAM1) interaction with alpha 4 integrins. Lobb RR, et al. **Cell Adhes Commun** 1995 Dec;3(5):385-97

CD53 antigen and epidermal growth factor induce similar changes in the pattern of phorbol ester binding in a B cell lymphoma. Barcia R, et al. **Cell Immunol** 1996 Apr 10; 169(1):107-12

A comparison of proliferative response to IL-7 and expression of IL-7 receptors in intermediate TCR cells of the liver, spleen, and thymus. Miyaji C, et al. **Cell Immunol** 1996 May 1;169(2):159-65

Differential role of protein tyrosine phosphorylation/dephosphorylation in affinity regulation of beta 1 and beta 3 integrin in human fibroblasts. Takagi J, et al. **Cell Struct Funct** 1995 Oct;20(5):403-13

Components of biological variation in plasma haptoglobin: relationships to plasma fibrinogen and immune variables, including interleukin-6 and its receptor. Maes M, et al. **Clin Chim Acta** 1995 Jul 31;239(1):23-35

Signal transduction by the alpha 6 beta 4 integrin: distinct beta 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes. Mainiero F, et al. **EMBO J** 1995 Sep 15;14(18):4470-81

Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Crippes BA, et al. **Endocrinology** 1996 Mar;137(3):918-24

Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells. Halimi H, et al. **Eur Cytokine Netw** 1995 May-Jun;6(3):135-43

Stimulation of ADP-ribosyl cyclase activity of the cell surface antigen CD38 by zinc ions resulting from inhibition of its NAD+ glycohydrolase activity. Kukimoto I, et al. **Eur J Biochem** 1996 Jul 1;239(1):177-82

Different human interleukin-4 mutants preferentially activate human or murine common receptor gamma chain. Lischke A, et al. **Eur J Biochem** 1995 Nov 15;234(1):100-7

Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing. Müller-Newen G, et al. **Eur J Biochem** 1996 Mar 15; 236(3):837-42

Soluble human interleukin-6 receptor. Expression in insect cells, purification and characterization. Weiergräber O, et al. **Eur J Biochem** 1995 Dec 1;234(2):661-9

Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Creery WD, et al. **Eur J Immunol** 1996 Jun;26(6):1273-7

Comparison of CD28-B7.1 and B7.2 functional interaction in resting human T cells: phosphatidylinositol 3-kinase association to CD28 and cytokine production. Ghiotto-Ragueneau M, et al. **Eur J Immunol** 1996 Jan; 26(1):34-41

Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. Lien E, et al. **Eur J Immunol** 1995 Sep;25(9):2714-7

Interleukin-7 activates p56lck and p59fyn, two tyrosine kinases associated with the p90 interleukin-7 receptor in primary human T cells. Page TH, et al. **Eur J Immunol** 1995 Oct;25(10):2956-60

Ligation of TAPA-1 (CD81) or major histocompatibility complex class II in co-cultures of human B and T lymphocytes enhances interleukin-4 synthesis by antigen-specific CD4+ T cells. Secrist H, et al. **Eur J Immunol** 1996 Jul;26(7):1435-42

Biosynthetic transport of a major lysosomal membrane glycoprotein, lamp-1: convergence of biosynthetic and endocytic pathways occurs at three distinctive points. Akasaki K, et al. **Exp Cell Res** 1995 Oct;220(2):464-73

Bone sialoprotein coated on glass and plastic surfaces is recognized by different beta 3 integrins. Flores ME, et al. **Exp Cell Res** 1996 Aug 25;227(1):40-6

G alpha-16 complements the signal transduction cascade of chemotactic receptors for complement factor C5a (C5a-R) and N-formylated peptides (fMLF-R) in Xenopus laevis oocytes: G alpha-16 couples to chemotactic receptors in Xenopus oocytes. Burg M, et al. **FEBS Lett** 1995 Dec 27; 377(3):426-8

Dansyl cadaverine regulates ligand induced endocytosis of interleukin-8 receptor in human polymorphonuclear neutrophils. Ray E, et al. **FEBS Lett** 1996 Jan 15; 378(3):235-9

Use of immobilized synthetic peptides for the identification of contact sites between human interleukin-6 and its receptor. Weiergräber O, et al. **FEBS Lett** 1996 Jan 29; 379(2):122-6

Lateral mobility of Fc gamma RIIa is reduced by protein kinase C activation. Zhang F, et al. **FEBS Lett** 1995 Nov 27;376(1-2):77-80

Monovalent phage display of human interleukin (hIL)-6: selection of superbinder variants from a complex molecular repertoire in the hIL-6 D-helix. Cabibbo A, et al. **Gene** 1995 Dec 29;167(1-2):41-7

Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Linsley PS, et al. **Immunity** 1996 Jun;4(6):535-43

Cattle CTLA-4, CD28 and chicken CD28 bind CD86: MYPPPY is not conserved in cattle CD28. Parsons KR, et al. **Immunogenetics** 1996;43(6):388-91

Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Judge TA, et al. **Immunol Res** 1996; 15(1):38-49 (34 ref.)

Cytokine (IL-8, IL-6, TNF-alpha) and soluble TNF receptor-I release from human peripheral blood mononuclear cells after respiratory syncytial virus infection. Arnold R, et al. **Immunology** 1995 Jul; 85(3):364-72

Antagonistic peptides against human anaphylatoxin C5a. Kaneko Y, et al. **Immunology** 1995 Sep;86(1):149-54

Fc alpha receptors mediate release of tumour necrosis factor-alpha and interleukin-6 by human monocytes following receptor aggregation. Patry C, et al. **Immunology** 1995 Sep;86(1):1-5

Expression of interferon-gamma receptors on murine oligodendrocytes and its regulation by cytokines and mitogens. Torres C, et al. **Immunology** 1995 Oct;86(2):250-5

Proteolytic inactivation of the leukocyte C5a receptor by proteinases derived from Porphyromonas gingivalis. Jagels MA, et al. **Infect Immun** 1996 Jun;64(6):1984-91

Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. Vollmer P, et al. **Infect Immun** 1996 Sep;64(9):3646-51

Brucella abortus as a potential vaccine candidate: induction of interleukin-12 secretion and enhanced B7.1 and B7.2 and intercellular adhesion molecule 1 surface expression in elutriated human monocytes stimulated by heat-inactivated B. abortus. Zaitseva M, et al. **Infect Immun** 1996 Aug;64(8):3109-17

Pattern of soluble TNF receptors I and II in sepsis. Schröder J, et al. **Infection** 1995 May-Jun;23(3):143-8

Soluble interleukin-4 receptor in atopic children. Schauer U, et al. **Int Arch Allergy Immunol** 1995 Oct;108(2):175-82

Migration pathways of CD4 T cell subsets in vivo: the CD45RC- subset enters the thymus via alpha 4 integrin-VCAM-1 interaction. Bell EB, et al. **Int Immunol** 1995 Nov;7(11):1861-71

Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production. Mingari MC, et al. **Int Immunol** 1995 Apr; 7(4):697-703

Tyrosine-phosphorylated forms of Ig beta, CD22, TCR zeta and HOSS are major ligands for tandem SH2 domains of

Syk. Wienands J, et al. **Int Immunol** 1995 Nov;7(11):1701–8
Distribution of extracellular and cytoplasmic domains of the alpha 3 and alpha 6 integrin subunits in solid tumors. Patriarca C, et al. **Int J Cancer** 1995 Oct 9;63(2):182–9
Constituents of autocrine IL–6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies. Villunger A, et al. **Int J Cancer** 1996 Feb 8;65(4):498–505
Changes in beta 4 integrin expression and localization in vivo in response to corneal epithelial injury. Stepp MA, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1593–601
ADP–ribosyl cyclase and CD38 catalyze the synthesis of a calcium–mobilizing metabolite from NADP. Aarhus R, et al. **J Biol Chem** 1995 Dec 22;270(51):30327–33
CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin–8 receptor B. Determinants of high affinity binding and receptor activation are distinct. Ahuja SK, et al. **J Biol Chem** 1996 Jan 5;271(1):225–32
Synthesis, processing, and intracellular transport of CD36 during monocytic differentiation. Alessio M, et al. **J Biol Chem** 1996 Jan 19;271(3):1770–5
The amino–terminal immunoglobulin–like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane–proximal scavenger receptor cysteine–rich domain of CD6 with a 1:1 stoichiometry. Bowen MA, et al. **J Biol Chem** 1996 Jul 19;271(29):17390–6
Phosphoinositide 3–kinase and p72syk noncovalently associate with the low affinity Fc gamma receptor on human platelets through an immunoreceptor tyrosine–based activation motif. Reconstitution with synthetic phosphopeptides. Chacko GW, et al. **J Biol Chem** 1996 May 3;271(18):10775–81
Interleukin–6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein. Chevalier S, et al. **J Biol Chem** 1996 Jun 21; 271(25):14764–72
Definition of a composite binding site for gp130 in human interleukin–6. Ciapponi L, et al. **J Biol Chem** 1995 Dec 29;270(52):31249–54
Activation of the p21 pathway of growth arrest and apoptosis by the beta 4 integrin cytoplasmic domain. Clarke AS, et al. **J Biol Chem** 1995 Sep 29;270(39):22673–6
Physical association of Gi2alpha with interleukin–8 receptors. Damaj BB, et al. **J Biol Chem** 1996 May 31;271(22):12783–9
A di–leucine motif and an upstream serine in the interleukin–6 (IL–6) signal transducer gp130 mediate ligand–induced endocytosis and down–regulation of the IL–6 receptor. Dittrich E, et al. **J Biol Chem** 1996 Mar 8;271(10):5487–94
Calpain cleavage of the cytoplasmic domain of the integrin beta 3 subunit. Du X, et al. **J Biol Chem** 1995 Nov 3; 270(44):26146–51
Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. Gerhartz C, et al. **J Biol Chem** 1996 May 31; 271(22):12991–8
The interleukin–6 (IL–6) partial antagonist (Q159E,T162P)IL–6 interacts with the IL–6 receptor and gp130 but fails to induce a stable hexameric receptor complex. Hammacher A, et al. **J Biol Chem** 1996 Mar 8; 271(10):5464–73
N51 competes 125I–interleukin (IL)–8 binding to IL–8R beta but not IL–8R alpha. Structure–function analysis using N51/IL–8 chimeric molecules. Heinrich JN, et al. **J Biol Chem** 1995 Nov 24;270(47):28014–7
Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. Hemmann U, et al. **J Biol Chem** 1996 May 31;271(22):12999–3007
An allosteric Ca2+ binding site on the beta3–integrins that regulates the dissociation rate for RGD ligands. Hu DD, et al. **J Biol Chem** 1996 Sep 6;271(36):21745–51
Pertussis toxin–sensitive activation of phospholipase C by the C5a and fMet–Leu–Phe receptors. Jiang H, et al. **J Biol Chem** 1996 Jun 7;271(23):13430–4
Identification of an interferon–gamma receptor alpha chain sequence required for JAK–1 binding. Kaplan DH, et al. **J Biol Chem** 1996 Jan 5;271(1):9–12
Regulatory role of CD38 (ADP–ribosyl cyclase/cyclic ADP–ribose hydrolase) in insulin secretion by glucose in pancreatic beta cells. Enhanced insulin secretion in CD38–expressing transgenic mice. Kato I, et al. **J Biol Chem** 1995 Dec 15;270(50):30045–50
Tyrosine phosphorylation of the c–cbl proto–oncogene product mediated by cell surface antigen CD38 in HL–60 cells. Kontani K, et al. **J Biol Chem** 1996 Jan 19; 271(3):1534–7
A molecular basis for affinity modulation of Fab ligand binding to integrin alphaIIb beta3. Kunicki TJ, et al. **J Biol Chem** 1996 Aug 23;271(34):20315–21
Tumor necrosis factor induces lipopolysaccharide tolerance in a human adenocarcinoma cell line mainly through the TNF p55 receptor. Laegreid A, et al. **J Biol Chem** 1995 Oct 27;270(43):25418–25
Cytotoxic T lymphocyte–associated molecule–4, a high–avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. Leung HT, et al. **J Biol Chem** 1995 Oct 20;270(42):25107–14
Exchanging interleukin–8 and melanoma growth–stimulating activity receptor binding specificities. Lowman HB, et al. **J Biol Chem** 1996 Jun 14;271(24):14344–52
A molecular switch of chemokine receptor selectivity. Chemical modification of the interleukin–8 Leu25 –> Cys mutant. Lusti–Narasimhan M, et al. **J Biol Chem** 1996 Feb 9;271(6):3148–53
Two different cytoplasmic tails direct isoforms of the membrane cofactor protein (CD46) to the basolateral surface of Madin–Darby canine kidney cells. Maisner A, et al. **J Biol Chem** 1996 Aug 2;271(31):18853–8
Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcR gamma chain. Molecular basis for CD89/FcR gamma chain association. Morton HC, et al. **J Biol Chem** 1995 Dec 15; 270(50):29781–7
Receptors for interleukin (IL)–4 do not associate with the common gamma chain, and IL–4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells. Murata T, et al. **J Biol Chem** 1995 Dec 22;270(51):30829–36
Tumor necrosis factor (TNF)–alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. Peraldi P, et al. **J Biol Chem** 1996 May 31;271(22):13018–22
Role of the C terminus of the interleukin 8 receptor in signal transduction and internalization. Prado GN, et al. **J Biol Chem** 1996 Aug 9;271(32):19186–90
A single N–linked glycosylation site is implicated in the regulation of ligand recognition by the I–type lectins CD22 and CD33. Sgroi D, et al. **J Biol Chem** 1996 Aug 2; 271(31):18803–9
Localization of the putative sialic acid–binding site on the immunoglobulin superfamily cell–surface molecule CD22. van der Merwe PA, et al. **J Biol Chem** 1996 Apr 19; 271(16):9273–80
CD39 is an ecto–(Ca2+,Mg2+)–apyrase. Wang TF, et al. **J Biol Chem** 1996 Apr 26;271(17):9898–901
Mutagenesis studies of interleukin–8. Identification of a second epitope involved in receptor binding. Williams G, et al. **J Biol Chem** 1996 Apr 19;271(16):9579–86
Catalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14. Yu B, et al. **J Biol Chem** 1996 Feb 23;271(8):4100–5
Integrin–associated protein immunoglobulin domain is necessary for efficient vitronectin bead binding. Lindberg FP, et al. **J Cell Biol** 1996 Sep;134(5):1313–22
The targeting of Lamp1 to lysosomes is dependent on the spacing of its cytoplasmic tail tyrosine sorting motif relative to the membrane. Rohrer J, et al. **J Cell Biol** 1996 Feb; 132(4):565–76
Beta 1 integrin–dependent and –independent polymerization of fibronectin. Wennerberg K, et al. **J Cell Biol** 1996 Jan; 132(1–2):227–38
Soluble interleukin–6 (IL–6) receptor in the sera of pregnant women forms a complex with IL–6 and augments human chorionic gonadotropin production by normal human trophoblasts through binding to the IL–6 signal transducer. Matsuzaki N, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):2912–7
Detection of receptors for interleukin–6, interleukin–11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. Bellido T, et al. **J Clin Invest** 1996 Jan 15;97(2):431–7
Inhibition of submandibular and lacrimal gland infiltration in nonobese diabetic mice by transgenic expression of soluble TNF–receptor p55. Hunger RE, et al. **J Clin Invest** 1996 Aug 15;98(4):954–61
Regulation of interleukin–4 activity by soluble interleukin–4 receptors. Enssle K, et al. **J Clin Lab Anal** 1995;9(6):450–5 (38 ref.)
Decreased integrin alpha 2, but normal response to TGF–beta in scleroderma fibroblasts. Osada K, et al. **J Dermatol Sci** 1995 May;9(3):169–75
IL–6sR: release from MCF–7 breast cancer cells and role in regulating peripheral oestrogen synthesis. Singh A, et al. **J Endocrinol** 1995 Nov;147(2):R9–12
Localization of the binding site for the monocyte immunoglobulin (Ig) A–Fc receptor (CD89) to the domain boundary between Calpha2 and Calpha3 in human IgA1. Carayannopoulos L, et al. **J Exp Med** 1996 Apr 1; 183(4):1579–86
Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO–1/Fas–mediated apoptosis. Lagresle C, et al. **J Exp Med** 1996 Apr 1;183(4):1377–88
CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C–gamma(1) upon B cell activation. Law CL, et al. **J Exp Med** 1996 Feb 1;183(2):547–60
Costimulation by CD48 and B7–1 induces immunity against poorly immunogenic tumors. Li Y, et al. **J Exp Med** 1996 Feb 1;183(2):639–44
The function of the soluble interleukin 6 (IL–6) receptor in vivo: sensitization of human soluble IL–6 receptor transgenic mice towards IL–6 and prolongation of the plasma half–life of IL–6. Peters M, et al. **J Exp Med** 1996 Apr 1;183(4):1399–406
Expression of costimulatory molecules B7–1 (CD80), B7–2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. Windhagen A, et al. **J Exp Med** 1995 Dec 1; 182(6):1985–96
Interactions between the ectodomains of haemagglutinin and CD46 as a primary step in measles virus entry. Devaux P, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1477–81
Cell–to–cell contact via measles virus haemagglutinin–CD46 interaction triggers CD46 downregulation. Krantic S, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2793–800
Mice lacking the IFN–gamma receptor have impaired ability to resolve a lung eosinophilic inflammatory response associated with a prolonged capacity of T cells to exhibit a Th2 cytokine profile. Coyle AJ, et al. **J Immunol** 1996 Apr 15;156(8):2680–5
Interactions of CD80 and CD86 with CD28 and CTLA4. Ellis JH, et al. **J Immunol** 1996 Apr 15;156(8):2700–9
Stimulation of Fc(alpha) receptors induces tyrosine phosphorylation of phospholipase C–gamma(1), phosphatidylinositol phosphate hydrolysis, and Ca2+ mobilization in rat and human mesangial cells. Gómez–Guerrero C, et al. **J Immunol** 1996 Jun 1; 156(11):4369–76
Recombinant human growth–regulated oncogene–alpha induces T lymphocyte chemotaxis. A process regulated via IL–8 receptors by IFN–gamma, TNF–alpha, IL–4, IL–10, and IL–13. Jinquan T, et al. **J Immunol** 1995 Dec 1; 155(11):5359–68
Analysis of the site of interaction of CD28 with its counter–receptors CD80 and CD86 and correlation with function. Kariv I, et al. **J Immunol** 1996 Jul 1;157(1):29–38
Dissection of CR1, factor H, membrane cofactor protein, and factor B binding and functional sites in the third complement component. Lambris JD, et al. **J Immunol** 1996 Jun 15;156(12):4821–32
Membrane cofactor protein (MCP; CD46). Isoforms differ in protection against the classical pathway of complement. Liszewski MK, et al. **J Immunol** 1996 Jun 1;156(11):4415–21
CD59 and CD48 expressed by rat retinal pigment epithelial cells are major ligands for the CD2–mediated alternative pathway of T cell activation. Liversidge J, et al. **J Immunol** 1996 May 15;156(10):3696–703
Expression of ecto–adenosine deaminase and CD26 in human T cells triggered by the TCR–CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. Martin M, et al. **J Immunol** 1995 Nov 15;155(10):4630–43
A metalloprotease inhibitor blocks shedding of the IL–6 receptor and the p60 TNF receptor. Müllberg J, et al. **J Immunol** 1995 Dec 1;155(11):5198–205
CD66 family members are associated with tyrosine kinase activity in human neutrophils. Skubitz KM, et al. **J Immunol** 1995 Dec 1;155(11):5382–90
Impact of interferon–gamma receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis. Zhao YX, et al. **J Immunol** 1995 Dec 15; 155(12):5736–42
Quantification of measles virus by a virus receptor–dependent and haemagglutinin–specific T cell stimulation assay. Trescol–Biémont MC, et al. **J Immunol Methods** 1995 Dec 1;187(2):253–8
Functional CD86 (B7–2/B70) on cultured human Langerhans cells. Yokozeki H, et al. **J Invest Dermatol** 1996 Jan; 106(1):147–53
Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins. Koski CL, et al. **J Neurochem** 1996 Jan;66(1):303–12
Expression of the receptors for the C5a anaphylatoxin, interleukin–8 and FMLP by human astrocytes and microglia. Lacy M, et al. **J Neuroimmunol** 1995 Aug; 61(1):71–8
Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. Huang S, et al. **J Virol** 1996 Jul; 70(7):4502–8
Identification of two amino acids in the hemagglutinin glycoprotein of measles virus (MV) that govern hemadsorption, HeLa cell fusion, and CD46 downregulation: phenotypic markers that differentiate vaccine and wild–type MV strains. Lecouturier V, et al. **J Virol** 1996 Jul;70(7):4200–4
Receptor (CD46) modulation and complement–mediated lysis of uninfected cells after contact with measles virus–infected cells. Schneider–Schaulies J, et al. **J Virol** 1996 Jan;70(1):255–63
Expression of integrin alpha 3 in gastric and colorectal cancers: its relation to wall contraction and mode of invasion. Boku N, et al. **Jpn J Cancer Res** 1995 Oct; 86(10):934–40
Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement–mediated tumor cell lysis. Gorter A, et al. **Lab Invest** 1996 Jun; 74(6):1039–49
Differential interleukin–6 (IL–6) responses of three established myeloma cell lines in the presence of soluble human IL–6 receptors. Diamant M, et al. **Leuk Res** 1996 Apr;20(4):291–301
Megakaryocytic differentiation of a leukemic cell line, MC3, by phorbol ester: induction of glycoprotein IIb/IIIa and effects on expression of IL–6, IL–6 receptor, mpl and GATA genes. Okabe M, et al. **Leuk Res** 1995 Dec; 19(12):933–43
Ontogeny of membrane cofactor protein: phenotypic divergence in the fetal heart. Gorelick A, et al. **Lupus** 1995 Aug;4(4):293–6
Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane

domains (TM4 proteins). Berditchevski F, et al. **Mol Biol Cell** 1996 Feb;7(2):193–207

Specialized functional properties of the integrin alpha 4 cytoplasmic domain. Kassner PD, et al. **Mol Biol Cell** 1995 Jun;6(6):661–74

Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. Bach EA, et al. **Mol Cell Biol** 1996 Jun;16(6):3214–21

Estrogen enhances alpha v beta 3 integrin expression by avian osteoclast precursors via stabilization of beta 3 integrin mRNA. Li CF, et al. **Mol Endocrinol** 1995 Jul;9(7):805–13

Regulation of interleukin-8 receptor expression in human polymorphonuclear neutrophils. Manna SK, et al. **Mol Immunol** 1995 Aug;32(12):883–93

Molecular interactions between fibronectin and integrins during mouse blastocyst outgrowth. Yelian FD, et al. **Mol Reprod Dev** 1995 Aug;41(4):435–48

Beta 1 and beta 3 integrin upregulation in rapidly progressive glomerulonephritis. Baraldi A, et al. **Nephrol Dial Transplant** 1995;10(7):1155–61

Permeability of the blood–brain barrier to soluble cytokine receptors. Banks WA, et al. **Neuroimmunomodulation** 1995 May–Jun;2(3):161–5

Association of pp60c-src with biliary glycoprotein (CD66a), an adhesion molecule of the carcinoembryonic antigen family downregulated in colorectal carcinomas. Brümmer J, et al. **Oncogene** 1995 Oct 19;11(8):1649–55

The human IL-11 receptor requires gp130 for signalling: demonstration by molecular cloning of the receptor. Nandurkar HH, et al. **Oncogene** 1996 Feb 1;12(3):585–93

Suramin blocks binding of interleukin-4 to its receptors on human tumor cells and interleukin-4–induced mitogenic response. Leland P, et al. **Oncol Res** 1995;7(5):227–35

Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Jones JI, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2482–7

Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2. Jones SA, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6682–6

I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. Rothe M, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8241–6

Molecular model of the N-terminal receptor-binding domain of the human CD6 ligand ALCAM. Bajorath J, et al. **Protein Sci** 1995 Aug;4(8):1644–7

Crystallization of the complex of human IFN-gamma and the extracellular domain of the IFN-gamma receptor. Chène C, et al. **Proteins** 1995 Dec;23(4):591–4

Blocking CD28/B7 with soluble competitors: immunological phenotype of mCTLA4-H gamma 1 transgenic mice. Lane P. **Res Immunol** 1995 Mar–Apr;146(3):176–9 (30 ref.)

CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy? van Gool SW, et al. **Res Immunol** 1995 Mar–Apr;146(3):183–96 (106 ref.)

Lack of interferon-gamma receptor does not influence the outcome of infection in murine schistosomiasis mansoni. Akhiani AA, et al. **Scand J Immunol** 1996 Mar;43(3):257–62

Decrease in cAMP levels promoted by CD48-CD2 interaction correlates with inhibition of apoptosis in B cells. Baixeras E, et al. **Scand J Immunol** 1996 Apr;43(4):406–12

Identification and characterization of specific receptor for interleukin-8 from the surface of human monocytes. Bishayi B, et al. **Scand J Immunol** 1996 May;43(5):531–6

A receptor for the selective uptake and degradation of proteins by lysosomes. Cuervo AM, et al. **Science** 1996 Jul 26;273(5274):501–3

Designer cytokines: targeting actions to cells of choice. Economides AN, et al. **Science** 1995 Nov 24; 270(5240):1351–3

CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Yang Y, et al. **Science** 1996 Sep 27;273(5283):1862–4

The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. Lauria F, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):428–34

Signal transduction through the IL-4 and insulin receptor families. Wang LM, et al. **Stem Cells (Dayt)** 1995 Jul; 13(4):360–8 (47 ref.)

Expression of prothrombinase activity and CD9 antigen on the surface of small vesicles from stimulated human endothelial cells. Kagawa H, et al. **Thromb Res** 1995 Dec 15;80(6):451–60

Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation. Toren A, et al. **Transplantation** 1996 Jul 15;62(1):138–42

CD46-mediated measles virus entry: a first key to host-range specificity. Gerlier D, et al. **Trends Microbiol** 1995 Sep; 3(9):338–45 (65 ref.)

Mode of entry of morbilliviruses. Wild TF, et al. **Vet Microbiol** 1995 May;44(2–4):267–70

Glycoprotein incorporation and HIV-1 infectivity despite exchange of the gp160 membrane-spanning domain. Wilk T, et al. **Virology** 1996 Apr 1;218(1):269–74

[Expression and characterization of CD46, membrane cofactor protein, in human colonic mucosa] Nakanishi S, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb; 19(1):53–9 (Eng. Abstr.) **(Jpn)**

[Demonstration and characterization of CD46, membrane cofactor protein in the stomach] Seto N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):81–6 (Eng. Abstr.) **(Jpn)**

[Complement regulatory proteins CR 1, MCP, DAF, and MACIF levels in patients with Behçet's disease] Kure T, et al. **Nippon Ganka Gakkai Zasshi** 1996 May;100(5):376–80 (Eng. Abstr.) **(Jpn)**

[A study of interleukin-6 and soluble interleukin-6 receptors during pregnancy and delivery] Ishizaki S. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1230–6 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Evidence for protein tyrosine kinase involvement in CD6-induced T cell proliferation. Osorio LM, et al. **Cell Immunol** 1995 Nov;166(1):44–52

Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Martin-Fontecha A, et al. **Eur J Immunol** 1996 Aug;26(8):1851–9

Expression of megakaryocytic and erythroid properties in human leukemic cells. Tani T, et al. **Exp Hematol** 1996 Feb;24(2):158–68

Effect of CD80 and CD86 on T cell cytokine production. Petro TM, et al. **Immunol Invest** 1995 Nov;24(6):965–76

Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Brett S, et al. **Immunology** 1996 May;88(1):13–9

CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Levine BL, et al. **Int Immunol** 1995 Jun;7(6):891–904

Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. Ueda Y, et al. **Int Immunol** 1995 Jun;7(6):957–66

Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. Brunschwig EB, et al. **J Immunol** 1995 Dec 15;155(12):5498–505

B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. Matulonis U, et al. **J Immunol** 1996 Feb 1; 156(3):1126–31

Costimulation of IL-4 production by murine B7-1 and B7-2 molecules. Natesan M, et al. **J Immunol** 1996 Apr 15; 156(8):2783–91

PHYSIOLOGY

Enhanced susceptibility to human immunodeficiency virus infection in CD4+ T lymphocytes genetically deficient in CD43. Srinivas RV, et al. **AIDS Res Hum Retroviruses** 1995 Sep;11(9):1015–21

Cytokine signal transduction through a homo- or heterodimer of gp130. Kishimoto T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:224–34 (22 ref.)

The CD69 activation pathway in rheumatoid arthritis synovial fluid T cells. Hernández-García C, et al. **Arthritis Rheum** 1996 Aug;39(8):1277–86

Molecular mechanisms of APO-1/Fas(CD95)-mediated apoptosis in tolerance and AIDS. Dhein J, et al. **Behring Inst Mitt** 1995 Jun;(96):13–20 (37 ref.)

Identification of the lysosomal membrane glycoprotein Lamp-1 as a receptor for type-1-fimbriated (mannose-specific) Escherichia coli. Karlsson A, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):168–72

Tumor necrosis factor alpha receptor p55 is under hormonal (follicle-stimulating hormone) control in testicular Sertoli cells. Mauduit C, et al. **Biochem Biophys Res Commun** 1996 Jul 25;224(3):631–7

Antibodies against the N-terminus of IL-8 receptor A inhibit neutrophil chemotaxis. Quan JM, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):405–11

The synthetic [Tyr5,12,Lys7]-polyphemusin II peptide (T22) binds to the CD4 cell surface molecule. Weeks BS, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):626–31

The 4F2hc surface antigen is necessary for expression of system L-like neutral amino acid-transport activity in C6-BU-1 rat glioma cells: evidence from expression studies in Xenopus laevis oocytes. Bröer S, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):863–70

C-type lectins of natural killer cells: carbohydrate ligands and role in tumour cell lysis. Bezouška K. **Biochem Soc Trans** 1996 Feb;24(1):156–61 (24 ref.)

Early response genes activated by stimulation of human B lymphocytes through different cell surface receptors. Newton JS, et al. **Biochem Soc Trans** 1996 Feb;24(1):7S

Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Benigni F, et al. **Blood** 1996 Mar 1;87(5):1851–4

Thrombopoietin stimulates colony-forming unit-megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit. Broudy VC, et al. **Blood** 1996 Sep 15;88(6):2026–32

Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Gribben JG, et al. **Blood** 1996 Jun 1; 87(11):4887–93

Antibody ligation of CD9 modifies production of myeloid cells in long-term cultures. Oritani K, et al. **Blood** 1996 Mar 15;87(6):2252–61

Characterization of Grb2-binding proteins in human platelets activated by Fc gamma RIIA cross-linking. Robinson A, et al. **Blood** 1996 Jul 15;88(2):522–30

Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation. Tuscano J, et al. **Blood** 1996 Jun 1;87(11):4723–30

Combined signaling through interleukin-7 receptors and flt3 but not c-kit potently and selectively promotes B-cell commitment and differentiation from uncommitted murine bone marrow progenitor cells. Veiby OP, et al. **Blood** 1996 Aug 15;88(4):1256–65

Expression and role in growth regulation of tumour necrosis factor receptors p55 and p75 in acute myeloblastic leukaemia cells. Carter A, et al. **Br J Haematol** 1996 Jan; 92(1):116–26

Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Demartis A, et al. **Cancer Res** 1996 Sep 15;56(18):4213–8

Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. Friedlander DR, et al. **Cancer Res** 1996 Apr 15;56(8):1939–47

CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Pellat-Deceunynck C, et al. **Cancer Res** 1996 Apr 15; 56(8):1909–16

Loss of the tumorigenic phenotype with in vitro, but not in vivo, passaging of a novel series of human bronchial epithelial cell lines: possible role of an alpha 5/beta 1-integrin-fibronectin interaction. Schiller JH, et al. **Cancer Res** 1995 Dec 15;55(24):6215–21

The role of ICAM expression in immunity and disease. Simmons DL. **Cancer Surv** 1995;24:141–55 (58 ref.)

Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Boldin MP, et al. **Cell** 1996 Jun 14;85(6):803–15

TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Hsu H, et al. **Cell** 1996 Jan 26;84(2):299–308

Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation. Simms PE, et al. **Clin Diagn Lab Immunol** 1996 May;3(3):301–4

Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Rabinovitz I, et al. **Clin Exp Metastasis** 1995 Nov;13(6):481–91

Involvement of alpha 6 and alpha v integrins in metastasis. Imhof BA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):195–203 (36 ref.)

Evidence for exclusive role in signalling of tumour necrosis factor p55 receptor and a potentiating function of p75 receptor on human endothelial cells. Leeuwenberg JF, et al. **Cytokine** 1995 Jul;7(5):457–62

Functional requirement of gp130-mediated signaling for growth and survival of mouse primordial germ cells in vitro and derivation of embryonic germ (EG) cells. Koshimizu U, et al. **Development** 1996 Apr;122(4):1235–42

Integrin alpha 6 expression is required for early nervous system development in Xenopus laevis. Lallier TE, et al. **Development** 1996 Aug;122(8):2539–54

The interleukin-7 receptor alpha chain transmits distinct signals for proliferation and differentiation during B lymphopoiesis. Corcoran AE, et al. **EMBO J** 1996 Apr 15;15(8):1924–32

Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. Yamanaka Y, et al. **EMBO J** 1996 Apr 1;15(7):1557–65

Participation of two Ser-Ser-Phe-Tyr repeats in interleukin-6 (IL-6)-binding sites of the human IL-6 receptor. Kalai M, et al. **Eur J Biochem** 1996 Jun 15; 238(3):714–23

A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro. Christiansen D, et al. **Eur J Immunol** 1996 Mar;26(3):578–85

Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand-dependent mechanism: CTLA4-Ig protects V beta 8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B. Lane P, et al. **Eur J Immunol** 1996 Apr;26(4):858–62

B cell early response gene expression coupled to B cell receptor, CD40 and interleukin-4 receptor co-stimulation: evidence for a role of the egr-2/krox 20 transcription factor in B cell proliferation. Newton JS, et al. **Eur J Immunol** 1996 Apr;26(4):811–6

Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells. Plumas J, et al. **Eur J Immunol** 1995 Dec;25(12):3332–41

Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells. Rattis FM, et al. **Eur J Immunol** 1996 Feb;26(2):449–53

Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity. Reiser H, et al. **Eur J Immunol** 1996 Apr;26(4):880-5

The interleukin-8 receptor B and CXC chemokines can mediate transendothelial migration of human skin homing T cells. Santamaria Babi LF, et al. **Eur J Immunol** 1996 Sep;26(9):2056-61

Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. Tuscano JM, et al. **Eur J Immunol** 1996 Jun;26(6):1246-52

Human B7-1 is more efficient than B7-2 in providing co-stimulation for alloantigen-specific T cells. van Dijk AM, et al. **Eur J Immunol** 1996 Sep;26(9):2275-8

The control of hyperacute rejection by genetic engineering of the donor species. White DJ, et al. **Eye** 1995;9 (Pt 2):185-9

Tumor necrosis factor (TNF) stimulates the production of nerve growth factor in fibroblasts via the 55-kDa type 1 TNF receptor. Hattori A, et al. **FEBS Lett** 1996 Jan 29; 379(2):157-60

What does CD68 in activated lymphocyte mean? [letter] Hameed A. **Hum Pathol** 1995 Nov;26(11):1285-6

Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor. Ryan JJ, et al. **Immunity** 1996 Feb;4(2):123-32

IL-4 function can be transferred to the IL-2 receptor by tyrosine containing sequences found in the IL-4 receptor alpha chain. Wang HY, et al. **Immunity** 1996 Feb; 4(2):113-21

Tumour necrosis factor receptor II (p75) signalling is required for the migration of Langerhans' cells. Wang B, et al. **Immunology** 1996 Jun;88(2):284-8

Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL-4 receptor. Renz H, et al. **Int Arch Allergy Immunol** 1996 Feb;109(2):167-76

Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Aigner S, et al. **Int Immunol** 1995 Oct;7(10):1557-65

A T cell lymphoma can provide potent co-stimulatory effects to T cells that are not mediated by B7-1, B7-2, CD40, HSA or CD70. Nieland JD, et al. **Int Immunol** 1995 Nov; 7(11):1827-38

CD86 (B70/B7-2) on endothelial cells co-stimulates allogeneic CD4+ T cells. Seino K, et al. **Int Immunol** 1995 Aug;7(8):1331-7

Involvement of alpha 1 and alpha 4 integrins in gut mucosal injury of graft-versus-host disease. Tanaka T, et al. **Int Immunol** 1995 Aug;7(8):1183-9

Abrogation of lung metastasis of human fibrosarcoma cells by ribozyme-mediated suppression of integrin alpha6 subunit expression. Yamamoto H, et al. **Int J Cancer** 1996 Feb 8;65(4):519-24

Functional significance of IL-4 receptor on B cells in IL-4-induced human IgE production. Yanagihara Y, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1145-51 (39 ref.)

A novel cytoplasmic domain of the p55 tumor necrosis factor receptor initiates the neutral sphingomyelinase pathway. Adam D, et al. **J Biol Chem** 1996 Jun 14;271(24):14617-22

The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. Ahuja SK, et al. **J Biol Chem** 1996 Aug 23;271(34):20545-50

Thrombin primes responsiveness of selective chemoattractant receptors at a site distal to G protein activation. Ali H, et al. **J Biol Chem** 1996 Feb 9;271(6):3200-6

Differential translocation of phospholipase C isozymes to integrin-mediated cytoskeletal complexes in thrombin-stimulated human platelets. Banno Y, et al. **J Biol Chem** 1996 Jun 21;271(25):14989-94

Diverging signal transduction pathways activated by interleukin 8 (IL-8) and related chemokines in human neutrophils. IL-8 and Gro-alpha differentially stimulate calcium influx through IL-8 receptors A and B. Damaj BB, et al. **J Biol Chem** 1996 Aug 23;271(34):20540-4

Specific induction of cell motility on laminin by alpha 7 integrin. Echtermeyer F, et al. **J Biol Chem** 1996 Jan 26; 271(4):2071-5

Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. Felding-Habermann B, et al. **J Biol Chem** 1996 Mar 8;271(10):5892-900

gp130 transducing receptor cross-linking is sufficient to induce interleukin-6 type responses. Fourcin M, et al. **J Biol Chem** 1996 May 17;271(20):11756-60

Genomic cloning, characterization, and functional analysis of the major surface adhesin Wi-1 on Blastomyces dermatitidis yeasts. Hogan LH, et al. **J Biol Chem** 1995 Dec 22;270(51):30725-32

Other kinases can substitute for Jak2 in signal transduction by interferon-gamma. Kotenko SV, et al. **J Biol Chem** 1996 Jul 19;271(29):17174-82

Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. Lai CF, et al. **J Biol Chem** 1996 Jun 14;271(24):13968-75

Signal transduction by CD28 costimulatory receptor on T cells. B7-1 and B7-2 regulation of tyrosine kinase adaptor molecules. Nunès JA, et al. **J Biol Chem** 1996 Jan 19; 271(3):1591-8

Cross-desensitization of chemoattractant receptors occurs at multiple levels. Evidence for a role for inhibition of phospholipase C activity. Richardson RM, et al. **J Biol Chem** 1995 Nov 17;270(46):27829-33

Selective activation of c-Jun kinase mitogen-activated protein kinase by CD40 on human B cells. Sakata N, et al. **J Biol Chem** 1995 Dec 22;270(51):30823-8

Ectopic expression of human and feline CD9 in a human B cell line confers beta 1 integrin-dependent motility on fibronectin and laminin substrates and enhanced tyrosine phosphorylation. Shaw AR, et al. **J Biol Chem** 1995 Oct 13;270(41):24092-9

Beta4 integrin is required for hemidesmosome formation, cell adhesion and cell survival. Dowling J, et al. **J Cell Biol** 1996 Jul;134(2):559-72

The intracellular functions of alpha6beta4 integrin are regulated by EGF. Mainiero F, et al. **J Cell Biol** 1996 Jul; 134(1):241-53

CD47 mediates post-adhesive events required for neutrophil migration across polarized intestinal epithelia. Parkos CA, et al. **J Cell Biol** 1996 Feb;132(3):437-50

Integrin alpha subunit ratios, cytoplasmic domains, and growth factor synergy regulate muscle proliferation and differentiation. Sastry SK, et al. **J Cell Biol** 1996 Apr; 133(1):169-84

The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. Sitrin RG, et al. **J Clin Invest** 1996 Apr 15;97(8):1942-51

Engaging CD19 or target of an antiproliferative antibody 1 on human B lymphocytes induces binding of B cells to the interfollicular stroma of human tonsils via integrin alpha 4/beta 1 and fibronectin. Behr S, et al. **J Exp Med** 1995 Nov 1;182(5):1191-9

Interleukin-7 receptor alpha is essential for the development of gamma delta + T cells, but not natural killer cells. He YW, et al. **J Exp Med** 1996 Jul 1;184(1):289-93

The alpha 4-integrin supports leukocyte rolling and adhesion in chronically inflamed postcapillary venules in vivo. Johnston B, et al. **J Exp Med** 1996 May 1;183(5):1995-2006

Function of the p55 tumor necrosis factor receptor "death domain" mediated by phosphatidylcholine-specific phospholipase C. Machleidt T, et al. **J Exp Med** 1996 Aug 1;184(2):725-33

The cytoplasmic domains of immunoglobulin (Ig) alpha and Ig beta can independently induce the precursor B cell transition and allelic exclusion. Papavasiliou F, et al. **J Exp Med** 1995 Nov 1;182(5):1389-94

The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. Romas E, et al. **J Exp Med** 1996 Jun 1; 183(6):2581-91

Erythropoietin-independent erythrocyte production: signals through gp130 and c-kit dramatically promote erythropoiesis from human CD34+ cells. Sui X, et al. **J Exp Med** 1996 Mar 1;183(3):837-45

A role for CD9 molecules in T cell activation. Tai XG, et al. **J Exp Med** 1996 Aug 1;184(2):753-8

Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. Udagawa N, et al. **J Exp Med** 1995 Nov 1;182(5):1461-8

A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. Welborn MB 3rd, et al. **J Exp Med** 1996 Jul 1;184(1):165-71

B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. Gajewski TF. **J Immunol** 1996 Jan 15;156(2):465-72

Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. Gajewski TF, et al. **J Immunol** 1996 Apr 15;156(8):2909-17

C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. Nilsson G, et al. **J Immunol** 1996 Aug 15;157(4):1693-8

Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. Norgauer J, et al. **J Immunol** 1996 Feb 1;156(3):1132-37

Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium. Thomas R, et al. **J Immunol** 1996 Apr 15;156(8):3074-86

Engagement of adhesion molecules (CD18, CD11a, CD45, CD44, and CD58) enhances human immunodeficiency virus type 1 replication in monocytic cells through a tumor necrosis factor-modulated pathway. Shattock RJ, et al. **J Infect Dis** 1996 Jul;174(1):54-62

Studies in vitro on the role of alpha v and beta 1 integrins in the adhesion of human dermal fibroblasts to provisional matrix proteins fibronectin, vitronectin, and fibrinogen. Gailit J, et al. **J Invest Dermatol** 1996 Jan;106(1):102-8

Unidirectional heterologous receptor desensitization between both the fMLP and C5a receptor and the IL-8 receptor. Blackwood RA, et al. **J Leukoc Biol** 1996 Jul;60(1):88-93

IL-4-dependent proliferation of BA/F3 cells expressing a growth-negative mutant of the human IL-4 receptor is restored by enforced expression of Bcl-2. Chung J, et al. **J Leukoc Biol** 1996 Apr;59(4):586-90

CD66a, CD66b, CD66c, and CD66d each independently stimulate neutrophils. Skubitz KM, et al. **J Leukoc Biol** 1996 Jul;60(1):106-17

Molecular analysis of the physiological and pathophysiological role of alpha 4-integrins. Kilger G, et al. **J Mol Med** 1995 Jul;7(7):347-54 (124 ref.)

Gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. Taga T. **J Neurochem** 1996 Jul;67(1):1-10 (90 ref.)

The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4. Benkirane M, et al. **J Virol** 1995 Nov;69(11):6904-10

Cell entry by measles virus: long hybrid receptors uncouple binding from membrane fusion. Buchholz CJ, et al. **J Virol** 1996 Jun;70(6):3716-23

Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain. van der Plas DC, et al. **Leukemia** 1996 Aug;10(8):1317-25

Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection. Seya T. **Microbiol Immunol** 1995;39(5):295-305 (82 ref.)

Schwann cell CD9 expression is regulated by axons. Banerjee SA, et al. **Mol Cell Neurosci** 1995 Oct;6(5):462-73

Induction of costimulatory molecules B7-1 and B7-2 in murine B cells. the CBA/N mouse reveals a role for Bruton's tyrosine kinase in CD40-mediated B7 induction. Goldstein MD, et al. **Mol Immunol** 1996 Apr;33(6):541-52

CD28 signal transduction pathways. A comparison of B7-1 and B7-2 regulation of the map kinases: ERK2 and Jun kinases. Nunes JA, et al. **Mol Immunol** 1996 Jan;33(1):63-70

Chromosome 22 complements apoptosis in Fas-and TNF-resistant mutant UK110 cells. Noguchi K, et al. **Oncogene** 1996 Jul 4;13(1):39-46

The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Baumann H, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8374-8

CD14 enhances cellular responses to endotoxin without imparting ligand-specific recognition. Delude RL, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9288-92

Predominant role of alpha 4-integrins for distinct steps of lymphoma metastasis. Gosslar U, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4821-6

Interleukin 7 receptor-deficient mice lack gammadelta T cells. Maki K, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7172-7

STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Minami M, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):3963-6

Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Yoshida K, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):407-11

Triggering of target of an antiproliferative antibody-1 (TAPA-1/CD81) up-regulates the release of tumour necrosis factor-alpha by the EBV-B lymphoblastoid cell line JY. Altomonte M, et al. **Scand J Immunol** 1996 Apr; 43(4):367-73

A role for CD81 in early T cell development. Boismenu R, et al. **Science** 1996 Jan 12;271(5246):198-200

Regulation of an early developmental checkpoint in the B cell pathway by Ig beta. Gong S, et al. **Science** 1996 Apr 19;272(5260):411-4

Mechanism of suppression of cell-mediated immunity by measles virus. Karp CL, et al. **Science** 1996 Jul 12; 273(5272):228-31

Receptor tails unlock developmental checkpoints for B lymphocytes [comment] Roth PE, et al. **Science** 1996 Jun 21;272(5269):1752-4 (7 ref.). Comment on: Science 1996 Jun 21;272(5269):1804-8.

Aberrant B cell development and immune response in mice with a compromised BCR complex [see comments] Torres RM, et al. **Science** 1996 Jun 21;272(5269):1804-8. Comment in: Science 1996 Jun 21;272(5269):1752-4.

The role of alpha v-integrins in tumour progression and metastasis. Marshall JF, et al. **Semin Cancer Biol** 1996 Jun; 7(3):129-38 (85 ref.)

Alpha 4 integrin-induced cytokine production and eosinophil function. Broide DH. **Springer Semin Immunopathol** 1995; 16(4):405-15 (85 ref.)

Alpha 4-integrin-dependent emigration of monocytes. Chuluyan HE, et al. **Springer Semin Immunopathol** 1995; 16(4):391-404 (82 ref.)

Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Shattil SJ. **Thromb Haemost** 1995 Jul;74(1):149-55 (98 ref.)

Expression of a truncated form of the human p55 TNF-receptor in bovine aortic endothelial cells renders them resistant to human TNF. Ferran C, et al. **Transplant Proc** 1996 Apr;28(2):618-9

Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Lenschow DJ, et al. **Transplantation** 1995 Nov 27;60(10):1171-8

[VLA and alpha6, beta4 integrins. Expression in normal and neoplastic human tissues] Hofman P, et al. **Arch Anat Cytol Pathol** 1995;43(5-6):309-24 (112 ref.) (Eng. Abstr.) **(Fre)**

[Cytokine binding proteins: a model of interleukin 6] Brailly H, et al. **Arch Inst Pasteur Tunis** 1994 Jul-Oct; 71(3-4):535-48 (35 ref.) **(Fre)**

THERAPEUTIC USE

Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Martin-Fontecha A, et al. **Eur J Immunol** 1996 Aug;26(8):1851-9

ANTIGENS, CD1

The CD1 family: a third lineage of antigen-presenting molecules. Porcelli SA. **Adv Immunol** 1995;59:1-98 (179 ref.)

ANALYSIS

Canine cutaneous histiocytoma is an epidermotropic Langerhans cell histiocytosis that expresses CD1 and specific beta 2-integrin molecules. Moore PF, et al. **Am J Pathol** 1996 May;148(5):1699-708

Differentiation of Langerhans cells from interdigitating cells using CD1a and S-100 protein antibodies. Shinzato M, et al. **Biotech Histochem** 1995 May;70(3):114-8

Distinctive dendritic cell subsets expressing factor XIIIa, CD1a, CD1b and CD1c in mycosis fungoides and psoriasis. Fivenson DP, et al. **J Cutan Pathol** 1995 Jun;22(3):223-8

CD1b is expressed in multiple sclerosis lesions. Battistini L, et al. **J Neuroimmunol** 1996 Jul;67(2):145-51

Distribution of CD1a-positive Langerhans cells and lymphocyte subsets in transitional cell carcinoma of the urinary bladder. An immunohistological study on frozen sections. Ioachim-Velogianni E, et al. **J Pathol** 1995 Dec; 177(4):401-6

BIOSYNTHESIS

Differential effects of interleukin-10 on the expression of HLA class II and CD1 molecules induced by granulocyte/macrophage colony-stimulating factor/interleukin-4. Thomssen H, et al. **Eur J Immunol** 1995 Sep;25(9):2465-70

CHEMISTRY

Structure and function of the CD1 family of MHC-like cell surface proteins. Blumberg RS, et al. **Immunol Rev** 1995 Oct;147:5-29 (86 ref.)

DRUG EFFECTS

Novel predictive assay for contact allergens using human skin explant cultures. Pistoor FH, et al. **Am J Pathol** 1996 Jul;149(1):337-43

GENETICS

The sheep CD1 gene family contains at least four CD1B homologues. Ferguson ED, et al. **Immunogenetics** 1996; 44(2):86-96

IMMUNOLOGY

Antigen-presenting function of the mouse CD1 molecule. Tangri S, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:288-96 (21 ref.)

MHC class I-like, class II-like and CD1 molecules: distinct roles in immunity. Beckman EM, et al. **Immunol Today** 1995 Jul;16(7):349-52 (38 ref.)

Positive selection of mouse NK1+ T cells by CD1-expressing cortical thymocytes. Bendelac A. **J Exp Med** 1995 Dec 1;182(6):2091-6

CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. Cardell S, et al. **J Exp Med** 1995 Oct 1;182(4):993-1004

CD1 and the expanding universe of T cell antigens. Porcelli SA, et al. **J Immunol** 1995 Oct 15;155(8):3709-10 (18 ref.)

METABOLISM

Antigen presenting and primary in vitro sensitizing capacity of CD1a+ dendritic cells generated from human blood. Degwert J, et al. **Adv Exp Med Biol** 1995;378:187-9

Importance of HLA-DR+ and CD1a+ epidermal cells for cytokine production in psoriasis. Dobmeyer JM, et al. **Adv Exp Med Biol** 1995;378:539-41

Mixed epidermal cell lymphocyte reaction: HLA-DR+ cells exhibit a greater immunostimulatory activity than CD1a+ cells. Dobmeyer TS, et al. **Adv Exp Med Biol** 1995; 378:393-6

Modulation of HLA-DR and CD1a expression on human cornea with low-dose UVB irradiation. Borderie VM, et al. **Curr Eye Res** 1996 Jun;15(6):669-79

TAP-independent, beta 2-microglobulin-dependent surface expression of functional mouse CD1.1. Brutkiewicz RR, et al. **J Exp Med** 1995 Dec 1;182(6):1913-9

Cytoplasmic tail-dependent localization of CD1b antigen-presenting molecules to MIICs. Sugita M, et al. **Science** 1996 Jul 19;273(5273):349-52

PHYSIOLOGY

Class I-like CD1A-C do not protect target cells from NK-mediated cytolysis. Storkus WJ, et al. **Cell Immunol** 1996 Jan 10;167(1):154-6

Structure and function of the CD1 family of MHC-like cell surface proteins. Blumberg RS, et al. **Immunol Rev** 1995 Oct;147:5-29 (86 ref.)

Antigen-presenting function of the TL antigen and mouse CD1 molecules. Cheroutre H, et al. **Immunol Rev** 1995 Oct;147:31-52 (73 ref.)

A pathway of costimulation that prevents anergy in CD28-T cells: B7-independent costimulation of CD1-restricted T cells. Behar SM, et al. **J Exp Med** 1995 Dec 1; 182(6):2007-18

ANTIGENS, CD2

ANALYSIS

A sensitive assay for detecting low-affinity interactions at the cell surface reveals no additional ligands for the adhesion pair rat CD2 and CD48. Brown MH, et al. **Eur J Immunol** 1995 Dec;25(12):3222-8

Functional assessment of CD2, CD3 and CD28 on the surface of peripheral blood T-cells from infants at low versus high genetic risk for atopy. Holt PG, et al. **Pediatr Allergy Immunol** 1995 May;6(2):80-4

BIOSYNTHESIS

The use of intracellular single-chain antibody fragments to inhibit specifically the expression of cell surface molecules. Greenman J, et al. **J Immunol Methods** 1996 Aug 14; 194(2):169-80

CHEMISTRY

NMR analysis of interacting soluble forms of the cell-cell recognition molecules CD2 and CD48. McAlister MS, et al. **Biochemistry** 1996 May 14;35(19):5982-91

CD2: an exception to the immunoglobulin superfamily concept? [letter] Davis SJ, et al. **Science** 1996 Aug 30; 273(5279):1241-2

GENETICS

A cell surface marker gene transferred with a retroviral vector into CD34+ cord blood cells is expressed by their T-cell progeny in the SCID-hu thymus. Champseix C, et al. **Blood** 1996 Jul 1;88(1):107-13

Apparent bypass of negative selection in CD8+ tumours in CD2-myc transgenic mice. Cameron ER, et al. **Br J Cancer** 1996 Jan;73(1):13-7

til-1: a novel proviral insertion locus for Moloney murine leukaemia virus in lymphomas of CD2-myc transgenic mice. Stewart M, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):443-6

Analysis of CD2 and TCR-beta gene expression in Jurkat cell mutants suggests a cis regulation of gene transcription. Kamoun M, et al. **J Immunol** 1995 Oct 15;155(8):3929-37

Locus control region function and heterochromatin-induced position effect variegation. Festenstein R, et al. **Science** 1996 Feb 23;271(5252):1123-5

IMMUNOLOGY

A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Société Française de Greffe de Moelle Osseuse. Cavazzana-Calvo M, et al. **Br J Haematol** 1996 Apr;93(1):131-8

Endothelial cells augment the expression of CD40 ligand on newly activated human CD4+ T cells through a CD2/LFA-3 signaling pathway. Karmann K, et al. **Eur J Immunol** 1996 Mar;26(3):610-7

A human monoclonal antibody to a human self-antigen, CD2 derived from human peripheral blood lymphocytes engrafted in SCID mice. Uchibayashi N, et al. **Hybridoma** 1995 Aug;14(4):313-21

Age-related defects in CD2 receptor-induced activation in human T-cell subsets. Beckman I, et al. **Immunology** 1995 Dec;86(4):533-6

CD2-mediated stimulation of the naive CD4+ T-cell subset promotes the development of skin-associated cutaneous lymphocyte antigen-positive memory cells. Liu L, et al. **Immunology** 1996 Jun;88(2):207-13

Human T-cell activation is mediate predominantly by direct recognition of porcine SLA and involves accessory molecule interaction of ICAM1/LFA 1 and CD2/LFA3. Herrlinger KR, et al. **Transplant Proc** 1996 Apr;28(2):650

An anti-CD2 monoclonal antibody that elicits alloantigen-specific hyporesponsiveness. Schad V, et al. **Transplant Proc** 1996 Aug;28(4):2051-3 (17 ref.)

Transmembrane signaling requirements of T cells: implications for regulation of alloimmunity. Suthanthiran M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):5-7 (25 ref.)

CD2 antigen targeting reduces intragraft expression of mRNA-encoding granzyme B and IL-10 and induces tolerance. Kapur S, et al. **Transplantation** 1996 Jul 27; 62(2):249-55

[Proliferation of PBMC in patients with Sjögren's syndrome via CD2 pathway] Wang X, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):395-9 (Eng. Abstr.) (Chi)

METABOLISM

Murine epidermal Langerhans cells express CD48, which is a counter-receptor for mouse CD2. Ozawa H, et al. **Arch Dermatol Res** 1995;287(6):524-8

Estimation of the dissociation constant of the cell adhesion molecules srCD2 and srCD48 using analytical ultracentrifugation. Silkowski H, et al. **Biochem Soc Trans** 1995 Aug;23(3):435S

Decreased levels of a soluble form of the human adhesion receptor CD58 (LFA-3) in sera and synovial fluids of patients with rheumatoid arthritis. Hoffmann JC, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):23-9

Ligation of either CD2 or CD28 rescues CD4+ T cells from HIV-gp120-induced apoptosis. Tuosto L, et al. **Eur J Immunol** 1995 Oct;25(10):2917-22

IL-4 is able to reverse the CD2-mediated negative apoptotic signal to CD4-CD8- alpha beta and/or gamma delta T lymphocytes. Spinozzi F, et al. **Immunology** 1995 Nov; 86(3):379-84

An enzymatic method to determine receptor-mediated endocytosis. Cobern L, et al. **J Biochem Biophys Methods** 1995 Nov;30(4):249-55

A role for phosphatidylinositol 3-kinase in the regulation of beta 1 integrin activity by the CD2 antigen. Shimizu Y, et al. **J Cell Biol** 1995 Dec;131(6 Pt 2):1867-80

The SH3 domain of p56lck binds to proline-rich sequences in the cytoplasmic domain of CD2. Bell GM, et al. **J Exp Med** 1996 Jan 1;183(1):169-78

A carbohydrate structure associated with CD15 (Lewis x) on myeloid cells is a novel ligand for human CD2. Warren HS, et al. **J Immunol** 1996 Apr 15;156(8):2866-73

Decrease in cAMP levels promoted by CD48-CD2 interaction correlates with inhibition of apoptosis in B cells. Baixeras E, et al. **Scand J Immunol** 1996 Apr;43(4):406-12

PHARMACOLOGY

CD2 regulates T cell-dependent induction of monocyte IL-1 beta mRNA during anti-CD3 mitogenesis. McAllister PT, et al. **Cell Immunol** 1996 May 25;170(1):120-6

CD2-induced apoptosis in activated human peripheral T cells: a Fas-independent pathway that requires early protein tyrosine phosphorylation. Mollereau B, et al. **J Immunol** 1996 May 1;156(9):3184-90

PHYSIOLOGY

Anti-CD2 monoclonal antibody-induced receptor changes. II. Interaction of CD2 and CD3. Lin J, et al. **Cell Immunol** 1996 Feb 1;167(2):249-58

Differential production of interleukin-3 in human T lymphocytes following either CD3 or CD2 receptor activation. Dilloo D, et al. **Exp Hematol** 1996 Mar; 24(4):537-43

Stimulation of the CD2 receptor pathway induces apoptosis in human T lymphotropic virus type I-infected cell lines. Guyot DJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 1;11(4):317-25

Recruitment of activated p56lck on endosomes of CD2-triggered T cells, colocalization with ZAP-70. Marie-Cardine A, et al. **J Biol Chem** 1996 Aug 23; 271(34):20734-9

Visualization of CD2 interaction with LFA-3 and determination of the two-dimensional dissociation constant for adhesion receptors in a contact area. Dustin ML, et al. **J Cell Biol** 1996 Feb;132(3):465-74

CD59 and CD48 expressed by rat retinal pigment epithelial cells are major ligands for the CD2-mediated alternative pathway of T cell activation. Liversidge J, et al. **J Immunol** 1996 May 15;156(10):3696-703

ANTIGENS, CD3

see related RECEPTORS, ANTIGEN, T-CELL

Natural killer (NK)-cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after "three-loci" HLA-incompatible bone marrow transplantation. Albi N, et al. **Blood** 1996 May 1; 87(9):3993-4000

The natural killer-related receptor for HLA-C expressed on T cells from CD3+ lymphoproliferative disease of granular lymphocytes displays either inhibitory or stimulatory function. Cambiaggi A, et al. **Blood** 1996 Mar 15; 87(6):2369-75

IL-12 is involved in the activation of CD3+ granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Zambello R, et al. **Br J Haematol** 1996 Feb;92(2):308-14

Precursor cells to CD3-intermediate (CD3int) liver mononuclear cells in the adult liver: further evidence for the extrathymic development of CD3int liver mononuclear cells. Kenai H, et al. **Eur J Immunol** 1995 Dec; 25(12):3365-9

Ligation of MHC class I molecules on peripheral blood T lymphocytes induces new phenotypes and functions. Bregenholt S, et al. **J Immunol** 1996 Aug 1;157(3):993-9

ANALYSIS

Clarification of CD3 immunoreactivity in nasal T/natural killer cell lymphomas: the neoplastic cells are often CD3 epsilon+ [letter; comment] Chan JK, et al. **Blood** 1996 Jan 15;87(2):839-41. Comment on: Blood 1995 May 15;85(10):2993-6.

T-cell form of chronic lymphocytic leukaemia: a reaffirmation of its existence. Wong KF, et al. **Br J Haematol** 1996 Apr;93(1):157-9

Polymorphic reticulosis is a neoplasm of large granular lymphocytes with CD3+ phenotype [letter; comment] Chan JK, et al. **Cancer** 1995 Aug 1;76(3):537–8. Comment on: Cancer 1995 Feb 1;75(3):894–901.

Analysis of the T cell receptor in the lymphoproliferative disease of granular lymphocytes: superantigen activation of clonal CD3+ granular lymphocytes. Zambello R, et al. **Cancer Res** 1995 Dec 15;55(24):6140–5

Expression and function of low-density lipoprotein receptors in CD3-CD16+CD56+ cells: effect of interleukin 2. De Sanctis JB, et al. **Cell Immunol** 1996 Jan 10;167(1):18–29

Characterization of tumor-specific cytotoxic effector cells with a novel CD3-/Thy-1+ phenotype. Sabapathy TK, et al. **Cell Immunol** 1995 Nov;166(1):141–53

Expression of GPI-anchored complement regulatory proteins CD55 and CD59 differentiates two subpopulations of human CD56+ CD3- lymphocytes (NK cells). Solomon KR, et al. **Cell Immunol** 1995 Oct 15;165(2):294–301

A CD3+CD8+ T cell population lacking CD5 antigen expression is expanded in peripheral blood of human immunodeficiency virus-infected patients. Indraccolo S, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):253–61

Vitiligo associated with lichen planus. Is there a pathogenetic relationship? Rubisz-Brzezinska J, et al. **Dermatology** 1996; 192(2):176–8

Discordant CD3 expression in lymphomas when studied on frozen and paraffin sections. Chan JK, et al. **Hum Pathol** 1995 Oct;26(10):1139–43 (48 ref.)

Peritoneal natural killer cytotoxicity and CD25+ CD3+ lymphocyte subpopulation are decreased in women with stage III–IV endometriosis. Ho HN, et al. **Hum Reprod** 1995 Oct;10(10):2671–5

Soluble mediators and cytokines produced by human CD3- leucocyte clones from decidualized endometrium. Deniz G, et al. **Immunology** 1996 Jan;87(1):92–8

Expression of functional molecules by human CD3- decidual granular leucocyte clones. Gudelj L, et al. **Immunology** 1996 Apr;87(4):609–15

Peripheral blood CD3 and CD4 T-lymphocyte reduction correlates with severity of liver cirrhosis. Lombardo L, et al. **Int J Clin Lab Res** 1995;25(3):153–6

Aggressive acute CD3+, CD56- T cell large granular lymphocyte leukemia with two stages of maturation arrest. Tordjman R, et al. **Leukemia** 1996 Sep;10(9):1514–9

Functional assessment of CD2, CD3 and CD28 on the surface of peripheral blood T-cells from infants at low versus high genetic risk for atopy. Holt PG, et al. **Pediatr Allergy Immunol** 1995 May;6(2):80–4

Expression and function of a CD3-like molecule on normal and abnormal human parathyroid cells. Hellman P, et al. **Surgery** 1995 Dec;118(6):1055–61; discussion 1062

BLOOD

Longstanding proliferation of CD3 negative large granular lymphocytes preceding the development of high grade non-Hodgkin's lymphoma. Smith SR, et al. **J Clin Pathol** 1995 Jul;48(7):672–5

Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells. Abouna GM, et al. **Transplant Proc** 1995 Oct;27(5):2676–8

CHEMISTRY

CD4-dependent and -independent association of protein tyrosine kinases to the T cell receptor/CD3 complex of CD4+ mouse T lymphocytes. Criado G, et al. **Eur J Immunol** 1996 Jun;26(6):1228–34

Porcine CD3 epsilon: its characterization, expression and involvement in activation of porcine T lymphocytes. Kirkham PA, et al. **Immunology** 1996 Apr;87(4):616–23

Role of CD3 gamma in T cell receptor assembly. Dietrich J, et al. **J Cell Biol** 1996 Feb;132(3):299–310

Defective interactions between TCR chains and CD3 heterodimers prevent membrane expression of TCR-alpha beta in human T cells. Arnaud J, et al. **J Immunol** 1996 Mar 15;156(6):2155–62

GENETICS

Altered T cell development in mice with a targeted mutation of the CD3-epsilon gene. Malissen M, et al. **EMBO J** 1995 Oct 2;14(19):4641–53

Differential expression of the T cell receptor/CD3 genes and their lymphoid-specific transcription factor genes in murine T cell x fibroblast and T cell x B cell hybrids. Yamada T, et al. **Eur J Immunol** 1995 Sep;25(9):2710–3

Cloning, sequencing and expression of the bovine CD3 epsilon and TCR-zeta chains, two invariant components of the T-cell receptor complex. Hagens G, et al. **Gene** 1996 Mar 9;169(2):165–71

CD3 delta and epsilon gene expression in CD3-CD16+ natural killer cell clones derived from thymic precursors. DeNofrio D, et al. **Hum Immunol** 1995 Aug;43(4):283–94

Localization of the antigen CD3, zeta polypeptide (CD3Z) to cattle chromosome 3q11-q14. Amarante MR, et al. **Mamm Genome** 1996 May;7(5):397–8

IMMUNOLOGY

Modulation of CD3-dependent lymphocyte proliferation by extracellular matrix proteins in atopic dermatitis. Glinski W, et al. **Acta Derm Venereol** 1995 Sep;75(5):353–6

Costimulation of CD3/TcR complex with either integrin or nonintegrin ligands protects CD4+ allergen-specific T-cell clones from programmed cell death. Agea E, et al. **Allergy** 1995 Aug;50(8):677–82

The effect of an anti-CD3 monoclonal antibody on bleomycin-induced lymphokine production and lung injury. Sharma SK, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):193–200

Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Renner C, et al. **Blood** 1996 Apr 1;87(7):2930–7

T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Renner C, et al. **Blood** 1996 Jul 1;88(1):236–41

Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor. Vallera DA, et al. **Blood** 1996 Sep 15;88(6):2342–53

PBPC grafts from healthy donors: analysis of CD34+ and CD3+ subpopulations. Dreger P, et al. **Bone Marrow Transplant** 1996 Mar;17 Suppl 2:S22–7

Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Luiten RM, et al. **Br J Cancer** 1996 Sep; 74(5):735–44

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Negri DR, et al. **Br J Cancer** 1995 Oct; 72(4):928–33

Eosinophilia associated with proliferation of CD(3+)4-(8-) alpha beta+ T cells with chromosome 16 anomalies. Kitano K, et al. **Br J Haematol** 1996 Feb;92(2):315–7

Interleukin-12 is a costimulatory cytokine for leukemic CD3+ large granular lymphocytes. Gentile TC, et al. **Cell Immunol** 1995 Nov;166(1):158–61

CD2 regulates T cell-dependent induction of monocyte IL-1 beta mRNA during anti-CD3 mitogenesis. McAllister PT, et al. **Cell Immunol** 1996 May 25;170(1):120–6

In vitro T cell unresponsiveness following low-dose injection of anti-CD3 MoAb. Ben-Amor A, et al. **Clin Exp Immunol** 1996 Mar;103(3):491–8

Administration of anti-CD3 monoclonal antibody during experimental Chagas' disease induces CD8+ cell-dependent lethal shock. Jacobs F, et al. **Clin Exp Immunol** 1996 Feb;103(2):233–8

Identification of koala T lymphocytes using an anti-human CD3 antibody. Wilkinson R, et al. **Dev Comp Immunol** 1995 Nov-Dec;19(6):537–45

Induction of T cell unresponsiveness by anti-CD3 antibodies occurs independently of co-stimulatory functions. Andris F, et al. **Eur J Immunol** 1996 May;26(5):1187–95

PCR cloning and sequencing of a CD3-specific monoclonal antibody. Thirion S, et al. **Immunogenetics** 1996;43(3):167–8

Phosphatidylinositol metabolism in lymphocytes of chronic alcoholic patients after anti-CD3 stimulation. Hrelia S, et al. **Immunol Lett** 1995 May;46(1-2):63–6

Physical interaction with monocytes rescues human mature CD4+ T-cell lines from anti-CD3-induced apoptosis. Yamauchi Y, et al. **Immunol Lett** 1995 May;46(1-2):85–92

Influence of MHC class I molecules on T-cell proliferation induced by CD3 or Thy-1 stimulation. Amirayan N, et al. **Immunology** 1995 Sep;86(1):71–8

Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies. Harada M, et al. **Immunology** 1996 Mar;87(3):447–53

An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. Thompson J, et al. **J Biol Chem** 1995 Nov 24;270(47):28037–41

Anti-CD3-induced changes in protein kinase C isozymes expression in human CD4+ and CD8+ T lymphocytes. Harris W, et al. **J Clin Immunol** 1995 Sep;15(5):232–41

Bifunctional antibody retargeting in vivo-activated T lymphocytes: simplifying clinical application. Chapoval AI, et al. **J Hematother** 1995 Dec;4(6):571–7

In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma. Demanet C, et al. **J Hematother** 1995 Oct;4(5):363–8

Anti-CD3:anti-IL-2 receptor-bispecific mAb-mediated immunomodulation. Low systemic toxicity, differential effect on lymphoid tissue, and inhibition of cell-mediated hypersensitivity. MacLean JA, et al. **J Immunol** 1995 Oct 1;155(7):3674–82

IFN-gamma receptor-deficient mice are hypersensitive to the anti-CD3-induced cytokine release syndrome and thymocyte apoptosis. Protective role of endogenous nitric oxide. Matthys P, et al. **J Immunol** 1995 Oct 15; 155(8):3823–9

IL-10 inhibits nuclear factor-kappa B/Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes. Romano MF, et al. **J Immunol** 1996 Mar 15;156(6):2119–23

Proteolytic cleavage of alpha-actinin by calpain in T cells stimulated with anti-CD3 monoclonal antibody. Selliah N, et al. **J Immunol** 1996 May 1;156(9):3215–21

Differentiation to T helper cells in the thymus. Gradual acquisition of T helper cell function by CD3+CD4+ cells. Vanhecke D, et al. **J Immunol** 1995 Nov 15;155(10):4711–8

Establishment of dengue virus-specific human CD4+ T lymphocyte clones from Percoll-purified T lymphoblasts by stimulation with monoclonal antibody to CD3 [letter] Zivny J, et al. **J Immunol Methods** 1995 Dec 15; 188(1):165–7

Stimulation of the T-cell antigen receptor-CD3 complex signaling pathway by the tyrosine phosphatase inhibitor pervanadate is mediated by inhibition of CD45: evidence for two interconnected Lck/Fyn- or zap-70-dependent signaling pathways. Imbert V, et al. **J Inflamm** 1996; 46(2):65–77

Expression of low density lipoprotein receptors in lymphoblasts induced by anti-CD3 antibody in patients with hypercholesterolemia. Shin BM, et al. **J Korean Med Sci** 1995 Oct;10(5):318–23

Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha. Yoshida J, et al. **J Surg Oncol** 1996 Jul;62(3):177–82

Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2. Borrione P, et al. **Leuk Lymphoma** 1996 Apr;21(3-4):325–30

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5-6):381–93 (160 ref.)

Clonal CD3+CD8+ large granular lymphocyte (LGL)/NK-associated (NKa) expansions: primary malignancies or secondary reactive phenomena? Richards SJ, et al. **Leuk Lymphoma** 1995 Apr;17(3-4):303–11

Down-regulation of T-cell proliferation in response to soluble anti-CD3 antibodies through development of redirected cytolytic activity eliminating costimulatory cells. Lwin T, et al. **Microbiol Immunol** 1995;39(8):599–606

Expression and characterization of a divalent chimeric anti-human CD3 single chain antibody. Ma S, et al. **Scand J Immunol** 1996 Feb;43(2):134–9

Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. Abbs IC, et al. **Ther Immunol** 1994 Dec;1(6):325–31

Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains. Haagen IA, et al. **Ther Immunol** 1994 Oct;1(5):279–87

Factors affecting therapeutic effect of anti-CD3 and CD4 monoclonal antibody in acute renal allograft rejection. Wang XH, et al. **Transplant Proc** 1996 Jun;28(3):1306–8

In vivo anti-CD3-driven cell activation. Cellular source of induced tumor necrosis factor, interleukin-1 beta, and interleukin-6. Goumy L, et al. **Transplantation** 1996 Jan 15;61(1):83–7

Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11). Henrickson M, et al. **Transplantation** 1995 Oct 27;60(8):828–35

The repetitive histologic pattern of vascular cardiac allograft rejection.Increased incidence associated with longer exposure to prophylactic murine monoclonal anti-CD3 antibody (OKT3). Ma H, et al. **Transplantation** 1996 Jul 27;62(2):205–10

The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Routledge EG, et al. **Transplantation** 1995 Oct 27; 60(8):847–53

In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells. Woodle ES, et al. **Transplantation** 1996 Mar 15; 61(5):798–803

Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. White CA, et al. **Virology** 1996 May 15;219(2):489–92

METABOLISM

Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry. Ginaldi L, et al. **Br J Haematol** 1996 Jun 2;93(4):921–7

Inhibition of phosphatidylinositol 3-kinase blocks T cell antigen receptor/CD3-induced activation of the mitogen-activated kinase Erk2. Von Willebrand M, et al. **Eur J Biochem** 1996 Feb 1;235(3):828–35

The protein interactions of the immunoglobulin receptor family tyrosine-based activation motifs present in the T cell receptor zeta subunits and the CD3 gamma, delta and epsilon chains. Osman N, et al. **Eur J Immunol** 1996 May; 26(5):1063–8

Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Tartour E, et al. **Int J Cancer** 1995 Oct 9;63(2):205–12

An enzymatic method to determine receptor-mediated endocytosis. Cobern L, et al. **J Biochem Biophys Methods** 1995 Nov;30(4):249–55

Physical dissociation of the TCR-CD3 complex accompanies receptor ligation. Kishimoto H, et al. **J Exp Med** 1995 Dec 1;182(6):1997–2006

Early activation signal transduction pathways of Th1 and Th2 cell clones stimulated with anti-CD3. Roles of protein tyrosine kinases in the signal for IL-2 and IL-4 production. Tamura T, et al. **J Immunol** 1995 Nov 15;155(10):4692–701

Human IL-13 production is negatively influenced by CD3

engagement. Enhancement of IL-13 production by cyclosporin A. van der Pouw Kraan TC, et al. **J Immunol** 1996 Mar 1;156(5):1818-23

The role of p56lck in CD4-mediated suppression of CD3-induced early signaling events in T lymphocytes. Baier-Bitterlich G, et al. **Life Sci** 1995 Mar 3; 56(15):1287-97

Increase in the specific activity of p50csk in proliferating T cells correlates with decreased specific activity of p56lck and p59fyn and reduced phosphorylation of CD3 subunits. Orchansky PL, et al. **Mol Immunol** 1996 Apr;33(6):531-40

Persistent CD3-crosslinking down-regulates interleukin-2 responsiveness in interleukin-2-competent cloned T cells: the possible involvement of protein kinase C. Landewé RB, et al. **Scand J Immunol** 1996 Jul;44(1):45-53

PHYSIOLOGY

A role for RANTES in T lymphocyte proliferation. Turner L, et al. **Biochem Soc Trans** 1996 Feb;24(1):93S

Anti-CD2 monoclonal antibody-induced receptor changes. II. Interaction of CD2 and CD3. Lin J, et al. **Cell Immunol** 1996 Feb 1;167(2):249-58

A revertant TCR gamma delta + cell clone which has lost MHC nonrestricted cytotoxic activity but retains redirected killing upon stimulation of the CD3 receptor. Visonneau S, et al. **Cell Immunol** 1995 Oct 15;165(2):252-65

Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Kono K, et al. **Eur J Immunol** 1996 Jun;26(6):1308-13

CD3-induced apoptosis of CD4+CD8+ thymocytes in the absence of clonotypic T cell antigen receptor. Tokoro Y, et al. **Eur J Immunol** 1996 May;26(5):1012-7

Differential production of interleukin-3 in human T lymphocytes following either CD3 or CD2 receptor activation. Dilloo D, et al. **Exp Hematol** 1996 Mar; 24(4):537-43

T cell receptor- and beta 1 integrin-mediated signals synergize to induce tyrosine phosphorylation of focal adhesion kinase (pp125FAK) in human T cells. Maguire JE, et al. **J Exp Med** 1995 Dec 1;182(6):2079-90

Immature T cells in peripheral lymphoid organs of recombinase-activating gene-1/-2-deficient mice. Thymus dependence and responsiveness to anti-CD3 epsilon antibody. Falk I, et al. **J Immunol** 1996 Feb 15; 156(4):1362-8

Cross-linking of the Fas/APO-1 antigen suppresses the CD3-mediated signal transduction events in human T lymphocytes. Kovacs B, et al. **J Immunol** 1995 Dec 15; 155(12):5543-9

Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the long-term survival of memory cells. Mueller DL, et al. **J Immunol** 1996 Mar 1;156(5):1764-71

Phosphatidylinositol hydrolysis in freshly isolated human T lymphocytes. Berney SM, et al. **J Immunol Methods** 1995 Oct 12;186(1):71-7

Contrasting in vivo effects on T helper cell functions induced by mitogenic (intact) versus nonmitogenic (F(ab')2) anti-CD3 monoclonal antibody. Sawchuk SS, et al. **Transplantation** 1995 Dec 15;60(11):1331-7

ANTIGENS, CD4

see related
CD4-CD8 RATIO
HIV ENVELOPE PROTEIN GP120

Stressed rats fail to expand the CD45RC+CD4+ (Th1-like) T cell subset in response to KLH: possible involvement of IFN-gamma. Fleshner M, et al. **Brain Behav Immun** 1995 Jun;9(2):101-12

Functional characterization of porcine CD4+CD8+ extrathymic T lymphocytes. Summerfield A, et al. **Cell Immunol** 1996 Mar 15;168(2):291-6

Selectively impaired development of intestinal T cell receptor gamma delta+ cells and liver CD4+ NK1+ T cell receptor alpha beta+ cells in T cell factor-1-deficient mice. Ohteki T, et al. **Eur J Immunol** 1996 Feb;26(2):351-5

Activity of neutral endopeptidase and aminopeptidase N in mouse thymic stromal cells which bind double-positive thymocytes. Small M, et al. **Eur J Immunol** 1996 Apr; 26(4):961-4

CD3-induced apoptosis of CD4+CD8+ thymocytes in the absence of clonotypic T cell antigen receptor. Tokoro Y, et al. **Eur J Immunol** 1996 May;26(5):1012-7

Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Sakihama T, et al. **Immunol Today** 1995 Dec;16(12):581-7 (43 ref.)

The ontogeny of class-regulation of CD4+ T lymphocyte populations. Carneiro J, et al. **Int Immunol** 1995 Aug; 7(8):1265-77 (37 ref.)

Human T cell repertoire generation in the absence of MHC class II expression results in a circulating CD4+CD8- population with altered physicochemical properties of complementarity-determining region 3. Henwood J, et al. **J Immunol** 1996 Feb 1;156(3):895-906

The effect of a depleting anti-CD4 monoclonal antibody on T cells and fetal pig islet xenograft survival in various strains of mice. Mandel T, et al. **Transplant Proc** 1995 Dec; 27(6):3569

ANALYSIS

Equianalgesic doses of subcutaneous but not intrathecal morphine alter phenotypic expression of cell surface markers and mitogen-induced proliferation in rat lymphocytes. Hamra JG, et al. **Anesthesiology** 1996 Aug; 85(2):355-65

A primary cutaneous non-T, non-B CD4+, CD56+ lymphoma. Dummer R, et al. **Arch Dermatol** 1996 May; 132(5):550-3

T-cell form of chronic lymphocytic leukaemia: a reaffirmation of its existence. Wong KF, et al. **Br J Haematol** 1996 Apr;93(1):157-9

Homing of CD4+CD56+ T lymphocytes into kidney allografts during tubular necrosis or rejection. Bachetoni A, et al. **Clin Transplant** 1995 Dec;9(6):433-7

CD4-negative cytotoxic T cells with a T cell receptor alpha/beta intermediate expression in CD8-deficient mice. Dalloul AH, et al. **Eur J Immunol** 1996 Jan;26(1):213-8

Differential induction of helper and killer T cells from isolated CD4+CD8+ thymocytes in suspension culture. Iwata M, et al. **Eur J Immunol** 1996 Sep;26(9):2081-6

Surface antigens on eosinophils in bronchial asthma and eosinophilic pneumonia. Sakamoto S, et al. **Int Arch Allergy Immunol** 1995;108 Suppl 1:6-8

Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. Harmon CB, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):404-10

CD4low TCRint thymocytes do not belong to the CD8 lineage maturation pathway. Lucas B, et al. **J Immunol** 1996 Mar 1;156(5):1743-47

Soluble versus cell-bound CD4, CD8 from bronchoalveolar lavage: correlation with pulmonary diagnoses in human immunodeficiency virus-infected individuals. Willie SK, et al. **J Leukoc Biol** 1996 Jun;59(6):813-6

Differential expression of cytokine genes in CD27-positive and -negative CD4 lymphocyte subsets from healthy humans and rheumatoid arthritis patients. Stoughs I, et al. **Rheumatol Int** 1996;15(6):249-54

The main infiltrating cell in xenograft rejection is a CD4+ macrophage and not a T lymphocyte. Wallgren AC, et al. **Transplantation** 1995 Sep 27;60(6):594-601

Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. Chackerian B, et al. **Virology** 1995 Nov 10; 213(2):386-94

HIV-1 mediates rapid apoptosis of lymphocytes from human CD4 transgenic but not normal rabbits. Leno M, et al. **Virology** 1995 Nov 10;213(2):450-4

[Discordance between CD4 values obtained by flow cytometry or by microscopy in HIV infected hemophiliac patients (letter)] Picchio G, et al. **Medicina (B Aires)** 1995; 55(1):90-2 **(Spa)**

BIOSYNTHESIS

Human leukocyte integrin CD18 promoter directs low levels of expression of a mutated human CD4 reporter gene in leukocytes of transgenic mice. Kwiatkowski BA, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):601-6

Inhibition of sphingolipid synthesis down-modulates CD4 expression by peripheral blood T lymphocytes and T lymphoma cells. Tamma SL, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):916-21

CD4 Expression by erythroid precursor cells in human bone marrow. Cleveland RP, et al. **Blood** 1996 Mar 15; 87(6):2275-82

Down-modulation of CD4+ T helper type 2 and type 0 cells by T helper type 1 cells via Fas/Fas-ligand interaction. Hahn S, et al. **Eur J Immunol** 1995 Sep; 25(9):2679-85

CD4 and CD8 expression and T cell antigen receptor gene rearrangement in early intrathymic precursor cells. Ismaili J, et al. **Eur J Immunol** 1996 Apr;26(4):731-7

Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia [see comments] Simon HU, et al. **J Exp Med** 1996 Mar 1;183(3):1071-82. Comment in: J Exp Med 1996 Mar 1;183(3):721-4.

CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. Chen BK, et al. **J Virol** 1996 Sep;70(9):6044-53

Interferon-gamma-induced downregulation of CD4 inhibits the entry of human immunodeficiency virus type-1 in primary monocytes. Dhawan S, et al. **Pathobiology** 1995; 63(2):93-9

Expression of intercellular adhesion molecule-1 and CD4/CD8 lymphocyte markers in perioperative liver allograft biopsies. Bhargava A, et al. **Transplant Proc** 1995 Oct;27(5):2814-5

BLOOD

Soluble CD4 antigen is increased in active coeliac disease. Blanco A, et al. **Adv Exp Med Biol** 1995;371B:1355-8

CEREBROSPINAL FLUID

Significance of elevated levels of soluble factors in the cerebrospinal fluid in patients with adult T-cell leukemia. Uozumi K, et al. **Leuk Lymphoma** 1995 Nov;19(5-6):437-45

CHEMISTRY

The structure of CD4. Brady RL, et al. **Curr Top Microbiol Immunol** 1996;205:1-18 (49 ref.)

The receptor for HIV: dissection of CD4 and studies on putative accessory factors. James W, et al. **Curr Top Microbiol Immunol** 1996;205:137-58 (152 ref.)

CD4-dependent and -independent association of protein tyrosine kinases to the T cell receptor/CD3 complex of CD4+ mouse T lymphocytes. Criado G, et al. **Eur J Immunol** 1996 Jun;26(6):1228-34

Characterization of conformation and dynamics of CD4 Fragment (81-92) TYICEVEDQKEE and its benzylated derivative by 1H NMR spectroscopy and molecular modeling: Relevance of conformation to biological function. Chang DK, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):222-32

CD4-IgG binding threshold for inactivation of human immunodeficiency virus type 1. Berkower I, et al. **J Infect Dis** 1996 Apr;173(4):863-9

Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. Neurath AR, et al. **J Mol Recognit** 1995 Sep-Oct;8(5):304-16

Human recombinant CD4 and CD4-derived synthetic peptides agglutinate immunoglobulin-coated latex particles. Evidence that residues 25-28 and 35-38 of human CD4 form two separate immunoglobulin binding sites. Lenert P, et al. **Mol Immunol** 1995 Dec;32(17-18):1399-404

Interdomain interactions in the chimeric protein toxin sCD4(178)-PE40: a differential scanning calorimetry (DSC) study. Davio SR, et al. **Pharm Res** 1995 May; 12(5):642-8

DRUG EFFECTS

CD4 down-modulation by ganglioside and phorbol ester inhibits human herpesvirus 7 infection. Yasukawa M, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2381-5

Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. Neurath AR, et al. **J Mol Recognit** 1995 Sep-Oct;8(5):304-16

GENETICS

Selenium and cellular immunity. Evidence that selenoproteins may be encoded in the +1 reading frame overlapping the human CD4, CD8, and HLA-DR genes. Taylor EW. **Biol Trace Elem Res** 1995 Aug-Sep;49(2-3):85-95 (37 ref.)

Increased and decreased relative risk for non-insulin-dependent diabetes mellitus conferred by HLA class II and by CD4 alleles. Ghabanbasani MZ, et al. **Clin Genet** 1995 May;47(5):225-30

Identification and characterization of a human CD4 silencer. Donda A, et al. **Eur J Immunol** 1996 Feb;26(2):493-500

Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock. Yeung RS, et al. **Eur J Immunol** 1996 May;26(5):1074-82

Sequence determination of an allele ladder for the STR polymorphism at the CD4 locus and application of the ladder in testing an Austrian Caucasian population sample. Glock B, et al. **Forensic Sci Int** 1996 Apr 2;78(2):125-30

A gene-rich cluster between the CD4 and triosephosphate isomerase genes at human chromosome 12p13. Ansari-Lari MA, et al. **Genome Res** 1996 Apr;6(4):314-26

Asymmetric redundancy in CD4 silencer function. Duncan DD, et al. **Immunity** 1996 Mar;4(3):301-11

Chromosomal localization of the genes encoding rat CD4, CD8alpha, and CD8beta. Dissen E, et al. **Immunogenetics** 1996;44(4):312-4

Genetic variability of the human CD4 V2 domain. Indraccolo S, et al. **Immunogenetics** 1996;44(1):70-2

Disrupted development of thymocytes expressing a transgenic TCR upon CD4 overexpression. Davis CB, et al. **Int Immunol** 1995 Dec;7(12):1977-86

Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1. Matano T, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3165-9

Mutations in human CD4 impair the functional interaction with different human and mouse class II isotypes and alleles. Fleury S, et al. **J Immunol** 1996 Mar 1; 156(5):1848-55

Characterization of an intronless CD4 minigene expressed in mature CD4 and CD8 T cells, but not expressed in immature thymocytes. Salmon P, et al. **J Immunol** 1996 Mar 1;156(5):1873-9

Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3' sulfo-galactosyl ceramide-positive cell line. Harouse JM, et al. **J Virol** 1995 Dec;69(12):7383-90

Human recombinant CD4 and CD4-derived synthetic peptides agglutinate immunoglobulin-coated latex particles. Evidence that residues 25-28 and 35-38 of human CD4 form two separate immunoglobulin binding sites. Lenert P, et al. **Mol Immunol** 1995 Dec;32(17-18):1399-404

Global patterns of linkage disequilibrium at the CD4 locus and modern human origins [see comments] Tishkoff SA.

THE PAPER AND INK USED IN THE ORIGINAL PUBLICATION MAY AFFECT THE QUALITY OF THE MICROFORM EDITION.

et al. **Science** 1996 Mar 8;271(5254):1380–7. Comment in: Science 1996 Mar 8;271(5254):1364.

[Construction and expression of the gene CD4V1V2–PE40, coding for a molecular targeted protein against AIDS] Zhao X, et al.
Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1995 Aug; 17(4):248–52 (Eng. Abstr.) **(Chi)**

[Expression of the HIV–1 CD4 receptor gene in insect cells using a baculoviral system] Belzhelarskaia SN, et al.
Mol Biol (Mosk) 1996 May–Jun;30(3):524–8 **(Rus)**

[Use of thermostable DNA polymerase from Thermus thermophilus KTP in a combined reverse transcription and amplification reaction for detecting CD4 receptor mRNA] Glukhov AI, et al. **Mol Biol (Mosk)** 1995 Jul–Aug; 29(4):942–9 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Treatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two children. Horneff G, et al. **Ann Rheum Dis** 1995 Oct;54(10):846–9

Percentage of anti–CD4 monoclonal antibody–coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Choy EH, et al.
Arthritis Rheum 1996 Jan;39(1):52–6

Double–blind, placebo–controlled multicenter trial using chimeric monoclonal anti–CD4 antibody, cM–T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Moreland LW, et al. **Arthritis Rheum** 1995 Nov;38(11):1581–8

Reduction of synovial inflammation after anti–CD4 monoclonal antibody treatment in early rheumatoid arthritis. Tak PP, et al. **Arthritis Rheum** 1995 Oct; 38(10):1457–65

Synthetic peptides derived from the fourth domain of CD4 antagonize off function and inhibit T cell activation. Satoh T, et al. **Biochem Biophys Res Commun** 1996 Jul 16; 224(2):438–43

Treatment of cutaneous T–cell lymphoma with chimeric anti–CD4 monoclonal antibody. Knox S, et al. **Blood** 1996 Feb 1;87(3):893–9

Inhibition of CD4 cross–linking–induced lymphocytes apoptosis by vesnarinone as a novel immunomodulating agent: vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion. Oyaizu N, et al. **Blood** 1996 Mar 15;87(6):2361–8

Anti–CD4 monoclonal antibodies suppress murine collagen–induced arthritis only at the time of primary immunisation. Williams RO, et al. **Cell Immunol** 1996 Jun 15;170(2):291–5

Clonal analysis of CD4 mediated accessory function on the effector activity of human CD4+ T cell subsets. Lamb JR, et al. **Clin Exp Allergy** 1995 Sep;25(9):839–47

Treatment with an anti–CD4 monoclonal antibody strongly ameliorates established rat adjuvant arthritis. Pelegrí C, et al. **Clin Exp Immunol** 1996 Feb;103(2):273–8

Two distinct mechanisms of cytotoxicity mediated by herpes simplex virus–specific CD4+ human cytotoxic T cell clones. Yasukawa M, et al. **Clin Immunol Immunopathol** 1996 Jan;78(1):70–6

Transplantation tolerance induced by antigen pretreatment and depleting anti–CD4 antibody depends on CD4+ T cell regulation during the induction phase of the response. Bushell A, et al. **Eur J Immunol** 1995 Sep;25(9):2643–9

Superantigens initiate cognate CD4+ T cell/B cell interactions leading to early activation and proliferation of B cells. al–Daccak R, et al. **Eur J Immunol** 1995 Sep; 25(9):2539–43

CD4/major histocompatibility complex class II interaction analyzed with CD4– and lymphocyte activation gene–3 (LAG–3)–Ig fusion proteins. Huard B, et al.
Eur J Immunol 1995 Sep;25(9):2718–21

Immunochemical characterization of antibody–coated nanoparticles. Velge–Roussel F, et al. **Experientia** 1996 Aug 15;52(8):803–6

Delay in corneal allograft rejection due to anti–CD4 antibody given alone and in combination with cyclosporin A and leflunomide. Coupland SE, et al. **Ger J Ophthalmol** 1995 Sep;4(5):294–301

TCR activation of ZAP70 is impaired in CD4+CD8+ thymocytes as a consequence of intrathymic interactions that diminish available p56lck. Wiest DL, et al.
Immunity 1996 May;4(5):495–504

Differential sensitivity of human naive and memory CD4+ T cells for dexamethasone. Nijhuis EW, et al.
Int Immunol 1995 Apr;7(4):591–5

Paradoxic effect of anti–CD4 therapy on lacrimal gland disease in MRL/Mp–lpr/lpr mice. Jabs DA, et al.
Invest Ophthalmol Vis Sci 1996 Jan;37(1):246–50

Blind T–cell homeostasis in CD4–deficient mice. Adleman LM, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Apr 1;11(4):334–40

The cytoplasmic domain of CD4 promotes the development of CD4 lineage T cells. Itano A, et al. **J Exp Med** 1996 Mar 1;183(3):731–41

The two membrane proximal domains of CD4 interact with the T cell receptor. Vignali DA, et al. **J Exp Med** 1996 May 1;183(5):2097–107

Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. Jeffs SA, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1403–10

A humanized, bispecific immunoadhesin–antibody that retargets CD3+ effectors to kill HIV–1–infected cells. Chamow SM, et al. **J Hematother** 1995 Oct;4(5):439–46

Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO– and CD45RO+ subsets. Brinkmann V, et al. **J Immunol** 1995 Oct 1;155(7):3322–8

CD4–imitating human antibodies in HIV infection and anti–idiotypic vaccination. Deckert PM, et al.
J Immunol 1996 Jan 15;156(2):826–33

An antibody that binds domain 1 of CD4 inhibits replication of HIV–1, but not HTLV–I, in a CD4–positive/p56lck–negative HTLV–I–transformed cell line. Lemasson I, et al. **J Immunol** 1996 Jan 15; 156(2):859–65

Human CD4–internal antigen anti–idiotypic monoclonal antibody: induction of a CD4–specific response in humans. Perosa F, et al. **J Immunol** 1996 May 1;156(9):3563–9

Humanization and molecular modeling of the anti–CD4 monoclonal antibody, OKT4A. Pulito VL, et al.
J Immunol 1996 Apr 15;156(8):2840–50

Peptides corresponding to CD4–interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo. Shen X, et al. **J Immunol** 1996 Jul 1;157(1):87–100

Differentiation to T helper cells in the thymus. Gradual acquisition of T helper cell function by CD3+CD4+ cells. Vanhecke D, et al. **J Immunol** 1995 Nov 15;155(10):4711–8

Rat adjuvant arthritis: imaging with technetium–99m–anti–CD4 Fab' fragments. Kinne RW, et al. **J Nucl Med** 1995 Dec;36(12):2268–75

Functional epitope analysis of the human CD4 molecule: antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3–like region of CD4. Benkirane M, et al. **J Virol** 1995 Nov; 69(11):6898–903

Quantitative model of antibody– and soluble CD4–mediated neutralization of primary isolates and T–cell line–adapted strains of human immunodeficiency virus type 1. Klasse PJ, et al. **J Virol** 1996 Jun;70(6):3668–77

Cross–clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4–IgG. Trkola A, et al.
J Virol 1995 Nov;69(11):6609–17

Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4–binding site. Vijh–Warrier S, et al. **J Virol** 1996 Jul;70(7):4466–73

Dependence of the murine antibody response to an anti–CDR2 VH peptide on immunogen formulation. Kanda P, et al. **Mol Immunol** 1995 Dec;32(17–18):1319–28

Anti–CD4 therapy for AIDS suggested by mathematical models. De Boer RJ, et al.
Proc R Soc Lond B Biol Sci 1996 Jul 22;263(1372):899–905

Soluble CD4: a link between specific immune mechanisms and non–specific inflammatory responses? Goto H, et al.
Scand J Immunol 1996 Jun;43(6):690–2

Anti–CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Hurez V, et al. **Ther Immunol** 1994 Oct;1(5):269–77

Tissue–specific effects of anti–CD4 therapy in induction of allograft unresponsiveness in high and low responder rats. Yin D, et al. **Transpl Immunol** 1995 Sep;3(3):258–64

Combined CTLA4Ig and anti–CD4/DC8 monoclonal antibody treatment prolongs survival of rat–to–mouse heterotopic cardiac xenografts. Rehman A, et al.
Transplant Proc 1996 Apr;28(2):660–1

Microchimerism and graft acceptance: IV. Cardiac allograft acceptance following anti–adhesion molecule antibody therapy. Suzuki H, et al. **Transplant Proc** 1996 Aug; 28(4):2058–60

Factors affecting therapeutic effect of anti–CD3 and CD4 monoclonal antibody in acute renal allograft rejection. Wang XH, et al. **Transplant Proc** 1996 Jun;28(3):1306–8

The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. Binder J, et al. **Transplantation** 1996 Mar 15;61(5):804–11

Expression of granzyme A and perforin in mouse heart transplants immunosuppressed with donor–specific transfusion and anti–CD4 monoclonal antibody. Chen RH, et al. **Transplantation** 1996 Feb 27;61(4):625–9

Effect of monoclonal anti–CD4 and anti–CD8 on skin allograft survival in mice treated with donor bone marrow cells. De Fazio SR, et al. **Transplantation** 1996 Jan 15; 61(1):104–10

Kinetics of induction of transplantation tolerance with a nondepleting anti–Cd4 monoclonal antibody and donor–specific transfusion before transplantation. A critical period of time is required for development of immunological unresponsiveness. Saitovitch D, et al.
Transplantation 1996 Jun 15;61(11):1642–7

Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV–1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. Devico A, et al. **Virology** 1996 Apr 1;218(1):258–63

Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus–specific cytotoxic T cells which recognise Epstein–Barr virus lytic antigen BHRF1. White CA, et al. **Virology** 1996 May 15;219(2):489–92

Prevention of spontaneous autoimmune thyroiditis in the obese strain (OS) chickens by treatment with a monoclonal anti–CD4 antibody. Cihak J, et al.
Zentralbl Veterinarmed A 1996 Jun;43(4):211–6

METABOLISM

Alanine substitution of two arginines in amino terminus of V3 of SIV disrupts CD4 binding whereas a similar replacement of two amino acids, lysine and arginine, in the carboxyl half of V3 prevents binding of a neutralizing monoclonal antibody. Javaherian K, et al.
AIDS Res Hum Retroviruses 1995 Sep;11(9):1101–5

Interaction of p56lck with CD4 in the yeast two–hybrid system. Campbell KS, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:89–92

Interaction of an anti–HIV peptide, T22, with gp120 and CD4. Tamamura H, et al.
Biochem Biophys Res Commun 1996 Feb 15;219(2):555–9

Modulation of CD4 lateral mobility in intact cells by an intracellularly applied antibody. Grebenkämper K, et al.
Biochem J 1995 Nov 15;312 (Pt 1):251–9

The CD4 determinant for downregulation by HIV–1 Nef directly binds to Nef. Mapping of the Nef binding surface by NMR. Grzesiek S, et al. **Biochemistry** 1996 Aug 13; 35(32):10256–61

Development of human megakaryocytes: I. Hematopoietic progenitors (CD34+ bone marrow cells) are enriched with megakaryocytes expressing CD4. Dolzhanskiy A, et al.
Blood 1996 Feb 15;87(4):1353–60

Human erythrocytes bearing electroinserted CD4 neutralize infection in vitro by primary isolates of human immunodeficiency virus type 1. Tosi PF, et al. **Blood** 1996 Jun 1;87(11):4839–44

IL–16– and other CD4 ligand–induced migration is dependent upon protein kinase C. Parada NA, et al.
Cell Immunol 1996 Feb 25;168(1):100–6

Effect of intrajejunal elemental diet perfusion on local secretion of soluble CD4 and CD8. Desreumaux P, et al.
Clin Exp Immunol 1996 May;104(2):293–6

Lipopolysaccharide (LPS) down–regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor (TNF) and IL–1 beta. Herbein G, et al. **Clin Exp Immunol** 1995 Nov;102(2):430–7

The regulation and function of the CD4 coreceptor during T lymphocyte development. Killeen N, et al.
Curr Top Microbiol Immunol 1996;205:89–106 (82 ref.)

The structural basis of CD4–MHC class II interactions: coreceptor contributions to T cell receptor antigen recognition and oligomerization–dependent signal transduction. König R, et al.
Curr Top Microbiol Immunol 1996;205:19–46 (93 ref.)

Endocytic and exocytic regulation of CD4 expression and function. Marsh M, et al. **Curr Top Microbiol Immunol** 1996;205:107–35 (143 ref.)

CD4 and signal transduction. Ravichandran KS, et al.
Curr Top Microbiol Immunol 1996;205:47–62 (97 ref.)

Renal catabolism of recombinant human soluble CD4 after intravenous administration to male Sprague–Dawley rats. Hepburn TW, et al. **Drug Metab Dispos** 1995 Oct; 23(10):1044–50

CD4 and CD45 regulate qualitatively distinct patterns of calcium mobilization in individual CD4+ T cells. Leitenberg D, et al. **Eur J Immunol** 1995 Sep;25(9):2445–51

HIV induces activation of phosphatidylinositol 4–kinase and mitogen–activated protein kinase by interacting with T cell CD4 surface molecules. Schmid–Antomarchi H, et al.
Eur J Immunol 1996 Mar;26(3):717–20

CD4+ cells in human ejaculates. Gil T, et al.
Hum Reprod 1995 Nov;10(11):2923–7

MHC class II–specific T cells can develop in the CD8 lineage when CD4 is absent. Matechak EO, et al. **Immunity** 1996 Apr;4(4):337–47

Analysis of recombinant human tumour necrosis factor–alpha–induced CD4 expression on human eosinophils. Hossain M, et al. **Immunology** 1996 Jun; 88(2):301–7

HIV–1 envelope glycoprotein gp120 down–regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor–alpha. Karsten V, et al. **Immunology** 1996 May;88(1):55–60

A synthetic conformational epitope from the C4 domain of HIV Gp120 that binds CD4. Robey FA, et al.
J Biol Chem 1996 Jul 26;271(30):17990–5

Simple enzyme immunoassay for titration of antibodies to the CD4–binding site of human immunodeficiency virus type 1 gp120. Turbica I, et al. **J Clin Microbiol** 1995 Dec; 33(12):3319–23

HIV–induced apoptosis requires the CD4 receptor cytoplasmic tail and is accelerated by interaction of CD4 with p56lck. Corbeil J, et al. **J Exp Med** 1996 Jan 1; 183(1):39–48

The extracellular domain of CD45 controls association with the CD4–T cell receptor complex and the response to antigen–specific stimulation. Leitenberg D, et al.
J Exp Med 1996 Jan 1;183(1):249–59

Mutations in human CD4 impair the functional interaction with different human and mouse class II isotypes and alleles. Fleury S, et al. **J Immunol** 1996 Mar 1; 156(5):1848–55

Peptides corresponding to CD4–interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo. Shen X, et al. **J Immunol** 1996 Jul 1;157(1):87–100

Collagen-induced arthritis in CD4- or CD8-deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis. Tada Y, et al. **J Immunol** 1996 Jun 1;156(11):4520-6

CD4 masking during human immunodeficiency virus type 1 infection, quantified on peripheral blood lymphocytes, is a potential marker of disease progression. Carrière D, et al. **J Infect Dis** 1996 Mar;173(3):565-73

Scientists figure out what makes HIV stick [news] Kuska B. **J Natl Cancer Inst** 1996 Aug 21;88(16):1102-3

Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier after conjugation to anti-transferrin receptor antibodies. Walus LR, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1067-75

Inhibition of Nef- and phorbol ester-induced CD4 degradation by macrolide antibiotics. Luo T, et al. **J Virol** 1996 Mar;70(3):1527-34

Characterization of a HTLV-I-infected cell line derived from a patient with adult T-cell leukemia with stable co-expression of CD4 and CD8. Rowe T, et al. **Leuk Res** 1995 Sep;19(9):621-8

The role of p56lck in CD4-mediated suppression of CD3-induced early signaling events in T lymphocytes. Baier-Bitterlich G, et al. **Life Sci** 1995 Mar 3; 56(15):1287-97

Fusin--a place for HIV-1 and T4 cells to meet. Dimitrov DS. **Nat Med** 1996 Jun;2(6):640-1

Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. Neurath AR, et al. **Nat Med** 1996 Feb;2(2):230-4

Identification of a major co-receptor for primary isolates of HIV-1 [see comments] Deng H, et al. **Nature** 1996 Jun 20;381(6584):661-6. Comment in: Nature 1996 Jun 20;381(6584):647-8.

Intercellular transfer of a glycosylphosphatidylinositol (GPI)-linked protein: release and uptake of CD4-GPI from recombinant adeno-associated virus-transduced HeLa cells. Anderson SM, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5894-8

Mutational analysis of HIV-1 Nef: identification of two mutants that are temperature-sensitive for CD4 downregulation. Aiken C, et al. **Virology** 1996 Mar 1; 217(1):293-300

Mutational analysis of HIV-1 gp160-mediated receptor interference: intracellular complex formation. Martin RA, et al. **Virology** 1996 Jun 15;220(2):461-72

Membrane anchorage of gp160 is necessary and sufficient to prevent CD4 transport to the cell surface. Martin RA, et al. **Virology** 1996 Jun 15;220(2):473-9

Heat-resistant factors in human erythrocyte membranes mediate CD4-dependent fusion with cells expressing HIV-1 envelope glycoproteins. Puri A, et al. **Virology** 1996 May 1;219(1):262-7

The human immunodeficiency virus type 1 Vpu protein tethered to the CD4 extracellular domain is localized to the plasma membrane and is biologically active in the secretory pathway of mammalian cells: implications for the mechanisms of Vpu function. Raja NU, et al. **Virology** 1996 Jun 1;220(1):141-51

Nef-CD4 physical interaction sensed with the yeast two-hybrid system. Rossi F, et al. **Virology** 1996 Mar 1; 217(1):397-403

PHARMACOLOGY

IL-16- and other CD4 ligand-induced migration is dependent upon protein kinase C. Parada NA, et al. **Cell Immunol** 1996 Feb 25;168(1):100-6

PHYSIOLOGY

Susceptibility of human monocytes to HIV type 1 infection in vitro is not dependent on their level of CD4 expression. Sonza S, et al. **AIDS Res Hum Retroviruses** 1995 Jul; 11(7):769-76

The synthetic [Tyr5,12,Lys7]-polyphemusin II peptide (T22) binds to the CD4 cell surface molecule. Weeks BS, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):626-31

The CD4 receptor plays essential but distinct roles in HIV-1 infection and induction of apoptosis in primary bone marrow GPIIb/IIIa+ megakaryocytes and the HEL cell line. Zauli G, et al. **Br J Haematol** 1995 Oct;91(2):290-8

Administration of a nondepleting anti-CD4 monoclonal antibody (W3/25) prevents adjuvant arthritis, even upon rechallenge: parallel administration of a depleting anti-CD8 monoclonal antibody (OX8) does not modify the effect of W3/25. Pelegrí C, et al. **Cell Immunol** 1995 Oct 15; 165(2):177-82

IL-2-resistant hyporesponsiveness induced by CD4 mAbs in OKT3-activated human T cells is reversed by CD45RA triggering. Robinet E, et al. **Cell Immunol** 1996 Jan 10; 167(1):1-7

The CD4 molecule. Roles in T lymphocytes and in HIV disease. Introduction. Littman DR. **Curr Top Microbiol Immunol** 1996;205:v-x (13 ref.)

The role of CD4 in HIV envelope-mediated pathogenesis. Siliciano RF. **Curr Top Microbiol Immunol** 1996;205:159-79 (121 ref.)

Cyclosporin A sensitivity of the HIV-1 long terminal repeat identifies distinct p56lck-dependent pathways activated by CD4 triggering. Di Somma MM, et al. **Eur J Immunol** 1996 Sep;26(9):2181-8

Mechanisms of opsonized HIV entry in normal B lymphocytes. Legendre C, et al. **FEBS Lett** 1996 Mar 4; 381(3):227-32

CD4-independent in vivo priming of murine CTL by optimal MHC class I-restricted peptides derived from intracellular pathogens. Dyall R, et al. **Int Immunol** 1995 Aug; 7(8):1205-12

Cross-linking of the TCR-CD3 complex with CD4, CD8 or LFA-1 induces an anti-apoptotic signal in thymocytes: the signal is canceled by FK506. Zhao Y, et al. **Int Immunol** 1995 Sep;7(9):1387-96

The function of the CD4 coreceptor in the development of T cells. Killeen N, et al. **Int Rev Immunol** 1995;13(1):15-27

The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. Freed EO, et al. **J Biol Chem** 1995 Oct 13;270(41):23883-6 (153 ref.)

Enhanced development of Th2-like primary CD4 effectors in response to sustained exposure to limited rIL-4 in vivo. Yoshimoto K, et al. **J Immunol** 1996 May 1;156(9):3267-74

Hyporesponsiveness in contact hypersensitivity and irritant contact dermatitis in CD4 gene targeted mouse. Kondo S, et al. **J Invest Dermatol** 1996 May;106(5):993-1000

The lectin jacalin triggers CD4-mediated lymphocyte signaling by binding CD4 through a protein-protein interaction. Lafont V, et al. **J Leukoc Biol** 1996 May; 59(5):691-6

The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4. Benkirane M, et al. **J Virol** 1995 Nov;69(11):6904-10

A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. Berson JF, et al. **J Virol** 1996 Sep; 70(9):6288-95

Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule. Bérubé P, et al. **J Virol** 1996 Jun;70(6):4009-16

Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer. Litwin V, et al. **J Virol** 1996 Sep;70(9):6437-41

Role of CD4 endocytosis in human immunodeficiency virus infection. Pelchen-Matthews A, et al. **J Virol** 1995 Dec; 69(12):8164-8

Interference to human immunodeficiency virus type 1 infection in the absence of downmodulation of the principal virus receptor, CD4. Volsky DJ, et al. **J Virol** 1996 Jun; 70(6):3823-33

A monoclonal antibody extends the half-life of an anti-HIV oligodeoxynucleotide and targets it to CD4+ cells. Morelli D, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4603-7

Dimerization of a chimeric CD4-interferon-alpha receptor reconstitutes the signaling events preceding STAT phosphorylation. Krishnan K, et al. **Oncogene** 1996 Jul 4; 13(1):125-33

Likely HIV cofactor found [news; comment] Cohen J. **Science** 1996 May 10;272(5263):809-10. Comment on: Science 1996 May 10;272(5263):872-7.

HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see comments] Feng Y, et al. **Science** 1996 May 10; 272(5263):872-7. Comment in: Science 1996 May 10;272(5263):809-10.

The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Chowers MY, et al. **Virology** 1995 Oct 1;212(2):451-7

ANTIGENS, CD5

Preferred usage of specific immunoglobulin gene segments in chronic lymphocytic leukaemia cells of three HLA-identical sisters. Hakim I, et al. **Br J Haematol** 1995 Dec;91(4):915-7

V gene sequences of human anti-ssDNA antibodies secreted by lupus-derived CD5-negative B cell hybridomas. Mitamura K, et al. **Clin Immunol Immunopathol** 1996 Feb; 78(2):152-60

Peritoneal cavity CD5 (Bla) B cells: cytokine induced IgA secretion and homing to intestinal lamina propria in SCID mice. Beagley KW, et al. **Immunol Cell Biol** 1995 Oct; 73(5):425-32

ANALYSIS

CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Ferry JA, et al. **Am J Clin Pathol** 1996 Jan;105(1):31-7

Reactivity of monoclonal antibodies OK-CLL (anti-CD5) with peripheral blood cells of patients with B cell lymphoproliferative disorders. Milošević D, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(1):23-9

The CD5+ B cells and myasthenia gravis. Araga S, et al. **Autoimmunity** 1995;20(2):129-34

Analysis of VH gene expression in CD5+ and CD5- B-cell chronic lymphocytic leukemia. Maloum K, et al. **Blood** 1995 Nov 15;86(10):3883-90

Increased numbers of CD5+ B cells and T cell receptor (TCR) gamma delta+ T cells are associated with younger age of onset in rheumatoid arthritis (RA). Hassan J, et al. **Clin Exp Immunol** 1996 Mar;103(3):353-6

A CD3+CD8+ T cell population lacking CD5 antigen expression is expanded in peripheral blood of human immunodeficiency virus-infected patients. Indraccolo S, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):253-61

Recurrent miscarriage is associated with increased numbers of CD5/20 positive lymphocytes and an increased incidence of thyroid antibodies. Roberts J, et al. **Eur J Endocrinol** 1996 Jan;134(1):84-6

Aggressive CD5-positive diffuse large B cell lymphoma showing c-myc rearrangements developed in a patient with autoimmune hemolytic anemia. Sonoki T, et al. **Int J Hematol** 1996 Jan;63(1):71-6

BIOSYNTHESIS

Clonal heterogeneity in membrane expression of CD5 in a patient with chronic lymphocytic leukemia. Hashimoto S, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:482-4

IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Kopf M, et al. **Immunity** 1996 Jan;4(1):15-24

GENETICS

Clonal analysis of IgM+ CD5+ CLL B cells. Schettino EW, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:485-91

Molecular linkage of the mouse CD5 and CD6 genes. Lecomte O, et al. **Immunogenetics** 1996;44(5):385-90

IMMUNOLOGY

Presentation of antigen by B cells subsets. I. Lyb-5+ and Lyb-5- B cells differ in ability to stimulate antigen specific T cells. Zimecki M, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(2):115-23

Presentation of antigen by B cell subsets. II. The role of CD5 B cells in the presentation of antigen to antigen-specific T cells. Zimecki M, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(5-6):349-53

Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Martin PJ, et al. **Blood** 1996 Aug 1; 88(3):824-30

Loss of the CD5+ and CD45RAhi B cell subsets in alcoholics. Cook RT, et al. **Clin Exp Immunol** 1996 Feb; 103(2):304-10

CD43 and CD5 antibodies define four normal and neoplastic B-cell subsets: a three-color flow cytometric study. Lynch EF, et al. **Cytometry** 1995 Sep 15;22(3):223-31

Monoclonal antibody BLT-1, specific for the bovine homologue of CD5, reacts with the majority of mature T cells, a subpopulation of B cells and stimulates T cell proliferation. Yang TJ, et al. **Dev Comp Immunol** 1995 Jul-Aug;19(4):337-46

Anti-CD5 extends the proliferative response of human CD5+ B cells activated with anti-IgM and interleukin-2. Jamin C, et al. **Eur J Immunol** 1996 Jan;26(1):57-62

CD5-mediated specific delivery of DNA to T lymphocytes: compartmentalization augmented by adenovirus. Merwin JR, et al. **J Immunol Methods** 1995 Oct 26;186(2):257-66

Effect of 12 neutralizing anti-cytokine antibodies on in vitro activation of B-cells. Interleukin-12 is required by B1a but not B2 cells. Jones BM. **Scand J Immunol** 1996 Jan; 43(1):64-72

[CD5-negative B-cell chronic lymphocytic leukemia (B-CLL) associated with massive splenomegaly and without lymphadenopathy] Yamada T, et al. **Rinsho Ketsueki** 1995 Oct;36(10):1230-2 (Eng. Abstr.) **(Jpn)**

[Use of an immunotoxin against the human T-lymphocyte CD5 antigen for removing "passenger" lymphocytes from kidney transplants] Shumakov VI, et al. **Dokl Akad Nauk** 1995 May;342(1):138-40 **(Rus)**

ISOLATION & PURIFICATION

Identification of a candidate CD5 homologue in the amphibian Xenopus laevis. Jürgens JB, et al. **J Immunol** 1995 Nov 1;155(9):4218-23

METABOLISM

Do CD5 B cells respond to oral antigens? Beagley KW, et al. **Adv Exp Med Biol** 1995;371B:1439-44

Heterogeneous expression of recombination activating genes and surface CD5 in CD3low CD4+ CD8+ thymocytes. Sheard M, et al. **Scand J Immunol** 1996 Jun;43(6):619-25

PHYSIOLOGY

CD5+B cells: differential capping and modulation of IgM and CD5. Jamin C, et al. **Scand J Immunol** 1996 Jan; 43(1):73-80

THERAPEUTIC USE

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Olsen NJ, et al. **Arthritis Rheum** 1996 Jul;39(7):1102-8

ANTIGENS, CD7

CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. Schmidt

D, et al. **J Clin Invest** 1996 May 1;97(9):2027–37
CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone: a case report. Nakajima H, et al. **Keio J Med** 1996 Jun;45(2):114–7

ANALYSIS

Human decidual CD7+ lymphocytes display a unique antigenic phenotype. Slukvin II, et al. **Adv Exp Med Biol** 1995;371A:387–90
Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. Harmon CB, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):404–10
Biological characteristics of CD7(+) acute leukemia. Miwa H, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):239–44 (21 ref.)
High prevalence of T cell receptor D delta 2(D delta)J delta rearrangement in CD7-positive early T cell acute lymphoblastic leukemia. Kimura N, et al. **Leukemia** 1996 Apr;10(4):650–7
Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Kornblau SM, et al. **Leukemia** 1995 Oct;9(10):1735–41
Acute undifferentiated leukemia with an unusual CD7+ CD56+ CD33+ immunophenotype of NK progenitors [letter] Reuss-Borst MA, et al. **Leukemia** 1996 May; 10(5):923–4

BLOOD

Monitoring of the disease progress in Sezary syndrome by cd7- cells using flow cytometry [letter] Collenberg C, et al. **Br J Dermatol** 1996 May;134(5):980–2

GENETICS

Decreased CD7 expression in cutaneous infiltrates of HIV-1+ patients. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Smith KJ, et al. **Am J Dermatopathol** 1995 Dec;17(6):564–9
The mouse CD7 gene: identification of a new element common to the human CD7 and mouse Thy-1 promoters. Lee DM, et al. **Immunogenetics** 1996;44(2):108–14

IMMUNOLOGY

Stage-dependent expression of CD7, CD45RO, CD45RA and CD25 on CD4-positive peripheral blood T-lymphocytes in cutaneous T-cell lymphoma. Jakob T, et al. **Acta Derm Venereol** 1996 Jan;76(1):34–6
CD7-positive Sézary syndrome with a Th1 cytokine profile. Yagi H, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):368–74

METABOLISM

Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry. Ginaldi L, et al. **Br J Haematol** 1996 Jun 2;93(4):921–7

PHYSIOLOGY

Cross-linking CD7 on myeloblasts results in granulocyte-macrophage colony-stimulating factor production. Hou Z, et al. **Blood** 1996 Jul 1;88(1):124–9
Biological characteristics of CD7(+) acute leukemia. Miwa H, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):239–44 (21 ref.)

ANTIGENS, CD8

see related
CD4–CD8 RATIO

Natural killer (NK)-cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after "three-loci" HLA-incompatible bone marrow transplantation. Albi N, et al. **Blood** 1996 May 1; 87(9):3993–4000
Functional characterization of porcine CD4+CD8+ extrathymic T lymphocytes. Summerfield A, et al. **Cell Immunol** 1996 Mar 15;168(2):291–6
Activity of neutral endopeptidase and aminopeptidase N in mouse thymic stromal cells which bind double-positive thymocytes. Small M, et al. **Eur J Immunol** 1996 Apr; 26(4):961–4
CD3-induced apoptosis of CD4+CD8+ thymocytes in the absence of clonotypic T cell antigen receptor. Tokoro Y, et al. **Eur J Immunol** 1996 May;26(5):1012–7
Human T cell repertoire generation in the absence of MHC class II expression results in a circulating CD4+CD8- population with altered physicochemical properties of complementarity-determining region 3. Henwood J, et al. **J Immunol** 1996 Feb 1;156(3):895–906

ANALYSIS

Effect of neonatal thymectomy on murine small intestinal intraepithelial lymphocytes expressing T cell receptor alpha beta and "clonally forbidden V beta s". Lin T, et al. **Adv Exp Med Biol** 1995;371A:129–31
Equianalgesic doses of subcutaneous but not intrathecal morphine alter phenotypic expression of cell surface markers and mitogen-induced proliferation in rat lymphocytes. Hamra JG, et al. **Anesthesiology** 1996 Aug; 85(2):355–65
A CD3+CD8+ T cell population lacking CD5 antigen expression is expanded in peripheral blood of human immunodeficiency virus-infected patients. Indraccolo S, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):253–61
Differential induction of helper and killer T cells from isolated CD4+CD8+ thymocytes in suspension culture. Iwata M, et al. **Eur J Immunol** 1996 Sep;26(9):2081–6
Down-regulation of CD8 on mature antigen-reactive T cells as a mechanism of peripheral tolerance. Zhang L, et al. **J Immunol** 1995 Oct 1;155(7):3464–71
Soluble versus cell-bound CD4, CD8 from bronchoalveolar lavage: correlation with pulmonary diagnoses in human immunodeficiency virus-infected individuals. Willsie SK, et al. **J Leukoc Biol** 1996 Jun;59(6):813–6
Immunophenotypic and molecular genetic characterization of a case of CD8+ B cell chronic lymphocytic leukemia. Attadia V, et al. **Leukemia** 1996 Sep;10(9):1544–50
Expansion of a peripheral blood perforin+ CD8+ T-cell subset in long-term surviving lung transplanted patients. Berthou C, et al. **Transplant Proc** 1996 Jun;28(3):1964–7

BIOSYNTHESIS

CD4 and CD8 expression and T cell antigen receptor gene rearrangement in early intrathymic precursor cells. Ismaili J, et al. **Eur J Immunol** 1996 Apr;26(4):731–7
Expansion of cytokine-producing CD4–CD8- T cells associated with abnormal Fas expression and hypereosinophilia [see comments] Simon HU, et al. **J Exp Med** 1996 Mar 1;183(3):1071–82. Comment in: J Exp Med 1996 Mar 1;183(3):721–4.
Expression of intercellular adhesion molecule-1 and CD4/CD8 lymphocyte markers in perioperative liver allograft biopsies. Bhargava A, et al. **Transplant Proc** 1995 Oct;27(5):2814–5

BLOOD

Maternal levels of serum-soluble CD8 and IL-2R are not significantly elevated in idiopathic preterm labour. Divers MJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct; 62(2):209–12
Serum TNF-alpha, sCD8 and sIL-2R levels in childhood tuberculosis. Barlan IB, et al. **Infection** 1995 Jul-Aug; 23(4):237–9
The role of CD8+, CD57+ cells in human cytomegalovirus and other viral infections. Wang EC, et al. **Scand J Infect Dis Suppl** 1995;99:69–77 (78 ref.)

CHEMISTRY

Identification of CD8 as a peanut agglutinin (PNA) receptor molecule on immature thymocytes. Wu W, et al. **J Exp Med** 1996 Aug 1;184(2):759–64
Functional dissociation of CD8 alpha's Ig homologue and connecting peptide domains. Meyerson HJ, et al. **J Immunol** 1996 Jan 15;156(2):574–84

GENETICS

Analysis of intestinal intraepithelial lymphocyte (IEL) T cells in mice expressing anti-CD8 immunoglobulin transgenes. Aicher WK, et al. **Adv Exp Med Biol** 1995;371A:125–8
Intestinal T cells in CD8 alpha knockout mice and T cell receptor transgenic mice. Fung-Leung WP, et al. **Adv Exp Med Biol** 1995;371A:121–4
Selenium and cellular immunity. Evidence that selenoproteins may be encoded in the +1 reading frame overlapping the human CD4, CD8, and HLA-DR genes. Taylor EW. **Biol Trace Elem Res** 1995 Aug-Sep;49(2-3):85–95 (37 ref.)
Non-tolerant B cells cause autoimmunity in anti-CD8 IgG2a-transgenic mice. Battegay M, et al. **Eur J Immunol** 1996 Jan;26(1):250–8
CD4-negative cytotoxic T cells with a T cell receptor alpha/beta intermediate expression in CD8-deficient mice. Dalloul AH, et al. **Eur J Immunol** 1996 Jan;26(1):213–8
Chromosomal localization of the genes encoding rat CD4, CD8alpha, and CD8beta. Dissen E, et al. **Immunogenetics** 1996;44(4):312–4
Bop: a new T-cell-restricted gene located upstream of and opposite to mouse CD8b. Hwang I, et al. **Immunogenetics** 1995;42(5):353–61
Characterization of the mouse CD8 beta chain-encoding gene promoter region. Kawachi Y, et al. **Immunogenetics** 1996;44(5):358–65
Chromosomal mapping of the second human CD8B gene locus. Zhang XL, et al. **Immunogenetics** 1996;43(4):220–6
Human CD8 transgene regulation of HLA recognition by murine T cells. LaFace DM, et al. **J Exp Med** 1995 Nov 1;182(5):1315–25
Development of CD8 alpha alpha+ intestinal intraepithelial T cells in beta 2-microglobulin- and/or TAP1-deficient mice. Fujiura Y, et al. **J Immunol** 1996 Apr 15; 156(8):2710–5

IMMUNOLOGY

Administration of anti-CD3 monoclonal antibody during experimental Chagas' disease induces CD8+ cell-dependent lethal shock. Jacobs F, et al. **Clin Exp Immunol** 1996 Feb;103(2):233–8
TCR activation of ZAP70 is impaired in CD4+CD8+ thymocytes as a consequence of intrathymic interactions that diminish available p56lck. Wiest DL, et al. **Immunity** 1996 May;4(5):495–504
Predominant involvement of CD8+CD28- lymphocytes in human immunodeficiency virus-specific cytotoxic activity. Fiorentino S, et al. **J Virol** 1996 Mar;70(3):2022–6
Clonal CD3+CD8+ large granular lymphocyte (LGL)/NK-associated (NKa) expansions: primary malignancies or secondary reactive phenomena? Richards SJ, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):303–11
On the role of antigen in maintaining cytotoxic T-cell memory. Kündig TM, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9716–23
Combined CTLA4Ig and anti-CD4/DC8 monoclonal antibody treatment prolongs survival of rat-to-mouse heterotopic cardiac xenografts. Rehman A, et al. **Transplant Proc** 1996 Apr;28(2):660–1
Microchimerism and graft acceptance: IV. Cardiac allograft acceptance following anti-adhesion molecule antibody therapy. Suzuki H, et al. **Transplant Proc** 1996 Aug; 28(4):2058–60
Effect of monoclonal anti-CD4 and anti-CD8 on skin allograft survival in mice treated with donor bone marrow cells. De Fazio SR, et al. **Transplantation** 1996 Jan 15; 61(1):104–10
Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. White CA, et al. **Virology** 1996 May 15;219(2):489–92

METABOLISM

Glycosylation and maturation rate of membrane and secretory forms of human CD8 alpha glycoprotein. Implications in the activation of T-lymphocytes. Serafini-Cessi F, et al. **Adv Exp Med Biol** 1995;376:135–45 (33 ref.)
Effect of intrajejunal elemental diet perfusion on local secretion of soluble CD4 and CD8. Desreumaux P, et al. **Clin Exp Immunol** 1996 May;104(2):293–6
MHC class II-specific T cells can develop in the CD8 lineage when CD4 is absent. Matechak EO, et al. **Immunity** 1996 Apr;4(4):337–47
Different fate of a single reporter protein containing KDEL or KKXX targeting signals stably expressed in mammalian cells. Martire G, et al. **J Biol Chem** 1996 Feb 16; 271(7):3541–7
Human intestinal epithelial cell-induced CD8+ T cell activation is mediated through CD8 and the activation of CD8-associated p56lck. Li Y, et al. **J Exp Med** 1995 Oct 1;182(4):1079–88
Interaction between CD8 and major histocompatibility complex (MHC) class I mediated by multiple contact surfaces that include the alpha 2 and alpha 3 domains of MHC class I. Sun J, et al. **J Exp Med** 1995 Nov 1; 182(5):1275–80
Thymocyte cell fate alteration by high levels of CD8alpha is independent of CD8-lck association. Smith DH, et al. **J Immunol** 1996 Aug 1;157(3):1087–95
Collagen-induced arthritis in CD4- or CD8-deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis. Tada Y, et al. **J Immunol** 1996 Jun 1;156(11):4520–6
Characterization of a HTLV-I-infected cell line derived from a patient with adult T-cell leukemia with stable co-expression of CD4 and CD8. Rowe T, et al. **Leuk Res** 1995 Sep;19(9):621–8

PHYSIOLOGY

Coreceptors and adapter proteins in T-cell signaling. Ravichandran KS, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:117–33 (91 ref.)
Administration of a nondepleting anti-CD4 monoclonal antibody (W3/25) prevents adjuvant arthritis, even upon rechallenge: parallel administration of a depleting anti-CD8 monoclonal antibody (OX8) does not modify the effect of W3/25. Pelegri C, et al. **Cell Immunol** 1995 Oct 15; 165(2):177–82
The p56lck SH2 domain mediates recruitment of CD8/p56lck to the activated T cell receptor/CD3/zeta complex. Thome M, et al. **Eur J Immunol** 1996 Sep;26(9):2093–2100
CD8-dependent CTL require co-engagement of CD8 and the TCR for phosphatidylinositol hydrolysis, but CD8-independent CTL do not and can kill in the absence of phosphatidylinositol hydrolysis. Knall C, et al. **Int Immunol** 1995 Jun;7(6):995–1004
Cross-linking of the TCR-CD3 complex with CD4, CD8 or LFA-1 induces an anti-apoptotic signal in thymocytes: the signal is canceled by FK506. Zhao Y, et al. **Int Immunol** 1995 Sep;7(9):1387–96
Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. Alexander-Miller MA, et al. **J Exp Med** 1996 Aug 1;184(2):485–92

ANTIGENS, CD10 see **MEMBRANE METALLO-ENDOPEPTIDASE**

ANTIGENS, CD11

ANALYSIS

Expression of CD11a and CD45R isoforms defines distinct subsets of CD8+ TCR alpha beta and TCR gamma delta

CTL in vivo. Hedlund G, et al. **Immunol Rev** 1995 Aug; 146:82–94 (33 ref.)

BIOSYNTHESIS

B-cell prolymphocytic leukemia expressing discordant myeloid-associated antigens in simultaneous specimens from bone marrow and peripheral blood. Emery CL, et al. **Cytometry** 1995 Sep 15;22(3):243–9

Activated human platelets express beta2 integrin. Philippeaux MM, et al. **Eur J Haematol** 1996 Mar;56(3):130–7

Adaptation to eccentric exercise: effect on CD64 and CD11b/CD18 expression. Pizza FX, et al. **J Appl Physiol** 1996 Jan;80(1):47–55

Regulation of polymorphonuclear neutrophil CD16 and CD11b/CD18 expression by matrix proteins during hypoxia is VLA-5, VLA-6 dependent. Simms H, et al. **J Immunol** 1995 Nov 15;155(10):4979–90

BLOOD

Measurement of CD11/CD18 integrin expression on the polymorphonuclear cell surface after incubation with synthetic vascular prostheses. Jakubiec B, et al. **ASAIO J** 1994 Jul–Sep;40(3):M616–8

The red cell LW blood group protein is an intercellular adhesion molecule which binds to CD11/CD18 leukocyte integrins. Bailly P, et al. **Eur J Immunol** 1995 Dec; 25(12):3316–20

Modulation of CD11b/CD18 on monocytes and granulocytes following hemodialysis membrane interaction in vitro. Thylén P, et al. **Int J Artif Organs** 1996 Mar;19(3):156–63

Supraceliac, but not infrarenal, aortic cross-clamping upregulates neutrophil integrin CD11b. Hill GE, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):515–8

GENETICS

Dithiocarbamates trigger differentiation and induction of CD11c gene through AP-1 in the myeloid lineage. Aragonés J, et al. **J Biol Chem** 1996 May 3; 271(18):10924–31

IMMUNOLOGY

A CD44 monoclonal antibody differentially regulates CD11a/CD18 binding to intercellular adhesion molecules CD54, CD102 and CD50. Vermot-Desroches C, et al. **Eur J Immunol** 1995 Sep;25(9):2460–4

Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Diebold RJ, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12215–9

METABOLISM

Expansion of CD11abright cells in CD8+CD45RA+ from HIV-infected patients: a new early marker for disease progression? Scala E, et al. **AIDS Res Hum Retroviruses** 1995 Nov;11(11):1327–33

Deformability and CD11/CD18 expression of sequestered neutrophils in normal and inflamed lungs. Brown DM, et al. **Am J Respir Cell Mol Biol** 1995 Nov;13(5):531–9

PHYSIOLOGY

Role of CD 11/CD 18 in neutrophil emigration during acute and recurrent Pseudomonas aeruginosa-induced pneumonia in rabbits. Kumasaka T, et al. **Am J Pathol** 1996 Apr;148(4):1297–305

CD11a–CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Pellat-Deceunynck C, et al. **Cancer Res** 1996 Apr 15; 56(8):1909–16

Leukocyte and endothelial adhesion molecules in ischaemia/reperfusion injuries. Winn RK, et al. **Ciba Found Symp** 1995;189:63–71; discussion 72–6, 77–8 (52 ref.)

The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. Sitrin RG, et al. **J Clin Invest** 1996 Apr 15;97(8):1942–51

Triggering of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappa B (p50/p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells. Thieblemont N, et al. **J Immunol** 1995 Nov 15;155(10):4861–7

The role of CD11/CD18 integrins in the reverse passive Arthus reaction in rat dermal tissue. Rote WE, et al. **J Leukoc Biol** 1996 Feb;59(2):254–61

ANTIGENS, CD11A see **LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1**

ANTIGENS, CD11B see **MACROPHAGE-1 ANTIGEN**

ANTIGENS, CD11C see **ANTIGEN P150,95**

ANTIGENS, CD13

MR-387A and B, new aminopeptidase N inhibitors, produced by Streptomyces neyagawaensis SL-387. Chung MC, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):99–102

ANALYSIS

Multiple gastric involvement by myeloid antigen CD13-positive non-secretory plasma cell leukaemia. Ohsaka A, et al. **Br J Haematol** 1996 Jan;92(1):134–6

Translocation (2;14)(p13;q32) in CD10+ ;CD13+ acute lymphatic leukemia. Berkowicz M, et al. **Cancer Genet Cytogenet** 1995 Sep;83(2):140–3

Localization and biosynthesis of aminopeptidase N in pig fetal small intestine. Danielsen EM, et al. **Gastroenterology** 1995 Oct;109(4):1039–50

1,25-dihydroxyvitamin D3 stimulates phagocytosis but suppresses HLA-DR and CD13 antigen expression in human mononuclear phagocytes. Tokuda N, et al. **Proc Soc Exp Biol Med** 1996 Mar;211(3):244–50

BIOSYNTHESIS

Overexpression of TGEV cell receptor impairs the production of virus particles. Delmas B, et al. **Adv Exp Med Biol** 1995;380:379–85

Functional and phenotypic upregulation of CD13/aminopeptidase-N on precursor-B acute lymphoblastic leukemia after in vitro stimulation. Makrynikola V, et al. **Exp Hematol** 1995 Oct;23(11):1173–9

Localization and biosynthesis of aminopeptidase N in pig fetal small intestine. Danielsen EM, et al. **Gastroenterology** 1995 Oct;109(4):1039–50

BLOOD

Identification of an alanine aminopeptidase in human maternal serum as a membrane-bound aminopeptidase N. Watanabe Y, et al. **Biol Chem Hoppe Seyler** 1995 Jul; 376(7):397–400

Loss and shedding of surface markers from the leukemic myeloid monocytic line THP-1 induced to undergo apoptosis. Brown SB, et al. **J Cell Biochem** 1996 Feb; 60(2):246–59

Aminopeptidase-N (CD13; gp 150): contrasting patterns of enzymatic activity in blood from patients with myeloid or lymphoid leukemia. Favaloro EJ, et al. **Leuk Res** 1995 Sep; 19(9):659–66

DRUG EFFECTS

Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Roques BP, et al. **NIDA Res Monogr** 1995; 147:104–45 (149 ref.)

GENETICS

Pseudopregnancy induces the expression of hepatocyte nuclear factor-1 beta and its target gene aminopeptidase N in rabbit endometrium via the epithelial promoter. Olsen J, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):31–7

Quantification of aminopeptidase N mRNA in T cells by competitive PCR. Wex T, et al. **FEBS Lett** 1995 Nov 6; 374(3):341–4

Sequence analysis, distribution and expression of an aminopeptidase N-encoding gene from Lactobacillus helveticus CNRZ32 [gene 155 (1995) 89–93] Christensen JE, et al. **Gene** 1995 Oct 16;164(1):189–90

Human aminopeptidase N is encoded by 20 exons. Lerche C, et al. **Mamm Genome** 1996 Sep;7(9):712–3

IMMUNOLOGY

Neutralization of human cytomegalovirus by human CD13-specific antibodies. Giugni TD, et al. **J Infect Dis** 1996 May;173(5):1062–71

Immunocytochemical studies of an antigen in a human T-cell lymphoma line (Jurkat) recognized by certain monoclonal antibodies to CD-13 (aminopeptidase-N). Murray H, et al. **Leuk Lymphoma** 1995 May;17(5–6):501–8

Cytomegalovirus-induced CD13-specific autoimmunity—a possible cause of chronic graft-vs-host disease. Soderberg C, et al. **Transplantation** 1996 Feb 27;61(4):600–9

CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients. Soderberg C, et al. **Transplantation** 1996 Feb 27;61(4):594–600

ISOLATION & PURIFICATION

Aminopeptidase N purified from gypsy moth brush border membrane vesicles is a specific receptor for Bacillus thuringiensis CryIAc toxin. Lee MK, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2845–9

METABOLISM

Domain III exchanges of Bacillus thuringiensis CryIA toxins affect binding to different gypsy moth midgut receptors. Lee MK, et al. **Biochem Biophys Res Commun** 1995 Nov 2;216(1):306–12

Decrease in cytosolic Aspartyl-aminopeptidase but not in Alanyl-aminopeptidase activity in the frontal cortex of the aged rat. Iribar C, et al. **Brain Res** 1995 Jul 31; 687(1–2):211–3

Monocyte- and cytokine-induced downregulation of angiotensin-converting enzyme in cultured human and porcine endothelial cells. Papapetropoulos A, et al. **Circ Res** 1996 Sep;79(3):512–23

Effect of sodium valproate on renal cell brush-border enzymes in rats. Cepelak I, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):673–7

Activity of neutral endopeptidase and aminopeptidase N in mouse thymic stromal cells which bind double-positive thymocytes. Small M, et al. **Eur J Immunol** 1996 Apr; 26(4):961–4

Biliary aminopeptidase-N and the cholesterol crystallisation defect in cholelithiasis. Núñez L, et al. **Gut** 1995 Sep; 37(3):422–6

Brush border membrane aminopeptidase-N in the midgut of the gypsy moth serves as the receptor for the CryIA(c) delta-endotoxin of Bacillus thuringiensis. Valaitis AP, et al. **Insect Biochem Mol Biol** 1995 Dec;25(10):1143–51

Transcytosis of aminopeptidase N in Caco-2 cells is mediated by a non-cytoplasmic signal. Vogel LK, et al. **J Biol Chem** 1995 Sep 29;270(39):22933–8

T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides. Larsen SL, et al. **J Exp Med** 1996 Jul 1;184(1):183–9

PHARMACOLOGY

Contribution of IL-1, CD14, and CD13 in the increased IL-6 production induced by in vitro monocyte-synoviocyte interactions. Chomarat P, et al. **J Immunol** 1995 Oct 1; 155(7):3645–52

Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Roques BP, et al. **NIDA Res Monogr** 1995; 147:104–45 (149 ref.)

PHYSIOLOGY

Cellular receptors for transmissible gastroenteritis virus on porcine enterocytes. Weingartl HM, et al. **Adv Exp Med Biol** 1995;380:325–9

URINE

Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Carraro M, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):444–8

[Alanine aminopeptidase in urine] Seki T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:445–6 (7 ref.) **(Jpn)**

ANTIGENS, CD14

Lipopolysaccharide induces the rapid tyrosine phosphorylation of the mitogen-activated protein kinases erk-1 and p38 in cultured human vascular endothelial cells requiring the presence of soluble CD14. Schumann RR, et al. **Blood** 1996 Apr 1;87(7):2805–14

CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Thieblemont N, et al. **Eur J Immunol** 1995 Dec; 25(12):3418–24

CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Zhou LJ, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2588–92

ADMINISTRATION & DOSAGE

Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. Hailman E, et al. **J Immunol** 1996 Jun 1;156(11):4384–90

ANALYSIS

Accelerated generation of CD14+ monocyte-lineage cells from the bone marrow of rheumatoid arthritis patients. Hirohata S, et al. **Arthritis Rheum** 1996 May;39(5):836–43

Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis. Frankenberger M, et al. **Blood** 1996 Jan 1;87(1):373–7

Increased soluble CD14 levels in BAL fluid in pulmonary tuberculosis. Hoheisel G, et al. **Chest** 1995 Dec; 108(6):1614–6

CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human skin. Werfel T, et al. **J Immunol** 1996 Aug 15;157(4):1729–35

The inflammatory response in pediatric biliary disease: macrophage phenotype and distribution. Tracy TF Jr, et al. **J Pediatr Surg** 1996 Jan;31(1):121–5; discussion 125–6

Monocyte-macrophage antigen expression on chondrocytes. Summers KL, et al. **J Rheumatol** 1995 Jul;22(7):1326–34

Endotoxin tolerance is induced in Chinese hamster ovary cell lines expressing human CD14. Kravchenko VV, et al. **Shock** 1996 Mar;5(3):194–201

BIOSYNTHESIS

Intramammary defense against infections induced by Escherichia coli in cows. Paape MJ, et al. **Am J Vet Res** 1996 Apr;57(4):477–82

Cytomegalovirus inhibits CD14 expression on human alveolar macrophages. Hopkins HA, et al. **J Infect Dis** 1996 Jul;174(1):69–74

BLOOD

CD14 expression in injured patients correlates with outcome. Heinzelmann M, et al. **Ann Surg** 1996 Jul;224(1):91–6

Increased soluble CD14 levels in patients on hemodialysis. Influence of dialysate endotoxin or incompatibility to dialyzer membranes? Mitzner S, et al. **ASAIO J** 1995

Jul-Sep;41(3):M707-8
Elevated levels of soluble CD14 in serum of patients with acute Plasmodium falciparum malaria. Wenisch C, et al. **Clin Exp Immunol** 1996 Jul;105(1):74-8
Increased serum concentration of soluble CD14 is a prognostic marker in gram-positive sepsis. Burgmann H, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):307-10
Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease. Oesterreicher C, et al. **J Hepatol** 1995 Oct;23(4):396-402
Function of soluble CD14 in serum from patients with septic shock. Landmann R, et al. **J Infect Dis** 1996 Mar; 173(3):661-8
Soluble CD14 in septic shock. Landmann R, et al. **Prog Clin Biol Res** 1995;392:375-80

CHEMISTRY

The myeloid differentiation antigen CD14 is N- and O-glycosylated. Contribution of N-linked glycosylation to different soluble CD14 isoforms. Stelter F, et al. **Eur J Biochem** 1996 Mar 1;236(2):457-64

GENETICS

Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Haziot A, et al. **Immunity** 1996 Apr;4(4):407-14
Prostaglandin E2 secretion, cell maturation, and CD14 expression by monocyte-derived macrophages from localized juvenile periodontitis patients. Shapira L, et al. **J Periodontol** 1996 Mar;67(3):224-8
Site-directed mutagenesis of baboon CD14 to the human sequence allows for antibody recognition and enhanced LPS binding. DeGraw JS, et al. **Prog Clin Biol Res** 1995; 392:365-8
Use of CD14 transfected cells to study LPS-antagonist action. Delude RL, et al. **Prog Clin Biol Res** 1995; 392:487-97

IMMUNOLOGY

Evaluation of monocyte counting with two automated instruments by the use of CD 14-specific immunomagnetic Dynabeads. Theodorsen L. **Clin Lab Haematol** 1995 Sep; 17(3):225-9
Helicobacter pylori and Porphyromonas gingivalis lipopolysaccharides are poorly transferred to recombinant soluble CD14. Cunningham MD, et al. **Infect Immun** 1996 Sep;64(9):3601-8
CD14-independent responses to LPS require a serum factor that is absent from neonates. Cohen L, et al. **J Immunol** 1995 Dec 1;155(11):5337-42
Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: evidence for chronic exposure to LPS. Nockher WA, et al. **Kidney Int** 1995 Nov; 48(5):1469-76
Therapeutic strategies to block LPS interactions with its receptor. Leturcq DJ, et al. **Prog Clin Biol Res** 1995; 392:473-7

METABOLISM

Lipopolysaccharide upregulates surface expression of CD14 on human alveolar macrophages. Hopkins HA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):L849-54
Knowledge of cellular receptors for bacterial endotoxin—1995. Viriyakosol S, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S190-5 (41 ref.)
Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Haziot A, et al. **Immunity** 1996 Apr;4(4):407-14
Human monocyte CD14 is upregulated by lipopolysaccharide. Landmann R, et al. **Infect Immun** 1996 May;64(5):1762-9
The N-terminal half of membrane CD14 is a functional cellular lipopolysaccharide receptor. Viriyakosol S, et al. **Infect Immun** 1996 Feb;64(2):653-6
Catalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14. Yu B, et al. **J Biol Chem** 1996 Feb 23;271(8):4100-5
Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses. Kusunoki T, et al. **J Exp Med** 1995 Dec 1;182(6):1673-82
LPS induces CD14 association with complement receptor type 3, which is reversed by neutrophil adhesion. Zarewych DM, et al. **J Immunol** 1996 Jan 15;156(2):430-3
LPS-dependent interaction of Mac-2-binding protein with immobilized CD14. Yu B, et al. **J Inflamm** 1995; 45(2):115-25
An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma. Aida Y, et al. **J Leukoc Biol** 1995 Dec;58(6):675-82
Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. Kiertscher SM, et al. **J Leukoc Biol** 1996 Feb;59(2):208-18
Cuprophane haemodialysis induces upregulation of LPS receptor (CD14) on monocytes: role of complement activation. Marchant A, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):657-62
Site-directed mutagenesis of baboon CD14 to the human sequence allows for antibody recognition and enhanced LPS binding. DeGraw JS, et al. **Prog Clin Biol Res** 1995; 392:365-8
Activation of endothelial cells by endotoxin: direct versus indirect pathways and the role of CD14. Pugin J, et al. **Prog Clin Biol Res** 1995;392:369-73
Modalities of endotoxin binding to CD14. Schütt C, et al. **Prog Clin Biol Res** 1995;392:339-48
Human monocytes lacking the membrane-bound form of the bacterial lipopolysaccharide (LPS) receptor CD14 can mount an LPS-induced oxidative burst response mediated by a soluble form of CD14. Schütt C, et al. **Res Immunol** 1995 Jul-Aug;146(6):339-50

PHARMACOLOGY

Contribution of IL-1, CD14, and CD13 in the increased IL-6 production induced by in vitro monocyte-synoviocyte interactions. Chomarat P, et al. **J Immunol** 1995 Oct 1; 155(7):3645-52
Recombinant soluble CD14 inhibits LPS-induced mortality in a murine model. Goyert SM, et al. **Prog Clin Biol Res** 1995;392:479-83

PHYSIOLOGY

LPS-mediated NF-kappa beta activation in rat Kupffer cells can be induced independently of CD14. Bellezzo JM, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):G956-61
Lipoteichoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway. Cleveland MG, et al. **Infect Immun** 1996 Jun; 64(6):1906-12
Potent CD14-mediated signalling of human leukocytes by Escherichia coli can be mediated by interaction of whole bacteria and host cells without extensive prior release of endotoxin. Katz SS, et al. **Infect Immun** 1996 Sep; 64(9):3592-600
Activation of human endothelial cells by viable or heat-killed gram-negative bacteria requires soluble CD14. Noel RF Jr, et al. **Infect Immun** 1995 Oct;63(10):4046-53
Genomic cloning, characterization, and functional analysis of the major surface adhesin WI-1 on Blastomyces dermatitidis yeasts. Hogan LH, et al. **J Biol Chem** 1995 Dec 22;270(51):30725-32
Lipopolysaccharide stimulates the tyrosine phosphorylation of mitogen-activated protein kinases p44, p42, and p41 in vascular endothelial cells in a soluble CD14-dependent manner. Role of protein tyrosine phosphorylation in lipopolysaccharide-induced stimulation of endothelial cells. Arditi M, et al. **J Immunol** 1995 Oct 15;155(8):3994-4003
Differential infection of porcine alveolar macrophage subpopulations by nonopsonized Mycobacterium bovis involves CD14 receptors. Khanna KV, et al. **J Leukoc Biol** 1996 Aug;60(2):214-20
Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/action through beta2 integrin in vivo. Mukaida N, et al. **J Leukoc Biol** 1996 Feb;59(2):145-51 (42 ref.)
CD14 mediate endotoxin induction of nitric oxide synthase in cultured brain glial cells. Galea E, et al. **J Neuroimmunol** 1996 Jan;64(1):19-28
Role of CD14 in hemorrhagic shock-induced alterations of the monocyte tumor necrosis factor response to endotoxin. Nwariaku F, et al. **J Trauma** 1996 Apr;40(4):564-7
CD14 enhances cellular responses to endotoxin without imparting ligand-specific recognition. Delude RL, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9288-92
CD14-deficient mice are exquisitely insensitive to the effects of LPS. Haziot A, et al. **Prog Clin Biol Res** 1995;392:349-51

TOXICITY

Soluble CD14 and lipopolysaccharide-binding protein from bovine serum enable bacterial lipopolysaccharide-mediated cytotoxicity and activation of bovine vascular endothelial cells in vitro. Yang Z, et al. **J Leukoc Biol** 1996 Feb; 59(2):241-7

ANTIGENS, CD15

ANALYSIS

An immunohistochemical study of lysozyme, CD-15 (Leu M1), and gross cystic disease fluid protein-15 in various skin tumors. Assessment of the specificity and sensitivity of markers of apocrine differentiation. Ansai S, et al. **Am J Dermatopathol** 1995 Jun;17(3):249-55
Changes in glycoconjugates revealed by lectin staining and stage-specific embryonic antigen-1 immunostaining in hamster submandibular glands during the postnatal period. Ito T, et al. **Anat Embryol (Berl)** 1995 Aug;192(2):101-6
Prognostic significance of Lewis related antigen expression in stage I non-small cell lung cancer [letter] Ogawa J, et al. **Eur J Cancer** 1995 Sep;31A(10):1716
CD15 and HKN-1 reveal cerebellar compartments with a complex overlap. Mai JK, et al. **Eur J Morphol** 1995 Apr; 33(2):101-7
Simultaneous demonstration of CD15 and alkaline phosphatase activity in cryostat sections of rat fetuses: a detailed technical description for the developing brain. Marani E, et al. **Eur J Morphol** 1995 Apr;33(2):137-47
Comparison of the pattern of expression of Leu-M1 antigen in adenocarcinomas, neutrophils and Hodgkin's disease by immunoelectron microscopy. Valente AM, et al. **Histochem Cell Biol** 1995 Mar;103(3):181-6
Expression of the CD15 antigen (Lewis x) in breast cancer. Brooks SA, et al. **Histochem J** 1995 Sep;27(9):689-93
A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin. Attanoos RL, et al. **Histopathology** 1995 Oct;27(4):361-6
Expression of CD15 in normal and metaplastic Paneth cells of the digestive tract. Ariza A, et al. **J Clin Pathol** 1996 Jun;49(6):474-7
Cutaneous Hodgkin's disease: an immunohistochemical analysis. Cerroni L, et al. **J Cutan Pathol** 1995 Jun; 22(3):229-35
Expression of sialyl Lewis(x) and Lewis(x) defines distinct stages of chicken B cell maturation. Masteller EL, et al. **J Immunol** 1995 Dec 15;155(12):5550-6
Lewis X antigen immunostaining in the diagnosis of transitional cell carcinoma. Loy TS, et al. **Mod Pathol** 1995 Aug;8(6):587-90
[Clinical value of carbohydrate antigens, sialyl Lewis-x and sialyl Lewis-a in gastrointestinal cancer] Nakamori S, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):165-71 (27 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Genetic evidence for the Lewis enzyme, which synthesizes type-1 Lewis antigens in colon tissue, and intracellular localization of the enzyme. Narimatsu H, et al. **Cancer Res** 1996 Jan 15;56(2):330-8
B-cell prolymphocytic leukemia expressing discordant myeloid-associated antigens in simultaneous specimens from bone marrow and peripheral blood. Emery CL, et al. **Cytometry** 1995 Sep 15;22(3):243-9
Expression of CD15 in a subset of dorsal root ganglion cells during the chick embryonic development. Andressen C, et al. **Eur J Morphol** 1995 Apr;33(2):109-18
Expression of the carbohydrate epitope 3-fucosyl-N-acetyl-lactosamine (CD 15) in the adult guinea pig inner ear. Meyer zum Gottesberge AM, et al. **Eur J Morphol** 1995 Apr;33(2):129-35
Age-related expression of the CD15 (3-fucosyl-N-acetyl-lactosamine) epitope in the monkey (Cercopithecus aethiops aethiops L.) lateral geniculate nucleus. Schönlau C, et al. **Eur J Morphol** 1995 Apr; 33(2):119-28
The biosynthesis of Lewis X in Helicobacter pylori. Chan NW, et al. **Glycobiology** 1995 Oct;5(7):683-8
Expression and localization of Lewis(x) glycolipids and GD1a ganglioside in human glioma cells. Ariga T, et al. **Glycoconj J** 1996 Apr;13(2):135-45
Helicobacter pylori expresses a complex surface carbohydrate, Lewis X. Sherburne R, et al. **Infect Immun** 1995 Dec;63(12):4564-8

CHEMISTRY

Monosialogangliosides of human myelogenous leukemia HL60 cells and normal human leukocytes. 1. Separation of E-selectin binding from nonbinding gangliosides, and absence of sialosyl-Le(x) having tetraosyl to octaosyl core. Stroud MR, et al. **Biochemistry** 1996 Jan 23;35(3):758-69
A total synthesis of glycononaosyl ceramide with a sialyl dimeric Le(x) sequence. Iida M, et al. **Carbohydr Res** 1995 Apr 30;270(2):C15-9
Chemical synthesis of a hexasaccharide comprising the Lewisx determinant linked beta-(1—>6) to a linear trimannosyl core and the precursor pentasaccharide lacking fucose. Jain RK, et al. **Carbohydr Res** 1996 Feb 28; 282(1):101-11
Expression and localization of Lewis(x) glycolipids and GD1a ganglioside in human glioma cells. Ariga T, et al. **Glycoconj J** 1996 Apr;13(2):135-45
Negative-ion fast atom bombardment and electrospray ionization tandem mass spectrometry for characterization of sulfated and sialyl Lewis-type glycosphingolipids. Ii T, et al. **Glycoconj J** 1996 Apr;13(2):273-83
Total synthesis of glycononaosyl ceramide with a sialyl dimeric Le(x)-sequence. Iida M, et al. **Glycoconj J** 1996 Apr;13(2):203-11
Synthesis of deoxygalactose-containing sialyl Le(X) ganglioside analogues to elucidate the structure necessary for selectin recognition. Komba S, et al. **Glycoconj J** 1996 Apr;13(2):241-54
The Le(x) carbohydrate sequence is recognized by antibody to L5, a functional antigen in early neural development. Streit A, et al. **J Neurochem** 1996 Feb;66(2):834-44

DRUG EFFECTS

Time-dependent alterations of 3-fucosyl-N-acetyl-lactosamine (CD15) expression in the endolymphatic sac of adult guinea pigs after glycerol administration. Meyer zum Gottesberge AM, et al. **Eur Arch Otorhinolaryngol** 1996;253(3):136-41

GENETICS

[Molecular biology of Lewis antigens--histo-blood type

antigens and sialyl Lewis antigens as tumor associated antigens] Narimatsu H. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):115–22 (39 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Localization of the CD15–epitope in the inner ear of the developing mouse. Meyer zym Gottesberge AM, et al. **Cell Tissue Res** 1996 Mar;283(3):395–401

Introduction: workshop summary of the CD15 monoclonal antibody panel from the Fifth International Workshop on Leukocyte Antigens. Ball ED. **Eur J Morphol** 1995 Apr; 33(2):95–100

Schistosoma mansoni infection in humans and primates induces cytolytic antibodies to surface Le(x) determinants on myeloid cells. Nyame AK, et al. **Exp Parasitol** 1996 Mar;82(2):191–200

Lacto–N–fucopentaose III (Lewis x), a target of the antibody response in mice vaccinated with irradiated cercariae of Schistosoma mansoni. Richter D, et al. **Infect Immun** 1996 May;64(5):1826–31

A combination of CD34 selection and complement–mediated immunopurging (anti–CD15 monoclonal antibody) eliminates tumor cells while sparing normal progenitor cells. Nimgaonkar M, et al. **J Hematother** 1996 Feb; 5(1):39–48

Sialyl Lewis(x) oligosaccharide reduces ischemia–reperfusion injury in the rabbit ear. Han KT, et al. **J Immunol** 1995 Oct 15;155(8):4011–5

A major role for CD62P/CD15s interaction in leukocyte margination during hemodialysis. Stuard S, et al. **Kidney Int** 1995 Jul;48(1):93–102

Highly expressed human sialyl Lewis antigen on cell surface of streptococcus gallolyticus [letter] Hirota K, et al. **Lancet** 1996 Mar 16;347(9003):760

METABOLISM

Specificity analysis of three clonal and five non–clonal alpha 1,3–L–fucosyltransferases with sulfated, sialylated, or fucosylated synthetic carbohydrates as acceptors in relation to the assembly of 3'–sialyl–6'–sulfo Lewis x (the L–selectin ligand) and related complex structures. Chandrasekaran EV, et al. **Biochemistry** 1996 Jul 9;35(27):8925–33

Synthesis of a divalent sialyl Lewis x O–glycan, a potent inhibitor of lymphocyte–endothelium adhesion. Evidence that multivalency enhances the saccharide binding to L–selectin. Maaheimo H, et al. **Eur J Biochem** 1995 Dec 1;234(2):616–25

F protein induced fusion of Sendai viral envelopes with mouse teratocarcinoma cells through Le(x)–Le(x) interaction. Kumar M, et al. **FEBS Lett** 1996 Aug 5; 391(1–2):17–20

Expression of sialyl Lewis(x) in hepatocellular carcinoma. Tori A, et al. **Hepatogastroenterology** 1995 Nov–Dec; 42(6):939–43

Tissue targeting of multivalent Le(x)–terminated N–linked oligosaccharides in mice. Chiu MH, et al. **J Biol Chem** 1995 Oct 13;270(41):24024–31

Transcriptional regulation of alpha1,3–galactosyltransferase in embryonal carcinoma cells by retinoic acid. Masking of Lewis X antigens by alpha–galactosylation. Cho SK, et al. **J Biol Chem** 1996 Feb 9;271(6):3238–46

A carbohydrate structure associated with CD15 (Lewis x) on myeloid cells is a novel ligand for human CD2. Warren HS, et al. **J Immunol** 1996 Apr 15;156(8):2866–73

Immunohistochemical expression of sialyl Tn, sialyl Lewis a, sialyl Lewis a–b–, and sialyl Lewis x in primary tumor and metastatic lymph nodes in human gastric cancer. Ikeda Y, et al. **J Surg Oncol** 1996 Jul;62(3):171–6

PHARMACOLOGY

Leukotriene C4/D4 induces P–selectin and sialyl Lewis(x)–dependent alterations in leukocyte kinetics in vivo. Kanwar S, et al. **Circ Res** 1995 Nov;77(5):879–87

Studies on selectin blocker. 1. Structure–activity relationships of sialyl Lewis X analogs. Ohmoto H, et al. **J Med Chem** 1996 Mar 15;39(6):1339–43

PHYSIOLOGY

Carbohydrate–mediated sorting in aggregating embryonal carcinoma cells. Boubelik M, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):283–8

Sialyl Lewis X moiety on rat polymorphonuclear leukocytes responsible for binding to rat E–selectin. Misugi E, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):547–54

ANTIGENS, CD16 see **RECEPTORS, IGG**

ANTIGENS, CD18

see related
ANTIGEN P150,95
LEUKOCYTE ADHESION DEFICIENCY SYNDROME
LYMPHOCYTE FUNCTION–ASSOCIATED ANTIGEN–1
MACROPHAGE–1 ANTIGEN

Effects of CD11b/18 monoclonal antibody on rats with permanent middle cerebral artery occlusion. Garcia JH, et al. **Am J Pathol** 1996 Jan;148(1):241–8

ANALYSIS

Canine cutaneous histiocytoma is an epidermotropic Langerhans cell histiocytosis that expresses CD1 and specific beta 2–integrin molecules. Moore PF, et al. **Am J Pathol** 1996 May;148(5):1699–708

Radiographic and immunohistochemical analysis of leukocyte adhesion deficiency in Holstein heifers. Nagahata H, et al. **Can J Vet Res** 1995 Oct;59(4):316–8

Effect of adenosine on the expression of beta(2) integrins and L–selectin of human polymorphonuclear leukocytes in vitro. Thiel M, et al. **J Leukoc Biol** 1996 May; 59(5):671–82

BIOSYNTHESIS

Intramammary defense against infections induced by Escherichia coli in cows. Paape MJ, et al. **Am J Vet Res** 1996 Apr;57(4):477–82

Hydrogen peroxide and superoxide modulate leukocyte adhesion molecule expression and leukocyte endothelial adhesion. Fraticelli A, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):251–9

Effect of tumor necrosis factor–induced integrin activation on Fc gamma receptor II–mediated signal transduction: relevance for activation of neutrophils by anti–proteinase 3 or anti–myeloperoxidase antibodies. Reumaux D, et al. **Blood** 1995 Oct 15;86(8):3189–95

Activated human platelets express beta2 integrin. Philippeaux MM, et al. **Eur J Haematol** 1996 Mar;56(3):130–7

Transient endotoxemia during burn wound revision causes leukocyte beta 2 integrin up–regulation and cytokine release. Ljunghusen O, et al. **Inflammation** 1995 Aug; 19(4):457–68

Adaptation to eccentric exercise: effect on CD64 and CD11b/CD18 expression. Pizza FX, et al. **J Appl Physiol** 1996 Jan;80(1):47–55

BLOOD

Expression of neutrophil and monocyte CD11B/CD18 adhesion molecules at different sites of the coronary tree in unstable angina pectoris. de Servi S, et al. **Am J Cardiol** 1996 Sep 1;78(5):564–8

Measurement of CD11/CD18 integrin expression on the polymorphonuclear cell surface after incubation with synthetic vascular prostheses. Jakubiec B, et al. **ASAIO J** 1994 Jul–Sep;40(3):M616–8

The red cell LW blood group protein is an intercellular adhesion molecule which binds to CD11/CD18 leukocyte integrins. Bailly P, et al. **Eur J Immunol** 1995 Dec; 25(12):3316–20

Cell adhesion molecules CD11a and CD18 in blood monocytes in old age and the consequences for immunological dysfunction. Preliminary results. Chiricolo M, et al. **Gerontology** 1995;41(4):227–34

Modulation of CD11b/CD18 on monocytes and granulocytes following hemodialysis membrane interaction in vitro. Thylén P, et al. **Int J Artif Organs** 1996 Mar;19(3):156–63

Effects of trauma on leukocyte intercellular adhesion molecule–1, CD11b, and CD18 expressions. Scannell G, et al. **J Trauma** 1995 Oct;39(4):641–4

CHEMISTRY

Biochemical and phenotypic characterization of the ovine beta 2 (leucocyte) integrins. Gupta VK, et al. **J Comp Pathol** 1995 May;112(4):339–49

DRUG EFFECTS

Chemotactic factors stimulate CD18–dependent canine neutrophil adherence and motility on lung fibroblasts. Burns AR, et al. **J Immunol** 1996 May 1;156(9):3389–401

A natural glycoprotein inhibitor (NIF) of CD11b/CD18 reduces leukocyte adhesion in the liver after hemorrhagic shock. Bauer C, et al. **Shock** 1995 Sep;4(3):187–92

GENETICS

Simultaneous analysis of bovine kappa–casein and BLAD alleles by multiplex PCR followed by parallel digestion with two restriction enzymes. Zsolnai A, et al. **Anim Genet** 1996 Jun;27(3):207–9

Human leukocyte integrin CD18 promoter directs low levels of expression of a mutated human CD4 reporter gene in leukocytes of transgenic mice. Kwiatkowski BA, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):601–6

Retroviral–mediated gene transfer in human bone marrow cells growth in continuous perfusion culture vessels. Eipers PG, et al. **Blood** 1995 Nov 15;86(10):3754–62

Retroviral–mediated gene expression in human myelomonocytic cells: a comparison of hematopoietic cell promoters to viral promoters. Malik P, et al. **Blood** 1995 Oct 15;86(8):2993–3005

GABP and PU.1 compete for binding, yet cooperate to increase CD18 (beta 2 leukocyte integrin) transcription. Rosmarin AG, et al. **J Biol Chem** 1995 Oct 6; 270(40):23627–33

Recognition of leukochimerism during genotyping for bovine leukocyte adhesion deficiency (BLAD) by polymerase–chain–reaction–amplified DNA extracted from blood. Ryncarz RE, et al. **J Vet Diagn Invest** 1995 Oct; 7(4):569–72

IMMUNOLOGY

Anti–CD18 antibody does not block ileal injury induced by phorbol myristate acetate. Overdahl MC, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1331–6

CD18–independent mechanism of neutrophil emigration in the rabbit lung after ischemia–reperfusion. Thomas DD, et al. **Ann Thorac Surg** 1995 Nov;60(5):1360–6

Effect of tumor necrosis factor–induced integrin activation on Fc gamma receptor II–mediated signal transduction: relevance for activation of neutrophils by anti–proteinase 3 or anti–myeloperoxidase antibodies. Reumaux D, et al. **Blood** 1995 Oct 15;86(8):3189–95

Molecular characterization of antigenic polymorphisms (Ond(a) and Mart(a)) of the beta 2 family recognized by human leukocyte alloantisera. Simsek S, et al. **Blood** 1996 Aug 15;88(4):1350–8

Effects of low dose intra–arterial monoclonal antibodies to ICAM–1 and CD11/CD18 on local and systemic consequences of ischaemia–reperfusion injury in skeletal muscle. Breidahl AF, et al. **Br J Plast Surg** 1996 Jun; 49(4):202–9

Postischemic treatment (2–4 h) with anti–CD11b and anti–CD18 monoclonal antibodies are neuroprotective after transient (2 h) focal cerebral ischemia in the rat. Zhang ZG, et al. **Brain Res** 1995 Nov 6;698(1–2):79–85

KIM127, an antibody that promotes adhesion, maps to a region of CD18 that includes cysteine–rich repeats. Stephens P, et al. **Cell Adhes Commun** 1995 Dec;3(5):375–84

Lymphocytes utilize CD11b/CD18 for adhesion to Candida albicans. Forsyth CB, et al. **Cell Immunol** 1996 May 25; 170(1):91–100

Neutrophil sequestration and pulmonary dysfunction in a canine model of open heart surgery with cardiopulmonary bypass. Evidence for a CD18–dependent mechanism. Dreyer WJ, et al. **Circulation** 1995 Oct 15;92(8):2276–83

Polymorphonuclear leucocyte migration through human dermal fibroblast monolayers is dependent on both beta 2–integrin (CD11/CD18) and beta 1–integrin (CD29) mechanisms. Gao JX, et al. **Immunology** 1995 Jul; 85(3):485–94

Prevention of endotoxin shock by an antibody against leukocyte integrin beta 2 through inhibiting production and action of TNF. Watanabe S, et al. **Int Immunol** 1995 Jul; 7(7):1037–46

An anti–CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48–hour reperfusion. Arai M, et al. **J Am Coll Cardiol** 1996 Apr; 27(5):1278–85

Biochemical and phenotypic characterization of the ovine beta 2 (leucocyte) integrins. Gupta VK, et al. **J Comp Pathol** 1995 May;112(4):339–49

LFA–1–deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. Schmits R, et al. **J Exp Med** 1996 Apr 1;183(4):1415–26

CD18 antibody treatment limits early myocardial reperfusion injury after initial leukocyte deposition. McDonagh PF, et al. **J Surg Res** 1996 Aug;64(2):139–49

Anti–CD 18 monoclonal antibody slows experimental aortic aneurysm expansion. Ricci MA, et al. **J Vasc Surg** 1996 Feb;23(2):301–7

Leukocyte CD18 receptors may be a better target than ICAM–1 ligands for reducing histologic evidence of cellular and vascular rejection in the rabbit. Sadahiro M, et al. **Transpl Int** 1995;8(6):452–8

METABOLISM

Expansion of CD11abright cells in CD8+CD45RA+ from HIV–infected patients: a new early marker for disease progression? Scala E, et al. **AIDS Res Hum Retroviruses** 1995 Nov;11(11):1327–33

Deformability and CD11/CD18 expression of sequestered neutrophils in normal and inflamed lungs. Brown DM, et al. **Am J Respir Cell Mol Biol** 1995 Nov;13(5):531–9

Ca2+ signalling mechanisms of the beta 2 integrin on neutrophils: involvement of phospholipase C gamma 2 and Ins(1,4,5)P3. Hellberg C, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):403–9

Investigation of the complement receptor 3 (CD11b/CD18) in human rectal epithelium. Hussain LA, et al. **Clin Exp Immunol** 1995 Nov;102(2):384–8

LFA–1 subunit expression in ulcerative colitis patients. Kirman I, et al. **Dig Dis Sci** 1996 Apr;41(4):670–6

Expression of beta–2–integrins and L–selectin by leukocytes and changes in acute–phase reactants in total hip replacement surgery. Høgevold HE, et al. **Eur Surg Res** 1996;28(3):190–200

The C–C chemokine MCP–1 differentially modulates the avidity of beta 1 and beta 2 integrins on T lymphocytes. Carr MW, et al. **Immunity** 1996 Feb;4(2):179–87

A novel leukointegrin, alpha d beta 2, binds preferentially to ICAM–3. Van der Vieren M, et al. **Immunity** 1995 Dec; 3(6):683–90

Identification of haptoglobin as an alternative ligand for CD11b/CD18. El Ghmati SM, et al. **J Immunol** 1996 Apr 1;156(7):2542–52

Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. Huang S, et al. **J Virol** 1996 Jul; 70(7):4502–8

Study of CD11a/CD18 expression and mRNA synthesis in human polymorphonuclear cells. Scavuzzo M, et al.

Transplant Proc 1995 Dec;27(6):3557-8
[Effect of adhesiveness of white blood cells on pulmonary vascular permeability and resistance] Tanita T, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1995 Aug; 33(8):868-72 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Soluble intercellular adhesion molecule-1 provokes polymorphonuclear leukocyte elastase release by CD18. Barnett CC, et al. **Surgery** 1996 Aug;120(2):395-401; discussion 401-2

PHYSIOLOGY

Role of CD 11/CD 18 in neutrophil emigration during acute and recurrent Pseudomonas aeruginosa-induced pneumonia in rabbits. Kumasaka T, et al. **Am J Pathol** 1996 Apr;148(4):1297-305

Inhibitors of farnesyl and geranylgeranyl methyltransferases prevent beta 2 integrin-induced actin polymerization without affecting beta 2 integrin-induced Ca2+ signaling in neutrophils. Molony L, et al.
Biochem Biophys Res Commun 1996 Jun 25;223(3):612-7

Integrin triggered Ca2+ signalling in human neutrophils. Pettit EJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):70S

Superoxide and hydrogen peroxide induce CD18-mediated adhesion in the postischemic heart. Serrano CV Jr, et al. **Biochim Biophys Acta** 1996 Aug 23;1316(3):191-202

Beta 2-integrin (CD11b/CD18) is the primary adhesive glycoprotein complex involved in neutrophil-mediated immune injury to human sperm. D'Cruz OJ, et al.
Biol Reprod 1995 Nov;53(5):1118-30

Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Diacovo TG, et al. **Blood** 1996 Jul 1;88(1):146-57

Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. Kuijper PH, et al. **Blood** 1996 Apr 15;87(8):3271-81

Continuous activation and deactivation of integrin CD11b/CD18 during de novo expression enables rolling neutrophils to immobilize on platelets. Sheikh S, et al. **Blood** 1996 Jun 15;87(12):5040-50

Target cell-induced apoptosis of interleukin-2-activated human natural killer cells: roles of cell surface molecules and intracellular events. Yamauchi A, et al. **Blood** 1996 Jun 15;87(12):5127-35

Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Gamero AM, et al.
Cancer Res 1995 Nov 1;55(21):4988-94

CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Pellat-Deceunynck C, et al. **Cancer Res** 1996 Apr 15; 56(8):1909-16

Mononuclear leukocytes invade rabbit arterial intima during thickening formation via CD18-and VLA-4-dependent mechanisms and stimulate smooth muscle migration. Kling D, et al. **Circ Res** 1995 Dec;77(6):1121-8

Beta2 integrins and ICAM-1 are involved in establishment of the intestinal mucosal T cell compartment. Huleatt JW, et al. **Immunity** 1996 Sep;5(3):263-73

Prevention of endotoxin-induced acute lethality in Propionibacterium acnes-primed rabbits by an antibody to leukocyte integrin beta 2 with concomitant reduction of cytokine production. Ikeda N, et al. **Infect Immun** 1995 Dec;63(12):4812-7

Genomic cloning, characterization, and functional analysis of the major surface adhesin WI-1 on Blastomyces dermatitidis yeasts. Hogan LH, et al. **J Biol Chem** 1995 Dec 22;270(51):30725-32

Role of MacMARCKS in integrin-dependent macrophage spreading and tyrosine phosphorylation of paxillin. Li J, et al. **J Biol Chem** 1996 May 31;271(22):12985-90

Anti-CD18 attenuates deleterious effects of cardiopulmonary bypass and hypothermic circulatory arrest in piglets. Aoki M, et al. **J Card Surg** 1995 Jul;10(4 Suppl):407-17

The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. Sitrin RG, et al. **J Clin Invest** 1996 Apr 15;97(8):1942-51

Chemotactic factors stimulate CD18-dependent canine neutrophil adherence and motility on lung fibroblasts. Burns AR, et al. **J Immunol** 1996 May 1;156(9):3389-401

Respiratory syncytial virus infection enhances neutrophil and eosinophil adhesion to cultured respiratory epithelial cells. Roles of CD18 and intercellular adhesion molecule-1. Stark JM, et al. **J Immunol** 1996 Jun 15;156(12):4774-82

Cross-linking of CD18 primes human neutrophils for activation of the respiratory burst in response to specific stimuli: implications for adhesion-dependent physiological responses in neutrophils. Liles WC, et al.
J Leukoc Biol 1995 Dec;58(6):690-7

Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/action through beta2 integrin in vivo. Mukaida N, et al. **J Leukoc Biol** 1996 Feb;59(2):145-51 (42 ref.)

The role of CD11/CD18 integrins in the reverse passive Arthus reaction in rat dermal tissue. Rote WE, et al. **J Leukoc Biol** 1996 Feb;59(2):254-61

Beta2 integrins mediate protein tyrosine phosphorylation in human neutrophils. Walzog B, et al. **J Leukoc Biol** 1996 May;59(5):747-53

The biologic role of B2 integrins in the host response to expanded polytetrafluoroethylene. Benton LD, et al.
J Surg Res 1996 Aug;64(2):116-9

Inhibition of selectin- and integrin-mediated inflammatory response after burn injury. Nwariaku F, et al.
J Surg Res 1996 Jun;63(1):355-8

Tumor necrosis factor-alpha augments the pro-inflammatory interaction between PMN and GBM via a CD18 dependent mechanism. Donovan KL, et al. **Kidney Int** 1995 Sep; 48(3):698-704

A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice. Bullard DC, et al.
Proc Natl Acad Sci U S A 1996 Mar 5;93(5):2116-21

Antibody to CD18 reduces neutrophil and T lymphocyte infiltration and vascular cell adhesion molecule-1 expression in cardiac rejection. Akimoto H, et al.
Transplantation 1996 Jun 15;61(11):1610-7

ANTIGENS, CD19

ANALYSIS

Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients. Macintyre EA, et al. **Blood** 1995 Dec 15;86(12):4691-8

Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis. McSweeney PA, et al. **Blood** 1996 Jul 15;88(2):622-32

99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphoma. Vervoordeldonk SF, et al. **Cancer Immunol Immunother** 1996 Jun;42(5):291-6

A subpopulation of B220+ cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors. Rolink A, et al. **J Exp Med** 1996 Jan 1; 183(1):187-94

BLOOD

Reciprocal alteration in circulating TJ6+ CD19+ and TJ6+ CD56+ leukocytes in early pregnancy predicts success or miscarriage. Coulam CB, et al. **Am J Reprod Immunol** 1995 Oct;34(4):219-24

Circulating CD19+ blood cell levels in myeloma. ECOG Myeloma Clinical Trials Laboratory Study Group [letter] Kay NE, et al. **Blood** 1995 Nov 15;86(10):4000-1

IMMUNOLOGY

A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Stone MJ, et al. **Blood** 1996 Aug 15; 88(4):1188-97

Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies. De Gast GC, et al.
J Hematother 1995 Oct;4(5):433-7

Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration. Conry RM, et al.
J Immunother Emphasis Tumor Immunol 1995 Nov; 18(4):231-41

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5-6):381-93 (160 ref.)

Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains. Haagen IA, et al.
Ther Immunol 1994 Oct;1(5):279-87

METABOLISM

Immunoglobulin recombinase gene activity is modulated reciprocally by interleukin 7 and CD19 in B cell progenitors. Billips LG, et al. **J Exp Med** 1995 Oct 1; 182(4):973-82

The signaling activity of murine CD19 is regulated during cell development. Krop I, et al. **J Immunol** 1996 Jul 1; 157(1):48-56

CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Scheuermann RH, et al.
Leuk Lymphoma 1995 Aug;18(5-6):385-97 (94 ref.)

Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bcl-2-independent regulator of apoptosis in human B-lineage lymphoma cells. Myers DE, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9575-9

The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Sato S, et al.
Proc Natl Acad Sci U S A 1995 Dec 5;92(25):11558-62

PHYSIOLOGY

Self-renewal of B-1 lymphocytes is dependent on CD19. Krop I, et al. **Eur J Immunol** 1996 Jan;26(1):238-42

Signal transduction through the beta1 integrin family surface adhesion molecules VLA-4 and VLA-5 of human B-cell precursors activates CD19 receptor-associated protein-tyrosine kinases. Xiao J, et al. **J Biol Chem** 1996 Mar 29;271(13):7659-64

Engaging CD19 or target of an antiproliferative antibody 1 on human B lymphocytes induces binding of B cells to the interfollicular stroma of human tonsils via integrin alpha 4/beta 1 and fibronectin. Behr S, et al. **J Exp Med** 1995 Nov 1;182(5):1191-9

ANTIGENS, CD20

ANALYSIS

CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Algino KM, et al.
Am J Clin Pathol 1996 Jul;106(1):78-81

Recurrent miscarriage is associated with increased numbers of CD5/20 positive lymphocytes and an increased incidence of thyroid antibodies. Roberts J, et al.
Eur J Endocrinol 1996 Jan;134(1):84-6

BLOOD

Circulating CD20dim T-lymphocytes increase with age: evidence for a memory cytotoxic phenotype. Storie I, et al. **Clin Lab Haematol** 1995 Dec;17(4):323-8

IMMUNOLOGY

CD20 and CD40 mediated mitogenic responses in B-lineage acute lymphoblastic leukaemia. Smiers FJ, et al.
Br J Haematol 1996 Apr;93(1):125-30

METABOLISM

Engagement of CD20 suppresses apoptosis in germinal center B cells. Holder M, et al. **Eur J Immunol** 1995 Nov; 25(11):3160-4

ANTIGENS, CD21 see **RECEPTORS, COMPLEMENT 3D**

ANTIGENS, CD23 see **RECEPTORS, IGE**

ANTIGENS, CD25 see **RECEPTORS, INTERLEUKIN-2**

ANTIGENS, CD26

ANALYSIS

Staining for dipeptidyl aminopeptidase IV activity in nodular thyroid diseases. Iwabuchi H, et al. **Acta Cytol** 1996 Mar-Apr;40(2):158-63

Mitogenic stimulation of human lymphocytes mediated by a cell surface elastase. Packard BZ, et al.
Biochim Biophys Acta 1995 Oct 19;1269(1):51-6

CD26 and CD31 surface antigen expression on human colostral T cells. Bertotto A, et al. **Biol Neonate** 1995; 68(4):259-63

CD40: a sensitive marker of Reed-Sternberg cells [letter] Carbone A, et al. **Blood** 1996 Jun 1;87(11):4918-9

Rapid isolation of endosomes from BHK cells: identification of DPP IV (CD26) in endosomes. Horstkorte R, et al.
Exp Cell Res 1996 Aug 1;226(2):398-401

An update on the diagnostic relevance of CD26 antigen expression in CD30 positive anaplastic large cell lymphomas [letter] Carbone A, et al. **Hum Pathol** 1995 Oct; 26(10):1169-70

CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma. Tanaka T, et al. **Int J Cancer** 1995 Oct 20;64(5):326-31

Aminopeptidase M and dipeptidyl peptidase IV activity in epithelial skin tumors: a histochemical study. Moehrle MC, et al. **J Cutan Pathol** 1995 Jun;22(3):241-7

[CD26/dipeptidyl peptidase IV and thyroid peroxidase as molecular markers for differentiated thyroid carcinoma] Umeki K, et al. **Rinsho Byori** 1996 Jan;44(1):42-50 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Carbone A, et al. **Blood** 1995 Dec 15;86(12):4617-26

Demonstration of differentiation in hepatocyte progenitor cells using dipeptidyl peptidase IV deficient mutant rats. Sigal SH, et al. **Cell Mol Biol Res** 1995;41(1):39-47

Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. Duke-Cohan JS, et al. **J Immunol** 1996 Mar 1;156(5):1714-21

Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. Martin M, et al. **J Immunol** 1995 Nov 15;155(10):4630-43

CD26 expression in leprosy and other granulomatous diseases correlates with the production of interferon-gamma. Scheel-Toellner D, et al. **Lab Invest** 1995 Nov;73(5):685-90

BLOOD

[Dipeptidyl-peptidase IV of human lymphocytes in patients with primary biliary cirrhosis and UDCA therapy] Kürktschiev D, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:104-5 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Alterations in structure and cellular localization of molecular forms of DP IV/CD26 during T cell activation. Kähne T, et al. **Cell Immunol** 1996 May 25;170(1):63-70

THE PAPER AND INK USED IN THE ORIGINAL PUBLICATION MAY AFFECT THE QUALITY OF THE MICROFORM EDITION

A model of the active site of dipeptidyl peptidase IV predicted by comparative molecular field analysis and molecular modelling simulations. Brandt W, et al. **Int J Pept Protein Res** 1995 Dec;46(6):494–507

Characterization of molecular aggregates of alpha 1 beta 1–integrin and other rat liver membrane proteins by combination of size–exclusion chromatography and chemical cross–linking. Löster K, et al. **J Chromatogr A** 1995 Sep 8;711(1):187–99

DRUG EFFECTS

Dipeptide–derived diphenyl phosphonate esters: mechanism–based inhibitors of dipeptidyl peptidase IV. Lambeir AM, et al. **Biochim Biophys Acta** 1996 May 21; 1290(1):76–82

Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti–inflammatory drug diclofenac. Hargus SJ, et al. **Chem Res Toxicol** 1995 Dec; 8(8):993–6

GENETICS

Human dipeptidyl peptidase IV gene promoter: tissue–specific regulation from a TATA–less GC–rich sequence characteristic of a housekeeping gene promoter. Böhm SK, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):835–43

Expression of CD26/dipeptidyl peptidase IV in adult T cell leukemia/lymphoma (ATLL). Kondo S, et al. **Leuk Res** 1996 Apr;20(4):357–63

An X–prolyl dipeptidyl aminopeptidase (pepX) gene from Lactobacillus helveticus. Vesanto E, et al. **Microbiology** 1995 Dec;14i (Pt 12):3067–75

IMMUNOLOGY

Inhibition of dipeptidyl peptidase IV (DP IV) by anti–DP IV antibodies and non–substrate X–X–Pro– oligopeptides ascertained by capillary electrophoresis. Hoffmann T, et al. **J Chromatogr A** 1995 Nov 17;716(1–2):355–62

A longitudinal study of the T cell activation marker CD26 in chronic progressive multiple sclerosis. Constantinescu CS, et al. **J Neurol Sci** 1995 Jun;130(2):178–82

ISOLATION & PURIFICATION

Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26/dipeptidyl peptidase IV (EC 3.4.14.5). de Meester I, et al. **J Immunol Methods** 1996 Jan 16;189(1):99–105

METABOLISM

Desialylation of rat intraepithelial lymphocytes: effects on proliferation and dipeptidyl peptidase IV activity. Boyaka PN, et al. **Adv Exp Med Biol** 1995;371A:133–6

Aminoacylpyrrolidine–2–nitriles: potent and stable inhibitors of dipeptidyl–peptidase IV (CD 26). Li J, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):148–54

Reduced cell surface expression of a mutated dipeptidyl peptidase IV (DPP IV/CD26) correlates with the generation of a beta strand in its C–terminal domain. David F, et al. **Biochem Biophys Res Commun** 1996 May 24; 222(3):833–8

The cysteine–rich region of dipeptidyl peptidase IV (CD 26) is the collagen–binding site. Löster K, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):341–8

Keratinocytes express dipeptidyl–peptidase IV (CD26) in benign and malignant skin diseases. Novelli M, et al. **Br J Dermatol** 1996 Jun;134(6):1052–6

Alterations in structure and cellular localization of molecular forms of DP IV/CD26 during T cell activation. Kähne T, et al. **Cell Immunol** 1996 May 25;170(1):63–70

A new mechanism in serine proteases catalysis exhibited by dipeptidyl peptidase IV (DP IV)––Results of PM3 semiempirical thermodynamic studies supported by experimental results. Brandt W, et al. **Eur J Biochem** 1996 Feb 15;236(1):109–14

Dipeptidyl–peptidase IV–beta, a novel form of cell–surface–expressed protein with dipeptidyl–peptidase IV activity. Jacotot E, et al. **Eur J Biochem** 1996 Jul 15; 239(2):248–58

Specific binding of adenosine deaminase but not HIV–1 transactivator protein Tat to human CD26. Blanco J, et al. **Exp Cell Res** 1996 May 25;225(1):102–11

Studies of liver repopulation using the dipeptidyl peptidase IV–deficient rat and other rodent recipients: cell size and structure relationships regulate capacity for increased transplanted hepatocyte mass in the liver lobule. Rajvanshi P, et al. **Hepatology** 1996 Mar;23(3):482–96

Enzymatic activity of DPIV/CD26 is involved in PMA–induced hyperphosphorylation of p56lck. Kähne T, et al. **Immunol Lett** 1995 May;46(1–2):189–93

Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. Mentzel S, et al. **J Histochem Cytochem** 1996 May;44(5):445–61

Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. Dong RP, et al. **J Immunol** 1996 Feb 15;156(4):1349–55

HIV and CD26 [comment] Dalgleish A. **Nat Med** 1995 Sep; 1(9):881–2 (20 ref.). Comment on: Nat Med 1995 Sep;1(9):919–26.

PHARMACOLOGY

Potentiation of the immune response in HIV–1+ individuals. Schmitz T, et al. **J Clin Invest** 1996 Mar 15;97(6):1545–9

The involvement of dipeptidyl peptidase IV in brush–border degradation of GRF(1–29)NH2 by intestinal mucosal cells. Bai JP, et al. **J Pharm Pharmacol** 1995 Aug;47(8):698–701

PHYSIOLOGY

CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis. Gerli R, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):31–7

Lu–ECAM–1 and DPP IV in lung metastasis. Elble RC, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):107–22 (77 ref.)

Immunoadsorption of hepatic vesicles carrying newly synthesized dipeptidyl peptidase IV and polymeric IgA receptor. Barr VA, et al. **J Biol Chem** 1995 Nov 17; 270(46):27834–44

CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV–1 strains in a T–cell line [see comments] Oravecz T, et al. **Nat Med** 1995 Sep; 1(9):919–26. Comment in: Nat Med 1995 Sep;1(9):881–2.

URINE

Diagnostic significance of urinary enzymes for diabetes mellitus and hypertension. Ishii N, et al. **Enzyme Protein** 1994–95;48(3):174–82

Urinary excretion of adenosine deaminase binding protein in neonates treated with tobramycin. Gordjani N, et al. **Pediatr Nephrol** 1995 Aug;9(4):419–22

ANTIGENS, CD27

ANALYSIS

Enrichment of differentiated CD45RBdim,CD27– memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Kohem CL, et al. **Arthritis Rheum** 1996 May;39(5):844–54

Expression of the T–cell activation antigens CD27 and CD28 in normal and psoriatic skin. De Rie MA, et al. **Clin Exp Dermatol** 1996 Mar;21(2):104–11

Differential expression of cytokine genes in CD27–positive and –negative CD4 lymphocyte subsets from healthy humans and rheumatoid arthritis patients. Stonāns I, et al. **Rheumatol Int** 1996;15(6):249–54

BIOSYNTHESIS

Expression of the activation antigen CD27 in rheumatoid arthritis. Tak PP, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):129–38

OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. al–Shamkhani A, et al. **Eur J Immunol** 1996 Aug; 26(8):1695–9

Induction of OX40, a receptor of gp34, on T cells by trans–acting transcriptional activator, Tax, of human T–cell leukemia virus type I. Higashimura N, et al. **Jpn J Cancer Res** 1996 Mar;87(3):227–31

Enhanced T lymphocyte expression of LFA–1, ICAM–1, and the TNF receptor family member OX40 in HgCl2–induced systemic autoimmunity. Roos A, et al. **Scand J Immunol** 1996 May;43(5):507–18

CEREBROSPINAL FLUID

Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Kersten MJ, et al. **Blood** 1996 Mar 1; 87(5):1985–9

IMMUNOLOGY

CD27/CD70 interaction directly drives B cell IgG and IgM synthesis. Agematsu K, et al. **Eur J Immunol** 1995 Oct; 25(10):2825–9

Novel mAbs reveal potent co–stimulatory activity of murine CD27. Gravestein LA, et al. **Int Immunol** 1995 Apr; 7(4):551–7

The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. Imura A, et al. **J Exp Med** 1996 May 1;183(5):2185–95

Selective depletion of myelin–reactive T cells with the anti–OX–40 antibody ameliorates autoimmune encephalomyelitis. Weinberg AD, et al. **Nat Med** 1996 Feb; 2(2):183–9

METABOLISM

OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. al–Shamkhani A, et al. **Eur J Immunol** 1996 Aug; 26(8):1695–9

PHYSIOLOGY

CD27 cooperates with the pre–T cell receptor in the regulation of murine T cell development. Gravestein LA, et al. **J Exp Med** 1996 Aug 1;184(2):675–85

The T cell–B cell interaction via OX40–OX40L is necessary for the T cell–dependent humoral immune response. Stüber E, et al. **J Exp Med** 1996 Mar 1;183(3):979–89

CD27–CD70 interaction: unravelling its implication in normal and neoplastic B–cell growth. Lens SM, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):51–9 (78 ref.)

CD27–CD70 interactions regulate B–cell activation by T cells. Kobata T, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11249–53

ANTIGENS, CD28

see related
ANTIGENS, CD80

CD28 and apoptosis. Boise LH, et al. **Curr Opin Immunol** 1995 Oct;7(5):620–5 (49 ref.)

Activation of the IL–2 gene promoter by HTLV–I tax involves induction of NF–AT complexes bound to the CD28–responsive element. Good L, et al. **EMBO J** 1996 Jul 15;15(14):3744–50

CD4+ CD7– CD28– T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. Schmidt D, et al. **J Clin Invest** 1996 May 1;97(9):2027–37

ANALYSIS

The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Liu MF, et al. **Arthritis Rheum** 1996 Jan;39(1):110–4

Expression of the T–cell activation antigens CD27 and CD28 in normal and psoriatic skin. De Rie MA, et al. **Clin Exp Dermatol** 1996 Mar;21(2):104–11

Similarity of expression of activation markers and CD28 on gamma delta and alpha beta–receptor T cells in HIV infection. Jouen–Beades F, et al. **Clin Immunol Immunopathol** 1996 May;79(2):189–93

Strong increase in the percentage of the CD8bright+ CD28– T–cells and delayed engraftment associated with cyclosporine–induced autologous GVHD. Garin L, et al. **Eur J Haematol** 1996 Mar;56(3):119–23

Expression of both B7–1 and CD28 contributes to the IL–2 responsiveness of CTLL–2 cells. Belani R, et al. **Immunology** 1996 Feb;87(2):271–4

Functional assessment of CD2, CD3 and CD28 on the surface of peripheral blood T–cells from infants at low versus high genetic risk for atopy. Holt PG, et al. **Pediatr Allergy Immunol** 1995 May;6(2):80–4

BIOSYNTHESIS

Human immunodeficiency virus type 1 infection of CD4+ T cells down–regulates the expression of CD28: effect on T cell activation and cytokine production. Haffar OK, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):262–70

Chicken T cell coreceptors. Vainio O, et al. **Folia Biol (Praha)** 1994;40(6):497–504

Chagasic patients lack CD28 expression on many of their circulating T lymphocytes. Dutra WO, et al. **Scand J Immunol** 1996 Jan;43(1):88–93

CHEMISTRY

Chicken T cell coreceptors. Vainio O, et al. **Folia Biol (Praha)** 1994;40(6):497–504

Two distinct intracytoplasmic regions of the T–cell adhesion molecule CD28 participate in phosphatidylinositol 3–kinase association. Pagès F, et al. **J Biol Chem** 1996 Apr 19; 271(16):9403–9

GENETICS

Induction of unresponsiveness and impaired T cell expansion by staphylococcal enterotoxin B in CD28–deficient mice. Mittrücker HW, et al. **J Exp Med** 1996 Jun 1;183(6):2481–8

Protection against lethal toxic shock by targeted disruption of the CD28 gene. Saha B, et al. **J Exp Med** 1996 Jun 1;183(6):2675–80

Alloreactive gamma delta thymocytes utilize distinct costimulatory signals from peripheral T cells. Penninger JM, et al. **J Immunol** 1995 Oct 15;155(8):3847–55

Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis. Trunch A, et al. **Mol Immunol** 1996 Feb;33(3):321–34

IMMUNOLOGY

T cells from patients with Hodgkin's disease have a defective T–cell receptor zeta chain expression that is reversible by T–cell stimulation with CD3 and CD28. Renner C, et al. **Blood** 1996 Jul 1;88(1):236–41

Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T–cell subsets in a preclinical model. Renner C, et al. **Blood** 1996 Apr 1;87(7):2930–7

Selective CD4+ T cell deletion after specific activation in HIV–infected individuals; protection by anti–CD28 monoclonal antibodies. Cottrez F, et al. **Clin Exp Immunol** 1996 Jul;105(1):31–8

Costimulation and its role in organ transplantation. Bluestone JA. **Clin Transplant** 1996 Feb;10(1 Pt 2):104–9 (23 ref.)

Evidence for intact CD28 signaling in T cell hyporesponsiveness induced by the HIV–1 nef gene. Collette Y, et al. **Eur J Immunol** 1996 Aug;26(8):1788–93

Selective CD28pYMNM mutations implicate phosphatidylinositol 3–kinase in CD86–CD28–mediated costimulation. Cai YC, et al. **Immunity** 1995 Oct; 3(4):417–26

Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Miller SD, et al. **Immunity** 1995 Dec;3(6):739–45

Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies. Harada M, et al. **Immunology** 1996 Mar;87(3):447–53

B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. Johnston JV, et al. **J Exp Med** 1996 Mar 1;183(3):791–800

In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma. Demanet C, et al. **J Hematother** 1995 Oct;4(5):363–8

Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies. Renner C, et al. **J Hematother** 1995 Oct;4(5):447–51

B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors. Guerder S, et al. **J Immunol** 1995 Dec 1;155(11):5167–74

Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. Hurtado JC, et al. **J Immunol** 1995 Oct 1;155(7):3360–7

Protective immunity induced by B7/CD28-costimulated gamma delta T cells to the EL-4 lymphoma in allogenic athymic mice. Li Y, et al. **J Immunol** 1995 Dec 15; 155(12):5705–10

Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. Monteiro J, et al. **J Immunol** 1996 May 15;156(10):3587–90

Induction of tolerance in freshly isolated alloreactive T cells by activated T cell stimulators is not due to the absence of CD28-B7 interaction. Satyaraj E, et al. **J Immunol** 1995 Nov 15;155(10):4669–75

In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. Yang G, et al. **J Immunol** 1995 Oct 15;155(8):3897–903

Predominant involvement of CD8+CD28- lymphocytes in human immunodeficiency virus-specific cytotoxic activity. Fiorentino S, et al. **J Virol** 1996 Mar;70(3):2022–6

Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Larsen CP, et al. **Nature** 1996 May 30;381(6581):434–8

T cell costimulation through the CD28 receptor. Green JM, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):41–6

The critical role of CD28 signalling in the prevention of human T-cell anergy. Boussiotis VA, et al. **Res Immunol** 1995 Mar-Apr;146(3):140–9 (72 ref.)

Mechanisms of CD28 signalling. Schneider H, et al. **Res Immunol** 1995 Mar-Apr;146(3):149–54 (59 ref.)

The Yin and Yang of T cell costimulation [see comments] Allison JP, et al. **Science** 1995 Nov 10;270(5238):932–3 (17 ref.). Comment in: Science 1995 Nov 10;270(5238):985–8.

Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Levine BL, et al. **Science** 1996 Jun 28;272(5270):1939–43

Long-term survival of rat to mouse cardiac xenografts with prolonged blockade of CD28-B7 interaction combined with peritransplant T-cell depletion. Rehman A, et al. **Surgery** 1996 Aug;120(2):205–12

Rapid induction of cytolytic T cells via CD28 stimulation for cellular immunotherapy. Blum S, et al. **Ther Immunol** 1994 Jun;1(3):143–52

METABOLISM

Characterisation of a serine/threonine kinase which mediates CD28 phosphorylation following activation by B7.1. Parry RV, et al. **Biochem Soc Trans** 1996 Feb;24(1):87S

CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination. Champagne E, et al. **Eur J Immunol** 1996 Jul; 26(7):1595–602

Comparison of CD28-B7.1 and B7.2 functional interaction in resting human T cells: phosphatidylinositol 3-kinase association to CD28 and cytokine production. Ghiotto-Ragueneau M, et al. **Eur J Immunol** 1996 Jan; 26(1):34–41

Ligation of either CD2 or CD28 rescues CD4+ T cells from HIV-gp120-induced apoptosis. Tuosto L, et al. **Eur J Immunol** 1995 Oct;25(10):2917–22

CD28:B7 interactions promote T cell adhesion. Turcovski-Corrales SM, et al. **Eur J Immunol** 1995 Nov; 25(11):3087–93

Cattle CTLA-4, CD28 and chicken CD28 bind CD86: MYPPPY is not conserved in cattle CD28. Parsons KR, et al. **Immunogenetics** 1996;43(6):388–91

Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Judge TA, et al. **Immunol Res** 1996; 15(1):38–49 (34 ref.)

Nuclear appearance of a factor that binds the CD28 response element within the interleukin-2 enhancer correlates with interleukin-2 production. Civil A, et al. **J Biol Chem** 1996 Apr 5;271(14):8321–7

Functional LCK Is required for optimal CD28-mediated activation of the TEC family tyrosine kinase EMT/ITK. Gibson S, et al. **J Biol Chem** 1996 Mar 22;271(12):7079–83

Differential phosphorylation of the T lymphocyte costimulatory receptor CD28. Activation-dependent changes and regulation by protein kinase C. Hutchcroft JE, et al. **J Biol Chem** 1996 Jun 7;271(23):13362–70

Two distinct intracytoplasmic regions of the T-cell adhesion molecule CD28 participate in phosphatidylinositol 3-kinase association. Pagès F, et al. **J Biol Chem** 1996 Apr 19; 271(16):9403–9

TCR-independent activation of human CD4+ 45RO- T cells by anti-CD28 plus IL-2: Induction of clonal expansion and priming for a Th2 phenotype. Brinkmann V, et al. **J Immunol** 1996 Jun 1;156(11):4100–6

Interactions of CD80 and CD86 with CD28 and CTLA4. Ellis JH, et al. **J Immunol** 1996 Apr 15;156(8):2700–9

Signaling through CD28/CTLA-4 family receptors: puzzling participation of phosphatidylinositol-3 kinase. Hutchcroft JE, et al. **J Immunol** 1996 Jun 1;156(11):4071–4 (69 ref.)

Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function. Kariv I, et al. **J Immunol** 1996 Jul 1;157(1):29–38

CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. Khoury SJ, et al. **J Immunol** 1995 Nov 15;155(10):4521–4

CD28 delivers costimulatory signals independently of its association with phosphatidylinositol 3-kinase. Truitt KE, et al. **J Immunol** 1995 Nov 15;155(10):4702–10

CD28 expression is not essential for positive and negative selection of thymocytes or peripheral T cell tolerance. Walunas TL, et al. **J Immunol** 1996 Feb 1;156(3):1006–13

CD28-mediated up-regulation of beta 1-integrin adhesion involves phosphatidylinositol 3-kinase. Zell T, et al. **J Immunol** 1996 Feb 1;156(3):883–6

Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Rossi E, et al. **Leukemia** 1996 Mar;10(3):494–7

Phorbol ester treatment inhibits phosphatidylinositol 3-kinase activation by, and association with, CD28, a T-lymphocyte surface receptor. Hutchcroft JE, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8808–12

Signalling intermediates of CD28. Ben-Neriah Y, et al. **Res Immunol** 1995 Mar-Apr;146(3):154–8 (28 ref.)

CD28 costimulation regulates long-term expression of the three genes (alpha, beta, gamma) encoding the high-affinity IL2 receptor. Cerdan C, et al. **Res Immunol** 1995 Mar-Apr; 146(3):164–8 (43 ref.)

The role of CD28 in the activation of T lymphocytes to proliferate in response to IL4. Chiodetti L, et al. **Res Immunol** 1995 Mar-Apr;146(3):169–71 (23 ref.)

Regulation of IL2 gene transcription via the T-cell accessory molecule CD28. Civil A, et al. **Res Immunol** 1995 Mar-Apr; 146(3):158–64 (19 ref.)

Blocking CD28/B7 with soluble competitors: immunological phenotype of mCTLA4-H gamma 1 transgenic mice. Lane P. **Res Immunol** 1995 Mar-Apr;146(3):176–9 (30 ref.)

CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation. Linsley PS, et al. **Res Immunol** 1995 Mar-Apr;146(3):130–40 (78 ref.)

CD28 and T-cell activation. Olive D, et al. **Res Immunol** 1995 Mar-Apr;146(3):127–9

T-cell costimulation via CD28-CD80/CD86 and CD40-CD40 ligand interactions. Somoza C, et al. **Res Immunol** 1995 Mar-Apr;146(3):171–6 (50 ref.)

CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Yang Y, et al. **Science** 1996 Sep 27;273(5283):1862–4

Activation of extracellular signal-regulated protein kinase (ERK/MAP kinase) following CD28 cross-linking: activation in cells lacking p56lck. August A, et al. **Tissue Antigens** 1995 Sep;46(3 (Pt 1)):155–62

Skin allograft rejection in CD28-deficient mice. Kawai K, et al. **Transplantation** 1996 Feb 15;61(3):352–5

PHARMACOLOGY

Can co-stimulated tumor immunity be therapeutically efficacious? Hellström KE, et al. **Immunol Rev** 1995 Jun; 145:123–45 (110 ref.)

Pharmacological inhibition of CD28-stimulated T cell activation. Wancio D, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S203–4

CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. Radvanyi LG, et al. **J Immunol** 1996 Mar 1;156(5):1788–98

CD28-mediated up-regulation of beta 1-integrin adhesion involves phosphatidylinositol 3-kinase. Zell T, et al. **J Immunol** 1996 Feb 1;156(3):883–6

T helper-independent activation of human CD8+ cells: the role of CD28 costimulation. Van Gool SW, et al. **Scand J Immunol** 1996 Jul;44(1):21–9

PHYSIOLOGY

Costimulation of CD4+ T cells via CD28 modulates human immunodeficiency virus type 1 infection and replication in vitro. Smithgall MD, et al. **AIDS Res Hum Retroviruses** 1995 Aug;11(8):885–92

Mechanisms of enhanced nuclear translocation of the transcription factors c-Rel and NF-kappa B by CD28 costimulation in human T lymphocytes. Lai JH, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:220–3

Involvement of phosphatidylinositol 3-kinase in the activation of p70 S6 kinase by the T cell costimulatory molecule CD28. Parry RV, et al. **Biochem Soc Trans** 1996 Feb;24(1):88S

Phosphoinositide 3-kinase and CD28-mediated T-cell co-stimulation. Ward SG. **Biochem Soc Trans** 1996 Feb; 24(1):240–5 (50 ref.)

Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Gribben JG, et al. **Blood** 1996 Jun 1; 87(11):4887–93

Critical role of CD28/B7 costimulation in the development of human Th2 cytokine-producing cells. Webb LM, et al. **Blood** 1995 Nov 1;86(9):3479–86

An age-related decrease in rescue from T cell death following costimulation mediated by CD28. Engwerda CR, et al. **Cell Immunol** 1996 May 25;170(1):141–8

Reversal of the inhibitory effects of HIV-gp120 on CD4+ T cells by stimulation through the CD28 pathway. Faith A, et al. **Clin Exp Immunol** 1996 Aug;105(2):225–30

Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients. García-Cózar FJ, et al. **Clin Exp Immunol** 1996 Apr;104(1):72–9

Signalling via CD28 of human naive neonatal T lymphocytes. Hassan J, et al. **Clin Exp Immunol** 1995 Oct;102(1):192–8

Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand-dependent mechanism: CTLA4-Ig protects V beta 8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B. Lane P, et al. **Eur J Immunol** 1996 Apr;26(4):858–62

CD28-dependent killing by human YT cells requires phosphatidylinositol 3-kinase activation. Lu Y, et al. **Eur J Immunol** 1996 Jun;26(6):1278–84

CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Lenschow DJ, et al. **Immunity** 1996 Sep;5(3):285–93

Upstream-downstream: CD28 cosignaling pathways and T cell function. Rudd CE. **Immunity** 1996 Jun;4(6):527–34 (71 ref.)

T-Cell co-stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor. Chaux P, et al. **Int J Cancer** 1996 Apr 10;66(2):244–8

Signal transduction by CD28 costimulatory receptor on T cells. B7-1 and B7-2 regulation of tyrosine kinase adaptor molecules. Nunès JA, et al. **J Biol Chem** 1996 Jan 19; 271(3):1591–8

A pathway of costimulation that prevents anergy in CD28-T cells: B7-independent costimulation of CD1-restricted T cells. Behar SM, et al. **J Exp Med** 1995 Dec 1; 182(6):2007–18

The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells. Griggs ND, et al. **J Exp Med** 1996 Mar 1;183(3):801–10

CTLA-4 ligation blocks CD28-dependent T cell activation. Walunas TL, et al. **J Exp Med** 1996 Jun 1;183(6):2541–50

Induction of autoimmunity in the absence of CD28 costimulation. Bachmaier K, et al. **J Immunol** 1996 Aug 15;157(4):1752–7

Vitamin A down-regulation of IFN-gamma synthesis in cloned mouse Th1 lymphocytes depends on the CD28 costimulatory pathway. Cantorna MT, et al. **J Immunol** 1996 Apr 15;156(8):2674–9

Activated B cells express CD28/B7-independent costimulatory activity. Ding L, et al. **J Immunol** 1996 Aug 15;157(4):1389–96

B7/CD28-dependent and -independent induction of CD40 ligand expression. Ding L, et al. **J Immunol** 1995 Dec 1; 155(11):5124–32

CD28 is required for germinal center formation. Ferguson SE, et al. **J Immunol** 1996 Jun 15;156(12):4576–81

The role of CD28 costimulation in immune-mediated responses against mouse mammary tumor viruses. Palmer LD, et al. **J Immunol** 1996 Mar 15;156(6):2112–8

CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. Perrin PJ, et al. **J Immunol** 1996 Aug 15;157(4):1333–6

CD28-mediated cytotoxicity by the human leukemic NK cell line YT involves tyrosine phosphorylation, activation of phosphatidylinositol 3-kinase, and protein kinase C. Teng JM, et al. **J Immunol** 1996 May 1;156(9):3222–32

Structural requirements for CD28-mediated costimulation of IL-2 production in Jurkat T cells. Truitt KE, et al. **J Immunol** 1996 Jun 15;156(12):4539–41

Phosphatidylinositol hydrolysis in freshly isolated human T lymphocytes. Berney SM, et al. **J Immunol Methods** 1995 Oct 12;186(1):71–7

CD28-mediated costimulation in the absence of phosphatidylinositol 3-kinase association and activation. Crooks ME, et al. **Mol Cell Biol** 1995 Dec;15(12):6820–8

CD28 signal transduction pathways. A comparison of B7-1 and B7-2 regulation of the map kinases: ERK2 and Jun kinases. Nunes JA, et al. **Mol Immunol** 1996 Jan;33(1):63–70

The CD28 costimulatory pathway. Leung HT, et al. **Ther Immunol** 1994 Aug;1(4):217–28 (104 ref.)

TOXICITY

CD28-mediated cytotoxicity of YT natural killer cells on B7-positive targets induces rapid necrotic death independent of granule exocytosis. Roger R, et al. **Cell Immunol** 1996 Feb 25;168(1):24–32

ANTIGENS, CD29

see related
RECEPTORS, FIBRONECTIN
RECEPTORS, VERY LATE ANTIGEN

ANALYSIS

Beta 1 integrin expression: a marker of lymphatic metastases in cutaneous malignant melanoma. Hieken TJ, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2321-4

The role of phosphorylation in modulating beta 1 integrin localization. Barreuther MF, et al. **Exp Cell Res** 1996 Jan 10;222(1):10-5

Expression of beta 1 integrin in normal, dysplastic and neoplastic canine mammary gland. Restucci B, et al. **J Comp Pathol** 1995 Aug;113(2):165-73

Immunogold localization of beta 1-integrin in bone: effect of glucocorticoids and insulin-like growth factor I on integrins and osteocyte formation. Gohel AR, et al. **J Histochem Cytochem** 1995 Nov;43(11):1085-96

Over-expression of transfected N-myc oncogene in human SKNSH neuroblastoma cells down-regulates expression of beta 1 integrin subunit. Judware R, et al. **Oncogene** 1995 Dec 21;11(12):2599-607

Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastases. Hieken TJ, et al. **Surgery** 1995 Oct;118(4):669-73; discussion 673-5

BIOSYNTHESIS

Expression of VLA-4 and L-selectin in human gut-associated lymphoid tissue (GALT). Farstad IN, et al. **Adv Exp Med Biol** 1995;371A:91-6

Differential expression of VLA beta 1 (CD29) on monocytes from patients with endometriosis. Gebel HM, et al. **Am J Reprod Immunol** 1995 Nov;34(5):317-22

Expression of beta 1-integrins on epiphyseal chondrocytes is reduced by ofloxacin. Förster C, et al. **Drugs** 1995;49 Suppl 2:279-82

Natural human interferon-alpha enhances the expression of intracellular adhesion molecule-1, integrin alpha 2 and beta 1 by a mucosal epithelial cell line. Dao T, et al. **Folia Biol (Praha)** 1995;41(5):213-25

Induction of mouse beta integrin expression following transfection with human alpha 4 chain. Webb DL, et al. **J Cell Biochem** 1996 Apr;61(1):127-38

Expression of beta 1 integrins in human endometrial stromal and decidual cells. Shiokawa S, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1533-40

Immunogold localization of beta 1-integrin in bone: effect of glucocorticoids and insulin-like growth factor I on integrins and osteocyte formation. Gohel AR, et al. **J Histochem Cytochem** 1995 Nov;43(11):1085-96

Assembly and function of integrin receptors is dependent on opposing alpha and beta cytoplasmic domains. Briesewitz R, et al. **Mol Biol Cell** 1995 Aug;6(8):997-1010

CHEMISTRY

The novel structural motif Gln795-Gln802 in the integrin beta 1C cytoplasmic domain regulates cell proliferation. Fornaro M, et al. **J Biol Chem** 1995 Oct 20;270(42):24666-9

Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. Luque A, et al. **J Biol Chem** 1996 May 10; 271(19):11067-75

Critical residues for ligand binding in an I domain-like structure of the integrin beta1 subunit. Puzon-McLaughlin W, et al. **J Biol Chem** 1996 Aug 23;271(34):20438-43

DRUG EFFECTS

The expression of integrin alpha 2 beta 1 and attachment to type I collagen of melanoma cells are preferentially induced by tumour promoter, TPA (12-O-tetradecanoyl phorbol-13-acetate). Eguchi H, et al. **Br J Dermatol** 1996 Jan;134(1):33-9

GENETICS

Embryonic lineage of vascular smooth muscle cells determines responses to collagen matrices and integrin receptor expression. Thieszen SL, et al. **Exp Cell Res** 1996 Aug 25;227(1):135-45

Developmental regulation of murine integrin beta 1 subunit- and Hsc73-encoding genes in mammary gland: sequence of a new mouse Hsc73 cDNA. Soulier S, et al. **Gene** 1996 Jun 26;172(2):285-9

Control of integrin expression by extracellular matrix. Delcommenne M, et al. **J Biol Chem** 1995 Nov 10; 270(45):26794-801

IMMUNOLOGY

Alteration of glomerular permeability to macromolecules induced by cross-linking of beta 1 integrin receptors. Adler S, et al. **Am J Pathol** 1996 Sep;149(3):987-96

Polymorphonuclear leucocyte migration through human dermal fibroblast monolayers is dependent on both beta 2-integrin (CD11/CD18) and beta 1-integrin (CD29) mechanisms. Gao JX, et al. **Immunology** 1995 Jul; 85(3):485-94

Identification and functional characterization of mouse CD29 with a mAb. Noto K, et al. **Int Immunol** 1995 May; 7(5):835-42

CD29: true marker of "memory"? [letter; comment] Mahalingam M. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 1;11(4):411. Comment on: J Acquir Immune Defic Syndr Hum Retrovirol 1995 Oct 1;10(2):107-14.

Monoclonal antibody 9EG7 defines a novel beta 1 integrin epitope induced by soluble ligand and manganese, but inhibited by calcium. Bazzoni G, et al. **J Biol Chem** 1995 Oct 27;270(43):25570-7

The inhibitory anti-beta1 integrin monoclonal antibody 13 recognizes an epitope that is attenuated by ligand occupancy. Evidence for allosteric inhibition of integrin function. Mould AP, et al. **J Biol Chem** 1996 Aug 23; 271(34):20365-74

METABOLISM

beta 1-Integrin expression and function in human bladder cancer cells: modulation by TNF alpha. Nista A, et al. **Anticancer Res** 1996 Mar-Apr;16(2):581-8

CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta 1 integrins in human melanoma. Radford KJ, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):13-8

Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Bhatia R, et al. **Blood** 1996 May 1;87(9):3883-91

alpha6beta1-Integrin, a major cell surface carrier of beta1-6-branched oligosaccharides, mediates migration of EJ-ras-transformed fibroblasts on laminin-1 independently of its glycosylation state. Jasiulionis MG, et al. **Cancer Res** 1996 Apr 1;56(7):1682-9

Increased glycosylation of beta 1 integrins affects the interaction of transformed S115 mammary epithelial cells with laminin-1. Leppä S, et al. **Cell Growth Differ** 1995 Jul;6(7):853-61

Differential role of protein tyrosine phosphorylation/dephosphorylation in affinity regulation of beta 1 and beta 3 integrin in human fibroblasts. Takagi J, et al. **Cell Struct Funct** 1995 Oct;20(5):403-13

Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Kostenuik PJ, et al. **Clin Exp Metastasis** 1996 Jan;14(1):19-26

The role of phosphorylation in modulating beta 1 integrin localization. Barreuther MF, et al. **Exp Cell Res** 1996 Jan 10;222(1):10-5

Integrin-dependent control of inositol lipid synthesis in vascular endothelial cells and smooth muscle cells. McNamee HP, et al. **Exp Cell Res** 1996 Apr 10; 224(1):116-22

The C-C chemokine MCP-1 differentially modulates the avidity of beta 1 and beta 2 integrins on T lymphocytes. Carr MW, et al. **Immunity** 1996 Feb;4(2):179-87

IL-4-induced B cell migration involves transient interactions between beta 1 integrins and extracellular matrix components. Elenström-Magnusson C, et al. **Int Immunol** 1995 Apr;7(4):567-73

The cell-binding domain of intimin from enteropathogenic Escherichia coli binds to beta1 integrins. Frankel G, et al. **J Biol Chem** 1996 Aug 23;271(34):20359-64

Collagen and collagenase gene expression in three-dimensional collagen lattices are differentially regulated by alpha 1 beta 1 and alpha 2 beta 1 integrins. Langholz O, et al. **J Cell Biol** 1995 Dec;131(6 Pt 2):1903-15

A role for phosphatidylinositol 3-kinase in the regulation of beta 1 integrin activity by the CD2 antigen. Shimizu Y, et al. **J Cell Biol** 1995 Dec;131(6 Pt 2):1867-80

Stimulation of beta1 integrins on fibroblasts induces PDGF independent tyrosine phosphorylation of PDGF beta-receptors. Sundberg C, et al. **J Cell Biol** 1996 Feb; 132(4):741-52

Beta 1 integrin-dependent and -independent polymerization of fibronectin. Wennerberg K, et al. **J Cell Biol** 1996 Jan; 132(1-2):227-38

Distribution of beta1 integrin during development of chick tarsometatarsal skin in vivo and in vitro. Akimoto Y, et al. **J Histochem Cytochem** 1996 May;44(5):411-22

CD28-mediated up-regulation of beta 1-integrin adhesion involves phosphatidylinositol 3-kinase. Zell T, et al. **J Immunol** 1996 Feb 1;156(3):883-6

Extracellular matrix and beta 1 integrin expression in nodal and extranodal T-cell lymphomas. Jaspars LH, et al. **J Pathol** 1996 Jan;178(1):36-43

Proteolytic disruption of laminin-integrin complexes on muscle cells during synapse formation. Anderson MJ, et al. **Mol Cell Biol** 1996 Sep;16(9):4972-84

Molecular interactions between fibronectin and integrins during mouse blastocyst outgrowth. Yelian FD, et al. **Mol Reprod Dev** 1995 Aug;41(4):435-48

Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Hannigan GE, et al. **Nature** 1996 Jan 4;379(6560):91-6

Beta 1 and beta 3 integrin upregulation in rapidly progressive glomerulonephritis. Baraldi A, et al. **Nephrol Dial Transplant** 1995;10(7):1155-61

Usage of beta 1 integrin ligands by B cells is developmentally regulated in avian bursa. Palojoki E, et al. **Scand J Immunol** 1995 Oct;42(4):473-9

PHYSIOLOGY

Functional regulation of beta 1 integrins on human eosinophils by divalent cations and cytokines. Werfel SJ, et al. **Am J Respir Cell Mol Biol** 1996 Jan;14(1):44-52

Beta 1 integrin antibodies inhibit chondrocyte terminal differentiation in whole sterna. Hirsch MS, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:267-70

Stimulation of tyrosine phosphorylation after ligation of beta7 and beta1 integrins on human B cells. Manie SN, et al. **Blood** 1996 Mar 1;87(5):1855-61

Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. Friedlander DR, et al. **Cancer Res** 1996 Apr 15;56(8):1939-47

Loss of the tumorigenic phenotype with in vitro, but not in vivo, passaging of a novel series of human bronchial epithelial cell lines: possible role of an alpha 5/beta 1-integrin-fibronectin interaction. Schiller JH, et al. **Cancer Res** 1995 Dec 15;55(24):6215-21

Mononuclear leukocytes invade rabbit arterial intima during thickening formation via CD18-and VLA-4-dependent mechanisms and stimulate smooth muscle migration. Kling D, et al. **Circ Res** 1995 Dec;77(6):1121-8

Regulation of beta1-integrin function in cultured human vascular smooth muscle cells. Seki J, et al. **Circ Res** 1996 Apr;78(4):596-605

Integrin alpha 2 beta 1 mediates interactions between developing embryonic retinal cells and collagen. Bradshaw AD, et al. **Development** 1995 Nov;121(11):3593-602

Divalent cations ($Mg2+$, $Ca2+$) differentially influence the beta 1 integrin-mediated migration of human fibroblasts and keratinocytes to different extracellular matrix proteins. Lange TS, et al. **Exp Dermatol** 1995 Jun;4(3):130-7

beta1-Integrins dominate cell traffic of leukemic cells in human bone-marrow stroma. Van der Velde-Zimmerman D, et al. **Int J Cancer** 1996 Apr 10;66(2):225-33

Mutations in the cytoplasmic domain of the integrin beta1 chain indicate a role for endocytosis factors in bacterial internalization. Van Nhieu GT, et al. **J Biol Chem** 1996 Mar 29;271(13):7665-72

Control of beta1 integrin function. Localization of stimulatory epitopes. Wilkins JA, et al. **J Biol Chem** 1996 Feb 9;271(6):3046-51

Signal transduction through the beta1 integrin family surface adhesion molecules VLA-4 and VLA-5 of human B-cell precursors activates CD19 receptor-associated protein-tyrosine kinases. Xiao J, et al. **J Biol Chem** 1996 Mar 29;271(13):7659-64

Beta 1D integrin displaces the beta 1A isoform in striated muscles: localization at junctional structures and signaling potential in nonmuscle cells. Belkin AM, et al. **J Cell Biol** 1996 Jan;132(1-2):211-26

Investigation of the role of beta 1 integrins in cell-cell adhesion. Weitzman JB, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3635-44

Studies in vitro on the role of alpha v and beta 1 integrins in the adhesion of human dermal fibroblasts to provisional matrix proteins fibronectin, vitronectin, and fibrinogen. Gailit J, et al. **J Invest Dermatol** 1996 Jan;106(1):102-8

Induction of homotypic lymphocyte aggregation: evidence for a novel activation state of the beta1 integrin. Neelamegham S, et al. **J Leukoc Biol** 1996 Jun;59(6):872-82

Beta 1 integrins signal lipid second messengers required during cell adhesion. Auer KL, et al. **Mol Biol Cell** 1995 Oct;6(10):1305-13

Impaired migration but not differentiation of haematopoietic stem cells in the absence of beta1 integrins. Hirsch E, et al. **Nature** 1996 Mar 14;380(6570):171-5

Platelet adhesion at high shear rates: the roles of von Willebrand factor/GPIb and the beta 1 integrin alpha 2 beta 1. Gralnick HR, et al. **Thromb Res** 1996 Jan 1; 81(1):113-9

ULTRASTRUCTURE

Up-regulation of a novel integrin alpha-chain (alpha mt) on human fetal myotubes. Gullberg D, et al. **Dev Dyn** 1995 Sep;204(1):57-65

ANTIGENS, CD30

Pediatric small cell variant of Ki-1 (CD30) + T-cell lymphoma with germ-line configuration of the T-cell receptor gene. Toren A, et al. **Acta Oncol** 1996;35(2):243-5

The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. DeCoteau JF, et al. **Blood** 1996 Apr 15; 87(8):3437-41

Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. Vonderheid EC, et al. **J Am Acad Dermatol** 1996 Mar;34(3):470-81

Local expansion of allergen-specific CD30+Th2-type gamma delta T cells in bronchial asthma. Spinozzi F, et al. **Mol Med** 1995 Nov;1(7):821-6

ANALYSIS

Fine needle aspiration cytology, histology and immunohistochemistry of anaplastic large cell Ki-1-positive lymphoma. A report of three cases. McCluggage WG, et al. **Acta Cytol** 1996 Jul-Aug;

40(4):779–85
CD30-positive cutaneous large cell lymphomas. A comparative study of clinicopathologic and molecular features of 16 cases. Macgrogan G, et al. **Am J Clin Pathol** 1996 Apr;105(4):440–50
Immunohistochemical comparative investigations of lymphatic tissue in reactive processes, myasthenic thymuses and Hodgkin's disease. Zółtowska A. **Arch Immunol Ther Exp (Warsz)** 1995;43(1):15–22
High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Gerli R, et al. **Clin Exp Immunol** 1995 Dec;102(3):547–50
Pityriasis lichenoides of childhood with atypical CD30-positive cells and clonal T-cell receptor gene rearrangements. Panhans A, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):489–90
Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation. Bengtsson A, et al. **J Leukoc Biol** 1995 Dec;58(6):683–9
Within the spectral forms of leprosy cellbound CD30 cannot be regarded as an operational marker for the Th-2-like reaction [letter; comment] Seitzer U, et al. **J Leukoc Biol** 1996 Feb;59(2):311. Comment on: J Leukoc Biol 1995 May;57(5):726–30.
16-year experience at M. D. Anderson Cancer Center with primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large cell lymphoma. Romaguera JE, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):97–102
Peripheral blood identification of neoplastic cells and the tumoral growth fraction by double immunocytochemical study in a case of anaplastic CD30-positive large cell lymphoma [letter] Tarin F, et al. **Leukemia** 1996 Sep; 10(9):1560

BLOOD

Serum levels of soluble CD30 in chronic hepatitis B virus infection. Fattovich G, et al. **Clin Exp Immunol** 1996 Jan; 103(1):105–10
Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Caligaris-Cappio F, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):339–43
Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Krams SM, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):311–20
CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. Chilosi M, et al. **Eur J Immunol** 1996 Feb;26(2):329–34

GENETICS

Somatic hypermutation occurs in B cells of terminal deoxynucleotidyl transferase-, CD23-, interleukin-4-, IgD- and CD30-deficient mouse mutants. Texidó G, et al. **Eur J Immunol** 1996 Aug;26(8):1966–9

IMMUNOLOGY

Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappabeta transcription factor. Gruss HJ, et al. **Blood** 1996 Mar 15;87(6):2443–9
Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Renner C, et al. **Blood** 1996 Apr 1;87(7):2930–7
Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. Terenzi A, et al. **Br J Haematol** 1996 Mar;92(4):872–9
In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Tian ZG, et al. **Cancer Res** 1995 Nov 15; 55(22):5335–41
Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Amakawa R, et al. **Cell** 1996 Feb 23;84(4):551–62
Role for CD30 antigen in human T helper 2-type responses. Romagnani S. **Ciba Found Symp** 1995;195:55–62; discussion 62–7 (43 ref.)
Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Schnell R, et al. **Int J Cancer** 1995 Oct 9;63(2):238–44
Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies. Renner C, et al. **J Hematother** 1995 Oct;4(5):447–51

METABOLISM

CD30 ligation induces nuclear factor-kappa B activation in human T cell lines. McDonald PP, et al. **Eur J Immunol** 1995 Oct;25(10):2870–6
A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Hansen HP, et al. **Int J Cancer** 1995 Nov 27;63(5):750–6
CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. Gedrich RW, et al. **J Biol Chem** 1996 May 31; 271(22):12852–8
T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. Lee SY, et al. **J Exp Med** 1996 Feb 1;183(2):669–74
Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies. Sforzini S, et al. **J Hematother** 1995 Oct; 4(5):429–32
CD30 expression does not discriminate between human Th1- and Th2-type T cells. Hamann D, et al. **J Immunol** 1996 Feb 15;156(4):1387–91
CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Lee SY, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9699–703

PHYSIOLOGY

CD30 molecule (Ki-1 Ag): more than just a marker of CD30+ lymphoma. Pizzolo G, et al. **Haematologica** 1995 Jul–Aug;80(4):357–66
CD30-mediated signaling promotes the development of human T helper type 2-like T cells. Del Prete G, et al. **J Exp Med** 1995 Dec 1;182(6):1655–61
Structure and expression of murine CD30 and its role in cytokine production. Bowen MA, et al. **J Immunol** 1996 Jan 15;156(2):442–9
CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. de Bruin PC, et al. **Leukemia** 1995 Oct;9(10):1620–7 (166 ref.)

ANTIGENS, CD32 see **RECEPTORS, IGG**

ANTIGENS, CD34

Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Spafford MF, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):627–32
Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Haase D, et al. **Blood** 1995 Oct 15;86(8):2906–12
CD34: structure, biology, and clinical utility. Krause DS, et al. **Blood** 1996 Jan 1;87(1):1–13 (141 ref.)
Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Mrózek E, et al. **Blood** 1996 Apr 1;87(7):2632–40
Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. Rosti V, et al. **Blood** 1995 Nov 1;86(9):3387–93
Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro. Shah AJ, et al. **Blood** 1996 May 1;87(9):3563–70
Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemia. Terpstra W, et al. **Blood** 1996 Mar 15;87(6):2187–94
Transplantation of allogeneic CD34+ peripheral blood stem cells (PBSC) in patients with advanced hematologic malignancy. Bensinger WI, et al. **Bone Marrow Transplant** 1996 Mar;17 Suppl 2:S38–9
CD34+ cell subsets and platelet recovery after PBSC autograft [letter] Buscemi F, et al. **Bone Marrow Transplant** 1995 Dec;16(6):855–6
Mobilization and purification of CD34+ cells from normal donors regimens with G-CSF, GM-CSF, or a combination of both. Ho AD, et al. **Bone Marrow Transplant** 1996 Mar; 17 Suppl 2:S34–7
Enrichment of allogeneic CD34+ cells and T cell depletion by percoll density gradient centrifugation. Negrin RS, et al. **Bone Marrow Transplant** 1996 Mar;17 Suppl 2:S31–3
Effects of recombinant human thrombopoietin on megakaryocyte colony formation and megakaryocyte ploidy by human CD34+ cells in a serum-free system. Angchaisuksiri P, et al. **Br J Haematol** 1996 Apr;93(1):13–7
Second transplantation with CD34+ bone marrow cells selected from a two-loci HLA-mismatched sibling for a patient with chronic myeloid leukaemia. Fujimori Y, et al. **Br J Haematol** 1996 Jul;94(1):123–5
Generation of human natural killer cells from peripheral blood CD34+ cells mobilized by granulocyte colony-stimulating factor. Takenaka K, et al. **Br J Haematol** 1996 Mar;92(4):788–94
CD34 stem/progenitor cells purified from cryopreserved normal cord blood can be transduced with high efficiency by a retroviral vector and expanded ex vivo with stable integration and expression of Fanconi anemia complementation C gene. Lu L, et al. **Cell Transplant** 1995 Sep–Oct;4(5):493–503
Fetal bone marrow CD34+CD41+ cells are enriched for multipotent hematopoietic progenitors, but not for pluripotent stem cells. Murray LJ, et al. **Exp Hematol** 1996 Feb;24(2):236–45
Characterization of eosinophils generated in vitro from CD34+ peripheral blood progenitor cells. Rosenberg HF, et al. **Exp Hematol** 1996 Jul;24(8):888–93
Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene [see comments] Hanania EG, et al. **Gene Ther** 1995 Jun;2(4):285–94. Comment in: Gene Ther 1995 Jun;2(4):233–4.
CD34-positive cells: biology and clinical relevance. Stella CC, et al. **Haematologica** 1995 Jul–Aug;80(4):367–87 (156 ref.)
Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. Young JW, et al. **J Exp Med** 1995 Oct 1;182(4):1111–9
Inhibition of purified CD34+ hematopoietic progenitor cells by human immunodeficiency virus 1 or gp120 mediated by endogenous transforming growth factor beta 1. Zauli G, et al. **J Exp Med** 1996 Jan 1;183(1):99–108
CD34+ cell positive selection from mobilized peripheral blood by an indirect immunomagnetic method: effect of the type of mobilization and assessment of tumor depletion ability. Cancelas JA, et al. **J Hematother** 1995 Dec; 4(6):531–8
CD34+ progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing. Colter M, et al. **J Hematother** 1996 Apr;5(2):179–84 (22 ref.)
Immunomagnetic selection of CD34+ cells from fresh peripheral blood mononuclear cell preparations using two different separation techniques. Papadimitriou CA, et al. **J Hematother** 1995 Dec;4(6):539–44
Does CD34+ cell selection enrich malignant stem cells in B cell (and other) malignancies? [letter] Reading CL. **J Hematother** 1996 Apr;5(2):97–8
Clinical use of selected and expanded peripheral blood CD34+ cells: a preliminary report of feasibility and safety. Zimmerman TM, et al. **J Hematother** 1995 Dec;4(6):527–9
High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. Akkina RK, et al. **J Virol** 1996 Apr;70(4):2581–5
CD34+/CD33+ blast cells: correlation with FAB subtypes. Rigolin GM, et al. **Leuk Lymphoma** 1995;18 Suppl 1:43–8
Generation of human T lymphocytes from bone marrow CD34+ cells in vitro. Freedman AR, et al. **Nat Med** 1996 Jan;2(1):46–51
Retrovirus-mediated transfer and expression of swine MHC class II genes in CD34+ monkey stem cells. Banerjee PT, et al. **Transplant Proc** 1996 Apr;28(2):747–8

ANALYSIS

Deficiency of CD34+ c-kit+ and CD34+38- hematopoietic precursors in aplastic anemia after immunosuppressive treatment. Manz CY, et al. **Am J Hematol** 1996 Aug; 52(4):264–74
CD34 positivity in solitary fibrous tumor of the liver [letter; comment] Bost F, et al. **Am J Surg Pathol** 1995 Nov; 19(11):1334–5. Comment on: Am J Surg Pathol 1994 Aug;18(8):814–20. Comment on: Am J Surg Pathol 1994 Oct;18(10):992–8.
GIST [letter; comment] Tamsen A, et al. **Am J Surg Pathol** 1995 Dec;19(12):1444–5. Comment on: Am J Surg Pathol 1995 Jan;19(1):59–70.
Establishment and characterization of a novel CD34-positive human myeloid leukemia cell line: MHH225 growing in serum-free culture. Hassan HT, et al. **Ann Hematol** 1995 Sep;71(3):111–7
Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution. Schwella N, et al. **Ann Hematol** 1995 Nov;71(5):227–34
Use of control cells to standardize enumeration of CD34+ stem cells. Roth P, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:370–2
Optimization of gene transfer using cationic lipids in cell lines and primary human CD4+ and CD34+ hematopoietic cells. Harrison GS, et al. **Biotechniques** 1995 Nov; 19(5):816–23
The value of flow cytometric analysis of platelet glycoprotein expression of CD34+ cells measured under conditions that prevent P-selectin-mediated binding of platelets. Dercksen MW, et al. **Blood** 1995 Nov 15;86(10):3771–82
CD34+ endothelial cell lines derived from murine yolk sac induce the proliferation and differentiation of yolk sac CD34+ hematopoietic progenitors. Fennie C, et al. **Blood** 1995 Dec 15;86(12):4454–67
A functional comparison of CD34 + CD38- cells in cord blood and bone marrow. Hao QL, et al. **Blood** 1995 Nov 15;86(10):3745–53
Phenotypic, molecular, and functional characterization of human peripheral blood CD34+/THY1+ cells. Humeau L, et al. **Blood** 1996 Feb 1;87(3):949–55
Exposure of human CD34+ cells to human immunodeficiency virus type 1 does not influence their expansion and proliferation of hematopoietic progenitors in vitro. Kaushal S, et al. **Blood** 1996 Jul 1;88(1):130–7
Concomitant mobilization of plasma cells and hematopoietic

progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Lemoli RM, et al. **Blood** 1996 Feb 15;87(4):1625–34

Detection of clonal CD34+19+ progenitors in bone marrow of BCL2–IgH–positive follicular lymphoma patients. Macintyre EA, et al. **Blood** 1995 Dec 15;86(12):4691–8

Peripheral blood harvest of unaffected CD34+ CD38– hematopoietic precursors in paroxysmal nocturnal hemoglobinuria. Prince GM, et al. **Blood** 1995 Nov 1; 86(9):3381–6

Highly effective CD34+ selection of granulocyte colony–stimulating factor–mobilized allogeneic peripheral blood progenitor cells [letter] Schreiner T, et al. **Blood** 1996 Aug 15;88(4):1517–8

Aorta–associated CD34+ hematopoietic cells in the early human embryo. Tavian M, et al. **Blood** 1996 Jan 1; 87(1):67–72

Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha–interferon–resistant or –intolerant patients with chronic myeloid leukemia. Van den Berg D, et al. **Blood** 1996 May 15;87(10):4348–57

An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Weaver CH, et al. **Blood** 1995 Nov 15; 86(10):3961–9

Positive selection of CD34+ cells from cryopreserved peripheral blood stem cells after thawing: technical aspects and clinical use. Bohbot A, et al. **Bone Marrow Transplant** 1996 Feb;17(2):259–64

The composition of CD34 subpopulations differs between bone marrow, blood and cord blood. Fritsch G, et al. **Bone Marrow Transplant** 1996 Feb;17(2):169–78

Filgrastim post–chemotherapy mobilizes more CD34+ cells compared to its use during steady–state haemopoiesis [letter; comment] Perez–Oteyza J, et al. **Bone Marrow Transplant** 1995 Aug;16(2):324–5. Comment on: Bone Marrow Transplant 1994 Nov;14(5):827–32.

Transplantation of allogeneic rhG–CSF mobilized peripheral CD34+ cells from an HLA–identical unrelated donor. Stockschläder M, et al. **Bone Marrow Transplant** 1995 Nov; 16(5):719–22

Extent of variability inherent in measurements of CD34–positive cells in different human haemopoietic tissues. Titley I, et al. **Bone Marrow Transplant** 1995 Oct; 16(4):611–6

Expression of the CD34 antigen distinguishes Kaposi's sarcoma from pseudo–Kaposi's sarcoma (acroangiodermatitis). Kanitakis J, et al. **Br J Dermatol** 1996 Jan;134(1):44–6

Decreased L–selectin expression in CD34–positive cells from patients with chronic myelocytic leukaemia. Kawaishi K, et al. **Br J Haematol** 1996 May;93(2):367–74

Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Maciejewski JP, et al. **Br J Haematol** 1995 Sep;91(1):245–52

G–CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma. Mahé B, et al. **Br J Haematol** 1996 Feb; 92(2):263–8

Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes. Oriani A, et al. **Br J Haematol** 1996 Feb; 92(2):360–4

An ICAM–1 like cell adhesion molecule is responsible for CD34 positive haemopoietic stem cells adhesion to bone–marrow stroma. Rao SG, et al. **Cell Biol Int** 1996 Apr;20(4):255–9

Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability. Garcia C, et al. **Dermatol Surg** 1996 Feb;22(2):177–9

Analysis of CD34–positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry. Kanter–Lewensohn L, et al. **Eur J Haematol** 1996 Mar; 56(3):124–9

Long–term cultures to evaluate engraftment potential of CD34+ cells from peripheral blood after mobilization by chemotherapy with and without GM–CSF. Benboubker L, et al. **Exp Hematol** 1995 Dec;23(14):1568–73

High–level expression of a novel epitope of CD59 identifies a subset of CD34+ bone marrow cells highly enriched for pluripotent stem cells. Hill B, et al. **Exp Hematol** 1996 Jul;24(8):936–43

5–Fluorouracil–resistant CD34+ cell population from peripheral blood of CML patients contains BCR–ABL–negative progenitor cells. Jazwiec B, et al. **Exp Hematol** 1995 Dec;23(14):1509–14

Effects of CD34+ selection and T cell immunodepletion on cord blood hematopoietic progenitors: relevance to stem cell transplantation. Laver J, et al. **Exp Hematol** 1995 Dec; 23(14):1492–6

Efficient retroviral mediated transfer of the glucocerebrosidase gene in CD34+ enriched umbilical cord blood human hematopoietic progenitors. Mannion–Henderson J, et al. **Exp Hematol** 1995 Dec; 23(14):1628–32

Differential expression of L–selectin, VLA–4, and LFA–1 on CD34+ progenitor cells from bone marrow and peripheral blood during G–CSF–enhanced recovery. Möhle R, et al. **Exp Hematol** 1995 Dec;23(14):1535–42

Analysis of cord blood CD34+ cells purified after cryopreservation. Nicol A, et al. **Exp Hematol** 1995 Dec; 23(14):1589–94

Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Siena S, et al. **Exp Hematol** 1995 Dec; 23(14):1463–71

Identification of CD34+ subsets after glycoprotease selection: engraftment of CD34+Thy–1+Lin– stem cells in fetal sheep. Sutherland DR, et al. **Exp Hematol** 1996 Jun;24(7):795–806

Lineage commitment of CD34+ human hematopoietic progenitor cells. Tjønnfjord GE, et al. **Exp Hematol** 1996 Jul;24(8):875–82

Human CD34+ cell EST database: single–pass sequencing of 402 clones from a directional cDNA library. Yang Y, et al. **Exp Hematol** 1996 Apr;24(5):605–12

Cell kinetics of CD34–positive hematopoietic cells following chemotherapy plus colony–stimulating factors in advanced breast cancer. Danova M, et al. **Int J Cancer** 1995 Nov 27;63(5):646–51

CD34 cell separation: from basic research to clinical applications. Nadali G, et al. **Int J Clin Lab Res** 1995; 25(3):121–7 (39 ref.)

CD34–positive blastoma in a patient with idiopathic myelofibrosis. Komeno T, et al. **Intern Med** 1995 Oct; 34(10):1035–7

Differential expression of granulocyte–macrophage colony–stimulating factor and IL–3 receptor subunits on human CD34+ cells and leukemic cell lines. Kurata H, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1083–99

CD34–reactive fibrous papule of the nose. Shea CR, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):342–5

Evaluating efficiency of bone marrow harvest and its manipulation––role of CD 34 positivity. Parikh PM, et al. **J Assoc Physicians India** 1995 Jul;43(7):470–2

Interleukin–1 beta suppresses apoptosis in CD34 positive bone marrow cells through activation of the type I IL–1 receptor. Rodriguez C, et al. **J Cell Physiol** 1996 Feb; 166(2):387–96

CD34–positive cells isolated from cryopreserved peripheral–blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. Alcorn MJ, et al. **J Clin Oncol** 1996 Jun;14(6):1839–47

Factors that influence collection and engraftment of autologous peripheral–blood stem cells. Bensinger W, et al. **J Clin Oncol** 1995 Oct;13(10):2547–55

CD34 immunoperoxidase staining for the diagnosis of myelodysplastic syndromes and chronic myeloid leukaemia [letter; comment] Orazi A. **J Clin Pathol** 1995 Sep;48(9):884 . Comment on: J Clin Pathol 1995 Apr;48(4):291–4.

Immunostaining for CD31 and CD34 in Kaposi sarcoma. Russell Jones R, et al. **J Clin Pathol** 1995 Nov; 48(11):1011–6

Use of CD34 in assessing the relationship between stroma and tumor in desmoplastic keratinocytic neoplasms. Kirchmann TT, et al. **J Cutan Pathol** 1995 Oct;22(5):422–6

CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM–CSF+TNF alpha. Caux C, et al. **J Exp Med** 1996 Aug 1;184(2):695–706

Erythropoietin–independent erythrocyte production: signals through gp130 and c–kit dramatically promote erythropoiesis from human CD34+ cells. Sui X, et al. **J Exp Med** 1996 Mar 1;183(3):837–45

Bioreactor expansion of human bone marrow: comparison of unprocessed, density–separated, and CD34–enriched cells. Koller MR, et al. **J Hematother** 1995 Jun;4(3):159–69

A combination of CD34 selection and complement–mediated immunopurging (anti–CD15 monoclonal antibody) eliminates tumor cells while sparing normal progenitor cells. Nimgaonkar M, et al. **J Hematother** 1996 Feb; 5(1):39–48

Large volume ex vivo expansion of CD34–positive hematopoietic progenitor cells for transplantation. Purdy MH, et al. **J Hematother** 1995 Dec;4(6):515–25

CD34+ leukemic cells assessed by different CD34 monoclonal antibodies. Lanza F, et al. **Leuk Lymphoma** 1995;18 Suppl 1:25–30

Expression and long–term prognostic value of CD34 in childhood and adult acute lymphoblastic leukemia. Vanhaeke DR, et al. **Leuk Lymphoma** 1995 Dec; 20(1–2):137–42

Phenotype and progeny of primitive adherent human hematopoietic progenitors. Gordon MY, et al. **Leukemia** 1996 Aug;10(8):1347–53

Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Macedo A, et al. **Leukemia** 1995 Nov;9(11):1896–901

Cell surface expression of the multidrug resistance P–glycoprotein (P–170) as detected by monoclonal antibody MRK–16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. Sievers EL, et al. **Leukemia** 1995 Dec;9(12):2042–8

Engraftment of gene–modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Kohn DB, et al. **Nat Med** 1995 Oct;1(10):1017–23

Long–term lymphohematopoietic reconstitution by a single CD34–low/negative hematopoietic stem cell. Osawa M, et al. **Science** 1996 Jul 12;273(5272):242–5

Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems. de Wynter EA, et al. **Stem Cells (Dayt)** 1995 Sep;13(5):524–32

[Molecular and biological features of human CD34+ Hematopoietic stem/progenitor cells] Xi YZ. **Sheng Li Ke Hsueh Chin Chan** 1995 Oct;26(4):317–23 (20 ref.) (Eng. Abstr.) **(Chi)**

[Role of CD34 in the diagnosis of dermatofibrosarcoma protuberans (letter)] Santelli G, et al. **Ann Pathol** 1996; 16(2):149–50 **(Fre)**

[Residual placental blood and bone marrow as sources of hematopoietic stem cells for allogenic stem cell transplantation. Comparative analysis of hematopoietic potential] Köhler A, et al. **Klin Padiatr** 1995 Jul–Aug; 207(4):215–8 (Eng. Abstr.) **(Ger)**

[CD34 detection––an immunohistochemical contribution to differential diagnosis of soft tissue tumors] Katenkamp D, et al. **Pathologe** 1996 May;17(3):195–201 (Eng. Abstr.) **(Ger)**

[Techniques of positive isolation of CD34(+) cells. Personal experience with the immunomagnetic method] Markiewicz M, et al. **Acta Haematol Pol** 1996;27(1):57–63 (Eng. Abstr.) **(Pol)**

[Clinical and immunologic characteristics of CD 34 positive acute myeloid leukemia] Adamczyk–Cioch MB, et al. **Pol Arch Med Wewn** 1995 Jul;94(1):40–6 (Eng. Abstr.) **(Pol)**

BIOSYNTHESIS

CD117/CD34 expression in leukemic blasts. Wells SJ, et al. **Am J Clin Pathol** 1996 Aug;106(2):192–5

Leukemia–associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Porwit–MacDonald A, et al. **Blood** 1996 Feb 1;87(3):1162–9

Selective modulation of the expression of L–selectin ligands by an immune response. Hoke D, et al. **Curr Biol** 1995 Jun 1;5(6):670–8

CD34–positive early human thymocytes: T cell receptor and cytokine receptor gene expression. Ktorza S, et al. **Eur J Immunol** 1995 Sep;25(9):2471–8

CD34 expression in endothelial cells of small hepatocellular carcinoma: its correlation with tumour progression and angiographic findings. Maeda T, et al. **J Gastroenterol Hepatol** 1995 Nov–Dec;10(6):650–4

Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML. Sperling C, et al. **Leuk Lymphoma** 1995 May;17(5–6):417–26

Expression and long–term prognostic value of CD34 in childhood and adult acute lymphoblastic leukemia. Vanhaeke DR, et al. **Leuk Lymphoma** 1995 Dec; 20(1–2):137–42

The expression of the endothelial cell antigen CD34 in demyelinating disease. Allen IV, et al. **Neuropathol Appl Neurobiol** 1996 Apr;22(2):101–7

BLOOD

c–kit–positive cells and CD34–positive cells in cryopreserved peripheral blood stem cell samples. Yamane T, et al. **Acta Haematol** 1995;94(2):112–3

Cytokine mobilized blood CD34–expressing cells are not cycling [letter] Siegert W, et al. **Bone Marrow Transplant** 1996 Mar;17(3):467–70

Studies of P–glycoprotein in chronic myelogenous leukaemia patients: expression, activity and correlations with CD34 antigen. Turkina AG, et al. **Br J Haematol** 1996 Jan; 92(1):88–96

Human stem cell factor protects CD34 positive human myeloid leukaemia cells from chemotherapy–induced apoptosis [letter] Hassan HT, et al. **Eur J Cancer** 1995 Oct; 31A(11):1883–4

Generation of antigen–presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients. Fisch P, et al. **Eur J Immunol** 1996 Mar;26(3):595–600

Flow cytometric characterization of CD34+ hematopoietic progenitor cells in mobilized peripheral blood and bone marrow of cancer patients. D'Arena G, et al. **Haematologica** 1996 May–Jun;81(3):216–23

Whole megakaryocytes are present among CD34+ cells in the peripheral blood of patients with acute myeloid leukemia after intensive chemotherapy. Delfini C, et al. **Haematologica** 1996 May–Jun;81(3):284–5

Inhibitory effects of interleukin 12 on retroviral gene transduction into CD34 cord blood myeloid progenitors mediated by induction of tumor necrosis factor–alpha. Xiao M, et al. **J Hematother** 1996 Apr;5(2):171–7

GENETICS

Decreased expression of the human progenitor cell antigen (CD34) in morphea. Skobieranda K, et al. **Am J Dermatopathol** 1995 Oct;17(5):471–5

Retroviral–mediated gene expression in human myelomonocytic cells: a comparison of hematopoietic cell promoters to viral promoters. Malik P, et al. **Blood** 1995 Oct 15;86(8):2993–3005

The myeloid zinc finger gene, MZF–1, regulates the CD34

promoter in vitro. Morris JF, et al. **Blood** 1995 Nov 15; 86(10):3640–7

Influence of interleukin–3, interleukin–6, and stem cell factor on retroviral transduction of rhesus monkey CD34+ hematopoietic progenitor cells measured in vitro and in vivo. van Beusechem VW, et al. **Gene Ther** 1995 Jun; 2(4):245–55

Transduction of CD34–enriched human peripheral and umbilical cord blood progenitors using a retroviral vector with the Fanconi anemia group C gene. Walsh CE, et al. **J Investig Med** 1995 Aug;43(4):379–85

Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c–myb promoter activity. Perrotti D, et al. **Mol Cell Biol** 1995 Nov;15(11):6075–87

[Phenotypic differences between CD34 positive cells in various transplantation tissues] Fritsch G, et al. **Klin Padiatr** 1995 Jul–Aug;207(4):211–4 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Canine CD34: cloning of the cDNA and evaluation of an antiserum to recombinant protein. McSweeney PA, et al. **Blood** 1996 Sep 15;88(6):1992–2003

CD34–deficient mice have reduced eosinophil accumulation after allergen exposure and show a novel crossreactive 90–kD protein. Suzuki A, et al. **Blood** 1996 May 1; 87(9):3550–62

PBPC grafts from healthy donors: analysis of CD34+ and CD3+ subpopulations. Dreger P, et al. **Bone Marrow Transplant** 1996 Mar;17 Suppl 2:S22–7

CD34+ cell immunoselection from G–CSF–alone–primed peripheral blood in children with low body mass. Kanold J, et al. **Br J Haematol** 1995 Oct;91(2):431–3

Lack of DNA synthesis among CD34+ cells in cord blood and in cytokine–mobilized blood [see comments] Leitner A, et al. **Br J Haematol** 1996 Feb;92(2):255–62. Comment in: Br J Haematol 1996 Jun 1;93(3):737–8.

A standardized flow cytometry protocol for mobilized peripheral CD34+ cells estimation and collection for autotransplantation in cancer patients. Brando B, et al. **Eur J Histochem** 1994;38 Suppl 1:21–6 (12 ref.)

Differential cytokine effects on primitive (CD34+CD38–) human hematopoietic cells: novel responses to Flt3–ligand and thrombopoietin. Petzer AL, et al. **J Exp Med** 1996 Jun 1;183(6):2551–8

Lymphokine–activated killer cells can discriminate CD34+ leukemia cells from normal hematopoietic progenitor cells. Komatsu F, et al. **J Hematother** 1996 Feb;5(1):49–56

CD34 expression in adult acute lymphoblastic leukemia. Cacciola E, et al. **Leuk Lymphoma** 1995;18 Suppl 1:31–6

Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors. Migita M, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12075–9

[The effect of GM–CSF/IL–3 on the grafting efficiency of CD34+ hemopoietic progenitor cells from umbilical cord blood] Pei XT, et al. **Sheng Li Hsueh Pao** 1995 Oct; 47(5):485–90 (Eng. Abstr.) **(Chi)**

ISOLATION & PURIFICATION

[Autologous transplantation of hematopoietic precursor cells following CD34 selection] Tichelli A, et al. **Schweiz Med Wochenschr** 1996 Feb 10;126(6):201–6 (Eng. Abstr.) **(Ger)**

METABOLISM

Characterization of human CD34+ derived dendritic/Langerhans cells (D–Lc). Caux C, et al. **Adv Exp Med Biol** 1995;378:1–5

Immunophenotyping of hematological neoplasms. I. Expression of progenitor cell surface antigen (CD34). Koubek K, et al. **Adv Exp Med Biol** 1995;371B:897–9

Activation of primary allogeneic CD8+ T cells by dendritic cells generated in vitro from CD34+ cord blood progenitor cells. Wettendorff M, et al. **Adv Exp Med Biol** 1995;378:371–4

Macrophage inflammatory protein–1 alpha receptors are present on cells enriched for CD34 expression from patients with chronic myeloid leukemia. Chasty RC, et al. **Blood** 1995 Dec 1;86(11):4270–7

Separation of myeloid and erythroid progenitors based on expression of CD34 and c–kit. De Jong MO, et al. **Blood** 1995 Dec 1;86(11):4076–85

Development of human megakaryocytes: I. Hematopoietic progenitors (CD34+ bone marrow cells) are enriched with megakaryocytes expressing CD4. Dolzhanskiy A, et al. **Blood** 1996 Feb 15;87(4):1353–60

Granulomonocyte–associated lysosomal protein expression during in vitro expansion and differentiation of CD34+ hematopoietic progenitor cells. Scheinecker C, et al. **Blood** 1995 Dec 1;86(11):4115–23

Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow. von Laer D, et al. **Blood** 1995 Dec 1;86(11):4086–90

Comparative quantitative expression of bcl–2 by normal and leukaemic myeloid cells. Bradbury DA, et al. **Br J Haematol** 1995 Oct;91(2):374–9

Adhesion molecule expression on CD34+ progenitor cells from normal and aplastic anaemia bone marrow. Karakantza M, et al. **Br J Haematol** 1995 Dec;91(4):800–3

Highly purified CD34–positive cells reconstitute hematopoiesis. Civin CI, et al. **J Clin Oncol** 1996 Aug; 14(8):2224–33

CD34 antigen expression in adult acute lymphoblastic leukemia [letter] Kraguljac N, et al. **Leukemia** 1996 Jan; 10(1):190–1

The effect of high–dose methylprednisolone on CD34–positive bone marrow cells in the children with acute myeloblastic leukemia. Tuncer AM, et al. **Turk J Pediatr** 1995 Oct–Dec;37(4):345–9

PHARMACOLOGY

A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations. Chasty R, et al. **Leuk Res** 1996 May;20(5):391–5

PHYSIOLOGY

Hematopoietic defects in mice lacking the sialomucin CD34. Cheng J, et al. **Blood** 1996 Jan 15;87(2):479–90

Early commitment to the eosinophil lineage by cultured human peripheral blood CD34+ cells: messenger RNA analysis. Shalit M, et al. **J Allergy Clin Immunol** 1996 Aug; 98(2):344–54

Sialomucin CD34 is the major L–selectin ligand in human tonsil high endothelial venules. Puri KD, et al. **J Cell Biol** 1995 Oct;131(1):261–70

The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion. Healy L, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12240–4

[Recent data and current studies of epidermal Langerhans cells] Dezutter–Dambuyant C. **Pathol Biol (Paris)** 1995 Dec;43(10):841–7 (78 ref.) (Eng. Abstr.) **(Fre)**

[In vitro differenciation and functions of dendritic cells obtained from CD34+ hematopoietic progenitors] Dubois B, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):829–40 (88 ref.) (Eng. Abstr.) **(Fre)**

[The function of the CD34 molecule: still an unknown] Inglés Esteve J, et al. **Sangre (Barc)** 1996 Feb;41(1):47–54 (75 ref.) **(Spa)**

ANTIGENS, CD35 see **RECEPTORS, COMPLEMENT 3B**

ANTIGENS, CD36

ANALYSIS

Reduced uptake of oxidized low density lipoproteins in monocyte–derived macrophages from CD36–deficient subjects. Nozaki S, et al. **J Clin Invest** 1995 Oct; 96(4):1859–65

BIOSYNTHESIS

Regulation of monocyte CD36 and thrombospondin–1 expression by soluble mediators. Yesner LM, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1019–25

Regulated expression of CD36 during monocyte–to–macrophage differentiation: potential role of CD36 in foam cell formation. Huh HY, et al. **Blood** 1996 Mar 1;87(5):2020–8

N–3 but not N–6 fatty acids reduce the expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Pietsch A, et al. **Cell Biochem Funct** 1995 Sep;13(3):211–6

Structural and functional characterization of the human CD36 gene promoter: identification of a proximal PEBP2/CBF site. Armesilla AL, et al. **J Biol Chem** 1996 Mar 29;271(13):7781–7

BLOOD

CD36–positive stress reticulocytosis in sickle cell anemia [see comments] Browne PV, et al. **J Lab Clin Med** 1996 Apr; 127(4):340–7. Comment in: J Lab Clin Med 1996 Apr;127(4):321–5.

CHEMISTRY

CD36 is spatially associated with glycoprotein IIb–IIIa (alpha IIb beta 3) on the surface of resting platelets. Dorahy DJ, et al. **Biochem Biophys Res Commun** 1996 Jan 17; 218(2):575–81

Identification of a domain (155–183) on CD36 implicated in the phagocytosis of apoptotic neutrophils. Navazo MD, et al. **J Biol Chem** 1996 Jun 28;271(26):15381–5

GENETICS

A single nucleotide insertion in codon 317 of the CD36 gene leads to CD36 deficiency. Kashiwagi H, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1026–32

Human platelet glycoproteins V and IX: mapping of two leucine–rich glycoprotein genes to chromosome 3 and analysis of structures. Yagi M, et al. **Biochemistry** 1995 Dec 12;34(49):16132–7

Structural and functional characterization of the human CD36 gene promoter: identification of a proximal PEBP2/CBF site. Armesilla AL, et al. **J Biol Chem** 1996 Mar 29;271(13):7781–7

Family studies of type II CD36 deficient subjects: linkage of a CD36 allele to a platelet–specific mRNA expression defect(s) causing type II CD36 deficiency. Kashiwagi H, et al. **Thromb Haemost** 1995 Aug;74(2):758–63

Incidence of the Nak(a)–negative platelet phenotype in African Americans is similar to that of Asians. Curtis BR, et al. **Transfusion** 1996 Apr;36(4):331–4

IMMUNOLOGY

Antibodies to CD36 (GPIV) inhibit platelet adhesion to subendothelial surfaces under flow conditions. Diaz–Ricart M, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):883–8

Inhibition of platelet adhesion to collagen by monoclonal anti–CD36 antibodies. Matsuno K, et al. **Br J Haematol** 1996 Mar;92(4):960–7

Inhibition of breast cancer progression by an antibody to a thrombospondin–1 receptor. Wang TN, et al. **Surgery** 1996 Aug;120(2):449–54

ISOLATION & PURIFICATION

Croquemort, a novel Drosophila hemocyte/macrophage receptor that recognizes apoptotic cells. Franc NC, et al. **Immunity** 1996 May;4(5):431–43

METABOLISM

A detergent–sensitive 113–kDa conformer/complex of CD36 exists on the platelet surface. Rhinehart–Jones T, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):115–8

Identification on human CD36 of a domain (155–183) implicated in binding oxidized low–density lipoproteins (Ox–LDL). Puente Navazo MD, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1033–9

Increased platelet CD36 constitutes a common marker in myeloproliferative disorders. Thibert V, et al. **Br J Haematol** 1995 Nov;91(3):618–24

Synthesis, processing, and intracellular transport of CD36 during monocytic differentiation. Alessio M, et al. **J Biol Chem** 1996 Jan 19;271(3):1770–5

Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36. Ryeom SW, et al. **J Biol Chem** 1996 Aug 23; 271(34):20536–9

Scavenger receptor BI (SR–BI) is up–regulated in adrenal gland in apolipoprotein A–I and hepatic lipase knock–out mice as a response to depletion of cholesterol stores. In vivo evidence that SR–BI is a functional high density lipoprotein receptor under feedback control. Wang N, et al. **J Biol Chem** 1996 Aug 30;271(35):21001–4

Neutrophil thrombospondin receptors are linked to GTP–binding proteins. Suchard SJ, et al. **J Cell Physiol** 1996 Jul;168(1):217–27

Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. Landschulz KT, et al. **J Clin Invest** 1996 Aug 15;98(4):984–95

Thrombospondin receptor (CD36) expression of human keratinocytes during wound healing in a SCID mouse/human skin repair model. Simon M Jr, et al. **J Dermatol** 1996 May;23(5):305–9

Macrophages, but not Langerhans cell–like cells of dendritic lineage, express the CD36 molecule in normal human dermis: relevance to downregulatory cutaneous immune responses? Lonati A, et al. **J Invest Dermatol** 1996 Jan; 106(1):96–101

Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport. Ibrahimi A, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2646–51

Identification of scavenger receptor SR–BI as a high density lipoprotein receptor [see comments] Acton S, et al. **Science** 1996 Jan 26;271(5248):518–20. Comment in: Science 1996 Jan 26;271(5248):460–1.

A docking receptor for HDL cholesterol esters [comment] Steinberg D. **Science** 1996 Jan 26;271(5248):460–1 (15 ref.) . Comment on: Science 1996 Jan 26;271(5248):518–20.

Posttransfusion purpura–like syndrome associated with CD36 (Naka) isoimmunization. Bierling P, et al. **Transfusion** 1995 Sep;35(9):777–82

PHYSIOLOGY

Antibodies to CD36 (GPIV) inhibit platelet adhesion to subendothelial surfaces under flow conditions. Diaz–Ricart M, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):883–8

Glycoprotein IV–independent adhesion of sickle red blood cells to immobilized thrombospondin under flow conditions. Joneckis CC, et al. **Blood** 1996 Jun 1; 87(11):4862–70

Stimulation of platelet glycoprotein IIb–IIIa (alpha IIb beta 3–integrin) functional activity by a monoclonal antibody to the N–terminal region of glycoprotein IIIa. Mazurov AV, et al. **FEBS Lett** 1996 Aug 5;391(1–2):84–8

CD36 and intercellular adhesion molecule 1 mediate adhesion of developing Plasmodium falciparum gametocytes. Rogers NJ, et al. **Infect Immun** 1996 Apr;64(4):1480–3

To tell the truth: will the real CD36 please stand up? [editorial; comment] Asch A. **J Lab Clin Med** 1996 Apr; 127(4):321–5. Comment on: J Lab Clin Med 1996 Apr;127(4):340–7.

[Platelet collagen receptors] Kralisz U. **Postepy Biochem** 1995;41(3):188–94 (78 ref.) **(Pol)**

ANTIGENS, CD40

CD40 ligand deficiency presenting as unresponsive neutropenia. Andrews FJ, et al. **Arch Dis Child** 1996 May; 74(5):458–9

Identification of a CD40L gene mutation and genetic counselling in a family with immunodeficiency with hyperimmunoglobulinemia M. Kraakman ME, et al. **Clin Genet** 1995 Jul;48(1):46–8

ANALYSIS

CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma [see comments] Pammer J, et al. **Am J Pathol** 1996 May;148(5):1387–96. Comment in: Am J Pathol 1996 May;148(5):1323–9.

CD40: a sensitive marker of Reed–Sternberg cells [letter] Carbone A, et al. **Blood** 1996 Jun 1;87(11):4918–9

BIOSYNTHESIS

Modulation of expression of class II MHC and CD40 molecules in murine B cells by various muramyl dipeptides. Cohen LY, et al. **Cell Immunol** 1996 Apr 10;169(1):75–84

CD40 expression and function in murine B cell ontogeny. Castigli E, et al. **Int Immunol** 1996 Mar;8(3):405–411

Induction of CD40 in promyelocytic HL60 cells cultured with retinoic acid and/or various cytokines. Shinagawa T, et al. **J Biochem (Tokyo)** 1995 Sep;118(3):534–40

Acquisition of CD40 expression during murine B-cell differentiation. Grandien A, et al. **Scand J Immunol** 1996 Jan;43(1):47–55

BLOOD

CD40 expression by human peripheral blood eosinophils. Ohkawara Y, et al. **J Clin Invest** 1996 Apr 1;97(7):1761–6

CHEMISTRY

Monomeric and dimeric forms of soluble receptors can differ in their neutralization potential. Lauffer L, et al. **Behring Inst Mitt** 1995 Jun;(96):21–31

Cross-linking CD40 on B cells preferentially induces stress-activated protein kinases rather than mitogen-activated protein kinases. Berberich I, et al. **EMBO J** 1996 Jan 2;15(1):92–101

Cleavable CD40lg fusion proteins and the binding to sgp39. Hollenbaugh D, et al. **J Immunol Methods** 1995 Dec 15; 188(1):1–7

DRUG EFFECTS

Demonstration of functional CD40 in B-lineage acute lymphoblastic leukemia cells in response to T-cell CD40 ligand. Renard N, et al. **Blood** 1996 Jun 15;87(12):5162–70

Differential regulatory effects of cAMP-elevating agents on human normal and neoplastic B cell functional response following ligation of surface immunoglobulin and CD40. Kelly K, et al. **Cell Immunol** 1995 Nov;166(1):93–102

GENETICS

The human CD40 gene lies within chromosome 20q deletions associated with myeloid malignancies. Asimakopoulos FA, et al. **Br J Haematol** 1996 Jan;92(1):127–30

Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses. Ma J, et al. **J Immunol** 1996 Jul 1;157(1):417–26

Impaired T cell–mediated macrophage activation in CD40 ligand–deficient mice. Stout RD, et al. **J Immunol** 1996 Jan 1;156(1):8–11

IMMUNOLOGY

CD20 and CD40 mediated mitogenic responses in B-lineage acute lymphoblastic leukaemia. Smiers FJ, et al. **Br J Haematol** 1996 Apr;93(1):125–30

Hyper-IgM syndrome associated with rheumatoid arthritis: report of RA in a patient with primary impaired CD40 pathway. Sibilia J, et al. **Br J Rheumatol** 1996 Mar; 35(3):282–4

Nerve growth-factor and anti–CD40 provide opposite signals for the production of IgE in interleukin-4–treated lymphocytes. Brodie C, et al. **Eur J Immunol** 1996 Jan; 26(1):171–8

B cell–B cell interaction through intercellular adhesion molecule–1 and lymphocyte functional antigen–1 regulates immunoglobulin E synthesis by B cells stimulated with interleukin-4 and anti–CD40 antibody. Katada Y, et al. **Eur J Immunol** 1996 Jan;26(1):192–200

CD40 and its ligand in host defense. Noelle RJ. **Immunity** 1996 May;4(5):415–9 (43 ref.)

Anti–CD40 monoclonal antibody induces the proliferation of murine B cells as a B-cell mitogen through a distinct pathway from receptors for antigens or lipopolysaccharide. Nomura J, et al. **Immunol Lett** 1995 Mar;45(3):195–203

CD40 antibodies defining distinct epitopes display qualitative differences in their induction of B-cell differentiation. Björck P, et al. **Immunology** 1996 Feb;87(2):291–5

Ligation of CD40 with soluble CD40 ligand reverses anti–immunoglobulin-mediated negative signalling in murine B lymphoma cell lines but not in immature B cells from neonatal mice. Marshall-Clarke S, et al. **Immunology** 1996 Apr;87(4):624–32

CD40-activated human naive surface IgD+ B cells produce IgG2 in response to activated T-cell supernatant. Servet-Delprat C, et al. **Immunology** 1995 Jul;85(3):435–41

Properties of mouse CD40: differential expression of CD40 epitopes on dendritic cells and epithelial cells. Van Den Berg TK, et al. **Immunology** 1996 Jun;88(2):294–300

Effect of interleukin-10 on anti–CD40- and interleukin-4–induced immunoglobulin E production by human lymphocytes. Uejima Y, et al. **Int Arch Allergy Immunol** 1996 Jul;110(3):225–32

Therapeutic potential for blockade of the CD40 ligand, gp39. Buhlmann JE, et al. **J Clin Immunol** 1996 Mar;16(2):83–9 (56 ref.)

CD40L–deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. Borrow P, et al. **J Exp Med** 1996 May 1;183(5):2129–42

High level IL–12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL–4 and IL–10. Koch F, et al. **J Exp Med** 1996 Aug 1;184(2):741–6

Interleukin–10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. Malisan F, et al. **J Exp Med** 1996 Mar 1; 183(3):937–47

CD40–CD40 ligand interactions are critical in T–B cooperation but not for other anti–viral CD4+ T cell functions. Oxenius A, et al. **J Exp Med** 1996 May 1; 183(5):2209–18

Opposing roles of CD95 (Fas/APO–1) and CD40 in the death and rescue of human low density tonsillar B cells. Cleary AM, et al. **J Immunol** 1995 Oct 1;155(7):3329–37

Cytokine activation sensitizes human monocytic and endothelial cells to the cytotoxic effects of an anti–CD40 immunotoxin. Francisco JA, et al. **J Immunol** 1996 Aug 15;157(4):1652–8

Human follicular dendritic cells enhance cytokine-dependent growth and differentiation of CD40-activated B cells. Grouard G, et al. **J Immunol** 1995 Oct 1;155(7):3345–52

Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. Kiener PA, et al. **J Immunol** 1995 Nov 15;155(10):4917–25

Suppression of murine allergic contact dermatitis by CTLA4Ig. Tolerance induction of Th2 responses requires additional blockade of CD40–ligand. Tang A, et al. **J Immunol** 1996 Jul 1;157(1):117–25

Antibody to the ligand for CD40 (gp39) inhibits murine AIDS–associated splenomegaly, hypergammaglobulinemia, and immunodeficiency in disease–susceptible C57BL/6 mice. Green KA, et al. **J Virol** 1996 Apr;70(4):2569–75

Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the 'CD40 system'. Planken EV, et al. **Leukemia** 1996 Mar;10(3):488–93

Getting to know you: viruses meet CD40 ligand [comment] McFadden G. **Nat Med** 1995 May;1(5):408–9. Comment on: Nat Med 1995 May;1(5):437–41.

CD40 ligand has potent antiviral activity [see comments] Ruby J, et al. **Nat Med** 1995 May;1(5):437–41. Comment in: Nat Med 1995 May;1(5):408–9.

Impairment of antigen–specific T–cell priming in mice lacking CD40 ligand. Grewal IS, et al. **Nature** 1995 Dec 7;378(6557):617–20

Long–term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Larsen CP, et al. **Nature** 1996 May 30;381(6581):434–8

CD40 ligand–transduced co–stimulation of T cells in the development of helper function. van Essen D, et al. **Nature** 1995 Dec 7;378(6557):620–3

CD40–gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40–gp39 pathway. Larsen CP, et al. **Transplantation** 1996 Jan 15;61(1):4–9

CD40/CD40L interactions and cytokines regulate HIV replication in B cells in vitro. Gras G, et al. **Virology** 1996 Jun 15;220(2):309–19

METABOLISM

Functional CD40 antigen on B cells, dendritic cells and fibroblasts. Banchereau J, et al. **Adv Exp Med Biol** 1995; 378:79–83

Human dendritic cells enhance growth and differentiation of CD40 activated B cells. Dubois B, et al. **Adv Exp Med Biol** 1995;378:397–9

Human dendritic cells can drive CD40–activated sIgD+ B cells to mount mucosal–type humoral response. Fayette J, et al. **Adv Exp Med Biol** 1995;378:401–3

Human follicular dendritic cells promote both proliferation and differentiation of CD40 activated B cells. Grouard G, et al. **Adv Exp Med Biol** 1995;378:337–40

CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Carbone A, et al. **Am J Pathol** 1995 Oct;147(4):912–22

Monomeric and dimeric forms of soluble receptors can differ in their neutralization potential. Lauffer L, et al. **Behring Inst Mitt** 1995 Jun;(96):21–31

CD40 expression by human fibroblasts. Fries KM, et al. **Clin Immunol Immunopathol** 1995 Oct;77(1):42–51

CD40–CD40 ligand (CD40L) interactions and X–linked hyperIgM syndrome (HIGMX–1). Ramesh N, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S208–13 (37 ref.)

Rapid induction of a novel costimulatory activity on B cells by CD40 ligand. Wu Y, et al. **Curr Biol** 1995 Nov 1; 5(11):1303–11

Functional CD40 ligand expression on T lymphocytes in the absence of T cell receptor engagement: involvement in interleukin–2–induced interleukin–12 and interferon–gamma production. Armant M, et al. **Eur J Immunol** 1996 Jul;26(7):1430–4

Activation of mitogen–activated protein kinases via CD40 is distinct from that stimulated by surface IgM on B cells. Kashiwada M, et al. **Eur J Immunol** 1996 Jul;26(7):1451–8

CD40–mediated lymphotoxin alpha expression in human B cells is tyrosine kinase dependent. Worm M, et al. **Eur J Immunol** 1995 Sep;25(9):2438–44

Ligation of CD40 rescues Ramos–Burkitt lymphoma B cells from calcium ionophore– and antigen receptor–triggered apoptosis by inhibiting activation of the cysteine protease CPP32/Yama and cleavage of its substrate PARP. An S, et al. **FEBS Lett** 1996 May 20;386(2–3):115–22

Disruption of CD40–CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Soong L, et al. **Immunity** 1996 Mar;4(3):263–73

Induction of LFA–1 independent human B cell proliferation and differentiation by binding of CD40 with its ligand. Néron S, et al. **Immunol Invest** 1996 Jan–Mar;25(1–2):79–89

CD40 cross–linking inhibits specific antibody production by human B cells. Callard RE, et al. **Int Immunol** 1995 Nov; 7(11):1809–15

Evidence for a CD40 response element, distinct from the IL–4 response element, in the germline epsilon promoter. Fujita K, et al. **Int Immunol** 1995 Sep;7(9):1529–33

Immunodeficiency with hyperimmunoglobulinemia M in two female patients is not associated with abnormalities of CD40 or CD40 ligand expression. Oliva A, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):403–10

Human native soluble CD40L is a biologically active trimer, processed inside microsomes. Pietravalle F, et al. **J Biol Chem** 1996 Mar 15;271(11):5965–7

Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. Koshy M, et al. **J Clin Invest** 1996 Aug 1;98(3):826–37

CD40 and B cell antigen receptor dual triggering of resting B lymphocytes turns on a partial germinal center phenotype. Galibert L, et al. **J Exp Med** 1996 Jan 1; 183(1):77–85

A novel function of CD40: induction of cell death in transformed cells. Hess S, et al. **J Exp Med** 1996 Jan 1; 183(1):159–67

Ligation of CD40 influences the function of human Ig–secreting B cell hybridomas both positively and negatively. Bergman MC, et al. **J Immunol** 1996 May 1; 156(9):3118–32

CD40 function in nonhematopoietic cells. Nuclear factor kappa B mobilization and induction of IL–6 production. Hess S, et al. **J Immunol** 1995 Nov 15;155(10):4588–95

CD40–mediated signaling in B cells. Balancing cell survival, growth, and death. Kehry MR. **J Immunol** 1996 Apr 1; 156(7):2345–8 (77 ref.)

CD40 expressed on thymic epithelial cells provides costimulation for proliferation but not for apoptosis of human thymocytes. Ruggiero G, et al. **J Immunol** 1996 May 15;156(10):3737–46

Maintenance of nuclear factor–kappa B/Rel and c–myc expression during CD40 ligand rescue of WEHI 231 early B cells from receptor–mediated apoptosis through modulation of I kappa B proteins. Schauer SL, et al. **J Immunol** 1996 Jul 1;157(1):81–6

CD40 ligand is expressed and functional on activated neonatal T cells. Splawski JB, et al. **J Immunol** 1996 Jan 1;156(1):119–27

Inhibition of the CD40–CD40ligand pathway prevents murine membranous glomerulonephritis. Biancone L, et al. **Kidney Int** 1995 Aug;48(2):458–68

CD40–CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Gerritse K, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2499–504

Induction of alloantigen–specific tolerance by B cells from CD40–deficient mice. Holländer GA, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4994–8

TRAF5, a novel tumor necrosis factor receptor–associated factor family protein, mediates CD40 signaling. Ishida TK, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9437–42

Characterization of a 23–kDa protein associated with CD40. Morio T, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5; 92(25):11633–6

PHARMACOLOGY

CD40–CD40 ligand interactions stimulate B cell antigen processing. Faassen AE, et al. **Eur J Immunol** 1995 Dec; 25(12):3249–55

CD40/CD40 ligand interactions are required for T cell–dependent production of interleukin–12 by mouse macrophages. Kennedy MK, et al. **Eur J Immunol** 1996 Feb;26(2):370–8

Accessory signaling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy with interleukin–12 for interferon–gamma production. Peng X, et al. **Eur J Immunol** 1996 Jul;26(7):1621–7

CD40–mediated regulation of interleukin–4 signaling pathways in B lymphocytes. Siepmann K, et al. **Eur J Immunol** 1996 Jul;26(7):1544–52

Long–term cultured CD40–activated B lymphocytes differentiate into plasma cells in response to IL–10 but not

IL-4. Rousset F, et al. **Int Immunol** 1995 Aug;7(8):1243-53
Cytokine activation sensitizes human monocytic and endothelial cells to the cytotoxic effects of an anti-CD40 immunotoxin. Francisco JA, et al. **J Immunol** 1996 Aug 15;157(4):1652-8
Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. Kato T, et al. **J Immunol** 1996 May 15; 156(10):3932-8
Activation of human monocytes through CD40 induces matrix metalloproteinases. Malik N, et al. **J Immunol** 1996 May 15;156(10):3952-60

PHYSIOLOGY

Early response genes activated by stimulation of human B lymphocytes through different cell surface receptors. Newton JS, et al. **Biochem Soc Trans** 1996 Feb;24(1):7S
Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. Tuscano JM, et al. **Blood** 1996 Aug 15;88(4):1359-64
CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Pellat-Deceunynck C, et al. **Cancer Res** 1996 Apr 15; 56(8):1909-16
Regulation of B cell growth and differentiation via CD21 and CD40. Axcrona K, et al. **Eur J Immunol** 1996 Sep; 26(9):2203-7
Human epidermal keratinocytes are induced to secrete interleukin-6 and co-stimulate T lymphocyte proliferation by a CD40-dependent mechanism. Gaspari AA, et al. **Eur J Immunol** 1996 Jun;26(6):1371-7
Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand-dependent pathway. McLellan AD, et al. **Eur J Immunol** 1996 Jun;26(6):1204-10
Synergistic effect between CD40 and class II signals overcome the requirement for class II dimerization in superantigen-induced cytokine gene expression. Mehindate K, et al. **Eur J Immunol** 1996 Sep;26(9):2075-80
B cell early response gene expression coupled to B cell receptor, CD40 and interleukin-4 receptor co-stimulation: evidence for a role of the egr-2/krox 20 transcription factor in B cell proliferation. Newton JS, et al. **Eur J Immunol** 1996 Apr;26(4):811-6
Triggering through CD40 promotes interleukin-4-induced CD23 production and enhanced soluble CD23 release in atopic disease. Paterson RL, et al. **Eur J Immunol** 1996 Sep;26(9):1979-84
The differentiation of human memory B cells into specific antibody-secreting cells is CD40 independent. Silvy A, et al. **Eur J Immunol** 1996 Mar;26(3):517-24
TANK, a co-inducer with TRAF2 of TNF- and CD 40L-mediated NF-kappaB activation. Cheng G, et al. **Genes Dev** 1996 Apr 15;10(8):963-73
CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Campbell KA, et al. **Immunity** 1996 Mar;4(3):283-9
Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Kamanaka M, et al. **Immunity** 1996 Mar;4(3):275-81
IgE-producing hybridomas established after B-cell culture in the CD40 system. Zürcher AW, et al. **Immunol Lett** 1995 May;46(1-2):49-57
A T cell lymphoma can provide potent co-stimulatory effects to T cells that are not mediated by B7-1, B7-2, CD40, HSA or CD70. Nieland JD, et al. **Int Immunol** 1995 Nov; 7(11):1827-38
Role of LFA-1/ICAM-1-dependent cell adhesion in CD40-mediated inhibition of anti-IgM antibody-induced B-cell death. Mayumi M, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1136-44
Selective activation of c-Jun kinase mitogen-activated protein kinase by CD40 on human B cells. Sakata N, et al. **J Biol Chem** 1995 Dec 22;270(51):30823-8
Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. Cella M, et al. **J Exp Med** 1996 Aug 1;184(2):747-52
Fas ligation induces apoptosis of CD40-activated human B lymphocytes. Garrone P, et al. **J Exp Med** 1995 Nov 1; 182(5):1265-73
CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. Schattner EJ, et al. **J Exp Med** 1995 Nov 1;182(5):1557-65
Activation mediated by RP105 but not CD40 makes normal B cells susceptible to anti-IgM-induced apoptosis: a role for Fc receptor coligation. Yamashita Y, et al. **J Exp Med** 1996 Jul 1;184(1):113-20
Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. Yellin MJ, et al. **J Exp Med** 1995 Dec 1;182(6):1857-64
Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. Anti-Ig down-regulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis. Choe J, et al. **J Immunol** 1996 Aug 1;157(3):1006-16
Protective antibodies in murine Lyme disease arise independently of CD40 ligand. Fikrig E, et al. **J Immunol** 1996 Jul 1;157(1):1-3
Different CD40-mediated signaling events require distinct CD40 structural features. Hostager BS, et al. **J Immunol** 1996 Aug 1;157(3):1047-53
CD40 signaling-mediated induction of Bcl-XL, Cdk4, and Cdk6. Implication of their cooperation in selective B cell growth. Ishida T, et al. **J Immunol** 1995 Dec 15; 155(12):5527-35
A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death. Lens SM, et al. **J Immunol** 1996 Jan 15;156(2):507-14
CD40 ligation results in protein kinase C-independent activation of ERK and JNK in resting murine splenic B cells. Li YY, et al. **J Immunol** 1996 Aug 15;157(4):1440-7
CD40-mediated stimulation contributes to lymphocyte proliferation, antibody production, eosinophilia, and mastocytosis during an in vivo type 2 response, but is not required for T cell IL-4 production. Lu P, et al. **J Immunol** 1996 May 1;156(9):3327-33
Modulation of anti-IgM-induced B cell apoptosis by Bcl-xL and CD40 in WEHI-231 cells. Dissociation from cell cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction. Merino R, et al. **J Immunol** 1995 Oct 15;155(8):3830-8
Functional expression of CD40 antigen on human epidermal Langerhans cells. Péguet-Navarro J, et al. **J Immunol** 1995 Nov 1;155(9):4241-7
CD40 expressed on thymic epithelial cells provides costimulation for proliferation but not for apoptosis of human thymocytes. Ruggiero G, et al. **J Immunol** 1996 May 15;156(10):3737-46
CD40 ligand is expressed and functional on activated neonatal T cells. Splawski JB, et al. **J Immunol** 1996 Jan 1;156(1):119-27
Induction of bcl-x by CD40 engagement rescues sIg-induced apoptosis in murine B cells. Wang Z, et al. **J Immunol** 1995 Oct 15;155(8):3722-5
Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. Yang Y, et al. **J Virol** 1996 Sep;70(9):6370-7
Activation of NF-kappaB/Rel by CD40 engagement induces the mouse germ line immunoglobulin Cgamma1 promoter. Lin SC, et al. **Mol Cell Biol** 1996 Sep;16(9):4591-603
Induction of costimulatory molecules B7-1 and B7-2 in murine B cells. the CBA/N mouse reveals a role for Bruton's tyrosine kinase in CD40-mediated B7 induction. Goldstein MD, et al. **Mol Immunol** 1996 Apr;33(6):541-52
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) elevates basal B-cell intracellular calcium concentration and suppresses surface Ig- but not CD40-induced antibody secretion. Karras JG, et al. **Toxicol Appl Pharmacol** 1996 Apr; 137(2):275-84

ANTIGENS, CD41 see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

ANTIGENS, CD42A see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

ANTIGENS, CD42B see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

ANTIGENS, CD42C see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

ANTIGENS, CD42D see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

ANTIGENS, CD44

Enzyme-linked hyaluronectin: a unique reagent for hyaluronan assay and tissue location and for hyaluronidase activity detection. Delpech B, et al. **Anal Biochem** 1995 Jul 20;229(1):35-41
Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Spafford MF, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):627-32
Natural killer cell precursors in the CD44neg/dim T-cell receptor population of mouse bone marrow. Delfino DV, et al. **Blood** 1996 Mar 15;87(6):2394-400
Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. Yamaguchi A, et al. **J Clin Oncol** 1996 Apr;14(4):1122-7

ANALYSIS

Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Yeo TK, et al. **Am J Pathol** 1996 Jun;148(6):1733-40
A method to radioiodinate hyaluronic acid and its use as a probe to detect hyaluronic acid-binding proteins. Rao CM, et al. **Anal Biochem** 1996 Apr 5;236(1):171-3
Biotinylated hyaluronic acid as a probe for identifying hyaluronic acid-binding proteins. Yang B, et al. **Anal Biochem** 1995 Jul 1;228(2):299-306
Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers. de la Torre M, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2791-5
Expression of the adhesion molecule CD44v3 is a prognostic factor in vulvar carcinoma. Tempfer C, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):2029-31
Combined detection of CD44 isoforms by exon-specific RT-PCR and immunohistochemistry in primary human brain tumors and brain metastases. Frank S, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):794-801
Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44. Sinn HP, et al. **Breast Cancer Res Treat** 1995;36(3):307-313
The expression of CD44 adhesion molecules on seminoma cells. A new marker for early detection of the tumor. Hadziselimovic F, et al. **Cancer** 1996 Feb 1;77(3):429-30
Progression in gastric carcinoma relative to the ratio of CD44 epithelial variant transcript to CD44 hematopoietic variant transcript. Miwa T, et al. **Cancer** 1996 Jan 1;77(1):25-9
CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Friedrichs K, et al. **Cancer Res** 1995 Nov 15;55(22):5424-33
Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. Gansauge F, et al. **Cancer Res** 1995 Dec 1;55(23):5499-503
Are CD44 variant isoforms involved in human tumour progression? Günthert U, et al. **Cancer Surv** 1995;24:19-42 (116 ref.)
Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Christiansen H, et al. **Eur J Cancer** 1995;31A(4):541-4
Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors. Combaret V, et al. **Eur J Cancer** 1995;31A(4):545-9
Prognostic value of CD44 splice variants in human stage III cervical cancer. Kainz C, et al. **Eur J Cancer** 1995 Sep; 31A(10):1706-9
Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s. Terpe HJ, et al. **Eur J Cancer** 1995;31A(4):549-52 (60 ref.)
A CD44 variant exon 6 epitope as a prognostic indicator in breast cancer. Schumacher U, et al. **Eur J Surg Oncol** 1996 Jun;22(3):259-61
CD44 expression in fetal rat bone: in vivo and in vitro analysis. Jamal HH, et al. **Exp Cell Res** 1996 Mar 15; 223(2):467-77
Accessible hyaluronan receptors identical to ICAM-1 in mouse mast-cell tumours. Gustafson S, et al. **Glycoconj J** 1995 Jun;12(3):350-5
CD-44: a marker of metastases of head and neck melanomas. Korabiowska M, et al. **In Vivo** 1995 May-Jun;9(3):253-6
Increased susceptibility to primary infection with Listeria monocytogenes in germfree mice may be due to lack of accumulation of L-selectin+ CD44+ T cells in sites of inflammation. Inagaki H, et al. **Infect Immun** 1996 Aug; 64(8):3280-7
Immunohistochemical detection of adhesion molecule CD44 splice variants in lymph node metastases of cervical cancer. Kainz C, et al. **Int J Cancer** 1996 Jun 21;69(3):170-3
CD44 expression in dysplastic epithelium and squamous-cell carcinoma of the esophagus. Roye GD, et al. **Int J Cancer** 1996 Aug 22;69(4):254-8
CD44 standard and variant isoform expression in human epidermal skin tumors is not correlated with tumor aggressiveness but down-regulated during proliferation and tumor de-differentiation. Seelentag WK, et al. **Int J Cancer** 1996 Jun 21;69(3):218-24
Localisation and cellular origin of hyaluronectin. Ponting JM, et al. **J Anat** 1995 Oct;187 (Pt 2):331-46
Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. Combaret V, et al. **J Clin Oncol** 1996 Jan;14(1):25-34
Expression of CD44H and CD44v3 in normal oesophagus, Barrett mucosa and oesophageal carcinoma. Castellà E, et al. **J Clin Pathol** 1996 Jun;49(6):489-92
Cellular distribution of CD44 gene transcripts in colorectal carcinomas and in normal colonic mucosa. Gorham H, et al. **J Clin Pathol** 1996 Jun;49(6):482-8
OCT embedded sections of pathological specimens as a source of high quality RNA for reverse transcriptase/polymerase chain reaction. Irving JA, et al. **J Clin Pathol** 1996 Mar;49(3):258-9
Abnormal expression of the human CD44 gene in early colorectal malignancy with special reference to variant exon 9 (9v). Kawahara K, et al. **J Clin Pathol** 1996 Jun; 49(6):478-81
CD44v6 is a marker for systemic spread in cutaneous T-cell lymphomas. A comparative study between nodal and cutaneous lymphomas. Dommann SN, et al. **J Cutan Pathol** 1995 Oct;22(5):407-12
Spatial distribution of CD44 and hyaluronan in the proximal tibia of the growing rat. Noonan KJ, et al. **J Orthop Res** 1996 Jul;14(4):573-81
Standard and variant CD44 isoforms are commonly expressed in lung cancer of the non-small cell type but not of the small cell type. Ariza A, et al. **J Pathol** 1995 Dec; 177(4):363-8
Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies. Taylor DD, et al. **J Soc Gynecol Investig** 1996 Sep-Oct;3(5):289-94
CD44 variants in ulcerative colitis and Crohn's disease [letter; comment] Kitano A, et al. **Lancet** 1996 Jul 27; 348(9022):266-7. Comment on: Lancet 1995 May 13;345(8959):1205-9. Comment on: Lancet 1996 May 18;347(9012):1413-4.
Expression of CD44 variants in differential diagnosis of ulcerative colitis and Crohn's disease [letter; comment] [see comments] Papadogiannakis N, et al. **Lancet** 1996 May 18;

347(9012):1413-4. Comment on: Lancet 1995 May 13;345(8959):1205-9. Comment in: Lancet 1996 Jul 27;348(9022):268-7.

Expression of CD44v6 in ulcerative colitis and Crohn's disease [letter; comment] Reinisch W, et al. **Lancet** 1996 Apr 13;347(9007):1049. Comment on: Lancet 1995 May 13;345(8959):1205-9.

Expression of CD44 splice variants in normal respiratory epithelium and bronchial carcinomas: no evidence for altered CD44 splicing in metastasis. Givehohian M, et al. **Oncogene** 1996 Mar 7;12(5):1137-44

Expression of CD44 isoforms in human prostate tumor cell lines. Stevens JW, et al. **Prostate** 1996 Mar;28(3):153-61

Expression of CD44 isoforms in human renal cell carcinomas. Heider KH, et al. **Virchows Arch** 1996 Jul;428(4-5):267-73

Expression of CD44 splice variants in human skin and epidermal tumours. Seiter S, et al. **Virchows Arch** 1996 Jun; 428(3):141-9

[Immunohistochemical characterization of CD44 molecules expressed in human brain metastases] Li H, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep;17(5):325-7 (Eng. Abstr.) **(Chi)**

[Crohn disease or hemorrhagic reetocolitis? CD 44V6 and CD 44V3 adhesion molecules can make the difference] Lémann M. **Gastroenterol Clin Biol** 1995 Aug-Sep; 19(8-9):741-2 **(Fre)**

[Expression of CD44 isoforms--a new histopathologic parameter in colorectal carcinoma?] Finke LH, et al. **Zentralbl Chir** 1996;121(6):450-4 (Eng. Abstr.) **(Ger)**

[Expression of CD44 variant isoforms in human primary colon carcinomas and metastasis] Shibuya Y, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:169-73 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Differential expression and localization of integrins and CD44 in the membrane domains of human uterine epithelial cells during the menstrual cycle. Albers A, et al. **Acta Anat (Basel)** 1995;153(1):12-9

Differential expression of CD44 in rabbit uterine epithelium during early pregnancy. Hohn HP, et al. **Acta Anat (Basel)** 1995;152(3):185-94

Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Terpe HJ, et al. **Am J Pathol** 1996 Feb;148(2):453-63

Distinct expression patterns of CD44 isoforms during human lung development and in pulmonary fibrosis. Kasper M, et al. **Am J Respir Cell Mol Biol** 1995 Dec;13(6):648-56

CD44 in growing normal and neoplastic rat cartilage. Stevens JW, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:333-6

A splice variant of CD44 expressed in the rat apical ectodermal ridge contributes to limb outgrowth. Wainwright D, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:345-9

Up-regulation of CD44 and ICAM-1 expression on gastric epithelial cells by H. pylori. Fan XG, et al. **APMIS** 1995 Oct;103(10):744-8

Differentiation-associated changes in CD44 isoform expression during normal hematopoiesis and their alteration in chronic myeloid leukemia. Ghaffari S, et al. **Blood** 1995 Oct 15;86(8):2976-85

Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Sleeman JP, et al. **Cancer Res** 1996 Jul 1;56(13):3134-41

Induction of a hyaluronan receptor, CD44, during embryonal carcinoma and embryonic stem cell differentiation. Wheatley SC, et al. **Cell Adhes Commun** 1995 Aug; 3(3):217-30

The role of CD44 splice variants in human metastatic cancer. Sleeman J, et al. **Ciba Found Symp** 1995;189:142-51; discussion 151-6, 174-6 (43 ref.)

Expression of a specific subset of CD44 variant transcripts in NOD pancreatic islets. Milde KF, et al. **Diabetes** 1996 Jun;45(6):718-24

Expression of CD44 and variant isoforms in cervical intraepithelial neoplasia. Dellas A, et al. **Gynecol Oncol** 1996 Aug;62(2):218-25

Expression of CD44 isoforms during bleomycin-or radiation-induced pulmonary fibrosis in rats and mini-pigs. Kasper M, et al. **Histochem Cell Biol** 1996 Mar; 105(3):221-30

Stimulatory effects of pleural fluids from mesothelioma patients on CD44 expression, hyaluronan production and cell proliferation in primary cultures of normal mesothelial and transformed cells. Teder P, et al. **Int J Cancer** 1996 Jul 29;67(3):393-8

Transforming growth factor-beta1 stimulates multiple protein interactions at a unique cis-element in the 3'-untranslated region of the hyaluronan receptor RHAMM mRNA. Amara FM, et al. **J Biol Chem** 1996 Jun 21;271(25):15279-84

Increased expression of CD44 in bovine articular chondrocytes by catabolic cellular mediators. Chow G, et al. **J Biol Chem** 1995 Nov 17;270(46):27734-41

Role of CD44 in the reaction of vascular smooth muscle cells to arterial wall injury. Jain M, et al. **J Clin Invest** 1996 Feb 1;97(3):596-603

Role of CD44 in the reaction of vascular smooth muscle cells to arterial wall injury. Jain M, et al. **J Clin Invest** 1996 Aug 1;98(3):877

Accelerated immune response in transgenic mice expressing rat CD44v4-v7 on T cells. Moll J, et al. **J Immunol** 1996 Mar 15;156(6):2085-94

Importance of different CD44v6 expression in human gastric intestinal and diffuse type cancers for metastatic lymphogenic spreading. Dämmrich J, et al. **J Mol Med** 1995 Aug;73(8):395-401

CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. Zöller M. **J Mol Med** 1995 Sep;73(9):425-38 (265 ref.)

Gene therapeutic approach to primary and metastatic brain tumors: I. CD44 variant pre-RNA alternative splicing as a CEPT control element. Asman DC, et al. **J Neurooncol** 1995 Dec;26(3):243-50

Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system. Baltuch GH, et al. **J Neurooncol** 1995 Dec;26(3):191-8 (62 ref.)

Expression of variant CD44 epitopes in human astrocytic brain tumors. Eibl RH, et al. **J Neurooncol** 1995 Dec; 26(3):165-70

Gene therapeutic approaches to primary and metastatic brain tumors: II. ribozyme-mediated suppression of CD44 expression. Ge L, et al. **J Neurooncol** 1995 Dec;26(3):251-7

Expression of CD44 splice variants in human primary brain tumors. Kaaijk P, et al. **J Neurooncol** 1995 Dec; 26(3):185-90

Schwann cell tumors express characteristic patterns of CD44 splice variants. Sherman L, et al. **J Neurooncol** 1995 Dec; 26(3):171-84 (57 ref.)

The clinical significance of malfunction of the CD44 locus in malignancy. Tarin D, et al. **J Neurooncol** 1995 Dec; 26(3):209-19 (59 ref.)

Cytokine-mediated modulation of integrin, ICAM-1 and CD44 expression on human uveal melanoma cells in vitro. Creyghton WM, et al. **Melanoma Res** 1995 Aug;5(4):235-42

Expression of CD44 and the pattern of CD44 alternative splicing in uveal melanoma. Danen EH, et al. **Melanoma Res** 1996 Feb;6(1):31-5

Role of EGR1 in regulation of stimulus-dependent CD44 transcription in B lymphocytes. Maltzman JS, et al. **Mol Cell Biol** 1996 May;16(5):2283-94

In vivo and in vitro expression of adhesion molecules by peripheral blood lymphocytes from patients with primary Sjogren's syndrome: culture-associated enhancement of LECAM-1 and CD44. Aziz KE, et al. **Rheumatol Int** 1995; 15(2):69-74

CD44 expression in rejecting rat small bowel allografts. Uff CR, et al. **Transplantation** 1995 Nov 15;60(9):985-9

[Expression of CD44 isoforms in normal human liver and also in regenerative and neoplastic liver changes] Seelentag WK, et al. **Verh Dtsch Ges Pathol** 1995;79:144-7 (Eng. Abstr.) **(Ger)**

BLOOD

Systemic levels of soluble CD44 variant 6 (sCD44v6) in chronic inflammatory bowel disease [letter] Folwaczny C, et al. **Am J Gastroenterol** 1996 Aug;91(8):1680-1

Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Sliutz G, et al. **Br J Cancer** 1995 Dec;72(6):1494-7

Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. Jung K, et al. **Eur J Cancer** 1996 Apr;32A(4):627-30

Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. Harn HJ, et al. **J Clin Gastroenterol** 1996 Mar;22(2):107-10

CHEMISTRY

Modulation of the hyaluronan receptor, CD44, by its transmembrane and cytoplasmic domains. Sheikh H, et al. **Biochem Soc Trans** 1995 Nov;23(4):831-5 (33 ref.)

The protein fold of the hyaluronate-binding proteoglycan tandem repeat domain of link protein, aggrecan and CD44 is similar to that of the C-type lectin superfamily. Brissett NC, et al. **FEBS Lett** 1996 Jun 17;388(2-3):211-6

Expression of CD44 variants in human inflammatory synovitis. Hale LP, et al. **J Clin Immunol** 1995 Nov; 15(6):300-11

A cysteine residue located in the transmembrane domain of CD44 is important in binding of CD44 to hyaluronic acid. Liu D, et al. **J Exp Med** 1996 May 1;183(5):1987-94

DRUG EFFECTS

Hyaluronan receptor antagonists alter skin inflammation and fibrosis following injury. Savani RC, et al. **Proc West Pharmacol Soc** 1995;38:131-6 (68 ref.)

GENETICS

Differential expression of CD44 in malignant cutaneous epithelial neoplasms. Prieto VG, et al. **Am J Dermatopathol** 1995 Oct;17(5):447-51

Progressive loss of CD44 gene expression in invasive bladder cancer. Sugino T, et al. **Am J Pathol** 1996 Sep; 149(3):873-82

A splice variant of CD44 expressed in the rat apical ectodermal ridge contributes to limb outgrowth. Wainwright D, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:345-9

CD 44 exon v6 as a predictor of lymphatic metastases in cervical carcinoma--an immunocytochemical study of 94 cases. Biesold C, et al. **Arch Gynecol Obstet** 1995; 256(3):147-53

Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. Gotley DC, et al. **Br J Cancer** 1996 Aug;74(3):342-51

Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Sliutz G, et al. **Br J Cancer** 1995 Dec;72(6):1494-7

Prognostic value of immunohistochemically detected CD44 expression in patients with carcinoma of the vulva. Tempfer C, et al. **Cancer** 1996 Jul 15;78(2):273-7

Restricted patterns of CD44 variant exon expression in human papillary thyroid carcinoma. Ermak G, et al. **Cancer Res** 1996 Mar 1;56(5):1037-42

Deregulated alternative splicing of CD44 messenger RNA transcripts in neoplastic and nonneoplastic lesions of the human thyroid. Ermak G, et al. **Cancer Res** 1995 Oct 15; 55(20):4594-8

Oncogene-dependent expression of CD44 in Balb/c 3T3 derivatives: correlation with metastatic competence. Kogerman P, et al. **Clin Exp Metastasis** 1996 Jan; 14(1):73-82

CD44 exon variant 6 epitope and hyaluronate synthase are expressed on HT29 human colorectal carcinoma cells in a SCID mouse model of metastasis formation. Mitchell BS, et al. **Clin Exp Metastasis** 1996 Mar;14(2):107-14

Trans-acting factors regulate the expression of CD44 splice variants. Konig H, et al. **EMBO J** 1996 Aug 1; 15(15):4030-9

Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. Heider KH, et al. **Eur J Cancer** 1995 Dec;31A(13-14):2385-91

Expression of CD44 splice variants in human transitional cell carcinoma. Takada S, et al. **Eur Urol** 1996;29(3):370-3

Expression of variant CD44-messenger RNA in colorectal adenocarcinomas and adenomatous polyps in humans. Imazeki F, et al. **Gastroenterology** 1996 Feb;110(2):362-8

Characterization of the murine gene encoding the hyaluronan receptor RHAMM. Entwistle J, et al. **Gene** 1995 Oct 3; 163(2):233-8

The human and mouse receptors for hyaluronan-mediated motility, RHAMM, genes (HMMR) map to human chromosome 5q33.2-qter and mouse chromosome 11. Spicer AP, et al. **Genomics** 1995 Nov 1;30(1):115-7

Increasing incidence of CD44v7/8 epitope expression during uterine cervical carcinogenesis. Dall P, et al. **Int J Cancer** 1996 Apr 22;69(2):79-85

Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Higashikawa K, et al. **Int J Cancer** 1996 Mar 28;66(1):11-7

Altered expression of CD44 isoforms in squamous-cell carcinomas and cell lines derived from them. Hudson DL, et al. **Int J Cancer** 1996 May 16;66(4):457-63

CD44 expression patterns in breast and colon tumors: a PCR-based study of splice variants. Rodriguez C, et al. **Int J Cancer** 1995 Oct 20;64(5):347-54

Molecular cloning of human fibroblast hyaluronic acid-binding protein confirms its identity with P-32, a protein co-purified with splicing factor SF2. Hyaluronic acid-binding protein as P-32 protein, co-purified with splicing factor SF2. Deb TB, et al. **J Biol Chem** 1996 Jan 26;271(4):2206-12

A blood group-related polymorphism of CD44 abolishes a hyaluronan-binding consensus sequence without preventing hyaluronan binding. Telen MJ, et al. **J Biol Chem** 1996 Mar 22;271(12):7147-53

A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44. Yu Q, et al. **J Biol Chem** 1996 Aug 23;271(34):20603-7

Detection of exfoliated carcinoma cells in colonic luminal washings by identification of deranged patterns of expression of the CD44 gene. Yoshida K, et al. **J Clin Pathol** 1996 Apr;49(4):300-5

Accelerated immune response in transgenic mice expressing rat CD44v4-v7 on T cells. Moll J, et al. **J Immunol** 1996 Mar 15;156(6):2085-94

Identification of CD44 splice variant in Korean colorectal cancers and cell lines. Suh SI, et al. **J Korean Med Sci** 1995 Jun;10(3):169-75

The clinical significance of malfunction of the CD44 locus in malignancy. Tarin D, et al. **J Neurooncol** 1995 Dec; 26(3):209-19 (59 ref.)

Retention of CD44 introns in bladder cancer: understanding the alternative splicing of pre-mRNA opens new insights into the pathogenesis of human cancers [editorial] Cooper DL. **J Pathol** 1995 Sep;177(1):1-3 (28 ref.)

Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. Matsumura Y, et al. **J Pathol** 1995 Sep;177(1):11-20

High-level expression of the CD44 variant sharing exon v10 in renal cancer. Kan M, et al. **Jpn J Cancer Res** 1995 Sep; 86(9):847-53

Expression of CD44 variant exons 8-10 in gastric cancer. Yamaguchi A, et al. **Jpn J Cancer Res** 1995 Dec; 86(12):1166-71

Enhanced expression of CD44 isoforms in nonobese diabetic (NOD) mice. Milde KF, et al. **Transplant Proc** 1995 Dec; 27(6):3409

Expression of CD44 splice variants in human skin and epidermal tumours. Seiter S, et al. **Virchows Arch** 1996 Jun; 428(3):141-9

[CD44 expression patterns in primary and secondary brain

tumors] Li H, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Sep;75(9):525–8, 573 (Eng. Abstr.) **(Chi)**

[Expression of CD44–standard in 182 primary neuroblastomas] Christiansen H, et al. **Klin Padiatr** 1995 Jul–Aug;207(4):219–21 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Adhesion of human hematopoietic progenitor cells to bone–marrow–derived stromal cells is enhanced by antibodies to CD44. Oostendorp RA, et al. **Acta Haematol** 1996;95(3–4):243–7

A CD44 monoclonal antibody differentially regulates CD11a/CD18 binding to intercellular adhesion molecules CD54, CD102 and CD50. Vermot–Desroches C, et al. **Eur J Immunol** 1995 Sep;25(9):2460–4

Homotypic cell aggregation via conformational change of CD44 molecule induced by anti–CD44 monoclonal antibodies. Cao L, et al. **Immunobiology** 1995 Jun; 193(1):1–14

Characterization of an anti–CD44 single–chain FV antibody that stimulates natural killer cell activity and induces TNF alpha release. Tan PH, et al. **Immunol Invest** 1995 Nov; 24(6):907–26

Modulation of superantigen–induced T–cell deletion by antibody anti–Pgp–1 (CD44). Ayroldi E, et al. **Immunology** 1996 Feb;87(2):191–7

CD44 and hyaluronan–dependent rolling interactions of lymphocytes on tonsillar stroma. Clark RA, et al. **J Cell Biol** 1996 Aug;134(4):1075–87

CD44 exhibits a cell type dependent interaction with triton X–100 insoluble, lipid rich, plasma membrane domains. Neame SJ, et al. **J Cell Sci** 1995 Sep;108 (Pt 9):3127–35

A case of pretibial myxedema associated with Graves' disease: an immunohistochemical study of serum–derived hyaluronan–associated protein. Shishido M, et al. **J Dermatol** 1995 Dec;22(12):948–52

Alternative triggering molecules and single chain bispecific antibodies. Segal DM, et al. **J Hematother** 1995 Oct; 4(5):377–82 (31 ref.)

Lutheran antigens, CD44–related antigens, and Lutheran regulatory genes. Telen MJ. **Transfus Clin Biol** 1995; 2(4):291–301 (70 ref.)

[Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease] **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1492–3 **(Ger)**

METABOLISM

Expression of CD44 antigen by Langerhans cells and Thy1+ dendritic epidermal cells—ontogenetic variation and its role in migration. Osada A, et al. **Adv Exp Med Biol** 1995; 378:117–9

Immunolocalization of CD44 and heparan sulfate chains on the stratum intermedium and papillary layer in the rat enamel organ. Nakamura H, et al. **Arch Histol Cytol** 1995 Aug;58(3):323–34

A novel ligand blot assay detects different hyaluronan–binding proteins in rat liver hepatocytes and sinusoidal endothelial cells. Yannariello–Brown J, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):314–9

Modulation of the hyaluronan receptor, CD44, by its transmembrane and cytoplasmic domains. Sheikh H, et al. **Biochem Soc Trans** 1995 Nov;23(4):831–5 (33 ref.)

Expression of CD44 isoforms in basal cell carcinomas. Baum HP, et al. **Br J Dermatol** 1996 Mar;134(3):465–8

An aggressive subtype of B–CLL is characterized by strong CD44 expression and lack of CD11c. Eistere W, et al. **Br J Haematol** 1996 Jun 1;93(3):661–9

Implication of CD44 in adhesion–mediated overproduction of TGF–beta and IL–1 in monocytes from patients with bone marrow fibrosis. Rameshwar P, et al. **Br J Haematol** 1996 Apr;93(1):22–9

Difference in expression of CD44 splice variants between proximal and distal adenocarcinoma of the large bowel. Mulder JW, et al. **Br J Surg** 1995 Nov;82(11):1468–70

Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study. Zhang XH, et al. **Br J Urol** 1996 Mar;77(3):441–4

Oncogene–dependent expression of CD44 in Balb/c 3T3 derivatives: correlation with metastatic competence. Kogerman P, et al. **Clin Exp Metastasis** 1996 Jan; 14(1):73–82

Epidermal growth factor modulates cell attachment to hyaluronic acid by the cell surface glycoprotein CD44. Zhang M, et al. **Clin Exp Metastasis** 1996 May;14(3):268–76

Interactions between CD44 and hyaluronic acid: their role in tumor growth and metastasis. Sy MS, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):129–53 (150 ref.)

CD44 expression and modulation on human neuroblastoma tumours and cell lines. Gross N, et al. **Eur J Cancer** 1995; 31A(4):471–5

Expression of CD44v6 is associated with cellular dysplasia in colorectal epithelial cells. Orzechowski HD, et al. **Eur J Cancer** 1995 Nov;31A(12):2073–9

Expression of CD44 and its variants on gastric epithelial cells of patients with Helicobacter pylori colonisation. Fan X, et al. **Gut** 1996 Apr;38(4):507–12

CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein–Barr virus–transformed human B cells. Kryworuckho M, et al. **Immunology** 1995 Sep;86(1):41–8

CD44 plays a co–stimulatory role in murine T cell activation: ligation of CD44 selectively co–stimulates IL–2 production, but not proliferation in TCR–stimulated murine Th1 cells. Sommer F, et al. **Int Immunol** 1995 Nov;7(11):1779–86

Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements. Okado T, et al. **Int J Cancer** 1995 Dec 11;63(6):823–30

Stimulatory effects of pleural fluids from mesothelioma patients on CD44 expression, hyaluronan production and cell proliferation in primary cultures of normal mesothelial and transformed cells. Teder P, et al. **Int J Cancer** 1996 Jul 29;67(3):393–8

Expression of CD44 splice variants in bladder cancer. Kan M, et al. **Int J Urol** 1995 Nov;2(5):295–301

A di–hydrophobic Leu–Val motif regulates the basolateral localization of CD44 in polarized Madin–Darby canine kidney epithelial cells. Sheikh H, et al. **J Biol Chem** 1996 May 24;271(21):12185–90

Signaling through CD44 is mediated by tyrosine kinases. Association with p56lck in T lymphocytes. Taher TE, et al. **J Biol Chem** 1996 Feb 2;271(5):2863–7

Keratan sulfate modification of CD44 modulates adhesion to hyaluronate. Takahashi K, et al. **J Biol Chem** 1996 Apr 19;271(16):9490–6

Glycosylation of CD44 is implicated in CD44–mediated cell adhesion to hyaluronan. Bartolazzi A, et al. **J Cell Biol** 1996 Mar;132(6):1199–208

Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. Bennett KL, et al. **J Cell Biol** 1995 Dec;131(6 Pt 1):1623–33

Early detachment of colon carcinoma cells during CD95(APO–1/Fas)–mediated apoptosis. I. De–adhesion from hyaluronate by shedding of CD44. Günthert AR, et al. **J Cell Biol** 1996 Aug;134(4):1089–96

Relation between stage, grade, proliferation, and expression of p53 and CD44 in adenomas and carcinomas of the colorectum. Jackson PA, et al. **J Clin Pathol** 1995 Dec; 48(12):1098–101

CD44v6 is a marker for systemic spread in cutaneous T–cell lymphomas. A comparative study between nodal and cutaneous lymphomas. Dommann SN, et al. **J Cutan Pathol** 1995 Oct;22(5):407–12

A cysteine residue located in the transmembrane domain of CD44 is important in binding of CD44 to hyaluronic acid. Liu D, et al. **J Exp Med** 1996 May 1;183(5):1987–94

Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. Mohapatra S, et al. **J Exp Med** 1996 Apr 1;183(4):1663–8

In vitro culture of human peripheral blood monocytes induces hyaluronan binding and up–regulates monocyte variant CD44 isoform expression. Levesque MC, et al. **J Immunol** 1996 Feb 15;156(4):1557–65

N–terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding. Liao HX, et al. **J Immunol** 1995 Oct 15; 155(8):3938–45

Molecular mechanisms regulating the hyaluronan binding activity of the adhesion protein CD44. Chiu RK, et al. **J Neurooncol** 1995 Dec;26(3):231–9

Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. Herold–Mende C, et al. **J Pathol** 1996 May;179(1):66–73

CD44 is expressed in hepatocellular carcinomas showing vascular invasion. Mathew J, et al. **J Pathol** 1996 May; 179(1):74–9

Hyaluronan, CD44 and fibronectin in rabbit corneal epithelial wound healing. Asari A, et al. **Jpn J Ophthalmol** 1996; 40(1):18–25

CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Takahashi K, et al. **Oncogene** 1995 Dec 7;11(11):2223–32

Overexpression of CD44 in pl85(neu)–transfected NIH3T3 cells promotes an up–regulation of hyaluronic acid–mediated membrane–cytoskeleton interaction and cell adhesion. Zhu D, et al. **Oncogene** 1996 Jun 6;12(11):2309–14

Quantitative and qualitative changes in CD44 and MEL–14 expression by T cells in C57BL/6 mice during aging. Barrat F, et al. **Res Immunol** 1995 Jan;146(1):23–34

Receptor–ligand interaction between CD44 and osteopontin (Eta–1). Weber GF, et al. **Science** 1996 Jan 26; 271(5248):509–12

[Expression of CD44 variant 6 and its metastatic potential in squamous cell carcinoma of the oral cavity] Kunishi M, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1045–8 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

HIV acquires functional adhesion receptors from host cells. Guo MM, et al. **AIDS Res Hum Retroviruses** 1995 Sep; 11(9):1007–13

Inhibition of HIV type 1 infection of mononuclear phagocytes by anti–CD44 antibodies. Rivadeneira ED, et al. **AIDS Res Hum Retroviruses** 1995 May;11(5):541–6

Restoration of CD44H expression in colon carcinomas reduces tumorigenicity. Tanabe KK, et al. **Ann Surg** 1995 Oct;222(4):493–501; discussion 501–3

CD–44 is not involved in the metastatic spread of ovarian cancer in vivo. Speiser P, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2767–9

Hyaluronan–dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan–mediated motility (RHAMM) and CD44. Masellis–Smith A, et al. **Blood** 1996 Mar 1;87(5):1891–9

Adhesion molecules on intermediate TCR cells. II. Hepatoprotective effects of hyaluronic acid on acute liver injury. Nakayama M, et al. **Cell Immunol** 1995 Dec; 166(2):275–85

CD44 in malignant disorders. Günthert U. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):271–85 (93 ref.)

Does soluble CD44 reflect the clinical behavior of human cancer? Ristamäki R, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):155–66 (53 ref.)

The CD44 proteins in embryonic development and in cancer. Sherman L, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):249–69 (123 ref.)

Joint features of metastasis formation and lymphocyte maturation and activation. Zöller M. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):215–47 (330 ref.)

CD44 in colon cancer. Herrlich P, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1110–2 (32 ref.)

Involvement of CD44 variant isoforms in hyaluronate adhesion by human activated T cells. Galluzzo E, et al. **Eur J Immunol** 1995 Oct;25(10):2932–9

An antibody to CD44 enhances hematopoiesis in long–term marrow cultures. Rossbach HC, et al. **Exp Hematol** 1996 Feb;24(2):221–7

Role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: an immunohistochemistry study. Ariza A, et al. **Hum Pathol** 1995 Oct;26(10):1144–7

CD44 plays a co–stimulatory role in murine T cell activation: ligation of CD44 selectively co–stimulates IL–2 production, but not proliferation in TCR–stimulated murine Th1 cells. Sommer F, et al. **Int Immunol** 1995 Nov;7(11):1779–86

Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro. Koochekpour S, et al. **Int J Cancer** 1995 Nov 3;63(3):450–4

Suppression of CD44 expression decreases migration and invasion of human glioma cells. Okada H, et al. **Int J Cancer** 1996 Apr 10;66(2):255–60

Endothelial CD44H mediates adhesion of a melanoma cell line to quiescent human endothelial cells in vitro. Price EA, et al. **Int J Cancer** 1996 Feb 8;65(4):513–8

Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Trochon V, et al. **Int J Cancer** 1996 May 29;66(5):664–8

Targeted disruption of CD44 in MDAY–D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity. Driessens MH, et al. **J Cell Biol** 1995 Dec;131(6 Pt 2):1849–55

Involvement of CD44 and the cytoskeletal linker protein ankyrin in human neutrophil bacterial phagocytosis. Moffat FL Jr, et al. **J Cell Physiol** 1996 Sep;168(3):638–47

CD44–related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix. Henke CA, et al. **J Clin Invest** 1996 Jun 1;97(11):2541–52

CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte–endothelial cell primary adhesion pathway. DeGrendele HC, et al. **J Exp Med** 1996 Mar 1;183(3):1119–30

Leukocyte function–associated antigen 1 (LFA–1) and CD44 are signalling molecules for cytoskeleton–dependent morphological changes in activated T cells. Kelleher D, et al. **J Leukoc Biol** 1995 Nov;58(5):539–46

Involvement of CD44 and its variant isoforms in membrane–cytoskeleton interaction, cell adhesion and tumor metastasis. Bourrguignon LY, et al. **J Neurooncol** 1995 Dec;26(3):201–8 (44 ref.)

Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis. Hall CL, et al. **J Neurooncol** 1995 Dec;26(3):221–9 (84 ref.)

To metastasize or not? Selection of CD44 splice sites. Cooper DL, et al. **Nat Med** 1995 Jul;1(7):635–7

Anti–CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Mikecz K, et al. **Nat Med** 1995 Jun;1(6):558–63

ANTIGENS, CD45

Stressed rats fail to expand the CD45RC+CD4+ (Th1–like) T cell subset in response to KLH: possible involvement of IFN–gamma. Fleshner M, et al. **Brain Behav Immun** 1995 Jun;9(2):101–12

ANALYSIS

Modulation of T–cell adhesion markers, and the CD45R and CD57 antigens in human alcoholics. Cook RT, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):555–63

High frequency of CD45RO expression in AIDS–related B–cell non–Hodgkin's lymphomas. Gloghini A, et al. **Am J Clin Pathol** 1995 Dec;104(6):680–8

Inflammatory bowel disease in C.B–17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Leach MW, et al. **Am J Pathol** 1996 May; 148(5):1503–15

Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Wagner AD, et al. **Am J Pathol** 1996 Jun;148(6):1925-33

Cell-type specificity of anti-CD45 autoantibodies in systemic lupus erythematosus. Czyzyk J, et al. **Arthritis Rheum** 1996 Apr;39(4):592-9

Enrichment of differentiated CD45RBdim,CD27- memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Kohem CL, et al. **Arthritis Rheum** 1996 May;39(5):844-54

Identification of properties that can distinguish primitive populations of stromal-cell-responsive lympho-myeloid cells from cells that are stromal-cell-responsive but lymphoid-restricted and cells that have lympho-myeloid potential but are also capable of competitively repopulating myeloablated recipients. Lemieux ME, et al. **Blood** 1996 Sep 1;88(5):1639-48

Flow cytometric identification of a minority population of MHC class II positive cells in the normal rat retina distinct from CD45lowCD11b/c+CD4low parenchymal microglia. Dick AD, et al. **Br J Ophthalmol** 1995 Sep; 79(9):834-40

The CD45RB-associated epitope defined by monoclonal antibody CZ-1 is an activation and memory marker for mouse CD4 T cells. Varga SM, et al. **Cell Immunol** 1996 Jan 10;167(1):56-62

Expanded CD4+CD45RO+ phenotype and defective proliferative response in T lymphocytes from patients with Crohn's disease. Roman LI, et al. **Gastroenterology** 1996 Apr;110(4):1008-19

Lectin-activated CD4+CD45RA+ T-lymphocytes have no ability to kill monocytes. Pryjma J, et al. **Immunol Invest** 1996 Jan-Mar;25(1-2):1-11

Expression of CD11a and CD45R isoforms defines distinct subsets of CD8+ TCR alpha beta and TCR gamma delta CTL in vivo. Hedlund G, et al. **Immunol Rev** 1995 Aug; 146:82-94 (33 ref.)

Phenotypical characterization of peripheral blood T cells in patients with coeliac disease: elevation of antigen-primed CD45RO+ T lymphocytes. Kerttula TO, et al. **Immunology** 1995 Sep;86(1):104-9

Surface antigens on eosinophils in bronchial asthma and eosinophilic pneumonia. Sakamoto S, et al. **Int Arch Allergy Immunol** 1995;108 Suppl 1:6-8

Functional CD4+ T cell subsets defined by expression of CD45RC and NTA260 antigens and age-associated polarization in murine lupus. Nishimura H, et al. **Int Immunol** 1995 Jul;7(7):1115-23

CD45RO and CD45RA positive cell populations in idiopathic membranous and IgA glomerulopathy. Lee AH, et al. **J Clin Pathol** 1996 Jan;49(1):43-7

A subpopulation of B220+ cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors. Rolink A, et al. **J Exp Med** 1996 Jan 1; 183(1):187-94

Stimulation of IgE and IgA production by CD45RA T helper cells in atopic patients. Nasert S, et al. **J Immunol** 1996 Jul 1;157(1):441-8

The CD45RA+ (quiescent) cellular phenotype is overabundant relative to the CD45RA- phenotype within the involuted splenic T cell population of weanling mice subjected to wasting protein-energy malnutrition. Woodward BD, et al. **J Nutr** 1995 Oct;125(10):2471-82

CD45RO+ T-cells immunoregulate spontaneous in vitro immunoglobulin production by normal and chronic lymphocytic leukaemia B-cells. Frolova EA, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):103-11

Identification of CD45 (leucocyte common antigen) in the domestic cat. Hunt P, et al. **Res Vet Sci** 1995 Nov; 59(3):201-4

Characterization of a murine monoclonal antibody reactive with a leukocyte common antigen and its application to bone marrow transplantation. Amirghofran Z, et al. **Transplant Proc** 1995 Oct;27(5):2657-8

CD45 isoforms and lymphocyte activation antigens in acute renal allograft rejection. Battochio A, et al. **Transplant Proc** 1996 Feb;28(1):482-3

The use of immunocytochemistry (LCA and LEU-7) in diagnosis of renal allograft rejection. Gibson IW, et al. **Transplant Proc** 1996 Feb;28(1):457-64

Graft-infiltrating T helper cells, CD45RC phenotype, and Th1/Th2-related cytokines in donor-specific transfusion-induced tolerance in adult rats. Josien R, et al. **Transplantation** 1995 Nov 27;60(10):1131-9

[CD45 gating for flow cytometric analysis of acute leukemia] Miyazaki T, et al. **Rinsho Ketsueki** 1996 Mar;37(3):214-20 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Differential expression of CD45RA and CD45RO molecules on human decidual and peripheral blood lymphocytes at early stage of pregnancy. Slukvin II, et al. **Am J Reprod Immunol** 1996 Jan;35(1):16-22

Deficient quantitative expression of CD45 isoforms on CD4+ and CD8+ T cell subpopulations and subsets of CD45RA(low)CD45RO(low) T cells in newborn blood. Chheda S, et al. **Biol Neonate** 1996;69(2):128-32

BLOOD

Differential expression of CD45RA and CD45RO molecules on human decidual and peripheral blood lymphocytes at early stage of pregnancy. Slukvin II, et al. **Am J Reprod Immunol** 1996 Jan;35(1):16-22

CD 45 gating correlates with bone marrow differential. Rainer RO, et al. **Cytometry** 1995 Jun 15;22(2):139-45

CD45RO expression on bovine T cells: relation to biological function. Bembridge GP, et al. **Immunology** 1995 Dec; 86(4):537-44

CHEMISTRY

Characterization of lineage restricted forms of a Xenopus CD45 homologue. Barritt LC, et al. **Dev Comp Immunol** 1995 Nov-Dec;19(6):525-36

CD45 protein-tyrosine phosphatase associates with the WW domain-containing protein, CD45AP, through the transmembrane region. MCFarland ED, et al. **J Biol Chem** 1995 Nov 24;270(47):28103-7

Comparison of CD45 extracellular domain sequences from divergent vertebrate species suggests the conservation of three fibronectin type III domains. Okumura M, et al. **J Immunol** 1996 Aug 15;157(4):1569-75

CLASSIFICATION

CD45 isoforms on human CD4+ T-cell subsets. Shanafelt MC, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):433-40

GENETICS

Altered CD45 expression in malignant B-1 cells. Dang AM, et al. **Cell Immunol** 1996 May 1;169(2):196-207

IMMUNOLOGY

Stage-dependent expression of CD7, CD45RO, CD45RA and CD25 on CD4-positive peripheral blood T-lymphocytes in cutaneous T-cell lymphoma. Jakob T, et al. **Acta Derm Venereol** 1996 Jan;76(1):34-6

Expansion of CD11abright cells in CD8+CD45RA+ from HIV-infected patients: a new early marker for disease progression? Scala E, et al. **AIDS Res Hum Retroviruses** 1995 Nov;11(11):1327-33

Pro-vs-anti-CD45 [letter] Neiman RS, et al. **Am J Surg Pathol** 1996 Apr;20(4):507-9

4-1BB is expressed on CD45RAhiROhi transitional T cell in humans. Garni-Wagner BA, et al. **Cell Immunol** 1996 Apr 10;169(1):91-8

Loss of the CD5+ and CD45RAhi B cell subsets in alcoholics. Cook RT, et al. **Clin Exp Immunol** 1996 Feb; 103(2):304-10

Regulation of immune function by protein tyrosine phosphatases. Okumura M, et al. **Curr Opin Immunol** 1995 Jun;7(3):312-9 (101 ref.)

Epitope-specific engagement of the protein tyrosine phosphatase CD45 induces tumor necrosis factor-alpha gene expression via transcriptional mechanisms. Estoppey O, et al. **Eur J Immunol** 1996 Jul;26(7):1475-80

Interleukin-13 is produced by activated human CD45RA+ and CD45RO+ T cells: modulation by interleukin-4 and interleukin-12. Jung T, et al. **Eur J Immunol** 1996 Mar; 26(3):571-7

Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice. de Kroon JF, et al. **Exp Hematol** 1996 Jul;24(8):919-26

Genetically determined CD45 variant of value in leucocyte tracing in vivo in the pig. Binns RM, et al. **Immunology** 1995 Sep;86(1):25-33

Migration pathways of CD4 T cell subsets in vivo: the CD45RC- subset enters the thymus via alpha 4 integrin-VCAM-1 interaction. Bell EB, et al. **Int Immunol** 1995 Nov;7(11):1861-71

The accumulation of B220+ CD4- CD8- (DN) T cells in C3H-lpr/lpr mice is not accelerated by the stimulation of CD8+ T cells or B220+ DN T cells with staphylococcal enterotoxin B and occurs independently of V beta 8+ T cells. Giese T, et al. **Int Immunol** 1995 Aug;7(8):1213-23

Increase in percentage of CD45RO+/CD8+ cells is associated with previous severe primary HIV infection [see comments] Bruunsgaard H, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):107-14. Comment in: J Acquir Immune Defic Syndr Hum Retrovirol 1996 Apr 1;11(4):411.

Immobilized antibodies to CD45 induce rapid morphologic changes and increased tyrosine phosphorylation of p56lck-associated proteins in T cells. Arendt CW, et al. **J Immunol** 1995 Dec 1;155(11):5095-103

Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO- and CD45RO+ subsets. Brinkmann V, et al. **J Immunol** 1995 Oct 1;155(7):3322-8

CD45 monoclonal antibodies inhibit TCR-mediated calcium signals, calmodulin-kinase IV/Gr activation, and oncoprotein 18 phosphorylation. Shivnan E, et al. **J Immunol** 1996 Jul 1;157(1):101-9

Cross-linking of CD45 on NK cells stimulates p56lck-mediated tyrosine phosphorylation and IFN-gamma production. Xu X, et al. **J Immunol** 1995 Dec 1;155(11):5241-8

Stimulation of the T-cell antigen receptor-CD3 complex signaling pathway by the tyrosine phosphatase inhibitor pervanadate is mediated by inhibition of CD45: evidence for two interconnected Lck/Fyn- or zap-70-dependent signaling pathways. Imbert V, et al. **J Inflamm** 1996; 46(2):65-77

CD45RO+ T-cells immunoregulate spontaneous in vitro immunoglobulin production by normal and chronic lymphocytic leukaemia B-cells. Frolova EA, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):103-11

Prevention and reversal of renal allograft rejection by antibody against CD45RB. Lazarovits AI, et al. **Nature** 1996 Apr 25;380(6576):717-20

Low immunogenicity of therapeutic rat CD45 antibodies when used for pre-treatment of donor organs for transplantation. Watts MJ, et al. **Ther Immunol** 1995 Feb; 2(1):23-9

Effects of monoclonal antibody against CD45RB on peripheral blood mononuclear cell proliferation and on HLA-DR and adhesion molecule expression on thyrocytes of patients with autoimmune thyroid disease. Nishikawa M, et al. **Thyroid** 1995 Aug;5(4):265-72

Perfusion of pig hearts with anti-CD45 monoclonal antibody to label interstitial dendritic cells before xenotransplantation. Casey JJ, et al. **Transplant Proc** 1996 Apr;28(2):801-2

METABOLISM

Cytosolic inactivation of translocated neutrophil plasma membrane protein tyrosine phosphatase. Cui Y, et al. **Blood** 1996 Jan 1;87(1):341-9

Expression of the leucocyte common antigen (LCA, CD45) isoforms RA and RO in acute haematological malignancies: possible relevance in the definition of new overlap points between normal and leukaemic haemopoiesis. Schiavone EM, et al. **Br J Haematol** 1995 Dec;91(4):899-906

Effect of HIV vertical transmission on the ontogeny of T cell antigens involved in the regulation of humoral immune response. Brugnoni D, et al. **Clin Exp Immunol** 1995 Nov; 102(2):238-42

CD4+ lymphocytes from HIV-infected patients display impaired CD45-associated tyrosine phosphatase activity which is enhanced by anti-oxidants. Cayota A, et al. **Clin Exp Immunol** 1996 Apr;104(1):11-7

Spontaneous proliferation of memory (CD45RO+) and naive (CD45RO-) subsets of CD4 cells and CD8 cells in human T lymphotropic virus (HTLV) infection: distinctive patterns for HTLV-I versus HTLV-II. Prince HE, et al. **Clin Exp Immunol** 1995 Nov;102(2):256-61

Detection of restricted isoform expression and tyrosine phosphatase activity of CD45 in murine dendritic cells. Haidl ID, et al. **Eur J Immunol** 1995 Dec;25(12):3370-4

CD4 and CD45 regulate qualitatively distinct patterns of calcium mobilization in individual CD4+ T cells. Leitenberg D, et al. **Eur J Immunol** 1995 Sep;25(9):2445-51

Identification of the sites of interaction between lymphocyte phosphatase-associated phosphoprotein (LPAP) and CD45. Bruyns E, et al. **J Biol Chem** 1995 Dec 29; 270(52):31372-6

An activated epidermal growth factor receptor/Lck chimera restores early T cell receptor-mediated calcium response in a CD45-deficient T cell line. Duplay P, et al. **J Biol Chem** 1996 Jul 26;271(30):17896-902

Selective regulation of Lyn tyrosine kinase by CD45 in immature B cells. Katagiri T, et al. **J Biol Chem** 1995 Nov 24;270(47):27987-90

The transmembrane protein-tyrosine phosphatase CD45 is associated with decreased insulin receptor signaling. Kulas DT, et al. **J Biol Chem** 1996 Jan 12;271(2):755-60

CD45 protein-tyrosine phosphatase associates with the WW domain-containing protein, CD45AP, through the transmembrane region. MCFarland ED, et al. **J Biol Chem** 1995 Nov 24;270(47):28103-7

Demonstration of a direct interaction between p56lck and the cytoplasmic domain of CD45 in vitro. Ng DH, et al. **J Biol Chem** 1996 Jan 19;271(3):1295-300

A unique CD45 glycoform recognized by the serum mannan-binding protein in immature thymocytes. Uemura K, et al. **J Biol Chem** 1996 Mar 1;271(9):4581-4

Immunoglobulin-mediated signal transduction in B cells from CD45-deficient mice. Benatar T, et al. **J Exp Med** 1996 Jan 1;183(1):329-34

CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4+CD8+ thymocytes, and B cell maturation. Byth KF, et al. **J Exp Med** 1996 Apr 1;183(4):1707-18

The extracellular domain of CD45 controls association with the CD4-T cell receptor complex and the response to antigen-specific stimulation. Leitenberg D, et al. **J Exp Med** 1996 Jan 1;183(1):249-59

CD45 ligation induces programmed cell death in T and B lymphocytes. Klaus SJ, et al. **J Immunol** 1996 Apr 15; 156(8):2743-53

CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets. Poppema S, et al. **Leuk Lymphoma** 1996 Jan;20(3-4):217-22 (63 ref.)

The levels of memory (CD45RA-, RO+) CD4+ and CD8+ peripheral blood T-lymphocytes correlate with IgM rheumatoid factors in rheumatoid arthritis. Neidhart M, et al. **Rheumatol Int** 1996;15(5):201-9

Ig-isotype patterns of primary and secondary B cell responses to Plasmodium chabaudi chabaudi correlate with IFN-gamma and IL-4 cytokine production with CD45RB expression by CD4+ spleen cells. D'Império Lima MR, et al. **Scand J Immunol** 1996 Mar;43(3):263-70

CD45 engagement induces L-selectin down-regulation.

ANTIGENS, CD45

Stibenz D, et al. **Scand J Immunol** 1996 Jul;44(1):37–44

PHARMACOLOGY

CD45 ligation induces programmed cell death in T and B lymphocytes. Klaus SJ, et al. **J Immunol** 1996 Apr 15; 156(8):2743–53

CD45 engagement induces L-selectin down-regulation. Stibenz D, et al. **Scand J Immunol** 1996 Jul;44(1):37–44

PHYSIOLOGY

Involvement of CD45 in dexamethasone- and heat shock-induced apoptosis of rat thymocytes. Troiano L, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):941–8

Fas ligation induces apoptosis and Jun kinase activation independently of CD45 and Lck in human T cells. Latinis KM, et al. **Blood** 1996 Feb 1;87(3):871–5

IL-2-resistant hyporesponsiveness induced by CD4 mAbs in OKT3-activated human T cells is reversed by CD45RA triggering. Robinet E, et al. **Cell Immunol** 1996 Jan 10; 167(1):1–7

Pathogenic and protective roles of CD45RB(low) CD4+ cells correlate with cytokine profiles in the spontaneously autoimmune diabetic mouse. Shimada A, et al. **Diabetes** 1996 Jan;45(1):71–8

Differential requirements of CD45 for lymphocyte development and function. Kong YY, et al. **Eur J Immunol** 1995 Dec;25(12):3431–6

Distinct isoforms of the CD45 protein-tyrosine phosphatase differentially regulate interleukin 2 secretion and activation signal pathways involving Vav in T cells. McKenney DW, et al. **J Biol Chem** 1995 Oct 20;270(42):24949–54

Differential expression of CD40 ligand on T cell subsets. Implications for different roles of CD45RA+ and CD45RO+ cells in IgE production. Patel HR, et al. **J Immunol** 1996 Mar 1;156(5):1781–87

Enhanced generation of NK cells with intact cytotoxic function in CD45 exon 6-deficient mice. Yamada H, et al. **J Immunol** 1996 Aug 15;157(4):1523–8

Mutational analysis of Lck in CD45-negative T cells: dominant role of tyrosine 394 phosphorylation in kinase activity. D'Oro U, et al. **Mol Cell Biol** 1996 Sep; 16(9):4996–5003

Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45. Cyster JG, et al. **Nature** 1996 May 23;381(6580):325–8

Association of CD45 with Lck and components of the Ras signalling pathway in pervanadate-treated mouse T-cell lines. Lee JM, et al. **Oncogene** 1996 Jan 18;12(2):253–63

Positive and negative regulation of leukocyte activation by protein tyrosine phosphatases. Thomas ML. **Semin Immunol** 1995 Aug;7(4):279–88 (85 ref.)

ANTIGENS, CD54 see **INTERCELLULAR ADHESION MOLECULE-1**

ANTIGENS, CD55

ANALYSIS

Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Niehans GA, et al. **Am J Pathol** 1996 Jul;149(1):129–42

Peripheral blood harvest of unaffected CD34+ CD38- hematopoietic precursors in paroxysmal nocturnal hemoglobinuria. Prince GM, et al. **Blood** 1995 Nov 1; 86(9):3381–6

Expression of GPI-anchored complement regulatory proteins CD55 and CD59 differentiates two subpopulations of human CD56+ CD3- lymphocytes (NK cells). Solomon KR, et al. **Cell Immunol** 1995 Oct 15;165(2):294–301

Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas. Goslings WR, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1884–91

BIOSYNTHESIS

Decreased expression of endometrial decay accelerating factor (DAF), a complement regulatory protein, in patients with luteal phase defect. Kaul A, et al. **Am J Reprod Immunol** 1995 Oct;34(4):236–40

Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines. Hatanaka M, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):969–76

Human nasal epithelium adsorbs complement C3-related fragments and expresses cell membrane complement regulatory proteins. Varsano S, et al. **Laryngoscope** 1996 May;106(5 Pt 1):599–604

Development and analysis of transgenic pigs expressing the human complement regulatory protein CD59 and DAF. Byrne G, et al. **Transplant Proc** 1996 Apr;28(2):759

Up-regulation of human decay accelerating factor on cultured endothelium from transgenic pigs in response to inflammatory stimuli. Carrington CA, et al. **Transplant Proc** 1996 Apr;28(2):582

Longitudinal analysis of the expression of human decay accelerating factor on peripheral blood mononuclear cells and in the plasma of transgenic pigs. Cozzi E, et al. **Transplant Proc** 1996 Apr;28(2):860–1

Fluorescence in situ hybridisation to analyse DAF transgenic jigsaw pigs. Kuipers HW, et al. **Transplant Proc** 1996 Apr; 28(2):629–30

Human complement regulatory proteins expressed in transgenic swine protect swine xenografts from humoral injury. McCurry KR, et al. **Transplant Proc** 1996 Apr; 28(2):758

Human MCP and DHF double transgenic mice are protected from human complement attack in an in vivo model. Mulder LC, et al. **Transplant Proc** 1996 Apr;28(2):589

Characterization of complement-mediated liver damage and protection in control and transgenic mice for human complement blockers MCP and DAF. Mulder LC, et al. **Transplant Proc** 1996 Feb;28(1):127–9

High-level tissue specific expression of human CD59, MCP, and DAF proteins from genomic clones in transgenic mice. Oldham ER, et al. **Transplant Proc** 1996 Apr;28(2):693

Human decay accelerating factor expressed on endothelial cells of transgenic pigs affects complement activation in an ex vivo liver perfusion model. Pascher A, et al. **Transplant Proc** 1996 Apr;28(2):754–5

Targeted in vivo gene transfection modulated hyperacute rejection of pig lungs perfused with human blood. Pierson RN 3rd, et al. **Transplant Proc** 1996 Apr;28(2):763

The effect of h-DAF expression on endothelial cell activation of porcine xenografts. Pino-Chavez G, et al. **Transplant Proc** 1996 Apr;28(2):590–1

Role of human decay accelerating factor expression on porcine kidneys during xenogeneic ex vivo hemoperfusion. Storck M, et al. **Transplant Proc** 1996 Apr;28(2):587–8

The fertility and breeding potential of boars expressing a functional regulator of human complement activation. Tucker AW, et al. **Transplant Proc** 1996 Apr;28(2):642

Decay-accelerating factor transgenic mouse hearts are protected from human complement-mediated attack. van Denderen BJ, et al. **Transplant Proc** 1996 Apr;28(2):583–4

BLOOD

Expression of complement regulatory proteins on fetal blood cells in utero. Jarvis JN, et al. **Biol Neonate** 1996; 69(4):225–9

The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Hall SE, et al. **Blood** 1996 Jun 15;87(12):5332–40

GENETICS

Genetic engineering of the donor species to control hyperacute xenograft rejection. White DJ, et al. **Adv Nephrol Necker Hosp** 1995;24:331–40

Molecular cloning of murine decay accelerating factor by immunoscreening. Fukuoka Y, et al. **Int Immunol** 1996 Mar; 8(3):379–85

New ways to avoid organ rejection buoy hopes [news] Roush W. **Science** 1995 Oct 13;270(5234):234–5

Expression and function of human CD59 and human CD55 in transgenic mice. Somerville C, et al. **Transplant Proc** 1995 Dec;27(6):3565–6

Expression of functional decay-accelerating factor in transgenic mice. van Denderen B, et al. **Transplant Proc** 1995 Dec;27(6):3567–8

IMMUNOLOGY

How can human DAF and HRF20 prevent HAR in transgenic mice? Koike C, et al. **Transplant Proc** 1996 Apr; 28(2):599–600

METABOLISM

Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Bjørge L, et al. **Cancer Immunol Immunother** 1996 Mar;42(3):185–92

Differential expression of complement proteins and regulatory decay accelerating factor in relation to differentiation of cultured human colon adenocarcinoma cell lines. Bernet-Camard MF, et al. **Gut** 1996 Feb; 38(2):248–53

Pathogenicity of the diffusely adhering strain Escherichia coli C1845: F1845 adhesin-decay accelerating factor interaction, brush border microvillus injury, and actin disassembly in cultured human intestinal epithelial cells. Bernet-Camard MF, et al. **Infect Immun** 1996 Jun; 64(6):1918–28

Rapid cyclic changes in density and accessibility of endometrial ligands for Escherichia coli Dr fimbriae. Kaul AK, et al. **Infect Immun** 1996 Feb;64(2):611–5

Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. Brodbeck WG, et al. **J Immunol** 1996 Apr 1;156(7):2528–33

Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). Spear GT, et al. **J Immunol** 1995 Nov 1;155(9):4376–81

Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins. Koski CL, et al. **J Neurochem** 1996 Jan;66(1):303–12

Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Gorter A, et al. **Lab Invest** 1996 Jun; 74(6):1039–49

[Complement regulatory proteins CR 1, MCP, DAF, and MACIF levels in patients with Behçet's disease] Kure T, et al. **Nippon Ganka Gakkai Zasshi** 1996 May;100(5):376–80 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Homologous restriction of complement-mediated cell lysis can be markedly enhanced by blocking decay-accelerating factor. Zhong RK, et al. **Br J Haematol** 1995 Oct; 91(2):269–74

Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). Stoiber H, et al. **J Exp Med** 1996 Jan 1; 183(1):307–10

PHYSIOLOGY

A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro. Christiansen D, et al. **Eur J Immunol** 1996 Mar;26(3):578–85

The control of hyperacute rejection by genetic engineering of the donor species. White DJ, et al. **Eye** 1995;9 (Pt 2):185–9

A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex. Fodor WL, et al. **J Immunol** 1995 Nov 1;155(9):4135–8

Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection. Seya T. **Microbiol Immunol** 1995;39(5):295–305 (82 ref.)

Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria. Telen MJ. **Transfus Clin Biol** 1995;2(4):277–90 (73 ref.)

Transgenic human DAF-expressing porcine livers: their function during hemoperfusion with human blood. Pöhlein C, et al. **Transplant Proc** 1996 Apr;28(2):770–1

Reduced human neutrophil adhesion to porcine endothelia expressing human decay accelerating factor. Richards AC, et al. **Transplant Proc** 1996 Apr;28(2):636

Human decay accelerating factor successfully protects pig hearts from hyperacute rejection by human blood. Schmoeckel M, et al. **Transplant Proc** 1996 Apr;28(2):768–9

Expression and function of human CD59 and human CD55 in transgenic mice. Somerville C, et al. **Transplant Proc** 1995 Dec;27(6):3565–6

Protection of xenogeneic cardiac endothelium from human complement by expression of CD59 or DAF in transgenic mice. Byrne GW, et al. **Transplantation** 1995 Nov 27; 60(10):1149–56

Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack. van Denderen BJ, et al. **Transplantation** 1996 Feb 27;61(4):582–8

ANTIGENS, CD56

Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Mrózek E, et al. **Blood** 1996 Apr 1;87(7):2632–40

Progesterone stimulates the induction of human endometrial CD56+ lymphocytes in an in vitro culture system. Inoue T, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1502–7

ANALYSIS

Anti-Leu-19 is a marker for nervous tissue in the mucosa of the human rectum. Driessen A, et al. **Acta Anat (Basel)** 1995;153(2):127–34

CD56 lymphomas [letter; comment] Emile JF, et al. **Am J Surg Pathol** 1996 Feb;20(2):252–3. Comment on: Am J Surg Pathol 1993 Dec;17(12):1289–99. Comment on: Am J Surg Pathol 1995 Mar;19(3):284–96.

A primary cutaneous non-T, non-B CD4+, CD56+ lymphoma. Dummer R, et al. **Arch Dermatol** 1996 May; 132(5):550–3

Expression and function of low-density lipoprotein receptors in CD3-CD16+CD56+ cells: effect of interleukin 2. De Sanctis JB, et al. **Cell Immunol** 1996 Jan 10;167(1):18–29

Expression of GPI-anchored complement regulatory proteins CD55 and CD59 differentiates two subpopulations of human CD56+ CD3- lymphocytes (NK cells). Solomon KR, et al. **Cell Immunol** 1995 Oct 15;165(2):294–301

Increased CD56+ natural killer cells and related cytokines in major depression. Seidel A, et al. **Clin Immunol Immunopathol** 1996 Jan;78(1):83–5

Homing of CD4+CD56+ T lymphocytes into kidney allografts during tubular necrosis or rejection. Bachetoni A, et al. **Clin Transplant** 1995 Dec;9(6):433–7

CC chemokines induce the generation of killer cells from CD56+ cells. Maghazachi AA, et al. **Eur J Immunol** 1996 Feb;26(2):315–9

Differential phenotypic properties of human peripheral blood CD56dim+ and CD56bright+ natural killer cell subpopulations. Sedlmayr P, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):308–13

Acute undifferentiated leukemia with an unusual CD7+ CD56+ CD33+ immunophenotype of NK progenitors [letter] Reuss-Borst MA, et al. **Leukemia** 1996 May; 10(5):923–4

Aggressive acute CD3+, CD56- T cell large granular lymphocyte leukemia with two stages of maturation arrest. Tordjman R, et al. **Leukemia** 1996 Sep;10(9):1514–9

[Functional significance of CD56 large granular lymphocytes in the decidua in early pregnancy in the human] Marzusch K, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:88–92 (Eng. Abstr.) **(Ger)**

BLOOD

Reciprocal alteration in circulating TJ6+ CD19+ and TJ6+ CD56+ leukocytes in early pregnancy predicts success or miscarriage. Coulam CB, et al. **Am J Reprod Immunol** 1995 Oct;34(4):219–24

Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes. Ong F, et al. **Blood** 1996 Jan 15;87(2):712–6

IMMUNOLOGY

Utility of a paraffin section–reactive CD56 antibody (123C3) for characterization and diagnosis of lymphomas. Tsang WY, et al. **Am J Surg Pathol** 1996 Feb;20(2):202–10

Comparison of hexose acetate–specific receptors isolated from human leukocytes showing competitive inhibition of human CD56+NK and LAK cytotoxicity. Hauer J, et al. **Immunol Lett** 1995 Nov;48(1):53–7

Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. Hu PF, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Nov 1;10(3):331–40

METABOLISM

CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Pierson BA, et al. **Blood** 1996 Sep 15; 88(6):2279–87

Cutaneous CD56+ large T-cell lymphoma associated with high serum concentration of IL-2. Wasik MA, et al. **Hum Pathol** 1996 Jul;27(7):738–44

Expression of N-CAM (CD56) on acute leukemia cells: relationship with disease characteristics and outcome. Thomas X, et al. **Leuk Lymphoma** 1995 Oct; 19(3–4):295–300

PHYSIOLOGY

Optimizing production of human monoclonal IgG antibodies by in vitro–primed human PBMC: influence of CD56+ NK cell depletion. Puhlmann CM, et al. **Hybridoma** 1995 Aug;14(4):391–6

ANTIGENS, CD57

ANALYSIS

The HNK-1 carbohydrate epitope in the anterior segment of the eye. The inner connective tissue layer of the human ciliary body as a distinct element. Uusitalo M. **Acta Ophthalmol Scand** 1995 Aug;73(4):363

Modulation of T-cell adhesion markers, and the CD45R and CD57 antigens in human alcoholics. Cook RT, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):555–63

Immunohistochemical study of HNK-1 (Leu-7) antigen in prostate cancer and its clinical significance. Liu X, et al. **Chin Med J (Engl)** 1995 Jul;108(7):516–21

Origin of CD57+ T cells which increase at tumour sites in patients with colorectal cancer. Okada T, et al. **Clin Exp Immunol** 1995 Oct;102(1):159–66

CD15 and HKN-1 reveal cerebellar compartments with a complex overlap. Mai JK, et al. **Eur J Morphol** 1995 Apr; 33(2):101–7

Enhanced expression of novel CD57+CD8+ LAK cells from cats infected with feline immunodeficiency virus. Zhao Y, et al. **J Leukoc Biol** 1995 Oct;58(4):423–31

Phenotype of Hodgkin and Sternberg-Reed cells and expression of CD57 (LEU7) antigen. Papadimitriou CS, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):125–30

The use of immunocytochemistry (LCA and LEU-7) in diagnosis of renal allograft rejection. Gibson IW, et al. **Transplant Proc** 1996 Feb;28(1):457–64

[Alcian Blue and Leu 7 in the diagnosis of thyroid malignancy] Dušková J. **Cesk Patol** 1995 Dec;31(4):111–3 (Eng. Abstr.) **(Cze)**

BIOSYNTHESIS

Phenotype of Hodgkin and Sternberg-Reed cells and expression of CD57 (LEU7) antigen. Papadimitriou CS, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):125–30

BLOOD

The role of CD8+, CD57+ cells in human cytomegalovirus and other viral infections. Wang EC, et al. **Scand J Infect Dis Suppl** 1995;99:69–77 (78 ref.)

IMMUNOLOGY

The HNK-1 carbohydrate epitope in the anterior segment of the eye. The inner connective tissue layer of the human ciliary body as a distinct element. Uusitalo M. **Acta Ophthalmol Scand** 1995 Aug;73(4):363

Immunoglobulin production induced by CD57+ GC-derived helper T cells in vitro requires addition of exogenous IL-2. Andersson E, et al. **Cell Immunol** 1996 May 1;169(2):166–73

High correlations of anti-CMV titers with lymphocyte activation status and CD57 antibody-binding capacity as estimated with three-color, quantitative flow cytometry in blood donors. Lenkei R, et al. **Clin Immunol Immunopathol** 1995 Nov;77(2):131–8

CD8highCD57+ T lymphocytes in normal, healthy individuals are oligoclonal and respond to human cytomegalovirus. Wang EC, et al. **J Immunol** 1995 Nov 15;155(10):5046–56

METABOLISM

The enigma of CD57+CD28- T cell expansion—anergy or activation? Kern F, et al. **Clin Exp Immunol** 1996 Apr; 104(1):180–4

Characterization of a 21 amino acid peptide sequence of the laminin G2 domain that is involved in HNK-1 carbohydrate binding and cell adhesion. Hall H, et al. **Glycobiology** 1995 Jun;5(4):435–41

PHYSIOLOGY

Functions of the L2/HNK-1 carbohydrate in the nervous system. Schachner M, et al. **Prog Brain Res** 1995;105:183–8 (39 ref.)

ANTIGENS, CD58

ADMINISTRATION & DOSAGE

The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates. Chisholm PL, et al. **Ther Immunol** 1994 Aug;1(4):205–16

ANALYSIS

Enhancement of lymphokine–activated killer cell cytotoxicity implicated in the increased expression of surface adhesion molecules on tumor cells treated with anticancer agents. Ishihata R, et al. **Cancer Invest** 1996; 14(5):427–34

Expression of leukocyte cell adhesion molecules on gastric carcinomas: possible involvement of LFA-3 expression in the development of distant metastases. Mayer B, et al. **Int J Cancer** 1995 Dec 20;64(6):415–23

Monocyte–macrophage antigen expression on chondrocytes. Summers KL, et al. **J Rheumatol** 1995 Jul;22(7):1326–34

BIOSYNTHESIS

Lymphocyte binding to K562 cells: effect of target cell irradiation and correlation with ICAM-1 and LFA-3 expression. Zamai L, et al. **Eur J Histochem** 1994;38 Suppl 1:53–60

IMMUNOLOGY

Human T-cell activation is mediate predominantly by direct recognition of porcine SLA and involves accessory molecule interaction of ICAM1/LFA 1 and CD2/LFA3. Herrlinger KR, et al. **Transplant Proc** 1996 Apr;28(2):650

METABOLISM

Decreased levels of a soluble form of the human adhesion receptor CD58 (LFA-3) in sera and synovial fluids of patients with rheumatoid arthritis. Hoffmann JC, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):23–9

PHYSIOLOGY

Endothelial cells augment the expression of CD40 ligand on newly activated human CD4+ T cells through a CD2/LFA-3 signaling pathway. Karmann K, et al. **Eur J Immunol** 1996 Mar;26(3):610–7

The primary alloresponse of human CD4+ T cells is dependent on B7 (CD80), augmented by CD58, but relatively uninfluenced by CD54 expression. Hargreaves R, et al. **Int Immunol** 1995 Sep;7(9):1505–13

Visualization of CD2 interaction with LFA-3 and determination of the two-dimensional dissociation constant for adhesion receptors in a contact area. Dustin ML, et al. **J Cell Biol** 1996 Feb;132(3):465–74

Histamine selectively enhances human immunoglobulin E (IgE) and IgG4 production induced by anti-CD58 monoclonal antibody. Kimata H, et al. **J Exp Med** 1996 Aug 1;184(2):357–64

Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells. Gwin JL, et al. **J Surg Res** 1996 Jan;60(1):129–36

THERAPEUTIC USE

Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Kaplon RJ, et al. **Transplantation** 1996 Feb 15;61(3):356–63

ANTIGENS, CD59

ANALYSIS

Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Niehans GA, et al. **Am J Pathol** 1996 Jul;149(1):129–42

Identification of the complement regulatory protein CD59 in human colostrum and milk. Bjørge L, et al. **Am J Reprod Immunol** 1996 Jan;35(1):43–50

Peripheral blood harvest of unaffected CD34+ CD38- hematopoietic precursors in paroxysmal nocturnal hemoglobinuria. Prince GM, et al. **Blood** 1995 Nov 1; 86(9):3381–6

Expression of GPI-anchored complement regulatory proteins CD55 and CD59 differentiates two subpopulations of human CD56+ CD3- lymphocytes (NK cells). Solomon KR, et al. **Cell Immunol** 1995 Oct 15;165(2):294–301

Expression and function of membrane regulators of complement on rat astrocytes in culture. Rogers CA, et al. **Immunology** 1996 May;88(1):153–61

Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas. Goslings WR, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1884–91

BIOSYNTHESIS

Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines. Hatanaka M, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):969–76

Human nasal epithelium adsorbs complement C3-related fragments and expresses cell membrane complement regulatory proteins. Varsano S, et al. **Laryngoscope** 1996 May;106(5 Pt 1):599–604

Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement. Diamond LE, et al. **Transpl Immunol** 1995 Dec;3(4):305–12

Development and analysis of transgenic pigs expressing the human complement regulatory protein CD59 and DAF. Byrne G, et al. **Transplant Proc** 1996 Apr;28(2):759

Regulation of complement activation in rat liver ischemia and reperfusion: expression of endothelial CD59 (RIP). Chávez-Cartaya R, et al. **Transplant Proc** 1995 Oct; 27(5):2852–4

Human complement regulatory proteins expressed in transgenic swine protect swine xenografts from humoral injury. McCurry KR, et al. **Transplant Proc** 1996 Apr; 28(2):758

Xenoreactivity in the pig islet to human combination: feasibility of adenovirus-mediated gene transfer into pig islets. Mirenda V, et al. **Transplant Proc** 1996 Apr; 28(2):808–10

High-level tissue specific expression of human CD59, MCP, and DAF proteins from genomic clones in transgenic mice. Oldham ER, et al. **Transplant Proc** 1996 Apr;28(2):693

Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Diamond LE, et al. **Transplantation** 1996 Apr 27;61(8):1241–9

BLOOD

The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Hall SE, et al. **Blood** 1996 Jun 15;87(12):5332–40

CHEMISTRY

Immunohistochemical localization of C9 neoantigen and the terminal complement inhibitory protein CD59 in human endometrium. Ratnoff WD, et al. **Am J Reprod Immunol** 1995 Aug;34(2):72–9

Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis. Meri S, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):923–35

Extracellular domain of type I receptor for transforming growth factor-beta: molecular modelling using protectin (CD59) as a template. Jokiranta TS, et al. **FEBS Lett** 1995 Nov 27;376(1–2):31–6

GENETICS

Analysis of the gene that encodes the complement regulatory protein, membrane inhibitor of reactive lysis (CD59). Identification of an alternatively spliced exon and characterization of the transcriptional regulatory regions of the promoter. Holguin MH, et al. **J Immunol** 1996 Aug 15;157(4):1659–68

C5b-8 step lysis of swine endothelial cells by human complement and functional feature of transfected CD59. Miyagawa S, et al. **Scand J Immunol** 1996 Apr;43(4):361–6

Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement. Diamond LE, et al. **Transpl Immunol** 1995 Dec;3(4):305–12

Expression and function of human CD59 and human CD55 in transgenic mice. Somerville C, et al. **Transplant Proc** 1995 Dec;27(6):3565–6

Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model.

Kroshus TJ, et al. **Transplantation** 1996 May 27; 61(10):1513–21

IMMUNOLOGY

Protection of gingival epithelium against complement-mediated damage by strong expression of the membrane attack complex inhibitor protectin (CD59). Rautemaa R, et al. **J Dent Res** 1996 Jan;75(1):568–74

CD59 and CD48 expressed by rat retinal pigment epithelial cells are major ligands for the CD2-mediated alternative pathway of T cell activation. Liversidge J, et al. **J Immunol** 1996 May 15;156(10):3696–703

How can human DAF and HRF20 prevent HAR in transgenic mice? Koike C, et al. **Transplant Proc** 1996 Apr; 28(2):599–600

Functional feature of C5b–8–step lysis of swine endothelial cell– transfected CD59. Miyagawa S, et al. **Transplant Proc** 1996 Apr;28(2):597–8

METABOLISM

Signalling through neutrophil Fc gamma RIII, Fc gamma RII, and CD59 is not impaired in active rheumatoid arthritis. Jones J, et al. **Ann Rheum Dis** 1996 May; 55(5):294–7

Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59. Husler T, et al. **Biochemistry** 1996 Mar 12;35(10):3263–9

Shedding and enrichment of the glycolipid-anchored complement lysis inhibitor protectin (CD59) into milk fat globules. Hakulinen J, et al. **Immunology** 1995 Jul; 85(3):495–501

Endocytosis of GPI-anchored proteins in human lymphocytes: role of glycolipid-based domains, actin cytoskeleton, and protein kinases. Deckert M, et al. **J Cell Biol** 1996 May;133(4):791–9

CD59 and CD48 expressed by rat retinal pigment epithelial cells are major ligands for the CD2-mediated alternative pathway of T cell activation. Liversidge J, et al. **J Immunol** 1996 May 15;156(10):3696–703

Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). Spear GT, et al. **J Immunol** 1995 Nov 1;155(9):4376–81

Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins. Koski CL, et al. **J Neurochem** 1996 Jan;66(1):303–12

Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Gorter A, et al. **Lab Invest** 1996 Jun; 74(6):1039–49

Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisole. Bjørge L, et al. **Scand J Immunol** 1995 Nov;42(5):512–6

PHARMACOLOGY

Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Brasoveanu LI, et al. **Lab Invest** 1996 Jan;74(1):33–42

PHYSIOLOGY

Functional activity of the membrane-associated complement inhibitor CD59 in a pig-to-human in vitro model for hyperacute xenograft rejection. Heckl-Ostreicher B, et al. **Clin Exp Immunol** 1995 Dec;102(3):589–95

Exogenous glycosyl phosphatidylinositol-anchored CD59 associates with kinases in membrane clusters on U937 cells and becomes Ca(2+)-signaling competent. van den Berg CW, et al. **J Cell Biol** 1995 Nov;131(3):669–77

A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex. Fodor WL, et al. **J Immunol** 1995 Nov 1;155(9):4135–8

Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Quigg RJ, et al. **Kidney Int** 1995 Aug; 48(2):412–21

C5b–8 step lysis of swine endothelial cells by human complement and functional feature of transfected CD59. Miyagawa S, et al. **Scand J Immunol** 1996 Apr;43(4):361–6

Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria. Telen MJ. **Transfus Clin Biol** 1995;2(4):277–90 (73 ref.)

Enhanced survival of porcine endothelial cells and lung xenografts expressing human CD59. Norin AJ, et al. **Transplant Proc** 1996 Apr;28(2):797–8

Expression and function of human CD59 and human CD55 in transgenic mice. Somerville C, et al. **Transplant Proc** 1995 Dec;27(6):3565–6

Protection of xenogeneic cardiac endothelium from human complement by expression of CD59 or DAF in transgenic mice. Byrne GW, et al. **Transplantation** 1995 Nov 27; 60(10):1149–56

ANTIGENS, CD62E see **E-SELECTIN**

ANTIGENS, CD62L see **L-SELECTIN**

ANTIGENS, CD62P see **P-SELECTIN**

ANTIGENS, CD64 see **RECEPTORS, IGG**

ANTIGENS, CD73 see **5'-NUCLEOTIDASE**

ANTIGENS, CD80

Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Dunussi-Joannopoulos K, et al. **Blood** 1996 Apr 1;87(7):2938–46

ANALYSIS

Expression of both B7-1 and CD28 contributes to the IL-2 responsiveness of CTLL-2 cells. Belani R, et al. **Immunology** 1996 Feb;87(2):271–4

Both a precursor and a mature population of dendritic cells can bind HIV. However, only the mature population that expresses CD80 can pass infection to unstimulated CD4+ T cells. Weissman D, et al. **J Immunol** 1995 Oct 15; 155(8):4111–7

Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Chaux P, et al. **Lab Invest** 1996 May;74(5):975–83

BIOSYNTHESIS

Decreased inducible expression of CD80 and CD86 in human monocytes after ultraviolet-B irradiation: its involvement in inactivation of allogenecity. Fujihara M, et al. **Blood** 1996 Mar 15;87(6):2386–93

Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduces their capacity to induce systemic immunity. Katsanis E, et al. **Cancer Gene Ther** 1996 Mar-Apr;3(2):75–82

B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines. Iezzi G, et al. **Cancer Res** 1996 Jan 1;56(1):11–5

Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Buelens C, et al. **Eur J Immunol** 1995 Sep; 25(9):2668–72

Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells. Rattis FM, et al. **Eur J Immunol** 1996 Feb;26(2):449–53

Low-dose UVB radiation perturbs the functional expression of B7.1 and B7.2 co-stimulatory molecules on human Langerhans cells. Weiss JM, et al. **Eur J Immunol** 1995 Oct;25(10):2858–62

Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: regulation by CD4+ T cells. Wolthers KC, et al. **Eur J Immunol** 1996 Aug;26(8):1700–6

Coexpression of B7-1 and viral ("self") transgenes in pancreatic beta cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. von Herrath MG, et al. **Immunity** 1995 Dec;3(6):727–38

Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? Huang AY, et al. **J Exp Med** 1996 Mar 1;183(3):769–76

A cell type-specific enhancer in the human B7.1 gene regulated by NF-kappaB. Zhao J, et al. **J Exp Med** 1996 Mar 1;183(3):777–89

Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. Baskar S, et al. **J Immunol** 1996 May 15;156(10):3821–7

IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. Rao JB, et al. **J Immunol** 1996 May 1; 156(9):3357–65

Phenotypic changes in Langerhans' cells after infection with arboviruses: a role in the immune response to epidermally acquired viral infection? Johnston LJ, et al. **J Virol** 1996 Jul;70(7):4761–6

Lipopolysaccharide effectively up-regulates B7-1 (CD80) expression and costimulatory function of human monocytes. Schmittel A, et al. **Scand J Immunol** 1995 Dec; 42(6):701–4

CHEMISTRY

Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2). Morton PA, et al. **J Immunol** 1996 Feb 1;156(3):1047–54

DRUG EFFECTS

Interferon-gamma and interleukin-10 inhibit antigen presentation by Langerhans cells for T helper type 1 cells by suppressing their CD80 (B7-1) expression. Ozawa H, et al. **Eur J Immunol** 1996 Mar;26(3):648–52

GENETICS

B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 (Ad-B7) expression vector. Dessureault S, et al. **Ann Surg Oncol** 1996 May;3(3):317–24

Expression and function of CD80 and CD86 costimulator molecules on synovial dendritic cells in chronic arthritis. Summers KL, et al. **Arthritis Rheum** 1996 Aug; 39(8):1287–91

Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. Cayeux S, et al. **Hum Gene Ther** 1996 Mar 1; 7(4):525–9

Cloning and partial characterization of the mouse B7-1 promoter. Antonia SJ, et al. **Immunogenetics** 1996; 43(4):234–7

Islet-infiltrating t lymphocytes in insulin-dependent diabetic patients express CD80 (B7-1) and CD86 (B7-2). Imagawa A, et al. **J Autoimmun** 1996 Jun;9(3):391–6

A cell type-specific enhancer in the human B7.1 gene regulated by NF-kappaB. Zhao J, et al. **J Exp Med** 1996 Mar 1;183(3):777–89

Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. Levitsky HI, et al. **J Immunol** 1996 May 15;156(10):3858–65

Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis. Trunch A, et al. **Mol Immunol** 1996 Feb;33(3):321–34

IMMUNOLOGY

T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture. Satoh J, et al. **Brain Res** 1995 Dec 15;704(1):92–6

Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule. Morecki S, et al. **Cancer Immunol Immunother** 1995 Oct;41(4):236–42

Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Chamberlain RS, et al. **Cancer Res** 1996 Jun 15;56(12):2832–6

Expression of CD80 enhances immunogenicity of cervical carcinoma cells in vitro. Kaufmann AM, et al. **Cell Immunol** 1996 May 1;169(2):246–51

CD28-mediated cytotoxicity of YT natural killer cells on B7-positive targets induces rapid necrotic death independent of granule exocytosis. Roger R, et al. **Cell Immunol** 1996 Feb 25;168(1):24–32

Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients. García-Cózar FJ, et al. **Clin Exp Immunol** 1996 Apr;104(1):72–9

Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Nakajima A, et al. **Eur J Immunol** 1995 Nov;25(11):3060–9

Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Miller SD, et al. **Immunity** 1995 Dec;3(6):739–45

Role of B7 signaling in the differentiation of naive CD4+ T cells to effector interleukin-4-producing T helper cells. Gause WC, et al. **Immunol Res** 1995;14(3):176–88 (84 ref.)

B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. Perrin PJ, et al. **Immunol Res** 1995; 14(3):189–99 (47 ref.)

Maturation of neonatal human CD4 T cells: III. Role of B7 co-stimulation at priming. Yang LP, et al. **Int Immunol** 1995 Dec;7(12):1987–93

Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. Racke MK, et al. **J Clin Invest** 1995 Nov;96(5):2195–203

B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. Johnston JV, et al. **J Exp Med** 1996 Mar 1;183(3):791–800

CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. Wong FS, et al. **J Exp Med** 1996 Jan 1;183(1):67–76

A reassessment of the role of B7-1 expression in tumor rejection. Wu TC, et al. **J Exp Med** 1995 Nov 1; 182(5):1415–21

Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. Gajewski TF, et al. **J Immunol** 1996 Apr 15;156(8):2909–17

B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors. Guerder S, et al. **J Immunol** 1995 Dec 1;155(11):5167–74

Costimulatory effects of T cell proliferation during infection with human T lymphotropic virus types I and II are mediated through CD80 and CD86 ligands. Lal RB, et al. **J Immunol** 1996 Aug 1;157(3):1288–96

Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. Levitsky HI, et al. **J Immunol** 1996 May 15;156(10):3858–65

Protective immunity induced by B7/CD28-costimulated gamma delta T cells to the EL-4 lymphoma in allogenic athymic mice. Li Y, et al. **J Immunol** 1995 Dec 15; 155(12):5705–10

IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. Rao JB, et al. **J Immunol** 1996 May 1;

156(9):3357–65
In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. Yang G, et al. **J Immunol** 1995 Oct 15;155(8):3897–903
Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis. Perrin PJ, et al. **J Neuroimmunol** 1996 Mar;65(1):31–9
T cell costimulation through the CD28 receptor. Green JM, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):41–6
Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen. He XS, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7274–8
Activation of CD4+ T lymphocytes form interleukin 2-deficient mice by costimulatory B7 molecules. Razi-Wolf Z, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2903–8
Requirement of CD80 and CD86 molecules for antigen presentation by eosinophils. Tamura N, et al. **Scand J Immunol** 1996 Sep;44(3):229–38
Specific acceptance of cardiac allografts after treatment with antibodies to CD80 and CD86 in mice. Bashuda H, et al. **Transplant Proc** 1996 Apr;28(2):1039–41

METABOLISM

Expression of B7 costimulator molecules on mouse dendritic cells. Inaba K, et al. **Adv Exp Med Biol** 1995;378:65–70
Improved isolation of dendritic cells in chronic arthritic joints reveals no B7 (CD80) surface expression. Summers KL, et al. **Adv Exp Med Biol** 1995;378:561–3
CD80 expression in rheumatoid arthritis: comment on the article by Ranheim and Kipps [letter] Thomas R, et al. **Arthritis Rheum** 1995 Dec;38(12):1863–5
Defective antigen-presenting cell function in patients with systemic lupus erythematosus. Tsokos GC, et al. **Arthritis Rheum** 1996 Apr;39(4):600–9
Differential expression of the costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid synovial tissue. Balsa A, et al. **Br J Rheumatol** 1996 Jan;35(1):33–7
Expression of CD80 enhances immunogenicity of cervical carcinoma cells in vitro. Kaufmann AM, et al. **Cell Immunol** 1996 May 1;169(2):246–51
CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination. Champagne E, et al. **Eur J Immunol** 1996 Jul; 26(7):1595–602
Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Creery WD, et al. **Eur J Immunol** 1996 Jun;26(6):1273–7
Comparison of CD28–B7.1 and B7.2 functional interaction in resting human T cells: phosphatidylinositol 3-kinase association to CD28 and cytokine production. Ghiotto-Ragueneau M, et al. **Eur J Immunol** 1996 Jan; 26(1):34–41
Macrophage-T cell interaction in murine salmonellosis: selective down-regulation of ICAM-1 and B7 molecules in infected macrophages and its probable role in cell-mediated immunity. Gupta S, et al. **Eur J Immunol** 1996 Mar;26(3):563–70
CD28:B7 interactions promote T cell adhesion. Turcovski-Corrales SM, et al. **Eur J Immunol** 1995 Nov; 25(11):3087–93
Antigen-presenting function and B7 expression of murine sinusoidal endothelial cells and Kupffer cells. Lohse AW, et al. **Gastroenterology** 1996 Apr;110(4):1175–81
Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Linsley PS, et al. **Immunity** 1996 Jun;4(6):535–43
Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Judge TA, et al. **Immunol Res** 1996; 15(1):38–49 (34 ref.)
Brucella abortus as a potential vaccine candidate: induction of interleukin-12 secretion and enhanced B7.1 and B7.2 and intercellular adhesion molecule 1 surface expression in elutriated human monocytes stimulated by heat-inactivated B. abortus. Zaitseva M, et al. **Infect Immun** 1996 Aug;64(8):3109–17
Pancreatic expression of B7 co-stimulatory molecules in the non-obese diabetic mouse. Stephens LA, et al. **Int Immunol** 1995 Dec;7(12):1885–95
Cytotoxic T lymphocyte-associated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. Leung HT, et al. **J Biol Chem** 1995 Oct 20;270(42):25107–14
Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. Li Y, et al. **J Exp Med** 1996 Feb 1;183(2):639–44
Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. Windhagen A, et al. **J Exp Med** 1995 Dec 1; 182(6):1985–96
Interactions of CD80 and CD86 with CD28 and CTLA4. Ellis JH, et al. **J Immunol** 1996 Apr 15;156(8):2700–9
Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function. Kariv I, et al. **J Immunol** 1996 Jul 1;157(1):29–38
Constitutive expression of B7-1 (CD80) on mouse keratinocytes does not prevent development of chemically induced skin papillomas and carcinomas. Williams IR, et al. **J Immunol** 1996 May 1;156(9):3382–8
CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy? van Gool SW, et al. **Res Immunol** 1995 Mar-Apr;146(3):183–96 (106 ref.)

PHARMACOLOGY

B7-1 synergizes with interleukin-12 in interleukin-2 receptor alpha expression by mouse T helper 1 clones. Igarashi O, et al. **Eur J Immunol** 1996 Feb;26(2):300–6
Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Martin-Fontecha A, et al. **Eur J Immunol** 1996 Aug;26(8):1851–9
B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Salvadori S, et al. **Hum Gene Ther** 1995 Oct; 6(10):1299–306
Effect of CD80 and CD86 on T cell cytokine production. Petro TM, et al. **Immunol Invest** 1995 Nov;24(6):965–76
Can co-stimulated tumor immunity be therapeutically efficacious? Hellström KE, et al. **Immunol Rev** 1995 Jun; 145:123–45 (110 ref.)
CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Levine BL, et al. **Int Immunol** 1995 Jun;7(6):891–904
Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. Ueda Y, et al. **Int Immunol** 1995 Jun;7(6):957–66
Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. Brunschwig EB, et al. **J Immunol** 1995 Dec 15;155(12):5498–505
B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. Matulonis U, et al. **J Immunol** 1996 Feb 1; 156(3):1126–31
Costimulation of IL-4 production by murine B7-1 and B7-2 molecules. Natesan M, et al. **J Immunol** 1996 Apr 15; 156(8):2783–91

PHYSIOLOGY

Characterisation of a serine/threonine kinase which mediates CD28 phosphorylation following activation by B7.1. Parry RV, et al. **Biochem Soc Trans** 1996 Feb;24(1):87S
Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Gribben JG, et al. **Blood** 1996 Jun 1; 87(11):4887–93
Critical role of CD28/B7 costimulation in the development of human Th2 cytokine-producing cells. Webb LM, et al. **Blood** 1995 Nov 1;86(9):3479–86
B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Yeh KY, et al. **Cell Immunol** 1995 Oct 15; 165(2):217–24
IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL). De Wit D, et al. **Clin Exp Immunol** 1996 Aug;105(2):353–9
Development of immunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7.1) is not sufficient to restore impaired primary T cell activation in vitro. Habicht A, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2396–402
Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand-dependent mechanism: CTLA4-Ig protects V beta 8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B. Lane P, et al. **Eur J Immunol** 1996 Apr;26(4):858–62
Rapid induction of tumor necrosis factor cytotoxicity in naive splenic T cells by simultaneous CD80 (B7.1) and CD54 (ICAM-1) co-stimulation. Nishio M, et al. **Eur J Immunol** 1996 Sep;26(9):2160–4
Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells. Plumas J, et al. **Eur J Immunol** 1995 Dec;25(12):3332–41
Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells. Rattis FM, et al. **Eur J Immunol** 1996 Feb;26(2):449–53
Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity. Reiser H, et al. **Eur J Immunol** 1996 Apr;26(4):880–5
A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Sulé-Suso J, et al. **Eur J Immunol** 1995 Oct; 25(10):2737–42
Human B7-1 is more efficient than B7-2 in providing co-stimulation for alloantigen-specific T cells. van Dijk AM, et al. **Eur J Immunol** 1996 Sep;26(9):2275–8
Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Zitvogel L, et al. **Eur J Immunol** 1996 Jun;26(6):1335–41
CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Lenschow DJ, et al. **Immunity** 1996 Sep;5(3):285–93
The primary alloresponse of human CD4+ T cells is dependent on B7 (CD80), augmented by CD58, but relatively uninfluenced by CD54 expression. Hargreaves R, et al. **Int Immunol** 1995 Sep;7(9):1505–13
A T cell lymphoma can provide potent co-stimulatory effects to T cells that are not mediated by B7-1, B7-2, CD40, HSA or CD70. Nieland JD, et al. **Int Immunol** 1995 Nov; 7(11):1827–38
T cell activation by antigens on human melanoma cells—co-stimulation by B7-1 is neither sufficient nor necessary to stimulate IL-2 secretion by melanoma-specific T cell clones in vitro. Viret C, et al. **Int Immunol** 1995 Oct;7(10):1535–43
T-Cell co-stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor. Chaux P, et al. **Int J Cancer** 1996 Apr 10;66(2):244–8
Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice. Fujii H, et al. **Int J Cancer** 1996 Apr 10; 66(2):219–24
Signal transduction by CD28 costimulatory receptor on T cells. B7-1 and B7-2 regulation of tyrosine kinase adaptor molecules. Nunès JA, et al. **J Biol Chem** 1996 Jan 19; 271(3):1591–8
A pathway of costimulation that prevents anergy in CD28-T cells: B7-independent costimulation of CD1-restricted T cells. Behar SM, et al. **J Exp Med** 1995 Dec 1; 182(6):2007–18
Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. Boussiotis VA, et al. **J Exp Med** 1996 Aug 1;184(2):365–76
Differing roles for B7 and intercellular adhesion molecule-1 in negative selection of thymocytes [see comments] Kishimoto H, et al. **J Exp Med** 1996 Aug 1;184(2):531–7 . Comment in: J Exp Med 1996 Aug 1;184(2):305–9.
Activated B cells express CD28/B7-independent costimulatory activity. Ding L, et al. **J Immunol** 1996 Aug 15;157(4):1389–96
B7/CD28-dependent and -independent induction of CD40 ligand expression. Ding L, et al. **J Immunol** 1995 Dec 1; 155(11):5124–32
B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. Gajewski TF. **J Immunol** 1996 Jan 15;156(2):465–72
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. Gajewski TF, et al. **J Immunol** 1996 Apr 15;156(8):2909–17
Induction of costimulatory molecules B7-1 and B7-2 in murine B cells. the CBA/N mouse reveals a role for Bruton's tyrosine kinase in CD40-mediated B7 induction. Goldstein MD, et al. **Mol Immunol** 1996 Apr;33(6):541–52
CD28 signal transduction pathways. A comparison of B7-1 and B7-2 regulation of the map kinases: ERK2 and Jun kinases. Nunes JA, et al. **Mol Immunol** 1996 Jan;33(1):63–70
The CD28 costimulatory pathway. Leung HT, et al. **Ther Immunol** 1994 Aug;1(4):217–28 (104 ref.)
Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Lenschow DJ, et al. **Transplantation** 1995 Nov 27;60(10):1171–8

THERAPEUTIC USE

B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Coughlin CM, et al. **Cancer Res** 1995 Nov 1;55(21):4980–7
Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Martin-Fontecha A, et al. **Eur J Immunol** 1996 Aug;26(8):1851–9

ANTIGENS, CD90 see **ANTIGENS, THY-1**

ANTIGENS, CD95

Decreased Fas antigen receptor expression in testicular tumor cell lines derived from polyomavirus large T-antigen transgenic mice. Lebel M, et al. **Oncogene** 1996 Mar 7; 12(5):1127–35

ANALYSIS

Expression of Fas antigen and Bcl-2 protein in hepatocellular carcinoma. Hamazaki K, et al. **Acta Med Okayama** 1995 Aug;49(4):227–30
The Fas antigen is detected on immature B cells and the representative cell lines show Fas-mediated apoptosis. Nishiuchi R, et al. **Br J Haematol** 1996 Feb;92(2):302–7
Expression of Fas/APO-1 during the progression of astrocytomas. Tachibana O, et al. **Cancer Res** 1995 Dec 1;55(23):5528–30
B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo-1/fas), diminished CD38 expression, and undergo enhanced apoptosis. Saxon A, et al. **Clin Exp Immunol** 1995 Oct;102(1):17–25
Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Xerri L, et al. **Histopathology** 1995 Sep;27(3):235–41
Immunological evidence for the expression of the Fas antigen in the infant and adult human ovary during follicular regression and atresia. Kondo H, et al.

J Clin Endocrinol Metab 1996 Jul;81(7):2702–10
Identification of the Fas antigen in human gingiva. Yoshioka C, et al. J Dent Res 1996 Jun;75(6):1353–7
FAS is highly expressed in the germinal center but is not required for regulation of the B-cell response to antigen. Smith KG, et al. Proc Natl Acad Sci U S A 1995 Dec 5;92(25):11628–32
Demonstration of apoptosis in neuroblastoma and its relationship to tumour regression. Koizumi H, et al. Virchows Arch 1995;427(2):167–73
[Fas antigen expression and apoptosis in liver tissues of patients with chronic hepatitis B] Mochizuki K, et al. Nippon Rinsho 1995 Oct;53 Suppl:228–33 (17 ref.) (Jpn)
[Immunohistochemical observation of Fas in the liver of chronic hepatitis B and its ultrastructural localization] Takatani M, et al. Nippon Rinsho 1995 Oct;53 Suppl:234–40 (23 ref.) (Jpn)
[Immunohistochemical observation of Fas in the liver with chronic hepatitis C] Takatani M, et al. Nippon Rinsho 1995 Sep;53 Suppl:667–74 (23 ref.) (Jpn)
[Immunostaining of anti-Fas IgG1 antibody in diseased human muscle] Sahashi K, et al. Rinsho Shinkeigaku 1995 Jul;35(7):764–9 (Eng. Abstr.) (Jpn)

BIOSYNTHESIS

Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Higaki K, et al. Am J Pathol 1996 Aug; 149(2):429–37
Fas antigen expression on synovial cells was down-regulated by interleukin 1 beta. Tsuboi M, et al. Biochem Biophys Res Commun 1996 Jan 5;218(1):280–5
Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. Liu C, et al. Biochem J 1995 Sep 15;310 (Pt 3):957–63
Fas-mediated apoptosis in cultured human eosinophils. Druilhe A, et al. Blood 1996 Apr 1;87(7):2822–30
Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome [letter] Gersuk GM, et al. Blood 1996 Aug 1;88(3):1122–3
Inhibition of CD4 cross-linking-induced lymphocytes apoptosis by vesnarinone as a novel immunomodulating agent: vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion. Oyaizu N, et al. Blood 1996 Mar 15;87(6):2361–8
Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Maciejewski JP, et al. Br J Haematol 1995 Sep;91(1):245–52
Fas antigen expression in brains of patients with Alzheimer-type dementia. Nishimura T, et al. Brain Res 1995 Oct 16;695(2):137–45
Expression of apoptosis-preventing Bcl-2 protein and -inducing Fas antigen in glomeruli of IgA nephropathy. Yoshimura A, et al. Contrib Nephrol 1996;118:48–53
Expression of the Fas antigen in patients infected with human immunodeficiency virus. McCloskey TW, et al. Cytometry 1995 Jun 15;22(2):111–4
Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in IDDM. Giordano C, et al. Diabetologia 1995 Dec;38(12):1449–54
Expression and function of the Fas receptor on human blood and tissue eosinophils. Hebestreit H, et al. Eur J Immunol 1996 Aug;26(8):1775–80
Expression and function of Fas antigen on activated murine B cells. Wang J, et al. Eur J Immunol 1996 Jan;26(1):92–6
Existence of a small population of IL-2R beta hi TCRint cells in SCG and MRL-lpr/lpr mice which produce normal Fas mRNA and Fas molecules from the lpr gene. Yamagiwa S, et al. Eur J Immunol 1996 Jul;26(7):1409–16
Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Fukuo K, et al. Hypertension 1996 Mar;27(3 Pt 2):823–6
Regulation of CD95 (APO-1) expression and the induction of apoptosis in human T cells: changes in old age. Lechner H, et al. Int Arch Allergy Immunol 1996 Jul;110(3):238–43
The Fas-Fas ligand system and other modulators of apoptosis in the cornea. Wilson SE, et al. Invest Ophthalmol Vis Sci 1996 Jul;37(8):1582–92
Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2. Martinez-Valdez H, et al. J Exp Med 1996 Mar 1;183(3):971–7
CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. Schattner EJ, et al. J Exp Med 1995 Nov 1;182(5):1557–65
Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia [see comments] Simon HU, et al. J Exp Med 1996 Mar 1;183(3):1071–82. Comment in: J Exp Med 1996 Mar 1;183(3):721–4.
Apoptosis associated with ex vivo down-regulation of Bcl-2 and up-regulation of Fas in potential cytotoxic CD8+ T lymphocytes during HIV infection. Boudet F, et al. J Immunol 1996 Mar 15;156(6):2282–93
A new alternative splice variant of the mouse Fas antigen with a deletion in the N-terminal portion of the extracellular domain. Nakajima T, et al. Life Sci 1996; 58(9):761–8
Fas antigen expression and apoptosis induction of in vitro cultured hepatocytes with high concentrations of cyclosporine A. Yokoyama I, et al. Transplant Proc 1996 Jun;28(3):1383–4

BLOOD

Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Goel N, et al. Arthritis Rheum 1995 Dec;38(12):1738–43
Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Knipping E, et al. Arthritis Rheum 1995 Dec;38(12):1735–7
Relationship between susceptibility to apoptosis and Fas expression in peripheral blood T cells from uremic patients: a possible mechanism for lymphopenia in chronic renal failure. Matsumoto Y, et al. Biochem Biophys Res Commun 1995 Oct 4;215(1):98–105
Abnormal expression of apoptosis-related antigens, Fas and bcl-2, on circulating T-lymphocyte subsets in primary Sjögren's syndrome. Ichikawa Y, et al. Clin Exp Rheumatol 1995 May-Jun;13(3):307–13
Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Munker R, et al. Leukemia 1996 Sep;10(9):1531–3
Nitrite/nitrate (NOx) and sFas antigen levels in patients with multiple organ failure. Endo S, et al. Res Commun Mol Pathol Pharmacol 1996 May;92(2):253–6

CHEMISTRY

Interactions of cellular polypeptides with the cytoplasmic domain of the mouse Fas antigen. Orlinick JR, et al. J Biol Chem 1996 Apr 12;271(15):8627–32
An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. Papoff G, et al. J Immunol 1996 Jun 15;156(12):4622–30

GENETICS

Search for rearrangements and/or allelic loss of the fas/APO-1 gene in 101 human lymphomas. Xerri L, et al. Am J Clin Pathol 1995 Oct;104(4):424–30
Paneth cells express high levels of CD95 ligand transcripts: a unique property among gastrointestinal epithelia. Möller P, et al. Am J Pathol 1996 Jul;149(1):9–13
Inhibition of Fas antigen-mediated apoptosis of rheumatoid synovial cells in vitro by transforming growth factor beta 1. Kawakami A, et al. Arthritis Rheum 1996 Aug; 39(8):1267–76
Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. Liu C, et al. Biochem J 1995 Sep 15;310 (Pt 3):957–63
Abnormal complement-mediated immune clearance in MRL-lpr/+ heterozygote mice: dose-dependent effect of the Fas antigen mutation. Meryhew NL, et al. Clin Immunol Immunopathol 1996 Mar;78(3):236–44
Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. Strasser A. Curr Opin Immunol 1995 Apr;7(2):228–34 (97 ref.)
Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/APO-1) gene. Rudert F, et al. DNA Cell Biol 1995 Nov;14(11):931–7
Cloning and characterization of the bovine Fas. Yoo J, et al. DNA Cell Biol 1996 Mar;15(3):227–34
Elucidation of the protein kinase C-dependent apoptosis pathway in distinct subsets of T lymphocytes in MRL-lpr/lpr mice. Ohkusu K, et al. Eur J Immunol 1995 Nov;25(11):3180–6
Existence of a small population of IL-2R beta hi TCRint cells in SCG and MRL-lpr/lpr mice which produce normal Fas mRNA and Fas molecules from the lpr gene. Yamagiwa S, et al. Eur J Immunol 1996 Jul;26(7):1409–16
pLEF, a novel vector for expression of glutathione S-transferase fusion proteins in mammalian cells. Rudert F, et al. Gene 1996 Mar 9;169(2):281–2
A novel gene product that couples TCR signaling to Fas(CD95) expression in activation-induced cell death. Park CG, et al. Immunity 1996 Jun;4(6):583–91
Functional significance of the Fas molecule in naive lymphocytes. Senju S, et al. Int Immunol 1996 Mar; 8(3):423–31
Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. French LE, et al. J Cell Biol 1996 Apr; 133(2):335–43
A naturally occurring soluble isoform of murine Fas generated by alternative splicing. Hughes DP, et al. J Exp Med 1995 Nov 1;182(5):1395–401
Increased susceptibility of fas mutant MRL-lpr/lpr mice to staphylococcal enterotoxin B-induced septic shock. Mountz JD, et al. J Immunol 1995 Nov 15;155(10):4829–37
bcl-2 transgenic Lpr mice show profound enhancement of lymphadenopathy. Reap EA, et al. J Immunol 1995 Dec 1;155(11):5455–62
Expression of biologically active mouse and human CD95/APO-1/Fas ligand in the baculovirus system. Mariani SM, et al. J Immunol Methods 1996 Jun 14; 193(1):63–70
Interferon-gamma-dependent stimulation of Fas antigen in SV40-transformed human keratinocytes: modulation of the apoptotic process by protein kinase C. Takahashi H, et al. J Invest Dermatol 1995 Dec;105(6):810–5
Clinical, immunological, and pathological consequences of Fas-deficient conditions. Le Deist F, et al. Lancet 1996 Sep 14;348(9029):719–23
A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis. Zhang J, et al. Mol Cell Biol 1996 Jun; 16(6):2756–63
Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Adachi M, et al. Nat Genet 1995 Nov;11(3):294–300
Role of Fas apoptosis and MHC genes in 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced immunotoxicity of T cells. Rhile MJ, et al. Toxicology 1996 Jun 17;110(1-3):153–67

IMMUNOLOGY

Cytotoxic T lymphocytes: the newly identified Fas (CD95)-mediated killing mechanism and a novel aspect of their biological functions. Takayama H, et al. Adv Immunol 1995;60:289–321 (180 ref.)
Role of calmodulin in HIV-potentiated Fas-mediated apoptosis. Pan Z, et al. Am J Pathol 1996 Sep;149(3):903–10
Insufficient expression of Fas antigen on helper T cells in Behçet's disease. Nakamura S, et al. Br J Ophthalmol 1996 Feb;80(2):174–6
Die and let live: eliminating dangerous lymphocytes. Abbas AK. Cell 1996 Mar 8;84(5):655–7 (15 ref.)
Cytotoxic T lymphocytes specific for the synthetic VEINCTR peptide, a sequence found within the Fas molecule and env gp120 in the blood of HIV-1 seropositive individuals. Moukrim Z, et al. Cell Mol Biol (Noisy-le-grand) 1995 May;41(3):439–44
Inhibition of CD95 (Fas/Apo1)-mediated apoptosis by vaccinia virus WR. Heinkelein M, et al. Clin Exp Immunol 1996 Jan;103(1):8–14
Autoimmunity. The Fas track. Rathmell JC, et al. Curr Biol 1995 Nov 1;5(11):1218–21 (31 ref.)
Apoptosis-related fas antigen on memory T cells in aqueous humor of uveitis patients. Ohta K, et al. Curr Eye Res 1996 Mar;15(3):299–306
Cell-free reconstitution of Fas-, UV radiation- and ceramide-induced apoptosis. Martin SJ, et al. EMBO J 1995 Nov 1;14(21):5191–200
Down-modulation of CD4+ T helper type 2 and type 0 cells by T helper type 1 cells via Fas/Fas-ligand interaction. Hahn S, et al. Eur J Immunol 1995 Sep; 25(9):2679–85
Expression and function of the Fas receptor on human blood and tissue eosinophils. Hebestreit H, et al. Eur J Immunol 1996 Aug;26(8):1775–80
Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2-deficient mice. Kneitz B, et al. Eur J Immunol 1995 Sep;25(9):2572–7
Mechanisms of peripheral T cell deletion: anergized T cells are Fas resistant but undergo proliferation-associated apoptosis. Miethke T, et al. Eur J Immunol 1996 Jul; 26(7):1459–67
mtDNA-depleted U937 cells are sensitive to TNF and Fas-mediated cytotoxicity. Gamen S, et al. FEBS Lett 1995 Nov 27;376(1-2):15–8
Anatomy of autoantibody production: dominant localization of antibody-producing cells to T cell zones in Fas-deficient mice. Jacobson BA, et al. Immunity 1995 Oct;3(4):509–19
Fas bridging cell death and cytotoxicity: the reaper connection. Golstein P, et al. Immunol Rev 1995 Aug; 146:45–56 (58 ref.)
Mapping of the linear site on the Fas/APO-1 molecule targeted by the prototypic anti-Fas mAb. Fadeel B, et al. Int Immunol 1995 Dec;7(12):1967–75
Functional significance of the Fas molecule in naive lymphocytes. Senju S, et al. Int Immunol 1996 Mar; 8(3):423–31
Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice. Fujisawa K, et al. J Clin Invest 1996 Jul 15;98(2):271–8
The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. Baker MB, et al. J Exp Med 1996 Jun 1; 183(6):2645–56
Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide. Brossart P, et al. J Exp Med 1996 Jun 1;183(6):2449–58
Fas and the art of lymphocyte maintenance [comment] Lenardo MJ. J Exp Med 1996 Mar 1;183(3):721–4 (31 ref.) . Comment on: J Exp Med 1996 Mar 1;183(3):1071–82.
Fas- and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF-beta 1. Cerwenka A, et al. J Immunol 1996 Jan 15;156(2):459–64
Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells. Cleary AM, et al. J Immunol 1995 Oct 1;155(7):3329–37
Activated alpha beta+CD8+, but not alpha alpha-CD8+, TCR-alpha beta+ murine intestinal intraepithelial lymphocytes can mediate perforin-based cytotoxicity, whereas both subsets are active in Fas-based cytotoxicity. Gelfanov V, et al. J Immunol 1996 Jan 1;156(1):35–41
Regulation of the Fas lytic pathway in cloned CTL. Glass A, et al. J Immunol 1996 May 15;156(10):3638–44
Stimulation of phosphatidylinositol turnover is a key event for Fas-dependent, activation-induced apoptosis in human T lymphocytes. Izquierdo M, et al. J Immunol 1996 Jul 1;157(1):21–8
Bcl-2 blocks glucocorticoid- but not Fas- or activation-induced apoptosis in a T cell hybridoma.

THE PAPER AND INK USED IN THE ORIGINAL PUBLICATION MAY AFFECT THE QUALITY OF THE MICROFORM EDITION.

Memon SA, et al. **J Immunol** 1995 Nov 15;155(10):4644–52

Qualitative and quantitative differences in the cellular responses mediated through Fas antigen and tumor necrosis factor receptor. Totpal K, et al.
J Interferon Cytokine Res 1996 Mar;16(3):259–67

Type II muscle fibers are stained by anti-Fas antibody. Yamada H, et al. **J Neurol Sci** 1995 Dec;134(1-2):115–8

Tumor necrosis factor-alpha gene transfer augments anti-Fas antibody-mediated apoptosis in human glioma cells. Mizuno M, et al. **Jpn J Cancer Res** 1996 May;87(5):543–7

Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells. González-Cuadrado S, et al. **Kidney Int** 1996 Apr;49(4):1064–70

A role for CD95 ligand in preventing graft rejection [see comments] Bellgrau D, et al. **Nature** 1995 Oct 19; 377(6550):630–2. Comment in: Nature 1995 Oct 19;377(6550):576. Comment in: Nature 1996 Feb 22;379(6567):682.

Immunology. Ways around rejection [news; comment] Vaux DL. **Nature** 1995 Oct 19;377(6550):576–7. Comment on: Nature 1995 Oct 19;377(6550):630–2.

A role for the Fas antigen in lupus? [editorial] Singh AK. **Postgrad Med J** 1996 Jan;72(843):4–5

Apoptosis of nur77/N10-transgenic thymocytes involves the Fas/Fas ligand pathway. Weih F, et al.
Proc Natl Acad Sci U S A 1996 May 28;93(11):5533–8

[Role of Fas system in apoptosis induced by hepatitis C virus infection] Mita E, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:198–202 (14 ref.) **(Jpn)**

METABOLISM

Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Bárcena A, et al. **Blood** 1996 Sep 15;88(6):2013–25

Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children. Bäumler CB, et al. **Blood** 1996 Sep 1;88(5):1741–6

Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy. Min YH, et al. **Br J Haematol** 1996 Jun 2;93(4):928–30

Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Midis GP, et al. **Cancer Res** 1996 Sep 1;56(17):3870–4

Synergy between T cell Receptor and Fas (CD95/APO-1) signaling in mouse thymocyte death. Fisher GH, et al.
Cell Immunol 1996 Apr 10;169(1):99–106

B cell lines from a subset of patients with common variable immunodeficiency undergo enhanced apoptosis associated with an increased display of CD95 (Apo-1/fas), diminished CD38 expression, and decreased IgG and IgA production. Guo BC, et al. **Cell Immunol** 1995 Nov;166(1):83–92

Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. Cifone MG, et al. **EMBO J** 1995 Dec 1; 14(23):5859–68

Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. Kischkel FC, et al. **EMBO J** 1995 Nov 15;14(22):5579–88

CPP32 inhibition prevents Fas-induced ceramide generation and apoptosis in human cells. Gamen S, et al.
FEBS Lett 1996 Jul 22;390(2):232–7

Sequential activation of three distinct ICE-like activities in Fas-ligated Jurkat cells. Greidinger EL, et al.
FEBS Lett 1996 Jul 29;390(3):299–303

The death domain motif found in Fas (Apo-1) and TNF receptor is present in proteins involved in apoptosis and axonal guidance. Hofmann K, et al. **FEBS Lett** 1995 Sep 11;371(3):321–3

Retrobulbar fibroblasts from patients with Graves' ophthalmopathy induce downregulation of APO-1 in T lymphocytes and protect T cells from apoptosis during coculture. Mohácsi A, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):327–33

Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells. Watanabe D, et al. **Int Immunol** 1995 Dec;7(12):1949–56

Fas-induced activation of the cell death-related protease CPP32 Is inhibited by Bcl-2 and by ICE family protease inhibitors. Armstrong RC, et al. **J Biol Chem** 1996 Jul 12; 271(28):16850–5

An interleukin-1beta converting enzyme-like protease is a key component of Fas-mediated apoptosis. Darmon AJ, et al. **J Biol Chem** 1996 Sep 6;271(36):21699–702

The CD95 (APO-1/Fas) receptor activates NF-kappaB independently of its cytotoxic function. Ponton A, et al. **J Biol Chem** 1996 Apr 12;271(15):8991–5

Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. A potential role for the acidic sphingomyelinase pathway in normal immunoregulation. De Maria R, et al. **J Clin Invest** 1996 Jan 15;97(2):316–22

Fas ligation induces apoptosis of CD40-activated human B lymphocytes. Garrone P, et al. **J Exp Med** 1995 Nov 1; 182(5):1265–73

Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. Liles WC, et al.
J Exp Med 1996 Aug 1;184(2):429–40

A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. Süss G, et al.
J Exp Med 1996 Apr 1;183(4):1789–96

Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. Abreu-Martin MT, et al. **J Immunol** 1995 Nov 1;155(9):4147–54

CD95 (Fas/Apo-1)-induced apoptosis results in loss of glucose transporter function. Berridge MV, et al.
J Immunol 1996 Jun 1;156(11):4092–9

Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. Ehl S, et al. **J Immunol** 1996 Apr 1;156(7):2357–60

Expression of Fas antigen and Bcl-2 in human glomerulonephritis. Takemura T, et al. **Kidney Int** 1995 Dec;48(6):1886–92

Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Friesen C, et al. **Nat Med** 1996 May;2(5):574–7

Correlation between the number of apoptotic cells and expression of the apoptosis-related antigens Fas, Le(y) and bcl-2 protein in non-Hodgkin's lymphomas. Aftabuddin M, et al. **Pathol Int** 1995 Jun;45(6):422–9

A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis. Chu K, et al.
Proc Natl Acad Sci U S A 1995 Dec 5;92(25):11894–8

Expression of apoptosis-inducing CD95 (Fas/Apo-1) on human beta-cells sorted by flow-cytometry and cultured in vitro. Stassi G, et al. **Transplant Proc** 1995 Dec; 27(6):3271–5

[Expression of ductal Fas antigen in sialoadenitis of Sjögren's syndrome] Matsumura R, et al. **Nippon Rinsho** 1995 Oct; 53(10):2446–50 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Analysis of Fas and bcl-2 expression on peripheral blood lymphocytes from primary Sjögren's syndrome] Ohashi H, et al. **Nippon Rinsho** 1995 Oct;53(10):2451–5 (24 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha. Deiss LP, et al. **EMBO J** 1996 Aug 1; 15(15):3861–70

Fas-mediated apoptosis is modulated by intracellular glutathione in human T cells. Chiba T, et al.
Eur J Immunol 1996 May;26(5):1164–9

Fas (CD95)/Fas ligand interactions regulate antigen-specific, major histocompatibility complex-restricted T/B cell proliferative responses. Ozdemirli M, et al.
Eur J Immunol 1996 Feb;26(2):415–9

CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Griffith TS, et al. **Immunity** 1996 Jul;5(1):7–16

A novel anti-apoptosis serum factor that down-regulates fas-mediated apoptosis. Kikuchi H, et al.
J Biochem (Tokyo) 1995 May;117(5):936–9

ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. Duan H, et al. **J Biol Chem** 1996 Jan 19; 271(3):1621–5

CPP32/apopain is a key interleukin 1 beta converting enzyme-like protease involved in Fas-mediated apoptosis. Schlegel J, et al. **J Biol Chem** 1996 Jan 26;271(4):1841–4

Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production. Rensing-Ehl A, et al.
J Inflamm 1995;45(3):161–74

PHYSIOLOGY

Fas and perforin cytotoxic pathways are not the major effector mechanisms in allogeneic resistance to bone marrow. Baker M, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:368–9

Induction of Fas-mediated apoptosis on circulating lymphocytes by surgical stress. Oka M, et al. **Ann Surg** 1996 Apr;223(4):434–40

Molecular mechanisms of APO-1/Fas(CD95)-mediated apoptosis in tolerance and AIDS. Dhein J, et al.
Behring Inst Mitt 1995 Jun;(96):13–20 (37 ref.)

The novel regulatory mechanism of Fas system-mediated apoptosis in mesangial cells: implication to mesangial proliferative glomerulonephritis. Yasutomo K, et al.
Biochem Biophys Res Commun 1996 Feb 6;219(1):89–95

Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Estaquier J, et al. **Blood** 1996 Jun 15; 87(12):4959–66

Fas receptor (CD95)-mediated apoptosis is induced in leukemic cells entering G1B compartment of the cell cycle. Komada Y, et al. **Blood** 1995 Nov 15;86(10):3848–60

Fas ligation induces apoptosis and Jun kinase activation independently of CD45 and Lck in human T cells. Latinis KM, et al. **Blood** 1996 Feb 1;87(3):871–5

CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. Schattner EJ, et al. **Blood** 1996 Aug 15;88(4):1375–82

Involvement of CPP32/Yama(-like) proteases in Fas-mediated apoptosis. Hasegawa J, et al. **Cancer Res** 1996 Apr 15;56(8):1713–8

Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Mori S, et al. **Cancer Res** 1996 Apr 15;56(8):1874–9

Hormone-induced apoptosis by Fas-nuclear receptor fusion proteins: novel biological tools for controlling apoptosis in vivo. Takebayashi H, et al. **Cancer Res** 1996 Sep 15; 56(18):4164–70

Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Boldin MP, et al.
Cell 1996 Jun 14;85(6):803–15

FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Muzio M, et al.
Cell 1996 Jun 14;85(6):817–27

A recessive mutant of the U937 cell line acquired resistance to anti-Fas and anti-p55 tumor necrosis factor receptor antibody-induced apoptosis. Noguchi K, et al.
Cell Growth Differ 1995 Oct;6(10):1271–7

Regulation of T-cell death genes: selective inhibition of FasL- but not Fas-mediated function. Cui H, et al.
Cell Immunol 1996 Feb 1;167(2):276–84

Characterization of lpr-derived T cell hybridomas: Fas-deficient hybridomas are deathless, growth-arrested, and cytotoxic upon activation. Cui H, et al.
Cell Immunol 1996 Feb 1;167(2):302–12

Fas-mediated cytotoxicity remains intact in perforin and granzyme B antisense transfectants of a human NK-like cell line. Montel AH, et al. **Cell Immunol** 1995 Oct 15; 165(2):312–7

Fas involvement in cytotoxicity mediated by human NK cells. Montel AH, et al. **Cell Immunol** 1995 Dec; 166(2):236–46

Inhibition of apoptosis and augmentation of lymphoproliferation in bcl-2 transgenic Fas/Fas ligand-defective mice. Tamura A, et al. **Cell Immunol** 1996 Mar 15;168(2):220–8

In vivo role of IL-10 and IL-12 during development of Sjögren's syndrome in MRL/lpr mice. Yanagi K, et al.
Cell Immunol 1996 Mar 15;168(2):243–50

Superoxide anion is a natural inhibitor of FAS-mediated cell death. Clément MV, et al. **EMBO J** 1996 Jan 15; 15(2):216–25

Apoptosis by a cytosolic extract from Fas-activated cells. Enari M, et al. **EMBO J** 1995 Nov 1;14(21):5201–8

Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. Strasser A, et al. **EMBO J** 1995 Dec 15;14(24):6136–47

Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle. Suzuki A, et al.
EMBO J 1996 Jan 15;15(2):211–15

Fas/APO-1/CD95 system as a mediator of granulosa cell apoptosis in ovarian follicle atresia. Hakuno N, et al.
Endocrinology 1996 May;137(5):1938–48

Different apoptotic pathways mediated by Fas and the tumor-necrosis-factor receptor. Cytosolic phospholipase A2 is not involved in Fas-mediated apoptosis. Enari M, et al. **Eur J Biochem** 1996 Mar 1;236(2):533–8

Activated B cells express functional Fas ligand. Hahne M, et al. **Eur J Immunol** 1996 Mar;26(3):721–4

Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand. Müller KP, et al. **Eur J Immunol** 1995 Oct;25(10):2996–9

Expression and function of the murine CD95/FasR/APO-1 receptor in relation to B cell ontogeny. Onel KB, et al.
Eur J Immunol 1995 Oct;25(10):2940–7

Neurons induced to express major histocompatibility complex class I antigen are killed via the perforin and not the Fas (APO-1/CD95) pathway. Rensing-Ehl A, et al.
Eur J Immunol 1996 Sep;26(9):2271–4

JNK, but not MAPK, activation is associated with Fas-mediated apoptosis in human T cells. Wilson DJ, et al. **Eur J Immunol** 1996 May;26(5):989–94

Comparison of apoptosis signaling through T cell receptor, fas, and calcium ionophore. Maecker HT, et al.
Exp Cell Res 1996 Jan 10;222(1):95–102

The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Sytwu HK, et al. **Immunity** 1996 Jul; 5(1):17–30

The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Van Parijs L, et al. **Immunity** 1996 Mar;4(3):321–8

Fas-mediated cytotoxicity--a new immunoregulatory and pathogenic function of Th1 CD4+ T cells. Yagita H, et al. **Immunol Rev** 1995 Aug;146:223–39 (71 ref.)

Fas and FasL in the homeostatic regulation of immune responses. Lynch DH, et al. **Immunol Today** 1995 Dec; 16(12):569–74 (61 ref.)

Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Mogil RJ, et al.
Int Immunol 1995 Sep;7(9):1451–8

APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. Peter ME, et al. **Int Immunol** 1995 Nov;7(11):1873–7

A physical interaction between the cell death protein Fas and the tyrosine kinase p59fynT. Atkinson EA, et al.
J Biol Chem 1996 Mar 15;271(11):5968–71

FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. Chinnaiyan AM, et al. **J Biol Chem** 1996 Mar 1;271(9):4961–5

Loss of function of cytochrome c in Jurkat cells undergoing fas-mediated apoptosis. Krippner A, et al. **J Biol Chem** 1996 Aug 30;271(35):21629-36

D4-GDI, a substrate of CPP32, is proteolyzed during Fas-induced apoptosis. Na S, et al. **J Biol Chem** 1996 May 10;271(19):11209-13

Tyrosine phosphorylation-dependent suppression of a voltage-gated K+ channel in T lymphocytes upon Fas stimulation. Szabò I, et al. **J Biol Chem** 1996 Aug 23; 271(34):20465-9

Swapping between Fas and granulocyte colony-stimulating factor receptor. Takahashi T, et al. **J Biol Chem** 1996 Jul 19;271(29):17555-60

Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. van den Dobbelsteen DJ, et al. **J Biol Chem** 1996 Jun 28; 271(26):15420-7

Early detachment of colon carcinoma cells during CD95(APO-1/Fas)-mediated apoptosis. I. De-adhesion from hyaluronate by shedding of CD44. Günthert AR, et al. **J Cell Biol** 1996 Aug;134(4):1089-96

Activation of the Fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways. Tsuyuki S, et al. **J Clin Invest** 1995 Dec; 96(6):2924-31

Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. Casiano CA, et al. **J Exp Med** 1996 Aug 1;184(2):765-70

T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. Estaquier J, et al. **J Exp Med** 1995 Dec 1; 182(6):1759-67

Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. Galle PR, et al. **J Exp Med** 1995 Nov 1;182(5):1223-30

A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. Rodriguez I, et al. **J Exp Med** 1996 Mar 1;183(3):1031-6

A potential mechanism of "cross-talk" between the p55 tumor necrosis factor receptor and Fas/APO1: proteins binding to the death domains of the two receptors also bind to each other. Varfolomeev EE, et al. **J Exp Med** 1996 Mar 1;183(3):1271-5

Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. Cascino I, et al. **J Immunol** 1996 Jan 1; 156(1):13-7

Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. Anti-Ig down-regulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis. Choe J, et al. **J Immunol** 1996 Aug 1;157(3):1006-16

Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. Edwards CK 3rd, et al. **J Immunol** 1996 Aug 15;157(4):1758-72

Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. Kataoka T, et al. **J Immunol** 1996 May 15;156(10):3678-86

Relation of oxidative stress and glutathione synthesis to CD95(Fas/APO-1)-mediated apoptosis of adult T cell leukemia cells. Kohno T, et al. **J Immunol** 1996 Jun 15; 156(12):4722-8

Cross-linking of the Fas/APO-1 antigen suppresses the CD3-mediated signal transduction events in human T lymphocytes. Kovacs B, et al. **J Immunol** 1995 Dec 15; 155(12):5543-9

Regulation of apoptosis in neutrophils--Fas track to death? Liles WC, et al. **J Immunol** 1995 Oct 1;155(7):3289-91 (71 ref.)

CD2-induced apoptosis in activated human peripheral T cells: a Fas-independent pathway that requires early protein tyrosine phosphorylation. Mollereau B, et al. **J Immunol** 1996 May 1;156(9):3184-90

CD95 engagement releases calcium from intracellular stores of long term activated, apoptosis-prone gammadelta T cells. Rovere P, et al. **J Immunol** 1996 Jun 15; 156(12):4631-7

Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis. Activation-induced death can occur without Fas receptor. Tuček-Szabo CL, et al. **J Immunol** 1996 Jan 1;156(1):192-200

Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. Um HD, et al. **J Immunol** 1996 May 1;156(9):3469-77

Lupus in the Fas lane? Singh AK. **J R Coll Physicians Lond** 1995 Nov-Dec;29(6):475-8 (40 ref.)

Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Dong C, et al. **Lab Invest** 1996 May; 74(5):921-31

Glimmers of clinical relevance for Fas [news] Rowe PM. **Lancet** 1996 May 18;347(9012):1398

Effect of anti-APO1 on spontaneous apoptosis of B cells in chronic lymphocytic leukaemia: the role of bcl-2 and interleukin 4. Mainou-Fowler T, et al. **Leuk Lymphoma** 1995 Oct;19(3-4):301-8

A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis. Zhang J, et al. **Mol Cell Biol** 1996 Jun; 16(6):2756-63

Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Lacronique V, et al. **Nat Med** 1996 Jan;2(1):80-6

Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Enari M, et al. **Nature** 1996 Apr 25;380(6576):723-6

Resistance to Fas-mediated apoptosis in human hepatoma cells. Natoli G, et al. **Oncogene** 1995 Sep 21;11(6):1157-64

Chromosome 22 complements apoptosis in Fas-and TNF-resistant mutant UK110 cells. Noguchi K, et al. **Oncogene** 1996 Jul 4;13(1):39-46

Fas-dependent apoptosis is impaired by SV40 T-antigen in transgenic liver. Rouquet N, et al. **Oncogene** 1995 Sep 21; 11(6):1061-7

Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Suzuki A, et al. **Oncogene** 1996 Jul 4;13(1):31-7

Enhanced and accelerated lymphoproliferation in Fas-null mice. Adachi M, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2131-6

Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway. Ashany D, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11225-9

Tumor dormancy and cell signaling: anti-mu-induced apoptosis in human B-lymphoma cells is not caused by an APO-1-APO-1 ligand interaction. Racila E, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2165-8

[The Fas/APO-1 antigen--a molecule mediating apoptosis] Baryshnikov AIu, et al. **Gematol Transfuziol** 1995 Nov-Dec;40(6):35-8 (28 ref.) **(Rus)**

TOXICITY

The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Kägi D, et al. **Eur J Immunol** 1995 Dec;25(12):3256-62

ANTIGENS, CD106 see **VASCULAR CELL ADHESION MOLECULE-1**

ANTIGENS, CD115 see **RECEPTORS, MACROPHAGE COLONY-STIMULATING FACTOR**

ANTIGENS, CD116 see **RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR**

ANTIGENS, CD117 see **PROTO-ONCOGENE PROTEINS C-KIT**

ANTIGENS, CDW121A see **RECEPTORS, INTERLEUKIN-1**

ANTIGENS, CDW121B see **RECEPTORS, INTERLEUKIN-1**

ANTIGENS, CD122 see **RECEPTORS, INTERLEUKIN-2**

ANTIGENS, DIFFERENTIATION

Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro. Shah AJ, et al. **Blood** 1996 May 1;87(9):3563-70

ADMINISTRATION & DOSAGE

Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice [letter] Srinivas NR, et al. **J Pharm Sci** 1995 Dec;84(12):1488-9

Secretion of CTLA4Ig by an SV40 T antigen-transformed islet cell line inhibits graft rejection against the neoantigen. Lew AM, et al. **Transplantation** 1996 Jul 15;62(1):83-9

CTLA4Ig alone or in combination with low-dose cyclosporine fails to reverse acute rejection of renal allograft in the rat. Perico N, et al. **Transplantation** 1996 May 15;61(9):1320-2

ANALYSIS

Deficiency of CD34+ c-kit+ and CD34+38- hematopoietic precursors in aplastic anemia after immunosuppressive treatment. Manz CY, et al. **Am J Hematol** 1996 Aug; 52(4):264-74

Galectin-3, a beta-galactoside-binding animal lectin, is a marker of anaplastic large-cell lymphoma. Konstantinov KN, et al. **Am J Pathol** 1996 Jan;148(1):25-30

Monocyte/macrophage differentiation in early multiple sclerosis lesions. Brück W, et al. **Ann Neurol** 1995 Nov; 38(5):788-96

A porcine homolog of human integrin alpha 6 is a differentiation antigen of granulosa cells. Fujiwara H, et al. **Biol Reprod** 1995 Aug;53(2):407-17

The value of flow cytometric analysis of platelet glycoprotein expression of CD34+ cells measured under conditions that prevent P-selectin-mediated binding of platelets. Dercksen MW, et al. **Blood** 1995 Nov 15;86(10):3771-82

A functional comparison of CD34 + CD38- cells in cord blood and bone marrow. Hao QL, et al. **Blood** 1995 Nov 15;86(10):3745-53

Peripheral blood harvest of unaffected CD34+ CD38- hematopoietic precursors in paroxysmal nocturnal hemoglobinuria. Prince GM, et al. **Blood** 1995 Nov 1; 86(9):3381-6

Expression of murine CD38 defines a population of long-term reconstituting hematopoietic stem cells. Randall TD, et al. **Blood** 1996 May 15;87(10):4057-67

B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo-1/fas), diminished CD38 expression, and undergo enhanced apoptosis. Saxon A, et al. **Clin Exp Immunol** 1995 Oct;102(1):17-25

Intranuclear distribution of galectin-3 in mouse 3T3 fibroblasts: comparative analyses by immunofluorescence and immunoelectron microscopy. Hubert M, et al. **Exp Cell Res** 1995 Oct;220(2):397-406

Expression of megakaryocytic and erythroid properties in human leukemic cells. Tani T, et al. **Exp Hematol** 1996 Feb;24(2):158-68

Role of F4/80+ cells during induction of hapten-specific contact hypersensitivity. Kurimoto I, et al. **Immunology** 1995 Aug;85(4):621-9

Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Gong JH, et al. **Infect Immun** 1996 Mar; 64(3):913-8

Functional chemotactic factor CP-10 and MRP-14 are abundant in murine abscesses. Kocher M, et al. **Infect Immun** 1996 Apr;64(4):1342-50

Cytotoxic T lymphocyte-associated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. Leung HT, et al. **J Biol Chem** 1995 Oct 20;270(42):25107-14

Kimura's disease and angiolymphoid hyperplasia with eosinophilia: new observations from immunohistochemical studies of lymphocyte markers, endothelial antigens, and granulocyte proteins. Helander SD, et al. **J Cutan Pathol** 1995 Aug;22(4):319-26

CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. Prall F, et al. **J Histochem Cytochem** 1996 Jan;44(1):35-41

Use of monoclonal antibodies and flow cytometry to cluster and analyze leukocyte differentiation molecules. Davis WC, et al. **Methods Mol Biol** 1995;45:149-67

The purification and characterization of fetal liver hematopoietic stem cells. Morrison SJ, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10302-6

Phenotype of infiltrating cells in an ex vivo model of human antiporcine hyperacute cardiac xenograft rejection. Ibrahim S, et al. **Transplant Proc** 1996 Apr;28(2):777

BIOSYNTHESIS

Differential expression of leucocyte protein L1 (calprotectin) by monocytes and intestinal macrophages. Rugtveit J, et al. **Adv Exp Med Biol** 1995;371A:207-10

Human T lymphotropic virus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3. Hsu DK, et al. **Am J Pathol** 1996 May;148(5):1661-70

Effect of rhG-CSF on the mobilization of CD38 and HLA-DR subfractions of CD34+ peripheral blood progenitor cells. Lozano ML, et al. **Ann Hematol** 1995 Sep; 71(3):105-10

Induction of CD38/NADase and its monoclonal antibody-induced tyrosine phosphorylation in human leukemia cell lines. Kontani K, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):466-71

Induction of hematopoietic commitment and erythromyeloid differentiation in embryonal stem cells constitutively expressing c-myb. Melotti P, et al. **Blood** 1996 Mar 15; 87(6):2221-34

Post-translational modification of CD38 protein into a high molecular weight form alters its catalytic properties. Umar S, et al. **J Biol Chem** 1996 Jul 5;271(27):15922-7

Granulocyte macrophage colony stimulating factor produced in lesioned peripheral nerves induces the up-regulation of cell surface expression of MAC-2 by macrophages and Schwann cells. Saada A, et al. **J Cell Biol** 1996 Apr; 133(1):159-67

Galectin-3 expression and effects on cyst enlargement and tubulogenesis in kidney epithelial MDCK cells cultured in three-dimensional matrices in vitro. Bao Q, et al. **J Cell Sci** 1995 Aug;108 (Pt 8):2791-800

Phosphorylation of MRP14, an S100 protein expressed during monocytic differentiation, modulates Ca(2+)-dependent translocation from cytoplasm to membranes and cytoskeleton. van den Bos C, et al. **J Immunol** 1996 Feb 1;156(3):1247-54

High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. Kramer G, et al. **J Urol** 1995 Nov;154(5):1636-41

CD49f (alpha 6 integrin) and CD66a (BGP) are specifically induced by retinoids during human monocytic differentiation. Botling J, et al. **Leukemia** 1995 Dec; 9(12):2034-41

Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Kay MA, et al. **Nat Genet** 1995 Oct;11(2):191-7

A cDNA clone encoding an IgE-binding protein from

Brassica anther has significant sequence similarity to Ca(2+)-binding proteins. Toriyama K, et al. **Plant Mol Biol** 1995 Dec;29(6):1157-65

BLOOD

Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane. Ramaschi G, et al. **Blood** 1996 Mar 15;87(6):2308-13

Immunohistochemical distribution and serum levels of the Ca(2+)-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn's disease. Lügering N, et al. **Digestion** 1995;56(5):406-14

The myeloic related protein MRP8/14 (27E10 antigen)--usefulness as a potential marker for disease activity in ulcerative colitis and putative biological function. Lügering N, et al. **Eur J Clin Invest** 1995 Sep; 25(9):659-64

CD66b, CD66c and carcinoembryonic antigen (CEA) are independently regulated markers in sera of tumor patients. Grunert F, et al. **Int J Cancer** 1995 Nov 3;63(3):349-55

[Creation and evaluation of the effectiveness of a computer database based on results of screening of donors for markers of viral hepatitis B and C] Nizhechik IuS, et al. **Gematol Transfuziol** 1995 Jul-Aug;40(4):44-5 **(Rus)**

CHEMISTRY

The S100 family protein MRP-14 (S100A9) has homology with the contact domain of high molecular weight kininogen. Hessian PA, et al. **FEBS Lett** 1995 Sep 11; 371(3):271-5

Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2). Morton PA, et al. **J Immunol** 1996 Feb 1;156(3):1047-54

A cDNA clone encoding an IgE-binding protein from Brassica anther has significant sequence similarity to Ca(2+)-binding proteins. Toriyama K, et al. **Plant Mol Biol** 1995 Dec;29(6):1157-65

Crystallization of ADP-ribosyl cyclase from Aplysia californica. Pradas GS, et al. **Proteins** 1996 Jan;24(1):138-40

DRUG EFFECTS

Inhibition of NAD+ glycohydrolase and ADP-ribosyl cyclase activities of leukocyte cell surface antigen CD38 by gangliosides. Hara-Yokoyama M, et al. **J Biol Chem** 1996 May 31;271(22):12951-5

GENETICS

An Mse I RFLP in the human CTLA4 promotor. Deichmann K, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):817-8

Molecular characterisation of the genomic locus of the mouse MRP8 gene. Nacken W, et al. **Biochim Biophys Acta** 1996 Jan 17;1315(1):1-5

A leader open reading frame is essential for the expression in Escherichia coli of GC-rich leuB gene of an extreme thermophile, Thermus thermophilus. Ishida M, et al. **FEMS Microbiol Lett** 1996 Jan 1;135(1):137-42

Cloning of the cDNA encoding rabbit galectin-3. Gaudin JC, et al. **Gene** 1995 Oct 3;163(2):249-52

Nucleotide sequence of the ACI rat CTLA-4 molecule. Oaks MK, et al. **Immunogenetics** 1996;43(3):173-4

Regulatory role of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in insulin secretion by glucose in pancreatic beta cells. Enhanced insulin secretion in CD38-expressing transgenic mice. Kato I, et al. **J Biol Chem** 1995 Dec 15;270(50):30045-50

Molecular cloning of F4/80, a murine macrophage-restricted cell surface glycoprotein with homology to the G-protein-linked transmembrane 7 hormone receptor family. McKnight AJ, et al. **J Biol Chem** 1996 Jan 5; 271(1):486-9

Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2). Morton PA, et al. **J Immunol** 1996 Feb 1;156(3):1047-54

Regulation of CTLA-4 expression during T cell activation. Perkins D, et al. **J Immunol** 1996 Jun 1;156(11):4154-9

Expression of galectin-3 modulates T-cell growth and apoptosis. Yang RY, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6737-42

Blocking CD28/B7 with soluble competitors: immunological phenotype of mCTLA4-H gamma 1 transgenic mice. Lane P. **Res Immunol** 1995 Mar-Apr;146(3):176-9 (30 ref.)

HISTORY

A little bit of CD history [editorial; comment] LeBien TW. **Transfusion** 1996 Mar;36(3):197-9. Comment on: Transfusion 1996 Mar;36(3):268-85.

IMMUNOLOGY

Characterization of a new antigen expressed by B and myeloid lineage cells identified by the monoclonal antibody LIP-6. Holmes KL, et al. **Cell Immunol** 1995 Nov; 166(1):131-40

Murine CD38: an immunoregulatory ectoenzyme. Lund F, et al. **Immunol Today** 1995 Oct;16(10):469-73 (46 ref.)

Uterine adenomatoid tumors: immunohistochemical characteristics with emphasis on Ber-EP4 immunoreactivity and distinction from adenocarcinoma. Otis CN. **Int J Gynecol Pathol** 1996 Apr;15(2):146-51

Evidence for IgG autoantibodies to galectin-3, a beta-galactoside-binding lectin (Mac-2, epsilon binding protein, or carbohydrate binding protein 35) in human serum. Mathews KP, et al. **J Clin Immunol** 1995 Nov; 15(6):329-37

Characterization of human thymic epithelial cell surface antigens: phenotypic similarity of thymic epithelial cells to epidermal keratinocytes. Patel DD, et al. **J Clin Immunol** 1995 Mar;15(2):80-92

Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin. Petzer AL, et al. **J Exp Med** 1996 Jun 1;183(6):2551-8

Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. Arima T, et al. **J Immunol** 1996 Jun 15;156(12):4916-24

Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. Gajewski TF, et al. **J Immunol** 1996 Apr 15;156(8):2909-17

Analysis of thymic subpopulations expressing the activation antigen GL7. Expression, genetics, and function. Hathcock KS, et al. **J Immunol** 1995 Nov 15;155(10):4575-81

A CD66a-specific, activation-dependent epitope detected by recombinant human single chain fragments (scFvs) on CHO transfectants and activated granulocytes. Jantscheff P, et al. **J Leukoc Biol** 1996 Jun;59(6):891-901

CD38 ligation induces tyrosine phosphorylation of Bruton tyrosine kinase and enhanced expression of interleukin 5-receptor alpha chain: synergistic effects with interleukin 5. Kikuchi Y, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11814-8

The Yin and Yang of T cell costimulation [see comments] Allison JP, et al. **Science** 1995 Nov 10;270(5238):932-3 (17 ref.). Comment in: Science 1995 Nov 10;270(5238):985-8.

Enhancement of antitumor immunity by CTLA-4 blockade [see comments] Leach DR, et al. **Science** 1996 Mar 22; 271(5256):1734-6. Comment in: Science 1996 Mar 22;271(5256):1691.

Releasing the brakes on antitumor immune response [comment] Pardoll D. **Science** 1996 Mar 22;271(5256):1691 . Comment on: Science 1996 Mar 22;271(5256):1734-6.

ISOLATION & PURIFICATION

Isolation of the murine S100 protein MRP14 (14 kDa migration-inhibitory-factor-related protein) from activated spleen cells: characterization of post-translational modifications and zinc binding. Raftery MJ, et al. **Biochem J** 1996 May 15;316 (Pt 1):285-93

Immunochemical analysis of carcinoembryonic antigen (CEA)-related antigens differentially localized in intracellular granules of human neutrophils. Kuroki M, et al. **Immunol Invest** 1995 Aug;24(5):829-43

L3T4(CD4)-, Lyt-2(CD8)- and Mac-1(CD11b)-phenotypic leukocytes in murine cryptococcal meningoencephalitis. Dobrick P, et al. **Mycopathologia** 1995 Sep;131(3):159-66

METABOLISM

Defect of the CTLA4-Ig ligands on tumor-infiltrating dendritic cells. Chaux P, et al. **Adv Exp Med Biol** 1995; 378:389-92

New molecules on dendritic cells and their interactions with T lymphocytes. Hart DN, et al. **Adv Exp Med Biol** 1995; 378:351-4

Adhesion and costimulatory molecules on human FDC in vitro. Tsunoda R, et al. **Adv Exp Med Biol** 1995;378:273-5

Inhibition of cADPR-Hydrolase by ADP-ribose potentiates cADPR synthesis from beta-NAD+. Genazzani AA, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):502-7

Galectin-3 binding potentials of mouse tumor EHS and human placental laminins. Ochieng J, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):402-6

Galectin-3 is a nuclear matrix protein which binds RNA. Wang L, et al. **Biochem Biophys Res Commun** 1995 Dec 5;217(1):292-303

Isolation of the murine S100 protein MRP14 (14 kDa migration-inhibitory-factor-related protein) from activated spleen cells: characterization of post-translational modifications and zinc binding. Raftery MJ, et al. **Biochem J** 1996 May 15;316 (Pt 1):285-93

Modulation of functional properties of galectin-3 by monoclonal antibodies binding to the non-lectin domains. Liu FT, et al. **Biochemistry** 1996 May 14;35(19):6073-9

New aspects of the physiological significance of NAD, poly ADP-ribose and cyclic ADP-ribose. Okamoto H, et al. **Biochimie** 1995;77(5):356-63 (41 ref.)

Neuronal localization of CD38 antigen in the human brain. Mizuguchi M, et al. **Brain Res** 1995 Oct 30;697(1-2):235-40

B cell lines from a subset of patients with common variable immunodeficiency undergo enhanced apoptosis associated with an increased display of CD95 (Apo-1/fas), diminished CD38 expression, and decreased IgG and IgA production. Guo BC, et al. **Cell Immunol** 1995 Nov;166(1):83-92

During HIV infection, CD4+ CD38+ T-cells are the predominant circulating CD4+ subset whose HLA-DR positivity increases with disease progression and whose V beta repertoire is similar to that of CD4+ CD38- T-cells. Ramzaoui S, et al. **Clin Immunol Immunopathol** 1995 Oct; 77(1):33-41

Stimulation of ADP-ribosyl cyclase activity of the cell surface antigen CD38 by zinc ions resulting from inhibition of its NAD+ glycohydrolase activity. Kukimoto I, et al. **Eur J Biochem** 1996 Jul 1;239(1):177-82

1995 Mack-Forster Award Lecture. Review. Mast cell differentiation antigens: expression in normal and malignant cells and use for diagnostic purposes. Valent P. **Eur J Clin Invest** 1995 Oct;25(10):715-20 (51 ref.)

CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination. Champagne E, et al. **Eur J Immunol** 1996 Jul; 26(7):1595-602

Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Linsley PS, et al. **Immunity** 1996 Jun;4(6):535-43

Cattle CTLA-4, CD28 and chicken CD28 bind CD86: MYPPPY is not conserved in cattle CD28. Parsons KR, et al. **Immunogenetics** 1996;43(6):388-91

ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. Aarhus R, et al. **J Biol Chem** 1995 Dec 22;270(51):30327-33

Regulatory role of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in insulin secretion by glucose in pancreatic beta cells. Enhanced insulin secretion in CD38-expressing transgenic mice. Kato I, et al. **J Biol Chem** 1995 Dec 15;270(50):30045-50

Tyrosine phosphorylation of the c-cbl proto-oncogene product mediated by cell surface antigen CD38 in HL-60 cells. Kontani K, et al. **J Biol Chem** 1996 Jan 19; 271(3):1534-7

2'-Phospho-cyclic ADP-ribose, a calcium-mobilizing agent derived from NADP. Vu CQ, et al. **J Biol Chem** 1996 Mar 1;271(9):4747-54

Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. Deaglio S, et al. **J Immunol** 1996 Jan 15;156(2):727-34

Coordinated regulation in human T cells of nucleotide-hydrolyzing ecto-enzymatic activities, including CD38 and PC-1. Possible role in the recycling of nicotinamide adenine dinucleotide metabolites. Deterre P, et al. **J Immunol** 1996 Aug 15;157(4):1381-8

Interactions of CD80 and CD86 with CD28 and CTLA4. Ellis JH, et al. **J Immunol** 1996 Apr 15;156(8):2700-9

Signaling through CD28/CTLA-4 family receptors: puzzling participation of phosphatidylinositol-3 kinase. Hutchcroft JE, et al. **J Immunol** 1996 Jun 1;156(11):4071-4 (69 ref.)

The animal lectin galectin-3 interacts with bacterial lipopolysaccharides via two independent sites. Mey A, et al. **J Immunol** 1996 Feb 15;156(4):1572-7

CD66 family members are associated with tyrosine kinase activity in human neutrophils. Skubitz KM, et al. **J Immunol** 1995 Dec 1;155(11):5382-90

Expression of leukocyte differentiation antigens during the differentiation of HL-60 cells induced by 1,25-dihydroxyvitamin D3: comparison with the maturation of normal monocytic and granulocytic bone marrow cells. Brackman D, et al. **J Leukoc Biol** 1995 Nov; 58(5):547-55

Decreased expression of galectin-3 is associated with progression of human breast cancer. Castronovo V, et al. **J Pathol** 1996 May;179(1):43-8

Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. Kasper M, et al. **J Pathol** 1996 Jul;179(3):309-16

Expression of markers of differentiation in normal bronchial epithelium and bronchial dysplasia. Pendleton N, et al. **J Pathol** 1996 Feb;178(2):146-50

The adhesion molecule E-cadherin and a surface antigen recognized by the antibody 9C4 are selectively expressed on erythroid cells of defined maturational stages. Bühring HJ, et al. **Leukemia** 1996 Jan;10(1):106-16

Posttranslational changes in band 3 in adult and aging brain following treatment with ergoloid mesylates, comparison to changes observed in Alzheimer's disease. Cover CC, et al. **Life Sci** 1996;58(8):655-64

Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Vlassara H, et al. **Mol Med** 1995 Sep;1(6):634-46

Association of pp60c-src with biliary glycoprotein (CD66a), an adhesion molecule of the carcinoembryonic antigen family downregulated in colorectal carcinomas. Brümmer J, et al. **Oncogene** 1995 Oct 19;11(8):1649-55

CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation. Linsley PS, et al. **Res Immunol** 1995 Mar-Apr;146(3):130-40 (78 ref.)

Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Marengère LE, et al. **Science** 1996 May 24;272(5265):1170-3

PHARMACOLOGY

Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis. McIntosh KR, et al. **Cell Immunol** 1995 Nov;166(1):103-12

Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand-dependent mechanism: CTLA4-Ig protects V beta 8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B. Lane P, et al. **Eur J Immunol** 1996 Apr;26(4):858-62

Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig

modulates T cell and macrophage activation and attenuates arteriosclerosis. Russell ME, et al. **J Clin Invest** 1996 Feb 1;97(3):833–8

The in vivo mechanism of action of CTLA4Ig. Judge TA, et al. **J Immunol** 1996 Mar 15;156(6):2294–9

CD28–B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. Khoury SJ, et al. **J Immunol** 1995 Nov 15;155(10):4521–4

Galectin–3 promotes adhesion of human neutrophils to laminin. Kuwabara I, et al. **J Immunol** 1996 May 15; 156(10):3939–44

Opposing effects of CTLA4–Ig and anti–CD80 (B7–1) plus anti–CD86 (B7–2) on experimental allergic encephalomyelitis. Perrin PJ, et al. **J Neuroimmunol** 1996 Mar;65(1):31–9

The time course of CTLAIg effect on cardiac allograft rejection. Bolling SF, et al. **J Surg Res** 1996 Jun;63(1):320–3

CTLA4Ig Inhibits humoral and cellular immune responses to concordant xenografts. Ibrahim S, et al. **Transplant Proc** 1996 Apr;28(2):715–6

PHYSIOLOGY

The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Brandtzaeg P, et al. **Adv Exp Med Biol** 1995;371A:201–6 (30 ref.)

Expression and function of galectin–3, a beta–galactoside–binding lectin, in human monocytes and macrophages. Liu FT, et al. **Am J Pathol** 1995 Oct; 147(4):1016–28

CD38–mediated growth suppression of B–cell progenitors requires activation of phosphatidylinositol 3–kinase and involves its association with the protein product of the c–cbl proto–oncogene. Kitanaka A, et al. **Blood** 1996 Jul 15;88(2):590–8

CD38 expression distinguishes two groups of B–cell chronic lymphocytic leukemias with different responses to anti–IgM antibodies and propensity to apoptosis. Zupo S, et al. **Blood** 1996 Aug 15;88(4):1365–74

Loss of CTLA–4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA–4. Tivol EA, et al. **Immunity** 1995 Nov;3(5):541–7

A T cell lymphoma can provide potent co–stimulatory effects to T cells that are not mediated by B7–1, B7–2, CD40, HSA or CD70. Nieland JD, et al. **Int Immunol** 1995 Nov; 7(11):1827–38

Effects of the carbohydrate–binding protein galectin–3 on the invasiveness of human breast carcinoma cells. Le Marer N, et al. **J Cell Physiol** 1996 Jul;168(1):51–8

Galectin–3 expression and effects on cyst enlargement and tubulogenesis in kidney epithelial MDCK cells cultured in three–dimensional matrices in vitro. Bao Q, et al. **J Cell Sci** 1995 Aug;108 (Pt 8):2791–800

CTLA–4: a negative regulator of autoimmune disease. Karandikar NJ, et al. **J Exp Med** 1996 Aug 1;184(2):783–8

CTLA–4 engagement inhibits IL–2 accumulation and cell cycle progression upon activation of resting T cells. Krummel MF, et al. **J Exp Med** 1996 Jun 1;183(6):2533–40

CTLA–4 ligation blocks CD28–dependent T cell activation. Walunas TL, et al. **J Exp Med** 1996 Jun 1;183(6):2541–50

Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7–1 over B7–2 for active tumor immunization. Gajewski TF, et al. **J Immunol** 1996 Apr 15;156(8):2909–17

Signaling through CD38 augments B cell antigen receptor (BCR) responses and is dependent on BCR expression. Lund FE, et al. **J Immunol** 1996 Aug 15;157(4):1455–67

CTLA–4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. Perrin PJ, et al. **J Immunol** 1996 Aug 15;157(4):1333–6

CD38 signal transduction in human B cell precursors. Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C–gamma and phosphatidylinositol 3–kinase. Silvennoinen O, et al. **J Immunol** 1996 Jan 1;156(1):100–7

Phosphorylation of MRP14, an S100 protein expressed during monocytic differentiation, modulates Ca(2+)–dependent translocation from cytoplasm to membranes and cytoskeleton. van den Bos C, et al. **J Immunol** 1996 Feb 1;156(3):1247–54

CD66a, CD66b, CD66c, and CD66d each independently stimulate neutrophils. Skubitz KM, et al. **J Leukoc Biol** 1996 Jul;60(1):106–17

A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice. Srinivas NR, et al. **J Pharm Sci** 1996 Mar;85(3):296–8

Galectin–3, a laminin binding protein, fails to modulate adhesion of human melanoma cells to laminin. van den Brûle FA, et al. **Neoplasma** 1995;42(5):215–9

Lymphoproliferative disorders with early lethality in mice deficient in Ctla–4 [see comments] Waterhouse P, et al. **Science** 1995 Nov 10;270(5238):985–8. Comment in: Science 1995 Nov 10;270(5238):932–3.

The CD28 costimulatory pathway. Leung HT, et al. **Ther Immunol** 1994 Aug;1(4):217–28 (104 ref.)

THERAPEUTIC USE

Intervention of CD4+ cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig. Chu EB, et al. **J Immunol** 1996 Feb 1;156(3):1262–8

Suppression of murine allergic contact dermatitis by CTLA4Ig. Tolerance induction of Th2 responses requires additional blockade of CD40–ligand. Tang A, et al. **J Immunol** 1996 Jul 1;157(1):117–25

Combined CTLA4Ig and anti–CD4/DC8 monoclonal antibody treatment prolongs survival of rat–to–mouse heterotopic cardiac xenografts. Rehman A, et al. **Transplant Proc** 1996 Apr;28(2):660–1

Prolongation of rat to mouse skin and heart xenograft survival by combined CTLA4Ig and anti–CD4/CD8 antibody. Tu Y, et al. **Transplant Proc** 1996 Aug; 28(4):2061–2

CTLA4–Ig prolongs survival of microencapsulated rabbit islet xenografts in spontaneously diabetic Nod mice. Weber CJ, et al. **Transplant Proc** 1996 Apr;28(2):821–3

CTLA4–Ig plus bone marrow induces long–term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism. Pearson TC, et al. **Transplantstion** 1996 Apr 15;61(7):997–1004

ANTIGENS, DIFFERENTIATION, B–CELL see **ANTIGENS, DIFFERENTIATION, B–LYMPHOCYTE**

ANTIGENS, DIFFERENTIATION, B–LYMPHOCYTE

[CD22: a cell adhesion molecule that displays alpha 2–6–linked sialic acid–binding lectin activity] Hanasaki K. **Seikagaku** 1995 Aug;67(8):1040–7 (15 ref.) **(Jpn)**

ANALYSIS

Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin–Reed Sternberg cells. Wolf J, et al. **Blood** 1996 Apr 15;87(8):3418–28

Reversible G1 arrest induced by dimethyl sulfoxide in human lymphoid cell lines: dimethyl sulfoxide inhibits IL–6–induced differentiation of SKW6–CL4 into IgM–secreting plasma cells. Teraoka H, et al. **Exp Cell Res** 1996 Jan 10;222(1):218–24

Immunohistological staining of lymphoid tissue in four Australian marsupial species using species cross–reactive antibodies. Hemsley SW, et al. **Immunol Cell Biol** 1995 Aug; 73(4):321–5

BIOSYNTHESIS

CD40 and B cell antigen receptor dual triggering of resting B lymphocytes turns on a partial germinal center phenotype. Galibert L, et al. **J Exp Med** 1996 Jan 1; 183(1):77–85

CHEMISTRY

Potential sites for processing of the human invariant chain by cathepsins D and E. Kageyama T, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):549–53

Invariant chain structure and MHC class II function. Cresswell P. **Cell** 1996 Feb 23;84(4):505–7 (17 ref.)

Molecular mimicry: CLIP, MHC Class II supermotifs and MAIDS [letter] Morse HC 3rd. **Immunol Today** 1996 Jan; 17(1):47–8

Structure–activity relationship of the leucine–based sorting motifs in the cytosolic tail of the major histocompatibility complex–associated invariant chain. Motta A, et al. **J Biol Chem** 1995 Nov 10;270(45):27165–71

The amino–terminal immunoglobulin–like domain of sialoadhesin contains the sialic acid binding site. Comparison with CD22. Nath D, et al. **J Biol Chem** 1995 Nov 3;270(44):26184–91

A single N–linked glycosylation site is implicated in the regulation of ligand recognition by the I–type lectins CD22 and CD33. Sgroi D, et al. **J Biol Chem** 1996 Aug 2; 271(31):18803–9

Localization of the putative sialic acid–binding site on the immunoglobulin superfamily cell–surface molecule CD22. van der Merwe PA, et al. **J Biol Chem** 1996 Apr 19; 271(16):9273–80

The structure of an intermediate in class II MHC maturation: CLIP bound to HLA–DR3. Ghosh P, et al. **Nature** 1995 Nov 30;378(6556):457–62

Direct observation of disordered regions in the major histocompatibility complex class II–associated invariant chain. Jasanoff A, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9900–4

Invariant chain made in Escherichia coli has an exposed N–terminal segment that blocks antigen binding to HLA–DR1 and a trimeric C–terminal segment that binds empty HLA–DR1. Park SJ, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11289–93

Truncation of the class II beta–chain cytoplasmic domain influences the level of class II/invariant chain–derived peptide complexes. Smiley ST, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):241–4

GENETICS

Identification of bovine invariant chain (Ii) gene by nucleotide sequencing. Niimi M, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):7–12

Molecular characterization of the pan–B cell antigen CDw78 as a MHC class II molecule by direct expression cloning of the transcription factor CIITA. Slack JL, et al. **Int Immunol** 1995 Jul;7(7):1087–92

Specific destruction of islet transplants in NOD<–>C57BL/6 and NOD<–>C3H/Tif embryo aggregation chimeras irrespective of allelic differences in beta–cell antigens. Leijon K, et al. **J Autoimmun** 1995 Jun; 8(3):347–56

Phenotype and function of CD4+ T cells in mice lacking invariant chain. Wong P, et al. **J Immunol** 1996 Mar 15; 156(6):2133–42

Construction and characterization of a humanized, internalizing, B–cell (CD22)–specific, leukemia/lymphoma antibody, LL2. Leung SO, et al. **Mol Immunol** 1995 Dec; 32(17–18):1413–27

IMMUNOLOGY

The repertoire of T cells shaped by a single MHC/peptide ligand. Ignatowicz L, et al. **Cell** 1996 Feb 23;84(4):521–9

A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex–specific monoclonal antibody. Eastman S, et al. **Eur J Immunol** 1996 Feb;26(2):385–93

T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates. Morkowski S, et al. **J Exp Med** 1995 Nov 1;182(5):1403–13

Ig domains 1 and 2 of murine CD22 constitute the ligand–binding domain and bind multiple sialylated ligands expressed on B and T cells. Law CL, et al. **J Immunol** 1995 Oct 1;155(7):3368–76

An anti–CD72 immunotoxin against therapy–refractory B–lineage acute lymphoblastic leukemia. Myers DE, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):119–22

Clip binds to HLA class II using methionine–based, allele–dependent motifs as well as allele–independent supermotifs. Geluk A, et al. **Mol Immunol** 1995 Sep; 32(13):975–81

METABOLISM

Analysis of invariant chain processing in 3 day cultured rat Langerhans cells. Neiss U, et al. **Adv Exp Med Biol** 1995; 378:223–5

Potential sites for processing of the human invariant chain by cathepsins D and E. Kageyama T, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):549–53

Ecto–sialyltransferase of human B lymphocytes reconstitutes differentiation markers in the presence of exogenous CMP–N–acetyl neuraminic acid. Gross HJ, et al. **Blood** 1996 Jun 15;87(12):5113–26

Evidence for invariant chain 85–101 (CLIP) binding in the antigen binding site of MHC class II molecules. Bangia N, et al. **Int Immunol** 1995 Oct;7(10):1585–91

Kinetics of the reactions between the invariant chain (85–99) peptide and proteins of the murine class II MHC. Liang MN, et al. **Int Immunol** 1995 Sep;7(9):1397–404

Tyrosine–phosphorylated forms of Ig beta, CD22, TCR zeta and HOSS are major ligands for tandem SH2 domains of Syk. Wienands J, et al. **Int Immunol** 1995 Nov;7(11):1701–8

A single N–linked glycosylation site is implicated in the regulation of ligand recognition by the I–type lectins CD22 and CD33. Sgroi D, et al. **J Biol Chem** 1996 Aug 2; 271(31):18803–9

Localization of the putative sialic acid–binding site on the immunoglobulin superfamily cell–surface molecule CD22. van der Merwe PA, et al. **J Biol Chem** 1996 Apr 19; 271(16):9273–80

Isoforms of the invariant chain regulate transport of MHC class II molecules to antigen processing compartments. Warmerdam PA, et al. **J Cell Biol** 1996 Apr;133(2):281–91

CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C–gamma(1) upon B cell activation. Law CL, et al. **J Exp Med** 1996 Feb 1;183(2):547–60

Inhibition of invariant chain (Ii)–calnexin interaction results in enhanced degradation of Ii but does not prevent the assembly of alpha beta Ii complexes. Romagnoli P, et al. **J Exp Med** 1995 Dec 1;182(6):2027–36

Variation in HLA–DM expression influences conversion of MHC class II alpha beta:class II–associated invariant chain peptide complexes to mature peptide–bound class II alpha beta dimers in a normal B cell line. Ramachandra L, et al. **J Immunol** 1996 Mar 15;156(6):2196 – 2204

Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA–DR. Vogt AB, et al. **J Immunol** 1995 Nov 15;155(10):4757–65

Modulation of antigen presentation and class II expression by a class II–associated invariant chain peptide. Zechel MA, et al. **J Immunol** 1996 Jun 1;156(11):4232–9

The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules. Hitzel C, et al. **Mol Immunol** 1996 Jan; 33(1):25–31

The MHC class II–associated invariant chain–derived peptide clip binds to the peptide–binding groove of class II molecules. Wu S, et al. **Mol Immunol** 1996 Mar–Apr; 33(4–5):371–7

Kinetic analysis of peptide loading onto HLA–DR molecules mediated by HLA–DM. Vogt AB, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9724–9

Self–release of CLIP in peptide loading of HLA–DR molecules. Kropshofer H, et al. **Science** 1995 Nov 24; 270(5240):1357–9

Another twist to MHC-peptide recognition [comment] Wilson IA. **Science** 1996 May 17;272(5264):973-4 (20 ref.) . Comment on: Nature 1996 May 17;272(5264):1001-4.
Glycoprotein incorporation and HIV-1 infectivity despite exchange of the gp160 membrane-spanning domain. Wilk T, et al. **Virology** 1996 Apr 1;218(1):269-74

PHARMACOLOGY

Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. Bevec T, et al. **J Exp Med** 1996 Apr 1; 183(4):1331-8

PHYSIOLOGY

Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation. Tuscano J, et al. **Blood** 1996 Jun 1;87(11):4723-30
Antiviral immune responses of mice lacking MHC class II or its associated invariant chain. Battegay M, et al. **Cell Immunol** 1996 Jan 10;167(1):115-21
Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system. Oxenius A, et al. **Eur J Immunol** 1995 Dec;25(12):3402-11
Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. Tuscano JM, et al. **Eur J Immunol** 1996 Jun;26(6):1246-52
Potent effects of low levels of MHC class II-associated invariant chain on CD4+ T cell development. Naujokas MF, et al. **Immunity** 1995 Sep;3(3):359-72
Reconstitution of invariant chain function in transgenic mice in vivo by individual p31 and p41 isoforms. Shachar I, et al. **Immunity** 1995 Sep;3(3):373-83
Major histocompatibility class II peptide occupancy, antigen presentation, and CD4+ T cell function in mice lacking the p41 isoform of invariant chain. Takaesu NT, et al. **Immunity** 1995 Sep;3(3):385-96
Structure-activity relationship of the leucine-based sorting motifs in the cytosolic tail of the major histocompatibility complex-associated invariant chain. Motta A, et al. **J Biol Chem** 1995 Nov 10;270(45):27165-71
Biosynthesis of major histocompatibility complex molecules and generation of T cells in Ii TAP1 double-mutant mice. Tourne S, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20; 93(4):1464-9
Requirement for invariant chain in B cell maturation and function. Shachar I, et al. **Science** 1996 Oct 4; 274(5284):106-8

ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE

Immunologic differentiation of absolute lymphocyte count with an integrated flow cytometric system: a new concept for absolute T cell subset determinations. Mercolino TJ, et al. **Cytometry** 1995 Mar 15;22(1):48-59
Statistical comparison of established T-cell epitope predictors against a large database of human and murine antigens. Deavin AJ, et al. **Mol Immunol** 1996 Feb;33(2):145-55

ANALYSIS

Ontogeny and immunohistochemical localization of thymus-dependent and thymus-independent RT6+ cells in the rat. Waite DJ, et al. **Am J Pathol** 1996 Jun; 148(6):2043-56
CD69 expression and tumour necrosis factor-alpha immunoreactivity in the inflammatory cell infiltrate of halo naevi. Fernández-Herrera J, et al. **Br J Dermatol** 1996 Mar; 134(3):388-93
CDW60, which identifies the acetylated form of GD3 gangliosides, is strongly expressed in human basal cell carcinoma. Heidenheim M, et al. **Br J Dermatol** 1995 Sep; 133(3):392-7
Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Reddish MA, et al. **Cancer Immunol Immunother** 1996 Jun;42(5):303-9
Similarity of expression of activation markers and CD28 on gamma delta and alpha beta-receptor T cells in HIV infection. Jouen-Beades F, et al. **Clin Immunol Immunopathol** 1996 May;79(2):189-93
Immunohistological staining of lymphoid tissue in four Australian marsupial species using species cross-reactive antibodies. Hemsley SW, et al. **Immunol Cell Biol** 1995 Aug; 73(4):321-5
Identification of a mouse protein homologous to the human CD6 T cell surface protein and sequence of the corresponding cDNA. Robinson WH, et al. **J Immunol** 1995 Nov 15;155(10):4739-48
[Importance of the expression of the C6 molecule on cells in chronic lymphatic leukemia] Krejsek J, et al. **Vnitr Lek** 1996 Apr;42(4):274-7 (Eng. Abstr.) **(Cze)**

BIOSYNTHESIS

Activation antigen expression on human T cells. I. Analysis by two-colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissue. Amlot PL, et al. **Clin Exp Immunol** 1996 Jul;105(1):176-82
Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection. Vanham G, et al. **Clin Exp Immunol** 1996 Jan;103(1):30-4
Expression of an avian CD6 candidate is restricted to alpha beta T cells, splenic CD8+ gamma delta T cells and embryonic natural killer cells. Göbel TW, et al. **Eur J Immunol** 1996 Aug;26(8):1743-7
Endothelial cells augment the expression of CD40 ligand on newly activated human CD4+ T cells through a CD2/LFA-3 signaling pathway. Karmann K, et al. **Eur J Immunol** 1996 Mar;26(3):610-7
Raf-1 provides a dominant but not exclusive signal for the induction of CD69 expression on T cells. Taylor-Fishwick DA, et al. **Eur J Immunol** 1995 Dec;25(12):3215-21
Expression of CD69 after in vitro stimulation: a rapid method for quantitating impaired lymphocyte responses in HIV-infected individuals. Krowka JF, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):95-104
Lack of IL-2 cytokine expression despite Il-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers. Coventry BJ, et al. **J Immunol** 1996 May 1;156(9):3486-92
Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. Luttmann W, et al. **J Immunol** 1996 Aug 15;157(4):1678-83
Expression of CD60 on multiple cell lineages in inflammatory synovitis. Carr K, et al. **Lab Invest** 1995 Sep;73(3):332-8
Role of monocytes in the up-regulation of the early activation marker CD69 on B and T murine lymphocytes induced by microbial mitogens. Vilanova M, et al. **Scand J Immunol** 1996 Feb;43(2):155-63

BLOOD

Activation antigen expression on human T cells. I. Analysis by two-colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissue. Amlot PL, et al. **Clin Exp Immunol** 1996 Jul;105(1):176-82

CHEMISTRY

Human CD6 possesses a large, alternatively spliced cytoplasmic domain. Robinson WH, et al. **Eur J Immunol** 1995 Oct;25(10):2765-9

DRUG EFFECTS

Raf-1 provides a dominant but not exclusive signal for the induction of CD69 expression on T cells. Taylor-Fishwick DA, et al. **Eur J Immunol** 1995 Dec;25(12):3215-21
Evidence for the promotion of positive selection of thymocytes by Ah receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin. Kremer J, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):413-27
Docosahexaenoic and eicosapentaenoic acids inhibit human lymphoproliferative responses in vitro but not the expression of T cell surface activation markers. Khalfoun B, et al. **Scand J Immunol** 1996 Mar;43(3):248-56

GENETICS

Complete nucleotide sequence of the mouse CTLA8 gene. Yao Z, et al. **Gene** 1996 Feb 12;168(2):223-5
Molecular linkage of the mouse CD5 and CD6 genes. Lecomte O, et al. **Immunogenetics** 1996;44(5):385-90

IMMUNOLOGY

T-cell recognition of antigen. A process controlled by transient intermolecular interactions. Boniface JJ, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:62-9 (34 ref.)
CD40 ligand expression on the surface of colostral T cells. Bertotto A, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar;74(2):F135-6
Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte-macrophage colony-stimulating factor. Walsh GM, et al. **Blood** 1996 Apr 1;87(7):2815-21
Comparison of corticosteroid- and L3T4+ antibody-immunosuppressed mouse models of Pneumocystis carinii pneumonia for evaluation of drugs and leukocytes. Bartlett MS, et al. **Clin Diagn Lab Immunol** 1994 Sep;1(5):511-6
Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction. Starling GC, et al. **Eur J Immunol** 1996 Apr; 26(4):738-46
A method for monoclonal antibody isotype switching: anti-CD60 VH expression in a heavy chain-deficient hybridoma variant. Kozarsky KF, et al. **Hybridoma** 1995 Dec;14(6):597-601
Modulation of WC1, a lineage-specific cell surface molecule of gamma/delta T cells augments cellular proliferation. Hanby-Flarida MD, et al. **Immunology** 1996 May; 88(1):116-23
Differentiation between MHC-restricted and non-MHC-restricted porcine cytolytic T lymphocytes. Pauly T, et al. **Immunology** 1996 Jun;88(2):238-46
CD1 and the expanding universe of T cell antigens. Porcelli SA, et al. **J Immunol** 1995 Oct 15;155(8):3709-10 (18 ref.)
Modulation of TCR-mediated signaling pathway by thymic shared antigen-1 (TSA-1)/stem cell antigen-2 (Sca-2). Saitoh S, et al. **J Immunol** 1995 Dec 15;155(12):5574-81
Anti-CD69 antibodies enhance phorbol-dependent glucose metabolism and Ca2+ levels in human thymocytes. Antagonist effect of cyclosporin A. Conde M, et al. **J Leukoc Biol** 1996 Aug;60(2):278-84

METABOLISM

Altered expression of T cell differentiation antigens in T cells isolated from the large intestine of patients with Crohn's disease or ulcerative colitis. Ullrich R, et al. **Adv Exp Med Biol** 1995;371B:1283-5
Submicromolar La3+ concentrations block the calcium release-activated channel, and impair CD69 and CD25 expression in CD3- or thapsigargin-activated Jurkat cells. Aussel C, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):909-13
CD69 on synovial T cells in rheumatoid arthritis correlates with disease activity [letter] Iannone F, et al. **Br J Rheumatol** 1996 Apr;35(4):397
Trifluoperazine reduces the expression of CD69 in phytohemagglutinin-activated lymphocytes. Pires V, et al. **Braz J Med Biol Res** 1996 Apr;29(4):479-83
CD53 antigen and epidermal growth factor induce similar changes in the pattern of phorbol ester binding in a B cell lymphoma. Barcia R, et al. **Cell Immunol** 1996 Apr 10; 169(1):107-12
The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry. Bowen MA, et al. **J Biol Chem** 1996 Jul 19;271(29):17390-6
Differential expression of T cell antigens in normal peripheral blood lymphocytes: a quantitative analysis by flow cytometry. Ginaldi L, et al. **J Clin Pathol** 1996 Jul; 49(7):539-44
Molecular model of the N-terminal receptor-binding domain of the human CD6 ligand ALCAM. Bajorath J, et al. **Protein Sci** 1995 Aug;4(8):1644-7
Docosahexaenoic and eicosapentaenoic acids inhibit human lymphoproliferative responses in vitro but not the expression of T cell surface activation markers. Khalfoun B, et al. **Scand J Immunol** 1996 Mar;43(3):248-56

PHARMACOLOGY

Differential activation of cell-mediated immune functions by encapsulated and surface-linked liposomal antigens. Fortin A, et al. **Cell Immunol** 1996 May 1;169(2):208-17
Evidence for protein tyrosine kinase involvement in CD6-induced T cell proliferation. Osorio LM, et al. **Cell Immunol** 1995 Nov;166(1):44-52

PHYSIOLOGY

The CD69 activation pathway in rheumatoid arthritis synovial fluid T cells. Hernández-García C, et al. **Arthritis Rheum** 1996 Aug;39(8):1277-86
C-type lectins of natural killer cells: carbohydrate ligands and role in tumour cell lysis. Bezouška K. **Biochem Soc Trans** 1996 Feb;24(1):156-61 (24 ref.)
Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation. Simms PE, et al. **Clin Diagn Lab Immunol** 1996 May;3(3):301-4
Ontogeny and thymus-dependence of T cell surface antigens in Xenopus: flow cytometric studies on monoclonal antibody-stained thymus and spleen. Gravenor I, et al. **Dev Comp Immunol** 1995 Nov-Dec;19(6):507-23
Differential expression of CD40 ligand on T cell subsets. Implications for different roles of CD45RA+ and CD45RO+ cells in IgE production. Patel HR, et al. **J Immunol** 1996 Mar 1;156(5):1781-87

ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC

CD34+/CD33+ blast cells: correlation with FAB subtypes. Rigolin GM, et al. **Leuk Lymphoma** 1995;18 Suppl 1:43-8

ANALYSIS

Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms. Nakase K, et al. **Am J Clin Pathol** 1996 Jun;105(6):761-8
CD26 and CD31 surface antigen expression on human colostral T cells. Bertotto A, et al. **Biol Neonate** 1995; 68(4):259-63
Recombinant human macrophage colony-stimulating factor in nonhuman primates: selective expansion of a CD16+ monocyte subset with phenotypic similarity to primate natural killer cells. Munn DH, et al. **Blood** 1996 Aug 15; 88(4):1215-24
Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Preti HA, et al. **Cancer** 1995 Nov 1; 76(9):1564-70
Quantitative evaluation of lysozyme- and CD68-positive Kupffer cells in diethylnitrosamine-induced hepatocellular carcinomas in monkeys. Lapis K, et al. **Carcinogenesis** 1995 Dec;16(12):3083-5
Granular cell epulis [letter; comment] Charles A. **Hum Pathol** 1996 Jan;27(1):96. Comment on: Hum Pathol

1994 Nov;25(11):1172–8.
What does CD68 in activated lymphocyte mean? [letter] Hameed A. **Hum Pathol** 1995 Nov;26(11):1285–6
Immunostaining for CD31 and CD34 in Kaposi sarcoma. Russell Jones R, et al. **J Clin Pathol** 1995 Nov; 48(11):1011–6
Immunohistochemical detection of CD31 antigen in normal and neoplastic canine endothelial cells. Ferrer L, et al. **J Comp Pathol** 1995 May;112(4):319–26
CD31 immunoreactivity in mesenchymal neoplasms of the skin and subcutis: report of 145 cases and review of putative immunohistologic markers of endothelial differentiation. DeYoung BR, et al. **J Cutan Pathol** 1995 Jun;22(3):215–22 (45 ref.)
Colocalization of scavenger receptor in CD68 positive foam cells in verruciform xanthoma. Furue M, et al. **J Dermatol Sci** 1995 Nov;10(3):213–9
The inflammatory response in pediatric biliary disease: macrophage phenotype and distribution. Tracy TF Jr, et al. **J Pediatr Surg** 1996 Jan;31(1):121–5; discussion 125–6
Acute undifferentiated leukemia with an unusual CD7+ CD56+ CD33+ immunophenotype of NK progenitors [letter] Reuss-Borst MA, et al. **Leukemia** 1996 May; 10(5):923–4
Platelet endothelial cell adhesion molecule-1 (PECAM-1): a potential prognostic marker involved in leukocyte infiltration of renal cell carcinoma. Anastassiou G, et al. **Oncology** 1996 Mar-Apr;53(2):127–32
CD68+ reactive histiocytosis complicating early gastric cancer [letter] Ogawa Y, et al. **Pathol Int** 1995 Sep; 45(9):698–701
The use of CD31 and collagen IV as vascular markers. A study of 56 vascular lesions [see comments] Schmidt D, et al. **Pathol Res Pract** 1995 Jun;191(5):410–4. Comment in: Pathol Res Pract 1996 Jan;192(1):94–5.
Regarding Schmidt, D., von Hochstetter A.R., "The use of CD31 and collagen IV as vascular markers" [letter; comment] Tuccari G, et al. **Pathol Res Pract** 1996 Jan; 192(1):94–5. Comment on: Pathol Res Pract 1995 Jun;191(5):410–4.

BIOSYNTHESIS

Expression of adhesion molecules is specific and time-dependent in cytokine-stimulated endothelial cells in culture. Scholz D, et al. **Cell Tissue Res** 1996 Jun; 284(3):415–23
Inhibition of platelet endothelial cell adhesion molecule-1 synthesis and leukocyte transmigration in endothelial cells by the combined action of TNF-alpha and IFN-gamma. Rival Y, et al. **J Immunol** 1996 Aug 1;157(3):1233–41

BLOOD

Functional role of PECAM-1/CD31 molecule expressed on human cord blood progenitors. El-Marsafy S, et al. **Leukemia** 1996 Aug;10(8):1340–6

CHEMISTRY

A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CD33. Sgroi D, et al. **J Biol Chem** 1996 Aug 2; 271(31):18803–9
Platelet endothelial cell adhesion molecule-1 (PECAM-1) homophilic adhesion is mediated by immunoglobulin-like domains 1 and 2 and depends on the cytoplasmic domain and the level of surface expression. Sun J, et al. **J Biol Chem** 1996 Aug 2;271(31):18561–70
Individually distinct Ig homology domains in PECAM-1 regulate homophilic binding and modulate receptor affinity. Sun QH, et al. **J Biol Chem** 1996 May 10;271(19):11090–8
The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Ramprasad MP, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9580–4

DRUG EFFECTS

Vascular endothelial platelet endothelial adhesion molecule-1 (PECAM-1) expression is decreased by TNF-alpha and IFN-gamma. Evidence for cytokine-induced destabilization of messenger ribonucleic acid transcripts in bovine endothelial cells. Stewart RJ, et al. **J Immunol** 1996 Feb 1;156(3):1221–8

GENETICS

Alternative splicing of a specific cytoplasmic exon alters the binding characteristics of murine platelet/endothelial cell adhesion molecule-1 (PECAM-1). Yan HC, et al. **J Biol Chem** 1995 Oct 6;270(40):23672–80
Vascular endothelial platelet endothelial adhesion molecule-1 (PECAM-1) expression is decreased by TNF-alpha and IFN-gamma. Evidence for cytokine-induced destabilization of messenger ribonucleic acid transcripts in bovine endothelial cells. Stewart RJ, et al. **J Immunol** 1996 Feb 1;156(3):1221–8
In vivo effects of chicken myelomonocytic growth factor: delivery via a viral vector. York JJ, et al. **J Immunol** 1996 Apr 15;156(8):2991–7
Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease [see comments] Behar E, et al. **N Engl J Med** 1996 Feb 1;334(5):286–91. Comment in: N Engl J Med 1996 Feb 1;334(5):323–4.
Minor histocompatibility antigens and marrow transplantation [editorial; comment] Kernan NA, et al. **N Engl J Med** 1996 Feb 1;334(5):323–4. Comment on: N Engl J Med 1996 Feb 1;334(5):281–5. Comment on: N Engl J Med 1996 Feb 1;334(5):286–91.

IMMUNOLOGY

Human capillary endothelial cells from abdominal wall adipose tissue: isolation using an anti-pecam antibody. Springhorn JP, et al. **In Vitro Cell Dev Biol Anim** 1995 Jun;31(6):473–81
Individually distinct Ig homology domains in PECAM-1 regulate homophilic binding and modulate receptor affinity. Sun QH, et al. **J Biol Chem** 1996 May 10;271(19):11090–8
Roles of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in natural killer cell transendothelial migration and beta 2 integrin activation. Berman ME, et al. **J Immunol** 1996 Feb 15;156(4):1515–24
Blockade of platelet endothelial cell adhesion molecule-1 protects against myocardial ischemia and reperfusion injury in cats. Murohara T, et al. **J Immunol** 1996 May 1; 156(9):3550–7
Internalization of human macrophage surface antigens induced by monoclonal antibodies. Audran R, et al. **J Immunol Methods** 1995 Dec 15;188(1):147–54

METABOLISM

Tumor necrosis factor alpha-induced vascular leakage involves PECAM1 phosphorylation. Ferrero E, et al. **Cancer Res** 1996 Jul 15;56(14):3211–5
CD31 (PECAM-1) is a differentiation antigen lost during human CD4 T-cell maturation into Th1 or Th2 effector cells. Demeure CE, et al. **Immunology** 1996 May; 88(1):110–5
A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CD33. Sgroi D, et al. **J Biol Chem** 1996 Aug 2; 271(31):18803–9
Alternative splicing of a specific cytoplasmic exon alters the binding characteristics of murine platelet/endothelial cell adhesion molecule-1 (PECAM-1). Yan HC, et al. **J Biol Chem** 1995 Oct 6;270(40):23672–80
Internalization of human macrophage surface antigens induced by monoclonal antibodies. Audran R, et al. **J Immunol Methods** 1995 Dec 15;188(1):147–54
Myelomonocytic antigens in B-cell chronic lymphocytic leukemia. Tassies D, et al. **Leuk Res** 1995 Nov;19(11):841–8
Immunophenotyping of human bone marrow-derived macrophages. Köller M, et al. **Scand J Immunol** 1996 Jun; 43(6):626–32

PHARMACOLOGY

In vivo effects of chicken myelomonocytic growth factor: delivery via a viral vector. York JJ, et al. **J Immunol** 1996 Apr 15;156(8):2991–7

PHYSIOLOGY

CD31-triggered rearrangement of the actin cytoskeleton in human natural killer cells. Poggi A, et al. **Eur J Immunol** 1996 Apr;26(4):817–24
CD31/PECAM-1-driven chemokine-independent transmigration of human T lymphocytes. Zocchi MR, et al. **Eur J Immunol** 1996 Apr;26(4):759–67
The platelet endothelial cell adhesion molecule-1 (PECAM1) contributes to endothelial barrier function. Ferrero E, et al. **FEBS Lett** 1995 Nov 6;374(3):323–6
What does CD68 in activated lymphocyte mean? [letter] Hameed A. **Hum Pathol** 1995 Nov;26(11):1285–6
Platelet endothelial cell adhesion molecule-1 (PECAM-1) homophilic adhesion is mediated by immunoglobulin-like domains 1 and 2 and depends on the cytoplasmic domain and the level of surface expression. Sun J, et al. **J Biol Chem** 1996 Aug 2;271(31):18561–70
Human myeloid cell nuclear differentiation antigen binds specifically to nucleolin. Xie J, et al. **J Cell Biochem** 1995 Dec;59(4):529–36
Migration of monocytes across endothelium and passage through extracellular matrix involve separate molecular domains of PECAM-1. Liao F, et al. **J Exp Med** 1995 Nov 1;182(5):1337–43
Interaction of CD31 with a heterophilic counterreceptor involved in downregulation of human T cell responses. Prager E, et al. **J Exp Med** 1996 Jul 1;184(1):41–50
An anti-platelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane. Wakelin MW, et al. **J Exp Med** 1996 Jul 1;184(1):229–39
PECAM-1: its expression and function as a cell adhesion molecule on hemopoietic and endothelial cells. Watt SM, et al. **Leuk Lymphoma** 1995 Apr;17(3-4):229–44 (85 ref.)
Role of platelet-endothelial cell adhesion molecule (PECAM) in platelet adhesion/aggregation over injured but not denuded endothelium in vivo and ex vivo. Rosenblum WI, et al. **Stroke** 1996 Apr;27(4):709–11

ANTIGENS, DIFFERENTIATION, T-CELL see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

ANTIGENS, FUNGAL

Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D. Ikeda R, et al. **Clin Diagn Lab Immunol** 1996 Jan; 3(1):89–92
Aspergillus fumigatus antigens. López-Medrano R, et al. **Microbiology** 1995 Oct;141 (Pt 10):2699–704

ADVERSE EFFECTS

Characteristics of mold allergy. Iversen M, et al. **J Investig Allergol Clin Immunol** 1995 Jul-Aug;5(4):205–8
[Candida vasculitis] Bourrain JL, et al. **Allerg Immunol (Paris)** 1995 Dec;27(10):375–6 (Eng. Abstr.) **(Fre)**

ANALYSIS

Detection of candidal antigens in autoimmune polyglandular syndrome type I. Peterson P, et al. **Clin Diagn Lab Immunol** 1996 May;3(3):290–4
Immunochemical analysis of the H and M glycoproteins from Histoplasma capsulatum. Zancopé-Oliveira RM, et al. **Clin Diagn Lab Immunol** 1994 Sep;1(5):563–8
Tools and trends in the detection of Aspergillus fumigatus. Latgé JP. **Curr Top Med Mycol** 1995;6:245–81 (137 ref.)
Immunoblotting patterns in the serodiagnosis of aspergilloma: antibody response to the 90kDa Aspergillus fumigatus antigen. López-Medrano R, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):146–52
An immunodominant 90-kilodalton Aspergillus fumigatus antigen is the subunit of a catalase. López-Medrano R, et al. **Infect Immun** 1995 Dec;63(12):4774–80
Improved diagnosis of allergic bronchopulmonary aspergillosis with gp66 (formerly antigen 7) of Aspergillus fumigatus for specific IgE detection. Little SA, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):55–63
Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. Verweij PE, et al. **J Clin Microbiol** 1995 Dec;33(12):3150–3
An exoantigen test for the rapid identification of medically significant Fusarium species. Sekhon AS, et al. **J Med Vet Mycol** 1995 Sep-Oct;33(5):287–9
Isolation and partial characterization of a Paracoccidioides brasiliensis 58 kDa extracellular glycoprotein which is recognized by human immune sera. Figueroa JI, et al. **Trans R Soc Trop Med Hyg** 1995 Sep-Oct;89(5):566–72
Immunohistochemical diagnosis of systemic bovine zygomycosis by murine monoclonal antibodies. Jensen HE, et al. **Vet Pathol** 1996 Mar;33(2):176–83

BIOSYNTHESIS

Cloning, characterization, and epitope expression of the major diagnostic antigen of Paracoccidioides brasiliensis. Cisalpino PS, et al. **J Biol Chem** 1996 Feb 23;271(8):4553–60
Expression and isoforms of gp43 in different strains of Paracoccidioides brasiliensis. Campos MC, et al. **J Med Vet Mycol** 1995 Jul-Aug;33(4):223–7
Variability in expression of antigens responsible for serotype specificity in Candida albicans. Barturen B, et al. **Microbiology** 1995 Jul;141 (Pt 7):1535–43
Dynamic expression of cell-surface antigens probed with Candida albicans-specific monoclonal antibodies. Deslauriers N, et al. **Microbiology** 1996 May;142 (Pt 5):1239–48

BLOOD

Elevated Candida antigen titers are associated with neutrophil dysfunction after injury. Sweeney JF, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):111–4
Plasma (1—>3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. Miyazaki T, et al. **J Clin Microbiol** 1995 Dec;33(12):3115–8
Comparative assessment of the detection of candidal antigens as a diagnostic tool. Matthews RC. **J Med Vet Mycol** 1996 Jan-Feb;34(1):1–10 (83 ref.)

CEREBROSPINAL FLUID

Western blot analysis of cerebrospinal fluid for detection of Aspergillus antigens. Ray P, et al. **Mycopathologia** 1995 Aug;131(2):103–6

CHEMISTRY

Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Lee SC, et al. **Am J Pathol** 1996 Apr; 148(4):1267–74
Structural characterization of a new galactofuranose-containing glycolipid antigen of Paracoccidioides brasiliensis. Levery SB, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):639–45
Existence of novel branched side chains containing beta-1,2 and alpha-1,6 linkages corresponding to antigenic factor 9 in the mannan of Candida guilliermondii. Shibata N, et al. **J Biol Chem** 1996 Apr 19;271(16):9259–66
Immunochemical study of a Paracoccidioides brasiliensis polysaccharide-like antigen. Mendes-Giannini MJ, et al. **J Med Vet Mycol** 1995 Nov-Dec;33(6):379–83

DIAGNOSTIC USE

Biochemistry and molecular biology of the main diagnostic antigen of Paracoccidioides brasiliensis. Travassos LR, et al. **Arch Med Res** 1995 Autumn;26(3):297–304 (30 ref.)

Sensitivity and specificity of an isoelectric focusing fraction of Blastomyces dermatitidis yeast lysate antigen for the detection of canine blastomycosis. Fisher MA, et al. **Mycoses** 1995 May–Jun;38(5–6):177–82

DRUG EFFECTS

Effects of tunicamycin on glycoprotein antigens of Aspergillus fumigatus. Hearn VM, et al. **Microbios** 1996; 85(345):239–50

GENETICS

Cloning and sequence analysis of the cDNA for a protein from Coccidioides immitis with immunogenic potential. Dugger KO, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):485–9

An allergenic polypeptide representing a variable region of hsp 70 cloned from a cDNA library of Cladosporium herbarum. Zhang L, et al. **Clin Exp Allergy** 1996 Jan; 26(1):88–95

Multi-gene family of major surface glycoproteins of Pneumocystis carinii: full-size cDNA cloning and expression. Kitada K, et al. **DNA Res** 1994;1(2):57–66

Molecular and biochemical characterization of a Coccidioides immitis-specific antigen. Pan S, et al. **Infect Immun** 1995 Oct;63(10):3994–4002

Molecular cloning and characterization of the Coccidioides immitis complement fixation/chitinase antigen. Yang C, et al. **Infect Immun** 1996 Jun;64(6):1992–7

Molecular cloning and characterization of Coccidioides immitis antigen 2 cDNA. Zhu Y, et al. **Infect Immun** 1996 Jul;64(7):2695–9

Structure and regulation of the Candida albicans ADH1 gene encoding an immunogenic alcohol dehydrogenase. Bertram G, et al. **Yeast** 1996 Feb;12(2):115–27

IMMUNOLOGY

Candida antigen and antibody assays [letter; comment] Klingspor L. **Acta Paediatr** 1995 Aug;84(8):964. Comment on: Acta Paediatr 1995 Feb;84(2):183–7.

Aspergillus fumigatus somatic antigens: comparison between two methods of preparation and immunochemical characterization. Madrenys-Brunet N, et al. **Allergol Immunopathol (Madr)** 1995 Jul–Aug;23(4):164–70

Studies on shared antigenic/allergenic components among fungi. Verma J, et al. **Allergy** 1995 Oct;50(10):811–6

Specific IgG4 responses during chronic and transient antigen exposure in aspergillosis. Tomee JF, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1952–7

Antigen-specific immunosuppression in paracoccidioidomycosis. Benard G, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):7–12

The prevalence of dermatophyte infection in well-controlled diabetics and the response to Trichophyton antigen. Buxton PK, et al. **Br J Dermatol** 1996 May;134(5):900–3

Monoclonal antibodies against a 97-kilodalton antigen from Aspergillus flavus. Hetherington SV, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):63–7

Chronic mucocutaneous candidiasis. I. Altered antigen-stimulated IL-2, IL-4, IL-6 and interferon-gamma (IFN-gamma) production. Lilic D, et al. **Clin Exp Immunol** 1996 Aug;105(2):205–12

Chronic mucocutaneous candidiasis. II. Class and subclass of specific antibody responses in vivo and in vitro. Lilic D, et al. **Clin Exp Immunol** 1996 Aug;105(2):213–9

Capsaicin pre-treatment prevents the development of antigen-induced airway hyperresponsiveness in neonatally immunised rabbits. Herd CM, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):111–9

Molecular cloning of yeast cytochrome c-like polypeptide expressed in human lung carcinoma: an antigen recognizable by lung cancer-specific human monoclonal antibody. Kawamoto S, et al. **In Vitro Cell Dev Biol Anim** 1995 Oct;31(9):724–9

Antigenic differences associated with genetically distinct Pneumocystis carinii from rats. Vasquez J, et al. **Infect Immun** 1996 Jan;64(1):290–7

Genomic cloning, characterization, and functional analysis of the major surface adhesin WI-1 on Blastomyces dermatitidis yeasts. Hogan LH, et al. **J Biol Chem** 1995 Dec 22;270(51):30725–32

Humoral and cell-mediated autoimmunity in allergy to Aspergillus fumigatus. Crameri R, et al. **J Exp Med** 1996 Jul 1;184(1):265–70

Definition of a Trichophyton protein associated with delayed hypersensitivity in humans. Evidence for immediate (IgE and IgG4) and delayed hypersensitivity to a single protein. Woodfolk JA, et al. **J Immunol** 1996 Feb 15; 156(4):1695–701

Cerebrospinal fluid antibodies detected by ELISA against a 33-kDa antigen from spherules of Coccidioides immitis in patients with coccidioidal meningitis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Galgiani JN, et al. **J Infect Dis** 1996 Feb; 173(2):499–502

Biochemical, antigenic and allergenic characterization of crude extracts of Drechslera (Helminthosporium) monoceras. Menezes EA, et al. **Mycopathologia** 1995 Aug; 131(2):75–81

Induction and detection of cell-mediated reactions with different Blastomyces dermatitidis antigenic preparations. Abuodeh RO, et al. **Mycoses** 1996 Mar–Apr;39(3–4):85–93

T-cell activation, anergy and immunomodulation by molecules of viral, fungal and vegetal origin. Bemer V, et al. **Res Immunol** 1995 May–Jun;146(4–5):249–62 (81 ref.)

Hypersensitivity pneumonitis induced by a smut fungus Ustilago esculenta. Yoshida K, et al. **Thorax** 1996 Jun; 51(6):650–1; discussion 656–7

ISOLATION & PURIFICATION

Purification of a Candida albicans germ tube specific antigen. Marot-Leblond A, et al. **FEMS Immunol Med Microbiol** 1995 Oct;12(2):127–36

Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-Candida cell-mediated immune responses in humans. Gomez MJ, et al. **Infect Immun** 1996 Jul;64(7):2577–84

[Isolation of an Paracoccidioides brasiliensis exoantigen from solid culture media] Gago J, et al. **Rev Argent Microbiol** 1995 Jul–Sep;27(3):139–45 (Eng. Abstr.) **(Spa)**

METABOLISM

Dynamic expression of cell wall proteins of Candida albicans revealed by probes from cDNA clones. Alloush HM, et al. **J Med Vet Mycol** 1996 Mar–Apr;34(2):91–7

PHARMACOLOGY

Cross-reactivity between Aspergillus fumigatus and Penicillium. Brouwer J. **Int Arch Allergy Immunol** 1996 Jun;110(2):166–73

PHYSIOLOGY

Effect of monoclonal antibodies directed against Candida albicans cell wall antigens on the adhesion of the fungus to polystyrene. San Millan R, et al. **Microbiology** 1996 Aug; 142 (Pt 8):2271–7

THERAPEUTIC USE

Optimization of a mouse immunization protocol with Paracoccidioides brasiliensis antigens. Almeida AV, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):45–9

ANTIGENS, HELMINTH

Immunodiagnosis of Taenia saginata in cattle using hydrophobic antigens from T. hydatigena metacestode cyst fluid. Bøgh HO, et al. **Appl Parasitol** 1995 Aug;36(3):226–38

Immunodiagnostic moieties in somatic and excretory/secretory antigens of Fasciola gigantica. Yadav SC, et al. **Indian J Exp Biol** 1995 Nov;33(11):824–8

A cloned major Schistosoma mansoni egg antigen with homologies to small heat shock proteins elicits Th1 responsiveness. Cai Y, et al. **Infect Immun** 1996 May; 64(5):1750–5

Antigens from Taenia crassiceps cysticerci used in complement fixation, enzyme-linked immunosorbent assay, and western blot (immunoblot) for diagnosis of neurocysticercosis. Garcia E, et al. **J Clin Microbiol** 1995 Dec;33(12):3324–5

Studies on the most reactive purified antigen for immuno-diagnosis of hydatid disease. Abdel Aal TM, et al. **J Egypt Soc Parasitol** 1996 Aug;26(2):297–303

Immunization against Trichinella spiralis using antigens from different life-cycle stages experimental study in mice. Darwish RA, et al. **J Egypt Soc Parasitol** 1996 Apr; 26(1):19–26

High levels of spontaneous and parasite antigen-driven interleukin-10 production are associated with antigen-specific hyporesponsiveness in human lymphatic filariasis. Mahanty S, et al. **J Infect Dis** 1996 Mar; 173(3):769–73

ADMINISTRATION & DOSAGE

Vaccination of sheep against haemonchosis with H11, a gut membrane-derived protective antigen from the adult parasite: prevention of the periparturient rise and colostral transfer of protective immunity. Andrews SJ, et al. **Int J Parasitol** 1995 Jul;25(7):839–46

ANALYSIS

Field trial of the coproantigen-based diagnosis of Taenia solium taeniasis by enzyme-linked immunosorbent assay. Allan JC, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):352–6

Antigenic components of excretory-secretory products of adult Fasciola hepatica recognized in human infections. Sampaio-Silva ML, et al. **Am J Trop Med Hyg** 1996 Feb; 54(2):146–8

Immunoblot evaluation of IgG and IgG-subclass antibody responses for immunodiagnosis of human alveolar echinococcosis. Wen H, et al. **Ann Trop Med Parasitol** 1995 Oct;89(5):485–95

Detection of Taenia saginata antigens in faeces by ELISA. Machnicka B, et al. **Appl Parasitol** 1996 Jun;37(2):106–10

Factors conditioning detection of Taenia saginata antigens in faeces. Machnicka B, et al. **Appl Parasitol** 1996 Jun; 37(2):99–105

Use of a monoclonal antibody against the antigen B of Echinococcus granulosus for purification and detection of antigen B. Ortona E, et al. **Appl Parasitol** 1995 Aug; 36(3):220–5

Dirofilaria immitis: ultrastructural localization, molecular characterization, and analysis of the expression of p27, a small heat shock protein homolog of nematodes. Lillibridge CD, et al. **Exp Parasitol** 1996 Jun;83(1):30–45

A novel 95-kilodalton antigen of Wuchereria bancrofti infective larvae identified by species-specific monoclonal antibodies. Burkot TR, et al. **Infect Immun** 1996 Feb; 64(2):485–8

Detection of Trichinella pseudospiralis antigen in the parenteral phase in experimentally infected mice. Boulos LM, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):9–17

Specific diagnostic antigens of Echinococcus granulosus detected by western blot. Ayadi A, et al. **Parasite** 1995 Jun;2(2):119–23

Immunoelectron microscopical localization of a circulating antigen in the excretory system of Schistosoma mansoni. Ultrastructural localization studies of the excretory system of S. mansoni. Bogers JJ, et al. **Parasitol Res** 1995; 81(5):375–81

Ultrastructural colocalization of phosphorylcholine and a phosphorylcholine-associated epitope in first-stage larvae of Trichinella spiralis. Hernández S, et al. **Parasitol Res** 1995;81(8):643–50

Immunohistochemical and ultrastructural localization of Schistosoma mansoni soluble egg antigens processed by the infected host. Bogers JJ, et al. **Parasitology** 1996 Jun; 112 (Pt 6):537–43

Detection of gastrointestinal nematodes by a coproantigen capture ELISA. Johnson MJ, et al. **Res Vet Sci** 1996 Jan; 60(1):7–12

[Ultrastructural antigenic localization in Paragonimus iloktsuenensis during developmental stage by immunogold labeling method] Kim HS, et al. **Korean J Parasitol** 1995 Dec;33(4):365–76 (Eng. Abstr.) **(Kor)**

[Phosphocholine antigens in muscle larvae of Trichinella spiralis] Bitkowska E. **Wiad Parazytol** 1996;42(1):57–63 (37 ref.) (Eng. Abstr.) **(Pol)**

[Characterization of surface antigens of the nematode parasite Trichinella spiralis: study of its role in protection mechanisms and their usefulness in the diagnosis of trichinosis] Ortega-Pierres MG. **Gac Med Mex** 1995 Jan–Feb;131(1):2–12; discussion 13 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Effect of ivermectin prophylaxis on antibody responses to Onchocerca volvulus recombinant antigens in experimentally infected chimpanzees. Chandrashekar R, et al. **Int J Parasitol** 1995 Aug;25(8):983–8

Molecular cloning, expression, and localization of E1, an Onchocerca volvulus antigen with similarity to brain ankyrin. Erttmann KD, et al. **J Biol Chem** 1996 Jan 19; 271(3):1645–50

Serum-free culturing of adult Schistosoma mansoni in dialysis bags for the production of excretory/secretory antigens. Call JL, et al. **J Parasitol** 1995 Oct;81(5):742–6

A putative protein related to human chemokines encoded antisense to the cDNA of an Onchocerca volvulus antigen. Erttmann KD, et al. **Trop Med Parasitol** 1995 Jun; 46(2):123–30

BLOOD

Optimization of the Magnetic Bead Antigen Capture Enzyme Immuno Assay for the detection of circulating anodic antigens in mixed Schistosoma infections. Ndhlovu P, et al. **Acta Trop** 1995 Jun;59(3):223–35

Circulating anodic antigen for detection of Schistosoma mansoni infection in Egyptian patients. El-Morshedy H, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):149–53

Bancroftian filariasis: the patterns of filarial-specific immunoglobulin G1 (IgG1), IgG4, and circulating antigens in an endemic community of northeastern Tanzania. Simonsen PE, et al. **Am J Trop Med Hyg** 1996 Jul; 55(1):69–75

Human cysticercosis: risk factors associated with circulating serum antigens in an open community of San Luis Potosi, Mexico. Aranda-Alvarez JG, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):689–92

Bancroftian filariasis: profile of serum antifilarial antibody and circulating parasite antigen. Wamae CN, et al. **East Afr Med J** 1995 Aug;72(8):492–4

Th1-like antifilarial immune responses predominate in antigen-negative persons. Dimock KA, et al. **Infect Immun** 1996 Aug;64(8):2962–7

Detection of circulating Trichinella pseudospiralis antigen by enzyme linked immunosorbant assay (ELISA). Hegazy IH, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):217–25

Analysis of worm burden variation in human Schistosoma mansoni infections by determination of serum levels of circulating anodic antigen and circulating cathodic antigen. Van Lieshout L, et al. **J Infect Dis** 1995 Nov; 172(5):1336–42

Analysis of Fasciola sp. antigen by enzyme-linked immunotransfer blot using sera from experimentally and naturally infected cattle. Itagaki T, et al. **J Vet Med Sci** 1995 Jun;57(3):511–3

Serum levels of circulating anodic antigen and circulating

cathodic antigen detected in mice infected with Schistosoma japonicum or S. mansoni. Van 't Wout AB, et al. **Parasitol Res** 1995;81(5):434–7

Comparison of the circulating anodic antigen detection assay and urine filtration to diagnose Schistosoma haematobium infections in Mali. De Clercq D, et al.
Trans R Soc Trop Med Hyg 1995 Jul–Aug;89(4):395–7

Detection of circulating Trichinella spiralis muscle larva antigens in serum samples of experimentally and naturally infected swine. Arriaga C, et al. **Vet Parasitol** 1995 Jul; 58(4):319–26

Detection of circulating antigen in sera of Fasciola gigantica–infected cattle with antibodies reactive with a Fasciola–specific 88–kDa antigen. Fagbemi BO, et al.
Vet Parasitol 1995 Jun;58(3):235–46

Comparison of single and trickle infections of pigs with eggs of the Asian Taenia. Fall EH, et al. **Vet Parasitol** 1996 Feb;61(3–4):231–7

Diagnosis of Taenia saginata cysticercosis in Kenyan cattle by antibody and antigen ELISA. Onyango–Abuje JA, et al. **Vet Parasitol** 1996 Feb;61(3–4):221–30

Use of excretory/secretory antigens for the serodiagnosis of Anoplocephala perfoliata cestodosis. Proudman CJ, et al. **Vet Parasitol** 1996 Feb;61(3–4):239–47

Enzyme–linked immunoelectrotransfer blot analysis of excretory–secretory proteins of Fascioloides magna and Fasciola hepatica. Qureshi T, et al. **Vet Parasitol** 1995 Jul; 58(4):357–63

[Observation on dynamics of circulating antigen from patients with cysticercosis before and after treatment] Zhang Y, et al.
Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih 1995;13(3):222–4 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Immunodominant synthetic peptides of Taenia crassiceps in murine and human cysticercosis. Gevorkian G, et al.
Immunol Lett 1996 Mar;49(3):185–9

DIAGNOSTIC USE

[The efficiency of the serological reactions with Trichinella spiralis somatic antigen in the diagnosis of human trichinelliasis caused by infection with natural and synanthropic Trichinella isolates] Poletaeva OG, et al.
Med Parazitol (Mosk) 1995 Apr–Jun;(2):33–5 (Eng. Abstr.) **(Rus)**

GENETICS

Molecular cloning of a cDNA encoding filarial common antigen. Sun S, et al. **Chin Med J (Engl)** 1995 Jun; 108(6):466–8

Loa loa: structural diversity of a 15–kDa repetitive antigen. Ajuh PM, et al. **Exp Parasitol** 1995 Sep;81(2):145–53

Molecular cloning and characterization of the filarial LIM domain proteins AvL3–1 and OvL3–1. Oberländer U, et al. **Exp Parasitol** 1995 Dec;81(4):592–9

Onchocerca volvulus: identification and characterization of an immunogenic eggshell protein (Oveg1). Tume C, et al.
Exp Parasitol 1995 Dec;81(4):445–52

Identification and cDNA cloning of two novel low molecular weight host–protective antigens from Taenia ovis oncospheres. Harrison GB, et al. **Int J Parasitol** 1996 Feb; 26(2):195–204

Molecular analysis of antigens targeted by protective antibodies in rapid expulsion of Trichinella spiralis [Mol. Biochem. Parasitol. 65 (1994) 201] Arasu P, et al.
Mol Biochem Parasitol 1995 Jul;73(1–2):295

Cloning and sequencing of an excretory/secretory antigen from Ostertagia ostertagi fourth–stage larvae containing multiple tandem repeats. de Graaf DC, et al.
Mol Biochem Parasitol 1995 Jun;72(1–2):239–41

Sequence and immunogenicity of the 23–kDa transmembrane antigen of Schistosoma haematobium. Inal J, et al.
Mol Biochem Parasitol 1995 Nov;74(2):217–21

Characterization of the gene family encoding a host–protective antigen of the tapeworm Taenia ovis. Waterkeyn JG, et al. **Mol Biochem Parasitol** 1995 Jul; 73(1–2):123–31

Cloning and immunological characterisation of Echinococcus granulosus ferritin. Ersfeld K, et al. **Parasitol Res** 1995; 81(5):382–7

Haemonchus contortus GA1 antigens: related, phospholipase C–sensitive, apical gut membrane proteins encoded as a polyprotein and released from the nematode during infection. Jasmer DP, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8642–7

[Isolation and expression of recombinant diagnostic antigen gene of Schistosoma japonicum] Zhang Z, et al.
Chung Hua I Hsueh Tsa Chih 1995 Jun;75(6):329–32, 381 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Differential recognition of microfilarial chitinase, a transmission–blocking vaccine candidate antigen, by sera from patients with Brugian and Bancroftian filariasis. Dissanayake S, et al. **Am J Trop Med Hyg** 1995 Sep; 53(3):289–94

Detection of antibodies to surface antigens of Angiostrongylus cantonensis by ELISA. Chang JH, et al.
Ann Trop Med Parasitol 1995 Oct;89(5):569–72

Immunochemical characterization of Ancylostoma caninum antigens. Schnieder T, et al. **Appl Parasitol** 1996 Jun; 37(2):146–52

Vaccination of mice against Taenia taeniaeformis using antigen fractions partitioned with Triton X–114. Schnieder T, et al. **Appl Parasitol** 1996 Jan;37(1):1–7

Antigen induced eosinophilia protects gerbils (Meriones unguiculatus) against experimental amebic abscess of the liver. Velázquez JR, et al. **Arch Med Res** 1995;26 Spec No:S93–8

Ivermectin–induced immunopotentiation in onchocerciasis: recognition of selected antigens following a single dose of ivermectin. Akuffo H, et al. **Clin Exp Immunol** 1996 Feb;103(2):244–52

Immunoregulation in onchocerciasis: predominance of Th1–type responsiveness to low molecular weight antigens of Onchocerca volvulus in exposed individuals without microfilaridermia and clinical disease. Lüder CG, et al.
Clin Exp Immunol 1996 Aug;105(2):245–53

Early development and progression of lymphocyte–stimulatory cross–reactive idiotypes expressed on antibodies to soluble egg antigens during Schistosoma mansoni infection of mice. Bosshardt SC, et al.
Eur J Immunol 1996 Jan;26(1):272–5

Human basophils release interleukin–4 after stimulation with Schistosoma mansoni egg antigen. Falcone FH, et al.
Eur J Immunol 1996 May;26(5):1147–55

Cellular immune responses of jirds to extracts of life cycle stages and adult excretory secretory products during the early development of Brugia pahangi. Rao UR, et al.
Exp Parasitol 1996 Apr;82(3):255–66

An immunodominant antigen of Brugia malayi is an asparaginyl–tRNA synthetase. Kron M, et al.
FEBS Lett 1995 Oct 23;374(1):122–4

Canine IgE monoclonal antibody specific for a filarial antigen: production by a canine x murine heterohybridoma using B cells from a clinically affected lymph node. Gebhard D, et al. **Immunology** 1995 Jul;85(3):429–34

The contrasting effects of CD8+ T cells on primary, established and Nippostrongylus brasiliensis–induced IgE responses. Holmes BJ, et al. **Immunology** 1996 Jun; 88(2):252–60

High levels of protection induced by a 40–mer synthetic peptide vaccine against the intestinal nematode parasite Trichinella spiralis. Robinson K, et al. **Immunology** 1995 Dec;86(4):495–8

Immune response to Schistosoma mansoni phosphoglycerate kinase during natural and experimental infection: identification of a schistosome–specific B–cell epitope. Lee KW, et al. **Infect Immun** 1995 Nov;63(11):4307–11

Immunoglobulin A response in murine schistosomiasis: stimulatory role of egg antigens. Poulain–Godefroy O, et al. **Infect Immun** 1996 Mar;64(3):763–8

Onchocerca volvulus larval antigen, OvB20, induces partial protection in a rodent model of onchocerciasis. Taylor MJ, et al. **Infect Immun** 1995 Nov;63(11):4417–22

Differential antibody isotype reactivity to specific antigens in human lymphatic filariasis: gp15/400 preferentially induces immunoglobulin E (IgE), IgG4, and IgG2. Yazdanbakhsh M, et al. **Infect Immun** 1995 Oct; 63(10):3772–9

Effect of ivermectin prophylaxis on antibody responses to Onchocerca volvulus recombinant antigens in experimentally infected chimpanzees. Chandrashekar R, et al. **Int J Parasitol** 1995 Aug;25(8):983–8

Progress on vaccination against Haemonchus contortus. Newton SE. **Int J Parasitol** 1995 Nov;25(11):1281–9 (35 ref.)

Immune response of lambs to vaccination with Ostertagia circumcincta surface antigens eliciting bile antibody responses. Wedrychowicz H, et al. **Int J Parasitol** 1995 Sep;25(9):1111–21

Endothelin–1 contributes to antigen–induced airway hyperresponsiveness. Noguchi K, et al. **J Appl Physiol** 1995 Sep;79(3):700–5

Identification of chitinase as the immunodominant filarial antigen recognized by sera of vaccinated rodents. Adam R, et al. **J Biol Chem** 1996 Jan 19;271(3):1441–7

Molecular and immunological characterization of hr44, a human ocular component immunologically cross–reactive with antigen Ov39 of Onchocerca volvulus. Braun G, et al. **J Exp Med** 1995 Oct 1;182(4):1121–31

Allergic reactivity and IgG subclasses to a proteinase fraction of Setaria digitata in filariasis. Beuria MK, et al.
J Helminthol 1995 Sep;69(3):181–5

Anisakis simplex: stage–specific antigens recognized by mice. Iglesias R, et al. **J Helminthol** 1995 Dec;69(4):319–24

Recombinant IL–10 and IL–10/Fc treatment down–regulate egg antigen–specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis.
Flores–Villanueva PO, et al. **J Immunol** 1996 May 1; 156(9):3315–20

Induction of Th1 cell–mediated protective immunity to Schistosoma mansoni by co–administration of larval antigens and IL–12 as an adjuvant. Mountford AP, et al.
J Immunol 1996 Jun 15;156(12):4739–45

Immunoregulation in onchocerciasis: persons with ocular inflammatory disease produce a Th2–like response to Onchocerca volvulus antigen. Plier DA, et al.
J Infect Dis 1996 Aug;174(2):380–6

Cutaneous immediate and late phase reactions to schistosomin in schistosomiasis patients. Marotto PC, et al.
J Investig Allergol Clin Immunol 1995 Sep–Oct;5(5):269–71

Cysticercosis: identification and cloning of protective recombinant antigens. Manoutcharian K, et al.
J Parasitol 1996 Apr;82(2):250–4

Metacercarial precipitin test for diagnosis of human fascioliasis. Farag HF, et al. **J Trop Med Hyg** 1995 Dec; 98(6):428–30

Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein. Hillyer GV.
Mem Inst Oswaldo Cruz 1995 Mar–Apr;90(2):249–53 (17 ref.)

Vaccination against schistosomiasis and fascioliasis with the new recombinant antigen Sm14: potential basis of a multi–valent anti–helminth vaccine? Tendler M, et al.
Mem Inst Oswaldo Cruz 1995 Mar–Apr;90(2):255–6

Sequence and immunogenicity of the 23–kDa transmembrane antigen of Schistosoma haematobium. Inal J, et al.
Mol Biochem Parasitol 1995 Nov;74(2):217–21

Evaluation of Dirofilaria immitis excretory/secretory products for seroepidemiological studies on human dirofilariosis. Santamaría B, et al. **Parasite** 1995 Sep; 2(3):269–73

Immunoprophylactic potential of a 120 kDa Brugia malayi adult antigen fraction, BmA–2, in lymphatic filariasis. Chenthamarakshan V, et al. **Parasite Immunol** 1995 Jun; 17(6):277–85

Humoral immune response of children with chronic schistosomiasis. Isotype recognition of adult worm antigens. Noya O, et al. **Parasite Immunol** 1995 Jun; 17(6):319–28

Comparison of antibody isotype responses to Schistosoma mansoni antigens by infected and putative resistant individuals living in an endemic area. Viana IR, et al.
Parasite Immunol 1995 Jun;17(6):297–304

Further characterization of the 38 kDa antigen from Echinococcus granulosus (hydatid disease) cyst fluid: evidence for antigenic heterogeneity and reactivity with anti–P1 antibodies. Zhang LH, et al. **Parasite Immunol** 1995 Jun;17(6):287–96

Antibody response to a protease secreted by Trichinella spiralis muscle larvae. de Armas–Serra C, et al.
Parasitol Res 1995;81(6):540–2

Parasite vaccine development: large–scale recovery of immunogenic Taenia ovis fusion protein GST–45W(B/X) from Escherichia coli inclusion bodies. Dempster RP, et al. **Parasitol Res** 1996;82(4):291–6

Antigenic cross–reactivity in mice between third–stage larvae of Anisakis simplex and other nematodes. Iglesias R, et al. **Parasitol Res** 1996;82(4):378–81

Immunodominance, competition and evolution in immunological responses to helminth parasite antigens. Austin DJ, et al. **Parasitology** 1996 Aug;113 (Pt 2):157–72

Schistosoma: analysis of monoclonal antibodies reactive with the circulating antigens CAA and CCA. Deelder AM, et al. **Parasitology** 1996 Jan;112 (Pt 1):21–35

Characterization of fractionated Schistosoma mansoni soluble adult worm antigens that elicit human cell proliferation and granuloma formation in vitro. Hirsch C, et al.
Parasitology 1996 Jun;112 (Pt 6):529–35

A Schistosoma mansoni fatty acid–binding protein, Sm14, is the potential basis of a dual–purpose anti–helminth vaccine. Tendler M, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):269–73

Immunisation of sheep with an integral membrane glycoprotein complex of Haemonchus contortus and with its major polypeptide components. Smith SK, et al.
Res Vet Sci 1996 Jan;60(1):1–6

Interferon–gamma production by peripheral blood mononuclear cells from residents of an area endemic for Schistosoma mansoni. Viana IR, et al.
Trans R Soc Trop Med Hyg 1994 Jul–Aug;88(4):466–70

Evaluation of Fasciola excretory–secretory (E/S) product in diagnosis of acute human fasciolosis by IgM ELISA. Osman MM, et al. **Trop Med Parasitol** 1995 Jun;46(2):115–8

Inability to reproduce protection against Teladorsagia circumcincta in sheep with a purified stage–specific 31 kDa antigen complex [letter] Morton RE, et al. **Vaccine** 1995; 13(15):1482

Humoral and cellular responses following local immunization with a surface antigen of the gastrointestinal parasite Haemonchus contortus. Jacobs HJ, et al.
Vet Immunol Immunopathol 1995 Oct;48(3–4):323–32

Involvement of excretion–secretion products from Fasciola hepatica inducing suppression of the cellular immune responses. Cervi L, et al. **Vet Parasitol** 1996 Jan; 61(1–2):97–111

Systemic antibody responses of calves to low molecular weight Cooperia oncophora antigens. Nieuwland MG, et al. **Vet Parasitol** 1995 Oct;59(3–4):231–9

Low molecular weight Cooperia oncophora antigens: characterization and humoral immune responses in calves mono–infected with 100,000 infective larvae. Parmentier HK, et al. **Vet Parasitol** 1995 Oct;59(3–4):219–30

[Development of an immunoenzyme test for the diagnosis of human cysticercosis using a heterologous antigen] Tamburrini A, et al. **Parassitologia** 1995 Dec;37(2–3):195–8 (Eng. Abstr.) **(Ita)**

[Immunoenzyme analysis in the diagnosis of opisthorchiasis. I. The development of an immunoenzyme method for determining IgM antibodies to the Opisthorchis antigen] Meniavtseva TA, et al. **Med Parazitol (Mosk)** 1996

Jan-Mar;(1):41-3 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Identification of Onchocerca volvulus collagen as an antigen mainly recognized by antibodies in chronic hyper-reactive onchodermatitis (sowda). Garate T, et al. **Am J Trop Med Hyg** 1996 May;54(5):490-7

Identification and partial purification of a 26 kilodalton antigen of adult Haemonchus contortus. Gomez-Muñoz MT, et al. **Int J Parasitol** 1996 Mar;26(3):311-8

Identification and cDNA cloning of two novel low molecular weight host-protective antigens from Taenia ovis oncospheres. Harrison GB, et al. **Int J Parasitol** 1996 Feb; 26(2):195-204

Antigens in phenotypes of Heligmosomoides polygyrus raised selectively from different strains of mice. Tang J, et al. **Int J Parasitol** 1995 Jul;25(7):847-52

Em18 and Em16, new serologic marker epitopes for alveolar echinococcosis in western blot analysis, are the only two epitopes recognized by commercially available weak positive (cut off) sera for Em2plus-ELISA. Ito A, et al. **J Helminthol** 1995 Dec;69(4):369-71

Isolation, characterization and immunolocalization of a globin-like antigen from Ostertagia ostertagi adults. de Graaf DC, et al. **Parasitology** 1996 Jul;113 (Pt 1):63-9

METABOLISM

Schistosoma mansoni: in vitro and in vivo excretion of CAA and CCA by developing schistosomula and adult worms. van Dam GJ, et al. **J Parasitol** 1996 Aug;82(4):557-64

THERAPEUTIC USE

Synthetic peptide vaccines for schistosomiasis. Harn DA, et al. **Pharm Biotechnol** 1995;6:891-905 (41 ref.)

URINE

Fluctuation of schistosome circulating antigen levels in urine of individuals with Schistosoma mansoni infection in Burundi. Van Etten L, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):348-51

ANTIGENS, HEPATITIS see **HEPATITIS ANTIGENS**

ANTIGENS, HETEROGENETIC see **ANTIGENS, HETEROPHILE**

ANTIGENS, HETEROPHILE

ANALYSIS

Identification of Forssman as a major guinea pig xenoantigen. Cairns T, et al. **Transplant Proc** 1996 Apr;28(2):575

Human anti-B alloantibodies recognize xenoantigens on pig red blood cells and endothelial cells. Gautreau C, et al. **Transplant Proc** 1996 Apr;28(2):563

Xenoreactivity in the pig islet to human combination: feasibility of adenovirus-mediated gene transfer into pig islets. Mirenda V, et al. **Transplant Proc** 1996 Apr; 28(2):808-10

Major oligosaccharide epitopes found in tissues of 23 animal species, potential donors for organ xenotransplantation. Oriol R, et al. **Transplant Proc** 1996 Apr;28(2):794

BIOSYNTHESIS

Variation in expression of biologically reactive xenoantigen does not correlate with expression of Gal alpha (1-3)Gal. Alvarado CG, et al. **Transplant Proc** 1996 Apr;28(2):555

Expression of newborn pig endothelial cell xenoantigens recognized by baboon natural xenoantibody. Xu H, et al. **Transplant Proc** 1996 Apr;28(2):627

BLOOD

[Immunophenotypic heterogeneity of CD7+CD4-CD8--acute leukemia] Abramenko IV, et al. **Gematol Transfuziol** 1995 Jul-Aug;40(4):10-3 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

[A comparative study of the synthesis of membrane hetero-organic antigens of kidney origin on tissue slices and isolated cells after a single carcinogenic exposure in rats] Ivanov VA, et al. **Tsitologiia** 1995;37(3):227-31 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Characterization of porcine platelet glycoproteins recognized by human natural "anti-gal" antibodies. Thibaudeau K, et al. **Blood** 1996 Jun 1;87(11):4636-42

Production of monoclonal antibodies directed to Hanganutziu-Deicher active gangliosides, N-glycolylneuraminic acid-containing gangliosides. Watarai S, et al. **J Biochem (Tokyo)** 1995 May;117(5):1062-9

Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein. Hillyer GV. **Mem Inst Oswaldo Cruz** 1995 Mar-Apr;90(2):249-53 (17 ref.)

Further characterization of the 38 kDa antigen from Echinococcus granulosus (hydatid disease) cyst fluid: evidence for antigenic heterogeneity and reactivity with anti-P1 antibodies. Zhang LH, et al. **Parasite Immunol** 1995 Jun;17(6):287-96

The humoral immune response in humans following ex vivo perfusion of porcine livers. Cotterell AH, et al. **Transplant Proc** 1996 Apr;28(2):546

Two genetic approaches to the galactose alpha 1,3 galactose xenoantigen. d'Apice AJ, et al. **Transplant Proc** 1996 Apr; 28(2):540

Increased anti-Gal activity in diabetic patients transplanted with porcine islet cells. Galili U, et al. **Transplant Proc** 1996 Apr;28(2):564-6

New World monkeys as a primate model for xenografts in the absence of anti-Gal. Galili U, et al. **Transplant Proc** 1996 Apr;28(2):567-8

The effect of plasmapheresis and deoxyspergualin or cyclophosphamide treatment on anti-porcine Gal-alpha (1,3)-Gal antibody titres in humans. Gannedahl G, et al. **Transplant Proc** 1996 Apr;28(2):551

Polymorphism within the human anti-pig repertoire. Goldberg LC, et al. **Transplant Proc** 1996 Apr;28(2):549-50

Loss of antigenicity at one month after liver transplantation and change of serum antibody titer to donor antigens. Gu W, et al. **Transplant Proc** 1996 Apr;28(2):1084-5

Overlapping recognition of xenogeneic carbohydrate ligands by human natural killer lymphocytes and natural antibodies. Inverardi L, et al. **Transplant Proc** 1996 Apr;28(2):552

Converting alpha-Gal epitope of pig into H antigen. Koike C, et al. **Transplant Proc** 1996 Apr;28(2):553

Identification and characterization of a peptide mimeotope of galactose alpha 1,3 galactose. Kooyman DL, et al. **Transplant Proc** 1996 Apr;28(2):554

Porcine islet cell antigens are recognized by xenoreactive natural human antibodies of both IgG and IgM subtypes. Korbutt GS, et al. **Transplant Proc** 1996 Apr;28(2):837-8

Murine monoclonal anti-idiotypic antibodies directed against human anti-alpha Gal antibodies prevent rejection of pig cells in culture: implications for pig-to-human organ xenotransplantation. Koren E, et al. **Transplant Proc** 1996 Apr;28(2):559

Porcine endothelial cell membrane antigens recognized by human and baboon xenoreactive antibodies during organ perfusion. Lin SS, et al. **Transplant Proc** 1996 Apr;28(2):607

Targeting of activated T-cells with natural cytotoxic antibodies via an IL2-hapten conjugate prolongs graft survival. Lussow AR, et al. **Transplant Proc** 1996 Apr; 28(2):571-2

Characterization of xenoreactive natural antibodies: interactions with carbohydrate determinants. Parker W, et al. **Transplant Proc** 1996 Apr;28(2):548

Specific xenogeneic (human) tolerance in immunosuppressed mice by combined donor-derived human transferrin and antigens. Pierpaoli W, et al. **Transplant Proc** 1996 Apr; 28(2):711-2

Concordant xenoreactive and alloreactive cell-mediated immune responses are relatively comparable. Rehman A, et al. **Transplant Proc** 1996 Apr;28(2):658-9

The mechanism of xenogeneic cell-mediated lympholysis between human and pig cells. Yamada K, et al. **Transplant Proc** 1996 Apr;28(2):757

Characterization of human IgG-binding xenoantigens expressed by porcine aortic endothelial cells. Cooke SP, et al. **Transplantation** 1995 Dec 15;60(11):1274-84

The alpha-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation. Tearle RG, et al. **Transplantation** 1996 Jan 15;61(1):13-9

[The accumulation in immune lymphocytes of the RNA sequences complementary to the gene controlling the synthesis of the corresponding heterologous antigen] Nikolaeva AI. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec;(6):63-4 **(Rus)**

ISOLATION & PURIFICATION

[The isolation and characteristics of a protein from human and bovine kidneys close in molecular and biochemical properties to non-histone chromosomal antigen PP23] Grandilevskaia AB, et al. **Tsitologiia** 1995;37(4):298-303 (Eng. Abstr.) **(Rus)**

METABOLISM

Beta 2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles. Chonn A, et al. **J Biol Chem** 1995 Oct 27;270(43):25845-9

ANTIGENS, HLA-A see **HLA-A ANTIGENS**

ANTIGENS, HLA-B see **HLA-B ANTIGENS**

ANTIGENS, HLA-C see **HLA-C ANTIGENS**

ANTIGENS, HLA-D see **HLA-D ANTIGENS**

ANTIGENS, HUMAN PLATELET

Blood group A antigen expression in platelets is prominently associated with glycoprotein Ib and IIb. Evidence for an A1/A2 difference. Hou M, et al. **Transfus Med** 1996 Mar; 6(1):51-9

ANALYSIS

Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Semple JW, et al. **Blood** 1996 May 15;87(10):4245-54

Frequency of human platelet antigens among blood donors in northeastern Thailand. Urwijitaroon Y, et al. **Transfusion** 1995 Oct;35(10):868-70

BLOOD

A whole blood assay for platelet HPA1 (PLA1) phenotyping applicable to large-scale screening. Bessos H, et al. **Br J Haematol** 1996 Jan;92(1):221-5

Platelet alloantigens HPA-1, -2, -3, -5 and -6b in Finns. Kekomäki S, et al. **Transfus Med** 1995 Sep;5(3):193-8

DNA-based typing of human platelet antigen systems by polymerase chain reaction-single-strand conformation polymorphism method. Fujiwara K, et al. **Vox Sang** 1995; 69(4):347-51

Neonatal alloimmune thrombocytopenia in Taiwan due to an antibody against a labile component of HPA-3a (Baka). Lin M, et al. **Vox Sang** 1995;69(4):336-40

GENETICS

Molecular genotyping of fetal platelet antigens with uncultured amniocytes. Khouzami AN, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1202-6

Bilateral linkage between a new deletion polymorphism in intron 21 of the GP IIb gene and the HPA-3b (Bakb) determinant. Peyruchaud O, et al. **Br J Haematol** 1995 Nov; 91(3):747-51

Platelet alloantigens HPA-1, -2, -3, -5 and -6b in Finns. Kekomäki S, et al. **Transfus Med** 1995 Sep;5(3):193-8

Human platelet antigen-2 and -3 genotyping by PCR-SSP. Metcalfe P, et al. **Transfus Med** 1995 Dec;5(4):285-8

Incidence of the Nak(a)-negative platelet phenotype in African Americans is similar to that of Asians. Curtis BR, et al. **Transfusion** 1996 Apr;36(4):331-4

Gene frequencies of the five major human platelet antigens in African American, white, and Korean populations. Kim HO, et al. **Transfusion** 1995 Oct;35(10):863-7

IMMUNOLOGY

Antiplatelet antibodies in childhood idiopathic thrombocytopenic purpura [letter] Ozsoylu S. **Am J Hematol** 1996 Apr;51(4):328

Antenatal diagnosis and management of fetomaternal alloimmune thrombocytopenia. Dickinson JE, et al. **Am J Perinatol** 1995 Sep;12(5):333-5

Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Brighton TA, et al. **Blood** 1996 Jul 1; 88(1):194-201

A human monoclonal antibody specific for the leucine-33 (P1A1, HPA-1a) form of platelet glycoprotein IIIa from a V gene phage display library. Griffin HM, et al. **Blood** 1995 Dec 15;86(12):4430-6

Extracellular epitopes of platelet glycoprotein Ib alpha reactive with serum antibodies from patients with chronic idiopathic thrombocytopenic purpura. He R, et al. **Blood** 1995 Nov 15;86(10):3789-96

Perinatal intracranial hemorrhage due to severe neonatal alloimmune thrombocytopenic purpura (NAITP) associated with anti-Yukb (HPA-4a) antibodies. Matsui K, et al. **Brain Dev** 1995 Sep-Oct;17(5):352-5

Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes. Arfors L, et al. **Eur J Haematol** 1996 Apr;56(4):230-4

Is immune thrombocytopenic purpura (ITP) due to natural antibodies specific to platelets? [letter] Souberbielle BE. **Eur J Haematol** 1996 Mar;56(3):178-80

Platelet-specific antibodies in transfused patients. Uhrynowska M, et al. **Eur J Haematol** 1996 Apr; 56(4):248-51

The serological investigation of patients with autoimmune thrombocytopenia. Kelton JG. **Thromb Haemost** 1995 Jul; 74(1):228-33

Human platelet alloantigens: recent findings, new perspectives. Newman PJ, et al. **Thromb Haemost** 1995 Jul; 74(1):234-9 (26 ref.)

Characterization of antibodies directed against platelet cryptantigens detected during the immunological study of 356 consecutive patients with presumed autoimmune thrombocytopenia (AITP). Muñiz-Diaz E, et al. **Transfus Med** 1995 Sep;5(3):185-91

Flow cytometric detection of platelet-reactive antibodies and application in platelet crossmatching. Köhler M, et al. **Transfusion** 1996 Mar;36(3):250-5

Alloimmunization against Iy, a low-frequency antigen on platelet glycoprotein Ib/IX as a cause of severe neonatal alloimmune thrombocytopenic purpura. Kiefel V, et al. **Vox Sang** 1995;69(3):250-4

The therapeutic value of HPA-1a-negative platelet transfusion in post-transfusion purpura complicated by life-threatening haemorrhage. Win N, et al. **Vox Sang** 1995; 69(2):138-9

[Platelet antigens: immunology and immuno-allergology] de Sousa JC, et al. **Allerg Immunol (Paris)** 1996 Feb; 28(2):48-51 (22 ref.) (Eng. Abstr.) **(Fre)**

ANTIGENS, HUMAN PLATELET

[Diagnosis and therapy of fetal alloimmune thrombocytopenia] Marzusch K, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):587–91 (29 ref.) (Eng. Abstr.) **(Ger)**

[Post-transfusion purpura. Description of 2 cases diagnosed at the same hospital in a 6-month period] Muñiz-Díaz E, et al. **Sangre (Barc)** 1996 Feb;41(1):59–64 (Eng. Abstr.) **(Spa)**

ANTIGENS, IMMUNE RESPONSE see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

ANTIGENS, IMMUNODOMINANT see **IMMUNODOMINANT EPITOPES**

ANTIGENS, KI-1 see **ANTIGENS, CD30**

ANTIGENS, LEUKEMIA, COMMON ACUTE LYMPHOBLASTIC see **MEMBRANE METALLO-ENDOPEPTIDASE**

ANTIGENS, LY

Tissue expression, structure and function of the murine Ly-6 family of molecules. Gumley TP, et al. **Immunol Cell Biol** 1995 Aug;73(4):277–96 (111 ref.)

ANALYSIS

Searching for hematopoietic stem cells. II. The heterogeneity of Thy-1.1(lo)Lin(-/lo)Sca-1+ mouse hematopoietic stem cells separated by counterflow centrifugal elutriation. Uchida N, et al. **Exp Hematol** 1996 Apr;24(5):649–59

In vivo self-renewal of c-Kit+ Sca-1+ Lin(low/-) hemopoietic stem cells. Osawa M, et al. **J Immunol** 1996 May 1;156(9):3207–14

BIOSYNTHESIS

Hematopoietic stem cell antigen-1 (Sca-1) expression in different lymphoid tissues of female mice treated with GnRH agonist. Rao LV, et al. **Am J Reprod Immunol** 1995 Oct;34(4):257–66

The Ly-6E.1 (Sca-1) gene requires a 3'chromatin-dependent region for high-level gamma-interferon-induced hematopoietic cell expression. Sinclair A, et al. **Blood** 1996 Apr 1;87(7):2750–61

GENETICS

Autoimmune diabetes-prone NOD mice express the Lyt2 alpha (Lyt2.1) and Lyt3 alpha (Lyt3.1) alleles of CD8. Johnson-Tardieu JM, et al. **Immunogenetics** 1996; 43(1-2):6–12

Isolation and characterization of cDNA clones for Humly9: the human homologue of mouse Ly9. Sandrin MS, et al. **Immunogenetics** 1996;43(1-2):13–9

Identification through bioinformatics of cDNAs encoding human thymic shared Ag-1/stem cell Ag-2. A new member of the human Ly-6 family. Capone MC, et al. **J Immunol** 1996 Aug 1;157(3):969–73

IMMUNOLOGY

The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Yu YY, et al. **Immunity** 1996 Jan; 4(1):67–76

Ly-6C+ natural T (NT) cells mediate immune surveillance against NK-sensitive and NK-resistant transplantable tumours in certain strains of mice. Martiniello R, et al. **Int J Cancer** 1996 May 16;66(4):532–7

Modulation of TCR-mediated signaling pathway by thymic shared antigen-1 (TSA-1)/stem cell antigen-2 (Sca-2). Saitoh S, et al. **J Immunol** 1995 Dec 15;155(12):5574–81

METABOLISM

Recognition of class I major histocompatibility complex molecules by Ly-49: specificities and domain interactions. Brennan J, et al. **J Exp Med** 1996 Apr 1;183(4):1553–9

Identification and functional analysis of Ly-6A/E as a thymic and bone marrow stromal antigen. Izon DJ, et al. **J Immunol** 1996 Apr 1;156(7):2391–9

ANTIGENS, MINOR LYMPHOCYTE STIMULATORY see **MINOR LYMPHOCYTE STIMULATORY ANTIGENS**

ANTIGENS, NEOPLASM

The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. DeCoteau JF, et al. **Blood** 1996 Apr 15; 87(8):3437–41

Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemia. Terpstra W, et al. **Blood** 1996 Mar 15;87(6):2187–94

Tumor antigens in astrocytic gliomas. Kurpad SN, et al. **Glia** 1995 Nov;15(3):244–56 (105 ref.)

Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Sensi M, et al. **Immunol Today** 1995 Dec;16(12):588–95 (64 ref.)

CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone: a case report. Nakajima H, et al. **Keio J Med** 1996 Jun;45(2):114–7

Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Darnell RB. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4529–36 (107 ref.)

Studies on the expression of T-(Gal beta (1-3) GalNAc alpha 1-O-R) and T-like antigens in normal and pathologic human and rat urothelium. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;176:7–46 (188 ref.)

Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination? Coulie PG. **Stem Cells (Dayt)** 1995 Jul;13(4):393–403 (65 ref.)

ADMINISTRATION & DOSAGE

Antimetastatic effect of immunization with liposome-encapsulated tumor cell-membrane proteins obtained from experimental tumors. Aliño SF, et al. **Immunopharmacol Immunotoxicol** 1995 Aug;17(3):419–36

Researchers transfer immunity to a woman with cancer [news] Jenks S. **J Natl Cancer Inst** 1995 May 17; 87(10):711–2

ANALYSIS

Quantitative immunocytochemical assays of topoisomerase II in lung adenocarcinoma cell lines. Correlation to topoisomerase II alpha content and topoisomerase II catalytic activity. Yamazaki K, et al. **Acta Oncol** 1996; 35(4):417–23

The pattern of HMB-45 antibody staining in compound Spitz nevi. Bergman R, et al. **Am J Dermatopathol** 1995 Dec; 17(6):542–6

Patterns of cell proliferation in actinic keratoacanthomas and squamous cell carcinomas of the skin. Immunohistochemical study using the MIB 1 antibody in formalin-fixed paraffin sections [see comments] Skálová A, et al. **Am J Dermatopathol** 1995 Aug;17(4):332–4. Comment in: Am J Dermatopathol 1995 Aug;17(4):319–20.

Flow cytometric analysis of T and Tn epitopes on chronic lymphocytic leukemia cells. Aller CT, et al. **Am J Hematol** 1996 May;52(1):29–38

Proliferation indices of vestibular schwannomas by Ki-67 and proliferating cell nuclear antigen. Szeremeta W, et al. **Am J Otol** 1995 Sep;16(5):616–9

Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. Rudolph P, et al. **Am J Pathol** 1995 Dec;147(6):1615–25

Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts. Yang JM, et al. **Am J Surg** 1996 Jan;171(1):126–9; discussion 129–30

GIST [letter; comment] Tamsen A, et al. **Am J Surg Pathol** 1995 Dec;19(12):1444–5. Comment on: Am J Surg Pathol 1995 Jan;19(1):59–70.

Detection of MAGE-1, -2, and -3 messenger RNA in tissue samples derived from lung and mammary tumors. Ferlazzo G, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:448–52

Development of murine (OC-147) and human (H-106) monoclonal antibodies reactive with a 53-kDa ovarian tumor-associated antigen. Mruthinti S, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:264–8

Microwave-enhanced immunohistochemical staining of a formalin-sensitive antigen-laminin receptor. Chew EC, et al. **Anticancer Res** 1996 Jan-Feb;16(1):353–7

Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers. de la Torre M, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2791–5

Concordance between serum and cytosolic levels of CEA, CA125 and SCC antigens in patients with non-small cell lung cancer. Diez M, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2811–7

TAG-72 expression and its role in the biological evaluation of human colorectal cancer. Guadagni F, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2141–8 (71 ref.)

Identification with monoclonal antibody 140.240 of a structural variant of melanotransferrin shed by human melanoma cell lines in vitro. Liao SK. **Anticancer Res** 1996 Jan-Feb;16(1):171–6

Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Lundin J, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2659–68

Effects of two benzo[a]phenothiazines on multi-drug resistance (mdr) and tumor antigen expression. Molnár J, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2013–6

Tumor markers as targets for selective diagnostic and therapeutic procedures. Roselli M, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2187–92 (59 ref.)

Expression of sarcoma-associated antigens p102 and p200 in human sarcoma cell lines. Song S, et al. **Anticancer Res** 1996 May-Jun;16(3A):1171–5

Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer. van Dongen GA, et al. **Anticancer Res** 1996 Jul-Aug;16(4C):2409–13 (41 ref.)

The association of vascular proliferation with HPV status and epithelial PCNA positivity in cervical intraepithelial lesions. Soini Y, et al. **APMIS** 1996 Mar;104(3):183–90

Neuroectodermal antigens persist in benign and malignant salivary gland tumor cultures. Levin RJ, et al. **Arch Otolaryngol Head Neck Surg** 1996 May;122(5):551–7; discussion 557–8

Selection of a peptide with affinity for the tumor-associated TAG72 antigen from a phage-displayed library. Gui J, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):414–9

Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Behm FG, et al. **Blood** 1996 Feb 1; 87(3):1134–9

CD40: a sensitive marker of Reed-Sternberg cells [letter] Carbone A, et al. **Blood** 1996 Jun 1;87(11):4918–9

Clarification of CD3 immunoreactivity in nasal T/natural killer cell lymphomas: the neoplastic cells are often CD3 epsilon+ [letter; comment] Chan JK, et al. **Blood** 1996 Jan 15;87(2):839–41. Comment on: Blood 1995 May 15;85(10):2993–6.

Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Creutzig U, et al. **Blood** 1995 Oct 15; 86(8):3097–108

Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis. McSweeney PA, et al. **Blood** 1996 Jul 15;88(2):622–32

Analysis of VH gene expression in CD5+ and CD5- B-cell chronic lymphocytic leukemia. Maloum K, et al. **Blood** 1995 Nov 15;86(10):3883–90

Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer. Ross AA, et al. **Bone Marrow Transplant** 1995 Jun;15(6):929–33

Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas. Ellis PA, et al. **Br J Cancer** 1996 Mar;73(5):640–3

Endothelial Tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis. Salvén P, et al. **Br J Cancer** 1996 Jul;74(1):69–72

Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Schadendorf D, et al. **Br J Cancer** 1996 Jul;74(2):194–9

Generation of human monoclonal antibodies recognising membranous antigens of the lung adenocarcinoma cell line A549 using an AMeX immunohistostaining method. Yoshinari K, et al. **Br J Cancer** 1996 Aug;74(3):359–67

Multiple gastric involvement by myeloid antigen CD13-positive non-secretory plasma cell leukaemia. Ohsaka A, et al. **Br J Haematol** 1996 Jan;92(1):134–6

Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium. Rothenberger S, et al. **Brain Res** 1996 Mar 11;712(1):117–21

Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma. Bevilacqua P, et al. **Breast Cancer Res Treat** 1996;37(2):123–33

P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Seymour L, et al. **Breast Cancer Res Treat** 1995;36(1):61–9

Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation. Cao Y, et al. **Cancer** 1995 Nov 15; 76(10):1700–8

Flow cytometric identification of cell surface markers on cultured human colonic cell lines using monoclonal antibodies. Han JS, et al. **Cancer** 1995 Jul 15;76(2):195–200

Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Heegaard S, et al. **Cancer** 1995 Nov 15;76(10):1809–13

MIB-1 staining index and peritumoral brain edema of meningiomas. Ide M, et al. **Cancer** 1996 Jul 1;78(1):133–43

Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Kros JM, et al. **Cancer** 1996 Sep 1;78(5):1107–13

The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer. Lara PC, et al. **Cancer** 1995 Sep 1;76(5):758–64

Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen. Murphy GP, et al. **Cancer** 1996 Aug 15;78(4):809–18

Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB-1 and PC10 labeling indices. Oka K, et al. **Cancer** 1996 Jun 1;77(11):2280–5

Analysis of the prognostic significance of cytosolic determination of CA 125 tumor-associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with nonsmall cell lung carcinoma. Picardo AL, et al. **Cancer** 1996 Mar 15;77(6):1066–72

A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Sonoda K, et al. **Cancer** 1996 Apr 15;77(8):1501–9

Autoantibodies against p53 are not increased in human ascites and pleural effusions. Munker R, et al. **Cancer Immunol Immunother** 1996 Mar;42(3):200–1

2B1 antigen characteristically expressed on extracellular matrices of human malignant tumors is a large chondroitin

sulfate proteoglycan, PG-M/versican. Isogai Z, et al. **Cancer Res** 1996 Sep 1;56(17):3902-8

TuAg.1 is the liver isoform of the rat colon tumor-associated antigen pE4 and a member of the immunoglobulin-like supergene family. Lim YP, et al. **Cancer Res** 1996 Sep 1; 56(17):3934-40

Production of a novel monoclonal antibody, JT-95, which can detect antigen of thyroid carcinoma. Takeyama H, et al. **Cancer Res** 1996 Apr 15;56(8):1817-22

Antigen retrieval: p53 staining in benign, pre-malignant and malignant tissues of the larynx. Tan LK, et al. **Clin Otolaryngol** 1996 Apr;21(2):147-50

T and Tn pancarcinoma markers: autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast carcinoma immunotherapy. Springer GF. **Crit Rev Oncog** 1995;6(1):57-85 (220 ref.)

Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Christiansen H, et al. **Eur J Cancer** 1995;31A(4):541-4

Evaluation of Ki-67 expression as a prognostic feature in hepatocellular carcinoma in cirrhosis [letter] Colleoni M, et al. **Eur J Cancer** 1995;31A(9):1547-8

Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors. Combaret V, et al. **Eur J Cancer** 1995;31A(4):545-9

Correlations of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma. Karlsson M, et al. **Eur J Cancer** 1996 Feb;32A(2):357-62

Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s. Terpe HJ, et al. **Eur J Cancer** 1995;31A(4):549-52 (60 ref.)

Immunostaining of human melanomas by a monoclonal antibody to B700 mouse melanoma antigen. Xu X, et al. **Eur J Cancer** 1996 Jan;32A(1):168-73

The Thomsen-Friedenreich (T) simple mucin-type carbohydrate antigen in salivary gland carcinomas. Therkildsen MH, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):361-7

C-myc oncogene expression in human melanoma and its relationship with tumour antigenicity. Grover R, et al. **Eur J Surg Oncol** 1996 Aug;22(4):342-6

A CD44 variant exon 6 epitope as a prognostic indicator in breast cancer. Schumacher U, et al. **Eur J Surg Oncol** 1996 Jun;22(3):259-61

Expression of a cell surface antigen recognized by the monoclonal antibody AUA1 in bladder carcinoma: an immunohistochemical study. Zorzos J, et al. **Eur Urol** 1995; 28(3):251-4

Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma. Vail DM, et al. **Exp Hematol** 1996 Jun;24(7):807-15

The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Inoue H, et al. **Gastroenterology** 1995 Nov;109(5):1522-5

Immunohistochemical localization of epidermal growth factor receptor and epithelial antigen in tumors of the human conjunctiva, eyelid, lacrimal gland, and orbit. Kodama T, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Nov;233(11):672-6

Immunodetection of squamous cell carcinoma-associated variant of nuclear protein. Rakowicz-Szulczynska EM, et al. **Gynecol Oncol** 1996 Feb;60(2):255-63

Comparison of the pattern of expression of Leu-M1 antigen in adenocarcinomas, neutrophils and Hodgkin's disease by immunoelectron microscopy. Valente AM, et al. **Histochem Cell Biol** 1995 Mar;103(3):181-6

A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin. Attanoos RL, et al. **Histopathology** 1995 Oct;27(4):361-6

Immunohistochemical staining of ovarian granulosa cell tumours with MIC2 antibody. Loo KT, et al. **Histopathology** 1995 Oct;27(4):388-90

Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Langford LA, et al. **Hum Pathol** 1996 Apr;27(4):350-4

Expression and function of membrane regulators of complement on rat astrocytes in culture. Rogers CA, et al. **Immunology** 1996 May;88(1):153-61

Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. Altmeyer A, et al. **Int J Cancer** 1996 Aug 22;69(4):340-9

Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumours. Andrews PW, et al. **Int J Cancer** 1996 Jun 11;66(6):806-16

Characterization of a prostate carcinoma mucin-like antigen (PMA). Beckett ML, et al. **Int J Cancer** 1995 Sep 15; 62(6):703-10

Monoclonal antibodies against recombinant-MAGE-1 protein identify a cross-reacting 72-kDa antigen which is co-expressed with MAGE-1 protein in melanoma cells. Carrel S, et al. **Int J Cancer** 1996 Jul 29;67(3):417-22

Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Inoue H, et al. **Int J Cancer** 1995 Nov 15;63(4):523-6

Characterisation of the tumour-associated carbohydrate epitope recognised by monoclonal antibody 4D3. Pinczower GD, et al. **Int J Cancer** 1996 May 29; 66(5):636-44

Similarity of TALLA-1, a T-cell acute lymphoblastic leukemia antigen, to GP37 [letter] Seon BK. **Int J Cancer** 1995 Nov 3;63(3):474

CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma. Tanaka T, et al. **Int J Cancer** 1995 Oct 20;64(5):326-31

A monoclonal antibody KIS-1 recognizing a new membrane antigen on human squamous-cell carcinoma. Toh U, et al. **Int J Cancer** 1996 May 29;66(5):600-6

Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. Yamada A, et al. **Int J Cancer** 1995 Dec 20;64(6):388-93

A cell-surface epitope associated with liver-preferential metastasis detected by the new monoclonal antibody 3H4 in the murine tumor model ER 15-P. Wulf GG, et al. **J Cancer Res Clin Oncol** 1996;122(8):476-82

Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue. Buist MR, et al. **J Clin Pathol** 1995 Jul;48(7):631-6

Expression of CD44H and CD44v3 in normal oesophagus, Barrett mucosa and oesophageal carcinoma. Castellà E, et al. **J Clin Pathol** 1996 Jun;49(6):489-92

Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia. Cordone I, et al. **J Clin Pathol** 1995 Oct;48(10):955-60

Cellular distribution of CD44 gene transcripts in colorectal carcinomas and in normal colonic mucosa. Gorham H, et al. **J Clin Pathol** 1996 Jun;49(6):482-8

Abnormal expression of the human CD44 gene in early colorectal malignancy with special reference to variant exon 9 (9v). Kawahara K, et al. **J Clin Pathol** 1996 Jun; 49(6):478-81

Establishment of an enzyme-linked immunosorbent assay (ELISA) for measuring cellular MAGE-4 protein on human cancers. Shichijo S, et al. **J Immunol Methods** 1995 Oct 12;186(1):137-49

Proliferative potential of meningiomas evaluated by proliferating cell nuclear antigen expression. Nakabayashi H, et al. **J Neurooncol** 1995;24(3):209-17

The use of antigen retrieval for immunohistochemical detection of p53 over-expression in malignant and benign oral mucosa: a cautionary note. Dowell SP, et al. **J Oral Pathol Med** 1996 Feb;25(2):60-4

CD25-negative hairy cell leukaemia: intracytoplasmic detection of Tac antigen and interferon-induced surface expression. Tison T, et al. **J Pathol** 1995 Sep;177(1):41-7

Immunologic characterization of tumor markers in human ovarian cancer cell lines. Kutteh WH, et al. **J Soc Gynecol Investig** 1996 Jul-Aug;3(4):216-22

Prognostic significance of Ki-67 labeling index in urothelial tumors of the renal pelvis and ureter. Masuda M, et al. **J Urol** 1996 Jun;155(6):1877-80; discussion 1880-1

Frequent development of murine T-cell lymphomas with TcR alpha/beta+, CD4-/8- phenotype after implantation of human inflammatory breast cancer cells in BALB/c nude mice. Wakasugi H, et al. **Jpn J Cancer Res** 1995 Nov; 86(11):1086-96

Biological heterogeneity of diffuse mixed small and large cell non-Hodgkin's lymphomas assessed by DNA flow cytometry and Ki67. Palestro G, et al. **Leuk Lymphoma** 1995 Nov;19(5-6):467-72

Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes. Groeneveld K, et al. **Leukemia** 1996 Aug;10(8):1383-9

Acute undifferentiated leukemia with an unusual CD7+ CD56+ CD33+ immunophenotype of NK progenitors [letter] Reuss-Borst MA, et al. **Leukemia** 1996 May; 10(5):923-4

Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Rothe G, et al. **Leukemia** 1996 May;10(5):877-95

Ber-EP4 immunoreactivity in normal skin and cutaneous neoplasms. Jimenez FJ, et al. **Mod Pathol** 1995 Oct; 8(8):854-8

Identification of a 60-kD antigen associated with malignant growth of human breast tissue. Chatterjee A, et al. **Oncology** 1996 Sep-Oct;53(5):422-5

Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma. Victorzon M, et al. **Oncology** 1996 May-Jun;53(3):182-91

Comparative distribution of S-100 protein and antigen HMB-45 in various types of melanomas and naevi. Mirecka J, et al. **Pol J Pathol** 1995;46(3):167-72

Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Bertsch DJ, et al. **Surgery** 1995 Oct;118(4):634-8; discussion 638-9 (9 ref.)

[Future of malignant stage I melanoma. Immunology and immunotherapy] Nicolas JF, et al. **Ann Dermatol Venereol** 1995;122(5):324-35 (105 ref.) **(Fre)**

[Role of CD34 in the diagnosis of dermatofibrosarcoma protuberans (letter)] Santelli G, et al. **Ann Pathol** 1996; 16(2):149-50 **(Fre)**

[Ag-NORs, nucleus-nucleolus-associated antigens (Ki67, PCNA, P-105 and p-120): prognostic markers of meningioma recurrence] Crafa P, et al. **Acta Biomed Ateneo Parmense** 1994;65(5-6):297-308 (Eng. Abstr.) **(Ita)**

[Value of neuron specific enolase levels and squamous cell carcinoma antigen in bronchial lavage fluid in patients with lung cancer] Załęska J, et al. **Pneumonol Alergol Pol** 1996; 64(1-2):11-8 (Eng. Abstr.) **(Pol)**

[Immunohistochemical study of the expression of proliferating cell nuclear antigen in astrocytic gliomas of the cerebral hemispheres] Korshunov AG, et al. **Arkh Patol** 1996 Mar-Apr;58(2):32-7 (Eng. Abstr.) **(Rus)**

[Inverted transitional-cell papilloma: the expression of the Ki-67 nuclear antigen as a prognostic factor] Valero Puerta JA, et al. **Arch Esp Urol** 1995 Nov;48(9):887-92 (Eng. Abstr.) **(Spa)**

[Study of the squamous cell carcinoma (SCC) antigen in benign diseases] Gris JM, et al. **Med Clin (Barc)** 1996 Feb 17;106(6):205-8 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Clonal heterogeneity in membrane expression of CD5 in a patient with chronic lymphocytic leukemia. Hashimoto S, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:482-4

Evidence for the release of autocrine growth factor(s) by Hodgkin's cell lines. Imam SA, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1727-32

Modulation of the rat tumor-associated shedding antigen (CE7) and augmentation of immunogenicity by irradiation. Shibata T, et al. **Anticancer Res** 1996 Jan-Feb;16(1):99-104

Modifications of tumor-associated antigen expression on human lung cancer cells by hyperthermia and cytokine. Takahashi T, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2601-6

Expression of the serpin genes squamous cell carcinoma antigen and leupin in human tissues. Barnes RC, et al. **Biochem Soc Trans** 1996 Feb;24(1):110S

Expression of Thy-1 antigen (CDw90) on adult acute leukemia blast cells [letter] Campos L, et al. **Blood** 1996 Jan 1;87(1):413-4

The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Carbone A, et al. **Blood** 1995 Dec 15;86(12):4617-26

Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Porwit-MacDonald A, et al. **Blood** 1996 Feb 1;87(3):1162-9

The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Smith FO, et al. **Blood** 1996 Feb 1;87(3):1123-33

Bladder carcinomas and normal urothelium universally express gp200-MR6, a molecule functionally associated with the interleukin 4 receptor (CD 124). Tungekar MF, et al. **Br J Cancer** 1996 Feb;73(4):429-32

Immunogenicity and immunosensitivity of ex vivo human carcinomas: interferon gamma and tumour necrosis factor alpha treatment of tumour cells potentiates their interaction with autologous blood lymphocytes. Vánky F, et al. **Cancer Immunol Immunother** 1995 Oct;41(4):217-26

Expression of a specific mouse germ cell nuclear antigen (GCNA1) by early embryonic testicular teratoma cells in 129/Sv-Sl/+ mice. Wang D, et al. **Cancer Lett** 1996 Feb 27;100(1-2):31-6

Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Henderson RA, et al. **Cancer Res** 1996 Aug 15; 56(16):3763-70

Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. Murray JL, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5925s-5928s

B-cell prolymphocytic leukemia expressing discordant myeloid-associated antigens in simultaneous specimens from bone marrow and peripheral blood. Emery CL, et al. **Cytometry** 1995 Sep 15;22(3):243-9

Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF. Schmid I, et al. **Cytometry** 1995 Jun 15;22(2):103-10

FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects. Visani G, et al. **Eur J Haematol** 1996 May;56(5):308-12

Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast. Concha A, et al. **Eur J Immunogenet** 1995 Aug;22(4):299-310

The murine homolog of human Ep-CAM, a homotypic adhesion molecule, is expressed by thymocytes and thymic epithelial cells. Nelson AJ, et al. **Eur J Immunol** 1996 Feb; 26(2):401-8

Expression of CD44 and variant isoforms in cervical intraepithelial neoplasia. Dellas A, et al. **Gynecol Oncol** 1996 Aug;62(2):218-25

Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Hamel NW, et al. **Gynecol Oncol** 1996 Aug;62(2):192-8

Locus-specific de novo methylation down-regulates MHC class I in S49 lymphomas. Rubocki RJ, et al. **Immunogenetics** 1996;43(1-2):63-7

Infrequent expression of the MAGE gene family in uveal melanomas. Mulcahy KA, et al. **Int J Cancer** 1996 Jun

11;66(6):738–42

MAGE BAGE and GAGE genes expression in fresh epithelial ovarian carcinomas [letter] Russo V, et al. **Int J Cancer** 1996 Jul 29;67(3):457–60

Prognostic value of an assessment of ABH(0) isoantigens and Thomsen–Friedenreich (TF) antigen expression in patients with urinary bladder tumours. Dobrowolski ZF, et al. **Int Urol Nephrol** 1995;27(4):395–404

Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. Wang RF, et al. **J Exp Med** 1996 Mar 1;183(3):1131–40

Ki–67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy [see comments] Bettencourt MC, et al. **J Urol** 1996 Sep;156(3):1064–8. Comment in: J Urol 1996 Sep;156(3):1069–70.

Differential expression of B29 (CD79b) and mb–1 (CD79a) proteins in acute lymphoblastic leukaemia. Astsaturov IA, et al. **Leukemia** 1996 May;10(5):769–73

Studies on the expression and immunogenicity of the B50 melanoma antigen and its relationship with calreticulin. Bijwaard K, et al. **Melanoma Res** 1995 Oct;5(5):327–36

The activation of human gene MAGE–1 in tumor cells is correlated with genome–wide demethylation. De Smet C, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7149–53

Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Orlow SJ, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10152–6

Surface–epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA–1 a member of the galectin gene family. Su ZZ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7252–7

Tumor necrosis factor–alpha stimulates the production of squamous cell carcinoma antigen in normal squamous cells. Numa F, et al. **Tumour Biol** 1996;17(2):97–101

Upregulation of prostate–specific membrane antigen after androgen–deprivation therapy. Wright GL Jr, et al. **Urology** 1996 Aug;48(2):326–34

BLOOD

Use of tetranectin, CA–125 and CASA to predict residual tumor and survival at second– and third–look operations for ovarian cancer. Høgdall CK, et al. **Acta Oncol** 1996; 35(1):63–9

Clinical value of TPS, CEA and CA 15–3 in breast cancer patients. Blijlevens NM, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2711–6

Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer? Eskelinen M, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2351–6

A new tumour associated antigen of non–small cell lung cancer: tumour liberated proteins (TLP)—a possible new tumor marker. Garaci E, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2253–5

Assessment of response to carboplatin in patients with hormone–refractory prostate cancer: a critical analysis of drug activity. Miglietta L, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2825–8

Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Pasanen PA, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2731–7

New markers for breast carcinoma–associated antigen in comparison with CA 15–3. van Dalen A. **Anticancer Res** 1996 Jul–Aug;16(4B):2339–43

A reappraisal of the squamous cell carcinoma antigen as a tumor marker in head and neck cancer. Snyderman CH, et al. **Arch Otolaryngol Head Neck Surg** 1995 Nov; 121(11):1294–7

Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy. Sproston AR, et al. **Br J Cancer** 1995 Dec;72(6):1536–40

CA15–3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer. Devine PL, et al. **Breast Cancer Res Treat** 1995 Jun;34(3):245–51

Clinical value of pretreatment serum Cyfra 21–1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Gaarenstroom KN, et al. **Cancer** 1995 Sep 1;76(5):807–13

Serum squamous cell carcinoma antigen: a potential marker for benign vulval disease? Abukhalil I, et al. **Clin Exp Obstet Gynecol** 1995;22(4):265–7

Elevation and fluctuation of serum CA 19–9 and SPAN–1 levels after administration of sulfonylurea in a diabetic patient with Lewis(a–,b–) blood phenotype [letter] Yoshioka K. **Diabetes Care** 1995 Oct;18(10):1397–9

Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. Jung K, et al. **Eur J Cancer** 1996 Apr;32A(4):627–30

Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome. Scambia G, et al. **Eur J Cancer** 1996 Feb; 32A(2):259–63

A simple and sensitive assay for determination of human anti–idiotypic anti–B72.3 antibodies, which is not affected by the presence of tumour–associated glycoprotein 72. Reinsberg J, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):237–44

Epithelial ovarian carcinoma of low malignant potential. Darai E, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):141–5

Predictive and prognostic values of cancer–associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second–look laparotomy for ovarian cancer. Kierkegaard O, et al. **Gynecol Oncol** 1995 Nov;59(2):251–4

CD30 molecule (Ki–1 Ag): more than just a marker of CD30+ lymphoma. Pizzolo G, et al. **Haematologica** 1995 Jul–Aug;80(4):357–66

Analysis of the temporal compressibility of breast tumour marker assays: development of a "near patient" assay. Murray A, et al. **Int J Biol Markers** 1995 Oct–Dec; 10(4):200–5

Clinical evaluations of a new ovarian cancer marker, COX–1. Lee G, et al. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S27–32

The 90K tumor–associated antigen and clinical progression in human immunodeficiency virus infection. Iacobelli S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):450–6

Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early–stage cervical carcinoma. Duk JM, et al. **J Clin Oncol** 1996 Jan; 14(1):111–8

Re: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer [letter; comment] Sun WH, et al. **J Urol** 1996 Sep;156(3):1137–8 . Comment on: J Urol 1995 Aug;154(2 Pt 1):379–83; discussion 383–4.

Hydronephrosis and hydroureter with extremely high levels of serum carbohydrate antigens 19–9 and SPan–1: a case report. Takase K, et al. **J Urol** 1996 Apr;155(4):1386

Monitoring lung cancer with tissue polypeptide antigen: an ancillary, profitable serum test to evaluate treatment response and posttreatment disease status. Buccheri G, et al. **Lung Cancer** 1995 Oct;13(2):155–68

CEA, CYFRA21–1 and SCC in non–small cell lung cancer [see comments] Moro D, et al. **Lung Cancer** 1995 Oct; 13(2):169–76. Comment in: Lung Cancer 1995 Oct;13(2):177–9.

Serum (circulating) tumor markers for breast cancer. Hayes DF. **Recent Results Cancer Res** 1996;140:101–13 (52 ref.)

Prognostic significance of SCC antigen in the serum of patients with head and neck cancer. Molina R, et al. **Tumour Biol** 1996;17(2):81–9

[Clinical evaluation of TPA–assay kit using monoclonal antibodies] Saga T, et al. **Gan To Kagaku Ryoho** 1996 Apr; 23(5):615–21 (Eng. Abstr.) **(Jpn)**

[Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA–M "Daiichi" kit] Sakahara H, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):733–43 (Eng. Abstr.) **(Jpn)**

[A case of hydronephrosis with high level of serum Span–1 antigen and CA19–9] Kondoh K, et al. **Hinyokika Kiyo** 1996 Jan;42(1):51–3 (Eng. Abstr.) **(Jpn)**

[Finding antigens using immunoenzyme methods characterized by nonhistone proteins in hyperplastic and neoplastic endometrium in women] Miturski R. **Ginekol Pol** 1995 May;66(5):277–9 (Eng. Abstr.) **(Pol)**

CEREBROSPINAL FLUID

Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Kersten MJ, et al. **Blood** 1996 Mar 1; 87(5):1985–9

CHEMISTRY

Synthesis of a radioiodinated photoreactive MAGE–1 peptide derivative and photoaffinity labeling of cell–associated human leukocyte antigen–A1 molecules. Anjuère F, et al. **Anal Biochem** 1995 Jul 20;229(1):61–7

Amino acid investigations of tumor–associated antigen of Mc31 transformed cells. Wesselinova D. **Cancer Biochem Biophys** 1995 Nov;15(2):103–6

MUC1 glycoforms in breast cancer—cell line T47D as a model for carcinoma–associated alterations of O–glycosylation. Hanisch FG, et al. **Eur J Biochem** 1996 Feb 15;236(1):318–27

Expression of gp40, the murine homologue of human epithelial cell adhesion molecule (Ep–CAM), by murine dendritic cells. Borkowski TA, et al. **Eur J Immunol** 1996 Jan;26(1):110–4

Molecular heterogeneity of tumor rejection antigen/heat shock protein GP96. Feldweg AM, et al. **Int J Cancer** 1995 Oct 9;63(2):310–4

X–ray structure of the uncomplexed anti–tumor antibody BR96 and comparison with its antigen–bound form. Sheriff S, et al. **J Mol Biol** 1996 Jun 28;259(5):938–46

A novel intracellular antigen in HL–60 cells that changes in molecular weight after granulocytic and monocytic differentiation. Katsura Y, et al. **Leuk Res** 1995 Sep; 19(9):613–20

CLASSIFICATION

[Kinds of cancer–associated antigens and their properties] Sawabu N. **Nippon Rinsho** 1996 Jun;54(6):1489–93 (4 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSTIC USE

Immunohistochemical study on the prognostic value of MIB–1 in gastric carcinoma. Müller W, et al. **Br J Cancer** 1996 Sep;74(5):759–65

DRUG EFFECTS

Cis–diamminedichloroplatinum(II) augments expression of tumor–associated antigens on human gastric cancer cell line KATO–3 and increases susceptibility and binding of tumor cells to various cytotoxic effector cells. Hayashi H, et al. **J Surg Oncol** 1996 Jul;62(3):162–70

[A comparative study of the synthesis of membrane hetero–organic antigens of kidney origin on tissue slices and isolated cells after a single carcinogenic exposure in rats] Ivanov VA, et al. **Tsitologila** 1995;37(3):227–31 (Eng. Abstr.) **(Rus)**

GENETICS

Evaluation of oncofetal protein–related mRNA transport activity as a potential early cancer marker in dogs with malignant neoplasms. Stromberg PC, et al. **Am J Vet Res** 1995 Dec;56(12):1559–63

Surface phenotype and immunoglobulin heavy chain gene usage in chronic B–cell leukemias. Ikematsu W, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:492–5

Clonal analysis of IgM+ CD5+ CLL B cells. Schettino EW, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:485–91

Expression of MAGE genes in human colorectal carcinoma. Mori M, et al. **Ann Surg** 1996 Aug;224(2):183–8

The immunotherapy of solid cancers based on cloning the genes encoding tumor–rejection antigens. Rosenberg SA. **Annu Rev Med** 1996;47:481–91 (38 ref.)

Prognostic significance of T antigen expression in patients with gastric carcinoma. Chung YS, et al. **Cancer** 1996 May 1;77(9):1768–73

Rejection antigen peptides on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes: derivation from the normally untranslated 5' region of the c–akt proto–oncogene activated by long terminal repeat. Wada H, et al. **Cancer Res** 1995 Nov 1;55(21):4780–3

Tumors antigens encoded by oncogenes and the impact of oncogenes upon the immune responses. Appleman LJ, et al. **Cell Immunol** 1996 May 25;170(1):1–10 (129 ref.)

Molecular characterization of the gene locus of the human cell proliferation–associated nuclear protein defined by monoclonal antibody Ki–67. Duchrow M, et al. **Cell Prolif** 1996 Jan;29(1):1–12

Genes coding for tumor–specific rejection antigens. Boon T, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:617–22

T cell tolerance and activation to a transgene–encoded tumor antigen. Antoniou A, et al. **Eur J Immunol** 1996 May; 26(5):1094–102

Isolation of tissue–type plasminogen activator, cathepsin H, and non–specific cross–reacting antigen from SK–PC–1 pancreas cancer cells using subtractive hybridization. Paciucci R, et al. **FEBS Lett** 1996 Apr 29;385(1–2):72–6

The expression of tumor–rejection antigen "MAGE" genes in human gastric carcinoma. Inoue H, et al. **Gastroenterology** 1995 Nov;109(5):1522–5

Structure, chromosomal location, and expression pattern of three mouse genes homologous to the human MAGE genes. De Backer O, et al. **Genomics** 1995 Jul 1;28(1):74–83

Localization of the human achaete–scute homolog gene (ASCL1) distal to phenylalanine hydroxylase (PAH) and proximal to tumor rejection antigen (TRA1) on chromosome 12q22–q23. Renault B, et al. **Genomics** 1995 Nov 1;30(1):81–3

Localization and physical mapping of the prostate–specific membrane antigen (PSM) gene to human chromosome 11. Rinker–Schaeffer CW, et al. **Genomics** 1995 Nov 1; 30(1):105–8

The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Rogner UC, et al. **Genomics** 1995 Oct 10;29(3):725–31

The expression of epidermal growth factor receptor, HER–2/Neu, p53, and Ki–67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Swisher EM, et al. **Gynecol Oncol** 1996 Jan;60(1):81–8

Prostate tissue specificity of the prostate–specific antigen promoter isolated from a patient with prostate cancer. Pang S, et al. **Hum Gene Ther** 1995 Nov;6(11):1417–26

Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. Ciernik IF, et al. **Hybridoma** 1995 Apr;14(2):139–42

The SMAGE gene family is expressed in post–meiotic spermatids during mouse germ cell differentiation. Chomez P, et al. **Immunogenetics** 1996;43(1–2):97–100

A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Gaugler B, et al. **Immunogenetics** 1996;44(5):323–30

A peptide encoded by the human MAGE3 gene and presented by HLA–B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Herman J, et al. **Immunogenetics** 1996;43(6):377–83

Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Van Pel A, et al. **Immunol Rev** 1995 Jun; 145:229–50 (92 ref.)

Expression of MAGE genes in primary and metastatic cutaneous melanoma. Brasseur F, et al. **Int J Cancer** 1995 Nov 3;63(3):375–80

Expression of the MAGE gene family in human head–and–neck squamous–cell carcinomas. Eura M, et al. **Int J Cancer** 1995 Oct 20;64(5):304–8

Peptide–specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART–1/Melan–A,

gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Spagnoli GC, et al. **Int J Cancer** 1995 Oct 20;64(5):309-15

Human tumor rejection antigens MAGE. Itoh K, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):385-90 (33 ref.)

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. Guilloux Y, et al. **J Exp Med** 1996 Mar 1;183(3):1173-83

Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. Wang RF, et al. **J Exp Med** 1996 Mar 1;183(3):1131-40

Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. Anichini A, et al. **J Immunol** 1996 Jan 1;156(1):208-17

Unique protein expression by the TBJ clonal derivative of C1300 murine neuroblastoma. Vegunta RK, et al. **J Pediatr Surg** 1995 Dec;30(12):1668-72

Expression of MAGE-1 gene by esophageal carcinomas. Toh Y, et al. **Jpn J Cancer Res** 1995 Aug;86(8):714-7

Expression of CD44 variant exons 8-10 in gastric cancer. Yamaguchi A, et al. **Jpn J Cancer Res** 1995 Dec; 86(12):1166-71

Expression of MAGE gene family in lung cancers. Sakata M. **Kurume Med J** 1996;43(1):55-61

Isolation and chromosomal location of mE4, a novel murine gene of the immunoglobulin superfamily. Chadéneau C, et al. **Mamm Genome** 1996 Aug;7(8):636-7

DNA immunization induces protective immunity against B-cell lymphoma. Syrengelas AD, et al. **Nat Med** 1996 Sep;2(9):1038-41

Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Carter RE, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):749-53

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Chang K, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):136-40

The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. De Smet C, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7149-53

Human neoplasms elicit multiple specific immune responses in the autologous host. Sahin U, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11810-3

IMMUNOLOGY

Correlation between presence of clonal rearrangements of immunoglobulin heavy chain genes and B-cell antigen expression in Hodgkin's disease. Orazi A, et al. **Am J Clin Pathol** 1995 Oct;104(4):413-8

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212-26 (23 ref.)

IgG generated against benign tumor-associated antigens prevented the effects of 1,2-dimethylhydrazine in rats. Zusman I, et al. **Anticancer Res** 1996 May-Jun; 16(3A):1183-6

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Disis ML, et al. **Blood** 1996 Jul 1;88(1):202-10

Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self-antigen: implications for lymphomagenesis in acquired immunodeficiency syndrome. Roncella S, et al. **Blood** 1996 Jul 15; 88(2):599-608

Allogeneic mouse T cell lines distinguish three Balb/c leukemias from each other and from non-leukemic lymphocytes. Sebens T, et al. **Bone Marrow Transplant** 1995 Sep;16(3):443-9

Expression of alpha-3/4-monofucosylated polylactosaminoglycan epitope, as defined by monoclonal antibody FW6, is a marker of the colorectal adenoma-carcinoma sequence. Baldus SE, et al. **Cancer** 1995 Sep 15;76(6):954-60

Costimulation of T-cell-mediated tumor immunity. Hellström KE, et al. **Cancer Chemother Pharmacol** 1996; 38 Suppl:S40-1 (30 ref.)

Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Adluri S, et al. **Cancer Immunol Immunother** 1995 Sep;41(3):185-92

Protection against metastasis by immunization with an allogeneic lymphocyte antigen. Egawa K, et al. **Cancer Immunol Immunother** 1995 Dec;41(6):384-8

The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Graham RA, et al. **Cancer Immunol Immunother** 1996 Feb;42(2):71-80 (61 ref.)

Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: identification of its antigen as a neutral glycolipid. Kingsley EA, et al. **Cancer Immunol Immunother** 1995 Dec;41(6):348-54

Identification of peptide epitopes of MAGE-1, -2, -3 that demonstrate HLA-A3-specific binding. McIntyre CA, et al. **Cancer Immunol Immunother** 1996 May;42(4):246-50

Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule. Morecki S, et al. **Cancer Immunol Immunother** 1995 Oct;41(4):236-42

Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor. Amoroso AR, et al. **Cancer Res** 1996 Jan 1; 56(1):113-20

Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Bakker AB, et al. **Cancer Res** 1995 Nov 15;55(22):5330-4

Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen. Bright RK, et al. **Cancer Res** 1996 Mar 1; 56(5):1126-30

Biological activity of two humanized antibodies against two different breast cancer antigens and comparison to their original murine forms. Ceriani RL, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5852s-5856s

Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Hu X, et al. **Cancer Res** 1996 Jun 1;56(11):2479-83

Construction of phosphorylatable monoclonal antibody to a tumor-associated antigen. Lin L, et al. **Cancer Res** 1996 Sep 15;56(18):4250-4

Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. McLaughlin JP, et al. **Cancer Res** 1996 May 15;56(10):2361-7

Selection of tumor-specific epitopes on target antigens for radioimmunotherapy of breast cancer. Peterson JA, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5847s-5851s

Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Salgaller ML, et al. **Cancer Res** 1995 Nov 1;55(21):4972-9

Antigenic cancer cells that escape immune destruction are stimulated by host cells. Seung LP, et al. **Cancer Res** 1995 Nov 1;55(21):5094-100

MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Toso JF, et al. **Cancer Res** 1996 Jan 1;56(1):16-20

Rejection antigen peptides on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes: derivation from the normally untranslated 5' region of the c-akt proto-oncogene activated by long terminal repeat. Wada H, et al. **Cancer Res** 1995 Nov 1;55(21):4780-3

In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine. Hsieh-Ma ST, et al. **Clin Immunol Immunopathol** 1996 Aug; 80(2):185-93

New tumor antigens recognized by T cells. Van den Eynde B, et al. **Curr Opin Immunol** 1995 Oct;7(5):674-81 (71 ref.)

Curing metastases? Gene and peptide therapy. Eisenbach L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):85-100 (150 ref.)

CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Grohmann U, et al. **Eur J Immunol** 1995 Oct; 25(10):2797-802

HLA class II-restricted recognition of common tumor epitopes on human melanoma cells by CD4+ melanoma-infiltrating lymphocytes. Le Dréan E, et al. **Eur J Immunol** 1995 Oct;25(10):2732-6

Proliferation index determined by MIB-1 and recurrence in endometrial cancer. Geisler JP, et al. **Gynecol Oncol** 1996 Jun;61(3):373-7

Specific targeting of adriamycin conjugates with monoclonal antibodies to hepatoma associated antigens to intrahepatic tumors in athymic mice. Adler R, et al. **Hepatology** 1995 Nov;22(5):1482-7

Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro. Moradpour D, et al. **Hepatology** 1995 Nov;22(5):1527-37

Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses. Buckley DT, et al. **Hum Antibodies Hybridomas** 1995;6(2):68-72

A genetically engineered single-gene-encoded anti-TAG72 chimeric antibody secreted from myeloma cells. Qi Y, et al. **Hum Antibodies Hybridomas** 1995;6(4):161-6

Cloned antigens and antiidiotypes. Herlyn D, et al. **Hybridoma** 1995 Apr;14(2):159-66

A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Herman J, et al. **Immunogenetics** 1996;43(6):377-83

Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. Iakoubov L, et al. **Immunol Lett** 1995 Jul-Aug;47(1-2):147-9

Immunity to oncogenic proteins. Cheever MA, et al. **Immunol Rev** 1995 Jun;145:33-59 (81 ref.)

Tumor therapy by immune recruitment with bispecific antibodies. Renner C, et al. **Immunol Rev** 1995 Jun; 145:179-209 (153 ref.)

TCR usage in CTLs recognizing melanoma/melanocyte antigens [letter] Maeurer MJ, et al. **Immunol Today** 1995 Dec;16(12):603-4

Molecular cloning of yeast cytochrome c-like polypeptide expressed in human lung carcinoma: an antigen recognizable by lung cancer-specific human monoclonal antibody. Kawamoto S, et al. **In Vitro Cell Dev Biol Anim** 1995 Oct;31(9):724-9

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Jäeger E, et al. **Int J Cancer** 1996 Apr 10;66(2):162-9

Monoclonal anti-idiotypic antibody functionally mimics the human gastrointestinal carcinoma epitope GA733. Maruyama H, et al. **Int J Cancer** 1996 Feb 8;65(4):547-53

Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Warnier G, et al. **Int J Cancer** 1996 Jul 17;67(2):303-10

MAUB is a new mucin antigen associated with bladder cancer. Bergeron A, et al. **J Biol Chem** 1996 Mar 22; 271(12):6933-40

Novel colorectal adenocarcinoma-associated 40- and 47-kDa protein antigens recognized by anti-60-kDa heat shock protein antibody. Otaka M, et al. **J Clin Gastroenterol** 1995 Oct;21(3):224-9

Production and characterisation of an antimelanoma monoclonal antibody KBA.62 using a new melanoma cell line reactive on paraffin wax embedded sections. Cohen-Knafo E, et al. **J Clin Pathol** 1995 Sep;48(9):826-31

Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes. Blake J, et al. **J Exp Med** 1996 Jul 1;184(1):121-30

Human tumor antigens recognized by T lymphocytes. Boon T, et al. **J Exp Med** 1996 Mar 1;183(3):725-9 (60 ref.)

Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. Dudley ME, et al. **J Exp Med** 1996 Aug 1; 184(2):441-7

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. Hara I, et al. **J Exp Med** 1995 Nov 1; 182(5):1609-14

B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. Johnston JV, et al. **J Exp Med** 1996 Mar 1;183(3):791-800

Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). Loftus DJ, et al. **J Exp Med** 1996 Aug 1;184(2):647-57

Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. Romero P, et al. **J Exp Med** 1995 Oct 1; 182(4):1019-28

Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity [comment] Young JW, et al. **J Exp Med** 1996 Jan 1; 183(1):7-11. Comment on: J Exp Med 1996 Jan 1;183(1):87-97. Comment on: J Exp Med 1996 Jan 1;183(1):283-7. Comment on: J Exp Med 1996 Jan 1;183(1):317-22.

Lymphokine-activated killer cells can discriminate CD34+ leukemia cells from normal hematopoietic progenitor cells. Komatsu F, et al. **J Hematother** 1996 Feb;5(1):49-56

Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects. Kroesen BJ, et al. **J Hematother** 1995 Oct;4(5):409-14

Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. Liu L, et al. **J Hematother** 1995 Oct;4(5):477-83

A combination of CD34 selection and complement-mediated immunopurging (anti-CD15 monoclonal antibody) eliminates tumor cells while sparing normal progenitor cells. Nimgaonkar M, et al. **J Hematother** 1996 Feb; 5(1):39-48

Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies. Renner C, et al. **J Hematother** 1995 Oct;4(5):447-51

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Weiner LM, et al. **J Hematother** 1995 Oct;4(5):453-6

CTL in mice immunized with human mucin 1 are MHC-restricted. Apostolopoulos V, et al. **J Immunol** 1995 Dec 1;155(11):5089-94

IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. Bianchi R, et al. **J Immunol** 1996 Aug 15;157(4):1589-97

Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. Chen PW, et al. **J Immunol** 1996 Jan 1;156(1):224-31

Expression of activated H-rasval12 in nontumorigenic and non-cross-reactive syngeneic cells induces tumor antigens cross-reactive with rat mammary adenocarcinoma 13762. Frey AB, et al. **J Immunol** 1995 Nov 15;155(10):4783-9

Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. Ramarathinam L, et al. **J Immunol** 1995 Dec 1;155(11):5323-9

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. Rivoltini L, et al. **J Immunol** 1996 May 15;156(10):3882-91

Thymus-leukemia antigen interacts with T cells and self-peptides. Sharma P, et al. **J Immunol** 1996 Feb 1; 156(3):987-96

Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. Herr W, et al. **J Immunol Methods** 1996 May 27;191(2):131-42

p23 transplantation antigen mRNA is differentially expressed in human fetal brain. Joseph R, et al. **J Neurol Sci** 1995 Jun;130(2):224-7

Therapy and imaging of pancreatic carcinoma xenografts with radioiodine-labeled chimeric monoclonal antibody A10 and its Fab fragment. Kamigaki T, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1216-23

Human melanoma antigens recognized by T lymphocytes. Kawakami Y, et al. **Keio J Med** 1996 Jun;45(2):100-8 (78 ref.)

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5-6):381-93 (160 ref.)

Targeting of non-small cell lung cancer using HMFG1-99mTc monoclonal antibodies. Pavlović S, et al. **Med Pregl** 1993;46 Suppl 1:26-8

Studies on the expression and immunogenicity of the B50 melanoma antigen and its relationship with calreticulin. Bijwaard K, et al. **Melanoma Res** 1995 Oct;5(5):327-36

Nuclear morphometry and the MIB-1 index in rhabdomyosarcoma. Noguchi S, et al. **Mod Pathol** 1996 Mar;9(3):253-60

Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Falo LD Jr, et al. **Nat Med** 1995 Jul;1(7):649-53

Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Liu SQ, et al. **Nat Med** 1995 Mar;1(3):267-71

Serum p53 antibodies as early markers of lung cancer. Lubin R, et al. **Nat Med** 1995 Jul;1(7):701-2

Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides [see comments] Mandelboim O, et al. **Nat Med** 1995 Nov;1(11):1179-83. Comment in: Nat Med 1995 Nov;1(11):1140.

A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Pan ZK, et al. **Nat Med** 1995 May;1(5):471-7

Peptide vaccination against cancer? [comment] Strominger JL. **Nat Med** 1995 Nov;1(11):1140. Comment on: Nat Med 1995 Nov;1(11):1179-83.

Serial in vitro transfer of hypersensitivity to cancer antigens by sensitised lymphocytes. Fazio M, et al. **Panminerva Med** 1995 Dec;37(4):186-9

Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Chen YT, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5915-9

The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Huang AY, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9730-5

Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Ollert MW, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4498-503

Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Pecher G, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1699-704

Human neoplasms elicit multiple specific immune responses in the autologous host. Sahin U, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11810-3

Targeting p53 as a general tumor antigen. Theobald M, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11993-7

Regulation by tumour antigens defines a role for PP2A in signal transduction. Mumby M. **Semin Cancer Biol** 1995 Aug;6(4):229-37 (59 ref.)

[Dendritic cells and immune function in cancer] Chaux P. **Pathol Biol (Paris)** 1995 Dec;43(10):897-903 (53 ref.) (Eng. Abstr.) **(Fre)**

[Dendritic cells and tumor cell therapy] Pioche C, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):904-9 (43 ref.) (Eng. Abstr.) **(Fre)**

[How do melanoma cells circumvent the immune response? Consequences for future therapy attempts and current biopsy processing] Dummer R, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1638-41 (24 ref.) (Eng. Abstr.) **(Ger)**

[Can monoclonal antibodies to a carcinoma-specific cell surface molecule prevent liver metastasis of human colorectal carcinoma and effectively treat already existing micrometastases?] Burkart C, et al. **Z Gastroenterol** 1996 Jan;34(1):41-2 **(Ger)**

[Tumor rejection antigen and cancer immunotherapy] Matsutake T, et al. **Gan To Kagaku Ryoho** 1995 Nov; 22(13):1871-7 (37 ref.) (Eng. Abstr.) **(Jpn)**

[Tumor-rejection antigens expressed on human squamous cell carcinoma] Itoh K, et al. **Hum Cell** 1995 Dec;8(4):149-54 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Analysis of tumor rejection antigen peptides recognized by specific CTL] Uenaka A, et al. **Nippon Rinsho** 1996 Jan; 54(1):242-9 (20 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Osteoclastic giant cell tumor of the pancreas: an immunohistochemical study. Dizon MA, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):306-9

Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines. Van den Eynde B, et al. **Biochem Soc Trans** 1995 Aug;23(3):681-6 (38 ref.)

A hematopoietic organ-specific 49-kD nuclear antigen: predominance in immature normal and tumor granulocytes and detection in hematopoietic precursor cells. Lee BC, et al. **Blood** 1996 Mar 15;87(6):2283-91

[The isolation and characteristics of a protein from human and bovine kidneys close in molecular and biochemical properties to non-histone chromosomal antigen PP23] Grandilevskaia AB, et al. **Tsitologiia** 1995;37(4):298-303 (Eng. Abstr.) **(Rus)**

METABOLISM

The immune stimulatory protein 90K increases major histocompatibility complex class I expression in a human breast cancer cell line. Natoli C, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):617-20

Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Diez M, et al. **Br J Cancer** 1996 May;73(10):1248-54

Expression of CD44 isoforms in basal cell carcinomas. Baum HP, et al. **Br J Dermatol** 1996 Mar;134(3):465-8

Properties of the carcinoma-associated antigen MH 99/KS 1/4 in normal and transformed human keratinocytes: regulation of synthesis, molecular cross-linking and ultrastructural localization. Schön MP, et al. **Br J Dermatol** 1995 Aug;133(2):176-85

Identification of peptide epitopes of MAGE-1, -2, -3 that demonstrate HLA-A3-specific binding. McIntyre CA, et al. **Cancer Immunol Immunother** 1996 May;42(4):246-50

Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies. Spencer DI, et al. **Cancer Lett** 1996 Feb 27; 100(1-2):11-5

Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Midis GP, et al. **Cancer Res** 1996 Sep 1;56(17):3870-4

Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro. Protti MP, et al. **Cancer Res** 1996 Mar 15;56(6):1210-3

Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. van Elsas A, et al. **Eur J Immunol** 1996 Aug;26(8):1683-9

Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Jäger E, et al. **Int J Cancer** 1996 May 16;66(4):470-6

Multifocal heterogeneity in villin and Ep-CAM expression in Barrett's esophagus. Kumble S, et al. **Int J Cancer** 1996 Mar 28;66(1):48-54

MAGE-1 gene is expressed in T-cell leukemia [letter] Schichijo S, et al. **Int J Cancer** 1996 Mar 1;65(5):709-10

HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44. Luescher IF, et al. **J Biol Chem** 1996 May 24;271(21):12463-71

Imparting exquisite specificity to peanut agglutinin for the tumor-associated Thomsen-Friedenreich antigen by redesign of its combining site. Sharma V, et al. **J Biol Chem** 1996 Aug 30;271(35):21209-13

Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. Roselli M, et al. **J Clin Oncol** 1996 Jul;14(7):2031-42

Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies. Sforzini S, et al. **J Hematother** 1995 Oct; 4(5):429-32

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. Rivoltini L, et al. **J Immunol** 1996 May 15;156(10):3882-91

Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. Bubendorf L, et al. **J Pathol** 1996 Apr;178(4):437-41

Decreased expression of galectin-3 is associated with progression of human breast cancer. Castronovo V, et al. **J Pathol** 1996 May;179(1):43-8

Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. Herold-Mende C, et al. **J Pathol** 1996 May;179(1):66-73

The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. Jensen V, et al. **J Pathol** 1995 Aug;176(4):343-52

CD44 is expressed in hepatocellular carcinomas showing vascular invasion. Mathew J, et al. **J Pathol** 1996 May; 179(1):74-9

Immunohistochemical expression of sialyl Tn, sialyl Lewis a, sialyl Lewis a-b-, and sialyl Lewis x in primary tumor and metastatic lymph nodes in human gastric cancer. Ikeda Y, et al. **J Surg Oncol** 1996 Jul;62(3):171-6

Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Nieland TJ, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):6135-9

Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Vogt AB, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9724-9

Identification of a decapeptide with the binding reactivity for tumor-associated TAG72 antigen from a phage displayed library. Gui J, et al. **Proteins** 1996 Mar; 24(3):352-8

Reactivity of tissue-specific antigens in N-methyl-N'-nitro-N-nitrosoguanidine-induced neoplasms and normal tissues from medaka (Oryzias latipes). Bunton TE, et al. **Toxicol Pathol** 1996 May-Jun; 24(3):331-8

E-cadherin, NCAM, and EpCAM expression in human fetal pancreata. Cirulli V, et al. **Transplant Proc** 1995 Dec; 27(6):3335

PHARMACOLOGY

Serine protease inhibitor activity of recombinant squamous cell carcinoma antigen towards chymotrypsin, as demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Nawata S, et al. **Electrophoresis** 1995 Jun;16(6):1027-30

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Tjoa B, et al. **Prostate** 1996 Jan;28(1):65-9

PHYSIOLOGY

Expression and function of squamous cell carcinoma antigen. Kato H. **Anticancer Res** 1996 Jul-Aug;16(4B):2149-53 (19 ref.)

CD-44 is not involved in the metastatic spread of ovarian cancer in vivo. Speiser P, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2767-9

Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion. Izumoto S, et al. **Cancer Res** 1996 Mar 15;56(6):1440-4

CD44 in colon cancer. Herrlich P, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1110-2 (32 ref.)

Expression levels of stress protein gp96 are not limiting for major histocompatibility complex class I-restricted antigen presentation. Lammert E, et al. **Eur J Immunol** 1996 Apr; 26(4):875-9

Antigen-presenting function of the TL antigen and mouse CD1 molecules. Cheroutre H, et al. **Immunol Rev** 1995 Oct;147:31-52 (73 ref.)

Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells. Zhang K, et al. **J Cell Biochem** 1996 Mar 15; 60(4):538-49

Role of host antigen receptor-bearing and antigen receptor-negative cells in immune response to rat adenocarcinoma 13762. Frey AB. **J Immunol** 1996 May 15;156(10):3841-9

The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. Buckanovich RJ, et al. **J Neurosci** 1996 Feb 1;16(3):1114-22

A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Wesseling J, et al. **Mol Biol Cell** 1996 Apr; 7(4):565-77

[Immunostimulating protein 90K in ovarian carcinoma] Zeimet AG, et al. **Gynakol Geburtshilfliche Rundsch** 1996; 36(1):44-5 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Rosenberg SA. **Annu Rev Med** 1996;47:481-91 (38 ref.)

Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Gabrilovich DI, et al. **Cell Immunol** 1996 May 25;170(1):111-9

T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Melief CJ, et al. **Immunol Rev** 1995 Jun; 145:167-77 (42 ref.)

From defined human tumor antigens to effective immunization? Boon T, et al. **Immunol Today** 1995 Jul; 16(7):334-6 (18 ref.)

A new model of active specific immunotherapy using interleukin-1 and sonicated tumor supernatant in murine tumor system. Moriguchi Y, et al. **J Surg Oncol** 1996 Jun; 62(2):78-85

URINE

Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma. Yao WJ, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2819-23

ANTIGENS, NEOPLASM, VIRAL see **ANTIGENS, VIRAL, TUMOR**

ANTIGENS, PLATELET-SPECIFIC see **ANTIGENS, HUMAN PLATELET**

ANTIGENS, POLYOMAVIRUS TRANSFORMING

ANALYSIS

Genetic analysis of polyomavirus large T nuclear localization: nuclear localization is required for productive association with pRb family members. Howes SH, et al. **J Virol** 1996 Jun;70(6):3581–8

BIOSYNTHESIS

Establishment and characterization of immortalized human coronary endothelial cells. Nakano R, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):715–22

Normal human endometrial cells in culture: characterization and immortalization of epithelial and stromal cells by SV 40 large T antigen. Merviel P, et al. **Biol Cell** 1995; 84(3):187–93

Scleroderma-derived human fibroblasts retain abnormal phenotypic and functional characteristics following retroviral transduction with the SV40 tsT antigen. Xu S, et al. **Exp Cell Res** 1995 Oct;220(2):407–14

Expression of the human cGMP-dependent protein kinase II gene is lost upon introduction of SV40 T antigen or immortalization in human cells. Fujii M, et al. **FEBS Lett** 1995 Nov 20;375(3):263–7

SV40 T-antigen induces breast cancer formation with a high efficiency in lactating and virgin WAP-SV-T transgenic animals but with a low efficiency in ovariectomized animals. Santarelli R, et al. **Oncogene** 1996 Feb 1; 12(3):495–505

In vivo expression of a single viral DNA-binding protein generates systemic lupus erythematosus-related autoimmunity to double-stranded DNA and histones. Moens U, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19; 92(26):12393–7

Derivation of immortalized swine stromal cell lines. Paguio CG, et al. **Transplant Proc** 1996 Apr;28(2):791

CHEMISTRY

Modification of an N-terminal regulatory domain of T antigen restores p53-T antigen complex formation in the absence of an essential metal ion cofactor. Kernohan NM, et al. **J Biol Chem** 1996 Mar 1;271(9):4954–60

Biochemical characterization and localization of JC virus large T antigen phosphorylation domains. Swenson JJ, et al. **Virology** 1995 Oct 1;212(2):295–308

GENETICS

Conditional transformation of mouse liver epithelial cells. An in vitro model for analysis of genetic events in hepatocarcinogenesis. Lee GH, et al. **Am J Pathol** 1995 Dec;147(6):1811–22

An epitope on Ki antigen recognized by autoantibodies from lupus patients shows homology with the SV40 large T antigen nuclear localization signal. Takasaki Y, et al. **Arthritis Rheum** 1996 May;39(5):855–62

Human papillomavirus 11 E5a delays the growth restriction induced by temperature shift in temperature-sensitive simian virus 40 T antigen-immortalized keratinocytes. Tsao YP, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):712–20

Establishment of vasopressin-responsive early proximal tubular cell lines derived from transgenic mice harboring temperature-sensitive simian virus 40 large T-antigen gene. Takeda M, et al. **Biochem Mol Biol Int** 1995 Oct; 37(3):507–15

Syndecan-1 alterations during the tumorigenic progression of human colonic Caco-2 cells induced by human Ha-ras or polyoma middle T oncogenes. Levy P, et al. **Br J Cancer** 1996 Aug;74(3):423–31

HIV genome transcription induced by polyoma virus middle T antigen through both enhancer- and promoter-dependent LTR activation. Jacqué JM, et al. **C R Acad Sci III** 1995 Dec;318(12):1227–32

Immortalization of human fibroblasts by SV40 large T antigen results in the reduction of cyclin D1 expression and subunit association with proliferating cell nuclear antigen and Waf1. Peterson SR, et al. **Cancer Res** 1995 Oct 15;55(20):4651–7

Characterization of human buccal epithelial cells transfected with the simian virus 40 T-antigen gene. Kulkarni PS, et al. **Carcinogenesis** 1995 Oct;16(10):2515–21

Induction of tetraploid DNA content by mutant simian virus 40 T antigen that has reduced complex formation with p53. Lehman JM, et al. **Cytometry** 1996 Feb 1;23(2):126–30

Biological characterization of gastric surface mucous cell line GSM06 from transgenic mice harboring temperature-sensitive simian virus 40 large T-antigen gene. Tabuchi Y, et al. **Digestion** 1996;57(2):141–8

Targeting simian virus 40 T antigen to the osteoclast in transgenic mice causes osteoclast tumors and transformation and apoptosis of osteoclasts. Boyce BF, et al. **Endocrinology** 1995 Dec;136(12):5751–9

Human endometrial fibroblasts immortalized by simian virus 40 large T antigen differentiate in response to a decidualization stimulus. Brosens JJ, et al. **Endocrinology** 1996 Jun;137(6):2225–31

Establishment of long-term myogenic cultures from patients with Duchenne muscular dystrophy by retroviral transduction of a temperature-sensitive SV40 large T antigen. Simon LV, et al. **Exp Cell Res** 1996 May 1; 224(2):264–71

Trilateral tumors in four different lines of transgenic mice expressing SV40 T-antigen. Marcus DM, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):392–6

Estradiol-dependent uterine leiomyomas in transgenic mice. Romagnolo B, et al. **J Clin Invest** 1996 Aug 1;98(3):777–84

Molecular remodelling in hypertrophied hearts from polyomavirus large T-antigen transgenic mice. Holder EL, et al. **Mol Cell Biochem** 1995 Nov 22;152(2):131–41

Establishment of human microglial cell lines after transfection of primary cultures of embryonic microglial cells with the SV40 large T antigen. Janabi N, et al. **Neurosci Lett** 1995 Aug 4;195(2):105–8

Trans-splicing and alternative-tandem-cis-splicing: two ways by which mammalian cells generate a truncated SV40 T-antigen. Eul J, et al. **Nucleic Acids Res** 1996 May 1; 24(9):1653–61

Gene targeting in rat embryo fibroblasts promoted by the polyomavirus large T antigen. Francès V, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):1999–2004

Database of mutations that alter the large tumor antigen in simian virus 40. Kierstead TD, et al. **Nucleic Acids Res** 1996 Jan 1;24(1):125–6

The three transforming regions of SV40 T antigen are required for immortalization of primary mouse embryo fibroblasts. Conzen SD, et al. **Oncogene** 1995 Dec 7; 11(11):2295–302

Formation of undifferentiated mesenteric tumors in transgenic mice expressing human neurotropic polymavirus early protein. Franks RR, et al. **Oncogene** 1996 Jun 20; 12(12):2573–8

Inactivation of p53 and the development of tetraploidy in the elastase-SV40 T antigen transgenic mouse pancreas. Ramel S, et al. **Pancreas** 1995 Oct;11(3):213–22

Evidence for activities inhibiting in trans initiation of DNA replication in extract prepared from irradiated cells. Wang Y, et al. **Radiat Res** 1996 Apr;145(4):408–18

Development of colonic and pancreatic endocrine tumours in mice expressing a glucagon-SV40 T antigen transgene. Asa SL, et al. **Virchows Arch** 1996 Mar;427(6):595–606

Identification of a variable region at the carboxy terminus of SV40 large T-antigen. Stewart AR, et al. **Virology** 1996 Jul 15;221(2):355–61

[Establishment of immortalized cell lines with differentiation phenotypes from the transgenic mice harboring temperature-sensitive SV40 T-antigen gene] Obinata M. **Seikagaku** 1995 Dec;67(12):1391–6 (11 ref.) **(Jpn)**

IMMUNOLOGY

Nucleic acid vaccination against virally induced tumors. Bright RK, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:241–51

Reversal of the temperature-shift-induced growth restriction of a temperature-sensitive simian virus 40 T-antigen-transformed human fibroblast cell line by treatment with retinoic acid. Tsao YP, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):707–11

Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein. Antonia SJ, et al. **Int Immunol** 1995 May;7(5):715–25

SV40 T antigen increases the expression and activities of p34cdc2, cyclin A, and cyclin B prior to immortalization of human diploid fibroblasts. Chang TH, et al. **J Cell Biochem** 1996 Feb;60(2):161–72

Breaking immunologic ignorance to an antigenic peptide of simian virus 40 large T antigen. Soldevila G, et al. **J Immunol** 1995 Dec 15;155(12):5590–600

Protective immunity in BALB/c mice against the simian virus 40-induced mKSA tumor resulting from injection of recombinant large T antigen. Requirement of CD8+ T lymphocytes. Zerrahn J, et al. **J Immunol** 1996 May 15; 156(10):3919–24

A short peptide eluted from the H-2Kb molecule of a polyomavirus-positive tumor corresponds to polyomavirus large T antigen peptide at amino acids 578 to 585 and induces polyomavirus-specific immunity. Berke Z, et al. **J Virol** 1996 May;70(5):3093–7

Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. Mylin LM, et al. **J Virol** 1995 Nov;69(11):6665–77

p53 inhibits JC virus DNA replication in vivo and interacts with JC virus large T-antigen. Staib C, et al. **Virology** 1996 May 1;219(1):237–46

METABOLISM

Distinct phosphorylation sites differentially influence facilitated transport of an NLS-protein and its subsequent intranuclear binding. Vancurova I, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):419–27

Evidence for an inhibitory feedback loop regulating simian virus 40 large T-antigen fusion protein nuclear transport. Seydel U, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):33–9

Cellular Ras partly mediates gap junction closure by the polyoma virus middle tumor antigen. Brownell HL, et al. **Cancer Lett** 1996 May 15;103(1):99–106

Changes in O6-methylguanine-DNA methyltransferase expression during immortalization of cloned human fibroblasts. Harris LC, et al. **Carcinogenesis** 1996 Feb; 17(2):219–24

Phosphorylation of T antigen and p53 in carcinogen-treated SV40-transformed Chinese hamster cells. Paley EL. **Carcinogenesis** 1996 May;17(5):939–45

The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct isoforms of the transcriptional co-activator, p300. Avantaggiati ML, et al. **EMBO J** 1996 May 1;15(9):2236–48

A casein-kinase-2-related protein kinase is tightly associated with the large T antigen of simian virus 40. Götz C, et al. **Eur J Biochem** 1995 Oct 1;233(1):327–34

A melanoma cell line sensitive to expression of a fusion protein binding the retinoblastoma protein family pocket domain. Khan S, et al. **Exp Cell Res** 1996 Feb 25; 223(1):171–82

TAF-like function of SV40 large T antigen. Damania B, et al. **Genes Dev** 1996 Jun 1;10(11):1369–81

SV40 large T antigen transactivates the human cdc2 promoter by inducing a CCAAT box binding factor. Chen H, et al. **J Biol Chem** 1996 Jun 14;271(24):13959–67

Modification of an N-terminal regulatory domain of T antigen restores p53-T antigen complex formation in the absence of an essential metal ion cofactor. Kernohan NM, et al. **J Biol Chem** 1996 Mar 1;271(9):4954–60

A consensus cAMP-dependent protein kinase (PK-A) site in place of the CcN motif casein kinase II site simian virus 40 large T-antigen confers PK-A-mediated regulation of nuclear import. Xiao CY, et al. **J Biol Chem** 1996 Mar 15;271(11):6451–7

Polyomavirus middle-T antigen lacking a membrane anchor sequence accumulates in the nucleus. Messerschmitt A, et al. **J Gen Virol** 1996 Jan;77 (Pt 1):17–26

Thymic epithelial neoplasms in transgenic mice expressing SV40 T antigen under the control of an erythroid-specific enhancer. Teitz T, et al. **J Pathol** 1995 Nov;177(3):309–15

Interaction between T antigen and TEA domain of the factor TEF-1 derepresses simian virus 40 late promoter in vitro: identification of T-antigen domains important for transcription control. Berger LC, et al. **J Virol** 1996 Feb; 70(2):1203–12

Murine polyomavirus and simian virus 40 large T antigens produce different structural alterations in viral origin DNA. Bhattacharyya S, et al. **J Virol** 1995 Dec;69(12):7579–85

Polyomavirus middle-T antigen associates with the kinase domain of Src-related tyrosine kinases. Dunant NM, et al. **J Virol** 1996 Mar;70(3):1323–30

The major transcriptional transactivation domain of simian virus 40 large T antigen associates nonconcurrently with multiple components of the transcriptional preinitiation complex. Johnston SD, et al. **J Virol** 1996 Feb; 70(2):1191–202

Sequences flanking the pentanucleotide T-antigen binding sites in the polyomavirus core origin help determine selectivity of DNA replication. Li L, et al. **J Virol** 1995 Dec;69(12):7570–8

Mechanisms of simian virus 40 T-antigen activation by phosphorylation of threonine 124. McVey D, et al. **J Virol** 1996 Jun;70(6):3887–93

Simian virus 40 large T antigen alters the phosphorylation state of the RB-related proteins p130 and p107. Stubdal H, et al. **J Virol** 1996 May;70(5):2781–8

An N-terminal deletion mutant of simian virus 40 (SV40) large T antigen oligomerizes incorrectly on SV40 DNA but retains the ability to bind to DNA polymerase alpha and replicate SV40 DNA in vitro. Weisshart K, et al. **J Virol** 1996 Jun;70(6):3509–16

Association of p300 and CBP with simian virus 40 large T antigen. Eckner R, et al. **Mol Cell Biol** 1996 Jul; 16(7):3454–64

Inhibition of cell proliferation by C/EBP alpha occurs in many cell types, does not require the presence of p53 or Rb, and is not affected by large T-antigen. Hendricks-Taylor LR, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4726–33

Unwinding of the third strand of a DNA triple helix, a novel activity of the SV40 large T-antigen helicase. Kopel V, et al. **Nucleic Acids Res** 1996 Jan 15;24(2):330–5

The viral oncoproteins Ad5 E1A, HPV16 E7 and SV40 TAg bind a common region of the TBP-associated factor-110. Mazzarelli JM, et al. **Oncogene** 1995 Nov 2;11(9):1859–64

Purified JC virus T antigen derived from insect cells preferentially interacts with binding site II of the viral core origin under replication conditions. Bollag B, et al. **Virology** 1996 Apr 1;218(1):81–93

Simian virus 40 large-T bypasses the translational block imposed by the phosphorylation of eIF-2 alpha. Swaminathan S, et al. **Virology** 1996 May 1;219(1):321–3

[The characteristics of the transport into the nucleus of conjugates with normal and mutant nucleophilic sequences] Barbul AI, et al. **Tsitologiia** 1995;37(12):1223–9 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

SV40 large T antigen interferes with adult myosin heavy chain expression, but not with differentiation of human satellite cells. Mouly V, et al. **Exp Cell Res** 1996 Jun 15; 225(2):268–76

ANTIGENS, POLYOMAVIRUS TRANSFORMING

PHYSIOLOGY

A model for the T-antigen-induced structural alteration of the SV40 replication origin based upon experiments with specific probes for bent, straight, and unwound DNA. Han FX, et al. **Biochemistry** 1996 Jun 18;35(24):7993-8001

p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Shibata MA, et al. **Cancer Res** 1996 Jul 1;56(13):2998-3003

Inhibition of c-ras reactivates thyroglobulin synthesis in middle-T transformed thyroid cells. Di Jeso B, et al. **Cell Growth Differ** 1995 Oct;6(10):1315-9

Mutation of p53 is not a prerequisite for immortalization of human fibroblasts by SV40 T antigen. Moorwood K, et al. **Exp Cell Res** 1996 Mar 15;223(2):308-13

The SV40 T-antigen induces premature apoptotic mammary gland involution during late pregnancy in transgenic mice. Tzeng YJ, et al. **FEBS Lett** 1996 Feb 19;380(3):215-8

Alterations of the thymic selection process in transgenic mice expressing SV40 large T antigen. Lee WH, et al. **Int J Cancer** 1996 Jul 29;67(3):399-404

Activation and nuclear translocation of mitogen-activated protein kinases by polyomavirus middle-T or serum depend on phosphatidylinositol 3-kinase. Urich M, et al. **J Biol Chem** 1995 Dec 8;270(49):29286-92

Suppression of platelet-derived growth factor alpha- and beta-receptor mRNA levels in human fibroblasts by SV40 T/t antigen. Wang JL, et al. **J Cell Physiol** 1996 Jan; 166(1):12-21

BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control. Harris KF, et al. **J Virol** 1996 Apr;70(4):2378-86

The block of adipocyte differentiation by a C-terminally truncated, but not by full-length, simian virus 40 large tumor antigen is dependent on an intact retinoblastoma susceptibility protein family binding domain. Higgins C, et al. **J Virol** 1996 Feb;70(2):745-52

Elements of the polyomavirus replication origin required for homologous recombination mediated by large T antigen. Laurent S, et al. **J Virol** 1995 Nov;69(11):7304-8

Functional implications of mutations within polyomavirus large T antigen Rb-binding domain: effects on pRb and p107 binding in vitro and immortalization activity in vivo. Pilon AA, et al. **J Virol** 1996 Jul;70(7):4457-65

The inhibition of cultured myoblast differentiation by the simian virus 40 large T antigen occurs after myogenin expression and Rb up-regulation and is not exerted by transformation-competent cytoplasmic mutants. Tedesco D, et al. **J Virol** 1995 Nov;69(11):6947-57

SV40 large T antigen-induced inhibition of terminal differentiation of primary skeletal muscle cells is associated with a block in the expression of MyoD and myogenin. Van De Klundert FA, et al. **Mol Biol Rep** 1994-95; 20(3):143-8

Role of pRb-related proteins in simian virus 40 large-T-antigen-mediated transformation. Zalvide J, et al. **Mol Cell Biol** 1995 Oct;15(10):5800-10

Compensatory apoptosis in response to SV40 large T antigen expression in the liver. Allemand I, et al. **Oncogene** 1995 Dec 21;11(12):2583-90

Urokinase-type plasminogen activator gene regulation by polyomavirus middle-T antigen. Besser D, et al. **Oncogene** 1995 Dec 7;11(11):2383-91

Induction of c-myc mediated apoptosis in SV40-transformed rat fibroblasts. Lenahan MK, et al. **Oncogene** 1996 May 2;12(9):1847-54

Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Martin DC, et al. **Oncogene** 1996 Aug 1;13(3):569-76

Fas-dependent apoptosis is impaired by SV40 T-antigen in transgenic liver. Rouquet N, et al. **Oncogene** 1995 Sep 21; 11(6):1061-7

Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Ewald D, et al. **Science** 1996 Sep 6;273(5280):1384-6

Reduced levels of alpha1(XI) procollagen mRNA in SV40-transformed cells. Sompayrac L, et al. **Virology** 1996 Apr 15;218(2):412-6

ANTIGENS, PROTOZOAN

The effect of the length of a malarial epitope on its antigenicity and immunogenicity in an epitope presentation system using the Pseudomonas aeruginosa outer membrane protein OprF as the carrier. Wong RS, et al. **FEMS Microbiol Lett** 1996 Jul 1;140(2-3):209-14

Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys. Hui GS, et al. **Infect Immun** 1996 May;64(5):1502-9

Utility of recombinant flagellar calcium-binding protein for serodiagnosis of Trypanosoma cruzi infection. Godsel LM, et al. **J Clin Microbiol** 1995 Aug;33(8):2082-5

rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. Badaró R, et al. **J Infect Dis** 1996 Mar;173(3):758-61

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1 Egan AF, et al. **J Infect Dis** 1996 Mar;173(3):765-9

Detection and characterization by immunoblot analysis of potentially diagnostic Leishmania infantum polypeptides in human visceral leishmaniasis. Cardeñosa N, et al. **Parasite Immunol** 1995 Oct;17(10):509-16

Human V delta 2+ gamma delta T-cell tolerance to foreign antigens of Toxoplasma gondii. Hara T, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5136-40

The effect of temperature on the stability of the synthetic SPf(66)n malaria vaccine. López MC, et al. **Vaccine** 1995 Sep;13(13):1180-2

ADMINISTRATION & DOSAGE

Peritoneal macrophages from C57BL/6 mice orally immunized with Toxoplasma gondii antigens in association with cholera toxin possess an enhanced ability to inhibit parasite multiplication. Bourguin I, et al. **FEMS Immunol Med Microbiol** 1995 Oct;12(2):121-6

Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Burghaus PA, et al. **Infect Immun** 1996 Sep;64(9):3614-9

Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Daly TM, et al. **Infect Immun** 1996 Jul;64(7):2602-8

ANALYSIS

In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas' heart disease. Bellotti G, et al. **Am Heart J** 1996 Feb;131(2):301-7

Detection of Plasmodium vivax and Plasmodium falciparum circumsporozoite antigen in anopheline mosquitoes collected in southern Thailand. Rattanarithikul R, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):114-21

Identification of antigens of pathogenic free-living amoebae by protein immunoblotting with rabbit immune and human sera. Powell EL, et al. **Clin Diagn Lab Immunol** 1994 Sep; 1(5):493-9

Leishmania amazonensis: cultivation and characterization of axenic amastigote-like organisms. Hodgkinson VH, et al. **Exp Parasitol** 1996 Jun;83(1):94-105

Specialized surface adaptations of Giardia lamblia. Aley SB, et al. **Infect Agents Dis** 1995 Sep;4(3):161-6 (32 ref.)

Characterization and immunoprotective properties of a monoclonal antibody against the major oocyst wall protein of Eimeria tenella. Karim MJ, et al. **Infect Immun** 1996 Apr;64(4):1227-32

Citrate synthase purified from Tetrahymena mitochondria is identical with Tetrahymena 14-nm filament protein. Kojima H, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):189-95

Evaluation of GiardEIA kit for giardiasis diagnosis. Boghdadi AM, et al. **J Egypt Soc Parasitol** 1995 Dec; 25(3):625-30

Comparison between the prospect Cryptosporidium Microtiter Assay and the immunofluorescent test in the diagnosis of cryptosporidiosis. Boghdadi AM. **J Egypt Soc Parasitol** 1996 Apr;26(1):243-7

Detection of Cryptosporidium antigen in stool samples among diarrhoeic children. Hassan MM, et al. **J Egypt Soc Parasitol** 1995 Dec;25(3):599-606

Plasmodium falciparum rhoptry proteins of 140/130/110 kd (Rhop-H) are located in an electron lucent compartment in the neck of the rhoptries. Sam-Yellowe TY, et al. **J Eukaryot Microbiol** 1995 May-Jun;42(3):224-31

An assay for the identification of antigens recognized by cytotoxic T cells, based on transient transfection of COS cells. Toye P, et al. **J Immunol Methods** 1995 Nov 16; 187(1):95-101

Reactivity of various leishmanial antigens in a direct agglutination test and their value in differentiating post-kala azar dermal leishmaniasis from leprosy and other skin conditions. El Harith A, et al. **J Med Microbiol** 1996 Feb;44(2):141-6

Toxoplasma gondii: appearance of specific markers during the development of tissue cysts in vitro. Lane A, et al. **Parasitol Res** 1996;82(4):340-6

The FML (Fucose Mannose Ligand) of Leishmania donovani. a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar. de Sousa CB, et al. **Rev Soc Bras Med Trop** 1996 Mar-Apr; 29(2):153-63

Patterns of Cryptosporidium antigen and oocyst excretion in calves studied by reverse passive haemagglutination and light microscopy. Farrington M, et al. **Vet Parasitol** 1995 Nov;60(1-2):7-16

Cryptosporidium parvum oocyst antigens recognized by sera from infected asymptomatic adult cattle. Lorenzo MJ, et al. **Vet Parasitol** 1995 Nov;60(1-2):17-25

Identification of an immunodominant 40 kDa merozoite antigen common to the Australian T and Dixie vaccine strains of Babesia bovis and the development of diagnostic tests specific for these strains. Molloy JB, et al. **Vet Parasitol** 1995 Dec;60(3-4):229-40

Giardiasis in travellers: evaluation of an antigen-capture ELISA for the detection of Giardia lamblia-antigen in stool. Jelinek T, et al. **Z Gastroenterol** 1996 Apr; 34(4):237-40

[Detection of Toxoplasma antigens and antibodies in mice infected with different strains of Toxoplasma gondii] Lee YH, et al. **Korean J Parasitol** 1995 Sep;33(3):201-10 (Eng. Abstr.) **(Kor)**

[Detection of fecal Cryptosporidium parvum antigens using an ELISA technique] Weitz JC. **Rev Med Chil** 1995 Mar; 123(3):330-3 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

The release of the variant surface protein of Giardia to its soluble isoform is mediated by the selective cleavage of the conserved carboxy-terminal domain. Papanastasiou P, et al. **Biochemistry** 1996 Aug 6;35(31):10143-8

Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects. Barral A, et al. **Int J Dermatol** 1995 Jul;34(7):474-9

Interconnection between organellar functions, development and drug resistance in the protozoan parasite, Toxoplasma gondii. Tomavo S, et al. **Int J Parasitol** 1995 Nov; 25(11):1293-9

BLOOD

Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). Aribot G, et al. **Am J Trop Med Hyg** 1996 May;54(5):449-57

Toxoplasma gondii surface antigen-1 in sera of HIV-infected patients as an indicator of reactivated toxoplasmosis. Letillois MF, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):899-903

Serological reactivity against cyst and tachyzoite antigens of Toxoplasma gondii determined by FAST-ELISA. Zhang YW, et al. **J Clin Pathol** 1995 Oct;48(10):908-11

T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. Krzych U, et al. **J Immunol** 1995 Oct 15;155(8):4072-7

Serological diagnosis of visceral leishmaniasis by a dot-enzyme immunoassay for the detection of a Leishmania donovani-related circulating antigen. Senaldi G, et al. **J Immunol Methods** 1996 Jun 14;193(1):9-15

Sensitivity of antigen ELISA test for detecting Trypanosoma evansi antigen in horses in the subtropical area of Argentina. Monzón CM, et al. **J Parasitol** 1995 Oct; 81(5):806-8

Detection by Western blot of four antigens characterizing acute clinical leishmaniasis due to Leishmania infantum. Marty P, et al. **Trans R Soc Trop Med Hyg** 1995 Nov-Dec; 89(6):690-1

Fine specificity of immune responses to epitopic sequences in synthetic peptides containing B and T epitopes from the conserved Plasmodium falciparum blood-stage antigens. Chatterjee S, et al. **Vaccine** 1995;13(15):1474-81

CHEMISTRY

Identification and characterization of Neospora caninum tachyzoite antigens useful for diagnosis of neosporosis. Bjerkas I, et al. **Clin Diagn Lab Immunol** 1994 Mar; 1(2):214-21

A conserved peptide sequence of the Plasmodium falciparum circumsporozoite protein and antipeptide antibodies inhibit Plasmodium berghei sporozoite invasion of Hep-G2 cells and protect immunized mice against P. berghei sporozoite challenge. Chatterjee S, et al. **Infect Immun** 1995 Nov; 63(11):4375-81

Efficient binding of reduced peptide bond pseudopeptides to major histocompatibility complex class I molecule. Guichard G, et al. **J Biol Chem** 1995 Nov 3;270(44):26057-9

A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes. Bottius E, et al. **J Immunol** 1996 Apr 15; 156(8):2874-84

The SAG2 antigen of Toxoplasma gondii and the 31-kDa surface antigen of Sarcocystis muris share similar sequence features. Cesbron-Delauw MF. **Parasitol Res** 1995; 81(5):444-5

DIAGNOSTIC USE

Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. Singh S, et al. **J Parasitol** 1995 Dec;81(6):1000-3

Use of a recombinant Trypanosoma cruzi protein antigen to monitor cure of Chagas disease. Guevara AG, et al. **Trans R Soc Trop Med Hyg** 1995 Jul-Aug;89(4):447-8

Evaluation of three serological tests for the detection of antiamebic antibodies applied to sera of patients from an area endemic for amebiasis. Lotter H, et al. **Trop Med Parasitol** 1995 Sep;46(3):180-2

GENETICS

Nitrocellulose immunoblotting for identification and molecular gene cloning of Eimeria maxima antigens that stimulate lymphocyte proliferation. Bumstead JM, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):524-30

A new cysteine-rich protein-encoding gene family in Giardia duodenalis. Chen N, et al. **Gene** 1996 Feb 22;169(1):33-8

Sequence, codon usage and cysteine periodicity of the SerH1 gene and in the encoded surface protein of Tetrahymena thermophila. Deak JC, et al. **Gene** 1995 Oct 16;164(1):163-6

Expression of genes encoding two major Theileria annulata merozoite surface antigens in Escherichia coli and a Salmonella typhimurium aroA vaccine strain. d'Oliveira C, et al. **Gene** 1996 Jun 12;172(1):33-9

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage

vaccine candidate for Plasmodium falciparum malaria. Tine JA, et al. **Infect Immun** 1996 Sep;64(9):3833–44

Identification of neutralization and diagnostic epitopes on PIM, the polymorphic immunodominant molecule of Theileria parva. Toye P, et al. **Infect Immun** 1996 May; 64(5):1832–8

Seroprevalence and specificity of human responses to the Plasmodium falciparum rhoptry protein Rhop–3 determined by using a C–terminal recombinant protein. Yang JC, et al. **Infect Immun** 1996 Sep;64(9):3584–91

Giardia lamblia: identification and characterization of a variant–specific surface protein gene family. Nash TE, et al. **J Eukaryot Microbiol** 1995 Sep–Oct;42(5):604–9

Analysis of a repeat–containing family of Giardia lamblia variant–specific surface protein genes: diversity through gene duplication and divergence. Yang YM, et al. **J Eukaryot Microbiol** 1995 Sep–Oct;42(5):439–44

COS cell expression cloning of Pfg377, a Plasmodium falciparum gametocyte antigen associated with osmiophilic bodies. Alano P, et al. **Mol Biochem Parasitol** 1995 Nov; 74(2):143–56

Merozoite surface antigen 2 (MSA–2) gene of Plasmodium falciparum strains from India. Bhattacharya P, et al. **Mol Biochem Parasitol** 1995 Oct;74(1):125–7

Sequence analysis of apical membrane antigen 1 (AMA–1) of Plasmodium cynomolgi bastianelli. Dutta S, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):267–70

Extensive polymorphism at the Gp63 locus in field isolates of Leishmania peruviana. Espinoza JR, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):203–13

The Leishmania promastigote surface antigen 2 complex is differentially expressed during the parasite life cycle. Handman E, et al. **Mol Biochem Parasitol** 1995 Nov; 74(2):189–200

A direct and rapid sequencing strategy for the Plasmodium falciparum antigen gene gp190/MSA1. Pan W, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):241–4

Cloning of a bradyzoite–specific gene of Toxoplasma gondii encoding a cytoplasmic antigen. Parmley SF, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):253–7

Selection of diversity at putative glycosylation sites in the immunodominant merozoite/piroplasm surface antigen of Theileria parasites. Shiels BR, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):149–62

Structure and sequence variation of the genes encoding the polymorphic, immunodominant molecule (PIM), an antigen of Theileria parva recognized by inhibitory monoclonal antibodies. Toye P, et al. **Mol Biochem Parasitol** 1995 Jul; 73(1–2):165–77

Sequence variations in the non–repetitive regions of the liver stage–specific antigen–1 (LSA–1) of Plasmodium falciparum from field isolates. Yang C, et al. **Mol Biochem Parasitol** 1995 May;71(2):291–4

Naked DNA for malaria vaccines [news] Fricker J. **Mol Med Today** 1996 Mar;2(3):91

Characterization of genomic clones encoding two microneme antigens of Sarcocystis muris (Apicomplexa). Klein H, et al. **Parasitol Res** 1996;82(3):230–7

Variant antigens and endothelial receptor adhesion in Plasmodium falciparum. Gardner JP, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3503–8

The 5' coding region of Paramecium surface antigen genes controls mutually exclusive transcription. Leeck CL, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2838–43

Serum and colostrum antibody responses induced by jet–injection of sheep with DNA encoding a Cryptosporidium parvum antigen. Jenkins M, et al. **Vaccine** 1995 Dec;13(17):1658–64

Mapping of two overlapping linear epitopes in Pfg27 recognized by Plasmodium falciparum transmission–blocking monoclonal antibodies. Ploton IN, et al. **Vaccine** 1995 Sep;13(13):1161–9

[Sequence analysis of apical membrane antigen I from a Plasmodium falciparum isolate collected from Mengpeng Township, Yunnan Province] Zhang L, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(3):203–8 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Serum antibodies to Trypanosoma cruzi antigens in Atacameños patients from highland of northern Chile. González J, et al. **Acta Trop** 1996 Feb;60(4):225–36

Cross–reactive epitope among proteins in Plasmodium falciparum Maurer's clefts and primate leukocytes and platelets. Klotz FW, et al. **Am J Trop Med Hyg** 1996 Jun; 54(6):655–9

Studies on cryopreservation of Toxoplasma gondii and its antigenicity in mice. Lin DB, et al. **Am J Trop Med Hyg** 1995 Oct;53(4):392–6

Parasitized erythrocyte membrane antigens of Plasmodium brasilianum: relationships with the ring–infected erythrocyte surface antigen of Plasmodium falciparum. Sulzer AJ, et al. **Am J Trop Med Hyg** 1995 Dec; 53(6):618–23

Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein–1 in protecting Papua New Guinean children from malaria morbidity. al–Yaman F, et al. **Am J Trop Med Hyg** 1996 May;54(5):443–8

Characterization of helper T cell responses against rhoptry–associated protein 1 (RAP–1) of babesial parasites. Brown WC, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:128–35

Nucleic acid malaria vaccines. Current status and potential. Hoffman SL, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:88–94 (11 ref.)

Asymptomatic malaria parasitaemia and seroreactivities to Plasmodium falciparum antigens in blood donors from Ibadan, south–western Nigeria. Achidi EA, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):601–10

Visceral leishmaniasis in Ethiopia. I. Cross–sectional leishmanin skin test in an endemic locality. Ali A, et al. **Ann Trop Med Parasitol** 1993 Apr;87(2):157–61

Detection of anti–Plasmodium falciparum antibodies directed against a repetitive peptide of the gametocyte antigen Pfs2400 in malaria patients in Brazil. Marrelli MT, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):593–99

Prevalence of antibodies to the repeat epitope of the circumsporozoite protein of Plasmodium vivax in San Luis Potosi, Mexico. Mota J, et al. **Arch Med Res** 1996 Summer; 27(2):233–6

Characterization of cell–mediated responses to Eimeria acervulina antigens. Martin A, et al. **Avian Dis** 1995 Jul–Sep;39(3):538–47

Antigen–specific Il–4– and IL–10–secreting CD4+ lymphocytes increase in vivo susceptibility to Trypanosoma cruzi infection. Barbosa de Oliveira LC, et al. **Cell Immunol** 1996 May 25;170(1):41–53

Activation of nonspecific cytotoxic cells with a multiple antigenic peptide: specificity and requirements for receptor crosslinkage. Jaso–Friedmann L, et al. **Cell Immunol** 1996 Jun 15;170(2):195–201

Nitrocellulose immunoblotting for identification and molecular gene cloning of Eimeria maxima antigens that stimulate lymphocyte proliferation. Bumstead JM, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):524–30

Immunologic cross–reactivity between structural proteins of human T–cell lymphotropic virus type I and the blood stage of Plasmodium falciparum. Lal RB, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):5–10

Experimental immunization against cutaneous leishmaniasis using Leishmania major subcellular fractions alone or in combination with Phlebotomus duboscqi gut antigens. Mbati PA, et al. **East Afr Med J** 1995 Aug;72(8):519–22

Cytotoxic T lymphocytes to Plasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania. Lalvani A, et al. **Eur J Immunol** 1996 Apr;26(4):773–9

Plasmodium falciparum: differential parasite growth inhibition mediated by antibodies to the antigens Pf332 and Pf155/RESA. Ahlborg N, et al. **Exp Parasitol** 1996 Mar; 82(2):155–63

Antibody response in dogs experimentally infected with Leishmania infantum: infection course antigen markers. Carrera L, et al. **Exp Parasitol** 1996 Mar;82(2):139–46

Conservation of neutralizing determinants between the sporozoite surface antigens of Theileria annulata and Theileria parva. Knight P, et al. **Exp Parasitol** 1996 Apr; 82(3):229–41

Immunological characterization and expression in Escherichia coli and baculovirus systems of a Trypanosoma vivax antigen detected in the blood of infected animals. Masake RA, et al. **Exp Parasitol** 1995 Dec;81(4):536–45

Toxoplasma gondii: characterization of a monoclonal antibody recognizing antigens of 36 and 38 kDa with acid phosphatase activity located in dense granules and rhoptries. Metsis A, et al. **Exp Parasitol** 1995 Dec; 81(4):472–9

Babesia bigemina: identification of B cell epitopes associated with parasitized erythrocytes. Vidotto O, et al. **Exp Parasitol** 1995 Dec;81(4):491–500

Establishment of T–helper type 1– and T–helper type 2–like human Toxoplasma antigen–specific T–cell clones. Däubener W, et al. **Immunology** 1995 Sep;86(1):79–84

Comparative evaluation of somatic & excretory–secretory antigens of Entamoeba histolytica in serodiagnosis of human amoebiasis by ELISA. Pal S, et al. **Indian J Med Res** 1996 Jul;104:152–6

Plasmodium falciparum stimuli for human gammadelta T cells are related to phosphorylated antigens of mycobacteria. Behr C, et al. **Infect Immun** 1996 Aug; 64(8):2892–6

Babesia bovis rhoptry–associated protein 1 is immunodominant for T helper cells of immune cattle and contains T–cell epitopes conserved among geographically distant B. bovis strains. Brown WC, et al. **Infect Immun** 1996 Aug;64(8):3341–50

Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Debard N, et al. **Infect Immun** 1996 Jun;64(6):2158–66

Cytokines and antibody subclass associated with protective immunity against blood–stage malaria in mice vaccinated with the C terminus of merozoite surface protein 1 plus a novel adjuvant. De Souza JB, et al. **Infect Immun** 1996 Sep;64(9):3532–6

Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Handman E, et al. **Infect Immun** 1995 Nov;63(11):4261–7

Identification of T–cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA–1) in an adult population exposed to malaria. Lal AA, et al. **Infect Immun** 1996 Mar;64(3):1054–9

Serological analysis of antigenic heterogeneity of Giardia lamblia variant surface proteins. Müller N, et al. **Infect Immun** 1996 Apr;64(4):1385–90

Conservation of the sporozoite p67 vaccine antigen in cattle–derived Theileria parva stocks with different cross–immunity profiles. Nene V, et al. **Infect Immun** 1996 Jun;64(6):2056–61

CD4+ T–helper lymphocyte responses against Babesia bigemina rhoptry–associated protein I. Rodríguez SD, et al. **Infect Immun** 1996 Jun;64(6):2079–87

Epitopes recognized by human T lymphocytes in the ROP2 protein antigen of Toxoplasma gondii. Saavedra R, et al. **Infect Immun** 1996 Sep;64(9):3858–62

A recombinant protein based on the Trypanosoma cruzi metacyclic trypomastigote 82–kilodalton antigen that induces and effective immune response to acute infection. Santori F R, et al. **Infect Immun** 1996 Apr;64(4):1093–9

Human T–cell activation by 14– and 18–kilodalton nuclear proteins of Leishmania infantum. Suffia I, et al. **Infect Immun** 1995 Oct;63(10):3765–71

Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Taylor RR, et al. **Infect Immun** 1995 Nov;63(11):4382–8

Seroprevalence and specificity of human responses to the Plasmodium falciparum rhoptry protein Rhop–3 determined by using a C–terminal recombinant protein. Yang JC, et al. **Infect Immun** 1996 Sep;64(9):3584–91

Antigens released at schizont burst stimulate Plasmodium falciparum–specific CD4+ T cells from non–exposed donors: potential for cross–reactive memory T cells to cause disease. Currier J, et al. **Int Immunol** 1995 May; 7(5):821–33

Irradiated sporozoite vaccine induces HLA–B8–restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. Wizel B, et al. **J Exp Med** 1995 Nov 1; 182(5):1435–45

Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen–specific IFN–gamma response and increased production of T helper 2 cytokines. Krishnan L, et al. **J Immunol** 1996 Jan 15;156(2):644–52

MHC class I–dependent presentation of exoerythrocytic antigens to CD8+ T lymphocytes is required for protective immunity against Plasmodium berghei. White KL, et al. **J Immunol** 1996 May 1;156(9):3374–81

Identification of Leishmania chagasi antigens recognized by human lymphocytes. Jeronimo SM, et al. **J Infect Dis** 1995 Oct;172(4):1055–60

An immunohistochemical method for detecting bradyzoite antigen (BAG5) in Toxoplasma gondii–infected tissues cross–reacts with a Neospora caninum bradyzoite antigen. McAllister MM, et al. **J Parasitol** 1996 Apr;82(2):354–5

Trypanosoma rangeli: epimastigote immunogenicity and cross–reaction with Trypanosoma cruzi. Saldaña A, et al. **J Parasitol** 1996 Apr;82(2):363–6

Prevalence of antibodies to potential malaria vaccine antigens in an endemic area of the State of Rondônia (Brazil). Balthazar–Guedes HC, et al. **Mem Inst Oswaldo Cruz** 1995 Jul–Aug;90(4):511–2

Advances toward the development of an asexual blood stage MSP–1 vaccine of Plasmodium vivax. Levitus G, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:81–4 (13 ref.)

Naturally acquired antibodies against the major merozoite surface coat protein (MSP–1) of Plasmodium falciparum acquired by residents in an endemic area of Colombia. Terrientes ZI, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:55–61

Aspects of immunity for the AMA–1 family of molecules in humans and non–human primates malarias. Thomas AW, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:67–70

Epitope tagging of flagellar proteins. Diener DR. **Methods Cell Biol** 1995;47:545–50

Induction of Plasmodium falciparum sporozoite–neutralizing antibodies upon vaccination with recombinant Pfs16 vaccinia virus and/or recombinant Pfs16 protein produced in yeast. Moelans II, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):179–92

Characterisation and reactivity of a glycidic antigenic component in Toxoplasma gondii. Zotti C, et al. **New Microbiol** 1996 Apr;19(2):97–105

Immunogens containing sequences from antigen Pf332 induce Plasmodium falciparum–reactive antibodies which inhibit parasite growth but not cytoadherence. Ahlborg N, et al. **Parasite Immunol** 1995 Jul;17(7):341–52

Cellular and humoral immune responses to recombinant antigens in sheep infected with Toxoplasma gondii. Coughlan SN, et al. **Parasite Immunol** 1995 Sep;17(9):465–8

The combined epidermal growth factor–like modules of Plasmodium yoelii Merozoite Surface Protein–1 are required for a protective immune response to the parasite. Ling IT, et al. **Parasite Immunol** 1995 Aug;17(8):425–33

Immunity to Plasmodium berghei exoerythrocytic forms derived from irradiated sporozoites. Chatterjee S, et al. **Parasitol Res** 1996;82(4):297–303

Detection of an "epimastigote–like" intracellular stage of Trypanosoma cruzi. Faucher JF, et al. **Parasitol Res** 1995; 81(5):441–3

Characterization and comparison of merozoite antigens of different Babesia canis isolates by serological and immunological investigations. Hauschild S, et al. **Parasitol Res** 1995;81(8):638–42

Electron microscopical investigation of surface alterations

on Giardia lamblia trophozoites after exposure to a cytotoxic monoclonal antibody. Hemphill A, et al. **Parasitol Res** 1996;82(3):206–10

The role of MHC- and non-MHC-associated genes in determining the human immune response to malaria antigens. Riley EM. **Parasitology** 1996;112 Suppl:S39–51 (78 ref.)

Entamoeba histolytica: detection of coproantigens by purified antibody in the capture sandwich ELISA. Urdaneta H, et al. **Rev Inst Med Trop Sao Paulo** 1994 Nov–Dec; 36(6):539–45

Trypanosoma cruzi cytosolic alkaline antigens (FI) induce polyclonal activation in murine normal B cells. Montes CL, et al. **Scand J Immunol** 1996 Aug;44(2):93–100

Humoral immune responses to the Plasmodium falciparum antigen Pf155 RESA in adults with differential clinical conditions from an Indian zone where malaria is endemic. Biswas S, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):219–27

[NANP]19–5.1. A malaria vaccine field trial in Nigerian children. Reber-Liske R, et al. **Trop Geogr Med** 1995; 47(2):61–3

Evaluation of circumsporozoite antibody testing as a sero-epidemiological tool for the detection of Plasmodium falciparum infection in non-immune travelers. Jelinek T, et al. **Trop Med Parasitol** 1995 Sep;46(3):154–7

Relationship of antibodies to soluble Plasmodium falciparum antigen (Pf70) and protection against malaria in a human population living under intense transmission in Kinshasa, Zaire. Tshefu K, et al. **Trop Med Parasitol** 1995 Jun; 46(2):72–6

Theileria annulata sporozoite antigen fused to hepatitis B core antigen used in a vaccination trial. Boulter NR, et al. **Vaccine** 1995 Sep;13(13):1152–60

Serum and colostrum antibody responses induced by jet-injection of sheep with DNA encoding a Cryptosporidium parvum antigen. Jenkins M, et al. **Vaccine** 1995 Dec;13(17):1658–64

Effect of surface antigen-1 (SA-1) immune lymphocyte subsets and naive cell subsets in protecting scid mice from initial and persistent infection with Cryptosporidium parvum. Tatalick LM, et al. **Vet Immunol Immunopathol** 1995 Jul;47(1–2):43–55

Conservation of merozoite membrane and apical complex B cell epitopes among Babesia bigemina and Babesia bovis strains isolated in Brazil. Madruga CR, et al. **Vet Parasitol** 1996 Jan;61(1–2):21–30

Identification of an immunodominant 40 kDa merozoite antigen common to the Australian T and Dixie vaccine strains of Babesia bovis and the development of diagnostic tests specific for these strains. Molloy JB, et al. **Vet Parasitol** 1995 Dec;60(3–4):229–40

Exoantigens of an attenuated strain of Babesia bovis used as a vaccine against bovine babesiosis. Patarroyo JH, et al. **Vet Parasitol** 1995 Oct;59(3–4):189–99

Attempts to protect severe combined immunodeficient (scid) mice with antibody enriched for reactivity to Cryptosporidium parvum surface antigen-1. Tatalick LM, et al. **Vet Parasitol** 1995 Jul;58(4):281–90

[Exploration on experimental conditions of dot-ELISA for Trichomonas vaginalis using intact parasite antigen-monoclonal antibody detecting system] Yu C, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):138–41 (Eng. Abstr.) **(Chi)**

[Antigenic variation and the problem of vaccines against African trypanosomes] Pays E. **Bull Mem Acad R Med Belg** 1995;150(1–2):123–31; discussion 131–5 (Eng. Abstr.) **(Fre)**

[Immune response against Plasmodium falciparum merozoite antigens and HLA restriction] Dieye A, et al. **Med Trop (Mars)** 1995;55(4 Suppl):69–70 **(Fre)**

[Vaccines blocking transmission (letter)] Sauerwein R. **Med Trop (Mars)** 1995;55(4 Suppl):118 **(Fre)**

[Towards a vaccination against malaria] Ambroise-Thomas P. **Rev Med Interne** 1995;16(9):717–23 (48 ref.) (Eng. Abstr.) **(Fre)**

[The proliferative response of T cells against cruzipain in chronic chagasic cardiopathy] Pedrosa RC, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):331–9 (Eng. Abstr.) **(Por)**

[Delayed hypersensitivity to Trypanosoma cruzi antigen. I — Experimental study in rabbits] Teixeira AR. **Rev Soc Bras Med Trop** 1995 Jul–Sep;28(3):249–57 (Eng. Abstr.) **(Por)**

[Delayed hypersensitivity to Trypanosoma cruzi antigen. II—Use of the skin test with T12E antigen for the diagnosis of Chagas disease] Teixeira AR, et al. **Rev Soc Bras Med Trop** 1995 Jul–Sep;28(3):259–65 (Eng. Abstr.) **(Por)**

[Delayed hypersensitivity to Trypanosoma cruzi antigen. III—Sensitivity of the skin test with T12E antigen in the diagnosis of Chagas disease in hospitalized patients] Teixeira AR, et al. **Rev Soc Bras Med Trop** 1995 Jul–Sep; 28(3):267–71 (Eng. Abstr.) **(Por)**

ISOLATION & PURIFICATION

A rapid dipstick antigen capture assay for the diagnosis of falciparum malaria. WHO Informal Consultation on Recent Advances in Diagnostic Techniques and Vaccines for Malaria. **Bull World Health Organ** 1996;74(1):47–54

Trypanosoma cruzi: a 52-kDa protein sharing sequence homology with glutathione S-transferase is localized in parasite organelles morphologically resembling reservosomes. Ouaissi MA, et al. **Exp Parasitol** 1995 Dec; 81(4):453–61

Rapid diagnosis of Entamoeba infection by using Entamoeba and Entamoeba histolytica stool antigen detection kits. Haque R, et al. **J Clin Microbiol** 1995 Oct;33(10):2558–61

Humoral and mucosal IgA antibody response to a recombinant 52-kDa cysteine-rich portion of the Entamoeba histolytica galactose-inhibitable lectin correlates with detection of native 170-kDa lectin antigen in serum of patients with amebic colitis. Abou-el-Magd I, et al. **J Infect Dis** 1996 Jul;174(1):157–62

[Detection of Giardia antigens in feces by immunoenzymatic method; advantages and disadvantages of commercially available diagnostic kits] Bitkowska E, et al. **Med Dosw Mikrobiol** 1995;47(1–2):95–9 (Eng. Abstr.) **(Pol)**

METABOLISM

Plasmodium falciparum: effects of membrane modulating agents on direct binding of rhoptry proteins to human erythrocytes. Ndengele MM, et al. **Exp Parasitol** 1995 Sep; 81(2):191–201

Contact-dependent transfer of the galactose-specific lectin of Entamoeba histolytica to the lateral surface of enterocytes in culture. Leroy A, et al. **Infect Immun** 1995 Nov;63(11):4253–60

Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages. Prina E, et al. **J Immunol** 1996 Jun 1;156(11):4318–27

Surface localization, regulation, and biologic properties of the 96-kDa alcohol/aldehyde dehydrogenase (EhADH2) of pathogenic Entamoeba histolytica. Flores BM, et al. **J Infect Dis** 1996 Jan;173(1):226–31

Processing of the Plasmodium chabaudi chabaudi AS merozoite surface protein 1 in vivo and in vitro. O'Dea KP, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):111–9

An iron-binding Trypanosoma cruzi urinary antigen. Corral RS, et al. **Parasite** 1995 Dec;2(4):339–44

Antigenic alteration in major piroplasm surface proteins of Theileria sergenti during infection. Zhuang WZ, et al. **Vet Parasitol** 1995 Dec;60(3–4):191–8

PHYSIOLOGY

Role of the Plasmodium falciparum mature-parasite-infected erythrocyte surface antigen (MESA/PfEMP-2) in malarial infection of erythrocytes. Magowan C, et al. **Blood** 1995 Oct 15;86(8):3196–204

Upregulation of ICAM-1, IL-1 and reactive oxygen intermediates (ROI) by exogenous antigens from Plasmodium falciparum parasites in vitro, and of sICAM-1 in the acute phase of malaria. Prada J, et al. **J Chemother** 1995 Oct;7(5):424–6

THERAPEUTIC USE

A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Chang SP, et al. **Infect Immun** 1996 Jan;64(1):253–61

Responses to vaccination in strains of mice that differ in susceptibility to coccidiosis. Rose ME, et al. **Infect Immun** 1996 Jan;64(1):246–52

Exploitation of parasite derived antigen in therapeutic success of human cutaneous leishmaniasis in Brazil. Monjour L, et al. **Mem Inst Oswaldo Cruz** 1994 Jul–Sep;89(3):479–83

URINE

Usefulness of the detection of Toxoplasma gondii antigens in AIDS patients. Fachado A, et al. **Rev Inst Med Trop Sao Paulo** 1994 Nov–Dec;36(6):525–9

ANTIGENS, SURFACE

Determination of the efficiency of K99-F41 fimbrial antigen vaccine in newborn calves. Yano T, et al. **Braz J Med Biol Res** 1995 Jun;28(6):651–4

Peripheral blood cell preparation influences the level of expression of leukocyte cell surface markers as assessed with quantitative multicolor flow cytometry. Islam D, et al. **Cytometry** 1995 Jun 15;22(2):128–34

Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14+L1+ monocyte derived cells. Rugtveit J, et al. **Gut** 1995 Sep;37(3):367–73

Tissue expression, structure and function of the murine Ly-6 family of molecules. Gumley TP, et al. **Immunol Cell Biol** 1995 Aug;73(4):277–96 (111 ref.)

Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys. Hui GS, et al. **Infect Immun** 1996 May;64(5):1502–9

Variant colony surface antigenic phenotypes within mycoplasma strain populations: implications for species identification and strain standardization. Rosengarten R, et al. **J Clin Microbiol** 1996 Jan;34(1):149–58

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1 Egan AF, et al. **J Infect Dis** 1996 Mar;173(3):765–9

Ultrastructural studies of the megakaryoblastic leukemias of Down syndrome. Zipursky A, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):341–7

Monoclonal antibodies against antigens exposed on the surface of vegetative forms and spores of Myxococcus virescens. Martinelli F, et al. **New Microbiol** 1995 Oct; 18(4):399–407

Studies on the expression of T-(Gal beta (1–3) GalNAc alpha 1-O-R) and T-like antigens in normal and pathologic human and rat urothelium. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;176:7–46 (188 ref.)

[K-antigen as a marker of Klebsiella pneumoniae and its use in clinical and epidemiological analysis (literature review)] Priamukhina NS, et al. **Klin Lab Diagn** 1996 Mar–Apr; (2):47–9 (29 ref.) **(Rus)**

ANALYSIS

The pattern of HMB-45 antibody staining in compound Spitz nevi. Bergman R, et al. **Am J Dermatopathol** 1995 Dec; 17(6):542–6

Enhanced membrane expression of the 52 kDa Ro(SS-A) and La(SS-B) antigens by human keratinocytes induced by TNF alpha. Dörner T, et al. **Ann Rheum Dis** 1995 Nov; 54(11):904–9

Malaria cytoadherence: binding sites for an anti-adhesive antibody on Plasmodium falciparum-infected erythrocytes. Land KM, et al. **Ann Trop Med Parasitol** 1995 Dec; 89(6):685–6

Alteration of Chlamydia trachomatis biologic behavior in synovial membranes. Suppression of surface antigen production in reactive arthritis and Reiter's syndrome. Nanagara R, et al. **Arthritis Rheum** 1995 Oct;38(10):1410–7

Identification of the S-Endo 1 endothelial-associated antigen. Bardin N, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):210–6

CD26 and CD31 surface antigen expression on human colostral T cells. Bertotto A, et al. **Biol Neonate** 1995; 68(4):259–63

Abnormal expression of integrin alpha 6 beta 4 in cervical intraepithelial neoplasia. Aplin JD, et al. **Br J Cancer** 1996 Jul;74(2):240–5

Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium. Rothenberger S, et al. **Brain Res** 1996 Mar 11;712(1):117–21

Flow cytometric identification of cell surface markers on cultured human colonic cell lines using monoclonal antibodies. Han JS, et al. **Cancer** 1995 Jul 15;76(2):195–200

Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen. Murphy GP, et al. **Cancer** 1996 Aug 15;78(4):809–18

Production of a novel monoclonal antibody, JT-95, which can detect antigen of thyroid carcinoma. Takeyama H, et al. **Cancer Res** 1996 Apr 15;56(8):1817–22

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of EDTA-extracted cell-surface protein antigens is a simple and reproducible method for typing Clostridium difficile. Ogunsola FT, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S327–30

Expression of a cell surface antigen recognized by the monoclonal antibody AUA1 in bladder carcinoma: an immunohistochemical study. Zorzos J, et al. **Eur Urol** 1995; 28(3):251–4

Localization of 7H6 tight junction-associated antigen along the cell border of vascular endothelial cells correlates with paracellular barrier function against ions, large molecules, and cancer cells. Satoh H, et al. **Exp Cell Res** 1996 Feb 1;222(2):269–74

Apoptosis is associated with reduced expression of complement regulatory molecules, adhesion molecules and other receptors on polymorphonuclear leucocytes: functional relevance and role in inflammation. Jones J, et al. **Immunology** 1995 Dec;86(4):651–60

Identification of a molecule uniquely expressed on a gamma/delta TCR+ subset within bovine intestinal intraepithelial lymphocytes. Parsons KR, et al. **Immunology** 1996 Jan;87(1):64–70

Specialized surface adaptations of Giardia lamblia. Aley SB, et al. **Infect Agents Dis** 1995 Sep;4(3):161–6 (32 ref.)

A novel co-stimulatory T cell antigen co-expressed on renal cell carcinoma. Labuda T, et al. **Int Immunol** 1995 Sep; 7(9):1425–32

Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumours. Andrews PW, et al. **Int J Cancer** 1996 Jun 11;66(6):806–16

A monoclonal antibody KIS-1 recognizing a new membrane antigen on human squamous-cell carcinoma. Toh U, et al. **Int J Cancer** 1996 May 29;66(5):600–6

Immunophenotypic features of epiplexus cells and their response to interferon gamma injected intraperitoneally in postnatal rats. Lu J, et al. **J Anat** 1994 Aug;185 (Pt 1):75–84

The distribution of Na+,K(+)-ATPase and 5A11 antigen in apical microvilli of the retinal pigment epithelium is unrelated to alpha-spectrin. Rizzolo LJ, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3623–33

Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. Onrust SV, et al. **J Clin Invest** 1996 Jan 1;97(1):54–64

Identification of a mouse protein homologous to the human CD6 T cell surface protein and sequence of the corresponding cDNA. Robinson WH, et al. **J Immunol**

1995 Nov 15;155(10):4739–48

A simplified method for the coordinate examination of apoptosis and surface phenotype of murine lymphocytes. Douglas RS, et al. **J Immunol Methods** 1995 Dec 27; 188(2):219–28

A simple immunomagnetic bead–based technique for the detection of surface molecules capable of inducing T cell functional polarisation. Rubbi CP, et al. **J Immunol Methods** 1996 Jun 10;192(1–2):157–64

Production and immunohistochemical characterization of specific antibody to oviductal fluid of miniature 'Shiba' goat. Kimura J, et al. **J Vet Med Sci** 1995 Jun;57(3):427–31

Levels of CAF7 (CD98) expression correlate with the complete remission duration in childhood acute leukemia. Taskov H, et al. **Leuk Res** 1996 Jan;20(1):75–9

Cell surface expression of the multidrug resistance P–glycoprotein (P–170) as detected by monoclonal antibody MRK–16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. Sievers EL, et al. **Leukemia** 1995 Dec;9(12):2042–8

Identification of an inducible surface molecule specific to fusing macrophages. Saginario C, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12210–4

Stratified squamous epithelia produce mucin–like glycoproteins. Gipson IK, et al. **Tissue Cell** 1995 Aug; 27(4):397–404

Simple mucin–type carbohydrate antigens (T, sialosyl–T, Tn and sialosyl–Tn) in breast carcinogenesis. Schmitt FC, et al. **Virchows Arch** 1995;427(3):251–8

[Leukocyte surface antigen] Nakahara K. **Nippon Rinsho** 1996 Jun;54(6):1536–41 (8 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Alpha 6 beta 4 integrin and newly deposited laminin–1 and laminin–5 form the adhesion mechanism of gastric carcinoma. Continuous expression of laminins but not that of collagen VII is preserved in invasive parts of the carcinomas: implications for acquisition of the invading phenotype. Tani T, et al. **Am J Pathol** 1996 Sep; 149(3):781–93

Clonal heterogeneity in membrane expression of CD5 in a patient with chronic lymphocytic leukemia. Hashimoto S, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:482–4

The human hair follicle: glycoprotein–related antigenic profile of distinct keratinocyte populations in vivo and their alterations in vitro. Schön MP, et al. **Arch Dermatol Res** 1995;287(6):591–8

Expression of apogens and engulfens during programmed cell death in the nervous system of the chick embryo. Takashita N, et al. **Arch Histol Cytol** 1995 Jun;58(2):243–8

The release of the variant surface protein of Giardia to its soluble isoform is mediated by the selective cleavage of the conserved carboxy–terminal domain. Papanastasiou P, et al. **Biochemistry** 1996 Aug 6;35(31):10143–8

High expression of NKR–P1 is not an absolute requirement for natural killer activity in BDIX rats. Pinard D, et al. **Cancer Immunol Immunother** 1996 Jan;42(1):15–23

Synaptotagmin I, synaptobrevin II, and syntaxin I are coexpressed in rat and gerbil pinealocytes. Redecker P. **Cell Tissue Res** 1996 Mar;283(3):443–54

Alterations in phenotype and cell–surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM–CSF or rhGM–CSF. Schmid I, et al. **Cytometry** 1995 Jun 15;22(2):103–10

Cloning and sequence analysis of human breast epithelial antigen BA46 reveals an RGD cell adhesion sequence presented on an epidermal growth factor–like domain. Couto JR, et al. **DNA Cell Biol** 1996 Apr;15(4):281–6

CTX, a novel molecule specifically expressed on the surface of cortical thymocytes in Xenopus. Chrétien I, et al. **Eur J Immunol** 1996 Apr;26(4):780–91

T cell activation through Thy–1 is associated with the expression of a surface protein (p100) on a subset of CD4 cells. Lehuen A, et al. **Int Immunol** 1995 Apr;7(4):607–16

Expression pattern of the cell adhesion molecules. E–cadherin, P–cadherin and alpha 6 beta 4 intergrin is altered in pre–malignant skin tumors of p53–deficient mice. Cano A, et al. **Int J Cancer** 1996 Jan 17;65(2):254–62

Identification and functional differentiation of two type I fatty acid synthases in Brevibacterium ammoniagenes. Stuible HP, et al. **J Bacteriol** 1996 Aug;178(16):4787–93

Direct demonstration of antigenic substitution of Borrelia burgdorferi ex vivo: exploration of the paradox of the early immune response to outer surface proteins A and C in Lyme disease. Montgomery RR, et al. **J Exp Med** 1996 Jan 1;183(1):261–9

Induction of heat–stable antigen expression by phagocytosis is involved in in vitro activation of unprimed CTL by macrophages. De Bruijn ML, et al. **J Immunol** 1996 Apr 15;156(8):2686–92

Phenotypic change and proliferation of murine Kupffer cells by colony–stimulating factors. Hashimoto S, et al. **J Interferon Cytokine Res** 1996 Mar;16(3):237–43

Dynamic expression of cell–surface antigens probed with Candida albicans–specific monoclonal antibodies. Deslauriers N, et al. **Microbiology** 1996 May;142 (Pt 5):1239–48

Expression and quantification of IgG and IgM molecules on the surface of lymphocytes of cattle infected with bovine leukaemia virus. Levkut M, et al. **Res Vet Sci** 1995 Jul; 59(1):45–9

Upregulation of prostate–specific membrane antigen after androgen–deprivation therapy. Wright GL Jr, et al. **Urology** 1996 Aug;48(2):326–34

BLOOD

Elevated levels of the soluble form of bone marrow stromal cell antigen 1 in the sera of patients with severe rheumatoid arthritis. Lee BO, et al. **Arthritis Rheum** 1996 Apr; 39(4):629–37

Loss and shedding of surface markers from the leukemic myeloid monocytic line THP–1 induced to undergo apoptosis. Brown SB, et al. **J Cell Biochem** 1996 Feb; 60(2):246–59

Collagenase and Dispase enzymes disrupt lymphocyte surface molecules. Abuzakouk M, et al. **J Immunol Methods** 1996 Aug 14;194(2):211–6

Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Casciola–Rosen L, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1624–9

Blood group terminology 1995. ISBT Working Party on terminology for red cell surface antigens. Daniels GL, et al. **Vox Sang** 1995;69(3):265–79

CEREBROSPINAL FLUID

Detection of Borrelia burgdorferi–specific antigen in antibody–negative cerebrospinal fluid in neurologic Lyme disease. Coyle PK, et al. **Neurology** 1995 Nov;45(11):2010–5

CHEMISTRY

The variable surface glycolipids of mycobacteria: structures, synthesis of epitopes, and biological properties. Aspinall GO, et al. **Adv Carbohydr Chem Biochem** 1995;51:169–242 (226 ref.)

NMR reinvestigation of the capsular K27 polysaccharide (K27 antigen) from Escherichia coli O8:K27:H–. Jann B, et al. **Carbohydr Res** 1995 Nov 22;277(2):353–8

Cloning and sequence analysis of human breast epithelial antigen BA46 reveals an RGD cell adhesion sequence presented on an epidermal growth factor–like domain. Couto JR, et al. **DNA Cell Biol** 1996 Apr;15(4):281–6

Recombinant prespore–specific antigen from Dictyostelium discoideum is a beta–sheet glycoprotein with a spacer peptide modified by O–linked N–acetylglucosamine. Zachara NE, et al. **Eur J Biochem** 1996 Jun 1;238(2):511–8

Mapping of a surface–exposed, conformational epitope of the P6 protein of Haemophilus influenzae. Bogdan JA Jr, et al. **Infect Immun** 1995 Nov;63(11):4395–401

Variation in repeat number within the alpha C protein of group B streptococci alters antigenicity and protective epitopes. Gravekamp C, et al. **Infect Immun** 1996 Sep; 64(9):3576–83

A novel cell surface polysaccharide in Pseudomonas putida WCS358, which shares characteristics with Escherichia coli K antigens, is not involved in root colonization. de Weger LA, et al. **J Bacteriol** 1996 Apr;178(7):1955–61

Identification of the border between fibronectin type III homologous repeats 2 and 3 of the neural cell adhesion molecule L1 as a neurite outgrowth promoting and signal transducing domain. Appel F, et al. **J Neurobiol** 1995 Nov; 28(3):297–312

Crystallization and preliminary X–ray analysis of Borrelia burgdorferi outer surface protein A (OspA) complexed with a murine monoclonal antibody Fab fragment. Li H, et al. **J Struct Biol** 1995 Nov–Dec;115(3):335–7

The SAG2 antigen of Toxoplasma gondii and the 31–kDa surface antigen of Sarcocystis muris share similar sequence features. Cesbron–Delauw MF. **Parasitol Res** 1995; 81(5):444–5

Prediction of the antigenic sites of the cystic fibrosis transmembrane conductance regulator protein by molecular modelling. Gallet X, et al. **Protein Eng** 1995 Aug; 8(8):829–34

DIAGNOSTIC USE

Use of recombinant antigens of Borrelia burgdorferi in serologic tests for diagnosis of lyme borreliosis. Magnarelli LA, et al. **J Clin Microbiol** 1996 Feb;34(2):237–40

GENETICS

Multiple expression of Ly–6C and accumulation of a Ly–6C pre–mRNA in activated macrophages involved in rejection of an allografted tumor. Takikawa O, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):247–53

Cloning of the murine counterpart of the tumor–associated antigen H–L6: epitope mapping of the human and murine L6 antigens. Edwards CP, et al. **Biochemistry** 1995 Oct 3;34(39):12653–60

Kell typing by allele–specific PCR (ASP). Avent ND, et al. **Br J Haematol** 1996 Jun 1;93(3):728–30

Assignment of the gene for gp 130RB13–6 (Pdnpno) to rat chromosome band 1p12 by in situ hybridization. Koelsch BU, et al. **Cytogenet Cell Genet** 1996;73(3):228

Molecular cloning and characterization of a transmembrane surface antigen in human cells. Li E, et al. **Eur J Biochem** 1996 Jun 15;238(3):631–8

Rat HPC–1/syntaxin 1A and syntaxin 1B interrupt intracellular membrane transport and inhibit secretion of the extracellular matrix in embryonic cells of an amphibian. Komazaki S, et al. **Exp Cell Res** 1995 Nov;221(1):11–8

A new cysteine–rich protein–encoding gene family in Giardia duodenalis. Chen N, et al. **Gene** 1996 Feb 22;169(1):33–8

Sequence, codon usage and cysteine periodicity of the SerH1 gene and in the encoded surface protein of Tetrahymena thermophila. Deak JC, et al. **Gene** 1995 Oct 16;164(1):163–6

Expression of genes encoding two major Theileria annulata merozoite surface antigens in Escherichia coli and a Salmonella typhimurium aroA vaccine strain. d'Oliveira C, et al. **Gene** 1996 Jun 12;172(1):33–9

Epidermal surface antigen (MS17S1) is highly conserved between mouse and human. Cho YJ, et al. **Genomics** 1995 May 20;27(2):251–8

Localization and physical mapping of the prostate–specific membrane antigen (PSM) gene to human chromosome 11. Rinker–Schaeffer CW, et al. **Genomics** 1995 Nov 1; 30(1):105–8

Antigenic topology of the P29 surface lipoprotein of Mycoplasma fermentans: differential display of epitopes results in high–frequency phase variation. Theiss P, et al. **Infect Immun** 1996 May;64(5):1800–9

The structural gene encoding human enterotoxigenic Escherichia coli PCFO20 is homologous to that for porcine 987P. Viboud GI, et al. **Infect Immun** 1996 Apr; 64(4):1233–9

Giardia lamblia: identification and characterization of a variant–specific surface protein gene family. Nash TE, et al. **J Eukaryot Microbiol** 1995 Sep–Oct;42(5):604–9

Analysis of a repeat–containing family of Giardia lamblia variant–specific surface protein genes: diversity through gene duplication and divergence. Yang YM, et al. **J Eukaryot Microbiol** 1995 Sep–Oct;42(5):439–44

An ospA frame shift, identified from DNA in Lyme arthritis synovial fluid, results in an outer surface protein A that does not bind protective antibodies. Fikrig E, et al. **J Immunol** 1995 Dec 15;155(12):5700–4

Identification and characterization of a novel surface antigen gene induced in mast cells activated through the high affinity IgE receptor. Pirozzi G, et al. **J Immunol** 1995 Dec 15;155(12):5811–8

A powerful new technique for isolating genes encoding cell surface antigens using retroviral expression cloning. Zannettino AC, et al. **J Immunol** 1996 Jan 15;156(2):611–20

A modified screening method for pcDNA–1 expression libraries which is applicable to both surface and intracellular antigens. Cloning of a colon carcinoma antigen. Grimm T, et al. **J Immunol Methods** 1995 Oct 26;186(2):305–12

Sequence analysis of ospA genes shows homogeneity within Borrelia burgdorferi sensu stricto and Borrelia afzelii strains but reveals major subgroups within the Borrelia garinii species. Will G, et al. **Med Microbiol Immunol (Berl)** 1995 Aug;184(2):73–80

Merozoite surface antigen 2 (MSA–2) gene of Plasmodium falciparum strains from India. Bhattacharya P, et al. **Mol Biochem Parasitol** 1995 Oct;74(1):125–7

Sequence analysis of apical membrane antigen 1 (AMA–1) of Plasmodium cynomolgi bastianelli. Dutta S, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):267–70

The Leishmania promastigote surface antigen 2 complex is differentially expressed during the parasite life cycle. Handman E, et al. **Mol Biochem Parasitol** 1995 Nov; 74(2):189–200

Sequence and immunogenicity of the 23–kDa transmembrane antigen of Schistosoma haematobium. Inal J, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):217–21

A direct and rapid sequencing strategy for the Plasmodium falciparum antigen gene gp190/MSA1. Pan W, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):241–4

Prostate–specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Carter RE, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):749–53

The 5' coding region of Paramecium surface antigen genes controls mutually exclusive transcription. Leeck CL, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2838–43

[Cloning of a cluster of genes encoding coli–surface antigen 6(CS6) of human enterotoxigenic E. coli] Yang X, et al. **Wei Sheng Wu Hsueh Pao** 1995 Oct;35(5):390–3 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Generation and characterization of monoclonal antibodies specific to surface antigens of human trophoblast cells. Yoshiki T, et al. **Am J Reprod Immunol** 1995 Sep; 34(3):148–55

Evaluation of antibodies reactive with porcine lymphocytes and lymphoma cells in formalin–fixed, paraffin–embedded, antigen–retrieved tissue sections. Tanimoto T, et al. **Am J Vet Res** 1996 Jun;57(6):853–9

Detection of antibodies to surface antigens of Angiostrongylus cantonensis by ELISA. Chang JH, et al. **Ann Trop Med Parasitol** 1995 Oct;89(5):569–72

The gut associated addressins: lymphocyte homing in the gut. De Keyser F, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):25–39 (65 ref.)

Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML–BFM–87. Creutzig U, et al. **Blood** 1995 Oct 15; 86(8):3097–108

Protection against metastasis by immunization with an allogeneic lymphocyte antigen. Egawa K, et al.

Cancer Immunol Immunother 1995 Dec;41(6):384–8

NKR-P1+ cells localize selectively in Rat 9L gliosarcomas but have reduced cytolytic function. Chambers WH, et al. **Cancer Res** 1996 Aug 1;56(15):3516–25

On the validity of "functional affinity" determination for antibodies binding to cell surface antigens or other polyvalent antigens. Mattes MJ. **Cancer Res** 1995 Dec 1; 55(23 Suppl):5733s–5735s

Serum antibody response to the superficial and released components of Helicobacter pylori. Bazillou M, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):310–7

Purification of Borrelia burgdorferi outer surface protein A (OspA) and analysis of antibody binding domains. Jiang W, et al. **Clin Diagn Lab Immunol** 1994 Jul;1(4):406–12

Cytotoxicity to endothelial cells by sera from aged MRL/lpr/lpr mice is associated with autoimmunity to cell surface heparan sulfate. Dimitriu-Bona A, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):234–40

Expression of cell surface markers and myelin proteins in cultured oligodendrocytes from neonatal brain of rat and mouse: a comparative study. Duchala CS, et al. **Dev Neurosci** 1995;17(2):70–80

Specific detection of anti-cell surface antibodies in herpes gestationis sera. Hashimoto T, et al. **Exp Dermatol** 1996 Apr;5(2):96–101

Monoclonal antibodies recognized bovine leukocyte antigens used in immuno-scanning electron microscopy. Levkut M, et al. **Folia Histochem Cytobiol** 1995;33(3):179–81

Diagnostic relevance of abortion-associated human embryonic antigen expressed on the cell surface of tumour promoter-treated Bloom syndrome cells. Shiraishi Y, et al. **Hum Reprod** 1995 Jul;10(7):1694–701

Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. Iakoubov L, et al. **Immunol Lett** 1995 Jul–Aug;47(1–2):147–9

Modulation of WC1, a lineage-specific cell surface molecule of gamma/delta T cells augments cellular proliferation. Hanby-Flarida MD, et al. **Immunology** 1996 May; 88(1):116–23

Induction of immune responses to functional determinants of a cell surface streptococcal antigen. Todryk SM, et al. **Immunology** 1996 Jan;87(1):55–63

Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Handman E, et al. **Infect Immun** 1995 Nov;63(11):4261–7

Dominant recognition of a Borrelia burgdorferi outer surface protein A peptide by T helper cells in patients with treatment-resistant Lyme arthritis. Kamradt T, et al. **Infect Immun** 1996 Apr;64(4):1284–9

Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha. Larsson C, et al. **Infect Immun** 1996 Sep;64(9):3518–23

Identification of surface-exposed linear B-cell epitopes of the nonfimbrial adhesin CS31A of Escherichia coli by using overlapping peptides and antipeptide antibodies. Méchin MC, et al. **Infect Immun** 1996 Sep;64(9):3555–64

Serological analysis of antigenic heterogeneity of Giardia lamblia variant surface proteins. Müller N, et al. **Infect Immun** 1996 Apr;64(4):1385–90

Targeting vaccinia virus-expressed secretory beta subunit of human chorionic gonadotropin to the cell surface induces antibodies. Srinivasan J, et al. **Infect Immun** 1995 Dec; 63(12):4907–11

A strategy for identifying candidate sperm antigens for immunocontraception: isolation of human testis cDNA clones using polyclonal antisera directed against hamster acrosomal membrane preparation. Adoyo PA, et al. **Int J Androl** 1995 Jun;18 Suppl 1:32–8

Immune response of lambs to vaccination with Ostertagia circumcincta surface antigens eliciting bile antibody responses. Wedrychowicz H, et al. **Int J Parasitol** 1995 Sep;25(9):1111–21

Lyme borreliosis in transgenic mice tolerant to Borrelia burgdorferi OspA or B. Fikrig E, et al. **J Clin Invest** 1995 Oct;96(4):1706–14

Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. de Silva AM, et al. **J Exp Med** 1996 Jan 1;183(1):271–5

Generation of a new gamma delta T cell-specific monoclonal antibody (GD3.5). Biochemical comparisons of GD3.5 antigen with the previously described Workshop Cluster 1 (WC1) family. Jones WM, et al. **J Immunol** 1996 May 15;156(10):3772–9

Internalization of human macrophage surface antigens induced by monoclonal antibodies. Audran R, et al. **J Immunol Methods** 1995 Dec 15;188(1):147–54

Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. Schoen RT, et al. **J Infect Dis** 1995 Nov;172(5):1324–9

Development and evaluation of an ELISA to detect Escherichia coli K88 (F4) fimbrial antibody levels. Vazquez F, et al. **J Med Microbiol** 1996 Jun;44(6):453–63

Monoclonal autoantibody SCH94.03, which promotes central nervous system remyelination, recognizes an antigen on the surface of oligodendrocytes. Asakura K, et al. **J Neurosci Res** 1996 Feb 1;43(3):273–281

Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves. Taylor G, et al. **J Virol** 1995 Nov;69(11):6658–64

Human melanoma antigens recognized by T lymphocytes. Kawakami Y, et al. **Keio J Med** 1996 Jun;45(2):100–8 (78 ref.)

Highly expressed human sialyl Lewis antigen on cell surface of streptococcus gallolyticus [letter] Hirota K, et al. **Lancet** 1996 Mar 16;347(9003):760

A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Oeuvray C, et al. **Mem Inst Oswaldo Cruz** 1994; 89 Suppl 2:77–80

Transmission blocking immunity as observed in a feeder system and serological reactivity to Pfs 48/45 and Pfs230 in field sera. Roeffen W, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:13–5

Monoclonal antibodies to cell-specific cell surface carbohydrates in plant cell biology and development. Pennell RI, et al. **Methods Cell Biol** 1995;49:123–41 (61 ref.)

Functional activities of antibodies directed against surface lipoproteins of Borrelia hermsii. Sambri V, et al. **Microbiol Immunol** 1995;39(8):623–7

Sequence and immunogenicity of the 23-kDa transmembrane antigen of Schistosoma haematobium. Inal J, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):217–21

Characterization and comparison of the lytic function of NKR-P1+ and NKR-P1-rat natural killer cell clones established from NKR-P1bright/TCR alpha beta-cell lines. Brissette-Storkus C, et al. **Nat Immun** 1995; 14(2):98–113

Cholinergic-specific glycoconjugates. Whittaker VP, et al. **Neurochem Res** 1995 Nov;20(11):1377–87 (47 ref.)

Electron microscopical investigation of surface alterations on Giardia lamblia trophozoites after exposure to a cytotoxic monoclonal antibody. Hemphill A, et al. **Parasitol Res** 1996;82(3):206–10

Surface antigen cross-linking triggers forced exit of a protozoan parasite from its host. Clark TG, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6825–9

Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Hess J, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1458–63

Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. Madoff LC, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30; 93(9):4131–6

Fc gamma receptor expression on sheep afferent lymph dendritic cells and rapid modulation of cell surface phenotype following Fc gamma receptor engagement in vitro and in vivo. Coughlan SN, et al. **Scand J Immunol** 1996 Jan;43(1):31–8

Inhibition of platelet aggregation by an SLE-derived human hybridoma autoantibody against an activation-dependent antigen. Xu H, et al. **Thromb Haemost** 1995 Oct; 74(4):1152–62

Porcine endothelial cell membrane antigens recognized by human and baboon xenoreactive antibodies during organ perfusion. Lin SS, et al. **Transplant Proc** 1996 Apr;28(2):607

Phenotypic variation of carbohydrate surface antigens and the pathogenesis of Haemophilus influenzae infections. Roche RJ, et al. **Trends Microbiol** 1995 Aug;3(8):304–9 (60 ref.)

Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2. Johnson BJ, et al. **Vaccine** 1995 Aug; 13(12):1086–94

The surface phenotype of swine blood and tissue eosinophil granulocytes. Magyar A, et al. **Vet Immunol Immunopathol** 1995 Aug;47(3–4):273–81

The effects of continuous and intermittent delivery of antigens of Boophilus microplus on the development of murine antibodies. Ehrenhofer C, et al. **Vet Parasitol** 1995 Oct;59(3–4):263–73

Conservation of merozoite membrane and apical complex B cell epitopes among Babesia bigemina and Babesia bovis strains isolated in Brazil. Madruga CR, et al. **Vet Parasitol** 1996 Jan;61(1–2):21–30

Attempts to protect severe combined immunodeficient (scid) mice with antibody enriched for reactivity to Cryptosporidium parvum surface antigen-1. Tatalick LM, et al. **Vet Parasitol** 1995 Jul;58(4):281–90

[Vaccines blocking transmission (letter)] Sauerwein R. **Med Trop (Mars)** 1995;55(4 Suppl):118 **(Fre)**

[Follicular dendritic cells: phenotype, origin and functions] Heinen E. **Pathol Biol (Paris)** 1995 Dec;43(10):848–57 (43 ref.) (Eng. Abstr.) **(Fre)**

[Can monoclonal antibodies to a carcinoma-specific cell surface molecule prevent liver metastasis of human colorectal carcinoma and effectively treat already existing micrometastases?] Burkart C, et al. **Z Gastroenterol** 1996 Jan;34(1):41–2 **(Ger)**

[An analysis of the B-cell epitopes recognized in hypervariable region 1 of hepatitis C virus in chronic persistent hepatitis] Nakamoto Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:117–22 **(Jpn)**

[Preparation and study of properties of anti-idiotypic antibodies, carrying hemagglutinating paratopes of tick-borne encephalitis virus on their surface] Protopopova EV, et al. **Vopr Virusol** 1996 Mar–Apr;41(2):50–3 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

New chlamydial antigen as a serological marker in HIV infection [letter] Ratti G, et al. **Lancet** 1995 Sep 30; 346(8979):912

Isolation of K88 antigen variants (ab, ac, ad) from porcine enterotoxigenic Escherichia coli belonging to different serotypes. González EA, et al. **Microbiol Immunol** 1995; 39(12):937–42

Intra-acrosomal 155,000 dalton protein increases the antigenicity during mouse sperm maturation in the epididymis: a study using a monoclonal antibody MC101. Toshimori K, et al. **Mol Reprod Dev** 1995 Sep;42(1):72–9

METABOLISM

Mechanisms of NK recognition and activation based on lectin-saccharide interactions. Pospisil M, et al. **Adv Exp Med Biol** 1995;371A:307–11

A detergent-sensitive 113-kDa conformer/complex of CD36 exists on the platelet surface. Rhinehart-Jones T, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):115–8

Human red blood cell Wright antigens: a genetic and evolutionary perspective on glycophorin A-band 3 interaction. Huang CH, et al. **Blood** 1996 May 1; 87(9):3942–7

The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cress AE, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):219–28 (67 ref.)

Signal transduction by the alpha 6 beta 4 integrin: distinct beta 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes. Mainiero F, et al. **EMBO J** 1995 Sep 15;14(18):4470–81

Molecular cloning and characterization of a transmembrane surface antigen in human cells. Li E, et al. **Eur J Biochem** 1996 Jun 15;238(3):631–8

The distribution of TM-316-associated surface antigen on polymorphonuclear leucocytes: an immunoelectron microscopic study. Mato TK, et al. **Experientia** 1995 Sep 29;51(9–10):947–52

Adhesion of K88ab to guinea pig erythrocytes: effect on membrane enzyme activities. Caloca MJ, et al. **Infect Immun** 1996 Aug;64(8):3416–8

Porcine 987P glycolipid receptors on intestinal brush borders and their cognate bacterial ligands. Khan AS, et al. **Infect Immun** 1996 Sep;64(9):3688–93

Up-regulation of antigens on alveolar macrophages in quartz exposed rats. Lundahl J, et al. **Inflammation** 1995 Oct; 19(5):543–8

Particle agglutination assay for detection of albumin and IgG binding cell surface components of Helicobacter pylori. Reza AH, et al. **Int J Med Microbiol Virol Parasitol Infect Dis** 1995 Apr; 282(3):255–64

Identification of major and minor chaperone proteins involved in the export of 987P fimbriae. Edwards RA, et al. **J Bacteriol** 1996 Jun;178(12):3426–33

Ca2+ regulates the interaction between synaptotagmin and syntaxin 1. Chapman ER, et al. **J Biol Chem** 1995 Oct 6; 270(40):23667–71

Expression and functional role of syntaxin 1/HPC-1 in pancreatic beta cells. Syntaxin 1A, but not 1B, plays a negative role in regulatory insulin release pathway. Nagamatsu S, et al. **J Biol Chem** 1996 Jan 12;271(2):1160–5

A zinc-binding domain is required for targeting the maternal nuclear protein PwA33 to lampbrush chromosome loops. Bellini M, et al. **J Cell Biol** 1995 Nov;131(3):563–70

Anchorage mediated by integrin alpha6beta4 to laminin 5 (epiligrin) regulates tyrosine phosphorylation of a membrane-associated 80-kD protein. Xia Y, et al. **J Cell Biol** 1996 Feb;132(4):727–40

Human lupus anti-spliceosome A protein autoantibodies bind contiguous surface structures and segregate into two sequential epitope binding patterns. James JA, et al. **J Immunol** 1996 May 15;156(10):4018–26

Internalization of human macrophage surface antigens induced by monoclonal antibodies. Audran R, et al. **J Immunol Methods** 1995 Dec 15;188(1):147–54

Dynamic expression of cell wall proteins of Candida albicans revealed by probes from cDNA clones. Alloush HM, et al. **J Med Vet Mycol** 1996 Mar–Apr;34(2):91–7

Human lymphocytes incubated in vitro share multiple characteristics with geriatric-derived lymphocytes: a potential in vitro model for aging? Tu KY, et al. **Mech Ageing Dev** 1995 Aug 8;82(2–3):105–28

Subcellular localization and topology of the K88 usher FaeD in Escherichia coli. Valent QA, et al. **Mol Microbiol** 1995 Jun;16(6):1243–57

Cell surface changes of hemopoietic cells during normal and leukemic differentiation: an immuno-scanning electron microscopy study. Soligo D, et al. **Scanning Microsc** 1995 Mar;9(1):175–83; discussion 183–4

Platelet-mediated lymphocyte delivery to high endothelial venules. Diacovo TG, et al. **Science** 1996 Jul 12; 273(5272):252–5

A family of murine NK cell receptors specific for target cell MHC class I molecules. Yokoyama WM, et al. **Semin Immunol** 1995 Apr;7(2):89–101 (93 ref.)

Patterns of inflammatory vascular endothelial changes in murine liver grafts. Dahmen U, et al. **Transplantation** 1995 Sep 27;60(6):577–84

PHARMACOLOGY

The outer surface lipoprotein A of Borrelia burgdorferi provides direct and indirect augmenting/co-stimulatory signals for the activation of CD4+ and CD8+ T cells [corrected and republished with original paging, article originally printed in Immunol Lett 1995 Feb;45(1-2):137-42] Simon MM, et al. **Immunol Lett** 1995 Jun;46(3):137-42

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Tjoa B, et al. **Prostate** 1996 Jan;28(1):65-9

PHYSIOLOGY

The 4F2hc surface antigen is necessary for expression of system L-like neutral amino acid-transport activity in C6-BU-1 rat glioma cells: evidence from expression studies in Xenopus laevis oocytes. Bröer S, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):863-70

C-type lectins of natural killer cells: carbohydrate ligands and role in tumour cell lysis. Bezouška K. **Biochem Soc Trans** 1996 Feb;24(1):156-61 (24 ref.)

Distribution of ligand-occupied alpha IIb beta 3 in resting and activated human platelets determined by expression of a novel class of ligand-induced binding site recognized by monoclonal antibody AP6. Nurden P, et al. **Blood** 1996 Aug 1;88(3):887-99

Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion. Izumoto S, et al. **Cancer Res** 1996 Mar 15;56(6):1440-4

Glycosylphosphatidylinositol (GPI)-anchored surface antigens in the allogeneic activation of T cells. Schubert J, et al. **Clin Exp Immunol** 1995 Oct;102(1):199-203

Role of syntaxin in mouse pancreatic beta cells. Martín F, et al. **Diabetologia** 1995 Jul;38(7):860-3

Expression of human NKRP1A by CD34+ immature thymocytes: NKRP1A-mediated regulation of proliferation and cytolytic activity. Poggi A, et al. **Eur J Immunol** 1996 Jun;26(6):1266-72

Evidence that syntaxin 1A is involved in storage in the secretory pathway. Bittner MA, et al. **J Biol Chem** 1996 May 10;271(19):11214-21

ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. Wolfsberg TG, et al. **J Cell Biol** 1995 Oct;131(2):275-8 (22 ref.)

Interferon gamma production by natural killer (NK) cells and NK1.1+ T cells upon NKR-P1 cross-linking. Arase H, et al. **J Exp Med** 1996 May 1;183(5):2391-6

A simple immunomagnetic bead-based technique for the detection of surface molecules capable of inducing T cell functional polarisation. Rubbi CP, et al. **J Immunol Methods** 1996 Jun 10;192(1-2):157-64

Plasma-membrane-bound macromolecules are dynamically aggregated to form non-random codistribution patterns of selected functional elements. Do pattern recognition processes govern antigen presentation and intercellular interactions? Vereb G, et al. **J Mol Recognit** 1995 Jul-Aug; 8(4):237-46 (78 ref.)

Functional impact of syntaxin on gating of N-type and Q-type calcium channels. Bezprozvanny I, et al. **Nature** 1995 Dec 7;378(6557):623-6

RADIATION EFFECTS

Ultraviolet B irradiation and cytomegalovirus infection synergize to induce the cell surface expression of 52-kD/Ro antigen. Zhu J. **Clin Exp Immunol** 1996 Jan; 103(1):47-53

THERAPEUTIC USE

A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Chang SP, et al. **Infect Immun** 1996 Jan;64(1):253-61

Sera from OspA-vaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi. Straubinger RK, et al. **J Clin Microbiol** 1995 Oct;33(10):2745-51

TOXICITY

Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. Schoen RT, et al. **J Infect Dis** 1995 Nov;172(5):1324-9

ANTIGENS, SYNTHETIC see VACCINES, SYNTHETIC

ANTIGENS, T-INDEPENDENT

IMMUNOLOGY

Are polysaccharide antibody responses independent: the T cell enigma? Lane P. **Clin Exp Immunol** 1996 Jul; 105(1):10-1 (16 ref.)

T cell independent antigens. Mond JJ, et al. **Curr Opin Immunol** 1995 Jun;7(3):349-54 (55 ref.)

T cell-independent B cell response to self-monosialogangliosides: primary response monoclonal antibodies. Alfonso M, et al. **Hybridoma** 1995 Jun; 14(3):209-16

The one signal theory of B cell activation revisited: a role for surface immunoglobulin in regulating T-independent antibody responses? Mamchak AA, et al. **Immunol Cell Biol** 1995 Jun;73(3):266-71 (29 ref.)

In vivo interleukin-4 regulation of antibody responses in euthymic and athymic mice to a T-independent antigen (hydroxyethyl starch). Macedo-Soares F, et al. **Int Arch Allergy Immunol** 1996 Jun;110(2):174-81

Bacterial lipoproteins may substitute for cytokines in the humoral immune response to T cell-independent type II antigens. Snapper CM, et al. **J Immunol** 1995 Dec 15; 155(12):5582-9

The role of NK cells during in vivo antigen-specific antibody responses. Wilder JA, et al. **J Immunol** 1996 Jan 1; 156(1):146-52

PHYSIOLOGY

T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Bachmann MF, et al. **Eur J Immunol** 1995 Dec; 25(12):3445-51

ANTIGENS, THY-1

ANALYSIS

Phenotypic, molecular, and functional characterization of human peripheral blood CD34+/THY1+ cells. Humeau L, et al. **Blood** 1996 Feb 1;87(3):949-55

Characterization of tumor-specific cytotoxic effector cells with a novel CD3-/Thy-1+ phenotype. Sabapathy TK, et al. **Cell Immunol** 1995 Nov;166(1):141-53

Thy-1+ dendritic cells express truncated form of POMC mRNA. Farooqui JZ, et al. **Exp Dermatol** 1995 Oct; 4(5):297-301

Optimizing the CD34+ and CD34+Thy-1+ stem cell content of peripheral blood collections. Stewart AK, et al. **Exp Hematol** 1995 Dec;23(14):1619-27

Searching for hematopoietic stem cells. II. The heterogeneity of Thy-1.1(lo)Lin(-/lo)Sca-1+ mouse hematopoietic stem cells separated by counterflow centrifugal elutriation. Uchida N, et al. **Exp Hematol** 1996 Apr;24(5):649-59

Positive and negative regulation of Thy-1 expression on B lymphocytes by IL-4. Louie SW, et al. **Int Immunol** 1995 Sep;7(9):1497-503

Dysregulated expression of the IL-2 receptor beta-chain abrogates development of NK cells and Thy-1+ dendritic epidermal cells in transgenic mice. Suwa H, et al. **Int Immunol** 1995 Sep;7(9):1441-9

Thy1(+) lymphocytes with LAK-like activity are present in rat liver sinusoids. Shimada M. **Kurume Med J** 1995; 42(4):211-20

BIOSYNTHESIS

Expression of Thy-1 antigen in germ-free and conventional piglets. Pospíšil R, et al. **Adv Exp Med Biol** 1995; 371A:453-7

Expression of Thy-1 antigen (CDw90) on adult acute leukemia blast cells [letter] Campos L, et al. **Blood** 1996 Jan 1;87(1):413-4

A new reporter system for detection of retroviral infection. Planelles V, et al. **Gene Ther** 1995 Aug;2(6):369-76

Retinal Thy-1 expression during development. Liu CJ, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1469-73

Developmental regulation of Thy 1.2 rate of synthesis in the mouse cerebellum. Radrizzani M, et al. **J Neurosci Res** 1995 Oct 1;42(2):220-7

CHEMISTRY

Molecular modelling of glycoproteins by homology with non-glycosylated protein domains, computer simulated glycosylation and molecular dynamics. Renouf DV, et al. **Adv Exp Med Biol** 1995;376:37-45

Detection of temporary lateral confinement of membrane proteins using single-particle tracking analysis. Simson R, et al. **Biophys J** 1995 Sep;69(3):989-93

GENETICS

The mouse CD7 gene: identification of a new element common to the human CD7 and mouse Thy-1 promoters. Lee DM, et al. **Immunogenetics** 1996;44(2):108-14

Detection of MspI RFLP in human THY1 gene by the polymerase chain reaction. Fu J, et al. **Jpn J Hum Genet** 1995 Sep;40(3):279-80

IMMUNOLOGY

Thy-1-mediated activation of rat basophilic leukemia cells does not require co-expression of the high-affinity IgE receptor. Dráberová L, et al. **Eur J Immunol** 1995 Sep; 25(9):2428-32

Influence of MHC class I molecules on T-cell proliferation induced by CD3 or Thy-1 stimulation. Amirayan N, et al. **Immunology** 1995 Sep;86(1):71-8

Thy-1-mediated activation of rat mast cells: the role of Thy-1 membrane microdomains. Dráberová L, et al. **Immunology** 1996 Jan;87(1):141-8

A novel anti-Thy-1 (CD90) monoclonal antibody induces apoptosis in mouse malignant T-lymphoma cells in spite of inducing bcl-2 expression. Fujita N, et al. **Int J Cancer** 1996 May 16;66(4):544-50

Effect of acteoside on mesangial proliferation in rat anti-Thy 1 nephritis. Hattori T, et al. **Nippon Jinzo Gakkai Shi** 1996 May;38(5):202-12

METABOLISM

Aggregation of Thy-1 glycoprotein induces tyrosine phosphorylation of different proteins in isolated rat mast cells and rat basophilic leukemia cells. Dráberová L, et al. **Adv Exp Med Biol** 1995;371A:297-301

Expression of CD44 antigen by Langerhans cells and Thy1+ dendritic epidermal cells--ontogenetic variation and its role in migration. Osada A, et al. **Adv Exp Med Biol** 1995; 378:117-9

Peripheral blood CD34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor. Donahue RE, et al. **Blood** 1996 Feb 15;87(4):1644-53

Identification and characterization of novel dermal Thy-1 antigen-bearing dendritic cells in murine skin. Tamaki K, et al. **J Invest Dermatol** 1996 Mar;106(3):571-5

Changes in Thy-1 antigen immunoreactivity in the rat retina during pre- and postnatal development. Schmid S, et al. **Neurosci Lett** 1995 Oct 20;199(2):91-4

PHYSIOLOGY

Thy-1 induced on rat endothelium regulates vascular permeability at sites of inflammation. Ishizu A, et al. **Int Immunol** 1995 Dec;7(12):1939-47

T cell activation through Thy-1 is associated with the expression of a surface protein (p100) on a subset of CD4 cells. Lehuen A, et al. **Int Immunol** 1995 Apr;7(4):607-16

Thy-1-mediated phosphatidylinositol turnover in cultured rat glomerular mesangial cell. Narisawa-Saito M, et al. **J Cell Physiol** 1996 Sep;168(3):705-10

Normal spatial learning despite regional inhibition of LTP in mice lacking Thy-1. Nosten-Bertrand M, et al. **Nature** 1996 Feb 29;379(6568):826-9

An astrocytic binding site for neuronal Thy-1 and its effect on neurite outgrowth. Dreyer EB, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11195-9

[Expression and role of Thy-1 on endothelial cells at sites of inflammation--a novel function of Thy-1; vascular permeability regulation] Ishizu A. **Hokkaido Igaku Zasshi** 1995 Sep;70(5):687-96 (Eng. Abstr.) **(Jpn)**

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE

Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope. Fontenot JD, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):245-60

Studies on the expression of T-(Gal beta (1-3) GalNAc alpha 1-O-R) and T-like antigens in normal and pathologic human and rat urothelium. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;176:7-46 (188 ref.)

ADMINISTRATION & DOSAGE

T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma. Springer GF, et al. **Cancer Detect Prev** 1995;19(4):374-80

ANALYSIS

Flow cytometric analysis of T and Tn epitopes on chronic lymphocytic leukemia cells. Aller CT, et al. **Am J Hematol** 1996 May;52(1):29-38

A simple mucus test for cancer screening. Shamsuddin AM. **Anticancer Res** 1996 Jul-Aug;16(4B):2193-9 (57 ref.)

Thomsen-Friedenreich (T) antigen as marker of myoepithelial and basal cells in the parotid gland, pleomorphic adenomas and adenoid cystic carcinomas. An immunohistological comparison between T and sialosyl-T antigens, alpha-smooth muscle actin and cytokeratin 14. Therkildsen MH, et al. **APMIS** 1995 Jul-Aug; 103(7-8):558-67

Peanut agglutinin (PNA) binding glycoproteins on human urothelial cell lines of different grades of transformation. Duś D, et al. **Arch Immunol Ther Exp (Warsz)** 1995; 43(5-6):273-80

Quantitation of MCA, CA 19.9, CA 125 and TSA levels in lung cancer. Yenisey C, et al. **Biochem Soc Trans** 1995 Nov;23(4):530S

Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Molina R, et al. **Breast Cancer Res Treat** 1995;36(1):41-8

Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation. Cao Y, et al. **Cancer** 1995 Nov 15; 76(10):1700-8

Sialosyl Tn antigen expression is associated with the prognosis of patients with advanced gastric cancer [letter; comment] David L, et al. **Cancer** 1996 Jul 1;78(1):177-8. Comment on: Cancer 1995 Nov 1;76(9):1529-36.

Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients. Villena V, et al. **Cancer** 1996 Aug 15;78(4):736-40

T and Tn pancarcinoma markers: autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast carcinoma immunotherapy. Springer

GF. **Crit Rev Oncog** 1995;6(1):57-85 (220 ref.)

The Thomsen-Friedenreich (T) simple mucin-type carbohydrate antigen in salivary gland carcinomas. Therkildsen MH, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):361-7

Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma. Hasholzner U, et al. **Int J Cancer** 1996 Aug 22;69(4):329-34

Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen. Kishimoto T, et al. **Int J Cancer** 1996 Aug 22;69(4):290-4

A risk score for predicting outcome in patients with gastric cancer, based on stage, sialyl-Tn immunoreactivity and ploidy--a multivariate analysis. Victorzon M, et al. **Int J Cancer** 1996 Jul 17;67(2):190-3

Sialyl Tn antigen is an independent predictor of outcome in patients with gastric cancer. Victorzon M, et al. **Int J Cancer** 1996 Jan 26;65(3):295-300

Sialosyl-Tn antigen as a marker of gastric cancer progression: an international study. Werther JL, et al. **Int J Cancer** 1996 Jun 21;69(3):193-9

CA 50: a tumor marker for gastrointestinal malignancies. Bunworasate U, et al. **J Med Assoc Thai** 1995 May; 78(5):255-70 (155 ref.)

Circadian rhythms of the salivary proliferation markers CA130 and CA125 in clinical health. Portela A, et al. **Rev Esp Fisiol** 1995 Jun;51(2):107-8

T-antigens in primary non-invasive and superficially invasive human urinary bladder tumors: the correlation to tumor recurrence and tumor progression. A mini-review. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;172:45-9 (55 ref.)

Simple mucin-type carbohydrate antigens (T, sialosyl-T, Tn and sialosyl-Tn) in breast carcinogenesis. Schmitt FC, et al. **Virchows Arch** 1995;427(3):251-8

[Blood group antigen expression in papillary carcinoma of the thyroid gland. An immunohistochemical and clinical study of expression of Lewis, ABO and related antigens] Larena A, et al. **Langenbecks Arch Chir** 1996;381(2):102-13 (Eng. Abstr.) **(Ger)**

[Clinical value of carbohydrate antigens, sialyl Lewis-x and sialyl Lewis-a in gastrointestinal cancer] Nakamori S, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):165-71 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Carbohydrate antigens as tumor marker] Ohkura H. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):145-51 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Evaluation of blood-group-related carbohydrate antigens in thyroid neoplasms] Yokota M, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Sep;98(9):1381-6 (Eng. Abstr.) **(Jpn)**

[Biological function of cancer-associated carbohydrate antigens] Kannagi R. **Nippon Rinsho** 1996 Jun;54(6):1551-9 (33 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Expression of mucin carbohydrate antigens (T, Tn and sialyl Tn) and MUC-1 gene product in intraductal papillary-mucinous neoplasm of the pancreas. Terada T, et al. **Am J Clin Pathol** 1996 May;105(5):613-20

Expression of Tn and sialyl-Tn antigens in the neoplastic transformation of uterine cervical epithelial cells. Terasawa K, et al. **Cancer Res** 1996 May 1;56(9):2229-32

Inhibition of mucin synthesis by benzyl-alpha-GalNAc in KATO III gastric cancer and Caco-2 colon cancer cells. Byrd JC, et al. **Eur J Cancer** 1995;31A(9):1498-505

Prognostic value of an assessment of ABH(0) isoantigens and Thomsen-Friedenreich (TF) antigen expression in patients with urinary bladder tumours. Dobrowolski ZF, et al. **Int Urol Nephrol** 1995;27(4):395-404

BLOOD

Serum CA 242 and CEA detect different patients with recurrent colorectal cancer. Carpelan-Holmström MA, et al. **Anticancer Res** 1996 Mar-Apr;16(2):981-6

Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer. Lindmark G, et al. **Anticancer Res** 1996 Mar-Apr;16(2):895-8

Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9. Lundin J, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2181-6

Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients. Spila A, et al. **Anticancer Res** 1996 Jul-Aug; 16(4B):2241-7

Immunoluminometric assay for determining CA 72-4 in patients with gynecological tumors. Heinze T, et al. **Clin Chem** 1996 Mar;42(3):472-4

Differences in serum tumor markers between colon and rectal cancer. Comparison of CA 242 and carcinoembryonic antigen. Carpelan-Holmström MA, et al. **Dis Colon Rectum** 1996 Jul;39(7):799-805

Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer. Carpelan-Holmström M, et al. **Eur J Cancer** 1996 Jun;32A(7):1156-61

A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700. van Dalen A, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):377-84

Circulating blood group related carbohydrate antigens as tumour markers. Orntoft TF, et al. **Glycoconj J** 1995 Jun; 12(3):200-5 (41 ref.)

Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Tamakoshi K, et al. **Gynecol Oncol** 1996 Jul;62(1):67-72

Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer. Safi F, et al. **Int J Biol Markers** 1995 Apr-Jun;10(2):100-6

CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA. Torres M, et al. **Int J Biol Markers** 1995 Apr-Jun;10(2):94-9

Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA. Pezzilli R, et al. **Ital J Gastroenterol** 1995 Jul-Aug;27(6):296-9

The necessity for T-cryptantigen activation screening in babies with necrotising enterocolitis. Kirsten GF, et al. **S Afr Med J** 1996 May;86(5):546-8

Suspected extragonadal germ-cell cancer syndrome presenting with an orbital mass and elevation of serum CEA, CA 19-9 and CA50 levels. Cruz JJ, et al. **Tumori** 1995 Sep-Oct;81(5):378-80

Detection of tumor-associated antigens in sera of canine cancer patients by monoclonal antibodies generated against canine mammary carcinoma cells. Wang J, et al. **Vet Immunol Immunopathol** 1995 Oct;48(3-4):193-207

[Significance of CEA and CA242 in the diagnosis of colorectal carcinoma] Wu J, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov;17(6):438-40 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Sialyl-Tn-KLH, glycoconjugate analysis and stability by high-pH anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD). Jorge P, et al. **Glycobiology** 1995 Dec;5(8):759-64

Monoclonal antibody LU-BCRU-G7 against a breast tumour-associated glycoprotein recognizes the disaccharide Gal beta 1-3GlcNAc. Rye PD, et al. **Glycobiology** 1995 Jun;5(4):385-9

Analysis of serine/threonine-linked oligosaccharides derived by alkaline-borohydride treatment of mucin glycoproteins electroblotted onto membranes: comparison of the saccharide profiles of the 390 kDa and 350 kDa forms of epitectin. Zhu Q, et al. **Glycoconj J** 1995 Oct;12(5):639-44

GENETICS

Prognostic significance of T antigen expression in patients with gastric carcinoma. Chung YS, et al. **Cancer** 1996 May 1;77(9):1768-73

IMMUNOLOGY

Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Adluri S, et al. **Cancer Immunol Immunother** 1995 Sep;41(3):185-92

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Reddish MA, et al. **Cancer Immunol Immunother** 1996 Jun;42(5):303-9

Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Zhang S, et al. **Cancer Res** 1996 Jul 15; 56(14):3315-9

Murine bispecific antibody 1A10 directed to human transferrin receptor and a 42-kDa tumor-associated glycoprotein. Shi T, et al. **Clin Immunol Immunopathol** 1996 Feb;78(2):188-95

Monoclonal antibodies recognising sialyl-Tn: production and application to immunochemistry. Devine PL, et al. **Dis Markers** 1995 Aug;12(3):175-86

MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Finn OJ, et al. **Immunol Rev** 1995 Jun;145:61-89 (112 ref.)

Spectral differences between epitopes in the cronomes of salivary CA130 and CA125. Portela A, et al. **In Vivo** 1995 Jul-Aug;9(4):341-6

Concurrent immunohistochemical staining of tumor-infiltrating lymphocytes and carcinoma-associated T (Thomsen-Friedenreich)/Tn antigens in human breast carcinoma. Wang BL, et al. **J Histochem Cytochem** 1996 Feb;44(2):187-91

Thomsen-Friedenreich and PK antigens in pig-to-human xenotransplantation. Cairns T, et al. **Transplant Proc** 1996 Apr;28(2):795-6

ISOLATION & PURIFICATION

Molecular cloning and expression of cDNA encoding human macrophage C-type lectin. Its unique carbohydrate binding specificity for Tn antigen. Suzuki N, et al. **J Immunol** 1996 Jan 1;156(1):128-35

METABOLISM

Comparative study of CA242 and CA19-9 in chronic pancreatitis. Furuya N, et al. **Br J Cancer** 1996 Feb; 73(3):372-6

Sialosyl Tn antigen expression is associated with the prognosis of patients with advanced gastric cancer [see comments] Yamada T, et al. **Cancer** 1995 Nov 1; 76(9):1529-36. Comment in: Cancer 1996 Jul 1;78(1):177-8.

Binding studies on the combining site of a GalNAc alpha 1-->-specific lectin with Thomsen-Friedenreich activity prepared from green marine algae Codium fragile subspecies tomentosoides. Wu AM, et al. **Eur J Biochem** 1995 Oct 1;233(1):145-51

Prognostic implications of Sialosyl-Tn antigen expression in sinonasal intestinal-type adenocarcinoma. Franchi A, et al. **Eur J Cancer B Oral Oncol** 1996 Mar;32B(2):123-7

Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: a retrospective case-control study. Itzkowitz SH, et al. **Gastroenterology** 1996 Mar; 110(3):694-704

Chronome of urinary 6-sulfoxy-melatonin excretion, circulating CA125, cancer progression and therapeutic response. Cornélissen G, et al. **In Vivo** 1995 Jul-Aug; 9(4):375-8

Simple mucin-type carbohydrates in normal and malignant human endometrium. Ravn V, et al. **Int J Gynecol Pathol** 1995 Apr;14(2):158-66

Imparting exquisite specificity to peanut agglutinin for the tumor-associated Thomsen-Friedenreich antigen by redesign of its combining site. Sharma V, et al. **J Biol Chem** 1996 Aug 30;271(35):21209-13

Immunohistochemical expression of sialyl Tn, sialyl Lewis a, sialyl Lewis a-b-, and sialyl Lewis x in primary tumor and metastatic lymph nodes in human gastric cancer. Ikeda Y, et al. **J Surg Oncol** 1996 Jul;62(3):171-6

A comparative study of peanut agglutinin and amaranthin binding to human urinary bladder tumor glycoproteins. Langkilde NC, et al. **Scand J Urol Nephrol Suppl** 1995; 172:57-64

[Carbohydrate antigens in carcinoma invasion and metastasis] Izumi Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb; 97(2):140-4 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of carbohydrate antigen in lung cancers] Miyake M. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):160-4 (19 ref.) **(Jpn)**

[Biological malignant potential and carbohydrate antigens in breast cancer] Narita T, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):172-6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Prognosis of colorectal cancer and sialyl-lea antigen] Watanabe M, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb; 97(2):177-81 (13 ref.) **(Jpn)**

PHYSIOLOGY

Possible roles of tumor-associated carbohydrate antigens. Fukuda M. **Cancer Res** 1996 May 15;56(10):2237-44 (92 ref.)

Adherence of Salmonella typhimurium to Caco-2 cells: identification of a glycoconjugate receptor. Giannasca KT, et al. **Infect Immun** 1996 Jan;64(1):135-45

[Functions of mucin molecules in gastrointestinal cancer] Imai K, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb; 97(2):152-9 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Carbohydrate antigens as cell adhesion molecules] Kannagi R. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):131-9 (43 ref.) (Eng. Abstr.) **(Jpn)**

[Antisense strategies in studies on the role of sugar chains in phenotype expression of neoplasms] Ugorski M. **Postepy Hig Med Dosw** 1995;49(1):77-84 (22 ref.) (Eng. Abstr.) **(Pol)**

URINE

Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, M-CSF and CA130. Xu F, et al. **In Vivo** 1995 Jul-Aug;9(4):407-12

ANTIGENS, VIRAL

T cell epitopes of bovine respiratory syncytial virus attachment glycoprotein. Rankin R, et al. **Biochem Soc Trans** 1995 Aug;23(3):483S

An ELISA for porcine reproductive and respiratory syndrome: production of antigen of high quality. Cho HJ, et al. **Can J Vet Res** 1996 Apr;60(2):89-93

Antigenic heterogeneity of avian paramyxoviruses of serotype 2 ("Yucaipa-like") isolated from domestic and wild birds in Israel. Lipkind M, et al. **Comp Immunol Microbiol Infect Dis** 1995 Jun;18(3):189-207

Superantigenic characteristics of mouse mammary tumor viruses play a critical role in susceptibility to infection in mice. Pucillo CE, et al. **Immunol Res** 1995;14(1):58-68 (62 ref.)

Antigenic differences between a field isolate and vaccine strains of bovine viral diarrhea virus. Reddy JR, et al. **J Clin Microbiol** 1995 Aug;33(8):2159-61

Antigenic properties and diagnostic potential of puumala virus nucleocapsid protein expressed in insect cells. Vapalahti O, et al. **J Clin Microbiol** 1996 Jan;34(1):119-25

Immunoglobulin A-specific serodiagnosis of acute human cytomegalovirus infection by using recombinant viral antigens. Vornhagen R, et al. **J Clin Microbiol** 1996 Apr; 34(4):1020-3

Recognition of nonstructural protein peptides by cytotoxic T lymphocytes raised against Japanese encephalitis virus. Murali-Krishna K, et al. **Microbiol Immunol** 1995; 39(12):1021-24

Comparison of native and subunit antigens as ELISA reagents for the detection of antibodies against scabby mouth virus. Chin JC, et al. **Vet Microbiol** 1995 Sep; 46(1-3):327-34

ADMINISTRATION & DOSAGE

T cell responses in macaques after vaginal immunization with particulate SIV p27 antigen. Panagiotidi C, et al. **Adv Exp Med Biol** 1995;371B:1575–80

In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. Fayolle C, et al. **J Immunol** 1996 Jun 15;156(12):4697–706

Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes. Partidos CD, et al. **Mol Immunol** 1996 Apr;33(6):485–91

Retrovirus and retrotransposon particles as antigen presentation and delivery systems. Adams SE, et al. **Pharm Biotechnol** 1995;6:769–86 (63 ref.)

ANALYSIS

Molecular differentiation of transmissible gastroenteritis virus and porcine respiratory coronavirus strains. Correlation with antigenicity and pathogenicity. Jackwood DJ, et al. **Adv Exp Med Biol** 1995;380:35–41

Epstein–Barr virus infection and associated products (LMP, EBNA2, vIL–10) in nodal non–Hodgkin's lymphoma of human immunodeficiency virus–negative Japanese. Ohshima K, et al. **Am J Hematol** 1996 May;52(1):21–8

Hantavirus antigen detection using human serum immunoglobulin M as the capturing antibody in an enzyme–linked immunosorbent assay. Alexeyev OA, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):367–71

Dengue–2 virus infection of human bone marrow: characterization of dengue–2 antigen–positive stromal cells. Rothwell SW, et al. **Am J Trop Med Hyg** 1996 May; 54(5):503–10

Morphologic changes and immunohistochemical detection of viral antigen in ovaries from cattle persistently infected with bovine viral diarrhea virus. Grooms DL, et al. **Am J Vet Res** 1996 Jun;57(6):830–3

Molecular diagnosis of nasopharyngeal carcinoma: a review. Gan YY, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):71–4 (32 ref.)

Effect of leukocyte concentration and inoculum volume on the laboratory identification of cytomegalovirus in peripheral blood by the centrifugation culture–antigen detection methodology. Lipson SM, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):53–6

Occurrence and role of an early antigen and evidence for transforming ability of porcine circovirus. Tischer I, et al. **Arch Virol** 1995;140(10):1799–816

Comparison of neutralizing epitopes among infectious bursal disease viruses using radioimmunoprecipitation. Whetzel PL, et al. **Avian Dis** 1995 Jul–Sep;39(3):499–506

Development and evaluation of co–agglutination test to detect rotavirus antigens in stools of patients with diarrhoea. Islam MN, et al. **Bangladesh Med Res Counc Bull** 1995 Apr;21(1):11–7

Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Lemström K, et al. **Circulation** 1995 Nov 1;92(9):2594–604

A Dot enzyme linked immunosorbent assay (Dot ELISA): comparison with standard fluorescent antibody test (FAT) for the diagnosis of rabies in animals. Jayakumar R, et al. **Comp Immunol Microbiol Infect Dis** 1995 Sep;18(4):269–73

Hepatitis A–vaccines: a comparison between three methods of antigen determination. Burkhardt F, et al. **Dev Biol Stand** 1996;86:129–35

Enzyme–linked immunosorbent assay assessment of bovine viral diarrhoea virus antigen in inactivated vaccines using polyclonal or monoclonal antibodies. Ludemann LR, et al. **Dev Biol Stand** 1996;86:337

Immunoperoxidase histochemistry as a diagnostic tool for detection of equine arteritis virus antigen in formalin fixed tissues. Lopez JW, et al. **Equine Vet J** 1996 Jan;28(1):77–9

Prospective study of adenovirus antigen detection in eye swabs by radioimmune dot–blot. Morris DJ, et al. **Eye** 1995; 9 (Pt 5):629–32

Subcellular distribution of large and small hepatitis delta antigen in hepatocytes of hepatitis delta virus superinfected woodchucks. Cullen JM, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1090–100

Evaluation of four methods for the diagnosis of respiratory syncytial virus infection in older adults. Falsey AR, et al. **J Am Geriatr Soc** 1996 Jan;44(1):71–3

Monoclonal antibodies for detection of Norwalk virus antigen in stools. Herrmann JE, et al. **J Clin Microbiol** 1995 Sep;33(9):2511–3

EBNA expression in Reed–Sternberg like cells in post–transplant lymphoproliferative disorders [letter; comment] Chetty R, et al. **J Clin Pathol** 1996 Mar;49(3):270 . Comment on: J Clin Pathol 1995 Sep;48(9):845–8.

Conformational and linear epitopes on virus–like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2. Volpers C, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2661–7

A comparative study of histological conditions suitable for both immunofluorescence and in situ hybridization in the detection of Herpesvirus and its antigens in chicken tissues. Holland MS, et al. **J Histochem Cytochem** 1996 Mar; 44(3):259–65

Mapping of the dominant neutralizing antigenic site of a virus using infected cells. Roost HP, et al. **J Immunol Methods** 1996 Feb 5;189(2):233–42

Identification of antigenic regions in the GB hepatitis viruses GBV–A, GBV–B, and GBV–C. Pilot–Matias TJ, et al. **J Med Virol** 1996 Apr;48(4):329–38

In situ detection of the Epstein–Barr virus–encoded nuclear antigen 1 in oral hairy leukoplakia and virus–associated carcinomas. Murray PG, et al. **J Pathol** 1996 Jan; 178(1):44–7

Detection of bovine viral diarrhoea virus antigen and RNA in oviduct and granulosa cells of persistently infected cattle. Booth PJ, et al. **J Reprod Fertil** 1995 Sep;105(1):17–24

Development and application of an immunohistochemical staining technique to detect avian polyomaviral antigen in tissue sections. Fitzgerald SD, et al. **J Vet Diagn Invest** 1995 Oct;7(4):444–50

Comparison of immunogold silver staining (IGSS) with two immunoperoxidase staining systems for the detection of porcine reproductive and respiratory syndrome virus (PRRSV) antigens in formalin–fixed tissues. Larochelle R, et al. **J Vet Diagn Invest** 1995 Oct;7(4):540–3

Rapid diagnosis of influenza type A infection: comparison of shell–vial culture, directigen flu–A and enzyme–linked immunosorbent assay. Marcante R, et al. **New Microbiol** 1996 Apr;19(2):141–7

Serological comparison of type A foot and mouth disease virus isolates from Thailand. Doughty WJ, et al. **Rev Sci Tech** 1995 Sep;14(3):547–55

Multiple–infected diagnostic specimens from foot and mouth disease endemic regions. Ferris NP, et al. **Rev Sci Tech** 1995 Sep;14(3):557–65

Single radial haemolysis for the detection of goat pox virus antigen and antibody. Tiwari AK, et al. **Trop Anim Health Prod** 1996 Feb;28(1):117–20

Antigenic analysis of Japanese encephalitis viruses in Asia by using monoclonal antibodies. Hasegawa H, et al. **Vaccine** 1995 Dec;13(17):1713–21

Immune responses of the camel (Camelus dromedarius) to contagious ecthyma (Orf) virus infection. Azwai SM, et al. **Vet Microbiol** 1995 Nov;47(1–2):119–31

The immunodominant proteins of reticuloendotheliosis virus. Davidson I, et al. **Vet Microbiol** 1996 Apr;49(3–4):273–84

Six antigenic groups within the genus pestivirus as identified by cross neutralization assays. Dekker A, et al. **Vet Microbiol** 1995 Dec;47(3–4):317–29

An antigen detection immunoassay for big liver and spleen disease agent. Ellis TM, et al. **Vet Microbiol** 1995 Sep; 46(1–3):315–26

Development of a simple, rapid and accurate in vitro whole blood technique for the detection and semi–quantification of FIV cellular viremia. Guiot AL, et al. **Vet Microbiol** 1995 Dec;47(3–4):331–42

Comparison of the antigen distribution of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Halbur PG, et al. **Vet Pathol** 1996 Mar;33(2):159–70

Distribution of virus and viral antigen in specific pathogen–free calves following inoculation with noncytopathic bovine viral diarrhea virus. Marshall DJ, et al. **Vet Pathol** 1996 May;33(3):311–8

Antigenic types of canine parvoviruses prevailing in Taiwan. Chang WL, et al. **Vet Rec** 1996 May 4;138(18):447

Detection of FeLV antigen [letter; comment] Jarrett O. **Vet Rec** 1995 Jul 29;137(5):127. Comment on: Vet Rec 1995 May 20;136(20):516–8. Comment on: Vet Rec 1995 Aug 19;137(8):200.

Detection of FeLV antigen [letter; comment] Tribe GW, et al. **Vet Rec** 1995 Aug 19;137(8):200. Comment on: Vet Rec 1995 Jul 1;137(1):28. Comment on: Vet Rec 1995 Jul 29;137(5):127.

Antigenic type distribution among canine parvoviruses in dogs and cats in Germany. Truyen U, et al. **Vet Rec** 1996 Apr 13;138(15):365–6

Detection of FeLV antigen [letter; comment] [see comments] Weijer K, et al. **Vet Rec** 1995 Jul 29;137(5):127. Comment on: Vet Rec 1995 May 20;136(20):516–8. Comment on: Vet Rec 1995 Jul 1;137(1):28. Comment in: Vet Rec 1995 Aug 19;137(8):200.

Demonstration of infectious salmon anaemia (ISA) viral antigens in cell cultures and tissue sections. Falk K, et al. **Vet Res** 1995;26(5–6):499–504

Aluminosilicates enhance the infectivity of cytomegalovirus in urine using centrifugation–enhanced antigen detection technology. Lee SH, et al. **Zentralbl Bakteriol** 1996 Apr; 283(4):502–14

[Detections of hepatitis C virus RNA and NS3 antigen and their relation to liver histopathology] Wang F, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Nov;75(11):670–2, 709–10 (Eng. Abstr.) **(Chi)**

[Polyvalent hyperimmune immunoglobulins prevent the infection of monocytic type cells by human cytomegalovirus] Delannoy AS, et al. **Pathol Biol (Paris)** 1996 May;44(5):461–3 (Eng. Abstr.) **(Fre)**

[Quantitative detection of pp65 intraleukocyte cytomegalic antigen in renal transplantation] Le Goff C, et al. **Presse Med** 1995 Dec 2;24(37):1731–5 (Eng. Abstr.) **(Fre)**

[Evolution of canine parvovirus: loss and gain of the feline host] Truyen U. **Tierarztl Prax** 1996 Jun;24(3):316–8 (Eng. Abstr.) **(Ger)**

[Early diagnosis of HCMV infections in patients undergoing transplantation of the kidney] Cavallo R, et al. **G Batteriol Virol Immunol** 1994 Jan–Dec;86(1–12):29–42 (Eng. Abstr.) **(Ita)**

[Viral tumor markers] Ohtsuru A, et al. **Nippon Rinsho** 1996 Jun;54(6):1529–35 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Development of an optimal scheme for calculating results of the use of an immunoenzyme test–system for determining the antigenic activity of a cultured antirabies vaccine] Tsetlin EM, et al. **Vopr Virusol** 1996 Jan–Feb;41(1):21–4 (Eng. Abstr.) **(Rus)**

[The phenotypic characteristics of healthy carriers of the antigenic structures of the influenza A virus] Tsybalova LM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr;(2):32–6 (Eng. Abstr.) **(Rus)**

[Distribution of p27 and gp70 feline leukemia virus antigens in various tissues] Kovačević S, et al. **Vojnosanit Pregl** 1994 Jul–Aug;51(4):277–80 (Eng. Abstr.) **(Scr)**

[Rotavirus infection: clinical characteristics and time of elimination of the rotavirus antigen in the feces] Mesa F, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):106–10 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Human endogenous retrovirus K does not encode mouse mammary tumor virus–related antigens in human breast carcinomas. Vogetseder W, et al. **AIDS Res Hum Retroviruses** 1995 Jul;11(7):869–72

Multiple gene expression in baculovirus system. Third generation vaccines for bluetongue disease and African horsesickness disease. Roy P. **Ann N Y Acad Sci** 1996 Jul 23;791:318–32

bcl–2, Epstein–Barr virus–latent membrane protein, EBNA–1, and EBNA–2 staining in posttransplantation lymphoproliferative disorders [letter; comment] Chetty R, et al. **Blood** 1996 Jun 15;87(12):5395. Comment on: Blood 1996 Jan 15;87(2):706–11.

Fast inducible repair of microinjected UV–irradiated SV40 DNA in monkey kidney cells. Ghaskadbi S, et al. **Cell Mol Biol Res** 1995;41(1):67–72

Epstein Barr virus (EBV)–carrying cells of a chronic lymphocytic leukemia (CLL) subpopulation express EBNA1 and LMPs but not EBNA2 in vivo. Laytragoon–Lewin N, et al. **Int J Cancer** 1995 Nov 15; 63(4):486–90

B cell–specific activation of the Epstein–Barr virus–encoded C promoter compared with the wide–range activation of the W promoter. Contreras–Brodin B, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1159–62

oriP is essential for EBNA gene promoter activity in Epstein–Barr virus–immortalized lymphoblastoid cell lines. Puglielli MT, et al. **J Virol** 1996 Sep;70(9):5758–68

Stimulation of mouse mammary tumor virus superantigen expression by an intragenic enhancer. Reuss FU, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9293–7

Stages of Marek's disease virus latency defined by variable sensitivity to interferon modulation of viral antigen expression. Volpini LM, et al. **Vet Microbiol** 1995 Nov; 47(1–2):99–109

Exogenous mouse mammary tumor virus (MMTV) infection induces endogenous MMTV sag expression. Xu L, et al. **Virology** 1996 Jan 15;215(2):113–23

Increase of antigen production in BLV–infected cell lines via additional expression of tax. Wagner HJ, et al. **Zentralbl Veterinarmed [B]** 1995 Nov;42(9):543–50

BLOOD

CMV–antigenemia after allogeneic bone marrow transplantation: correlation of CMV–antigen positive cell numbers with transplant–related mortality. Bacigalupo A, et al. **Bone Marrow Transplant** 1995 Jul;16(1):155–61

Detection improvement of cytomegalovirus antigen in human peripheral blood using monoclonal antibodies and automated reading of cell preparations. Boland GJ, et al. **Eur J Clin Invest** 1995 Sep;25(9):639–46

Role of antigenemia assay in the early diagnosis and prediction of human cytomegalovirus organ involvement in AIDS patients. Francisci D, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):498–503

CMV–antigenemia in peripheral blood for the diagnosis of CMV disease in HIV–infected patients. Salzberger B, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 1;11(4):365–9

Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease. Wetherill PE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):33–7

High–level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow–up. Bek B, et al. **J Clin Microbiol** 1996 Feb;34(2):457–9

Comparison of two leukocyte extraction methods for cytomegalovirus antigenemia assay. García A, et al. **J Clin Microbiol** 1996 Jan;34(1):182–4

Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence. Landry ML, et al. **J Clin Microbiol** 1996 May;34(5):1337–9

Cytomegalovirus antigenemia as a marker for antiviral therapy after heart transplantation [letter] Iberer F, et al. **J Heart Lung Transplant** 1996 Mar;15(3):314–5

Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients. Prezzi C, et al.

J Immunol 1996 Jun 1;156(11):4504–13

Cytomegalovirus in bronchoalveolar lavage specimens from patients with AIDS: comparison with antigenaemia and viraemia. Angelici E, et al. **J Med Microbiol** 1996 Aug; 45(2):149–52

Rapid and sensitive streptavidin–biotin amplified fluorogenic enzyme–linked immunosorbent–assay for direct detection and identification of dengue viral antigens in serum. Malergue F, et al. **J Med Virol** 1995 Sep;47(1):43–7

Shortened survival in infants vertically infected with human immunodeficiency virus with elevated p24 antigenemia. Arlievsky NZ, et al. **J Pediatr** 1995 Oct;127(4):538–43

Effect of cytopathic bovine viral diarrhea virus (BVDV) superinfection on viral antigen association with platelets, viremia, and specific antibody levels in two heifers persistently infected with noncytopathic BVDV. Bezek DM, et al. **J Vet Diagn Invest** 1995 Jul;7(3):395–7

Evaluation of the enzyme–linked immunosorbent assay for the rapid screening and detection of classical swine fever virus antigens in the blood of pigs. Depner K, et al. **Rev Sci Tech** 1995 Sep;14(3):677–89

The cytomegalovirus antigenemia assay: a plea for standardization. The TH, et al. **Scand J Infect Dis Suppl** 1995;99:25–9 (31 ref.)

Definitions of cytomegalovirus disease after heart transplantation: antigenemia as a marker for antiviral therapy. Iberer F, et al. **Transpl Int** 1996;9(3):236–42

CMV antigenemia assay using indirect ALP–immunostaining in bone marrow transplant recipients. Kurihara T, et al. **Transplant Proc** 1996 Jun;28(3):1750–3

Early diagnosis of CMV syndrome after kidney transplantation: comparison between CMV antigenemia and PCR assay. Tanabe K, et al. **Transplant Proc** 1996 Jun; 28(3):1508–10

Detection of human cytomegalovirus myocardial involvement by polymerase chain reaction during systemic infection and correlation with pp65 antigenemia and DNAemia in infected heart recipients. Ghisetti V, et al. **Transplantation** 1996 Apr 15;61(7):1072–5

Human parvovirus B19 infection in blood donors. Tsujimura M, et al. **Vox Sang** 1995;69(3):206–12

CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation. Iberer F, et al. **Wien Klin Wochenschr** 1995;107(23):718–22

Influenza. **Wkly Epidemiol Rec** 1995 Sep 29;70(39):277–8 **(Eng, Fre)**

CHEMISTRY

Sequence analysis of echoviruses in a major antigenic region eliciting enteroviral cross–reactive antibodies. Samuelson A, et al. **Arch Virol** 1995;140(11):2085–91

The effects of post–translational side–chain modifications on the stimulatory activity, serum stability and conformation of synthetic peptides carrying T helper cell epitopes. Otvos L Jr, et al. **Biochim Biophys Acta** 1996 Aug 21;1313(1):11–9

Crystal structure of the DNA–binding domain of the Epstein–Barr virus origin–binding protein, EBNA1, bound to DNA. Bochkarev A, et al. **Cell** 1996 Mar 8;84(5):791–800

Crystal structure of the DNA–binding domain of the Epstein–Barr virus origin–binding protein EBNA 1. Bochkarev A, et al. **Cell** 1995 Oct 6;83(1):39–46

Stereochemical analysis of the antigenic tip of the V3 loop peptide of HIV–1 gp120. Gunasekaran K, et al. **Int J Pept Protein Res** 1995 Nov;46(5):359–65

Domains of the Epstein–Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters. Sjöblom A, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2669–78

Picture story. Not just another copycat. **Nat Struct Biol** 1996 May;3(5):403

Crystal structure of SIV matrix antigen and implications for virus assembly. Rao Z, et al. **Nature** 1995 Dec 14; 378(6558):743–7

Interactions of protein antigens with antibodies. Davies DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):7–12 (69 ref.)

Recombinant and virion–derived soluble and particulate immunogens for vaccination against tick–borne encephalitis. Heinz FX, et al. **Vaccine** 1995 Dec; 13(17):1636–42

A potential proline–rich motif upstream of the immunoreceptor tyrosine–based activation motif in bovine leukemia virus gp30, Epstein–Barr virus LMP2A, herpesvirus papio LMP2A, and African horsesickness virus VP7 [letter] Cantor GH. **Virology** 1996 Jun 15;220(2):265–6

CLASSIFICATION

Evaluation of different turkey rhinotracheitis viruses used as antigens for serological testing following live vaccination and challenge. Eterradossi N, et al. **Zentralbl Veterinarmed [B]** 1995 May;42(3):175–86

[Antigenic types of circulating rotavirus in children with acute diarrhea in Santiago de Chile] O'Ryan M, et al. **Rev Med Chil** 1995 May;123(5):549–59 (Eng. Abstr.) **(Spa)**

DIAGNOSTIC USE

Recombinant mono– and polyantigens to detect cytomegalovirus–specific immunoglobulin M in human sera by enzyme immunoassay. Landini MP, et al. **J Clin Microbiol** 1995 Oct;33(10):2535–42

Production of recombinant hantavirus nucleocapsid protein expressed in silkworm larvae and its use as a diagnostic antigen in detecting antibodies in serum from infected rats. Yoshimatsu K, et al. **Lab Anim Sci** 1995 Dec;45(6):641–6 (8 ref.)

[Serological diagnosis for human parvovirus B19 infection by an enzyme immunoassay kit with recombinant antigens synthesized in a baculovirus expression system] Yoto Y, et al. **Kansenshogaku Zasshi** 1995 Oct;69(10):1135–40 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Interferon modulation of Marek's disease virus genome expression in chicken cell lines. Volpini LM, et al. **Avian Dis** 1996 Jan–Mar;40(1):78–87

Alteration of the trypsin–sensitive antigenic site of foot–and–mouth disease virus following direct binding to an ELISA plate [letter] Pattnaik B, et al. **J Immunol Methods** 1996 Jun 10;192(1–2):195–7

GENETICS

Expression and stability of herpes simplex virus antigens in Salmonella typhimurium. Bowen JC, et al. **Adv Exp Med Biol** 1995;371B:1543–6

Antigenic and genomic variations among cytopathic and non–cytopathic strains of bovine enteric coronavirus. Dea S, et al. **Adv Exp Med Biol** 1995;380:99–101

Recombinant infectious hematopoietic necrosis virus and viral hemorrhagic septicemia virus glycoprotein epitopes expressed in Aeromonas salmonicida induce protective immunity in rainbow trout (Oncorhynchus mykiss). Noonan B, et al. **Appl Environ Microbiol** 1995 Oct; 61(10):3586–91

Expression of the rubella virus structural proteins by an infectious Sindbis virus vector. Chen JP, et al. **Arch Virol** 1995;140(11):2075–84

Immunogenicity, antigenicity, and protection efficacy of baculovirus expressed VP4 trypsin cleavage products, VP5(1)* and VP8* from rhesus rotavirus. Dunn SJ, et al. **Arch Virol** 1995;140(11):1969–78

Coding strategy of the S and M genomic segments of a hantavirus representing a new subtype of the Puumala serotype. Reip A, et al. **Arch Virol** 1995;140(11):2011–26

Molecular analysis of rice ragged stunt oryzavirus segment 9 and sequence conservation among isolates from Thailand and India. Upadhyaya NM, et al. **Arch Virol** 1995; 140(11):1945–56

A recombinant fowlpox virus expressing the envelope antigen of subgroup A avian leukosis/sarcoma virus. Nazerian K, et al. **Avian Dis** 1995 Jul–Sep;39(3):514–20

Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Prösch S, et al. **Biol Chem Hoppe Seyler** 1996 Mar;377(3):195–201

Switching viral latency to viral lysis: a novel therapeutic approach for Epstein–Barr virus–associated neoplasia. Gutiérrez MI, et al. **Cancer Res** 1996 Mar 1;56(5):969–72

Budding of rabies virus particles in the absence of the spike glycoprotein. Mebatsion T, et al. **Cell** 1996 Mar 22; 84(6):941–51

Expression of Epstein–Barr virus nuclear antigen–1 induces B cell neoplasia in transgenic mice. Wilson JB, et al. **EMBO J** 1996 Jun 17;15(12):3117–26

Nucleotide sequences of env and 3'LTRORf genes of endogenous mouse mammary tumor viruses encoding superantigen specific for TcrVbeta2. Nakamura N, et al. **Immunogenetics** 1996;44(4):319–20

Epstein Barr virus (EBV)–carrying cells of a chronic lymphocytic leukemia (CLL) subpopulation express EBNA1 and LMPS but not EBNA2 in vivo. Laytragoon–Lewin N, et al. **Int J Cancer** 1996 Mar 1; 65(5):714–5

Novel hypotheses for the roles of EBNA–1 and BHRF1 in EBV–related cancers. Horner D, et al. **Intervirology** 1995; 38(3–4):195–205

Different genomic fragments encode for two human herpesvirus 6 early proteins that share a cross–reactive antigen. Iyengar S, et al. **Intervirology** 1994;37(6):340–7

Molecular relationships between 21 human rhinovirus serotypes. Horsnell C, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2549–55

Domains of the Epstein–Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters. Sjöblom A, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2669–78

Identification of a naturally occurring recombinant Epstein–Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequences. Burrows JM, et al. **J Virol** 1996 Jul;70(7):4829–33

Transcription start sites downstream of the Epstein–Barr virus (EBV) Fp promoter in early–passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA–1 protein. Nonkwelo C, et al. **J Virol** 1996 Jan;70(1):623–7

oriP is essential for EBNA gene promoter activity in Epstein–Barr virus–immortalized lymphoblastoid cell lines. Puglielli MT, et al. **J Virol** 1996 Sep;70(9):5758–68

Transcription of the Epstein–Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells. Schlager S, et al. **J Virol** 1996 Jun;70(6):3561–70

Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCC–MSB1 MDV–transformed lymphoblastoid cells. Xie Q, et al. **J Virol** 1996 Feb;70(2):1125–31

Sequence identification of antigenic variants in plaque isolates of foot–and–mouth disease virus. Meyer RF, et al. **J Virol Methods** 1995 Oct;55(2):281–3

Localization of the mouse mammary tumor provirus, Mtv44, on chromosome 11. Fairchild SP, et al. **Mamm Genome** 1995 Jul;6(7):472–3

Truncated mammalian Notch1 activates CBF1/RBPJk–repressed genes by a mechanism resembling that of Epstein–Barr virus EBNA2. Hsieh JJ, et al. **Mol Cell Biol** 1996 Mar;16(3):952–9

Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas. Bhatia K, et al. **Oncogene** 1996 Jul 4;13(1):177–81

Expression of Epstein–Barr nuclear antigen 2 in kidney tubule cells induce tumors in transgenic mice. Törnell J, et al. **Oncogene** 1996 Apr 4;12(7):1521–8

Redefining the Epstein–Barr virus–encoded nuclear antigen EBNA–1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Schaefer BC, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10565–9

Structural comparison of two strains of foot–and–mouth disease virus subtype O1 and a laboratory antigenic variant, G67. Lea S, et al. **Structure** 1995 Jun 15;3(6):571–80

Antigenic variants in a plaque–isolate of foot–and–mouth disease virus: implications for vaccine production. Piatti P, et al. **Vaccine** 1995;13(8):781–4 (23 ref.)

Repetitive sequence in the Epstein–Barr virus EBNA–3C gene is related to a family of minisatellite arrays in the human genome. Fujiwara S, et al. **Virus Genes** 1995; 11(1):31–5

Capsid diversity in small round–structured viruses: molecular characterization of an antigenically distinct human enteric calicivirus. Green SM, et al. **Virus Res** 1995 Aug; 37(3):271–83

IMMUNOLOGY

Immunogenicity of the whole antigen and glycoprotein I of varicella–zoster virus (VZV) and the VZV skin test antigen. Kawano S, et al. **Acta Paediatr Jpn** 1996 Apr; 38(2):121–3

Antigenic similarity of central European encephalitis and louping–ill viruses. Hubálek Z, et al. **Acta Virol** 1995 Dec; 39(5–6):251–6

R–subtype of early antigen of the Epstein–Barr virus in the diagnostics of the chronic form of infectious mononucleosis [letter] Kotuliak J. **Acta Virol** 1995 Jun;39(3):183–4

Production and immunogenicity of multiple antigenic peptide (MAP) constructs derived from the S1 glycoprotein of infectious bronchitis virus (IBV). Jackwood MW, et al. **Adv Exp Med Biol** 1995;380:213–9

New functions for mucosal IgA. Lamm ME, et al. **Adv Exp Med Biol** 1995;371A:647–50

Intracellular neutralization of Sendai and influenza viruses by IgA monoclonal antibodies. Mazanec MB, et al. **Adv Exp Med Biol** 1995;371A:651–4

Minimal signal requirements for superantigen–specific T cell–driven B cell proliferation. Wetzel GD. **Adv Exp Med Biol** 1995;371A:137–40

Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Elfgren K, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):937–42

DNA immunization with bovine herpesvirus–1 genes. Babiuk LA, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:47–63 (56 ref.)

Molecular mimicry between Fc receptors and viral antigens. Oleszak EL. **Arch Immunol Ther Exp (Warsz)** 1994; 42(2):83–8 (53 ref.)

Antigenic relationships of hantavirus strains analysed by monoclonal antibodies. Dzagurova T, et al. **Arch Virol** 1995;140(10):1763–73

HA1 domain of influenza A (H3N2) viruses in Finland in 1989–1995: evolution, egg–adaptation and relationship to vaccine strains. Pyhälä R, et al. **Arch Virol** 1996; 141(6):1033–46

Detection of respiratory syncytial virus (RSV) antigen in the lungs of guinea pigs 6 weeks after experimental infection and despite of the production of neutralizing antibodies. Streckert HJ, et al. **Arch Virol** 1996; 141(3–4):401–10

Induction of protective antibody responses against pseudorabies virus by intranasal vaccination with glycoprotein B in mice. Takada A, et al. **Arch Virol** 1995; 140(9):1629–35

Topography and immunogenicity of bluetongue virus VP7 epitopes. Wang LF, et al. **Arch Virol** 1996;141(1):111–23

Anti–EBNA1/anti–EBNA2 ratio decreases significantly in patients with progression of HIV infection. Winkelspecht B, et al. **Arch Virol** 1996;141(5):857–64

Serum p53 accumulation and altered antibody responses to Epstein–Barr virus proteins precede diagnosis of haemopoietic malignancies of lymphoid origin. Lehtinen T, et al. **Br J Haematol** 1996 Apr;93(1):104–10

Antigenic comparison of Canadian and US isolates of porcine reproductive and respiratory syndrome virus using

monoclonal antibodies to the nucleocapsid protein. Magar R, et al. **Can J Vet Res** 1995 Jul;59(3):232–4

Increased immunogenicity of inactivated influenza virus vaccine containing purified surface antigen compared with whole virus in elderly women. Powers DC. **Clin Diagn Lab Immunol** 1994 Jan;1(1):16–20

Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides. Reali E, et al. **Clin Exp Immunol** 1996 Aug;105(2):369–75

CD28/CTLA4–B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination. Champagne E, et al. **Eur J Immunol** 1996 Jul; 26(7):1595–602

Recognition of altered self major histocompatibility complex molecules modulated by specific peptide interactions. Nepom GT, et al. **Eur J Immunol** 1996 Apr;26(4):949–52

T cells with dual antigen specificity in T cell receptor transgenic mice rejecting allografts. Simpson E, et al. **Eur J Immunol** 1995 Oct;25(10):2813–7

IgD–receptor up-regulation on human peripheral blood T cells in response to IgD in vitro or antigen in vivo correlates with the antibody response to influenza vaccination. Swenson CD, et al. **Eur J Immunol** 1996 Feb; 26(2):340–4

Lipid vesicle–entrapped influenza A antigen modulates the influenza A–specific human antibody response in immune reconstituted SCID–human mice. Walker W, et al. **Eur J Immunol** 1996 Jul;26(7):1664–7

A point mutation in HLA–A*0201 results in failure to bind the TAP complex and to present virus-derived peptides to CTL. Peace-Brewer AL, et al. **Immunity** 1996 May; 4(5):505–14

Both H-2– and non–H-2–linked genes influence influenza nucleoprotein epitope recognition by CD4+ T cells. Brett SJ, et al. **Immunology** 1996 Jan;87(1):42–8

Differential activation of mouse hepatitis virus–specific CD4+ cytotoxic T cells is defined by peptide length. Heemskerk MH, et al. **Immunology** 1995 Aug;85(4):517–22

The induction of respiratory syncytial virus–specific cytotoxic T-cell responses following immunization with a synthetic peptide containing a fusion peptide linked to a cytotoxic T lymphocyte epitope. Hsu SC, et al. **Immunology** 1995 Jul;85(3):347–50

Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus–like particles. Layton GT, et al. **Immunology** 1996 Feb;87(2):171–8

Low avidity recognition of a class II–restricted neo-self peptide by virus–specific T cells. Cerasoli DM, et al. **Int Immunol** 1995 Jun;7(6):935–45

Binding of viral antigens to major histocompatibility complex class I H-2Db molecules is controlled by dominant negative elements at peptide non-anchor residues. Implications for peptide selection and presentation. Hudrisier D, et al. **J Biol Chem** 1996 Jul 26; 271(30):17829–36

Transgenic mice that express different forms of the influenza virus hemagglutinin as a neo–self-antigen. Caton AJ, et al. **J Clin Immunol** 1995 Nov;15(6 Suppl):106S–112S

Induction of long-lived germinal centers associated with persisting antigen after viral infection. Bachmann MF, et al. **J Exp Med** 1996 May 1;183(5):2259–69

Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. Bender A, et al. **J Exp Med** 1995 Dec 1;182(6):1663–71

T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. Burrows SR, et al. **J Exp Med** 1995 Dec 1;182(6):1703–15

Activation and negative selection of functionally distinct subsets of antibody-secreting cells by influenza hemagglutinin as a viral and a neo–self antigen. Caton AJ, et al. **J Exp Med** 1996 Jan 1;183(1):13–26

Genetic basis for T cell recognition of a major histocompatibility complex class II–restricted neo–self peptide. Cerasoli DM, et al. **J Exp Med** 1995 Nov 1; 182(5):1327–36

Strictly transporter of antigen presentation (TAP)–dependent presentation of an immunodominant cytotoxic T lymphocyte epitope in the signal sequence of a virus protein. Hombach J, et al. **J Exp Med** 1995 Nov 1; 182(5):1615–9

The life span of major histocompatibility complex–peptide complexes influences the efficiency of presentation and immunogenicity of two class I–restricted cytotoxic T lymphocyte epitopes in the Epstein–Barr virus nuclear antigen 4. Levitsky V, et al. **J Exp Med** 1996 Mar 1; 183(3):915–26

A novel mechanism of retrovirus inactivation in human serum mediated by anti–alpha–galactosyl natural antibody. Rother RP, et al. **J Exp Med** 1995 Nov 1;182(5):1345–55

The use of mammary tumor virus (Mtv)–negative and single–Mtv mice to evaluate the effects of endogenous viral superantigens on the T cell repertoire. Scherer MT, et al. **J Exp Med** 1995 Nov 1;182(5):1493–504

The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen. Yang B, et al. **J Exp Med** 1996 Apr 1;183(4):1545–52

Common epitope on protein VI of enteric adenoviruses from subgenera A and F. Grydsuk JD, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1811–9

Full protection against African horsesickness (AHS) in horses induced by baculovirus–derived AHS virus serotype 4 VP2, VP5 and VP7. Martínez-Torrecuadrada JL, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1211–21

Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. Urban M, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1537–47

Differences in the avidity of TCR interactions with a superantigenic ligand affect negative selection but do not allow positive selection. Chervonsky AV, et al. **J Immunol** 1995 Dec 1;155(11):5115–23

In vivo T cell response to viral superantigen. Selective migration rather than proliferation. Le Bon A, et al. **J Immunol** 1996 Jun 15;156(12):4602–8

Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response. Mitchell BM, et al. **J Immunol** 1996 Jan 1; 156(1):246–55

Alteration of the trypsin-sensitive antigenic site of foot-and-mouth disease virus following direct binding to an ELISA plate [letter] Pattnaik B, et al. **J Immunol Methods** 1996 Jun 10;192(1–2):195–7

Assessment of variation in trypsin-sensitive neutralizable antigenic site of type O foot-and-mouth disease virus (FMDV) isolates using a Mab-binding inhibition assay [letter] Pattnaik B, et al. **J Immunol Methods** 1996 Jun 10; 192(1–2):191–3

Detection of human serum antibodies to the BFRF3 Epstein-Barr virus capsid component by means of a DNA–binding assay. Shedd D, et al. **J Infect Dis** 1995 Nov;172(5):1367–70

Human T cell proliferative response to polypeptides from adenovirus type 2 [letter; comment] Souberbielle BE, et al. **J Infect Dis** 1995 Nov;172(5):1421–2. Comment on: J Infect Dis 1995 May;171(5):1090–6.

Cellular immunity in measles vaccine failure: demonstration of measles antigen–specific lymphoproliferative responses despite limited serum antibody production after revaccination. Ward BJ, et al. **J Infect Dis** 1995 Dec; 172(6):1591–5

Guinea pig and human cytomegaloviruses do not share cross-reactive neutralizing epitopes. Adler SP, et al. **J Med Virol** 1995 Sep;47(1):48–51

Evaluation of subgroup-specific peptides of the G protein of respiratory syncytial virus for characterization of the immune response. Akerlind-Stopner B, et al. **J Med Virol** 1995 Oct;47(2):120–5

Synthetic peptides deduced from the amino acid sequence of Epstein-Barr virus nuclear antigen 6 (EBNA 6): antigenic properties, production of monoreactive reagents, and analysis of antibody responses in man. Falk K, et al. **J Med Virol** 1995 Aug;46(4):349–57

Immunohistochemical identification of varicella–zoster virus gene 63–encoded protein (IE63) and late (gE) protein on smears and cutaneous biopsies: implications for diagnostic use. Nikkels AF, et al. **J Med Virol** 1995 Dec;47(4):342–7

Human B-cell epitopes of Puumala virus nucleocapsid protein, the major antigen in early serological response. Vapalahti O, et al. **J Med Virol** 1995 Aug;46(4):293–303

Human microglia activate lymphoproliferative responses to recall viral antigens. Dhib-Jalbut S, et al. **J Neuroimmunol** 1996 Mar;65(1):67–73

Comparison of agar-gel precipitin responses among strains of fowl adenovirus using antigens prepared from chorioallantoic membranes and chicken kidney cell cultures. Takase K, et al. **J Vet Med Sci** 1995 Apr; 57(2):327–30

A longitudinal study of feline immunodeficiency virus–specific cytotoxic T lymphocytes in experimentally infected cats, using antigen–specific induction. Beatty JA, et al. **J Virol** 1996 Sep;70(9):6199–206

Epitopes exposed on hepatitis delta virus ribonucleoproteins. Bichko VV, et al. **J Virol** 1996 Sep;70(9):5807–11

Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. Christensen ND, et al. **J Virol** 1996 Feb; 70(2):960–5

Differing T-cell requirements for recombinant retrovirus vaccines. Hasenkrug KJ, et al. **J Virol** 1996 Jan; 70(1):368–72

In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen. Krummenacher C, et al. **J Virol** 1996 May;70(5):3026–31

A recombinant adenovirus expressing an Epstein–Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro. Morgan SM, et al. **J Virol** 1996 Apr;70(4):2394–402

Synthesis and application of hepatitis E virus peptides to diagnosis. Qi Z, et al. **J Virol Methods** 1995 Sep;55(1):55–66

Epitope mapping of the NS4 and NS5 gene products of hepatitis C virus and the use of a chimeric NS4–NS5 synthetic peptide for serodiagnosis. Rosa C, et al. **J Virol Methods** 1995 Oct;55(2):219–32

Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs. Robuccio JA, et al. **Lab Anim Sci** 1995 Aug;45(4):420–6

Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Ohlin M, et al. **Mol Immunol** 1996 Jan;33(1):47–56

Seroconversion to antibodies against Kaposi's sarcoma–associated herpesvirus–related latent nuclear antigens before the development of Kaposi's sarcoma. Gao SJ, et al. **N Engl J Med** 1996 Jul 25;335(4):233–41

Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus [see comments] Donnelly JJ, et al. **Nat Med** 1995 Jun;1(6):583–7 . Comment in: Nat Med 1995 Jun;1(6):521–2.

Paving the way towards DNA vaccines [comment] Krishnan S, et al. **Nat Med** 1995 Jun;1(6):521–2. Comment on: Nat Med 1995 Jun;1(6):583–7.

The use of sucrose–acetone–extracted Rift Valley fever virus antigen derived from cell culture in an indirect enzyme–linked immunosorbent assay and haemagglutination–inhibition test. Paweska JT, et al. **Onderstepoort J Vet Res** 1995 Dec;62(4):227–33

Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow–derived cells. Doe B, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8578–83

The immunodominant major histocompatibility complex class I–restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Huang AY, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9730–5

Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. Liblau RS, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3031–6

T-cell activation, anergy and immunomodulation by molecules of viral, fungal and vegetal origin. Bemer V, et al. **Res Immunol** 1995 May–Jun;146(4–5):249–62 (81 ref.)

Phenotypic analysis of antigen-specific T lymphocytes. Altman JD, et al. **Science** 1996 Oct 4;274(5284):94–6

Viral peptide specific cytotoxic T lymphocytes are of high avidity to host–MHC but only low avidity to donor–MHC after allogeneic bone marrow transplantation. Kyburz D, et al. **Transpl Immunol** 1995 Jun;3(2):143–50

The N-terminal 303 amino acids of the human cytomegalovirus envelope glycoprotein B (UL55) and the exon 4 region of the major immediate early protein 1 (UL123) induce a cytotoxic T-cell response. Berencsi K, et al. **Vaccine** 1996 Apr;14(5):369–74

Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick–borne encephalitis. Heinz FX, et al. **Vaccine** 1995 Dec; 13(17):1636–42

Preparation and characterization of a purified influenza virus neuraminidase vaccine. Hocart M, et al. **Vaccine** 1995 Dec; 13(18):1793–8

Antigenicity and immunogenicity of recombinant envelope glycoproteins of SIVmac32H with different in vivo passage histories. Hulskotte EG, et al. **Vaccine** 1995 Sep; 13(13):1187–97

Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome–formulated hepatitis A vaccine in Thais. Poovorawan Y, et al. **Vaccine** 1995 Jul; 13(10):891–3

A new epitope presenting system displays a HIV–1 V3 loop sequence and induces neutralizing antibodies. Scodeller EA, et al. **Vaccine** 1995 Sep;13(13):1233–9

Gene fusion of cholera toxin B subunit and HBV PreS2 epitope and the antigenicity of fusion protein. Shi CH, et al. **Vaccine** 1995 Jul;13(10):933–7

Antigenic differences among pestiviruses. Edwards S, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):563–77 (107 ref.)

Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. Andrew M, et al. **Vet Immunol Immunopathol** 1995 Aug;47(3–4):311–22

Comparison of Freund's adjuvant and TiterMax in inducing anti–idiotype to idiotypic antibodies against pseudorabies virus antigens. Zhou EM, et al. **Vet Immunol Immunopathol** 1995 Sep;48(1–2):113–22

Induction of antibodies to the bluetongue virus core polypeptide VP7 in sheep by internal image rabbit antiidiotypic antibodies. Lin M, et al. **Viral Immunol** 1996; 9(1):35–43

Molecular basis of antigenic variation between the glycoproteins C of respiratory bovine herpesvirus 1 (BHV–1) and neurovirulent BHV–5. Chowdhury SI. **Virology** 1995 Nov 10;213(2):558–68

Antigenic sites on the receptor–binding domain of human adenovirus type 2 fiber. Fender P, et al. **Virology** 1995 Dec 1;214(1):110–7

Antigenic mapping of the recombinant Norwalk virus capsid protein using monoclonal antibodies. Hardy ME, et al. **Virology** 1996 Mar 1;217(1):252–61

Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein–Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Khanna R, et al. **Virology** 1995 Dec 20;214(2):633–7

Antigenic variation of SIV: mutations in V4 alter the neutralization profile. Kinsey NE, et al. **Virology** 1996 Jul 1;221(1):14–21

Protein–protein interactions between Epstein–Barr virus nuclear antigen–LP and cellular gene products: binding of 70–kilodalton heat shock proteins. Kitay MK, et al. **Virology** 1996 Jun 1;220(1):91–9

Characterization of Mengo virus neutralization epitopes. II. Infection of mice with an attenuated virus. Kobasa D, et al. **Virology** 1995 Dec 1;214(1):118–27

Kinetic and functional mapping of viral epitopes using biosensor technology. Saunal H, et al. **Virology** 1995 Nov 10;213(2):462–71

ANTIGENS, VIRAL

Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Schoppel K, et al. **Virology** 1996 Feb 1; 216(1):133–45

Induction of antibodies protecting against transmissible gastroenteritis coronavirus (TGEV) by recombinant adenovirus expressing TGEV spike protein. Torres JM, et al. **Virology** 1995 Nov 10;213(2):503–16

Preparation of monoclonal antibodies against Marek's disease virus serotype 1 glycoprotein D expressed by a recombinant baculovirus. Ono M, et al. **Virus Res** 1995 Oct;38(2–3):219–30

Isolation of caliciviruses from skunks that are antigenically and genotypically related to San Miguel sea lion virus. Seal BS, et al. **Virus Res** 1995 Jun;37(1):1–12

A helper T-cell epitope of the E7 protein of human papillomavirus type 16 in BALB/c mice. Vandebriel RJ, et al. **Virus Res** 1995 Jun;37(1):13–22

Virus-neutralization domains on the oligomeric (230 kDa) forms of antigen B of herpesvirus of turkeys and Marek's disease virus differ in cross-serotypic activity. Davidson I, et al. **Zentralbl Veterinarmed [B]** 1995 Apr;42(2):100–9

[Seroepidemiology of human parvovirus B19 using recombinant VP1 + VP2 particle antigen] Matsunaga Y, et al. **Kansenshogaku Zasshi** 1995 Dec;69(12):1371–5 (Eng. Abstr.) **(Jpn)**

[T cell proliferative responses to HCV-related antigens] Mori H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:170–3 **(Jpn)**

[Immunodominant regions of core protein of hepatitis C virus and antibody-assays employing two recombinant core proteins, p22 and JCC4] Ohba H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:212–23 **(Jpn)**

[Antibodies generated against hepatitis C virus (HCV) core antigen: IgM and IgA antibody against HCV core] Sato S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:253–9 (16 ref.) **(Jpn)**

[Preparation of monoclonal antibodies to super early human cytomegalovirus proteins and their use for detecting infected cells] Makarova NE, et al. **Vopr Virusol** 1996 Jan-Feb;41(1):28–32 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Newly recognised hantavirus in Siberian lemmings [letter] Plyusnin A, et al. **Lancet** 1996 Jun 29;347(9018):1835

Pathomorphological and immunohistological findings in cattle experimentally infected with rinderpest virus isolates of different pathogenicity. Wohlsein P, et al. **Vet Microbiol** 1995 May;44(2–4):141–9

High molecular weight polypeptide bands specific for equine herpesvirus 4. Zheng M, et al. **Vet Microbiol** 1995 Sep; 46(1–3):203–11

Use of a single anti-nucleocapsid monoclonal antibody to detect rabies antigen in formalin-fixed, paraffin-embedded tissues. Hamir AN, et al. **Vet Rec** 1996 Feb 3;138(5):114–5

Detection of FeLV antigen [letter; comment] [see comments] Webb PJ. **Vet Rec** 1995 Jul 1;137(1):28. Comment on: Vet Rec 1995 May 20;136(20):516–8. Comment in: Vet Rec 1995 Jul 29;137(5):127. Comment in: Vet Rec 1995 Aug 19;137(8):200.

METABOLISM

Beta cell-specific expression of retroviral mRNAs and group-specific antigen and the development of beta cell-specific autoimmunity in non-obese diabetic mice. Pak CY, et al. **Autoimmunity** 1995;20(1):19–24

Expression of the chemokine receptor BLR2/EBI1 is specifically transactivated by Epstein-Barr virus nuclear antigen 2. Burgstahler R, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):737–43

Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells. Jochner N, et al. **EMBO J** 1996 Jan 15;15(2):375–82

A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. D'Amaro J, et al. **Hum Immunol** 1995 May; 43(1):13–8

Identification of Epstein-Barr virus nuclear antigen 1 protein domains that direct interactions at a distance between DNA-bound proteins. Laine A, et al. **J Biol Chem** 1995 Dec 29;270(52):30914–8

Down-regulation of Epstein-Barr virus nuclear antigen 1 in Reed-Sternberg cells of Hodgkin's disease [see comments] Khan G, et al. **J Clin Pathol** 1995 Sep; 48(9):845–8. Comment in: J Clin Pathol 1996 Mar;49(3):270.

Mutational analysis of the Epstein-Barr virus nuclear antigen 2 by far-Western blotting and DNA-binding studies. Sauder C, et al. **J Gen Virol** 1996 May;77 (Pt 5):991–6

PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter. Sjöblom A, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2679–92

Reversible nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 and hsp70 proteins after exposure to heat shock or cell density congestion. Szekely L, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2423–32

EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes. Johannsen E, et al. **J Virol** 1996 Jun;70(6):4179–83

Cellular or viral protein binding to a cytomegalovirus promoter transcription initiation site: effects on transcription. Macias MP, et al. **J Virol** 1996 Jun; 70(6):3628–35

The Epstein-Barr virus nuclear antigen leader protein associates with hsp72/hsc73. Mannick JB, et al. **J Virol** 1995 Dec;69(12):8169–72

The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). Robertson ES, et al. **J Virol** 1996 May;70(5):3068–74

Cooperative assembly of EBNA1 on the Epstein-Barr virus latent origin of replication. Summers H, et al. **J Virol** 1996 Feb;70(2):1228–31

The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies. Szekely L, et al. **J Virol** 1996 Apr;70(4):2562–8

Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA. Waltzer L, et al. **J Virol** 1996 Sep;70(9):5909–15

Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1. Wu DY, et al. **J Virol** 1996 Sep;70(9):6020–8

A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jkappa. Zhao B, et al. **J Virol** 1996 Jul;70(7):4228–36

Picture Story. Three's company. Felsenfeld AL. **Nat Struct Biol** 1996 Jan;3(1):23

RBP-J kappa repression activity is mediated by a co-repressor and antagonized by the Epstein-Barr virus transcription factor EBNA2. Waltzer L, et al. **Nucleic Acids Res** 1995 Dec 25;23(24):4939–45

Immunohistological demonstration of feline infectious peritonitis virus antigen in paraffin-embedded tissues using feline ascites or murine monoclonal antibodies. Tammer R, et al. **Vet Immunol Immunopathol** 1995 Nov; 49(1–2):177–82

Epstein-Barr virus nuclear antigen 2-estrogen receptor fusion proteins transactivate viral and cellular genes and interact with RBP-J kappa in a conditional fashion. Kempkes B, et al. **Virology** 1995 Dec 20;214(2):675–9

Biochemical analysis of the major vaccinia virus envelope antigen. Schmutz C, et al. **Virology** 1995 Oct 20; 213(1):19–27

PHARMACOLOGY

Recipient polyclonal B cell activation and immunoglobulin production induced by priming with a retroviral superantigen. Modlin CS, et al. **Cell Immunol** 1996 May 1;169(2):252–63

Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activate memory cytotoxic T lymphocytes. Reali E, et al. **J Leukoc Biol** 1996 Aug; 60(2):207–13

PHYSIOLOGY

T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Bachmann MF, et al. **Eur J Immunol** 1995 Dec; 25(12):3445–51

Tumorigenicity of EBNA2-transfected cells. Shimakage M, et al. **FEBS Lett** 1995 Sep 11;371(3):245–8

Epstein-Barr virus EBNA-LP and transcription regulation properties of pRB, p107 and p53 in transfection assays. Inman GJ, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2141–9

Epstein-Barr virus nuclear antigen 2 (EBNA2)-oestrogen receptor fusion proteins complement the EBNA2-deficient Epstein-Barr virus strain P3HR1 in transformation of primary B cells but suppress growth of human B cell lymphoma lines. Kempkes B, et al. **J Gen Virol** 1996 Feb; 77 (Pt 2):227–37

Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters. Sjöblom A, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2669–78

Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. Bain M, et al. **J Virol** 1996 Apr;70(4):2481–9

Human cytomegalovirus immediate-early 2 (IE2) protein can transactivate the human hsp70 promoter by alleviation of Dr1-mediated repression. Caswell R, et al. **J Virol** 1996 Jun;70(6):4028–37

Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity. Chen W, et al. **J Virol** 1996 Jul; 70(7):4849–53

The N-terminal half of EBNA2, except for seven prolines, is not essential for primary B-lymphocyte growth transformation. Yalamanchili R, et al. **J Virol** 1996 Apr; 70(4):2468–73

THERAPEUTIC USE

Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Judde JG, et al. **Hum Gene Ther** 1996 Mar 20;7(5):647–53

Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. Kirchner HH, et al. **World J Urol** 1995;13(3):171–3

URINE

Evaluation of antigen and antibody detection in urine specimens from children with congenital human cytomegalovirus infection. Koopmans M, et al. **J Med Virol** 1995 Aug;46(4):321–8

ANTIGENS, VIRAL, TUMOR

ADMINISTRATION & DOSAGE

T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma. Springer GF, et al. **Cancer Detect Prev** 1995;19(4):374–80

ANALYSIS

Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. Miller G, et al. **N Engl J Med** 1996 May 16; 334(20):1292–7

[Suitability of monoclonal reagents for antigen determination in T-antigen activation] Strobel E. **Infusionsther Transfusionsmed** 1995 Aug;22(4):249–57 (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Metastatic prostate cancer in a transgenic mouse. Gingrich JR, et al. **Cancer Res** 1996 Sep 15;56(18):4096–102

Relationships between intermediate filaments and cell-specific functions in renal cell lines derived from transgenic mice harboring the temperature-sensitive T antigen. Cluzeaud F, et al. **J Cell Physiol** 1996 Apr; 167(1):22–35

Relationship between expression of epidermal growth factor and simian virus 40 T antigen in a line of transgenic mice. Lafond RE, et al. **Transgenic Res** 1995 Sep;4(5):306–14

BLOOD

Expression of the T antigen on a T-lymphoid cell line, supT1. Nakada H, et al. **Glycoconj J** 1995 Jun;12(3):356–9

DRUG EFFECTS

Quantitative flow cytometry reveals a hierarchy of glucocorticoid effect on cell surface mouse mammary tumor virus gp52. Ritzi EM. **J Steroid Biochem Mol Biol** 1996 Jan;57(1–2):33–42

GENETICS

Large T antigen coding sequences of two DNA tumor viruses, BK and SV40, and nonrandom chromosome changes in two glioblastoma cell lines. Tognon M, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):17–23

Temperature sensitive simian virus 40 large T antigen immortalization of murine odontoblast cell cultures: establishment of clonal odontoblast cell line. MacDougall M, et al. **Connect Tissue Res** 1995;33(1–3):97–103

Immortalized murine osteoblasts derived from BMP 2-T-antigen expressing transgenic mice. Ghosh-Choudhury N, et al. **Endocrinology** 1996 Jan; 137(1):331–9

Human JC virus nuclear factor 1 binding motifs and large tumor antigen region rquired for transactivation of late promoter. Kumar KU, et al. **J Neurochem** 1996 Aug; 67(2):473–81

IMMUNOLOGY

Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Lin KY, et al. **Cancer Res** 1996 Jan 1; 56(1):21–6

Lack of MMTV superantigen presentation in MHC class II-deficient mice. Beutner U, et al. **Cell Immunol** 1996 Mar 15;168(2):141–7

METABOLISM

Requirements for mouse mammary tumour virus internalization in mouse mammary epithelial cells. Bolander FF Jr. **J Gen Virol** 1996 Apr;77 (Pt 4):793–6

Activation of the human thymidine kinase (TK) promoter by simian virus 40 large T antigen requires both the T antigen pRb family-binding domain and TK promoter sequences resembling E2F-binding sites. Anderson MM, et al. **J Virol** 1996 Sep;70(9):6304–13

Phosphatidylinositol 3-kinase binding to polyoma virus middle tumor antigen mediates elevation of glucose transport by increasing translocation of the GLUT1 transporter. Young AT, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11613–7

PHYSIOLOGY

Rat embryo fibroblasts immortalized with simian virus 40 large T antigen undergo senescence upon its inactivation. Gonos ES, et al. **Mol Cell Biol** 1996 Sep;16(9):5127–38

ANTIGENS, XENOGENEIC see **ANTIGENS, HETEROPHILE**

ANTIGLOBULIN CONSUMPTION TEST see **COOMBS' TEST**

ANTIGLOBULIN TEST see COOMBS' TEST

ANTIGLOBULINS see ANTIBODIES, ANTI-IDIOTYPIC

ANTIGOUT AGENTS see GOUT SUPPRESSANTS

ANTIGRAVITY SUITS see G SUITS

ANTI-HBAG see HEPATITIS B ANTIBODIES

ANTI-HCV ANTIBODIES see HEPATITIS C ANTIBODIES

ANTIHEMOPHILIC FACTOR see FACTOR VIII

ANTIHEPARIN FACTOR see PLATELET FACTOR 4

ANTI-HEPATITIS B ANTIGENS see HEPATITIS B ANTIBODIES

ANTI-HEPATITIS C VIRUS ANTIBODIES see HEPATITIS C ANTIBODIES

ANTIHISTAMINES see HISTAMINE H1 ANTAGONISTS

ANTIHISTAMINES, CLASSICAL see HISTAMINE H1 ANTAGONISTS

ANTIHISTAMINICS, CLASSICAL see HISTAMINE H1 ANTAGONISTS

ANTIHISTAMINICS, H1 see HISTAMINE H1 ANTAGONISTS

ANTIHISTAMINICS, H2 see HISTAMINE H2 ANTAGONISTS

ANTI-HIV POSITIVITY see HIV SEROPOSITIVITY

ANTI-HUMAN GLOBULIN COMPLEMENT-DEPENDENT CYTOTOXICITY TESTS see CYTOTOXICITY TESTS, IMMUNOLOGIC

ANTI-HUMAN GLOBULIN CONSUMPTION TEST see COOMBS' TEST

ANTIHYPERTENSIVE AGENTS

see related
ADRENERGIC ALPHA-ANTAGONISTS
ADRENERGIC BETA-ANTAGONISTS
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
DIURETICS
GANGLIONIC BLOCKERS
VASODILATOR AGENTS

Atypical drug abuse: a case report involving clonidine. Dy EC, et al. **Am Fam Physician** 1996 Sep 1;54(3):1035–8

Preliminary study on controlled hypotension induced by nimodipine in craniocerebral surgery. Zhang P, et al. **Chin Med J (Engl)** 1995 Jun;108(6):420–2

Drugs for hypertension. **Conn Med** 1995 Sep;59(9):545–50

Low-dose thiazides in the treatment of hypertension: benefits and risks in perspective. Silverberg DS, et al. **J Hum Hypertens** 1995 Nov;9(11):869–73 (80 ref.)

Discovery of losartan, the first angiotensin II receptor antagonist. Timmermans PB, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S3–18 (199 ref.)

Angiotensin receptor antagonists: focus on losartan. Johnston CI. **Lancet** 1995 Nov 25;346(8987):1403–7 (36 ref.)

Promotion of Coversyl by Servier [letter] Vitry A, et al. **Lancet** 1996 May 18;347(9012):1411

Trends in antihypertensive prescribing. Penrose A, et al. **N Z Med J** 1996 Jan 26;109(1014):4–7

[Losartan. The first non-peptide angiotensin II receptor antagonist for treatment of hypertension] Ibsen H, et al. **Ugeskr Laeger** 1996 Jun 24;158(26):3798–802 **(Dan)**

ADMINISTRATION & DOSAGE

Risk factors and differential antihypertensive therapies. Os I. **Acta Med Austriaca** 1995;22(3):45–7 (31 ref.)

Use of enalapril in neonatal hypertension. Schilder JL, et al. **Acta Paediatr** 1995 Dec;84(12):1426–8

Evaluation of blood pressure response to the combination of enalapril (single dose) and diltiazem ER (four different doses) in systemic hypertension. Applegate WB, et al. **Am J Cardiol** 1996 Jul 1;78(1):51–5

Editorial: combination therapy for systemic hypertension (15 September 1995) [letter] Lip GY, et al. **Am J Cardiol** 1996 Jul 1;78(1):129–30

Alternatives to oral antihypertensive agents [letter; comment] Burnakis TG. **Am J Health Syst Pharm** 1995 Nov 15; 52(22):2598; discussion 2599. Comment on: Am J Health Syst Pharm 1995 Jul 15;52(14):1514–6, 1518.

Intravenous antihypertensive agents for patients unable to take oral medications [see comments] Zigmont EA, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1514–6, 1518 . Comment in: Am J Health Syst Pharm 1995 Nov 15;52(22):2598; discussion 2599. Comment in: Am J Health Syst Pharm 1995 Nov 15;52(22):2598–9.

The emerging role of chronotherapeutics in managing hypertension. Panel discussion. Black HR, et al. **Am J Hypertens** 1996 Apr;9(4 Pt 3):34S–39S

A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. Friedman RH, et al. **Am J Hypertens** 1996 Apr;9(4 Pt 1):285–92

Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Olschewski H, et al. **Ann Intern Med** 1996 May 1;124(9):820–4

Self-initiated modification of hypertension treatment in response to perceived problems. Wallenius SH, et al. **Ann Pharmacother** 1995 Dec;29(12):1213–17

Skin depigmentation related to transdermal clonidine therapy [letter] Doe N, et al. **Arch Intern Med** 1995 Oct 23; 155(19):2129

Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Hirschl MM, et al. **Arch Intern Med** 1995 Nov 13;155(20):2217–23

Predictive value of ambulatory blood pressure shortly after withdrawal of antihypertensive drugs in primary care patients. Beltman FW, et al. **BMJ** 1996 Aug 17; 313(7054):404–6

Sublingual timolol—an alternative to topical medication in glaucoma? Sadiq SA, et al. **Br J Ophthalmol** 1996 Jun; 80(6):532–5

One vs. two doses of 1.0% apraclonidine for prophylaxis of intraocular pressure spike after argon laser trabeculoplasty. Birt CM, et al. **Can J Ophthalmol** 1995 Aug;30(5):266–9

Antihypertensive efficacy of optimally titrated doses of once-daily sustained-release diltiazem: a placebo-controlled trial. DILPLACOMP Study Group. Ollivier JP, et al. **Cardiology** 1995;86(6):481–7

A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension. Chen MF, et al. **Cardiovasc Drugs Ther** 1995 Jun;9(3):401–6

Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension. The Canadian Multicenter Diltiazem-CD Hypertension Trial Group. Ruddy TD, et al. **Cardiovasc Drugs Ther** 1995 Jun;9(3):413–20

Evaluation of antihypertensive effects of once-a-day isradipine and fosinopril: a double-blind crossover study by means of ambulatory blood pressure monitoring. Perticone F, et al. **Clin Cardiol** 1995 Jul;18(7):401–7

Hypotensive effects of a new transdermal delivery system for clonidine (M-5041T) in spontaneously and renal hypertensive rats. Ishii R, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S374–6

Miscompliance by proxy. Jamieson MJ, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):594

Comparison between a bid and a tid regimen: improved compliance with no improved antihypertensive effect. The EOL Research Group. Boissel JP, et al. **Eur J Clin Pharmacol** 1996;50(1–2):63–7

Determination of (+)- and (–)-nicardipine concentrations in human serum and their correlation with the antihypertensive effect after oral administration of racemic nicardipine. Iwaoka T, et al. **Eur J Clin Pharmacol** 1995; 48(5):345–9

Influence of repeated prazosin administration on cardiovascular responses in rats and rabbits. Hui SC, et al. **Experientia** 1996 Jan 16;52(1):66–9

Hypotensive response to losartan in normal rats. Role of Ang II and the area postrema. Collister JP, et al. **Hypertension** 1996 Mar;27(3 Pt 2):598–606

The effects of antihypertensive treatment on cognitive function: results from the HOPE study. Starr JM, et al. **J Am Geriatr Soc** 1996 Apr;44(4):411–5

Hypertension: a multietiological disease requires a multifactorial approach [editorial; comment] Trotman BW. **J Assoc Acad Minor Phys** 1995;6(4):124. Comment on: J Assoc Acad Minor Phys 1995;6(4):125–9.

The use of intrapleural clonidine for postoperative pain control. Canver CC, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):183–5

Anti-hypertensive effects of intravenous compared with oral captopril. Sramek JJ, et al. **J Hum Hypertens** 1995 Nov; 9(11):875–8

Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. Schneider M, et al. **J Hypertens** 1996 May;14(5):669–77

Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? Bakris GL, et al. **J Hypertens Suppl** 1995 Aug;13(2):S95–101 (52 ref.)

Guidelines for the treatment of hypertension: an American view. Fifth Joint National Committee. Kaplan NM. **J Hypertens Suppl** 1995 Aug;13(2):S113–7 (16 ref.)

The pharmacological basis for the combination of calcium channel antagonists and angiotensin converting enzyme inhibitors in the treatment of hypertension. Osswald H, et al. **J Hypertens Suppl** 1995 Aug;13(2):S21–8 (58 ref.)

Main objectives and new aspects of combination treatment of hypertension. Waeber B, et al. **J Hypertens Suppl** 1995 Aug;13(2):S15–9 (17 ref.)

Practical relevance of the 24-hour trough: peak ratio of antihypertensive drugs. Zannad F. **J Hypertens Suppl** 1995 Aug;13(2):S109–12 (41 ref.)

Sublingual nifedipine compared with intravenous hydrallazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice. Jegasothy R, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):21–4

Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations. Bialer M, et al. **J Pharm Sci** 1995 Oct;84(10):1160–3

When to use antihypertensives [editorial] Swales J. **Practitioner** 1996 Jun;240(1563):351

Non-responders. Os I. **Wien Med Wochenschr** 1995; 145(15–16):357–60 (32 ref.)

[Treatment of hypertension with a fixed combination of bopindolol and chlorthalidone (Sandoretic)] Widimský J, et al. **Vnitr Lek** 1996 Apr;42(4):223–8 (Eng. Abstr.) **(Cze)**

[Hypertensive crises (letter)] Strandgaard S. **Ugeskr Laeger** 1996 Aug 5;158(32):4535–6 **(Dan)**

[Comparison of blood pressure profile during exercise with benazepril 10 mg and benazepril 5 mg/hydrochlorothiazide 6.25 mg fixed combination] Boutelant S, et al. **Therapie** 1995 Jul-Aug;50(4):313–8 (Eng. Abstr.) **(Fre)**

[Double blind randomized comparative study of two antihypertensive combinations. Enalapril-hydrochlorothiazide versus enalapril-nifedipine in 240 hypertensive patients resistant to monotherapy] Frances Y, et al. **Therapie** 1996 Jan-Feb;51(1):35–9 (Eng. Abstr.) **(Fre)**

[Comparison of clinical and ambulatory measurements of blood pressure with benazepril alone or combined with hydrochlorothiazide in hypertension] Le Feuvre C, et al. **Therapie** 1996 Jan-Feb;51(1):27–34 (Eng. Abstr.) **(Fre)**

[Antihypertensive therapy in stroke: acute therapy, primary and secondary prevention] Brainin M. **Acta Med Austriaca** 1995;22(3):54–7 (36 ref.) (Eng. Abstr.) **(Ger)**

[Refractory hypertension—principles of combination therapy] Hitzenberger G. **Acta Med Austriaca** 1995; 22(3):43–5 (14 ref.) (Eng. Abstr.) **(Ger)**

[Antihypertensive therapy in renal failure] Mayer G. **Acta Med Austriaca** 1995;22(3):51–3 (19 ref.) (Eng. Abstr.) **(Ger)**

[Why is there no sustained-release form of captopril?] Thürmann P, et al. **Dtsch Med Wochenschr** 1996 Aug 23; 121(34–35):1072 **(Ger)**

[Effectiveness and tolerance of combined verapamil retard and hydrochlorothiazide. Results of a double-blind, randomized study] von Manteuffel GE, et al. **Fortschr Med** 1995 Sep 20;113(26):374–8 (Eng. Abstr.) **(Ger)**

[Interactions between antihypertensive agents of different mechanisms of action] Hitzenberger G. **Wien Med Wochenschr** 1995;145(15–16):352–4 (22 ref.) (Eng. Abstr.) **(Ger)**

[Patient compliance of hypertensive patients in the physician's practice] Magometschnigg D. **Wien Med Wochenschr** 1995;145(15–16):360–4 (Eng. Abstr.) **(Ger)**

[What are the therapeutic consequences of evaluating hypertensive patients with 24-hour blood pressure monitors and blood pressure self-measurement?] Zweiker R, et al. **Wien Med Wochenschr** 1995;145(15–16):365–72 (74 ref.) (Eng. Abstr.) **(Ger)**

[Use of medication for hypertension and coronary heart disease by Russian immigrants] Ben-Noun L. **Harefuah** 1995 Nov 15;129(10):392–4, 446 (Eng. Abstr.) **(Heb)**

[Cilazapril replacing captopril in the therapy of medium-severe essential hypertension] Kovács P, et al. **Orv Hetil** 1995 Oct 15;136(42):2273–8 (Eng. Abstr.) **(Hun)**

[The treatability of refractory or resistant hypertension by personalized antihypertensive chronotherapy based on ambulatory monitoring of the arterial pressure] Cugini P. **Recenti Prog Med** 1996 Feb;87(2):51–7 (Eng. Abstr.) **(Ita)**

[Anti-hypertensive therapy in chronic hemodialysis] Takabatake T. **Nippon Naika Gakkai Zasshi** 1995 Oct 10; 84(10):1643–7 (5 ref.) **(Jpn)**

[Effects of chronic losartan treatment on myocardial, vascular structure and reactivity with aging in spontaneously hypertensive rats (SHR): its effects compared with those of captopril] Nishimura N, et al. **Nippon Yakurigaku Zasshi** 1995 Jun;105(6):479–89 (Eng. Abstr.) **(Jpn)**

[Antihypertensive effects of repeated oral administration of cilnidipine, a novel calcium antagonist, in 2K1C renal hypertensive dogs] Takahara A, et al. **Nippon Yakurigaku Zasshi** 1995 Oct;106(4):279–87 (Eng. Abstr.) **(Jpn)**

[Treatment of hypertension—change to the expensive! (letter)] Swensen E, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3070 **(Nor)**

[Efficacy and tolerability of the captopril and hydrochlorothiazide combination in the treatment of mild to moderate hypertension. Multicenter study] Velasco-Cornejo IF, et al. **Arq Bras Cardiol** 1995 Jun; 64(6):571–5 (Eng. Abstr.) **(Por)**

[An assessment of the efficacy of Lomir in treating hypertension in patients in the early period after aortocoronary bypass operations] Tskhovrebov SV, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):58–60 (Eng. Abstr.) **(Rus)**

[The pharmacokinetics of propranolol and its conjugated metabolites in patients with chronic ischemic heart disease and arterial hypertension with a one-time and course intake

of the drug] Belolipetskaia VG, et al. **Eksp Klin Farmakol** 1995 Nov-Dec;58(6):56-9 (Eng. Abstr.) **(Rus)**

[Chrono-pharmacodynamic effects of sinepres in patients with hypertension] Akhmetov KZh, et al. **Klin Med (Mosk)** 1995;73(4):97 **(Rus)**

[The evaluation of cilazapril efficacy in patients with stable arterial hypertension (a randomized study)] Belousov IuB, et al. **Ter Arkh** 1995;67(9):53-6 (Eng. Abstr.) **(Rus)**

[The antihypertensive activity of benazepril in the long-term treatment of hypertension patients and its effect on adrenal cortical function] Ol'binskaia LI, et al. **Ter Arkh** 1995; 67(9):56-8 (Eng. Abstr.) **(Rus)**

[The antihypertensive effect of lisinopril in a single daily dosage. A study of arterial pressure with ambulatory monitoring] González Romero S, et al. **Arch Inst Cardiol Mex** 1995 Sep-Oct;65(5):435-43 (Eng. Abstr.) **(Spa)**

[Fixed combinations of antihypertensive drugs (letter; comment)] Pascual J, et al. **Med Clin (Barc)** 1996 Apr 13; 106(14):558. Comment on: Med Clin (Barc) 1995 Apr 29;104(16):620-1. **(Spa)**

[Combination drugs in the treatment of hypertension. Simpler for patients, physicians and pharmacies] Himmelmann A, et al. **Lakartidningen** 1995 Sep 27;92(39):3557-8, 3563 (20 ref.) **(Swe)**

ADVERSE EFFECTS

Cardiac failure aggravated by timolol eye drops: preoperative improvement by changing to pilocarpine. Bäcklund M, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):379-81

Sexually speaking ... the dance. Cavalier M. **Alaska Med** 1995 Jul-Sep;37(3):113

Association of metoprolol and retroperitoneal fibrosis. Ahmad S. **Am Heart J** 1996 Jan;131(1):202-3

Renal cell cancer in hypertensive patients more likely related to lead exposure than to antihypertensive medication [letter; comment] Kurt TL. **Am J Epidemiol** 1995 Nov 15; 142(10):1123. Comment on: Am J Epidemiol 1994 Nov 1;140(9):792-804. Comment on: Am J Epidemiol 1994 Nov 1;140(9):821-9.

Variations in magnesium and zinc in hypertensive patients receiving different treatments. Rubio-Luengo MA, et al. **Am J Hypertens** 1995 Jul;8(7):689-95

Monitoring and management of antihypertensive therapy induced deterioration in acute ischemic stroke [letter] Treib J, et al. **Am J Hypertens** 1996 May;9(5):513-4

Sodium nitroprusside administration [letter; comment] Jarka RM. **Anesth Analg** 1996 Mar;82(3):669. Comment on: Anesth Analg 1995 Jul;81(1):152-62.

Diuretics and sudden cardiac death [letter; comment] Aursnes A. **Ann Intern Med** 1996 Aug 15;125(4):346;discussion 348-9. Comment on: Ann Intern Med 1995 Oct 1;123(7):481-7.

Diuretics and sudden cardiac death [letter; comment] Cabell CH, et al. **Ann Intern Med** 1996 Aug 15;125(4):347; discussion 347-8. Comment on: Ann Intern Med 1995 Oct 1;123(7):481-7.

Beta-blockers and sudden cardiac death [letter; comment] Messerli FH. **Ann Intern Med** 1996 Aug 15;125(4):349. Comment on: Ann Intern Med 1995 Sep 1;123(5):358-67.

Renal impairment associated with losartan [letter] Saine DR, et al. **Ann Intern Med** 1996 Apr 15;124(8):775

Diuretics and sudden cardiac death [letter; comment] Winkelmann BR. **Ann Intern Med** 1996 Aug 15; 125(4):347-8; discussion 348-9. Comment on: Ann Intern Med 1995 Oct 1;123(7):481-7.

Comment: thiazide-induced pulmonary edema. Biron P. **Ann Pharmacother** 1996 Apr;30(4):415-6

Skin depigmentation related to transdermal clonidine therapy [letter] Doe N, et al. **Arch Intern Med** 1995 Oct 23; 155(19):2129

Calcium antagonists and mortality. Another case of the need for clinical judgment [editorial; comment] [see comments] Fagan TC. **Arch Intern Med** 1995 Nov 13;155(20):2145. Comment on: Arch Intern Med 1995 Nov 13;155(20):2150-6. Comment on: Arch Intern Med 1995 Nov 13;155(20):2157-61. Comment in: Arch Intern Med 1996 May 27;156(10):1115-6.

Portal-systemic encephalopathy and gastrointestinal bleeding after cardioselective beta-blocker (metoprolol) administration to patients with portal hypertension. Uribe M, et al. **Arch Med Res** 1995 Autumn;26(3):221-6

Bilateral acute angle-closure glaucoma associated with drug sensitivity to hydrochlorothiazide [letter] Geanon JD, et al. **Arch Ophthalmol** 1995 Oct;113(10):1231-2

Triplex-DNA stabilization by hydralazine and the presence of anti-(triplex DNA) antibodies in patients treated with hydralazine. Thomas TJ, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):183-8

Angiotensin converting enzyme inhibitor therapy and acute pancreatitis. Madsen JS, et al. **Blood Press** 1995 Nov; 4(6):369-71

Factors influencing the success of withdrawal of antihypertensive drug therapy. Jennings GL, et al. **Blood Press Suppl** 1995;2:99-107 (28 ref.)

Effect of antihypertensive treatment on cognitive function of older patients. Effect is not proved [letter; comment] Irvine CD, et al. **BMJ** 1996 Jul 20;313(7050):166-7. Comment on: BMJ 1996 Mar 30;312(7034):801-5.

Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs: population based cohort study [see comments] Merlo J, et al. **BMJ** 1996 Aug 24;313(7055):457-61. Comment in: BMJ 1996 Aug 24;313(7055):437-8.

Drug-induced Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with hydralazine. Gilmour E, et al. **Br J Dermatol** 1995 Sep;133(3):490-1

Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought. Burvenich H. **Bull Soc Belge Ophtalmol** 1995;257:63-6; discussion 66-7

Heretical report on the efficacy of blood pressure treatment in a population setting [editorial] Lund-Johansen P. **Cardiovasc Drugs Ther** 1995 Jun;9(3):373-4

Zinc, hydrochlorothiazide and sexual dysfunction. Khedun SM, et al. **Cent Afr J Med** 1995 Oct;41(10):312-5

Corrections to the nifedipine meta-analysis [letter] Furberg CD, et al. **Circulation** 1996 Apr 1;93(7):1475-6

Nifedipine study [letter; comment] Lichtlen PR. **Circulation** 1996 Apr 1;93(7):1472; discussion 1473. Comment on: Circulation 1995 Sep 1;92(5):1326-31.

Calcium blockers and risk of myocardial infarction and coronary heart disease mortality [letter; comment] Mehta JL, et al. **Circulation** 1996 Apr 1;93(7):1472; discussion 1473 . Comment on: Circulation 1995 Sep 1;92(5):1326-31.

Nifedipine in patients with heart disease [letter] Phillips RA, et al. **Circulation** 1996 Apr 1;93(7):1474-5

Nifedipine trials [letter; comment] Rafflenbeul W. **Circulation** 1996 Apr 1;93(7):1473-4. Comment on: Circulation 1995 Sep 1;92(5):1068-73. Comment on: Circulation 1995 Sep 1;92(5):1074-8. Comment on: Circulation 1995 Sep 1;92(5):1326-31.

Nimodipine in patients with heart disease [letter; comment] Roine RO. **Circulation** 1996 Apr 1;93(7):1472-3; discussion 1473. Comment on: Circulation 1995 Sep 1;92(5):1326-31.

Enalapril-induced toxic pustuloderma. Ferguson JE, et al. **Clin Exp Dermatol** 1996 Jan;21(1):54-5

omega-Conotoxin GVIA and prazosin, but not felodipine, cause postural hypotension in rabbits. Hawkes AL, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):711-6

Brief treatment of SHR with an ACE inhibitor fails to cause long-term normotension but markedly increases mortality. Lan L, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S345-6

Generalized pustular eruption associated with converting enzyme inhibitor therapy. Carroll J, et al. **Cutis** 1995 Nov; 56(5):276-8

Captopril-induced acute pancreatitis. Jeandidier N, et al. **Diabetes Care** 1995 Mar;18(3):410-1

The changing face of hypertension and antihypertensive agents. Kitler ME. **Drugs Aging** 1996 Jan;8(1):5-11 (43 ref.)

Effects of ACE inhibition on endurance exercise haemodynamics in trained subjects with mild hypertension. Palatini P, et al. **Eur J Clin Pharmacol** 1995;48(6):435-9

Uterine and fetal hemodynamics and fetal cardiac function after atenolol and pindolol infusion. A randomized study. Räsänen J, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):195-201

Fulminant hepatic failure caused by ecarazine hydrochloride (a hydralazine derivative). Tameda Y, et al. **Hepatology** 1996 Mar;23(3):465-70

Hydralazine-induced lupus: yet another autoantibody! Pirmohamed M. **Hum Exp Toxicol** 1996 Apr;15(4):361-2

Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non-diabetic hypertensive subjects. Satia MC, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):237-41

International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. McLaughlin JK, et al. **Int J Cancer** 1995 Oct 9;63(2):216-21

Accupril- and Cozaar-induced angioedema in the same patient [letter] Boxer M. **J Allergy Clin Immunol** 1996 Aug; 98(2):471

A delayed answer to the calcium blocker question [editorial] Parmley WW. **J Am Coll Cardiol** 1996 Feb;27(2):510-1

Enalapril and peripheral neuropathy [letter] Ahmad S. **J Am Geriatr Soc** 1995 Oct;43(10):1182

Severe hyponatremia associated with ramipril therapy in an old woman [letter] Tilly-Gentric A. **J Am Geriatr Soc** 1995 Dec;43(12):1448-9

Epidemiology of the adverse hemodynamic events occurring during "clonidine anesthesia": a prospective open trial of intraoperative intravenous clonidine. De Kock M, et al. **J Clin Anesth** 1995 Aug;7(5):403-10

The incidence of depression in new users of beta-blockers and selected antihypertensives. Gerstman BB, et al. **J Clin Epidemiol** 1996 Jul;49(7):809-15

Pharmacokinetics and safety of a novel, long-acting, prodrug-type potassium channel opener, Y-27152, in healthy volunteers. Uematsu T, et al. **J Clin Pharmacol** 1996 May;36(5):439-51

Clonidine-induced bradycardia. Golusinski LL Jr, et al. **J Fam Pract** 1995 Oct;41(4):399-401

Calcium channel blockers and myocardial infarction. Smith GN. **J Fam Pract** 1996 Jan;42(1):30-2

Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs--the rationale and benefits of combining felodipine and metoprolol. Trenkwalder P, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S37-42 (17 ref.)

Antihypertensive therapy: safety and efficacy of drugs and publications [editorial] Frohlich ED, et al. **J Hypertens** 1996 Mar;14(3):273-5

Perioperative angioedema in a patient on long-term angiotensin-converting enzyme (ACE)-inhibitor therapy. Ogbureke KU, et al. **J Oral Maxillofac Surg** 1996 Jul; 54(7):917-20 (18 ref.)

Can hydrochlorothiazide cause lupus? [letter] Rich MW, et al. **J Rheumatol** 1995 May;22(5):1001

Losartan and severe migraine [letter] Ahmad S. **JAMA** 1995 Oct 25;274(16):1266-7

Myocardial infarction associated with antihypertensive drug therapy [letter; comment] Feeman WE Jr. **JAMA** 1996 Feb 21;275(7):515; discussion 516-7. Comment on: JAMA 1995 Aug 23-30;274(8):620-5.

Does antihypertensive therapy modify chronic allograft failure? Raine AE. **Kidney Int Suppl** 1995 Dec;52:S107-11

Calcium antagonists and gastrointestinal haemorrhage: the balancing act [comment] Gordon RD. **Lancet** 1996 Apr 20;347(9008):1056. Comment on: Lancet 1996 Apr 20;347(9008):1061-5.

Antihypertensive drugs and risk of malignant diseases [letter; comment] Hardell L, et al. **Lancet** 1996 Aug 24; 348(9026):542. Comment on: Lancet 1996 Aug 24;348(9026):487.

Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old [see comments] Pahor M, et al. **Lancet** 1996 Apr 20; 347(9008):1061-5. Comment in: Lancet 1996 Apr 20;347(9008):1056.

Reversible ageusia associated with losartan [letter] Schlienger RG, et al. **Lancet** 1996 Feb 17;347(8999):471-2

Potential adverse effects of blood pressure lowering--J-curve revisited. Staessen JA. **Lancet** 1996 Sep 14;348(9029):696-7

Trumping the ACE [letter] Vane J. **Lancet** 1995 Sep 30; 346(8979):916

Angioedema induced by the angiotensin II blocker losartan [letter] Acker CG, et al. **N Engl J Med** 1995 Dec 7; 333(23):1572

Losartan-induced azotemia in a diabetic recipient of a kidney transplant [letter] Cohen LS, et al. **N Engl J Med** 1996 May 9;334(19):1271-2

Hydralazine-induced constrictive pericarditis. Franssen CF, et al. **Neth J Med** 1996 May;48(5):193-7 (21 ref.)

DL-tetrahydropalmatine-produced hypotension and bradycardia in rats through the inhibition of central nervous dopaminergic mechanisms. Chueh FY, et al. **Pharmacology** 1995 Oct;51(4):237-44

The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Jick H, et al. **Pharmacotherapy** 1996 May-Jun;16(3):321-6

Minoxidil, hypercoagulability and thromboembolic disease of the lung. Keohane SG, et al. **Postgrad Med J** 1996 Apr; 72(846):229-30

Mania secondary to lisinopril therapy [letter] Skop BP, et al. **Psychosomatics** 1995 Sep-Oct;36(5):508-9

Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. Short AK, et al. **QJM** 1995 Nov; 88(11):775-83

Stroke and hypertension. Antihypertensive therapy withdrawal. Popa G, et al. **Rom J Neurol Psychiatry** 1995 Jan-Mar;33(1):29-35

Losartan and angina pectoris. Ahmad S. **Tex Heart Inst J** 1995;22(4):347-8

At risk nephrons and the decline in renal function in response to treatment of hypertension. Walker WG, et al. **Trans Am Clin Climatol Assoc** 1995;107:134-43; discussion 143-5 (26 ref.)

[Psychotropic effects of angiotensin-converting enzyme inhibitors: what are the arguments?] Mesure G, et al. **Encephale** 1995 Sep-Oct;21(5):609-14 (59 ref.) (Eng. Abstr.) **(Fre)**

[Life-threatening postoperative angioedema following treatment with an angiotensin converting enzyme inhibitor] Maier C. **Anaesthesist** 1995 Dec;44(12):875-9 (Eng. Abstr.) **(Ger)**

[Timolol eyedrops and sinusitis (letter)] Bergsmark J. **Tidsskr Nor Laegeforen** 1996 May 30;116(14):1716 **(Nor)**

[Side effects of antihypertensive drugs] Córdoba García R. **Aten Primaria** 1996 Apr 15;17(6):420-4 (54 ref.) **(Spa)**

[Leukocytoclastic vasculitis in relation to amlodipine administration (letter)] del Río Fernández MC, et al. **Rev Clin Esp** 1995 Oct;195(10):738-9 **(Spa)**

[Concomitant therapies in the clinical trial in Alzheimer's disease] Bermejo F, et al. **Rev Neurol** 1995 Jan-Feb; 23(119):118-24 (81 ref.) (Eng. Abstr.) **(Spa)**

[Myalgia during treatment with Cozaar] **Lakartidningen** 1995 Dec 20;92(51-52):4916 **(Swe)**

ANALYSIS

Determination of reserpine and chlorothiazide in commercial tablets by liquid chromatography with fluorescence and UV absorbance detectors in series. Cieri UR. **J AOAC Int** 1995 Nov-Dec;78(6):1384-7

Simultaneous determination of enalapril maleate and hydrochlorothiazide by first-derivative ultraviolet spectrophotometry and high-performance liquid chromatography. el Walily AF, et al. **J Pharm Biomed Anal** 1995 Jun;13(7):851-6

Immunohistochemical localization of adrenomedullin in canine heart and aorta. Jougasaki M, et al. **Peptides** 1995; 16(4):773-5

ANTAGONISTS & INHIBITORS

Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis. Moreno H Jr, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):93–6

Metoclopramide blocks bromocriptine induced antihypertensive effect in hypertensive patients. Luchsinger A, et al. **Int J Clin Pharmacol Ther** 1995 Sep;33(9):509–12

[To what extent can prostaglandin synthesis inhibitors of the non-steroidal antirheumatic (NSAR) type modify the effect of ACE inhibitors?] Grote L. **Internist (Berl)** 1995 Dec; 36(12):1203–4 **(Ger)**

[The neurohumoral mechanisms of the efficacy of therapeutic plasmapheresis in patients with resistant forms of arterial hypertension] Volos BE, et al. **Lik Sprava** 1995 Jul–Aug; (7–8):11–4 **(Rus)**

BLOOD

Determination of (+)- and (–)-nicardipine concentrations in human serum and their correlation with the antihypertensive effect after oral administration of racemic nicardipine. Iwaoka T, et al. **Eur J Clin Pharmacol** 1995; 48(5):345–9

Plasma adrenomedullin in various diseases and exercise-induced change in adrenomedullin in healthy subjects. Tanaka M, et al. **Intern Med** 1995 Aug; 34(8):728–33

Automation and validation of the high-performance liquid chromatographic-radioimmunoassay method for the determination of lacidipine in plasma. Braggio S, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):383–9

Development and validation of column-switching high-performance liquid chromatographic methods for the determination of a potent AII receptor antagonist, TCV-116, and its metabolites in human serum and urine. Lee JW, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):287–98

[Beta-blocking agents] Suzuki M. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:978–82 (16 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Novel 2-amino-1,4-dihydropyridine calcium antagonists. I. Synthesis and antihypertensive effects of 2-amino-1,4-dihydropyridine derivatives having nitroxy-alkoxycarbonyl groups at 3- and/or 5-position. Kobayashi T, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):788–96

Novel 2-amino-1,4-dihydropyridine calcium antagonists. II. Synthesis and antihypertensive effects of 2-amino-1,4-dihydropyridine derivatives having N,N-dialkylaminoalkoxycarbonyl groups at 3- and/or 5-position. Kobayashi T, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):797–817

Studies on agents with vasodilator and beta-blocking activities. III. Synthesis and activity of optical isomers of TZC-1370. Seki T, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1719–23

Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers. Yamamoto S, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):734–45

Diphenylpropionic acids as new AT1 selective angiotensin II antagonists. Almansa C, et al. **J Med Chem** 1996 May 24;39(11):2197–206

Derivatives of 5-[[1-(4'-carboxybenzyl) imidazolyl]methylidene]hydantoins as orally active angiotensin II receptor antagonists. Edmunds JJ, et al. **J Med Chem** 1995 Sep 15;38(19):3759–71

Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. Fournie-Zaluski MC, et al. **J Med Chem** 1996 Jun 21;39(13):2594–608

[Synthesis of certain derivatives of 5-methoxy-3-[(benzazole-2-yl) thioacetylamino]-2,3-dihydrobenzofuran and research on their antihypertensive activities] Turan-Zitouni G, et al. **Ann Pharm Fr** 1996;54(3):109–11 (Eng. Abstr.) **(Fre)**

CHEMISTRY

A non-peptide angiotensin II receptor antagonist: 2-butyl-6-dimethoxymethyl-5-phenyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazo[5,4-b]pyridine. Shin W, et al. **Acta Crystallogr C** 1996 Apr 15;52 (Pt 4):1019–22

Diphenylpropionic acids as new AT1 selective angiotensin II antagonists. Almansa C, et al. **J Med Chem** 1996 May 24;39(11):2197–206

The effect of excipients on glass transition temperatures for FK906 in the frozen and lyophilized states. Jang JW, et al. **PDA J Pharm Sci Technol** 1995 Jul–Aug;49(4):166–74

Renin inhibitors. Rosenberg SH. **Prog Med Chem** 1995; 32:37–114 (296 ref.)

[Potassium channel activators: comparative structural study of pinacidil, diazoxide and cromakalim] Dupont L, et al. **Ann Pharm Fr** 1995;53(5):201–8 (Eng. Abstr.) **(Fre)**

CONTRAINDICATIONS

Don't get stung with the adrenergic blockers (beta or alpha)! Watson A. **Aust Fam Physician** 1995 Oct;24(10):1879

Exercise guidelines for patients with high blood pressure: an update [letter] Pescatello LS, et al. **J Cardpulm Rehabil** 1995 May–Jun;15(3):239–40

Myocardial infarction associated with antihypertensive drug therapy [letter; comment] Cooper RS, et al. **JAMA** 1996 Feb 21;275(7):515–6; discussion 516–7. Comment on: JAMA 1995 Aug 23–30;274(8):620–5. Comment on: JAMA 1995 Aug 23–30;274(8):654–5.

DIAGNOSTIC USE

Role of captopril renography in the diagnosis of renovascular hypertension. Mittal BR, et al. **Am J Kidney Dis** 1996 Aug; 28(2):209–13

[An acute pharmacological test in predicting the efficacy of hypotensive therapy] Logunov OV. **Voen Med Zh** 1992 Feb;(2):61 **(Rus)**

ECONOMICS

Experts discuss cost-effective treatment of hypertension during world conference in Canada. Cottrell K. **Can Med Assoc J** 1995 Nov 1;153(9):1332–5

Cost-effectiveness of hypertension treatment. Ménard J. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):399–413 (77 ref.)

'White-coat' hypertension in patients with newly diagnosed hypertension: evaluation of prevalence by ambulatory monitoring and impact on cost of health care. Pierdomenico SD, et al. **Eur Heart J** 1995 May;16(5):692–7

Cost of hypertension treatment [letter] Ahluwalia JS, et al. **J Gen Intern Med** 1996 Apr;11(4):252–3

Choosing antihypertensive therapy [editorial; comment] Katzman DA, et al. **J Gen Intern Med** 1995 Dec; 10(12):700–2. Comment on: J Gen Intern Med 1995 Dec;10(12):686–8.

Cost of hypertension treatment [see comments] Odell TW, et al. **J Gen Intern Med** 1995 Dec;10(12):686–8. Comment in: J Gen Intern Med 1995 Dec;10(12):700–2.

Trends in the use of blood pressure lowering medications in Auckland, and associated costs, 1982–94. Trye P, et al. **N Z Med J** 1996 Jul 26;109(1026):270–2

The costs of treating hypertension: what are the long-term realities of cost containment and pharmacoeconomics? Elliott WJ. **Postgrad Med** 1996 Apr;99(4):241–8, 251–2

[The cost/benefit of antihypertensive therapy] Pessina AC. **Ann Ital Med Int** 1995 Oct;10 Suppl:96S–98S (16 ref.) (Eng. Abstr.) **(Ita)**

[The cost of antihypertensive drug combinations (letter; comment)] Buitrago F. **Med Clin (Barc)** 1996 May 4; 106(17):677. Comment on: Med Clin (Barc) 1995 Apr 29;104(16):620–1. **(Spa)**

HISTORY

[Scientific raisins from 125 years SMW (Swiss Medical Weekly). Experimental studies on the cardiovascular effects of the blood pressure-lowering hydrazinophthalazine derivatives apresoline and nepresole. 1953 (classical article)] Bein HJ, et al. **Schweiz Med Wochenschr** 1995 Nov 11;125(45):2207–11 **(Ger)**

IMMUNOLOGY

Adrenomedullin-immunoreactive neurons in the paraventricular and supraoptic nuclei of the rat. Ueta Y, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):37–40

METABOLISM

Sodium nitroprusside metabolism in children [letter; comment] Kazim R, et al. **Anesth Analg** 1996 Jun; 82(6):1301–2. Comment on: Anesth Analg 1995 Nov;81(5):952–6.

CV-11974, the active metabolite of TCV-116 (Candesarten), inhibits the synergistic or additive effect of different growth factors on angiotensin II-induced proliferation of vascular smooth muscle cells. Sachinidis A, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):123–6

Comparative affinities of human adrenomedullin for 125I-labelled human alpha calcitonin gene related peptide ([125I]hCGRP alpha) and 125I-labelled Bolton-Hunter rat amylin ([125I]BHrAMY) specific binding sites in the rat brain. van Rossum D, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1084–8

Acetylation and its role in the mutagenicity of the antihypertensive agent hydralazine. Lemke LE, et al. **Drug Metab Dispos** 1995 May;23(5):559–65

Selectivity of rilmenidine for I1-imidazoline-binding sites in rabbit proximal tubule cells. Gargalidis-Moudanos C, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S59–62

First-pass metabolism of diltiazem in anesthetized rabbits: role of extrahepatic organs. Lefebvre M, et al. **Pharm Res** 1996 Jan;13(1):124–8

PHARMACOKINETICS

Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Sowunmi A, et al. **Br J Clin Pharmacol** 1995 Nov;40(5):489–93

Clinical pharmacokinetics and efficacy of renin inhibitors. Rongen GA, et al. **Clin Pharmacokinet** 1995 Jul;29(1):6–14 (71 ref.)

Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Goldberg MR, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):268–74

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Lo MW, et al. **Clin Pharmacol Ther** 1995 Dec;58(6):641–9

Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension. Fettner SH, et al. **Eur J Clin Pharmacol** 1995;48(5):351–9

Influence of renal failure on cytochrome P450 activity in hypertensive patients using a "cocktail" of antipyrine and nifedipine. Lanchote VL, et al. **Eur J Clin Pharmacol** 1996; 50(1–2):83–9

The effect of pH on the buccal and sublingual absorption of captopril. McElnay JC, et al. **Eur J Clin Pharmacol** 1995; 48(5):373–9

Disposition of a new rate-controlled formulation of prazosin in the treatment of hypertension during pregnancy: transplacental passage of prazosin. Bourget P, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul–Sep; 20(3):233–41

Pharmacokinetics and safety of a novel, long-acting, prodrug-type potassium channel opener, Y-27152, in healthy volunteers. Uematsu T, et al. **J Clin Pharmacol** 1996 May;36(5):439–51

Interaction between clonidine and cyclosporine A [letter] Gilbert RD, et al. **Nephron** 1995;71(1):105

[Clinical pharmacokinetics of fluorazole] Firsov AA, et al. **Antibiot Khimioter** 1995 Sep;40(9):42–6 (Eng. Abstr.) **(Rus)**

[The pharmacokinetics of propranolol and its conjugated metabolites in patients with chronic ischemic heart disease and arterial hypertension with a one-time and course intake of the drug] Belolipetskaia VG, et al. **Eksp Klin Farmakol** 1995 Nov–Dec;58(6):56–9 (Eng. Abstr.) **(Rus)**

[The pharmacokinetics of different drug forms of nifedipine when used singly and in a course as monotherapy and in combination with Cordanum and triampur preparations in patients with arterial hypertension] Kukes VG, et al. **Eksp Klin Farmakol** 1995 Nov–Dec;58(6):22–5 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

The effect of ketanserin upon postoperative blood pressure, cerebral blood flow and oxygen metabolism in patients subjected to craniotomy for cerebral tumours. Felding M, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):582–5

Angiotensin-II receptor antagonists: a new class of antihypertensive agents. Weir MR. **Am Fam Physician** 1996 Feb 1;53(2):589–94 (26 ref.)

Effect of aging and chronic angiotensin I converting enzyme inhibition on the endothelial function of the mesenteric arterial bed of the rat. Atkinson J. **Am J Cardiol** 1995 Nov 24;76(15):19E–23E

Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. Leenen FH, et al. **Am J Cardiol** 1996 Jul 15;78(2):203–7

Disparate effects of antihypertensive drugs on large artery distensibility and compliance in hypertension. Van Bortel LM, et al. **Am J Cardiol** 1995 Nov 24;76(15):46E–49E (24 ref.)

Torsemide: a new loop diuretic. Fowler SF, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1771–80; quiz 1814–5 (60 ref.)

Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. Andersson PE, et al. **Am J Hypertens** 1996 Apr;9(4 Pt 1):323–33

Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. Hernández Hernández R, et al. **Am J Hypertens** 1996 May;9(5):437–44

Review: the effects of antihypertensive agents on serum lipids. Madu EC, et al. **Am J Med Sci** 1996 Aug; 312(2):76–84 (143 ref.)

New angiotensin-II blocker. Lilley LL, et al. **Am J Nurs** 1996 Mar;96(3):20

Losartan improves baroreflex control of heart rate of coarcted hypertensive rats. Santos CM, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H812–8

Effect of sodium nitroprusside and diethylcarbamazine on hypoxic pulmonary vasoconstriction and regional distribution of pulmonary blood flow in experimental pneumonia. Light RB. **Am J Respir Crit Care Med** 1996 Jan;153(1):325–30

Beta 2-adrenoceptor density of human lymphocytes after nitroprusside-induced hypotension. Heesen M, et al. **Anesth Analg** 1995 Dec;81(6):1250–4

Trimethaphan versus sodium nitroprusside for the control of proximal hypertension during thoracic aortic cross-clamping: the effects on spinal cord ischemia. Simpson JI, et al. **Anesth Analg** 1996 Jan;82(1):68–74

Dose-response analysis of acute hypotensive and renal effects of atrial natriuretic peptide in the rat. Caron N, et al. **Arch Int Pharmacodyn Ther** 1995 May–Jun;329(3):379–96

Effects of brimonidine on aqueous humor dynamics in human eyes. Toris CB, et al. **Arch Ophthalmol** 1995 Dec; 113(12):1514–7

Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Aybak M, et al. **Arzneimittelforschung** 1995 Dec;45(12):1271–3

Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and

independent hypertensive models. Nagata S, et al. **Arzneimittelforschung** 1995 Aug;45(8):853–8

Kukoamine A and other hydrophobic acylpolyamines: potent and selective inhibitors of Crithidia fasciculata trypanothione reductase. Ponasik JA, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):371–5

Guanidine thiol--a new activator of soluble guanylate cyclase with antihypertensive and antiaggregatory properties. Severina IS, et al. **Biochem Mol Biol Int** 1995 Jul;36(4):913–25

Antihypertensive effect of sesamin. I. Protection against deoxycorticosterone acetate-salt-induced hypertension and cardiovascular hypertrophy. Matsumura Y, et al. **Biol Pharm Bull** 1995 Jul;18(7):1016–9

Comparison of the effects of urapidil and sodium nitroprusside on haemodynamic state, myocardial metabolism and function in patients during coronary artery surgery. van der Stroom JG, et al. **Br J Anaesth** 1996 May; 76(5):645–51

Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. De Smet M, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):571–5

The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomic function in mild to moderate hypertension. Panfilov V, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):563–9

Angiotensin II antagonists: a new class of antihypertensive agent. Waeber B, et al. **Br J Clin Pract** 1996 Jul-Aug; 50(5):265–8 (35 ref.)

Absence of a losartan interaction with renal lithium excretion in the rat. Barthelmebs M, et al. **Br J Pharmacol** 1995 Oct; 116(4):2166–9

Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats. Bunting MW, et al. **Br J Pharmacol** 1995 Dec; 116(8):3181–90

Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Gardiner SM, et al. **Br J Pharmacol** 1995 Oct;116(4):2237–44

Effects of pH on responses to adenosine, CGS 21680, carbachol and nitroprusside in the isolated perfused superior mesenteric arterial bed of the rat. Hiley CR, et al. **Br J Pharmacol** 1995 Nov;116(6):2641–6

Endothelial function in spontaneously hypertensive rats: influence of quinapril treatment. Kähönen M, et al. **Br J Pharmacol** 1995 Jul;115(5):859–67

Attenuation of adrenomedullin-induced renal vasodilatation by NG-nitro L-arginine but not glibenclamide. Miura K, et al. **Br J Pharmacol** 1995 Jul;115(6):917–24

The role of the peripheral sympathetic nervous system in the natriuresis following central administration of an I1 imidazoline agonist, moxonidine. Penner SB, et al. **Br J Pharmacol** 1995 Nov;116(6):2631–6

Subtypes of losartan-sensitive angiotensin receptor in the rabbit pulmonary artery. Sim MK, et al. **Br J Pharmacol** 1996 Apr;117(7):1504–6

Upregulation of imidazoline receptors in the medulla oblongata accounts for the enhanced hypotensive effect of clonidine in aortic barodenervated rats. el-Mas MM, et al. **Brain Res** 1995 Sep 11;691(1-2):195–204

Differential microcirculation dynamics during deliberate hypotension induced by nicardipine, PGE1 and trimethaphan in rat mesentery. Takakura K, et al. **Can J Anaesth** 1995 Nov;42(11):1035–9

Rat adrenomedullin induces a selective arterial vasodilation via CGRP1 receptors in the double-perfused mesenteric bed of the rat. Berthiaume N, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1080–3

Antihypertensive effect of corilagin in the rat. Cheng JT, et al. **Can J Physiol Pharmacol** 1995 Oct;73(10):1425–9

Vasodilator effect of human adrenomedullin(13–52) on hypertensive rats. Tian Q, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1065–9

Mechanisms of the antihypertensive effects of dietary calcium and role of calcitonin gene related peptide in hypertension. Wimalawansa SJ, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):981–5

Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. Zhu YC, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):827–31 (39 ref.)

Renin inhibition. Kleinert HD. **Cardiovasc Drugs Ther** 1995 Oct;9(5):645–55 (80 ref.)

Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats. Traub O, et al. **Cardiovasc Drugs Ther** 1995 Jun;9(3):421–9

Novel 2-amino-1,4-dihydropyridine calcium antagonists. I. Synthesis and antihypertensive effects of 2-amino-1,4-dihydropyridine derivatives having nitroxy-alkoxycarbonyl groups at 3- and/or 5-position. Kobayashi T, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):788–96

Novel 2-amino-1,4-dihydropyridine calcium antagonists. II. Synthesis and antihypertensive effects of 2-amino-1,4-dihydropyridine derivatives having N,N-dialkylaminoalkoxycarbonyl groups at 3- and/or 5-position. Kobayashi T, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):797–817

Studies on agents with vasodilator and beta-blocking activities. III. Synthesis and activity of optical isomers of TZC-1370. Seki T, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1719–23

Studies on adrenomedullin: a novel hypotensive peptide. Tian Q, et al. **Chin Med J (Engl)** 1995 Oct;108(10):781–2

Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. Horio T, et al. **Circ Res** 1995 Oct; 77(4):660–4

Preconditioning of bovine endothelial cells. The protective effect is mediated by an adenosine A2 receptor through a protein kinase C signaling pathway. Zhou X, et al. **Circ Res** 1996 Jan;78(1):73–81

Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Ogawa T, et al. **Circulation** 1996 Jun 1;93(11):2059–67

In vivo pharmacology of L-159,913, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. Gabel RA, et al. **Clin Exp Hypertens** 1995 Aug;17(6):931–53

New central mediators as targets of centrally acting antihypertensive drugs. van Zwieten PA. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):291–303 (38 ref.)

Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials. Zanchetti A. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):489–99 (12 ref.)

Antihypertensive effect of thermolysin digest of dried bonito in spontaneously hypertensive rat. Fujita H, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S304–5

Ocular fundus changes in malignant or precocious stroke-prone spontaneously hypertensive rats after administration of antihypertensive drugs. Hamada Y, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S132–3

Baroreceptor function is restored by antihypertensive therapy through lowering of blood pressure in adult SHR. Ichikawa M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S67–9

Haemodynamic responses to rat adrenomedullin in anaesthetized spontaneously hypertensive rats. Ishiyama Y, et al. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):614–8

The influence of the renin angiotensin system on abnormal expression of nerve growth factor in the spontaneously hypertensive rat. Jeffreson S, et al. **Clin Exp Pharmacol Physiol** 1995 Jun-Jul;22(6-7):478–80

Antihypertensive effects, determined by a telemetry method, of trichloromethiazide and 7-O-ethylfangchinoline, a derivative of tetrandrine, in spontaneously hypertensive rats. Kawashima K, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S300–1

Suppression of vascular transforming growth factor-beta 1 and extracellular matrix gene expressions by cilazapril and nifedipine in hypertensive rats. Kim S, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S355–6

Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. Kwan CY. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S297–9 (12 ref.)

Effect of dose on trough peak ratio of antihypertensive drugs in elderly hypertensive males. Morgan TO, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):778–80

Effect of an antihypertensive drug on brain angiotensin II levels in renal and spontaneously hypertensive rats. Morishita R, et al. **Clin Exp Pharmacol Physiol** 1995 Sep; 22(9):665–9

AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats. Sugimoto K, et al. **Clin Exp Pharmacol Physiol** 1996 Apr; 23(4):282–6

Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men. Goldberg MR, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):72–82

Effect of angiotensin-converting enzyme inhibitors on resistance artery structure and endothelium-dependent relaxation in two-kidney, one-clip Goldblatt hypertensive and sham-operated rats. Bennett MA, et al. **Clin Sci (Colch)** 1996 Jan;90(1):21–9

Angiotensin II receptor antagonism: losartan - sites and mechanisms of action. Triggle DJ. **Clin Ther** 1995 Nov-Dec;17(6):1005–30 (132 ref.)

Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Pate DW, et al. **Curr Eye Res** 1995 Sep;14(9):791–7

Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Brouillet E, et al. **Curr Opin Neurol** 1995 Dec;8(6):469–73 (44 ref.)

Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective beta-blocker. Vachiery F, et al. **Dig Dis Sci** 1996 Sep;41(9):1722–6

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Feuerstein GZ, et al. **Eur Heart J** 1996 Apr;17 Suppl B:24–9 (24 ref.)

Effect of moxonidine on urinary electrolyte excretion and renal haemodynamics in man. Wiecek A, et al. **Eur J Clin Pharmacol** 1995;48(3-4):203–8

Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonist. Aiyar N, et al. **Eur J Pharmacol** 1995 Sep 5;283(1-3):63–72

Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors. Chow L, et al. **Eur J Pharmacol** 1995 Aug 25; 282(1-3):77–86

Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action. Christophe B, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):161–71

Adrenomedullin and calcitonin gene-related peptide in the rat isolated kidney and in the anaesthetised rat: in vitro and in vivo effects. Haynes JM, et al. **Eur J Pharmacol** 1995 Jun 23;280(1):91–4

Effect of nitrendipine on renal cortical and papillary autoregulation in hypertensive rats. Huang C, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):1–10

Ebelactone B, an inhibitor of urinary carboxypeptidase Y-like kininase, prevents the development of deoxycorticosterone acetate-salt hypertension in rats. Majima M, et al. **Eur J Pharmacol** 1995 Sep 15;284(1-2):1–11

The selective angiotensin AT1 receptor antagonist LR-B/081 potently inhibits drinking induced by central injection of angiotensin II in rats. Polidori C, et al. **Eur J Pharmacol** 1995 Apr 24;277(2-3):223–8

Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Popoli P, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):215–7

Early administration of YT-146, an adenosine A2 receptor agonist, inhibits neointimal thickening after rat femoral artery endothelium injury. Takiguchi Y, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):205–7

Involvement of peripheral presynaptic inhibition in the reduction of sympathetic tone by moxonidine, rilmenidine and UK 14304. Urban R, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):29–37

Involvement of alpha 2-adrenoceptors in the cardiovascular effects of moxonidine. Urban R, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):19–28

Effect of sodium nitroprusside on cerebral haemodynamics during cross-clamping of the descending thoracic aorta in pigs. Strømholm T, et al. **Eur J Surg** 1996 Apr; 162(4):329–34

Effect of sodium nitroprusside on cardiac output during cross-clamping of the descending thoracic aorta in pigs. Aadahl P, et al. **Eur Surg Res** 1995;27(5):323–31

Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH. Bamberger CM, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):205–8

Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease. Maneuf YP, et al. **Exp Neurol** 1996 May;139(1):12–6

Biological effects of hesperidin, a Citrus flavonoid. (Note III): antihypertensive and diuretic activity in rat. Galati EM, et al. **Farmaco** 1996 Mar;51(3):219–21

Effects of a newly developed transdermal clonidine delivery system (M-5041T) on EEG sleep-wake cycle in relation to plasma concentration in rabbits. Kimura K, et al. **Gen Pharmacol** 1996 Jan;27(1):73–7

Cardiovascular selectivity of 1,4-dihydropyridine derivatives, efonidipine (NZ-105), nicardipine and structure related compounds in isolated guinea-pig tissues. Masuda Y, et al. **Gen Pharmacol** 1995 Mar;26(2):339–45

Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension. Ito K, et al. **Hypertens Res** 1995 Mar;18(1):69–75

Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Ando S, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1160–6

Calcium channel blockers as inhibitors of angiotensin I-converting enzyme. Casarini DE, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1145–8

Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Dworkin LD, et al. **Hypertension** 1996 Feb;27(2):245–50

Interaction of adrenomedullin and platelet-derived growth factor on rat mesangial cell production of endothelin. Kohno M, et al. **Hypertension** 1996 Mar;27(3 Pt 2):663–7

Aberrant adenylyl cyclase/cAMP signal transduction and G protein levels in platelets from hypertensive patients improve with antihypertensive drug therapy. Marcil J, et al. **Hypertension** 1996 Jul;28(1):83–90

Contrasting effect of antihypertensive treatment on the renal response to L-arginine. Mimran A, et al. **Hypertension** 1995 Dec;26(6 Pt 1):937–41

Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Oliveira DR, et al. **Hypertension** 1996 Jun;27(6):1284–90

Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Seljeflot I, et al. **Hypertension** 1996 Jun; 27(6):1299–304

Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs. Susic D, et al. **Hypertension** 1996 Aug;28(2):265–8

Altered cerebrovascular response to a potassium channel opener in hypertensive rats. Takaba H, et al. **Hypertension** 1996 Jul;28(1):143–6

Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Takase H, et al. **Hypertension** 1996 Jan; 27(1):25–31

Inhibition of aldosterone production by adrenomedullin, a hypotensive peptide, in the rat. Yamaguchi T, et al.

Hypertension 1995 Aug;28(2):308–14

Diuretic, hypotensive and hypoglycaemic effect of Phyllanthus amarus. Srividya N, et al. **Indian J Exp Biol** 1995 Nov;33(11):861–4

Ketanserin effects on insulin sensitivity in nonobese, nondiabetic hypertensive patients: an evaluation by the euglycemic–hyperinsulinemic clamp technique. Fogari R, et al. **Int J Clin Pharmacol Ther** 1995 Aug;33(8):453–6

Influence of urapidil on cerebrospinal fluid pressure in humans with uncompromised intracranial compliance. Hörmann C, et al. **Intensive Care Med** 1995 Oct; 21(10):853–5

Interactions of the cardiac chronotropic effects of rilmenidine with the autonomic nervous system in conscious dogs: comparison with clonidine. Boucher M, et al. **J Auton Pharmacol** 1996 Feb;16(1):13–20

Reduced ambulatory heart rate response to physical work and complaints of fatigue among hypertensive males treated with beta-blockers. Kristal-Boneh E, et al. **J Behav Med** 1995 Apr;18(2):113–26

Isoflurane versus sodium nitroprusside for the control of proximal hypertension during thoracic aortic cross-clamping: effects on spinal cord ischemia. Simpson JI, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):491–6

Ketanserin lowers erythropoietin concentration in hemodialyzed patients treated with the hormone. Borawski J, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):621–6

Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. Campbell DJ, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):233–40

Effects of losartan on contractile responses of conductance and resistance arteries from rats. Corriu C, et al. **J Cardiovasc Pharmacol** 1995 Nov;26(5):688–92

Coronary and systemic hemodynamic effects of the putative nitric oxide donor, FK 409, in comparison with nitroglycerin in conscious and anesthetized dogs. Drieu la Rochelle C, et al. **J Cardiovasc Pharmacol** 1995 Oct; 26(4):555–63

Effects of rilmenidine and clonidine on the electroencephalogram, saccadic eye movements, and psychomotor function. Harron DW, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S48–54

Effects of KRN4884, a novel K channel opener, on the cardiovascular system in anesthetized dogs: a comparison with levcromakalim, nilvadipine, and nifedipine. Izumi H, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):189–97

Effects of ketanserin on heart rate and blood pressure variability: implications for the effect on the baroreflex mechanisms. Kingma R, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):445–52

Carotid arterial changes produced by a centrally mediated antihypertensive agent in hypertensive rats. Levy BI, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):666–73

Brain structures involved in the hypotensive effects of rilmenidine: evaluation by [14C]2-deoxyglucose autoradiography. Macrae IM, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S55–8

Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats. Morita O, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):880–7

Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects. Ogihara T, et al. **J Cardiovasc Pharmacol** 1995 Sep; 26(3):490–4

Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. Okada H, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):564–9

Effects of the angiotensin II receptor antagonist losartan on 24-hour blood pressure profiles of primary and secondary hypertensive rats. Schnecko A, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):214–21

Renal I1-imidazoline receptor-selective compounds mediate natriuresis in the rat. Smyth DD, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S63–7

Relative contribution of alpha 1-adrenoceptor blocking activity to the hypotensive effect of the novel calcium antagonist monatepil. Sugimoto T, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):55–60

The effects of losartan and captopril on vasopressor actions of cirazoline in the absence and presence of SZL-49 and nifedipine. Tabrizchi R, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):137–44

Cardiovascular effects of the novel potassium channel opener UR-8225. Tamargo J, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):295–305

Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. Vaur L, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):127–31

Proadrenomedullin NH2-terminal 20 peptide inhibits the voltage-gated Ca2+ channel current through a pertussis toxin-sensitive G protein in rat pheochromocytoma-derived PC 12 cells. Takano K, et al. **J Clin Invest** 1996 Jul 1;98(1):14–7

Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. Kong AN, et al. **J Clin Pharmacol** 1995 Oct;35(10):1008–15

Effect of losartan, an angiotensin II receptor antagonist, on response of cortisol and aldosterone to adrenocorticotrophic hormone. Sasaki M, et al. **J Clin Pharmacol** 1995 Aug;35(8):776–9

Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension. Sasaki M, et al. **J Clin Pharmacol** 1996 May; 36(5):403–8

Long-term effects of antihypertensive treatment and good glycemic control on plasma lipids in diabetic rats. Reddi AS, et al. **J Diabetes Complications** 1995 Jul–Sep;9(3):163–9

In vitro screening of traditional medicines for anti-hypertensive effect based on inhibition of the angiotensin converting enzyme (ACE). Hansen K, et al. **J Ethnopharmacol** 1995 Aug 11;48(1):43–51

Pharmacology of Casimiroa edulis; III. Relaxant and contractile effects in rat aortic rings. Magos GA, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):1–8

Losartan: the first angiotensin receptor antagonist in clinical use. Beevers DG. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S1

Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. Dahlöf B. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S37–44 (84 ref.)

ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group. Ramsay LE, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S51–4

Endothelium-dependent relaxation in resistance arteries from spontaneously hypertensive rats: effect of long-term treatment with perindopril, quinapril, hydralazine or amlodipine. Bennett MA, et al. **J Hypertens** 1996 Mar; 14(3):389–97

A comparison between the haemodynamic effects of oral nifedipine and intravenous dihydralazine in patients with severe pre-eclampsia. Visser W, et al. **J Hypertens** 1995 Jul;13(7):791–5

Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Fink CA, et al. **J Med Chem** 1996 Aug 2;39(16):3158–68

The furoxan system as a useful tool for balancing "hybrids" with mixed alpha 1-antagonist and NO-like vasodilator activities. Fruttero R, et al. **J Med Chem** 1995 Dec 8; 38(25):4944–9

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. Wexler RR, et al. **J Med Chem** 1996 Feb 2;39(3):625–56 (326 ref.)

Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. Yanagisawa H, et al. **J Med Chem** 1996 Jan 5;39(1):323–38

Antihypertensive effects of captopril without adverse effects on glucose tolerance in hyperinsulinemic rhesus monkeys. Bodkin NL, et al. **J Med Primatol** 1995 Jan;24(1):1–6

Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. Hanatani A, et al. **J Mol Cell Cardiol** 1995 Sep; 27(9):1905–14

Effects of cromakalim and nicorandil on intraocular pressure after topical administration in rabbit eyes. Chiang CH, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):195–201

AGN 191976: a novel thromboxane A2-mimetic with ocular hypotensive properties. Krauss AH, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):203–12

Topically applied hydralazine: effects on systemic cardiovascular parameters, blood-aqueous barrier, and aqueous humor dynamics in normotensive humans. Larsson LI, et al. **J Ocul Pharmacol Ther** 1995 Summer;11(2):145–56

Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations. Bialer M, et al. **J Pharm Sci** 1995 Oct;84(10):1160–3

Synthesis and antihypertensive activity of N-(alkyl/alkenyl/aryl)-N-heterocyclic ureas and thioureas. Vajragupta O, et al. **J Pharm Sci** 1996 Mar; 85(3):258–61

Blood pressure (BP) and renal vasoconstrictor responses to acute blockade of nitric oxide: persistence of renal vasoconstriction despite normalization of BP with either verapamil or sodium nitroprusside. Baylis C, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1135–41

SB 203220: a novel angiotensin II receptor antagonist and renoprotective agent. Brooks DP, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1222–7

Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits. Chan CK, et al. **J Pharmacol Exp Ther** 1996 Feb; 276(2):411–20

Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. Edwards RM, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):125–9

Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. Hatch M, et al. **J Pharmacol Exp Ther** 1996 Jan; 276(1):187–93

Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, U-97018. Kushida H, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1042–53

Effect of a calcium antagonist on renal hemodynamics in salt-loaded spontaneously hypertensive rats. Shimosawa T, et al. **Jpn Heart J** 1995 Nov;36(6):797–805

Adrenomedullin stimulates calcium efflux from adrenal chromaffin cells in culture: possible involvement of an Na+/Ca2+ exchange mechanism. Houchi H, et al. **Life Sci** 1996;58(2):PL 35–40

Adrenomedullin and calcitonin gene-related peptide inhibit aldosterone secretion in rats, acting via a common receptor. Mazzocchi G, et al. **Life Sci** 1996;58(10):839–44

Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular beta-blocker, in dogs. Polgar P, et al. **Life Sci** 1995;56(14):1207–13

Effect of antihypertensive treatment with alacepril on insulin resistance in diabetic spontaneously hypertensive rats. Sato T, et al. **Metabolism** 1996 Apr;45(4):457–62

Indapamide treatment modifies the vascular reactivity of normotensive rat mesenteric arteries ex vivo. Tarkkila L, et al. **Methods Find Exp Clin Pharmacol** 1996 Jan–Feb; 18(1):5–11

Effect of hydralazine on myocardial plasma membrane fatty acid binding protein (PM-FABP) during diabetes mellitus. Heyliger CE, et al. **Mol Cell Biochem** 1995 Jul 5; 148(1):39–44

Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. Reaven GM, et al. **N Engl J Med** 1996 Feb 8;334(6):374–81 (85 ref.)

Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nabokov A, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):514–20

Effect of diltiazem and methyldopa on gestation-related renal complications in rats with adriamycin nephrosis. Relationship to glomerular prostanoid synthesis. Podjarny E, et al. **Nephrol Dial Transplant** 1995;10(9):1598–602

No acute change of serum erythropoietin in response to hypocalcemia or antihypertensive agents in uremic patients. Ureña P, et al. **Nephron** 1995;70(2):197–201

Caprylic acid, a medium chain saturated fatty acid, inhibits the sodium inward current in neuroglioma (NG108-15) cells. Lamas JA, et al. **Neurosci Lett** 1995 Oct 6; 198(3):181–4

Clonidine and rilmenidine suppress hypotension-induced Fos expression in the lower brainstem of the conscious rabbit. Li YW, et al. **Neuroscience** 1995 May;66(2):391–402

Adenosine A2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Morelli M, et al. **Neuroscience** 1995 Jul;67(1):49–55

Influence of anti-hypertensive drugs on glomerular hemodynamics. Ito S, et al. **Nippon Jinzo Gakkai Shi** 1996 Mar;38(3):115–8 (20 ref.)

A new antihypertensive class: the angiotensin receptor antagonist [news] Kupecz D. **Nurse Pract** 1996 Mar; 21(3):106, 109, 113–4

Hypotensive effects of [D-Tyr27,36, D-Thr32]Neuropeptide Y (27-36). Roscoe AK, et al. **Peptides** 1995;16(8):1411–5

Central imidazoline receptors as a target for centrally acting antihypertensive drugs. van Zwieten PA. **Pharm World Sci** 1995 Nov 24;17(6):186–90 (28 ref.)

Interactions between endothelial mediators. Gryglewski RJ. **Pharmacol Toxicol** 1995 Jul;77(1):1–9 (120 ref.)

Furosemide elicits immediate sympathoexcitation via a renal mechanism independent of angiotensin II. Petersen JS, et al. **Pharmacol Toxicol** 1995 Aug;77(2):106–13

Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Lopez BL, et al. **Pharmacology** 1995 Sep;51(3):165–73

MR-14134, a new benzothiazepine with central hypotensive action. Prieto P, et al. **Pharmacology** 1995 Aug;51(2):84–95

Age and carotid artery occlusive disease are important determinants of cerebral blood flow changes after antihypertensive therapy. Fagan SC, et al. **Pharmacotherapy** 1995 Sep–Oct;15(5):573–8

Chronic Losartan treatment blocks isoproterenol-induced dipsogenesis. Iyer SN, et al. **Physiol Behav** 1995 Aug; 58(2):283–6

Early genes induction in spontaneously hypertensive rats left ventricle with angiotensin-converting enzyme inhibitors but not hydralazine. Susic D, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):266–9

Renal effects of adrenomedullin in the rat. Vari RC, et al. **Proc Soc Exp Biol Med** 1996 Feb;211(2):178–83

Pinacidil-induced relaxation in pulmonary arteries isolated from pulmonary hypertensive and normotensive rats and pre-contracted with different spasmogens. Wanstall JC, et al. **Pulm Pharmacol** 1994 Dec;7(6):401–8

A new trend in the therapy of orthostatic arterial hypotension: prevention by propranolol or metoclopramide of the excessive adrenaline release of brainstem infarct patients with postural hypotension. Stoica E, et al. **Rom J Neurol Psychiatry** 1995 Jul–Dec;33(3–4):203–14

A comparison of the metabolic effects of captopril and atenolol on glucose, insulin and lipoproteins in patients with mild-to-moderate essential hypertension. Maritz FJ, et al. **S Afr Med J** 1995 Dec;85(12 Pt 2):1342–5

Structure and function of the rat basilar artery during chronic nitric oxide synthase inhibition. Moreau P, et al. **Stroke** 1995 Oct;26(10):1922–8; discussion 1928–9

Indapamide accentuates cardiac chronotropic responses to epidermal growth factor in chick cardiomyocytes. Rabkin SW. **Tissue Cell** 1996 Aug;28(4):469–72

[Captopril in improving vascular structure and lowering blood pressure] Chen D, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jun;75(6):355–9, 383–4 (Eng. Abstr.) **(Chi)**

[Adrenomedullin] Zeng Z. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):635–7 (14 ref.) **(Chi)**

[Observation on hypotensive action of adrenomedullin and

its distribution in tissues] Song LW, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):408–11 (Eng. Abstr.) **(Chi)**

[A study on hypotensive mechanism of adrenomedullin (13–52)] Zhao D, et al. **Sheng Li Hsueh Pao** 1995 Jun; 47(3):218–24 (Eng. Abstr.) **(Chi)**

[Effects of taurine and enalapril on blood pressure, platelet aggregation and the regression of left ventricular hypertrophy in two–kidney–one–clip renovascular hypertensive rats] Ji Y, et al. **Yao Hsueh Hsueh Pao** 1995 Dec;30(12):886–90 (Eng. Abstr.) **(Chi)**

[Effects of bisoprolol and ramipril on short–term variability of systolic blood pressure during mental stress test: spectrum analysis] Elkohen M, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88(8):1075–80 (Eng. Abstr.) **(Fre)**

[Chronic and acute effect of cycletanine in NO–dependent hypertensive pregnant rats] Van Overloop B, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88(8):1223–7 (Eng. Abstr.) **(Fre)**

[Angiotensin receptor antagonists. A new class of antihypertensive agents] Mann J. **Dtsch Med Wochenschr** 1996 Apr 26;121(17):568–71 (22 ref.) **(Ger)**

[Role of ambulatory blood pressure monitoring in the evaluation of the therapeutic efficacy of antihypertensive drugs. Trough/peak relation] Nobre F. **Arq Bras Cardiol** 1995 Mar;64(3):247–9 (27 ref.) **(Por)**

[The effect of urapidil on blood pressure, renal hemodynamics, lipid and glucose metabolism] Sanjuliani AF, et al. **Arq Bras Cardiol** 1995 Jul;65(1):59–63 (Eng. Abstr.) **(Por)**

[A new activator of soluble guanylate cyclase generated by nitric oxide and having antihypertensive and anti–aggregation properties] Busygina OG, et al. **Biokhimiia** 1995 Sep;60(9):1460–7 (Eng. Abstr.) **(Rus)**

[The hypotensive effect of clonidine during direct and radiotelemetric recording of the arterial pressure in rats] Maiorov DN, et al. **Eksp Klin Farmakol** 1995 Nov–Dec; 58(6):19–21 (Eng. Abstr.) **(Rus)**

[Chrono–pharmacodynamic effects of sinepres in patients with hypertension] Akhmetov KZh, et al. **Klin Med (Mosk)** 1995;73(4):97 **(Rus)**

[The effect of cilazapril on left ventricular function and myocardial perfusion in patients with essential hypertension (hypertensive disease) stage II] Karpov RS, et al. **Ter Arkh** 1995;67(9):50–3 (Eng. Abstr.) **(Rus)**

[Historical perspective of renin–angiotensin system blocking in the treatment of arterial hypertension (editorial)] Coca A, et al. **Med Clin (Barc)** 1996 Mar 30;106(12):457–9 **(Spa)**

POISONING

Poisoning with anti–hypertensive drugs: alpha–adrenoceptor antagonists. Lip GY, et al. **J Hum Hypertens** 1995 Jul; 9(7):523–6 (21 ref.)

Poisoning with anti–hypertensive drugs: methyldopa and clonidine. Zarifis J, et al. **J Hum Hypertens** 1995 Oct; 9(10):787–90 (31 ref.)

Ultra–high dose trimethaphan in an infant with severe hypertension. Hammer GB. **J Toxicol Clin Toxicol** 1996; 34(2):227–9

[Acute voluntary poisoning with acebutolol (letter)] Darmanaden R, et al. **Therapie** 1995 Nov–Dec;50(6):591–3 (18 ref.) **(Fre)**

SUPPLY & DISTRIBUTION

Discontinuation of Sotazide [letter] Millar RS. **S Afr Med J** 1996 Apr;86(4):381

THERAPEUTIC USE

Fenoldopam for hypertensive emergencies [editorial; comment] Hoekstra JW. **Acad Emerg Med** 1995 Nov; 2(11):947–8. Comment on: Acad Emerg Med 1995 Nov;2(11):959–65.

Comparison of antihypertensive effects of nicardipine with nitroglycerin for perioperative hypertension. Chen TL, et al. **Acta Anaesthesiol Sin** 1995 Dec;33(4):199–204

Hypertension and non–insulin–dependent diabetes. A comparison between an angiotensin–converting enzyme inhibitor and a calcium antagonist. Crepaldi G, et al. **Acta Diabetol** 1995 Oct;32(3):203–8

Relationship between body mass index (BMI) and changes in plasma total and HDL–cholesterol levels during treatment of hypertension in African patients. Ahaneku JE, et al. **Acta Med Okayama** 1995 Oct;49(5):267–70

Blood glucose levels in hypertensive patients during treatment with different antihypertensive agents. Ahaneku JE. **Acta Med Okayama** 1996 Apr;50(2):107–10

Diuretic effect of cilazapril and dopamine system in the spontaneously hypertensive rat. Watanabe H, et al. **Acta Med Okayama** 1995 Oct;49(5):247–52

Molecular manifestations of cardiac hypertrophy in the spontaneously hypertensive rat effects of antihypertensive treatments. Kessler–Icekson G, et al. **Adv Exp Med Biol** 1995;382:195–203

Where do the new agents fit in hypertension management? [editorial; comment] Kopes–Kerr CP. **Am Fam Physician** 1996 Jun;53(8):2427–8. Comment on: Am Fam Physician 1996 Jun;53(8):2553–60.

Management of hypertension, Part II [see comments] Moser M. **Am Fam Physician** 1996 Jun;53(8):2553–60 (21 ref.). Comment in: Am Fam Physician 1996 Jun;53(8):2427–8.

Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Awan NA, et al. **Am Heart J** 1996 Jan; 131(1):177–85 (81 ref.)

Three–period crossover trial with ambulatory blood pressure monitoring for evaluating antihypertensive therapy. Meeves S, et al. **Am Heart J** 1995 Oct;130(4):841–8

Implications of the links between hypertension and myocardial infarction for choice of drug therapy in patients with hypertension. Meredith PA. **Am Heart J** 1996 Jul; 132(1 Pt 2 Su):222–8 (29 ref.)

Angio–converting enzyme inhibition after myocardial infarction: the the Trandolapril Cardiac Evaluation Study. Torp–Pedersen C, et al. **Am Heart J** 1996 Jul;132(1 Pt 2 Su):235–43

A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Ames RP. **Am J Cardiol** 1996 Feb 22;77(6):12b–16b

Effect of indapamide on left ventricular hypertrophy in hypertension: a meta–analysis. Carey PA, et al. **Am J Cardiol** 1996 Feb 22;77(6):17b–19b

Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Devereux RB, et al. **Am J Cardiol** 1996 Jul 1;78(1):61–5

Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Donnelly R, et al. **Am J Cardiol** 1996 Feb 22;77(6):26B–30B (33 ref.)

Chronic low–dose treatment with perindopril improves cardiac function in stroke–prone spontaneously hypertensive rats by potentiation of endogenous bradykinin. Gohlke P, et al. **Am J Cardiol** 1995 Nov 24; 76(15):41E–45E

Microvascular angina in systemic hypertension: diagnosis and treatment with enalapril. Iriarte MM, et al. **Am J Cardiol** 1995 Nov 2;76(13):31D–34D (18 ref.)

Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience). Kannel WB. **Am J Cardiol** 1996 Feb 22;77(6):6B–11B (19 ref.)

Diuretics: cornerstone of antihypertensive therapy. Kaplan NM. **Am J Cardiol** 1996 Feb 22;77(6):3B–5B (22 ref.)

Sex– and age–related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Kloner RA, et al. **Am J Cardiol** 1996 Apr 1; 77(9):713–22

Impact of medical therapy on pulmonary hypertension in patients with congestive heart failure awaiting cardiac transplantation. Levine TB, et al. **Am J Cardiol** 1996 Aug 15;78(4):440–3

Indapamide is superior to thiazide in the preservation of renal function in patients with renal insufficiency and systemic hypertension. Madkour H, et al. **Am J Cardiol** 1996 Feb 22;77(6):23B–25B

Reduction in left ventricular mass in patients with systemic hypertension treated with enalapril, lisinopril, or fosenopril. Oren S, et al. **Am J Cardiol** 1996 Jan 1;77(1):93–6

Antihypertensive treatment in hypertensive patients with normal left ventricular mass is associated with left ventricular remodeling and improved diastolic function. Schulman DS, et al. **Am J Cardiol** 1996 Jul 1;78(1):56–60

Vascular wall thickness in hypertension: the Perindopril Regression of Vascular Thickening European Community Trial: PROTECT. Stumpe KO, et al. **Am J Cardiol** 1995 Nov 24;76(15):50E–54E

Indapamide regresses, but transdermal clonidine does not regress, left ventricular hypertrophy in hypertensive diabetic patients. Tan SA, et al. **Am J Cardiol** 1996 Feb 22;77(6):20B–22B

Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists. Vogt M, et al. **Am J Cardiol** 1995 Nov 2;76(13):24D–30D (52 ref.)

Effects of enalapril on heart rate variability in patients with congestive heart failure. Zhang YH, et al. **Am J Cardiol** 1995 Nov 15;76(14):1045–8

Hypertension, stroke, and noncompliance: an avoidable triad. Futterman LG, et al. **Am J Crit Care** 1996 May;5(3):227–33

Prevention and treatment of diabetic nephropathy. Foote EF. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1781–92 (94 ref.)

Torsemide: a new loop diuretic. Fowler SF, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1771–80; quiz 1814–5 (60 ref.)

Antihypertensive Drug Therapy. The effect of JNC criteria on prescribing patterns and patient status through the first year. Alderman MH, et al. **Am J Hypertens** 1996 May; 9(5):413–8

The coronary artery disease paradox. Black HR. **Am J Hypertens** 1996 Apr;9(4 Pt 3):2S–10S (66 ref.)

The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy. Chan P, et al. **Am J Hypertens** 1995 Nov;8(11):1099–104

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group [see comments] Davis BR, et al. **Am J Hypertens** 1996 Apr;9(4 Pt 1):342–60 . Comment in: Am J Hypertens 1996 Apr;9(4 Pt 1):409–11.

Reduction of development of left ventricular hypertrophy in salt–loaded Dahl salt–sensitive rats by angiotensin II receptor inhibition. de Simone G, et al. **Am J Hypertens** 1996 Mar;9(3):216–22

Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. Dominguez LJ, et al. **Am J Hypertens** 1995 Aug;8(8):808–14

ALLHAT: the largest and most important clinical trial in hypertension ever done in the USA. Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial [editorial; comment] Elliott WJ. **Am J Hypertens** 1996 Apr; 9(4 Pt 1):409–11. Comment on: Am J Hypertens 1996 Apr;9(4 Pt 1):342–60.

Alpha–blockade and thiazide treatment of hypertension. A double–blind randomized trail comparing doxazosin and hydrochlorothiazide. Grimm RH Jr, et al. **Am J Hypertens** 1996 May;9(5):445–54

Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. Fosinopril/Hydrochlorothiazide Investigators. Guthrie R, et al. **Am J Hypertens** 1996 Apr; 9(4 Pt 1):306–11

The efficacy and tolerability of enalapril in a formulation with a very low dose of hydrochlorothiazide in hypertensive patients resistent to enalapril monotherapy. Guul SJ, et al. **Am J Hypertens** 1995 Jul;8(7):727–31

The blood pressure response to antihypertensive treatment with lisinopril or bendrofluazide is related to the calcium and magnesium contents in skeletal muscle. Haenni A, et al. **Am J Hypertens** 1996 Mar;9(3):273–6

Cardioprotective potential of antihypertensives. Hansson L. **Am J Hypertens** 1995 Oct;8(10 Pt 2):49S–52S (20 ref.)

Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension. Hernández Hernández R, et al. **Am J Hypertens** 1996 May;9(5):437–44

Changes in frequency of orthostatic hypotension in elderly hypertensive patients under medications. Masuo K, et al. **Am J Hypertens** 1996 Mar;9(3):263–8

Lessons on the interaction of race and antihypertensive drugs from the VA cooperative study group on antihypertensive agents. Materson BJ. **Am J Hypertens** 1995 Dec;8(12 Pt 2):91s–93s (13 ref.)

Blood pressure evaluation by noninvasive and traditional methods. Consistencies and discrepancies among photoplethysmomanometry, office sphygmomanometry, and ambulatory monitoring. Effects of blood pressure measurement. Musso NR, et al. **Am J Hypertens** 1996 Apr; 9(4 Pt 1):293–9

Differential effects of felodipine and nifedipine on 24–h blood pressure and left ventricular mass. Myers MG, et al. **Am J Hypertens** 1995 Jul;8(7):712–8

Overtreatment of hypertension in the community? Myers MG, et al. **Am J Hypertens** 1996 May;9(5):419–25

Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms. Opsahl JA, et al. **Am J Hypertens** 1995 Nov;8(11):1090–8

Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats. Panizo A, et al. **Am J Hypertens** 1995 Aug;8(8):815–22

Time–dependent effect of isradipine on the nocturnal hypertension in chronic renal failure. Portaluppi F, et al. **Am J Hypertens** 1995 Jul;8(7):719–26

Are antihypertensive drugs similar in protecting the kidney? Ritz E. **Am J Hypertens** 1995 Oct;8(10 Pt 2):53S–58S (45 ref.)

A chronotherapeutic approach to the management of hypertension. White WB. **Am J Hypertens** 1996 Apr;9(4 Pt 3):29S–33S (27 ref.)

Mechanisms for interethnic differences in antihypertensive drug response. Wood AJ. **Am J Hypertens** 1995 Dec;8(12 Pt 2):128s

Short–term increase in prostaglandin I2 synthesis caused by cicletanine in patients with essential hypertension [editorial] Yasu T, et al. **Am J Hypertens** 1995 Sep;8(9):944–8

The beneficial effect of angiotensin–converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Laffel LM, et al. **Am J Med** 1995 Nov;99(5):497–504

Absolute cardiovascular risk: the basis for deciding to treat. Alderman MH. **Am J Nephrol** 1996;16(3):182–9 (40 ref.)

Differing effects of antihypertensive agents on urinary albumin excretion. Weir MR. **Am J Nephrol** 1996; 16(3):237–45 (69 ref.)

New angiotensin–II blocker. Lilley LL, et al. **Am J Nurs** 1996 Mar;96(3):20

Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo–controlled study. Wide–Swensson DH, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):872–8

ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapril in mild to moderate hypertension. Petersen JR, et al. **Angiology** 1996 Mar;47(3):233–40

Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long–acting calcium antagonists. Bakris GL, et al. **Ann Intern Med** 1996 Aug 1;125(3):201–4

A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Moncica I, et al. **Arch Dis Child** 1995 Aug;73(2):154–6

Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Chrysant SG, et al. **Arch Fam Med** 1996 Jan;5(1):17-24; discussion 25

Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials. Pearce KA, et al. **Arch Fam Med** 1995 Nov;4(11):943-9; discussion 950

Angiotensin II receptor blockers. A new class of antihypertensive drugs. Velasquez MT. **Arch Fam Med** 1996 Jun;5(6):351-6 (60 ref.)

A low-dose perspective on the calcium antagonist controversy [letter; comment] Bloomfield RL, et al. **Arch Intern Med** 1996 May 27;156(10):1115-6. Comment on: Arch Intern Med 1995 Nov 13;155(20):2145. Comment on: Arch Intern Med 1995 Nov 13;155(20):2150-6. Comment on: Arch Intern Med 1995 Nov 13;155(20):2157-61.

Calcium antagonists should continue to be used for first-line treatment of hypertension [see comments] Epstein M. **Arch Intern Med** 1995 Nov 13;155(20):2150-6 (52 ref.). Comment in: Arch Intern Med 1995 Nov 13;155(20):2145. Comment in: Arch Intern Med 1996 May 27;156(10):1115-6.

Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con side [see comments] Furberg CD, et al. **Arch Intern Med** 1995 Nov 13; 155(20):2157-61 (32 ref.). Comment in: Arch Intern Med 1995 Nov 13;155(20):2145. Comment in: Arch Intern Med 1996 May 27;156(10):1115-6.

Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study. Lewis CE, et al. **Arch Intern Med** 1996 Feb 26;156(4):377-85

Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. MacKay JH, et al. **Arch Intern Med** 1996 Feb 12;156(3):278-85

Effect of sustained release diltiazem (Diltiazem-R) in patients with stable effort angina. Kaku T, et al. **Artery** 1994; 21(4):193-207

Antihypertensive effect of levcromakalim in patients with essential hypertension. Study by 24-h ambulatory blood pressure monitoring. Suzuki S, et al. **Arzneimittelforschung** 1995 Aug;45(8):859-64

Antihypertensive effect of sesamin. II. Protection against two-kidney, one-clip renal hypertension and cardiovascular hypertrophy. Kita S, et al. **Biol Pharm Bull** 1995 Sep;18(9):1283-5

Adaptation of antihypertensive drug treatment with increasing age: from the young to the elderly. Focus on urapidil. **Blood Press** 1995;Suppl 3:1-73

Trough-to-peak versus surface ratio in the assessment of antihypertensive agents. APTH Investigators. Ambulatory Blood Pressure and Treatment of Hypertension. Bieniaszewski L, et al. **Blood Press** 1995 Nov;4(6):350-7

Hemorheology of arterial hypertension: influence of urapidil. Delamaire M, et al. **Blood Press** 1995;Suppl 3:58-61

Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press** 1995;Suppl 3:21-5 (21 ref.)

The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability. With special reference to age and gender. Hansson L, et al. **Blood Press** 1995 Sep;4(5):313-9

Quality of life in hypertensive patients treated with either carvedilol or enalapril. Ostergren J, et al. **Blood Press** 1996 Jan;5(1):41-9

Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Ruilope LM, et al. **Blood Press** 1996 Jan;5(1):32-40

Effects of cilazapril on renal haemodynamics and function in hypertensive patients: a randomised controlled study versus hydrochlorothiazide. Scaglione R, et al. **Blood Press** 1995 Nov;4(6):363-8

Effect of enalapril on erythrocytosis in hypertensive patients with renal disease. Shand BI, et al. **Blood Press** 1995 Jul; 4(4):238-40

Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. Sihm I, et al. **Blood Press** 1995 Jul;4(4):241-8

Potential beneficial effects of urapidil in primary and secondary prevention of stroke. Späh F, et al. **Blood Press** 1995;Suppl 3:62-7 (49 ref.)

Pharmacological backgrounds of the drug treatment of hypertension in the elderly. van Zwieten PA. **Blood Press** 1995;Suppl 3:15-20 (33 ref.)

Combined treatment with captopril, hydrochlorothiazide and pravastatin in dyslipidemic hypertensive patients. Waeber B, et al. **Blood Press** 1995 Nov;4(6):358-62

Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Zanchetti A. **Blood Press** 1995;Suppl 3:38-46

Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. Adnot S, et al. **Blood Press Suppl** 1995;3:47-57

Hypertension in the elderly: benefits of treatment. Chalmers J. **Blood Press Suppl** 1995;3:6-10

Hemorheology of arterial hypertension: influence of urapidil. Delamaire M, et al. **Blood Press Suppl** 1995;3:58-61

Characteristics of an ideal antihypertensive therapy for elderly hypertensives. Hansson L, et al. **Blood Press Suppl** 1995;3:68-72

Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press Suppl** 1995;3:21-5 (21 ref.)

Cost-benefit aspects of treatment of hypertension in the elderly. Lindholm LH, et al. **Blood Press Suppl** 1995;3:11-4

Potential beneficial effects of urapidil in primary and secondary prevention of stroke. Späh F, et al. **Blood Press Suppl** 1995;3:62-7

Pharmacological backgrounds of the drug treatment of hypertension in the elderly. Van Zwieten PA. **Blood Press Suppl** 1995;3:15-20 (33 ref.)

Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Zanchetti A. **Blood Press Suppl** 1995;3:38-46

Treating hypertension: the evidence from clinical trials [editorial; comment] Simon JA. **BMJ** 1996 Aug 24; 313(7055):437-8. Comment on: BMJ 1996 Aug 24;313(7055):457-61.

Doxazosin: a new approach to hypertension and benign prostatic hyperplasia. Pool JL. **Br J Clin Pract** 1996 Apr-May;50(3):154-63 (70 ref.)

Prevention by blockade of angiotensin subtype1-receptors of the development of genetic hypertension but not its heritability. Madeddu P, et al. **Br J Pharmacol** 1995 Jun; 115(4):557-62

Nicardipine, verapamil and response to intubation [letter; comment] Tobias JD. **Can J Anaesth** 1995 Jul;42(7):659-60 . Comment on: Can J Anaesth 1994 Dec;41(12):1185-8.

Drug treatment of hypertension in the elderly. Lund-Johansen P. **Cardiologia** 1995 Jul;40(7):465-75 (88 ref.)

Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril. Alcocer L, et al. **Cardiovasc Drugs Ther** 1995 Jun;9(3):431-6

Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. Breithaupt-Grögler K, et al. **Cardiovasc Drugs Ther** 1996 Mar;10(1):49-57

Metabolic effects of isradipine in non-insulin-dependent diabetes mellitus (NIDDM) hypertensive patients [letter] Ferrara LA, et al. **Cardiovasc Drugs Ther** 1995 Jun; 9(3):459-60

Changes in urinary enzyme levels following the use of antihypertensive agents in patients with essential hypertension. Obatomi DK, et al. **Cardiovasc Drugs Ther** 1995 Jun;9(3):407-12

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Pitt B, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):693-700 (80 ref.)

Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. **Chin Med J (Engl)** 1995 Sep;108(9):710-7

Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension. Hui Y, et al. **Chin Med J (Engl)** 1995 Sep;108(9):678-81

Short-term and long-term effects of benazepril in mild to moderate hypertensives. Chen CH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Jul;56(1):12-22

Have long-term benefits of antihypertensive therapy been underestimated? Provocative findings from the Framingham Heart Study [editorial] Chobanian AV. **Circulation** 1996 Feb 15;93(4):638-40

Changes in red blood cell glutathione and glutathione-dependent enzymes on long-term treatment with captopril and enalapril. Golik A, et al. **Clin Chim Acta** 1995 Aug 31;240(1):89-94

Cardiovascular structural alterations in hypertension: effect of treatment. Agabiti-Rosei E, et al. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):513-22 (42 ref.)

The therapeutic approach to the control of hypertension. Its impact on health policy. Arroyo P, et al. **Clin Exp Hypertens** 1995 Oct;17(7):1121-6

Impact of guidelines for antihypertensive treatment on clinical practice. Chalmers J. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):415-23 (15 ref.)

Compliance with antihypertensive treatment. Costa FV. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):463-72 (20 ref.)

The case for a greater blood pressure fall. Hansson L. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):425-34 (19 ref.)

Antihypertensive treatment in the elderly. Lindholm LH. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):435-47 (33 ref.)

Ambulatory blood pressure, blood pressure variability and antihypertensive treatment. Mancia G, et al. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):449-62 (22 ref.)

Cost-effectiveness of hypertension treatment. Ménard J. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):399-413 (77 ref.)

Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment. Suzuki M, et al. **Clin Exp Hypertens** 1995 Nov;17(8):1257-68

Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Whelton PK, et al. **Clin Exp Hypertens** 1996 Apr-May; 18(3-4):569-79 (17 ref.)

Protective effect of nicardipine treatment on cerebrovascular microanatomical changes in spontaneously hypertensive rats. Amenta F, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S331-2

Influence of long-term treatment with the dihydropyridine-type calcium antagonist nicardipine on renal microanatomical changes in spontaneously hypertensive rats. Amenta F, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S333-4

Hypotensive effects of a new transdermal delivery system for clonidine (M-5041T) in spontaneously and renal hypertensive rats. Ishii R, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S374-6

Effect of an angiotensin II receptor antagonist, TCV-116, on neointimal formation following balloon injury in the SHR carotid artery. Kino H, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S360-2

Cardiovascular and renal protective effects of losartan in spontaneously hypertensive rats with diabetes mellitus. Kohzuki M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22 Suppl 1:S366-7

Renin-angiotensin system in the antihypertensive effect of isoteoline in spontaneously hypertensive rats. Markov M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S368-70

Sesame lignans modulate cholesterol metabolism in the stroke-prone spontaneously hypertensive rat. Ogawa H, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S310-2

Electroencephalographic evaluation of the therapeutic efficiency of antihypertensive agents on M-SHRSP. Ohta Y, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S377-9

Stroke-prone SHR and arteriolipidosis-prone SHR as models for atherosclerosis: their mechanisms and application for nutritional and pharmacological studies. Yamori Y, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S244-5

Meta-analysis of three trials with quinapril in the treatment of mild-to-moderate hypertension in the Mexican population. Alcocer L, et al. **Clin Ther** 1995 May-Jun; 17(3):552-60; discussion 516

Efficacy of long-term treatment with nipradilol, a nitroester-containing beta-blocker, in patients with mild-to-moderate essential hypertension. Haneda T, et al. **Clin Ther** 1995 Jul-Aug;17(4):667-79

Isradipine versus captopril in patients with essential hypertension. Manolis AJ, et al. **Clin Ther** 1995 Jul-Aug; 17(4):648-55

Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Townsend R, et al. **Clin Ther** 1995 Sep-Oct;17(5):911-23

Effects of long-term cilazapril treatment on glucose and lipid metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus. Uchida K, et al. **Clin Ther** 1995 Jul-Aug;17(4):729-34

Comparison of the efficacy and safety of nifedipine coat-core versus amlodipine in the treatment of patients with mild-to-moderate essential hypertension. Hypertension Study Group. Zidek W, et al. **Clin Ther** 1995 Jul-Aug; 17(4):686-700

Diabetes and hypertension. Smolar EN. **Compr Ther** 1995 Oct;21(10):597-601 (25 ref.)

Treatment modalities for hypertensive patients with intracranial pathology: options and risks. Tietjen CS, et al. **Crit Care Med** 1996 Feb;24(2):311-22 (86 ref.)

Newer antihypertensive drugs. Gregoire JR, et al. **Curr Opin Cardiol** 1995 Sep;10(5):445-9 (38 ref.)

Pharmacology and therapeutics. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):B132-54

Are angiotensin-converting enzyme inhibitors the renal protective antihypertensive drugs of choice? [editorial] Bauer JH. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):427-31 (23 ref.)

Measuring the effects of antihypertensive therapy upon the quality of life. Fletcher A. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):538-42 (33 ref.)

Antihypertensive therapy in the era of evidence based medical practice: what to do until the facts are in [editorial] Oparil S. **Curr Opin Nephrol Hypertens** 1996 Mar; 5(2):159-61

The management of hypertension in diabetes: with special reference to diabetic kidney disease. Leese GP, et al. **Diabet Med** 1996 May;13(5):401-10 (145 ref.)

Mortality and morbidity in treated hypertensive type 2 diabetic patients with micro- or macroproteinuria. Sawicki PT, et al. **Diabet Med** 1995 Oct;12(10):893-8

Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Velussi M, et al. **Diabetes** 1996 Feb;45(2):216-22

Effect of chronic intermittent intravenous insulin therapy on antihypertensive medication requirements in IDDM subjects with hypertension and nephropathy. Aoki TT, et al. **Diabetes Care** 1995 Sep;18(9):1260-5

Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. Chan JC, et al. **Diabetes Care** 1995 Jul;18(7):1001-6

Effects of enalapril and nitrendipine on the excretion of epidermal growth factor and albumin in hypertensive NIDDM patients. Josefsberg Z, et al. **Diabetes Care** 1995 May;18(5):690-3

Renoprotective effect of enalapril in uninephrectomized spontaneously hypertensive rats with neonatal streptozotocin-induced diabetes. Sato Y, et al. **Diabetes Res Clin Pract** 1995 Sep;29(3):153–61

A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Harper R, et al. **Diabetologia** 1995 Jul; 38(7):853–9

Losartan—a new antihypertensive. **Drug Ther Bull** 1995 Oct; 33(10):73–4

Guidelines for the drug treatment of hypertensive crises. Hirschl MM. **Drugs** 1995 Dec;50(6):991–1000

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Plosker GL, et al. **Drugs** 1995 Aug;50(2):334–63 (239 ref.)

Risk and management of hypertension-related left ventricular hypertrophy. Teo KK. **Drugs** 1995 Dec;50(6):959–70 (80 ref.)

Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Dunn CJ, et al. **Drugs Aging** 1995 Nov; 7(5):394–411 (111 ref.)

The changing face of hypertension and antihypertensive agents. Kitler ME. **Drugs Aging** 1996 Jan;8(1):5–11 (43 ref.)

Hypertensive emergencies. Murphy C. **Emerg Med Clin North Am** 1995 Nov;13(4):973–1007 (141 ref.)

Nonemergent hypertension. New perspectives for the emergency medicine physician. Thach AM, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):1009–35 (107 ref.)

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Feuerstein GZ, et al. **Eur Heart J** 1995 Jul;16 Suppl F:38–42 (21 ref.)

Benefits of adherence to anti-hypertensive drug therapy. Flack JM, et al. **Eur Heart J** 1996 Mar;17 Suppl A:16–20

Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. Fogari R, et al. **Eur Heart J** 1995 Aug;16(8):1120–5

Directions in antihypertensive treatment—our future from the past. Maisch B, et al. **Eur Heart J** 1995 May;16 Suppl C:74–83 (75 ref.)

Benefit and costs of anti-hypertensive treatment. Mancia G, et al. **Eur Heart J** 1996 Mar;17 Suppl A:25–8

Comparison between a bid and a tid regimen: improved compliance with no improved antihypertensive effect. The EOL Research Group. Boissel JP, et al. **Eur J Clin Pharmacol** 1996;50(1–2):63–7

Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension. Fettner SH, et al. **Eur J Clin Pharmacol** 1995;48(5):351–9

Ebelactone B, an inhibitor of urinary carboxypeptidase Y-like kininase, prevents the development of deoxycorticosterone acetate-salt hypertension in rats. Majima M, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):1–11

Neuropsychological consequences of antihypertensive medication use. Muldoon MF, et al. **Exp Aging Res** 1995 Oct-Dec;21(4):353–68 (68 ref.)

Effects of antihypertensive therapy on blood pressure and renal function in rats with hypertension due to chronic blockade of nitric oxide synthesis. Erley CM, et al. **Exp Nephrol** 1995 Sep-Oct;3(5):293–9

Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. The Syst-Eur Investigators. Celis H, et al. **Fam Pract** 1996 Apr;13(2):138–43

Doing randomized controlled trials in a developing country: some practical realities. Glasgow NJ, et al. **Fam Pract** 1996 Feb;13(1):98–103

Cardiovascular variability after rilmenidine challenge: assessment of acute dosing effects by means of spectral analysis. Girard A, et al. **Fundam Clin Pharmacol** 1995; 9(4):366–71

Sclerotherapy versus sclerotherapy and propranolol in the prevention of rebleeding from oesophageal varices: a randomised study. Elsayed SS, et al. **Gut** 1996 May; 38(5):770–4

Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension. Woodmansey PA, et al. **Heart** 1996 Feb;75(2):171–3

Should calcium antagonists be first line drugs in hypertension? Furberg CD, et al. **Herz** 1995 Dec; 20(6):365–9 (10 ref.)

Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients. Ishimitsu T, et al. **Hypertens Res** 1996 Mar;19(1):43–9

Comparison of first-line antihypertensive drugs by a randomized cross-over method—a preliminary report. Kojima S, et al. **Hypertens Res** 1995 Dec;18(4):303–5

Differences in ischemic threshold and nitrate efficacy between normotensive and hypertensive patients with stable angina pectoris. Marmor A, et al. **Hypertens Res** 1995 Jun;18(2):119–24

A diuretic is more effective than a beta-blocker in hypertensive patients not controlled on amlodipine and lisinopril. Antonios TF, et al. **Hypertension** 1996 Jun; 27(6):1325–8

Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy. Dieguez-Lucena JL, et al. **Hypertension** 1996 Jul;28(1):98–103

Antihypertensive therapy: safety and efficacy of drugs and publications [editorial] Frohlich ED, et al. **Hypertension** 1996 Mar;27(3 Pt 1):317–8

Comparison of early and late start of antihypertensive agents and baroreceptor reflexes. Kumagai K, et al. **Hypertension** 1996 Feb;27(2):209–18

Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rat. Navarro-Cid J, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1074–8

Effect of 1 year of lisinopril treatment on cardiac autonomic control in hypertensive patients with left ventricular hypertrophy. Petretta M, et al. **Hypertension** 1996 Mar;27(3 Pt 1):330–8

Antihypertensive treatment efficacy in type II diabetes mellitus. Dissociation between casual and 24-hour ambulatory blood pressure. Spanish Multicenter Study Group. Puig JG, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1093–9

Effect of antihypertensive therapy on small artery structure in hypertensive patients [letter; comment] Schiffrin EL. **Hypertension** 1995 Oct;26(4):716–8. Comment on: Hypertension 1995 Apr;25(4 Pt 1):474–81.

The trough-to-peak ratio as an instrument to evaluate antihypertensive drugs. The APTH Investigators. Ambulatory Blood Pressure and Treatment of Hypertension Trial. Staessen JA, et al. **Hypertension** 1995 Dec;26(6 Pt 1):942–9

Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action. Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Staessen JA, et al. **Hypertension** 1996 Mar;27(3 Pt 1):414–20

Hypertension and CHD risk: whither alpha-1 blockers? Pandit RB. **Indian Heart J** 1996 May-Jun;48(3):265–71 (41 ref.)

Effects of nitroxazepine on diastolic blood pressure in mild hypertensive patients—a short term clinical study. Balani ND, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):293–5

Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non-diabetic hypertensive subjects. Satia MC, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):237–41

Plasma levels of beta-endorphin, leucine enkephalin and arginine vasopressin in patients with essential hypertension and the effects of clonidine. Zheng X, et al. **Int J Cardiol** 1995 Oct;51(3):233–44

The significance of ethnicity for health promotion: patients' use of anti-hypertensive drugs in inner London. Morgan M. **Int J Epidemiol** 1995;24 Suppl 1:S79–84

Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat. Gin T, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):281–9

Survival after myocardial infarction in rats: captopril versus losartan. Milavetz JJ, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):714–9

Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. Moser M, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1214–8

Safety and efficacy of quinapril in hypertensive geriatric patients [letter] Howes LG, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1135

Myocardial infarction and antihypertensive drug therapy [letter; comment] Safar ME. **J Am Geriatr Soc** 1996 Jul; 44(7):881–2. Comment on: J Am Geriatr Soc 1995 Nov;43(11):1191–7.

Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group [published erratum appears in J Am Soc Nephrol 1995 Oct;6(4):1318] Klahr S, et al. **J Am Soc Nephrol** 1995 Jun;5(12):2037–47

Controversy in the pharmacologic treatment of hypertension in African Americans [see comments] Lockette W. **J Assoc Acad Minor Phys** 1995;6(4):125–9 (32 ref.). Comment in: J Assoc Acad Minor Phys 1995;6(4):124.

Should diuretics be combined with calcium antagonists? [letter] Lazar AI. **J Assoc Physicians India** 1996 Jan; 44(1):71–2

Tolerability of enalapril in mild to moderate hypertension. Sharma S, et al. **J Assoc Physicians India** 1995 Jul; 43(7):475–6

A comparison of amrinone with sodium nitroprusside for control of hemodynamics during infrarenal abdominal aortic surgery. Dentz ME, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):486–90

Imidazoline Receptors in a Comprehensive Approach to Hypertension. Proceedings of an international symposium. Berlin, Germany, September 10, 1994. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S1–67

Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus. Araki M, et al. **J Cardiovasc Pharmacol** 1995 Jul; 26(1):61–5

Effects of indapamide on atherosclerosis development in cholesterol-fed rabbits. Del Rio M, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):973–8

Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine. Grandi AM, et al. **J Cardiovasc Pharmacol** 1995 Nov;26(5):737–41

Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. Maggi E, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):532–8

Rilmenidine prevents epinephrine-induced arrhythmias in halothane-anesthetized dogs. Mammoto T, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S40–3

Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. Morel Y, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):306–11

Comparative effects of rilmenidine and atenolol on tests of autonomic function and mental and dynamic exercise in patients with essential hypertension. Panfilov V, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S44–7

Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. Romero R, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):114–8

Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril. Scemama M, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 2:S34–9

Effects of chronic nifedipine treatment on streptozotocin-induced diabetic rats. Shah TS, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):6–12

Double-blind comparison of antihypertensive treatment with ramipril and piretanide, given alone or in combination. Thijs L, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):33–8

Rilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass. Trimarco B, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S29–33

Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension. van Paassen P, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):39–45

Intravenous trimethaphan during epidural plus general anesthesia decreases the direct radial artery pressure lower than the brachial artery pressure. Nagata N, et al. **J Clin Anesth** 1996 May;8(3):180–7

Trimethaphan (Arfonad) control of hypertension and tachycardia during electroconvulsive therapy: a double-blind study. Petrides G, et al. **J Clin Anesth** 1996 Mar;8(2):104–9

Management of hypertensive urgencies and emergencies. Abdelwahab W, et al. **J Clin Pharmacol** 1995 Aug; 35(8):747–62 (100 ref.)

Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. Frishman WH, et al. **J Clin Pharmacol** 1995 Nov;35(11):1060–6

Effects of amlodipine on 24-hour ambulatory blood pressure profiles, electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension. Skoularigis J, et al. **J Clin Pharmacol** 1995 Nov;35(11):1052–9

Effects of intensification of antihypertensive care in diabetic nephropathy. Sawicki PT, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):315–7

Longitudinal evaluation of renal function in non-insulin-dependent diabetic patients with early nephropathy: effects of angiotensin-converting enzyme inhibition. Vora JP, et al. **J Diabetes Complications** 1996 Mar-Apr;10(2):88–93

Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. Chiang HT, et al. **J Gastroenterol Hepatol** 1995 May-Jun;10(3):256–60

Implementation of local guidelines for cost-effective management of hypertension. A trial of the firm system [see comments] Aucott JN, et al. **J Gen Intern Med** 1996 Mar;11(3):139–46. Comment in: J Gen Intern Med 1996 Mar;11(3):185–6.

Smoking cessation and the nicotine patch: much more to be done [editorial; comment] Kimmel SE, et al. **J Gen Intern Med** 1995 Dec;10(12):697–8. Comment on: J Gen Intern Med 1995 Dec;10(12):656–62.

The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. Gurwitz JH, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):M74–9

Anti-hypertensive therapy by losartan. How effective is AT1 receptor blockade? [editorial; comment] Brunner HR. **J Hum Hypertens** 1995 Nov;9(11):859–60. Comment on: J Hum Hypertens 1995 Nov;9(11):861–7.

Comparison of ramipril and nitrendipine [letter; comment] Chan JC, et al. **J Hum Hypertens** 1995 Nov;9(11):931. Comment on: J Hum Hypertens 1995 Feb;9(2):131–5.

Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. Chan JC, et al. **J Hum Hypertens** 1995 Sep;9(9):765–71

Comparison of amlodipine and quinapril on ambulatory blood pressure and platelet function in hypertension. Ding YA, et al. **J Hum Hypertens** 1995 Aug;9(8):637–41

Analysis of trough:peak ratio and the assessment of anti-hypertensive drug action. Elliott HL, et al. **J Hum Hypertens** 1995 Jun;9(6):423–7

Measurement of trough-to-peak ratios of four anti-hypertensive drugs on the basis of 24 h ambulatory blood pressure monitoring: different methods may give

different results. Gama G, et al. **J Hum Hypertens** 1995 Jul;9(7):575–80

The future role of losartan. Hansson L. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S55–8 (24 ref.)

Managing hypertension in general practice: can we do better? Hosie J, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S15–8 (7 ref.)

What are the implications for the community of the discrepancy between the theory and practice of BP control? Jackson R. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S25–8 (8 ref.)

Body mass index, blood pressure, diabetes and the risk of anti-hypertensive drug treatment: 12-year follow-up of middle-aged people in eastern Finland. Jousilahti P, et al. **J Hum Hypertens** 1995 Oct;9(10):847–54

Is insulin resistance a predictor of the blood pressure response to anti-hypertensive treatment? Lind L, et al. **J Hum Hypertens** 1995 Sep;9(9):759–63

Current issues in the control of hypertension. Lund-Johansen P. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S25–8 (31 ref.)

Improving the management of hypertension in clinical practice. Mancia G. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S29–31 (13 ref.)

Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. Materson BJ, et al. **J Hum Hypertens** 1995 Oct;9(10):791–6

Limiting factors in the control of BP: why is there a gap between theory and practice? Ménard J, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S19–23 (17 ref.)

Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? Moan A, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S45–50

Effect of long-term celiprolol therapy on haemostasis in essential hypertension. Okrucká A, et al. **J Hum Hypertens** 1995 Sep;9(9):773–6

The hidden truth: what do the clinical trials really tell us about BP control? Ruilope LM. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S3–7 (13 ref.)

New ideas for treating hypertension. Schachter M. **J Hum Hypertens** 1995 Aug;9(8):663–7 (40 ref.)

The heterogeneity of hypertension: why doesn't every patient respond to every antihypertensive drug? Sever P. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S33–6 (8 ref.)

Management guidelines for hypertension: is anyone taking notice? Swales JD. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S9–13 (13 ref.)

Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs—the rationale and benefits of combining felodipine and metoprolol. Trenkwalder P, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S37–42 (17 ref.)

Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent. Weber MA, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S29–35

Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension. White WB, et al. **J Hum Hypertens** 1995 Nov;9(11):879–84

A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice. The OCAPI Study Group. Optimiser le Choix d'un Anti-hypertenseur de Première Intention. Boissel JP, et al. **J Hypertens** 1995 Sep; 13(9):1059–67

Mechanisms responsible for sustained hypotension after captopril treatment. Chen DG, et al. **J Hypertens** 1995 Oct; 13(10):1113–21

Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. Dudley C, et al. **J Hypertens** 1996 Feb;14(2):259–62

New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. Gueyffier F, et al. **J Hypertens** 1996 Jan;10(1):1–8

Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. Muiesan ML, et al. **J Hypertens** 1995 Oct;13(10):1091–5

Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. Omboni S, et al. **J Hypertens** 1995 Oct; 13(10):1105–12

Prostacyclin biosynthesis in essential hypertension before and during treatment. Ritter JM, et al. **J Hypertens** 1996 Jan; 10(1):37–42

Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. Ruff D, et al. **J Hypertens** 1996 Feb;14(2):263–70

Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. Sawicki PT, et al. **J Hypertens** 1995 Aug; 13(8):933–8

Insulin, hypertension and antihypertensive drugs in elderly patients: the Rotterdam Study. Stolk RP, et al. **J Hypertens** 1996 Feb;14(2):237–42

Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats. Wyss JM, et al. **J Hypertens** 1995 Sep; 13(9):1037–42

Antihypertensive effects of trandolapril and nitrendipine in the elderly: a controlled trial with special emphasis on time effect profiles. Zannad F, et al. **J Hypertens** 1996 Jan; 10(1):51–5

Managing the elderly hypertensive patient beyond blood pressure reduction. Holzgreve H. **J Hypertens Suppl** 1995 Aug;13(2):S103–7 (15 ref.)

Metabolic aspects of the treatment of hypertension. Lithell H. **J Hypertens Suppl** 1995 Aug;13(2):S77–80 (29 ref.)

Update on the use of angiotensin converting enzyme inhibitors and calcium antagonists in postinfarction patients. Persson S. **J Hypertens Suppl** 1995 Aug;13(2):S57–63 (33 ref.)

Hypertension in the non-insulin-dependent diabetes mellitus syndrome: a critical review of therapeutic intervention. Rett K, et al. **J Hypertens Suppl** 1995 Aug;13(2):S81–5 (26 ref.)

Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy. Ruilope LM. **J Hypertens Suppl** 1995 Aug;13(2):S91–3 (26 ref.)

Guidelines for the management of hypertension: the World Health Organization/International Society of Hypertension view. World Health Organization. International Society of Hypertension. Zanchetti A. **J Hypertens Suppl** 1995 Aug; 13(2):S119–22 (19 ref.)

Comparative evaluation of the antihypertensive efficacy of once-daily sustained-release isradipine and lacidipine using 24-hour ambulatory blood-pressure monitoring. Galderisi M, et al. **J Int Med Res** 1995 Jul–Aug;23(4):234–43

Antihypertensive and metabolic effects of doxazosin in hypertensive patients with concomitant non-insulin-dependent diabetes mellitus. Inoue Y, et al. **J Int Med Res** 1996 Jan–Feb;24(1):138–46

Antihypertensive efficacy and safe use of once-daily sustained-release diltiazem in the elderly: a comparison with captopril. The Dilcacomp Study Group. Nicaise J, et al. **J Int Med Res** 1995 Jul–Aug;23(4):244–53

The ALLHAT challenges [letter] Anderson RJ, et al. **J Natl Med Assoc** 1996 Jun;88(6):335, 368

The detection and management of hypertension [letter; comment] Smith BH. **J Public Health Med** 1995 Dec; 17(4):490–1. Comment on: J Public Health Med 1995 Mar;17(1):57–62.

Myocardial infarction associated with antihypertensive drug therapy [letter; comment] Blandino DA. **JAMA** 1996 Feb 21;275(7):516; discussion 517. Comment on: JAMA 1995 Aug 23–30;274(8):654–5. Comment on: JAMA 1995 Aug 23–30;274(8):620–5.

Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial [see comments] Borhani NO, et al. **JAMA** 1996 Sep 11;276(10):785–91. Comment in: JAMA 1996 Sep 11;276(10):829–30.

Choice of antihypertensive therapy during pregnancy [letter] Casele HL, et al. **JAMA** 1996 Sep 11;276(10):780

Calcium channel blockers. Lessons learned from MIDAS and other clinical trials [editorial; comment] Chobanian AV. **JAMA** 1996 Sep 11;276(10):829–30. Comment on: JAMA 1996 Sep 11;276(10):785–91.

Regression of left ventricular hypertrophy. How and why? [editorial; comment] Devereux RB. **JAMA** 1996 May 15; 275(19):1517–8. Comment on: JAMA 1996 May 15;275(19):1507–13.

Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group [see comments] Grimm RH Jr, et al. **JAMA** 1996 May 22–29;275(20):1549–56. Comment in: JAMA 1996 May 22–29;275(20):1604–6.

Choice of initial therapy for hypertension [see comments] Kaplan NM, et al. **JAMA** 1996 May 22–29;275(20):1577–80 . Comment in: JAMA 1996 May 22–29;275(20):1604–6.

Regression of left ventricular hypertrophy [letter; comment] Liebson PR, et al. **JAMA** 1996 Aug 21;276(7):526–7. Comment on: JAMA 1996 May 15;275(19):1507–13.

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies [see comments] Schmieder RE, et al. **JAMA** 1996 May 15;275(19):1507–13. Comment in: JAMA 1996 May 15;275(19):1517–8. Comment in: JAMA 1996 Aug 21;276(7):526–7. Comment in: JAMA 1996 Aug 21;276(7):527.

Effect of trichlormethiazide and captopril on nitric oxide synthase activity in the kidney of deoxycorticosterone acetate-salt hypertensive rats. Takanohashi A, et al. **Jpn Heart J** 1996 Mar;37(2):251–9

The effects of nisoldipine on carotid artery stiffness and left ventricular functions. Tavli T, et al. **Jpn Heart J** 1995 Sep; 36(5):629–37

Long-term therapy of hypertension. Yoo WS. **Korean J Intern Med** 1995 Jul;10(2):79–86 (25 ref.)

Criticism of Servier re perindopril [letter] Alliot LS. **Lancet** 1996 Mar 23;347(9004):832

Risks and benefits of calcium antagonists [letter] Collins R, et al. **Lancet** 1995 Oct 7;346(8980):961–2

Have expert panel guidelines kept pace with new concepts in hypertension? [see comments] Levy D. **Lancet** 1995 Oct 28;346(8983):1112–3. Comment in: Lancet 1995 Dec 16;346(8990):1631.

Fructus aurantii reduced portal pressure in portal hypertensive rats. Huang YT, et al. **Life Sci** 1995; 57(22):2011–20

Zinc and magnesium serum levels in patients with benign prostatic hyperplasia (BPH) before and after prazosin therapy. Dutkiewicz S. **Mater Med Pol** 1995 Jan–Mar; 27(1):15–7

A practical guideline for management of hypertension in patients with diabetes. Fatourechi V, et al. **Mayo Clin Proc** 1996 Jan;71(1):53–8 (37 ref.)

Nisoldipine--a new calcium channel blocker for hypertension. **Med Lett Drugs Ther** 1996 Feb 16; 38(968):13–4

Decreased vascular reactivity in metformin-treated fructose-hypertensive rats. Verma S, et al. **Metabolism** 1996 Sep;45(9):1053–5

Primary and secondary results of the modification of diet in renal disease study. Klahr S. **Miner Electrolyte Metab** 1996;22(1–3):138–42

Treatment of hypertension in pregnant women. Sibai BM. **N Engl J Med** 1996 Jul 25;335(4):257–65 (93 ref.)

Trends in the use of blood pressure lowering medications in Auckland, and associated costs, 1982–94. Trye P, et al. **N Z Med J** 1996 Jul 26;109(1026):270–2

Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Gansevoort RT, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):1963–74

The effect of ACE inhibitors and other antihypertensive agents on insulin resistance [editorial] Lithell H. **Nephrol Dial Transplant** 1995;10(5):589–91

Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Weidmann P, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:39–45

Renal involvement in essential hypertension and treatment effects. de Leeuw PW, et al. **Neth J Med** 1995 Oct; 47(4):199–204 (43 ref.)

Reversibility of left ventricular hypertrophy by antihypertensive drugs. Fagard RH. **Neth J Med** 1995 Oct; 47(4):173–9 (47 ref.)

Effects of antihypertensive drugs on large artery compliance. Slama M, et al. **Neth J Med** 1995 Oct;47(4):162–8 (48 ref.)

The use of calcium-channel blockers in pregnancy. Lewis R, et al. **New Horiz** 1996 Feb;4(1):115–22 (45 ref.)

Current considerations in patients with coexistent diabetes and hypertension. Wood MH. **Nurse Pract** 1996 Apr; 21(4):19–20, 27–31 (24 ref.)

Pattern electroretinogram in treated ocular hypertension: a cross-sectional study after timolol maleate therapy. Colotto A, et al. **Ophthalmic Res** 1995;27(3):168–77

Oscillatory potentials in subjects with treated hypertension. Ravalico G, et al. **Ophthalmologica** 1995;209(4):187–9

A therapeutic approach to hypertension [letter; comment] Hombhanje F. P N G Med J 1995 Mar;38(1):62–3. Comment on: P N G Med J 1993 Mar;36(1):63–70.

Nicardipine: perioperative applications in children. Tobias JD, et al. **Paediatr Anaesth** 1995;5(3):171–6

Renal artery stenosis in infants: long-term medical treatment before surgery. Bendel-Stenzel M, et al. **Pediatr Nephrol** 1996 Apr;10(2):147–51

When should essential hypertension in childhood be treated and how? Ingelfinger JR. **Pediatr Nephrol** 1995 Oct; 9(5):552

Analysis of pharmacotherapy of hypertension in out-patients. Vlček J, et al. **Pharm World Sci** 1995 May 26;17(3):81–6

Antihypertensive drug use in the long-term care facility: a pilot study and review of the literature. Fish JT, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):785–8 (11 ref.)

Hypertensive crises. The need for urgent management [see comments] Varon J, et al. **Postgrad Med** 1996 Jan; 99(1):189–91, 195–6, 199–200, passim (21 ref.). Comment in: Postgrad Med 1996 Mar;99(3):70–1.

Antihypertensive effects of AT-112, a newly synthesized quinazoline derivative, in spontaneously hypertensive rats. Tseng CJ, et al. **Proc Natl Sci Counc Repub China B** 1995 Jul;19(3):159–65

Cardiac hypertrophy in copper-deficient rats is not attenuated by angiotensin II receptor antagonist L-158,809. Lear PM, et al. **Proc Soc Exp Biol Med** 1996 Jul; 212(3):284–92

Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease. Kanno Y, et al. **QJM** 1996 Jan;89(1):65–70

Comparison of the effects of a low-protein diet with the effects of a converting enzyme inhibitor on the progression of renal insufficiency in hypertensive rats. Cervenka L, et al. **Ren Fail** 1996 Mar;18(2):173–80

Lisinopril and diltiazem reduce left ventricular mass without changing blood pressure in normotensive subjects with exaggerated blood pressure response to exercise. Polónia J, et al. **Rev Port Cardiol** 1996 Mar;15(3):185–93, 179

Stress reactivity in responder and non-responder hypertensives treated with verapamil and enalapril. Nazzaro P, et al. **Riv Eur Sci Med Farmacol** 1995 Jul–Aug; 17(4):105–13

Treatment of myocardial infarction: hypotensive effect of different thrombolytic agents. Puletti M, et al. **Riv Eur Sci Med Farmacol** 1994 Sep–Dec;16(5–6):113–8

A new trend in the therapy of orthostatic arterial hypotension: prevention by propranolol or metoclopramide of the excessive adrenaline release of brainstem infarct patients with postural hypotension. Stoica E, et al. **Rom J Neurol Psychiatry** 1995 Jul–Dec;33(3–4):203–14

Bisoprolol launched in South Africa [news] **S Afr Med J** 1996 Apr;86 Suppl 2:C119–20

A new class of antihypertensive: angiotensin II receptor antagonists. McCoy R. **S D J Med** 1995 Sep;48(9):319–20

Who is using antihypertensive drugs? A prescription analysis from Finland. Wallenius S, et al. **Scand J Prim Health Care** 1996 Mar;14(1):54–61

Blood pressure lowering for the primary and secondary prevention of coronary and cerebrovascular disease. MacMahon S, et al. **Schweiz Med Wochenschr** 1995 Dec 26;125(51–52):2479–86 (28 ref.)

Felodipine as an alternative to more expensive calcium antagonists in mild to moderate hypertension. Landry FJ, et al. **South Med J** 1996 Jun;89(6):573–7

Do the effects of blood pressure control on the progression of diabetic nephropathy depend on disease stage? Katagiri T, et al. **Tohoku J Exp Med** 1995 Aug;176(4):219–25

Glomerulosclerosis in kidney transplants: pathophysiologic mechanisms. Paul L, et al. **Transplant Proc** 1996 Feb; 28(1):480–1

[Controlled hypotension against a background of nimodipine during an operation on neurosurgical patients with hypertension] Karadimov D. **Khirurgiia (Sofiia)** 1995; 48(5):26–8 (Eng. Abstr.) **(Bul)**

[Clinical and laboratory studies of effect of longevity-antihypertensive-mixture on elderly hypertension with kidney deficiency] Zhou WQ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Sep; 15(9):532–5 (Eng. Abstr.) **(Chi)**

[24-hour effectiveness and tolerance of perindopril (Prestarium), an ACE inhibitor, in the treatment of mild to moderate hypertension. A 1-year Czech and Slovak study] Widimsky J, et al. **Vnitr Lek** 1995 Jul;41(7):441–4 (Eng. Abstr.) **(Cze)**

[Personal clinical experience in the treatment of arterial hypertension using amlodipine] Zicha J. **Vnitr Lek** 1996 Mar;42(3):153–6 (Eng. Abstr.) **(Cze)**

[Venous occlusion in the retina as complication of insufficiently treated hypertension] van Gool CA, et al. **Ned Tijdschr Geneeskd** 1996 Aug 10;140(32):1629–30 **(Dut)**

[Evaluation of trandolapril alone or in combination with a calcium channel blocker in hypertensive patients over 60 years of age] Gosse P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Nov;44(9):517–24 (Eng. Abstr.) **(Fre)**

[Course of ischemic risk in treated atheromatous hypertensive patients. The PRIHAM study] Godeau P, et al. **Ann Med Interne (Paris)** 1995;146(8):530–5 (Eng. Abstr.) **(Fre)**

[Ambulatory blood pressure monitoring and clinical trials] Andréjak M, et al. **Arch Mal Coeur Vaiss** 1995 Aug; 88(8):1175–8 (Eng. Abstr.) **(Fre)**

[Therapeutic benefit of a low dose of indapamide: results of a double-blind against placebo European controlled study] Asmar R, et al. **Arch Mal Coeur Vaiss** 1995 Aug; 88(8):1083–7 (Eng. Abstr.) **(Fre)**

[Resistant arterial hypertension] Bobrie G, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88(8):1183–5 (Eng. Abstr.) **(Fre)**

[Comparison of different methods in the assessment of the ratio of hypertensive patients responding to antihypertensive treatment] Nguyen G, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88(8):1171–4 (Eng. Abstr.) **(Fre)**

[Quality of blood pressure control in general practice and in the HOT study. French Research Group HOT (Hypertension Optimal Treatment)] Raveau-Landon C. **Arch Mal Coeur Vaiss** 1995 Aug;88(8):1179–81 (Eng. Abstr.) **(Fre)**

[Evaluation of the efficacy and the tolerance of cicletanine in hypertensive subjects over 65 years of age. Three frequent clinical situations in urban practice] Amah G, et al. **Presse Med** 1995 Dec 16–23;24(39):1912–6 **(Fre)**

[Pharmaco-epidemiologic evaluation of rilmenidine in 18,235 hypertensive patients] Luccioni R. **Presse Med** 1995 Dec 9;24(38):1857–64 (Eng. Abstr.) **(Fre)**

[Pharmaclinics. Drug of the month. Captopril (Capoten) in diabetic nephropathies] Scheen AJ. **Rev Med Liege** 1995 Oct;50(10):445–6 **(Fre)**

[Diagnosis and treatment of hypertensive emergencies] Burnier M, et al. **Schweiz Med Wochenschr** 1995 Nov 25; 125(47):2261–6 (8 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of arterial hypertension. Re-emergence of diuretics] Guelpa G. **Schweiz Rundsch Med Prax** 1995 Nov 14;84(46):1356–7 (Eng. Abstr.) **(Fre)**

[Diagnosis and treatment of arterial hypertension in the elderly] Waeber B, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):150–4 (19 ref.) (Eng. Abstr.) **(Fre)**

[Antihypertensive therapy and coronary heart disease: significance of the effect of concomitant cardiovascular risk factors] Huber K, et al. **Acta Med Austriaca** 1995; 22(3):48–51 (47 ref.) (Eng. Abstr.) **(Ger)**

[Decreasing the antihypertensive dosage during longterm treatment and complete regression of left ventricular hypertrophy] Franz IW, et al. **Dtsch Med Wochenschr** 1996 Apr 12;121(15):472–7; discussion 478 (Eng. Abstr.) **(Ger)**

[Angiotensin receptor antagonists. A new class of antihypertensive agents] Mann J. **Dtsch Med Wochenschr** 1996 Apr 26;121(17):568–71 (22 ref.) **(Ger)**

[Retrospective studies and prospects of therapy for hypertension] Maisch B, et al. **Herz** 1995 Dec;20(6):370–89 (96 ref.) (Eng. Abstr.) **(Ger)**

[Angiotensin II receptor antagonists. Clinical relevance] Scholze J. **Internist (Berl)** 1996 Jun;37(6):636–42 (47 ref.) **(Ger)**

[Therapy of hypertension 1996. Effectiveness, tolerance, cost-benefit aspects] Rahn KH. **Med Klin** 1996 Jun 15; 91(6):380–3 (8 ref.) **(Ger)**

[Rational hypertension treatment] Canova CR. **Schweiz Med Wochenschr** 1996 Aug 17;126(33):1394–9 (Eng. Abstr.) **(Ger)**

[Hypertension in the elderly] Reinhart WH. **Schweiz Med Wochenschr** 1996 Aug 24;126(34):1442–5 (19 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of hypertension in elderly patients] Vetter W, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31; 84(44):1277–81 (25 ref.) (Eng. Abstr.) **(Ger)**

[Initial results of the HOT-study in Switzerland (hypertension optimal treatment)] Waeber B, et al. **Schweiz Rundsch Med Prax** 1995 Nov 28;84(48):1432–4 (Eng. Abstr.) **(Ger)**

[Beta blockers and diuretics: therapeutic drugs of first choice in diabetes mellitus and hypertension] Sawicki PT. **Wien Klin Wochenschr** 1995;107(21):629–39 (98 ref.) (Eng. Abstr.) **(Ger)**

[Results of the 3rd Consensus Conference on "Individualized Therapy of Hypertension" and brief explanation of individual evaluation] **Wien Med Wochenschr** 1995; 145(15–16):339–49 (0 ref.) **(Ger)**

[Evaluation of the antihypertensive drugs carvedilol, doxazosin and moxonidine] Dominiak P. **Wien Med Wochenschr** 1995;145(15–16):373–82 (92 ref.) (Eng. Abstr.) **(Ger)**

[Individualized therapy of hypertension. The Austrian Professional Group of Clinical Pharmacology] Magometschnigg D, et al. **Wien Med Wochenschr** 1995; 145(15–16):349–52 (Eng. Abstr.) **(Ger)**

[A multicenter study of lisinopril in the treatment of mild to moderate hypertension] Yodfat Y. **Harefuah** 1995 Jul; 129(1–2):26–9, 78 (Eng. Abstr.) **(Heb)**

[Selected passages from the clinical trials of Cordaflex] Somogyi M, et al. **Acta Pharm Hung** 1996 Jan;66(1):47–51 (16 ref.) (Eng. Abstr.) **(Hun)**

[Basic principles of current trends in the management of hypertension and kidney disease in pregnancy] Vajó Z, et al. **Orv Hetil** 1995 Nov 19;136(47):2561–6 (45 ref.) (Eng. Abstr.) **(Hun)**

[New therapeutic outlooks in the treatment of the hypertensive patient] Ambrosioni E, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:78S–81S (20 ref.) (Eng. Abstr.) **(Ita)**

[The preliminary clinical evidence from the ELSA study. The European Lacidipine Study on Atherosclerosis] Leonetti G. **Ann Ital Med Int** 1995 Oct;10 Suppl:74S–77S (Eng. Abstr.) **(Ita)**

[The intervention trial in the evaluation of antihypertensive therapy] Mancia G, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:108S–111S (20 ref.) (Eng. Abstr.) **(Ita)**

[Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension] Puddu P, et al. **Clin Ter** 1995 Dec; 146(12):801–10 (Eng. Abstr.) **(Ita)**

[The treatment of intraoperative arterial hypertension with Urapidil] Filosso PL. **Minerva Cardioangiol** 1996 Apr; 44(4):197–207 (45 ref.) **(Ita)**

[Antihypertensive treatment with nitrendipine] Nalin G, et al. **Minerva Cardioangiol** 1996 Jan–Feb;44(1–2):67–72 (Eng. Abstr.) **(Ita)**

[Balanced beta--alpha-blocker treatment with carvedilol in mild-moderate arterial hypertension] Perocchio M, et al. **Minerva Cardioangiol** 1996 Mar;44(3):115–21 (Eng. Abstr.) **(Ita)**

[The use of ambulatory pressure monitoring for evaluating antihypertensive treatment in clinical practice] Fortini A, et al. **Minerva Med** 1995 Dec;86(12):527–35 (Eng. Abstr.) **(Ita)**

[Blood pressure and body mass index of hypertensive patients before and during the medication] Kawada T, et al. **Sangyo Eiseigaku Zasshi** 1995 Nov;37(6):419–20 **(Jpn)**

[Status of ongoing controlled clinical trials of hypertension treatment (letter)] Hernes KH. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):535 **(Nor)**

[Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist] Kjeldsen SE, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):504–7 (25 ref.) (Eng. Abstr.) **(Nor)**

[Status of ongoing controlled clinical trials on hypertension] Kjeldsen SE, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10; 116(1):61–3 (Eng. Abstr.) **(Nor)**

[Physicians' view on drug therapy for hypertension. A questionnaire in the county of Hordaland] Smiseth OA, et al. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1588–90 (Eng. Abstr.) **(Nor)**

[Evaluation of the antihypertensive efficacy of urapidil in the treatment of hypertension emergencies] Blaszyk K, et al. **Pol Arch Med Wewn** 1995 Dec;94(6):512–7 (Eng. Abstr.) **(Pol)**

[Multiple-action drugs--new direction in pharmacotherapy of hypertension (editorial)] Drzewoski J. **Pol Arch Med Wewn** 1995 Aug;94(2):97–104 **(Pol)**

[The effect of hypotensive drugs on left ventricular mass and diastolic function] Spring A, et al. **Pol Arch Med Wewn** 1995 Jul;94(1):47–58 (Eng. Abstr.) **(Pol)**

[Imidazol receptor agonists--new possibilities for treating hypertension] Nowicki M, et al. **Postepy Hig Med Dosw** 1995;49(5):631–43 (56 ref.) (Eng. Abstr.) **(Pol)**

[Hypertensive crises] Da Silva PM, et al. **Acta Med Port** 1995 Dec;8(12):685–90 (Eng. Abstr.) **(Por)**

[Our point of view. Trough to peak ratio of antihypertensive drugs: methodologic issues and clinical implications] Polónia J. **Rev Port Cardiol** 1996 Apr;15(4):281–92 (30 ref.) **(Por)**

[Lomir in the treatment of arterial hypertension after angioplastic surgery] Lebedeva RN, et al. **Anesteziol Reanimatol** 1996 Mar-Apr;(2):65–7 (Eng. Abstr.) **(Rus)**

[Anesthesiological care in removal of jugular glomus tumor. First experience with the use of urapidil] Lubnin AIu, et al. **Anesteziol Reanimatol** 1996 Mar-Apr;(2):50–3 **(Rus)**

[Changes in cardiohemodynamic indicators during use of verapamil for preventing and treating hypertensive complications of pregnancy] Gromyko GL. **Biull Eksp Biol Med** 1995 Nov;120(11):547–50 **(Rus)**

[The relationship between cell membrane adrenoreceptor response and insulinemia in hypertension patients undergoing calcium antagonist treatment] Dlusskaia IG, et al. **Eksp Klin Farmakol** 1995 Nov-Dec;58(6):49–51 (Eng. Abstr.) **(Rus)**

[Effectiveness and tolerance of benazepril versus captopril in patients with hypertension] Ol'binskaia LI, et al. **Klin Med (Mosk)** 1995;73(5):36–8 (Eng. Abstr.) **(Rus)**

[Chronosensitivity to adelphane-esidrex and sinepres and effectiveness of treatment of patients with hypertension] Zaslavskaia RM, et al. **Klin Med (Mosk)** 1995;73(4):57–60 (Eng. Abstr.) **(Rus)**

[The use of the delayed-action form of korinfar in arterial hypertension, stenocardia and hypertrophic cardiomyopathy] Barats SS, et al. **Ter Arkh** 1996; 68(1):39–42 (Eng. Abstr.) **(Rus)**

[The use of perindopril (prestarium) in arterial hypertension] Filatova NP. **Ter Arkh** 1995;67(9):81–3 (35 ref.) **(Rus)**

[The lipid peroxidation indices of hypertension patients undergoing combined therapy with anaprilin, korinfar and hypothiazide] Iarema NI, et al. **Ter Arkh** 1995;67(8):28–30 (Eng. Abstr.) **(Rus)**

[The effect of long-term monotherapy with preparations from the 4 basic groups of antihypertensive agents on the quality of life in patients with mild and moderate arterial hypertension. The Multicenter Captopril and the Quality of Life Study. The working group of the Multicenter Captopril and the Quality of Life Study] Metelitsa VI, et al. **Ter Arkh** 1995;67(9):45–50 (Eng. Abstr.) **(Rus)**

[Biochemical changes in hypertensive patients during a 1-year cross-over study of treatment with hydrochlorothiazide and propranolol] Bagatin J, et al. **Lijec Vjesn** 1996 Jan–Feb;118(1–2):11–6 (Eng. Abstr.) **(Scr)**

[A comparative study of the efficacy of lisinopril versus quinapril in controlling light to moderate arterial hypertension. A follow-up with ABPM] Motero Carrasco J. **Rev Esp Cardiol** 1995 Nov;48(11):746–53 (Eng. Abstr.) **(Spa)**

TOXICITY

Acetylation and its role in the mutagenicity of the antihypertensive agent hydralazine. Lemke LE, et al. **Drug Metab Dispos** 1995 May;23(5):559–65

Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. Spence SG, et al. **Teratology** 1995 Jun; 51(6):367–82

Evaluation of the reproductive and developmental toxicity of the AT1-selective angiotensin II receptor antagonist losartan in rats. Spence SG, et al. **Teratology** 1995 Jun; 51(6):383–97

[A myocardial lesion induced by hydralazine] Ferreira C, et al. **Rev Port Cardiol** 1995 Nov;14(11):853–8 **(Por)**

[Evaluation of the toxicity of indorenate on reproduction] Chamorro G, et al. **Arch Inst Cardiol Mex** 1995 Jul-Aug; 65(4):300–6 (Eng. Abstr.) **(Spa)**

URINE

Urinary excretion of cicletanine in the rat. Stereochemical aspects. Vistelle R, et al. **Drug Metab Dispos** 1995 Sep; 23(9):988–92

Development and validation of column-switching high-performance liquid chromatographic methods for the determination of a potent AII receptor antagonist, TCV-116, and its metabolites in human serum and urine. Lee JW, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):287–98

ANTI-IDIOTYPE ANTIBODIES see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTI-INFECTIVE AGENTS

see related
ANTHELMINTICS
ANTIPROTOZOAL AGENTS

Production in Escherichia of moricin, a novel type antibacterial peptide from the silkworm, Bombyx mori. Hara S, et al. **Biochem Biophys Res Commun** 1996 Mar

27;220(3):664–9
Molecular cloning of cDNAs encoding precursors of frog skin antimicrobial peptides from Rana rugosa. Park JM, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):23–5
Over the counter drugs. Working party will see whether antimicrobials should be available [letter; comment] Finch RG, et al. **BMJ** 1996 Jul 13;313(7049):115. Comment on: BMJ 1996 Mar 9;312(7031):629–32.
NO inhibitions: antimicrobial properties of nitric oxide. De Groote MA, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S162–5 (55 ref.)
cDNA sequences of three sheep myeloid cathelicidins. Bagella L, et al. **FEBS Lett** 1995 Dec 4;376(3):225–8
Antimicrobial activity of a 13 amino acid tryptophan-rich peptide derived from a putative porcine precursor protein of a novel family of antibacterial peptides. Lawyer C, et al. **FEBS Lett** 1996 Jul 15;390(1):95–8
Structures of genes for two cathelin-associated antimicrobial peptides: prophenin-2 and PR-39. Zhao C, et al. **FEBS Lett** 1995 Dec 4;376(3):130–4
Human enteric defensin genes: chromosomal map position and a model for possible evolutionary relationships. Bevins CL, et al. **Genomics** 1996 Jan 1;31(1):95–106
Cloning and characterization of cDNAs encoding the antibacterial peptide, defensin A, from the mosquito, Aedes aegypti. Cho WL, et al. **Insect Biochem Mol Biol** 1996 Apr; 26(4):395–402
AHI perspectives: flexible drug labeling and its impact on the drug development process. Break-out session. **J Am Vet Med Assoc** 1995 Oct 1;207(7):905–8; discussion 909–10
AVMA/Practice Group perspectives: use of drug labels in the prescription of antimicrobial therapy. Representing the American Animal Hospital Association (AAHA). Reid J. **J Am Vet Med Assoc** 1995 Oct 1;207(7):879–80; discussion 890–4
The panorama of cyclosporin research. Balakrishnan K, et al. **J Basic Microbiol** 1996;36(2):121–47 (292 ref.)
Human enteric defensins. Gene structure and developmental expression. Mallow EB, et al. **J Biol Chem** 1996 Feb 23; 271(8):4038–45
Proceedings of the VIII Mediterranean Congress of Chemotherapy. Athens, Greece, 24–29 May 1992. **J Chemother** 1993 May;5 Suppl 1:1–830
Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes. Dentener MA, et al. **J Infect Dis** 1996 Jan;173(1):252–5
Bacteriocidal qualities of ixodid tick (Acarina: Ixodidae) salivary cement plugs and their changes under the influence of a viral tick-borne pathogen. Alekseev AN, et al. **J Med Entomol** 1995 Sep;32(5):578–82
Laxative components of a generic drug [letter] Guidotti JL. **Lancet** 1996 Mar 2;347(9001):621
Oligosaccharide anti-infective agents. Zopf D, et al. **Lancet** 1996 Apr 13;347(9007):1017–21 (28 ref.)
Somatic cell mapping of beta-defensin genes to cattle syntenic group U25 and fluorescence in situ localization to chromosome 27. Gallagher DS Jr, et al. **Mamm Genome** 1995 Aug;6(8):554–6
[Prescription of antiretroviral and prophylactic drugs in HIV diseases: reality of medical practices] Bourdillon F, et al. **Ann Med Interne (Paris)** 1995;146(7):500–4 (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Prantera C, et al. **Am J Gastroenterol** 1996 Feb;91(2):328–32
Reducing antimicrobial dosing errors in a neonatal intensive care unit. Gard JW, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1508, 1512–3
Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Heldman AW, et al. **Am J Med** 1996 Jul;101(1):68–76
Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. DeRiso AJ 2nd, et al. **Chest** 1996 Jun;109(6):1556–61
Evaluation of short-course therapy with cefixime or rifampin for eradication of pharyngeally carried group A streptococci. The Ontario GAS Study Group. Davies HD, et al. **Clin Infect Dis** 1995 Nov;21(5):1294–9
Use of an Itraconazole/allopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS. Raffi F, et al. **Clin Infect Dis** 1995 Nov;21(5):1338–9
High-dose recombinant endotoxin neutralizing protein improves survival in rabbits, with Escherichia coli sepsis. Saladino RA, et al. **Crit Care Med** 1996 Jul;24(7):1203–7
Efficacy of metronidazole lavage in treatment of intraperitoneal sepsis. A prospective study. Saha SK. **Dig Dis Sci** 1996 Jul;41(7):1313–8
Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Rauws EA, et al. **Drugs** 1995 Dec; 50(6):984–90
Practical guidelines for the treatment of cholera. Seas C, et al. **Drugs** 1996 Jun;51(6):966–73 (24 ref.)
Use of antimicrobial-impregnated polymethyl methacrylate. Tobias KM, et al. **J Am Vet Med Assoc** 1996 Mar 15; 208(6):841–5 (50 ref.)
Use of antimicrobial-impregnated polymethyl methacrylate beads for treatment of chronic, refractory septic arthritis and osteomyelitis of the digit in a bull. Trostle SS, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):404–7
AVMA/Practice Group perspectives: use of drug labels in the prescription of antimicrobial therapy. Representing the American Association of Avian Pathologists (AAAP). Wages DP. **J Am Vet Med Assoc** 1995 Oct 1;207(7):880–1; discussion 890–4
Concentration controlled and concentration defined clinical trials: do they offer any advantages for antimicrobial chemotherapy? MacGowan A. **J Antimicrob Chemother** 1996 Jan;37(1):1–5
Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. Ferris DG, et al. **J Fam Pract** 1995 Nov; 41(5):443–9
Triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse: comparison of 1 week and 2 week regimens and recrudescence rates over 12 months. Chen TS, et al. **J Gastroenterol Hepatol** 1995 May-Jun;10(3):300–5
Three vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis [letter; comment] Sawyer J, et al. **JAMA** 1995 Nov 1;274(17):1341; discussion 1341–2. Comment on: JAMA 1995 Apr 5;273(13):1015–21.
Three vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis [letter; comment] Shahar E. **JAMA** 1995 Nov 1;274(17):1341; discussion 1341–2. Comment on: JAMA 1995 Apr 5;273(12):1015–21.
Pharmacokinetics and drug dosage adjustment to renal impairment [editorial] Keller F, et al. **Nephrol Dial Transplant** 1995;10(9):1516–20
Bacterial infections transmitted from the donor: antibiotic prophylaxis in the donor. Pacholczyk MJ, et al. **Transplant Proc** 1996 Feb;28(1):184–5
[Preparation of oral berberine bisulfate liposomes] Xue Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Dec; 20(12):730–1, 762–3 (Eng. Abstr.) **(Chi)**
[Prospective randomized comparison of the effects of pefloxacin and clindamycin with cefoxitin after hepatobiliary and pancreatic operations] Fried M, et al. **Rozhl Chir** 1995 Sep;74(6):290–2 (Eng. Abstr.) **(Cze)**
[Flumequine in rainbow trout: not so difficult (letter)] Bootsma R. **Tijdschr Diergeneeskd** 1996 Mar 1;121(5):132–3 **(Dut)**
[Treatment by oral route of urinary tract infections in children (letter; comment)] Bensman A. **Arch Pediatr** 1995 Sep;2(9):897. Comment on: Arch Pediatr 1995 Feb;2(2):136–42. **(Fre)**
[Prevention and treatment of acute suppurative infection in emergency abdominal surgery] Ashrafov AA, et al. **Klin Khir** 1995;(4):29–31 **(Rus)**
[The antibacterial and immunocorrective action of ozone therapy in peritonitis] Vasil'ev IT, et al. **Vestn Khir Im I I Grek** 1995;154(3):56–60 (Eng. Abstr.) **(Rus)**
[Use of taurolin in the prevention of septic complications in emergency abdominal surgery] Popović M, et al. **Acta Chir Iugosl** 1991;38(1):23–33 (Eng. Abstr.) **(Scc)**

ADVERSE EFFECTS

Case reports: trimethoprim-sulfamethoxazole-induced meningitis in patients with HIV infection. Jurado R, et al. **Am J Med Sci** 1996 Jul;312(1):27–9
Drug-induced transient myopia and angle-closure glaucoma associated with supraciliary choroidal effusion. Postel EA, et al. **Am J Ophthalmol** 1996 Jul;122(1):110–2
Sulfadiazine-induced multiple urolithiasis and acute renal failure in a patient with AIDS and Toxoplasma encephalitis. Diaz F, et al. **Ann Pharmacother** 1996 Jan; 30(1):41–2
Colonization and infection with Enterococcus faecalis in intensive care units: the role of antimicrobial agents. Bonten MJ, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2783–6
A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Wilton LV, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):277–84
The risks and benefits of antimicrobial therapy in pregnancy. Garland SM, et al. **Drug Saf** 1995 Sep;13(3):188–205 (46 ref.)
Comparative study of efficacy and safety of ciprofloxacin and cefixime in the treatment of acute exacerbations of chronic bronchitis after first-line treatment failure. French Study Group. Nouvet G, et al. **Drugs** 1995;49 Suppl 2:423–5
Dapsone toxicity: some current perspectives. Coleman MD. **Gen Pharmacol** 1995 Nov;26(7):1461–7 (51 ref.)
Swollen lesion on the abdomen. Could this violaceous blister be related to patient's treatment for UTIs? Levine N. **Geriatrics** 1996 May;51(5):55
Compounds that pose a risk for the "sulfur"-sensitive patient. Kuritzky L. **Hosp Pract (Off Ed)** 1995 Oct 15; 30(10):76L–76O
Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals. Sin DD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):477–81
Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. Walker DC, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):918–23 (21 ref.)
Iron overload as a mechanism for the lowered survival in AIDS patients receiving dapsone-iron protoxalate for secondary prophylaxis of Pneumocystis carinii pneumonia [letter; comment] Weinberg GA. **J Infect Dis** 1996 Jul; 174(1):241–2. Comment on: J Infect Dis 1995 Sep;172(3):656–64.
Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Becker K, et al. **Medicine (Baltimore)** 1996 Jul;75(4):185–94 (56 ref.)
Trimethoprim and sulfonamide-associated meningoencephalitis with MRI correlates. Blumenfeld H, et al. **Neurology** 1996 Feb;46(2):556–8
A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Jick H, et al. **Pharmacotherapy** 1995 Jul-Aug;15(4):428–32
Hyperkalemia associated with high-dose trimethoprim-sulfamethoxazole in a patient with the acquired immunodeficiency syndrome. Mihm LB, et al. **Pharmacotherapy** 1995 Nov-Dec;15(6):793–7
A retrospective evaluation of adverse reactions to trimethoprim-sulphonamide combinations in dogs and cats. Noli C, et al. **Vet Q** 1995 Dec;17(4):123–8
Side effects of oral antimicrobial agents in the horse: a comparison of pivampicillin and trimethoprim/sulphadiazine. Ensink JM, et al. **Vet Rec** 1996 Mar 16;138(11):253–6
[Kidney insufficiency: toxicity factor of methyl-bromo-hydroxyquinoline (letter)] Zeraidi N, et al. **Ann Med Interne (Paris)** 1995;146(8):593–5 (16 ref.) **(Fre)**
[Convulsions associated with pyrimethamine overdose (letter)] Duveau E, et al. **Arch Pediatr** 1996 Mar;3(3):286–7 **(Fre)**
[Skin reactions following administration of sulfonamide (letter; comment)] Labrèze C, et al. **Arch Pediatr** 1995 Nov; 2(11):1125–6. Comment on: Arch Pediatr 1995 May;2(5):494–5. **(Fre)**
[Toxic dermatitis caused by pyrimethamine in patients with acquired immunodeficiency virus infection (letter)] Piketty C, et al. **Presse Med** 1995 Nov 25;24(36):1710 **(Fre)**
[Hyperkalemia induced by high-dose trimethoprim (letter)] Rispal P, et al. **Presse Med** 1995 Dec 2;24(37):1754 **(Fre)**
[Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis] Caumes E. **Rev Mal Respir** 1996; 13(2):101–6 (45 ref.) (Eng. Abstr.) **(Fre)**
[Acute renal insufficiency caused by a sulfadiazine in a patient with cerebral toxoplasmosis and AIDS (letter)] Rodríguez-Carballeira M, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):125–7 **(Spa)**
[Anaphylaxis caused by cefixime with tolerance to other beta lactams (letter)] Vilas Martínez F, et al. **Med Clin (Barc)** 1996 Mar 23;106(11):439 **(Spa)**

ANALYSIS

Determination of furazolidone in porcine tissue using thermospray liquid chromatography-mass spectrometry and a study of the pharmacokinetics and stability of its residues. McCracken RJ, et al. **Analyst** 1995 Sep; 120(9):2347–51
Determination of nitroimidazole residues in poultry tissues, serum and eggs by high-performance liquid chromatography. Semeniuk S, et al. **Biomed Chromatogr** 1995 Sep-Oct;9(5):238–42
Longitudinal analysis of human salivary immunoglobulins, nonimmune antimicrobial agents, and microflora after tonsillectomy. Kirstilä V, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):110–5
Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. Zanetti M, et al. **FEBS Lett** 1995 Oct 23;374(1):1–5 (55 ref.)
The effect of cooking on veterinary drug residues in food: 3. Sulphamethazine (sulphadimidine). Rose MD, et al. **Food Addit Contam** 1995 Nov-Dec;12(6):739–50
Screening for antibacterial agents in three species of sea cucumbers from coastal areas of Sabah. Ridzwan BH, et al. **Gen Pharmacol** 1995 Nov;26(7):1539–43
Functional chemotactic factor CP-10 and MRP-14 are abundant in murine abscesses. Kocher M, et al. **Infect Immun** 1996 Apr;64(4):1342–50
Liquid chromatographic determination of sulfadiazine in salmon by postcolumn derivatization and fluorescence detection. Gehring TA, et al. **J AOAC Int** 1995 Sep-Oct; 78(5):1161–4
Antibacterial polyphenols from olive oil mill waste waters. Capasso R, et al. **J Appl Bacteriol** 1995 Oct;79(4):393–8
Analysis of sulfamethazine in the presence of sulfamerazine or sulfadiazine by first-derivative photochemically induced fluorescence. Sanchez Pena M, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1107–12
[Quantitative determination of ursolic acid in folium Ilicis cornutae (gouguye) gathered in different and periods] Guo Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Oct; 20(10):591–2, 638 (Eng. Abstr.) **(Chi)**
[Content determination of baicalin by ultraviolet second order derivative spectra] Lou H, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Feb;21(2):97–9, 128 (Eng. Abstr.) **(Chi)**

ANTI-INFECTIVE AGENTS

ANTAGONISTS & INHIBITORS

Identification of inhibitors of melittin using nonsupport-bound combinatorial libraries. Blondelle SE, et al. **J Biol Chem** 1996 Feb 23;271(8):4093-9

[The resistance to antibiotics and chemotherapeutic agents of Shigella strains isolated from HIV-seropositive children] Sfartz S, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Apr-Jun;40(2):145-8 **(Rum)**

BLOOD

Plasma lipopolysaccharide binding protein and bactericidal/permeability increasing factor in CRF and HD patients. Pereira BJ, et al. **J Am Soc Nephrol** 1996 Mar; 7(3):479-87

Plasma bactericidal/permeability-increasing protein concentrations in critically ill children with the sepsis syndrome. Wong HR, et al. **Pediatr Infect Dis J** 1995 Dec; 14(12):1087-91

[Sulfa drugs] Fukaya K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1017-9 (6 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Synthesis and antimicrobial activity of substituted benzimidazole, benzothiazole and imidazole derivatives. Küçükbay H, et al. **Arzneimittelforschung** 1995 Dec; 45(12):1331-4

Synthesis and antibacterial activity of substituted 4-arylaminopyrimido[5,4-c]cinnolines. Nargund LV, et al. **Arzneimittelforschung** 1995 Oct;45(10):1131-2

Potentially active antimicrobial agents from 2-benzenesulfonyloxyphenyl-3,1-benzoxazine-4-one derivative. Habib OM, et al. **Boll Chim Farm** 1995 Oct; 134(9):503-8

Evaluation of some arylhydrazones of p-aminobenzoic acid hydrazide as antimicrobial agents and their in vitro hepatic microsomal metabolism. Komurcu SG, et al. **Boll Chim Farm** 1995 Jul-Aug;134(7):375-9

5-Alkoxyimidazoquinolones as potential antibacterial agents. Synthesis and structure-activity relationships. Fujita M, et al. **Chem Pharm Bull (Tokyo)** 1996 May;44(5):987-90

Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity. Tamamura H, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):853-8

Synthesis and antibacterial activities of optically active substituted 1,2-dihydro-6-oxo-6H-pyrrolo[3,2,1-ij]quinoline-5-carboxylic acids. Tsuji K, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1678-82

Synthesis and antimicrobial activity of some new 1-[4-(4-fluorobenzoylamino)-benzoyl]-4-substituted thiosemicarbazides. Durgun BB, et al. **Drug Metabol Drug Interact** 1995;12(2):145-50

Synthesis of 3-methyl-4-[(2,4-dihydro-4-substituted-3H-1,2,4-triazole-3-thione-5-yl) phenylhydrazono]-5-isoxazolone and evaluation of their antimicrobial activities. Kömürcü SG, et al. **Drug Metabol Drug Interact** 1995;12(2):161-9

Synthesis and characterization of certain thiourea derivatives starting from 1,2,4-triazoline-3-thiones as potential antibacterial and antifungal agents. Küçükgüzel I, et al. **Drug Metabol Drug Interact** 1995;12(2):151-60

Synthesis and solution structure of the antimicrobial peptide protegrin-1. Aumelas A, et al. **Eur J Biochem** 1996 May 1;237(3):575-83

Pyrazolo[1,5-a]pyrido[3,4-e]pyrimidin-6-ones. I. Synthesis and in vitro antimicrobial evaluation. Bruni F, et al. **Farmaco** 1996 Jun;51(6):451-5

Synthesis and antibacterial activity of C-4 thio- and dithiocarbamate monobactam derivatives. Cascio G, et al. **Farmaco** 1996 Mar;51(3):189-96

Synthesis and antimicrobial activity of new tetrahydro-2H-1,3,5-thiadiazine-2-thione derivatives. Ilhan E, et al. **Farmaco** 1995 Nov;50(11):787-90

Synthesis and antimicrobial activity of some tetramethylenethieno[2,3-d]pyrimidine derivatives. Ismail KA, et al. **Farmaco** 1995 Sep;50(9):611-6

Synthesis and antimicrobial activity of some new piperidinyl benzimidazoles. Kuş C, et al. **Farmaco** 1996 Jun;51(6):413-7

Synthesis and biological activity of novel metal complexes of 2-acetylpyridine thiosemicarbazones. Offiong OE, et al. **Farmaco** 1995 Sep;50(9):625-32

Research on antibacterial and antifungal agents. XII--Synthesis and antimicrobial activity of some Mannich bases of diarylpyrroles. Porretta GC, et al. **Farmaco** 1995 Sep;50(9):617-23

Synthesis and antimicrobial properties of N-substituted halides of (E)-azastilbenols. Prukala W, et al. **Farmaco** 1995 Nov;50(11):779-82

Synthesis and antimicrobial activity of some 2-(2-oxobenzothiazole-3-yl)-1-arylethanone derivatives. Simsek R, et al. **Farmaco** 1995 Dec;50(12):893-4

2-(4-Pyridyl)-delta 2-1,3,4-oxadiazolines from isonicotinoylhydrazones and diazomethane as potential antimycobacterial and anti-HIV agents. V. Vigorita MG, et al. **Farmaco** 1995 Nov;50(11):783-6

Synthesis and study of derivatives of cyclic carbamides with antiviral and antimicrobial action. Sidzhakova D, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):28

Design of 16-residue peptides possessing antimicrobial and hemolytic activities or only antimicrobial activity from an inactive peptide. Thennarasu S, et al. **Int J Pept Protein Res** 1995 Dec;46(6):480-6

Synthesis and characterization of indolicidin, a tryptophan-rich antimicrobial peptide from bovine neutrophils. van Abel RJ, et al. **Int J Pept Protein Res** 1995 May;45(5):401-9

Studies on the synthesis and antibacterial activity of new carbamoylpyrrolidinylthiocarbapenems. Lee HW, et al. **J Antibiot (Tokyo)** 1995 Sep;48(9):1046-8

Synthesis and antibacterial activity of 2-(isoxazolidinio-5-yl)carbapenem derivatives. Nishi K, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1481-7

Carboxamides and hydrazide of glycopeptide antibiotic eremomycin. Synthesis and antibacterial activity. Pavlov AY, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):194-8

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. Brickner SJ, et al. **J Med Chem** 1996 Feb 2;39(3):673-9

Studies on 6-aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-methylquinolones. Cecchetti V, et al. **J Med Chem** 1996 Jan 19;39(2):436-45

Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci. Heinze-Krauss I, et al. **J Med Chem** 1996 Apr 26; 39(9):1864-71

High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. Kuyper LF, et al. **J Med Chem** 1996 Feb 16;39(4):892-903

Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents. Li Q, et al. **J Med Chem** 1996 Aug 2;39(16):3070-88

Synthetic antimicrobial peptide design. Powell WA, et al. **Mol Plant Microbe Interact** 1995 Sep-Oct;8(5):792-4

On the synthesis of pyridazomycin congeners. Part 2: L-alpha-Amino acids bearing a terminal azinium or diazinium system. Easmon J, et al. **Pharmazie** 1996 Feb; 51(2):76-83

New antimicrobial rhodanines. Makhlouf AM, et al. **Pharmazie** 1996 Jun;51(6):430-1

[Synthesis and antimicrobial action of 4-arylideneamino-3-(alpha,alpha-diphenyl-alpha-hydroxmethyl)-1,4-dihydro-5H-1,2,4-triazino-5-thiones and 6-arene-3-(alpha,alpha-diphenyl-alpha-hydroxymethyl)-7H-s-triazolo(3,4- b) (1,2,4)thiadiazine] Ilhan E, et al. **Pharmazie** 1996 Feb;51(2):123-4 **(Ger)**

CHEMISTRY

8-Hydroxy-7-nitroquinoline-5-sulfonic acid monohydrate. Balasubramanian TP, et al. **Acta Crystallogr C** 1996 Apr 15;52 (Pt 4):1017-9

Stability of cefotaxime sodium and metronidazole in 0.9% sodium chloride injection or in ready-to-use metronidazole bags. Belliveau PP, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1561-3

Isolation and characterization of a new member of the insect defensin family from a beetle, Allomyrina dichotoma. Miyanoshita A, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):526-31

Identification and isolation of the bactericidal domains in the proteinase inhibitor aprotinin. Pellegrini A, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):559-65

Conformational and functional study of magainin 2 in model membrane environments using the new approach of systematic double-D-amino acid replacement. Wieprecht T, et al. **Biochemistry** 1996 Aug 20;35(33):10844-53

Molecular diversity of peptidomimetics: approaches to the solid-phase synthesis of peptidosulfonamides. de Bont DB, et al. **Bioorg Med Chem** 1996 May;4(5):667-72

Structural functions of antimicrobial long-chain alcohols and phenols. Kubo I, et al. **Bioorg Med Chem** 1995 Jul; 3(7):873-80

Synthesis and solution structure of the antimicrobial peptide protegrin-1. Aumelas A, et al. **Eur J Biochem** 1996 May 1;237(3):575-83

The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Gudmundsson GH, et al. **Eur J Biochem** 1996 Jun 1;238(2):325-32

Antibacterial and immunostimulating casein-derived substances from milk: casecidin, isracidin peptides. Lahov E, et al. **Food Chem Toxicol** 1996 Jan;34(1):131-45 (49 ref.)

D-enantiomers of 15-residue cecropin A-melittin hybrids. Merrifield EL, et al. **Int J Pept Protein Res** 1995 Sep-Oct; 46(3-4):214-20

Structural and charge requirements for antimicrobial and hemolytic activity in the peptide PKLLETFLSKWIG, corresponding to the hydrophobic region of the antimicrobial protein bovine seminalplasmin. Sitaram N, et al. **Int J Pept Protein Res** 1995 Aug;46(2):166-73

New metabolites with nematicidal and antimicrobial activities from the ascomycete Lachnum papyraceum (Karst.) Karst. VIII. Isolation, structure determination and biological activities of minor metabolites structurally related to mycorrhizin A. Shan R, et al. **J Antibiot (Tokyo)** 1996 May; 49(5):447-52

Drug chirality: a consideration of the significance of the stereochemistry of antimicrobial agents. Hutt AJ, et al. **J Antimicrob Chemother** 1996 Jan;37(1):7-32 (83 ref.)

Moricin, a novel type of antibacterial peptide isolated from the silkworm, Bombyx mori. Hara S, et al. **J Biol Chem** 1995 Dec 15;270(50):29923-7

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. Barbachyn MR, et al. **J Med Chem** 1996 Feb 2;39(3):680-5

Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters. Bergmann KE, et al. **J Med Chem** 1996 Aug 16; 39(17):3394-400

The chemistry of Pseudomonic acid. 15. Synthesis and antibacterial activity of a series of 5-alkyl, 5-alkenyl, and 5-heterosubstituted oxazoles. Brown P, et al. **J Med Chem** 1996 Jan 19;39(2):446-57

Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7. Renau TE, et al. **J Med Chem** 1996 Feb 2;39(3):729-35

The structures of new lanostane triterpenes from the fruiting bodies of Hebeloma senescens. Garlaschelli L, et al. **J Nat Prod** 1995 Jul;58(7):992-1002

Biological activities of pyrrolidinoindoline alkaloids from Calycodendron milnei. Saad HE, et al. **Planta Med** 1995 Aug;61(4):313-6

Isolation of an ovine pulmonary surfactant-associated anionic peptide bactericidal for Pasteurella haemolytica. Brogden KA, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):412-6

Structure-activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Fehlbaum P, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1221-5

Comparison of the effects of hydrophobicity, amphiphilicity, and alpha-helicity on the activities of antimicrobial peptides. Pathak N, et al. **Proteins** 1995 Jun;22(2):182-6

[Determination of paracetmol caffeine and ephedrine hydrochloride in likeshu capsules] Wu C, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):443-6 (Eng. Abstr.) **(Chi)**

ECONOMICS

Cost-effectiveness decision analysis of intramuscular ceftriaxone versus oral cefixime in adolescents with gonococcal cervicitis. Friedland LR, et al. **Ann Emerg Med** 1996 Mar;27(3):299-304

Consequences of incomplete antibacterial treatment for chlamydial pelvic inflammatory disease. Rosenberg MJ, et al. **Drugs** 1995;49 Suppl 2:504-5

HISTORY

[Gerhard Domagk, 100th birthday of the pathologist and Nobel Prize winner] Böcker W. **Pathologe** 1995 Nov; 16(6):383-5 **(Ger)**

IMMUNOLOGY

Aedes aegypti: induced antibacterial proteins reduce the establishment and development of Brugia malayi. Lowenberger CA, et al. **Exp Parasitol** 1996 Jul; 83(2):191-201

ISOLATION & PURIFICATION

Purification and characterization of a novel antibacterial protein from the marine bacterium D2. James SG, et al. **Appl Environ Microbiol** 1996 Aug;62(8):2783-8

A novel antimicrobial peptide from Bufo bufo gargarizans. Park CB, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):408-13

Antibacterial activity in the coelomocytes of the sea urchin Paracentrotus lividus. Stabili L, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):639-44

Metchnikowin, a novel immune-inducible proline-rich peptide from Drosophila with antibacterial and antifungal properties. Levashina EA, et al. **Eur J Biochem** 1995 Oct 15;233(2):694-700

Formation of pores in Escherichia coli cell membranes by a cecropin isolated from hemolymph of Heliothis virescens larvae. Lockey TD, et al. **Eur J Biochem** 1996 Feb 15; 236(1):263-71

Casocidin-I: a casein-alpha s2 derived peptide exhibits antibacterial activity. Zucht HD, et al. **FEBS Lett** 1995 Sep 25;372(2-3):185-8

New metabolites with nematicidal and antimicrobial activities from the ascomycete Lachnum papyraceum (Karst.) Karst. VIII. Isolation, structure determination and biological activities of minor metabolites structurally related to mycorrhizin A. Shan R, et al. **J Antibiot (Tokyo)** 1996 May; 49(5):447-52

Innate immunity. Isolation of several cysteine-rich antimicrobial peptides from the blood of a mollusc, Mytilus edulis. Charlet M, et al. **J Biol Chem** 1996 Sep 6; 271(36):21808-13

Purification and characterization of N-beta-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine, a novel antibacterial substance of Sarcophaga peregrina (flesh fly). Leem JY, et al. **J Biol Chem** 1996 Jun 7;271(23):13573-7

Rat neutrophil defensins. Precursor structures and expression

during neutrophilic myelopoiesis. Yount NY, et al. **J Immunol** 1995 Nov 1;155(9):4476–84

Sesquiterpene/quinol from a New Zealand liverwort, Riccardia crassa. Perry NB, et al. **J Nat Prod** 1995 Jul; 58(7):1131–5

Isolation and characterization of cytotoxic and antibacterial tetrasaccharide glycosides from Ipomoea stans. Reynolds WF, et al. **J Nat Prod** 1995 Nov;58(11):1730–4

Makaluvamines H–M and damirone C from the pohnpeian sponge Zyzzya fuliginosa. Schmidt EW, et al. **J Nat Prod** 1995 Dec;58(12):1861–7

Flavonoids of Artemisia austriaca. Cubukçu B, et al. **Planta Med** 1995 Oct;61(5):488

Isolation and antibacterial activity of marchantin A, a cyclic bis(bibenzyl) constituent of Hungarian Marchantia polymorpha. Kámory E, et al. **Planta Med** 1995 Aug; 61(4):387–8

Antibacterial and antifungal polyine compounds from Glehnia littoralis ssp. leiocarpa. Matsuura H, et al. **Planta Med** 1996 Jun;62(3):256–9

Antibacterial diterpenic acids from Brazilian propolis. Bankova V, et al. **Z Naturforsch [C]** 1996 May–Jun; 51(5–6):277–80

A cytotoxic principle of Tamarindus indica, di–n–butyl malate and the structure–activity relationship of its analogues. Kobayashi A, et al. **Z Naturforsch [C]** 1996 Mar–Apr;51(3–4):233–42

METABOLISM

Mononuclear cell line THP–1 internalizes bactericidal/permeability–increasing protein by a non–receptor–mediated mechanism consistent with pinocytosis. Burnett RJ, et al. **Arch Surg** 1996 Feb; 131(2):200–5; discussion 206

Arylacetamide deacetylase activity towards monoacetyldapsone. Species comparison, factors that influence activity, and comparison with 2–acetylaminofluorene and p–nitrophenyl acetate hydrolysis. Preuss CV, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1661–8

Interaction of the mammalian antibacterial peptide cecropin P1 with phospholipid vesicles. Gazit E, et al. **Biochemistry** 1995 Sep 12;34(36):11479–88

Kinetics of pore formation by an antimicrobial peptide, magainin 2, in phospholipid bilayers. Matsuzaki K, et al. **Biochemistry** 1995 Oct 3;34(39):12553–9

Transport of the antibacterial agent (6S)–6–fluoroshikimate and other shikimate analogues by the shikimate transport system of Escherichia coli. Jude DA, et al. **Biochim Biophys Acta** 1996 Mar 13;1279(2):125–9

Polyethers. Birch AW, et al. **Biotechnology** 1995;28:443–76 (100 ref.)

N–Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Gill HJ, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):531–8

Crown gall culture and production of tanshinone in Salvia miltiorrhiza. Zhang Y, et al. **Chin J Biotechnol** 1995; 11(2):137–41

Deposition kinetics, metabolism and urinary excretion of sulfathiazole following oral administration in sheep. Jain SK, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Oct; 102(10):394–5

In vitro metabolism of sulfathiazole in rumen fluid and its metabolism and disposition kinetics following intraruminal administration in sheep. Jain SK, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 May;102(5):193–5

The C–terminal bisphosphorylated proenkephalin–A–(209–237)–peptide from adrenal medullary chromaffin granules possesses antibacterial activity. Goumon Y, et al. **Eur J Biochem** 1996 Feb 1; 235(3):516–25

Coordinate induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory mediators lipopolysaccharide and tumor necrosis factor alpha. Russell JP, et al. **Infect Immun** 1996 May;64(5):1565–8

Production and isolation of two novel esperamicins in a chemically defined medium. Lam KS, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1497–501

Rapid and selective high–performance liquid chromatographic method for the determination of metronidazole and its active metabolite in human plasma, saliva and gastric juice. Jessa MJ, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):374–9

Binding between lipopolysaccharide and cecropin A. De Lucca AJ, et al. **Mol Cell Biochem** 1995 Oct 18; 151(2):141–8

Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation–modified proteins to a conserved motif [see comments] Li YM, et al. **Nat Med** 1995 Oct;1(10):1057–61. Comment in: Nat Med 1995 Oct;1(10):1002–4.

A recessive mutation, immune deficiency (imd), defines two distinct control pathways in the Drosophila host defense. Lemaitre B, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9465–9

[Cell cultured of Macleaya cordata--a producer of antimicrobial benzo[c]phenanthridine alkaloids] Fonin VS, et al. **Antibiot Khimioter** 1995 Aug;40(8):17–22 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Pharmacokinetics and antitumour activity of a new anthracycline, DA–125, after intravenous administration to subcutaneously implanted Lewis–lung–carcinoma–bearing mice. Lee SD, et al. **Biopharm Drug Dispos** 1995 Aug; 16(6):489–505

The pharmacokinetics of 8–methoxypsoralen following i.v. administration in humans. Billard V, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):347–60

The influence of multiple oral doses of zileuton on the steady–state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N–acetylsulfapyridine. Awni WM, et al. **Clin Pharmacokinet** 1995;29 Suppl 2:98–104

Local antibacterial therapy for the management of orthopaedic infections. Pharmacokinetic considerations. Henry SL, et al. **Clin Pharmacokinet** 1995 Jul;29(1):36–45 (88 ref.)

Clinical pharmacokinetics in patients with burns. Jaehde U, et al. **Clin Pharmacokinet** 1995 Jul;29(1):15–28 (75 ref.)

Pharmacokinetics of lamivudine administered alone and with trimethoprim–sulfamethoxazole. Moore KH, et al. **Clin Pharmacol Ther** 1996 May;59(5):550–8

Kinetic behaviour of sulphaquinoxaline and amprolium in chickens. el–Sayed MG, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec;102(12):481–5

Antibacterial agents in renal failure. Livornese LL Jr, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):591–614 (41 ref.)

AHI perspectives: flexible drug labeling and its impact on the drug development process. A clinical pharmacologist's perspective. Ter Hune TN. **J Am Vet Med Assoc** 1995 Oct 1;207(7):898; discussion 902–4

Enteric absorption of ciprofloxacin during the immediate postoperative period. Cohn SM, et al. **J Antimicrob Chemother** 1995 Oct;36(4):717–21

Marked variation in pyrimethamine disposition in AIDS patients treated for cerebral toxoplasmosis. Winstanley P, et al. **J Antimicrob Chemother** 1995 Aug;36(2):435–9

Isolation, identification and determination of sulfadiazine and its hydroxy metabolites and conjugates from man and rhesus monkey by high–performance liquid chromatography. Vree TB, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):111–23

Comparative plasma and tissue pharmacokinetics and drug residue profiles of different chemotherapeutants in fowls and rabbits. Li T, et al. **J Vet Pharmacol Ther** 1995 Aug; 18(4):260–73

Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. Mengelers MJ, et al. **J Vet Pharmacol Ther** 1995 Aug;18(4):243–53

Plasma/muscle ratios of sulfadimethoxine residues in channel catfish (Ictalurus punctatus). Walker CC, et al. **J Vet Pharmacol Ther** 1995 Aug;18(4):306–10

Pharmacokinetics and drug dosage adjustment to renal impairment [editorial] Keller F, et al. **Nephrol Dial Transplant** 1995;10(9):1516–20

Pharmacokinetics and therapeutic potential for repeated oral doses of trimethoprim/sulphachlorpyridazine in horses. van Duijkeren E, et al. **Vet Rec** 1995 Nov 4;137(19):483–6

Absorption, tissue distribution, metabolism and excretion of ormetoprim and sulphadimethoxine in Atlantic salmon (Salmo salar) after intravenous and oral administration of Romet. Samuelsen OB, et al. **Xenobiotica** 1995 Nov; 25(11):1169–80

PHARMACOLOGY

Cationic bactericidal peptides. Hancock RE, et al. **Adv Microb Physiol** 1995;37:135–75 (215 ref.)

Prolonged effect of omeprazole on the 14C–urea breath test. Chey WD, et al. **Am J Gastroenterol** 1996 Jan;91(1):89–92

Study documents spread of drug–resistant pneumococci [news] **Am J Health Syst Pharm** 1995 Oct 15;52(20):2164

Trimethoprim and tetracycline inhibit airway epithelial sodium absorption. Middleton PG, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):18–23

Recent advances: antiinfectives. Briceland LL, et al. **Ann Pharmacother** 1995 Oct;29(10):1035–40 (49 ref.)

Use of time–kill methodology to assess antimicrobial combinations against metronidazole–susceptible and metronidazole–resistant strains of Helicobacter pylori. Coudron PE, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2641–4

Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Doern GV, et al. **Antimicrob Agents Chemother** 1996 Apr; 40(4):891–4

Susceptibilities of Bordetella pertussis strains to antimicrobial peptides. Fernandez RC, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1041–3

Antimicrobial properties of tea (Camellia sinensis L.). Hamilton–Miller JM. **Antimicrob Agents Chemother** 1995 Nov;39(11):2375–7 (48 ref.)

In vitro activities of the lichen secondary metabolites vulpinic acid, (+)–usnic acid, and (–)–usnic acid against aerobic and anaerobic microorganisms. Lauterwein M, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2541–3

First characterization of inhibitor–resistant TEM (IRT) beta–lactamases in Klebsiella pneumoniae strains. Lemozy J, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2580–2

In vitro activities of oxazolidinones U–100592 and U–100766 against penicillin–resistant and cephalosporin–resistant strains of Streptococcus pneumoniae. Mason EO Jr, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1039–40

Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Masuda N, et al. **Antimicrob Agents Chemother** 1996 Apr; 40(4):909–13

Growth inhibition of Ureaplasma urealyticum by the proton pump inhibitor lansoprazole: direct attribution to inhibition by lansoprazole of urease activity and urea–induced ATP synthesis in U. urealyticum. Nagata K, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2187–92

Antimicrobial and mercury resistance in aerobic gram–negative bacilli in fecal flora among persons with and without dental amalgam fillings. Osterblad M, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2499–502

In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Poulos CD, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2220–3

Bacterial activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions. Shibata K, et al. **Antimicrob Agents Chemother** 1995 Jun; 39(6):1295–9

In vitro antimicrobial susceptibilities of strains of Yersinia pestis. Smith MD, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2153–4

SB 205952, a novel semisynthetic monic acid analog with at least two modes of action. Wilson JM, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1925–33

In vitro activities of U–100592 and U–100766, novel oxazolidinone antibacterial agents. Zurenko GE, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):839–45

Physico–chemical properties and biological activities of erythromycin nalidixate. Goswami BB, et al. **Arzneimittelforschung** 1995 Jul;45(7):813–4

Effect of semduramicin, salinomycin, and monensin on performance, shank pigmentation, and coccidial lesions in broiler chickens in floor pens. McDougald LR, et al. **Avian Dis** 1996 Jan–Mar;40(1):68–71

Identification and isolation of the bactericidal domains in the proteinase inhibitor aprotinin. Pellegrini A, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):559–65

Rapid identification of compounds with enhanced antimicrobial activity by using conformationally defined combinatorial libraries. Blondelle SE, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):141–7

An antimicrobial peptide, magainin 2, induced rapid flip–flop of phospholipids coupled with pore formation and peptide translocation. Matsuzaki K, et al. **Biochemistry** 1996 Sep 3;35(35):11361–8

Magainin–induced cytotoxicity in eukaryotic cells: kinetics, dose–response and channel characteristics. Haimovich B, et al. **Biochim Biophys Acta** 1995 Dec 13;1240(2):149–58

The biological activity of cyclic bis(bibenzyls): a rational approach. Keseru GM, et al. **Bioorg Med Chem** 1995 Nov; 3(11):1511–7

Antitumor and antimicrobial activities of Fe(II)/Fe(III) complexes derived from some heterocyclic compounds. Mishra L, et al. **Bioorg Med Chem** 1995 Sep;3(9):1241–5

Pharmacokinetics and antitumour activity of a new anthracycline, DA–125, after intravenous administration to subcutaneously implanted Lewis–lung–carcinoma–bearing mice. Lee SD, et al. **Biopharm Drug Dispos** 1995 Aug; 16(6):489–505

Interaction of mastoparan–B from venom of a hornet in Taiwan with phospholipid bilayers and its antimicrobial activity. Park NG, et al. **Biopolymers** 1995 Dec; 36(6):793–801

Wine as a digestive aid: comparative antimicrobial effects of bismuth salicylate and red and white wine [see comments] Weisse ME, et al. **BMJ** 1995 Dec 23–30; 311(7021):1657–60. Comment in: BMJ 1996 Mar 9;312(7031):642.

Evaluation of some arylhydrazones of p–aminobenzoic acid hydrazide as antimicrobial agents and their in vitro hepatic microsomal metabolism. Komurcu SG, et al. **Boll Chim Farm** 1995 Jul–Aug;134(7):375–9

Antibacterial action of dental cements: an in vitro study. Morrier JJ, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct; 38(3–4):87–93

Bactericidal effects of ozone at nonspermicidal concentrations. Gradil C, et al. **Can J Vet Res** 1995 Jul; 59(3):183–6

Drug interaction and pharmacological considerations during anti–infective therapy in cancer patients. Petitjean O, et al. **Cancer Treat Res** 1995;79:255–80 (223 ref.)

5–Alkoxyimidazoquinolones as potential antibacterial agents. Synthesis and structure–activity relationships. Fujita M, et al. **Chem Pharm Bull (Tokyo)** 1996 May;44(5):987–90

Synthesis of protegrin–related peptides and their antibacterial and anti–human immunodeficiency virus activity. Tamamura H, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):853–8

In vitro activity of trimethoprim in association with sulfimidazole against aerobic gram–negative and gram–positive microorganisms and Clostridia. Castelli M, et al. **Chemotherapy** 1995 Sep–Oct;41(5):337–44

Comparison of the E test and a proportion dilution method for susceptibility testing of Mycobacterium kansasii. Fabry W, et al. **Chemotherapy** 1995 Jul–Aug;41(4):247–52

Antibacterial activity in the coelomocytes of the sea urchin

Paracentrotus lividus. Stabili L, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):639–44

In-vitro activity of antibacterial drugs and clinical practice. **Drug Ther Bull** 1995 Sep;33(9):71–2 (12 ref.)

The susceptibility of Mycobacterium tuberculosis and atypical mycobacteria in northern Israel. Cahana Z, et al. **Drugs** 1995;49 Suppl 2:171–2

Comparative in vitro activity of ciprofloxacin vs 8 antimicrobial agents against nosocomial multiresistant P. aeruginosa strains. Giamarellos-Bourboulis EJ, et al. **Drugs** 1995;49 Suppl 2:203–4

Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Wiseman LR, et al. **Drugs** 1995 Jul;50(1):73–101 (195 ref.)

The C-terminal bisphosphorylated proenkephalin-A-(209–237)-peptide from adrenal medullary chromaffin granules possesses antibacterial activity. Goumon Y, et al. **Eur J Biochem** 1996 Feb 1; 235(3):516–25

A class of highly potent antibacterial peptides derived from pardaxin, a pore-forming peptide isolated from Moses sole fish Pardachirus marmoratus. Oren Z, et al. **Eur J Biochem** 1996 Apr 1;237(1):303–10

Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori. Nakao M, et al. **Eur J Clin Microbiol Infect Dis** 1995 May;14(5):391–9

Changes in susceptibility of Salmonella enteritidis, Salmonella typhimurium, and Salmonella virchow to six antimicrobial agents in a Spanish hospital, 1980–1994. Ramos JM, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jan;15(1):85–8

Inactivation of diaminopyrimidines and sulfonamides in Barbour-Stoenner-Kelly medium for isolation of Borrelia burgdorferi [letter] Reisinger EC, et al. **Eur J Clin Microbiol Infect Dis** 1995 Aug;14(8):732–3

Antibacterial effect of 2-hydroxy-N-(3,4-dimethyl-5-isoxazolyl)-1, 4-naphthoquinone-4-imine on Staphylococcus aureus. Bogdanov P, et al. **Experientia** 1996 Jun 15;52(6):600–4

Unusual antimicrobial compounds from Aeollanthus buchnerianus. Dellar JE, et al. **Experientia** 1996 Feb 15; 52(2):175–9

Pharmacological aspects and therapeutic applications of lysozymes. Sava G. **EXS** 1996;75:433–49 (79 ref.)

Chromonyl-aminosalicylic acid derivatives as possible antimycobacterial agents. Lácová M, et al. **Farmaco** 1995 Dec;50(12):885–8

Molecular analysis of the sheep cathelin family reveals a novel antimicrobial peptide. Mahoney MM, et al. **FEBS Lett** 1995 Dec 27;377(3):519–22

Antibacterial activity of peptides homologous to a loop region in human lactoferrin. Odell EW, et al. **FEBS Lett** 1996 Mar 11;382(1–2):175–8

Broad spectrum antibiotic activity of the skin-PYY. Vouldoukis I, et al. **FEBS Lett** 1996 Feb 19;380(3):237–40

High sensitivity of Mycobacterium species to the bactericidal activity by polylysine. Delihas N, et al. **FEMS Microbiol Lett** 1995 Oct 15;132(3):233–7

Structure-activity relationships of some 4-quinazolylthiosemicarbazides and their triazolo derivatives. Jantová S, et al. **Folia Microbiol (Praha)** 1994; 39(6):471–4

Inhibitory effect of flumequine, enoxacin and norfloxacin on the GABA-induced contractile effect on the guinea pig ileum. Koutsoviti-Papadopoulou M, et al. **Gen Pharmacol** 1995 Oct;26(6):1391–5

Furazolidone in typhoid fever--correlation of clinical efficacy with serum bactericidal activity. Kumar AS, et al. **Indian Pediatr** 1995 May;32(5):533–8

Pharmacodynamics of antimicrobial agents. Bactericidal and postantibiotic effects. Levison ME. **Infect Dis Clin North Am** 1995 Sep;9(3):483–95 (26 ref.)

In vitro testing of antimicrobial agents. Woods GL. **Infect Dis Clin North Am** 1995 Sep;9(3):463–81 (60 ref.)

Staphylocidal action of thrombin-induced platelet microbicidal protein is not solely dependent on transmembrane potential. Koo SP, et al. **Infect Immun** 1996 Mar;64(3):1070–4

In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis. Miyakawa Y, et al. **Infect Immun** 1996 Mar;64(3):926–32

Involvement of reactive oxygen intermediates in tumor necrosis factor alpha-dependent bacteriostasis of Mycobacterium avium. Sarmento A, et al. **Infect Immun** 1996 Aug;64(8):3224–30

Susceptibility of Chlamydia trachomatis to protegrins and defensins. Yasin B, et al. **Infect Immun** 1996 Mar; 64(3):709–13

Resistance to platelet microbicidal protein results in increased severity of experimental Candida albicans endocarditis. Yeaman MR, et al. **Infect Immun** 1996 Apr;64(4):1379–84

The pro-oxidative riminophenazine B669 neutralizes the inhibitory effects of Mycobacterium tuberculosis on phagocyte antimicrobial activity. Wadee AA, et al. **Int J Immunopharmacol** 1995 Oct;17(10):849–56

Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. Pauwels R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):211–21 (70 ref.)

Antibacterial susceptibility patterns for microbial isolates associated with infectious keratitis in horses: 63 cases (1986–1994). Moore CP, et al. **J Am Vet Med Assoc** 1995 Oct 1;207(7):928–33

AHI perspectives: flexible drug labeling and its impact on the drug development process. In vitro microbiological aspects of flexible labeling. Watts JL. **J Am Vet Med Assoc** 1995 Oct 1;207(7):896–7; discussion 902–4

In vitro antimicrobial activity and structure-activity relationship of C-2 triazolylthio and pyridinylmethylthio carbapenems. Fiakpui C, et al. **J Antibiot (Tokyo)** 1996 Feb; 49(2):212–5

Synthesis and antibacterial activity of 2-(isoxazolidinio-5-yl)carbapenem derivatives. Nishi K, et al. **J Antibiot (Tokyo)** 1995 Dec;48(12):1481–7

Carboxamides and hydrazide of glycopeptide antibiotic eremomycin. Synthesis and antibacterial activity. Pavlov AY, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):194–8

BO-2727, meropenem and imipenem disc diffusion susceptibility testing criteria [letter] Barry AL, et al. **J Antimicrob Chemother** 1995 Aug;36(2):444–6

In-vitro activity of two glycylcyclines against enterococci resistant to other agents. Fraise AP, et al. **J Antimicrob Chemother** 1995 Jun;35(6):877–81

In-vitro inhibitory activity of gamma-linolenic acid on Escherichia coli strains and its influence on their susceptibilities to various antimicrobial agents. Giamarellos-Bourboulis EJ, et al. **J Antimicrob Chemother** 1995 Aug;36(2):327–34

Comparative susceptibility of Legionella pneumophila and Legionella longbeachae to 12 antimicrobial agents. Nimmo GR, et al. **J Antimicrob Chemother** 1995 Jul;36(1):219–23

Mechanism of sulphadiazine enhancement of trimethoprim activity against sulphadiazine-resistant Enterococcus faecalis. Richards RM, et al. **J Antimicrob Chemother** 1995 Oct;36(4):607–18

In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii. Romand S, et al. **J Antimicrob Chemother** 1995 Jun;35(6):821–32

Redox potential and oxygen concentration as factors in the susceptibility of Helicobacter pylori to nitroheterocyclic drugs. Smith MA, et al. **J Antimicrob Chemother** 1995 Jun; 35(6):751–64

Susceptibility testing of Streptococcus pneumoniae to trimethoprim [letter] Tremlett CH, et al. **J Antimicrob Chemother** 1995 Jun;35(6):915–6

In-vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis. Zanetti S, et al. **J Antimicrob Chemother** 1996 Feb;37(2):357–9

Inhibitory effects of sucrose monolaurate, alone and in combination with organic acids, on Listeria monocytogenes and Staphylococcus aureus. Monk JD, et al. **J Appl Bacteriol** 1996 Jul;81(1):7–18

In vitro inhibition of Helicobacter pylori by extracts of thyme. Tabak M, et al. **J Appl Bacteriol** 1996 Jun; 80(6):667–72

A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in Vibrio cholerae O139. Waldor MK, et al. **J Bacteriol** 1996 Jul;178(14):4157–65

Escherichia coli chorismate synthase catalyzes the conversion of (6S)-6-fluoro-5-enolpyruvylshikimate-3-phosphate to 6-fluorochorismate. Implications for the enzyme mechanism and the antimicrobial action of (6S)-6-fluoroshikimate. Bornemann S, et al. **J Biol Chem** 1995 Sep 29;270(39):22811–5

Mode of action of the antimicrobial peptide indolicidin. Falla TJ, et al. **J Biol Chem** 1996 Aug 9;271(32):19298–303

Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells. Higazi AAR, et al. **J Biol Chem** 1996 Jul 26;271(30):17650–5

Diastereoisomers of cytolysins, a novel class of potent antibacterial peptides. Shai Y, et al. **J Biol Chem** 1996 Mar 29;271(13):7305–8

In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria. García-Rodríguez JA, et al. **J Chemother** 1995 Jun;7(3):189–96

Bactericidal kinetics and postantibiotic effect of sparfloxacin against selected species of respiratory pathogens. Speciale A, et al. **J Chemother** 1995 Dec;7(6):530–4

The inhibiting effect of aqueous Azadirachta indica (Neem) extract upon bacterial properties influencing in vitro plaque formation. Wolinsky LE, et al. **J Dent Res** 1996 Feb; 75(2):816–22

Antimicrobial activity of Paliurus spina-christi Mill. (Christ's thorn). Brantner A, et al. **J Ethnopharmacol** 1996 Jun; 52(2):119–22

The antimicrobial properties of chile peppers (Capsicum species) and their uses in Mayan medicine. Cichewicz RH, et al. **J Ethnopharmacol** 1996 Jun;52(2):61–70

Antibacterial activity and phytochemical analysis of Vochysia divergens (Vochysiaceae). Hess SC, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):97–100

Screening of some Cuban medicinal plants for antimicrobial activity. Martínez MJ, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):171–4

Antibacterial activity of Helichrysum aureonitens (Asteraceae). Meyer JJ, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):109–11

Carrier herbal medicine: an evaluation of the antimicrobial and anticancer activity in some frequently used remedies. Ritch-Krc EM, et al. **J Ethnopharmacol** 1996 Jul 5; 52(3):151–6

Antimicrobial activity of Guinea-Bissau traditional remedies. Silva O, et al. **J Ethnopharmacol** 1996 Jan;50(1):55–9

Comparative study on the antibacterial activity of phytochemical flavanones against methicillin-resistant Staphylococcus aureus. Tsuchiya H, et al. **J Ethnopharmacol** 1996 Jan;50(1):27–34

Antimicrobial activity of extracts of three major plants from the Chihuahuan desert. Verástegui MA, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):175–7

Screening of hundred Rwandese medicinal plants for antimicrobial and antiviral properties. Vlietinck AJ, et al. **J Ethnopharmacol** 1995 Apr;46(1):31–47

Infection resistance of surface modified catheters with either short-lived or prolonged activity. Sampath LA, et al. **J Hosp Infect** 1995 Jul;30(3):201–10

Cobalt(II), nickel(II), and copper(II) complexes of sulfanilamide derivatives: synthesis, spectroscopic studies, and antibacterial activity. Crystal structure of [Co(sulfacetamide)2(NCS)2]. Blasco F, et al. **J Inorg Biochem** 1996 Feb;61(2):143–54

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. Barbachyn MR, et al. **J Med Chem** 1996 Feb 2;39(3):680–5

Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters. Bergmann KE, et al. **J Med Chem** 1996 Aug 16; 39(17):3394–400

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. Brickner SJ, et al. **J Med Chem** 1996 Feb 2;39(3):673–9

The chemistry of Pseudomonic acid. 15. Synthesis and antibacterial activity of a series of 5-alkyl, 5-alkenyl, and 5-heterosubstituted oxazoles. Brown P, et al. **J Med Chem** 1996 Jan 19;39(2):446–57

Studies on 6-aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-methylquinolones. Cecchetti V, et al. **J Med Chem** 1996 Jan 19;39(2):436–45

Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. Cynamon MH, et al. **J Med Chem** 1995 Sep 29;38(20):3902–7

Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci. Heinze-Krauss I, et al. **J Med Chem** 1996 Apr 26; 39(9):1864–71

De novo antimicrobial peptides with low mammalian cell toxicity. Javadpour MM, et al. **J Med Chem** 1996 Aug 2; 39(16):3107–13

Structure-activity relationship of omeprazole and analogues as Helicobacter pylori urease inhibitors. Kühler TC, et al. **J Med Chem** 1995 Dec 8;38(25):4906–16

High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. Kuyper LF, et al. **J Med Chem** 1996 Feb 16;39(4):892–903

Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations. Piper JR, et al. **J Med Chem** 1996 Mar 15;39(6):1271–80

Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7. Renau TE, et al. **J Med Chem** 1996 Feb 2;39(3):729–35

Ionophore properties of monensin derivatives studied on human erythrocytes by 23Na NMR and K+ and H+ potentiometry: relationship with antimicrobial and antimalarial activities. Rochdi M, et al. **J Med Chem** 1996 Jan 19;39(2):588–95

The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. Sanchez JP, et al. **J Med Chem** 1995 Oct 27;38(22):4478–87

Susceptibility of oral bacterial biofilms to antimicrobial agents. Wilson M. **J Med Microbiol** 1996 Feb;44(2):79–87 (54 ref.)

Cacospongionolide B, a new sesterterpene from the sponge Fasciospongia cavernosa. De Rosa S, et al. **J Nat Prod** 1995 Nov;58(11):1776–80

Whole mouth microbiota effects following subgingival delivery of sanguinarium. Godowski KC, et al. **J Periodontol** 1995 Oct;66(10):870–7

Susceptibility of Helicobacter pylori to antimicrobial agents: effect of ebrotidine and ranitidine. Piotrowski J, et al. **J Physiol Pharmacol** 1995 Dec;46(4):463–9

Potency of antibacterial drugs in milk as analysed by beta-glucuronidase-based fluorometry. Fang W, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):422–8

Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates. Spreng M, et al. **J Vet Pharmacol Ther** 1995 Aug; 18(4):284–9

Drug resistance and conjugative R plasmids in Escherichia coli strains isolated from migratory waterfowl. Tsubokura M, et al. **J Wildl Dis** 1995 Jul;31(3):352–7

Ceftibuten--a new oral cephalosporin. **Med Lett Drugs Ther** 1996 Mar 15;38(970):23–4

Lethal effect of carbonyl cyanide m-chlorophenylhydrazone on Escherichia coli and a halotolerant Brevibacterium species. Nagata S. **Microbios** 1995;81(327):73-83

Antibacterial activity of essential oils from Cymbopogon: inter- and intra-specific differences. Pattnaik S, et al. **Microbios** 1995;84(341):239-45

Antimicrobial susceptibilities of regional pathogenic strains of Nocardia isolated from mycetomas. Durán EL, et al. **Mycopathologia** 1995 Sep;131(3):167-72

Effect of acteoside on mesangial proliferation in rat anti-Thy 1 nephritis. Hattori T, et al. **Nippon Jinzo Gakkai Shi** 1996 May;38(5):202-12

Application of the rough sets theory to the analysis of structure-activity-relationships of antimicrobial pyridinium compounds. Krysinski J. **Pharmazie** 1995 Sep;50(9):593-7

A potent antimicrobial protein from onion seeds showing sequence homology to plant lipid transfer proteins. Cammue BP, et al. **Plant Physiol** 1995 Oct;109(2):445-55

Assays of the biological activities of two fatty acid derivatives formed in the edible mushrooms cantharellus cibarius and C. tubaeformis as a response to injury. Anke H, et al. **Planta Med** 1996 Apr;62(2):181-3

Antimicrobial activity of tannins from Terminalia citrina [letter] Burapadaja S, et al. **Planta Med** 1995 Aug; 61(4):365-6

In vitro biological activities of alkaloids from Cryptolepis sanguinolenta. Cimanga K, et al. **Planta Med** 1996 Feb; 62(1):22-7

Biological activities of cyanobacteria: evaluation of extracts and pure compounds. Falch BS, et al. **Planta Med** 1995 Aug;61(4):321-8

Antifungal and antibacterial chalcones from Myrica serrata. Gafner S, et al. **Planta Med** 1996 Feb;62(1):67-9

Mode of antibacterial action of totarol, a diterpene from Podocarpus nagi. Haraguchi H, et al. **Planta Med** 1996 Apr; 62(2):122-5

Sesquiterpenes with antibacterial activity from Epaltes mexicana. Kato T, et al. **Planta Med** 1996 Feb;62(1):66-7

An antibacterial thiophene from Balsamorhiza sagittata. Matsuura H, et al. **Planta Med** 1996 Feb;62(1):65-6

Comparison of antimicrobial properties of monoterpenes and their carbonylated products. Naigre R, et al. **Planta Med** 1996 Jun;62(3):275-7

Two flavones from Artemisia giraldii and their antimicrobial activity. Zheng WF, et al. **Planta Med** 1996 Apr; 62(2):160-2

Structure-activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Fehlbaum P, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1221-5

Topoisomerase IV is a target of quinolones in Escherichia coli. Khodursky AB, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11801-5

Corticostatins/defensins inhibit in vitro NK activity and cytokine production by human peripheral blood mononuclear cells. Masera RG, et al. **Regul Pept** 1996 Apr 9;62(1):13-21

The morphological effects of two antimicrobial peptides, hecate-1 and melittin, on Escherichia coli. Henk WG, et al. **Scanning Microsc** 1995 Jun;9(2):501-7

Effect of sulfamethazine on phenobarbital and benzo[a]pyrene induced hepatic microsomal mixed function oxidase system in rats. Kodam KM, et al. **Toxicol Lett** 1996 Sep;87(1):25-30

Bacterial responses to host-defense peptides. Groisman EA. **Trends Microbiol** 1996 Apr;4(4):127-8; discussion 128-9 (17 ref.)

Influence of flumequine on in vivo mitogen responses of European eel (Anguilla anguilla L., 1758) lymphoid cells. van der Heijden MH, et al. **Vet Immunol Immunopathol** 1995 Jul;47(1-2):143-52

Sensitivity of Australian isolates of Salmonella enteritidis to nitrofurantoin and furazolidone. Cox JM, et al. **Vet Microbiol** 1996 Apr;49(3-4):305-8

Sensitivity of strains of Serpulina hyodysenteriae isolated in Hungary to chemotherapeutic drugs [see comments] Molnár L. **Vet Rec** 1996 Feb 17;138(7):158-60. Comment in: Vet Rec 1996 Mar 23;138(12):288.

Effect of concurrent feeding of furazolidone and sodium chloride upon some clinical, pathological and cardiac morphometric parameters in broiler chicks. Islam N, et al. **Zentralbl Veterinarmed A** 1995 Apr;42(2):91-8

[Technology of processing carbonized root of Sanguisorba of ficinalis L. and the quality standards for its prepared pieces] Ding A, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Dec;20(12):725-8, 762 (Eng. Abstr.) **(Chi)**

[Furazolidone resistance of E. coli from chicken intestines after prophylactic treatment with bioptivet GB in animal feed] Kobe A, et al. **Berl Munch Tierarztl Wochenschr** 1996 Jan;109(1):14-7 (Eng. Abstr.) **(Ger)**

[Propolis: its use in technology and research] Gallo FR, et al. **Boll Chim Farm** 1995 Oct;134(9):483-91 (15 ref.) (Eng. Abstr.) **(Ita)**

[The opiate-like and antimicrobial bioactivities of food protein peptides] Kharchenko EP. **Fiziol Zh Im I M Sechenova** 1996 Feb;82(2):71-8 (Eng. Abstr.) **(Rus)**

[The anti-infective properties of mammalian earwax] Sokolov VE, et al. **Izv Akad Nauk Ser Biol** 1995 Sep-Oct; (5):579-85 (Eng. Abstr.) **(Rus)**

[Modern methods and means for the rapid determination of the sensitivity of the causative agents of dangerous infectious diseases to antibiotics and chemical preparations] D'iakov SI, et al. **Voen Med Zh** 1996 Mar;317(3):44-7 (17 ref.) **(Rus)**

[The effect of monensin on a rumen strain of Enterococcus faecium CCM 4231] Lauková A, et al. **Vet Med (Praha)** 1995 Nov;40(11):337-9 (Eng. Abstr.) **(Slo)**

POISONING

Fatal poisoning due to dapsone in a patient with grossly elevated methaemoglobin levels [letter] Wagner A, et al. **Br J Dermatol** 1995 Nov;133(5):816-7

STANDARDS

AHI perspectives: flexible drug labeling and its impact on the drug development process. Practicality of clinical development. Copeland DD. **J Am Vet Med Assoc** 1995 Oct 1;207(7):895-6; discussion 902-4

THERAPEUTIC USE

Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antinori A, et al. **AIDS** 1995 Dec; 9(12):1343-50

Cure of Helicobacter pylori infection: role of duration of treatment with omeprazole and amoxicillin. Adamek RJ, et al. **Am J Gastroenterol** 1996 Jan;91(1):98-100

4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection. de Boer WA, et al. **Am J Gastroenterol** 1996 Sep;91(9):1778-82

Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. Santander C, et al. **Am J Gastroenterol** 1996 Aug;91(8):1549-52

Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects. Thijs JC, et al. **Am J Gastroenterol** 1996 Jan;91(1):93-7

Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication [letter] Tursi A, et al. **Am J Gastroenterol** 1996 Aug;91(8):1668-70

Computer-assisted antimicrobial surveillance in a community teaching hospital. Jozefiak ET, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1536-40

Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Beumont MG, et al. **Am J Med** 1996 Jun;100(6):611-6

Past, present, and future of antimicrobial agents. Moellering RC Jr. **Am J Med** 1995 Dec 29;99(6A):11S-18S (37 ref.)

Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Oken MM, et al. **Am J Med** 1996 Jun;100(6):624-8

Case report: reversal of decreased bone mass by antibiotic treatment in a patient with Whipple's disease. Carnevale V, et al. **Am J Med Sci** 1996 Mar;311(3):145-7

Liver failure induces a systemic inflammatory response. Prevention by recombinant N-terminal bactericidal/permeability-increasing protein. Boermeester MA, et al. **Am J Pathol** 1995 Nov;147(5):1428-40

Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Safrin S, et al. **Ann Intern Med** 1996 May 1;124(9):792-802

Prophylaxis of pneumocystis pneumonia and toxoplasmosis [letter; comment] Zamora L, et al. **Ann Intern Med** 1996 Jun 15;124(12):1096. Comment on: Ann Intern Med 1995 May 15;122(10):755-61.

Nonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondii. Araujo FG, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2696-701

Relapse of Toxoplasma encephalitis and susceptibility to pyrimethamine: lack of evidence of treatment-induced resistance [letter] Caramello P, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2371-2

Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Hong YL, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1756-63

Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. Hughes WT, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):962-5

Relevance of Chlamydia pneumoniae murine pneumonitis model to evaluation of antimicrobial agents. Masson ND, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1959-64

Switch therapy in community-acquired pneumonia [letter; comment] Nathwani D, et al. **Arch Intern Med** 1996 Jun 10;156(11):1235. Comment on: Arch Intern Med 1995 Jun 26;155(12):1273-6.

Local antibacterial therapy for the management of orthopaedic infections. Pharmacokinetic considerations. Henry SL, et al. **Clin Pharmacokinet** 1995 Jul;29(1):36-45 (88 ref.)

Results of a survey of children with acute bacterial conjunctivitis treated with trimethoprim-polymyxin B ophthalmic solution. Wagner RS. **Clin Ther** 1995 Sep-Oct; 17(5):875-81

Comparison of early and late treatment with a recombinant endotoxin neutralizing protein in a rat model of Escherichia coli sepsis. Weiner DL, et al. **Crit Care Med** 1996 Sep; 24(9):1514-7

Gonorrhoea: single-dose oral treatment. Kohl PK, et al. **Curr Probl Dermatol** 1996;24:82-9 (29 ref.)

Antimicrobial treatment of psoriasis. Skinner RB Jr, et al. **Dermatol Clin** 1995 Oct;13(4):909-13 (18 ref.)

Metronidazole affects Helicobacter pylori related nonulcer dyspepsia and symptoms from carbohydrate malabsorption [letter; comment] Born P. **Dig Dis Sci** 1995 Dec;40(12):2731 . Comment on: Dig Dis Sci 1995 Jan;40(1):114-9.

Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers. Sung JJ, et al. **Dig Dis Sci** 1996 Mar;41(3):453-7

In-vitro activity of antibacterial drugs and clinical practice. **Drug Ther Bull** 1995 Sep;33(9):71-2 (12 ref.)

Antimicrobial treatment of adults with cholera due to Vibrio cholerae 0139 (synonym Bengal). Khan WA, et al. **Drugs** 1995;49 Suppl 2:460-2

Oral ciprofloxacin vs intravenous therapy with nonquinolone agents. A study of 291 infections. Lorian V, et al. **Drugs** 1995;49 Suppl 2:477-9

Comparative study of efficacy and safety of ciprofloxacin and cefixime in the treatment of acute exacerbations of chronic bronchitis after first-line treatment failure. French Study Group. Nouvet G, et al. **Drugs** 1995;49 Suppl 2:423-5

Bacterial meningitis. Practical guidelines for management. Rockowitz J, et al. **Drugs** 1995 Nov;50(5):838-53 (98 ref.)

Antimicrobial treatment of cholera. Salam MA, et al. **Drugs** 1995;49 Suppl 2:466-9

Effects of lysine-arginine association on immune functions in patients with recurrent infections. Azzarà A, et al. **Drugs Exp Clin Res** 1995;21(2):71-8

Evaluation of in vitro and in vivo antimicrobial activity of a new topical antiinfective agent. D'Urso CM, et al. **Drugs Exp Clin Res** 1995;21(2):65-70

Prophylactic effect of ornidazole on experimental tetanus in mice. Erenmemisoglu A, et al. **Drugs Exp Clin Res** 1995; 21(2):59-63

Helicobacter pylori may induce bile reflux: link between H pylori and bile induced injury to gastric epithelium. Ladas SD, et al. **Gut** 1996 Jan;38(1):15-8

Chloramphenicol-furazolidone combination in enteric fever [letter] Bairwa A, et al. **Indian Pediatr** 1995 Jan;32(1):109

Comparative efficacy of furazolidone and nalidixic acid in the empirical treatment of acute invasive diarrhea: randomized clinical trial. Dutta P, et al. **Indian Pediatr** 1995 Jan;32(1):13-9

Adjuncts to antibacterial therapy. Frank MO, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):769-81 (63 ref.)

Principles of selection and use of antibacterial agents. Hessen MT, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):531-45 (61 ref.)

Antibacterial agents in pregnancy. Korzeniowski OM. **Infect Dis Clin North Am** 1995 Sep;9(3):639-51 (65 ref.)

Antibacterial agents in infections of the central nervous system and eye. Papastamelos AG, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):615-37 (81 ref.)

Antimicrobial agents for treatment of infectious keratitis in horses. Moore CP, et al. **J Am Vet Med Assoc** 1995 Oct 1;207(7):855-62 (29 ref.)

AVMA/Practice Group perspectives: use of drug labels in the prescription of antimicrobial therapy. Representing the American Association of Bovine Practitioners (AABP). Riddell MG Jr. **J Am Vet Med Assoc** 1995 Oct 1; 207(7):882-3; discussion 890-4

The scid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy. Kunz S, et al. **J Antimicrob Chemother** 1995 Jul;36(1):137-55

The management of mycobacterial infection--a UK survey [letter] Lovering AM, et al. **J Antimicrob Chemother** 1995 Oct;36(4):745-7

Over the counter anti-infectives--of benefit to whom? Reeves DS, et al. **J Antimicrob Chemother** 1995 Sep; 36(3):579-84

In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii. Romand S, et al. **J Antimicrob Chemother** 1995 Jun;35(6):821-32

Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. Wilcox MH, et al. **J Antimicrob Chemother** 1995 Oct;36(4):673-9

Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. Cazzola M, et al. **J Chemother** 1995 Oct;7(5):432-41

Betalactam therapy and intestinal flora. Novelli A, et al. **J Chemother** 1995 May;7 Suppl 1:25-31

Methicillin-resistant coagulase-negative staphylococcal osteomyelitis and its relationship to broad-spectrum oral antibiosis in a predominantly diabetic population. Armstrong DG, et al. **J Foot Ankle Surg** 1995 Nov-Dec; 34(6):563-6

Effect of the eradication of Helicobacter pylori on duo... ulcer healing and ulcer relapse: randomized controlled study in Japan. Shirotani T, et al. **J Gastroenterol** 1996 Apr;31(2):175-81

Metronidazole resistance: a predictor of failure of Helicobacter pylori eradication by triple therapy. Midolo PD, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):290-2

Guidelines for the diagnosis and treatment of dysentery [letter] Sokhey J. **J Indian Med Assoc** 1995 Aug;93(8):319

Antibiotic prophylaxis for the prevention of donor-acquired Toxoplasma gondii infection in transplant patients [letter; comment] Wreghitt TG, et al. **J Infect** 1995 Nov; 31(3):253–4. Comment on: J Infect 1994 Nov;29(3):249–53.

Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. Leport C, et al. **J Infect Dis** 1996 Jan;173(1):91–7

Tarnished gold: sixty years of antimicrobial drug use and misuse [editorial] Greenwood D. **J Med Microbiol** 1995 Dec;43(6):395–6 (12 ref.)

Outpatient therapy with ceftriaxone and oral cefixime for selected febrile children with sickle cell disease. Williams LL, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):257–61

One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients. Sito E, et al. **J Physiol Pharmacol** 1996 Mar; 47(1):221–8

Eusol: the plastic surgeon's choice? Humzah MD, et al. **J R Coll Surg Edinb** 1996 Aug;41(4):269–70

Clinical observation of qingjie liyan mixture in the treatment of 46 cases of chronic pharyngitis. Liu B, et al. **J Tradit Chin Med** 1995 Sep;15(3):180–2

Short course chemotherapy with cefixime in children with multidrug-resistant Salmonella typhi Septicaemia. Girgis NI, et al. **J Trop Pediatr** 1995 Dec;41(6):364–5

Lactobacillus GG and acute diarrhoea in young children in the tropics. Pant AR, et al. **J Trop Pediatr** 1996 Jun; 42(3):162–5

Medication of feedlot calves infected with Eimeria spp. by a combination of sulfamonomethoxine and ormetoprim. Hasbullah, et al. **J Vet Med Sci** 1996 Feb;58(2):169–70

Design of field trials for the evaluation of antibacterial products for therapy of bovine clinical mastitis. Schukken YH, et al. **J Vet Pharmacol Ther** 1995 Aug;18(4):274–83

Three vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis [letter; comment] Rosborough TK, et al. **JAMA** 1995 Nov 1;274(17):1341; discussion 1341–2. Comment on: JAMA 1995 Apr 5;273(13):1015–21.

35-year-old woman with ulcerating skin lesions. Shields RC, et al. **Mayo Clin Proc** 1996 Jan;71(1):59–62

The choice of antibacterial drugs. **Med Lett Drugs Ther** 1996 Mar 29;38(971):25–34

Management of HIV infection. A 1995–96 overview for the clinician. Henry K. **Minn Med** 1995 Nov;78(11):17–24 (25 ref.)

Empiricism and Wegener's granulomatosis [editorial; comment] DeRemee RA. **N Engl J Med** 1996 Jul 4; 335(1):54–5. Comment on: N Engl J Med 1996 Jul 4;335(1):16–20.

Trimethoprim–sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group [see comments] Stegeman CA, et al. **N Engl J Med** 1996 Jul 4;335(1):16–20 . Comment in: N Engl J Med 1996 Jul 4;335(1):54–5.

An audit of low dose triple therapy for eradication of Helicobacter pylori. Fraser AG, et al. **N Z Med J** 1996 Aug 9;109(1027):290–2

Cure of a solitary brainstem abscess with antibiotic therapy: case report. Fulgham JR, et al. **Neurology** 1996 May; 46(5):1451–4 (10 ref.)

Brown recluse spider envenomation of the eyelid: an animal model. Cole HP 3rd, et al. **Ophthal Plast Reconstr Surg** 1995 Sep;11(3):153–64

Microbiology and antimicrobial therapy of spinal infections. Sapico FL. **Orthop Clin North Am** 1996 Jan;27(1):9–13 (22 ref.)

Randomized trial of the efficacy of trimethoprim–sulfamethoxazole and prednisone in preventing post–tympanostomy tube morbidity. Daly KA, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1068–74

A randomized trial of chloramphenicol vs. trimethoprim–sulfamethoxazole for the treatment of malnourished children with community-acquired pneumonia. Mulholland EK, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):959–65

Evaluation of the effect of sulphametoxazole and trimethoprim in patients with Machado-Joseph disease. Correia M, et al. **Rev Neurol** 1995 May-Jun;23(121):632–4

Randomized study of sulfamethoxazole–trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. Nielsen TL, et al. **Scand J Infect Dis** 1995;27(3):217–20

Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. Korraa H, et al. **South Med J** 1996 Mar;89(3):272–7 (38 ref.)

Convulsions in childhood shigellosis and antimicrobial resistance patterns of shigella isolates. Oztürk MK, et al. **Turk J Pediatr** 1996 Apr-Jun;38(2):183–8

Effect of antibiotic treatment on competitive exclusion against Salmonella enteritidis PT4 in broilers. Bolder NM, et al. **Vet Rec** 1995 Sep 30;137(14):350–1

Preliminary observations on the efficacy of an iodophor in reducing the mortality in chickens experimentally affected by the 'hydropericardium syndrome'. Abdul-Aziz TA, et al. **Vet Res Commun** 1996;20(2):191–4

[Clinical observation on perinatal Chlamydia trachomata infection] Huo X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):460–2 (Eng. Abstr.) **(Chi)**

[Endophthalmitis. 2: treatment] Bron A. **J Fr Ophtalmol** 1996; 19(4):294–314 (164 ref.) **(Fre)**

[Decision analysis of congenital toxoplasmosis in the absence of exact knowledge of the treatment benefits and secondary effects] Ecochard R, et al. **Rev Epidemiol Sante Publique** 1996 Apr;44(2):145–54 (Eng. Abstr.) **(Fre)**

[A trial of using sulperazone (cefoperazone/sulbactam) in the combined treatment of patients with a burn infection] Iakovlev VP, et al. **Antibiot Khimioter** 1995 May; 40(5):38–41 (Eng. Abstr.) **(Rus)**

[The combined preparation ligentin in the treatment of inflammatory disease of the urogenital organs] Kisina VI. **Antibiot Khimioter** 1995 Jul;40(7):43–4 (Eng. Abstr.) **(Rus)**

[Use of antimicrobial materials containing sangviritrin in the prevention of nosocomial infections] Sedov AV, et al. **Gig Sanit** 1996 Mar-Apr;(2):36–8 **(Rus)**

[Antibacterial therapy in the combined treatment of periodontitis] Romanov AE, et al. **Stomatologiia (Mosk)** 1996;75(1):23–5 (Eng. Abstr.) **(Rus)**

[The probiotic correction of microecological and immune disorders in gastroduodenal pathology in children] Lykova EA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr;(2):88–91 (Eng. Abstr.) **(Rus)**

[Wegener's granulomatosis of the nasal fossa] Ibáñez-Bermúdez F, et al. **Acta Otorrinolaringol Esp** 1995 Sep-Oct;46(5):361–4 (Eng. Abstr.) **(Spa)**

[Helicobacter pylori eradication heals the duodenal ulcer. Randomized, simple, and controlled study with omeprazole] Piñero R, et al. **G E N** 1995 Apr-Jun; 49(2):111–5 (Eng. Abstr.) **(Spa)**

[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr-Jun; 49(2):116–22 (21 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Experimental furazolidone toxicosis in broiler chicks: effect of dosage, duration and age upon clinical signs and some blood parameters. Zaman Q, et al. **Acta Vet Hung** 1995; 43(2–3):359–67

Safety of silver oxide-impregnated silastic tympanostomy tubes. Chole RA, et al. **Am J Otol** 1995 Nov;16(6):722–4

An in vitro study on the cytotoxicity of chlorhexidine digluconate to human gingival cells. Babich H, et al. **Cell Biol Toxicol** 1995 Apr;11(2):79–88

Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Linseman DA, et al. **Fundam Appl Toxicol** 1995 Nov;28(1):59–64

Studies on the mechanism of trimethoprim-induced hyperkalemia. Eiam-Ong S, et al. **Kidney Int** 1996 May; 49(5):1372–8

Furazolidone toxicosis in young broiler chicks: morphometric and pathological observations on heart and testes. Khan MZ, et al. **Vet Hum Toxicol** 1995 Aug;37(4):314–8

Effect of sulfamethazine on mixed function oxidase in chickens. Kodam KM, et al. **Vet Hum Toxicol** 1995 Aug; 37(4):340–2

URINE

Determination of sulphonamides in human urine by azo dye precolumn derivatization and micellar liquid chromatography. Simó-Alfonso EF, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):183–7

Microbiologic assay for detection of antimicrobial agents in urine. Wu JJ, et al. **J Formos Med Assoc** 1996 Jun; 95(6):464–8

[Drug residues in untreated swine] Kietzmann M, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Nov;102(11):441–2 (Eng. Abstr.) **(Ger)**

ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE

A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium. Gensberg K, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1–2):57–60

[Fluoroquinolones] Damas P. **Rev Med Liege** 1996 Jan; 51(1):50–2 **(Fre)**

ADMINISTRATION & DOSAGE

An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Prantera C, et al. **Am J Gastroenterol** 1996 Feb;91(2):328–32

Sustained release of liposome-encapsulated enrofloxacin after intramuscular administration in rabbits. Cabanes A, et al. **Am J Vet Res** 1995 Nov;56(11):1498–501

Treatment of chronic ear disease. Topical ciprofloxacin vs topical gentamicin. Tutkun A, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1414–6

Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. Zhang Y, et al. **Arthritis Rheum** 1996 Jul;39(7):1238–43

Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Cornelissen JJ, et al. **Clin Infect Dis** 1995 Nov;21(5):1300–2

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Kennedy N, et al. **Clin Infect Dis** 1996 May;22(5):827–33

Safety evaluation of a new formulation of intravenous ofloxacin. Stein GE. **Drugs** 1995;49 Suppl 2:497–8

Comparison of 2 oral ofloxacin regimens for the treatment of bacteriuria in elderly subjects. Zorbas P, et al. **Drugs** 1995;49 Suppl 2:384–6

Antibiotic prophylaxis for ERCP: a randomized clinical trial comparing ciprofloxacin and cefuroxime in 200 patients at high risk of cholangitis. Mehal WZ, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):841–5

Oral ciprofloxacin versus intravenous cefuroxime as prophylaxis against postoperative infection in vascular surgery: a randomised double-blind, prospective multicentre study. Risberg B, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):346–51

Randomized trial of prevention of biliary stent occlusion by ursodeoxycholic acid plus norfloxacin. Tarnasky PR, et al. **Gastrointest Endosc** 1995 Jul;42(1):103–4

A randomized trial of pefloxacin plus klindamicin and cefoxitin in hepatobiliary and pancreatic surgery. Fried M, et al. **Hepatogastroenterology** 1996 Jan-Feb;43(7):306–8

A double-blind comparative study of ofloxacin otic drops versus neomycin-polymyxin B-hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. Tong MC, et al. **J Laryngol Otol** 1996 Apr; 110(4):309–14

Oral fleroxacin prophylaxis in transurethral surgery. Gasser TC, et al. **J Urol** 1996 Jul;156(1):146–8 (27 ref.)

Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis. Kim IT, et al. **Korean J Ophthalmol** 1996 Jun;10(1):8–17

Antibiotic prophylaxis for patients undergoing transurethral resection of the prostate. Hall JC, et al. **Urology** 1996 Jun; 47(6):852–6

[Treatment of uncomplicated gonorrhea in adults. New guidelines from the working group against gonorrhea] Aavitsland P, et al. **Tidsskr Nor Laegeforen** 1996 May 20; 116(13):1577–80 (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Case report: ofloxacin-induced hypersensitivity vasculitis. Pipek R, et al. **Am J Med Sci** 1996 Feb;311(2):82–3

Hypertension associated with ciprofloxacin use in an infant [letter] Atasoy H, et al. **Ann Pharmacother** 1995 Oct; 29(10):1049

Probable ciprofloxacin induced cholestasis [letter] Aggarwal A, et al. **Aust N Z J Med** 1995 Oct;25(5):541–2

Fixed drug eruption due to ciprofloxacin. Dhar S, et al. **Br J Dermatol** 1996 Jan;134(1):156–8

Use of the new quinolones during pregnancy. Koren G. **Can Fam Physician** 1996 Jun;42:1097–9

Photosensitivity induced by fleroxacin. Kimura M, et al. **Clin Exp Dermatol** 1996 Jan;21(1):46–7

Tolerability of fluoroquinolone antibiotics. Past, present and future. Ball P, et al. **Drug Saf** 1995 Dec;13(6):343–58 (130 ref.)

A reappraisal of quinolone tolerability. The experience of their musculoskeletal adverse effects. Hayem G, et al. **Drug Saf** 1995 Dec;13(6):338–42

Fluoroquinolone toxicities. An update. Lietman PS. **Drugs** 1995;49 Suppl 2:159–63 (20 ref.)

Surveillance of adverse reactions due to ciprofloxacin in Japan. Matsuno K, et al. **Drugs** 1995;49 Suppl 2:495–6

Efficacy and safety of single oral dose sparfloxacin vs ciprofloxacin in acute gonococcal urethritis in males. A multicentre international study. Moi H, et al. **Drugs** 1995; 49 Suppl 2:387–9

Comparative study of efficacy and safety of ciprofloxacin and cefixime in the treatment of acute exacerbations of chronic bronchitis after first-line treatment failure. French Study Group. Nouvet G, et al. **Drugs** 1995;49 Suppl 2:423–5

Safety evaluation of a new formulation of intravenous ofloxacin. Stein GE. **Drugs** 1995;49 Suppl 2:497–8

Nightmare due to ciprofloxacin in young patients. Dey SK. **Indian Pediatr** 1995 Aug;32(8):918–20

Flush induced by fluoroquinolones in canine skin. Kurata M, et al. **Inflamm Res** 1995 Nov;44(11):461–5

Ofloxacin-induced vasculitis. Ceyhan BB, et al. **Intern Med** 1995 Sep;34(9):872–4

Peripheral sensory disturbances related to treatment with fluoroquinolones. Hedenmalm K, et al. **J Antimicrob Chemother** 1996 Apr;37(4):831–7

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. Jaillon P, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:161–7 (4 ref.)

Safety profile of sparfloxacin in the treatment of respiratory tract infections. Rubinstein E. **J Antimicrob Chemother** 1996 May;37 Suppl A:145–60

Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Teng R, et al. **J Antimicrob Chemother** 1995 Aug;36(2):385–94

Cholestatic hepatitis related to quinolones: a report of two cases [letter] Hautekeete ML, et al. **J Hepatol** 1995 Dec;

23(6):759–60

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Sep 11;276(10):774

Ciprofloxacin–induced acute interstitial nephritis [letter] Reece RJ, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):393

Long–term magnetic resonance survey of cartilage damage in leukemic children treated with fluoroquinolones. Aricò M, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):713–4

Headache and visual disturbance. Thacker AK, et al. **Postgrad Med J** 1996 Jan;72(843):61–3

Pharmacokinetics and tolerance of a new fluoroquinolone antimicrobial drug after single oral doses in healthy volunteers. Tanaka M, et al. **Xenobiotica** 1995 Nov; 25(10):1119–25

[Rupture of the long biceps tendon following ingestion of fluoroquinolone (letter)] Guérin B, et al. **Ann Med Interne (Paris)** 1996;147(1):69 **(Fre)**

[Tendinopathy and fluoroquinolones] Castagnola C, et al. **Ann Urol (Paris)** 1996;30(3):129–30 (Eng. Abstr.) **(Fre)**

[Use of quinolones in children and articular risk] Schaad UB. **Arch Pediatr** 1996 Feb;3(2):183–4 **(Fre)**

[Tendinopathies and fluoroquinolones: a public health problem? Value of drug monitoring studies] Pierfitte C. **Bull Soc Sci Med Grand Duche Luxemb** 1995;132(3):39–40 **(Fre)**

[Secondary effects of fluoroquinolones: experience of French drug monitoring] Scheen AJ. **Rev Med Liege** 1995 Nov; 50(11):492–3 **(Fre)**

[Ciprofloxacin–associated bilateral acute achilles tendinitis] Mirovsky Y, et al. **Harefuah** 1995 Dec 1;129(11):470–2, 535 (Eng. Abstr.) **(Heb)**

[Muscular symptoms during fluoroquinolone treatment may be adverse effects] **Lakartidningen** 1995 Oct 18;92(42):3923 **(Swe)**

[Rupture of the Achilles tendon after ciproxine therapy] Hugo–Persson M. **Lakartidningen** 1996 Apr 17;93(16):1520 **(Swe)**

ANALYSIS

Simultaneous determination of theophylline, enoxacin and ciprofloxacin in human plasma and saliva by high–performance liquid chromatography. Zhai S, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):372–6

High–pressure liquid chromatographic methods for ciprofloxacin hydrochloride and related compounds in raw materials. Lacroix PM, et al. **J Pharm Biomed Anal** 1996 Mar;14(5):641–54

Spectrophotometric and spectrofluorimetric estimation of ciprofloxacin and norfloxacin by ternary complex formation with eosin and palladium(II). el Walily AF, et al. **J Pharm Biomed Anal** 1996 Mar;14(5):561–9

[Fluoroquinolone] Matsumoto F, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1010–6 (12 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1–ofloxacin. Giron KP, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2798–800

BLOOD

Simultaneous determination of rufloxacin and theophylline by high–performance liquid chromatography in human plasma. Carlucci G, et al. **Analyst** 1995 Oct;120(10):2493–5

Determination of ofloxacin in human plasma using high–performance liquid chromatography and fluorescence detection. Macek J, et al. **J Chromatogr B Biomed Appl** 1995 Nov 17;673(2):316–9

Stereospecific high–performance liquid chromatographic assay of lomefloxacin in human plasma. Foster RT, et al. **J Pharm Biomed Anal** 1995 Sep;13(10):1243–8

A 19F NMR study of lomefloxacin in human erythrocytes and its interaction with hemoglobin. Knaub SR, et al. **J Pharm Biomed Anal** 1995 Sep;13(10):1225–33

Determination of pefloxacin and its main active metabolite in human serum by high–performance liquid chromatography. Abanmi N, et al. **Ther Drug Monit** 1996 Apr;18(2):158–63

CHEMICAL SYNTHESIS

Studies on pyridonecarboxylic acids. IV. Synthesis and antibacterial activity evaluation of S–(–)– and R–(+)–6–fluoro–1–methyl–4–oxo–7–(1–piperazinyl)–4H–[1,3]thiazeto[3,2–a]quinoline–3–carboxylic acids. Segawa J, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1238–40

Studies on quinolone antibacterials. V. Synthesis and antibacterial activity of chiral 5–amino–7–(4–substituted–3–amino–1–pyrrolidinyl)–6–fluoro–1,4–dihydro–8–methyl–4–oxoquinoline–3–carboxylic acids and derivatives. Yoshida T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul;44(7):1376–86

CHEMISTRY

Ciprofloxacin–ampicillin sulbactam incompatibility [letter] Melonakos TK. **Ann Pharmacother** 1996 Jan;30(1):87

Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. Mizuki Y, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:41–55 (46 ref.)

Synthesis, characterization and antibacterial activity of novel Fe(III), Co(II), and Zn(II) complexes with norfloxacin. Gao F, et al. **J Inorg Biochem** 1995 Oct;60(1):61–7

Quinolones: structure–activity relationships and future predictions. Tillotson GS. **J Med Microbiol** 1996 May; 44(5):320–4 (19 ref.)

[Studies on structure of light degradation products of (–)–(S)–10–(1–aminocyclopropyl)–9–fluoro–3–methyl–7–oxo–2,3–dihyd ro–7H–pyrido[1,2,3–de][1,4]benzoxazine–6–carboxylic acid (T–3761) in aqueous solution and solid state] Demachi K, et al. **Yakugaku Zasshi** 1995 Sep;115(9):716–31 (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Classification and structure–activity relationships of fluoroquinolones. Bryskier A, et al. **Drugs** 1995;49 Suppl 2:16–28 (27 ref.)

ECONOMICS

Preference for costly fluoroquinolones by casual workers and daily wage earners in developing countries. Arya SC. **Drugs** 1995;49 Suppl 2:499–500

Decreased fluoroquinolone use with a pharmacy service–pharmaceutical company partnership. North DS. **Drugs** 1995;49 Suppl 2:501–3

IMMUNOLOGY

[Antigenicity studies of prulifloxacin (NM441)] Tateda C, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:231–9 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Investigation of enantioselective separation of quinolonecarboxylic acids by capillary zone electrophoresis using vancomycin as a chiral selector. Arai T, et al. **J Chromatogr A** 1996 Jun 7;736(1–2):303–11

METABOLISM

Intracellular accumulation of norfloxacin in Mycobacterium smegmatis. Corti S, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2466–71

DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase–DNA complex. Critchlow SE, et al. **Biochemistry** 1996 Jun 11;35(23):7387–93

Sparfloxacin secretion across Caco–2 cells involves a multidrug resistance–like mechanism. Cormet E, et al. **Drugs** 1995;49 Suppl 2:307–9

Uptake of ciprofloxacin in methicillin–resistant Staphylococcus aureus. Zhang YX, et al. **Drugs** 1995;49 Suppl 2:192–3

Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. Liu J, et al. **J Bacteriol** 1996 Jul;178(13):3791–5

PHARMACOKINETICS

Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring. Aramayona JJ, et al. **Am J Vet Res** 1996 Apr;57(4):547–53

Sustained release of liposome–encapsulated enrofloxacin after intramuscular administration in rabbits. Cabanes A, et al. **Am J Vet Res** 1995 Nov;56(11):1498–501

Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. Meinen JB, et al. **Am J Vet Res** 1995 Sep;56(9):1219–24

Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? Cooke CE, et al. **Ann Pharmacother** 1996 Apr;30(4):364–6

Open–label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Child J, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2749–51

Effects of traditional Chinese medicines on pharmacokinetics of levofloxacin. Hasegawa T, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2135–7

Single– and multiple–dose pharmacokinetics of AM–1155, a new 6–fluoro–8–methoxy quinolone, in humans. Nakashima M, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2635–40

Pharmacokinetic study of fibrin clot–ciprofloxacin complex: an in vitro and in vivo experimental investigation. Tsourvakas S, et al. **Arch Orthop Trauma Surg** 1995; 114(5):295–7

Increased norfloxacin skin permeability for fatty alcohol propylene glycol (FAPG) ointment by optimized process of preparation: behavior of stearic acid in stratum corneum lipids. Lin HH, et al. **Biol Pharm Bull** 1995 Nov; 18(11):1560–5

Evaluation of the effects of ambroxol on the ofloxacin concentrations in bronchial tissues in COPD patients with infectious exacerbation. Paganin F, et al. **Biopharm Drug Dispos** 1995 Jul;16(5):393–401

Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Jaehde U, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):532–41

Iron–ovotransferrin preparation does not interfere with ciprofloxacin absorption. Pazzucconi F, et al. **Clin Pharmacol Ther** 1996 Apr;59(4):418–22

Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12–h cefotaxime alone and in combination with other antibiotics. Nix DE, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):71–6

Antimicrobial activity, pharmacokinetics and clinical studies of balofloxacin (Q–35) in obstetrics and gynaecology. Cho N, et al. **Drugs** 1995;49 Suppl 2:391–2

Comparison of models for studying the intestinal elimination of ciprofloxacin in the rat. Dautrey S, et al. **Drugs** 1995; 49 Suppl 2:310–1

Pharmacokinetics of ofloxacin––measurement of drug concentration in saliva of patients with impaired renal function. Fujita K, et al. **Drugs** 1995;49 Suppl 2:312–3

Differences between albino and pigmented rabbit eyes in the intraocular pharmacokinetics of sparfloxacin. Fukuda M, et al. **Drugs** 1995;49 Suppl 2:314–6

Comparative assessment of the pharmacokinetics and pharmacodynamics of ciprofloxacin after single i.v. doses of 200 and 400mg. Garraffo R, et al. **Drugs** 1995;49 Suppl 2:317–20

The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers. Hoogkamer JF, et al. **Drugs** 1995;49 Suppl 2:346–8

Pharmacokinetics of CFC–222 in animals. Jung YH, et al. **Drugs** 1995;49 Suppl 2:321–2

Effect of ferrous sulfate on the absorption of sparfloxacin in healthy volunteers and rats. Kanemitsu K, et al. **Drugs** 1995;49 Suppl 2:352–6

Pharmacokinetic study of a new quinolone, DW–116. Lee DK. **Drugs** 1995;49 Suppl 2:323–5

Clinical experience with OPC–17116 in the treatment of gynaecological infections and its penetration into gynaecological tissues. Japanese Collaborative Study Group of OPC–17116 in Gynaecology. Matsuda S. **Drugs** 1995;49 Suppl 2:395–8

NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients. Mikamo H, et al. **Drugs** 1995;49 Suppl 2:326–30

Excretion of new quinolones and their glucuronide conjugates into human bile. Murakami K, et al. **Drugs** 1995; 49 Suppl 2:331–2

Levofloxacin: penetration into sputum and once–daily treatment of respiratory tract infections. Nakamori Y, et al. **Drugs** 1995;49 Suppl 2:418–9

Stereoselectivity of ofloxacin intestinal transport in the rat. Rabbaa L, et al. **Drugs** 1995;49 Suppl 2:333–4

Pharmacokinetics of T–3761 in healthy volunteers. Saito A. **Drugs** 1995;49 Suppl 2:335–6

Effects of antacid on absorption and excretion of new quinolones. Shiba K, et al. **Drugs** 1995;49 Suppl 2:360–1

Penetration of NM441, a new quinolone, into human bile and gallbladder tissue. Tanimura H, et al. **Drugs** 1995;49 Suppl 2:337–40

Gallbladder tissue concentrations, biliary excretion and pharmacokinetics of OPC–17116. Tanimura H, et al. **Drugs** 1995;49 Suppl 2:341–3

The pharmacokinetics and distribution of ofloxacin into the lower respiratory tract. Walstad RA, et al. **Drugs** 1995;49 Suppl 2:344–5

Cimetidine does not alter sparfloxacin pharmacokinetics. Gries JM, et al. **Int J Clin Pharmacol Ther** 1995 Nov; 33(11):585–7

A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. Madaras–Kelly KJ, et al. **J Antimicrob Chemother** 1996 Apr;37(4):703–10

Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. Mizuki Y, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:41–55 (46 ref.)

Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. Montay G. **J Antimicrob Chemother** 1996 May;37 Suppl A:27–39 (20 ref.)

Pharmacokinetics and safety of trovafloxacin (CP–99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Teng R, et al. **J Antimicrob Chemother** 1995 Aug;36(2):385–94

A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. Wise R, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:57–63 (18 ref.)

Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed–phase high–performance liquid chromatography. Teng R, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):53–9

Availability of 0.3% ofloxacin ointment and solution in human conjunctiva and aqueous humor. Tang–Liu D, et al. **J Ocul Pharmacol Ther** 1995 Spring;11(1):57–63

Biophysical models as an approach to study passive absorption in drug development: 6–fluoroquinolones. Merino V, et al. **J Pharm Sci** 1995 Jun;84(6):777–82

A randomized prospective comparison of antibiotic tissue levels in the corpora cavernosa of patients undergoing penile prosthesis implantation using gentamicin plus cefazolin versus an oral fluoroquinolone for prophylaxis. Schwartz BF, et al. **J Urol** 1996 Sep;156(3):991–4

Effect of water deprivation on the disposition kinetics of enrofloxacin in camels. Gavrielli R, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):333–9

Pharmacokinetics of enrofloxacin after single intravenous,

intramuscular and subcutaneous injections in lactating cows. Kaartinen L, et al. **J Vet Pharmacol Ther** 1995 Oct; 18(5):357–62

Ofloxacin concentrations in serum, saliva and pleural effusion of patients with pulmonary tuberculosis and lung cancer. Miya T, et al. **Jpn J Antibiot** 1995 Jul;48(7):960–4

Pharmacokinetics of topically applied ciprofloxacin in rabbit tears. Green LC, et al. **Jpn J Ophthalmol** 1996;40(1):123–6

Penetration of topical 0.3% ciprofloxacin into human aqueous humor. Kalayci D, et al. **Ophthalmic Surg Lasers** 1996 Jan; 27(1):21–4

The intestinal transport mechanism of fluoroquinolones: inhibitory effect of ciprofloxacin, an enoxacin derivative, on the membrane potential–dependent uptake of enoxacin. Hirano T, et al. **Pharm Res** 1995 Sep;12(9):1299–303

Characterization of the transport properties of a quinolone antibiotic, fleroxacin, in rat choroid plexus. Ooie T, et al. **Pharm Res** 1996 Apr;13(4):523–7

Pharmacokinetics and tolerance of a new fluoroquinolone antimicrobial drug after single oral doses in healthy volunteers. Tanaka M, et al. **Xenobiotica** 1995 Nov; 25(10):1119–25

Ciprofloxacin pharmacokinetics in dogs following oral administration. Abadia AR, et al.
Zentralbl Veterinarmed A 1995 Oct;42(8):505–11

[Excretion of fluoroquinolones into saliva] Kelentey BA, et al. **Fogorv Sz** 1995 Sep;88(9):293–7 (Eng. Abstr.) **(Hun)**

[Pharmacokinetic study of sparfloxacin in patients receiving regular hemodialysis] Aoki N, et al. **Jpn J Antibiot** 1995 Aug;48(8):999–1002 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetics of balofloxacin in the intraocular tissues of pigmented rabbits] Ooishi M, et al. **Jpn J Antibiot** 1995 Sep;48(9):1274–80 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis] Sato H, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jul;100(7):513–9 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetics of fluoroquinolones in patients with renal insufficiency] Iakovlev SV, et al. **Antibiot Khimioter** 1995 Oct;40(10):39–47 (57 ref.) **(Rus)**

[Lomefloxacin pharmacokinetics in patients in the terminal stage of chronic renal insufficiency, undergoing treatment with programmed hemodialysis] Kolendo SE, et al. **Antibiot Khimioter** 1995 Mar;40(3):47–51 (Eng. Abstr.) **(Rus)**

[Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis] Cotera A, et al. **Rev Med Chil** 1995 Jun;123(6):742–8 (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: epidemiology and risk factors [see comments] Gordon SM, et al. **Ann Intern Med** 1996 Sep 15;125(6):465–70. Comment in: Ann Intern Med 1996 Sep 15;125(6):507–9.

Antibiotic–resistant neisseria gonorrhoeae: the calm before another storm? [editorial; comment] Hansfield HH, et al. **Ann Intern Med** 1996 Sep 15;125(6):507–9. Comment on: Ann Intern Med 1996 Sep 15;125(6):465–70.

Characterization of fluoroquinolone–resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Alangaden GJ, et al.
Antimicrob Agents Chemother 1995 Aug;39(8):1700–3

In vitro evaluation of DV–7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram–positive aerobic organisms and anaerobes. Biedenbach DJ, et al.
Antimicrob Agents Chemother 1995 Jul;39(7):1636–42

Antimicrobial activity of CS–940, a new trifluorinated quinolone. Biedenbach DJ, et al.
Antimicrob Agents Chemother 1995 Oct;39(10):2325–30

In vitro activities of ciprofloxacin, cefotaxime, ceftriaxone, chloramphenicol, and rifampin against fully susceptible and moderately penicillin–resistant Neisseria meningitidis. Blondeau JM, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2577–9

Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Cambau E, et al.
Antimicrob Agents Chemother 1995 Oct;39(10):2248–52

Activities of three investigational fluoroquinolones (BAY y 3118, DU–6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin. Carlyn CJ, et al.
Antimicrob Agents Chemother 1995 Jul;39(7):1606–8

In vitro and in vivo activities of clinafloxacin, CI–990 (PD 131112), and PD 138312 versus enterococci. Cohen MA, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2123–7

Quinolone–resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Deguchi T, et al.
Antimicrob Agents Chemother 1996 Apr;40(4):1020–3

In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae. Dhople AM, et al. **Antimicrob Agents Chemother** 1995 Sep; 39(9):2116–9

Genetic evidence for a role of parC mutations in development of high–level fluoroquinolone resistance in Escherichia coli. Heisig P. **Antimicrob Agents Chemother** 1996 Apr; 40(4):879–85

Intracellular activities of RP 59500 (quinupristin–dalfopristin) and sparfloxacin against Enterococcus faecium. Herrera–Insúa I, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):886–90

Improved bactericidal activity of Q–35 against quinolone–resistant staphylococci. Ito T, et al.
Antimicrob Agents Chemother 1995 Jul;39(7):1522–5

Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP–99,219). Kenny GE, et al.
Antimicrob Agents Chemother 1996 Apr;40(4):1048–9

Contribution of the C–8 substituent of DU–6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Kitamura A, et al.
Antimicrob Agents Chemother 1995 Jul;39(7):1467–71

Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. Klepser ME, et al.
Antimicrob Agents Chemother 1995 Nov;39(11):2503–10

Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin. Knapp JS, et al.
Antimicrob Agents Chemother 1995 Nov;39(11):2442–5

Antibacterial action of ciprofloxacin. Mason DJ, et al.
Antimicrob Agents Chemother 1995 Dec;39(12):2752–8

Sequence of quinolone resistance–determining region of gyrA gene for clinical isolates and for an in vitro–selected quinolone–resistant strain of Coxiella burnetii. Musso D, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):870–3

In vitro and in vivo antifungal activities of DU–6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Nakajima R, et al.
Antimicrob Agents Chemother 1995 Jul;39(7):1517–21

In vitro antibacterial activity of DU–6859a, a new fluoroquinolone. Nakane T, et al.
Antimicrob Agents Chemother 1995 Dec;39(12):2822–6

Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity. Nassar F, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2490–3

Detection of gyrA and gyrB mutations in quinolone–resistant clinical isolates of Escherichia coli by single–strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Ouabdesselam S, et al.
Antimicrob Agents Chemother 1995 Aug;39(8):1667–70

Fluconazole resistance due to energy–dependent drug efflux in Candida glabrata. Parkinson T, et al.
Antimicrob Agents Chemother 1995 Aug;39(8):1696–9

Salmonella typhimurium gyrA mutations associated with fluoroquinolone resistance. Reyna F, et al.
Antimicrob Agents Chemother 1995 Jul;39(7):1621–3

Emergence of in vitro resistance to fluoroquinolones in Neisseria gonorrhoeae isolated in Japan. Tanaka M, et al.
Antimicrob Agents Chemother 1995 Oct;39(10):2367–70

Modulation of biofilms of Pseudomonas aeruginosa by quinolones. Yassien M, et al.
Antimicrob Agents Chemother 1995 Oct;39(10):2262–8

Effects cn growth of single short courses of fluoroquinolones. Bethell DB, et al. **Arch Dis Child** 1996 Jan;74(1):44–6

Dose titration study of enrofloxacin (Baytril) against respiratory colibacillosis in Muscovy ducks. Kempf I, et al. **Avian Dis** 1995 Jul–Sep;39(3):480–8

Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis. Banerjee SK, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):362–8

Enoxacin is an inducer of CYP1A2 in rat liver. Schulz TG, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1517–20

Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in British Columbia: an imported phenomenon. Patrick D, et al. **Can Commun Dis Rep** 1995 Aug 15;21(15):137–9 **(Eng, Fre)**

Studies on pyridonecarboxylic acids. IV. Synthesis and antibacterial activity evaluation of S–(–)– and R–(+)–6–fluoro–1–methyl–4–oxo–7–(1–piperazinyl)–4H–[1,3]thiazeto[3,2–a]quinoline–3–carboxylic acids. Segawa J, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1238–40

Studies on quinolone antibacterials. V. Synthesis and antibacterial activity of chiral 5–amino–7–(4–substituted–3–amino–1–pyrrolidinyl)–6–fluoro–1,4–dihydro–8–methyl–4–oxoquinoline–3–carboxylic acids and derivatives. Yoshida T, et al.
Chem Pharm Bull (Tokyo) 1996 Jul;44(7):1376–86

Impact of rufloxacin and ciprofloxacin on the intestinal microflora in a germ–free mice model. Gismondo MR, et al. **Chemotherapy** 1995 Jul–Aug;41(4):281–8

Bactericidal activity, morphological alterations, and synergistic interactions of rufloxacin, a new fluoroquinolone, alone and in combination with its N–desmethylate D derivative (MF 922). Marchese A, et al. **Chemotherapy** 1996 Mar–Apr;42(2):90–9

A multicenter comparative study of the in vitro activity of fleroxacin and other antimicrobial agents. Markowitz SM, et al. **Chemotherapy** 1995 Nov–Dec;41(6):477–86

An in vitro investigation of the bioactivities of ciprofloxacin and the new fluoroquinolone agents clinafloxacin (CI–960) and PD 131628 against Mycobacterium tuberculosis in human macrophages. Van Rensburg CE, et al.
Chemotherapy 1995 Jul–Aug;41(4):234–8

Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Musser JM. **Clin Microbiol Rev** 1995 Oct; 8(4):496–514 (181 ref.)

Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation. McLellan RA, et al. **Clin Pharmacol Ther** 1995 Sep; 58(3):322–7

Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone–resistant isolates. Cormican MG, et al.
Diagn Microbiol Infect Dis 1995 Apr;21(4):227–30

Multi–center validation of proposed disk diffusion susceptibility testing interpretive criteria for lomefloxacin using more than 1,500 clinical isolates. Cormican MG, et al. **Diagn Microbiol Infect Dis** 1996 Mar;24(3):169–72

Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI–960, AM–1091, PD127371) and fleroxacin (Ro 23–6240, AM–833) following studies with a challenge panel of ciprofloxacin–resistant clinical isolates. Jones RN, et al. **Diagn Microbiol Infect Dis** 1995 Apr; 21(4):209–13

Comparison of susceptibility to extended–spectrum beta–lactam antibiotics and ciprofloxacin among gram–negative bacilli isolated from intensive care units. Liu PY, et al. **Diagn Microbiol Infect Dis** 1995 Jul; 22(3):285–91

Classification and structure–activity relationships of fluoroquinolones. Bryskier A, et al. **Drugs** 1995;49 Suppl 2:16–28 (27 ref.)

Changes in susceptibility to ciprofloxacin in a community in northern Israel. Cahana Z, et al. **Drugs** 1995;49 Suppl 2:173–4

Ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa from Italian patients. Corti G, et al. **Drugs** 1995; 49 Suppl 2:175–6

Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae. Dalhoff A. **Drugs** 1995;49 Suppl 2:194–6

Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Davis R, et al.
Drugs 1996 Jun;51(6):1019–74 (517 ref.)

In vitro activity of fluoroquinolones against gram–positive bacteria. Eliopoulos GM. **Drugs** 1995;49 Suppl 2:48–57 (37 ref.)

Expression of beta 1–integrins on epiphyseal chondrocytes is reduced by ofloxacin. Förster C, et al. **Drugs** 1995;49 Suppl 2:279–82

In vitro susceptibility to ciprofloxacin of bacterial strains isolated from chronic otitis media and chronic sinusitis. Gaillot O, et al. **Drugs** 1995;49 Suppl 2:200–2

Comparative in vitro activity of ciprofloxacin vs 8 antimicrobial agents against nosocomial multiresistant P. aeruginosa strains. Giamarellos–Bourboulis EJ, et al.
Drugs 1995;49 Suppl 2:203–4

In vitro antimicrobial activity of CP–99,219, a new 7–azabicyclonaphthyridone. Jones RN. **Drugs** 1995;49 Suppl 2:205–7

Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres. Jones RN, et al. **Drugs** 1995;49 Suppl 2:179–81

Evaluation of the anti–rickettsial activity of fluoroquinolones. Keren G, et al. **Drugs** 1995;49 Suppl 2:208–10

Susceptibility of bacterial isolates from complicated skin and skin structure infections to cefazolin, imipenem–cilastatin, ciprofloxacin and ofloxacin. Liu HH, et al. **Drugs** 1995;49 Suppl 2:215–8

Effect of inhibitors of protein kinase C on enhanced superoxide production of human leucocytes by ofloxacin and fleroxacin. Matsumoto T, et al. **Drugs** 1995;49 Suppl 2:286–8

Restorative effect of ofloxacin on inhibited chemiluminescence response of PMNs by sera from uraemic patients. Matsumoto T, et al. **Drugs** 1995;49 Suppl 2:289–90

NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients. Mikamo H, et al. **Drugs** 1995;49 Suppl 2:326–30

Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones. Molinari G, et al. **Drugs** 1995;49 Suppl 2:222–5

The new 4–quinolones DU–6859a and DV–7751a show enhanced activity against Streptococcus pneumoniae. Morrissey I, et al. **Drugs** 1995;49 Suppl 2:228–9

The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine. Nicolau DP, et al. **Drugs** 1995;49 Suppl 2:357–9

In vitro activity of nadifloxacin against both methicillin–susceptible and –resistant clinical isolates of Staphylococcus aureus from patients with skin infections. Nishijima S, et al. **Drugs** 1995;49 Suppl 2:230–2

Activity of DU–6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC–17116 against 112 penicillin–susceptible and –resistant pneumococci. Pankuch GA, et al. **Drugs** 1995;49 Suppl 2:235–7

The antimicrobial activity of sparfloxacin, a new quinolone. Paradelis AG, et al. **Drugs** 1995;49 Suppl 2:238–9

In vitro and in vivo antibacterial activities of CFC–222, a novel broad spectrum fluoroquinolone. Park KH, et al.
Drugs 1995;49 Suppl 2:240–2

Mechanisms of resistance to fluoroquinolones: state–of–the–art 1992–1994. Piddock LJ. **Drugs** 1995;49 Suppl 2:29–35 (27 ref.)

In vitro susceptibility of mycoplasmas to a new quinolone,

BAY Y 3118. Renaudin H, et al. **Drugs** 1995;49 Suppl 2:243–5

In vitro activity of ofloxacin, ciprofloxacin, and cefoperazone alone and in combination against Xanthomonas maltophilia. Ristow TA, et al. **Drugs** 1995;49 Suppl 2:246–9

In vitro and in vivo activities of sparfloxacin in Legionella infections. Saito A, et al. **Drugs** 1995;49 Suppl 2:250–2

Ofloxacin alters expression of integrins on chondrocytes from mouse fetuses in vitro. Shakibaei M, et al. **Drugs** 1995;49 Suppl 2:293–5

In vitro effect of ciprofloxacin and ofloxacin on murine and human colon carcinoma cell lines. Shalit I, et al. **Drugs** 1995;49 Suppl 2:296–7

In vitro activity of sparfloxacin against selected gram-negative blood culture isolates. Siristonpun Y, et al. **Drugs** 1995;49 Suppl 2:256

Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections. Soejima R, et al. **Drugs** 1995;49 Suppl 2:257–9

In vitro activity and clinical efficacy of ciprofloxacin in otorhinolaryngeal infections. Speciale A, et al. **Drugs** 1995; 49 Suppl 2:403–5

Fluoroquinolone resistance patterns after formulary addition of ofloxacin. A clinical isolate study. Stein GE. **Drugs** 1995; 49 Suppl 2:188–9

Effect of ciprofloxacin on cholinergic neuro-effector transmission in airway smooth muscle. Tamaoki J, et al. **Drugs** 1995;49 Suppl 2:298–300

Comparative in vitro activity of BAY Y 3118 against selected species. Verbist L, et al. **Drugs** 1995;49 Suppl 2:264–5

Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris. Vogt K, et al. **Drugs** 1995;49 Suppl 2:266–8

Effect of ciprofloxacin and other quinolones on granulocyte function assessed by flow cytometry. Wenisch C, et al. **Drugs** 1995;49 Suppl 2:301–3

In vitro antibacterial activity of levofloxacin. Zhang YY, et al. **Drugs** 1995;49 Suppl 2:274–5

In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin. Mirelis B, et al. **Drugs Exp Clin Res** 1995; 21(4):129–38

Multicenter Spanish study of ciprofloxacin susceptibility in gram-negative bacteria. The Spanish Study Group on Quinolone Resistance. García-Rodríguez JA, et al. **Eur J Clin Microbiol Infect Dis** 1995 May;14(5):456–9

Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients. Gimeno C, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jan;15(1):82–5

A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium. Gensberg K, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1-2):57–60

Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock. Llovet JM, et al. **Hepatology** 1996 Apr; 23(4):781–7

Ciprofloxacin prevents the inhibitory effects of acute ethanol exposure on hepatic regeneration in the rat. Minuk GY, et al. **Hepatology** 1995 Dec;22(6):1797–800

Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States [letter; comment] Blumberg HM, et al. **Infect Control Hosp Epidemiol** 1995 Nov;16(11):620–1. Comment on: Infect Control Hosp Epidemiol 1995 Feb;16(2):71–5.

Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens. Jenkins SG, et al. **Infection** 1995 May-Jun;23(3):154–61

Determination of the minimal effective dosages of ofloxacin and sparfloxacin against M. leprae in the mouse foot pad system. Traore I, et al. **Int J Lepr Other Mycobact Dis** 1996 Jun;64(2):142–5

In vitro effects of aminoglycosides and fluoroquinolones on keratocytes. Seitz B, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):656–65

Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates. Murphy SP, et al. **Ir J Med Sci** 1995 Oct-Dec;164(4):271–3

In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. Baquero F, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:1–18 (76 ref.)

In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits. Barry AL, et al. **J Antimicrob Chemother** 1996 Feb;37(2):365–9

Activity of CI-960 alone and in combination with amoxycillin against Listeria monocytogenes, and comparison with other quinolones. Boisivon A, et al. **J Antimicrob Chemother** 1995 Sep;36(3):527–30

Mutations of the gyrA gene of clinical isolates of Salmonella typhimurium and three other Salmonella species leading to decreased susceptibilities to 4-quinolone drugs. Brown JC, et al. **J Antimicrob Chemother** 1996 Feb;37(2):351–6

In-vitro activity of trovafloxacin (CP99,219) tested by two methods against 150 vancomycin-resistant enterococcal isolates [letter] Cormican MG, et al. **J Antimicrob Chemother** 1996 Apr;37(4):847–9

Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria. Cormican MG, et al. **J Antimicrob Chemother** 1995 Aug; 36(2):431–4

Lower respiratory tract infection due to ciprofloxacin resistant Moraxella catarrhalis [letter] Cunliffe NA, et al. **J Antimicrob Chemother** 1995 Jul;36(1):273–4

In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. Edelstein PH, et al. **J Antimicrob Chemother** 1996 Jan; 37(1):117–26

Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. Fass RJ, et al. **J Antimicrob Chemother** 1995 Aug;36(2):343–53

Increasing ciprofloxacin resistance in salmonellas in England and Wales 1991–1994. Frost JA, et al. **J Antimicrob Chemother** 1996 Jan;37(1):85–91

Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. Gaunt PN, et al. **J Antimicrob Chemother** 1996 Apr;37(4):747–57

Antibacterial properties of AM-1155, a new 8-methoxy quinolone. Hosaka M, et al. **J Antimicrob Chemother** 1995 Aug;36(2):293–301

SYN987, SYN1193, and SYN1253, new quinolones highly active against gram-positive cocci. Kitzis MD, et al. **J Antimicrob Chemother** 1995 Jul;36(1):209–13

In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae [letter] Klugman K, et al. **J Antimicrob Chemother** 1995 Nov;36(5):873–4

Comparison of rufloxacin and norfloxacin effects on faecal flora. Marco F, et al. **J Antimicrob Chemother** 1995 Jun; 35(6):895–901

Activity of sparfloxacin on Staphylococcus epidermidis attached to plastic catheters. Pascual A, et al. **J Antimicrob Chemother** 1995 Aug;36(2):425–30

Comparative in-vitro activity of sparfloxacin against genital pathogens. Perea EJ, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:19–25

Comparative in-vitro activity of sparfloxacin and eight other antimicrobial agents against clinical isolates of non-tuberculous mycobacteria. Sánchez-Carrillo C, et al. **J Antimicrob Chemother** 1996 Jan;37(1):151–4

Comparative in-vitro activity of CP-99219, a new quinolone, against respiratory pathogens. Sefton AM, et al. **J Antimicrob Chemother** 1996 Apr;37(4):803–8

Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)). Sewell DL, et al. **J Antimicrob Chemother** 1996 Jan;37(1):139–43

Ofloxacin, norfloxacin and ceftazidime increase the production of alginate and promote the formation of biofilm of Pseudomonas aeruginosa in vitro [letter] Takahashi A, et al. **J Antimicrob Chemother** 1995 Oct;36(4):743–5

Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology. Visalli MA, et al. **J Antimicrob Chemother** 1996 Jan; 37(1):77–84

Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. Pan XS, et al. **J Bacteriol** 1996 Jul;178(14):4060–9

In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria. García-Rodríguez JA, et al. **J Chemother** 1995 Jun;7(3):189–96

Effects of lomefloxacin and sparfloxacin on human platelet aggregation. Losasso C, et al. **J Chemother** 1995 Oct; 7(5):420–3

In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. Moneib NA. **J Chemother** 1995 Dec; 7(6):525–9

Detection of ciprofloxacin resistance mutations in Campylobacter jejuni gyrA by nonradioisotopic single-strand conformation polymorphism and direct DNA sequencing. Charvalos E, et al. **J Clin Lab Anal** 1996; 10(3):129–33

Low incidence of quinolone resistance in gram-negative bacteria after five-years use of ofloxacin in prophylaxis during afebrile neutropenia [letter; comment] Kunova A, et al. **J Hosp Infect** 1996 Feb;32(2):155–6. Comment on: J Hosp Infect 1995 Jan;29(1):19–33.

Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones. Nishijima S, et al. **J Int Med Res** 1996 Jan-Feb;24(1):12–6

Quinolones: structure-activity relationships and future predictions. Tillotson GS. **J Med Microbiol** 1996 May; 44(5):320–4 (19 ref.)

Impairment of phagocytic cell respiratory burst by UVA in the presence of fluoroquinolones: an oxygen-dependent phototoxic damage to cell surface microvilli. Saniabadi AR, et al. **J Photochem Photobiol B** 1996 Apr;33(2):137–42

Enrofloxacin-theophylline interaction: influence of enrofloxacin on theophylline steady-state pharmacokinetics in the beagle dog. Intorre L, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):352–6

The effects of enrofloxacin on hepatic microsomal mixed function oxidases in broiler chickens. Shlosberg A, et al. **J Vet Pharmacol Ther** 1995 Aug;18(4):311–3

In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone. Imamori K, et al. **Jpn J Antibiot** 1995 Dec;48(12):1891–8

High-level ciprofloxacin-resistant Neisseria gonorrhoeae and heterosexually acquired infections in Victoria [letter] Griffith JM, et al. **Med J Aust** 1996 Jan 15;164(2):125

Establishment of a national surveillance program for antimicrobial resistance in Salmonella. **MMWR Morb Mortal Wkly Rep** 1996 Feb 9;45(5):110–1

Fluoroquinolone resistance in Neisseria gonorrhoeae—Colorado and Washington, 1995. **MMWR Morb Mortal Wkly Rep** 1995 Oct 20;44(41):761–4

Ciprofloxacin resistant Neisseria gonorrhoea in New Zealand [letter] Coughlan EP, et al. **N Z Med J** 1996 Mar 8; 109(1017):82

A patch clamp study of the effects of ciprofloxacin and biphenyl acetic acid on rat hippocampal neurone GABAA and ionotropic glutamate receptors. Halliwell RF, et al. **Neuropharmacology** 1995 Dec;34(12):1615–24

The intestinal transport mechanism of fluoroquinolones: inhibitory effect of ciprofloxacin, an enoxacin derivative, on the membrane potential-dependent uptake of enoxacin. Hirano T, et al. **Pharm Res** 1995 Sep;12(9):1299–303

Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Takiff HE, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):362–6

Resistance to quinolones in mycobacteria. Cambau E, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):52–9 (41 ref.)

Antimycobacterial quinolones: a comparative analysis of structure-activity and structure-cytotoxicity relationships. Klopman G, et al. **Res Microbiol** 1996 Jan-Feb; 147(1-2):86–96 (32 ref.)

In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Saito H, et al. **Tuber Lung Dis** 1995 Oct;76(5):377–80

Metabolism of theophylline and its inhibition by fluoroquinolones in rat hepatic microsomes. Davis JD, et al. **Xenobiotica** 1995 Jun;25(6):563–73

[Comparative study of minimal inhibiting concentrations of doxycycline, ofloxacin and erythromycin against 18 recent isolates from Chlamydia trachomatis (1994–1995)] Bianchi A, et al. **Pathol Biol (Paris)** 1996 May;44(5):347–50 (Eng. Abstr.) **(Fre)**

[In vitro activity of a new fluoroquinolone, marbofloxacin (RO 09-1168) against strictly anaerobic bacteria and some bacteria from human fecal flora] Dubreuil L, et al. **Pathol Biol (Paris)** 1996 May;44(5):333–6 (Eng. Abstr.) **(Fre)**

[In vitro activity of a new quinolone, NM 394, against Chlamydia trachomatis] Poutiers F, et al. **Pathol Biol (Paris)** 1996 May;44(5):351–4 (Eng. Abstr.) **(Fre)**

[Antimicrobial activities of norfloxacin against clinical isolates from ocular infections] Koguchi M, et al. **Jpn J Antibiot** 1995 Aug;48(8):1009–25 (Eng. Abstr.) **(Jpn)**

[Activities of antipseudomonal agents against clinical isolates of Pseudomonas aeruginosa] Murase M, et al. **Jpn J Antibiot** 1995 Oct;48(10):1581–9 (Eng. Abstr.) **(Jpn)**

[In vitro antibacterial activity of balofloxacin (BLFX) against isolates from patients with bacterial enteritis] Fukuyama M, et al. **Kansenshogaku Zasshi** 1995 Sep;69(9):987–90 (Eng. Abstr.) **(Jpn)**

[In vitro antimicrobial activity of a new quinolone, levofloxacin, against atypical mycobacteria] Oya S, et al. **Kekkaku** 1995 Nov;70(11):615–9 (Eng. Abstr.) **(Jpn)**

[Sensitivity of Yersinia pseudotuberculosis to pefloxacin] Zaĭtseva EA, et al. **Antibiot Khimioter** 1995 Jul;40(7):22–4 (Eng. Abstr.) **(Rus)**

[Postantibiotic effects and postantibiotic effects of subinhibitory levels of quinolines on Pseudomonas aeruginosa] Hoštacká A. **Epidemiol Mikrobiol Imunol** 1996 May;45(2):56–8 (Eng. Abstr.) **(Slo)**

[The effect of subinhibitory concentrations of norfloxacin, erythromycin and roxithromycin on Pseudomonas aeruginosa virulence factors] Hoštacká A. **Epidemiol Mikrobiol Imunol** 1995 Sep;44(3):115–7 (Eng. Abstr.) **(Slo)**

[Mechanism of action and resistance to fluoroquinolones] Alarcón T, et al. **Enferm Infecc Microbiol Clin** 1996 Feb; 14(2):111–7 (83 ref.) **(Spa)**

[Septic shock caused by Escherichia coli resistant to a ciprofloxacin after extracorporeal shockwave lithotripsy (letter)] Angel Blasco M, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):128–9 **(Spa)**

[Isolation of a strain of Campylobacter jejuni resistant to fluoroquinolones and sensitive to nalidixic acid (letter)] Reina J, et al. **Enferm Infecc Microbiol Clin** 1996 Feb; 14(2):124–5 **(Spa)**

RADIATION EFFECTS

Photodegradation of fluoroquinolones using a continuous-flow photochemical reaction unit [letter] McMullin CM, et al. **J Antimicrob Chemother** 1996 Feb; 37(2):392–4

ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE

THERAPEUTIC USE

New options for spontaneous bacterial prophylaxis: costly or cost effective? Levy MJ, et al. **Am J Gastroenterol** 1996 May;91(5):1050–1

Fluoroquinolone use for acute cystitis in an IPA–model managed care organization. Aforismo JF, et al. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2702–4

Fluoroquinolones in the treatment of bacterial keratitis. Bower KS, et al. **Am J Ophthalmol** 1996 Jun;121(6):712–5

Ofloxacin eardrop treatment for active chronic suppurative otitis media: prospective randomized study. Yuen PW, et al. **Am J Otol** 1994 Sep;15(5):670–3

Efficacy of ciprofloxacin in enteric fever: comparison of treatment duration in sensitive and multidrug–resistant Salmonella. Alam MN, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):306–11

Short report: pefloxacin does not potentiate quinine efficacy against Plasmodium falciparum malaria. Deloron P, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):646–7

Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. Meinen JB, et al. **Am J Vet Res** 1995 Sep;56(9):1219–24

Comparing the efficacy of pefloxacin and ciprofloxacin in the treatment of acute uncomplicated gonococcal urethritis in males. Leow YH, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):515–8

Quinolone–based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram–positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Bow EJ, et al. **Ann Intern Med** 1996 Aug 1;125(3):183–90

Enrofloxacin to control Anaplasma marginale infections. Guglielmone AA, et al. **Ann N Y Acad Sci** 1996 Jul 23; 791:471–2

Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin. Porco FV, et al. **Ann Pharmacother** 1995 Nov;29(11):1122–3

Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra–abdominal infections. The Intra–Abdominal Infection Study Group. Solomkin JS, et al. **Ann Surg** 1996 Mar;223(3):303–15

Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. Atkinson BA, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2316–9

Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign–body infection by methicillin–resistant Staphylococcus aureus. Cagni A, et al. **Antimicrob Agents Chemother** 1995 Aug; 39(8):1655–60

In vivo efficacy of trovafloxacin (CP–99,219), a new quinolone with extended activities against gram–positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Girard AE, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2210–6

Evaluation of CP–99,219, a new fluoroquinolone, for treatment of experimental penicillin– and cephalosporin–resistant pneumococcal meningitis. París MM, et al. **Antimicrob Agents Chemother** 1995 Jun; 39(6):1243–6

In vivo therapeutic efficacies of PD 138312 and PD 140248, two novel fluoronaphthyridines with outstanding gram–positive potency. Shapiro MA, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2183–6

Two or three days of ofloxacin treatment for uncomplicated multidrug–resistant typhoid fever in children. Vinh H, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):958–61

Uncomplicate the treatment of uncomplicated urinary tract infections [letter; comment] Ditmanson LF, et al. **Arch Intern Med** 1996 Jan 8;156(1):111–3. Comment on: Arch Intern Med 1995 Mar 13;155(5):485–94.

Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis [letter] Baker RS, et al. **Arch Ophthalmol** 1996 May;114(5):632–3

Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. O'Brien TP, et al. **Arch Ophthalmol** 1995 Oct;113(10):1257–65

Evaluation of enrofloxacin against egg transmission of Mycoplasma gallisepticum. Ortiz A, et al. **Avian Dis** 1995 Oct–Dec;39(4):830–6

Infection after transrectal core biopsies of the prostate—risk factors and antibiotic prophylaxis. Aus G, et al. **Br J Urol** 1996 Jun;77(6):851–5

Comparison of oral ciprofloxacin and amoxycillin in treating infective exacerbations of bronchiectasis in Hong Kong. Chan TH, et al. **Chemotherapy** 1996 Mar–Apr;42(2):150–6

Sparfloxacin therapy for experimental endocarditis caused by methicillin–resistant Staphylococcus aureus. Maserati R, et al. **Chemotherapy** 1996 Mar–Apr;42(2):133–9

Therapeutic efficacy of intravenous and oral ciprofloxacin in experimental murine infections. Nishino T, et al. **Chemotherapy** 1996 Mar–Apr;42(2):140–5

Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Kuschner RA, et al. **Clin Infect Dis** 1995 Sep;21(3):536–41

Oral ciprofloxacin for treatment of infection following nail puncture wounds of the foot. Raz R, et al. **Clin Infect Dis** 1995 Jul;21(1):194–5

Comparison of enoxacin versus trimethoprim–sulfamethoxazole in the treatment of patients with complicated urinary tract infection. Gottlieb PL. **Clin Ther** 1995 May–Jun;17(3):493–502

Multicenter, phase IV evaluation of intravenous ciprofloxacin as initial therapy in patients with lower respiratory tract, urinary tract, and skin/skin structure infections. Pankey GA. **Clin Ther** 1995 May–Jun;17(3):353–65

Effect of subinhibitory concentrations of pefloxacin in infection in mice due to susceptible or resistant strains. Carsenti–Etesse H, et al. **Drugs** 1995;49 Suppl 2:276–8

Release of pefloxacin bonded on catheters after intraperitoneal implantation in mice. Carsenti–Etesse H, et al. **Drugs** 1995;49 Suppl 2:304–6

Antimicrobial activity, pharmacokinetics and clinical studies of balofloxacin (Q–35) in obstetrics and gynaecology. Cho N, et al. **Drugs** 1995;49 Suppl 2:391–2

Fluoroquinolones in paediatrics—1995. Dagan R. **Drugs** 1995; 49 Suppl 2:92–9 (54 ref.)

Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Davis R, et al. **Drugs** 1996 Jun;51(6):1019–74 (517 ref.)

Oral ciprofloxacin in the treatment of cholera. Gotuzzo E, et al. **Drugs** 1995;49 Suppl 2:451–3

Sparfloxacin empirical therapy in community–acquired pneumonia. Results of a meta–analysis of 2 comparative studies. Grassi GG, et al. **Drugs** 1995;49 Suppl 2:406–8

Single dose ofloxacin in the eradication of pharyngeal carriage of Neisseria meningitidis. Halstensen A, et al. **Drugs** 1995;49 Suppl 2:399–400

Double–blind comparison of ofloxacin for 3 days and placebo in acute bacterial enteritis. Halstensen A, et al. **Drugs** 1995; 49 Suppl 2:454–6

Experimental and clinical studies of sparfloxacin in Mycoplasma pneumoniae infection. Kaku M, et al. **Drugs** 1995;49 Suppl 2:412–3

Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin. Kawahara S, et al. **Drugs** 1995;49 Suppl 2:414–5

Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections. Kawai T. **Drugs** 1995;49 Suppl 2:416–7

Activity of levofloxacin, ofloxacin, D–ofloxacin and ciprofloxacin against systemic and respiratory tract infections in laboratory animals. Klesel N, et al. **Drugs** 1995; 49 Suppl 2:211–4

Interim results from a multicentre clinical trial of T–3761 in Japan. Kobayashi H. **Drugs** 1995;49 Suppl 2:470–1

Once–daily ofloxacin for hospitalised patients with severe bacterial infections. Landau Z, et al. **Drugs** 1995;49 Suppl 2:472–3

Comparative efficacies of oral pefloxacin in uncomplicated cystitis. Single dose or 3–day therapy. Leelarasamee A, et al. **Drugs** 1995;49 Suppl 2:365–7

Phase IV study (postmarketing surveillance) of Tarivid (ofloxacin) in China. Li JT, et al. **Drugs** 1995;49 Suppl 2:474–6

Oral ciprofloxacin vs intravenous therapy with nonquinolone agents. A study of 291 infections. Lorian V, et al. **Drugs** 1995;49 Suppl 2:477–9

A randomised controlled trial of ofloxacin 200 mg 4 times daily or twice daily vs ciprofloxacin 500 mg twice daily in elderly nursing home patients with complicated UTI. McCue JD, et al. **Drugs** 1995;49 Suppl 2:368–73

Single dose UTI prophylaxis in transurethral surgery. Oral ofloxacin vs parenteral cefotaxime. Madsen PO, et al. **Drugs** 1995;49 Suppl 2:480–2

Clinical experience with OPC–17116 in the treatment of gynaecological infections and its penetration into gynaecological tissues. Japanese Collaborative Study Group of OPC–17116 in Gynaecology. Matsuda S. **Drugs** 1995;49 Suppl 2:395–8

Clinical study of T–3761 in obstetrics and gynaecology. Matsuda S. **Drugs** 1995;49 Suppl 2:393–4

Efficacy and safety of single oral dose sparfloxacin vs ciprofloxacin in acute gonococcal urethritis in males. A multicentre international study. Moi H, et al. **Drugs** 1995; 49 Suppl 2:387–9

Levofloxacin: penetration into sputum and once–daily treatment of respiratory tract infections. Nakamori Y, et al. **Drugs** 1995;49 Suppl 2:418–9

Ofloxacin. Therapeutic results in Chlamydia trachomatis genital infection. Nedeljkovic M, et al. **Drugs** 1995;49 Suppl 2:390

A comparative study of short course ciprofloxacin treatment in typhoid and paratyphoid fever. Nelwan RH, et al. **Drugs** 1995;49 Suppl 2:463–5

Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections. Niki Y, et al. **Drugs** 1995;49 Suppl 2:420–2

Comparative study of efficacy and safety of ciprofloxacin and cefixime in the treatment of acute exacerbations of chronic bronchitis after first–line treatment failure. French Study Group. Nouvet G, et al. **Drugs** 1995;49 Suppl 2:423–5

Levofloxacin in patients with severe respiratory tract infection. Odagiri S. **Drugs** 1995;49 Suppl 2:426–7

Ciprofloxacin in the treatment of serious infections in systemic lupus erythematosus. Oh HM, et al. **Drugs** 1995; 49 Suppl 2:486–7

Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections. Sato A, et al. **Drugs** 1995;49 Suppl 2:428–9

Study of the effects of AM–1155 in a rat chronic respiratory tract infection model with Pseudomonas aeruginosa. Sato A, et al. **Drugs** 1995;49 Suppl 2:253–5

A comparative study of ofloxacin twice and three times daily in the treatment of respiratory tract infections. Sawae Y, et al. **Drugs** 1995;49 Suppl 2:430–2

Pharmacokinetic and clinical studies of T–3761 in otorhinolaryngeal infections. Shinkawa A, et al. **Drugs** 1995;49 Suppl 2:401–2

Oral levofloxacin 600 mg and 300 mg daily doses in difficult–to–treat respiratory infections. Shishido H, et al. **Drugs** 1995;49 Suppl 2:433–5

Comparison of ciprofloxacin with imipenem in the treatment of severe pneumonia in hospitalised geriatric patients. Siami GA, et al. **Drugs** 1995;49 Suppl 2:436–8

The use of fluoroquinolones in sexually transmitted diseases in Southeast Asia. Sivayathorn A. **Drugs** 1995;49 Suppl 2:123–7 (23 ref.)

Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin. Snydman D, et al. **Drugs** 1995; 49 Suppl 2:439–41

In vitro activity and clinical efficacy of ciprofloxacin in otorhinolaryngeal infections. Speciale A, et al. **Drugs** 1995; 49 Suppl 2:403–5

Effectiveness of ofloxacin therapy in preventing functional impairment and increased mortality in elderly patients with bacteriuria. Staszewska–Pistoni M, et al. **Drugs** 1995;49 Suppl 2:374–5

Causative organisms in acute exacerbation of chronic airways disease and response to ofloxacin therapy. Sufarlan AW, et al. **Drugs** 1995;49 Suppl 2:442–5

Laboratory and clinical study of balofloxacin (Q–35), a new fluoroquinolone, in urinary tract infection. Suzuki K, et al. **Drugs** 1995;49 Suppl 2:376–8

Laboratory and clinical study of T–3761, a new fluoroquinolone, in urinary tract infection. Suzuki K, et al. **Drugs** 1995;49 Suppl 2:379–81

Initial clinical experience with clinafloxacin in the treatment of serious infections. Tack KJ, et al. **Drugs** 1995;49 Suppl 2:488–91

Clinical assessment of indices for the prognosis of urinary tract infection in elderly patients receiving prophylaxis with norfloxacin. Toba K, et al. **Drugs** 1995;49 Suppl 2:382–3

Efficacy of ofloxacin in lower respiratory tract infections bacteriologically diagnosed by fibreoptic–bronchoscopy aspirate culture. Tomašic–Cvitanovic S, et al. **Drugs** 1995; 49 Suppl 2:446–7

Clinical efficacy of ofloxacin in acute exacerbations of chronic respiratory disease. Watanabe K, et al. **Drugs** 1995; 49 Suppl 2:448–50

Comparison of 2 oral ofloxacin regimens for the treatment of bacteriuria in elderly subjects. Zorbas P, et al. **Drugs** 1995;49 Suppl 2:384–6

Use of norfloxacin for prevention of symptomatic urinary tract infection in chronically catheterized patients. Rutschmann OT, et al. **Eur J Clin Microbiol Infect Dis** 1995 May;14(5):441–4

Determinants of complications after multiple transrectal core biopsies of the prostate. Norberg M, et al. **Eur Radiol** 1996; 6(4):457–61

Effects of hepatic stimulator substance, herbal medicine, selenium/vitamin E, and ciprofloxacin on cirrhosis in the rat. Zhang M, et al. **Gastroenterology** 1996 Apr; 110(4):1150–5

Antibiotic prophylaxis of ERCP with ciprofloxacin [letter; comment] Mohandas KM, et al. **Gastrointest Endosc** 1996 Feb;43(2 Pt 1):175. Comment on: Gastrointest Endosc 1994 Nov–Dec;40(6):716–21.

Successful treatment of donovanosis with ciprofloxacin [letter] Ahmed BA, et al. **Genitourin Med** 1996 Feb; 72(1):73–4

Ciprofloxacin resistant Neisseria gonorrhoeae [letter] Thompson C, et al. **Genitourin Med** 1995 Dec;71(6):412–3

Importation into the UK of a strain of Neisseria gonorrhoeae resistant to penicillin, ciprofloxacin and tetracycline [letter] Turner A, et al. **Genitourin Med** 1995 Oct;71(5):331–2

Ciprofloxacin and long–term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Rolachon A, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1171–4

Effect of additional oral ofloxacin administration in the treatment of multidrug–resistant tuberculosis. Sharma SK, et al. **Indian J Chest Dis Allied Sci** 1996 Apr–Jun;38(2):73–9

Treatment of severe Salmonella typhimurium infection with ciprofloxacin. Dutta P, et al. **Indian Pediatr** 1995 Jul; 32(7):804–7

Fluoroquinolones. Hendershot EF. **Infect Dis Clin North Am** 1995 Sep;9(3):715–30 (44 ref.)

A randomised, multinational study with sequential therapy comparing ciprofloxacin twice daily and ofloxacin once daily. Bassaris H, et al. **Infection** 1995 Jul–Aug;23(4):227–33

Efficacy and tolerability of brodimoprim od versus norfloxacin bid in the treatment of bacterial urinary tract infections. Scaglione F, et al. **Int J Clin Pharmacol Res** 1995;15(3):121–5

Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double–blind, randomised, parallel, multicentre study. Allegra L, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:93–104

Sparfloxacin for the treatment of community–acquired

pneumonia: a pooled data analysis of two studies. Aubier M, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:73–82

Efficacy of quinolones in preventing Staphylococcus aureus–induced abscess in mice. Cohen MA, et al. **J Antimicrob Chemother** 1995 Sep;36(3):551–5

A placebo controlled evaluation of lomefloxacin in the treatment of bacterial diarrhoea in the community. Ellis-Pegler RB, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):259–63

Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. Sinusitis Study Group. Gehanno P, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:105–14

Study design, methodology and statistical analyses in the clinical development of sparfloxacin. Genevois E, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:65–72

Comparative efficacy and safety of single oral doses of sparfloxacin versus ciprofloxacin in the treatment of acute gonococcal urethritis in men. Moi H, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:115–22

Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection. Naber KG, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:135–44

Early single dose therapy with ofloxacin for empirical treatment of acute gastroenteritis: a randomised, placebo-controlled double-blind clinical trial. Noguerado A, et al. **J Antimicrob Chemother** 1995 Oct;36(4):665–72

A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of non-gonococcal urethritis in men. Phillips I, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:123–34

Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group. Portier H, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:83–91

Safety profile of sparfloxacin in the treatment of respiratory tract infections. Rubinstein E. **J Antimicrob Chemother** 1996 May;37 Suppl A:145–60

Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice. Russell P, et al. **J Antimicrob Chemother** 1996 Apr; 37(4):769–74

Fluoroquinolones and bacterial enteritis, when and for whom? Wiström J, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):23–39 (84 ref.)

Treatment of experimental endocarditis due to multidrug-resistant Enterococcus faecium with clinafloxacin and penicillin. Zaman MM, et al. **J Antimicrob Chemother** 1996 Jan;37(1):127–32

Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. Borcherding SM, et al. **J Fam Pract** 1996 Jan;42(1):69–78 (70 ref.)

Clinical evaluation of ciprofloxacin ophthalmic solution in the treatment of refractory bacterial keratitis. Tsai AC, et al. **J Formos Med Assoc** 1995 Dec;94(12):760–4

Oral ciprofloxacin as prophylaxis in gastroduodenal surgery. McArdle CS, et al. **J Hosp Infect** 1995 Jul;30(3):211–6

Quinolone resistance in Oligella urethralis–associated chronic ambulatory peritoneal dialysis peritonitis. Riley UB, et al. **J Infect** 1996 Mar;32(2):155–6

Lower respiratory tract infection therapy—the role of ciprofloxacin. Ball AP, et al. **J Int Med Res** 1995 Sep–Oct; 23(5):315–27 (55 ref.)

Combined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients. Sampoonachot P, et al. **J Med Assoc Thai** 1996 Apr; 79(4):210–7

Ofloxacin otic solution as treatment of chronic suppurative otitis media and diffuse bacterial otitis externa. Sumitsawan Y, et al. **J Med Assoc Thai** 1995 Sep;78(9):455–9

Efficacy of sustained release ciprofloxacin microspheres against device-associated Pseudomonas aeruginosa biofilm infection in a rabbit peritoneal model. Owusu-Ababio G, et al. **J Med Microbiol** 1995 Nov;43(5):368–76

Comparative study of marbofloxacin and amoxicillin–clavulanic acid in the treatment of urinary tract infections in dogs. Cotard JP, et al. **J Small Anim Pract** 1995 Aug;36(8):349–53

Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. Seay TM, et al. **J Urol** 1996 Feb;155(2):757–62

An audit of ciprofloxacin use in severe life threatening infection at the AKUH [letter] Abdulla AM. **JPMA J Pak Med Assoc** 1996 Jan;46(1):25–7

Ciprofloxacin in multi-resistant infections in childhood: an audit. Khan DM, et al. **JPMA J Pak Med Assoc** 1995 Jun; 45(6):147–50

Bayer promotional publications misleading about effect of ciprofloxacin on hospital admissions [letter] Barton SB, et al. **Lancet** 1995 Oct 21;346(8982):1102

Ciprofloxacin-resistant Salmonella typhi in the UK [letter] Rowe B, et al. **Lancet** 1995 Nov 11;346(8985):1302

Fluoroquinolone antibiotics in children with multidrug resistant typhoid [letter] White NJ, et al. **Lancet** 1996 Aug 24;348(9026):547

Long-term treatment of pulmonary tuberculosis with ofloxacin in a subject with liver cirrhosis [see comments] Bagnato GF, et al. **Monaldi Arch Chest Dis** 1995 Aug; 50(4):279–81. Comment in: Monaldi Arch Chest Dis 1996 Apr;51(2):159–60.

Long-term treatment of pulmonary tuberculosis with ofloxacin in a subject with liver cirrhosis [letter; comment] Bagnato GF, et al. **Monaldi Arch Chest Dis** 1996 Apr; 51(2):159–60. Comment on: Monaldi Arch Chest Dis 1995 Aug;50(4):279–81.

Protective role of the pefloxacin–IFN-gamma association in Leishmania major–infected mice. Zucca M, et al. **New Microbiol** 1996 Jan;19(1):39–46

Rickettsial spotted fever infections: another pediatric indication for fluoroquinolones? [letter; comment] Tsai TF, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):635. Comment on: Pediatr Infect Dis J 1995 Jan;14(1):1–9.

Treatment of infections caused by rapidly growing mycobacteria in the era of the newer macrolides. Wallace RJ Jr. **Res Microbiol** 1996 Jan–Feb;147(1–2):30–5 (34 ref.)

Additive effect of continuous low-dose ofloxacin on erythromycin therapy for sinobronchial syndrome. Ishiura Y, et al. **Respir Med** 1995 Nov;89(10):677–84

Successful treatment of ozena with ciprofloxacin. Nielsen BC, et al. **Rhinology** 1995 Jun;33(2):57–60

Short-term quinolones for successful eradication of multiply resistant Vibrio cholerae in adult patients. Doğanci L, et al. **Scand J Infect Dis** 1995;27(4):425–6

Prospective randomized open study between ciprofloxacin and a combination of sulfadiazine and trimethoprim in antibiotic prophylaxis in connection with transurethral prostatectomy. Lukkarinen O, et al. **Scand J Urol Nephrol** 1996 Feb;30(1):33–6

Efficacy of ciprofloxacin in the eradication of Helicobacter pylori. Dresner D, et al. **South Med J** 1996 Aug;89(8):775–8

Postoperative infections in immunocompromised patients after oncological surgery. Ranchere JY, et al. **Support Care Cancer** 1995 Nov;3(6):409–13

Fluoroquinolone antimicrobials [letter] López-Vélez R, et al. **Trop Geogr Med** 1995;47(4):183

[Prevention of urinary infections as a complication in endoscopic surgery] Rovný R, et al. **Rozhl Chir** 1995 Nov; 74(7):361–2 (Eng. Abstr.) (Cze)

[Fluoroquinolones in antimicrobial therapy and prophylaxis in surgery] Vyhnánek F, et al. **Rozhl Chir** 1995 Sep; 74(6):257–61 (Eng. Abstr.) (Cze)

[Use of fluoroquinolones in children] Gendrel D. **Arch Pediatr** 1996;3 Suppl 1:292s–294s (Fre)

[Use of quinolones in children and articular risk] Schaad UB. **Arch Pediatr** 1996 Feb;3(2):183–4 (Fre)

[Search for bacterial contamination of the aqueous humor during cataract surgery with and without local antibiotic prophylaxis] Saint-Blancat P, et al. **J Fr Ophtalmol** 1995; 18(11):650–5 (Eng. Abstr.) (Fre)

[Treatment of cystitis in women] Lobel B. **Presse Med** 1995 Oct 28;24(32):1527–9 (9 ref.) (Eng. Abstr.) (Fre)

[Successful antibiotic therapy with ciprofloxacin in pleural empyema caused by Salmonella enteritidis] Sion ML, et al. **Med Klin** 1996 Mar 15;91(3):174–6 (Ger)

[Seminal plasma cytokines in nonbacterial prostatitis: changes following sparfloxacin treatment] Yasumoto R, et al. **Hinyokika Kiyo** 1995 Oct;41(10):771–4 (Eng. Abstr.) (Jpn)

[Comparative clinical study of azithromycin with tosufloxacin tosilate in the treatment of acute odontogenic infection] Sasaki J, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1093–118 (Eng. Abstr.) (Jpn)

[clinical study of balofloxacin on infectious enteritis and assessment of the fecal drug concentration and intestinal microbial flora in patients with inpatients with infectious enteritis. Research group of balofloxacin on infectious enteritis] Obana M, et al. **Kansenshogaku Zasshi** 1995 Sep; 69(9):991–1006 (Eng. Abstr.) (Jpn)

[Fluoroquinolones in clinical practice. Pefloxacin (abaktal, peflacine)] Fomina IP, et al. **Antibiot Khimioter** 1995 Nov–Dec;40(11–12):70–7 (28 ref.) (Rus)

[Effectiveness of pefloxacin in the surgical clinic] Iakovlev VP, et al. **Antibiot Khimioter** 1995 Aug;40(8):43–5 (Eng. Abstr.) (Rus)

[Effect of fluoroquinolones on the interaction of phagocytic cells with pathogens, lymphocyte function and immune response] Iordanova AI, et al. **Antibiot Khimioter** 1995 Aug; 40(8):50–6 (Rus)

[Effectiveness of pefloxacin in brucellosis] Kurmanova KB, et al. **Antibiot Khimioter** 1995 Jul;40(7):39–42 (Eng. Abstr.) (Rus)

[Evaluation of the effectiveness of the use of pefloxacin in combined radiation-thermal injury] Makarov GF, et al. **Antibiot Khimioter** 1995 Aug;40(8):36–9 (Eng. Abstr.) (Rus)

[Standardization of conditions for the evaluation of effectiveness of antibacterial drugs in pneumonic plague in sacred baboons] Romanov VE, et al. **Antibiot Khimioter** 1995 Jun;40(6):23–30 (Eng. Abstr.) (Rus)

[A clinical evaluation of the efficacy of using Zanocin (ofloxacin) in surgery] Saenko VF, et al. **Klin Khir** 1995; (9–10):18–9 (Rus)

[Experience in the use of ofloxacin in the prevention and treatment of wound infection in burns] Alekseev AA, et al. **Klin Med (Mosk)** 1995;73(6):46–51 (Eng. Abstr.) (Rus)

[Clinical effectiveness of ciprofloxacin in a female patient with peptic ulcer associated with Helicobacter infection] Il'chenko AA, et al. **Klin Med (Mosk)** 1995;73(6):64–5 (Rus)

[Ciprofloxacin in the treatment of chronic bacterial prostatitis] Trapeznikova MF, et al. **Urol Nefrol (Mosk)** 1995 Sep–Oct;(5):20–3 (Eng. Abstr.) (Rus)

TOXICITY

Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Kato M, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1979–83

Sparfloxacin phototoxicity: potential photoaugmentation by ultraviolet A and B sources. Tokura Y, et al. **Arch Dermatol Res** 1996;288(1):45–50

LD50 value, phototoxicity and convulsion induction test of the new quinolone antibacterial agent (S)-10-[(S)-(8-amino-6-azaspiro[3,4]octan-6-yl)]-9-fluoro-2, 3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxyl ic acid hemihydrate in laboratory animals. Shimoda K, et al. **Arzneimittelforschung** 1996 Jun;46(6):625–8

Evaluation of photosensitising ability of quinolones in guinea-pigs. Horio T, et al. **Drugs** 1995;49 Suppl 2:283–5

Absence of neuromuscular blocking activity of sparfloxacin. Paradelis AG, et al. **Drugs** 1995;49 Suppl 2:291–2

Analysis of the ciprofloxacin-induced mutations in Salmonella typhimurium. Clerch B, et al. **Environ Mol Mutagen** 1996;27(2):110–5

Effect of bile duct ligation and unilateral nephrectomy on brain concentration and convulsant potential of the quinolone antibacterial agent levofloxacin in rats. Akahane K, et al. **Fundam Appl Toxicol** 1996 Feb;29(2):280–6

Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Linseman DA, et al. **Fundam Appl Toxicol** 1995 Nov;28(1):59–64

Effects of new quinolone antibacterial agents on mammalian chromosomes. Shimada H, et al. **J Toxicol Environ Health** 1996 Feb 9;47(2):115–23

Antimutagens reduce ofloxacin-induced bleaching in Euglena gracilis. Ebringer L, et al. **Mutat Res** 1996 Feb 29;359(2):85–93

[Single and 4-week oral toxicity studies of prulifloxacin (NM441) in aged dogs] Ihara T, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:149–69 (Eng. Abstr.) (Jpn)

[A 13-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 5-week recovery test] Ishibashi S, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:89–111 (Eng. Abstr.) (Jpn)

[A 4-week intravenous toxicity study of the active metabolite (NM394) of prulifloxacin (NM441) in rats followed by a 4-week recovery test] Ishida S, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:131–48 (Eng. Abstr.) (Jpn)

[Mutagenicity studies of prulifloxacin (NM441) and the active metabolite (NM394)] Iwakura K, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:241–57 (Eng. Abstr.) (Jpn)

[A photoallergenicity study of prulifloxacin (NM441) in guinea pigs] Kamata K, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:259–65 (Eng. Abstr.) (Jpn)

[Renal toxicity of prulifloxacin (NM441) in rats] Kawaminami A, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:267–76 (Eng. Abstr.) (Jpn)

[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(1)—A fertility study in rats by oral administration] Morinaga T, et al. **J Toxicol Sci** 1996 Jun; 21 Suppl 1:171–85 (Eng. Abstr.) (Jpn)

[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(4)—A perinatal and postnatal study in rats by oral administration] Morinaga T, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:219–30 (Eng. Abstr.) (Jpn)

[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(2)—A teratogenicity study in rats by oral administration] Morinaga T, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:187–206 (Eng. Abstr.) (Jpn)

[Reproductive and developmental toxicity studies of prulifloxacin (NM441)(3)—A teratogenicity study in rabbits by oral administration] Morinaga T, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:207–17 (Eng. Abstr.) (Jpn)

[A 4-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 4-week recovery test] Nishimura N, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:45–70 (Eng. Abstr.) (Jpn)

[A 4-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 4-week recovery test] Oda S, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:71–88 (Eng. Abstr.) (Jpn)

[Single-dose toxicity studies of prulifloxacin (NM441) in mice, rats and dogs and the active metabolite (NM394) in rats] Shimazu H, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:33–44 (Eng. Abstr.) (Jpn)

[A 13-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 5-week recovery test] Yoshida M, et al. **J Toxicol Sci** 1996 Jun;21 Suppl 1:113–29 (Eng. Abstr.) (Jpn)

ANTI-INFECTIVE AGENTS, LOCAL

see related

DISINFECTANTS

Failure of antiseptic bonding to prevent central venous catheter-related infection and sepsis. Ciresi DL, et al. **Am Surg** 1996 Aug;62(8):641–6

Antiseptics and disinfectants. Current issues. Terleckyj B,

et al. **J Am Podiatr Med Assoc** 1995 Aug;85(8):439–45 (32 ref.)

Management of skin-grafted burn wounds with Xeroform and layers of dry coarse-mesh gauze dressing results in excellent graft take and minimal nursing time. Hansbrough W, et al. **J Burn Care Rehabil** 1995 Sep–Oct;16(5):531–4

Guidelines for a policy on the use of antiseptics and disinfectants. The Hospital Infection Control Group of Thailand. **J Med Assoc Thai** 1995 Jul;78 Suppl 2:S131

Antimicrobial skin preparations for the maxillofacial region. Morgan JP 3rd, et al. **J Oral Maxillofac Surg** 1996 Jan; 54(1):89–94 (56 ref.)

[New antiseptics and disinfectants in surgery. I] Pkhakadze Tla, et al. **Khirurgiia (Mosk)** 1995;(6):34–7 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Do topical antibiotics provide improved prophylaxis against bacterial growth in the presence of polypropylene mesh? Troy MG, et al. **Am J Surg** 1996 Apr;171(4):391–3

Antiseptic catheter gel and urinary tract infection after short-term postoperative catheterization in women. Schiøtz HA. **Arch Gynecol Obstet** 1996;258(2):97–100

An analysis of bacteremias during dental extractions. A double-blind, placebo-controlled study of chlorhexidine. Lockhart PB. **Arch Intern Med** 1996 Mar 11;156(5):513–20 (67 ref.)

Reducing the risk of Chlamydia trachomatis genital tract infection by evaluating the prophylactic potential of vaginally applied chemicals. Lyons JM, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S174–7

Dental properties of antiseptic throat lozenges formulated with sugars or Lycasin. Grenby TH. **J Clin Pharm Ther** 1995 Aug;20(4):235–41

Efficacy of barrier-type postmilking teat germicides against intramammary infection. Nickerson SC, et al. **J Dairy Sci** 1995 Nov;78(11):2496–501

Nonsurgical treatment of patients with periodontal disease. Loesche WJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):533–43

Choice of wound dressings and ointments. Brown CD, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1081–91 (52 ref.)

Management of post-ethmoidectomy crust formation: randomized single-blind clinical trial comparing pressurized seawater versus antiseptic/mucolytic saline. Pigret D, et al. **Rhinology** 1996 Mar;34(1):38–40

[The use of the preparation Betadiner in some forms of colpitis] Marinov B, et al. **Akush Ginekol (Sofiia)** 1995; 34(1):39–40 **(Bul)**

[Efficacy of various methods for preoperative vaginal antisepsis] Enzelsberger H, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):707–10 (Eng. Abstr.) **(Ger)**

[Microbiological studies of stomatological periodontal films containing a derivative of chlorocinnamic aldehyde] Davtian LL, et al. **Mikrobiol Z** 1995 Sep–Oct;57(5):78–83 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Hydrogen peroxide: an unusual cause of arterial and venous gas embolism. Neff SP, et al. **Anaesthesia** 1996 Jul; 51(7):683–4

Topical iodine and neonatal hypothyroidism. Gordon CM, et al. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1336–9

Benzyl alcohol allergy. Li M, et al. **Australas J Dermatol** 1995 Nov;36(4):219–20

Recurrent fixed drug eruption due to clioquinol [letter] Janier M, et al. **Br J Dermatol** 1995 Dec;133(6):1013–4

Contact sensitivity to 5 different ingredients of a topical medicament (Imacort cream). Brand CU, et al. **Contact Dermatitis** 1995 Aug;33(2):137

Contact dermatitis caused by cetrimide in antiseptics. Lee JY, et al. **Contact Dermatitis** 1995 Sep;33(3):168–71

Acute allergic contact dermatitis from Medi-Swabs, with negative patch tests to the individual ingredients, including isopropyl alcohol. Leow YH, et al. **Contact Dermatitis** 1995 Aug;33(2):125–6

Allergic contact dermatitis due to thymol. Lorenzi S, et al. **Contact Dermatitis** 1995 Dec;33(6):439–40

Skin ulceration due to povidone-iodine. Mochida K, et al. **Contact Dermatitis** 1995 Jul;33(1):61–2

Toxic keratopathy due to the accidental use of chlorhexidine, cetrimide and cialit. van Rij G, et al. **Doc Ophthalmol** 1995; 90(1):7–14

Allergy to Unna boots in four patients. Praditsuwan P, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):906–8

The comparative tea staining potential of phenolic, chlorhexidine and anti-adhesive mouthrinses. Addy M, et al. **J Clin Periodontol** 1995 Dec;22(12):923–8

Survey of dairy managers in the Pacific Northwest identifying factors associated with teat chapping. Burmeister JE, et al. **J Dairy Sci** 1995 Sep;78(9):2073–82

Haemodynamic and electrophysiological acute toxic effects of mercury in anaesthetized rats and in langendorff perfused rat hearts. Massaroni L, et al. **Pharmacol Res** 1995 Jul–Aug; 32(1–2):27–36

[Prescription formulations with clioquinol] Ippen H. **Hautarzt** 1995 Dec;46(12):873 **(Ger)**

[Allergic reaction to merthiolate (a disinfectant) based on material from the Occupational Medicine Institute in Lodz] Kieć-Swierczyńska M. **Med Pr** 1996;47(2):125–31 (Eng. Abstr.) **(Pol)**

[Caustic esophagitis and gastritis due to hydrogen peroxide (letter)] Espín Jaime B, et al. **An Esp Pediatr** 1996 Mar; 44(3):298–9 **(Spa)**

[Daily administration of nose drops can cause chronic nasal congestion] Graf P, et al. **Lakartidningen** 1996 Jan 24; 93(4):259–62 (17 ref.) **(Swe)**

ANALYSIS

Macrophages have cell surface IL-10 that regulates macrophage bactericidal activity. Fleming SD, et al. **J Immunol** 1996 Feb 1;156(3):1143–50

CHEMISTRY

Comparative staining in vitro and plaque inhibitory properties in vivo of 0.12% and 0.2% chlorhexidine mouthrinses. Smith RG, et al. **J Clin Periodontol** 1995 Aug; 22(8):613–7

HISTORY

Coming together during World War I: medicine's response to the challenges of trench warfare. Schwartz ED. **Pharos** 1995 Fall;58(4):5–9

METABOLISM

Simultaneous determination of malachite green and its metabolite leucomalachite green in eel plasma using post-column oxidation. Hajee CA, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):219–27

PHARMACOKINETICS

Effect of urinary alkalinisation and acidification on the tissue distribution of hexachlorophene in rats. Flanagan RJ, et al. **Hum Exp Toxicol** 1995 Oct;14(10):795–800

Comparative killing kinetics of methicillin-resistant Staphylococcus aureus by bacitracin or mupirocin. Chapnick EK, et al. **Infect Control Hosp Epidemiol** 1996 Mar;17(3):178–80

Effect on neonatal thyroid function of povidone-iodine used on mothers during perinatal period. Koga Y, et al. **J Obstet Gynaecol** 1995 Dec;21(6):581–5

N-[5-nitro-2-furfurylidene]-3-amino-2-oxazolidinone activation by the human intestinal cell line Caco-2 monitored through noninvasive electron spin resonance spectroscopy. Rossi L, et al. **Mol Pharmacol** 1996 Mar; 49(3):547–55

PHARMACOLOGY

Mouth-rinsing with chlorhexidine causes a delayed, temporary increase in the levels of oral viridans streptococci. Vaahtoniemi LH, et al. **Acta Odontol Scand** 1995 Aug;53(4):226–9

Effects of potentiated chlorhexidine on bacteria and tarsocrural joints in ponies. Klohnen A, et al. **Am J Vet Res** 1996 May;57(5):756–61

Effects of chlorhexidine on human taste perception. Helms JA, et al. **Arch Oral Biol** 1995 Oct;40(10):913–20

Antimicrobial actions of fluoride for oral bacteria. Marquis RE. **Can J Microbiol** 1995 Nov;41(11):955–64 (92 ref.)

Interaction of chlorhexidine with cytoplasmic membranes of Streptococcus mutans GS-5. Koontongkaew S, et al. **Caries Res** 1995;29(5):413–7

The effect of the extract of the miswak (chewing sticks) used in Jordan and the Middle East on oral bacteria. Al lafi T, et al. **Int Dent J** 1995 Jun;45(3):218–22

The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro. O'Connor TJ, et al. **Int J STD AIDS** 1995 Jul–Aug;6(4):267–72

Reducing bacterial aerosol contamination with a chlorhexidine gluconate pre-rinse. Logothetis DD, et al. **J Am Dent Assoc** 1995 Dec;126(12):1634–9

In-vitro activity of chlorhexidine, hexetidine and bacitracin against perinatal pathogens [letter] Adriaanse AH, et al. **J Antimicrob Chemother** 1996 Jan;37(1):192–4

In vitro activity of metronidazole alone and in combination with clotrimazole against clinical isolates of Trichomonas vaginalis. Debbia EA, et al. **J Chemother** 1996 Apr; 8(2):96–101

An approach to efficacy screening of mouthrinses: studies on a group of French products (I). Staining and antimicrobial properties in vitro. Addy M, et al. **J Clin Periodontol** 1995 Sep;22(9):718–22

The effect of triclosan on mediators of gingival inflammation. Gaffar A, et al. **J Clin Periodontol** 1995 Jun;22(6):480–4

Effects of triclosan on the rat phrenic nerve-diaphragm preparation. Kjaerheim V, et al. **J Clin Periodontol** 1995 Jun;22(6):488–93

Antimicrobial abilities of various dentine bonding agents and restorative materials. Palenik CJ, et al. **J Dent** 1996 Jul; 24(4):289–95

Effect of sucrose monolaurate on acid production, levels of glycolytic intermediates, and enzyme activities of Streptococcus mutans NCTC 10449. Iwami Y, et al. **J Dent Res** 1995 Sep;74(9):1613–7

In-vitro activity of a catheter loaded with silver and teicoplanin to prevent bacterial and fungal colonization [letter] Jansen B, et al. **J Hosp Infect** 1995 Nov;31(3):238–41

Do 'chlorine covers' exert a sustained bactericidal effect on the bacterial hand flora? Koller W, et al. **J Hosp Infect** 1995 Nov;31(3):169–76

Efficacy of gentian violet in the eradication of methicillin-resistant Staphylococcus aureus from skin lesions. Saji M, et al. **J Hosp Infect** 1995 Nov;31(3):225–8

Potentiation of the effects of chlorhexidine diacetate and cetylpyridinium chloride on mycobacteria by ethambutol. Broadley SJ, et al. **J Med Microbiol** 1995 Dec;43(6):458–60

In vitro inhibition of bacteria from root canals of primary teeth by various dental materials. Tchaou WS, et al. **Pediatr Dent** 1995 Sep–Oct;17(5):351–5

The effect of formulation on the antimicrobial activity of cetylpyridinium chloride in candy based lozenges. Richards RM, et al. **Pharm Res** 1996 Apr;13(4):583–7

[Effects of the most frequently used solutions and ointments in routine surgical practice] Bravo C, et al. **Rozhl Chir** 1995 Sep;74(6):273–6 (Eng. Abstr.) **(Cze)**

[In vitro changes induced by phenylmercury nitrate on fungi causing keratitis. Scanning electron microscopy study] Duhamel C, et al. **J Fr Ophtalmol** 1995;18(12):819–21 (Eng. Abstr.) **(Fre)**

[Comparison of the effectiveness of sodium azide and merthiolate as bacteriocidal agents--a NMR study] Schiller J, et al. **Biomed Tech (Berl)** 1995 Sep;40(9):250–4 (Eng. Abstr.) **(Ger)**

[Epidemiology of microbial resistance to biocides] Hingst V, et al. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):232–51 (Eng. Abstr.) **(Ger)**

[Epidemiology and reasons for microbial resistance to biocides] Kaulfers PM. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):252–9 (Eng. Abstr.) **(Ger)**

[Effects of antiseptics against methicillin-resistant Staphylococcus aureus] Watanabe Y, et al. **Kansenshogaku Zasshi** 1995 Nov;69(11):1235–43 (Eng. Abstr.) **(Jpn)**

[Betadine for antisepsis of the conjunctival sac] Philips RH, et al. **Klin Oczna** 1995 Jul–Sep;97(7–8):255–6 (Eng. Abstr.) **(Pol)**

[Ribosomal RNA degradation in gram-negative and gram-positive bacteria under the action of minimal bactericidal doses of chlorhexidine and heating] Lishchenko NN, et al. **Antibiot Khimioter** 1995 Sep; 40(9):20–5 (Eng. Abstr.) **(Rus)**

POISONING

Fatal iatrogenic iodine toxicity in a nine-week old infant. Kurt TL, et al. **J Toxicol Clin Toxicol** 1996;34(2):231–4

Clinical course of severe poisoning with thiomersal. Pfab R, et al. **J Toxicol Clin Toxicol** 1996;34(4):453–60

"When I have fears that I may cease to be ...." hydrogen peroxide poisoning. Mack RB. **N C Med J** 1995 Dec; 56(12):624–6

Melaleuca oil poisoning in a 17-month-old. Del Beccaro MA. **Vet Hum Toxicol** 1995 Dec;37(6):557–8

THERAPEUTIC USE

Mupirocin ointment with and without chlorhexidine baths in the eradication of Staphylococcus aureus nasal carriage in nursing home residents. Watanakunakorn C, et al. **Am J Infect Control** 1995 Oct;23(5):306–9

Topical sphingolipids in antisepsis and antifungal therapy. Bibel DJ, et al. **Clin Exp Dermatol** 1995 Sep;20(5):395–400

Disinfecting agents for removing adherent bacteria from orthopaedic hardware. Moussa FW, et al. **Clin Orthop** 1996 Aug;(329):255–62

Immune response inhibition by irrigating subchondral bone with cytotoxic agents. Rodrigo JJ, et al. **Clin Orthop** 1996 May;(326):96–106

Antimicrobial activity of glycerine-ichthammol in otitis externa. Ahmed K, et al. **Clin Otolaryngol** 1995 Jun; 20(3):201–3

Comprehensive treatment of inflammatory diseases of parodontium by antiseptic and antiinflammatory agents made in Bulgaria. Botushanov P, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):100–1

Topical antibacterial agents. Kaye ET, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):547–59 (58 ref.)

A study into the prevention of fissure caries using an antimicrobial varnish. Bratthall D, et al. **Int Dent J** 1995 Aug;45(4):245–54

Assessing the contribution of anaerobic microflora of the tongue to oral malodor. De Boever EH, et al. **J Am Dent Assoc** 1995 Oct;126(10):1384–93

Assessing pre-procedural subgingival irrigation and rinsing with an antiseptic mouthrinse to reduce bacteremia. Fine DH, et al. **J Am Dent Assoc** 1996 May;127(5):641–2, 645–6

Preventing post-treatment bacteremia: comparing topical povidone-iodine and chlorhexidine [see comments] Rahn R, et al. **J Am Dent Assoc** 1995 Aug;126(8):1145–9. Comment in: J Am Dent Assoc 1995 Nov;126(11):1474, 1476.

Effects of a chlorhexidine varnish on the gingival status of adolescents. Valente MI, et al. **J Can Dent Assoc** 1996 Jan; 62(1):46–8

Triclosan reduces the clinical symptoms of the allergic patch test reaction (APR) elicited with 1% nickel sulphate in sensitised patients. Barkvoll P, et al. **J Clin Periodontol** 1995 Jun;22(6):485–7

The effect of a commercially available triclosan-containing toothpaste compared to a sodium-fluoride-containing

toothpaste and a chlorhexidine rinse on 4-day plaque regrowth. Binney A, et al. **J Clin Periodontol** 1995 Nov; 22(11):830-4

The use of plaque area and plaque index to measure the effect of fluoride and chlorhexidine toothpastes on 24-h plaque regrowth. Claydon N, et al. **J Clin Periodontol** 1995 Jul; 22(7):540-2

A comparative clinical study: the use of human type I collagen with and without the addition of metronidazole in the GTR method of treatment of periodontal disease. Dowell P, et al. **J Clin Periodontol** 1995 Jul;22(7):543-9

A 6-month home-usage trial of 0.1% and 0.2% delmopinol mouthwashes (II). Effects on the plaque microflora. Elworthy AJ, et al. **J Clin Periodontol** 1995 Jul; 22(7):527-32

Principles of pharmacologic intervention. Goodson JM. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):268-72 (17 ref.)

An approach to efficacy screening of mouthrinses: studies on a group of French products (II). Inhibition of salivary bacteria and plaque in vivo. Harper PR, et al. **J Clin Periodontol** 1995 Sep;22(9):723-7

Plaque formation and gingivitis after mouthrinsing with 0.2% delmopinol hydrochloride, 0.2% chlorhexidine digluconate and placebo for 4 weeks, following an initial professional tooth cleaning. Hase JC, et al. **J Clin Periodontol** 1995 Jul; 22(7):533-9

Triclosan inhibits histamine-induced inflammation in human skin. Kjaerheim V, et al. **J Clin Periodontol** 1995 Jun; 22(6):423-6

The effect of oxidising mouthrinses compared with chlorhexidine on salivary bacterial counts and plaque regrowth. Moran J, et al. **J Clin Periodontol** 1995 Oct; 22(10):750-5

The comparative effects on plaque regrowth of phenolic chlorhexidine and anti-adhesive mouthrinses. Moran J, et al. **J Clin Periodontol** 1995 Dec;22(12):929-34

The effects on chronic periodontitis of a subgingivally-placed redox agent in a slow release device. Ower PC, et al. **J Clin Periodontol** 1995 Jun;22(6):494-500

The effect of triclosan on developing gingivitis. Ramberg P, et al. **J Clin Periodontol** 1995 Jun;22(6):442-8

The effects of antimicrobial mouthrinses on de novo plaque formation at sites with healthy and inflamed gingivae. Ramberg P, et al. **J Clin Periodontol** 1996 Jan;23(1):7-11

The efficacy of an anti-gingivitis chewing gum. Smith AJ, et al. **J Clin Periodontol** 1996 Jan;23(1):19-23

Comparative staining in vitro and plaque inhibitory properties in vivo of 0.12% and 0.2% chlorhexidine mouthrinses. Smith RG, et al. **J Clin Periodontol** 1995 Aug; 22(8):613-7

Topical metronidazole application compared with subgingival scaling. A clinical and microbiological study on recall patients. Stelzel M, et al. **J Clin Periodontol** 1996 Jan;23(1):24-9

Efficacy on supragingival plaque control of cetylpyridinium chloride in a slow-release dosage form. Vandekerckhove BN, et al. **J Clin Periodontol** 1995 Nov;22(11):824-9

Efficacy of a barrier teat dip containing .55% chlorhexidine for prevention of bovine mastitis. Hogan JS, et al. **J Dairy Sci** 1995 Nov;78(11):2502-6

A meta-analysis of clinical studies on the caries-inhibiting effect of chlorhexidine treatment. van Rijkom HM, et al. **J Dent Res** 1996 Feb;75(2):790-5

Glycerol and ichthammol: medicinal solution or mythical potion? Nilssen E, et al. **J Laryngol Otol** 1996 Apr; 110(4):319-21

The effect of an antiseptic mouthrinse on implant maintenance: plaque and peri-implant gingival tissues. Ciancio SG, et al. **J Periodontol** 1995 Nov;66(11):962-5

Use of chlorhexidine chewing gum significantly reduces dental plaque formation compared to use of similar xylitol and sorbitol products. Tellefsen G, et al. **J Periodontol** 1996 Mar;67(3):181-3

Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. Smack DP, et al. **JAMA** 1996 Sep 25;276(12):972-7

The effect of local application of chlorhexidine on plaque and gingivitis. Lee YC, et al. **N Z Dent J** 1996 Mar; 92(407):13-5

Use of furazolidone for the treatment of microsporidiosis due to Enterocytozoon bieneusi in patients with AIDS. Dionisio D, et al. **Recenti Prog Med** 1995 Oct;86(10):394-7

Treatment of Acanthamoeba keratitis [letter] Niszl IA, et al. **S Afr Med J** 1996 May;86(5):566

Vaginal scrub prophylaxis in abdominal hysterectomy. Vinkomin V. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):188-92

Field trial evaluation of two teat dips containing nisin or polyvinylpyrrolidone iodophor designed for use before and after milking. Sérieys F, et al. **Vet Res** 1996;27(3):295-303

[The effect of different topical agents on pseudomonas infection of burn wound] Guo Z, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Nov;11(6):421-4 (Eng. Abstr.) **(Chi)**

[Antiseptics in skin diseases] Wolkenstein P, et al. **Ann Dermatol Venereol** 1996;123(5):343-8 (50 ref.) **(Fre)**

[Sclerotherapy with Betadine for simple cysts of the kidney. Apropos of 7 cases] Ibnatya A, et al. **J Urol (Paris)** 1995; 101(5-6):237-9 (Eng. Abstr.) **(Fre)**

[Medical treatment of seromucous otitis] Renou G, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):327-8 (Eng. Abstr.) **(Fre)**

[Effectiveness of local treatment using a PVP-iodine compound for retained placenta in cows] Geiser S, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jul;108(7):264-8 (Eng. Abstr.) **(Ger)**

[Povidone-iodine eyedrops for the prevention of newborn conjunctivitis] Buchmann P. **Dtsch Med Wochenschr** 1995 Nov 24;120(47):1645 **(Ger)**

[Local antisepsis in infected total hip endoprosthesis] Wagner M. **Orthopade** 1995 Aug;24(4):319-25 (Eng. Abstr.) **(Ger)**

[New antiseptics and disinfectants in surgery (2)] Pkhakadze TYa, et al. **Khirurgiia (Mosk)** 1996;(1):52-6 (Eng. Abstr.) **(Rus)**

[The use of Betadine in surgery] Osipov IS, et al. **Voen Med Zh** 1996 Feb;317(2):35-7 **(Rus)**

TOXICITY

Effect of exposure to malachite green solution on common carp fry with Dactylogyrus vastator (monogenea) infection. Molnár K. **Acta Vet Hung** 1995;43(2-3):277-86

Toxicological aspects of topical silver pharmaceuticals. Hollinger MA. **Crit Rev Toxicol** 1996 May;26(3):255-60 (57 ref.)

Toxic effects of wound irrigation solutions on cultured tibiae and osteoblasts. Kaysinger KK, et al. **J Orthop Trauma** 1995;9(4):303-11

Toxic effects of some conifer resin acids and tea tree oil on human epithelial and fibroblast cells. Söderberg TA, et al. **Toxicology** 1996 Feb 22;107(2):99-109

Nephrotoxicity of inorganic mercury co-administrated with L-cysteine. Zalups RK, et al. **Toxicology** 1996 May 3; 109(1):15-29

ANTI-INFECTIVE AGENTS, QUINOLONE

Proceedings of the 5th International Symposium on New Quinolones. Singapore, August 25-27, 1994. **Drugs** 1995;49 Suppl 2:1-505

[Proper evaluation and uses of quinolone antibiotics (editorial)] Liu Y. **Chung Hua I Hsueh Tsa Chih** 1996 Jan; 76(1):5-6 **(Chi)**

ADMINISTRATION & DOSAGE

Controlled release of newer quinolones from biodegradable systems based on poly(lactic acid). Andreopoulos AG. **J Biomater Appl** 1995 Oct;10(2):163-70

ADVERSE EFFECTS

Magnetic resonance imaging in diagnosis of potential arthropathogenicity in children receiving quinolones. No evidence of quinolone-induced arthropathy. Danisovicová A, et al. **Drugs** 1995;49 Suppl 2:492-4

ANALYSIS

Simultaneous quantitative determination of metronidazole and nalidixic acid in tablets by difference spectroscopy. Parimoo P, et al. **J Pharm Biomed Anal** 1996 Feb; 14(4):389-93

Multiresidue determination of quinolone antibiotics using liquid chromatography coupled to atmospheric-pressure chemical ionization mass spectrometry and tandem mass spectrometry. Doerge DR, et al. **Rapid Commun Mass Spectrom** 1995;9(11):1012-6

CEREBROSPINAL FLUID

Effect of fenbufen on the penetration of quinolone antibiotics into cerebrospinal fluid. Comparative study with 5 quinolones. Iwamoto K, et al. **Drugs** 1995;49 Suppl 2:349-51

CHEMICAL SYNTHESIS

Syntheses and biological activities of new N1-aryl substituted quinolone antibacterials. Jürgens j, et al. **Arch Pharm (Weinheim)** 1996 Apr;329(4):179-90

Synthesis and biological properties of substituted 1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acids. Miyamoto H, et al. **Bioorg Med Chem** 1995 Dec; 3(12):1699-706

Imidazo- and triazoloquinolones as antibacterial agents. Synthesis and structure-activity relationships. Fujita M, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2123-32

CHEMISTRY

Studies on quinolone antibacterials. IV. Structure-activity relationships of antibacterial activity and side effects for 5- or 8-substituted and 5,8-disubstituted-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-1, 4-dihydro-4-oxoquinoline-3-carboxylic acids. Yoshida T, et al. **Chem Pharm Bull (Tokyo)** 1996 May;44(5):1074-85

METABOLISM

Synthesis of possible metabolites of 1-cyclopropyl-1,4-dihydro-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)- 4-oxo-3-quinolinecarboxylic acid (Grepafloxacin, OPC-17116). Morita S, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2246-52

PHARMACOKINETICS

Comparison of the pharmacodynamic properties of quinolones. Wiedemann B, et al. **Drugs** 1995;49 Suppl 2:269-71

Effect of dietary protein content on nalidixic acid disposition in chickens. Abd el-Aziz MI, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 May;102(5):195-8

PHARMACOLOGY

Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones. Guillemin I, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2145-9

Influence of a newly developed quinolone, T-3761, on pharmacokinetics of theophylline in rats. Hasegawa T, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2138-40

DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa. Yonezawa M, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1970-2

Sensitivity of selected members of the family Halobacteriaceae to quinolone antimicrobial compounds. Oren A. **Arch Microbiol** 1996 May;165(5):354-8

Syntheses and biological activities of new N1-aryl substituted quinolone antibacterials. Jürgens j, et al. **Arch Pharm (Weinheim)** 1996 Apr;329(4):179-90

Application of the dynamic quantitative structure-activity relationship method for modeling antibacterial activity of quinolone derivatives. Kamenska V, et al. **Arzneimittelforschung** 1996 Apr;46(4):423-8

Influence of temperature on mutational resistance to 4-quinolones. Parte AC, et al. **Arzneimittelforschung** 1996 Apr;46(4):429-32

Molecular mechanisms of drug inhibition of DNA gyrase. Lewis RJ, et al. **Bioessays** 1996 Aug;18(8):661-71 (73 ref.)

Synthesis and biological properties of substituted 1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acids. Miyamoto H, et al. **Bioorg Med Chem** 1995 Dec; 3(12):1699-706

Resistance to quinolones among Campylobacter species--Ontario. Preston MA, et al. **Can Commun Dis Rep** 1995 Sep 15;21(17):156-60 **(Eng, Fre)**

Studies on quinolone antibacterials. IV. Structure-activity relationships of antibacterial activity and side effects for 5- or 8-substituted and 5,8-disubstituted-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-1, 4-dihydro-4-oxoquinoline-3-carboxylic acids. Yoshida T, et al. **Chem Pharm Bull (Tokyo)** 1996 May;44(5):1074-85

Quinolone activity against anaerobes: microbiological aspects. Appelbaum PC. **Drugs** 1995;49 Suppl 2:76-80 (42 ref.)

Quinolone susceptibility of multiply-resistant Flavobacterium meningosepticum clinical isolates in one urban hospital. Bolash NK, et al. **Drugs** 1995;49 Suppl 2:168-70

Pharmacodynamics of quinolones. Dalhoff A. **Drugs** 1995;49 Suppl 2:197-9

Activity of quinolones against gram-positive cocci: clinical features. Giamarellou H. **Drugs** 1995;49 Suppl 2:58-66 (60 ref.)

Epidemiology of quinolone resistance: Europe and North and South America. Goldstein FW, et al. **Drugs** 1995;49 Suppl 2:36-42 (49 ref.)

Susceptibility to new quinolones of Pseudomonas aeruginosa isolated from a patient with chronic respiratory tract infection. Goto H, et al. **Drugs** 1995;49 Suppl 2:177-8

Quinolone mode of action. Hooper DC. **Drugs** 1995;49 Suppl 2:10-5 (32 ref.)

Activity of quinolones against mycobacteria. Jacobs MR. **Drugs** 1995;49 Suppl 2:67-75 (29 ref.)

Analysis of quinolone resistance genes in a clinical isolate of quinolone-resistant MRSA. Kojima T, et al. **Drugs** 1995; 49 Suppl 2:182-4

In vitro and in vivo antibacterial activities of broad spectrum quinolones against clinical bacterial isolates. Matsumoto T, et al. **Drugs** 1995;49 Suppl 2:219-21

In vitro activity of new quinolones against anaerobic bacteria. Nord CE, et al. **Drugs** 1995;49 Suppl 2:233-4

Effect of quinolones on the human intestinal microflora. Nord CE. **Drugs** 1995;49 Suppl 2:81-5 (22 ref.)

Effect of quinolone use on antimicrobial susceptibility patterns over a 5-year period. Segreti J, et al. **Drugs** 1995; 49 Suppl 2:185-7

Epidemiology of quinolone resistance. Eastern hemisphere. Turnidge J. **Drugs** 1995;49 Suppl 2:43-7

Effect of ciprofloxacin and other quinolones on granulocyte function assessed by flow cytometry. Wenisch C, et al. **Drugs** 1995;49 Suppl 2:301-3

Comparison of the pharmacodynamic properties of quinolones. Wiedemann B, et al. **Drugs** 1995;49 Suppl 2:269-71

In vitro activity of MF 5137, a new potent 6-aminoquinolone. Wise R, et al. **Drugs** 1995;49 Suppl 2:272-3

Quinolone resistance mechanisms in Klebsiella pneumoniae. Xiao YH, et al. **Drugs** 1995;49 Suppl 2:190-1

Outer membrane alterations in Pseudomonas aeruginosa after five-day exposure to quinolones and carbapenems. Cipriani

P, et al. **Drugs Exp Clin Res** 1995;21(4):139–44

Resistance patterns to beta-lactams and quinolones in clinical isolates of bacteria from Cuban hospitals. Gonzáles I, et al. **Int J Clin Pharmacol Res** 1995;15(1):17–22

The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Child J, et al. **J Antimicrob Chemother** 1995 Jun; 35(6):869–76

Quinolone resistance in clinical strains of Campylobacter jejuni and Campylobacter coli [letter] Harnett N, et al. **J Antimicrob Chemother** 1995 Jul;36(1):269–70

High frequency of mutations at codon 83 of the gyrA gene of quinolone-resistant clinical isolates of Escherichia coli [letter] Ruiz J, et al. **J Antimicrob Chemother** 1995 Oct; 36(4):737–8

In-vitro activity of a new quinolone (CP-99,219) compared with ciprofloxacin, pefloxacin, azithromycin and penicillin against Neisseria gonorrhoeae. van Rijsoort-Vos JH, et al. **J Antimicrob Chemother** 1995 Jul;36(1):215–8

DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. Chen CR, et al. **J Mol Biol** 1996 May 17;258(4):627–37

Analysis of the NH2-terminal 87th amino acid of Escherichia coli GyrA in quinolone-resistance. Yonezawa M, et al. **Microbiol Immunol** 1995;39(7):517–20

Efficiency of MucAB and Escherichia coli UmuDC proteins in quinolone and UV mutagenesis in Salmonella typhimurium: effect of MucA and UmuD processing. Clerch B, et al. **Mutat Res** 1996 Feb 1;349(2):201–8

Nalidixic acid-resistant Shigella dysenteriae type I in KwaZulu-Natal [letter] Karas JA, et al. **S Afr Med J** 1996 Jan;86(1):93

[The effect of subinhibitory concentrations of quinolone and macrolide antibiotics on production of thermolabile hemolysins in Pseudomonas aeruginosa] Hybenová D, et al. **Epidemiol Mikrobiol Imunol** 1995 Dec;44(4):169–70 (Eng. Abstr.) **(Cze)**

[Susceptibility to quinolones of Salmonella isolated from men and animals] Avril JL, et al. **Pathol Biol (Paris)** 1995 Apr; 43(4):270–3 (Eng. Abstr.) **(Fre)**

[Study of clinically isolated new quinolones-resistant Haemophilus influenzae. Part 1] Suzuki Y, et al. **Jpn J Antibiot** 1995 Aug;48(8):1026–32 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Role of quinolones in the treatment of diarrhoeal diseases. Akalin HE. **Drugs** 1995;49 Suppl 2:128–31 (31 ref.)

Quinolones in the elderly. Bergan T. **Drugs** 1995;49 Suppl 2:112–4 (25 ref.)

The role of new quinolones in the treatment of respiratory tract infections. Finch RG. **Drugs** 1995;49 Suppl 2:144–51 (20 ref.)

The use of quinolones as therapy in granulocytopenic cancer patients. Comparison with other antimicrobials. Krcméry V Jr. **Drugs** 1995;49 Suppl 2:139–43 (30 ref.)

Quinolones and osteomyelitis: state-of-the-art. Lew DP, et al. **Drugs** 1995;49 Suppl 2:100–11 (48 ref.)

Short course quinolone therapy of typhoid fever in developing countries. Limson BM. **Drugs** 1995;49 Suppl 2:136–8 (21 ref.)

Veterinary use of new quinolones in Japan. Nakamura S. **Drugs** 1995;49 Suppl 2:152–8 (41 ref.)

Prophylactic use of the new quinolones for prevention of nosocomial infection in the intensive care unit. Potgieter PD, et al. **Drugs** 1995;49 Suppl 2:86–91 (34 ref.)

Quinolones in sexually transmitted diseases. Global experience. Ridgway GL. **Drugs** 1995;49 Suppl 2:115–22 (46 ref.)

Effect of quinolone use on antimicrobial susceptibility patterns over a 5-year period. Segreti J, et al. **Drugs** 1995; 49 Suppl 2:185–7

Evaluation of the activity of different quinolones in the experimental chlamydial salpingitis mouse model. Thomas D, et al. **Drugs** 1995;49 Suppl 2:261–3

A guide to the treatment of lower respiratory tract infections. Vogel F. **Drugs** 1995 Jul;50(1):62–72 (56 ref.)

The new quinolones in the treatment of diarrhoea and typhoid fever. Waiz A. **Drugs** 1995;49 Suppl 2:132–5 (54 ref.)

Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. Klesel N, et al. **J Antimicrob Chemother** 1995 Jun;35(6):805–19

Antibiotic treatment of ophthalmic infection: new developments. Andrews V. **J Hosp Infect** 1995 Jun;30 Suppl:268–74

Systemic prophylaxis of experimental staphylococcal endophthalmitis: comparative efficacy of sparfloxacin, pefloxacin, imipenem, vancomycin, and amikacin. Marrakchi-Benjaafar S, et al. **J Infect Dis** 1995 Nov; 172(5):1312–6

High-level quinolone resistance in Neisseria gonorrhoeae: a report of two cases. Tapsall JW, et al. **Sex Transm Dis** 1995 Sep-Oct;22(5):310–1

[Prevention using quinolones in transurethral surgery] Gasser TC. **Ann Urol (Paris)** 1996;30(3):124–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Urinary infections and the role of quinolones] Rutschmann O. **Rev Med Suisse Romande** 1996 May;116(5):405–8 (34 ref.) **(Fre)**

[Antibacterial therapy in the combined treatment of periodontitis] Romanov AE, et al. **Stomatologiia (Mosk)** 1996;75(1):23–5 (Eng. Abstr.) **(Rus)**

TOXICITY

Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolone-induced arthropathy. Stahlmann R, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2013–8

Activity of hepatic drug metabolizing enzymes following nalidixic acid dosed feed treatment in F344 rats and B6C3F1 mice. Dudley CN, et al. **Pharmacol Toxicol** 1995 Nov;77(5):352–4

ANTI-INFECTIVE AGENTS, TOPICAL see **ANTI-INFECTIVE AGENTS, LOCAL**

ANTI-INFECTIVE AGENTS, URINARY

ADMINISTRATION & DOSAGE

Dosage regimens of trimethoprim/sulfamethoxazole (TPM/SMX) in patients with renal dysfunction [letter] Nahata MC. **Ann Pharmacother** 1995 Dec;29(12):1300

ADVERSE EFFECTS

Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Beumont MG, et al. **Am J Med** 1996 Jun;100(6):611–6

Sulfa drug reaction. Lilley LL, et al. **Am J Nurs** 1996 Jan; 96(1):14

Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Alappan R, et al. **Ann Intern Med** 1996 Feb 1;124(3):316–20

Severe hyperkalemia with trimethoprim-quinapril [letter] Thomas RJ. **Ann Pharmacother** 1996 Apr;30(4):413–4

Patch testing in an unusual case of toxic epidermal necrolysis. Klein CE, et al. **Contact Dermatitis** 1995 Dec;33(6):448–9

Co-trimoxazole use restricted. **Drug Ther Bull** 1995 Dec; 33(12):92–3

Treatment of anaphylaxis following oral co-trimoxazole [letter] Kumar AS. **Indian Pediatr** 1996 Mar;33(3):249–50

Anaphylaxis to trimethoprim [letter] Cabañas R, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):137–8

Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV-infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis. Hennessy S, et al. **J Gen Intern Med** 1995 Jul;10(7):380–6

Trimethoprim and sulfonamide-associated meningoencephalitis with MRI correlates. Blumenfeld H, et al. **Neurology** 1996 Feb;46(2):556–8

[Interaction between warfarin and nalidic acid] Gulløv AL, et al. **Ugeskr Laeger** 1996 Sep 9;158(37):5174–5 (Eng. Abstr.) **(Dan)**

[Surgically treated chronic bilateral Achilles tendon disease, without spontaneous rupture, caused by perfloxacin (letter)] Beuchard J, et al. **Presse Med** 1996 Jun 29;25(23):1083 **(Fre)**

[Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis. Clinico-immunological demonstration of its allergic origin] Cario E, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):129–32 (10 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Pyrrolo[2,3-d]pyrimidines and pyrido[2,3-d]pyrimidines as conformationally restricted analogues of the antibacterial agent trimethoprim. Kuyper LF, et al. **Bioorg Med Chem** 1996 Apr;4(4):593–602

METABOLISM

[Study of the elimination of residues and local tissue injury following intramuscular injection of a solution of the combination trimethoprim/sulfatroxazole in pigs] Szancer J, et al. **Tijdschr Diergeneeskd** 1996 Mar 15;121(6):156–8 (Eng. Abstr.) **(Dut)**

PHARMACOLOGY

Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men. Witt JM, et al. **Ann Pharmacother** 1996 Apr;30(4):347–50

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). III. Secular changes in susceptibility] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Sep;48(9):1174–263 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Sep;48(9):1131–60 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Urinary tract infections in elderly women. Nygaard IE, et al. **Am Fam Physician** 1996 Jan;53(1):175–82 (29 ref.)

Comparing the efficacy of pefloxacin and ciprofloxacin in the treatment of acute uncomplicated gonococcal urethritis in males. Leow YH, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):515–8

Uncomplicate the treatment of uncomplicated urinary tract infections [letter; comment] Ditmanson LF, et al. **Arch Intern Med** 1996 Jan 8;156(1):111–3. Comment on: Arch Intern Med 1995 Mar 13;155(5):485–94.

Treatment of urinary tract infections. Korman TM, et al. **Aust Fam Physician** 1995 Dec;24(12):2205–11 (5 ref.)

Comparison of enoxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with complicated urinary tract infection. Gottlieb PL. **Clin Ther** 1995 May-Jun;17(3):493–502

Cotrimoxazole. Rationale for re-examining its indications for use. Howe RA, et al. **Drug Saf** 1996 Apr;14(4):213–8 (35 ref.)

Evaluation of clinical efficacy of antimicrobials in complicated urinary tract infections. Comparison of Japanese criteria with IDSA guidelines. Infectious Diseases Society of America. Kawada Y, et al. **Drugs** 1995;49 Suppl 2:362–4

Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. Lundstrom TS, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):747–67 (91 ref.)

Does treatment of asymptomatic bacteriuria in older ambulatory women reduce subsequent symptoms of urinary tract infection? Abrutyn E, et al. **J Am Geriatr Soc** 1996 Mar;44(3):293–5

Atypical presentation of systematic nocardiosis and successful treatment with meropenem. Velasco N, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):709–10

Inefficacy of pefloxacin in steroid-responsive nephrotic syndrome [letter] Bagga A, et al. **Pediatr Nephrol** 1995 Dec; 9(6):793–4

Prospective randomized open study between ciprofloxacin and a combination of sulfadiazine and trimethoprim in antibiotic prophylaxis in connection with transurethral prostatectomy. Lukkarinen O, et al. **Scand J Urol Nephrol** 1996 Feb;30(1):33–6

Prophylaxis against spontaneous bacterial peritonitis. Is trimethoprim-sulfamethoxazole the answer? Xavier S, et al. **Trop Gastroenterol** 1996 Jan-Mar;17(1):61–3

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). II. Background of patients] Kumamoto Y, et al. **Jpn J Antibiot** 1995 Sep;48(9):1161–73 (Eng. Abstr.) **(Jpn)**

ANTI-INFLAMMATORY AGENTS

Immunosuppressive and anti-inflammatory properties of interleukin 10. de Vries JE. **Ann Med** 1995 Oct;27(5):537–41 (48 ref.)

Molecular mechanisms of anti-inflammatory action of glucocorticoids. Cato AC, et al. **Bioessays** 1996 May; 18(5):371–8 (67 ref.)

Allergic contact dermatitis due to burdock (Arctium lappa). Rodriguez P, et al. **Contact Dermatitis** 1995 Aug; 33(2):134–5

Photoprotective and antiinflammatory effects of topical glycolic acid. Perricone NV, et al. **Dermatol Surg** 1996 May;22(5):435–7

A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes. Grey ST, et al. **J Immunol** 1996 Mar 15;156(6):2256–63

Complement-specific antibodies: designing novel anti-inflammatories. Matis LA, et al. **Nat Med** 1995 Aug; 1(8):839–42 (18 ref.)

Phosphodiesterase type IV inhibitors. Palfreyman MN, et al. **Prog Med Chem** 1996;33:1–52 (306 ref.)

ADMINISTRATION & DOSAGE

The adjuvant therapy of pemphigus. An update. Bystryn JC, et al. **Arch Dermatol** 1996 Feb;132(2):203–12 (89 ref.)

The antiinflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis. Ornstein MH, et al. **Arthritis Rheum** 1996 Jan; 39(1):157–61

Rheumatoid arthritis and heparin [letter] Gaffney A, et al. **Br J Rheumatol** 1996 Aug;35(8):808–9

Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in diabetic hamsters. Bouskela E, et al. **Int J Microcirc Clin Exp** 1995 Nov-Dec;15(6):293–300

Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. Ardizzone S, et al. **J Clin Gastroenterol** 1995 Dec;21(4):287–9

Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease [see comments] Belluzzi A, et al. **N Engl J Med** 1996 Jun 13;334(24):1557–60. Comment in: N Engl J Med 1996 Jun 13;334(24):1599–1600.

ADVERSE EFFECTS

Sulphasalazine-induced agranulocytosis successfully treated with filgrastim [letter] Crawford GP, et al. **Aust N Z J Med** 1996 Apr;26(2):240

Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of wegener's granulomatosis. Salerno SM, et al. **Chest** 1996 Aug;110(2):556–9

Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. Nakajima H, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:115–7

Drug induced otalgia due to mesalazine and sulphasalazine. Wareing M, et al. **J Laryngol Otol** 1996 May;110(5):466–7

CHEMICAL SYNTHESIS

[Stereoselective synthesis and pharmacological properties of metabolites of new antiinflammatory agent. 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide (FK3311)] Nakamura K, et al. **Yakugaku Zasshi** 1995 Nov; 115(11):928–36 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Isomaki P, et al. **Arthritis Rheum** 1996 Mar;39(3):386–95

Modulation of expression of the anti-inflammatory cytokines interleukin-13 and interleukin-10 by interleukin-3. Marietta EV, et al. **Eur J Immunol** 1996 Jan;26(1):49–56

METABOLISM

Characterization of a novel anti-inflammatory factor produced by RM3/1 macrophages derived from glucocorticoid treated human monocytes. Hamann W, et al. **Inflamm Res** 1995 Dec;44(12):535–40

[Antioxidant and anti-inflammatory protection of vascular endothelial cells by new synthetic mimics of glutathione peroxidase] Chaudière J, et al. **C R Seances Soc Biol Fil** 1995;189(5):861–82 (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine. Awni WM, et al. **Clin Pharmacokinet** 1995;29 Suppl 2:98–104

PHARMACOLOGY

An antiinflammatory effect of lidocaine? [editorial; comment] Lisander B. **Acta Anaesthesiol Scand** 1996 Mar;40(3):285–6 . Comment on: Acta Anaesthesiol Scand 1996 Mar;40(3):287–92.

The anti-inflammatory effects of Chinese crude drug prescriptions on experimental arthritis. Lin CC, et al. **Am J Chin Med** 1995;23(2):145–52

Attempt to pharmacologically modulate procoagulant activity of lipopolysaccharide-stimulated adherent bovine alveolar macrophages. Olchowy TW, et al. **Am J Vet Res** 1996 May;57(5):659–63

Budesonide or prednisolone in active Crohn's disease [editorial] Baert F, et al. **Ann Med** 1995 Dec;27(6):631

The anti-inflammatory activity of N-substituted indazolones in mice. Tse E, et al. **Arch Pharm (Weinheim)** 1996 Jan; 329(1):35–40

Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Multiparameter analysis of disease magnetic resonance imaging and bone mineral density measurements. Bradbeer JN, et al. **Arthritis Rheum** 1996 Mar;39(3):504–14

Anti-inflammatory mechanisms of glucocorticoids. Barnes PJ. **Biochem Soc Trans** 1995 Nov;23(4):940–5 (50 ref.)

Inhibition of adhesion molecule expression by N-alkylthiopyridine-benzo[b]thiophene-2-carboxamides. Boschelli DH, et al. **Bioorg Med Chem** 1996 Apr; 4(4):557–62

Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro. Anderson R, et al. **Br J Pharmacol** 1996 Apr;117(7):1387–94

Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits. Gozzard N, et al. **Br J Pharmacol** 1996 Apr;117(7):1405–12

Sulphasalazine, sulphapyridine or 5-aminosalicylic acid—which is the active moiety in rheumatoid arthritis? Bird HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:16–9 (11 ref.)

A novel action of glucocorticoids—NF-kappa B inhibition [editorial] Boumpas DT. **Br J Rheumatol** 1996 Aug; 35(8):709–10

The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism. Cronstein BN. **Br J Rheumatol** 1995 Nov;34 Suppl 2:30–2 (20 ref.)

Sulphasalazine: mechanism of action in rheumatoid arthritis. Smedegård G, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:7–15 (133 ref.)

Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases. Bruin KF, et al. **Eur J Gastroenterol Hepatol** 1995 Aug; 7(8):791–5

Fenspiride: an anti-inflammatory drug with potential benefits in the treatment of endotoxemia. De Castro CM, et al. **Eur J Pharmacol** 1995 Dec 29;294(2-3):669–76

Delayed anti-inflammatory action of nedocromil sodium in the rat paw is dependent on de novo protein synthesis. Raud J, et al. **Eur J Pharmacol** 1995 Aug 25; 282(1-3):207–11

Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Banner KH, et al. **Eur Respir J** 1995 Jun; 8(6):996–1000 (50 ref.)

Modulation of the bronchial inflammation in sensitized guinea-pigs by FK506, nedocromil sodium and dexamethasone. Lapa e Silva JR, et al. **Eur Respir J** 1995 Aug;8(8):1321–7

Generation of TNF alpha, IFN gamma, IL-6, IL-4 and IL-10 in mouse serum from trichinellosis: effect of the anti-inflammatory compound 4-deoxypyridoxine (4-DPD). Frydas S, et al. **Immunol Lett** 1996 Mar; 49(3):179–84

The anti-inflammatory activity of some sulphonamides in albino rats. Hiremath SV, et al. **Indian J Med Res** 1996 Feb;103:120–5

Effects of chlomipramine and fluoxetine on subcutaneous carrageenin-induced inflammation in the rat. Bianchi M, et al. **Inflamm Res** 1995 Nov;44(11):466–9

Characterization of a novel anti-inflammatory factor produced by RM3/1 macrophages derived from glucocorticoid treated human monocytes. Hamann W, et al. **Inflamm Res** 1995 Dec;44(12):535–40

Cetirizine exerts anti-inflammatory effects on human neutrophils. Köller M, et al. **Int Arch Allergy Immunol** 1996 May;110(1):52–6

Survival and morphology of isolated pancreatic acinar cells from rats with induced acute pancreatitis are not improved with anti-inflammatory drugs. Richter F, et al. **Int J Pancreatol** 1995 Oct;18(2):145–52

Ethnopharmacology of bear gall bladder: I. Li YW, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):27–31

TNF/IL-1-inducible protein TSG-6 potentiates plasmin inhibition by inter-alpha-inhibitor and exerts a strong anti-inflammatory effect in vivo. Wisniewski HG, et al. **J Immunol** 1996 Feb 15;156(4):1609–15

Anti-inflammatory treatment influences neuronal apoptotic cell death in the dentate gyrus in experimental pneumococcal meningitis. Zysk G, et al. **J Neuropathol Exp Neurol** 1996 Jun;55(6):722–8

Effect of oleanolic acid on complement in adjuvant- and carrageenan-induced inflammation in rats. Kapil A, et al. **J Pharm Pharmacol** 1995 Jul;47(7):585–7

Effects of intravenous nonsteroidal antiinflammatory drugs on a C-fiber reflex elicited by a wide range of stimulus intensities in the rat. Bustamante D, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1232–43

Anti-inflammatory properties of Gö 6850: a selective inhibitor of protein kinase C. Jacobson PB, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):995–1002

Amelioration by Kupffer cell blockade in hepatic damage induced by cold preservation with subsequent plasma-supplemented perfusion. Nakamura T, et al. **J Surg Res** 1996 May;62(2):207–15

Methotrexate for inflammatory bowel disease: pharmacology and preliminary results [see comments] Egan LJ, et al. **Mayo Clin Proc** 1996 Jan;71(1):69–80 (98 ref.). Comment in: Mayo Clin Proc 1996 Jan;71(1):104–5.

Immunomodulatory actions of xanthines and isoenzyme selective phosphodiesterase inhibitors. Banner KH, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):286–92 (96 ref.)

Proliferation of hepatocytes and attenuation from carbon tetrachloride hepatotoxicity by gadolinium chloride in rats. Ishiyama H, et al. **Pharmacol Toxicol** 1995 Oct;77(4):293–8

Mechanism of action of anti-inflammatory drugs. Vane JR, et al. **Scand J Rheumatol Suppl** 1996;102:9–21 (75 ref.)

[Establishing human, conjunctival fibroblast cultures as a test system for evaluating ophthalmic drugs] Frantz A, et al. **Klin Monatsbl Augenheilkd** 1996 Mar;208(3):181–7 (Eng. Abstr.) **(Ger)**

[Stereoselective synthesis and pharmacological properties of metabolites of new antiinflammatory agent. 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide (FK3311)] Nakamura K, et al. **Yakugaku Zasshi** 1995 Nov; 115(11):928–36 (Eng. Abstr.) **(Jpn)**

[Antimicrobial and anti-inflammatory actions of tea-leaf saponin] Sagesaka YM, et al. **Yakugaku Zasshi** 1996 Mar; 116(3):238–43 (Eng. Abstr.) **(Jpn)**

[Heparin—new perspectives on its antiinflammatory action] Krasnowska M, et al. **Postepy Hig Med Dosw** 1995; 49(5):661–9 (56 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Small-bowel obstruction and the effects of lidocaine, atropine and hexamethonium on inflammation and fluid losses [see comments] Nellgård P, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):287–92. Comment in: Acta Anaesthesiol Scand 1996 Mar;40(3):285–6.

Asthma treatment in schoolchildren: lung function in different therapeutic groups. Korppi M, et al. **Acta Paediatr** 1996 Feb;85(2):190–4

Modern treatment of asthma in children. Zeffren BS, et al. **Adv Pediatr** 1996;43:423–68 (214 ref.)

Chloroquine for mild to moderately active ulcerative colitis: comparison with sulfasalazine. Goenka MK, et al. **Am J Gastroenterol** 1996 May;91(5):917–21

Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulfasalazine [letter] Mantzaris GJ, et al. **Am J Gastroenterol** 1995 Oct; 90(10):1900

Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Diamant Z, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1790–5

Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy. Calonge M, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):124–30

Anti-inflammatory drugs in the fight against Alzheimer's disease. McGeer PL, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:213–20 (16 ref.)

Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Sais G, et al. **Arch Dermatol** 1995 Dec; 131(12):1399–402

Treatment of recurrent aphthous stomatitis with pentoxifylline [letter] Pizarro A, et al. **Br J Dermatol** 1995 Oct;133(4):659–60

Sulphapyridine—a new agent for the treatment of ocular cicatricial pemphigoid. Elder MJ, et al. **Br J Ophthalmol** 1996 Jun;80(6):549–52

Anti-inflammatory agents in allergic diseases [editorial] Bonham CA, et al. **Clin Exp Immunol** 1995 Oct;102(1):1–5 (45 ref.)

Treatment of early rheumatoid arthritis: a review of current and future concepts and therapy [see comments] Dawes PT, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):381–94 (87 ref.). Comment in: Clin Exp Rheumatol 1996 Jan-Feb;14(1):106.

Clinical evaluation of high-molecular-weight sodium hyaluronate for the treatment of patients with periarthritis of the shoulder. Itokazu M, et al. **Clin Ther** 1995 Sep-Oct; 17(5):946–55

Cheilitis granulomatosa treated with metronidazole. Miralles J, et al. **Dermatology** 1995;191(3):252–3

Changes in urinary nitrate and nitrite during treatment of ulcerative colitis. Sasajima K, et al. **Digestion** 1996; 57(3):170–3

Comprehensive treatment of inflammatory diseases of parodontium by antiseptic and antiinflammatory agents made in Bulgaria. Botushanov P, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):100–1

Decrease in hospitalization for treatment of childhood asthma with increased use of antiinflammatory treatment, despite an increase in prevalence of asthma. Wennergren G, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):742–8

Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. Bouscarat F, et al. **J Am Acad Dermatol** 1996 Apr;34(4):683–4

Anti-inflammatory activity of the bark of Hippocratea excelsa. Perez RM, et al. **J Ethnopharmacol** 1995 Jul 7; 47(2):85–90

Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. Munakata A, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:108–11

The pharmacological modulation of angiogenesis in chronic granulomatous inflammation. Colville-Nash PR, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1463–72

Sulfasalazine: a definitively efficient treatment for psoriatic arthritis [letter] Goupille P, et al. **J Rheumatol** 1996 Apr; 23(4):791–2

Antiinflammatory drugs in the treatment of Alzheimer's disease [editorial] MacKenzie IR. **J Rheumatol** 1996 May; 23(5):806–8

Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. Hill GE, et al. **J Thorac Cardiovasc Surg** 1995 Dec; 110(6):1658–62

Methotrexate for refractory Crohn's disease: preliminary answers to definitive questions [editorial; comment] Kozarek RA. **Mayo Clin Proc** 1996 Jan;71(1):104–5. Comment on: Mayo Clin Proc 1996 Jan;71(1):69–80.

Nedocromil sodium (Tilade) metered aerosol in the treatment of chronic cough [letter] Young IH. **Med J Aust** 1996 Jun 17;164(12):755

Anti-inflammatory treatment of asthma in children. What strategy is appropriate? Frazier CA. **N C Med J** 1995 Dec; 56(12):616–8 (15 ref.)

Keeping Crohn's disease quiet [editorial; comment] Hodgson HJ. **N Engl J Med** 1996 Jun 13;334(24):1599–1600. Comment on: N Engl J Med 1996 Jun 13;334(24):1557–60.

Sudeck's atrophy of the left tibiotarsal joint in a renal transplant patient: effects of medical and physical therapy [letter] Campieri C, et al. **Nephron** 1995;71(1):122–3

Investigational agents for rheumatoid arthritis. Merkel PA, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):779–96 (85 ref.)

Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Fujii T, et al. **Thorax** 1995 Dec;50(12):1246–52

Application of corbrin capsule in human renal transplantation. Min Z, et al. **Transplant Proc** 1996 Jun; 28(3):1626–8

[Treatment of asthma; are there still questions? (see comments)] van Schayck CP. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):72–7 (47 ref.). Comment in: Ned Tijdschr Geneeskd 1996 Mar 2;140(9):508–9. **(Dut)**

[Use of anti-inflammatory drugs in children] Hoppu K, et al. **Duodecim** 1994;110(6):607–14 (29 ref.) **(Fin)**

[Changing treatment of inflammatory bowel diseases] Karvonen AL, et al. **Duodecim** 1994;110(20):1945–54 (58 ref.) **(Fin)**

[Blood prolactin under the effect of protirelin in spondylarthropathies. Treatment trial of 4 cases of reactive arthritis and 2 cases of psoriatic arthritis with bromocriptine] Eulry F, et al. **Ann Med Interne (Paris)** 1996;147(1):15–9 (Eng. Abstr.) **(Fre)**

[Treatment of inflammation with anti-inflammatory cytokines: example in models of auto-immune diseases] Bessis N, et al. **C R Seances Soc Biol Fil** 1995;189(4):579–90 (33 ref.) (Eng. Abstr.) **(Fre)**

[The leukotriene signal pathway--a very promising point of entry for inhibitors in therapy of inflammatory diseases] Müller MJ. **Pharm Unserer Zeit** 1995 Sep;24(5):264–72 (53 ref.) **(Ger)**

ANTI-INFLAMMATORY AGENTS, GOLD see **ANTIRHEUMATIC AGENTS, GOLD**

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL

Diluted effect from diluted mesalamine rectal suspension? [letter; comment] Wiita B, et al. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2136–7. Comment on: Am J Hosp Pharm 1994 Dec 1;51(23):2955–7.

The addition of tenoxicam to prilocaine for intravenous regional anaesthesia. Jones NC, et al. **Anaesthesia** 1996 May;51(5):446–8

Comparison of diclofenac sodium and morphine sulphate for postoperative analgesia after day case inguinal hernia surgery. McEvoy A, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):363–6

Over the counter drugs. GPs lack awareness of non-steroidal anti-inflammatory drugs available over the counter [letter; comment] Pal B. **BMJ** 1996 Jul 13;313(7049):116. Comment on: BMJ 1996 Mar 9;312(7031):593–4. Comment on: BMJ 1996 Mar 9;312(7031):617–8.

Analgesic and anti-inflammatory effects of lignocaine-prilocaine (EMLA) cream in human burn injury. Pedersen JL, et al. **Br J Anaesth** 1996 Jun; 76(6):806–10

Characteristics of ulcers of the small bowel induced by non-steroidal anti-inflammatory drugs in the rat: implications for clinical practice. Collins AJ, et al. **Br J Rheumatol** 1995 Aug;34(8):727–31

Intravenous ketorolac vs diclofenac for analgesia after maxillofacial surgery. Tarkkila P, et al. **Can J Anaesth** 1996 Mar;43(3):216–20

Utilization of sialic acid-binding synthetic peptide sequences derived from pertussis toxin as novel anti-inflammatory agents. Heerze LD, et al. **Glycobiology** 1995 Jun; 5(4):427–33

AVMA conveys concerns to CVM on dipyrone ban [news] **J Am Vet Med Assoc** 1996 Feb 15;208(4):460

Indomethacin and Alzheimer's disease. Smalheiser NR, et al. **Neurology** 1996 Feb;46(2):583

Use of nonsteroidal anti-inflammatory drugs in cancer. Pace V. **Palliat Med** 1995 Oct;9(4):273–86 (105 ref.)

[Misleading advertising on a new NSAID (letter)] Hammer J. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):301 **(Nor)**

[The use of an analgin-novocaine-platyphylline mixture for arresting the pain attack and treating trigeminal neuralgia] Sheshelovskii EG, et al. **Stomatologiia (Mosk)** 1996;75(1):44 **(Rus)**

[Nabumetone] Simón M, et al. **Rev Med Univ Navarra** 1995 Jul-Sep;39(3):164–72 (51 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Effect of intravenous ketoprofen on pain after outpatient laparoscopic sterilisation. Eriksson H. **Acta Anaesthesiol Scand** 1995 Oct;39(7):975–8

Gastric mucosal injury and adaptation to oral and rectal administration of naproxen. Lipscomb GR, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):133–8

A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Kam L, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1338–42

Salsalate, morphine, and postoperative ileus. Cheng G, et al. **Am J Surg** 1996 Jan;171(1):85–8; discussion 88–9

Analgesia for day surgery. Evaluation of the effect of diclofenac given before or after surgery with or without bupivacaine infiltration. Chan A, et al. **Anaesthesia** 1996 Jun;51(6):592–5

The effect of a combination of rectal diclofenac and caudal bupivacaine on postoperative analgesia in children. Gadiyar V, et al. **Anaesthesia** 1995 Sep;50(9):820–2

Topical ibuprofen for skin analgesia prior to venepuncture. Smith AJ, et al. **Anaesthesia** 1996 May;51(5):495–7

Systemic piroxicam as an adjunct to patient-controlled analgesia with alfentanil for postoperative pain relief. Van Lancker P, et al. **Anaesthesia** 1996 Jul;51(7):658–62

Patients' attitudes to rectal drug administration [see comments] Vyvyan HA, et al. **Anaesthesia** 1995 Nov; 50(11):983–4. Comment in: Anaesthesia 1996 Apr;51(4):401–2. Comment in: Anaesthesia 1996 Apr;51(4):402.

Postoperative analgesia in dental day case surgery. A comparison between Feldene 'Melt' (piroxicam) and diclofenac suppositories. Wakeling HG, et al. **Anaesthesia** 1996 Aug;51(8):784–6

Off-label use of ketorolac [letter; comment] Finnegan MA. **Anesth Analg** 1996 Jul;83(1):197. Comment on: Anesth Analg 1995 Jun;80(6):1154–7.

Sustained-release ibuprofen as an adjunct to morphine patient-controlled analgesia. Plummer JL, et al. **Anesth Analg** 1996 Jul;83(1):92–6

Postarthroscopic meniscus repair analgesia with intraarticular ketorolac or morphine. Reuben SS, et al. **Anesth Analg** 1996 May;82(5):1036–9

Nonsteroidal antiinflammatory drugs, opioids, and routine anesthesia [letter; comment] van den Berg AA. **Anesth Analg** 1995 Nov;81(5):1110–1. Comment on: Anesth Analg 1994 Dec;79(6):1178–90.

Prophylactic use of epidural mepivacaine/morphine, systemic diclofenac, and metamizole reduces postoperative morphine consumption after major abdominal surgery. Rockemann MG, et al. **Anesthesiology** 1996 May; 84(5):1027–34

Dual therapy with doxycycline and ketoprofen compared to doxycycline in the treatment of uncomplicated non-gonococcal urethritis. Tay YK, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):519–22

An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. **Ann Intern Med** 1996 Jan 15;124(2):204–11

A prospective, double-blind, randomized study of the effects of perioperative steroids on palatoplasty patients. Senders CW, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar; 122(3):267–70

Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone [see comments] Blackburn WD Jr, et al. **Arthritis Rheum** 1995 Oct;38(10):1447–56. Comment in: Arthritis Rheum 1996 Jul;39(7):1263–4.

Peritonsillar infiltration with low-dose tenoxicam after tonsillectomy. Knudsen KE, et al. **Br J Anaesth** 1995 Sep; 75(3):286–8

Naproxen after day-case laparoscopic sterilization [letter; comment] Williams PI. **Br J Anaesth** 1996 Jan;76(1):168. Comment on: Br J Anaesth 1995 Jul;75(1):12–4.

Evaluation of different doses of soluble ibuprofen and ibuprofen tablets in postoperative dental pain. Seymour RA, et al. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):110–4

An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Bevis PJ, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:56–60

Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device. de Klerk E, et al. **Br J Rheumatol** 1996 Jan;35(1):60–5

Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Ghozlan PR, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:51–5

Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Hosie J, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:39–43

A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Huskisson EC, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:29–34

A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Lindén B, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:35–8

A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Reginster JY, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:17–21

Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration. Stei P, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:44–50

A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Wojtulewski JA, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:22–8

Comparative effects of three doses of intravenous ketorolac or morphine on emesis and analgesia for restorative dental surgery in children. Purday JP, et al. **Can J Anaesth** 1996 Mar;43(3):221–5

Use of ketoprofen as an antipyretic in cats. Glew A, et al. **Can Vet J** 1996 Apr;37(4):222–5

Ultrasonographic renal changes associated with phenylbutazone administration in three foals. Léveillé R, et al. **Can Vet J** 1996 Apr;37(4):235–6

Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Martínez ME, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct-Nov; 4(7):703–7

Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Auvinet B, et al. **Clin Ther** 1995 Nov-Dec;17(6):1078–98

Endoscopic assessment of the effects of dipyrone (metamizol) in comparison to paracetamol and placebo on the gastric and duodenal mucosa of healthy adult volunteers. Bianchi Porro G, et al. **Digestion** 1996;57(3):186–90

A comparison between ketorolac and diclofenac in laparoscopic sterilization. Chui PT, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):597–601

Peri-operative administration of rectal diclofenac sodium. The effect on renal function in patients undergoing minor orthopaedic surgery. Irwin MG, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):403–6

Intramuscular NSAIDS reduce post-operative pain after minor outpatient anaesthesia. Jakobsson J, et al. **Eur J Anaesthesiol** 1996 Jan;13(1):67–71

Tonic versus phasic pain: dose-related effects of ketoprofen. Hummel T, et al. **Eur J Clin Pharmacol** 1995;49(1-2):7–14

Preparation and characterisation of polyphosphazene-based controlled release systems for naproxen. Caliceti P, et al. **Farmaco** 1995 Dec;50(12):867–74

Emergency treatment of renal colic with intravenous ketoprofen. el-Baz MA, et al. **Int Urol Nephrol** 1995; 27(3):245–9

Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. Ardizzone S, et al. **J Clin Gastroenterol** 1995 Dec;21(4):287–9

Enhanced in vivo performance of liposomal indomethacin derived from effervescent granule based proliposomes. Katare OP, et al. **J Microencapsul** 1995 Sep-Oct; 12(5):487–93

Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. Roy SD, et al. **J Pharm Sci** 1995 Oct; 84(10):1190–6

Pulse methylprednisolone in rheumatoid arthritis: effects on peripheral blood and synovial fluid neutrophil surface phenotype. Youssef P, et al. **J Rheumatol** 1995 Nov; 22(11):2065–71

Systemic use of pentosan polysulphate in the treatment of osteoarthritis. Read RA, et al. **J Small Anim Pract** 1996 Mar;37(3):108–14

Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. Varvarigou A, et al. **JAMA** 1996 Feb 21;275(7):539–44

A case of oral lichen planus with chronic hepatitis C successfully treated by glycyrrhizin. Nagao Y, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):940–4

Local anaesthetic on Filshie clips [letter; comment] Boyd JJ. **Lancet** 1995 Oct 14;346(8981):1033; discussion 1033–4 . Comment on: Lancet 1995 Jul 8;346(8967):82–5.

Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in albino rat. Babu PS, et al. **Mol Cell Biochem** 1995 Nov 8; 152(1):13–21

The effect of ketorolac as an adjuvant to local anaesthetic infiltration for analgesia in paediatric umbilical hernia surgery. Graham SG, et al. **Paediatr Anaesth** 1995; 5(3):161–3

Interrupted response to indomethacin treatment [letter] Kenagy DN. **Pediatr Nephrol** 1995 Dec;9(6):790–1

Ionic strength dependence of dissolution for Eudragit S-100 coated pellets. Kararli TT, et al. **Pharm Res** 1995 Nov; 12(11):1813–6

Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Reddy BS. **Prev Med** 1996 Jan-Feb;25(1):48–50 (13 ref.)

Intravenous ketorolac and subarachnoid opioid analgesia in the management of acute postoperative pain. Gwirtz KH, et al. **Reg Anesth** 1995 Sep-Oct;20(5):395–401

Comparative effects of nabumetone, naproxen, piroxicam, and diclofenac on rat gastric irritancy following acute exposure to OTC non-steroidal anti-inflammatory agents and other gastric irritants. Carryl OR, et al. **Scand J Rheumatol** 1995;24(6):336–41

Schizophrenia, Alzheimer's disease, and anti-inflammatory agents. Oken RJ, et al. **Schizophr Bull** 1996;22(1):1–4 (24 ref.)

Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5'-monophosphate challenge in asthma. Wang M, et al. **Thorax** 1996 Aug;51(8):799–804

A comparison of the effect of intramuscular diclofenac, ketorolac or piroxicam on postoperative pain following laparoscopy. O'Hanlon JJ, et al. **Ulster Med J** 1996 May; 65(1):51–4

Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. Gross V, et al. **Z Gastroenterol** 1995 Oct;33(10):581–4

[Non-steroidal antirheumatic ointments in the treatment of primary periarticular and intramuscular fibrositis] Vachtenheim J. **Vnitr Lek** 1995 Sep;41(9):609–12 (Eng. Abstr.) **(Cze)**

[Eight days of naproxen therapy can prevent heterotopic ossification after total hip alloplasty] Gebuhr PH, et al. **Ugeskr Laeger** 1996 Feb 19;158(8):1076–8 (Eng. Abstr.) **(Dan)**

[Oral gamma-linoleic acid (Epogam) in the treatment of atopic dermatitis] Lindskov R, et al. **Ugeskr Laeger** 1995 Oct 16;157(42):5872–4 **(Dan)**

[Acetylsalicylic acid in acute and postherpetic neuralgia should no be dissolved in chloroform] van Horssen N. **Ned Tijdschr Geneeskd** 1995 Aug 12;139(32):1657 **(Dut)**

[Differential indications of non-opioid drugs for postoperative analgesia II. Quantification of the analgesic effect of a combination of metamizol plus diclofenac via patient-controlled analgesia] Steffen P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):216–21 (Eng. Abstr.) **(Ger)**

[Differential administration of non-opioids in postoperative analgesia, I. Quantification of the analgesic effect of metamizole using patient-controlled analgesia] Steffen P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr;31(3):143–7 (Eng. Abstr.) **(Ger)**

[Crohn disease: prevention and drug therapy] Gross V, et al. **Chirurg** 1995 Aug;66(8):757–63 (42 ref.) (Eng. Abstr.)

(Ger)

[Anti-inflammatory effects and aqueous humor concentration of various nonsteroidal anti-inflammatory drugs in extracapsular cataract surgery] Hessemer V, et al. **Klin Monatsbl Augenheilkd** 1996 Mar;208(3):161–6 (Eng. Abstr.) **(Ger)**

[5-aminosalicylic acid and chronic inflammatory bowel diseases in children] Klotz U. **Klin Padiatr** 1995 Sep–Oct; 207(5):285–7 (18 ref.) (Eng. Abstr.) **(Ger)**

[Effect of non-steroidal anti-inflammatory drugs on inflammatory reaction. An animal experiment study] Struck HG, et al. **Ophthalmologe** 1995 Dec;92(6):849–53 (Eng. Abstr.) **(Ger)**

[Treatment of muscular injuries with diclofenac-diethylammonium emulsion gel] Böhmer D, et al. **Sportverletz Sportschaden** 1995 Sep;9(3):94–5 **(Ger)**

[Clinical trial comparing a new NSAID with 2 different dosages and diclofenac in patients with arthralgia in acute phase] Alicicco E, et al. **Clin Ter** 1995 Oct;146(10):595–601 (Eng. Abstr.) **(Ita)**

[Clinical evaluation of cinnoxicam 30 mg in patients with osteoarthrosis. A double-blind controlled study] Bestetti F. **Minerva Med** 1996 Mar;87(3):117–22 (Eng. Abstr.) **(Ita)**

[Clinical evaluation of 30 mg cinnoxicam in patients with osteoarthrosis. Double blind controlled trial] Peretti G. **Minerva Med** 1996 Apr;87(4):155–60 (Eng. Abstr.) **(Ita)**

[The relief of postoperative pain by suppositories of buprenorphine or NSAID] Akatsuka M, et al. **Masui** 1996 Mar;45(3):298–303 (Eng. Abstr.) **(Jpn)**

[The effect of indomethacin suppository in preventing mesenteric traction syndrome] Koyama K, et al. **Masui** 1995 Aug;44(8):1131–4 (Eng. Abstr.) **(Jpn)**

[Effects of preoperatively administered flurbiprofen axetil on the action of inhaled anesthesia and postoperative pain] Yamazaki Y, et al. **Masui** 1995 Sep;44(9):1238–41 (Eng. Abstr.) **(Jpn)**

[A long-term clinical analysis of the rheumatoid patients treated by a combination of GST and CCA] Minami M, et al. **Ryumachi** 1995 Oct;35(5):780–91 (Eng. Abstr.) **(Jpn)**

[The use of dalargin for treating recurrent aphthous stomatitis] Maksimovskaia LN. **Stomatologiia (Mosk)** 1995; 74(4):15 **(Rus)**

[The effect of the ultraphonophoesis of deresinated naphthalan in patients with a history of exudative pleurisy] Insanov AB, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec; (6):18–20 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Streptococcal myositis and tissue necrosis with intramuscular administration of diclofenac (Voltaren). Rygnestad T, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1128–30

Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis. Schapowal AG, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):235–50 (0 ref.)

Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. Aabakken L, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):151–6

Mast cells do not contribute to nonsteroidal anti-inflammatory drug-induced gastric mucosal injury in rodents. Rioux KP, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):173–80

Do non-steroidal anti-inflammatory drugs have an effect on gastric cell turnover? Sant SM, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):575–9

Cross-sensitivity among oxicams in piroxicam-caused fixed drug eruption: two case reports. Ordoqui E, et al. **Allergy** 1995 Sep;50(9):741–4

Vanishing bile duct syndrome temporally associated with ibuprofen use. Alam I, et al. **Am J Gastroenterol** 1996 Aug; 91(8):1626–30

Cutaneous hypersensitivity reaction to mesalazine [letter] Aparicio J, et al. **Am J Gastroenterol** 1996 Mar;91(3):620–1

Mesalamine-induced lung toxicity. Bitton A, et al. **Am J Gastroenterol** 1996 May;91(5):1039–40 (10 ref.)

Prostaglandins, NSAIDS, and GI mucosal integrity: can we identify patients at risk of NSAID-induced gastric injury? [editorial; comment] Dajani EZ. **Am J Gastroenterol** 1996 May;91(5):835–6. Comment on: Am J Gastroenterol 1996 May;91(5):873–8.

Diverticular bleeding: are nonsteroidal anti-inflammatory drugs risk factors for hemorrhage and can colonoscopy predict outcome for patients? Foutch PG. **Am J Gastroenterol** 1995 Oct;90(10):1779–84

Nonsteroidal anti-inflammatory drug-induced colonic strictures: two cases and literature review. Gargot D, et al. **Am J Gastroenterol** 1995 Nov;90(11):2035–8 (18 ref.)

Misoprostol and NSAID ulcers [editorial] Isaacs P. **Am J Gastroenterol** 1996 Feb;91(2):187–8

Folliculitis and mesalamine [letter] Lizasoain J, et al. **Am J Gastroenterol** 1996 Apr;91(4):819–20

The relationship between the content of aggressive and protective components in gastric juice and endoscopic findings after naproxen sodium and acetaminophen administration. Marcinkiewicz M, et al. **Am J Gastroenterol** 1996 Feb;91(2):360–5

Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Raskin JB, et al. **Am J Gastroenterol** 1996 Feb;91(2):223–7

Upper gastrointestinal hemorrhage associated with cutaneous application of diclofenac gel. Zimmerman J, et al. **Am J Gastroenterol** 1995 Nov;90(11):2032–4

Nonsteroidal anti-inflammatory drugs and necrotizing fasciitis. Browne BA, et al. **Am J Health Syst Pharm** 1996 Feb 1;53(3):265–9

Analgesic nephropathy. Proceedings of a symposium. June 1995. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S1–70

The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Bennett WM, et al. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S56–62 (28 ref.)

Does aspirin cause acute or chronic renal failure in experimental animals and in humans? D'Agati V. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S24–9 (34 ref.)

Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents. Matzke GR. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S63–70 (38 ref.)

Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Bjorkman DJ. **Am J Med** 1996 Jul 31;101(1A):25S–32S (88 ref.)

Gastrointestinal ulceration with NSAIDs [letter; comment] Cantu TG, et al. **Am J Med** 1995 Oct;99(4):440–1. Comment on: Am J Med 1994 Mar;96(3):274–81.

Gastrointestinal complications of nonsteroidal antiinflammatory drugs: prophylactic and therapeutic strategies [letter; comment] Soloman DH, et al. **Am J Med** 1995 Oct;99(4):441–3. Comment on: Am J Med 1994 Mar;96(3):274–81.

Case report: diclofenac-induced rhabdomyolysis. Delrio FG, et al. **Am J Med Sci** 1996 Aug;312(2):95–7

Emergency! Bleeding gastric ulcer. Tolbert CG, et al. **Am J Nurs** 1996 Feb;96(2):48

Doppler echocardiographic findings of indomethacin-induced occlusion of the fetal ductus arteriosus. Takahashi Y, et al. **Am J Perinatol** 1996 Jan; 13(1):15–8

Noninvasive detection of nonsteroidal anti-inflammatory drug-induced gastropathy in dogs. Meddings JB, et al. **Am J Vet Res** 1995 Aug;56(8):977–81

Diclofenac and post-tonsillectomy haemorrhage [letter] Purday J, et al. **Anaesthesia** 1995 Sep;50(9):827–8

Ischemic stroke following an intramuscular injection of diclofenac. Case report. Kornowski R, et al. **Angiology** 1995 Dec;46(12):1145–7

Misoprostol and nonsteroidal anti-inflammatory drugs [letter; comment] Bubb MR. **Ann Intern Med** 1996 Jun 1; 124(11):1015; discussion 1015–6. Comment on: Ann Intern Med 1995 Aug 15;123(4):309–10.

Misoprostol and gastrointestinal complications in patients taking nonsteroidal anti-inflammatory drugs for rheumatoid arthritis [letter; comment] Grossman CM. **Ann Intern Med** 1996 May 15;124(10):926–7. Comment on: Ann Intern Med 1995 Aug 15;123(4):241–9.

Misoprostol and gastrointestinal complications in patients taking nonsteroidal anti-inflammatory drugs for rheumatoid arthritis [letter; comment] Hammer HF. **Ann Intern Med** 1996 May 15;124(10):927. Comment on: Ann Intern Med 1995 Aug 15;123(4):241–9.

Misoprostol and gastrointestinal complications in patients taking nonsteroidal anti-inflammatory drugs for rheumatoid arthritis [letter; comment] Madhok R, et al. **Ann Intern Med** 1996 May 15;124(10):926; discussion 927. Comment on: Ann Intern Med 1995 Aug 15;123(4):241–9.

Misoprostol and nonsteroidal anti-inflammatory drugs [letter; comment] Moore JR. **Ann Intern Med** 1996 Jun 1; 124(11):1015; discussion 1015–6. Comment on: Ann Intern Med 1995 Aug 15;123(4):309–10.

Misoprostol and nonsteroidal anti-inflammatory drugs [letter; comment] Silverstein FE. **Ann Intern Med** 1996 Jun 1; 124(11):1015; discussion 1015–6. Comment on: Ann Intern Med 1995 Aug 15;123(4):309–10.

Misoprostol and gastrointestinal complications in patients taking nonsteroidal anti-inflammatory drugs for rheumatoid arthritis [letter; comment] Wendel TD. **Ann Intern Med** 1996 May 15;124(10):926; discussion 927. Comment on: Ann Intern Med 1995 Aug 15;123(4):241–9.

Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance [see comments] Chan TY. **Ann Pharmacother** 1995 Dec;29(12):1274–83 (89 ref.). Comment in: Ann Pharmacother 1995 Dec;29(12):1289–91.

Leukocytoclastic vasculitis and hemoptysis after treatment with aceclofenac [letter] Epelde F, et al. **Ann Pharmacother** 1995 Nov;29(11):1168

Warfarin and nonsteroidal antiinflammatory drugs: why not? [editorial; comment] Frazee LA, et al. **Ann Pharmacother** 1995 Dec;29(12):1289–91. Comment on: Ann Pharmacother 1995 Dec;29(12):1274–83.

Diclofenac-associated thrombocytopenia and neutropenia. Kim HL, et al. **Ann Pharmacother** 1995 Jul–Aug; 29(7–8):713–5

Autoimmune hemolytic anemia induced by diclofenac [letter] López A, et al. **Ann Pharmacother** 1995 Jul–Aug; 29(7–8):787

Gastrointestinal complications associated with intramuscular ketorolac tromethamine therapy in the elderly. Maliekal J, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):698–701

Impact of preexisting health conditions on the outcome of an adverse drug reaction alerting program: gastrointestinal disorders before piroxicam and sulindac therapy. Rawson NS. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):676–80

Experience in the development of a postmarketing surveillance network: the pharmacy medication monitoring program. Willison DJ, et al. **Ann Pharmacother** 1995 Dec; 29(12):1208–13

Oral mucosal ulceration from disopyramide [letter] Wittkowsky AK, et al. **Ann Pharmacother** 1995 Dec; 29(12):1299–1300

Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement? [letter; comment] Price AJ, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):395. Comment on: Ann R Coll Surg Engl 1995 Jan;77(1):35–7.

A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Mahmud T, et al. **Ann Rheum Dis** 1996 Apr;55(4):211–3 (31 ref.)

Complications of cutaneous surgery in patients who are taking warfarin, aspirin, or nonsteroidal anti-inflammatory drugs. Otley CC, et al. **Arch Dermatol** 1996 Feb; 132(2):161–6

NSAID gastropathy. A new understanding. Roth SH. **Arch Intern Med** 1996 Aug 12–26;156(15):1623–8 (82 ref.)

Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Singh G, et al. **Arch Intern Med** 1996 Jul 22;156(14):1530–6

Corneal sensitivity and burning sensation. Comparing topical ketorolac and diclofenac. Seitz B, et al. **Arch Ophthalmol** 1996 Aug;114(8):921–4

Nonsteroidal antiinflammatory drug-induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis. Davies NM, et al. **Arthritis Rheum** 1996 Feb; 39(2):321–4 (15 ref.)

Nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children. Dowd JE, et al. **Arthritis Rheum** 1995 Sep;38(9):1225–31

Side-effects of drugs used in the treatment of rheumatoid arthritis. Evans PJ, et al. **Biochem Soc Symp** 1995; 61:195–207 (49 ref.)

Misoprostol in patients taking non-steroidal anti-inflammatory drugs. This reduction in risk is deemed worth while in other circumstances [letter; comment] Blenkiron P. **BMJ** 1996 Mar 30;312(7034):846–7. Comment on: BMJ 1995 Dec 9;311(7019):1518–9.

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Henry D, et al. **BMJ** 1996 Jun 22;312(7046):1563–6

Misoprostol in patients taking non-steroidal anti-inflammatory drugs [editorial] [see comments] Maiden N, et al. **BMJ** 1995 Dec 9;311(7019):1518–9. Comment in: BMJ 1996 Mar 30;312(7034):846; discussion 847. Comment in: BMJ 1996 Mar 30;312(7034):846–7.

Cardiac arrest due to severe hyperkalaemia in patient taking nabumetone and low salt diet. Pal B, et al. **BMJ** 1995 Dec 2;311(7018):1486–7

Misoprostol in patients taking non-steroidal anti-inflammatory drugs. Analysis excluded in important events [letter; comment] Shield MJ, et al. **BMJ** 1996 Mar 30;312(7034):846; discussion 847. Comment on: BMJ 1995 Dec 9;311(7019):1518–9.

NSAID for caesarean section [letter; comment] Jones SF. **Br J Anaesth** 1995 Nov;75(5):666. Comment on: Br J Anaesth 1995 Jun;74(6):643–6.

Lack of photosensitising potential of tenidap, a novel anti-rheumatic agent. Ferguson J, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:63S–66S

Acute liver injury and droxicam use in the region of Friuli-Venezia Giulia [letter] García-Rodríguez LA, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):104–5

Salivary gland swelling following naproxen therapy. Knulst AC, et al. **Br J Dermatol** 1995 Oct;133(4):647–9

Infertility may sometimes be associated with NSAID consumption. Akil M, et al. **Br J Rheumatol** 1996 Jan; 35(1):76–8

Safety of meloxicam: a global analysis of clinical trials. Distel M, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:68–77

Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs. Smith G, et al. **Br J Rheumatol** 1996 May;35(5):458–62

Impairment of renal function after treatment of a burn patient with diclofenac, a non-steroidal antiinflammatory drug. Jonsson CE, et al. **Burns** 1995 Sep;21(6):471–3

Dermacase. Fixed drug eruption. Enta T. **Can Fam Physician** 1996 Jun;42:1099, 1101

An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants. Tannenbaum H, et al. **Can Med Assoc J** 1996 Jul 1;155(1):77–88 (99 ref.)

Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Langenbach R, et al. **Cell** 1995 Nov 3;83(3):483–92

Adverse pulmonary effects of mesalamine [letter; comment] Muzzi A, et al. **Chest** 1995 Oct;108(4):1181. Comment on: Chest 1992 May;101(5):1469–71.

Rheumatoid arthritis exacerbation by G-CSF treatment for bucillamine-induced agranulocytosis [letter] Nakashima H, et al. **Clin Exp Rheumatol** 1995 Sep–Oct;13(5):677–9

Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Stevens DL. **Clin Infect Dis** 1995 Oct;

21(4):977-80
Ketorolac-induced acute renal failure and hyperkalemia [letter] Kelley M, et al. **Clin Nephrol** 1995 Oct;44(4):276-7
Do patients with epistaxis have drug-induced platelet dysfunction? Livesey JR, et al. **Clin Otolaryngol** 1995 Oct; 20(5):407-10
Allergy and intolerance to nonsteroidal anti-inflammatory agents. Arnaud A. **Clin Rev Allergy Immunol** 1995 Fall; 13(3):245-51 (26 ref.)
Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Franck H, et al. **Clin Rheumatol** 1996 Mar;15(2):163-7
Effects of two non-steroidal anti-inflammatory drugs (NSAIDs) and gentamicin on renal function [comment] **Clin Sci (Colch)** 1996 Aug;91(2):119. Comment on: Clin Sci (Colch) 1996 Aug;91(2):187-91.
Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium [see comments] Farag MM, et al. **Clin Sci (Colch)** 1996 Aug;91(2):187-91. Comment in: Clin Sci (Colch) 1996 Aug;91(2):119.
Gastrointestinal blood loss induced by bromfenac sodium, aspirin, and placebo. Cohen A. **Clin Ther** 1995 Nov-Dec; 17(6):1110-7
Safety profile of over-the-counter naproxen sodium. DeArmond B, et al. **Clin Ther** 1995 Jul-Aug;17(4):587-601; discussion 586
Erythema-multiforme-like contact dermatitis due to phenylbutazone. Kerre S, et al. **Contact Dermatitis** 1995 Sep;33(3):213-4
Ampiroxicam-induced photosensitivity. Kurumaji Y. **Contact Dermatitis** 1996 Apr;34(4):298-9
Allergic contact dermatitis of the eyelids and conjunctivitis from diclofenac. Valsecchi R, et al. **Contact Dermatitis** 1996 Feb;34(2):150-1
Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eyedrops. Shimazaki J, et al. **Cornea** 1995 Nov;14(6):623-7
Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Boelsterli UA, et al. **Crit Rev Toxicol** 1995;25(3):207-35 (245 ref.)
Nonsteroidal anti-inflammatory drugs: gastroduodenal injury and beyond. Bernsdorff KR, et al. **Dig Dis** 1995 Jul-Aug; 13(4):251-66 (134 ref.)
Nonsteroidal anti-inflammatory drugs and gastrointestinal disease: pathophysiology, treatment and prevention. Bjorkman DJ, et al. **Dig Dis** 1995 Mar-Apr;13(2):119-29 (81 ref.)
Pleuropericarditis related to the use of mesalamine. Gujral N, et al. **Dig Dis Sci** 1996 Mar;41(3):624-6 (12 ref.)
Pathogenesis of NSAID colitis [letter] Guslandi M. **Dig Dis Sci** 1996 Aug;41(8):1653
Nonsteroidal antiinflammatory drug-induced colitis and misoprostol [letter] Hebuterne X, et al. **Dig Dis Sci** 1996 Mar;41(3):520-1
Neutropenia does not prevent etodolac- or indomethacin-induced gastrointestinal damage in the rat. Melarange R, et al. **Dig Dis Sci** 1995 Dec;40(12):2694-703
Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly [letter; comment] Tait C, et al. **Dig Dis Sci** 1996 Apr;41(4):798-9. Comment on: Dig Dis Sci 1995 Jun;40(6):1345-50.
Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Davies NM. **Dis Colon Rectum** 1995 Dec; 38(12):1311-21 (105 ref.)
Colonic ulceration associated with nonsteroidal anti-inflammatory drugs. Report of three cases. Kaufman HL, et al. **Dis Colon Rectum** 1996 Jun;39(6):705-10 (36 ref.)
Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. de Leeuw PW. **Drugs** 1996 Feb; 51(2):179-87 (49 ref.)
Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Davis R, et al. **Drugs Aging** 1995 Nov;7(5):372-93 (76 ref.)
Use of misoprostol in the elderly: is the expense justified? Stucki G, et al. **Drugs Aging** 1996 Feb;8(2):84-8 (24 ref.)
Ulcer site and complications: relation to Helicobacter pylori infection and NSAID use. al-Assi MT, et al. **Endoscopy** 1996 Feb;28(2):229-33
NSAIDs-induced digestive hemorrhage and esophageal pseudotumor: a case report. Sacca' N, et al. **Endoscopy** 1995 Oct;27(8):632
Toxicity of different nonsteroidal antiinflammatory drugs [letter; comment] Glasner P, et al. **Epidemiology** 1995 Jul; 6(4):466-7. Comment on: Epidemiology 1995 Jan;6(1):49-54.
A comparison of intravenous and inhalational maintenance anaesthesia for endoscopic procedures in the aspirin intolerance syndrome. Novak-Jankovič V, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):345-9
Emergency hospital admissions. Blower AL. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):11-2
Review of Arthrotec clinical data. McKenna F. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):25-9 (9 ref.)
NSAIDs and the gut--where are we now? Shield M. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):13-23 (62 ref.)
Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats [see comments] Babyatsky MW, et al. **Gastroenterology** 1996 Feb; 110(2):489-97. Comment in: Gastroenterology 1996 Feb;110(2):632-5.
Is a pound of prevention worth an ounce of cure? Fennerty MB. **Gastroenterology** 1996 Mar;110(3):958-60
Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. McCafferty DM, et al. **Gastroenterology** 1995 Oct;109(4):1173-80
Increased gastroduodenal concentrations of transforming growth factor alpha in adaptation to aspirin in monkeys and rats. Romano M, et al. **Gastroenterology** 1996 May; 110(5):1448-55
Non-steroidal anti-inflammatory drug-induced gastric damage in experimental animals: underlying pathological mechanisms. Trevethick MA, et al. **Gen Pharmacol** 1995 Nov;26(7):1455-9 (63 ref.)
Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal anti-inflammatory drugs. Hudson N, et al. **Gut** 1995 Aug;37(2):191-4
Mesalazine induced exacerbation of ulcerative colitis. Kapur KC, et al. **Gut** 1995 Dec;37(6):838-9
Effect of allopurinol, sulphasalazine, and vitamin C on aspirin induced gastroduodenal injury in human volunteers. McAlindon ME, et al. **Gut** 1996 Apr;38(4):518-24
Release of sulfidoleukotrienes in vitro: its relevance in the diagnosis of pseudoallergy to acetylsalicylic acid. Czech W, et al. **Inflamm Res** 1995 Jul;44(7):291-5
Yellow nail induced by bucillamine. Ishizaki C, et al. **Int J Dermatol** 1995 Jul;34(7):493-4
Role of early vascular damage in the pathogenesis of gastric haemorrhagic mucosal lesions induced by indomethacin in rats. Gyömber E, et al. **Int J Exp Pathol** 1996 Feb;77(1):1-6
Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Browning CH. **Int J Psychiatry Med** 1996; 26(1):25-34
Nephrogenic diabetes insipidus induced by lobenzarit disodium treatment in patients with rheumatoid arthritis. Sakane N, et al. **Intern Med** 1996 Feb;35(2):119-22 (17 ref.)
Ketotifen is protective against indomethacin-induced intestinal ulceration in the rat. Zahavi I, et al. **Isr J Med Sci** 1996 May;32(5):312-5
Effects of age, Helicobacter pylori, and NSAID usage on the upper gastrointestinal tract [letter] Hui E, et al. **J Am Geriatr Soc** 1996 Aug;44(8):1010-2
Effect of ketorolac tromethamine on bleeding and on requirements for analgesia after total knee arthroplasty [letter; comment] Dodenhoff RM. **J Bone Joint Surg Am** 1996 Jun;78(6):968. Comment on: J Bone Joint Surg Am 1995 Jul;77(7):998-1002.
Effect of ketorolac tromethamine on bleeding and on requirements for analgesia after total knee arthroplasty [letter; comment] Linville D. **J Bone Joint Surg Am** 1996 Jun;78(6):967-8. Comment on: J Bone Joint Surg Am 1995 Jul;77(7):998-1002.
Comparing the toxicity of two drugs in the framework of spontaneous reporting: a confidence interval approach. Tubert-Bitter P, et al. **J Clin Epidemiol** 1996 Jan; 49(1):121-3
Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication. Buchman AL, et al. **J Clin Gastroenterol** 1996 Apr;22(3):224-6
Leukopenia and thrombocytopenia as adverse effects of treatment with 5-aminosalicylic suppositories. Casellas F, et al. **J Clin Gastroenterol** 1996 Mar;22(2):160-1
Possible association of acute pancreatitis with naproxen. Castiella A, et al. **J Clin Gastroenterol** 1995 Oct;21(3):258
Reversible prolonged skin bleeding time in acute gastrointestinal bleeding presumed due to NSAIDs. Day JP, et al. **J Clin Gastroenterol** 1996 Mar;22(2):96-103
Nonsteroidal antiinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. Valentini M, et al. **J Clin Oncol** 1995 Oct;13(10):2637-42
Piroxicam induced Stevens-Johnson syndrome. Katoh N, et al. **J Dermatol** 1995 Sep;22(9):677-80
Acute sensorineural hearing loss following intravenous ketorolac administration. Schaab KC, et al. **J Emerg Med** 1995 Jul-Aug;13(4):509-13
Correlation between transmucosal potential difference and morphological damage during aspirin injury of gastric mucosa in rats. Cook GA, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):264-9
The effect of misoprostol on indomethacin-induced renal dysfunction in well-compensated cirrhosis. Wong F, et al. **J Hepatol** 1995 Jul;23(1):1-7
Do non-steroidal anti-inflammatory drugs induce sister chromatid exchanges in T lymphocytes? Ozkul Y, et al. **J Int Med Res** 1996 Jan-Feb;24(1):84-7
Renal complications associated with use of nonsteroidal anti-inflammatory agents. Palmer BF. **J Investig Med** 1995 Dec;43(6):516-33 (174 ref.)
Problems and pitfalls in providing acute and short-term pain relief with nonsteroidal anti-inflammatory agents. Hubbell K. **J La State Med Soc** 1996 Jan;148(1):13-8
Interaction of low molecular weight heparin with ketorolac. Green D, et al. **J Lab Clin Med** 1996 Jun;127(6):583-7
A risk assessment of cervical manipulation vs. NSAIDs for the treatment of neck pain. Dabbs V, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):530-6 (43 ref.)
Oxygen radical scavengers are protective against indomethacin-induced intestinal ulceration in the rat. Zahavi I, et al. **J Pediatr Gastroenterol Nutr** 1995 Aug; 21(2):154-7
The toxicity of nonsteroidal antiinflammatory drugs and antirheumatic drugs: an introduction. Brooks PM. **J Rheumatol** 1995 May;22(5):982
Indomethacin hastens large joint osteoarthritis in humans--how strong is the evidence? [editorial] Doherty M, et al. **J Rheumatol** 1995 Nov;22(11):2013-6 (32 ref.)
ARAMIS and toxicity measurement. (Arthritis Rheumatism and Aging Medical Information System). Fries JF. **J Rheumatol** 1995 May;22(5):995-7
Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. Saag KG, et al. **J Rheumatol** 1995 Nov; 22(11):2142-7
When Goody's Powder is not so good. Hamdy RC, et al. **J Tenn Med Assoc** 1996 Feb;89(2):43-4
Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. Radford MG Jr, et al. **JAMA** 1996 Aug 14;276(6):466-9
Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study [see comments] Strom BL, et al. **JAMA** 1996 Feb 7; 275(5):376-82. Comment in: JAMA 1996 Aug 7;276(5):372.
NSAIDs, Cox-2 inhibitors, and the gut [letter; comment] [see comments] Bennett A, et al. **Lancet** 1995 Oct 21; 346(8982):1105. Comment on: Lancet 1995 Aug 26;346(8974):521-2. Comment in: Lancet 1995 Dec 16;346(8990):1629.
Non-steroidal anti-inflammatory drugs, salicylates, and colitis [letter] Gleeson MH, et al. **Lancet** 1996 Mar 30; 347(9005):904-5
NSAIDs, Cox-2 inhibitors, and the gut [letter; comment] Hayllar J, et al. **Lancet** 1995 Dec 16;346(8990):1629. Comment on: Lancet 1995 Oct 21;346(8982):1105.
Antagonism to calcium antagonists [letter] Pilotto A, et al. **Lancet** 1996 Jun 22;347(9017):1761-2
NSAIDs, Cox-2 inhibitors, and the gut [letter; comment] Vane JR. **Lancet** 1995 Oct 21;346(8982):1105-6. Comment on: Lancet 1995 Aug 26;346(8974):521-2.
Fatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug [letter] Gabb GM. **Med J Aust** 1996 Jun 3;164(11):700-1
Acetaminophen, NSAIDs and alcohol. **Med Lett Drugs Ther** 1996 Jun 21;38(977):55-6
Asthma death induced by ibuprofen [see comments] Antonicelli L, et al. **Monaldi Arch Chest Dis** 1995 Aug; 50(4):276-8. Comment in: Monaldi Arch Chest Dis 1995 Aug;50(4):256-7.
Clinical problem-solving. The domino principle. Jaffe R, et al. **N Engl J Med** 1996 Aug 1;335(5):340-1
Aspirin and the risk of colorectal cancer in women [letter; comment] Kaufmann HJ. **N Engl J Med** 1996 Jan 11; 334(2):120; discussion 121-2. Comment on: N Engl J Med 1995 Sep 7;333(10):656-8.
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. Taha AS, et al. **N Engl J Med** 1996 May 30;334(22):1435-9
Naproxen induced thrombocytopenia: a case report. Hunt PJ, et al. **N Z Med J** 1995 Nov 24;108(1012):483-4
Aspirin, salicylate and gastrointestinal injury [letter; comment] Fernández AG, et al. **Nat Med** 1995 Jul; 1(7):602-3. Comment on: Nat Med 1995 Feb;1(2):154-8.
Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury [see comments] Lichtenberger LM, et al. **Nat Med** 1995 Feb; 1(2):154-8. Comment in: Nat Med 1995 Jul;1(7):602-3.
Mesalazine-associated interstitial nephritis. World MJ, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):614-21
HLA class II display by circulating T lymphocytes in nonsteroidal anti-inflammatory nephritis induced by drugs [letter] Ishikawa S, et al. **Nephron** 1995;70(4):497-8
Asthma caused by topical application of ketorolac. Sitenga GL, et al. **Ophthalmology** 1996 Jun;103(6):890-2
Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents [letter; comment] van der Heijden B, et al. **Pediatr Nephrol** 1995 Oct;9(5):675. Comment on: Pediatr Nephrol 1994 Dec;8(6):700-4.
Ketorolac-induced acute renal failure in a previously healthy adolescent. Buck ML, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):294-6
Poly(D,L-lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: gastrointestinal tolerance following intravenous and oral administration. Guterres SS, et al. **Pharm Res** 1995 Oct;12(10):1545-7
Nabumetone-associated interstitial nephritis. Blackwell E, et al. **Pharmacotherapy** 1995 Sep-Oct;15(5):669-72
The development of clinical practice guidelines for treatment of peptic acid diseases in a VA ambulatory care clinic--a comment. Holt RJ, et al. **Pharmacotherapy** 1996 May-Jun; 16(3):480-1; discussion 482-3
Toxic epidermal necrolysis associated with indomethacin therapy [letter] Lear JT, et al. **Postgrad Med J** 1996 Mar; 72(845):186-7
A reader's guide to the evaluation of causation. Podrebarac T, et al. **Postgrad Med J** 1996 Mar;72(845):131-6 (19 ref.)
Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs. Sacanella E, et al. **Postgrad Med J** 1996 Jan;72(843):57-8
Risk factors for gastrointestinal complications of nonsteroidal antiinflammatory drugs. Florent C, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):125-30 (44 ref.)
Prevention of gastrointestinal damage induced by nonsalicylate nonsteroidal antiinflammatory drugs. Florent C, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):131-4 (15 ref.)
Hepatotoxicity due to lysine salt of bendazac. Alcalde M,

et al. **Scand J Gastroenterol** 1996 Feb;31(2):206–8

Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Hansen JM, et al. **Scand J Gastroenterol** 1996 Feb;31(2):126–30

Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Meling TR, et al. **Scand J Gastroenterol** 1996 Apr;31(4):339–44

NSAID-associated upper gastrointestinal damage in patients with rheumatoid arthritis. Dijkmans BA, et al. **Scand J Gastroenterol Suppl** 1995;212:105–8 (26 ref.)

Review of clinical trials and benefit/risk ratio of meloxicam. Barner A. **Scand J Rheumatol Suppl** 1996;102:29–37 (15 ref.)

Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. Fries J. **Scand J Rheumatol Suppl** 1996;102:3–8

Selective cyclooxygenase inhibition: promise for future NSAID therapy? Fries JF. **Scand J Rheumatol Suppl** 1996; 102:1

Aspirin, a silent risk factor in urology. Zhu JP, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):369–74 (64 ref.)

Agranulocytosis and near fatal sepsis due to 'Mexican aspirin' (dipyrone). Dorr VJ, et al. **South Med J** 1996 Jun; 89(6):612–4

Nonsteroidal anti-inflammatory drugs and the gut. Hirschowitz BI. **South Med J** 1996 Mar;89(3):259–63 (20 ref.)

[Misoprostol: prevention of ulcers caused by NSAID] Matzen P, et al. **Ugeskr Laeger** 1996 Aug 19;158(34):4782–5 **(Dan)**

['Stomach-friendly' NSAIDs: careful optimism? (see comments)] Lems WF, et al. **Ned Tijdschr Geneeskd** 1995 Nov 4;139(44):2232–5 (23 ref.). Comment in: Ned Tijdschr Geneeskd 1995 Dec 30;139(52):2757–8. **(Dut)**

[Stomach-friendly NSAIDs: careful optimism? (letter; comment)] van Rijthoven AW. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2757–8. Comment on: Ned Tijdschr Geneeskd 1995 Nov 4;139(44):2232–5. **(Dut)**

[Contact photoallergic eczema caused by ketoprofen] Jeanmougin M, et al. **Ann Dermatol Venereol** 1996; 123(4):251–5 (Eng. Abstr.) **(Fre)**

[Severe contact dermatitis caused by bufexamac with large flap desquamation] Landrieux C, et al. **Ann Dermatol Venereol** 1996;123(3):198–9 **(Fre)**

[Adverse effects of ketoprofen after intrauterine exposure. Value of plasma determination] Llanas B, et al. **Arch Pediatr** 1996 Mar;3(3):248–53 (Eng. Abstr.) **(Fre)**

[Severe diarrhea with hypokalemia attributed to diacetylrhein (letter)] Blondon H, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):851–2 **(Fre)**

[Intestinal complications induced by non-steroidal anti-steroidal anti-inflammatory agents] Hochain P, et al. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B79–83 **(Fre)**

[Hemorrhagic esophageal papilloma associated with the ingestion of non-steroidal anti-inflammatory agents (letter)] Mastour M, et al. **Gastroenterol Clin Biol** 1996; 20(4):406–7 **(Fre)**

[Role of ranitidine in the treatment and prevention of NSAID-induced digestive lesions] Bommelaer G. **Rev Med Suisse Romande** 1995 Oct;115(10):799–802 **(Fre)**

[Ulcerative colitis and pericarditis. The role of mesalazine hypersensitivity] Loizeau E. **Rev Med Suisse Romande** 1995 Nov;115(11):935–8 **(Fre)**

[Mesalazine (letter)] Netzer P. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):42 **(Ger)**

[Benign colonic ulcer. Case report and differential diagnosis] Rexroth G. **Fortschr Med** 1995 Oct 30;113(30):427–30 (Eng. Abstr.) **(Ger)**

[Acetylsalicylic acid as an augmentation factor in food allergy] Möller R, et al. **Hautarzt** 1996 Apr;47(4):281–3 (Eng. Abstr.) **(Ger)**

[To what extent can prostaglandin synthesis inhibitors of the non-steroidal antirheumatic (NSAR) type modify the effect of ACE inhibitors?] Grote L. **Internist (Berl)** 1995 Dec; 36(12):1203–4 **(Ger)**

[Nonsteroidal antirheumatic drugs and acetylsalicylic acid: adverse effects distal to the duodenum] Gut A, et al. **Schweiz Med Wochenschr** 1996 Apr 13;126(15):616–25 (95 ref.) (Eng. Abstr.) **(Ger)**

[Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease] Netzer P. **Schweiz Med Wochenschr** 1995 Dec 16;125(50):2438–42 (Eng. Abstr.) **(Ger)**

[Bleeding after endoscopic biopsy and polypectomy—do nonsteroidal anti-rheumatic drugs increase the risk?] von Ritter C, et al. **Z Gastroenterol** 1995 Nov;33(11):683–4 **(Ger)**

[Cutaneous side-effects of nonsteroidal anti-inflammatory drugs (NSAID)] Gebhardt M, et al. **Z Rheumatol** 1995 Nov-Dec;54(6):405–12 (49 ref.) (Eng. Abstr.) **(Ger)**

[Prevention and treatment of upper gastrointestinal bleeding by nonsteroidal anti-inflammatory drugs] Bar-Dayan Y, et al. **Harefuah** 1996 Apr 15;130(8):535–7 (34 ref.) **(Heb)**

[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121–4 (50 ref.) (Eng. Abstr.) **(Hun)**

[Dieulafoy ulcer associated with acute drug-induced gastritis: a rare case] Reddavid M, et al. **Minerva Chir** 1995 May; 50(5):515–7 (Eng. Abstr.) **(Ita)**

[A case of interstitial pneumonia with chronic hepatitis C following interferon-alfa and sho-saiko-to therapy] Sugiyama H, et al. **Arerugi** 1995 Jul;44(7):711–4 **(Jpn)**

[Serum phospholipase A2 activity in patients with aspirin-induced asthma] Toyoshima M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):691–4 (Eng. Abstr.) **(Jpn)**

[Aspirin-induced asthma] Sakakibara H. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):227–33 (5 ref.) **(Jpn)**

[Clinical aspects of drug-induced tubulo-interstitial nephropathy] Shibasaki T. **Nippon Rinsho** 1995 Aug; 53(8):2047–51 (7 ref.) (Eng. Abstr.) **(Jpn)**

[A case of chronic hepatitis C developing drug induced intrahepatic cholestasis due to anti-inflammatory drug during interferon therapy] Niiya M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):272–5 **(Jpn)**

[Bucillamin induced lung injury in rheumatoid arthritis] Inokuma S, et al. **Ryumachi** 1996 Feb;36(1):34–42 (Eng. Abstr.) **(Jpn)**

[Helicobacter pylori, nonsteroidal anti-inflammatory agents and gastroduodenal changes] Teixeira AV. **Acta Med Port** 1995 Sep;8(9):517–21 (70 ref.) (Eng. Abstr.) **(Por)**

[Pathomorphology of kidney lesions induced by non-steroidal anti-inflammatory drugs] Postishil' IuA. **Arkh Patol** 1995 Sep–Oct;57(5):70–4 (Eng. Abstr.) **(Rus)**

[The influence of retinol, tocopherol and cimetidine on the ulcerogenic effect of Orthofen, indomethacin and naproxen] Stanislavchuk NA, et al. **Eksp Klin Farmakol** 1995 Nov-Dec;58(6):33–5 (Eng. Abstr.) **(Rus)**

[A possible association between the maternal administration of metamizole and persistent pulmonary hypertension in a newborn infant] Martí Solé JJ, et al. **An Esp Pediatr** 1996 Apr;44(4):387–8 (10 ref.) **(Spa)**

[Colitis induced by non-steroidal anti-inflammatory agents (letter)] Rodríguez Carballeira M, et al. **An Med Interna** 1995 Oct;12(10):513 **(Spa)**

[Hepatic tolerance of aceclofenac] Marsicano LJ, et al. **G E N** 1994 Oct-Dec;48(4):250–5 (Eng. Abstr.) **(Spa)**

[Chronic autoimmune hepatitis following cholestatic hepatitis caused by droxicam] Pérez-Aguilar F, et al. **Med Clin (Barc)** 1996 Mar 30;106(12):460–2 (Eng. Abstr.) **(Spa)**

[Droxicam-induced toxic hepatitis] Berenguer M, et al. **Rev Esp Enferm Dig** 1996 Jan;88(1):49–52 (Eng. Abstr.) **(Spa)**

[Morphology of gastric mucosa lesions induced by nonsteroidal anti-inflammatory agents] Valenzuela M, et al. **Rev Esp Enferm Dig** 1996 May;88(5):351–8 (55 ref.) **(Spa)**

[Drug-induced extrapyramidal disorders (see comments)] Horga JF, et al. **Rev Neurol** 1995 Sep-Oct;23(123):961–3 (Eng. Abstr.). Comment in: Rev Neurol 1996 May;24(129):584–5. **(Spa)**

[Myoclonic encephalopathy induced by diclofenac treatment] Sánchez Valiente S. **Rev Neurol** 1995 Nov-Dec; 23(124):1226–7 (Eng. Abstr.) **(Spa)**

[Severe abdominal symptoms may be disguised by NSAID preparations] **Lakartidningen** 1996 May 29;93(22):2169 **(Swe)**

[The psyche and the skin suffer most under the effect of Relifex] **Lakartidningen** 1996 Feb 7;93(6):490 **(Swe)**

[Wrong interpretation and wrong figures on adverse effects of Relifex (letter)] Ohman G. **Lakartidningen** 1996 Mar 13; 93(11):990 **(Swe)**

ANALYSIS

A partially automated pretreatment module for routine analyses for seventeen non-steroid antiinflammatory drugs in race horses using gas chromatography/mass spectrometry. Cárdenas S, et al. **Anal Chem** 1996 Jan 1; 68(1):118–23

Determination of ajmalicine in reserpine raw materials by liquid chromatography with fluorescence detection. Cieri UR. **J AOAC Int** 1995 Jul-Aug;78(4):944–5

Determination of flunixin in milk by liquid chromatography with confirmation by gas chromatography/mass spectrometry and selected ion monitoring. Rupp HS, et al. **J AOAC Int** 1995 Jul-Aug;78(4):959–67

Flow-injection spectrofluorimetric determination of flufenamic and mefenamic acid in pharmaceuticals. Albero MI, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1113–7

High-performance liquid chromatographic determination of 1-benzyl-1H-indazol-3-ol in benzydamine in pharmaceutical formulations. Carlucci G, et al. **J Pharm Biomed Anal** 1996 Mar;14(5):655–7

Europium(III) ion probe spectrofluorometric determination of diclofenac sodium. Carreira LA, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1331–7

Electrochemical oxidation of CBS-113 A, a new anti-inflammatory drug: applicability to liquid chromatography-electrochemical detection. Leroy P, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1133–40

Determination of some non-steroid anti-inflammatory drugs by capillary isotachophoresis. Pospíšilová M, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1147–52

[Enzyme immunoassay for determination of tiaprofenic acid (Surgam)] Unterhalt B, et al. **Pharmazie** 1995 Aug; 50(8):571–2 **(Ger)**

ANTAGONISTS & INHIBITORS

The beta 3-adrenoceptor agonist CL316243 prevents indomethacin-induced jejunal ulceration in the rat by reversing early villous shortening. Anthony A, et al. **J Pathol** 1996 Jul;179(3):340–6

BLOOD

Inversion of (R)- to (S)-ketoprofen in eight animal species. Aberg G, et al. **Chirality** 1995;7(5):383–7

Detection of non-steroidal anti-inflammatory drugs in equine plasma and urine by gas chromatography-mass spectrometry. González G, et al. **J Chromatogr A** 1996 Jan 5;719(1):251–64

Determination of ibuprofen in erythrocytes and plasma by high performance liquid chromatography. Sochor J, et al. **J Pharm Biomed Anal** 1995 Jun;13(7):899–903

Pharmacokinetics of tiaprofenic acid in humans: lack of stereoselectivity in plasma using both direct and precolumn derivatization methods. Vakily M, et al. **J Pharm Sci** 1996 Jun;85(6):638–42

Moment analysis of stereoselective enterohepatic circulation and unidirectional chiral inversion of ketoprofen enantiomers in rat. Yasui H, et al. **J Pharm Sci** 1996 Jun; 85(6):580–5

Concentration-dependent plasma protein binding of flurbiprofen in the rat: an in vivo microdialysis study. Evrard PA, et al. **Pharm Res** 1996 Jan;13(1):18–22

Determination of aminopyrine and dipyrone metabolites in urine [letter] Agúndez JA, et al. **Ther Drug Monit** 1996 Feb;18(1):104–7

The determination of aminopyrine and dipyrone metabolites [letter] Zylber-Katz E, et al. **Ther Drug Monit** 1996 Feb; 18(1):103–4

[Salicylic acid] Onouchi T, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:1040–2 (13 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Synthesis of new 2-([(phenoxy or phenyl)acetyl]amino)benzoic acid derivatives as 3 alpha-hydroxysteroid dehydrogenase inhibitors and potential antiinflammatory agents. Daidone G, et al. **Arch Pharm (Weinheim)** 1995 Oct;328(10):705–8

Synthesis and anti-inflammatory evaluation of new sulfamoylheterocarboxylic derivatives. Díaz JA, et al. **Arch Pharm (Weinheim)** 1996 May;329(5):229–38

Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Loll PJ, et al. **Biochemistry** 1996 Jun 11;35(23):7330–40

Syntheses and anti-inflammatory activities of O-acyloximes. II. Katagi T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):145–9

Synthesis and antiplatelet, antiinflammatory and antiallergic activities of 2,3-disubstituted 1,4-naphthoquinones. Lien JC, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun;44(6):1181–7

Synthesis and pharmacological properties of thieno[2',3':4,5]pyrimido [2,1-b][1,3,4]thiadiazine derivatives. Santagati A, et al. **Farmaco** 1995 Sep; 50(9):605–9

Synthesis and antiinflammatory activity of 2,3-dihydro-1,4-benzodioxin methyl carboxylic acids. Vázquez MT, et al. **Farmaco** 1996 Mar;51(3):215–7

Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha. Cottam HB, et al. **J Med Chem** 1996 Jan 5; 39(1):2–9

Rational design and synthesis of small molecule, non-oligosaccharide selectin inhibitors: (alpha-D-mannopyranosyloxy)biphenyl-substituted carboxylic acids. Kogan TP, et al. **J Med Chem** 1995 Dec 22;38(26):4976–84

Discovery of the hemifumarate and (alpha-L-alanyloxy)methyl ether as prodrugs of an antirheumatic oxindole: prodrugs for the enolic OH group. Robinson RP, et al. **J Med Chem** 1996 Jan 5;39(1):10–8

CHEMISTRY

Positive interference by azapropazone (Rheumox) in the measurement of total thyroxine using the Ciba-Corning ACS:180 immunoassay analyser. Smart JM, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):424–5

Spectroscopic characterization of bendazac and benzydamine: possible photochemical modes of action. Jez JM, et al. **Biochem Biophys Res Commun** 1996 Apr 16; 221(2):266–70

Azulene derivatives as TXA2/PGH2 receptor antagonists—II. Synthesis and biological activity of 6-mono- and 6-dihydroxylated-isopropylazulenes. Yokota M, et al. **Bioorg Med Chem** 1996 Apr;4(4):575–91

Chirality and the actions of anti-inflammatory drugs [editorial] Evans AM. **Br Vet J** 1996 Mar;152(2):135–8

Circular dichroism of ketoprofen complexed to serum albumins: conformational selection by the protein: a novel optical purity determination technique. Zandomeneghi M. **Chirality** 1995;7(6):446–51

Linear and non linear competition plots in the deoxyribose assay for determination of rate constants for reaction of nonsteroidal antiinflammatory drugs with hydroxyl radicals. Parij N, et al. **Free Radic Res** 1995 Dec;23(6):571–9

A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. Gierse JK, et al.

J Biol Chem 1996 Jun 28;271(26):15810-4

Diarylspiro[2.4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationships. Huang HC, et al. **J Med Chem** 1996 Jan 5;39(1):253-66

Approaches for improving the stability of ketorolac in powder blends. Brandl M, et al. **J Pharm Sci** 1995 Oct; 84(10):1151-3

Zwitterionic nature of tenoxicam: crystal structures and thermal analyses of a polymorph of tenoxicam and a 1:1 tenoxicam:acetonitrile solvate. Caira MR, et al. **J Pharm Sci** 1995 Jul;84(7):884-8

Inclusion complexation of heptakis(2,6-di-O-ethyl)-beta-cyclodextrin with tiaprofenic acid: pharmacokinetic consequences of a pH-dependent release and stereoselective dissolution. Vakily M, et al. **J Pharm Sci** 1995 Aug;84(8):1014-9

Hydrogen bonding in a non-steroidal anti-inflammatory drug—Naproxen. Velazquez MM, et al. **J Photochem Photobiol B** 1995 Jul;29(1):23-31

Structure of disintegrating pellets with regard to fractal geometry. Schröder M, et al. **Pharm Res** 1995 Nov; 12(11):1694-700

CLASSIFICATION

Practical classification for the use of nonsteroidal anti-inflammatory drugs. Friedman SL. **J Am Podiatr Med Assoc** 1996 Jun;86(6):263-5 (0 ref.)

CONTRAINDICATIONS

First do no harm. Robinson M. **Am J Gastroenterol** 1996 Aug;91(8):1664-5

Aspirin is a hazard for vitreoretinal surgery [letter] Elaxel CJ, et al. **Br J Ophthalmol** 1996 May;80(5):486

Juvenile rheumatoid arthritis [letter; comment] Freis PC. **J Am Board Fam Pract** 1995 Jul-Aug;8(4):341-2. Comment on: J Am Board Fam Pract 1995 Jan-Feb;8(1):46-8.

DIAGNOSTIC USE

Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Hilsden RJ, et al. **Gastroenterology** 1996 May;110(5):1395-403

Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Nasser S, et al. **Thorax** 1996 Jan; 51(1):64-70

ECONOMICS

Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia's senior population. Kephart G, et al. **Clin Ther** 1995 Nov-Dec; 17(6):1159-73

A survey of physician knowledge of drug costs. Hoffman J, et al. **J Pain Symptom Manage** 1995 Aug;10(6):432-5

Assessing the cost effectiveness of NSAID: an international perspective. Drummond M, et al. **J Rheumatol** 1995 Jul; 22(7):1408-11 (5 ref.)

Cost savings and prescribing protocols for nonsteroidal anti-inflammatory drugs [letter; comment] Briner WW Jr, et al. **JAMA** 1996 Aug 21;276(7):526. Comment on: JAMA 1996 Mar 27;275(12):926-30.

Cost savings using a stepped-care prescribing protocol for nonsteroidal anti-inflammatory drugs [see comments] Jones DL, et al. **JAMA** 1996 Mar 27;275(12):926-30. Comment in: JAMA 1996 Aug 21;276(7):525-6. Comment in: JAMA 1996 Aug 21;276(7):526.

Cost savings and prescribing protocols for nonsteroidal anti-inflammatory drugs [letter; comment] Rothschild BM. **JAMA** 1996 Aug 21;276(7):525-6. Comment on: JAMA 1996 Mar 27;275(12):926-30.

Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs [letter; comment] Frey HS. **N Engl J Med** 1995 Nov 9;333(19):1289-90. Comment on: N Engl J Med 1995 Jun 15;332(24):1612-7.

Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs [letter; comment] Lehmann DF. **N Engl J Med** 1995 Nov 9;333(19):1289; discussion 1290. Comment on: N Engl J Med 1995 Jun 15;332(24):1612-7.

HISTORY

[Aspirin, an always current drug] Van Cauwenberge H. **Rev Med Liege** 1996 Jan;51(1):7-18 (29 ref.) **(Fre)**

IMMUNOLOGY

The atopy trait in hypersensitivity to nonsteroidal anti-inflammatory drugs. Bochenek G, et al. **Allergy** 1996 Jan;51(1):16-23

Allergy and intolerance to nonsteroidal anti-inflammatory agents. Arnaud A. **Clin Rev Allergy Immunol** 1995 Fall; 13(3):245-51 (26 ref.)

Hypersensitivity to nonsteroidal anti-inflammatory drugs [letter] Zia-Amirhosseini PZ, et al. **Nat Med** 1995 Jan; 1(1):2-4

ISOLATION & PURIFICATION

Isolation of inhibitors of TPA-induced mouse ear edema from Hoelen, Poria cocos. Nukaya H, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):847-9

Antiinflammatory effects of different extracts and harpagoside isolated from Scrophularia frutescens L. García D, et al. **Farmaco** 1996 Jun;51(6):443-6

Antiinflammatory C-glucosyl chromone from Aloe barbadensis. Hutter JA, et al. **J Nat Prod** 1996 May; 59(5):541-3

Isolation of two new antiinflammatory biflavanoids from Sarcophyte piriei. Ogundaini A, et al. **J Nat Prod** 1996 Jun;59(6):587-90

Antiviral and antiphlogistic activities of Hamamelis virginiana bark. Erdelmeier CA, et al. **Planta Med** 1996 Jun;62(3):241-5

Potent antiplatelet, anti-inflammatory and antiallergic isoflavanquinones from the roots of Abrus precatorius. Kuo SC, et al. **Planta Med** 1995 Aug;61(4):307-12

Anti-inflammatory compounds isolated from Menyanthes trifoliata L. Huang C, et al. **Yao Hsueh Hsueh Pao** 1995; 30(8):621-6

METABOLISM

Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses. Soma LR, et al. **Am J Vet Res** 1996 Apr;57(4):517-21

Intracellular distribution of ibuprofen within monocytes. Menzel EJ, et al. **Arzneimitteiforschung** 1996 Apr; 46(4):394-8

Synthesis and mass-spectrometric characterization of human serum albumins modified by covalent binding of two non-steroidal anti-inflammatory drugs: tolmetin and zomepirac. Zia-Amirhosseini P, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):431-5

Ebselen-binding equilibria between plasma and target proteins. Ullrich V, et al. **Biochem Pharmacol** 1996 Jul 12; 52(1):15-9

Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Loll PJ, et al. **Biochemistry** 1996 Jun 11;35(23):7330-40

Stereospecific taurine conjugation of the trans-OH metabolite (active metabolite) of CS-670, a new 2-arylpropionic acid nonsteroidal anti-inflammatory drug, in dogs. Asami M, et al. **Biol Pharm Bull** 1995 Nov; 18(11):1584-9

Non-invasive detection of ibuprofen in vivo 13C-NMR signals in rats. Chen CN, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):204-7

In vitro fenoprofenyl-coenzyme A thioester formation: interspecies variations. Soraci A, et al. **Chirality** 1995; 7(7):534-40

Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Engel G, et al. **Clin Pharmacol Ther** 1996 Jun;59(6):613-23

Interaction of 5-aminosalicylic acid with nitric oxide on rat aortic strips and human platelets. Pallapies D, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):145-9

Enantiomeric composition of amphetamine and methamphetamine derived from the precursor compound famprofazone. Cody JT. **Forensic Sci Int** 1996 Jul 12; 80(3):189-99

The pharmacokinetics and metabolism of SC-53228, a specific leukotriene B4 receptor antagonist. Paulson S, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S143-4

The effect of co-administered drugs on oxaprozin binding to human serum albumin. Aubry AF, et al. **J Pharm Pharmacol** 1995 Nov;47(11):937-44

Enantioselective effects of experimental diabetes mellitus on the metabolism of ibuprofen. Qian X, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1192-8

Binding of anti-inflammatory alpha-melanocyte-stimulating-hormone peptides and proinflammatory cytokines to receptors on melanoma cells. Lyson K, et al. **Neuroimmunomodulation** 1994 Mar-Apr; 1(2):121-6

Interactions of pentosan polysulfate with cartilage matrix proteins and synovial fibroblasts derived from patients with osteoarthritis. Ghosh P, et al. **Osteoarthritis Cartilage** 1996 Mar;4(1):43-53

Regional drug delivery I: permeability characteristics of the rat 6-day-old air pouch model of inflammation. Martin SW, et al. **Pharm Res** 1995 Dec;12(12):1980-6

Analysis of diclofenac and four of its metabolites in human urine by HPLC. Sawchuk RJ, et al. **Pharm Res** 1995 May; 12(5):756-62

Protein binding of acetylsalicylic acid and salicylic acid in porcine and human serum. Lee S, et al. **Vet Hum Toxicol** 1995 Jun;37(3):224-5

PHARMACOKINETICS

Pharmacokinetics and bioavailability of percutaneous ibuprofen. Kleinbloesem CH, et al. **Arzneimittelforschung** 1995 Oct;45(10):1117-21

Phenylbutazone in racing greyhounds: plasma and urinary residues 24 and 48 hours after a single intravenous administration. Mills PC, et al. **Aust Vet J** 1995 Aug; 72(8):304-8

Time-dependent changes in the pharmacokinetics and renal excretion of xanthine derivative enprofylline induced by bacterial endotoxin in rats. Nadai M, et al. **Biol Pharm Bull** 1995 Aug;18(8):1089-93

Pharmacokinetic parameters of antipyrine in dog after hepatectomy. Galtier M, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):669-84

Dose dependent pharmacokinetics of naproxen in man. Niazi SK, et al. **Biopharm Drug Dispos** 1996 May;17(4):355-61

A population pharmacokinetic study of alminoprofen penetration into synovial fluid. Tod M, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):627-34

Tenidap sodium decreases renal clearance and increases steady-state concentrations of lithium in healthy volunteers. Apseloff G, et al. **Br J Clin Pharmacol** 1995; 39 Suppl 1:25S-28S

The effects of age and gender on the pharmacokinetics of tenidap sodium in patients with rheumatoid arthritis and osteoarthritis. Caldwell JR, et al. **Br J Clin Pharmacol** 1995; 39 Suppl 1:3S-9S

Stereoselective disposition of ibuprofen in patients with compromised renal haemodynamics. Chen CY, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):67-72

Pharmacokinetics of tenidap sodium administered with food or antacid in healthy volunteers. Coates PE, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:17S-19S

Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects. Gardner MJ, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:11S-15S

Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of (R)-ibuprofen in humans. Knights KM, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):153-6

The pharmacokinetics of tenidap sodium: introduction. Pullar T. **Br J Clin Pharmacol** 1995;39 Suppl 1:1S-2S (0 ref.)

The use of microdialysis for the study of drug kinetics: some methodological considerations illustrated with antipyrine in rat frontal cortex. Patsalos PN, et al. **Br J Pharmacol** 1995 Jun;115(3):503-9

A review of the clinical pharmacokinetics of meloxicam. Türck D, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:13-6 (28 ref.)

Evaluation of carprofen in calves using a tissue cage model of inflammation. Lees P, et al. **Br Vet J** 1996 Mar; 152(2):199-211

Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. Elder DJ, et al. **Cancer Res** 1996 May 15;56(10):2273-6

Effect of nonionic surfactants on the percutaneous absorption tenoxicam. Endo M, et al. **Chem Pharm Bull (Tokyo)** 1996 Apr;44(4):865-7

Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. Landoni MF, et al. **Chirality** 1995; 7(8):586-97

Albumin binding sites for etodolac enantiomers. Mignot I, et al. **Chirality** 1996;8(3):271-80

The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers. Awni WM, et al. **Clin Pharmacokinet** 1995;29 Suppl 2:112-24

Hepatic drug clearance in patients with mild cystic fibrosis. Kearns GL, et al. **Clin Pharmacol Ther** 1996 May; 59(5):529-40

Distribution and concentrations of 5-aminosalicylic acid in rectosigmoid biopsy specimens after rectal administration. Schoonjans R, et al. **Dis Colon Rectum** 1996 Jul; 39(7):788-93

Stereoselective reversible binding properties of the glucuronide conjugates of fenoprofen enantiomers to human serum albumin. Bischer A, et al. **Drug Metab Dispos** 1995 Sep;23(9):900-3

Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. Castillo M, et al. **Drug Metab Dispos** 1995 May;23(5):566-72

Stereoselective disposition of naproxen glucuronide in the rat. Iwaki M, et al. **Drug Metab Dispos** 1995 Oct; 23(10):1099-103

Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Schmid J, et al. **Drug Metab Dispos** 1995 Nov;23(11):1206-13

Pharmacokinetic optimisation of drug therapy in elderly patients. Parker BM, et al. **Drugs Aging** 1995 Jul;7(1):10-8 (38 ref.)

Practical implications of pharmacokinetic and pharmacodynamic (PK/PD) modelling of drug dose regimens [editorial; comment] Baggot JD. **Equine Vet J** 1995 Jul;27(4):245-6. Comment on: Equine Vet J 1995 Jul;27(4):247-56.

Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling [see comments] Landoni MF, et al. **Equine Vet J** 1995 Jul; 27(4):247-56. Comment in: Equine Vet J 1995 Jul;27(4):245-6.

Pharmacodynamics and pharmacokinetics of carprofen in the horse. Lees P, et al. **Equine Vet J** 1994 May;26(3):203-8

The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. Busch U, et al. **Eur J Clin Pharmacol** 1995;48(3-4):269-72

Comparison of the bioavailability of dexibuprofen administered alone or as part of racemic ibuprofen. Gabard B, et al. **Eur J Clin Pharmacol** 1995;48(6):505-11

Influence of renal failure on cytochrome P450 activity in

hypertensive patients using a "cocktail" of antipyrine and nifedipine. Lanchote VL, et al. **Eur J Clin Pharmacol** 1996; 50(1-2):83-9

Concentration-response relationships for three nonsteroidal anti-inflammatory drugs in the rat intestine. Ford J, et al. **Hum Exp Toxicol** 1995 Jul;14(7):573-9

The pharmacokinetics and metabolism of SC-53228, a specific leukotriene B4 receptor antagonist. Paulson S, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S143-4

Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. Macía MA, et al. **Int J Clin Pharmacol Ther** 1995 Jun;33(6):333-9

Intrasubject variability in bioequivalence studies illustrated by the example of ibuprofen. Wagener HH, et al. **Int J Clin Pharmacol Ther** 1996 Jan;34(1):21-31

Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Rabiah PK, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):613-8

Stereospecific determination of tiaprofenic acid in plasma: problems with drug degradation. Geisslinger G, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):77-81

Effects of aging on antipyrine clearance: predictive factors of metabolizing capacity. Jorquera F, et al. **J Clin Pharmacol** 1995 Sep;35(9):895-901

Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers. Waldman SA, et al. **J Clin Pharmacol** 1996 May;36(5):462-8

Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine. Yang BB, et al. **J Clin Pharmacol** 1996 Apr;36(4):356-60

Bioavailability of controlled release mesalazine (5-ASA) preparations. Rasmussen SN. **J Gastroenterol** 1995 Nov;30 Suppl 8:112-4

Assessment of antipyrine kinetics from saliva or plasma: influence of age. Jorquera F, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1141-5

Location of binding sites on immobilized human serum albumin for some nonsteroidal anti-inflammatory drugs. Rahim S, et al. **J Pharm Sci** 1995 Aug;84(8):949-52

Permeability of pure enantiomers of ketorolac through human cadaver skin. Roy SD, et al. **J Pharm Sci** 1995 Aug; 84(8):987-90

Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. Roy SD, et al. **J Pharm Sci** 1995 Oct; 84(10):1190-6

Tenoxicam pharmacokinetics in rats: a population model. Troconiz IF, et al. **J Pharm Sci** 1995 Dec;84(12):1482-7

Inclusion complexation of heptakis(2,6-di-O-ethyl)-beta-cyclodextrin with tiaprofenic acid: pharmacokinetic consequences of a pH-dependent release and stereoselective dissolution. Vakily M, et al. **J Pharm Sci** 1995 Aug;84(8):1014-9

Pharmacokinetics of tiaprofenic acid in humans: lack of stereoselectivity in plasma using both direct and precolumn derivatization methods. Vakily M, et al. **J Pharm Sci** 1996 Jun;85(6):638-42

Moment analysis of stereoselective biliary excretion and chiral inversion of ketoprofen enantiomers in perfused rat liver. Yasui H, et al. **J Pharm Sci** 1995 Nov;84(11):1327-31

Assessment of intestinal permeability changes induced by nonsteroidal anti-inflammatory drugs in the rat. Ford J, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):9-16

Lack of effect of ivermectin on antipyrine and erythromycin disposition in calves. Bohlen DM, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):476-8

Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. Landoni MF, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):446-50

Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. Landoni MF, et al. **J Vet Pharmacol Ther** 1995 Oct;18(5):315-24

Pharmacokinetics of flunixin and its effect on prostaglandin F2 alpha metabolite concentrations after oral and intravenous administration in heifers. Odensvik K. **J Vet Pharmacol Ther** 1995 Aug;18(4):254-9

In vitro percutaneous absorption of piroxicam through synthetic membranes and abdominal rat skin. Santoyo S, et al. **Pharm Acta Helv** 1996 Jul;71(2):141-6

Intravenous microdialysis in the mouse and the rat: development and pharmacokinetic application of a new probe. Evrard PA, et al. **Pharm Res** 1996 Jan;13(1):12-7

Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. Stevens AJ, et al. **Pharm Res** 1995 Dec;12(12):1987-96

The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. Vakily M, et al. **Pharm Res** 1995 Nov;12(11):1652-7

Pharmacodynamics and enantioselective pharmacokinetics of carprofen in the cat. Taylor PM, et al. **Res Vet Sci** 1996 Mar;60(2):144-51

Meloxicam: metabolic profile and biotransformation products in the rat. Schmid J, et al. **Xenobiotica** 1995 Nov; 25(11):1219-36

Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission. Ewe K, et al. **Z Gastroenterol** 1996 Apr;34(4):225-9

Comparison of the kinetics of sodium meclofenamate versus meclofenamic acid after oral administration to sheep. Encinas T, et al. **Zentralbl Veterinarmed A** 1995 May; 42(3):177-83

[Effect of enhancers on the permeation of ketoprofen in vitro] Hu JH, et al. **Yao Hsueh Hsueh Pao** 1996;31(1):48-53 (Eng. Abstr.) (Chi)

[Pharmacokinetics and tolerance of an orally administered combination preparation containing phenylbutazone and prednisolone in the dog] Kietzmann M, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jan;103(1):14-6 (Eng. Abstr.) (Ger)

[Effect of mestranol on pharmacokinetics of phenazone in the rabbit] Gawrońska-Szklarz B, et al. **Ginekol Pol** 1996 Jan;67(1):1-6 (Eng. Abstr.) (Pol)

PHARMACOLOGY

Treatment of resistant A/J mice with methylprednisolone (MP) results in loss of resistance to murine hepatitis strain 3 (MHV-3) and induction of macrophage procoagulant activity (PCA). Fingerote RJ, et al. **Adv Exp Med Biol** 1995;380:89-94

Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products. Lauritsen K, et al. **Adv Exp Med Biol** 1995;371B:1301-6 (66 ref.)

Effects of mesalazine on lamina propria white cell functions. Verspaget HW. **Adv Exp Med Biol** 1995;371A:317-20 (20 ref.)

Leukocyte-endothelial cell interactions: potential targets for mesalazine in Crohn's disease. Wakefield AJ, et al. **Adv Exp Med Biol** 1995;371B:1307-11 (72 ref.)

Do non-steroidal anti-inflammatory drugs have an effect on gastric cell turnover? [letter] Goodlad RA. **Aliment Pharmacol Ther** 1996 Apr;10(2):215

The effects of aminosalicylic acid derivatives on nitric oxide in a cell-free system. Reynolds PD, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):491-5

Limiting lipid peroxidation in the nonischemic zone of infarcted rat hearts by indomethacin improves left ventricular function without affecting myocardial healing and remodeling. Sulpice T, et al. **Am Heart J** 1996 Apr; 131(4):681-8

Acute and chronic effects of nonsteroidal antiinflammatory drugs on glomerular filtration rate in elderly patients. Murray MD, et al. **Am J Med Sci** 1995 Nov;310(5):188-97

Influence of indomethacin on bone turnover related to orthodontic tooth movement in miniature pigs. Giunta D, et al. **Am J Orthod Dentofacial Orthop** 1995 Oct; 108(4):361-6

Effect of a leukotriene B4 receptor antagonist SC-53228 on ozone-induced airway hyperresponsiveness and inflammation in dogs. Stevens WH, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1443-8

Pharmacologic interaction of furosemide and phenylbutazone in horses. Hinchcliff KW, et al. **Am J Vet Res** 1995 Sep; 56(9):1206-12

Comparative efficacy of topically applied flurbiprofen, diclofenac, tolmetin, and suprofen for the treatment of experimentally induced blood-aqueous barrier disruption in dogs. Ward DA. **Am J Vet Res** 1996 Jun;57(6):875-8

Drug-NSAID interactions. Small RE, et al. **Am Pharm** 1995 Mar;NS35(3):53-5

An evaluation of the antiinflammatory effects of intraarticular synthetic beta-endorphin in the canine model. Martinez JH, et al. **Anesth Analg** 1996 Jan;82(1):177-81

Anti-inflammatory effects of theophylline: modulation of cytokine production. Mascali JJ, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):34-8

Effect of SC-41930, a potent selective leukotriene B4 receptor antagonist, in the guinea pig model of middle ear inflammation. Sutbeyaz Y, et al. **Ann Otol Rhinol Laryngol** 1996 Jun;105(6):476-80

Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects. Kubacka RT, et al. **Ann Pharmacother** 1996 Jan;30(1):20-6

Prostaglandin endoperoxide synthetase isoenzymes: the clinical relevance of selective inhibition. Frölich JC. **Ann Rheum Dis** 1995 Dec;54(12):942-3

Protection against peroxynitrite dependent tyrosine nitration and alpha 1-antiproteinase inactivation by some anti-inflammatory drugs and by the antibiotic tetracycline. Whiteman M, et al. **Ann Rheum Dis** 1996 Jun;55(6):383-7

The effect of 5-aminosalicylic acid, hydrocortisone and indomethacin on gamma interferon induced expression of HLA-DR antigens on colonic epithelium. Radwan P, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:104-8

Non-steroidal anti-inflammatory agents, Part 19. E-2-pyrrolizin-5-yl acrylic acids as potent dual or selective inhibitors of bovine cyclooxygenase and 5-lipoxygenase. Dannhardt G, et al. **Arch Pharm (Weinheim)** 1995 Sep;328(9):681-6

Aspirin-like drugs can protect human T lymphocytes against benzoquinone cytotoxicity: evidence for a NAD(P)H:quinone reductase-dependent mechanism. Flescher E, et al. **Arch Toxicol** 1995;69(10):684-9

The effects of the phospholipase A2 inhibitor, manoalide, on cartilage degradation, stromelysin expression, and synovial fluid cell count induced by intraarticular injection of human recombinant interleukin-1 alpha in the rabbit. Schrier DJ, et al. **Arthritis Rheum** 1996 Aug;39(8):1292-9

Comparison of the anti-inflammatory effect and gastrointestinal tolerability of aceclofenac and diclofenac. Arañó A, et al. **Arzneimittelforschung** 1996 Apr; 46(4):398-400

Possible modes of action of nimesulide in controlling neutrophilic inflammation. Dallegri F, et al. **Arzneimittelforschung** 1995 Oct;45(10):1114-7 (36 ref.)

Differential inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulide. Maffei Facino R, et al. **Arzneimittelforschung** 1995 Oct;45(10):1102-9

Activity of nimesulide on constitutive and inducible cyclooxygenases. Tavares IA, et al. **Arzneimittelforschung** 1995 Oct;45(10):1093-5

Inhibition of the production of platelet activating factor and of leukotriene B4 in activated neutrophils by nimesulide due to an elevation of intracellular cyclic adenosine monophosphate. Tool AT, et al. **Arzneimittelforschung** 1995 Oct;45(10):1110-4

Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Vago T, et al. **Arzneimittelforschung** 1995 Oct; 45(10):1096-8

Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Miyazawa K, et al. **Atherosclerosis** 1995 Dec;118(2):213-21

Influence of anti-rheumatic drugs on gut permeability and on the gut associated lymphoid tissue. Bjarnason I, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):165-76 (75 ref.)

Nonsteroidal antiinflammatory drugs inhibit cyclooxygenase-2 enzyme activity but not mRNA expression in human macrophages. Barrios-Rodiles M, et al. **Biochem Biophys Res Commun** 1996 Aug 23; 225(3):896-900

Suppression of inducible nitric oxide synthase mRNA expression by tryptoquinone A. Niwa M, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):579-85

Induction of cytochrome P-450 BM-3 (CYP 102) by non-steroidal anti-inflammatory drugs in Bacillus megaterium. English N, et al. **Biochem J** 1996 May 15;316 (Pt 1):279-83

Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Barnette MS, et al. **Biochem Pharmacol** 1996 Apr 12;51(7):949-56

Differential effects of tenidap on the zymosan- and lipopolysaccharide-induced expression of mRNA for proinflammatory cytokines in macrophages. Bondeson J, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):35-42

Effects of tenidap on superoxide-generating enzymes. Non-competitive inhibition of xanthine oxidase. Chatham WW, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):811-4

Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings. Engelhardt G, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):21-8

Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Engelhardt G, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):29-38

Regulation of prostaglandin H synthase 2 expression in human monocytes by the marine natural products manoalide and scalaradial. Novel effects independent of inhibition of lipid mediator production. Glaser KB, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):913-22

Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Hanif R, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):237-45

Reduction of intracellular pH by tenidap. Involvement of cellular anion transporters in the pH change. McNiff P, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1421-32

Determining selectivity of drugs by quantitative two-dimensional gel analysis. A study of tenidap, piroxicam, and dexamethasone. Otterness IG, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):917-25

A novel diterpenoid labdane from Sideritis javalambrensis inhibits eicosanoid generation from stimulated macrophages but enhances arachidonate release. Pang L, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):863-8

Selective inhibition of neutrophil function by a peptide derived from lipocortin 1 N-terminus. Perretti M, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1037-42

Inhibitor-induced changes in the intrinsic fluorescence of human cyclooxygenase-2. Houtzager V, et al. **Biochemistry** 1996 Aug 20;35(33):10974-84

Kinetics of the interaction of nonsteroidal antiinflammatory drugs with prostaglandin endoperoxide synthase-1 studied by limited proteolysis. Kalgutkar AS, et al. **Biochemistry** 1996 Jul 16;35(28):9076-82

Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketoreductase family. Bunce CM, et al. **Biochim Biophys Acta** 1996 May 28;1311(3):189-98

Immunochemical detection of protein adducts in cultured human hepatocytes exposed to diclofenac. Gil ML, et al. **Biochim Biophys Acta** 1995 Dec 12;1272(3):140-6

Inhibitory effect of some oxygenated stigmastane-type sterols on 12-O-tetradecanoylphorbol-13-acetate-induced inflammation in mice. Kimura Y, et al. **Biol Pharm Bull** 1995 Nov;18(11):1617-9

Inhibitory effect of isoliquiritin, a compound in licorice root, on angiogenesis in vivo and tube formation in vitro. Kobayashi S, et al. **Biol Pharm Bull** 1995 Oct;18(10):1382-6

Induction of cytochrome P450 3A (CYP 3A) by E 5110, a non-steroidal anti-inflammatory agent (NSAID), and typical CYP 3A inducers in primary cultures of dog hepatocytes. Nishibe Y, et al. **Biol Pharm Bull** 1995 Aug; 18(8):1142-4

A polysaccharide fraction of shosaiko-to active in augmentation of natural killer activity by oral administration. Yamaoka Y, et al. **Biol Pharm Bull** 1995 Jun;18(6):846-9

Effect of theophylline on the production of interleukin-1 beta, tumor necrosis factor-alpha, and interleukin-8 by human peripheral blood mononuclear cells. Yoshimura T, et al. **Biol Pharm Bull** 1995 Oct;18(10):1405-8

N-substituted aminohydroxypyridines as potential non-opioid analgesic agents. Viaud MC, et al. **Bioorg Med Chem** 1995 Jul;3(7):929-37

Azulene derivatives as TXA2/PGH2 receptor antagonists--II. Synthesis and biological activity of 6-mono- and 6-dihydroxylated-isopropylazulenes. Yokota M, et al. **Bioorg Med Chem** 1996 Apr;4(4):575-91

Effect of tenidap sodium on the pharmacodynamics and plasma protein binding of warfarin in healthy volunteers. Apseloff G, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:29S-33S

The effect of tenidap sodium on the disposition and plasma protein binding of phenytoin in healthy male volunteers. Blum RA, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:35S-38S

An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive. Coates PE, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:47S-50S

The effect of meloxicam on the pharmacokinetics of beta-acetyl-digoxin. Degner FL, et al. **Br J Clin Pharmacol** 1995 Nov;40(5):486-8

Effect of tenidap sodium on digoxin pharmacokinetics in healthy young men. Dewland PM, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:43S-46S

Effects of azapropazone on pain-related brain activity in human subjects. Lötsch J, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):545-52

Effects of peripherally and centrally acting analgesics on somato-sensory evoked potentials. Moore UJ, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):111-7

The effect of tenidap on the anti-hypertensive efficacy of ACE inhibitors in patients treated for mild to moderate hypertension. Rapeport WG, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:57S-61S

The effect of tenidap on the anti-hypertensive efficacy of thiazide diuretics in patients treated for mild to moderate hypertension. Rapeport WG, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:51S-55S

Tenidap sodium does not alter the clearance or plasma protein binding of tolbutamide in healthy male volunteers. Wilner KD, et al. **Br J Clin Pharmacol** 1995;39 Suppl 1:39S-42S

Structure-activity relationships for a series of phenylglycine derivatives acting at metabotropic glutamate receptors (mGluRs). Bedingfield JS, et al. **Br J Pharmacol** 1995 Dec; 116(8):3323-9

Inhibition of inducible nitric oxide synthase expression by novel nonsteroidal anti-inflammatory derivatives with gastrointestinal-sparing properties. Cirino G, et al. **Br J Pharmacol** 1996 Apr;117(7):1421-6

The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation. Gupta P, et al. **Br J Pharmacol** 1995 Nov; 116(5):2385-90

Protective effect of NO on gastric lesions and inhibition of expression of gastric inducible NOS by flurbiprofen and its nitro-derivative, nitroflurbiprofen. Mariotto S, et al. **Br J Pharmacol** 1995 Sep;116(2):1713-4

Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-inda none (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Panara MR, et al. **Br J Pharmacol** 1995 Nov;116(5):2429-34

Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram. Pettipher ER, et al. **Br J Pharmacol** 1996 Apr;117(7):1530-4

Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis? Bird HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:16-9 (11 ref.)

Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Engelhardt G. **Br J Rheumatol** 1996 Apr;35 Suppl 1:4-12 (69 ref.)

A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Patoia L, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:61-7

Introduction: mechanism of action of NSAIDs. Vane JR. **Br J Rheumatol** 1996 Apr;35 Suppl 1:1-3

Pharmacodynamics and chiral pharmacokinetics of carprofen in calves. Delatour P, et al. **Br Vet J** 1996 Mar; 152(2):183-98

Chirality and the actions of anti-inflammatory drugs [editorial] Evans AM. **Br Vet J** 1996 Mar;152(2):135-8

Effects of three dietary phytochemicals from tea, rosemary and turmeric on inflammation-induced nitrite production. Chan MM, et al. **Cancer Lett** 1995 Sep 4;96(1):23-9

Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Jacoby RF, et al. **Cancer Res** 1996 Feb 15;56(4):710-4

Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Rao KV, et al. **Carcinogenesis** 1996 Jul; 17(7):1435-8

Inhibition of the tumor promoting action of 12-O-tetradecanoylphorbol-13-acetate by tubeimoside III isolated from Bolbostemma paniculatum. Yu L, et al. **Carcinogenesis** 1995 Dec;16(12):3045-8

Suppression of interleukin-1 and tumor necrosis factor-alpha production by acanthoic acid, (-)-pimara-9(11),15-dien-19-oic acid, and it antifibrotic effects in vivo. Kang HS, et al. **Cell Immunol** 1996 Jun 15;170(2):212-21

Dexamethasone induces an increase in intracellular and membrane-associated lipocortin-1 (annexin-1) in rat astrocyte primary cultures. McLeod JD, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):193-205

Syntheses and anti-inflammatory activities of O-acyloximes. II. Katagi T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan; 44(1):145-9

Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug diclofenac. Hargus SJ, et al. **Chem Res Toxicol** 1995 Dec; 8(8):993-6

Effect of encapsulation on the anti-inflammatory properties of superoxide dismutase after oral administration. Regnault C, et al. **Clin Chim Acta** 1995 Sep 15;240(2):117-27

Distribution and anti-inflammatory effect of mesalazine on carrageenan-induced colitis in the rabbit. Kitano A, et al. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):305-9

NSAID: an update on their analgesic effects. Walker JS. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):855-60

Small bowel permeability--a variable effect of NSAIDS. Choi VM, et al. **Clin Invest Med** 1995 Oct;18(5):357-61

Effects of nabumetone on prostanoid biosynthesis in humans. Cipollone F, et al. **Clin Pharmacol Ther** 1995 Sep; 58(3):335-41

Cytokine-processing enzymes. Stopping the cuts. Dinarello CA, et al. **Curr Biol** 1995 Jun 1;5(6):587-90 (34 ref.)

Interleukin 13 suppresses cytokine production and stimulates the production of 15-HETE in PBMC. A comparison between IL-4 and IL-13. Deleuran B, et al. **Cytokine** 1995 May;7(4):319-24

Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production. Tsuboi I, et al. **Cytokine** 1995 May;7(4):372-9

Influence of spasmolytic analgesics on motility of sphincter of Oddi. Brandstätter G, et al. **Dig Dis Sci** 1996 Sep; 41(9):1814-8

Influence of Helicobacter pylori on gastric mucosal adaptation to naproxen in man. Lipscomb GR, et al. **Dig Dis Sci** 1996 Aug;41(8):1583-8

Effects of ursodiol or ibuprofen on contraction of gallbladder and bile among obese patients during weight loss. Marks JW, et al. **Dig Dis Sci** 1996 Feb;41(2):242-9

Influence of age on natural and delayed healing of experimentally-induced gastric ulcers in rats. Penney AG, et al. **Dig Dis Sci** 1996 Sep;41(9):1838-44

NSAID-induced delay in gastric ulcer healing is not associated with decreased epithelial cell proliferation in rats. Penney AG, et al. **Dig Dis Sci** 1995 Dec; 40(12):2684-93

Effect of NSAIDs on gallbladder bile composition. Sterling RK, et al. **Dig Dis Sci** 1995 Oct;40(10):2220-6

Indomethacin interferes with epidermal growth factor binding and proliferative response of gastric KATO III cells. Fujiwara Y, et al. **Digestion** 1995;56(5):364-9

Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac. Marques C, et al. **Doc Ophthalmol** 1995; 90(4):395-404

Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases. Plosker GL, et al. **Drugs** 1995 Dec;50(6):1050-75 (146 ref.)

Ulcerogenicity and effect on inhibition of prostaglandin generation of indometacin farnesil, a prodrug of indomethacin, in rat gastric mucosa: comparison with indomethacin or loxoprofen. Arakawa T, et al. **Drugs Exp Clin Res** 1995;21(3):85-8

Lack of activity of azapropazone in the hot-plate test and in 5-HT1A and 5-HT2 receptor subtypes in rat brain membranes. Pini LA, et al. **Drugs Exp Clin Res** 1995; 21(5):181-6

Practical implications of pharmacokinetic and pharmacodynamic (PK/PD) modelling of drug dose regimens [editorial; comment] Baggot JD. **Equine Vet J** 1995 Jul;27(4):245-6. Comment on: Equine Vet J 1995 Jul;27(4):247-56.

Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling [see comments] Landoni MF, et al. **Equine Vet J** 1995 Jul; 27(4):247-56. Comment in: Equine Vet J 1995 Jul;27(4):245-6.

Pharmacodynamics and pharmacokinetics of carprofen in the horse. Lees P, et al. **Equine Vet J** 1994 May;26(3):203-8

Renal and endocrine effects of flosulide, after single and repeated administration to healthy volunteers. Brunel P, et al. **Eur J Clin Pharmacol** 1995;49(3):193-201

Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers. Müller FO, et al. **Eur J Clin Pharmacol** 1995;48(3-4):247-51

Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a sigma ligand. Bourrie B, et al. **Eur J Immunol** 1995 Oct;25(10):2882-7

Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac-1 and E-selectin expression. Zhou L, et al. **Eur J Immunol** 1996 Jan; 26(1):120-9

Effect of flurbiprofen on acetylcholine-induced pupillary contraction. Tabandeh H, et al. **Eur J Ophthalmol** 1995 Jul-Sep;5(3):177-80

Effect of berbamine on cytosolic phospholipase A2 activation in rabbit platelets. Akiba S, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):343-50

LCB 2183 inhibits tracheal hyperreactivity and pulmonary inflammation in mouse airways. Buckley TL, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):103-9

Effects of marine 2-polyprenyl-1,4-hydroquinones on phospholipase A2 activity and some inflammatory responses. Gil B, et al. **Eur J Pharmacol** 1995 Oct 24; 285(3):281-8

Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone. Klemm P, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):69-74

Antinociceptive effect of alpha-trinositol, a novel D-myo-inositol phosphate derivative, in the formalin test in rats. Malmberg AB, et al. **Eur J Pharmacol** 1995 Dec 29;294(2-3):609-15

Inhaled lysine acetylsalicylate (L-ASA) attenuates the bronchoconstrictor response to adenosine 5'-monophosphate (AMP) in asthmatic subjects. Crimi N, et al. **Eur Respir J** 1995 Jun;8(6):905-12

Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Shiff SJ, et al. **Exp Cell Res** 1996 Jan 10; 222(1):179-88

Drug effects on triiodothyronine uptake by rat anterior pituitary cells in vitro. Lim CF, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):151-7

Effects of age on the pharmacodynamics of naproxen in the rat. Satterwhite JH, et al. **Exp Gerontol** 1995 Sep-Oct; 30(5):505-15

Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. D'Andrea G, et al. **Funct Neurol** 1995 Mar-Apr;10(2):91-8

Inhibition of rats adjuvant arthritis by a bradykinin antagonist Hoe 140 and its influence on kallikreins. Sharma JN, et al. **Gen Pharmacol** 1996 Jan;27(1):133-6

Gastric adaptation to injury by repeated doses of aspirin strengthens mucosal defence against subsequent exposure to various strong irritants in rats. Brzozowski T, et al. **Gut** 1995 Dec;37(6):749-57

5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferon. Di Paolo MC, et al. **Gut** 1996 Jan;38(1):115-9

Comparison of effects of calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers. Murray FE, et al. **Gut** 1996 Jan;38(1):11-4

Oral administration of protease inhibits enterotoxigenic Escherichia coli receptor activity in piglet small intestine. Mynott TL, et al. **Gut** 1996 Jan;38(1):28-32

Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study. Schnitzler M, et al. **Gut** 1996 May;38(5):707-13

Effect of longterm misoprostol coadministration with non-steroidal anti-inflammatory drugs: a histological study. Shah K, et al. **Gut** 1995 Aug;37(2):195-8

Immunohistochemical properties of dipyrone-induced cytochromes P450 in rats. Kraul H, et al. **Hum Exp Toxicol** 1996 Jan;15(1):45-50

2-(2,3-dimethylchromon-6-yl) propanoic acid (OVS-103): a potent anti-inflammatory agent. Bani S, et al. **Indian J Exp Biol** 1995 Nov;33(11):841-4

Antioxidant and anti-inflammatory property of Sandhika: a compound herbal drug. Chaurasia S, et al. **Indian J Exp Biol** 1995 Jun;33(6):428-32

Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Engelhardt G, et al. **Inflamm Res** 1995 Oct; 44(10):423-33

Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox 2 inhibitors. Grossman CJ, et al. **Inflamm Res** 1995 Jun;44(6):253-7

The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A. Hartman DA, et al. **Inflamm Res** 1995 Jul;44(7):269-74

Pulmonary antiallergic and antiinflammatory effects of a novel, orally-active phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats. Howell RE, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S172-3

Effects of metamizol on nociceptive responses to stimulation

of the ureter and on ureter motility in anaesthetised rats. Laird JM, et al. **Inflamm Res** 1996 Mar;45(3):150–4

Differential effects of prednisolone and indomethacin on zymosan-induced inflammation in a modified murine tissue-chamber model. Oluyomi AO, et al. **Inflamm Res** 1995 Aug;44(8):350–6

Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal anti inflammatory drugs indomethacin, diclofenac and naproxen. Sacerdote P, et al. **Inflamm Res** 1995 Nov;44(11):486–90

Anti-inflammatory activity of an orally active peptide sequence from PF-4 on acute inflammation and DTH. Talmadge JE, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S199–200

Measurement and drug induced modulation of interleukin-1 level during zymosan peritonitis in mice. Török K, et al. **Inflamm Res** 1995 Jun;44(6):248–52

Antinociceptive activities of non-steroidal antiinflammatory drugs (NSAIDs) following intracerebroventricular (i.c.v.) and intrathecal (i.t.) administration in mice. Walter TL, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S133–4

KW-4679, an antiallergic drug, inhibits the production of inflammatory lipids in human polymorphonuclear leukocytes and guinea pig eosinophils. Ikemura T, et al. **Int Arch Allergy Immunol** 1996 May;110(1):57–63

Cetirizine exerts anti-inflammatory effects on human neutrophils. Köller M, et al. **Int Arch Allergy Immunol** 1996 May;110(1):52–6

Decrease in systemic tolerance to fed ovalbumin in indomethacin-treated mice. Louis E, et al. **Int Arch Allergy Immunol** 1996 Jan;109(1):21–6

The modulatory effect of tetrandrine on the CD23, CD25 and HLA-DR expression and cytokine production in different groups of asthmatic patients. Tsai JJ, et al. **Int Arch Allergy Immunol** 1995 Oct;108(2):183–8

Immunomodulating effects of the new anti-rheumatic drug tenidap on collagen-induced arthritis. Matsushita I, et al. **Int J Immunopharmacol** 1995 Mar;17(3):213–9

Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. Ritchie DM, et al. **Int J Immunopharmacol** 1995 Oct;17(10):805–12

Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine. Crawley JB, et al. **J Biol Chem** 1996 Jul 5;271(27):16357–62

Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. Mancini JA, et al. **J Biol Chem** 1995 Dec 8;270(49):29372–7

Thiazolidine diones, specific ligands of the nuclear receptor retinoid Z receptor/retinoid acid receptor-related orphan receptor alpha with potent antiarthritic activity. Missbach M, et al. **J Biol Chem** 1996 Jun 7;271(23):13515–22

Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected] [published erratum appears in J Biol Chem 1995 Dec 15;270(50):30235] Singh S, et al. **J Biol Chem** 1995 Oct 20;270(42):24995–5000

Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. Bienvenu J, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S80–4

Effects of diclofenac sodium and indomethacin on proliferation and collagen synthesis of lens epithelial cells in vitro. Nishi O, et al. **J Cataract Refract Surg** 1995 Jul; 21(4):461–5

The effect of triclosan on mediators of gingival inflammation. Gaffar A, et al. **J Clin Periodontol** 1995 Jun;22(6):480–4

Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers. Waldman SA, et al. **J Clin Pharmacol** 1996 May;36(5):462–8

Anti-inflammatory activity of Vitis elongata. Alam MS, et al. **J Ethnopharmacol** 1995 Aug 11;48(1):59–60

Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. Tunón H, et al. **J Ethnopharmacol** 1995 Oct;48(2):61–76

The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. Gurwitz JH, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):M74–9

Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. Johnson AG, et al. **J Hum Hypertens** 1996 Apr;10(4):257–61

In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. Blackwell TS, et al. **J Immunol** 1996 Aug 15;157(4):1630–7

The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. Gadangi P, et al. **J Immunol** 1996 Mar 1;156(5):1937–41

Mechanism of action of bicyclic imidazoles defines a translational regulatory pathway for tumor necrosis factor alpha. Prichett W, et al. **J Inflamm** 1995;45(2):97–105

Neuropeptide regulation of cytokine expression: effects of VIP and Ro 25-1553. Tang H, et al. **J Interferon Cytokine Res** 1995 Nov;15(11):993–1003

Comparative efficacy of nonsteroidal anti-inflammatory drugs and anti-thromboxane agents in a rabbit adhesion-prevention model. LeGrand EK, et al. **J Invest Surg** 1995 May-Jun;8(3):187–94

Cytokine inhibition preserves renal hemodynamic function following mesangial cell immune injury. Pan CG, et al. **J Investig Med** 1996 Aug;44(6):375–81

Novel actions of aspirin and sodium salicylate: discordant effects on nitric oxide synthesis and induction of nitric oxide synthase mRNA in a murine macrophage cell line. Kepka-Lenhart D, et al. **J Leukoc Biol** 1996 Jun; 59(6):840–6

Inhibition of E-selectin-, ICAM-1-, and VCAM-1-mediated cell adhesion by benzo[b]thiophene-, benzofuran-, indole-, and naphthalene-2-carboxamides: identification of PD 144795 as an antiinflammatory agent. Boschelli DH, et al. **J Med Chem** 1995 Oct 27;38(22):4597–614

Dibenzoxepinone hydroxylamines and hydroxamic acids: dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity. Hamer RR, et al. **J Med Chem** 1996 Jan 5;39(1):246–52

Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. Hibi S, et al. **J Med Chem** 1996 Aug 2;39(16):3148–57

Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. Li JJ, et al. **J Med Chem** 1996 Apr 26;39(9):1846–56

1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. Li JJ, et al. **J Med Chem** 1995 Oct 27;38(22):4570–8

Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase. Malamas MS, et al. **J Med Chem** 1996 Jan 5;39(1):237–45

Antiinflammatory 4,5-diarylpyrroles. 2. Activity as a function of cyclooxygenase-2 inhibition. Wilkerson WW, et al. **J Med Chem** 1995 Sep 29;38(20):3895–901

Enhanced in vivo performance of liposomal indomethacin derived from effervescent granule based proliposomes. Katare OP, et al. **J Microencapsul** 1995 Sep-Oct; 12(5):487–93

Effect of graduated intravenous and standard rectal doses of indomethacin on cerebral blood flow in healthy volunteers. Jensen K, et al. **J Neurosurg Anesthesiol** 1996 Apr;8(2):111–6

The use of trabeculectomy to study the pharmacological modulation of ophthalmic wound healing. Schwade ND, et al. **J Ocul Pharmacol Ther** 1995 Summer;11(2):113–23

Effects of interleukin-1 blockers on ophthalmic wound healing in a rabbit model of trabeculectomy. Schwade ND, et al. **J Ocul Pharmacol Ther** 1995 Summer;11(2):125–34

Mechanisms of antagonism of interleukin-1 alpha by synthetic interleukin-1 blockers. Xiao JG, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):369–78

Effect of nonsteroidal antiinflammatory drugs on fracture healing: a laboratory study in rats. Altman RD, et al. **J Orthop Trauma** 1995;9(5):392–400

Effect of sodium naproxen on inflammatory response induced by anterior chamber paracentesis in the rabbit. Bucolo C, et al. **J Pharm Pharmacol** 1995 Sep;47(9):708–12

Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. Homma M, et al. **J Pharm Pharmacol** 1995 Aug;47(8):687–92

Anti-inflammatory effect of magnolol, isolated from Magnolia officinalis, on A23187-induced pleurisy in mice. Wang JP, et al. **J Pharm Pharmacol** 1995 Oct;47(10):857–60

Different effects of indomethacin and nabumetone on prostaglandin-mediated gastric responses to central vagal activation in rats. Cardin S, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):667–73

Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. Chan CC, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1531–7

Novel anti-inflammatory compounds prevent CD11b/CD18, alpha M beta 2 (Mac-1)-dependent neutrophil adhesion without blocking activation-induced changes in Mac-1. Endemann G, et al. **J Pharmacol Exp Ther** 1996 Jan; 276(1):5–12

Lack of antidiuretic activity of lanreotide in the diabetes insipidus rat. Fan NY, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):875–81

Leukotriene B4 modulates in vivo expression of delayed-type hypersensitivity by a receptor-mediated mechanism: regulation by lipoxin A4. Feng Z, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):950–6

Tenidap, an anti-inflammatory agent, discharges intracellular Ca++ store and inhibits Ca++ influx in cultured human gingival fibroblasts. Fujii A, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1447–52

Anti-inflammatory properties of Gö 6850: a selective inhibitor of protein kinase C. Jacobson PB, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):995–1002

New antiinflammatory compounds that inhibit tumor necrosis factor production: probable interaction with protein kinase C activation. Lang F, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):171–6

Different effects of three bisphosphonates on nitric oxide production by RAW 264 macrophage-like cells in vitro. Makkonen N, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):1097–102

Nonsteroidal anti-inflammatory drugs activate carbonic anhydrase by a direct mechanism of action. Puscas I, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1464–6

Type II collagen-induced arthritis in the diabetic-resistant biobreeding rat: inflammatory and histopathological features of joint pathology and effects of antiinflammatory and antirheumatic drugs on this chronic arthritic process. Smith RJ, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1801–13

Aceclofenac, a new nonsteroidal antiinflammatory drug, decreases the expression and function of some adhesion molecules on human neutrophils. González-Alvaro I, et al. **J Rheumatol** 1996 Apr;23(4):723–9

The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. Kremer JM, et al. **J Rheumatol** 1995 Nov; 22(11):2072–7

Effects of D-myo-Inositol-1,2,6-triphosphate on eicosanoid formation in burned skin. Tarnow P, et al. **J Surg Res** 1996 Apr;62(1):1–4

Neutrophil adhesion blockade with NPC 15669 decreases pulmonary injury after total cardiopulmonary bypass. Friedman M, et al. **J Thorac Cardiovasc Surg** 1996 Feb; 111(2):460–8

The dose-related effects of phenylbutazone and a methylprednisolone acetate formulation (Depo-Medrol) on cultured explants of equine carpal articular cartilage. Jolly WT, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):429–37

Complementary effects of paeoniflorin and glycyrrhizin on intracellular Ca2+ mobilization in the nerve-stimulated skeletal muscle of mice. Dezaki K, et al. **Jpn J Pharmacol** 1995 Nov;69(3):281–4

A canine model for determination of the therapeutic index of cytokine inhibitors. Sekut L, et al. **Lab Anim Sci** 1995 Dec;45(6):647–51

Spasmolytic and calmodulin inhibitory effect of non-steroidal anti-inflammatory drugs in vitro. Cantabrana B, et al. **Life Sci** 1995;57(14):1333–41

Anti-inflammatory activity of amylin and CGRP in different experimental models of inflammation. Clementi G, et al. **Life Sci** 1995;57(14):PL193–7

Diclofenac inhibits endothelial cell adhesion molecule expression induced with lipopolysaccharide. Sakai A. **Life Sci** 1996 May 24;58(26):2377–87

Low concentrations of nonsteroidal anti-inflammatory drugs affect cell functions. Sergeeva MG, et al. **Life Sci** 1995 Mar 10;56(16):PL313–9

Effects of nonsteroidal antiinflammatory drugs on renal plasma flow and glomerular filtration rate in patients with glomerulonephritis. Stošić Z, et al. **Med Pregl** 1993;46 Suppl 1:36–7

Influence of butibufen on enzyme activity and lysosomal stabilization ex vivo: a comparative study with hydrocortisone and acetylsalicylic acid. Alamo C, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun;17(5):303–10

Inhibition of interleukin-1 beta production by SKF86002: evidence of two sites of in vitro activity and of a time and system dependence. Perregaux DG, et al. **Mol Pharmacol** 1995 Sep;48(3):433–42

Aspirin and inflammation [editorial; comment] **Nat Struct Biol** 1995 Aug;2(8):605–6. Comment on: Nat Struct Biol 1995 Aug;2(8):637–47.

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase [see comments] Loll PJ, et al. **Nat Struct Biol** 1995 Aug; 2(8):637–43. Comment in: Nat Struct Biol 1995 Aug;2(8):605–6.

The non-peptide NK1 receptor antagonist SR140333 produces long-lasting inhibition of neurogenic inflammation, but does not influence acute chemo- or thermonociception in rats. Amann R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug; 352(2):201–5

A patch clamp study of the effects of ciprofloxacin and biphenyl acetic acid on rat hippocampal neurone GABAA and ionotropic glutamate receptors. Halliwell RF, et al. **Neuropharmacology** 1995 Dec;34(12):1615–24

Carrageenan oedema and spinal Fos-LI neurones are reduced by piroxicam in the rat. Buritova J, et al. **Neuroreport** 1995 Jul 10;6(10):1385–8

Aspirin and acetaminophen reduced both Fos expression in rat lumbar spinal cord and inflammatory signs produced by carrageenin inflammation. Honoré P, et al. **Pain** 1995 Dec;63(3):365–75

Expansion and comments on non-steroidal anti-inflammatory drugs and spinal nociception processing (Pain, 59 (1994) 9-43) [letter; comment] Russell AL. **Pain** 1995 Jun; 61(3):494–5. Comment on: Pain 1994 Oct;59(1):9–43.

Acute effects of indometacin on cerebral blood flow in man. Nitter WH, et al. **Pharmacology** 1995 Jun;51(1):48–55

Effect of high lipid diet and allopurinol on the development of experimentally induced arthritis in rats. Yossif AM, et al. **Pharmacology** 1995 Sep;51(3):160–4

Nonsteroidal anti-inflammatory drugs alter body temperature and suppress melatonin in humans. Murphy PJ, et al. **Physiol Behav** 1996 Jan;59(1):133–9

Non-phenolic linear diarylheptanoids from Curcuma xanthorrhiza: a novel type of topical anti-inflammatory agents: structure-activity relationship. Claeson P, et al. **Planta Med** 1996 Jun;62(3):236–40

Anti-inflammatory and analgesic activity of Baccharis trimera: identification of its active constituents. Gené RM, et al. **Planta Med** 1996 Jun;62(3):232–5

Phenylethanoids in the herb of Plantago lanceolata and inhibitory effect on arachidonic acid-induced mouse ear edema [letter] Murai M, et al. **Planta Med** 1995 Oct; 61(5):479–80

NSAIDs and anticoagulant therapy [letter; comment] Cohen RB. **Postgrad Med** 1996 Jan;99(1):44, 47. Comment on: Postgrad Med 1995 Sep;98(3):153–4, 159–62, 164–5, passim.

Development of novel anti-inflammatory agents: a pharmacologic perspective on leukotrienes and their receptors. Jackson WT, et al. **Prog Drug Res** 1996; 46:115–68 (322 ref.)

Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor. Kane GC, et al. **Prostaglandins** 1995 Jul;50(1):1–18

Effect of ibuprofen on thrombin-induced pulmonary edema in the rat. Ahn CM, et al. **Pulm Pharmacol** 1994 Dec; 7(6):393–9

Allergen-induced glycoconjugate secretion in guinea-pig trachea in vivo: modulation by indomethacin, BW B70C and ZD-2138. Yeadon M, et al. **Pulm Pharmacol** 1995 Feb; 8(1):53–63

Quantitative analysis of angiogenesis and growth of bone: effect of indomethacin exposure in a combined in vitro–in vivo approach. Leunig M, et al. **Res Exp Med (Berl)** 1995; 195(5):275–88

Action of clofazimine on the Mycobacterium avium complex. Warek U, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):43–8

Pharmacodynamics and enantioselective pharmacokinetics of carprofen in the cat. Taylor PM, et al. **Res Vet Sci** 1996 Mar;60(2):144–51

Phospholipase A2 inhibitors: a challenge for the future. Berenbaum F. **Rev Rhum Engl Ed** 1995 Jun;62(6):409–14 (45 ref.)

Tenidap, but not nonsteroidal anti-inflammatory drugs, inhibits T-cell proliferation and cytokine induction. Dolhain RJ, et al. **Scand J Immunol** 1995 Dec;42(6):686–93

Closing in on a stomach-sparing aspirin substitute [news] Service RF. **Science** 1996 Sep 20;273(5282):1660

Anti-inflammatory activity of croconazole, a broad-spectrum antimycotic agent, in the arachidonic acid-induced mouse ear swelling test. Steinmann D, et al. **Skin Pharmacol** 1995;8(4):211–4

Aspirin as a free radical scavenger: consequences for therapy of cerebrovascular ischemia [letter] Kuhn W, et al. **Stroke** 1995 Oct;26(10):1959–60

In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera. Dasgupta A, et al. **Ther Drug Monit** 1996 Feb;18(1):97–9

Mechanisms in tumor promotion: guidance for risk assessment and cancer chemoprevention. Marks F, et al. **Toxicol Lett** 1995 Dec;82–83:907–17

Effect of indomethacin on thrombin-induced pulmonary edema in the rat. Ahn CM, et al. **Ups J Med Sci** 1995; 100(2):125–35

Comparative pharmacodynamics of flunixin, ketoprofen and tolfenamic acid in calves. Landoni MF, et al. **Vet Rec** 1995 Oct 21;137(17):428–31

Modulation of endotoxin-induced andrological alterations by flunixin meglumine in the boar. Wallgren M, et al. **Zentralbl Veterinarmed A** 1995 Aug;42(6):357–69

[Comparative study on pharmacological effects of various species of Pueraria] Zhou Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Oct;20(10):619–21, 640 (Eng. Abstr.) **(Chi)**

[Effect of tripchlorolide (T4) of Tripterygium wilfordii Hook on the production of endothelin-1 by endothelial cells of human umbilical vein] Yao Q, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Jun; 17(3):228–9 (Eng. Abstr.) **(Chi)**

[Bradykinin antagonism in ischemia and reperfusion of the pancreas] Hoffmann T, et al. **Zentralbl Chir** 1996; 121(5):412–22; discussion 422–3 (Eng. Abstr.) **(Ger)**

[Non-steroidal anti-inflammatory drugs (NSAIDs)] Miura Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1031–5 (20 ref.) **(Jpn)**

[Mechanism of analgesic action of Y-23023, a new non-steroidal anti-inflammatory drug] Ochi H, et al. **Nippon Yakurigaku Zasshi** 1995 Oct;106(4):271–7 (Eng. Abstr.) **(Jpn)**

[Investigations concerning the effect of nabumetone on gastric mucosa] Gołąb T, et al. **Pol Arch Med Wewn** 1996 May;95(5):414–9 (Eng. Abstr.) **(Pol)**

[Sodium diclofenac effect, after interruption of the stercoraceous peritonitis, on the rat colon. Study of mechanical resistance and collagen concentration] Verderese LR, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep–Oct; 50(5):254–8 (Eng. Abstr.) **(Por)**

[The effect of paracetamol and its combinations with acetylsalicylic and ascorbic acids on lipid peroxidation processes in the rat liver] Chalka LA, et al. **Eksp Klin Farmakol** 1996 Jan–Feb;59(1):43–6 (Eng. Abstr.) **(Rus)**

[The central component in the mechanism of the analgesic action of nonsteroidal anti-inflammatory agents] Lemina EIu, et al. **Eksp Klin Farmakol** 1995 Jul–Aug;58(4):59–62 (52 ref.) **(Rus)**

[Use of benzofurocaine in stimulation of regenerative processes in the surgical treatment of patients with chronic suppurative otitis media] Semenov FV, et al. **Vestn Otorinolaringol** 1996 Mar–Apr;(2):45–8 (Eng. Abstr.) **(Rus)**

[Effects on arterial pressure of the use of anti-inflammatory nonsteroidal agents (letter)] Urrutia Bazán LG, et al. **Aten Primaria** 1995 Sep 15;16(4):230 **(Spa)**

[Helicobacter pylori, gastric ulcer and non-steroidal anti-inflammatory agents] Boixeda D, et al. **Med Clin (Barc)** 1996 Feb 17;106(6):209–12 (Eng. Abstr.) **(Spa)**

POISONING

Transient myocardial dysfunction in a child with salicylate toxicity. Ralston ME, et al. **J Emerg Med** 1995 Sep–Oct; 13(5):657–9

Systemic inflammatory response syndrome caused by chronic salicylate intoxication. Chalasani N, et al. **South Med J** 1996 May;89(5):479–82

SUPPLY & DISTRIBUTION

Availability of over-the-counter drugs for arthritis in Sao Paulo, Brazil. Ferraz MB, et al. **Soc Sci Med** 1996 Apr; 42(8):1129–31

THERAPEUTIC USE

Is preoperative ketorolac a useful adjunct to regional anesthesia for inguinal herniorrhaphy? Ben-David B, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):358–63

Urinary excretion of melanocyte metabolites during treatment with chloroquine phosphate. Sjölin-Forsberg G, et al. **Acta Derm Venereol** 1995 Jul;75(4):287–9

Clofazimine in inflammatory facial dermatosis--granuloma faciale and lipogranulomatosis subcutanea (Rothmann-Makai) [letter] Wollina U, et al. **Acta Derm Venereol** 1996 Jan;76(1):77–9

Prevention of heterotopic ossification with tenoxicam following total hip arthroplasty: a double-blind, placebo-controlled dose-finding study. Burssens A, et al. **Acta Orthop Belg** 1995;61(3):205–11

Heterotopic ossification after hip arthroplasty: a randomized double-blind multicenter study tenoxicam in 147 hips. Gebuhr P, et al. **Acta Orthop Scand** 1996 Feb;67(1):29–32

Unanswered questions about Helicobacter pylori. Walsh JH. **Aliment Pharmacol Ther** 1995;9 Suppl 1:31–7 (72 ref.)

Single-dose intramuscular ketorolac versus diclofenac for pain management in renal colic. Stein A, et al. **Am J Emerg Med** 1996 Jul;14(4):385–7

Recall accuracy for prescription medications: self-report compared with database information. West SL, et al. **Am J Epidemiol** 1995 Nov 15;142(10):1103–12

Esophagoprotection with NSAIDs: the way forward [letter; comment] Morgan G. **Am J Gastroenterol** 1996 Jun; 91(6):1277–8. Comment on: Am J Gastroenterol 1995 May;90(5):754–7. Comment on: Am J Gastroenterol 1995 May;90(5):846–7; discussion 847–9.

High-dose biscoclaurine alkaloids together with prednisolone raise platelet counts in chronic idiopathic thrombocytopenic purpura [letter] Saito N, et al. **Am J Hematol** 1996 Feb;51(2):173–4

Therapeutic uses of aspirin in renal diseases. Winchester JF. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S20–3 (44 ref.)

Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection. Polisson R. **Am J Med** 1996 Feb 26;100(2A):31S–36S (29 ref.)

Salsalate, morphine, and postoperative ileus. Cheng G, et al. **Am J Surg** 1996 Jan;171(1):85–8; discussion 88–9

Effect of phenylbutazone and flunixin meglumine on acute toxic mastitis in dairy cows. Dascanio JJ, et al. **Am J Vet Res** 1995 Sep;56(9):1213–8

Effect of oral administration of flunixin meglumine on the inflammatory response to endotoxin in heifers. Odensvik K, et al. **Am J Vet Res** 1996 Feb;57(2):201–4

Effects of pretreatment with ketoprofen and phenylbutazone on experimentally induced synovitis in horses. Owens JG, et al. **Am J Vet Res** 1996 Jun;57(6):866–74

A comparison of diclofenac with ketorolac for pain relief after knee arthroscopy. Dennis AR, et al. **Anaesthesia** 1995 Oct;50(10):904–6

Reduction of postburn hyperalgesia after local injection of ketorolac in healthy volunteers. Lundell JC, et al. **Anesthesiology** 1996 Mar;84(3):502–9

Not all bone loss created equal [letter] Eisenberger YS. **Angle Orthod** 1996;66(2):85

Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Shrestha M, et al. **Ann Emerg Med** 1995 Dec;26(6):682–6

Topical nonsteroidal antiinflammatory drugs for acute soft tissue injuries. Heyneman CA. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):780–2 (14 ref.)

Colorectal cancer: surgical prophylaxis and chemoprevention [see comments] Nugent KP. **Ann R Coll Surg Engl** 1995 Sep;77(5):372–6 (55 ref.). Comment in: Ann R Coll Surg Engl 1996 Mar;78(2):154–5.

Tenidap: not just another NSAID? Canvin JM, et al. **Ann Rheum Dis** 1996 Feb;55(2):79–82 (29 ref.)

The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Breitner JC. **Annu Rev Med** 1996;47:401–11 (81 ref.)

New pharmacological strategies for pain relief. Dray A, et al. **Annu Rev Pharmacol Toxicol** 1996;36:253–80 (193 ref.)

Comparing efficacy and tolerability of ibuprofen and paracetamol in fever. McIntyre J, et al. **Arch Dis Child** 1996 Feb;74(2):164–7

Aspirin treatment and increased generation of cysteinyl leukotrienes in Kawasaki disease [letter; comment] Shimizu T, et al. **Arch Dis Child** 1996 Jan;74(1):90–1. Comment on: Arch Dis Child 1995 Jun;72(6):526–7.

Prophylactic indomethacin: systematic review and meta-analysis. Fowlie PW. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar;74(2):F81–7 (35 ref.)

Practical management of osteoarthritis. Integration of pharmacologic and nonpharmacologic measures. Griffin MR, et al. **Arch Fam Med** 1995 Dec;4(12):1049–55 (102 ref.)

Colorectal cancer protection by endoscopic and NSAID combination [letter] Morgan GP. **Arch Intern Med** 1996 Apr 22;156(8):910

A remembrance of Fred, the lowland gorilla. Atkinson JP. **Arthritis Rheum** 1996 Jun;39(6):891–3

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Mladenovic V, et al. **Arthritis Rheum** 1995 Nov; 38(11):1595–603

The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Nickerson-Nutter CL, et al. **Arthritis Rheum** 1996 Mar;39(3):515–21

Protective effect of furosemide combined with non-steroidal anti-inflammatory drugs administered by inhalation route on guinea-pigs anaphylaxis model. Berti F, et al. **Arzneimittelforschung** 1995 Oct;45(10):1098–102

Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. Furst DE. **Baillieres Clin Rheumatol** 1995 Nov;9(4):711–29 (41 ref.)

Does pre-incisional thoracic extradural block combined with diclofenac reduce postoperative pain after abdominal hysterectomy? [see comments] Espinet A, et al. **Br J Anaesth** 1996 Feb;76(2):209–13. Comment in: Br J Anaesth 1996 Jul;77(1):128–9.

Pre-emptive analgesia with NSAID--what does it achieve? [letter; comment] Hudspith MJ, et al. **Br J Anaesth** 1996 Jul;77(1):128–9. Comment on: Br J Anaesth 1996 Feb;76(2):209–13.

Experimental pain techniques [letter] Walker JS, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):349–50

Pain control after hysterectomy: an observer-blind, randomised trial of lornoxicam versus tramadol. Ilias W, et al. **Br J Clin Pract** 1996 Jun;50(4):197–202

Angiolymphoid hyperplasia with eosinophilia: successful treatment with indomethacin farnesil [letter] Nomura K, et al. **Br J Dermatol** 1996 Jan;134(1):189–90

The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology. Koay P. **Br J Ophthalmol** 1996 May;80(5):480–5 (98 ref.)

Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. Elford PR, et al. **Br J Pharmacol** 1995 Jun;115(4):601–6

Modulation of normal tissue responses to radiation [letter] El-Agamawi AY, et al. **Br J Radiol** 1996 Apr;69(820):374–5

Use of contrast enhanced MRI in the assessment of therapeutic response to a disease-modifying antirheumatic drug. Case study of a patient with rheumatoid arthritis--6- and 24-month follow up. Jevtic V, et al. **Br J Rheumatol** 1995 Oct;34(10):956–9

Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Maillefert JF, et al. **Br J Rheumatol** 1996 May;35(5):430–5

Tenidap versus diclofenac in rheumatoid arthritis [letter; comment] Swaak AJ. **Br J Rheumatol** 1996 Jun;35(6):602 . Comment on: Br J Rheumatol 1995 Jun;34(6):554–63.

Quality of life assessment in patients undergoing treatment for oesophageal carcinoma [letter; comment] Morgan G. **Br J Surg** 1996 Mar;83(3):423–4. Comment on: Br J Surg 1995 Dec;82(12):1682–5.

Intramuscular tenoxicam to treat acute renal colic. Al-Waili NS. **Br J Urol** 1996 Jan;77(1):15–6

Treating musculoskeletal disease with NSAIDs. Practitioner's guide. Bellamy N. **Can Fam Physician** 1996 Mar;42:482–6, 489–92 (38 ref.)

Indomethacin and ketorolac given preoperatively are equally effective in reducing early postoperative pain after laparoscopic cholecystectomy. Forse A, et al. **Can J Surg** 1996 Feb;39(1):26–30

Aspirin and reduced risk of esophageal carcinoma. Funkhouser EM, et al. **Cancer** 1995 Oct 1;76(7):1116–9

Chemoprevention of the naturally occurring carcinogen 1-hydroxyanthraquinone-induced carcinogenesis by the nonsteroidal anti-inflammatory drug indomethacin in rats. Tanaka T, et al. **Cancer Detect Prev** 1995;19(5):418–25

G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. DuBois RN, et al. **Cancer Res** 1996 Feb 15; 56(4):733–7

Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Pereira MA, et al. **Carcinogenesis** 1996 Feb;17(2):373–6

Indomethacin and alpha-tocopheral enhanced survival in endotoxic rats. Ashorobi RB, et al. **Cent Afr J Med** 1995 Jul;41(7):216–9

Ketoprofen, paracetamol and placebo in the treatment of

episodic tension-type headache. Dahlöf CG, et al. **Cephalalgia** 1996 Apr;16(2):117-23

Analgesics and NSAIDs in the treatment of the acute migraine attack. Pfaffenrath V, et al. **Cephalalgia** 1995 Oct; 15 Suppl 15:14-20 (53 ref.)

Prophylactic treatment of migraine: evaluation of clinical trials and choice among drugs. Tfelt-Hansen P. **Cephalalgia** 1995 Oct;15 Suppl 15:29-32 (15 ref.)

Good morning, evening primrose oil [editorial] Goonaratna C. **Ceylon Med J** 1995 Dec;40(4):132-3

Aspirin--friend or fiend? [letter] Mendis BL. **Ceylon Med J** 1996 Jun;41(2):76-7

Atrial myxoma mimicking systemic disease. Profile modified by flurbiprofen administration. Boullanger N, et al. **Chest** 1996 May;109(5):1400-1

Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease. Brzezinski A, et al. **Cleve Clin J Med** 1995 Sep-Oct;62(5):317-23 (37 ref.)

Anti-inflammatory effects of long-acting beta-agonists in asthma [editorial] Bradding P. **Clin Exp Allergy** 1995 Oct; 25(10):912-4 (36 ref.)

Differential effects of methotrexate and liposomally conjugated methotrexate in rat adjuvant-induced arthritis. Williams AS, et al. **Clin Exp Immunol** 1995 Dec; 102(3):560-5

Effective pain management in terminal care. Dahl JL. **Clin Geriatr Med** 1996 May;12(2):279-300 (92 ref.)

Indomethacin. Gordon MC, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):697-705 (23 ref.)

A case of recurrent Caffey's disease treated with naproxen. Thometz JG, et al. **Clin Orthop** 1996 Feb;(323):304-9

Diclofenac and post-tonsillectomy haemorrhage [letter; comment] Robb PJ, et al. **Clin Otolaryngol** 1995 Oct; 20(5):483-4. Comment on: Clin Otolaryngol 1994 Aug;19(4):344-5.

Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Ward DE, et al. **Clin Rheumatol** 1995 Nov; 14(6):656-62

Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study. Dore R, et al. **Clin Ther** 1995 Jul-Aug;17(4):656-66

Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia's senior population. Kephart G, et al. **Clin Ther** 1995 Nov-Dec; 17(6):1159-73

Results of a survey of patients with ocular allergy treated with topical ketorolac tromethamine. Raizman MB. **Clin Ther** 1995 Sep-Oct;17(5):882-90

Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. Schnitzer TJ, et al. **Clin Ther** 1995 Jul-Aug; 17(4):602-12

Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. Weaver A, et al. **Clin Ther** 1995 Jul-Aug; 17(4):735-45

Lithium-induced nephrogenic diabetes insipidus treated with intravenous ketorolac. Burke C, et al. **Crit Care Med** 1995 Nov;23(11):1924-7

A multi-centre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. Pasero G, et al. **Curr Med Res Opin** 1995;13(6):305-15

NSAIDS, free radicals, and reflux esophagitis [letter] Morgan G. **Dig Dis Sci** 1996 Sep;41(9):1863

Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Peleg II, et al. **Dig Dis Sci** 1996 Jul;41(7):1319-26

Complete regression of villous adenomas of the colon using piroxicam, a nonsteroidal anti-inflammatory drug. Gowen GF. **Dis Colon Rectum** 1996 Jan;39(1):101-2

Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Nugent KP, et al. **Dis Colon Rectum** 1996 Jun;39(6):659-62

Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Balfour JA, et al. **Drugs** 1996 Apr;51(4):639-57 (76 ref.)

Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases. Plosker GL, et al. **Drugs** 1995 Dec;50(6):1050-75 (146 ref.)

Pharmacological intervention in older patients with rheumatoid arthritis. Quality of life aspects. Bendtsen P, et al. **Drugs Aging** 1995 Nov;7(5):338-46 (55 ref.)

Comparison ketoprofen, ibuprofen and naproxen sodium in the treatment of tension-type headache. Lange R, et al. **Drugs Exp Clin Res** 1995;21(3):89-96

The early effects of intravenous L-propionyl carnitine on ulcerative trophic lesions of the lower limbs in arteriopathic patients: a controlled randomized study. Persico G, et al. **Drugs Exp Clin Res** 1995;21(5):187-98

Effects of ketoprofen and phenylbutazone on chronic hoof pain and lameness in the horse. Owens JG, et al. **Equine Vet J** 1995 Jul;27(4):296-300

Current concepts in the diagnosis and treatment of sudden sensorineural hearing loss. Schweinfurth JM, et al. **Eur Arch Otorhinolaryngol** 1996;253(3):117-21

The protocol for a European double-blind trial of aspirin and resistant starch in familial adenomatous polyposis: the CAPP study. Concerted Action Polyposis Prevention. Burn J, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1385-6

The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Giardiello FM, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1071-6 (55 ref.)

Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Florent C, et al. **Eur J Gastroenterol Hepatol** 1996 Mar;8(3):229-33

Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group [see comments] Fockens P, et al. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1025-30. Comment in: Eur J Gastroenterol Hepatol 1995 Nov;7(11):1017-9.

5-aminosalicylates in inflammatory bowel disease--the more the merrier? [editorial; comment] Forbes A. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1017-9. Comment on: Eur J Gastroenterol Hepatol 1995 Nov;7(11):1025-30.

IL-12 inhibits endotoxin-induced inflammation in the eye. Whitcup SM, et al. **Eur J Immunol** 1996 May;26(5):995-9

Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester. Wallace JL, et al. **Eur J Pharmacol** 1995 Jun 23;280(1):63-8

Arthrotec, diclofenac and ibuprofen in general practice. Kiff PS, et al. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):31-8

Review of Arthrotec clinical data. McKenna F. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):25-9 (9 ref.)

Arthrotec in general practice. Proceedings from the clinical investigator meeting held May 1994, Leeds, UK [editorial] Mowat AG. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):1-2

The potential of NSAIDs in the treatment of oesophageal carcinoma. Morgan G. **Eur J Surg Oncol** 1996 Jun; 22(3):217-9

In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Llewellyn-Jones CG, et al. **Eur Respir J** 1995 Sep;8(9):1479-87

Inhibitory properties of triethylphosphine goldlupinylsulfide in adjuvant-induced arthritis in rats. Ghia M, et al. **Farmaco** 1995 Sep;50(9):601-4

Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. D'Andrea G, et al. **Funct Neurol** 1995 Mar-Apr;10(2):91-8

NSAID trials, sporadic adenomas, and conservative inferences [letter; comment] Hawk E, et al. **Gastroenterology** 1996 Feb;110(2):654-5. Comment on: Gastroenterology 1995 Apr;108(4):1083-7.

Endoscopy, nonsteroidal anti-inflammatory drug, and omeprazole regimen in colorectal cancer prevention [letter; comment] Morgan G. **Gastroenterology** 1996 Apr; 110(4):1323. Comment on: Gastroenterology 1995 Oct;109(4):1188-96.

The effect of argon laser trabeculoplasty on the blood-aqueous barrier and intraocular pressure in human glaucomatous eyes treated with diclofenac 0.1%. Diestelhorst M, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Sep;233(9):559-62

Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Giardiello FM, et al. **Gut** 1996 Apr;38(4):578-81

Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers. Morgan G. **Gut** 1996 May;38(5):646-8

Alternatives in drug treatment of chronic paroxysmal hemicrania. Evers S, et al. **Headache** 1996 Jul-Aug; 36(7):429-32

The placebo effect in acute headache management: ketorolac, meperidine, and saline in the emergency department. Harden RN, et al. **Headache** 1996 Jun;36(6):352-6

Chronic paroxysmal hemicrania and hemicrania continua. Interval between indomethacin administration and response. Pareja J, et al. **Headache** 1996 Jan;36(1):20-3

A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua. Sjaastad O, et al. **Headache** 1995 Oct;35(9):549-50

Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. Engelhardt G, et al. **Inflamm Res** 1995 Dec; 44(12):548-55

Leflunomide: an active antiinflammatory and antiproliferative agent in models of dermatologic disease. Kurtz ES, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S187-8

Anti-inflammatory effects of sulfatides in selectin-dependent acute lung injury [published erratum appears in Int Immunol 1995 Oct;7(10):1699] Mulligan MS, et al. **Int Immunol** 1995 Jul;7(7):1107-13

Comparative efficacy of diclofenac dispersible 50 mg and ibuprofen 400 mg in patients with primary dysmenorrhea. A randomized, double-blind, within-patient, placebo-controlled study. Marchini M, et al. **Int J Clin Pharmacol Ther** 1995 Sep;33(9):491-7

Combined treatment with ren-shen-yang-rong-tang (Japanese name: ninjin-youei-to) plus prednisolone on adjuvant-induced arthritis in Lewis rat. Harigai E, et al. **Int J Immunopharmacol** 1995 May;17(5):411-8

Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis. Ueno M, et al. **Int J Immunopharmacol** 1995 Jul;17(7):597-603

The role of nonsteroidal antiinflammatory drugs in ocular inflammation. Samiy N, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):195-206 (38 ref.)

The effect of low dose diclofenac sodium administered locally on heterotopic bone formation in rats. Risto O, et al. **Int Orthop** 1995;19(6):392-5

The role of arginine, indomethacin and kallikrein in the treatment of oligoasthenospermia. Aydin S, et al. **Int Urol Nephrol** 1995;27(2):199-202

A study of symptomatic drug use in migraine without aura. Maggioni F, et al. **Ital J Neurol Sci** 1995 Oct;16(7):459-65

An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. **J Allergy Clin Immunol** 1996 Jun;97(6):1218-24

Theophylline: potential antiinflammatory effects in nocturnal asthma. Kraft M, et al. **J Allergy Clin Immunol** 1996 Jun; 97(6):1242-6

A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. Shalita A, et al. **J Am Acad Dermatol** 1996 Mar;34(3):482-5

Could aspirin/NSAID treatment preserve independence and decrease the need for institutionalization of older rheumatoid arthritis patients [letter] Leibovitz A, et al. **J Am Geriatr Soc** 1996 Feb;44(2):216

Protective effect of chronic NSAID use on cognitive decline in older persons. Rozzini R, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1025-9

Copperhead snakebite of the foot [letter] Reid H, et al. **J Am Podiatr Med Assoc** 1996 Jul;86(7):347-9

Choice of antipyretic in children. Khubchandani RP, et al. **J Assoc Physicians India** 1995 Sep;43(9):614-6

Anti-inflammatory medication after muscle injury. A treatment resulting in short-term improvement but subsequent loss of muscle function. Mishra DK, et al. **J Bone Joint Surg Am** 1995 Oct;77(10):1510-9

Efficacy of ketorolac in the management of pain associated with root canal treatment. Battrum D, et al. **J Can Dent Assoc** 1996 Jan;62(1):36-42

Pentoxifylline in severe inflammatory response syndrome. Graninger W, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S134-8 (37 ref.)

Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? Alberts DS, et al. **J Cell Biochem Suppl** 1995; 22:18-23

Triclosan reduces the clinical symptoms of the allergic patch test reaction (APR) elicited with 1% nickel sulphate in sensitised patients. Barkvoll P, et al. **J Clin Periodontol** 1995 Jun;22(6):485-7

Adjunctive supragingival irrigation with acetylsalicylic acid in periodontal supportive therapy. Flemmig TF, et al. **J Clin Periodontol** 1995 Jun;22(6):427-33

Efficacy of systemically administered acetylsalicylic acid plus scaling on periodontal health and elastase-alpha 1-proteinase inhibitor in gingival crevicular fluid. Flemmig TF, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):153-9

Triclosan inhibits histamine-induced inflammation in human skin. Kjaerheim V, et al. **J Clin Periodontol** 1995 Jun; 22(6):423-6

The effect of triclosan on developing gingivitis. Ramberg P, et al. **J Clin Periodontol** 1995 Jun;22(6):442-8

Low back pain [letter] Lexchin J. **J Emerg Med** 1995 Nov-Dec;13(6):820

Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. Munakata A, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:108-11

Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. Nakajima H, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:115-7

Sulindac and indomethacin inhibit formation of aberrant crypt foci in the colons of dimethyl hydrazine treated rats. Charalambous D, et al. **J Gastroenterol Hepatol** 1996 Jan; 11(1):88-92

Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. Polónia J, et al. **J Hypertens** 1995 Aug;13(8):925-31

Reduction of hepatic reperfusion injury by indomethacin-mediated vasoconstriction: a rat model with temporary splenocaval shunt. Spiegel HU, et al. **J Invest Surg** 1995 Sep-Oct;8(5):363-9

Relapsing polychondritis presented as inner ear involvement. Kimura Y, et al. **J Laryngol Otol** 1996 Feb;110(2):154-7

A risk assessment of spinal manipulation vs. NSAIDs for the treatment of neck pain [letter] Nilsson N. **J Manipulative Physiol Ther** 1996 Mar-Apr;19(3):220-1

Studies on selectin blockers. 2. Novel selectin blocker as potential therapeutics for inflammatory disorders. Wada Y, et al. **J Med Chem** 1996 May 10;39(10):2055-9

Prospective study of regular aspirin use and the risk of breast cancer [see comments] Egan KM, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):988-93. Comment in: J Natl Cancer Inst 1996 Jul 17;88(14):941-2.

Growth inhibition of rat glioma cells in vitro and in vivo by aspirin. Aas AT, et al. **J Neurooncol** 1995;24(2):171-80

Ketorolac appears to decrease polyuria during intracranial surgery. Williams EL. **J Neurosurg Anesthesiol** 1996 Jan; 8(1):35-9

Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. Laibovitz RA, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):361-8

Safety of intravenous ketorolac therapy in children and cost savings with a unit dosing system. Houck CS, et al. **J Pediatr** 1996 Aug;129(2):292–6

Low-dose aspirin and prednisone treatment of pregnancy loss caused by lupus anticoagulants. Harger JH, et al. **J Perinatol** 1995 Nov–Dec;15(6):463–9

A comparison of 2 analgesic regimens for the control of postoperative periodontal discomfort. Tucker PW, et al. **J Periodontol** 1996 Feb;67(2):125–9

The pharmacological modulation of angiogenesis in chronic granulomatous inflammation. Colville-Nash PR, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1463–72

NSAID chemoprevention of colorectal adenomas and oesophageal metaplasia [letter; comment] Morgan G. **J R Soc Med** 1996 Apr;89(4):237. Comment on: J R Soc Med 1995 Nov;88(11):625–8.

A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. Bellamy N, et al. **J Rheumatol** 1995 May;22(5):915–20

A quantitative one-dimensional magnetic resonance imaging technique in adjuvant arthritis: the assessment of disease progression and indomethacin efficacy. Borah B, et al. **J Rheumatol** 1995 May;22(5):855–62

Quantitative microfocal radiography detects changes in OA knee joint space width in patients in placebo controlled trial of NSAID therapy [see comments] Buckland-Wright JC, et al. **J Rheumatol** 1995 May;22(5):937–43. Comment in: J Rheumatol 1995 May;22(5):807–8.

Tenidap and flurbiprofen enhance uptake of matrix metalloproteinase inhibitor 4-dedimethylaminotetracycline in inflamed joints of adjuvant arthritic rats. Leung MK, et al. **J Rheumatol** 1995 Sep;22(9):1726–31

More evidence links NSAID, estrogen use with reduced Alzheimer risk [news] Stephenson J. **JAMA** 1996 May 8; 275(18):1389–90

Are aspirin and other non-steroidal anti-inflammatory drugs effective in the prevention and treatment of colorectal cancer? [letter] Elder DJ, et al. **Lancet** 1996 Aug 17; 348(9025):485

Dexamethasone in bronchiolitis: a randomised controlled trial [see comments] Roosevelt G, et al. **Lancet** 1996 Aug 3; 348(9023):292–5. Comment in: Lancet 1996 Aug 3;348(9023):279–81.

The estrogen antagonist tamoxifen inhibits carrageenan induced inflammation in LEW/N female rats. Misiewicz B, et al. **Life Sci** 1996;58(16):PL281–6

Lewy body diseases: possible new directions in prophylaxis and therapy. Oken RJ. **Med Hypotheses** 1996 Mar; 46(3):222–4

Pattern of non-steroidal anti-inflammatory drug use in Australia 1990–1994. A report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. McManus P, et al. **Med J Aust** 1996 May 20; 164(10):589–92

Aspirin and colon cancer [letter; comment] Goldberg Y. **N Engl J Med** 1996 Mar 21;334(12):800–1. Comment on: N Engl J Med 1995 Sep 7;333(10):609–14. Comment on: N Engl J Med 1995 Sep 7;333(10):656–8.

Aspirin and the risk of colorectal cancer in women [letter; comment] Johnson KA, et al. **N Engl J Med** 1996 Jan 11; 334(2):119; discussion 121. Comment on: N Engl J Med 1995 Sep 7;333(10):609–14.

Aspirin and the risk of colorectal cancer in women [letter; comment] van Bodegraven AA, et al. **N Engl J Med** 1996 Jan 11;334(2):120; discussion 121–2. Comment on: N Engl J Med 1995 Sep 7;333(10):609–14. Comment on: N Engl J Med 1995 Sep 7;333(10):656–8.

Renal effects of captopril, indomethacin and nifedipine in nephrotic patients after an oral protein load. Garini G, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):628–34

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Breitner JC, et al. **Neurobiol Aging** 1995 Jul–Aug; 16(4):523–30

Nonsteroidal anti-inflammatory drugs in Alzheimer's disease [letter; comment] Haruda FD. **Neurology** 1995 Nov; 45(11):2116. Comment on: Neurology 1995 Jan;45(1):51–5.

Interaction of indometacin farnesil, a new nonsteroidal antiinflammatory drug with peripheral blood mononuclear cells from patients with rheumatoid arthritis. Hirohata S, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr; 19(2):136–44

Regular NSAID use appears to reduce breast cancer severity [news] **Oncology (Huntingt)** 1996 Apr;10(4):544, 546

NSAIDs may prevent colon cancer through apoptosis, not anti-inflammatory effects [news] **Oncology (Huntingt)** 1996 Apr;10(4):624

The treatment of pain following excimer laser photorefractive keratectomy: additive effect of local anesthetic drops, topical diclofenac, and bandage soft contact. Cherry PM. **Ophthalmic Surg Lasers** 1996 May; 27(5 Suppl):S477–80

Effect of steroids and nonsteroidal anti-inflammatory agents on stromal wound healing following excimer laser keratectomy in rabbits. Park SC, et al. **Ophthalmic Surg Lasers** 1996 May;27(5 Suppl):S481–6

New treatments for anterior uveitis [editorial] Dunn JP. **Ophthalmology** 1996 Mar;103(3):355–6

Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Roberts CW. **Ophthalmology** 1996 Apr;103(4):636–9

Effects of diclofenac eye drops on corneal epithelial structure and function after small-incision cataract surgery. Shimazaki J, et al. **Ophthalmology** 1996 Jan;103(1):50–7

The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Adams ME, et al. **Osteoarthritis Cartilage** 1995 Dec;3(4):213–25

Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future. Giannini EH, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1099–125 (89 ref.)

Antenatal exposure to steroids and the additional prophylaxis effect of indomethacin to prevent intraventricular hemorrhage [letter] Ment LR, et al. **Pediatrics** 1996 Apr; 97(4):601

Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Van Marter LJ, et al. **Pediatrics** 1996 May;97(5):658–63

The influence of carbon tetrachloride-induced liver damage on the inflammatory reaction elicited by carrageenan and its treatment with diclofenac. Agha AM, et al. **Pharmacol Res** 1995 Jul–Aug;32(1–2):75–84

Cytochrome P4502E1 inhibition by propylene glycol prevents acetaminophen (paracetamol) hepatotoxicity in mice without cytochrome P4501A2 inhibition. Thomsen MS, et al. **Pharmacol Toxicol** 1995 Jun;76(6):395–9

Potentiation of merocyanine 540-mediated photodynamic therapy by salicylate and related drugs. Traul DL, et al. **Photochem Photobiol** 1995 Oct;62(4):790–9

The quest for the ideal therapy for giant cell arteritis [letter; comment] Gonzalez-Gay MA. **Rev Rhum Engl Ed** 1995 Jul–Sep;62(7–8):539. Comment on: Rev Rhum Ed Fr 1994;61(7–8):485–90.

Therapeutic trials in digital osteoarthritis. A critical review. Trêves R, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):33S–41S

The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. Kornasoff D, et al. **Rheumatol Int** 1996;15(6):225–30

Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. Martin-Mola E, et al. **Rheumatol Int** 1995;15(3):111–6

Experimental AA-amyloidosis in mice is inhibited by treatment with the anti-rheumatic drug tenidap. Husebekk A, et al. **Scand J Immunol** 1996 May;43(5):551–5

Serum values of pepsinogens and antibodies to Helicobacter pylori in relation to a history of peptic ulcer disease and NSAID use. Janssen M, et al. **Scand J Rheumatol** 1995; 24(4):204–8

Clinical implications of selective cyclooxygenase-2 inhibition. Emery P. **Scand J Rheumatol Suppl** 1996; 102:23–8

Flurbinitroxybutylester: a novel anti-inflammatory drug has enhanced antithrombotic activity. Cirino G, et al. **Thromb Res** 1995 Jul 1;79(1):73–81

The effects of gynaecological surgery on coagulation activation, fibrinolysis and fibrinolytic inhibitor in patients with and without ketorolac infusion. Koh SC, et al. **Thromb Res** 1995 Sep 15;79(5–6):501–14

Islet protective effect of pravastatin from nonspecific inflammation in mouse pancreatic islet isografts. Arita S, et al. **Transplant Proc** 1996 Apr;28(2):924

Regression of large pelvic desmoid tumor by tamoxifen and sulindac. Izes JK, et al. **Urology** 1996 May;47(5):756–9

Dose-response relationship for the antipyretic effect of meloxicam in an endotoxin model in cats. Justus C, et al. **Vet Res Commun** 1995;19(4):321–30

[Recent advances in experimental and clinical study on ligustrazine in treating respiratory disease] Zhang KJ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):638–40 (22 ref.) **(Chi)**

[Antifebrile and anti-inflammatory effects of radix Cynanchi atrati] Xue B, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Dec;20(12):751–2, 764 (Eng. Abstr.) **(Chi)**

[Naclof in the treatment of chronic non-infectious conjunctivitis] Pitrová S, et al. **Cesk Slov Oftalmol** 1996 Feb;52(1):15–9 (Eng. Abstr.) **(Cze)**

[Aminosalicylates in the treatment of idiopathic inflammatory bowel disease] Lukáš K. **Vnitr Lek** 1996 Feb;42(2):117–9 **(Cze)**

[Indications for antineoplastic effects of nonsteroidal anti-inflammatory drugs] Kooy A, et al. **Ned Tijdschr Geneeskd** 1995 Nov 4;139(44):2235–9 (49 ref.) **(Dut)**

[Peripheral arthritis in family practice] de Bock GH. **Tijdschr Gerontol Geriatr** 1996 Apr;27(2):67–72 (Eng. Abstr.) **(Dut)**

[Avoiding certainty while treating the pain (letter)] Orko R. **Duodecim** 1994;110(21):2026–7 **(Fin)**

[Comparative study of the efficacy and tolerability of 0.1 and 0.03 p.100 adapalene gel and 0.025 p.100 tretinoin gel in the treatment of acne] Alirezai M, et al. **Ann Dermatol Venereol** 1996;123(3):165–70 (Eng. Abstr.) **(Fre)**

[Optimal use of non opioid analgesics] Fletcher D. **Cah Anesthesiol** 1995;43(3):239–49 (Eng. Abstr.) **(Fre)**

[Apyrexia induced by non-steroidal anti-inflammatory agents in 5 cases of Hodgkin disease [letter] Dossou-Gbete L, et al. **Rev Med Interne** 1995;16(9):726 **(Fre)**

[Pharmaclinics--how I treat... Crohn disease] Belaiche J. **Rev Med Liege** 1995 Oct;50(10):409–10 **(Fre)**

[Pharma clinics: how I treat... Inflammatory intestinal diseases and pregnancy] Belaiche J. **Rev Med Liege** 1995 Nov;50(11):449–50 **(Fre)**

[Nonsteroidal anti-inflammatory drugs] Malaise M. **Rev Med Liege** 1996 Jan;51(1):123–5 **(Fre)**

[5-Aminosalicylic acid in the prevention of recurrences of Crohn's disease] Del Corso L, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1723–7 (Eng. Abstr.) **(Ger)**

[Alzheimer disease: anti-inflammatory agents could be of therapeutic value (interview by Elisabeth B. Moosmann)] Bauer J. **Fortschr Med** 1996 Apr 10;114(10):16–8 **(Ger)**

[Clinical application of extracts of Echinacea purpurea or Echinacea pallida. Critical evaluation of controlled clinical studies] Dorsch W. **Z Arztl Fortbild (Jena)** 1996 Apr; 90(2):117–22 (20 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation of the effectiveness and tolerability of MED 15 vs. piroxicam in patients with acute epicondylitis] Meloni P, et al. **Clin Ter** 1995 Jun–Jul;146(6–7):453–6 (Eng. Abstr.) **(Ita)**

[Efficacy and tolerability 80 mg granulated ketoprofen lysine salt in posttraumatic orodental pain: double blind vs placebo study] Balzanelli B, et al. **Minerva Stomatol** 1996 Jan–Feb;45(1–2):53–9 (Eng. Abstr.) **(Ita)**

[Analgesic and anti-inflammatory effect of (+/-)-N,N-dimethylcarbamoylmethyl 2-[7-(2-methyl-5H-[1] benzopyrano [2,3-b] pyridyl)] propionate (Y-23023), a new non-steroidal anti-inflammatory drug] Iwahisa Y, et al. **Nippon Yakurigaku Zasshi** 1995 Aug;106(2):99–111 (Eng. Abstr.) **(Jpn)**

[Establish the optimal dosage of TSA-234 (rhSOD) in the treatment of osteoarthritis] **Ryumachi** 1995 Jun;35(3):621–35 **(Jpn)**

[Autoimmune hemolytic anemia and ulcerative colitis] Rebocho L, et al. **Acta Med Port** 1995 Dec;8(12):701–3 (Eng. Abstr.) **(Por)**

[Non steroidal anti-inflammatory drugs and rheumatic diseases] Cossermelli W, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Mar–Apr; 50(2):115–24 (58 ref.) (Eng. Abstr.) **(Por)**

[A method for assessing the analgesic action of drug preparations] Gorbonosov IV, et al. **Eksp Klin Farmakol** 1996 Jan–Feb;59(1):71–3 (Eng. Abstr.) **(Rus)**

[The experimental treatment of chronic periodontitis using ortofen] Chumakov AA, et al. **Stomatologiia (Mosk)** 1995; 74(4):8–10 **(Rus)**

[The treatment of acute periodontitis using sodium diclofenac experimentally] Chumakov AA, et al. **Stomatologiia (Mosk)** 1995;74(2):5–7 **(Rus)**

[Treatment of experimental herpesvirus infection with nonsteroidal anti-inflammatory agents] Evstropov AN, et al. **Vopr Virusol** 1996 Mar–Apr;41(2):66–70 (Eng. Abstr.) **(Rus)**

[Anti-proteinuria effects of nonsteroidal anti-inflammatory drugs in patients with nephrotic syndrome: an illusion or a read improvement?] Stošić Z, et al. **Med Pregl** 1995; 48(5–6):155–8 (Eng. Abstr.) **(Scr)**

[Treatment with nonsteroidal inflammatory agents in the aged] Krajčík S, et al. **Vnitr Lek** 1995 Jul;41(7):488–92 (Eng. Abstr.) **(Slo)**

[Flubiprofen vs dipyrone combined with hyoscine: the analgesic efficacy in renal colic] Mora Durban MJ, et al. **Arch Esp Urol** 1995 Nov;48(9):867–73 (Eng. Abstr.) **(Spa)**

[Postoperative analgesia in herniated disk surgery. Comparative study of diclofenac , lysine acetylsalicylate, and ketorolac] Izquierdo E, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):316–9 (Eng. Abstr.) **(Spa)**

[Treatment with sulindac of adenomatous polyps in familial polyposis] Cerdán FJ, et al. **Rev Esp Enferm Dig** 1995 Aug; 87(8):574–6 (Eng. Abstr.) **(Spa)**

[Acetyl-salicylic acid and trifusal in the prevention of atherothrombotic stroke] Alvarez Sabín J. **Rev Neurol** 1995 Sep–Oct;23(123):1091–5 (36 ref.) **(Spa)**

[Analgesics and non-steroidal anti-inflammatory agents in the treatment of migraine] Iglesias F, et al. **Rev Neurol** 1995;23 Suppl 2:S157–61 (20 ref.) **(Spa)**

TOXICITY

Re: Gastrointestinal blood loss with low-dose aspirin [letter; comment] Petroski D. **Am J Gastroenterol** 1995 Nov; 90(11):2071. Comment on: Am J Gastroenterol 1995 Apr;90(4):581–5.

Acetaminophen/aspirin mixtures: experimental data. Porter GA. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S30–3 (11 ref.)

Comparison of the anti-inflammatory effect and gastrointestinal tolerability of aceclofenac and diclofenac. Arañó A, et al. **Arzneimittelforschung** 1996 Apr; 46(4):398–400

Studies on the gastric tolerability of the new non-steroidal anti-inflammatory drug amtolmetin guacyl. Tubaro E, et al. **Arzneimittelforschung** 1995 Dec;45(12):1298–302

Differential cytotoxic effects of mizoribine and its aglycone on human and murine cells and on normal and enzyme-deficient human cells. Terai C, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1099–102

Induction of nitric oxide synthase and microvascular injury in the rat jejunum provoked by indomethacin. Whittle BJ, et al. **Br J Pharmacol** 1995 Oct;116(4):2286–90

Effects of the nonsteroidal anti-inflammatory drug piroxicam on rat liver mitochondria. Salgueiro-Pagadigorria CL, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1996 Jan;113(1):85-91

Effects of the nonsteroidal anti-inflammatory drug piroxicam on energy metabolism in the perfused rat liver. Salgueiro-Pagadigorria CL, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1996 Jan;113(1):93-8

Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens. Santucci L, et al. **Dig Dis Sci** 1995 Sep;40(9):2074-80

Gastric mucosal adaptation to diclofenac injury. Skeljo MV, et al. **Dig Dis Sci** 1996 Jan;41(1):32-9

Role of neutrophil-mediated inflammation in aspirin-induced gastric mucosal injury. Yoshida N, et al. **Dig Dis Sci** 1995 Nov;40(11):2300-4

Diethyldithiocarbamate, a superoxide dismutase inhibitor, reduces indomethacin-induced gastric lesions in rats. Takeuchi K, et al. **Digestion** 1996;57(3):201-9

Ulcerogenicity and effect on inhibition of prostaglandin generation of indometacin farnesil, a prodrug of indomethacin, in rat gastric mucosa: comparison with indomethacin or loxoprofen. Arakawa T, et al.
Drugs Exp Clin Res 1995;21(3):85-8

A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Laine L, et al. **Gastrointest Endosc** 1995 Nov; 42(5):428-33

Cardiac hypertrophy in rats after intravenous administration of CI-959, a novel antiinflammatory compound: morphologic features and pharmacokinetic and pharmacodynamic mechanisms. Low JE, et al.
J Cardiovasc Pharmacol 1995 Jun;25(6):930-9

Aggravating process induced by indomethacin on chronic gastric lesion in rat. Role of polymorphonuclear leucocytes. Martin MJ, et al. **J Pharm Pharmacol** 1995 Nov; 47(11):907-13

Assessment of intestinal permeability changes induced by nonsteroidal anti-inflammatory drugs in the rat. Ford J, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):9-16

A new technique for continuous measurement and recording of gastric potential difference in the rat: evaluation of NSAID-induced gastric mucosal damage. Scarpignato C, et al. **J Pharmacol Toxicol Methods** 1995 Oct;34(2):63-72

Evaluation of ketoprofen (R,S and R/S) phototoxicity by a battery of in vitro assays. Boscá F, et al.
J Photochem Photobiol B 1995 Dec;31(3):133-8

The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Goldberg Y, et al. **Oncogene** 1996 Feb 15;12(4):893-901

Failure of calcium antagonistic agents to prevent hepatotoxicity induced by diclofenac. Schmitz G, et al. **Pharmacol Toxicol** 1995 Jul;77(1):32-5

The developmental toxicity of indomethacin and sulindac. Lione A, et al. **Reprod Toxicol** 1995 Jan-Feb;9(1):7-20 (111 ref.)

Effects of acetaminophen and hydroxyurea on spermatogenesis and sperm chromatin structure in laboratory mice. Wiger R, et al. **Reprod Toxicol** 1995 Jan-Feb;9(1):21-33

Gastric adaptation to aspirin and stress enhances gastric mucosal resistance against the damage by strong irritants. Brzozowski T, et al. **Scand J Gastroenterol** 1996 Feb; 31(2):118-25

Protection of the gastroduodenal mucosa from the effects of diclofenac sodium: role of highly selective vagotomy and misoprostol. Giannoukas AD, et al. **World J Surg** 1996 May;20(4):501-5 discussion 505-6

[Toxicity of drugs on nasal mucocilia and the method of its evaluation] Jiang XG, et al. **Yao Hsueh Hsueh Pao** 1995 Nov;30(11):848-53 (Eng. Abstr.) **(Chi)**

[Experimental data on bases of MAC of piroxicam in the air of workplace] Bogachuk GP, et al.
Med Tr Prom Ekol 1996;(4):26-8 (Eng. Abstr.) **(Rus)**

URINE

Detection of non-steroidal anti-inflammatory drugs in equine plasma and urine by gas chromatography-mass spectrometry. González G, et al. **J Chromatogr A** 1996 Jan 5;719(1):251-64

Analysis of diclofenac and four of its metabolites in human urine by HPLC. Sawchuk RJ, et al. **Pharm Res** 1995 May; 12(5):756-62

Disposition and urinary excretion of phenylbutazone in normal and febrile greyhounds. Mills PC, et al.
Res Vet Sci 1995 Nov;59(3):261-6

ANTI-INFLAMMATORY AGENTS, STEROIDAL

ADMINISTRATION & DOSAGE

Cutaneous alternariosis occurring in a patient treated with local intrarectal corticosteroids [letter] Machet L, et al. **Acta Derm Venereol** 1995 Jul;75(4):328-9

Effects of administration of high dose hydrocortisone on Bell's palsy. Watanabe S, et al.
Acta Otolaryngol Suppl (Stockh) 1996;522:108-10

Intermittent treatment with inhaled steroids for deterioration of asthma due to upper respiratory tract infections. Svedmyr J, et al. **Acta Paediatr** 1995 Aug;84(8):884-8

Pulse methylprednisolone therapy in children with membranoproliferative glomerulonephritis. Emre S, et al. **Acta Paediatr Jpn** 1995 Oct;37(5):626-9

Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Kamada AK, et al.
Am J Respir Crit Care Med 1996 Jun;153(6 Pt 1):1739-48 (86 ref.)

Nocturnal cortisol secretion in healthy adults before and after inhalation of budesonide. Nikolaizik WH, et al.
Am J Respir Crit Care Med 1996 Jan;153(1):97-101

Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Drouin M, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):153-60

Herpetic trigeminal trophic syndrome. Treatment with acyclovir and sublesional triamcinolone. Shea CR, et al. **Arch Dermatol** 1996 Jun;132(6):613-4

The effects of inhaled beclomethasone dipropionate on lung function and histamine responsiveness in recurrently wheezy infants. Stick SM, et al. **Arch Dis Child** 1995 Oct; 73(4):327-32

Pustular psoriasis of pregnancy. Lee SH, et al.
Australas J Dermatol 1995 Nov;36(4):199-200

Efficacy of a small single dose of oral dexamethasone for outpatient croup: a double blind placebo controlled clinical trial. Geelhoed GC, et al. **BMJ** 1996 Jul 20;313(7050):140-2

Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Beckers RC, et al.
Br J Dermatol 1995 Aug;133(2):289-93

Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Bleehen SS, et al. **Br J Dermatol** 1995 Oct;133(4):592-7

Topical 0.05% betamethasone dipropionate: efficacy in psoriasis with once a day vs. twice a day application [letter] Singh S, et al. **Br J Dermatol** 1995 Sep;133(3):497-8

Quantitative assessment of synovial inflammation by dynamic gadolinium-enhanced magnetic resonance imaging. A study of the effect of intra-articular methylprednisolone on the rate of early synovial enhancement. Ostergaard M, et al. **Br J Rheumatol** 1996 Jan;35(1):50-9

Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis. Callen J. **Cutis** 1996 Feb;57(2 Suppl):45-50

A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of eczema. Delescluse J, et al. **Cutis** 1996 Feb; 57(2 Suppl):32-8

Comparison of cosmetic and physicochemical properties of six topical corticosteroid creams. Hadzija BW, et al.
Cutis 1996 Feb;57(2 Suppl):13-8

Comparison of fluticasone propionate cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, in the treatment of eczema. Juhlin L. **Cutis** 1996 Feb;57(2 Suppl):51-6

Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. Lebwohl M. **Cutis** 1996 Feb;57(2 Suppl):62-8

A comparison of fluticasone propionate ointment, 0.005%, and hydrocortisone-17-butyrate ointment, 0.1%, in the treatment of psoriasis. Nurnberger FG. **Cutis** 1996 Feb;57(2 Suppl):39-44

Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis. Roberts DT. **Cutis** 1996 Feb;57(2 Suppl):27-31

A comparison of twice-daily and once-daily administration of fluticasone propionate cream, 0.05%, in the treatment of eczema. Tharp MD. **Cutis** 1996 Feb;57(2 Suppl):19-26

Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Kharitonov SA, et al. **Eur Respir J** 1996 Feb;9(2):196-201

Endoscopic treatment of stenosis in recurrent Crohn's disease with balloon dilation combined with local corticosteroid injection. Ramboer C, et al. **Gastrointest Endosc** 1995 Sep; 42(3):252-5

Successful steroid withdrawal half a year after kidney transplantation. Yagisawa T, et al. **Int Urol Nephrol** 1995; 27(4):495-501

The delivery of aerosolized steroids from MDIs with nozzle extensions: quantitative laboratory evaluation of a method to improve aerosol delivery to intubated patients. Hess D, et al. **Intensive Care Med** 1995 Nov;21(11):945-51 (36 ref.)

Counseling patients about allergic rhinitis. Swanson KA.
J Am Pharm Assoc (Wash) 1996 May;NS36(5):300-7 (40 ref.)

Treatment of Kawasaki disease with corticosteroid [letter] Shinohara M, et al. **J Pediatr** 1996 Sep;129(3):483-4; discussion 484-5

Treatment of Kawasaki disease with corticosteroid [letter] Shulman ST, et al. **J Pediatr** 1996 Sep;129(3):483; discussion 484-5

Chondroprotective effect of betamethasone in lapine pyogenic arthritis. Stricker SJ, et al. **J Pediatr Orthop** 1996 Mar-Apr;16(2):231-6

Liposome-incorporated dexamethasone palmitate inhibits in-vitro lymphocyte response to mitogen. Benameur H, et al. **J Pharm Pharmacol** 1995 Oct;47(10):812-7

Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis. Nolen H 3rd, et al.
J Pharm Sci 1995 Jun;84(6):677-81

Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. Di Munno O, et al. **J Rheumatol** 1995 Aug;22(8):1492-8

Treatment of rheumatoid joint inflammation with intrasynovial triamcinolone hexacetonide. McCarty DJ, et al. **J Rheumatol** 1995 Sep;22(9):1631-5

Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis. Kim IT, et al.
Korean J Ophthalmol 1996 Jun;10(1):8-17

Late-onset renal dysfunction in a patient with non-Hodgkin's lymphoma following an autologous bone marrow transplantation. Tamura H, et al.
Nippon Jinzo Gakkai Shi 1995 Aug;37(8):474-80

Dramatic response to levamisole and low-dose prednisolone in 23 patients with oral lichen planus: a 6-year prospective follow-up study. Lu SY, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Dec;80(6):705-9

Intra-articular hyaluronic acid compared to intra-articular triamcinolone hexacetonide in inflammatory knee osteoarthritis. Jones AC, et al. **Osteoarthritis Cartilage** 1995 Dec;3(4):269-73

Inhaled steroids in the treatment of pertussis [letter] Winrow AP. **Pediatr Infect Dis J** 1995 Oct;14(10):922

Kenalog warning [letter] Hoefflin SM.
Plast Reconstr Surg 1996 Jun;97(7):1516-7

Power Doppler sonography of synovitis: assessment of therapeutic response--preliminary observations. Newman JS, et al. **Radiology** 1996 Feb;198(2):582-4

Effect of inhaled beclomethasone on serum markers of collagen metabolism in postmenopausal asthmatic women. Puolijoki H, et al. **Respir Med** 1996 Jul;90(6):339-42

Systemic effects of epidural dexamethasone injections. Maillefert JF, et al. **Rev Rhum Engl Ed** 1995 Jun; 62(6):429-32

Therapy study on the experimental injury of spinal cord. IV. High doses of methyl-prednisolone. Anghelescu N, et al. **Rom J Neurol Psychiatry** 1995 Jul-Dec;33(3-4):241-9

Effects of plain and controlled-ileal-release budesonide formulations in experimental ileitis. Boyd AJ, et al.
Scand J Gastroenterol 1995 Oct;30(10):974-81

Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease. Baehr PH, et al.
Transplantation 1995 Dec 15;60(11):1231-8

Comparison of topical cyclosporin and dexamethasone for the treatment of chronic superficial keratitis in dogs. Williams DL, et al. **Vet Rec** 1995 Dec 16;137(25):635-9

Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. Gross V, et al. **Z Gastroenterol** 1995 Oct;33(10):581-4

[Fluticasone propionate--a new inhalation steroid for the treatment of bronchial asthma] Lange P, et al.
Ugeskr Laeger 1996 Jan 22;158(4):439-44 **(Dan)**

[Crohn disease: prevention and drug therapy] Gross V, et al. **Chirurg** 1995 Aug;66(8):757-63 (42 ref.) (Eng. Abstr.) **(Ger)**

[Intra-articular morphine versus steroid administration to the acutely painful joint in gonarthrosis and arthritis (letter)] Stein A, et al. **Dtsch Med Wochenschr** 1996 Feb 23; 121(8):255 **(Ger)**

[Asthma therapy with topically active steroids] Matthys H. **Internist (Berl)** 1995 Oct;36(10):1005-9 (21 ref.) **(Ger)**

[Position paper on propellants in measured dose aerosol dispensers. The German Respiratory League] Wettengel R. **Med Klin** 1995 Nov 15;90(11):617 **(Ger)**

[Effects of inhalation of a glucocorticoid using metered-dose propellant gas aerosol and Turbohaler--a roentgen pilot study] Vogel H, et al. **Pneumologie** 1995 Oct;49(10):559-60 **(Ger)**

[Chronopharmacology of reversible airway obstruction] Haen E. **Wien Med Wochenschr** 1995;145(17-18):439-45 (38 ref.) (Eng. Abstr.) **(Ger)**

[Comparison of active and passive fixation of steroid emitting atrial electrodes] Schuchert A, et al. **Z Kardiol** 1996 Apr; 85(4):255-9 (Eng. Abstr.) **(Ger)**

[Successful therapeutic management of risk pregnancy in primary Sjögren syndrome with plasmapheresis and dexamethasone] Feist E, et al. **Z Rheumatol** 1996 Mar-Apr; 55(2):127-32 (Eng. Abstr.) **(Ger)**

[Early effects of intravenous steroid therapy on cell recruitment in sputum of chronic asthmatics] Maeda Y, et al. **Arerugi** 1995 Sep;44(9):1111-6 (Eng. Abstr.) **(Jpn)**

[Steroid-responsive sensorineural hearing loss with low tone loss] Toriya R, et al. **Fukuoka Igaku Zasshi** 1995 Nov; 86(11):417-23 (Eng. Abstr.) **(Jpn)**

[A case of nephrotic syndrome associated with severe interstitial pneumonitis due to cyclophosphamide whose life was saved by steroid pulse therapy] Yamada H, et al. **Nippon Jinzo Gakkai Shi** 1995 Sep;37(9):518-22 (Eng. Abstr.) **(Jpn)**

[A case of acute eosinophilic pneumonia: bronchoalveolar lavage findings before and after steroid treatment] Kawaguchi H, et al.

Nippon Kyobu Shikkan Gakkai Zasshi 1995 Jul;33(7):738–44 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Inhaled beclomethasone in long-term management of asthma: optimal dose and optimal duration of treatment] Kudo K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep;33(9):956–65 (Eng. Abstr.) **(Jpn)**

[A case of Churg-Strauss syndrome presenting positive anti-neutrophil cytoplasmic autoantibodies] Hisayama F, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10; 84(8):1327–8 **(Jpn)**

[Steroid inhalation therapy of asthma] Hozawa S. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):205–9 (5 ref.) **(Jpn)**

[Steroid inhalation therapy of bronchial asthma] Makino S. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2085–90 (9 ref.) **(Jpn)**

[Secondary gastrointestinal amyloidosis: successful treatment with TPN, prednisolone and colchicine therapy. Report of a case] Muramatsu S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct;92(10):1770–5 **(Jpn)**

[Treatment with bolus methylprednisolone for pure red cell aplasia after ABO incompatible bone marrow transplantation in a patient with chronic myelocytic leukemia] Furuya H, et al. **Rinsho Ketsueki** 1995 Nov; 36(11):1279–83 (Eng. Abstr.) **(Jpn)**

[Acute disseminated encephalomyelitis (ADEM)-like exacerbation in the patients with cryptococcus meningitis treated successfully by steroid pulse therapy] Hasegawa Y, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):914–7 (Eng. Abstr.) **(Jpn)**

[Prenatal steroid treatment--a 4-year material] Anderssen SH, et al. **Tidsskr Nor Laegeforen** 1996 Aug 20; 116(19):2307–10 (Eng. Abstr.) **(Nor)**

[Experience in the use of lymphatic infusion preparations in multimodal treatment of patients with giant lung abscess] Opanasenko NS. **Klin Khir** 1996;(1):25–7 **(Rus)**

[Successful treatment of rapidly progressive glomerulonephritis associated with Henoch-Schoenlein purpura with high doses of methylprednisolone (letter)] Ljutić D. **Lijec Vjesn** 1995 Sep-Oct;117(9–10):256–7 **(Scr)**

[The combined use of diprospan and laser irradiation of the joints in rheumatoid arthritis patients] Lysenko HI, et al. **Lik Sprava** 1995 May-Jun;(5–6):77–80 (Eng. Abstr.) **(Ukr)**

ADVERSE EFFECTS

Adult-onset celiac disease hidden by chronic steroid therapy for a skin disease [letter; comment] Confalonieri F, et al. **Am J Med** 1995 Oct;99(4):439–40. Comment on: Am J Med 1993 Sep;95(3):341.

Serious adverse events with low-dose, long-term corticosteroid therapy in rheumatoid arthritis [letter; comment] Roger L. **Am J Med** 1995 Dec;99(6):692–4. Comment on: Am J Med 1994 Feb;96(2):115–23.

Treatment of persistent glaucoma secondary to periocular corticosteroids. Akduman L, et al. **Am J Ophthalmol** 1996 Aug;122(2):275–7

Bilateral exudative retinal detachment complicating systemic corticosteroid therapy in the presence of renal failure. Desatnik HR, et al. **Am J Ophthalmol** 1996 Sep; 122(3):432–4

Diagnosis and treatment of an ophthalmic artery occlusion during an intralesional injection of corticosteroid into an eyelid capillary hemangioma. Egbert JE, et al. **Am J Ophthalmol** 1996 Jun;121(6):638–42

Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Decramer M, et al. **Am J Respir Crit Care Med** 1996 Jun; 153(6 Pt 1):1958–64

Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Kamada AK, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1739–48 (86 ref.)

Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma. Martinati LC, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):232–6

Coronary artery spasm during anaphylaxis [letter] Machiels JP, et al. **Ann Emerg Med** 1996 May;27(5):674–5

Invasive aspergillosis: a life-threatening complication of short-term steroid treatment. Conesa D, et al. **Ann Pharmacother** 1995 Dec;29(12):1235–7

Effect of dexamethasone on the decrease of serum phenytoin concentrations [letter] Recuenco I, et al. **Ann Pharmacother** 1995 Sep;29(9):935

Cushing's syndrome in postburn children following intralesional triamcinolone injection. Ritota PC, et al. **Ann Plast Surg** 1996 May;36(5):508–11

Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Peel NF, et al. **Ann Rheum Dis** 1995 Oct;54(10):801–6

Bilateral jawline nodules in a child with a brain-stem glioma. Poststeroid panniculitis. Reichel M, et al. **Arch Dermatol** 1995 Dec;131(12):1448–9, 1451–2

Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids [see comments] Leibowitz HM, et al. **Arch Ophthalmol** 1996 Aug; 114(8):933–7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1000–1.

Fluticasone propionate is associated with severe infection after endoscopic polypectomy. Mostafa BE. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):729–31

Concerns of secondary fever in Streptococcus pneumoniae meningitis in an era of increasing antibiotic resistance. Esterle TM, et al. **Arch Pediatr Adolesc Med** 1996 May; 150(5):552–4

Oral prednisone as a risk factor for infections in children with asthma. Grant CC, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):58–63

Bone density in young patients with congenital adrenal hyperplasia. Mora S, et al. **Bone** 1996 Apr;18(4):337–40

Retinal and choroidal embolization following soft-tissue maxillary injection of corticosteroids. Nianiaris NA, et al. **Can J Ophthalmol** 1995 Oct;30(6):321–3

Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Lems WF, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):293–7

Screening for corticosteroid contact hypersensitivity. Boffa MJ, et al. **Contact Dermatitis** 1995 Sep;33(3):149–51

Probable active sensitization to tixocortol pivalate. Goldsmith PC, et al. **Contact Dermatitis** 1995 Dec;33(6):429

Delayed hypersensitivity reaction to the preservative myristyl picolinium chloride. Goulden V, et al. **Contact Dermatitis** 1995 Sep;33(3):209–10

Contact allergy to topical corticosteroids: a screening study with a corticosteroid mix. Portuguese Contact Dermatitis Research Group (GPEDC). Pecegueiro M. **Contact Dermatitis** 1995 Sep;33(3):196–7

Is tixocortol pivalate a photoallergen? Wilkinson SM, et al. **Contact Dermatitis** 1995 Jul;33(1):55–6

Fluticasone propionate: safety profile. Johnson M. **Cutis** 1996 Feb;57(2 Suppl):10–2 (15 ref.)

Sensitisation to corticosteroids. Consequences for anti-inflammatory therapy. Dooms-Goossens A. **Drug Saf** 1995 Aug;13(2):123–9 (47 ref.)

Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency and association with adrenal function. Roy A, et al. **Eur Respir J** 1996 Feb;9(2):226–31

Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers. Carpani de Kaski M, et al. **Gut** 1995 Nov;37(5):613–6

Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. Hanania NA, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):571–9

Hospital acquired pulmonary nocardiosis complicating polymyositis. Gupta D, et al. **J Assoc Physicians India** 1995 Sep;43(9):641–2

High dose hydrocortisone therapy complicating acute severe asthma [letter] Mehta S. **J Assoc Physicians India** 1995 Sep; 43(9):658

The primary role of steroids on the osteoporosis in juvenile rheumatoid patients evaluated by dual energy X-ray absorptiometry. Falcini F, et al. **J Endocrinol Invest** 1996 Mar;19(3):165–9

Nerve injury following steroid injection for carpal tunnel syndrome. A report of two cases. Tavares SP, et al. **J Hand Surg [Br]** 1996 Apr;21(2):208–9

Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate. Packe GE, et al. **J R Coll Physicians Lond** 1996 Mar-Apr;30(2):128–32

Cardiac effects of dexamethasone in very low birth weight infants. Bensky AS, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):818–21

Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. Naber D, et al. **Psychoneuroendocrinology** 1996 Jan; 21(1):25–31

Vitrectomy for accidental intraocular steroid injection. Gopal L, et al. **Retina** 1995;15(4):295–9

Medication errors result in costly claims for ophthalmologists. Brick DC. **Surv Ophthalmol** 1995 Nov-Dec;40(3):232–6

Clinical analysis of steroid glaucoma. Kong L, et al. **Yen Ko Hsueh Pao** 1995 Mar;11(1):53–6

[Evaluation of the therapeutic activity of and gastric lesions due to new NSAID versus placebo in patients with osteoarticular diseases] Delfino M, et al. **Clin Ter** 1996 Mar; 147(3):113–6 (Eng. Abstr.) **(Ita)**

[Retinal detachment after accidental intra-vitreous Depo-Medrol injection. A case report] Philips RH, et al. **Klin Oczna** 1995 Mar-Apr;97(3–4):82–5 (Eng. Abstr.) **(Pol)**

[Generalized cryptococcosis in secondary immunodeficiency induced by long-term steroid therapy (on the 100th anniversary of the day of first discovery in 1894)] Khmelynitski i OK, et al. **Arkh Patol** 1995 Nov-Dec; 57(6):66–70 (Eng. Abstr.) **(Rus)**

[Toxic epidermal necrolysis in a patient treated with high doses of deflazacort (letter)] Navarro Llanos A, et al. **Med Clin (Barc)** 1996 Apr 20;106(15):599 **(Spa)**

[Increased risk of adrenal cortex failure after treatment of allergic rhinitis (letter)] Rolandsson O. **Lakartidningen** 1996 Jul 10;93(28–29):2564 **(Swe)**

ANALYSIS

Biochemical quantification of triamcinolone in subconjunctival depots [letter; comment] Goldstein DA, et al. **Arch Ophthalmol** 1996 Mar;114(3):363–4. Comment on: Arch Ophthalmol 1995 Jul;113(7):867–9.

Determination of dexamethasone sodium phosphate in the vitreous by high performance liquid chromatography. Kwak HW, et al. **Korean J Ophthalmol** 1995 Dec;9(2):79–83

ANTAGONISTS & INHIBITORS

Inhibition of dexamethasone-induced cytoskeletal changes in cultured human trabecular meshwork cells by tetrahydrocortisol. Clark AF, et al. **Invest Ophthalmol Vis Sci** 1996 Apr;37(5):805–13

CHEMICAL SYNTHESIS

Anti-inflammatory and antishock water-soluble polyesters of glucocorticoids with low level systemic toxicity. Timofeevski SL, et al. **Pharm Res** 1996 Mar;13(3):476–80

Steroidal anti-inflammatory antedrugs: synthesis and pharmacological evaluation of 16 alpha-alkoxycarbonyl-17-deoxyprednisolone derivatives. Yoon KJ, et al. **Steroids** 1995 Jul;60(7):445–51

PHARMACOKINETICS

Pharmacokinetics of topical hydrocortisone at plasma level after applications once or twice daily in patients with widespread dermatitis. Aalto-Korte K, et al. **Br J Dermatol** 1995 Aug;133(2):259–63

Quantifying systemic absorption of topical hydrocortisone in erythroderma. Aalto-Korte K, et al. **Br J Dermatol** 1995 Sep;133(3):403–8

Pharmacokinetic interactions between zileuton and prednisone. Awni WM, et al. **Clin Pharmacokinet** 1995;29 Suppl 2:105–11

The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Harris RZ, et al. **Clin Pharmacol Ther** 1996 Apr; 59(4):429–35

Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Slayter KL, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):312–21

Residues of some veterinary drugs in animals and foods. Monographs prepared by the forty-third meeting of the Joint FAO/WHO Expert Committee on Food Additives. **FAO Food Nutr Pap** 1995;41(7):1–112

Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Kristinsson JK, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1199–203

Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. Homma M, et al. **J Pharm Pharmacol** 1995 Aug;47(8):687–92

Topographic distribution of prednisolone in the lens after organ culture. Kojima M, et al. **Ophthalmic Res** 1995;27 Suppl 1:25–33

Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Möllmann H, et al. **Pharm Res** 1995 Jul; 12(7):1096–100

Pharmacokinetic studies of cortisol after oral administration of deuterium-labelled cortisol to a normal human subject. Kasuya Y, et al. **Rapid Commun Mass Spectrom** 1995;Spec No:S29–34

[Pharmacokinetics and tolerance of an orally administered combination preparation containing phenylbutazone and prednisolone in the dog] Kietzmann M, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jan;103(1):14–6 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Comparison of the effect of hydrocortisone, hydrocortisone-17-butyrate and betamethasone on collagen synthesis in human skin in vivo. Haapasaari KM, et al. **Acta Derm Venereol** 1995 Jul;75(4):269–71

Prenatal starvation, betamethasone and lung development in newborn rats. Stettner S, et al. **Acta Vet Hung** 1995; 43(2-3):303–9

Betamethasone and adult rat lung surfactant lipids. Stettner S, et al. **Acta Vet Hung** 1995;43(2–3):291–6

The effect of betamethasone on phosphatidylcholine species composition in fetal rat lungs. Stettner S, et al. **Acta Vet Hung** 1995;43(2–3):297–302

The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease. Breese EJ, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):547–52

Treatment of hepatitis B surface antigen carriers in the early stage of the infection using recombinant alpha-interferon with steroid priming. Guan R, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):535–40

Reduction of cortisol levels after single intra-articular and intramuscular steroid injection. Lazarevic MB, et al. **Am J Med** 1995 Oct;99(4):370–3

Nocturnal cortisol secretion in healthy adults before and after inhalation of budesonide. Nikolaizik WH, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):97–101

Influence of methylprednisolone acetate on osteochondral healing in exercised tarsocrural joints of horses. Carter BG, et al. **Am J Vet Res** 1996 Jun;57(6):914–22

Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Lems WF, et al. **Ann Rheum Dis** 1996 May; 55(5):288–93

Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. Cabellos C, et al.

Antimicrob Agents Chemother 1995 Sep;39(9):2158–60
Endotoxin, tumor necrosis factor, and dexamethasone effects on human endothelial cell fibronectin dynamics: synthesis, matrix assembly, and receptor expression. Romer LH, et al. **Biochem Cell Biol** 1995 Jul–Aug;73(7–8):515–24
Changes in the cellular distribution of lipocortin-1 (Annexin-1) in C6 glioma cells after exposure to dexamethasone. McLeod JD, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1103–7
Glucocorticoids inhibit apoptosis of human neutrophils. Liles WC, et al. **Blood** 1995 Oct 15;86(8):3181–8
The effect of glucocorticoids on proliferation of human cultured airway smooth muscle. Stewart AG, et al. **Br J Pharmacol** 1995 Dec;116(8):3219–26
Topical corticosteroids potentiate mucin secretion in the normal nose. MacGregor FB, et al. **Clin Otolaryngol** 1996 Feb;21(1):76–9
Changes in calcium and bone metabolism during treatment with low dose prednisone in young, healthy, male volunteers. Lems WF, et al. **Clin Rheumatol** 1995 Jul; 14(4):420–4
Dexamethasone inhibits inorganic phosphate stimulated Ca(2+)-dependent damage of isolated rat liver and renal cortex mitochondria. Campbell PI, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):221–5
Insulin transport from plasma into the central nervous system is inhibited by dexamethasone in dogs. Baura GD, et al. **Diabetes** 1996 Jan;45(1):86–90
Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Spencer CM, et al. **Drugs** 1995 Nov;50(5):854–72 (51 ref.)
Differences in down-regulation of glucocorticoid receptor mRNA by cortisol, prednisolone and dexamethasone in HeLa cells. Shimojo M, et al. **Endocr J** 1995 Oct; 42(5):629–36
Changes in prostaglandin synthesis and metabolism associated with labour, and the influence of dexamethasone, RU 486 and progesterone. Brennand JE, et al. **Eur J Endocrinol** 1995 Nov;133(5):527–33
Expression of inducible nitric oxide synthase mRNA in Brown Norway rats exposed to ozone: effect of dexamethasone. Haddad EB, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):287–90
Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone. Klemm P, et al. **Eur J Pharmacol** 1995 Jul 25;281(1):69–74
Dexamethasone and methylprednisolone affect rat peritoneal phagocyte chemiluminescence after administration in vivo. Røshol H, et al. **Eur J Pharmacol** 1995 Nov 3;286(1):9–17
The effects of an inhaled corticosteroid on oxygen radical production by bronchoalveolar cells after allergen or ozone in dogs. Stevens WH, et al. **Eur J Pharmacol** 1995 Oct 6;293(3):251–7
Modulation of ICAM-1 expression in human alveolar macrophages in vitro. Fattal-German M, et al. **Eur Respir J** 1996 Mar;9(3):463–71
Effects of moguisteine, a peripheral nonnarcotic antitussive agent, on airway inflammation in guinea-pigs in vivo. Gallico L, et al. **Eur Respir J** 1996 Mar;9(3):478–85
Treatment of mild asthma with inhaled corticosteroids: is discontinuation of therapy possible? van Grunsven PM, et al. **Fam Med** 1996 Jan;28(1):46–51
Ozone induction of cytokine-induced neutrophil chemoattractant (CINC) and nuclear factor-kappa b in rat lung: inhibition by corticosteroids. Haddad EB, et al. **FEBS Lett** 1996 Feb 5;379(3):265–8
Monocyte chemotactic protein-1 (MCP-1) mRNA is down-regulated in human dermal fibroblasts by dexamethasone: differential regulation by TGF-beta. Slavin J, et al. **Growth Factors** 1995;12(2):151–7
Induced expression of the new cytokine, activin A, in human monocytes: inhibition by glucocorticoids and retinoic acid. Yu J, et al. **Immunology** 1996 Jul;88(3):368–74
Rapid non-genomic effects of hydrocortisone on rat mast cells. Dukhanin A, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S15–6
The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A. Hartman DA, et al. **Inflamm Res** 1995 Jul;44(7):269–74
Modulation of the endothelial procoagulant response to lipopolysaccharide and tumour necrosis factor-alpha in-vitro: the effects of dexamethasone, pentoxifylline, iloprost and a polyclonal anti-human IL-1 alpha antibody. Heyderman RS, et al. **Inflamm Res** 1995 Jul;44(7):275–80
TNF-alpha participates in an IgE-mediated cutaneous reaction in mast cell deficient, WBB6F1-W/Wv mice. Nagai H, et al. **Inflamm Res** 1996 Mar;45(3):136–40
Differential effects of prednisolone and indomethacin on zymosan-induced inflammation in a modified murine tissue-chamber model. Oluyomi AO, et al. **Inflamm Res** 1995 Aug;44(8):350–6
Measurement and drug induced modulation of interleukin-1 level during zymosan peritonitis in mice. Török K, et al. **Inflamm Res** 1995 Jun;44(6):248–52
Time-dependent cytokine production in the croton oil-induced mouse ear oedema and inhibition by prednisolone. Towbin H, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S160–1
Molecular actions of glucocorticoids: an introduction. Baraniuk JN. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):141–2
Modulation by dexamethasone of phospholipase A2 activities in endotoxemic guinea pigs. De Castro CM, et al. **J Appl Physiol** 1995 Oct;79(4):1271–7
Cortisol inhibits the synthesis of insulin-like growth factor-binding protein-5 in bone cell cultures by transcriptional mechanisms. Gabbitas B, et al. **J Biol Chem** 1996 Apr 12;271(15):9033–8
Nitric oxide: an important articular free radical. Murrell GA, et al. **J Bone Joint Surg Am** 1996 Feb;78(2):265–74
Effects of local injection of corticosteroids on the healing of ligaments. A follow-up report. Wiggins ME, et al. **J Bone Joint Surg Am** 1995 Nov;77(11):1682–91
Effect of RU 486 on the atrophogenic and antiinflammatory effects of glucocorticoids in skin. Iwasaki K, et al. **J Dermatol Sci** 1995 Sep;10(2):151–8
Budesonide inhibits T cell-initiated epithelial pathophysiology in an in vitro model of inflammation. McKay DM, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):403–10
Effect of corticosteroids on rabbits corneal keratocytes after photorefractive keratectomy. You X, et al. **J Refract Surg** 1995 Nov-Dec;11(6):460–7
The dose-related effects of phenylbutazone and a methylprednisolone acetate formulation (Depo-Medrol) on cultured explants of equine carpal articular cartilage. Jolly WT, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):429–37
Influence of butibufen on enzyme activity and lysosomal stabilization ex vivo: a comparative study with hydrocortisone and acetylsalicylic acid. Alamo C, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun;17(5):303–10
An electrophysiological investigation of the effects of cisplatin and the protective actions of dexamethasone on cultured dorsal root ganglion neurones from neonatal rats. Scott RH, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep;352(3):247–55
Combined corticosteroid and catecholamine stimulation of aqueous humor flow. Jacob E, et al. **Ophthalmology** 1996 Aug;103(8):1303–8
Postnatal rat lung retinoic acid receptor (RAR) mRNA expression and effects of dexamethasone on RAR beta mRNA. Grummer MA, et al. **Pediatr Pulmonol** 1995 Oct; 20(4):234–40
Anti-inflammatory and antishock water-soluble polyesters of glucocorticoids with low level systemic toxicity. Timofeevski SL, et al. **Pharm Res** 1996 Mar;13(3):476–80
Fast negative feedback actions of corticosterone and of dexamethasone on CRF-stimulated ACTH secretion in rats. Hinz B, et al. **Pharmazie** 1995 Sep;50(9):638–9
The effect of combination therapy with cyclosporine A and hydrocortisone on glucose metabolism in diabetic rats following pancreatic islet transplantation. Saudek F, et al. **Physiol Res** 1995;44(2):79–86
Inhibitory potency of isoprenaline on guinea-pig and gravid human myometrium following extraneuronal uptake blockade. Kousides M, et al. **Reprod Fertil Dev** 1995; 7(1):59–66
Fluticasone propionate--an update on preclinical and clinical experience. Fuller R, et al. **Respir Med** 1995 Sep;89 Suppl A:3–18 (59 ref.)
Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis [see comments] Auphan N, et al. **Science** 1995 Oct 13;270(5234):286–90. Comment in: Science 1995 Oct 13;270(5234):232–3.
Cellular and topical in vivo inflammatory murine models in the evaluation of inhibitors of phospholipase A2. Glaser KB, et al. **Skin Pharmacol** 1995;8(6):300–8
The effect of the treatment of high-dose methylprednisolone on Na(+)-K(+)/Mg(+2) ATPase activity and lipid peroxidation and ultrastructural findings following cerebral contusion in rat. Ildan F, et al. **Surg Neurol** 1995 Dec; 44(6):573–80
Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Clark DJ, et al. **Thorax** 1996 Mar;51(3):262–6
[Chronotolerance of corticosterone on DNA synthesis in young growing rats] Barbason H, et al. **Pathol Biol (Paris)** 1996 Mar;44(3):212–5 (Eng. Abstr.) (Fre)
[Suppression by methylprednisolone of the expression of LFA-1 by alveolar macrophages in irradiated rat lungs] Katoh H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Mar;34(3):275–80 (Eng. Abstr.) (Jpn)
[Experimental femoral neck fractures in rats after prolonged steroid therapy] Jabłoński M, et al. **Chir Narzadow Ruchu Ortop Pol** 1993;58(6):463–9 (Eng. Abstr.) (Pol)
[Effects of prednisone and azathioprine treatment on oligoclonal IGG in the cerebrospinal fluid of multiple sclerosis patients. Preliminary communication] Losy J, et al. **Neurol Neurochir Pol** 1996 Mar-Apr;30(2):201–11 (Eng. Abstr.) (Pol)

SUPPLY & DISTRIBUTION

Availability of over-the-counter drugs for arthritis in Sao Paulo, Brazil. Ferraz MB, et al. **Soc Sci Med** 1996 Apr; 42(8):1129–31

THERAPEUTIC USE

The effect on joint fluid concentration of neuropeptide Y by intra-articular injection of glucocorticoid in temporomandibular joint arthritis. Alstergren P, et al. **Acta Odontol Scand** 1996 Feb;54(1):1–7
Effects of administration of high dose hydrocortisone on Bell's palsy. Watanabe S, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:108–10
Intralesional steroids in Langerhans cell histiocytosis of bone. Bernstrand C, et al. **Acta Paediatr** 1996 Apr;85(4):502–4
Asthma treatment in schoolchildren: lung function in different therapeutic groups. Korppi M, et al. **Acta Paediatr** 1996 Feb;85(2):190–4
False-negative single-photon emission CT in AIDS lymphoma: lack of effect of steroids [letter] Campbell BG, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):1000–2
Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Lémann M, et al. **Ailment Pharmacol Ther** 1995 Oct;9(5):557–62
Effects of chemical pretreatment on posttraumatic cortical edema in the rat. Biros MH, et al. **Am J Emerg Med** 1996 Jan;14(1):27–32
Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Skinner M, et al. **Am J Med** 1996 Mar;100(3):290–8
Comparative treatment of experimental Staphylococcus aureus endophthalmitis. Aguilar HE, et al. **Am J Ophthalmol** 1996 Mar;121(3):310–7
Supratarsal injection of corticosteroid in the treatment of refractory vernal keratoconjunctivitis. Holsclaw DS, et al. **Am J Ophthalmol** 1996 Mar;121(3):243–9
Effect of topical anti-inflammatory treatment on the outcome of laser trabeculoplasty. The Fluorometholone-Laser Trabeculoplasty Study Group. Shin DH, et al. **Am J Ophthalmol** 1996 Sep;122(3):349–54
Trial of beclomethasone dipropionate by metered-dose inhaler in ventilator-dependent neonates less than 1500 grams. Giep T, et al. **Am J Perinatol** 1996 Jan;13(1):5–9
Is the time for steroids in treatment of asthma over? [letter] Kanwar BA, et al. **Am J Respir Crit Care Med** 1996 Sep; 154(3 Pt 1):823–4
Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Pedersen B, et al. **Am J Respir Crit Care Med** 1996 May; 153(5):1519–29
Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. Okamoto LJ, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):455–61
Eosinophil activity reflects clinical status in patients with asthma before and during a prednisolone course. Skedinger M, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):250–5
Outpatient management of acute urticaria: the role of prednisone [see comments] Pollack CV Jr, et al. **Ann Emerg Med** 1995 Nov;26(5):547–51. Comment in: Ann Emerg Med 1996 Apr;27(4):527–8.
Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Scarfone RJ, et al. **Ann Emerg Med** 1995 Oct;26(4):480–6
Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Gourley MF, et al. **Ann Intern Med** 1996 Oct 1;125(7):549–57
Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. Adour KK, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):371–8
Cushing's syndrome in postburn children following intralesional triamcinolone injection. Ritota PC, et al. **Ann Plast Surg** 1996 May;36(5):508–11
Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. Krogsgaard MR, et al. **Ann Rheum Dis** 1996 Feb;55(2):143–6
Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone. Stichtenoth DO, et al. **Ann Rheum Dis** 1995 Oct; 54(10):820–4
The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Breitner JC. **Annu Rev Med** 1996;47:401–11 (81 ref.)
Effect of intravitreal dexamethasone in treatment of pneumococcal endophthalmitis in rabbits. Park SS, et al. **Arch Ophthalmol** 1995 Oct;113(10):1324–9
Corticosteroid therapy of eye disease. Fifty years later [editorial; comment] Raizman M. **Arch Ophthalmol** 1996 Aug;114(8):1000–1 (25 ref.). Comment on: Arch Ophthalmol 1996 Aug;114(8):933–7.
The effects of corticosteroids of adenoviral replication. Romanowski EG, et al. **Arch Ophthalmol** 1996 May; 114(5):581–5
The effect of intravenous dexamethasone in pediatric adenotonsillectomy. April MM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):117–20
Anti-inflammatory therapy reduces wheezing after bronchiolitis. Reijonen T, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):512–7
Effect of inhaled corticosteroids on bronchial hyperresponsiveness in patients with mild asthma. Wongtim S, et al. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):81–5
Drug trials in neuropathy. Hughes RA, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):607–27 (87 ref.)
Corticosteroids in the management of croup [editorial] [see

comments] Doull I. **BMJ** 1995 Nov 11;311(7015):1244. Comment in: BMJ 1996 Feb 24;312(7029):510; discussion 510–1. Comment in: BMJ 1996 Feb 24;312(7029):510–11.

Therapy of cyclophosphamide-induced nasal congestion [letter] Lipton JH. **Bone Marrow Transplant** 1995 Oct; 16(4):634

Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Chopra S, et al. **Br J Dermatol** 1996 Jun; 134(6):1109–12 (19 ref.)

Systemic corticosteroids are important in the treatment of Fournier's gangrene: a case report. Schultz ES, et al. **Br J Dermatol** 1995 Oct;133(4):633–4

Oral prednisone in the treatment of acne agminata. Uesugi Y, et al. **Br J Dermatol** 1996 Jun;134(6):1098–100

Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokines (granulocyte colony-stimulating factor and erythropoietin) and high-dose methylprednisolone. Imai Y, et al. **Br J Haematol** 1996 Apr;93(1):146–50

The role of corticosteroids in rheumatoid arthritis [editorial] Byron M. **Br J Hosp Med** 1996 Mar 6–19;55(5):235–6

Effects of allopurinol and steroids on inflammation and oxidative tissue damage in experimental lens induced uveitis: a biochemical and morphological study. Augustin AJ, et al. **Br J Ophthalmol** 1996 May;80(5):451–7

A randomized double-blind controlled trial of sulphasalazine combined with pulses of methylprednisolone or placebo in the treatment of rheumatoid arthritis. Ciconelli RM, et al. **Br J Rheumatol** 1996 Feb;35(2):150–4

Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation [see comments] Snell GI, et al. **Chest** 1996 Apr;109(4):874–8. Comment in: Chest 1996 Apr;109(4):857–9.

Treat patients who have nocturnal asthma with anti-inflammatory drugs first [letter; comment] Wempe JB, et al. **Chest** 1996 Apr;109(4):1130. Comment on: Chest 1995 Feb;107(2):406–12.

Controlled comparison of two fluorometholone formulations in the antigen challenge model of allergic conjunctivitis. Harper DG, et al. **CLAO J** 1995 Oct;21(4):256–60

Extra-adrenal effects of metyrapone include inhibition of the 11-oxoreductase activity of 11 beta-hydroxysteroid dehydrogenase: a model for 11-HSD I deficiency. Raven PW, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):637–44

Transient osteoporosis of the hip: successful response to deflazacort. Carmona-Ortells L, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):653–5

GISC protocol experience in the treatment of essential mixed cryoglobulinaemia. Pioltelli P, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S187–90

Interleukin-6 activity in dogs with juvenile polyarteritis syndrome: effect of corticosteroids. Hogenesch H, et al. **Clin Immunol Immunopathol** 1995 Oct;77(1):107–10

Use of Ga-67 imaging in diagnosis and follow-up after steroid treatment of retroperitoneal fibrosis. Talati SJ, et al. **Clin Nucl Med** 1995 Nov;20(11):995–7

Successful treatment with corticosteroid in a patient with progressive diaphyseal dysplasia [letter] Bourantas K, et al. **Clin Rheumatol** 1995 Jul;14(4):485–6

Henoch-Schonlein purpura associated with coxsackie-virus B1 infection [letter] Costa MM, et al. **Clin Rheumatol** 1995 Jul;14(4):488–90

Large vessel vasculitis without temporal artery involvement: isolated form of giant cell arteritis? Lambert M, et al. **Clin Rheumatol** 1996 Mar;15(2):174–80

Topical corticosteroids in clinical practice: focus on fluticasone propionate. Piacquadio DJ. **Cutis** 1996 Feb;57(2 Suppl):4–9 (19 ref.)

The treatment of infantile spasms by paediatric neurologists in the UK and Ireland [letter] Appleton RE. **Dev Med Child Neurol** 1996 Mar;38(3):278–9

Demonstration of efficacy of combining corticosteroids and colchicine in two patients with idiopathic sclerosing mesenteritis. Généreau T, et al. **Dig Dis Sci** 1996 Apr; 41(4):684–8

Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Markham A, et al. **Drugs** 1995 Aug; 50(2):317–33 (68 ref.)

Somatostatin 14 and joint inflammation: evidence for intraarticular efficacy of prolonged administration in rheumatoid arthritis. Fioravanti A, et al. **Drugs Exp Clin Res** 1995;21(3):97–103

Triadic nose drops in the treatment of chronic sinusitis. Zhu FG. **East Afr Med J** 1995 Dec;72(12):816–7

Dexamethasone in meconium aspiration [letter; comment] Ng PC. **Eur J Pediatr** 1995 Sep;154(9):754–5. Comment on: Eur J Pediatr 1994 Nov;153(11):864.

Prevention of mouse-rat brain xenograft rejection by a combination therapy of cyclosporin A, prednisolone and azathioprine. Pedersen EB, et al. **Exp Brain Res** 1995; 106(2):181–6

Diclofenac and prednisolone inhibit endotoxin-induced uveitis in rabbits [letter] Kulkarni PS, et al. **Exp Eye Res** 1995 Dec;61(6):767–8

Efficacy of first-time steroid injection for painful heel syndrome. Miller RA, et al. **Foot Ankle Int** 1995 Oct; 16(10):610–2

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Modigliani R, et al. **Gastroenterology** 1996 Mar;110(3):688–93

Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy. Kjeldsen J, et al. **Gut** 1995 Dec;37(6):805–10

A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Lee FI, et al. **Gut** 1996 Feb;38(2):229–33

Inverted skin changes induced by estrogen and estrogen/glucocorticoid on aging dermis. Cortés-Gallegos V, et al. **Gynecol Endocrinol** 1996 Apr;10(2):125–8

IVIG, anti-D or oral prednisolone in acute ITP? **Indian Pediatr** 1995 Feb;32(2):263–4

A novel contact hypersensitivity model for rank-ordering formulated corticosteroids. Bailey SC, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S162–3

Inhibition of PAF-, LPS-, and cytokine-induced granulocyte accumulation in guinea pig lung by dexamethasone: evidence that inhibition of IL-5 release is responsible for the selective inhibition of eosinophilia by glucocorticoids in guinea-pigs. Whelan CJ. **Inflamm Res** 1996 Apr;45(4):166–70

Combined drug therapy with diltiazem, dextran, and hydrocortisone (DDH therapy) for late cerebral vasospasm after aneurysmal subarachnoid hemorrhage: assessment of efficacy and safety in an open clinical study. Kawano T, et al. **Int J Clin Pharmacol Ther** 1995 Sep;33(9):513–7

Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis. Pai BS, et al. **Int J Dermatol** 1995 Oct; 34(10):726–8

Steroid pulse therapy in lupus cystitis [see comments] Segawa C, et al. **Intern Med** 1996 Feb;35(2):155–8. Comment in: Intern Med 1996 Feb;35(2):87–8.

Do corticosteroids influence the disease course or mortality in Guillain-Barre' syndrome? Singh NK, et al. **J Assoc Physicians India** 1996 Jan;44(1):22–4

Hydrocortisone pretreatment for attenuation of protamine-induced adverse hemodynamic reactions [letter] Baraka A, et al. **J Cardiothorac Vasc Anesth** 1995 Aug; 9(4):481–2

Bilateral inguinal scrofuloderma during steroid therapy in a patient with bullous pemphigoid. Kawabata E, et al. **J Dermatol** 1995 Aug;22(8):582–6 (22 ref.)

Fibrous invasive (Riedel's) thyroiditis with critical response to steroid treatment. Bagnasco M, et al. **J Endocrinol Invest** 1995 Apr;18(4):305–7

Treatment of croup with nebulized dexamethasone. Adelman A. **J Fam Pract** 1996 Jul;43(1):19–20

Corticosteroids for the management of ulcerative colitis. Oshitani N, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:118–20

Treatment of trigger finger in patients with diabetes mellitus. Griggs SM, et al. **J Hand Surg [Am]** 1995 Sep;20(5):787–9

Steroid injection for carpal tunnel syndrome. Irwin LR, et al. **J Hand Surg [Br]** 1996 Jun;21(3):355–7

Combined high-dose 7S-IgG and dexamethasone is effective in severe polyneuropathy of the POEMS syndrome [letter] Henze T, et al. **J Neurol** 1995 Jul;242(7):482–3

Dexamethasone treatment for acute bacterial meningitis: how strong is the evidence for routine use? [letter] McIntyre P. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):464–5

The Optic Neuritis Treatment Trial. Putting the results in perspective. The Optic Neuritis Study Group. Beck RW, et al. **J Neuroophthalmol** 1995 Sep;15(3):131–5

Optic neuritis treatment trial [letter] Levi L. **J Neuroophthalmol** 1995 Dec;15(4):261–2; discussion 262–3

High-dose oral dexamethasone therapy for chronic childhood idiopathic thrombocytopenic purpura. Adams DM, et al. **J Pediatr** 1996 Feb;128(2):281–3

Acute scrotum caused by Henoch-Schönlein purpura, with immediate response to short-term steroid therapy. Ben-Chaim J, et al. **J Pediatr Surg** 1995 Oct;30(10):1509–10

Prenatal hormonal therapy improves pulmonary compliance in the nitrofen-induced CDH rat model [letter] Karamanoukian HL, et al. **J Pediatr Surg** 1996 Mar; 31(3):462–3

Low-dose aspirin and prednisone treatment of pregnancy loss caused by lupus anticoagulants. Harger JH, et al. **J Perinatol** 1995 Nov-Dec;15(6):463–9

What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? Criswell LA, et al. **J Rheumatol** 1995 May;22(5):829–35

Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. Ferraccioli G, et al. **J Rheumatol** 1996 Apr;23(4):624–8

A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. Krogsgaard MR, et al. **J Rheumatol** 1995 Sep;22(9):1660–2

Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. Hill GE, et al. **J Thorac Cardiovasc Surg** 1995 Dec; 110(6):1658–62

Reducing ischemia-reperfusion injury in rat island groin flaps by dexamethasone and BW755C. Dolan RW, et al. **Laryngoscope** 1995 Dec;105(12 Pt 1):1322–5

MRI evaluation of dexamethasone acetate therapy for osteoarthritis in the hand. Tankhiwale A, et al. **Magn Reson Imaging** 1995;13(6):911–4

Immunosuppressive therapy for myocarditis [letter; comment] Cunnion RE, et al. **N Engl J Med** 1995 Dec 21;333(25):1713; discussion 1714. Comment on: N Engl J Med 1995 Aug 3;333(5):269–75.

Successful trial of steroids in two haemodialysis patients with inflammatory disease and anaemia unresponsive to recombinant erythropoietin [letter] Tzanakis I, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):400–1

Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Kobayashi Y, et al. **Nephron** 1996;72(2):237–42

Methylprednisolone pulse therapy for severe absorption fever due to perirenal hematoma after percutaneous renal biopsy [letter] Yang CW, et al. **Nephron** 1996;73(1):120–1

Serum LDH: a marker of disease activity and its response to therapy in idiopathic pulmonary fibrosis. van Krugten M, et al. **Neth J Med** 1996 Jun;48(6):220–3

Low-dose, short-term oral prednisone in the treatment of carpal tunnel syndrome. Herskovitz S, et al. **Neurology** 1995 Oct;45(10):1923–5

Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Rosenberg GA, et al. **Neurology** 1996 Jun;46(6):1626–32

Successful treatment of transverse myelitis in a child with systemic lupus erythematosus. Baca V, et al. **Neuropediatrics** 1996 Feb;27(1):42–4

MRI in Graves orbitopathy: recognition of enlarged muscles and prediction of steroid response. Polito E, et al. **Ophthalmologica** 1995;209(4):182–6

New treatments for anterior uveitis [editorial] Dunn JP. **Ophthalmology** 1996 Mar;103(3):355–6

Are systemic corticosteroids useful in the management of orbital pseudotumors? Mombaerts I, et al. **Ophthalmology** 1996 Mar;103(3):521–8

What we have learned from the optic neuritis treatment trial [letter] Tanaka GH. **Ophthalmology** 1996 Mar;103(3):346–7

Localized fibromyalgia in a child. Bassan H, et al. **Paediatr Anaesth** 1995;5(4):263–5

Randomized trial of the efficacy of trimethoprim-sulfamethoxazole and prednisone in preventing post-tympanostomy tube morbidity. Daly KA, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1068–74

High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randonized, blinded study. Baram TZ, et al. **Pediatrics** 1996 Mar;97(3):375–9

Dexamethasone for bacterial meningitis [letter; comment] Long SS. **Pediatrics** 1996 Jan;97(1):147–8. Comment on: Pediatrics 1995 Jan;95(1):21–8. Comment on: Pediatrics 1995 Jan;95(1):29–31.

Influence of steroids on postoperative swelling after facialplasty: a prospective, randomized study. Rapaport DP, et al. **Plast Reconstr Surg** 1995 Dec;96(7):1547–52

Corticosteroid-sparing strategies in the treatment of retinal vasculitis in systemic lupus erythematosus. Neumann R, et al. **Retina** 1995;15(3):201–12

Evaluation of the results of endotoxic shock (ES) treatment with dopamine (DA) and hydrocortisone (H). Barczyk J, et al. **Rocz Akad Med Bialymst** 1995;40(1):187–94

Therapy study on the experimental injury of spinal cord. IV. High doses of methyl-prednisolone. Anghelescu N, et al. **Rom J Neurol Psychiatry** 1995 Jul-Dec;33(3–4):241–9

Relative efficacy of hydrocortisone and methylprednisolone in acute severe asthma. Hall CM, et al. **S Afr Med J** 1995 Nov;85(11):1153–6

Relative efficacy of hydrocortisone and methylprednisolone in acute severe asthma [letter] Straughan JL. **S Afr Med J** 1996 Mar;86(3):273

Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Neumann K, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):47–55

The effect of the treatment of high-dose methylprednisolone on Na(+)-K(+)/Mg(+2) ATPase activity and lipid peroxidation and ultrastructural findings following cerebral contusion in rat. Ildan F, et al. **Surg Neurol** 1995 Dec; 44(6):573–80

Glucocorticosteroids and pulmonary sarcoidosis [editorial; comment] Selroos O. **Thorax** 1996 Mar;51(3):229–30. Comment on: Thorax 1996 Mar;51(3):238–47.

Acute asthma during pregnancy. Stenius-Aarniala BS, et al. **Thorax** 1996 Apr;51(4):411–4

Bacterial meningitis in developing countries [letter; comment] Vince JD. **Trop Doct** 1996 Apr;26(2):91–2. Comment on: Trop Doct 1995 Jan;25(1):5–8.

Treatment of X-linked lymphoproliferative disease (Duncan disease) with high-dose methylprednisolone and etoposide (VP-16). Gürgey A, et al. **Turk J Pediatr** 1996 Apr-Jun; 38(2):217–22

[For the present Duchenne' disease should not be treated with prednisone] Jennekens FG, et al. **Ned Tijdschr Geneeskd** 1996 May 25;140(21):1109–11 (21 ref.) **(Dut)**

[Local corticosteroid therapy in a severe form of pemphigoid gestationis (letter)] Guillaume JC, et al. **Ann Dermatol Venereol** 1996;123(1):31 **(Fre)**

[Pharma-clinics. Drug of the month. Fluticasone propionate (Flixotide)] Scheen AJ. **Rev Med Liege** 1996 Feb; 51(2):195–7 **(Fre)**

[Evaluation of the therapeutic activity of and gastric lesions due to new NSAID versus placebo in patients with osteoarticular diseases] Delfino M, et al. **Clin Ter** 1996 Mar; 147(3):113–6 (Eng. Abstr.) **(Ita)**

[Aortic dissection similar to giant cell arteritis: diagnostic difficulties and efficacy of steroid therapy] Cordioli E, et al. **Minerva Med** 1995 Jul-Aug;86(7–8):331–5 (Eng. Abstr.)

(Ita)
[Vascular hyperfragility in systemic lupus erythematosus treated with low doses of cortisone] Longo F, et al. **Pediatr Med Chir** 1995 Nov-Dec;17(6):535-7 (Eng. Abstr.) (Ita)
[Recent view on drug therapy of bronchial asthma] Mano K. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):417-22 (9 ref.) (Jpn)
[A case of lupus cystitis successfully treated with corticosteroid accompanied by gastrointestinal symptoms] Sato M, et al. **Ryumachi** 1995 Oct;35(5):814-20 (38 ref.) (Eng. Abstr.) (Jpn)
[Efficacy of flunisolide in treatment of patients with bronchial asthma] Romański B, et al. **Pneumonol Alergol Pol** 1995; 63(9-10):527-31 (Eng. Abstr.) (Pol)
[Effect of flunisolide on exacerbation of clinical symptoms, spirometric parameters, consumption of B2-adrenergic drugs and levels of cortisol and ECP in serum of patients with bronchial asthma] Siergiejko Z, et al. **Pneumonol Alergol Pol** 1995;63 Suppl 2:76-82 (Eng. Abstr.) (Pol)
[Autoimmune hemolytic anemia associated with Castleman's disease. Response of both diseases to glucocorticoid treatment (letter; comment)] Gómez-Espuch J, et al. **Med Clin (Barc)** 1996 May 4;106(17):677-8. Comment on: Med Clin (Barc) 1995 Nov 11;105(16):638-9. (Spa)
[Corticosteroids in chronic obstructive pulmonary disease (editorial)] Roncoroni AJ. **Medicina (B Aires)** 1995; 55(3):270-3 (Spa)
[Comparative study of the effectiveness of 2 oral corticoids in the control of severe crisis of bronchial asthma: deflazacort and prednisone] Chapela R. **Rev Alerg Mex** 1995 Jul-Aug;42(4):64-8 (Eng. Abstr.) (Spa)
[Advances in the topical steroid treatment of inflammatory bowel diseases] Díaz Blasco J, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):802-7 (62 ref.) (Spa)
[Comparison of 2 treatment strategies with prednisone and interferon in chronic hepatitis B] Gómez Camacho F, et al. **Rev Esp Enferm Dig** 1996 Mar;88(3):185-90 (Eng. Abstr.) (Spa)
[New treatments for multiple sclerosis] Masdeu JC. **Rev Neurol** 1996 Jun;24(130):708-11 (38 ref.) (Spa)

TOXICITY

Review of the toxicology of beclomethasone dipropionate. Libretto SE. **Arch Toxicol** 1995;69(8):509-25 (68 ref.)
Effects of a delayed steroid injection on ligament healing using a rabbit medial collateral ligament model. Walsh WR, et al. **Biomaterials** 1995 Aug;16(12):905-10
Glucocorticoid-induced cataract of developing chick embryo as a screening model for anticataract agents. Lee JW, et al. **J Ocul Pharmacol Ther** 1995 Winter;11(4):533-41

ANTI-INFLAMMATORY AGENTS, TOPICAL

ADVERSE EFFECTS

Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids [see comments] Leibowitz HM, et al. **Arch Ophthalmol** 1996 Aug; 114(8):933-7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1000-1.
Probable active sensitization to tixocortol pivalate. Goldsmith PC, et al. **Contact Dermatitis** 1995 Dec;33(6):429
Contact dermatitis from hydroxyethyl salicylate. Reichert C, et al. **Contact Dermatitis** 1995 Oct;33(4):275-6
Ultrasound description and quantification of irritant reactions induced by dithranol at different concentrations. A comparison with visual assessment and colorimetric measurements. Schiavi ME, et al. **Contact Dermatitis** 1996 Apr;34(4):272-7

ANALYSIS

Flow-injection spectrofluorimetric determination of flufenamic and mefenamic acid in pharmaceuticals. Albero MI, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1113-7

CHEMICAL SYNTHESIS

Steroidal anti-inflammatory antedrugs: synthesis and pharmacological evaluation of 16 alpha-alkoxycarbonyl-17-deoxyprednisolone derivatives. Yoon KJ, et al. **Steroids** 1995 Jul;60(7):445-51

PHARMACOLOGY

Novel 10-substituted antipsoriatic anthrones as inhibitors of epidermal 12-lipoxygenase and lipid peroxidation in membranes. Müller K, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2077-83
Effects of dithranol on neutrophil superoxide generation in patients with psoriasis. Kavanagh GM, et al. **Br J Dermatol** 1996 Feb;134(2):234-7
Effects of indole-3-acetic acid on croton oil- and arachidonic acid-induced mouse ear edema. Jones LH, et al. **Inflamm Res** 1995 Sep;44(9):372-5
Anti-psoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes. Schmidt KN, et al. **J Immunol** 1996 Jun 1;156(11):4514-9
Treatment of head injury in mice, using a fructose 1,6-diphosphate and dimethyl sulfoxide combination. de la Torre JC. **Neurosurgery** 1995 Aug;37(2):273-9
Dimethyl sulfoxide does not trigger urine histamine release in interstitial cystitis. Stout L, et al. **Urology** 1995 Nov; 46(5):653-6

THERAPEUTIC USE

Treatment of acute reflex sympathetic dystrophy with DMSO 50% in a fatty cream. Zuurmond WW, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):364-7
Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Foster CS, et al. **Am J Ophthalmol** 1996 Aug;122(2):171-82
Extensive lichen amyloidosus refractory to DMSO. Kobayashi T, et al. **J Dermatol** 1995 Oct;22(10):755-8
[Advances in the topical steroid treatment of inflammatory bowel diseases] Díaz Blasco J, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):802-7 (62 ref.) (Spa)

ANTILEPROTIC AGENTS see **LEPROSTATIC AGENTS**

ANTILIPEMIC AGENTS

[Dyslipidemia, lipid lowering drugs and thrombosis] Ambrosi P, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1641-5 (31 ref.) (Eng. Abstr.) (Fre)

ADMINISTRATION & DOSAGE

Effect of feeding clofibrate-containing diet on the hepatic NAD+ level in rats. Loo Y, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun;41(3):341-7
Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Gardner SF, et al. **Pharmacotherapy** 1996 May-Jun;16(3):419-23
[Personal experience with 200mg of micronized fenofibrate (Lipanthyl 200 M) in the treatment of primary dyslipidemias] Vaverková H, et al. **Vnitr Lek** 1996 Apr; 42(4):239-45 (Eng. Abstr.) (Cze)
[Does the cardiologists' report on lipids forget primary prevention? (letter)] Nordestgaard BG. **Ugeskr Laeger** 1996 Jun 10;158(24):3478-9 (Dan)
[Modifying increased plasma cholesterol levels in secondary prevention of coronary heart disease] Jost S, et al. **Z Kardiol** 1995 Aug;84(8):577-95 (159 ref.) (Eng. Abstr.) (Ger)
[Hyperlipidemia, coronary disease and antilipemic drugs—do they help?] Hansteen V. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3602-3 (Nor)
[Treatment of hyperlipidemia (letter)] Haraldsen M. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):112 (Nor)
[Treatment of hyperlipidemia. Guidelines for treatment of hyperlipidemia for secondary prevention of ischemic heart disease] Ose L. **Tidsskr Nor Laegeforen** 1995 Nov 30; 115(29):3629-31 (Eng. Abstr.) (Nor)
[The effect of micronized phenofibrate on the lipoproteins of the blood plasma at different initial lipid levels] Perova NV, et al. **Ter Arkh** 1996;68(1):71-6 (Eng. Abstr.) (Rus)
[Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia] Jover E, et al. **Med Clin (Barc)** 1996 May 25;106(20):776-9 (Eng. Abstr.) (Spa)
[Where are we when it comes to lipids? (letter)] Hellström K. **Lakartidningen** 1995 Nov 15;92(46):4317-8 (Swe)
[Is mortality among healthy persons with lipid regulation decreasing in the long run? (letter)] Lindeberg S. **Lakartidningen** 1996 Feb 28;93(9):765-6 (Swe)

ADVERSE EFFECTS

Bezalip-induced anaphylaxis [letter] Toubi E, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):370
Photosensitivity to simvastatin with an unusual response to photopatch and photo tests. Morimoto K, et al. **Contact Dermatitis** 1995 Oct;33(4):274
Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy. Abdul-Ghaffar NU, et al. **J Clin Gastroenterol** 1995 Dec;21(4):340-1
Carcinogenicity of lipid-lowering drugs [letter; comment] **JAMA** 1996 May 15;275(19):1481-2. Comment on: JAMA 1996 Jan 3;275(1):55-60.
Carcinogenicity of lipid-lowering drugs [letter; comment] Cattley RC. **JAMA** 1996 May 15;275(19):1479; discussion 1481-2. Comment on: JAMA 1996 Jan 3;275(1):55-60.
Does lowering cholesterol cause cancer? [comment] Dalen JE, et al. **JAMA** 1996 Jan 3;275(1):67-9. Comment on: JAMA 1996 Jan 3;275(1):55-60.
Carcinogenicity of lipid-lowering drugs [letter; comment] Illingworth R. **JAMA** 1996 May 15;275(19):1479-80; discussion 1481-2. Comment on: JAMA 1996 Jan 3;275(1):55-60.
Carcinogenicity of lipid-lowering drugs [letter; comment] Laws A. **JAMA** 1996 May 15;275(19):1480; discussion 1481-2. Comment on: JAMA 1996 Jan 3;275(1):55-60.
Carcinogenicity of lipid-lowering drugs [letter; comment] Pahor M. **JAMA** 1996 May 15;275(19):1480; discussion 1481-2. Comment on: JAMA 1996 Jan 3;275(1):55-60.
Carcinogenicity of lipid-lowering drugs [letter; comment] Tobert JA. **JAMA** 1996 May 15;275(19):1480-2. Comment on: JAMA 1996 Jan 3;275(1):55-60.
Fibrate monotherapy and profound hypoalphalipoproteinaemia [letter] Olukoga AO, et al. **Postgrad Med J** 1996 Mar;72(845):189
[Toxic myopathies related to the administration of hypolipidemic agents: are the drugs the only things responsible?] Galiana J, et al. **Rev Clin Esp** 1995 Sep; 195(9):620-2 (28 ref.) (Eng. Abstr.) (Spa)

BLOOD

Sensitive high-performance liquid chromatographic assay method for the determination of guggulsterone in serum. Singh SK, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):173-6

CHEMICAL SYNTHESIS

Synthesis and pharmacological studies of 3-amino-2-methyl-1-phenyl-propanones as hypolipidemic agents in rodents. Huang Y, et al. **Arch Pharm (Weinheim)** 1996 Jul;329(7):329-38
Synthesis of 1,2-diacyl-3-nicotinoyl glycerol derivatives and evaluation of their acute effects on plasma lipids in the rat. Cordi A, et al. **Arzneimittelforschung** 1995 Sep; 45(9):997-1001
ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme. Gribble AD, et al. **J Med Chem** 1996 Aug 30;39(18):3569-84
Synthesis and hypolipidemic activities of novel 2-[4-[diethoxyphosphoryl)methyl]phenyl]quinazolines and 4(3H)-quinazolinones. Kurogi Y, et al. **J Med Chem** 1996 Mar 29;39(7):1433-7
Synthesis and hypolipidemic evaluation of beta-alkylaminopropiophenone and beta-alkylaminopropio-2'-naphthone derivatives in rodents. Huang Y, et al. **Pharmazie** 1996 Apr;51(4):199-206

CHEMISTRY

[Evolutionary programming for finding "structure-activity" relationships in a series of 3-phenoxychromone and 3-phenoxy-4-hydroxycoumarin derivatives] Tetko IV, et al. **Bioorg Khim** 1995 Oct;21(10):809-15 (Eng. Abstr.) (Rus)

ECONOMICS

Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease [letter; comment] Jolain B, et al. **Clin Ther** 1995 May-Jun; 17(3):572-80. Comment on: Clin Ther 1994 Nov-Dec;16(6):1052-62; discussion 1036.

METABOLISM

Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma. Bailey MJ, et al. **Chem Res Toxicol** 1996 Apr-May; 9(3):659-66
In vitro inhibition of low-density lipoprotein oxidation by a gemfibrozil metabolite. Kawamura M, et al. **Clin Chem** 1996 Apr;42(4):644-5
Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment. Raedsch R, et al. **Eur J Drug Metab Pharmacokinet** 1995 Apr-Jun; 20(2):113-8
Tetradecylthioacetic acid incorporated into very low density lipoprotein: changes in the fatty acid composition and reduced plasma lipids in cholesterol-fed hamsters. Frøyland L, et al. **J Lipid Res** 1995 Dec;36(12):2529-40

PHARMACOKINETICS

Reactivity of gemfibrozil 1-o-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats. Sallustio BC, et al. **Drug Metab Dispos** 1995 Sep;23(9):892-9

PHARMACOLOGY

Effects of Acipimox on the metabolism of free fatty acids and very low lipoprotein triglyceride. Hannah JS, et al. **Acta Diabetol** 1995 Dec;32(4):279-83
Difference between guinea pig and rat in the liver peroxisomal response to equivalent plasmatic level of ciprofibrate. Pacot C, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):181-8
Synthesis and pharmacological studies of 3-amino-2-methyl-1-phenyl-propanones as hypolipidemic agents in rodents. Huang Y, et al. **Arch Pharm (Weinheim)** 1996 Jul;329(7):329-38
Hypolipidemic activity of 3-amino-1-(2,3,4-mononitro-, mono-, or dihalophenyl)propan-1-ones in rodents. Huang Y, et al. **Arch Pharm (Weinheim)** 1996 Jul;329(7):339-46
Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Guérin M, et al. **Arterioscler Thromb Vasc Biol** 1996 Jun;16(6):763-72
Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2). Jin FY, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1052-62
Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Chianale J, et al.

Biochem J 1996 Mar 15;314 (Pt 3):781–6

Alteration in gene expression of branched-chain keto acid dehydrogenase kinase but not in gene expression of its substrate in the liver of clofibrate-treated rats. Paul HS, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):411–7

Inducers of adipose conversion activate transcription promoted by a peroxisome proliferators response element in 3T3-L1 cells. Brandes R, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1949–51

Translactational induction of CYP4A expression in 10.5-day neonatal rats by the hypolipidemic drug clofibrate. Simpson AE, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2021–32

Short-term inhibition of fatty acid and cholesterol biosynthesis by the lipid-lowering drug gemfibrozil in primary rat hepatocyte cultures and rat liver in vivo. Hemingway CJ, et al. **Biochem Soc Trans** 1995 Aug; 23(3):496S

Hydrogen peroxide metabolism during peroxisome proliferation by fenofibrate. Arnaiz SL, et al. **Biochim Biophys Acta** 1995 Dec 12;1272(3):175–80

Cholesterol lowering action of HOE 402 in the normolipidemic and hypercholesterolemic golden Syrian hamster. Hoffmann A, et al. **Biochim Biophys Acta** 1996 Jan 5;1299(1):95–102

A comparison of the effects of fluvastatin and bezafibrate on exercise metabolism: a placebo-controlled study in healthy normolipidaemic subjects. Eagles CJ, et al. **Br J Clin Pharmacol** 1996 May;41(5):381–7

Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guinea-pigs. Vázquez M, et al. **Br J Pharmacol** 1995 Dec;116(8):3337–43

Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats. Vázquez M, et al. **Br J Pharmacol** 1995 Oct;116(3):2067–75

Ciprofibrate represses alpha 2u-globulin expression in liver and inhibits d-limonene nephrotoxicity. Alvares K, et al. **Carcinogenesis** 1996 Feb;17(2):311–6

Lipid-regulating action of gemfibrozil in the stroke-prone spontaneously hypertensive rat. Ogawa H, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S313–5

Hypolipidemic agents alter hepatic mitochondrial respiration in vitro. Chance DS, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):317–23

Alteration of lipid profile in hyperlipidemic rabbits by allicin, an active constituent of garlic. Eilat S, et al. **Coron Artery Dis** 1995 Dec;6(12):985–90

Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes. Christie AW, et al. **Diabetologia** 1996 Jan; 39(1):45–53

Disordered gastric motor function in diabetes mellitus [letter; comment] Mikhailidis DP, et al. **Diabetologia** 1995 May; 38(5):632. Comment on: Diabetologia 1994 Jun;37(6):543–51.

Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients. Piatti PM, et al. **Diabetologia** 1996 Jan;39(1):103–12

Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes. Zangar RC, et al. **Drug Metab Dispos** 1995 Jul;23(7):681–7

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Spencer CM, et al. **Drugs** 1996 Jun;51(6):982–1018 (234 ref.)

Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Berthou L, et al. **Eur J Biochem** 1995 Aug 15;232(1):179–87

Potentiating effects of clofibric acid on the differentiation of HL-60 human promyelocytic leukemia cells induced by retinoids. Nilsson A, et al. **Eur J Cell Biol** 1995 Aug; 67(4):379–85

Differential induction of peroxisomal enzymes by hypolipidaemics in human (HepG2) and rat (MH1C1) hepatoma cell lines. Stangl H, et al. **Eur J Clin Chem Clin Biochem** 1995 Nov;33(11):775–83

Nerve function in galactosaemic rats: effects of evening primrose oil and doxazosin. Dines CD, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):303–9

Effects of benfluorex metabolites on membrane fluidity and insulin-related processes. Orsière TG, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):237–43

Human HepG2 and rat Fao hepatic-derived cell lines show different responses to ciprofibrate, a peroxisome proliferator: analysis by flow cytometry. Passilly P, et al. **Exp Cell Res** 1996 Mar 15;223(2):436–42

Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. Vittek J. **Experientia** 1995 Sep 29;51(9–10):927–35 (68 ref.)

Biological effects of hesperidin, a Citrus flavonoid. (note II): hypolipidemic activity on experimental hypercholesterolemia in rat. Monforte MT, et al. **Farmaco** 1995 Sep;50(9):595–9

Protection against acetaminophen hepatotoxicity by a single dose of clofibrate: effects on selective protein arylation and glutathione depletion. Manautou JE, et al. **Fundam Appl Toxicol** 1996 Feb;29(2):229–37

The effect of AL0671, a novel potassium channel opener, on potassium current in rat aortic smooth muscle cells. Matzno S, et al. **Gen Pharmacol** 1995 Oct;26(6):1327–34

Antiperoxide effects of S-allyl cysteine sulphoxide isolated from Allium sativum Linn and gugulipid in cholesterol diet fed rats. Sheela CG, et al. **Indian J Exp Biol** 1995 May; 33(5):337–41

Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients. Branchi A, et al. **Int J Clin Pharmacol Ther** 1995 Jun;33(6):345–50

Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat. Staels B, et al. **Isr J Med Sci** 1996 Jun;32(6):490–8

Changes in biliary lipid secretion and cholic acid kinetics induced by diet, diet plus simvastatin and diet plus ursodeoxycholic acid in obese subjects. Mazzella G, et al. **Ital J Gastroenterol** 1995 Oct-Nov;27(8):441–5

Effect of phenobarbital and the peroxisome proliferator ciprofibrate on gamma-Glutamyltranspeptidase activity and leukotriene C4 concentration in cultured rat hepatocytes. Hong JT, et al. **J Biochem Toxicol** 1995 Oct; 10(5):239–243

Transcriptional suppression of the transferrin gene by hypolipidemic peroxisome proliferators. Hertz R, et al. **J Biol Chem** 1996 Jan 5;271(1):218–24

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. Berthou L, et al. **J Clin Invest** 1996 Jun 1; 97(11):2408–16

Niceritrol prevents the decrease in red blood cell 2,3-diphosphoglycerate and neuropathy in streptozotocin-induced diabetic rats. Hotta N, et al. **J Diabetes Complications** 1995 Jul-Sep;9(3):133–9

Lipid clearing agents in steroid-induced osteoporosis. Wang GJ, et al. **J Formos Med Assoc** 1995 Oct;94(10):589–92

Nonradioactive in situ hybridization for detection of mRNAs encoding for peroxisomal proteins: heterogeneous hepatic lobular distribution after treatment with a single dose of bezafibrate. Schad A, et al. **J Histochem Cytochem** 1996 Aug;44(8):825–34

Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. Haubenwallner S, et al. **J Lipid Res** 1995 Dec;36(12):2541–51

MDL 29311, a phenolic antioxidant, interferes with the interaction of apoC with VLDL: a possible explanation for its triglyceride-lowering effect. Sheetz MJ. **J Lipid Res** 1995 Dec;36(12):2609–21

Orally active squalene synthase inhibitors: bis((acyloxy)alkyl) prodrugs of the alpha-phosphonosulfonic acid moiety. Dickson JK Jr, et al. **J Med Chem** 1996 Feb 2;39(3):661–4

11-Ketotigogenin cellobioside (pamaqueside): a potent cholesterol absorption inhibitor in the hamster. McCarthy PA, et al. **J Med Chem** 1996 May 10;39(10):1935–7

alpha-Phosphonosulfonic acids: potent and selective inhibitors of squalene synthase. Magnin DR, et al. **J Med Chem** 1996 Feb 2;39(3):657–60

Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors. Tsai JC, et al. **J Pharm Sci** 1996 Jun;85(6):643–8

Acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid levels in hyperthyroidism. Lee EJ, et al. **Metabolism** 1995 Nov;44(11):1509–12

Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity. Maccario M, et al. **Metabolism** 1996 Mar;45(3):342–6

Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity. Nam SY, et al. **Metabolism** 1996 May;45(5):594–7

Effect of hydralazine on myocardial plasma membrane fatty acid binding protein (PM-FABP) during diabetes mellitus. Heyliger CE, et al. **Mol Cell Biochem** 1995 Jul 5; 148(1):39–44

Etofibrate suppresses neointima formation of the ballooned common carotid artery of rats. Kinscherf R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Oct; 352(4):424–8

Effects of bezafibrate on erythrocyte membrane phospholipids in alcohol-treated rats. Fujioka S, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Feb; 31(1):67–80

Cardiovascular and antilipolytic effects of the adenosine agonist GR79236. Merkel LA, et al. **Pharmacology** 1995 Oct;51(4):224–36

A study on the antihypercholesterolemic and antihyperlipidemic effects of cabbage extracts and their phytochemical evaluation. Jahodář L, et al. **Pharmazie** 1995 Dec;50(12):833–4

Effects of 4'-chlordiazepam on glycemia and serum lipids in hyperlipidemic rats: interactions with PK 11195 and flumazenil. Cuparencu B, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jul;89(1):57–66

Modification of lipogenesis in the isolated hamster flank organ through clofibric acid. Venencie PY, et al. **Skin Pharmacol** 1995;8(4):203–6

Studies on date waste dietary fibers as hypolipidemic agent in rats. Jwanny EW, et al. **Z Ernahrungswiss** 1996 Mar; 35(1):39–44

[Experimental study on anti-atherosclerotic effect of tongmai jiangzhi oral liquor] Lu CS, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):479–82 (Eng. Abstr.) **(Chi)**

[Effect of olbetam on hyperlipidemia in NIDDM] Yu Y, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec; 26(4):427–9 (Eng. Abstr.) **(Chi)**

[Decrease in atherogenicity of blood serum in vitro under the effect of polyunsaturated phosphatidylcholine micelles] Nikitina NA, et al. **Biull Eksp Biol Med** 1995 May; 119(5):497–501 **(Rus)**

THERAPEUTIC USE

Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study. Vahlquist C, et al. **Acta Derm Venereol** 1995 Sep;75(5):377–80

The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease [editorial] Roberts WC. **Am J Cardiol** 1996 Aug 1; 78(3):377–8

The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. Rubins HB, et al. **Am J Cardiol** 1996 Sep 1;78(5):572–5

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group [see comments] Davis BR, et al. **Am J Hypertens** 1996 Apr;9(4 Pt 1):342–60 . Comment in: Am J Hypertens 1996 Apr;9(4 Pt 1):409–11.

ALLHAT: the largest and most important clinical trial in hypertension ever done in the USA. Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial [editorial; comment] Elliott WJ. **Am J Hypertens** 1996 Apr; 9(4 Pt 1):409–11. Comment on: Am J Hypertens 1996 Apr;9(4 Pt 1):342–60.

Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Schectman G, et al. **Am J Med** 1996 Feb; 100(2):197–204

Assessing the independent effect of dietary counseling and hypolipidemic medications on serum lipids. Fleming RM, et al. **Angiology** 1996 Sep;47(9):831–40

Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Collinson PO, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):159–61

Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Pasternak RC, et al. **Ann Intern Med** 1996 Oct 1;125(7):529–40

Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient. Kirk JK, et al. **Ann Pharmacother** 1995 Sep;29(9):879–91 (98 ref.)

Low dose colestipol in adolescents with familial hypercholesterolaemia. Tonstad S, et al. **Arch Dis Child** 1996 Feb;74(2):157–60

Preventive efficacy of nutritional counseling [editorial; comment] Kannel WB. **Arch Intern Med** 1996 Jun 10; 156(11):1138–9. Comment on: Arch Intern Med 1996 Jun 10;156(11):1205–13.

Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Gaw A, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):236–49

Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition. Föger B, et al. **Atherosclerosis** 1995 Oct;117(2):253–61

Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. Pazzucconi F, et al. **Atherosclerosis** 1995 Oct; 117(2):189–98

Treatment of lipids. Implications for the general practitioner. Simons LA. **Aust Fam Physician** 1996 Jul;25(7):1053–9 (6 ref.)

Currently available hypolipidaemic drugs and future therapeutic developments. Farmer JA, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):825–47 (59 ref.)

Increasing prescription of drugs for secondary prevention of myocardial infarction. Lipid lowering drugs should be considered too [letter; comment] Taylor A, et al. **BMJ** 1996 Jan 27;312(7025):252. Comment on: BMJ 1995 Oct 7;311(7010):917–8.

Angiographic trials of lipid-lowering therapy: end of an era? Thompson GR. **Br Heart J** 1995 Oct;74(4):343–7 (27 ref.)

The acceptability of resin therapy to patients attending a hospital lipid clinic. Iversen SA, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):92–4

Fluvastatin in combination with other lipid-lowering agents. Jokubaitis LA. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:28–32 (4 ref.)

Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Azen SP, et al. **Circulation** 1996 Jan 1;93(1):34–41

Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Guetta V, et al. **Circulation** 1996 May 15;93(10):1928–37 (153 ref.)

Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia

and combined hyperlipidemia. Bruckert E, et al. **Clin Cardiol** 1995 Nov;18(11):621–9

A comparison of lovastatin. an HMG–CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia. Bell DS. **Clin Ther** 1995 Sep–Oct;17(5):901–10

Cost–effectiveness analysis of lipid–modifying therapy in Canada: comparison of HMG–CoA reductase inhibitors in the primary prevention of coronary heart disease [letter; comment] Jolain B, et al. **Clin Ther** 1995 May–Jun; 17(3):572–80. Comment on: Clin Ther 1994 Nov–Dec;16(6):1052–62; discussion 1036.

Post–transplant hyperlipidemia: risk factors and response to dietary modification and gemfibrozil therapy. Bastani B, et al. **Clin Transplant** 1995 Aug;9(4):340–8

Management of hyperlipidemia in diabetes. Vinik AI, et al. **Compr Ther** 1995 Oct;21(10):602–9 (50 ref.)

Prevention of restenosis by bezafibrate after successful coronary angioplasty. Ishiwata S, et al. **Coron Artery Dis** 1995 Nov;6(11):883–9

Hyperlipidemia and its management in renal disease. Massy ZA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar; 5(2):141–6 (63 ref.)

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Spencer CM, et al. **Drugs** 1996 Jun;51(6):982–1018 (234 ref.)

Design features of a five–year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). de Faire U, et al. **Drugs Exp Clin Res** 1995;21(3):105–24

Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy. Nemeth A, et al. **Eur J Clin Chem Clin Biochem** 1995 Nov;33(11):799–804

Effects of long–term therapy with either heparin or low–molecular–weight heparin on serum lipid levels. A prospective study. Monreal M, et al. **Haemostasis** 1995 Nov–Dec;25(6):283–7

Ursodeoxycholic acid or clofibrate in the treatment of non–alcohol–induced steatohepatitis: a pilot study. Laurin J, et al. **Hepatology** 1996 Jun;23(6):1464–7

Effects of fluvastatin, a new inhibitor of HMG–CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients. Sasaki J, et al. **Int J Clin Pharmacol Ther** 1995 Jul;33(7):420–6

Lipid lowering and coronary risk. Gotto AM Jr. **Isr J Med Sci** 1996 Jun;32(6):355–9 (27 ref.)

Exercise–induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol–lowering drug therapy with bezafibrate. Seiler C, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1615–22

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. Steinmetz A, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):563–70

Cholesterol awareness and treatment in patients with coronary artery disease participating in cardiac rehabilitation. Bairey Merz CN, et al. **J Cardpulm Rehabil** 1996 Mar–Apr;16(2):117–22

Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin–mediated glucose disposal and plasma insulin concentrations. Jeng CY, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2550–3

Number–needed–to–treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy. Rembold CM. **J Fam Pract** 1996 Jun;42(6):577–86

Fenofibrate, probucol, and other lipid–lowering treatments in heart transplant recipients [letter] de Lorgeril M, et al. **J Heart Lung Transplant** 1996 May;15(5):539–40

Increased prevalence of atherosclerotic wall changes in patients with hyperlipidaemia after renal transplantation. Jogestrand T, et al. **J Intern Med** 1996 Feb;239(2):177–80

Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients. Kahri J, et al. **J Intern Med** 1995 Nov;238(5):429–36

Yishou jiangzhi (de–blood–lipid) tablets in the treatment of hyperlipemia. Guan Y, et al. **J Tradit Chin Med** 1995 Sep; 15(3):178–9

Treatment of hyperlipidemia in women. Walsh JM, et al. **JAMA** 1995 Oct 11;274(14):1152–8

Persistence of balloon–induced arterial injury with hyperlipidemia despite gemfibrozil. Lundgren C, et al. **Jpn Heart J** 1996 Jan;37(1):119–26

Dual roles of HMG–CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Katznelson S, et al. **Kidney Int Suppl** 1995 Dec;52:S112–5 (30 ref.)

What is the role of lipid lowering therapy in heart–allograft failure? Reichart B, et al. **Kidney Int Suppl** 1995 Dec; 52:S52–5

Clinical utility of antilipidemic therapies in chronic renal allograft failure. Wanner C, et al. **Kidney Int Suppl** 1995 Dec;52:S60–2 (38 ref.)

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Ericsson CG, et al. **Lancet** 1996 Mar 30;347(9005):849–53

Abnormal lipid profiles on fibrate derivatives [letter] McLeod AJ, et al. **Lancet** 1996 Jan 27;347(8996):261

Targeting lipid–lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Ramsay LE, et al. **Lancet** 1996 Aug 10;348(9024):387–8

Taurine accelerates the regression of hypercholesterolemia in stroke–prone spontaneously hypertensive rats. Murakami S, et al. **Life Sci** 1996;58(19):1643–51

Apparent discontinuation rates in patients prescribed lipid–lowering drugs. Simons LA, et al. **Med J Aust** 1996 Feb 19;164(4):208–11

Choice of lipid–lowering drugs. **Med Lett Drugs Ther** 1996 Aug 2;38(980):67–70

Bezafibrate therapy in patients with isolated low high–density lipoprotein cholesterol levels may have a beneficial effect in prevention of atherosclerosis. Weintraub MS, et al. **Metabolism** 1995 Nov;44(11):1401–9

The prevention of coronary heart disease in women [letter; comment] Margolis KL, et al. **N Engl J Med** 1995 Dec 7;333(23):1570–1; discussion 1571–2. Comment on: N Engl J Med 1995 Jun 29;332(26):1758–66.

Pharmacologic prevention of coronary artery disease. What do clinical trials show? Milani RV, et al. **Postgrad Med** 1996 Feb;99(2):109–12, 115–20 (38 ref.)

Hyperlipidemia. When does treatment make a difference? Wise GR, et al. **Postgrad Med** 1996 Jul;100(1):138–49 (17 ref.)

Heart attacks: gone with the century? [editorial] [see comments] Brown MS, et al. **Science** 1996 May 3; 272(5262):629. Comment in: Science 1996 Jul 5;273(5271):15. Comment in: Science 1996 Jul 5;273(5271):15–6.

[Using a lipid clearing drug to prevent osteocytes damage of the femoral head in steroid–treated rabbits] Zhou M, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jan;76(1):13–6 (Eng. Abstr.) (Chi)

[The effect of polyene phosphatidylcholine administration on lipid metabolism and glucose tolerance in patients with hyperlipoproteinemia IIB] Zeman M, et al. **Sb Lek** 1995; 96(1):43–8 (Eng. Abstr.) (Cze)

[Zocor lobby? (letter)] Kruse P. **Ugeskr Laeger** 1996 Apr 29;158(18):2557–8 (Dan)

[Pharma clinics. Drug of the month. Acipimox (Olbetam)] Scheen AJ. **Rev Med Liege** 1995 Nov;50(11):489–90 (Fre)

[Should lipid–lowering agents be prescribed in myasthenia?] Windler E. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):80 (Ger)

[HMG–CoA reductase inhibitors for prevention and treatment of coronary heart disease. Effective reduction of cardiac events and mortality] Windler E. **Fortschr Med** 1996 Mar 20;114(8):89–90 (Ger)

[Lipid–lowering therapy—from the '80s to the '90s. International symposium, Berlin, 19 September 1992] **Internist (Berl)** 1993 Feb;34(2 Suppl):1–15 (Ger)

[Secondary prevention of coronary heart disease with lipid lowering drugs. Evaluating outcome eliminates the controversy] Pedersen TR. **Internist (Berl)** 1995 Dec; 36(12):1174–8 (32 ref.) (Ger)

[Mixed dyslipoproteinemias: new therapeutic opportunities] Capurso A. **Ann Ital Med Int** 1995 Oct;10 Suppl:44S–47S (20 ref.) (Eng. Abstr.) (Ita)

[Anti–atheromatous effects of fenofibrate, a hypolipidemic drug. I: Anti–atheromatous effects are independent of its hypolipidemic effect in cholesterol–fed rabbits] Saitoh K, et al. **Nippon Yakurigaku Zasshi** 1995 Jul;106(1):41–50 (Eng. Abstr.) (Jpn)

[Anti–atheromatous effects of fenofibrate, a hypolipidemic drug. II: Anti–atheromatous effects are independent of its hypolipidemic effect in hereditary hyperlipidemic rabbits] Saitoh K, et al. **Nippon Yakurigaku Zasshi** 1995 Jul; 106(1):51–60 (Eng. Abstr.) (Jpn)

[Comparative study of gemfibrozil versus pravastatin in the treatment of patients with coronary artery disease and low HDL cholesterol levels] Santos RD, et al. **Arq Bras Cardiol** 1995 Aug;65(2):181–3 (Eng. Abstr.) (Por)

[Prophylactic and correcting effect of polyethylene oxide Polyox WSR–301 in experimental lipoidosis in rats] Sokolova IA, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):587–9 (Rus)

[Antihyperlipidemic actions in the treatment of nephropathies] Neverov NI, et al. **Ter Arkh** 1995;67(8):15–7 (Eng. Abstr.) (Rus)

[Effectiveness of non–starch polysaccharide crylan in experimental hyperlipidemia] Remezova OV, et al. **Vopr Pitan** 1995;(2):14–6 (Eng. Abstr.) (Rus)

[Etofylline clofibrate in the treatment of diabetic dyslipidemia: results of a 6–month period of therapy] Rajecová E, et al. **Vnitr Lek** 1995 Oct;41(10):677–81 (Eng. Abstr.) (Slo)

[Limitations of interventions against hypercholesterolemia (letter)] Ripoll MA. **Aten Primaria** 1996 Mar 15;17(4):305–6 (Spa)

[Profitability of hypolipidemic drug treatment (letter)] Gérvas J, et al. **Med Clin (Barc)** 1996 Jun 1;107(1):37–8 (Spa)

[Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post–transplantation hyperlipemia (letter; comment)] Martínez–Castelao A. **Med Clin (Barc)** 1995 Nov 25;105(18):719. Comment on: Med Clin (Barc) 1994 Feb 5;102(4):139–41. (Spa)

[Profitability of hypolipidemic drug treatments (letter)] Subías Lorén PJ, et al. **Med Clin (Barc)** 1996 Jun 1;107(1):37 (Spa)

[Fenofibrate and arteriosclerosis. The new developments of the last 5 years (editorial)] Millán Núñez Cortés J, et al. **Rev Clin Esp** 1995 Dec;195(12):817–9 (46 ref.) (Spa)

[The relationship between clinical events and the angiographic lesions in coronary atherosclerosis. Hypolipemic treatment and plaque stabilization] Castro Beiras A, et al. **Rev Esp Cardiol** 1995;48 Suppl 5:23–30 (47 ref.) (Eng. Abstr.) (Spa)

[The practical aspects of lipid management in secondary prevention] de Teresa Galván E, et al. **Rev Esp Cardiol** 1995;48 Suppl 5:52–6 (16 ref.) (Eng. Abstr.) (Spa)

[Why the cardiologists should be interested in lipids?] López–Sendón JL, et al. **Rev Esp Cardiol** 1995;48 Suppl 2:23–32 (61 ref.) (Eng. Abstr.) (Spa)

[Need for a long–term program in the follow–up of anti–lipid treatment following coronary artery surgery?] Israelsson B, et al. **Nord Med** 1995;110(8–9):221–3 (Eng. Abstr.) (Swe)

TOXICITY

Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid. Wilson MW, et al. **Arch Toxicol** 1995;69(7):491–7

Incidence of pancreatic and testicular tumors in rats treated with ciprofibrate, a peroxisome proliferator. Rao MS, et al. **Cancer Lett** 1995 Nov 6;97(2):185–8

Gemfibrozil–induced peroxisome proliferation and hepatomegaly in male F344 rats. Sausen PJ, et al. **Cancer Lett** 1995 Nov 6;97(2):263–8

Peroxisome proliferation and microsomal enzyme induction by the hypolipidemic CI–924 in rats and mice: relationship to tumorgenicity. Hofstra AH, et al. **Fundam Appl Toxicol** 1995 Sep;27(2):277–86

Hepatic and adrenal toxicity of a novel lipid regulator in beagle dogs. Wolfgang GH, et al. **Fundam Appl Toxicol** 1995 Jul;26(2):272–81

Carcinogenicity of lipid–lowering drugs [see comments] Newman TB, et al. **JAMA** 1996 Jan 3;275(1):55–60 (54 ref.) . Comment in: JAMA 1996 Jan 3;275(1):67–9. Comment in: JAMA 1996 May 15;275(19):1479; discussion 1481–2. Comment in: JAMA 1996 May 15;275(19):1479–80; discussion 1481–2. Comment in: JAMA 1996 May 15;275(19):1480; discussion 1481–2. Comment in: JAMA 1996 May 15;275(19):1480–1; discussion 1481–2. Comment in: JAMA 1996 May 15;275(19):1481–2.

Reduction of the concentrations of prostaglandins E2 and F2alpha, and thromboxane B2 in cultured rat hepatocytes treated with the peroxisome proliferator ciprofibrate. Leung LK, et al. **Toxicol Lett** 1996 Jun;85(3):143–9

Hepatotumorigenicity and peroxisome proliferation induced by the hypolipidemic CI–924 in a two–year study in male and female B6C3F1 mice. Walker RM, et al. **Toxicol Pathol** 1996 May–Jun;24(3):265–72

ANTILYMPHOBLAST GLOBULINS see **ANTILYMPHOCYTE SERUM**

ANTILYMPHOCYTE ANTIBODIES see **ANTILYMPHOCYTE SERUM**

ANTILYMPHOCYTE GLOBULIN see **ANTILYMPHOCYTE SERUM**

ANTILYMPHOCYTE SERUM

The crime of saving lives: the FDA, John Najarian, and Minnesota ALG [letter] Collins WA, et al. **Arch Surg** 1996 Apr;131(4):451–2

United States v Najarian. A postmortem on regulatory misdirection. Lundquist JW. **Arch Surg** 1996 Sep; 131(9):911–4

Brain interleukin–1 is involved in generation of the serum suppressive factor induced by restraint stress in mice. Zuo YC, et al. **Neuroimmunomodulation** 1995 Mar–Apr; 2(2):82–7

ADMINISTRATION & DOSAGE

Pilot study of antithymocyte globulin in systemic sclerosis. Matteson EL, et al. **Arthritis Rheum** 1996 Jul;39(7):1132–7

Low–dose ATGAM treatment sufficiently reduces total T–cell counts and remains clinically effective in prophylactic and anti–rejection protocols. Ekberg H, et al. **Transplant Proc** 1995 Dec;27(6):3430–1

Three–day or ten–day ATG treatment for steroid–resistant rejection in kidney transplanted patients. Olausson M, et al. **Transplant Proc** 1995 Dec;27(6):3434–5

Successful transfer of immune unresponsiveness to concordant rat islet xenografts. Goss JA, et al. **Transplantation** 1996 Jan 15;61(1):9–13

Mechanism by which additional monoclonal antibody (mAB) injections overcome the requirement for thymic irradiation to achieve mixed chimerism in mice receiving bone marrow transplantation after conditioning with anti–T cell mABs and 3–Gy whole body irradiation. Tomita Y, et al. **Transplantation** 1996 Feb 15;61(3):477–85

Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti–T cell mABs and 3–Gy whole body irradiation. Tomita Y, et al. **Transplantation** 1996 Feb 15;61(3):469–77

Beneficial effect of graft perfusion with anti–T cell receptor

monoclonal antibodies on survival of small bowel allografts in rat recipients treated with brequinar alone or in combination with cyclosporine and sirolimus. Wang M, et al. **Transplantation** 1996 Feb 15;61(3):458–64

[The treatment results in patients with aplastic anemia using different doses of antilymphocyte globulin] Abdulkadyrov KM, et al. **Ter Arkh** 1995;67(8):51–4 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Persistent growth impairment of bone marrow stroma after antilymphocyte globulin treatment for severe aplastic anaemia and its association with relapse. Nissen C, et al. **Eur J Haematol** 1995 Oct;55(4):255–61

Antilymphoblastic globulin in renal transplant patients: no allergic reactions: a correction [letter] Chou SN. **JAMA** 1995 Dec 6;274(21):1676

Minimizing the toxicity of antilymphocyte antibody therapy. Pascual M, et al. **Transplant Proc** 1996 Aug;28(4):2113–4 (15 ref.)

BIOSYNTHESIS

Flow cytometry: its use in pediatric renal transplantation utilizing polyclonal induction. Bunchman TE. **Cytometry** 1995 Mar 15;22(1):16–21

BLOOD

Attempts to isolation and characterization of autolymphocytotoxins from syphilitic sera. Podwińska J, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(5–6):447–51

Complement-dependent cytotoxic antibodies to human T lymphotropic virus type I (HTLV-I)-infected cells in the sera of HTLV-I-infected individuals. Plotnicky-Gilquin H, et al. **Clin Exp Immunol** 1996 Jul;105(1):39–45

[Deficiency of maternal recognition of fetal-placental antigens in pregnancy complicated by idiopathic growth retardation] Dudarewicz L, et al. **Ginekol Pol** 1995 Sep; 66(9):498–501 (Eng. Abstr.) **(Pol)**

ECONOMICS

Two approaches to comparing hospital charges between cadaveric renal transplant patients who received orthoclone OKT 3 sterile solution or Atgam sterile solution for induction therapy. Schommer JC, et al. **Clin Ther** 1995 Jul–Aug;17(4):749–69; discussion 748

HISTORY

The crime of saving lives. The FDA, John Najarian, and Minnesota ALG. Wilson LG. **Arch Surg** 1995 Oct; 130(10):1035–9

IMMUNOLOGY

Evaluation of antibodies reactive with porcine lymphocytes and lymphoma cells in formalin-fixed, paraffin-embedded, antigen-retrieved tissue sections. Tanimoto T, et al. **Am J Vet Res** 1996 Jun;57(6):853–9

Antibody-mediated hemolytic anemia following ABO-mismatched organ transplantation: contributory role of HLA matching and polyclonal antilymphocyte globulin. Fabrega AJ, et al. **Clin Transplant** 1996 Apr;10(2):166–9

Pilot study of low-dose azathioprine in presensitized patients awaiting heart or lung transplantation. Keogh A, et al. **J Heart Lung Transplant** 1995 Sep–Oct;14(5):945–9

METABOLISM

The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Bunn D, et al. **Clin Nephrol** 1996 Jan;45(1):29–32

PHARMACOLOGY

Immunomodulation with intrathymic grafts or anti-lymphocyte serum promotes long-term intraspinal allograft survival. Theele DP, et al. **Cell Transplant** 1996 Mar–Apr;5(2):243–55

Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. Bonnefoy-Berard N, et al. **J Heart Lung Transplant** 1996 May;15(5):435–42 (52 ref.)

Inhibition of ATG-induced experimental transplantation tolerance with LS2616. Olausson M, et al. **Transplant Proc** 1995 Dec;27(6):3541–3

RADIATION EFFECTS

[The sterilization of Antilympholin by a radiation method combined with filtration] Serova LD, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec;(6):7 **(Rus)**

THERAPEUTIC USE

Deficiency of CD34+ c-kit+ and CD34+38- hematopoietic precursors in aplastic anemia after immunosuppressive treatment. Manz CY, et al. **Am J Hematol** 1996 Aug; 52(4):264–74

Graft failure after donor leucocyte infusion in relapsed chronic myeloid leukaemia: successful treatment with cyclophosphamide and antithymocyte globulin followed by peripheral blood stem cell infusion. Keil F, et al. **Br J Haematol** 1996 Jul;94(1):120–2

Response to immunosuppressive therapy and an HLA-DRB1 allele in patients with aplastic anaemia: HLA-DRB1*1501 does not predict response to antithymocyte globulin. Nakao S, et al. **Br J Haematol** 1996 Jan;92(1):155–8

Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation [see comments] Snell GI, et al. **Chest** 1996 Apr;109(4):874–8. Comment in: Chest 1996 Apr;109(4):857–9.

Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Hagen EC, et al. **Clin Nephrol** 1995 Jun;43(6):351–9

Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era. Hariharan S, et al. **Clin Transplant** 1996 Apr;10(2):186–90

Flow cytometry: its use in pediatric renal transplantation utilizing polyclonal induction. Bunchman TE. **Cytometry** 1995 Mar 15;22(1):16–21

Treatment of aplastic anaemia with antilymphocyte globulin and cyclosporin. Marsh JC, et al. **Int J Hematol** 1995 Oct; 62(3):133–44 (79 ref.)

Bone marrow transplantation in pediatric patients with severe aplastic anemia: cyclophosphamide and anti-thymocyte globulin conditioning followed by recombinant human granulocyte-macrophage colony stimulating factor. Bunin N, et al. **J Pediatr Hematol Oncol** 1996 Feb;18(1):68–71

Tolerance to cardiac allografts requires a time lag between intrathymic treatment and transplantation. Goldstein C, et al. **J Surg Res** 1996 Jun;63(1):83–5

Cardia allograft unresponsiveness using a posttransplant strategy : characterization of the graft infiltrate. Krieger NR, et al. **J Surg Res** 1996 Jun;63(1):86–92

Durability of donor-specific and organ-specific heart transplant tolerance induced by intrathymic pretreatment with allogeneic spleen cells. Shen Z, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):429–31

Anti-lymphocyte globulin therapy in aplastic anaemia--a university hospital experience. Leong KW, et al. **Med J Malaysia** 1995 Jun;50(2):158–61

Analysis of donor reactive cells in ALS-treated mice bearing skin allografts after the intrathymic injection of donor specific spleen cells. Ohzato H, et al. **Transpl Immunol** 1995 Mar;3(1):33–8

Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells. Abouna GM, et al. **Transplant Proc** 1995 Oct;27(5):2676–8

Islet and kidney transplantation using ATG and cyclosporin monotherapy and a central facility for islet isolation and purification. Birkeland SA, et al. **Transplant Proc** 1995 Dec; 27(6):3150–7

Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation. Bruce DS, et al. **Transplant Proc** 1996 Aug;28(4):2136–7

Developments in immunosuppressive therapy. Daar AS. **Transplant Proc** 1995 Oct;27(5):2671–5 (5 ref.)

Combined pancreas-kidney transplants using quadruple immunosuppression therapy: a comparison between antilymphoblast and antithymocyte globulins. Fasola CG, et al. **Transplant Proc** 1995 Dec;27(6):3135–6

Improved cadaveric kidney graft survival with initiation of antilymphocyte globulin pretransplant in patients with a positive flow cytometry crossmatch. Hong JH, et al. **Transplant Proc** 1996 Jun;28(3):1340–1

Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation. Kitabayashi K, et al. **Transplant Proc** 1996 Jun;28(3):1973–5

Treatment of steroid resistant acute rejection after renal transplantation. Oh CK, et al. **Transplant Proc** 1996 Jun; 28(3):1453–4

Intrathymic inoculations of donor leukocytes evoke differential cellular immune responses during cardiac allogenic and xenogenic transplant. Parhar RS, et al. **Transplant Proc** 1996 Apr;28(2):675–7

Successful pancreas-renal transplantation without anti-T-cell antibody induction. Shapiro ME, et al. **Transplant Proc** 1995 Dec;27(6):3087–8

A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients. Stratta RJ, et al. **Transplant Proc** 1996 Apr;28(2):917–8

Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function. Sumrani N, et al. **Transplant Proc** 1996 Feb;28(1):400–1

Impact of antipassenger lymphocyte globulin on functional graft survival of discordant xenoislet grafts from a large animal donor. Troppmann C, et al. **Transplant Proc** 1996 Apr;28(2):842–4

Antithymocyte globulin preparations after heart transplantation. Cytokine responses in vivo and in vitro. Grant SC, et al. **Transplantation** 1995 Oct 15;60(7):684–9

Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantation. Kesten S, et al. **Transplantation** 1996 Feb 15;61(3):427–30

Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Kimball JA, et al. **Transplantation** 1995 Dec 27; 60(12):1379–83

Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin. Indudhara R, et al. **Urology** 1996 Jun;47(6):807–12

[Aplastic anemia with giant splenomegaly and myelofibrosis successfully treated with antilymphocyte globulin] Kaito K, et al. **Rinsho Ketsueki** 1995 Aug;36(8):786–91 (Eng. Abstr.) **(Jpn)**

[Urgent allogeneic bone marrow transplantation using a preparative regimen of cyclophosphamide anti-human thymocytes rabbit globulin in a patient with severe aplastic anemia with pneumonia] Okamoto T, et al. **Rinsho Ketsueki** 1996 Jan;37(1):72–6 (Eng. Abstr.) **(Jpn)**

ANTIMALARIALS

Structure-activity relationships of the antimalarial agent artemisinin. 4. Effect of substitution at C-3. Avery MA, et al. **J Med Chem** 1996 Jul 19;39(15):2900–6

Malaria, the submerged disease. Olliaro P, et al. **JAMA** 1996 Jan 17;275(3):230–3 (54 ref.)

Assessment of the association between three pfmdr1 point mutations and chloroquine resistance in vitro of Malaysian Plasmodium falciparum isolates. Cox-Singh J, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):436–7

ADMINISTRATION & DOSAGE

Very low-dose chloroquine treatment for porphyria cutanea tarda [letter] Drago F, et al. **Acta Derm Venereol** 1995 Jul; 75(4):329–30

Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. Darbar D, et al. **Am J Health Syst Pharm** 1996 Mar 15;53(6):655–8

Randomized controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated Plasmodium falciparum malaria in Brazil. Duarte EC, et al. **Am J Trop Med Hyg** 1996 Feb; 54(2):197–202

Comparative clinical trial of artesunate followed by mefloquine in the treatment of acute uncomplicated falciparum malaria: two- and three-day regimens. Looareesuwan S, et al. **Am J Trop Med Hyg** 1996 Feb; 54(2):210–3

Gametocytocidal activity of alpha/beta arteether by the oral route of administration. Tripathi R, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):652–4

Dosage regimens of trimethoprim/sulfamethoxazole (TPM/SMX) in patients with renal dysfunction [letter] Nahata MC. **Ann Pharmacother** 1995 Dec;29(12):1300

Distinction between parasitologic and clinical efficacy of antimalarial agents [letter; comment] Kotb M. **J Infect Dis** 1996 Jan;173(1):275–6. Comment on: J Infect Dis 1995 Jun;171(6):1569–75.

Characterization, in vitro and in vivo studies on primaquine diphosphate liposomes. Arica B, et al. **J Microencapsul** 1995 Sep–Oct;12(5):469–85

Combination drug therapy of seropositive rheumatoid arthritis [see comments] McCarty DJ, et al. **J Rheumatol** 1995 Sep;22(9):1636–45. Comment in: J Rheumatol 1995 Sep;22(9):1611–7.

Efficacy of a 3-day oral regimen of quinine in an area of northern Nigeria with low-grade resistance of Plasmodium falciparum to chloroquine and sulphadoxine-pyrimethamine. Adagu SI, et al. **J Trop Med Hyg** 1995 Oct;98(5):296–8

Effect of training on the clinical management of malaria by medical assistants in Ghana. Ofori-Adjei D, et al. **Soc Sci Med** 1996 Apr;42(8):1169–76

The use of chloroquine in combination with artemisinin derivatives [letter; comment] Kirby GC. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):699. Comment on: Trans R Soc Trop Med Hyg 1995 Mar–Apr;89(2):215–6.

Mefloquine/sulfadoxine/pyrimethamine for malaria [letter; comment] Peters W. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):699. Comment on: Trans R Soc Trop Med Hyg 1995 May–Jun;89(3):303–5.

[A preliminary study on the inhibitory action of target-primaqine on the exoerythrocytic forms of Plasmodium yoelii yoelii] Song J, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):117–9 (Eng. Abstr.) **(Chi)**

[Rectal quinine, an alternative to parenteral injections for the treatment of childhood malaria. Clinical, parasitological and pharmacological study] Barennes H, et al. **Med Trop (Mars)** 1995;55(4 Suppl):91–4 (Eng. Abstr.) **(Fre)**

[An efficacy and tolerance study of oral artesunate alone and in combination with mefloquine in the treatment of uncomplicated falciparum malaria in an endemic area of Pará, Brazil] Cardoso B da S, et al. **Rev Soc Bras Med Trop** 1996 May-Jun;29(3):251–7 (Eng. Abstr.) **(Por)**

[Clarithromycin combined with pyrimethamine in cerebral toxoplasmosis--a a report of 2 cases] Dalston MO, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):409–13 (11 ref.) (Eng. Abstr.) **(Por)**

[False safety with homeopathic agents. Swedes became ill with malaria in spite of prophylaxis] Carlsson T, et al. **Lakartidningen** 1995 Nov 22;92(47):4467–8 **(Swe)**

[Chemical control is necessary for eradication of malaria (letter; comment)] Widmark G. **Lakartidningen** 1995 Nov 22;92(47):4406. Comment on: Lakartidningen 1995 Oct 11;92(41):3800, 3803. **(Swe)**

ADVERSE EFFECTS

The antipruritic effects of chlorpheniramine, cyproheptadine and sulphapyridine monitored with limb activity meters on chloroquine induced pruritus among patients with malaria. Osifo NG. **Afr J Med Med Sci** 1995 Mar; 24(1):67–73

Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Jaspers CA, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):230–4

Cardiac effects of standard-dose halofantrine therapy. Matson PA, et al. **Am J Trop Med Hyg** 1996 Mar; 54(3):229–31

Mefloquine-induced psychosis [letter] Piening RB, et al. **Ann Emerg Med** 1996 Jun;27(6):792–3

Cutaneous vasculitis associated with mefloquine [letter] White AC Jr, et al. **Ann Intern Med** 1995 Dec 1;123(11):894

Retinal toxicity in long term hydroxychloroquine treatment. Mavrikakis M, et al. **Ann Rheum Dis** 1996 Mar;55(3):187–9

Quinine induced lupus-like syndrome and cardiolipin antibodies [letter] Rosa-Re D, et al. **Ann Rheum Dis** 1996 Aug;55(8):559–60

Side-effects of drugs used in the treatment of rheumatoid arthritis. Evans PJ, et al. **Biochem Soc Symp** 1995; 61:195–207 (49 ref.)

Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. Barrett PJ, et al. **BMJ** 1996 Aug 31; 313(7056):525–8

Legal aid won for malaria drug case [news] Dyer C. **BMJ** 1996 Sep 14;313(7058):643

Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. ter Kuile FO, et al. **Bull World Health Organ** 1995; 73(5):631–42

CNS adverse events associated with antimalarial agents. Fact or fiction? Phillips-Howard PA, et al. **Drug Saf** 1995 Jun; 12(6):370–83 (77 ref.)

Psychiatric complications of chloroquine. Bhatia MS, et al. **Indian Pediatr** 1995 Mar;32(3):351–3

Chloroquine pruritus: a possible fixed cutaneous reaction. George AO. **Int J Dermatol** 1996 May;35(5):323–4

Hypoglycemia after oral quinine administration [letter] Kochar DK, et al. **J Assoc Physicians India** 1995 Sep; 43(9):654, 657

Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. Kano S, et al. **Kansenshogaku Zasshi** 1995 Dec;69(12):1408–12

Uncertainty about mefloquine will take time to resolve [news] Choo V. **Lancet** 1996 Mar 30;347(9005):891

Malaria prophylaxis and the media [letter] Clift S, et al. **Lancet** 1996 Aug 3;348(9023):344

Neuropsychiatric reactions with mefloquine chemoprophylaxis [letter] Croft AM, et al. **Lancet** 1996 Feb 3;347(8997):326

Blackwater fever after halofantrine [letter] Orlando G, et al. **Lancet** 1996 May 18;347(9012):1408–9

Drug-induced hepatotoxicity [letter; comment] Noble A, et al. **N Engl J Med** 1996 Mar 28;334(13):864. Comment on: N Engl J Med 1995 Oct 26;333(17):1118–27.

Mefloquine and scuba diving [letter] [see comments] Wright D. **N Z Med J** 1995 Dec 8;108(1013):514. Comment in: N Z Med J 1996 Feb 23;109(1016):61–2.

Pancytopenia due to Paludrine (proguanil hydrochloride) [letter] Houben MH, et al. **Nephron** 1995;71(3):368

Cardiac complications of halofantrine: a prospective study of 20 patients. Monlun E, et al. **Trans R Soc Trop Med Hyg** 1995 Jul-Aug;89(4):430–3

Mefloquine-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subject. Pous E, et al. **Trans R Soc Trop Med Hyg** 1995 Jul-Aug;89(4):434

Acute psychosis after mefloquine. Report of six cases. Sowunmi A, et al. **Trop Geogr Med** 1995;47(4):179–80

[Granulomatous hepatitis attributed to the combination pyrimethamine-chloroquine] van Everdingen-Bongers JJ, et al. **Ned Tijdschr Geneeskd** 1996 Feb 10;140(6):320–2 (Eng. Abstr.) **(Dut)**

[Electrocardiographic changes due to halofantrine in the treatment of malaria: therapeutic implications] Giudicelli CP, et al. **Bull Acad Natl Med** 1996 Jan;180(1):71–80; discussion 80–2 (Eng. Abstr.) **(Fre)**

[Macular complications of synthetic antimalarials. Apropos of a case] Ducousso F, et al. **J Fr Ophtalmol** 1995; 18(8-9):553–8 (Eng. Abstr.) **(Fre)**

[Prolonged QT interval and cardiac toxicity due to halofantrine (letter)] Fourcade L, et al. **Med Trop (Mars)** 1995;55(2):182–3 **(Fre)**

[Monitoring of long QT interval during treatment of malaria with halofantrine (letter)] Nicolas X, et al. **Med Trop (Mars)** 1995;55(4):394–5 **(Fre)**

[A case report. Thrombocytopenia and granulomatous hepatitis caused by quinine] Horney E, et al. **Lakartidningen** 1996 Jan 31;93(5):361–4 **(Swe)**

ANALYSIS

Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. Kusaka M, et al. **Am J Trop Med Hyg** 1996 Feb; 54(2):189–96

Unreliability of saliva samples for monitoring chloroquine and proguanil levels during anti-malarial chemoprophylaxis. Rault JP, et al. **Gen Pharmacol** 1996 Jan;27(1):65–7

A rapid, cost-effective liquid chromatographic method for the determination of chloroquine and desethylchloroquine in biological fluids. Walker O, et al. **Ther Drug Monit** 1996 Feb;18(1):92–6

ANTAGONISTS & INHIBITORS

[The evolution over time of the in-vitro resistance of Plasmodium falciparum to antimalarial drugs in 2 areas of the Brazilian Amazonia with distinct socioeconomic and geographic characteristics] Couto AA, et al. **Rev Soc Bras Med Trop** 1995 Oct-Dec;28(4):357–65 (Eng. Abstr.) **(Por)**

[Malaria resistant to chemotherapy] Năşcuţiu AM. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul-Dec; 40(3-4):271–6 (16 ref.) **(Rum)**

[Ca++ ion transport blockers as reversants of the drug resistance of malarial parasites. 1. The effect of verapamil on the resistance to chloroquine in vivo of Plasmodium berghei and in vitro of Plasmodium falciparum] Rabinovich SA, et al. **Med Parazitol (Mosk)** 1996 Jan-Mar;(1):18–22 (Eng. Abstr.) **(Rus)**

BLOOD

High-performance liquid chromatographic determination of primaquine and carboxyprimaquine concentrations in plasma and blood cells in Plasmodium vivax malaria cases following chronic dosage with primaquine. Dua VK, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):93–8

New solid-phase extraction for an improved high-performance liquid chromatographic procedure for the quantitation of halofantrine and monodesbutylhalofantrine in blood or plasma. Gaillard Y, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23; 668(2):315–21

Quantification of the individual enantiomer plasma concentrations of the candidate antimalarial agent N4-[2,6-dimethoxy-4-methyl-5-[(3-trifluoromethyl) phenoxy]-8-quinolinyl] - 1,4-pentanediamine (WR 238,605). Karle JM, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):251–7

Measurement of physiological concentrations of dapsone and its monoacetyl metabolite: a miniaturised assay for liquid or filter paper-absorbed samples. Mberu EK, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):385–7

Determination of artemether and dihydroartemisinin in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies. Navaratnam V, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21; 669(2):289–94

A liquid chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma. Brocks DR, et al. **J Pharm Biomed Anal** 1995 Jun; 13(7):911–8

Relationship between plasma and saliva quinine levels in humans. Babalola CP, et al. **Ther Drug Monit** 1996 Feb; 18(1):30–3

A simple method for assessing quinine pre-treatment in acute malaria. Silamut K, et al. **Trans R Soc Trop Med Hyg** 1995 Nov-Dec;89(6):665–7

CHEMICAL SYNTHESIS

Synthesis and activity of some quinolone derivatives against Plasmodium falciparum in vitro. Domínguez J, et al. **Farmaco** 1996 Jun;51(6):407–12

Structure-activity relationships of the antimalarial agent artemisinin. 2. Effect of heteroatom substitution at O-11: synthesis and bioassay of N-alkyl-11-aza-9-desmethylartemisinins. Avery MA, et al. **J Med Chem** 1995 Dec 22;38(26):5038–44

Synthesis and antimalarial activities of several fluorinated artemisinin derivatives. Pu YM, et al. **J Med Chem** 1995 Sep 29;38(20):4120–4

Toward a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium- and rhodium-chloroquine complexes. Sánchez-Delgado RA, et al. **J Med Chem** 1996 Mar 1;39(5):1095–99

CHEMISTRY

An intermediate for chloroquine analogs: (E)-2-(4,7-dichloro-2-quinolinyl)-3-(dimethylamino)-2-propenal. Mague JT, et al. **Acta Crystallogr C** 1995 Jul 15;51 (Pt 7):1423–5

Novel bisquinoline antimalarials. Synthesis, antimalarial activity, and inhibition of haem polymerisation. Raynes K, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):551–9

Quantum pharmacological analysis of structure-activity relationships for mefloquine antimalarial drugs using optimal transformations. Nguyen-Cong V, et al. **J Chem Inf Comput Sci** 1996 Jan-Feb;36(1):114–7

The iron environment in heme and heme-antimalarial complexes of pharmacological interest. Adams PA, et al. **J Inorg Biochem** 1996 Jul;63(1):69–77

Molecular modeling studies of the artemisinin (qinghaosu)-hemin interaction: docking between the antimalarial agent and its putative receptor. Shukla KL, et al. **J Mol Graph** 1995 Aug;13(4):215–22

A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. Humberstone AJ, et al. **J Pharm Sci** 1996 May;85(5):525–9

CONTRAINDICATIONS

Malaria prophylaxis [letter; comment] Ingram RJ, et al. **N Z Med J** 1996 Feb 23;109(1016):61–2. Comment on: N Z Med J 1995 Dec 8;108(1013):514.

HISTORY

Conflicts of interest: the genesis of synthetic antimalarial agents in peace and war. Greenwood D. **J Antimicrob Chemother** 1995 Nov;36(5):857–72

Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Verdrager J. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):23–8 (18 ref.)

The use of quinine for treatment and control of malaria in The Netherlands. Verhave JP. **Trop Geogr Med** 1995; 47(6):252–8

ISOLATION & PURIFICATION

Indonesian Medicinal Plants. XIV. Characterization of 3'-O-Caffeoylsweroside, a new secoiridoid glucoside, and kelampayosides A and B, two new phenolic apioglucosides, from the bark of Anthocephalus chinensis (Rubiaceae). Kitagawa I, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun; 44(6):1162–7

Costaricine, a new antiplasmodial bisbenzylisoquinoline alkaloid from Nectandra salicifolia trunk bark. Böhlke M, et al. **J Nat Prod** 1996 Jun;59(6):576–80

METABOLISM

The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Tingle MD, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1113–9

An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Halliday RC, et al. **Br J Clin Pharmacol** 1995 Oct; 40(4):369–78

Chloroquine resistance is not associated with drug metabolism in Plasmodium falciparum. Berger BJ, et al. **J Parasitol** 1995 Dec;81(6):1004–8

Metabolism of quinine in man: identification of a major metabolite, and effects of smoking and rifampicin pretreatment. Wanwimolruk S, et al. **J Pharm Pharmacol** 1995 Nov;47(11):957–63

Microbial and mammalian metabolism studies on the semisynthetic antimalarial, deoxoartemisinin. Khalifa SI, et al. **Pharm Res** 1995 Oct;12(10):1493–8

PHARMACOKINETICS

Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. Darbar D, et al. **Am J Health Syst Pharm** 1996 Mar 15;53(6):655–8

Quinine pharmacokinetics in young children with severe malaria. van Hensbroek MB, et al. **Am J Trop Med Hyg** 1996 Mar;54(3):237–42

The role of drug accumulation in 4-aminoquinoline antimalarial potency. The influence of structural substitution and physicochemical properties. Hawley SR, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):723–33

Pharmacokinetics of quinine in chronic liver disease. Auprayoon P, et al. **Br J Clin Pharmacol** 1995 Nov; 40(5):494–7

Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria. Barennes H, et al. **Br J Clin Pharmacol** 1996 May; 41(5):389–95

Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Ducharme J, et al. **Br J Clin Pharmacol** 1995 Aug; 40(2):127–33

Enantioselective disposition of hydroxychloroquine [letter] McLachlan AJ, et al. **Br J Clin Pharmacol** 1996 Apr; 41(4):347–9

Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. Wanwimolruk S, et al. **Br J Clin Pharmacol** 1995 Jul; 40(1):87–91

Stereoselective disposition of hydroxychloroquine and its metabolite in rats. Wei Y, et al. **Chirality** 1995;7(8):598–604

Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Skjelbo E, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):304–11

Disposition of quinine in plasma after a single oral and intramuscular dose in healthy adult Africans. Sowunmi A. **East Afr Med J** 1996 Feb;73(2):111–4

Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. Nielsen F, et al. **Eur J Clin Pharmacol** 1995;48(6):501–4

Pharmacokinetics of quinine in patients with chronic renal failure. Rimchala P, et al. **Eur J Clin Pharmacol** 1996; 49(6):497–501

Transport of artemisinin and sodium artesunate in Caco-2 intestinal epithelial cells. Augustijns P, et al. **J Pharm Sci** 1996 Jun;85(6):577-9

A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. Humberstone AJ, et al. **J Pharm Sci** 1996 May;85(5):525-9

Relationship between plasma and saliva quinine levels in humans. Babalola CP, et al. **Ther Drug Monit** 1996 Feb; 18(1):30-3

Human pharmacokinetics of chloroquine and proguanil delivered in a single capsule for malaria chemoprophylaxis. Touze JE, et al. **Trop Med Parasitol** 1995 Sep;46(3):158-60

[Study of pharmacokinetics of liver targeting antimalarial agent neoglycoalbumin-primaquine conjugate (NGA-PQ) and primaquine phosphate in mouse] Li TL, et al. **Yao Hsueh Hsueh Pao** 1995;30(10):721-5 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Iron chelators: mode of action as antimalarials. Cabantchik ZI, et al. **Acta Haematol** 1996;95(1):70-7 (40 ref.)

Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine. Alin MH, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):639-45

In vitro activity of atovaquone against the African isolates and clones of Plasmodium falciparum. Basco LK, et al. **Am J Trop Med Hyg** 1995 Oct;53(4):388-91

In vitro susceptibility of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine, and sulfadoxine/pyrimethamine in Equatorial Guinea. Benito A, et al. **Am J Trop Med Hyg** 1995 Nov;53(5):526-31

In vitro antimalarial activity of vegetal extracts used in West African traditional medicine. Benoit F, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):67-71

Effect of pH on in vitro potency of amantadine against Plasmodium falciparum. Evans SG, et al. **Am J Trop Med Hyg** 1996 Mar;54(3):232-6

The effects of pyronaridine on the morphology of Plasmodium falciparum in Aotus trivirgatus. Kawai S, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):223-9

Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Reeder JC, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):209-13

Rapid detection of pyrimethamine susceptibility of Plasmodium falciparum by restriction endonuclease digestion of the dihydrofolate reductase gene. Zindrou S, et al. **Am J Trop Med Hyg** 1996 Feb;54(2):185-8

Effects of zinc-desferrioxamine on Plasmodium falciparum in culture. Chevion M, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1902-5

Potent antimalarial activity of the alkaloid nitidine, isolated from a Kenyan herbal remedy. Gakunju DM, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2606-9

Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance. Gassis S, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):914-9

Simple, fast, and accurate fluorometric method to determine drug susceptibility of Plasmodium falciparum in 24-well suspension cultures. Smeijsters LJ, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):835-8

Methionine recycling pathways and antimalarial drug design. Sufrin JR, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2511-5

Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Vennerstrom JL, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2671-7

Effects of mefloquine on Ca2+ uptake by crude microsomes of rabbit skeletal muscle. Go ML, et al. **Arch Int Pharmacodyn Ther** 1995 Mar-Apr;329(2):255-71 (29 ref.)

Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine. Jiang MC, et al. **Biochem Biophys Res Commun** 1996 Sep 4;226(1):1-7

Mode of antimalarial effect of methylene blue and some of its analogues on Plasmodium falciparum in culture and their inhibition of P. vinckei petteri and P. yoelii nigeriensis in vivo. Atamna H, et al. **Biochem Pharmacol** 1996 Mar 8; 51(5):693-700

Novel bisquinoline antimalarials. Synthesis, antimalarial activity, and inhibition of haem polymerisation. Raynes K, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):551-9

Antimalarial activity of oxidized starch and cellulose imine derivatives. Ohara MT, et al. **Boll Chim Farm** 1995 Oct; 134(9):522-7

Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes. Masimirembwa CM, et al. **Br J Clin Pharmacol** 1996 Apr; 41(4):344-6

Haemolysis of Plasmodium falciparum trophozoite-infected erythrocytes after artemisinin exposure. Orjih AU. **Br J Haematol** 1996 Feb;92(2):324-8

Changes in the resistance of Plasmodium falciparum to chloroquine in Hainan, China. Liu DQ, et al. **Bull World Health Organ** 1995;73(4):483-6

Reactive oxygen generation by azomethine H: a new antimalarial drug. Novelli EL, et al. **Can J Physiol Pharmacol** 1995 Aug;73(8):1189-94

Effects of artesunate on immune function in mice. Lin PY, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):441-4

The effects of gossypol and chloroquine interaction on serum electrolytes of protein-malnourished rats. Nwoha PU, et al. **Contraception** 1995 Oct;52(4):255-9

Reduced level of serum cholesterol in low protein-fed Wistar rats administered gossypol and chloroquine. Nwoha PU, et al. **Contraception** 1995 Oct;52(4):261-5

Antigonococcal activity of 11 drugs used for therapy or prophylaxis of malaria. Mehaffey PC, et al. **Diagn Microbiol Infect Dis** 1995 Sep-Oct;23(1-2):11-13

An improved pharmacodynamic model for formation of methemoglobin by antimalarial drugs. Fasanmade AA, et al. **Drug Metab Dispos** 1995 May;23(5):573-6

Plasmodium falciparum: molecular characterization of multidrug-resistant Cambodian isolates. Basco LK, et al. **Exp Parasitol** 1996 Mar;82(2):97-103

Plasmodium falciparum: recrudescence of parasites in culture. Nakazawa S, et al. **Exp Parasitol** 1995 Dec;81(4):556-63

Sodium beta-artelinate--a new potential gametocytocide. Tripathi R, et al. **Exp Parasitol** 1996 Apr;82(3):251-4

Inhibition of invasion and intraerythrocytic development of Plasmodium falciparum by kinase inhibitors. Dluzewski AR, et al. **Experientia** 1996 Jun 15;52(6):621-3

Synthesis and activity of some quinolone derivatives against Plasmodium falciparum in vitro. Domínguez J, et al. **Farmaco** 1996 Jun;51(6):407-12

In vitro antimalarial activity of monoterpenic fragment analogues of aplasmomycin. Biswas S, et al. **Indian J Exp Biol** 1995 Jul;33(7):521-3

Antimalarial properties of soy-bean fat emulsions. Deharo E, et al. **Int J Parasitol** 1995 Dec;25(12):1457-62

Quinine specifically inhibits the proteolipid subunit of the F0F1 H+ -ATPase of Streptococcus pneumoniae. Muñoz R, et al. **J Bacteriol** 1996 Apr;178(8):2455-8

Quantum pharmacological analysis of structure-activity relationships for mefloquine antimalarial drugs using optimal transformations. Nguyen-Cong V, et al. **J Chem Inf Comput Sci** 1996 Jan-Feb;36(1):114-7

Malaria remedies of the Kenyah of the Apo Kayan, East Kalimantan, Indonesian Borneo: a quantitative assessment of local consensus as an indicator of biological efficacy. Leaman DJ, et al. **J Ethnopharmacol** 1995 Nov 17; 49(1):1-16

Antimalarial activity of novel arylene bis(methylketone) compounds. Berger BJ, et al. **J Infect Dis** 1996 Sep; 174(3):659-62

Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. Udomsangpetch R, et al. **J Infect Dis** 1996 Mar;173(3):691-8

The iron environment in heme and heme-antimalarial complexes of pharmacological interest. Adams PA, et al. **J Inorg Biochem** 1996 Jul;63(1):69-77

Mode of action of iron (III) chelators as antimalarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. Tsafack A, et al. **J Lab Clin Med** 1996 Jun;127(6):574-82

Structure-activity relationships of the antimalarial agent artemisinin. 3. Total synthesis of (+)-13-carbaartemisinin and related tetra- and tricyclic structures. Avery MA, et al. **J Med Chem** 1996 Apr 26;39(9):1885-97

Structure-activity relationships of the antimalarial agent artemisinin. 2. Effect of heteroatom substitution at O-11: synthesis and bioassay of N-alkyl-11-aza-9-desmethylartemisinins. Avery MA, et al. **J Med Chem** 1995 Dec 22;38(26):5038-44

In vitro antimalarial activity of chalcones and their derivatives. Li R, et al. **J Med Chem** 1995 Dec 22; 38(26):5031-7

Ionophore properties of monensin derivatives studied on human erythrocytes by 23Na NMR and K+ and H+ potentiometry: relationship with antimicrobial and antimalarial activities. Rochdi M, et al. **J Med Chem** 1996 Jan 19;39(2):588-95

Syntheses and antimalarial activities of N-substituted 11-azaartemisinins. Torok DS, et al. **J Med Chem** 1995 Dec 22;38(26):5045-50

Effect of halofantrine and its desbutyl metabolite on lymphocyte proliferation dynamics. Fasanmade AA, et al. **Life Sci** 1995;57(14):PL175-80

Pharmacology and pharmacokinetics of new antimalarials. Watkins WM. **Med Trop (Mars)** 1995;55(4 Suppl):33-6 (31 ref.)

Use of a semi-nested PCR diagnosis test to evaluate antifolate resistance of Plasmodium falciparum isolates. Eldin de Pecoulas P, et al. **Mol Cell Probes** 1995 Dec;9(6):391-7

Recent developments and rationale towards new strategies for malarial chemotherapy. Vial H. **Parasite** 1996 Mar; 3(1):3-23 (148 ref.)

Sphingolipid synthesis as a target for chemotherapy against malaria parasites. Lauer SA, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9181-5

The pfmdr1 gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells. Ruetz S, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9942-7

Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Wu Y, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1130-4

Plasmodium berghei: sensitivity of chloroquine-resistant and chloroquine-sensitive strains to irradiation and the effect of irradiated malaria parasites on cytochrome P450-dependent monooxygenases. Song GH, et al. **Res Commun Mol Pathol Pharmacol** 1995 Oct;90(1):75-86

Malaria research. Inbred parasites may spur resistance [news; comment] Schmidt KF. **Science** 1995 Sep 22;269(5231):1670 . Comment on: Science 1995 Sep 22;269(5231):1709-11.

Activity in vitro of chloroquine, cycloguanil, and mefloquine against African isolates of Plasmodium falciparum: presumptive evidence for chemoprophylactic efficacy in Central and West Africa. Basco LK, et al. **Trans R Soc Trop Med Hyg** 1995 Nov-Dec;89(6):657-8

Inhibition of tumor necrosis factor production by antimalarial drugs used in cerebral malaria [letter; comment] Wetsteyn JC. **Trans R Soc Trop Med Hyg** 1995 Nov-Dec;89(6):700 . Comment on: Trans R Soc Trop Med Hyg 1995 Mar-Apr;89(2):215-6.

Field research, relief work and war: does chloroquine-resistance occur in displaced populations of southern Sudan? [letter] Guthmann JP, et al. **Trop Doct** 1996 Apr;26(2):89-90

Falciparum malaria, imported into The Netherlands, 1979-1988. I. Epidemiological aspects. Wetsteyn JC, et al. **Trop Geogr Med** 1995;47(2):53-60

The antimalarial drug, Ro 42-1611 (arteflene), does not affect cytoadherence and cytokine-inducing properties of Plasmodium falciparum malaria parasites. Jakobsen PH, et al. **Trop Med Parasitol** 1995 Jun;46(2):88-92

Evaluation of resistant-reversal, CDRI compound 87/209 and its possible mode of action in rodent experimental malaria. Srivastava R, et al. **Trop Med Parasitol** 1995 Jun; 46(2):83-7

[Sensitivity of Plasmodium falciparum to seven antimalarials in China-Laos border] Yang H, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):111-3 (Eng. Abstr.) **(Chi)**

[Malaria and drug resistance] Kager PA, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):151-5 (20 ref.) (Eng. Abstr.) **(Dut)**

[Sensitivity in vivo and in vitro of Plasmodium falciparum to chloroquine and amodiaquine in Bangangte (west Cameroon)] Agnamey PP, et al. **Bull Soc Pathol Exot** 1995 Mar;88(4):149-51 (Eng. Abstr.) **(Fre)**

[Evaluation of Plasmodium falciparum resistance to antimalarial drugs] Parzy D, et al. **Med Trop (Mars)** 1995; 55(3):211-5 **(Fre)**

[Malaria parasite DNA and RNA changes connected with acquired resistance to chloroquine] Pankova TG, et al. **Mol Biol (Mosk)** 1996 Jan-Feb;30(1):43-50 **(Rus)**

[The effect of an antimalarial agent (chloroquine) on acute phase reactants in patients with rheumatoid arthritis] Jajić Z, et al. **Reumatizam** 1994;41(2):5-7 (Eng. Abstr.) **(Scr)**

POISONING

The effect of hypertonic sodium bicarbonate on QRS duration in rats poisoned with chloroquine. Curry SC, et al. **J Toxicol Clin Toxicol** 1996;34(1):73-6

Hypokalaemia and acute chloroquine ingestion [letter; comment] Buchanan N. **Lancet** 1996 Feb 10; 347(8998):404-5. Comment on: Lancet 1995 Sep 30;346(8979):877-80.

Hypokalaemia related to acute chloroquine ingestion [see comments] Clemessy JL, et al. **Lancet** 1995 Sep 30; 346(8979):877-80. Comment in: Lancet 1995 Dec 16;346(8990):1625. Comment in: Lancet 1996 Feb 10;347(8998):404-5.

[Chloroquine poisoning] Semb SO, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):478-80 (Eng. Abstr.) **(Nor)**

SUPPLY & DISTRIBUTION

Availability of parenteral quinidine gluconate for treatment of severe or complicated malaria. **MMWR Morb Mortal Wkly Rep** 1996 Jun 14;45(23):494-5

THERAPEUTIC USE

Clinical studies of iron chelators in malaria. Mabeza GF, et al. **Acta Haematol** 1996;95(1):78-86 (69 ref.)

Mefloquine insusceptibility of malaria in Thailand not promoted by nonregulated drug-use. Plasai V, et al. **Acta Trop** 1996 Feb;60(4):281-9

Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine. Alin MH, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):639-45

Increase of birth weight following chloroquine chemoprophylaxis during the first pregnancy: results of a randomized trial in Cameroon. Cot M, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):581-5

Short report: pefloxacin does not potentiate quinine efficacy against Plasmodium falciparum malaria. Deloron P, et al. **Am J Trop Med Hyg** 1995 Dec;53(6):646-7

Compliance with antimalarial chemoprophylaxis and the subsequent development of malaria: a matched case-control study. Gyorkos TW, et al. **Am J Trop Med Hyg** 1995 Nov; 53(5):511-7

Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Looareesuwan S, et al. **Am J Trop Med Hyg** 1996 Feb; 54(2):205-9

Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Looareesuwan S, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):62-6

Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria. Luxemburger C, et al. **Am J Trop Med Hyg** 1995 Nov;53(5):522–5

Parasite viability during treatment of severe falciparum malaria: differential effects of artemether and quinine. Murphy S, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):303–5

Evaluation of maternal practices, efficacy, and cost–effectiveness of alternative antimalarial regimens for use in pregnancy: chloroquine and sulfadoxine–pyrimethamine. Schultz LJ, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):87–94

Comparability of treatment groups and risk factors for parasitemia at the first antenatal clinic visit in a study of malaria treatment and prevention in pregnancy in rural Malawi. Steketee RW, et al. **Am J Trop Med Hyg** 1996; 55(1 Suppl):17–23

The problem of malaria and malaria control in pregnancy in sub–Saharan Africa. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):2–7

Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):24–32

The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):33–41

Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type–1. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):42–9

Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):50–6

Objectives and methodology in a study of malaria treatment and prevention in pregnancy in rural Malawi: The Mangochi Malaria Research Project. Steketee RW, et al. **Am J Trop Med Hyg** 1996;55(1 Suppl):8–16

Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. Touze JE, et al. **Am J Trop Med Hyg** 1996 Mar;54(3):225–8

Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Anderson SL, et al. **Ann Intern Med** 1995 Nov 15;123(10):771–3

Efficacy and tolerance in adults of a short (3 days) course of quinine for uncomplicated falciparum malaria. Ringwald P, et al. **Ann Soc Belg Med Trop** 1995 Jun;75(2):141–3

Efficacy and tolerability of a sequential, artesunate suppository plus mefloquine, treatment of severe falciparum malaria. Looareesuwan S, et al. **Ann Trop Med Parasitol** 1995 Oct;89(5):469–75

The chemotherapy of rodent malaria. LII. Response of Plasmodium yoelii ssp. NS to mefloquine and its enantiomers. Peters W, et al. **Ann Trop Med Parasitol** 1995 Oct;89(5):465–8

The chemotherapy of rodent malaria. L. The activities of some synthetic 1,2,4–trioxanes against chloroquine–sensitive and chloroquine–resistant parasites. Part 3: Observations on 'Fenozan–50F', a difluorinated 3,3'–spirocyclopentane 1,2,4–trioxane. Peters W, et al. **Ann Trop Med Parasitol** 1993 Apr;87(2):111–23

A comparative study of parenteral chloroquine, quinine and pyrimethamine–sulfadoxine in the treatment of Gambian children with complicated, non–cerebral malaria. Giadom B, et al. **Ann Trop Paediatr** 1996 Jun;16(2):85–91

Open comparison of artemether and mefloquine in uncomplicated Plasmodium falciparum hyperparasitaemia in children. Sowunmi A, et al. **Ann Trop Paediatr** 1996 Mar;16(1):5–9

Mechanisms of drug resistance in malaria. Cowman AF. **Aust N Z J Med** 1995 Dec;25(6):837–44 (89 ref.)

Status of antimalarial drugs under development. Olliaro PL, et al. **Bull World Health Organ** 1995;73(5):565–71 (35 ref.)

Canadian recommendations for the prevention and treatment of malaria among international travellers. Committee to Advise on Tropical Medicine and Travel (CATMAT). **Can Commun Dis Rep** 1995 Oct;21 Suppl 3:1–18 **(Eng, Fre)**

In vivo efficacy of chloroquine, halofantrine, pyrimethamine–sulfadoxine and qinghaosu (artesunate) in the treatment of malaria in Calabar, Nigeria. Ezedinachi E. **Cent Afr J Med** 1996 Apr;42(4):109–11

Some considerations for the prophylaxis of malaria in the non–immune traveller [letter] Makanda CD. **Cent Afr J Med** 1995 Jul;41(7):233–4

A case of dual chloroquine and halofantrine treatment failure in Zimbabwe. Mharakurwa S. **Cent Afr J Med** 1995 Oct; 41(10):327–9

Artemether resistant P. falciparum [letter] Turner GD. **Cent Afr J Med** 1995 Aug;41(8):263

Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S–mephenytoin oxidation in Tanzanians. Skjelbo E, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):304–11

Halofantrine in the treatment of malaria [letter; comment] Horton J. **Drug Saf** 1995 Oct;13(4):271–2. Comment on: Drug Saf 1995 Apr;12(4):264–73.

Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Barradell LB, et al. **Drugs** 1995 Oct;50(4):714–41 (101 ref.)

Disease–modifying antirheumatic drugs. Potential effects in older patients. Gardner G, et al. **Drugs Aging** 1995 Dec; 7(6):420–37 (43 ref.)

A randomised controlled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine and Fansidar in the treatment of uncomplicated malaria in children. Anabwani GM, et al. **East Afr Med J** 1996 Mar;73(3):155–8

Efficacy of halofantrine in the treatment of uncomplicated falciparum malaria. Mbori–Ngacha DA, et al. **East Afr Med J** 1995 Dec;72(12):796–9

Response of Plasmodium falciparum to chloroquine and Fansidar in vivo and chloroquine and amodiaquine in vitro in Uganda. Nevill CG, et al. **East Afr Med J** 1995 Jun; 72(6):349–54

A note on present trend of chloroquine sensitivity of P. falciparum in Malkangiri District, Orissa. Das LK, et al. **Indian J Malariol** 1996 Mar;33(1):48–51

Halofantrine in the treatment of falciparum malaria. Patel KH, et al. **Indian J Malariol** 1995 Mar;32(1):1–5

Chloroquine versus amodiaquine in the treatment of Plasmodium falciparum malaria in northeast India. Misra SP, et al. **Indian J Med Res** 1995 Sep;102:119–23

Studies on ammonia–metabolizing enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice. Agrawal A, et al. **Int J Parasitol** 1996 Apr; 26(4):451–5

Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. Metzger W, et al. **J Antimicrob Chemother** 1995 Oct;36(4):723–8

Minimal effective dose of mefloquine/sulfadoxine/pyrimethamine in mild Plasmodium falciparum malaria [letter] Radloff PD, et al. **J Antimicrob Chemother** 1995 Sep;36(3):586–7

General practitioners and treatment of malaria–need for continuing medical education [letter] Garg M, et al. **J Assoc Physicians India** 1995 Aug;43(8):584–5

Resurgence of malaria and drug resistance in plasmodium falciparum and vivax species in Bombay [letter] Sorabjee JS. **J Assoc Physicians India** 1996 Jan;44(1):71

Selective high–performance liquid chromatographic determination of artesunate and alpha– and beta–dihydroartemisinin in patients with falciparum malaria. Batty KT, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):345–50

Long–term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia. Hopperus Buma AP, et al. **J Infect Dis** 1996 Jun;173(6):1506–9

Impact of UK malaria prophylaxis policy on imported malaria [letter] Behrens RH, et al. **Lancet** 1996 Aug 3; 348(9023):344–5

Pyronaridine [letter; comment] Foster S. **Lancet** 1996 Apr 27;347(9009):1190. Comment on: Lancet 1996 Jan 6;347(8993):24–8.

Randomised placebo–controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Fryauff DJ, et al. **Lancet** 1995 Nov 4;346(8984):1190–3

Mefloquine in malaria prophylaxis: low efficacy or low compliance? [letter; comment] Handschin J, et al. **Lancet** 1995 Nov 11;346(8985):1294. Comment on: Lancet 1995 Aug 26;346(8974):574.

Pyronaridine [letter; comment] Looareesuwan S, et al. **Lancet** 1996 Apr 27;347(9009):1189–90. Comment on: Lancet 1996 Jan 6;347(8993):24–8.

Pyronaridine against multiresistant falciparum malaria [letter; comment] Peters W. **Lancet** 1996 Mar 2;347(9001):625. Comment on: Lancet 1996 Jan 6;347(8993):2–3. Comment on: Lancet 1996 Jan 6;347(8993):24–8.

Effects of artemisinin derivatives on malaria transmissibility. Price RN, et al. **Lancet** 1996 Jun 15;347(9016):1654–8

Atovaquone and proguanil for Plasmodium falciparum malaria. Radloff PD, et al. **Lancet** 1996 Jun 1; 347(9014):1511–4

Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa [see comments] Ringwald P, et al. **Lancet** 1996 Jan 6; 347(8993):24–8. Comment in: Lancet 1996 Jan 6;347(8993):2–3. Comment in: Lancet 1996 Mar 2;347(9001):625. Comment in: Lancet 1996 Apr 27;347(9009):1189–90. Comment in: Lancet 1996 Apr 27;347(9009):1190.

Pyronaridine: a promising drug for Africa? [comment] [see comments] Winstanley P. **Lancet** 1996 Jan 6;347(8993):2–3 . Comment on: Lancet 1996 Jan 6;347(8993):24–8. Comment in: Lancet 1996 Mar 2;347(9001):625.

Present development concerning antimalarial activity of phospholipid metabolism inhibitors with special reference to in vivo activity. Ancelin ML, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:85–90

Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Meshnick SR, et al. **Microbiol Rev** 1996 Jun;60(2):301–15 (189 ref.)

Artemether in severe malaria—still too many deaths [editorial; comment] Hoffman SL. **N Engl J Med** 1996 Jul 11;335(2):124–6. Comment on: N Engl J Med 1996 Jul 11;335(2):69–75. Comment on: N Engl J Med 1996 Jul 11;335(2):76–83.

A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria [see comments] Tran TH, et al. **N Engl J Med** 1996 Jul 11;335(2):76–83. Comment in: N Engl J Med 1996 Jul 11;335(2):124–6.

A trial of artemether or quinine in children with cerebral malaria [see comments] van Hensbroek MB, et al. **N Engl J Med** 1996 Jul 11;335(2):69–75. Comment in: N Engl J Med 1996 Jul 11;335(2):124–6.

The treatment of malaria. White NJ. **N Engl J Med** 1996 Sep 12;335(11):800–6 (49 ref.)

A closer look at malaria in india [letter] Chaudhury RR. **Nat Med** 1996 Aug;2(8):833

The effect of some 2–substituted quinolines isolated from Galipea longiflora on Plasmodium vinckei petteri infected mice. Gantier JC, et al. **Planta Med** 1996 Jun;62(3):285–6

Drug treatment of toxoplasmic encephalitis in acquired immunodeficiency syndrome. Winstanley P. **Postgrad Med J** 1995 Jul;71(837):404–8

Increasing chloroquine resistance — the Mpumalanga Lowveld story, 1990–1995 [letter] Kruger P, et al. **S Afr Med J** 1996 Mar;86(3):280–1

In vivo study of the response of Plasmodium falciparum to standard mefloquine/sulfadoxine/pyrimethamine (MSP) treatment among gem miners returning from Cambodia. Thimasarn K, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):204–12

Antimalarial drug response of Plasmodium falciparum from Zaria, Nigeria. Adagu IS, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):422–5

Intrarectal Quinimax (an association of Cinchona alkaloids) for the treatment of Plasmodium falciparum malaria in children in Niger: efficacy and pharmacokinetics. Barennes H, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug; 89(4):418–21

Sensitivity of Plasmodium falciparum to amodiaquine and chloroquine in central Africa: a comparative study in vivo and in vitro. Brasseur P, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct;89(5):528–30

Vivax malaria resistant to chloroquine: case reports from Bombay. Garg M, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):656–7

Mortality and morbidity from malaria after stopping malaria chemoprophylaxis. Greenwood BM, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):629–33

Comparison of artemether and quinine in the treatment of severe falciparum malaria in south–east Thailand. Karbwang J, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):668–71

Artesunate versus artemether in combination with mefloquine for the treatment of multidrug–resistant falciparum malaria. Price RN, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct; 89(5):523–7

Reducing the oral quinine–quinidine–cinchonin (Quinimax) treatment of uncomplicated malaria to three days does not increase the recurrence of attacks among children living in a highly endemic area of Senegal. Rogier C, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr;90(2):175–8

High level of resistance of Plasmodium falciparum to sulfadoxine–pyrimethamine in children in Tanzania. Rønn AM, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr; 90(2):179–81

Artemether treatment of sulfadoxine/pyrimethamine–resistant Plasmodium falciparum malaria in children. Sowunmi A, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):435–6

Clinical response and susceptibility in vitro of Plasmodium vivax to the standard regimen of chloroquine in Thailand. Tan–ariya P, et al. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):426–9

Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. ter Kuile FO, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):660–4

Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. van Hensbroek MB, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec; 89(6):672–6

Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine–sulfadoxine in Rwandan patients in a refugee camp in Zaire. Wolday D, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):654–6

Fluoroquinolone antimicrobials [letter] López–Vélez R, et al. **Trop Geogr Med** 1995;47(4):183

Comparison of three malaria chemoprophylactic regimens in residents in east, central and southern Africa. A prospective, randomized multicentre trial in The Netherlands. Wetsteyn JC, et al. **Trop Geogr Med** 1995; 47(3):103–6

Falciparum malaria, imported into The Netherlands, 1979–1988. II. Clinical features. Wetsteyn JC, et al. **Trop Geogr Med** 1995;47(3):97–102

Plasmodium berghei mouse model: antimalarial activity of new alkaloid salts and of thiosemicarbazone and acridine derivatives. Loiseau PM, et al. **Trop Med Int Health** 1996 Jun;1(3):379–84

A randomized trial of chloroquine, amodiaquine and pyrimethamine–sulphadoxine in Gambian children with uncomplicated malaria. Müller O, et al. **Trop Med Int Health** 1996 Feb;1(1):124–32

Efficacy of sulphadoxine/pyrimethamine for Plasmodium falciparum malaria in Malawian children under five years of age. Nwanyanwu OC, et al. **Trop Med Int Health** 1996 Apr;1(2):231–5

Stand–by treatment of suspected malaria in travellers. Nothdurft HD, et al. **Trop Med Parasitol** 1995 Sep; 46(3):161–3

ANTIMALARIALS

Evaluation of resistant-reversal, CDRI compound 87/209 and its possible mode of action in rodent experimental malaria. Srivastava R, et al. **Trop Med Parasitol** 1995 Jun; 46(2):83–7

[Malaria prevention: recommendations adapted once more. Work Group Malaria Prophylaxis] **Ned Tijdschr Geneeskd** 1996 Apr 20;140(16):892–3 **(Dut)**

[Malaria in a changed health care system in Vietnam] Bont L, et al. **Ned Tijdschr Geneeskd** 1995 Sep 23; 139(38):1928–31 (Eng. Abstr.) **(Dut)**

[Malaria in 1994: a challenge for the clinician] Eyckmans L. **Bull Mem Acad R Med Belg** 1994;149(8–11):389–93; discussion 393–6 (Eng. Abstr.) **(Fre)**

[The role of qinghaosu derivatives in the treatment of malaria in 1995] Ambroise-Thomas P. **Med Trop (Mars)** 1995;55(3 Suppl):18–20 (7 ref.) **(Fre)**

[For new antimalarial drugs: the methods of fundamental research] Ambroise-Thomas P. **Med Trop (Mars)** 1995;55(4 Suppl):23–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Decision making policies on the utilization of antimalarials in response to a modification of chloroquine efficacity. Applications to Africa] Baudon D. **Med Trop (Mars)** 1995; 55(4 Suppl):37–40 (5 ref.) (Eng. Abstr.) **(Fre)**

[Qinghao derivatives in the treatment of severe malaria (letter)] Danis M. **Med Trop (Mars)** 1995;55(4 Suppl):115 (8 ref.) **(Fre)**

[Plasmodium falciparum hematozoan morphological alterations in Gabon children treated with artemether] Kombila M, et al. **Med Trop (Mars)** 1995;55(4 Suppl):97–100 **(Fre)**

[The status of malaria chemoresistance in Africa] Le Bras J. **Med Trop (Mars)** 1995;55(4 Suppl):9–13 (24 ref.) (Eng. Abstr.) **(Fre)**

[Current perspectives in antimalarial therapy] Le Bras J. **Med Trop (Mars)** 1995;55(3 Suppl):13–7 (8 ref.) **(Fre)**

[Reflections on past antimalarial molecules (letter)] Lesbordes JL, et al. **Med Trop (Mars)** 1995;55(4 Suppl):116 **(Fre)**

[Epidemiological surveillance of Plasmodium falciparum sensitivity to chloroquine in Cameroon: necessity of public health policy adaptation] Louis FJ, et al. **Med Trop (Mars)** 1995;55(4 Suppl):77–9 **(Fre)**

[Practical aspects of oral quinine utilization in french speaking Africa] Ravinet L. **Med Trop (Mars)** 1995;55(4 Suppl):88–90 **(Fre)**

[In vivo evaluation of Plasmodium falciparum sensitivity to chloroquine in Moundou, Chad (letter)] Renaudin P, et al. **Med Trop (Mars)** 1995;55(3):286 **(Fre)**

[Adjuvant treatments of cerebral malaria (letter)] Touze JE, et al. **Med Trop (Mars)** 1995;55(4 Suppl):116 **(Fre)**

[Correct usage of amino alcohols] Touze JE. **Med Trop (Mars)** 1995;55(3 Suppl):24–5 (8 ref.) **(Fre)**

[Role of modulators in Plasmodium falciparum resistance to antimalarials] Verdier F, et al. **Med Trop (Mars)** 1995;55(4 Suppl):27–32 (20 ref.) (Eng. Abstr.) **(Fre)**

[How to perform and interpret the results of a chemoresistance test of Plasmodium falciparum in malaria patients in a tropical region] Guiguemdé RT, et al. **Sante** 1996 May–Jun;6(3):187–91 (Eng. Abstr.) **(Fre)**

[Antimalarial preparations in rheumatology: new prospects] Nasonov EL. **Ter Arkh** 1996;68(1):67–71 (50 ref.) **(Rus)**

[Chloroquine in the treatment of psoriatic arthritis] Jajić Z, et al. **Reumatizam** 1995;42(2):7–9 (Eng. Abstr.) **(Scr)**

[The halofantrine treatment of Plasmodium falciparum malaria. Clinical experience] Villota Arrieta J, et al. **An Esp Pediatr** 1996 Feb;44(2):117–20 (Eng. Abstr.) **(Spa)**

TOXICITY

Arteether neurotoxicity in the absence of deficits in behavioural performance in rats. Genovese RF, et al. **Ann Trop Med Parasitol** 1995 Aug;89(4):447–9

Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells. Glickstein H, et al. **Blood** 1996 Jun 1;87(11):4871–8

Chloroquine-induced lipidosis in the rat retina: functional and morphological changes after withdrawal of the drug. Duncker G, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jun;234(6):378–81

Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine. Toimela T, et al. **Ophthalmic Res** 1995;27 Suppl 1:150–3

Effects of chloroquine and its enantiomers on the development of rat embryos in vitro. Tagoe CN, et al. **Teratology** 1995 Sep;52(3):137–42

The antimalarials quinacrine and chloroquine induce weak lysosomal storage of sulphated glycosaminoglycans in cell culture and in vivo. Lüllmann-Rauch R, et al. **Toxicology** 1996 Jun 17;110(1–3):27–37

URINE

Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population. Wanwimolruk S, et al. **Br J Clin Pharmacol** 1995 Aug; 40(2):166–9

Japanese poor metabolizers of proguanil do not have an increased risk of malaria chemoprophylaxis breakthrough. Mberu EK, et al. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):658–9

ANTIMANIC AGENTS

ADMINISTRATION & DOSAGE

Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. Sachs GS. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):32S–47S (87 ref.)

[Calcium antagonists and lithium in preventive treatment of manic-depressive disorder] Sarfati Y, et al. **Encephale** 1996 Mar–Apr;22(2):149–53 (43 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use. Posner L, et al. **Am J Nephrol** 1996;16(4):339–43

Hypotension resistant to therapy with alpha receptor agonists complicating cardiopulmonary bypass: lithium as a potential cause. Berkowitz DE, et al. **Anesth Analg** 1996 May;82(5):1082–5

Comment: effect of lithium in water handling [letter; comment] Boyce EG. **Ann Pharmacother** 1995 Dec; 29(12):1304. Comment on: Ann Pharmacother 1995 Jul–Aug;29(7–8):663–6.

Treatment of valproate-induced alopecia [letter] Fatemi SH, et al. **Ann Pharmacother** 1995 Dec;29(12):1302

Lithium carbonate-gluten intolerance [letter] Lumley F. **Aust N Z J Psychiatry** 1995 Sep;29(3):520–1

Lithium-induced diabetes insipidus in a surgical patient: report of a case and review of the literature. Gray EJ, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):909–12 (20 ref.)

BLOOD

Systemic lithium reabsorption from lithium-chloride-coated heat and moisture exchangers. Rosi R, et al. **Intensive Care Med** 1995 Nov;21(11):937–40

[Lithium carbonate] Higuchi S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:942–4 (9 ref.) **(Jpn)**

PHARMACOKINETICS

Variability of brain lithium levels during maintenance treatment: a magnetic resonance spectroscopy study. Sachs GS, et al. **Biol Psychiatry** 1995 Oct 1;38(7):422–8

PHARMACOLOGY

The effect of prolonged administration of lithium on the level of dopamine D2 receptor mRNA in the rat striatum and nucleus accumbens. Dziedzicka-Wasylewska M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):29–34

The effect of concomitant use of neuroleptic drugs and lithium on the erythrocyte/plasma lithium ratio in Iranian patients with bipolar disorder. Azizabadi-Farahani M, et al. **J Clin Pharm Ther** 1996 Feb;21(1):3–7

The effect of prolonged lithium administration on the cAMP level in the rat striatum. Dziedzicka-Wasylewska M, et al. **Pol J Pharmacol** 1995 Mar–Apr;47(2):115–20

Circadian variation in rat brain AP-1 DNA binding activity after cholinergic stimulation: modulation by lithium. Williams MB, et al. **Psychopharmacology (Berl)** 1995 Dec; 122(4):363–8

Inositol monophosphatase—a putative target for Li+ in the treatment of bipolar disorder. Atack JR, et al. **Trends Neurosci** 1995 Aug;18(8):343–9 (97 ref.)

POISONING

Does acyclovir increase serum lithium levels? Sylvester RK, et al. **Pharmacotherapy** 1996 May–Jun;16(3):466–8

THERAPEUTIC USE

Treatment of manic episodes: zuclopenthixol and clonazepam versus lithium and clonazepam. Gouliaev G, et al. **Acta Psychiatr Scand** 1996 Feb;93(2):119–24

Divalproex sodium as a treatment for borderline personality disorder. Wilcox JA. **Ann Clin Psychiatry** 1995 Mar; 7(1):33–7

How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory. Belmaker RH, et al. **Annu Rev Med** 1996;47:47–56 (23 ref.)

Plasma GABA predicts acute response to divalproex in mania. Petty F, et al. **Biol Psychiatry** 1996 Feb 15; 39(4):278–84

A pharmacological approach to the quagmire of comorbidity in juvenile mania [comment] Wozniak J, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):826–8 . Comment on: J Am Acad Child Adolesc Psychiatry 1995 Jun;34(6):705–8.

The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. Frye MA, et al. **J Clin Psychiatry** 1996 Jan;57(1):17–21

The use of valproate in an elderly population with affective symptoms. Kando JC, et al. **J Clin Psychiatry** 1996 Jun; 57(6):238–40

Role of newer medications for bipolar disorder. Bowden CL. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):48S–55S (65 ref.)

Predictors of response to mood stabilizers. Calabrese JR, et al. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):24S–31S (88 ref.)

Outcome in the pharmacologic treatment of bipolar disorder. Keck PE Jr, et al. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):15S–23S (86 ref.)

Psychotherapy in combination with drug treatment for bipolar disorder. Miklowitz DJ. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):56S–66S (68 ref.)

The emerging role of valproate in bipolar disorder and other psychiatric disorders. Guay DR. **Pharmacotherapy** 1995 Sep–Oct;15(5):631–47 (146 ref.)

Informational needs of patients hospitalized for bipolar disorder. Pollack LE. **Psychiatr Serv** 1995 Nov; 46(11):1191–4

Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Maes M, et al. **Psychiatry Res** 1995 Oct 16;58(3):217–25

Changes in platelet monoamine oxidase and plasma dopamine-beta-hydroxylase activities in lithium-treated bipolar patients. Sofuoğlu S, et al. **Psychiatry Res** 1995 Nov 29;59(1–2):165–70

Inositol monophosphatase—a putative target for Li+ in the treatment of bipolar disorder. Atack JR, et al. **Trends Neurosci** 1995 Aug;18(8):343–9 (97 ref.)

ANTIMETABOLITES

Radiolabeled IUdR. Proceedings of a meeting. Boston, Massachusetts, October 4, 1994. **J Nucl Med** 1996 Apr;37(4 Suppl):1S–32S

ADMINISTRATION & DOSAGE

Intradermal fluorouracil and epinephrine injectable gel for treatment of psoriatic plaques [letter] Lowe NJ, et al. **Arch Dermatol** 1995 Nov;131(11):1340–1

Heat-stabilized albumin microspheres as a sustained drug delivery system for the antimetabolite, 5-fluorouracil. Truter EJ. **Artif Cells Blood Substit Immobil Biotechnol** 1995;23(5):579–86

Use of an Itraconazole/allopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS. Raffi F, et al. **Clin Infect Dis** 1995 Nov;21(5):1338–9

Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): response to methotrexate and mercaptopurine. Horneff G, et al. **Med Pediatr Oncol** 1996 Sep;27(3):187–92 (24 ref.)

[Low dosage of homoharringtonine for prevention of cicatrization after glaucoma filtering surgery] Shi F, et al. **Chung Hua Yen Ko Tsa Chih** 1995 Sep;31(5):345–6 (Eng. Abstr.) **(Chi)**

[Biodegradable controlled-release 5-FU implant in the surgery for glaucoma. Experimental study] Hostyn P, et al. **J Fr Ophtalmol** 1996;19(2):133–9 (Eng. Abstr.) **(Fre)**

DIAGNOSTIC USE

Bromodeoxyuridine labeling index in glioblastoma multiforme: relation to radiation response, age, and survival. Barker FG, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):803–8

Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose [see comments] Effert PJ, et al. **J Urol** 1996 Mar;155(3):994–8. Comment in: J Urol 1996 Mar;155(3):1004.

METABOLISM

D-cycloserine transport in human intestinal epithelial (Caco-2) cells: mediation by a H(+)-coupled amino acid transporter. Thwaites DT, et al. **Br J Pharmacol** 1995 Jul; 115(5):761–6

Brain 2-deoxyglucose levels related to maternal behavior-inducing stimuli in the rat. Del Cerro MC, et al. **Brain Res** 1995 Oct 23;696(1–2):213–20

Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Hoganson DK, et al. **Cancer Res** 1996 Mar 15;56(6):1315–23

L-homoarginine studies provide insight into the antimetabolic properties of L-canavanine. Rosenthal GA, et al. **Insect Biochem Mol Biol** 1996 Apr;26(4):389–94

PHARMACOKINETICS

Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity. Gnanalingham KK, et al. **J Neural Transm Gen Sect** 1995; 101(1–3):65–82

In vitro evaluation of donor liver preservation fluids on human hepatocyte function. Thomas P, et al. **Transpl Int** 1995;8(6):426–33

PHARMACOLOGY

Effects of some heavy metals on growth, pigment and antibiotic production by Streptomyces galbus. Raytapadar S, et al. **Acta Microbiol Immunol Hung** 1995;42(2):171–7

Influence of both salvage and DNA damage response pathways on resistance to chemotherapeutic antimetabolites. Pickard M, et al. **Biochem Pharmacol** 1996 Aug 9;52(3):425–31

Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. Pressacco J, et al. **Br J Cancer** 1995 Oct;72(4):939–42

Enzyme induction by L-buthionine (S,R)-sulfoximine in cultured mouse hepatoma cells. Shertzer HG, et al. **Chem Res Toxicol** 1995 Apr-May;8(3):431-6

Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in Ribavirin-treated patients using a high performance liquid chromatography linked method. Montero C, et al. **Clin Chim Acta** 1995 Jul 14;238(2):169-78

Antimetabolite interactions with epidermal growth factor. Kopecky EA, et al. **Curr Eye Res** 1996 Mar;15(3):247-53

Molecular characterization of trimethoprim resistance in salmonellas isolated in Sicily, 1985-1988. Agodi A, et al. **Eur J Epidemiol** 1995 Feb;11(1):33-8

Allopurinol effects in rat liver transplantation on recovery of energy metabolism and free radical-induced damage. Kusumoto K, et al. **Eur Surg Res** 1995;27(5):285-91

Effect of exercise and 2-deoxyglucose on the K+ channel opener action of CGRP in the guinea pig ureter. Maggi CA, et al. **Gen Pharmacol** 1996 Jan;27(1):95-100

Evidence for an inducible repair-recombination system in the female germ line of Drosophila melanogaster. I. Induction by inhibitors of nucleotide synthesis and by gamma rays. Bregliano JC, et al. **Genetics** 1995 Oct; 141(2):571-8

Corneal endothelial wound repair in normal and mitotically inhibited cultures. Mohay J, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Nov; 233(11):727-36

Cycloheximide-induced apoptosis in Burkitt lymphoma (BJA-B) cells with and without Epstein-Barr virus infection. Ishii HH, et al. **Immunol Cell Biol** 1995 Oct; 73(5):463-8

L-cycloserine, an inhibitor of sphingolipid biosynthesis, inhibits HIV-1 cytopathic effects, replication, and infectivity. Mizrachi Y, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):137-41

The effects of d-cycloserine, a partial agonist at the glycine binding site, on spatial learning and working memory in scopolamine-treated rats. Pitkänen M, et al. **J Neural Transm Park Dis Dement Sect** 1995;9(2-3):133-44

Long-term potentiation in hippocampal slices induced by temporary suppression of glycolysis. Tekkök S, et al. **J Neurophysiol** 1995 Dec;74(6):2763-6

Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition. Di Lisa F, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):1-13

Adenosine dialdehyde blocks the disappearance of two nerve growth factor-induced insoluble proteins. VanDenburg JY, et al. **J Protein Chem** 1995 Jul;14(5):291-7

Characteristics of the anticoccidial activity of 6-azauracil. Kobayashi N, et al. **J Vet Med Sci** 1996 Feb;58(2):115-20

Age-dependent susceptibility of CNS glial populations in situ to the antimetabolite 6-aminonicotinamide. Krum JM. **Mol Chem Neuropathol** 1995 Oct;26(2):79-94

Inhibition of glutathione synthesis of Ascaris suum by buthionine sulfoximine. Hussein AS, et al. **Parasitol Res** 1996;82(4):372-4

Intraventricular glucose blocks feeding induced by 2-deoxy-D-glucose but not mercaptoacetate. Singer LK, et al. **Physiol Behav** 1996 Apr-May;59(4-5):921-3

Effects of 2-deoxyglucose, a metabolic inhibitor, on spontaneous contraction and adrenoceptor responsiveness in cultured rat ventricular myocytes. Kanaya N, et al. **Res Commun Mol Pathol Pharmacol** 1995 Jul;89(1):101-10

[Effects of allopurinol on damage caused by ischemia and reperfusion of skeletal muscles: an in vivo spectroscopic analysis (31P-MR) in rats] Gürke L, et al. **Ann Ital Chir** 1996 Jan-Feb;67(1):73-5 (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

The long-term outcome of ulcerative colitis treated with 6-mercaptopurine [see comments] George J, et al. **Am J Gastroenterol** 1996 Sep;91(9):1711-4. Comment in: Am J Gastroenterol 1996 Sep;91(9):1689-90.

6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come [editorial; comment] Peppercorn MA. **Am J Gastroenterol** 1996 Sep; 91(9):1689-90. Comment on: Am J Gastroenterol 1996 Sep;91(9):1711-4.

Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole. Dockx P, et al. **Br J Dermatol** 1995 Sep; 133(3):426-32

Free radical generation and the role of allopurinol as a cardioprotective agent during coronary artery bypass grafting surgery. Movahed A, et al. **Can J Cardiol** 1996 Feb;12(2):138-44

Gene therapy for metastatic malignant melanoma: evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration. Klatzmann D. **Hum Gene Ther** 1996 Jan 20;7(2):255-67

Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU. Borhani H, et al. **Int Ophthalmol** 1995;19(1):43-9

Use of allopurinol to treat visceral leishmaniosis in a dog. Lester SJ, et al. **J Am Vet Med Assoc** 1996 Aug 1; 209(3):615-7

Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double-blind controlled study. Persson BE, et al. **J Urol** 1996 Mar;155(3):961-4

Use of clodronate in multiple myeloma. Jantunen E, et al. **Leuk Lymphoma** 1995 Oct;19(3-4):207-11 (29 ref.)

Trabeculectomy with intraoperative sponge 5-fluorouracil. Mora JS, et al. **Ophthalmology** 1996 Jun;103(6):963-70 (28 ref.)

[Azathioprine maintains remission in autoimmune hepatitis (letter)] Pariente E-A. **Gastroenterol Clin Biol** 1996; 20(3):328-30 (Fre)

[Use of methotrexate in spondylarthropathies. Review of the literature] Toussirot E, et al. **Rev Med Interne** 1996; 17(4):333-9 (40 ref.) (Eng. Abstr.) (Fre)

TOXICITY

Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir. Tong XW, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1611-7

Effect of acute and chronic glutathione depletion on renal function in the rat. Garber SL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):237-41

Azidothymidine and interferon-alpha in vitro effects on hematopoiesis: protective in vitro activity of IL-1 and GM-CSF. Castello G, et al. **Exp Hematol** 1995 Dec; 23(13):1367-71

Acute-phase response in rat to carbon tetrachloride-azathioprine induced cirrhosis and partial hepatectomy of cirrhotic liver. Fouad FM, et al. **J Toxicol Environ Health** 1996 Apr 19;47(6):601-15

Persistence of increased levels of ribosomal gene activity in CHO-K1 cells treated in vitro with demethylating agents. Giancotti P, et al. **Mutat Res** 1995 Dec;348(4):187-92

The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Fick J, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11071-5

Inhibitors of glycolytic metabolism affect neurulation-staged mouse conceptuses in vitro. Hunter ES 3rd, et al. **Teratology** 1995 Dec;52(6):317-23

Biological modeling of 5-fluorouracil developmental toxicity. Shuey DL, et al. **Toxicology** 1995 Sep 1;102(1-2):207-13 (23 ref.)

ANTIMETABOLITES, ANTINEOPLASTIC

ADMINISTRATION & DOSAGE

Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer. Alba E, et al. **Am J Clin Oncol** 1996 Apr;19(2):140-3

M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. Bellmunt J, et al. **Am J Clin Oncol** 1996 Aug;19(4):344-8

Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma. Bensmaine M el-A, et al. **Am J Clin Oncol** 1996 Aug;19(4):356-62

Cisplatin and UFT modulated with leucovorin for the treatment of Advanced non-small-cell lung cancer. Feliu J, et al. **Am J Clin Oncol** 1996 Apr;19(2):121-4

Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma. Kim YH, et al. **Am J Clin Oncol** 1996 Apr; 19(2):212-6

Successful treatment of sorivudine-related agranulocytosis with granulocyte-colony stimulating factor [letter] Sato H, et al. **Am J Hematol** 1995 Nov;50(3):227

Prognostic evaluation of preoperative combined treatment for advanced cancer in the lower rectum with radiation, intraluminal hyperthermia, and 5-fluorouracil suppository. Ichikawa D, et al. **Am J Surg** 1996 Mar;171(3):346-50

Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Staley CA, et al. **Am J Surg** 1996 Jan;171(1):118-24; discussion 124-5

High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. Gökbuget N, et al. **Ann Hematol** 1996 Apr;72(4):194-201 (58 ref.)

Suppository delivery of 5-fluorouracil in rectal cancer. Galandiuk S, et al. **Ann Surg Oncol** 1996 May;3(3):270-6

Treatment of hepatic-metastatic colorectal cancer with a chemotherapeutic emulsion: interim results of a phase I trial. Rubin JT, et al. **Ann Surg Oncol** 1995 Jul;2(4):351-9

Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. Port JL, et al. **Ann Thorac Surg** 1996 Sep;62(3):848-52

High-dose cytarabine induction for acute myeloid leukemia [letter; comment] Shepherd JD, et al. **Blood** 1996 Jul 15; 88(2):754-5. Comment on: Blood 1996 Mar 1;87(5):1710-7.

Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases. Fordy C, et al. **Br J Cancer** 1995 Oct;72(4):1023-5

Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro. Perron MJ, et al. **Br J Cancer** 1996 Feb;73(3):281-7

Response to regional chemotherapy in patients with variant hepatic arterial anatomy. Doughty JC, et al. **Br J Surg** 1996 May;83(5):652-3

Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study. Berenberg JL, et al. **Cancer** 1995 Sep 1;76(5):715-9

Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma [see comments] Chi KH, et al. **Cancer** 1995 Dec 1;76(11):2186-92. Comment in: Cancer 1996 Aug 1;78(3):566-7.

Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. Feliu J, et al. **Cancer** 1996 Jul 15;78(2):211-6

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Gamelin EC, et al. **Cancer** 1996 Feb 1;77(3):441-51

Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Robertson JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):674-9 (48 ref.)

Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Israel VK, et al. **Cancer Chemother Pharmacol** 1995; 37(1-2):32-8

Multi-chemothermoimmunotherapy for human colon adenocarcinoma in vitro. Klostergaard J, et al. **Cancer Chemother Pharmacol** 1996;37(3):235-41

Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors. Veerman G, et al. **Cancer Chemother Pharmacol** 1996;38(4):335-42

Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Gallo JM, et al. **Cancer Res** 1995 Oct 15;55(20):4507-11

Concepts in use of high-dose methotrexate therapy. Treon SP, et al. **Clin Chem** 1996 Aug;42(8 Pt 2):1322-9 (66 ref.)

High dose 5-fluorouracil (5-FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5-FU treatment: results of a phase II study [letter] Jäger E, et al. **Eur J Cancer** 1995 Sep;31A(10):1717

Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma. Penna C, et al. **Eur J Cancer** 1996 Jun;32A(7):1117-22 (47 ref.)

Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. Petrioli R, et al. **Eur J Cancer** 1995 Nov; 31A(12):2105-8

The 'pinch-off phenomenon': a radiological symptom for potential fracture of an implanted permanent subclavian catheter system. Schlangen JT, et al. **Eur J Radiol** 1995 Jul;20(2):112-3

Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department. Carey PD, et al. **Eur J Surg Oncol** 1995 Dec;21(6):653-7

Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer. Denehy TR, et al. **Gynecol Oncol** 1996 Jan;60(1):64-71 (21 ref.)

A new method of intra-arterial regional chemotherapy with more selective drug delivery for locally advanced pancreatic cancer. Ohigashi H, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):338-45

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. Masson E, et al. **J Clin Invest** 1996 Jan 1;97(1):73-80

Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica [see comments] Conter V, et al. **J Clin Oncol** 1995 Oct;13(10):2497-502. Comment in: J Clin Oncol 1995 Oct;13(10):2480-2.

Carboxypeptidase G2 rescue after high-dose methotrexate. DeAngelis LM, et al. **J Clin Oncol** 1996 Jul;14(7):2145-9

The value of high-dose methotrexate-based neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone. Ham SJ, et al. **J Clin Oncol** 1996 Feb;14(2):490-6

Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. O'Dwyer PJ, et al. **J Clin Oncol** 1996 Jan;14(1):249-56

In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. Stein AS, et al. **J Clin Oncol** 1996 Aug; 14(8):2206-16

Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study. Garufi C, et al. **J Infus Chemother** 1995;5(3 Suppl 1):134-7

A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. Lévi F, et al. **J Infus Chemother** 1995;5(3 Suppl 1):153-8

Reappraisal of hepatic arterial infusion in the treatment of

nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer [see comments] **J Natl Cancer Inst** 1996 Mar 6;88(5):252-8. Comment in: J Natl Cancer Inst 1996 Mar 6;88(5):223-4.

Re: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer [letter] Anand A, et al. **J Natl Cancer Inst** 1996 Jun 19; 88(12):838-9

Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. Hansen RM, et al. **J Natl Cancer Inst** 1996 May 15;88(10):668-74

Augmentation by aphidicolin of 1-beta-D-arabinofuranosylcytosine-induced c-jun and NF-kappa B activation in a human myeloid leukemia cell line: correlation with apoptosis. Kuwakado K, et al. **Leuk Res** 1995 Sep;19(9):645-50

Second-line treatment with high-dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard-dose 5-fluorouracil treatment. Jäger E, et al. **Oncology** 1995 Nov-Dec;52(6):470-3

Autoradiographic imaging of the distribution of 5-fluorouracil through cervical tissue following in vitro surface application of a bioadhesive cervical patch. Woolfson AD, et al. **Pharm Res** 1995 May;12(5):676-81

Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Braakhuis BJ, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):42-6

Toxicity study of hepatic artery infusion chemotherapy with massive dose FUDR in rats. Zeng ZS, et al. **Surg Oncol** 1995 Jun;4(3):147-55

Differential permeability of the blood-tumour barrier in intracerebral tumour-bearing rats: antidrug antibody to achieve systemic drug rescue. Kroll RA, et al. **Ther Immunol** 1994 Dec;1(6):333-41

[Primary cerebral non-Hodgkin's lymphoma. Intensive chemotherapy supported by crania radiotherapy] Jensen MK, et al. **Ugeskr Laeger** 1996 Jul 29;158(31):4413-5 (Eng. Abstr.) **(Dan)**

[Role of intralesional administration of bleomycin in the treatment of warts] Vanhooteghem O, et al. **Ann Dermatol Venereol** 1996;123(1):53-8 **(Fre)**

[Therapeutic effectiveness of hyperthermia and relation to glutathione concentration in the tumor tissues] Nakagawa S, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1549-50 **(Jpn)**

[Endoscopic injection of methotrexate bound to activated carbon particles in the treatment of gastric cancer] Ohyama T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1632-4 (Eng. Abstr.) **(Jpn)**

[Pharmacological and biochemical investigation of intracavital fluorinated pyrimidine chemotherapy] Shibata H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1613-5 (Eng. Abstr.) **(Jpn)**

[A case of acute myelocytic leukemia in relapse controlled by continuous home administration of Ara-C] Takimoto Y, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):495-8 (Eng. Abstr.) **(Jpn)**

[A case of recurrent multiple HCC after surgical resection showing regression by two TAEs using 5-FU and zinostatin stimalamer] Takiya S, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1205-8 (Eng. Abstr.) **(Jpn)**

[Assessment of serial carcinoembryonic antigen (CEA): monitor to evaluate efficacy of continuous intrahepatic chemotherapy for nonresectable liver metastases of colorectal carcinomas] Yasuno M, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1556-9 (Eng. Abstr.) **(Jpn)**

[Clinico-pathological studies on three preoperative combined treatments for rectal cancer] Yoshioka Y, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1551-4 (Eng. Abstr.) **(Jpn)**

[Successful treatment of a 74-year-old man with refractory anemia with excess of blasts in transformation (RAEB in T) by low-dose Ara-C injection] Wataya S, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jun;32(6):438-41 (Eng. Abstr.) **(Jpn)**

[Hypoplastic mixed lineage leukemia successfully treated with low-dose cytosine arabinoside] Sasaki S, et al. **Rinsho Ketsueki** 1996 Mar;37(3):233-8 (Eng. Abstr.) **(Jpn)**

[Biochemical modulation by leucovorin of the antineoplastic effect of fluorofur in disseminated colorectal cancer] Manziuk LV, et al. **Vopr Onkol** 1996;42(3):33-6 **(Rus)**

[Possible effect of administration methods on pharmacological action. Study of cytostatic therapy in advanced cancer] Larsson PA, et al. **Lakartidningen** 1995 Dec 13;92(50):4793-6 **(Swe)**

ADVERSE EFFECTS

Acute renal insufficiency due to viral infection caused by cytomegalovirus (CMV) during treatment with methotrexate. Maiche AG. **Acta Oncol** 1995;34(7):969-70

Severe complications after high-dose methotrexate treatment. Takami M, et al. **Acta Oncol** 1995;34(5):611-2

Magnetic resonance imaging and neurological evaluation after treatment with high-dose methotrexate for acute lymphocytic leukaemia in young children. Seidel H, et al. **Acta Paediatr** 1996 Apr;85(4):450-3

Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Stéphan F, et al. **Am J Med** 1995 Dec;99(6):685-8

Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II study. Steward WP, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:33-7

Safety profile of gemcitabine. Tonato M, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:27-32 (11 ref.)

High-dose methotrexate-induced bullous variant of acral erythema [letter; comment] Hellier I, et al. **Arch Dermatol** 1996 May;132(5):590-1. Comment on: Arch Dermatol 1993 Jan;129(1):43-5.

Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma. Mader RM, et al. **Arch Environ Health** 1996 Jul-Aug;51(4):310-4

Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach. Emerson SS. **Biometrics** 1995 Sep;51(3):1152-62

Methotrexate and delayed engraftment in allogeneic bone marrow transplantation [letter] Bonini A, et al. **Bone Marrow Transplant** 1995 Nov;16(5):729-30

Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Fidler P, et al. **Cancer** 1996 Feb 1;77(3):522-5

Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Widemann BC, et al. **Cancer** 1995 Aug 1;76(3):521-6

5-methyltetrahydrofolate or 5-formyltetrahydrofolic acid to modulate 5-fluorouracil's cytotoxic activity in vivo. A phase II study in patients with advanced colon cancer. Porta C, et al. **Cancer Chemother Pharmacol** 1996; 38(2):195-7

Clinical, toxicological and pharmacological aspects of gemcitabine. Guchelaar HJ, et al. **Cancer Treat Rev** 1996 Jan;22(1):15-31 (54 ref.)

Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy. Maruyama S, et al. **Dig Dis Sci** 1995 Dec;40(12):2602-7

Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Brink HM, et al. **Doc Ophthalmol** 1995; 90(1):1-6 (23 ref.)

Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta [letter] Beuzeboc P, et al. **Eur J Cancer** 1996 Feb;32A(2):369-70

Octreotide treatment of chemotherapy-induced diarrhoea [letter] Ginopoulos P, et al. **Eur J Cancer** 1996 Jan; 32A(1):182-3

5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? [letter] Lieutaud T, et al. **Eur J Cancer** 1996 Feb;32A(2):368-9

Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Sonis S, et al. **Eur J Cancer B Oral Oncol** 1995 Jul;31B(4):261-6

Tumor lysis syndrome induced by fludarabine monophosphate: a case report [letter] Nakhoul F, et al. **Eur J Haematol** 1996 Apr;56(4):254-5 (12 ref.)

Infectious complications after 2-chlorodeoxyadenosine therapy. Van Den Neste E, et al. **Eur J Haematol** 1996 Apr;56(4):235-40

Polyserositis as an unusual sign of methotrexate toxicity. Klein Z, et al. **Gynecol Oncol** 1996 Jun;61(3):446-7

A phase I study of acivicin in refractory pediatric solid tumors. A Pediatric Oncology Group study. Baruchel S, et al. **Invest New Drugs** 1995;13(3):211-6

A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer. Haas NB, et al. **Invest New Drugs** 1995;13(3):229-33

Maculopapular rashes secondary to gemcitabine injection for non-small-cell lung cancer [letter] Chen YM, et al. **J Clin Oncol** 1996 May;14(5):1743-4

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. Clarke SJ, et al. **J Clin Oncol** 1996 May;14(5):1495-503

Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy. Tiersten A, et al. **J Clin Oncol** 1996 Jul; 14(7):2043-6

Transient Ara-C leukoencephalopathy: MR findings. Patel AG, et al. **J Comput Assist Tomogr** 1996 Jan-Feb; 20(1):161-2

Fatal bone marrow necrosis following fludarabine administration in a patient with indolent lymphoma. Aboulafia DM, et al. **Leuk Lymphoma** 1995 Sep; 19(1-2):181-4

Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics. Berkovitch M, et al. **Med Pediatr Oncol** 1996 Feb; 26(2):85-9

Cryotherapy reduces fluorouracil-related side effects. McAtee N, et al. **Oncol Nurs Forum** 1995 Sep;22(8):1287-8

Fatal hepatotoxicity associated with 6-mercaptopurine therapy [letter] Laidlaw ST, et al. **Postgrad Med J** 1995 Oct;71(840):639

Have enteric infections a role in 5-fluorouracil-associated diarrhea? Cascinu S, et al. **Support Care Cancer** 1995 Sep; 3(5):322-3

Methotrexate-induced leukoencephalopathy. A case report. Ilhan I, et al. **Turk J Pediatr** 1995 Jul-Sep;37(3):275-8

[Cerebellar toxicity of cytosine-arabinoside in a young man following cerebral anoxia (letter)] Beaudreuil J, et al. **Ann Med Interne (Paris)** 1995;146(8):597-8 **(Fre)**

[Radiological case of the month. Leukoencephalopathy caused by methotrexate in a child treated for acute lymphoblastic leukemia] Gnansounou M, et al. **Arch Pediatr** 1996 Jan;3(1):85-7 **(Fre)**

[Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency] Beuzeboc P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):324-7 (24 ref.) (Eng. Abstr.) **(Fre)**

[5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?] Maurer U, et al. **Strahlenther Onkol** 1996 May;172(5):257-9 (Eng. Abstr.) **(Ger)**

ANALYSIS

Quantification of 5-fluorouracil incorporation into RNA of human and murine tumors as measured with a sensitive gas chromatography-mass spectrometry assay. Peters GJ, et al. **Anal Biochem** 1995 Oct 10;231(1):157-63

Measurement of 5-fluorouracil in scalp hair: a possible index of patient compliance with oral adjuvant chemotherapy. Uematsu T, et al. **Eur J Clin Pharmacol** 1996;50(1-2):109-13

BLOOD

Simple high-performance liquid chromatographic method for the quantitation of 5-fluorouracil in human plasma. Compagnon P, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):380-3

[Rhythmic component of twelve hours] Metzger G, et al. **Pathol Biol (Paris)** 1996 Mar;44(3):179-82 (Eng. Abstr.) **(Fre)**

[Methotrexate (MTX)] Yamada M. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:1053-5 (8 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Synthesis and preliminary in vitro screening of lipophilic alpha, gamma-bis(amides) as potential prodrugs of methotrexate. Pignatello R, et al. **Anticancer Drug Des** 1996 Apr;11(3):253-64

Synthesis and biological activity of O-alkyl-3-N-aminoacyloxymethyl-5-fluoro-2'-deoxyuridine derivatives. Harada N, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun;44(6):1196-201

Synthesis and antitumor activities of 5'-O-aminoacyl-3'-O-benzyl derivatives of 2'-deoxy-5-fluorouridine and related compounds. Uemura A, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):150-5

Chemical synthesis of benzamide adenine dinucleotide: inhibition of inosine monophosphate dehydrogenase (types I and II). Zatorski A, et al. **J Med Chem** 1996 Jun 7; 39(12):2422-6

Synthesis and antitumor activity of 5-fluorouracil derivatives. Ozaki S. **Med Res Rev** 1996 Jan;16(1):51-86 (55 ref.)

CHEMISTRY

Synthesis and evaluation of potential N pi and N sigma metal chelation sites within the beta-hydroxy-L-histidine subunit of bleomycin A2: functional characterization of imidazole N pi metal complexation. Boger DL, et al. **Bioorg Med Chem** 1996 Feb;4(2):195-207

Ab initio quantum mechanical and X-ray crystallographic studies of gemcitabine and 2'-deoxy cytosine. Hausheer FH, et al. **Comput Chem** 1996 Aug;20(4):459-67

Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs. Martel P, et al. **J Pharm Biomed Anal** 1996 Feb;14(4):395-9

The release of 5-fluorouracil from a swellable matrix of a triblock copolymer of epsilon-caprolactone and ethylene oxide. Martini LG, et al. **Pharm Res** 1995 Nov; 12(11):1786-90

[Stability of 5-fluorouracil solutions according to different parameters] Barberi-Heyob M, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):1025-31 (Eng. Abstr.) **(Fre)**

DIAGNOSTIC USE

Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis. Dolbeare F. **Histochem J** 1995 Dec; 27(12):923-64 (468 ref.)

[Use of rhodamine 123 for the detection of multidrug resistance] Canitrot Y, et al. **Bull Cancer (Paris)** 1995 Sep; 82(9):687-97 (86 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Preclinical characteristics of gemcitabine. Plunkett W, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:7-13 (33 ref.)

Enzymatic elimination of fluoride from alpha-fluoro-beta-alanine. Porter DJ, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1475-84

Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro. Sen S, et al. **Br J Cancer** 1996 Feb;73(4):525-30

Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Ludescher C, et al. **Br J Haematol** 1995 Nov;91(3):652-7

Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate

carcinoma DU-145 cells. Grove KL, et al. **Cancer Res** 1996 Sep 15;56(18):4187-91

Fluoropyrimidine catabolism. Diasio RB, et al. **Cancer Treat Res** 1995;78:71-93 (103 ref.)

Detection and identification of 6-methylmercapto-8-hydoxypurine, a major metabolite of 6-mercaptopurine, in plasma during intravenous administration. Keuzenkamp-Jansen CW, et al. **Clin Chem** 1996 Mar;42(3):380-6

Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Lu Z, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):512-22

Kinetics and metabolism of 2-chloro-2'-deoxyadenosine and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine in the isolated perfused rat liver. Albertioni F, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul-Sep; 20(3):225-32

Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. Brigle KE, et al. **J Biol Chem** 1995 Sep 29;270(39):22974-9

The binding of 5-fluorouracil to native and modified human serum albumin: UV, CD, and 1H and 19F NMR investigation. Bertucci C, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1087-93

Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. Noordhuis P, et al. **Leuk Res** 1996 Feb;20(2):127-34

Biology and pharmacology of thiopurines. Aarbakke J. **Pediatr Hematol Oncol** 1995 Sep-Oct;12(5):511-9

Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Plunkett W, et al. **Semin Oncol** 1995 Aug; 22(4 Suppl 11):3-10 (26 ref.)

PHARMACOKINETICS

Intraocular levels of methotrexate after intravenous administration. de Smet MD, et al. **Am J Ophthalmol** 1996 Apr;121(4):442-4

Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines. Utz I, et al. **Anticancer Res** 1996 Jan-Feb;16(1):289-96

2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerations. Liliemark J, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):7-10 (19 ref.)

Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities. Barberi-Heyob M, et al. **Cancer Chemother Pharmacol** 1995;37(1-2):110-6

Bioavailability of subcutaneous 5-fluorouracil: a case report. Eatock MM, et al. **Cancer Chemother Pharmacol** 1996; 38(1):110-2

Determination of extracellular methotrexate tissue levels by microdialysis in a rat model. Ekstrøm PO, et al. **Cancer Chemother Pharmacol** 1996;37(5):394-400

Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Innocenti F, et al. **Cancer Chemother Pharmacol** 1996;37(5):409-14

5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo. Tausch-Treml R, et al. **Cancer Chemother Pharmacol** 1996;37(3):259-65

A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. Meropol NJ, et al. **Invest New Drugs** 1995;13(2):149-55

Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug. Takemura Y, et al. **J Cancer Res Clin Oncol** 1996; 122(2):109-17

Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats. Chio CC, et al. **J Neurooncol** 1995;25(2):89-95

Targeting 6-thioguanine to the kidney with S-(guanin-6-yl)-L-cysteine. Elfarra AA, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1298-304

Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid. b1p6uller J, et al. **Med Oncol** 1995 Mar;12(1):47-53

Slow penetration of [3H] tiazofurin into guinea pig brain by a saturable mechanism. Redzic ZB, et al. **Methods Find Exp Clin Pharmacol** 1995 Jul-Aug; 17(6):407-14

Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells. Chen G, et al. **Mol Pharmacol** 1995 Oct;48(4):758-65

Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure. Zoubek A, et al. **Pediatr Hematol Oncol** 1995 Sep-Oct;12(5):471-7

Influence of counter ions on the skin permeation of methotrexate from water--oil microemulsions. Trotta M, et al. **Pharm Acta Helv** 1996 Jul;71(2):135-40

Autoradiographic imaging of the distribution of 5-fluorouracil through cervical tissue following in vitro surface application of a bioadhesive cervical patch. Woolfson AD, et al. **Pharm Res** 1995 May;12(5):676-81

Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. Marchbanks K, et al. **Pharmacotherapy** 1995 Jul-Aug;15(4):451-7

Dosage adjustment of high-dose methotrexate using Bayesian estimation: a comparative study of two different concentrations at the end of 8-h infusions. Pignon T, et al. **Ther Drug Monit** 1995 Oct;17(5):471-8

PHARMACOLOGY

Thiopurine induced disturbance of DNA methylation in human malignant cells. De Abreu R, et al. **Adv Enzyme Regul** 1995;35:251-63

Neutrophil and monocyte phagocytic functions in patients with colorectal adenocarcinoma during fluorouracil therapy. Lukač J, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2805-9

Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210. Góra-Tybor J, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):39-42

Discovery, mechanism and expected clinical significance of selective cytotoxicity of 2-chloro-2'-deoxyadenosine (2-CdA). Grieb P. **Arch Immunol Ther Exp (Warsz)** 1994; 42(1):1-5 (34 ref.)

Apoptotic death of lymphocytes upon treatment with 2-chloro-2'-deoxyadenosine (2-CdA). Lassota P, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):17-23

Alteration of morphogenetic cell interactions by 1-beta-D-arabinofuranosylcytosine in Bufo arenarum embryo. Peralta MA, et al. **Biocell** 1995 Aug;19(2):159-73

Activation of cyclin E-dependent kinase by DNA-damage signals during apoptosis. Dou QP, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):771-80

Antitumour effects of pure diastereoisomers of 5-formyltetrahydrofolate in hepatic transplants of a rodent colon carcinoma model. Carlsson G, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1347-51

Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation. Hudgins WR, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1273-9

Suppression of plasma estradiol and progesterone concentrations by buthionine sulfoximine in female rats. Kang YJ, et al. **Biochem Pharmacol** 1996 Feb 23; 51(4):567-70

Cloning and characterization of full-length cDNAs coding for the DNA topoisomerase II beta from Chinese hamster lung cells sensitive and resistant 9-OH-ellipticine. Dereuddre S, et al. **Biochim Biophys Acta** 1995 Nov 7; 1264(2):178-82

Augmentation of tumor immunity by 6-mercaptopurine (6-MP) and its analogs in the double grafted tumor system in mice. Kashida T, et al. **Biol Pharm Bull** 1995 Nov; 18(11):1492-7

Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Datta R, et al. **Blood** 1996 Sep 15;88(6):1936-43

Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Gandhi V, et al. **Blood** 1996 Jan 1;87(1):256-64

Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis. Pickard M, et al. **Br J Cancer** 1995 Dec;72(6):1389-96

Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Sliutz G, et al. **Br J Cancer** 1996 Jul;74(2):172-7

Antimetabolites. Johnston PG, et al. **Cancer Chemother Biol Response Modif** 1996;16:1-27 (77 ref.)

Cancer chemotherapy and biological response modifiers annual 16. Introduction. Pinedo HM, et al. **Cancer Chemother Biol Response Modif** 1996;16:xvii-xviii (77 ref.)

Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase. Haaz MC, et al. **Cancer Chemother Pharmacol** 1996;38(1):52-8

Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside. Hageboutros A, et al. **Cancer Chemother Pharmacol** 1996;37(3):229-34

Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937. Horber DH, et al. **Cancer Chemother Pharmacol** 1995;36(6):483-92

Dependence of fluorodeoxyuridine-induced cytotoxicity and megabase DNA fragment formation on S phase progression in HT29 cells. Tang HY, et al. **Cancer Chemother Pharmacol** 1996;37(5):486-90

A novel in vitro model system for studying the action of ara-C. Wills P, et al. **Cancer Chemother Pharmacol** 1996; 38(4):366-72

Investigations on the mechanisms of methotrexate resistance in a cisplatin-resistant L1210 murine leukemia cell subline. Wroblewski DH, et al. **Cancer Chemother Pharmacol** 1996; 37(4):337-42

Title aggregation patterns of argyrophilic nucleolar organizer regions induced by 5-fluorouracil in the nuclei of MCF-7 human breast cancer cells. Nishihara T, et al. **Cancer Lett** 1996 Feb 27;100(1-2):95-8

The effects of 5-fluorouracil and doxorubicin on expression of human immunodeficiency virus type 1 long terminal repeat. Panozzo J, et al. **Cancer Lett** 1996 Aug 2; 105(2):217-23

Separate pathways for p53 induction by ionizing radiation and N-(phosphonoacetyl)-L-aspartate. Chen CY, et al. **Cancer Res** 1996 Aug 15;56(16):3659-62

Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Chen ZH, et al. **Cancer Res** 1996 Mar 1;56(5):1083-90

Attenuation of interleukin 2-induced pulmonary vascular leak syndrome by low doses of oral methotrexate. DeJoy SQ, et al. **Cancer Res** 1995 Nov 1;55(21):4929-35

Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Hapke DM, et al. **Cancer Res** 1996 May 15;56(10):2343-7

5-Fluorouracil suppresses nitric oxide biosynthesis in colon carcinoma cells. Jin Y, et al. **Cancer Res** 1996 May 1; 56(9):1978-82

Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Xie KC, et al. **Cancer Res** 1996 Jul 1;56(13):3030-7

Aspects of one-carbon folate cycling related to fluoropyrimidine and antifolate therapy. Spears CP, et al. **Cancer Treat Res** 1995;78:115-34 (128 ref.)

A comparison of the propensity for gene amplification between near-tetraploid and near-diploid V79 clones resistant to 150 nM methotrexate. Hashimoto MW, et al. **Carcinogenesis** 1996 Mar;17(3):389-94

Synthesis and antitumor activities of 5'-O-aminoacyl-3'-O-benzyl derivatives of 2'-deoxy-5-fluorouridine and related compounds. Uemura A, et al. **Chem Pharm Bull (Tokyo)** 1996 Jan;44(1):150-5

Specific induction of uncoiling in NORs of human acrocentric chromosomes by 5-azacytidine and 5-azadeoxicytidine. Malheiro I, et al. **Cytobios** 1995; 83(332):17-23

The role of interferon-alpha as a modulator of fluorouracil and leucovorin. Grem JL, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1316-20 (29 ref.)

Role of leucovorin dosing and administration schedule. Jolivet J. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1311-5 (52 ref.)

Thymidylate synthase and drug resistance. Peters GJ, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1299-305 (41 ref.)

The antimetabolite Tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells. Timár J, et al. **Eur J Cancer** 1996 Jan;32A(1):152-9

A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Linke SP, et al. **Genes Dev** 1996 Apr 15; 10(8):934-47

The thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells. Beck C, et al. **Hum Gene Ther** 1995 Dec;6(12):1525-30

Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. Shack S, et al. **Int J Cancer** 1995 Sep 27;63(1):124-9

The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells. Takemura Y, et al. **Int J Cancer** 1996 Mar 28;66(1):29-36

On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP). Versantvoort CH, et al. **Int J Cancer** 1995 Dec 11;63(6):855-62

Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression. Lawrence TS, et al. **Int J Radiat Biol** 1996 Sep;70(3):273-80

PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells. Yang JL, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 15;34(5):1073-9

A single point mutation in CTP synthetase of Chlamydia trachomatis confers resistance to cyclopentenyl cytosine. Wylie JL, et al. **J Biol Chem** 1996 Jun 28;271(26):15393-400

Accumulation of cells at G2/M stage by low dose-rate irradiation renders the cell population more susceptible to the subsequent induction of 6-thioguanine-resistant mutations by 252Cf fission neutrons. Tauchi H, et al. **J Radiat Res (Tokyo)** 1996 Mar;37(1):49-57

Phenylacetate is an inhibitor of prostatic growth and development in organ culture. Lipschutz JH, et al. **J Urol** 1996 May;155(5):1762-70

Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Ohashi M, et al. **Jpn J Cancer Res** 1995 Sep;86(9):819-27

Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs. Takemura Y, et al. **Jpn J Cancer Res** 1996 Jul;87(7):773-80

Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Bouffard DY, et al. **Leuk Res** 1995 Nov;19(11):849-56

Inhibitory effect of a nucleoside analog, acyclovir, on leukemia cells. Nishimaki J, et al. **Leuk Res** 1996 May;

20(5):415–20

Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. Noordhuis P, et al. **Leuk Res** 1996 Feb;20(2):127–34

Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement. Santini V, et al. **Leuk Res** 1996 Jan;20(1):37–45

Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2. Hedley DW, et al. **Leukemia** 1996 Jul;10(7):1143–9

Synthesis and antitumor activity of 5-fluorouracil derivatives. Ozaki S. **Med Res Rev** 1996 Jan;16(1):51–86 (55 ref.)

Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Danesi R, et al. **Mol Pharmacol** 1996 Jun;49(6):972–9

Do human lymphocytes exposed to the fallout of the Chernobyl accident exhibit an adaptive response? 2. Challenge with bleomycin. Tedeschi B, et al. **Mutat Res** 1995 Nov;332(1–2):39–44

Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Manome Y, et al. **Nat Med** 1996 May;2(5):567–73

In vitro antileukemic activity and chemical transformation of the 5'-chloro-5'-deoxy derivative of cyclocytidine. Stankovičová M, et al. **Neoplasma** 1995;42(5):255–8

Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells. Kisara S, et al. **Oncol Res** 1995; 7(3–4):191–200

Contrasting patterns of DNA fragmentation induced by thymidylate synthase inhibitors, ZD1694 and AG-331. Panadero A, et al. **Oncol Res** 1995;7(2):73–81

Effect of methotrexate on the intracellular phosphoribosyl pyrophosphate level and glucose transport of Ehrlich ascites tumor cells in vitro. Fung KP, et al. **Oncology** 1996 Jan–Feb;53(1):27–30

Methotrexate does not interfere with an appetitive Pavlovian conditioning task in Sprague-Dawley rats. Stock HS, et al. **Physiol Behav** 1995 Nov;58(5):969–73

Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Cronauer MV, et al. **Prostate** 1996 Mar;28(3):172–81

Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Esquenet M, et al. **Prostate** 1996 Mar;28(3):182–94

Effect of bromodeoxyuridine on radiation-induced DNA damage and repair based on DNA fragment size using pulsed-field gel electrophoresis. Lawrence TS, et al. **Radiat Res** 1995 Dec;144(3):282–7

Effects of 5-azacytidine on physiological differentiation of Streptomyces antibioticus. Novella IS, et al. **Res Microbiol** 1995 Nov-Dec;146(9):721–8

Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Swann PF, et al. **Science** 1996 Aug 23;273(5278):1109–11

Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Csoka K, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):47–53

Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Gandhi V, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):61–7

Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Heinemann V, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):11–8

Interaction between cisplatin and gemcitabine in vitro and in vivo. Peters GJ, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):72–9

Consequences of 2',2'-difluorodeoxycytidine (gemcitabine) on replicative DNA synthesis in intact HL-60 cells. Ross DD, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):26–34

Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780. Ruiz van Haperen VW, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):35–41

Assessing sensitivity in suspension to cytosine arabinoside: statistical analysis, associations with clinical outcome and experimental design. Minkin S, et al. **Stat Med** 1995 May 15–30;14(9–10):1081–95; discussion 1097

Comparative in vitro and in vivo study of a nitroxyl derivative of 5-fluorouracil (magnizil) on human gastrointestinal tumors. Seminara P, et al. **Tumori** 1995 Jul–Aug;81(4):278–82

[The ribonucleotide reductase enzyme as a target for enzyme-directed chemotherapy effects of trimidox (3,4,5-trihydroxybenzohydroxamidoxim), a new inhibitor of ribonucleotide reductases] Findenig G, et al. **Wien Klin Wochenschr** 1995;107(22):694–7 (28 ref.) (Eng. Abstr.) **(Ger)**

[The effect of 5-fluorouracil on the clonogenic hematopoietic cells (CFU-S) of embryonic and sexually mature mice] Domaratskaia EI, et al. **Izv Akad Nauk Ser Biol** 1995 Jul–Aug;(4):398–402 (Eng. Abstr.) **(Rus)**

POISONING

Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2. O'Marcaigh AS, et al. **Mayo Clin Proc** 1996 Feb;71(2):161–5

THERAPEUTIC USE

Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro. Behnam Motlagh P, et al. **Acta Oncol** 1995;34(6):871–5

A pilot study of concomitant protracted venous infusion 5-fluorouracil and hyperfractionated radiotherapy in rectal tumors. Arcangeli G, et al. **Am J Clin Oncol** 1995 Oct; 18(5):369–75

Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association. Atkins JN, et al. **Am J Clin Oncol** 1996 Feb; 19(1):23–5

Efficacy of the association of folinic acid and 5-fluorouracil alone versus folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma. Colucci G, et al. **Am J Clin Oncol** 1995 Dec; 18(6):519–24

A phase II trial of 5-fluorouracil and l-leucovorin in patients with metastatic colorectal cancer. Erlichman C, et al. **Am J Clin Oncol** 1996 Feb;19(1):26–31

5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Stuart K, et al. **Am J Clin Oncol** 1996 Apr; 19(2):136–9

Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. Goodman ER, et al. **Am Surg** 1996 Jun; 62(6):435–42

Gemcitabine in the treatment of non-small-cell lung cancer. Burkes RL, et al. **Ann Oncol** 1995;6 Suppl 3:S57–60

'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group. Cunningham D, et al. **Ann Oncol** 1996 Feb;7(2):179–82

A phase II study of Tomudex in relapsed epithelial ovarian cancer. Gore ME, et al. **Ann Oncol** 1995 Sep;6(7):724–5

Preoperative adjuvant radiation with chemotherapy for rectal cancer: its impact on stage of disease and the role of endorectal ultrasound. Bernini A, et al. **Ann Surg Oncol** 1996 Mar;3(2):131–5

Gemcitabine hydrochloride: combination of activity and tolerability. Proceedings of a symposium. Jerusalem, Israel, November 14, 1993. **Anticancer Drugs** 1995 Dec;6 Suppl 6:5–65

Current chemotherapy of advanced non-small cell lung cancer. Abratt RP. **Anticancer Drugs** 1995 Dec;6 Suppl 6:15–8 (29 ref.)

Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer. Koch P, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:49–54

Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Lund B, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:61–2

Gemcitabine in advanced breast cancer. Possinger K. **Anticancer Drugs** 1995 Dec;6 Suppl 6:55–9

Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. Shepherd FA. **Anticancer Drugs** 1995 Dec;6 Suppl 6:19–25 (13 ref.)

Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II study. Steward WP, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:33–7

Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Thatcher N, et al. **Anticancer Drugs** 1995 Dec; 6 Suppl 6:39–48 (68 ref.)

A clinical nude mouse metastatic model for highly malignant human pancreatic cancer. An Z, et al. **Anticancer Res** 1996 Mar-Apr;16(2):627–31

Successful treatment of Sézary syndrome with lymphomatous transformation to large cell lymphoma with fludarabine phosphate [letter] Nikko AP, et al. **Arch Dermatol** 1996 Aug;132(8):978–9

2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerations. Liliemark J, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):7–10 (19 ref.)

Treatment of patients with hairy cell leukemia with 2-chloro-2'-deoxyadenosine (2-CdA). Robak T, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):25–9

Inefficacy of low-dose intraoperative fluorouracil in the treatment of primary pterygium [letter] Maldonado MJ, et al. **Arch Ophthalmol** 1995 Nov;113(11):1356–7

Cytarabine therapy for refractory cutaneous lupus. Yung RL, et al. **Arthritis Rheum** 1995 Sep;38(9):1341–3

Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia. Keuzenkamp-Jansen CW, et al. **Biochem Pharmacol** 1996 May 3;51(9):1165–71

On plotting renovated samples. Smith PJ. **Biometrics** 1995 Sep;51(3):1147–51

Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Kuzel TM, et al. **Blood** 1996 Feb 1;87(3):906–11

2-Chlorodeoxyadenosine as first-line treatment in bronchus-associated lymphoid tissue lymphoma [letter] Neumeister P, et al. **Blood** 1996 Apr 15;87(8):3526

A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Anderson H, et al. **Br J Cancer** 1996 Aug;74(3):460–2

Phase II study of gemcitabine in patients with advanced pancreatic cancer. Carmichael J, et al. **Br J Cancer** 1996 Jan;73(1):101–5

A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Smith I, et al. **Br J Cancer** 1996 Aug; 74(3):479–81

Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. Marsh RD, et al. **Cancer** 1996 Jul 15; 78(2):217–25

Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma. Matei D, et al. **Cancer** 1995 Oct 15;76(8):1330–5

Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Moore M. **Cancer** 1996 Aug 1;78(3 Suppl):633–8 (21 ref.)

Bleomycin. Lazo JS, et al. **Cancer Chemother Biol Response Modif** 1996;16:39–47 (55 ref.)

Cancers of the large bowel and hepatobiliary tract. Vaughn DJ, et al. **Cancer Chemother Biol Response Modif** 1996; 16:495–510 (63 ref.)

Gemcitabine: a phase II study in patients with advanced renal cancer. De Mulder PH, et al. **Cancer Chemother Pharmacol** 1996;37(5):491–5

Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemias. Waud WR, et al. **Cancer Chemother Pharmacol** 1996;38(2):178–80

6-Mercaptopurine dose escalation and its effect on drug tolerance in childhood lymphoblastic leukaemia. Welch JC, et al. **Cancer Chemother Pharmacol** 1996;38(1):113–6

Interleukin-3 plus low-dose cytosine arabinoside for advanced myelodysplasia: a pilot study. EORTC Leukemia Group. Gerhartz HH, et al. **Cancer Invest** 1996; 14(4):299–306

Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. Alati T, et al. **Cancer Res** 1996 May 15;56(10):331–5

Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Tanaka T, et al. **Cancer Res** 1996 Mar 15;56(6):1341–5

Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Trinh QT, et al. **Cancer Res** 1995 Nov 1;55(21):4808–12

Clinical, toxicological and pharmacological aspects of gemcitabine. Guchelaar HJ, et al. **Cancer Treat Rev** 1996 Jan;22(1):15–31 (54 ref.)

Adjuvant radiation therapy for colon cancer. Minsky BD. **Cancer Treat Rev** 1995 Sep;21(5):407–14 (18 ref.)

Methotrexate eluted from bone cement: effect on giant cell tumor of bone in vitro. Kirchen ME, et al. **Clin Orthop** 1996 Jul;(328):294–303

'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. Cunningham D, et al. **Eur J Cancer** 1995 Nov;31A(12):1945–54

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Gatzemeier U, et al. **Eur J Cancer** 1996 Feb;32A(2):243–8

Thymidylate synthase inhibition, a dead end? [editorial] Herrmann R. **Eur J Cancer** 1995 Nov;31A(12):1919–20 (7 ref.)

ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Jackman AL, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1277–82 (30 ref.)

Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer. Olver IN, et al. **Eur J Cancer** 1996 Feb;32A(2):249–54

A pilot study of a new therapeutic approach in the treatment of locally advanced stages of rectal cancer: neoadjuvant radiation, chemotherapy and regional hyperthermia. Riess H, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1356–60

Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma. Scheithauer W, et al. **Eur J Cancer** 1995 Nov; 31A(12):1981–6

p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Brett MC, et al. **Eur J Surg Oncol** 1996 Apr;22(2):182–5

Management of low-risk gestational trophoblastic tumors with etoposide (VP16) in patients resistant to methotrexate. Mangili G, et al. **Gynecol Oncol** 1996 May;61(2):218–20

Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin. Préfontaine M, et al. **Gynecol Oncol** 1996 May;61(2):249–52

p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Benhattar J, et al. **Int J Cancer** 1996 Jun 21;69(3):190–2

Chronic ectopic pregnancy after clinically successful methotrexate treatment of ectopic pregnancy. Dunn RC,

et al. **Int J Gynaecol Obstet** 1995 Dec;51(3):247–9

Enhancement of the effectiveness of methotrexate for the treatment of solid tumours by application of local hyperthermia. Schopman EM, et al. **Int J Hyperthermia** 1995 Jul–Aug;11(4):561–73

A phase I study of combined radiation therapy with 5–fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma. Hsue V, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):445–50

Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30–positive lymphoproliferative disorders. Vonderheid EC, et al. **J Am Acad Dermatol** 1996 Mar;34(3):470–81

Low–dose methotrexate to treat erythrodermic cutaneous T–cell lymphoma: results in twenty–nine patients. Zackheim HS, et al. **J Am Acad Dermatol** 1996 Apr; 34(4):626–31

Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. Newmark HL, et al. **J Cell Biochem Suppl** 1995;22:247–53 (45 ref.)

Advanced breast cancer: a phase II trial with gemcitabine. Carmichael J, et al. **J Clin Oncol** 1995 Nov;13(11):2731–6

Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil [see comments] Findlay M, et al. **J Clin Oncol** 1996 Mar;14(3):700–8. Comment in: J Clin Oncol 1996 Mar;14(3):691–6.

Phase II trial of fludarabine monophosphate as first–line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. Solal–Céligny P, et al. **J Clin Oncol** 1996 Feb;14(2):514–9

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. Zalcberg JR, et al. **J Clin Oncol** 1996 Mar; 14(3):716–21

Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma [see comments] Cao S, et al. **J Natl Cancer Inst** 1996 Apr 3;88(7):430–6. Comment in: J Natl Cancer Inst 1996 Apr 3;88(7):393–5.

Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule? [editorial; comment] Doroshow JH. **J Natl Cancer Inst** 1996 Apr 3; 88(7):393–5 (24 ref.). Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):430–6.

Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium–99m–labeled gem–bisphosphonate conjugate of methotrexate. Hosain F, et al. **J Nucl Med** 1996 Jan;37(1):105–7

Metabolism of intravenously administered high–dose 6–mercaptopurine with and without allopurinol treatment in patients with non–hodgkin lymphoma. Keuzenkamp–Jansen CW, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):145–50

Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: treatment with low–dose arabinosyl cytosine [see comments] Tchernia G, et al. **J Pediatr Hematol Oncol** 1996 Feb;18(1):59–62. Comment in: J Pediatr Hematol Oncol 1996 Feb;18(1):10–2.

Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin–2, interferon–alpha and 5–fluorouracil [see comments] Hofmockel G, et al. **J Urol** 1996 Jul;156(1):18–21. Comment in: J Urol 1996 Jul;156(1):40.

Fludarabine in chronic leukaemia [comment] Astrow AB. **Lancet** 1996 May 25;347(9013):1420–1. Comment on: Lancet 1996 May 25;347(9013):1432–8.

Fludarabine monophosphate in refractory B–chronic lymphocytic leukemia: maintenance may be significant to sustain response. Angelopoulou MA, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):321–4

Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low–grade lymphomas. Fenchel K, et al. **Leuk Lymphoma** 1995 Aug;18(5–6):485–92

Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Seymour JF, et al. **Leuk Lymphoma** 1995 Aug;18(5–6):493–6

Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte–macrophage colony–stimulating factor. (GM–CSF). Economopoulos T, et al. **Leuk Res** 1996 May; 20(5):385–90

High–dose ara–C in older adults with acute leukemia. Herzig RH. **Leukemia** 1996 Apr;10 Suppl 1:S10–1

Postremission therapy of acute myeloid leukemia in older adults. Schiller GJ. **Leukemia** 1996 Apr;10 Suppl 1:S18–20 (19 ref.)

Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate. Spencer HT, et al. **Leukemia** 1996 Mar;10(3):439–46

Gemcitabine in non–small cell lung cancer. Sørensen JB. **Lung Cancer** 1995 Apr;12 Suppl 1:S173–5 (8 ref.)

Simultaneous 3D NMR spectroscopy of fluorine and phosphorus in human liver during 5–fluorouracil chemotherapy. Li CW, et al. **Magn Reson Med** 1996 Jun; 35(6):841–7

Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin–based chemotherapy. Fountzilas G, et al. **Med Pediatr Oncol** 1996 May;26(5):305–17 (45 ref.)

All–trans retinoic acid and short–time, high–dose cytarabine in two children with acute promyelocytic leukemia. Schmitt K, et al. **Med Pediatr Oncol** 1996 Apr;26(4):254–7

5–Fluorouracil and d,l–leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Porta C, et al. **Oncology** 1995 Nov–Dec;52(6):487–91

ODAC recommends full approval for Gemzar for pancreatic cancer [news] **Oncology (Huntingt)** 1995 Sep;9(9):799–800

Gemcitabine—status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog. Symposium proceedings. Amsterdam, The Netherlands, March 15, 1994. **Semin Oncol** 1995 Aug;22(4 Suppl 11):1–82

Clinical development of new fluoropyrimidines: a major improvement in colorectal cancer treatment? Colleoni M, et al. **Tumori** 1995 Sep–Oct;81(5):303–7 (44 ref.)

[Contribution of an induction treatment in the surgical treatment of locally advanced non–small–cell cancers] Massard G, et al. **Ann Chir** 1995;49(9):841–8 (Eng. Abstr.) (Fre)

[Association of 5–FU, CDDP and hypofractionated radiotherapy in recurrences of subtentorial astrocytomas and malignant gliomas in adults] Bolla M, et al. **Bull Cancer Radiother** 1990;77(1):53–9 (Eng. Abstr.) (Fre)

[Severe myalgias: an unusual undesirable effect of levamisole combined with 5–fluorouracil (letter)] Buecher B, et al. **Gastroenterol Clin Biol** 1996;20(4):407–8 (Fre)

[Use of 5–fluorouracil in digestive cancer] Setiz JF, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B80–88 (68 ref.) (Fre)

[LY188011 phase I study. Research Group of Gemcitabine (LY188011)] Taguchi T, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1011–8 (Eng. Abstr.) (Jpn)

[Nitroxyl radical Tempol as a modulator of toxic and antineoplastic effect of 6–mercaptopurine] Konovalova NP, et al. **Vopr Onkol** 1996;42(3):57–63 (Eng. Abstr.) (Rus)

[Factors of the therapeutic effectiveness of 5–fluorouracil] Manziuk LV, et al. **Vopr Onkol** 1996;42(2):31–6 (33 ref.) (Rus)

TOXICITY

Preclinical characteristics of gemcitabine. Plunkett W, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:7–13 (33 ref.)

Combined effect of 5–fluorouracil and recombinant tumor necrosis factor against human gastric carcinoma cell lines. Li Y, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1771–4

Effect of oral chemotherapy on the mitochondrial size of mouse intestinal cells. Bessler H, et al. **Cancer Chemother Pharmacol** 1996;38(1):35–8

Functional aspects of membrane folate receptors in human breast cancer cells with transport–related resistance to methotrexate. Pinard MF, et al. **Cancer Chemother Pharmacol** 1996;38(3):281–8

Protective effect of an acidic glycoprotein obtained from culture of Chlorella vulgaris against myelosuppression by 5–fluorouracil. Konishi F, et al. **Cancer Immunol Immunother** 1996 Jun;42(5):268–74

Lisofylline inhibits transforming growth factor beta release and enhances trilineage hematopoietic recovery after 5–fluorouracil treatment in mice. Clarke E, et al. **Cancer Res** 1996 Jan 1;56(1):105–12

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5–fluorouracil toxicity. Wei X, et al. **J Clin Invest** 1996 Aug 1;98(3):610–5

Comparison of chemically induced DNA breakage in cellular and subcellular systems using the comet assay. Kasamatsu T, et al. **Mutat Res** 1996 Jul 10;369(1–2):1–6

Inhibitors of thymine nucleotide biosynthesis: antimetabolites that provoke genetic change via primary non–DNA targets. Kunz BA. **Mutat Res** 1996 Aug 17;355(1–2):129–40 (135 ref.)

Interaction of photodynamically induced cell killing and dark cytotoxicity of rhodamine 123. VanDerWal J, et al. **Photochem Photobiol** 1995 Oct;62(4):757–63

Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Li W, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24; 92(22):10436–40

Contrasting mechanisms of the myeloprotective effects of interleukin–1 against ionizing radiation and cytotoxic 5–fluorouracil. Neta R, et al. **Radiat Res** 1996 May; 145(5):624–31

Neonatal mouse hip joint and hindlimb anomalies induced by prenatal exposure to Ara–C. Chiba K, et al. **Reprod Toxicol** 1996 May–Jun;10(3):215–9

The influence of 5–fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Cwikiel M, et al. **Scanning Microsc** 1995 Jun;9(2):561–76

Toxicity study of hepatic artery infusion chemotherapy with massive dose FUDR in rats. Zeng ZS, et al. **Surg Oncol** 1995 Jun;4(3):147–55

[Nitroxyl radical Tempol as a modulator of toxic and antineoplastic effect of 6–mercaptopurine] Konovalova NP, et al. **Vopr Onkol** 1996;42(3):57–63 (Eng. Abstr.) (Rus)

ANTIMITOTIC AGENTS see **ANTINEOPLASTIC AGENTS**

ANTIMONY

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus–infected patients. Ribera E, et al. **Am J Med** 1996 May;100(5):496–501

ADMINISTRATION & DOSAGE

Treatment of post–kala–azar dermal leishmaniasis [letter; comment] Singh S, et al. **Int J Dermatol** 1995 Sep; 34(9):668–9. Comment on: Int J Dermatol 1994 Mar;33(3):153–6.

Intrarectal glucantime. Marsden PD. **Rev Soc Bras Med Trop** 1996 May–Jun;29(3):295

ADVERSE EFFECTS

Do microbiota cause emission of stibine from cot mattresses? [letter; comment] [see comments] Thompson M, et al. **Lancet** 1995 Dec 9;346(8989):1557–8. Comment on: Lancet 1995 Apr 22;345(8956):1045. Comment in: Lancet 1995 Dec 9;346(8989):1503. Comment in: Lancet 1996 Mar 2;347(9001):616.

ANALYSIS

Multi–element detection of organometals by supercritical fluid chromatography with inductively coupled plasma mass spectrometric detection. Kumar UT, et al. **J Chromatogr Sci** 1995 Nov;33(11):606–10

Antimony detected in necropsy tissues may derive from contaminated formalin [letter] Byard RW, et al. **Lancet** 1995 Dec 16;346(8990):1633–4

Antimony, cot mattresses, and SIDS [letter; comment] Taylor A. **Lancet** 1996 Mar 2;347(9001):616. Comment on: Lancet 1995 Dec 9;346(8989):1557–8.

DIAGNOSTIC USE

Tc–99m antimony sulfate lymphoscintigraphy to demonstrate lymphatic communication between the peritoneal cavity and the scrotum. Lu G, et al. **Clin Nucl Med** 1995 Aug; 20(8):706–8

Mammary lymphoscintigraphy in breast cancer [see comments] Uren RF, et al. **J Nucl Med** 1995 Oct; 36(10):1775–80. Comment in: J Nucl Med 1995 Oct;36(10):1780–3.

METABOLISM

Use of INAA to study Se, Sb, Zn and Co levels of yeast cells. Czauderna M, et al. **Appl Radiat Isot** 1995 Dec; 46(12):1295–8

PHARMACOKINETICS

Disposition of antimony after the administration of N–methylglucamine antimoniate to dogs. Valladares JE, et al. **Vet Rec** 1996 Feb 24;138(8):181–3

PHARMACOLOGY

In vitro antileishmanial properties of tri– and pentavalent antimonial preparations. Roberts WL, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1234–9

The role of arsenic–thiol interactions in metalloregulation of the ars operon. Shi W, et al. **J Biol Chem** 1996 Apr 19;271(16):9291–7

[Effect of the drug stibyl on the enzymatic activity of the antioxidant defense system in chickens] Kalytka VV, et al. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):76–80 (Eng. Abstr.) (Ukr)

THERAPEUTIC USE

Treatment of kala azar [letter] Ozsoylu S. **Lancet** 1996 Jun 15;347(9016):1701

Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma–interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine. Lustig V, et al. **Neth J Med** 1995 Aug; 47(2):66–9

TOXICITY

Assessment of a possible genotoxic environmental risk in sheep bred on grounds with strongly elevated contents of mercury, arsenic and antimony. Gebel T, et al. **Mutat Res** 1996 Jul 5;368(3–4):267–74

[Clinical and pathogenetic features of exposure of workers to antimonate ore] Lobanova EA, et al. **Med Tr Prom Ekol** 1996;(4):12–5 (Eng. Abstr.) (Rus)

ANTIMONY GLUCONATE SODIUM see **ANTIMONY SODIUM GLUCONATE**

ANTIMONY POTASSIUM TARTRATE

ADMINISTRATION & DOSAGE

[The use of topical tartar emetic in cutaneous leishmaniasis] Romero GA, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug; 29(4):377 (Por)

ANTIMONY SODIUM GLUCONATE

ADVERSE EFFECTS

Acute pancreatitis associated with sodium stibogluconate treatment in a patient with human immunodeficiency virus [letter] Domingo P, et al. **Arch Intern Med** 1996 May 13; 156(9):1029, 1032

Reversible peripheral neuropathy associated with sodium stibogluconate therapy for American cutaneous leishmaniasis. Brummitt CF, et al. **Clin Infect Dis** 1996 May; 22(5):878–9

Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate [letter; comment] McBride MO, et al. **Clin Infect Dis** 1995 Sep;21(3):710. Comment on: Clin Infect Dis 1994 Jan;18(1):83–90.

Hepatotoxicity of sodium stibogluconate therapy for American cutaneous leishmaniasis. Hepburn NC, et al. **Trans R Soc Trop Med Hyg** 1994 Jul–Aug;88(4):453–5

Does antimony therapy cause bleeding in kala-azar patients and why? Chowdhury MA, et al. **Trop Doct** 1995 Oct; 25(4):188–9

THERAPEUTIC USE

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Ribera E, et al. **Am J Med** 1996 May;100(5):496–501

Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. Sundar S, et al. **J Infect Dis** 1996 Mar;173(3):762–5

ANTIMUSCARINIC AGENTS see **MUSCARINIC ANTAGONISTS**

ANTIMUTAGENIC AGENTS

see related

ANTICARCINOGENIC AGENTS

Mouse MTH1 protein with 8-oxo-7,8-dihydro-2'-deoxyguanosine 5'-triphosphatase activity that prevents transversion mutation. cDNA cloning and tissue distribution. Kakuma T, et al. **J Biol Chem** 1995 Oct 27;270(43):25942–8

The isfA mutation inhibits mutator activity and processing of UmuD protein in Escherichia coli recA730 strains. Bębenek A, et al. **Mol Gen Genet** 1996 Apr 10; 250(6):674–80

The 4th International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis. Banff, Canada, 4–9 September 1994. **Mutat Res** 1996 Feb 19;350(1):1–294

The 4th International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis: a summary. Liviero L, et al. **Mutat Res** 1996 Feb 19;350(1):287–93

ADMINISTRATION & DOSAGE

Dietary supplements of antioxidants reduce hprt mutant frequency in splenocytes of aging mice. Gaziev AI, et al. **Mutat Res** 1995 Oct;338(1–6):77–86

ANALYSIS

Antimutagenicity and catechin content of soluble instant teas. Constable A, et al. **Mutagenesis** 1996 Mar;11(2):189–94

Relationship between antimutagenic activity and major components of various teas. Yen GC, et al. **Mutagenesis** 1996 Jan;11(1):37–41

CHEMISTRY

Study of the forces of stabilizing complexes between chlorophylls and heterocyclic amine mutagens. Dashwood R, et al. **Environ Mol Mutagen** 1996;27(3):211–8

ISOLATION & PURIFICATION

Palmitic acid is the major fatty acid responsible for significant anti-N-methyl-N'-nitro-N-nitroguanidine (MNNG) activity in yogurt. Nadathur SR, et al. **Mutat Res** 1996 Apr 4;359(3):179–89

METABOLISM

Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33278. Mitchell JL, et al. **Carcinogenesis** 1995 Dec;16(12):3063–8

PHARMACOKINETICS

Fate and distribution of (14C]S-(N,N-diethyldithiocarbamoyl)-N-acetyl-L-cysteine, an antimutagenic mixed disulfide from disulfiram, in rats. Lee BH, et al. **Arzneimittelforschung** 1995 Dec; 45(12):1319–23

PHARMACOLOGY

Inhibitory effects of chlorophyllin on chemically induced mutagenesis and carcinogenesis. Surh YJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:246–9

Inhibitory effects of mixed disulfides from disulfiram on the metabolism and genotoxicity of N-nitrosodiethylamine. Lee BH, et al. **Arzneimittelforschung** 1995 Sep;45(9):1024–8

Inhibition of hepatocellular carcinoma development and erythrocyte polyamine levels in ODS rats fed on 3'-methyl-4-dimethylaminoazobenzene by hemicalcium ascorbate, 2-O-octadecylascorbic acid, and ascorbyl palmitate. Shimpo K, et al. **Cancer Detect Prev** 1996; 20(2):137–45

Identification of antimutagenic substances in an extract of edible red alga, Porphyra tenera (asakusa-nori). Okai Y, et al. **Cancer Lett** 1996 Feb 27;100(1–2):235–40

All-trans beta-carotene enhances mitogenic responses and ornithine decarboxylase activity of BALB/c 3T3 fibroblast cells induced by tumor promoter and fetal bovine serum but suppresses mutagen-dependent umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002). Okai Y, et al. **Cancer Lett** 1996 Jan 19;99(1):15–21

In vivo antimutagenic activity of beta-carotene in rat spleen lymphocytes. Aidoo A, et al. **Carcinogenesis** 1995 Sep; 16(9):2237–41

Strong anti-mutagenic activity of the novel lipophilic antioxidant 1-O-hexyl-2,3,5-trimethylhydroquinone against heterocyclic amine-induced mutagenesis in the Ames assay and its effect on metabolic activation of 2-amino-6-methyldipyrido[1,2-a:3',2'-d] imidazole (Glu-p-1). Hirose M, et al. **Carcinogenesis** 1995 Sep; 16(9):2227–32

Chemoprotective effects of capsaicin and diallyl sulfide against mutagenesis or tumorigenesis by vinyl carbamate and N-nitrosodimethylamine. Surh YJ, et al. **Carcinogenesis** 1995 Oct;16(10):2467–71

Mechanisms of chlorophyllin anticarcinogenesis against aflatoxin B1: complex formation with the carcinogen. Breinholt V, et al. **Chem Res Toxicol** 1995 Jun;8(4):506–14

Recent progress in the study of anticancer drugs originating from plants and traditional medicine in China. Han R. **Chin Med J (Engl)** 1995 Oct;108(10):729–31 (9 ref.)

Taurine and ellagic acid: two differently-acting natural antioxidants. Cozzi R, et al. **Environ Mol Mutagen** 1995; 26(3):248–54

Mutagenic synergy between paraoxon and plant-activated m-phenylenediamine or 2-acetoxyacetylaminofluorene. Gichner T, et al. **Environ Mol Mutagen** 1996;27(1):59–66

Anti-genotoxic effects in mice after the interaction between coffee and dietary constituents. Abraham SK. **Food Chem Toxicol** 1996 Jan;34(1):15–20

Effect of eugenol on the genotoxicity of established mutagens in the liver. Rompelberg CJ, et al. **Food Chem Toxicol** 1996 Jan;34(1):33–42

Antimutagenic effects of polyphenols isolated from Terminalia bellerica myroblan in Salmonella typhimurium. Padam SK, et al. **Indian J Exp Biol** 1996 Feb;34(2):98–102

Mutagenicity and anti-mutagenicity of selected spices. Soudamini KK, et al. **Indian J Physiol Pharmacol** 1995 Oct; 39(4):347–53

Paradoxical effect of Sudan III on the in vivo and in vitro genotoxicity elicited by 7,12-dimethylbenz(a)anthracene. Hatakeyama S, et al. **J Biochem Toxicol** 1995 Jun; 10(3):143–9

Promotive action of acylated ascorbate on cellular DNA synthesis and growth at low doses in contrast to inhibitory action at high doses or upon combination with hyperthermia. Kageyama K, et al. **J Cancer Res Clin Oncol** 1996;122(1):41–4

Effects of nine active ingredients in Chinese herbal medicine sho-saiko-to on 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide mutagenicity. Ohtsuka M, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1131–5

Inhibition of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline-mediated DNA-adduct formation by chlorophyllin in Drosophila. Sugiyama C, et al. **Jpn J Cancer Res** 1996 Apr;87(4):325–8

Decreased levels of 2-amino-3-methylimidazo[4,5-f]quinoline-DNA adducts in rats treated with beta-carotene, alpha-tocopherol and freeze-dried aloe. Uehara N, et al. **Jpn J Cancer Res** 1996 Apr;87(4):342–8

Protective effects of alpha-hederin, chlorophyllin and ascorbic acid towards the induction of micronuclei by doxorubicin in cultured human lymphocytes. Amara-Mokrane YA, et al. **Mutagenesis** 1996 Mar; 11(2):161–7

Transplacental effect of stobadine on cyclophosphamide induced micronucleus frequency in mice. Chorvatovičová D, et al. **Mutagenesis** 1995 Nov;10(6):531–4

Suppressive effects of methyl methacrylate on the mutagenicity and DNA adduct formation induced by 1-nitropyrene and benzo[a]pyrene. Chou LS, et al. **Mutagenesis** 1996 Mar;11(2):177–81

Influence of benzylisothiocyanate and 13-cis-retinoic acid on micronucleus formation induced by benzo[a]pyrene. AlDosari A, et al. **Mutat Res** 1996 Jun 10;352(1–2):1–7

Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) mutagenicity by black and green tea extracts and polyphenols. Apostolides Z, et al. **Mutat Res** 1996 Apr 4;359(3):159–63

Inhibitory effect of hemin, chlorophyllin and related pyrrole pigments on the mutagenicity of benzo[a]pyrene and its metabolites. Arimoto S, et al. **Mutat Res** 1995 Dec; 345(3–4):127–35

Antimutagenicity of yogurt. Bakalinsky AT, et al. **Mutat Res** 1996 Feb 19;350(1):199–200

Field bean protease inhibitor mitigates the sister-chromatid exchanges induced by bromoform and depresses the spontaneous sister-chromatid exchange frequency of human lymphocytes in vitro. Banerji AP, et al. **Mutat Res** 1996 May 17;360(1):29–35

Modulatory effects of polycyclic aromatic hydrocarbons on the mutagenicity of 1-nitropyrene: a structure-activity relationship study. Cherng SH, et al. **Mutat Res** 1996 Apr 6;367(4):177–85

Antimutagens reduce ofloxacin-induced bleaching in Euglena gracilis. Ebringer L, et al. **Mutat Res** 1996 Feb 29;359(2):85–93

Anti-mutagenic agents are also co-recombinogenic and can be converted into co-mutagens. Fahrig R. **Mutat Res** 1996 Feb 19;350(1):59–67

Co-recombinogenic and anti-mutagenic effects of diethylhexylphthalate, inactiveness of pentachlorophenol in the spot test with mice. Fahrig R, et al. **Mutat Res** 1996 Jul 5;354(1):59–67

Shark-cartilage containing preparation protects cells against hydrogen peroxide induced damage and mutagenesis. Gomes EM, et al. **Mutat Res** 1996 Apr 6;367(4):204–8

Anticlastogenic effects of galangin against mitomycin C-induced micronuclei in reticulocytes of mice. Heo MY, et al. **Mutat Res** 1996 May 17;360(1):37–41

Effects of phenethyl isothiocyanate on metabolism and on genotoxicity of dimethylnitrosamine and 2-amino-1-methyl-6-phenylimidazo[4, 5-beta]pyridine (PhIP). Knasmüller S, et al. **Mutat Res** 1996 Feb 19; 350(1):93–102

Study on the antimutagenic effect of pine needle extract. Kong Z, et al. **Mutat Res** 1995 Aug;347(3–4):101–4

Frameshift mutagenesis by 9-aminoacridine: antimutagenic effects of adenosine compounds. Kopsidas G, et al. **Mutat Res** 1996 Jun 10;352(1–2):135–42

Mutual interactions among ingredients of betel quid in inducing genotoxicity on Chinese hamster ovary cells. Lee CH, et al. **Mutat Res** 1996 Feb;367(2):99–104

Inhibition of mutagenicity of N-nitrosamines by tobacco smoke and its constituents. Lee CK, et al. **Mutat Res** 1996 Feb;367(2):83–92

Effects of indomethacin and arachidonic acid on sister chromatid exchange induction by styrene and styrene-7,8-oxide. Lee SH, et al. **Mutat Res** 1995 Oct; 348(2):93–9

Antimutagenicity of ellagic acid against aflatoxin B1 in the Salmonella microsuspension assay. Loarca-Piña G, et al. **Mutat Res** 1996 May 17;360(1):15–21

Natural antimutagenic agents. Mitscher LA, et al. **Mutat Res** 1996 Feb 19;350(1):143–52 (38 ref.)

Effect of chlorophyllin on gamma ray induced micronuclei in polychromatic erythrocytes of murine peripheral blood determined by the ABC strategy. Morales-Ramírez P, et al. **Mutat Res** 1996 Feb;367(2):51–6

In vivo radioprotective effect of chlorophyllin on sister chromatid exchange induction in murine spermatogonial cells. Morales-Ramírez P, et al. **Mutat Res** 1995 Aug; 344(1–2):73–8

Inhibitory effect of curcumin on SOS functions induced by UV irradiation. Oda Y. **Mutat Res** 1995 Oct;348(2):67–73

Plant activation and its role in environmental mutagenesis and antimutagenesis. Plewa MJ, et al. **Mutat Res** 1996 Feb 19;350(1):163–71

Effect of eugenol on the mutagenicity of benzo[a]pyrene and the formation of benzo[a]pyrene-DNA adducts in the lambda-lacZ-transgenic mouse. Rompelberg CJ, et al. **Mutat Res** 1996 Jul 10;369(1–2):87–96

Radioprotective effects of antioxidative plant flavonoids in mice. Shimoi K, et al. **Mutat Res** 1996 Feb 19;350(1):153–61

In vivo radioprotection with garlic extract. Singh SP, et al. **Mutat Res** 1995 Dec;345(3–4):147–53

Inhibition of covalent DNA binding and mutagenicity of benzo[a]pyrene by isopropyl-2-(1,3-dithietane-2-ylidene)-2-[N-(4-methylthiazol-2-yl) carbamoyl]acetate (YH439), a novel hepatoprotective agent. Surh YJ, et al. **Mutat Res** 1996 Apr 6;367(4):219–24

Inhibition by quercetin and luteolin of chromosomal alterations induced by salted, deep-fried fish and mutton in rats. Taj S, et al. **Mutat Res** 1996 Jul 10;369(1–2):97–106

Antigenotoxic spinasterol from Cucurbita maxima flowers. Villaseñor IM, et al. **Mutat Res** 1996 Jun 10;360(2):89–93

Activity profiles of antimutagens: in vitro and in vivo data. Waters MD, et al. **Mutat Res** 1996 Feb 19;350(1):109–29 (117 ref.)

Assessment of antimutagenic effects of stobadine dihydrochloride on MNNG-induced mutations in Chinese hamster cells V79. Horváthová E, et al. **Neoplasma** 1995; 42(5):259–64

Inhibition of bacterial mutagenesis by Citrus flavonoids. Calomme M, et al. **Planta Med** 1996 Jun;62(3):222–6

[Protective effects of sodium selenite and selenomethionine on genotoxicity to human peripheral lymphocytes induced by arsenic] Hu G, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1996 Jan;30(1):26–9 (Eng. Abstr.) **(Chi)**

[Preliminary studies on the desmutagenic mechanism of white silk fowl's melanin] Yuan Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):301–3, inside cover (Eng. Abstr.) **(Chi)**

[Anti-promoting and anti-mutagenic actions of G9315] Fu N, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):349–52 (Eng. Abstr.) **(Chi)**

[Antimutagenic activity of beta-carotene] Khabibulina VM, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):276–8 **(Rus)**

[Antiradical activity of a diallyl series ternary copolymer in realizing an antimutagenic effect] Odin AP, et al. **Biull Eksp Biol Med** 1995 Sep;120(9):265–7 **(Rus)**

[Antimutagenic action of bacterial culture liquid on mutagenesis induced by 2-nitrofluorene in Salmonella typhimurium strains] Vorob'eva LI, et al. **Genetika** 1995 Jul;31(7):901–7 (Eng. Abstr.) **(Rus)**

[Bioantimutagenic effect of the culture fluid of Streptococcus faecalis on mutagenesis induced by 2-nitrofluorene in Salmonella typhimurium TA 1538 and TA 98] Vorob'eva LI, et al. **Mikrobiologiia** 1996 Jan–Feb;65(1):79–83 (Eng. Abstr.) **(Rus)**

[The antimutagenic activity of ternary diallyl copolymers] Aleksandrova VA, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):746–51 (Eng. Abstr.) **(Rus)**

[The anticlastogenic effect of ascorbic acid in relation to the damages induced in human lymphocytes by the photomutagenic action of 8-methoxypsoralen and by ammonium molybdate] Makedonov GP, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):726–9 (Eng. Abstr.) **(Rus)**

[The modifying action of a complex of physiologically active substances isolated from the human amnion on chromosome damage] Timchenko OI, et al. **Tsitol Genet** 1995 Sep–Oct; 29(5):49–54 (Eng. Abstr.) **(Rus)**

[Effects of interferon inducers on chemically-induced mutagenesis and carcinogenesis] Loginova NS, et al. **Vestn Ross Akad Med Nauk** 1996;(3):28–33 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

[Vitamin A derivatives and prevention of bronchial cancers] Thiberville L, et al. **Rev Mal Respir** 1996;13(2):193–5 (19 ref.) **(Fre)**

ANTIMYCIN A

PHARMACOLOGY

The respiratory-chain poison antimycin A promotes the formation of DNA single-strand breaks and reduces toxicity in U937 cells exposed to t-butylhydroperoxide. Guidarelli A, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):371–5

Source of oxygen free radicals produced by rat hepatocytes during postanoxic reoxygenation. Caraceni P, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):249–54

TOXICITY

Oxygen dependence of hepatocyte susceptibility to mitochondrial respiratory inhibitors. Niknahad H, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1859–65

ANTINEMATODAL AGENTS

[Abdominal angiostrongyliasis: its prevention by the destruction of infecting larvae in food treated with salt, vinegar or sodium hypochlorite] Zanini GM, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):389–92 (Eng. Abstr.) **(Por)**

ADMINISTRATION & DOSAGE

Ivermectin-induced immunopotentiation in onchocerciasis: recognition of selected antigens following a single dose of ivermectin. Akuffo H, et al. **Clin Exp Immunol** 1996 Feb;103(2):244–52

Ivermectin in the treatment of Physaloptera preputialis in two cats. Gustafson BW. **J Am Anim Hosp Assoc** 1995 Sep–Oct;31(5):416–8

Single doses of ivermectin 400 micrograms/kg-1: the most effective dosage in bancroftian filariasis. Moulia-Pelat JP, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):124–7

Administration of fenbendazole in urea molasses block to dairy buffaloes in India. Sanyal PK, et al. **Trop Anim Health Prod** 1995 Aug;27(3):186–90

Response of cattle treated with a fenbendazole slow release bolus to challenge from nematodes the following season. Kerboeuf D, et al. **Vet Parasitol** 1996 Mar;62(1-2):107–18

Control of lungworm [letter] Mawhinney I. **Vet Rec** 1996 Mar 16;138(11):263

Control of lungworm [letter] Williams PC. **Vet Rec** 1996 Mar 16;138(11):263

ADVERSE EFFECTS

Update of the mortality experience of employees with occupational exposure to 1,2-dibromo-3-chloropropane (DBCP). Olsen GW, et al. **Am J Ind Med** 1995 Sep; 28(3):399–410

Severe cholestasis and sicca syndrome after thiabendazole [letter] Bion E, et al. **J Hepatol** 1995 Dec;23(6):762–3

[Differential diagnosis of delayed encephalopathy induced by anthelmintic imidazoles] Zheng R. **Chung Hua Nei Ko Tsa Chih** 1995 Jul;34(7):468–71 (Eng. Abstr.) **(Chi)**

ANALYSIS

Liquid chromatographic determination of mebendazole and its metabolites, aminomebendazole and hydroxymebendazole, in eel muscle tissue. Hajee CA, et al. **J AOAC Int** 1996 May–Jun;79(3):645–51

CHEMICAL SYNTHESIS

[The synthesis and study of the acute toxicity and anthelmintic activity of new 2-methylthiobenzimidazoles] Podushkin VIu, et al. **Med Parazitol (Mosk)** 1995 Jul–Sep; (3):38–40 (Eng. Abstr.) **(Rus)**

CHEMISTRY

New metabolites with nematicidal and antimicrobial activities from the ascomycete Lachnum papyraceum (Karst.) Karst. VIII. Isolation, structure determination and biological activities of minor metabolites structurally related to mycorrhizin A. Shan R, et al. **J Antibiot (Tokyo)** 1996 May; 49(5):447–52

ECONOMICS

Anthelmintic sales in the highveld region of Eastern Transvaal. Louw JP. **J S Afr Vet Assoc** 1995 Jun; 66(2):66–70

ISOLATION & PURIFICATION

New metabolites with nematicidal and antimicrobial activities from the ascomycete Lachnum papyraceum (Karst.) Karst. VIII. Isolation, structure determination and biological activities of minor metabolites structurally related to mycorrhizin A. Shan R, et al. **J Antibiot (Tokyo)** 1996 May; 49(5):447–52

PHARMACOLOGY

Effects of mebendazole on protein biosynthesis and secretion in human-derived fibroblast cultures. Soto H, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):289–99

Ophiobolin M and analogues, noncompetitive inhibitors of ivermectin binding with nematocidal activity. Tsipouras A, et al. **Bioorg Med Chem** 1996 Apr;4(4):531–6

The effect of intraoperative mebendazole–albendazole applications on the hepatobiliary system. Erzurumlu K, et al. **Eur Surg Res** 1995;27(5):340–5

Effects of piperazine derivatives on the activity of frog skeletal muscle fibers. Radicheva N, et al. **Gen Pharmacol** 1995 Oct;26(6):1431–9

In vitro studies on the relative sensitivity to ivermectin of Necator americanus and Ancylostoma ceylanicum. Richards JC, et al. **Int J Parasitol** 1995 Oct;25(10):1185–91

Cochlioquinone A, an inhibitor of diacylglycerol kinase. Machida T, et al. **J Antibiot (Tokyo)** 1995 Oct; 48(10):1076–80

Effect of ivermectin on Caenorhabditis elegans larvae previously exposed to alcoholic immobilization. Smith H, et al. **J Parasitol** 1996 Feb;82(1):187–8

Inhibition of glutathione synthesis of Ascaris suum by buthionine sulfoximine. Hussein AS, et al. **Parasitol Res** 1996;82(4):372–4

Effects of PF1022A on adult Angiostrongylus cantonensis in the pulmonary arteries and larvae migrating into the central nervous system of rats. Kachi S, et al. **Parasitol Res** 1995;81(8):631–7

In vitro effects of VD-99-11 on Angiostrongylus cantonensis and isolated frog rectus. Lee HH, et al. **Parasitol Res** 1995; 81(7):615–21

SUPPLY & DISTRIBUTION

[Ivermectin: problems with donation and distribution] Resnikoff S. **Med Trop (Mars)** 1995;55(3 Suppl):28–9 **(Fre)**

THERAPEUTIC USE

Community-based ivermectin distributors: onchocerciasis control at the village level in Plateau State, Nigeria. Richards F Jr, et al. **Acta Trop** 1996 Apr;61(2):137–44

A field survey on anthelmintic resistance in equine small strongyles in Norway. Ihler CF. **Acta Vet Scand** 1995; 36(1):135–43

Case report: strongyloidiasis refractory to treatment with ivermectin. Ashraf M, et al. **Am J Med Sci** 1996 Apr; 311(4):178–9

Ivermectin distribution and the cultural context of forest onchocerciasis in South Province, Cameroon. Hewlett BS, et al. **Am J Trop Med Hyg** 1996 May;54(5):517–22

Persistent anthelmintic activity of ivermectin against gastrointestinal nematodes of cattle. Williams JC, et al. **Am J Vet Res** 1995 Sep;56(9):1169–75

Resumption of menstruation in three women with secondary amenorrhoea after treatment with ivermectin. Anosike JC, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):693–4

A study on the prevention of prenatal and galactogenic Toxocara canis infections in pups by treatment of infected bitches with ivermectin or doramectin. Epe C, et al. **Appl Parasitol** 1995 May;36(2):115–23

Use of an ivermectin bolus against gastrointestinal nematode and lungworm infections in first-year grazing calves. Schnieder T, et al. **Appl Parasitol** 1996 Jan;37(1):38–44

Efficacy of an ivermectin and pyrantel pamoate combination against adult hookworm, Ancylostoma braziliense, in dogs. Shoop WL, et al. **Aust Vet J** 1996 Mar;73(3):84–5

The efficacy of three anthelmintic drugs given in a single dose. Sorensen E, et al. **Ceylon Med J** 1996 Jun;41(2):42–5

Integrated control of Onchocerca volvulus infection in a hyperendemic zone in Sierra Leone. Gbakima AA. **East Afr Med J** 1996 Mar;73(3):159–63

Trichostrongylus colubriformis infection in rabbits: persistence of the distal adaptive response to parasitism after anthelmintic treatment. Hoste H, et al. **J Comp Pathol** 1995 Aug;113(2):145–53

Sub-acute intestinal obstruction by Strongyloides stercoralis [letter] Beeching NJ, et al. **J Infect** 1996 Mar;32(2):170

A cost-effectiveness analysis of anthelminthic intervention for community control of soil-transmitted helminth infection: levamisole and Ascaris lumbricoides. Holland CV, et al. **J Parasitol** 1996 Aug;82(4):527–30

Chemotherapy of human nematodes: learning from the problems in sheep. Coles GC. **J R Soc Med** 1995 Nov; 88(11):649P–651P (10 ref.)

Efficacy of ivermectin pour-on against Ostertagia ostertagi infection and residues in the American bison, Bison bison. Marley SE, et al. **J Wildl Dis** 1995 Jan;31(1):62–5

Efficacy of ivermectin against nematodes infecting field populations of snowshoe hares (Lepus americanus) in Yukon, Canada. Sovell JR, et al. **J Wildl Dis** 1996 Jan; 32(1):23–30

Selective treatment and targeted chemotherapy: effect on prevalence and intensity of infection for two intestinal helminths in Nepalese children. Curtale F. **Panminerva Med** 1995 Dec;37(4):214–9

Content of some microelements in chickens with ascaridiasis under combined drug treatment. Damyanova A, et al. **Parasitol Res** 1995;81(7):549–52

Targeted anthelminthic treatment of school children: effect of frequency of application on the intensity of Ascaris lumbricoides infection in children from rural Nigerian villages. Holland CV, et al. **Parasitology** 1996 Jul;113 (Pt 1):87–95

Anti-nematode activity of sixteen compounds against Trichinella spiralis in mice--a possible new screen for macrofilaricides. Surin J. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):128–34

Rate of reinfection with intestinal nematodes after treatment of children with mebendazole or albendazole in a highly endemic area. Albonico M, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct;89(5):538–41

A community trial of ivermectin for onchocerciasis in Sierra Leone: compliance and parasitological profiles after three and a half years of intervention. Whitworth JA, et al. **Trop Med Int Health** 1996 Feb;1(1):52–8

Efficacy of pyrantel tartrate against experimental infections with Haemonchus contortus, Teladorsagia circumcincta and Trichostrongylus colubriformis in goats. Chartier C, et al. **Vet Parasitol** 1995 Aug;59(1):69–73

The combined effect of fenbendazole treatment and a move to aftermath 7 or 9 weeks after turnout on Dictyocaulus viviparus infections in calves. Eysker M, et al. **Vet Parasitol** 1995 Dec;60(3-4):339–48

Potential for misinterpretation of the faecal egg count reduction test for levamisole resistance in gastrointestinal nematodes of sheep. Grimshaw WT, et al. **Vet Parasitol** 1996 Apr;62(3-4):267–73

Efficacy of a spring strategic fenbendazole treatment program to reduce numbers of Ostertagia ostertagi inhibited larvae in beef stocker cattle. Williams JC, et al. **Vet Parasitol** 1995 Sep;59(2):127–37

Influence of chemoprophylaxis on protective immunity to nematodes in cattle: a two-year study comparing four control strategies. Fisher MA, et al. **Vet Rec** 1995 Dec 2;137(23):581–5

Multigeneric resistance to oxfendazole by nematodes in cattle. Hosking BC, et al. **Vet Rec** 1996 Jan 20;138(3):67–8

Evaluation of mebendazole activity on experimental murine toxocariasis by immune complexes determination. Bardon R, et al. **Zentralbl Veterinarmed [B]** 1995 Jun;42(4):235–46

[Ivermectin in the treatment of onchocercosis] Queguiner P. **Med Trop (Mars)** 1995;55(3 Suppl):26–7 **(Fre)**

[Strongyloides stercoralis hyperinfection] Gelber M, et al. **Harefuah** 1996 Jan 15;130(2):90–2, 143 (Eng. Abstr.) **(Heb)**

[Effectiveness of vermox in the treatment of helminthiasis] Dotsenko VA, et al. **Klin Med (Mosk)** 1995;73(6):57–8 **(Rus)**

[Comparative effectiveness of anthelmintic preparations in trichocephaliasis] Dotsenko VA, et al. **Klin Med (Mosk)** 1995;73(4):94 **(Rus)**

TOXICITY

Studies on multispecific resistance of gastrointestinal nematodes to benzimidazoles on dairy-goat farms. Cabaret J, et al. **Vet Parasitol** 1995 Dec;60(3-4):331–7

ANTINEOPLASTIC AGENTS

see related
ANTICARCINOGENIC AGENTS
CHEMOEMBOLIZATION, THERAPEUTIC
INFUSIONS, INTRA-ARTERIAL
PERFUSION, REGIONAL
TUMOR LYSIS SYNDROME

Role of endogenous interferon gamma in murine tumor growth and tumor necrosis factor alpha antitumor efficacy. Doherty GM, et al. **Ann Surg Oncol** 1996 Mar;3(2):198–203

Potent antitumor activity of quinolone compounds with an unsaturated aminoazabicyclo group at the C-7 position of the quinolone ring. Arakawa H, et al. **Anticancer Drug Des** 1996 Apr;11(3):221–9

Biophysical and biological evaluation of porphyrin–bisacridine conjugates. Karagianis G, et al. **Anticancer Drug Des** 1996 Apr;11(3):205–20

Identification of anthracenyl–dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs. Meikle I, et al. **Anticancer Drug Des** 1995 Oct;10(7):515–27

Antitumor mechanisms of Eubacterium lentum and its components. Hatta M. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):129–37

A model for the T–antigen–induced structural alteration of the SV40 replication origin based upon experiments with specific probes for bent, straight, and unwound DNA. Han FX, et al. **Biochemistry** 1996 Jun 18;35(24):7993–8001

An adduct of cis–diamminedichloroplatinum(II) and poly(ethylene glycol)poly(L–lysine)–succinate: synthesis and cytotoxic properties. Bogdanov AA Jr, et al. **Bioconjug Chem** 1996 Jan–Feb;7(1):144–9

Triggering effects of BCG vaccine on antitumor and interleukin–1 secretory activity of T cell lymphokine–primed macrophages. Seledtsova GV, et al. **Biomed Pharmacother** 1995;49(7–8):369–74

A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Munker R, et al. **Blood** 1996 Sep 15; 88(6):2201–9

Novel anti–tumour activity of 2,3,5–trimethyl–6–(3–pyridylmethyl)–1,4– benzoquinone (CV–6504) against established murine adenocarcinomas (MAC). Hussey HJ, et al. **Br J Cancer** 1996 May; 73(10):1187–92

New in vitro screening model for the discovery of antileukemic anticancer agents. Valeriote F, et al. **Cancer Invest** 1996;14(2):124–41

Anticancer and antioxidant activity of synthetic chalcones and related compounds. Anto RJ, et al. **Cancer Lett** 1995 Oct 20;97(1):33–7

Availability of anticancer drugs in the United States, Europe, and Japan from 1960 through 1991. Brown JS, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):243–56

EORTC Early Drug Development Meeting 1995, 21–24 June, Corfu, Greece. Lehnert M. **Eur J Cancer** 1995 Oct; 31A(11):1760–2

Structure–activity relationship of 17 structural analogues of n–butyric acid upon c–myc expression. Rottleb C, et al. **Int J Cancer** 1996 Sep 4;67(5):724–9

Molecular targets in the National Cancer Institute drug screen. Bates SE, et al. **J Cancer Res Clin Oncol** 1995; 121(9–10):495–500 (20 ref.)

Current concepts of treatment in medical oncology: new anticancer drugs. Unger C. **J Cancer Res Clin Oncol** 1996; 122(4):189–98 (29 ref.)

Proceedings of the VIII Mediterranean Congress of Chemotherapy. Athens, Greece, 24–29 May 1992. **J Chemother** 1993 May;5 Suppl 1:1–830

Determination of vinorelbine in biological fluids by high–performance liquid chromatography [letter; comment] Levêque D, et al. **J Chromatogr B Biomed Appl** 1995 Oct 20;672(2):314. Comment on: J Chromatogr B Biomed Appl 1995 Jan 20;663(2):390–4.

Bisindolylmaleimides linked to DNA minor groove binding lexitropsins: synthesis, inhibitory activity against topoisomerase I, and biological evaluation. Xie G, et al. **J Med Chem** 1996 Mar 1;39(5):1049–55

Move by FDA will speed approval of drugs across Europe [news] Reynolds T. **J Natl Cancer Inst** 1996 Jan 17;88(2):78

Joint venture strengthens U.S.–Europe cooperation on new cancer drugs [news] Reynolds T. **J Natl Cancer Inst** 1996 Jan 17;88(2):76–7

SH2 and SH3 domains: potential targets for anti–cancer drug design. Smithgall TE. **J Pharmacol Toxicol Methods** 1995 Nov;34(3):125–32 (52 ref.)

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Apr 24;275(16):1224

Monitoring of occupational exposure to cytostatic anticancer agents. Sorsa M, et al. **Mutat Res** 1996 Aug 17; 355(1–2):253–61 (58 ref.)

Anticancer drugs [letter; comment] Reese DM. **Nature** 1995 Dec 7;378(6557):532. Comment on: Nature 1995 Oct 19;377(6550):580–1. Comment on: Nature 1995 Oct 19;377(6550):649–52.

New therapeutic agents marketed in 1995. Hussar DA. **Pa Med** 1996 Jun;99(6):35–6, 39–40

[Physicochemical properties of a beta–glucan from Sclerotinia sclerotiorum] Liu R, et al. **Wei Sheng Wu Hsueh Pao** 1995 Apr;35(2):103–8 (Eng. Abstr.) **(Chi)**

[Dose optimization in clinical oncology: pharmacokinetic–pharmacodynamic relationship] Canal P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):256–65 (65 ref.) (Eng. Abstr.) **(Fre)**

[Cisplatin and carboplatin—update] Geffen DB, et al. **Harefuah** 1995 Aug;129(3–4):131–5 (40 ref.) **(Heb)**

[Anticancer agents and apoptosis] Fukuoka K, et al. **Nippon Rinsho** 1996 Jan;54(1):250–8 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Design of antitumor 2'–deoxy–(2'–C–substituted) cytidines] Matsuda A. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1232–41 (18 ref.) **(Jpn)**

[Is tributyrate effective against cancer? Usual clinical studies on the discussed miracle medicine are not available] Wikner BN, et al. **Lakartidningen** 1996 Sep 11;93(37):3161–2 **(Swe)**

ADMINISTRATION & DOSAGE

Exfoliated tumour cells and locally recurrent colorectal cancer. Basha G, et al. **Acta Chir Belg** 1996 Apr;96(2):66–70 (41 ref.)

Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study. Lunardi P, et al. **Acta Neurochir (Wien)** 1996; 138(2):215–20

Is the MVP regimen less active than previously described? Results of a phase II study in advanced non–small cell lung cancer. Ferrigno D, et al. **Acta Oncol** 1996;35(4):435–9

Effect of granulocyte–macrophage colony–stimulating factor (GM–CSF) on hematologic toxicity induced by high–dose chemotherapy in patients with metastatic breast cancer. Hansen F, et al. **Acta Oncol** 1995;34(7):919–24

High–dose methotrexate causes short–term suppression of growth in rabbits. Moëll C, et al. **Acta Paediatr** 1995 Nov; 84(11):1237–40

Cisplatin, 5–fluorouracil, and high–dose folinic acid in patients with advanced unresectable head and neck cancer. Alba E, et al. **Am J Clin Oncol** 1996 Apr;19(2):140–3

M–CAVI, a neoadjuvant carboplatin–based regimen for the treatment of T2–4N0M0 carcinoma of the bladder. Bellmunt J, et al. **Am J Clin Oncol** 1996 Aug;19(4):344–8

Neoadjuvant chemotherapy with cisplatin–vindesine–5–fluorouracil and folinic acid for locally advanced head and neck carcinoma. Bensmaine M el–A, et al. **Am J Clin Oncol** 1996 Aug;19(4):356–62

Salvage chemotherapy with mitomycin, vindesine, and cisplatin (MiViP) in recurrent carcinoma of the cervix. Delaloye JF, et al. **Am J Clin Oncol** 1996 Apr;19(2):204–6

High–dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer. deMagalhaes–Silverman M, et al. **Am J Clin Oncol** 1996 Apr;19(2):169–73

Cisplatin and UFT modulated with leucovorin for the treatment of Advanced non–small–cell lung cancer. Feliu J, et al. **Am J Clin Oncol** 1996 Apr;19(2):121–4

Phase II trial of mitoxantrone and cisplatin in advanced non–small–cell lung cancer. Feun LG, et al. **Am J Clin Oncol** 1996 Apr;19(2):190–2

The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG–8921). Flaherty LE, et al. **Am J Clin Oncol** 1996 Apr;19(2):108–13

Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small–cell lung cancer. Frytak S, et al. **Am J Clin Oncol** 1996 Apr;19(2):193–8

A combination of vinblastine and doxorubicin with interferon alpha. Jekunen A, et al. **Am J Clin Oncol** 1996 Aug; 19(4):384–5

Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma. Leone B, et al. **Am J Clin Oncol** 1996 Apr;19(2):132–5

Concurrent 72–hour continuous infusion of etoposide and cisplatin in metastatic breast cancer. Remick SC, et al. **Am J Clin Oncol** 1996 Apr;19(2):125–31

Etoposide–cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small–cell carcinoma of the lung. Shaw EG, et al. **Am J Clin Oncol** 1996 Apr; 19(2):154–8

A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa. Stein ME, et al. **Am J Clin Oncol** 1996 Aug;19(4):386–8

High–dose chemotherapy with stem–cell rescue for the treatment of breast cancer. McCauley DL. **Am J Health Syst Pharm** 1996 Mar 1;53(5):521–34; quiz 561–2 (87 ref.)

Will increases in dose intensity improve outcome: pro [see comments] Hryniuk W. **Am J Med** 1995 Dec 29; 99(6A):69S–70S. Comment in: Am J Med 1995 Dec 29;99(6A):71S–76S.

Will increases in dose intensity improve outcome: con [comment] Souhami RL. **Am J Med** 1995 Dec 29; 99(6A):71S–76S (39 ref.). Comment on: Am J Med 1995 Dec 29;99(6A):69S–70S.

Will increases in chemotherapy dose intensity improve outcome of patients with common malignancies? Tannock I. **Am J Med** 1995 Dec 29;99(6A):68S–69S

Preventing chemo errors [letter] Donovan CT. **Am J Nurs** 1996 Apr;96(4):20

Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb. Huber R, et al. **Am J Surg** 1995 Oct;170(4):345–52

Regional hyperthermic perfusion with cisplatin following surgery for malignant melanoma of the extremities. Papa MZ, et al. **Am J Surg** 1996 Apr;171(4):416–20

What accounts for the association of vegetables and fruits with lower incidence of cancers and coronary heart disease? [editorial; comment] Omenn GS. **Ann Epidemiol** 1995 Jul;5(4):333–5 (12 ref.). Comment on: Ann Epidemiol 1995 Jul;5(4):255–60. Comment on: Ann Epidemiol 1995 Jul;5(4):261–9.

High–dose chemotherapy for breast cancer. Gradishar WJ, et al. **Ann Intern Med** 1996 Oct 1;125(7):599–604 (55 ref.)

Clinical pharmacokinetics of cumulative very high dose of cisplatin in chemotherapy resistant solid tumors. Tebano MT, et al. **Ann Ist Super Sanita** 1995;31(3):351–7

Dose–intensive chemotherapy in breast cancer—the need for appropriate measures of outcome [editorial] Basser RL. **Ann Oncol** 1995 Sep;6(7):633–5 (23 ref.)

High–dose chemotherapy of solid tumours. Crown J. **Ann Oncol** 1995;6 Suppl 1:11–4; discussion 14–5 (57 ref.)

Experience with dose and schedule variations in germ cell tumors. De Mulder PH, et al. **Anticancer Drugs** 1995 Oct; 6 Suppl 5:43–52 (57 ref.)

The importance of dose and schedule in cancer chemotherapy: breast cancer. Leonard RC. **Anticancer Drugs** 1995 Oct;6 Suppl 5:17–27 (75 ref.)

The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer. Mainwaring PN, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:29–41 (116 ref.)

The problem of thrombocytopenia and its management. Newland AC. **Anticancer Drugs** 1995 Oct;6 Suppl 5:65–73 (76 ref.)

The importance of dose and schedule in chemotherapy for small cell lung cancer. Ranson M, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:53–63 (112 ref.)

The importance of dose and schedule in cancer chemotherapy: haematological cancer. Sweetenham JW. **Anticancer Drugs** 1995 Oct;6 Suppl 5:7–15 (50 ref.)

Palliative chemoembolization of hepatocellular carcinoma with mitoxantrone, Lipiodol, and Gelfoam. A phase II study. Civalleri D, et al. **Anticancer Res** 1996 Mar–Apr; 16(2):937–41

Intraperitoneal infusion of recombinant human tumor necrosis factor and mitoxantrone in neoplastic ascites: a feasibility study. Del Mastro L, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2207–12

An open–label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate. Fearon KC, et al. **Anticancer Res** 1996 Mar–Apr;16(2):867–74

Treatment of superficial bladder cancer with intravesical perfusion of rIL–2: a follow–up study. Ferlazzo G, et al. **Anticancer Res** 1996 Mar–Apr;16(2):979–80

A phase I study of 5–day continuous venous infusion of carboplatin at circadian rhythm–modulated rate compared with constant rate. Natoli C, et al. **Anticancer Res** 1996 May–Jun;16(3A):1275–9

Establishment of an experimental model for continuous intraportal infusion of chemo/immunotherapeutic agents in the rat. Rafique M, et al. **Anticancer Res** 1995 Sep–Oct; 15(5B):1869–72

Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK–432 plus IL–2 in gastric cancer patients. Yamaguchi Y, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2201–6

Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery. Zhao Q, et al. **Antisense Res Dev** 1995 Fall;5(3):185–92

Hyperthermic intraoperative intraperitoneal chemotherapy safety considerations. White SK, et al. **AORN J** 1996 Apr; 63(4):716–24

Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment [see comments] Sorkin P, et al. **Arch Surg** 1995 Oct;130(10):1079–84. Comment in: Arch Surg 1996 Feb;131(2):220.

Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalan. van Ginkel RJ, et al. **Arch Surg** 1996 Jun;131(6):672–4

N–[4–hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot study. Gravallese EM, et al. **Arthritis Rheum** 1996 Jun;39(6):1021–6

Alpha–fetoprotein–mediated targeting of anti–cancer drugs to tumor cells in vitro. Severin SE, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):385–92

Immunoliposome–mediated targeting of anti–cancer drugs in vivo. Allen TM, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1073–9

Site–specific prodrug activation by antibody–beta–lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis. Meyer DL, et al. **Bioconjug Chem** 1995 Jul–Aug; 6(4):440–6

Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Solary E, et al. **Blood** 1996 Aug 15;88(4):1198–205

Administration of recombinant human granulocyte–macrophage colony–stimulating factor after chemotherapy regulates the expression and secretion of monocyte tumor necrosis factor (TNF) and TNF receptors p55 and p75. Williams MA, et al. **Blood** 1995 Dec 1; 86(11):4234–42

Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non–small–cell lung cancer: a phase I and pharmacokinetic study. Groen HJ, et al. **Br J Cancer** 1995 Oct;72(4):992–7

Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy. Mizuguchi H, et al. **Br J Cancer** 1996 Feb;73(4):472–6

Sphingomyelin–cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Webb MS, et al. **Br J Cancer** 1995 Oct;72(4):896–904

Towards quality control in cancer chemotherapy. Woodman C, et al. **Br J Cancer** 1996 Jan;73(1):117–8

Chemotherapy of metastatic bowel cancer. Ross PJ, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):263–6 (20 ref.)

Arterial therapy of hepatic colorectal metastases. Vauthey JN, et al. **Br J Surg** 1996 Apr;83(4):447–55 (104 ref.)

Intravesical mitozantrone in recurrent superficial bladder cancer [letter; comment] Newling DW. **Br J Urol** 1995 Dec;76(6):814. Comment on: Br J Urol 1995 Jun;75(6):740–3.

A mathematical model of periodically pulsed chemotherapy: tumor recurrence and metastasis in a competitive environment. Panetta JC. **Bull Math Biol** 1996 May; 58(3):425–47

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [letter; comment] Anand A, et al. **Cancer** 1996 May 1; 77(9):1959–60. Comment on: Cancer 1995 Dec 1;76(11):2230–6.

Elimination of dose limiting toxicities of cisplatin, 5–fluorouracil, and leucovorin using a weekly 24–hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma [see comments] Chi KH, et al. **Cancer** 1995 Dec 1;76(11):2186–92. Comment in: Cancer 1996 Aug 1;78(3):566–7.

Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Jacquet P, et al. **Cancer** 1996 Jun 15;77(12):2622–9

Regional chemotherapy plus hemofiltration for the treatment of regionally advanced malignancy [editorial] Muchmore JH. **Cancer** 1996 Sep 1;78(5):941–3

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [see comments] Shin DM, et al. **Cancer** 1995 Dec 1; 76(11):2230–6. Comment in: Cancer 1996 May 1;77(9):1959–60.

Evaluation of low dose alpha–interferon (Roferon–A) in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. Marshall ME, et al. **Cancer Biother** 1995 Fall;10(3):205–9

Alcohol consumption and risk of colorectal cancer in a cohort of Finnish men. Glynn SA, et al. **Cancer Causes Control** 1996 Mar;7(2):214–23

European School of Oncology European consensus on the use of granulocyte colony–stimulating factor: the example of breast cancer. Antoine EC, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S103–9 (71 ref.)

Biological characterization of L–asparaginase liposomal formulations. Gaspar MM, et al. **Cancer Chemother Pharmacol** 1996;38(4):373–7

Histopathological changes in rabbit uterus carcinoma after transcatheter arterial embolization using cisplatin. Harima Y, et al. **Cancer Chemother Pharmacol** 1996;38(4):317–22

Multi–chemothermoimmunotherapy for human colon adenocarcinoma in vitro. Klostergaard J, et al. **Cancer Chemother Pharmacol** 1996;37(3):235–41

Pharmacokinetic evaluation of high–dose etoposide phosphate after a 2–hour infusion in patients with solid tumors. Kreis W, et al. **Cancer Chemother Pharmacol** 1996; 38(4):378–84

A phase I and pharmacology study of an oral platinum complex, JM216: dose–dependent pharmacokinetics with single–dose administration. McKeage MJ, et al. **Cancer Chemother Pharmacol** 1995;36(6):451–8

Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Politi PM, et al. **Cancer Chemother Pharmacol** 1995;36(6):513–23

Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbits. Ramirez LH, et al. **Cancer Chemother Pharmacol** 1996;37(4):371–6

Cisplatin and continuous infusion of fluorouracil followed by radiation and weekly carboplatin in the treatment of locally advanced head and neck cancer: a Hellenic Cooperative Oncology Group study [see comments] Fountzilas G, et al. **Cancer Invest** 1996;14(3):189–96. Comment in: Cancer Invest 1996;14(3):285–6.

Treatment of advanced malignancies with high–dose acetaminophen and N–acetylcysteine rescue. Kobrinsky NL, et al. **Cancer Invest** 1996;14(3):202–10

Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies? Markman M. **Cancer Invest** 1995;13(6):625–8 (27 ref.)

Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Kurbacher CM, et al. **Cancer Lett** 1996 Jun 5;103(2):183–9

Potential advantages in therapeutic index of OK–432 ointment to abdominal skin over systemic applied in a mouse model. Matsuoka H, et al. **Cancer Lett** 1996 Mar 19;101(1):15–20

Inhibition of tumor promotion in SENCAR mouse skin by ethanol extract of Zingiber officinale rhizome. Katiyar SK, et al. **Cancer Res** 1996 Mar 1;56(5):1023–30

Antitumor activity of 1 M tegafur–0.4 M 5–chloro–2,4–dihydroxypyridine–1 M potassium oxonate (S–1) against human colon carcinoma orthotopically implanted into nude rats. Shirasaka T, et al. **Cancer Res** 1996 Jun 1;56(11):2602–6

Reversible, p16–mediated cell cycle arrest as protection from chemotherapy. Stone S, et al. **Cancer Res** 1996 Jul 15; 56(14):3199–202

Extended intraarterial cisplatin infusion for treatment of gynecologic cancer after alteration of intrapelvic blood flow and implantation of a vascular access device. Yamada T, et al. **Cardiovasc Intervent Radiol** 1996 May–Jun; 19(3):139–45

Preoperative chemotherapy with carboplatin alone in high risk medulloblastoma. Di Rocco C, et al. **Childs Nerv Syst** 1995 Oct;11(10):574–8

Effects of preoperative chemotherapy on gastric carcinoma: the relationship between histopathologic response and prognosis. Kumagai K, et al. **Clin Ther** 1995 Sep–Oct; 17(5):936–45

High–dose chemotherapy for malignancies: a review. Roman–Unfer S, et al. **Compr Ther** 1996 Feb;22(2):107–20 (128 ref.)

Biphasic changes in serum hepatocyte growth factor after transarterial chemoembolization therapy for hepato–cellular carcinoma. Yamazaki H, et al. **Cytokine** 1996 Feb;8(2):178–82

Portable pumps in cancer chemotherapy: how to deal with marked fluctuations in 5–fluorouracil blood concentrations [letter] Etienne MC, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2414–5

Regional chemotherapy of colorectal cancer. Kemeny NE. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1271–6 (45 ref.)

Intralesional sustained–release chemotherapy with therapeutic implants for treatment of canine sun–induced squamous cell carcinoma. Kitchell BK, et al. **Eur J Cancer** 1995 Nov;31A(12):2093–8

High–dose chemotherapy for breast cancer. Leonard RC. **Eur J Cancer** 1996 Feb;32A(2):205–8 (30 ref.)

Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lévi F, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1264–70 (43 ref.)

Haemopoietic stem cell inhibition: potential for dose intensification. Marshall E. **Eur J Cancer** 1995 Sep; 31A(10):1586–91 (92 ref.)

Phase I and pharmacokinetic study of a water–soluble etoposide prodrug, etoposide phosphate (BMY–40481). Millward MJ, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2409–11

High dose chemotherapy with haemopoietic support for breast cancer. Steward WP. **Eur J Cancer** 1995;31A Suppl 7:S21–4 (18 ref.)

Leakage measurement during selective limb perfusion using a gamma probe. Sandrock D, et al. **Eur J Nucl Med** 1996 May;23(5):534–8

Intra–arterial liposomal adriamycin for metastatic adenocarcinoma of the liver. Konno H, et al. **Eur Surg Res** 1995;27(5):301–6

Patient compliance with crucial drug regimens: implications for prostate cancer. Urquhart J. **Eur Urol** 1996;29 Suppl 2:124–31 (62 ref.)

Chemotherapeutic tumour targeting using clostridial spores. Minton NP, et al. **FEMS Microbiol Rev** 1995 Oct; 17(3):357–64 (40 ref.)

Antibody–targeted polymer–bound drugs. Říhová B. **Folia Microbiol (Praha)** 1995;40(4):367–84 (121 ref.)

Chemoembolisation with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma. Ryder SD, et al. **Gut** 1996 Jan;38(1):125–8

Use of the Veress needle for instillation of intraperitoneal chemotherapy. Menczer J. **Gynecol Oncol** 1995 Nov; 59(2):249–50

Prognosis of small hepatocellular carcinoma (less than 3 cm) after percutaneous acetic acid injection: study of 91 cases. Ohnishi K, et al. **Hepatology** 1996 May;23(5):994–1002

High–dose chemotherapy and autologous bone marrow plus peripheral blood stem cell transplantation for patients with lymphoma or metastatic breast cancer: use of marker genes to investigate hematopoietic reconstitution in adults. Douer D, et al. **Hum Gene Ther** 1996 Mar 20;7(5):669–84

An example of the effects of drug resistance on the optimal schedule for a single drug in cancer chemotherapy. Murray JM. **IMA J Math Appl Med Biol** 1995;12(1):55–69

Interstitial and transurethral photodynamic therapy of the canine prostate using meso–tetra–(m–hydroxyphenyl) chlorin. Chang SC, et al. **Int J Cancer** 1996 Aug 7; 67(4):555–62

Anti–vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Hill SA, et al. **Int J Cancer** 1995 Sep 27;63(1):119–23

Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow. Hori K, et al. **Int J Cancer** 1996 Jan 26;65(3):360–4

High–dose therapy/stem cell support: comparison of mice and humans. Teicher BA, et al. **Int J Cancer** 1996 Mar 1;65(5):695–9

Local interferon therapy for melanoma patients. Ikić D, et al. **Int J Dermatol** 1995 Dec;34(12):872–4

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913–8 (35 ref.). Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969–70.

Feasibility, toxicity, and preliminary results of weekly loco–regional hyperthermia and cisplatin in patients with previously irradiated recurrent cervical carcinoma or locally advanced bladder cancer. Rietbroek RC, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):887–93

Phase I trial of ilmofosine as a 24 hour infusion weekly. von Mehren M, et al. **Invest New Drugs** 1995;13(3):205–10

Polycythemia vera in a cat and management with hydroxyurea. Evans LM, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct;31(5):434–8

New biodegradable oligoesters for pharmaceutical application. Wada R, et al. **J Biomater Sci Polym Ed** 1996; 7(8):715–25

Difficulties defining the role of high–dose chemotherapy in the management of breast cancer [editorial] Markman M. **J Cancer Res Clin Oncol** 1995;121(11):631–2

Regional chemotherapy: revisited [editorial] Markman M. **J Cancer Res Clin Oncol** 1996;122(1):1–2 (11 ref.)

Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4–alkyl derivatives of 1–beta–D–arabinofuranosylcytosine. Schwendener RA, et al. **J Cancer Res Clin Oncol** 1996;122(2):102–8

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. Chabot GG, et al. **J Clin Oncol** 1996 Jul; 14(7):2020–30

Oral cladribine as primary therapy for patients with B–cell chronic lymphocytic leukemia. Juliusson G, et al. **J Clin Oncol** 1996 Jul;14(7):2160–6

Phase II study of intravenous topotecan as a 5–day infusion for refractory epithelial ovarian carcinoma. Kudelka AP, et al. **J Clin Oncol** 1996 May;14(5):1552–7

Dose–escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. Larson RA, et al. **J Clin Oncol** 1996 Jan;14(1):188–95

Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer. Lind MJ, et al. **J Clin Oncol** 1996 Mar;14(3):800–5

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. Rinaldi DA, et al. **J Clin Oncol** 1995 Nov;13(11):2842–50

Pharmacokinetic study of oral and bolus intravenous 2–chlorodeoxyadenosine in patients with malignancy. Saven A, et al. **J Clin Oncol** 1996 Mar;14(3):978–83

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I–II study of weekly cisplatin/interferon alfa–2a. Soulié P, et al. **J Clin Oncol** 1996 Mar;14(3):878–85

Nanoparticulate systems in drug delivery and targeting [editorial] Kreuter J. **J Drug Target** 1995;3(3):171–3

Benzo[a]pyrene–induced respiratory tract cancer in hamsters fed a diet rich in beta–carotene. A histomorphological study. Wolterbeek AP, et al. **J Environ Pathol Toxicol Oncol** 1995;14(1):35–43

Chemosensitivity test for repeated arterial infusion chemotherapy by reservoir for unresectable hepatocellular carcinoma. Denda T, et al. **J Gastroenterol Hepatol** 1995 Jul–Aug;10(4):446–53

Current concepts for chronochemotherapy of cancer. Laerum OD, et al. **J Infus Chemother** 1995;5(3 Suppl 1):159–70 (189 ref.)

Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. Leach SD, et al. **J Infus Chemother** 1995 Summer;5(3):104–11 (46 ref.)

Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. Dinney CP, et al. **J Interferon Cytokine Res** 1995 Jun;15(6):585–92

Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi–cytokine inducer OK–432. Kitahara S, et al. **J Laryngol Otol** 1996 May; 110(5):449–53

Cancer therapy during Ramadan [letter] Celik I, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):838

Evaluating the clinical and economic trade–offs of hepatic arterial infusion [editorial; comment] Cole BF. **J Natl Cancer Inst** 1996 Mar 6;88(5):223–4. Comment on: J Natl Cancer Inst 1996 Mar 6;88(5):252–88.

Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. Hansen RM, et al. **J Natl Cancer Inst** 1996 May 15;88(10):668–74

Whatever happened to beta carotene? [news] Holzman D. **J Natl Cancer Inst** 1995 Dec 6;87(23):1739–41

Polymers help guide cancer drugs to tumor targets—and keep them there [news] Reynolds T. **J Natl Cancer Inst** 1995 Nov 1;87(21):1582–4

Importance of alpha–carotene, beta–carotene, and other phytochemicals in the etiology of lung cancer. Ziegler RG, et al. **J Natl Cancer Inst** 1996 May 1;88(9):612–5

Implantable pumps for drug delivery to the brain. Bakhshi S, et al. **J Neurooncol** 1995 Nov;26(2):133–9 (68 ref.)

Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release. Buahin KG, et al. **J Neurooncol** 1995 Nov;26(2):103–10

Distribution of drugs following controlled delivery to the brain interstitium. Mak M, et al. **J Neurooncol** 1995 Nov; 26(2):91–102 (61 ref.)

Iodine–131–metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit. Tristam M, et al.

J Nucl Med 1996 Jun;37(6):1058–63

OK–432 therapy for lymphangioma in children: why and how does it work? Ogita S, et al. **J Pediatr Surg** 1996 Apr; 31(4):477–80

A novel skeletal drug delivery system using self–setting calcium phosphate cement. 9: Effects of the mixing solution volume on anticancer drug release from homogeneous drug–loaded cement. Otsuka M, et al. **J Pharm Sci** 1995 Jun;84(6):733–6

Design, synthesis, and pharmacokinetic evaluation of a chemical delivery system for drug targeting to lung tissue. Saah M, et al. **J Pharm Sci** 1996 May;85(5):496–504

An in vitro–in vivo validation of the isolated perfused tumor and skin flap preparation as a model of cisplatin delivery to tumors. Vaden SL, et al.
J Pharmacol Toxicol Methods 1996 Jun;35(3):173–7

High dose chemotherapy for breast cancer: the case for trials in adjuvant therapy. Leonard RC. **J R Soc Med** 1996 Jun; 89(6):337P–9P (22 ref.)

Intramedullary cisplatin chemotherapy: experience in four dogs with osteosarcoma. Hahn KA, et al.
J Small Anim Pract 1996 Apr;37(4):187–92

Cisplatin–based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors. Culine S, et al.
J Surg Oncol 1996 Mar;61(3):195–8

Pharmacokinetics of cis–diamminedichloroplatinum (II) given as low–dose and high–dose infusions. Kurihara N, et al. **J Surg Oncol** 1996 Jun;62(2):135–8

Totally implanted device for long–term intravenous chemotherapy: experience in 123 adult patients with solid neoplasms. Puig–la Calle J Jr, et al. **J Surg Oncol** 1996 Aug;62(4):273–8

Interleukin–2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. Lopez Hänninen E, et al. **J Urol** 1996 Jan;155(1):19–25

Enhanced anticancer effect of vincristine with methionine infusion after methionine–depleting total parenteral nutrition in tumor–bearing rats. Goseki N, et al.
Jpn J Cancer Res 1996 Feb;87(2):194–9

Improvement of intraperitoneal chemotherapy for rat ovarian cancer using cisplatin–containing microspheres. Kumagai S, et al. **Jpn J Cancer Res** 1996 Apr;87(4):412–7

Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid–tumor–bearing mouse models. Watanabe T, et al. **Jpn J Cancer Res** 1996 Feb;87(2):184–93

Experimental intraperitoneal administration of cisplatin–activated carbon for rat ovarian adenocarcinomas. Sugiyama T, et al. **Kurume Med J** 1996;43(1):33–9

Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Childhood ALL Collaborative Group. **Lancet** 1996 Jun 29;347(9018):1783–8

High–dose chemotherapy with autologous bone marrow/stem–cell rescue in lung cancer. Basade MM, et al. **Lancet** 1996 Mar 30;347(9005):847–8

Unproven breast–cancer therapy widely used in USA [news] McCarthy M. **Lancet** 1996 Jun 8;347(9015):1617

Treatment of inoperable ovarian cancer with interleukin–2 and carboplatinum [letter] Malaguarnera M, et al.
Lancet 1995 Dec 16;346(8990):1627

Beta–carotene takes a collective beating [news] [see comments] Rowe PM. **Lancet** 1996 Jan 27;347(8996):249. Comment in: Lancet 1996 Apr 6;347(9006):967–8.

Caution with beta–carotene supplements [letter; comment] Woodall AA, et al. **Lancet** 1996 Apr 6;347(9006):967–8. Comment on: Lancet 1996 Jan 27;347(8996):249.

"Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract. I. Histoculture experiments. Robbins KT, et al. **Laryngoscope** 1996 Jan; 106(1 Pt 1):32–6

"Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract. II. Clinical studies. Robbins KT, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):37–42

Survival of childhood acute lymphoblastic leukemia: results of therapy at Tata Memorial Hospital, Bombay, India. Vaidya SJ, et al. **Leuk Lymphoma** 1996 Jan;20(3–4):311–5

Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Mohammad RM, et al. **Leuk Res** 1995 Sep;19(9):667–73

Oral therapy for small cell lung cancer. Postmus PE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S63–70 (29 ref.)

Treating solid tumours with high dose chemotherapy [editorial] Tattersall MH. **Med J Aust** 1995 Nov 20; 163(10):512–3

Pharmacokinetic interaction of 5–fluorouracil and interferon alpha–2b with or without folinic acid. b1p6uller J, et al. **Med Oncol** 1995 Mar;12(1):47–53

Treatment of childhood Hodgkin's disease with ABVD without radiotherapy. Behrendt H, et al.
Med Pediatr Oncol 1996 Apr;26(4):244–8

Errors involving pediatric patients receiving chemotherapy: a literature review. Trinkle R, et al. **Med Pediatr Oncol** 1996 May;26(5):344–51 (47 ref.)

Advances in chemotherapy for brain tumors. Conrad CA, et al. **Neurol Clin** 1995 Nov;13(4):795–812 (106 ref.)

New delivery systems for brain tumor therapy. Sipos EP, et al. **Neurol Clin** 1995 Nov;13(4):813–25 (81 ref.)

Intratumoral chemotherapy. Walter KA, et al.
Neurosurgery 1995 Dec;37(6):1128–45 (131 ref.)

Improved antitumor activity of cis–Bis–neodecanoato–trans–R,R–1,2–diaminocyclohexaneplatinum (II) entrapped in long–circulating liposomes. Li S, et al. **Oncol Res** 1995; 7(12):611–7

Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Ratain MJ, et al.
Pharmacogenetics 1996 Feb;6(1):93–101

Omega–3 fatty acid–containing liposomes in cancer therapy. Jenski LJ, et al. **Proc Soc Exp Biol Med** 1995 Dec; 210(3):227–33

Intraarterial infusion of cisplatin with and without preoperative concurrent radiation for urinary bladder cancer: a preliminary report. Monzen Y, et al.
Radiat Med 1995 May–Jun;13(3):149–52

Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Bartolozzi C, et al. **Radiology** 1995 Dec;197(3):812–8

CT–guided intraarterial chemotherapy in locally advanced tumors. Görich J, et al. **Radiology** 1996 May;199(2):567–70

Delivery of molecular medicine to solid tumors. Jain RK. **Science** 1996 Feb 23;271(5252):1079–80

Phase I/II study of paclitaxel plus cisplatin as first–line chemotherapy for advanced non–small cell lung cancer: preliminary results. Belli L, et al. **Semin Oncol** 1995 Dec; 22(6 Suppl 15):29–33

Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose–escalation study. Chang AY, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):74–7

A phase I/II study of paclitaxel plus cisplatin as first–line therapy for head and neck cancers: preliminary results. Hitt R, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):50–4

Paclitaxel combined with carboplatin in the first–line treatment of advanced ovarian cancer. Meerpohl HG, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):7–12

A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non–small cell lung cancer: preliminary results of an ongoing study. Natale RB.
Semin Oncol 1995 Dec;22(6 Suppl 15):34–7

Combination regimens of paclitaxel and the platinum drugs as first–line regimens for ovarian cancer. Ozols RF.
Semin Oncol 1995 Dec;22(6 Suppl 15):1–6 (17 ref.)

Phase I trial of dose–escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. Palackdharry CS. **Semin Oncol** 1996 Jun;23(3 Suppl 6):78–83

Analysis of dose–response relationships in the setting of high–dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer. Perkins JB, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):42–6

Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non–small lung cancer. Souquet PJ, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):8–10

Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. Vokes EE, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):48–52

Prevalence of muscle injury following intra–arterial chemotherapy. Kuno RC, et al. **Skeletal Radiol** 1996 May; 25(4):345–8

An extension of the continual reassessment methods using a preliminary up–and–down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Møller S. **Stat Med** 1995 May 15–30; 14(9–10):911–22; discussion 923

Laparoscopic intra–arterial catheter implantation for regional chemotherapy of liver metastasis. Feliciotti F, et al.
Surg Endosc 1996 Apr;10(4):449–52

Wound recurrence after laparoscopic colectomy for cancer. New rationale for intraoperative intraperitoneal chemotherapy [editorial] Jacquet P, et al. **Surg Endosc** 1996 Mar;10(3):295–6

Soluble intercellular adhesion molecule–1 and serum cytokines in melanoma patients treated with liposomes containing muramyl tripeptide. Favaro D, et al. **Tumori** 1995 May–Jun;81(3):185–90

High–dose chemotherapy for breast cancer: twenty years later. Whom should we treat? And when? Wright–Browne V, et al. **Tumori** 1996 May–Jun;82(3):187–92 (45 ref.)

Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder. Serretta V, et al. **Urology** 1996 May;47(5):647–51

Clinico–pathological studies on the effect of different anti–neoplastic chemotherapy regimens on transmissible venereal tumours in dogs. Singh J, et al.
Vet Res Commun 1996;20(1):71–81

[Pharmacokinetic study of intraperitoneal chemotherapy with high–dose cisplatin for advanced ovarian cancer] Deng C, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar; 31(3):159–62 (Eng. Abstr.) **(Chi)**

[Studies on lung targeting gelatin microspheres of mitoxantrone] Wang JH, et al. **Yao Hsueh Hsueh Pao** 1995; 30(7):549–55 (Eng. Abstr.) **(Chi)**

[Studies on CDDP–albumin microspheres for hepatic arterial chemoembolization] Zhang YQ, et al.
Yao Hsueh Hsueh Pao 1995;30(7):543–8 (Eng. Abstr.) **(Chi)**

[High–dose chemotherapy and autologous bone marrow transplantation in solid tumors. A review] Handberg J, et al. **Ugeskr Laeger** 1996 Jul 15;158(29):4175–80 (40 ref.) (Eng. Abstr.) **(Dan)**

[Transfusion–refractory thrombocytopenia during chemotherapy: pathogenesis, frequency and treatment] Helleberg C, et al. **Ugeskr Laeger** 1995 Sep 11; 157(37):5082–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[High–dose chemotherapy in solid tumors—a therapeutic breakthrough? (editorial)] Jense TS. **Ugeskr Laeger** 1996 Jul 15;158(29):4169 **(Dan)**

[Primary cerebral non–Hodgkin's lymphoma. Intensive chemotherapy supported by crania radiotherapy] Jensen MK, et al. **Ugeskr Laeger** 1996 Jul 29;158(31):4413–5 (Eng. Abstr.) **(Dan)**

[Immediate intraperitoneal chemotherapy after surgery for the reduction of peritoneal malignancies: for what purpose and for whom? (editorial)] Elias D. **Ann Chir** 1995; 49(7):567–72 (34 ref.) (Eng. Abstr.) **(Fre)**

[Definitive results of a phase I study of a chemotherapy regimen using cisplatin and paclitaxel for non–small cell bronchial cancer] Sculier JP, et al. **Rev Mal Respir** 1995; 12(6):609–14 (Eng. Abstr.) **(Fre)**

[Long–term infusion of L–asparaginase—an alternative to intramuscular injection?] Rodriguez T, et al.
Klin Padiatr 1995 Jul–Aug;207(4):207–10 (Eng. Abstr.) **(Ger)**

[Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations] Hanauske AR. **Med Klin** 1996 Apr 12;91 Suppl 3:68–70 (28 ref.) **(Ger)**

[Methods for optimizing cytostatic drug therapy] Lipp HP. **Med Monatsschr Pharm** 1995 Oct;18(10):282–91 (63 ref.) **(Ger)**

[Superselective intra–arterial chemotherapy in therapy–refractory lymph node recurrences of breast carcinoma] Krämer S, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 May;164(5):422–6 (Eng. Abstr.) **(Ger)**

[Results of resection and adjuvant therapy of liver metastases of primary colorectal tumors—a review of the literature] Lorenz M, et al. **Zentralbl Chir** 1995;120(10):769–79 (74 ref.) (Eng. Abstr.) **(Ger)**

[Regional adjuvant therapy in colorectal liver metastases: requirements for clinical therapy studies from the statistical viewpoint (see comments)] Müller HH, et al.
Zentralbl Chir 1995;120(10):755–9 (10 ref.) (Eng. Abstr.). Comment in: Zentralbl Chir 1995;120(10):753–4. **(Ger)**

[Effectiveness of intra–arterial chemotherapy in the management of intra–oral cancers and their lymphatic metastases] Suba Z, et al. **Fogorv Sz** 1995 Oct;88(10):331–8 (Eng. Abstr.) **(Hun)**

[Normalization of the prolactin values during alfa–interferon therapy: the considerations with a female patient with anti–HCV–positive chronic hepatitis and prolactin–secreting hypophyseal microadenoma] Zennaro R, et al. **Clin Ter** 1996 Apr;147(4):169–71 (Eng. Abstr.) **(Ita)**

[Therapeutic effect of adenovirus–mediated transfer of the wild–type p53 gene with cisplatin] Fujiwara T, et al.
Gan To Kagaku Ryoho 1996 Jul;23(8):1085–8 **(Jpn)**

[Two cases of long–term survival with hepatocellular carcinoma following targeting therapy with SMANCS/lipiodol] Inoue Y, et al.
Gan To Kagaku Ryoho 1996 Jan;23(1):99–101 (Eng. Abstr.) **(Jpn)**

[Chemoradiation therapy with low–dose carboplatin for squamous cell carcinoma of the esophagus] Kohnoe S, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1652–6 (Eng. Abstr.) **(Jpn)**

[Antitumor effects of liposome–entrapped carboplatin (Lipo–CBDCA) after intraperitoneal administration in rats bearing carcinomatous peritonitis] Mizuno I, et al.
Gan To Kagaku Ryoho 1995 Sep;22(11):1598–601 (Eng. Abstr.) **(Jpn)**

[Antibiotic and anti–cancer pasting for putrefactive cancers] Okuyama S, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1851–3 **(Jpn)**

[A case of hepatocellular carcinoma responding to oral administration of 5'–DFUR] Tanaka Y, et al.
Gan To Kagaku Ryoho 1996 Mar;23(4):483–6 (Eng. Abstr.) **(Jpn)**

[Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer] Kotake T, et al. **Hinyokika Kiyo** 1996 Feb;42(2):143–53 (Eng. Abstr.) **(Jpn)**

[Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer] Kotake T, et al.
Hinyokika Kiyo 1996 Feb;42(2):157–68 (Eng. Abstr.) **(Jpn)**

[The study of the biological activation induced by the lymphocyte transfusion—the induction of the bio–reproducing protein (BRP)] Sato I. **Hum Cell** 1995 Sep; 8(3):77–84 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Hepatic arterial perfusion scintigraphy with 99mTc–MAA for assessment of the hepatic distribution of drugs given by intrahepatic arterial infusion] Katayama M, et al.
Kaku Igaku 1996 Mar;33(3):233–40 (Eng. Abstr.) **(Jpn)**

[Oral administration of OK–432 is an effective immunotherapy against colon cancer—a study in a murine mesenteric lymphnode metastasis model] Nukata Y, et al.
Nippon Geka Gakkai Zasshi 1995 Oct;96(10):671–9 (Eng.

Abstr.) **(Jpn)**

[Continuous subcutaneous injection therapy with interferon-alpha for renal cell carcinoma patients with bone metastasis] Maruoka M, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1488–92 (Eng. Abstr.) **(Jpn)**

[Clinical investigation of renal pelvic and ureteral cancer with special reference to adjuvant chemotherapy] Shinohara M, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Aug; 86(8):1375–82 (Eng. Abstr.) **(Jpn)**

[Intermittent intra-arterial chemotherapy for the treatment of patients with bladder cancer or prostate cancer using implantable injection pump] Sumiyoshi Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):682–7 (Eng. Abstr.) **(Jpn)**

[Continuous intra-arterial infusion therapy via the occiptial artery for head and neck tumors: second choice treatment] Itoh Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Dec;55(15):1066–7 (Eng. Abstr.) **(Jpn)**

[Successful chemotherapy and concurrent radiotherapy for metastatic lung. mediastinal malignant fibrous histiocytoma] Ishihama H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct; 43(10):1757–61 (Eng. Abstr.) **(Jpn)**

[Chemotherapy of hepatocellular carcinoma] Okada S. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2028–31 (5 ref.) **(Jpn)**

[Neoadjuvant chemotherapy in advanced gynecologic cancer] Hirabayashi K. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):797–802 (7 ref.) **(Jpn)**

[High-dose therapy with cytostatic agents as primary treatment of advanced breast cancer] Matheson I. **Tidsskr Nor Laegeforen** 1996 Jun 20;116(16):1904–6 (18 ref.) (Eng. Abstr.) **(Nor)**

[The antimetastatic effect of low doses of lonidamine] Konovalova NI, et al. **Izv Akad Nauk Ser Biol** 1995 Nov–Dec;(6):750–3 (Eng. Abstr.) **(Rus)**

[The use of polyplatilen in patients with malignant tumors of the skin and locomotor apparatus] Shalimov SA, et al. **Klin Khir** 1995;(6):4–6 **(Rus)**

[Experience and perspectives in the use of liposomal form of antineoplastic drugs in clinical oncology] Shal'kov IuL, et al. **Klin Khir** 1995;(5):21–3 **(Rus)**

[The effect of an injection of N-methylformamide into mice on the cell cycle and cell morphology of ascitic hepatoma 22A] Proskuriakov SIa, et al. **Tsitologiia** 1996;38(2):129–34 (Eng. Abstr.) **(Rus)**

[Effectiveness of free and liposomal forms of platinum and anthracycline antibiotics for hepatic metastasis of GA-1 and P-388 tumors in mice] Kaledin VI, et al. **Vopr Onkol** 1996;42(3):64–6 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Activated lymphocytes in the marrow cell suspension decrease the mafosfamide-induced CFU-GM cytotoxicity. Woźny T, et al. **Acta Haematol Pol** 1995;26(4):367–75

5-Fluorouracil/levamisole induced intrahepatic fat infiltration imitating liver metastasis. Norum J. **Acta Oncol** 1995;34(7):971–2

Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Sigurdardóttir V, et al. **Acta Oncol** 1996; 35(2):149–58

Severe hepatobiliary complication in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid. Sindermann J, et al. **Acta Oncol** 1996;35(4):499–501

Effect of chemotherapy on growth. Ogilvy-Stuart AL, et al. **Acta Paediatr Suppl** 1995 Sep;411:52–6 (46 ref.)

Frequency and clinical implications of delayed nausea and delayed emesis. Morrow GR, et al. **Am J Clin Oncol** 1996 Apr;19(2):199–203

Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting. Berard CM, et al. **Am J Health Syst Pharm** 1995 Sep 1;52(17):1879–85

Quality-assurance testing of staff pharmacists handling cytotoxic agents. Harrison BR, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):402–7

Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Furgerson JL, et al. **Am J Hematol** 1996 Feb; 51(2):137–40

Acute esophageal stricture after induction chemotherapy for acute leukemia [letter] Kim HK. **Am J Hematol** 1996 Aug; 52(4):335–6

Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one. Tisdale JF, et al. **Am J Hematol** 1996 Feb;51(2):152–7

Bradycardia due to mitoxantrone exacerbated by previous anthracycline therapy [letter] Umemoto M, et al. **Am J Hematol** 1996 Aug;52(4):327–8

Successful allogeneic bone marrow transplantation in a patient with ATRA-induced pseudotumor cerebri [letter] Varadi G, et al. **Am J Hematol** 1995 Oct;50(2):147–8

Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate. Hemady RK, et al. **Am J Ophthalmol** 1996 Mar;121(3):291–6

Temporal bone histopathology of cisplatin ototoxicity. Hinojosa R, et al. **Am J Otol** 1995 Nov;16(6):731–40

Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Bow EJ, et al. **Ann Intern Med** 1996 Aug 1;125(3):183–90

The Raynaud phenomenon and interferon therapy [letter] Creutzig A, et al. **Ann Intern Med** 1996 Sep 1;125(5):423

Anthracycline-induced cardiotoxicity. Shan K, et al. **Ann Intern Med** 1996 Jul 1;125(1):47–58 (146 ref.)

Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. **Ann Oncol** 1995 Oct;6(8):805–10

Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine [letter; comment] Bazarbachi A, et al. **Ann Oncol** 1995 Sep; 6(7):730–1. Comment on: Ann Oncol 1995 Mar;6(3):300–1.

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Griffin AM, et al. **Ann Oncol** 1996 Feb;7(2):189–95

Acute promyelocytic leukemia with t(15;17) following inhibition of DNA topoisomerase II [editorial; comment] Pedersen-Bjergaard J. **Ann Oncol** 1995 Oct;6(8):751–3. Comment on: Ann Oncol 1995 Oct;6(8):777–9. Comment on: Ann Oncol 1995 Oct;6(8):781–8.

Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial. Adams M, et al. **Anticancer Drugs** 1995 Aug;6(4):514–21

Pattern of carboplatin-induced emesis. The German Ondansetron Study Group. du Bois A, et al. **Anticancer Drugs** 1995 Oct;6(5):645–51

Carboplatin-related idiosyncrasy. Inbar M, et al. **Anticancer Drugs** 1995 Dec;6(6):775–6

The problem of thrombocytopenia and its management. Newland AC. **Anticancer Drugs** 1995 Oct;6 Suppl 5:65–73 (76 ref.)

Efficacy of two oral dose regimens of granisetron. Maisano R, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2287–90

Granisetron–dexamethasone combination for multiple day cisplatin. Pronzato P, et al. **Anticancer Res** 1995 Sep–Oct; 15(5B):2261–3

Adverse effects at adjuvant treatment of liver metastases in rat with RSU-1069 + microspheres, or liposomal MTP-PE. Wang L, et al. **Anticancer Res** 1995 Sep–Oct; 15(5B):2077–80

Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Biron F, et al. **Antiviral Res** 1996 Jan;29(1):111–3

Hyperthermic intraoperative intraperitoneal chemotherapy safety considerations. White SK, et al. **AORN J** 1996 Apr; 63(4):716–24

Keratoacanthomas and skin neoplasms associated with suramin therapy [letter] Kobayashi K, et al. **Arch Dermatol** 1996 Jan;132(1):96–8

Cutaneous eruptions from suramin. A clinical and histopathologic study of 60 patients. Lowitt MH, et al. **Arch Dermatol** 1995 Oct;131(10):1147–53 (30 ref.)

Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment [see comments] Sorkin P, et al. **Arch Surg** 1995 Oct;130(10):1079–84. Comment in: Arch Surg 1996 Feb;131(2):220.

Reduced neutral DNase activity in the urine of children after cytostatic therapy. Reitz M, et al. **Arzneimittelforschung** 1996 Apr;46(4):438–41

The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma. Cavo M, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):795–813 (58 ref.)

Role of 5-hydroxytryptamine3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy. Karim F, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):685–92 (64 ref.)

Interim analyses in 2 x 2 crossover trials. Cook RJ. **Biometrics** 1995 Sep;51(3):932–45

Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Pedersen-Bjergaard J, et al. **Blood** 1995 Nov 1; 86(9):3542–52

Alleviation of cisplatin nephrotoxicity: efficacy of local intra-arterial injection concomitant with hemodialysis. Yura T, et al. **Blood Purif** 1996;14(2):146–56

Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy. Apperley JF, et al. **Blood Rev** 1995 Jun;9(2):93–116 (158 ref.)

Quantitative determination of immunological components of salivary gland secretion in transplant recipients. Dens F, et al. **Bone Marrow Transplant** 1996 Mar;17(3):421–3

Multi-organ dysfunction associated with high-dose carboplatin therapy prior to autologous transplantation. Grigg A, et al. **Bone Marrow Transplant** 1996 Jan; 17(1):67–74

Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hemopoietic progenitor mobilization. Olivieri A, et al. **Bone Marrow Transplant** 1995 Dec;16(6):765–70

Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients. Alfieri AB, et al. **Br J Cancer** 1995 Oct; 72(4):1013–5

Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies. Cubeddu LX, et al. **Br J Cancer** 1995 Oct;72(4):1033–8

Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Hickman PF, et al. **Br J Cancer** 1995 Oct;72(4):998–1003

Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Matsui K, et al. **Br J Cancer** 1996 Jan;73(2):217–21

The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial. Chua DT, et al. **Br J Clin Pharmacol** 1996 May; 41(5):403–8

Pseudo-dermatomyositis induced by long-term hydroxyurea therapy: report of two cases [letter] Bahadoran P, et al. **Br J Dermatol** 1996 Jun;134(6):1161–3

Hydroxyurea-induced dermatomyositis-like eruption. Senet P, et al. **Br J Dermatol** 1995 Sep;133(3):455–9 (32 ref.)

Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Myint H, et al. **Br J Haematol** 1995 Oct;91(2):341–4

Platinum agents and secondary myeloid leukaemia: two cases treated only with platinum-based drugs. Philpott NJ, et al. **Br J Haematol** 1996 Jun 2;93(4):884–7

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Moreau T, et al. **Brain** 1996 Feb;119 (Pt 1):225–37

Propofol and chemotherapy-induced emesis [letter; comment] Jones P, et al. **Can J Anaesth** 1995 Jul;42(7):659 . Comment on: Can J Anaesth 1994 Nov;41(11):1117–9.

Common drugs and the progress of cancer [letter; comment] Brown JH. **Can Med Assoc J** 1996 Jan 1;154(1):16–7. Comment on: Can Med Assoc J 1995 Sep 1;153(5):569–71.

Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy [letter; comment] Anand A, et al. **Cancer** 1996 May 1;77(9):1960–1. Comment on: Cancer 1995 Dec 1;76(11):2319–29.

Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study. Burdach SE, et al. **Cancer** 1995 Aug 1;76(3):510–6

Sleep protects against chemotherapy induced emesis. Domínguez-Ortega L, et al. **Cancer** 1996 Apr 15; 77(8):1566–70

Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting [letter; comment] Fedele P, et al. **Cancer** 1995 Aug 1;76(3):535–6 . Comment on: Cancer 1994 Oct 1;74(7):1945–52.

Localized cisplatin hyperpigmentation induced by pressure. A case report. Al-Lamki Z, et al. **Cancer** 1996 Apr 15; 77(8):1578–81

Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial [see comments] Mantovani G, et al. **Cancer** 1996 Mar 1;77(5):941–8. Comment in: Cancer 1996 Mar 1;77(5):823–33.

Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Morrow GR, et al. **Cancer** 1995 Aug 1; 76(3):343–57 (121 ref.)

Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma. Picco P, et al. **Cancer** 1995 Nov 1; 76(9):1662–4

Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis--a case report. Savarese DM, et al. **Cancer** 1996 Jan 15;77(2):387–94

Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S, et al. **Cancer** 1996 Feb 15;77(4):733–42

Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. Chang TC, et al. **Cancer Chemother Pharmacol** 1996;37(3):279–85

A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Harman GS, et al. **Cancer Chemother Pharmacol** 1996;38(4):323–8

Chromosome aberrations and pharmacokinetics in patients receiving tauromustine as either a single or a repeated dose. Hartley-Asp B, et al. **Cancer Chemother Pharmacol** 1996; 38(4):309–16

Is interleukin 3 active in anticancer drug-induced thrombocytopenia? Newland AC. **Cancer Chemother Pharmacol** 1996;38 Suppl:S83–8 (46 ref.)

Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patients. Kreis W, et al. **Cancer Invest** 1996;14(4):320–7

Radiation recall dermatitis induced by edatrexate in a patient with breast cancer. Perez EA, et al. **Cancer Invest** 1995; 13(6):604–7

Differences in nausea, vomiting, and retching between younger and older outpatients receiving cancer chemotherapy. Dodd MJ, et al. **Cancer Nurs** 1996 Jun; 19(3):155–61

Programmed instruction: Cancer therapy. Associated late effects. Rodriguez CS, et al. **Cancer Nurs** 1996 Jun; 19(3):214–27; quiz 228

Programmed instruction: cancer therapy. Associated late effects (II). Rodriguez CS, et al. **Cancer Nurs** 1996 Aug; 19(4):320–8; quiz 329–31

Menstrual cycles in nurses handling antineoplastic drugs. Shortridge LA, et al. **Cancer Nurs** 1995 Dec;18(6):439–44

Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system. Zwaveling JH, et al. **Cancer Res** 1996 Sep 1;56(17):3948–53

Emesis and anti–emesis. Naylor RJ, et al. **Cancer Surv** 1994; 21:117–35 (138 ref.)

Tumor lysis syndrome following single–dose mitoxantrone. Benekli M, et al. **Chemotherapy** 1995 Nov–Dec;41(6):470–2

Effects of cisplatin on urinary thromboxane B2 excretion. Blöchl–Daum B, et al. **Clin Pharmacol Ther** 1995 Oct; 58(4):418–24

Oral complications of local and systemic cancer treatment. Carl W. **Curr Opin Oncol** 1995 Jul;7(4):320–4 (28 ref.)

Management of diarrhea induced by tumors or cancer therapy. Cascinu S. **Curr Opin Oncol** 1995 Jul;7(4):325–9 (63 ref.)

Cardiotoxicity and cardioprotection during chemotherapy. Hochster H, et al. **Curr Opin Oncol** 1995 Jul;7(4):304–9 (37 ref.)

Cardiovascular toxicity with cancer chemotherapy. Frishman WH, et al. **Curr Probl Cardiol** 1996 Apr;21(4):225–86 (227 ref.)

Cutaneous side effects associated with interferon–alpha therapy: a review. Chang LW, et al. **Cutis** 1995 Sep; 56(3):144 (14 ref.)

Comparative adverse effect profiles of platinum drugs. McKeage MJ. **Drug Saf** 1995 Oct;13(4):228–44 (154 ref.)

The use of quinolones as therapy in granulocytopenic cancer patients. Comparison with other antimicrobials. Krcméry V Jr. **Drugs** 1995;49 Suppl 2:139–43 (30 ref.)

Monitoring chemotherapy–induced hearing loss in children. Bellman SC. **Eur J Cancer** 1996 Jun;32A(7):1185–8 (25 ref.)

Ondansetron for the control of dacarbazine–induced emesis [letter] Campora E, et al. **Eur J Cancer** 1995 Sep; 31A(10):1720–1

Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Capizzi RL, et al. **Eur J Cancer** 1995;31A Suppl 1:S8–13 (11 ref.)

Amifostine (WR–2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. Douay L, et al. **Eur J Cancer** 1995;31A Suppl 1:S14–6

Magnesium supplements with cisplatin chemotherapy. Lofts FJ, et al. **Eur J Cancer** 1996 Mar;32A(3):556–7

Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR–2721): preclinical aspects. Peters GJ, et al. **Eur J Cancer** 1995;31A Suppl 1:S1–7 (45 ref.)

Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Sleijfer S, et al. **Eur J Cancer** 1996 Mar; 32A(3):550–2

Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloride for prophylactic treatment of emesis induced by cisplatin chemotherapy. Tsukuda M, et al. **Eur J Cancer** 1995 Sep;31A(10):1647–9

Salivary immunoglobulins in cancer patients with chemotherapy–related oral mucosa damage. Janković L, et al. **Eur J Cancer B Oral Oncol** 1995 May;31B(3):160–5

A database for mucositis induced by cancer chemotherapy. Sonis ST, et al. **Eur J Cancer B Oral Oncol** 1995 Jul; 31B(4):258–60

Cryptococcal meningitis following fludarabine treatment for chronic lymphocytic leukemia [letter] Leenders A, et al. **Eur J Clin Microbiol Infect Dis** 1995 Sep;14(9):826–8

Effects of Erwinia–asparaginase on the coagulation system. Carlsson H, et al. **Eur J Haematol** 1995 Nov;55(5):289–93

Influence of selected clinical events on the need for red blood cell transfusion in patients with severe cytopenia following myeloablative chemotherapy. Friis LS, et al. **Eur J Haematol** 1996 Jan–Feb;56(1–2):23–9

Inhibition of hypercoagulation by antithrombin substitution in E. coli L–asparaginase–treated children. Nowak–Göttl U, et al. **Eur J Haematol** 1996 Jan–Feb;56(1–2):35–8

Intensive chemotherapy and bone marrow transplantation: the challenge of fungal infections. Introduction. Linch DC. **Eur J Haematol Suppl** 1996;57:5–6

Iodine–123 metaiodobenzylguanidine in the assessment of late cardiac effects from cancer therapy. Valdés Olmos RA, et al. **Eur J Nucl Med** 1996 Apr;23(4):453–8

The influence of serum tumor necrosis factor–alpha and interleukin–6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Hall PD, et al. **Exp Hematol** 1995 Nov;23(12):1256–60

Improvement of erythroid toxicity by lentinan and erythropoietin in mice treated with chemotherapeutic agents. Takatsuki F, et al. **Exp Hematol** 1996 Feb; 24(3):416–22

Protecting bone marrow by gene therapy [editorial; comment] Sikora K. **Gene Ther** 1995 Jun;2(4):233–4. Comment on: Gene Ther 1995 Jun;2(4):279–84. Comment on: Gene Ther 1995 Jun;2(4):285–94.

Retrospective review of gynecologic oncology patients with therapy–induced neutropenic fever. McMeekin DS, et al. **Gynecol Oncol** 1996 Aug;62(2):247–53

Hyperglycemia secondary to megestrol acetate for endometrial neoplasia. Rose PG. **Gynecol Oncol** 1996 Apr; 61(1):139–41

Late effects of treatment for Wilms tumor. Green DM, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1317–27 (83 ref.)

Chemotherapy and neutropenia. Kim SK, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):377–95 (123 ref.)

Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Moake JL, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):485–97 (66 ref.)

Hemolytic disorders associated with cancer. Rytting M, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):365–76 (87 ref.)

p53 mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies. Moll UM, et al. **Hum Pathol** 1995 Dec; 26(12):1293–301

Protection against cytosine arabinoside–induced alopecia by minoxidil in a rat animal model. Hussein AM. **Int J Dermatol** 1995 Jul;34(7):470–3

Philadelphia chromosome–negative cells with trisomy 8 after busulfan and interferon treatment of Ph1–positive chronic myelogenous leukemia. Izumi T, et al. **Int J Hematol** 1996 Jul;64(1):73–7 (17 ref.)

Abdomino–pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology. Formenti SC, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):993–1001

Phase II study of topotecan in metastatic hormone–refractory prostate cancer. Hudes GR, et al. **Invest New Drugs** 1995; 13(3):235–40

A phase I study of sulofenur in refractory pediatric malignant solid tumors. Pratt CB, et al. **Invest New Drugs** 1995; 13(1):63–6

Phase I trial of pentosan polysulfate. Swain SM, et al. **Invest New Drugs** 1995;13(1):55–62

An overview of the oral complications of adult patients with malignant haematological conditions who have undergone radiotherapy or chemotherapy. Coleman S. **J Adv Nurs** 1995 Dec;22(6):1085–91 (47 ref.)

Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. Prentice AG, et al. **J Antimicrob Chemother** 1995 Oct;36(4):657–63

Chemotherapy–associated neurotoxicity: an important side effect–impacting on quality, rather than quantity, of life [editorial] Markman M. **J Cancer Res Clin Oncol** 1996; 122(9):511–2

Granulocyte–macrophage colony stimulating factor (rh–GM–CSF) in the treatment of chemotherapy–induced neutropenia. Gözdasoglu S, et al. **J Chemother** 1995 Oct; 7(5):467–9

Cancer chemotherapy in the elderly. Conti JA, et al. **J Clin Gastroenterol** 1995 Jul;21(1):65–71 (63 ref.)

Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. Bertelli G, et al. **J Clin Oncol** 1995 Nov;13(11):2851–5

Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. Blay JY, et al. **J Clin Oncol** 1996 Feb;14(2):636–43

Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. Furman WL, et al. **J Clin Oncol** 1996 May;14(5):1504–11

Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children [editorial] Lipshultz SE. **J Clin Oncol** 1996 Feb;14(2):328–31

Is oral ondansetron really efficacious in the control of cisplatin–induced delayed emesis? [letter; comment] Martin M. **J Clin Oncol** 1996 Apr;14(4):1401–2. Comment on: J Clin Oncol 1995 Sep;13(9):2408–16.

Schedule–dependent edatrexate toxicity [letter; comment] Perez EA. **J Clin Oncol** 1996 Jan;14(1):322–3. Comment on: J Clin Oncol 1995 Jul;13(7):1649–55.

Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. Swain SM, et al. **J Clin Oncol** 1996 May;14(5):1565–72

Randomized placebo–controlled trial of granulocyte–macrophage colony–stimulating factor in patients with chemotherapy–related febrile neutropenia. Vellenga E, et al. **J Clin Oncol** 1996 Feb;14(2):619–27

Role of granulocyte–macrophage colony–stimulating factor in chemotherapy–induced oral mucositis [letter; comment] Wardley AM, et al. **J Clin Oncol** 1996 May;14(5):1741–3 . Comment on: J Clin Oncol 1995 Oct;13(10):2620–8.

Sinusoidal fetal heart rate pattern during chemotherapy in a pregnant woman with acute myelogenous leukemia. Hsu KF, et al. **J Formos Med Assoc** 1995 Sep;94(9):562–5

Mediastinal mass following chemotherapy in patients with Ewing sarcoma and osteosarcoma. Panadero MA, et al. **J Intern Med** 1996 May;239(5):457–60

Audiological findings in a Phase I protocol investigating the effect of WR 2721, high–dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. Rubin JS, et al. **J Laryngol Otol** 1995 Aug; 109(8):744–7

Cisplatin in children: hearing loss correlates with iris and skin pigmentation. Todd NW, et al. **J Laryngol Otol** 1995 Oct;109(10):926–9

Clinical niche sought for platelet–boosting drugs [news] Jenks S. **J Natl Cancer Inst** 1996 Aug 21;88(16):1104

The secondary leukemias: challenges and research directions. Smith MA, et al. **J Natl Cancer Inst** 1996 Apr 3; 88(7):407–18 (199 ref.)

Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease [see comments] van Leeuwen FE, et al. **J Natl Cancer Inst** 1995 Oct 18;87(20):1530–7. Comment in: J Natl Cancer Inst 1995 Oct 18;87(20):1502–3.

Intra–arterial cisplatin in malignant brain tumors: incidence and severity of otic toxicity. Assietti R, et al. **J Neurooncol** 1996 Mar;27(3):251–8

Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. Weitzner MA, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer; 7(3):347–50

Mucositis management practices for hospitalized patients: national survey results. Mueller BA, et al. **J Pain Symptom Manage** 1995 Oct;10(7):510–20

Pediatric phase I drug tolerance: a review and comparison of recent adult and pediatric phase I trials. Carlson L, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):250–6 (83 ref.)

Central nervous system toxicity of cancer therapy in children. Moore IM. **J Pediatr Oncol Nurs** 1995 Oct;12(4):203–10; discussion 211 (50 ref.)

Pharmacodynamic analysis of hematologic profiles. Rosner GL, et al. **J Pharmacokinet Biopharm** 1994 Dec; 22(6):499–524

Occurrence of monocytoid B lymphocytes in lymph nodes of patients treated by chemotherapy. Ohnishi A, et al. **J Surg Oncol** 1996 Aug;62(4):245–8

Determinants of myelosuppression in the treatment of non–small cell lung cancer with cisplatin–containing chemotherapy. Matsui K, et al. **Jpn J Cancer Res** 1996 Jul;87(7):781–6

Serum cytokine level fluctuations in chemotherapy–induced myelosuppression. Chen YM, et al. **Jpn J Clin Oncol** 1996 Feb;26(1):18–23

A randomized cross–over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin–induced delayed emesis. Sekine I, et al. **Jpn J Clin Oncol** 1996 Jun; 26(3):164–8

Plasma free iron and chemotherapy toxicity. Beare S, et al. **Lancet** 1996 Feb 10;347(8998):342–3

Fludarabine treatment and transfusion–associated graft–versus–host disease [letter] Williamson LM, et al. **Lancet** 1996 Aug 17;348(9025):472–3

Fulminant 2–chlorodeoxyadenosine–related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma. Warzocha K, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):343–6

Minimising the side effects of cancer chemotherapy [editorial; comment] Green M. **Med J Aust** 1996 Mar 18;164(6):326 . Comment on: Med J Aust 1996 Mar 18;164(6):337–40.

An open multicentre study of tropisetron for cisplatin–induced nausea and vomiting [see comments] Olver IN, et al. **Med J Aust** 1996 Mar 18;164(6):337–40. Comment in: Med J Aust 1996 Mar 18;164(6):326.

Interferon–induced acute renal failure: a case report and literature review. Horowitz R, et al. **Med Oncol** 1995 Mar; 12(1):55–7 (10 ref.)

Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy. Benoit Y, et al. **Med Pediatr Oncol** 1995 Dec;25(6):457–62

Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Broome CB, et al. **Med Pediatr Oncol** 1996 Feb;26(2):105–10

Ifosfamide tolerance in osteosarcoma patients previously treated with cis–diamminedichloroplatinum–II: renal, hematologic, and neurologic observations. Canpolat C, et al. **Med Pediatr Oncol** 1996 Jan;26(1):36–47

Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor–bearing rats. Le Bricon T, et al. **Metabolism** 1995 Oct;44(10):1340–8

The clinical use of mutagenic anticancer drugs [editorial] Ferguson LR, et al. **Mutat Res** 1996 Aug 17;355(1–2):1–12

Mutagenic and carcinogenic properties of platinum–based anticancer drugs. Sanderson BJ, et al. **Mutat Res** 1996 Aug 17;355(1–2):59–70 (59 ref.)

Pulmonary tuberculosis after fludarabine for chronic lymphocytic leukaemia [letter] Ghosh K, et al. **Natl Med J India** 1995 Nov–Dec;8(6):294–5

Progressive renal failure after cisplatin therapy. Jakob SM, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):370–3

'Complicated migraine–like episodes' in children following cranial irradiation and chemotherapy. Shuper A, et al. **Neurology** 1995 Oct;45(10):1837–40

Carmofur–induced leukoencephalopathy: MRI. Matsumoto S, et al. **Neuroradiology** 1995 Nov;37(8):649–52

Perceived concerns of pregnant women with breast cancer treated with chemotherapy. Bandyk EA, et al. **Oncol Nurs Forum** 1995 Jul;22(6):975–7

A flow sheet for follow–up after chemotherapy extravasation. Davis ME, et al. **Oncol Nurs Forum** 1995 Jul;22(6):979–83

Recalled side effects and self–care actions of patients receiving inpatient chemotherapy. Foltz AT, et al. **Oncol Nurs Forum** 1996 May;23(4):679–83

Nurses' perceptions of antiemetic effectiveness. Rhodes VA,

et al. **Oncol Nurs Forum** 1995 Sep;22(8):1243–52

Mechanisms and Management of Nausea and Emesis Associated with Cancer Therapy. Symposium proceedings. Marlow, United Kingdom, October 13–14, 1994. **Oncology** 1996 Jun;53 Suppl 1:1–110

Serotonin mechanisms in chemotherapy–induced emesis in cancer patients. Cubeddu LX. **Oncology** 1996 Jun;53 Suppl 1:18–25 (34 ref.)

Pathophysiology, severity, pattern, and risk factors for carboplatin–induced emesis. du Bois A, et al. **Oncology** 1996 Jun;53 Suppl 1:46–50 (29 ref.)

Evaluation of late nephrotoxicity in long–term survivors of Hodgkin's disease. Fels LM, et al. **Oncology** 1996 Jan–Feb; 53(1):73–8

Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin. Gralla RJ, et al. **Oncology** 1996 Jun;53 Suppl 1:86–91

Management of cisplatin–induced delayed emesis. Hesketh P. **Oncology** 1996 Jun;53 Suppl 1:73–7 (14 ref.)

The severity and pattern of emesis following different cytotoxic agents. Martin M. **Oncology** 1996 Jun;53 Suppl 1:26–31 (16 ref.)

Mechanisms of chemotherapy/radiotherapy–induced emesis in animal models. Naylor RJ, et al. **Oncology** 1996 Jun;53 Suppl 1:8–17 (77 ref.)

Quality of life studies in chemotherapy–induced emesis. Osoba D, et al. **Oncology** 1996 Jun;53 Suppl 1:92–5

5–HT3 receptor antagonists in the control of cisplatin–induced delayed emesis. Ossi M, et al. **Oncology** 1996 Jun;53 Suppl 1:78–85

Control of acute cisplatin–induced emesis over repeat courses of chemotherapy. Italian Group for Antiemetic Research. Roila F. **Oncology** 1996 Jun;53 Suppl 1:65–72

Management of other non–cisplatin–induced emesis. Schmoll HJ, et al. **Oncology** 1996 Jun;53 Suppl 1:51–5 (24 ref.)

Management of cyclophosphamide–induced emesis over repeat courses. Soukop M. **Oncology** 1996 Jun;53 Suppl 1:39–45

Optimal control of acute cisplatin–induced emesis. Verweij J, et al. **Oncology** 1996 Jun;53 Suppl 1:56–64 (80 ref.)

Phase II study shows that significantly fewer rhIL–11 treated patients require platelet transfusions [news] **Oncology (Huntingt)** 1995 Aug;9(8):785

Clinical trials referral resource. Cancer chemoprevention and control trials. Brawley OW, et al. **Oncology (Huntingt)** 1996 Apr;10(4):499–500

Is there a better way? Bioethical reflections on palliative cytotoxic drug use [editorial] McGrath P, et al. **Palliat Med** 1995 Oct;9(4):269–71

Late effects of cancer treatment in children. Ried H, et al. **Pediatr Dent** 1995 Jul–Aug;17(4):273–84 (117 ref.)

Prevention of emesis by tropisetron in children receiving combined chemotherapy with cisplatin. Berberoglu S. **Pediatr Hematol Oncol** 1995 Sep–Oct;12(5):479–83

Influence of treatment modalities on prepubertal growth in children with acute lymphoblastic leukemia [editorial] Moëll C, et al. **Pediatr Hematol Oncol** 1995 Sep–Oct; 12(5):425–7

Granulocyte functions in children with cancer are differentially sensitive to the toxic effect of chemotherapy. Lejeune M, et al. **Pediatr Res** 1996 May;39(5):835–42

Role of nausea in the development of aversions to a beverage paired with chemotherapy treatment in cancer patients. Schwartz MD, et al. **Physiol Behav** 1996 Apr–May; 59(4–5):659–63

A phase I trial of hypoxoside as an oral prodrug for cancer therapy—absence of toxicity. Smit BJ, et al. **S Afr Med J** 1995 Sep;85(9):865–70

Sucralfate: prophylaxis of mucosal damage during cancer therapy. Henriksson R, et al. **Scand J Gastroenterol Suppl** 1995;210:45–7 (29 ref.)

Future development of amifostine in cancer treatment. Alberts DS, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):90–9 (61 ref.)

Amifostine and chemotherapy–related thrombocytopenia. Budd GT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):49–52 (31 ref.)

Amifostine: the preclinical basis for broad–spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Capizzi R. **Semin Oncol** 1996 Aug;23(4 Suppl 8):2–17 (99 ref.)

Preventing chemotherapy–induced nausea and vomiting: an update and a review of emesis. Ettinger DS. **Semin Oncol** 1995 Aug;22(4 Suppl 10):6–18 (109 ref.)

Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Hesketh P. **Semin Oncol** 1995 Aug;22(4 Suppl 10):19–23 (23 ref.)

Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. List AF, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):58–63

Overview: oral granisetron (Kytril tablets) prophylaxis for chemotherapy–induced nausea and vomiting. Perez EA. **Semin Oncol** 1995 Aug;22(4 Suppl 10):1–2

Dose–ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Hesketh PJ, et al. **Support Care Cancer** 1996 Mar;4(2):141–6

Dexamethasone improves the efficacy of granisetron in the first 24 h following high–dose cisplatin chemotherapy. Latreille J, et al. **Support Care Cancer** 1995 Sep;3(5):307–12

Cisplatin–associated anaemia in patients with solid tumours. A retrospective evaluation and considerations relative to erythropoietin administration. Locatelli MC, et al. **Support Care Cancer** 1996 May;4(3):218–9

Postoperative infections in immunocompromised patients after oncological surgery. Ranchere JY, et al. **Support Care Cancer** 1995 Nov;3(6):409–13

Prevention of chemotherapy–induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double–blind, randomized, phase III study). Wurnig C, et al. **Transfusion** 1996 Feb;36(2):155–9

Prevention of highly emetogenic chemotherapy–induced vomiting: a double blind, randomized crossover study to compare pancopride (LAS 30451) and pancopride plus dexamethasone. Aranda E, et al. **Tumori** 1995 Nov–Dec; 81(6):432–4

Neutropenic colitis predominantly involving the transverse colon: CT aspect of an unusual presentation. Stein ME, et al. **Tumori** 1995 Nov–Dec;81(6):477–8

[Recompounding of intravesical Bacillus Calmette–Guerin] Jørgenson M, et al. **Ugeskr Laeger** 1996 May 20; 158(21):2996 **(Dan)**

[Vascular disorders following chemotherapy] van der Lelie J, et al. **Ned Tijdschr Geneeskd** 1995 Nov 11;139(45):2296–9 (24 ref.) **(Dut)**

[Tumor lysis syndrome in a dog] Piek CJ, et al. **Tijdschr Diergeneeskd** 1996 Feb 1;121(3):64–6 (Eng. Abstr.) **(Dut)**

[Chemotherapy and cardiotoxicity] Brestescher C, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):443–7 (Eng. Abstr.) **(Fre)**

[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine] Perrot JL, et al. **Ann Dermatol Venereol** 1995;122(10):663–6 (Eng. Abstr.) **(Fre)**

[Thrombotic microangiopathy after chemo–embolization with cisplatin (letter)] Blanche P, et al. **Ann Med Interne (Paris)** 1995;146(6):452 **(Fre)**

[Development of interferon antibodies during the treatment of skin diseases with low–dose recombinant interferon alpha–2a] Corbillet V, et al. **Ann Med Interne (Paris)** 1995; 146(6):399–403 (Eng. Abstr.) **(Fre)**

[Immunoblastic lymphoma following hairy cell leukemia treated with interferon alpha–2a (letter)] Granier H, et al. **Ann Med Interne (Paris)** 1996;147(3):221–2 **(Fre)**

[Early detection of cardiotoxicity of anthracyclines. Value of isotopic method] Massing JL, et al. **Arch Mal Coeur Vaiss** 1996 Jan;89(1):57–62 (Eng. Abstr.) **(Fre)**

[Cytotoxic chemotherapy in elderly patients: present and future] Freyer G, et al. **Bull Cancer (Paris)** 1995 Jul; 82(7):531–40 (66 ref.) (Eng. Abstr.) **(Fre)**

[Mental confusion syndromes in oncology] Reich MG, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):115–28 (73 ref.) (Eng. Abstr.) **(Fre)**

[Late complications of chemoradiotherapeutic combinations: fundamental aspects and clinical experience] Balosso J, et al. **Bull Cancer Radiother** 1995;82(2):101–12 (37 ref.) **(Fre)**

[Drug–induced acute pancreatitis] Grangé JD, et al. **Gastroenterol Clin Biol** 1995;19(5 Pt 2):B67–70 **(Fre)**

[Oro–dental manifestations of leukemia in children] Nikoui M, et al. **J Can Dent Assoc** 1996 May;62(5):443–6, 449–50 (41 ref.) (Eng. Abstr.) **(Fre)**

[Breast cancer after Hodgkin's disease (letter)] Cutuli B. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):301–2 **(Fre)**

[Thymus hyperplasia following chemotherapy] Cumin I, et al. **Presse Med** 1996 Feb 24;25(7):291–2 (13 ref.) (Eng. Abstr.) **(Fre)**

[Nephrotic syndrome complicating treatment with interferon alpha] Dhib M, et al. **Presse Med** 1996 Jun 29;25(23):1066–8 (18 ref.) (Eng. Abstr.) **(Fre)**

[Hematopoietic growth factors in iatrogenic neutropenia in oncology (editorial)] Klastersky J. **Rev Mal Respir** 1995; 12(5):407–8 **(Fre)**

[Hypomagnesemic and hypocalcemic coma, convulsions and ocular motility disorders after chemotherapy with platinum compounds] Bachmeyer C, et al. **Rev Med Interne** 1996; 17(6):467–9 (Eng. Abstr.) **(Fre)**

[Hypocalcemia caused by hypomagnesemia during a treatment with cisplatin (letter)] Brousse C, et al. **Rev Med Interne** 1996;17(6):498 **(Fre)**

[Renal tolerability of cisplatin (editorial)] Escudier B. **Rev Med Interne** 1996;17(6):450–1 **(Fre)**

[Convulsions in a patient treated for ovarian adenocarcinoma] Le Moing V, et al. **Rev Med Interne** 1996;17 Suppl 2:234s–236s **(Fre)**

[First case of urticaria due to dacarbazine (letter)] Bourry C, et al. **Therapie** 1995 Nov–Dec;50(6):588–9 **(Fre)**

[No cross hypersensitivity between molgramostim and filgrastime: apropos of a case (letter)] Chichmanian RM, et al. **Therapie** 1995 Sep–Oct;50(5):478–9 **(Fre)**

[Allogeneic stem cell transplantation. A valuable alternative after myoablative chemotherapy] Unterhuber R. **Fortschr Med** 1996 May 20;114(14):175–6 **(Ger)**

[Cardiotoxicity and cardioprotection in chemo– and radiotherapy for malignant diseases (editorial)] Wagdi P, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1216–9 (46 ref.) **(Ger)**

[Granisetron, a antiemetic for treatment of cytostatic drug–induced vomiting: results of a practice–oriented study] Golaszewski T, et al. **Wien Klin Wochenschr** 1995; 107(20):613–21 (Eng. Abstr.) **(Ger)**

[Main cardiotoxic drugs] Pettirossi G, et al. **Clin Ter** 1996 Jan–Feb;147(1–2):67–77 (34 ref.) (Eng. Abstr.) **(Ita)**

[The prevention of work risks deriving from the use of chemotherapeutic antineoplastics in the health environment: the consensus document (November 1995)] **Med Lav** 1996 Jan–Feb;87(1):78–86 (0 ref.) **(Ita)**

[The development of a new QOL Questionnaire on chemotherapy – induced emesis and vomiting—investigation of reliability and validity. Group for Investigation of QOL Questionnaire for Anti–Emetics Used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double–Blind Comparative study] Ishihara Y, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):745–55 (Eng. Abstr.) **(Jpn)**

[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP] Kimura E, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):477–81 (Eng. Abstr.) **(Jpn)**

[A comparative study of the effect of granisetron and a combination of granisetron plus steroids on cancer chemotherapy induced emesis] Nukariya N, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1821–9 (Eng. Abstr.) **(Jpn)**

[Side effects of cancer chemotherapy and steps to deal with them] Taguchi T. **Gan To Kagaku Ryoho** 1995 Dec; 22(14):2017–28 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Pathogenic mechanism of fulminant hepatic failure in HBs Ag carrier after withdrawal of cytotoxic chemotherapy] Inoue K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:467–72 (22 ref.) **(Jpn)**

[Tubulointerstitial changes in some hematological disorders] Morita H, et al. **Nippon Rinsho** 1995 Aug;53(8):2007–12 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Usefulness of continuous subcutaneous infusion of G–CSF for neutropenia due to chemotherapy for cancer] Tateoka K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep; 47(9):953–4 **(Jpn)**

[Drug–induced nephrotoxicity] Takeda M, et al. **Nippon Yakurigaku Zasshi** 1996 Jan;107(1):1–8 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Efficacy of early administration of G–CSF after intensive chemotherapy in acute leukemia: a randomized controlled trial. Tokai Infection Study Group on Hematological Disorders] Takeyama H, et al. **Rinsho Ketsueki** 1995 Nov; 36(11):1257–65 (Eng. Abstr.) **(Jpn)**

[Polyneuropathy in non–Hodgkin lymphoma] Bilińska M, et al. **Neurol Neurochir Pol** 1995 May–Jun;29(3):343–52 (Eng. Abstr.) **(Pol)**

[Long term results of treatment with cytostatic drugs on respiratory function tests in children] Koehler M, et al. **Pneumonol Pol** 1990 Jul–Aug;58(7–8):374–7 (Eng. Abstr.) **(Pol)**

[Late hematologic status after chemotherapy observed in patients 3 to 10 years after treatment] Pawlicki M, et al. **Przegl Lek** 1995;52(7):344–6 (Eng. Abstr.) **(Pol)**

[The cytogenetic reaction of the lymphocytes to in–vitro irradiation in children born to patients after antitumor radio– and chemotherapy] Vorobtsova IE, et al. **Tsitologiia** 1995;37(5–6):449–57 (Eng. Abstr.) **(Rus)**

[High–resolution electrocardiography in monitoring myocardial damage after therapy with anthracyclines in children] Mladosievičová B, et al. **Bratisl Lek Listy** 1996 May;97(5):289–97 (Eng. Abstr.) **(Slo)**

[Lung toxicity of cancer treatment] de Castro Carpeño J, et al. **Med Clin (Barc)** 1995 Nov 18;105(17):661–8 (76 ref.) **(Spa)**

[Fludarabine and fatal hemolytic anemia (letter)] López L, et al. **Sangre (Barc)** 1995 Aug;40(4):335–6 **(Spa)**

[Acute myocardial infarction after cytostatic therapy] Stolt CM. **Lakartidningen** 1995 Nov 22;92(47):4421–2 **(Swe)**

ANALYSIS

An anti–neoplastic glycan isolated from Mycobacterium bovis (BCG vaccine). Wang R, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):867–72

Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity. Groot K, et al. **Int J Pept Protein Res** 1995 Jun;45(6):561–6

Determination of ajmalicine in reserpine raw materials by liquid chromatography with fluorescence detection. Cieri UR. **J AOAC Int** 1995 Jul–Aug;78(4):944–5

Precision in capillary electrophoresis with respect to quantitative analysis of suramin. Hettiarachchi K, et al. **J Chromatogr A** 1995 Nov 24;717(1–2):191–202

Highly sensitive coupled–column high–performance liquid chromatographic method for the separation and quantitation of the diastereomers of leucovorin and 5–methyltetrahydrofolate in serum and urine. Schleyer E, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21; 669(2):319–30

ANTAGONISTS & INHIBITORS

Activin A inhibits growth and hexamethylene bisacetamide–induced differentiation in human retinoblastoma Y–79 cells. Zhang Z, et al. **Anticancer Res** 1996 Jan–Feb;16(1):269–72

[The molecular mechanisms of the multiple drug resistance of tumors] Leont'eva OV. **Antibiot Khimioter** 1995 May;

40(5):48–60 (84 ref.) **(Rus)**

[The biochemical mechanisms of drug resistance to N-alkyl-N-nitrosoureas and derivatives of cis-dichlorodiammineplatinum] Gorbacheva LB. **Vopr Onkol** 1995;41(2):50–1 **(Rus)**

[Nitroxyl radical Tempol as a modulator of toxic and antineoplastic effect of 6-mercaptopurine] Konovalova NP, et al. **Vopr Onkol** 1996;42(3):57–63 (Eng. Abstr.) **(Rus)**

BLOOD

Reduced albumin binding promotes the stability and activity of topotecan in human blood. Mi Z, et al. **Biochemistry** 1995 Oct 24;34(42):13722–8

Development and validation of a chiral high-performance liquid chromatography assay for rogletimide and rogletimide-N-oxide isomers in plasma. Etienne MC, et al. **Cancer Chemother Pharmacol** 1996;38(4):343–8

A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Ghazal-Aswad S, et al. **Cancer Chemother Pharmacol** 1996;37(5):429–34

Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Peng B, et al. **Eur J Cancer** 1995 Oct;31A(11):1804–10

Binding of a new multidrug resistance modulator, S9788, to human plasma proteins and erythrocytes. Urien S, et al. **Invest New Drugs** 1995;13(1):37–41

Determination of alpha-difluoromethylornithine in blood by microdialysis sampling and capillary electrophoresis with UV detection. Hu T, et al. **J Chromatogr A** 1995 Nov 17; 716(1–2):381–8

Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry. Poon GK, et al. **J Chromatogr A** 1995 Sep 29;712(1):61–6

A column-switching high-performance liquid chromatographic assay for a novel cytotoxic thioxanthone derivative (WIN 33377) in mouse plasma with toxicokinetic results from a mouse LD10 study. Drozd ML, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):145–51

High-performance liquid chromatography with fluorometric detection for monitoring of etoposide and its cis-isomer in plasma and leukaemic cells. Liliemark E, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):311–7

Sensitive high-performance liquid chromatographic method for the determination of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and erythrocytes. Rentsch KM, et al. **J Chromatogr B Biomed Appl** 1995 Nov 17;673(2):259–66

High-performance liquid chromatographic determination of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone in plasma. Rodgers AH, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18;670(2):365–8

High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. Rosing H, et al. **J Chromatogr B Biomed Appl** 1995 Jun 9;668(1):107–15

Specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea in plasma. Supko JG, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):351–62

Determination of the two diastereoisomers of lobaplatin (D-19466) in plasma ultrafiltrate of cancer patients with a normal or an impaired kidney or liver function by high-performance liquid chromatography with ultraviolet detection. Welink J, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):107–11

Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-hodgkin lymphoma. Keuzenkamp-Jansen CW, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):145–50

High-performance liquid chromatographic determination of cis-dichlorodiammineplatinum(II) in plasma ultrafiltrate. Augey V, et al. **J Pharm Biomed Anal** 1995 Aug; 13(9):1173–8

An on-line semi-automated solid-phase extraction procedure for high-performance liquid chromatographic determination of lonidamine in serum. Bottalico C, et al. **J Pharm Biomed Anal** 1995 Oct;13(11):1349–53

[HPLC determination of 4-[4"-(2",2",6",6"-tetramethyl-1"-piperidinyloxy) amino]-4'-demethylepipodophyllotoxin in rat plasma and studies of its pharmacokinetics] Jia ZP, et al. **Yao Hsueh Hsueh Pao** 1995;30(10):768–72 (Eng. Abstr.) **(Chi)**

[Anticancer drugs] Fujita H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1043–52 (15 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Pyrimido [4,5,6-kl] acridines, a new class of potential anticancer agents. Synthesis and biological evaluation. Antonini I, et al. **Anticancer Drug Des** 1996 Jun; 11(4):339–49

Bis-naphthalimides 3: synthesis and antitumor activity of N,N'-bis[2-(1,8-naphthalimido)-ethyl] alkanediamines. Braña MF, et al. **Anticancer Drug Des** 1996 Jun; 11(4):297–309

Pyrazole-related nucleosides. 4. Synthesis and antitumor activity of some 1-tetrahydropyranyl-4-substituted pyrazoles. Manfredini S, et al. **Anticancer Drug Des** 1996 Apr;11(3):193–204

Synthesis and biological evaluation of a new series of phenylhydroquinone derivatives as inhibitors of EGF-R-associated PTK activity. Million ME, et al. **Anticancer Drug Des** 1996 Mar;11(2):129–53

Synthesis of novel androgen-linked phosphoramide mustard prodrugs and growth-inhibitory activity in human breast cancer cells. Roth T, et al. **Anticancer Drug Des** 1995 Dec; 10(8):655–66

Synthesis and antitumor activity of some analogues of flavone acetic acid. Valenti P, et al. **Anticancer Drug Des** 1996 Apr; 11(3):243–52

Synthesis of ether-linked analogues of lysophosphatidate and their effect on the proliferation of human epithelial cancer cells in vitro. Ashagbley A, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1813–8

Antitumor activity of phenothiazine-related compounds. Nagy S, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1915–8

Synthesis, antitumoral and antiviral evaluation of halo- and demethyl-yatein derivatives. Medarde M, et al. **Arch Pharm (Weinheim)** 1995 Sep;328(9):640–4

Synthesis, structure and antitumor activity of new benz[d,e]isoquinoline-1,3-diones. Braña MF, et al. **Arzneimittelforschung** 1995 Dec;45(12):1311–8

In vitro evaluation of the potential antitumor activity of an N-acridyl-pentanoyloxypyridine-2-thione derivative. Nocentini G, et al. **Arzneimittelforschung** 1995 Oct; 45(10):1127–30

Improved cytotoxicity of antitumor compounds deliverable by the LDL pathway. Dubowchik GM, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):427–39

Synthesis of key analogs of bleomycin A2 that permit a systematic evaluation of the linker region: identification of an exceptionally prominent role for the L-threonine substituent. Boger DL, et al. **Bioorg Med Chem** 1995 Sep; 3(9):1281–95

Design and synthesis of new mitochondrial cytotoxin N-thiadiazolylanilines that inhibit tumor cell growth. Hori H, et al. **Bioorg Med Chem** 1996 Feb;4(2):247–53

Heterocondensed quinazolones: synthesis and protein-tyrosine kinase inhibitory activity of 3,4-dihydro-1H,6H-[1,4] oxazino-[3,4-b]quinazolin-6-one derivatives. Orfi L, et al. **Bioorg Med Chem** 1996 Apr; 4(4):547–51

Cytotoxic activity of diorganotin(IV) complexes of some xanthate derivatives. Rashan LJ, et al. **Boll Chim Farm** 1995 Sep;134(8):464–6

Water-soluble antitumor agents. I. Synthesis and biological activity of 6-S-aminoacyloxymethyl mercaptopurine derivatives. Harada N, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1793–6

Improved total synthesis and structure-activity relationship of arenastatin A, a potent cytotoxic spongean depsipeptide. Kobayashi M, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep; 43(9):1598–600

Synthesis and antitumor activity of novel dolastatin 10 analogs. Miyazaki K, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1706–18

Synthesis of carboxymethylpullulan-peptide-doxorubicin conjugates and their properties. Nogusa H, et al. **Chem Pharm Bull (Tokyo)** 1995 Nov;43(11):1931–6

Synthesis, DNA interaction and antineoplastic activity of semicarbazone derivatives. Asís SE, et al. **Farmaco** 1996 Jun;51(6):419–23

Polycondensed nitrogen heterocycles. Part 27. Indolo[3,2-c]cinnoline. Synthesis and antileukemic activity. Cirrincione G, et al. **Farmaco** 1995 Dec;50(12):849–52

2-Diazopyrroles: synthesis and antileukemic activity. Cirrincione G, et al. **Farmaco** 1996 Apr;51(4):275–7

Synthesis and anticancer properties of pyrimido[4,5-b]quinolines. Długosz A, et al. **Farmaco** 1996 May;51(5):367–74

Synthesis and in vitro antitumor activity evaluation of 9-substituted 1,2,3,4-tetrahydrocarbazoles. Grasso S, et al. **Farmaco** 1996 Apr;51(4):269–74

Synthesis and antitumour activity of fluorinated 1-aza and 1,8-diazaanthraquinones. Ramos MT, et al. **Farmaco** 1996 May;51(5):375–9

Synthesis and cytostatic activity of some sulfamido-anthraquinones. Teijeira M, et al. **Farmaco** 1996 Jun;51(6):447–50

Synthesis and biological evaluation of substituted phosphate triester alkyl lyso phospholipids (ALPs) as novel potential anti-neoplastic agents. McGuigan C, et al. **FEBS Lett** 1995 Sep 25;372(2–3):259–63

Synthesis and antimetastatic activity of 6-trichloroacetamido and 6-guanidino analogues of siastatin B. Satoh T, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):321–5

Platinum(II) complexes of 4-methoxy- and 4-chlorobenzoic acid hydrazides. Synthesis, characterization, and cytotoxic effect. Dodoff N, et al. **J Inorg Biochem** 1995 Dec; 60(4):257–66

Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer. Akama T, et al. **J Med Chem** 1996 Aug 30;39(18):3461–9

Synthesis, antitumor activity, and chemical properties of silaplatin and related platinum (II) and platinum (IV) complexes derived from beta-silyl amines. Anderson WK, et al. **J Med Chem** 1995 Sep 15;38(19):3789–97

Potential antitumor agents. 24. Synthesis and pharmacological behavior of imidazo[2,1-b]thiazole guanylhydrazones bearing at least one chlorine. Andreani A, et al. **J Med Chem** 1996 Jul 5;39(14):2852–5

Quinazoline antifolate thymidylate synthase inhibitors: gamma-linked L-D, D-D, and D-L dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583). Bavetsias V, et al. **J Med Chem** 1996 Jan 5;39(1):73–85

3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. Chan FC, et al. **J Med Chem** 1996 Aug 16;39(17):3319–23

Synthesis and evaluation of novel thymidine analogs as antitumor and antiviral agents. Chen X, et al. **J Med Chem** 1996 Aug 16;39(17):3412–7

Structure-activity relationship for antineoplastic imidazoacridinones: synthesis and antileukemic activity in vivo. Cholody WM, et al. **J Med Chem** 1996 Mar 1; 39(5):1028–32

Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates. Devraj R, et al. **J Med Chem** 1996 Aug 16;39(17):3367–74

New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link. Dowell RI, et al. **J Med Chem** 1996 Mar 1;39(5):1100–5

Synthesis and evaluation of the antiproliferative effects of 1-O-hexadecyl-2-O-methyl-3-O-(2'-acetamido-2'-deoxy-beta-D- glucopyranosyl)-sn-glycerol and 1-O-hexadecyl-2-O-methyl-3-O-(2'-amino-2'-deoxy-beta-D-glucopyranosyl)-sn-glycerol on epithelial cancer cell growth. Erukulla RK, et al. **J Med Chem** 1996 Mar 29;39(7):1545–8

6-Substituted and 5,6-disubstituted derivatives of uridine: stereoselective synthesis, interaction with uridine phosphorylase, and in vitro antitumor activity. Felczak K, et al. **J Med Chem** 1996 Apr 12;39(8):1720–8

Furanfurin and thiophenfurin: two novel tiazofurin analogues. Synthesis, structure, antitumor activity, and interactions with inosine monophosphate dehydrogenase. Franchetti P, et al. **J Med Chem** 1995 Sep 15;38(19):3829–37

Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines. Gangjee A, et al. **J Med Chem** 1995 Sep 15;38(19):3798–805

5-Arylthio-substituted 2-amino-4-oxo-6-methylpyrrolo[2,3-d]pyrimidine antifolates as thymidylate synthase inhibitors and antitumor agents. Gangjee A, et al. **J Med Chem** 1995 Oct 27; 38(22):4495–502

Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity. Gatto B, et al. **J Med Chem** 1996 Aug 2; 39(16):3114–22

Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase. Jones TR, et al. **J Med Chem** 1996 Feb 16;39(4):904–17

Substituted 2,5'-Bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity. Kim JS, et al. **J Med Chem** 1996 Feb 16;39(4):992–8

Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity. Kim JY, et al. **J Med Chem** 1996 Jul 5;39(14):2812–8

Synthesis and X-ray crystal structure of trans,cis-[Pt(OAc)2l2(en)]: a novel type of cisplatin analog that can be photolyzed by visible light to DNA-binding and cytotoxic species in vitro. Kratochwil NA, et al. **J Med Chem** 1996 Jun 21;39(13):2499–507

Synthesis and cytotoxicity of 1,2-disubstituted naphth[2,3-d]imidazole-4,9-diones and related compounds. Kuo SC, et al. **J Med Chem** 1996 Mar 29;39(7):1447–51

High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. Kuyper LF, et al. **J Med Chem** 1996 Feb 16;39(4):892–903

Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecane. Li Y, et al. **J Med Chem** 1996 Jan 5;39(1):339–41

Synthesis and biological activity of 3- and 5-amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. Liu MC, et al. **J Med Chem** 1996 Jun 21;39(13):2586–93

Synthesis and antitumor activity of 4- and 5-substituted derivatives of isoquinoline-1-carboxaldehyde thiosemicarbazone. Liu MC, et al. **J Med Chem** 1995 Oct 13;38(21):4234–43

Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins. Macchia M, et al. **J Med Chem** 1996 Mar 29;39(7):1352–6

Nucleoside analogs. 14. The synthesis of antitumor activity in mice of molecular combinations of 5-fluorouracil and N-(2-Chloroethyl)-N-nitrosourea moieties separated by a three-carbon chain. McElhinney RS, et al. **J Med Chem** 1996 Mar 29;39(7):1403–12

Synthesis and growth inhibitory properties of glycosides of 1-O-hexadecyl-2-O-methyl-sn-glycerol, analogs of the antitumor ether lipid ET-18-OCH3 (edelfosine). Marino-Albernas JR, et al. **J Med Chem** 1996 Aug 16; 39(17):3241–7

Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. Palmer BD, et al. **J Med Chem** 1996 Jun 21;39(13):2518-28

Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. Rowlands MG, et al. **J Med Chem** 1995 Oct 13; 38(21):4191-7

6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships. Sami SM, et al. **J Med Chem** 1996 Apr 12;39(8):1609-18

Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. Shi DF, et al. **J Med Chem** 1996 Aug 16; 39(17):3375-84

A 5'-(trifluoromethyl)anthracycline glycoside: synthesis of antitumor-active 7-O-(2,6-dideoxy-6,6,6-trifluoro-alpha-L-lyxo-hexopyranosyl) adriamycinone. Takagi Y, et al. **J Med Chem** 1996 Apr 12;39(8):1582-8

Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. Tercel M, et al. **J Med Chem** 1996 Mar 1;39(5):1084-94

Antitumor activity of S-(p-bromobenzyl)glutathione diesters in vitro: a structure-activity study. Thornalley PJ, et al. **J Med Chem** 1996 Aug 16;39(17):3409-11

Antitumor agents. 166. Synthesis and biological evaluation of 5,6,7,8-substituted-2-phenylthiochromen-4-ones. Wang HK, et al. **J Med Chem** 1996 May 10;39(10):1975-80

2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase. Williams TM, et al. **J Med Chem** 1996 Mar 29;39(7):1345-8

Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components. Rau T, et al. **Met Ions Biol Syst** 1996; 32:339-78 (95 ref.)

Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide. Garg PK, et al. **Nucl Med Biol** 1995 May;22(4):467-73

Synthesis and biological activity of 1,2,4-triazinotriazinone derivatives. Abdel-Halim AM, et al. **Pharmazie** 1995 Nov; 50(11):726-9

Synthesis and cytotoxicity of amine-borane adducts of cyclohexylamines and toluidines. Burnham BS, et al. **Pharmazie** 1995 Dec;50(12):779-83

Synthesis and cytotoxic evaluation of some Mannich bases of alicyclic ketones. Dimmock JR, et al. **Pharmazie** 1995 Oct;50(10):668-71

Antitumor and immunosuppressive activity of Merbarone's analogues and arylidenehydrazinopyrimidines. Długosz A, et al. **Pharmazie** 1995 Aug;50(8):529-34

Cytotoxic activity of some (E)-7-arylidene-2 H,6 H-naphtho-[1,8-bc]furan-2,6-diones and correlation with their electronic parameters. Do Nascimento SC, et al. **Pharmazie** 1995 Aug;50(8):563-5

[Synthesis of substituted benzeneseleninic acid and its antineoplastic activity] Zheng S, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):371-4 (Eng. Abstr.) **(Chi)**

[Synthesis of retinoids with a modified polar group and their antitumor activity. Report I] Deribina EL, et al. **Bioorg Khim** 1995 Dec;21(12):941-9 (Eng. Abstr.) **(Rus)**

[Synthesis and biological properties of pyrimidine 2'-deoxynucleosides modified by a residue of quinaldic acid] Ektova LV, et al. **Bioorg Khim** 1995 Aug;21(8):625-31 (Eng. Abstr.) **(Rus)**

[Acyclic nucleoside analogs: synthesis and cytotoxic properties of acyl derivatives of 3'(5')-amino-3'(5')-deoxy-2',3'-secoadenosine] Goriunova OV, et al. **Bioorg Khim** 1995 Aug;21(8):617-24 (Eng. Abstr.) **(Rus)**

CHEMISTRY

1-(p-carbamoylphenyl)-3,3-dimethyl-triazene, an antitumour agent. Bullerwell WL, et al. **Acta Crystallogr C** 1995 Dec 15;51 (Pt 12):2624-7

Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. Henry DW, et al. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2570-3

Structural identification of the degradation products of the antitumor peptide antagonist [Arg6,D-Trp7,9,MePhe8]substance P (6-11). Reubsaet JL, et al. **Anal Chem** 1995 Dec 1;67(23):4431-6

Chirality of a 1,10-bisacetoxymitosene compound. Impact on reductive activation, DNA interstrand cross-linking and antitumour activity. Maliepaard M, et al. **Anticancer Drug Des** 1996 Jul;11(5):403-13

QSAR of acridines, III. Structure-activity relationship for antitumour imidazoacridinones and intercorrelations between in vivo and in vitro tests. Mazerska Z, et al. **Anticancer Drug Des** 1996 Jan;11(1):73-88

A 1H NMR analysis of the interaction between terephthalamide derivatives and the oligonucleotide duplex d(GGTAATTACC)2. Pavlopoulos S, et al. **Anticancer Drug Des** 1995 Dec;10(8):623-39

Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Pettit GR, et al. **Anticancer Drug Des** 1995 Oct;10(7):529-44

A role for density functional calculations in the rational design of bioreductive cobalt complexes? Wu JH, et al. **Anticancer Drug Des** 1996 Jul;11(5):415-20

Direct radioiodination of metabolic 8-hydroxy-quinolyl-glucuronide, as a potential anti-cancer drug. Unak T, et al. **Appl Radiat Isot** 1996 Jul; 47(7):645-7

Temperature induced interstrand crosslinks in cisplatin-DNA adducts detected by electrophoresis and UV spectrophotometer. Narasimhan V, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):843-51

Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives. Interactions with tubulin. Hamel E, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):53-9

HPLC and 31P NMR characterization of the reaction between antitumor platinum agents and the phosphorothioate chemoprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). Thompson DC, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1413-9

Interactions of acridine antitumor agents with DNA: binding energies and groove preferences. Crenshaw JM, et al. **Biochemistry** 1995 Oct 17;34(41):13682-7

Spectroscopic characterization of the alkylated alpha-sarcin cytotoxin: analysis of the structural requirements for the protein-lipid bilayer hydrophobic interaction. Gasset M, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):43-52

Thermal unfolding of the cytotoxin alpha-sarcin: phospholipid binding induces destabilization of the protein structure. Gasset M, et al. **Biochim Biophys Acta** 1995 Sep 27;1252(1):126-34

Interdigitation of bilayers from ether lipid analogs: (R)-PAF, (R)-Lyso-PAF and the antineoplastic (R)-ET-18-OMe. Xie X, et al. **Biochim Biophys Acta** 1996 Aug 14; 1283(1):111-8

Stabilization of Octastatin, a somatostatin analogue. Preparation of freeze-dried products for parenteral injection. Pourrat H, et al. **Biol Pharm Bull** 1995 May; 18(5):766-71

DNA-DNA interstrand cross-linking by cis-diamminedichloroplatinum(II): N7(dG)-to-N7(dG) cross-linking at 5'-d(GC) in synthetic oligonucleotides. Huang H, et al. **Bioorg Med Chem** 1995 Jun;3(6):659-69

Kinetics and mechanism of general acid-catalysed thiolytic cleavage of 9-anilinoacridine. Khan MN, et al. **Bioorg Med Chem** 1995 Jul;3(7):881-90

Asymmetry and dynamics in bis-intercalated DNA. Peek ME, et al. **Bioorg Med Chem** 1995 Jun;3(6):693-9

Multiple DNA binding modes of anthracene-9-carbonyl-N1-spermine. Rodger A, et al. **Bioorg Med Chem** 1995 Jun;3(6):861-72

Studies on the synthesis and biological activities of 4'-(R)-hydroxy-5'-(S)-hydroxymethyl-tetrahydrofuranyl purines and pyrimidines. Yu HW, et al. **Bioorg Med Chem** 1996 Apr;4(4):609-14

The effect of ionic strength on melting of DNA modified by platinum(II) complexes. Zaludová R, et al. **Biophys Chem** 1996 Jun 11;60(3):135-42

Conformational analysis of dolastatin 10: an NMR and theoretical approach. Benedetti E, et al. **Biopolymers** 1995 Oct;36(4):525-38

Properties of Auricularia auricula-judae beta-D-glucan in dilute solution. Zhang L, et al. **Biopolymers** 1995 Dec; 36(6):695-700

Pressure tuning infrared spectroscopic study of cisplatin-induced structural changes in a phosphatidylserine model membrane. Taylor KD, et al. **Br J Cancer** 1995 Dec;72(6):1400-5

Analysis of HMG protein binding to DNA modified with the anticancer drug cisplatin. Cryer JE, et al. **Cancer Chemother Pharmacol** 1996;38(2):163-8

Modification of mitomycin C-induced clastogenicity by Terminalia catappa L. in vitro and in vivo. Liu TY, et al. **Cancer Lett** 1996 Jul 19;105(1):113-8

Diaziquone-glutathione conjugates: characterization and mechanisms of formation. Gutierrez PL, et al. **Chem Res Toxicol** 1995 Apr-May;8(3):455-64

Partial N-terminal amino acid sequence of the anti-neoplastic urinary protein (ANUP) and the anti-tumour effect of the N-terminal nonapeptide of the unique cytokine present in human granulocytes. Ridge RJ, et al. **Cytokine** 1996 Jan; 8(1):1-5

Acylfulvenes, a new class of potent antitumor agents. McMorris TC, et al. **Experientia** 1996 Jan 16;52(1):75-80

DNA recognition by two mitoxantrone analogues: influence of the hydroxyl groups. Bailly C, et al. **FEBS Lett** 1996 Feb 5;379(3):269-72

Structure of transient radicals from cytostatic-active p-alkoxyphenols by continuous-flow EPR. Lassmann G, et al. **Free Radic Biol Med** 1995 Nov;19(5):533-9

Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Lifely MR, et al. **Glycobiology** 1995 Dec;5(8):813-22

Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice. Kuroda K, et al. **Int J Cancer** 1995 Sep 27;63(1):152-7

Structure of the spiroketal-macrolide ossamycin. Kirst HA, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):162-7

Louisianins A, B, C and D: non-steroidal growth inhibitors of testosterone-responsive SC 115 cells. II. Physico-chemical properties and structural elucidation. Takamatsu S, et al. **J Antibiot (Tokyo)** 1995 Oct; 48(10):1090-4

Designing of chimeric DNA/RNA hammerhead ribozymes to be targeted against AML1/MTG8 mRNA. Kozu T, et al. **J Cancer Res Clin Oncol** 1996;122(4):254-6

Molecular modeling in the discovery of drug leads. Milne GW, et al. **J Chem Inf Comput Sci** 1996 Jul-Aug; 36(4):726-30

Use of principal component analysis for the study of the retention behaviour of anticancer drugs on a beta-cyclodextrin polymer-coated silica column. Cserháti T, et al. **J Chromatogr A** 1996 Mar 29;728(1-2):67-73

Isolation and photodynamic effects of hematoporphyrin derivative components: a chromatographic analysis of the starting materials. Owens JW, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):295-309

Conformational behaviour of the antineoplastic peptide dolastatin-10 and of two mutated derivatives. Fantucci P, et al. **J Comput Aided Mol Des** 1995 Oct;9(5):425-38

Palladium(II) complexes of dialkyl alpha-Anilinobenzylphosphonates. Synthesis, characterization, and cytostatic activity. Curić M, et al. **J Inorg Biochem** 1996 Aug 1;63(2):125-42

Unusual reactivity of cisplatin analogs that bear o-phenylenediamine ligands: insights for the design of more effective cytotoxic agents. Köckerbauer R, et al. **J Inorg Biochem** 1996 Jun;62(4):281-98

The interaction of antitumor-active anthraquinones with biologically important redox couples: I. Spectrophotometric investigation of the interaction of carminic acid and mitoxantrone with the iron (II, III) and copper (I, II) redox couples. Tütem E, et al. **J Inorg Biochem** 1996 Feb;61(2):79-96

Antitumor activity of the Cu(II)-mitoxantrone complex and its interaction with deoxyribonucleic acid. Yang P, et al. **J Inorg Biochem** 1996 May 1;62(2):137-45

Antitumor agents. 163. Three-dimensional quantitative structure-activity relationship study of 4'-O-demethylepipodophyllotoxin analogs using the modified CoMFA/q2-GRS approach. Cho SJ, et al. **J Med Chem** 1996 Mar 29;39(7):1383-95

Synthesis and X-ray crystal structure of trans,cis-[Pt(OAc)2I2(en)]: a novel type of cisplatin analog that can be photolyzed by visible light to DNA-binding and cytotoxic species in vitro. Kratochwil NA, et al. **J Med Chem** 1996 Jun 21;39(13):2499-507

In vivo activity and hydrophobicity of cytostatic aziridinyl quinones. Moret EE, et al. **J Med Chem** 1996 Feb 2; 39(3):720-8

Mapping the aspartic acid binding site of Escherichia coli asparagine synthetase B using substrate analogs. Parr IB, et al. **J Med Chem** 1996 Jun 7;39(12):2367-78

Analogues of 10-deazaaminopterin and 5-alkyl-5,10-dideazaaminopterin with the 4-substituted 1-naphthoyl group in the place of 4-substituted benzoyl. Piper JR, et al. **J Med Chem** 1996 Jan 19;39(2):614-8

Structure-activity relationships of cytotoxic cholesterol-modified DNA duplexes. Reed MW, et al. **J Med Chem** 1995 Oct 27;38(22):4587-96

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. Traxler PM, et al. **J Med Chem** 1996 Jun 7;39(12):2285-92

Antitumor activity and stereochemistry of acetylenic alcohols from the sponge Cribrochalina vasculum. Hallock YF, et al. **J Nat Prod** 1995 Dec;58(12):1801-7

Sinugibberol, a new cytotoxic cembranoid diterpene from the soft coral Sinularia gibberosa. Hou RS, et al. **J Nat Prod** 1995 Jul;58(7):1126-30

Uprolides D-G, 2. A rare family of 4,7-oxa-bridged cembranolides from the Caribbean gorgonian Eunicea mammosa. Rodríguez AD, et al. **J Nat Prod** 1995 Aug; 58(8):1209-16

Water/n-octanol partition coefficients of 1,2-dithiole-3-thiones. Bona M, et al. **J Pharm Sci** 1995 Sep;84(9):1107-12

Relationship between cell-killing efficiency and number of platinum atoms binding to DNA, RNA, and protein molecules in HeLa cells treated with cis-diamine(glycolato)platinum(II). Akaboshi M, et al. **Jpn J Cancer Res** 1996 Feb;87(2):178-83

Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Bloemink MJ, et al. **Met Ions Biol Syst** 1996;32:641-85 (191 ref.)

Interactions of metallopharmaceuticals with DNA. Clarke MJ, et al. **Met Ions Biol Syst** 1996;32:727-80 (235 ref.)

Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Farrell N. **Met Ions Biol Syst** 1996;32:603-39 (104 ref.)

Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids. Lippert B. **Met Ions Biol Syst** 1996;33:105-41 (153 ref.)

Cancer chemotherapy. Heavy metal revival [news; comment] [see comments] Petsko GA. **Nature** 1995 Oct 19; 377(6550):580-1. Comment on: Nature 1995 Oct 19;377(6550):649-52. Comment in: Nature 1995 Dec 7;378(6557):532.

ANTINEOPLASTIC AGENTS

Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin [see comments] Takahara PM, et al. **Nature** 1995 Oct 19; 377(6550):649-52. Comment in: Nature 1995 Oct 19;377(6550):580. Comment in: Nature 1995 Dec 7;378(6557):532.

The width of the minor groove affects the binding of the bisquaternary heterocycle SN-6999 to duplex DNA. Rydzewski JM, et al. **Nucleic Acids Res** 1996 Apr 1; 24(7):1287-93

Suppression of c-myc oncogene expression by a polyamine-complexed triplex forming oligonucleotide in MCF-7 breast cancer cells. Thomas TJ, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3594-9

The influence of formulation excipients on the stability of the novel antitumor agent carzelesin (U-80,244). Jonkman-De Vries JD, et al. **PDA J Pharm Sci Technol** 1995 Nov-Dec;49(6):283-8

Stabilization of Octastatin, a somatostatin analogue: comparative accelerated stability studies of two formulations for freeze-dried products. Barthomeuf C, et al. **Pharm Acta Helv** 1996 Jul;71(2):161-6

Photoinstability of some tyrphostin drugs: chemical consequences of crystallinity. Kumar N, et al. **Pharm Res** 1995 Nov;12(11):1708-15

Interactions between N-aspartyl chlorin e6, detergent micelles and plasma lipoproteins. Kessel D. **Photochem Photobiol** 1995 Jun;61(6):646-9

Biological activities of pyrrolidinoindoline alkaloids from Calycodendron milnei. Saad HE, et al. **Planta Med** 1995 Aug;61(4):313-6

Chemical and biological properties of cytotoxic alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Liu MC, et al. **Prog Med Chem** 1995; 32:1-35 (157 ref.)

Electrospray ionization mass spectrometry of covalent ligand-oligonucleotide adducts: evidence for specific duplex ion formation. Wickham G, et al. **Rapid Commun Mass Spectrom** 1995;Spec No:S197-203

Immunohistological reaction mechanism of anti-monosialoganglioside monoclonal antibody, MAb 202, showing predominant cytotoxicity for malignant melanoma. Ota T, et al. **Tohoku J Exp Med** 1995 Sep; 177(1):1-12

DIAGNOSTIC USE

Detection of squamous neoplasia by fluorescence imaging comparing porfimer sodium fluorescence to tissue autofluorescence in the hamster cheek-pouch model. Pathak I, et al. **Am J Surg** 1995 Nov;170(5):423-6

The role of MIBG scintigraphy in the management of a case of metastatic glomus jugulare tumour. Nilssen E, et al. **J Laryngol Otol** 1996 Apr;110(4):373-5

ECONOMICS

The effect of medicare reimbursement policies on the cost and setting of cancer chemotherapy. Cowan DH. **Cancer Invest** 1996;14(2):184-6

Symposium on health economics in oncology. Freiburg, Germany, June 1995. Kranich AL, et al. **J Cancer Res Clin Oncol** 1995;121(11):691-3

Economic and quality of life outcomes: the four-step pharmacoeconomic research model. Arikian SR, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):33-6

HISTORY

The history of the oxazaphosphorine cytostatics. Brock N. **Cancer** 1996 Aug 1;78(3):542-7

Cancer chemotherapy 1973-present: a personal perspective. Carter SK. **J Cancer Res Clin Oncol** 1995;121(9-10):501-4

IMMUNOLOGY

A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Pan ZK, et al. **Nat Med** 1995 May;1(5):471-7

ISOLATION & PURIFICATION

Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl) ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity. Gust R, et al. **Arch Pharm (Weinheim)** 1995 Sep;328(9):645-53

Cytotoxic limonoids and tetranortriterpenoids from Melia azedarach. Itokawa H, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1171-5

Purification, characterization and anti-tumor activity of a new cytokine, histiocyte-secreted-factor (HSF). Satomi N, et al. **Int J Cancer** 1996 Apr 10;66(2):209-13

Louisianins A, B, C and D: non-steroidal growth inhibitors of testosterone-responsive SC 115 cells. I. Taxonomy, fermentation, isolation and biological characteristics. Komiyama K, et al. **J Antibiot (Tokyo)** 1995 Oct; 48(10):1086-9

Selectively cytotoxic diterpenes from Euphorbia poisonii. Fatope MO, et al. **J Med Chem** 1996 Feb 16;39(4):1005-8

An antimitotic and cytotoxic chalcone from Fissistigma lanuginosum. Alias Y, et al. **J Nat Prod** 1995 Aug; 58(8):1160-6

Isolation and structure identification of an active DNA strand-scission agent, (+)-3,4-di-hydroxy-8,9-methylenedioxypterocarpan. Chaudhuri SK, et al. **J Nat Prod** 1995 Dec;58(12):1966-9

New steroid acids from Antrodia cinnamomea, a fungal parasite of Cinnamomum micranthum. Chen CH, et al. **J Nat Prod** 1995 Nov;58(11):1655-61

Majapolene A, a cytotoxic peroxide, and related sesquiterpenes from the red alga Laurencia majuscula. Erickson KL, et al. **J Nat Prod** 1995 Dec;58(12):1848-60

Chemical constituents of halophilic facultatively anaerobic bacteria, 1. Fu X, et al. **J Nat Prod** 1995 Dec;58(12):1950-4

Cytotoxicity and mode of action of aeroplysinin-1 and a related dienonefrom the sponge Aplysina aerophoba. Koulman A, et al. **J Nat Prod** 1996 Jun;59(6):591-4

Dendroamides, new cyclic hexapeptides from a blue-green alga. Multidrug-resistance reversing activity of dendroamide A. Ogino J, et al. **J Nat Prod** 1996 Jun; 59(6):581-6

Mycalolides D and E, new cytotoxic macrolides from a collection of the stony coral Tubastrea faulkneri. Rashid MA, et al. **J Nat Prod** 1995 Jul;58(7):1120-5

Sodwanones G, H, and I, new cytotoxic triterpenes from a marine sponge. Rudi A, et al. **J Nat Prod** 1995 Nov; 58(11):1702-12

Globostellatic acids A-D, new cytotoxic isomalabaricane triterpenes from the marine sponge Stelletta globostellata. Ryu G, et al. **J Nat Prod** 1996 May;59(5):512-4

Three new cytotoxic sesterterpenes from the marine sponge Hyrtios cf. erectus. Ryu G, et al. **J Nat Prod** 1996 May; 59(5):515-7

Keenamide A, a bioactive cyclic peptide from the marine mollusk Pleurobranchus forskalii. Wesson KJ, et al. **J Nat Prod** 1996 Jun;59(6):629-31

METABOLISM

Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505. Cummings J, et al. **Anticancer Drug Des** 1996 Jul;11(5):367-82

Sequence-specific binding of antitumour bisquaternary ammonium heterocycles to DNA and inhibition of polymerase activity in vitro. Kittler L, et al. **Anticancer Drug Des** 1996 Mar;11(2):101-15

Photolysis of an iodoplatinum(IV) diamine complex to cytotoxic species by visible light. Kratochwil NA, et al. **Anticancer Drug Des** 1996 Mar;11(2):155-71

Myeloperoxidase oxidizes mitoxantrone to metabolites which bind covalently to DNA and RNA. Panousis C, et al. **Anticancer Drug Des** 1995 Dec;10(8):593-605

The direct reduction of cytochrome c by some anthraquinone antitumor compounds. Tarasiuk J, et al. **Anticancer Drug Des** 1996 Apr;11(3):183-92

Saturation reversal of the multidrug pump using many reversers in low-dose combinations. Lyubimov E, et al. **Anticancer Drugs** 1995 Dec;6(6):727-35

Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Raynaud FI, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1857-62

Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase. Barham HM, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):829-37

Effect of DNA conformation on cisplatin adduct formation. Bubley GJ, et al. **Biochem Pharmacol** 1996 Mar 8; 51(5):717-21

Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins. Kašpárková J, et al. **Biochemistry** 1995 Sep 26;34(38):12379-87

Interaction of bovine brain tubulin with the 4(1H)-pyrizinone derivative IKP104, an antimitotic drug with a complex set of effects on the conformational stability of the tubulin molecule. Luduena RF, et al. **Biochemistry** 1995 Dec 5; 34(48):15751-9

Kinetics of pore formation by an antimicrobial peptide, magainin 2, in phospholipid bilayers. Matsuzaki K, et al. **Biochemistry** 1995 Oct 3;34(39):12553-9

The role of the MDR protein in altered drug translocation across tumor cell membranes. Roepe PD. **Biochim Biophys Acta** 1995 Dec 20;1241(3):385-405 (135 ref.)

The interaction of the anti-cancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride ion concentration. Speelmans G, et al. **Biochim Biophys Acta** 1996 Aug 14;1283(1):60-6

Inactivation of (1-->3)-beta-D-glucan in mice. Miura T, et al. **Biol Pharm Bull** 1995 Dec;18(12):1797-1801

Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Evans SM, et al. **Br J Cancer** 1995 Oct;72(4):875-82

Metabolism of the broad-spectrum neuropeptide growth factor antagonist: [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P. Jones DA, et al. **Br J Cancer** 1996 Mar;73(6):715-20

Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Koch CJ, et al. **Br J Cancer** 1995 Oct;72(4):869-74

Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels. Raynaud FI, et al. **Br J Cancer** 1996 Aug;74(3):380-6

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Schellens JH, et al. **Br J Cancer** 1996 May;73(10):1268-71

The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Kivistö KT, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):523-30 (73 ref.)

Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography. Cummings J, et al. **Cancer Chemother Pharmacol** 1995;37(1-2):103-9

Comparison of the uptake of retinoids 13-cis-retinoic acid and Ro 13-6298 delivered to HL-60 cells by serum albumin or low-density lipoprotein. Mouawad R, et al. **Cancer Chemother Pharmacol** 1996;38(2):198-201

Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Raynaud FI, et al. **Cancer Chemother Pharmacol** 1996;38(2):155-62

2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Evans SM, et al. **Cancer Res** 1996 Jan 15;56(2):405-11

32P-postlabelling analysis of adducts formed by mitoxantrone and ametantrone with DNA and homopolydeoxyribonucleotides after enzymatic activation. Dackiewicz P, et al. **Chem Biol Interact** 1995 Nov 17; 98(2):153-66

Muscle cells produce a low molecular weight factor with anti-cancer activity. Djaldetti M, et al. **Clin Exp Metastasis** 1996 May;14(3):189-96

Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing. Wilson WR, et al. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):881-5

Studies on cis-DDP, [Pt(Dach)(MePhSO)Cl]+ and [PtNH3)2(N-Py)Cl]+ binding to fumarase. Yalçin G. **Drug Metabol Drug Interact** 1995;12(2):105-15

Lack of effect of corticosteroids and tamoxifen on suramin protein binding and in vitro activity. Driscoll DL, et al. **Eur J Cancer** 1996 Feb;32A(2):311-5

Kinetics and metabolism of 2-chloro-2'-deoxyadenosine and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine in the isolated perfused rat liver. Albertioni F, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul-Sep; 20(3):225-32

Interaction of cytostatics and chemosensitizers with the dexniguldipine binding site on P-glycoprotein. Boer R, et al. **Eur J Pharmacol** 1996 Jan 11;295(2-3):253-60

Inhibition of human leukaemia 60 cell growth by mercapturic acid metabolites of phenylethyl isothiocyanate. Adesida A, et al. **Food Chem Toxicol** 1996 Apr;34(4):385-92

Oxidizability and subsequent cytotoxicity of chylomicrons to monocytic U937 and endothelial cells are dependent on dietary fatty acid composition. Mabile L, et al. **Free Radic Biol Med** 1995 Nov;19(5):599-607

In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hirschowitz EA, et al. **Hum Gene Ther** 1995 Aug;6(8):1055-63

Interleukin 1 (IL-1) production is not essential for acquired resistance of human A375 melanoma cells to anti-proliferative effect of IL-1. Itoh S, et al. **Int J Cancer** 1996 Mar 15;65(6):805-11

DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Mellish KJ, et al. **Int J Cancer** 1995 Sep 15;62(6):717-23

Irradiation-enhanced binding of carboplatin to DNA. Yang LX, et al. **Int J Radiat Biol** 1995 Dec;68(6):609-14

Molecular cloning and sequencing of the cytostatic G protein-activated protein kinase PAK I. Jakobi R, et al. **J Biol Chem** 1996 Mar 15;271(11):6206-11

Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. Loe DW, et al. **J Biol Chem** 1996 Apr 19;271(16):9675-82

Direct gas chromatographic determination of dechloroethylcyclophosphamide following microsomal incubation of cyclophosphamide. Bohnenstengel F, et al. **J Chromatogr B Biomed Appl** 1995 Oct 20;672(2):271-6

Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. Huang S, et al. **J Interferon Cytokine Res** 1995 Jul;15(7):655-65

A new paclitaxel photoaffinity analog with a 3-(4-benzoylphenyl)propanoyl probe for characterization of drug-binding sites on tubulin and P-glycoprotein. Ojima I, et al. **J Med Chem** 1995 Sep 29;38(20):3891-4

How does the MRP/GS-X pump export doxorubicin? [letter] Ishikawa T, et al. **J Natl Cancer Inst** 1995 Nov 1; 87(21):1639-40

Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines. Strickland DK, et al. **J Neurooncol** 1995;25(1):9-17

On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia

treatment. Arnér ES. **Leuk Lymphoma** 1996 Apr; 21(3–4):225–31 (64 ref.)

Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance. Sewell GJ. **Med Oncol** 1995 Mar;12(1):9–14 (43 ref.)

Proteins that bind to and mediate the biological activity of platinum anticancer drug-DNA adducts. Whitehead JP, et al. **Met Ions Biol Syst** 1996;32:687–726 (111 ref.)

Ligand-induced distortion of an active site in thymidylate synthase upon binding anticancer drug 1843U89. Weichsel A, et al. **Nat Struct Biol** 1995 Dec;2(12):1095–101

Metabolism of the anticancer peptide H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2. Jones DA, et al. **Peptides** 1995;16(5):777–83

ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Paul S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6929–34

PHARMACOKINETICS

Clinical pharmacokinetics of cumulative very high dose of cisplatin in chemotherapy resistant solid tumors. Tebano MT, et al. **Ann Ist Super Sanita** 1995;31(3):351–7

Pharmacokinetics, metabolism, tissue and tumour distribution of the neuropeptide growth factor antagonist [Arg6, D-Trp7,9, NmePhe8]- substance P(6–11) in nude mice bearing the H69 small-cell lung cancer xenograft. Cummings J, et al. **Ann Oncol** 1995 Jul;6(6):595–602

Evaluation of two dose individualisation methods for carboplatin. Desoize B, et al. **Anticancer Res** 1996 Jul–Aug; 16(4A):2073–8

Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats. Esposito M, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2541–7

Pharmacokinetics of a new platinum compound, cis-(glycolato-O,O) [(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclohexane]plat inum (II) in dogs. Kim DK, et al. **Anticancer Res** 1996 May–Jun;16(3A):1167–9

Carboplatin-based chemotherapy in patients undergoing hemodialysis. Yanagawa H, et al. **Anticancer Res** 1996 Jan–Feb;16(1):533–5

Pharmacokinetics of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane]platinum(II) in rats. Cho YB, et al. **Arzneimittelforschung** 1996 Jun;46(6):629–34

Systemic application of cysteine-2:1-crotonal adduct for pharmacokinetic studies of tumor models in rats and mice. Tillian M, et al. **Arzneimittelforschung** 1996 Jun;46(6):640–2

Modulation of the antitumor effect and tissue distribution of highly branched (1—>3)-beta-D-glucan, SSG, by carrageenan. Suda M, et al. **Biol Pharm Bull** 1995 May; 18(5):772–5

Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. Baxter LT, et al. **Br J Cancer** 1996 Feb;73(4):447–56

Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis. Blöchl-Daum B, et al. **Br J Cancer** 1996 Apr;73(7):920–4

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Howell A, et al. **Br J Cancer** 1996 Jul;74(2):300–8

Photofrin accumulation in malignant and host cell populations of various tumours. Korbelik M, et al. **Br J Cancer** 1996 Feb;73(4):506–13

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Patterson AV, et al. **Br J Cancer** 1995 Nov;72(5):1144–50

Plasma clearance of an antibody—enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo. Rogers GT, et al. **Br J Cancer** 1995 Dec;72(6):1357–63

Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. van Warmerdam LJ, et al. **Br J Cancer** 1996 Apr; 73(8):979–84

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Baker SD, et al. **Cancer Chemother Pharmacol** 1996;37(3):195–202

Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice. Eiseman JL, et al. **Cancer Chemother Pharmacol** 1996;38(1):13–20

Long-term pharmacokinetic behavior of platinum after cisplatin administration. Gamelin E, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):97–102

Chromosome aberrations and pharmacokinetics in patients receiving tauromustine as either a single or a repeated dose. Hartley-Asp B, et al. **Cancer Chemother Pharmacol** 1996; 38(4):309–16

A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941. Jodrell DI, et al. **Cancer Chemother Pharmacol** 1996;37(4):356–62

Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Johnsson A, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):23–31

Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. Kastrissios H, et al. **Cancer Chemother Pharmacol** 1996;38(5):425–30

Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics. Kim DK, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):1–6

Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. Kreis W, et al. **Cancer Chemother Pharmacol** 1996; 38(4):378–84

Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing. Lan LB, et al. **Cancer Chemother Pharmacol** 1996;38(2):181–90

Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation. Los G, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):150–4

Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Ma J, et al. **Cancer Chemother Pharmacol** 1996;37(4):382–4

Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Mross K, et al. **Cancer Chemother Pharmacol** 1996;38(3):217–24

Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC-366140). Palomino E, et al. **Cancer Chemother Pharmacol** 1996;38(5):453–8

Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs. Price GS, et al. **Cancer Chemother Pharmacol** 1996;38(2):129–35

Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbits. Ramirez LH, et al. **Cancer Chemother Pharmacol** 1996;37(4):371–6

Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine. Reichelová V, et al. **Cancer Chemother Pharmacol** 1995;36(6):524–9

Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat. Stüben J, et al. **Cancer Chemother Pharmacol** 1996;38(4):355–65

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. van Warmerdam LJ, et al. **Cancer Chemother Pharmacol** 1996;38(3):254–60

Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patients. Kreis W, et al. **Cancer Invest** 1996;14(4):320–7

Effects of anesthetics on ormaplatin biotransformations in the Fischer 344 rat [letter] Thompson DC, et al. **Cancer Invest** 1995;13(5):555–7

Co-localization of suramin and serum albumin in lysosomes of suramin-treated human colon cancer cells. Baghdiguian S, et al. **Cancer Lett** 1996 Mar 29;101(2):179–84

Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Breuninger LM, et al. **Cancer Res** 1995 Nov 15;55(22):5342–7

Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Elliott PJ, et al. **Cancer Res** 1996 Sep 1;56(17):3998–4005

Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Gerweck LE, et al. **Cancer Res** 1996 Mar 15;56(6):1194–8

MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Koya K, et al. **Cancer Res** 1996 Feb 1;56(3):538–43

Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Netti PA, et al. **Cancer Res** 1995 Nov 15;55(22):5451–8

Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Zhang X, et al. **Cancer Res** 1996 Feb 15;56(4):802–8

Pharmacokinetic/cytokinetic principles in the chemotherapy of solid tumours. Baguley BC, et al. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):825–8

The allometric approach for interspecies scaling of pharmacokinetics and toxicity of anti-cancer drugs. Paxton JW. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):851–4

Population pharmacokinetics of carboplatin in children. Chatelut E, et al. **Clin Pharmacol Ther** 1996 Apr; 59(4):436–43

Pharmacokinetics, tissue distribution, and excretion of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II) in dogs. Cho YB, et al. **Drug Metab Dispos** 1995 Nov;23(11):1280–5

Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog. Phillips LR, et al. **Drug Metab Dispos** 1995 Jul;23(7):676–80

Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. Roy SK, et al. **Drug Metab Dispos** 1995 Dec;23(12):1394–9

Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation. Valles B, et al. **Drug Metab Dispos** 1995 Oct;23(10):1051–7

Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by quantitative autoradiography. Baghdiguian S, et al. **Eur J Cancer** 1996 Mar;32A(3):525–32

Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study. Iliadis A, et al. **Eur J Cancer** 1996 Mar;32A(3):455–60

Pharmacokinetic modelling--a prelude to therapeutic drug monitoring for all cancer patients? [editorial; comment] Judson IR. **Eur J Cancer** 1995 Oct;31A(11):1733–5 (24 ref.) . Comment on: Eur J Cancer 1995 Oct;31A(11):1794–8. Comment on: Eur J Cancer 1995 Oct;31A(11):1804–10.

Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. Mairs RJ, et al. **Eur J Cancer** 1995; 31A(4):576–81

The effect of different dose levels of degradable starch microspheres (Spherex) on the distribution of a cytotoxic drug after regional administration to tumour-bearing rats. Teder H, et al. **Eur J Cancer** 1995 Sep;31A(10):1701–5

In vivo and in vitro kinetics of mofarotene in mouse, rat, dog and man. Vallès B, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jan–Mar; 20(1):49–53

Penetration of [3H] tiazofurin into guinea pig eye by a saturable mechanism. Redžić ZB, et al. **Eur J Ophthalmol** 1995 Apr–Jun;5(2):131–5

The disposition of new arabinosylcytosine derivative--5'-chloro-5'-deoxy-arabinosylcytosine--in rats. Novotný L, et al. **Gen Pharmacol** 1995 Sep;26(5):1101–5

Comparative entry of carboplatin and sucrose in endolymph in the rat cochlea. Laurell G, et al. **Hear Res** 1995 Aug; 88(1–2):222–6

Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Montaldo PG, et al. **Int J Cancer** 1996 Jul 3; 67(1):95–100

Effect of whole-body hyperthermia on lonidamine and doxorubicin pharmacokinetics and toxicity in dogs. Price GS, et al. **Int J Hyperthermia** 1995 Jul–Aug;11(4):545–59

Effect of whole-body hyperthermia on the pharmacokinetics and toxicity of lonidamine in dogs. Price GS, et al. **Int J Hyperthermia** 1995 Jul–Aug;11(4):531–44

Irradiation enhances cellular uptake of carboplatin. Yang LX, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):641–6

Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion. Dirix L, et al. **Invest New Drugs** 1995;13(2):133–6

Preclinical pharmacokinetics and antitumor activity of imexon. Dorr RT, et al. **Invest New Drugs** 1995;13(2):113–6

Phase I trial of diaziquone (AZQ) plus GM-CSF. Hartmann LC, et al. **Invest New Drugs** 1995;13(2):175–6

Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons. Marshall MV, et al. **Invest New Drugs** 1995;13(1):33–6

Tiazofurine uptake by the isolated guinea pig heart. Mitrović DM, et al. **J Chemother** 1995 Dec;7(6):543–8

High-performance liquid chromatographic assay for CI-980, a novel 1-deaza-7,8-dihydropteridine anticancer agent, in human plasma and urine. Bullen WW, et al. **J Chromatogr B Biomed Appl** 1995 Jun 9;668(1):141–51

All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship. Agadir A, et al. **J Clin Oncol** 1995 Oct;13(10):2517–23

Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. Kaul S, et al. **J Clin Oncol** 1995 Nov;13(11):2835–41

Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. Saven A, et al. **J Clin Oncol** 1996 Mar;14(3):978–83

Pharmacokinetics of carboplatin in a patient with cervical cancer with ureteric obstruction before, during, and after hemodialysis. el-Yazigi A, et al. **J Clin Pharmacol** 1995 Oct;35(10):1003–7

Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. Greenwald RB, et al. **J Med Chem** 1996 May 10;39(10):1938–40

Pharmacological blood-brain barrier modification for selective drug delivery. Cloughesy TF, et al. **J Neurooncol** 1995 Nov;26(2):125–32 (39 ref.)

Distribution of drugs following controlled delivery to the brain interstitium. Mak M, et al. **J Neurooncol** 1995 Nov; 26(2):91–102 (61 ref.)

Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. Lave T, et al. **J Pharm Sci** 1995 Nov; 84(11):1285–90

The disposition, tissue distribution, and cellular transport of N-[[(trimethylamino)boryl]carbonyl]-L-phenylalanine methyl ester in CF1 mice. Miller MC 3rd, et al. **J Pharm Sci** 1995 Aug;84(8):933–6

Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. Laughlin KM, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1049-57

Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. Kurihara N, et al. **J Surg Oncol** 1996 Jun;62(2):135-8

Pharmacokinetics and haematological effects of a single intravenous dose of mitoxantrone in cats. Kochevar DT, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):471-5

Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity. Gruber A, et al. **Leuk Res** 1995 Oct;19(10):757-61

Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. Alessi-Severini S, et al. **Leukemia** 1995 Oct; 9(10):1674-9

Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer. Le Cesne A, et al. **Lung Cancer** 1995 Aug;13(1):69-78

Selective uptake of the anticancer drug bendamustine by liver and kidney tissues following its intravenous administration to mice. Bezek S, et al.
Methods Find Exp Clin Pharmacol 1996 Mar;18(2):117-22

Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells. Chen G, et al.
Mol Pharmacol 1995 Oct;48(4):758-65

Possible correlation between ormaplatin biotransformations and neurotoxicity. Sakata M, et al. **Oncol Res** 1995; 7(2):67-71

Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Teicher BA, et al. **Oncol Res** 1995;7(5):237-43

In vitro-in vivo correlation in anticancer drug sensitivity test using AUC-based concentrations and collagen gel droplet-embedded culture. Inaba M, et al. **Oncology** 1996 May-Jun;53(3):250-7

Transfection of human cytochrome P-450 reductase cDNA and its effect on the sensitivity to toxins. Sawamura AO, et al. **Oncology** 1996 Sep-Oct;53(5):406-11

Physicochemical characterization of protein-free low density lipoprotein models and influence of drug loading. Gerke A, et al. **Pharm Res** 1996 Jan;13(1):44-51

Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Gosland M, et al.
Pharmacotherapy 1996 Jan-Feb;16(1):16-39 (200 ref.)

Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. Schwickert HC, et al. **Radiology** 1996 Mar; 198(3):893-8

The pharmacokinetic behaviour of hypoxoside taken orally by patients with lung cancer in a phase I trial. Albrecht CF, et al. **S Afr Med J** 1995 Sep;85(9):861-5

Morphological characterisation of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy. Albrecht CF, et al. **S Afr Med J** 1995 Sep;85(9):853-60

Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements? van Warmerdam LJ, et al. **Ther Drug Monit** 1995 Oct; 17(5):465-70

Drug targeting and metabolic investigations of cryoprepared tumor cells with analytical electron energy loss spectroscopy. Wolf B, et al. **Tumour Biol** 1996;17(4):234-50

[Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer] Deng C, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar; 31(3):159-62 (Eng. Abstr.) **(Chi)**

[Study on pharmacokinetics of mitoxantrone polycyanoacrylate nanoparticles freeze-dried injection by HPLC column switching technique] Zhang ZR, et al.
Yao Hsueh Hsueh Pao 1995 Nov;30(11):843-7 (Eng. Abstr.) **(Chi)**

[Pharmacology of regional chemotherapy of colorectal liver metastases] Schalhorn A, et al. **Zentralbl Chir** 1995; 120(10):764-8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level] Fujita H, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1783-7 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetics of SK & F 104864 in experimental animals. II. Tissue distribution] Fujita H, et al.
Gan To Kagaku Ryoho 1995 Oct;22(12):1789-92 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetic study of intraperitoneally administered plachitin for non-curative gastrointestinal cancer] Tabara H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1473-6 (Eng. Abstr.) **(Jpn)**

[Experimental study on cisplatin microspheres incorporated in polylactic acid and polyethylene glycol acid] Tokuda K, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1641-3 (Eng. Abstr.) **(Jpn)**

[Intratumoral pharmacokinetics following intraarterial administration of MCNU in patients with malignant gliomas] Yamasaki T, et al. **No Shinkei Geka** 1995 Nov; 23(11):963-9 (Eng. Abstr.) **(Jpn)**

[Mechanism of resistance to antitumor agents--its involvement in blood-brain barrier] Tsuruo T.
Yakugaku Zasshi 1995 Jul;115(7):513-22 (36 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Restricted effect of formycin A and non-glucidic nutrients upon insulin release in islets from rats with hereditary or acquired non-insulin-dependent diabetes. Giroix MH, et al. **Acta Diabetol** 1995 Oct;32(3):198-202

Absence of misincorporation of pyrimidines in DNA after treatment with a combination of cisplatin (CIS-diammine-dichloro-platinum) amd 5-fluorouracil of mouse sarcoma cells. Nylén U, et al. **Acta Oncol** 1996; 35(2):229-35

High-dose methotrexate causes short-term suppression of growth in rabbits. Moëll C, et al. **Acta Paediatr** 1995 Nov; 84(11):1237-40

Effect of cyclosporin A on human bone marrow granulocyte-macrophage progenitors with anti-cancer agents. Ishida Y, et al. **Acta Paediatr Jpn** 1995 Oct; 37(5):610-3

Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Brown PD. **Adv Enzyme Regul** 1995; 35:293-301

Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo. Cory JG, et al.
Adv Enzyme Regul 1995;35:55-68

DNA topoisomerase II isozymes involved in anticancer drug action and resistance. Fernandes DJ, et al.
Adv Enzyme Regul 1995;35:265-81

Review article: drug development in gastroenterology--the changing view of industry. Parsons ME, et al.
Aliment Pharmacol Ther 1995 Oct;9(5):457-63 (14 ref.)

The role of tumor necrosis factor receptors in tumor necrosis factor-alpha-mediated cytolysis of ovarian cancer cell lines. Kost ER, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):145-53

Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Graniela Sirè EA, et al. **Ann Oncol** 1995 Jul;6(6):589-93

Effects of the hematopoietic growth factors GM-CSF, IL-3, and IL-6 on human tumor colony-forming units taken directly from patients. Izquierdo MA, et al. **Ann Oncol** 1995 Nov;6(9):927-32

Folate-based thymidylate synthase inhibitors as anticancer drugs. Jackman AL, et al. **Ann Oncol** 1995 Nov;6(9):871-81 (84 ref.)

Anticancer drug development at Lilly Research Laboratories. Pearce HL. **Ann Oncol** 1995;6 Suppl 1:55-62 (39 ref.)

Inhibition of bladder tumor cell implantation in cauterized urothelium, without inhibition of healing, by a fibronectin-related peptide (GRGDS). Hyacinthe LM, et al. **Ann Surg Oncol** 1995 Sep;2(5):450-6

Pyrimido [4,5,6-kl] acridines, a new class of potential anticancer agents. Synthesis and biological evaluation. Antonini I, et al. **Anticancer Drug Des** 1996 Jun; 11(4):339-49

Bis-naphthalimides 3: synthesis and antitumor activity of N,N'-bis[2-(1,8-naphthalimido)-ethyl] alkanediamines. Braña MF, et al. **Anticancer Drug Des** 1996 Jun; 11(4):297-309

Design, synthesis and topoisomerase II inhibition activity of 4'-demethylepipodophyllotoxin-lexitropsin conjugates. Gupta R, et al. **Anticancer Drug Des** 1996 Jun;11(4):325-38

SRC as a target for anti-cancer drugs. Levitzki A.
Anticancer Drug Des 1996 Apr;11(3):175-82 (45 ref.)

Characteristics of the antitumor activity of M-16 and M-18, major metabolites of a new mitomycin C derivative KW-2149, in mice. Ashizawa T, et al.
Anticancer Drugs 1995 Dec;6(6):763-70

Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Dengler WA, et al. **Anticancer Drugs** 1995 Aug;6(4):522-32

Relationship of mitochondrial function and cellular adenosine triphosphate levels to pMC540 and merodantoin cytotoxicity in MCF-7 human breast cancer cells. Gulliya KS, et al. **Anticancer Drugs** 1995 Aug;6(4):545-52

Cytotoxic effect of calcein acetoxymethyl ester on human tumor cell lines: drug delivery by intracellular trapping. Liminga G, et al. **Anticancer Drugs** 1995 Aug;6(4):578-85

Inhibition of colon cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA of the Ki-ras gene. Sakakura C, et al. **Anticancer Drugs** 1995 Aug; 6(4):553-61

Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone. Saunders DE, et al. **Anticancer Drugs** 1995 Aug;6(4):562-9

Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line. Zhao R, et al. **Anticancer Drugs** 1995 Oct;6(5):657-68

Advantage of in vivo chemosensitivity assay to detect vincristine-resistance in a human epidermoid carcinoma xenograft. Abe Y, et al. **Anticancer Res** 1996 Mar-Apr; 16(2):729-34

The ability of polyamine analogues to induce Z-DNA structure in synthetic polynucleotides in vitro inversely correlates with their effects on cytotoxicity of cis-diaminedichloroplatinum (II) (CDDP) in human brain tumor cell lines. Basu HS, et al. **Anticancer Res** 1996 Jan-Feb;16(1):39-47

Calcipotriol (MC 903), a synthetic derivative of vitamin D3 stimulates differentiation of squamous carcinoma cell line in the raft culture. Cho KH, et al. **Anticancer Res** 1996 Jan-Feb;16(1):337-47

Benzodiazepine-induced inhibition of human malignant melanoma (M-6) cell growth. Crocker CE, et al.
Anticancer Res 1996 May-Jun;16(3A):1259-63

Effect on cell survival and protein synthesis of benzylidene-glucose (BG) and the deuterated analogue P-1013 in cultured cells. Dunsaed CB, et al.
Anticancer Res 1995 Sep-Oct;15(5B):1921-7

Early stage monitoring of miltefosine induced apoptosis in KB cells by multinuclear NMR spectroscopy. Engelmann J, et al. **Anticancer Res** 1996 May-Jun;16(3B):1429-39

Mutant H-ras overexpression inhibits drug and U.V. induced apoptosis. Fernandes RS, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1691-705

Cell growth inhibitory effects of caulerpenyne, a sesquiterpenoid from the marine algae Caulerpa taxifolia. Fischel JL, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):2155-60

Sensitivity of anticancer drugs in NIH3T3' cells transfected with oncogenes accompanied by pSV2neo vector. Gao XS, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):1911-4

Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours. Goddard PM, et al. **Anticancer Res** 1996 Jan-Feb;16(1):33-8

Transcatheter arterial embolization with cisplatin: apoptosis in VX2 tumour uterus transplants. Harima Y, et al.
Anticancer Res 1996 Jan-Feb;16(1):193-9

Immunological analysis of inhibition of lung metastases by fucoidan (GIV-A) prepared from brown seaweed Sargassum thunbergii. Itoh H, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):1937-47

Systemic administration of a synthetic lipid A derivative, DT-5461a, reduces tumor blood flow through endogenous TNF production in hepatic cancer model of VX2 carcinoma in rabbits. Jimbo T, et al. **Anticancer Res** 1996 Jan-Feb;16(1):359-64

Enhancement of antitumor effects of new analogue of platinum, cis-diammine (glycolato) platinum (254-S) combined with hyperthermia in vivo. Jo A, et al.
Anticancer Res 1996 Jan-Feb;16(1):301-4

Cytotoxicity of antitumor agents toward cultured murine leukemia L1210 cells under a serum-deprived apoptotic condition. Kasamatsu T, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2597-600

In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II). Kim DK, et al.
Anticancer Res 1996 Jan-Feb;16(1):251-6

Effect of flavone acetic acid on endothelial cell proliferation: evidence for antiangiogenic properties. Lindsay CK, et al.
Anticancer Res 1996 Jan-Feb;16(1):425-31

Chlorpromazine-induced hypothermia: effect on tumour progression and survival in mice. Lundgren-Eriksson L, et al. **Anticancer Res** 1996 Jan-Feb;16(1):333-5

Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo. McKenzie RC, et al.
Anticancer Res 1996 Jan-Feb;16(1):437-41

Antitumor effect of carboplatin combined with hyperthermia on Ehrlich-ascites tumor in vivo. Mizuuchi H, et al.
Anticancer Res 1996 Jan-Feb;16(1):381-7

Effects of two benzo[a]phenothiazines on multi-drug resistance (mdr) and tumor antigen expression. Molnár J, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2013-6

Effect of heat-drug sequences on thermoenhancement and uptake of cis-DDP in human pharyngeal carcinoma. Ohtsubo T, et al. **Anticancer Res** 1996 Jan-Feb; 16(1):297-300

Effect of lonidamine on the mitochondrial potential in situ in Ehrlich ascites tumor cells. Pulselli R, et al.
Anticancer Res 1996 Jan-Feb;16(1):419-23

Antitumor and antiproliferative effects of a fucan extracted from ascophyllum nodosum against a non-small-cell bronchopulmonary carcinoma line. Riou D, et al.
Anticancer Res 1996 May-Jun;16(3A):1213-8

Induction by 5-aza-2'-deoxycytidine, an inhibitor of DNA methylation, of Le(y) antigen, apoptosis and differentiation in human lung cancer cells. Saitoh F, et al.
Anticancer Res 1995 Sep-Oct;15(5B):2137-43

Induction of DNA fragmentation in human myelogenous leukaemic cell lines by phenothiazine-related compounds. Sakagami H, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2533-40

In vitro and in vivo interactions of D-penicillamine with tumors. Samoszuk M, et al. **Anticancer Res** 1996 May-Jun; 16(3A):1219-23

Dinaline inhibits amino acid transport and proliferation of colon carcinoma cells in vitro. Schaider H, et al.
Anticancer Res 1995 Nov-Dec;15(6B):2501-9

The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors. Schimmel L, et al. **Anticancer Res** 1996 Jan-Feb;16(1):375-80

Involvement of intracellular glutathione in induction of apoptosis by cisplatin in a human pharyngeal carcinoma cell line. Sugimoto C, et al. **Anticancer Res** 1996 Mar-Apr;

16(2):675–80

Cytostatic and cytotoxic action of Z–1, 1–dichloro–2,3–diphenylcyclopropane in three human breast cancer cell lines. ter Haar E, et al. **Anticancer Res** 1996 May–Jun;16(3A):1107–15

Reversal of multidrug resistance by amitriptyline in vitro. Varga A, et al. **Anticancer Res** 1996 Jan–Feb;16(1):209–11

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1867–80 (184 ref.)

Induction of Ley antigen by 5–aza–2'–deoxycytidine in association with differentiation and apoptosis in human pancreatic cancer cells. Yamada T, et al. **Anticancer Res** 1996 Mar–Apr;16(2):735–40

IP6–induced growth inhibition and differentiation of HT–29 human colon cancer cells: involvement of intracellular inositol phosphates. Yang GY, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2479–87

Activin A inhibits growth and hexamethylene bisacetamide–induced differentiation in human retinoblastoma Y–79 cells. Zhang Z, et al. **Anticancer Res** 1996 Jan–Feb;16(1):269–72

Interferon–alpha inhibits the DNA synthesis induced by PDGF and EGF in cultured meningioma cells. Zhang ZJ, et al. **Anticancer Res** 1996 Mar–Apr;16(2):717–23

Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m–AMSA. Lin JH, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):293–9

Assessment of effect of photosensitizers on cytotoxicity of photodynamic therapy in human breast cancer cell cultures. Koechli OR, et al. **Arch Gynecol Obstet** 1995;256(4):167–76

Pharmacological properties of racemic chlorobromofosfamide. Juszkiewicz M, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(5–6):405–13

In vitro primary antitumor screen of imidazole platinum complexes. Kuduk–Jaworska J. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):77–82

Experimental antitumor activity and toxicity of the selected triazolo– and imidazoacridinones. Kuśnierczyk H, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(5–6):415–23

Synergistic antiproliferative activity of tumor necrosis factor alpha (TNF–alpha) and lovastatin. Sora MK, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):269–74

Interferon gamma enhances lymphokine–activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma. Scher RL, et al. **Arch Otolaryngol Head Neck Surg** 1995 Nov; 121(11):1271–5

Synthesis, antitumoral and antiviral evaluation of halo– and demethyl–yatein derivatives. Medarde M, et al. **Arch Pharm (Weinheim)** 1995 Sep;328(9):640–4

Sensitizing properties of new N–(2–arylalkyl) propionamides in drug–sensitive and multidrug–resistant tumor cells. Ros F, et al. **Arch Pharm (Weinheim)** 1995 Dec; 328(11–12):755–9

Preclinical pharmacology and possible mechanism of action of the novel antitumor agent 5–(4'–piperidinomethylphenyl)–2,3–dihydroimidazo [2,1–a]isoquinoline. Houlihan WJ, et al. **Arzneimittelforschung** 1995 Oct;45(10):1133–7

A predictive screening model for in vitro selection of agents with potential antitumor activity. Nocentini G, et al. **Arzneimittelforschung** 1995 Dec;45(12):1306–11

Didemnin B induces cell death by apoptosis: the fastest induction of apoptosis ever described. Grubb DR, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1130–6

Saikosaponin b2–induced apoptosis of cultured B16 melanoma cell line through down–regulation of PKC activity. Zong Z, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):480–5

Stable intracellular acidification upon polyamine depletion induced by alpha–difluoromethylornithine or N1,N12–bis(ethyl)spermine in L1210 leukaemia cells. Poulin R, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):749–56

An anti–neoplastic glycan isolated from Mycobacterium bovis (BCG vaccine). Wang R, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):867–72

The synthetic retinoid N–(4–hydroxyphenyl) retinamide (4–HPR) exerts antiproliferative and apoptosis–inducing effects in the androgen–independent human prostatic JCA–1 cells. Hsieh TC, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):499–506

Internucleosomal DNA cleavage in HeLa cells exposed to cisplatin. Maldonado V, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):691–6

Mitochondria–bound hexokinase from rabbit reticulocytes is resistant to the inactivation induced by Fe(II)/ascorbate. Stocchi V, et al. **Biochem Mol Biol Int** 1995 Apr; 35(5):1133–42

Deleterious effect of formycin A on tumor islet cells. Rasschaert J, et al. **Biochem Mol Med** 1995 Apr; 54(2):138–41

Induction of DT–diaphorase by doxorubicin and combination therapy with mitomycin C in vitro. Begleiter A, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1281–6

Biochemical pharmacology of penclomedine (NSC–338720). Benvenuto JA, et al. **Biochem Pharmacol** 1995 Oct 12; 50(8):1157–64

Inhibition of Na+/H+ exchanger activity by an alkyl–lysophospholipid analogue in a human breast cancer cell line. Besson P, et al. **Biochem Pharmacol** 1996 May 3;51(9):1153–8

Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T–lymphocytes. da Silva CP, et al. **Biochem Pharmacol** 1996 May 17;51(10):1331–40

Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts. De Pooter CM, et al. **Biochem Pharmacol** 1996 Mar 8; 51(5):629–34

Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF–7 breast cancer cells. Grem JL, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1649–59

Studies on the antitumor effects of analogues of 5,8–dideazaisofolic acid and 5,8–dideazaisoaminopterin. Hagan RL, et al. **Biochem Pharmacol** 1995 Sep 7; 50(6):803–9

A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF–187 (dexrazoxane). Hasinoff BB, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):953–8

Comparison of aza–anthracenedione–induced DNA damage and cytotoxicity in experimental tumor cells. Hazlehurst LA, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1087–94

Effect of v–rasH on sensitivity of NCI–H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin. Kaufmann SH, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):1987–93

Structurally modified trimethine thiacarbocyanine dyes. Effect of N–alkyl substituents on antineoplastic behavior. Krieg M, et al. **Biochem Pharmacol** 1996 Jun 14; 51(11):1461–7

Induction of differentiation and down–regulation of c–myb gene expression in ML–1 human myeloblastic leukemia cells by the clinically effective anti–leukemia agent meisoindigo. Liu XM, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1545–51

A novel vitamin D analog with two double bonds in its side chain. A potent inducer of osteoblastic cell differentiation. Mahonen A, et al. **Biochem Pharmacol** 1996 Apr 12; 51(7):887–92

The 2,2'–bipyridyl–6–carbothioamide copper (II) complex differs from the iron (II) complex in its biochemical effects in tumor cells, suggesting possible differences in the mechanism leading to cytotoxicity. Nocentini G, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):65–71

Characterization of the catecholamine extraneuronal uptake2 carrier in human glioma cell lines SK–MG–1 and SKI–1 in relation to (2–chloroethyl)–3–sarcosinamide–1–nitrosourea (SarCNU) selective cytotoxicity. Noë AJ, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1639–48

Increased DT–diaphorase expression and cross–resistance to mitomycin C in a series of cisplatin–resistant human ovarian cancer cell lines. O'Dwyer PJ, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):21–7

Cell cycle–dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators. Renton FJ, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1553–61

Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Soldan M, et al. **Biochem Pharmacol** 1996 Jan 26; 51(2):117–23

Proton release from HeLa cells and alkalization of cytoplasm induced by diferric transferrin or ferricyanide and its inhibition by the diarylsulfonylurea antitumor drug N–(4–methylphenylsulfonyl)–N'–(4–cholorophenyl) urea (LY181984). Sun E, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1461–8

Differential effects of ethyl 5–amino–2–methyl–1,2–dihydro–3–phenylpyrido[3,4–b]pyrazin–7–yl carbamate analogs modified at position C2 on tubulin polymerization, binding, and conformational changes. Barbier P, et al. **Biochemistry** 1995 Dec 26; 34(51):16821–9

Position–specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity. Bigioni M, et al. **Biochemistry** 1996 Jan 9;35(1):153–9

Changing a leucine to a lysine residue makes NaeI endonuclease hypersensitive to DNA intercalative drugs. Jo K, et al. **Biochemistry** 1996 Aug 6;35(31):10014–8

Reduced albumin binding promotes the stability and activity of topotecan in human blood. Mi Z, et al. **Biochemistry** 1995 Oct 24;34(42):13722–8

Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. ter Haar E, et al. **Biochemistry** 1996 Jan 9;35(1):243–50

Inactivation of ribonucleotide reductase by (E)–2'–fluoromethylene–2'–deoxycytidine 5'–diphosphate: a paradigm for nucleotide mechanism–based inhibitors. van der Donk WA, et al. **Biochemistry** 1996 Jun 25; 35(25):8381–91

Biological activity of 26–succinylbryostatin 1. Bignami GS, et al. **Biochim Biophys Acta** 1996 Jul 24;1312(3):197–206

Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin. Chao JC, et al. **Biochim Biophys Acta** 1996 Jun 7;1307(2):213–9

The antitumor sulfonylurea N–(4–methylphenylsulfonyl)–N'–(4–chlorophenyl) urea (LY181984) inhibits NADH oxidase activity of HeLa plasma membranes. Morré DJ, et al. **Biochim Biophys Acta** 1995 Nov 22;1240(1):11–7

Antitumor sulfonylurea–inhibited NADH oxidase of cultured HeLa cells shed into media. Morré DJ, et al. **Biochim Biophys Acta** 1996 Apr 26;1280(2):197–206

NADH oxidase activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea N–(4–methylphenylsulfonyl)–N'–(4–chlorophenyl) urea (LY181984) at an external site. Morré DJ. **Biochim Biophys Acta** 1995 Dec 13;1240(2):201–8

Retinol–binding protein secretion from the liver of N–(4–hydroxyphenyl) retinamide–treated rats. Ritter SJ, et al. **Biochim Biophys Acta** 1996 Jun 4;1290(2):157–64

Diallyl disulfide inhibits the proliferation of human tumor cells in culture. Sundaram SG, et al. **Biochim Biophys Acta** 1996 Jan 17;1315(1):15–20

Reversion of malignant phenotype by 5–iodo–6–amino–1,2–benzopyrone a non–covalently binding ligand of poly(ADP–ribose) polymerase. Bauer PI, et al. **Biochimie** 1995;77(5):374–7

Cytotoxic effects of several hopanoids on mouse leukemia L1210 and P388 cells. Chen Z, et al. **Biol Pharm Bull** 1995 Mar;18(3):421–3

Antitumorigenic activities of chalcones. I. Inhibitory effects of chalcone derivatives on 32Pi–incorporation into phospholipids of HeLa cells promoted by 12–O–tetradecanoyl–phorbol 13–acetate (TPA). Iwata S, et al. **Biol Pharm Bull** 1995 Dec;18(12):1710–13

Amino acids and peptides. XXVI. Laminin–related peptide poly(ethylene glycol) hybrids and their inhibitory effect on experimental metastasis. Kawasaki K, et al. **Biol Pharm Bull** 1995 Dec;18(12):1714–7

Specific hybrid liposomes composed of phosphatidylcholine and polyoxyethylenealkyl ether with markedly enhanced inhibitory effects on the growth of tumor cells in vitro. Matsumoto Y, et al. **Biol Pharm Bull** 1995 Oct; 18(10):1456–8

Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside–Rb2, 20(R)– and 20(S)–ginsenoside–Rg3, of red ginseng. Mochizuki M, et al. **Biol Pharm Bull** 1995 Sep;18(9):1197–202

Immunostimulatory and antitumor activities of monoglycosylceramides having various sugar moieties. Motoki K, et al. **Biol Pharm Bull** 1995 Nov;18(11):1487–91

Modulation of the antitumor effect and tissue distribution of highly branched (1—>3)–beta–D–glucan, SSG, by carrageenan. Suda M, et al. **Biol Pharm Bull** 1995 May; 18(5):772–5

Synergistic anti–tumor effects of mitomycin C and bile salts against L1210 cells. Tamura T, et al. **Biol Pharm Bull** 1995 Aug;18(8):1109–13

Relationships between chemical characteristics and anticomplementary activity of fucans. Blondin C, et al. **Biomaterials** 1996 Mar;17(6):597–603

Antitumor activity of titanocene amino acid complexes. Köpf–Maier P, et al. **Biometals** 1996 Jul;9(3):267–71

Synthesis of key analogs of bleomycin A2 that permit a systematic evaluation of the linker region: identification of an exceptionally prominent role for the L–threonine substituent. Boger DL, et al. **Bioorg Med Chem** 1995 Sep; 3(9):1281–95

Novel cytotoxic DNA sequence and minor groove targeted photosensitizers: conjugates of pyrene and netropsin analogues. Hartley JA, et al. **Bioorg Med Chem** 1995 Jun; 3(6):623–9

Antitumor and antimicrobial activities of Fe(II)/Fe(III) complexes derived from some heterocyclic compounds. Mishra L, et al. **Bioorg Med Chem** 1995 Sep;3(9):1241–5

Heterocondensed quinazolones: synthesis and protein–tyrosine kinase inhibitory activity of 3,4–dihydro–1H,6H–[1,4] oxazino–[3,4–b]quinazolin–6–one derivatives. Orfi L, et al. **Bioorg Med Chem** 1996 Apr; 4(4):547–51

Pharmaceutical and biological properties of doxorubicin encapsulated in liposomes (L–ADM): the effect of repeated administration on the systemic phagocytic activity and pharmacokinetics. Yachi K, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):653–67

Granzyme B and perforin lytic proteins are expressed in CD34+ peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony–stimulating factor. Berthou C, et al. **Blood** 1995 Nov 1;86(9):3500–6

Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia. Bosanquet AG, et al. **Blood** 1996 Mar 1;87(5):1962–71

Inhibition of myeloma cell growth by dexamethasone and all–trans retinoic acid: synergy through modulation of interleukin–6 autocrine loop at multiple sites. Chen YH, et al. **Blood** 1996 Jan 1;87(1):314–23

Human CD34+ hematopoietic progenitors have low, cytokine–unresponsive O6–alkylguanine–DNA alkyltransferase and are sensitive to O6–benzylguanine plus BCNU. Gerson SL, et al. **Blood** 1996 Sep 1;88(5):1649–55

AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto–differentiating effects on acute promyelocytic leukemia cells. Gianni M, et al. **Blood** 1996 Feb 15;87(4):1520–31

Predictive value of the steady–state peripheral blood progenitor cell (PBPC) counts for the yield of PBPC collected by leukapheresis after mobilization by granulocyte colony–stimulating factor (G–CSF) alone or chemotherapy and G–CSF [letter; comment] Husson B, et al. **Blood** 1996 Apr 15;87(8):3526–8. Comment on: Blood

1995 May 1;85(9):2619–26.

Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF–1) with retinoic acid–resistant features. Kizaki M, et al. **Blood** 1996 Sep 1;88(5):1824–33

Enhancement of activity of 1alpha, 25–dihydroxyvitamin D3 for growth inhibition and differentiation induction of human myelomonocytic leukemia cells by tretinoin tocoferil, an alpha–tocopherol ester of all–trans retinoic acid. Makishima M, et al. **Blood** 1996 Apr 15;87(8):3384–94

The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Richardson DR, et al. **Blood** 1995 Dec 1;86(11):4295–306

Upregulated expression of BCL–2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Tu Y, et al. **Blood** 1996 Sep 1; 88(5):1805–12

Potentiation of temozolomide–induced cytotoxicity: a comparative study of the biological effects of poly(ADP–ribose) polymerase inhibitors. Boulton S, et al. **Br J Cancer** 1995 Oct;72(4):849–56

Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine). Ciomei M, et al. **Br J Cancer** 1995 Dec;72(6):1504–8

Effect of cisplatin and c–myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Del Bufalo D, et al. **Br J Cancer** 1996 Aug;74(3):387–93

Growth inhibition in clonal subpopulations of a human epithelioid sarcoma cell line by retinoic acid and tumour necrosis factor alpha. Engers R, et al. **Br J Cancer** 1996 Feb;73(4):491–8

Preclinical studies with the anti–CD19–saporin immunotoxin BU12–SAPORIN for the treatment of human–B–cell tumours. Flavell DJ, et al. **Br J Cancer** 1995 Dec; 72(6):1373–9

Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin–B and LL–15. García–Rocha M, et al. **Br J Cancer** 1996 Apr;73(8):875–83

Cisplatin and taxol activate different signal pathways regulating cellular injury–induced expression of GADD153. Gately DP, et al. **Br J Cancer** 1996 Jan; 73(1):18–23

Carboplatin– and cisplatin–induced potentiation of moderate–dose radiation cytotoxicity in human lung cancer cell lines. Groen HJ, et al. **Br J Cancer** 1995 Dec; 72(6):1406–11

DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Hejmadi MV, et al. **Br J Cancer** 1996 Feb;73(4):499–505

Citrus flavone tangeretin inhibits leukaemic HL–60 cell growth partially through induction of apoptosis with less cytotoxicity on normal lymphocytes. Hirano T, et al. **Br J Cancer** 1995 Dec;72(6):1380–8

Inhibition of angiogenesis and murine tumour growth by laminarin sulphate. Hoffman R, et al. **Br J Cancer** 1996 May;73(10):1183–6

Inhibition of the growth of transformed and neoplastic cells by the dipeptide carnosine. Holliday R, et al. **Br J Cancer** 1996 Apr;73(8):966–71

Cell cycle–dependent cytotoxicity and induction of apoptosis by liposomal N4–hexadecyl–1–beta–D–arabinofuranosylcytosine. Horber DH, et al. **Br J Cancer** 1995 Nov;72(5):1067–73

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Houlbrook S, et al. **Br J Cancer** 1995 Dec;72(6):1454–61

Pharmacokinetics, pharmacological and anti–tumour effects of the specific anti–oestrogen ICI 182780 in women with advanced breast cancer. Howell A, et al. **Br J Cancer** 1996 Jul;74(2):300–8

Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Huschtscha LI, et al. **Br J Cancer** 1996 Jan;73(1):54–60

Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy. Katsumoto Y, et al. **Br J Cancer** 1996 Jan;73(1):110–6

Transforming growth factor beta 1 (TGF–beta 1) produced in tumour tissue after chemotherapy acts as a lymphokine–activated killer attractant. Kuramitsu Y, et al. **Br J Cancer** 1996 Jul;74(2):274–9

The effect of tirapazamine (SR–4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Lartigau E, et al. **Br J Cancer** 1996 Jun;73(12):1480–5

Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. Lemus–Wilson A, et al. **Br J Cancer** 1995 Dec;72(6):1435–40

Antiproliferative effects of the arotinoid Ro 40–8757 in human gastrointestinal and pancreatic cancer cell lines: combinations with 5–fluorouracil and interferon–alpha. Louvet C, et al. **Br J Cancer** 1996 Aug;74(3):394–9

p53–independent death and p53–induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Malcomson RD, et al. **Br J Cancer** 1995 Oct; 72(4):952–7

A novel styryl diphenylamine derivative reverts the transformed phenotype of human fibrosarcoma HT1080 cells. Ohizumi I, et al. **Br J Cancer** 1995 Nov;72(5):1219–23

NG–nitro–L–arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2–induced capillary leakage and reduces tumour growth in adenocarcinoma–bearing mice. Orucevic A, et al. **Br J Cancer** 1996 Jan;73(2):189–96

Do telomerase antagonists represent a novel anti–cancer strategy? [editorial] Parkinson EK. **Br J Cancer** 1996 Jan; 73(1):1–4 (47 ref.)

Relationship between the exposure to cisplatin, DNA–adduct formation in leucocytes and tumour response in patients with solid tumours. Schellens JH, et al. **Br J Cancer** 1996 Jun;73(12):1569–75

Tirapazamine–induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Siim BG, et al. **Br J Cancer** 1996 Apr;73(8):952–60

Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Sliutz G, et al. **Br J Cancer** 1996 Jul;74(2):172–7

Pressure tuning infrared spectroscopic study of cisplatin–induced structural changes in a phosphatidylserine model membrane. Taylor KD, et al. **Br J Cancer** 1995 Dec;72(6):1400–5

Drug sensitivity testing for clinical samples from oesophageal cancer using adhesive tumour cell culture system. Terashima M, et al. **Br J Cancer** 1996 Jul;74(1):73–7

Potentiation of temozolomide and BCNU cytotoxicity by O(6)–benzylguanine: a comparative study in vitro. Wedge SR, et al. **Br J Cancer** 1996 Feb;73(4):482–90

The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti–tumour effects. Yamagata M, et al. **Br J Cancer** 1996 Jun; 73(11):1328–34

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Zilembo N, et al. **Br J Cancer** 1995 Oct;72(4):1007–12

Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Guinee DG Jr, et al. **Cancer** 1996 Aug 15;78(4):729–35

Synergistic action of taxol and tiazofurin in human ovarian, pancreatic and lung carcinoma cells. Taniki T, et al. **Cancer Biochem Biophys** 1993 Sep;13(4):295–302

Antimicrotubule effects of the novel antitumor benzoylphenylurea derivative HO–221. Ando N, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):63–9

Collateral sensitivity to radiation and cis–platinum in a multidrug–resistant human leukemia cell line. Cho J, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):168–72

Differentiation of HL–60 cells distinguishes between cytostatic and cytotoxic effects of the alkylphospholipid ET–18–OCH3. Civoli F, et al. **Cancer Chemother Pharmacol** 1996;38(3):269–72

Phase I trial of fluorouracil modulation by N–phosphonacetyl–L–aspartate and 6–methylmercaptopurine ribonucleoside. Hageboutros A, et al. **Cancer Chemother Pharmacol** 1996;37(3):229–34

The effect of treatment with high dose melphalan, cisplatin or carboplatin on levels of glutathione in plasma, erythrocytes, mononuclear cells and urine. Hogarth L, et al. **Cancer Chemother Pharmacol** 1996;37(5):479–85

ICRF–187 rescue in etoposide treatment in vivo. A model targeting high–dose topoisomerase II poisons to CNS tumors. Holm B, et al. **Cancer Chemother Pharmacol** 1996; 38(3):203–9

Cellular pharmacology of N4–hexadecyl–1–beta–D–arabinofuranosylcytosine in the human leukemic cell lines K–562 and U–937. Horber DH, et al. **Cancer Chemother Pharmacol** 1995;36(6):483–92

Epidermal growth factor receptor–dependent cytotoxic effect by an EGF–ribonuclease conjugate on human cancer cell lines—a trial for less immunogenic chimeric toxin. Jinno H, et al. **Cancer Chemother Pharmacol** 1996; 38(4):303–8

Comparison of the antitumor activity of bryostatins 1, 5, and 8. Kraft AS, et al. **Cancer Chemother Pharmacol** 1996; 37(3):271–8

The effect of 9–beta–D–arabinofuranosyl–2–fluoroadenine and 1–beta–D–arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells. Loughlin S, et al. **Cancer Chemother Pharmacol** 1996;38(3):261–8

Isozyme–specific glutathione S–transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Morgan AS, et al. **Cancer Chemother Pharmacol** 1996; 37(4):363–70

In vivo antitumor activity of cis–bis–neodecanoato–trans–R,R–1, 2–diaminocyclohexane platinum(II) formulated in long–circulating liposomes. Mori A, et al. **Cancer Chemother Pharmacol** 1996; 37(5):435–44

cis–Diamminedichloroplatinum(II)–induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Ormerod MG, et al. **Cancer Chemother Pharmacol** 1996;37(5):463–71

Cross–resistance and collateral sensitivity to natural product drugs in cisplatin–sensitive and –resistant rat lymphoma and human ovarian carcinoma cells. Parekh H, et al. **Cancer Chemother Pharmacol** 1996;37(5):457–62

Morphonuclear characterization of drug resistance by means of digital cell–image analysis: an in vitro assessment. Pauwels O, et al. **Cancer Chemother Pharmacol** 1995; 37(1–2):179–86

Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. Reid JM, et al. **Cancer Chemother Pharmacol** 1996;38(4):329–34

Flavone acetic acid increases the cytotoxicity of mitomycin C when combined with hyperthermia. Takeuchi H, et al. **Cancer Chemother Pharmacol** 1996;38(1):1–8

Preclinical pharmacology and antitumour activity of the novel sequence–selective DNA minor–groove cross–linking agent DSB–120. Walton MI, et al. **Cancer Chemother Pharmacol** 1996;38(5):431–8

Investigations on the mechanisms of methotrexate resistance in a cisplatin–resistant L1210 murine leukemia cell subline. Wroblewski DH, et al. **Cancer Chemother Pharmacol** 1996; 37(4):337–42

Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4–hydroperoxycyclophosphamide. Moreb J, et al. **Cancer Gene Ther** 1996 Jan–Feb;3(1):24–30

Protective effect of an acidic glycoprotein obtained from culture of Chlorella vulgaris against myelosuppression by 5–fluorouracil. Konishi F, et al. **Cancer Immunol Immunother** 1996 Jun;42(5):268–74

Antiproliferative effects of bacillus Calmette–Guerin and interferon alpha 2b on human bladder cancer cells in vitro. Pryor K, et al. **Cancer Immunol Immunother** 1995 Nov; 41(5):309–16

Insulin–like growth factor–1 inhibits cell death induced by anticancer drugs in the MCF–7 cells: involvement of growth factors in drug resistance. Geier A, et al. **Cancer Invest** 1995;13(5):480–6

Enhancement of lymphokine–activated killer cell cytotoxicity implicated in the increased expression of surface adhesion molecules on tumor cells treated with anticancer agents. Ishihata R, et al. **Cancer Invest** 1996; 14(5):427–34

Effects of UFT (mixed compound of tegafur and uracil) on cell kinetics and inhibition of thymidylate synthase in L1210 ascites tumor. Kagawa Y, et al. **Cancer Invest** 1995; 13(5):470–4

Role of vitamin D3 on the activity patterns of hepatic drug metabolizing enzymes in transplantable murine lymphoma. Sardar S, et al. **Cancer Invest** 1996;14(4):328–34

The effect of 3'–deoxyadenosine N(1)–oxide on growth in vitro and in vivo on Ehrlich ascites tumor and on a human squamous lung cell carcinoma xenograft in nude mice. Svendsen KR, et al. **Cancer Invest** 1996;14(1):19–24

Antisense oligodeoxynucleotides as clinical therapeutic agents. Tonkinson JL, et al. **Cancer Invest** 1996;14(1):54–65 (103 ref.)

Opposite effect of a cAMP analogue on tumoral growth related to hormone dependence of a murine mammary tumor. Actis AM, et al. **Cancer Lett** 1995 Sep 4;96(1):81–5

Azelaic acid decreases the fibrinolytic potential of cultured human melanoma cells in vitro. Addo–Boadu K, et al. **Cancer Lett** 1996 Jun 5;103(2):125–9

Inhibition of aromatase activity and growth suppression by 4–methoxy–4–androstene–3,17–dione in an androgen sensitive human prostatic carcinoma cell line. Block JL, et al. **Cancer Lett** 1996 Mar 29;101(2):143–8

Tamoxifen and somatostatin affect tumours by inducing apoptosis. Candi E, et al. **Cancer Lett** 1995 Sep 4; 96(1):141–5

The antitumoral compound Kahalalide F acts on cell lysosomes. García–Rocha M, et al. **Cancer Lett** 1996 Jan 19;99(1):43–50

A labile hyperphosphorylated c–Fos protein is induced in mouse fibroblast cells treated with a combination of phorbol ester and anti–tumor promoter curcumin. Huang TS, et al. **Cancer Lett** 1995 Sep 4;96(1):1–7

Association of inhibition of cell growth by O–phospho–L–tyrosine with decreased tyrosine phosphorylation. Mishra S, et al. **Cancer Lett** 1996 Apr 19;102(1–2):65–71

Effect of beta–carotene on the expression of 3–hydroxy–3–methylglutaryl coenzyme A reductase in rat liver. Moreno FS, et al. **Cancer Lett** 1995 Sep 25; 96(2):201–8

trans,trans–2,4–decadienal: cytotoxicity and effect on glutathione level in human erythroleukemia (HEL) cells. Nappez C, et al. **Cancer Lett** 1996 Jan 19;99(1):115–9

Effects of novel 3,4–bisphenylhex(3)enes on cell proliferation in malignant and normal cells. Pechan R, et al. **Cancer Lett** 1996 Jan 2;98(2):163–8

Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Pendyala L, et al. **Cancer Lett** 1995 Nov 6;97(2):177–84

Inhibition of 7,12–dimethylbenz[a]anthracene (DMBA)–induced mammary tumorigenesis and DMBA–DNA adduct formation by curcumin. Singletary K, et al. **Cancer Lett** 1996 Jun 5;103(2):137–41

Sonodynamically induced antitumor effect of pheophorbide a. Umemura K, et al. **Cancer Lett** 1996 Apr 19; 102(1–2):151–7

Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Urdiales JL, et al. **Cancer Lett** 1996 Apr 19;102(1–2):31–7

Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Vandewalle B, et al. **Cancer Lett** 1995 Oct 20;97(1):99–106

Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo. Vincent TS, et al. **Cancer Lett** 1996 May 15;103(1):49–56

The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D. Wieder T, et al. **Cancer Lett** 1996 Feb 27;100(1–2):71–9

Inhibitory effect of Korean mistletoe (Viscum album coloratum) extract on tumour angiogenesis and metastasis of haematogenous and non–haematogenous tumour cells in mice. Yoon TJ, et al. **Cancer Lett** 1995 Oct 20; 97(1):83–91

Growth inhibition and apoptosis in human neuroblastoma SK–N–SH cells induced by hypericin, a potent inhibitor of protein kinase C. Zhang W, et al. **Cancer Lett** 1995 Sep 4;96(1):31–5

Altered regulation of message stability and tumor promoter–responsive cis–trans interactions of ribonucleotide reductase R1 and R2 messenger RNAs in hydroxyurea–resistant cells. Amara FM, et al. **Cancer Res** 1995 Oct 15;55(20):4503–6

Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Andreotti PE, et al. **Cancer Res** 1995 Nov 15; 55(22):5276–82

Microsatellite instability, apoptosis, and loss of p53 function in drug–resistant tumor cells. Anthoney DA, et al. **Cancer Res** 1996 Mar 15;56(6):1374–81

Transfection of glutathione S–transferase (GST)–pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Ban N, et al. **Cancer Res** 1996 Aug 1; 56(15):3577–82

Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Berger B, et al. **Cancer Res** 1996 May 1;56(9):2094–104

ET–18–OCH3 inhibits nuclear factor–kappa B activation by 12–O–tetradecanoylphorbol–13–acetate but not by tumor necrosis factor–alpha or interleukin 1 alpha. Daniel LW, et al. **Cancer Res** 1995 Nov 1;55(21):4844–9

Inhibition of Growth of Human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C–alpha expression. Dean N, et al. **Cancer Res** 1996 Aug 1;56(15):3499–507

Failure to dephosphorylate retinoblastoma protein in drug–resistant cells. Dou QP, et al. **Cancer Res** 1995 Nov 15;55(22):5222–5

Potential role for retinoic acid receptor–gamma in the inhibition of breast cancer cells by selective retinoids and interferons. Fanjul AN, et al. **Cancer Res** 1996 Apr 1; 56(7):1571–7

Antiproliferative and angiostatic activity of suramin analogues. Firsching A, et al. **Cancer Res** 1995 Nov 1; 55(21):4957–61

Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Gatto B, et al. **Cancer Res** 1996 Jun 15;56(12):2795–800

Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti–topoisomerase II agents. Hsiung Y, et al. **Cancer Res** 1996 Jan 1;56(1):91–9

Regulation of the expression of E–cadherin on human cancer cells by gamma–linolenic acid (GLA). Jiang WG, et al. **Cancer Res** 1995 Nov 1;55(21):5043–8

Dual action of tirapazamine in the induction of DNA strand breaks. Jones GD, et al. **Cancer Res** 1996 Apr 1; 56(7):1584–90

Design and analysis of in vitro antitumor pharmacodynamic studies. Kalns JE, et al. **Cancer Res** 1995 Nov 15; 55(22):5315–22

Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9–cis–retinoic acid. Kane KF, et al. **Cancer Res** 1996 Feb 1;56(3):623–32

Comparison of N–(4–hydroxyphenyl)retinamide and all–trans–retinoic acid in the regulation of retinoid receptor–mediated gene expression in human breast cancer cell lines. Kazmi SM, et al. **Cancer Res** 1996 Mar 1; 56(5):1056–62

MKT–077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Koya K, et al. **Cancer Res** 1996 Feb 1;56(3):538–43

Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Kusumoto H, et al. **Cancer Res** 1996 Jun 1;56(11):2573–83

Differential sensitivity of human and mouse alkyltransferase to O6–benzylguanine using a transgenic model. Liu L, et al. **Cancer Res** 1996 Apr 15;56(8):1880–5

Point mutations in human O6–alkylguanine–DNA alkyltransferase prevent the sensitization by O6–benzylguanine to killing by N,N'–bis (2–chloroethyl)–N–nitrosourea. Loktionova NA, et al. **Cancer Res** 1996 Apr 1;56(7):1578–83

Inhibition of tumor growth and neovascularization by an anti–gastric ulcer agent, irsogladine. Ono M, et al. **Cancer Res** 1996 Apr 1;56(7):1512–6

The differential expression of cytokeratin 18 in cisplatin–sensitive and –resistant human ovarian adenocarcinoma cells and its association with drug sensitivity. Parekh HK, et al. **Cancer Res** 1995 Nov 15; 55(22):5203–6

In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. Piepmeier JM, et al. **Cancer Res** 1996 Jan 15;56(2):359–61

Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response. Qin Z, et al. **Cancer Res** 1995 Nov 1;55(21):4747–51

Increase of beta(III)– and beta(IVa)–tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Ranganathan S, et al. **Cancer Res** 1996 Jun 1; 56(11):2584–9

A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage–dependent and –independent growth of human tumor cell lines. Sepp–Lorenzino L, et al. **Cancer Res** 1995 Nov 15;55(22):5302–9

Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. Serve H, et al. **Cancer Res** 1996 Aug 1;56(15):3583–8

The erbstatin analogue methyl 2,5–dihydroxycinnamate cross–links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition. Stanwell C, et al. **Cancer Res** 1995 Nov 1;55(21):4950–6

Flk–1 as a target for tumor growth inhibition. Strawn LM, et al. **Cancer Res** 1996 Aug 1;56(15):3540–5

The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C–independent mechanism: dissociation of activities using 26–epi–bryostatin 1. Szallasi Z, et al. **Cancer Res** 1996 May 1;56(9):2105–11

Use of hydroxyurea to alter drug resistance of human tumor cells. Van den Berg C, et al. **Cancer Treat Res** 1995; 78:95–114 (123 ref.)

New drugs. The anthrapyrazoles. Gogas H, et al. **Cancer Treat Rev** 1996 Nov;21(6):541–52 (53 ref.)

Targeting of O6–methylguanine–DNA methyltransferase (MGMT) activity by antimessenger oligonucleotide sensitizes CHO/Mex+ transfected cells to mitozolomide. Citti L, et al. **Carcinogenesis** 1996 Jan;17(1):25–9

Inhibitory effect of dietary 4–ipomeanol on DNA adduct formation by the food mutagen 2–amino–3–methylimidazo[4,5–f]quinoline (IQ) in male CDF1 mice. Cummings DA, et al. **Carcinogenesis** 1995 Oct; 16(10):2523–9

Transfer and expression of human O6–methylguanine–DNA methyltransferase cDNA confers resistance of Mer– HeLa MR cells to 1–(4–amino–2–methyl–5–pyrimidinyl)methyl–3–(2–chloroethyl)–3–nitrosoure a. Yang J, et al. **Carcinogenesis** 1995 Sep;16(9):2271–4

Enhancement of 5–fluorouracil cytotoxicity by cisplatin in brain tumour cell lines. Mineura K, et al. **Cell Biol Int** 1996 May;20(5):355–7

Induction of cell differentiation potentiates apoptosis triggered by prior exposure to DNA–damaging drugs. Bhatia U, et al. **Cell Growth Differ** 1995 Aug;6(8):937–44

Studies evaluating the antitumor activity and toxicity of interleukin–15, a new T cell growth factor: comparison with interleukin–2. Munger W, et al. **Cell Immunol** 1995 Oct 15;165(2):289–93

Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent. Coluccia M, et al. **Chem Biol Interact** 1995 Dec 22;98(3):251–66

Quinone–induced apoptosis in human colon adenocarcinoma cells via DT–diaphorase mediated bioactivation. Sun X, et al. **Chem Biol Interact** 1996 May 6;100(3):267–76

Water–soluble antitumor agents. I. Synthesis and biological activity of 6–S–aminoacyloxymethyl mercaptopurine derivatives. Harada N, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1793–6

Amino acids and peptides. XXV. Preparation of fibronectin–related peptide poly(ethylene glycol) hybrids and their inhibitory effect on experimental metastasis. Kawasaki K, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec; 43(12):2133–8

Synthesis and antitumor activity of phenyl carbocyclic oxetanocin and related compounds. Maruyama T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul;44(7):1407–11

Synthesis and antitumor activity of novel dolastatin 10 analogs. Miyazaki K, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1706–18

Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours. Algarra I, et al. **Clin Exp Immunol** 1996 Mar;103(3):499–505

Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. Conway JG, et al. **Clin Exp Metastasis** 1996 Mar;14(2):115–24

Anti–metastatic prostacyclins inhibit the adhesion of colon carcinoma to endothelial cells by blocking E–selectin expression. Daneker GW, et al. **Clin Exp Metastasis** 1996 May;14(3):230–8

In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor–associated antigens is augmented by the iron chelator deferoxamine. Hsieh–Ma ST, et al. **Clin Immunol Immunopathol** 1996 Aug; 80(2):185–93

Downregulation of interleukin–2 and apha–chain interleukin–2 receptor biosynthesis by cisplatin in human peripheral lymphocytes. Sfikakis PP, et al. **Clin Immunol Immunopathol** 1996 Apr;79(1):43–9

Etoposide combined with interferon alfa–2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Mick R, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):349–59

Biological activity of disulfated polyhydroxysteroids from the Pacific brittle star Ophiopholis aculeata. Aminin DL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):201–4

Anticarcinogenic, hypocholesterolemic, and antagonistic activities of Lactobacillus acidophilus. Mital BK, et al. **Crit Rev Microbiol** 1995;21(3):175–214 (371 ref.)

Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Nocentini G. **Crit Rev Oncol Hematol** 1996 Mar;22(2):89–126 (335 ref.)

Advances in glyoxalase research. Glyoxalase expression in malignancy, anti–proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S–D–lactoylglutathione, and methylglyoxal–modified protein binding and endocytosis by the advanced glycation endproduct receptor. Thornalley PJ. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):99–128 (225 ref.)

Anticancer drugs acting against signaling pathways. Powis G. **Curr Opin Oncol** 1995 Nov;7(6):554–9 (95 ref.)

Specific induction of uncoiling in NORs of human acrocentric chromosomes by 5–azacytidine and 5–azadeoxicytidine. Malheiro I, et al. **Cytobios** 1995; 83(332):17–23

Cytokines oncostatin M and interleukin 1 regulate the expression of the IL–6 receptor (gp80, gp130). Geisterfer M, et al. **Cytokine** 1995 Aug;7(6):503–9

Transcriptional upregulation of TGF–alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells. Liu L, et al. **Cytokine** 1995 Jul; 7(5):449–56

Augmentation of TNF cytotoxicity by protein kinase C inhibitors: role of arachidonic acid and manganese superoxide dismutase. Prezioso JA, et al. **Cytokine** 1995 Aug;7(6):517–25

Cytotoxicity in L929 murine fibrosarcoma cells after triggering of transfected human p75 tumour necrosis factor (TNF) receptor is mediated by endogenous murine TNF. Vercammen D, et al. **Cytokine** 1995 Jul;7(5):463–70

Human breast adenocarcinoma MCF–7/0 cells electroporated with cytosolic class 3 aldehyde dehydrogenases obtained from tumor cells and a normal tissue exhibit differential sensitivity to mafosfamide. Sreerama L, et al. **Drug Metab Dispos** 1995 Oct; 23(10):1080–4

Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. Gillis JC, et al. **Drugs** 1995 Nov;50(5):897–923 (160 ref.)

Epitope peptides from interleukin–6 receptor which inhibit the growth of human myeloma cells. Halimi H, et al. **Eur Cytokine Netw** 1995 May–Jun;6(3):135–43

Cytotoxicity of TGF alpha–PE40 and correlation to expression of epidermal growth factor receptor. Berger DP, et al. **Eur J Cancer** 1995 Nov;31A(12):2067–72

Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Berkovic D, et al. **Eur J Cancer** 1995 Nov;31A(12):2080–5

Meta–iodobenzylguanidine (MIBG) inhibits malate and succinate driven mitochondrial ATP synthesis in the human neuroblastoma cell line SK–N–BE(2c). Cornelissen J, et al. **Eur J Cancer** 1995;31A(4):582–6

From amsacrine to DACA (N–[2–(dimethylamino)ethyl]acridine–4–carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Finlay GJ, et al. **Eur J Cancer** 1996 Apr; 32A(4):708–14

Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB. Fleer EA, et al. **Eur J Cancer** 1996 Mar;32A(3):506–11

Antiproliferative potential of cytostatic drugs on neuroblastoma cells in vitro. Fulda S, et al. **Eur J Cancer** 1995;31A(4):616–21

Androgen–like and anti–androgen–like effects of antiprogestins in human mammary cancer cells. Hackenberg R, et al. **Eur J Cancer** 1996 Apr; 32A(4):696–701

Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro. Hanauske AR, et al. **Eur J Cancer** 1995 Sep;31A(10):1677–81

Apoptosis and chemotherapy resistance. Hickman JA. **Eur J Cancer** 1996 Jun;32A(6):921–6 (67 ref.)

Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Masters JR, et al. **Eur J Cancer** 1996 Jun;32A(7):1248–53

Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of 9–cis and all–trans retinoic acid. Redfern CP, et al. **Eur J Cancer** 1995;31A(4):486–94 (73 ref.)

Effect of tyrphostin combined with a substance P related antagonist on small cell lung cancer cell growth in vitro. Seckl MJ, et al. **Eur J Cancer** 1996 Feb;32A(2):342–5

Cyclopentenyl cytosine and neuroblastoma SK–N–BE(2)–C cell line cells. Slingerland RJ, et al. **Eur J Cancer** 1995; 31A(4):627–31

Improved pharmacodynamics of L–asparaginase–loaded in

human red blood cells. Kravtzoff R, et al. **Eur J Clin Pharmacol** 1996;49(6):465–70

Failure to label red blood cells adequately in daily practice using an in vivo method: methodological and clinical considerations [letter; comment] Eising EG, et al. **Eur J Nucl Med** 1995 Jun;22(6):587. Comment on: Eur J Nucl Med 1995 Jan;22(1):61–7.

Interaction of cytostatics and chemosensitizers with the dexniguldipine binding site on P-glycoprotein. Boer R, et al. **Eur J Pharmacol** 1996 Jan 11;295(2–3):253–60

Lipid A and the lipid A analogue anti-tumour compound ONO-4007 induce nitric oxide synthase in vitro and in vivo. Hattori Y, et al. **Eur J Pharmacol** 1995 Oct 15; 291(2):83–90

Effect of a new de-N-acetyl-lysoglycosphingolipid on some tumour models. Tubaro E, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):555–63

Hexamethylene bisacetamide-induced differentiation of Friend virus-transformed murine erythroleukemia cells is associated with parallel changes in casein kinase II and guanine nucleotide exchange factor activities. Aroor AR, et al. **Exp Hematol** 1995 Oct;23(11):1204–11

Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients. Einat M, et al. **Exp Hematol** 1995 Dec;23(14):1439–44

Antimitotic and antiviral activities of Kelletinin A in HTLV-1 infected MT2 cells. Silvestri I, et al. **Experientia** 1995 Nov 15;51(11):1076–80

Heterocyclic betaines containing pi-deficient and pi-excessive moieties. Synthetic and biological aspects. Alcalde E, et al. **Farmaco** 1996 Jun;51(6):381–93 (51 ref.)

Synthesis and anticancer properties of pyrimido[4,5-b]quinolines. Długosz A, et al. **Farmaco** 1996 May;51(5):367–74

The cytostatic activity of 5-(1-azidovinyl)-2'-deoxyuridine (AzVDU) against herpes simplex virus thymidine kinase gene-transfected FM3A cells is due to inhibition of thymidylate synthase and enhanced by UV light (lambda = 254 nm) exposure. Balzarini J, et al. **FEBS Lett** 1995 Oct 2;373(1):41–4

Protein tyrosine kinase inhibitors prevent didemnin B-induced apoptosis in HL-60 cells. Johnson KL, et al. **FEBS Lett** 1996 Mar 25;383(1–2):1–5

Interaction of cryptophycin 1 with tubulin and microtubules. Kerksiek K, et al. **FEBS Lett** 1995 Dec 11;377(1):59–61

DNA protein flow cytometry of dissociated cultures of human anaplastic gliomas. Pattern of proliferation and differentiation, and the effect of a new cytostatic drug cladribine (2-CdA). Grieb P, et al. **Folia Neuropathol** 1995; 33(3):145–52

Inhibition of human leukaemia 60 cell growth by mercapturic acid metabolites of phenylethyl isothiocyanate. Adesida A, et al. **Food Chem Toxicol** 1996 Apr;34(4):385–92

Induction of micronucleus formation in mouse splenocytes by the soy isoflavone genistein in vitro but not in vivo. Record IR, et al. **Food Chem Toxicol** 1995 Nov; 33(11):919–22

Suppression by anticancer agents of reactive oxygen generation from polymorphonuclear leukocytes. Ueta E, et al. **Free Radic Res** 1996 Jan;24(1):39–53

Inhibitory effect of 22O-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Kawa S, et al. **Gastroenterology** 1996 May;110(5):1605–13

Mechanisms of resistance to topoisomerases poisons. Prost S. **Gen Pharmacol** 1995 Dec;26(8):1673–84 (88 ref.)

Signal transduction by Ras-like GTPases: a potential target for anticancer drugs. Spaargaren M, et al. **Gene Expr** 1995; 4(6):345–56 (122 ref.)

Pattern and frequency of nocodazole induced meiotic nondisjunction in oocytes of mice carrying the 'tobacco mouse' metacentric Rb(16.17)7Bnr. Everett CA, et al. **Genet Res** 1995 Aug;66(1):35–43

Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study. Schnitzler M, et al. **Gut** 1996 May;38(5):707–13

Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines. Manetta A, et al. **Gynecol Oncol** 1996 Feb;60(2):203–12

Apoptosis induction with purine analogs on freshly isolated chronic myeloid leukemia cells [letter] Zinzani PL, et al. **Haematologica** 1995 Jul-Aug;80(4):390–1

Effect of cisplatin administration on the electrochemical composition of endolymph in the rat cochlea. Laurell G, et al. **Hear Res** 1995 Jul;87(1–2):16–20

Promoting apoptosis. Alison M. **Hum Exp Toxicol** 1995 Aug; 14(8):697–8

Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect". Chen CY, et al. **Hum Gene Ther** 1995 Nov;6(11):1467–76

Two genes controlling acute phase responses by the antitumor polysacch aride, lentinan. Maeda YY, et al. **Immunogenetics** 1996;43(4):215–9

Modulation of LIF expression in human melanoma cells by oncostatin M. Heymann D, et al. **Immunol Lett** 1995 Jun; 46(3):245–51

Reversal of doxorubicin-resistance in solid tumors by clomipramine. Pommerenke EW, et al. **In Vivo** 1995 Mar-Apr;9(2):99–101

Influence of glycyrrhizin on the evolution and respiration of Ehrlich ascites tumour cells. Rossi T, et al. **In Vivo** 1995 May-Jun;9(3):183–6

Growth inhibitory effects of pMC540 and merodantoin on established MCF-7 human breast tumor xenografts. Sharma R, et al. **In Vivo** 1995 Mar-Apr;9(2):103–8

Microtubule-disrupting agents inhibit nitric oxide production in murine peritoneal macrophages stimulated with lipopolysaccharide or paclitaxel (Taxol). Kirikae T, et al. **Infect Immun** 1996 Aug;64(8):3379–84

Mitoxantrone induces nonimmunological histamine release from rat mast cells. Estévez MD, et al. **Inflamm Res** 1996 Mar;45(3):113–7

Differentiation of U-937 promonocytic cells with mitomycin C or cis-diamminedichloroplatinum II. Ballester A, et al. **Int J Cancer** 1996 Mar 15;65(6):791–5

Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. Basu A, et al. **Int J Cancer** 1995 Nov 15;63(4):597–603

Noncytotoxic alkyl-lysophospholipid treatment increases sensitivity of leukemic K562 cells to lysis by natural killer (NK) cells. Botzler C, et al. **Int J Cancer** 1996 Mar 1; 65(5):633–8

SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo. Cammisuli S, et al. **Int J Cancer** 1996 Jan 26;65(3):351–9

Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients. Csoka K, et al. **Int J Cancer** 1995 Nov 3;63(3):356–60

Tetraphenylphosphonium chloride induced MR-visible lipid accumulation in a malignant human breast cell line. Delikatny EJ, et al. **Int J Cancer** 1996 Jul 3;67(1):72–9

Anti-tumor and anti-angiogenic effects in mice of heparin conjugated to angiostatic steroids. Derbyshire EJ, et al. **Int J Cancer** 1995 Nov 27;63(5):694–701

Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Esaki T, et al. **Int J Cancer** 1996 Feb 8;65(4):479–84

Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Grunt TW, et al. **Int J Cancer** 1995 Nov 15;63(4):560–7

Modulation of cisplatin sensitivity and accumulation by interferon alpha-2A in human squamous carcinoma cell lines. Gupta V, et al. **Int J Cancer** 1995 Nov 3;63(3):419–22

Growth control of human colon-adenocarcinoma-derived Caco-2 cells by vitamin-D compounds and extracellular calcium in vitro: relation to c-myc-oncogene and vitamin-D-receptor expression. Hulla W, et al. **Int J Cancer** 1995 Sep 15;62(6):711–6

Interleukin 1 (IL-1) production is not essential for acquired resistance of human A375 melanoma cells to anti-proliferative effect of IL-1. Itoh S, et al. **Int J Cancer** 1996 Mar 15;65(6):805–11

Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Iwadate Y, et al. **Int J Cancer** 1996 Jun 21;69(3):236–40

Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models. Kobayashi H, et al. **Int J Cancer** 1995 Nov 3; 63(3):455–62

DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Mellish KJ, et al. **Int J Cancer** 1995 Sep 15;62(6):717–23

Inhibition of methionine uptake by cis-diamminedichloroplatinum (II) in experimental brain tumors. Mineura K, et al. **Int J Cancer** 1996 Sep 4; 67(5):681–3

The potent anti-proliferative effect of 20-epi analogues of 1,25 dihydroxyvitamin D3 in human breast-cancer MCF-7 cells is related to promoter selectivity. Mørk Hansen C, et al. **Int J Cancer** 1996 Sep 4;67(5):739–42

Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line. Normanno N, et al. **Int J Cancer** 1995 Sep 15; 62(6):762–6

Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Pinski J, et al. **Int J Cancer** 1996 Mar 15;65(6):870–4

Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Preuss I, et al. **Int J Cancer** 1996 Feb 8;65(4):506–12

Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. Qin Y, et al. **Int J Cancer** 1995 Oct 9;63(2):257–62

Effects of organic and inorganic selenium compounds on rat mammary tumor cells. Ronai Z, et al. **Int J Cancer** 1995 Nov 3;63(3):428–34

Oncogene expression is modulated by recombinant human interferon-beta in human breast-cancer cells. Sica G, et al. **Int J Cancer** 1996 Jul 29;67(3):441–6

Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Supino R, et al. **Int J Cancer** 1996 Feb 8;65(4):491–7

Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines. Toffoli G, et al. **Int J Cancer** 1996 Jul 3;67(1):129–37

Effects of aminoglutethimide, alone and in combination with surgical castration, on pancreatic carcinogenesis in rats and hamsters. Visser CJ, et al. **Int J Cancer** 1995 Nov 27; 63(5):732–7

Genetic basis of drug sensitivity in human testis tumour cells. Wang X, et al. **Int J Cancer** 1996 Feb 8;65(4):426–31

c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of P185c-erbB-2-overexpressing ovarian carcinoma cells. Wiechen K, et al. **Int J Cancer** 1995 Nov 15;63(4):604–8

Studies of natural killer cell activity in a drug-free, healthy population. Response to a challenge with taxol, estramustine and lipopolysaccharide. Puente J, et al. **Int J Clin Pharmacol Ther** 1995 Aug;33(8):457–61

Lentinan augments skin reaction induced by bradykinin: its correlation with vascular dilatation and hemorrhage responses and antitumor activities. Takatsuki F, et al. **Int J Immunopharmacol** 1995 Jun;17(6):465–74

Stimulation of macrophages with IFN gamma or TNF alpha shuts off the suppressive effect played by PGE2. Zicari A, et al. **Int J Immunopharmacol** 1995 Sep;17(9):779–86

Concomitant low dose-rate irradiation and cisplatin treatment in ovarian carcinoma cell lines sensitive and resistant to cisplatin treatment. Raaphorst GP, et al. **Int J Radiat Biol** 1996 May;69(5):623–31

Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. Britten RA, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):367–74

The nuclear matrix as a site of anticancer drug action. Fernandes DJ, et al. **Int Rev Cytol** 1995;162A:539–76 (260 ref.)

The effects of thiotepa, mitomycin C, BCG and interferon instillation on urothelium. Polat O, et al. **Int Urol Nephrol** 1996;28(1):43–8

FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis. Sola F, et al. **Invasion Metastasis** 1995;15(5–6):222–31

Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units in vitro. Depenbrock H, et al. **Invest New Drugs** 1995; 13(2):117–23

Comparative efficacy of DMP 840 against mouse and human solid tumor models. LoRusso P, et al. **Invest New Drugs** 1995;13(3):195–203

Stimulation of tumor growth in vitro and in vivo by suramin on the VX2 model. Ramirez LH, et al. **Invest New Drugs** 1995;13(1):51–3

Selective effects of DNA damaging agents on HIV long terminal repeat activation and virus replication in vitro. Manome Y, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):109–16

New anthracycline metabolites produced by the aklavinone 11-hydroxylase gene in Streptomyces galilaeus ATCC 31133. Kim HS, et al. **J Antibiot (Tokyo)** 1996 Apr; 49(4):355–60

Louisianins A, B, C and D: non-steroidal growth inhibitors of testosterone-responsive SC 115 cells. I. Taxonomy, fermentation, isolation and biological characteristics. Komiyama K, et al. **J Antibiot (Tokyo)** 1995 Oct; 48(10):1086–9

Synthesis and antimetastatic activity of 6-trichloroacetamido and 6-guanidino analogues of siastatin B. Satoh T, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):321–5

Response of Saccharomyces cerevisiae strains to antineoplastic agents. Delitheos A, et al. **J Appl Bacteriol** 1995 Oct;79(4):379–83

Stimulation of glycosphingolipid biosynthesis by L-threo-1-phenyl-2-decanoylamino-1-propanol and its homologs in B16 melanoma cells. Inokuchi J, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):766–73

Activation of smooth muscle alpha-actin promoter in ras-transformed cells by treatments with antimitotic agents: correlation with stimulation of SRF:SRE mediated gene transcription. Kumar CC, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1285–92

ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. Loe DW, et al. **J Biol Chem** 1996 Apr 19;271(16):9683–9

Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected] [published erratum appears in J Biol Chem 1995 Dec 15;270(50):30235] Singh S, et al. **J Biol Chem** 1995 Oct 20;270(42):24995–5000

Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin. Smith CD, et al. **J Biol Chem** 1996 Mar 15;271(11):6192–8

Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. Smith CD, et al. **J Biol Chem** 1995 Nov 24;270(47):28145–52

The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. Watabe M, et al. **J Biol Chem** 1996 Jun 14;271(24):14067–72

The association of lipid activators with the amphipathic helical domain of CTP:phosphocholine cytidylyltransferase accelerates catalysis by increasing the affinity of the enzyme for CTP. Yang W, et al. **J Biol Chem** 1995 Oct 13;270(41):23951–7

Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy X-ray absorptiometric and histomorphometric study. Chen HK, et al. **J Bone Miner Res** 1995 Aug;10(8):1256–62

Comparative effects of 1,25-dihydroxyvitamin D3 and EB 1089 on mouse renal and intestinal 25-hydroxyvitamin D3-24-hydroxylase. Roy S, et al. **J Bone Miner Res** 1995 Dec;10(12):1951-9

Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia. Bando T, et al. **J Cancer Res Clin Oncol** 1996;122(1):21-6

Preferential inhibition of DNA polymerases alpha, delta, and epsilon from Novikoff hepatoma cells by inhibitors of cell proliferation. Fox G, et al. **J Cancer Res Clin Oncol** 1996; 122(2):78-94

Intraarterial hepatic chemotherapy with fluorouracil, fluorodeoxyuridine, mitomycin C, cisplatin or methotrexate as single-agent anticancer drugs for a transplanted experimental liver tumor in rats. Kurth S, et al. **J Cancer Res Clin Oncol** 1996;122(7):421-6

Suppression of the proliferation and migration of oncogenic ras-dependent cell lines, cultured in a three-dimensional collagen matrix, by flavonoid-structured molecules. Lü HQ, et al. **J Cancer Res Clin Oncol** 1996;122(6):335-42

Dexniguldipine hydrochloride, a protein-kinase-C-specific inhibitor, affects the cell cycle, differentiation, P-glycoprotein levels, and nuclear protein phosphorylation in Friend erythroleukemia cells. Patterson KK, et al. **J Cancer Res Clin Oncol** 1996;122(8):465-75

Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin). Thurman GB, et al. **J Cancer Res Clin Oncol** 1996; 122(9):549-53

Local hyperthermic treatment does not enhance mitoxantrone effectiveness for responses of a rat solid tumour regrowing after irradiation. van Bree C, et al. **J Cancer Res Clin Oncol** 1996;122(3):147-53

Effect of cis-diamminedichloroplatinum (II) on rat thymocyte membrane potential. Florio S, et al. **J Chemother** 1996 Apr;8(2):147-53

Effects of 1-tetradecylperhydroazepine and 1-pentadecylpiperidine N-oxides on Ehrlich ascites mitochondria. Miko M, et al. **J Chemother** 1995 Oct; 7(5):446-8

Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines. Ohta K, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2607-12

Altered interaction of Cis-dichlorodiammineplatinum(II)--modified alpha 2-macroglobulin (alpha 2M) with the low density lipoprotein receptor-related protein/alpha 2M receptor but not the alpha 2M signaling receptor. Howard GC, et al. **J Clin Invest** 1996 Mar 1;97(5):1193-203

Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. Sasada T, et al. **J Clin Invest** 1996 May 15;97(10):2268-76

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. van der Pluijm G, et al. **J Clin Invest** 1996 Aug 1;98(3):698-705

(1-->3)-beta-D-glucan in culture fluid of fungi activates factor G, a limulus coagulation factor. Miyazaki T, et al. **J Clin Lab Anal** 1995;9(5):334-9

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. Dahut W, et al. **J Clin Oncol** 1996 Apr;14(4):1236-44

Effect of camel urine on the cytological and biochemical changes induced by cyclophosphamide in mice. al-Harbi MM, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):129-37

Carrier herbal medicine: an evaluation of the antimicrobial and anticancer activity in some frequently used remedies. Ritch-Krc EM, et al. **J Ethnopharmacol** 1996 Jul 5; 52(3):151-6

Ayurvedic herbal drugs with possible cytostatic activity. Smit HF, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):75-84 (53 ref.)

Platinum(II) complexes of 4-methoxy- and 4-chlorobenzoic acid hydrazides. Synthesis, characterization, and cytotoxic effect. Dodoff N, et al. **J Inorg Biochem** 1995 Dec; 60(4):257-66

Synthesis, characterization, and DNA modification induced by a novel Pt-berenil compound with cytotoxic activity. González VM, et al. **J Inorg Biochem** 1996 Jul;63(1):57-68

Natural human interferon-alpha inhibits the adhesion of a human carcinoma cell line to human vascular endothelium. Dao T, et al. **J Interferon Cytokine Res** 1995 Oct; 15(10):869-76

Correlation of in vitro and in vivo effects of interferon-gamma with the spontaneous regression of a rat histiocytoma. Kausalya S, et al. **J Interferon Cytokine Res** 1995 Jul;15(7):647-54

22-Oxa calcitriol is a less potent regulator of keratinocyte proliferation and differentiation due to decreased cellular uptake and enhanced catabolism. Bikle DD, et al. **J Invest Dermatol** 1995 Nov;105(5):693-8

Antitumor activity of five new platinum complexes having a glycolate leaving ligand. Hong WS, et al. **J Korean Med Sci** 1995 Aug;10(4):269-74

Synthesis, antitumor activity, and chemical properties of silaplatin and related platinum (II) and platinum (IV) complexes derived from beta-silyl amines. Anderson WK, et al. **J Med Chem** 1995 Sep 15;38(19):3789-97

Antitumor agents. 164. Podophenazine, 2",3"-dichloropodophenazine, benzopodophenazine, and their 4 beta-p-nitroaniline derivatives as novel DNA topoisomerase II inhibitors. Cho SJ, et al. **J Med Chem** 1996 Mar 29;39(7):1396-402

Topoisomerase II-mediated DNA cleavage by adocia- and xestoquinones from the Philippine sponge Xestospongia sp. Concepción GP, et al. **J Med Chem** 1995 Oct 27; 38(22):4503-7

Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines. Gangjee A, et al. **J Med Chem** 1995 Sep 15;38(19):3798-805

Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. Greenwald RB, et al. **J Med Chem** 1996 Jan 19;39(2):424-31

Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[(octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt. Houlihan WJ, et al. **J Med Chem** 1996 Jan 19;39(2):605-8

Alkyl and alkoxyethyl antineoplastic phospholipids. Koufaki M, et al. **J Med Chem** 1996 Jun 21;39(13):2609-14

Synthesis and cytotoxicity of 1,2-disubstituted naphth[2,3-d]imidazole-4,9-diones and related compounds. Kuo SC, et al. **J Med Chem** 1996 Mar 29;39(7):1447-51

High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. Kuyper LF, et al. **J Med Chem** 1996 Feb 16;39(4):892-903

Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin. Lackey K, et al. **J Med Chem** 1996 Feb 2;39(3):713-9

Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. Lee HH, et al. **J Med Chem** 1996 Jun 21; 39(13):2508-17

Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. Leftheris K, et al. **J Med Chem** 1996 Jan 5;39(1):224-36

Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. 2. Monge A, et al. **J Med Chem** 1995 Oct 27;38(22):4488-94

In vivo activity and hydrophobicity of cytostatic aziridinyl quinones. Moret EE, et al. **J Med Chem** 1996 Feb 2; 39(3):720-8

Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. Norman BH, et al. **J Med Chem** 1996 Mar 1;39(5):1106-11

Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. Palmer BD, et al. **J Med Chem** 1996 Jun 21;39(13):2518-28

Effects of multidrug resistance (MDR1) P-glycoprotein expression levels and coordination metal on the cytotoxic potency of multidentate (N4O2) (ethylenediamine)bis[propyl(R-benzylimino)]metal(III) cations. Sharma V, et al. **J Med Chem** 1996 Aug 30; 39(18):3483-90

Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)- hydrazines. Shyam K, et al. **J Med Chem** 1996 Feb 2;39(3):796-801

Antitumor agents. 166. Synthesis and biological evaluation of 5,6,7,8-substituted-2-phenylthiochromen-4-ones. Wang HK, et al. **J Med Chem** 1996 May 10;39(10):1975-80

Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells. Zhang L, et al. **J Med Chem** 1996 Jul 5;39(14):2659-63

The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine. Gartenhaus RB, et al. **J Mol Med** 1996 Mar;74(3):143-7

Mechanism-based antitumor screening of Caribbean marine organisms: isolation and structure determination of novel diterpenoids from the gorgonian Eunicea tourneforti. Govindan M, et al. **J Nat Prod** 1995 Aug;58(8):1174-84

Antitumor activity and stereochemistry of acetylenic alcohols from the sponge Cribrochalina vasculum. Hallock YF, et al. **J Nat Prod** 1995 Dec;58(12):1801-7

Sinugibberol, a new cytotoxic cembranoid diterpene from the soft coral Sinularia gibberosa. Hou RS, et al. **J Nat Prod** 1995 Jul;58(7):1126-30

Cytotoxic compounds from a two-sponge association. Jung JH, et al. **J Nat Prod** 1995 Nov;58(11):1722-6

Mycalolides D and E, new cytotoxic macrolides from a collection of the stony coral Tubastrea faulkneri. Rashid MA, et al. **J Nat Prod** 1995 Jul;58(7):1120-5

DNA repair: enzymatic mechanisms and relevance to drug response. Chaney SG, et al. **J Natl Cancer Inst** 1996 Oct 2;88(19):1346-60 (253 ref.)

Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. Croix BS, et al. **J Natl Cancer Inst** 1996 Sep 18; 88(18):1285-96

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! [editorial; comment] Eisenberger MA, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):779-81. Comment on: J Natl Cancer Inst 1996 Jun 19;88(12):794-801.

Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9 Fitzsimmons SA, et al. **J Natl Cancer Inst** 1996 Mar 6;88(5):259-69

Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line [see comments] Hochhauser D, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1269-75. Comment in: J Natl Cancer Inst 1996 Sep 18;88(18):1255-6.

Apoptosis provides new targets for chemotherapy [news] Holzman D. **J Natl Cancer Inst** 1996 Aug 21; 88(16):1098-100

Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines [see comments] Kalemkerian GP, et al. **J Natl Cancer Inst** 1995 Nov 15; 87(22):1674-80. Comment in: J Natl Cancer Inst 1995 Nov 15;87(22):1655-7.

Regulatory genes and drug sensitivity [editorial; comment] Kohn KW. **J Natl Cancer Inst** 1996 Sep 18;88(18):1255-6. Comment on: J Natl Cancer Inst 1996 Sep 18;88(18):1269-75.

Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. O'Reilly S, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):817-24

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. Osborne CK, et al. **J Natl Cancer Inst** 1995 May 17; 87(10):746-50

Re: Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and E09 [letter] Pritsos C. **J Natl Cancer Inst** 1996 Aug 21;88(16):1161-3

Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. Rybak SM, et al. **J Natl Cancer Inst** 1996 Jun 5;88(11):747-53

Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism [editorial; comment] Stein C.A.. **J Natl Cancer Inst** 1996 Apr 3; 88(7):391-3 (9 ref.). Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):419-29.

Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy [letter] Takahashi Y, et al. **J Natl Cancer Inst** 1995 Aug 16;87(16):1262-3

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer [see comments] Thalmann GN, et al. **J Natl Cancer Inst** 1996 Jun 19;88(12):794-801. Comment in: J Natl Cancer Inst 1996 Jun 19;88(12):779-81.

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. Wang Q, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):956-65

Angiogenesis research enjoys growth spurt in the 1990s [news] Ziegler J. **J Natl Cancer Inst** 1996 Jun 19; 88(12):786-8

Relationship between expression of a major apurinic/apyrimidinic endonuclease (APEX nuclease) and susceptibility to genotoxic agents in human glioma cell lines. Ono Y, et al. **J Neurooncol** 1995;25(3):183-92

Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines. Strickland DK, et al. **J Neurooncol** 1995;25(1):9-17

Disruption of cerebellar maturation by an antimitotic agent impairs the ontogeny of eyeblink conditioning in rats. Freeman JH Jr, et al. **J Neurosci** 1995 Nov;15(11):7301-14

Glial growth factor 2, a soluble neuregulin, directly increases Schwann cell motility and indirectly promotes neurite outgrowth. Mahanthappa NK, et al. **J Neurosci** 1996 Aug 1;16(15):4673-83

Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. Ferguson PJ. **J Otolaryngol** 1995 Aug;24(4):242-52 (100 ref.)

Further studies on the ex-vivo effects of procarbazine and monomethylhydrazine on rat semicarbazide-sensitive amine oxidase and monoamine oxidase activities. Holt A, et al. **J Pharm Pharmacol** 1995 Oct;47(10):837-45

Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF-beta 1 in vivo. Lagadec P, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):926-33

Down-regulation of metallothionein expression in human and murine hepatocellular tumors: association with the tumor-necrotizing and antineoplastic effects of cadmium in mice. Waalkes MP, et al. **J Pharmacol Exp Ther** 1996 May;277(2):1026-33

Cis-diamminedichloroplatinum(II) augments expression of tumor-associated antigens on human gastric cancer cell line KATO-3 and increases susceptibility and binding of tumor cells to various cytotoxic effector cells. Hayashi H, et al. **J Surg Oncol** 1996 Jul;62(3):162-70

Antitumor activity of cis-diamminedichloroplatinum (II) depends on its time x concentration product against human gastric cancer cell lines in vitro. Kurihara N, et al. **J Surg Oncol** 1995 Dec;60(4):238-41

Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125FAK) in prostate carcinoma. Duncan MD, et al. **J Surg Res** 1996 Jun;63(1):359-63

The effect of lovastatin on [3H]thymidine uptake in HTC-4 and LLC-L1 tumor cells. Morris TJ, et al. **J Surg Res** 1996 Mar;61(2):367-72

Antimetastatic effect of a novel indolocarbazole (NB-506) on IMC-HM murine tumor cells metastasized to the liver.

Arakawa H, et al. **Jpn J Cancer Res** 1996 May;87(5):518–23
Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon carcinoma 26 Iigo M, et al. **Jpn J Cancer Res** 1995 Sep;86(9):867–72
Enhancement of the antitumor effect by combined use of high–energy shock waves and ATX–70. Maruyama M, et al. **Jpn J Cancer Res** 1995 Sep;86(9):800–1
A new water–soluble camptothecin derivative, DX–8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Mitsui I, et al. **Jpn J Cancer Res** 1995 Aug;86(8):776–82
Non–P–glycoprotein–mediated atypical multidrug resistance in a human bladder cancer cell line. Naito S, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1112–8
Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU–2285 in combination with single and fractionated irradiation. Shibata T, et al. **Jpn J Cancer Res** 1996 Jan;87(1):98–104
Anti–tumor activity of arginine deiminase from Mycoplasma argini and its growth–inhibitory mechanism. Takaku H, et al. **Jpn J Cancer Res** 1995 Sep;86(9):840–6
Evaluation of the relative cytotoxic effects of anticancer agents in serum–supplemented versus serum–free media using a tetrazolium colorimetric assay. Tsai CM, et al. **Jpn J Cancer Res** 1996 Jan;87(1):91–7
Inhibition of tumor cell haptotaxis by sodium D–glucaro–delta–lactam (ND2001). Tsuruoka T, et al. **Jpn J Cancer Res** 1995 Nov;86(11):1080–5
Modification of chemo–radiosensitivity of a human lung cancer cell line by introduction of the glutathione S–transferase pi gene. Miyara H, et al. **Jpn J Clin Oncol** 1996 Feb;26(1):1–5
Influence of nocodazole on the development of donor blastomeres from 16–cell stage bovine embryos in nuclear transfer. Tanaka H, et al. **Jpn J Vet Res** 1995 Jun;43(1):1–14
On the phosphorylation of 2–chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Arnér ES. **Leuk Lymphoma** 1996 Apr; 21(3–4):225–31 (64 ref.)
In vitro sensitivity of B–CLL cells to fludarabine and interferons. Di Raimondo F, et al. **Leuk Lymphoma** 1995 May;17(5–6):449–53
Antitumor effect in cyclosporine A– or FK506–treated mice after syngeneic bone marrow transplantation. Hashino S, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):331–7
Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Kaspers GJ, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):407–16
Selective inhibitors of 5–lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Anderson KM, et al. **Leuk Res** 1995 Nov; 19(11):789–801
Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology. Bosanquet AG, et al. **Leuk Res** 1996 Feb; 20(2):143–53
ASTA–Z 7557 impairs human natural killer (NK) cell activity. Condiotti R, et al. **Leuk Res** 1996 Feb;20(2):169–74
Potentiation of tumor necrosis factor–mediated cytotoxicity on human myeloid cell lines: effects of interferons versus dimethylsulphoxide. Depraetere S, et al. **Leuk Res** 1995 Nov;19(11):803–9
Inhibition of human leukaemia 60 cell growth by S–D–lactoylglutathione in vitro. Mediation by metabolism to N–D–lactoylcysteine and induction of apoptosis. Edwards LG, et al. **Leuk Res** 1996 Jan;20(1):17–26
Comparison of the effects of 2–chlorodeoxyadenosine and melphalan myeloma cell lines. Hjertner O, et al. **Leuk Res** 1996 Feb;20(2):155–60
A cardiotonic steroid bufalin–like factor in human plasma induces leukemia cell differentiation. Numazawa S, et al. **Leuk Res** 1995 Dec;19(12):945–53
Erythroid differentiation and growth inhibition of K562 cells by 2',5'–dideoxyadenosine: synergism with interferon–alpha. Ogawa K, et al. **Leuk Res** 1995 Oct; 19(10):749–55
Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara–C uptake enhancement. Santini V, et al. **Leuk Res** 1996 Jan;20(1):37–45
Effects of bryostatin–5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency. van der Hem KG, et al. **Leuk Res** 1995 Sep;19(9):651–7
Comparison of antitumor activities of 2–chlorodeoxyadenosine and 9–beta–arabinosyl–2–fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Begleiter A, et al. **Leukemia** 1995 Nov;9(11):1875–81
Induction of the PML protein by interferons in normal and APL cells. Chelbi–Alix MK, et al. **Leukemia** 1995 Dec; 9(12):2027–33
Direct evidence for the participation of bcl–2 in the regulation by retinoic acid of the Ara–C sensitivity of leukemic stem cells. Hu ZB, et al. **Leukemia** 1995 Oct; 9(10):1667–73
In vitro chemosensitivity assessed with the MTT assay in childhood acute non–lymphoblastic leukemia. Klumper E, et al. **Leukemia** 1995 Nov;9(11):1864–9
Induction of apoptosis by cordycepin in ADA–inhibited TdT–positive leukemia cells. Koç Y, et al. **Leukemia** 1996 Jun;10(6):1019–24
Effect of AS101 on bryostatin 1–mediated differentiation induction, cell cycle arrest, and modulation of drug–induced apoptosis in human myeloid leukemia cells. Rao AS, et al. **Leukemia** 1996 Jul;10(7):1150–8
Enhancement effect of O6–fluorobenzylguanines on chloroethylnitrosourea cytotoxicity in tumor cells. Mineura K, et al. **Life Sci** 1996;58(19):PL303–8
Modulation of 5–fluorouracil by interferon: a review of potential cellular targets. Horowitz R, et al. **Med Oncol** 1995 Mar;12(1):3–8 (48 ref.)
Interaction of alpha–interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance. Sewell GJ. **Med Oncol** 1995 Mar;12(1):9–14 (43 ref.)
Antimitotic natural products and their interactions with tubulin. Hamel E. **Med Res Rev** 1996 Mar;16(2):207–31 (143 ref.)
In vitro digital cell image analysis of morphonuclear modifications induced by natural DNA–interacting anticancer drugs in three neoplastic cell lines. Pauwels O, et al. **Methods Find Exp Clin Pharmacol** 1995 Apr; 17(3):151–62
Mutational specificity of 1–(2–chloroethyl)–3–cyclohexyl–1–nitrosourea in the Escherichia coli lacI gene of O6–alkylguanine–DNA alkyltransferase–proficient and –deficient strains. Jurado J, et al. **Mol Carcinog** 1995 Dec;14(4):233–9
Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer. Kondapaka BS, et al. **Mol Cell Endocrinol** 1996 Mar 1;117(1):53–8
Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM–23014 analog. Tatoud R, et al. **Mol Cell Endocrinol** 1995 Sep 22;113(2):195–204
Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT–diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Beall HD, et al. **Mol Pharmacol** 1995 Sep;48(3):499–504
Characterization of the interaction of the marine cyanobacterial natural product curacin A with the colchicine site of tubulin and initial structure–activity studies with analogues. Blokhin AV, et al. **Mol Pharmacol** 1995 Sep;48(3):523–31
Structural requirements for activity of propafenone–type modulators in P–glycoprotein–mediated multidrug resistance. Chiba P, et al. **Mol Pharmacol** 1996 Jun; 49(6):1122–30
Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517. Gupta M, et al. **Mol Pharmacol** 1995 Oct;48(4):658–65
In vitro transcription of DNA containing 2–chloro–2'–deoxyadenosine monophosphate. Hentosh P, et al. **Mol Pharmacol** 1995 Nov;48(5):897–904
The 1'–substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity. Rene B, et al. **Mol Pharmacol** 1996 Feb;49(2):343–50
Separation of resistance to antitumor diarylsulfonylurea agents from collateral sensitivity to mitochondrial toxins. Shu LL, et al. **Mol Pharmacol** 1996 Apr;49(4):595–601
Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Skladanowski A, et al. **Mol Pharmacol** 1996 May; 49(5):772–80
The in vitro more efficiently repaired cisplatin adduct cis–Pt.GG is in vivo a more mutagenic lesion than the relative slowly repaired cis–Pt.GCG adduct. Brandsma JA, et al. **Mutat Res** 1996 Jan 2;362(1):29–40
The HMG–domain protein Ixr1 blocks excision repair of cisplatin–DNA adducts in yeast. McA'Nulty MM, et al. **Mutat Res** 1996 Jan 2;362(1):75–86
Interferon–alpha or beta potentiate platinum analogous in human glioblastoma cell lines. Stanzione S, et al. **Mutat Res** 1995 Nov;348(3):131–5
DNA damage, p53 and anticancer therapies. Milner J. **Nat Med** 1995 Sep;1(9):879–80 (8 ref.)
Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C–raf kinase [see comments] Monia BP, et al. **Nat Med** 1996 Jun;2(6):668–75 . Comment in: Nat Med 1996 Jun;2(6):634–5.
Inhibition of acute lymphoblastic leukaemia by a Jak–2 inhibitor. Meydan N, et al. **Nature** 1996 Feb 15; 379(6566):645–8
Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 [see comments] Waldman T, et al. **Nature** 1996 Jun 20;381(6584):713–6. Comment in: Nature 1996 Jun 20;381(6584):643–4.
Death of cultured human neuroblastoma cells induced by HIV–1 gp120 is prevented by NMDA receptor antagonists and inhibitors of nitric oxide and cyclooxygenase. Corasaniti MT, et al. **Neurodegeneration** 1995 Sep; 4(3):315–21
Effects of trapidil and suramin on growth factor–induced calcium response and tyrosine phosphorylation in human glioma cells. Bando K, et al. **Neurol Med Chir (Tokyo)** 1995 Sep;35(9):631–8
Brain effect of intracarotid administration of cisplatinum. Schiffer J, et al. **Neurol Res** 1996 Feb;18(1):87–8
Differential regulation of C3 gene expression in human astroglioma cells by interferon–gamma and interleukin–1 beta. Barnum SR, et al. **Neurosci Lett** 1995 Sep 8; 197(2):121–4
Inhibitors of protein tyrosine phosphorylation reduce the proliferation of two human glioma cell lines. Oude Weernink PA, et al. **Neurosurgery** 1996 Jan;38(1):108–13; discussion 113–4
Cytotoxicity of cis–parinaric acid in cultured malignant gliomas. Traynelis VC, et al. **Neurosurgery** 1995 Sep; 37(3):484–9
Strand–specific measurement of cisplatin–induced DNA damage and repair using quantitative PCR. Bingham JP, et al. **Nucleic Acids Res** 1996 Mar 1;24(5):987–9
Strategic down–regulation of DNA polymerase beta by antisense RNA sensitizes mammalian cells to specific DNA damaging agents. Horton JK, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):3810–5
Inhibition of oncogene expression by green tea and (–)–epigallocatechin gallate in mice. Hu G, et al. **Nutr Cancer** 1995;24(2):203–9
RRR–alpha–tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Israel K, et al. **Nutr Cancer** 1995;24(2):161–9
RRR–alpha–tocopheryl succinate inhibits DNA synthesis and enhances the production and secretion of biologically active transforming growth factor–beta by avian retrovirus–transformed lymphoid cells. Simmons–Menchaca M, et al. **Nutr Cancer** 1995; 24(2):171–85
Inhibition of growth of estrogen receptor positive and estrogen receptor negative breast cancer cells in culture by AA–etherA, a stable 2–5A derivative. Latham KE, et al. **Oncogene** 1996 Feb 15;12(4):827–37
The anti–proliferative effect of vitamin D3 analogues is not mediated by inhibition of the AP–1 pathway, but may be related to promoter selectivity. Nayeri S, et al. **Oncogene** 1995 Nov 2;11(9):1853–8
Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD. Sonoda H, et al. **Oncogene** 1996 Jul 4;13(1):143–9
Differential regulation of cell cycle machinery by various antiproliferative agents is linked to macrophage arrest at distinct G1 checkpoints. Vadiveloo PK, et al. **Oncogene** 1996 Aug 1;13(3):599–608
Induction of p53 and increased sensitivity to cisplatin in ataxia–telangiectasia cells. Zhang N, et al. **Oncogene** 1996 Aug 1;13(3):655–9
Difloxacin reverses multidrug resistance in HL–60/AR cells that overexpress the multidrug resistance–related protein (MRP) gene. Gollapudi S, et al. **Oncol Res** 1995;7(5):213–25
Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal. Kessel D, et al. **Oncol Res** 1995; 7(5):207–12
Antitumor effect of keto–diepoxides isolated from the fungus Nattrassia mangiferae. King I, et al. **Oncol Res** 1995; 7(1):1–5
Suramin blocks binding of interleukin–4 to its receptors on human tumor cells and interleukin–4–induced mitogenic response. Leland P, et al. **Oncol Res** 1995;7(5):227–35
Cisplatin–induced alterations in the expression of the mRNAs for UV–damage recognition protein. Vaisman A, et al. **Oncol Res** 1996;8(1):7–12
P–glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Yang X, et al. **Oncol Res** 1995;7(12):619–24
In vitro–in vivo correlation in anticancer drug sensitivity test using AUC–based concentrations and collagen gel droplet–embedded culture. Inaba M, et al. **Oncology** 1996 May–Jun;53(3):250–7
Effect of cisplatin exposure on the degree of N–myc amplification in small cell lung carcinoma cell lines with N–myc amplification. Mizushima Y, et al. **Oncology** 1996 Sep–Oct;53(5):417–21
Transfection of human cytochrome P–450 reductase cDNA and its effect on the sensitivity to toxins. Sawamura AO, et al. **Oncology** 1996 Sep–Oct;53(5):406–11
Inhibitory effect of alkane–6,8–diols, the components of safflower, on tumor promotion by 12–O–tetradecanoylphorbol–13–acetate in two–stage carcinogenesis in mouse skin. Yasukawa K, et al. **Oncology** 1996 Mar–Apr;53(2):133–6
Effects of a new synthetic lipid A on endogenous tumor necrosis factor production and antitumor activity against human pancreatic cancer cells. Satake K, et al. **Pancreas** 1996 Apr;12(3):260–6
Selective inhibition of adhesion molecule expression by edelfosine (ET–18–OCH3) on human umbilical vein or microvascular endothelium. Bosse DC, et al. **Pathobiology** 1995;63(2):109–14
Effect of different exposures to desferrioxamine on neuroblastoma cell lines. Valle P, et al. **Pediatr Hematol Oncol** 1995 Sep–Oct;12(5):439–46
Circadian rhythms and cancer chemotherapy. Focan C. **Pharmacol Ther** 1995;67(1):1–52 (289 ref.)
The effects of age and chemotherapy on gentamicin pharmacokinetics and dosing in pediatric oncology patients. Ho KK, et al. **Pharmacotherapy** 1995 Nov–Dec; 15(6):754–64
Synthesis and biological activity of 1,2,4–triazinotriazinone derivatives. Abdel–Halim AM, et al. **Pharmazie** 1995 Nov; 50(11):726–9

Cytotoxic activity of some (E)-7-arylidene-2 H,6 H-naphtho-[1,8-bc]furan-2,6-diones and correlation with their electronic parameters. Do Nascimento SC, et al. **Pharmazie** 1995 Aug;50(8):563-5

Investigation of cytotoxic effects of 8 norbornane derivatives on 4 human cancer cell lines using the MTT assay. Jäger W, et al. **Pharmazie** 1995 Sep;50(9):619-21

Photodynamic activities and skin photosensitivity of the bis(dimethylthexylsiloxy)silicon 2,3-naphthalocyanine in mice. Brasseur N, et al. **Photochem Photobiol** 1995 Dec; 62(6):1058-65

Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas. Cincotta L, et al. **Photochem Photobiol** 1996 Feb;63(2):229-37

Antiplasmodial activities and cytotoxic effects of aqueous extracts and sesquiterpene lactones from Neurolaena lobata. François G, et al. **Planta Med** 1996 Apr;62(2):126-9

A general genetic approach in Escherichia coli for determining the mechanism(s) of action of tumoricidal agents: application to DMP 840, a tumoricidal agent. Chatterjee PK, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8950-4

Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Dou QP, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9019-23

Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Kranz DM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9057-61

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Richon VM, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5705-8

Cytotoxic action of cis-unsaturated fatty acids on human cervical carcinoma (HeLa) cells in vitro. Sagar PS, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):287-99

Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model. Neubauer BL, et al. **Prostate** 1995 Oct;27(4):220-9

Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid. Smets G, et al. **Prostate** 1995 Sep;27(3):129-40

Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation. Grégoire V, et al. **Radiother Oncol** 1995 Jul;36(1):50-5

Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40. Siegall CB. **Recent Results Cancer Res** 1996;140:51-60 (21 ref.)

Antitumor effects of a refined polysaccharide peptide fraction isolated from Coriolus versicolor: in vitro and in vivo studies. Dong Y, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):140-8

Effect of NDGA on beef heart mitochondria and EMT6 mouse mammary carcinoma cells. Shi L, et al. **Res Commun Mol Pathol Pharmacol** 1995 Nov;90(2):235-54

Antitumor activity of zinostatin stimalamer (YM881) in human hepatoma cell lines and VX2 liver tumor-bearing rabbits. Tanaka S, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):155-63

Antitumor mechanisms of zinostatin stimalamer (YM881). Tanaka S, et al. **Res Commun Mol Pathol Pharmacol** 1996 May;92(2):165-76

Bryostatins trigger human polymorphonuclear neutrophil and monocyte oxidative metabolism: association with in vitro antineoplastic activity. Esa AH, et al. **Res Immunol** 1995 Jul-Aug;146(6):351-61

Changes of some biochemical and hematological parameters following administration of daunorubicin in rabbits. Geršl V, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(2):79-84

Scanning electron microscopy and transmission electron microscopy aspects of synergistic antitumor activity of vitamin C - vitamin K3 combinations against human prostatic carcinoma cells. Gilloteaux J, et al. **Scanning Microsc** 1995 Mar;9(1):159-73

Solution structure of a cisplatin-induced DNA interstrand cross-link. Huang H, et al. **Science** 1995 Dec 15; 270(5243):1842-5

Medicinal chemistry of difluoropurines. Andis SL, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):54-60

Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Gandhi V, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):61-7

Interaction between cisplatin and gemcitabine in vitro and in vivo. Peters GJ, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):72-9

Retinoids induced t-PA synthesis by C6 glioma cells--role in tumoral haemorrhagic necrosis. Pernod G, et al. **Thromb Haemost** 1996 Feb;75(2):332-8

Immunohistological reaction mechanism of anti-monosialoganglioside monoclonal antibody, MAb 202, showing predominant cytotoxicity for malignant melanoma. Ota T, et al. **Tohoku J Exp Med** 1995 Sep; 177(1):1-12

A new in vitro model of specific targeting therapy of cancer: retargeting of PWM-LAK cells with bispecific antibodies greatly enhances cytotoxicity to hepatocellular carcinoma. Saijyo S, et al. **Tohoku J Exp Med** 1996 Feb;178(2):113-27

Modulators of signal transduction as cancer chemotherapeutic agents--novel mechanisms and toxicities. Gescher A. **Toxicol Lett** 1995 Dec;82-83:159-65 (19 ref.)

Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections. Webb IJ, et al. **Transfusion** 1996 Feb;36(2):160-7

Cardiac and pulmonary effects of alpha tumor necrosis factor administered by isolation perfusion. Villani F, et al. **Tumori** 1995 May-Jun;81(3):197-200

Vinblastine and 5-fluorouracil sensitivity of xenografts of four pancreatic ductal adenocarcinomas: is there a correlation with histological and cytological tumour differentiation? Vergeylen A, et al. **Virchows Arch** 1995; 427(3):317-22

Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein--an overview. Ecker G, et al. **Wien Klin Wochenschr** 1995;107(22):681-6 (51 ref.)

Effects of a novel DNA-damaging agent on the budding yeast Saccharomyces cerevisiae cell cycle. Popolo L, et al. **Yeast** 1996 Mar 30;12(4):349-59

[The differentiation-inducing effect of tanshinone and retinoic acid on human cervical carcinoma cell line in vitro] Yuan S, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov; 17(6):422-4 (Eng. Abstr.) (Chi)

[Enhancement of antitumor effect of cisplatin on human ovarian cancer by cyclosporin A in vitro and in vivo] Zhou Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan; 31(1):25-8 (Eng. Abstr.) (Chi)

[Assignment of differentiation-relevant cDNA RA538 on human chromosomes by fluorescence in situ hybridization] Zheng W, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Apr; 76(4):305-7 (Eng. Abstr.) (Chi)

[Effect of RII on the biological properties of human nasopharyngeal carcinoma cell lines] Han L, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):353-8 (Eng. Abstr.) (Chi)

[Synthesis of substituted benzeneseleninic acid and its antineoplastic activity] Zheng S, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):371-4 (Eng. Abstr.) (Chi)

[An EGFR antisense oligodeoxynucleotides and its phosphorothioate analogue inhibit the growth of human hepatocarcinoma BEL-7404 cells] Lin JQ, et al. **Shih Yen Sheng Wu Hsueh Pao** 1995 Sep;28(3):241-6 (Eng. Abstr.) (Chi)

[Effect of dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2, 2'-dicarboxylate (DDB) on several phenotypes of Bel-7402 hepatocarcinoma cell line and its mechanism] Liu ZY, et al. **Yao Hsueh Hsueh Pao** 1996;31(2):101-6 (Eng. Abstr.) (Chi)

[Effect of S9788, cyclosporin A and verapamil on intracellular accumulation of doxorubicin, daunorubicin and daunorubicinol in primary rat hepatocyte culture] Le Bot MA, et al. **Ann Biol Clin (Paris)** 1996;54(1):21-4 (Eng. Abstr.) (Fre)

[Contribution of computers to pharmacokinetics, Bayesian approach and population pharmacokinetics] Hecquet B. **Bull Cancer (Paris)** 1995 Dec;82 Suppl 5:607s-611s (Eng. Abstr.) (Fre)

[Modulation of integrin alpha-v-beta-1 expression on human tumor cells by leukemia inhibitory factor (LIF) and oncostatin M (OSM)] Heymann D, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):13-21 (41 ref.) (Eng. Abstr.) (Fre)

[Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil] Massart C, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):39-45 (32 ref.) (Eng. Abstr.) (Fre)

[Inflammation cytokines and peroxidation of low density lipoproteins (LDL)] Mazière JC, et al. **C R Seances Soc Biol Fil** 1995;189(5):811-25 (Eng. Abstr.) (Fre)

[Do cell cycle changes of human ovarian carcinoma cells after exposure to cytostatic drugs in vitro correlate with cytotoxicity?] Petru E, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:15-8 (Eng. Abstr.) (Ger)

[Comparison of the cytostatic effect of epirubicin and mitoxantrone on native breast carcinoma cells using the ATP tumor chemosensitivity assay] Kurbacher CM, et al. **Zentralbl Gynakol** 1996;118(5):271-8 (Eng. Abstr.) (Ger)

[Update on the use of interferons in clinical practice] Lauta VM. **Clin Ter** 1995 Jun-Jul;146(6-7):393-448 (160 ref.) (Eng. Abstr.) (Ita)

[Pidotimod causes apoptotic cell death and inhibits the proliferative activity of YAC-1 tumor cells in vitro] Migliorati G, et al. **Drugs Exp Clin Res** 1993;19 Suppl:1-7 (Ita)

[Design of a new antitumor nucleoside CNDAC, against solid tumors] Matsuda A. **Gan To Kagaku Ryoho** 1996 Jan; 23(2):202-10 (Eng. Abstr.) (Jpn)

[Current problems in development of new anticancer agents for new molecular targets] Nishii K. **Gan To Kagaku Ryoho** 1996 Jan;23(2):211-8 (12 ref.) (Eng. Abstr.) (Jpn)

[Cell cycle regulation by anticancer agent] Nomoto T, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1719-23 (20 ref.) (Eng. Abstr.) (Jpn)

[In vitro chemosensitivity test for seven undifferentiated thyroid carcinoma cell lines using MTT assay] Osawa Y, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):471-6 (Eng. Abstr.) (Jpn)

[Chemosensitivity test for thyroid cancer by in vitro MTT assay] Sasaki F, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1777-81 (Eng. Abstr.) (Jpn)

[The results of chemosensitivity test for clear cell adenocarcinoma of the ovary] Shimizu Y, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):945-7 (Jpn)

[In vitro direct antiproliferative activity and in vivo antitumor activity of bropirimine against bladder cancer] Tahara M, et al. **Gan To Kagaku Ryoho** 1996 Jul; 23(8):1039-44 (Eng. Abstr.) (Jpn)

[Flow cytometric analysis of cell cycle for the action mechanism of antineoplastic agents] Kawamoto K. **Hum Cell** 1995 Sep;8(3):85-8 (Eng. Abstr.) (Jpn)

[Cancer chemosensitivity test--from laboratory to clinic] Kubota T. **Hum Cell** 1995 Dec;8(4):189-94 (11 ref.) (Eng. Abstr.) (Jpn)

[Establishment of a cisplatin-resistant new human endometrial adenocarcinoma cell line, Sawano cells] Satoh T, et al. **Hum Cell** 1995 Jun;8(2):67-72 (Eng. Abstr.) (Jpn)

[Potential and limitation of scintillation assay (TIA) for clinical chemotherapy] Tanigawa N, et al. **Hum Cell** 1995 Dec;8(4):173-8 (Eng. Abstr.) (Jpn)

[Chemosensitivity of cultured meningiomas] Tsuchida T, et al. **Hum Cell** 1995 Dec;8(4):155-6 (Eng. Abstr.) (Jpn)

[Studies on the in vivo and in vitro chemosensitivity tests using human tumor xenografts] Yamada Y, et al. **Hum Cell** 1995 Dec;8(4):179-84 (Eng. Abstr.) (Jpn)

[Effects of chemotherapy on the basis of the results of MTT assay for patients with gastrointestinal cancer] Yamaue H, et al. **Hum Cell** 1995 Dec;8(4):185-8 (Eng. Abstr.) (Jpn)

[Efficacy of the chemosensitivity test using collagen gel matrix-supported culture system for urogenital tumors] Ogihara M, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):740-7 (Eng. Abstr.) (Jpn)

[Effect of anticancer drugs on invasive capacity of human small-cell lung cancer cells in vitro] Morikawa T, et al. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):320-8 (Eng. Abstr.) (Jpn)

[On the novel differentiation-apoptosis inducers in tumor cells] Nakaya K. **Tanpakushitsu Kakusan Koso** 1996 Feb; 41(2):119-26 (38 ref.) (Jpn)

[Strategies for studies on mechanism of action of antineoplastic agents] Kuśnierczyk H. **Postepy Hig Med Dosw** 1995;49(1):85-96 (20 ref.) (Eng. Abstr.) (Pol)

[Modulation of the antitumor activity of 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosoure a by O(6)-methyl-2'-deoxyguanosine--a new inhibitor of O(6)-alkylguanine-DNA-alkyltransferase] Dederer LIu, et al. **Biokhimiia** 1995 Sep;60(9):1521-9 (Eng. Abstr.) (Rus)

[Synthesis of retinoids with a modified polar group and their antitumor activity. Report I] Deribina EL, et al. **Bioorg Khim** 1995 Dec;21(12):941-9 (Eng. Abstr.) (Rus)

[Cytotoxicity of carotene compounds on human cultured epidermal carcinoma cells] Orlova VF, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):515-8 (Rus)

[A myelopeptide (bivalfor), possessing antitumor activity] Strelkov LA, et al. **Biull Eksp Biol Med** 1995 May; 119(5):530-2 (Rus)

[The pharmacological properties of preparations from the aziridinyl triazine group] Stukov AN, et al. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):58-60 (Eng. Abstr.) (Rus)

[Regulating effect of the hematopoiesis-inducing microenvironment on hematopoietic processes as affected by cytostatic drugs] Dygal AM, et al. **Gematol Transfuziol** 1995 Sep-Oct;40(5):11-5 (Eng. Abstr.) (Rus)

[A comparative study of the action of 1-methyl-1-nitrosourea and 1,3-dimethyl-1-nitrosourea on tumor cell DNA in vitro and in vivo by the alkaline elution method] Bliukhterova NV, et al. **Izv Akad Nauk Ser Biol** 1996 May-Jun;(3):276-81 (Eng. Abstr.) (Rus)

[The action of tiazofurin on the development of sea urchin embryos and larvae] Buznikov GA, et al. **Ontogenez** 1996 Jan-Feb;27(1):62-9 (Rus)

[The search for active antitumor agents among triphenylethylene derivatives] Sergeev PV, et al. **Vopr Onkol** 1995;41(2):49 (Rus)

POISONING

Cisplatin-induced autonomic neuropathy: does it really exist? Vandertop WP, et al. **J Neurooncol** 1996 Jan;27(1):53-60

A case of massive cisplatin overdose managed by plasmapheresis. Jung HK, et al. **Korean J Intern Med** 1995 Jul;10(2):150-4

THERAPEUTIC USE

2-Chloro-2'-deoxyadenosine [editorial] Delannoy A, et al. **Acta Clin Belg** 1995;50(4):193-6 (10 ref.)

Role of deferoxamine in tumor therapy. Donfrancesco A, et al. **Acta Haematol** 1996;95(1):66-9 (16 ref.)

Present research trends in cancer chemotherapy. Eckhardt S. **Acta Med Hung** 1994;50(3–4):133–40 (14 ref.)

Adjuvant chemotherapy in stage IB neuroendocrine small cell carcinoma of the cervix. Abulafia O, et al. **Acta Obstet Gynecol Scand** 1995 Oct;74(9):740–4

Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro. Behnam Motlagh P, et al. **Acta Oncol** 1995;34(6):871–5

High-dose therapy with autologous bone marrow stem cell support in primary and metastatic human breast cancer. A review. Bergh J. **Acta Oncol** 1995;34(5):669–74 (48 ref.)

Chronobiology. Implications for cancer chemotherapy. Bjarnason GA. **Acta Oncol** 1995;34(5):615–24 (120 ref.)

Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements. Glimelius B, et al. **Acta Oncol** 1996;35(2):141–8

Effects of interferons and tumour necrosis factor-alpha on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line. Suarez Pestana E, et al. **Acta Oncol** 1996;35(4):473–8

Chemotherapy for advanced bladder carcinoma: new molecules and regimens. Abi-Aad AS. **Acta Urol Belg** 1996 May;64(2):43–5 (19 ref.)

New molecules and treatment modulation in advanced prostatic cancer. Mahler C, et al. **Acta Urol Belg** 1996 May; 64(2):95–8

A phase II trail of aminothiadiazole in patients with mixed mesodermal tumors of the uterine corpus: a Gynecologic Oncology Group study. Asbury R, et al. **Am J Clin Oncol** 1996 Aug;19(4):400–2

Aminothiadiazole in the treatment of advanced leiomyosarcoma of the uterine corpus. A Gynecologic Oncology Group study. Asbury R, et al. **Am J Clin Oncol** 1995 Oct;18(5):397–9

The group sequential triangular test for phase II cancer clinical trials. Bellissant E, et al. **Am J Clin Oncol** 1996 Aug;19(4):422–30

Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma. Falkson CI. **Am J Clin Oncol** 1996 Jun;19(3):268–70

Prognostic implications of chemoresistance-sensitivity assays for colorectal and appendiceal cancer. Fernandez-Trigo V, et al. **Am J Clin Oncol** 1995 Oct;18(5):454–60

A phase II trial of merbarone (NSC 336628) as salvage therapy for squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Look KY, et al. **Am J Clin Oncol** 1995 Oct;18(5):441–3

A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Look KY, et al. **Am J Clin Oncol** 1996 Feb;19(1):7–9

A phase II trial of gallium nitrate (NSC #15200) in nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Malfetano JH, et al. **Am J Clin Oncol** 1995 Dec;18(6):495–7

A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Malfetano JH, et al. **Am J Clin Oncol** 1996 Apr;19(2):184–6

A phase II study of fazarabine (NSC 281272) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Manetta A, et al. **Am J Clin Oncol** 1995 Oct;18(5):439–40

Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. Mani S, et al. **Am J Clin Oncol** 1996 Apr;19(2):187–9 (19 ref.)

Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. Mani S, et al. **Am J Clin Oncol** 1996 Apr;19(2):149–53 (26 ref.)

Phase II trial of CHIP for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group Study. Marshall ME, et al. **Am J Clin Oncol** 1995 Oct;18(5):400–2

Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. Moore DF Jr, et al. **Am J Clin Oncol** 1995 Dec;18(6):525–7

Survival of patients with neuroblastoma treated with 125-I MIBG. Sisson JC, et al. **Am J Clin Oncol** 1996 Apr; 19(2):144–8

5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Stuart K, et al. **Am J Clin Oncol** 1996 Apr; 19(2):136–9

Study affirms primacy of paclitaxel-cisplatin in advanced ovarian cancer [news] **Am J Health Syst Pharm** 1996 Mar 1;53(5):498

New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy [news] **Am J Health Syst Pharm** 1995 Oct 1;52(19):2076

Preventing medication errors in cancer chemotherapy [see comments] Cohen MR, et al. **Am J Health Syst Pharm** 1996 Apr 1;53(7):737–46. Comment in: Am J Health Syst Pharm 1996 Apr 1;53(7):733.

High-dose chemotherapy with stem-cell rescue for the treatment of breast cancer. McCauley DL. **Am J Health Syst Pharm** 1996 Mar 1;53(5):521–34; quiz 561–2 (87 ref.)

Prolonged survival and probable cure in chronic myelogenous leukemia [letter] Gabor EP. **Am J Hematol** 1995 Oct;50(2):149

Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Cortes J, et al. **Am J Med** 1996 Apr;100(4):452–5

Combination of BRMs with chemotherapy. Tursz T. **Am J Med** 1995 Dec 29;99(6A):56S–58S (7 ref.)

Interferon-alpha therapy for chronic myelogenous leukemia. Wetzler M, et al. **Am J Med** 1995 Oct;99(4):402–11 (67 ref.)

Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Roberts JP, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1917–23; discussion 1923–4

Ocular manifestation of hairy cell leukemia with dramatic response to 2-chloro-deoxy-adenosine. Robinson A, et al. **Am J Ophthalmol** 1996 Jan;121(1):97–9

Bleomycin sclerotherapy in patients with congenital lymphatic malformation in the head and neck. Sung MW, et al. **Am J Otolaryngol** 1995 Jul-Aug;16(4):236–41

Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer. Wanebo HJ, et al. **Am J Surg** 1995 Nov;170(5):512–6

Intratumoral administration of carboplatin for treatment of squamous cell carcinomas of the nasal plane in cats. Théon AP, et al. **Am J Vet Res** 1996 Feb;57(2):205–10

2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy. Brugiatelli M, et al. **Ann Hematol** 1996 Aug;73(2):79–84

Allogenic bone marrow transplantation or chemotherapy for patients with acute myeloid leukemia in first complete remission: a decision analysis approach. Hertenstein B, et al. **Ann Hematol** 1996 Apr;72(4):223–30 (47 ref.)

Therapy of childhood acute myelogenous leukemias. Vormoor J, et al. **Ann Hematol** 1996 Jul;73(1):11–24 (24 ref.)

Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Kattan MW, et al. **Ann Intern Med** 1996 Oct 1;125(7):541–8

Preparative regimens: chemotherapy versus chemoradiotherapy. A historical perspective. Santos GW. **Ann N Y Acad Sci** 1995 Dec 29;770:1–7 (38 ref.)

Italy: 'much ado...' [news] **Ann Oncol** 1995 Oct;6(8):743

Phase II study of subcutaneous rHu-interleukin-2 and rHu-interferon alpha-2a in previously treated patients with multiple myeloma. Belch AR, et al. **Ann Oncol** 1995 Sep; 6(7):721–3

Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica [see comments] Bolis G, et al. **Ann Oncol** 1995 Nov;6(9):887–93. Comment in: Ann Oncol 1995 Nov;6(9):865–6.

Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Bramwell VH, et al. **Ann Oncol** 1995 Oct;6(8):847–9

Matrix metalloproteinase inhibition: a review of anti-tumour activity. Brown PD, et al. **Ann Oncol** 1995 Dec; 6(10):967–74 (48 ref.)

Chemotherapy of stage IIIB and IV non-small-cell lung cancer. Cojean I, et al. **Ann Oncol** 1995;6 Suppl 3:S41–4

Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group. Creemers GJ, et al. **Ann Oncol** 1995 Oct;6(8):844–6

Dealing with initial chemotherapy doses: a new basis for treatment optimisation in limited small-cell lung cancer. Le Cesne A, et al. **Ann Oncol** 1995;6 Suppl 3:S53–6 (26 ref.)

Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Macdonald D, et al. **Ann Oncol** 1996 Feb;7(2):205–7

Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Smyth JF, et al. **Ann Oncol** 1995 Nov; 6(9):948–9

New drugs in the treatment of non-small cell lung cancer. Steward WP, et al. **Ann Oncol** 1995;6 Suppl 1:49–54 (38 ref.)

Induction or concomitant chemotherapy and radiotherapy for non-small-cell lung cancer: myth or reality. Van Houtte P. **Ann Oncol** 1995;6 Suppl 3:S37–40 (21 ref.)

TCNU in colorectal cancer. How many patients are needed to demonstrate that a drug doesn't work? [letter] Wils J. **Ann Oncol** 1996 Feb;7(2):211

Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Gattis WA, et al. **Ann Pharmacother** 1996 May;30(5):520–6 (20 ref.)

Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Agarwala SS, et al. **Ann Surg Oncol** 1995 Jul; 2(4):365–71 (44 ref.)

Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate. Seidmon EJ, et al. **Ann Surg Oncol** 1995 Nov;2(6):550–6

P-glycoproteins and multidrug resistance. Bellamy WT. **Annu Rev Pharmacol Toxicol** 1996;36:161–83 (127 ref.)

Current chemotherapy of advanced non-small cell lung cancer. Abratt RP. **Anticancer Drugs** 1995 Dec;6 Suppl 6:15–8 (29 ref.)

Phase I and pharmacokinetic study of etoposide phosphate. Brooks DJ, et al. **Anticancer Drugs** 1995 Oct;6(5):637–44

Experience with dose and schedule variations in germ cell tumors. De Mulder PH, et al. **Anticancer Drugs** 1995 Oct; 6 Suppl 5:43–52 (57 ref.)

Treatment of metastatic malignant melanoma. Falkson CI. **Anticancer Drugs** 1995 Dec;6(6):709–16 (120 ref.)

The importance of dose and schedule in cancer chemotherapy: breast cancer. Leonard RC. **Anticancer Drugs** 1995 Oct;6 Suppl 5:17–27 (75 ref.)

The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer. Mainwaring PN, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:29–41 (116 ref.)

Evaluation of certain ureas and nitrosoureas of 2,3-dihydro-1,4-benzothiazines against Sarcoma-180 solid tumors in vivo. Nyati MK, et al. **Anticancer Drugs** 1995 Oct;6(5):693–6

The importance of dose and schedule in chemotherapy for small cell lung cancer. Ranson M, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:53–63 (112 ref.)

The importance of dose and schedule in cancer chemotherapy: haematological cancer. Sweetenham JW. **Anticancer Drugs** 1995 Oct;6 Suppl 5:7–15 (50 ref.)

Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Thatcher N, et al. **Anticancer Drugs** 1995 Dec; 6 Suppl 6:39–48 (68 ref.)

Evidence for different mechanisms of EMT-6 tumor necrosis by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin: tumor cell survival and blood flow. Chan WS, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1887–92

Evaluation of two dose individualisation methods for carboplatin. Desoize B, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):2073–8

Antineoplastic activities of alpha-, beta-, and gamma-alkylaminopropiophenone derivatives in mice and in murine and human tissue culture cells. Huang Y, et al. **Anticancer Res** 1996 Mar-Apr;16(2):597–604

Induction of MxA mRNA in patients with neuroendocrine tumors after interferon treatment. Lack of correlation with antitumor response. Imam H, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2191–5

Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Miglietta L, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2825–8

Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Raynaud FI, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1857–62

Mitoxantrone in elderly women with advanced breast cancer: a phase II study. Repetto L, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2297–300

Lysozyme stimulates lymphocyte response to ConA and IL-2 and potentiates 5-fluorouracil action on advanced carcinomas. Sava G, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):1883–8

Therapeutic potency of transduction with herpes simplex virus thymidine kinase gene against multidrug resistant mouse leukemia cells. Takenaga K, et al. **Anticancer Res** 1996 Mar-Apr;16(2):681–5

Antitumour activity of photosensitized hypericin on A431 cell xenografts. Vandenbogaerde AL, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1619–25

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1867–80 (184 ref.)

Carboplatin-based chemotherapy in patients undergoing hemodialysis. Yanagawa H, et al. **Anticancer Res** 1996 Jan-Feb;16(1):533–5

Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer. Yokoe T, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):2069–72

Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Biron F, et al. **Antiviral Res** 1996 Jan;29(1):111–3

Antileukemic and Immunosuppressive Properties of 2-Chloro-2'-Deoxyadenosine (2-CdA). Symposium proceedings. Warsaw, Poland, November 23, 1992. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):1–82

Antitumor activity of bestatin and thiorphan in mice. Kowalski J, et al. **Arch Immunol Ther Exp (Warsz)** 1995; 43(5–6):265–71

2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia. Krykowski E, et al. **Arch Immunol Ther Exp (Warsz)** 1995; 43(5–6):317–21

Growth inhibition of transplantable tumors in mice by mIL-2-secreting murine plasmocytoma cells used alone or in combination with a cytostatic agent. Pajtasz-Piasecka E, et al. **Arch Immunol Ther Exp (Warsz)** 1995; 43(5–6):281–92

Growth inhibition of squamous cell carcinoma xenografts with the polyamine analogue BE 4444. Auchter RM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Sep; 122(9):977–81

Is surgery necessary in stage III and stage IV cancer of the head and neck that responds to induction chemotherapy? Poulsen M, et al. **Arch Otolaryngol Head Neck Surg** 1996 May;122(5):467–71

Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing. Dupuis NP, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):423–9

The role of chemotherapy in the treatment of multiple myeloma. Bergsagel DE. **Baillieres Clin Haematol** 1995 Dec;8(4):783–94 (38 ref.)

Modulation of multidrug resistance in multiple myeloma. Sonneveld P. **Baillieres Clin Haematol** 1995 Dec; 8(4):831–44 (107 ref.)

Drug trials in neuropathy. Hughes RA, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):607–27 (87 ref.)

IL2-ricin fusion toxin is selectively cytotoxic in vitro to IL2 receptor-bearing tumor cells. Frankel A, et al. **Bioconjug Chem** 1995 Nov–Dec;6(6):666–72

Antimetastatic activities of synthetic Arg-Gly-Asp-Ser (RGDS) and Arg-Leu-Asp-Ser (RLDS) peptide analogues and their inhibitory mechanisms. Fujii H, et al. **Biol Pharm Bull** 1995 Dec;18(12):1681–8

Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice. LaCasse EC, et al. **Blood** 1996 Sep 1;88(5):1561–7

Infrequent alterations of the RAR alpha gene in acute myelogenous leukemias, retinoic acid-resistant acute promyelocytic leukemias, myelodysplastic syndromes, and cell lines. Morosetti R, et al. **Blood** 1996 May 15; 87(10):4399–403

Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine. Konwalinka G, et al. **Blood Cells Mol Dis** 1995;21(2):142–51

High-dose therapy for breast cancer. Vahdat L, et al. **Blood Rev** 1995 Sep;9(3):191–200 (118 ref.)

Specialist surgeons and survival in breast cancer. Large differences in survival are not explained [letter; comment] Baum M. **BMJ** 1996 May 4;312(7039):1155. Comment on: BMJ 1996 Jan 20;312(7024):145–8.

Chemotherapy for non-small cell lung cancer [editorial; comment] [see comments] Carbone DP, et al. **BMJ** 1995 Oct 7;311(7010):889–90. Comment on: BMJ 1995 Oct 7;311(7010):899–909. Comment in: BMJ 1996 Jan 27;312(7025):248–9. Comment in: BMJ 1996 Jan 27;312(7025):249.

ABC of urology. Recommended treatment of paediatric tumours is misleading [letter] Pinkerton CR, et al. **BMJ** 1996 Aug 24;313(7055):492; discussion 493

Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. Damon LE, et al. **Bone Marrow Transplant** 1996 Jan;17(1):93–9

High-dose chemotherapy with autologous marrow rescue for malignant brain tumors: analysis of the impact of prior chemotherapy and cranio-spinal irradiation on hematopoietic recovery. Faulkner LB, et al. **Bone Marrow Transplant** 1996 Mar;17(3):389–94

Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumours. Alder JD, et al. **Br J Cancer** 1996 Mar;73(5):560–4

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. Betticher DC, et al. **Br J Cancer** 1995 Dec;72(6):1551–5

Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Blomqvist C, et al. **Br J Cancer** 1996 May;73(9):1074–9

Mathematical modelling of tumour response in primary breast cancer. Cameron DA, et al. **Br J Cancer** 1996 Jun; 73(11):1409–16

Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Gazet JC, et al. **Br J Cancer** 1996 Mar;73(6):758–62

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. Gerrits CJ, et al. **Br J Cancer** 1996 Mar; 73(6):744–50

The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients. Ghazal-Aswad S, et al. **Br J Cancer** 1996 Aug;74(3):468–73

A prognostic index for multiple myeloma. Grignani G, et al. **Br J Cancer** 1996 May;73(9):1101–7

Inhibition of angiogenesis, tumour growth and experimental metastasis of human fibrosarcoma cells HT1080 by a multimeric form of the laminin sequence Tyr-Ile-Gly-Ser-Arg (YIGSR). Iwamoto Y, et al. **Br J Cancer** 1996 Mar;73(5):589–95

Evaluation of porphyrin C analogues for photodynamic therapy of cerebral glioma. Karagianis G, et al. **Br J Cancer** 1996 Feb;73(4):514–21

Tallimustine in advanced previously untreated colorectal cancer, a phase II study. Punt CJ, et al. **Br J Cancer** 1996 Mar;73(6):803–4

DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Smitskamp-Wilms E, et al. **Br J Cancer** 1995 Oct; 72(4):917–21

Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Walker TL, et al. **Br J Cancer** 1996 Mar;73(5):610–4

O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Wedge SR, et al. **Br J Cancer** 1996 May;73(9):1049–52

A patient with plaque-stage mycosis fungoides has successfully been treated with long-term administration of IFN-gamma and has been in complete remission for more than 6 years. Horikoshi T, et al. **Br J Dermatol** 1996 Jan; 134(1):130–3

2-Chloro-deoxyadenosine therapy for giant lymph node hyperplasia. Bordeleau L, et al. **Br J Haematol** 1995 Nov; 91(3):668–70

Transfusion-associated graft-versus-host disease (TA-GVHD) in fludarabine-treated patients: is it time to irradiate blood component? [letter; comment] Briones J, et al. **Br J Haematol** 1996 Jun 1;93(3):739–41. Comment on: Br J Haematol 1995 Oct;91(2):409–11.

Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia [see comments] Briz M, et al. **Br J Haematol** 1995 Oct;91(2):409–11. Comment in: Br J Haematol 1996 Jun 1;93(3):739–41.

Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. DeLima M, et al. **Br J Haematol** 1996 Apr;93(1):89–95

Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Ferrara F, et al. **Br J Haematol** 1996 Mar;92(3):627–31

In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Klumper E, et al. **Br J Haematol** 1996 Jun 2;93(4):903–10

2-Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. Mercieca J, et al. **Br J Haematol** 1996 May;93(2):409–11

Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy. Min YH, et al. **Br J Haematol** 1996 Jun 2;93(4):928–30

Relation of blast cell survival and proliferation to chemotherapy resistance in AML. Nørgaard JM, et al. **Br J Haematol** 1996 Jun 2;93(4):888–97

Adjuvant chemotherapy for colorectal cancer. Kerr DJ, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):259–62 (17 ref.)

Cis-platinum neoadjuvant chemotherapy in a pregnant woman with invasive carcinoma of the uterine cervix. Giacalone PL, et al. **Br J Obstet Gynaecol** 1996 Sep; 103(9):932–4

Successful pregnancy after treatment of stage III bilateral ovarian dysgerminoma. Hudson CN, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):1015–6

Efficacy of tumoricidal agents in vitro and in vivo [letter; comment] Hubens G, et al. **Br J Surg** 1996 Jan;83(1):132–3 . Comment on: Br J Surg 1995 Aug;82(8):1050–2.

Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Yamamoto M, et al. **Br J Surg** 1996 Mar;83(3):336–40

Melanoma: chemotherapy. Lee SM, et al. **Br Med Bull** 1995 Jul;51(3):609–30 (151 ref.)

Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology. Di Leo A, et al. **Breast Cancer Res Treat** 1995 Jun;34(3):237–44

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Murray R, et al. **Breast Cancer Res Treat** 1995 Sep;35(3):249–53

Systemic treatment of cancer [see comments] Krakoff IH. **CA Cancer J Clin** 1996 May–Jun;46(3):134–41. Comment in: CA Cancer J Clin 1996 May–Jun;46(3):131–6.

Phase II evaluation of topotecan for pediatric central nervous system tumors. Blaney SM, et al. **Cancer** 1996 Aug 1; 78(3):527–31

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Dawson NA, et al. **Cancer** 1995 Aug 1; 76(3):453–62

A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma. Di Leo A, et al. **Cancer** 1996 Jul 1;78(1):35–42

Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2. A case report. Fathallah-Shaykh HM, et al. **Cancer** 1996 Apr 15; 77(8):1544–50

Cisplatin-based chemotherapy of primary extragonadal germ cell tumors. A single institution experience. Gerl A, et al. **Cancer** 1996 Feb 1;77(3):526–32

Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Ishii H, et al. **Cancer** 1996 May 1;77(9):1792–6

Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Jain N, et al. **Cancer** 1996 May 1;77(9):1797–808

Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy [see comments] Ludwig H, et al. **Cancer** 1995 Dec 1;76(11):2319–29. Comment in: Cancer 1996 May 1;77(9):1960–1.

Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies. Monfardini S, et al. **Cancer** 1995 Jul 15;76(2):333–8

Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Oka H, et al. **Cancer** 1995 Sep 1;76(5):743–9

Complete remission seven years after treatment for metastatic malignant melanoma [see comments] Petit T, et al. **Cancer** 1996 Mar 1;77(5):900–2. Comment in: Cancer 1996 Aug 1;78(3):571.

Promising new therapies in the treatment of advanced ovarian cancer. Runowicz CD, et al. **Cancer** 1995 Nov 15; 76(10 Suppl):2028–33 (37 ref.)

Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial. See WA, et al. **Cancer** 1996 Mar 1;77(5):924–7

Radiotherapy as a cisplatin-sensitizer in a resistant ovarian carcinoma cell line. Siler DF, et al. **Cancer** 1996 May 1; 77(9):1850–3

Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group. Dillman RO, et al. **Cancer Biother** 1995 Winter;10(4):265–71

Chemotherapy of head and neck cancer. LaFollette S, et al. **Cancer Chemother Biol Response Modif** 1996;16:462–73 (50 ref.)

Brain tumors. Obbens EA, et al. **Cancer Chemother Biol Response Modif** 1996;16:625–43 (39 ref.)

New anticancer agents. Weiss GR, et al. **Cancer Chemother Biol Response Modif** 1996;16:132–67 (205 ref.)

The 11th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium. Cytokines and New Anticancer Agents on the Horizon of Oncology. Nagoya, Japan, 24–25 November 1995. **Cancer Chemother Pharmacol** 1996;38 Suppl:S1–119

Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. Aherne GW, et al. **Cancer Chemother Pharmacol** 1996;38(3):225–32

Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics. Conley BA, et al. **Cancer Chemother Pharmacol** 1995; 37(1–2):139–49

Promising new agents in the treatment of non-small cell lung cancer. Edelman, MJ, et al. **Cancer Chemother Pharmacol** 1996;37(5):385–93 (96 ref.)

Phase I–II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Hoffman K, et al. **Cancer Chemother Pharmacol** 1996;37(3):254–8

Characteristic antitumor activity of cytarabine ocfosfate against human colorectal adenocarcinoma xenografts in nude mice. Koga K, et al. **Cancer Chemother Pharmacol** 1995;36(6):459–62

A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer. Nardi M, et al. **Cancer Chemother Pharmacol** 1996;38(3):298–301

A phase I and pharmacokinetics study of prolonged ambulatory-infusion carboplatin. Olver IN, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):79–85

Angiogenesis as a new target for cancer treatment. Ono M, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S78–82 (38 ref.)

Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft. Pratesi G, et al. **Cancer Chemother Pharmacol** 1996;38(2):123–8

Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine. Robertson LE, et al. **Cancer Chemother Pharmacol** 1996;37(5):445–50

Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Teicher BA, et al. **Cancer Chemother Pharmacol** 1996; 38(2):169–77

A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N') platinum in patients with refractory advanced breast cancer. Theriault RL, et al. **Cancer Chemother Pharmacol** 1996;38(3):289–91

New promising anticancer agents in development: what comes next? Verweij J. **Cancer Chemother Pharmacol** 1996; 38 Suppl:S3–10 (69 ref.)

Differentiation and tumor response to retinobenzoic acid RE-80 in a malignant conversion model. Kulesz-Martin MF, et al. **Cancer Detect Prev** 1995;19(4):355–66

Effect of beta-carotene supplementation on serum alpha-tocopherol concentration. Fontham ET, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov; 4(7):801–3

Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents. Greenwald P, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov; 4(7):691–702 (175 ref.)

Chemotherapy Foundation Symposium XIII, Innovative Cancer Chemotherapy for Tomorrow. New York City, NY, USA. Abstracts. **Cancer Invest** 1996;14 Suppl 1:1–73

Should cost be considered in the overall evaluation of phase II clinical trials of new antineoplastic therapies? Markman M. **Cancer Invest** 1996;14(5):498–500

Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Triozzi PL, et al. **Cancer Invest** 1996;14(4):293–8

Anti-tumor promoting activity of Dryopteris phlorophenone

derivatives. Kapadia GJ, et al. **Cancer Lett** 1996 Aug 2; 105(2):161–5

Glucosylceramide synthetase inhibitor, D–threo–1–phenyl–2–decanoylamino–3–morpholino–1–propanol exhibits a novel decarcinogenic activity against Shope carcinoma cells. Kyogashima M, et al. **Cancer Lett** 1996 Mar 19;101(1):25–30

Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Liao S, et al. **Cancer Lett** 1995 Sep 25;96(2):239–43

Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Stark MJ, et al. **Cancer Lett** 1995 Sep 4; 96(1):15–21

Assessing new anti–tumour agents and strategies in oncogene transgenic mice. Thomas H, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):91–5 (18 ref.)

Psychosocial aspects of participation in early anticancer drug trials. Report of a pilot study. Cox K, et al. **Cancer Nurs** 1996 Jun;19(3):177–86

The influence of personal message with music on anxiety and side effects associated with chemotherapy. Sabo CE, et al. **Cancer Nurs** 1996 Aug;19(4):283–9

Sexual functioning in women with breast cancer after treatment with adjuvant therapy. Young–McCaughan S. **Cancer Nurs** 1996 Aug;19(4):308–19

Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Danks MK, et al. **Cancer Res** 1996 Apr 1;56(7):1664–73

Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB–94). Eccles SA, et al. **Cancer Res** 1996 Jun 15;56(12):2815–22

Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Kohn EC, et al. **Cancer Res** 1996 Feb 1;56(3):569–73

Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Nagasu T, et al. **Cancer Res** 1995 Nov 15;55(22):5310–4

Evaluation of efficient chemoembolization mixtures by magnetic resonance imaging therapy monitoring: an experimental study on the VX2 tumor in the rabbit liver. Pauser S, et al. **Cancer Res** 1996 Apr 15;56(8):1863–7

High–dose chemotherapy with peripheral blood progenitor autografting. Crown JP, et al. **Cancer Treat Res** 1995; 78:209–26 (115 ref.)

The reversal of multidrug resistance. Fisher GA, et al. **Cancer Treat Res** 1995;78:45–70 (138 ref.)

Potential for protein kinase C inhibitors in cancer therapy. Philip PA, et al. **Cancer Treat Res** 1995;78:3–27 (156 ref.)

High–dose chemotherapy and autologous stem cell transplantation for breast cancer. Weaver CH, et al. **Cancer Treat Res** 1995;76:59–85 (104 ref.)

Versatile intermediates in the selective modification of the amino function of 2–amino–2–deoxy–D–mannopyranose and the 3–position of 2–acetamido–2–deoxy–D–mannose: potential membrane modifiers in neoplastic control. Angelino NJ, et al. **Carbohydr Res** 1995 Oct 16; 276(1):99–115

Liarozole potentiates the cancer chemopreventive activity of and the up–regulation of gap junctional communication and connexin43 expression by retinoic acid and beta–carotene in 10T1/2 cells. Acevedo P, et al. **Carcinogenesis** 1995 Sep;16(9):2215–22

Efficient designs for testing new agents and regimens. Ardizzoni A. **Chest** 1996 May;109(5 Suppl):83S–86S

Chemotherapy for advanced disease. How to raise enthusiasm. McVie JG. **Chest** 1996 May;109(5 Suppl):80S–82S

CNS–85 trial: a cooperative pediatric CNS tumor study—results of treatment of medulloblastoma patients. Pezzotta S, et al. **Childs Nerv Syst** 1996 Feb;12(2):87–96

Somatostatin receptors: clinical implications for endocrinology and oncology. Lamberts SW, et al. **Ciba Found Symp** 1995;190:222–36; discussion 236–9 (48 ref.)

Induction of inflammatory cytokines in effusion cavity by OK–432 injection therapy for patients with malignant effusion: role of interferon–gamma in enhancement of surface expression of ICAM–1 on tumor cells in vivo. Kitsuki H, et al. **Clin Immunol Immunopathol** 1996 Mar; 78(3):283–90

Chemotherapy for progressive pilocytic astrocytomas in the chiasmo–hypothalamic regions. Nishio S, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):300–6

Recombinant human erythropoietin for anaemia in Chinese cancer patients on chemotherapy [letter] Chan AT, et al. **Clin Oncol (R Coll Radiol)** 1995;7(4):272

The search for optimal chemotherapy for advanced epithelial ovarian cancer. Harrington KJ, et al. **Clin Oncol (R Coll Radiol)** 1995;7(6):359–65 (63 ref.)

Simultaneous carboplatin and radiotherapy for all stages of head and neck squamous cell carcinoma. Hosokawa Y, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):168–72

Weight gain as an indicator of response to chemotherapy for oesophageal carcinoma. Steyn RS, et al. **Clin Oncol (R Coll Radiol)** 1995;7(6):382–4

Beta–interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study. Recchia F, et al. **Clin Ter** 1995 Oct;146(10):603–10

Management of cancer in the aged. Balducci L, et al. **Compr Ther** 1996 Feb;22(2):88–93 (28 ref.)

The treatment of hormone refractory prostate cancer. Panvichian R, et al. **Compr Ther** 1996 Feb;22(2):81–7 (27 ref.)

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Verweij J, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):193–201 (58 ref.)

Treatment of malignant glioma in adults. Forsyth PA, et al. **Curr Opin Neurol** 1995 Dec;8(6):414–8 (56 ref.)

Chemotherapy for gynecologic malignancies. Vermorken JB, et al. **Curr Opin Oncol** 1995 Sep;7(5):457–65 (79 ref.)

Immunological and biochemical modulation in the treatment of advanced colorectal cancer: update and future directions. Hilgenfeld RU, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):217–40 (93 ref.)

Adjuvant therapy of stage IIIb melanoma with interferon alfa–2b: clinical and immunological relevance. Doveil GC, et al. **Dermatology** 1995;191(3):234–9

Ulcerated haemangioma successfully treated with interferon alfa–2b and topical granulocyte–macrophage colony–stimulating factor. Illum N, et al. **Dermatology** 1995;191(4):315–7

Confluent and reticulated papillomatosis: response to topical calcipotriol [letter] Kürkçüoğlu N, et al. **Dermatology** 1995; 191(4):341–2

Risks and benefits of retinoids in the chemoprevention of cancer. de Palo G, et al. **Drug Saf** 1995 Oct;13(4):245–56 (80 ref.)

Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. Gillis JC, et al. **Drugs** 1995 Nov;50(5):897–923 (160 ref.)

Current drug treatment guidelines for epithelial ovarian cancer. Lorigan PC, et al. **Drugs** 1996 Apr;51(4):571–84 (65 ref.)

Potential of antineoplastons in diseases of old age. Burzynski SR. **Drugs Aging** 1995 Sep;7(3):157–67 (175 ref.)

The role of the immune system in anti–tumour responses. Potential for drug therapy. Dermime S, et al. **Drugs Aging** 1995 Oct;7(4):266–77 (152 ref.)

Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Perry CM, et al. **Drugs Aging** 1995 Jul;7(1):49–74 (124 ref.)

The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells [editorial] Mertelsmann R. **Eur Cytokine Netw** 1995 Mar–Apr;6(2):79–82 (12 ref.)

Effects of intrapleural mitoxantrone and mepacrine on malignant pleural effusion—a randomised study. Bjermer L, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2203–8

Prevention of second primary tumours with a second generation retinoid in squamous cell carcinoma of oral cavity and oropharynx: long term follow–up [letter] Bolla M, et al. **Eur J Cancer** 1996 Feb;32A(2):375–6

Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer [letter] Colleoni M, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2426–7

Salvage chemotherapy in non–dysgerminomatous germ cell tumours of the ovary [letter] Culine S, et al. **Eur J Cancer** 1995 Oct;31A(11):1890–1

First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. De Kraker J, et al. **Eur J Cancer** 1995;31A(4):600–2

The dithiane Ro 44–5912 enhances vinblastine sensitivity of drug resistant and parental KB lines in vivo. Eliason JF, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2354–61

Pregnancy during alpha–interferon therapy in patients with advanced Hodgkin's disease [letter] Ferrari VD, et al. **Eur J Cancer** 1995 Nov;31A(12):2121–2

Radiolabelled mIBG in the treatment of neuroblastoma. Gaze MN, et al. **Eur J Cancer** 1996 Jan;32A(1):93–6 (33 ref.)

Antitumour activity and retinotoxicity of ethyldeshydroxy–sparsomycin in mice. Hofs HP, et al. **Eur J Cancer** 1995;31A(9):1526–30

Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Piccart MJ, et al. **Eur J Cancer** 1995;31A Suppl 7:S1–10 (117 ref.)

Trofosfamide is effective in refractory non–Hodgkin's lymphoma [letter] Salminen E, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2419–20

Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome. Scambia G, et al. **Eur J Cancer** 1996 Feb; 32A(2):259–63

Pamidronate infusions as single–agent therapy for bone metastases: a phase II trial in patients with breast cancer. Tyrrell CT, et al. **Eur J Cancer** 1995 Nov;31A(12):1976–80

Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group [letter] Urosevic V, et al. **Eur J Cancer** 1996 Jan;32A(1):181–2

Vinorelbine for recurrent adenocarcinoma–like salivary gland malignancies [letter] Airoldi M, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):213–4

A phase I/II study on hyperfractionated chemoradiation using chemotherapy as part of each fraction of treatment in locally far advanced head and neck cancer [letter] Villar A, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):401–2

Influence of anethole treatment on the tumour induced by Ehrlich ascites carcinoma cells in paw of Swiss albino mice. al–Harbi MM, et al. **Eur J Cancer Prev** 1995 Aug; 4(4):307–18

Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Delgrange E, et al. **Eur J Endocrinol** 1996 Apr;134(4):454–6

High–dose epirubicin in platinum–pretreated patients with ovarian carcinoma: the EORTC–GCCG experience. Vermorken JB, et al. **Eur J Gynaecol Oncol** 1995; 16(6):433–8

Effect of cytokines on the toxicity of cytostatic drugs on leukemic cells in vitro and in vivo. Sundman–Engberg B, et al. **Eur J Haematol** 1996 Jan–Feb;56(1–2):1–6

Serum albumin (SA) accumulation by bronchogenic tumours: a tracer technique may help with patient selection for SA–delivered chemotherapy. Clorius JH, et al. **Eur J Nucl Med** 1995 Sep;22(9):989–96

Application of alpha–aminoisobutyric acid, L–methionine, thymidine and 2–fluoro–2–deoxy–D–glucose to monitor effects of chemotherapy in a human colon carcinoma cell line. Schaider H, et al. **Eur J Nucl Med** 1996 Jan; 23(1):55–60

Successful treatment of a recurrent large cystic hygroma in a child with intracystic injection of OK–432 [letter] Hase T, et al. **Eur J Pediatr** 1996 May;155(5):424

The potential of NSAIDs in the treatment of oesophageal carcinoma. Morgan G. **Eur J Surg Oncol** 1996 Jun; 22(3):217–9

A modified technique for ethanol injection of liver tumors: preliminary results. Elgindy NM, et al. **Eur Radiol** 1996; 6(4):494–501

Protein 1 (Clara cell protein) serum levels in lung cancer patients receiving chemotherapy. Nomori H, et al. **Eur Respir J** 1995 Oct;8(10):1654–7

Colony–stimulating factors as an adjunct to chemotherapy in small cell lung cancer. Urban T, et al. **Eur Respir J** 1996 Mar;9(3):596–602 (66 ref.)

Prostate Cancer: Current Issues, New Approaches. Proceedings of an international congress. London, England, October 19–21, 1995. **Eur Urol** 1996;29 Suppl 2:1–135

Clinical progress with a new antiandrogen, Casodex (bicalutamide). Blackledge GR. **Eur Urol** 1996;29 Suppl 2:96–104 (15 ref.)

The development of Casodex (bicalutamide): preclinical studies. Furr BJ. **Eur Urol** 1996;29 Suppl 2:83–95 (53 ref.)

A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group. Kaisary AV, et al. **Eur Urol** 1995;28(3):215–22

Primary metastatic carcinoma of the prostate in younger men: a plea to think over usual therapeutic strategies. Maier U, et al. **Eur Urol** 1996;29(2):221–3

Carboplatin monochemotherapy in elderly patients with nonoperable transitional cell carcinoma of the bladder: a two–stage, phase II study. Segati R, et al. **Eur Urol** 1996; 29(3):312–6; discussion 317

Retinoid differentiation therapy in promyelocytic leukemia. Chomienne C, et al. **FASEB J** 1996 Jul;10(9):1025–30 (67 ref.)

Barrett's esophagus: photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer [see comments] Overholt BF, et al. **Gastrointest Endosc** 1995 Jul;42(1):64–70. Comment in: Gastrointest Endosc 1995 Jul;42(1):96–8.

A phase I study of intraperitoneal interferon–alpha 2b and intravenous cis–platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study. Moore DH, et al. **Gynecol Oncol** 1995 Nov; 59(2):267–72 (25 ref.)

Salvage chemotherapy for refractory transitional cell carcinoma of the ovary (TCC). Sweeten KM, et al. **Gynecol Oncol** 1995 Nov;59(2):211–5

Sensitization of human ovarian tumor cells by subtoxic CDDP to anti–fas antibody–mediated cytotoxicity and apoptosis. Uslu R, et al. **Gynecol Oncol** 1996 Aug; 62(2):282–91

Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. Clavio M, et al. **Haematologica** 1996 May–Jun;81(3):238–44

Peripheral blood and bone marrow changes after treatment with ATRA and G–CSF in AML, APL and blast crisis following Vaquez's disease. Notario A, et al. **Haematologica** 1996 May–Jun;81(3):261–4

Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Nowak–Göttl U, et al. **Haematologica** 1996 Mar–Apr; 81(2):127–31

Management of L–asparaginase induced prothrombotic state in acute lymphoblastic leukemia [letter; comment] Parma M, et al. **Haematologica** 1996 Mar–Apr;81(2):191. Comment on: Haematologica 1995 Sep–Oct;80(5):451–3.

Results of single–agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Demetri GD, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):765–85 (123 ref.)

Adjuvant chemotherapy for soft tissue sarcomas. Mertens WC, et al. **Hematol Oncol Clin North Am** 1995 Aug; 9(4):801–15 (41 ref.)

Chemotherapy for mycosis fungoides and the Sézary syndrome. Rosen ST, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1109–16 (18 ref.)

New drugs for the treatment of sarcomas. van Oosterom AT, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):909–25 (74 ref.)

Systemic adjuvant chemotherapy for soft tissue sarcomas. Zalupski MM, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):787–800 (49 ref.)

Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy. Boehme MW, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):1053–61

The role of chemotherapy in the treatment of adenocarcinoma of the pancreas. Fennelly D, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):356–62 (30 ref.)

Specific targeting of adriamycin conjugates with monoclonal antibodies to hepatoma associated antigens to intrahepatic tumors in athymic mice. Adler R, et al. **Hepatology** 1995 Nov;22(5):1482–7

Can interferon alfa treatment prevent hepatocellular carcinoma in patients with chronic hepatitis C infection and compensated cirrhosis? Harper SE, et al. **Hepatology** 1996 Apr;23(4):930–3

Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Roth JA. **Hum Gene Ther** 1996 May 20;7(8):1013–30

Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs. Usher JR, et al. **IMA J Math Appl Med Biol** 1996 Jun;13(2):99–126

Assessment of the therapeutic potential of cytokines, cytotoxic drugs and effector cell populations for the treatment of multiple myeloma using the 5T33 murine myeloma model. Manning LS, et al. **Immunol Cell Biol** 1995 Aug;73(4):326–32

Systemic in vivo antitumor activity of interleukin-12 against both transplantable and primary tumor. Nishimura T, et al. **Immunol Lett** 1995 Dec;48(2):149–52

Structural alterations induced by photodynamic action of hematoporphyrin derivative (HpD) in plasma membrane of glioblastoma (U-87MG) cells: time dependent fluorescence spectroscopic study. Joshi K, et al. **Indian J Biochem Biophys** 1995 Aug;32(4):200–6

Response of mouse sarcoma-180 to cis-platin in combination with radiation & hyperthermia. Rao BS, et al. **Indian J Med Res** 1996 Jun;103:315–22

Histamine metabolism in mastocytosis patients treated with interferon alpha-2b. Granerus G, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S41–3

Combined therapy with cisplatin and interferon alpha-2b (INTRON-A) in patients with penile carcinoma. Analysis of 2'5' oligo (A) synthetase and circulating interferon [letter] Mouratidou D, et al. **Int J Biol Markers** 1996 Jan–Mar;11(1):55–7

SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo. Cammisuli S, et al. **Int J Cancer** 1996 Jan 26;65(3):351–9

Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes. Davies SL, et al. **Int J Cancer** 1996 Jan 3; 65(1):63–6

Drug resistance, illustration of the complexity of translational research. Steiner Award lecture 1995. Pinedo HM. **Int J Cancer** 1996 Mar 1;65(5):561–6 (62 ref.)

Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. Warenius HM, et al. **Int J Cancer** 1996 Jul 17; 67(2):224–31

A prescreening system for potential antiproliferative agents: implications for local treatment strategies of postangioplasty restenosis. Voisard R, et al. **Int J Cardiol** 1995 Aug;51(1):15–28

Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Kusumoto T, et al. **Int J Hyperthermia** 1995 Jul–Aug;11(4):575–86

Whole-body hyperthermia and lonidamine as adjuvant therapy to treatment with cisplatin with or without local radiation in mouse bearing the Lewis lung carcinoma. Teicher BA, et al. **Int J Hyperthermia** 1995 Sep–Oct; 11(5):637–45

A biochemical evaluation of oral squamous cell carcinoma growth by measurement of specific activity of succinate dehydrogenase in the subrenal capsule assay. Munakata H, et al. **Int J Oral Maxillofac Surg** 1995 Jun;24(3):216–20

New versus old: pancreatic cancer and chemoradiation attempts [editorial; comment] Peacock JL. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):969–70. Comment on: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):913–8.

Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Lamm DL, et al. **Int J Urol** 1995 Jun;2 Suppl 2:23–35 (38 ref.)

Ultrasonographic monitoring of the effects of preoperative chemotherapy in osteosarcoma and Ewing's sarcoma. Kinoshita T, et al. **Int Orthop** 1995;19(5):312–4

Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy. Kisbenedek L, et al. **Int Urol Nephrol** 1995; 27(3):325–9

Induction therapy with all-trans retinoic acid for acute promyelocytic leukemia: a clinical study of 10 cases, including a fatal [correction of fetal] case with thromboembolism. Tsukada N, et al. **Intern Med** 1996 Jan; 35(1):10–4

Synthetic cell-adhesive laminin peptide YIGSR conjugated with polyethylene glycol has improved antimetastatic activity due to a longer half-life in blood. Kaneda Y, et al. **Invasion Metastasis** 1995;15(3–4):156–62

Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588). Chang AY, et al. **Invest New Drugs** 1995;13(2):137–41

A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer. Degardin M, et al. **Invest New Drugs** 1995; 13(3):253–5

Experience of the treatment with Sehydrin (Hydrazine Sulfate, HS) in the advanced cancer patients. Filov VA, et al. **Invest New Drugs** 1995;13(1):89–97

Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Goss G, et al. **Invest New Drugs** 1995;13(3):257–60

Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Puc HS, et al. **Invest New Drugs** 1995;13(2):163–5

Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study. Rosen F, et al. **Invest New Drugs** 1995;13(3):249–52

Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study. Slavik M, et al. **Invest New Drugs** 1995;13(2):143–7

A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study. Sosman JA, et al. **Invest New Drugs** 1995;13(1):83–7

Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: a Southwest Oncology Group study. Williamson SK, et al. **Invest New Drugs** 1995;13(1):67–71

Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study. Williamson SK, et al. **Invest New Drugs** 1995; 13(2):167–70

Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience [see comments] Cohen AM, et al. **Isr J Med Sci** 1995 Oct;31(10):604–10. Comment in: Isr J Med Sci 1995 Oct;31(10):635–7.

A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. Fischl MA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 1;11(4):379–84

Successful treatment of generalized lichen planus with recombinant interferon alfa-2b. Hildebrand A, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):880–3

Beta carotene and cancer: where are we now? [letter] Edes TE. **J Am Coll Nutr** 1995 Jun;14(3):306–7

Adjuvant carboplatin treatment for seminoma clinical stage I. Dieckmann KP, et al. **J Cancer Res Clin Oncol** 1996; 122(1):63–6

Carboplatin and cisplatin: are they equivalent in efficacy in "optimal residual" advanced ovarian cancer? [editorial] Markman M. **J Cancer Res Clin Oncol** 1996;122(8):443–4

Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. Kohl NE, et al. **J Cell Biochem Suppl** 1995;22:145–50 (29 ref.)

Concurrent carboplatin and radiotherapy in the treatment of squamous cell carcinoma of the head and neck, stage IV. Preliminary data of a phase II study. Maisano R, et al. **J Chemother** 1995 Dec;7(6):549–53

Oral etoposide as second-line chemotherapy for colorectal cancer: a GISCAD study. Gruppo Italiano Studio Carcinomi Apparato Digerente. Zaniboni A, et al. **J Chemother** 1995 Jun;7(3):246–8

All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship. Agadir A, et al. **J Clin Oncol** 1995 Oct;13(10):2517–23

Finally, a successful adjuvant therapy for high-risk melanoma [editorial; comment] Balch CM, et al. **J Clin Oncol** 1996 Jan;14(1):1–3. Comment on: J Clin Oncol 1996 Jan;14(1):7–17.

High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. Bensinger WI, et al. **J Clin Oncol** 1996 May;14(5):1447–56

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. Buzdar A, et al. **J Clin Oncol** 1996 Jul;14(7):2000–11

Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil [see comments] Findlay M, et al. **J Clin Oncol** 1996 Mar;14(3):700–8. Comment in: J Clin Oncol 1996 Mar;14(3):691–6.

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. Gause BL, et al. **J Clin Oncol** 1996 Aug; 14(8):2234–41

Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. Geller RB. **J Clin Oncol** 1996 Apr;14(4):1371–82 (65 ref.)

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. Jones S, et al. **J Clin Oncol** 1995 Oct;13(10):2567–74

Carboplatin and cisplatin in medulloblastoma at diagnosis: "comparable efficacy?" [letter; comment] Mastrangelo R, et al. **J Clin Oncol** 1996 May;14(5):1741. Comment on: J Clin Oncol 1995 Sep;13(9):2247–54.

Clinical prognostic factors in adjuvant melanoma trial [letter; comment] Nathanson L. **J Clin Oncol** 1996 Jun; 14(6):1967–8. Comment on: J Clin Oncol 1996 Jan;14(1):7–17.

Chemotherapy in malignant pleural mesothelioma. A review. Ong ST, et al. **J Clin Oncol** 1996 Mar;14(3):1007–17 (79 ref.)

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. Perez-Soler R, et al. **J Clin Oncol** 1996 Feb;14(2):503–13

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. Pujade-Lauraine E, et al. **J Clin Oncol** 1996 Feb;14(2):343–50

Adjuvant interferon alfa-2b for high-risk melanoma [letter; comment] Retsas S. **J Clin Oncol** 1996 Jun;14(6):1968–9. Comment on: J Clin Oncol 1996 Jan;14(1):7–17.

Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. Rowinsky EK, et al. **J Clin Oncol** 1996 Apr;14(4):1224–35

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. Rustin GJ, et al. **J Clin Oncol** 1996 May;14(5):1545–51

Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. El-Sayed S, et al. **J Clin Oncol** 1996 Mar;14(3):838–47

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Schiller JH, et al. **J Clin Oncol** 1996 Aug;14(8):2345–52

Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. Smith TL, et al. **J Clin Oncol** 1996 Jan;14(1):287–95

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. Sridhara R, et al. **J Clin Oncol** 1995 Dec; 13(12):2944–53

Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. Taal BG, et al. **J Clin Oncol** 1996 Jun; 14(6):1829–38

Optimal treatment for untreated patients with hairy cell leukemia? [letter; comment] Troussard X, et al. **J Clin Oncol** 1995 Oct;13(10):2677–9. Comment on: J Clin Oncol 1995 Apr;13(4):974–82.

Proliferative activity in metastatic malignant melanoma: comparison of pre-treatment and post-treatment metastases. Barksdale SK, et al. **J Cutan Pathol** 1995 Aug; 22(4):354–8

Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. Alpsoy E, et al. **J Dermatol** 1996 Jun; 23(6):394–6

Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion and concomitant infusion of either carboplatin or beta-interferon. Nakayama J, et al. **J Dermatol** 1996 Jan; 23(1):6–15

A prospective randomized trial comparing blood- and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy [letter; comment] Janssen WE, et al. **J Hematother** 1995 Jun;4(3):139–40. Comment on: J Hematother 1994 Winter;3(4):299–304.

The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma. Kalechman Y, et al. **J Immunol** 1996 Feb 1;156(3):1101–9

IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer. Ogilvie AC, et al. **J Immunol** 1996 Jan 1;156(1):389–94

The role of chemotherapy for metastatic gastric cancer. O'Brien ME, et al. **J Infus Chemother** 1995 Summer; 5(3):112–6 (45 ref.)

Use of chemotherapy to cure head and neck cancer [editorial] Taylor SG 4th. **J Infus Chemother** 1995 Spring;5(2):44–5

Synergistic effects between recombinant interleukin-2 and the synthetic immunomodulator murabutide: selective enhancement of cytokine release and potentiation of antitumor activity. Bahr GM, et al. **J Interferon Cytokine Res** 1996 Feb;16(2):169–78

Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2. Bernsen MR, et al. **J Interferon Cytokine Res** 1995 Jul;15(7):641–5

Interleukin-8 inhibits non-small cell lung cancer proliferation: a possible role for regulation of tumor growth by autocrine and paracrine pathways. Wang J, et al. **J Interferon Cytokine Res** 1996 Jan;16(1):53-60

Structure-activity relationship for antineoplastic imidazoacridinones: synthesis and antileukemic activity in vivo. Cholody WM, et al. **J Med Chem** 1996 Mar 1; 39(5):1028-32

Synthesis and antitumor activity of 4- and 5-substituted derivatives of isoquinoline-1-carboxaldehyde thiosemicarbazone. Liu MC, et al. **J Med Chem** 1995 Oct 13;38(21):4234-43

Long-term freedom from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma [letter] Kirn DH, et al. **J Natl Cancer Inst** 1996 Jun 5;88(11):764-5

Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer [see comments] Kundu N, et al. **J Natl Cancer Inst** 1996 Apr 17;88(8):536-41. Comment in: J Natl Cancer Inst 1996 Apr 17;88(8):479-80.

Basic research plays a key role in new patient treatments [news] Law C. **J Natl Cancer Inst** 1996 Jul 3;88(13):869

Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice [see comments] Leonetti C, et al. **J Natl Cancer Inst** 1996 Apr 3;88(7):419-29. Comment in: J Natl Cancer Inst 1996 Apr 3;88(7):391-3.

Re:Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study [letter; comment] Lollini PL, et al. **J Natl Cancer Inst** 1996 Jul 3;88(13):926-7. Comment on: J Natl Cancer Inst 1995 Nov 15;87(22):1710-3.

Topotecan: after FDA and ASCO, what's next? [news] McNeil C. **J Natl Cancer Inst** 1996 Jun 19;88(12):788-9

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study [see comments] Meyskens FL Jr, et al. **J Natl Cancer Inst** 1995 Nov 15; 87(22):1710-3. Comment in: J Natl Cancer Inst 1996 Jul 3;88(13):926-7.

Chemotherapy's benefits bring hope of progress for NSCLC [news] Reynolds T. **J Natl Cancer Inst** 1995 Nov 15; 87(22):1661-2

Aspirin and breast cancer: no surprises yet [editorial; comment] Rosenberg L. **J Natl Cancer Inst** 1996 Jul 17; 88(14):941-2. Comment on: J Natl Cancer Inst 1996 Jul 17;88(14):988-93.

Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101. Sredni B, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1276-84

Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. Thompson HJ, et al. **J Natl Cancer Inst** 1995 Aug 16;87(16):1259-60

Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. Wigginton JM, et al. **J Natl Cancer Inst** 1996 Jan 3;88(1):38-43

Re: Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas [letter; comment] Wynder EL. **J Natl Cancer Inst** 1996 Mar 20;88(6):377-8. Comment on: J Natl Cancer Inst 1995 Dec 6;87(23):1760-6.

Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. Beitz J, et al. **J Natl Cancer Inst Monogr** 1996;(20):7-9

Cancer chemoprevention. Hong WK, et al. **J Natl Cancer Inst Monogr** 1995;(17):49-53 (29 ref.)

Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. Boiardi A, et al. **J Neurooncol** 1996 Feb;27(2):157-62

Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release. Buahin KG, et al. **J Neurooncol** 1995 Nov;26(2):103-10

Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? Dupuis-Girod S, et al. **J Neurooncol** 1996 Jan;27(1):87-98

Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A. Hiesiger EM, et al. **J Neurooncol** 1995; 25(2):143-54

Response of brain metastases from breast cancer to megestrol acetate: a case report. Stewart DJ, et al. **J Neurooncol** 1995; 24(3):299-301

Response of brain tumors to chemotherapy, evaluated in a clinically relevant xenograft model. White L, et al. **J Neurooncol** 1995;25(1):39-47

Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. Li XN, et al. **J Neurosurg** 1996 May;84(5):831-8

Diallyl disulfide suppresses the growth of human colon tumor cell xenografts in athymic nude mice. Sundaram SG, et al. **J Nutr** 1996 May;126(5):1355-61

4-oxo retinoic acid for refractory acute promyelocytic leukemia in children with all-trans retinoic acid therapy. Takitani K, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Aug; 41(4):493-8

Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. Ferguson PJ. **J Otolaryngol** 1995 Aug;24(4):242-52 (100 ref.)

Sclerosing of recurrent lymphangioma using OK-432. Mikhail M, et al. **J Pediatr Surg** 1995 Aug;30(8):1159-60

The potential of a novel polyamine transport inhibitor in cancer chemotherapy. Aziz SM, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):185-92

Growth inhibitory effects on human colon adenocarcinoma-derived Caco-2 cells and calcemic potential of 1 alpha,25-dihydroxyvitamin D3 analogs: structure-function relationships. Bischof MG, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1254-60

Cavernous haemangioma with Kasabach-Merritt syndrome: treatment with alpha-interferon. Ettlinger JJ, et al. **J R Soc Med** 1996 Jan;89(1):55P-6P

Type II mixed cryoglobulinemia treated with fludarabine [letter] Enzenauer RJ, et al. **J Rheumatol** 1996 Apr; 23(4):794-5

Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, Pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. Helle SI, et al. **J Steroid Biochem Mol Biol** 1996 Feb;57(3-4):167-71

Suppressive effect of iodine on DMBA-induced breast tumor growth in the rat. Funahashi H, et al. **J Surg Oncol** 1996 Mar;61(3):209-13

Antitumour activity of cis-diamminedichloroplatinum (II) against human tumour xenografts depends on its area under the curve in nude mice. Kurihara N, et al. **J Surg Oncol** 1996 Feb;61(2):138-42

Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas. Ratto GB, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):614-22

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer [see comments] Gleave ME, et al. **J Urol** 1996 Jan; 155(1):213-9. Comment in: J Urol 1996 Jan;155(1):226-7.

Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil [see comments] Hofmockel G, et al. **J Urol** 1996 Jul;156(1):18-21. Comment in: J Urol 1996 Jul;156(1):40.

In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers. Sarosdy MF, et al. **J Urol** 1996 Jun;155(6):2085-9

Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced bladder cancer overview collaboration. Scher HI. **J Urol** 1995 Nov;154(5):1970

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. Soloway MS, et al. **J Urol** 1995 Dec; 154(6):2110-4

Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). Bergman PJ, et al. **J Vet Intern Med** 1996 Mar-Apr;10(2):76-81

The antitumor activity of the DNA fraction from Mycobacterium bovis BCG (MY-1) for glioblastoma. Nakaichi M, et al. **J Vet Med Sci** 1995 Jun;57(3):583-5

Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. Ito T, et al. **Jpn J Cancer Res** 1996 Feb; 87(2):113-6

Inhibition of in vitro tumor cell invasion by ginsenoside Rg3. Shinkai K, et al. **Jpn J Cancer Res** 1996 Apr;87(4):357-62

Sonodynamically induced antitumor effect of a gallium-porphyrin complex, ATX-70. Yumita N, et al. **Jpn J Cancer Res** 1996 Mar;87(3):310-6

The confusion associated with breast cancer chemotherapy in Japan: the first year's experience at the Division of Oncology and Hematology, National Cancer Center Hospital East. Ohtsu T, et al. **Jpn J Clin Oncol** 1995 Dec; 25(6):267-72

The effect of Antineoplaston, a new antitumor agent on malignant brain tumors. Sugita Y, et al. **Kurume Med J** 1995;42(3):133-40

Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma. Tsuda H, et al. **Kurume Med J** 1996;43(2):137-47

Oral etoposide and palliative treatment for small-cell lung cancer [comment] Aapro MS. **Lancet** 1996 Aug 31; 348(9027):559. Comment on: Lancet 1996 Aug 31;348(9027):563-6.

Interferon and hepatocellular carcinoma [letter; comment] Andreone P, et al. **Lancet** 1996 Jan 20;347(8995):195. Comment on: Lancet 1995 Oct 21;346(8982):1051-5.

FDA approve bark-derived drug [news] Barnett AA. **Lancet** 1996 Jun 8;347(9015):1613

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party [see comments] Girling DJ. **Lancet** 1996 Aug 31;348(9027):563-6. Comment in: Lancet 1996 Aug 31;348(9027):559.

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL [see comments] Johnson S, et al. **Lancet** 1996 May 25;347(9013):1432-8. Comment in: Lancet 1996 May 25;347(9013):1420-1.

Interferon and hepatocellular carcinoma [letter; comment] Koretz RL. **Lancet** 1996 Jan 20;347(8995):194-5. Comment on: Lancet 1995 Oct 21;346(8982):1051-5.

Alpha-interferon in chronic myelogenous leukaemia [see comments] Kumar L, et al. **Lancet** 1995 Oct 14; 346(8981):984-6 (12 ref.). Comment in: Lancet 1996 Jan 6;347(8993):57-8.

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis [see comments] Nishiguchi S, et al. **Lancet** 1995 Oct 21;346(8982):1051-5. Comment in: Lancet 1995 Oct 21;346(8982):1049-50. Comment in: Lancet 1996 Jan 20;347(8995):194-5. Comment in: Lancet 1996 Jan 20;347(8995):195.

Remission of leukaemic meningitis after fludarabine [letter] Paolini R, et al. **Lancet** 1995 Oct 7;346(8980):972

Fertility after prolonged chemotherapy for metastatic malignant disease [letter] Retsas S, et al. **Lancet** 1996 Mar 9;347(9002):687

Fludarabine treatment and transfusion-associated graft-versus-host disease [letter] Saven A. **Lancet** 1996 Aug 17;348(9025):473

Tackling liver cancer with interferon [comment] [published erratum appears in Lancet 1995 Dec 2;346(8988):1502] Schluger LK, et al. **Lancet** 1995 Oct 21;346(8982):1049-50. Comment on: Lancet 1995 Oct 21;346(8982):1051-5.

Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia. Gjedde SB, et al. **Leuk Lymphoma** 1996 Apr;21(3-4):317-20

Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach. Jehn U, et al. **Leuk Lymphoma** 1995 Sep;19(1-2):153-7

Cyclosporine A in chronic lymphocytic leukemia: dual anti-leukemic and immunosuppressive role? Wright SJ, et al. **Leuk Lymphoma** 1995 Dec;20(1-2):131-6

High-dose chemotherapy in adult acute myeloid leukemia: rationale and results. Stasi R, et al. **Leuk Res** 1996 Jul; 20(7):535-49 (70 ref.)

Chronic myeloid leukemia, BCR/ABL transcript, response to alpha-interferon and survival. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. **Leukemia** 1995 Oct;9(10):1648-52

Does it matter how remission is achieved in acute leukemia? Bishop JF. **Leukemia** 1996 Apr;10 Suppl 1:S7-9 (6 ref.)

An adolescent with HTLV-I-associated adult T cell leukemia treated with interferon-alfa and zidovudine. Broniscer A, et al. **Leukemia** 1996 Jul;10(7):1244-8

New chemotherapeutic agents in acute myeloid leukemia. Kantarjian HM, et al. **Leukemia** 1996 Apr;10 Suppl 1:S4-6 (0 ref.)

Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia. Kantarjian HM, et al. **Leukemia** 1996 Mar;10(3):396-401

In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Klumper E, et al. **Leukemia** 1995 Nov;9(11):1864-9

Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. Larson RA. **Leukemia** 1996 Apr;10 Suppl 1:S23-5 (7 ref.)

The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. List AF. **Leukemia** 1996 Apr;10 Suppl 1:S36-8 (0 ref.)

2-Chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine? [letter]. Schirmer M, et al. **Leukemia** 1996 Jul;10(7):1253-4

Differentiating therapy in acute myeloid leukemia. Tallman MS. **Leukemia** 1996 Aug;10(8):1262-8 (62 ref.)

Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia. Tallman MS. **Leukemia** 1996 Apr;10 Suppl 1:S12-5 (28 ref.)

Concomitant complete remission of APL and smoldering ATL following ATRA therapy in a patient with the two diseases simultaneously [letter] Tsukasaki K, et al. **Leukemia** 1995 Oct;9(10):1797-8

Interpreting data in AML. Wiernik PH. **Leukemia** 1996 Apr; 10 Suppl 1:S44-5

Pharmacokinetic and pharmacodynamic optimization of intraperitoneal chemotherapy. Balthasar JP, et al. **Life Sci** 1996;58(7):535-43 (71 ref.)

Camptothecin analogues in the treatment of non-small cell lung cancer. Ardizzoni A. **Lung Cancer** 1995 Apr;12 Suppl 1:S177-85 (19 ref.)

Scheduling of chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Bishop JF. **Lung Cancer** 1995 Jun;12 Suppl 2:S53-61 (52 ref.)

Biological response modifiers. Calabresi F, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S193-8 (28 ref.)

New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. Comis RL, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S63-99 (163 ref.)

New drugs for treating small cell lung cancer. Ettinger DS. **Lung Cancer** 1995 Jun;12 Suppl 3:S53-61 (20 ref.)

New drugs in non-small cell lung cancer. An overview. Giaccone G. **Lung Cancer** 1995 Apr;12 Suppl 1:S155-62 (35 ref.)

Edatrexate studies in non-small cell lung cancer. Gralla RJ. **Lung Cancer** 1995 Apr;12 Suppl 1:S187-91 (21 ref.)

Etoposide phosphate or etoposide with cisplatin in the treatment of small cell lung cancer: randomized phase II

trial. Greco FA, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S85–95

Phase I–II and pharmacokinetic study of a new fotemustine schedule in advanced non–small cell lung cancer. Le Cesne A, et al. **Lung Cancer** 1995 Aug;13(1):69–78

Future directions and strategies. McVie JG. **Lung Cancer** 1995 Apr;12 Suppl 1:S199–201

Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Marino P, et al. **Lung Cancer** 1995 Aug;13(1):1–12

MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Knopp MV, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):633–58 (42 ref.)

Two types of cancer cells and cytotoxic therapies. Hirata Y. **Med Hypotheses** 1996 Jan;46(1):30–2

Successful cancer therapy with promethazine: the rationale. Jones GR. **Med Hypotheses** 1996 Jan;46(1):25–9 (28 ref.)

Bicalutamide for prostate cancer. **Med Lett Drugs Ther** 1996 Jun 21;38(977):56–7

Alpha interferon as an immunomodulator in the treatment of patients with tumors. Alvarez-Mon M, et al. **Med Oncol** 1995 Mar;12(1):15–21 (45 ref.)

Interferons and other cytokines in head and neck cancer. Hamasaki VK, et al. **Med Oncol** 1995 Mar;12(1):23–33 (64 ref.)

Interferon and chronic myelogenous leukaemia. Lauta VM. **Med Oncol** 1995 Mar;12(1):41–6 (27 ref.)

Interferon and multiple myeloma. Lauta VM. **Med Oncol** 1995 Mar;12(1):63–9 (31 ref.)

Alpha interferon: new associations in haematology/oncology. The Montpellier experience. Rossi JF. **Med Oncol** 1995 Mar;12(1):59–61 (23 ref.)

The role of alpha interferon in the biomodulation of disease: preface. Wadler S. **Med Oncol** 1995 Mar;12(1):1–2

Use of all-trans retinoic acid to treat acute promyelocytic leukemia: a case with very severe features at the onset in Nicaragua. Flores A, et al. **Med Pediatr Oncol** 1996 Apr; 26(4):258–60

Phase I trial of extracellular adenosine 5'-triphosphate in patients with advanced cancer. Haskell CM, et al. **Med Pediatr Oncol** 1996 Sep;27(3):165–73

Interferon-alpha for neurofibromas. Kebudi R, et al. **Med Pediatr Oncol** 1996 Mar;26(3):220–2

All-trans retinoic acid and short-time, high-dose cytarabine in two children with acute promyelocytic leukemia. Schmitt K, et al. **Med Pediatr Oncol** 1996 Apr;26(4):254–7

RSV infection complicating the therapy of pediatric malignancies: report of six cases. Vettenranta K, et al. **Med Pediatr Oncol** 1996 Apr;26(4):261–3

Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients. Clemente C, et al. **Melanoma Res** 1996 Feb;6(1):63–9

Antitumor activity of vanadium compounds. Djordjevic C. **Met Ions Biol Syst** 1995;31:595–616 (89 ref.)

Angiogenesis promoters and inhibitors: potential therapeutic implications. Mousa SA. **Mol Med Today** 1996 Apr; 2(4):140–2

Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpatient resource utilization. Freund DA, et al. **Monogr Natl Cancer Inst** 1995;(19):37–40

Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma [letter] Bower JH, et al. **Mov Disord** 1995 Sep;10(5):681–2

Antioxidant vitamins: getting to the heart of the matter [letter] Scott RS. **N Z Med J** 1996 Aug 23;109(1028):324

Oddball p53 in testicular tumors. Chresta CM, et al. **Nat Med** 1996 Jul;2(7):745–6

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice [see comments] Kohl NE, et al. **Nat Med** 1995 Aug; 1(8):792–7. Comment in: Nat Med 1995 Aug;1(8):747–8.

Rational cancer therapy [comment] Lowy DR, et al. **Nat Med** 1995 Aug;1(8):747–8. Comment on: Nat Med 1995 Aug;1(8):792–7.

Intra-arterial ACNU and cisplatin chemotherapy for the treatment of glioblastoma multiforme. Iwadate Y, et al. **Neurol Med Chir (Tokyo)** 1995 Aug;35(8):598–603

Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Freilich RJ, et al. **Neurology** 1996 Feb;46(2):435–9

The role of cladribine in the treatment of lymphoid malignancies. Nelson MC, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1395–400 (22 ref.)

Update on the diagnosis of and therapy for acute promyelocytic leukemia and chronic myelogenous leukemia. Wujcik D. **Oncol Nurs Forum** 1996 Apr; 23(3):478–87 (70 ref.)

Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Bruzzone M, et al. **Oncology** 1996 Sep–Oct;53(5):349–53

Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: a pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin. Falkson CI, et al. **Oncology** 1996 Jul–Aug;53(4):313–7

Local hyperthermia, radiation, and chemotherapy in locally advanced malignancies. Feyerabend T, et al. **Oncology** 1996 May–Jun;53(3):214–20

Clinical trials referral resource. Clinical trials with 9-aminocamptothecin. **Oncology (Huntingt)** 1995 Aug; 9(8):727–31

Chemotherapy enhancer passes first test [news] **Oncology (Huntingt)** 1995 Nov;9(11):1180

Clinical trials referral resource. Clinical trials of suramin. Cheson BD, et al. **Oncology (Huntingt)** 1995 Feb;9(2):161, 163

New anticancer agents in clinical development. Eckardt J, et al. **Oncology (Huntingt)** 1995 Nov;9(11):1191–9 (0 ref.)

New anticancer agents in clinical development. Eckardt J, et al. **Oncology (Huntingt)** 1995 Dec;9(12):1321–8; 1331; discussion 1332–4 (147 ref.)

Decision analysis: a practical example. Smith TJ, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):37–45

Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin. de Souza OF, et al. **Ophthalmologica** 1995;209(4):212–6

Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Ishii H, et al. **Pancreas** 1996 Apr;12(3):267–71

An adolescent case of retroperitoneal pure choriocarcinoma: successful treatment with MCNU-containing high-dose chemotherapy followed by autologous bone marrow transplantation after multiple brain metastases. Nagatoshi Y, et al. **Pediatr Hematol Oncol** 1996 Mar–Apr;13(2):167–71

Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. Kuan CT, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):974–8

Paclitaxel: a unique tubulin interacting anticancer agent. Vyas DM, et al. **Prog Med Chem** 1995;32:289–337 (301 ref.)

Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Denmeade SR, et al. **Prostate** 1996 Apr;28(4):251–65 (94 ref.)

Suramin as adjuvant therapy with radical prostatectomy. Saffrin R, et al. **Prostate** 1996 May;28(5):325–7

Cross resistance and collateral sensitivity between cytotoxic drugs and radiation in two human bladder cell lines. Pauwels O, et al. **Radiother Oncol** 1996 Apr;39(1):81–6

The use of radioimmunotherapy in combination with bioreductive agents. Langmuir VK. **Recent Results Cancer Res** 1996;141:137–43 (40 ref.)

The role of anthracyclines in adjuvant chemotherapy of breast cancer: a critical appraisal. Mouridsen HT. **Recent Results Cancer Res** 1996;140:191–9 (33 ref.)

Reconceptualizing family caregiving: family-based illness care during chemotherapy. Schumacher KL. **Res Nurs Health** 1996 Aug;19(4):261–71

A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia. Hocepied AM, et al. **S Afr Med J** 1996 May;86(5):549–50

Fighting cancer by attacking its blood supply. Folkman J. **Sci Am** 1996 Sep;275(3):150–4 (0 ref.)

Ancient remedy performs new tricks [news] Mervis J. **Science** 1996 Aug 2;273(5275):578

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Wiseman GA, et al. **Semin Nucl Med** 1995 Jul;25(3):272–8 (39 ref.)

High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. Bearman SI, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):60–7 (62 ref.)

Colorectal cancer: hepatic-directed therapy—the role of surgery, regional chemotherapy, and novel modalities. Busch E, et al. **Semin Oncol** 1995 Oct;22(5):494–508 (110 ref.)

Adjuvant therapy of gastric cancer: the Japanese experience. Fukushima M. **Semin Oncol** 1996 Jun;23(3):369–78 (52 ref.)

The role of primary chemotherapy in early breast cancer. Harris L, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):31–42 (46 ref.)

Adjuvant and neoadjuvant therapy for gastric cancer. Kelsen DP. **Semin Oncol** 1996 Jun;23(3):379–89 (48 ref.)

Adjuvant therapy for cutaneous melanoma. Nathan FE, et al. **Semin Oncol** 1995 Dec;22(6):647–61 (85 ref.)

Adjuvant systemic therapy of prostate cancer. Raghavan D. **Semin Oncol** 1995 Dec;22(6):633–40 (72 ref.)

Chemotherapy for advanced breast cancer: a current perspective. Seidman AD. **Semin Oncol** 1996 Feb;23(1 Suppl 2):55–9 (44 ref.)

Neoadjuvant and adjuvant chemotherapy for invasive bladder cancer. Smith MR, et al. **Semin Oncol** 1995 Dec; 22(6):625–32 (28 ref.)

The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix. Wadler S, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):64–8 (33 ref.)

Chemotherapy and radiation therapy for laryngeal cancer. Hall SW, et al. **Semin Speech Lang** 1995 Aug;16(3):233–9

Prodrugs in cancer chemotherapy. Connors TA, et al. **Stem Cells (Dayt)** 1995 Sep;13(5):501–11 (76 ref.)

High-dose chemotherapy with stem cell reinfusion and growth factor support for solid tumors. de Vries EG, et al. **Stem Cells (Dayt)** 1995 Nov;13(6):597–606

Quantitative and qualitative comparative analysis of gradient-separated hematopoietic cells from cord blood and chemotherapy-mobilized peripheral blood. Sato J, et al. **Stem Cells (Dayt)** 1995 Sep;13(5):548–55

Antiestrogenic activity of two 11 beta-estradiol derivatives on MCF-7 breast cancer cells. Jin L, et al. **Steroids** 1995 Aug;60(8):512–8

Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. Cascinu S, et al. **Support Care Cancer** 1996 Jan;4(1):31–3

The role of bisphosphonates in the treatment of bone metastases—the U.S. experience. Harvey HA, et al. **Support Care Cancer** 1996 May;4(3):213–7

Adjuvant chemotherapy in the node-negative breast cancer patient. Styblo TM, et al. **Surg Clin North Am** 1996 Apr; 76(2):327–41 (26 ref.)

The role of cytotoxic chemotherapy in the treatment of malignant brain tumors. Kornblith PL. **Surg Neurol** 1995 Dec;44(6):551–2

Investigation of chemoresistance-related genes mRNA expression for selecting anticancer agents in successful adjuvant chemotherapy for a case of recurrent glioblastoma. Nagane M, et al. **Surg Neurol** 1995 Nov; 44(5):462–8; discussion 468–70

The effect of high-energy shock wave therapy combined with cisplatin on mouse hepatoma. Maruyama M, et al. **Surg Today** 1995;25(11):987–8

Granulocyte-macrophage colony-stimulating factor inhibits tumor growth during the postoperative period. Hill AD, et al. **Surgery** 1996 Feb;119(2):178–85

Combined carboplatin and cytosine arabinoside in metastatic melanoma refractory to dacarbazine. Bajetta E, et al. **Tumori** 1995 Jul–Aug;81(4):238–40

Effects of one-year adjuvant treatment with tamoxifen on bone mineral density in postmenopausal breast cancer women. Barni S, et al. **Tumori** 1996 Jan–Feb;82(1):65–7

Clinical development of new fluoropyrimidines: a major improvement in colorectal cancer treatment? Colleoni M, et al. **Tumori** 1995 Sep–Oct;81(5):303–7 (44 ref.)

Megestrol acetate in unresectable hepatocellular carcinoma. Colleoni M, et al. **Tumori** 1995 Sep–Oct;81(5):351–3

Steroid hormone levels in patients with advanced breast cancer during therapy with droloxifene: a pilot study. Dalski J, et al. **Tumori** 1996 Jan–Feb;82(1):45–7

Doxifluridine: an active agent in advanced gastrointestinal cancer. Di Bartolomeo M, et al. **Tumori** 1995 May–Jun;81(3 Suppl):147–50

Radiation and concurrent carboplatin administration in locally advanced head and neck cancer. A Hellenic Cooperative Oncology Group Study. Fountzilas G, et al. **Tumori** 1995 Sep–Oct;81(5):354–8 (19 ref.)

Effectiveness of fludarabine in advanced B-cell chronic lymphocytic leukemia. Montillo M, et al. **Tumori** 1995 Nov–Dec;81(6):419–23

Long-lasting complete remission of pulmonary metastases consequent to renal cell carcinoma obtained with interferon-beta therapy: review of the literature and a case report. Scoponi C, et al. **Tumori** 1995 May–Jun;81(3):201–3 (24 ref.)

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Chodak G, et al. **Urology** 1995 Dec; 46(6):849–55

Chemotherapy for invasive bladder cancer. Malkowicz SB, et al. **Urology** 1996 Apr;47(4):602–14 (105 ref.)

Cytostatic treatment in veterinary medicine. Rutteman GR, et al. **Vet Q** 1995 Apr;17 Suppl 1:S25–7 (4 ref.)

[Treatment of inoperable non-small cell bronchogenic carcinoma with a combination of cisplatin and vinorelbine—preliminary evaluation] Adam Z, et al. **Vnitr Lek** 1996 Mar;42(3):175–80 (Eng. Abstr.) **(Cze)**

[Control of the myocardial pump function during cytostatic treatment with anthracycline] Hesse B, et al. **Ugeskr Laeger** 1996 Aug 12;158(33):4628–30 **(Dan)**

[Treatment of brain tumors investigation by positron emission tomography] Jarden JO. **Ugeskr Laeger** 1996 Jul 8; 158(28):4086–90 (Eng. Abstr.) **(Dan)**

[Late recurrence of stomach cancer in a patient treated with a H2 receptor antagonist] Overgaard H, et al. **Ugeskr Laeger** 1996 May 6;158(19):2717–8 (Eng. Abstr.) **(Dan)**

[Indications for antineoplastic effects of nonsteroidal anti-inflammatory drugs] Kooy A, et al. **Ned Tijdschr Geneeskd** 1995 Nov 4;139(44):2235–9 (49 ref.) **(Dut)**

[Successful ambulatory treatment of patients with hairy-cell leukemia using one cycle of the purine analog cladribine. 'Hemato-oncologic volwassen Nederland' (HOVON) Study Group] Raemaekers JM, et al. **Ned Tijdschr Geneeskd** 1996 Aug 3;140(31):1600–4 (Eng. Abstr.) **(Dut)**

[Chemotherapy in brain tumors] van den Bent MJ, et al. **Ned Tijdschr Geneeskd** 1996 Mar 30;140(13):702–6 (42 ref.) **(Dut)**

[Contribution of an induction treatment in the surgical treatment of locally advanced non-small-cell cancers] Massard G, et al. **Ann Chir** 1995;49(9):841–8 (Eng. Abstr.) **(Fre)**

[Topoisomerases: therapeutic value] Faure P, et al. **Ann Pharm Fr** 1996;54(1):40–4 (Eng. Abstr.) **(Fre)**

[Current therapeutic methods in onco-hematology] Madelaine-Chambrin I, et al. **Ann Pharm Fr** 1996; 54(2):73–6 (15 ref.) (Eng. Abstr.) **(Fre)**

[A new concept: treatment using differentiation of the malignant cell in man] Degos L. **Bull Acad Natl Med** 1995 Nov;179(8):1689–700 (39 ref.) (Eng. Abstr.) **(Fre)**

[Topoisomerase I inhibitors. Review of phase II trials with

irinotecan (CPT-11) and topotecan] Bonneterre J. **Bull Cancer (Paris)** 1995 Aug;82(8):623-8 (52 ref.) (Eng. Abstr.) **(Fre)**

[Medical chemoprevention of cancers. From the point of view of social sciences] Bourret P, et al. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:224s-229s (Eng. Abstr.) **(Fre)**

[Use of vinorelbine in non-small cell bronchial cancer: current aspects and perspectives] Douillard JY. **Bull Cancer (Paris)** 1996 Feb;83(2):157-62 **(Fre)**

[Prevention and chemoprevention in cancerology. A quantitative analysis of medical literature] Eisinger F. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:151s-154s (Eng. Abstr.) **(Fre)**

[Chemotherapy of metastatic endometrial carcinoma. Review of the literature] Pierga JY, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):1005-18 (110 ref.) (Eng. Abstr.) **(Fre)**

[86th meeting of the American Association for Cancer Research "New drugs in cancerology" Toronto, (Canada), March 18-22, 1995] Rodier JM. **Bull Cancer (Paris)** 1995 Aug;82(8):676-9 **(Fre)**

[Prevention of second primary cancer with vitamin supplementation in patients treated for head and neck cancers] Bairati I, et al. **Bull Cancer Radiother** 1996; 83(1):12-6 (37 ref.) (Eng. Abstr.) **(Fre)**

[Resistance to chemotherapy: current therapeutic approach] Ries F, et al. **Bull Soc Sci Med Grand Duche Luxemb** 1995; 132(3):19-26 (60 ref.) **(Fre)**

[Resistance to chemotherapy in cancers of the kidney and therapeutic perspectives] Oudard S, et al. **J Urol (Paris)** 1995;101(3):122-4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Use of biodegradable microspheres in experimental anticancer therapy. Chronopharmacological application] Milis G, et al. **Pathol Biol (Paris)** 1996 Mar;44(3):208-11 (Eng. Abstr.) **(Fre)**

[Tumor lysis syndrome in chronic lymphoid leukemia treated with chlorambucil and prednisone (letter)] Alliot C, et al. **Presse Med** 1995 Sep 2-9;24(25):1178 **(Fre)**

[Chemotherapy of metastatic soft tissue sarcoma] Le Cesne A. **Presse Med** 1995 Sep 16;24(26):1214-20 (53 ref.) (Eng. Abstr.) **(Fre)**

[[Therapeutic perspectives in multiple sclerosis (editorial)] Lubetzki C, et al. **Presse Med** 1996 Jun 15;25(21):964-6 (10 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of metastatic carcinoid tumors with interferon-alpha. Five cases] Votte A, et al. **Presse Med** 1996 Jan 20;25(2):63-7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Use of interferon alpha in multiple myeloma] Harousseau JL, et al. **Rev Med Interne** 1996;17(6):488-95 (53 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of tumor response during chemotherapy of bronchial cancer] Pujol JL, et al. **Rev Med Interne** 1995; 16(10):759-66 (36 ref.) (Eng. Abstr.) **(Fre)**

[Multiple spinal cord metastases of small cell bronchial cancer. Role of chemotherapy (letter)] Ferroir JP, et al. **Rev Pneumol Clin** 1995;51(4):260-2 **(Fre)**

[The treatment of carcinoid of the small intestine with octreotide and alpha-interferon. A call for participation in a randomized study (letter] Ahrén B. **Dtsch Med Wochenschr** 1996 May 31;121(22):744-5 **(Ger)**

[New drugs in therapy of breast carcinoma] Grunewald R. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):M75-81 (65 ref.) **(Ger)**

-Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay- Kurbacher CM, et al. **Geburtshilfe Frauenheilkd** 1996 Feb; 56(2):70-8 (Eng. Abstr.) **(Ger)**

[Anti-angiogenesis: a new concept in therapy of solid malignancies?] Schweigerer L. **Med Klin** 1995 Dec 15; 90(12):709-12 (52 ref.) **(Ger)**

[Tumor diagnosis, therapy and drug targeting with magnetic fluids] Günther D. **Pharm Unserer Zeit** 1996 May; 25(3):130-4 (10 ref.) **(Ger)**

[Chemotherapy of gastrointestinal carcinomas and non-small-cell pulmonary carcinoma: a controversy] Fey MF, et al. **Schweiz Med Wochenschr** 1996 May 18; 126(20):872-8 (26 ref.) (Eng. Abstr.) **(Ger)**

[Neoadjuvant cisplatin chemotherapy and radical cystectomy in bladder carcinoma] Dunst J. **Strahlenther Onkol** 1996 Aug;172(8):463-4 **(Ger)**

[Adjuvant chemotherapy improves survival in head and neck tumors] Wendt TG. **Strahlenther Onkol** 1995 Dec; 171(12):719-20 **(Ger)**

[Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study] Otto T, et al. **Urologe A** 1996 Mar;35(2):142-5 (Eng. Abstr.) **(Ger)**

[Recombinant human erythropoietin in the treatment of anemic patients undergoing chemotherapy for cancer] Bösze P, et al. **Orv Hetil** 1995 Nov 19;136(47):2567-72 (Eng. Abstr.) **(Hun)**

[Use of taxol in the management of malignant tumors] Eckhardt S. **Orv Hetil** 1995 Sep 10;136(37):1987-93 (85 ref.) (Eng. Abstr.) **(Hun)**

[Platinum-based antineoplastic agents: biomedical applications and therapeutic aspects] Dominici C, et al. **Ann Ist Super Sanita** 1995;31(2):289-94 (52 ref.) (Eng. Abstr.) **(Ita)**

[Interferons in the therapy of solid tumors] Tomao S, et al. **Clin Ter** 1995 Aug-Sep;146(8-9):491-502 (96 ref.) (Eng. Abstr.) **(Ita)**

[What is the role of neoadjuvant therapy in prostate cancer?] Witjes WP, et al. **Minerva Urol Nefrol** 1995 Dec; 47(4):209-14 (53 ref.) **(Ita)**

[Recent advance in chemotherapy for advanced colorectal cancer] Aiba K. **Gan To Kagaku Ryoho** 1996 Apr; 23(5):535-48 (83 ref.) (Eng. Abstr.) **(Jpn)**

[Current status and problems in clinical trial for new anticancer drug in Japan] Fukuoka M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):141-5 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Photodynamic therapy of centrally located early-stage lung cancer] Furuse K. **Gan To Kagaku Ryoho** 1996 Jan; 23(1):27-30 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The potential of interleukin-12 for use in cancer therapy] Gately MK, et al. **Gan To Kagaku Ryoho** 1996 Jul; 23(8):961-71 (74 ref.) (Eng. Abstr.) **(Jpn)**

[Novel targets for cancer chemotherapy] Inoue S. **Gan To Kagaku Ryoho** 1996 Jan;23(2):191-201 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Photodynamic therapy for multiple primary lung cancer] Konaka C, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):31-5 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Impact of rapid advancement of international standardization on technical requirements for new drug registration] Kurokawa T. **Gan To Kagaku Ryoho** 1996 Apr; 23(5):509-16 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Photodynamic therapy for gastric cancer] Mimura S, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):41-6 (5 ref.) (Eng. Abstr.) **(Jpn)**

[T cell receptor V beta repertoire of locoregional lymphocytes in malignant effusions] Miyahara E, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1622-5 (Eng. Abstr.) **(Jpn)**

[Influence of intratumor administration of OK-432 on the tumor selectivity of 5'-DFUR] Ogawa K, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2095-100 (Eng. Abstr.) **(Jpn)**

[Nedaplatin] Ota K. **Gan To Kagaku Ryoho** 1996 Feb; 23(3):379-87 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Contribution of Japan to develop new anticancer agents] Sajjo N. **Gan To Kagaku Ryoho** 1996 Jan;23(2):242-6 (0 ref.) (Eng. Abstr.) **(Jpn)**

[Photodynamic therapy for esophageal cancer] Shimao H, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):36-40 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR] Taguchi T. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1019-29 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of photodynamic therapy] Takemura T, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):16-21 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Development of new anti-cancer agents in Europe] Terada K. **Gan To Kagaku Ryoho** 1996 Jan;23(2):231-7 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Immunotherapy of patients with head and neck carcinomas] Tsukuda M. **Gan To Kagaku Ryoho** 1996 Feb;23(3):283-90 (32 ref.) (Eng. Abstr.) **(Jpn)**

[Evaluation of drug sensitivities to gastric cancers by SDI test--study of quality control of SDI test by simulation test] Yamauchi M, et al. **Hum Cell** 1995 Dec;8(4):163-72 (Eng. Abstr.) **(Jpn)**

[Effects of chemotherapy on the basis of the results of MTT assay for patients with gastrointestinal cancer] Yamaue H, et al. **Hum Cell** 1995 Dec;8(4):185-8 (Eng. Abstr.) **(Jpn)**

[Case report: rheumatoid arthritis complicated by chronic myelogenous leukemia treated with interferon] Abe T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):70-5 (Eng. Abstr.) **(Jpn)**

[Choices of antineoplastic chemotherapy in cancer surgical patients] Saito K, et al. **Nippon Geka Gakkai Zasshi** 1995 Sep;96(9):610-1 **(Jpn)**

[Expression of GP160 mRNA in renal cell carcinoma: an attempt to predict the sensitivity of IFN-alpha therapy] Kimura F, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Sep;86(9):1424-8 (Eng. Abstr.) **(Jpn)**

[Successful treatment of hemopneumothorax with intrapleural OK432 in pulmonary metastases of cutaneous angiosarcoma] Takizawa T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1334-7 (Eng. Abstr.) **(Jpn)**

[Preventive use of retinoids for occurrence of liver neoplasm] Muto Y. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2032-7 (5 ref.) **(Jpn)**

[Drug therapy of hematologic malignancy] Shimoyama M. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):337-41 (15 ref.) **(Jpn)**

[Mechanism of action of antileukemic agents in leukemia chemotherapy] Nakamura T. **Rinsho Ketsueki** 1996 May; 37(5):380-91 (29 ref.) **(Jpn)**

[Colon cancer and vitamin D—in vivo growth inhibition of colon cancer by a fluorinated analogue of 1,25-(OH)2D3, DD-003] Tanaka N, et al. **Seikagaku** 1996 Mar;68(3):214-9 (19 ref.) **(Jpn)**

[Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders] Pawelski S. **Acta Haematol Pol** 1995;26(3):263-8 (32 ref.) (Eng. Abstr.) **(Pol)**

[Clinical pharmacology of all-trans retinoic acid (ATRA)] Robak T. **Acta Haematol Pol** 1995;26(3):269-77 (34 ref.) (Eng. Abstr.) **(Pol)**

[Bone marrow changes in patients with hairy cell leukemia after 2-chlorodeoxyadenosine treatment] Urasiński I, et al. **Acta Haematol Pol** 1996;27(1):49-55 (Eng. Abstr.) **(Pol)**

[Polyneuropathy in non-Hodgkin lymphoma] Bilińska M, et al. **Neurol Neurochir Pol** 1995 May-Jun;29(3):343-52 (Eng. Abstr.) **(Pol)**

[Role of chemotherapy in treatment of osteosarcoma] Perek D, et al. **Pediatr Pol** 1995 Nov;70(11):939-47 (39 ref.) (Eng. Abstr.) **(Pol)**

[Principles of procedure for patients treated with cytostatics] Kuliczkowski K. **Pol Arch Med Wewn** 1995 May; 93(5):377-83 (29 ref.) **(Pol)**

[Selected aspects concerning the possibility of improving treatment results for malignant neoplasms (editorial)] Pawlicki M. **Pol Arch Med Wewn** 1995 Jan;93(1):1-8 **(Pol)**

[The mechanism of the antitumor action of Bacillus intermedius ribonuclease] Kurinenko BM, et al. **Antibiot Khimioter** 1995 May;40(5):12-5 (Eng. Abstr.) **(Rus)**

[New approaches to antitumor therapy: the use of preparations acting on processes regulated by epidermal and/or alpha-transforming growth factors] Kushlinskiĭ NE, et al. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):74-80 (64 ref.) **(Rus)**

[Use of autologous hematopoietic stem cells from peripheral blood for transplantation in patients with hematologic and solid neoplasms after high-dose chemotherapy] Ptushkin VV, et al. **Gematol Transfuziol** 1996 Jan-Feb;41(1):9-13 (Eng. Abstr.) **(Rus)**

[Advances and difficulties of present-day treatment of acute myeloblastic leukemia] Selidovkin GD, et al. **Gematol Transfuziol** 1996 Jan-Feb;41(1):6-9 (Eng. Abstr.) **(Rus)**

[Cyproterone acetate (Androcur-depo) in the treatment of inoperable prostatic cancer] Stepanov VN, et al. **Urol Nefrol (Mosk)** 1995 Nov-Dec;(6):33-6 (Eng. Abstr.) **(Rus)**

[The effectiveness of reaferone in chronic myeloid leukemia assessed with ultrasonic and histomorphologic examination] Abdulkadyrov KM, et al. **Vopr Onkol** 1996;42(3):51-6 (Eng. Abstr.) **(Rus)**

[Decreasing the toxicity of antitumor preparations—the way to enhancing treatment efficacy in malignant tumors] Bogush TA, et al. **Vopr Onkol** 1995;41(2):52-3 **(Rus)**

[The outlook for combining antitumor and activation therapies] Garkavi LKh, et al. **Vopr Onkol** 1995;41(2):47-8 **(Rus)**

[The current potentials and outlook for drug therapy in oncology] Gershanovich ML, et al. **Vopr Onkol** 1995; 41(2):116-24 **(Rus)**

[The pharmacological protection of the body from malignant tumor metastasis] Kinzirskiĭ AS. **Vopr Onkol** 1995; 41(2):46-7 **(Rus)**

[First experience with thermoradiochemotherapy for patients with squamous cell carcinoma of the anal canal] Knysh VI, et al. **Vopr Onkol** 1996;42(3):79-81 **(Rus)**

[The photodynamic therapy of malignant tumors in basic sites with the preparations photohem and photosens (the results of 3 years of observations)] Sokolov VV, et al. **Vopr Onkol** 1995;41(2):134-8 **(Rus)**

[The experimental chemotherapy of malignant tumors today] Syrkin AB, et al. **Vopr Onkol** 1995;41(2):41-5 (23 ref.) **(Rus)**

[New antitumor preparations] Tiuliandin SA. **Vopr Onkol** 1995;41(2):131-3 **(Rus)**

[The determination of individual sensitivity to cytostatics in breast cancer] Voznyĭ EK, et al. **Vopr Onkol** 1995; 41(2):129-30 **(Rus)**

[Can tamoxifen relieve fibromyalgia? (letter)] Simonson N. **Lakartidningen** 1996 Jan 31;93(5):340 **(Swe)**

TOXICITY

Micronuclei induction by carboplatin in human lymphocyte subpopulations. Slavutsky I, et al. **Anticancer Drugs** 1995 Dec;6(6):758-62

Influence of culture media and multidrug resistance on the wheat germ agglutinin (WGA) glycocytochemical expression of two human glioblastoma cell lines. Camby I, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1719-25

Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay. Engblom P, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1743-7

Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines. Houlbrook S, et al. **Anticancer Res** 1996 Jul-Aug; 16(4A):1603-10

In vitro assessment for neurotoxicity of antitumor agents before local administration into central nervous system. Moriuchi S, et al. **Anticancer Res** 1996 Jan-Feb; 16(1):135-40

Antitumor activity of phenothiazine-related compounds. Nagy S, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1915-8

In vitro chemosensitivity testing of human tumours by collagen gel droplet culture and image analysis. Tanigawa N, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1925-30

Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar. Cleaveland ES, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):654-9

Reduction of cis-platinum induced nephrotoxicity by zinc histidine complex : the possible implication of nitric oxide.

Srivastava RC, et al. **Biochem Mol Biol Int** 1995 Jul; 36(4):855–62

4–Ipomeanol and 2–aminoanthracene cytotoxicity in C3H/10T1/2 cells expressing rabbit cytochrome P450 4B1. Smith PB, et al. **Biochem Pharmacol** 1995 Nov 9; 50(10):1567–75

Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes. Nováková O, et al. **Biochemistry** 1995 Sep 26;34(38):12369–78

The stereospecific cytotoxic potency of (6R) and (6S)–5,10–dideazatetrahydrofolate correlates with cellular folylpolyglutamate synthetase levels. Lehman NL. **Biochimie** 1995;77(4):273–8

Improved cytotoxicity of antitumor compounds deliverable by the LDL pathway. Dubowchik GM, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):427–39

Studies on the activity of barnase toxins in vitro and in vivo. Prior TI, et al. **Bioconjug Chem** 1996 Jan–Feb;7(1):23–9

Potentiation of the cytotoxicity of chloroethylnitrosourea by O6–arylmethylguanines. Kohda K, et al. **Biol Pharm Bull** 1995 Mar;18(3):424–30

Relationship between age and nephrotoxicity following single low–dose cisplatin (CDDP) injection in rats. Namikawa K, et al. **Biol Pharm Bull** 1995 Jul;18(7):957–62

A silicon–based biosensor for real–time toxicity testing in normal versus cancer liver cells. Nicolini C, et al. **Biosens Bioelectron** 1995 Fall;10(8):723–33

Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide. Asano T, et al. **Br J Cancer** 1996 Jun; 73(11):1373–80

Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P–glycoprotein in multidrug–resistant MCF–7/Adr cells. Budworth J, et al. **Br J Cancer** 1996 May;73(9):1063–8

Enhancement of sensitivity of human lung adenocarcinoma cells to growth–inhibitory activity of interferon alpha by differentiation–inducing agents. Goto I, et al. **Br J Cancer** 1996 Aug;74(4):546–54

Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L–trans)1,2–diaminocyclohexaneplatinum (II). Rischin D, et al. **Br J Cancer** 1996 Aug;74(4):590–6

Effect of modulation of the transferrin receptor on gallium–67 uptake and cytotoxicity in lymphoma cell lines. van Leeuwen–Stok AE, et al. **Br J Cancer** 1996 Aug; 74(4):619–24

Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor–alpha and cis–diamminedichloroplatinum. Uslu R, et al. **Cancer** 1996 Feb 15;77(4):725–32

Imidazoacridinones arrest cell–cycle progression in the G2 phase of L1210 cells. Augustin E, et al. **Cancer Chemother Pharmacol** 1996;38(1):39–44

The formation and persistence of carboplatin–DNA adducts in rats. Blommaert FA, et al. **Cancer Chemother Pharmacol** 1996;38(3):273–80

Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin–resistant variant (C13*). Moorehead RA, et al. **Cancer Chemother Pharmacol** 1996; 38(3):245–53

Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs. Price GS, et al. **Cancer Chemother Pharmacol** 1996;38(2):129–35

A novel antitumor compound, NC–190, induces topoisomerase II–dependent DNA cleavage and DNA fragmentation. Yamagishi T, et al. **Cancer Chemother Pharmacol** 1996;38(1):29–34

Effects of N(g)–methyl–L–arginine, an inhibitor of nitric oxide synthesis, on interleukin–2–induced capillary leakage and antitumor responses in healthy and tumor–bearing mice. Orucevic A, et al. **Cancer Immunol Immunother** 1996 Jan;42(1):38–46

Studies on the mechanism of sulofenur and LY295501 toxicity: effect on the regulation of cytosolic calcium in relation to cytotoxicity in normal and tumorigenic rat kidney cell lines. Phelps PC, et al. **Cancer Lett** 1995 Oct 20;97(1):7–15

Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Berger B, et al. **Cancer Res** 1996 May 1;56(9):2094–104

Endogenous interleukin 6 is a resistance factor for cis–diamminedichloroplatinum and etoposide–mediated cytotoxicity of human prostate carcinoma cell lines. Borsellino N, et al. **Cancer Res** 1995 Oct 15;55(20):4633–9

Synergism between cisplatin and topoisomerase I inhibitors, NB–506 and SN–38, in human small cell lung cancer cells. Fukuda M, et al. **Cancer Res** 1996 Feb 15;56(4):789–93

Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Hawkins DS, et al. **Cancer Res** 1996 Feb 15;56(4):892–8

Selective damage to carcinoma mitochondria by the rhodacyanine MKT–077. Modica–Napolitano JS, et al. **Cancer Res** 1996 Feb 1;56(3):544–50

Role of the human Y box–binding protein YB–1 in cellular sensitivity to the DNA–damaging agents cisplatin, mitomycin C, and ultraviolet light. Ohga T, et al. **Cancer Res** 1996 Sep 15;56(18):4224–8

Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Pizer ES, et al. **Cancer Res** 1996 Feb 15;56(4):745–51

Cytotoxic effects of gemcitabine–containing regimens against human non–small cell lung cancer cell lines which express different levels of p185neu. Tsai CM, et al. **Cancer Res** 1996 Feb 15;56(4):794–801

In vivo administration of MKT–077 causes partial yet reversible impairment of mitochondrial function. Weisberg EL, et al. **Cancer Res** 1996 Feb 1;56(3):551–5

Molecular mechanisms of toxic effects of fotemustine in rat hepatocytes and subcellular rat liver fractions. Brakenhoff JP, et al. **Carcinogenesis** 1996 Apr;17(4):715–24

Drug–resistant breast cancer cells frequently retain expression of a functional wild–type p53 protein. Gudas JM, et al. **Carcinogenesis** 1996 Jul;17(7):1417–27

The role of acetylation in the mutagenicity of the antitumor agent, batracylin. Stevens GJ, et al. **Carcinogenesis** 1996 Jan;17(1):115–9

Cytotoxic limonoids and tetranortriterpenoids from Melia azedarach. Itokawa H, et al. **Chem Pharm Bull (Tokyo)** 1995 Jul;43(7):1171–5

The allometric approach for interspecies scaling of pharmacokinetics and toxicity of anti–cancer drugs. Paxton JW. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):851–4

Comparative nephrotoxic effects of cis–platinum (II), cis–palladium (II), and cis–rhodium (III) metal coordination compounds in rat kidneys. Bikhazi AB, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jul;111(3):423–7

Toxicity and excretion of cisplatin in the avian kidney. Cacini W, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):343–50

Cisplatin–induced apoptosis in mouse proximal tubular cell line. Takeda M, et al. **Contrib Nephrol** 1996;118:24–8

Strategies to prevent nephrotoxicity of anticancer drugs. Skinner R. **Curr Opin Oncol** 1995 Jul;7(4):310–5 (38 ref.)

Partial N–terminal amino acid sequence of the anti–neoplastic urinary protein (ANUP) and the anti–tumour effect of the N–terminal nonapeptide of the unique cytokine present in human granulocytes. Ridge RJ, et al. **Cytokine** 1996 Jan; 8(1):1–5

Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells. Chapman RS, et al. **Cytometry** 1995 Jul 1;20(3):245–56

Cytotoxic evaluation of some N–acyl and N–acyloxy analogues of 3,5–bis(arylidene)–4–piperidones. Dimmock JR, et al. **Drug Des Discov** 1994 Jul;12(1):19–28

Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine. Ferguson LR, et al. **Environ Mol Mutagen** 1996; 27(4):255–62

Effect of cytokines on the toxicity of cytostatic drugs on leukemic cells in vitro and in vivo. Sundman–Engberg B, et al. **Eur J Haematol** 1996 Jan–Feb;56(1–2):1–6

The synthetic tetrapeptide AcSDKP protects cells that reconstitute long–term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654). Genevay MC, et al. **Exp Hematol** 1996 Jan;24(1):77–81

Effect of the immunomodulator AS101 on chemotherapy–induced multilineage myelosuppression, thrombocytopenia, and anemia in mice. Kalechman Y, et al. **Exp Hematol** 1995 Dec;23(13):1358–66

Neuropeptides and morphological changes in cisplatin–induced dorsal root ganglion neuronopathy. Barajon I, et al. **Exp Neurol** 1996 Mar;138(1):93–104

Mutagenicity of cytostatic drugs in a bacterial system. II. DNA–repair test. Marhan J. **Folia Microbiol (Praha)** 1995; 40(5):462–66

Mutagenicity of cytostatic drugs in a bacterial system. I. Ames test. Marhan J. **Folia Microbiol (Praha)** 1995; 40(5):457–61

Oxidizability and subsequent cytotoxicity of chylomicrons to monocytic U937 and endothelial cells are dependent on dietary fatty acid composition. Mabile L, et al. **Free Radic Biol Med** 1995 Nov;19(5):599–607

Cellular injury induced by oxidative stress is mediated through lysosomal damage. Ollinger K, et al. **Free Radic Biol Med** 1995 Nov;19(5):565–74

Developmental toxicity of N–methylformamide administered by gavage to CD rats and New Zealand white rabbits. Kelich SL, et al. **Fundam Appl Toxicol** 1995 Sep; 27(2):239–46

The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR–2721 on ameliorating cisplatin–induced ototoxicity. Church MW, et al. **Hear Res** 1995 Jun;86(1–2):195–203

Diet is a risk factor in cisplatin ototoxicity. Lautermann J, et al. **Hear Res** 1995 Aug;88(1–2):47–53

An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Cece R, et al. **Histol Histopathol** 1995 Oct; 10(4):837–45

Comparison of the toxicities of cisplatin and a new cisplatin–procaine complex to rat renal cortical slices. Zhang JG, et al. **Hum Exp Toxicol** 1996 Jan;15(1):59–63

Altered biological distribution and decreased neuromuscular toxicity of niosome encapsulated vincristine. Parthasarathi G, et al. **Indian J Exp Biol** 1996 Feb;34(2):124–30

Effect of quercetin on the genotoxic potential of cisplatin. Cross HJ, et al. **Int J Cancer** 1996 May 3;66(3):404–8

Interaction of ionizing radiation with topotecan in two human tumor cell lines. Marchesini R, et al. **Int J Cancer** 1996 May 3;66(3):342–6

Effect of whole–body hyperthermia on the pharmacokinetics and toxicity of lonidamine in dogs. Price GS, et al. **Int J Hyperthermia** 1995 Jul–Aug;11(4):531–44

Cytotoxicity of gallium nitrate in vitro using bladder cancer cells. Aoyagi T, et al. **Int J Urol** 1995 Nov;2(5):288–94

Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P–glycoprotein pharmacophore as revealed by its ATPase activity. Borgnia MJ, et al. **J Biol Chem** 1996 Feb 9;271(6):3163–71

Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha–ras. Monia BP, et al. **J Biol Chem** 1996 Jun 14;271(24):14533–40

Partial inhibition of multidrug resistance by safingol is independent of modulation of P–glycoprotein substrate activities and correlated with inhibition of protein kinase C. Sachs CW, et al. **J Biol Chem** 1995 Nov 3; 270(44):26639–48

Cytosine deaminase gene as a positive selection marker. Wei K, et al. **J Biol Chem** 1996 Feb 16;271(7):3812–6

Antitumor activity of the Cu(II)–mitoxantrone complex and its interaction with deoxyribonucleic acid. Yang P, et al. **J Inorg Biochem** 1996 May 1;62(2):137–45

Novel mutein of tumor necrosis factor alpha (F4614) with reduced hypotensive effect. Shikama H, et al. **J Interferon Cytokine Res** 1995 Aug;15(8):677–84

Selectively cytotoxic diterpenes from Euphorbia poisonii. Fatope MO, et al. **J Med Chem** 1996 Feb 16;39(4):1005–8

Synthesis and growth inhibitory properties of glycosides of 1–O–hexadecyl–2–O–methyl–sn–glycerol, analogs of the antitumor ether lipid ET–18–OCH3 (edelfosine). Marino–Albernas JR, et al. **J Med Chem** 1996 Aug 16; 39(17):3241–7

Antitumor activity of S–(p–bromobenzyl)glutathione diesters in vitro: a structure–activity study. Thornalley PJ, et al. **J Med Chem** 1996 Aug 16;39(17):3409–11

Chemotherapy–induced hemolytic uremic syndrome: description of a potential animal model. Hillyer CD, et al. **J Med Primatol** 1995 Feb;24(2):68–73

Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double–tracer autoradiography in rats. Sugimoto S, et al. **J Neurooncol** 1995;24(3):229–40

Effect of YM294, recombinant human interleukin–11, on carboplatin–induced thrombocytopenia in rats. Taguchi K, et al. **J Pharm Sci** 1995 Dec;84(12):1442–5

Ultrastructural aspects of DRG satellite cell involvement in experimental cisplatin neuronopathy. Cece R, et al. **J Submicrosc Cytol Pathol** 1995 Oct;27(4):417–25

Effects of a new platinum complex on male fertility in rats—collaborative work to determine the optimal period and optimal parameters to detect effects on male fertility in rats. Mizoguchi K, et al. **J Toxicol Sci** 1995 Aug; 20(3):207–16

Effects of repeated doses of compound E for 4 and 9 weeks on the male reproductive organs. Okada F, et al. **J Toxicol Sci** 1995 Aug;20(3):217–27

Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Leibbrandt ME, et al. **Kidney Int** 1995 Sep;48(3):761–70

Quantitative study of vestibulotoxicity induced by gentamicin or cisplatin in the guinea pig. Nakayama M, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):162–7

New chemotherapy agents in the treatment of advanced non–small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. Comis RL, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S63–99 (163 ref.)

Dose–finding study of paclitaxel (Taxol) plus cisplatin in patients with non–small cell lung cancer. European Lung Cancer Working Party. Klastersky J, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S117–25

Current status of structure–activity relationships of platinum anticancer drugs: activation of the trans geometry. Farrell N. **Met Ions Biol Syst** 1996;32:603–39 (104 ref.)

Glutathione–associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Tew KD, et al. **Mol Pharmacol** 1996 Jul;50(1):149–59

Interleukin–1 alpha–induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo. Wang Z, et al. **Mol Pharmacol** 1996 Feb;49(2):269–75

An optimal, generalized sampling time of 30 +/– 6 h after double dosing in the mouse peripheral blood micronucleus test. Higashikuni N, et al. **Mutagenesis** 1995 Jul;10(4):313–9

Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes. Ferguson LR, et al. **Mutat Res** 1996 Aug 17; 355(1–2):91–101 (81 ref.)

Hydroxyurea induces recombination in dividing but not in G1 or G2 cell cycle arrested yeast cells. Galli A, et al. **Mutat Res** 1996 Jul 5;354(1):69–75

Genetic activity profiles of anticancer drugs. Jackson MA, et al. **Mutat Res** 1996 Aug 17;355(1–2):171–208

Mutagenicity of nitrobenzyl derivatives: potential bioreductive anticancer agents. Juneja TR, et al. **Mutat Res** 1995 Nov;348(3):137–45

Effect of preinduction of metallothionein synthesis on clastogenicity of anticancer drugs in mice. Nakagawa I, et al. **Mutat Res** 1995 Sep;348(1):37–43

ANTINEOPLASTIC AGENTS

Characterization of carboplatin-resistant sublines derived from human larynx carcinoma cells. Osmak M, et al. **Mutat Res** 1995 Aug;347(3-4):141-50

A comparison of the genotoxic effects of carboplatin and cisplatin in Escherichia coli. Overbeck TL, et al. **Mutat Res** 1996 Apr 2;362(3):249-59

Cytogenetic damage measured in human sperm following cancer chemotherapy. Robbins WA. **Mutat Res** 1996 Aug 17;355(1-2):235-52 (109 ref.)

The mutagenic properties of DNA minor-groove binding ligands. Turner PR, et al. **Mutat Res** 1996 Aug 17; 355(1-2):141-69 (116 ref.)

Mutagenicity of anticancer drugs in mammalian germ cells. Witt KL, et al. **Mutat Res** 1996 Aug 17;355(1-2):209-34 (207 ref.)

An electrophysiological investigation of the effects of cisplatin and the protective actions of dexamethasone on cultured dorsal root ganglion neurones from neonatal rats. Scott RH, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep;352(3):247-55

Cisplatin nephrotoxicity and protection by silibinin. Gaedeke J, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):55-62

Modification of cisplatin-induced renal p-aminohippurate uptake alteration and lipid peroxidation by thiols, Ginkgo biloba extract, deferoxamine and torbafylline. Inselmann G, et al. **Nephron** 1995;70(4):425-9

The development of striatal patch/matrix organization after prenatal methylazoxymethanol: a combined immunocytochemical and bromo-deoxy-uridine birthdating study. Snyder-Keller AM. **Neuroscience** 1995 Oct;68(3):751-63

Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Williams PC, et al. **Neurosurgery** 1995 Jul;37(1):17-27; discussion 27-8

The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Goldberg Y, et al. **Oncogene** 1996 Feb 15;12(4):893-901

Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Zhang L, et al. **Oncogene** 1996 Feb 1;12(3):571-6

Experimental study on safety for granulopoiesis in simultaneous therapy with recombinant human granulocyte colony-stimulating factor and chemotherapy. Kabaya K, et al. **Oncol Res** 1995;7(3-4):165-71

Possible correlation between ormaplatin biotransformations and neurotoxicity. Sakata M, et al. **Oncol Res** 1995; 7(2):67-71

Pentoxifylline potentiates the antitumor effect of cisplatin and etoposide on human lung cancer cell lines. Ohsaki Y, et al. **Oncology** 1996 Jul-Aug;53(4):327-33

Ototoxicity of the new platinum anticancer agent TRK-710 in comparison with cisplatin. Saito T, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Sep-Oct; 57(5):250-5

Effect of doxorubicin and phenytoin on sea urchin development. Sconzo G, et al. **Pharmazie** 1995 Sep; 50(9):616-9

Cytotoxicity of diterpenes from Premna schimperi and Premna oligotricha [letter] Habtemariam S. **Planta Med** 1995 Aug;61(4):368-9

The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Fick J, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11071-5

Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. Kuan CT, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):974-8

Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Li W, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24; 92(22):10436-40

The role of the renin-angiotensin system in cisplatin nephrotoxicity. Deegan PM, et al. **Ren Fail** 1995 Nov; 17(6):665-74

Protective effect of N-benzoyl-beta-alanine against cisplatin nephrotoxicity in rats. Tokunaga J, et al. **Ren Fail** 1996 Mar;18(2):225-40

Testicular degeneration induced in rat offspring by maternal treatment with sobuzoxane. Kato I, et al. **Reprod Toxicol** 1996 May-Jun;10(3):209-14

Nephrotoxic effects of platinum cytostatics--preventative effects of nifedipine and cimetidine. Haragsim L, et al. **Sb Lek** 1994;95(3):173-83

Semiquantitative analysis by scanning electron microscopy of cochlear hair cell damage by ototoxic drugs. Saito T, et al. **Scanning Microsc** 1995 Mar;9(1):271-80; discussion 280-1

Measurement of DNA integrity and structure in Xenopus embryos in the presence of hydroxyurea, actinomycin-D, and triethylenemelamine using the fluorescent probe Hoechst 33258. Stringer BK, et al. **Teratog Carcinog Mutagen** 1995;15(2):53-62

Anticancer drug toxicity via cytokine production: the hydroxyurea paradigm. Navarra P, et al. **Toxicol Lett** 1995 Dec;82-83:167-71

Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide. Deegan PM, et al. **Toxicology** 1996 Jan 8;106(1-3):159-66

[Protection from procarbazine induced testicular toxicity by gonadal steroid hormones] Ye W, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Jun; 17(3):204-9 (Eng. Abstr.) **(Chi)**

[Reduced nutritional status enhances ototoxicity] Lautermann J, et al. **Laryngorhinootologie** 1995 Dec;74(12):724-7 (Eng. Abstr.) **(Ger)**

[Decreasing the toxicity of antitumor preparations--the way to enhancing treatment efficacy in malignant tumors] Bogush TA, et al. **Vopr Onkol** 1995;41(2):52-3 **(Rus)**

ANTINEOPLASTIC AGENTS, ALKYLATING

ADMINISTRATION & DOSAGE

Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study. Andersson H, et al. **Acta Oncol** 1995;34(6):821-7

High-dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer. deMagalhaes-Silverman M, et al. **Am J Clin Oncol** 1996 Apr;19(2):169-73

Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma. Leone B, et al. **Am J Clin Oncol** 1996 Apr;19(2):132-5

A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa. Stein ME, et al. **Am J Clin Oncol** 1996 Aug;19(4):386-8

Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. Williamson SK, et al. **Am J Clin Oncol** 1996 Aug; 19(4):368-70

Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalan. van Ginkel RJ, et al. **Arch Surg** 1996 Jun;131(6):672-4

Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer. Levi JA, et al. **Aust N Z J Med** 1995 Oct;25(5):474-8

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [letter; comment] Anand A, et al. **Cancer** 1996 May 1; 77(9):1959-60. Comment on: Cancer 1995 Dec 1;76(11):2230-6.

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [see comments] Shin DM, et al. **Cancer** 1995 Dec 1; 76(11):2230-6. Comment in: Cancer 1996 May 1;77(9):1959-60.

A phase I pilot study of BCNU plus thymidine in patients with refractory cancer. Schultz MZ, et al. **Cancer Invest** 1996;14(3):218-24

ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts. Blakey DC, et al. **Cancer Res** 1996 Jul 15;56(14):3287-92

Intrathecal chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea encapsulated into hybrid liposomes for meningeal gliomatosis: an experimental study. Kitamura I, et al. **Cancer Res** 1996 Sep 1;56(17):3986-92

Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Sangfelt O, et al. **Int J Cancer** 1995 Oct 9; 63(2):190-2

Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs [see comments] Klop WM, et al. **J Am Coll Surg** 1996 Jun;182(6):467-72. Comment in: J Am Coll Surg 1996 Jun;182(6):547-8.

Effective therapy: repeat limb perfusion for recurrent melanoma [editorial; comment] Krementz ET. **J Am Coll Surg** 1996 Jun;182(6):547-8. Comment on: J Am Coll Surg 1996 Jun;182(6):467-72.

Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. Bregni M, et al. **J Clin Oncol** 1996 Feb;14(2):628-35

Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. Hammel P, et al. **J Clin Oncol** 1995 Oct;13(10):2524-9

The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. Brem H, et al. **J Neurooncol** 1995 Nov;26(2):111-23

Fractionated high-dose cyclophosphamide for advanced pediatric solid tumors. Chan LL, et al. **J Pediatr Hematol Oncol** 1996 Feb;18(1):63-7

Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Meyskens FL Jr, et al. **Leuk Res** 1995 Sep;19(9):605-12

Mobilization/transplantation of peripheral blood progenitor cells for aggressive non-Hodgkin's lymphoma with marrow involvement. Santini G, et al. **Leukemia** 1996 Jun; 10 Suppl 2:s88-91

Heat-mediated selective delivery of liposome-associated melphalan in murine melanoma. Chelvi PT, et al. **Melanoma Res** 1995 Oct;5(5):321-6

Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. Chang AY, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):74-7

Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies. Hoffman PC, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):11-5

Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Hudis CA, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):18-23

Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. Masters GA, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):11-8

Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. Palackdharry CS. **Semin Oncol** 1996 Jun;23(3 Suppl 6):78-83

Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer. Perkins JB, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):42-6

Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer. Souquet PJ, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):8-10

The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix. Thigpen T, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):56-64 (52 ref.)

High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. Tursz T. **Semin Oncol** 1996 Jun;23(3 Suppl 7):34-9

Ifosfamide in the treatment of pediatric malignancies. Voûte PA, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 7):8-11

[In vitro induction of apoptosis in chronic lymphoid leukemia B lymphocytes by theophylline: therapeutic applications] Binet JL, et al. **Bull Acad Natl Med** 1995 Oct; 179(7):1379-91; discussion 1391-2 (Eng. Abstr.) **(Fre)**

[Study on conservative treatment of retinoblastoma--effect of intravitreal injection of melphalan on the rabbit retina] Ueda M, et al. **Nippon Ganka Gakkai Zasshi** 1995 Nov; 99(11):1230-5 (Eng. Abstr.) **(Jpn)**

[Clinicopathological evaluation of etoposide or estramustine phosphate in castrated patients with advanced prostatic cancer] Matsuda H, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct;86(10):1530-7 (Eng. Abstr.) **(Jpn)**

[The cytogenetic effect of ultralow doses of nitrosomethylurea] Fomina MM, et al. **Izv Akad Nauk Ser Biol** 1995 Jul-Aug;(4):430-4 (Eng. Abstr.) **(Rus)**

[Chemoembolization of the hepatic artery in the treatment of primary and metastatic liver cancer] Granov AM, et al. **Vestn Rentgenol Radiol** 1996 Mar-Apr;(2):34-8 (Eng. Abstr.) **(Rus)**

[Regression of portal vein thrombus after intravascular treatment of a patient with hepatic metastasis of carcinoid] Tarazov PG, et al. **Vestn Rentgenol Radiol** 1995 May-Jun; (3):51-2 **(Rus)**

ADVERSE EFFECTS

Increased risk of leukaemia in patients with juvenile chronic arthritis treated with chlorambucil. Kauppi MJ, et al. **Acta Paediatr** 1996 Feb;85(2):248-50

Effect of polysaccharide-peptide (PSP), an extract from yun-zhi, on chemotherapy-induced cytopenias. Zhou LQ, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):143-6

Ifosfamide-induced nonconvulsive status epilepticus. Bhardwaj A, et al. **Ann Pharmacother** 1995 Dec; 29(12):1237-9

Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies. deMagalhaes-Silverman M, et al. **Bone Marrow Transplant** 1996 Mar;17(3):329-33

Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Prince HM, et al. **Br J Haematol** 1996 Apr; 93(1):142-5

Karyotype conversion in two patients with chronic myeloid leukaemia after busulphan-induced marrow hypoplasia. Xue Y, et al. **Br J Haematol** 1996 Mar;92(4):944-6

Severe, irreversible renal failure after ifosfamide treatment. A clinicopathologic report of two patients. Berns JS, et al. **Cancer** 1995 Aug 1;76(3):497-500

A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Ho PT, et al. **Cancer** 1995 Dec 15;76(12):2557-64

Human papillomavirus in cyclophosphamide and diverticulum-associated squamous cell carcinoma of urinary bladder: a case report. Wang JS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Apr;57(4):305-9

Variability in DNA repair and individual susceptibility to genotoxins. Kyrtopoulos SA. **Clin Chem** 1995 Dec;41(12 Pt 2):1848-53 (51 ref.)

High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. Zwaveling JH, et al. **Crit Care Med** 1996 May; 24(5):765-70

Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics [see comments] Boddy AV, et al. **Eur J Cancer** 1996 Jun;32A(7):1179–84. Comment in: Eur J Cancer 1996 Jun;32A(7):1100–1.

Ifosfamide and paediatrics: should this marriage be saved? [editorial; comment] Womer RB. **Eur J Cancer** 1996 Jun; 32A(7):1100–1. Comment on: Eur J Cancer 1996 Jun;32A(7):1179–84.

Recombinant human erythropoietin at high doses stimulates thrombopoiesis: treatment for protracted severe myelosuppression complicating interferon-alpha and busulfan therapy for chronic myelogenous leukaemia [letter] Kitagawa S, et al. **Eur J Haematol** 1995 Oct; 55(4):285–6

Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Izumi T, et al. **Int J Hematol** 1996 Jul;64(1):73–7 (17 ref.)

Hyperbaric oxygenation therapy for cyclophosphamide-induced haemorrhagic cystitis. Yazawa H, et al. **Int Urol Nephrol** 1995;27(4):381–5

Allergic reactions to cyclophosphamide: delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients. Popescu NA, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):26–33

Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. Hawkins MM, et al. **J Natl Cancer Inst** 1996 Mar 6;88(5):270–8

The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. Brem H, et al. **J Neurooncol** 1995 Nov;26(2):111–23

Clobazam for seizure prophylaxis during busulfan chemotherapy [letter] Schwarer AP, et al. **Lancet** 1995 Nov 4;346(8984):1238

Ifosfamide nephrotoxicity in children: histopathological features in two cases. Morland BJ, et al. **Med Pediatr Oncol** 1996 Jul;27(1):57–61 (17 ref.)

Progressive glomerular toxicity of ifosfamide in children. Prasad VK, et al. **Med Pediatr Oncol** 1996 Sep;27(3):149–55

Local and systemic toxicity in borderline true hyperthermic isolated perfusion for lower limb melanoma. Pace M, et al. **Melanoma Res** 1995 Oct;5(5):371–6

Diphenhydramine provides relief of cyclophosphamide-related symptoms. Purl S, et al. **Oncol Nurs Forum** 1996 Apr;23(3):542

Ethmoid sinus leiomyosarcoma after cyclophosphamide treatment. Reich DS, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):495–8

Concentrating capacity in ifosfamide-induced severe renal dysfunction. Rossi R, et al. **Ren Fail** 1995 Sep;17(5):551–7

Oral administration of mesna with ifosfamide. Goren MP. **Semin Oncol** 1996 Jun;23(3 Suppl 6):91–6 (51 ref.)

Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. Markman M, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):97–8

Recall lung pneumonitis due to carmustine after radiotherapy. Thomas PS, et al. **Thorax** 1995 Oct;50(10):1116–8

Intravesical thiotepa-induced eosinophilic cystitis. Choe JM, et al. **Urology** 1995 Nov;46(5):729–31 (15 ref.)

[Transitional cell carcinoma of the ureter and cyclophosphamide: apropos of a case] Ponsot Y, et al. **Prog Urol** 1995 Sep;5(4):578–9 (8 ref.) (Eng. Abstr.) **(Fre)**

[Successful treatment with methylene blue of ifosfamide-induced central nervous system effects (letter)] Demandt M, et al. **Dtsch Med Wochenschr** 1996 Apr 26; 121(17):575 **(Ger)**

ANTAGONISTS & INHIBITORS

Protective effect of the thiol agent WR-2721 against cyclophosphamide-induced cytotoxicity in the mouse erythropoietic system. Mazur L, et al. **Acta Physiol Hung** 1995;83(2):189–94

BLOOD

A gas-chromatographic assay method for busulfan with sensitivity for test dose therapeutic monitoring. Burns RB, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1073–8

CHEMICAL SYNTHESIS

Nitroimidazole-based "extruded mustards" designed as reductively activated hypoxia-selective cytotoxins. Hay MP, et al. **Anticancer Drug Des** 1996 Jul;11(5):383–402

Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase. Satyam A, et al. **J Med Chem** 1996 Apr 12;39(8):1736–47

Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). Springer CJ, et al. **J Med Chem** 1995 Dec 22;38(26):5051–65

Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. Tercel M, et al. **J Med Chem** 1996 Mar 1;39(5):1084–94

CHEMISTRY

Synthesis, DNA binding, footprinting and in vitro antitumour studies of a meta-hydroxy analogue of Hoechst 33258. Ebrahimi SE, et al. **Anticancer Drug Des** 1995 Sep; 10(6):463–79

DNA alkylation by minor groove-binding N1-alkoxyalkyl-bis-benzimidazoles. Gupta R, et al. **Anticancer Drug Des** 1995 Sep;10(6):451–61

Stability of ifosfamide in solutions for multiday infusion by external pump. Leone L, et al. **Anticancer Drugs** 1995 Aug; 6(4):604–7

Effects of bizelesin (U-77779), a bifunctional alkylating minor groove agent, on genomic and simian virus 40 DNA. Woynarowski JM, et al. **Biochemistry** 1995 Oct 10; 34(40):13042–50

Sequence specificity of alkylation for a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size: evidence for increased cytotoxicity with enhanced sequence specificity. Wyatt MD, et al. **Biochemistry** 1995 Oct 10;34(40):13034–41

CBI-CDPBO1 and CBI-CDPBI1: CC-1065 analogs containing deep-seated modifications in the DNA binding subunit. Boger DL, et al. **Bioorg Med Chem** 1995 Jun; 3(6):761–7

Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Bhagwatwar HP, et al. **Cancer Chemother Pharmacol** 1996;37(5):401–8

Trenimon: structure and reactivity of a versatile chemical agent. Rademacher P, et al. **Mutat Res** 1995 Nov; 340(1):37–49 (76 ref.)

METABOLISM

Sequence-specific DNA interactions by novel alkylating anthracycline derivatives. Marchini S, et al. **Anticancer Drug Des** 1995 Dec;10(8):641–53

Structural characterization of the 1:1 adduct formed between the antitumor antibiotic hedamycin and the oligonucleotide duplex d(CACGTG)2 by 2D NMR spectroscopy. Pavlopoulos S, et al. **Biochemistry** 1996 Jul 23; 35(29):9314–24

Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Boddy AV, et al. **Cancer Chemother Pharmacol** 1996;38(2):147–54

Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients. Granvil CP, et al. **Cancer Chemother Pharmacol** 1996;37(5):451–6

Postlabeling detection of DNA adducts of antitumor alkylating agents. Zhou GH, et al. **Cancer Chemother Pharmacol** 1996;38(1):71–80

Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Gibbs JP, et al. **Cancer Res** 1996 Aug 15;56(16):3678–81

Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Dirven HA, et al. **Chem Res Toxicol** 1995 Oct-Nov;8(7):979–86

PHARMACOKINETICS

Excretion of a radiolabelled anticancer biodegradable polymeric implant from the rabbit brain. Domb AJ, et al. **Biomaterials** 1995 Sep;16(14):1069–72

3-methyladenine-DNA-glycosylase and O6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines. Damia G, et al. **Br J Cancer** 1996 Apr;73(7):861–5

Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients. Granvil CP, et al. **Cancer Chemother Pharmacol** 1996;37(5):451–6

ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour. Masters JR, et al. **Cancer Chemother Pharmacol** 1996; 38(1):59–64

Dosing of thioTEPA for myeloablative therapy. Przepiorka D, et al. **Cancer Chemother Pharmacol** 1995;37(1-2):155–60

Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Vassal G, et al. **Cancer Chemother Pharmacol** 1996;37(3):247–53

Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Devineni D, et al. **Cancer Res** 1996 May 1;56(9):1983–7

Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C. Xia H, et al. **Cancer Res** 1996 Aug 1;56(15):3495–8

Short-term versus continuous infusion: no influence on ifosfamide side-chain metabolism [letter] Boos J, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2417–8

Pharmacokinetics of the 13C labeled anticancer agent temozolomide detected in vivo by selective cross-polarization transfer. Artemov D, et al. **Magn Reson Med** 1995 Sep;34(3):338–42

Influence of Aroclor 1254, phenobarbital, beta-naphthoflavone, and ethanol pretreatment on the biotransformation of cyclophosphamide in male and female rats. Sessink PJ, et al. **Toxicology** 1996 Aug 16; 112(2):141–50

PHARMACOLOGY

Antitumor activity of an alkylating derivative of dipyridamole. Andreani A, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1831–3

In vitro cytotoxic activity of two potential anticancer drugs isolated from Strychnos: strychnopentamine and usambarensine. Bonjean KA, et al. **Anticancer Res** 1996 May-Jun;16(3A):1129–37

On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Basak J. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):509–14

Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea. Pegg AE, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1141–8

The influence of linker chain length on the sequence specificity of DNA damage by n-bromoalkylphenanthridinium bromides in plasmid DNA and in intact human cells. Murray V, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1-2):79–86

Synthesis, DNA interactions and biological activity of DNA minor groove targeted polybenzamide-linked nitrogen mustards. Atwell GJ, et al. **Bioorg Med Chem** 1995 Jun; 3(6):679–91

Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumor cells. Frank AJ, et al. **Blood** 1996 Aug 1;88(3):977–84

Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas. Kaaijk P, et al. **Br J Cancer** 1996 Jul; 74(2):187–93

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Wedge SR, et al. **Br J Cancer** 1996 Feb;73(4):482–90

Antitumor activity of treosulfan in human lung carcinomas. Köpf-Maier P, et al. **Cancer Chemother Pharmacol** 1996; 37(3):211–21

Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta. Moynihan K, et al. **Cancer Chemother Pharmacol** 1996;38(4):349–54

Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome. Gorelik L, et al. **Cancer Immunol Immunother** 1995 Dec;41(6):363–74

Effects of ifosfamide on immunocompetent effector cells. Multhoff G, et al. **Cancer Immunol Immunother** 1996 May; 42(4):251–4

Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Chen L, et al. **Cancer Res** 1996 Mar 15;56(6):1331–40

DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Eder JP Jr, et al. **Cancer Res** 1995 Dec 15;55(24):6109–16

Increased sensitivity to cisplatin by nm23-transfected tumor cell lines. Ferguson AW, et al. **Cancer Res** 1996 Jul 1; 56(13):2931–5

Increased resistance to N,N',N"-triethylenethiophosphoramide (thiotepa) in cells expressing the Escherichia coli formamidopyrimidine-DNA glycosylase. Gill RD, et al. **Cancer Res** 1996 Aug 15;56(16):3721–4

Transfection of complementary DNAs for the heavy and light subunits of human gamma-glutamylcysteine synthetase results in an elevation of intracellular glutathione and resistance to melphalan. Mulcahy RT, et al. **Cancer Res** 1995 Nov 1;55(21):4771–5

Wild-type p53 renders mouse astrocytes resistant to 1,3-Bis(2-chloroethyl)-1-nitrosourea despite the absent of a p53-dependent cell cycle arrest. Nutt CL, et al. **Cancer Res** 1996 Jun 15;56(12):2748–51

Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Mattes WB, et al. **Carcinogenesis** 1996 Apr;17(4):643–8

Chronometaanalysis: circasemiseptan (3.5-day) pattern in mitotic activity of murine sarcoma after treatment with cyclophosphamide. Focan C, et al. **In Vivo** 1995 Jul-Aug; 9(4):401–6

Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Damia G, et al. **Int J Cancer** 1996 Jun 11;66(6):779–83

De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross-linking and lethality. Bunting KD, et al. **J Biol Chem** 1996 May 17;271(20):11884–90

Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. Bunting KD, et al. **J Biol Chem** 1996 May 17;271(20):11891–6

Inhibition of initiation of simian virus 40 DNA replication in infected BSC-1 cells by the DNA alkylating drug adozelesin. Cobuzzi RJ Jr, et al. **J Biol Chem** 1996 Aug 16;271(33):19852–9

Protonophoric activity of ellipticine and isomers across the energy-transducing membrane of mitochondria. Schwaller MA, et al. **J Biol Chem** 1995 Sep 29;270(39):22709–13

Effect of camel urine on the cytological and biochemical changes induced by cyclophosphamide in mice. al-Harbi MM, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):129–37

In vivo antitumor activity of hexamethylmelamine against human breast, stomach and colon carcinoma xenografts. Tanino H, et al. **Jpn J Cancer Res** 1995 Aug;86(8):770–5

Comparison of the effects of 2–chlorodeoxyadenosine and melphalan myeloma cell lines. Hjertner O, et al. **Leuk Res** 1996 Feb;20(2):155–60

Triazene compounds induce apoptosis in O6–alkylguanine–DNA alkyltransferase deficient leukemia cell lines. Tentori L, et al. **Leukemia** 1995 Nov; 9(11):1888–95

Buthionine sulfoximine induction of gamma–L–glutamyl–L–cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine–induced DNA–DNA cross–linking and cytotoxicity in human glioma cells. Ali–Osman F, et al. **Mol Pharmacol** 1996 Jun; 49(6):1012–20

DNA adducts from chemotherapeutic agents. Lawley PD, et al. **Mutat Res** 1996 Aug 17;355(1–2):13–40 (174 ref.)

Identification of a 116 kDa protein able to bind 1,3–bis(2–chloroethyl)–1–nitrosourea–damaged DNA as poly(ADP–ribose) polymerase. Malapetsa A, et al. **Mutat Res** 1996 Jan 2;362(1):41–50

Thymidine kinase deficient cells with decreased TTP pools are hypersensitive to DNA alkylating agents. Wakazono Y, et al. **Mutat Res** 1996 Jan 2;362(1):119–25

Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi–functional alkylating agents. Yen L, et al. **Mutat Res** 1995 Nov;337(3):179–89

In vivo and in vitro studies of cyclophosphamide chemotherapy in a mouse mammary carcinoma by 31P NMR spectroscopy. Street JC, et al. **NMR Biomed** 1995 Jun;8(4):149–58

The use of alpha–DNA as an internal standard in the detection and quantitation of DNA damage in specific genes using Southern blotting. Sunters A, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2456–7

Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild–type and repair–deficient cell lines [corrected and republished with original paging, article originally printed in Oncol Res 1995;7(1):39–47] Kim SY, et al. **Oncol Res** 1995;7(5):39–47

Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild–type and repair–deficient cell lines [corrected and republished in Oncol Res 1995;7(5):39–47] Rockwell S, et al. **Oncol Res** 1995;7(1):39–47

Characterization of alkylating versus intercalating anticancer drug–induced effects on cell survival, cell cycle kinetic and morphonuclear pattern of three neoplastic cells lines growing in vitro. Pauwels O, et al. **Pharm Res** 1995 Jul; 12(7):1011–8

Toward antibody–directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing. Wentworth P, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):799–803

Cyclophosphamide administered repeatedly to the male rat and as a single dose to the female rat. Its effects on hepatic and pulmonary P450 and associated enzymes. Angley MT, et al. **Xenobiotica** 1995 Nov;25(10):1051–62

Effect of cyclophosphamide administration on the activity and relative content of hepatic P4502D1 in rat. Laslett TJ, et al. **Xenobiotica** 1995 Nov;25(10):1031–9

THERAPEUTIC USE

Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro. Behnam Motlagh P, et al. **Acta Oncol** 1995;34(6):871–5

Increased risk of leukaemia in patients with juvenile chronic arthritis treated with chlorambucil. Kauppi MJ, et al. **Acta Paediatr** 1996 Feb;85(2):248–50

A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. Huber MH, et al. **Am J Clin Oncol** 1996 Aug;19(4):379–82

Evaluation of ifosfamide plus mesna as first–line chemotherapy in women with metastatic breast cancer. Ingle JN, et al. **Am J Clin Oncol** 1995 Dec;18(6):498–501

Intermediate doses of cyclophosphamide alone or following adriamycin in advanced breast cancer. A pilot study. Zambetti M, et al. **Am J Clin Oncol** 1996 Feb;19(1):82–6

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Skinner M, et al. **Am J Med** 1996 Mar;100(3):290–8

Antitumor activity of an alkylating derivative of dipyridamole. Andreani A, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1831–3

Conventional isolated hyperthermic antiblastic perfusion in the treatment of recurrent limb melanoma. Decian F, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2017–24

Interferon–alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon–alpha [letter] Hasford J, et al. **Blood** 1996 Jun 15;87(12):5384–91

High–dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement [letter] Moreau P, et al. **Blood** 1996 Apr 1; 87(7):3063–4

Autotransplants in multiple myeloma: what have we learned? Vesole DH, et al. **Blood** 1996 Aug 1;88(3):838–47

Tandem high–dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bitran JD, et al. **Bone Marrow Transplant** 1996 Feb;17(2):157–62

Anti–tumour effects of an antibody–carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Blakey DC, et al. **Br J Cancer** 1995 Nov;72(5):1083–8

Intermediate–dose melphalan (IDM) combined with G–CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma. Lokhorst HM, et al. **Br J Haematol** 1996 Jan;92(1):44–8

A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Ringdén O, et al. **Br J Haematol** 1996 Jun 1;93(3):637–45

Single–centre prospective study of isolated limb perfusion with melphalan in the treatment of subungual malignant melanoma. Lingam MK, et al. **Br J Surg** 1995 Oct; 82(10):1343–5

Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83–02. Werner–Wasik M, et al. **Cancer** 1996 Apr 15;77(8):1535–43

Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporine. Steele TA, et al. **Cancer Biother** 1995 Winter;10(4):307–15

Alkylating agents. Berger NA. **Cancer Chemother Biol Response Modif** 1996;16:28–38 (68 ref.)

Phase II study of second–line treatment with high–dose cyclophosphamide in recurrent metastatic breast cancer. Hansen F, et al. **Cancer Chemother Pharmacol** 1996; 37(4):377–81

Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice. Muckenschnabel I, et al. **Cancer Chemother Pharmacol** 1996;38(1):88–94

Transforming growth factor–beta in in vivo resistance. Teicher BA, et al. **Cancer Chemother Pharmacol** 1996; 37(6):601–9

Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Belanich M, et al. **Cancer Res** 1996 Feb 15;56(4):783–8

Estramustine revisited. Kreis W. **Cancer Treat Res** 1995; 78:163–84 (90 ref.)

Inter– and intracellular heterogeneity of O6–alkylguanine–DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy. Lee SM, et al. **Carcinogenesis** 1996 Apr; 17(4):637–41

Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Lee CR, et al. **Eur J Gynaecol Oncol** 1996;17(2):99–103

Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Rose PG, et al. **Gynecol Oncol** 1996 Jul;62(1):100–2

Topical treatment of early cutaneous T–cell lymphoma. Ramsay DL, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1031–56 (84 ref.)

Pharmacology, relative bioavailability, and toxicity of three different oral cyclophosphamide preparations in a randomized, cross–over study. Stewart DJ, et al. **Invest New Drugs** 1995;13(1):99–107

Autologous peripheral–blood progenitor–cell support following high–dosechemotherapy or chemoradiotherapy in patients with high–risk multiple myeloma. Marit G, et al. **J Clin Oncol** 1996 Apr;14(4):1306–13

Ifosfamide seven–day infusion for recurrent and cisplatin refractory ovarian cancer. Dorval T, et al. **J Infus Chemother** 1996 Winter;6(1):47–9

A phase II study of every other day high–dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study. Heideman RL, et al. **J Neurooncol** 1995;25(1):77–84

Results of a randomized trial comparing intra–arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A. Hiesiger EM, et al. **J Neurooncol** 1995; 25(2):143–54

Isolated hyperthermic limb perfusion chemotherapy in Merkel cell tumour: a case report. Dawson R, et al. **J R Coll Surg Edinb** 1996 Aug;41(4):255–6

Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia [letter] Binet JL, et al. **Leukemia** 1995 Dec; 9(12):2159–61

Low–dose melphalan for treatment of high–risk myelodysplastic syndromes. Omoto E, et al. **Leukemia** 1996 Apr;10(4):609–14

Treatment of patients with pineoblastoma with high dose cyclophosphamide. Ashley DM, et al. **Med Pediatr Oncol** 1996 Jun;26(6):387–92

Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high–dose cyclophosphamide. McCowage G, et al. **Med Pediatr Oncol** 1996 Jul;27(1):32–9

Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience. Pratt CB, et al. **Med Pediatr Oncol** 1996 Sep;27(3):145–8

Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. Sutton G, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):747–50

Elimination of EL–4 and L1210 murine tumors by 1,3–bis (2–chloroethyl)–1–nitrosourea requires an intact immune response. Steele TA, et al. **Proc Soc Exp Biol Med** 1996 May;212(1):63–8

Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node–positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project. Schmidt JD, et al. **Prostate** 1996 Jan;28(1):51–7

Interactions of BMS–181174 and radiation: studies with EMT6 cells in vitro and in solid tumors. Rockwell S, et al. **Radiother Oncol** 1996 Apr;39(1):65–71

Clinical Applications of Alkylating Agents. Proceedings of a Cleveland Clinic Foundation CME program. January 12–13, 1996. **Semin Oncol** 1996 Jun;23(3 Suppl 6):1–104; quiz 105–16

Ifosfamide in the treatment of lymphoma. Coiffier B. **Semin Oncol** 1996 Jun;23(3 Suppl 7):2–7 (46 ref.)

Ifosfamide in the treatment of soft tissue sarcomas. Connelly EF, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):16–21 (21 ref.)

High–dose ifosfamide in the treatment of sarcomas of soft tissues and bone. Demetri GD. **Semin Oncol** 1996 Jun;23(3 Suppl 6):22–6 (19 ref.)

Ifosfamide in the treatment of small cell lung cancer. Ettinger DS. **Semin Oncol** 1996 Jun;23(3 Suppl 6):2–6 (20 ref.)

Ifosfamide in non–small cell lung cancer. Johnson DH. **Semin Oncol** 1996 Jun;23(3 Suppl 6):7–10 (27 ref.)

Ifosfamide in the treatment of ovarian cancer. Markman M. **Semin Oncol** 1996 Jun;23(3 Suppl 6):47–9 (22 ref.)

Ifosfamide in the treatment of germ cell tumors. Nichols CR. **Semin Oncol** 1996 Jun;23(3 Suppl 6):65–73 (55 ref.)

Ifosfamide in the treatment of breast cancer. Overmoyer BA. **Semin Oncol** 1996 Jun;23(3 Suppl 6):38–41 (24 ref.)

Ifosfamide in the treatment of non–Hodgkin's lymphoma. Pohlman B. **Semin Oncol** 1996 Jun;23(3 Suppl 6):27–32 (24 ref.)

Ongoing clinical studies of ifosfamide for pediatric cancer in the United States. Pratt CB. **Semin Oncol** 1996 Jun;23(3 Suppl 6):84–90 (51 ref.)

Ifosfamide in the treatment of bladder cancer. Roth BJ. **Semin Oncol** 1996 Jun;23(3 Suppl 6):50–5 (48 ref.)

Dose–intensive ifosfamide for the treatment of non–Hodgkin's lymphoma. Vose JM. **Semin Oncol** 1996 Jun;23(3 Suppl 6):33–7 (20 ref.)

[Treatment of multiple myeloma—melphalan monotherapy after bone marrow transplantation] Hájek R, et al. **Vnitr Lek** 1996 Apr;42(4):278–84 (0 ref.) (Eng. Abstr.) **(Cze)**

[Efficacy of the tumor necrosis factor–alpha (rTNF–alpha) associated with interferon–gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4–year experience] Lejeune F, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):561–7 (Eng. Abstr.) **(Fre)**

[Ifosfamide in pediatric malignancy—experiences in the Northern Israel Oncology Center] Roguin A, et al. **Harefuah** 1996 Apr 15;130(8):511–4, 584 (Eng. Abstr.) **(Heb)**

[A clinico–morphological analysis of the efficacy of therapy in chronic glomerulonephritis using prednisone, a cytostatic, an anticoagulant and an antiaggregant] Ratner MIa, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):32–5 (Eng. Abstr.) **(Rus)**

[Neuro–Behçet: a follow–up of 4 cases treated with chlorambucil] Mateos–Colino A, et al. **An Med Interna** 1995 Dec;12(12):600–2 (Eng. Abstr.) **(Spa)**

TOXICITY

Cytotoxicity of BMS–181174. Effects of hypoxia, dicoumarol, and repair deficits. Rockwell S, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1239–43

Retrovirus–mediated transfer of the human O6–methylguanine–DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Wang G, et al. **Biochem Pharmacol** 1996 May 3;51(9):1221–8

Alkylation of DNA and its aftermath. Lawley PD. **Bioessays** 1995 Jun;17(6):561–8 (54 ref.)

Long–term protection of hematopoiesis against the cytotoxic effects of multiple doses of nitrosourea by retrovirus–mediated expression of human O6–alkylguanine–DNA–alkyltransferase. Jelínek J, et al. **Blood** 1996 Mar 1;87(5):1957–61

Effect of oral chemotherapy on the mitochondrial size of mouse intestinal cells. Bessler H, et al. **Cancer Chemother Pharmacol** 1996;38(1):35–8

Doxorubicin–induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors. van Acker SA, et al. **Cancer Chemother Pharmacol** 1996;38(1):95–101

O6–alkylguanine–DNA alkyltransferase attenuates

triazene–induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia. Graziani G, et al. **Cancer Res** 1995 Dec 15;55(24):6231–6

Mutational fingerprint induced by the antineoplastic drug chloroethyl–cyclohexyl–nitrosourea in mammalian cells. Inga A, et al. **Cancer Res** 1995 Oct 15;55(20):4658–63

Hexamethylmelamine is a potent inducer of deletions in male germ cells of Drosophila melanogaster. Aguirrezabalaga I, et al. **Carcinogenesis** 1995 Nov;16(11):2679–83

Repair of 1–(2–chloroethyl)–3–cyclohexyl–1–nitrosourea–induced damage by mammalian cell extracts. Cappelli E, et al. **Carcinogenesis** 1995 Sep;16(9):2267–70

Ultrastructural study of the effect of cyclophosphamide on the growth area of incisor teeth of DBA/2 and C57BL/6 mice. Anton E. **Int J Exp Pathol** 1996 Apr;77(2):83–8

Nephrotoxicity of ifosfamide in rats. Springate JE, et al. **J Appl Toxicol** 1995 Sep–Oct;15(5):399–402

Morphological evaluation of cyclophosphamide testicular toxicity in rats using quantitative morphometry of spermatogenic cycle stages. Matsui H, et al. **J Toxicol Sci** 1995 Sep;20(4):407–14

Genotoxicity of trophosphamide in mouse germ cells: assessment of micronuclei in spermatids and chromosome aberrations in one–cell zygotes. Tiveron C, et al. **Mutagenesis** 1996 Jan;11(1):125–30

Concentration–dependent mutational hotspots induced by the antineoplastic drug chloroethyl–cyclohexyl–nitroso–urea in mammalian cells. Fronza G, et al. **Mutat Res** 1996 Jun 10;352(1–2):47–9

Dominant lethal and heritable translocation tests with chlorambucil and melphalan in male mice. Generoso WM, et al. **Mutat Res** 1995 Dec;345(3–4):167–80

Rat hepatocytes with elevated metallothionein expression are resistant to N–methyl–N'–nitro–N–nitrosoguanidine cytotoxicity. Moffatt P, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):200–7

Dose–response relationships of cytotoxicity, PFC response and histology in the spleen in rats treated with alkylating agents. Doi T, et al. **Toxicology** 1996 Jan 22;107(1):47–60

ANTINEOPLASTIC AGENTS, COMBINED

A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer. Scher HI. **J Urol** 1995 Nov;154(5):1970–1

ADMINISTRATION & DOSAGE

The use of DAV (DTIC, ACNU and VCR) and natural interferon–beta combination therapy in malignant melanoma [letter] Nagatani T, et al. **Acta Derm Venereol** 1995 Nov;75(6):494

Optimal number of chemotherapy courses in advanced nonseminomatous testicular carcinoma. Kennedy BJ, et al. **Am J Clin Oncol** 1995 Dec;18(6):463–8

Factors influencing prognosis after dose–intensive therapy for recurrent or refractory Hodgkin's disease. Results of sequential trials: a case for treating patients with resistant disease. Ahmed T, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:305–14

High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts. Fields KK, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:288–304 (27 ref.)

An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose–intensive epiadriamycin–cyclophosphamide regimen in chemotherapy–naive patients with locally advanced or metastatic breast cancer. Piccart MJ, et al. **Ann Oncol** 1995 Sep;6(7):673–7

Accelerated chemotherapy with high–dose epirubicin and cyclophosphamide plus r–met–HUG–CSF in locally advanced and metastatic breast cancer. Scinto AF, et al. **Ann Oncol** 1995 Sep;6(7):665–71

Haematological support of high–dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. Tarella C, et al. **Ann Oncol** 1995;6 Suppl 4:3–8 (30 ref.)

Regional chemotherapy for colorectal hepatic metastases: evidence for improved survival with new drug combinations. Sutanto–Ward E, et al. **Ann Surg Oncol** 1996 Jan;3(1):36–43

Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon–occlusion technique. Wanebo HJ, et al. **Ann Surg Oncol** 1996 May; 3(3):295–303

Chronomodulated infusion of 5–fluorouracil, folinic acid and carboplatin in colorectal cancer: a pilot study. Natoli C, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2841–2

Adjuvant chemotherapy for non–metastatic osteosarcoma of the extremities in two New Zealand cancer centres [letter] Craft AW, et al. **Aust N Z J Med** 1996 Apr;26(2):230

Timed–sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Woods WG, et al. **Blood** 1996 Jun 15;87(12):4979–89

Phase I study of high–dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support [letter] Lotz JP, et al. **Bone Marrow Transplant** 1995 Dec; 16(6):858–9

Circulating progenitors following high–dose sequential (HDS) chemotherapy with G–CSF: short intervals between drug courses severely impair progenitor mobilization. Tarella C, et al. **Bone Marrow Transplant** 1995 Aug; 16(2):223–8

Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high–dose chemotherapy: the role of induction chemotherapy. Vredenburgh JJ, et al. **Bone Marrow Transplant** 1995 Dec;16(6):815–21

Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. English MW, et al. **Br J Cancer** 1996 Mar;73(6):776–80

High–dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease—a pragmatic prognostic index. O'Brien ME, et al. **Br J Cancer** 1996 May;73(10):1272–7

Phase II study of a short course of weekly high–dose cisplatin combined with long–term oral etoposide in metastatic colorectal cancer. Planting AS, et al. **Br J Cancer** 1996 May;73(10):1265–7

A controlled study of intravesical epirubicin with or without alpha 2b–interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group. Raitanen MP, et al. **Br J Urol** 1995 Dec;76(6):697–701

Sequential treatment of recurrent mesenteric desmoid tumor. Bauernhofer T, et al. **Cancer** 1996 Mar 15;77(6):1061–5 (44 ref.)

Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience. Farhat F, et al. **Cancer** 1996 Mar 15;77(6):1193–7

Regional perfusion with hemofiltration (chemofiltration) for the treatment of patients with regionally advanced cancer. Gutman M, et al. **Cancer** 1996 Sep 1;78(5):1125–30

Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors—Part one. Model projections for cost based on charges. Lokich JJ, et al. **Cancer** 1996 Jul 15;78(2):294–9

Comparison of costs for infusion versus bolus chemotherapy administration—Part two. Use of charges versus reimbursement for cost basis. Lokich JJ, et al. **Cancer** 1996 Jul 15;78(2):300–3

Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Long GD, et al. **Cancer** 1995 Sep 1;76(5):860–8

Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone–refractory prostate carcinoma patients. Maulard–Durdux C, et al. **Cancer** 1996 Mar 15;77(6):1144–8

Regional chemotherapy for inoperable pancreatic carcinoma. Muchmore JH, et al. **Cancer** 1996 Aug 1;78(3 Suppl):664–73

Phase I/II study of neoadjuvant intraarterial chemotherapy with mitomycin–C, vincristine, and cisplatin in patients with stage IIb bulky cervical carcinoma. Park SY, et al. **Cancer** 1995 Sep 1;76(5):814–23

A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma. Pisansky TM, et al. **Cancer** 1996 Jun 15;77(12):2520–8

Schedule–dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Chou TC, et al. **Cancer Chemother Pharmacol** 1996;37(3):222–8

Targeted cancer chemotherapy with arterial microcapsule chemoembolization: review of 1013 patients. Kato T, et al. **Cancer Chemother Pharmacol** 1996;37(4):289–96

Difference in CDDP penetration into CSF between selective intraarterial chemotherapy in patients with malignant glioma and intravenous or intracarotid administration in patients with metastatic brain tumor. Nakagawa H, et al. **Cancer Chemother Pharmacol** 1996;37(4):317–26

Protracted continuous infusion of 5–fluorouracil in combination with doxorubicin, vincristine, and oral cyclophosphamide in advanced breast cancer [see comments] Raymond E, et al. **Cancer Invest** 1996;14(2):91–7 . Comment in: Cancer Invest 1996;14(2):178–9.

Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Moore JC, et al. **Cancer Lett** 1995 Nov 27;98(1):83–7

Combination chemotherapy and photodynamic therapy with N–(2–hydroxypropyl) methacrylamide copolymer–bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Peterson CM, et al. **Cancer Res** 1996 Sep 1;56(17):3980–5

Schedule–dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro. Akutsu M, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2341–6

Very high–dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Benedetti–Panici P, et al. **Eur J Cancer** 1995 Nov; 31A(12):1987–92

Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study. Blomqvist C, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2406–8

Schedule–dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Braakhuis BJ, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2335–40

Increasing the dose intensity of chemotherapy by means of granulocyte–colony stimulating factor (G–CSF) support in the treatment of small cell lung cancer (SCLC) [letter] Girling DJ, et al. **Eur J Cancer** 1996 Jun;32A(7):1263

Feasibility and compliance of epirubicin plus ambulatory continuous infusion ifosfamide at escalating doses in advanced soft tissue sarcomas: a phase I study [letter] Palumbo R, et al. **Eur J Cancer** 1995;31A(9):1552–3

High–dose therapy followed by autologous bone marrow transplantation in previously untreated high grade non–Hodgkin's lymphoma: 10–year long–term results [letter] Zinzani PL, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2421–2

Treatment of non–resectable pelvic malignancies by isolated pelvic perfusion. A preliminary study. Kocaoglu H, et al. **Eur J Surg Oncol** 1995 Oct;21(5):535–40

Induction chemotherapy via hepatic artery for gallbladder carcinoma. Lai DT, et al. **Eur J Surg Oncol** 1995 Dec; 21(6):690–1

Meta–analysis comparing cisplatin total dose intensity and survival. Ben–David Y, et al. **Gynecol Oncol** 1995 Oct; 59(1):93–101

Prolonged continuous infusion cisplatin and 5–fluorouracil with radiation for locally advanced carcinoma of the vulva. Eifel PJ, et al. **Gynecol Oncol** 1995 Oct;59(1):51–6 (22 ref.)

Rapid increase in plasma tenascin–C concentration after isolated limb perfusion with high–dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors. Schienk S, et al. **Int J Cancer** 1995 Nov 27;63(5):665–72

Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony–stimulating factor for urothelial cancer—phase I/II study. Yoshida O, et al. **Int J Urol** 1995 Nov;2(5):316–21

An intensive chemotherapy of adult T–cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony–stimulating factor support. Taguchi H, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):182–6

Can protocol–specified doses of chemotherapy and radiotherapy be used as a measure of treatment actually received? A CCG/NIH study on long–term survivors of acute lymphocytic leukemia. Haupt R, et al. **J Clin Epidemiol** 1996 Jun;49(6):687–90

Dose–intensive metastatic breast cancer chemotherapy [letter; comment] Cohen MH. **J Clin Oncol** 1996 Feb; 14(2):685–6. Comment on: J Clin Oncol 1995 Oct;13(10):2483–9.

High–dose versus low–dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord–Ovest. Conte PF, et al. **J Clin Oncol** 1996 Feb;14(2):351–6

Phase I/II study of 72–hour infusional paclitaxel and doxorubicin with granulocyte colony–stimulating factor in patients with metastatic breast cancer. Fisherman JS, et al. **J Clin Oncol** 1996 Mar;14(3):774–82

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose–escalation study. Fraker DL, et al. **J Clin Oncol** 1996 Feb;14(2):479–89

Vinblastine, bleomycin, and methotrexate chemotherapy plus extended–field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience. Gobbi PG, et al. **J Clin Oncol** 1996 Feb;14(2):527–33

Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony–stimulating factor in women with previously treated metastatic breast cancer. Kennedy MJ, et al. **J Clin Oncol** 1996 Mar;14(3):783–91

High–dose chemotherapy of breast cancer: is the question answered? [editorial; comment] [see comments] Kennedy MJ. **J Clin Oncol** 1995 Oct;13(10):2477–9. Comment on: J Clin Oncol 1995 Oct;13(10):2483–9. Comment in: J Clin Oncol 1996 Feb;14(2):684–5.

High–dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. Mahoney DH Jr, et al. **J Clin Oncol** 1996 Feb;14(2):382–8

High–dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non–Hodgkin's lymphoma with partial response to front–line chemotherapy: a prospective randomized italian multicenter study. Martelli M, et al. **J Clin Oncol** 1996 Feb;14(2):534–42

Adjuvant chemotherapy for high–risk clinical stage I nonseminomatous testicular germ cell cancer: long–term results of a prospective trial. Pont J, et al. **J Clin Oncol** 1996 Feb;14(2):441–8

Treatment of primary cutaneous B–cell lymphomas of follicle center cell origin: a clinical follow–up study of 55 patients treated with radiotherapy or polychemotherapy. Rijlaarsdam JU, et al. **J Clin Oncol** 1996 Feb;14(2):549–55

Feasibility of multiple courses of high–dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. Rodenhuis S, et al. **J Clin Oncol** 1996 May;14(5):1473–83

Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary

CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. Schultz C, et al. **J Clin Oncol** 1996 Feb;14(2):556-64

High-dose chemotherapy for breast cancer [letter; comment] Spiridonidis CH, et al. **J Clin Oncol** 1996 Feb;14(2):686. Comment on: J Clin Oncol 1995 Oct;13(10):2483-9.

Risk stratification for high-dose chemotherapy in metastatic breast cancer [letter; comment] Subar M. **J Clin Oncol** 1996 Feb;14(2):686-7. Comment on: J Clin Oncol 1995 Oct;13(10):2483-9.

Hypertensive intra-arterial chemotherapy for endometrial carcinoma assessed by transvaginal Doppler ultrasound and magnetic resonance imaging. Hata K, et al. **J Clin Ultrasound** 1995 Sep;23(7):407-11

Hepatic perfusion abnormalities during treatment with hepatic arterial infusion chemotherapy: value of CT arteriography using an implantable port system. Seki H, et al. **J Comput Assist Tomogr** 1996 May-Jun;20(3):343-8

Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trial. Deprés-Brummer P, et al. **J Infus Chemother** 1995;5(3 Suppl 1):144-7

Ambulatory chronotherapy with 5-fluorouracil, folinic acid, and carboplatin for advanced non-small cell lung cancer. A phase II feasibility trial. Focan C, et al. **J Infus Chemother** 1995;5(3 Suppl 1):148-52

Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE). Lokich J, et al. **J Infus Chemother** 1996 Winter;6(1):39-42

Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) +/- etoposide. Lokich J, et al. **J Infus Chemother** 1996 Winter;6(1):43-6

Attempted dose intensified cyclophosphamide, etoposide, and granulocyte colony-stimulating factor for treatment of malignant astrocytoma. Newton HB, et al. **J Neurooncol** 1995;24(3):285-92

Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience. Lee JD, et al. **J Surg Oncol** 1995 Dec;60(4):262-7

Effects of intraportal administration of chemoimmunotherapeutic agents on natural killer cell activity in the rat liver. Rafique M, et al. **J Surg Oncol** 1995 Nov;60(3):154-9

5-fluorouracil and allopurinol combined with recombinant interferon-alpha 2b in the treatment of patients with advanced prostate cancer: a phase I/II study. Glazier DB, et al. **J Urol** 1996 Feb;155(2):624-7

Effect of administering cyclophosphamide and vitamin E on the levels of tumor-marker enzymes in rats with experimentally induced fibrosarcoma. Vinitha R, et al. **Jpn J Med Sci Biol** 1995 Jun;48(3):145-56

High-dose chemotherapy with autologous bone marrow/stem-cell rescue in lung cancer. Basade MM, et al. **Lancet** 1996 Mar 30;347(9005):847-8

Breast cancer studies in The Netherlands [letter] de Vries EG, et al. **Lancet** 1996 Aug 10;348(9024):407-8

Bone marrow involvement, in intensively treated patients with intermediate grade non-Hodgkin's lymphoma, is a risk factor for granulocytopenia and fever. Kitay-Cohen Y, et al. **Leuk Lymphoma** 1996 Jan;20(3-4):333-6

Treatment of young relapsed Hodgkin's disease patients with high-dose chemotherapy followed by peripheral blood stem cell transplantation. Matsuzaki A, et al. **Leuk Lymphoma** 1995 Aug;18(5-6):505-9

Treatment of adult patients with acute lymphocytic leukemia in relapse. Mazza JJ, et al. **Leuk Lymphoma** 1996 Jan; 20(3-4):317-9

Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Berman E, et al. **Leukemia** 1995 Oct;9(10):1631-7

A phase II trial of combined chemotherapy and surgery in stage IIIA non-small cell lung cancer. Darwish S, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S71-8

Interleukin-1 alpha and soluble interleukin-2 receptor during small cell lung cancer chemotherapy: comparison of high chemotherapy dose with rhGM-CSF and standard chemotherapy dose without rhGM-CSF. Gautier V, et al. **Lung Cancer** 1995 Oct;13(2):145-53

Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2). Kris MG, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S47-57 (38 ref.)

Neoadjuvant chemotherapy of locally advanced non-small cell lung cancer. Pujol JL, et al. **Lung Cancer** 1995 Apr; 12 Suppl 1:S107-18 (46 ref.)

Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. Rosell R, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S59-70

Pregnancies after endolymphatic therapy of residual retroperitoneal Hodgkin lymphoma. Hirnle P, et al. **Lymphology** 1995 Jun;28(2):73-7

Treatment of endodermal sinus tumor in children using a regimen that lacks bleomycin. Frazier AL, et al. **Med Pediatr Oncol** 1996 Aug;27(2):69-73

Relationship between dose schedule and charges for treatment on National Wilms' Tumor Study-4. A report from the National Wilms' Tumor Study Group. Green DM, et al. **Monogr Natl Cancer Inst** 1995;(19):21-5

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. Attal M, et al. **N Engl J Med** 1996 Jul 11;335(2):91-7

Hematopoietic reconstitution with autologous stem cells [letter; comment] Juliusson G. **N Engl J Med** 1996 Jan 25;334(4):271-2. Comment on: N Engl J Med 1995 Aug 3;333(5):283-7.

Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. Ravindranath Y, et al. **N Engl J Med** 1996 May 30;334(22):1428-34

The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer [see comments] Recht A, et al. **N Engl J Med** 1996 May 23; 334(21):1356-61. Comment in: N Engl J Med 1996 May 23;334(21):1397-9.

Clinical trials referral resource. Cheson BD, et al. **Oncology (Huntingt)** 1995 Dec;9(12):1292, 1297-8

Role of chemotherapy dose intensification in the treatment of advanced ovarian cancer. Fennelly D, et al. **Oncology (Huntingt)** 1995 Oct;9(10):911-21; discussion 922, 924, 926 (59 ref.)

Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better? Gaynor ER, et al. **Oncology (Huntingt)** 1995 Dec;9(12):1273-9; discussion 1283-4 (18 ref.)

New approaches to adjuvant chemotherapy for breast cancer. Hudis C. **Pharmacotherapy** 1996 May-Jun;16(3 Pt 2):88S-93S (16 ref.)

High-dose cytotoxic therapy with autologous bone marrow or peripheral blood progenitor cell transplantation in malignant lymphomas. Cucuianu A, et al. **Rom J Intern Med** 1995 Jul-Dec;33(3-4):211-25

Activity and safety of epirubicin plus paclitaxel in advanced breast cancer. Conte PF, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 1):28-32

Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Luck HJ, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 1):33-6

Non-invasive loco-regional therapy for hepatocellular carcinoma. Tanikawa K. **Semin Surg Oncol** 1996 May-Jun; 12(3):189-92 (15 ref.)

High-dose therapy and autologous blood stem cell transplantation in multiple myeloma: preliminary results of a randomized trial involving 167 patients. Fermand JP, et al. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:156-9

[Results of treatment protocols for leukemia in children: apropos of studies of the EORTC-CLCG group] Suciu S, et al. **Arch Pediatr** 1996;3 Suppl 1:197s-200s (Fre)

[Implantable sites in cancerology. The percutaneous technique. Results of a homogeneous series of 141 cases] Maillart P, et al. **J Chir (Paris)** 1995 Dec;132(12):495-8 (Eng. Abstr.) (Fre)

[The fully implantable minimally invasive hepatic artery catheter for locoregional chemotherapy of nonresectable liver metastases in defective conventional implanted therapy catheters] Germer CT, et al. **Chirurg** 1996 Apr; 67(4):458-62 (Eng. Abstr.) (Ger)

[High dose chemotherapy in treatment of breast carcinoma: current status and limits of this method of therapy] Derigs HG, et al. **Geburtshilfe Frauenheilkd** 1996 Apr;56(4):190-7 (40 ref.) (Eng. Abstr.) (Ger)

[Intra-arterial treatment of therapy-resistant residual tumors of the pelvis] Görich J, et al. **Strahlenther Onkol** 1995 Dec; 171(12):671-8 (Eng. Abstr.) (Ger)

[Regional therapy breast cancer liver metastases] Lorenz M, et al. **Zentralbl Chir** 1995;120(10):786-90 (Eng. Abstr.) (Ger)

[Locally advanced carcinoma of the cervix uteri (stage IIB-IIIB TNM-UICC): radiotherapy combined with simultaneous daily low-dose platinum. Phase II study] Micheletti E, et al. **Radiol Med (Torino)** 1996 May; 91(5):628-34 (Eng. Abstr.) (Ita)

[High-dose chemotherapy rescued with peripheral blood stem cell transplantation for high-risk patients with breast cancer] Kim S, et al. **Gan To Kagaku Ryoho** 1996 Apr; 23(5):635-8 (Jpn)

[A case of unresectable gastric cancer responding to combined therapy with intraperitoneal cisplatinum administration and continuous intravenous infusion of 5-fluorouracil] Kokufu I, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2107-9 (Eng. Abstr.) (Jpn)

[A case of gastric cancer responding well to MTX/5-FU (methotrexate/5-fluorouracil) and PMUE (CDDP, MMC, UFT, etoposide) therapies upon lymphnode recurrence] Konishi K, et al. **Gan To Kagaku Ryoho** 1995 Nov; 22(13):1969-72 (Eng. Abstr.) (Jpn)

[A study of chemotherapy for patients with severely advanced gastric cancer--comparison of chemotherapy and route] Kosaka T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1582-5 (Eng. Abstr.) (Jpn)

[Low-dose FP (5-FU+low-dose CDDP) therapy for far advanced upper gastro-intestinal carcinoma] Nakamura M, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2081-6 (Eng. Abstr.) (Jpn)

[Neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil) in the treatment of stage III cervical cancer] Narimatsu A, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2087-93 (Eng. Abstr.) (Jpn)

[Five-day continuous intravenous infusion of cisplatin and etoposide for extensive stage small cell lung cancer] Okazaki M, et al. **Gan To Kagaku Ryoho** 1995 Nov; 22(13):1987-9 (Jpn)

[A case of hepatocellular carcinoma responding to oral administration of UFT] Onodera H, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):911-3 (Eng. Abstr.) (Jpn)

[Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--growth-inhibitory activity of combination against human tumor xenograft] Saito H, et al. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1919-25 (Eng. Abstr.) (Jpn)

[Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil] Yuasa C, et al. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1927-32 (Eng. Abstr.) (Jpn)

[Two cases of multiple liver metastases (H3) from colon cancer treated by home hepatic arterial infusion chemotherapy] Yuasa N, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:457-61 (Eng. Abstr.) (Jpn)

[Comparison of hormone therapy alone and in combination with chemotherapy of cisplatin and methotrexate in newly diagnosed patients with stage D2 prostatic cancer] Komatus H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):789-96 (Eng. Abstr.) (Jpn)

[Experimental and clinical trial of degradable starch microspheres (DSM) in treatment of hepatic neoplasm: Part 2. Clinical study] Yamada T. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Sep; 55(11):732-8 (Eng. Abstr.) (Jpn)

[Usefulness and problems of high dose chemotherapy using CBDCA, VP-16, and MCNU with peripheral blood stem cell transplantation in pediatric malignant brain tumors] Sasajima T, et al. **No To Shinkei** 1996 Jul;48(7):653-8 (Eng. Abstr.) (Jpn)

[Reactive hemophagocytic syndrome responded to combination chemotherapy with steroid pulse therapy] Okuda T, et al. **Rinsho Ketsueki** 1995 Nov;36(11):1316-20 (Eng. Abstr.) (Jpn)

[Current aspects of the treatment of osteogenic sarcoma] Glukhovskaia IIu, et al. **Klin Khir** 1995;(5):32-3 (Rus)

[Effectiveness of preoperative intraperitoneal polychemotherapy in patients with stomach cancer] Vinnik IuA. **Klin Khir** 1996;(1):42-4 (Rus)

[High-dose therapy with autologous bone marrow transplantation in patients with resistant forms of lymphogranulomatosis] Rossiev VA, et al. **Ter Arkh** 1995; 67(7):80-1 (Rus)

[The use of high-dose chemotherapy in the treatment of breast cancer (comment)] Espinosa E, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):56-8 (21 ref.). Comment on: Med Clin (Barc) 1995 May 13;104(18):702-8. (Spa)

[High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means] Sola Rocabert C, et al. **Med Clin (Barc)** 1995 Oct 7;105(11):407-11 (Eng. Abstr.) (Spa)

[Leukemia and pregnancy. Review apropos of a clinical case] Perucca E, et al. **Rev Chil Obstet Ginecol** 1995; 60(2):118-23; discussion 123-4 (13 ref.) (Eng. Abstr.) (Spa)

[Possible effect of administration methods on pharmacological action. Study of cytostatic therapy in advanced cancer] Larsson PA, et al. **Lakartidningen** 1995 Dec 13;92(50):4793-6 (Swe)

[The intraperitoneal chemotherapy of patients with ovarian cancer] Shparyk IaV, et al. **Vrach Delo** 1995 Jan-Feb; (1-2):29-35 (48 ref.) (Ukr)

ADVERSE EFFECTS

Bilateral submandibular salivary gland enlargement during chemotherapy for acute myeloid leukaemia--beneficial effect of propranolol. Dabadghao S, et al. **Acta Haematol** 1996;96(2):112

Development of polycythaemia rubra vera following treatment for centroblastic lymphoma. Harrison P, et al. **Acta Haematol** 1996;96(2):113-4

Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. Jørgensen M, et al. **Acta Oncol** 1996;35(2):159-63

Acute myocardial infarction in man treated with epirubicin for non-Hodgkin lymphoma. Aydiner A, et al. **Am J Clin Oncol** 1995 Oct;18(5):444-8

Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. Geller RB, et al. **Am J Hematol** 1995 Nov;50(3):167-72

Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. Gillis S, et al. **Am J Hematol** 1996 Jan;51(1):26-31

Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. Yau JC, et al. **Am J Hematol** 1996 Apr; 51(4):289-95

Prophylactic antibiotics for the prevention of early infection

in multiple myeloma. Oken MM, et al. **Am J Med** 1996 Jun;100(6):624–8

Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer. Runowicz CD, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1151–9; discussion 1159–60

Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature [see comments] Hoffmann L, et al. **Ann Oncol** 1995 Oct;6(8):781–8 (32 ref.). Comment in: Ann Oncol 1995 Oct;6(8):751–3.

The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease. de Graaf H, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2851–6

Early hematological toxicity of adjuvant perioperative intraportal and intravenous chemotherapy with fluorouracil, mitomycin and heparin in colorectal cancer. Swiss Group for Clinical Cancer Research. Weber W, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2197–200

Restorative effect of romurtide for thrombocytopenia associated with intensive anticancer drug treatment and/or irradiation in patients with gastrointestinal cancer. Yano K, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2883–7

Minoxidil induced hair growth after leukaemia treatment? [letter] Vickers MA, et al. **Arch Dis Child** 1995 Aug; 73(2):184

Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X. Wheeler K, et al. **Arch Dis Child** 1996 Feb;74(2):101–7

Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy. Schned AR, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):96–100

Autologous progenitor cell transplantation: prior exposure to stem cell–toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Dreger P, et al. **Blood** 1995 Nov 15;86(10):3970–8

A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Gordon MS, et al. **Blood** 1996 May 1;87(9):3615–24

True histiocytic lymphoma following therapy for lymphoblastic neoplasms. Soslow RA, et al. **Blood** 1996 Jun 15;87(12):5207–12

A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Tepler I, et al. **Blood** 1996 May 1;87(9):3607–14

A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. Welte K, et al. **Blood** 1996 Apr 15;87(8):3143–50

High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose–toxicity study. Ager S, et al. **Bone Marrow Transplant** 1996 Mar; 17(3):335–40

Rapid development of disseminated superficial porokeratosis after transplant induction therapy. Fields LL, et al. **Bone Marrow Transplant** 1995 Jun;15(6):993–5

High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Haas R, et al. **Bone Marrow Transplant** 1996 Feb; 17(2):149–55

Hyperinsulinemia in children and adolescents after bone marrow transplantation. Lorini R, et al. **Bone Marrow Transplant** 1995 Jun;15(6):873–7

Acute myeloid leukemia and myelodysplasia following intensive chemotherapy for breast cancer. Roman-Unfer S, et al. **Bone Marrow Transplant** 1995 Jul;16(1):163–8

Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy. Zimmerman TM, et al. **Bone Marrow Transplant** 1995 Jun;15(6):923–7 (29 ref.)

Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. de Wit R, et al. **Br J Cancer** 1996 Jul;74(2):323–6

Fingertip necrosis during chemotherapy with bleomycin, vincristine and methotrexate for HIV-related Kaposi's sarcoma [letter] Pechère M, et al. **Br J Dermatol** 1996 Feb; 134(2):378–9

Recall phenomenon with the unusual presence of eccrine squamous syringometaplasia. Rios-Buceta L, et al. **Br J Dermatol** 1995 Oct;133(4):630–2

Motility of rhG-CSF-induced neutrophils in patients undergoing chemotherapy: evidence for inhibition detected by image analysis. Azzarà A, et al. **Br J Haematol** 1996 Jan;92(1):161–8

Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow. Schwartz GN, et al. **Br J Haematol** 1996 Mar;92(3):537–47

Haemoperitoneum due to necrosis of bulky retroperitoneal metastases: an unusual complication of chemotherapy for testicular cancer. Rodier JM, et al. **Br J Urol** 1996 Jun; 77(6):919–20

Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity? Locker GJ, et al. **Breast Cancer Res Treat** 1995 Jun;34(3):213–9

Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study. Bonneterre J, et al. **Bull Cancer (Paris)** 1995 Dec; 82(12):1038–43

Acute rhabdomyolysis after concurrent administration of interleukin-2, interferon-alfa, and chemotherapy for metastatic melanoma. Anderlini P, et al. **Cancer** 1995 Aug 15;76(4):678–9

Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Barasch A, et al. **Cancer** 1995 Dec 15;76(12):2550–6

Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin. Cleri LB, et al. **Cancer** 1995 Sep 1;76(5):774–8

Localized cisplatin hyperpigmentation induced by pressure. A case report. Al-Lamki Z, et al. **Cancer** 1996 Apr 15; 77(8):1578–81

Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. van der Lelie H, et al. **Cancer** 1995 Dec 1;76(11):2338–42 (21 ref.)

Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Walsh TJ, et al. **Cancer** 1995 Dec 1;76(11):2357–62

Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens. Barrenetxea G, et al. **Cancer Chemother Pharmacol** 1996;38(5):471–5

Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer. Soda H, et al. **Cancer Chemother Pharmacol** 1996;38(1):9–12

Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. Figueredo AT, et al. **Cancer Invest** 1995;13(6):608–11

Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Bow EJ, et al. **Clin Infect Dis** 1995 Aug;21(2):361–9

Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy? Croockewit AJ, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):1–6 (31 ref.)

Case report: bilateral recurrent tension pneumothorax complicating combination chemotherapy for soft tissue sarcoma. Fenlon HM, et al. **Clin Radiol** 1996 Apr; 51(4):302–4

A personal experience with SIRS and MODS. Bone RC. **Crit Care Med** 1996 Aug;24(8):1417–8

Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cartee L, et al. **Cytokine** 1995 Jul;7(5):471–7

Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma. Schulte-Huermann P, et al. **Dermatology** 1995;191(1):65–7

Severe chronic active hepatitis induced by UFTR containing tegafur and uracil. Kobayashi F, et al. **Dig Dis Sci** 1995 Nov;40(11):2434–7

Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy. Maruyama S, et al. **Dig Dis Sci** 1995 Dec;40(12):2602–7

Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Berger CC, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2229–38

Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy. Dranitsaris G, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2174–80

Chemotherapy-induced onycholysis [letter] Makris A, et al. **Eur J Cancer** 1996 Feb;32A(2):374–5

Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. Meden H, et al. **Eur J Gynaecol Oncol** 1996;17(2):114–22

Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) after treatment with cyclophosphamide, alpha-interferon and betamethasone in a patient with multiple myeloma [letter] Björck E, et al. **Eur J Haematol** 1996 May;56(5):323–5

Serum granulocyte colony-stimulating factor (G-CSF) and interleukin-1 (IL-1) concentrations after chemotherapy-induced neutropenia in normal and tumor-bearing dogs. Bravo L, et al. **Exp Hematol** 1996 Jan;24(1):11–7

Hepar lobatum carcinomatosum due to chemotherapy of a metastatic breast carcinoma. Uhlmann F, et al. **Gen Diagn Pathol** 1996 Mar;141(3–4):279–84 (21 ref.)

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Connelly E, et al. **Gynecol Oncol** 1996 Aug;62(2):166–8

Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Emoto M, et al. **Gynecol Oncol** 1996 Jun;61(3):369–72

A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis. Sabbatini R, et al. **Haematologica** 1995 Sep–Oct;80(5):416–20

Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). Lipton JH, et al. **Hematol Oncol** 1996 Mar;14(1):29–31

Combination chemotherapy for breast carcinoma using a combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) causes a platelet aggregation defect. Kumar A, et al. **Int J Cancer** 1996 Apr 10;66(2):159–61

The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models. Sredni B, et al. **Int J Cancer** 1996 Jan 3; 65(1):97–103

Severe reaction after chemoradiotherapy of nasopharyngeal carcinoma with collagen disease [letter] Hareyama M, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):971

Rhabdomyolysis complicating polymicrobial sepsis in a patient with acute leukemia. Funada H, et al. **Intern Med** 1996 Jan;35(1):36–8

A randomized trial of minoxidil in chemotherapy-induced alopecia. Duvic M, et al. **J Am Acad Dermatol** 1996 Jul; 35(1):74–8

Canities--reversal with chemotherapy. Babu KG, et al. **J Assoc Physicians India** 1995 Aug;43(8):577

Mediastinal infusion of epirubicin and 5-fluorouracil. A complication of totally implantable central venous systems. Report of a case. Rodier JM, et al. **J Cancer Res Clin Oncol** 1996;122(9):566–7

Analysis of thrombocytopenia due to carboplatin combined with etoposide in elderly patients with lung cancer. Shibata K, et al. **J Cancer Res Clin Oncol** 1996;122(7):437–42

Late effects of chemoradiotherapy in pediatric Hodgkin's disease. Gözdasoglu S, et al. **J Chemother** 1995 Oct; 7(5):463–6

Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. Bui BN, et al. **J Clin Oncol** 1995 Oct;13(10):2629–36

Major toxicity of cisplatin, fluorouracil, and leucovorin following chemoradiotherapy in patients with nasopharyngeal carcinoma [letter; comment] Celik I, et al. **J Clin Oncol** 1996 Mar;14(3):1043–4. Comment on: J Clin Oncol 1995 Oct;13(10):2620–8.

Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy [see comments] Chi KH, et al. **J Clin Oncol** 1995 Oct; 13(10):2620–8. Comment in: J Clin Oncol 1996 Mar;14(3):1043–4. Comment in: J Clin Oncol 1996 May;14(5):1741–3.

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. Kemp G, et al. **J Clin Oncol** 1996 Jul;14(7):2101–12

Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel [letter] Miller AA, et al. **J Clin Oncol** 1996 Jun;14(6):1964–5

Paclitaxel and doxorubicin in metastatic breast cancer [letter; comment] Sharma S. **J Clin Oncol** 1996 Apr;14(4):1403. Comment on: J Clin Oncol 1995 Nov;13(11):2688–99.

Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. Small EJ, et al. **J Clin Oncol** 1996 May;14(5):1617–25

Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice [see comments] Waber DP, et al. **J Clin Oncol** 1995 Oct;13(10):2490–6. Comment in: J Clin Oncol 1995 Oct;13(10):2480–2.

Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. Weintraub M, et al. **J Clin Oncol** 1996 Mar; 14(3):935–40

Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma. Fu KK, et al. **J Clin Pharm Ther** 1995 Jun; 20(3):167–72

Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. Skubitz KM, et al. **J Lab Clin Med** 1996 Feb;127(2):223–8

Antineoplastic-associated colitis in Chulalongkorn University Hospital. Sriuranpong V, et al. **J Med Assoc Thai** 1995 Aug;78(8):424–30

Inflammatory bowel disease associated with levamisole and fluorouracil chemotherapy for colon cancer [letter] Atkins CD. **J Natl Cancer Inst** 1996 Mar 6;88(5):303–4

Body wars: effect of friendly fire (cancer therapy) [editorial; comment] Boice JD Jr, et al. **J Natl Cancer Inst** 1995 May 17;87(10):705–6. Comment on: J Natl Cancer Inst 1995 May 17;87(10):732–41.

Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. de Wit R, et al. **J Natl Cancer Inst** 1996 Oct 2; 88(19):1393–8

A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. Gelber RD, et al. **J Natl Cancer Inst** 1996 Aug 7;88(15):1039–45

Severe neurotoxicity from vinorelbine-paclitaxel combinations [letter; comment] Parimoo D, et al.

J Natl Cancer Inst 1996 Aug 7;88(15):1079–80. Comment on: J Natl Cancer Inst 1995 Jul 19;87(14):1072–7.

A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. Mustafa MM, et al. **J Pediatr** 1996 Jun;128(6):847–9

Pyomyositis during induction chemotherapy for acute lymphocytic leukemia. Corden TE, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):323–6

Chemotherapy-induced non-Hodgkin's lymphoma in a patient with Hodgkin's disease—a case report. Burney IA, et al. **JPMA J Pak Med Assoc** 1996 Jan;46(1):14–5

Severe acute metabolic acidosis and Wernicke's encephalopathy following chemotherapy with 5-fluorouracil and cisplatin: case report and review of the literature. Kondo K, et al. **Jpn J Clin Oncol** 1996 Aug; 26(4):234–6

Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Tsuda H, et al. **Kurume Med J** 1995; 42(4):241–9

Childhood neoplasia and Haemophilus influenzae type b vaccine failure [letter] Jenkins DR, et al. **Lancet** 1996 Jul 13;348(9020):131

Intermittent G-CSF to maintain dose intensity of chemotherapy for Hodgkin's disease. Clarke K, et al. **Leuk Lymphoma** 1995 Nov;19(5-6):521–2

Short-term rhG-CSF priming before chemotherapy does mobilize blood progenitors but does not prevent chemotherapy induced myelotoxicity: a randomized study of patients with non-Hodgkin's lymphomas. Hansen PB, et al. **Leuk Lymphoma** 1995 Nov;19(5-6):453–60

Calla positive acute lymphoblastic leukemia after etoposide-based therapy for Ewing's sarcoma. Kapoor G, et al. **Leuk Res** 1995 Oct;19(10):771–2

L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Pui CH, et al. **Leukemia** 1995 Oct; 9(10):1680–4

Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue. Freilich RJ, et al. **Med Pediatr Oncol** 1996 Feb;26(2):95–100

Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol. Ilveskoski I, et al. **Med Pediatr Oncol** 1996 Jul;27(1):26–31

Pulmonary function in children treated for rhabdomyosarcoma. Kaplan E, et al. **Med Pediatr Oncol** 1996 Aug;27(2):79–84

Long-term pulmonary toxicity of multiagent chemotherapy including bleomycin and cyclophosphamide in osteosarcoma survivors. Kharasch VS, et al. **Med Pediatr Oncol** 1996 Aug;27(2):85–91

Gonadal function following chemotherapy for childhood Hodgkin's disease. Mackie EJ, et al. **Med Pediatr Oncol** 1996 Aug;27(2):74–8

Late cardiotoxicity after treatment for a malignant bone tumor. Postma A, et al. **Med Pediatr Oncol** 1996 Apr; 26(4):230–7

The histological and immunohistochemical changes in the skin of patients with melanoma who develop changes in skin pigmentation following immunotherapy. Salter J, et al. **Melanoma Res** 1995 Aug;5(4):267–71

High dose therapy and autologous bone marrow versus blood cell rescue. South Island Bone Marrow Transplant Unit. Hill GR, et al. **N Z Med J** 1996 Feb 23;109(1016):45–8

Atypical MRI findings in treatment-related leukoencephalopathy: case report. Ohmoto Y, et al. **Neuroradiology** 1996 Feb;38(2):128–33 (30 ref.)

Randomized trial of dietician counseling to try to prevent weight gain associated with breast cancer adjuvant chemotherapy. Loprinzi CL, et al. **Oncology** 1996 May-Jun;53(3):228–32

Optimal control of cyclophosphamide-induced emesis. Stewart A. **Oncology** 1996 Jun;53 Suppl 1:32–8 (38 ref.)

Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. Khawly JA, et al. **Ophthalmology** 1996 Jan;103(1):87–95

A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. Verdi CJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):36–42

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) in children undergoing high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Abe T, et al. **Pediatr Hematol Oncol** 1995 Jul-Aug; 12(4):363–9

Intrathecal chemotherapy-related myeloencephalopathy in a young child with acute lymphoblastic leukemia. García-Tena J, et al. **Pediatr Hematol Oncol** 1995 Jul-Aug; 12(4):377–85

Influence of treatment modalities on prepubertal growth in children with acute lymphoblastic leukemia. Groot-Loonen JJ, et al. **Pediatr Hematol Oncol** 1995 Jul-Aug;12(4):343–53

Early toxicity of intensified conditioning with etoposide combined with total body irradiation/cyclophosphamide or busulfan/cyclophosphamide in children undergoing autologous or allogeneic bone marrow transplantation. Horstmann M, et al. **Pediatr Hematol Oncol** 1996 Jan-Feb; 13(1):45–53

Comparative effect of 100 versus 250 micrograms/m2/day of G-CSF in pediatric patients with neutropenia induced by chemotherapy. Kubota M, et al. **Pediatr Hematol Oncol** 1995 Jul-Aug;12(4):393–7

Prevention of tumor lysis syndrome using continuous veno-venous hemofiltration. Saccente SL, et al. **Pediatr Nephrol** 1995 Oct;9(5):569–73

Chemotherapy plays a major role in the inhibition of catch-up growth during maintenance therapy for childhood acute lymphoblastic leukemia. Groot-Loonen JJ, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):693–5

Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety. Catimel G, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 1):24–7

A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. Barbounis V, et al. **Support Care Cancer** 1995 Sep;3(5):301–6

Lethal tracheal dissolution during treatment for thyroid lymphoma. Melnyk A, et al. **Thorax** 1995 Oct;50(10):1120–1

[A clinical trial Furlutal in the prevention of anorexia, weight loss and myelosuppression due to chemotherapy] Wang J, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):283–5 (Eng. Abstr.) **(Chi)**

[The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial] Zeng W, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):294–7 (Eng. Abstr.) **(Chi)**

[Clinical analysis of 6 cases of gestational trophoblastic neoplasms complicated by cardiotoxicity after chemotherapies] Wu Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jun;30(6):366–8 (Eng. Abstr.) **(Chi)**

[Effects of traditional Chinese medicine in chemotherapy of acute leukemia] Li HY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):628–9 **(Chi)**

[Severe esophagitis in leukemia and lymphoma in children (letter)] Thumerelle C, et al. **Arch Pediatr** 1996 Apr; 3(4):399–401 **(Fre)**

[Acute cerebellar syndrome after treatment with 5-fluorouracil] Barbieux C, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):77–80 (Eng. Abstr.) **(Fre)**

[Future trends in chemotherapy and impact on the management of emesis] Catimel G, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):1067–71 (Eng. Abstr.) **(Fre)**

[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting] Depierre A. **Bull Cancer (Paris)** 1996 Feb;83(2):147–53 (29 ref.) (Eng. Abstr.) **(Fre)**

[Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin] Harousseau JL. **Bull Cancer (Paris)** 1996 Jan;83(1):71–76 (27 ref.) (Eng. Abstr.) **(Fre)**

[Semen preservation and gonadal toxicity in the treatment of non Hodgkin lymphoma. Experience at the Gustave-Roussy Institute from 1980 to 1993] Naccache P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):307–14 (Eng. Abstr.) **(Fre)**

[Sclerosing peritonitis. A series of 10 cases and review of the literature] Carbonnel F, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):876–82 (33 ref.) (Eng. Abstr.) **(Fre)**

[Anatomo-clinical conference: differential diagnosis of diffuse pneumopathies in bronchial cancer (clinical conference(] Berghmans T, et al. **Rev Med Brux** 1996 Jun; 17(3):132–5 (Eng. Abstr.) **(Fre)**

[Arterial thrombosis in a patient after chemotherapy (BEP protocol) for extra-gonadal dysgerminoma (letter)] Schmidt J, et al. **Therapie** 1995 Sep-Oct;50(5):476–8 **(Fre)**

[Therapy-induced formation of ascites and pleural effusion during initial chemotherapy in a patient with non-Hodgkin's lymphoma. Ascites and pleural effusion during initial chemotherapy] Gruhn B, et al. **Klin Padiatr** 1995 Nov-Dec;207(6):317–20 (Eng. Abstr.) **(Ger)**

[Severe neuropathy after chemo- and radiotherapy of Ewing sarcoma] Lilje C, et al. **Klin Padiatr** 1995 Jul-Aug; 207(4):204–6 (Eng. Abstr.) **(Ger)**

[Effect of various therapeutic protocols on growth and final height of children with acute lymphoblastic leukemia or non-Hodgkin's lymphoma] Timme J, et al. **Klin Padiatr** 1995 Sep-Oct;207(5):267–70 (Eng. Abstr.) **(Ger)**

[Paraplegia following intrathecal chemotherapy] Beretta F, et al. **Schweiz Med Wochenschr** 1996 Jun 22; 126(25):1107–11 (Eng. Abstr.) **(Ger)**

[Modification of liver parameters by adjuvant administration of proteolytic enzymes following chemotherapy in patients with ovarian carcinoma] Lahousen M. **Wien Med Wochenschr** 1995;145(24):663–8 (Eng. Abstr.) **(Ger)**

[Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors] Kitada M, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):87–91 (Eng. Abstr.) **(Jpn)**

[A case of secondary leukemia in anaplastic seminoma patient treated with long-term chemotherapy] Kamai T, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 May;87(5):875–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Leukoencephalopathy in a patient being treated for small cell lung cancer] Kaneko T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1130–4 (Eng. Abstr.) **(Jpn)**

[Secondary myeloid/natural killer cell acute leukemia appeared in multiple myeloma treated with melphalan] Kaya H, et al. **Rinsho Ketsueki** 1995 Jul;36(7):682–6 (Eng. Abstr.) **(Jpn)**

[Therapy-related AML(M2) with t(8;21) that developed three years after chemotherapy for hepatocellular carcinoma] Miyata A, et al. **Rinsho Ketsueki** 1996 May; 37(5):448–51 (Eng. Abstr.) **(Jpn)**

[Assessment of cardiac toxicity by 123I-MIBG myocardial SPECT in elderly non-Hodgkin lymphoma patients treated with COP-BLAM and G-CSF] Niitsu N, et al. **Rinsho Ketsueki** 1995 Nov;36(11):1326–8 (Eng. Abstr.) **(Jpn)**

[Acute myeloid leukemia (M1) following chemotherapy for Ki-1 lymphoma complicated with rheumatoid arthritis] Yoshida K, et al. **Rinsho Ketsueki** 1995 Dec;36(12):1365–71 (Eng. Abstr.) **(Jpn)**

[Nephrotoxicity evaluation of cytostatic agents in children with acute lymphoblastic leukemia] Tomaszewska B, et al. **Pediatr Pol** 1995 Nov;70(11):915–20 (Eng. Abstr.) **(Pol)**

[Multiple neoplasms after a well succeeded treatment of Hodgkin's disease] Moraes-Souza H, et al. **Rev Assoc Med Bras** 1995 Jan-Feb;41(1):77–9 (Eng. Abstr.) **(Por)**

[Spontaneous pneumothorax in response to chemotherapy of metastatic germinal tumor (letter)] Vicente P, et al. **An Med Interna** 1995 Jun;12(6):307–8 **(Spa)**

[Electrolytic changes in children with acute lymphoblastic leukemia during remission induction] Benítez H, et al. **Sangre (Barc)** 1995 Jun;40(3):213–7 (Eng. Abstr.) **(Spa)**

ANTAGONISTS & INHIBITORS

Vitamin E protects intestinal basolateral membrane from CMF-induced damages in rat. Subramaniam S, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):263–6

DIAGNOSTIC USE

Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Zinzani PL, et al. **Leuk Lymphoma** 1995 Oct; 19(3-4):329–35

ECONOMICS

Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Uyl-de Groot CA, et al. **Bone Marrow Transplant** 1995 Sep;16(3):463–70

Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges. Lokich JJ, et al. **Cancer** 1996 Jul 15;78(2):294–9

Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis. Lokich JJ, et al. **Cancer** 1996 Jul 15;78(2):300–3

Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. The Japan Adult Leukemia Study Group. Takeshita A, et al. **Cancer** 1995 Aug 15;76(4):602–8

Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens. Norum J, et al. **J Chemother** 1995 Oct;7(5):455–9

METABOLISM

Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Meropol NJ, et al. **Semin Oncol** 1995 Oct;22(5):509–24 (153 ref.)

PHARMACOKINETICS

Pharmacokinetics and anti-tumour activity of B.4152, a reactive molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, and its uracil analogue. Loadman PM, et al. **Anticancer Drug Des** 1996 Mar; 11(2):117–28

Reversal of multidrug resistance by amitriptyline in vitro. Varga A, et al. **Anticancer Res** 1996 Jan-Feb;16(1):209–11

Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. English MW, et al. **Br J Cancer** 1996 Mar;73(6):776–80

Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Lemaire M, et al. **Cancer Chemother Pharmacol** 1996; 38(5):481–6

Difference in CDDP penetration into CSF between selective intraarterial chemotherapy in patients with malignant glioma and intravenous or intracarotid administration in patients with metastatic brain tumor. Nakagawa H, et al. **Cancer Chemother Pharmacol** 1996;37(4):317–26

Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Vassal G, et al. **Cancer Chemother Pharmacol** 1996;37(3):247–53

In vitro investigation of a combination of two drugs, cisplatin and carboplatin, as a function of the area under the c/t curve. Kobayashi K, et al. **J Cancer Res Clin Oncol** 1995; 121(12):715–20

Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. Kerr DJ, et al. **J Clin Oncol** 1995 Dec;13(12):2968–72

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4–hydroxycyclophosphamide regimen in breast cancer patients. Sandström M, et al. **J Clin Oncol** 1996 May; 14(5):1581–8

Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Calvert AH, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):91–8; discussion 99–100

Pharmacokinetics of paclitaxel and carboplatin in combination. Kearns CM, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):1–4; discussion 5–7

A clinical and pharmacokinetic study of high–dose carboplatin, paclitaxel, granulocyte colony–stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. Shea T, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):80–5

PHARMACOLOGY

Chemosensitizing effect of tamoxifen and ICI 182,780 on parental and adriamycin–resistant MCF–7 human breast cancer cells. de Vincenzo R, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:517–20

Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses. Garcia P, et al. **Anticancer Drugs** 1995 Aug;6(4):533–44

Combination therapy with 5–fluorouracil and L–canavanine: in vitro and in vivo studies. Swaffar DS, et al. **Anticancer Drugs** 1995 Aug;6(4):586–93

Growth inhibition of breast cancer cell lines by combinations of anti–P185HER2 monoclonal antibody and cytokines. Kopreski MS, et al. **Anticancer Res** 1996 Jan–Feb; 16(1):433–6

Immunohistochemical characterisation of immunological changes at the tumour site after chemo–immunotherapy with doxorubicin, interleukin–2 and interferon–gamma. Lumsden AJ, et al. **Anticancer Res** 1996 May–Jun; 16(3A):1145–54

Reversal of multidrug resistance by amitriptyline in vitro. Varga A, et al. **Anticancer Res** 1996 Jan–Feb;16(1):209–11

Interaction of retinoic acid and interferon–alpha in breast cancer cell lines. Widschwendter M, et al. **Anticancer Res** 1996 Jan–Feb;16(1):369–74

Antitumor activity of menogaril alone, and in combination against human mammary cancer models in mice and rats. Yoshida M, et al. **Anticancer Res** 1996 May–Jun; 16(3A):1155–9

Influence of 2–chloro–2'–deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210. Góra–Tybor J, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):39–42

Effect of captopril and thiorphan on the proliferation of human neoplastic cell lines and their influence on cytostatic activity of interferon alpha or cytotoxic activity of doxorubicin. Kowalski J, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(1):47–50

Antitumour effects of pure diastereoisomers of 5–formyltetrahydrofolate in hepatic transplants of a rodent colon carcinoma model. Carlsson G, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1347–51

An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Weaver CH, et al. **Blood** 1995 Nov 15; 86(10):3961–9

Schedule–dependent interaction between paclitaxel and 5–fluorouracil in human carcinoma cell lines in vitro. Kano Y, et al. **Br J Cancer** 1996 Sep;74(5):704–10

Activity– and schedule–dependent interactions of paclitaxel, etoposide and hydroperoxy–ifosfamide in cisplatin–sensitive and –refractory human ovarian carcinoma cell lines. Klaassen U, et al. **Br J Cancer** 1996 Jul;74(2):224–8

The effect of tirapazamine (SR–4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Lartigau E, et al. **Br J Cancer** 1996 Jun;73(12):1480–5

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine–resistant prolactinomas. Missale C, et al. **Br J Cancer** 1995 Dec;72(6):1397–9

Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P–glycoprotein. Quesada AR, et al. **Br J Cancer** 1996 Sep;74(5):677–82

Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Sliutz G, et al. **Br J Cancer** 1996 Jul;74(2):172–7

Potentiation of cytotoxic therapies by TNP–470 and minocycline in mice bearing EMT–6 mammary carcinoma. Teicher BA, et al. **Breast Cancer Res Treat** 1995; 36(2):227–36

Growth inhibitory action of brefeldin A with taxol and tiazofurin in human breast carcinoma cells. Yeh YA, et al. **Cancer Biochem Biophys** 1995 Jun;15(1):11–7

Schedule–dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Chou TC, et al. **Cancer Chemother Pharmacol** 1996;37(3):222–8

Potentiation of antitumor and antimetastatic activities of adriamycin by a novel N–alkylated dihydropyridine, AC394, and its enantiomers in colon cancer–bearing mice. Ohishi K, et al. **Cancer Chemother Pharmacol** 1996; 38(5):446–52

Specific anti–EL4–lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin–2. Ehrke MJ, et al. **Cancer Immunol Immunother** 1996 May;42(4):221–30

Effect of human recombinant interferon–alpha on the activity of cis–diamminedichloroplatinum(II) in human non–small cell lung cancer xenografts. French RC, et al. **Cancer Invest** 1995;13(6):595–603

Synergism of the polyamine analogue, N1,N11–bisethylnorspermine with cis–diaminedichloroplatinum (II) against murine neoplastic cell lines in vitro and in vivo. Hawthorne TR, et al. **Cancer Lett** 1996 Jan 19;99(1):99–107

Combined effects of 13–cis–retinoic acid, tamoxifen and interferon on the growth of human breast cancer cells. Lama G, et al. **Cancer Lett** 1996 Feb 27;100(1–2):181–9

Synergistic inhibitory effects of interferon–alpha and 5–fluorouracil in meningioma cells in vitro. Zhang ZJ, et al. **Cancer Lett** 1996 Feb 27;100(1–2):99–105

Combination of a potent 20–epi–vitamin D3 analogue (KH 1060) with 9–cis–retinoic acid irreversibly inhibits clonal growth, decreases bcl–2 expression, and induces apoptosis in HL–60 leukemic cells. Elstner E, et al. **Cancer Res** 1996 Aug 1;56(15):3570–6

delta 12–Prostaglandin–J2 is cytotoxic in human malignancies and synergizes with both cisplatin and radiation. McClay EF, et al. **Cancer Res** 1996 Sep 1;56(17):3866–9

Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin. McClay EF, et al. **Cancer Res** 1996 Sep 1;56(17):3993–7

Changes in erythrocyte membrane lipids in breast cancer after radiotherapy and chemotherapy. Vasigara Singh W, et al. **Chemotherapy** 1996 Jan–Feb;42(1):65–70

Effects of TNF alone or in combination with chemotherapeutic agents on human ovarian cancers in vitro and in nude mice. Zhao E, et al. **Chin Med J (Engl)** 1995 Aug;108(8):571–5

Immunomodulatory effects of alpha interferon and thymostimulin in patients with neoplasias. Munno I, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):503–5

Etoposide combined with interferon alfa–2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Mick R, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):349–59

Azidothymidine in combination with 5–fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA–induced strand–breaks. Andreuccetti M, et al. **Eur J Cancer** 1996 Jun;32A(7):1219–26

The role of interferon–alpha as a modulator of fluorouracil and leucovorin. Grem JL, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1316–20 (29 ref.)

The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5–fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts. Jansen WJ, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2313–9

In vivo effects of 4–amidinoindan–1–one 2'–amidinohydrazone (CGP 48664A) and alpha–difluoromethylornithine (DFMO) on L1210 growth, cell–cycle phase distribution and polyamine contents. Dorhout B, et al. **Int J Cancer** 1995 Sep 15;62(6):738–42

Inhibition of cell growth by combination of alpha–difluoromethylornithine and an inhibitor of spermine synthase. He Y, et al. **J Biochem (Tokyo)** 1995 Apr; 117(4):824–9

Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol–induced growth of MCF–7 breast cancer cells. Di Monaco M, et al. **J Cancer Res Clin Oncol** 1995; 121(12):710–4

In vitro investigation of a combination of two drugs, cisplatin and carboplatin, as a function of the area under the c/t curve. Kobayashi K, et al. **J Cancer Res Clin Oncol** 1995; 121(12):715–20

An attempt to enhance chemosensitivity of quiescent cell populations in solid tumors by combined treatment with nicotinamide and carbogen. Masunaga S, et al. **J Cancer Res Clin Oncol** 1996;122(9):533–40

Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509–035) in the CC531 rat colon carcinoma model. Van de Vrie W, et al. **J Cancer Res Clin Oncol** 1996;122(7):403–8

Interferon–gamma and tumor necrosis factor–alpha treatment of ex vivo human carcinoma cells potentiates their interaction with allogeneic lymphocytes. Vánky F, et al. **J Interferon Cytokine Res** 1996 Mar;16(3):201–7

Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833 [see comments] Beketic–Oreskovic L, et al. **J Natl Cancer Inst** 1995 Nov 1;87(21):1593–602. Comment in: J Natl Cancer Inst 1995 Nov 1;87(21):1573–5.

The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers? [editorial; comment] Greco WR, et al. **J Natl Cancer Inst** 1996 Jun 5;88(11):699–700. Comment on: J Natl Cancer Inst 1996 Jun 5;88(11):734–41.

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines [see comments] Kaufmann SH, et al. **J Natl Cancer Inst** 1996 Jun 5; 88(11):734–41. Comment in: J Natl Cancer Inst 1996 Jun 5;88(11):699–700.

Enhancement of vincristine cytotoxicity in drug–resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. Rybak SM, et al. **J Natl Cancer Inst** 1996 Jun 5;88(11):747–53

Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. Stein U, et al. **J Natl Cancer Inst** 1996 Oct 2;88(19):1383–92

Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. Prasanna P, et al. **J Neurochem** 1996 Feb;66(2):710–6

Dipyridamole combined with tumor necrosis factor–alpha enhances inhibition of proliferation in human tumor cell lines. Suzuki N, et al. **Jpn J Cancer Res** 1995 Aug; 86(8):761–9

Mechanisms of inhibition of IL–6–mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines. Shiao RT, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):293–303

Influence of rhGM–CSF on Ara–C sensitivity of patients with acute myeloid leukemia in relapse: a flow cytometry study. Lacombe F, et al. **Leuk Res** 1996 Jun;20(6):481–9

Modulation of cisplatin resistance in acquired–resistant nonsmall cell lung cancer cells. Lai SL, et al. **Oncol Res** 1995;7(1):31–8

Antitumor effect of arterial administration of a medium–chain triglyceride solution of an angiogenesis inhibitor, TNP–470, in rabbits bearing VX–2 carcinoma. Yanai S, et al. **Pharm Res** 1995 May;12(5):653–7

Possible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities [letter] Malacarne P, et al. **Recenti Prog Med** 1996 Mar;87(3):135

The modulating effect of interferon alpha–2a on the antitumor activity of UFT against a human gastric carcinoma xenograft, SC–1–NU, in nude mice. Kubota T, et al. **Surg Today** 1996;26(1):12–4

[Synergistic effects of tumor necrosis factor interferon–gamma and chemotherapeutic drugs on human ovarian cancer cell lines in vitro] Li J, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov;17(6):429–31 (Eng. Abstr.) **(Chi)**

[Evaluation of subrenal capsule assay (SRC) for clinical cancers] Akao S, et al. **Gan To Kagaku Ryoho** 1996 Apr; 23(5):607–13 (Eng. Abstr.) **(Jpn)**

[Light and electron microscopic examination compared to evaluation by tumor size in subrenal capsule assay for chemosensitivity testing in esophageal cancer] Akao S, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1813–9 (Eng. Abstr.) **(Jpn)**

[Effects of carboplatin combination with etoposide against leukemia/lymphoma cell lines] Akutsu M, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):297–302 (Eng. Abstr.) **(Jpn)**

[Effect of 2–chlorodeoxyadenosine, arabinoside cytosine and doxorubicin on acute myeloid leukemia clonogenic cell proliferation] Sawiński K, et al. **Acta Haematol Pol** 1995; 26(3):279–84 (Eng. Abstr.) **(Pol)**

[Effect of chemotherapy on hematopoietic stem cells in peripheral blood] Nieto MJ, et al. **Sangre (Barc)** 1996 Feb; 41(1):29–35 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

CT evaluation of the resectability of gastric cancer postchemotherapy. Gossios K, et al. **Abdom Imaging** 1996 Jul–Aug;21(4):293–8

Combination therapy with interferon alfa–2b and hydroxyurea during the accelerated phase of chronic myelogenous leukemia. Bourantas KL, et al. **Acta Haematol** 1996;95(2):117–21

Evaluation of cytosine arabinoside, carboplatin and etoposide chemotherapy in the treatment of relapsing and refractory non–Hodgkin's lymphoma. Niitsu N, et al. **Acta Haematol** 1996;96(1):36–40

Treatment for adult acute myeloid leukemia: where we stand in 1995 [editorial] Wiernik PH. **Acta Haematol Pol** 1995; 26(3):231–7

Vinorelbine and cisplatin in the treatment of advanced non–small cell lung cancer: results of a multicenter Czech study. Adam Z, et al. **Acta Med Austriaca** 1995;22(5):120–4

Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumours. Bodrogi I, et al. **Acta Med Hung** 1994;50(3–4):275–92

Chemotherapy of advanced breast cancer. Szántó J. **Acta Med Hung** 1994;50(3–4):185–93 (28 ref.)

New aspects in the treatment of bone sarcomas. Szendröi M. **Acta Med Hung** 1994;50(3–4):237–44 (14 ref.)

Combined therapy with interleukin 2 and indomethacin in mice inoculated with MH134 hepatoma. Tanaka N, et al. **Acta Med Okayama** 1995 Oct;49(5):241–5

Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study. Andersson H, et al. **Acta Oncol** 1995;34(6):821–7

Combination chemotherapy with a five–drug regimen for invasive thymoma. Bjerrum OW, et al. **Acta Oncol** 1996; 35(1):71–3

Chemotherapy and radiotherapy in locally advanced cervical cancer. Brunet J, et al. **Acta Oncol** 1995;34(7):941–4

A prospective evaluation of the treatment of primary or metastatic liver carcinoma with hepatic arterial infusion chemotherapy. Cakmakli S, et al. **Acta Oncol** 1996;

35(4):441–4
Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment. Cwikiel M, et al. **Acta Oncol** 1996;35(1):75–9
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE–BOP) combination chemotherapy in the treatment of refractory and relapsed non–Hodgkin's lymphoma. Dinçol D, et al. **Acta Oncol** 1995;34(7):937–40
Methyl–GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non–Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group. Enblad G, et al. **Acta Oncol** 1996; 35(2):165–70
Is the MVP regimen less active than previously described? Results of a phase II study in advanced non–small cell lung cancer. Ferrigno D, et al. **Acta Oncol** 1996;35(4):435–9
Sustained–release metoclopramide plus methylprednisolone versus placebo plus methylprednisolone as antiemetic prophylaxis during non–cisplatin chemotherapy. A randomized double–blind cross–over trial. Hansen O, et al. **Acta Oncol** 1996;35(1):57–61
Surgery for cure followed by chemotherapy in small cell carcinoma of the lung. For the ISC–Lung Cancer Study Group. Karrer K, et al. **Acta Oncol** 1995;34(7):899–906
Combined interferon and vinblastine treatment in advanced renal cell cancer. Kellokumpu–Lehtinen P, et al. **Acta Oncol** 1995;34(7):975–7
A pilot study of interferon alpha and 5–fluorouracil in hepatocellular carcinoma. Mughal TI, et al. **Acta Oncol** 1996;35(2):248
Full chemotherapy in elderly patients with small cell bronchial carcinoma. Nõu E. **Acta Oncol** 1996; 35(4):399–406
Disease extent and response to chemotherapy in non–small cell lung cancer. Satoh H, et al. **Acta Oncol** 1996; 35(1):106–7
Systemic mitomycin C as second–line treatment for metastatic urothelial cancer. Sengeløv L, et al. **Acta Oncol** 1995;34(7):978–9
p53 expression and the result of adjuvant therapy of breast cancer. Stål O, et al. **Acta Oncol** 1995;34(6):767–70
Peripheral blood T cell subsets as prognostic indicators of chemotherapy outcome in AIDS patients with large cell lymphoma. Patarca R, et al. **AIDS Res Hum Retroviruses** 1996 May 20;12(8):645–9
Cisplatin, 5–fluorouracil, and high–dose folinic acid in patients with advanced unresectable head and neck cancer. Alba E, et al. **Am J Clin Oncol** 1996 Apr;19(2):140–3
A phase II study of tamoxifen combined with cisplatin–interleukin 2 and alpha–interferon in metastatic melanoma. Antoine EC, et al. **Am J Clin Oncol** 1995 Oct; 18(5):421–4
Recombinant interferon ALFA–2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma. Bafaloukos D, et al. **Am J Clin Oncol** 1996 Jun;19(3):296–300
M–CAVI, a neoadjuvant carboplatin–based regimen for the treatment of T2–4N0M0 carcinoma of the bladder. Bellmunt J, et al. **Am J Clin Oncol** 1996 Aug;19(4):344–8
Neoadjuvant chemotherapy with cisplatin–vindesine–5–fluorouracil and folinic acid for locally advanced head and neck carcinoma. Bensmaine M el–A, et al. **Am J Clin Oncol** 1996 Aug;19(4):356–62
Phase I–II trial of recombinant interferon alpha–2b with cisplatin and 5–fluorouracil in recurrent and/or metastatic carcinoma of head and neck. Bensmaine ME, et al. **Am J Clin Oncol** 1996 Jun;19(3):249–54
Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Cascinu S, et al. **Am J Clin Oncol** 1996 Aug;19(4):371–4
Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long–term results. Colozza M, et al. **Am J Clin Oncol** 1996 Feb;19(1):10–7
Efficacy of the association of folinic acid and 5–fluorouracil alone versus folinic acid and 5–fluorouracil plus 4–epidoxorubicin in the treatment of advanced gastric carcinoma. Colucci G, et al. **Am J Clin Oncol** 1995 Dec; 18(6):519–24
Salvage chemotherapy with mitomycin, vindesine, and cisplatin (MiViP) in recurrent carcinoma of the cervix. Delaloye JF, et al. **Am J Clin Oncol** 1996 Apr;19(2):204–6
High–dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer. deMagalhaes–Silverman M, et al. **Am J Clin Oncol** 1996 Apr;19(2):169–73
High–dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Di Costanzo F, et al. **Am J Clin Oncol** 1996 Jun;19(3):307–10
Cisplatin and UFT modulated with leucovorin for the treatment of Advanced non–small–cell lung cancer. Feliu J, et al. **Am J Clin Oncol** 1996 Apr;19(2):121–4
Phase II trial of mitoxantrone and cisplatin in advanced non–small–cell lung cancer. Feun LG, et al. **Am J Clin Oncol** 1996 Apr;19(2):190–2
Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma. Feun LG, et al. **Am J Clin Oncol** 1995 Dec;18(6):488–90
The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG–8921). Flaherty LE, et al. **Am J Clin Oncol** 1996 Apr;19(2):108–13
Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small–cell lung cancer. Frytak S, et al. **Am J Clin Oncol** 1996 Apr;19(2):193–8
Treatment of stage III–IV non–small–cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM). Gebbia V, et al. **Am J Clin Oncol** 1996 Jun; 19(3):278–80
Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa–2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Gertz MA, et al. **Am J Clin Oncol** 1995 Dec;18(6):475–80
Prospective phase I/II studies of definitive irradiation and chemotherapy for advanced gynecologic malignancies. Grigsby PW, et al. **Am J Clin Oncol** 1996 Feb;19(1):1–6
Concurrent 5–fluorouracil, daily low–dose cisplatin, and radiotherapy in stage IIIB cervical cancer. A phase II prospective study. Hsu WL, et al. **Am J Clin Oncol** 1996 Jun;19(3):263–7
A combination of vinblastine and doxorubicin with interferon alpha. Jekunen A, et al. **Am J Clin Oncol** 1996 Aug; 19(4):384–5
Phase II trial of 5–fluorouracil, folinic acid, and N,N1,N11–triethylenethiophosphoramide (thiotepa) in patients with advanced breast cancer. Joseph G, et al. **Am J Clin Oncol** 1995 Oct;18(5):385–8
High–dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer. Kalaycioglu ME, et al. **Am J Clin Oncol** 1995 Dec; 18(6):491–4
The role of neoadjuvant intraarterial infusion chemotherapy with cisplatin and bleomycin for locally advanced cervical cancer. Kigawa J, et al. **Am J Clin Oncol** 1996 Jun; 19(3):255–9
Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma. Kim YH, et al. **Am J Clin Oncol** 1996 Apr; 19(2):212–6
Combined application of cisplatin, vindesine, hyaluronidase and radiation for treatment of advanced squamous cell carcinoma of the head and neck. Klocker J, et al. **Am J Clin Oncol** 1995 Oct;18(5):425–8
Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma. Leone B, et al. **Am J Clin Oncol** 1996 Apr;19(2):132–5
Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia. Letendre L, et al. **Am J Clin Oncol** 1995 Oct;18(5):382–4
Accelerated epirubicin–ifosfamide–dacarbazine regimen in patients with adult soft tissue sarcomas. Michelotti A, et al. **Am J Clin Oncol** 1996 Feb;19(1):78–81
Prophylactic filgrastim (G–CSF) during mitomycin–C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. Muhonen T, et al. **Am J Clin Oncol** 1996 Jun;19(3):232–4
Phase I study of a carboplatin–cisplatin–etoposide combination chemotherapy in advanced non–small–cell lung cancer. Nakano H, et al. **Am J Clin Oncol** 1996 Jun; 19(3):245–8
Myxoid malignant fibrous histiocytoma: experience with chemotherapy. Patel SR, et al. **Am J Clin Oncol** 1995 Dec; 18(6):528–31
Phase II trial of isotretinoin and recombinant interferon alfa–2a in metastatic colorectal carcinoma. Pazdur R, et al. **Am J Clin Oncol** 1995 Oct;18(5):436–8
Chemotherapy for Merkel cell carcinoma with carboplatin and etoposide. Pectasides D, et al. **Am J Clin Oncol** 1995 Oct;18(5):418–20
Simultaneous radiochemotherapy for recurrent and metastatic breast carcinoma: evaluation of two treatment concepts. Plasswilm L, et al. **Am J Clin Oncol** 1996 Aug; 19(4):403–7
Randomized trial of 5–fluorouracil and high–dose folinic acid with or without alpha–2B interferon in advanced colorectal cancer. Recchia F, et al. **Am J Clin Oncol** 1996 Jun; 19(3):301–4
Concurrent 72–hour continuous infusion of etoposide and cisplatin in metastatic breast cancer. Remick SC, et al. **Am J Clin Oncol** 1996 Apr;19(2):125–31
Chemotherapy of Mediterranean abdominal lymphoma. Retrospective comparison of chemotherapy protocols in Iranian patients. Salimi M, et al. **Am J Clin Oncol** 1996 Feb;19(1):18–22
Etoposide–cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small–cell carcinoma of the lung. Shaw EG, et al. **Am J Clin Oncol** 1996 Apr; 19(2):154–8
A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa. Stein ME, et al. **Am J Clin Oncol** 1996 Aug;19(4):386–8
Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy. Takahashi T, et al. **Am J Clin Oncol** 1996 Aug;19(4):408–15
A pilot trial of 5–FU, leucovorin, and cisplatin with or without adriamycin in advanced cancer. Vaughn DJ, et al. **Am J Clin Oncol** 1996 Jun;19(3):241–4
Phase II evaluation of low–dose continuous 5–fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study. Williamson SK, et al. **Am J Clin Oncol** 1995 Dec;18(6):484–7
Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. Williamson SK, et al. **Am J Clin Oncol** 1996 Aug; 19(4):368–70
Treatment of metastatic adrenal cortical carcinoma with etoposide (VP–16) and cisplatin after failure with o,p'DDD. Clinical case reports. Zidan J, et al. **Am J Clin Oncol** 1996 Jun;19(3):229–31
Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improve the prognosis in aggressive malignant lymphoma. Avilés A, et al. **Am J Hematol** 1996 Aug;52(4):275–80
HyperCVAD for VAD–resistant multiple myeloma. Dimopoulos MA, et al. **Am J Hematol** 1996 Jun;52(2):77–81
Pilot study of 5–azacytidine (5–AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia. Kritz AD, et al. **Am J Hematol** 1996 Feb;51(2):117–21
Loss of HBsAg in chronic hepatitis B carrier following high–dose chemotherapy and autologous peripheral blood stem cell rescue for lymphoma [letter] Lau GK, et al. **Am J Hematol** 1995 Dec;50(4):317–8
Phase II study of high–dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer. Cain JM, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1688–94; discussion 1694
Visual function after laser hyperthermia and chemotherapy for macular retinoblastoma. Lueder GT, et al. **Am J Ophthalmol** 1996 May;121(5):582–4
Lung cancer chemotherapy. Response–survival relationship depends on the method of chest tumor response evaluation. Pujol JL, et al. **Am J Respir Crit Care Med** 1996 Jan; 153(1):243–9
Improved survival with preoperative chemotherapy followed by resection uncompromised by tumor response for advanced squamous cell carcinoma of the head and neck. Loré JM Jr, et al. **Am J Surg** 1995 Nov;170(5):506–11
The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Jain V, et al. **Am Surg** 1996 Feb;62(2):162–5
Serum 5'-nucleotidase and alkaline phosphatase activities after high dose chemotherapy and bone marrow transplantation in cases of malignancy in children. Clerc–Renaud P, et al. **Ann Biol Clin (Paris)** 1995; 53(3):125–30
Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose–intensive chemotherapy. Bokemeyer C, et al. **Ann Hematol** 1996 Jan;72(1):1–9 (62 ref.)
Intensive induction and consolidation chemotherapy in a young woman with acute myeloid leukemia and severe chronic renal failure. Hardegger TP, et al. **Ann Hematol** 1996 May;72(5):327–8
High–dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long–term follow–up of a prospective multicenter trial. Heil G, et al. **Ann Hematol** 1995 Nov; 71(5):219–25
Primary plasma cell leukemia with extensive dense osteosclerosis: complete remission following combination chemotherapy. Kuo MC, et al. **Ann Hematol** 1995 Sep; 71(3):147–51
Kinetics of minimal residual disease during induction/consolidation therapy in standard–risk adult B–lineage acute lymphoblastic leukemia. Scholten C, et al. **Ann Hematol** 1995 Oct;71(4):155–60
Plasma levels of IL–1, TNF alpha, IL–6, IL–8, G–CSF, and IL1–RA during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia. Schönbohn H, et al. **Ann Hematol** 1995 Oct;71(4):161–8
Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single–center study. Thalhammer F, et al. **Ann Hematol** 1996 Apr;72(4):216–22
Interferon–alpha 2b added to melphalan–prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group [see comments] **Ann Intern Med** 1996 Jan 15; 124(2):212–22. Comment in: Ann Intern Med 1996 Jan 15;124(2):264–5.
Effects of primary chemotherapy on biological parameters of locally advanced breast cancer. Collecchi P, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:419–26
A phase I trial of intermittent high–dose alpha–interferon and dexamethasone in metastatic renal cell carcinoma. Amato R, et al. **Ann Oncol** 1995 Nov;6(9):911–4
Phase II trial of 5–fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. André T, et al. **Ann Oncol** 1996 Feb;7(2):173–8
Ambulatory low–toxicity chemotherapy in non–small–cell lung carcinoma by continuous 28–day infusion of alternating cisplatin and 5–fluorouracil. Bedini AV, et al.

Ann Oncol 1995 Oct;6(8):838–40

Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma—a multicenter phase II study. Bergmann L, et al. **Ann Oncol** 1995 Dec;6(10):1019–24

High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Bierman PJ, et al. **Ann Oncol** 1996 Feb;7(2):151–6

Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial. Björkholm M, et al. **Ann Oncol** 1995 Nov; 6(9):895–9

Chemotherapy in advanced non-small-cell lung cancer. The experience of Italian Cooperative Groups. Crinò L. **Ann Oncol** 1995;6 Suppl 3:S45–7

Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer. Crown J, et al. **Ann Oncol** 1995;6 Suppl 4:21–6 (61 ref.)

Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG). Diehl V, et al. **Ann Oncol** 1995 Nov; 6(9):901–10

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease [see comments] Fermé C, et al. **Ann Oncol** 1995 Jul;6(6):543–9. Comment in: Ann Oncol 1995 Jul;6(6):517–8.

Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma. Gabarre J, et al. **Ann Oncol** 1995 Dec; 6(10):1025–32

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial. Gebbia V, et al. **Ann Oncol** 1995 Dec;6(10):987–91

The role of induction therapy and surgery for stage IIIA lung cancer. Ginsberg RJ. **Ann Oncol** 1995;6 Suppl 3:S29–32 (32 ref.)

Assessment of 'quality of life' using a daily diary card in a randomised trial of chemotherapy in small-cell lung cancer. Gower NH, et al. **Ann Oncol** 1995 Jul;6(6):575–80

Rationale for high-dose chemotherapy and application of haematopoietic growth factors in acute myeloid leukaemia. Hiddemann W, et al. **Ann Oncol** 1995;6 Suppl 4:27–31 (33 ref.)

A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer. Huan SD, et al. **Ann Oncol** 1995 Oct;6(8):836–7

A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours. Hughes MJ, et al. **Ann Oncol** 1996 Feb;7(2):208–10

Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects. Lopez M, et al. **Ann Oncol** 1995 Dec;6(10):1011–7

High-dose chemotherapy for breast cancer: clinical advantages of autologous peripheral blood progenitor cells (PBPC) compared with autologous bone marrow transplantation (ABMT). Martin M. **Ann Oncol** 1995;6 Suppl 4:33–7 (18 ref.)

Cisplatin and protracted venous infusion 5-fluorouracil (CF)—good symptom relief with low toxicity in advanced pancreatic carcinoma. Nicolson M, et al. **Ann Oncol** 1995 Oct;6(8):801–4

First-line systemic therapy for metastatic breast cancer and management of pleural effusion. Perrone F, et al. **Ann Oncol** 1995 Dec;6(10):1033–43 (93 ref.)

Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Pirker R, et al. **Ann Oncol** 1995 Oct;6(8):833–5

A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial [see comments] Planting A, et al. **Ann Oncol** 1996 Feb; 7(2):139–44. Comment in: Ann Oncol 1996 Feb;7(2):119–20.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Planting AS, et al. **Ann Oncol** 1995 Jul; 6(6):613–5

Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. Poorter RL, et al. **Ann Oncol** 1995 Dec; 6(10):1048–9

A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Rodriguez MA, et al. **Ann Oncol** 1995 Jul;6(6):609–11

Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer. Sagaster P, et al. **Ann Oncol** 1995 Dec; 6(10):999–1003

High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Seymour JF, et al. **Ann Oncol** 1996 Feb; 7(2):157–63

Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Lowy AM, et al. **Ann Surg** 1996 Feb;223(2):177–85

5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Pouliquen X, et al. **Ann Surg** 1996 Feb; 223(2):127–33

Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy [see comments] Bauer RL, et al. **Ann Surg Oncol** 1995 Jul;2(4):288–94. Comment in: Ann Surg Oncol 1995 Jul;2(4):283–5.

Doxorubicin for inflammatory breast cancer: a red humor for a red tumor? [editorial; comment] Legler CM, et al. **Ann Surg Oncol** 1995 Jul;2(4):283–5. Comment on: Ann Surg Oncol 1995 Jul;2(4):288–94.

Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy. Lise M, et al. **Ann Surg Oncol** 1995 Nov;2(6):495–501

Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Macdonald JS, et al. **Ann Surg Oncol** 1995 Nov;2(6):488–94

Combination chemotherapy for disseminated malignant melanoma. Abbott KL, et al. **Anticancer Drugs** 1995 Aug; 6(4):489–97 (74 ref.)

Current chemotherapy of advanced non-small cell lung cancer. Abratt RP. **Anticancer Drugs** 1995 Dec;6 Suppl 6:15–8 (29 ref.)

Escalating dose of tegafur combined with oral etoposide in metastatic gastric carcinoma. Cascinu S, et al. **Anticancer Drugs** 1995 Aug;6(4):608–11

Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer. Koch P, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:49–54

Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts. Smith JP, et al. **Anticancer Drugs** 1995 Dec; 6(6):717–26

Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II study. Steward WP, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:33–7

Combination therapy with 5-fluorouracil and L-canavanine: in vitro and in vivo studies. Swaffar DS, et al. **Anticancer Drugs** 1995 Aug;6(4):586–93

Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Thatcher N, et al. **Anticancer Drugs** 1995 Dec; 6 Suppl 6:39–48 (68 ref.)

5-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: a pilot study. Tsavaris N, et al. **Anticancer Drugs** 1995 Aug;6(4):599–603

Ineffectiveness of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX regimen) as a salvage therapy in advanced colorectal cancers and other gastrointestinal tumors. Adenis A, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):2063–7

Concomitant administration of two standard regimens of chemotherapy and radiotherapy in advanced squamous carcinoma of the head and neck: a feasibility study. Benasso M, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2651–4

Palliative chemotherapy in metastatic colorectal carcinoma: comparison of two chemotherapeutic regimens. Bremnes RM, et al. **Anticancer Res** 1996 Mar-Apr;16(2):921–6

Natural interferon-beta and tamoxifen in hormone-resistant patients with advanced breast cancer. Buzzi E, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2187–90

Combination therapy with subcutaneous interleukin-2 and interferon-alpha in advanced renal cancer patients with poor prognostic factors. Canobbio L, et al. **Anticancer Res** 1996 Jan-Feb;16(1):541–4

Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Canobbio L, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2687–90

The clinical impact of FEM regimen (5-fluorouracil, 4-epidoxorubicin and mitomycin-C) in advanced gastric cancer patients. Cascinu S, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2781–3

Immunological alterations induced by adjuvant treatment of postoperative colon carcinoma Duke's B or C with levamisole in combination with 5-FU. De Brabander M, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2271–7

D-CECaT as preoperative chemotherapy for unresectable neuroblastoma in children over one year of age. Donfrancesco A, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):2347–50

Pilot trial of a combination comprising of consecutive oral administration of UFT, and two-divided administration of CDDP in non-small cell lung cancer. Gemma A, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2691–5

Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Iino Y, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2907–11

Usefulness of lymphocyte subset change as an indicator for predicting survival time and effectiveness of treatment with the immunopotentiator lentinan. Matsuoka H, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2291–6

Neo-adjuvant chemotherapy with carboplatin, 4-epiadriamycin and teniposide (CET) in locally advanced cancer of the cardia and the lower oesophagus: a phase II study. Plukker JT, et al. **Anticancer Res** 1995 Sep-Oct; 15(5B):2357–61

Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorin. Pronzato P, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2679–82

Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial. Salvati F, et al. **Anticancer Res** 1996 Mar-Apr;16(2):1001–4

Anti-proliferative and cytokinetic effects of tumor necrosis factor-alpha, interferon-alpha and 5-fluorouracil on a human tumor xenograft. Tanaka N, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):1949–52

Mitomycin C, methotrexate, and vincristine with medroxyprogesterone acetate or predniso one for doxorubicin resistant advanced breast cancer—a randomized control study. Tashiro H, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2229–37

Efficacy of the association of 13-cis-retinoic acid (13cRA) and alpha-interferon 2a (alpha-IFN 2a) in moderate-severe cervical intraepithelial neoplasia (CIN II-III): a pilot study. Toma S, et al. **Anticancer Res** 1996 Mar-Apr;16(2):931–6

Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer. Yokoe T, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):2069–72

Phase II trial of mitoxantrone, doxifluridine and medroxyprogesterone acetate as second-line treatment for anthracycline-resistant metastatic breast cancer. Yokoe T, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2303–5

Failure of interferon alfa and isotretinoin combination therapy in the nevoid basal cell carcinoma syndrome [letter] Sollitto RB, et al. **Arch Dermatol** 1996 Jan;132(1):94–5

Maintenance treatment and shared care in lymphoblastic leukaemia. Chessells JM. **Arch Dis Child** 1995 Oct; 73(4):368–73

An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children. Lashford LS, et al. **Arch Dis Child** 1996 Mar;74(3):219–23

Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Ibrahim NK, et al. **Arch Intern Med** 1996 Apr 22;156(8):882–8

Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base. Brasnu D, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):765–8

Preresection chemotherapy improves survival for children with Askin tumors. Sawin RS, et al. **Arch Surg** 1996 Aug; 131(8):877–80

Preoperative "chemoradiation" for stages II and III rectal carcinoma. Stryker SJ, et al. **Arch Surg** 1996 May; 131(5):514–8; discussion 518–9

The role of neoadjuvant therapy in surgically resectable esophageal cancer. Swisher SG, et al. **Arch Surg** 1996 Aug; 131(8):819–24; discussion 824–5

Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centres. Jameson MB, et al. **Aust N Z J Med** 1995 Jun;25(3):224–9

Cytotoxic chemotherapy and radiotherapy in a patient with breast cancer and variegate porphyria (VP) [letter] Scarlett JD, et al. **Aust N Z J Med** 1995 Dec;25(6):742–3

Prolonged survival follows resection of oesophageal SCC downstaged by prior chemoradiotherapy. Bessell JR, et al. **Aust N Z J Surg** 1996 Apr;66(4):214–7

Primary peritoneal carcinoma: a treatable subset of patients with adenocarcinoma of unknown primary. Della-Fiorentina SA, et al. **Aust N Z J Surg** 1996 Feb; 66(2):124–5

Biochemical modulation of tumor cell energy. IV. Evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically-induced tumor regression. Colofiore JR, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1943–8

Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia. Keuzenkamp-Jansen CW, et al. **Biochem Pharmacol** 1996 May 3;51(9):1165–71

Correlation of retention of tumor methylmercaptopurine riboside-5'-phosphate with effectiveness in CD8F1 murine mammary tumor regression. Nord LD, et al. **Biochem Pharmacol** 1996 Mar 8;51(5):621–7

Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach. Emerson SS. **Biometrics** 1995 Sep;51(3):1152–62

AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Avvisati G, et al. **Blood** 1996 Aug 15; 88(4):1390–8

Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. Bacigalupo A, et al. **Blood** 1996 Jul 1;88(1):353–7

Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Delforge M, et al. **Blood** 1995 Nov 15;86(10):3660–7

Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Gandhi V, et al. **Blood** 1996 Jan 1;87(1):256–64

Improved outcome in adult B-cell acute lymphoblastic leukemia. Hoelzer D, et al. **Blood** 1996 Jan 15;87(2):495–508

Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. Liu C, et al. **Blood** 1996 May 1; 87(9):3892–8

Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. O'Shaughnessy JA, et al. **Blood** 1996 Mar 15;87(6):2205–11

A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. O'Shaughnessy JA, et al. **Blood** 1995 Oct 15;86(8):2913–21

Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Rivera GK, et al. **Blood** 1996 Aug 1;88(3):831–7

Aggressive treatment for postcardiac transplant lymphoproliferation. Swinnen LJ, et al. **Blood** 1995 Nov 1;86(9):3333–40

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group [see comments] **BMJ** 1995 Oct 7; 311(7010):899–909. Comment in: BMJ 1995 Oct 7;311(7010):889–90.

Chemotherapy in non-small cell lung cancer. It may not be ethical to ask patients to participate in future trials [letter; comment] Harding M. **BMJ** 1996 Jan 27;312(7025):249. Comment on: BMJ 1995 Oct 7;311(7010):889–90.

Chemotherapy in non-small cell lung cancer. Quality of life was ignored in meta-analysis [letter; comment] Higginson I. **BMJ** 1996 Jan 27;312(7025):249. Comment on: BMJ 1995 Oct 7;311(7010):889–90.

Chemotherapy in non-small cell lung cancer. Large trial will reduce uncertainty. Steering Committee of the Big Lung Trial [letter; comment] Stephens RJ, et al. **BMJ** 1996 Jan 27;312(7025):248–9. Comment on: BMJ 1995 Oct 7;311(7010):889–90.

Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation. Ager S, et al. **Bone Marrow Transplant** 1995 Jul;16(1):79–83

Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow. Almici C, et al. **Bone Marrow Transplant** 1995 Jul;16(1):95–101

Long-term remission obtained by intensive chemotherapy against a leukemic relapse and subsequent graft-versus-host disease following an allogeneic BMT in a patient with myelodysplastic syndrome [letter] Azuno Y, et al. **Bone Marrow Transplant** 1996 Mar;17(3):463–4

Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bitran JD, et al. **Bone Marrow Transplant** 1996 Feb;17(2):157–62

Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. Broun ER, et al. **Bone Marrow Transplant** 1995 Sep;16(3):353–8

Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival. Burns LJ, et al. **Bone Marrow Transplant** 1995 Jul;16(1):13–8

Busulphan and melphalan prior to autologous transplantation for myeloid malignancies. Cony-Makhoul P, et al. **Bone Marrow Transplant** 1995 Jul;16(1):69–70

Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Demirer T, et al. **Bone Marrow Transplant** 1996 Mar; 17(3):341–6

Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation. Forés R, et al. **Bone Marrow Transplant** 1996 Mar;17(3):439–41

Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma. Henon P, et al. **Bone Marrow Transplant** 1995 Jul;16(1):19–25

High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease. Lumley MA, et al. **Bone Marrow Transplant** 1996 Mar; 17(3):383–8

High-dose busulfan and melphalan before bone marrow transplantation for acute nonlymphoblastic leukemia. Martino R, et al. **Bone Marrow Transplant** 1995 Aug; 16(2):209–12

Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukemia. Mehta J, et al. **Bone Marrow Transplant** 1996 Jan;17(1):25–9

Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Michel G, et al. **Bone Marrow Transplant** 1996 Feb;17(2):191–6

Successful pregnancy after allogeneic bone marrow transplantation following conditioning including a 10-Gy single exposure total body irradiation [letter; comment] Milpied N, et al. **Bone Marrow Transplant** 1996 Mar; 17(3):467. Comment on: Bone Marrow Transplant 1995 Apr;15(4):637–8.

Quality of life in long-term survivors of marrow transplantation: comparison with a matched group receiving maintenance chemotherapy. Molassiotis A, et al. **Bone Marrow Transplant** 1996 Feb;17(2):249–58

DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Olivieri A, et al. **Bone Marrow Transplant** 1995 Jul;16(1):85–93

Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center. Powles R, et al. **Bone Marrow Transplant** 1995 Aug;16(2):241–7

High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study. Saez RA, et al. **Bone Marrow Transplant** 1995 Oct;16(4):507–14

Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma. Scheid C, et al. **Bone Marrow Transplant** 1995 Jun;15(6):901–6

Successful paternity of twins following bone marrow transplantation with busulfan, melphalan and cyclophosphamide conditioning. Shepherd JD, et al. **Bone Marrow Transplant** 1996 Mar;17(3):461–2

Chemotherapy and recombinant human granulocyte colony-stimulating factor primed donor leukocyte infusion for treatment of relapse after allogeneic bone marrow transplantation. Sica S, et al. **Bone Marrow Transplant** 1995 Sep;16(3):483–5

A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy. Sosman JA, et al. **Bone Marrow Transplant** 1995 Nov;16(5):655–61

Phase I–II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma. Valteau-Couanet D, et al. **Bone Marrow Transplant** 1995 Oct;16(4):515–20

Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle. von Bueltzingsloewen A, et al. **Bone Marrow Transplant** 1995 Oct;16(4):521–7

Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party. **Br J Cancer** 1996 Feb;73(3):406–13

Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB–IV. Bakker M, et al. **Br J Cancer** 1995 Dec; 72(6):1547–50

Endocrinological late effects after chemotherapy for testicular cancer. Berger CC, et al. **Br J Cancer** 1996 May; 73(9):1108–14

Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Blomqvist C, et al. **Br J Cancer** 1996 May;73(9):1074–9

Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. Bonnefoi H, et al. **Br J Cancer** 1996 Feb; 73(3):391–6

Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma. Brugnatelli S, et al. **Br J Cancer** 1996 Mar;73(6):794–7

Mathematical modelling of tumour response in primary breast cancer. Cameron DA, et al. **Br J Cancer** 1996 Jun; 73(11):1409–16

Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I–II study of the Southern Italy Oncology Group (GOIM). Colucci G, et al. **Br J Cancer** 1995 Nov;72(5):1245–50

A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Evans TR, et al. **Br J Cancer** 1996 May;73(10):1260–4

Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. Facendola G, et al. **Br J Cancer** 1995 Dec;72(6):1531–5

Prognosis after salvage treatment for unselected male patients with germ cell tumours. Gerl A, et al. **Br J Cancer** 1995 Oct;72(4):1026–32

Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study. González-Manzano R, et al. **Br J Cancer** 1995 Nov; 72(5):1294–9

Cancer cell progression and chemoimmunotherapy--dual effects in the induction of resistance to therapy. Hamuro J, et al. **Br J Cancer** 1996 Feb;73(4):465–71

A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer. Iaffaioli RV, et al. **Br J Cancer** 1995 Nov;72(5):1256–8

A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial. James LE, et al. **Br J Cancer** 1996 Jun;73(12):1563–8

A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report. Linch DC, et al. **Br J Cancer** 1996 Jul;74(2):318–22

A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group. Nakano T, et al. **Br J Cancer** 1996 May;73(9):1096–100

Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Neri B, et al. **Br J Cancer** 1996 Feb;73(4):549–52

A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer. Pronzato P, et al. **Br J Cancer** 1996 Jun;73(11):1425–7

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. van der Wall E, et al. **Br J Cancer** 1996 May;73(9):1080–5

Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. van Slooten HJ, et al. **Br J Cancer** 1996 Jul;74(1):78–85

Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. van Warmerdam LJ, et al. **Br J Cancer** 1996 Apr; 73(8):979–84

Curing gastric cancer--hone the scalpel with magic? [editorial] Webb A, et al. **Br J Cancer** 1996 Feb;73(4):418–9

High-dose chemotherapy with autologous stem cell transplantation in a patient with a CD30+ anaplastic large cell lymphoma of the skin [letter] Reinhold U, et al. **Br J Dermatol** 1996 Apr;134(4):811–3

A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Cook G, et al. **Br J Haematol** 1996 Jun 2;93(4):931–4

Mobilization of Philadelphia-negative peripheral blood mononuclear cells in chronic myeloid leukaemia using hydroxyurea and G-CSF (filgrastim). Johnson RJ, et al. **Br J Haematol** 1996 Jun 2;93(4):863–8

A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Lie SO, et al. **Br J Haematol** 1996 Jul;94(1):82–8

The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. GIMEMA Cooperative Group, Italy. Mandelli F, et al. **Br J Haematol** 1996 Mar;92(3):665–72

The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Prince HM, et al. **Br J Haematol** 1996 Mar;92(4):880–9

Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party. Rees JK, et al. **Br J Haematol** 1996 Jul;94(1):89–98

Regulated plasma levels of colony-stimulating factors, interleukin-6 and interleukin-10 in patients with acute leukaemia and non-hodgkin's lymphoma undergoing cytoreductive chemotherapy. Reisbach G, et al. **Br J Haematol** 1996 Mar;92(4):907–12

Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Wisløff F, et al. **Br J Haematol** 1996 Mar;92(3):604–13

Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Wisløff F, et al. **Br J Haematol** 1996 Aug;94(2):324–32

New drugs for the management of lung cancer. Giaccone G. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):634–8 (45 ref.)

Adjuvant treatment in high-risk breast cancer [editorial] Jones A. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):156–8

High-dose chemotherapy with stem cell rescue for solid tumours. Protheroe AS, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):437–41 (29 ref.)

Treatment of carcinomas of the uterine cervix which remain bulky after initial external beam radiotherapy: a pilot study using integrated cytotoxic chemotherapy prior to brachytherapy. Tan LT, et al. **Br J Radiol** 1996 Feb;

69(818):165–71
Preoperative chemotherapy for stage III–IV gastric carcinoma: feasibility, response and outcome after complete resection. Fink U, et al. **Br J Surg** 1995 Sep;82(9):1248–52
Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response. Igawa M, et al. **Br J Urol** 1995 Sep; 76(3):321–4
A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Joffe JK, et al. **Br J Urol** 1996 May;77(5):638–49
Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy. Pu YS, et al. **Br J Urol** 1996 Jan;77(1):76–85
Retroperitoneal metastatic germ-cell testis cancer, presenting different findings on computed tomography and different responses to chemotherapy. Suzuki K, et al. **Br J Urol** 1996 Apr;77(4):608–10
Conservative management of stage T2 or T3a bladder cancer with deep transurethral resection followed by four cycles of chemotherapy. Uygur MC, et al. **Br J Urol** 1996 Aug; 78(2):201–4
Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. Iaffaioli RV, et al. **Breast Cancer Res Treat** 1995 Sep;35(3):243–8
Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients. Mammoliti S, et al. **Breast Cancer Res Treat** 1996; 37(1):93–6
Chemotherapy for desmoid tumours in association with familial adenomatous polyposis: a report of three cases. Hamilton L, et al. **Can J Surg** 1996 Jun;39(3):247–52 (21 ref.)
Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [letter; comment] Anand A, et al. **Cancer** 1996 May 1; 77(9):1959–60. Comment on: Cancer 1995 Dec 1;76(11):2230–6.
Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Bai F, et al. **Cancer** 1996 Aug 1;78(3):416–21
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Bamias A, et al. **Cancer** 1996 May 15;77(10):1978–85
High dose folinic acid and 5-fluorouracil bolus and continuous infusion for patients with advanced colorectal cancer. Bécouarn YH, et al. **Cancer** 1995 Oct 1; 76(7):1126–31
Gestational trophoblastic disease. Berkowitz RS, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2079–85 (81 ref.)
Long term results of a phase I/II study of aggressive chemotherapy and sequential upper and lower hemibody radiation for patients with extensive stage small cell lung cancer. Bonner JA, et al. **Cancer** 1995 Aug 1;76(3):406–12
Creatine kinase elevation associated with 5-fluorouracil and levamisole therapy for carcinoma of the colon. A case report. Cersosimo RJ, et al. **Cancer** 1996 Apr 1;77(7):1250–3
Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cheng AL, et al. **Cancer** 1996 Mar 1;77(5):872–7
Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma [see comments] Chi KH, et al. **Cancer** 1995 Dec 1;76(11):2186–92. Comment in: Cancer 1996 Aug 1;78(3):566–7.
Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group Study [letter] Colucci G. **Cancer** 1996 Mar 1;77(5): 1002–3
Is paclitaxel and cisplatin a cost-effective first-line therapy for advance ovarian carcinoma? Covens A, et al. **Cancer** 1996 May 15;77(10):2086–91
Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques). Dautzenberg B, et al. **Cancer** 1995 Sep 1;76(5):779–86
The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research. De Lisi V, et al. **Cancer** 1996 Jan 15;77(2):245–50
Accelerated fractionation radiotherapy and concomitant chemotherapy in patients with stage IV inoperable head and neck cancer. Dragovic J, et al. **Cancer** 1995 Nov 1; 76(9):1655–61
High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults [letter; comment] Droz JP, et al. **Cancer** 1995 Jul 1; 76(1):154–5. Comment on: Cancer 1995 Feb 1;75(3):874–85.
A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. Elias L, et al. **Cancer** 1996 Sep 1;78(5):1085–8
Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma. Eton O, et al. **Cancer** 1996 Mar 1;77(5):893–9
Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients. Farhat F, et al. **Cancer** 1996 Apr 1;77(7):1363–6
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. Feliu J, et al. **Cancer** 1996 Jul 15;78(2):211–6
Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group. Figlin RA, et al. **Cancer** 1996 Sep 1;78(5):998–1003
Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Fizazi K, et al. **Cancer** 1996 Apr 1;77(7):1315–23
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support. Fleming GF, et al. **Cancer** 1996 Jun 1;77(11):2308–12
Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. Hussain M, et al. **Cancer** 1995 Oct 1;76(7):1233–7
Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial. Ianniello GP, et al. **Cancer** 1996 Jul 1;78(1):63–9
A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck. Johnson JT, et al. **Cancer** 1996 Jan 1;77(1):181–5
Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer. Jones DV Jr, et al. **Cancer** 1995 Nov 15; 76(10):1709–14
Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan. Katakami N, et al. **Cancer** 1996 Jan 1;77(1):63–70
Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma. Kornek G, et al. **Cancer** 1995 Oct 15;76(8):1356–62
Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Kumar P, et al. **Cancer** 1996 Jun 1;77(11):2393–9
A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study. Kuriya S, et al. **Cancer** 1996 Aug 1;78(3):422–6
Bulky centroblastic non-Hodgkin's lymphoma of the cranium vault mimicking brain involvement managed with chemotherapy: a case report. Landys KE, et al. **Cancer** 1995 Oct 1;76(7):1261–7
Resection and adjuvant chemotherapy of pulmonary blastoma. A case report [letter; comment] Larsen H, et al. **Cancer** 1996 Aug 1;78(3):569. Comment on: Cancer 1995 Nov 1;76(9):1537–9.
Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer [letter; comment] Le Péchoux C, et al. **Cancer** 1995 Aug 1;76(3):530–1. Comment on: Cancer 1994 Oct 1;74(7):1874–81.
Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time. Levine AM, et al. **Cancer** 1996 Aug 1; 78(3):517–26
Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors [letter; comment] Lokich J. **Cancer** 1995 Nov 1;76(9):1686. Comment on: Cancer 1995 Jun 15;75(12):2966–70.
Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy. Lönn U, et al. **Cancer** 1996 Jan 1;77(1):107–12
Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Lotz JP, et al. **Cancer** 1996 Jun 15;77(12):2550–9
Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. Lupi G, et al. **Cancer** 1996 Apr 15;77(8):1472–8
Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Lupoli G, et al. **Cancer** 1996 Sep 1;78(5):1114–8
Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. Mariette X, et al. **Cancer** 1995 Nov 1;76(9):1559–63
Results of combined modality therapy for patients with anal cancer (E7283). An Eastern Cooperative Oncology Group study. Martenson JA, et al. **Cancer** 1995 Nov 15; 76(10):1731–6
Malignant mixed müllerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy. Muntz HG, et al. **Cancer** 1995 Oct 1; 76(7):1209–13
A 15-year experience with chemotherapy of patients with paraganglioma. Patel SR, et al. **Cancer** 1995 Oct 15; 76(8):1476–80
Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Petrioli R, et al. **Cancer** 1996 Jan 15;77(2):344–51
Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis [letter; comment] Pignon JP, et al. **Cancer** 1996 Jun 1;77(11):2413–4 . Comment on: Cancer 1995 Aug 15;76(4):593–601.
The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients--results of the NBL 90 Study of the French Society of Pediatric Oncology. Plantaz D, et al. **Cancer** 1996 Jul 15;78(2):311–9
Multimodal treatment with neoadjuvant intraarterial chemotherapy and radical surgery in patients with stage IIIB–IVA cervical cancer. A preliminary study. Scarabelli C, et al. **Cancer** 1995 Sep 15;76(6):1019–26
Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Schleusener JT, et al. **Cancer** 1996 Apr 1; 77(7):1284–91
Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma [letter; comment] Schwarz LR. **Cancer** 1996 Aug 1;78(3):566–7. Comment on: Cancer 1995 Dec 1;76(11):2186–92.
Platinum analogue combination chemotherapy: cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors. Sengeløv L, et al. **Cancer** 1995 Nov 15;76(10):1797–803
Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [see comments] Shin DM, et al. **Cancer** 1995 Dec 1; 76(11):2230–6. Comment in: Cancer 1996 May 1;77(9):1959–60.
A clinical trial of continuous cisplatin-fluorouracil induction chemotherapy and supracricoid partial laryngectomy for glottic carcinoma classified as T2 [letter; comment] Singer MI. **Cancer** 1995 Jul 1;76(1):149–51. Comment on: Cancer 1994 Nov 15;74(10):2781–90.
Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Stamatoullas A, et al. **Cancer** 1996 Jun 1;77(11):2302–7
Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection. Sugimachi K, et al. **Cancer** 1996 Jan 1;77(1):36–43
Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. Sundfør K, et al. **Cancer** 1996 Jun 1;77(11):2371–8
Combination chemotherapy with doxorubicin, bleomycin, and vindesine for AIDS-related Kaposi's sarcoma. Tavio M, et al. **Cancer** 1996 May 15;77(10):2117–22
Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma. Temeck BK, et al. **Cancer** 1996 Jun 15;77(12):2432–9
Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. Tirelli U, et al. **Cancer** 1996 May 15;77(10):2127–31
Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study. Tummarello D, et al. **Cancer** 1996 Jun 1; 77(11):2251–7
5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer [letter; comment] Vermeulen PB, et al. **Cancer** 1995 Aug 1;76(3):528–30. Comment on: Cancer 1995 Mar 1;75(5):1072–6.
Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. Wadler S, et al. **Cancer** 1996 Jul 1;78(1):30–4
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S, et al. **Cancer** 1996 Feb 15;77(4):733–42
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Wexler LH, et al. **Cancer** 1996 Aug 15;

78(4):901–11

Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Zaniboni A, et al. **Cancer** 1995 Nov 15;76(10):1694–9

Intensive short cause chemotherapy followed by radiotherapy of locally advanced nasopharyngeal carcinoma. Zidan J, et al. **Cancer** 1996 May 15; 77(10):1973–7

Antitumor effects of pirarubicin and epirubicin in combination with doxifluridine and cisplatin against mouse P388 leukemia. Agata N, et al. **Cancer Biochem Biophys** 1995 Nov;15(2):95–101

Treatment of refractory low grade lymphoma with chlorambucil alternating with interferon and radiotherapy. Avilés A, et al. **Cancer Biother** 1995 Winter;10(4):273–7

Phase II study of mitomycin, ifosfamide and cisplatin in adenocarcinoma of the oesophagus. Allen SM, et al. **Cancer Chemother Pharmacol** 1996;37(5):496–8

Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin's lymphoma. Barbui T, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S110–4

A weekly alternating chemotherapy regimen with low toxicity for the treatment of aggressive lymphoma. Bower M, et al. **Cancer Chemother Pharmacol** 1996;38(1):106–9

Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer. Cascinu S, et al. **Cancer Chemother Pharmacol** 1996;38(4):385–6

Promising new agents in the treatment of non-small cell lung cancer. Edelman, MJ, et al. **Cancer Chemother Pharmacol** 1996;37(5):385–93 (96 ref.)

Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen. Feliu J, et al. **Cancer Chemother Pharmacol** 1996;38(2):191–4

A phase I trial of 5-day continuous infusion cisplatin and interferon alpha. Gosland MP, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):39–46

Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer. Gridelli C, et al. **Cancer Chemother Pharmacol** 1996;37(6):613–5

Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer. Ichikura T, et al. **Cancer Chemother Pharmacol** 1996;38(5):401–5

Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Israel VK, et al. **Cancer Chemother Pharmacol** 1995; 37(1–2):32–8

High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer. Kamphuis JT, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):190–2

Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study. Kudoh S, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S89–95

A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer. Moore MJ, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):86–90

A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer. Nardi M, et al. **Cancer Chemother Pharmacol** 1996;38(3):298–301

Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. Polyzos A, et al. **Cancer Chemother Pharmacol** 1996;38(3):292–7

Carboplatin and vinorelbine in advanced non-small-cell lung cancer. Pronzato P, et al. **Cancer Chemother Pharmacol** 1996;37(6):610–2

Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron. Schröder CP, et al. **Cancer Chemother Pharmacol** 1995;36(6):477–82

Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Teicher BA, et al. **Cancer Chemother Pharmacol** 1996; 38(2):169–77

Carboplatin pharmacokinetics in young children with brain tumors. Tonda ME, et al. **Cancer Chemother Pharmacol** 1996;38(5):395–400

Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat. Van Ginckel R, et al. **Cancer Chemother Pharmacol** 1996;38(1):21–8

Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. Yeo W, et al. **Cancer Chemother Pharmacol** 1996; 38(5):466–70

Influence of different combinations of tamoxifen and toremifene on estrogen receptor-positive breast cancer cell lines. Coradini D, et al. **Cancer Detect Prev** 1995; 19(4):348–54

t(7;11) and trilineage myelodysplasia in acute myelomonocytic leukemia. Inaba T, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):72–5

Intradermal administration of lipopolysaccharide in treatment of human cancer. Goto S, et al. **Cancer Immunol Immunother** 1996 May;42(4):255–61

Combination immunotherapy with OK-432, recombinant granulocyte-colony-stimulating factor and recombinant interleukin-2 for human hepatocellular carcinoma. Himoto T, et al. **Cancer Immunol Immunother** 1996 Feb; 42(2):127–31

Peripheral natural killer cell activity and intraperitoneal soluble p55 tumor necrosis factor receptor in patients with malignant ascites: two possible indicators for response to intraperitoneal combined tumor necrosis factor alpha and interferon gamma treatment. Ott MG, et al. **Cancer Immunol Immunother** 1996 Jan;42(1):31–7

Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL). Tentori L, et al. **Cancer Immunol Immunother** 1995 Dec;41(6):375–83

Phase I trial of high-dose infused zidovudine combined with leucovorin plus fluorouracil. Beitz JG, et al. **Cancer Invest** 1995;13(5):464–9

Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil. Chiou TJ, et al. **Cancer Invest** 1996;14(3):197–201

High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas [see comments] Güllü I, et al. **Cancer Invest** 1996;14(3):239–42. Comment in: Cancer Invest 1996;14(3):290–1.

Combination cisplatin and carboplatin in advanced squamous cell carcinoma of the head and neck. Patton JF, et al. **Cancer Invest** 1996;14(2):98–102

The case for adjuvant radiation therapy in advanced Hodgkin's disease. Prosnitz LR, et al. **Cancer Invest** 1996; 14(4):361–70 (77 ref.)

5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Tetef M, et al. **Cancer Invest** 1995;13(5):460–3

Response of small cell carcinoma of pancreas to a small cell lung cancer regimen: a case report. Wahid NA, et al. **Cancer Invest** 1996;14(4):335–9

Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update. Yu L, et al. **Cancer Invest** 1995;13(6):567–72

Prolongation of survival period and improvement of cancer cachexia by long-term administration of UFT. Nukatsuka M, et al. **Cancer Lett** 1996 Jul 12;104(2):197–203

Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Anderson IC, et al. **Cancer Res** 1996 Feb 15;56(4):715–8

Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Gallo JM, et al. **Cancer Res** 1995 Oct 15;55(20):4507–11

Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU. Schold SC Jr, et al. **Cancer Res** 1996 May 1;56(9):2076–81

Systemic therapy of skin carcinoma. Kempf RA. **Cancer Treat Res** 1995;78:137–62 (122 ref.)

Recent clinical advances with camptothecin analogues. Slichenmyer WJ, et al. **Cancer Treat Res** 1995;78:29–43 (103 ref.)

Palliative treatment for advanced gastrointestinal cancer: is response a suitable end-point? Jäger E, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:113–5

Chemotherapy in locally advanced head and neck cancer: a critical reappraisal. Jassem J, et al. **Cancer Treat Rev** 1995 Sep;21(5):447–62 (106 ref.)

Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Hunt KJ, et al. **Chest** 1996 May;109(5):1239–42

Multimodality therapy including surgical resection for limited small cell lung cancer. Chen X, et al. **Chin Med J (Engl)** 1995 Sep;108(9):689–91

The combination of melphalan, cyclophosphamide and cytosine arabinoside as a conditioning regimen for autologous bone marrow transplantation for acute leukemia. Wang C, et al. **Chin Med J (Engl)** 1996 Apr; 109(4):304–7

Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report. Hsu HC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Nov; 56(5):305–11

High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Wang WS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Feb;57(2):100–5

Complete atrioventricular block due to large cell lymphoma: resolution with chemotherapy. Giudici MC, et al. **Clin Cardiol** 1996 Mar;19(3):262–4

Intense gallbladder uptake associated with chemotherapy. An unusual finding in pediatric skeletal scintigraphy. Lowry PA, et al. **Clin Nucl Med** 1995 Nov;20(11):976–8

Suppressed hepatic uptake of Ga-67 after chemotherapy for non-Hodgkin's lymphoma. Thakore K, et al. **Clin Nucl Med** 1996 Jan;21(1):65–6

Effects on pulmonary function of two regimens of chemotherapy for AIDS related Kaposi's sarcoma. Denton AS, et al. **Clin Oncol (R Coll Radiol)** 1996;8(1):48–50

The search for optimal chemotherapy for advanced epithelial ovarian cancer. Harrington KJ, et al. **Clin Oncol (R Coll Radiol)** 1995;7(6):359–65 (63 ref.)

Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study. Moore DF, et al. **Clin Oncol (R Coll Radiol)** 1995;7(5):300–3

VACOP-B chemotherapy for high grade non-Hodgkin's lymphoma in pregnancy. Rodriguez JM, et al. **Clin Oncol (R Coll Radiol)** 1995;7(5):319–20

VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients. Singer JM, et al. **Clin Oncol (R Coll Radiol)** 1995; 7(6):366–70

Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party. Thatcher N, et al. **Clin Oncol (R Coll Radiol)** 1995;7(5):293–9

Ascending cord necrosis. Complication of intrathecal chemotherapy with radiologic-pathologic correlation. Bellon JR, et al. **Clin Pediatr (Phila)** 1995 Sep;34(9):506–9

CT evaluation of treatment response in advanced gastric cancer. Ng VW, et al. **Clin Radiol** 1996 Mar;51(3):215–20

Musculoskeletal tumour disorders [editorial] Marcove RC. **Compr Ther** 1996 Jan;22(1):7

The treatment of hormone refractory prostate cancer. Panvichian R, et al. **Compr Ther** 1996 Feb;22(2):81–7 (27 ref.)

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Verweij J, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):193–201 (58 ref.)

Chemotherapy for gynecologic malignancies. Vermorken JB, et al. **Curr Opin Oncol** 1995 Sep;7(5):457–65 (79 ref.)

Endorectal ultrasound of T3 and T4 rectal cancers after preoperative chemoradiation. Williamson PR, et al. **Dis Colon Rectum** 1996 Jan;39(1):45–9

Current drug treatment guidelines for epithelial ovarian cancer. Lorigan PC, et al. **Drugs** 1996 Apr;51(4):571–84 (65 ref.)

The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells [editorial] Mertelsmann R. **Eur Cytokine Netw** 1995 Mar-Apr;6(2):79–82 (12 ref.)

A prospective randomised study in limited disease small cell carcinoma--doxorubicin and vincristine plus either cyclophosphamide or etoposide. Abratt RP, et al. **Eur J Cancer** 1995 Sep;31A(10):1637–9

Carboplatin and ifosfamide and selective consolidation in advanced seminoma. Amato RJ, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2223–8

Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF). Andreyev HJ, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2209–14

Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts. Arvelo F, et al. **Eur J Cancer** 1995 Oct;31A(11):1862–8

Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study. Bergmann L, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2164–8

Thyroid cancer: different outcomes to chemotherapy according to tumour histology [letter] Biganzoli L, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2423–4

Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Cancer Institute. Bonadonna G. **Eur J Cancer** 1996 Feb; 32A(2):209–14 (31 ref.)

Accelerated cisplatin-based chemotherapy for advanced bladder cancer. Boshoff C, et al. **Eur J Cancer** 1995 Sep; 31A(10):1633–6

Chemotherapy for ovarian germ cell tumours [see comments] Bower M, et al. **Eur J Cancer** 1996 Apr;32A(4):593–7. Comment in: Eur J Cancer 1996 Apr;32A(4):572–3.

Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy. A retrospective study of 63 cases [letter] Cany L, et al. **Eur J Cancer** 1996 Feb;32A(2):370–1

The treatment of advanced neuroblastoma. Results of the Spanish Neuroblastoma Study Group (SNSG) studies. Castel V, et al. **Eur J Cancer** 1995;31A(4):642–5

A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Cotto C, et al. **Eur J Cancer** 1996 Jan;32A(1):69–71

An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. Di Leo A, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2248–54

Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group. Donfrancesco A, et al. **Eur J Cancer** 1995;31A(4):612–5

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Ellis PA, et al.

Eur J Cancer 1995 Sep;31A(10):1594–8

Dose intensification of carboplatin and etoposide as first–line combination chemotherapy in small cell lung cancer [letter] Ellis PA, et al. **Eur J Cancer** 1995 Oct;31A(11):1888–9

Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM–CSF. Ford PA, et al. **Eur J Cancer** 1996 Apr;32A(4):631–5

Sequential chemoimmunotherapy for advanced non–small cell lung cancer using cisplatin, etoposide, thymosin–alpha 1 and interferon–alpha 2a. Garaci E, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2403–5

Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study [letter] Gardin G, et al. **Eur J Cancer** 1996 Jan;32A(1):176–7

Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. González–Barón M, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2215–9

Phase II study of intensive CEV (carboplatin, epirubicin and VP–16) plus G–CSF (granulocyte–colony stimulating factor) in extensive small cell lung cancer [letter] Gridelli C, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2424–6

Subcutaneous recombinant interleukin–2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma. Guida M, et al. **Eur J Cancer** 1996 Apr;32A(4):730–3

Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment–resistant advanced breast cancer. Gurney H, et al. **Eur J Cancer** 1995 Oct;31A(11):1773–7

Randomised phase II study of epirubicin–vindesine versus mitoxantrone–vindesine in metastatic breast cancer. Hausmaninger H, et al. **Eur J Cancer** 1995 Dec; 31A(13–14):2169–73

Lobaplatin in combination with methotrexate and vinblastine in patients with transitional cell carcinoma of the urinary tract—a pilot phase I/(II) study [letter] Jung P, et al. **Eur J Cancer** 1995 Oct;31A(11):1891–2

Chemotherapy for ovarian germ cell tumours [editorial; comment] Kaufmann M, et al. **Eur J Cancer** 1996 Apr; 32A(4):572–3. Comment on: Eur J Cancer 1996 Apr;32A(4):593–7.

A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. Kristensen GB, et al. **Eur J Cancer** 1995 Oct; 31A(11):1778–80

First experience with prognostic factors in unselected neuroblastoma patients. The Austrian Neuroblastoma 87 Study. Ladenstein R, et al. **Eur J Cancer** 1995; 31A(4):637–41

Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5–fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Leichman L, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1306–10

Mitoxantrone, 5–fluorouracil and leucovorin in metastatic breast cancer [letter] Lemmens J, et al. **Eur J Cancer** 1995 Nov;31A(12):2114–5

Mixed response to chemotherapy, a new entity in soft tissue sarcomas [letter] Liem GS, et al. **Eur J Cancer** 1995 Nov; 31A(12):2113–4

Anaplastic large cell lymphoma (CD30+/Ki–1+). Analysis of 35 cases followed at GISL centres. Longo G, et al. **Eur J Cancer** 1995 Oct;31A(11):1763–7

Intrapatient comparison of single–agent epirubicin with or without lonidamine in metastatic breast cancer. Lopez M, et al. **Eur J Cancer** 1995 Sep;31A(10):1611–4

Problems with the evaluation of response after induction chemotherapy in breast cancer [letter] Mannesse CK, et al. **Eur J Cancer** 1995 Oct;31A(11):1886–7

A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta–iodobenzylguanidine (MIBG) and cisplatin. Mastrangelo R, et al. **Eur J Cancer** 1995;31A(4):606–11

Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Matthay KK, et al. **Eur J Cancer** 1995; 31A(4):572–5

Adenocarcinoma of the eccrine sweat gland: response to both combination chemotherapy and local field irradiation [letter] Mertens WC, et al. **Eur J Cancer** 1996 Feb; 32A(2):372–3

Phase II study of infusional cisplatin in combination with etoposide in the treatment of small cell lung cancer. Mori K, et al. **Eur J Cancer** 1995 Oct;31A(11):1781–4

Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5–year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan. Morimoto T, et al. **Eur J Cancer** 1996 Feb;32A(2):235–42

Ewing's sarcoma of the ribs. A report from the cooperative Ewing's sarcoma study. Ozaki T, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2284–8

Early alternating chemotherapy and radiotherapy schedule in limited disease stage small cell lung cancer. Purohit A, et al. **Eur J Cancer** 1995;31A(9):1434–6

Sequential chemotherapy, beta interferon, retinoids and tamoxifen in the treatment of metastatic breast cancer. A pilot study [letter] Recchia F, et al. **Eur J Cancer** 1995 Oct;31A(11):1887–8

Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon–alpha for metastatic melanoma [letter] Reinhold U, et al. **Eur J Cancer** 1996 Jan;32A(1):180

Plasma c–erbB2 concentrations in relation to chemotherapy in breast cancer patients. Revillion F, et al. **Eur J Cancer** 1996 Feb;32A(2):231–4

Different doses of epirubicin associated with fixed doses of cyclophosphamide and 5–fluorouracil: a randomised study in advanced breast cancer [letter] Riccardi A, et al. **Eur J Cancer** 1995;31A(9):1549–51

Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non–resectable oesophageal cancer. Roca E, et al. **Eur J Cancer** 1996 Mar; 32A(3):429–32

Ribonucleotide reductase inhibition in the treatment of advanced prostate cancer: an experimental approach with hydroxyurea and gallium nitrate in 20 patients [letter] Santarossa S, et al. **Eur J Cancer** 1995 Sep;31A(10):1718

Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Scholl SM, et al. **Eur J Cancer** 1995 Nov;31A(12):1969–75

Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co–operative oncology group study. Skarlos DV, et al. **Eur J Cancer** 1996 Mar; 32A(3):421–8

Genitourinary group phase II study of chemotherapy in stage T3–4 N0–X M0 transitional cell cancer of the bladder: prognostic factor analysis. Splinter TA, et al. **Eur J Cancer** 1996 Jun;32A(7):1129–34

Phase II trial of N–(phosphonacetyl)–L–aspartate (PALA), 5–fluorouracil and recombinant interferon–alpha–2b in patients with advanced gastric carcinoma. Wadler S, et al. **Eur J Cancer** 1996 Jun;32A(7):1254–6

Chemotherapy with doxorubicin, etoposide and cyclophosphamide (DEC) in ovarian cancer persistent after platinum–based treatment [letter] Zanetta G, et al. **Eur J Cancer** 1996 Jan;32A(1):178–9

Treatment of non–Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy. Avilés A, et al. **Eur J Cancer B Oral Oncol** 1996 Jan;32B(1):19–23

A retrospective study of the use of cisplatinum–5–fluorouracil neoadjuvant chemotherapy in cervical–node–positive nasopharyngeal carcinoma (NPC). Teo PM, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):373–9

Chemoprevention by melatonin and combined melatonin–tamoxifen therapy of second generation nitroso–methylurea–induced mammary tumours in rats. Kothari A, et al. **Eur J Cancer Prev** 1995 Dec;4(6):497–500

Preoperative chemotherapy and immunochemotherapy for locally advanced stage IIIA and IIIB non small cell lung cancer. Preliminary results. Ciriaco P, et al. **Eur J Cardiothorac Surg** 1995;9(6):305–9

Pleuropneumonectomy and postoperative adjuvant chemotherapy for carcinomatous pleuritis in primary lung cancer: a case report of long–term survival. Yokoi K, et al. **Eur J Cardiothorac Surg** 1996;10(2):141–3

A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers. Behbakht K, et al. **Eur J Gynaecol Oncol** 1996;17(1):7–12

Tamoxifen, megestrol acetate, and beta interferon in endometrial cancer. Cardone A, et al. **Eur J Gynaecol Oncol** 1995;16(6):500–5

Cyclophosphamide, methotrexate, 5–fluorouracil, and folinic acid (CMFF) as first line chemotherapy for treatment of advanced breast cancer. A pilot study. Glaubitz M, et al. **Eur J Gynaecol Oncol** 1995;16(4):258–62

Influence of metronidazole and tamoxifen in a case of otherwise untreated ulcerous breast carcinoma. Heirler F, et al. **Eur J Gynaecol Oncol** 1995;16(6):448–52

Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single–agent paclitaxel. Johnston CM, et al. **Eur J Gynaecol Oncol** 1995; 16(6):439–47

Chemotherapy and cervical cancer: present trends. Zarcone R, et al. **Eur J Gynaecol Oncol** 1996;17(2):148–50

Nonsecretory multiple myeloma [letter] Bourantas K. **Eur J Haematol** 1996 Jan–Feb;56(1–2):109–11

Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non–Hodgkin's lymphoma. Hopfinger G, et al. **Eur J Haematol** 1995 Oct;55(4):223–7

Intensive remission induction therapy for chronic myeloid leukemia in blast phase with a goal of post–remission bone marrow transplant—a pilot study. Lipton JH, et al. **Eur J Haematol** 1996 Jul;57(1):42–5

Cytologic examination of broncho–alveolar fluid during the retinoic acid syndrome [letter] Maloisel F, et al. **Eur J Haematol** 1996 May;56(5):319–20

Biweekly COP–BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G–CSF) for intermediate–grade non–Hodgkin's lymphoma. Niitsu N, et al. **Eur J Haematol** 1996 Mar; 56(3):163–7

Inhibition of hypercoagulation by antithrombin substitution in E. coli L–asparaginase–treated children. Nowak–Göttl U, et al. **Eur J Haematol** 1996 Jan–Feb;56(1–2):35–8

Angiocentric T–cell lymphoma associated with diabetes insipidus [letter] Ramsahoye BH, et al. **Eur J Haematol** 1996 Jan–Feb;56(1–2):100–3

FLAG (fludarabine, cytarabine, G–CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects. Visani G, et al. **Eur J Haematol** 1996 May;56(5):308–12

FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low–grade non–Hodgkin's lymphoma. Zinzani PL, et al. **Eur J Haematol** 1995 Oct;55(4):262–6

Quantitative evaluation of thallium–201 uptake in predicting chemotherapeutic response of osteosarcoma. Lin J, et al. **Eur J Nucl Med** 1995 Jun;22(6):553–5

Mixed mesodermal sarcoma of the ovary in a young patient. Fowler JM, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):249–53

Modulation of expression of p53 and cell proliferation in locally advanced cervical carcinoma after neoadjuvant combination chemotherapy. Garzetti GG, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):31–6

Personal surgical experience. The impact of malignant disease on the life and practice of surgeons. Malignant myeloma and stem cell transplantation. Dunn DC. **Eur J Surg Oncol** 1995 Oct;21(5):558–60

Palliative intra–arterial (i.a.) chemotherapy with carboplatin (CBDCA) and 5–FU in unresectable advanced (stage III and IV) head and neck cancer using implantable port–systems. Eckardt A, et al. **Eur J Surg Oncol** 1995 Oct;21(5):486–9

Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma. Kerin MJ, et al. **Eur J Surg Oncol** 1995 Oct; 21(5):548–50

Neoadjuvant treatment in oesophageal cancer: the needs for future trials. The Rotterdam Esophageal Tumor Study Group. Kok TC, et al. **Eur J Surg Oncol** 1996 Aug; 22(4):323–5 (30 ref.)

A randomized trial of cimetidine with 5–fluorouracil and folinic acid in metastatic colorectal cancer. Links M, et al. **Eur J Surg Oncol** 1995 Oct;21(5):523–5

Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti–tumour approach. Manusama ER, et al. **Eur J Surg Oncol** 1996 Apr; 22(2):152–7

Effect of ranitidine and low–dose interleukin–2 in vitro on NK–cell activity in peripheral blood from patients with liver metastases from colorectal cancer. Nielsen HJ, et al. **Eur J Surg Oncol** 1995 Oct;21(5):526–30

Long–term survival in two cases of colorectal carcinoma following a new chemotherapy regimen and subsequent metastasectomy [letter] Van den Hout BM, et al. **Eur J Surg Oncol** 1995 Oct;21(5):583

Protein 1 (Clara cell protein) serum levels in lung cancer patients receiving chemotherapy. Nomori H, et al. **Eur Respir J** 1995 Oct;8(10):1654–7

Intratesticular effects of cisplatin–based chemotherapy. Dieckmann KP, et al. **Eur Urol** 1995;28(1):25–30

Postchemotherapy surgery in nonseminomatous testicular tumors. Horňák M, et al. **Eur Urol** 1996;29(3):325–30

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against. Jewett MA, et al. **Eur Urol** 1996;29 Suppl 2:45–8 (11 ref.)

Prognostic factors of primary transitional cell carcinoma of the upper urinary tract. Lee SH, et al. **Eur Urol** 1996; 29(3):266–70; discussion 271

Five–year results of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy plus radical cystectomy in locally advanced bladder cancer. Scattoni V, et al. **Eur Urol** 1995; 28(2):102–7

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for. Scher HI. **Eur Urol** 1996;29 Suppl 2:40–4 (36 ref.)

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone–releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:105–9

The DNA and steroid binding domains of the glucocorticoid receptor are not altered in mononuclear cells of treated CLL patients. Soufi M, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):175–83

A marrow harvest procedure under local anesthesia. Dicke KA, et al. **Exp Hematol** 1995 Oct;23(11):1229–32

A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara–C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. Smith RJ, et al. **Exp Hematol** 1995 Dec; 23(14):1581–8

Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non–Hodgkin's lymphoma. Vail DM, et al. **Exp Hematol** 1996 Jun;24(7):807–15

Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Raoul JL, et al. **Gut** 1995 Aug; 37(2):174–6

Growth inhibition of uterine cervical cancer cells by a sequential administration of anticancer drugs and irradiation. Morishita K, et al. **Gynecol Obstet Invest** 1995; 40(1):57–60

A phase II trial of neoadjuvant chemotherapy prior to radical hysterectomy and/or radiation therapy in the management of advanced carcinoma of the uterine cervix. Bloss JD, et al. **Gynecol Oncol** 1995 Oct;59(1):105–10

Combination chemotherapy with etoposide, cisplatin, and

doxorubicin in mixed müllerian tumors of the adnexa. Cass I, et al. **Gynecol Oncol** 1996 Jun;61(3):309–14

Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5–fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma. Cornelison TL, et al. **Gynecol Oncol** 1995 Nov;59(2):243–8

Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study. Currie J, et al. **Gynecol Oncol** 1996 Apr;61(1):27–30

Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP–16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Currie JL, et al. **Gynecol Oncol** 1996 Apr;61(1):94–6

Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high–risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH–PLND): a randomized phase III trial [see comments] Curtin JP, et al. **Gynecol Oncol** 1996 Apr;61(1):3–10. Comment in: Gynecol Oncol 1996 Apr;61(1):1–2.

A single institution experience with weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Hoffman MS, et al. **Gynecol Oncol** 1996 Feb; 60(2):292–4

Chemotherapy treatment of chyloperitoneum and peritoneal carcinomatosis due to cervical cancer—review of literature. Keung YK, et al. **Gynecol Oncol** 1996 Jun;61(3):448–50 (11 ref.)

A phase I/II study of dose–intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor–prognosis advanced–stage epithelial ovarian cancer. Kohn EC, et al. **Gynecol Oncol** 1996 Aug;62(2):181–91

Concurrent preoperative chemotherapy with 5–fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. Landoni F, et al. **Gynecol Oncol** 1996 Jun; 61(3):321–7

High complete response rate of concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the uterine cervix. Lin JC, et al. **Gynecol Oncol** 1996 Apr;61(1):101–8

Surgically documented responses to paclitaxel and cisplatin in patients with primary peritoneal carcinoma. Menzin AW, et al. **Gynecol Oncol** 1996 Jul;62(1):55–8

Intraperitoneal mitoxantrone or floxuridine: effects on time–to–failure and survival in patients with minimal residual ovarian cancer after second–look laparotomy—a randomized phase II study by theSouthwest Oncology Group. Muggia FM, et al. **Gynecol Oncol** 1996 Jun; 61(3):395–402

Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5–fluorouracil: a phase II study. Pierga JY, et al. **Gynecol Oncol** 1996 Jan;60(1):59–63

A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary. Reed E, et al. **Gynecol Oncol** 1996 Jun;61(3):349–53

Neoadjuvant chemotherapy in uterine papillary serous carcinoma. Resnik E, et al. **Gynecol Oncol** 1996 Jul; 62(1):123–7

Phase II trial with neoadjuvant chemotherapy [letter] Sardi JE. **Gynecol Oncol** 1996 Aug;62(2):321–2

Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Sutton G, et al. **Gynecol Oncol** 1996 Aug; 62(2):226–9

Donor buffy–coat infusion and chemotherapy for leukemia in relapse after marrow transplantation. Bogdanić V, et al. **Haematologica** 1995 Jul–Aug;80(4):338–40

Whole megakaryocytes are present among CD34+ cells in the peripheral blood of patients with acute myeloid leukemia after intensive chemotherapy. Delfini C, et al. **Haematologica** 1996 May–Jun;81(3):284–5

Granulocytic sarcoma in nonleukemic children: report of two new cases successfully treated by local radiation therapy and systemic chemotherapy. Fiorillo A, et al. **Haematologica** 1996 Mar–Apr;81(2):155–8

Long–term molecular remission after conventional chemotherapy in a patient with Philadelphia–negative acute lymphoblastic leukemia. Ladetto M, et al. **Haematologica** 1996 Mar–Apr;81(2):159–61

A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non–Hodgkin's lymphoma. Lambertenghi Deliliers G, et al. **Haematologica** 1995 Jul–Aug;80(4):318–24

Purine analogs (fludarabine and 2–chlorodeoxyadenosine) as apoptosis–inducing drugs in CML therapy [letter] Martinelli G, et al. **Haematologica** 1996 May–Jun; 81(3):286–7

In vitro sensitivity of chronic lymphocytic leukemia B–cells to fludarabine, 2–chlorodeoxyadenosine and chlorambucil: correlation with clinico–hematological and immunophenotypic features. Morabito F, et al. **Haematologica** 1996 May–Jun;81(3):224–31

FLU–ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low–grade non–Hodgkin's lymphoma. Zinzani PL, et al. **Haematologica** 1996 Mar–Apr;81(2):168–71

Results of single–agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Demetri GD, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):765–85 (123 ref.)

Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation. Jaffe N, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):825–40 (79 ref.)

Intrathoracic hyperthermochemotherapeutic perfusion for the intrathoracic malignancies in gastric cancer. Fujimura T, et al. **Hepatogastroenterology** 1995 Nov–Dec; 42(6):878–84

Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma. Lygidakis NJ, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):1039–52

Carboplatin–based combination chemotherapy for testicular cancer: relationship among administration dose of carboplatin, renal function and myelosuppression. Suzuki K, et al. **Hinyokika Kiyo** 1995 Oct;41(10):775–80

Intra–arterial chemotherapy for muscle–invasive urinary bladder cancer. Takahashi N, et al. **Hinyokika Kiyo** 1996 Apr;42(4):263–8

Therapeutic effect of CDDP and VP–16 against human bladder cancers. Gotoh A, et al. **In Vivo** 1995 May–Jun; 9(3):263–7

Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin–based chemotherapy in advanced ovarian carcinoma. Cornarotti M, et al. **Int J Cancer** 1996 Aug 7;67(4):479–84

Cell kinetics of CD34–positive hematopoietic cells following chemotherapy plus colony–stimulating factors in advanced breast cancer. Danova M, et al. **Int J Cancer** 1995 Nov 27;63(5):646–51

Cyclophosphamide plus tumor necrosis factor–alpha chemoimmunotherapy cured mice: life–long immunity and rejection of re–implanted primary lymphoma. Ehrke MJ, et al. **Int J Cancer** 1995 Nov 3;63(3):463–71

Anti–tumor activity of tumor necrosis factor in combination with interferon–gamma is not affected by prior tolerization. Takahashi N, et al. **Int J Cancer** 1995 Dec 11;63(6):846–54

Adjuvant therapy with 5–fluoro–1–(2–tetrahydrofuryl)–2,4 (1H,3H)–pyrimidinedione (UFT) and Bestatin in patients with transitional cell carcinoma of the bladder—comparison between UFT therapy alone and UFT therapy in combination with Bestatin. Uchibayashi T, et al. **Int J Clin Pharmacol Ther** 1995 Aug;33(8):465–8

Chemotherapy for AIDS–related and endemic African Kaposi's sarcoma in southern Africa. Stein ME, et al. **Int J Dermatol** 1995 Oct;34(10):729–32

Pilot study of local hyperthermia, radiation therapy, etanidazole, and cisplatin for advanced superficial tumours. Bornstein BA, et al. **Int J Hyperthermia** 1995 Jul–Aug; 11(4):489–99

Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression–free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):463–9

Central nervous system lymphomas: progress in chemotherapy and radiotherapy [editorial; comment] Brada M. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):769–71 . Comment on: Int J Radiat Oncol Biol Phys 1995 Oct 15;33(3):663–73.

Early evaluation of abdominal/hepatic irradiation and 5–fluorouracil/leucovorin infusion after pancreaticoduodenectomy. Carducci MA, et al. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):143–50

A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma [see comments] Chan AT, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):569–77. Comment in: Int J Radiat Oncol Biol Phys 1995 Oct 15;33(3):761–3.

Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Goldwein JW, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):899–904

A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6–mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. Halperin EC, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):793–802

Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer. Jeremic B, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):303–8

Concurrent cisplatin–vindesine and hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer. Le Péchoux C, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):519–25

The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. Markiewicz DA, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 1;35(4):661–8

Initial results of a phase II trial of high dose radiation therapy, 5–fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study. Martenson JA, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 1;35(4):745–9

Primary central nervous syst•m non–Hodgkin's lymphoma: survival advantages with combined initial therapy? [see comments] O'Neill BP, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):663–73. Comment in: Int J Radiat Oncol Biol Phys 1995 Oct 15;33(3):769–71.

The use of mammography in breast preservation in locally advanced breast cancer. Pierce L, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):571–7

Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. Reboul F, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1;35(2):343–50

Prognostic value of tumor regression during radiotherapy or chemoradiotherapy for advanced head and neck cancers: regarding Jaulerry et al. IJROBP 33(2):271–279; 1995 [letter; comment] Vikram B. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):971. Comment on: Int J Radiat Oncol Biol Phys 1995 Sep 30;33(2):271–9.

Timing of radiotherapy and chemotherapy following breast–conserving surgery for patients with node–positive breast cancer. International Breast Cancer Study Group [see comments] Wallgren A, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 1;35(4):649–59. Comment in: Int J Radiat Oncol Biol Phys 1996 Jul 1;35(4):843–4.

Prospective trial of combined hyperfractionated radiotherapy and bronchial arterial infusion of chemotherapy for locally advanced nonsmall cell lung cancer. Wang G, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):309–13

Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers. Kakehi Y, et al. **Int J Urol** 1995 Nov; 2(5):309–15

Recurrent intraabdominal cancer with intestinal obstruction. Averbach AM, et al. **Int Surg** 1995 Apr–Jun;80(2):141–6

Etoposide, epirubicin and carboplatin in hormone–refractory prostate cancer. Fuse H, et al. **Int Urol Nephrol** 1996; 28(1):79–85

Conservative management of advanced bladder cancer. Lekili M, et al. **Int Urol Nephrol** 1995;27(6):747–52

Phase II study of cisplatin, 5–fluorouracil and interferon–alpha in recurrent carcinoma of the cervix. Gonzales–de Léon C, et al. **Invest New Drugs** 1995; 13(1):73–6

Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin. Hofs HP, et al. **Invest New Drugs** 1995;13(1):23–32

Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Tetef M, et al. **Invest New Drugs** 1995;13(2):157–62

A phase II study of interleukin–2 with and without beta–interferon in the treatment of advanced renal cell carcinoma. Witte RS, et al. **Invest New Drugs** 1995; 13(3):241–7

Interferon–alpha–2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience [see comments] Cohen AM, et al. **Isr J Med Sci** 1995 Oct;31(10):604–10. Comment in: Isr J Med Sci 1995 Oct;31(10):635–7.

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin–2 and interferon–alpha. Canobbio L, et al. **J Cancer Res Clin Oncol** 1995;121(12):753–6

Phase II study of 5–fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. Clark J, et al. **J Cancer Res Clin Oncol** 1996; 122(9):554–8

Randomised trial of vindesine and etoposide +/– dexverapamil in advanced non–small cell lung cancer: first results. Gatzemeier U, et al. **J Cancer Res Clin Oncol** 1995; 121 Suppl 3:R17–20

Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. Mickisch GH, et al. **J Cancer Res Clin Oncol** 1995;121 Suppl 3:R11–6

Dexverapamil as resistance modifier in acute myeloid leukaemia. Pirker R, et al. **J Cancer Res Clin Oncol** 1995; 121 Suppl 3:R21–4

Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage–colony–stimulating factor in patients with advanced pancreatic adenocarcinoma. Scheithauer W, et al. **J Cancer Res Clin Oncol** 1995;121 Suppl 3:R7–10

Dexverapamil to overcome epirubicin resistance in advanced breast cancer. Thürlimann B, et al. **J Cancer Res Clin Oncol** 1995;121 Suppl 3:R3–6

Modulation of multidrug resistance by dexverapamil in EPOCH–refractory lymphomas. Wilson WH, et al. **J Cancer Res Clin Oncol** 1995;121 Suppl 3:R25–9

Changing pattern of relapse in osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. Bacci G, et al. **J Chemother** 1995 Jun; 7(3):230–9

Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients. Hastürk S, et al. **J Chemother** 1996 Apr;8(2):159–64

Treatment of advanced urothelial carcinoma with M–VECA (methotrexate, vinblastine, epirubicin and carboplatin). Lorusso V, et al. **J Chemother** 1996 Apr;8(2):154–8

Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. Piccioni D, et al. **J Chemother** 1995 Jun;7(3):224–9

Genetic instability in patients with Hodgkin's disease undergoing chemotherapy. Abdallah JM, et al. **J Clin Invest** 1995 Dec;96(6):2744–7

Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. International Breast Cancer Study Group. **J Clin Oncol** 1996 Jun;14(6):1885–94

Acute myeloid leukemia-type chemotherapy for myelodysplasia [letter; comment] Anderlini P, et al. **J Clin Oncol** 1996 Apr;14(4):1404–5. Comment on: J Clin Oncol 1996 Jan;14(1):220–6.

Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors [see comments] Anderson JE, et al. **J Clin Oncol** 1996 Jan; 14(1):220–6. Comment in: J Clin Oncol 1996 Apr;14(4):1404–5.

Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. Bajetta E, et al. **J Clin Oncol** 1995 Oct;13(10):2613–9

Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. Bessell EM, et al. **J Clin Oncol** 1996 Mar; 14(3):945–54

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial [see comments] Bezwoda WR, et al. **J Clin Oncol** 1995 Oct;13(10):2483–9. Comment in: J Clin Oncol 1995 Oct;13(10):2477–9. Comment in: J Clin Oncol 1996 Feb;14(2):685–6. Comment in: J Clin Oncol 1996 Feb;14(2):686. Comment in: J Clin Oncol 1996 Feb;14(2):686–7.

Tumor size and prognosis in aggressively treated osteosarcoma. Bieling P, et al. **J Clin Oncol** 1996 Mar; 14(3):848–58 (38 ref.)

Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. Bladé J, et al. **J Clin Oncol** 1996 Jul;14(7):2167–73

Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. Blijham G, et al. **J Clin Oncol** 1996 Aug;14(8):2266–73

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. Bookman MA, et al. **J Clin Oncol** 1996 Jun;14(6):1895–902

Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. Bow EJ, et al. **J Clin Oncol** 1996 Apr;14(4):1345–52

Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. Bowman WP, et al. **J Clin Oncol** 1996 Apr;14(4):1252–61

Response to 13-cis-retinoic acid plus interferon alfa-2a in two patients with therapy-refractory advanced renal cell carcinoma [letter] Buer J, et al. **J Clin Oncol** 1995 Oct; 13(10):2679–80

Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. Clahsen PC, et al. **J Clin Oncol** 1996 Mar;14(3):745–53

Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. Colonna P, et al. **J Clin Oncol** 1996 Jun;14(6):1928–35

Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica [see comments] Conter V, et al. **J Clin Oncol** 1995 Oct;13(10):2497–502. Comment in: J Clin Oncol 1995 Oct;13(10):2480–2.

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. Coombes RC, et al. **J Clin Oncol** 1996 Jan; 14(1):35–45

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. Crump M, et al. **J Clin Oncol** 1996 Jan; 14(1):66–9

Adjuvant chemotherapy in pathologic Stage II nonseminomatous testicular cancer: are two cycles of etoposide-cisplatin a standard option? [letter; comment] Culine S, et al. **J Clin Oncol** 1996 Jul;14(7):2187–8. Comment on: J Clin Oncol 1995 Nov;13(11):2700–4.

Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. Cullen MH, et al. **J Clin Oncol** 1996 Apr;14(4):1106–13

Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. Dogliotti L, et al. **J Clin Oncol** 1996 Apr;14(4):1165–72

Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer. Eisbruch A, et al. **J Clin Oncol** 1996 Aug; 14(8):2322–30

Intravenous azidothymidine with fluorouracil and leucovorin: a phase I–II study in previously untreated metastatic colorectal cancer patients. Falcone A, et al. **J Clin Oncol** 1996 Mar;14(3):729–36

Chemotherapy as adjuvant therapy for completely resected non-small-cell lung cancer: have we made progress? [editorial; comment] Feld R. **J Clin Oncol** 1996 Apr; 14(4):1045–7. Comment on: J Clin Oncol 1996 Apr;14(4):1048–54.

Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. Fields KK, et al. **J Clin Oncol** 1996 Jun;14(6):1868–76

Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil [see comments] Fisher B, et al. **J Clin Oncol** 1996 Jul;14(7):1982–92. Comment in: J Clin Oncol 1996 Jul;14(7):1971–3.

CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial. Fridrik MA, et al. **J Clin Oncol** 1996 Jan;14(1):227–32

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. Gelmon KA, et al. **J Clin Oncol** 1996 Apr;14(4):1185–91

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Giaccone G, et al. **J Clin Oncol** 1996 Mar;14(3):814–20

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study [see comments] Gianni L, et al. **J Clin Oncol** 1995 Nov;13(11):2688–99. Comment in: J Clin Oncol 1996 Apr;14(4):1403.

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. Gill PS, et al. **J Clin Oncol** 1996 Aug; 14(8):2353–64

Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM. Gordon LI, et al. **J Clin Oncol** 1996 Apr;14(4):1275–81

Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. Greco FA, et al. **J Clin Oncol** 1996 May; 14(5):1642–8

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. Greenberg PA, et al. **J Clin Oncol** 1996 Aug; 14(8):2197–205

Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial. Hainsworth JD, et al. **J Clin Oncol** 1996 May;14(5):1611–6

The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. Hernberg M, et al. **J Clin Oncol** 1996 May;14(5):1690–6

Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. Hirsch A, et al. **J Clin Oncol** 1996 Apr;14(4):1297–305

Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. Holland HK, et al. **J Clin Oncol** 1996 Apr;14(4):1156–64

Cyclophosphamide, methotrexate, and fluorouracil: still the gold standard? [editorial; comment] Hudis CA. **J Clin Oncol** 1996 Jul;14(7):1971–3. Comment on: J Clin Oncol 1996 Jul;14(7):1982–92.

Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial.Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. Jäger E, et al. **J Clin Oncol** 1996 Aug; 14(8):2274–9

Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. Jeremic B, et al. **J Clin Oncol** 1996 Apr;14(4):1065–70

Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. Johnson BE, et al. **J Clin Oncol** 1996 Mar;14(3):806–13

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. Johnson DH, et al. **J Clin Oncol** 1996 Jul;14(7):2054–60

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. Kaye SB, et al. **J Clin Oncol** 1996 Jul;14(7):2113–9

Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. Kelsen D, et al. **J Clin Oncol** 1996 Jun; 14(6):1818–28

Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. Kerr DJ, et al. **J Clin Oncol** 1995 Dec;13(12):2968–72

Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. Kobayashi T, et al. **J Clin Oncol** 1996 Jan;14(1):204–13

Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. Kushner BH, et al. **J Clin Oncol** 1996 May; 14(5):1526–31

Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. Kushner BH, et al. **J Clin Oncol** 1995 Nov;13(11):2796–804

Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results. Laccourreye O, et al. **J Clin Oncol** 1996 Aug;14(8):2331–6

Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. Lee JS, et al. **J Clin Oncol** 1996 Apr;14(4):1055–64

Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. Lise M, et al. **J Clin Oncol** 1995 Nov;13(11):2757–63

Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. Loehrer PJ Sr, et al. **J Clin Oncol** 1995 Oct; 13(10):2594–9

Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation. McCowage GB, et al. **J Clin Oncol** 1995 Nov;13(11):2789–95

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. McLaughlin P, et al. **J Clin Oncol** 1996 Apr;14(4):1262–8

Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Magrath I, et al. **J Clin Oncol** 1996 Mar;14(3):925–34

Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122. Minsky BD, et al. **J Clin Oncol** 1996 Jan;14(1):149–55

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. Misset JL, et al. **J Clin Oncol** 1996 Apr; 14(4):1136–45

Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. Moertel CG, et al. **J Clin Oncol** 1995 Dec;13(12):2936–43

Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors [see comments] Motzer RJ, et al. **J Clin Oncol** 1995 Nov;13(11):2700–4. Comment in: J Clin Oncol 1996 Jul;14(7):2187–8.

High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. Motzer RJ, et al. **J Clin Oncol** 1996 Apr;14(4):1098–105

Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. O'Dwyer PJ, et al. **J Clin Oncol** 1996 Jan;14(1):249–56

Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. Patt YZ, et al. **J Clin Oncol** 1996 Aug;14(8):2311–5

Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. Perloff M, et al. **J Clin Oncol** 1996 May; 14(5):1589–98

Selecting treatment for children with acute lymphoblastic leukemia [editorial; comment] [see comments] Pinkel D. **J Clin Oncol** 1996 Jan;14(1):4–6. Comment on: J Clin Oncol 1996 Jan;14(1):18–24. Comment in: J Clin Oncol 1996 Feb;14(2):680–1.

Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. Ribas A, et al. **J Clin Oncol** 1996 May;14(5):1573–80

Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. Rivkin SE, et al. **J Clin Oncol** 1996 Jan;14(1):46–51

Randomized double-blind placebo-controlled trial of

cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. Rowland KM Jr, et al. **J Clin Oncol** 1996 Jan;14(1):135-41

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. Rusthoven JJ, et al. **J Clin Oncol** 1996 Jul;14(7):2083-90

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. Sandström M, et al. **J Clin Oncol** 1996 May; 14(5):1581-8

Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. Sarris AH, et al. **J Clin Oncol** 1996 Jan; 14(1):233-9

Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. Saven A, et al. **J Clin Oncol** 1996 Jul;14(7):2139-44

Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. Schiller JH, et al. **J Clin Oncol** 1996 Jun;14(6):1913-21

Cytoreduction and prognosis in childhood acute lymphoblastic leukemia [letter] Schrappe M, et al. **J Clin Oncol** 1996 Aug;14(8):2403-6

Results of a stage-based protocol for the treatment of retinoblastoma. Schvartzman E, et al. **J Clin Oncol** 1996 May;14(5):1532-6

Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. Schwella N, et al. **J Clin Oncol** 1996 Apr; 14(4):1114-21

Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. Sculier JP, et al. **J Clin Oncol** 1996 Aug;14(8):2337-44

Randomized cooperative study of perioperative chemotherapy in breast cancer. Sertoli MR, et al. **J Clin Oncol** 1995 Nov;13(11):2712-21

Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. Seymour MT, et al. **J Clin Oncol** 1996 Aug;14(8):2280-8

Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose. Shepherd FA, et al. **J Clin Oncol** 1996 May; 14(5):1656-62

High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. Shipp MA, et al. **J Clin Oncol** 1995 Dec;13(12):2916-23

Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation. Sierra J, et al. **J Clin Oncol** 1996 Apr;14(4):1353-63

Influence of age on the treatment of limited-stage small-cell lung cancer. Siu LL, et al. **J Clin Oncol** 1996 Mar; 14(3):821-8

Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. Small EJ, et al. **J Clin Oncol** 1996 May;14(5):1617-25

Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. Sonneveld P, et al. **J Clin Oncol** 1995 Oct; 13(10):2530-9

Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Splinter TA, et al. **J Clin Oncol** 1996 Jan;14(1):127-34

Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. Stahl M, et al. **J Clin Oncol** 1996 Mar;14(3):829-37

In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. Stein AS, et al. **J Clin Oncol** 1996 Aug; 14(8):2206-16

High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. Stemmer SM, et al. **J Clin Oncol** 1996 May; 14(5):1463-72

Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. Steuber CP, et al. **J Clin Oncol** 1996 May; 14(5):1521-5

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points [see comments] Tannock IF, et al. **J Clin Oncol** 1996 Jun;14(6):1756-64. Comment in: J Clin Oncol 1996 Jun;14(6):1753-5.

Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. Teodorovic I, et al. **J Clin Oncol** 1995 Nov;13(11):2819-26

Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. Tester W, et al. **J Clin Oncol** 1996 Jan;14(1):119-26

New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. Thall PF, et al. **J Clin Oncol** 1996 Jan;14(1):296-303

Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. Tolcher AW, et al. **J Clin Oncol** 1996 Jan;14(1):95-102

High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. Veerman AJ, et al. **J Clin Oncol** 1996 Mar;14(3):911-8

Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. Viviani S, et al. **J Clin Oncol** 1996 May;14(5):1421-30

One hundred thirteen men with hormone-refractory prostate cancer died today [editorial; comment] Vogelzang NJ. **J Clin Oncol** 1996 Jun;14(6):1753-5. Comment on: J Clin Oncol 1996 Jun;14(6):1756-64.

Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. Vokes EE, et al. **J Clin Oncol** 1996 May;14(5):1663-71

Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery [see comments] Wada H, et al. **J Clin Oncol** 1996 Apr;14(4):1048-54. Comment in: J Clin Oncol 1996 Apr;14(4):1045-7.

Chemotherapy for colorectal carcinoma: observations regarding recent clinical trials using biochemical modulation [letter; comment] Wadler S, et al. **J Clin Oncol** 1995 Oct;13(10):2676-7. Comment on: J Clin Oncol 1995 Jun;13(6):1287-90.

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. Wasserheit C, et al. **J Clin Oncol** 1996 Jul; 14(7):1993-9

Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. Wexler LH, et al. **J Clin Oncol** 1996 Mar; 14(3):901-10

Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. Wibault P, et al. **J Clin Oncol** 1996 Apr;14(4):1192-200

Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. Zinzani PL, et al. **J Clin Oncol** 1996 Mar;14(3):955-62

Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. Zittoun R, et al. **J Clin Oncol** 1996 Jul;14(7):2150-9

Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer. Darnton SJ, et al. **J Clin Pathol** 1995 Nov;48(11):1064-6

P-glycoprotein positive, drug resistant invasive lymphoepithelial thymoma: treatment response to chemotherapy with cyclosporin and quinine. Gala JL, et al. **J Clin Pathol** 1995 Jul;48(7):679-81

Cytokine profile of tumor cells in mycosis fungoides: successful treatment with intra-lesional interferon-gamma combined with chemotherapy. Yamamoto T, et al. **J Dermatol** 1995 Sep;22(9):650-4

Autologous transplantation with peripheral blood stem cells in children and young adults after myeloablative treatment: nonrandomized comparison between GM-CSF and G-CSF for mobilization. Klingebiel T, et al. **J Hematother** 1995 Aug;4(4):307-14

Immunohistochemical features of HLA-DR antigen expression and lymphoid infiltrates in gastric carcinoma after low-dose interleukin-2 and mitomycin C. Inoue H, et al. **J Immunother Emphasis Tumor Immunol** 1995 May; 17(4):255-62

Phase I trial of sequential cyclophosphamide, cyclosporin A, and interferon-alpha in patients with cancer: attempt to induce autologous graft-versus-host reaction to elicit an antitumor response. Redman BG, et al. **J Immunother Emphasis Tumor Immunol** 1995 Aug; 18(2):115-8

Four days' continuous infusion of cisplatin-5-fluorouracil and short daily infusion of high-dose leucovorin as induction chemotherapy for locally advanced head and neck cancer. Cruz JJ, et al. **J Infus Chemother** 1995 Summer;5(3):125-8

Etoposide plus cisplatin followed by thoracic radiation for stage IIIB non-small cell lung cancer: MAOP study 2188. Lokich J, et al. **J Infus Chemother** 1995 Spring;5(2):70-2

Use of chemotherapy to cure head and neck cancer [editorial] Taylor SG 4th. **J Infus Chemother** 1995 Spring;5(2):44-5

Low-dose, continuous infusion 5-fluorouracil and oral etoposide for the treatment of advanced sarcomas. Zalupski MM, et al. **J Infus Chemother** 1995 Summer;5(3):129-31

Potential for interferon-alpha-based therapy in mesothelioma: assessment in a murine model. Bielefeldt-Ohmann H, et al. **J Interferon Cytokine Res** 1995 Mar;15(3):213-23

Interferon-alpha enhances the cytotoxic and cytostatic activities of chemotherapeutic drugs in human myeloid leukemia cells. Hassan HT, et al. **J Interferon Cytokine Res** 1996 Feb;16(2):139-46

Regression of human breast cancer xenografts in response to intralesional treatment with interferons alpha and gamma potentiated by tumor necrosis factor. Ozzello L, et al. **J Interferon Cytokine Res** 1995 Oct;15(10):839-48

Interferon-beta, retinoids, and tamoxifen in the treatment of metastatic breast cancer: a phase II study. Recchia F, et al. **J Interferon Cytokine Res** 1995 Jul;15(7):605-10

Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon. Lee JT, et al. **J Korean Med Sci** 1996 Feb;11(1):26-32

Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. Reddick WE, et al. **J Magn Reson Imaging** 1995 Nov-Dec; 5(6):689-94

Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. Anzano MA, et al. **J Natl Cancer Inst** 1996 Jan 17;88(2):123-5

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial [see comments] Dillman RO, et al. **J Natl Cancer Inst** 1996 Sep 4;88(17):1210-5. Comment in: J Natl Cancer Inst 1996 Sep 4;88(17):1175-7.

Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. Elledge RM, et al. **J Natl Cancer Inst** 1995 Aug 16;87(16):1254-6

Another look at induction chemotherapy for organ preservation in patients with head and neck cancer [editorial; comment] Forastiere AA. **J Natl Cancer Inst** 1996 Jul 3;88(13):855-6. Comment on: J Natl Cancer Inst 1996 Jul 3;88(13):890-0.

Primary chemotherapy of advanced head and neck cancer: where do we go from here? [editorial; comment] Glisson BS, et al. **J Natl Cancer Inst** 1996 May 1;88(9):567-8. Comment on: J Natl Cancer Inst 1996 May 1;88(9):583-9.

Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. Janik JE, et al. **J Natl Cancer Inst** 1996 Jan 3;88(1):44-9

Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group [see comments] Lefebvre JL, et al. **J Natl Cancer Inst** 1996 Jul 3;88(13):890-9. Comment in: J Natl Cancer Inst 1996 Jul 3;88(13):855-6.

Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck [see comments] Merlano M, et al. **J Natl Cancer Inst** 1996 May 1; 88(9):583-9. Comment in: J Natl Cancer Inst 1996 May 1;88(9):567-8.

Evaluation of response to postradiation eight in one chemotherapy in childhood brain tumors. Ayan I, et al. **J Neurooncol** 1995 Oct;26(1):65-72

Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. Kiu MC, et al. **J Neurooncol** 1995;25(3):215-20

Ganciclovir mediated regression of rat brain tumors expressing the herpes simplex virus thymidine kinase imaged by magnetic resonance. Maron A, et al. **J Neurooncol** 1995;24(3):259-65

Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy. Report of a case. Scaioli V, et al. **J Neurooncol** 1995;25(3):221-5

Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas. Stewart DJ, et al. **J Neurooncol** 1995;24(2):189-94

Adjuvant combined modality therapy for malignant meningiomas. Chamberlain MC. **J Neurosurg** 1996 May; 84(5):733-6

Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. Bassa P, et al. **J Nucl Med** 1996 Jun;37(6):931-8

Thallium-201 scintigraphy to assess effect of chemotherapy in osteosarcoma. Ohtomo K, et al. **J Nucl Med** 1996 Sep; 37(9):1444-8

FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. van Ginkel RJ, et al. **J Nucl Med** 1996 Jun;37(6):984-90

Combination treatment with cisplatin and schizophyllan for 7,12-dimethylbenz(a)anthracene-induced rat ovarian adenocarcinoma. Sugiyama T, et al. **J Obstet Gynaecol** 1995 Oct;21(5):521-7

Enhanced magnetic resonance imaging in monitoring of conservative treatment of cervical pregnancy. Takashima

M, et al. **J Obstet Gynaecol** 1995 Dec;21(6):545–50

The frequency and consequences of varicella exposure and varicella infection in children receiving maintenance therapy for acute lymphoblastic leukemia. Buda K, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):106–12

Successful treatment of a primary cardiac leiomyosarcoma with ifosfamide and etoposide. Han P, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):314–7

Perspectives on investigational chemotherapy and biologic therapy for childhood brain tumors. Kadota RP. **J Pediatr Hematol Oncol** 1996 Feb;18(1):13–22 (110 ref.)

Pediatric germ cell tumor. An experience with BEP. Kapoor G, et al. **J Pediatr Hematol Oncol** 1995 Nov;17(4):318–24

Desmoplastic small cell tumor: a report of three cases and a review of the literature. Kretschmar CS, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):293–8 (29 ref.)

Intestinal perforation 14 years after abdominal irradiation and chemotherapy for Wilms tumor. Rao SP, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):187–90

Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. Ruymann FB, et al. **J Pediatr Hematol Oncol** 1995 Nov;17(4):331–7

Chemotherapeutic treatment of malignant chordoma in children. Scimeca PG, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):237–40 (10 ref.)

Childhood acute lymphoblastic leukemia relapse in the uterine cervix. Tsuruchi N, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):311–3

Vesiculated erythrocytes as a determination of splenic reticuloendothelial function in pediatric patients with Hodgkin's disease. Weiner MA, et al. **J Pediatr Hematol Oncol** 1995 Nov;17(4):338–41

Hodgkin disease in children: reduced tailored chemotherapy for stage I–II disease. Yaniv I, et al. **J Pediatr Hematol Oncol** 1996 Feb;18(1):76–80

Retinal detachment in a child as the first sign of leukemic relapse: histopathology, MRI findings, treatment, and tumor-free follow up. Primack JD, et al. **J Pediatr Ophthalmol Strabismus** 1995 Jul–Aug;32(4):253–6

Preliminary evaluation of the use of high dose rate brachytherapy in conjunction with external beam radiation and chemotherapy in the definitive management of cervical carcinoma. Boulware RJ, et al. **J S C Med Assoc** 1996 Jul;92(7):311–5

Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors. Culine S, et al. **J Surg Oncol** 1996 Mar;61(3):195–8

Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose ACMF with tamoxifen for premenopausal, node-positive breast cancer patients: results of a prospective randomized study. Fukutomi T, et al. **J Surg Oncol** 1995 Dec;60(4):242–6

Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer. Ito K, et al. **J Surg Oncol** 1996 May; 62(1):4–9

Postradiotherapy hypothyroidism: radiation dose response and chemotherapeutic radiosensitization at less than 40 Gy. Kuten A, et al. **J Surg Oncol** 1996 Apr;61(4):281–3

Potentiation of antitumor activity of mitomycin C by estradiol: studies of human breast carcinoma xenografts serially transplanted into nude mice. Oka S, et al. **J Surg Oncol** 1996 Apr;61(4):256–61

Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. Sauter ER, et al. **J Surg Oncol** 1995 Oct;60(2):100–5

Neoadjuvant chemotherapy in locally advanced breast cancer. Singh G, et al. **J Surg Oncol** 1996 Jan;61(1):38–41

Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors [see comments] Angulo JC, et al. **J Urol** 1996 Jun;155(6):1897–902. Comment in: J Urol 1996 Jun;155(6):1910–1.

Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. Donat SM, et al. **J Urol** 1996 Aug;156(2 Pt 1):368–71

Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. Fleshner NE, et al. **J Urol** 1995 Nov; 154(5):1642–5; discussion 1645–6

A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer [see comments] Freiha F, et al. **J Urol** 1996 Feb;155(2):495–9; discussion 499–500. Comment in: J Urol 1996 Feb;155(2):504–5.

Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer [see comments] Maffezzini M, et al. **J Urol** 1996 Jan;155(1):91–3. Comment in: J Urol 1996 Jan;155(1):103–4.

Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group [see comments] Malmström PU, et al. **J Urol** 1996 Jun;155(6):1903–6. Comment in: J Urol 1996 Jun;155(6):1910–1.

Combination chemotherapy with intra-arterial cisplatin and doxorubicin plus intravenous methotrexate and vincristine for locally advanced bladder cancer. Kyushu University Urological and Radiological Oncology Group. Naito S, et al. **J Urol** 1995 Nov;154(5):1704–9

Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy [see comments] Sekine H, et al. **J Urol** 1996 Jan;155(1):94–8; discussion 98–9. Comment in: J Urol 1996 Jan;155(1):103–4.

Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. Tu SM, et al. **J Urol** 1995 Nov; 154(5):1719–22

Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience [see comments] Wei CH, et al. **J Urol** 1996 Jan;155(1):118–21. Comment in: J Urol 1996 Jan;155(1):122.

Dramatic response to ifosfamide, mesna and doxorubicin chemotherapy regimen in an adult with clear cell sarcoma of the kidney. Yalçin S, et al. **J Urol** 1996 Jun;155(6):2024

Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Oshita F, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1198–202

Intensive chemotherapy for anaplastic thyroid carcinoma: combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte granulocyte colony-stimulating factor support. Chemotherapy Committee, The Japanese Society of Thyroid Surgery. **Jpn J Clin Oncol** 1995 Oct;25(5):203–7

Comparison of peripheral blood stem cells mobilized with granulocyte colony-stimulating factor with or without prior standard-dose chemotherapy in patients with malignancy. Kobayashi N, et al. **Jpn J Clin Oncol** 1995 Dec;25(6):250–7

Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. Muro K, et al. **Jpn J Clin Oncol** 1996 Apr;26(2):65–9

Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Ohtsu A, et al. **Jpn J Clin Oncol** 1995 Dec;25(6):261–6

Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. Okusaka T, et al. **Jpn J Clin Oncol** 1996 Aug;26(4):215–20

Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results. Oshita F, et al. **Jpn J Clin Oncol** 1995 Oct;25(5):208–12

Patient with extensive small cell lung cancer given moderately dose-intensified chemotherapy and peripheral blood stem cell support. Shimizu E, et al. **Jpn J Clin Oncol** 1995 Oct;25(5):213–7

The community clinical oncology program: its effect on clinical practice [comment] Warnecke RB, et al. **Jt Comm J Qual Improv** 1995 Jul;21(7):336–9. Comment on: Jt Comm J Qual Improv 1995 Jul;21(7):347–51.

Clinical characteristics of and response to combination chemotherapy and subsequent application of international prognostic index in non-Hodgkin's lymphoma--an experience from a medical center in Southern Taiwan. Hsieh CI, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Feb; 12(2):69–82

CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone: a case report. Nakajima H, et al. **Keio J Med** 1996 Jun;45(2):114–7

Testicular germ cell tumors. Results of the GPO MAHO studies -82, -88, -92. Haas RJ, et al. **Klin Padiatr** 1995 Jul–Aug;207(4):145–50

Autologous bone-marrow transplants compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission: a matched-pair analysis. The Berlin–Frankfurt–Münster Study Group. Borgmann A, et al. **Lancet** 1995 Sep 30;346(8979):873–6

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival [see comments] Gelber RD, et al. **Lancet** 1996 Apr 20;347(9008):1066–71 . Comment in: Lancet 1996 Apr 20;347(9008):1057–8.

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL [see comments] Johnson S, et al. **Lancet** 1996 May 25;347(9013):1432–8. Comment in: Lancet 1996 May 25;347(9013):1420–1.

Postmenopausal breast cancer: is the short-term pain worth the long-term gain? [comment] Pritchard KI. **Lancet** 1996 Apr 20;347(9008):1057–8. Comment on: Lancet 1996 Apr 20;347(9008):1066–71.

Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Vento S, et al. **Lancet** 1996 Jan 13;347(8994):92–3

Anti-androgens in treatment of prostate cancer [letter; comment] Waxman J, et al. **Lancet** 1995 Oct 14; 346(8981):1030. Comment on: Lancet 1995 Jul 29;346(8970):265–9.

Aggressive non-Hodgkin's lymphoma: long-term results of full dose CHOP chemotherapy, and analysis of prognostic determinant. Bezwoda WR, et al. **Leuk Lymphoma** 1996 Jan;20(3–4):303–10

t(15;17) hypergranular acute promyelocytic leukemia (M3) developing into a t(3;6) M3 without t(15;17) at relapse. Desangles F, et al. **Leuk Lymphoma** 1995 Sep;19(1–2):185–8

Alpha-interferon and corticosteroids as initial treatment in small cleaved-cell lymphoma. Flecknoe-Brown S. **Leuk Lymphoma** 1995 Jul;18(3–4):353–6

Acute monocytic leukemia: a single institution experience. Fung H, et al. **Leuk Lymphoma** 1995 Oct;19(3–4):259–65

Successful chemotherapy including epirubicin in a pregnant non-Hodgkin's lymphoma patient. Goldwasser F, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):173–6

DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas. Goss P, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):123–9

A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients. Goss P, et al. **Leuk Lymphoma** 1995 Jun; 18(1–2):145–52

Multidrug resistance (Mdr1) gene expression in peripheral blasts from patients with acute leukemia only rarely increases during disease progression after combination chemotherapy. Gruber A, et al. **Leuk Lymphoma** 1995 Aug; 18(5–6):435–42

Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy. Haim N, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):321–6

Aggressive chemotherapy in the treatment of Burkitt's and non-Burkitt's undifferentiated lymphoma. Mazza JJ, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):289–96

Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Mills W, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):263–70

P-COMM-B induction chemotherapy in intermediate and high grade non-Hodgkin's lymphoma. Phillips JK, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):137–43

A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. Phillips JK, et al. **Leuk Lymphoma** 1995 May;17(5–6):465–72

Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukemia (MDS-AML). Pogliani EM, et al. **Leuk Lymphoma** 1995 Nov;19(5–6):473–7

A phase I–II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Przepiorka D, et al. **Leuk Lymphoma** 1995 May;17(5–6):427–33

Intensive therapy and autologous stem cell transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Reece DE, et al. **Leuk Lymphoma** 1996 Apr; 21(3–4):245–53 (55 ref.)

Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen. Sawada KI, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):103–9

ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL). Silingardi V, et al. **Leuk Lymphoma** 1995 Apr; 17(3–4):313–20

Combination chemotherapy (RCM protocol: response-oriented cyclic multidrug protocol) for the acute or lymphoma type adult T-cell leukemia. Uozumi K, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):317–23

Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation. Varterasian M, et al. **Leuk Lymphoma** 1995 Dec; 20(1–2):59–65

MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia. Visani G, et al. **Leuk Lymphoma** 1995 Nov;19(5–6):447–51

VAD-cyclosporine therapy for VAD-resistant multiple myeloma. Weber D, et al. **Leuk Lymphoma** 1995 Sep; 19(1–2):159–63

Primary Mediastinal B-cell lymphoma with sclerosis: clinical and therapeutic evaluation of 22 patients. Zinzani PL, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):311–6

Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity. Gruber A, et al. **Leuk Res** 1995 Oct;19(10):757–61

Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: a pilot study. Iwao N, et al. **Leuk Res** 1995 Dec;19(12):899–903

A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis. Kouides PA, et al. **Leuk Res** 1995 Oct;19(10):763–70

Prognostic value of early response to chemotherapy assessed by the day 15 bone marrow aspiration in adult acute lymphoblastic leukemia: a prospective analysis of 437 cases and its application for designing induction chemotherapy trials. Sebban C, et al. **Leuk Res** 1995 Nov;19(11):861–8

Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia.

Shpilberg O, et al. **Leuk Res** 1995 Dec;19(12):893–7

High–dose chemotherapy in adult acute myeloid leukemia: rationale and results. Stasi R, et al. **Leuk Res** 1996 Jul; 20(7):535–49 (70 ref.)

A phase II study of VP–16, intermediate–dose Ara–C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia. Amadori S, et al. **Leukemia** 1996 May;10(5):766–8

Factors predicting complete remission and subsequent disease–free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Anderlini P, et al. **Leukemia** 1996 Jun; 10(6):964–9

Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Anderlini P, et al. **Leukemia** 1996 Apr;10(4):600–8

Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia [letter] Binet JL, et al. **Leukemia** 1995 Dec; 9(12):2159–61

Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD? [editorial] Canellos GP. **Leukemia** 1996 Jun;10 Suppl 2:s68

High–dose therapy autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first–line therapy: analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol. EBMT/ANZLG/Intergroup HD01 Trial. Federico M, et al. **Leukemia** 1996 Jun;10 Suppl 2:s69–71

Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25–year period. Ferrari A, et al. **Leukemia** 1995 Oct; 9(10):1643–7

Collection, analysis and transplantation of Ph–negative blood precursor cells in chronic myeloid leukemia. Frassoni F, et al. **Leukemia** 1996 Jun;10 Suppl 2:s30–2

Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Gale RP, et al. **Leukemia** 1996 Jan;10(1):13–9

Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Hasle H, et al. **Leukemia** 1996 Aug;10(8):1269–73

Blast cell proliferative activity and sensitivity to GM–CSF in vitro are associated with early response to TAD–9 induction therapy in acute myeloid leukemia. Jahns–Streubel G, et al. **Leukemia** 1995 Nov;9(11):1857–63

New chemotherapeutic agents in acute myeloid leukemia. Kantarjian HM, et al. **Leukemia** 1996 Apr;10 Suppl 1:S4–6 (0 ref.)

Prognostic significance of peanut agglutinin binding in childhood acute lymphoblastic leukemia. Kaspers GJ, et al. **Leukemia** 1996 Apr;10(4):675–81

Clinical and laboratory studies of 2–chlorodeoxyadenosine +/– cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Kornblau SM, et al. **Leukemia** 1996 Oct;10(10):1563–9

Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first–line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Liso V, et al. **Leukemia** 1996 Sep;10(9):1443–52

The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. List AF. **Leukemia** 1996 Apr;10 Suppl 1:S36–8 (0 ref.)

Serum G–CSF levels in patients undergoing G–CSF/chemotherapy mobilized peripheral stem cell harvest and predictors of neutrophil and platelet recovery. Maharaj D, et al. **Leukemia** 1995 Oct;9 Suppl 1:S113–7

Granulocyte colony–stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Maslak PG, et al. **Leukemia** 1996 Jan;10(1):32–9

Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. Masson E, et al. **Leukemia** 1996 Jan;10(1):56–60

A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Reiffers J, et al. **Leukemia** 1996 Mar;10(3):389–95

Oral idarubicin pharmacokinetics—correlation of trough level with idarubicin area under curve. Schleyer E, et al. **Leukemia** 1996 Apr;10(4):707–12

Incidence and clinical outcome of children with BCR/ABL–positive acute lymphoblastic leukemia (ALL). A prospective RT–PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL–BFM–90 and CoALL–05–92. Schlieben S, et al. **Leukemia** 1996 Jun;10(6):957–63

Hodgkin's disease: from basic science to clinical application. Tesch H, et al. **Leukemia** 1996 Jun;10 Suppl 2:s74–7 (21 ref.)

Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low–grade non–Hodgkin's lymphoma. German Low–Grade Lymphoma Study Group. Unterhalt M, et al. **Leukemia** 1996 May;10(5):836–43

Recombinant human interleukin–3 (rH IL–3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. Wielenga JJ, et al. **Leukemia** 1996 Jan;10(1):43–7

Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer. Carney DN. **Lung Cancer** 1995 Jun;12 Suppl 3:S77–83 (10 ref.)

Economic value of gemcitabine compared to cisplatin and etoposide in non–small cell lung cancer [see comments] Copley–Merriman C, et al. **Lung Cancer** 1996 Feb; 14(1):45–61. Comment in: Lung Cancer 1996 Feb;14(1):13–7.

Superiority of three–drug combination chemotherapy versus cisplatin–etoposide in advanced non–small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research. Crinò L, et al. **Lung Cancer** 1995 Apr; 12 Suppl 1:S125–32

Trials with mitomycin, ifosfamide and cisplatin in non–small cell lung cancer. Cullen MH. **Lung Cancer** 1995 Apr;12 Suppl 1:S95–106 (12 ref.)

New drugs for treating small cell lung cancer. Ettinger DS. **Lung Cancer** 1995 Jun;12 Suppl 3:S53–61 (20 ref.)

Adjuvant chemotherapy: results and perspectives. Evans WK. **Lung Cancer** 1995 Apr;12 Suppl 1:S35–45 (27 ref.)

Etoposide phosphate or etoposide with cisplatin in the treatment of small cell lung cancer: randomized phase II trial. Greco FA, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S85–95

Pre–treatment prognostic factors in patients with stage III non–small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy. Jeremic B, et al. **Lung Cancer** 1995 Aug; 13(1):21–30

Impact of chemotherapy on survival in locally advanced non–small cell lung cancer: the Gustave–Roussy experience. Le Cesne A, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S79–85 (25 ref.)

Single–agent chemotherapy versus combination chemotherapy in advanced non–small cell lung cancer: a quality and meta–analysis study. Marino P, et al. **Lung Cancer** 1995 Aug;13(1):1–12

Non–uniform dose/time fractionated radiation therapy and chemotherapy for non–small cell lung cancer. Mohiuddin M, et al. **Lung Cancer** 1995 Aug;13(1):57–67

Multicenter randomized trial comparing cisplatin–mitomycin–vinorelbine versus cisplatin–mitomycin–vindesine in advanced non–small cell lung cancer. 'Groupe Français de Pneumo–Cancérologie'. Pérol M, et al. **Lung Cancer** 1996 Feb;14(1):119–34

Oral therapy for small cell lung cancer. Postmus PE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S63–70 (29 ref.)

Phase I trial of gemcitabine and cisplatin in advanced non–small cell lung cancer: a preliminary report. Shepherd FA, et al. **Lung Cancer** 1996 Feb;14(1):135–44

Meta–analysis of randomised trials of systemic chemotherapy versus supportive treatment in non–resectable non–small cell lung cancer. Souquet PJ, et al. **Lung Cancer** 1995 Apr; 12 Suppl 1:S147–54

Combined platinum etoposide with radiation therapy in limited stage small cell lung cancer: an effective treatment strategy. Turrisi AT 3rd. **Lung Cancer** 1995 Jun;12 Suppl 3:S41–51 (26 ref.)

Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non–small cell lung cancer. Urban T, et al. **Lung Cancer** 1996 Feb;14(1):109–17

Cost analysis of hospital treatment—two chemotherapic regimens for non–surgical non–small cell lung cancer. GFPC (Groupe Français Pneumo Cancérologie) [see comments] Vergnenègre A, et al. **Lung Cancer** 1996 Feb; 14(1):31–44. Comment in: Lung Cancer 1996 Feb;14(1):13–7.

Surgical treatment of small cell carcinoma of the lung: advantage of preoperative chemotherapy. Wada H, et al. **Lung Cancer** 1995 Aug;13(1):45–56

Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer. Beitler JJ, et al. **Med Oncol** 1995 Jun;12(2):115–20

Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma. Falkson CI. **Med Oncol** 1995 Mar;12(1):35–40

The role of alpha interferon in the biomodulation of disease: preface. Wadler S. **Med Oncol** 1995 Mar;12(1):1–2

Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL–2 and alpha–IFN. Wersäll P, et al. **Med Oncol** 1995 Jun;12(2):69–77

Successful treatment of orbital rhabdomyosarcoma in two infants using chemotherapy alone. Alvarez Silván AM, et al. **Med Pediatr Oncol** 1996 Mar;26(3):186–9

Mitoxantrone–containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872. Béhar C, et al. **Med Pediatr Oncol** 1996 Mar; 26(3):173–9

Treatment of childhood Hodgkin's disease with ABVD without radiotherapy. Behrendt H, et al. **Med Pediatr Oncol** 1996 Apr;26(4):244–8

Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio–spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study. Evans AE, et al. **Med Pediatr Oncol** 1996 Jul;27(1):8–14

Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group. Green DM, et al. **Med Pediatr Oncol** 1996 Mar;26(3):147–52

"Chemotherapy for unresectable pancreatoblastoma" [letter] Hord JD, et al. **Med Pediatr Oncol** 1996 Jun;26(6):432–3

Randomized comparison of moderate–dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study. Lange BJ, et al. **Med Pediatr Oncol** 1996 Jul;27(1):15–20

Case report: pulmonary blastoma in children—response to chemotherapy. Lobo–Sanahuja F, et al. **Med Pediatr Oncol** 1996 Mar;26(3):196–200

Treatment of high–risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu–Yamaguchi Children's Cancer Study Group in Japan. Matsuzaki A, et al. **Med Pediatr Oncol** 1996 Jan;26(1):10–9

Pancreatic blastomatous tumor in a child responding to therapy used for hepatoblastoma: case report and review of the literature. Morgan ER, et al. **Med Pediatr Oncol** 1996 Apr;26(4):284–92 (29 ref.)

Induction toxicity of a modified Memorial Sloan–Kettering–New York II Protocol in children with relapsed acute lymphoblastic leukemia: a single institution study. Morland BJ, et al. **Med Pediatr Oncol** 1996 Sep; 27(3):139–44

Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience. Pratt CB, et al. **Med Pediatr Oncol** 1996 Sep;27(3):145–8

Dacarbazine and interferon–alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations. Betticher DC, et al. **Melanoma Res** 1995 Aug;5(4):277–82

Phase II trial of recombinant interferon–alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. Feun LG, et al. **Melanoma Res** 1995 Aug; 5(4):273–6

Addition of dacarbazine or cisplatin to interferon–alpha/interleukin–2 in metastatic melanoma: toxicity and immunological effects. Keilholz U, et al. **Melanoma Res** 1995 Aug;5(4):283–7

Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5–year follow–up. Lattanzi SC, et al. **Melanoma Res** 1995 Oct;5(5):365–9

Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. Rixe O, et al. **Melanoma Res** 1995 Dec;5(6):419–24

Design and conduct of a double–blind, placebo–controlled trial of daunorubicin and cytarabine with or without granulocyte colony–stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study. Godwin J. **Monogr Natl Cancer Inst** 1995; (19):31–5

Potential evaluation of the incremental cost–effectiveness of paclitaxel in advanced non–small–cell lung cancer (Eastern Cooperative Oncology Group 5592). Hillner BE. **Monogr Natl Cancer Inst** 1995;(19):65–7

Randomized, comparative study of high–dose (with autologous bone marrow support) versus low–dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CALGB Protocol 9082). Cancer and Leukemia Group B. Hurd DD, et al. **Monogr Natl Cancer Inst** 1995;(19):41–4

Phase III trial (E5592) comparing cisplatin plus etoposide with cisplatin plus paclitaxel at two dose levels for treatment of advanced non–small–cell lung cancer. Eastern Cooperative Oncology Group. Johnson DH. **Monogr Natl Cancer Inst** 1995;(19):61–3

Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122. Randall ME, et al. **Monogr Natl Cancer Inst** 1995;(19):13–5

Economic evaluation of high–dose chemotherapy and bone marrow transplantation for patients with breast cancer of stage II or IIIA with more than 10 positive lymph nodes at surgical excision. Schulman KA, et al. **Monogr Natl Cancer Inst** 1995;(19):45–50

Economic considerations in comparing whole abdominal radiotherapy with combination doxorubicin–cisplatin chemotherapy in advanced endometrial carcinoma: how much economic data should be collected? Weeks JC. **Monogr Natl Cancer Inst** 1995;(19):17–9

Sarcomas: the role of adjuvant chemotherapy and a proposed new staging system. Baker LH, et al. **Monogr Pathol** 1996; 38:240–51 (49 ref.)

Autologous bone marrow transplantation in relapsed non–Hodgkin's lymphoma [letter; comment] Atkins CD. **N Engl J Med** 1996 Apr 11;334(15):990; discussion 991–2 . Comment on: N Engl J Med 1995 Dec 7;333(23):1540–5.

Chemotherapy for ovarian cancer [letter; comment] Cvitkovic E, et al. **N Engl J Med** 1996 May 9;334(19):1269; discussion 1270. Comment on: N Engl J Med 1996 Jan 4;334(1):1–6.

Autologous bone marrow transplantation in relapsed non–Hodgkin's lymphoma [letter; comment] Koehne CH, et al. **N Engl J Med** 1996 Apr 11;334(15):990–1; discussion 991–2. Comment on: N Engl J Med 1995 Dec 7;333(23):1540–5.

Chemotherapy for ovarian cancer [letter] Lacave AJ, et al.

N Engl J Med 1996 May 9;334(19):1269-70

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [see comments] McGuire WP, et al. N Engl J Med 1996 Jan 4;334(1):1-6. Comment in: N Engl J Med 1996 Jan 4;334(1):50-1. Comment in: N Engl J Med 1996 May 9;334(19):1268-9; discussion 1270. Comment in: N Engl J Med 1996 May 9;334(19):1269; discussion 1270.

New therapy for ovarian cancer [editorial; comment] Neijt JP. N Engl J Med 1996 Jan 4;334(1):50-1. Comment on: N Engl J Med 1996 Jan 4;334(1):1-6.

Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma [letter; comment] Pagano JS. N Engl J Med 1995 Nov 9;333(19):1285-6. Comment on: N Engl J Med 1995 Jun 29;332(26):1744-8.

Chemotherapy for ovarian cancer [letter; comment] Parmar MK, et al. N Engl J Med 1996 May 9;334(19):1268-9; discussion 1270. Comment on: N Engl J Med 1996 Jan 4;334(1):1-6.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma [see comments] Philip T, et al. N Engl J Med 1995 Dec 7; 333(23):1540-5. Comment in: N Engl J Med 1995 Dec 7;333(23):1565-6. Comment in: N Engl J Med 1996 Apr 11;334(15):990; discussion 991-2. Comment in: N Engl J Med 1996 Apr 11;334(15):990-1; discussion 991-2. Comment in: N Engl J Med 1996 Apr 11;334(15):991; discussion 991-2.

Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma. Lymphoma Study Group of the Japan Clinical Oncology Group [letter; comment] Tobinai K, et al. N Engl J Med 1995 Nov 9;333(19):1285; discussion 1286. Comment on: N Engl J Med 1995 Jun 29;332(26):1744-8.

Treatment for non-Hodgkin's lymphoma in relapse. What are the alternatives? [editorial; comment] Vose JM. N Engl J Med 1995 Dec 7;333(23):1565-6. Comment on: N Engl J Med 1995 Dec 7;333(23):1540-5.

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma [see comments] Walsh TN, et al. N Engl J Med 1996 Aug 15;335(7):462-7. Comment in: N Engl J Med 1996 Aug 15;335(7):509-10.

The clinical and histopathological effects of combined chemotherapy using cisplatin and peplomycin to treat cancer of the tongue. Tohnai I, et al. Nagoya J Med Sci 1995 Dec;58(3-4):171-7

Adjuvant therapy of colon cancer: towards a new consensus [editorial] Blijham GH. Neth J Med 1996 Jul;49(1):1-3 (19 ref.)

Adjuvant treatment of colorectal cancer in The Netherlands: a commentary [letter] Wils J. Neth J Med 1996 Jul; 49(1):52-5

M-Bacod as first treatment for primary CNS lymphoma [letter; comment] Boiardi A, et al. Neurology 1996 Jan; 46(1):286-8. Comment on: Neurology 1994 Sep;44(9):1721-7.

Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Cher L, et al. Neurology 1996 Jun;46(6):1757-9

Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Freilich RJ, et al. Neurology 1996 Feb;46(2):435-9

Low-grade oligodendroglioma responds to chemotherapy. Mason WP, et al. Neurology 1996 Jan;46(1):203-7

Chemosensitive epidural spinal cord disease in non-Hodgkins lymphoma. Wong ET, et al. Neurology 1996 Jun; 46(6):1543-7

Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Williams PC, et al. Neurosurgery 1995 Jul;37(1):17-27; discussion 27-8

A case of advanced male breast cancer successfully treated by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy combined with tamoxifen. Tanaka Y, et al. Nippon Geka Hokan 1995 Jan 1;64(1):15-22

Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma. Kuliszkiewicz-Janus M, et al. NMR Biomed 1995 May; 8(3):127-32

31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion. Sijens PE, et al. NMR Biomed 1995 Aug;8(5):215-24

Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Gershenson DM, et al. Obstet Gynecol 1996 Apr; 87(4):527-31

Neoadjuvant chemotherapy for locally advanced cervical cancer--where does it stand?: a review. Edelmann DZ, et al. Obstet Gynecol Surv 1996 May;51(5):305-13 (63 ref.)

A dose-escalating study of carboplatin combined with vinorelbine in non-small-cell lung cancer. Colleoni M, et al. Oncology 1996 Sep-Oct;53(5):364-8

Mitoxantrone, fluorouracil plus L-leucovorin, and vinorelbine in pretreated advanced breast cancer. Colleoni M, et al. Oncology 1995 Nov-Dec;52(6):435-8

Epidoxorubicin and double biochemical 5-fluorouracil modulation with folinic acid and human lymphoblastoid interferon in advanced gastric carcinoma: a multicentric phase II study of the Southern Italy Oncology Group (GOIM). Colucci G, et al. Oncology 1996 Jul-Aug; 53(4):269-74

Significance of methotrexate serum level achieved in patients with gastrointestinal malignancies treated with sequential methotrexate, L-folinic acid and 5-fluorouracil. Comella P, et al. Oncology 1996 May-Jun;53(3):198-203

Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. de Graaf H, et al. Oncology 1996 Jul-Aug;53(4):289-94

Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: a pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin. Falkson CI, et al. Oncology 1996 Jul-Aug;53(4):313-7

Local hyperthermia, radiation, and chemotherapy in locally advanced malignancies. Feyerabend T, et al. Oncology 1996 May-Jun;53(3):214-20

Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Study. Fountzilas G, et al. Oncology 1996 Mar-Apr; 53(2):137-46

Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: results of a phase II study. Jäger E, et al. Oncology 1996 Jan-Feb; 53(1):58-63

Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice. Lasek W, et al. Oncology 1996 Jan-Feb;53(1):31-7

Randomized trial of dietician counseling to try to prevent weight gain associated with breast cancer adjuvant chemotherapy. Loprinzi CL, et al. Oncology 1996 May-Jun;53(3):228-32

Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Malacarne P, et al. Oncology 1996 May-Jun;53(3):210-3

Phase II study of 5-fluorouracil and interferon-gamma in patients with metastatic colorectal cancer. A Hellenic Cooperative Oncology Group Study. Pavlidis N, et al. Oncology 1996 Mar-Apr;53(2):159-62

Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer. Vici P, et al. Oncology 1996 Jan-Feb;53(1):16-8

A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Wada T, et al. Oncology 1996 May-Jun;53(3):221-7

Vasoacting agents flavone acetic acid and hydralazine given in combination enhance antitumor effects under condition of hyperthermia. Yamamoto M, et al. Oncology 1996 Mar-Apr;53(2):147-52

Primary T cell leptomeningeal lymphoma--successful treatment with systemic chemotherapy. Yeh KH, et al. Oncology 1995 Nov-Dec;52(6):501-4

Intensified VICE regimen may improve SCLC survival [news] Oncology (Huntingt) 1996 Apr;10(4):554

New sequential dosing regimen shows promise in node-positive breast cancer [news] Oncology (Huntingt) 1996 Apr;10(4):552-3

MoAb to block growth signals plus chemo may act synergistically to kill tumor cells [news] Oncology (Huntingt) 1996 Apr;10(4):591-2

Health resource utilization in ABMT with and without G-CSF in stage III/IV breast cancer patients. Lawless GD, et al. Oncology (Huntingt) 1995 Nov;9(11 Suppl):107-10

"8 in 1" [editorial] Cohen IJ. Pediatr Hematol Oncol 1996 May-Jun;13(3):iii-v

Chemotherapy with the "8 in 1" protocol for malignant brain tumors in children: a population-based study in Finland. Ilveskoski I, et al. Pediatr Hematol Oncol 1996 Jan-Feb; 13(1):69-80

Treatment results of Hodgkin's disease in Indian children. Kapoor G, et al. Pediatr Hematol Oncol 1995 Nov-Dec; 12(6):559-69

Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies. Lydaki E, et al. Pediatr Hematol Oncol 1995 Nov-Dec;12(6):551-8

Superior sagittal sinus thrombosis complicating maintenance treatment for acute lymphoblastic leukemia. Nicholson JC, et al. Pediatr Hematol Oncol 1996 May-Jun;13(3):287-91

Varicella zoster infections in children with acute lymphoblastic leukemia. Poulsen A, et al. Pediatr Hematol Oncol 1996 May-Jun;13(3):231-8

Prognostic variables and survival in pediatric acute lymphoblastic leukemias: cancer institute experience. Shanta V, et al. Pediatr Hematol Oncol 1996 May-Jun; 13(3):205-16

Hybrid (COPP/ABV) therapy in childhood Hodgkin's disease: a study of 53 cases during 1989-1993 at the Cancer Institute, Madras. Sripada PV, et al. Pediatr Hematol Oncol 1995 Jul-Aug;12(4):333-41

Masked Hodgkin's disease: the pruriginous disguise [letter] Stefanato CM, et al. Pediatr Hematol Oncol 1996 May-Jun; 13(3):293-4

Successful multidrug chemotherapy of olfactory neuroblastoma in an 8-year-old child. Załęska-Czepko E, et al. Pediatr Hematol Oncol 1996 Mar-Apr;13(2):191-3

Management of patients with breast cancer: from chemotherapy to stem cell support. Introduction. Gilbert CJ. Pharmacotherapy 1996 May-Jun;16(3 Pt 2):85S-87S

Quality of life in patients with metastatic colorectal cancer receiving chemotherapy: a randomized, double-blind trial comparing 5-FU versus 5-FU with leucovorin. Sullivan BA, et al. Pharmacotherapy 1995 Sep-Oct;15(5):600-7

Adjuvant systemic therapy for breast cancer. Issues for primary care physicians. Berkowitz LD, et al. Postgrad Med 1995 Oct;98(4):85-8, 91, 94 (2 ref.)

Adjuvant treatment of breast cancer. Akerley WL 3rd. R I Med 1995 Sep;78(9):250-3 (12 ref.)

Chemotherapy given for lung cancer causes incidental and long-term cure of fungal skin infection. Memon AS. R I Med 1995 Nov;78(11):320

Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Helvie MA, et al. Radiology 1996 Feb;198(2):327-32

Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Vinnicombe SJ, et al. Radiology 1996 Feb;198(2):333-40

Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer. Christie DR, et al. Radiother Oncol 1995 Dec;37(3):181-9

Future developments in adjuvant systemic therapy for high-risk breast cancer. Bonadonna G. Recent Results Cancer Res 1996;140:227-34 (16 ref.)

Adjuvant systemic therapy: the issues of timing and sequence. Castiglione-Gertsch M, et al. Recent Results Cancer Res 1996;140:201-13 (22 ref.)

The primary use of chemotherapy for operable breast cancer: does systemic therapy make surgery superfluous? Rudenstam CM. Recent Results Cancer Res 1996; 140:177-88 (21 ref.)

VIII. Women's health perception and breast cancer: issues of fertility, hormone substitution, and cancer prevention. Valagussa P, et al. Recent Results Cancer Res 1996; 140:277-83

Recent advances in the management of acute leukaemia in adults [letter; comment] Jacobs P. S Afr Med J 1994 Nov; 84(11):784-6. Comment on: S Afr Med J 1994 Jun;84(6):315-7.

Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. Aisner J, et al. Semin Oncol 1995 Oct;22(5 Suppl 12):17-21

The activity of paclitaxel in gastrointestinal tumors. Ajani JA, et al. Semin Oncol 1995 Oct;22(5 Suppl 12):46-50; discussion 51-3

Carboplatin versus cisplatin in ovarian cancer. Alberts DS. Semin Oncol 1995 Oct;22(5 Suppl 12):88-90 (6 ref.)

A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer. Amadori D, et al. Semin Oncol 1996 Feb;23(1 Suppl 1):19-23

Epirubicin and ifosfamide in metastatic breast cancer. Becher R, et al. Semin Oncol 1996 Jun;23(3 Suppl 7):28-33

Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results. Belli L, et al. Semin Oncol 1995 Dec; 22(6 Suppl 15):29-33

Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. Benner SE, et al. Semin Oncol 1995 Oct;22(5 Suppl 12):22-5

Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Bissery MC, et al. Semin Oncol 1995 Dec;22(6 Suppl 13):3-16

Role of chemotherapy for advanced colorectal cancer: new opportunities. Bleiberg H. Semin Oncol 1996 Feb;23(1 Suppl 3):42-50 (71 ref.)

Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Bolis G. Semin Oncol 1995 Dec;22(6 Suppl 14):32-4

A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study. Bunn PA Jr, et al. Semin Oncol 1995 Oct;22(5 Suppl 12):54-8; discussion 59-60

Docetaxel (Taxotere) in combination: a step forward. Burris HA 3rd, et al. Semin Oncol 1995 Dec;22(6 Suppl 13):35-40

Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Calvert AH, et al. Semin Oncol 1995 Oct;22(5 Suppl 12):91-8; discussion 99-100

Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. Chang AY, et al. Semin Oncol 1996 Jun;23(3 Suppl 6):74-7

Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer. Chang AY, et al. Semin Oncol 1996 Apr;23(2 Suppl 5):19-21

Ifosfamide in the treatment of lymphoma. Coiffier B. Semin Oncol 1996 Jun;23(3 Suppl 7):2-7 (46 ref.)

Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1). Crawford J, et al. Semin Oncol 1996 Apr;23(2 Suppl 5):22-4

Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer. Creaven P, et al. Semin Oncol 1995 Oct;22(5 Suppl 12):13-6

Treatment of advanced breast cancer: How much chemotherapy is enough? [see comments] DiPaola RS, et

al. **Semin Oncol** 1996 Jun;23(3):xv–xxii; discussion xxii–xxiv . Comment in: Semin Oncol 1996 Jun;23(3):xxii–xxiv.

Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. Dombernowsky P, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 1):13–8 (17 ref.)

Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Dombernowsky P, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):13–7 (14 ref.)

Perioperative therapy of non-small cell lung cancer: a review of adjuvant and neoadjuvant approaches. Friedland DM, et al. **Semin Oncol** 1995 Dec;22(6):571–81 (41 ref.)

Biweekly paclitaxel in the treatment of patients with metastatic breast cancer. Gelmon KA. **Semin Oncol** 1995 Oct;22(5 Suppl 12):117–22

Adjuvant and neoadjuvant treatment for primary brain tumors in adults. Grossman SA, et al. **Semin Oncol** 1995 Dec;22(6):530–9 (75 ref.)

Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy. Hainsworth JD, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):45–9

Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma. Hanauske AR, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):35–9

Adjuvant systemic therapy for breast cancer. Harris DT. **Semin Oncol** 1995 Dec;22(6):553–70 (123 ref.)

Dose-intensive chemotherapy with etoposide-cyclophosphamide for advanced breast cancer. North American Marrow Transplant Group. Herzig RH, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 4):28–32

A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Hitt R, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):50–4

Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies. Hoffman PC, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):11–5

Paclitaxel-containing combination chemotherapy for metastatic breast cancer. Hortobagyi GN, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 1):53–7

Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Hudes GR, et al. **Semin Oncol** 1995 Oct; 22(5 Suppl 12):41–5

Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Hudis C, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 1):58–64

Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Hudis CA, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):18–23

Adjuvant and neoadjuvant treatment of head and neck cancers: the next chapter. Jacobs C, et al. **Semin Oncol** 1995 Dec;22(6):540–52 (66 ref.)

Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer. Klaassen U, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 1):44–7

Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis. Klaassen U, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):7–11

The role of ifosfamide in small cell lung cancer. Loehrer PJ Sr. **Semin Oncol** 1996 Jun;23(3 Suppl 7):40–4 (29 ref.)

Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. Masters GA, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):11–8

Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer. Meerpohl HG, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):7–12

Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Meropol NJ, et al. **Semin Oncol** 1995 Oct;22(5):509–24 (153 ref.)

Adjuvant chemotherapy for patients with stage II nonseminomatous testis cancer. Motzer RJ. **Semin Oncol** 1995 Dec;22(6):641–6 (33 ref.)

A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study. Natale RB. **Semin Oncol** 1995 Dec;22(6 Suppl 15):34–7

Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Ozols RF. **Semin Oncol** 1995 Dec;22(6 Suppl 15):1–6 (17 ref.)

Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. Palackdharry CS. **Semin Oncol** 1996 Jun;23(3 Suppl 6):78–83

Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience. Paul DM, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 1):48–52

Extensive stage small cell lung cancer: determining suitability for outpatient management of febrile neutropenia. Rapp JS, et al. **Semin Oncol** 1996 Apr;23(2):xv–xxii; discussion xxii

Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Rose PG. **Semin Oncol** 1996 Aug;23(4 Suppl 8):83–9

The role of ifosfamide in the treatment of testicular and urothelial malignancies. Roth BJ. **Semin Oncol** 1996 Jun; 23(3 Suppl 7):19–27 (83 ref.)

The role of paclitaxel in the therapy of bladder cancer. Roth BJ. **Semin Oncol** 1995 Oct;22(5 Suppl 12):33–40 (73 ref.)

High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer. Schiller JH. **Semin Oncol** 1996 Aug;23(4 Suppl 8):78–82

Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. Seidman AD, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):108–16 (53 ref.)

A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. Shea T, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):80–5

Adjuvant therapy of colon cancer. Shulman K, et al. **Semin Oncol** 1995 Dec;22(6):600–10 (108 ref.)

Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience. Sledge GW Jr. **Semin Oncol** 1995 Oct;22(5 Suppl 12):123–5; discussion 126–9

Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer. Souquet PJ, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):8–10

The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Thigpen T, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):67–75 (25 ref.)

The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix. Thigpen T, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):56–64 (52 ref.)

Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Tolcher AW. **Semin Oncol** 1996 Feb;23(1 Suppl 1):37–43 (22 ref.)

Ifosfamide-based chemotherapy for non-small cell lung cancer: phase I/II studies at the University of Chicago. Vokes EE, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 7):15–8

Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. Vokes EE, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):48–52

Ifosfamide in the treatment of pediatric malignancies. Voûte PA, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 7):8–11

The treatment of advanced gastric cancer. Wils J. **Semin Oncol** 1996 Jun;23(3):397–406 (73 ref.)

The role of chemotherapy in the management of the patient with T3b bladder cancer. Millikan R, et al. **Semin Urol Oncol** 1996 May;14(2):81–5 (23 ref.)

Osteosarcoma after chemotherapy for neuroblastoma. Kriss VM, et al. **Skeletal Radiol** 1995 Nov;24(8):633–5

A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group. Cole BF, et al. **Stat Med** 1995 Aug 30;14(16):1771–84

A Bayesian analysis of bivariate survival data from a multicentre cancer clinical trial. Gustafson P. **Stat Med** 1995 Dec 15;14(23):2523–35

Results of treatment of inoperable recurrences of laryngeal cancer after total laryngectomy. Sas-Korczyńska B, et al. **Strahlenther Onkol** 1996 Feb;172(2):99–102

Chemotherapy of human small-cell gastrointestinal carcinoma xenografts in nude mice. Aizawa K, et al. **Surg Oncol** 1995 Jun;4(3):139–45

Pre-operative induction chemotherapy for small cell carcinoma of the oesophagus: a case report. NG EK, et al. **Surg Oncol** 1995;4(2):121–3

Endocrine and cytotoxic therapies for the management of advanced local breast cancer. Current clinical investigation. Parker LM, et al. **Surg Oncol Clin N Am** 1995 Oct; 4(4):779–90

Complete response of transverse colon carcinoma to S1, a new chemotherapy agent: report of a case. Mimori K, et al. **Surg Today** 1995;25(8):741–4

Islet cell carcinoma treated by induction regional chemotherapy and radical total pancreatectomy with liver revascularization and small bowel autotransplantation. Lai DT, et al. **Surgery** 1996 Jan;119(1):112–4

Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Yonemura Y, et al. **Surgery** 1996 Apr;119(4):437–44

Neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer. Milroy R, et al. **Thorax** 1995 Sep;50 Suppl 1:S25–30 (54 ref.)

Preoperative chemotherapy, major liver resection, and transplantation for primary malignancies in children. Otte JB, et al. **Transplant Proc** 1996 Aug;28(4):2393–4

Prolonging survival in inoperable pancreatic cancer with combination chemotherapy. Goel AK, et al. **Trop Gastroenterol** 1995 Apr-Jun;16(2):141–3

Carboplatin and etoposide in an out-patient schedule for the palliation of advanced non-small-cell lung cancer. Aitini E, et al. **Tumori** 1995 Nov-Dec;81(6):429–31

Phase II trial of oral tegafur and folinic acid with mitoxantrone as first-line regimen in patients with metastatic breast cancer. Alonso V, et al. **Tumori** 1996 Jan-Feb;82(1):61–4

Adjuvant treatment in operable stage II and III rectal cancer. Aurelio P, et al. **Tumori** 1995 May-Jun;81(3 Suppl):109–13

Combined carboplatin and cytosine arabinoside in metastatic melanoma refractory to dacarbazine. Bajetta E, et al. **Tumori** 1995 Jul-Aug;81(4):238–40

Cisplatin and VP16 in metastatic breast carcinoma as a third-line chemotherapy: a randomized study comparing low versus high doses of cisplatin. Ceci G, et al. **Tumori** 1995 Jul-Aug;81(4):241–4

Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Colleoni M, et al. **Tumori** 1996 Jan-Feb;82(1):53–6

Cisplatin-vinorelbine combination chemotherapy in locally advanced non-small cell lung cancer. Frontini L, et al. **Tumori** 1996 Jan-Feb;82(1):57–60

Survival after chemotherapy with cisplatin and infusion of bleomycin prior to local-regional treatment in pyriform sinus cancer. Grau JJ, et al. **Tumori** 1996 May-Jun; 82(3):221–4

Procarbazine, CCNU, vincristine combination in the treatment of brain tumors. Güllü IH, et al. **Tumori** 1996 May-Jun;82(3):228–31

A phase II study of mitomycin C, vindesine and cisplatin combined with alpha interferon in advanced non-small cell lung cancer. Silva RR, et al. **Tumori** 1996 Jan-Feb; 82(1):68–71

Effectiveness of early chemotherapy treatment in anaplastic astrocytoma patients. Silvani A, et al. **Tumori** 1995 Nov-Dec;81(6):424–8

Mitomycin-C and lonidamine as second-line therapy for colorectal cancer: a phase II study. Zaniboni A, et al. **Tumori** 1995 Nov-Dec;81(6):435–7

Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Igawa M, et al. **Urol Int** 1995;55(2):74–7

Intraoperative irradiation: another option for the treatment of > or = 3 cm residual mass following chemotherapy for advanced testicular seminoma. Ravi R, et al. **Urol Int** 1995;55(3):137–40

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer [letter; comment] Crawford ED. **Urology** 1995 Dec; 46(6):899–901. Comment on: Urology 1995 May;45(5):745–52.

Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. Hall MC, et al. **Urology** 1996 Jun;47(6):826–30

Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine. Naik H, et al. **Urology** 1996 Sep;48(3):508–11

Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine. Papadopoulos I, et al. **Urology** 1996 Sep;48(3):373–8

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. Schellhammer P, et al. **Urology** 1996 Jan;47(1A Suppl):54–60; discussion 80–4

Effect of hepatic artery chemotherapy on survival of patients with hepatic metastases from colorectal carcinoma treated with cryotherapy. Preketes AP, et al. **World J Surg** 1995 Sep-Oct;19(5):768–71

Resection of stage III non-small cell lung cancer following induction therapy. Rusch VW. **World J Surg** 1995 Nov-Dec;19(6):817–22 (35 ref.)

Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging. Sato H, et al. **World J Surg** 1995 Nov-Dec;19(6):836–42

Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. Atzpodien J, et al. **World J Urol** 1995; 13(3):174–7

[VM-26 plus CCNU in the prevention of brain metastasis in lung cancer patients] Li J, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):314–5 (Eng. Abstr.) **(Chi)**

[CF/5-FU-DDP therapy for esophageal carcinoma] Wang R, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep; 17(5):362–4 (Eng. Abstr.) **(Chi)**

[Disease-free survival of acute leukemia patients receiving autologous bone marrow transplant following intensive chemotherapy--a report of 11 cases] Xia X, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):307–10 (Eng. Abstr.) **(Chi)**

[The clinical efficacy of CAC regimen in the treatment of advanced breast cancer] Zhang P, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Sep;17(5):365–7 (Eng. Abstr.) **(Chi)**

[Clinical trial of oral etoposide in the treatment of malignancies] Zhang X, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov;17(6):454–7 (Eng. Abstr.) **(Chi)**

[Adjuvant chemotherapy in advanced squamous cell carcinoma of the head and neck] Zhou T, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995;30(3):171–3 (Eng. Abstr.) **(Chi)**

[Combination chemotherapy of 5-fluorouracil and nitrocaphane for the treatment of malignant trophoblastic tumor] Ju L, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Apr;31(4):212–5 (Eng. Abstr.) **(Chi)**

[Comparison between the roles of aminoglutethimide and hydroxyprogesterone caproates in the treatment of endometrial cancer] Liu XS, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):479–82 (Eng. Abstr.) **(Chi)**

[Study of autologous bone marrow transplantation in the treatment of gynecologic carcinoma] Tu C, et al.

Chung Hua Fu Chan Ko Tsa Chih 1995 Aug;30(8):475–8 (Eng. Abstr.) **(Chi)**

[Selective arterial catheterization in the management of drug-resistant choriocarcinoma] Yang X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Apr;31(4):199–202 (Eng. Abstr.) **(Chi)**

[Effects of ACM sequential chemotherapy on ovarian function in trophoblastic tumors] Shi Y, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jan;76(1):45–8 (Eng. Abstr.) **(Chi)**

[Clinical studies of preoperative tumor reductive chemotherapy with PPV regimen in the treatment of oral squamous cell carcinoma] Jin Y, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 May; 30(3):166–8 **(Chi)**

[A clinical analysis of 15 cases of acute leukemia complicating pregnancy] Hou Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Apr;34(4):260–2 (Eng. Abstr.) **(Chi)**

[Chemotherapy of chiasmal gliomas in children] Helcl F. **Bratisl Lek Listy** 1995 Apr;96(4):223–6 (Eng. Abstr.) **(Cze)**

[Was chemotherapy beneficial for the patients with advanced ovarian cancer? A comparison of survival and resource use in two different time periods] Bertelsen K, et al. **Ugeskr Laeger** 1996 Aug 19;158(34):4767–70 (Eng. Abstr.) **(Dan)**

[Role of chemotherapy in non-small cell lung carcinoma] Giaccone G, et al. **Ned Tijdschr Geneeskd** 1996 May 25; 140(21):1111–4 (21 ref.) **(Dut)**

[Treatment of patients with trophoblastic tumors in the Academic Medical Center: 31 patients in 10 years, 1983–1992 (see comments)] Laan R, et al. **Ned Tijdschr Geneeskd** 1995 Sep 9;139(36):1829–34 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1995 Nov 18;139(46):2393–4. **(Dut)**

[Autologous stem cell support allows use of high-dose chemotherapy in breast cancer (editorial)] Joensuu H, et al. **Duodecim** 1994;110(12):1121–3 **(Fin)**

[The treatment of non-Hodgkin lymphoma in elderly patients] Salminen E. **Duodecim** 1994;110(21):1993–8 **(Fin)**

[Therapeutic choices in cancer of the rectum] **Ann Chir** 1995; 49(5):373–81 (0 ref.) **(Fre)**

[Concomitant preoperative radiochemotherapy for rectal cancers] Bosset JF, et al. **Ann Chir** 1996;50(4):302–10; discussion 311 (53 ref.) (Eng. Abstr.) **(Fre)**

[Current treatment of cancers of the anal canal] Gérard JP, et al. **Ann Chir** 1995;49(5):363–8; discussion 368–72 (39 ref.) (Eng. Abstr.) **(Fre)**

[Retroperitoneal extragonadal germinal choriocarcinoma: description of a case and the complex therapeutic approach] Lindenmeir T, et al. **Ann Urol (Paris)** 1996;30(2):94–8 (Eng. Abstr.) **(Fre)**

[Complete regression of cardiac non-Hodgkin's lymphoma after 23 months with chemotherapy] Pettelot G, et al. **Arch Mal Coeur Vaiss** 1996 Mar;89(3):379–81 (Eng. Abstr.) **(Fre)**

[Results of treatment protocols apropos of thr Boston program] Leclerc JM, et al. **Arch Pediatr** 1996;3 Suppl 1:201s–203s **(Fre)**

[Cerebral germ cell tumors in adults. A retrospective study of 19 cases] Agranat P, et al. **Bull Cancer (Paris)** 1995 Aug; 82(8):650–9 (Eng. Abstr.) **(Fre)**

[Concomitant radiochemotherapy with cisplatin (CDDP), 5-fluorouracil (5-FU) and mitomycin C (MMC) in locally advanced carcinoma of the oropharynx. Results of a phase II trial] Berger C, et al. **Bull Cancer (Paris)** 1995 Dec; 82(12):1044–51 (38 ref.) (Eng. Abstr.) **(Fre)**

[Salvage therapy of relapsing or refractory malignant lymphoma with non-myelotoxic combined chemotherapy. Results of combination of cisplatin, bleomycin, methyl-GAG and prednisolone (Cis-BMP)] Brault P, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):1032–7 (Eng. Abstr.) **(Fre)**

[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination] Cappelaere P, et al. **Bull Cancer (Paris)** 1995 Sep;82(9):732–7 (Eng. Abstr.) **(Fre)**

[Hodgkin disease: should high-risk patients be selected and chemotherapy be intensified?] Carde P. **Bull Cancer (Paris)** 1995 Aug;82(8):637–49 (58 ref.) (Eng. Abstr.) **(Fre)**

[Carboplatin and etoposide combination for the treatment of recurrent epithelial ovarian cancer] Chauvergne J, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):315–23 (52 ref.) (Eng. Abstr.) **(Fre)**

[Maintenance of the dose-intensity of chemotherapy combining carboplatin, cyclophosphamide, etoposide in women with ovarian cancer aged 70 and over] Delva R, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):63–69 (36 ref.) (Eng. Abstr.) **(Fre)**

[Survival results after 10 years of 39 patients with inflammatory breast cancer treated by two different neoadjuvant chemotherapy protocols] Eichler F, et al. **Bull Cancer (Paris)** 1996 Mar;83(3):234–8 (Eng. Abstr.) **(Fre)**

[Standards, options and recommendations for a successful practice in chemotherapy. National Federation of Centers for the Fight against Cancer] Heron JF, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):823–34 (44 ref.) **(Fre)**

[Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer] Le Chevalier T, et al. **Bull Cancer (Paris)** 1996 May;83(5):385–94 (Eng. Abstr.) **(Fre)**

[Is there a place for chemotherapy in the initial treatment of cervical cancer? Review of the literature] Lhommé C, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):276–92 (67 ref.) (Eng. Abstr.) **(Fre)**

[Preoperative radio-chemotherapy of stage III unresectable non-small cell lung cancer: results of a pilot study] Reboul F, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):300–6 (Eng. Abstr.) **(Fre)**

[Association of 5-FU, CDDP and hypofractionated radiotherapy in recurrences of subtentorial astrocytomas and malignant gliomas in adults] Bolla M, et al. **Bull Cancer Radiother** 1990;77(1):53–9 (Eng. Abstr.) **(Fre)**

[Cancers of the esophagus. Combined modality therapy by radiotherapy, chemotherapy with or without surgery] Calais G, et al. **Bull Cancer Radiother** 1995;82(2):137–46 (67 ref.) **(Fre)**

[Cancers of the base of the tongue and hypopharynx: results of a multicenter randomized trial of chemotherapy prior to locoregional treatment] Gedouin D, et al. **Bull Cancer Radiother** 1996;83(2):104–7 (Eng. Abstr.) **(Fre)**

[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial] Haddad E, et al. **Bull Cancer Radiother** 1996;83(2):97–103 (35 ref.) (Eng. Abstr.) **(Fre)**

[Perioperative chemotherapy of squamous cell carcinoma of the hypopharynx] Mamelle G, et al. **Bull Cancer Radiother** 1996;83(2):115–7 (Eng. Abstr.) **(Fre)**

[Cancers of the breast. First line chemotherapy for cancers of the breast] Mauriac L. **Bull Cancer Radiother** 1995; 82(2):158–67 (82 ref.) **(Fre)**

[Concomitant radiochemotherapy in locally advanced ORL cancers: a prospective study of 68 cases] Maylin C, et al. **Bull Cancer Radiother** 1996;83(2):108–10 (Eng. Abstr.) **(Fre)**

[Induction polychemotherapy before radiotherapy in carcinoma of the cavum. The experience of the Ibn Rochd-Casablanca Oncology Centre] Samlali R, et al. **Bull Cancer Radiother** 1996;83(2):111–4 (Eng. Abstr.) **(Fre)**

[Chemotherapy of osteogenic sarcomas] Brain E, et al. **Chirurgie** 1994–95;120(13):193–8 (70 ref.) **(Fre)**

[High-dose therapy and hematopoietic cell autotransplantation in the treatment of adult gynecologic tumors] Lotz JP, et al. **Contracept Fertil Sex** 1996 Apr; 24(4):307–18 (71 ref.) (Eng. Abstr.) **(Fre)**

[Chemotherapy for gynecologic tumors] Machover D. **Contracept Fertil Sex** 1996 Apr;24(4):264–7 (0 ref.) **(Fre)**

[Multivariate analysis of the prognostic and predictive factors of response to concomitant radiochemotherapy in epidermoid cancers of the esophagus. Value of immunodetection of protein p53] Seitz JF, et al. **Gastroenterol Clin Biol** 1995 May;19(5):465–74 (Eng. Abstr.) **(Fre)**

[Treatment of stage I non-seminomatous germ cell tumors of the testis] Droz JP. **Presse Med** 1995 Oct 28; 24(32):1501–3 (10 ref.) (Eng. Abstr.) **(Fre)**

[Chemotherapy of metastatic soft tissue sarcoma] Le Cesne A. **Presse Med** 1995 Sep 16;24(26):1214–20 (53 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic role of coagulation in small cell lung cancers] LeBeau B. **Rev Mal Respir** 1996;13(1):21–6 (41 ref.) (Eng. Abstr.) **(Fre)**

[Definitive results of a phase I study of a chemotherapy regimen using cisplatin and paclitaxel for non-small cell bronchial cancer] Sculier JP, et al. **Rev Mal Respir** 1995; 12(6):609–14 (Eng. Abstr.) **(Fre)**

[Respective indications for hormone therapy, induction chemotherapy and adjuvant chemotherapy in breast cancer without clinically discernable distant metastases] Roy JA, et al. **Rev Med Brux** 1995 Jul-Aug;16(4):242–4 (Eng. Abstr.) **(Fre)**

[Adjuvant regional chemotherapy in resected advanced pancreas carcinoma] Gansauge F, et al. **Chirurg** 1996 Apr; 67(4):362–5 (Eng. Abstr.) **(Ger)**

[Indications for chemotherapy in multiple myeloma] Heyll A, et al. **Dtsch Med Wochenschr** 1996 May 17;121(20):675 **(Ger)**

[Antineoplastic chemotherapy in metastatic Wilm's tumor] Quietzsch D. **Fortschr Med** 1995 Jul 20;113(20–21):317–9 (Eng. Abstr.) **(Ger)**

-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study- Kuhn W, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):105–10 (Eng. Abstr.) **(Ger)**

[Primary therapy of advanced ovarian carcinoma: current status and perspectives] Köchli OR, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):3–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Chemotherapy of juvenile angiofibroma--an alternative?] Schick B, et al. **HNO** 1996 Mar;44(3):148–52 (Eng. Abstr.) **(Ger)**

[Modern strategies in therapy of acute myeloid leukemia (AML) in adulthood. I. Primary treatment of de novo AML] Jehn U, et al. **Internist (Berl)** 1996 Jun;37(6):661–8 (17 ref.) **(Ger)**

[II. Leukemia in the elderly, secondary, recurrent and refractory leukemia, chloroma] Jehn U, et al. **Internist (Berl)** 1996 Jun;37(6):669–77 (18 ref.) **(Ger)**

[Follow-up of malignant metastatic pheochromocytoma. Discussion of the therapeutic strategy] Fett W, et al. **Med Klin** 1995 Nov 15;90(11):661–4, 672 **(Ger)**

[Regional chemotherapy in advanced pancreatic carcinoma] Gansauge F, et al. **Med Klin** 1995 Sep 15;90(9):501–5 (Eng. Abstr.) **(Ger)**

[Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group] Hübner G, et al. **Med Klin** 1996 Apr 12;91 Suppl 3:26–32 (Eng. Abstr.) **(Ger)**

[Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a] Kirchner HH, et al. **Med Klin** 1996 Apr 12;91 Suppl 3:44–9 (Eng. Abstr.) **(Ger)**

[Progress in development of chemotherapy of colorectal carcinoma] Köhne CH. **Med Klin** 1996 Apr 12;91 Suppl 3:33–7 (Eng. Abstr.) **(Ger)**

[Clinical studies on combination of ifosfamide, carboplatin and etoposide (ICE) with whole body hyperthermia] Wiedemann GJ, et al. **Med Klin** 1996 May 15;91(5):279–83 (59 ref.) **(Ger)**

[Therapy-induced changes in osteosarcoma after neoadjuvant chemotherapy (COSS 86 Therapy Study). Correlation between morphologic findings and clinical follow-up] Werner M, et al. **Pathologe** 1996 Jan;17(1):35–43 (Eng. Abstr.) **(Ger)**

[Germ cell tumors in children and adolescents] Göbel U, et al. **Schweiz Rundsch Med Prax** 1995 Sep 26;84(39):1063–7 (9 ref.) (Eng. Abstr.) **(Ger)**

[Integrative concept on the treatment of highly malignant non-Hodgkin lymphomas] Havemann K, et al. **Schweiz Rundsch Med Prax** 1996 Mar 19;85(12):353–6 (26 ref.) (Eng. Abstr.) **(Ger)**

[Adjuvant treatment of colonic carcinoma] Rochlitz CF, et al. **Schweiz Rundsch Med Prax** 1995 Nov 21;84(47):1373–6 (Eng. Abstr.) **(Ger)**

[Radiotherapy and/or chemotherapy in children with primitive neuroectodermal tumor (PNET) of the pineal region] Dunst J. **Strahlenther Onkol** 1996 Feb;172(2):108–9 **(Ger)**

[Simultaneous radiochemotherapy in recurrent and metastatic breast neoplasm. Clinical experience] Plasswilm L, et al. **Strahlenther Onkol** 1995 Dec;171(12):689–93 (Eng. Abstr.) **(Ger)**

[Radiochemotherapy and simultaneous hormonal therapy of locally advanced prostatic carcinoma] Strnad V, et al. **Strahlenther Onkol** 1996 Apr;172(4):225–8 (Eng. Abstr.) **(Ger)**

[Current status of therapy and prognosis in acute adult leukemia] Gmür J. **Ther Umsch** 1996 Feb;53(2):111–6 (Eng. Abstr.) **(Ger)**

[Multiple myeloma] Peest D. **Ther Umsch** 1996 Feb; 53(2):147–51 (17 ref.) (Eng. Abstr.) **(Ger)**

[Study by the Working Group in Gynecologic Oncology for therapeutic optimization in advanced FIGO IIb–IV ovarian carcinoma: cisplatin–paclitaxel vs. carboplatin–paclitaxel. AGO Protocol Ovar-3] Mettler L. **Zentralbl Gynakol** 1996;118(6):379–4 **(Ger)**

[Paclitaxel (Taxol)—drug of choice in ovarian cancer] Fishman A. **Harefuah** 1996 Apr 15;130(8):557–60 (47 ref.) **(Heb)**

[Ifosfamide in pediatric malignancy—experiences in the Northern Israel Oncology Center] Roguin A, et al. **Harefuah** 1996 Apr 15;130(8):511–4, 584 (Eng. Abstr.) **(Heb)**

[Angiocentric T-cell lymphoma of the lung] Csanaky G, et al. **Orv Hetil** 1996 Mar 3;137(9):473–6 (28 ref.) (Eng. Abstr.) **(Hun)**

[Primary gastric lymphoma. 14 clinical cases] Pradella P, et al. **Minerva Chir** 1995 Jul-Aug;50(7–8):637–41 (Eng. Abstr.) **(Ita)**

[Neoadjuvant chemotherapy in malignant fibrous histiocytoma of the limbs: 10 years of experience (1983–1992) at the Rizzoli Orthopedic Institute] Bacci G, et al. **Minerva Med** 1996 Apr;87(4):135–46 (Eng. Abstr.) **(Ita)**

[Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patients treated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)] Bacci G, et al. **Minerva Pediatr** 1995 Nov;47(11):457–69 (Eng. Abstr.) **(Ita)**

[Intra-arterial 5-FU/intra-venous MTX therapy for metastatic liver lesions] Adachi S, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1457–9 (Eng. Abstr.) **(Jpn)**

[A case of advanced esophageal cancer showing good partial response by combination therapy of low dose 5-FU and low dose CDDP] Akagi T, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):103–6 (Eng. Abstr.) **(Jpn)**

[A case of alpha-fetoprotein producing mediastinal germ cell tumor treated with preoperative chemotherapy] Arai K,

et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1213–5 (Eng. Abstr.) **(Jpn)**

[Correlation between an enzyme (glutathione S-transferase-pi) and effects of chemotherapy (cisplatin + etoposide)] Arai T, et al. **Gan To Kagaku Ryoho** 1996 Jun; 23(7):881–5 (Eng. Abstr.) **(Jpn)**

[Mega-dose chemotherapy with peripheral blood stem cell transplantation (PBS-CT) for small cell lung cancer (SCLC)] Chou T, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1741–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group] Chubachi A, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2101–6 (Eng. Abstr.) **(Jpn)**

[Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high-risk solid tumor] Endo M, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1762–70 (32 ref.) (Eng. Abstr.) **(Jpn)**

[A randomized controlled study of maintenance therapy with (2"R)-4'-O-tetrahydropyranyladriamycin for advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in Japan] Enomoto K, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):871–80 (Eng. Abstr.) **(Jpn)**

[A case of ovarian malignant Sertoli-Leidig cell tumor treated with CBDCA, etoposide and epirubicin chemotherapy] Fujimoto A, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1843–6 (Eng. Abstr.) **(Jpn)**

[Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer] Fujimura T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1610–2 (Eng. Abstr.) **(Jpn)**

[Evaluation of chemotherapy for stage IV non-small cell lung cancer employing a regression tree type method for quality-adjusted survival analysis to determine prognostic factors] Fujita A, et al. **Gan To Kagaku Ryoho** 1996 Mar; 23(4):433–8 (Eng. Abstr.) **(Jpn)**

[Clinical implication of p53 analysis on DNA-damaging therapies of human gastric and rectal cancers] Fujiwara T, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1081–3 **(Jpn)**

[A randomized controlled study of post-operative adjuvant therapy in non-small cell lung cancer] Fukushima M, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):303–9 (Eng. Abstr.) **(Jpn)**

[A combination chemotherapy with CDDP and 5-FU effective for pulmonary metastases in a case of parotid gland carcinoma] Furuse S, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1059–62 (Eng. Abstr.) **(Jpn)**

[Study of hepatic arterial infusion chemotherapy for prophylaxis of liver metastases of colorectal cancer after hepatic resection] Hanada H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1497–9 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for advanced urothelial cancer patients with a combination of low-dose consecutive cisplatin and etoposide] Hashimoto H, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):941–4 **(Jpn)**

[Efficacy of repeated hepatic dearterialization combined with intra-arterial infusion chemotherapy for unresectable tumors of the liver] Hashimoto N, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1586–9 (Eng. Abstr.) **(Jpn)**

[High-dose chemotherapy (HDCT) with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer patients with poor prognosis] Hayakawa S, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1756–61 (13 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of concomitant UFT-E and CDDP against lung epidermoid carcinoma] Hayashi Y, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1063–7 (Eng. Abstr.) **(Jpn)**

[Treatment for hormone-refractory or relapsing prostatic cancer] Hirao Y, et al. **Gan To Kagaku Ryoho** 1996 Mar; 23(4):418–26 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Hepatic arterial infusion therapy for gastric liver metastasis using implanted reservoir] Hoshima M, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1515–8 (Eng. Abstr.) **(Jpn)**

[A case of AFP (alpha-fetoprotein) producing gastric cancer successfully treated with FEP (5-FU, Epirubicin, cisplatin) therapy by continuous venous daily infusion of 5-FU and low-dose CDDP] Hoshino K, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1197–200 (Eng. Abstr.) **(Jpn)**

[Intra-arterial infusion chemotherapy for advanced liver metastases from lung cancer via implantable vascular access: report of six cases] Hyogo H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1577–81 (Eng. Abstr.) **(Jpn)**

[Combination therapy of doxifluridine, pirarubicin and cisplatin for human gastric cancers implanted in nude mice] Inaba M, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1793–8 (Eng. Abstr.) **(Jpn)**

[Head and neck cancer] Inuyama Y, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1136–42 (19 ref.) (Eng. Abstr.) **(Jpn)**

[A case of common bile duct cancer responding to MMC leucovorin, 5-FU, and UFT combination chemotherapy and radiation] Ishikawa T, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):773–7 (Eng. Abstr.) **(Jpn)**

[The experience of concurrent radiotherapy and chemotherapy for advanced or recurrent esophageal cancers--continuous infusion of 5-FU and low dose cisplatin] Itoh Y, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1855–8 **(Jpn)**

[A case of intrahepatic infusion chemotherapy with angiotensin II human for liver metastasis from early gastric cancer] Iwasaki Y, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1674–8 (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer remarkably responding to preoperative UFT-E therapy] Iwazaki R, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):355–9 (Eng. Abstr.) **(Jpn)**

[Biweekly cyclophosphamide, epirubicin, vincristine and prednisolone (CEOP) chemotherapy for the elderly patients with aggressive non-Hodgkin's lymphoma. Tochigi Malignant Lymphoma Study Group for the Elderly Patients] Izumi T, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):797–800 **(Jpn)**

[Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma] Kajino T, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):115–7 (Eng. Abstr.) **(Jpn)**

[Successful treatment of recurrent endometrial stromal sarcoma by radiotherapy and intra-arterial chemotherapy with CDDP and ADM] Kakimoto K, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1209–12 (Eng. Abstr.) **(Jpn)**

[Comparative study of the combined effect of HCFU and dipyridamole (DP) in colorectal carcinoma--TS inhibition rate. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma] Kanno H, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):715–20 (Eng. Abstr.) **(Jpn)**

[Germ cell tumor] Kasai M, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1749–55 (19 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of far advanced gastric cancer with multiple liver metastasis (H3) treated with transarterial intermittent chemotherapy and intradermal administration of low molecular lipopolysaccharide (LPSp) extracted from Pantoea agglomerans] Kasugai H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1690–3 (Eng. Abstr.) **(Jpn)**

[Neoadjuvant therapy followed by administration of UFT for breast cancer patients] Kataoka T, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):369–72 **(Jpn)**

[A case of superior vena cava syndrome treated with combination radiation and CRE (CBDCA and VP-16) therapy] Kato M, et al. **Gan To Kagaku Ryoho** 1996 Jan; 23(1):119–22 (Eng. Abstr.) **(Jpn)**

[Evaluation of chemotherapy in the treatment of advanced colorectal cancer--pilot study of 5-FU by biochemical modulation] Katsumata K, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):459–64 (Eng. Abstr.) **(Jpn)**

[Salvage therapy for refractory testicular cancer] Kawai K, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1129–35 (35 ref.) (Eng. Abstr.) **(Jpn)**

[A case of recurrent breast cancer responding to long-term treatment with 5'-DFUR combined with MPA] Kimura M, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1183–5 (Eng. Abstr.) **(Jpn)**

[Evaluation of intraoperative peritoneal cytology and intraperitoneal chemotherapy using CDDP combined with MMC for gastric carcinomatous peritonitis] Kitamura M, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1523–6 (Eng. Abstr.) **(Jpn)**

[Leucovorin.5-FU therapy for advanced gastric cancer as a neoadjuvant chemotherapy] Kitamura M, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2115–7 **(Jpn)**

[Rhabdomyosarcoma of the bladder: a case report] Kobayashi H, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):365–8 (Eng. Abstr.) **(Jpn)**

[The study of chemotherapy via the reservoir to colo-rectal cancer patients with liver metastases] Kohashi S, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1566–9 (Eng. Abstr.) **(Jpn)**

[Chemotherapy of head and neck cancer] Kohno N, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):277–82 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Outcomes of effective treatment of cases of metastatic liver tumors by intra-arterial infusion chemotherapy] Koizumi T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1573–6 (Eng. Abstr.) **(Jpn)**

[Chemotherapy of small cell lung cancer] Komiya T, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1116–23 (36 ref.) (Eng. Abstr.) **(Jpn)**

[A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin] Kondo K, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1839–42 (Eng. Abstr.) **(Jpn)**

[A prospective randomized clinical trial comparing intra-arterial chemotherapy alone and when combined with hyperthermia for metastatic liver cancer] Kondo M, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1807–11 (Eng. Abstr.) **(Jpn)**

[Alternating chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP); etoposide, procarbazine, vindesine and prednisolone (EPVP) as a treatment for advanced-stage Hodgkin's disease] Kumagai K, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):499–501 **(Jpn)**

[A case report of small cell carcinoma of the esophagus with remarkable response to neoadjuvant chemotherapy] Kumegawa H, et al. **Gan To Kagaku Ryoho** 1996 Mar; 23(4):487–90 (Eng. Abstr.) **(Jpn)**

[A case of malignant fibrous histiocytoma treated with intraarterial chemotherapy under complete venous isolation and charcoal hemoperfusion] Kusunoki N, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1711–4 (Eng. Abstr.) **(Jpn)**

[Complications in the intraperitoneal chemotherapy with the implantable intraperitoneal port and the strategy for the prevention of the complication] Maruyama M, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1469–72 (Eng. Abstr.) **(Jpn)**

[Combination chemotherapy with POMB/ACE (cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, etoposide) in advanced non-seminomatous testicular tumor] Masuda F, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1847–50 (Eng. Abstr.) **(Jpn)**

[Combination phase I trials] Masuda N. **Gan To Kagaku Ryoho** 1996 Jan;23(2):219–25 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Low-dose combination cytarabine and etoposide for myeloid crisis transformed from unclassified chronic myeloproliferative disorder] Matano S, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1055–8 (Eng. Abstr.) **(Jpn)**

[Combination chemotherapy of ifosfamide and etoposide for advanced neuroblastoma] Matsumoto K, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2119–21 **(Jpn)**

[A case report of prostate cancer resistant to endocrine therapy successfully treated with intra-arterial chemotherapy] Mima H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1694–6 (Eng. Abstr.) **(Jpn)**

[Comparison of CAF plus MPA with CAF plus TAM for advanced or recurrent breast cancer--Kyushu CAFT Study Group of Advanced or Recurrent Breast Cancer] Mitsuyama S, et al. **Gan To Kagaku Ryoho** 1995 Dec; 22(14):2073–80 (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer with liver metastasis with no recurrence and long survival] Miyaji M, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):915–8 (Eng. Abstr.) **(Jpn)**

[High-dose chemotherapy with autologous bone marrow transplantation or peripheral blood stem cell transplantation--testicular cancer] Miyanaga N, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1771–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Autologous hematopoietic stem cell transplantation for the treatment of breast cancer] Mukaiyama T, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1731–40 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Combination of intra-hepatic arterial infusion of low-dose cisplatin and oral administration of high-dose doxyfluridine for patients with liver metastases of gastric cancer] Nakagawa H, et al. **Gan To Kagaku Ryoho** 1996 May; 23(6):783–5 (Eng. Abstr.) **(Jpn)**

[Comparative clinical study of adjuvant postoperative chemotherapy (5-FU, Tegafur, 5-FU + MMC) in curatively resected cases of gastric cancer. Study Group on 5-FU Oral Adjuvant Chemotherapy in Gastric Cancer] Nakajima T, et al. **Gan To Kagaku Ryoho** 1996 Aug; 23(9):1161–8 (Eng. Abstr.) **(Jpn)**

[Concurrent high-dose thoracic irradiation plus daily low-dose cisplatin and vindesine in locally advanced unresectable stage III non-small cell lung cancer] Nakano K, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):57–61 (Eng. Abstr.) **(Jpn)**

[Postoperative adjuvant arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma] Nakashima K, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1483–5 (Eng. Abstr.) **(Jpn)**

[Association between p53 expression and chemosensitivity in advanced and recurrent gastric cancer] Nakata B, et al. **Gan To Kagaku Ryoho** 1996 Jun;23 Suppl 2:151–3 (Eng. Abstr.) **(Jpn)**

[Combination therapy of high dose 5'-DFUR+MMC for advanced or recurrent gastric cancer. 5'-DFUR Joint Research Group in the Osaka District for Gastric Cancer] Nakata E, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1799–806 (Eng. Abstr.) **(Jpn)**

[Three cases of uterine cervical adenocarcinoma successfully treated by neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil)] Narimatsu A, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):111–4 (Eng. Abstr.) **(Jpn)**

[Evaluation of preoperative chemotherapy for colorectal cancer] Nishimura G, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):69–74 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for recurrent ovarian cancer] Nishimura H, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1124–8 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Combined chemotherapy with MMC, ADM, CDDP, etoposide (VP-16) and 5'-DFUR, (MACVD therapy) as a second-line chemotherapy for metastatic gastric cancer: three cases] Nishisaki H, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):923–8 (Eng. Abstr.) **(Jpn)**

[Chemo-endocrine therapy including mitomycin C and

medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer] Nomura Y, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):439-45 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Prolongation of survival and antitumor activity of antitumor drugs in murine cancer cachexia model] Nukatsuka M, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):887-92 (Eng. Abstr.) **(Jpn)**

[Non-Hodgkin lymphoma] Ogawa M. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1143-8 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Combined chemotherapy with 5-FU and low dose CDDP for advanced or recurrent cancer of the digestive system and home anti-cancer chemotherapy] Ogura T, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:433-8 (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer responding to chemotherapy and radiotherapy] Ohta J, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):491-4 (Eng. Abstr.) **(Jpn)**

[A case of carcinomatous peritonitis for which combination therapy of 5-FU, leucovorin and cisplatin was effective] Okabe T, et al. **Gan To Kagaku Ryoho** 1996 Feb; 23(3):349-53 (Eng. Abstr.) **(Jpn)**

[Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer] Osawa S, et al. **Gan To Kagaku Ryoho** 1996 Feb; 23(3):327-31 (Eng. Abstr.) **(Jpn)**

[A case of recurrent breast carcinoma with metastatic foci in the lung and pleura treated successfully with biochemical modulation of 5-fluorouracil by low-dose cisplatin] Oura S, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1069-71 (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer with lung and liver metastasis treated by CDDP and 5-FU] Sakata Y, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):627-30 (Eng. Abstr.) **(Jpn)**

[Chronochemotherapy in two cases of metastatic liver cancer] Sato T. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1697-701 (Eng. Abstr.) **(Jpn)**

[Induction chemotherapy followed by adjuvant surgery (IC-AS) in patients with stage I-II small cell lung cancer (SCLC)] Shibayama T, et al. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1953-8 (Eng. Abstr.) **(Jpn)**

[Dual biochemical modulation therapy using 5-FU, leucovorin and cisplatin on human rectal carcinoma xenografts in nude mouse] Shibusawa M, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1149-52 (Eng. Abstr.) **(Jpn)**

[Experience in intra-hepatic-arterial chemotherapy and hepatic resection for metastatic colorectal cancer] Shimada H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1570-2 (Eng. Abstr.) **(Jpn)**

[A case of advanced esophageal cancer made resectable by preoperative combination therapy with 5-FU and CDDP] Shimakawa T, et al. **Gan To Kagaku Ryoho** 1995 Nov; 22(13):1977-81 (Eng. Abstr.) **(Jpn)**

[Advantages and disadvantages of the intraarterial chemotherapy using a reservoir as postoperative adjuvant therapy for hepatocellular carcinoma] Shimamura T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1511-4 (Eng. Abstr.) **(Jpn)**

[A case report: complete remission of stage IV uterine cervix carcinoma by immuno-chemotherapy with intraarterial infusion using implantable reservoir system] Shimizu A, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1706-10 (Eng. Abstr.) **(Jpn)**

[Successful treatment of clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT-11 and mitomycin C] Shimizu Y, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):587-93 (Eng. Abstr.) **(Jpn)**

[Highly effective preoperative intraarterial infusion chemotherapy with CDDP for progressive uterine corpus cancer with a Sister Mary Joseph's nodule] Shirai T, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):791-5 (Eng. Abstr.) **(Jpn)**

[Determination of 5-FU tissue concentrations after oral UFT administration in tumors of the head and neck] Somekawa Y, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):75-9 (Eng. Abstr.) **(Jpn)**

[Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA] Sonoo H, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):447-54 (Eng. Abstr.) **(Jpn)**

[A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil with both leucovorin and cisplatin against liver metastases of colorectal cancer] Sugiyama Y, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1460-3 (Eng. Abstr.) **(Jpn)**

[Prophylactic intra-arterial chemotherapy for CR patients with invasive bladder cancer after induction therapy] Sumiyoshi Y, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1657-9 (Eng. Abstr.) **(Jpn)**

[Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract] Takada T, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):707-14 (Eng. Abstr.) **(Jpn)**

[Clinical study of ambulatory cancer chemotherapy for advanced colorectal cancer] Takahashi N, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:447-52 (Eng. Abstr.) **(Jpn)**

[Intraperitoneal infusion therapy of MTX and 5-FU for advanced gastric cancer and its peritoneal metastasis] Takamatsu S, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1619-21 (Eng. Abstr.) **(Jpn)**

[UFT/CDDP preoperative chemotherapy for progressive gastric cancer--histological antitumor effects and thymidylate synthase inhibition rate] Tanaka S, et al. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1947-51 (Eng. Abstr.) **(Jpn)**

[Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with periaortic lymph node metastasis] Tanaka T, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):929-32 (Eng. Abstr.) **(Jpn)**

[Effect of leucovorin and 5-FU for advanced colorectal cancer patients] Tanemura H, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):579-86 (Eng. Abstr.) **(Jpn)**

[A case of histological complete remission by preoperative intraarterial infusion chemotherapy] Taniguchi Y, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1702-5 (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer treated effectively with neo-adjuvant chemotherapy using l-leucovorin and 5-FU] Terada J, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1835-8 (Eng. Abstr.) **(Jpn)**

[High dose chemotherapy followed by hematopoietic stem cell transplantation for malignant lymphoma] Tobinai K. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1724-30 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Three cases of drug-induced hemolytic uremic syndrome] Tohda S, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):361-4 (Eng. Abstr.) **(Jpn)**

[A case of nonresectable advanced gastric cancer responding to combined chemotherapy with 5'-DFUR, CDDP, and MMC] Tohyama Y, et al. **Gan To Kagaku Ryoho** 1996 Jun; 23(7):933-6 (Eng. Abstr.) **(Jpn)**

[A case of early gastric cancer transformed from adenoma by chemotherapy and radiotherapy] Tomono H, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):919-22 (Eng. Abstr.) **(Jpn)**

[A case of effective chemotherapy by combination of 5'-DFUR and MMC for recurrent colon cancer with multiple liver metastasis] Tsuji K, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1077-9 (Eng. Abstr.) **(Jpn)**

[Outpatient chemotherapy with continuous infusion of 5-fluorouracil (CI 5-FU) and intravenous bolus leucovorin (IVB LV) in advanced gastrointestinal cancer: the second report] Tsuji Y, et al. **Gan To Kagaku Ryoho** 1995 Dec; 22 Suppl 4:439-46 (Eng. Abstr.) **(Jpn)**

[A case of hepatocellular carcinoma with reduction of primary tumor and disappearance of multiple lung metastasis] Tsurumachi T, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):631-4 (Eng. Abstr.) **(Jpn)**

[Successful combination chemotherapy for a post-operative gastric cancer patient with multiple liver metastases and elevated CEA] Tsuzuki H, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):779-81 (Eng. Abstr.) **(Jpn)**

[Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice] Watanabe A, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):291-6 (Eng. Abstr.) **(Jpn)**

[Study of serum CDDP concentrations in patients with advanced or recurrent adeno-or squamous cell carcinoma under combination chemotherapy of 5-FU (CIV) and low-dose CDDP (IV)] Yagihashi A, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):63-7 (Eng. Abstr.) **(Jpn)**

[Study on the combined preoperative treatment with CDDP and HCFU for gastric cancer] Yamaguchi R, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1089-91 **(Jpn)**

[The study of continuous arterial infusion chemotherapy with CDDP and 5-FU in patients with hepatocellular carcinoma] Yanagi I, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1508-10 (Eng. Abstr.) **(Jpn)**

[Preoperative neoadjuvant chemotherapy with a combination of 5-fluorouracil, adriamycin and cisplatin (FAP) for advanced esophageal cancer invading trachea or main bronchus] Yasuda T, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1538-41 (Eng. Abstr.) **(Jpn)**

[Efficacy of intra-arterial chemotherapy with reservoir for patients with unresectable hepatocellular carcinoma] Yasuhara M, et al. **Gan To Kagaku Ryoho** 1996 Mar; 23(4):455-8 (Eng. Abstr.) **(Jpn)**

[A case of unresectable advanced gastric cancer responding remarkably to combined chemotherapy with 5-fluorouracil and low-dose cisplatin] Yasumoto K, et al. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1973-6 (Eng. Abstr.) **(Jpn)**

[A comparison of intra-arterial chemoembolization and infusion chemotherapy for liver metastases of breast cancer] Yayoi E, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1519-22 (Eng. Abstr.) **(Jpn)**

[FAM as a palliative chemotherapy for gastric cancer with bone metastasis] Yumoto Y, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):107-10 (Eng. Abstr.) **(Jpn)**

[A case of adult pure yolk sac tumor of the testis achieving pathological complete response by chemotherapy] Hashimoto Y, et al. **Hinyokika Kiyo** 1995 Oct;41(10):813-6 (Eng. Abstr.) **(Jpn)**

[Combination therapy with estrogen and UFT in newly diagnosed prostatic cancer (poorly differentiated, stage D2)] Kondo I, et al. **Hinyokika Kiyo** 1996 Mar;42(3):201-6 (Eng. Abstr.) **(Jpn)**

[Three cases of lung metastases of renal cell carcinoma treated with a combination of interferon-alpha, 5-fluorouracil and leucovorin] Togashi M, et al. **Hinyokika Kiyo** 1996 Jan;42(1):43-5 (Eng. Abstr.) **(Jpn)**

[Mechanisms of enhanced accumulation of transferred LAK cells into tumor sites after chemotherapy] Kuramitsu Y. **Hokkaido Igaku Zasshi** 1995 May;70(3):507-17 (Eng. Abstr.) **(Jpn)**

[Anti-tumor effects of an angiogenesis inhibitor, TNP-470 (AGM-1470) alone and in combination with cisplatinum, and changes in serum copper levels in liver cancer bearing rats] Matsuoka S. **Hokkaido Igaku Zasshi** 1996 Jan; 71(1):69-80 (Eng. Abstr.) **(Jpn)**

[Efficiency of combination chemotherapy and interferon-alpha therapy in a patient with AIDS-related cutaneous and gastrointestinal Kaposi's sarcoma] Sawayama Y, et al. **Kansenshogaku Zasshi** 1996 Jun; 70(6):621-6 (Eng. Abstr.) **(Jpn)**

[IgD-lambda type multiple myeloma associated with IgG-kappa type benign monoclonal gammopathy] Shimada H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr; 18(2):235-40 (Eng. Abstr.) **(Jpn)**

[Adjuvant chemotherapy for advanced gastric cancer] Furukawa H, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):312-6 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment of advanced gastric carcinoma based on histologic type] Kaminishi M, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):297-301 (Eng. Abstr.) **(Jpn)**

[Treatment of advanced testis cancer with a high dose chemotherapy regimen (PVeBV)] Kashiwagi A, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jan;87(1):35-41 (Eng. Abstr.) **(Jpn)**

[The long-term effect and outcome of preoperative chemotherapy combined with radiation therapy for bladder cancer] Nasu T, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 May;87(5):857-64 (Eng. Abstr.) **(Jpn)**

[Primary retroperitoneal pure choriocarcinoma] Okubo Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec; 86(12):1784-8 (14 ref.) (Eng. Abstr.) **(Jpn)**

[5-Fluorouracil and alpha-2a interferon in patients with hormone-refractory prostate cancer] Shinohara N, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct;86(10):1557-62 (Eng. Abstr.) **(Jpn)**

[Results of radiotherapy combined with CDDP (BAI) plus VP-16 in the treatment of inoperable non-small cell lung cancer] Moriyama T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Feb; 56(3):116-20 (Eng. Abstr.) **(Jpn)**

[Experimental study and clinical application of a new combination chemotherapy with cis-platinum, adriamycin and carboquone in patients with advanced prostate cancer] Ito H. **Nippon Ika Daigaku Zasshi** 1995 Oct;62(5):456-68 (Eng. Abstr.) **(Jpn)**

[An advanced invasive thymoma that responded remarkably to neoadjuvant chemotherapy with carboplatin, adriamycin, and etoposide] Bando S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1135-40 (Eng. Abstr.) **(Jpn)**

[Pulmonary malignant fibrous histiocytoma treated with cisplatin plus etoposide followed by surgery] Morikawa T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep; 33(9):993-8 (Eng. Abstr.) **(Jpn)**

[A case of mycosis fungoides with pulmonary involvement: effect of etoposide and prednisolone] Nasuhara Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep; 33(9):1013-8 (Eng. Abstr.) **(Jpn)**

[Autopsy case of angiotropic lymphoma complicated with interstitial pneumonia during VEPA therapy and monocytosis in the early stage] Fujikawa I, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):271-3 **(Jpn)**

[Chemotherapy of solid tumor] Ogawa M. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):342-6 (28 ref.) **(Jpn)**

[Usefulness of COP-BLAM therapy with concomitant G-CSF in elderly patients with non-Hodgkin's lymphoma in comparison with patients not given G-CSF] Niitsu N, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jun;32(6):410-5 (Eng. Abstr.) **(Jpn)**

[Combined effects of sizofiran and rG-CSF on myelosuppression in cancer chemotherapy] Hoshino T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar; 48(3):206-12 (Eng. Abstr.) **(Jpn)**

[Adjuvant chemotherapy with cyclophosphamide, adriamycin, and CDDP (CAP) for high risk endometrial cancer after complete surgery] Tsunoda H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jan;48(1):45-51 (Eng. Abstr.) **(Jpn)**

[A case of pineoblastoma successfully treated with surgery, combined chemotherapy of cisplatin and etoposide, and radiotherapy] Akiyama Y, et al. **No Shinkei Geka** 1995 Oct; 23(10):921–5 (Eng. Abstr.) **(Jpn)**

[Therapy related leukemia] Fujisawa S, et al. **Rinsho Ketsueki** 1995 Oct;36(10):1163–9 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for B lymphoid malignancy in childhood—results in BLK88 protocol] Hibi S, et al. **Rinsho Ketsueki** 1996 Apr;37(4):297–302 (Eng. Abstr.) **(Jpn)**

[Successful treatment of splenomegaly and anemia by VP therapy in idiopathic myelofibrosis complicated with acromegaly: a case report] Imai Y, et al. **Rinsho Ketsueki** 1995 Oct;36(10):1233–6 (Eng. Abstr.) **(Jpn)**

[Acute myelogenous leukemia with diabetes insipidus without desmopression administration by anti-leukemic chemotherapy] Ino Y, et al. **Rinsho Ketsueki** 1995 Dec; 36(12):1359–64 (Eng. Abstr.) **(Jpn)**

[Successful combination chemotherapy including deoxycoformycin in a case of cutaneous T cell lymphoma] Kodama K, et al. **Rinsho Ketsueki** 1996 Jan;37(1):65–71 (Eng. Abstr.) **(Jpn)**

[Reversion to chronic phase of chronic myelogenous leukemia in blast crisis with small-dose daunorubicin and oral prednisolone] Kuyama J, et al. **Rinsho Ketsueki** 1995 Dec;36(12):1353–8 (Eng. Abstr.) **(Jpn)**

[Trial of combined cytosine arabinoside with granulocyte colony-stimulating factor therapy or refractory acute myeloid leukemia] Mori H, et al. **Rinsho Ketsueki** 1995 Jul; 36(7):648–56 (Eng. Abstr.) **(Jpn)**

[Intermittent-dose ara-C/daunomycin therapy combined with cyclosporin-A and G-CSF led to a fourth remission in a patient with acute promyelocytic leukemia] Motomura S, et al. **Rinsho Ketsueki** 1995 Aug;36(8):762–7 (Eng. Abstr.) **(Jpn)**

[Chemotherapy with concomitant IFN treatment in three HBV carriers (mutant strain) with malignant lymphoma] Niitsu N, et al. **Rinsho Ketsueki** 1995 Aug;36(8):780–5 (Eng. Abstr.) **(Jpn)**

[Acute lymphoblastic leukemia with marked morphologic abnormalities after chemotherapy for gastric cancer] Ogata M, et al. **Rinsho Ketsueki** 1996 Jan;37(1):29–34 (Eng. Abstr.) **(Jpn)**

[Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive combination chemotherapy] Tsurumi H, et al. **Rinsho Ketsueki** 1995 Jul; 36(7):657–64 (Eng. Abstr.) **(Jpn)**

[Non-Hodgkin's lymphoma of the uterine cervix] Plewicka M, et al. **Ginekol Pol** 1995 Apr;66(4):246–8 (Eng. Abstr.) **(Pol)**

[Multidrug chemotherapy in a 8-year old child with advanced olfactory neuroblastoma] Cwiklińska M, et al. **Pediatr Pol** 1995 Nov;70(11):981–3 (Eng. Abstr.) **(Pol)**

[Chemotherapy with combined treatment of malignant germ cell tumors in children] Zalęska-Czepko E. **Pediatr Pol** 1995 Nov;70(11):955–8 (33 ref.) (Eng. Abstr.) **(Pol)**

[Clinical and immunologic characteristics of CD 34 positive acute myeloid leukemia] Adamczyk-Cioch MB, et al. **Pol Arch Med Wewn** 1995 Jul;94(1):40–6 (Eng. Abstr.) **(Pol)**

[Hypothermia during chemotherapy for lymphomas] Gabryś K, et al. **Pol Arch Med Wewn** 1995 Feb;93(2):130–4 (Eng. Abstr.) **(Pol)**

[Evaluation of early treatment results in Hodgkin's disease during the cytostatic protocol containing methotrexate] Kotlarek-Haus S, et al. **Pol Arch Med Wewn** 1995 Mar; 93(3):228–33 (Eng. Abstr.) **(Pol)**

[Cardiotoxic effect of the herec-TNF alpha preparation given intravenously to patients with advanced neoplasms] Muc M, et al. **Przegl Lek** 1996;53(2):78–82 (Eng. Abstr.) **(Pol)**

[Current principles of treatment of acute nonlymphoblastic leukemia] Moiseev SI, et al. **Gematol Transfuziol** 1996 Jan-Feb;41(1):3–6 (Eng. Abstr.) **(Rus)**

[Use of recombinant alpha2-interferon in combination with myelosan for the treatment of patients with chronic myeloid leukemia] Petukhov VI, et al. **Gematol Transfuziol** 1996 Jan-Feb;41(1):26–30 (Eng. Abstr.) **(Rus)**

[New approach to the treatment of primary malignant non-Hodgkin's lymphoma of the stomach] Korobko VB, et al. **Klin Khir** 1996;(1):39–42 **(Rus)**

[The combined chemoradiotherapy of lymphosarcomas] Kruglova GV, et al. **Ter Arkh** 1995;67(10):60–3 **(Rus)**

[An experimental study of the antitumor activity of preparations in a model of prostatic cancer] Burenin IS, et al. **Urol Nefrol (Mosk)** 1995 Sep-Oct;(5):33–5 (Eng. Abstr.) **(Rus)**

[The chemotherapy of nonseminomatous testicular tumors] Tiuliandin SA, et al. **Urol Nefrol (Mosk)** 1996 Mar-Apr; (2):26–9 (Eng. Abstr.) **(Rus)**

[The radiation and chemoradiation treatments of generalized low-grade non-Hodgkin's lymphomas. 2. The late results] Kharchenko VP, et al. **Vestn Rentgenol Radiol** 1996 Mar-Apr;(2):30–3 (Eng. Abstr.) **(Rus)**

[The radiation and chemoradiation treatments of generalized low-grade non-Hodgkin's lymphomas. 1. The immediate results] Sotnikov VM, et al. **Vestn Rentgenol Radiol** 1996 Mar-Apr;(2):26–9 (Eng. Abstr.) **(Rus)**

[Possibilities of adoptive immunochemotherapy in the treatment of non-small-cell lung cancer] Davydov MI, et al. **Vestn Ross Akad Med Nauk** 1996;(3):3–9 **(Rus)**

[Neoadjuvant drug therapy as a predictor of the efficacy of castration] Bogdanova NV, et al. **Vopr Onkol** 1995; 41(2):130–1 **(Rus)**

[The neoadjuvant therapy of malignant tumors] Lichinitser MR. **Vopr Onkol** 1995;41(2):127 **(Rus)**

[The individualization of the drug therapy of ovarian cancer] Novikov EG, et al. **Vopr Onkol** 1995;41(2):124–5 **(Rus)**

[The results of treatment by the Madrid Pediatric Oncology Group according to the BFM protocols in non-Hodgkin's B-cell lymphoma and acute B-cell lymphoblastic leukemia in pediatric patients] Vivanco Martinez JL, et al. **An Esp Pediatr** 1996 Jan;44(1):11–6 (Eng. Abstr.) **(Spa)**

[Medical treatment of 44 patients with anal canal carcinoma. Argentinian Intergroup for the treatment of gastrointestinal tumors (IATTGI)] Roca E, et al. **Medicina (B Aires)** 1995; 55(3):243–8 (Eng. Abstr.) **(Spa)**

[Cutaneous tumoral infiltration: intraarterial palliative chemotherapy] Alonso Curbera G, et al. **Rev Clin Esp** 1995 Nov;195(11):809–10 **(Spa)**

[Phase II trial with navelbine + cisplatin + etoposide in the treatment of inoperable non-small cell lung carcinoma] Richardet E, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53(1):27–32 (Eng. Abstr.) **(Spa)**

[Advanced germinal tumors of the testicle: clinical experience with cisplatin, bleomycin and vinblastine (PVB) or etoposide (BEP)] Alonso Curbera G, et al. **Rev Med Univ Navarra** 1993 Jan-Mar;38(1):13–8 (Eng. Abstr.) **(Spa)**

[Adjuvant chemotherapy of gastric cancer] Shparik IaV. **Klin Khir** 1995;(5):38–41 (36 ref.) **(Ukr)**

[Adjuvant therapy of breast cancer without regional metastases] Shparik IaV, et al. **Klin Khir** 1995;(5):42–6 (47 ref.) **(Ukr)**

[Adjuvant chemotherapy of colonic cancer] Shparyk IaV, et al. **Klin Khir** 1995;(6):38–41 (32 ref.) **(Ukr)**

[Regional adjuvant chemotherapy in colorectal cancer] Shparyk IaV, et al. **Klin Khir** 1995;(9-10):41–5 (38 ref.) **(Ukr)**

TOXICITY

Effect of some anticancer drugs and combined chemotherapy on renal toxicity. Skrętkowicz J, et al. **Biol Signals** 1996 Jan-Feb;5(1):51–8

Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Pouna P, et al. **Br J Pharmacol** 1996 Apr; 117(7):1593–9

Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. Iaffaioli RV, et al. **Breast Cancer Res Treat** 1995 Sep;35(3):243–8

FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. Zinzani PL, et al. **Eur J Haematol** 1995 Oct;55(4):262–6

Vitamin E protects intestinal basolateral membrane from CMF-induced damages in rat. Subramaniam S, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):263–6

Etoposide phosphate or etoposide with cisplatin in the treatment of small cell lung cancer: randomized phase II trial. Greco FA, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S85–95

Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. European Lung Cancer Working Party. Klastersky J, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S117–25

Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Williams PC, et al. **Neurosurgery** 1995 Jul;37(1):17–27; discussion 27–8

[Cardioprotection in chemo- and radiotherapy for malignant diseases—an echocardiographic pilot study] Wagdi P, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1220–3 (Eng. Abstr.) **(Ger)**

[Nitroxyl radicals—modifiers of the toxic action of cytostatics] Konovalova NP. **Vopr Onkol** 1995;41(2):49–50 **(Rus)**

ANTINEOPLASTIC AGENTS, HORMONAL

The effect of tamoxifen on the endometrium. Barakat RR. **Oncology (Huntingt)** 1995 Feb;9(2):129–34; discussion 139–40, 142 (27 ref.)

[Tamoxifen—effects and side-effects (comment)] Erikstein BK. **Tidsskr Nor Laegeforen** 1996 Jun 20;116(16):1872. Comment on: Tidsskr Nor Laegeforen 1996 Jun 20;116(16):1877–9. **(Nor)**

ADMINISTRATION & DOSAGE

Quality of life and intermittent hormonal therapy. da Silva FC. **Acta Urol Belg** 1996 May;64(2):93

The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921). Flaherty LE, et al. **Am J Clin Oncol** 1996 Apr;19(2):108–13

New data refine role of adjuvant tamoxifen in early breast cancer [news] **Am J Health Syst Pharm** 1996 Jan 15; 53(2):123–4

Natural interferon-beta and tamoxifen in hormone-resistant patients with advanced breast cancer. Buzzi E, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2187–90

A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer. A Study of the Eastern Cooperative Oncology Group (E2185). Cobau CD, et al. **Cancer** 1996 Feb 1;77(3):483–9

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Small EJ, et al. **Cancer** 1995 Oct 15;76(8):1428–34

Adjuvant tamoxifen: 5 year control of dormant disease? [letter] Merimsky O, et al. **Eur J Cancer** 1996 Jan; 32A(1):174

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Arnold R, et al. **Gut** 1996 Mar;38(3):430–8

Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Sangfelt O, et al. **Int J Cancer** 1995 Oct 9; 63(2):190–2

Androgens in the topical treatment of lichen sclerosus. Paslin D. **Int J Dermatol** 1996 Apr;35(4):298–301

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. Hayes DF, et al. **J Clin Oncol** 1995 Oct; 13(10):2556–66

High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Lentz SS, et al. **J Clin Oncol** 1996 Feb;14(2):357–61

Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. Dalkin BL, et al. **J Urol** 1996 Apr;155(4):1357–60

A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer. Debruyne FM, et al. **J Urol** 1996 Apr;155(4):1352–4

Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. Herrada J, et al. **J Urol** 1996 Feb;155(2):620–3

Low-dose cyproterone acetate plus mini-dose diethylstilbestrol—a protocol for reversible medical castration. Goldenberg SL, et al. **Urology** 1996 Jun; 47(6):882–4

[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma] DeAntoni E, et al. **Urologe A** 1995 Sep;34(5):382–8 (14 ref.) (Eng. Abstr.) **(Ger)**

[Renaissance of estrogen therapy in advanced prostate carcinoma?] Smith PH, et al. **Urologe A** 1995 Sep; 34(5):393–7 (17 ref.) (Eng. Abstr.) **(Ger)**

[Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status] Stege R, et al. **Urologe A** 1995 Sep;34(5):398–403 (52 ref.) (Eng. Abstr.) **(Ger)**

[Advanced prostatic carcinoma—which hormone therapy when?] Studer UE. **Urologe A** 1995 Sep;34(5):361–6 (34 ref.) **(Ger)**

[Results of long-term follow-up in treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enantone-Gyn monthly depot)] Regidor PA, et al. **Zentralbl Gynakol** 1996;118(5):283–90 (Eng. Abstr.) **(Ger)**

[Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer] Mitsuyama S, et al. **Gan To Kagaku Ryoho** 1996 Aug; 23(9):1153–60 (Eng. Abstr.) **(Jpn)**

[A case of multiple liver metastasis from ileac carcinoid effectively treated with continuous intraarterial infusion of somatostatin analog] Wadamori K, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1669–72 (Eng. Abstr.) **(Jpn)**

[A comparison of intra-arterial chemoembolization and infusion chemotherapy for liver metastases of breast cancer] Yayoi E, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1519–22 (Eng. Abstr.) **(Jpn)**

[Intralymphatic administration of estramustine phosphate] Sakamoto H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1271–2 **(Jpn)**

ADVERSE EFFECTS

Bilateral jawline nodules in a child with a brain-stem glioma. Poststeroid panniculitis. Reichel M, et al. **Arch Dermatol** 1995 Dec;131(12):1448–9, 1451–2

Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy. Schned AR, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):96–100

Adjuvant treatment with tamoxifen. Side effects may have been overstated [letter; comment] Baum M. **BMJ** 1996 Apr 20;312(7037):1036. Comment on: BMJ 1996 Feb 17;312(7028):389–90.

Adjuvant treatment with tamoxifen. Multicentre trial should be welcomed [letter; comment] Corder AP. **BMJ** 1996 Apr 20;312(7037):1037. Comment on: BMJ 1996 Feb

17;312(7028):389–90.
International group evaluates tamoxifen risks for women [news] Court C. **BMJ** 1996 Mar 2;312(7030):529
Adjuvant treatment with tamoxifen. Recruitment into studies assessing optimum duration of treatment must continue [letter; comment] Earl H, et al. **BMJ** 1996 Apr 20; 312(7037):1036–7. Comment on: **BMJ** 1996 Feb 17;312(7028):389–90.
Adjuvant treatment with tamoxifen. Clinicians must share knowledge with their patients more readily [letter; comment] Goodare H. **BMJ** 1996 Apr 20;312(7037):1037 . Comment on: BMJ 1996 Feb 17;312(7028):389–90.
Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. McDonald CC, et al. **BMJ** 1995 Oct 14;311(7011):977–80
Adjuvant treatment with tamoxifen. Local research ethics committees should review their approval of prevention trial [letter; comment] Read C. **BMJ** 1996 Apr 20; 312(7037):1036. Comment on: BMJ 1996 Feb 17;312(7028):389–90.
Flutamide-induced cyanosis refractory to methylene blue therapy. Kouides PA, et al. **Br J Haematol** 1996 Jul; 94(1):73–5
Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status. McGonigle KF, et al. **Cancer Lett** 1996 Mar 19; 101(1):59–66
Tamoxifen associated uterine pathology in rodents: relevance to women. Carthew P, et al. **Carcinogenesis** 1996 Aug; 17(8):1577–82
Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. Morsi A, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):121–4
Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Kleinman D, et al. **Endocrinology** 1996 Mar;137(3):1089–95
Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy. Sasco AJ, et al. **Epidemiology** 1996 Jan;7(1):9–13
The effects of tamoxifen treatment on the endometrium. Daniel Y, et al. **Fertil Steril** 1996 Jun;65(6):1083–9 (94 ref.)
Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Paoletti AM, et al. **Fertil Steril** 1996 Apr;65(4):707–10
Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen [see comments] Cohen I, et al. **Gynecol Oncol** 1996 Jan;60(1):54–8. Comment in: Gynecol Oncol 1996 Apr;61(1):158–60.
A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Robinson DC, et al. **Gynecol Oncol** 1995 Nov;59(2):186–90
Effects of luteinizing hormone-releasing hormone (LH-RH) analogue on the function of the isolated rabbit corpus cavernosum. Itoh Y, et al. **Hinyokika Kiyo** 1996 Mar; 42(3):215–20
Tamoxifen treatment and its consequences [letter] Shulman A, et al. **Hum Reprod** 1995 Aug;10(8):2174–5
Tamoxifen treatment and its consequences [letter; comment] Thylan S. **Hum Reprod** 1995 Aug;10(8):2174. Comment on: Hum Reprod 1994 Aug;9(8):1427–9.
Ocular toxicity of tamoxifen. Sekhar GC, et al. **Indian J Ophthalmol** 1995 Mar;43(1):23–6
Hemothorax after Lupron therapy of a patient with pleural endometriosis—a case report and literature review. Margolis MT, et al. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):53–5
Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. Cohen I, et al. **Int J Gynecol Pathol** 1996 Apr; 15(2):152–7
Flutamide-induced liver toxicity including fatal hepatic necrosis. Crownover RL, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):911–5
Progestogens and Cushing's syndrome. Harte C, et al. **Ir J Med Sci** 1995 Oct–Dec;164(4):274–5
Depression during hormonal treatment of prostate cancer. Rosenblatt DE, et al. **J Am Board Fam Pract** 1995 Jul–Aug; 8(4):317–20
Uterine neoplasms in patients treated with tamoxifen. Silva EG, et al. **J Cell Biochem Suppl** 1995;23:179–83 (22 ref.)
Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. Fisher B. **J Clin Oncol** 1996 Mar;14(3):1027–39
Megestrol acetate-induced adrenal suppression [letter] Loprinzi CL, et al. **J Clin Oncol** 1996 Feb;14(2):689
Tamoxifen-associated eye disease. A review. Nayfield SG, et al. **J Clin Oncol** 1996 Mar;14(3):1018–26 (58 ref.)
Radiotherapy-related lung fibrosis enhanced by tamoxifen. Bentzen SM, et al. **J Natl Cancer Inst** 1996 Jul 3; 88(13):918–22
Second cancers after adjuvant tamoxifen therapy for breast cancer. Curtis RE, et al. **J Natl Cancer Inst** 1996 Jun 19; 88(12):832–4
Endometrial cancers from tamoxifen are not more aggressive [news] Ziegler J. **J Natl Cancer Inst** 1996 Aug 21; 88(16):1101
Tamoxifen-induced growth of leiomyomas. A case report. Kang J, et al. **J Reprod Med** 1996 Feb;41(2):119–20
Sonohysterography for ultrasonographic evaluation of tamoxifen-associated cystic thickened endometrium. Achiron R, et al. **J Ultrasound Med** 1995 Sep;14(9):685–8
Flutamide hepatotoxicity [see comments] Wysowski DK, et al. **J Urol** 1996 Jan;155(1):209–12. Comment in: J Urol 1996 Jan;155(1):226–7.
Safety of tamoxifen [letter] Coleman MP. **Lancet** 1996 Mar 23;347(9004):836–7
Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Van Dongen-Melman JE, et al. **Pediatr Res** 1995 Jul;38(1):86–90
Tamoxifen and endometrial cancer: from experiment to patient. Assikis VJ, et al. **Recent Results Cancer Res** 1996; 140:61–71 (41 ref.)
Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study. Achiron R, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):116–20
[Fulminant hepatitis caused by flutamide (letter)] Andréjak M, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):121–2 (Fre)
[Expansive uterine myoma during tamoxifen therapy. 11 cases] Le Bouëdec G, et al. **Presse Med** 1995 Nov 25; 24(36):1694–6 (18 ref.) (Eng. Abstr.) (Fre)
[Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape] Barthélémy Y, et al. **Prog Urol** 1996 Feb;6(1):93–7 (Eng. Abstr.) (Fre)
[Gynecologic monitoring of tamoxifen treatment of breast cancer] Le Bouedec G, et al. **Rev Fr Gynecol Obstet** 1995 Jul–Sep;90(7–9):379–82 (30 ref.) (Fre)
[Acute respiratory distress syndrome after injection of leuprorelin (letter)] Gamelin L, et al. **Therapie** 1995 Nov–Dec;50(6):587–8 (Fre)
[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma] Bruchovsky N, et al. **Urologe A** 1995 Sep;34(5):389–92 (8 ref.) (Eng. Abstr.) (Ger)
[Morphologic endometrium changes with tamoxifen] Dallenbach-Hellweg G, et al. **Zentralbl Gynakol** 1996; 118(6):365–9 (Eng. Abstr.) (Ger)
[Long-term observations of the extent and reversibility of bone demineralization after leuprorelin acetate depot therapy] Spitz J, et al. **Zentralbl Gynakol** 1996; 118(4):198–205 (Eng. Abstr.) (Ger)
[Long-term assessment of bone loss in patients treated with GnRH agonists] Polatti F, et al. **Minerva Ginecol** 1995 May; 47(5):193–6 (Eng. Abstr.) (Ita)
[Tamoxifen and endometrial cancer. A case report (see comments)] Orbo A, et al. **Tidsskr Nor Laegeforen** 1996 Jun 20;116(16):1877–8 (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1996 Jun 20;116(16):1872. (Nor)
[Colonic perforation during combined steroid and radiotherapy. Diagnosis and treatment] Wiig JN, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):731–2 (Eng. Abstr.) (Nor)

ANALYSIS

Liquid chromatographic separation and measurement of optical isomers of aminoglutethimide and its acetyl metabolite in plasma, saliva, and urine. Alshowaier IA, et al. **Ther Drug Monit** 1995 Oct;17(5):538–43

BLOOD

A high-pressure liquid chromatographic method for measuring mitotane
[1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethane] and its metabolite
1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethene in plasma. Andersen A, et al. **Ther Drug Monit** 1995 Oct;17(5):526–31

CHEMICAL SYNTHESIS

2-Phenylindoles with sulfur containing side chains. Estrogen receptor affinity, antiestrogenic potency, and antitumor activity. Biberger C, et al. **J Steroid Biochem Mol Biol** 1996 Apr;58(1):31–43

CHEMISTRY

Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation. Kuramochi H. **J Med Chem** 1996 Jul 19;39(15):2877–86

ECONOMICS

Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Bennett CL, et al. **Cancer** 1996 May 1;77(9):1854–61

HISTORY

Hormonal intervention in breast cancer. Past, present, and future. Osborne MP. **Ann N Y Acad Sci** 1996 Apr 30; 784:427–32

METABOLISM

XPS and TOF-SIMS microanalysis of a peptide/polymer drug delivery device. John CM, et al. **Anal Chem** 1995 Nov 1;67(21):3871–8
Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Dehal SS, et al. **Cancer Res** 1996 Mar 15;56(6):1283–90
Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. Phillips DH, et al. **Carcinogenesis** 1996 May;17(5):1149–52

PHARMACOKINETICS

Pharmacokinetics and bioavailability of tamoxifen in postmenopausal healthy women. Fuchs WS, et al. **Arzneimittelforschung** 1996 Apr;46(4):418–22
Bioavailability of buserelin and gonadorelin in suspensions. Dolińska B, et al. **Boll Chim Farm** 1995 Sep;134(8):459–60
Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma. Toko T, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):7–13
Age-related difference in tamoxifen disposition. Peyrade F, et al. **Clin Pharmacol Ther** 1996 Apr;59(4):401–10
Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats. Matsubara K, et al. **J Pharm Sci** 1995 Nov;84(11):1295–300
Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer. Lien EA, et al. **J Steroid Biochem Mol Biol** 1995 Nov;55(2):229–31

PHARMACOLOGY

Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone. Saunders DE, et al. **Anticancer Drugs** 1995 Aug;6(4):562–9
The effect of ICI 164384 and beta-interferon on the growth and steroid receptor profile of breast cancer cell lines. Coradini D, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2557–61
Dihydrotestosterone affects the growth of hormone-unresponsive breast cancer cells: an indirect action. Di Monaco M, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2581–4
Estramustine-binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest. Eklöv S, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1819–22
Influence of cyclopropyl antiestrogens on the cell cycle kinetics of MCF-7 human breast cancer cells. Jain PT, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2529–32
Effect of tamoxifen on measurements of hemostasis in healthy women. Mannucci PM, et al. **Arch Intern Med** 1996 Sep 9;156(16):1806–10
Glucocorticoids decrease the production of parathyroid hormone-related protein in vitro but not in vivo in the Walker carcinosarcoma 256 rat model. Schilling T, et al. **Bone** 1996 Apr;18(4):315–9
Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen. Benson JR, et al. **Br J Cancer** 1996 Aug;74(3):352–8
Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells. Perry RR, et al. **Br J Cancer** 1995 Dec;72(6):1441–6
Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia. Maung ZT, et al. **Br J Haematol** 1995 Sep;91(1):93–100
Tamoxifen elicits rapid transmembrane lipid signal responses in human breast cancer cells. Cabot MC, et al. **Breast Cancer Res Treat** 1995;36(3):299–306
Elemental composition of bone minerals in women with breast cancer treated with adjuvant tamoxifen. Kalef-Ezra JA, et al. **Breast Cancer Res Treat** 1996;37(2):161–8
Cell cycle expression of steroid receptors determined by image analysis on human breast cancer cell line: a hypothesis on the effects of antiestrogens. Rostagno P, et al. **Breast Cancer Res Treat** 1996;37(1):77–87
Octreotide reduces the kinetic index, proliferating cell nuclear antigen-maximum proliferative index, in patients with colorectal cancer. Stewart GJ, et al. **Cancer** 1995 Aug 15;76(4):572–8
Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor—positive human cancer cell lines. Pályi I, et al. **Cancer Detect Prev** 1996;20(2):146–52
Tamoxifen antagonizes proliferation and invasion of estrogen receptor-negative metastatic follicular thyroid cancer cells via protein kinase C. Hoelting T, et al. **Cancer Lett** 1996 Feb 27;100(1–2):89–93
Effect of tamoxifen on intraperitoneal N-nitroso-N-methylurea induced tumors. Martin G, et al. **Cancer Lett** 1996 Feb 27;100(1–2):227–34
Presence of an insulin-like growth factor I autocrine loop predicts uterine fibroid responsiveness to tamoxifen. Howe SR, et al. **Cancer Res** 1996 Sep 1;56(17):4049–55
Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Osborne MR, et al. **Cancer Res** 1996 Jan 1;56(1):66–71
Effect of dietary fat or tamoxifen on the expansion of cells harboring Ha-ras oncogenes in mammary glands from methylnitrosourea-treated rats. Hu Z, et al. **Carcinogenesis** 1995 Sep;16(9):2281–4
Goserelin. A review of its pharmacodynamic and

pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Perry CM, et al. **Drugs** 1996 Feb; 51(2):319–46 (113 ref.)

Lack of effect of corticosteroids and tamoxifen on suramin protein binding and in vitro activity. Driscoll DL, et al. **Eur J Cancer** 1996 Feb;32A(2):311–5

Glucocorticoid receptors and growth inhibitory effects of dexamethasone in human lung cancer cell lines. Hofmann J, et al. **Eur J Cancer** 1995 Nov;31A(12):2053–8

Effect of octreotide infusion on hepatic and tumour blood flow in two experimental models of liver metastases. Davies N, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):971–4

Inhibition of endothelial adhesion and invasion by breast carcinoma cells may contribute towards the anti-metastatic effects of tamoxifen. Bliss RD, et al. **Eur J Surg Oncol** 1996 Feb;22(1):27–33

Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Tomás E, et al. **Gynecol Oncol** 1995 Nov;59(2):261–6

1,25 dihydroxyvitamin D and dexamethasone decrease in vivo Walker carcinoma growth, but not parathyroid hormone related protein secretion. Cohen-Solal ME, et al. **Horm Metab Res** 1995 Sep;27(9):403–7

Influence of dexamethasone and 1,25-Dihydroxyvitamin D on Walker carcinosarcoma 256 growth and parathyroid hormone-related protein secretion [letter] Schilling T, et al. **Horm Metab Res** 1996 Apr;28(4):209–10

The effect of Toremifene on the expression of some genes in human mononuclear cells. Kellen JA. **In Vivo** 1995 May-Jun;9(3):215–7

Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. Hoelting T, et al. **J Clin Endocrinol Metab** 1996 Jul; 81(7):2638–41

Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Ito C, et al. **J Clin Oncol** 1996 Aug;14(8):2370–6

Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. Jiang SY, et al. **J Hepatol** 1995 Dec;23(6):712–9

Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog? [editorial; comment] Gelmann EP. **J Natl Cancer Inst** 1996 Mar 6;88(5):224–6. Comment on: J Natl Cancer Inst 1996 Mar 6;88(5):279–84.

Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells [see comments] Kang Y, et al. **J Natl Cancer Inst** 1996 Mar 6;88(5):279–84 . Comment in: J Natl Cancer Inst 1996 Mar 6;88(5):224–6.

Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. Robertson CN, et al. **J Natl Cancer Inst** 1996 Jul 3;88(13):908–17

Androgen-controlled specific gene expression in neuroblastoma cells. Yerramilli-Rao P, et al. **J Neurol Sci** 1995 May;129 Suppl:131–5

The effects of dexamethasone on experimental brain tumors: I. Transcapillary transport and blood flow in RG-2 rat gliomas. Molnar P, et al. **J Neurooncol** 1995;25(1):19–28

The effects of dexamethasone on transcapillary transport in experimental brain tumors: II. Canine brain tumors. Warnke PC, et al. **J Neurooncol** 1995;25(1):29–38

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):107–11 (36 ref.)

Somatostatin and its cyclic octapeptide analog SMS 201-995 as inhibitors of proliferation of human acute lymphoblastic and acute myeloid leukemia. Santini V, et al. **Leuk Res** 1995 Oct;19(10):707–12

Mechanisms of glucocorticoid resistance in human leukemic cells: implication of abnormal 90 and 70 kDa heat shock proteins. Kojika S, et al. **Leukemia** 1996 Jun;10(6):994–9

Gynaecologic effects of tamoxifen. Kuo DY, et al. **Med Oncol** 1995 Jun;12(2):87–94 (79 ref.)

Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Kaspers GJ, et al. **Med Pediatr Oncol** 1996 Aug;27(2):114–21

The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors. Pollack IF, et al. **Pediatr Neurosurg** 1995;22(6):281–8

Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Fisher WE, et al. **Surgery** 1996 Aug;120(2):234–40; discussion 240–1

Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. Pienta KJ, et al. **Urology** 1996 Jul;48(1):164–70

[Somatostatin receptors: a new pathway into the tumor?] Fehmann HC, et al. **Z Gastroenterol** 1996 May;34(5):298–9 **(Ger)**

THERAPEUTIC USE

Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. The South Sweden Breast Cancer Group. Fernö M, et al. **Acta Oncol** 1996; 35(1):17–22

Experience with hormonal therapy in advanced epithelial ovarian cancer. van der Vange N, et al. **Acta Oncol** 1995; 34(6):813–20

Complete hormonal blockage--antiandrogens. Bierkens AF, et al. **Acta Urol Belg** 1996 May;64(2):77–9

Controversies surrounding hormonal deprivation. Denis LJ. **Acta Urol Belg** 1996 May;64(2):81–4

Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy. Scalliet P. **Acta Urol Belg** 1996 May;64(2):63–4

Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense? Schulman CC, et al. **Acta Urol Belg** 1996 May;64(2):57–61 (32 ref.)

Tamoxifen therapy--long-term results and complications. Moore MP, et al. **Adv Surg** 1996;29:263–9 (29 ref.)

Aromatase inhibitors: current status. Ibrahim NK, et al. **Am J Clin Oncol** 1995 Oct;18(5):407–17 (142 ref.)

Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports. Zidan J, et al. **Am J Clin Oncol** 1996 Jun;19(3):229–31

Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis [letter] Sica S, et al. **Am J Hematol** 1996 Mar;51(3):248–9

Case reports: continuous corticosteroids for refractory poorly differentiated lymphocytic lymphoma. Newcom SR. **Am J Med Sci** 1996 Sep;312(3):136–7

Histopathologic findings in 107 uterine leiomyomas treated with leuprolide acetate compared with 126 controls. Sreenan JJ, et al. **Am J Surg Pathol** 1996 Apr;20(4):427–32

Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Nicholson RI, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:325–35 (60 ref.)

111In-octreotide scintigraphy: a tool to select patients with endocrine pancreatic tumors for octreotide treatment? Keymeulen B, et al. **Ann Nucl Med** 1995 Aug;9(3):149–52

Hypoxemia due to right-to-left shunt in the carcinoid syndrome; beneficial response to octreotide [letter] Hart D, et al. **Ann Oncol** 1995 Nov;6(9):952–4

Progress toward hormonal therapy of gastrointestinal cancer [see comments] Bold RJ, et al. **Ann Surg** 1996 Jan; 223(1):4–11 (36 ref.). Comment in: Ann Surg 1996 Jan;223(1):12–3.

Hormonal therapy for gastrointestinal cancer [editorial; comment] Lillemoe KD. **Ann Surg** 1996 Jan;223(1):12–3. Comment on: Ann Surg 1996 Jan;223(1):4–11.

Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group. Lunglmayr G. **Anticancer Drugs** 1995 Aug; 6(4):508–13

Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Tonetti DA, et al. **Anticancer Drugs** 1995 Aug;6(4):498–507 (87 ref.)

Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Canobbio L, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2687–90

A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Jager W, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2639–42

Adjuvant treatment for breast cancer in the elderly. Marchei P, et al. **Anticancer Res** 1996 Mar-Apr;16(2):911–3

Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide [letter] Pavlovic M, et al. **Arch Dermatol** 1995 Oct;131(10):1207–9

Long term adjuvant therapy for primary breast cancer [editorial] [see comments] Bulbrook RD. **BMJ** 1996 Feb 17;312(7028):389–90. Comment in: BMJ 1996 Apr 20;312(7037):1036. Comment in: BMJ 1996 Apr 20;312(7037):1036–7. Comment in: BMJ 1996 Apr 20;312(7037):1037.

Adjuvant treatment with tamoxifen. Care is necessary [letter] Bulbrook RD. **BMJ** 1996 Aug 24;313(7055):493–4

Adjuvant treatment with tamoxifen. Informed consent and follow up in aTTom trial are inadequate [letter] Cunningham H. **BMJ** 1996 Aug 24;313(7055):494

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Archer SG, et al. **Br J Cancer** 1995 Nov;72(5):1259–66

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. Bonnefoi HR, et al. **Br J Cancer** 1996 Feb;73(4):539–42

Changes in expression of transforming growth factor beta mRNA isoform in patients undergoing tamoxifen therapy. MacCallum J, et al. **Br J Cancer** 1996 Aug;74(3):474–8

Long-term follow-up of elderly patients with operable breast cancer treated with surgery without axillary dissection plus adjuvant tamoxifen. Martelli G, et al. **Br J Cancer** 1995 Nov;72(5):1251–5

Aromatase inhibitors--where are we now? [editorial] Miller WR. **Br J Cancer** 1996 Feb;73(4):415–7

Hormone replacement therapy as treatment of breast cancer--a phase II study of Org OD 14 (tibilone). O'Brien M, et al. **Br J Cancer** 1996 May;73(9):1086–8

Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases. Soubeyran I, et al. **Br J Cancer** 1996 Mar; 73(6):735–43

Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Stewart HJ, et al. **Br J Cancer** 1996 Jul;74(2):297–9

Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. Aston K, et al. **Br J Obstet Gynaecol** 1995 Oct; 102(10):835–7

Octreotide inhibits the growth and development of three types of experimental liver metastasis [letter; comment] Frizelle FA. **Br J Surg** 1995 Nov;82(11):1577. Comment on: Br J Surg 1995 Jun;82(6):840–3.

Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results. Abbas F, et al. **Br J Urol** 1996 Mar;77(3):423–8

Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial. Zalcberg JR, et al. **Br J Urol** 1996 Jun;77(6):865–9

Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Engan T, et al. **Breast Cancer Res Treat** 1995;36(3):287–97

Recurrence-free survival in breast cancer improved by adjuvant tamoxifen--especially for progesterone receptor positive tumors with a high proliferation. Fernö M, et al. **Breast Cancer Res Treat** 1995;36(1):23–34

Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: a randomized study. Gundersen S, et al. **Breast Cancer Res Treat** 1995;36(1):49–53

Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer. Jordan VC. **Breast Cancer Res Treat** 1995;36(3):267–85 (123 ref.)

Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Meakin JW, et al. **Breast Cancer Res Treat** 1996;37(1):11–9

High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB). Perry JJ, et al. **Breast Cancer Res Treat** 1995;36(1):35–40

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Eriksson S, et al. **Calcif Tissue Int** 1995 Aug;57(2):97–9

Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Bennett CL, et al. **Cancer** 1996 May 1;77(9):1854–61

Phase II study of flutamide in the treatment of hepatocellular carcinoma. Chao Y, et al. **Cancer** 1996 Feb 15;77(4):635–9

Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials. Dhodapkar MV, et al. **Cancer** 1996 Feb 15;77(4):683–90

A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic [see comments] Goldberg RM, et al. **Cancer** 1995 Sep 15;76(6):961–6. Comment in: Cancer 1996 May 1;77(9):1956–7.

The expression of insulin-like growth factor and its binding protein mRNA in the endometrium of postmenopausal patients with breast cancer receiving tamoxifen. Laatikainen TJ, et al. **Cancer** 1995 Oct 15;76(8):1406–10

Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. Miller AA, et al. **Cancer** 1996 Aug 15;78(4):789–93

A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma [letter; comment] Morris DL. **Cancer** 1996 May 1;77(9):1956–7. Comment on: Cancer 1995 Sep 15;76(6):961–6.

In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Sokoloff MH, et al. **Cancer** 1996 May 1;77(9):1862–72

Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status. Ilanchezhian S, et al. **Cancer Biochem Biophys** 1995 Nov; 15(2):83–90

Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen. Feliu J, et al. **Cancer Chemother Pharmacol** 1996;38(2):191–4

In vivo studies of the new gonadotropin-releasing hormone antagonist--copolymer conjugates having antitumor activity. Vincze B, et al. **Cancer Detect Prev** 1996; 20(2):153–9

Type of estrogen receptor determines response to antiestrogen therapy. Villa E, et al. **Cancer Res** 1996 Sep 1;56(17):3883–5

Estimating the cost-effectiveness of flutamide in metastatic cancer. Hillner BE. **Cancer Treat Rev** 1996 Jan;22 Suppl A:103–8

Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Middleman MN, et al. **Cancer Treat Rev** 1996 Mar;22(2):105–18 (61 ref.)

Use of somatostatin analog for localization and treatment of ACTH secreting bronchial carcinoid tumor. Christin-Maitre S, et al. **Chest** 1996 Mar;109(3):845–6

Dexamethasone-suppressible adrenal tumour in untreated 21-hydroxylase deficiency [letter] Bevan JS, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):733–7

Endocrine effects of GnRH analogue with low-dose hormone replacement therapy in women with endometriosis. Howell R, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):609–15

Mifepristone: antineoplastic studies. Sartor O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):498–505 (28 ref.)

A prospective randomized trial to evaluate different oral dose regimens of medroxyprogesterone acetate in women with advanced breast cancer. Clinton OP, et al. **Clin Oncol (R Coll Radiol)** 1995;7(4):251–6

Hormone resistance in cancer: the role of abnormal steroid receptors. Sluyser M. **Crit Rev Oncog** 1994;5(6):539–54 (122 ref.)

Recent advances in hormonal therapy for cancer. Traynor A. **Curr Opin Oncol** 1995 Nov;7(6):572–81 (75 ref.)

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Perry CM, et al. **Drugs** 1996 Feb; 51(2):319–46 (113 ref.)

Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly. Tsukamoto N, et al. **Endocr J** 1994 Aug;41(4):437–44

New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity [editorial; comment] Castiglione-Gertsch M. **Eur J Cancer** 1996 Mar; 32A(3):393–5. Comment on: Eur J Cancer 1996 Mar;32A(3):404–12.

New endocrine therapies for breast cancer. Howell A, et al. **Eur J Cancer** 1996 Apr;32A(4):576–88 (106 ref.)

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer [see comments] Jonat W, et al. **Eur J Cancer** 1996 Mar;32A(3):404–12. Comment in: Eur J Cancer 1996 Mar;32A(3):393–5.

Assessment of five serum marker assays in patients with advanced breast cancer treated with medroxyprogesterone acetate. Murray A, et al. **Eur J Cancer** 1995 Sep; 31A(10):1605–10

Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression. Oliver RT, et al. **Eur J Cancer** 1996 Mar;32A(3):396–7 (20 ref.)

Beneficial effects of octreotide in a patient with a metastatic paraganglioma [letter] Tenenbaum F, et al. **Eur J Cancer** 1996 Apr;32A(4):737

The use of the tumour marker CA19-9 in evaluating the response to tamoxifen therapy in patients with unresectable adenocarcinoma of the pancreas [letter] Wong A, et al. **Eur J Cancer** 1995 Nov;31A(12):2118–9

Chemoprevention by melatonin and combined melatonin-tamoxifen therapy of second generation nitroso-methylurea-induced mammary tumours in rats. Kothari A, et al. **Eur J Cancer Prev** 1995 Dec;4(6):497–500

In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide [see comments] Ezzat S, et al. **Eur J Endocrinol** 1995 Dec; 133(6):686–90. Comment in: Eur J Endocrinol 1995 Dec;133(6):675–7.

Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid: superiority of continuous versus intermittent administration to control hormonal secretion. Lefebvre S, et al. **Eur J Endocrinol** 1995 Sep;133(3):320–4

Iodine-131 labelled octreotide: not an option for somatostatin receptor therapy. Bakker WH, et al. **Eur J Nucl Med** 1996 Jul;23(7):775–81

The effect of steroid on thallium-201 uptake by malignant gliomas. Namba H, et al. **Eur J Nucl Med** 1996 Aug; 23(8):991–2

Estrogen and progesterone receptor content of GnRH analogue pretreated and untreated uterine leiomyomata. Regidor PA, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):69–73

Locally advanced breast cancer: long-term results of a randomized trial comparing primary treatment with tamoxifen or radiotherapy in post-menopausal women. Willsher PC, et al. **Eur J Surg Oncol** 1996 Feb;22(1):34–7

Combined androgen blockade. Crawford ED. **Eur Urol** 1996; 29 Suppl 2:54–61 (28 ref.)

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against. Jewett MA, et al. **Eur Urol** 1996;29 Suppl 2:45–8 (11 ref.)

The management of hormone refractory prostate cancer. Newling DW. **Eur Urol** 1996;29 Suppl 2:69–74 (24 ref.)

The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Robinson MR, et al. **Eur Urol** 1995;28(4):273–83

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for. Scher HI. **Eur Urol** 1996;29 Suppl 2:40–4 (36 ref.)

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:105–9

The role of induction androgen deprivation prior to radical prostatectomy. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:114–8 (27 ref.)

Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate. Voges GE, et al. **Eur Urol** 1995; 28(3):209–14

Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study. Benagiano G, et al. **Fertil Steril** 1996 Aug;66(2):223–9

The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Sener AB, et al. **Fertil Steril** 1996 Feb;65(2):354–7

Tamoxifen treatment in hepatocellular carcinoma [letter] Farinati F. **Gastroenterology** 1996 Jul;111(1):272–4

Variant liver estrogen and response to tamoxifen [letter] Villa E, et al. **Gastroenterology** 1996 Jul;111(1):271–2

Recurrent esophagorespiratory fistula in a patient with metastatic breast cancer: long-term palliation with endoprostheses and hormonal therapy. Taal BG, et al. **Gastrointest Endosc** 1995 Jul;42(1):84–8

Whither tamoxifen [editorial; comment] Edmonson JH. **Gynecol Oncol** 1996 Jul;62(1):1–3. Comment on: Gynecol Oncol 1996 Jul;62(1):4–6.

Octreotide in the management of bowel obstruction in terminal ovarian cancer. Mangili G, et al. **Gynecol Oncol** 1996 Jun;61(3):345–8

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report [see comments] Markman M, et al. **Gynecol Oncol** 1996 Jul; 62(1):4–6. Comment in: Gynecol Oncol 1996 Jul 62(1):1–3.

Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy. Boehme MW, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):1053–61

The nuclear channel system in endometrial adenocarcinoma exposed to medroxyprogesterone acetate. Horbelt DV, et al. **Hum Pathol** 1996 Jan;27(1):9–14

Anti-estrogens enhance the therapeutic effect of lymphokine-activated killer cells on the P815 murine mastocytoma. Baral E, et al. **Int J Cancer** 1996 Aug 7; 67(4):580–5

Oxytocin and oxytocin-analogue F314 inhibit cell proliferation and tumor growth of rat and mouse mammary carcinomas. Cassoni P, et al. **Int J Cancer** 1996 Jun 11; 66(6):817–20

C-erb-b2/int-2 amplification appears faster in breast-cancer patients receiving second-line endocrine treatment. Lönn U, et al. **Int J Cancer** 1996 Aug 22;69(4):273–7

Hemothorax after Lupron therapy of a patient with pleural endometriosis—a case report and literature review. Margolis MT, et al. **Int J Fertil Menopausal Stud** 1996 Jan-Feb;41(1):53–5

Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin. Crow J, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):235–42

The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. Fowble B, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 1;35(4):669–77

The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Schild SE, et al. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):535–41

The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Yang FE, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1009–17

Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation. Sasagawa I, et al. **Int Urol Nephrol** 1995;27(6):769–74

Radiotherapy and tamoxifen for aggressive fibromatosis—a case report. Vidayasagar MS, et al. **J Assoc Physicians India** 1996 Jan;44(1):58–60

The future of antihormone therapy: innovations based on an established principle. Parczyk K, et al. **J Cancer Res Clin Oncol** 1996;122(7):383–96 (82 ref.)

Maximal androgen blockade in combination with methotrexate for treatment of metastatic prostate cancer. Sagaster P, et al. **J Cancer Res Clin Oncol** 1996; 122(3):171–76

Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. Chang A, et al. **J Clin Oncol** 1996 Aug; 14(8):2250–7

Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholestenol conversion to lathosterol in women with breast cancer. Gylling H, et al. **J Clin Oncol** 1995 Dec;13(12):2900–5

Antiestrogens and the reduction in circulating cholesterol [letter] Jordan VC. **J Clin Oncol** 1996 Aug;14(8):2407–8

Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. Saarto T, et al. **J Clin Oncol** 1996 Feb;14(2):429–33

BCPT drops enrollment target [news] Smigel K. **J Natl Cancer Inst** 1996 Oct 2;88(19):1340

Can mammographic densities predict effects of tamoxifen on the breast? [letter] Ursin G, et al. **J Natl Cancer Inst** 1996 Jan 17;88(2):128–9

Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study [news] Ziegler J. **J Natl Cancer Inst** 1996 Aug 21;88(16):1100–2

Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin. Ueki M, et al. **J Obstet Gynaecol** 1995 Feb;21(1):1–7

Endocrine treatment of cancer. Gulliford T, et al. **J R Soc Med** 1996 Aug;89(8):448–53 (37 ref.)

2-Phenylindoles with sulfur containing side chains. Estrogen receptor affinity, antiestrogenic potency, and antitumor activity. Biberger C, et al. **J Steroid Biochem Mol Biol** 1996 Apr;58(1):31–43

The control and biological importance of intratumoural aromatase in breast cancer. Dowsett M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):145–50 (22 ref.)

Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. Geisler J, et al. **J Steroid Biochem Mol Biol** 1995 Nov;55(2):193–5

Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Hackenberg R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):113–7 (56 ref.)

Treatment of breast cancer in elderly patients. van Dalsen AD, et al. **J Surg Oncol** 1995 Oct;60(2):80–2

Weight gain in women receiving adjuvant chemotherapy for breast cancer. Faber-Langendoen K. **JAMA** 1996 Sep 18; 276(11):855–6

Chemoprevention of breast cancer [clinical conference] O'Shaughnessy JA. **JAMA** 1996 May 1;275(17):1349–53

Estrogen therapy for prostate carcinoma. Presti JC Jr. **JAMA** 1996 Apr 17;275(15):1153

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival [see comments] Gelber RD, et al. **Lancet** 1996 Apr 20;347(9008):1066–71 . Comment in: Lancet 1996 Apr 20;347(9008):1057–8.

Endocrine therapy in breast cancer [letter; comment] Johnson AE. **Lancet** 1996 Mar 16;347(9003):761. Comment on: Lancet 1996 Jan 27;347(8996):260.

Tamoxifen and menopausal status: risks and benefits [letter] Sasco AJ. **Lancet** 1996 Mar 16;347(9003):761

Effective control of bone pain by octreotide in a patient with metastatic gastrinoma. Burgess JR, et al. **Med J Aust** 1996 Jun 17;164(12):725–7

Octreotide. Lamberts SW, et al. **N Engl J Med** 1996 Jan 25;334(4):246–54 (76 ref.)

A case of primary glucocorticoid resistance. Kawakubo A, et al. **Nagoya J Med Sci** 1995 Dec;58(3–4):143–7

Oestrogen and bone density: a comparison of tamoxifen and hypo-oestrogenaemia. Leslie WD, et al. **Nucl Med Commun** 1995 Aug;16(8):698–702

Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Marshall LA, et al. **Obstet Gynecol** 1996 Mar;87(3):350–4

Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. Noberasco C, et al. **Oncology** 1995 Nov-Dec;52(6):454–7

Current status of endocrine therapy for metastatic breast cancer. Kimmick G, et al. **Oncology (Huntingt)** 1995 Sep; 9(9):877–86, 889–90; discussion 892–4 (129 ref.)

Advanced prostate cancer. Endocrine therapies and palliative measures. Taub M, et al. **Postgrad Med** 1996 Sep; 100(3):139–40, 143–6, 152 passim (16 ref.)

The effects of octreotide in a patient with Nelson's syndrome. Kelestimur F, et al. **Postgrad Med J** 1996 Jan;72(843):53–4

Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice? Denis L. **Prostate** 1995 Nov;27(5):233–40 (43 ref.)

The case for early endocrine treatment of advanced or metastatic prostate cancer. Schmidt JD. **Prostate** 1996 Mar; 28(3):201–4

Carcinoma of prostate: case against immediate hormonal therapy. Smith PH. **Prostate** 1996 Mar;28(3):205–8

Adjuvant treatment of breast cancer. Akerley WL 3rd. **R I Med** 1995 Sep;78(9):250–3 (12 ref.)

MR imaging appearance of the uterus in postmenopausal women receiving tamoxifen therapy for breast cancer: histopathologic correlation. Ascher SM, et al. **Radiology** 1996 Jul;200(1):105–10

Current and future roles of adjuvant endocrine therapy in the management of early carcinoma of the breast. Baum M, et al. **Recent Results Cancer Res** 1996;140:215–26 (30 ref.)

Long-term tamoxifen trial halted [news] Marshall E. **Science** 1995 Dec 8;270(5242):1562

Histopathological effects of androgen deprivation in prostatic cancer. Civantos F, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):22–31

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Gleave ME, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):39–45; discussion 46–7 (26 ref.)

Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Lerner SE, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):12–20; discussion 21 (36 ref.)

Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer. Roach M 3rd. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):32–7; discussion 38 (33 ref.)

Neoadjuvant hormonal treatment before radical prostatectomy. Watson RB, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):48–55; discussion 55–6 (59 ref.)

Pamidronate in patients with painful bone metastases, who

failed initial treatment with hormones and/or chemotherapy. Cascinu S, et al. **Support Care Cancer** 1996 Jan;4(1):31–3

Endocrine and cytotoxic therapies for the management of advanced local breast cancer. Current clinical investigation. Parker LM, et al. **Surg Oncol Clin N Am** 1995 Oct; 4(4):779–90

Hormonal treatment of advanced breast cancer. Tellez C, et al. **Surg Oncol Clin N Am** 1995 Oct;4(4):751–77 (199 ref.)

Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system. Abe O, et al. **Surg Today** 1995;25(8):701–10

Pulmonary benign metastasising leiomyoma: response to treatment with goserelin. Jacobson TZ, et al. **Thorax** 1995 Nov;50(11):1225–6

Psoriasis and tamoxifen therapy: a case report. Ferrari VD, et al. **Tumori** 1996 May–Jun;82(3):262–3

Pulmonary lymphangioleiomyomatosis: a case report in postmenopausal woman treated with pleurodesis and progesterone (medroxyprogesterone acetate). Zanella A, et al. **Tumori** 1996 Jan–Feb;82(1):96–8

Endometrial blood flow response to estrogen replacement therapy and tamoxifen in asymptomatic, postmenopausal women: a transvaginal Doppler study. Achiron R, et al. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):411–4

Bicalutamide (Casodex): The Critical Issues 1996. Proceedings of a meeting. Boston, Massachusetts, July 6–9, 1995. **Urology** 1996 Jan;47(1A Suppl):1–96

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Chodak G, et al. **Urology** 1995 Dec; 46(6):849–55

Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. Gomella LG, et al. **Urology** 1996 Jun;47(6):870–7

Effect of flutamide and flutamide plus castration on prostate size in patients with previously untreated prostate cancer. Noldus J, et al. **Urology** 1996 May;47(5):713–8

Response to treatment with progesterone in a patient with pulmonary lymphangioleiomyomatosis. Rajjoub S, et al. **W V Med J** 1995 Nov–Dec;91(7):322–3

[Comparison between the roles of aminoglutethimide and hydroxyprogesterone caproates in the treatment of endometrial cancer] Liu XS, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):479–82 (Eng. Abstr.) **(Chi)**

[Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results] Hermans BP, et al. **Acta Urol Belg** 1996 Mar;64(1):27–31 **(Fre)**

[Determining factors for adjuvant treatment of breast cancer in the Côte d'Or region 1982–1990. Registry of gynecologic cancers at the Côte d'Or] Coudert B, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):54–62 (Eng. Abstr.) **(Fre)**

[Treatment of hepatocellular carcinoma with tamoxifen] Raoul JL. **Gastroenterol Clin Biol** 1996 Mar;20(2):221–2 **(Fre)**

[Treatment of metastatic cancer of the prostate] Fournier G, et al. **Presse Med** 1995 Oct 28;24(32):1465–70 (10 ref.) (Eng. Abstr.) **(Fre)**

[Hormone replacement therapy in menopausal women previously treated for breast cancer (editorial)] This P. **Presse Med** 1996 Feb 3;25(4):141–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Hot flushes in men after surgical or pharmacologic castration] Aubert J, et al. **Prog Urol** 1995 Sep;5(4):507–9 (13 ref.) (Eng. Abstr.) **(Fre)**

[Respective indications for hormone therapy, induction chemotherapy and adjuvant chemotherapy in breast cancer without clinically discernable distant metastases] Roy JA, et al. **Rev Med Brux** 1995 Jul–Aug;16(4):242–4 (Eng. Abstr.) **(Fre)**

[Pulmonary lymphangiomyomatosis: a 3-year follow-up of medroxyprogesterone acetate therapy. Apropos of a case] Druelle S, et al. **Rev Pneumol Clin** 1995;51(5):284–7 (Eng. Abstr.) **(Fre)**

[The treatment of carcinoid of the small intestine with octreotide and alpha-interferon. A call for participation in a randomized study (letter] Ahrén B. **Dtsch Med Wochenschr** 1996 May 31;121(22):744–5 **(Ger)**

[Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide] Scheffold N, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1463–7 (21 ref.) (Eng. Abstr.) **(Ger)**

[New strategies of drugs for treatment of hormone-related tumors] von Angerer E. **Pharm Unserer Zeit** 1996 Apr; 25(2):74–84 (42 ref.) **(Ger)**

[Medical therapy of locally advanced prostatic neoplasms] Boccardo F, et al. **Minerva Urol Nefrol** 1995 Dec; 47(4):203–8 **(Ita)**

[Comments on radical prostatectomy three month after hormone therapy] Selvaggi FP, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):215–7 **(Ita)**

[Efficacy of steroid therapy in a case of hepatic hemangioendothelioma in childhood] Repetto T, et al. **Pediatr Med Chir** 1996 Mar–Apr;18(2):213–5 (Eng. Abstr.) **(Ita)**

[New direction of cancer hormonal therapy—concepts of this issue] Akaza H. **Gan To Kagaku Ryoho** 1996 May;23(6):667 **(Jpn)**

[An overview of clinical trials in endocrine therapy for cancer] Hinotsu S, et al. **Gan To Kagaku Ryoho** 1996 May; 23(6):689–94 (9 ref.) (Eng. Abstr.) **(Jpn)**

[QOL assessment in the treatment of prostate cancer] Isaka S. **Gan To Kagaku Ryoho** 1996 Mar;23(4):427–31 (Eng. Abstr.) **(Jpn)**

[Progress of endocrine therapy for prostate cancer and results] Kanetake H. **Gan To Kagaku Ryoho** 1996 Mar; 23(4):413–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Strategy of drug development for hormone-dependent tumor] Kudoh M. **Gan To Kagaku Ryoho** 1996 May; 23(6):668–72 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Effectiveness of LH-RH agonist for bone metastases of breast cancer—report of a case] Kudoh S, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):787–90 (Eng. Abstr.) **(Jpn)**

[Hormone therapy of endometrial carcinoma] Kuramoto H, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):673–7 (19 ref.) (Eng. Abstr.) **(Jpn)**

[New development of endocrine therapy in prostate cancer] Naito S. **Gan To Kagaku Ryoho** 1996 May;23(6):684–8 (18 ref.) (Eng. Abstr.) **(Jpn)**

[A case of breast cancer with metastasis of multiple organs showing marked efficacy of medroxyprogesterone acetate (MPA)] Shimada K, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):623–6 (Eng. Abstr.) **(Jpn)**

[New developments in hormonal therapy for breast cancer] Tominaga T. **Gan To Kagaku Ryoho** 1996 May;23(6):678–83 (1 ref.) (Eng. Abstr.) **(Jpn)**

[Introduction of a new aromatase inhibitor fadrozole hydrochloride hydsate] Tsukagoshi S. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1991–7 (Eng. Abstr.) **(Jpn)**

[Recent problems on the endocrine and chemotherapy] Nishiya I, et al. **Hum Cell** 1995 Sep;8(3):107–14 (39 ref.) (Eng. Abstr.) **(Jpn)**

[Prognostic factors in patients with advanced prostatic cancer (stage D2) initially treated with endocrine therapy] Matsuda H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):688–94 (Eng. Abstr.) **(Jpn)**

[Successful treatment of carcinoid syndrome in two cases of bronchial carcinoid] Katakami N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1313–8 (Eng. Abstr.) **(Jpn)**

[Usefulness of Doppler ultrasound in predicting the effect of gonadotropin-releasing hormone agonist (GnRHa) on myoma uteri] Yoshioka N. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1255–60 (Eng. Abstr.) **(Jpn)**

[Pharmacologic treatment for polycystic ovary syndrome] Maciejewska M. **Ginekol Pol** 1995 Oct;66(10):569–77 (Eng. Abstr.) **(Pol)**

[Pharmacologic treatment of mild proliferation of prostatic cancer (editorial)] Dutkiewicz S. **Pol Tyg Lek** 1996 Feb; 51(6–9):67–72 (Eng. Abstr.) **(Pol)**

[Effectiveness of adjuvant hormone therapy in breast cancer] Semiglazov VF, et al. **Vopr Onkol** 1996;42(1):56–61 (Eng. Abstr.) **(Rus)**

[The adjuvant hormonal therapy of breast cancer] Semiglazov VF, et al. **Vopr Onkol** 1995;41(2):126 **(Rus)**

[Leukoregulin—a new possibility in the treatment of virus infections and malignant tumors] Bojić I. **Vojnosanit Pregl** 1994 Nov–Dec;51(6):540–2 (20 ref.) **(Scr)**

[Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast] Calzada L, et al. **Ginecol Obstet Mex** 1996 Mar; 64:135–9 (Eng. Abstr.) **(Spa)**

TOXICITY

Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. Sargent LM, et al. **Carcinogenesis** 1996 May;17(5):1051–6

A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and their metabolites. Cunningham A, et al. **Mutat Res** 1996 Jan 17;349(1):85–94

Drug toxicity mechanisms in human hepatoma HepG2 cells: cyclosporin A and tamoxifen. Duthie SJ, et al. **Xenobiotica** 1995 Nov;25(10):1151–64

ANTINEOPLASTIC AGENTS, PHYTOGENIC

Endophytic taxol-producing fungi from bald cypress, Taxodium distichum. Li JY, et al. **Microbiology** 1996 Aug; 142 (Pt 8):2223–6

20th Belgian-Dutch LOF-Symposium on Pharmacognosy and Natural Products Chemistry. Paclitaxel and other taxanes as new anti-cancer drugs. Leiden, The Netherlands, 24 November 1995. Abstracts. **Pharm World Sci** 1995 Nov 24;17(6 Suppl N):N1–14

[Paclitaxel (Taxol)] Hájek R. **Cas Lek Cesk** 1996 Jun 12; 135(12):393–6 (20 ref.) (Eng. Abstr.) **(Cze)**

[Antineoplastic effects of natural substances] Tumová L, et al. **Ceska Slov Farm** 1996 Mar;45(2):83–7 (Eng. Abstr.) **(Cze)**

ADMINISTRATION & DOSAGE

Is the MVP regimen less active than previously described? Results of a phase II study in advanced non-small cell lung cancer. Ferrigno D, et al. **Acta Oncol** 1996;35(4):435–9

M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. Bellmunt J, et al. **Am J Clin Oncol** 1996 Aug;19(4):344–8

Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma. Bensmaine M el-A, et al. **Am J Clin Oncol** 1996 Aug;19(4):356–62

Salvage chemotherapy with mitomycin, vindesine, and cisplatin (MiViP) in recurrent carcinoma of the cervix. Delaloye JF, et al. **Am J Clin Oncol** 1996 Apr;19(2):204–6

High-dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer. deMagalhaes-Silverman M, et al. **Am J Clin Oncol** 1996 Apr;19(2):169–73

A combination of vinblastine and doxorubicin with interferon alpha. Jekunen A, et al. **Am J Clin Oncol** 1996 Aug; 19(4):384–5

Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer. Remick SC, et al. **Am J Clin Oncol** 1996 Apr;19(2):125–31

Etoposide-cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small-cell carcinoma of the lung. Shaw EG, et al. **Am J Clin Oncol** 1996 Apr; 19(2):154–8

Theoretical and practical aspects of paclitaxel scheduling [editorial; comment] Gianni L. **Ann Oncol** 1995 Nov; 6(9):861–3 (26 ref.). Comment on: Ann Oncol 1995 Nov;6(9):883–5.

Multi-day fractionated administration schedule for paclitaxel [see comments] Lokich J, et al. **Ann Oncol** 1995 Nov; 6(9):883–5. Comment in: Ann Oncol 1995 Nov;6(9):861–3.

Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. de Jong RS, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2319–30 (120 ref.)

Antitumor activity of vincristine encapsulated in glucuronide-modified long-circulating liposomes in mice bearing Meth A sarcoma. Tokudome Y, et al. **Biochim Biophys Acta** 1996 Feb 21;1279(1):70–4

Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. Feliu J, et al. **Cancer** 1996 Jul 15;78(2):211–6

Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Boman NL, et al. **Cancer Chemother Pharmacol** 1996;37(4):351–5

Plasma alcohol concentrations in patients following paclitaxel infusion. Webster LK, et al. **Cancer Chemother Pharmacol** 1996;37(5):499–501

Role of intralesional vinblastine administration in treatment of intraoral Kaposi's sarcoma in AIDS. Flaitz CM, et al. **Eur J Cancer B Oral Oncol** 1995 Jul;31B(4):280–5

Response of recurrent medulloblastoma to low-dose oral etoposide. Ashley DM, et al. **J Clin Oncol** 1996 Jun; 14(6):1922–7

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. Boote DJ, et al. **J Clin Oncol** 1996 Feb;14(2):610–8

Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. Glantz MJ, et al. **J Clin Oncol** 1996 Feb;14(2):600–9

Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. Joel SP, et al. **J Clin Oncol** 1996 Jun;14(6):1903–12

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. Nabholtz JM, et al. **J Clin Oncol** 1996 Jun;14(6):1858–67

Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. Relling MV, et al. **J Clin Oncol** 1996 Feb;14(2):399–404

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Seidman AD, et al. **J Clin Oncol** 1996 Jun;14(6):1877–84

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. Seidman AD, et al. **J Clin Oncol** 1995 Oct;13(10):2575–81

No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. Younes A, et al. **J Clin Oncol** 1996 Feb; 14(2):543–8

Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. Rischin D, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1297–301

Clinical trial of daily low-dose oral etoposide for patients with residual or recurrent cancer of the ovary or uterus. Yasumizu T, et al. **J Obstet Gynaecol** 1995 Dec; 21(6):569–76

Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. Sharma A, et al. **J Pharm Sci** 1995 Dec;84(12):1400–4

Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer. Ando Y, et al. **Jpn J Cancer Res** 1996 Feb;87(2):200–5

An early phase II study of etoposide (VP-16) in advanced gastric cancer. Yamao T, et al. **Jpn J Clin Oncol** 1996 Feb; 26(1):36–41

Targeting of teniposide to the mononuclear phagocytic system (MPS) by incorporation in liposomes and submicron lipid particles; an autoradiographic study in mice. Liliemark E, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):113-8

Treatment of childhood Hodgkin's disease with ABVD without radiotherapy. Behrendt H, et al. **Med Pediatr Oncol** 1996 Apr;26(4):244-8

Administering Navelbine: a controversy [letter; comment] Cormier AC, et al. **Oncol Nurs Forum** 1995 Nov-Dec; 22(10):1475-6. Comment on: Oncol Nurs Forum 1995 May;22(4):635-46. Comment on: Oncol Nurs Forum 1995 May;22(4):707-10.

Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Furuse K, et al. **Oncology** 1996 Mar-Apr; 53(2):169-72

Development of a polymeric surgical paste formulation for taxol. Winternitz CI, et al. **Pharm Res** 1996 Mar; 13(3):368-75

Plasticizer extraction of Taxol infusion solution from various infusion devices. Mass B, et al. **Pharm World Sci** 1996 Apr; 18(2):78-82

Embryotoxicity of free and liposome-encapsulated taxol in the chick. Scialli AR, et al. **Pharmacology** 1995 Sep; 51(3):145-51

Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results. Belli L, et al. **Semin Oncol** 1995 Dec; 22(6 Suppl 15):29-33

Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer. Chang AY, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):19-21

Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. Chang AY, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):74-7

Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1). Crawford J, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):22-4

Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Dombernowsky P, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):13-7 (14 ref.)

A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Hitt R, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):50-4

Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies. Hoffman PC, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):11-5

Single-agent paclitaxel for the treatment of breast cancer: an overview. Hortobagyi GN, et al. **Semin Oncol** 1996 Feb; 23(1 Suppl 1):4-9 (17 ref.)

Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Hudis CA, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):18-23

Intraperitoneal paclitaxel in the management of ovarian cancer. Markman M. **Semin Oncol** 1995 Oct;22(5 Suppl 12):86-7

Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. Masters GA, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):11-8

Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer. Meerpohl HG, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):7-12

A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study. Natale RB. **Semin Oncol** 1995 Dec;22(6 Suppl 15):34-7

Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Ozols RF. **Semin Oncol** 1995 Dec;22(6 Suppl 15):1-6 (17 ref.)

Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. Palackdharry CS. **Semin Oncol** 1996 Jun;23(3 Suppl 6):78-83

Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer. Perkins JB, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):42-6

Role of paclitaxel in the treatment of breast cancer: the American Cooperative Group Experience. Sledge GW Jr. **Semin Oncol** 1996 Feb;23(1 Suppl 1):10-2 (9 ref.)

Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer. Souquet PJ, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):8-10

Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. Vokes EE, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):48-52

[Etoposide: specificity of prolonged oral administration] Munck JN. **Bull Cancer (Paris)** 1996 May;83(5):352-60 (66 ref.) (Eng. Abstr.) **(Fre)**

[Definitive results of a phase I study of a chemotherapy regimen using cisplatin and paclitaxel for non-small cell bronchial cancer] Sculier JP, et al. **Rev Mal Respir** 1995; 12(6):609-14 (Eng. Abstr.) **(Fre)**

[Clinicopathological evaluation of etoposide or estramustine phosphate in castrated patients with advanced prostatic cancer] Matsuda H, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Oct;86(10):1530-7 (Eng. Abstr.) **(Jpn)**

[Combined effects of sizofiran and rG-CSF on myelosuppression in cancer chemotherapy] Hoshino T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Mar; 48(3):206-12 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Needlestick injuries and hazardous drugs [letter] Mateu J, et al. **Am J Health Syst Pharm** 1996 May 1;53(9):1068, 1071

Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Böhme A, et al. **Ann Hematol** 1995 Dec;71(6):311-2

Transient pulmonary infiltrates: a hypersensitivity reaction to paclitaxel [letter] Ramanathan RK, et al. **Ann Intern Med** 1996 Jan 15;124(2):278

Hypersensitivity reactions to etoposide. Hoetelmans RM, et al. **Ann Pharmacother** 1996 Apr;30(4):367-71 (25 ref.)

Paclitaxel-induced cardiotoxicity. An ultrastructural study. Shek TW, et al. **Arch Pathol Lab Med** 1996 Jan; 120(1):89-91

Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613-4 (7 ref.)

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Dieras V, et al. **Br J Cancer** 1996 Aug;74(4):650-6

Association of acquired Pelger-Huet anomaly with taxoid therapy. Juneja SK, et al. **Br J Haematol** 1996 Apr; 93(1):139-41

Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Battafarano DF, et al. **Cancer** 1995 Jul 1;76(1):110-5

Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Dorr RT, et al. **Cancer** 1996 Jul 1;78(1):152-6

Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia. Shaklai S, et al. **Cancer** 1996 Jun 1; 77(11):2313-7

Hypertensive reactions associated with paclitaxel. Solimando DA, et al. **Cancer Invest** 1996;14(4):340-2

Pulmonary infiltrates following administration of paclitaxel. Ramanathan RK, et al. **Chest** 1996 Jul;110(1):289-92

Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11) [letter] Boisseau M, et al. **Eur J Cancer** 1996 Apr;32A(4):737-8

Paclitaxel-induced "recall" soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses. du Bois A, et al. **Gynecol Oncol** 1996 Jan;60(1):94-6

Effect of short-term dietary administration of eugenol in humans. Rompelberg CJ, et al. **Hum Exp Toxicol** 1996 Feb; 15(2):129-35

Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results. Einzig AI, et al. **Invest New Drugs** 1995;13(3):223-7

Cutaneous manifestations of Taxol therapy. Link CJ Jr, et al. **Invest New Drugs** 1995;13(3):261-3

A phase II trial of paclitaxel (Taxol) as first line treatment in advanced breast cancer. Swain SM, et al. **Invest New Drugs** 1995;13(3):217-22

Successful parenteral desensitization to paclitaxel. Essayan DM, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):42-6

Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption. Young PC, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):313-4

Paclitaxel hypersensitivity revisited [letter; comment] Essayan DM, et al. **J Clin Oncol** 1996 Mar;14(3):1042. Comment on: J Clin Oncol 1993 May;11(5):885-90. Comment on: J Clin Oncol 1993 Dec;11(12):2456-7.

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. Francis P, et al. **J Clin Oncol** 1995 Dec; 13(12):2961-7

Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. Mick R, et al. **J Clin Oncol** 1996 Jul;14(7):2012-9

Safety profile of single-dose dexamethasone premedication for paclitaxel [letter] Parikh B, et al. **J Clin Oncol** 1996 Jul;14(7):2189-90

Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. Reckzeh B, et al. **J Clin Oncol** 1996 Apr;14(4):1071-6

Paclitaxel premedication regimens [letter] Boehm DK, et al. **J Natl Cancer Inst** 1996 Apr 3;88(7):463-5

Typhlitis associated with docetaxel treatment [letter] Cardenal F, et al. **J Natl Cancer Inst** 1996 Aug 7; 88(15):1078-9

Re:Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum [letter] Guffroy M, et al. **J Natl Cancer Inst** 1996 Sep 4;88(17):1240-1

Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation [letter] Hidalgo M, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1320

Paclitaxel-induced severe neuropathy in patients with previous radiotherapy to the head and neck region [letter] Liu JM, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):1000-2

Severe neurotoxicity from vinorelbine-paclitaxel combinations [letter; comment] Parimoo D, et al. **J Natl Cancer Inst** 1996 Aug 7;88(15):1079-80. Comment on: J Natl Cancer Inst 1995 Jul 19;87(14):1072-7.

Response to dexamethasone in patients with fluid retention after docetaxel [letter] Chan S, et al. **Lancet** 1996 May 25; 347(9013):1486-7

Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Pui CH, et al. **Leukemia** 1995 Dec;9(12):1990-6

Case report: paclitaxel-induced myocardial ischemia. Soe MS, et al. **Md Med J** 1996 Jan;45(1):41-3 (4 ref.)

Paclitaxel-induced radiation recall dermatitis. McCarty MJ, et al. **Med Pediatr Oncol** 1996 Sep;27(3):185-6

Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease. Neumann Y, et al. **Med Pediatr Oncol** 1996 Apr;26(4):280-3

Docetaxel neuropathy [editorial; comment] Apfel SC. **Neurology** 1996 Jan;46(1):2-3. Comment on: Neurology 1996 Jan;46(1):104-8. Comment on: Neurology 1996 Jan;46(1):108-11.

Motor neuropathy due to docetaxel and paclitaxel. Freilich RJ, et al. **Neurology** 1996 Jul;47(1):115-8

Peripheral neurotoxicity induced by docetaxel [see comments] Hilkens PH, et al. **Neurology** 1996 Jan; 46(1):104-8. Comment in: Neurology 1996 Jan;46(1):2-3.

Peripheral neuropathy secondary to docetaxel (Taxotere) [see comments] New PZ, et al. **Neurology** 1996 Jan;46(1):108-11. Comment in: Neurology 1996 Jan;46(1):2-3.

Transient encephalopathy after paclitaxel (Taxol) infusion. Perry JR, et al. **Neurology** 1996 Jun;46(6):1596-9 (15 ref.)

Use caution when managing paclitaxel and taxotere infiltrations. Goodman M, et al. **Oncol Nurs Forum** 1996 Apr;23(3):541-2

Patient experiences adverse drug reaction to etoposide for adenocarcinoma of the lung. Ives RK. **Oncol Nurs Forum** 1995 Sep;22(8):1289

Vincristine therapy for children with acute lymphoblastic leukemia impairs conduction in the entire peripheral nerve. Vainionpää L, et al. **Pediatr Neurol** 1995 Nov;13(4):314-8

Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia. Payne JY, et al. **South Med J** 1996 May;89(5):542-5

Pain at tumor site after vinorelbine injection: description of an unexpected side effect. Colleoni M, et al. **Tumori** 1995 May-Jun;81(3):194-6

[Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats] Takasuna K, et al. **Nippon Yakurigaku Zasshi** 1995 Jun;105(6):447-60 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Screening of polyacetylenic alcohols in crude drugs using the ELISA for panaxytriol. Saita T, et al. **Biol Pharm Bull** 1995 Jul;18(7):933-7

Rapid screening of taxol metabolites in human microsomes by liquid chromatography/electrospray ionization-mass spectrometry. Poon GK, et al. **Rapid Commun Mass Spectrom** 1996;10(10):1165-8

[Colorimetric method for the determination of carboxymethyl pachyman] Chen G, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep;20(9):543-4, 576 (Eng. Abstr.) **(Chi)**

[Quantitative determination of ursolic acid in folium Ilicis cornutae (gouguye) gathered in different and periods] Guo Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Oct; 20(10):591-2, 638 (Eng. Abstr.) **(Chi)**

ANTAGONISTS & INHIBITORS

ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Holm B, et al. **Cancer Chemother Pharmacol** 1996; 38(3):203-9

Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Takasuna K, et al. **Jpn J Cancer Res** 1995 Oct;86(10):978-84

BIOSYNTHESIS

Purification and characterization of taxa-4(5),11(12)-diene synthase from Pacific yew (Taxus brevifolia) that catalyzes the first committed step of taxol biosynthesis. Hezari M, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):437-44

The search for a taxol-producing microorganism among the endophytic fungi of the Pacific yew, Taxus brevifolia. Stierle A, et al. **J Nat Prod** 1995 Sep;58(9):1315-24

BLOOD

Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. Mayer LD, et al. **Anal Biochem** 1995 Dec 10;232(2):149-57

Limited sampling models for reliable estimation of etoposide area under the curve [see comments] Holz JB, et al. **Eur J Cancer** 1995 Oct;31A(11):1794-8. Comment in: Eur J Cancer 1995 Oct;31A(11):1733-5.

Sensitive high-performance liquid chromatographic method with fluorescence detection for measurement of vinorelbine plasma concentrations. Robieux I, et al.

J Chromatogr B Biomed Appl 1996 Jan 12;675(1):183–7
High–performance liquid chromatographic determination of irinotecan (CPT–11) and its active metabolite (SN–38) in human plasma. Sumiyoshi H, et al.
J Chromatogr B Biomed Appl 1995 Aug 18;670(2):309–16
Expedient liquid chromatographic assay for paclitaxel in plasma after its administration to cancer patients. el–Yazigi A, et al. **Ther Drug Monit** 1995 Oct;17(5):511–5

CEREBROSPINAL FLUID

Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. Relling MV, et al. **J Clin Oncol** 1996 Feb;14(2):399–404

CHEMICAL SYNTHESIS

Synthesis of podophyllotoxin congeners as potential DNA topoisomerase II inhibitors. Kamal A, et al.
Anticancer Drug Des 1995 Oct;10(7):545–54
Key analogs of the tetrapeptide subunit of RA–VII and deoxybouvardin. Boger DL, et al. **Bioorg Med Chem** 1995 Dec;3(12):1579–93
Fluorescent and biotinylated analogues of docetaxel: synthesis and biological evaluation. Dubois J, et al.
Bioorg Med Chem 1995 Oct;3(10):1357–68
Synthesis and evaluation of pyrazolignans. A new class of cytotoxic agents. Gordaliza M, et al. **Bioorg Med Chem** 1995 Sep;3(9):1203–10
Strategies for the synthesis of some complex antitumor alkaloids. Pandit UK. **Farmaco** 1995 Nov;50(11):749–54 (32 ref.)
Novel cytotoxic 3'–(tert–butyl) 3'–dephenyl analogs of paclitaxel and docetaxel. Ali SM, et al. **J Med Chem** 1995 Sep 15;38(19):3821–8
Preparation of phenolic paclitaxel metabolites. Park H, et al. **J Med Chem** 1996 Jul 5;39(14):2705–9

CHEMISTRY

Meliavolkenin, a new bioactive triterpenoid from Melia volkensii (Meliaceae). Zeng L, et al. **Bioorg Med Chem** 1995 Apr;3(4):383–90
Stability of the i.v. and oral formulations of etoposide in solution. Joel SP, et al. **Cancer Chemother Pharmacol** 1995; 37(1–2):117–24
A convenient tubulin–based quantitative assay for paclitaxel (Taxol) derivatives more effective in inducing assembly than the parent compound Lin CM, et al.
Cancer Chemother Pharmacol 1996;38(2):136–40
Lipid–complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. Sugarman SM, et al. **Cancer Chemother Pharmacol** 1996;37(6):531–8
Longimicins A–D: novel bioactive acetogenins from Asimina longifolia (annonaceae) and structure–activity relationships of asimicin type of annonaceous acetogenins. Ye Q, et al.
J Med Chem 1996 Apr 26;39(9):1790–6
Immunoenzymatic methods applied to the search for bioactive taxoids from Taxus baccata. Guo Y, et al.
J Nat Prod 1995 Jul;58(7):1015–23
Coriadienin, the first annonaceous acetogenin with two double bonds isolated from Annona coriaceae. Meneses da Silva EL, et al. **J Nat Prod** 1996 May;59(5):528–30
Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. Sharma US, et al.
J Pharm Sci 1995 Oct;84(10):1223–30
Recent advances in Annonaceous acetogenins. Zeng L, et al. **Nat Prod Rep** 1996 Aug;13(4):275–306 (177 ref.)
Development of a polymeric surgical paste formulation for taxol. Winternitz CI, et al. **Pharm Res** 1996 Mar; 13(3):368–75
Cytotoxicity and NMR spectral assignments of ergolide and bigelovin. Wang Q, et al. **Planta Med** 1996 Apr;62(2):166–8
[Cytotoxicity of aspidospermane indole alkaloids with a modified tryptamine chain] Lewin G. **J Nat Prod** 1995 Jul; 58(7):1089–91 **(Fre)**

ISOLATION & PURIFICATION

Longifolicin, longicoricin, and gigantetroneninone, three novel bioactive mono–tetrahydrofuran annonaceous acetogenins from Asimina longifolia (Annonaceae). Ye Q, et al. **Bioorg Med Chem** 1996 Apr;4(4):537–45
Solution forms of antitumor cyclic pentapeptides with 3,4–dichlorinated proline residues, astins A and C, from Aster tataricus. Morita H, et al.
Chem Pharm Bull (Tokyo) 1995 Aug;43(8):1395–7
Antitumor germacranolides from Anvillea garcinii. Abdel Sattar E, et al. **J Nat Prod** 1996 Apr;59(4):403–5
An antimitotic and cytotoxic chalcone from Fissistigma lanuginosum. Alias Y, et al. **J Nat Prod** 1995 Aug; 58(8):1160–6
New polyoxypregnane ester derivatives from Leptadenia hastata. Aquino R, et al. **J Nat Prod** 1996 Jun;59(6):555–64
Tonkinecin, a novel bioactive annonaceous acetogenin from Uvaria tonkinesis. Chen Y, et al. **J Nat Prod** 1996 May; 59(5):507–9
Gummiferol, a cytotoxic polyacetylene from the leaves of Adenia gummifera. Fullas F, et al. **J Nat Prod** 1995 Oct; 58(10):1625–8
Bruceanols G and H cytotoxic quassinoids from Brucea antidysenterica. Imamura K, et al. **J Nat Prod** 1995 Dec; 58(12):1915–9
Antitumor agents, 162. Cell–based assays for identifying novel DNA topoisomerase inhibitors: studies on the constituents of Fatsia japonica. Kitanaka S, et al.
J Nat Prod 1995 Nov;58(11):1647–54
Celahinine A, a new sesquiterpene pyridine alkaloid from Celastrus hindsii. Kuo YH, et al. **J Nat Prod** 1995 Nov; 58(11):1735–8
Agastaquinone, a new cytotoxic diterpenoid quinone from Agastache rugosa. Lee HK, et al. **J Nat Prod** 1995 Nov; 58(11):1718–21
Bruceosides D, E, and F, three new cytotoxic quassinoid glucosides from Brucea javanica. Ohnishi S, et al.
J Nat Prod 1995 Jul;58(7):1032–8
Sesquiterpene/quinol from a New Zealand liverwort, Riccardia crassa. Perry NB, et al. **J Nat Prod** 1995 Jul; 58(7):1131–5
Isolation and characterization of cytotoxic and antibacterial tetrasaccharide glycosides from Ipomoea stans. Reynolds WF, et al. **J Nat Prod** 1995 Nov;58(11):1730–4
Rollinecins A and B: two new bioactive annonaceous acetogenins from Rollinia mucosa. Shi G, et al.
J Nat Prod 1996 May;59(5):548–51
Asimilobin and cis– and trans–murisolinones, novel bioactive Annonaceous acetogenins from the seeds of Asimina triloba. Woo MH, et al. **J Nat Prod** 1995 Oct; 58(10):1533–42
Additional bioactive acetogenins, annomutacin and (2,4–trans and cis)–10R–annonacin–A–ones, from the leaves of Annona muricata. Wu FE, et al. **J Nat Prod** 1995 Sep; 58(9):1430–7
Longicin and goniothalamicinone: novel bioactive monotetrahydrofuran acetogenins from Asimina longifolia. Ye Q, et al. **J Nat Prod** 1995 Sep;58(9):1398–406
Isolation of anti–leukemia compounds from Citrus reticulata. Mak NK, et al. **Life Sci** 1996;58(15):1269–76
A new large–scale process for taxol and related taxanes from Taxus brevifolia. Rao KV, et al. **Pharm Res** 1995 Jul; 12(7):1003–10
Isolation of E–1–(4'–Hydroxyphenyl)–but–1–en–3–one from Scutellaria barbata. Ducki S, et al. **Planta Med** 1996 Apr; 62(2):185–6

METABOLISM

Species–specific differences in taxol transport and cytotoxicity against human and rodent tumor cells. Evidence for an alternate transport system. Parekh H, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):301–11
Interaction of a fluorescent paclitaxel analogue with tubulin. Sengupta S, et al. **Biochemistry** 1995 Sep 19; 34(37):11889–94
Inhibition of Na+/K(+)–ATPase by phenoxyl radicals of etoposide (VP–16): role of sulfhydryls oxidation. Kurella EG, et al. **Biochim Biophys Acta** 1995 Nov 21; 1232(1–2):52–8
Metabolism of irinotecan to SN–38 in a tissue–isolated tumor model. Atsumi R, et al. **Biol Pharm Bull** 1995 Jul; 18(7):1024–6
Pharmacokinetics of SN–38 [(+)–(4S)–4,11–diethyl–4,9–dihydroxy–1H–pyrano[3',4':6,7]–indolizino[1,2–b]quinoline–3,14(4H,12H)–dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C–SN–38 to rats. Atsumi R, et al. **Biol Pharm Bull** 1995 Aug;18(8):1114–9
Partial purification and characterization of an esterase acting on the anticancer pro–drugs, 7–ethylcamptothecin derivatives. Fujita Y, et al. **Biol Pharm Bull** 1995 May; 18(5):648–52
Etoposide protein binding in cancer patients. Liu B, et al.
Cancer Chemother Pharmacol 1995;36(6):506–12
Identification and properties of a major plasma metabolite of irinotecan (CPT–11) isolated from the plasma of patients. Rivory LP, et al. **Cancer Res** 1996 Aug 15;56(16):3689–94
Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Royer I, et al. **Cancer Res** 1996 Jan 1;56(1):58–65
The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Senter PD, et al.
Cancer Res 1996 Apr 1;56(7):1471–4
Dexamethasone induction of taxol metabolism in the rat. Anderson CD, et al. **Drug Metab Dispos** 1995 Nov; 23(11):1286–90
Anti–calmodulin potency of indol alkaloids in in vitro systems. Molnár A, et al. **Eur J Pharmacol** 1995 Oct 15; 291(2):73–82
Small–intestinal transfer mechanism of prunasin, the primary metabolite of the cyanogenic glycoside amygdalin. Strugala GJ, et al. **Hum Exp Toxicol** 1995 Nov;14(11):895–901
Targeting plant toxins to the urokinase and alpha 2–macroglobulin receptors. Cavallaro U, et al.
Semin Cancer Biol 1995 Oct;6(5):269–78 (60 ref.)

PHARMACOKINETICS

Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3–hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Huizing MT, et al. **Ann Oncol** 1995 Sep;6(7):699–704
Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug–resistant CHO cells. Turner RN, et al.
Br J Cancer 1996 Apr;73(7):856–60
Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN–38. Chabot GG. **Cancer Chemother Pharmacol** 1995; 36(6):463–72
Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Ellis AG, et al. **Cancer Chemother Pharmacol** 1996;38(1):81–7
Pharmacological attempts to improve the bioavailability of oral etoposide. Joel SP, et al.
Cancer Chemother Pharmacol 1995;37(1–2):125–33
Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed–effect modeling and nonparametric maximum–likelihood estimation.
Launay–Iliadis MC, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):47–54
The distribution of systemically administered [3H]–paclitaxel in rats: a quantitative autoradiographic study. Lesser GJ, et al. **Cancer Chemother Pharmacol** 1995;37(1–2):173–8
Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. Millward MJ, et al. **Cancer Chemother Pharmacol** 1995; 37(1–2):161–7
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Gupta E, et al. **Cancer Res** 1996 Mar 15;56(6):1309–14
Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Marre F, et al. **Cancer Res** 1996 Mar 15;56(6):1296–302
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Sparreboom A, et al. **Cancer Res** 1996 May 1;56(9):2112–5
Etoposide combined with interferon alfa–2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Mick R, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):349–59
Pharmacokinetics of vinorelbine in patients with liver metastases. Robieux I, et al. **Clin Pharmacol Ther** 1996 Jan; 59(1):32–40
Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Innocenti F, et al.
Drug Metab Dispos 1995 Jul;23(7):713–7
Limited–sampling models for irinotecan pharmacokinetics–pharmacodynamics: prediction of biliary index and intestinal toxicity. Mick R, et al.
J Clin Oncol 1996 Jul;14(7):2012–9
Phase I crossover study of paclitaxel with r–verapamil in patients with metastatic breast cancer. Tolcher AW, et al.
J Clin Oncol 1996 Apr;14(4):1173–84
Induction of hepatic P–glycoprotein enhances biliary excretion of vincristine in rats. Watanabe T, et al.
J Hepatol 1995 Oct;23(4):440–8
Does paclitaxel penetrate into brain tumor tissue? [letter] Heimans JJ, et al. **J Natl Cancer Inst** 1995 Dec 6; 87(23):1804–5
Altered pharmacokinetics of vinblastine in Mdr1a P–glycoprotein–deficient Mice. van Asperen J, et al.
J Natl Cancer Inst 1996 Jul 17;88(14):994–9
Cepharanthin, a multidrug resistant modifier, is a substrate for P–glycoprotein. Hirai M, et al.
J Pharmacol Exp Ther 1995 Oct;275(1):73–8
Beta–tubulin and P–glycoprotein: major determinants of vincristine accumulation in B–CLL cells. Reichle A, et al.
Leuk Res 1995 Nov;19(11):823–9

PHARMACOLOGY

ICRF–193 modifies etoposide–induced apoptosis in thymocytes. Tanimoto C, et al. **Acta Med Okayama** 1995 Dec;49(6):281–6
Effects of Taxol on choriocarcinoma cells. Marth C, et al.
Am J Obstet Gynecol 1995 Dec;173(6):1835–42
Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells. Kurosawa M, et al.
Ann Hematol 1996 Jan;72(1):17–21
Apoptosis susceptibility of human carcinoma and leukemia cell lines to taxol. Relationship with cell cycle and drug concentration. Gangemi RM, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:550–4
Effects of taxol on TNF–alpha and IL–6 production by human peripheral blood cells. Losi E, et al.
Ann N Y Acad Sci 1996 Apr 30;784:525–8
Synthesis of a series of cytotoxic 2–acyl–1,2–dihydroellipticines which inhibit topoisomerase II Devraj R, et al. **Anticancer Drug Des** 1996 Jun; 11(4):311–24
Camptothecin cytotoxic effects in vitro: dependency on exposure duration and dose. Helson L, et al.
Anticancer Drugs 1995 Aug;6(4):612–4
Inhibition of cellular chemotactic invasion by a vinca alkaloid, conophylline. Amino N, et al. **Anticancer Res** 1996 Jan–Feb;16(1):55–9
In vitro cytotoxic activity of two potential anticancer drugs isolated from Strychnos: strychnopentamine and usambarensine. Bonjean KA, et al. **Anticancer Res** 1996 May–Jun;16(3A):1129–37
Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin. Decorti G, et al. **Anticancer Res** 1996 Jan–Feb;16(1):317–20
MCF–7 cell cycle arrested at G1 through ursolic acid, and increased reduction of tetrazolium salts. Es–Saady D, et al. **Anticancer Res** 1996 Jan–Feb;16(1):481–6
Effect of cepharanthin and hyperthermia on the intracellular accumulation of adriamycin in the NIH3T3 cell lines transfected with oncogenes accompanied with pSV2neo

vector. Gaoi XS, et al. **Anticancer Res** 1995 Sep–Oct; 15(5B):1991–6

Sensitivity to taxoid derivatives of a newly established human endometrioid ovarian adenocarcinoma radioresistant cell line. Griffon G, et al. **Anticancer Res** 1996 Jan–Feb; 16(1):177–87

Cytotoxicity of paclitaxel in comparison with other anticancer agents against neoplastic cells obtained from clinical gastrointestinal carcinoma tissue. Matsuoka H, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2001–6

Modification of the blood–brain barrier permeability following intracarotid infusion of vinorelbine. Mouchard–Delmas C, et al. **Anticancer Res** 1995 Nov–Dec; 15(6B):2593–6

Suppression by coffee cherry of the growth of spontaneous mammary tumours in SHN mice. Nagasawa H, et al. **Anticancer Res** 1996 Jan–Feb;16(1):151–3

Endometrial cancer cell lines are sensitive to paclitaxel. Rantanen V, et al. **Anticancer Res** 1996 Jan–Feb;16(1):475–9

Effects of taxol on the polymerization and posttranslational modification of class III beta–tubulin in P19 embryonal carcinoma cells. Laferrière NB, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):687–94 (36 ref.)

Selective damage to the active X chromosome by camptothecin and amsacrine as determined by an allele–specific alkaline unwinding assay. Austin MJ, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1317–9

Effect of v–rasH on sensitivity of NCI–H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin. Kaufmann SH, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):1987–93

Selective induction of cell death in cancer cells by gallic acid. Inoue M, et al. **Biol Pharm Bull** 1995 Nov; 18(11):1526–30

Cytotoxic activity of bryonolic acid isolated from transformed hairy roots of Trichosanthes kirilowii var. japonica. Kondo T, et al. **Biol Pharm Bull** 1995 May; 18(5):726–9

Hinokitiol induces differentiation of teratocarcinoma F9 cells. Muto N, et al. **Biol Pharm Bull** 1995 Nov;18(11):1576–9

Combined effect of d–limonene pretreatment and temperature on the rat skin permeation of lipophilic and hydrophilic drugs. Ohara N, et al. **Biol Pharm Bull** 1995 Mar; 18(3):439–42

Comparison of the immunopharmacological activities of triple and single–helical schizophyllan in mice. Ohno N, et al. **Biol Pharm Bull** 1995 Sep;18(9):1242–7

Studies on constituents with cytotoxic and cytostatic activity of two Turkish medicinal plants Phlomis armeniaca and Scutellaria salviifolia. Saracoglu I, et al. **Biol Pharm Bull** 1995 Oct;18(10):1396–400

Synthesis and evaluation of pyrazolignans. A new class of cytotoxic agents. Gordaliza M, et al. **Bioorg Med Chem** 1995 Sep;3(9):1203–10

The biological activity of cyclic bis(bibenzyls): a rational approach. Keseru GM, et al. **Bioorg Med Chem** 1995 Nov; 3(11):1511–7

Meliavolkenin, a new bioactive triterpenoid from Melia volkensii (Meliaceae). Zeng L, et al. **Bioorg Med Chem** 1995 Apr;3(4):383–90

The absolute configuration of adjacent bis–THF acetogenins and asiminocin, a novel highly potent asimicin isomer from Asimina triloba. Zhao GX, et al. **Bioorg Med Chem** 1996 Jan;4(1):25–32

In vivo effects of recombinant human lymphotoxin on human medulloblastoma xenograft: enhancement of antitumor activity of etoposide. Mikami T, et al. **Biotherapy** 1994; 8(1):7–17

In vitro and in vivo antileukemic activity of B43–pokeweed antiviral protein against radiation–resistant human B–cell precursor leukemia cells. Waddick KG, et al. **Blood** 1995 Dec 1;86(11):4228–33

Cisplatin and taxol activate different signal pathways regulating cellular injury–induced expression of GADD153. Gately DP, et al. **Br J Cancer** 1996 Jan; 73(1):18–23

Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti–mitotic effects and induction of apoptosis in human tumour cells. Kawamura KI, et al. **Br J Cancer** 1996 Jan;73(2):183–8

Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug–resistant CHO cells. Turner RN, et al. **Br J Cancer** 1996 Apr;73(7):856–60

Sensitivity of vincristine–sensitive K562 and vincristine–resistant K562–Lucena 1 cells to anthracyclines and reversal of multidrug resistance. Maia RC, et al. **Braz J Med Biol Res** 1996 Apr;29(4):467–72

Homoharringtonine: an effective new natural product in cancer chemotherapy. Zhou DC, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):987–95 (83 ref.)

Taxanes. Fojo A. **Cancer Chemother Biol Response Modif** 1996;16:57–67 (42 ref.)

Docetaxel and paclitaxel inhibit DNA–adduct formation and intracellular accumulation of cisplatin in human leukocytes. Ma J, et al. **Cancer Chemother Pharmacol** 1996;37(4):382–4

Retardation of rat sciatic nerve regeneration after local application of minute doses of vincristine. Ruigt GS, et al. **Cancer Chemother Pharmacol** 1995;36(6):530–5

Cellular resistance to the antimelanoma immunotoxin ZME–gelonin and strategies to target resistant cells. Rosenblum MG, et al. **Cancer Immunol Immunother** 1996 Feb;42(2):115–21

Suppression of tumor cell growth by anthocyanins in vitro. Kamei H, et al. **Cancer Invest** 1995;13(6):590–4

Effects of curcumin on the formation of benzo[alpha]pyrene derived DNA adducts in vitro. Deshpande SS, et al. **Cancer Lett** 1995 Sep 4;96(1):71–80

Crocin, safranal and picrocrocin from saffron (Crocus sativus L.) inhibit the growth of human cancer cells in vitro. Escribano J, et al. **Cancer Lett** 1996 Feb 27;100(1–2):23–30

Inhibition of metabolic activation of 4–(methylnitrosamino)–1–(3–pyridyl)–1–butanone by limonene. Morse MA, et al. **Cancer Lett** 1996 Jul 12; 104(2):211–7

Tumor cell growth inhibition by several Annonaceous acetogenins in an in vitro disk diffusion assay. Oberlies NH, et al. **Cancer Lett** 1995 Sep 4;96(1):55–62

Anti–tumor activity of the crude saponins obtained from asparagus. Shao Y, et al. **Cancer Lett** 1996 Jun 24; 104(1):31–6

Postnatal modulation of hepatic biotransformation system enzymes via translactational exposure of F1 mouse pups to turmeric and curcumin. Singh A, et al. **Cancer Lett** 1995 Sep 4;96(1):87–93

DNA damage induced by etoposide; a comparison of two different methods for determination of strand breaks in DNA. Walles SA, et al. **Cancer Lett** 1996 Aug 2; 105(2):153–9

Resistance mechanisms in human sarcoma mutants derived by single–step exposure to paclitaxel (Taxol). Dumontet C, et al. **Cancer Res** 1996 Mar 1;56(5):1091–7

Pharmacodynamics of taxol in human head and neck tumors. Gan Y, et al. **Cancer Res** 1996 May 1;56(9):2086–93

Riboflavin–mediated photosensitization of Vinca alkaloids distorts drug sensitivity assays. Granzow C, et al. **Cancer Res** 1995 Nov 1;55(21):4837–43

Taxol induces bcl–2 phosphorylation and death of prostate cancer cells. Haldar S, et al. **Cancer Res** 1996 Mar 15; 56(6):1253–5

Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line. Le Moyec L, et al. **Cancer Res** 1996 Aug 1;56(15):3461–7

Taxol–dependent transcriptional activation of IL–8 expression in a subset of human ovarian cancer. Lee LF, et al. **Cancer Res** 1996 Mar 15;56(6):1303–8

Protease inhibitors induce specific changes in protein tyrosine phosphorylation that correlate with inhibition of apoptosis in myeloid cells. Lumelsky NL, et al. **Cancer Res** 1996 Sep 1;56(17):3909–14

Brain–derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Scala S, et al. **Cancer Res** 1996 Aug 15;56(16):3737–42

BCL–2 expression delays drug–induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Yin DX, et al. **Cancer Res** 1995 Nov 1; 55(21):4922–8

Recent clinical advances with camptothecin analogues. Slichenmyer WJ, et al. **Cancer Treat Res** 1995;78:29–43 (103 ref.)

The comparative clinical pharmacology of vincristine and vindesine: does vindesine offer any advantage in clinical use? Joel S. **Cancer Treat Rev** 1996 Nov;21(6):513–25 (75 ref.)

Characterization of the antitumor–promoting activity of camptothecin in SENCAR mouse skin. Gao XM, et al. **Carcinogenesis** 1996 May;17(5):1141–8

The anti–cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription. Ljungman M, et al. **Carcinogenesis** 1996 Jan;17(1):31–5

VP16 hypersensitivity and increased faulty recombination in ataxia telangiectasia lymphocytes characterized by the tandem translocation t(14;14)(q11;q32). Petrinelli P, et al. **Carcinogenesis** 1996 Feb;17(2):203–7

Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Thompson LU, et al. **Carcinogenesis** 1996 Jun;17(6):1373–6

Cyclic peptides from higher plants. XXVIII. Antitumor activity and hepatic microsomal biotransformation of cyclic pentapeptides, astins, from Aster tataricus. Morita H, et al. **Chem Pharm Bull (Tokyo)** 1996 May;44(5):1026–32

Recent progress in the study of anticancer drugs originating from plants and traditional medicine in China. Han R. **Chin Med J (Engl)** 1995 Oct;108(10):729–31 (9 ref.)

Effects and mode of action of 1,4–naphthoquinones isolated from Calceolaria sessilis on tumoral cells and Trypanosoma parasites. Morello A, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Oct;112(2):119–28

How does taxol stabilize microtubules? Arnal I, et al. **Curr Biol** 1995 Aug 1;5(8):900–8

Multidrug resistance proteins and other drug transport–related resistance to natural product agents. Broxterman HJ, et al. **Curr Opin Oncol** 1995 Nov; 7(6):532–40 (78 ref.)

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Fulton B, et al. **Drugs** 1996 Jun;51(6):1075–92 (86 ref.)

Early clinical studies with docetaxel. Docetaxel Investigators Group. Aapro M, et al. **Eur J Cancer** 1995;31A Suppl 4:S7–10 (13 ref.)

Preclinical pharmacology of docetaxel. Bissery MC. **Eur J Cancer** 1995;31A Suppl 4:S1–6 (42 ref.)

Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro. Lowis SP, et al. **Eur J Cancer** 1995;31A(4):622–6

Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Riccardi A, et al. **Eur J Cancer** 1995;31A(4):494–9

Behavior of nuclear matrix proteins during camptothecin–induced apoptosis in HL–60 human leukemia cells. Zweyer M, et al. **Exp Cell Res** 1995 Nov;221(1):27–40

Resistance of Ehrlich tumor cells to apoptosis can be due to accumulation of heat shock proteins. Gabai VL, et al. **FEBS Lett** 1995 Nov 13;375(1–2):21–6

The diverse effect of topoisomerase I specific inhibitor (camptothecin) on normal and BCR/ABL–dependent hematopoietic cells proliferation: therapeutic implications. Fertala J, et al. **Folia Histochem Cytobiol** 1995;33(3):187–92

Comparison of the performance of anti–CD7 and anti–CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T–cell acute lymphoblastic leukemia cell line. Flavell DJ, et al. **Hematol Oncol** 1995 Jul–Aug; 13(4):185–200

Dissociation between the mitogenic effect and antitumor activity of seed extract from Aeginetia indica L. Chai JG, et al. **Immunopharmacology** 1995 Sep;30(3):209–15

Specific effect of vincristine on epididymis. Averal HI, et al. **Indian J Exp Biol** 1996 Jan;34(1):53–6

Biologically active principles isolated from Salacia oblonga wall. Augusti KT, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):415–7

Paclitaxel (Taxol)–induced NF–kappaB translocation in murine macrophages. Perera PY, et al. **Infect Immun** 1996 Mar;64(3):878–84

Enhanced interaction between tubulin and microtubule–associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Nishio K, et al. **Int J Cancer** 1995 Nov 27;63(5):688–93

Antitumor activity of daphnane–type diterpene gnidimacrin isolated from Stellera chamaejasme L. Yoshida M, et al. **Int J Cancer** 1996 Apr 10;66(2):268–73

P–glycoprotein mediated resistance to 5'–nor–anhydro–vinblastine (Navelbine). Adams DJ, et al. **Invest New Drugs** 1995;13(1):13–21

Effects of vinorelbine on epidermal growth factor–receptor binding of human breast cancer cell lines in vitro. Depenbrock H, et al. **Invest New Drugs** 1995;13(3):187–93

Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Dykes DJ, et al. **Invest New Drugs** 1995;13(1):1–11

In vivo inhibition of lens regrowth by fibroblast growth factor 2–saporin. Behar–Cohen FF, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2434–48

No increased risk of Taxol toxicity in older patients [letter] Lichtman SM, et al. **J Am Geriatr Soc** 1996 Apr;44(4):472–4

Altered expression of M beta 2, the class II beta–tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. Haber M, et al. **J Biol Chem** 1995 Dec 29;270(52):31269–75

Paclitaxel–induced apoptotic changes followed by time–lapse video microscopy in cell lines established from head and neck cancer. Pulkkinen JO, et al. **J Cancer Res Clin Oncol** 1996;122(4):214–8

Vincristine induction of mutant and wild–type human multidrug–resistance promoters is cell–type–specific and dose–dependent. Stein U, et al. **J Cancer Res Clin Oncol** 1996;122(5):275–82

Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase–I: evidence for cell cycle–independent toxicity. Morris EJ, et al. **J Cell Biol** 1996 Aug;134(3):757–70

Cytotoxic and anti–tumour properties of certain taxa of Umbelliferae with special reference to Centella asiatica (L.) Urban. Babu TD, et al. **J Ethnopharmacol** 1995 Aug 11; 48(1):53–7

Pharmacology of oleanolic acid and ursolic acid. Liu J. **J Ethnopharmacol** 1995 Dec 1;49(2):57–68 (91 ref.)

Potentiation of antiproliferative effects of monoclonal antibody Lym–1 and immunoconjugate Lym–1–gelonin on human Burkitt's lymphoma cells with gamma–interferon and tumor necrosis factor. O'Boyle KP, et al. **J Immunother Emphasis Tumor Immunol** 1995 Nov; 18(4):221–30

Bacterial lipopolysaccharide confers resistance to G418, doxorubicin, and taxol in the murine macrophage cell line, RAW264. Sweet MJ, et al. **J Leukoc Biol** 1996 Feb; 59(2):280–6

Novel cytotoxic 3'–(tert–butyl) 3'–dephenyl analogs of paclitaxel and docetaxel. Ali SM, et al. **J Med Chem** 1995 Sep 15;38(19):3821–8

Longimicins A–D: novel bioactive acetogenins from Asimina longifolia (annonaceae) and structure–activity relationships of asimicin type of annonaceous acetogenins. Ye Q, et al. **J Med Chem** 1996 Apr 26;39(9):1790–6

Irinotecan (CPT–11) and characteristic mucosal changes in the mouse ileum and cecum. Ikuno N, et al. **J Natl Cancer Inst** 1995 Dec 20;87(24):1876–83

Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. Milross CG, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1308–14

Cytotoxicity, cell cycle kinetics and morphonuclear–induced effects of Vinca alkaloid anticancer agents. Pauwels O, et

al. **J Pharm Pharmacol** 1995 Oct;47(10):870–5
Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. Sharma US, et al. **J Pharm Sci** 1995 Oct;84(10):1223–30
Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance. Chen G, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1271–7
Exposure to vinorelbine inhibits in vitro proliferation and invasiveness of transitional cell bladder carcinoma. Bonfil RD, et al. **J Urol** 1996 Aug;156(2 Pt 1):517–21
Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells. Hirohashi Y, et al. **Jpn J Cancer Res** 1995 Nov; 86(11):1097–105
Overexpression of multidrug resistance protein gene in human cancer cell lines selected for drug resistance to epipodophyllotoxins. Koike K, et al. **Jpn J Cancer Res** 1996 Jul;87(7):765–72
Antiproliferative effect of basic fibroblast growth factor-saporin mitotoxin on keratocytes in culture. Wee WR, et al. **Korean J Ophthalmol** 1996 Jun;10(1):1–7
Selective toxicity of vincristine against chronic lymphocytic leukaemia in vitro. The Tampere CLL Group [letter] Vilpo J, et al. **Lancet** 1996 May 25;347(9013):1491–2
An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia. Myers DE, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):119–22
Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule. Myers DE, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):93–102
The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies. Pantazis P. **Leuk Res** 1995 Nov;19(11):775–88 (151 ref.)
Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Gieseler F, et al. **Leukemia** 1996 Jul; 10 Suppl 3:S46–S49
Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Gieseler F, et al. **Leukemia** 1996 Jul; 10(7):1177–80
Isolation of anti-leukemia compounds from Citrus reticulata. Mak NK, et al. **Life Sci** 1996;58(15):1269–76
LPS and Taxol activate Lyn kinase autophosphorylation in Lps(n), but not in Lpsd), macrophages. Henricson BE, et al. **Mol Med** 1995 May;1(4):428–35
Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Woods CM, et al. **Mol Med** 1995 Jul;1(5):506–26
Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells. Anyanwutaku IO, et al. **Mol Pharmacol** 1996 Apr;49(4):721–6
Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Ganapathi R, et al. **Mol Pharmacol** 1996 Aug;50(2):243–8
Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. Ritke MK, et al. **Mol Pharmacol** 1995 Nov;48(5):798–805
Genetic toxicology of mitotic spindle inhibitors used as anticancer drugs. Kirsch-Volders M, et al. **Mutat Res** 1996 Aug 17;355(1–2):103–28 (220 ref.)
p53 activity and chemotherapy [letter; comment] Delia D, et al. **Nat Med** 1996 Jul;2(7):724–5. Comment on: Nat Med 1996 Jan;2(1):72–9.
Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase [published erratum appears in Nat Med 1995 Jun;1(6):598] Gerhäuser C, et al. **Nat Med** 1995 Mar; 1(3):260–6
Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Pisha E, et al. **Nat Med** 1995 Oct;1(10):1046–51
Vincristine disturbs spontaneous firing of the afferent nerve fibre in ampullary electroreceptor organs. Heijmen PS, et al. **Neuroscience** 1996 May;72(2):585–91
The steroidogenic and morphological effects of paclitaxel on cultured ovarian cancer cells. Cameron MR, et al. **Oncol Res** 1995;7(3–4):145–56
DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Chen M, et al. **Oncol Res** 1995;7(2):103–11
Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells. Kisara S, et al. **Oncol Res** 1995; 7(3–4):191–200
Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Yun J, et al. **Oncol Res** 1995;7(12):583–90
Epidermal growth factor regulates topoisomerase II activity and drug sensitivity in human KB cells. Allen GC, et al. **Otolaryngol Head Neck Surg** 1996 Jun;114(6):785–92
Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Rivory LP, et al. **Pharmacol Ther** 1995;68(2):269–96 (170 ref.)
Cytotoxicity of triterpenoid saponins. Part 1: Activities against tumor cells in vitro and hemolytical index. Bader G, et al. **Pharmazie** 1996 Jun;51(6):414–7
Decursin: a cytotoxic agent and protein kinase C activator from the root of Angelica gigas. Ahn KS, et al. **Planta Med** 1996 Feb;62(1):7–9
Bistetrahydrofuranoid acetogenins from Rollinia sericea. Barnes JN, et al. **Planta Med** 1995 Oct;61(5):486–7
In vitro anticancer activity of fruit extracts from Vaccinium species. Bomser J, et al. **Planta Med** 1996 Jun;62(3):212–6
A cytotoxic diacetylene from Dendropanax arboreus [letter] Setzer WN, et al. **Planta Med** 1995 Oct;61(5):470–1
Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by Tubeimoside I. Yu L, et al. **Planta Med** 1996 Apr; 62(2):119–21
In vitro cytotoxicity of chaparrin from Castela texana. Calzado-Flores C, et al. **Proc West Pharmacol Soc** 1995; 38:49–50
Effects of the pyrrolizidine alkaloid, retrorsine, on sulfur metabolism, in the liver. Yan CC, et al. **Proc West Pharmacol Soc** 1995;38:37–40
Preclinical evaluation of CPT-11 and its active metabolite SN-38. Lavelle F, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 3):11–20 (44 ref.)
Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Pommier Y. **Semin Oncol** 1996 Feb;23(1 Suppl 3):3–10 (87 ref.)
Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. Pienta KJ, et al. **Urology** 1996 Jul;48(1):164–70
[Effect of Achyranthes bidentata polysaccharides (ABP) on antitumor activity and immune function of S180-bearing mice] Yu S, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul;17(4):275–8 (Eng. Abstr.) **(Chi)**
[The differentiation-inducing effect of tanshinone and retinoic acid on human cervical carcinoma cell line in vitro] Yuan S, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Nov; 17(6):422–4 (Eng. Abstr.) **(Chi)**
[Inducing effect of dimethy-4, 4'-dimethoxy-5, 6,5',6-dimethylenedioxybipheny-2, 2'-dicarboxylate (DDB) on differentiation of leukemia HL-60 cells] Liu Z, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Mar;76(3):214–7 (Eng. Abstr.) **(Chi)**
[Inhibitory action of Chinese compound prescription for reinforcing vital energy and invigorating blood circulation on cancer cell multiplication] Li P, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Feb;21(2):113–5, inside back cover (Eng. Abstr.) **(Chi)**
[Cytocidal effect of HH07A, a derivative of hainanensine, on L1210 cells in vitro] Ye YM, et al. **Yao Hsueh Hsueh Pao** 1995;30(7):491–4 (Eng. Abstr.) **(Chi)**
[Modification of the response to paclitaxel of human differentiated colon cancer line after long-term treatment at very low dose] Carles G, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):135–8 (Eng. Abstr.) **(Fre)**
[Pharmacology of Catharanthus alkaloids] Levêque D, et al. **Bull Cancer (Paris)** 1996 Mar;83(3):176–86 (90 ref.) (Eng. Abstr.) **(Fre)**
[Cytotoxicity of aspidospermane indole alkaloids with a modified tryptamine chain] Lewin G. **J Nat Prod** 1995 Jul; 58(7):1089–91 **(Fre)**
[Combined effect of Paclitaxel and ionizing radiation. Experimental data of in-vitro and in-vivo models] Rübe C, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:2–5 (30 ref.) **(Ger)**
[The results of chemosensitivity test for clear cell adenocarcinoma of the ovary] Shimizu Y, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):945–7 **(Jpn)**

THERAPEUTIC USE

Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo. Sharad AC, et al. **Acta Oncol** 1996;35(1):95–100
Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Bruno S, et al. **Am J Clin Oncol** 1995 Oct;18(5):392–6
Long-term cure of a non-small-cell lung cancer treated by monochemotherapy. Jacoulet P, et al. **Am J Clin Oncol** 1996 Jun;19(3):260–2
Study affirms primacy of paclitaxel-cisplatin in advanced ovarian cancer [news] **Am J Health Syst Pharm** 1996 Mar 1;53(5):498
Lung cancer chemotherapy. Response-survival relationship depends on the method of chest tumor response evaluation. Pujol JL, et al. **Am J Respir Crit Care Med** 1996 Jan; 153(1):243–9
Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer. Alberola V, et al. **Ann Oncol** 1995;6 Suppl 3:S49–52
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Fumoleau P, et al. **Ann Oncol** 1996 Feb;7(2):165–71
Intralesional vinblastine for treating AIDS-associated Kaposi's sarcoma of the oropharynx and larynx. Friedman M, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):272–4
Vinorelbine: a new antineoplastic drug for the treatment of non-small-cell lung cancer. Jones SF, et al. **Ann Pharmacother** 1996 May;30(5):501–6 (29 ref.)
The role of vindesine in oncology--recommendations after 10 years' experience. Dancey J, et al. **Anticancer Drugs** 1995 Oct;6(5):625–36 (122 ref.)
Docetaxel: meeting the challenge of non-small cell lung cancer management. Le Chevalier T. **Anticancer Drugs** 1995 Jul;6 Suppl 4:13–7 (23 ref.)
Docetaxel: a new defence in the management of breast cancer. Piccart M. **Anticancer Drugs** 1995 Jul;6 Suppl 4:7–11 (12 ref.)
Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Rougier P. **Anticancer Drugs** 1995 Jul;6 Suppl 4:25–9 (16 ref.)
Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas. Verweij J. **Anticancer Drugs** 1995 Jul;6 Suppl 4:19–24
Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Friess H, et al. **Anticancer Res** 1996 Mar-Apr;16(2):915–20
Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer. Phillips KA, et al. **Aust N Z J Med** 1995 Aug;25(4):337–43
Preparation and antitumor activities of beta-(1-->6) branched (1-->3)-beta-D-glucan derivatives. Usui S, et al. **Biol Pharm Bull** 1995 Dec;18(12):1630–6
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. O'Brien S, et al. **Blood** 1995 Nov 1;86(9):3322–6
Microtubule changes in hematologic malignant cells treated with paclitaxel and comparison with vincristine cytotoxicity. Hirose Y, et al. **Blood Cells Mol Dis** 1995; 21(2):119–30
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Adachi I, et al. **Br J Cancer** 1996 Jan;73(2):210–6
Current perspectives on camptothecins in cancer treatment [editorial] Dancey J, et al. **Br J Cancer** 1996 Aug; 74(3):327–38 (146 ref.)
Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer. Kerr DJ, et al. **Br J Cancer** 1995 Nov; 72(5):1267–9
Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent. Kobayashi H, et al. **Br J Cancer** 1995 Nov;72(5):1131–7
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Vassal G, et al. **Br J Cancer** 1996 Aug;74(4):537–45
Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. Terenzi A, et al. **Br J Haematol** 1996 Mar;92(4):872–9
Phase II study of oral etoposide for patients with advanced breast cancer. Atienza DM, et al. **Cancer** 1995 Dec 15; 76(12):2485–90 (39 ref.)
A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Balcerzak SP, et al. **Cancer** 1995 Dec 1;76(11):2248–52
Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Chang YF, et al. **Cancer** 1996 Jan 1;77(1):14–8
CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel? Davelaar EM, et al. **Cancer** 1996 Jul 1; 78(1):118–27
Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model. Davol P, et al. **Cancer** 1995 Jul 1; 76(1):79–85
In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma cell lines. Jaakkola M, et al. **Cancer** 1996 May 1;77(9):1940–6
Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Jain N, et al. **Cancer** 1996 May 1;77(9):1797–808
Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Patel SR, et al. **Cancer** 1996 Aug 15;78(4):741–4
Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. Murren JR, et al. **Cancer Chemother Pharmacol** 1996;38(1):65–70
Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer. Robert F, et al. **Cancer Chemother Pharmacol** 1996; 38(5):459–65
Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes. Saijo N, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S11–5 (21 ref.)
The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains. Ghetie V, et al. **Cancer Lett** 1995 Nov 27;98(1):97–101
Inhibitory effects of green tea infusion on in vitro invasion and in vivo metastasis of mouse lung carcinoma cells. Sazuka M, et al. **Cancer Lett** 1995 Nov 27;98(1):27–31
Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide. Kubo A, et al. **Cancer Res** 1996 Mar 15;56(6):1232–6
Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Potmesil M, et al. **Cancer Res** 1995 Dec 1;55(23):5637–41

Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Utsugi T, et al. **Cancer Res** 1996 Jun 15;56(12):2809-14

Taxoid compounds in breast cancer: current status and future prospects. Piccart MJ. **Cancer Treat Res** 1995;78:185-207 (56 ref.)

Vinorelbine: an overview. Johnson SA, et al. **Cancer Treat Rev** 1996 Mar;22(2):127-42 (88 ref.)

Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. Pronk LC, et al. **Cancer Treat Rev** 1995 Sep;21(5):463-78 (93 ref.)

Prevention of 20-methylcholanthrene-induced sarcoma by a mistletoe extract, Iscador. Kuttan G, et al. **Carcinogenesis** 1996 May;17(5):1107-9

Taking the path of combining traditional Chinese medicine with Western medicine in cancer research and control. Yu R. **Chin Med J (Engl)** 1995 Oct;108(10):732-3 (0 ref.)

Vincristine as therapy for idiopathic thrombocytopenic purpura in patients infected with human immunodeficiency virus [letter] Ena J, et al. **Clin Infect Dis** 1996 May; 22(5):880-1

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Fulton B, et al. **Drugs** 1996 Jun;51(6):1075-92 (86 ref.)

CPT-11 (irinotecan) in the treatment of colorectal cancer. Armand JP, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1283-7 (41 ref.)

An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eisenhauer EA, et al. **Eur J Cancer** 1995;31A Suppl 4:S11-3

A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Fountzilas G, et al. **Eur J Cancer** 1996 Jan;32A(1):47-51

Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. Kaye SB, et al. **Eur J Cancer** 1995;31A Suppl 4:S14-7

Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Klaassen U, et al. **Eur J Cancer** 1996 Mar; 32A(3):547-9

Docetaxel in stage III and IV non-small cell lung cancer. Rigas JR. **Eur J Cancer** 1995;31A Suppl 4:S18-20

Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Tanaka M, et al. **Eur J Cancer** 1996 Feb;32A(2):226-30

Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. Verweij J, et al. **Eur J Cancer** 1995;31A Suppl 4:S21-4

A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis. Balat O, et al. **Eur J Gynaecol Oncol** 1996; 17(3):232-3

Extra-pelvic metastasis of endometrioid carcinoma; resistance to chemo-radiation therapy—response to paclitaxel treatment. Case report. Hornreich G, et al. **Eur J Gynaecol Oncol** 1995;16(4):263-7

Absence of an association between G-CSF support and clinical response in heavily pre-treated ovarian cancer patients receiving salvage chemotherapy with paclitaxel (Taxol). Johnston CM, et al. **Eur J Gynaecol Oncol** 1995; 16(4):251-7

Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Tresukosol D, et al. **Eur J Gynaecol Oncol** 1996;17(3):188-91

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Ball HG, et al. **Gynecol Oncol** 1996 Aug;62(2):278-81

Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases. Jones WB, et al. **Gynecol Oncol** 1996 Apr;61(1):126-30

Management of low-risk gestational trophoblastic tumors with etoposide (VP16) in patients resistant to methotrexate. Mangili G, et al. **Gynecol Oncol** 1996 May;61(2):218-20

Concomitant immunity against tumor development is enhanced by the oral administration of a kampo medicine, Hochu-ekki-to (TJ-41: Bu-Zhong-Yi-Qi-Tang). Harada M, et al. **Immunopharmacol Immunotoxicol** 1995 Nov; 17(4):687-703

Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines. Zhou DC, et al. **Int J Cancer** 1996 Jan 26;65(3):365-71

Prevention and therapy of mammary cancer by monoterpenes. Gould MN. **J Cell Biochem Suppl** 1995; 22:139-44

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy [see comments] Bedikian AY, et al. **J Clin Oncol** 1995 Dec;13(12):2895-9. Comment in: J Clin Oncol 1995 Dec;13(12):2865-7.

Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. Conroy T, et al. **J Clin Oncol** 1996 Jan;14(1):164-70

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. Conti JA, et al. **J Clin Oncol** 1996 Mar;14(3):709-15

Docetaxel. Cortes JE, et al. **J Clin Oncol** 1995 Oct; 13(10):2643-55 (104 ref.)

Docetaxel: an active drug for squamous cell carcinoma of the head and neck. Dreyfuss AI, et al. **J Clin Oncol** 1996 May;14(5):1672-8

Docetaxel: current status and future prospects [editorial; comment] Eisenhauer E. **J Clin Oncol** 1995 Dec; 13(12):2865-8. Comment on: J Clin Oncol 1995 Dec;13(12):2879-85. Comment on: J Clin Oncol 1995 Dec;13(12):2886-94. Comment on: J Clin Oncol 1995 Dec;13(12):2895-9.

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. Francis P, et al. **J Clin Oncol** 1995 Dec; 13(12):2961-7

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. Hudis CA, et al. **J Clin Oncol** 1996 Jan;14(1):58-65

Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. Jones DV Jr, et al. **J Clin Oncol** 1996 Aug;14(8):2306-10

Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. Kunitoh H, et al. **J Clin Oncol** 1996 May;14(5):1649-55

Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. McGuire WP, et al. **J Clin Oncol** 1996 Mar;14(3):792-5

Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. Markman M, et al. **J Clin Oncol** 1996 Mar; 14(3):796-9

Phase II study of paclitaxel in patients with recurrent malignant glioma. Prados MD, et al. **J Clin Oncol** 1996 Aug;14(8):2316-21

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer [see comments] Ravdin PM, et al. **J Clin Oncol** 1995 Dec;13(12):2879-85. Comment in: J Clin Oncol 1995 Dec;13(12):2865-7.

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. Rothenberg ML, et al. **J Clin Oncol** 1996 Apr;14(4):1128-35

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. Trudeau ME, et al. **J Clin Oncol** 1996 Feb; 14(2):422-8

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer [see comments] Valero V, et al. **J Clin Oncol** 1995 Dec; 13(12):2886-94. Comment in: J Clin Oncol 1995 Dec;13(12):2865-7.

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. Weber BL, et al. **J Clin Oncol** 1995 Nov;13(11):2722-30

Paclitaxel in patients with platinum-resistant ovarian cancer: a selected review of literature and clinical experience. Kudelka AP, et al. **J Med Assoc Thai** 1996 Apr;79(4):240-5 (26 ref.)

Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. Fulton D, et al. **J Neurooncol** 1996 Feb;27(2):149-55

Intralesional vinblastine injections for the treatment of oral Kaposi's sarcoma: report of 10 patients with 2-year follow-up. McCormick SU. **J Oral Maxillofac Surg** 1996 May;54(5):583-7; discussion 588-9

Camptothecins: new enthusiasm for an old drug [news] Rowe PM. **Lancet** 1996 Mar 30;347(9005):892

Response of B-cell lymphoma to a combination of bispecific antibodies and saporin. French RR, et al. **Leuk Res** 1996 Jul;20(7):607-17

Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Feldman EJ, et al. **Leukemia** 1996 Jan;10(1):40-2

Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study of paclitaxel. Seiter K, et al. **Leukemia** 1995 Nov;9(11):1961-6

New drugs for treating small cell lung cancer. Ettinger DS. **Lung Cancer** 1995 Jun;12 Suppl 3:S53-61 (20 ref.)

Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Francis PA, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S163-72 (40 ref.)

Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Gatzemeier U, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S101-6

Etoposide: sometimes the drug of choice in Wegener's granulomatosis? Pedersen RS, et al. **Nephrol Dial Transplant** 1995;10(9):1759-61

Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Bruzzone M, et al. **Oncology** 1996 Sep-Oct;53(5):349-53

Navelbine promising as a radiosensitizer in non-small-cell lung cancer [news] **Oncology (Huntingt)** 1995 Aug;9(8):783

Current status of vinorelbine for breast cancer. Smith GA. **Oncology (Huntingt)** 1995 Aug;9(8):767-73; discussion 774, 776, 779 (41 ref.)

Etoposide in Langerhans cell histiocytosis in children: a preliminary experience. Basade MM, et al. **Pediatr Hematol Oncol** 1996 Mar-Apr;13(2):159-62

Taxoids: new weapons against cancer. Nicolaou KC, et al. **Sci Am** 1996 Jun;274(6):94-8

The activity of paclitaxel in gastrointestinal tumors. Ajani JA, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):46-50; discussion 51-3

Paclitaxel: current developmental approaches of the National Cancer Institute. Arbuck SG. **Semin Oncol** 1995 Dec;22(6 Suppl 15):55-63

CPT-11: clinical experience in phase I studies. Armand JP. **Semin Oncol** 1996 Feb;23(1 Suppl 3):27-33 (22 ref.)

Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Bissery MC, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 13):3-16

Future developments for paclitaxel in the treatment of breast cancer. Bonadonna G. **Semin Oncol** 1996 Feb;23(1 Suppl 1):65-8

Docetaxel (Taxotere) in combination: a step forward. Burris HA 3rd, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 13):35-40

The role of taxanes in the treatment of breast cancer. Capri G, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):68-75 (62 ref.)

Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. Choy H, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):38-44 (41 ref.)

Update: vinorelbine (navelbine) in non-small cell lung cancer. Crawford J. **Semin Oncol** 1996 Apr;23(2 Suppl 5):2-7 (24 ref.)

Single-agent paclitaxel at first relapse following adjuvant chemotherapy for breast cancer. Davidson NG. **Semin Oncol** 1995 Dec;22(6 Suppl 14):2-6

Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial. Gatzemeier U, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):24-8

Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy. Hainsworth JD, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):45-9

Paclitaxel and simultaneous radiation in the treatment of stage III A/B non-small cell lung cancer. Havemann K, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):19-22

Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer. Hillner BE, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):25-30

Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Paine GD, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):35-9

Taxoids: effective agents in anthracycline-resistant breast cancer. Ravdin PM. **Semin Oncol** 1995 Dec;22(6 Suppl 13):29-34 (34 ref.)

Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Rosell R, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):12-8

The role of paclitaxel in the therapy of bladder cancer. Roth BJ. **Semin Oncol** 1995 Oct;22(5 Suppl 12):33-40 (73 ref.)

CPT-11: an original spectrum of clinical activity. Rothenberg ML. **Semin Oncol** 1996 Feb;23(1 Suppl 3):21-6 (38 ref.)

CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Rougier P, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 3):34-41 (35 ref.)

Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. Seidman AD, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):108-16 (53 ref.)

The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience. Thigpen T, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):23-31 (30 ref.)

Docetaxel (Taxotere): an overview of first-line monotherapy. Trudeau ME. **Semin Oncol** 1995 Dec;22(6 Suppl 13):17-21

Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer. van Oosterom AT. **Semin Oncol** 1995 Dec;22(6 Suppl 13):22-8

The role of paclitaxel in the treatment of head and neck cancer. Vokes EE, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):8-12 (27 ref.)

Recurrent breast cancer treated successfully with mitomycin-C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel—a case report. Sekine I, et al. **Tohoku J Exp Med** 1996 Mar; 178(3):331-7

Treatment of X-linked lymphoproliferative disease (Duncan disease) with high-dose methylprednisolone and etoposide (VP-16). Gürgey A, et al. **Turk J Pediatr** 1996 Apr-Jun; 38(2):217-22

[A preliminary observation of preventive and blocking effect of Gynostemma pentaphyllum (Thunb) Makino on esophageal cancer in rats] Wang C, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):430-2 (Eng. Abstr.) **(Chi)**

[Taxans in the treatment of ovarian cancer] Tuxen MK, et al. **Ugeskr Laeger** 1996 Jul 1;158(27):3951-2 **(Dan)**

[Paclitaxel, a new anticancer drug] Jekunen A, et al. **Duodecim** 1994;110(13):1235-40 (39 ref.) **(Fin)**

[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials] Couteau C, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):3-10 (Eng. Abstr.) **(Fre)**

[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy] Fumoleau P, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):629-36 (58 ref.) (Eng. Abstr.) **(Fre)**

[Preclinical and clinical results in the simultaneous

radiochemotherapy of head and neck tumors with Paclitaxel] Hoffmann W, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:15–20 **(Ger)**

[Taxol and simultaneous radiotherapy in stage IIIA and IIIB, locally advanced, non-small-cell bronchial carcinoma. Phase-I clinical trial] Vogt HG, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:9–15 **(Ger)**

[Paclitaxel and simultaneous radiotherapy in stage-III non-small-cell bronchial carcinoma] Wolf M, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:5–8 **(Ger)**

[Paclitaxel (Taxol)—drug of choice in ovarian cancer] Fishman A. **Harefuah** 1996 Apr 15;130(8):557–60 (47 ref.) **(Heb)**

[Clinical effects and immunological analysis of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion of gastric carcinoma] Hazama S, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1595–7 (Eng. Abstr.) **(Jpn)**

[Current status of phase I and phase II trials—experience in Habikino from 1988 to 1994] Masuda N, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(2):166–71 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion] Noda K, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):317–25 (Eng. Abstr.) **(Jpn)**

[Early phase II study of BMS-181339 (paclitaxel) in patients with non-small cell lung cancer. BMS-181339 Non-Small Cell Lung Cancer Study Group] Yoneda S, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):695–701 (Eng. Abstr.) **(Jpn)**

[Studies on the bioactive constituents of Aurantii Fructus Immaturus] Satoh Y, et al. **Yakugaku Zasshi** 1996 Mar; 116(3):244–50 (Eng. Abstr.) **(Jpn)**

TOXICITY

Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. McLeod HL, et al. **Br J Cancer** 1996 Aug;74(4):508–12

Effect of the exposure dose of etoposide on the cell growth and cell kinetics of human ovarian cancer cells. Ohishi Y, et al. **Cancer Chemother Pharmacol** 1996;38(2):141–6

Influence of various concentrations of taxol on cell survival, micronuclei induction, and LDH activity in cultured V79 cells. Jagetia GC, et al. **Cancer Lett** 1995 Sep 25; 96(2):195–200

Cytotoxic effects of sinococuline. Liu WK, et al. **Cancer Lett** 1996 Feb 6;99(2):217–24

Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Blagosklonny MV, et al. **Cancer Res** 1996 Apr 15;56(8):1851–4

Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Chresta CM, et al. **Cancer Res** 1996 Apr 15;56(8):1834–41

Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Fukuda M, et al. **Cancer Res** 1996 Feb 15;56(4):789–93

Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Hennequin C, et al. **Cancer Res** 1996 Apr 15;56(8):1842–50

Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Jordan MA, et al. **Cancer Res** 1996 Feb 15;56(4):816–25

Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Takasuna K, et al. **Cancer Res** 1996 Aug 15;56(16):3752–7

Detection of centromeres in vinblastine- and radiation-induced micronuclei of human lymphocytes using FISH with an alpha satellite pancentromeric DNA probe. Huber R, et al. **Environ Mol Mutagen** 1996; 27(2):105–9

Cytotoxic effects of FGF2-saporin on bovine epithelial lens cells in vitro. Behar-Cohen FF, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2425–33

Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis. Boer HH, et al. **J Neurooncol** 1995;25(1):49–57

Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. Akerley W, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S107–15

Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Gatzemeier U, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S101–6

Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. European Lung Cancer Working Party. Klastersky J, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S117–25

Numerical and structural chromosome aberrations induced by etoposide (VP16) during oocyte maturation of mice: transmission to one-cell zygotes and damage to dictyate oocytes. Mailhes JB, et al. **Mutagenesis** 1996 Jul; 11(4):357–61

Treatment of mice with a novel antineoplastic agent taxol before irradiation increases the frequency of micronuclei in the bone marrow. Jagetia GC, et al. **Mutat Res** 1996 Feb 1;349(2):219–27

Genetic toxicology of mitotic spindle inhibitors used as anticancer drugs. Kirsch-Volders M, et al. **Mutat Res** 1996 Aug 17;355(1-2):103–28 (220 ref.)

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis [see comments] Wahl AF, et al. **Nat Med** 1996 Jan;2(1):72–9. Comment in: Nat Med 1996 Jul;2(7):724–5.

Embryotoxicity of free and liposome-encapsulated taxol in the chick. Scialli AR, et al. **Pharmacology** 1995 Sep; 51(3):145–51

Assays of the biological activities of two fatty acid derivatives formed in the edible mushrooms cantharellus cibarius and C. tubaeformis as a response to injury. Anke H, et al. **Planta Med** 1996 Apr;62(2):181–3

An estimation of Citrullus colocynthis toxicity for chicks. Bakhiet AO, et al. **Vet Hum Toxicol** 1995 Aug;37(4):356–8

ANTINEOPLASTIC ANTIBIOTICS see **ANTIBIOTICS, ANTINEOPLASTIC**

ANTINEOPLASTIC ANTIMETABOLITES see **ANTIMETABOLITES, ANTINEOPLASTIC**

ANTINEOPLASTIC DRUG COMBINATIONS see **ANTINEOPLASTIC AGENTS, COMBINED**

ANTINEOPLASTIC DRUG RESISTANCE see **DRUG RESISTANCE, NEOPLASM**

ANTINEOPLASTICS, BOTANICAL see **ANTINEOPLASTIC AGENTS, PHYTOGENIC**

ANTINOCICEPTIVE AGENTS see **ANALGESICS**

ANTINUCLEAR ANTIBODIES see **ANTIBODIES, ANTINUCLEAR**

ANTINUCLEAR ANTIBODY TEST, FLUORESCENT see **FLUORESCENT ANTIBODY TECHNIQUE**

ANTINUCLEAR FACTORS see **ANTIBODIES, ANTINUCLEAR**

ANTIONCOGENES see **GENES, SUPPRESSOR, TUMOR**

ANTIOXIDANTS

see related
OXIDATIVE STRESS
PHARMACEUTIC AIDS

The enzymatic antioxidant system in blood and glutathione status in human immunodeficiency virus (HIV)-infected patients: effects of supplementation with selenium or beta-carotene. Delmas-Beauvieux MC, et al. **Am J Clin Nutr** 1996 Jul;64(1):101–7

Antioxidant status in cystic fibrosis patients [letter; comment] Winklhofer-Roob BM. **Am J Clin Nutr** 1996 Jan; 63(1):138–9. Comment on: Am J Clin Nutr 1995 Apr;61(4):843–7.

Catalase and glutathione reductase protection of human alveolar macrophages during oxidant exposure in vitro. Pietarinen P, et al. **Am J Respir Cell Mol Biol** 1995 Oct; 13(4):434–41

The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data [see comments] Jha P, et al. **Ann Intern Med** 1995 Dec 1; 123(11):860–72 (55 ref.). Comment in: Ann Intern Med 1995 Dec 1;123(11):887.

Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Salah N, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):339–46

Micronutrients, antioxidants and risk of cancer. Schorah CJ. **Bibl Nutr Dieta** 1995;(52):92–107 (101 ref.)

Glutathione-linked thiol peroxidase activity of human serum albumin: a possible antioxidant role of serum albumin in blood plasma. Cha MK, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):619–25

Inhibition of the thiol-specific antioxidant activity of rat liver MSP23 protein by hemin. Ishii T, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):970–5

Role of bilirubin as an antioxidant in an ischemia-reperfusion of rat liver and induction of heme oxygenase. Yamaguchi T, et al. **Biochem Biophys Res Commun** 1996 Jun 5; 223(1):129–35

Anti-oxidants and apoptosis. McGowan AJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):229–33 (35 ref.)

The rat liver glutathione S-transferase Ya subunit gene: characterization of the binding properties of a nuclear protein from HepG2 cells that has high affinity for the antioxidant response element. Liu S, et al. **Biochemistry** 1996 Sep 3;35(35):11517–21

Antioxidative activity of ubiquinol-10 at physiologic concentrations in human low density lipoprotein. Kontush A, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):177–87

Effect of vitamin E, vitamin C and beta-carotene on LDL oxidation and atherosclerosis. Jialal I, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:97G–103G (97 ref.)

Antioxidants in the Mediterranean diet. Mancini M, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:105G–109G (20 ref.)

Interaction of family history of breast cancer and dietary antioxidants with breast cancer risk (New York, United States). Ambrosone CB, et al. **Cancer Causes Control** 1995 Sep;6(5):407–15

Anticancer and antioxidant activity of synthetic chalcones and related compounds. Anto RJ, et al. **Cancer Lett** 1995 Oct 20;97(1):33–7

Hibiscus protocatechuic acid protects against oxidative damage induced by tert-butylhydroperoxide in rat primary hepatocytes. Tseng TH, et al. **Chem Biol Interact** 1996 Aug 14;101(2):137–48

Low-density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. Jialal I, et al. **Clin Chem** 1996 Apr;42(4):498–506 (92 ref.)

The effect of simple hypothermic preservation with Trolox and ascorbate on lipid peroxidation in dog kidneys. McAnulty JF, et al. **Cryobiology** 1996 Apr;33(2):217–25

Photoprotective and antiinflammatory effects of topical glycolic acid. Perricone NV, et al. **Dermatol Surg** 1996 May;22(5):435–7

Aminophylline: could it act as an antioxidant in vivo? Lapenna D, et al. **Eur J Clin Invest** 1995 Jul;25(7):464–70

Functional diversity of the pineal hormone melatonin: its role as an antioxidant. Reiter RJ. **Exp Clin Endocrinol Diabetes** 1996;104(1):10–6 (52 ref.)

Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. Antolín I, et al. **FASEB J** 1996 Jun;10(8):882–90

A potential anti-oxidant protein in a ferrous iron-oxidizing Sulfolobus species. Burton NP, et al. **FEMS Microbiol Lett** 1995 Dec 1;134(1):91–5

Antioxidative role of ocular melanin pigment in the model of lens induced uveitis. Bilgihan A, et al. **Free Radic Biol Med** 1995 Dec;19(6):883–5

Quenching of reactive oxidative species by probucol and comparison with other antioxidants. Bisby RH, et al. **Free Radic Biol Med** 1996;20(3):411–20

Inhibition of hydroxyl radical production by lactobionate, adenine, and tempol. Charloux C, et al. **Free Radic Biol Med** 1995 Nov;19(5):699–704

Impact of vitamin E supplement in standard laboratory animal diet on microvascular manifestation of ischemia/reperfusion injury. Willy C, et al. **Free Radic Biol Med** 1995 Dec;19(6):919–26

Serum beta-carotene, vitamin E, vitamin C and malondialdehyde levels in several types of cancer. Torun M, et al. **J Clin Pharm Ther** 1995 Oct;20(5):259–63

Repression of acute gastric mucosal lesions by antioxidant-containing fraction from fermented products of okara (bean-curd residue). Yokota T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Apr;42(2):167–72

Antioxidant activity of dioscorea and dehydroepiandrosterone (DHEA) in older humans. Araghiniknam M, et al. **Life Sci** 1996;59(11):PL147–57

Dietary antioxidants in disease prevention. Gordon M. **Nat Prod Rep** 1996 Aug;13(4):265–73 (130 ref.)

Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Kaul N, et al. **Nutrition** 1995 Sep-Oct;11(5 Suppl):551–4

Radioprotective and antioxidant effects of zinc aspartate and bio-normalizer in children with acute myelo- and lympholeukemias. Korkina L, et al. **Nutrition** 1995 Sep-Oct;11(5 Suppl):555–8

Lazaroids protect isolated rat pancreatic acinar cells against damage induced by free radicals. Niederau C, et al. **Pancreas** 1995 Aug;11(2):107–21

Ultraviolet-B- and ozone-induced biochemical changes in antioxidant enzymes of Arabidopsis thaliana. Rao MV, et al. **Plant Physiol** 1996 Jan;110(1):125–36

Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Mohora M, et al. **Rom J Intern Med** 1995 Jul-Dec;33(3-4):237–42

Antioxidant protection of egg lecithin liposomes during sonication. Gabrielska J, et al. **Z Naturforsch [C]** 1995 Jul-Aug;50(7-8):561–4

[Antioxidants in nutrition and their importance in the anti-/oxidative balance in the immune system] Biesalski HK, et al. **Immun Infekt** 1995 Oct;23(5):166–73 (72 ref.) (Eng. Abstr.) **(Ger)**

[Lipid peroxidation and antioxidant system in neurovascular disorders among poultry farm workers] Dobzhanskiĭ IS, et al. **Med Tr Prom Ekol** 1995;(10):37–9 (Eng. Abstr.) **(Rus)**

[Effects of antioxidant state on individual susceptibility to silicosis (an experimental study)] Kislitsina NS, et al. **Med Tr Prom Ekol** 1995;(10):31–4 (Eng. Abstr.) **(Rus)**

[The tissue antioxidant system in the early postnatal development of rats] L'vova SP, et al. **Ontogenez** 1996 May-Jun;27(3):204–7 (Eng. Abstr.) **(Rus)**

[The activity of the glutathione antioxidative system in the blood of patients with acute nonepidemic parotitis] Dolgov SN, et al. **Stomatologiia (Mosk)** 1995;74(3):38–40 (Eng. Abstr.) **(Rus)**

[A comparative analysis of the oxygen-binding and antioxidant properties of the blood of laboratory animals and the muskrat Ondatra zibethica] Korobov VN, et al. **Zh Evol Biokhim Fiziol** 1995 May-Jun;31(3):369–72 (Eng. Abstr.) **(Rus)**

[New findings on reactive oxidative materials and their role in biological systems] Jovičić A, et al. **Vojnosanit Pregl** 1995 Nov-Dec;52(6):579–84 (24 ref.) **(Scr)**

[Lipid peroxidation and antioxidant system activity in the brain, stomach and heart tissues and blood serum of rats under stress] Voronych NM, et al. **Fiziol Zh** 1994 Sep-Dec; 40(5-6):114–7 (Eng. Abstr.) **(Ukr)**

[The indices of the antioxidant system and the status of the cerebral blood supply in patients with an ischemic stroke

on apitherapy] Samoliuk VA. **Vrach Delo** 1995 Jan–Feb; (1–2):68–70 (Eng. Abstr.) **(Ukr)**

ADMINISTRATION & DOSAGE

Effects of alpha–tocopherol and beta–carotene supplements on cancer incidence in the Alpha–Tocopherol Beta–Carotene Cancer Prevention Study. Albanes D, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1427S–1430S

Considerations of the scientific substantiation for antioxidant vitamins and beta–carotene in disease prevention. Blumberg JB. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1521S–1526S (59 ref.)

Evidence from cancer intervention and biomarker studies and the development of biochemical markers. Bowen PE, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1403S–1409S (54 ref.)

Antioxidants in oral cancer prevention. Garewal H. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1410S–1416S (54 ref.)

Antioxidant vitamin–cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Hennekens CH, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1377S–1380S (26 ref.)

Epidemiologic evidence of a role of carotenoids in cardiovascular disease prevention. Kohlmeier L, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1370S–1376S (38 ref.)

Prevention of cervical intraepithelial neoplasia and cervical cancer. Meyskens FL Jr, et al. **Am J Clin Nutr** 1995 Dec; 62(6 Suppl):1417S–1419S (24 ref.)

Evidence for protection against age–related macular degeneration by carotenoids and antioxidant vitamins. Snodderly DM. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1448S–1461S (153 ref.)

Relations among aging, antioxidant status, and cataract. Taylor A, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1439S–1447S (80 ref.)

Epidemiologic evidence for beta–carotene and cancer prevention. van Poppel G, et al. **Am J Clin Nutr** 1995 Dec; 62(6 Suppl):1393S–1402S (127 ref.)

Possible immunologic involvement of antioxidants in cancer prevention. Zhang YH, et al. **Am J Clin Nutr** 1995 Dec; 62(6 Suppl):1477S–1482S

Dietary antioxidants and cognitive function in a population–based sample of older persons. The Rotterdam Study. Jama JW, et al. **Am J Epidemiol** 1996 Aug 1; 144(3):275–80

Dietary vitamin C and beta–carotene and risk of death in middle–aged men. The Western Electric Study. Pandey DK, et al. **Am J Epidemiol** 1995 Dec 15;142(12):1269–78

Retinol, antioxidant vitamins, and cancers of the upper digestive tract in a prospective cohort study of postmenopausal women. Zheng W, et al. **Am J Epidemiol** 1995 Nov 1;142(9):955–60

Antioxidants and age–related eye disease. Current and future perspectives. Christen WG, et al. **Ann Epidemiol** 1996 Jan; 6(1):60–6 (79 ref.)

A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group [see comments] Manson JE, et al. **Ann Epidemiol** 1995 Jul;5(4):261–9. Comment in: Ann Epidemiol 1995 Jul;5(4):333–5.

Dietary lipids and antioxidants in Parkinson's disease: a population–based, case–control study. Logroscino G, et al. **Ann Neurol** 1996 Jan;39(1):89–94

Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Keli SO, et al. **Arch Intern Med** 1996 Mar 25;156(6):637–42

Association of zinc and antioxidant nutrients with age–related maculopathy. Mares–Perlman JA, et al. **Arch Ophthalmol** 1996 Aug;114(8):991–7

Effect of the antioxidant N,N'–diphenyl 1,4–phenylenediamine (DPPD) on atherosclerosis in apoE–deficient mice. Tangirala RK, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1625–30

Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? McAlindon TE, et al. **Arthritis Rheum** 1996 Apr; 39(4):648–56

Response of [Ah] battery genes to compounds that protect against menadione toxicity. Vasiliou V, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1885–91

Hyperbaric oxygen therapy and oxygen toxicity. Ortolani O, et al. **Boll Soc Ital Biol Sper** 1995 Nov–Dec; 71(11–12):325–31

Vitamin E incorporated into a very–low–fat meal is absorbed from the intestine of young rats. Brink EJ, et al. **Br J Nutr** 1996 Jun;75(6):939–48

Glutathione S–transferase mu genotype, diet, and smoking as determinants of sister chromatid exchange frequency in lymphocytes. Cheng TJ, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul–Aug; 4(5):535–42

Antioxidant supplementation decreases oxidative DNA damage in human lymphocytes. Duthie SJ, et al. **Cancer Res** 1996 Mar 15;56(6):1291–5

Dietary antioxidants and carotid artery wall thickness. The ARIC Study. Atherosclerosis Risk in Communities Study. Kritchevsky SB, et al. **Circulation** 1995 Oct 15; 92(8):2142–50

The effect of zinc supplementation on plasma lipids and low–density lipoprotein oxidation in males. Gatto LM, et al. **Free Radic Biol Med** 1995 Oct;19(4):517–21

Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis: improvement during vitamin E supplementation. Winklhofer–Roob BM, et al. **Free Radic Biol Med** 1995 Dec;19(6):725–33

Do dietary and supplementary intakes of antioxidants differ with smoking status? Zondervan KT, et al. **Int J Epidemiol** 1996 Feb;25(1):70–9

Dietary antioxidants and plasma lipids: the Cardia Study. Slattery ML, et al. **J Am Coll Nutr** 1995 Dec;14(6):635–42

Prevention of phorbol myristate acetate–induced acute lung injury by alpha–tocopherol liposomes. Suntres ZE, et al. **J Drug Target** 1995;3(3):201–8

Fish oil and antioxidants after heart transplantation: future strategies or eye of newt and wing of bat revisited? Young JB. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S250–4 (29 ref.)

Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. Herrick AL, et al. **J Rheumatol** 1996 Apr;23(4):650–3

Cardioprotection in patients undergoing chemo– and/or radiotherapy for neoplastic disease. A pilot study. Wagdi P, et al. **Jpn Heart J** 1996 May;37(3):353–9

Beta–carotene takes a collective beating [news] [see comments] Rowe PM. **Lancet** 1996 Jan 27;347(8996):249. Comment in: Lancet 1996 Apr 6;347(9006):967–8.

Caution with beta–carotene supplements [letter; comment] Woodall AA, et al. **Lancet** 1996 Apr 6;347(9006):967–8. Comment on: Lancet 1996 Jan 27;347(8996):249.

Dietary supplements of antioxidants reduce hprt mutant frequency in splenocytes of aging mice. Gaziev AI, et al. **Mutat Res** 1995 Oct;338(1–6):77–86

Antioxidant vitamins, cancer, and cardiovascular disease [letter] DeGrand D. **N Engl J Med** 1996 Oct 3;335(14):1066; discussion 1068–9

Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women [see comments] Kushi LH, et al. **N Engl J Med** 1996 May 2;334(18):1156–62. Comment in: N Engl J Med 1996 May 2;334(18):1189–90.

Antioxidant vitamins, cancer, and cardiovascular disease [letter] Pietrzik K. **N Engl J Med** 1996 Oct 3; 335(14):1065–6; discussion 1067–8

Future vitamin and antioxidant RDAs for health promotion. Lachance PA. **Prev Med** 1996 Jan–Feb;25(1):46–7

The effect of lazaroid (U74500A), a novel inhibitor of lipid peroxidation, on 24–hour heart preservation. A study based on a working model using cross–circulated blood–perfused rabbit hearts. Nishida T, et al. **Transplantation** 1996 Jan 27;61(2):194–9

Lazaroid U–74389G for 48–hour canine liver preservation. Todo S, et al. **Transplantation** 1996 Jan 27;61(2):189–94

Antioxidative vitamin treatment: effect on lipid peroxidation and limb swelling after revascularization operations. Rabl H, et al. **World J Surg** 1995 Sep–Oct;19(5):738–44

[Free oxygen radicals during transplantation surgery] Bolbjerg ML, et al. **Ugeskr Laeger** 1995 Oct 16; 157(42):5841–5 (40 ref.) (Eng. Abstr.) **(Dan)**

[Beta–carotene—problems in health studies of simple antioxidants (letter)] Volkmann H. **Ugeskr Laeger** 1996 Jun 24;158(26):3794–5 **(Dan)**

[Antioxidative vitamins and cataracts in the elderly] Heseker H. **Z Ernahrungswiss** 1995 Sep;34(3):167–76 (68 ref.) (Eng. Abstr.) **(Ger)**

[Can vitamin E prevent development of coronary heart disease?] Nguyen KN, et al. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1109–13 (61 ref.) (Eng. Abstr.) **(Nor)**

[Possibilities of the use of oxymethacil as an antioxidant in the prevention of intoxication in industrial surroundings and ecologically unhealthy areas] Maksimov GG, et al. **Med Tr Prom Ekol** 1995;(12):14–7 (Eng. Abstr.) **(Rus)**

[Energy metabolic changes in the cardiorespiratory system of patients with chronic bronchitis under the action of galvanization and dalargin electrophoresis on the area of the chest cavity] Mizin VI. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Jul–Aug;(4):7–10 (Eng. Abstr.) **(Rus)**

[Supplementation of DL–alpha–tocopherol acetate in children with chronic cholestasis and vitamin E deficiency] Velasco Benítez CA, et al. **Rev Gastroenterol Mex** 1996 Jan–Mar;61(1):14–8 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Safety of antioxidant vitamins and beta–carotene. Diplock AT. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1510S–1516S (56 ref.)

Antioxidants and cardiovascular disease: why do we still not have the answers? [editorial; comment] Chalmers TC. **Ann Intern Med** 1995 Dec 1;123(11):887. Comment on: Ann Intern Med 1995 Dec 1;123(11):860–72.

Safety of antioxidant vitamins. Meyers DG, et al. **Arch Intern Med** 1996 May 13;156(9):925–35 (208 ref.)

[Safety of antioxidants] Mäntylä E, et al. **Duodecim** 1994; 110(17):1629–39 (59 ref.) **(Fin)**

ANALYSIS

The effect of simvastatin treatment on natural antioxidants in low–density lipoproteins and high–energy phosphates and ubiquinone in skeletal muscle. Laaksonen R, et al. **Am J Cardiol** 1996 Apr 15;77(10):851–4

Dietary intake, plasma levels of antioxidant vitamins, and oxidative stress in relation to coronary artery disease in elderly subjects. Singh RB, et al. **Am J Cardiol** 1995 Dec 15;76(17):1233–8

Influence of combined antioxidant nutrient intakes on their plasma concentrations in an elderly population. Jacques PF, et al. **Am J Clin Nutr** 1995 Dec;62(6):1228–33

Antioxidant status in long–term adherents to a strict uncooked vegan diet. Rauma AL, et al. **Am J Clin Nutr** 1995 Dec;62(6):1221–7

Antioxidants in hereditary pancreatitis. Mathew P, et al. **Am J Gastroenterol** 1996 Aug;91(8):1558–62

The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Benzie IFF, et al. **Anal Biochem** 1996 Jul 15;239(1):70–6

Monitoring of ubiquinol–10, ubiquinone–10, carotenoids, and tocopherols in neonatal plasma microsamples using high–performance liquid chromatography with coulometric electrochemical detection. Finckh B, et al. **Anal Biochem** 1995 Dec 10;232(2):210–6

Serum antioxidants and age–related macular degeneration in a population–based case–control study. Mares–Perlman JA, et al. **Arch Ophthalmol** 1995 Dec;113(12):1518–23

Dialysis of isolated low density lipoprotein induces a loss of lipophilic antioxidants and increases the susceptibility to oxidation in vitro. Scheek LM, et al. **Atherosclerosis** 1995 Sep;117(1):139–44

Advanced Maillard reaction and crosslinking of corneal collagen in diabetes. Sady C, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):793–7

Plasma antioxidant enzymes and oxidized lipoproteins in hypercholesterolemic rabbits. Silva EL, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):679–87

Changes in serum antioxidant concentrations during infection with caprine lentivirus. Mdurvwa EG, et al. **Cell Mol Biol (Noisy–le–grand)** 1995;41 Suppl 1:S65–72

Direct evidence that initial oxidative stress triggered by preconditioning contributes to second window of protection by endogenous antioxidant enzyme in myocytes. Zhou X, et al. **Circulation** 1996 Mar 15;93(6):1177–84

Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Ahotupa M, et al. **Clin Biochem** 1996 Apr;29(2):139–44

Fatty acids and plasma antioxidants in HIV–positive patients: correlation with nutritional and immunological status. Constans J, et al. **Clin Biochem** 1995 Aug;28(4):421–6

Antioxidant profile of human erythrocytes after kidney transplantation. Hussain SA, et al. **Clin Biochem** 1995 Dec; 28(6):607–10

Antioxidant activity of resveratrol in red wine [letter; comment] [see comments] Miller NJ, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1789. Comment on: Clin Chem 1995 Jan;41(1):32–5. Comment in: Clin Chem 1996 Jan;42(1):113–4.

Blood antioxidants (vitamin E and beta–carotene) in long–term low density lipoprotein apheresis. Assogba U, et al. **Clin Chim Acta** 1995 Mar 31;235(2):147–57

Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Borrelli E, et al. **Crit Care Med** 1996 Mar;24(3):392–7 (38 ref.)

Consumption of reduced–fat products: effects on parameters of anti–oxidative capacity. Velthuis–te Wierik EJ, et al. **Eur J Clin Nutr** 1996 Apr;50(4):214–9

Is there an unidentified defence mechanism against infection in human plasma? Aejmelaeus R, et al. **FEBS Lett** 1996 Apr 15;384(2):128–30

Immunohistochemical localization of antioxidant enzymes during hamster kidney development. Oberley TD, et al. **Histochem J** 1995 Aug;27(8):575–86

Determinants of plasma anti–oxidant vitamin levels in a population at high risk for stomach cancer. Buiatti E, et al. **Int J Cancer** 1996 Jan 26;65(3):317–22

Prediction of male cancer mortality by plasma levels of interacting vitamins: 17–year follow–up of the prospective Basel study. Eichholzer M, et al. **Int J Cancer** 1996 Apr 10;66(2):145–50

Comparison of two levels of vitamin C supplementation on antioxidant vitamin status in elderly institutionalized subjects. Birlouez–Aragon I, et al. **Int J Vitam Nutr Res** 1995;65(4):261–6

Systemic oxidative stress and its relationship with age and illness. Associazione Medica "Sabin" [see comments] Mezzetti A, et al. **J Am Geriatr Soc** 1996 Jul;44(7):823–7 . Comment in: J Am Geriatr Soc 1996 Jul;44(7):873–5.

Antioxidant and glutathione–associated enzymes in Wilms' tumour after chemotherapy. Gajewska J, et al. **J Cancer Res Clin Oncol** 1996;122(8):483–8

Regulation of GTP cyclohydrolase I gene expression and tetrahydrobiopterin content in cultured sympathetic neurons by leukemia inhibitory factor and ciliary neurotrophic factor. Stegenga SL, et al. **J Neurochem** 1996 Jun;66(6):2541–5

Oxidant–antioxidant status alterations in cancer patients: relationship to tumor progression. Gerber M, et al. **J Nutr** 1996 Apr;126(4 Suppl):1201S–7S

Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. Herrick AL, et al. **J Rheumatol** 1996 Apr;23(4):650–3

The in vivo effect of different bedding materials on the antioxidant levels of rat heart, lung and liver tissue. Potgieter FJ, et al. **J S Afr Vet Assoc** 1996 Mar;67(1):27–30

Alteration of antioxidant status following sympathectomy: differential effects of modified plasma levels of adrenaline

and noradrenaline. Toleikis PM, et al. **Mol Cell Biochem** 1995 Nov 8;152(1):39–49

Smoking and low antioxidant levels increase oxidative damage to sperm DNA. Fraga CG, et al. **Mutat Res** 1996 Apr 13;351(2):199–203

Red blood cell antioxidants in human volunteers exposed to ozone. Vender RL, et al. **Toxicol Ind Health** 1994 Jan–Apr; 10(1–2):53–8

[Erythrocyte and plasma antioxidant activity in diabetes mellitus type I] Ndahimana J, et al. **Presse Med** 1996 Feb 10;25(5):188–92 (Eng. Abstr.) **(Fre)**

[An absent correlation between antioxidant blood concentrations and the remission response of preoperatively treated breast carcinomas] Hartmann A, et al. **Strahlenther Onkol** 1996 Aug;172(8):434–8 (Eng. Abstr.) **(Ger)**

[Antioxidant status in vegetarians living in Bratislava] Cerhata D, et al. **Bratisl Lek Listy** 1995 Aug;96(8):450–1 **(Slo)**

CHEMICAL SYNTHESIS

Synthesis, antioxidant properties, biological activity and molecular modelling of a series of chalcogen analogues of the 5-lipoxygenase inhibitor DuP 654. Engman L, et al. **Bioorg Med Chem** 1995 Sep;3(9):1255–62

Antioxidant properties of amidothionophosphates: novel antioxidant molecules. Tirosh O, et al. **Free Radic Biol Med** 1996;20(3):421–32

Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity. Bundy GL, et al. **J Med Chem** 1995 Oct 13;38(21):4161–3

Synthesis and evaluation of 3',5'-di-tert-butyl-4'-hydroxyflavones as potential inhibitors of low density lipoprotein (LDL) oxidation. Lewin G, et al. **J Nat Prod** 1995 Dec;58(12):1840–7

CHEMISTRY

NO-redox paradox: direct oxidation of alpha-tocopherol and alpha-tocopherol-mediated oxidation of ascorbate. Gorbunov NV, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):835–41

Characterisation of novel indenoindoles. Part II. Redox-recycling with ascorbate. Björquist P, et al. **Biochem Pharmacol** 1996 May 17;51(10):1403–10

Iron coordination by catechol derivative antioxidants. Kawabata T, et al. **Biochem Pharmacol** 1996 Jun 14; 51(11):1569–77

Characterization of novel indenoindoles. Part I. Structure-activity relationships in different model systems of lipid peroxidation. Westerlund C, et al. **Biochem Pharmacol** 1996 May 17;51(10):1397–402

How to characterize an antioxidant: an update. Halliwell B. **Biochem Soc Symp** 1995;61:73–101 (229 ref.)

Plant polyphenols: free radical scavengers or chain-breaking antioxidants? Rice-Evans C. **Biochem Soc Symp** 1995; 61:103–16 (53 ref.)

Antioxidants in food packaging: a risk factor? Scott G. **Biochem Soc Symp** 1995;61:225–46 (28 ref.)

Antioxidant properties of demethyldiisoeugenol. Ko FN, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):145–52

Metastability of dimiristoylphosphatidylethanolamine as studied by FT-IR and the effect of alpha-tocopherol. Salgado J, et al. **Biochim Biophys Acta** 1995 Nov 1; 1239(2):213–25

Antioxidant activity of natural flavonoids is governed by number and location of their aromatic hydroxyl groups. Chen ZY, et al. **Chem Phys Lipids** 1996 Mar 29; 79(2):157–63

Antioxidant activities of carotenes and xanthophylls. Miller NJ, et al. **FEBS Lett** 1996 Apr 22;384(3):240–2

Effects of temperature and mixing on polymer adjuvant migration to corn oil and water. Limm W, et al. **Food Addit Contam** 1995 Jul-Aug;12(4):609–24

Characterization of drugs as antioxidant prophylactics. Aruoma OI. **Free Radic Biol Med** 1996;20(5):675–705 (473 ref.)

Beta-carotene as an interceptor of free radicals. Ozhogina OA, et al. **Free Radic Biol Med** 1995 Nov;19(5):575–81

Structural aspects of antioxidant activity of flavonoids. van Acker SA, et al. **Free Radic Biol Med** 1996;20(3):331–42

Effect of deep-fat frying on fat oxidation in soybean oil. Goburdhun D, et al. **Int J Food Sci Nutr** 1995 Nov; 46(4):363–71

Scavenging of nitrogen dioxide, thiyl, and sulfonyl free radicals by the nutritional antioxidant beta-carotene. Everett SA, et al. **J Biol Chem** 1996 Feb 23;271(8):3988–94

Use of linoleic acid radiolysis for assay of antioxidant action of anethole dithiolethione. Christen MO, et al. **Methods Enzymol** 1995;252:324–31

Cold light fluorimetry: a microtitration technology for cell culture to evaluate anethole dithiolethione and other biothiols. Rat P, et al. **Methods Enzymol** 1995;252:331–40

Atom level electrotopological state indexes in QSAR: designing and testing antithyroid agents. Abou-Shaaban RR, et al. **Pharm Res** 1996 Jan;13(1):129–36

Formation of F2-isoprostanes in oxidized low density lipoprotein: inhibitory effect of hydroxytyrosol. Salami M, et al. **Pharmacol Res** 1995 May;31(5):275–9

[Dietary plant phospholipids as stabilizers of oil solutions of beta-carotene] Karagodina ZV, et al. **Vopr Pitan** 1995; (4):37–9 (Eng. Abstr.) **(Rus)**

[Antioxidant properties of products of the interaction of amino acids with carbohydrates under conditions of the Maillard reaction] Kaytka VV, et al. **Ukr Biokhim Zh** 1995 Mar-Apr;67(2):71–5 (Eng. Abstr.) **(Ukr)**

ISOLATION & PURIFICATION

Antioxidant agents in raw materials and processed foods. Eriksson CE, et al. **Biochem Soc Symp** 1995;61:221–34 (106 ref.)

Marchantinquinone, isolated from Reboulia hemisphaerica, as inhibitor of lipid peroxidation and as free radical scavenger. Ko FN, et al. **Chem Biol Interact** 1995 Nov 17;98(2):131–43

Novel antioxidants from roasted perilla seed. Nagatsu A, et al. **Chem Pharm Bull (Tokyo)** 1995 May;43(5):887–9

Santolindiacetylene, a polyacetylene derivative isolated from the essential oil of Santolina canescens. Utrilla MP, et al. **J Nat Prod** 1995 Nov;58(11):1749–52

Antiperoxidative components in Thymus vulgaris. Haraguchi H, et al. **Planta Med** 1996 Jun;62(3):217–21

METABOLISM

Effects of an organophosphate on the antioxidant systems of fish tissues. Hai DQ, et al. **Acta Biol Hung** 1995; 46(1):39–50

Spermine protects in vivo the antioxidant enzymes in transiently hypoperfused rat brain. Farbiszewski R, et al. **Acta Neurobiol Exp (Warsz)** 1995;55(4):253–8

Why tetrahydrobiopterin? Mayer B, et al. **Adv Pharmacol** 1995;34:251–61 (50 ref.)

Liver antioxidant defenses in mice fed ethanol and the AIN-76A diet. Chen LH, et al. **Alcohol** 1995 Sep-Oct; 12(5):453–7

Influence of selenium supplementation in non-toxic doses on testis lipid peroxide and antioxidant levels in chronic alcohol-fed rats. Bekpinar S, et al. **Alcohol Alcohol** 1995 Sep;30(5):645–50

Tourniquet-induced exsanguination in patients requiring lower limb surgery. An ischemia-reperfusion model of oxidant and antioxidant metabolism. Mathru M, et al. **Anesthesiology** 1996 Jan;84(1):14–22

The effect of anticoagulant choice on apparent total antioxidant capacity using three different methods. Goode HF, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):413–6

Anticoagulant effects of antioxidant capacity [letter] Rea CA, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):174

Antioxidant activity of reduced plastoquinone in chloroplast thylakoid membranes. Hundal T, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):117–22

Chromate-induced chromium(V) formation in live mice and its control by cellular antioxidants: an L-band electron paramagnetic resonance study. Liu KJ, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):33–9

Antioxidants, tissue damage, and endurance in trained and untrained young male rats. Venditti P, et al. **Arch Biochem Biophys** 1996 Jul 1;331(1):63–8

Determination by enhanced luminescence technique of liver antioxidant capacity. Venditti P, et al. **Arch Physiol Biochem** 1995 Aug;103(4):484–91

Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolaemia and vascular disease. Blann AD, et al. **Atherosclerosis** 1995 Aug;116(2):191–8

Chinese hamster fibroblasts overexpressing CuZn-superoxide dismutase undergo a global reduction in antioxidants and an increasing sensitivity of DNA to oxidative damage. Teixeira HD, et al. **Biochem J** 1996 May 1;315 (Pt 3):821–5

Lack of evidence of oxidative damage in antioxidant-deficient strains of Saccharomyces cerevisiae. Fortuniak A, et al. **Biochem Mol Biol Int** 1996 May; 38(6):1271–6

Resistance to ionizing radiation and antioxidative defence in yeasts. Are antioxidant-deficient cells permanently stressed? Jaruga E, et al. **Biochem Mol Biol Int** 1995 Oct; 37(3):467–73

What determines the antioxidant potential of yeast cells? Lapshina EA, et al. **Biochem Mol Biol Int** 1995 Nov; 37(5):903–8

Exercise training alters kinetics of antioxidant enzymes in rat tissues. Somani SM, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):587–95

Reduction of lipoic acid by lipoamide dehydrogenase. Biewenga GP, et al. **Biochem Pharmacol** 1996 Feb 9; 51(3):233–8

Antioxidant status in the jejunum: effect of acute ethanol dosage. Marway JS, et al. **Biochem Soc Trans** 1995 Aug; 23(3):463S

Ascorbic acid recycling enhances the antioxidant reserve of human erythrocytes. May JM, et al. **Biochemistry** 1995 Oct 3;34(39):12721–8

Variations of hepatic antioxidant systems and DNA ploidy in rats aged 2 to 8 months. Sanz N, et al. **Biochim Biophys Acta** 1996 Mar 1;1315(2):123–30

Inhalation of nitric oxide: effect on cerebral hemodynamics and activity, and antioxidant status in the newborn lamb. Lopes Cardozo RH, et al. **Biol Neonate** 1996;69(4):284–92

Expression of genes encoding antioxidant enzymes in preimplantation mouse and cow embryos and primary bovine oviduct cultures employed for embryo coculture. Harvey MB, et al. **Biol Reprod** 1995 Sep;53(3):532–40

Selenium status, plasma zinc, copper, and magnesium in vegetarians. Kadrabová J, et al. **Biol Trace Elem Res** 1995 Oct;50(1):13–24

Tea flavonoids have little short term impact on serum antioxidant activity [letter] Maxwell S, et al. **BMJ** 1996 Jul 27;313(7051):229

Antioxidant consumption during exercise in intermittent claudication. Khaira HS, et al. **Br J Surg** 1995 Dec; 82(12):1660–2

Antioxidant depletion during aortic aneurysm repair. Khaira HS, et al. **Br J Surg** 1996 Mar;83(3):401–3

Endogenous antioxidant status in neoplastic and adjacent tissues in 1,2-dimethylhydrazine-induced colon cancer in rats: effects of olsalazine. Moghadasian MH, et al. **Carcinogenesis** 1996 May;17(5):983–7

Tumor progression and oxidant-antioxidant status. Saintot M, et al. **Carcinogenesis** 1996 Jun;17(6):1267–71

Liver endogenous antioxidant defenses in mice fed AIN-76A diet and infected with murine AIDS. Chen LH, et al. **Chem Biol Interact** 1996 Jan 5;99(1–3):17–28

Oxidant-antioxidant balance in granulocytes during ARDS. Effect of N-acetylcysteine. Laurent T, et al. **Chest** 1996 Jan;109(1):163–6

Automated assay of oxygen radical absorbance capacity with the COBAS FARA II. Cao G, et al. **Clin Chem** 1995 Dec; 41(12 Pt 1):1738–44

Micronutrient antioxidant status in black South Africans with chronic pancreatitis: opportunity for prophylaxis. Segal I, et al. **Clin Chim Acta** 1995 Jul 31;239(1):71–9

Free radical toxicology and antioxidant defence. Winterbourn CC. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):877–80

Total antioxidant capacity and lipid peroxidation during liver transplantation. Galley HF, et al. **Clin Sci (Colch)** 1995 Sep; 89(3):329–32

Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: a pilot study. Yoshida H, et al. **Clin Ther** 1995 May-Jun;17(3):379–89

Species-related variations in antioxidant components of gastric and duodenal mucosa. Moghadasian MH, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):703–9

Plasma antioxidant potential in severe sepsis: a comparison of survivors and nonsurvivors. Cowley HC, et al. **Crit Care Med** 1996 Jul;24(7):1179–83

Deficiency in antioxidant factors in patients with alcohol-related chronic pancreatitis. Van Gossum A, et al. **Dig Dis Sci** 1996 Jun;41(6):1225–31

Diethyldithiocarbamate protection against cisplatin nephrotoxicity: antioxidant system. Somani SM, et al. **Drug Chem Toxicol** 1995 May-Aug;18(2-3):151–70

Exercise and oxidative stress: role of the cellular antioxidant systems. Ji LL. **Exerc Sport Sci Rev** 1995;23:135–66 (140 ref.)

Antioxidant depletion, lipid peroxidation, and impairment of calcium transport induced by air-blast overpressure in rat lungs. Elsayed NM, et al. **Exp Lung Res** 1996 Mar-Apr; 22(2):179–200

Tissue protection against oxidative stress. Di Meo S, et al. **Experientia** 1996 Aug 15;52(8):786–94

Effect of various stressors on the level of lipid peroxide, antioxidants and Na+, K(+)-ATPase activity in rat brain. Shaheen AA, et al. **Experientia** 1996 Apr 15;52(4):336–9

Plasma and hepatic antioxidant control and vitamin A nutritional status. Subirade I, et al. **Experientia** 1996 Jul 15;52(7):687–90

Activities of antioxidant enzymes and formation of the glutathione adduct of hemoglobin (Hb ASSG) in epileptic patients with long-term antiepileptic therapy. Niketić V, et al. **Farmaco** 1995 Nov;50(11):811–3

Antioxidant and redox regulation of gene transcription. Sen CK, et al. **FASEB J** 1996 May;10(7):709–20 (94 ref.)

Depleted mucosal antioxidant defences in inflammatory bowel disease. Buffinton GD, et al. **Free Radic Biol Med** 1995 Dec;19(6):911–8

Cadmium resistance in A549 cells correlates with elevated glutathione content but not antioxidant enzymatic activities. Hatcher EL, et al. **Free Radic Biol Med** 1995 Dec;19(6):805–12

Levels of antioxidant nutrients in plasma and low density lipoproteins: a human volunteer supplementation study. Calzada C, et al. **Free Radic Res** 1995 Nov;23(5):489–503

Functional pleiotropy of the neurohormone melatonin: antioxidant protection and neuroendocrine regulation. Reiter RJ. **Front Neuroendocrinol** 1995 Oct;16(4):383–415 (133 ref.)

Immunogold analysis of antioxidant enzymes in common renal cancers. Oberley TD, et al. **Histol Histopathol** 1996 Jan;11(1):153–60

Jaundice in new born and erythrocyte and plasma antioxidant defence system. Majumder S, et al. **Indian J Exp Biol** 1995 Apr;33(4):303–5

Vitamin E protects guinea pig liver from lipid peroxidation without depressing levels of antioxidants. Cadenas S, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1175–81

Antioxidant enzyme activities and lipid peroxidation levels in exercised and hypertensive rat tissues. Hong H, et al. **Int J Biochem Cell Biol** 1995 Sep;27(9):923–31

Mechanisms of unusually high antioxidant activity of RSV-SR-transformed cells and of its suppression by activated p21ras. Deichman GI, et al. **Int J Cancer** 1996 Jun 11;66(6):747–52

Serum antioxidant potential, and lipoprotein oxidation in

female smokers following vitamin C supplementation. Mulholland CW, et al. **Int J Food Sci Nutr** 1996 May; 47(3):227–31

Comparative effectiveness of vitamin D3 and dietary vitamin E on peroxidation of lipids and enzymes of the hepatic antioxidant system in Sprague–Dawley rats. Sardar S, et al. **Int J Vitam Nutr Res** 1996;66(1):39–45

Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids. Rock CL, et al. **J Am Diet Assoc** 1996 Jul;96(7):693–702; quiz 703–4 (128 ref.)

Oxidative stress and aging: still a hypothesis [editorial; comment] Kritchevsky SB, et al. **J Am Geriatr Soc** 1996 Jul;44(7):873–5 (25 ref.). Comment on: J Am Geriatr Soc 1996 Jul;44(7):823–7.

Pulmonary oxygen toxicity in mice is characterized by alterations in ascorbate redox status. Rusakow LS, et al. **J Appl Physiol** 1995 Nov;79(5):1769–76

Oxidants and antioxidants in exercise. Sen CK. **J Appl Physiol** 1995 Sep;79(3):675–86 (100 ref.)

Removal of hydrogen peroxide by thiol-specific antioxidant enzyme (TSA) is involved with its antioxidant properties. TSA possesses thiol peroxidase activity. Netto LES, et al. **J Biol Chem** 1996 Jun 28;271(26):15315–21

Antioxidants and reduced functional capacity in the elderly: findings from the Nun Study. Snowdon DA, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):M10–6

Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC. Bird S, et al. **J Inherit Metab Dis** 1995;18(2):123–6

Oxybenzone oxidation following solar irradiation of skin: photoprotection versus antioxidant inactivation. Schallreuter KU, et al. **J Invest Dermatol** 1996 Mar; 106(3):583–6

Cellular cysteine generation does not contribute to the initiation of LDL oxidation. Santanam N, et al. **J Lipid Res** 1995 Oct;36(10):2203–11

Plasma levels of vitamin E in Parkinson's disease. Federico A, et al. **J Neural Transm Suppl** 1995;45:267–70

Increased antioxidant enzyme activity in amyloid beta protein–resistant cells. Sagara Y, et al. **J Neurosci** 1996 Jan 15;16(2):497–505

Dietary polyunsaturated fatty acids and aging modulate glutathione-related antioxidants in rat liver. Christon R, et al. **J Nutr** 1995 Dec;125(12):3062–70

Alteration of glutathione and antioxidant status with exercise in unfed and refed rats. Leeuwenburgh C, et al. **J Nutr** 1996 Jul;126(7):1833–43

Reduced, oxidized and protein–bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status—a possible element of the extracellular antioxidant defense system. Ueland PM, et al. **J Nutr** 1996 Apr;126(4 Suppl):1281S–4S (28 ref.)

Simultaneous dietary supplementation of sodium cholate and beta-carotene markedly enhances accumulation of beta-carotene in mice. Umegaki K, et al. **J Nutr** 1995 Dec; 125(12):3081–6

Effects of hypobaric hypoxia on antioxidant enzymes in rats. Nakanishi K, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):869–76

Lipid and antioxidant changes in semen of broiler fowl from 25 to 60 weeks of age. Kelso KA, et al. **J Reprod Fertil** 1996 Mar;106(2):201–6

Antioxidant activities and mRNA expression of superoxide dismutase, catalase, and glutathione peroxidase in normal and preeclamptic placentas. Wang Y, et al. **J Soc Gynecol Investig** 1996 Jul–Aug;3(4):179–84

Inactivation of glutaraldehyde by reaction with sodium bisulfite. Jordan SL, et al. **J Toxicol Environ Health** 1996 Feb 23;47(3):299–309

Tissue manganese concentrations and antioxidant enzyme activities in rats given total parenteral nutrition with and without supplemental manganese. Malecki EA, et al. **JPEN J Parenter Enteral Nutr** 1995 May–Jun;19(3):222–6

Modulation of antioxidant enzymes and programmed cell death by n-3 fatty acids. Fernandes G, et al. **Lipids** 1996 Mar;31 Suppl:S91–6

Antioxidant stoichiometry and the oxidative fate of vitamin E in peroxyl radical scavenging reactions. Liebler DC, et al. **Lipids** 1995 Sep;30(9):789–93

Determinants of antioxidant status in humans. Papas AM. **Lipids** 1996 Mar;31 Suppl:S77–82 (66 ref.)

Decreases in protective enzymes correlates with increased oxidative damage in the aging mouse brain. Mo JQ, et al. **Mech Ageing Dev** 1995 Jul 14;81(2–3):73–82

Hypothesis: spermine may be an important epidermal antioxidant. Løvaas E. **Med Hypotheses** 1995 Jul; 45(1):59–67 (125 ref.)

Metabolic disturbance in age-related macular degeneration. Wu L, et al. **Metab Pediatr Syst Ophthalmol** 1994; 17(1–4):38–40

Antioxidant defense system in lung of male and female rats: interactions with alcohol, copper, and type of dietary carbohydrate. Fields M, et al. **Metabolism** 1996 Jan; 45(1):49–56

Ebselen. Sies H. **Methods Enzymol** 1995;252:341–2 (18 ref.)

Modulations in antioxidant enzymes in different tissues of marine bivalve Perna viridis during heavy metal exposure. Prakash NT, et al. **Mol Cell Biochem** 1995 May 24; 146(2):107–13

Differences in the expression of heat-shock proteins and antioxidant enzymes between human and rodent pancreatic islets: implications for the pathogenesis of insulin-dependent diabetes mellitus. Welsh N, et al. **Mol Med** 1995 Nov;1(7):806–20

An investigation of antioxidant status, DNA repair capacity and mutation as a function of age in humans. Barnett YA, et al. **Mutat Res** 1995 Oct;338(1–6):115–28

Plasma fatty acid profile and prooxidative-antioxidative parameters in vegetarians. Krajčovičová-Kudláčková M, et al. **Nahrung** 1995;39(5–6):452–7

Effect of intake of exogenous vitamins C, E and beta-carotene on the antioxidative status in kidneys of rats with streptozotocin-induced diabetes. Mekiňová D, et al. **Nahrung** 1995;39(4):257–61

Antioxidant enzymes activity in polymorphonuclear leukocytes in chronic renal failure. Shurtz-Swirski R, et al. **Nephron** 1995;71(2):176–9

The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage. Reiter RJ. **Neurochem Int** 1995 Dec;27(6):453–60 (54 ref.)

Serial studies of free radical and antioxidant activity in motor neurone disease and the effect of selegiline [letter] Mitchell JD, et al. **Neurodegeneration** 1995 Jun;4(2):233–5

Gender differences in cerebral ascorbate levels and ascorbate loss in ischemia. Ferris DC, et al. **Neuroreport** 1995 Jul 31;6(11):1485–9

Detection of the lipid peroxidation product malonaldehyde in rat brain in vivo. Waterfall AH, et al. **Neurosci Lett** 1995 Nov 10;200(1):69–72

Alteration of antioxidant status in diabetic rats by chronic exposure to psychological stressors. Toleikis PM, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):355–66

Mechanism of cisplatin ototoxicity: antioxidant system. Ravi R, et al. **Pharmacol Toxicol** 1995 Jun;76(6):386–94

Effects of ultraviolet A and antioxidant defense in cultured fibroblasts and keratinocytes. Moysan A, et al. **Photodermatol Photoimmunol Photomed** 1996 Oct–Dec; 11(5–6):192–7

Differential accumulation of antioxidant mRNAs in Arabidopsis thaliana exposed to ozone. Conklin PL, et al. **Plant Physiol** 1995 Sep;109(1):203–12

Overexpression of glutathione reductase but not glutathione synthetase leads to increases in antioxidant capacity and resistance to photoinhibition in poplar trees. Foyer CH, et al. **Plant Physiol** 1995 Nov;109(3):1047–57

Effect of schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity. Ip SP, et al. **Planta Med** 1995 Oct;61(5):398–401

Effect of alpha-tocopherol on antioxidants, lipid peroxidation, and the incidence of pulmonary hypertension syndrome (ascites) in broilers. Bottje W, et al. **Poult Sci** 1995 Aug;74(8):1356–69

Antioxidant capacity in different tissues of young and old rats. Cao G, et al. **Proc Soc Exp Biol Med** 1996 Apr; 211(4):359–65

Total radical trapping antioxidant potential (TRAP) and exercise. Sharpe PC, et al. **QJM** 1996 Mar;89(3):223–8

Effect of in vivo heart irradiation on the development of antioxidant defenses and cardiac functions in the rat. Benderitter M, et al. **Radiat Res** 1995 Oct;144(1):64–72

Physiological changes in antioxidant defences in fetal and neonatal rat liver. Gonzalez MM, et al. **Reprod Fertil Dev** 1995;7(5):1375–80

The lipid peroxidation products and the enzymes of antioxidant system in patients with diabetes mellitus. Olczyk K, et al. **Rocz Akad Med Bialymst** 1994;39:93–9

Oxidative stress and antioxidant protection in degenerative psychoorganic syndrome in old agers. Negru T, et al. **Rom J Intern Med** 1995 Jan–Jun;33(1–2):55–60

Effects of estrogens on the redox chemistry of iron: a possible mechanism of the antioxidant action of estrogens. Ruiz-Larrea B, et al. **Steroids** 1995 Nov;60(11):780–3

Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease [editorial] Rahman I, et al. **Thorax** 1996 Apr;51(4):348–50

Oxidative stress and antioxidant defenses in plasma of patients with Behçet's disease. Köse K, et al. **Tohoku J Exp Med** 1995 Aug;176(4):239–48

Frequent hard physical activity lowered serum beta-carotene level in a population study of a rural city of Japan. Takatsuka N, et al. **Tohoku J Exp Med** 1995 Jul; 176(3):131–5

Antioxidant defense in rat brain after chronic treatment with anorectic drugs. D'Almeida V, et al. **Toxicol Lett** 1995 Nov 15;81(2–3):101–5

Antioxidant defense and free radical production in a rabbit model of kidney ischemia-reperfusion. Franssen C, et al. **Transplant Proc** 1995 Oct;27(5):2880–3

[The lipid peroxidation level and antioxidant status of the plasma in patients operated on under propofol (Diprivan) anesthesia] Khinev S, et al. **Khirurgiia (Sofiia)** 1995; 48(5):23–5 (Eng. Abstr.) **(Bul)**

[Role of vitamin E and C, carotenoids, ubiquinone and selenium in the antioxidative defense system] Alho H, et al. **Duodecim** 1994;110(17):1621–8 (49 ref.) **(Fin)**

[Why and how the results of antioxidant studies are reported (editorial)] Alho H, et al. **Duodecim** 1994;110(17):1608–10 **(Fin)**

[Role of free radicals and antioxidants in the cell defense system] Antila E. **Duodecim** 1994;110(17):1611–9 (27 ref.) **(Fin)**

[Oxidants and antioxidants. Biological effects and therapeutic perspectives] Urban T, et al. **Ann Chir** 1995;49(5):427–34 (55 ref.) (Eng. Abstr.) **(Fre)**

[Malignant hyperphenylalaninemia due to tetrahydrobiopterin deficiency] Leroux B, et al. **Arch Pediatr** 1996;3 Suppl 1:163s–166s **(Fre)**

[Antioxidant and anti-inflammatory protection of vascular endothelial cells by new synthetic mimics of glutathione peroxidase] Chaudière J, et al. **C R Seances Soc Biol Fil** 1995;189(5):861–82 (Eng. Abstr.) **(Fre)**

[Effect of olive oil and fish oil on parameters of lipids and antioxidants in hyperlipoproteinemia] Reuter W, et al. **Z Ernahrungswiss** 1995 Jun;34(2):151–9 (Eng. Abstr.) **(Ger)**

[Blood antioxidant defense in children with malignant disease. I. Plasma antioxidant activity and level of ceruloplasmin and transferrin] Gajewska J, et al. **Pediatr Pol** 1995 Nov; 70(11):907–10 (Eng. Abstr.) **(Pol)**

[Lipoproteins, antioxidants, and coronary cardiopathy] Guimarães AC. **Arq Bras Cardiol** 1995 Sep;65(3):289–95 (31 ref.) **(Por)**

[The effect of age and ischemia on the lipid peroxide and lipid-soluble antioxidant level in the human heart] Lebedev AV, et al. **Biull Eksp Biol Med** 1995 Jun;119(6):584–6 **(Rus)**

[Effects of an impulse magnetic field on lipid peroxidation and the antioxidant system of the testes in animal experiments] Kashkalda DA, et al. **Med Tr Prom Ekol** 1995; (10):14–7 (Eng. Abstr.) **(Rus)**

[Antioxidant system of mammalian liver and heart membranes during the postnatal ontogenesis period] Romanenko EB, et al. **Mol Biol (Mosk)** 1995 Nov–Dec;29(6):1391–7 **(Rus)**

[Effect of the histamine H2-receptor antagonist zantac on lipid peroxidation an antioxidant system in patients with gastroduodenal hemorrhage of ulcer etiology] Ermolov AS, et al. **Patol Fiziol Eksp Ter** 1996 Jan–Mar;(1):23–5 (Eng. Abstr.) **(Rus)**

[The erythrocyte pro-oxidant and antioxidant systems of patients with chronic kidney failure] Rud'ko IA, et al. **Ter Arkh** 1995;67(8):7–9 (Eng. Abstr.) **(Rus)**

[Anti-edematous action of EDTA, its effect on lipid peroxidation intensity and various components of the antioxidant system of the lungs in rats exposed to NO2] Galkin BN, et al. **Ukr Biokhim Zh** 1995 Jul–Aug;67(4):92–5 (Eng. Abstr.) **(Rus)**

[Change in the activity of antioxidant enzymes in the process of early ontogenesis of various species of Black Sea fishes] Rudneva-Titova II. **Ukr Biokhim Zh** 1995 Jan–Feb; 67(1):92–5 (Eng. Abstr.) **(Rus)**

[The ratio of processes of lipid peroxidation and antioxidant activity in gonads of Elasmobranchia and teleost fishes of the Black Sea] Rudneva-Titova II. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):72–9 (Eng. Abstr.) **(Rus)**

[The effect of the BITO preparation and various serum antioxidants on the intensity of lipid peroxidation in thermal trauma] L'vovskaia EI, et al. **Vopr Med Khim** 1995 May–Jun;41(3):31–4 (Eng. Abstr.) **(Rus)**

[Lipid peroxidation and status of the antioxidant system in opiate addiction, chronic alcoholism, or substance abuse caused by inhaling solvent vapors] Seledtsov AM. **Vopr Med Khim** 1995 May–Jun;41(3):50–3 (Eng. Abstr.) **(Rus)**

[Vitamins with antioxidant action and rheumatic diseases (a review)] Lobareva LS, et al. **Vopr Pitan** 1995;(4):24–9 (71 ref.) (Eng. Abstr.) **(Rus)**

[Levels of erythrocyte glutathione and ceruloplasmin and transferrin in the serum and their role in antioxidant protection] Mekiňová D, et al. **Bratisl Lek Listy** 1996 Apr; 97(4):196–9 (Eng. Abstr.) **(Slo)**

[Adenomatous and inflammatory colorectal polyps: antioxidative enzyme activity in the colon] Beňo I, et al. **Cas Lek Cesk** 1996 Apr 3;135(7):208–10 (Eng. Abstr.) **(Slo)**

[The antioxidative activity of the tissues and lipids in rats of different ages] Paranich AV, et al. **Fiziol Zh** 1995 Jan–Apr;41(1–2):29–36 (Eng. Abstr.) **(Ukr)**

[Changes in the lipid peroxidation processes and in the antioxidant system activity in a model of the ulcer process in the gastroduodenal area] Voronych NM. **Fiziol Zh** 1995 May–Aug;41(3–4):86–90 (Eng. Abstr.) **(Ukr)**

[Effect of the drug stibyl on the enzymatic activity of the antioxidant defense system in chickens] Kalytka VV, et al. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):76–80 (Eng. Abstr.) **(Ukr)**

[The antioxidant system and lipid peroxidation in chickens during postnatal ontogenesis] Kalytka VV, et al. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):80–5 (Eng. Abstr.) **(Ukr)**

PHARMACOKINETICS

Bioavailability of a natural isomer mixture compared with synthetic all-trans beta-carotene in human serum. Ben-Amotz A, et al. **Am J Clin Nutr** 1996 May; 63(5):729–34

Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Hollman PC, et al. **Am J Clin Nutr** 1995 Dec;62(6):1276–82

Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. Winklhofer-Roob BM, et al. **Am J Clin Nutr** 1996 May; 63(5):722–8

Response to a single oral dose of all-rac-alpha-tocopheryl acetate in patients with cystic fibrosis and in healthy individuals. Winklhofer-Roob BM, et al. **Am J Clin Nutr** 1996 May;63(5):717-21

In vitro and in vivo biotransformation of 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-D]pyrimidine (U-89843) in the rat. Zhao Z, et al. **Drug Metab Dispos** 1996 Feb;24(2):187-98

Biokinetics in humans of RRR-alpha-tocopherol: the free phenol, acetate ester, and succinate ester forms of vitamin E. Cheeseman KH, et al. **Free Radic Biol Med** 1995 Nov; 19(5):591-8

A stable nitroxide radical effectively decreases mucosal damage in experimental colitis. Karmeli F, et al. **Gut** 1995 Sep;37(3):386-93

The bioactive peptide cyclo(His-Pro) may be absorbed following ingestion of nutritional supplements that contain it. Mizuma H, et al. **J Am Coll Nutr** 1996 Apr;15(2):175-9

Compartmental analysis of the dynamics of beta-carotene metabolism in an adult volunteer. Novotny JA, et al. **J Lipid Res** 1995 Aug;36(8):1825-38

Pharmacokinetics and tolerability of ventricularly administered superoxide dismutase in monkeys and preliminary clinical observations in familial ALS. Smith RA, et al. **J Neurol Sci** 1995 May;129 Suppl:13-8

Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. Fleishaker JC, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):991-8

Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. Wienkers LC, et al. **J Pharmacol Exp Ther** 1996 May;277(2):982-90

PHARMACOLOGY

The pyridoindole antioxidant stobadine inhibited glycation-induced absorbance and fluorescence changes in albumin. Stefek M, et al. **Acta Diabetol** 1996 Mar; 33(1):35-40

Antioxidant properties of 5-aminosalicylic acid: potential mechanism for its protective effect in ulcerative colitis. Miles AM, et al. **Adv Exp Med Biol** 1995;371B:1317-21 (20 ref.)

Effect of the hydrophilic alpha-tocopherol analog MDL 74,405 on detection of hydroxyl radicals in stunned myocardium in dogs. Tang XL, et al. **Am Heart J** 1995 Nov;130(5):940-8

Effect of vitamin E on the anticoagulant response to warfarin. Kim JM, et al. **Am J Cardiol** 1996 Mar 1;77(7):545-6

Dietary antioxidants and cigarette smoke-induced biomolecular damage: a complex interaction. Eiserich JP, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1490S-1500S

Carotenoid and tocopherol concentrations in plasma, peripheral blood mononuclear cells, and red blood cells after long-term beta-carotene supplementation in men. Fotouhi N, et al. **Am J Clin Nutr** 1996 Apr;63(4):553-8

RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Fuller CJ, et al. **Am J Clin Nutr** 1996 May;63(5):753-9

Influence of combined antioxidant nutrient intakes on their plasma concentrations in an elderly population. Jacques PF, et al. **Am J Clin Nutr** 1995 Dec;62(6):1228-33

Antioxidants and immune response in aged persons: overview of present evidence. Meydani SN, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1462S-1476S (146 ref.)

Growth retardation in human cervical dysplasia-derived cell lines by beta-carotene through down-regulation of epidermal growth factor receptor. Muto Y, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1535S-1540S

Interaction among vitamin C, vitamin E, and beta-carotene. Niki E, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1322S-1326S

Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. Sies H, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1315S-1321S (87 ref.)

The present status of antioxidant vitamins and beta-carotene. Sies H, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1299S-1300S

Coantioxidants make alpha-tocopherol an efficient antioxidant for low-density lipoprotein. Thomas SR, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1357S-1364S (66 ref.)

Vitamin E: beyond antioxidant function. Traber MG, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1501S-1509S (91 ref.)

Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy. Wander RC, et al. **Am J Clin Nutr** 1996 Feb;63(2):184-93

Differential enhancement of gamma-glutamyl transpeptidase and gamma-glutamylcysteine synthetase by tert-butylhydroquinone in rat lung epithelial L2 cells. Liu RM, et al. **Am J Respir Cell Mol Biol** 1996 Feb;14(2):186-91

N-acetylcysteine inhibits loss of diaphragm function in streptozotocin-treated rats. Hida W, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1875-9

Propofol attenuates hydrogen peroxide-induced mechanical and metabolic derangements in the isolated rat heart. Kokita N, et al. **Anesthesiology** 1996 Jan;84(1):117-27

Aging and disease: extending functional life span. Harman D. **Ann N Y Acad Sci** 1996 Jun 15;786:321-36 (87 ref.)

Upregulation of antioxidant enzyme activities by deprenyl. Implications for life span extension. Kitani K, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:391-409

Catecholestrogen as a natural antioxidant. Komura S, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:419-29

Phenolic antioxidants induce UDP-glucuronosyltransferase in rat liver. Yang EK, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:231-6

The interaction between two antioxidants, sodium ascorbate and gallic acid: radical intensity and apoptosis induction. Sakagami H, et al. **Anticancer Res** 1996 May-Jun; 16(3A):1231-4

IP6-induced growth inhibition and differentiation of HT-29 human colon cancer cells: involvement of intracellular inositol phosphates. Yang GY, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2479-87

Effects of zinc-desferrioxamine on Plasmodium falciparum in culture. Chevion M, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1902-5

Effect of beta-carotene and canthaxanthin on tert-butyl hydroperoxide-induced lipid peroxidation in murine normal and tumor thymocytes. Palozza P, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):145-51

Action of beta-carotene as an antioxidant against lipid peroxidation. Tsuchihashi H, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):137-47

Efficacy of hypochlorous acid scavengers in the prevention of protein carbonyl formation. Yan LJ, et al. **Arch Biochem Biophys** 1996 Mar 15;327(2):330-4

Protective effects of free radical scavengers and antioxidants against smokeless tobacco extract (STE)-induced oxidative stress in macrophage J774A.1 cell cultures. Bagchi D, et al. **Arch Environ Contam Toxicol** 1995 Oct;29(3):424-8

Effects of propofol on alterations of multineuronal activity of limbic and mesencephalic structures and neurological deficit elicited by acute global cerebral ischemia. Cervantes M, et al. **Arch Med Res** 1995 Winter;26(4):385-95

Probucol downregulates E-selectin expression on cultured human vascular endothelial cells. Kaneko M, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1047-51

Superoxide dismutase and catalase cross-linked to polyhemoglobin reduces methemoglobin formation in vitro. Quebec EA, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(6):693-705

Effect of vitamin E on atherogenesis in LDL receptor-deficient rabbits. Fruebis J, et al. **Atherosclerosis** 1995 Oct;117(2):217-24

Toxicity of oxidized low density lipoproteins for vascular smooth muscle cells and partial protection by antioxidants. Guyton JR, et al. **Atherosclerosis** 1995 Dec;118(2):237-49

Dietary non-tocopherol antioxidants present in extra virgin olive oil increase the resistance of low density lipoproteins to oxidation in rabbits. Wiseman SA, et al. **Atherosclerosis** 1996 Feb;120(1-2):15-23

17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Behl C, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):473-82

Cyclic strain-induced plasminogen activator inhibitor-1 (PAI-1) release from endothelial cells involves reactive oxygen species. Cheng JJ, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):100-5

Antioxidant effects of Ilex paraguariensis: induction of decreased oxidability of human LDL in vivo. Gugliucci A. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):338-44

Increased production of hydroxyl radical by pericentral microsomes compared to periportal microsomes after pyrazole induction of cytochrome P4502E1. Kukielka E, et al. **Biochem Biophys Res Commun** 1995 Oct 13; 215(2):698-705

Differential distribution of ferulic acid to the major plasma constituents in relation to its potential as an antioxidant. Castelluccio C, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):691-4

Oxidized glutathione decreases luminal Ca2+ content of the endothelial cell ins(1,4,5)P3-sensitive Ca2+ store. Henschke PN, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):485-9

Characterization of the rat glutathione S-transferase Yc2 subunit gene, GSTA5: identification of a putative antioxidant-responsive element in the 5'-flanking region of rat GSTA5 that may mediate chemoprotection against aflatoxin B1. Pulford DJ, et al. **Biochem J** 1996 Aug 15; 318 (Pt 1):75-84

Bio-Catalyzer alpha . rho No. 11 (Bio-Normalizer) supplementation: effect on oxidative stress to isolated rat hearts. Haramaki N, et al. **Biochem Mol Biol Int** 1995 Aug; 36(6):1263-8

The influence of vitamin E and dihydrolipoic acid on cardiac energy and glutathione status under hypoxia-reoxygenation. Haramaki N, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):591-7

Scavenging activity of "beta catechin" on reactive oxygen species generated by photosensitization of riboflavin. Kumari MV, et al. **Biochem Mol Biol Int** 1996 May; 38(6):1163-70

Efficacy of Bio-Catalyzer alpha.rho no.11 (Bio-Normalizer) supplementation against peroxyl radical-induced oxidative damage in rat organ homogenates. Marcocci L, et al. **Biochem Mol Biol Int** 1996 Mar;38(3):535-41

Elucidation of antioxidant activity of dihydrolipoic acid toward hydroxyl radical using a novel hydroxyl radical generator NP-III. Matsugo S, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):375-83

Rabbit brain endoplasmic reticulum membranes as target for free radicals. Changes in Ca(2+)-transport and protection by stobadine. Račay P, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):569-77

Approaches that mitigate doxorubicin-induced delayed adverse effects on mitochondrial function in rat hearts; liposome-encapsulated doxorubicin or combination therapy with antioxidant. Sugiyama S, et al. **Biochem Mol Biol Int** 1995 Aug;36(5):1001-7

Reciprocal protective effects of all-trans retinol and alpha-tocopherol during lipid peroxidation in retinal membranes. Tesoriere L, et al. **Biochem Mol Biol Int** 1995 Sep;37(1):1-7

Antioxidant effects of "beta catechin". Yoneda T, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):995-1008

Scavenging effects of salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Zhao BL, et al. **Biochem Mol Biol Int** 1996 May;38(6):1171-82

Effects of hydroquinone-type and phenolic antioxidants on calcium signals and degranulation of RBL-2H3 cells. Akasaka K, et al. **Biochem Pharmacol** 1996 Jun 14; 51(11):1513-9

Membrane stabilizing, anti-oxidative interactions of propranolol and dexpropranolol with neutrophils. Anderson R, et al. **Biochem Pharmacol** 1996 Jul 26; 52(2):341-9

Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals. Comoglio A, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1313-6

Inhibition of oxidative insult in cultured cells by a novel 6-chromanol-containing antioxidant. Decker DE, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1063-70

The chemopreventive agent diallyl sulfide. A structurally atypical phenobarbital-type inducer. Dragnev KH, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2099-104

Thyronines and probucol inhibition of human capillary endothelial cell-induced low density lipoprotein oxidation. Hanna AN, et al. **Biochem Pharmacol** 1995 Nov 9; 50(10):1627-33

Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury. Haramaki N, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):839-43

Effect of stobadine on Cu(++)-mediated oxidation of low-density lipoprotein. Horakova L, et al. **Biochem Pharmacol** 1996 May 17;51(10):1277-82

The inhibitory effects of boldine, glaucine, and probucol on TPA-induced down regulation of gap junction function. Relationships to intracellular peroxides, protein kinase C translocation, and connexin 43 phosphorylation. Hu J, et al. **Biochem Pharmacol** 1995 Nov 9;50(10):1635-43

Antioxidant properties of dihydropyridines in isolated rat hearts. Kauder WF, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):811-9

Effects of salvianolic acid A on oxygen radicals released by rat neutrophils and on neutrophil function. Lin TJ, et al. **Biochem Pharmacol** 1996 May 3;51(9):1237-41

Protective effects of calcium channel blockers against free radical-impaired endothelial cell proliferation. Mak IT, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1531-4

Differential membrane interactions of calcium channel blockers. Implications for antioxidant activity. Mason RP, et al. **Biochem Pharmacol** 1996 Mar 8;51(5):653-60

Ebselen inhibition of apoptosis by reduction of peroxides. Ramakrishnan N, et al. **Biochem Pharmacol** 1996 Jun 14; 51(11):1443-51

Structure-function relationships of calcium antagonists. Effect on oxidative modification of low density lipoprotein. Rojstaczer N, et al. **Biochem Pharmacol** 1996 Jan 26; 51(2):141-50

Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Sugiyama Y, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):519-25

Inhibition of apoptosis by antioxidants in the human HL-60 leukemia cell line. Verhaegen S, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1021-9

Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Wu TW, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):859-62

Atherogenic and anti-atherogenic factors in the human diet. Addis PB, et al. **Biochem Soc Symp** 1995;61:259-71 (64 ref.)

Plant carotenoids and related molecules: important dietary antioxidants. Krinsky NI. **Biochem Soc Symp** 1995; 61:117-26 (47 ref.)

Tamoxifen as an antioxidant and cardioprotectant. Wiseman H. **Biochem Soc Symp** 1995;61:209-19 (65 ref.)

The effect of antioxidant supplementation on the oxidant-induced stress response in human lymphocytes. Brennan LA, et al. **Biochem Soc Trans** 1996 Feb;24(1):75S

Inhibition of NF kappa B activity by oxidative processes in intact cells mechanism of action of pyrolidine dithiocarbamate and diamide. Brennan P, et al. **Biochem Soc Trans** 1996 Feb;24(1):3S

Caffeine as an antioxidant: inhibition of lipid peroxidation induced by reactive oxygen species. Devasagayam TP, et al. **Biochim Biophys Acta** 1996 Jun 13;1282(1):63-70

Inhibitory effects of alkyl gallate and its derivatives on fatty acid desaturation. Kawashima H, et al. **Biochim Biophys Acta** 1996 Jan 5;1299(1):34-8

The influence of antioxidants and cycloheximide on the level of nitric oxide in the livers of mice in vivo. Mikoyan VD, et al. **Biochim Biophys Acta** 1995 Oct 19;1269(1):19–24

beta-carotene as a high-potency antioxidant to prevent the formation of phospholipid hydroperoxides in red blood cells of mice. Nakagawa K, et al. **Biochim Biophys Acta** 1996 Jan 5;1299(1):110–6

Inhibitory effect of sodium 5,6-benzylidene ascorbate (SBA) on the elevation of melanin biosynthesis induced by ultraviolet-A (UV-A) light in cultured B-16 melanoma cells. Kojima S, et al. **Biol Pharm Bull** 1995 Aug; 18(8):1076–80

Effect of tea (Camellia sinensis L.) on lipid peroxidation in rat liver and kidney: a comparison of green and black tea feeding. Sano M, et al. **Biol Pharm Bull** 1995 Jul; 18(7):1006–8

Synthesis, antioxidant properties, biological activity and molecular modelling of a series of chalcogen analogues of the 5-lipoxygenase inhibitor DuP 654. Engman L, et al. **Bioorg Med Chem** 1995 Sep;3(9):1255–62

Pycnogenol protects vascular endothelial cells from t-butyl hydroperoxide induced oxidant injury. Rong Y, et al. **Biotechnol Ther** 1994–95;5(3–4):117–26

In vitro antioxidant treatment recovers proliferative responses of anergic CD4+ lymphocytes from human immunodeficiency virus-infected individuals. Cayota A, et al. **Blood** 1996 Jun 1;87(11):4746–53

Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants. Chin S, et al. **Blood** 1995 Dec 1; 86(11):4331–6

Effects of proanthocyanidin on normal and reinnervated rat muscle. Ambrogini P, et al. **Boll Soc Ital Biol Sper** 1995 Jul–Aug;71(7–8):227–34

Effect of illuminated nifedipine, a potent antioxidant, on intestinal and vascular smooth muscles. Bauer V, et al. **Br J Pharmacol** 1995 Jul;115(6):871–4

Prevention by alpha-tocopherol and rutin of glutathione and ATP depletion induced by oxidized LDL in cultured endothelial cells. Schmitt A, et al. **Br J Pharmacol** 1995 Oct;116(3):1985–90

Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Pardo B, et al. **Brain Res** 1995 Jun 5;682(1–2):133–43

Traumatic neuronal injury in cortical cell culture is attenuated by 21-aminosteroids. Regan RF, et al. **Brain Res** 1995 Jun 5;682(1–2):144–50

Chronic antioxidant treatment improves the cognitive performance of aged rats. Socci DJ, et al. **Brain Res** 1995 Sep 25;693(1–2):88–94

Vitamin E stimulates trabecular bone formation and alters epiphyseal cartilage morphometry. Xu H, et al. **Calcif Tissue Int** 1995 Oct;57(4):293–300

Effect of selenium on lipids and some lipid metabolising enzymes in DMBA induced mammary tumor rats. Chidambaram N, et al. **Cancer Biochem Biophys** 1995 Jun; 15(1):41–7

Beta-carotene prevents lipid peroxidation and red blood cell membrane protein damage in experimental hepatocarcinogenesis. Sarkar A, et al. **Cancer Biochem Biophys** 1995 Nov;15(2):111–25

Effects of three dietary phytochemicals from tea, rosemary and turmeric on inflammation-induced nitrite production. Chan MM, et al. **Cancer Lett** 1995 Sep 4;96(1):23–9

Vitamin E blocks the cytotoxic effect of gamma-linolenic acid when administered as late as the time of onset of cell death—insight into the mechanism of fatty acid induced cytotoxicity. Ells GW, et al. **Cancer Lett** 1996 Jan 2; 98(2):207–11

Rosemary extract and carnosol stimulate rat liver glutathione-S-transferase and quinone reductase activities. Singletary KW. **Cancer Lett** 1996 Feb 27;100(1–2):139–44

Crocetin protects against oxidative damage in rat primary hepatocytes. Tseng TH, et al. **Cancer Lett** 1995 Oct 20; 97(1):61–7

Induction of NAD(P)H:quinone reductase by vitamins A, E and C in Colo205 colon cancer cells. Wang W, et al. **Cancer Lett** 1995 Nov 27;98(1):63–9

Regulation of carbonyl-reducing enzymes in rat liver by chemoprotectors. Ellis EM, et al. **Cancer Res** 1996 Jun 15; 56(12):2758–66

Effect of vitamin-antioxidant micronutrients on the frequency of spontaneous and in vitro gamma-ray-induced micronuclei in lymphocytes of donors: the age factor. Gaziev AI, et al. **Carcinogenesis** 1996 Mar;17(3):493–9

Strong anti-mutagenic activity of the novel lipophilic antioxidant 1-O-hexyl-2,3,5-trimethylhydroquinone against heterocyclic amine-induced mutagenesis in the Ames assay and its effect on metabolic activation of 2-amino-6-methyldipyrido[1,2-a:3',2'-d] imidazole (Glu-p-1). Hirose M, et al. **Carcinogenesis** 1995 Sep; 16(9):2227–32

Inhibitory effects of 1-O-hexyl-2,3,5-trimethylhydroquinone (HTHQ), green tea catechins and other antioxidants on 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole (Glu-P-1)-induced rat hepatocarcinogenesis and dose-dependent inhibition by HTHQ of lesion induction by Glu-P-1 or 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx). Hirose M, et al. **Carcinogenesis** 1995 Dec;16(12):3049–55

Endogenous antioxidant status in neoplastic and adjacent tissues in 1,2-dimethylhydrazine-induced colon cancer in rats: effects of olsalazine. Moghadasian MH, et al. **Carcinogenesis** 1996 May;17(5):983–7

Antioxidants inhibit the enhancement of malignant cell transformation induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Wölfle D, et al. **Carcinogenesis** 1996 Jun;17(6):1273–8

Lazaroids and deferoxamine attenuate the intracellular effects of oxyhaemoglobin in vascular smooth muscle. Vollrath B, et al. **Cardiovasc Res** 1995 Oct;30(4):619–26

N-acetyl-cysteine enhances cell adhesion properties of epithelial and lymphoid cells. Rivabene R, et al. **Cell Biol Int** 1995 Aug;19(8):681–6

Cytoprotective and antioxidant effects of boldine on tert-butyl hydroperoxide-induced damage to isolated hepatocytes. Bannach R, et al. **Cell Biol Toxicol** 1996 Apr; 12(2):89–100

Inhibition of neutrophil function by human milk. Grazioso CF, et al. **Cell Immunol** 1996 Mar 15;168(2):125–32

Antioxidant activity of natural flavonoids is governed by number and location of their aromatic hydroxyl groups. Chen ZY, et al. **Chem Phys Lipids** 1996 Mar 29; 79(2):157–63

The antioxidant effect of spermine NONOate in human low-density lipoprotein. Goss SP, et al. **Chem Res Toxicol** 1995 Jul–Aug;8(5):800–6

Exhaled ethane and antioxidant vitamin supplements in active smokers. Do BK, et al. **Chest** 1996 Jul;110(1):159–64

Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Levine GN, et al. **Circulation** 1996 Mar 15;93(6):1107–13

More on antioxidant activity of resveratrol in red wine [letter; comment] Goldberg DM. **Clin Chem** 1996 Jan;42(1):113–4 . Comment on: Clin Chem 1995 Dec;41(12 Pt 1):1789.

Lipid peroxidation and antioxidants as biomarkers of tissue damage. Gutteridge JM. **Clin Chem** 1995 Dec;41(12 Pt 2):1819–28 (56 ref.)

In vitro inhibition of low-density lipoprotein oxidation by a gemfibrozil metabolite. Kawamura M, et al. **Clin Chem** 1996 Apr;42(4):644–5

Effects of vitamin E supplementation on erythrocyte antioxidant defence mechanisms of smoking and non-smoking men. Brown KM, et al. **Clin Sci (Colch)** 1996 Jul;91(1):107–11

Free radicals, oxidative stress, oxidized low density lipoprotein (LDL), and the heart: antioxidants and other strategies to limit cardiovascular damage. Sinatra ST, et al. **Conn Med** 1995 Oct;59(10):579–88 (94 ref.)

Comparative cytoprotection of cultured corneal endothelial cells by water-soluble antioxidants against free-radical damage. Zeng LH, et al. **Cornea** 1995 Sep;14(5):509–14

Attenuation of 4-hydroxynonenal-induced cataractogenesis in rat lens by butylated hydroxytoluene. Srivastata SK, et al. **Curr Eye Res** 1996 Jul;15(7):749–54

The use of antioxidants in healing. Martin A. **Dermatol Surg** 1996 Feb;22(2):156–60 (30 ref.)

The antioxidant alpha-lipoic acid enhances insulin-stimulated glucose metabolism in insulin-resistant rat skeletal muscle. Jacob S, et al. **Diabetes** 1996 Aug;45(8):1024–9

Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. Kowluru RA, et al. **Diabetes** 1996 Sep;45(9):1233–7

Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats. Cotter MA, et al. **Diabetologia** 1995 Nov;38(11):1285–94

Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as antioxidant. Rösen P, et al. **Diabetologia** 1995 Oct;38(10):1157–68

Effect of vitamin E and selenium on hypothermic restraint stress and chemically-induced ulcers. al-Moutairy AR, et al. **Dig Dis Sci** 1996 Jun;41(6):1165–71

How 'safe' are antioxidant vitamins? Garewal HS, et al. **Drug Saf** 1995 Jul;13(1):8–14 (57 ref.)

Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. Buck M, et al. **EMBO J** 1996 Apr 15;15(8):1753–65

Superoxide anion is a natural inhibitor of FAS-mediated cell death. Clément MV, et al. **EMBO J** 1996 Jan 15; 15(2):216–25

Taurine and ellagic acid: two differently-acting natural antioxidants. Cozzi R, et al. **Environ Mol Mutagen** 1995; 26(3):248–54

In vivo antioxidant effect of green and black tea in man. Serafini M, et al. **Eur J Clin Nutr** 1996 Jan;50(1):28–32

Inhibition of aldosterone turn-off phenomenon following chronic adrenocorticotropin treatment with in vivo administration of antiglucocorticoid and antioxidants in rats. Ni H, et al. **Eur J Endocrinol** 1995 Nov;133(5):578–84

Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eshhar N, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):19–29

Influence of the 21-aminosteroid U74389F on ischemia-reperfusion injury in the rat. Paroni R, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):737–42

Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin. Sewerynek E, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):327–34

Anti-oxidant actions of oxymethazoline and xylomethazoline. Westerveld GJ, et al. **Eur J Pharmacol** 1995 Sep 15; 291(1):27–31

Protection by lazaroids of the erythrocyte (Ca2+, Mg2+)-ATPase against iron-induced inhibition. Zaidi A, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):133–9

Free radicals and exercise: effects of nutritional antioxidant supplementation. Kanter M. **Exerc Sport Sci Rev** 1995; 23:375–97 (142 ref.)

Effects of low oxygen tension and antioxidants on human erythropoiesis in vitro. Ono K, et al. **Exp Hematol** 1995 Dec;23(13):1372–7

Opposing effects of oxidants and antioxidants on K+ channel activity and tone in rat vascular tissue. Reeve HL, et al. **Exp Physiol** 1995 Sep;80(5):825–34

Antioxidant survey to assess antagonism to redox stress using a prokaryotic and an eukaryotic system. Baker H, et al. **Experientia** 1996 Jun 15;52(6):597–9

Inhibition of lipid peroxidation by diterpenoid from Podocarpus nagi. Haraguchi H, et al. **Experientia** 1996 Jun 15;52(6):573–6

Neuroprotection by melatonin from kainate-induced excitotoxicity in rats. Giusti P, et al. **FASEB J** 1996 Jun; 10(8):891–6

Trolox inhibits apoptosis in irradiated MOLT-4 lymphocytes. McClain DE, et al. **FASEB J** 1995 Oct;9(13):1345–54

The effect of heparin on Cu(2+)-mediated oxidation of human low-density lipoproteins. Albertini R, et al. **FEBS Lett** 1995 Dec 18;377(2):240–2

Role of retinoic acid and oxidative stress in embryonic stem cell death and neuronal differentiation. Castro-Obregón S, et al. **FEBS Lett** 1996 Feb 26;381(1–2):93–7

Antioxidants differentially affect nuclear factor kappa B-mediated nitric oxide synthase expression in vascular smooth muscle cells. Hecker M, et al. **FEBS Lett** 1996 Feb 19;380(3):224–8

Antioxidant properties of omeprazole. Lapenna D, et al. **FEBS Lett** 1996 Mar 11;382(1–2):189–92

The antioxidant properties of theaflavins and their gallate esters—radical scavengers or metal chelators? Miller NJ, et al. **FEBS Lett** 1996 Aug 19;392(1):40–4

Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth muscle cells. Schobersberger W, et al. **FEBS Lett** 1995 Dec 27;377(3):461–4

Protective effect of antioxidants on the impairment of sperm motility by activated polymorphonuclear leukocytes. Baker HW, et al. **Fertil Steril** 1996 Feb;65(2):411–9

The effect of antioxidant treatment on human spermatozoa and fertilization rate in an in vitro fertilization program. Geva E, et al. **Fertil Steril** 1996 Sep;66(3):430–4

General biological properties of antioxidant permeatoxins and their influence on natural and model membranes. Witek S, et al. **Folia Microbiol (Praha)** 1994;39(6):559–60

An evaluation of the antioxidant and antiviral action of extracts of rosemary and Provençal herbs. Aruoma OI, et al. **Food Chem Toxicol** 1996 May;34(5):449–56

Inhibitory effects of the dietary antioxidants butylated hydroxyanisole and butylated hydroxytoluene on bronchioloalveolar cell proliferation during the bleomycin-induced pulmonary fibrosing process in hamsters. Ikezaki S, et al. **Food Chem Toxicol** 1996 Apr; 34(4):327–35

Pentachlorophenol-induced oxidative DNA damage in mouse liver and protective effect of antioxidants. Sai-Kato K, et al. **Food Chem Toxicol** 1995 Oct;33(10):877–82

Antioxidant inhibition of thymocyte apoptosis by dihydrolipoic acid. Bustamante J, et al. **Free Radic Biol Med** 1995 Sep;19(3):339–47

Organotellurium compounds as efficient retarders of lipid peroxidation in methanol. Engman L, et al. **Free Radic Biol Med** 1995 Oct;19(4):441–52

Multiple antioxidants protect against heme protein and lipid oxidation in kidney tissue. Knudsen CA, et al. **Free Radic Biol Med** 1996;20(2):165–73

Inhibition of human low-density lipoprotein oxidation by caffeic acid and other hydroxycinnamic acid derivatives. Nardini M, et al. **Free Radic Biol Med** 1995 Nov; 19(5):541–52

Prooxidant activity of beta-carotene under 100% oxygen pressure in rat liver microsomes. Palozza P, et al. **Free Radic Biol Med** 1995 Dec;19(6):887–92

Flavonoids as antioxidant agents: importance of their interaction with biomembranes. Saija A, et al. **Free Radic Biol Med** 1995 Oct;19(4):481–6

21-aminosteroid and 2-(aminomethyl)chromans inhibition of arachidonic acid-induced lipid peroxidation and permeability enhancement in bovine brain microvessel endothelial cell monolayers. Shi F, et al. **Free Radic Biol Med** 1995 Sep;19(3):349–57

Antioxidant properties of amidothionophosphates: novel antioxidant molecules. Tirosh O, et al. **Free Radic Biol Med** 1996;20(3):421–32

The effect of dietary supplements on gene expression in mice tissues. Ushakova T, et al. **Free Radic Biol Med** 1996; 20(3):279–84

Structural aspects of antioxidant activity of flavonoids. van Acker SA, et al. **Free Radic Biol Med** 1996;20(3):331–42

Comparison of the effects of dietary vitamin E on in vivo and in vitro parameters of lipid peroxidation in the rabbit. Wiseman SA, et al. **Free Radic Biol Med** 1995 Nov; 19(5):617–26

Factors affecting DNA damage caused by lipid hydroperoxides and aldehydes. Yang MH, et al. **Free Radic Biol Med** 1996;20(2):225–36

7,8 Dihydroneopterin inhibits low density lipoprotein oxidation in vitro. Evidence that this macrophage secreted pteridine is an anti-oxidant. Gieseg SP, et al.

Free Radic Res 1995 Aug;23(2):123–36

Inhibition of oxidation of low density lipoprotein by vitamin E and related compounds. Gotoh N, et al. **Free Radic Res** 1996 Feb;24(2):123–34

Inhibition of neutrophil–superoxide generation by alpha–tocopherol and coenzyme Q. Kanno T, et al. **Free Radic Res** 1996;24(4):281–9

Antioxidative activity of 5,6,7,8–tetrahydrobiopterin and its inhibitory effect on paraquat–induced cell toxicity in cultured rat hepatocytes. Kojima S, et al. **Free Radic Res** 1995 Nov;23(5):419–30

Kinetic modelling of in vitro lipid peroxidation experiments—'low level' validation of a model of in vivo lipid peroxidation. Salvador A, et al. **Free Radic Res** 1995 Aug;23(2):151–72

Evaluation of the pro–oxidant and antioxidant actions of L–DOPA and dopamine in vitro: implications for Parkinson's disease. Spencer JP, et al. **Free Radic Res** 1996 Feb;24(2):95–105

Red cell vitamin E and oxidative damage: a dual role of reducing agents. Wang J, et al. **Free Radic Res** 1996; 24(4):291–8

Mangostin inhibits the oxidative modification of human low density lipoprotein. Williams P, et al. **Free Radic Res** 1995 Aug;23(2):175–84

Antioxidant activity of silybin in vivo during long–term iron overload in rats. Pietrangelo A, et al. **Gastroenterology** 1995 Dec;109(6):1941–9

Molecular actions of ebselen—an antiinflammatory antioxidant. Schewe T. **Gen Pharmacol** 1995 Oct; 26(6):1153–69 (91 ref.)

Effects of aging and antioxidants on glucose transport in rat adipocytes. Moustafa SA, et al. **Gerontology** 1995; 41(6):301–7

Correlations between lipid peroxide and glutathione levels in vitamin C supplemented fasting guinea pigs. Kaplan B. **Horm Metab Res** 1995 Sep;27(9):419–20

Antioxidant and anti–inflammatory property of Sandhika: a compound herbal drug. Chaurasia S, et al. **Indian J Exp Biol** 1995 Jun;33(6):428–32

Radioprotective and antioxidant action of caffeine: mechanistic considerations. Devasagayam TP, et al. **Indian J Exp Biol** 1996 Apr;34(4):291–7 (69 ref.)

Oxygen toxicity and antioxidants: state of the art. Sen CK. **Indian J Physiol Pharmacol** 1995 Jul;39(3):177–96 (91 ref.)

Antioxidant function of melanin in black fungi. Jacobson ES, et al. **Infect Immun** 1995 Dec;63(12):4944–5

Effects of indole–3–acetic acid on croton oil– and arachidonic acid–induced mouse ear edema. Jones LH, et al. **Inflamm Res** 1995 Sep;44(9):372–5

Effects of 2,5–di(tert–butyl)–1,4–hydroquinone on intracellular free Ca2+ levels and histamine secretion in RBL–2H3 cells. Kitajima S, et al. **Inflamm Res** 1995 Aug; 44(8):335–9

Dietary nitrite and scavenger antioxidants trace elements. de Angelis RC, et al. **Int J Food Sci Nutr** 1996 Jan;47(1):23–6

Reduction in endotoxin–induced organ dysfunction and cytokine secretion by a cyclic nitrone antioxidant. Downs TR, et al. **Int J Immunopharmacol** 1995 Jul;17(7):571–80

Hypoxic and posthypoxic neuronal injury in hippocampal cell culture: attenuation by lipophylic antioxidant U–18 and superoxide dismutase. Khaspekov LG, et al. **Int J Neurosci** 1995 May;82(1–2):33–45

Repair of dGMP hydroxyl radical adducts by verbascoside via electron transfer: a pulse radiolysis study. Li W, et al. **Int J Radiat Biol** 1996 Apr;69(4):481–5

Vitamin E prevents UVB–induced cell blebbing and cell death in A431 epidermoid cells. Straface E, et al. **Int J Radiat Biol** 1995 Nov;68(5):579–87

Antioxidants, carnitine, and choline as putative ergogenic aids. Kanter MM, et al. **Int J Sport Nutr** 1995 Jun;5 Suppl:S120–31 (73 ref.)

Effect of dietary supplementation of beta–carotene on human monocyte–macrophage–mediated oxidation of low density lipoprotein. Levy Y, et al. **Isr J Med Sci** 1996 Jun; 32(6):473–8

Role of oxidative stress in transition of hypertrophy to heart failure. Dhalla AK, et al. **J Am Coll Cardiol** 1996 Aug; 28(2):506–14

Antioxidants, oxidants and free radical stress in cardiovascular disease. Singh RB, et al. **J Assoc Physicians India** 1996 Jan;44(1):43–8 (55 ref.)

The rat quinone reductase antioxidant response element. Identification of the nucleotide sequence required for basal and inducible activity and detection of antioxidant response element–binding proteins in hepatoma and non–hepatoma cell lines. Favreau LV, et al. **J Biol Chem** 1995 Oct 13; 270(41):24468–74

Alpha–tocopherol as a reductant for Cu(II) in human lipoproteins. Triggering role in the initiation of lipoprotein oxidation. Kontush A, et al. **J Biol Chem** 1996 May 10; 271(19):11106–12

Antioxidants inhibit interleukin–1–induced cyclooxygenase and nitric–oxide synthase expression in rat mesangial cells. Evidence for post–transcriptional regulation. Tetsuka T, et al. **J Biol Chem** 1996 May 17;271(20):11689–93

Induction of apoptosis by pyrrolidinedithiocarbamate and N–acetylcysteine in vascular smooth muscle cells. Tsai JC, et al. **J Biol Chem** 1996 Feb 16;271(7):3667–70

Effects of high–dose vitamin C administration on bacterial translocation and lung neutrophil sequestration in burned mice. Zapata–Sirvent RL, et al. **J Burn Care Rehabil** 1995 Jul–Aug;16(4):422–8

Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non–small–cell lung cancer cell lines under hypoxia. Bando T, et al. **J Cancer Res Clin Oncol** 1996;122(1):21–6

Novel 21–aminosteroidlike compounds prevent iron–induced free radical–mediated injury to vascular endothelial cells. Pakala R, et al. **J Cardiovasc Pharmacol** 1995 Jun; 25(6):871–9

Beneficial effects of H290/51, a new lipid peroxidation inhibitor, on functional recovery after ischemia and reperfusion in isolated cold–arrested rat hearts. Wang QD, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):924–9

Nutrient antioxidants in the pathogenesis and prevention of cervical dysplasias and cancer. Romney SL, et al. **J Cell Biochem Suppl** 1995;23:96–103 (45 ref.)

Comparative study of the cytostatic effects of Oliphen and Ukrain. Voltchek I, et al. **J Chemother** 1996 Apr;8(2):144–6

Human suction blister interstitial fluid prevents metal ion–dependent oxidation of low density lipoprotein by macrophages and in cell–free systems. Dabbagh AJ, et al. **J Clin Invest** 1995 Oct;96(4):1958–66

BCL–2 expression or antioxidants prevent hyperglycemia–induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. Giardino I, et al. **J Clin Invest** 1996 Mar 15;97(6):1422–8

Beta–carotene inhibits atherosclerosis in hypercholesterolemic rabbits. Shaish A, et al. **J Clin Invest** 1995 Oct;96(4):2075–82

Vitamin C improves endothelium–dependent vasodilation in patients with non–insulin–dependent diabetes mellitus. Ting HH, et al. **J Clin Invest** 1996 Jan 1;97(1):22–8

Scavenging effects of Mallotus repandus on active oxygen species. Lin JM, et al. **J Ethnopharmacol** 1995 Jun; 46(3):175–81

The anti–oxidant activity of turmeric (Curcuma longa). Selvam R, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):59–67

Thiols decrease human interleukin (IL) 4 production and IL–4–induced immunoglobulin synthesis. Jeannin P, et al. **J Exp Med** 1995 Dec 1;182(6):1785–92

In vivo antioxidant treatment suppresses nuclear factor–kappa B activation and neutrophilic lung inflammation. Blackwell TS, et al. **J Immunol** 1996 Aug 15;157(4):1630–7

N–acetylcysteine enhances antibody–dependent cellular cytotoxicity in neutrophils and mononuclear cells from healthy adults and human immunodeficiency virus–infected patients. Roberts RL, et al. **J Infect Dis** 1995 Dec; 172(6):1492–502

Copper(II) complexes encapsulated in human red blood cells. Bonomo RP, et al. **J Inorg Biochem** 1995 Sep;59(4):773–84

Effects on health of dietary supplementation with 100 mg d–alpha–tocopheryl acetate, daily for 6 years. Takamatsu S, et al. **J Int Med Res** 1995 Sep–Oct;23(5):342–57

Antioxidant nutrients protect against UVB–induced oxidative damage to DNA of mouse keratinocytes in culture. Stewart MS, et al. **J Invest Dermatol** 1996 May;106(5):1086–9

Oxidative modification and antioxidant protection of human low density lipoprotein at high and low oxygen partial pressures. Hatta A, et al. **J Lipid Res** 1995 Nov; 36(11):2383–93

Effect of the antioxidant probucol on transplant arteriosclerosis in aorta–allografted rabbits. Andersen HO, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1561–71

Antioxidant effects of pyruvate in isolated rat hearts. Marcengill MB, et al. **J Mol Cell Cardiol** 1995 Sep; 27(9):2059–67

Synthesis and evaluation of 3',5'–di–tert–butyl–4'–hydroxyflavones as potential inhibitors of low density lipoprotein (LDL) oxidation. Lewin G, et al. **J Nat Prod** 1995 Dec;58(12):1840–7

Suppression of hyperacute and passively transferred experimental autoimmune encephalomyelitis by the anti–oxidant, butylated hydroxyanisole. Hansen LA, et al. **J Neuroimmunol** 1995 Oct;62(1):69–77

Effect of propofol on in vitro lipid peroxidation induced by different free radical generating systems: a comparison with vitamin E. Hans P, et al. **J Neurosurg Anesthesiol** 1996 Apr;8(2):154–8

Prevention of atherosclerosis with dietary antioxidants: fact or fiction? Duell PB. **J Nutr** 1996 Apr;126(4 Suppl):1067S–71S (38 ref.)

Prooxidant effects of antioxidant vitamins. Introduction. Herbert V. **J Nutr** 1996 Apr;126(4 Suppl):1197S–200S

Benefits and liabilities of vitamin A and carotenoids. Olson JA. **J Nutr** 1996 Apr;126(4 Suppl):1208S–12S (30 ref.)

The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. Schwartz JL. **J Nutr** 1996 Apr;126(4 Suppl):1221S–7S (42 ref.)

Simultaneous dietary supplementation of sodium cholate and beta–carotene markedly enhances accumulation of beta–carotene in mice. Umegaki K, et al. **J Nutr** 1995 Dec; 125(12):3081–6

Long–term supplementation of canthaxanthin does not inhibit gastric epithelial cell proliferation in Helicobacter mustelae–infected ferrets. Yu J, et al. **J Nutr** 1995 Oct; 125(10):2493–500

Modulation of corneal heme oxygenase expression by oxidative stress agents. Neil TK, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):455–68

Relaxant activity of three aporphine alkaloids from Annona cherimolia on isolated aorta of rat. Chuliá S, et al. **J Pharm Pharmacol** 1995 Aug;47(8):647–50

Enhanced effectiveness of dimethyl–4,4'–dimethoxy–5,6,5',6'–dimethylene dioxybiphenyl–2,2'–dicarboxylate in combination with garlic oil against experimental hepatic injury in rats and mice. Kim SG, et al. **J Pharm Pharmacol** 1995 Aug; 47(8):678–82

Scavenging of free–radicals and inhibition of lipid peroxidation by 3–phenylsydnone. Narla RS, et al. **J Pharm Pharmacol** 1995 Aug;47(8):623–5

Tissue distribution of LY231617, an antioxidant with neuroprotectant activity, in the rat. Brewster ME, et al. **J Pharm Sci** 1995 Jul;84(7):791–3

Protection of ischemic and reperfused rat myocardium by the nonglucocorticoid 21–aminosteroid U–74389G, a new inhibitor of lipid peroxidation. Campo GM, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):333–40

The 21–aminosteroid tirilazad mesylate protects against liver injury via membrane stabilization not inhibition of lipid peroxidation. Wang Y, et al. **J Pharmacol Exp Ther** 1996 May;277(2):714–20

The 21–aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats. Yue G, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):265–70

Protection of plasmid pBR322 DNA by flavonoids against single–stranded breaks induced by singlet molecular oxygen. Devasagayam TP, et al. **J Photochem Photobiol B** 1995 Oct;30(2–3):97–103

Effects of an antioxidant in a rabbit model of tourniquet–induced skeletal muscle ischemia–reperfusion injury. Mohler LR, et al. **J Surg Res** 1996 Jan;60(1):23–8

The effect of vitamin E and doxycycline on the development of intimal hyperplasia. Petrik PV, et al. **J Surg Res** 1996 Feb 1;60(2):279–83

Antioxidant activity of tetrandrine and its inhibition of quartz–induced lipid peroxidation. Shi X, et al. **J Toxicol Environ Health** 1995 Oct;46(2):233–48

Antioxidative action of the beta–adrenoceptor antagonist bopindolol and its metabolite 18–502. Aniya Y, et al. **Jpn J Pharmacol** 1995 Jul;68(3):323–9

Beyond oxidized LDL: the initiation and progression of atherosclerosis. Hirose N, et al. **Keio J Med** 1996 Jun; 45(2):90–4 (26 ref.)

Antioxidants reduce corneal light scattering after excimer keratectomy in rabbits. Jain S, et al. **Lasers Surg Med** 1995; 17(2):160–5

Thymosin alpha 1 protects liver and aorta from oxidative damage in atherosclerotic rabbits. Gökkusu C, et al. **Life Sci** 1996;59(13):1059–67

The antioxidant, U74389, ameliorates the depression of vascular reactivity caused by lipopolysaccharide. Loegering DJ, et al. **Life Sci** 1995;57(20):PL321–6

Endotoxin depletes ascorbate in the guinea pig heart. Protective effects of vitamins C and E against oxidative stress. Rojas C, et al. **Life Sci** 1996;59(8):649–57

Morin hydrate inhibits azo–initiator induced oxidation of human low density lipoprotein. Wu TW, et al. **Life Sci** 1996;58(2):PL 17–22

Antioxidants, lipoprotein oxidation, and arterial function. Bruckdorfer KR. **Lipids** 1996 Mar;31 Suppl:S83–5 (17 ref.)

Protection by multiple antioxidants against lipid peroxidation in rat liver homogenate. Chen H, et al. **Lipids** 1996 Jan; 31(1):47–50

Reinvestigation of the antioxidant properties of conjugated linoleic acid. van den Berg JJ, et al. **Lipids** 1995 Jul; 30(7):599–605

Factors affecting resistance of low density lipoproteins to oxidation. Ziouzenkova O, et al. **Lipids** 1996 Mar;31 Suppl:S71–6

Indenoindole depresses lipofuscin formation in cultured neonatal rat myocardial cells. Marzabadi MR, et al. **Mech Ageing Dev** 1995 Jun 9;80(3):189–97

Superior and distinct antioxidant effects of selected estrogen metabolites on lipid peroxidation. Tang M, et al. **Metabolism** 1996 Apr;45(4):411–4

Anethole dithiolethione: biochemical considerations. Christen MO. **Methods Enzymol** 1995;252:316–23 (40 ref.)

Suppression of protooncogene c–fos expression by antioxidant dihydrolipoic acid. Mizuno M, et al. **Methods Enzymol** 1995;252:180–6

Vascular effects of the 21–aminosteroid tirilazad mesylate: protection against oxidant stress. McKenna R, et al. **Methods Find Exp Clin Pharmacol** 1995 May;17(4):279–92

Antiperoxidative effects of platelet activating factor antagonists against iron–dependent lipid peroxidation in murine ventricular membranes. Reddy DS, et al. **Methods Find Exp Clin Pharmacol** 1995 Jul–Aug; 17(6):383–90

Alpha–tocopherol pretreatment improves endothelium–dependent vasodilation in aortic strips of young and aging rats exposed to oxidative stress. Guarnieri C, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):223–8

Antioxidant activity of allicin, an active principle in garlic. Prasad K, et al. **Mol Cell Biochem** 1995 Jul 19;148(2):183–9

Nordihydroguaiaretic acid and RHC 80267 potentiate astroglial injury during combined glucose–oxygen deprivation. Haun SE, et al. **Mol Chem Neuropathol** 1995 May;25(1):35–49

Characterization of hepatic nitric oxide synthase: identification as the cytokine–inducible form primarily regulated by oxidants. Duval DL, et al. **Mol Pharmacol** 1996 Aug;50(2):277–84

Antioxidant defences against reactive oxygen species causing genetic and other damage. Anderson D. **Mutat Res** 1996 Feb 19;350(1):103–8 (46 ref.)

Radioprotective effects of antioxidative plant flavonoids in mice. Shimoi K, et al. **Mutat Res** 1996 Feb 19;350(1):153–61

Effect of intake of exogenous vitamins C, E and beta–carotene on the antioxidative status in kidneys of rats with streptozotocin–induced diabetes. Mekiňová D, et al. **Nahrung** 1995;39(4):257–61

Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta–amyloid peptides. Miyata M, et al. **Nat Genet** 1996 Sep;14(1):55–61

Carotenoids protect against cell membrane damage by the nitrogen dioxide radical [letter] Böhm F, et al. **Nat Med** 1995 Feb;1(2):98–9

Taking tamoxifen to heart [letter] Wiseman H. **Nat Med** 1995 Dec;1(12):1226

Tolerance to nitrates and simultaneous upregulation of platelet activity prevented by enhancing antioxidant state. Bassenge E, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Feb; 353(3):363–7

Assessment of antimutagenic effects of stobadine dihydrochloride on MNNG–induced mutations in Chinese hamster cells V79. Horváthová E, et al. **Neoplasma** 1995; 42(5):259–64

Synergistic renal protection by combining alkaline–diuresis with lipid peroxidation inhibitors in rhabdomyolysis: possible interaction between oxidant and non–oxidant mechanisms. Salahudeen AK, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):635–42

The effects of ascorbic acid and oxiracetam on scopolamine–induced amnesia in a habituation test in aged mice. de Angelis L, et al. **Neurobiol Learn Mem** 1995 Sep; 64(2):119–24

Change in fluidity of brain endoplasmic reticulum membranes by oxygen free radicals: a protective effect of stobadine, alpha–tocopherol acetate, and butylated hydroxytoluene. Kaplán P, et al. **Neurochem Res** 1995 Jul;20(7):815–20

Retrograde perfusion of the cerebral vein with antioxidant LY231617 reduces brain damage in the rat focal ischemia model. Nagao T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec; 35(12):861–8

The suppression of age–related accumulation of lipid peroxides in rat brain by administration of Rooibos tea (Aspalathus linearis). Inanami O, et al. **Neurosci Lett** 1995 Aug 18;196(1–2):85–8

Tocotrienols from palm oil as potent inhibitors of lipid peroxidation and protein oxidation in rat brain mitochondria. Kamat JP, et al. **Neurosci Lett** 1995 Aug 11;195(3):179–82

Vascular permeability to growth hormone in the rat central nervous system after focal spinal cord injury. Influence of a new anti–oxidant H 290/51 and age. Mustafa A, et al. **Neurosci Res** 1995 Sep;23(2):185–94

Antioxidant and iron–chelating agents in cerebral vasospasm. Luo Z, et al. **Neurosurgery** 1995 Dec;37(6):1154–8; discussion 1158–9

Effects of 4–methylcatechol, a stimulator of endogenous nerve growth factor synthesis, on experimental acrylamide–induced neuropathy in rats. Saita K, et al. **Neurotoxicology** 1995 Fall;16(3):403–12

Identification of antioxidants for prevention of peroxide–mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor. Knepp VM, et al. **PDA J Pharm Sci Technol** 1996 May–Jun;50(3):163–71

The effect of high dose antenatal vitamin E on hypoxia–induced changes in newborn rats. Inan C, et al. **Pediatr Res** 1995 Nov;38(5):685–9

cAMP stimulation of CFTR–expressing Xenopus oocytes activates a chromanol–inhibitable K+ conductance. Mall M, et al. **Pflugers Arch** 1996 Jul;432(3):516–22

Nicanartine improves in vitro resistance of lipoproteins to oxidation. Dailly E, et al. **Pharm Res** 1996 Mar;13(3):457–61

Inhibition of alloxan–induced hyperglycaemia in mice by the pyridoindole stobadine. Stefek M, et al. **Pharmacol Toxicol** 1995 Nov;77(5):320–2

New pharmacologic approaches to acute spinal cord injury. Rhoney DH, et al. **Pharmacotherapy** 1996 May–Jun; 16(3):382–92 (82 ref.)

Dual role of melanins and melanin precursors as photoprotective and phototoxic agents: inhibition of ultraviolet radiation–induced lipid peroxidation. Schmitz S, et al. **Photochem Photobiol** 1995 Jun;61(6):650–5

Inhibition of bacterial mutagenesis by Citrus flavonoids. Calomme M, et al. **Planta Med** 1996 Jun;62(3):222–6

Lipoxygenase inhibition and antioxidant properties of protoberberine and aporphine alkaloids isolated from Mahonia aquifolium [letter] Mišík V, et al. **Planta Med** 1995 Aug;61(4):372–3

Prevention of hydrogen peroxide damage by soybean saponins to mouse fibroblasts. Yoshikoshi M, et al. **Planta Med** 1996 Jun;62(3):252–5

Vitamin E prevents oxidative modification of brain and lymphocyte band 3 proteins during aging. Poulin JE, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5600–3

The role of NF–kappaB in the angiogenic response of coronary microvessel endothelial cells. Stoltz RA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2832–7

d–alpha–tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties. Tasinato A, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12190–4

Atherosclerosis, oxidative stress, and antioxidant protection in endothelium–derived relaxing factor action. Keaney JF Jr, et al. **Prog Cardiovasc Dis** 1995 Sep–Oct;38(2):129–54 (202 ref.)

Clastogenic factors in the plasma of Chernobyl accident recovery workers: anticlastogenic effect of Ginkgo biloba extract. Emerit I, et al. **Radiat Res** 1995 Nov;144(2):198–205

No effect of beta–carotene supplementation on the susceptibility of low density lipoprotein to in vitro oxidation among hypercholesterolaemic, postmenopausal women. Nenseter MS, et al. **Scand J Clin Lab Invest** 1995 Oct;55(6):477–85

Antioxidants inhibit ethanol–induced gastric injury in the rat. Role of manganese, glycine, and carotene. Ligumsky M, et al. **Scand J Gastroenterol** 1995 Sep;30(9):854–60

Antioxidant and calcium channel blockers counteract endothelial barrier injury induced by acute pancreatitis in rats. Wang XD, et al. **Scand J Gastroenterol** 1995 Nov; 30(11):1129–36

Anti–oxidants inhibit the enhancement of the immune response caused by oil adjuvants. Di Gianni P, et al. **Scand J Immunol** 1996 Apr;43(4):413–20

Antioxidants attenuate endotoxin–gentamicin induced acute renal failure in rats. Zurovsky Y, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):147–54

Antioxidant defenses in metal–induced liver damage. Sokol RJ. **Semin Liver Dis** 1996 Feb;16(1):39–46 (40 ref.)

Acetaminophen–induced toxicity to human epidermoid cell line A431 and hepatoblastoma cell line Hep G2, in vitro, is diminished by silymarin. Shear NH, et al. **Skin Pharmacol** 1995;8(6):279–91

Tirilazad does not protect rat brain from brachytherapy–induced injury. Bernstein M, et al. **Surg Neurol** 1996 May;45(5):482–9

Coenzyme Q10 protects coronary endothelial function from ischemia reperfusion injury via an antioxidant effect. Yokoyama H, et al. **Surgery** 1996 Aug;120(2):189–96

Sod and GSH inhibit the high glucose–induced oxidative damage and the PDGF increased secretion in cultured human endothelial cells. Curcio F, et al. **Thromb Haemost** 1995 Sep;74(3):969–73

Plasma ascorbate protects coagulation factors against photooxidation. Parkkinen J, et al. **Thromb Haemost** 1996 Feb;75(2):292–7

Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil. Petroni A, et al. **Thromb Res** 1995 Apr 15;78(2):151–60

Effects of superoxide dismutase and U74389G on acute trimethyltin–induced cochlear dysfunction. Clerici WJ. **Toxicol Appl Pharmacol** 1996 Feb;136(2):236–42

Effect of methimazole on rat renal carcinogenesis induced by N–ethyl–N–hydroxyethylnitrosamine. Konishi N, et al. **Toxicol Pathol** 1995 Sep–Oct;23(5):606–11

Lazaroid U74500A enhances donor lung preservation in the rat transplant model. Du Z, et al. **Transplant Proc** 1995 Dec;27(6):3574–7

Lazaroid U74389G attenuates skeletal muscle reperfusion injury in a canine model. Hoballah JJ, et al. **Transplant Proc** 1995 Oct;27(5):2836–9

Impact of Lazaroid U74006F on ischemia and reperfusion injury of islets after transplantation in the rat. Shapiro AM, et al. **Transplant Proc** 1996 Feb;28(1):85–6

Cardioprotective effects of the lazaroid U74389G following cold preservation and transplantation of rat hearts. Duguay P, et al. **Transplantation** 1996 Apr 15;61(7):1023–8

Protective effects of an indenoindole antioxidant on coronary endothelial function after long–term storage. Wiklund L, et al. **Transplantation** 1995 Oct 27;60(8):774–8

Adenosine, antioxidant enzymes and cytoprotection. Ramkumar V, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):283–5 (31 ref.)

Antioxidant agents and colorectal carcinogenesis: role of beta–carotene, vitamin E and vitamin C. Pappalardo G, et al. **Tumori** 1996 Jan–Feb;82(1):6–11 (88 ref.)

Effect of fatty acid composition, cadmium and vitamin E intake on prooxidative–antioxidative state of rat liver. Krajčovičová–Kudláčková M, et al. **Vet Med (Praha)** 1995 Sep;40(9):293–8

Effects of garlic oil on rat hepatic P4502E1 expression. Kwak MK, et al. **Xenobiotica** 1995 Nov;25(10):1021–9

Antioxidant profile of mono– and dihydroxylated flavone derivatives in free radical generating systems. Montesinos MC, et al. **Z Naturforsch [C]** 1995 Jul–Aug;50(7–8):552–60

[Free radicals and antioxidants. Advantages of antioxidants in clinical medicine, truth or fiction? (editorial)] Huttunen J. **Duodecim** 1994;110(17):1606–8 (25 ref.) **(Fin)**

[Effect of the liposolubility of free radical scavengers on the production of antigen P24 from a HIV infected monocytic cell line] Edeas M, et al. **C R Seances Soc Biol Fil** 1995; 189(3):367–73 (Eng. Abstr.) **(Fre)**

[Substituted methoxyphenol with antioxidative activity: correlation between physicochemical and biological results] Souchard JP, et al. **C R Seances Soc Biol Fil** 1995; 189(6):1171–81 (Eng. Abstr.) **(Fre)**

[Effect of ethoxyquin on the utilization of selenium in growing pigs] Ji C, et al. **Arch Tierernahr** 1995;48(1–2):83–8 (Eng. Abstr.) **(Ger)**

[Free radicals in anesthesia and the role of exogenous antioxidants] Neri S, et al. **Riv Eur Sci Med Farmacol** 1994 Sep–Dec;16(5–6):125–30 (Eng. Abstr.) **(Ita)**

[A probucol analog protects lipoproteins from oxidation better than does probucol] Dmitriev LF, et al. **Biull Eksp Biol Med** 1995 May;119(5):491–3 **(Rus)**

[Effect of methyluracil and oxymethacil on free radical oxidation in model systems] Myshkin VA, et al. **Biull Eksp Biol Med** 1995 Aug;120(8):142–4 **(Rus)**

[Melatonin and epithalamin inhibit the process of free radical oxidation in rats] Anisimov VN, et al. **Dokl Akad Nauk** 1995 Aug;343(4):557–9 **(Rus)**

[Regulation by an antioxidant of growth, composition, and physico–chemical features of lipids from Saccharomyces cerevisiae] Reshetnik OA, et al. **Dokl Akad Nauk** 1996 Feb; 346(5):705–7 **(Rus)**

[Membrane–active preparations as correctors of the nephrotoxicity of gentamicin] Veshkurtseva IM, et al. **Eksp Klin Farmakol** 1995 Nov–Dec;58(6):36–9 (Eng. Abstr.) **(Rus)**

[The mutagenic and modifying properties of emoxipin studied by micronucleus assay in liver cells] Uryvaeva IV, et al. **Izv Akad Nauk Ser Biol** 1996 Jan–Feb;(1):5–9 (Eng. Abstr.) **(Rus)**

[Effect of the antioxidant dibunol on hemostatic parameters in patients with non–healing ulcers] Podoprigorova VG, et al. **Klin Med (Mosk)** 1996;74(1):43–5 (Eng. Abstr.) **(Rus)**

[Effectiveness of the use of synthetic opioid peptide in rats with traumatic shock] Mikhailova NN, et al. **Patol Fiziol Eksp Ter** 1995 Oct–Dec;(4):27–9 (Eng. Abstr.) **(Rus)**

[Stabilization of omega–3–polyunsaturated acids in fat from Mallotus villosus (Osmeridae) by the nontoxic, sulfur–containing antioxidant CO–3] Rezvukhin AI, et al. **Vopr Med Khim** 1995 May–Jun;41(3):37–9 (Eng. Abstr.) **(Rus)**

[Nitroxyl radical Tempol as a modulator of toxic and antineoplastic effect of 6–mercaptopurine] Konovalova NP, et al. **Vopr Onkol** 1996;42(3):57–63 (Eng. Abstr.) **(Rus)**

[The effect of the modified preparation Komplivit on blood coagulation] Solov'ev VG, et al. **Vopr Pitan** 1995;(4):30–2 (Eng. Abstr.) **(Rus)**

[Antioxidant activity of the drug distinol in vitro] Kalytka VV, et al. **Ukr Biokhim Zh** 1995 Jul–Aug;67(4):87–92 (Eng. Abstr.) **(Ukr)**

POISONING

[Chronic obstructive bronchopneumopathy after acute inhalation of sulfur anhydride. Apropos of a case] Ramakers M, et al. **Rev Pneumol Clin** 1995;51(6):343–7 (31 ref.) (Eng. Abstr.) **(Fre)**

RADIATION EFFECTS

[Effects of intravenous laser irradiation of blood on the sympathoadrenal, antioxidant and immune system in patients with cancer of the stomach and large intestine] Lal'chenko NA, et al. **Klin Khir** 1996;(1):36–9 **(Rus)**

STANDARDS

Oxidative damage and defense. Jacob RA, et al. **Am J Clin Nutr** 1996 Jun;63(6):985S–990S (43 ref.)

THERAPEUTIC USE

Response to oral beta–carotene supplementation in patients with cystic fibrosis: a 16–month follow–up study. Winklhofer–Roob BM, et al. **Acta Paediatr** 1995 Oct; 84(10):1132–6

Effects of antioxidant vitamins C and E on signal–averaged electrocardiogram in acute myocardial infarction. Chamiec T, et al. **Am J Cardiol** 1996 Feb 1;77(4):237–41

Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival–3). Singh RB, et al. **Am J Cardiol** 1996 Feb 1; 77(4):232–6

Antioxidant Vitamins and Beta–Carotene in Disease Prevention. Proceedings of a symposium. Berlin, Germany, October 10–12, 1994. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1299S–1540S

Beta–Carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. McLarty JW, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1431S–1438S

Trial of d–alpha–tocopherol in Huntington's disease. Peyser CE, et al. **Am J Psychiatry** 1995 Dec;152(12):1771–5

Effects of U–74389G, a novel 21–aminosteroid, on small intestinal ischemia and reperfusion injury in horses. Vatistas NJ, et al. **Am J Vet Res** 1996 May;57(5):762–70

An antistress and antiaging neurometabolic therapy. Accelerated lipofuscinolysis and stimulated anabolic regeneration by the antagonic–stress synergistic formula. Riga S, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:535–50

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. **Ann Neurol** 1996 Jan;39(1):37–45

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. **Ann Neurol** 1996 Jan;39(1):29–36

Prevention of radioinduced cystitis by orgotein: a randomized study. Sanchiz F, et al. **Anticancer Res** 1996 Jul–Aug; 16(4A):2025–8

Antioxidants in neonatal lung disease. Fardy CH, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Sep;73(2):F112–7 (66 ref.)

Protective effect of selenium on hemoglobin mediated lipid peroxidation in vivo. Simoni J, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(4):469–86

Improved survival and reversal of endothelial dysfunction by the 21-aminosteroid, U-74389G in splanchnic ischaemia-reperfusion injury in the rat. Squadrito F, et al. **Br J Pharmacol** 1995 Jun;115(3):395–400

Tirilazad prevention of reperfusion edema after focal ischemia in cynomolgus monkeys. Boisvert DP, et al. **Can J Neurol Sci** 1996 Feb;23(1):46–52

Antiarrhythmic effects of ceruloplasmin during reperfusion in the ischemic isolated rat heart. Atanasiu R, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1253–61

Effect of prolonged beta-carotene or DL-alpha-tocopheryl acetate supplementation on ornithine decarboxylase activity in human atrophic stomach mucosa. Bukin YV, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Dec; 4(8):865–70

Prevention of doxorubicin induced cardiotoxicity by catechin. Kozluca O, et al. **Cancer Lett** 1996 Jan 19; 99(1):1–6

Inhibition of the hepatocarcinogenicity of aflatoxin B1 in rats by low levels of the phenolic antioxidants butylated hydroxyanisole and butylated hydroxytoluene. Williams GM, et al. **Cancer Lett** 1996 Jun 24;104(1):49–53

Adjunctive treatment of murine neuroblastoma with 6-hydroxydopamine and Tempol. Purpura P, et al. **Cancer Res** 1996 May 15;56(10):2336–42

Accumulation of phosphatydilcholine-hydroperoxide in dialysis patients with diabetic nephropathy. Sanaka T, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S33–7

Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Ziegler D, et al. **Diabetologia** 1995 Dec;38(12):1425–33

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Feuerstein GZ, et al. **Eur Heart J** 1995 Jul;16 Suppl F:38–42 (21 ref.)

Antioxidants, Helicobacter pylori and stomach cancer in Venezuela. de Sanjosé S, et al. **Eur J Cancer Prev** 1996 Feb;5(1):57–62

Antioxidant properties of zinc [letter] Gatto LM, et al. **Eur J Clin Nutr** 1995 Nov;49(11):866–7

Characterization of drugs as antioxidant prophylactics. Aruoma OI. **Free Radic Biol Med** 1996;20(5):675–705 (473 ref.)

Taurine protects the heart from neutrophil-induced reperfusion injury. Raschke P, et al. **Free Radic Biol Med** 1995 Oct;19(4):461–71

Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Rybak LP, et al. **Fundam Appl Toxicol** 1995 Jul;26(2):293–300

Transdermal estradiol and medroxyprogesterone acetate in hormone replacement therapy are both antioxidants. Tranquilli AL, et al. **Gynecol Endocrinol** 1995 Jun; 9(2):137–41

Protective effects of few antioxidants on liver function in rats treated with cadmium and mercury. Rana SV, et al. **Indian J Exp Biol** 1996 Feb;34(2):177–9

Effects of the lazaroid U74389G (21 aminosteroid) on skeletal muscle reperfusion injury in rabbits. Hoballah JJ, et al. **Int Angiol** 1996 Mar;15(1):61–6

Epidemiologic studies of antioxidants and cancer in humans. Flagg EW, et al. **J Am Coll Nutr** 1995 Oct;14(5):419–27 (88 ref.)

Hemodynamic effects of delayed initiation of antioxidant therapy (beginning two hours after burn) in extensive third-degree burns. Tanaka H, et al. **J Burn Care Rehabil** 1995 Nov-Dec;16(6):610–5

Attenuation of reperfusion injury by the antioxidant n-propyl gallate. Bhatnagar A. **J Cardiovasc Pharmacol** 1995 Sep; 26(3):343–7

Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. Maggi E, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):532–8

beta-carotene and cancer chemoprevention. Buring JE, et al. **J Cell Biochem Suppl** 1995;22:226–30 (37 ref.)

N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. van Zandwijk N. **J Cell Biochem Suppl** 1995; 22:24–32 (48 ref.)

Clinical and biochemical findings in a Spanish boy with primary carnitine deficiency. Briones P, et al. **J Inherit Metab Dis** 1995;18(2):237–40

Effect of dietary antioxidant trace element supply on cardiac tolerance to ischemia-reperfusion in the rat. Pucheu S, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2303–14

Tetrahydrobiopterin double-blind, crossover trial in Machado-Joseph disease. Sakai T, et al. **J Neurol Sci** 1996 Mar;136(1-2):71–2

Tirilazad and subarachnoid hemorrhage [letter] Astrup J, et al. **J Neurosurg** 1996 Jun;84(6):1078–9

Lack of effect of postinjury treatment with methylprednisolone or tirilazad mesylate on the increase in eicosanoid levels in the acutely injured cat spinal cord. Hall ED, et al. **J Neurotrauma** 1995 Jun;12(3):245–56

Pitfalls and advances from the international tirilazad trial in moderate and severe head injury. Marshall LF, et al. **J Neurotrauma** 1995 Oct;12(5):929–32

Vitamin E supplementation in cystic fibrosis. Peters SA, et al. **J Pediatr Gastroenterol Nutr** 1996 May;22(4):341–5

Antioxidants and lupus erythematosis [letter] Cheraskin E. **J R Soc Health** 1996 Feb;116(1):13

Lazaroid therapy (methylaminochroman: U83836E) reduces vein graft intimal hyperplasia. Davies MG, et al. **J Surg Res** 1996 Jun;63(1):128–36

Attenuation of multiple organ dysfunction in a chronic sheep model by the 21-aminosteroid U74389G. Remmers D, et al. **J Surg Res** 1996 May;62(2):278–83

Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Tomeo AC, et al. **Lipids** 1995 Dec;30(12):1179–83

Protective effect of stobadine, a pyridoindole antioxidant, in hypoxia-reoxygenation injury of ganglionic and hippocampal neurotransmission. Stolc S, et al. **Mol Chem Neuropathol** 1995 Jun-Aug;25(2-3):199–212

Antioxidant vitamins, cancer, and cardiovascular disease [editorial; comment] Greenberg ER, et al. **N Engl J Med** 1996 May 2;334(18):1189–90. Comment on: N Engl J Med 1996 May 2;334(18):1145–9. Comment on: N Engl J Med 1996 May 2;334(18):1150–5. Comment on: N Engl J Med 1996 May 2;334(18):1156–62.

Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease [see comments] Hennekens CH, et al. **N Engl J Med** 1996 May 2;334(18):1145–9. Comment in: N Engl J Med 1996 May 2;334(18):1189–90.

Antioxidant vitamins, cancer, and cardiovascular disease [letter] Krinsky NI, et al. **N Engl J Med** 1996 Oct 3; 335(14):1066–7; discussion 10669

Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease [see comments] Omenn GS, et al. **N Engl J Med** 1996 May 2;334(18):1150–5 . Comment in: N Engl J Med 1996 May 2;334(18):1189–90.

Antioxidant vitamins, cancer, and cardiovascular disease [letter] von Eggers Doering W. **N Engl J Med** 1996 Oct 3;335(14):1065; discussion 1067–8

Antioxidant vitamins: getting to the heart of the matter [letter] Scott RS. **N Z Med J** 1996 Aug 23;109(1028):324

Nutritional antioxidants: their role in disease prevention. Winterbourn CC. **N Z Med J** 1995 Nov 10;108(1011):447–9

Contraction and relaxation of aortas from diabetic rats: effects of chronic anti-oxidant and aminoguanidine treatments. Archibald V, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Apr; 353(5):584–91

Sodium thiosulfate in the treatment of tumoral calcifications in a hemodialysis patient without hyperparathyroidism. Papadakis JT, et al. **Nephron** 1996;72(2):308–12

The role of N-acetylcysteine in the treatment of chronic obstructive pulmonary disease [editorial] van Herwaarden CL, et al. **Neth J Med** 1995 Aug;47(2):45–8 (21 ref.)

Retrograde perfusion of the cerebral vein with antioxidant LY231617 reduces brain damage in the rat focal ischemia model. Nagao T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec; 35(12):861–8

Influence of a 'brain protector' drug 21-amino steroid on the effects of experimental embolic stroke treated by thrombolysis. Orozco J, et al. **Neurol Res** 1995 Dec; 17(6):423–5

Antioxidant therapy in critical care medicine. Tanswell AK, et al. **New Horiz** 1995 May;3(2):330–41 (140 ref.)

The protective effect of probucol on adriamycin nephrosis in the rat. Futenma A, et al. **Nippon Jinzo Gakkai Shi** 1995 Nov;37(11):616–21

Altered cytokeratin expression in carcinogenesis inhibition by antioxidant nutrients. Schwartz JL, et al. **Nutr Cancer** 1995;24(1):47–56

1'-Acetoxychavicol acetate, a superoxide anion generation inhibitor, potently inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in ICR mouse skin. Murakami A, et al. **Oncology** 1996 Sep-Oct;53(5):386–91

Antioxidant therapy in the treatment of experimental acute corneal inflammation. Alio JL, et al. **Ophthalmic Res** 1995; 27(3):136–43

Antioxidants in pediatric gastrointestinal disease. Sokol RJ, et al. **Pediatr Clin North Am** 1996 Apr;43(2):471–88 (102 ref.)

Proline, ascorbic acid, or thioredoxin affect jaundice and mortality in Long Evans cinnamon rats. Hawkins RL, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):509–15

Natural antioxidants for the prevention of atherosclerosis. Odeh RM, et al. **Pharmacotherapy** 1995 Sep-Oct; 15(5):648–59 (105 ref.)

Oxidative stress and antioxidant therapy in Parkinson's disease. Ebadi M, et al. **Prog Neurobiol** 1996 Jan;48(1):1–19 (340 ref.)

Possibilities of brain protection with tirilazad after cardiac arrest. Sterz F, et al. **Semin Thromb Hemost** 1996; 22(1):105–12 (37 ref.)

Amelioration of impaired cerebral metabolism after severe acidotic ischemia by tirilazad posttreatment in dogs. Kim H, et al. **Stroke** 1996 Jan;27(1):114–21

Oxidants/antioxidants in idiopathic pulmonary fibrosis. MacNee W, et al. **Thorax** 1995 Sep;50 Suppl 1:S53–8 (64 ref.)

[Vasoactive intestinal polypeptide prevents injury of pulmonary vascular permeability due to xanthine with xanthine oxidase] Lin Y, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Aug; 17(4):259–63 (Eng. Abstr.) **(Chi)**

[Is ubiquinone worth noticing? (editorial)] Alho H. **Duodecim** 1994;110(4):369–71 (18 ref.) **(Fin)**

[SETTI-Study and antioxidants--more questions than answers (editorial)] Huttunen J, et al. **Duodecim** 1994; 110(12):1115–8 **(Fin)**

[Safety of antioxidants] Mäntylä E, et al. **Duodecim** 1994; 110(17):1629–39 (59 ref.) **(Fin)**

[Duchenne Boulogne myopathy and free radicals; potential value of lazaroids in the treatment of this disease] Poindron P, et al. **C R Seances Soc Biol Fil** 1995;189(6):1199–217 **(Fre)**

[Antioxidants support the intrinsic physical response (interview by Heinz W. Weismann)] Magnussen H. **Pneumologie** 1996 Jan;50(1):VII **(Ger)**

[Cardioprotection in chemo- and radiotherapy for malignant diseases--an echocardiographic pilot study] Wagdi P, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1220–3 (Eng. Abstr.) **(Ger)**

[Nutritional support, free radicals, and antioxidants (editorial)] Faintuch J, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 May-Jun; 50(3):133–5 (Eng. Abstr.) **(Por)**

[The antioxidant therapy of cholestatic liver depression in diabetics] Gushcha AL, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):13–8 (Eng. Abstr.) **(Rus)**

[Effects of antioxidant therapy on the energy metabolism system and antioxidant defense during the acute period of myocardial infarction] Sokolov IM. **Anesteziol Reanimatol** 1995 Sep-Oct;(5):21–3 (Eng. Abstr.) **(Rus)**

[The effect of oxypine on tissue edema in allergic rabbits] Bazanov GA. **Biull Eksp Biol Med** 1995 Jul;120(7):84–6 **(Rus)**

[The effects of preparations that influence the brain monoaminergic systems in pain syndromes] Danilova EI, et al. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):14–7 **(Rus)**

[The clinical significance of selenium deficiency in patients from the Samara region with cardiovascular diseases and its correction with the preparation Selena] Kuznetsov GP, et al. **Eksp Klin Farmakol** 1995 Sep-Oct;58(5):26–8 (Eng. Abstr.) **(Rus)**

[A trial of the efficacy of using the synthetic antioxidant dibunol in the chemotherapy of experimental tumors] Krutova TV, et al. **Izv Akad Nauk Ser Biol** 1996 May-Jun; (3):369–73 (Eng. Abstr.) **(Rus)**

[The dose-dependent effects of a combination of different classes of antioxidants exemplified by dibunol and beta-carotene] Minenkova EA, et al. **Izv Akad Nauk Ser Biol** 1996 Mar-Apr;(2):147–52 (Eng. Abstr.) **(Rus)**

[Aevit and glutamic acid in the treatment of patients with bronchial asthma] Daniliak IG, et al. **Klin Med (Mosk)** 1995; 73(5):50–3 (Eng. Abstr.) **(Rus)**

[Osteogenesis during the correction of burns with alpha-tocopherol] Koveshnikov VG, et al. **Morfologiia** 1994 Jul-Dec;107(7–12):67–75 (Eng. Abstr.) **(Rus)**

[The effect of antioxidants on functional brain disorders caused by low-intensity ionizing radiation] Godukhin OV, et al. **Radiats Biol Radioecol** 1995 Jul-Aug;35(4):500–6 (Eng. Abstr.) **(Rus)**

[The efficacy of emoxipin and neoton in unstable stenocardia] Golikov AP, et al. **Ter Arkh** 1996;68(1):31–3 (Eng. Abstr.) **(Rus)**

[Biochemical mechanisms of protective action of enomelanin during hemic hypoxia caused by carbon monoxide] Barinova IE, et al. **Ukr Biokhim Zh** 1995 Sep-Oct; 67(5):89–93 (Eng. Abstr.) **(Rus)**

[Antioxidant effect of metallothioneins in acute bromobenzene poisoning in mice] Koterov AN, et al. **Ukr Biokhim Zh** 1995 Sep-Oct;67(5):99–105 (Eng. Abstr.) **(Rus)**

[Treatment of primary open-angle glaucoma by the method of combined use of hyperbaric oxygenation and antioxidants] Popova ZS, et al. **Vestn Oftalmol** 1996 Jan-Mar;112(1):4–6 (Eng. Abstr.) **(Rus)**

[Role of lipid peroxidation in the pathogenesis of influenza and search for antiviral protective agents] Chetverikova LK, et al. **Vestn Ross Akad Med Nauk** 1996;(3):37–40 (Eng. Abstr.) **(Rus)**

[Effects of the antioxidant ionol on humoral immune response in experimental influenza] Meringova LF, et al. **Vestn Ross Akad Med Nauk** 1996;(3):34–7 (Eng. Abstr.) **(Rus)**

[First experience with thermoradiochemotherapy for patients with squamous cell carcinoma of the anal canal] Knysh VI, et al. **Vopr Onkol** 1996;42(3):79–81 **(Rus)**

[The antioxidant correction of cytogenetic disorders in viral hepatitis] Peresadin NA, et al. **Vrach Delo** 1995 Jan-Feb; (1-2):76–9 (Eng. Abstr.) **(Rus)**

[Thrombocytic serotoninergic markers in therapy-resistant patients with endogenous depression undergoing alpha-tocopherol treatment] Brusov OS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):72–6 (Eng. Abstr.) **(Rus)**

[The role of antioxidants in the prevention of tumors] Ginter E. **Bratisl Lek Listy** 1995 Apr;96(4):195–209 (32 ref.) (Eng. Abstr.) **(Slo)**

[Pharmacologic control of reperfusion dysrhythmias] Kovács

P, et al. **Ceska Slov Farm** 1995 Oct;44(5):257–60 (Eng. Abstr.) **(Slo)**

[The advantages of associating ischemia/reperfusion injury inhibitors with intravenous thrombolysis when treating focal brain ischemia: a description of experiments using rats] Alonso de Leciñana M, et al. **Rev Neurol** 1996 Feb; 24(126):207–13 (Eng. Abstr.) **(Spa)**

[Lipid peroxidation in an experimental study of an erosion–ulcer lesion of the stomach as affected by the new high–protein products and ethonium] Fediv OI, et al. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):79–85 (Eng. Abstr.) **(Ukr)**

[The morphofunctional changes in the ventricular myocardium in experimental infarct and its treatment by hyperbaric oxygenation and tocopherol acetate] Netliukh MA, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):84–8 (Eng. Abstr.) **(Ukr)**

TOXICITY

Toxicological studies on potentiated ionophores in chickens. III. Electrotoxicological investigations. Lehel J, et al. **Acta Vet Hung** 1995;43(2–3):347–54

Toxicological studies on potentiated ionophores in chickens. I. Tolerance study. Lehel J, et al. **Acta Vet Hung** 1995; 43(2–3):321–33

Toxicological studies on potentiated ionophores in chickens. II. Compatibility study. Lehel J, et al. **Acta Vet Hung** 1995; 43(2–3):335–45

Increased gamma–glutamylcysteine synthetase and gamma–glutamyl transpeptidase activities enhance resistance of rat lung epithelial L2 cells to quinone toxicity. Liu RM, et al. **Am J Respir Cell Mol Biol** 1996 Feb; 14(2):192–7

Glutathione conjugates of tert–butyl–hydroquinone, a metabolite of the urinary tract tumor promoter 3–tert–butyl–hydroxyanisole, are toxic to kidney and bladder. Peters MM, et al. **Cancer Res** 1996 Mar 1; 56(5):1006–11

A fly in the ointment. Induction of oxidative DNA damage and enhancement of cell proliferation in human lymphocytes in vitro by butylated hydroxyanisole. Phillips B. **Hum Exp Toxicol** 1995 Jun;14(6):541–2

Pulmonary phospholipid changes induced by butylated hydroxy toluene, an antioxidant, in rats. Tamizhselvi R, et al. **Indian J Exp Biol** 1995 Oct;33(10):796–7

Effects of dicoumarol on cytotoxicity caused by tert–butylhydroquinone in isolated rat hepatocytes. Nakagawa, Y. **Toxicol Lett** 1996 Feb;84(2):63–8

Hematological alterations in propylene glycol–dosed female rats are minimal. Saini M, et al. **Vet Hum Toxicol** 1996 Apr;38(2):81–5

[Comparative studies on a single dose toxicity of microsomal Ca(2+)ATPase inhibitor, 2,5–di(tert–butyl)–1,4–hydroquinone and its related analog, mono(tert–butyl)–1,4–hydroquinone, in rats] Kitajima S, et al. **Eisei Shikenjo Hokoku** 1995;(113):64–8 (Eng. Abstr.) **(Jpn)**

ANTIPAIN

PHARMACOLOGY

Suppression of UV– and interferon–alpha–refractoriness by antipain in human IFr cells established from RSa cells sensitive to both stimuli. Suzuki N. **J Cell Physiol** 1996 Apr;167(1):47–51

ANTIPARASITIC AGENTS

ANALYSIS

Simple and sensitive enzyme–linked immunosorbent assay for ivermectin. Mitsui Y, et al. **Am J Trop Med Hyg** 1996 Mar; 54(3):243–8

METABOLISM

Avermectins. MacNeil DJ. **Biotechnology** 1995;28:421–42 (59 ref.)

PHARMACOKINETICS

Controlled efficacy study of the bioequivalence of Strongid C and generic pyrantel tartrate in horses. Valdez RA, et al. **Vet Parasitol** 1995 Nov;60(1–2):83–102

PHARMACOLOGY

Anticryptosporidial activity of paromomycin [letter; comment] Cirioni O, et al. **J Infect Dis** 1995 Oct; 172(4):1169–70. Comment on: J Infect Dis 1994 Aug;170(2):419–24.

THERAPEUTIC USE

Effectiveness of the ivermectin sustained–release bolus in the control of bovine nematodosis. Yazwinski TA, et al. **Am J Vet Res** 1995 Dec;56(12):1599–602

Efficacy of an ivermectin and pyrantel pamoate combination against adult hookworm, Ancylostoma braziliense, in dogs. Shoop WL, et al. **Aust Vet J** 1996 Mar;73(3):84–5

Dreamtime, devastation and deviation: Australia's contribution to the chemotherapy of human parasitic infections. Boreham PF. **Int J Parasitol** 1995 Sep; 25(9):1009–22 (73 ref.)

Endectocidal drugs: ecological risks and counter–measures. Herd R. **Int J Parasitol** 1995 Aug;25(8):875–85 (82 ref.)

New trends in chemotherapy on human and animal blood parasites. Schrével J, et al. **Parasitol Res** 1996;82(3):283–4

Targeted chemotherapy for parasite infestations in rural black preschool children. Taylor M, et al. **S Afr Med J** 1995 Sep;85(9):870–4

[Treatment of intestinal parasitic diseases] Siikamäki H. **Duodecim** 1994;110(14):1349–55 (13 ref.) **(Fin)**

[Antiparasitic therapeutics. Proceedings of the 2nd Pharo and Laveran Hospital meeting. Marseille, 8 September 1995] **Med Trop (Mars)** 1995;55(3 Suppl):9–56 **(Fre)**

[Anti–parasitic therapies: good reasons to hope....(editorial)] Dessein A. **Med Trop (Mars)** 1995;55(3):223–4 **(Fre)**

ANTIPARKINSON AGENTS

ADMINISTRATION & DOSAGE

Treatment of Parkinson's disease with controlled–release Carbidopa/L–DOPA. Pahwa R, et al. **Adv Neurol** 1996; 69:487–91

Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients. Mizutani Y, et al. **Biol Pharm Bull** 1995 Dec;18(12):1729–37

Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Sam E, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jan–Mar; 20(1):27–33

Treatment of Parkinson's disease. Bergus G. **J Fam Pract** 1996 May;42(5):457–8

Single vs multiple daily dosing of aminoglycosides. Newton W. **J Fam Pract** 1996 May;42(5):456–7

Clinical analysis of Parkinson's disease treated by integration of traditional Chinese and western medicine. Li G. **J Tradit Chin Med** 1995 Sep;15(3):163–9

Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. van Laar T, et al. **Mov Disord** 1995 Jul; 10(4):433–9

[Effectiveness of slow release L–DOPA/benserazide in treatment of end–of–dose akinesia in Parkinson disease] Eichhorn TE, et al. **Nervenarzt** 1995 Dec;66(12):933–41 (Eng. Abstr.) **(Ger)**

[The use of the Sinemet–CR preparation in treating Parkinson's disease] Artem'ev DV, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(5):31–5 (Eng. Abstr.) **(Rus)**

[Changes in the indices of standing and walking in patients with infantile cerebral palsy under the influence of low doses of Nakom] Brin IL, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(5):39–43 (Eng. Abstr.) **(Rus)**

[The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti–parkinsonian drugs] Artázcoz Sanz MT, et al. **Rev Esp Salud Publica** 1995 Nov–Dec;69(6):479–85 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Parkinsonian rigidity, dopa–induced dyskinesia and chorea—dynamic studies on the basal ganglia–thalamocortical motor circuit using PET scan and depth microrecording. Hirato M, et al. **Acta Neurochir Suppl (Wien)** 1995;64:5–8

Involvement of serotonin in clinical features of Parkinson's disease and complications of L–DOPA therapy. Melamed E, et al. **Adv Neurol** 1996;69:545–50 (47 ref.)

Ondansetron, a 5–HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L–DOPA therapy in advanced Parkinson's disease. Zoldan J, et al. **Adv Neurol** 1996;69:541–4

Deprenyl in Parkinson's disease [letter] Korczyn AD, et al. **Ann Neurol** 1996 Aug;40(2):268–9

Pseudopheochromocytoma in a patient with Parkinson's disease [letter] Duarte J, et al. **Ann Pharmacother** 1996 May; 30(5):546

Prefrontal cortical and hippocampal modulation of haloperidol–induced catalepsy and apomorphine–induced stereotypic behaviors in the rat. Lipska BK, et al. **Biol Psychiatry** 1995 Aug 15;38(4):255–62

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients [letter; comment] Anderson KE, et al. **BMJ** 1996 Mar 16;312(7032):702; discussion 704–5. Comment on: BMJ 1995 Dec 16;311(7020):1583–4. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used [letter; comment] Gerlach M, et al. **BMJ** 1996 Mar 16;312(7032):704; discussion 704–5. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation [letter; comment] Jellinger KA. **BMJ** 1996 Mar 16; 312(7032):704–5. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom [see comments] Lees AJ. **BMJ** 1995 Dec 16;311(7020):1602–7. Comment in: BMJ 1995 Dec 16;311(7020):1583–4. Comment in: BMJ 1996 Mar 16;312(7032):702; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):702–3; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):703; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):703–4; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):704; discussion 704–5. Comment in: BMJ 1996 Mar 16;312(7032):704–5.

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality [letter; comment] Mäki–Ikola O, et al. **BMJ** 1996 Mar 16;312(7032):702; discussion 704–5. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary [letter; comment] Olanow CW, et al. **BMJ** 1996 Mar 16;312(7032):702–3; discussion 704–5. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations [letter; comment] Yu PH, et al. **BMJ** 1996 Mar 16;312(7032):703–4; discussion 704–5. Comment on: BMJ 1995 Dec 16;311(7020):1602–7.

Therapeutic dilemma: psychosis and Parkinson's disease [letter] Damecour CL, et al. **Can J Psychiatry** 1995 Dec; 40(10):640–1

Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Jiménez–Jiménez FJ, et al. **Clin Neuropharmacol** 1995 Jun;18(3):277–9

Neuroleptic malignant syndrome postoperative onset due to levodopa withdrawal. Young CC, et al. **J Clin Anesth** 1995 Dec;7(8):652–6

Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic–rigid syndromes. Rich SS, et al. **J Clin Psychiatry** 1995 Dec;56(12):556–9

Sublingual apomorphine: a new pharmacological approach in Parkinson's disease? Montastruc JL, et al. **J Neural Transm Suppl** 1995;45:157–61

Positron emission tomography of reversible intellectual impairment induced by long–term anticholinergic therapy. Nishiyama K, et al. **J Neurol Sci** 1995 Sep;132(1):89–92

Combined clozapine and electroconvulsive therapy for the treatment of drug–induced psychosis in Parkinson's disease. Factor SA, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):304–7

A 61–year–old man with Parkinson's disease [letter; comment] Hayes HD. **JAMA** 1996 Jul 10;276(2):103–4; discussion 104. Comment on: JAMA 1996 Mar 6;275(9):716–22.

Bipolar affective disorder and unilateral parkinsonism after a brainstem infarction. Kulisevsky J, et al. **Mov Disord** 1995 Nov;10(6):799–802

Amantadine–induced "vocal" myoclonus [letter] Pfeiffer RF. **Mov Disord** 1996 Jan;11(1):104–6

Zotepine in levodopa–induced Psychosis. Spieker S, et al. **Mov Disord** 1995 Nov;10(6):795–7

Levodopa in pregnancy [letter] von Graevenitz KS, et al. **Mov Disord** 1996 Jan;11(1):115–6

Suggestive evidence for bromocriptine–induced pleurisy. Klaassen RJ, et al. **Neth J Med** 1996 Jun;48(6):232–6

Improvement of levodopa–induced dyskinesia by propranolol in Parkinson's disease. Carpentier AF, et al. **Neurology** 1996 Jun;46(6):1548–51

Levodopa–induced dyskinesias are improved by fluoxetine. Durif F, et al. **Neurology** 1995 Oct;45(10):1855–8

[Value of clozapine in treatment of psychotic disorder in Parkinson disease] Abbar M, et al. **Encephale** 1996 Jan–Feb; 22(1):53–63 (46 ref.) (Eng. Abstr.) **(Fre)**

[Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease] Dubois B, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):103–5 **(Fre)**

[Reversible esophageal dysfunction as a side effect of levodopa] Kellner H, et al. **Bildgebung** 1996 Mar; 63(1):48–50 (Eng. Abstr.) **(Ger)**

[Levodopa and malignant melanoma—case report and review of the literature. A contribution to causal relationship between levodopa and the development of malignant melanoma] Kleinhans M, et al. **Hautarzt** 1996 Jun; 47(6):432–7 (29 ref.) (Eng. Abstr.) **(Ger)**

[Parkinson syndrome: iatrogenic causes, iatrogenic treatment results] Burgunder JM. **Schweiz Med Wochenschr** 1996 Mar 30;126(13):522–7 (22 ref.) (Eng. Abstr.) **(Ger)**

[Dopaminomimetic psychosis] Ilić T, et al. **Vojnosanit Pregl** 1995 Mar–Apr;52(2):184–8 **(Scr)**

CHEMICAL SYNTHESIS

(S)–(–)–5–ethynyl–3–(1–methyl–2–pyrrolidinyl)pyridine maleate (SIB–1508Y): a novel anti–parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. Cosford ND, et al. **J Med Chem** 1996 Aug 16;39(17):3235–7

ANTIPARKINSON AGENTS

CHEMISTRY

Compatibility of haloperidol and diphenhydramine in a hypodermic syringe [letter] Ukhun IA. **Ann Pharmacother** 1995 Nov;29(11):1168–9

Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Pappert EJ, et al. **Mov Disord** 1996 Jan;11(1):24–6

DIAGNOSTIC USE

[Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease] Miranda M, et al. **Rev Med Chil** 1995 Mar;123(3):326–9 (Eng. Abstr.) **(Spa)**

HISTORY

[Scientific raisins from 125 years SMW (Swiss Medical Weekly). On Parpanit, a new agents which modifies extrapyramidal motor disorders. 1946 (classical article)] Grünthal E. **Schweiz Med Wochenschr** 1995 Oct 14; 125(41):1959–61 **(Ger)**

PHARMACOKINETICS

Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA. Nutt JG. **Adv Neurol** 1996;69:493–6 (15 ref.)

The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. Roberts J, et al. **Br J Clin Pharmacol** 1996 Apr; 41(4):331–7

The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers. Roberts J, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):404–6

Pharmacodynamics of levodopa in Parkinson's disease. Nutt JG. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):837–40

Concentration-effect relationship of levodopa in patients with Parkinson's disease. Harder S, et al. **Clin Pharmacokinet** 1995 Oct;29(4):243–56 (51 ref.)

Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Sam E, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jan–Mar; 20(1):27–33

Human transplacental transfer of carbidopa/levodopa. Merchant CA, et al. **J Neural Transm Park Dis Dement Sect** 1995;9(2–3):239–42

Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline. Dostert P, et al. **J Neural Transm Suppl** 1995; 45:247–57

Pharmacokinetics of apomorphine in Parkinson's disease. Gancher S. **J Neural Transm Suppl** 1995;45:137–41 (21 ref.)

PHARMACOLOGY

N-Methyl-D-aspartate receptor participation in Parkinson's disease, a neurodegenerative disorder. Verma A, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:327

Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Asanuma M, et al. **Arch Int Pharmacodyn Ther** 1995 Mar–Apr; 329(2):221–30

L-DOPA and psychosis: evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone. Carey RJ, et al. **Biol Psychiatry** 1995 Nov 15;38(10):669–76

Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Lipska BK, et al. **Biol Psychiatry** 1995 Aug 15;38(4):255–62

The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers. Roberts J, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):404–6

Effects of 3-O-methyl on L-dopa-facilitated synthesis and efflux of dopamine from rat striatal slices. Chang WY, et al. **Br J Pharmacol** 1995 Nov;116(6):2637–40

Regulation of NK activity by the administration of bromocriptine in haloperidol-treated mice. Nozaki H, et al. **Brain Behav Immun** 1996 Mar;10(1):17–26

Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial. Stoltz M, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):342–53

The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors. Juszkiewicz M, et al. **Drugs Exp Clin Res** 1995;21(4):153–6

Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Benazzouz A, et al. **Eur J Pharmacol** 1995 Sep 25;284(3):299–307

Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease. Löschmann PA, et al. **Eur J Pharmacol** 1995 Sep 15;284(1–2):129–34

(S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. Cosford ND, et al. **J Med Chem** 1996 Aug 16;39(17):3235–7

Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response. Maggio R, et al. **J Neural Transm Suppl** 1995;45:133–6 (22 ref.)

Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study. Pizzolato G, et al. **J Neural Transm Suppl** 1995;45:113–22

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. Colosimo C, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):634–7

ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. Shiosaki K, et al. **J Pharmacol Exp Ther** 1996 Jan; 276(1):150–60

Levodopoa but not bromocriptine induces AP-1 and creb DNA-binding activity in the dopamine-depleted striatum of the rat. Kashihara K, et al. **Life Sci** 1996;58(10):PL 159–70

Slow increase of homovanillic acid in cerebrospinal fluid after levodopa administration. Raftopoulos C, et al. **Mov Disord** 1996 Jan;11(1):59–62

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Tedroff J, et al. **Neurology** 1996 May;46(5):1430–6

Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease. Hao R, et al. **Neurosci Lett** 1995 Nov 17;200(2):77–80

Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Herrero MT, et al. **Neuroscience** 1995 Oct;68(4):1189–98

[Automatic motion analysis of gait in patients with Parkinson disease: effects of levodopa and visual stimulations] Azulay JP, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):128–34 (Eng. Abstr.) **(Fre)**

SUPPLY & DISTRIBUTION

Anticholinergic antiparkinsonian therapy in outpatients treated with neuroleptic drugs: a prescription survey. Spila-Alegiani S, et al. **Eur J Clin Pharmacol** 1995; 48(6):513–7

THERAPEUTIC USE

Possible neuroprotective therapy for Parkinson's disease. Ogawa N. **Acta Med Okayama** 1995 Aug;49(4):179–85 (70 ref.)

Bromocriptine is ineffective in the treatment of chronic nonfluent aphasia. Ozeren A, et al. **Acta Neurol Belg** 1995 Dec;95(4):235–8

Estimate of parkinsonism prevalence through drug prescription histories in the Province of Rome, Italy. Menniti-Ippolito F, et al. **Acta Neurol Scand** 1995 Jul; 92(1):49–54

A study on the effect and tolerance of lisuride on Parkinson's disease. Bayülkem K, et al. **Adv Neurol** 1996;69:519–30

New drugs in the treatment of Parkinson's disease. An introduction. Bracco F. **Adv Neurol** 1996;69:513–7 (66 ref.)

Parkinson's disease: progression and mortality in the L-DOPA era. Di Rocco A, et al. **Adv Neurol** 1996;69:3–11

Controversies in the therapy of Parkinson's disease. Fahn S. **Adv Neurol** 1996;69:477–86 (72 ref.)

Early-onset parkinsonism with dystonia. Clinical and biochemical differences from hereditary progressive dystonia or DOPA-responsive dystonia. Furukawa Y, et al. **Adv Neurol** 1996;69:327–37

Genetic linkage studies in autosomal dominantly inherited L-DOPA responsive parkinsonism. Evaluation of candidate genes. Gasser T, et al. **Adv Neurol** 1996;69:87–95

Effects of L-DOPA on spatiotemporal contrast sensitivity in Parkinson's disease. Mestre DR, et al. **Adv Neurol** 1996; 69:503–11

Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA. Pahwa R, et al. **Adv Neurol** 1996; 69:487–91

Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease. Pirtošek Z, et al. **Adv Neurol** 1996; 69:535–40 (26 ref.)

Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study. Pizzolato G, et al. **Adv Neurol** 1996;69:467–73

A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. Rascol O, et al. **Adv Neurol** 1996; 69:531–4

Treatment options for early Parkinson's disease. Stacy M, et al. **Am Fam Physician** 1996 Mar;53(4):1281–7 (29 ref.)

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. **Ann Neurol** 1996 Jan;39(1):29–36

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. **Ann Neurol** 1996 Jan;39(1):37–45

Deprenyl and levodopa and Parkinson's disease progression [letter] Fowler JS, et al. **Ann Neurol** 1996 Aug;40(2):267–8

Deprenyl in Parkinson's disease [letter] Korczyn AD, et al. **Ann Neurol** 1996 Aug;40(2):268–9

Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease. Kushleika J, et al. **Ann Neurol** 1996 Mar;39(3):378–81

The effect of deprenyl and levodopa on the progression of Parkinson's disease. Olanow CW, et al. **Ann Neurol** 1995 Nov;38(5):771–7

Deprenyl's neuroprotective action remains unresolved [letter] van Hilten JJ, et al. **Ann Neurol** 1996 Aug;40(2):266–7

Treatment of Parkinson's disease. Eadie MJ. **Aust Fam Physician** 1995 Sep;24(9):1685–7, 1690–2

Selegiline in Parkinson's disease [editorial; comment] [see comments] Calne DB. **BMJ** 1995 Dec 16;311(7020):1583–4 . Comment on: BMJ 1995 Dec 16;311(7020):1602–7. Comment in: BMJ 1996 Mar 16;312(7032):702; discussion 704–5.

Treatment of Parkinson's disease in a patient with acute intermittent porphyria [letter] Gorchein A. **Br J Clin Pharmacol** 1995 Jul;40(1):105–6

Drug management of Parkinson's disease. Kishore A, et al. **Can Fam Physician** 1996 May;42:946–52 (13 ref.)

Amantadine treatment of a patient with anoxic brain injury. Edby K, et al. **Childs Nerv Syst** 1995 Oct;11(10):607–9

Experience of pergolide in the treatment of Chinese parkinsonian patients with dose-related fluctuations. Shan DE, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Nov; 56(5):312–8

L-deprenyl as an adjunct to low-dose bromocriptine in early Parkinson's disease: a short-term, double-blind, and prospective follow-up study. Calzetti S, et al. **Clin Neuropharmacol** 1995 Jun;18(3):250–7

Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Davis TL, et al. **Clin Neuropharmacol** 1995 Aug; 18(4):333–7

Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Jiménez-Jiménez FJ, et al. **Clin Neuropharmacol** 1995 Jun;18(3):277–9

Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease. Limousin P, et al. **Clin Neuropharmacol** 1995 Jun;18(3):258–65

Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings. Spieker S, et al. **Clin Neuropharmacol** 1995 Jun;18(3):266–72

Concentration-effect relationship of levodopa in patients with Parkinson's disease. Harder S, et al. **Clin Pharmacokinet** 1995 Oct;29(4):243–56 (51 ref.)

Management of parkinsonism and treatment of associated complications. Nutt JG. **Curr Opin Neurol** 1995 Aug; 8(4):327–30 (31 ref.)

Drugs for Parkinson's disease reviewed. **Drug Ther Bull** 1995 Jul;33(7):49–52 (25 ref.)

Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism. Kirollos C, et al. **Eur J Clin Pharmacol** 1996; 50(1–2):7–18

Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Kaur S, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):159–66

Short-latency median nerve somatosensory evoked potentials in three cases of parkinsonism and dopa responsive dystonia. Margari L, et al. **Funct Neurol** 1995 Mar–Apr; 10(2):99–105

Effects of intravenous L-dopa on P300 and regional cerebral blood flow in parkinsonism. Oishi M, et al. **Int J Neurosci** 1996 Mar;85(1–2):147–54

The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. Sieradzan K, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):51S–59S

An open label trial of pergolide in Thai patients with Parkinson's disease. Poungvarin N, et al. **J Med Assoc Thai** 1996 Apr;79(4):205–9

Effect of age and disease duration on parkinsonian motor scores under levodopa therapy. Ransmayr G, et al. **J Neural Transm Park Dis Dement Sect** 1995;9(2–3):177–88

Old and new dopamine agonists in Parkinson's disease. Proceedings of an international congress. Pisa, Italy, December 1993. **J Neural Transm Suppl** 1995;45:1–321

Dihydroergocryptine in the treatment of Parkinson's disease. Bonuccelli U, et al. **J Neural Transm Suppl** 1995;45:239–45 (33 ref.)

Ropinirole in the symptomatic treatment of Parkinson's disease. Brooks DJ, et al. **J Neural Transm Suppl** 1995; 45:231–8 (15 ref.)

Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients. Del Dotto P, et al. **J Neural Transm Suppl** 1995; 45:259–65

Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum? Melamed E. **J Neural Transm Suppl** 1995;45:57–60

The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. Molho ES, et al. **J Neural Transm Suppl** 1995;45:225–30

Pergolide mesylate in Parkinson's disease treatment. Pezzoli G, et al. **J Neural Transm Suppl** 1995;45:203–12 (48 ref.)

Dopaminergic agonists in the treatment of Parkinson's disease: a review. Piccoli F, et al. **J Neural Transm Suppl** 1995;45:187–95 (46 ref.)

Second generation of dopamine agonists: pros and cons. Rabey JM. **J Neural Transm Suppl** 1995;45:213–24 (63 ref.)

The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis. Sampaio C, et al. **J Neural Transm Suppl** 1995;45:197–202

Apomorphine SC treatment in parkinsonian patients with long-term L-dopa syndrome during L-dopa drug holiday. Scarzella L, et al. **J Neural Transm Suppl** 1995;45:163–70

N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study. Traversa R, et al. **J Neural Transm Suppl** 1995;45:177–85

Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study. Botez MI, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep;61(3):259–64

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on–off phenomenon. Colosimo C, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):634–7

Jaw movement dysfunction related to Parkinson's disease and partially modified by levodopa. Robertson LT, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):41–50

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. Ruottinen HM, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):36–40

Neuroprotection in Parkinson's disease [letter; comment] Montastruc JL, et al. **Lancet** 1996 Jan 20;347(8995):196. Comment on: Lancet 1995 Nov 11;346(8985):1305.

Neuroprotective mechanism of bromocriptine [letter] [see comments] Yamashita H, et al. **Lancet** 1995 Nov 11; 346(8985):1305. Comment in: Lancet 1996 Jan 20;347(8995):196.

Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic–L–amino acid decarboxylase and semicarbazide–sensitive amine oxidase in Parkinson's disease. Boomsma F, et al. **Life Sci** 1995;57(19):1753–9

Treatment of early Parkinson's disease: are complicated strategies justified? Ahlskog JE. **Mayo Clin Proc** 1996 Jul; 71(7):659–70 (90 ref.)

A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Bonnet AM, et al. **Mov Disord** 1995 Sep;10(5):668–71

Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Tan A, et al. **Mov Disord** 1996 Mar;11(2):214–6

Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Uitti RJ, et al. **Neurology** 1996 Jun;46(6):1551–6

Effects of the catechol–O–methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Tohgi H, et al. **Neurosci Lett** 1995 Jun 16;192(3):165–8

Trihexyphenidyl and isoprinosine in the treatment of subacute sclerosing panencephalitis. Nunes ML, et al. **Pediatr Neurol** 1995 Sep;13(2):153–6

Dopamine receptors—the present state of research and perspectives. Wolfarth S, et al. **Pol J Pharmacol** 1995 May–Jun;47(3):207–18 (95 ref.)

Moderate Parkinson's disease. Strategies for maximizing treatment. Silverstein PM. **Postgrad Med** 1996 Jan; 99(1):52–4, 61–3, 67–8, passim (21 ref.)

L–dopa therapy of uremic and idiopathic restless legs syndrome: a double–blind, crossover trial. Trenkwalder C, et al. **Sleep** 1995 Oct;18(8):681–8

Drug therapy for Parkinson's disease. Charles PD, et al. **South Med J** 1996 Sep;89(9):851–6 (22 ref.)

[L–dopa and antiparkinson agents] Delwaide PJ. **Rev Med Liege** 1996 Jan;51(1):61–4 **(Fre)**

[Initiation of treatment in Parkinson disease] Ghika J. **Schweiz Rundsch Med Prax** 1995 Sep 19;84(38):1018–20 (Eng. Abstr.) **(Fre)**

[New therapeutic possibilities with low–affinity NMDA receptor antagonists] Kornhuber J, et al. **Nervenarzt** 1996 Jan;67(1):77–82 (22 ref.) (Eng. Abstr.) **(Ger)**

[Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease] Dessibourg CA, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1235–8 (Eng. Abstr.) **(Ger)**

[Stage–adjusted treatment of idiopathic Parkinson syndrome] Ludin HP. **Wien Med Wochenschr** 1995;145(13):294–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Clinical aspects and conservative therapy of Parkinson disease] Dengler R. **Zentralbl Neurochir** 1995;56(4):148–52 (5 ref.) (Eng. Abstr.) **(Ger)**

[Present strategy and future perspective of therapy in Parkinson's disease] Kuno S. **No To Shinkei** 1996 Jan; 48(1):18–25 (35 ref.) **(Jpn)**

[A long–term clinical effect of selegiline hydrochloride on Parkinson's disease] Mizuno Y, et al. **No To Shinkei** 1996 May;48(5):467–72 (Eng. Abstr.) **(Jpn)**

[Therapeutic problems in the application of antiparkinsonian drugs in psychiatry] Piasecki T. **Psychiatr Pol** 1996 Jan–Feb;30(1):137–50 (26 ref.) (Eng. Abstr.) **(Pol)**

[Treatment of Parkinson disease] Cardoso F. **Arq Neuropsiquiatr** 1995 Mar;53(1):1–10 (34 ref.) (Eng. Abstr.) **(Por)**

[Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease] Ferraz HB, et al. **Arq Neuropsiquiatr** 1995 Jun;53(2):245–51 (Eng. Abstr.) **(Por)**

[The efficacy of the Umex treatment of parkinsonism patients in the initial stage of the disease] Fedorova NV, et al. **Ter Arkh** 1995;67(10):75–7 (Eng. Abstr.) **(Rus)**

[The neuroleptic malignant syndrome in an adolescent. Its treatment with dantrolene, bromocryptin and diazepam] Real Rodríguez B, et al. **An Esp Pediatr** 1996 Jan;44(1):60–2 (20 ref.) **(Spa)**

[The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti–parkinsonian drugs] Artázcoz Sanz MT, et al. **Rev Esp Salud Publica** 1995 Nov–Dec;69(6):479–85 (Eng. Abstr.) **(Spa)**

TOXICITY

Chronic L–DOPA administration induces dyskinesias in the 1–methyl–4– phenyl–1,2,3,6–tetrahydropyridine–treated common marmoset (Callithrix Jacchus). Pearce RK, et al. **Mov Disord** 1995 Nov;10(6):731–40

An appraisal of the antiparkinsonian activity of piribedil in 1–methyl–4–phenyl–1,2,3,6–tetrahydropyridine–treated common marmosets. Smith L, et al. **Mov Disord** 1996 Mar; 11(2):125–35

ANTIPERISTALTICS see **ANTIDIARRHEALS**

ANTIPHOSPHOLIPID ANTIBODIES see **ANTIBODIES, ANTIPHOSPHOLIPID**

ANTIPHOSPHOLIPID SYNDROME

What is going to happen tomorrow regarding the antiphospholipid syndrome? Jean–Charles Piette [interview] Piette JC. **Ann Med Interne (Paris)** 1995; 146(8):555–8

Anti phospholipid syndrome. Housley E. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):394–5

The antiphospholipid syndrome: when does the presence of antiphospholipid antibodies require therapy? Devine DV, et al. **Postgrad Med** 1996 Jun;99(6):105–8, 113–25 (26 ref.)

Protean clinical presentation of antiphospholipid–protein antibodies (APA). Triplett DA. **Thromb Haemost** 1995 Jul; 74(1):329–37 (138 ref.)

[Antiphospholipid syndrome] Koike T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1569–73 (5 ref.) **(Jpn)**

[Pregnancy and antiphospholipid syndrome] Aoki K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):852–62 (27 ref.) **(Jpn)**

BLOOD

Elevated levels of beta 2 glycoprotein–I (beta 2 GPI) in antiphospholipid antibody syndrome are due to increased amounts of beta 2 GPI in association with other plasma constituents. McNally T, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):411–6

The role of beta 2–glycoprotein I in the antiphospholipid syndrome. Krilis SA, et al. **Lupus** 1996 Apr;5(2):150–2 (16 ref.)

The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation? Merrill JT, et al. **Lupus** 1996 Feb;5(1):6–10 (63 ref.)

Antiphospholipid antibodies, haemostatic variables and thrombosis—a survey of 144 patients. Ames PR, et al. **Thromb Haemost** 1995 May;73(5):768–73

Effects of H1 histones and a monoclonal autoantibody to H1 histones on clot formation in vitro: possible implications in the antiphospholipid syndrome. Kheiri SA, et al. **Thromb Res** 1996 Apr 1;82(1):43–50

Detection of lupus anticoagulant: an evaluation of routines for preparation and storage of plasma. Schjetlein R, et al. **Thromb Res** 1995 Jul 1;79(1):135–40

CHEMICALLY INDUCED

Corticosteroid and hypercoagulability [letter; comment] Ozsoylu S. **Eur J Pediatr** 1995 Aug;154(8):687. Comment on: Eur J Pediatr 1994 Dec;153(12):891–3.

CLASSIFICATION

[Clinical subsets and phospholipid–dependent anti–beta 2–glycoprotein I antibodies in antiphospholipid syndrome] Kaburaki J, et al. **Rinsho Ketsueki** 1995 Oct;36(10):1170–4 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Aortic regurgitation progressing to aortic stenosis in antiphospholipid syndrome. Escalante A, et al. **Am Heart J** 1995 Oct;130(4):902–5

Giant gastric ulceration associated with antiphospholipid antibody syndrome. Kalman DR, et al. **Am J Gastroenterol** 1996 Jun;91(6):1244–7 (19 ref.)

Renal infarction and thrombosis of the infrarenal aorta in a 35–year–old man with primary antiphospholipid syndrome. Poux JM, et al. **Am J Kidney Dis** 1996 May; 27(5):721–5 (20 ref.)

Splinter hemorrhages following arterial puncture. Martens PB, et al. **Arthritis Rheum** 1996 Jan;39(1):169–70

Antiphospholipid antibodies and venous thromboembolism. Ginsberg JS, et al. **Blood** 1995 Nov 15;86(10):3685–91

Left ventricular thrombi in a patient with the antiphospholipid syndrome. Bruce D, et al. **Br Heart J** 1995 Aug;74(2):202–3

Increased levels of beta 2 glycoprotein–I antigen and beta 2 glycoprotein–I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. McNally T, et al. **Br J Rheumatol** 1995 Nov;34(11):1031–6

Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome. Hojnik M, et al. **Circulation** 1996 Apr 15;93(8):1579–87 (110 ref.)

Antiphospholipid syndrome in patients with cyanotic congenital heart disease. Martinez–Lavín M, et al. **Clin Exp Rheumatol** 1995 Jul–Aug;13(4):489–91

Prevalence and clinical significance of subungual splinter haemorrhages in patients with the antiphospholipid syndrome. Mujic F, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):327–31

Reversible renal failure due to the antiphospholipid antibody syndrome, pre–eclampsia and renal thrombotic microangiopathy. Kon SP, et al. **Clin Nephrol** 1995 Oct; 44(4):271–3

Recurrent pulmonary embolism and chronic multivessel thrombophlebitis associated with a right–to–left shunt in the antiphospholipid syndrome. Bremerich J, et al. **Clin Nucl Med** 1995 Nov;20(11):1028

Primary antiphospholipid syndrome associated with mesenteric inflammatory veno–occlusive disease. Gül A, et al. **Clin Rheumatol** 1996 Mar;15(2):207–10

The antiphospholipid syndrome. Edelman PL. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):427–31

Superior mesenteric artery thrombosis in a patient with the antiphospholipid syndrome. England RJ, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):372–3 (4 ref.)

Migrainous stroke: are antiphospholipid antibodies pathogenetic, a biological epiphenomenon, or an incidental laboratory aberration? [see comments] Gupta VK. **Eur Neurol** 1996;36(2):110–1. Comment in: Eur Neurol 1996;36(2):114.

Migrainous stroke and antiphospholipid antibodies: are they pathogenetically linked? [letter; comment] Silvestrini M. **Eur Neurol** 1996;36(2):114. Comment on: Eur Neurol 1996;36(2):110–1.

The antiphospholipid syndrome and ischemic colitis [clinical conference] Klestzick HN, et al. **Gastroenterologist** 1995 Sep;3(3):249–56

Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: lack of correlation with antiphospholipid antibodies. Gabrielli F, et al. **Int J Cardiol** 1995 Sep;51(2):117–26

Pulmonary hypertension and the antiphospholipid syndrome [editorial; comment] Koike T, et al. **Intern Med** 1995 Oct; 34(10):938. Comment on: Intern Med 1995 Oct;34(10):1030–4.

Transesophageal echocardiographic diagnosis of right atrial thrombi associated with the antiphospholipid syndrome. Day SM, et al. **J Am Soc Echocardiogr** 1995 Nov–Dec; 8(6):937–40

Antiphospholipid syndrome manifested by ischemic stroke in a patient with Crohn's disease. Mevorach D, et al. **J Clin Gastroenterol** 1996 Mar;22(2):141–3

Antiphospholipid syndrome associated with progressive systemic sclerosis. Chun WH, et al. **J Dermatol** 1996 May; 23(5):347–51

Systemic and cerebral vasculitis coexisting with disseminated coagulopathy in systemic lupus erythematosus associated with antiphospholipid syndrome. Lie JT, et al. **J Rheumatol** 1995 Nov;22(11):2173–6

Primary antiphospholipid syndrome presenting as chronic thromboembolic pulmonary hypertension. Treatment with thromboendarterectomy. Sandoval J, et al. **J Rheumatol** 1996 Apr;23(4):772–5

Catastrophic antiphospholipid syndrome with fatal acute course in rheumatoid arthritis. Voisin L, et al. **J Rheumatol** 1995 Aug;22(8):1586–8

Thrombocytopenia corrected by warfarin in antiphospholipid syndrome. Wisbey HL, et al. **J Rheumatol** 1996 Apr; 23(4):769–71

Fatal cerebral infarction in an asymptomatic young patient with primary antiphospholipid syndrome. Muneta S, et al. **Jpn Circ J** 1995 Sep;59(9):641–5

Reversal of thrombocytopenia following oral anticoagulation in two patients with primary antiphospholipid syndrome. Ames PR, et al. **Lupus** 1995 Dec;4(6):491–3

Budd–Chiari syndrome in the context of antiphospholipid syndrome: diagnostic and therapeutic implications [letter] Archimandritis A, et al. **Lupus** 1995 Aug;4(4):329–31

Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. García–Torres R, et al. **Lupus** 1996 Feb;5(1):56–61

Benign intracranial hypertension: a non–thrombotic complication of the primary antiphospholipid syndrome? Orefice G, et al. **Lupus** 1995 Aug;4(4):324–6

Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome. Suarez IM, et al. **Lupus** 1996 Feb;5(1):81–3

Renal infarction in a severely hypertensive patient with lupus erythematosus and antiphospholipid antibodies. Hernández D, et al. **Nephron** 1996;72(2):298–301

Reversible dementia and chorea in a young woman with the lupus anticoagulant. Van Horn G, et al. **Neurology** 1996 Jun;46(6):1599–603

Antiphospholipid antibody syndrome in childhood strokes. Takanashi J, et al. **Pediatr Neurol** 1995 Nov;13(4):323–6

Heparin monitoring in acute thrombosis associated with antiphospholipid antibody syndrome. Wittkowsky AK, et al. **Pharmacotherapy** 1995 Jul–Aug;15(4):517–21

Cerebral venous sinus thrombosis and antiphospholipid antibodies. Boggild MD, et al. **Postgrad Med J** 1995 Aug; 71(838):487–9

Radial artery occlusion in primary antiphospholipid syndrome after aortic valve replacement [letter] Asherson RA, et al. **S Afr Med J** 1995 Oct;85(10):1042

Adrenal insufficiency in the antiphospholipid antibody syndrome. Arnason JA, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):109–16 (27 ref.)

Antiphospholipid syndrome associated with seizures. Milstone A, et al. **South Med J** 1996 Jul;89(7):738–40

Renal allograft thrombosis associated with the antiphospholipid antibody syndrome. Knight RJ, et al. **Transplantation** 1995 Sep 27;60(6):614–5

[Pulmonary thrombectomy in a patient with antiphospholipid syndrome] Coignard E, et al. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1479–81 (Eng. Abstr.) **(Fre)**

[Antiphospholipid antibodies and deep venous thrombosis in hemorrhagic rectocolitis disclosed by pyoderma gangrenosum (letter)] Dupuis F, et al. **Presse Med** 1996 Jun 29;25(23):1084 **(Fre)**

[Inferior vena cava thrombosis developing in primary antiphospholipid syndrome] Tátrai T, et al. **Orv Hetil** 1996 Jan 21;137(3):135–7 (Eng. Abstr.) **(Hun)**

[Antiphospholipid antibody syndrome as a possible cause of paresis in a child] Zecca G, et al. **Pediatr Med Chir** 1995 Sep–Oct;17(5):451–4 (Eng. Abstr.) **(Ita)**

[A case of SLE associated with antiphospholipid syndrome and mitral stenosis] Takahashi M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):90–7 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Successful surgical treatment of mitral regurgitation associated with anti-phospholipid syndrome and systemic lupus erythematosus] Noji S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1176–81 (Eng. Abstr.) **(Jpn)**

[A case of Evans's syndrome with antiphospholipid antibody syndrome] Hirayama Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):611–3 **(Jpn)**

[A case of primary antiphospholipid antibody syndrome associated with procainamide induced systemic lupus erythematosus] Muramatsu M, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1736–8 **(Jpn)**

[The characteristics of kidney involvement in a female patient with systemic lupus erythematosus and the antiphospholipid syndrome] Kozlovskaia NL, et al. **Klin Med (Mosk)** 1995;73(3):93–6 (27 ref.) (Eng. Abstr.) **(Rus)**

[Transversal myelitis as initial manifestation of secondary antiphospholipid syndrome. Report of a case] Espinosa-Rosales F, et al. **Allergol Immunopathol (Madr)** 1995 Sep–Oct;23(5):248–50 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Multiple early percutaneous transluminal coronary angioplasty failures related to lupus anticoagulant. Chambers JD Jr, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):189–90

The lupus anticoagulant/antiphospholipid syndrome. Shapiro SS. **Annu Rev Med** 1996;47:533–53 (182 ref.)

Thrombocytopenia in the antiphospholipid syndrome. Galli M, et al. **Br J Haematol** 1996 Apr;93(1):1–5 (50 ref.)

Antiphospholipid syndrome in a patient with type I diabetes presenting as retinal artery occlusion [letter] Manzanares JM, et al. **Diabetes Care** 1996 Jan;19(1):92–4

Biochemical and Doppler predictors of poor perinatal outcome in a fetus with four umbilical vessels. Martinez JM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep; 62(1):145–7

Antiphospholipid antibody syndrome: an unusual cause of stroke in a 22-year-old female. Vassalluzzo CJ, et al. **J Emerg Med** 1995 Jul–Aug;13(4):485–8

Clinical characteristics of antiphospholipid antibody syndrome in children. von Scheven E, et al. **J Pediatr** 1996 Sep;129(3):339–45

Clinical quiz. Quiescent lupus nephritis with superimposed HUS. Baqi N, et al. **Pediatr Nephrol** 1995 Oct;9(5):669–70

Transverse myelitis: a complication of systemic lupus erythematosus that is associated with the antiphospholipid syndrome. Smyth AE, et al. **Ulster Med J** 1996 May; 65(1):91–4

Thrombosis of the terminal aorta, deep vein thrombosis, recurrent fetal loss, and antiphospholipid antibodies. Case report. Hohlfeld J, et al. **Vasa** 1996;25(2):194–9

[Recurrent leg ulcers, intra-alveolar hemorrhage, perforation of the nasal septum: primary antiphospholipid syndrome? (letter)] Callot V, et al. **Ann Med Interne (Paris)** 1995; 146(5):366–9 **(Fre)**

[Primary antiphospholipid syndrome with a familial element and myocardial infarct in an adolescent] Gaeta G, et al. **G Ital Cardiol** 1995 Aug;25(8):1025–30 (35 ref.) (Eng. Abstr.) **(Ita)**

[A case of beta 2-glycoprotein I-independent antiphospholipid syndrome] Ozawa N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Oct; 47(10):1079–82 **(Jpn)**

[Antiphospholipid syndrome as an interdisciplinary medical problem] Turkowska M, et al. **Pol Arch Med Wewn** 1996 May;95(5):486–92 (40 ref.) **(Pol)**

[The manifestations of IHD and the status of the coronary arteries in patients with the antiphospholipid syndrome] Karpov IuA, et al. **Ter Arkh** 1995;67(10):27–31 (Eng. Abstr.) **(Rus)**

[Idiopathic white atrophy and the primary antiphospholipid syndrome: a promise still unfulfilled (letter)] LLamas P, et al. **Rev Clin Esp** 1996 May;196(5):342–3 (10 ref.) **(Spa)**

DRUG THERAPY

The antiphospholipid syndrome. Edelman PL. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):427–31

Bone density studies in pregnant women receiving heparin. Shefras J, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):171–4

Aspirin, interleukin-3 and the antiphospholipid syndrome. Fishman P, et al. **Isr J Med Sci** 1996 Jan;32(1):13–7

Chronic herpes gestationis and antiphospholipid antibody syndrome successfully treated with cyclophosphamide. Castle SP, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):333–6

ETHNOLOGY

Association of HLA-DR5 (possibly DRB1*1201) with the primary antiphospholipid syndrome in Mexican patients. Vargas-Alarcon G, et al. **Arthritis Rheum** 1995 Sep; 38(9):1340–1

ETIOLOGY

The pathogenic role of anti-phosphatidylserine antibodies: active immunization with the antibodies leads to the induction of antiphospholipid syndrome. Yodfat O, et al. **Clin Immunol Immunopathol** 1996 Jan;78(1):14–20

Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Prieto J, et al. **Hepatology** 1996 Feb; 23(2):199–204

[Bilateral hemorrhage of the adrenal glands and antiphospholipid syndrome disclosing cancer (letter)] Horusitzky A, et al. **Ann Med Interne (Paris)** 1996; 147(1):64–6 **(Fre)**

[Conjugal circulating anticoagulant: apropos of a married couple (letter)] Disdier P, et al. **Presse Med** 1995 Oct 7; 24(29):1359 **(Fre)**

[Systemic lupus erythematosus and antiphospholipid antibody syndrome in a patient with congenital ichthyosiform erythroderma] Nishiyama S, et al. **Ryumachi** 1995 Aug; 35(4):688–92 (Eng. Abstr.) **(Jpn)**

GENETICS

High frequency of C4 "null" alleles in primary antiphospholipid syndrome (letter). Bentolila S, et al. **Ann Med Interne (Paris)** 1996;147(2):115–6

Familial primary antiphospholipid antibody syndrome. Bansal AS, et al. **Arthritis Rheum** 1996 Apr;39(4):705–6

Coexistence of familial antiphospholipid syndrome and factor V Leiden: impact on thrombotic diathesis. Brenner B, et al. **Br J Haematol** 1996 Jul;94(1):166–7

The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Dizon-Townson D, et al. **Thromb Haemost** 1995 Oct;74(4):1029–31

IMMUNOLOGY

Anti-phospholipid antibodies and cerebral vasospasm following subarachnoid haemorrhage. Hirashima Y, et al. **Acta Neurochir (Wien)** 1995;135(3–4):191–7

Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Camerlingo M, et al. **Acta Neurol Scand** 1995 Jul;92(1):69–71

Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Abu-Shakra M, et al. **Am J Med** 1995 Dec;99(6):624–8

A model for the antiphospholipid antibody syndrome: monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice. Vogt E, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):700–7

Monoclonal anticardiolipin autoantibodies established from the (New Zealand white x BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Mizutani H, et al. **Arthritis Rheum** 1995 Oct;38(10):1382–8

Association of HLA-DR5 (possibly DRB1*1201) with the primary antiphospholipid syndrome in Mexican patients. Vargas-Alarcon G, et al. **Arthritis Rheum** 1995 Sep; 38(9):1340–1

Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Sugi T, et al. **Blood** 1995 Oct 15;86(8):3083–9

The Michael Mason Prize Essay (1994). Antiphospholipid antibodies and disease. Mackworth-Young CG. **Br J Rheumatol** 1995 Nov;34(11):1009–30 (160 ref.)

Antibodies to endothelial cells and to beta 2-glycoprotein I in the antiphospholipid syndrome: prevalence and isotype distribution. Navarro M, et al. **Br J Rheumatol** 1996 Jun; 35(6):523–8

Characterization and specificity of anti-endothelial cell membrane antibodies and their relationship to thrombosis in primary antiphospholipid syndrome (APS). Hill MB, et al. **Clin Exp Immunol** 1995 Nov;102(2):368–72

Anti beta 2-glycoprotein I antibodies in a patient with catastrophic antiphospholipid syndrome. Pengo V, et al. **Clin Rheumatol** 1995 Nov;14(6):646–9

Anticardiolipin antibodies and antiphospholipid syndrome in chronic discoid lupus erythematosus. Ruffatti A, et al. **Clin Rheumatol** 1995 Jul;14(4):402–4

Antiphospholipid antibodies and antiphospholipid syndrome. Khamashta MA, et al. **Curr Opin Rheumatol** 1995 Sep; 7(5):389–94 (69 ref.)

Phospholipid-dependent anti-beta 2-glycoprotein I (beta 2-GPI) antibodies and antiphospholipid syndrome. Kaburaki J, et al. **Intern Med** 1996 Feb;35(2):105–10

The antiphospholipid-protein syndrome. Cines DB, et al. **J Clin Immunol** 1995 Nov;15(6 Suppl):86S–100S (186 ref.)

Clinical analysis of anti-cardiolipin.beta 2 glycoprotein I antibody positive patients in anti-phospholipid syndrome. Katayama I, et al. **J Dermatol Sci** 1995 May;9(3):215–20

Anticardiolipin antibodies and beta 2-glycoprotein I. Koike T, et al. **Lupus** 1996 Apr;5(2):156–7 (13 ref.)

Demonstration of antiphospholipid antibody heterogeneity by phospholipid column chromatography and salt gradient elution techniques. Walton SP, et al. **Lupus** 1995 Aug; 4(4):263–71

Anticardiolipin antibodies: clinical consequences of "low titers". Silver RM, et al. **Obstet Gynecol** 1996 Apr; 87(4):494–500

A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Olee T, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8606–11

Catastrophic anti-phospholipid syndrome in the absence of IgG anti-cardiolipin antibodies. Kennedy M, et al. **Scand J Rheumatol** 1995;24(6):389–91

Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Pierangeli SS, et al. **Thromb Haemost** 1995 Nov;74(5):1361–7

Anticardiolipin and anti-beta 2-GPI are two distinct populations of autoantibodies. Sorice M, et al. **Thromb Haemost** 1996 Feb;75(2):303–8

PATHOLOGY

Antiphospholipid syndrome in systemic lupus erythematosus--immunomorphological study of the central nervous system; case report. Borowska-Lehman J, et al. **Folia Neuropathol** 1995;33(4):231–3

Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Nayar R, et al. **Hum Pathol** 1996 Feb; 27(2):201–6 (36 ref.)

Widespread cutaneous necrosis as the initial manifestation of the antiphospholipid antibody syndrome. Abernethy ML, et al. **J Rheumatol** 1995 Jul;22(7):1380–3

PHYSIOPATHOLOGY

Case report: diabetic microangiopathic hemolytic anemia and thrombocytopenia with antiphospholipid syndrome. Morita H, et al. **Am J Med Sci** 1996 Mar;311(3):148–51

Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome. Gattorno M, et al. **Br J Rheumatol** 1995 Sep;34(9):873–81

Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. Mujic F, et al. **J Rheumatol** 1995 Aug; 22(8):1589–92

Will some day PAPS fade into SLE? [editorial; comment] Cabral AR, et al. **Lupus** 1996 Feb;5(1):4–5. Comment on: Lupus 1996 Feb;5(1):77–80.

Primary antiphospholipid syndrome evolving into systemic lupus erythematosus [see comments] Derksen RH, et al. **Lupus** 1996 Feb;5(1):77–80. Comment in: Lupus 1996 Feb;5(1):4–5.

Clinical manifestations and management of the antiphospholipid syndrome. Derksen RH. **Lupus** 1996 Apr; 5(2):167–9 (18 ref.)

Neurological and obstetric manifestations of the antiphospholipid syndrome. Gatenby PA. **Lupus** 1996 Apr; 5(2):170–2 (13 ref.)

Renal vein thrombosis as first clinical manifestation of the primary antiphospholipid syndrome. Ko WS, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1929–31

PREVENTION & CONTROL

[Aspirin during pregnancy. Indications and modalities of prescription after the publication of the later trials] Uzan S, et al. **Presse Med** 1996 Jan 6–13;25(1):31–6 (30 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Recurrent pulmonary embolism and chronic multivessel thrombophlebitis associated with a right-to-left shunt in the antiphospholipid syndrome. Bremerich J, et al. **Clin Nucl Med** 1995 Nov;20(11):1028

SURGERY

Coronary artery bypass grafting in a patient with antiphospholipid syndrome. Sakakibara N, et al. **Ann Thorac Surg** 1996 Feb;61(2):739–40

THERAPY

Primary antiphospholipid syndrome [letter] Quattrocolo G, et al. **Ital J Neurol Sci** 1995 Sep;16(6):392
Antiphospholipid syndrome [letter] Wadhwa S. **J Assoc Physicians India** 1995 Oct;43(10):725
Clinical manifestations and management of the antiphospholipid syndrome. Derksen RH. **Lupus** 1996 Apr; 5(2):167–9 (18 ref.)
[Antiphospholipid syndrome as an interdisciplinary medical problem] Turkowska M, et al. **Pol Arch Med Wewn** 1996 May;95(5):486–92 (40 ref.) **(Pol)**

ULTRASONOGRAPHY

M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome. Coudray N, et al. **Br Heart J** 1995 Nov; 74(5):531–5

ANTIPLASMIN

ANALYSIS

Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Robbie LA, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):539–45
Mediators of fibrinolysis in orthotopic liver transplantation. Cheema SP, et al. **Clin Transplant** 1996 Feb;10(1 Pt 1):24–7
[alpha 2-Plasmin inhibitor-plasmin complex (PIC)] Yoshikawa Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:55–8 (13 ref.) **(Jpn)**

DEFICIENCY

Operative treatment of intramedullary hematoma associated with congenital deficiency of alpha 2-plasmin inhibitor, A report of three cases. Miyauchi Y, et al. **J Bone Joint Surg Am** 1996 Sep;78(9):1409–14

METABOLISM

Reaction of human alpha2-antiplasmin and plasmin stopped-flow fluorescence kinetics. Christensen U, et al. **FEBS Lett** 1996 May 27;387(1):58–62
[Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):86–8 (Eng. Abstr.) **(Pol)**
[Antithrombin III and alpha 2-antiplasmin in blood of patients operated on for benign prostatic hyperplasia] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):75–6 (Eng. Abstr.) **(Pol)**

ANTIPLASMINS see **ANTIFIBRINOLYTIC AGENTS**

ANTIPLATELET AGENTS see **PLATELET AGGREGATION INHIBITORS**

ANTIPLATYHELMINTIC AGENTS

ADMINISTRATION & DOSAGE

Single-day praziquantel therapy for neurocysticercosis [letter] Corona T, et al. **N Engl J Med** 1996 Jan 11; 334(2):125
[The search for new antiparasitic agents. 16. A study of the anti-Fasciola activity of N-[(chloro-naphthyloxy)phenyl]benzamides] Petrov IuF, et al. **Med Parazitol (Mosk)** 1996 Jan-Mar;(1):25–6 (Eng. Abstr.) **(Rus)**
[The procedure for the wide use of praziquantel in a complex of measures to control opisthorchiasis. 2. The tolerance and efficacy of Russian-made azinox in mass treatment in foci] Zavoĭkin VD, et al. **Med Parazitol (Mosk)** 1995 Jul-Sep;(3):32–4 (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

[The technology for manufacturing antiparasitic preparations. 4. The development of a technology for producing the anthelmintic bromoksan in finely dispersed form and the evaluation of its antifascioliasis activity] Mikhallitsyn FS, et al. **Med Parazitol (Mosk)** 1995 Jul-Sep;(3):41–2 (Eng. Abstr.) **(Rus)**

HISTORY

[Original Mexican contributions to medicine. Praziquantel and neurocysticercosis. An honorable and transcendent Mexican priority] Quijano-Pitman F. **Gac Med Mex** 1995 Mar-Apr;131(2):241–2 **(Spa)**

METABOLISM

Avermectins and milbemycins against Fasciola hepatica: in vivo drug efficacy and in vitro receptor binding. Shoop WL, et al. **Int J Parasitol** 1995 Aug;25(8):923–7

PHARMACOKINETICS

Effect of diet on the excretion profile of ivermectin in cattle faeces. Cook DF, et al. **Int J Parasitol** 1996 Mar;26(3):291–5
Differences in the oral bioavailability of three rafoxanide formulations in sheep. Swan GE, et al. **J S Afr Vet Assoc** 1995 Dec;66(4):197–201
Plasma concentrations of praziquantel during the therapy of neurocysticerosis with praziquantel, in the presence of antiepileptics and dexamethasone. Na-Bangchang K, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):120–3

PHARMACOLOGY

Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Ismail M, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):214–8
Immunopharmacological aspects of praziquantel. Nyazema NZ, et al. **Cent Afr J Med** 1995 Sep;41(9):284–8
Praziquantel treatment normalizes intestinal myoelectric alterations associated with Hymenolepis diminuta-infected rats. Dwinell MB, et al. **J Parasitol** 1995 Dec;81(6):979–84

THERAPEUTIC USE

Schistosomiasis japonica and childhood nutritional status in northeastern Leyte, the Philippines: a randomized trial of praziquantel versus placebo. McGarvey ST, et al. **Am J Trop Med Hyg** 1996 May;54(5):498–502
Immune response of mice infected with Schistosoma mansoni is modulated by antifibrotic treatment. Giboda M, et al. **Ann Trop Med Parasitol** 1995 Aug;89(4):415–24
Avermectins and milbemycins against Fasciola hepatica: in vivo drug efficacy and in vitro receptor binding. Shoop WL, et al. **Int J Parasitol** 1995 Aug;25(8):923–7
Effect of anti-schistosomal treatment on schistosomal hepatic pathology: an experimental study in Syrian golden hamsters. Moustafa FE, et al. **J Egypt Soc Parasitol** 1996 Aug;26(2):517–24
Observations on possible immunity to reinfection among school children after schistosomiasis treatment. Nagaty IM, et al. **J Egypt Soc Parasitol** 1996 Aug;26(2):443–52
Schistosomiasis japonica in the Philippines: the long-term impact of population-based chemotherapy on infection, transmission, and morbidity. Olveda RM, et al. **J Infect Dis** 1996 Jul;174(1):163–72
Therapy with parasiticidal drugs in cysticercal encephalitis--is it indicated? [editorial] Thomson AJ. **S Afr Med J** 1996 Feb;86(2):138–9
Acute clonorchiasis. Ip M, et al. **Scand J Infect Dis** 1995; 27(6):645–6
Antibodies in serum of patients with clonorchiasis before and after treatment. Lin YL, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):114–9
Impact of population-based selective chemotherapy on prevalence and intensity of Schistosoma mansoni infections in the Nile Delta: Kafr El Sheikh. Barakat R, et al. **Trop Geogr Med** 1995;47(6):266–70
Changes in prevalence, intensity of infection and morbidity due to Schistosoma japonicum infection in a community following a single treatment with praziquantel. Zhao G, et al. **Trop Geogr Med** 1995;47(6):289–92
Effects of praziquantel on experimental Schistosoma bovis infection in goats. Johansen MV, et al. **Vet Parasitol** 1996 Mar;62(1-2):83–91
Evaluation of nitroxynil and closantel activity using ELISA and egg counts against Fasciola hepatica in experimentally and naturally infected cattle. Boulard C, et al. **Vet Res** 1995; 26(4):249–55
[Schistosomiasis at Marselisborg hospital 1981–1990] Tarp BD, et al. **Ugeskr Laeger** 1996 Feb 12;158(7):911–4 (Eng. Abstr.) **(Dan)**
[Value of bithionol in the treatment of hepatic fascioliasis in children (letter)] Abreu F, et al. **Arch Pediatr** 1996 Feb; 3(2):189–91 **(Fre)**
[Efficacy and tolerance of praziquantel (Biltricide) in the treatment of distomatosis caused by Fasciola hepatica] Moreau JA, et al. **Gastroenterol Clin Biol** 1995 May; 19(5):514–9 (Eng. Abstr.) **(Fre)**
[The myeloperoxidase of the polymorphonuclear leukocytes as a marker of the stage of Opisthorchis invasion and as an indicator of the efficacy of chemotherapy] Iakovleva VV, et al. **Med Parazitol (Mosk)** 1995 Jul-Sep;(3):34–7 (Eng. Abstr.) **(Rus)**

ANTIPORT see **ION TRANSPORT**

ANTIPORTERS

Ethnic origin and hypertension-associated alterations in sodium-lithium countertransport kinetics. Hardman TC, et al. **J Hum Hypertens** 1995 Aug;9(8):687–9

ANALYSIS

Localization of MIWC and GLIP water channel homologs in neuromuscular, epithelial and glandular tissues. Frigeri A, et al. **J Cell Sci** 1995 Sep;108 (Pt 9):2993–3002
Insulin resistance and not hyperinsulinaemia determines erythrocyte Na+/Li+ countertransport in non-insulin-dependent diabetes mellitus. Pinkney JH, et al. **J Hum Hypertens** 1995 Aug;9(8):685–6
Erythrocyte membrane cholesterol distribution in patients with untreated essential hypertension: correlation with sodium-lithium countertransport. Muriana FJ, et al. **J Hypertens** 1996 Apr;14(4):443–6

BIOSYNTHESIS

A widespread transposable element masks expression of a yeast copper transport gene. Knight SA, et al. **Genes Dev** 1996 Aug 1;10(15):1917–29

BLOOD

Iron transport into erythroid cells by the Na+/Mg2+ antiport. Stonell LM, et al. **Biochim Biophys Acta** 1996 Jun 13;1282(1):163–70
Erythrocyte sodium-lithium countertransport activity in non-nephropathic diabetic twins. Hardman TC, et al. **Diabetes Care** 1996 Jan;19(1):32–8
Validation of red cell sodium-lithium countertransport measurement--influence of different loading conditions. Besch W, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct; 33(10):715–9
Sodium-lithium countertransport and blood pressure change over time: the Gubbio study. Cirillo M, et al. **Hypertension** 1996 Jun;27(6):1305–11

CHEMISTRY

Topological disposition of tyrosine 486 in anion exchanger from human erythrocytes. Kalo MS. **Biochemistry** 1996 Jan 23;35(3):999–1009
His257 is a uniquely important histidine residue for tetracycline/H+ antiport function but not mandatory for full activity of the transposon Tn10-encoded metal-tetracycline/H+ antiporter. Yamaguchi A, et al. **Biochemistry** 1996 Apr 9;35(14):4359–64
Transmembrane glutamic acid residues play essential roles in the metal-tetracycline/H+ antiporter of Staphylococcus aureus. Fujihira E, et al. **FEBS Lett** 1996 Aug 12; 391(3):243–6
Asp-285 of the metal-tetracycline/H+ antiporter of Escherichia coli is essential for substrate binding. Kimura T, et al. **FEBS Lett** 1996 Jun 10;388(1):50–2
The NH2-terminal half of the Tn10-specified tetracycline efflux protein TetA contains a dimerization domain. McMurry LM, et al. **J Biol Chem** 1995 Sep 29; 270(39):22752–7
Mutational analysis and molecular modelling of an amino acid sequence motif conserved in antiporters but not symporters in a transporter superfamily. Varela MF, et al. **Mol Membr Biol** 1995 Oct-Dec;12(4):313–9

DRUG EFFECTS

Reduction of intracellular pH by tenidap. Involvement of cellular anion transporters in the pH change. McNiff P, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1421–32
Potassium channel activation by glutathione-S-conjugates in Escherichia coli: protection against methylglyoxal is mediated by cytoplasmic acidification. Ferguson GP, et al. **Mol Microbiol** 1995 Sep;17(6):1025–33

GENETICS

Anaerobically controlled expression system derived from the arcDABC operon of Pseudomonas aeruginosa: application to lipase production. Winteler HV, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3391–8
Second-site suppressor mutations for the Asp-66—>Cys mutant of the transposon Tn10-encoded metal-tetracycline/H+ antiporter of Escherichia coli. Yamaguchi A, et al. **Biochemistry** 1995 Sep 19; 34(37):11800–6
Chromosomal tetA(L) gene of Bacillus subtilis: regulation of expression and physiology of a tetA(L) deletion strain. Cheng J, et al. **J Bacteriol** 1996 May;178(10):2853–60
Chromosomal mapping of the rat Slc4a family of anion exchanger genes, Ae1, Ae2, and Ae3. Simon JS, et al. **Mamm Genome** 1996 May;7(5):380–2
The product of HUM1, a novel yeast gene, is required for vacuolar Ca2+/H+ exchange and is related to mammalian Na+/Ca2+ exchangers. Pozos TC, et al. **Mol Cell Biol** 1996 Jul;16(7):3730–41
CAX1, an H+/Ca2+ antiporter from Arabidopsis. Hirschi KD, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6; 93(16):8782–6
Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Takiff HE, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):362–6

ISOLATION & PURIFICATION

Identification and partial purification of PAPS translocase. Ozeran JD, et al. **Biochemistry** 1996 Mar 26; 35(12):3695–703

METABOLISM

Volume-associated osmolyte fluxes in cell lines with or without the anion exchanger. Sánchez-Olea R, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1280–6
Properties of the Na(+)-Ca2+ antiport of heart mitochondria. Jung DW, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:553–5
Reduction of intracellular pH by tenidap. Involvement of cellular anion transporters in the pH change. McNiff P, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1421–32
Identification and partial purification of PAPS translocase. Ozeran JD, et al. **Biochemistry** 1996 Mar 26; 35(12):3695–703
Kinetics of PAPS translocase: evidence for an antiport mechanism. Ozeran JD, et al. **Biochemistry** 1996 Mar 26;

ANTIPORTERS

35(12):3685–94

Mercaptide formed between the residue Cys70 and Hg2+ or Co2+ behaves as a functional positively charged side chain operative in the Arg70—>Cys mutant of the metal–tetracycline/H+ antiporter of Escherichia coli. Someya Y, et al. **Biochemistry** 1996 Jul 23;35(29):9385–91

Endogenous K+/H+ exchange activity in the Sf9 insect cell line. Vachon V, et al. **Biochemistry** 1995 Nov 21; 34(46):15157–64

Second-site suppressor mutations for the Asp–66—>Cys mutant of the transposon Tn10–encoded metal–tetracycline/H+ antiporter of Escherichia coli. Yamaguchi A, et al. **Biochemistry** 1995 Sep 19; 34(37):11800–6

Stimulation of oxidative phosphorylation by electrophoretic K+ entry associated to electroneutral K+/H+ exchange in yeast mitochondria. Manon S, et al. **Biochim Biophys Acta** 1995 Oct 10;1231(3):282–8

Cation–dependent uptake of zinc in human fibroblasts. Ackland ML, et al. **Biometals** 1996 Jan;9(1):29–37

Alterations in sodium metabolism as an etiological model for hypertension. Lijnen P. **Cardiovasc Drugs Ther** 1995 Jun; 9(3):377–99 (238 ref.)

Thyroid hormone regulates Na(+)-Ca2+ exchanger expression during postnatal maturation and in adult rabbit ventricular myocardium. Boerth SR, et al. **Cardiovasc Res** 1996 Feb;31 Spec No:E145–52

Renal chloride–bicarbonate exchangers. Godinich MJ, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):398–401 (34 ref.)

pH regulation in mouse sperm: identification of Na(+)–, Cl(–)–, and HCO3(–)–dependent and arylaminobenzoate–dependent regulatory mechanisms and characterization of their roles in sperm capacitation. Zeng Y, et al. **Dev Biol** 1996 Feb 1;173(2):510–20

Regulation of intracellular pH in the colonic epithelial cell line HT29 clone 19A. Busche R, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Apr;102(4):161–2

Erythrocyte Na(+)–H+ exchanger kinetics and Na(+)–Li+ countertransport activity in essential hypertensive patients. Delva P, et al. **Eur J Clin Invest** 1996 Jan;26(1):64–70

Cl/HCO(-3) exchanger is operative in isolated enterocytes from rat jejunum. Tosco M, et al. **Experientia** 1996 Mar 15;52(3):245–8

Reconstitution of the metal–tetracycline/H+ antiporter of Escherichia coli in proteoliposomes including F0F1–ATPase. Someya Y, et al. **FEBS Lett** 1995 Oct 23; 374(1):72–6

Measurement of sodium–lithium countertransport kinetics [letter; comment] Hardman T, et al. **Hypertension** 1996 Feb; 27(2):314–5; discussion 315–6. Comment on: Hypertension 1995 May;25(5):986–93.

Measurement of sodium–lithium countertransport kinetics [letter; comment] Thomas TH, et al. **Hypertension** 1996 Feb;27(2):313–4; discussion 316. Comment on: Hypertension 1995 May;25(5):986–93.

Measurement of sodium–lithium countertransport kinetics [letter] Wierzbicki AS. **Hypertension** 1996 Feb;27(2):315; discussion 316

Inner membrane anion channel and dicarboxylate carrier in brown adipose tissue mitochondria. Ježek P, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):659–66

Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. Liu J, et al. **J Bacteriol** 1996 Jul;178(13):3791–5

The NH2–terminal half of the Tn10–specified tetracycline efflux protein TetA contains a dimerization domain. McMurry LM, et al. **J Biol Chem** 1995 Sep 29; 270(39):22752–7

Mechanism for binding site diversity on ankyrin. Comparison of binding sites on ankyrin for neurofascin and the Cl–/HCO3– anion exchanger. Michaely P, et al. **J Biol Chem** 1995 Dec 29;270(52):31298–302

Mechanisms of nucleobase transport in rabbit choroid plexus. Evidence for a Na(+)–dependent nucleobase transporter with broad substrate selectivity. Washington CB, et al. **J Biol Chem** 1995 Sep 29;270(39):22816–9

Expression and function of bicarbonate/chloride exchangers in the preimplantation mouse embryo. Zhao Y, et al. **J Biol Chem** 1995 Oct 13;270(41):24428–34

Relation of sodium–lithium countertransport activity to markers of cardiovascular risk in normotensive subjects. Hardman TC, et al. **J Hum Hypertens** 1995 Jul;9(7):589–96

Functional coupling between sarcoplasmic reticulum and Na/Ca exchange in single myocytes of guinea–pig and rat heart. Janiak R, et al. **J Mol Cell Cardiol** 1996 Feb; 28(2):253–64

Sodium–magnesium antiport in Retzius neurones of the leech Hirudo medicinalis. Günzel D, et al. **J Physiol (Lond)** 1996 Mar 15;491 (Pt 3):595–608

L–arginine transport and metabolism in Giardia intestinalis support its position as a transition between the prokaryotic and eukaryotic kingdoms. Knodler LA, et al. **Microbiology** 1995 Sep;141 (Pt 9):2063–70

The product of HUM1, a novel yeast gene, is required for vacuolar Ca2+/H+ exchange and is related to mammalian Na+/Ca2+ exchangers. Pozos TC, et al. **Mol Cell Biol** 1996 Jul;16(7):3730–41

Thiol group control of sodium–lithium countertransport kinetics in uraemia: evidence of a membrane abnormality affected by haemodialysis. Rutherford PA, et al. **Nephron** 1996;72(2):184–8

[Role of components of formate–hydrogen–lyase in forming molecular hydrogen and their connection with proton–potassium exchange in anaerobically grown Escherichia coli] Bagramian KA, et al. **Biofizika** 1996 Mar–Apr;41(2):369–76 (Eng. Abstr.) **(Rus)**

[Modulation of Na+,K+–pump activity and Na+,Li+–exchange in rabbit erythrocytes at various stages of cholesterol feeding] Makarov VL. **Biokhimiia** 1995 Sep;60(9):1468–76 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Influence of cell membrane potential, and selectivity of the Na+/H+ exchanger and Cl–/HCO3– exchanger on the intracellular accumulation of adriamycin. Asaumi JI, et al. **Anticancer Res** 1996 Mar–Apr;16(2):725–8

N–terminal quarter part of tetracycline transporter from pACYC184 complements K+ uptake activity in K+ uptake–deficient mutants of Escherichia coli and Vibrio alginolyticus. Nakamura T, et al. **Biol Pharm Bull** 1995 Sep;18(9):1189–93

Activation of the Na(+)/H(+) antiporter, Na+/HCO3(–)/CO3(2–) cotransporter, or Cl(–)/HCO3(–) exchanger in spontaneous thymocyte apoptosis. Tsao N, et al. **J Immunol** 1996 Aug 1;157(3):1107–16

ANTIPROTOZOAL AGENTS

ADMINISTRATION & DOSAGE

Acanthamoeba keratitis: risk factors and outcome. Illingworth CD, et al. **Br J Ophthalmol** 1995 Dec; 79(12):1078–82

Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients. Saukkonen K, et al. **Chest** 1996 May;109(5):1250–5

The effects of multiple doses of ivermectin on ocular onchocerciasis. A six–year follow–up. Mabey D, et al. **Ophthalmology** 1996 Jul;103(7):1001–8

Intrarectal glucantime. Marsden PD. **Rev Soc Bras Med Trop** 1996 May–Jun;29(3):295

ADVERSE EFFECTS

Meglumine antimoniate–induced pancreatitis [letter] Torrús D, et al. **Am J Gastroenterol** 1996 Apr;91(4):820–1

Acute pancreatitis associated with sodium stibogluconate treatment in a patient with human immunodeficiency virus [letter] Domingo P, et al. **Arch Intern Med** 1996 May 13; 156(9):1029, 1032

Reversible peripheral neuropathy associated with sodium stibogluconate therapy for American cutaneous leishmaniasis. Brummitt CF, et al. **Clin Infect Dis** 1996 May; 22(5):878–9

Generalized contact dermatitis from acetarsone. Sasseville D, et al. **Contact Dermatitis** 1995 Dec;33(6):431–2

Diabetes mellitus associated with pentamidine isethionate in diffuse cutaneous leishmaniasis. Costa JM, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):405–7 (13 ref.)

Does antimony therapy cause bleeding in kala–azar patients and why? Chowdhury MA, et al. **Trop Doct** 1995 Oct; 25(4):188–9

[A case of urticaria during pentavalent antimony use in a patient with mucous leishmaniasis (letter)] Oliveira MR, et al. **Rev Soc Bras Med Trop** 1995 Jul–Sep;28(3):287 **(Por)**

ANALYSIS

High–performance thin–layer chromatographic method for the fluorescence detection of three nitroimidazole residues in pork and poultry tissue. Gaugain M, et al. **J Chromatogr A** 1996 Jun 21;737(2):343–6

Residues of dimetridazole in eggs after treatment of laying hens. Posyniak A, et al. **Vet Res Commun** 1996;20(2):167–74

CHEMISTRY

A new analogue of nifurtimox. Caracelli I, et al. **Acta Crystallogr C** 1996 May 15;52 (Pt 5):1281–2

Structure and activity of avermectins and milbemycins in animal health. Shoop WL, et al. **Vet Parasitol** 1995 Sep; 59(2):139–56 (54 ref.)

ISOLATION & PURIFICATION

Pessoine and spinosine, two catecholic berbines from Annona spinescens. Queiroz EF, et al. **J Nat Prod** 1996 Apr; 59(4):438–40

Plant metabolites active against Trypanosoma cruzi. Sepúlveda–Boza S, et al. **Planta Med** 1996 Apr;62(2):98–105 (63 ref.)

METABOLISM

3'–Deoxy–3'–fluoroinosine as a potent antileishmanial agent. The metabolism and selective cytotoxic effect of 3'–deoxy–3'–fluoroinosine against Leishmania tropica and L. donovani in vitro and in vivo. Shin IS, et al. **Parasitol Res** 1995;81(7):622–6

PHARMACOKINETICS

Pentamidine uptake in Leishmania donovani and Leishmania amazonensis promastigotes and axenic amastigotes. Basselin M, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):631–4

Tolerance and pharmacokinetics of antimony in a patient with renal failure [letter] Buffet P, et al. **Nephrol Dial Transplant** 1995;10(8):1477

A bioequivalence and pharmacokinetic evaluation of two commercial diminazene aceturate formulations administered intramuscularly to cattle. Gummow B, et al. **Onderstepoort J Vet Res** 1994 Dec;61(4):317–26

Pharmacokinetic interaction between intravenous 2',3'–dideoxyinosine and pentamidine in rats. Yeh TK, et al. **Pharm Res** 1996 Apr;13(4):628–32

Disposition of antimony after the administration of N–methylglucamine antimoniate to dogs. Valladares JE, et al. **Vet Rec** 1996 Feb 24;138(8):181–3

PHARMACOLOGY

New mechanisms of drug resistance in parasitic protozoa. Borst P, et al. **Annu Rev Microbiol** 1995;49:427–60 (196 ref.)

Susceptibility of Encephalitozoon cuniculi to several drugs in vitro. Franssen FF, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1265–8

In vitro activity of atovaquone against Leishmania chagasi promastigotes [letter] Jernigan JA, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1064

In vitro antileishmanial properties of tri– and pentavalent antimonial preparations. Roberts WL, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1234–9

The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria. Zhai L, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2742–8

A comparison of two methods for assessing drug sensitivity in Giardia duodenalis. Pearce DA, et al. **Appl Parasitol** 1996 Jun;37(2):111–6

Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL–mediated delivery. Mishra RK, et al. **Biochim Biophys Acta** 1995 Nov 7;1264(2):229–37

Prolonged isolated fever due to attenuated extracerebral toxoplasmosis in patients infected with human immunodeficiency virus who are receiving trimethoprim–sulfamethoxazole as prophylaxis. Zylberberg H, et al. **Clin Infect Dis** 1995 Sep;21(3):680–1

Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Spencer CM, et al. **Drugs** 1995 Jul;50(1):176–96 (64 ref.)

Sinefungin and taxol effects on cell cycle and cytoskeleton of Leishmania donovani promastigotes. Moulay L, et al. **Exp Cell Res** 1996 Aug 1;226(2):283–91

Leishmania amazonensis: multidrug resistance in vinblastine–resistant promastigotes is associated with rhodamine 123 efflux, DNA amplification, and RNA overexpression of a Leishmania mdr1 gene. Gueiros–Filho FJ, et al. **Exp Parasitol** 1995 Dec;81(4):480–90

Toxoplasma gondii: parasiticidal effects of bovine lactoferricin against parasites. Tanaka T, et al. **Exp Parasitol** 1995 Dec;81(4):614–7

Kinetoplast DNA minicircle binding proteins in a Leishmania Spp: interference of protein DNA interaction by berenil. Singh R, et al. **Indian J Biochem Biophys** 1995 Dec; 32(6):437–41

Giardicidal activity of lactoferrin and N–terminal peptides. Turchany JM, et al. **Infect Immun** 1995 Nov;63(11):4550–2

Protective effect of leflunomide on the natural course of Leishmania major–induced disease in genetically susceptible BALB/c mice. Solbach W, et al. **Int J Immunopharmacol** 1995 Jun;17(6):481–8

Interconnection between organellar functions, development and drug resistance in the protozoan parasite, Toxoplasma gondii. Tomavo S, et al. **Int J Parasitol** 1995 Nov; 25(11):1293–9

Inhibition of protein synthesis and amino acid transport by crystal violet in Trypanosoma cruzi. Hoffmann ME, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):293–7

Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. Ramos H, et al. **J Membr Biol** 1996 Jul;152(1):65–75

Colchicine decreases the infection by Toxoplasma gondii in cultured glial cells. Aguirre–Cruz L, et al. **J Parasitol** 1996 Apr;82(2):325–7

Giardia duodenalis: exposure to metronidazole inhibits competitive interactions between isolates of the parasite in vitro. Thompson RC, et al. **J Parasitol** 1996 Aug; 82(4):679–83

Correlation between inhibition of growth and arginine transport of Leishmania donovani promastigotes in vitro by diamidines. Kandpal M, et al. **Life Sci** 1996; 59(7):PL75–80

Effects of an asymmetric triazine derivative, HOE 092 V, on Glugea anomala, Moniez, 1887 (Microsporidia) parasitic in the three–spined stickleback Gasterosteus aculeatus. Schmahl G, et al. **Parasitol Res** 1996;82(3):225–9

Antiplasmodial activities and cytotoxic effects of aqueous extracts and sesquiterpene lactones from Neurolaena lobata. François G, et al. **Planta Med** 1996 Apr;62(2):126–9

Complementation of an Escherichia coli adhE mutant by the Entamoeba histolytica EhADH2 gene provides a method for the identification of new antiamebic drugs. Yong TS, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6464–9

Pentamidine is a specific, non–peptide, GPIIb/IIIa antagonist. Cox D, et al. **Thromb Haemost** 1996 Mar; 75(3):503–9

[Trypanocidal structure- activity relationship in 9-thioalkylacridines] Bsiri N, et al. **Ann Pharm Fr** 1996; 54(1):27-33 (Eng. Abstr.) **(Fre)**

[Resistance of Leishmania infantum to Glucantime: risk factors and therapeutic management] Piarroux R, et al. **Arch Pediatr** 1996 Apr;3(4):352-6 (Eng. Abstr.) **(Fre)**

SUPPLY & DISTRIBUTION

Treatment of giardiasis [letter; comment] Hammond JJ. **Postgrad Med** 1996 Jan;99(1):47. Comment on: Postgrad Med 1995 Aug;98(2):155-8.

THERAPEUTIC USE

Failure of atovaquone in the treatment of cerebral toxoplasmosis [letter] Durand JM, et al. **AIDS** 1995 Jul; 9(7):812-3

Clindamycin desensitization in an AIDS patient [letter] Marcos C, et al. **AIDS** 1995 Oct;9(10):1201-2

Criteria for use of atovaquone oral suspension in adult inpatients and outpatients. Goodwin SD, et al. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2460-2

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Ribera E, et al. **Am J Med** 1996 May;100(5):496-501

Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice. Martinez A, et al. **Am J Trop Med Hyg** 1996 Mar;54(3):249-52

Atovaquone in the treatment of Babesia microti infections in hamsters. Wittner M, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):219-22

Therapeutic approaches for AIDS-related toxoplasmosis [see comments] Behbahani R, et al. **Ann Pharmacother** 1995 Jul-Aug;29(7-8):760-8 (52 ref.). Comment in: Ann Pharmacother 1995 Dec;29(12):1303-4.

Topical fumagillin in the treatment of microsporidial keratoconjunctivitis in AIDS. Garvey MJ, et al. **Ann Pharmacother** 1995 Sep;29(9):872-4

Visceral leishmaniasis: rapid response to AmBisome treatment. Smith OP, et al. **Arch Dis Child** 1995 Aug; 73(2):157-9

The surface glycoconjugates of parasitic protozoa: potential targets for new drugs. McConville MJ. **Aust N Z J Med** 1995 Dec;25(6):768-76 (40 ref.)

Back up drug found for severe malaria [news] Wise J. **BMJ** 1996 Jul 20;313(7050):134

Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Peacock JE Jr, et al. **Bone Marrow Transplant** 1995 Jun;15(6):983-7 (23 ref.)

Human antiprotozoal therapy: past, present, and future. Khaw M, et al. **Clin Microbiol Rev** 1995 Jul;8(3):427-39 (182 ref.)

Problems in the treatment of kala-azar: case report. Nyakundi PM, et al. **East Afr Med J** 1995 Jun;72(6):406-8

Failure of itraconazole to prevent Enterocytozoon bieneusi infection [letter] Albrecht H, et al. **Genitourin Med** 1995 Oct;71(5):325-6

Visceral leishmaniasis during pregnancy treated with meglumine antimoniate. Utili R, et al. **Infection** 1995 May-Jun;23(3):182-3

Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B [letter] Mishra M. **J Assoc Physicians India** 1995 Apr;43(4):306

Diagnosis of disseminated microsporidian Encephalitozoon hellem infection by PCR-Southern analysis and successful treatment with albendazole and fumagillin. Didier ES, et al. **J Clin Microbiol** 1996 Apr;34(4):947-52

Disseminated Encephalitozoon (Septata) intestinalis infection in a patient with AIDS: novel diagnostic approaches and autopsy-confirmed parasitological cure following treatment with albendazole. Sobottka I, et al. **J Clin Microbiol** 1995 Nov;33(11):2948-52

A new intralesional therapy of cutaneous leishmaniasis with hypertonic sodium chloride solution. Sharquie KE. **J Dermatol** 1995 Oct;22(10):732-7

Abuse of Brolene eye drops with putative corneal infection [letter] Kinnear FB, et al. **J Infect** 1996 Mar;32(2):172-4

Successful prevention and treatment of babesiosis with atovaquone. Hughes WT, et al. **J Infect Dis** 1995 Oct; 172(4):1042-6

Successful chemotherapy in experimental leishmaniasis is influenced by the polarity of the T cell response before treatment. Nabors GS, et al. **J Infect Dis** 1996 Apr; 173(4):979-86

Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. Sundar S, et al. **J Infect Dis** 1996 Mar;173(3):762-5

Folinic acid supplements to pyrimethamine-sulfadiazine for Toxoplasma encephalitis are associated with better outcome [letter] Van Delden C, et al. **J Infect Dis** 1996 May;173(5):1294-5

Sterilisation of Babesia canis infections by imidocarb alone or in combination with diminazene. Penzhorn BL, et al. **J S Afr Vet Assoc** 1995 Sep;66(3):157-9

Secnidazole in the treatment of giardiasis [letter] Baqai R, et al. **JPMA J Pak Med Assoc** 1995 Oct;45(10):288

A new breakthrough in treatment of visceral leishmaniasis in children. Hassan M, et al. **JPMA J Pak Med Assoc** 1995 Jun;45(6):155-7

Treatment of kala azar [letter] Ozsoylu S. **Lancet** 1996 Jun 15;347(9016):1701

Antiparasitic drugs. Liu LX, et al. **N Engl J Med** 1996 May 2;334(18):1178-84 (100 ref.)

Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine. Lustig V, et al. **Neth J Med** 1995 Aug; 47(2):66-9

Lack of activity of artemether for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii infections in rat. Brun-Pascaud M, et al. **Parasite** 1996 Jun;3(2):187-9

Chemotherapy of human and animal coccidioses: state and perspectives. Haberkorn A. **Parasitol Res** 1996;82(3):193-9 (97 ref.)

Treatment of Acanthamoeba keratitis [letter] Niszl IA, et al. **S Afr Med J** 1996 May;86(5):566

Treatment with allopurinol and itraconazole changes lytic activity in patients with chronic, low grade Trypanosoma cruzi infection. Sánchez G, et al. **Trans R Soc Trop Med Hyg** 1995 Jul-Aug;89(4):438-9

Efficacy of albendazole and fenbendazole against Giardia infection in cattle. Xiao L, et al. **Vet Parasitol** 1996 Jan; 61(1-2):165-70

[Fansidar in the treatment of toxoplasmosis] Michalová K, et al. **Cesk Slov Oftalmol** 1996 Jul;52(3):173-8 (Eng. Abstr.) **(Cze)**

[Antiparasitic therapeutics: the present] Magnaval JF. **Med Trop (Mars)** 1995;55(3 Suppl):10-2 (15 ref.) **(Fre)**

[Effectiveness of aminosidine sulphate in severe visceral leishmaniasis, resistant to the treatment with pentavalent antimony] Castro C, et al. **Rev Soc Bras Med Trop** 1995 Jul-Sep;28(3):273-7 (Eng. Abstr.) **(Por)**

[Aminosidine in the treatment of mucocutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis] Romero GA, et al. **Rev Soc Bras Med Trop** 1996 Mar-Apr; 29(2):215-6 **(Por)**

[Intralesional treatment of cutaneous leishmaniasis: a report of two cases] Clarós P, et al. **Acta Otorrinolaringol Esp** 1996 Jan-Feb;47(1):67-70 (Eng. Abstr.) **(Spa)**

[Treatment of recurrent Isospora belli diarrhea (letter)] Gorricho Mendívil J, et al. **Rev Esp Enferm Dig** 1995 Aug; 87(8):612-3 **(Spa)**

TOXICITY

Reactive oxygen and nitrogen intermediates and products from polyamine degradation are Babesiacidal in vitro. Johnson WC, et al. **Ann N Y Acad Sci** 1996 Jul 23; 791:136-47

Effects of concurrent administration of monensin and selenium on erythrocyte glutathione peroxidase activity and liver selenium concentration in broiler chickens. Khan MZ, et al. **Biol Trace Elem Res** 1995 Aug-Sep; 49(2-3):129-38

Shiva-1: in vitro and in vivo tests of the effects of a novel, synthetic, lytic peptide on ocular cells. Shahsavari M, et al. **Int Ophthalmol** 1995;19(1):29-34

3'-Deoxy-3'-fluoroinosine as a potent antileishmanial agent. The metabolism and selective cytotoxic effect of 3'-deoxy-3'-fluoroinosine against Leishmania tropica and L. donovani in vitro and in vivo. Shin IS, et al. **Parasitol Res** 1995;81(7):622-6

In vitro responsiveness of Babesia bovis to imidocarb dipropionate and the selection of a drug-adapted line. Rodriguez RI, et al. **Vet Parasitol** 1996 Mar;62(1-2):35-41

ANTIPRURITICS

ADMINISTRATION & DOSAGE

[Antipruritic effect of antihistaminic and local anesthetic topical agents after iontophoretic histamine stimulation] Weisshaar E, et al. **Hautarzt** 1996 May;47(5):355-60 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Nasal receptors responding to cold and l-menthol airflow in the guinea pig. Sekizawa S, et al. **Respir Physiol** 1996 Mar;103(3):211-9

In vitro/in vivo difference in enhanced skin permeation of nicardipine hydrochloride by the 1-menthol-ethanol system. Kobayashi D, et al. **Skin Pharmacol** 1996;9(2):130-6

POISONING

Toxic reaction from topically applied doxepin in a child with eczema [letter] Vo MY, et al. **Arch Dermatol** 1995 Dec; 131(12):1467-8

A fatal case of alimemazine poisoning. Kintz P, et al. **J Anal Toxicol** 1995 Nov-Dec;19(7):591-4

THERAPEUTIC USE

The antipruritic effects of chlorpheniramine, cyproheptadine and sulphapyridine monitored with limb activity meters on chloroquine induced pruritus among patients with malaria. Osifo NG. **Afr J Med Med Sci** 1995 Mar; 24(1):67-73

Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Carson KL, et al. **Am J Gastroenterol** 1996 May;91(5):1022-3

The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. Drake LA, et al. **Arch Dermatol** 1995 Dec;131(12):1403-8

Treating pruritus. What's new in safe relief of symptoms? Millikan LE. **Postgrad Med** 1996 Jan;99(1):173-6, 179-84 (17 ref.)

ANTIPSYCHOTIC AGENTS

see related

DOPAMINE ANTAGONISTS

Barbiturates, neuroleptics, and propofol for sedation. Lund N, et al. **Crit Care Clin** 1995 Oct;11(4):875-86 (38 ref.)

[Recent progress in development of psychotropic drugs (2)--antipsychotics] Murasaki M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):191-210 (55 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

An effective computer-based tardive dyskinesia monitoring system. Hammond KW, et al. **Am J Med Qual** 1995 Fall; 10(3):133-7

Discontinuation of neuroleptics in community-dwelling individuals with mental retardation and mental illness. Pary RJ. **Am J Ment Retard** 1995 Sep;100(2):207-12

Cross-tapering clozapine and risperidone [letter] Koreen AR, et al. **Am J Psychiatry** 1995 Nov;152(11):1690

Efficacy of medium-dose clozapine for treatment-resistant schizophrenia [letter] Kurz M, et al. **Am J Psychiatry** 1995 Nov;152(11):1690-1

Risperidone: a once-daily dosage schedule. Gupta S, et al. **Ann Clin Psychiatry** 1995 Dec;7(4):211

A study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication. May P, et al. **Ann Clin Psychiatry** 1995 Dec;7(4):155-60

Start low and go slow: dosing of antipsychotic medications in elderly patients with dementia [letter] Gurwitz JH. **Arch Intern Med** 1995 Oct 9;155(18):2017-8

Neuroleptic prescribing in residents of nursing homes. Behaviour problems are underdocumented [letter; comment] Cameron H. **BMJ** 1996 Jun 29;312(7047):1668; discussion 1669. Comment on: BMJ 1996 Mar 9;312(7031):611-2.

Neuroleptic prescribing in residents of nursing homes. Dangerous to extrapolate local audit findings [letter; comment] McAllister-Williams RH, et al. **BMJ** 1996 Jun 29;312(7047):1667; discussion 1669. Comment on: BMJ 1996 Mar 9;312(7031):611-2.

Neuroleptic prescribing in residents of nursing homes. Geographical differences make extrapolation difficult [letter; comment] Passmore AP, et al. **BMJ** 1996 Jun 29; 312(7047):1667. Comment on: BMJ 1996 Mar 9;312(7031):611-2.

Neuroleptic prescribing in residents of nursing homes. Access to psychiatrists should be improved [letter; comment] Tarbuck AF. **BMJ** 1996 Jun 29;312(7047):1667-8; discussion 1669. Comment on: BMJ 1996 Mar 9;312(7031):611-2.

Neuroleptic prescribing in residents of nursing homes. Substantial study is imminent [letter; comment] Thacker S, et al. **BMJ** 1996 Jun 29;312(7047):1668; discussion 1669 . Comment on: BMJ 1996 Mar 9;312(7031):611-2.

Neuroleptic prescribing in residents of nursing homes. Use may be justified if other factors have been considered [letter; comment] Tobiansky R, et al. **BMJ** 1996 Jun 29; 312(7047):1668-9. Comment on: BMJ 1996 Mar 9;312(7031):611-2.

Low-dose maintenance clozapine treatment in the prophylaxis of bipolar affective disorder. Puri BK, et al. **Br J Clin Pract** 1995 Nov-Dec;49(6):333-4

Intramuscular injections in the anticoagulated state [letter] Aitken P, et al. **Br J Psychiatry** 1995 Aug;167(2):269

Risperidone in schizophrenia [letter] Bazire S. **Br J Psychiatry** 1996 Jan;168(1):128

Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Litman RE, et al. **Br J Psychiatry** 1996 May;168(5):571-9

Lead-in placebo washout period [letter] Volavka J. **Br J Psychiatry** 1995 Nov;167(5):694

Denouement of an execution competency case: is Perry pyrrhic? Mossman D. **Bull Am Acad Psychiatry Law** 1995; 23(2):269-84 (113 ref.)

Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen. Shriqui CL. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S38-48 (77 ref.)

Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men. Kleinbloesem CH, et al. **Clin Pharmacol Ther** 1996 Jun;59(6):675-85

Issues in drug administration in a psychiatric rehabilitation unit. Trauer T, et al. **Int J Soc Psychiatry** 1995 Autumn; 41(3):174-9

Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse. Heresco-Levy U, et al. **Isr J Psychiatry Relat Sci** 1995; 32(4):268-75

Implosive therapy as an adjunctive treatment in a psychotic disorder: a case report. Saper Z, et al. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):157-60

Why can low doses of sulpiride counteract depression? [letter] Okada F. **J Clin Psychopharmacol** 1995 Dec;

15(6):442–3
The prescribing of neuroleptic drugs for people with learning disabilities living in Leicestershire. Branford D, et al. **J Intellect Disabil Res** 1995 Dec;39 (Pt 6):495–500
Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. Chen CP, et al. **J Neurochem** 1996 Apr;66(4):1592–8
The clozapine clinic [letter] Camprubi M, et al. **Lancet** 1996 Jan 13;347(8994):124
Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies. Schooler NR, et al. **Psychiatr Q** 1995 Winter;66(4):279–92 (41 ref.)
Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Weiden P, et al. **Psychiatr Serv** 1995 Oct;46(10):1049–54
Risperidone and the treatment of delusions of parasitosis in an elderly patient. Gallucci G, et al. **Psychosomatics** 1995 Nov–Dec;36(6):578–80
Conventional antipsychotic medications for schizophrenia. Dixon LB, et al. **Schizophr Bull** 1995;21(4):567–77 (40 ref.)
Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Johns CA, et al. **Schizophr Bull** 1995;21(4):607–19 (85 ref.)
Maintenance medication for schizophrenia and schizoaffective patients. Lerner V, et al. **Schizophr Bull** 1995;21(4):693–701
Hospital at war: treatment changes in mental patients. Gelkopf M, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Nov;30(6):256–60
[Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature] Pélissolo A, et al. **Encephale** 1996 May–Jun;22(3):215–9 (25 ref.) (Eng. Abstr.) **(Fre)**
[The "neuroleptic threshold"—a review of the literature] Abraham D, et al. **Psychiatr Prax** 1996 May;23(3):109–16 (42 ref.) (Eng. Abstr.) **(Ger)**
[Which factors modify drug-compliance?] Albus M, et al. **Psychiatr Prax** 1995 Nov;22(6):228–30 (Eng. Abstr.) **(Ger)**
[Treatment of depression with a neuro-thymoleptic combination in general practice] Schirmer G. **Psychiatr Prax** 1996 Mar;23(2):99–100 **(Ger)**
[Maintenance therapy with low doses of clozapine in schizophrenia] Lisulov R, et al. **Med Pregl** 1995; 48(1–2):15–8 (Eng. Abstr.) **(Scr)**

ADVERSE EFFECTS

Electrocardiographic changes in patients receiving neuroleptic medication. Warner JP, et al. **Acta Psychiatr Scand** 1996 Apr;93(4):311–3
ST segment elevations without myocardial infarction in a patient on clozapine [letter] Ketch J, et al. **Am J Emerg Med** 1996 Jan;14(1):111–2
Concomitant use of antipsychotics with risperidone [letter; comment] Chouinard G. **Am J Health Syst Pharm** 1996 Feb 15;53(4):443. Comment on: Am J Health Syst Pharm 1995 May 1;52(9):1012.
Compulsive water drinking in the setting of anticholinergic drug use: an unrecognized cause of chronic renal failure. Singh H, et al. **Am J Kidney Dis** 1995 Oct;26(4):586–9
Aging and neuroleptic-induced acute dystonia [letter] Deleu D, et al. **Am J Psychiatry** 1996 Mar;153(3):447–8
Risperidone-induced dystonic reaction [letter] Faulk RS, et al. **Am J Psychiatry** 1996 Apr;153(4):577
Tardive dyskinesia and substrates of energy metabolism in CSF. Goff DC, et al. **Am J Psychiatry** 1995 Dec; 152(12):1730–6
Neuroleptic-induced bilateral temporomandibular joint dislocation [letter] Ibrahim ZY, et al. **Am J Psychiatry** 1996 Feb;153(2):293–4
Circadian pattern of acute, neuroleptic-induced dystonic reactions. Mazurek MF, et al. **Am J Psychiatry** 1996 May; 153(5):708–10
Critique of DSM-IV: associated features of neuroleptic-induced parkinsonism [letter] Segraves T, et al. **Am J Psychiatry** 1996 Jun;153(6):844
Clozapine-caused eosinophilic colitis. Friedberg JW, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):97–8
Delirium associated with clozapine and benzodiazepine combinations. Jackson CW, et al. **Ann Clin Psychiatry** 1995 Sep;7(3):139–41
Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients. John JP, et al. **Ann Clin Psychiatry** 1995 Sep;7(3):119–25
Neuroleptic malignant syndrome associated with clozapine treatment. Tsai G, et al. **Ann Clin Psychiatry** 1995 Jun; 7(2):91–5
Drugs associated with bullous pemphigoid. A case-control study. Bastuji-Garin S, et al. **Arch Dermatol** 1996 Mar; 132(3):272–6
Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Chakos MH, et al. **Arch Gen Psychiatry** 1996 Apr;53(4):313–9
Complicating factors in the analysis of acute drug-induced akathisia [letter; comment] Rosebush PI, et al. **Arch Gen Psychiatry** 1995 Oct;52(10):878–80. Comment on: Arch Gen Psychiatry 1994 Dec;51(12):963–74.
Erythromycin-induced clozapine toxic reaction. Cohen LG, et al. **Arch Intern Med** 1996 Mar 25;156(6):675–7
Disseminated intravascular coagulopathy and thrombocytopenia associated with clozapine-induced neuroleptic malignant syndrome [letter] Lowy A, et al. **Aust N Z J Med** 1995 Aug;25(4):368
Clozapine-induced neuroleptic malignant syndrome: another inconclusive case report [letter] Weller M, et al. **Aust N Z J Med** 1996 Apr;26(2):232–3
Neuroleptic-induced emesis: a new indication for clozapine? Bustillo JR, et al. **Biol Psychiatry** 1995 Aug 1;38(3):194–5
Fluctuation of tardive dyskinesia. Caligiuri MP, et al. **Biol Psychiatry** 1995 Sep 1;38(5):336–9
Neuroleptic malignant syndrome and catatonia: one entity or two? [editorial] Fink M. **Biol Psychiatry** 1996 Jan 1; 39(1):1–4 (30 ref.)
Sleep during clozapine-induced fever in a schizophrenic patient. Hinze-Selch D, et al. **Biol Psychiatry** 1995 Nov 15;38(10):690–3
Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Lipska BK, et al. **Biol Psychiatry** 1995 Aug 15;38(4):255–62
Clozapine-induced myoclonus and generalized seizures. Sajatovic M, et al. **Biol Psychiatry** 1996 Mar 1;39(5):367–70
Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Schultz SK, et al. **Biol Psychiatry** 1995 Dec 1;38(11):713–9
Immediate recurrence of psychotic symptoms after discontinuation of clozapine: a case report. Tanriverdi N, et al. **Biol Psychiatry** 1996 May 1;39(9):814–5
Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Verghese C, et al. **Biol Psychiatry** 1996 Jan 15;39(2):135–8
Physical illness in psychiatric patients may be managed poorly [comment] Davies T. **BMJ** 1996 Jan 13;312(7023):82 . Comment on: BMJ 1996 Jan 13;312(7023):79–82.
Increased mortality related to asthma among asthmatic patients using major tranquillisers. Underlying ill health is the main risk factor [letter] Jones A. **BMJ** 1996 Apr 13;312(7036):976
Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers [see comments] Joseph KS, et al. **BMJ** 1996 Jan 13; 312(7023):79–82. Comment in: BMJ 1996 Jan 13;312(7023):82. Comment in: BMJ 1996 Jan 13;312(7023):82–3.
Asthmatic patients with psychosis need special care [comment] Levy ML. **BMJ** 1996 Jan 13;312(7023):82–3. Comment on: BMJ 1996 Jan 13;312(7023):79–82.
Preventing local complications of depot neuroleptics [letter; comment] Muldoon C. **BMJ** 1995 Nov 18;311(7016):1368 . Comment on: BMJ 1995 Aug 12;311(7002):421.
Increased mortality related to asthma among asthmatic patients using major tranquillisers. Smoking may increase mortality when patients stop using tranquillisers [letter] Rozewic L. **BMJ** 1996 Apr 13;312(7036):976–7
Priapism associated with psychotropic drugs. Patel AG, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):315–9 (63 ref.)
Cardiovascular and autonomic function in Down syndrome--prescribing implications [letter] Carpenter PK. **Br J Psychiatry** 1995 Jul;167(1):118–9
Clozapine-induced hypersalivation and the alpha 2 adrenoceptor [letter] Corrigan FM, et al. **Br J Psychiatry** 1995 Sep;167(3):412
Antipsychotic drug-induced dysphoria [letter] Gray R, et al. **Br J Psychiatry** 1996 May;168(5):655–6
Neuroleptic associated extrapyramidal symptoms [letter] Maurer I, et al. **Br J Psychiatry** 1995 Oct;167(4):551–2
Successful treatment of tardive dystonia with clozapine and clonazepam. Shapleske J, et al. **Br J Psychiatry** 1996 Apr; 168(4):516–8
Self-measure of neuroleptic side-effects [letter; comment] Sikdar S. **Br J Psychiatry** 1995 Jul;167(1):113–4. Comment on: Br J Psychiatry 1995 May;166(5):650–3.
Clozapine-induced hypotension treated with moclobemide and Bovril [letter] Taylor D, et al. **Br J Psychiatry** 1995 Sep;167(3):409–10
Dystonia and neuroleptic medication [letter] Thorburn R. **Br J Psychiatry** 1995 Jul;167(1):114
Cyproheptadine treatment in neuroleptic-induced akathisia. Weiss D, et al. **Br J Psychiatry** 1995 Oct;167(4):483–6
Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models. Casey DE. **Br J Psychiatry Suppl** 1996 May;(29):32–9
Does electroconvulsive therapy exacerbate the elevation of creatinine phosphokinase caused by neuroleptics [letter] Geizer M, et al. **Can J Psychiatry** 1996 Mar;41(2):131
Tardive dyskinesia: a review. Latimer PR. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S49–54 (44 ref.)
Management of suspected neuroleptic malignant syndrome. Velamoor VR, et al. **Can J Psychiatry** 1995 Nov; 40(9):545–50 (33 ref.)
Tardive syndromes and other drug-induced movement disorders. Jankovic J. **Clin Neuropharmacol** 1995 Jun; 18(3):197–214 (124 ref.)
The relationship between clozapine and obsessive–compulsive disorder [letter] Levin Z, et al. **Compr Psychiatry** 1996 Jan–Feb;37(1):74
Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Harth Y, et al. **Drug Saf** 1996 Apr;14(4):252–9 (47 ref.)
Adverse effects of antipsychotic agents. Do newer agents offer advantages? Owens DG. **Drugs** 1996 Jun; 51(6):895–930 (195 ref.)
Oropharyngeal dysphagia due to iatrogenic neurological dysfunction. Buchholz DW. **Dysphagia** 1995 Fall; 10(4):248–54 (51 ref.)
Anticholinergic antiparkinsonian therapy in outpatients treated with neuroleptic drugs: a prescription survey. Spila-Alegiani S, et al. **Eur J Clin Pharmacol** 1995; 48(6):513–7
Differences between haloperidol- and pimozide-induced withdrawal syndrome: a role for Ca2+ channels. Antkiewicz-Michaluk L, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):459–67
Antipsychotic agents: a survey of the prevalence, severity and burden of side effects. Bhavnani SM, et al. **Int Clin Psychopharmacol** 1996 Mar;11(1):1–12
Trihexyphenidyl as a possible therapeutic option in clozapine-induced nocturnal enuresis. Poyurovsky M, et al. **Int Clin Psychopharmacol** 1996 Mar;11(1):61–3
Risperidone side effects [letter] Edleman RJ. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):4–5
Obsessive-compulsive symptoms with-neuroleptics [letter] McDougle CJ, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):837–8
Enuresis with combined risperidone and SSRI use [letter] Took KJ, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):840–1
Risperidone and tardive dyskinesia: a case report [letter] Addington DE, et al. **J Clin Psychiatry** 1995 Oct; 56(10):484–5
Diphenhydramine dependence: a need for awareness [letter] de Nesnera AP. **J Clin Psychiatry** 1996 Mar;57(3):136–7
Probable induction of mania by risperidone [letter] Koek RJ, et al. **J Clin Psychiatry** 1996 Apr;57(4):174–5
Comments to "interaction between caffeine and clozapine" [letter] Carrillo JA, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):376–7
Severe elevations in serum creatine kinase associated with clozapine [letter] Kirson JI, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):287–8
Neuroleptic malignant syndrome with risperidone [letter] Levin GM, et al. **J Clin Psychopharmacol** 1996 Apr; 16(2):192–3
Free radical scavenging enzyme activity and related trace metals in clozapine-induced agranulocytosis: a pilot study. Linday LA, et al. **J Clin Psychopharmacol** 1995 Oct; 15(5):353–60
Clozapine and leukocytosis [letter] Popli A, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):286–7
Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. Sachdev P, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):365–71 (29 ref.)
Unblinding in trials of the withdrawal of anticholinergic agents in patients maintained on neuroleptics. Double DB. **J Nerv Ment Dis** 1995 Sep;183(9):599–602
Laryngeal tardive dyskinesia. Fève A, et al. **J Neurol** 1995 Jul;242(7):455–9
Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs. Bocola V, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb; 60(2):213–6
Tardive dystonia after neuroleptic treatment of Tourette's syndrome [letter] Tarsy D, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):119
"Abnormal" EEG effects of clozapine [letter] Fink M. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):114–6
Positron–emission tomography in tardive dyskinesia. Pahl JJ, et al. **J Neuropsychiatry Clin Neurosci** 1995 Fall;7(4):457–65
Cerebral infarction in neuroleptic malignant syndrome. Pullicino P, et al. **J Neuropsychiatry Clin Neurosci** 1991 Winter;3(1):75–7
Risperidone and neuroleptic malignant syndrome [letter] Tarsy D. **JAMA** 1996 Feb 14;275(6):446
Current topics in neuroleptic-induced extrapyramidal symptoms in Japan. Inada T, et al. **Keio J Med** 1996 Jun; 45(2):95–9 (36 ref.)
Pirenzepine for clozapine-induced hypersalivation [letter] Fritze J, et al. **Lancet** 1995 Oct 14;346(8981):1034
Tardive tourettism after exposure to neuroleptic therapy. Bharucha KJ, et al. **Mov Disord** 1995 Nov;10(6):791–3 (17 ref.)
Death due to asphyxia linked to antipsychotic drugs. Jitsufuchi N, et al. **Nippon Hoigaku Zasshi** 1995 Aug; 49(4):255–9
Novel versus conventional antipsychotic drugs. Love RC. **Pharmacotherapy** 1996 Jan–Feb;16(1 Pt 2):6–10 (24 ref.)
Novel antipsychotics and neuroleptic malignant syndrome [letter; comment] Buckley P. **Psychiatr Serv** 1996 Apr; 47(4):431. Comment on: Psychiatr Serv 1995 Sep;46(9):951.
Risperidone and NMS? [letter] [see comments] Murray S, et al. **Psychiatr Serv** 1995 Sep;46(9):951. Comment in: Psychiatr Serv 1996 Apr;47(4):431.
Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Hoffman DC, et al. **Psychopharmacology (Berl)** 1995 Jul;120(2):128–33
Decreased bone mineral density in medicated psychiatric patients. Halbreich U, et al. **Psychosom Med** 1995 Sep–Oct; 57(5):485–91
Schizophrenia, Alzheimer's disease, and anti-inflammatory agents. Oken RJ, et al. **Schizophr Bull** 1996;22(1):1–4 (24 ref.)
The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Sachdev P. **Schizophr Bull** 1995;21(3):431–49 (130

ref.)
The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Sachdev P. **Schizophr Bull** 1995;21(3):451–61 (70 ref.)
Weight gain associated with neuroleptic medication: a review. Stanton JM. **Schizophr Bull** 1995;21(3):463–72 (100 ref.)
Myocarditis under therapy with clozapine [letter] Bandelow B, et al. **Schizophr Res** 1995 Nov;17(3):293–4
The treatment of tardive dyskinesia. Raja M.
Schweiz Arch Neurol Psychiatr 1996;147(1):13–8 (99 ref.)
[Psychiatric drugs as a risk factor in fatal heat exhaustion (letter; comment)] Clerkx MG, et al.
Ned Tijdschr Geneeskd 1996 Feb 17;140(7):388. Comment on: Ned Tijdschr Geneeskd 1995 Jul 8;139(27):1391–3. **(Dut)**
[Psychiatric medication as risk factor for fatal heat collapse (letter; comment)] Conemans JM.
Ned Tijdschr Geneeskd 1995 Aug 26;139(34):1759–60. Comment on: Ned Tijdschr Geneeskd 1995 Jul 8;39(27):1391–3. **(Dut)**
[Agranulocytosis caused by clozapine: the importance of leukocyte monitoring and efficacy of hematopoietic growth factors] van Melick EJ, et al. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2437–40 (18 ref.) (Eng. Abstr.) **(Dut)**
[Current aspects of the use of clozapine in the Châlons-sur-Marne Psychiatric Hospital: intestinal occlusion with clozapine] Théret L, et al.
Ann Med Psychol (Paris) 1995 Aug-Sep;153(7):474–7 (24 ref.) (Eng. Abstr.) **(Fre)**
[Tolerance of neuroleptics, deficit syndrome and cognitive functions] Kahn JP. **Encephale** 1996 Jun;22 Spec No 2:49–54 (35 ref.) (Eng. Abstr.) **(Fre)**
[Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms] Petit M, et al. **Encephale** 1996 Jun;22 Spec No 2:13–8 (20 ref.) (Eng. Abstr.) **(Fre)**
[Schizophrenic deficit syndrome and neurologic tolerance] Verdoux H, et al. **Encephale** 1996 Jun;22 Spec No 2:45–7 (27 ref.) (Eng. Abstr.) **(Fre)**
[Severe hepatitis, complicating heat-stroke induced by exertion, successfully treated by neuroleptic and anticholinergic agents (letter)] Dohin-Caplanne S, et al. **Gastroenterol Clin Biol** 1995 Jun-Jul;19(6-7):637–8 **(Fre)**
[Akathisia induced by low doses of neuroleptics after a pallidal infarction (letter)] Auzou P, et al. **Presse Med** 1996 Feb 17;25(6):260 **(Fre)**
[Polytrauma and malignant neuroleptic syndrome. Case presentation with diagnostic problems] Röther J, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Nov; 30(7):455–7 (Eng. Abstr.) **(Ger)**
[Torticollis spasmodicus as a manifestation of tardive dystonia] Silberbauer C, et al. **Fortschr Neurol Psychiatr** 1995 Oct;63(10):388–92 (Eng. Abstr.) **(Ger)**
[Drug-induced asterixis amplified by relative hypoglycemia] Poersch M, et al. **Nervenarzt** 1996 Apr;67(4):323–6 (Eng. Abstr.) **(Ger)**
[Neuroleptics and nicotine] Erdmann R. **Psychiatr Prax** 1995 Nov;22(6):223–7 (34 ref.) (Eng. Abstr.) **(Ger)**
[Drug-induced dystonia misinterpreted as hysteria] Magnusson A, et al. **Tidsskr Nor Laegeforen** 1996 Mar 10; 116(7):844–5 (Eng. Abstr.) **(Nor)**
[Neuroleptic malignant syndrome: a review of literature] Crespo Facorro B, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1995 Sep-Oct;23(5):273–8 (57 ref.) (Eng. Abstr.) **(Spa)**
[Drug-induced extrapyramidal disorders (see comments)] Horga JF, et al. **Rev Neurol** 1995 Sep-Oct;23(123):961–3 (Eng. Abstr.). Comment in: Rev Neurol 1996 May;24(129):584–5. **(Spa)**

ANALYSIS

[Analysis of some neuroleptics and carazolol in pork kidneys] Arneth W. **Z Lebensm Unters Forsch** 1995 Sep;201(3):261–5 (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

[Substances that increase the extracellular level of dopamine in the striatum prevent development of haloperido! catalepsy in rats] Gainetdinov RR, et al.
Biull Eksp Biol Med 1996 Apr;121(4):438–40 **(Rus)**

BLOOD

Significance of plasma thiothixene concentrations [letter] Markowitz JS, et al. **Ann Pharmacother** 1995 Jul-Aug; 29(7–8):789–90
Is there a relationship between antipsychotic blood levels and their clinical efficacy? An analysis of studies design and methodology. de Oliveira IR, et al.
Fundam Clin Pharmacol 1995;9(5):488–502
A rapid gas chromatographic method quantitating clozapine in human plasma or serum for the purpose of therapeutic monitoring. Jennison TA, et al. **J Anal Toxicol** 1995 Nov-Dec;19(7):537–41
Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. Catlow JT, et al.
J Chromatogr B Biomed Appl 1995 Jun 9;668(1):85–90
Column liquid chromatographic determination of clozapine and N-desmethylclozapine in human serum using solid-phase extraction. Gupta RN.
J Chromatogr B Biomed Appl 1995 Nov 17;673(2):311–5
Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography. Janiszewski JS, et al.
J Chromatogr B Biomed Appl 1995 Jun 9;668(1):133–9
Picogram determination of iloperidone in human plasma by solid-phase extraction and by high-performance liquid chromatography-selected-ion monitoring electrospray mass spectrometry. Mutlib AE, et al.
J Chromatogr B Biomed Appl 1995 Jul 21;669(2):237–46
Sensitive gas-liquid chromatographic method for the assay of the neuroleptic drug cis(Z)-flupentixol in human serum or plasma. Ulrich S. **J Chromatogr B Biomed Appl** 1995 Jun 9;668(1):31–40
Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. Chiu JA, et al.
J Pharm Biomed Anal 1996 Mar;14(5):609–15
A capillary gas-liquid chromatographic method for the assay of the neuroleptic drug zotepine in human serum or plasma. Ulrich S, et al. **J Pharm Biomed Anal** 1996 Feb;14(4):441–9
Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients. Huang HF, et al. **Psychiatry Res** 1995 Jul 28;57(2):101–8
Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Liu HC, et al.
Ther Drug Monit 1996 Apr;18(2):200–7

CHEMICAL SYNTHESIS

Drug development and the deficit syndrome of schizophrenia [editorial] Kirkpatrick B, et al. **Biol Psychiatry** 1995 Sep 1;38(5):277–8
Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds. Ishizumi K, et al.
Chem Pharm Bull (Tokyo) 1995 Dec;43(12):2139–51
Structure-activity relationship studies of CNS agents. XII. 1-[4-(4-aryl-1-piperazinyl)butyl]-3,4-dihydro-2(1H)-quinolinones: new 5-HT1A, 5-HT2 and D2 ligands with a potential antipsychotic activity. Mokrosz JL, et al.
Drug Des Discov 1994 Apr;11(3):197–203
(E)-(arylmethyleneaminoxy)acetamides as analogues of neuroleptic benzamides: synthesis and D2-dopaminergic binding affinity. Macchia M, et al. **Farmaco** 1995 Oct; 50(10):719–24
7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. Bolós J, et al. **J Med Chem** 1996 Jul 19;39(15):2962–70
Aryl 1-but-3-ynyl-4-phenyl-1,2,3,6-tetrahydropyridines as potential antipsychotic agents: synthesis and structure-activity relationships. Glase SA, et al.
J Med Chem 1996 Aug 2;39(16):3179–87
Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents. Norman MH, et al.
J Med Chem 1996 Mar 1;39(5):1172–88
Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4-[(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds. Ohmori J, et al.
J Med Chem 1996 Jul 5;39(14):2764–72
N-aryl-N'-benzylpiperazines as potential antipsychotic agents. Reitz AB, et al. **J Med Chem** 1995 Oct 13; 38(21):4211–22
(S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist. TenBrink RE, et al. **J Med Chem** 1996 Jun 21;39(13):2435–7

CHEMISTRY

Stability of ondansetron hydrochloride injection in various beverages. Yamreudeewong W, et al.
Am J Health Syst Pharm 1995 Sep 15;52(18):2011–4
Compatibility of haloperidol and diphenhydramine in a hypodermic syringe [letter] Ukhun IA.
Ann Pharmacother 1995 Nov;29(11):1168–9
Piperazinylalkyl heterocycles as potential antipsychotic agents. Scott MK, et al. **J Med Chem** 1995 Oct 13; 38(21):4198–210
Does the dopamine receptor subtype selectivity of antipsychotic agents provide useful leads for the development of novel therapeutic agents? Hacksell U, et al. **Pharmacol Toxicol** 1995 May;76(5):320–4 (21 ref.)

ECONOMICS

A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. Glazer WM, et al. **J Clin Psychiatry** 1996 Aug;57(8):337–45
Pharmacoeconomics of antipsychotic drug therapy. Hargreaves WA, et al. **J Clin Psychiatry** 1996;57 Suppl 9:66–76 (47 ref.)
Pharmaceutical Benefits Advisory Committee: some questions answered [letter] [see comments] Firestone A. **Med J Aust** 1996 Jan 1;164(1):52. Comment in: Med J Aust 1996 Mar 18;164(6):384.
Cost-benefits of new drugs [letter; comment] Daniel DG, et al. **Psychiatr Serv** 1995 Aug;46(8):835–6. Comment on: Psychiatr Serv 1995 Mar;46(3):291–2.
Pharmaceuticals and politics [editorial] Pelonero AL.
Psychiatr Serv 1995 Sep;46(9):857

ISOLATION & PURIFICATION

Development of a liquid chromatographic method for the control of related substances in chlorprothixene hydrochloride. Duignan GM, et al.
J Pharm Biomed Anal 1996 Feb;14(4):451–6

METABOLISM

[123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Klemm E, et al. **Am J Psychiatry** 1996 Feb; 153(2):183–90
Characterization of [3H]clozapine binding sites in rat brain. Kusumi I, et al. **J Neural Transm Gen Sect** 1995; 101(1-3):51–64
Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. Liu ZC, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1476–83
The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. Maggs JL, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1463–75
Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. Ring BJ, et al.
J Pharmacol Exp Ther 1996 Feb;276(2):658–66
Apparent absence of famotidine-antipsychotic drug interactions in patients with chronic schizophrenia [letter] Prell GD, et al. **J Psychiatry Neurosci** 1996 Jan;21(1):61–2
Dopamine receptor binding of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridine (HPTP), an intermediate metabolite of haloperidol. Brand L, et al.
Life Sci 1996;59(10):815–20
Clozapine: selective labeling of sites resembling 5HT6 serotonin receptors may reflect psychoactive profile. Glatt CE, et al. **Mol Med** 1995 May;1(4):398–406
Metabolism of sertindole: identification of the metabolites in the rat and dog, and species comparison of liver microsomal metabolism. Sakamoto K, et al. **Xenobiotica** 1995 Dec;25(12):1327–43
[The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors] Futamura T, et al. **Nippon Yakurigaku Zasshi** 1996 May;107(5):247–53 (Eng. Abstr.) **(Jpn)**
[Quantitative autoradiographic analysis of the binding of mosapramine to dopamine D3-receptors] Futamura T, et al. **Nippon Yakurigaku Zasshi** 1995 Nov;106(5):339–46 (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response. Nyberg S, et al. **Br J Psychiatry Suppl** 1996 May; (29):40–4
The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Jerling M, et al. **Clin Pharmacol Ther** 1996 Apr;59(4):423–8
Pharmacokinetics and presystemic hepatic first-pass elimination of a novel sigma receptor antagonist, DuP 734, in the rat. Kapil RP, et al. **Drug Metab Dispos** 1995 May; 23(5):603–6
Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone. Mutlib AE, et al.
Drug Metab Dispos 1995 Sep;23(9):951–64
Binding of neuroleptic drugs (trifluoperazine and rimcazole) to vanilloid receptors in porcine dorsal horn. Szallasi A, et al. **Eur J Pharmacol** 1996 Mar 18;298(3):321–7
Disposition of remoxipride in Chinese schizophrenic patients. Lin SK, et al. **Int J Clin Pharmacol Ther** 1996 Jan; 34(1):17–20
Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. Sainati SM, et al.
J Clin Pharmacol 1995 Jul;35(7):713–20
Pharmacokinetics of clozapine and risperidone: a review of recent literature. Byerly MJ, et al.
J Clin Psychopharmacol 1996 Apr;16(2):177–87 (78 ref.)
Clozapine levels after clozapine discontinuation [letter] de Leon J, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):193–4
Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. Chiu JA, et al.
J Pharm Biomed Anal 1996 Mar;14(5):609–15
Drug interactions and antipsychotic therapy. DeVane CL.
Pharmacotherapy 1996 Jan-Feb;16(1 Pt 2):15–20
The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats--a comparison with the pharmacokinetics of imipramine. Daniel W, et al.
Pol J Pharmacol 1995 Mar-Apr;47(2):127–36
Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients. Huang HF, et al. **Psychiatry Res** 1995 Jul 28;57(2):101–8
CSF and serum concentrations of clozapine and its demethyl

metabolite: a pilot study. Nordin C, et al. **Psychopharmacology (Berl)** 1995 Nov;122(2):104–7

Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Snoeck E, et al. **Psychopharmacology (Berl)** 1995 Dec;122(3):223–9

[Plasma levels of clozapine] Cešková E. **Ceska Slov Psychiatr** 1995 Aug;91(4):234–40 (Eng. Abstr.) **(Cze)**

[Importance of determining clozapine plasma level in follow-up of schizophrenic patients] Vailleau JL, et al. **Encephale** 1996 Mar–Apr;22(2):103–9 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Neuropeptide Y (NPY) and its mRNA in discrete brain areas after subchronic administration of neuroleptics. Herman ZS. **Acta Neurobiol Exp (Warsz)** 1996;56(1):55–61

Cautions in the clozapine-to-risperidone switch [letter] Gupta S, et al. **Ann Clin Psychiatry** 1995 Sep;7(3):149

Functional antagonistic properties of clozapine at the 5-HT3 receptor. Hermann B, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):957–60

Differential effects of neuroleptic agents on hepatic cytochrome P-450 isozymes in the male rat. Rane A, et al. **Biochim Biophys Acta** 1996 Aug 29;1291(1):60–6

Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia. Davila R, et al. **Biol Psychiatry** 1995 Aug 15;38(4):267–9

Clozapine does not elevate serum prolactin levels in healthy men. Lee HS, et al. **Biol Psychiatry** 1995 Dec 1; 38(11):762–4

Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Lipska BK, et al. **Biol Psychiatry** 1995 Aug 15;38(4):255–62

Monosialoganglioside cotreatment prevents haloperidol treatment-associated loss of cholinergic enzymes in rat brain. Mahadik SP, et al. **Biol Psychiatry** 1995 Aug 15; 38(4):246–54

Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations. Costall B, et al. **Br J Pharmacol** 1995 Dec;116(7):2989–99

Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Meltzer HY. **Br J Psychiatry Suppl** 1996 May;(29):23–31 (130 ref.)

Effects of CGS 21680 in vivo on dopamine D2 agonist binding in the rat brain. Hillefors-Berglund M, et al. **Brain Res** 1995 Aug 28;690(1):34–40

The effect of chronic treatment with a novel aryl-piperazine antipsychotic on monoamine receptors in rat brain. Shapiro LA, et al. **Brain Res** 1995 Apr 24;677(2):250–6

Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Wan W, et al. **Brain Res** 1995 Aug 7; 688(1–2):95–104

Effect of estrogen and neuroleptics on prolactin secretion and immunoreactive prolactin cells. Oliveira MC, et al. **Braz J Med Biol Res** 1996 Apr;29(4):521–5

Loxapine: an enigma [letter] Al-Jeshi A, et al. **Can J Psychiatry** 1996 Mar;41(2):131–2

Induction of c-fos mRNA in rat medial prefrontal cortex by antipsychotic drugs: role of dopamine D2 and D3 receptors. Merchant KM, et al. **Cereb Cortex** 1996 Jul–Aug; 6(4):561–70

Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds. Ishizumi K, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2139–51

Role of serotonin in the action of atypical antipsychotic drugs. Meltzer HY. **Clin Neurosci** 1995;3(2):64–75 (162 ref.)

Hypolipidemic agents alter hepatic mitochondrial respiration in vitro. Chance DS, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Jun;111(2):317–23

Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Arnt J. **Eur J Pharmacol** 1995 Sep 5; 283(1–3):55–62

Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. Didriksen M. **Eur J Pharmacol** 1995 Aug 15;281(3):241–50

Why does clozapine stimulate the motor activity of reserpine-pretreated rats when combined with a dopamine D1 receptor agonist? Jackson DM, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):137–44

Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Maurel-Remy S, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):R9–11

The subsensitivity of striatal glutamate receptors induced by chronic haloperidol in rats. Ossowska K. **Eur J Pharmacol** 1995 Dec 29;294(2–3):685–91

Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Sasaki H, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):71–6

Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Skarsfeldt T. **Eur J Pharmacol** 1995 Aug 15;281(3):289–94

Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Nyberg S, et al. **Int Clin Psychopharmacol** 1995 Nov;10(4):221–7

The effect of concomitant use of neuroleptic drugs and lithium on the erythrocyte/plasma lithium ratio in Iranian patients with bipolar disorder. Azizabadi-Farahani M, et al. **J Clin Pharm Ther** 1996 Feb;21(1):3–7

Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. Goldberg TE, et al. **J Clin Psychiatry** 1996;57 Suppl 9:62–5 (23 ref.)

Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity. Bøgesø KP, et al. **J Med Chem** 1995 Oct 27;38(22):4380–92

3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. Howard HR, et al. **J Med Chem** 1996 Jan 5;39(1):143–8

Effect of linking bridge modifications on the antipsychotic profile of some phthalimide and isoindolinone derivatives. Norman MH, et al. **J Med Chem** 1996 Jan 5;39(1):149–57

1-Phenyl-3-(aminomethyl)pyrroles as potential antipsychotic agents. Synthesis and dopamine receptor binding. Thurkauf A, et al. **J Med Chem** 1995 Dec 8; 38(25):4950–2

Identification, characterization and pharmacological profile of three metabolites of (R)-(+)-1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexen-1- yl)methyl]pyridine (CI-1007), a dopamine autoreceptor agonist and potential antipsychotic agent. Wright JL, et al. **J Med Chem** 1995 Dec 22; 38(26):5007–14

Long-term treatment with haloperidol or clozapine does not affect dopamine D4 receptors in rat frontal cortex. Kusumi I, et al. **J Neural Transm Gen Sect** 1995;101(1–3):231–5

Injection of apomorphine--a test to predict individual different dopaminergic sensitivity? Surmann A, et al. **J Neural Transm Suppl** 1995;45:143–55

Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. Parsons B, et al. **J Neurochem** 1995 Nov;65(5):2057–64

Repeated treatment with haloperidol and clozapine exerts differential effects on dye coupling between neurons in subregions of striatum and nucleus accumbens. Onn SP, et al. **J Neurosci** 1995 Nov;15(11):7024–36

Inhibition of the ATP-sensitive potassium channel in the guinea pig substantia nigra by BMS 181100 is not mediated by a sigma-binding site. O'Callaghan JF, et al. **J Neurosci Res** 1995 Sep 1;42(1):85–96

Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796. Seibyl JP, et al. **J Nucl Med** 1996 Jan;37(1):11–5

The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents. Bristow LJ, et al. **J Pharmacol Exp Ther** 1996 May;277(2):578–85

Differential effects of unique profile antipsychotic drugs on extracellular amino acids in the ventral pallidum and globus pallidus of rats. Chapman MA, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1586–94

Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. Inoue T, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):137–43

Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. Kehne JH, et al. **J Pharmacol Exp Ther** 1996 May;277(2):968–81

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Seeger TF, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):101–13

Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity. Szczepanik AM, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):913–20

The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. Szewczak MR, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1404–13

A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. Singh AN, et al. **J Psychiatry Neurosci** 1996 Jan;21(1):29–35

In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Schotte A, et al. **Jpn J Pharmacol** 1995 Dec;69(4):399–412

Genetic variation of 5-HT2A receptor and response to clozapine [letter; comment] Masellis M, et al. **Lancet** 1995 Oct 21;346(8982):1108. Comment on: Lancet 1995 Jul 29;346(8970):281–2.

The interaction of clozapine with the meta-chlorophenylpiperazine (mCPP) discriminative stimulus. Fiorella D, et al. **Life Sci** 1996;58(24):PL353–8

Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene. Hedlund E, et al. **Mol Pharmacol** 1996 Aug;50(2):342–50

Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Andersson JL, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Oct; 352(4):374–85

Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine. Korpi ER, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Oct; 352(4):365–73

The moderate affinity of clozapine at H3 receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics. Schlicker E, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Feb; 353(3):290–4

The interactions of typical and atypical antipsychotics with the (-)2, 5,-dimethoxy-4-methamphetamine (DOM) discriminative stimulus. Fiorella D, et al. **Neuropharmacology** 1995 Oct;34(10):1297–303

Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Semba J, et al. **Neuropharmacology** 1995 Jul; 34(7):785–91

New insights into the biology of schizophrenia through the mechanism of action of clozapine. Brunello N, et al. **Neuropsychopharmacology** 1995 Nov;13(3):177–213 (400 ref.)

Repeated inescapable stress produces a neuroleptic-like effect on the conditioned avoidance response. Friedhoff AJ, et al. **Neuropsychopharmacology** 1995 Oct;13(2):129–38

Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Kuoppamäki M, et al. **Neuropsychopharmacology** 1995 Oct;13(2):139–50

Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. Banerjee SP, et al. **Neuroreport** 1995 Dec 15;6(18):2500–4

Risperidone does not elevate neurotensin mRNA in rat nucleus accumbens and caudate-putamen. Mijnster MJ, et al. **Neuroreport** 1995 Nov 13;6(16):2209–12

Antipsychotics and neuropeptides: the atypical profile of CI-943 and its relationship to neurotensin. Liégeois JF, et al. **Neurosci Biobehav Rev** 1995 Winter;19(4):519–31 (101 ref.)

The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Deutch AY, et al. **Neuroscience** 1996 Jan;70(2):377–89

Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug action. Deutch AY, et al. **Neuroscience** 1995 May; 66(2):337–46

Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and caudate-putamen in rats. See RE, et al. **Neuroscience** 1996 May;72(1):99–104

Effects of acute and repeated clozapine injections on cholinomimetic-induced vacuous jaw movements. Chesler EJ, et al. **Pharmacol Biochem Behav** 1996 Jul;54(3):619–24

Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Fujikawa M, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):903–9

Chronic clozapine selectively decreases prefrontal cortex dopamine as shown by simultaneous cortical, accumbens, and striatal microdialysis in freely moving rats. Hernandez L, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):581–9

Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats. Johansson C, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):649–54

Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of parkinsonian tremor. Salamone J, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):179–83

Effect of jinkoh-eremol and agarospirol from agarwood on the central nervous system in mice. Okugawa H, et al. **Planta Med** 1996 Feb;62(1):2–6

Effects of subchronic treatments with SM-9018, a novel 5-HT2 and D2 antagonist, on dopamine and 5-HT receptors in rats. Ohno Y, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Oct; 19(6):1091–101

Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Bakshi VP, et al. **Psychopharmacology (Berl)** 1995 Nov; 122(2):198–201

The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Cools AR, et al. **Psychopharmacology (Berl)** 1995 Jun; 119(4):428–39

Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Corbett R, et al. **Psychopharmacology (Berl)** 1995 Jul; 120(1):67–74

Oral movement patterns induced in rats by local infusions into striatum depend upon the regimen of prior neuroleptic exposure. Ellison G, et al. **Psychopharmacology (Berl)** 1995 Sep;121(2):259–66

Effects of Antidepressants and antipsychotics on the 5HT2 receptor-mediated signal transducing system in human platelets. Ohsuka N, et al. **Psychopharmacology (Berl)** 1995 Oct;121(4):428–32

D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Roth BL, et al. **Psychopharmacology (Berl)** 1995 Aug;120(3):365–8

Examination of drug–induced and isolation–induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Varty GB, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):15–26

Decreased bone mineral density in medicated psychiatric patients. Halbreich U, et al. **Psychosom Med** 1995 Sep–Oct; 57(5):485–91

Ontogeny of the effect of antipsychotic drug treatment on neurotensin concentrations in the rat brain. Kinkead B, et al. **Synapse** 1995 Jul;20(3):244–8

Ultrastructural correlates of haloperidol–induced oral dyskinesias in rat striatum. Roberts RC, et al. **Synapse** 1995 Jul;20(3):234–43

[Neuroleptics or antipsychotic agents] Dresse A. **Rev Med Liege** 1996 Jan;51(1):65–9 **(Fre)**

[Antineurotic effect of the hydrazide of O–B–chloroethyl–para–N–dimethylaminophenylphosphinylacetic acid (amfazide)] Semin II, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):423–5 **(Rus)**

POISONING

Risperidone overdose [letter] Lo Vecchio F, et al. **Am J Emerg Med** 1996 Jan;14(1):95–6

Pediatric clozapine intoxication. Mady S, et al. **Am J Emerg Med** 1996 Sep;14(5):462–3

Extrapyramidal symptoms following accidental ingestion of risperidone in a child. Cheslik TA, et al. **Ann Pharmacother** 1996 Apr;30(4):360–3

Decreased R–R variation: a criterium for overdosage of tricyclic psychotropic drugs. Rechlin T. **Intensive Care Med** 1995 Jul;21(7):598–601

An overdose of risperidone. Springfield AC, et al. **J Anal Toxicol** 1996 May–Jun;20(3):202–3

[Acute neuroleptic poisoning] Turk R, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:73–5 (Eng. Abstr.) **(Scr)**

THERAPEUTIC USE

Integrating pharmacotherapy and psychotherapy: an emerging field of study. Beitman BD. **Acta Psychiatr Belg** 1996 May–Aug;96(3–4):201–17

Treatment of manic episodes: zuclopenthixol and clonazepam versus lithium and clonazepam. Gouliaev G, et al. **Acta Psychiatr Scand** 1996 Feb;93(2):119–24

Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double–blind, placebo–controlled, cross–over study. Terao T, et al. **Acta Psychiatr Scand** 1995 Sep;92(3):220–4

Combining risperidone with standard neuroleptics for refractory schizophrenic patients [letter] Bacher NM, et al. **Am J Psychiatry** 1996 Jan;153(1):137

Postpartum prophylaxis for women with bipolar disorder. Cohen LS, et al. **Am J Psychiatry** 1995 Nov;152(11):1641–5

Risperidone treatment of a psychotic adolescent [letter] Dicker R, et al. **Am J Psychiatry** 1996 Mar;153(3):441–2

Childhood–onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. Frazier JA, et al. **Am J Psychiatry** 1996 Apr;153(4):564–6

Treatment of somatic delusional disorder with atypical antipsychotic agents [letter] Songer DA, et al. **Am J Psychiatry** 1996 Apr;153(4):578–9

"Awakenings" effect with risperidone [letter] Stip E, et al. **Am J Psychiatry** 1995 Dec;152(12):1833

Course of treatment response in first–episode and chronic schizophrenia. Szymanski SR, et al. **Am J Psychiatry** 1996 Apr;153(4):519–25

Schizophrenia: a 100–year retrospective [letter; comment] Warner R. **Am J Psychiatry** 1995 Nov;152(11):1693; discussion 1694–5. Comment on: Am J Psychiatry 1994 Oct;151(10):1409–16.

Clozapine treatment of euphoric mania. Antonacci DJ, et al. **Ann Clin Psychiatry** 1995 Dec;7(4):203–6

Medication treatment in first–admission patients with psychotic affective disorders: preliminary findings on research–facility diagnostic agreement and rehospitalization. Fennig S, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):87–90

Risperidone: a once–daily dosage schedule. Gupta S, et al. **Ann Clin Psychiatry** 1995 Dec;7(4):211

Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Moeller FG, et al. **Ann Clin Psychiatry** 1995 Dec;7(4):167–73

Conversions from clozapine to other antipsychotic drugs [letter] Baldessarini RJ, et al. **Arch Gen Psychiatry** 1995 Dec;52(12):1071–2

Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic–naive first–episode patients and patients with disease exacerbation due to neuroleptic discontinuance. Akiyama K, et al. **Biol Psychiatry** 1995 Nov 15;38(10):639–48

Neuroleptic treatment and negative symptoms in deficit and nondeficit schizophrenia. Bustillo JR, et al. **Biol Psychiatry** 1995 Jul 1;38(1):64–7

Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia. Davila R, et al. **Biol Psychiatry** 1995 Aug 15;38(4):267–9

Symptoms in neuroleptic–naive, first–episode schizophrenia: response to risperidone. Kopala LC, et al. **Biol Psychiatry** 1996 Feb 15;39(4):296–8

Gender differences in neuroleptic nonresponsive clozapine–treated schizophrenics. Szymanski S, et al. **Biol Psychiatry** 1996 Feb 15;39(4):249–54

Early intervention for schizophrenia: can the course of the illness be altered? [editorial] Wyatt RJ. **Biol Psychiatry** 1995 Jul 1;38(1):1–3

Treatment resistance in schizophrenia [editorial] Johnstone EC, et al. **BMJ** 1996 Feb 10;312(7027):325–6

Survey of neuroleptic prescribing in residents of nursing homes in Glasgow [see comments] McGrath AM, et al. **BMJ** 1996 Mar 9;312(7031):611–2. Comment in: BMJ 1996 Jun 29;312(7047):1667. Comment in: BMJ 1996 Jun 29;312(7047):1667; discussion 1669. Comment in: BMJ 1996 Jun 29;312(7047):1667–8; discussion 1669. Comment in: BMJ 1996 Jun 29;312(7047):1668; discussion 1669. Comment in: BMJ 1996 Jun 29;312(7047):1668–9.

Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Kiivet RA, et al. **Br J Clin Pharmacol** 1995 Nov;40(5):467–76

A comparison of prescribed medication in learning disability patients before and after resettlement from hospital into the community. Obaydi H, et al. **Br J Clin Pract** 1995 Jul–Aug;49(4):192–3

Insight and adherence to treatment in psychotic disorders. Kemp RA, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):222–7 (46 ref.)

Schizophrenia: recent advances in psychopharmacology. Sharma T. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):194–8 (21 ref.)

Risperidone response after no clozapine response [letter] Avnon M, et al. **Br J Psychiatry** 1995 Nov;167(5):699

Effectiveness of clozapine in hospitalised people with chronic neuroleptic–resistant schizophrenia. Avnon M, et al. **Br J Psychiatry** 1995 Dec;167(6):760–4 (15 ref.)

Consent to neuroleptic medication for schizophrenia: clinical, ethical and legal issues. Brabbins C, et al. **Br J Psychiatry** 1996 May;168(5):540–4 (23 ref.)

A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse. Hirsch S, et al. **Br J Psychiatry** 1996 Jan;168(1):49–56

Clozapine, eating disorders and substance abuse. Obstacles to innovation in a peripheral hospital [editorial] Launer M. **Br J Psychiatry** 1995 Oct;167(4):431–3

Magnetic resonance imaging and single photon emission tomography in treatment–responsive and treatment–resistant schizophrenia. Lawrie SM, et al. **Br J Psychiatry** 1995 Aug;167(2):202–10

Successful treatment of tardive dystonia with clozapine and clonazepam. Shapleske J, et al. **Br J Psychiatry** 1996 Apr; 168(4):516–8

The treatment of negative symptoms: pharmacological and methodological issues. Carpenter WT Jr. **Br J Psychiatry Suppl** 1996 May;(29):17–22 (45 ref.)

ICI 204,636: a new atypical antipsychotic drug. Hirsch SR, et al. **Br J Psychiatry Suppl** 1996 May;(29):45–56

Perspectives on treatment needs in schizophrenia. Meise U, et al. **Br J Psychiatry Suppl** 1996 May;(29):9–16 (110 ref.)

Clozapine for tardive dyskinesia in adolescents. Levkovitch Y, et al. **Brain Dev** 1995 May–Jun;17(3):213–5

Violence and schizophrenia: clozapine as a specific antiaggressive agent. Buckley P, et al. **Bull Am Acad Psychiatry Law** 1995;23(4):607–11

Each of the following statements about the newer medications for schizophrenia, risperidone (risperidol) and clozapine (clozaril), is true, except: Patients receiving risperidone are at risk for agranulocytosis. **Can Fam Physician** 1995 Oct;41:1678, 1680

The clozapine experience from a family perspective. Dickson RA, et al. **Can J Psychiatry** 1995 Dec;40(10):627–9

Effect of risperidone on polydipsia and hyponatremia in schizophrenia [letter] Landry P. **Can J Psychiatry** 1995 Nov;40(9):566–7

Understanding schizophrenia: the impact of novel antipsychotics. Remington G. **Can J Psychiatry** 1995 Sep; 40(7 Suppl 2):S29–32 (39 ref.)

Improving prescribing practices in nursing homes [letter; comment] MacKnight C. **Can Med Assoc J** 1996 Jun 1; 154(11):1620. Comment on: Can Med Assoc J 1996 Apr 1;154(7):1013–7.

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Fabre LF Jr, et al. **Clin Ther** 1995 May–Jun;17(3):366–78

Efficacy and safety of risperidone in the long–term treatment of patients with schizophrenia. Lindström E, et al. **Clin Ther** 1995 May–Jun;17(3):402–12

Seizure activity in combined clozapine and ECT: a retrospective view. Cardwell BA, et al. **Convuls Ther** 1995 Jun;11(2):110–3

The drug treatment of patients with schizophrenia. **Drug Ther Bull** 1995 Nov;33(11):81–6 (43 ref.)

Adjunctive therapy in patients with Alzheimer's disease. A practical approach. Corey–Bloom J, et al. **Drugs Aging** 1995 Aug;7(2):79–87 (46 ref.)

Depressive symptoms and schizophrenia a psychopharmacological approach. Mauri MC, et al. **Encephale** 1995 Sep–Oct;21(5):555–8

Language of dysfunction in schizophrenia. Goren AR, et al. **Eur J Disord Commun** 1996;31(2):153–70

Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in Huntington's chorea. Piolti R, et al. **Eur Neurol** 1995;35(6):344–8

Is there a relationship between antipsychotic blood levels and their clinical efficacy? An analysis of studies design and methodology. de Oliveira IR, et al. **Fundam Clin Pharmacol** 1995;9(5):488–502

First clinical experience with olanzapine (LY 170053): results of an open–label safety and dose–ranging study in patients with schizophrenia. Baldwin DS, et al. **Int Clin Psychopharmacol** 1995 Nov;10(4):239–44

Risperidone appears safe in patients with antipsychotic–induced blood dyscrasias. Mahmood T, et al. **Int Clin Psychopharmacol** 1996 Mar;11(1):53–4

The use of risperidone in treatment–resistant schizophrenia: two case reports. Warner JP, et al. **Int Clin Psychopharmacol** 1996 Mar;11(1):65–6

Late–life delusional depression: acute and long–term treatment. Meyers BS. **Int Psychogeriatr** 1995;7 Suppl:113–24 (73 ref.)

Two–year trial of maintenance neuroleptic dose reduction in schizophrenic out–patients: predictors of relapse. Heresco–Levy U, et al. **Isr J Psychiatry Relat Sci** 1995; 32(4):268–75

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1124–32 (132 ref.)

Case study: neuroleptic withdrawal dyskinesia exacerbated by ongoing stimulant treatment. Connor DF, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1490–4

Tics and risperidone [letter] Diantoniis MR, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):839–40

Combined pharmacotherapy for TS and OCD [letter] Hawkridge S, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):703–4

Case study: risperidone in children and adolescents with schizophrenia. Quintana H, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1292–6

Case study: emergence of transient compulsive symptoms during treatment with clothiapine. Toren P, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1469–72

The combined pharmacotherapy controversy [letter; comment] Wakefield TP. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):1–2. Comment on: J Am Acad Child Adolesc Psychiatry 1995 May;34(5):540.

Risperidone for negative symptoms [letter] Zuddas A, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):838–9

Antipsychotic drug therapy: current status. **J Clin Psychiatry** 1996;57 Suppl 9:2–76

Assessment of therapeutic efficacy versus sedation with antipsychotic agents. **J Clin Psychiatry** 1996 Jun;57(6):1–12

Advances in CNS Drugs. Recent advances and considerations in the treatment of schizophrenia. **J Clin Psychiatry** 1996 Jul;57(7):315–26

Maintenance therapy of persons with schizophrenia. Carpenter WT Jr. **J Clin Psychiatry** 1996;57 Suppl 9:10–8 (118 ref.)

Antipsychotic medications in children and adolescents. Findling RL, et al. **J Clin Psychiatry** 1996;57 Suppl 9:19–23 (33 ref.)

Antipsychotics in bipolar disorder. Gelenberg AJ, et al. **J Clin Psychiatry** 1996;57 Suppl 9:49–52 (38 ref.)

Pharmacoeconomics of antipsychotic drug therapy. Hargreaves WA, et al. **J Clin Psychiatry** 1996;57 Suppl 9:66–76 (47 ref.)

Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. Keck PE, et al. **J Clin Psychiatry** 1996 Apr;57(4):147–51

New developments in the pharmacologic treatment of schizoaffective disorder. Keck PE Jr, et al. **J Clin Psychiatry** 1996;57 Suppl 9:41–8 (78 ref.)

Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. Keck PE Jr, et al. **J Clin Psychiatry** 1995 Oct;56(10):466–70

Factors influencing treatment response and outcome of first–episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Lieberman JA, et al. **J Clin Psychiatry** 1996;57 Suppl 9:5–9 (43 ref.)

Mania, psychosis, and antipsychotics. McElroy SL, et al. **J Clin Psychiatry** 1996;57 Suppl 3:14–26; discussion 47–9 (168 ref.)

Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. Peterson BS. **J Clin Psychiatry** 1996;57 Suppl 9:24–34 (82 ref.)

The use of risperidone in the treatment of bipolar disorder [letter] Schaffer CB, et al. **J Clin Psychiatry** 1996 Mar; 57(3):136

Treatment of the elderly suffering from psychosis and dementia. Sunderland T. **J Clin Psychiatry** 1996;57 Suppl 9:53–6 (30 ref.)

Risperidone in the treatment of mania. Tohen M, et al. **J Clin Psychiatry** 1996 Jun;57(6):249–53

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo–controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. Borison RL, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):158–69

Effect of risperidone on hostility in schizophrenia. Czobor P, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):243–9

Neuroleptic treatment of agitation and psychosis in dementia. Devanand DP, et al. **J Geriatr Psychiatry Neurol** 1995 Oct; 8 Suppl 1:S18–27 (141 ref.)

Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation. Raheja RK, et al. **J Geriatr Psychiatry Neurol** 1995 Jul;8(3):159–61

The use of anti-psychotic drugs with adults with learning disabilities and challenging behaviour. Kiernan C, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):263–74

Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. Bodkin JA, et al. **J Nerv Ment Dis** 1996 May; 184(5):295–301

Unblinding in trials of the withdrawal of anticholinergic agents in patients maintained on neuroleptics. Double DB. **J Nerv Ment Dis** 1995 Sep;183(9):599–602

Tardive dystonia after neuroleptic treatment of Tourette's syndrome [letter] Tarsy D, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):119

Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. Chacko RC, et al. **J Neuropsychiatry Clin Neurosci** 1995 Fall;7(4):471–5

Clinical utility of clozapine in 16 patients with neurological disease. Duffy JD, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):92–6

Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. Factor SA, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):304–7

Valproate in the treatment of behavioral agitation in elderly patients with dementia. Lott AD, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):314–9

Clozapine as a treatment for psychosis in Parkinson's disease: a review. Musser WS, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):1–9 (52 ref.)

Staff perceptions of clozapine and their role in treatment: initial observations. Mishara AL, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Oct;33(10):44–7

Clozapine for treatment of schizophrenia [letter; comment] Orr RD. **JAMA** 1996 Jan 17;275(3):186–7. Comment on: JAMA 1995 Sep 27;274(12):981–3.

Genetic variation of the 5-HT2A receptor and response to clozapine [letter; comment] Burnet PW, et al. **Lancet** 1995 Sep 30;346(8979):909. Comment on: Lancet 1995 Jul 29;346(8970):281–2.

Genetic variation of the 5-HT2A receptor and response to clozapine [letter; comment] Nöthen MM, et al. **Lancet** 1995 Sep 30;346(8979):908–9. Comment on: Lancet 1995 Jul 29;346(8970):281–2.

Monozygotic twins concordant for response to clozapine [letter] Vojvoda D, et al. **Lancet** 1996 Jan 6;347(8993):61

Efficacy of risperidone in idiopathic segmental dystonia [letter] Zuddas A, et al. **Lancet** 1996 Jan 13;347(8994):127–8

Zotepine in levodopa-induced Psychosis. Spieker S, et al. **Mov Disord** 1995 Nov;10(6):795–7

Schizophrenia. Kane JM. **N Engl J Med** 1996 Jan 4; 334(1):34–41 (97 ref.)

Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Sodhi MS, et al. **Neuroreport** 1995 Dec 29;7(1):169–72

Emergency pharmacotherapy: the evolving role of medications in the emergency department. Ellison JM, et al. **New Dir Ment Health Serv** 1995 Fall;(67):87–98 (64 ref.)

Does the dopamine receptor subtype selectivity of antipsychotic agents provide useful leads for the development of novel therapeutic agents? Hacksell U, et al. **Pharmacol Toxicol** 1995 May;76(5):320–4 (21 ref.)

Pathophysiology of schizophrenia and the role of newer antipsychotics. Risch SC. **Pharmacotherapy** 1996 Jan–Feb; 16(1 Pt 2):11–4

Chronic schizophrenia. Options for pharmacologic management. Pary R, et al. **Postgrad Med** 1995 Nov; 98(5):163–4, 167–70, 173 (25 ref.)

Ethnicity and psychopharmacology. Bridging the gap. Lin KM, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):635–47 (56 ref.)

Dose related response to clozapine in a state psychiatric hospital population: a naturalistic study. Gordon BJ, et al. **Psychiatr Q** 1996 Spring;67(1):65–74

Clozapine and recidivism [letter] Gordon BJ, et al. **Psychiatr Serv** 1995 Oct;46(10):1079

Risperidone guidelines [letter; comment] Klausner M, et al. **Psychiatr Serv** 1995 Sep;46(9):950–1. Comment on: Psychiatr Serv 1995 Mar;46(3):291–2.

The experiment that cannot be done [editorial] Lamb HR, et al. **Psychiatr Serv** 1996 Apr;47(4):333

Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients. Huang HF, et al. **Psychiatry Res** 1995 Jul 28;57(2):101–8

Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Maes M, et al. **Psychiatry Res** 1995 Oct 16;58(3):217–25

Decreased urinary peptide excretion in schizophrenic patients after neuroleptic treatment. Reichelt KL, et al. **Psychiatry Res** 1995 Sep 29;58(2):171–6

Saccadic abnormalities in psychotic patients. II. The role of neuroleptic treatment. Crawford TJ, et al. **Psychol Med** 1995 May;25(3):473–83

Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Waddington JL, et al. **Psychol Med** 1995 Jul;25(4):849–57

Neuroleptic treatment of elderly patients. Woerner MG, et al. **Psychopharmacol Bull** 1995;31(2):333–7

Clozapine: efficacy and safety. Buchanan RW. **Schizophr Bull** 1995;21(4):579–91 (80 ref.)

Clozapine eligibility among state hospital patients. Essock SM, et al. **Schizophr Bull** 1996;22(1):15–25

Personal therapy: a disorder-relevant psychotherapy for schizophrenia. Hogarty GE, et al. **Schizophr Bull** 1995; 21(3):379–93

Risperidone: efficacy and safety. Umbricht D, et al. **Schizophr Bull** 1995;21(4):593–606 (22 ref.)

Cognitive impairment as a target for pharmacological treatment in schizophrenia. Davidson M, et al. **Schizophr Res** 1995 Sep;17(1):123–9 (55 ref.)

Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis. Salokangas RK. **Schizophr Res** 1995 Jul;16(1):7–16

Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Weinberger DR, et al. **Schizophr Res** 1995 Aug 1;16(2):87–110 (215 ref.)

Hospital at war: treatment changes in mental patients. Gelkopf M, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Nov;30(6):256–60

Treatment of mania: relationship between response to verapamil and changes in plasma calcium and magnesium levels. Goodnick PJ. **South Med J** 1996 Feb;89(2):225–6

[Dopamine D4-receptor variants, schizophrenia and clozapine therapy] Ewald HL, et al. **Ugeskr Laeger** 1996 Jun 17;158(25):3601–3 (17 ref.) (Eng. Abstr.) **(Dan)**

[What is used as a drug for problem drinking?] Heinälä P, et al. **Duodecim** 1995;111(8):761–8 (30 ref.) **(Fin)**

[Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia] Lombertie ER, et al. **Ann Med Psychol (Paris)** 1995 Oct;153(8):531–4 (Eng. Abstr.) **(Fre)**

[Value of clozapine in treatment of psychotic disorder in Parkinson disease] Abbar M, et al. **Encephale** 1996 Jan–Feb; 22(1):53–63 (46 ref.) (Eng. Abstr.) **(Fre)**

[Associated psychotropic drugs in deficit schizophrenia] Beaufils B. **Encephale** 1996 Jun;22 Spec No 2:41–3 (18 ref.) (Eng. Abstr.) **(Fre)**

[Methodological constraints in evaluating anti-deficit effects] Boyer P, et al. **Encephale** 1996 Jun;22 Spec No 2:25–7 (16 ref.) (Eng. Abstr.) **(Fre)**

[Deficit schizophrenias (editorial)] Puech AJ. **Encephale** 1996 Jun;22 Spec No 2:1 **(Fre)**

[Incidence of the deficit form in refractory schizophrenia] Samuelian JC. **Encephale** 1996 Jun;22 Spec No 2:19–23 (30 ref.) (Eng. Abstr.) **(Fre)**

[Deficit schizophrenia: from pharmacology to clinical practice] Tassin JP. **Encephale** 1996 Jun;22 Spec No 2:9–12 (20 ref.) (Eng. Abstr.) **(Fre)**

[Profile of the action of neuroleptics in deficit schizophrenia] Vanelle JM. **Encephale** 1996 Jun;22 Spec No 2:33–9 (35 ref.) (Eng. Abstr.) **(Fre)**

[Clozapine in a Chinese population] Stip E, et al. **J Psychiatry Neurosci** 1996 Jul;21(4):283–4 **(Fre)**

[Long-term use of neuroleptics] Carrier L, et al. **Union Med Can** 1995 Nov;124(3):35–9 **(Fre)**

[Correlation between symptoms and diagnosis in pharmacotherapeutic decision process] Adelhard K, et al. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):123–31 (Eng. Abstr.) **(Ger)**

[Therapeutic use of neuroleptics. Satellite symposium "Risperdal: new horizons for the schizophrenic patient". 9th World Congress for Psychiatry, Rio de Janeiro, 6–12 June 1993] **Nervenarzt** 1993 Nov;64(11 Suppl):1–8 (Eng. Abstr.) **(Ger)**

[Psychoeducational-psychotherapeutic treatment of schizophrenic patients and their caregivers. Results of a 1-year catamnestic study] Hornung WP, et al. **Nervenarzt** 1995 Nov;66(11):828–34 (Eng. Abstr.) **(Ger)**

[The problem of drug compliance in schizophrenic patients (editorial)] Albus M. **Psychiatr Prax** 1995 Nov;22(6):221–2 **(Ger)**

[Recent developments in antipsychotic medication] Möller HJ. **Schweiz Arch Neurol Psychiatr** 1995;146(5):230–9 (50 ref.) (Eng. Abstr.) **(Ger)**

[Clozapine for resistant schizophrenia and characteristics of those responding] Talmon Y, et al. **Harefuah** 1995 Dec 1;129(11):451–4, 536 (Eng. Abstr.) **(Heb)**

[Pharmacotherapy of depression in patients with and without conversion from depression to mania in the course of bipolar affective disorder] Koszewska I. **Psychiatr Pol** 1996 Jan–Feb;30(1):99–111 (Eng. Abstr.) **(Pol)**

[Successful therapy of the psychiatric patient with catatonic paranoidal syndrome and monitoring of induced cytokine production] Leszek J, et al. **Psychiatr Pol** 1996 Jan–Feb; 30(1):65–74 (Eng. Abstr.) **(Pol)**

[Schizophrenia combination therapy with neuroleptics and benzodiazepines] Ruzikowska A. **Psychiatr Pol** 1996 Jan–Feb;30(1):55–64 (23 ref.) (Eng. Abstr.) **(Pol)**

[Pharmacological treatment of migraine: other treatments] Gómez Aranda F, et al. **Rev Neurol** 1995;23 Suppl 2:S198–200 (43 ref.) **(Spa)**

TOXICITY

Drug-induced oral dyskinesias in rats after traditional and new neuroleptics. Kakigi T, et al. **J Neural Transm Gen Sect** 1995;101(1–3):41–9

Enhancement of tumor growth by drugs with some common molecular actions. LaBella FS, et al. **Mol Carcinog** 1996 Jun;16(2):68–76 (91 ref.)

URINE

Determination of a cardiac antiarrhythmic, tricyclic antipsychotics and antidepressants in human and animal urine by micellar electrokinetic capillary chromatography using a bile salt. Aumatell A, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):331–44

ANTIPSYCHOTIC AGENTS, BUTYROPHENONE

The effect of droperidol on objective markers of patient cooperation and vital signs during esophagogastroduodenoscopy: a randomized, double-blind, placebo-controlled, prospective investigation. Barthel JS, et al. **Gastrointest Endosc** 1995 Jul;42(1):45–50

ADMINISTRATION & DOSAGE

Use of haloperidol infusions to control delirium in critically ill adults. Seneff MG, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):690–3

A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. Wei FC, et al. **J Clin Psychiatry** 1996 Jul; 57(7):298–302

Clonidine plus haloperidol in the treatment of schizophrenia/psychosis. Maas JW, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):361–4

[Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate] Viala A, et al. **Therapie** 1996 Jan–Feb;51(1):19–25 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

In vivo study of the mutagenicity of biperidine, pipotiazine, chlorpromazine, and haloperidol [letter] Smith M de A, et al. **Am J Med Genet** 1996 Apr 9;67(2):238

Clozapine in tardive Tourette syndrome. Jaffe E, et al. **Biol Psychiatry** 1995 Aug 1;38(3):196–7

Drug-induced dysphoria [letter] Anderson BG, et al. **Br J Psychiatry** 1996 Apr;168(4):520

Antipsychotic drug-induced dysphoria. King DJ, et al. **Br J Psychiatry** 1995 Oct;167(4):480–2

Case study: neuroleptic malignant syndrome without pyrexia. Hynes AF, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):959–62

Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. Darby JK, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):334–40

Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol [letter] McSwain ML, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):284

Neuroleptic malignant syndrome in a trauma patient [see comments] Burke C, et al. **J Trauma** 1995 Oct;39(4):796–8 (11 ref.). Comment in: J Trauma 1996 Apr;40(4):673.

Neuroleptic malignant syndrome in a trauma patient [letter; comment] Sing RF, et al. **J Trauma** 1996 Apr;40(4):673. Comment on: J Trauma 1995 Oct;39(4):796–8.

Rhabdomyolysis and acute renal failure during high-dose haloperidol therapy. Marsh SJ, et al. **Ren Fail** 1995 Jul; 17(4):475–8

[Tardive dyskinesia: an increased risk of neuroleptics in elderly women] Jessurun AY, et al. **Tijdschr Gerontol Geriatr** 1995 Oct;26(5):197–9 (Eng. Abstr.) **(Dut)**

[Polytrauma and malignant neuroleptic syndrome. Case presentation with diagnostic problems] Röther J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):455–7 (Eng. Abstr.) **(Ger)**

[Sedation without risk of addiction--the melperon alternative] Bengesser G. **Wien Med Wochenschr** 1995; 145(21):595–7 (Eng. Abstr.) **(Ger)**

[The neuroleptic malignant syndrome (NMS). A report of a clinical case with a protracted and recurrent course. A review of the literature] Marelli A, et al. **Minerva Med** 1996 Jan–Feb;87(1–2):45–51 (30 ref.) (Eng. Abstr.) **(Ita)**

[Drug-induced dystonia misinterpreted as hysteria] Magnusson A, et al. **Tidsskr Nor Laegeforen** 1996 Mar 10; 116(7):844–5 (Eng. Abstr.) **(Nor)**

ANTAGONISTS & INHIBITORS

Taurine prevents haloperidol-induced changes in striatal neurochemistry and behavior. Lidsky TI, et al. **Brain Res** 1995 Jul 17;686(1):104–6

BLOOD

Haloperidol plasma concentrations in Taiwanese psychiatric patients. Lane HY, et al. **J Formos Med Assoc** 1995 Nov; 94(11):671–8

[Haloperidol] Sakamoto N, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:938–41 (14 ref.) **(Jpn)**

METABOLISM

Water handling in patients receiving haloperidol decanoate [see comments] Rider JM, et al. **Ann Pharmacother** 1995 Jul-Aug;29(7-8):663-6. Comment in: Ann Pharmacother 1995 Dec;29(12):1304.

Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid. Aymard N, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1995 Nov; 19(7):1119-35

PHARMACOKINETICS

Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP. Igarashi K, et al. **Life Sci** 1995 Nov 17;57(26):2439-46

[Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses] Dutoit D, et al.
Encephale 1995 Nov-Dec;21(6):417-24 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Characterization of inhibition by haloperidol and chlorpromazine of a voltage-activated K+ current in rat phaeochromocytoma cells. Nakazawa K, et al.
Br J Pharmacol 1995 Nov;116(6):2603-10

Regulation of NK activity by the administration of bromocriptine in haloperidol-treated mice. Nozaki H, et al. **Brain Behav Immun** 1996 Mar;10(1):17-26

Effect of muscimol on haloperidol-induced alteration of neurotensin gene expression in the striatum and nucleus accumbens in the rat. Decker KP, et al. **Brain Res** 1995 Sep 11;691(1-2):9-17

The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Iwahashi K, et al.
Clin Neuropharmacol 1995 Jun;18(3):233-6

Effect of haloperidol on phospholipid biosynthesis in rat brain. Singh SP, et al. **Indian J Exp Biol** 1996 Feb; 34(2):111-4

Increase of aldosterone secretion following acute haloperidol administration: possible clinical implications. Liberini P, et al. **Int Clin Psychopharmacol** 1996 Mar;11(1):67-70

Haloperidol and apomorphine differentially affect neuropeptidase activity. Waters SM, et al.
J Pharmacol Exp Ther 1996 Apr;277(1):113-20

Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex. See RE, et al. **Neuroreport** 1995 Sep 11;6(13):1795-8

Suppression of HPA-axis activity by haloperidol after experimentally induced heat stress. Hennig J, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1995 Jul; 19(4):603-14

Time-dependent effects of a haloperidol challenge on energy metabolism in the normal human brain. Bartlett EJ, et al.
Psychiatry Res 1996 Mar 29;60(2-3):91-9

THERAPEUTIC USE

Haloperidol does not affect the level of serum-soluble interleukin-2 receptor in drug-free male schizophrenics. Kim CE, et al. **Biol Psychiatry** 1995 Dec 15;38(12):843-5

Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia. Levinson I, et al.
Biol Psychiatry 1995 Aug 1;38(3):198-200

Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. Silva RR, et al. **J Clin Psychiatry** 1996 Mar;57(3):129-35

Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid. Aymard N, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1995 Nov; 19(7):1119-35

Type I and type II schizophrenia: relations between tonic electrodermal activity and clinical ratings before and after haloperidol treatment. Maina G, et al. **Psychiatry Res** 1995 Jun 29;57(1):49-56

TOXICITY

Haloperidol-induced cell death--mechanism and protection with vitamin E in vitro. Behl C, et al. **Neuroreport** 1995 Dec 29;7(1):360-4

ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE

ADMINISTRATION & DOSAGE

A review of antipsychotic drug doses. Galletly CA.
Aust Clin Rev 1991;11:74-6

Disposable devices for the dispensing of oral drops. Study of photoprotectiveness and compatibility. Airaudo CB, et al. **J Biomater Sci Polym Ed** 1995;7(5):381-8

Improvement of some pharmaceutical properties of drugs by cyclodextrin complexation. 4. Chlorpromazine hydrochloride. Ammar HO, et al. **Pharmazie** 1995 Dec; 50(12):805-8

ADVERSE EFFECTS

Drug-induced vanishing bile duct syndrome: response to ursodiol. O'Brien CB, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1456-7 (10 ref.)

In vivo study of the mutagenicity of biperidine, pipotiazine, chlorpromazine, and haloperidol [letter] Smith M de A, et al. **Am J Med Genet** 1996 Apr 9;67(2):238

Severe rhinorrhea and respiratory distress in a neonate exposed to fluphenazine hydrochloride prenatally. Nath SP, et al. **Ann Pharmacother** 1996 Jan;30(1):35-7

Bilateral forearm compartment syndromes resulting from neuroleptic malignant syndrome. Schneider JM, et al.
J Hand Surg [Am] 1996 Mar;21(2):287-9

Catatonic syndrome following recovery from neuroleptic malignant syndrome. Dent J. **J Intellect Disabil Res** 1995 Oct;39 (Pt 5):457-9

Thioridazine cardiotoxicity [letter; comment] Hale P, et al. **J Toxicol Clin Toxicol** 1996;34(1):127-30. Comment on: J Toxicol Clin Toxicol 1995;33(3):199-204.

Causes of rhabdomyolysis [letter; comment] Rafool GJ.
Mayo Clin Proc 1995 Dec;70(12):1225. Comment on: Mayo Clin Proc 1995 May;70(5):473-6.

A unique case of tardive dystonia induced by short-term therapy with perazin. Lohmann T, et al.
Pharmacopsychiatry 1995 Nov;28(6):263-5

Toxic epidermal necrolysis following chlorpromazine ingestion complicated by SIADH [letter] Purcell P, et al.
Postgrad Med J 1996 Mar;72(845):186

[Akathisia induced by low doses of neuroleptics after a pallidal infarction (letter)] Auzou P, et al. **Presse Med** 1996 Feb 17;25(6):260 **(Fre)**

BLOOD

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Eap CB, et al.
Clin Pharmacol Ther 1996 Mar;59(3):322-31

Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Linnet K, et al. **Clin Pharmacol Ther** 1996 Jul;60(1):41-7

Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma. Eap CB, et al.
J Chromatogr B Biomed Appl 1995 Jul 21;669(2):271-9

Quantitative determination of perphenazine and its metabolites in plasma by high-performance liquid chromatography and coulometric detection. Foglia JP, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23;668(2):291-7

CHEMISTRY

Development of a melanin-based high-performance liquid chromatography stationary phase and its use in the study of drug-melanin binding interactions. Ibrahim H, et al.
Anal Biochem 1995 Aug 10;229(2):272-7

Chromatographic modelling of interactions between melanin and phenothiazine and dibenzazepine drugs. Radwańska A, et al. **Biomed Chromatogr** 1995 Sep-Oct;9(5):233-7

ISOLATION & PURIFICATION

Development of a melanin-based high-performance liquid chromatography stationary phase and its use in the study of drug-melanin binding interactions. Ibrahim H, et al.
Anal Biochem 1995 Aug 10;229(2):272-7

PHARMACOKINETICS

Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. Muralidharan G, et al. **Eur J Clin Pharmacol** 1996;50(1-2):121-8

Binding of neuroleptic drugs (trifluoperazine and rimcazole) to vanilloid receptors in porcine dorsal horn. Szallasi A, et al. **Eur J Pharmacol** 1996 Mar 18;298(3):321-7

Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. Aravagiri M, et al.
Neuropsychopharmacology 1995 Nov;13(3):235-47

Evidence for the lack of a human metabolic isotope effect of a deuterium analog of fluphenazine. Hadad S, et al.
Pharm Res 1995 Sep;12(9):1388-90

PHARMACOLOGY

Chlorpromazine stimulatory effect on iron uptake by rat brain synaptosomes. Demasi M, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):331-7

The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Webb MS, et al.
Biochim Biophys Acta 1995 Sep 13;1238(2):147-55

Characterization of inhibition by haloperidol and chlorpromazine of a voltage-activated K+ current in rat phaeochromocytoma cells. Nakazawa K, et al.
Br J Pharmacol 1995 Nov;116(6):2603-10

Chlorpromazine inhibits nitric oxide-mediated increase in intracellular cGMP in a mouse teratocarcinoma cell line. Fratelli M, et al. **Inflamm Res** 1995 Jul;44(7):287-90

Divalent cation channels activated by phenothiazines in membrane of rat ventricular myocytes. Lefevre T, et al.
J Membr Biol 1995 Sep;147(2):147-58

Trifluoperazine modulates [3H]resiniferatoxin binding by human and rat vanilloid (capsaicin) receptors and affects 45Ca uptake by adult rat dorsal root ganglion neurones. Acs G, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1090-8

Effects of chlorpromazine and diazepam on time estimation behavior and motivation in rats. Ferguson SA, et al.
Pharmacol Biochem Behav 1996 Jan;53(1):115-22

Changes in blink rates of Nigerian schizophrenics treated with chlorpromazine. Adamson TA. **West Afr J Med** 1995 Oct-Dec;14(4):194-7

POISONING

Upper airway compromise in acute chlorpromazine ingestion. Russell SA, et al. **Am J Emerg Med** 1996 Sep;14(5):467-8

Laryngeal dystonia [letter] Murray V. **Br J Psychiatry** 1995 Nov;167(5):698-9

[Acute poisoning with thioridazine] Schürch F, et al.
Dtsch Med Wochenschr 1996 Aug 16;121(33):1003-8 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

A new class of antiarrhythmic--defibrillatory compounds. Erez M, et al. **J Basic Clin Physiol Pharmacol** 1994 Jan-Mar;5(1):59-66

A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression. Stabl M, et al.
J Clin Psychopharmacol 1995 Aug;15(4 Suppl 2):41S-45S

[Perazine therapy. Seminar, Hamburg, 12-14 November 1992] **Nervenarzt** 1993 Jan;64(1 Suppl):1-8 **(Ger)**

URINE

Direct determination of some phenothiazine sedatives in greyhound urine by fluoroimmunoassay. Mounsey A, et al. **Analyst** 1996 Jul;121(7):955-8

Metabolism of levomepromazine in man. Hals PA, et al.
Eur J Drug Metab Pharmacokinet 1995 Jan-Mar; 20(1):61-71

ANTIPYRETICS see ANALGESICS, NON-NARCOTIC

ANTIPYRINE

ANALOGS & DERIVATIVES

Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Engel G, et al.
Clin Pharmacol Ther 1996 Jun;59(6):613-23

Laser-Doppler evaluation of rat brain microcirculation: comparison with the [14C]-iodoantipyrine method suggests discordance during cerebral blood flow increases. Fabricius M, et al. **J Cereb Blood Flow Metab** 1996 Jan;16(1):156-61

Structure of disintegrating pellets with regard to fractal geometry. Schröder M, et al. **Pharm Res** 1995 Nov; 12(11):1694-700

Protective effects of MCI-186 on cold kidney preservation/reperfusion injury in the rat. Masaki Y, et al.
Transplant Proc 1996 Jun;28(3):1885-6

[Scientific raisins from 125 years SMW (Swiss Medical Weekly). Chronic interstitial nephritis in abuse of phenacetin-containing analgesics (Saridon etc.) 1953 (classical article)] Zollinger HU.
Schweiz Med Wochenschr 1995 Nov 18;125(46):2253-4 **(Ger)**

DIAGNOSTIC USE

Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C. Coverdale S, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1065-71

Growth hormone treatment increases cytochrome P450-mediated antipyrine clearance in man. Cheung NW, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1999-2001

METABOLISM

Pulmonary vascular extraction and distribution of antipyrine with alveolar flooding. Cua WO, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1811-9

Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Engel G, et al.
Clin Pharmacol Ther 1996 Jun;59(6):613-23

Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Sharer JE, et al. **Drug Metab Dispos** 1996 Apr;24(4):487-94

[Initial prospective evaluation of cancer incidence in relation to metabolism of antipyrine and family history in patients with lung cancer] Radzikowska E, et al.
Pneumonol Alergol Pol 1996;64(1-2):45-9 (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

Pharmacokinetic parameters of antipyrine in dog after hepatectomy. Galtier M, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):669-84

The use of microdialysis for the study of drug kinetics: some

methodological considerations illustrated with antipyrine in rat frontal cortex. Patsalos PN, et al. **Br J Pharmacol** 1995 Jun;115(3):503–9

Influence of renal failure on cytochrome P450 activity in hypertensive patients using a "cocktail" of antipyrine and nifedipine. Lanchote VL, et al. **Eur J Clin Pharmacol** 1996; 50(1–2):83–9

Pharmacokinetics of antipyrine and theophylline: unaltered by multi–dose omeprazole treatment in rabbits [letter] Chandrashekhar SM, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):302–4

Effects of aging on antipyrine clearance: predictive factors of metabolizing capacity. Jorquera F, et al. **J Clin Pharmacol** 1995 Sep;35(9):895–901

Effects of atorvastatin, an HMG–CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine. Yang BB, et al. **J Clin Pharmacol** 1996 Apr;36(4):356–60

Assessment of antipyrine kinetics from saliva or plasma: influence of age. Jorquera F, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1141–5

Lack of effect of ivermectin on antipyrine and erythromycin disposition in calves. Bohlen DM, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):476–8

Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan. Figg WD, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):693–700

Experimental ovine fasciolosis: antipyrine clearance as indicator of liver damage. Ferre I, et al. **Vet Parasitol** 1996 Mar;62(1–2):93–100

[Effect of mestranol on pharmacokinetics of phenazone in the rabbit] Gawrońska–Szklarz B, et al. **Ginekol Pol** 1996 Jan;67(1):1–6 (Eng. Abstr.) **(Pol)**

[The relationship between antipyrine kinetics, the seromucoid content and the xanthine oxidase activity in the plasma of rats with acute and chronic inflammation] Lutsevich AN, et al. **Eksp Klin Farmakol** 1995 Jul–Aug;58(4):51–5 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Antipyrine, coumarin and glipizide affect n–acetylation measured by caffeine test. Klebovich I, et al. **Biomed Pharmacother** 1995;49(5):225–7

ANTIREJECTION THERAPY see **IMMUNOSUPPRESSION**

ANTIRHEUMATIC AGENTS

see related
ANTIMALARIALS
IMMUNOSUPPRESSIVE AGENTS

Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients. De La Mata J, et al. **Ann Rheum Dis** 1995 Nov;54(11):881–5

Clinical use of cyclosporin in rheumatoid arthritis. Richardson C, et al. **Drugs** 1995;50 Suppl 1:26–36 (53 ref.)

How many types of patients meet classification criteria? [letter; comment] Roth SH. **J Rheumatol** 1995 Jul; 22(7):1435; discussion 1435–6. Comment on: J Rheumatol 1994 Aug;21(8):1385–9.

ADMINISTRATION & DOSAGE

Cyclosporine dosing for RA [letter; comment] Redford TW, et al. **Am Pharm** 1995 Mar;NS35(3):5. Comment on: Am Pharm 1994 Nov;NS34(11):31–7, 41–2.

Low dose desensitisation does not reduce the toxicity of sulphasalazine in rheumatoid arthritis. McInnes IB, et al. **Ann Rheum Dis** 1996 May;55(5):328–30

Resolution of a soft–tissue sarcoma in a patient with rheumatoid arthritis after discontinuation of azathioprine therapy. Csuka ME, et al. **Arch Intern Med** 1996 Jul 22; 156(14):1573–6

Tenidap in rheumatoid arthritis. A 24–week double–blind comparison with hydroxychloroquine–plus–piroxicam, and piroxicam alone [see comments] Blackburn WD Jr, et al. **Arthritis Rheum** 1995 Oct;38(10):1447–56. Comment in: Arthritis Rheum 1996 Jul;39(7):1263–4.

Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Möttönen T, et al. **Arthritis Rheum** 1996 Jun;39(6):996–1005

Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Pasero G, et al. **Arthritis Rheum** 1996 Jun;39(6):1006–15

Long–term treatment with every–other–week methotrexate in rheumatoid arthritis patients with sustained disease improvement: comment on the article by Kremer et al [letter] Roth SH. **Arthritis Rheum** 1995 Dec;38(12):1865–6

Combination therapy with sulphasalazine and azathioprine [letter] Helliwell PS. **Br J Rheumatol** 1996 May;35(5):493–4

A single intra–articular injection of liposomally conjugated methotrexate suppresses joint inflammation in rat antigen–induced arthritis. Williams AS, et al. **Br J Rheumatol** 1996 Aug;35(8):719–24

Assessment of sulphasalazine as a treatment modality in Sjögren's disease in NZB/NZW F1 hybrid mice. Yeoman CM, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):53–7

Combination therapy with cyclosporin in rheumatoid arthritis. Yocum DE. **Drugs** 1995;50 Suppl 1:37–40 (20 ref.)

Combination drug therapy of seropositive rheumatoid arthritis [see comments] McCarty DJ, et al. **J Rheumatol** 1995 Sep;22(9):1636–45. Comment in: J Rheumatol 1995 Sep;22(9):1611–7.

Long–term therapy for rheumatoid arthritis [comment] Gómez–Reino JJ. **Lancet** 1996 Feb 10;347(8998):343–4. Comment on: Lancet 1996 Feb 10;347(8998):347–52.

Randomised placebo–controlled study of stopping second–line drugs in rheumatoid arthritis [see comments] ten Wolde S, et al. **Lancet** 1996 Feb 10;347(8998):347–52 . Comment in: Lancet 1996 Feb 10;347(8998):343–4.

Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome. Suarez IM, et al. **Lupus** 1996 Feb;5(1):81–3

Safe prescribing of methotrexate for rheumatoid arthritis [letter] Kirkham BW. **Med J Aust** 1995 Sep 4;163(5):278

Cyclosporine and methotrexate for severe rheumatoid arthritis [letter; comment] Malleson P. **N Engl J Med** 1995 Dec 7;333(23):1567; discussion 1568–9. Comment on: N Engl J Med 1995 Jul 20;333(3):137–41.

Treatment of rheumatoid arthritis [letter] Schinagl EF, et al. **N Engl J Med** 1996 Sep 12;335(11):822; discussion 822–3

Comparison of intramuscular gold and sulphasalazine in the treatment of early rheumatoid arthritis. A one year prospective study. Peltomaa R, et al. **Scand J Rheumatol** 1995;24(6):330–5

[Subcutaneous self–administration of methotrexate in rheumatoid arthritis (letter)] Huisman AM, et al. **Ned Tijdschr Geneeskd** 1996 Jul 27;140(30):1564–5 **(Dut)**

[Can indomethacin prolong arthritis?] Savolainen A, et al. **Duodecim** 1995;111(3):257–9 **(Fin)**

[Methotrexate and salazosulfapyridine in the long–term treatment of rheumatoid arthritis] Ichikawa Y, et al. **Ryumachi** 1995 Aug;35(4):663–70 (Eng. Abstr.) **(Jpn)**

[A long–term clinical analysis of the rheumatoid patients treated by a combination of GST and CCA] Minami M, et al. **Ryumachi** 1995 Oct;35(5):780–91 (Eng. Abstr.) **(Jpn)**

[Disease–modifying drugs in rheumatoid arthritis. Duration of treatment and reasons for withdrawal] Grefslie H, et al. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):958–62 (32 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Sulphasalazine desensitization in a paediatric patient with juvenile chronic arthritis. Kümmerle–Deschner J, et al. **Acta Paediatr** 1995 Aug;84(8):952–4

Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Hassan W. **Ann Rheum Dis** 1996 May; 55(5):273–5

Methotrexate osteopathy in long–term, low–dose methotrexate treatment for psoriasis and rheumatoid arthritis. Zonneveld IM, et al. **Arch Dermatol** 1996 Feb; 132(2):184–7

N–acetyl–beta–D–glucosaminidase enzymuria as an indicator in monitoring the therapy of some rheumatic diseases with potentially nephrotoxic drugs. Wiland P, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):331–6

Resolution of a soft–tissue sarcoma in a patient with rheumatoid arthritis after discontinuation of azathioprine therapy. Csuka ME, et al. **Arch Intern Med** 1996 Jul 22; 156(14):1573–6

Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Blanco R, et al. **Arthritis Rheum** 1996 Jun;39(6):1016–20 (19 ref.)

Hazards of low dose methotrexate [editorial] Conaghan PG, et al. **Aust N Z J Med** 1995 Dec;25(6):670–3 (30 ref.)

Reversible cutaneous lymphoma occurring during methotrexate therapy. Viraben R, et al. **Br J Dermatol** 1996 Jul;135(1):116–8

Pulmonary function in rheumatoid arthritis treated with low–dose methotrexate: a longitudinal study. Beyeler C, et al. **Br J Rheumatol** 1996 May;35(5):446–52

Sulphasalazine–induced autoimmune abnormalities in patients with rheumatic disease [letter] Borg AA. **Br J Rheumatol** 1995 Nov;34(11):1097–8

Folate supplementation and methotrexate. Dijkmans BA. **Br J Rheumatol** 1995 Dec;34(12):1172–4 (22 ref.)

Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Hilliquin P, et al. **Br J Rheumatol** 1996 May;35(5):441–5

Adverse events in methotrexate–treated rheumatoid arthritis patients. Sandoval DM, et al. **Br J Rheumatol** 1995 Nov; 34 Suppl 2:49–56 (76 ref.)

Methotrexate in rheumatoid arthritis: toxicity issues [editorial] Weinblatt ME. **Br J Rheumatol** 1996 May; 35(5):403–5 (27 ref.)

Bullous pemphigoid and penicillamine. Weller R, et al. **Clin Exp Dermatol** 1996 Mar;21(2):121–2

Thrombocytopenia in patients with rheumatoid arthritis on long–term treatment with low dose methotrexate. Franck H, et al. **Clin Rheumatol** 1996 Mar;15(2):163–7

Management of adverse effects of disease–modifying antirheumatic drugs. Wijnands MJ, et al. **Drug Saf** 1995 Oct;13(4):219–27 (31 ref.)

Safety aspects of cyclosporin in rheumatoid arthritis. Dijkmans BA. **Drugs** 1995;50 Suppl 1:41–7 (37 ref.)

Nodulosis during methotrexate therapy for rheumatoid arthritis. Das SK, et al. **J Assoc Physicians India** 1995 Sep; 43(9):651

Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Salloum E, et al. **J Clin Oncol** 1996 Jun;14(6):1943–9 (56 ref.)

Pustular psoriasis induced by hydroxychloroquine: a case report and review of the literature. Vine JE, et al. **J Dermatol** 1996 May;23(5):357–61

Toxicity of antirheumatic drugs. Toxicity Workgroup Leaders. Brooks PM, et al. **J Rheumatol** 1995 May; 22(5):998–9

The toxicity of nonsteroidal antiinflammatory drugs and antirheumatic drugs: an introduction. Brooks PM. **J Rheumatol** 1995 May;22(5):982

Adverse drug reactions and their measurement in the rheumatic diseases. Day RO, et al. **J Rheumatol** 1995 May; 22(5):983–8 (48 ref.)

A critical appraisal of toxicity indexes in rheumatology. Peloso PM, et al. **J Rheumatol** 1995 May;22(5):989–94

Gynecomastia after low dose methotrexate therapy for rheumatoid arthritis [letter; comment] Thomas E, et al. **J Rheumatol** 1995 Nov;22(11):2189. Comment on: J Rheumatol 1995 Apr;22(4):796–7.

Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. van der Veen MJ, et al. **J Rheumatol** 1995 Sep;22(9):1766–8 (20 ref.)

Goodpasture–like syndrome associated with anti–myeloperoxidase antibodies following penicillamine treatment. Gaskin G, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1925–8

Coexistent membranous nephropathy and ANCA–positive crescentic glomerulonephritis in association with penicillamine. Mathieson PW, et al. **Nephrol Dial Transplant** 1996 May;11(5):863–6 (26 ref.)

Pancytopenia and severe cytopenia induced by low–dose methotrexate. Eight case–reports and a review of one hundred cases from the literature (with twenty–four deaths) [see comments] Berthelot JM, et al. **Rev Rhum Engl Ed** 1995 Jul–Sep;62(7–8):477–86 (108 ref.). Comment in: Rev Rhum Engl Ed 1995 Jul–Sep;62(7–8):471–3.

D–penicillamine and gold salt treatments were complicated by myasthenia and pemphigus, respectively, in the same patient with rheumatoid arthritis. Ciompi ML, et al. **Rheumatol Int** 1995;15(3):95–7

Long–term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Schnabel A, et al. **Rheumatol Int** 1996;15(5):195–200

Major infection during methotrexate treatment for rheumatoid arthritis [letter] Schnabel A, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):357–9

[Polyarticular pain syndrome during treatment with cyclosporine for severe acute colitis (letter)] Andant C, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):219–20 **(Fre)**

[Follow–up and immunologic findings in drug–induced myasthenia] Brüggemann W, et al. **Med Klin** 1996 May 15;91(5):268–71 (Eng. Abstr.) **(Ger)**

[A case of rheumatoid arthritis complicated with salazosulfapyridine–induced aplastic anemia] Suwa A, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb; 18(1):116–22 (Eng. Abstr.) **(Jpn)**

[A case of rheumatoid arthritis with malignant lymphoma taking methotrexate] Hayakawa M, et al. **Ryumachi** 1995 Aug;35(4):678–82 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for malignant rheumatoid arthritis] Okuda Y, et al. **Ryumachi** 1995 Aug;35(4):699–704 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Myasthenia gravis caused by D–penicillamine (letter)] Sanz Gallego PJ, et al. **Aten Primaria** 1996 Mar 31;17(5):364–5 **(Spa)**

[Appearance of impotence in relation to the use of methotrexate (letter)] Riba N, et al. **Med Clin (Barc)** 1996 Apr 13;106(14):558 **(Spa)**

BLOOD

Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Stein CM, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):47–51

CHEMICAL SYNTHESIS

Antirheumatic agents. I. Novel methotrexate derivatives bearing an indoline moiety. Matsuoka H, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul;44(7):1332–7

CHEMISTRY

Adsorption of betamethasone disodium phosphate on ethylcellulose latex: an electrokinetic study. Vera P, et al. **J Pharm Sci** 1996 May;85(5):468–72

CONTRAINDICATIONS

Juvenile rheumatoid arthritis [letter; comment] Freis PC. **J Am Board Fam Pract** 1995 Jul–Aug;8(4):341–2. Comment on: J Am Board Fam Pract 1995 Jan–Feb;8(1):46–8.

Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis? [letter] Masson C, et al. **J Rheumatol** 1995 Nov;22(11):2191

ECONOMICS

The total cost of drug therapy for rheumatoid arthritis: comment on the article by Prashker and Meenan [letter]

Feinberg HL. **Arthritis Rheum** 1995 Dec;38(12):1862–3

A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. Anis AH, et al. **J Rheumatol** 1996 Apr; 23(4):609–16

PHARMACOKINETICS

Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Ducharme J, et al. **Br J Clin Pharmacol** 1995 Aug; 40(2):127–33

Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Furst DE. **Br J Rheumatol** 1995 Nov;34 Suppl 2:20–5 (50 ref.)

Stereoselective pharmacokinetics of [14C]-labeled KE-298, a new anti-rheumatic drug, in rats. Yoshida H, et al. **Chirality** 1996;8(3):258–63

Influence of food on the bioavailability of oral methotrexate in children. Dupuis LL, et al. **J Rheumatol** 1995 Aug; 22(8):1570–3

The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. Kremer JM, et al. **J Rheumatol** 1995 Nov; 22(11):2072–7

Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. Lafforgue P, et al. **J Rheumatol** 1995 May; 22(5):844–9

Concentration–effect studies--making sense of sparse concentration data? [letter] McLachlan AJ. **J Rheumatol** 1996 May;23(5):948–50

Pharmacokinetic studies of methotrexate in plasma and synovial fluid following i.v. bolus and topical routes of administration in dogs. Lu GW, et al. **Pharm Res** 1995 Oct; 12(10):1474–7

Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. Edno L, et al. **Ther Drug Monit** 1996 Apr;18(2):128–34

PHARMACOLOGY

Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis. Nakajima A, et al. **Ann Rheum Dis** 1996 Apr;55(4):237–42

Protection against peroxynitrite dependent tyrosine nitration and alpha 1–antiproteinase inactivation by some anti-inflammatory drugs and by the antibiotic tetracycline. Whiteman M, et al. **Ann Rheum Dis** 1996 Jun;55(6):383–7

Contrasting effect of oral and intravenous cyclophosphamide treatment on phenotypes of human peripheral blood lymphocytes. Lacki JK, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):291–4

Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis? Bird HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:16–9 (11 ref.)

The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism. Cronstein BN. **Br J Rheumatol** 1995 Nov;34 Suppl 2:30–2 (20 ref.)

Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis. Kremer JM. **Br J Rheumatol** 1995 Nov;34 Suppl 2:26–9 (37 ref.)

Sulphasalazine: mechanism of action in rheumatoid arthritis. Smedegård G, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:7–15 (133 ref.)

In vitro effects of methotrexate on human articular cartilage and bone-derived osteoblasts. van der Veen MJ, et al. **Br J Rheumatol** 1996 Apr;35(4):342–9

Mechanisms of the effects of methotrexate. Cronstein BN, et al. **Bull Rheum Dis** 1996 Aug;45(5):6–8

Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. Landewé RB, et al. **Clin Exp Immunol** 1995 Oct;102(1):144–51

Slow-acting antirheumatic drugs. Drug interactions of clinical significance. Munro RA, et al. **Drug Saf** 1995 Jul; 13(1):25–30 (34 ref.)

Inhibitory and disruptive effects of some antirheumatics on antigen-antibody complexes. Kallee E, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):711–4

Effect of stress and cyclosporine on ornithine decarboxylase activity in rat submaxillary lymph nodes. Esquifino AI, et al. **Eur J Pharmacol** 1995 Oct 16;285(2):143–9

Effect of chloroquine on arachidonic acid pathway in isolated mast cells. Drábiková K, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S13–4

Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. Ritchie DM, et al. **Int J Immunopharmacol** 1995 Oct;17(10):805–12

Nitric oxide: an important articular free radical. Murrell GA, et al. **J Bone Joint Surg Am** 1996 Feb;78(2):265–74

Cytokines in rheumatoid arthritis. Localization in arthritic joint tissue and regulation in vitro. Deleuran BW. **Scand J Rheumatol Suppl** 1996;104:1–34

[Changes in taste and smell caused by hydroxychloroquine (letter)] Weber JC, et al. **Presse Med** 1996 Feb 10;25(5):213 **(Fre)**

POISONING

[Methotrexate; fatal dosage errors due to inattention] Vesseur J, et al. **Ned Tijdschr Geneeskd** 1996 Jul 27;140(30):1533–5 **(Dut)**

THERAPEUTIC USE

Rheumatoid arthritis--changing theories and treatment modalities. van de Putte LB, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:10–3 (13 ref.)

Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities. Blackburn WD. **Am J Med** 1996 Feb 26;100(2A):24S–30S (47 ref.)

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial [see comments] van der Heide A, et al. **Ann Intern Med** 1996 Apr 15;124(8):699–707. Comment in: Ann Intern Med 1996 Apr 15;124(8):773–4.

Rheumatoid arthritis: treat now, not later! [editorial; comment] Weinblatt ME. **Ann Intern Med** 1996 Apr 15; 124(8):773–4. Comment on: Ann Intern Med 1996 Apr 15;124(8):699–707.

Urinary glucaric acid excretion in rheumatoid arthritis: influence of disease activity and disease modifying drugs. Addyman R, et al. **Ann Rheum Dis** 1996 Jul;55(7):478–81

Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Buchanan NM, et al. **Ann Rheum Dis** 1996 Jul;55(7):486–8

Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? van der Veen MJ, et al. **Ann Rheum Dis** 1996 Apr;55(4):218–23

Lymphocyte phenotype studies of rheumatoid arthritis patients treated with methotrexate. Lacki JK, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):287–90

Cytomegalovirus in methotrexate-treated rheumatoid arthritis patients: comment on the concise communication by Aglas et al [letter] Bowman S, et al. **Arthritis Rheum** 1995 Dec;38(12):1861–2

Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Fries JF, et al. **Arthritis Rheum** 1996 Apr;39(4):616–22

Sulfasalazine in psoriatic arthritis: a new or established indication? [letter] Goupille P, et al. **Arthritis Rheum** 1996 Apr;39(4):711–2

Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables. Kremer JM, et al. **Arthritis Rheum** 1995 Sep;38(9):1194–203

Healing phenomena of erosive changes in rheumatoid arthritis patients undergoing disease-modifying antirheumatic drug therapy. Rau R, et al. **Arthritis Rheum** 1996 Jan;39(1):162–8

Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Shapiro DL, et al. **Arthritis Rheum** 1995 Dec;38(12):1851–4 (24 ref.)

Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Willkens RF, et al. **Arthritis Rheum** 1995 Dec;38(12):1799–806

The epidemiology of drug treatment failure in rheumatoid arthritis. Wolfe F. **Baillieres Clin Rheumatol** 1995 Nov; 9(4):619–32 (40 ref.)

Radical Intervention in Early Rheumatoid Arthritis. The Case for Enteric-Coated Sulphasalazine, Methotrexate and Combination Regimes. Proceedings of a workshop. Camogli, Italy, September 1994. **Br J Rheumatol** 1995 Nov; 34 Suppl 2:1–112

The history of the use of sulphasalazine in rheumatology. Amos RS. **Br J Rheumatol** 1995 Nov;34 Suppl 2:2–6 (51 ref.)

Successful treatment of Reiter's syndrome in a patient with AIDS with methotrexate and corticosteroids [letter] Berenbaum F, et al. **Br J Rheumatol** 1996 Mar;35(3):295

Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Bologna C, et al. **Br J Rheumatol** 1996 May;35(5):453–7

Clinical efficacy of sulphasalazine--a review. Capell HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:35–9 (30 ref.)

A randomized double-blind controlled trial of sulphasalazine combined with pulses of methylprednisolone or placebo in the treatment of rheumatoid arthritis. Ciconelli RM, et al. **Br J Rheumatol** 1996 Feb;35(2):150–4

Are slow-acting anti-rheumatic drugs monitored too often? An audit of current clinical practice. Comer M, et al. **Br J Rheumatol** 1995 Oct;34(10):966–70

Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Emery P. **Br J Rheumatol** 1995 Nov;34 Suppl 2:87–90 (16 ref.)

How and when should combination therapy be used? The role of an anchor drug. Farr M, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:100–3 (38 ref.)

Rational disease-modifying anti-rheumatic drug (DMARD) therapy: is it possible? [editorial] Furst DE. **Br J Rheumatol** 1996 Aug;35(8):707–8

Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment. Gómez-Vaquero C, et al. **Br J Rheumatol** 1996 Jun;35(6):564–7

Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions. Haagsma CJ, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:104–8 (30 ref.)

An audit of methotrexate and folic acid for rheumatoid arthritis. Experience from a teaching centre. Jobanputra P, et al. **Br J Rheumatol** 1995 Oct;34(10):971–5

Sulphasalazine-induced systemic lupus erythematosus in a patient with rheumatoid arthritis [letter; comment] Khattak FH, et al. **Br J Rheumatol** 1996 Jan;35(1):104. Comment on: Br J Rheumatol 1995 May;34(5):435–9.

Clinical trial design for evaluating combination therapies. Paulus HE. **Br J Rheumatol** 1995 Nov;34 Suppl 2:92–5 (26 ref.)

Combination of sulphasalazine and methotrexate in the management of rheumatoid arthritis--view based on personal clinical experience. Shiroky JB. **Br J Rheumatol** 1995 Nov;34 Suppl 2:109–12

Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. van den Hoogen FH, et al. **Br J Rheumatol** 1996 Apr;35(4):364–72

Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis. van Riel PL, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:40–2

Efficacy of methotrexate in rheumatoid arthritis. Weinblatt ME. **Br J Rheumatol** 1995 Nov;34 Suppl 2:43–8 (49 ref.)

Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritis. Williams HJ. **Br J Rheumatol** 1995 Nov;34 Suppl 2:96–9 (34 ref.)

How do second-line agents work? Choy E, et al. **Br Med Bull** 1995 Apr;51(2):472–92 (124 ref.)

Pulmonary function in patients receiving long-term low-dose methotrexate. Cottin V, et al. **Chest** 1996 Apr;109(4):933–8

Methotrexate in rheumatoid arthritis: when NSAIDs fail. Flynn JA, et al. **Cleve Clin J Med** 1995 Nov-Dec; 62(6):351–9 (92 ref.)

A pilot study on the effectiveness of cyclosporine in type II mixed cryoglobulinemia. Ballarè M, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S201–3

Methotrexate: the agent of choice for chronic inflammatory disorders. A perspective ten years later [editorial] Gutiérrez-Ureña S, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):281–4

Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Spadaro A, et al. **Clin Exp Rheumatol** 1995 Sep-Oct; 13(5):589–93

Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy. Salaffi F, et al. **Clin Rheumatol** 1995 Jul;14(4):458–63

Soluble interleukin-2-receptor and interleukin-6 changes during low-dose methotrexate treatment in rheumatoid arthritis [letter] Spadaro A, et al. **Clin Rheumatol** 1996 Mar; 15(2):218–9

Treatment of scleroderma. Gelber AC, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):551–9 (66 ref.)

Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis [published erratum appears in Drugs 1995 Oct;50(4):625] Rains CP, et al. **Drugs** 1995 Jul;50(1):137–56 (134 ref.)

Clinical use of cyclosporin in rheumatoid arthritis. Richardson C, et al. **Drugs** 1995;50 Suppl 1:26–36 (53 ref.)

International consensus recommendations on cyclosporin use in rheumatoid arthritis. Tugwell P. **Drugs** 1995;50 Suppl 1:48–56 (32 ref.)

Disease-modifying antirheumatic drugs. Potential effects in older patients. Gardner G, et al. **Drugs Aging** 1995 Dec; 7(6):420–37 (43 ref.)

Comparison of polysulphated glycosaminoglycan and sodium hyaluronate with placebo in treatment of traumatic arthritis in horses. Gaustad G, et al. **Equine Vet J** 1995 Sep; 27(5):356–62

Novel synthetic retinoic acid inhibits rat collagen arthritis and differentially affects serum immunoglobulin subclass levels. Kuwabara K, et al. **FEBS Lett** 1996 Jan 8; 378(2):153–6

A review on the strategies for the development and application of new anti-arthritic agents. Lewis AJ, et al. **Immunopharmacol Immunotoxicol** 1995 Nov;17(4):607–63 (272 ref.)

Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: the regulation of lymph node cell populations and cytokine production. Haynes DR, et al. **Inflamm Res** 1996 Apr;45(4):159–65

Antiinflammatory activity of a Ghanaian antiarthritic herbal preparation: III. Kweifio-Okai G, et al. **J Ethnopharmacol** 1995 Apr;46(1):7–15

Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. Ravelli A, et al. **J Pediatr** 1996 Feb;128(2):275–8

Hydroxychloroquine in the treatment of erosive osteoarthritis. Bryant LR, et al. **J Rheumatol** 1995 Aug; 22(8):1527–31

A preliminary evaluation of hydroxyurea for the treatment of rheumatoid arthritis. Ehrlich LS, et al. **J Rheumatol** 1995 Sep;22(9):1646–50

Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. Ferraccioli G, et al. **J Rheumatol** 1996 Apr;23(4):624–8

Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. Gupta AK, et al. **J Rheumatol** 1995 May;22(5):894–8

ANTIRHEUMATIC AGENTS

Guidelines for testing slow acting drugs in arthritis--addendum [letter] Lequesne M, et al. **J Rheumatol** 1995 Jul;22(7):1442

Intravenous cyclophosphamide pulses in the treatment of pyoderma gangrenosum associated with rheumatoid arthritis [letter; comment] Nordstrom D. **J Rheumatol** 1995 May;22(5):1000-1. Comment on: J Rheumatol 1994 Jul;21(7):1352-6.

Steroid sparing effect of methotrexate in relapsing polychondritis. Park J, et al. **J Rheumatol** 1996 May; 23(5):937-8

Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis--a double blind study. Rao UR, et al. **J Rheumatol** 1995 Jul;22(7):1235-40

Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. Ravelli A, et al. **J Rheumatol** 1995 Aug; 22(8):1574-6

Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. Suarez-Almazor ME, et al. **J Rheumatol** 1995 May;22(5):836-43

Radiographic progression in rheumatoid arthritis: results of 3 comparative trials. van Riel PL, et al. **J Rheumatol** 1995 Sep;22(9):1797-9

Mysteclin V in the treatment of rheumatoid arthritis [letter] Laidlaw CD. **Med J Aust** 1996 Apr 15;164(8):512

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. O'Dell JR, et al. **N Engl J Med** 1996 May 16;334(20):1287-91

Cyclosporine and methotrexate for severe rheumatoid arthritis [letter; comment] Rosh JR, et al. **N Engl J Med** 1995 Dec 7;333(23):1567-8; discussion 1568-9. Comment on: N Engl J Med 1995 Jul 20;333(3):137-41.

Cyclosporine and methotrexate for severe rheumatoid arthritis [letter; comment] Schlesinger N, et al. **N Engl J Med** 1995 Dec 7;333(23):1567; discussion 1568-9. Comment on: N Engl J Med 1995 Jul 20;333(3):137-41.

Cyclosporine and methotrexate for severe rheumatoid arthritis [letter; comment] Steinberg AD. **N Engl J Med** 1995 Dec 7;333(23):1567; discussion 1568-9. Comment on: N Engl J Med 1995 Jul 20;333(3):137-41.

Treatment of rheumatoid arthritis [letter] Stohl W, et al. **N Engl J Med** 1996 Sep 12;335(11):821-2; discussion 821-2

Cyclosporine and methotrexate for severe rheumatoid arthritis [letter; comment] Storb R, et al. **N Engl J Med** 1995 Dec 7;333(23):1568; discussion 1568-9. Comment on: N Engl J Med 1995 Jul 20;333(3):137-41.

Treatment of rheumatoid arthritis [letter] Zurier RB, et al. **N Engl J Med** 1996 Sep 12;335(11):822; discussion 822-3

Treating rheumatoid arthritis with clotrimazole [letter; comment] Panayi GS. **Nat Med** 1995 Oct;1(10):977-8. Comment on: Nat Med 1995 Jun;1(6):534-40.

Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future. Giannini EH, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1099-125 (89 ref.)

The facts about methotrexate in rheumatoid arthritis [editorial; comment] Bannwarth B, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep;62(7-8):471-3. Comment on: Rev Rhum Engl Ed 1995 Jul-Sep;62(7-8):477-86.

Therapeutic trials in digital osteoarthritis. A critical review. Trèves R, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):33S-41S

The changing face of therapy for rheumatoid arthritis. Kremer JM. **Rheum Dis Clin North Am** 1995 Aug; 21(3):845-52 (34 ref.)

Investigational agents for rheumatoid arthritis. Merkel PA, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):779-96 (85 ref.)

Rheumatoid arthritis. Outcome measures. Paulus HE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):605-18 (52 ref.)

Production of TNF by monocytes of patients with early rheumatoid arthritis is increased. Leirisalo-Repo M, et al. **Scand J Rheumatol** 1995;24(6):366-71

Effects of methotrexate, sulphasalazine and aurothiomalate on polymorphonuclear leucocytes in rheumatoid arthritis. Storgaard M, et al. **Scand J Rheumatol** 1996;25(3):168-73

Assessment and follow-up of osteoarthritis of the limbs--outcome measures. Lequesne M. **Schweiz Med Wochenschr Suppl** 1996;80:8S-9S

Combination therapy of severe rheumatoid arthritis at an early stage of the disease. Tugwell P, et al. **Schweiz Med Wochenschr Suppl** 1996;80:20S-21S

[Methotrexate treatment in non-cancerous disorders] Cogan E. **Rev Med Brux** 1995 Jul-Aug;16(4):300-3 (Eng. Abstr.) **(Fre)**

[Methotrexate in rheumatology: a therapeutic revolution] Kaye O, et al. **Rev Med Liege** 1995 Nov;50(11):453-7 (10 ref.) **(Fre)**

[Therapy of rheumatoid arthritis] Sieper J, et al. **Dtsch Med Wochenschr** 1996 Apr 26;121(17):563-7 (12 ref.) **(Ger)**

[Methotrexate treatment of rheumatoid arthritis] Beyeler C. **Schweiz Med Wochenschr** 1996 Apr 27;126(17):703-12 (61 ref.) (Eng. Abstr.) **(Ger)**

[Felty syndrome: a therapy-resistant variant of chronic rheumatoid arthritis? 2 case reports and literature review] Brücker R, et al. **Schweiz Rundsch Med Prax** 1996 Apr 16;85(16):534-40 (38 ref.) (Eng. Abstr.) **(Ger)**

[Methotrexate therapy of polymyalgia rheumatica] Wagener P. **Z Rheumatol** 1995 Nov-Dec;54(6):413-6 (Eng. Abstr.) **(Ger)**

[Treatment of rheumatoid arthritis of senile onset with methotrexate] Biasi D, et al. **Recenti Prog Med** 1995 Dec; 86(12):472-5 (Eng. Abstr.) **(Ita)**

[Prognosis and outcome of rheumatoid arthritis. Influence of anti-rheumatic therapy on natural course of disease and objectives in daily treatment] Fujimori J, et al. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):396-400 (8 ref.) **(Jpn)**

[Prognosis and outcome of rheumatoid arthritis--10 to 16 years of anti-rheumatic therapy] Fujimori J, et al. **Ryumachi** 1995 Jun;35(3):543-51 (Eng. Abstr.) **(Jpn)**

[Development of standards by the Norwegian Society of Rheumatology. Control of disease modifying drugs] Kvien TK, et al. **Tidsskr Nor Laegeforen** 1996 Aug 20; 116(19):2315-8 (Eng. Abstr.) **(Nor)**

[Antimalarial preparations in rheumatology: new prospects] Nasonov EL. **Ter Arkh** 1996;68(1):67-71 (50 ref.) **(Rus)**

[Treatment with cyclosporine of refractory rheumatoid arthritis] Massardo L, et al. **Rev Med Chil** 1995 Feb; 123(2):215-24 (Eng. Abstr.) **(Spa)**

TOXICITY

Toxicity of combination therapies in rheumatoid arthritis: comment on the article by Willkens et al [letter] Stein CM. **Arthritis Rheum** 1996 Aug;39(8):1435-7

Effects of methotrexate on human osteoblasts in vitro: modulation by 1,25-dihydroxyvitamin D3. Scheven BA, et al. **J Bone Miner Res** 1995 Jun;10(6):874-80

ANTIRHEUMATIC AGENTS, GOLD

ADMINISTRATION & DOSAGE

A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Bendix G, et al. **Ann Rheum Dis** 1996 Mar;55(3):169-76

The second course of gold. Klinkhoff AV, et al. **J Rheumatol** 1995 Sep;22(9):1655-6

How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions. Klinkhoff AV, et al. **J Rheumatol** 1995 Sep;22(9):1657-9

[A long-term clinical analysis of the rheumatoid patients treated by a combination of GST and CCA] Minami M, et al. **Ryumachi** 1995 Oct;35(5):780-91 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Flare-up at contact allergy sites in a gold-treated rheumatic patient. Möller H, et al. **Acta Derm Venereol** 1996 Jan; 76(1):55-8

Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year followup. McKendry RJ, et al. **Arthritis Rheum** 1996 Jul; 39(7):1246-53

Chrysiasis revisited: a clinical and pathological study. Smith RW, et al. **Br J Dermatol** 1995 Nov;133(5):671-8

Neurological side effects in two patients receiving gold injections for rheumatoid arthritis. Hill C, et al. **Br J Rheumatol** 1995 Oct;34(10):989-90

Neurological signs in RA patients receiving gold [letter] Machtey I. **Br J Rheumatol** 1996 Aug;35(8):804

Constrictive bronchiolitis obliterans following gold therapy for psoriatic arthritis. Schwartzman KJ, et al. **Eur Respir J** 1995 Dec;8(12):2191-3

Chrysiasis after low-dose gold and UV light exposure. Fleming CJ, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):349-51

Artefacts in electron microscopy: ultrastructural features of chrysiasis. Culora GA, et al. **J Pathol** 1995 Aug; 176(4):421-5

Polyradiculoneuropathy induced by gold therapy [letter] Navaux F, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):467

D-penicillamine and gold salt treatments were complicated by myasthenia and pemphigus, respectively, in the same patient with rheumatoid arthritis. Ciompi ML, et al. **Rheumatol Int** 1995;15(3):95-7

[Myokimia induced by gold salts (see comments)] Garrido JA, et al. **Neurologia** 1995 Jun-Jul;10(6):235-7 (Eng. Abstr.). Comment in: Neurologia 1996 Feb;11(2):85-6. **(Spa)**

IMMUNOLOGY

Phagocytes render chemicals immunogenic: oxidation of gold(I) to the T cell-sensitizing gold(III) metabolite generated by mononuclear phagocytes. Goebel C, et al. **Arch Toxicol** 1995;69(7):450-9

PHARMACOLOGY

Auranofin inhibits the induction of interleukin 1 beta and tumor necrosis factor alpha mRNA in macrophages. Bondeson J, et al. **Biochem Pharmacol** 1995 Nov 27; 50(11):1753-9

Auranofin inhibits calcium uptake into opsonized-zymosan-stimulated neutrophils obtained from rats. Ishitani K, et al. **Inflamm Res** 1995 Nov;44(11):482-5

Zinc ions antagonize the inhibitory effect of aurothiomalate on glucocorticoid receptor function at physiological concentrations [published erratum appears in Mol Pharmacol 1996 Jan;49(1):207] Tanaka H, et al. **Mol Pharmacol** 1995 Nov;48(5):938-45

THERAPEUTIC USE

Influence of gold salts treatment on the serum concentration of IL-1 and IL-2 in patients with rheumatoid arthritis. Lewandowicz J, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(3-4):195-8

Inhibitory properties of triethylphosphine goldlupinylsulfide in adjuvant-induced arthritis in rats. Ghia M, et al. **Farmaco** 1995 Sep;50(9):601-4

Technetium-99m labelled polyclonal human IgG scintigraphy before and 26 weeks after initiation of parenteral gold treatment in patients with rheumatoid arthritis. de Bois MH, et al. **J Rheumatol** 1995 Aug; 22(8):1461-5

Plasma viscosity in the monitoring of therapy in rheumatoid arthritis patients. Gudmundsson M, et al. **Scand J Rheumatol** 1995;24(4):219-24

[A case of interstitial pneumonia in polymyositis difficult to distinguish from gold pneumonitis] Maeda K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):745-9 (Eng. Abstr.) **(Jpn)**

[Myokimia induced by gold salts (see comments)] Garrido JA, et al. **Neurologia** 1995 Jun-Jul;10(6):235-7 (Eng. Abstr.). Comment in: Neurologia 1996 Feb;11(2):85-6. **(Spa)**

TOXICITY

Serum IgE concentration and other immune manifestations of treatment with gold salts are linked to the MHC and IL4 regions in the rat. Kermarrec N, et al. **Genomics** 1996 Jan 1;31(1):111-4

ANTI-RHEUMATIC AGENTS, NON-STEROIDAL see **ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL**

ANTI-RHEUMATIC AGENTS, STEROIDAL see **ANTI-INFLAMMATORY AGENTS, STEROIDAL**

ANTISCHISTOSOMAL AGENTS see **SCHISTOSOMICIDES**

ANTISENSE DNA see **DNA, ANTISENSE**

ANTISENSE ELEMENTS (GENETICS)

see related
TRANSCRIPTION, GENETIC

Fas-mediated cytotoxicity remains intact in perforin and granzyme B antisense transfectants of a human NK-like cell line. Montel AH, et al. **Cell Immunol** 1995 Oct 15; 165(2):312-7

Stable transfection of embryonal carcinoma cells with MAP1A and MAP1B antisense sequences. Adam G, et al. **Gene Ther** 1994;1 Suppl 1:S56

Sense in antisense? Forsdyke DR. **J Mol Evol** 1995 Nov; 41(5):582-6

Inhibition of memory consolidation after active avoidance conditioning by antisense intervention with ependymin gene expression. Schmidt R, et al. **J Neurochem** 1995 Oct; 65(4):1465-71

Probing the function of novel genes in the nervous system: is antisense the answer? Hunter AJ, et al. **Trends Neurosci** 1995 Aug;18(8):329-31

[Regulation of gene expression by antisense molecule] Matsukura M. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1378-82 (20 ref.) **(Jpn)**

DIAGNOSTIC USE

Scintigraphic imaging of oncogenes with antisense probes: does it make sense? Urbain JL, et al. **Eur J Nucl Med** 1995 Jun;22(6):499-504

PHARMACOLOGY

Antisense inhibition of the 27 kDa heat shock protein production affects growth rate and cytoskeletal organization in MCF-7 cells. Mairesse N, et al. **Cell Biol Int** 1996 Mar;20(3):205-12

PHYSIOLOGY

Inhibition of HIV replication by sense and antisense rev response elements in HIV-based retroviral vectors. Kim JH, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 1;12(4):343-51

THERAPEUTIC USE

Antisense strategies and therapeutic applications. Putnam DA. **Am J Health Syst Pharm** 1996 Jan 15;53(2):151-60; quiz 182-3 (76 ref.)

Sense, antisense, nonsense: where's the right way? Bricca G. **J Mol Med** 1995 Aug;73(8):417-9

Antisense oncogene and tumor suppressor gene therapy of cancer. Zhang WW. **J Mol Med** 1996 Apr;74(4):191-204 (137 ref.)

ANTISENSE OLIGODEOXYRIBONUCLEOTIDES see **OLIGONUCLEOTIDES, ANTISENSE**

ANTISENSE OLIGONUCLEOTIDES see

OLIGONUCLEOTIDES, ANTISENSE

ANTISENSE OLIGORIBONUCLEOTIDES see **OLIGONUCLEOTIDES, ANTISENSE**

ANTISENSE PROBES see **ANTISENSE ELEMENTS (GENETICS)**

ANTISENSE RNA see **RNA, ANTISENSE**

ANTISEPSIS

No difference in catheter sepsis between standard and antiseptic central venous catheters. A prospective randomized trial. Pemberton LB, et al. **Arch Surg** 1996 Sep; 131(9):986–9

HISTORY

The beginning of antiseptic surgery in Australia. Hugh TB. **Aust N Z J Surg** 1995 Dec;65(12):887–9

METHODS

APIC guideline for handwashing and hand antisepsis in health care settings. Larson EL. **Am J Infect Control** 1995 Aug;23(4):251–69 (239 ref.)

Free-hand technique with ordinary antisepsis in abdominal US-guided fine-needle punctures: three-year experience. Caturelli E, et al. **Radiology** 1996 Jun;199(3):721–3

[Efficacy of various methods for preoperative vaginal antisepsis] Enzelsberger H, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):707–10 (Eng. Abstr.) **(Ger)**

STANDARDS

PDA comments on USP in-process revision <1116> microbiological evaluation of clean rooms and other controlled environments. Parenteral Drug Association. **PDA J Pharm Sci Technol** 1995 Nov-Dec;49(6):264–6

ANTISEPTICS see **ANTI-INFECTIVE AGENTS, LOCAL**

ANTISEPTICS, URINARY see **ANTI-INFECTIVE AGENTS, URINARY**

ANTISERA see **IMMUNE SERA**

ANTISEROTONERGIC AGENTS see **SEROTONIN ANTAGONISTS**

ANTI-SHOCK TROUSERS see **G SUITS**

ANTISICKLING AGENTS

ADMINISTRATION & DOSAGE

Hydroxyurea in sickle cell disease. Burke SM. **MCN Am J Matern Child Nurs** 1996 Jul-Aug;21(4):210

THERAPEUTIC USE

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. el-Hazmi MA, et al. **Acta Haematol** 1995;94(3):128–34

Bencyclane as an anti-sickling agent. Koçak R, et al. **Br J Haematol** 1996 Feb;92(2):329–31

Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial. Gupta VL, et al. **J Assoc Physicians India** 1995 Jul; 43(7):467–9

Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease [see comments] Brugnara C, et al. **J Clin Invest** 1996 Mar 1;97(5):1227–34. Comment in: J Clin Invest 1996 Mar 1;97(5):1135.

Hydroxyurea therapy in children severely affected with sickle cell disease. Scott JP, et al. **J Pediatr** 1996 Jun; 128(6):820–8

Sickle cell pain crisis [letter; comment] [see comments] Davies SC, et al. **Lancet** 1996 Jan 27;347(8996):263. Comment on: Lancet 1995 Nov 25;346(8987):1408–11. Comment in: Lancet 1996 Apr 27;347(9009):1190–1.

Sickle cell paths converge on hydroxyurea. Platt OS. **Nat Med** 1995 Apr;1(4):307–8

TOXICITY

Effect of methyl isocyanate on rabbit cardiac Na+, K(+)-ATPase. Jeevaratnam K. **Arch Toxicol** 1995; 69(10):694–7

ANTISOCIAL PERSONALITY DISORDER

A clinical investigation of malingering and psychopathy in hospitalized insanity acquittees. Gacono CB, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):387–97

What price the concept of psychopathic disorder? Prins H. **Med Sci Law** 1995 Oct;35(4):307–15 (56 ref.)

The philosophy of psychopathy. Stein DJ. **Perspect Biol Med** 1996 Summer;39(4):569–80 (26 ref.)

BLOOD

Platelet serotonin 2A (5-HT2A) receptor characteristics and parenting factors for boys at risk for delinquency: a preliminary report. Pine DS, et al. **Am J Psychiatry** 1996 Apr;153(4):538–44

Biosocial models of deviant behavior among male army veterans. Mazur A. **Biol Psychol** 1995 Nov 16;41(3):271–93

CLASSIFICATION

[Serial rapists. A heterogeneous group needs accurate classification] Belfrage H, et al. **Lakartidningen** 1996 Apr 3;93(14):1352–4 **(Swe)**

COMPLICATIONS

Gender effects on the clinical presentation of alcoholics at a psychiatric hospital. Cornelius JR, et al. **Compr Psychiatry** 1995 Nov-Dec;36(6):435–40

DIAGNOSIS

High autonomic arousal and electrodermal orienting at age 15 years as protective factors against criminal behavior at age 29 years. Raine A, et al. **Am J Psychiatry** 1995 Nov; 152(11):1595–600

Psychopathy--a clinical and legal dilemma [editorial] Reed J. **Br J Psychiatry** 1996 Jan;168(1):4–9 (20 ref.)

Personality and antisocial behavior in children and adolescents: an enquiry into Eysenck's and Gray's theories. Fonseca AC, et al. **J Abnorm Child Psychol** 1995 Dec; 23(6):767–81

DSM-IV antisocial personality disorder field trial. Widiger TA, et al. **J Abnorm Psychol** 1996 Feb;105(1):3–16

Construction and validation of risk assessments in a six-year follow-up of forensic patients: a tridimensional analysis. Menzies R, et al. **J Consult Clin Psychol** 1995 Oct; 63(5):766–78

Development and preliminary validation of a self-report measure of psychopathic personality traits in noncriminal populations. Lilienfeld SO, et al. **J Pers Assess** 1996 Jun; 66(3):488–524

Sociopathy: forever forensic? Robertson MD, et al. **Med J Aust** 1996 Mar 4;164(5):304–7 (24 ref.)

Six cases of patients with mental retardation who have antisocial personality disorder. Hurley AD, et al. **Psychiatr Serv** 1995 Aug;46(8):828–31

[Psychopathy and drug addiction] Theys JM. **Acta Psychiatr Belg** 1995 Mar-Apr;95(2):82–90 (Eng. Abstr.) **(Fre)**

[Law infringements by adolescents with borderline psychoneurotic disorders] Natarov VV. **Sud Med Ekspert** 1996 Apr-Jun;39(2):43–4 **(Rus)**

[Psychopathy and neuropsychology of the prefrontal cortex] Jurado MA, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May-Jun;24(3):148–55 (49 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Drug abuse and psychiatric comorbidity. Kokkevi A, et al. **Compr Psychiatry** 1995 Sep-Oct;36(5):329–37

ETHNOLOGY

The relation of prosocial and antisocial behavior to personality and peer relationships of Hong Kong Chinese adolescents. Ma HK, et al. **J Genet Psychol** 1996 Sep; 157(3):255–66

Personality styles and dynamics of Alaska Native and nonnative incarcerated men. Glass MH, et al. **J Pers Assess** 1996 Jun;66(3):583–603

[Hybrid pathologies: difficulties in intricate clinical cases] Florentin T, et al. **Ann Med Psychol (Paris)** 1995 Oct; 153(8):547–50 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Predictors of neuropsychological impairment in alcoholics: antisocial versus nonantisocial subtypes. Waldstein SR, et al. **Addict Behav** 1996 Jan-Feb;21(1):21–7

GENETICS

Family history of alcoholism and psychiatric co-morbidity in Brazilian male alcoholics and controls. Araujo NP, et al. **Addiction** 1995 Sep;90(9):1205–11

Homovanillic acid and dopamine-beta-hydroxylase in male youth: relationships with paternal substance abuse and antisocial behavior. Gabel S, et al. **Am J Drug Alcohol Abuse** 1995 Aug;21(3):363–78

Depression spectrum disease, I: The role of gene-environment interaction. Cadoret RJ, et al. **Am J Psychiatry** 1996 Jul;153(7):892–9

Genetic-environmental interaction in the genesis of aggressivity and conduct disorders. Cadoret RJ, et al. **Arch Gen Psychiatry** 1995 Nov;52(11):916–24

Antisocial behavior. Gershon ES. **Arch Gen Psychiatry** 1995 Nov;52(11):900–1

Differential heritability of adult and juvenile antisocial traits. Lyons MJ, et al. **Arch Gen Psychiatry** 1995 Nov; 52(11):906–15

Genetic questions for environmental studies. Differential parenting and psychopathology in adolescence. Reiss D, et al. **Arch Gen Psychiatry** 1995 Nov;52(11):925–36

Personality disorder in alcohol dependents [letter] Iwahashi K, et al. **Can J Psychiatry** 1995 Aug;40(6):362–3

Antisocial personality disorder: a biopsychosocial model. Paris J. **Can J Psychiatry** 1996 Mar;41(2):75–80 (70 ref.)

A dinucleotide repeat polymorphism at the gene for monoamine oxidase A and measures of aggressiveness. Vanyukov MM, et al. **Psychiatry Res** 1995 Nov 29; 59(1-2):35–41

Conflict marks crime conference [news] Roush W. **Science** 1995 Sep 29;269(5232):1808–9

METABOLISM

[Relationship of free and conjugated forms of catecholamines in depressive disorders in psychopathic personalities] Dmitrieva TB, et al. **Vopr Med Khim** 1995 Sep-Oct; 41(5):28–32 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Cardiac autonomic function during sleep of never-depressed borderline subjects: a pilot study. Battaglia M, et al. **J Psychiatr Res** 1995 Sep-Oct;29(5):397–405

Aggression and personality: association with amino acids and monoamine metabolites. Møller SE, et al. **Psychol Med** 1996 Mar;26(2):323–31

[Psychopathy and neuropsychology of the prefrontal cortex] Jurado MA, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May-Jun;24(3):148–55 (49 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Biosocial models of deviant behavior among male army veterans. Mazur A. **Biol Psychol** 1995 Nov 16;41(3):271–93

Antisocial boys and their friends in early adolescence: relationship characteristics, quality, and interactional process. Dishion TJ, et al. **Child Dev** 1995 Feb;66(1):139–51

Psychopathy, schizophrenia, alcohol abuse, and violent recidivism. Rice ME, et al. **Int J Law Psychiatry** 1995 Summer;18(3):333–42

Psychopathy and dual-task performance under focusing conditions. Kosson DS. **J Abnorm Psychol** 1996 Aug; 105(3):391–400

The Twelfth Jack Tizard Memorial Lecture. The development of offending and antisocial behaviour from childhood: key findings from the Cambridge Study in Delinquent Development. Farrington DP. **J Child Psychol Psychiatry** 1995 Sep;36(6):929–64

Prediction of adolescent aggression by childhood personality measures: a comparison of projective procedures, self-report tests, and behavior ratings. Graybill D, et al. **J Clin Psychol** 1996 Jan;52(1):61–6

Sociopathy: forever forensic? Robertson MD, et al. **Med J Aust** 1996 Mar 4;164(5):304–7 (24 ref.)

Correlations between the Hand Test Pathology score and Personality Assessment Inventory scales for pain clinic patients. George JM, et al. **Percept Mot Skills** 1995 Jun; 80(3 Pt 2):1377–8

The extreme regressive reaction of a psychopath. Conacher GN, et al. **Psychiatr Q** 1996 Spring;67(1):1–10

[Hybrid pathologies: difficulties in intricate clinical cases] Florentin T, et al. **Ann Med Psychol (Paris)** 1995 Oct; 153(8):547–50 (Eng. Abstr.) **(Fre)**

[Joy riding: multiple criminal car rides in an intoxicated state in relation to dyssocial personality with addictive tendencies] Knecht T. **Arch Kriminol** 1995 Jul-Aug; 196(1-2):1–5 (Eng. Abstr.) **(Ger)**

[Modified concept of psychopathy] Knecht T. **Schweiz Rundsch Med Prax** 1996 Jan 3;85(1-2):9–13 (Eng. Abstr.) **(Ger)**

[Dyssocial identity disorder (double identity) in psychopathology and poetry] Tölle R. **Z Klin Psychol Psychopathol Psychother** 1996;44(2):174–85 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Brain glucose metabolism in violent psychiatric patients: a preliminary study. Volkow ND, et al. **Psychiatry Res** 1995 Nov 10;61(4):243–53

REHABILITATION

'Psychopaths' in special hospitals [letter] Gordon H. **Br J Psychiatry** 1996 May;168(5):653

Young 'psychopaths' in special hospital: treatment and outcome. Reiss D, et al. **Br J Psychiatry** 1996 Jan; 168(1):99–104

Incurable psychopaths? Kristiansson M. **Bull Am Acad Psychiatry Law** 1995;23(4):555–62

The ethics of treating the "untreatable" [editorial] Christensen RC. **Psychiatr Serv** 1995 Dec;46(12):1217

THERAPY

[Can "psychopathy" be cured?] Huttunen MO. **Duodecim** 1994;110(1):69–74 (17 ref.) **(Fin)**

[Psychotherapy with dyssocial patients] Rauchfleisch U. **Schweiz Arch Neurol Psychiatr** 1995;146(3):115–20 (13 ref.) (Eng. Abstr.) **(Ger)**

URINE

Urinary excretion of bufotenin (N,N-dimethyl-5-hydroxytryptamine) is increased in suspicious violent offenders: a confirmatory study.

Kärkkäinen J, et al. **Psychiatry Res** 1995 Sep 29; 58(2):145–52

ANTISPASMODICS see **PARASYMPATHOLYTICS**

ANTISPERMATOGENIC AGENTS

PHARMACOLOGY

Contraceptive efficacy of testosterone–induced azoospermia and oligozoospermia in normal men. **Fertil Steril** 1996 Apr; 65(4):821–9

ANTISTREPTOLYSIN

BLOOD

[High activity of antistreptolysin–O in a case of IgM myeloma] Inatomi Y, et al. **Rinsho Ketsueki** 1996 May; 37(5):437–42 (Eng. Abstr.) **(Jpn)**

ANTITHROMBIN II see **ANTITHROMBIN III**

ANTITHROMBIN III

see related
ANTICOAGULANTS

ADMINISTRATION & DOSAGE

Use of antithrombin III concentrates to correct antithrombin III deficiency during vascular surgery. Jackson MR, et al. **J Vasc Surg** 1995 Dec;22(6):804–7

ANALYSIS

Properties of factor IX concentrates. Berntorp E. **Acta Haematol** 1995;94 Suppl 1:8–11

Influence of hormone replacement therapy (17 beta–OH estradiol and medroxyprogesterone acetate) on plasma concentration of prothrombin fragment F1+2 and thrombin–antithrombin III complex in postmenopausal woman. Ciepluch R, et al. **Acta Haematol Pol** 1996; 27(1):21–5

Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI–5 Investigators. Thrombolysis in Myocardial Infarction. Scharfstein JS, et al. **Am J Cardiol** 1996 Sep 1;78(5):503–10

Markers of in vivo activation of coagulation. Interrelationships change with intensity of oral anticoagulation. Solymoss S, et al. **Am J Clin Pathol** 1996 Mar;105(3):293–7

Thrombin–antithrombin III and prothrombin fragment 1.2 levels in early respiratory distress syndrome [letter] Yurdakök M, et al. **Am J Hematol** 1996 Mar;51(3):247–8

Enzyme–linked immunosorbent assay for thrombin–antithrombin III complexes in horses. Topper MJ, et al. **Am J Vet Res** 1996 Apr;57(4):427–31

Use of enzyme–linked immunosorbent assay to measure thrombin–antithrombin III complexes in horses with colic. Topper MJ, et al. **Am J Vet Res** 1996 Apr;57(4):456–62

Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Thompson SG, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):357–62

Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Mesters RM, et al. **Blood** 1996 Aug 1;88(3):881–6

Thrombin receptor–mediated synovial proliferation in patients with rheumatoid arthritis. Shin H, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):225–33

Haemostatic markers of procoagulant imbalance in Behçet's disease [letter] Haznedaroğlu IC, et al. **Eur J Haematol** 1996 Jul;57(1):107–8

Prothrombin fragment F1+2 and thrombin–antithrombin III complex (TAT) plasma levels in patients with gynecological cancer. Gadducci A, et al. **Gynecol Oncol** 1996 May;61(2):215–7

Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations. Petäjä J, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):665–71

Effect of critical injury on plasma antithrombin activity: low antithrombin levels are associated with thromboembolic complications. Owings JT, et al. **J Trauma** 1996 Sep; 41(3):396–405; discussion 405–6

Antithrombin levels related to infections and outcome. Wilson RF, et al. **J Trauma** 1996 Mar;40(3):384–7

Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease. Ozoran K, et al. **Scand J Rheumatol** 1995;24(6):376–82

Pre–operative plasma levels of thrombin–antithrombin III complexes correlate with the development of venous thrombosis after major hip or knee surgery. Ginsberg JS, et al. **Thromb Haemost** 1995 Aug;74(2):602–5

Parameters of haemostasis during acute venous thrombosis. Reiter W, et al. **Thromb Haemost** 1995 Aug;74(2):596–601

Treatment with recombinant human erythropoietin induces a moderate rise in hematocrit and thrombin antithrombin in healthy subjects. Clyne N, et al. **Thromb Res** 1995 Jul 1;79(1):125–9

Functional assay of plasma antithrombin using polyethylene glycol (PEG) defibrinated plasma. Li A, et al. **Thromb Res** 1995 Aug 15;79(4):395–403

[May (must?) in a for recurrent thrombophlebitis [with normal AT III/ protein C+S] fully "marcumarized" patient (with [otherwise?] negative contraindications) with acute posterior wall infarct (15 min "old") a brief lysis therapy be instituted?] Seitz R. **Internist (Berl)** 1995 Dec;36(12):1202 **(Ger)**

[Antithrombin III (AT III)] Okajima K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:43–7 (24 ref.) **(Jpn)**

[Thrombin antithrombin III complex (TAT)] Sakuragawa N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:48–50 (14 ref.) **(Jpn)**

[Significance of heparin elimination from plasma in the assessment of coagulogram and antithrombin III activity] Momot AP, et al. **Klin Lab Diagn** 1995 Sep–Oct;(5):31–4 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

[Alpha–fetoprotein producing hepatocellular carcinoma, AT–III producing hepatocellular carcinoma] Nakamura K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):265–8 (11 ref.) **(Jpn)**

CHEMISTRY

Identification of an epitope in antithrombin appearing on insertion of the reactive–bond loop into the A beta–sheet. Nordling K, et al. **Biochemistry** 1996 Aug 13; 35(32):10436–40

In vitro characterization of antithrombin III concentrates--a single–blind study. Hellstern P, et al. **Haemostasis** 1995 Jul–Aug;25(4):193–201

Interaction of antithrombin III with surface–immobilized albumin–heparin conjugates. van Delden CJ, et al. **J Biomed Mater Res** 1995 Nov;29(11):1317–29

DEFICIENCY

Deficient antithrombin III activity and enhanced fibrinolysis in patients with liver disease: evidence against a cause–effect relationship. Pirisi M, et al. **Acta Gastroenterol Belg** 1995 Mar–Apr;58(2):230–7

Aortic thrombosis in a neonate with hereditary antithrombin III deficiency: successful outcome with thrombolytic and replacement treatment. Sánchez J, et al. **Acta Paediatr** 1996 Feb;85(2):245–7

Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Bucalossi A, et al. **Am J Hematol** 1996 May;52(1):14–20

Disseminated intravascular coagulation and antithrombin III depression in acute fatty liver of pregnancy. Castro MA, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):211–6 (13 ref.)

Epidural caesarean section in a patient with congenital antithrombin III deficiency. Rowbottom SJ. **Anaesth Intensive Care** 1995 Aug;23(4):493–5

Portal vein thrombosis due to antithrombin III deficiency. A case report. Yonemitsu Y, et al. **Angiology** 1995 Nov; 46(11):1043–7

Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose– und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Pabinger I, et al. **Arterioscler Thromb Vasc Biol** 1996 Jun;16(6):742–8

Thrombocytopenia, antithrombin deficiency and extensive thromboembolism in pregnancy: treatment with low–molecular–weight heparin. Macklon NS, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):672–5

Ectopic transcript analysis in human antithrombin deficiency. Perry DJ. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):531–6

Hereditary deficiency of protein C, protein S and antithrombin III. Vittore CP, et al. **Can Assoc Radiol J** 1996 Aug;47(4):251–6

Antithrombin III deficiency during continuous venovenous hemodialysis. Bastien O, et al. **Contrib Nephrol** 1995; 116:154–8

Protein C, protein S, and antithrombin III in acute ocular occlusive diseases. Bertram B, et al. **Ger J Ophthalmol** 1995 Nov;4(6):332–5

Identification of the antithrombin III Kyoto mutation by restriction fragment length polymorphism analysis. Masuda H, et al. **Int J Hematol** 1995 Jun;61(4):197–204

Antithrombin III deficiency, deep venous thrombosis, and oral contraceptive use. Werner MJ. **J Adolesc Health** 1995 Sep;17(3):189–92

Use of antithrombin III concentrates to correct antithrombin III deficiency during vascular surgery. Jackson MR, et al. **J Vasc Surg** 1995 Dec;22(6):804–7

The risk of abortion and stillbirth in antithrombin–, protein C–, and protein S–deficient women. Sanson BJ, et al. **Thromb Haemost** 1996 Mar;75(3):387–8

Antithrombin III deficiency as a risk factor for catheter–related central vein thrombosis in cancer patients. De Cicco M, et al. **Thromb Res** 1995 Apr 15;78(2):127–37

[General anticoagulant factor deficiency related to venous thrombosis has been identified (editorial)] Syrjälä M. **Duodecim** 1994;110(14):1307–9 **(Fin)**

[Mesenteric vein infarction associated with congenital antithrombin III (ATIII) deficiency] Guillou YM, et al. **Ann Chir** 1996;50(1):72–5 (Eng. Abstr.) **(Fre)**

[Hereditary antithrombin III deficiency. Report of an obstetric case and review of the literature] Leal–Tijerina G, et al. **Ginecol Obstet Mex** 1996 Apr;64:177–83 (18 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSTIC USE

Thrombin–antithrombin III complexes as an additional diagnostic aid in pulmonary embolism. Carmassi F, et al. **Haemostasis** 1996 Jan–Feb;26(1):16–22

DRUG EFFECTS

Increased plasma thrombin–antithrombin III complex levels in non–insulin dependent diabetic patients with albuminuria are reduced by ethyl icosapentatenoate. Shimizu H, et al. **Thromb Haemost** 1995 Nov;74(5):1231–4

GENETICS

Two antithrombin mutations in a compound heterozygote: Met20Thr and Tyr166Cys. Perry DJ, et al. **Am J Hematol** 1995 Nov;50(3):215–6

Ligand–dependent enhancement of human antithrombin gene expression by retinoid X receptor alpha and thyroid hormone receptor beta. Niessen RW, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):263–70

Ectopic transcript analysis in human antithrombin deficiency. Perry DJ. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):531–6

Functional analysis of an unusual length polymorphism in the human antithrombin III (AT3) gene promoter. Winter PC, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):659–64

Linkage mapping in Papio baboons: conservation of a syntenic group of six markers on human chromosome 1. Rogers J, et al. **Genomics** 1995 Jul 20;28(2):251–4

Linkage disequilibrium between two loci (5' untranslated exon 1 and intron 5–DdeI) of the antithrombin III gene in three ethnic groups in Singapore. Liu Y, et al. **Hum Hered** 1995 Jul–Aug;45(4):192–8

Identification of the antithrombin III Kyoto mutation by restriction fragment length polymorphism analysis. Masuda H, et al. **Int J Hematol** 1995 Jun;61(4):197–204

A review of mutations causing deficiencies of antithrombin, protein C and protein S. Aiach M, et al. **Thromb Haemost** 1995 Jul;74(1):81–9 (120 ref.)

DNA length polymorphism present in the antithrombin III promoter region does not influence plasma antithrombin III activity levels [letter] Niessen RW, et al. **Thromb Haemost** 1996 Feb;75(2):376–7

Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. van Boven HH, et al. **Thromb Haemost** 1996 Mar;75(3):417–21

ISOLATION & PURIFICATION

Isolation and characterization of the tsetse thrombin inhibitor: a potent antithrombotic peptide from the saliva of Glossina morsitans morsitans. Cappello M, et al. **Am J Trop Med Hyg** 1996 May;54(5):475–80

METABOLISM

Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction. Biasucci LM, et al. **Am J Cardiol** 1996 Jan 1;77(1):85–7

An increased uptake of prothrombin, antithrombin, and fibrinogen by the rabbit balloon–deendothelialized aorta surface in vivo is maintained until reendothelialization is complete. Hatton MW, et al. **Arterioscler Thromb Vasc Biol** 1996 Sep;16(9):1147–55

Antithrombin and atherosclerosis in the Rotterdam Study. van der Bom JG, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):864–7

Mechanism of heparin activation of antithrombin. Evidence for reactive center loop preinsertion with expulsion upon heparin binding. Huntington JA, et al. **Biochemistry** 1996 Jul 2;35(26):8495–503

Identification of thrombin residues that modulate its interactions with antithrombin III and alpha 1–antitrypsin. Le Bonniec BF, et al. **Biochemistry** 1995 Sep 26; 34(38):12241–8

Tryptophan 60–D in the B–insertion loop of thrombin modulates the thrombin–antithrombin reaction. Rezaie AR. **Biochemistry** 1996 Feb 13;35(6):1918–24

Intracellular events determine the fate of antithrombin Utah. Sheffield WP, et al. **Blood** 1995 Nov 1;86(9):3461–7

Activation of antithrombin III isoforms by heparan sulphate glycosaminoglycans and other sulphated polysaccharides. Carlson TH, et al. **Blood Coagul Fibrinolysis** 1995 Jul; 6(5):474–80

Effect of sulfated xylans during the interaction of [125I]–thrombin with antithrombin III or heparin cofactor II of human plasma [published erratum appears in Eur J Drug Metab Pharmacokinet 1995 Apr–Jun;20(2):162] Simmons RB, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jan–Mar;20(1):73–7

In vitro characterization of antithrombin III concentrates—a single–blind study. Hellstern P, et al. **Haemostasis** 1995 Jul–Aug;25(4):193–201

Internalization of vitronectin–thrombin–antithrombin complex by endothelial cells leads to deposition of the complex into the subendothelial matrix. de Boer HC, et al. **J Biol Chem** 1995 Dec 22;270(51):30733–40

Cellular internalization and degradtion of antithrombin III–thrombin, heparin cofactor II–thrombin, and alpha1–antitrypsin–trypsin complexes is mediated by the low density lipoprotein receptor–related protein. Kounnas

MZ, et al. **J Biol Chem** 1996 Mar 15;271(11):6523–9

Requirement of lysine residues outside of the proposed pentasaccharide binding region for high affinity heparin binding and activation of human antithrombin III. Kridel SJ, et al. **J Biol Chem** 1996 Aug 23;271(34):20935–41

Structures of five sulfated hexasaccharides prepared from porcine intestinal heparin using bacterial heparinase. Structural variants with apparent biosynthetic precursor–product relationships for the antithrombin III–binding site. Tsuda H, et al. **J Biol Chem** 1996 May 3;271(18):10495–502

Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation. Tabbara IA, et al. **J Hematother** 1996 Feb;5(1):79–84

Multiple organ dysfunction syndrome in bone marrow transplantation. Haire WD, et al. **JAMA** 1995 Oct 25; 274(16):1289–95

Fetal and neonatal development of antithrombin III plasma activity and liver messenger RNA levels in sheep. Niessen RW, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):685–91

Circadian rhythms of fibrinogen and antithrombin III in liver cirrhosis. Pasqualetti P, et al. **Riv Eur Sci Med Farmacol** 1995 Jul–Aug;17(4):125–9

Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Boneu B, et al. **Thromb Haemost** 1995 Dec;74(6):1468–73

Insight into the mechanism of action of heparin cofactor II. Tollefsen DM. **Thromb Haemost** 1995 Nov;74(5):1209–14 (64 ref.)

Effects of hemodialysis and long-term erythropoietin treatment on protein C, and on free and total protein S. Clyne N, et al. **Thromb Res** 1995 Oct 15;80(2):161–8

Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Dahl OE, et al. **Thromb Res** 1995 Nov 15;80(4):299–306

TAT and PAP in hemodialysis patients: two cats in a bag? [letter] Haznedaroğlu IC, et al. **Thromb Res** 1995 Dec 1; 80(5):447–9

Heparan-dependent endothelial antithrombin binding is increased by butyrate. Justus AC, et al. **Thromb Res** 1995 Oct 15;80(2):125–33

Responsiveness of atiii and coagulation factors V and VII to a standardized oral fat load. Orth M, et al. **Thromb Res** 1995 Nov 1;80(3):265–70

Effects of low molecular weight heparin on a severely antithrombin III–decreased disseminated intravascular coagulation model in rabbits. Tazawa S, et al. **Thromb Res** 1995 Dec 1;80(5):391–8

[Relationship between anti-coagulation system changes of coronary heart disease patients and different syndrome-type in TCM] Liang TJ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):599–600 (Eng. Abstr.) **(Chi)**

[Antithrombin III and alpha 2-antiplasmin in blood of patients operated on for benign prostatic hyperplasia] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):75–6 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Uchiba M, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):L921–30

Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155. Garone L, et al. **Biochemistry** 1996 Jul 9;35(27):8881–9

Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. Jesty J, et al. **Blood** 1996 Mar 15;87(6):2301–7

Clearance of human factor XIa–inhibitor complexes in rats. Wuillemin WA, et al. **Br J Haematol** 1996 Jun 2;93(4):950–4

The inhibition of human factor VIIa–tissue factor by antithrombin III–heparin is enhanced by factor X on a human bladder carcinoma cell line. Hamamoto T, et al. **Int J Hematol** 1996 Jan;63(1):51–63

Kinetics of blood coagulation factor Xaalpha autoproteolytic conversion to factor Xabeta. Effect on inhibition by antithrombin, prothrombinase assembly, and enzyme activity. Pryzdial ELG, et al. **J Biol Chem** 1996 Jul 12; 271(28):16621–6

Cellular receptor structures for pseudorabies virus are blocked by antithrombin III. Voigt A, et al. **Med Microbiol Immunol (Berl)** 1995 Aug;184(2):97–103

Effects of antithrombin III and antivenom on procoagulant activity of Russell's viper venom in a whole blood model. Clemens R, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):143–8

The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII–mediated neutralization of factor Xa. Lormeau JC, et al. **Thromb Haemost** 1995 Dec;74(6):1474–7

Inhibitory effect of argatroban on thrombin–antithrombin III complex after percutaneous transluminal coronary angioplasty [letter] Sakamoto S, et al. **Thromb Haemost** 1995 Aug;74(2):801–2

Inhibition of prothrombinase by antithrombin–heparin at a macroscopic surface. Speijer H, et al. **Thromb Haemost** 1995 Apr;73(4):648–53

Effects of antithrombin III (AT III) and Trp49-modified AT III on plasma level of 6-keto-PGF1 alpha in rats. Uchiba M, et al. **Thromb Res** 1995 Nov 1;80(3):201–8

The anticoagulant effect of antithrombin III on hyperacute xenograft rejection. Takeshita K, et al. **Transplant Proc** 1996 Apr;28(2):631–2

PHYSIOLOGY

The role of thrombin and thrombin inhibitors in coronary angioplasty. Ali MN, et al. **Chest** 1995 Nov;108(5):1409–19 (78 ref.)

Some functional properties of teleost antithrombin. Salte R, et al. **Thromb Res** 1995 Nov 1;80(3):193–200

THERAPEUTIC USE

Aortic thrombosis in a neonate with hereditary antithrombin III deficiency: successful outcome with thrombolytic and replacement treatment. Sánchez J, et al. **Acta Paediatr** 1996 Feb;85(2):245–7

Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate. Patton DF, et al. **Bone Marrow Transplant** 1996 Mar;17(3):443–7

Thrombin inhibitors in fibrinolysis. A Hobson's choice of alternatives [editorial; comment] Loscalzo J. **Circulation** 1996 Sep 1;94(5):863–5. Comment on: Circulation 1996 Sep 1;94(5):911–21.

Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Nowak-Göttl U, et al. **Eur J Haematol** 1996 Jan–Feb;56(1–2):35–8

The plasma turnover of transfused antithrombin concentrate in patients with acquired antithrombin deficiency. Harper PL, et al. **Transfus Med** 1996 Mar;6(1):45–50

Prolongation of xenograft survival by soluble complement receptor type 1 and antithrombin–III combination therapy. Fujiwara I, et al. **Transplant Proc** 1996 Apr;28(2):685–6

ANTITHROMBIN VI see **FIBRIN FIBRINOGEN DEGRADATION PRODUCTS**

ANTITHROMBINS

see related
ANTICOAGULANTS

Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection. Robson SC, et al. **Transplantation** 1996 Mar 27;61(6):862–8

ADMINISTRATION & DOSAGE

Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting. Muller DW, et al. **Am Heart J** 1996 Feb; 131(2):211–8

Inhibition of thrombin by peptides containing Lysyl-alpha-keto carbonyl derivatives. Lewis SD, et al. **Thromb Haemost** 1995 Oct;74(4):1107–12

Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857. Rübsamen K, et al. **Thromb Haemost** 1995 Nov; 74(5):1353–60

Effective anticoagulation by argatroban during immunoadsorption therapy for malignant rheumatoid arthritis with a high polymorphonuclear leukocyte elastase level. Suzuki S, et al. **Thromb Res** 1995 Oct 1;80(1):93–8

ADVERSE EFFECTS

DDAVP reduces bleeding during continued hirudin administration in the rabbit. Bove CM, et al. **Thromb Haemost** 1996 Mar;75(3):471–5

BIOSYNTHESIS

Cloning of an avian antithrombin: developmental and hormonal regulation of expression. Tejada ML, et al. **Thromb Haemost** 1995 Apr;73(4):654–61

CHEMICAL SYNTHESIS

Active site-directed thrombin inhibitors: alpha-hydroxyacyl-prolyl-arginals. New orally active stable analogs of D-Phe-Pro-Arg-H. Bajusz S, et al. **Bioorg Med Chem** 1995 Aug;3(8):1079–89

Amide and alpha-keto carbonyl inhibitors of thrombin based on arginine and lysine: synthesis, stability and biological characterization. Brady SF, et al. **Bioorg Med Chem** 1995 Aug;3(8):1063–78

Azetidin-2-one derivatives as inhibitors of thrombin. Han WT, et al. **Bioorg Med Chem** 1995 Aug;3(8):1123–43

Peptide-derived transition state analogue inhibitors of thrombin; synthesis, activity and selectivity. Jetten M, et al. **Bioorg Med Chem** 1995 Aug;3(8):1099–114

Cyclotheonamide derivatives: synthesis and thrombin inhibition. Exploration of specific structure-function issues. Maryanoff BE, et al. **Bioorg Med Chem** 1995 Aug; 3(8):1025–38

Synthesis and comparison of tripeptidylfluoroalkane thrombin inhibitors. Neises B, et al. **Bioorg Med Chem** 1995 Aug;3(8):1049–61

Active site-directed thrombin inhibitors--II. Studies related to arginine/guanidine bioisosteres. St Laurent DR, et al. **Bioorg Med Chem** 1995 Aug;3(8):1145–56

Anticoagulant peptides; synthesis, stability and antithrombin activity of hirudin C-terminal-related peptides and their disulfated analog. Okayama T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul;44(7):1344–50

CHEMISTRY

Crystal structure of a peptidyl pyridinium methyl ketone inhibitor with thrombin. Rehse PH, et al. **Biochemistry** 1995 Sep 12;34(36):11537–44

Thrombin active site inhibitors. Das J, et al. **Bioorg Med Chem** 1995 Aug;3(8):999–1007 (57 ref.)

New tripeptidic thrombin inhibitors. Influence of P2 and P3 residues on activity and selectivity. De Nanteuil G, et al. **Bioorg Med Chem** 1995 Aug;3(8):1019–24

Crystallographic structure of a peptidyl keto acid inhibitor and human alpha-thrombin. Håkansson K, et al. **Bioorg Med Chem** 1995 Aug;3(8):1009–17

Molecular modeling studies of novel retro-binding tripeptide active-site inhibitors of thrombin. Lau WF, et al. **Bioorg Med Chem** 1995 Aug;3(8):1039–48

Three more cyclotheonamides, C, D, and E, potent thrombin inhibitors from the marine sponge Theonella swinhoei. Nakao Y, et al. **Bioorg Med Chem** 1995 Aug;3(8):1115–22

The X-ray crystal structure of thrombin in complex with N alpha-2-naphthylsulfonyl-L-3-amidino-phenylalanyl-4-methylpiperidide: the beneficial effect of filling out an empty cavity. Bergner A, et al. **J Enzym Inhib** 1995; 9(1):101–10

Synthetic low-molecular weight thrombin inhibitors: the ideal antithrombotic drug? An introduction. Stürzebecher J, et al. **J Enzym Inhib** 1995;9(1):1–2

Structure-activity relationships of inhibitors derived from 3-amidinophenylalanine. Stürzebecher J, et al. **J Enzym Inhib** 1995;9(1):87–99

DEFICIENCY

Molecular genetics of human antithrombin deficiency. Perry DJ, et al. **Hum Mutat** 1996;7(1):7–22 (119 ref.)

DRUG EFFECTS

Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin. Nowak G, et al. **Thromb Res** 1995 Nov 15;80(4):317–25

GENETICS

Annotation. The unhinged antithrombins [comment] Carrell RW, et al. **Br J Haematol** 1996 May;93(2):253–7 (39 ref.) . Comment on: Br J Haematol 1995 Mar;89(3):589–601.

Cloning of an avian antithrombin: developmental and hormonal regulation of expression. Tejada ML, et al. **Thromb Haemost** 1995 Apr;73(4):654–61

ISOLATION & PURIFICATION

Three more cyclotheonamides, C, D, and E, potent thrombin inhibitors from the marine sponge Theonella swinhoei. Nakao Y, et al. **Bioorg Med Chem** 1995 Aug;3(8):1115–22

BSTI, a trypsin inhibitor from skin secretions of Bombina bombina related to protease inhibitors of nematodes. Mignogna G, et al. **Protein Sci** 1996 Feb;5(2):357–62

METABOLISM

Effects of aging on the synthesis of antithrombin-binding sites on heparin chains and heparan sulphate chains in the rat. Horner AA. **Biochem J** 1995 Nov 15;312 (Pt 1):245–9

Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. Diehl KH, et al. **Haemostasis** 1995 Jul–Aug;25(4):182–92

The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion-transporting polypeptide. Eckhardt U, et al. **Hepatology** 1996 Aug;24(2):380–4

[Change in argatroban concentration within the vessel wall after local administration using hydrogel-coated balloon catheter] Imanishi T, et al. **J Cardiol** 1996 May;27(5):267–71 (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver. Interaction with bile acid transport systems. Eckhardt U, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):85–96

PHARMACOLOGY

Additional anticoagulant strategies for managing heparin-induced thrombocytopenia [letter] Nawarskas JJ, et al. **Am J Health Syst Pharm** 1996 Apr 15;53(8):945

Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Szczeklik A, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):948–54

Inhibition of prothrombinase at macroscopic lipid membranes: competition between antithrombin and prothrombin. Billy D, et al. **Biochemistry** 1995 Oct 17; 34(41):13699–704

Amide and alpha-keto carbonyl inhibitors of thrombin based on arginine and lysine: synthesis, stability and biological characterization. Brady SF, et al. **Bioorg Med Chem** 1995

Aug;3(8):1063–78

Peptide–derived transition state analogue inhibitors of thrombin; synthesis, activity and selectivity. Jetten M, et al. **Bioorg Med Chem** 1995 Aug;3(8):1099–114

Molecular modeling studies of novel retro–binding tripeptide active–site inhibitors of thrombin. Lau WF, et al. **Bioorg Med Chem** 1995 Aug;3(8):1039–48

Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46–6240), recombinant hirudin and heparin in human plasma. Gast A, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):553–60

Anticoagulant peptides; synthesis, stability and antithrombin activity of hirudin C–terminal–related peptides and their disulfated analog. Okayama T, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul;44(7):1344–50

Reduction of intimal hyperplasia by naroparcil, a 4–methylumbelliferyl beta–D–xyloside analogue, after arterial injury in the hypercholesterolemic rabbit. Steg PG, et al. **Circ Res** 1995 Nov;77(5):919–26

Antithrombotic effect of GYKI–14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin. Sudo Y, et al. **J Cardiovasc Pharmacol** 1996 Apr; 27(4):545–55

Thrombin inhibitors based on ketone derivatives of arginine and lysine. Jones DM, et al. **J Enzym Inhib** 1995;9(1):43–60

Design, synthesis and biological activity of novel rigid amidino–phenylalanine derivatives as inhibitors of thrombin. Mack H, et al. **J Enzym Inhib** 1995;9(1):73–86

Synthesis and characterisation of novel thrombin inhibitors based on 4–amidinophenylalanine. Reers M, et al. **J Enzym Inhib** 1995;9(1):61–72

Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. Stone SR, et al. **J Enzym Inhib** 1995; 9(1):3–15 (56 ref.)

Thrombin functions as an inflammatory mediator through activation of its receptor. Cirino G, et al. **J Exp Med** 1996 Mar 1;183(3):821–7

Human alpha–thrombin inhibition by the active site titrant N alpha–(N,N–dimethylcarbamoyl)–alpha–azalysine p–nitrophenyl ester: a comparative kinetic and X–ray crystallographic study. Nardini M, et al. **J Mol Biol** 1996 May 24;258(5):851–9

Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. Kawai H, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):780–5

Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Kawai H, et al. **Jpn J Pharmacol** 1995 Oct;69(2):143–8

Antithrombotic effect of TA–993, a novel 1,5–benzothiazepine derivative, in conscious rats. Narita H, et al. **Jpn J Pharmacol** 1995 Aug;68(4):397–404

Hirulog effect in rat endotoxin shock. Cicala C, et al. **Life Sci** 1995;57(20):PL307–13

Thrombin inhibitors reduce intrapulmonary accumulation of fibrinogen and procoagulant activity of bronchoalveolar lavage fluid during acute lung injury induced by pulmonary overdistention in newborn piglets. Schmidt B, et al. **Pediatr Res** 1996 May;39(5):798–804

Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Callas D, et al. **Thromb Haemost** 1995 Jul;74(1):473–81 (54 ref.)

Inhibitory effect of argatroban on thrombin–antithrombin III complex after percutaneous transluminal coronary angioplasty [letter] Sakamoto S, et al. **Thromb Haemost** 1995 Aug;74(2):801–2

Pharmacology of desmin (low molecular weight dermatan sulphate) in healthy volunteers following intravenous bolus administration of different dosages (200, 400, 800 mg). Dettori AG, et al. **Thromb Res** 1995 Aug 1;79(3):249–60

[Effect of argatroban on flap survival length] Yamamoto T. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):351–9 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Recombinant hirudin for prevention of experimental postoperative intraocular fibrin. Nasir MA, et al. **Am J Ophthalmol** 1996 May;121(5):554–60

What's in the pipeline? Manuel SM. **Am Pharm** 1995 Sep; NS35(9):8–9

Effects of inogatran, a new low–molecular–weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Gustafsson D, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):69–79

Thrombin inhibition in the acute phase of ischaemic stroke using argatroban. Kario K, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6(5):423–7

Thrombin inhibitors in acute myocardial infarction. Cannon CP. **Cardiol Clin** 1995 Aug;13(3):421–33 (73 ref.)

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial [see comments] Antman EM. **Circulation** 1996 Sep 1;94(5):911–21. Comment in: Circulation 1996 Sep 1;94(5):863–5.

Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Beimond BJ, et al. **Circulation** 1996 Jan 1;93(1):153–60

The 1995 European Society of Cardiology [news] Ferguson JJ 3rd. **Circulation** 1995 Nov 1;92(9):2359–63

Failure of thrombin inhibition to prevent intracoronary thrombosis in the dog. Belcher PR, et al. **Clin Sci (Colch)** 1996 May;90(5):363–8

Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Monreal M, et al. **Drugs Aging** 1996 Mar;8(3):171–82 (52 ref.)

r–hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study. Fox KA. **Eur Heart J** 1995 Jul;16 Suppl D:28–32 (15 ref.)

Recombinant hirudin and front–loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT–I (hirudin for the improvement of thrombolysis). Zeymer U, et al. **Eur Heart J** 1995 Jul;16 Suppl D:22–7

Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives. Agnelli G. **Int J Cardiol** 1995 Aug;49 Suppl:S77–87 (60 ref.)

Effects of napsagatran (Ro 46–6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. Roux S, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):71–8

Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Sarembock IJ, et al. **J Vasc Res** 1996 Jul–Aug;33(4):308–14

Hirudin and thrombosis prophylaxis [comment] Turpie AG. **Lancet** 1996 Mar 9;347(9002):632–3. Comment on: Lancet 1996 Mar 9;347(9002):635–9.

A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. **N Engl J Med** 1996 Sep 12; 335(11):775–82

New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon? Carter CJ. **Postgrad Med** 1996 Jun;99(6):129–36 (22 ref.)

Thrombin functions and antithrombotic intervention. Fenton JW 2nd. **Thromb Haemost** 1995 Jul;74(1):493–8 (63 ref.)

Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Harker LA, et al. **Thromb Haemost** 1995 Jul;74(1):464–72 (80 ref.)

The combination of thrombin inhibitor and thromboxane synthase inhibitor on experimental thrombosis and bleeding. Kawai H, et al. **Thromb Res** 1995 Dec 1;80(5):429–34

[Anticoagulant therapy with recombinant hirudin in patients with thrombopenia induced by heparin] Schiele F, et al. **Presse Med** 1996 May 4–11;25(16):757–60 (Eng. Abstr.) **(Fre)**

ANTITHROMBOTIC AGENTS see **FIBRINOLYTIC AGENTS**

ANTITHYROID AGENTS

ADMINISTRATION & DOSAGE

Response to methimazole in Graves' disease. The European Multicenter Study Group. Benker G, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):257–63

Effect of methimazole treatment of maternal thyrotoxicosis on thyroid function in breast–feeding infants. Azizi F. **J Pediatr** 1996 Jun;128(6):855–8

Is there one successful antithyroid regimen for Graves' disease? Braverman LE. **Lancet** 1996 Sep 14; 348(9029):697–8

[Basedow disease––thyrostatic drugs combined with thyroxine? (news)] von Werder K. **Fortschr Med** 1996 May 20;114(14):6–7 **(Ger)**

[The mechanism of the action of low doses of thyroid hormones on the stressor–induced changes in rat vascular tonus] Solodkov AP, et al. **Fiziol Zh Im I M Sechenova** 1995 Dec;81(12):95–100 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Successful treatment of carbimazole–induced agranulocytosis and severe sepsis with granulocyte macrophage colony stimulating factor. Freebairn RC, et al. **Anaesth Intensive Care** 1995 Aug;23(4):510–2

Association between the DRB1*08032 histocompatibility antigen and methimazole–induced agranulocytosis in Japanese patients with Graves disease. Tamai H, et al. **Ann Intern Med** 1996 Mar 1;124(5):490–4

Aplasia cutis congenita after exposure to methimazole: a causal relationship? Vogt T, et al. **Br J Dermatol** 1995 Dec; 133(6):994–6 (23 ref.)

Antineutrophil cytoplasmic antibody–positive crescentic glomerulonephritis associated with anti–thyroid drug treatment. D'Cruz D, et al. **Br J Rheumatol** 1995 Nov; 34(11):1090–1

Methimazole–induced agranulocytosis treated with recombinant human granulocyte colony–stimulating factor (rhG–CSF): a case report. Chien MN, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Nov;56(5):351–5

ANCA–associated vasculitis and lupus–like syndrome caused by methimazole. Kawachi Y, et al. **Clin Exp Dermatol** 1995 Jul;20(4):345–7

Fulminant hepatitis after carbimazole and propranolol administration. Epeirier JM, et al. **Eur J Gastroenterol Hepatol** 1996 Mar;8(3):287–8

[Acute pancreatitis and propylthiouracil (letter)] Collet T, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):952 **(Fre)**

CHEMISTRY

Atom level electrotopological state indexes in QSAR: designing and testing antithyroid agents. Abou–Shaaban RR, et al. **Pharm Res** 1996 Jan;13(1):129–36

PHARMACOKINETICS

A hyperthyroid patient with Graves' disease who was strongly resistant to methimazole: investigation on possible mechanisms of the resistance. Li H, et al. **Endocr J** 1995 Oct;42(5):697–704

PHARMACOLOGY

An increase in the blood thyroxine level after methylene blue in rats: the interaction with carbimazole. Nedvídková J, et al. **Endocr Res** 1995 Nov;21(4):709–17

Horseradish peroxidase inhibition by thiouracils. Zatón AM, et al. **FEBS Lett** 1995 Oct 30;374(2):192–4

Iodine metabolism in response to goitrogen induced altered thyroid status under conditions of moderate and high intake of iodine. Lakshmy R, et al. **Horm Metab Res** 1995 Oct; 27(10):450–4

The effects of methimazole on haematopoiesis in mice. Mak NK, et al. **Immunopharmacol Immunotoxicol** 1995 Nov; 17(4):745–57

Role of goitrogens in iodine deficiency disorders & brain development. Rao PS, et al. **Indian J Med Res** 1995 Nov; 102:223–6 (16 ref.)

Thyroid hormone is required for dietary fish oil to induce hypersecretion of biliary cholesterol in the rat. Prigge WF, et al. **Lipids** 1995 Sep;30(9):833–8

Methimazole has no dose–related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin–2 receptor, and beta 2–microglobulin in patients with Graves' disease. Escobar–Morreale HF, et al. **Thyroid** 1996 Feb;6(1):29–36

Porphyrin pi–cation and protein radicals in peroxidase catalysis and inhibition by anti–thyroid chemicals. Doerge DR, et al. **Xenobiotica** 1995 Jul;25(7):761–7

[The effect of carbimazole on lactate dehydrogenase isoenzymes and thyroid hormone levels in sheep] Sutiaková I, et al. **Vet Med (Praha)** 1995 Nov;40(11):341–4 (Eng. Abstr.) **(Slo)**

THERAPEUTIC USE

A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti–thyroid drugs. Kawai K, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):551–6

Glucose turnover, fuel oxidation and forearm substrate exchange in patients with thyrotoxicosis before and after medical treatment. Møller N, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):453–9

Active myocardial damage in hyperthyroidism. A concurrent mechanism of heart failure reversed by treatment. Martí V, et al. **Eur Heart J** 1995 Jul;16(7):1014–6

Increased serum interleukin–1 beta during treatment of hyperthyroidism with antithyroid drugs. Tsatsoulis A, et al. **Eur J Clin Invest** 1995 Sep;25(9):654–8

Prophylactic application of thyrostatic drugs during excessive iodine exposure in euthyroid patients with thyroid autonomy: a randomized study. Nolte, et al. **Eur J Endocrinol** 1996 Mar;134(3):337–41

The effect of diltiazem on the manifestations of hyperthyroidism and thyroid function tests. Keleştimur F, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):38–42

Low–dose oral propylthiouracil in the treatment of plaque psoriasis [letter] Elias AR, et al. **Int J Dermatol** 1995 Jul; 34(7):519–20

Epitopes for thyroid–stimulating antibodies in Graves' sera: a possible link of heterogeneity to differences in response to antithyroid drug treatment. Kim WB, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1758–67

Effect of methimazole with or without exogenous L–thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease. Rittmaster RS, et al. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3283–8

Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease. Kallner G, et al. **J Intern Med** 1996 Jun;239(6):525–9

Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug [see comments] McIver B, et al. **N Engl J Med** 1996 Jan 25;334(4):220–4. Comment in: N Engl J Med 1996 Jan 25;334(4):265–6.

Immunosuppression of Graves' hyperthyroidism––still an elusive goal [editorial; comment] Wiersinga WM. **N Engl J Med** 1996 Jan 25;334(4):265–6. Comment on: N Engl J Med 1996 Jan 25;334(4):220–4.

Successful treatment of recurrent non–immune hydrops secondary to fetal hyperthyroidism. Treadwell MC, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):838–40

[Treatment of hyperthyroidism with antithyroid drugs] Eber O. **Acta Med Austriaca** 1995;22(5):83–90 (21 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of Basedow–Graves disease in pregnancy] Konrády A. **Orv Hetil** 1995 Dec 10;136(50):2721–5 (Eng. Abstr.) **(Hun)**

TOXICITY

Developmental exposure to polychlorinated biphenyls (Aroclor 1254) reduces circulating thyroid hormone concentrations and causes hearing deficits in rats. Goldey ES, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):77–88

Alterations in rat brain thyroid hormone status following pre- and postnatal exposure to polychlorinated biphenyls (Aroclor 1254). Morse DC, et al. **Toxicol Appl Pharmacol** 1996 Feb;136(2):269–79

Olfactory toxicity of methimazole: dose–response and structure–activity studies and characterization of flavin–containing monooxygenase activity in the Long–Evans rat olfactory mucosa. Genter MB, et al. **Toxicol Pathol** 1995 Jul–Aug;23(4):477–86

ANTITOXINS

ADVERSE EFFECTS

Comment: leucovorin–phenytoin: a drug–drug interaction? [letter; comment] Tidwell BH, et al. **Ann Pharmacother** 1995 Dec;29(12):1303–4. Comment on: Ann Pharmacother 1995 Jul–Aug;29(7–8):726–35. Comment on: Ann Pharmacother 1995 Jul–Aug;29(7–8):760–8.

IMMUNOLOGY

Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin. Horowitz NS, et al. **Immunopharmacology** 1995 Nov;31(1):31–41

THERAPEUTIC USE

Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Leung DY. **Clin Exp Immunol** 1996 May;104 Suppl 1:49–54 (41 ref.)

Prophylactic and therapeutic efficacy of an avian antitoxin in ricin intoxication. Lemley PV, et al. **Ther Immunol** 1995 Apr;2(2):59–66

ANTITRICHOMONAL AGENTS

Determination of metronidazole in vaginal tissue by high–performance liquid chromatography using solid–phase extraction. Venkateshwaran TG, et al. **J Chromatogr B Biomed Appl** 1995 Oct 20;672(2):300–4

ADMINISTRATION & DOSAGE

An incremental dosing protocol for women with severe vaginal trichomoniasis and adverse reaction to metronidazole. Pearlman MD, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):934–6

Use of cefotaxime and metronidazole for treating cerebral abscesses [letter; comment] Gómez J, et al. **Clin Infect Dis** 1995 Sep;21(3):708. Comment on: Clin Infect Dis 1993 Nov;17(5):857–63.

Preliminary efficacy study of a bioadhesive vaginal metronidazole tablet in the treatment of bacterial vaginosis [letter] Bouckaert S, et al. **J Pharm Pharmacol** 1995 Nov; 47(11):970–1

Preparation and characterization of freeze–dried chitosan–poly(ethylene oxide) hydrogels for site–specific antibiotic delivery in the stomach. Patel VR, et al. **Pharm Res** 1996 Apr;13(4):588–93

[New guidelines from the Medical Products Agency: the triple regime against Helicobacter pylori is necessary. Treat only if the ulcer is verified] Blomgren K, et al. **Lakartidningen** 1996 Mar 13;93(11):1041–2, 1045 **(Swe)**

ADVERSE EFFECTS

Contact dermatitis from usnic acid in vaginal ovules. Rafanelli S, et al. **Contact Dermatitis** 1995 Oct;33(4):271–2

Metronidazole extravasation causing digital gangrene [letter] Bharani A, et al. **Indian J Physiol Pharmacol** 1995 Jul; 39(3):307–8

ANALYSIS

Simultaneous quantitative determination of metronidazole and nalidixic acid in tablets by difference spectroscopy. Parimoo P, et al. **J Pharm Biomed Anal** 1996 Feb; 14(4):389–93

CHEMISTRY

Stability of metronidazole and ceftizoxime sodium in ready–to–use metronidazole bags stored at 4 and 25 degrees C. Nahata MC, et al. **Am J Health Syst Pharm** 1996 May 1;53(9):1046–8

Stability of ceftizoxime sodium, ceftriaxone sodium, and ceftazidime with metronidazole in ready–to–use metronidazole bags. Rivers TE, et al. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2568–70

METABOLISM

Bacterial mutagens in the urine of patients under tinidazole treatment. Espinosa–Aguirre JJ, et al. **Mutat Res** 1996 Feb 29;359(2):133–40

PHARMACOKINETICS

Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? Cooke CE, et al. **Ann Pharmacother** 1996 Apr;30(4):364–6

Pharmacodynamics of metronidazole determined by a time–kill assay for Trichomonas vaginalis. Nix DE, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1848–52

PHARMACOLOGY

Propionylcarnitine excretion is not affected by metronidazole administration to patients with disorders of propionate metabolism. Burns SP, et al. **Eur J Pediatr** 1996 Jan; 155(1):31–5

An in vitro metronidazole susceptibility test for trichomoniasis using the InPouch TV test. Borchardt KA, et al. **Genitourin Med** 1996 Apr;72(2):132–5

In vitro activity of metronidazole alone and in combination with clotrimazole against clinical isolates of Trichomonas vaginalis. Debbia EA, et al. **J Chemother** 1996 Apr; 8(2):96–101

[Effect of Cladonia alpestris on Trichomonas vaginalis in vitro] Wu J, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):126–9 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double–blind, randomized trial. Bell GD, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):513–20

High effectiveness and safety of one–week antibiotic regimen in Helicobacter pylori eradication. Dalla Libera M, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):203–6

One–week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. Labenz J, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):207–10

Triple therapy with sucralfate, amoxycillin and metronidazole for healing duodenal ulcer and eradicating Helicobacter pylori infection. Stupnicki T, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):193–7

Use of prophylactic tinidazole to avoid the serious infections associated with total abdominal hysterectomy. Mittendorf R, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug;35(3):314–5

Bacteriological epidemiology and treatment of bacterial vaginosis. Mikamo H, et al. **Chemotherapy** 1996 Jan–Feb; 42(1):78–84

A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea. Signore RJ. **Cutis** 1995 Sep;56(3):177–9

Cefotaxime and metronidazole in severe intra–abdominal infection. Aprahamian C, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):183–8

Cephalosporin–metronidazole combinations in the management of intra–abdominal infections. Nicolau DP, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun; 22(1–2):189–94 (28 ref.)

Evaluation of a new bismuth–free triple therapy in nude mice and humans. Karita M, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S31–4

Chronic intestinal giardiasis with isolated levothyroxine malabsorption as reason for severe hypothyroidism—implications for localization of thyroid hormone absorption in the gut. Seppel T, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):180–2

Sexually acquired metronidazole–resistant trichomoniasis in a lesbian couple. Kellock D, et al. **Genitourin Med** 1996 Feb;72(1):60–1

Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Ching CK, et al. **Gut** 1996 May;38(5):675–8

A comparative clinical trial of albendazole versus metronidazole in children with giardiasis. Misra PK, et al. **Indian Pediatr** 1995 Jul;32(7):779–82

A comparative clinical trial of albendazole versus metronidazole in giardiasis. Misra PK, et al. **Indian Pediatr** 1995 Mar;32(3):291–4

Acne rosacea and Helicobacter pylori betrothed [letter] Wolf R. **Int J Dermatol** 1996 Apr;35(4):302–3

Treatment of vaginitis. Kükner S, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):43–7

Antimicrobial resistance and Helicobacter pylori. Goddard AF, et al. **J Antimicrob Chemother** 1996 Apr;37(4):639–43

Prevention and treatment of low–grade B–cell primary gastric lymphoma by anti–H. pylori therapy. Cammarota G, et al. **J Clin Gastroenterol** 1995 Sep;21(2):118–22

Bacterial vaginosis. Spaulding C. **J Fam Pract** 1995 Dec; 41(6):605–6

One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients. Sito E, et al. **J Physiol Pharmacol** 1996 Mar; 47(1):221–8

Single–dose secnidazole versus 10–day metronidazole therapy of giardiasis in Iranian children [letter] Rastegar–Lari A, et al. **J Trop Pediatr** 1996 Jun;42(3):184–5

Paromomycin for nitroimidazole–resistant trichomonosis [letter] Nyirjesy P, et al. **Lancet** 1995 Oct 21;346(8982):1110

Using metronidazole (Flagyl) for odor control. Melious N. **Oncol Nurs Forum** 1995 Jul;22(6):987–8

Metronidazole: utilization in the obstetric and gynecologic patient. Schwebke JR. **Sex Transm Dis** 1995 Nov–Dec; 22(6):370–6 (84 ref.)

[Amebic abscess of the liver: ultrasound guided puncture] Pham Van L, et al. **Ann Chir** 1996;50(4):340–3 (Eng. Abstr.) **(Fre)**

ANTITRUST LAWS

Physician–run health plans and antitrust. American College of Physicians. **Ann Intern Med** 1996 Jul 1;125(1):59–65 (20 ref.)

The saga of the Marshfield Clinic case [news] **Hosp Health Netw** 1995 Nov 20;69(22):22

What is a conspiracy? [letter; comment] Kantz WE. **J Am Dent Assoc** 1995 Dec;126(12):1598. Comment on: J Am Dent Assoc 1995 Oct;126(10):1438–9.

Insurance exemption to the antitrust laws. Sfikas PM. **J Am Dent Assoc** 1995 Dec;126(12):1674–7

What is restraint of trade? A review of the nation's antitrust laws. Sfikas PM. **J Am Dent Assoc** 1995 Nov; 126(11):1547–9

What is a conspiracy? A review of the nation's antitrust laws [see comments] Sfikas PM. **J Am Dent Assoc** 1995 Oct; 126(10):1438–9. Comment in: J Am Dent Assoc 1995 Dec;126(12):1598.

Impact of antitrust laws on physician networking and rural communities. Ross–Lee B, et al. **J Am Osteopath Assoc** 1995 Nov;95(11):670–5

And the answer is ... "sorry, but being excluded from participation in a managed care plan probably isn't an antitrust violation". Berg RN. **J Med Assoc Ga** 1996 Apr; 85(2):99–100

Price competition, professional cooperation and standards. Arnold PC. **Med J Aust** 1996 Sep 2;165(5):272–3

DSSNY, managed care and antitrust laws. A marriage of necessity. Plunkett LR. **N Y State Dent J** 1996 May; 62(5):8–11

The antitrust question: a new perspective. Orlowski SR. **Pa Med** 1996 Jun;99(6):16–7

Hope for antitrust relief. Besaw L. **Tex Med** 1996 Jun; 92(6):26–9

Physician practice mergers. Part II: The antitrust implications of a merger. Sinclair SE. **Va Med Q** 1995 Fall;122(4):284–9

ANTITRUST LIABILITY see **ANTITRUST LAWS**

ANTITUBERCULAR AGENTS

see related
TUBERCULOSIS, MULTIDRUG–RESISTANT

Improvised drug package for tuberculosis patients [letter] Johnson JL, et al. **Lancet** 1996 Mar 23;347(9004):834

[Status quo of pyrazinamide as an antituberculosis drug] Kameda K. **Kekkaku** 1995 Jul;70(7):445–55 (80 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Development of multidrug resistant tuberculosis following supervised care: a case for directly observed therapy [letter] Abel SJ, et al. **Aust N Z J Med** 1996 Apr;26(2):228–9

Directly observed treatment for tuberculosis. Treatment strategies will need to be changed because of drug resistance [letter; comment] Friedland JS, et al. **BMJ** 1996 Jul 6;313(7048):45–6. Comment on: BMJ 1996 Mar 23;312(7033):719–20.

Corticosteroids in the treatment of tuberculous pleurisy. A double–blind, placebo–controlled, randomized study. Wyser C, et al. **Chest** 1996 Aug;110(2):333–8

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Kennedy N, et al. **Clin Infect Dis** 1996 May;22(5):827–33

Results of directly observed short–course chemotherapy in 112,842 Chinese patients with smear–positive tuberculosis. China Tuberculosis Control Collaboration [see comments] **Lancet** 1996 Feb 10;347(8998):358–62. Comment in: Lancet 1996 Mar 23;347(9004):835. Comment in: Lancet 1996 Mar 23;347(9004):835–6.

Tuberculosis control policy in Nepal [letter; comment] Bam DS, et al. **Lancet** 1995 Oct 14;346(8981):1043. Comment on: Lancet 1995 Aug 5;346(8971):328.

Lessons to be learned from tuberculosis control in China [letter; comment] Squire SB, et al. **Lancet** 1996 Mar 23; 347(9004):835–6. Comment on: Lancet 1996 Feb 10;347(8998):358–62.

Lessons to be learned from tuberculosis control in China [letter; comment] Wilkinson D, et al. **Lancet** 1996 Mar 23; 347(9004):835. Comment on: Lancet 1996 Feb 10;347(8998):358–62.

"Kits' of anti–tubercular drugs [letter] Aggarwal P, et al. **Natl Med J India** 1996 May–Jun;9(3):143–4

Tuberculosis Control Programme Practical Guidelines, 1996—treatment regimens [letter] Peto RJ, et al. **S Afr Med J** 1996 May;86(5):560, 562

Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy [letter; comment] Campbell IA. **Tuber Lung Dis** 1995 Dec; 76(6):583. Comment on: Tuber Lung Dis 1995 Apr;76(2):104–8.

Impact of the change from an injectable to a fully oral regimen on patient adherence to ambulatory tuberculosis treatment in Dar es Salaam, Tanzania. Chum HJ, et al. **Tuber Lung Dis** 1995 Aug;76(4):286–9

Directly observed intermittent short–course chemotherapy

in the Kathmandu valley. Neher A, et al. **Tuber Lung Dis** 1996 Aug;77(4):302–7

A controlled clinical trial of short-course chemotherapy for tuberculoma of the brain. Rajeswari R, et al. **Tuber Lung Dis** 1995 Aug;76(4):311–7

Drug-resistant Mycobacterium tuberculosis in California, 1991 to 1992. Koo D, et al. **West J Med** 1995 Nov; 163(5):441–5

[Chest radiograph in assessing the results of treatment with 6-month short-course chemotherapy of pulmonary tuberculosis] Su J, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Jun; 18(3):173–4, 191–2 (Eng. Abstr.) **(Chi)**

[Controversy over tuberculosis therapy in HIV infected patients. Isoniazide therapy--brief chemotherapy (news)] Arnheim K. **Fortschr Med** 1995 Dec 20;113(35–36):14–5 **(Ger)**

[Interesting case of pulmonary alveolar proteinosis] Nakamura Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1909–11 **(Jpn)**

[Analysis of course and treatment results after treatment of pulmonary tuberculosis with early introduction of interrupted observation--preliminary report] Sedlaczek AM, et al. **Pneumonol Alergol Pol** 1995;63(5–6):293–7 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Antituberculous drugs and hepatotoxicity [letter; comment] Nishioka S de A. **Am J Gastroenterol** 1996 Jul;91(7):1471–2 . Comment on: Am J Gastroenterol 1995 Nov;90(11):1978–80.

Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients [see comments] Ozick LA, et al. **Am J Gastroenterol** 1995 Nov;90(11):1978–80. Comment in: Am J Gastroenterol 1996 Jul;91(7):1471–2.

Oxidative stress during antituberculous therapy in young and elderly patients. Walubo A, et al. **Biomed Environ Sci** 1995 Jun;8(2):106–13

PZA hypersensitivity [letter] Shorr AF, et al. **Chest** 1996 Mar;109(3):855–6

A death associated with therapy for nosocomially acquired multidrug-resistant tuberculosis [see comments] Weltman AC, et al. **Chest** 1996 Jul;110(1):279–81. Comment in: Chest 1996 Jul;101(1):8–9.

Toxic effects and drug interactions of antimycobacterial therapy. Chan-Tompkins NH. **Clin Dermatol** 1995 May-Jun;13(3):223–33 (99 ref.)

Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction. Yew WW, et al. **Drugs Exp Clin Res** 1995;21(2):79–83

The dark side of antituberculosis therapy: adverse events involving liver function [editorial; comment] Schaberg T. **Eur Respir J** 1995 Aug;8(8):1247–9. Comment on: Eur Respir J 1995 Aug;8(8):1384–8.

Anti-tuberculosis medication and the liver: dangers and recommendations in management [see comments] Thompson NP, et al. **Eur Respir J** 1995 Aug;8(8):1384–8 (39 ref.). Comment in: Eur Respir J 1995 Aug;8(8):1247–9.

Anti-tuberculosis drugs and liver toxicity [letter] Yew WW, et al. **Eur Respir J** 1996 Feb;9(2):389–90

Jaundice due to anti-tuberculous drugs--a dose related phenomenon. Mirchandani LV, et al. **J Assoc Physicians India** 1995 Nov;43(11):767–9

Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. Singh J, et al. **J Clin Gastroenterol** 1996 Apr;22(3):211–4

Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin. Chan CH, et al. **J Med** 1995;26(1–2):43–52

Visual function in recovered ethambutol optic neuropathy. Woung LC, et al. **J Ocul Pharmacol Ther** 1995 Fall; 11(3):411–9

Treatment of tuberculosis in developing countries [letter; comment] Elliott AM, et al. **Lancet** 1995 Oct 21; 346(8982):1098–9. Comment on: Lancet 1995 Sep 9;346(8976):657–60.

Alopecia side-effect of antituberculosis drugs [letter] FitzGerald JM, et al. **Lancet** 1996 Feb 17;347(8999):472

Treatment of tuberculosis in developing countries [letter; comment] Pozniak A. **Lancet** 1995 Oct 21;346(8982):1099 . Comment on: Lancet 1995 Sep 9;346(8976):657–60.

Suspected ethambutol-induced mania [letter] Pickles RW, et al. **Med J Aust** 1996 Apr 1;164(7):445–6

Hepatotoxic effects of tuberculosis therapy. A practical approach to a tricky management problem. Ali J. **Postgrad Med** 1996 May;99(5):217–20, 230–1, 235–6

HIV medicine: drug side effects and interactions. Bates CM. **Postgrad Med J** 1996 Jan;72(843):30–6 (27 ref.)

Study of paradoxical response to chemotherapy in tuberculous pleural effusion. Al-Majed SA. **Respir Med** 1996 Apr;90(4):211–4

Phenytoin toxicity due to concomitant antituberculosis therapy. Walubo A, et al. **S Afr Med J** 1995 Nov; 85(11):1175–6

Hepatotoxicity of antituberculosis drugs [letter] Kahana LM. **Thorax** 1996 Aug;51(8):873–4

Hepatotoxicity of antituberculosis drugs [editorial] Ormerod LP, et al. **Thorax** 1996 Feb;51(2):111–3

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Pande JN, et al. **Thorax** 1996 Feb; 51(2):132–6

Liver injury during antituberculosis treatment: an 11-year study. Døssing M, et al. **Tuber Lung Dis** 1996 Aug; 77(4):335–40

Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection [see comments] Elliott AM, et al. **Tuber Lung Dis** 1996 Feb; 77(1):27–9. Comment in: Tuber Lung Dis 1996 Feb;77(1):30–6.

Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Ormerod LP, et al. **Tuber Lung Dis** 1996 Feb;77(1):37–42

Rebuttal: time to call a halt to emotions in the assessment of thioacetazone. Rieder HL, et al. **Tuber Lung Dis** 1996 Apr;77(2):109–11

Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya [see comments] van Gorkom J, et al. **Tuber Lung Dis** 1996 Feb;77(1):30–6. Comment in: Tuber Lung Dis 1996 Feb;77(1):27–9.

Isoniazid-related fatal hepatitis. Millard PS, et al. **West J Med** 1996 Jun;164(6):486–91

ANALYSIS

High-performance liquid chromatographic analysis of the antituberculosis drugs aconiazide and isoniazid. Hansen EB Jr, et al. **J Chromatogr B Biomed Appl** 1995 Aug 18; 670(2):259–66

ANTAGONISTS & INHIBITORS

Resistance to antituberculosis drugs [letter] Tayler E. **Lancet** 1996 Sep 7;348(9028):688

BLOOD

Rapid, specific and sensitive method for isoniazid determination in serum. Sadeg N, et al. **J Chromatogr B Biomed Appl** 1996 Jan 12;675(1):113–7

Determination of pyrazinamide in human by high performance liquid chromatography. Revankar SN, et al. **J Postgrad Med** 1994 Jan-Mar;40(1):7–9

[Antituberculosis drug] Goromaru T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1002–5 (19 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

In vitro antimycobacterial activities of pyrazinamide analogs. Yamamoto S, et al. **Antimicrob Agents Chemother** 1995 Sep; 39(9):2088–91

Studies on pyrazine derivatives, XXIX: Synthesis of N1-thioamido substituted pyrazincarboxyamidrazones with expected tuberculostatic activity. Orlewska C, et al. **Pharmazie** 1995 Aug;50(8):565–6

CHEMISTRY

Stability of pyrazinamide in two suspensions. Nahata MC, et al. **Am J Health Syst Pharm** 1995 Jul 15;52(14):1558–60

ECONOMICS

The supply of antituberculosis drugs: price evolution. Chaulet P. **Tuber Lung Dis** 1995 Jun;76(3):261–3

PHARMACOKINETICS

Drug diffusion through cystic fibrotic mucus: steady-state permeation, rheologic properties, and glycoprotein morphology. Bhat PG, et al. **J Pharm Sci** 1996 Jun; 85(6):624–30

A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease. Wenning GK, et al. **Mov Disord** 1995 Sep; 10(5):664–7

Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Elliott AM, et al. **Tuber Lung Dis** 1995 Oct;76(5):463–7

PHARMACOLOGY

Potential interaction between isoniazid and selective serotonin-reuptake inhibitors [letter] Evans ME, et al. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2135–6

Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Cavalieri SJ, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1542–5

High-throughput screen for detecting antimycobacterial agents. Chung GA, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2235–8

Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex. Ellis LC, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2803–6

Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Mikušová K, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2484–9

Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Mor N, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2073–7

Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Ohno H, et al. **Antimicrob Agents Chemother** 1996 Apr; 40(4):1053–6

Mutations in katG gene sequences in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis are rare. Pretorius GS, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2276–81

Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Rouse DA, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2472–7

In vitro antimycobacterial activities of pyrazinamide analogs. Yamamoto S, et al. **Antimicrob Agents Chemother** 1995 Sep; 39(9):2088–91

Study on Mycobacterium tuberculosis: the primary drug resistance pattern. Siddique MA, et al. **Bangladesh Med Res Counc Bull** 1995 Apr;21(1):18–23

Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. Wanwimolruk S, et al. **Br J Clin Pharmacol** 1995 Jul; 40(1):87–91

Primary drug resistant tuberculosis in the Central Chest Clinic, Colombo. Perera J, et al. **Ceylon Med J** 1996 Jun; 41(2):51–4

Drug susceptibility of Mycobacterium tuberculosis isolates from a cohort of Haitian migrants evaluated in 1994 [letter; comment] Rusnak J, et al. **Clin Infect Dis** 1995 Oct; 21(4):1066. Comment on: Clin Infect Dis 1994 Nov;19(5):938–40.

Evaluation of mycobacteria growth indicator tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin. Reisner BS, et al. **Diagn Microbiol Infect Dis** 1995 Aug;22(4):325–9

Rapid drug susceptibility testing of Mycobacterium tuberculosis using conventional solid media. Schaberg T, et al. **Eur Respir J** 1995 Oct;8(10):1688–93

Effect of antituberculous drugs, isoniazid, pyrazinamide and rifampicin, on chemiluminescence of the human polymorphonuclear leukocytes. Demkow U, et al. **Folia Biol (Praha)** 1995;41(5):257–62

Overproduction of mycobacterial ribosomal protein S13 induces catalase/peroxidase activity and hypersensitivity to isoniazid in Mycobacterium smegmatis. Dubnau E, et al. **Gene** 1996 Apr 17;170(1):17–22

Effects of isoniazid treatment on human lymphocyte proliferative response, lymphocyte subsets and natural killer cell activity. Ravn P, et al. **Immunopharmacology** 1995 Sep;30(3):247–53

Short course chemotherapy in childhood tuberculosis [editorial] Chopra K. **Indian Pediatr** 1995 Jun;32(6):625–8 (10 ref.)

Rifampin-resistant, isoniazid-susceptible TB in HIV patients [news] Pugliese G. **Infect Control Hosp Epidemiol** 1995 Nov;16(11):622

Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. Miller MA, et al. **J Clin Microbiol** 1995 Sep;33(9):2468–70

Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. Yajko DM, et al. **J Clin Microbiol** 1995 Sep;33(9):2324–7

Initial and acquired drug resistance of Mycobacterium tuberculosis in east Delhi. Mahajan M, et al. **J Commun Dis** 1996 Mar;28(1):15–9

Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. Musser JM, et al. **J Infect Dis** 1996 Jan; 173(1):196–202

Potentiation of the effects of chlorhexidine diacetate and cetylpyridinium chloride on mycobacteria by ethambutol. Broadley SJ, et al. **J Med Microbiol** 1995 Dec;43(6):458–60

Evaluation of inhA gene and catalase-peroxidase gene among isoniazid-sensitive and resistant Mycobacterium tuberculosis isolates. O'Brien KL, et al. **Mol Cell Probes** 1996 Feb;10(1):1–6

Antimycobacterial activities of antisense oligodeoxynucleotide phosphorothioates in drug-resistant strains. Rapaport E, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):709–13

Glycosyltransferases as targets for inhibition of cell wall synthesis in M. tuberculosis and M. avium. Maddry JA, et al. **Res Microbiol** 1996 Jan-Feb;147(1–2):106–12 (25 ref.)

The structure and function of the isoniazid target in M. tuberculosis. Sacchettini JC, et al. **Res Microbiol** 1996 Jan-Feb;147(1–2):36–43 (29 ref.)

Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Sherman DR, et al. **Science** 1996 Jun 14;272(5268):1641–3

[Biological properties of Mycobacterium tuberculosis in relation to sensitivity to antibacterial preparations] Gol'shevskaia VI, et al. **Probl Tuberk** 1995;(4):37–40 (Eng. Abstr.) **(Rus)**

[Resistance of Mycobacterium tuberculosis in the province of Castellón] Moreno R, et al. **Arch Bronconeumol** 1996 Mar;32(3):118–21 (Eng. Abstr.) **(Spa)**

[Resistance of Mycobacterium tuberculosis in Mexican patients. I. Clinical features and risk factors] Sifuentes-Osornio J, et al. **Rev Invest Clin** 1995 Jul-Aug; 47(4):273–81 (Eng. Abstr.) **(Spa)**

POISONING

Acute isoniazid intoxication: a case report. Chang YD, et

al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Feb; 57(2):152–6

Isoniazid overdose: four case reports and review of the literature. Alvarez FG, et al. **Intensive Care Med** 1995 Aug; 21(8):641–4 (28 ref.)

Acute isoniazid neurotoxicity in an urban hospital [letter; comment] Kurbasic MP, et al. **Pediatrics** 1996 May; 97(5):782. Comment on: Pediatrics 1995 May;95(5):700–4.

Isoniazid neurotoxicity [letter; comment] Lewin PK. **Pediatrics** 1996 May;97(5):782–3. Comment on: Pediatrics 1995 May;95(5):700–4.

Hypoglycaemia in convalescent tuberculous children [letter] Gibson J. **Trop Doct** 1996 Apr;26(2):86–7

Treatment of acute isoniazid overdose in dogs. Villar D, et al. **Vet Hum Toxicol** 1995 Oct;37(5):473–7 (50 ref.)

THERAPEUTIC USE

When public health competes with individual needs. Schmidt TA. **Acad Emerg Med** 1995 Mar;2(3):217–22

Tuberculosis presenting as immune thrombocytopenic purpura. al-Majed SA, et al. **Acta Haematol** 1995; 94(3):135–8

Preventive therapy for tuberculosis in HIV infection: the promise and the reality [editorial] O'Brien RJ, et al. **AIDS** 1995 Jul;9(7):665–73 (83 ref.)

Outpatient management of tuberculosis [see comments] McColloster P, et al. **Am Fam Physician** 1996 Apr; 53(5):1579–94 (12 ref.). Comment in: Am Fam Physician 1996 Apr;53(5):1511–2.

Directly observed therapy for tuberculosis: the Harlem Hospital experience, 1993. el-Sadr W, et al. **Am J Public Health** 1996 Aug;86(8 Pt 1):1146–9

Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994 [see comments] Wilkinson D, et al. **Am J Public Health** 1996 Aug;86(8 Pt 1):1094–7. Comment in: Am J Public Health 1996 Aug;86(8 Pt 1):1071–3.

Relationship of isoniazid resistance to human immunodeficiency virus infection in patients with tuberculosis [see comments] Asch S, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1708–10. Comment in: Am J Respir Crit Care Med 1996 May;153(5):1472–3.

We reap what we sow [editorial] [see comments] Sbarbaro JA. **Am J Respir Crit Care Med** 1996 May;153(5):1472–3 . Comment in: Am J Respir Crit Care Med 1996 May;153(5):1708–10.

Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. The Makerere University-Case Western Reserve University Research Collaboration. Whalen C, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1977–81

Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice. Bermudez LE, et al. **Antimicrob Agents Chemother** 1996 Apr; 40(4):1033–5

Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Graham NM, et al. **Arch Intern Med** 1996 Apr 22;156(8):889–94

Isoniazid preventive therapy in areas of high isoniazid resistance [letter; comment] Moulding T. **Arch Intern Med** 1996 Mar 25;156(6):685–6. Comment on: Arch Intern Med 1995 Aug 7–21;155(15):1622–8.

Benefits of isoniazid preventive therapy [letter; comment] Rose DN. **Arch Intern Med** 1996 Mar 25;156(6):684–5. Comment on: Arch Intern Med 1995 Aug 7–21;155(15):1622–8.

Isoniazid preventive therapy [letter; comment] Salpeter SR. **Arch Intern Med** 1996 Apr 8;156(7):811. Comment on: Arch Intern Med 1995 Aug 7–21;155(15):1622–8.

Prophylaxis for tuberculosis in Europe—ongoing research. Carosi G, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S55–60 (31 ref.)

Predictors and outcome of multidrug-resistant tuberculosis. Salomon N, et al. **Clin Infect Dis** 1995 Nov;21(5):1245–52

Improved outcomes for patients with multidrug-resistant tuberculosis. Turett GS, et al. **Clin Infect Dis** 1995 Nov; 21(5):1238–44

Drug-resistant tuberculosis in northern Germany: a retrospective hospital-based study of 1,055 patients from 1984 until 1993 [see comments] Borchardt J, et al. **Eur Respir J** 1995 Jul;8(7):1076–83. Comment in: Eur Respir J 1995 Jul;8(7):1073–5.

Drug resistant tuberculosis: back to sanatoria, surgery and cod-liver oil? [editorial; comment] Veen J. **Eur Respir J** 1995 Jul;8(7):1073–5. Comment on: Eur Respir J 1995 Jul;8(7):1076–83. Comment on: Eur Respir J 1995 Jul;8(7):1184–92.

Drug-resistant tuberculosis in the 1990s [see comments] Yew WW, et al. **Eur Respir J** 1995 Jul;8(7):1184–92 (103 ref.) . Comment in: Eur Respir J 1995 Jul;8(7):1073–5.

Drug-resistant pulmonary tuberculosis [letter; comment] Zellweger JP. **Eur Respir J** 1995 Jun;8(6):1067. Comment on: Eur Respir J 1995 Feb;8(2):278–84.

Drug resistance in Mycobacterium tuberculosis. Cole ST, et al. **Eur Respir J Suppl** 1995 Sep;20:701s–713s (116 ref.)

New drugs for tuberculosis. Grassi C, et al. **Eur Respir J Suppl** 1995 Sep;20:714s–718s (73 ref.)

Transient tuberculous constrictive pericarditis. Gupta S, et al. **Indian Heart J** 1996 Jan–Feb;48(1):65–7

Intracranial tuberculoma manifesting during treatment. Ajay SK, et al. **Indian Pediatr** 1996 Mar;33(3):231–3

Chemotherapy for tuberculosis. Rajeshwari K. **Indian Pediatr** 1995 Aug;32(8):944–5

Alternatives to INH chemoprophylaxis [letter; comment] Sane SV, et al. **Indian Pediatr** 1995 Aug;32(8):935–7. Comment on: Indian Pediatr 1995 Jan;32(1):105.

Is INH alone enough for prophylaxis [letter] [see comments] Sanklecha MU, et al. **Indian Pediatr** 1995 Jan;32(1):105. Comment in: Indian Pediatr 1995 Aug;32(8):935–7.

Chemotherapy for tuberculosis. American Thoracic Society. Singh V. **Indian Pediatr** 1995 Aug;32(8):943–4

Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. Gourevitch MN, et al. **J Addict Dis** 1996;15(1):93–104

Evolution of a tubercular abscess on prolonged antitubercular treatment. Gupta PK, et al. **J Assoc Physicians India** 1996 Jan;44(1):67–8

Treatment of multidrug-resistant tuberculosis. Cohn DL. **J Hosp Infect** 1995 Jun;30 Suppl:322–8

Present-day management of pulmonary tuberculosis. Kundu AK, et al. **J Indian Med Assoc** 1995 Apr;93(4):144–8 (2 ref.)

Treatment of Myocardium avium complex infection: does the beige mouse model predict therapeutic outcome in humans? Sison JP, et al. **J Infect Dis** 1996 Mar;173(3):750–3

Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin. Chan CH, et al. **J Med** 1995;26(1–2):43–52

A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up. Punnotok J, et al. **J Med Assoc Thai** 1995 Jun;78(6):298–304

CD4 + T counts with a course of antituberculous therapy in healthy and HIV-infected patients. Saenghirunvattana S. **J Med Assoc Thai** 1996 Apr;79(4):246–8

Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals. Saenghirunvattana S. **J Med Assoc Thai** 1996 May; 79(5):285–7

Management of the obstetric patient with tuberculosis. Simpkins SM, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):305–12

Tuberculosis: diagnosis and treatment of resurgent disease. Strull GE, et al. **J Oral Maxillofac Surg** 1995 Nov; 53(11):1334–40 (23 ref.)

An outbreak of bovine tuberculosis in two herds in south west Scotland—veterinary and human public health response. Chalmers JW, et al. **J Public Health Med** 1996 Mar;18(1):54–8

Tuberculosis control policy in Nepal [letter; comment] Aoki M, et al. **Lancet** 1995 Oct 14;346(8981):1043–4. Comment on: Lancet 1995 Aug 5;346(8971):328.

Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi. Harries AD, et al. **Lancet** 1996 Mar 23; 347(9004):807–9

Treatment of tuberculosis in developing countries [letter] van Bogaert LJ. **Lancet** 1995 Oct 21;346(8982):1099–100

The most restrictive alternative. O'Connell J. **Med Health R I** 1996 Jan;79(1):35–6

Long-term treatment of pulmonary tuberculosis with ofloxacin in a subject with liver cirrhosis [see comments] Bagnato GF, et al. **Monaldi Arch Chest Dis** 1995 Aug; 50(4):279–81. Comment in: Monaldi Arch Chest Dis 1996 Apr;51(2):159–60.

Multidrug-resistant tuberculosis [letter; comment] Carlos L, et al. **N Engl J Med** 1996 Jan 25;334(4):267–8; discussion 268–9. Comment on: N Engl J Med 1995 Oct 5;333(14):907–11.

Multidrug-resistant tuberculosis [letter; comment] Iseman MD, et al. **N Engl J Med** 1996 Jan 25;334(4):267; discussion 268–9. Comment on: N Engl J Med 1995 Oct 5;333(14):907–11.

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group [see comments] Shafran SD, et al. **N Engl J Med** 1996 Aug 8;335(6):377–83 . Comment in: N Engl J Med 1996 Aug 8;335(6):428–30.

Whither the roles of rifater and rifamate? McConville JH. **Pa Med** 1996 Mar;99(3):24–5

Medical-surgical treatment of progressive tuberculous (Pott's) paraplegia in Gabon. Loembe PM. **Paraplegia** 1995 Oct;33(10):579–84

Tuberculous inguinal lymphadenitis. Challapalli M, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):723–4 (5 ref.)

Solving the dilemma of antimycobacterial chemotherapy. Rastogi N, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):7–10 (30 ref.)

The chemotherapy of tuberculosis—from the past to the future. Collazos J, et al. **Respir Med** 1995 Aug;89(7):463–9 (68 ref.)

Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. Botha FJ, et al. **S Afr Med J** 1996 Feb; 86(2):155–8

Control strategies for tuberculosis epidemics: new models for old problems. Blower SM, et al. **Science** 1996 Jul 26; 273(5274):497–500

Nutritional status and weight gain in patients with pulmonary tuberculosis in Tanzania. Kennedy N, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr;90(2):162–6

Importance of surveillance mycobacterial cultures after liver transplantation. Torre-Cisneros J, et al. **Transplantation** 1995 Nov 15;60(9):1054–5

Multi drug resistant tuberculosis. Dey AB, et al. **Trop Gastroenterol** 1995 Apr–Jun;16(2):92–100 (39 ref.)

Investigation into typical and atypical tuberculin sensitivity in the Royal Netherlands Army, resulting in a more rational indication for isoniazid prophylaxis. Bruins J, et al. **Tuber Lung Dis** 1995 Dec;76(6):540–4

Short course chemoprophylaxis with rifampicin, isoniazid and pyrazinamide for tuberculosis evaluated in gold miners with chronic silicosis: a double-blind placebo controlled trial. Cowie RL. **Tuber Lung Dis** 1996 Jun;77(3):239–43

Ethambutol versus streptomycin during the hospitalized intensive phase of tuberculosis treatment in Benin [letter] Gninafon M, et al. **Tuber Lung Dis** 1995 Aug;76(4):373–4

Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational randomized comparative study versus rifampicin [letter; comment] Gupta ML, et al. **Tuber Lung Dis** 1995 Dec;76(6):582–3. Comment on: Tuber Lung Dis 1994 Oct;75(5):341–7.

Rapid changes in thyroid function tests upon treatment of tuberculosis. Hill AR, et al. **Tuber Lung Dis** 1995 Jun; 76(3):223–9

Resistance to antituberculosis drugs in Japan. Hirano K, et al. **Tuber Lung Dis** 1996 Apr;77(2):130–5

Directly-observed therapy, patient education and combined drug formulations: complementary, not alternative, strategies in tuberculosis control [editorial] Iseman MD. **Tuber Lung Dis** 1996 Apr;77(2):101

The application of empiric antituberculosis treatment [letter] Lawn SD, et al. **Tuber Lung Dis** 1996 Jun;77(3):292

Rifabutin in the treatment of newly diagnosed pulmonary tuberculosis [letter] Mitchison DA. **Tuber Lung Dis** 1995 Jun;76(3):277

An uncontrolled trial of pefloxacin in the retreatment of patients with pulmonary tuberculosis. Rao S. **Tuber Lung Dis** 1995 Jun;76(3):219–22

Short-course therapy of pulmonary tuberculosis: doctor's compliance. Rothe TB, et al. **Tuber Lung Dis** 1996 Feb; 77(1):93–7

Isoniazid preventive therapy for pulmonary tuberculosis sequelae: which patients up to which age? Sarasin FP, et al. **Tuber Lung Dis** 1995 Oct;76(5):394–400

A challenge—to our practices and to our principles [editorial; comment] Sbarbaro JA. **Tuber Lung Dis** 1996 Feb;77(1):2–3 . Comment on: Tuber Lung Dis 1996 Feb;77(1):86–92.

A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Schwander S, et al. **Tuber Lung Dis** 1995 Jun;76(3):210–8

Pefloxacin and pulmonary tuberculosis [letter] Yew WW. **Tuber Lung Dis** 1996 Apr;77(2):194

[Comparison of in-vitro and in-vivo activities of enoxacin and ofloxacin against the Mycobacterium tuberculosis] Xu G, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Jun;18(3):175–7, 192 (Eng. Abstr.) **(Chi)**

[Comparison of routine therapeutic protocols used in Madagascar for the treatment of smear-positive pulmonary tuberculosis (preliminary results)] Boisier P, et al. **Arch Inst Pasteur Madagascar** 1995;62(1):72–6 (Eng. Abstr.) **(Fre)**

[Tuberculosis in aged persons residing in Quebec facilities: are screening and chemoprophylaxis indicated? (see comments)] Marchand RS, et al. **Can J Public Health** 1995 Jul–Aug;86(4):238–42 (55 ref.) (Eng. Abstr.). Comment in: Can J Public Health 1995 Jul–Aug;86(4):221–3. **(Fre)**

[Multidrug-resistant tuberculosis] Bouvet E. **Presse Med** 1996 Mar 2–9;25(8):393–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Antituberculer agents] Radermecker M. **Rev Med Liege** 1996 Jan;51(1):44–6 **(Fre)**

[Treatment of pleural tuberculosis with a short 4-month regimen: preliminary results] Bouayad Z, et al. **Tuber Lung Dis** 1995 Aug;76(4):367–9 (Eng. Abstr.) **(Fre)**

[Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose] Chaulet P, et al. **Tuber Lung Dis** 1995 Oct;76(5):407–12 (Eng. Abstr.) **(Fre)**

[Renaissance of tuberculosis?] Meyer FJ, et al. **Internist (Berl)** 1995 Dec;36(12):1162–73 (80 ref.) **(Ger)**

[The problem of resistance in the treatment of Mycobacterium infections: new experimental results and combinations for the treatment of tuberculosis and leprosy] Seydel JK, et al. **Pharm Unserer Zeit** 1995 Nov; 24(6):313–23 (14 ref.) **(Ger)**

[Incidence of resistance and risk factors for resistance in Mycobacterium tuberculosis. A retrospective study of 1,055 patients of a specialty hospital 1984 to 1993] Borchardt J, et al. **Pneumologie** 1996 Jan;50(1):28–35 (Eng. Abstr.) **(Ger)**

[Therapeutic approaches in diseases caused by mycobacteria] Urbanczik R. **Pneumologie** 1995 Dec;49 Suppl 3:649–52 (32 ref.) (Eng. Abstr.) **(Ger)**

[Therapy and prognosis of tuberculosis] Fischer B, et al. **Versicherungsmedizin** 1995 Dec 1;47(6):212–6 (12 ref.) (Eng. Abstr.) **(Ger)**

ANTITUBERCULAR AGENTS

[The present situation, treatment and prognosis of drug-resistant pulmonary tuberculosis. Cooperative Study Unit of Chemotherapy of Tuberculosis of the National Sanitoria in Japan] Sato K, et al. **Kekkaku** 1995 Oct; 70(10):585-9 (Eng. Abstr.) **(Jpn)**

[Emergency drug therapy of meningoencephalitis] Kuzuhara S. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1837-42 (5 ref.) **(Jpn)**

[Sloping posture on the unwell side for treatment of pulmonary tuberculosis combined with use of modern intensive antitubercular chemotherapy] Dobrzyński Z. **Pneumonol Alergol Pol** 1995;63(11-12):639-44 (Eng. Abstr.) **(Pol)**

[Oxidative metabolism changes in respiratory tract cells of guinea pigs during natural development of experimental tuberculosis and under specific chemotherapy] Kaminskaia GO, et al. **Probl Tuberk** 1996;(2):33-6 (Eng. Abstr.) **(Rus)**

[Efficacy and tolerance of the treatment of tuberculosis in the aged] Aguilar X, et al. **Arch Bronconeumol** 1996 Mar; 32(3):122-6 (Eng. Abstr.) **(Spa)**

[Multicenter transversal study of tuberculosis and drug resistance in Madrid (October 1993-April 1994)] **Med Clin (Barc)** 1996 Jan 13;106(1):1-6 (Eng. Abstr.) **(Spa)**

[Multidrug-resistant tuberculosis. Remarks and reflections on a controversial subject of current utmost importance (editorial)] Ausina V. **Med Clin (Barc)** 1996 Jan 13; 106(1):15-8 **(Spa)**

[Are microbiological studies necessary before starting tuberculosis chemoprophylaxis? (letter)] Barrasa Villar JI, et al. **Med Clin (Barc)** 1995 Oct 28;105(14):559 **(Spa)**

[The role of and changes in the copper and zinc levels and the activity of their related metalloenzymes in the blood of patients with destructive pulmonary tuberculosis during chemotherapy] Zozuliak VI. **Lik Sprava** 1995 May-Jun; (5-6):97-100 (Eng. Abstr.) **(Ukr)**

ANTITUMOR DRUG SCREENING ASSAYS see **DRUG SCREENING ASSAYS, ANTITUMOR**

ANTITUSSIVE AGENTS

see related
EXPECTORANTS

[Social psychiatric study of the over-the-counter antitussive drug abuse; shifts resulting from modification of the formulae] Seno E, et al. **Seishin Shinkeigaku Zasshi** 1996; 98(3):127-50 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients. Moroni M, et al. **Br J Cancer** 1996 Jul;74(2):309-11

ADVERSE EFFECTS

Acute dystonia in a child associated with therapeutic ingestion of a dextromethorphan containing cough and cold syrup [letter] Graudins A, et al. **J Toxicol Clin Toxicol** 1996;34(3):351-2

Dextromethorphan-induced mania. Polles A, et al. **Psychosomatics** 1996 Jan-Feb;37(1):71-4

[Syncope after niaprazine (Nopron) (letter)] Sarda H, et al. **Arch Pediatr** 1996 Jan;3(1):90 **(Fre)**

BLOOD

Simultaneous determination of dextrorphan and guaifenesin in human plasma by liquid chromatography with fluorescence detection. Stavchansky S, et al. **J Pharm Biomed Anal** 1995 Jun;13(7):919-25

CHEMISTRY

[Quantitative analysis of chlorpheniramine maleate in cough and cold drugs by ion-pair high-performance liquid chromatography for the simultaneous determination of chlorpheniramine and maleate] Yamato S, et al. **Yakugaku Zasshi** 1996 Apr;116(4):329-34 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Puqiedinone, a novel 5 alpha-cevanine alkaloid from the bulbs of Fritillaria puqiensis, an antitussive traditional Chinese medicine. Lin G, et al. **J Nat Prod** 1995 Nov; 58(11):1662-7

METABOLISM

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Eap CB, et al. **Clin Pharmacol Ther** 1996 Mar;59(3):322-31

PHARMACOKINETICS

Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Kévorkian JP, et al. **Clin Pharmacol Ther** 1996 May;59(5):583-92

Detection of codeine and phenobarbital in sweat collected with a sweat patch. Kintz P, et al. **J Anal Toxicol** 1996 May-Jun;20(3):197-201

PHARMACOLOGY

Discriminative stimulus properties of dextromethorphan in rats. Gavend M, et al. **Biomed Pharmacother** 1995; 49(10):456-64 (59 ref.)

Effects of moguisteine, a peripheral nonnarcotic antitussive agent, on airway inflammation in guinea-pigs in vivo. Gallico L, et al. **Eur Respir J** 1996 Mar;9(3):478-85

Effect of the two tachykinin antagonists, SR 48968 and SR 140333, on cough induced by citric acid in the unanaesthetized guinea pig. Girard V, et al. **Eur Respir J** 1995 Jul;8(7):1110-4

Antitussive and antibronchoconstriction actions of fenspiride in guinea-pigs. Laude EA, et al. **Eur Respir J** 1995 Oct; 8(10):1699-704

Effect of acetazolamide on cough induced by low-chloride-ion solutions in normal subjects: comparison with furosemide. Foresi A, et al. **J Allergy Clin Immunol** 1996 May;97(5):1093-9

Capsazepine inhibits cough induced by capsaicin and citric acid but not by hypertonic saline in guinea pigs. Lalloo UG, et al. **J Appl Physiol** 1995 Oct;79(4):1082-7

Antagonistic effect of buprenorphine on the antitussive effect of morphine is mediated via the activation of mu 1-opioid receptors. Kamei J, et al. **Life Sci** 1995;57(16):PL231-5

Recent advances in neuropharmacology of the centrally acting antitussive drugs. Kamei J. **Methods Find Exp Clin Pharmacol** 1995 Apr;17(3):193-205 (103 ref.)

[Pharmacological research on antiasthmatic liquid for oral administration] Zhao S, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):305-6, inside cover (Eng. Abstr.) **(Chi)**

POISONING

Fatal zipeprol and dextromethorphan poisonings in Korea. Yoo Y, et al. **J Anal Toxicol** 1996 May-Jun;20(3):155-8

A massive outbreak of food poisoning--a reminder of the importance of proper toxic waste control. Benadé JG. **S Afr Med J** 1996 May;86(5):551-2

THERAPEUTIC USE

Pharmacological studies of allergic cough in the guinea pig. Bolser DC, et al. **Eur J Pharmacol** 1995 Apr 24; 277(2-3):159-64

A randomized controlled trial of oral albuterol in acute cough. Littenberg B, et al. **J Fam Pract** 1996 Jan; 42(1):49-53

[Chronic persistent coughing successfully treated with ozagrel] Nishi K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Mar;34(3):350-4 (Eng. Abstr.) **(Jpn)**

URINE

Quantitative gas chromatographic analysis of 3-cyano-3,3-diphenylpropionic acid, the acidic metabolite of bezitramide (Burgodin), in urine. De Baere SM, et al. **J Anal Toxicol** 1996 May-Jun;20(3):159-64

ANTI-ULCER AGENTS

see related
HISTAMINE H2 ANTAGONISTS

[The antiulcer effect of corticosteroids and the blood flow in the gastric mucosa] Filaretova LP, et al. **Fiziol Zh Im I M Sechenova** 1996 Feb;82(2):61-70 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Repeat prescribing of ulcer healing drugs in general practice--prevalence and underlying diagnosis. Goudie BM, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):147-50

Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. Parente F, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):211-3

Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment. van der Hulst RW, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):165-71

Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Bertoni G, et al. **Am J Gastroenterol** 1996 Feb;91(2):258-63

Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Kuo B, et al. **Am J Gastroenterol** 1996 Aug;91(8):1532-8

Combined endoscopic thermal electrocoagulation with high dose omeprazole therapy in complicated heterotopic gastric mucosa of the esophagus. McBride MA, et al. **Am J Gastroenterol** 1995 Nov;90(11):2029-31

Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence. Porro GB, et al. **Am J Gastroenterol** 1996 Apr; 91(4):695-700

Lansoprazole: an alternative method of administration of a capsule dosage formulation. Chun AH, et al. **Clin Ther** 1995 May-Jun;17(3):441-7

Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Rauws EA, et al. **Drugs** 1995 Dec; 50(6):984-90

Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Moayyedi P, et al. **Eur J Gastroenterol Hepatol** 1995 Sep; 7(9):835-40

Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori. Takimoto T, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S63-6

Effect of Helicobacter pylori eradication on the healing and recurrence of peptic ulcer: combination therapy with low-dose omeprazole and clarithromycin. Uemura N, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S67-9

Low dose famotidine and cimetidine in single postprandial doses: a placebo controlled comparative study of overnight pH. Reilly TG, et al. **Gut** 1995 Sep;37(3):325-8

Optimal dose of omeprazole in combination with amoxicillin in eradicating H. pylori and preventing relapses in duodenal ulcer patients. Rokkas T, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):842-6

Sucralfate effervescent tablet: treatment of peptic ulcer disease and change in serum aluminium concentration. Schütze K, et al. **Hepatogastroenterology** 1995 Jul; 42(3):240-5

Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori. Furuta T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S107-11

Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration? Hoshino E, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S72-4

Studies of various administration methods for lansoprazole injection using 24-hour intragastric pH monitoring. Inoue M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S17-21

Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. Lanas A, et al. **J Clin Gastroenterol** 1995 Sep;21(2):103-6

Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing. Nakata H, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S118-20

Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method. Shimada T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S100-3

Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. Shimoyama T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S125-7

Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients. Shirai T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S128-31

Determining the optimal dose of lansoprazole injection by 24-hour intragastric pH monitoring. Sugiyama M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S14-6

Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. Sugiyama T, et al. **J Clin Gastroenterol** 1995; 20 Suppl 2:S104-6

Metronidazole resistance: a predictor of failure of Helicobacter pylori eradication by triple therapy. Midolo PD, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):290-2

Clarithromycin and omeprazole for Helicobacter pylori. **Med Lett Drugs Ther** 1996 Jun 7;38(976):51-2

Stress ulcer prophylaxis. Do critically ill patients need it? DePriest JL. **Postgrad Med** 1995 Oct;98(4):159-61, 165-6, 168 (23 ref.)

Non-bleeding visible vessel treatment: perendoscopic injection therapy versus omeprazole infusion. Grosso C, et al. **Scand J Gastroenterol** 1995 Sep;30(9):872-5

Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. Hatlebakk JG, et al. **Scand J Gastroenterol** 1995 Nov;30(11):1053-7

Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. Laursen LS, et al. **Scand J Gastroenterol** 1995 Sep;30(9):839-46

Prolonged treatment with omeprazole does not improve the eradication rate of Helicobacter pylori infection--a short history. Goh KL, et al. **Singapore Med J** 1995 Dec; 36(6):619-20

Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study. Labenz J, et al. **Z Gastroenterol** 1995 Oct;33(10):590-3

Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. Schütze K, et al. **Z Gastroenterol** 1995 Nov;33(11):651-3

[The effect of ranitidine on postoperative monocyte and neutrophil granulocyte function] Nielsen HJ, et al. **Ugeskr Laeger** 1995 Oct 30;157(44):6119-24 (Eng. Abstr.) **(Dan)**

[Recommendations and medical references 1996] **Ann Chir** 1996;50(2):182-8 **(Fre)**

[Prevention of stress ulcer in intensive care patients--pro] Tryba M. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):509-10 **(Ger)**

[Prevention of stress ulcer in intensive care patients--contra] Wiedeck H. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec;

30(8):507–8 (Ger)
[Dynamic imaging of gastric ulcer healing using the most modern Morph-Software] Jaspersen D, et al. **Bildgebung** 1996 Jun;63(2):101–4 (Eng. Abstr.) (Ger)
[Combined therapy with azithromycin and omeprazole for the eradication of Helicobacter pylori (letter)] Bokemeyer B. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1339 (Ger)
[One week triple therapy for eradication of Helicobacter pylori infection: simple and effective (letter)] Diehl HG. **Leber Magen Darm** 1995 Dec;25(6):283 (Ger)
[What is the effect of omeprazole in acute peptic ulcer hemorrhage? (letter)] Kohler B. **Leber Magen Darm** 1995 Jul;25(4):153 (Ger)
[Long-term therapy with omeprazole: when will it finally be approved? (letter)] Koop H. **Leber Magen Darm** 1995 Jul;25(4):153–4 (Ger)
[Modified triple therapy: what degree of acid inhibition is necessary? (letter)] Müller P, et al. **Leber Magen Darm** 1996 May;26(3):171–3 (Ger)
[Effectiveness of triple therapy to eradicate H. pylori in patients after failed therapy with omeprazole/amoxicillin] Zala G, et al. **Schweiz Med Wochenschr** 1996 Feb 3; 126(5):153–8 (Eng. Abstr.) (Ger)
[Helicobacter pylori and peptic ulcer—1995 therapeutic indications and recommendations of a Munster Expert Group] Domschke W, et al. **Z Gastroenterol** 1995 Oct; 33(10):598–601 (Ger)
[Do proton pump inhibitors after endoscopic control of acute ulcer hemorrhage have an advantage over H2 receptor antagonists?] Prassler R, et al. **Z Gastroenterol** 1995 Aug; 33(8):431–4 (Eng. Abstr.) (Ger)
[Omeprazole + clarithromycin + metronidazole—a new standard for eradication of Helicobacter pylori] Schepp W. **Z Gastroenterol** 1995 Oct;33(10):621–3 (Ger)
[Treatment with anti-secretory agents for symptomatic relief (letter)] Waldum HL, et al. **Tidsskr Nor Laegeforen** 1996 Apr 30;116(11):1384 (Nor)
[Is the omeprazole and amoxicillin combination useful in the treatment eradicating Helicobacter pylori in Spain?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):99–106 (Eng. Abstr.) (Spa)
[New guidelines from the Medical Products Agency: the triple regime against Helicobacter pylori is necessary. Treat only if the ulcer is verified] Blomgren K, et al. **Lakartidningen** 1996 Mar 13;93(11):1041–2, 1045 (Swe)

ADVERSE EFFECTS

Deterioration of renal function in a nephropathic diabetic patient during omeprazole plus amoxicillin therapy for Helicobacter pylori-associated duodenal ulcer [letter] Lorenzetti M, et al. **Acta Diabetol** 1995 Oct;32(3):209–10
Over-the-counter cimetidine and theophylline interaction [letter] Pride M, et al. **Am Fam Physician** 1995 Dec; 52(8):2180
Case report: ranitidine-induced bradycardia in a patient with dextrocardia. Yang J, et al. **Am J Med Sci** 1996 Sep; 312(3):133–5
Hyperprolactinemia and galactorrhea with standard-dose famotidine therapy [letter] Güven K, et al. **Ann Pharmacother** 1995 Jul-Aug;29(7–8):788
Intimate association of eosinophils to collagen bundles in eosinophilic myocarditis and ranitidine-induced hypersensitivity myocarditis. Kendell KR, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1154–60
Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. Neal KR, et al. **BMJ** 1996 Feb 17; 312(7028):414–5
Bronchospasm associated with cisapride. Pillans P. **BMJ** 1995 Dec 2;311(7018):1472
Bullous skin reaction induced by omeprazole [letter] Stenier C, et al. **Br J Dermatol** 1995 Aug;133(2):343–4
Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma. Gough A, et al. **Br J Rheumatol** 1995 Oct;34(10):976–7
Aggravation of parkinsonian tremor by cisapride. Sempere AP, et al. **Clin Neuropharmacol** 1995 Feb;18(1):76–8
Aluminum concentrations in critically ill children with renal impairment [letter; comment] Baines PB, et al. **Crit Care Med** 1995 Nov;23(11):1931. Comment on: Crit Care Med 1994 Nov;22(11):1769–73.
Hyponatremia with consciousness disturbance caused by omeprazole administration. A case report and literature review. Shiba S, et al. **Dig Dis Sci** 1996 Aug;41(8):1615–7 (5 ref.)
Ranitidine, diarrhoea, and lymphocytic colitis. Beaugerie L, et al. **Gut** 1995 Nov;37(5):708–11
Lichenoid eruptions due to the H2-receptor antagonists roxatidine and ranitidine [letter] Horiuchi Y, et al. **J Dermatol** 1996 Jul;23(7):510–2
Acute renal failure due to omeprazole [letter] O'Donnell D. **Med J Aust** 1996 Aug 19;165(4):234–5
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. Kuipers EJ, et al. **N Engl J Med** 1996 Apr 18;334(16):1018–22
Adverse drug reaction to oxethazine: a case report [letter] Ruttenberg D. **N Z Med J** 1995 Sep 22;108(1008):394
[Aluminum osteopathy in a patient hemodialysed for chronic renal insufficiency and treated by long term administration of sucralfate (letter)] Level C, et al. **Rev Med Interne** 1996; 17(4):348–9 (Fre)
[We hope that the responsible persons learn from the experience! (letter)] Blum AL, et al. **Leber Magen Darm** 1995 Jul;25(4):154–5 (Ger)
[Who is affected by blindness? (letter)] Classen M. **Leber Magen Darm** 1995 Jul;25(4):152–3 (Ger)
[Federal health office commentaries: false, misleading citations (letter)] Lessell S. **Leber Magen Darm** 1995 Jul; 25(4):152 (Ger)
[What can be learned from this case? (letter)] Petersen KH, et al. **Leber Magen Darm** 1995 Jul;25(4):155 (Ger)
[Treatment error, negligent physical injury and negligent homicide (letter)] Rösch W. **Leber Magen Darm** 1995 Jul; 25(4):154 (Ger)
[Once again: "A sick federal health office watches over health!" (editorial; comment)] Stolte M. **Leber Magen Darm** 1995 Jul;25(4):150–1. Comment on: Leber Magen Darm 1994 Sep;24(5):183–6. Comment on: Leber Magen Darm 1995 Jan;25(1):6–8, 11. Comment on: Leber Magen Darm 1995 Jan;25(1):39, 41. (Ger)

ANALYSIS

In vitro stability of ranitidine hydrochloride in enteral nutrient formulas. Crowther RS, et al. **Ann Pharmacother** 1995 Sep;29(9):859–62
Spectrophotometric determination of nizatidine in pharmaceutical formulations. Vladimirov S, et al. **J Pharm Biomed Anal** 1995 Jun;13(7):933–6

BLOOD

Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography. Karol MD, et al. **J Chromatogr B Biomed Appl** 1995 Jun 9;668(1):182–6
Analysis of cisapride in neonatal plasma using high-performance liquid chromatography with a base-stable column and fluorescence detection. Preechagoon Y, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):139–43
Determination of pirenzepine in human plasma using liquid chromatography with tandem mass spectrometric detection. Chavez CM, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1179–84
Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs. Mummaneni V, et al. **Pharm Res** 1995 May;12(5):780–6

CHEMICAL SYNTHESIS

Soft drugs. 21. Design and evaluation of soft analogs of propantheline. Brouillette G, et al. **J Pharm Sci** 1996 Jun; 85(6):619–23
[Thieno(2',3':3,4)pyrazolo(1,5-a)pyrimidines and -triazines: synthesis of a novel ring system] Briel D. **Pharmazie** 1995 Oct;50(10):675–8 (Eng. Abstr.) (Ger)

CHEMISTRY

A comparison of the conformation of sucrose octasulfate, free and bound to acidic fibroblast growth factor. Shen J, et al. **Carbohydr Res** 1995 Aug 25;273(2):115–27

ECONOMICS

Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia's senior population. Kephart G, et al. **Clin Ther** 1995 Nov-Dec; 17(6):1159–73
Cost-effectiveness of H. pylori eradication. Roesch W. **J Physiol Pharmacol** 1996 Mar;47(1):71–7 (20 ref.)

METABOLISM

Identification of the human P450 enzymes involved in lansoprazole metabolism. Pearce RE, et al. **J Pharmacol Exp Ther** 1996 May;277(2):805–16
Preferential binding of the novel prostaglandin SC-46275 to canine gastric versus intestinal receptors. Tsai BS, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):368–73
[Interaction between prostaglandin E and oral anticoagulants (letter)] Thijssen HW. **Presse Med** 1995 Nov 18;24(35):1665 (Fre)

PHARMACOKINETICS

Selective adherence of a sucralfate-tetracycline complex to gastric ulcers: implications for the treatment of Helicobacter pylori. Yokel RA, et al. **Biopharm Drug Dispos** 1995 Aug;16(6):475–9
Clinical pharmacokinetics in patients with burns. Jaehde U, et al. **Clin Pharmacokinet** 1995 Jul;29(1):15–28 (75 ref.)
Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. Larson C, et al. **Dig Dis Sci** 1996 Mar; 41(3):475–9
Autoradiographic demonstration of lansoprazole uptake sites in rat antrum and colon. Nakamura M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S8–13
Pharmacokinetics of lansoprazole in hemodialysis patients. Karol MD, et al. **J Clin Pharmacol** 1995 Aug;35(8):815–20
Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. Rost KL, et al. **J Hepatol** 1995 Sep;23(3):268–77
Disposition of polaprezinc (zinc L-carnosine complex) in rat gastrointestinal tract and effect of cimetidine on its adhesion to gastric tissues. Furuta S, et al. **J Pharm Pharmacol** 1995 Aug;47(8):632–6
The effect of mannitol on the oral bioavailability of cimetidine. Adkin DA, et al. **J Pharm Sci** 1995 Dec; 84(12):1405–9

PHARMACOLOGY

Gastric tonometry: effect of sucralfate on calculated intramural pH. Motsch J, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):666–70
Effect of omeprazole and feeding on plasma gastrin in patients with achlorhydria. Banerjee S, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):507–12
Review article: drug development in gastroenterology—the changing view of industry. Parsons ME, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):457–63 (14 ref.)
Cell kinetics of the gastric mucosa of patients treated with omeprazole [letter] Biasco G, et al. **Am J Gastroenterol** 1996 Mar;91(3):621–2
Marked rebound acid hypersecretion after treatment with ranitidine. el-Omar E, et al. **Am J Gastroenterol** 1996 Feb; 91(2):355–9
Gastric antisecretory and anti-ulcer actions of IL-1 in rat involve different IL-1 receptor types. Mugridge KG, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G763–9
Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Gustavson LE, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2078–83
Bacterial activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions. Shibata K, et al. **Antimicrob Agents Chemother** 1995 Jun; 39(6):1295–9
Effects of long-term omeprazole treatment on adult rat gastric mucosa—enhancement of the epithelial cell proliferation and suppression of its differentiation. Kakei N, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):861–8
Inhibition of Helicobacter pylori urease activity by ebrotidine. Piotrowski J, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):247–53
Mechanism of anti-urease action by the anti-ulcer drug ecabet sodium. Ito Y, et al. **Biol Pharm Bull** 1995 Jun; 18(6):850–3
Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test [letter] Tateishi T, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):411–2
Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine. Ono M, et al. **Cancer Res** 1996 Apr 1;56(7):1512–6
Effects of omeprazole on cell kinetics of carcinogen-induced colon tumours in rats. Hurwitz A, et al. **Cell Prolif** 1995 Oct;28(10):525–31
Studies on antiulcer agents. IV. Antiulcer effects of 2-benzylthio5,6,7,8-tetrahydro-4(3H)-quinazolinones and related compounds. Terashima K, et al. **Chem Pharm Bull (Tokyo)** 1995 Nov;43(11):2021–3
Studies on antiulcer agents. III. Plausible mechanism of antisecretory action of ethyl 2[(1H-benzimadazol-2-yl)sulfinylmethyl]-4-dimethylamino- 5-pyrimidinecarboxylate, an H+/K(+)-ATPase inhibitor, based on its reaction with thiols. Terashima K, et al. **Chem Pharm Bull (Tokyo)** 1995 Nov;43(11):1985–91
Comparative effects of omeprazole on xenobiotic metabolizing enzymes in the rat and human. Kashfi K, et al. **Clin Pharmacol Ther** 1995 Dec;58(6):625–30
Effect of omeprazole on changes in gastric and upper small intestine pH levels in patients with chronic pancreatitis. Nakamura T, et al. **Clin Ther** 1995 May-Jun;17(3):448–59
Cimetidine or ranitidine in renal transplant patients receiving cyclosporine. Barri YM, et al. **Clin Transplant** 1996 Feb; 10(1 Pt 1):34–8
Influence of cisapride on gastric emptying of solids and liquids monitored by 13C breath tests. Duan LP, et al. **Dig Dis Sci** 1995 Oct;40(10):2200–6
Capsaicin-sensitive sensory neurons are involved in bicarbonate secretion induced by lansoprazole, a proton pump inhibitor, in rats. Inada I, et al. **Dig Dis Sci** 1996 Apr;41(4):785–90
Gastric mucus generation in cirrhotic patients with portal hypertension. Effects of tetraprenylacetone. Iwao T, et al. **Dig Dis Sci** 1996 Sep;41(9):1727–32
Effect of long-term sucralfate ingestion on antral and fundic epithelial proliferation in the rat. Kuwayama H. **Dig Dis Sci** 1996 May;41(5):979–83
Effect of plaunotol on superoxide production activity in vivo [letter] Okabe N, et al. **Dig Dis Sci** 1995 Nov;40(11):2321–2
Effect of cisapride on gallbladder emptying and plasma CCK in normal and vagotomized human subjects. Patankar R, et al. **Dig Dis Sci** 1996 Mar;41(3):543–8
Effects of cisapride on salivary production in normal subjects. Patel R, et al. **Dig Dis Sci** 1996 Mar;41(3):480–4
High systemic HCO3(-) and topical 16,16-dimethyl-PGE2 protect gastric mucosa against luminal acid by enhancing its preepithelial buffer capacity. Ranta-Knuuttila T, et al. **Dig Dis Sci** 1996 Mar;41(3):492–7
Stimulatory effects of sucralfate on secretion and synthesis of mucus by rabbit gastric mucosal cells. Involvement of phospholipase C. Takahashi S, et al. **Dig Dis Sci** 1996 Mar; 41(3):498–504
Effects of pirenzepine on omeprazole-induced gastrin gene expression in rat antral tissues. Tari A, et al. **Dig Dis Sci** 1996 Jun;41(6):1150–6

Mechanisms for cytoprotection by vitamin U from ethanol-induced gastric mucosal damage in rats. Watanabe T, et al. **Dig Dis Sci** 1996 Jan;41(1):49–54

Rebamipide protects against activation of neutrophils by Helicobacter pylori. Yoshida N, et al. **Dig Dis Sci** 1996 Jun;41(6):1139–44

Effect of enprostil and cimetidine on ethanol-induced damage to intestinal epithelial cell lines IRD 98 and IEC 17. Giannarelli S, et al. **Digestion** 1995;56(6):509–15

Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Kromer W. **Digestion** 1995; 56(6):443–54 (90 ref.)

Effect of 10% ethanol and sofalcone on prostaglandin E2 content, mucus gel thickness, and experimental ulcers in the stomach of developing rats. Tabata M, et al. **Digestion** 1996;57(1):47–53

Effect of teprenone on portal hypertensive gastric mucosa. Tanoue K, et al. **Digestion** 1996;57(1):35–40

Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. Katashima M, et al. **Drug Metab Dispos** 1995 Jul; 23(7):718–23

Ebrotidine. Patel SS, et al. **Drugs** 1996 Jun;51(6):974–80; discussion 981 (41 ref.)

Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori. Nakao M, et al. **Eur J Clin Microbiol Infect Dis** 1995 May;14(5):391–9

The anti-ulcer drug sucralfate does not affect gastric nicotine levels. Lindell G, et al. **Eur J Clin Pharmacol** 1996; 49(6):511–3

Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. Rizzo N, et al. **Eur J Clin Pharmacol** 1996;49(6):491–5

Adenosine and propentofylline inhibit the proliferation of cultured microglial cells. Si QS, et al. **Exp Neurol** 1996 Feb;137(2):345–9

Antioxidant properties of omeprazole. Lapenna D, et al. **FEBS Lett** 1996 Mar 11;382(1-2):189–92

Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice [see comments] Goddard AF, et al. **Gastroenterology** 1996 Aug; 111(2):358–67. Comment in: Gastroenterology 1996 Aug;111(2):521–3.

Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Hirakawa T, et al. **Gastroenterology** 1996 Aug; 111(2):345–57

Gastric antisecretory activity of lansoprazole in different experimental models: comparison with omeprazole. Coruzzi G, et al. **Gen Pharmacol** 1995 Sep;26(5):1027–32

Gastroprotective activity of the novel proton pump inhibitor lansoprazole in the rat. Morini G, et al. **Gen Pharmacol** 1995 Sep;26(5):1021–5

Vasoinhibitory effect of leminoprazole, a H+,K(+)-ATPase inhibitor, on rat aortic rings. Okabe S, et al. **Gen Pharmacol** 1996 Jan;27(1):117–21

Inhibition of gastric mucosal mucin receptor by H. pylori lipopolysaccharide: effect of ebrotidine. Slomiany BL, et al. **Gen Pharmacol** 1995 Nov;26(7):1553–8

Effect of allopurinol, sulphasalazine, and vitamin C on aspirin induced gastroduodenal injury in human volunteers. McAlindon ME, et al. **Gut** 1996 Apr;38(4):518–24

Omeprazole promotes proximal duodenal mucosal bicarbonate secretion in humans. Mertz-Nielsen A, et al. **Gut** 1996 Jan;38(1):6–10

Effect of longterm misoprostol coadministration with non-steroidal anti-inflammatory drugs: a histological study. Shah K, et al. **Gut** 1995 Aug;37(2):195–8

Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Verdú EF, et al. **Gut** 1995 Dec;37(6):743–8

The importance of gastric emptying and mucosal folds in the adaptive cytoprotection of mild irritants in rats. Ko JK, et al. **Inflamm Res** 1995 Dec;44(12):518–22

Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. Serfaty-Lacrosniere C, et al. **J Am Coll Nutr** 1995 Aug; 14(4):364–8

Activity of sucralfate (sucrose octa-sulphate), an anti-ulcer agent, against opportunistic gram-negative bacilli. Bragman SG, et al. **J Antimicrob Chemother** 1995 Oct; 36(4):703–6

Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. Jonkers D, et al. **J Antimicrob Chemother** 1996 Jan; 37(1):145–50

Effects of DQ-2511 on neutral activity in afferent and efferent loops of gastric vago-vagal reflex pathways in the rat. Niijima A, et al. **J Auton Pharmacol** 1996 Feb; 16(1):49–53

Suppression of Acid Secretion by Lansoprazole and its Effects on Helicobacter pylori. II. Poster presentations from the 2nd International Colloquium on Proton Pump Inhibitors. Houston, Texas, September 29, 1994. **J Clin Gastroenterol** 1995;20 Suppl 2:S1–135

Effects of lansoprazole on ethanol-induced injury and PG synthetic activity in rat gastric mucosa. Fukuda T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S5–7

Effects of lansoprazole on mucosal regeneration in patients with gastric ulcers: evaluation using an electronic endoscope with a magnifying function. Hashimoto M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S59–61

Effects of lansoprazole on gastric ulcer healing and mucin content. Komuro Y, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S47–51

Lansoprazole reverses Helicobacter pylori-inhibited gastric epithelial cell growth. Nakajima N, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S90–2

13C-UBT using an infrared spectrometer for detection of Helicobacter pylori and for monitoring the effects of lansoprazole. Ohara H, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S115–7

Inhibitory effects of intravenous lansoprazole on gastric acid hypersecretion in patients with postoperative stress. Otani Y, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S22–6

Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. Sakaguchi M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S27–31

Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. Suzuki M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S93–6

Antiulcer activity of Pteleopsis suberosa. De Pasquale R, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):55–8

Single oral dose of cisapride accelerates gastric antral emptying in healthy humans: an ultrasonographic study. Takeda T, et al. **J Gastroenterol** 1996 Jun;31(3):323–8

Weakness of mucosal barrier in portal hypertensive gastropathy of alcoholic cirrhosis. Effects of propranolol and enprostil. Payen JL, et al. **J Hepatol** 1995 Dec; 23(6):689–96

Structure-activity relationship of omeprazole and analogues as Helicobacter pylori urease inhibitors. Kühler TC, et al. **J Med Chem** 1995 Dec 8;38(25):4906–16

Soft drugs. 21. Design and evaluation of soft analogs of propantheline. Brouillette G, et al. **J Pharm Sci** 1996 Jun; 85(6):619–23

Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. Chan CC, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1531–7

Roles of prostaglandins, nitric oxide and the capsaicin-sensitive sensory nerves in gastroprotection produced by ecabet sodium. Kinoshita M, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):494–501

H+-K+ ATPase inhibitors cause relaxation of guinea pig and human airway smooth muscle in vitro. Rhoden KJ, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):897–903

Stimulatory effect of leminoprazole on secretion and synthesis of mucus by rabbit gastric mucosal cells. Takahashi S, et al. **J Pharmacol Exp Ther** 1995 Dec; 275(3):1396–401

A new technique for continuous measurement and recording of gastric potential difference in the rat: evaluation of NSAID-induced gastric mucosal damage. Scarpignato C, et al. **J Pharmacol Toxicol Methods** 1995 Oct;34(2):63–72

Irsogladine inhibits ionomycin-induced decrease in intercellular communication in cultured rabbit gastric epithelial cells. Kameda Y, et al. **Jpn J Pharmacol** 1995 Nov;69(3):223–8

Sulpiride specifically attenuates psychological stress-induced gastric lesions in rodents. Nomura K, et al. **Jpn J Pharmacol** 1995 May;68(1):33–9

Mucosal protective effect of leminoprazole on reflux esophagitis induced in rats. Okabe S, et al. **Jpn J Pharmacol** 1995 Dec;69(4):317–23

Antisecretory effect of leminoprazole on histamine-stimulated gastric acid secretion in dogs: potent local effect. Okabe S, et al. **Jpn J Pharmacol** 1995 Oct; 69(2):91–100

Gastroprotective activity of FRG-8813, a novel histamine H2-receptor antagonist, in rats. Onodera S, et al. **Jpn J Pharmacol** 1995 Jun;68(2):161–73

Inhibitory effect of leminoprazole on acid secretion in parietal cells isolated from guinea pig gastric mucosa. Saito E, et al. **Jpn J Pharmacol** 1995 May;68(1):19–23

Antiulcer and gastric secretory activity of N-octanoyl gamma-aminobutyric acid. Sen S, et al. **Life Sci** 1995; 57(20):1877–85

Antiulcer activity of pentacaine and some of its derivatives: effect on experimentally induced gastric and duodenal lesions and on gastric acid secretion in rats. Nosálová V, et al. **Methods Find Exp Clin Pharmacol** 1995 Jul-Aug; 17(6):377–82

Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects. Timmer W, et al. **Methods Find Exp Clin Pharmacol** 1995 Sep;17(7):489–95

Finding new uses for thalidomide [news] Gershon D. **Nat Med** 1995 Dec;1(12):1230

Adenosine A1 and A2A receptors and nitrobenzylthioinosine-sensitive transporters in gerbil brain: no changes following long-term treatment with the adenosine transport inhibitor propentofylline. Parkinson FE, et al. **Neuropharmacology** 1996 Jan;35(1):79–89

Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. Zomorodi K, et al. **Pharm Res** 1995 Nov;12(11):1642–6

DQ-2511, having an antiulcer action, elicits vasodilation through an increase in cyclic GMP contents in rat arteries. Hatanaka S, et al. **Pharmacology** 1995 Sep;51(3):174–9

Characteristics of DQ2511-induced relaxation in isolated dog, monkey and human arteries. Okamura T, et al. **Pharmacology** 1995 Jun;50(6):370–9

The effect of cimetidine and ranitidine administration with zidovudine. Fletcher CV, et al. **Pharmacotherapy** 1995 Nov-Dec;15(6):701–8

Effects of sucralfate and ranitidine on aluminum concentrations in elderly volunteers. Moore JG, et al. **Pharmacotherapy** 1995 Nov-Dec;15(6):742–6

Assessment of the time course of drugs with inhibitory effects on hepatic metabolic activity using successive salivary caffeine tests. Soto J, et al. **Pharmacotherapy** 1995 Nov-Dec;15(6):781–4

Analogues of sabeluzole with gastric acid secretion inhibitory effect. Domány G, et al. **Pharmazie** 1996 Jun;51(6):427–8

Protective effect of teprenone on blood flow and incidence of histologic lesions in rat gastric mucosa after hemorrhage and retransfusion. Hachiya A, et al. **Scand J Gastroenterol** 1996 Apr;31(4):326–33

Effects of the anti-gastric secretory drugs IT-066 and omeprazole mitogenic activities in the gastric juice of the rat. Kasugai K, et al. **Scand J Gastroenterol** 1996 Feb; 31(2):111–7

Sucralfate counteracts the inhibition of gastric mucosal mucin receptor by Helicobacter pylori lipopolysaccharide. Slomiany A, et al. **Scand J Gastroenterol Suppl** 1995; 210:77–81

Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents. Slomiany BL, et al. **Scand J Gastroenterol Suppl** 1995;210:82–4

The liver regenerative response elicited by antisecretory agents in partially hepatectomized rats: a comparison between omeprazole and famotidine. Aono T. **Surg Today** 1995;25(9):816–21

Influence of stress ulcer prophylaxis on translocation of bacteria from the intestinal tract in rats [see comments] Georgopoulos A, et al. **Wien Klin Wochenschr** 1996; 108(11):321–5. Comment in: Wien Klin Wochenschr 1996;108(11):309–10.

Protection of the gastroduodenal mucosa from the effects of diclofenac sodium: role of highly selective vagotomy and misoprostol. Giannoukas AD, et al. **World J Surg** 1996 May;20(4):501–5 discussion 505–6

The history of acid inhibition. Baron JH. **Yale J Biol Med** 1994 May-Aug;67(3-4):97–106 (32 ref.)

[The protective effect of IL-1 beta on stress-induced gastric mucosal damage in rat] Huang Z, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):313–9 (Eng. Abstr.) **(Chi)**

[Gastrin/CCK-B receptor antagonists for a novel antiulcer agent] Miyata K, et al. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):171–80 (38 ref.) (Eng. Abstr.) **(Jpn)**

[The effect of the intragastric administration of prostaglandin E2 on mucus secretion in dogs] Krivova NA, et al. **Fiziol Zh Im I M Sechenova** 1995 Sep;81(9):65–71 (Eng. Abstr.) **(Rus)**

POISONING

Cisapride toxicosis in dogs. Volmer PA. **Vet Hum Toxicol** 1996 Apr;38(2):118–20 (20 ref.)

THERAPEUTIC USE

Radiographic findings of intractable gastric ulcers with H2-receptor antagonists. Okada M, et al. **Abdom Imaging** 1996 Mar-Apr;21(2):133–41

Serum pepsinogen values as possible markers for evaluating the possibility of peptic ulcer recurrence under H2-blocker half-dose maintenance therapy. Matsushima M, et al. **Adv Exp Med Biol** 1995;362:131–7

Intravenous administration of lansoprazole: a preliminary study of dose ranging and efficacy in upper gastrointestinal bleeding. Aoki T. **Aliment Pharmacol Ther** 1995;9 Suppl 1:51–7

A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group. Avner DL, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):521–8

The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Bardhan KD. **Aliment Pharmacol Ther** 1995;9 Suppl 1:15–25 (73 ref.)

Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial. Bell GD, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):513–20

High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. Dalla Libera M, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):203–6

Review article: the development of atrophic gastritis--Helicobacter pylori and the effects of acid suppressive therapy. Kuipers EJ, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):331–40 (97 ref.)

One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. Labenz J, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):207–10

Double-blind, randomized trial of roxatidine 150 mg in the early evening versus bedtime administration in the short-term treatment of duodenal ulcer. Lazzaroni M, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):425–31

Patterns of 24-hour oesophageal acid exposure after acute

withdrawal of acid suppression. Orr WC, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):571–4

Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Reilly TG, et al. **Aliment Pharmacol Ther** 1995 Oct; 9(5):483–90

Triple therapy with sucralfate, amoxycillin and metronidazole for healing duodenal ulcer and eradicating Helicobacter pylori infection. Stupnicki T, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):193–7

Predictive value of esophageal manometry and gastroesophageal pH monitoring for responsiveness of reflux disease to medical therapy in children. Cucchiara S, et al. **Am J Gastroenterol** 1996 Apr;91(4):680–5

Misoprostol and NSAID ulcers [editorial] Isaacs P. **Am J Gastroenterol** 1996 Feb;91(2):187–8

The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. Jhala NC, et al. **Am J Gastroenterol** 1995 Oct;90(10):1824–8

Should omeprazole be used for the treatment and prevention of duodenal ulcer as a monotherapeutic agent? [letter] Kadayifci A, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1279–80

Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Leite LP, et al. **Am J Gastroenterol** 1996 Aug;91(8):1527–31

Control of gastric acid with high dose H2-receptor antagonists after omeprazole failure: report of two cases. Leite LP, et al. **Am J Gastroenterol** 1995 Oct;90(10):1874–7

Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Raskin JB, et al. **Am J Gastroenterol** 1996 Feb;91(2):223–7

Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. Santander C, et al. **Am J Gastroenterol** 1996 Aug;91(8):1549–52

Helicobacter pylori and lanzoprazole [letter] Stermer E, et al. **Am J Gastroenterol** 1996 Aug;91(8):1667–8

Second proton-pump inhibitor marketed [news] **Am J Health Syst Pharm** 1995 Aug 1;52(15):1601

Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Harding SM, et al. **Am J Med** 1996 Apr;100(4):395–405

Omeprazole for the treatment of posterior laryngitis [letter; comment] Leite LP, et al. **Am J Med** 1995 Dec;99(6):694–5 . Comment on: Am J Med 1994 Apr;96(4):321–6.

The role of intragastric acidity and stress ulcus prophylaxis on colonization and infection in mechanically ventilated ICU patients. A stratified, randomized, double-blind study of sucralfate versus antacids. Bonten MJ, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1825–34

Acid aspiration prophylaxis for emergency Caesarean section. Stuart JC, et al. **Anaesthesia** 1996 May;51(5):415–21

A comparison of lansoprazole, omeprazole, and ranitidine for reducing preoperative gastric secretion in adult patients undergoing elective surgery. Nishina K, et al. **Anesth Analg** 1996 Apr;82(4):832–6

Esophageal ulcers in AIDS [letter; comment] Couderc LJ, et al. **Ann Intern Med** 1996 May 15;124(10):928; discussion 928–9. Comment on: Ann Intern Med 1995 Jul 15;123(2):143–9.

Esophageal ulcers in AIDS [letter; comment] Domingo P, et al. **Ann Intern Med** 1996 May 15;124(10):928; discussion 928–9. Comment on: Ann Intern Med 1995 Jul 15;123(2):143–9.

Cost effectiveness of screening for and eradication of Helicobacter pylori in young patients with dyspepsia. Studies'assumptions are removed from clinical practice [letter] Trimble I, et al. **BMJ** 1996 Sep 7;313(7057):622–3

Efficacy of nizatidine, clarithromycin and bismuth subcitrate therapy for Helicobacter pylori eradication in duodenal ulcer patients—a preliminary report. Papp J, et al. **Br J Clin Pract** 1996 Jul–Aug;50(5):249–53

The effect of ranitidine (as effervescent tablets) on the quality of life of GORD patients. Stacey JH, et al. **Br J Clin Pract** 1996 Jun;50(4):190–4, 196

Drug therapy of peptic ulcer disease. Ching CK, et al. **Br J Hosp Med** 1995 Jul 12–Aug 15;54(2–3):101–6 (39 ref.)

Intravenous omeprazole prevents rebleeding in peptic ulcer patients with a non-bleeding visible vessel: a preliminary report of a randomized controlled study. Chua RT, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Feb; 57(2):139–45

A multicenter, randomized, double-blind comparison of roxatidine with ranitidine in the treatment of patients with uncomplicated benign gastric ulcer disease. The Multicenter Roxatidine Cooperative Study Group. Brandstätter G, et al. **Clin Ther** 1995 May–Jun;17(3):467–78

Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia's senior population. Kephart G, et al. **Clin Ther** 1995 Nov–Dec; 17(6):1159–73

Clinical evaluation of teprenone, a mucosal protective agent, in the treatment of patients with gastric ulcers: a nationwide, multicenter clinical study. Shirakabe H, et al. **Clin Ther** 1995 Sep–Oct;17(5):924–35

Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis. Ben-Menachem T, et al. **Crit Care Med** 1996 Feb;24(2):338–45 (59 ref.)

Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine. Arakawa T, et al. **Dig Dis Sci** 1995 Nov;40(11):2469–72

Effects of sulglycotide on inflammation and epithelial cell turnover in active Helicobacter pylori+ chronic gastritis. A pilot study. Bazuro GE, et al. **Dig Dis Sci** 1996 Jan; 41(1):22–5

Therapy with omeprazole and clarithromycin increases serum carbamazepine levels in patients with H. pylori gastritis [letter; comment] Dammann HG. **Dig Dis Sci** 1996 Mar;41(3):519–20. Comment on: Dig Dis Sci 1995 Apr;40(4):912–5.

Nonsteroidal antiinflammatory drug-induced colitis and misoprostol [letter] Hebuterne X, et al. **Dig Dis Sci** 1996 Mar;41(3):520–1

Healing of gastric body ulcer with gastroprotective versus antisecretory treatment. Jablonská M. **Dig Dis Sci** 1995 Sep; 40(9):2016–8

Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers. Sung JJ, et al. **Dig Dis Sci** 1996 Mar;41(3):453–7

Placebo-controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux. Vaezi MF, et al. **Dig Dis Sci** 1996 Apr;41(4):754–63

A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders. Tack J, et al. **Drug Saf** 1995 Jun; 12(6):384–92 (103 ref.)

Ebrotidine. Patel SS, et al. **Drugs** 1996 Jun;51(6):974–80; discussion 981 (41 ref.)

Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Davis R, et al. **Drugs Aging** 1995 Nov;7(5):372–93 (76 ref.)

Use of misoprostol in the elderly: is the expense justified? Stucki G, et al. **Drugs Aging** 1996 Feb;8(2):84–8 (24 ref.)

Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: a prospective and randomized study. Villanueva C, et al. **Endoscopy** 1995 May;27(4):308–12

Transendoscopic electrocautery-induced gastric ulcers as a model for gastric healing studies in ponies. MacAllister CG, et al. **Equine Vet J** 1994 Mar;26(2):100–3

Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. Deltenre M, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S39–44

Combination therapy with mucosal protective agent for the eradication of Helicobacter pylori. Fukuda Y, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S45–7

Critical issues in the pathophysiology and management of peptic ulcer disease. Hunt RH, et al. **Eur J Gastroenterol Hepatol** 1995 Jul;7(7):685–99 (156 ref.)

Evaluation of a new bismuth-free triple therapy in nude mice and humans. Karita M, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S31–4

Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Poynard T, et al. **Eur J Gastroenterol Hepatol** 1995 Jul;7(7):661–5

Colloid bismuth versus famotidine in the treatment and prevention of duodenal ulcer relapse: results of a double-blind, double dummy randomized study. Masci E, et al. **Fundam Clin Pharmacol** 1995;9(3):280–3

Sucralfate suppresses Helicobacter pylori infection and reduces gastric acid secretion by 50% in patients with duodenal ulcer [see comments] Banerjee S, et al. **Gastroenterology** 1996 Mar;110(3):717–24. Comment in: Gastroenterology 1996 Mar;110(3):947–50.

Is a pound of prevention worth an ounce of cure? Fennerty MB. **Gastroenterology** 1996 Mar;110(3):958–60

Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer [see comments] Labenz J, et al. **Gastroenterology** 1996 Mar;110(3):725–32 . Comment in: Gastroenterology 1996 Mar;110(3):947–50.

Endoscopy, nonsteroidal anti-inflammatory drug, and omeprazole regimen in colorectal cancer prevention [letter; comment] Morgan G. **Gastroenterology** 1996 Apr; 110(4):1323. Comment on: Gastroenterology 1995 Oct;109(4):1188–96.

A prospective study of fungal infection of gastric ulcers: clinical significance and correlation with medical treatment. Wu CS, et al. **Gastrointest Endosc** 1995 Jul;42(1):56–8

Enhancement in the protective qualities of gastric mucus by ebrotidine during duodenal ulcer healing. Slomiany BL, et al. **Gen Pharmacol** 1995 Sep;26(5):1039–44

Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Borody TJ, et al. **Gut** 1995 Oct; 37(4):477–81

Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Holloway RH, et al. **Gut** 1996 May; 38(5):649–54

Effect of angiotensin converting enzyme inhibitor (captopril) on gastric ulcer production in pylorus ligated rats. Rao SP, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):296–8

Evaluation of gastric ulcer healing by lansoprazole by measurement of ulcer diameter. Aoyama N, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S86–9

Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. Asaki S, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S56–8

Clinical study on the pathophysiology and treatment of PPI-resistant ulcers. Ashida K, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S67–71

Quality of peptic ulcer healing induced by lansoprazole and roxatidine. Fujino MA, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S44–6

Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. Fukuda Y, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S132–5

Symptomatic response to omeprazole in inflammatory bowel disease. Guslandi M, et al. **J Clin Gastroenterol** 1996 Mar; 22(2):159–60

Factors affecting quality of ulcer healing after lansoprazole treatment. Ito G, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S62–6

Clinical efficacy of lansoprazole in eradication of Helicobacter pylori. Katoh M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S112–4

Effects of lansoprazole on gastric ulcer healing and mucin content. Komuro Y, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S47–51

The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. Mine T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S75–8

Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. Murakami M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S79–82

Clinical effectiveness of lansoprazole in patients with gastric ulcers: evaluation of quality of ulcer healing based on endoscopic ultrasonographic findings. Obara K, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S36–9

Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. Ogoshi K, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S97–9

Effect of lansoprazole on peptic ulcers. Ohashi T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S83–5

Comparison of lansoprazole and famotidine for gastric ulcer by endoscopic ultrasonography: a preliminary trial. Okai T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S32–5

Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine. Sakaguchi M, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S27–31

Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. Sugiyama T, et al. **J Clin Gastroenterol** 1995; 20 Suppl 2:S104–6

Efficacy of lansoprazole in eradication of Helicobacter pylori. Takimoto T, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S121–4

Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. Tsuji S, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S1–4

Endosonographic evaluation of the quality of ulcer healing induced by proton pump inhibitors. Tsukamoto Y, et al. **J Clin Gastroenterol** 1995;20 Suppl 2:S40–3

Nonsteroidal antiinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. Valentini M, et al. **J Clin Oncol** 1995 Oct;13(10):2637–42

Anti-ulcerogenic evaluation of the methanolic extracts of some indigenous medicinal plants of Pakistan in aspirin-ulcerated rats. Akhtar AH, et al. **J Ethnopharmacol** 1995 Apr;46(1):1–6

Anti-ulcer effect of the hot water extract of black tea (Camellia sinensis). Maity S, et al. **J Ethnopharmacol** 1995 Jun;46(3):167–74

Protective effect of UL-409, a herbal formulation against physical and chemical factor induced gastric and duodenal ulcers in experimental animals. Mitra SK, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):165–9

Treatment of Helicobacter pylori infection. Ebell MH. **J Fam Pract** 1996 Jun;42(6):568

Ethical use of placebos in clinical trials [letter; comment] Orr RD. **J Fam Pract** 1996 Jan;42(1):85–6. Comment on: J Fam Pract 1995 Aug;41(2):126–36.

A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease. Ching CK, et al. **J Gastroenterol** 1995 Oct; 30(5):607–14

Effect of the eradication of Helicobacter pylori on duodenal ulcer healing and ulcer relapse: randomized controlled study in Japan. Shirotani T, et al. **J Gastroenterol** 1996 Apr;31(2):175–81

Effects of pirenzepine on omeprazole-induced hypergastrinemia and acid suppression in peptic ulcer patients. Tari A, et al. **J Gastroenterol** 1996 Apr; 31(2):167–70

Roxatidine versus ranitidine in the treatment of duodenal ulcers: a randomized double-blind controlled multicentre study in Singapore. Fock KM, et al. **J Gastroenterol Hepatol** 1995 Jul–Aug;10(4):379–82

Comparison of roxatidine and famotidine on nocturnal gastric juice secretion. Tanioka H, et al. **J Int Med Res** 1996 Jan–Feb;24(1):88–91

Anti-ulcer activity of higher primary alcohols of beeswax. Carbajal D, et al. **J Pharm Pharmacol** 1995 Sep;47(9):731–3

Gastric and duodenal anti-ulcer activity of SKF 38393, a dopamine D1-receptor agonist in rats. Desai JK, et al. **J Pharm Pharmacol** 1995 Sep;47(9):734–8

Preventive effect of rebamipide on gastric lesions induced

by ischemia-reperfusion in the rat. Kim CD, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):340–4

Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. Berstad A, et al. **J Physiol Pharmacol** 1996 Mar;47(1):31–49 (45 ref.)

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59–69 (66 ref.)

Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection. Gabryelewicz A. **J Physiol Pharmacol** 1996 Mar;47(1):51–8 (44 ref.)

One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients. Sito E, et al. **J Physiol Pharmacol** 1996 Mar; 47(1):221–8

Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. Cook DJ, et al. **JAMA** 1996 Jan 24–31;275(4):308–14

Effects of famotidine vs antacid on gastric acidity: onset of action and symptom relief [letter] Decktor DL, et al. **JAMA** 1996 Sep 18;276(11):873–4

Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology [published erratum appears in JAMA 1996 May 1;275(17):1314] Soll AH. **JAMA** 1996 Feb 28;275(8):622–9 (99 ref.)

Lansoprazole--a new proton pump inhibitor [letter] Ahmed W, et al. **JPMA J Pak Med Assoc** 1995 May;45(5):144–5

Evaluation of physician intervention letters. Rascati KL, et al. **Med Care** 1996 Aug;34(8):760–6

Helicobacter pylori: how often are eradication therapies prescribed? [letter] Parkes AJ. **Med J Aust** 1995 Sep 18; 163(6):334

Maintenance therapies for reflux esophagitis [letter; comment] Grey MR. **N Engl J Med** 1996 Feb 29; 334(9):600–1. Comment on: N Engl J Med 1995 Oct 26;333(17):1106–10.

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. Taha AS, et al. **N Engl J Med** 1996 May 30;334(22):1435–9

Long-term therapy for reflux esophagitis [editorial; comment] Tytgat GN. **N Engl J Med** 1995 Oct 26; 333(17):1148–50. Comment on: N Engl J Med 1995 Oct 26;333(17):1106–10.

A comparison of five maintenance therapies for reflux esophagitis [see comments] Vigneri S, et al. **N Engl J Med** 1995 Oct 26;333(17):1106–10. Comment in: N Engl J Med 1995 Oct 26;333(17):1148–50. Comment in: N Engl J Med 1996 Feb 29;334(9):600–1.

Maintenance therapies for reflux esophagitis [letter; comment] Yarze JC. **N Engl J Med** 1996 Feb 29; 334(9):600–1. Comment on: N Engl J Med 1995 Oct 26;333(17):1106–10.

Stress bleeding prophylaxis in the ICU: obligate or obsolete? [editorial] Bonten MJ, et al. **Neth J Med** 1996 Jan;48(1):4–7 (24 ref.)

Effects of MCI-727 on pancreatic exocrine secretion and acute pancreatitis in two experimental rat models. Tachibana I, et al. **Pancreas** 1996 Mar;12(2):165–72

The development of clinical practice guidelines for treatment of peptic acid diseases in a VA ambulatory care clinic. Matsuyama JR, et al. **Pharmacotherapy** 1995 Sep–Oct; 15(5):608–13

Verification of decreased basal and stimulated serum pepsinogen-I levels is a useful non-invasive method for determining the success of eradication therapy for Helicobacter pylori. Gisbert JP, et al. **Scand J Gastroenterol** 1996 Feb;31(2):103–10

A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia. al-Quorain A, et al. **Scand J Gastroenterol** 1995 Jun; 30(6):531–4

Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study. Schepp W, et al. **Scand J Gastroenterol** 1995 Jun;30(6):511–4

Helicobacter pylori eradication: unravelling the facts. Dixon JS. **Scand J Gastroenterol Suppl** 1995;212:48–62 (244 ref.)

Suppression of Helicobacter pylori colonization with omeprazole. Fukuda Y. **Scand J Gastroenterol Suppl** 1996; 214:54–5; discussion 57–60

Quality of life and cost of therapy in reflux disease. Glise H. **Scand J Gastroenterol Suppl** 1995;210:38–42 (33 ref.)

Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori. Götz JM, et al. **Scand J Gastroenterol Suppl** 1995;212:34–7

Sucralfate: prophylaxis of mucosal damage during cancer therapy. Henriksson R, et al. **Scand J Gastroenterol Suppl** 1995;210:45–7 (29 ref.)

Nitric oxide in gastroprotective and ulcer healing effects of sucralfate. Konturek SJ, et al. **Scand J Gastroenterol Suppl** 1995;210:22–7

Long-term strategies for peptic ulcer. Korman MG. **Scand J Gastroenterol Suppl** 1995;210:60–3 (39 ref.)

Helicobacter pylori and peptic ulcer. Korman MG, et al. **Scand J Gastroenterol Suppl** 1995;210:92–6 (61 ref.)

Sucralfate in Helicobacter pylori eradication strategies. Lam SK, et al. **Scand J Gastroenterol Suppl** 1995;210:89–91 (19 ref.)

Gastro-oesophageal reflux and chronic respiratory disease in infants and children: treatment with cisapride. Olafsdottir E. **Scand J Gastroenterol Suppl** 1995;211:32–4

Stimulation of mucosal glutathione and angiogenesis: new mechanisms of gastroprotection and ulcer healing by sucralfate. Sandor Z, et al. **Scand J Gastroenterol Suppl** 1995;210:19–21

Growth factors: new 'endogenous drugs' for ulcer healing. Szabo S, et al. **Scand J Gastroenterol Suppl** 1995;210:15–8 (33 ref.)

The clinical use of cisapride in gastro-oesophageal reflux disease, with particular focus on the long-term treatment aspects. Tytgat GN. **Scand J Gastroenterol Suppl** 1995; 211:39–43

Effect of sucralfate on Helicobacter pylori and severity of gastritis in patients with duodenal ulcer. Winter TA, et al. **Scand J Gastroenterol Suppl** 1995;210:85–8

Efficacy of ciprofloxacin in the eradication of Helicobacter pylori. Dresner D, et al. **South Med J** 1996 Aug;89(8):775–8

Medical management of esophageal reflux. Hirschowitz BI. **Yale J Biol Med** 1994 May–Aug;67(3–4):223–31 (35 ref.)

[A clinical trial of lansoprazole in the treatment of duodenal ulcer] Pei Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Sep; 34(9):606–8 (Eng. Abstr.) **(Chi)**

[Protective effect of "wei tong ling" on gastric mucosa and influence on quality of gastric ulcer healing] Yan SQ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):612–4 (Eng. Abstr.) **(Chi)**

[Effects of composite xueliting on four gastric ulcer models in rats and mice] Yang JR, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jul; 15(7):416–8 (Eng. Abstr.) **(Chi)**

[Clinical study on treatment of peptic ulcer with bushen kangkui decoction] Yang Y, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):583–5 (Eng. Abstr.) **(Chi)**

[Proton pump blockers and their significance in gastroenterology] Dítě P, et al. **Vnitr Lek** 1995 Aug; 41(8):549–54 (23 ref.) (Eng. Abstr.) **(Cze)**

[Ulfamid Krka (famotidine) in monotherapy of peptic ulcer] Shonová O, et al. **Vnitr Lek** 1996 Feb;42(2):114 **(Cze)**

[Misoprostol: prevention of ulcers caused by NSAID] Matzen P, et al. **Ugeskr Laeger** 1996 Aug 19;158(34):4782–5 **(Dan)**

[Pantoprazole. A new acid pump inhibitor against peptic ulcer and reflux esophagitis] Wilson BV, et al. **Ugeskr Laeger** 1996 Mar 18;158(12):1695–7 **(Dan)**

[Recurrence of reflux esophagitis can be prevented with maintenance therapy with sucralfate] Tytgat GN, et al. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2432–7 (Eng. Abstr.) **(Dut)**

[What is the right therapeutic management of duodenal ulcer except in emergency?] Bouhnik Y. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S131–S134 (40 ref.) **(Fre)**

[Medical treatment of stomach ulcer except in emergency] Bretagne JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S73–S80 (68 ref.) **(Fre)**

[How to eradicate Helicobacter pylori?] Cayla R. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S119–S130 (83 ref.) **(Fre)**

[Treatment of stomach ulcer] Hudziak H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S136–S142 (51 ref.) **(Fre)**

[Therapeutic management of duodenal ulcer except in emergency: eradication of Helicobacter pylori] Lamouliatte H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S58–S63 (63 ref.) **(Fre)**

[Eradication of Helicobacter pylori and treatment of the stomach ulcer] Lamouliatte H. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):651–2 **(Fre)**

[Management of duodenal ulcer except in emergency: surgical treatment] Michot F, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S64–S72 (87 ref.) **(Fre)**

[Therapeutic management of duodenal ulcer except in emergency cases: antisecretory treatment] Ruszniewski P. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S53–S57 (48 ref.) **(Fre)**

[Importance of ranitidine in the eradication of Helicobacter pylori] Beglinger C. **Rev Med Suisse Romande** 1995 Oct; 115(10):795–7 **(Fre)**

[Role of ranitidine in the treatment and prevention of NSAID-induced digestive lesions] Bommelaer G. **Rev Med Suisse Romande** 1995 Oct;115(10):799–802 **(Fre)**

[Role of ranitidine in the treatment of peptic diseases (editorial)] Loizeau E. **Rev Med Suisse Romande** 1995 Oct; 115(10):765 **(Fre)**

[Role of ranitidine in the treatment of gastroesophageal reflux and its complications] Mainguet P. **Rev Med Suisse Romande** 1995 Oct;115(10):781–8 **(Fre)**

[Role of ranitidine in duodenal ulcerous disease] Mignon M, et al. **Rev Med Suisse Romande** 1995 Oct;115(10):789–93 **(Fre)**

[Remission of diarrhea of unknown origin in omeprazol therapy] Classen M, et al. **Dtsch Med Wochenschr** 1995 Oct 13;120(41):1414 **(Ger)**

[Roxatidine acetate in therapy of reflux esophagitis] Friedrich P, et al. **Fortschr Med** 1996 Jun 10;114(16):213–6 (Eng. Abstr.) **(Ger)**

[Treatment of acute peptic gastroduodenal ulcer: omeprazole is superior to ranitidine especially in the early phase of ulcer healing. A prospective controlled randomized serial endoscopy study] Hotz J, et al. **Leber Magen Darm** 1995 Jul;25(4):165–70 (Eng. Abstr.) **(Ger)**

[Gastroesophageal reflux: current status of therapy] Seifert E. **Leber Magen Darm** 1995 Jul;25(4):156–60, 163 (55 ref.) (Eng. Abstr.) **(Ger)**

[Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons] Holtmann G, et al. **Z Gastroenterol** 1996 May; 34(5):267–72 (Eng. Abstr.) **(Ger)**

[Prevention and treatment of upper gastrointestinal bleeding by nonsteroidal anti-inflammatory drugs] Bar-Dayan Y, et al. **Harefuah** 1996 Apr 15;130(8):535–7 (34 ref.) **(Heb)**

[Comparison of the effectiveness of anti-ulcer drugs and their influence on angiogenesis in healing of experimental chronic gastric ulcer] Hnatyszyn A. **Ann Acad Med Stetin** 1995;41:183–91 (Eng. Abstr.) **(Pol)**

[The influence of retinol, tocopherol and cimetidine on the ulcerogenic effect of Orthofen, indomethacin and naproxen] Stanislavchuk NA, et al. **Eksp Klin Farmakol** 1995 Nov–Dec;58(6):33–5 (Eng. Abstr.) **(Rus)**

[Losek (omeprazole), a new therapeutic agent in the treatment of peptic ulcer and hyperacidity states] Bulgakov SA. **Klin Med (Mosk)** 1995;73(5):11–6 (7 ref.) **(Rus)**

[Clinical aspects of Kvamatel (famotidine) administration] Golochevskaia VS. **Klin Med (Mosk)** 1996;74(1):45–7 (10 ref.) **(Rus)**

[Effects of traditional antiulcer therapy on the motor-secretory function and microcirculation in the gastric and duodenal wall in patients with duodenal ulcer] Orlov VA, et al. **Klin Med (Mosk)** 1995;73(4):96 **(Rus)**

[The efficacy of the synthetic prostaglandin Cytotec in preventing and treating symptomatic gastropathy] Normanskil ES, et al. **Voen Med Zh** 1996 Feb;317(2):33–5 **(Rus)**

[Stress-limiting effect of zantac in duodenal ulcer bleeding] Ermolov AS, et al. **Vopr Med Khim** 1995 Sep–Oct; 41(5):56–9 (Eng. Abstr.) **(Rus)**

[The effect of thymalin, dalargin and "Mucosalin" on the course of an experimental duodenal ulcer] Lukash NV, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):53–5 (Eng. Abstr.) **(Rus)**

[Treatment of duodenal ulcer with famotidine and proglumide] Tarabar D, et al. **Vojnosanit Pregl** 1995 Nov–Dec;52(6):563–7 (Eng. Abstr.) **(Ser)**

[Evaluation of treatment for the prevention of acute gastric lesions in stress, in rats] Laudanno OM, et al. **Acta Gastroenterol Latinoam** 1995;25(3):145–52 (Eng. Abstr.) **(Spa)**

[Helicobacter pylori eradication heals the duodenal ulcer. Randomized, simple, and controlled study with omeprazole] Piñero R, et al. **G E N** 1995 Apr–Jun; 49(2):111–5 (Eng. Abstr.) **(Spa)**

[Omeprazole and amoxycillin in the eradicating treatment of Helicobacter pylori] Gisbert JP, et al. **Rev Clin Esp** 1995 Nov;195(11):787–91 (74 ref.) **(Spa)**

[Evaluation of intravenous ranitidine and omeprazole effect on the 24-hour gastric ph-metry in duodenal ulcer hemorrhage] Artal A, et al. **Rev Esp Enferm Dig** 1996 Mar; 88(3):191–6 (Eng. Abstr.) **(Spa)**

[Comparison of 2 treatment schemes to eradicate Helicobacter pylori] Hoffenberg P, et al. **Rev Med Chil** 1995 Feb;123(2):185–91 (Eng. Abstr.) **(Spa)**

[An experimental study of the anti-ulcer effect of administering sodium succinate and a solution of whey in immobilization stress] Maliuk VI, et al. **Fiziol Zh** 1995 Jan–Apr;41(1–2):79–86 (Eng. Abstr.) **(Ukr)**

[Lipid peroxidation in an experimental study of an erosion-ulcer lesion of the stomach as affected by the new high-protein products and ethonium] Fediv OI, et al. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):79–85 (Eng. Abstr.) **(Ukr)**

TOXICITY

Embryotoxic effects of misoprostol in the mouse. Paumgartten FJ, et al. **Braz J Med Biol Res** 1995 Mar; 28(3):355–61

URINE

Identification of urinary metabolites of ecabapide in rat. Fujimaki Y, et al. **Xenobiotica** 1995 May;25(5):501–10

ANTIVENINS

Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis. Wilde H, et al. **Ann Intern Med** 1996 Aug 1;125(3):233–6 (22 ref.)

Detection and neutralization of B. jararaca venom in mice. Domingos MO, et al. **Braz J Med Biol Res** 1994 Nov; 27(11):2613–22

ADMINISTRATION & DOSAGE

Efficacy of widow spider antivenin [letter; comment] Pearl JM. **Ann Emerg Med** 1996 Feb;27(2):273. Comment on: Ann Emerg Med 1994 Dec;24(6):1198–9. Comment on: Ann Emerg Med 1995 Sep;26(3):393–4.

Pitviper bites: rational management in locales in which

copperheads and cottonmouths predominate. Lawrence WT, et al. **Ann Plast Surg** 1996 Mar;36(3):276–85

ADVERSE EFFECTS

In the tail of the taipan. A personal view of snakebite and serum sickness. Dyke T. **Med J Aust** 1995 Dec 4–18; 163(11–12):614–5

BIOSYNTHESIS

Antigenic cross-reactivity among components of Brazilian Elapidae snake venoms. Higashi HG, et al. **Braz J Med Biol Res** 1995 Jul;28(7):767–71

[Preparation of antivenins to scorpion venoms and a protection trials in animal models] Kharrat R, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):473–6 **(Fre)**

BLOOD

Levels of therapeutic antivenin and venom in a human snakebite victim. Ownby CL, et al. **South Med J** 1996 Aug; 89(8):803–6

IMMUNOLOGY

Neutralization of bee venom lethality by immune serum antibodies. Schumacher MJ, et al. **Am J Trop Med Hyg** 1996 Aug;55(2):197–201

METABOLISM

Evidence of the coevolution of a snake toxin and its endogenous antitoxin cloning, sequence and expression of a serum albumin cDNA of the Chinese cobra. Wang X, et al. **Biol Chem Hoppe Seyler** 1995 Sep;376(9):545–53

Snake F(ab')2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits. Pepin S, et al. **Pharm Res** 1995 Oct;12(10):1470–3

PHARMACOLOGY

Effects of antithrombin III and antivenom on procoagulant activity of Russell's viper venom in a whole blood model. Clemens R, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):143–8

(Evaluation of neutralizing ability of four commercially available antivenoms against the venom of Bothrops asper from Costa Rica) Bogarín G, et al. **Toxicon** 1995 Sep; 33(9):1242–7 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Determination of the neutralizing potency of horse antivenom against bothropic and crotalic venoms by indirect enzyme immunoassay. Barbosa CF, et al. **Braz J Med Biol Res** 1995 Oct;28(10):1077–80

THERAPEUTIC USE

Comparison of a new ovine antigen binding fragment (Fab) antivenin for United States Crotalidae with the commercial antivenin for protection against venom-induced lethality in mice. Consroe P, et al. **Am J Trop Med Hyg** 1995 Nov; 53(5):507–10

Efficacy of antivenom in the treatment of severe local envenomation by the hump-nosed viper (Hypnale hypnale). Sellahewa KH, et al. **Am J Trop Med Hyg** 1995 Sep; 53(3):260–2

Use of dantrolene in experimental scorpion envenomation by Androctonus australis hector [letter] Guieu R, et al. **Arch Toxicol** 1995;69(8):575–7

Treatment of black widow spider envenomation [letter; comment] Miller TA. **J Am Board Fam Pract** 1995 Nov–Dec;8(6):503. Comment on: J Am Board Fam Pract 1995 Jul–Aug;8(4):288–94.

Copperhead snakebite of the foot [letter] Reid H, et al. **J Am Podiatr Med Assoc** 1996 Jul;86(7):347–9

Do we need anti snake venom (ASV) for management of elapid ophitoxaemia. Bomb BS, et al. **J Assoc Physicians India** 1996 Jan;44(1):31–3

Early infusion of a purified monospecific F(ab')2 antivenom serum for Bothrops lanceolatus bites in Martinique [letter] Thomas L, et al. **Lancet** 1996 Feb 10;347(8998):406

Delayed but effective treatment of red-back spider envenomation [letter] Wells CL, et al. **Med J Aust** 1996 Apr 1;164(7):447

Brown recluse spider envenomation of the eyelid: an animal model. Cole HP 3rd, et al. **Ophthal Plast Reconstr Surg** 1995 Sep;11(3):153–64

New procedures and parameters for better evaluation of Androctonus australis garzonii (Aag) and Buthus occitanus tunetanus (Bot) scorpion envenomations and specific serotherapy treatment. Krifi MN, et al. **Toxicon** 1996 Feb; 34(2):257–66

Treatment of snake bites by Bothrops species and Lachesis muta in Ecuador: laboratory screening of candidate antivenoms. Theakston RD, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct;89(5):550–4

[Preparation of antivenins to scorpion venoms and a protection trials in animal models] Kharrat R, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):473–6 **(Fre)**

[Snake bites in children: antivenom early reaction frequency in patients pretreated with histamine antagonists H1 and H2 and hydrocortisone] Bucaretchi F, et al. **Rev Inst Med Trop Sao Paulo** 1994 Sep–Oct;36(5):451–7 (Eng. Abstr.) **(Por)**

ANTIVIRAL AGENTS

see related

REVERSE TRANSCRIPTASE INHIBITORS

Virus validation experiments on the production process of OCTAVI SDPlus. Biesert L, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S48–54

Preliminary clinical experience: pharmacokinetics and tolerance of a double-virus-inactivated factor VIII preparation. Martinowitz U. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S84–5

Competitive ELISA to evaluate the immunogenicity of double-virus-inactivated factor VIII in rabbits. Verdier F, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S62–4

Interferon-alpha and -gamma expression in the rat testis. Dejucq N, et al. **Endocrinology** 1995 Nov;136(11):4925–31

Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease. Saxena SK, et al. **J Biol Chem** 1996 Aug 23;271(34):20783–8

Herbs of the genus Phyllanthus in the treatment of chronic hepatitis B: observations with three preparations from different geographic sites. Wang M, et al. **J Lab Clin Med** 1995 Oct;126(4):350–2

Increased zidovudine prescribing associated with lamivudine availability [letter] Montaner JS, et al. **JAMA** 1996 Feb 28;275(8):598

Several new drugs shift direction of treatment and research for HIV/AIDS [news] Voelker R. **JAMA** 1996 Jan 10; 275(2):89–90

Protease inhibitors fly through FDA [news] Barnett AA. **Lancet** 1996 Mar 9;347(9002):678

Recent development in the design of antiviral agents. Saunders J, et al. **Med Res Rev** 1995 Nov;15(6):497–531 (86 ref.)

Rational drug design and HIV: hopes and limitations. Goody RS. **Nat Med** 1995 Jun;1(6):519–20

New therapeutic agents marketed in 1995. Hussar DA. **Pa Med** 1996 Jun;99(6):35–6, 39–40

Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Lambert DM, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5; 93(5):2186–91

Elimination of potential mutagenicity in platelet concentrates that are virally inactivated with psoralens and ultraviolet A light. Margolis-Nunno H, et al. **Transfusion** 1995 Oct; 35(10):855–62

Resistance to geminivirus infection by virus-induced expression of dianthin in transgenic plants. Hong Y, et al. **Virology** 1996 Jun 1;220(1):119–27

[Biological study of fullerene C60] Huang WD, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):367–9 (10 ref.) **(Chi)**

[Structure-activity relation study of anti-herpes associations with a 2'-deoxyuridine basic structure] Herdewijn P. **Verh K Acad Geneeskd Belg** 1995;57(6):601–15 (Eng. Abstr.) **(Dut)**

[Prescription of antiretroviral and prophylactic drugs in HIV diseases: reality of medical practices] Bourdillon F, et al. **Ann Med Interne (Paris)** 1995;146(7):500–4 (Eng. Abstr.) **(Fre)**

[Non-nucleoside antiretroviral agents] Sereni D, et al. **Presse Med** 1996 Mar 2–9;25(8):361–4, 366–9 (29 ref.) (Eng. Abstr.) **(Fre)**

[Chemical condoms supposed to prevent HIV infection (news)] **Geburtshilfe Frauenheilkd** 1996 Mar; 56(3):XVI–XVII **(Ger)**

[Evaluation of the antiviral activity of the disinfectant VIRKON] Bonfanti C, et al. **Ann Ig** 1995 Jan–Feb; 7(1):55–62 **(Ita)**

[New tests of virucidal activity of 2 disinfectants versus HBV DNA positive sera: slot-blot and polymerase chain reaction (PCR)] Vollaro L, et al. **Ann Ig** 1995 Jan–Feb;7(1):63–8 **(Ita)**

[Progress on antiviral agents] Shigeta S. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1555–8 (2 ref.) **(Jpn)**

[Design of S-adenosylhomocystein hydrolase (SHAase) inhibitors as potent anti-RNA viral agents] Shuto S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1261–7 (27 ref.) **(Jpn)**

[Didanosine] **Enferm Infecc Microbiol Clin** 1995 Oct; 13(8):487–90 (0 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Tolerance of a triple combination therapy with zidovudine, didanosine and interferon-alpha in seven HIV-infected patients [letter] Bissuel F, et al. **AIDS** 1995 Nov;9(11):1285

Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics. Dusserre N, et al. **AIDS** 1995 Aug;9(8):833–41

Lymphoid tissues targeting of liposome-encapsulated 2',3'-dideoxyinosine. Harvie P, et al. **AIDS** 1995 Jul; 9(7):701–7

Transdermal delivery of zalcitabine: in vitro skin permeation study. Kim DD, et al. **AIDS** 1995 Dec;9(12):1331–6

Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. Tassopoulos NC, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1734–8

Effect of daily administration period of natural alpha-interferon in patients with chronic hepatitis C. Toyoda H, et al. **Am J Gastroenterol** 1996 Apr;91(4):743–7

Ocular iontophoretic supplementation of intravenous foscarnet therapy. Yoshizumi MO, et al. **Am J Ophthalmol** 1996 Jul;122(1):86–90

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Di Bisceglie AM, et al. **Ann Intern Med** 1995 Dec 15;123(12):897–903

Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group. Graham NM, et al. **Ann Intern Med** 1996 Jun 15; 124(12):1031–8

Preemptive ganciclovir therapy in renal transplantation [letter] Tamm M, et al. **Ann Intern Med** 1996 Apr 1; 124(7):693–4

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Jacobs LD, et al. **Ann Neurol** 1996 Mar;39(3):285–94

Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma. Gabarre J, et al. **Ann Oncol** 1995 Dec; 6(10):1025–32

Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Omar RF, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1973–8

Combination therapy for HIV-1 infection-overview: preclinical and clinical analysis of antiretroviral combinations. Johnson VA. **Antiviral Res** 1996 Jan; 29(1):35–9 (21 ref.)

In vitro evaluation of combination therapies against hepatitis B virus replication. Korba BE. **Antiviral Res** 1996 Jan; 29(1):49–51

Overview: issues concerning the pharmacology of multiple drug regimens. Lietman PS. **Antiviral Res** 1996 Jan;29(1):65

Experts recommend longer treatment for hepatitis C virus [news] Roper CR, et al. **AORN J** 1995 Sep;62(3):358

The antiinflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis. Ornstein MH, et al. **Arthritis Rheum** 1996 Jan; 39(1):157–61

Combination drug treatment benefits patients with HIV [news] Boulton A. **BMJ** 1996 Aug 10;313(7053):320

Topical acyclovir is beneficial in recurrent herpes labialis [letter; comment] [see comments] Lamey PJ. **BMJ** 1996 Apr 13;312(7036):975. Comment on: BMJ 1996 Jan 6;312(7022):6. Comment in: BMJ 1996 Jul 6;313(7048):46.

Managing HIV disease without Delta [letter; comment] Seaton RA, et al. **BMJ** 1996 Jun 15;312(7045):1542. Comment on: BMJ 1996 Mar 2;312(7030):521–2.

Evidence for efficacy of topical acyclovir in recurrent herpes labialis is weak [letter; comment] Worrall G. **BMJ** 1996 Jul 6;313(7048):46. Comment on: BMJ 1996 Apr 13;312(7036):975.

Cytomegalovirus retinitis: are intraocular devices the answer? Tufail A, et al. **Br J Ophthalmol** 1995 Dec;79(12):1066–7

Randomized case-controlled trial of oral low-dose acyclovir for prevention of virus infections in recipients of renal allografts. Jiang J, et al. **Chin Med J (Engl)** 1995 Jun; 108(6):459–61

Clinical course and treatment of adults with severe measles pneumonitis [letter; comment] Goetz MB, et al. **Clin Infect Dis** 1995 Aug;21(2):443. Comment on: Clin Infect Dis 1994 Sep;19(3):454–62.

Clinical management of herpes zoster in the elderly patient. Beutner KR. **Compr Ther** 1996 Mar;22(3):183–6 (6 ref.)

Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial. Sánchez-Tapias JM, et al. **Gut** 1996 Apr;38(4):603–9

Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. Torrani Cerenzia M, et al. **Hepatology** 1996 Apr;23(4):657–61

Targeting HIV with liposome-encapsulated antivirals [editorial] Désormeaux A, et al. **Int J Med Microbiol Virol Parasitol Infect Dis** 1995 Apr; 282(3):225–31 (15 ref.)

Liver targeting of adenine arabinoside monophosphate (ara-AMP) by coupling to lactosaminated human serum albumin. Fiume L, et al. **Ital J Gastroenterol** 1995 May; 27(4):189–92

Inhibition of murine AIDS by combination of AZT and dideoxycytidine 5'-triphosphate. Fraternale A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):164–73

Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group. Gatell JM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jul; 12(3):249–58

Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. Kessler HA, et al.

J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jun 1;12(2):147–52

Efficacy, safety, and tolerance of low-dose, long-term interferon-alpha 2b and zidovudine in early-stage AIDS-associated Kaposi's sarcoma. Mauss S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):157–62

A new HIV/AIDS drug. **J Ark Med Soc** 1996 Jan;92(8):407

Efficacy of combination therapy with interferon and azidothymidine in chronic type C hepatitis: a pilot study. Tsutsumi M, et al. **J Gastroenterol** 1995 Aug;30(4):485–92

Long-term administration of natural interferon-alpha in patients with chronic hepatitis C: relationship to serum RNA concentration, HCV-RNA genotypes, histological changes and hepatitis C virus. Kumada T, et al. **J Gastroenterol Hepatol** 1996 Feb;11(2):159–65

Cytomegalovirus antigenemia as a marker for antiviral therapy after heart transplantation [letter] Iberer F, et al. **J Heart Lung Transplant** 1996 Mar;15(3):314–5

Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. Valenza M, et al. **J Heart Lung Transplant** 1995 Jul-Aug;14(4):659–65

Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). Pediatric AIDS Clinical Trials Group. Brady MT, et al. **J Infect Dis** 1996 May; 173(5):1097–106

Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. Griffith BP, et al. **J Infect Dis** 1996 May; 173(5):1252–5

Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trial. Kovacs JA, et al. **J Infect Dis** 1996 Apr;173(4):840–8

Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis. Kuppermann BD, et al. **J Infect Dis** 1996 Jan;173(1):18–23

Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 1. Stability studies for hairless rat skin permeation. Kim DD, et al. **J Pharm Sci** 1995 Sep;84(9):1061–6

Predominance of codon 215 mutation in reverse transcriptase-coding region of 3'-azido-3'-deoxythymidine (AZT)-resistant HIV-1 isolates after long-term AZT therapy. Kondo M. **Kansenshogaku Zasshi** 1995 Nov; 69(11):1278–85

A case of oral lichen planus with chronic hepatitis C successfully treated by glycyrrhizin. Nagao Y, et al. **Kansenshogaku Zasshi** 1995 Aug;69(8):940–4

Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee [see comments] **Lancet** 1996 Aug 3;348(9023):283–91. Comment in: Lancet 1996 Aug 3;348(9023):278–9.

Intraocular device for cytomegalovirus infection. Ernest JT. **Lancet** 1995 Oct 14;346(8981):983–4

New guidelines set for occupational HIV exposure [news] Rowe PM. **Lancet** 1996 Jul 6;348(9019):48

Delta in the real world [comment] Sherer R. **Lancet** 1996 Aug 3;348(9023):278–9. Comment on: Lancet 1996 Aug 3;348(9023):283–91.

Oral ganciclovir for cytomegalovirus retinitis [letter; comment] Torgovnick J. **N Engl J Med** 1996 Jan 4; 334(1):55–6. Comment on: N Engl J Med 1995 Sep 7;333(10):615–20.

Oral ganciclovir for cytomegalovirus retinitis [letter; comment] Van Natta ML, et al. **N Engl J Med** 1996 Jan 4;334(1):55; discussion 55–6. Comment on: N Engl J Med 1995 Sep 7;333(10):615–20.

Selective liver targeting of antivirals by recombinant chylomicrons—a new therapeutic approach to hepatitis B [see comments] Rensen PC, et al. **Nat Med** 1995 Mar; 1(3):221–5. Comment in: Nat Med 1995 Mar;1(3):210–1.

Enhancement of the anti-HIV-1 activity of ddAdo by coformycin, EHNA and deaza-EHNA derivatives. Marongiu ME, et al. **New Microbiol** 1995 Oct;18(4):359–70

Dose-dependent brain delivery of zidovudine through the use of a zidovudine chemical delivery system. Brewster ME, et al. **Pharm Res** 1995 May;12(5):796–8

Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices. Bjøro K, et al. **Scand J Gastroenterol** 1995 Nov;30(11):1119–24

Treatment of adenoviral pneumonitis with intravenous ribavirin and immunoglobulin. Sabroe I, et al. **Thorax** 1995 Nov;50(11):1219–20

Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Winston DJ, et al. **Transplantation** 1995 Dec 15;60(11):1357–60

[Treatment of herpes simplex keratouveitis with systemic and local administration of acyclovir] Říhová E, et al. **Cesk Slov Oftalmol** 1996 Apr;52(2):109–14 (Eng. Abstr.) **(Cze)**

[My experiences with Zovir herpes tablets (letter)] Ambjørn A. **Ugeskr Laeger** 1996 May 13;158(20):2867–8 **(Dan)**

[A new, very promising antiviral treatment of influenza] Hornsleth A. **Ugeskr Laeger** 1996 Apr 1;158(14):1985–6 **(Dan)**

[Selective targetting of antiviral agents to the liver] Jansen PL. **Ned Tijdschr Geneeskd** 1995 Sep 16;139(37):1868–9 **(Dut)**

[Treatment of chronic hepatitis C with lymphoblastic interferon. Long-term follow-up] Passariello N, et al. **Presse Med** 1995 Sep 16;24(26):1201–6 (Eng. Abstr.) **(Fre)**

[Euphoria in HIV therapy (news)] Weismann H. **Dtsch Med Wochenschr** 1996 Mar 8;121(10):A28 **(Ger)**

[Zidovudine therapy alone is not enough (news)] **Fortschr Med** 1995 Nov 20;113(32):13–4 **(Ger)**

[Selective increase of antiviral substances in the liver in hepatitis B by recombinant chylomicrons—a useful new therapeutic approach?] Gallwitz B, et al. **Z Gastroenterol** 1995 Dec;33(12):725–6 **(Ger)**

[Amantadine in the prevention of nosocomial influenza] Bíró L, et al. **Orv Hetil** 1996 Jan 28;137(4):171–4 (Eng. Abstr.) **(Hun)**

[Evaluation of two treatment schedules with different doses of interferon in chronic HBsAg+ anti-HBe+ hepatitis] Facciorusso D, et al. **Recenti Prog Med** 1996 Jan;87(1):12–5 (Eng. Abstr.) **(Ita)**

[Long term/intermittent treatment of chronic hepatitis C with recombinant interferon alfa-2b] Hakozaki Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:1001–6 **(Jpn)**

[Efficacy of interferon re-therapy and its adaptation in chronic hepatitis C] Matsuo S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:1012–6 **(Jpn)**

[Efficacy of interferon combined glycyrrhizin therapy in patients with interferon-resistant chronic hepatitis C] Okuno T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:1022–5 **(Jpn)**

[Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration] Shoji S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:997–1000 (10 ref.) **(Jpn)**

[Interferon treatment for chronic hepatitis C—assessment of 3 regimens in patients received more than 500 MU interferon treatment and their effect predictive factors for interferon treatment using multivariate analysis with the logistic regression model] Terada M. **Nippon Rinsho** 1995 Sep;53 Suppl:1007–11 **(Jpn)**

[Treatment of chronic hepatitis C with different regimens of interferon] Yamauchi M, et al. **Nippon Rinsho** 1995 Sep; 53 Suppl:991–6 **(Jpn)**

[Two cases of acute exacerbation of chronic hepatitis C improved after the administration of an immunosuppressive drug and interferon] Ikeda H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug;92(8):1200–5 **(Jpn)**

[A case of Guillain-Barré syndrome associated with anti-GM2 antibody due to cytomegalovirus infection—special reference to the effect of ganciclovir] Niwa K, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):652–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

[The use of ocular drug films of propolis in the sequelae of ophthalmic herpes] Maĭchuk IuF, et al. **Voen Med Zh** 1995 Dec;(12):36–9, 80 (Eng. Abstr.) **(Rus)**

[Intravitreal ganciclovir in cytomegalovirus retinitis in AIDS] Olea JL, et al. **Rev Clin Esp** 1996 Apr;196(4):208–12 (Eng. Abstr.) **(Spa)**

[Value of a short (7 days) prophylactic course of ganciclovir in the prevention of cytomegalovirus disease after heart transplantation] Giménez D, et al. **Rev Esp Cardiol** 1996 Jan;49(1):35–40 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Renal tubular acidosis following treatment with foscarnet [letter] Navarro JF, et al. **AIDS** 1995 Dec;9(12):1389–90

Re: life-threatening severe immune thrombocytopenia after alpha-interferon therapy for chronic hepatitis C infection [letter] Khan HA, et al. **Am J Gastroenterol** 1996 Apr; 91(4):821–2

Successful treatment of sorivudine-related agranulocytosis with granulocyte-colony stimulating factor [letter] Sato H, et al. **Am J Hematol** 1995 Nov;50(3):227

Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Navarro JF, et al. **Am J Kidney Dis** 1996 Mar;27(3):431–4 (16 ref.)

Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity. Casato M, et al. **Am J Med** 1995 Oct;99(4):386–91

Granulocytopenia after combined therapy with interferon and angiotensin- converting enzyme inhibitors: evidence for a synergistic hematologic toxicity [letter] Jacquot C, et al. **Am J Med** 1996 Aug;101(2):235–6

Adverse events from drug therapy for human immunodeficiency virus disease. Moore RD, et al. **Am J Med** 1996 Jul;101(1):34–40

Non-insulin-dependent diabetes mellitus developing during interferon-alpha therapy for chronic hepatitis C [letter] Chedin P, et al. **Ann Intern Med** 1996 Sep 15;125(6):521

Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Monto AS, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2224–8

Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Omar RF, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1973–8

Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Biron F, et al. **Antiviral Res** 1996 Jan;29(1):111–3

A penile ulceration in a patient with the acquired immunodeficiency syndrome. Foscarnet-induced penile ulceration. Fitzgerald E, et al. **Arch Dermatol** 1995 Dec; 131(12):1449, 1452

Acyclovir in chickenpox [letter] Jenks PJ, et al. **Arch Dis Child** 1996 Feb;74(2):184

Role of zidovudine antiretroviral therapy in the pathogenesis of acquired immunodeficiency syndrome-related lymphoma. Levine AM, et al. **Blood** 1995 Dec 15; 86(12):4612–6

Rapidly reversible increase in insulin requirement with interferon. Campbell S, et al. **BMJ** 1996 Jul 13;313(7049):92

Severe necroziting vasculitis in a patient with hepatitis C virus infection treated by interferon. Pateron D, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):79–81

Stevens-Johnson syndrome induced by treatment with acyclovir. Fazal BA, et al. **Clin Infect Dis** 1995 Oct; 21(4):1038–9

No evidence of contact sensitization to acyclovir in acute dermatitis of the lips following local application of Zovirax cream. Koch P. **Contact Dermatitis** 1995 Oct;33(4):255–7

Cutaneous side effects associated with interferon-alpha therapy: a review. Chang LW, et al. **Cutis** 1995 Sep; 56(3):144 (14 ref.)

Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. D'Amico E, et al. **Dig Dis Sci** 1995 Oct;40(10):2113–6 (20 ref.)

Development of granulomatous hepatitis during treatment with interferon-alpha 2b [letter] Propst A, et al. **Dig Dis Sci** 1995 Oct;40(10):2117–8

Pre-treatment with hydration and electrolytes may prevent dose limiting toxicities during foscarnet induction therapy [letter] Jayaweera D, et al. **Genitourin Med** 1995 Dec; 71(6):414–5

A comparative trial of recombinant interferon alpha 2A versus alpha 2 beta on myelosuppression in healthy adult volunteers. Wong S, et al. **Hepatogastroenterology** 1996 Jan-Feb;43(7):301–5

Does interferon precipitate rejection of liver allografts? [editorial] Min AD, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1333–5 (22 ref.)

Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Carella C, et al. **Horm Res** 1995;44(3):110–4

Endocrine evaluation in patients treated with interferon-alpha for chronic hepatitis C. Del Monte P, et al. **Horm Res** 1995;44(3):105–9

Erythema multiforme secondary to dideoxycytidine (ddC). Wardropper AG, et al. **Int J STD AIDS** 1995 Nov-Dec; 6(6):450

Intraocular hemorrhage developing during interferon therapy. Kuga K, et al. **Intern Med** 1996 Jan;35(1):15–8

Histiocytic cytophagic panniculitis which developed during interferon-alpha therapy. Kuno M, et al. **Intern Med** 1996 Feb;35(2):115–8

Sarcoidosis after interferon therapy for chronic active hepatitis C. Teragawa H, et al. **Intern Med** 1996 Jan; 35(1):19–23 (20 ref.)

Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. Fichtenbaum CJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):169–74

Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebo-controlled trials. Jacobson MA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):45–52

Interferon alfa-induced interstitial pneumonitis in a patient with cutaneous T-cell lymphoma. Nouri K, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):269–70

A pharmacokinetic and safety evaluation of a 28 day course of oral acyclovir in elderly patients with herpes zoster [letter] Moss PJ, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):271–3

New nucleoside analogues—time for caution? [letter] Nathwani D. **J Infect** 1995 Jul;31(1):82

Turns-amplitude analysis assessment of myopathies in HIV-infected patients. Lefaucheur JP, et al. **J Neurol Sci** 1996 Mar;136(1-2):148–53

Neuropsychological effects of Interferon Alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals. Mapou RL, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):74–81

Renal failure after treatment with ritonavir [letter] Duong M, et al. **Lancet** 1996 Sep 7;348(9028):693

Hepatitis B reactivation after lamivudine [letter] Honkoop P, et al. **Lancet** 1995 Oct 28;346(8983):1156–7

Hypersensitivity syndrome associated with zalcitabine therapy [letter] Tancrède-Bohin E, et al. **Lancet** 1996 Apr 6;347(9006):971

Severe toxicity of fialuridine (FIAU) [letter; comment] Gordon M. **N Engl J Med** 1996 Apr 25;334(17):1136–7; discussion 1137–8. Comment on: N Engl J Med 1995 Oct 26;333(17):1099–105.

Severe toxicity of fialuridine (FIAU) [letter; comment] Josephson L. **N Engl J Med** 1996 Apr 25;334(17):1135–6;

discussion 1137–8. Comment on: N Engl J Med 1995 Oct 26;333(17):1099–105.

Severe toxicity of fialuridine (FIAU) [letter; comment] Lewis W, et al. **N Engl J Med** 1996 Apr 25;334(17):1136; discussion 1137–8. Comment on: N Engl J Med 1995 Oct 26;333(17):1099–105. Comment on: N Engl J Med 1995 Oct 26;333(17):1146–8.

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B [see comments] McKenzie R, et al. **N Engl J Med** 1995 Oct 26;333(17):1099–105. Comment in: N Engl J Med 1995 Oct 26;333(17):1146–8. Comment in: N Engl J Med 1996 Apr 25;334(17):1135; discussion 1137–8. Comment in: N Engl J Med 1996 Apr 25;334(17):1135–6; discussion 1137–8. Comment in: N Engl J Med 1996 Apr 25;334(17):1136; discussion 1137–8. Comment in: N Engl J Med 1996 Apr 25;334(17):1136–7; discussion 1137–8.

Severe toxicity of fialuridine (FIAU) [letter; comment] Prince AM. **N Engl J Med** 1996 Apr 25;334(17):1136; discussion 1137–8. Comment on: N Engl J Med 1995 Oct 26;333(17):1099–105.

Mitochondrial toxicity—new adverse drug effects [editorial; comment] [see comments] Swartz MN. **N Engl J Med** 1995 Oct 26;333(17):1146–8. Comment on: N Engl J Med 1995 Oct 26;333(17):1099–105. Comment in: N Engl J Med 1996 Apr 25;334(17):1136; discussion 1137–8.

More on interferon-induced cutaneous necrosis [letter; comment] Trautinger F, et al. **N Engl J Med** 1995 Nov 2;333(18):1222–3; discussion 1223–4. Comment on: N Engl J Med 1995 Jun 8;332(23):1584.

Reversible acute renal failure caused by the combined use of foscarnet and cyclosporin in organ transplanted patients [see comments] Morales JM, et al.
Nephrol Dial Transplant 1995;10(6):882–3. Comment in: Nephrol Dial Transplant 1996 Jan;11(1):221.

Acute renal failure associated with foscarnet therapy [letter; comment] Navarro JF, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):221. Comment on: Nephrol Dial Transplant 1995;10(6):882–3.

Acyclovir-associated encephalopathy in haemodialysis [letter] Peces R, et al. **Nephrol Dial Transplant** 1996 Apr; 11(4):752

Cytochrome c oxidase deficiency in zidovudine myopathy affects perifascicular muscle fibres and arterial smooth muscle cells. Chairot P, et al.
Neuropathol Appl Neurobiol 1995 Dec;21(6):540–7

HIV medicine: drug side effects and interactions. Bates CM. **Postgrad Med J** 1996 Jan;72(843):30–6 (27 ref.)

Acyclovir triphosphate inhibits the diagnostic polymerase chain reaction for cytomegalovirus. Yedidag EN, et al.
Transplantation 1996 Jul 27;62(2):238–42

Hemodialysis removal of acyclovir. Leikin JB, et al.
Vet Hum Toxicol 1995 Jun;37(3):233–4

[Exacerbation of an autoimmune thrombocytopenic purpura during treatment with interferon alpha in a woman with chronic viral hepatitis C] Bacq Y, et al.
Gastroenterol Clin Biol 1996;20(3):303–6 (Eng. Abstr.) **(Fre)**

[Serum smooth muscle antibodies with anti-actin specificity appeared during treatment with interferon alpha (letter)] Grimbert S, et al. **Gastroenterol Clin Biol** 1996;20(4):404–5 **(Fre)**

[Depressive disorders and interferon alpha (editorial)] Hardy P. **Gastroenterol Clin Biol** 1996;20(3):255–7 (13 ref.) **(Fre)**

[Side effects of interferon-alpha] Vial T, et al.
Gastroenterol Clin Biol 1996;20(5):462–89 (305 ref.) **(Fre)**

[Myasthenia during interferon alpha therapy (letter)] Quilichini R, et al. **Presse Med** 1995 Sep 2–9;24(25):1178 **(Fre)**

[Evaluation of side effects of interferon-alpha in 72 patients treated for chronic active hepatitis C] Duché A, et al.
Therapie 1995 Sep–Oct;50(5):419–23 (Eng. Abstr.) **(Fre)**

[A case of interstitial pneumonia with chronic hepatitis C following interferon-alfa and sho-saiko-to therapy] Sugiyama H, et al. **Arerugi** 1995 Jul;44(7):711–4 **(Jpn)**

[A case of ventricular tachycardia occurred during interferon therapy in chronic hepatitis C] Omae A, et al.
Nippon Naika Gakkai Zasshi 1995 Oct 10;84(10):1734–5 **(Jpn)**

[Adverse effect of interferon therapy and its prevention] Sainokami S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:1026–33 (9 ref.) **(Jpn)**

[Acyclovir nephrotoxicity] Briso-Montiano JM, et al.
An Med Interna 1995 Oct;12(10):501–2 (Eng. Abstr.) **(Spa)**

[Tetany caused by foscarnet in a female patient with acquired immunodeficiency syndrome (letter)] Vela Moreno J, et al. **An Med Interna** 1995 Jul;12(7):358–9 **(Spa)**

[Ulcer in the urethral meatus and HIV infection (letter)] Len O, et al. **Enferm Infecc Microbiol Clin** 1995 Oct;13(8):497–8 **(Spa)**

[Permanent hypothyroidism after interferon-alpha treatment in chronic hepatitis C (letter)] Fernández Soto ML, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):76–7 **(Spa)**

[Pancreatic disease in patients with HIV treated with didanosine (DDI)] Ortega González E, et al.
Rev Esp Enferm Dig 1996 Feb;88(2):114–7 (Eng. Abstr.) **(Spa)**

ANALYSIS

Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: identification of a novel inhibitor of influenza virus. Kurtz S, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2204–9

Precision in capillary electrophoresis with respect to quantitative analysis of suramin. Hettiarachchi K, et al.
J Chromatogr A 1995 Nov 24;717(1–2):191–202

High-performance liquid chromatographic determination of the biologically active principle hypericin in phytotherapeutic vegetable extracts and alcoholic beverages. Micali G, et al. **J Chromatogr A** 1996 Apr 19; 731(1–2):336–9

High-performance liquid chromatographic determination of (–)-beta-D-2,6-diaminopurine dioxolane and its metabolite, dioxolane guanosine, using ultraviolet and on-line radiochemical detection. Rajagopalan P, et al.
J Chromatogr B Biomed Appl 1995 Oct 6;672(1):119–24

ANTAGONISTS & INHIBITORS

Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation [letter] Veal GJ, et al. **AIDS** 1996 May;10(5):546–8

HIV-1 gp 120 blocks jacalin-induced proliferative response in CD4+ T cells: jacalin as a useful surrogate marker for qualitative and quantitative deficiency of CD4+ T cells in HIV-1 infection. Tamma SM, et al.
Clin Immunol Immunopathol 1996 Sep;80(3 Pt 1):290–7

Antisense manganese superoxide dismutase mRNA inhibits the antiviral action of interferon-gamma and interferon-alpha. Raineri I, et al.
J Interferon Cytokine Res 1996 Jan;16(1):61–8

Brefeldin A inhibits the antiviral action of interferon against encephalomyocarditis virus. Sidhu GS, et al. **Virus Res** 1996 Feb;40(2):123–33

BLOOD

Strategies for control of zidovudine concentrations in serum. Noormohamed SE, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2792–7

High-performance liquid chromatography of fullerence (C60) in plasma using ultraviolet and mass spectrometric detection. Santa T, et al. **Biol Pharm Bull** 1995 Sep; 18(9):1171–4

Improved combined solid-phase extraction-RIA method for quantifying zalcitabine in plasma. Kastrissios H, et al.
Clin Chem 1996 Mar;42(3):465–6

Rapid and sensitive determination of zidovudine and zidovudine glucuronide in human plasma by ion-pair high-performance liquid chromatography. Nadal T, et al.
J Chromatogr A 1996 Jan 15;721(1):127–37

Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy [see comments] Livington DJ, et al.
J Infect Dis 1995 Nov;172(5):1238–45. Comment in: J Infect Dis 1996 Jun;173(6):1524–6.

Cationized hyperimmune immunoglobulins: pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice. Pardridge WM, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):246–52

Biodistribution and virus inactivation efficacy of a silicon phthalocyanine in red blood cell concentrates as a function of delivery vehicle. Ben-Hur E, et al.
Photochem Photobiol 1995 Sep;62(3):575–9

[Interferon-alpha controls HPV infection in cervix epithelium] Labeit D, et al. **Zentralbl Gynakol** 1995; 117(11):566–77 (Eng. Abstr.) **(Ger)**

CEREBROSPINAL FLUID

Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex. Burger DM, et al. **Pharm World Sci** 1995 Nov 24;17(6):218–21

CHEMICAL SYNTHESIS

Ether, carbonate and urethane deoxynucleoside derivatives as prodrugs. Hammer K, et al. **Acta Chem Scand** 1996 Jul; 50(7):609–22

Synthesis of an AZT-HEPT hybrid and homologous AzddU derivatives. Larsen E, et al. **Acta Chem Scand** 1996 May; 50(5):417–21

Synthesis, antitumoral and antiviral evaluation of halo- and demethyl-yatein derivatives. Medarde M, et al.
Arch Pharm (Weinheim) 1995 Sep;328(9):640–4

Differential antiviral activity of derivatized dextrans. Neyts J, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):743–51

Block polycationic oligonucleotide derivative: synthesis and inhibition of herpes virus reproduction. Vinogradov SV, et al. **Bioconjug Chem** 1996 Jan–Feb;7(1):3–6

New 1,2,6-thiadiazine dioxide acyclonucleosides: synthesis and antiviral evaluation. Esteban AI, et al.
Bioorg Med Chem 1995 Nov;3(11):1527–35

Parallel-compound synthesis: methodology for accelerating drug discovery. Selway CN, et al. **Bioorg Med Chem** 1996 May;4(5):645–54

Stereoselective synthesis, chemistry and antiviral evaluation of 1-(2,3-dideoxy-3-C-hydroxymethyl-beta-D-threo-pentofuranosyl)thymine derivatives. Wengel J, et al.
Bioorg Med Chem 1995 Sep;3(9):1223–9

Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere. Kiso Y.
Biopolymers 1996;40(2):235–44 (27 ref.)

Synthesis of sulfated octadecyl ribo-oligosaccharides with potent anti-AIDS virus activity by ring-opening polymerization of a 1,4-anhydroribose derivative. Choi YS, et al. **Carbohydr Res** 1996 Feb 28;282(1):113–23

Synthesis of curdlan sulfates having inhibitory effects in vitro against AIDS viruses HIV-1 and HIV-2. Yoshida T, et al. **Carbohydr Res** 1995 Oct 23;276(2):425–36

Meisenheimer rearrangement of azetopyridoindoles. VIII. Synthesis and antiviral activities of 12-carbaeudistomin analogs. Kurihara T, et al. **Chem Pharm Bull (Tokyo)** 1996 May;44(5):900–8

Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity. Tamamura H, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):853–8

Synthesis and biodistribution of [4-14C]-5-bromo-6-methoxy-5,6-dihydro-prodrug derivatives of 5-ethyl-2'-deoxyuridine. Cheraghali AM, et al. **Drug Des Discov** 1994 Jul;12(1):53–61

Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials. Artico M. **Farmaco** 1996 May;51(5):305–31 (92 ref.)

Anti-HIV agents. IV. Synthesis and in vitro anti-HIV activity of novel 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazoles. Chimirri A, et al. **Farmaco** 1996 Apr; 51(4):279–82

Synthesis of substituted quinazolone derivatives as potential anti-HIV agents (Part III). Desai NC, et al. **Farmaco** 1996 May;51(5):361–6

Synthesis and antirhinovirus activity of 3-(diethylamino)-5-phenylisoxazole derivatives. Mazzei M, et al. **Farmaco** 1996 May;51(5):351–9

Synthesis and anti-HIV activity of 10,11-dihydropyrrolo [1,2-b][1,2,5]benzothiadiazepine-11-acetic acid 5,5-dioxide derivatives and related compounds. Silvestri R, et al.
Farmaco 1996 Jun;51(6):425–30

2-(4-Pyridyl)-delta 2-1,3,4-oxadiazolines from isonicotinoylhydrazones and diazomethane as potential antimycobacterial and anti-HIV agents. V. Vigorita MG, et al. **Farmaco** 1995 Nov;50(11):783–6

Synthesis and study of derivatives of cyclic carbamides with antiviral and antimicrobial action. Sidzhakova D, et al.
Folia Med (Plovdiv) 1995;37(4A Suppl):28

New bellenamine homologs inhibiting human immunodeficiency virus type I infectivity. Kondo S, et al.
J Antibiot (Tokyo) 1996 Jan;49(1):113–8

Synthesis and antiviral activity of pyranosylphosphonic acid nucleotide analogues. Alexander P, et al. **J Med Chem** 1996 Mar 15;39(6):1321–30

Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. Bell FW, et al. **J Med Chem** 1995 Dec 8; 38(25):4929–36

Synthesis and anti-DNA viral activities in vitro of certain 2,4-disubstituted-7-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrrolo[2,3-d d pyrimidine nucleosides. Bhattacharya BK, et al. **J Med Chem** 1995 Sep 29; 38(20):3957–66

Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit human immunodeficiency virus replication. 2. Effect of heteroaromatic linkers on the activity of bicyclams. Bridger GJ, et al. **J Med Chem** 1996 Jan 5; 39(1):109–19

Hydroxylated aromatic inhibitors of HIV-1 integrase. Burke TR Jr, et al. **J Med Chem** 1995 Oct 13;38(21):4171–8

Synthesis and evaluation of novel thymidine analogs as antitumor and antiviral agents. Chen X, et al.
J Med Chem 1996 Aug 16;39(17):3412–7

Synthesis and biological evaluation of N6-cycloalkyl derivatives of 1-deazaadenine nucleosides: a new class of anti-human immunodeficiency virus agents. Cristalli G, et al. **J Med Chem** 1995 Sep 29;38(20):4019–25

Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors. Cushman M, et al. **J Med Chem** 1996 Aug 2;39(16):3217–27

Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
Danel K, et al. **J Med Chem** 1996 Jun 7;39(12):2427–31

A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. Dollé V, et al.
J Med Chem 1995 Nov 10;38(23):4679–86

Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 3. 6-Amino prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine. Driscoll JS, et al.
J Med Chem 1996 Apr 12;39(8):1619–25

Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents. Dvořáková H, et al.
J Med Chem 1996 Aug 16;39(17):3263–8

(–)-Arctigenin as a lead structure for inhibitors of human

immunodeficiency virus type-1 integrase. Eich E, et al. **J Med Chem** 1996 Jan 5;39(1):86–95

Paracyclophanes: a novel class of water-soluble inhibitors of HIV proteinase. Ettmayer P, et al. **J Med Chem** 1996 Aug 16;39(17):3291–9

Betulinic acid derivatives: a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action. Evers M, et al. **J Med Chem** 1996 Mar 1;39(5):1056–68

Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability. Fässler A, et al. **J Med Chem** 1996 Aug 2;39(16):3203–16

Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers. Flavin MT, et al. **J Med Chem** 1996 Mar 15;39(6):1303–13

Synthesis and antiviral activity of 8-aza analogs of chiral [2-(phosphonomethoxy) propyl]guanines. Franchetti P, et al. **J Med Chem** 1995 Sep 29;38(20):4007–13

Synthesis of substituted 1-norbornylamines with antiviral activity. García Martínez A, et al. **J Med Chem** 1995 Oct 27;38(22):4474–7

Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents. Gueiffier A, et al. **J Med Chem** 1996 Jul 5; 39(14):2856–9

Design, synthesis, and structure-activity relationship of novel dinucleotide analogs as agents against herpes and human immunodeficiency viruses. Hakimelahi GH, et al. **J Med Chem** 1995 Nov 10;38(23):4648–59

Nucleoside conjugates. 15. Synthesis and biological activity of anti-HIV nucleoside conjugates of ether and thioether phospholipids. Hong CI, et al. **J Med Chem** 1996 Apr 26; 39(9):1771–7

Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands. Jungheim LN, et al. **J Med Chem** 1996 Jan 5; 39(1):96–108

Synthesis and biological evaluation of N-acetylneuraminic acid-based rotavirus inhibitors. Kiefel MJ, et al. **J Med Chem** 1996 Mar 15;39(6):1314–20

Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2. Kolocouris N, et al. **J Med Chem** 1996 Aug 16;39(17):3307–18

Synthesis and evaluation of certain thiosangivamycin analogs as potential inhibitors of cell proliferation and human cytomegalovirus. Krawczyk SH, et al. **J Med Chem** 1995 Sep 29;38(20):4115–9

Synthesis and antiproliferative and antiviral activity of 2'-deoxy-2'-fluoroarabinofuranosyl analogs of the nucleoside antibiotics toyocamycin and sangivamycin. Krawczyk SH, et al. **J Med Chem** 1995 Sep 29; 38(20):4106–14

Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3'-azido-2',3'-dideoxythymidine 5'-monophosphate. Lefebvre I, et al. **J Med Chem** 1995 Sep 29;38(20):3941–50

Polyanion inhibitors of human immunodeficiency virus and other viruses. Part 2. Polymerized anionic surfactants derived from amino acids and dipeptides. Leydet A, et al. **J Med Chem** 1996 Apr 12;39(8):1626–34

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. Lin TS, et al. **J Med Chem** 1996 Apr 26;39(9):1757–9

Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents. Ma T, et al. **J Med Chem** 1996 Jul 5;39(14):2835–43

Effective inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition. Mammen M, et al. **J Med Chem** 1995 Oct 13;38(21):4179–90

Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design. Melnick M, et al. **J Med Chem** 1996 Jul 5;39(14):2795–811

Synthesis and biological evaluation of1',2'-seconucleo-5'-phosphonates. Racha S, et al. **J Med Chem** 1996 Mar 1; 39(5):1130–5

Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides. Rahim SG, et al. **J Med Chem** 1996 Feb 2;39(3):789–95

Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and + +thiosangivamycin: influence of various 7-substituents on antiviral activity. Renau TE, et al. **J Med Chem** 1996 Feb 16;39(4):873–80

Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: the effect of certain 4- and 4,6-substituents on the antiviral activity of pyrrolo[2,3-d]pyrimidines. Renau TE, et al. **J Med Chem** 1996 Aug 30;39(18):3470–6

Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry. Soler F, et al. **J Med Chem** 1996 Mar 1;39(5):1069–83

Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles. Townsend LB, et al. **J Med Chem** 1995 Sep 29; 38(20):4098–105

Synthesis and antiretroviral evaluation of new alkoxy and aryloxy phosphate derivatives of 3'-azido-3'-deoxythymidine. Tsotinis A, et al. **J Med Chem** 1996 Aug 16;39(17):3418–22

Synthesis and antiviral activity of 2'-deoxy-4'-thio purine nucleosides. Van Draanen NA, et al. **J Med Chem** 1996 Jan 19;39(2):538–42

A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. von Itzstein M, et al. **J Med Chem** 1996 Jan 19; 39(2):388–91

Phosphodiester amidates of allenic nucleoside analogues: anti-HIV activity and possible mechanism of action. Winter H, et al. **J Med Chem** 1996 Aug 16;39(17):3300–6

Synthesis and antiviral evaluation of certain disubstituted benzimidazole ribonucleosides. Zou R, et al. **J Med Chem** 1996 Aug 30;39(18):3477–82

Synthesis and biological activity of 1,2,4-triazinotriazinone derivatives. Abdel-Halim AM, et al. **Pharmazie** 1995 Nov; 50(11):726–9

Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Balzarini J, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7295–9

Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors. Balzarini J. **Verh K Acad Geneeskd Belg** 1995;57(6):575–600

[Bis((2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)alkyl) disulfane and 3-(mercaptoalkyl)quinazolin-2,4(1H,3H)-dione: synthesis by ring transformation and antiviral activity. 42. Heterocyclic azines with heteroatoms in the 1- and 3-positions] Gütschow M, et al. **Pharmazie** 1995 Oct; 50(10):672–5 (Eng. Abstr.) **(Ger)**

CHEMISTRY

2',3'-Dideoxy-3'-C,2'-N-[(3R,5R)-5-ethoxy-carbonyl-2-methyl-1, 2-isoxazolidine]-ribothymidine. Burkhart BM, et al. **Acta Crystallogr C** 1995 Jul 15;51 (Pt 7):1462–4

4-(Acetylamino)-3-hydroxy-5-nitrobenzoic acid. Jedrzejas MJ, et al. **Acta Crystallogr C** 1995 Sep 15;51 (Pt 9):1910–2

Structure of HIV-1 protease with KNI-272: a transition state mimetic inhibitor containing allophenylnorstatine. Baldwin ET, et al. **Adv Exp Med Biol** 1995;362:445–9

Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic. Kiso Y. **Adv Exp Med Biol** 1995;362:413–23

Kinetics of G-quartet-mediated tetramer formation. Wyatt JR, et al. **Biochemistry** 1996 Jun 18;35(24):8002–8

Synthesis and conformational analysis of pyrimidine nucleoside analogues with a rigid sugar moiety. Björsne M, et al. **Bioorg Med Chem** 1995 Apr;3(4):397–402

2-amino-9-(3-azido-2,3-dideoxy-beta-D-erythro-pentofuranosyl)-6-substituted-9H-purines: synthesis and anti-HIV activity. Freeman GA, et al. **Bioorg Med Chem** 1995 Apr;3(4):447–58

Development and biochemical characterization of a double-virus-inactivated factor VIII preparation. Robinson S, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S40–7

Structural analysis of antiviral sulfated alpha-D-(1-->3)-linked mannans. Kolender AA, et al. **Carbohydr Res** 1995 Aug 25;273(2):179–85

Structure-activity relationships in open ansa-chain rifamycin S derivatives as inhibitors of HIV-1 reverse transcriptase. Bartolucci C, et al. **Farmaco** 1995 Sep;50(9):587–93

Jacalin, a lectin interacting with O-linked sugars and mediating protection of CD4+ cells against HIV-1, binds to the external envelope glycoprotein gp120. Corbeau P, et al. **Immunol Lett** 1995 Jul-Aug;47(1-2):141–3

Characterization of conformation and dynamics of CD4 Fragment (81-92) TYICEVEDQKEE and its benzylated derivative by 1H NMR spectroscopy and molecular modeling: Relevance of conformation to biological function. Chang DK, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):222–32

Siamycins I and II, new anti-HIV-1 peptides: II. Sequence analysis and structure determination of siamycin I. Detlefsen DJ, et al. **J Antibiot (Tokyo)** 1995 Dec; 48(12):1515–7

Karalicin, a new biologically active compound from Pseudomonas fluorescens/putida. I. Production, isolation, physico-chemical properties and structure elucidation. Lampis G, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):260–2

NMR study of dideoxynucleotides with anti-human immunodeficiency virus (HIV) activity. Reddy DV, et al. **J Biochem Biophys Methods** 1996 Feb 5;31(3-4):113–21

Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. Bishop JS, et al. **J Biol Chem** 1996 Mar 8;271(10):5698–703

Competition between netropsin and restriction nuclease EcoRI for DNA binding. Sidorova NYu, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):367–85

Structure-activity correlation study of HIV-1 inhibitors: electronic and molecular parameters. Hannongbua S, et al. **J Comput Aided Mol Des** 1996 Apr;10(2):145–52

All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach. Gussio R, et al. **J Med Chem** 1996 Apr 12;39(8):1645–50

Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. Hopkins AL, et al. **J Med Chem** 1996 Apr 12;39(8):1589–600

Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. Joao HC, et al. **J Med Chem** 1995 Sep 15;38(19):3865–73

3D-quantitative structure-activity relationships of human immunodeficiency virus type-1 proteinase inhibitors: comparative molecular field analysis of 2-heterosubstituted statine derivatives-implications for the design of novel inhibitors. Kroemer RT, et al. **J Med Chem** 1995 Dec 8; 38(25):4917–28

Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series. Reich SH, et al. **J Med Chem** 1996 Jul 5;39(14):2781–94

Structure-activity relationships among 2-substituted 5,6-dichloro-, 4,6-dichloro-, and 4,5-dichloro-1-[(2-hydroxyethoxy) methyl]- and -1-[(1,3-dihydroxy-2-propoxy) methyl]benzimidazoles. Saluja S, et al. **J Med Chem** 1996 Feb 16;39(4):881–91

Study of a microencapsulation process of a virucide agent by a solvent evaporation technique. Legrand J, et al. **J Microencapsul** 1995 Nov-Dec;12(6):639–49

Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14. Oren DA, et al. **J Mol Biol** 1996 May 31;259(1):120–34

A novel basis of capsid stabilization by antiviral compounds. Phelps DK, et al. **J Mol Biol** 1995 Dec 8;254(4):544–51

Solubility behavior of lamivudine crystal forms in recrystallization solvents. Jozwiakowski MJ, et al. **J Pharm Sci** 1996 Feb;85(2):193–9

Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation. Kim DD, et al. **J Pharm Sci** 1996 Feb; 85(2):214–9

Preformulation studies of a novel HIV protease inhibitor, AG1343. Longer M, et al. **J Pharm Sci** 1995 Sep; 84(9):1090–3

Synthesis and biological activities of a phosphorodithioate analog of 2',5'-oligoadenylate. Beigelman L, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):3989–94

Design, biochemical, biophysical and biological properties of cooperative antisense oligonucleotides. Kandimalla ER, et al. **Nucleic Acids Res** 1995 Sep 11;23(17):3578–84

Biological activities of pyrrolidinoindoline alkaloids from Calycodendron milnei. Saad HE, et al. **Planta Med** 1995 Aug;61(4):313–6

Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Varghese JN, et al. **Protein Sci** 1995 Jun; 4(6):1081–7

Electron impact mass spectrometry of some potential anti-HIV nucleosides [letter] Santana L, et al. **Rapid Commun Mass Spectrom** 1996;10(10):1316–9

[Quantitative analysis of gamma-schizandrin in manganbao granules, a complex prescription of Chinese medicine] He Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep; 20(9):541–3, 575 (Eng. Abstr.) **(Chi)**

[Chromatographic support to remove solvent/detergent mixture utilized as viral attenuation agent] Guerrier L, et al. **Ann Pharm Fr** 1996;54(3):97–102 (Eng. Abstr.) **(Fre)**

[Proposition of chemical topology of principal antiviral molecules by a multiparameter mathematic model: the minimal length graph] Lacroix J, et al. **Ann Pharm Fr** 1996; 54(3):112–8 (Eng. Abstr.) **(Fre)**

[Human interferon: molecular mechanisms of antiviral activities] Yoshida I. **Nippon Rinsho** 1995 Sep;53 Suppl:909–22 (40 ref.) **(Jpn)**

DIAGNOSTIC USE

Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)

ECONOMICS

Home care reimbursement for intravenous ganciclovir therapy. Mozaffari E, et al. **Am J Health Syst Pharm** 1996 Jan 15;53(2):161–3

Cost effectiveness and AIDS: science or marketing? Proceedings of a workshop. Washington, D.C., January 28, 1995. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 4:S1–32

Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting. Mansergh G, et al. **JAMA** 1996 Jul 10;276(2):139–45

Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening. Mauskopf JA, et al. **JAMA** 1996 Jul 10;276(2):132–8

US states must cover protease inhibitors [news] Barnett AA. **Lancet** 1996 Jul 6;348(9019):52

The marketplace of HIV/AID$ [news] Cohen J. **Science** 1996 Jun 28;272(5270):1880–1

IMMUNOLOGY

Inhibitory effect of 3'-azido-3'-deoxythymidine on

proliferative responsiveness of CD8+ lymphocytes to interleukin-2. Mercure L, et al. **Clin Diagn Lab Immunol** 1994 Jul;1(4):482–5

Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. Milella M, et al. **Hepatogastroenterology** 1995 Jul;42(3):201–4

Getting to know you: viruses meet CD40 ligand [comment] McFadden G. **Nat Med** 1995 May;1(5):408–9. Comment on: Nat Med 1995 May;1(5):437–41.

CD40 ligand has potent antiviral activity [see comments] Ruby J, et al. **Nat Med** 1995 May;1(5):437–41. Comment in: Nat Med 1995 May;1(5):408–9.

ISOLATION & PURIFICATION

Anti-AIDS agents--XIX. Neotripterifordin, a novel anti-HIV principle from Tripterygium wilfordii: isolation and structural elucidation. Chen K, et al. **Bioorg Med Chem** 1995 Oct;3(10):1345–8

Isolation of pyropheophorbide a from the leaves of Atalantia monophylla (ROXB.) CORR. (Rutaceae) as a possible antiviral active principle against herpes simplex virus type 2. Chansakaow S, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul;44(7):1415–7

Isolation of brefeldin A. Kim HL, et al. **Gen Pharmacol** 1995 Mar;26(2):363–4

New cineromycins and musacins obtained by metabolite pattern analysis of Streptomyces griseoviridis (FH-S 1832). I. Taxonomy, fermentation, isolation and biological activity. Burkhardt K, et al. **J Antibiot (Tokyo)** 1996 May; 49(5):432–7

Sattabacins and sattazolins: new biologically active compounds with antiviral properties extracted from a Bacillus sp. Lampis G, et al. **J Antibiot (Tokyo)** 1995 Sep; 48(9):967–72

A new antiherpetic agent produced by Streptomyces sp. strain no. 758. Uyeda M, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1234–9

Isolation of anti-HIV-1 lignans from Larrea tridentata by counter-current chromatography. Gnabre JN, et al. **J Chromatogr A** 1996 Jan 8;719(2):353–64

Constituents of Ardisia japonica and their in vitro anti-HIV activity. Piacente S, et al. **J Nat Prod** 1996 Jun;59(6):565–9

New secosteroids from an undescribed gorgonian of the genus Muricella. Seo Y, et al. **J Nat Prod** 1995 Aug; 58(8):1291–5

Identification of ent-16 beta, 17-dihydroxykauran-19-oic acid as an anti-HIV principle and isolation of the new diterpenoids annosquamosins A and B from Annona squamosa. Wu YC, et al. **J Nat Prod** 1996 Jun;59(6):635–7

Antiviral and antiphlogistic activities of Hamamelis virginiana bark. Erdelmeier CA, et al. **Planta Med** 1996 Jun;62(3):241–5

Isorhamnetin sulphate from the leaves and stems of Oenanthe javanica in Korea [letter] Park JC, et al. **Planta Med** 1995 Aug;61(4):377–8

[Chemical constituents in the leaves of Mangifera persiciformis C.Y. Wu et Y.L. Ming] Si X, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):295–6, 320 (Eng. Abstr.) **(Chi)**

[Preparation and antiviral properties of Bacillus intermedius ribonuclease modified by chloranhydride of adamantanecarboxylic acid] Kurinenko BM, et al. **Antibiot Khimioter** 1995 Sep;40(9):17–9 (Eng. Abstr.) **(Rus)**

METABOLISM

Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. Jacobsson B, et al. **AIDS Res Hum Retroviruses** 1995 Jul;11(7):805–11

Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes. Koyano S, et al. **Antimicrob Agents Chemother** 1996 Apr; 40(4):920–3

Interaction of an anti-HIV peptide, T22, with gp120 and CD4. Tamamura H, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):555–9

The synthetic [Tyr5,12,Lys7]-polyphemusin II peptide (T22) binds to the CD4 cell surface molecule. Weeks BS, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):626–31

Synergistic binding of inhibitors to the protease from HIV type 1. Asante-Appiah E, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):113–7

Removal of anti-human immunodeficiency virus 2',3'-dideoxynucleoside monophosphates from DNA by a novel human cytosolic 3'—>5' exonuclease. Skalski V, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):815–21

HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Spence RA, et al. **Biochemistry** 1996 Jan 23; 35(3):1054–63

Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. Sampol E, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):83–6

Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human. Prueksaritanont T, et al. **Drug Metab Dispos** 1995 Jul; 23(7):688–95

Major structural differences between pokeweed antiviral protein and ricin A-chain do not account for their differing ribosome specificity. Chaddock JA, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):159–66

Binding of distamycin and chromomycin to human immunodeficiency type 1 virus DNA: a non-radioactive automated footprinting study. Feriotto G, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):85–93

DNA-nuclease activity of the single-chain ribosome-inactivating proteins dianthin 30, saporin 6 and gelonin. Roncuzzi L, et al. **FEBS Lett** 1996 Aug 19; 392(1):16–20

Metabolism of Zidovudine. Veal GJ, et al. **Gen Pharmacol** 1995 Nov;26(7):1469–75 (54 ref.)

Uptake and metabolism of BuCast: a glycoprotein processing inhibitor and a potential anti-HIV drug. Kang MS. **Glycobiology** 1996 Mar;6(2):209–16

Karalicin, a new biologically active compound from Pseudomonas fluorescens/putida. I. Production, isolation, physico-chemical properties and structure elucidation. Lampis G, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):260–2

Cellular phosphorylation of anti-HIV nucleosides. Role of nucleoside diphosphate kinase. Bourdais J, et al. **J Biol Chem** 1996 Apr 5;271(14):7887–90

Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. Orange JS, et al. **J Exp Med** 1995 Oct 1;182(4):1045–56

Effect of azoles on the glucuronidation of zidovudine by human liver UDP-glucuronosyltransferase [letter; comment] Asgari M, et al. **J Infect Dis** 1995 Dec; 172(6):1634–6. Comment on: J Infect Dis 1994 May;169(5):1103–7.

Identification of the respiratory syncytial virus-induced immunosuppressive factor produced by human peripheral blood mononuclear cells in vitro as interferon-alpha. Preston FM, et al. **J Infect Dis** 1995 Oct;172(4):919–26

Production of cytokines with antiviral activity by endothelial cells. Zaczyńska E, et al. **J Interferon Cytokine Res** 1995 Sep;15(9):811–4

Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. Kumar GN, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):423–31

Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Shaw T, et al. **Liver** 1995 Aug;15(4).169–84 (117 ref.)

Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Lewis W, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3592–7

Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. Filer CW, et al. **Xenobiotica** 1995 May;25(5):477–90

PHARMACOKINETICS

Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Smiley ML, et al. **Adv Exp Med Biol** 1996;394:33–9 (23 ref.)

Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics. Dusserre N, et al. **AIDS** 1995 Aug;9(8):833–41

Feto-maternal transfer of zidovudine: study on the perfused human placental cotyledon system [letter] Giroux M, et al. **AIDS** 1995 Jul;9(7):816–7

Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina. Tuntland T, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):856–63

Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. Blaney SM, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2779–82

Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Cundy KC, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2401–5

Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Cundy KC, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1247–52

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Horton CM, et al. **Antimicrob Agents Chemother** 1995 Oct; 39(10):2309–15

Pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in the neonatal macaque (Macaca nemestrina). Keller RD, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2829–31

Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). Moore KH, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2732–7

Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Robbins BL, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2304–8

Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Soul-Lawton J, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2759–64

Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling. Yuen GJ, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2350–2

Pharmacokinetics and toxicity of the human immunodeficiency virus inhibitor 1-ethoxymethyl-6-phenylselenenyl-5-ethyluracil in rodents. Ni L, et al. **Antiviral Res** 1995 May;27(1–2):39–47

Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles. Bijsterbosch MK, et al. **Biochem Pharmacol** 1996 Jul 12;52(1):113–21

Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Xiong X, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1563–7

Pharmacokinetics and hepatic first-pass effect of (-)-carbovir in the anesthetized rat. Soria I, et al. **Biopharm Drug Dispos** 1995 May;16(4):313–8

High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration. Morlet N, et al. **Br J Ophthalmol** 1996 Mar;80(3):214–6

Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Gallicano K, et al. **Clin Infect Dis** 1995 Oct;21(4):1008–11

Pharmacokinetics of new antiherpetic agents. Rolan P. **Clin Pharmacokinet** 1995 Nov;29(5):333–40 (32 ref.)

Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Stretcher BN. **Clin Pharmacokinet** 1995 Jul;29(1):46–65 (135 ref.)

Drug interactions with antiviral drugs. Taburet AM, et al. **Clin Pharmacokinet** 1996 May;30(5):385–401 (101 ref.)

Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Lee BL, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):14–21

Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Moore KH, et al. **Clin Pharmacol Ther** 1996 May;59(5):550–8

Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Nieforth KA, et al. **Clin Pharmacol Ther** 1996 Jun;59(6):636–46

Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine. Peck R, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):22–31

Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Anderson RD, et al. **Clin Ther** 1995 May-Jun;17(3):425–32

Synthesis and biodistribution of [4-14C]-5-bromo-6-methoxy-5,6-dihydro-prodrug derivatives of 5-ethyl-2'-deoxyuridine. Cheraghali AM, et al. **Drug Des Discov** 1994 Jul;12(1):53–61

Metabolism and pharmacokinetics of a double prodrug of ganciclovir in the rat and monkey. Krasny HC, et al. **Drug Metab Dispos** 1995 Nov;23(11):1242–7

Lymphatic distribution of 3'-azido-3'-deoxythymidine and 3'-azido-2',3'-dideoxyuridine in mice. Manouilov KK, et al. **Drug Metab Dispos** 1995 Jun;23(6):655–8

Characterization of the metabolites of the peptidomimetic human immunodeficiency virus type 1 protease inhibitor SK&F 107461 in rats using liquid chromatography/mass spectrometry. Potts W, et al. **Drug Metab Dispos** 1995 Aug; 23(8):799–805

Placental transfer and fetal disposition of 2',3'-dideoxycytidine and 2',3'-dideoxyinosine in the rhesus monkey. Sandberg JA, et al. **Drug Metab Dispos** 1995 Aug; 23(8):881–4

Pharmacokinetics of the antiviral agent 3-deazaneplanocin A. Coulombe RA Jr, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul-Sep; 20(3):197–202

Non-linear renal and biliary clearances of antiviral polyoxometalates in rats. Ni L, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul-Sep; 20(3):209–17

Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS. Burger D, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Oct 1;10(2):163–8

Zidovudine kinetics in the pregnant baboon. Garland M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):117–27

The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. Tierney M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 15;10(5):549–53

Zidovudine absorption and small intestinal function in HIV seropositive patients. Macnab KA, et al. **J Antimicrob Chemother** 1996 Apr;37(4):825–9

A pharmacokinetic and safety evaluation of a 28 day course of oral acyclovir in elderly patients with herpes zoster [letter] Moss PJ, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):271–3

Comparison of high-performance liquid chromatography and capillary zone electrophoresis in penciclovir biodegradation kinetic studies. Hsu LC, et al. **J Chromatogr B Biomed Appl** 1995 Jul 7;669(1):85–92

Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor.

Aweeka FT, et al. **J Clin Pharmacol** 1995 Sep;35(9):856–64

Effect of food on the relative bioavailability of oral ganciclovir. Lavelle J, et al. **J Clin Pharmacol** 1996 Mar; 36(3):238–41

Nonparametric expectation maximization population modeling of ganciclovir. Preston SL, et al. **J Clin Pharmacol** 1996 Apr;36(4):301–10

Iontophoresis for enhancing penetration of dermatologic and antiviral drugs. Gangarosa LP Sr, et al. **J Dermatol** 1995 Nov;22(11):865–75 (39 ref.)

Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection [letter; comment] Harb GE, et al. **J Infect Dis** 1996 Jan;173(1):273. Comment on: J Infect Dis 1994 Jun;169(6):1250–5.

Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS. Piketty C, et al. **J Infect Dis** 1996 Jul;174(1):188–90

In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5–halo–y–methoxy(or ethoxy)–5,6–dihydro–3'–azido–3'–deoxythymidine diastereomers as potential prodrugs of 3'–azido–3'–deoxythymidine. Wang L, et al. **J Med Chem** 1996 Feb 16;39(4):826–33

Accumulation of 5–ethyl–2'–deoxyuridine and its 5,6–dihydro prodrugs in murine lung and its potential clinical application. Cheraghali AM, et al. **J Pharm Pharmacol** 1995 Jul;47(7):595–600

Optimization of in vitro flux through hairless mouse skin of cidofovir, a potent nucleotide analog. Aspe E, et al. **J Pharm Sci** 1995 Jun;84(6):750–4

Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration–time transformations. Lave T, et al. **J Pharm Sci** 1995 Nov; 84(11):1285–90

Oral absorption of anti–AIDS nucleoside analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations. Sinko PJ, et al. **J Pharm Sci** 1995 Aug; 84(8):959–65

Oral absorption of anti–acquired immune deficiency syndrome nucleoside analogues. 2. Carrier–mediated intestinal transport of stavudine in rat and rabbit preparations. Waclawski AP, et al. **J Pharm Sci** 1996 May; 85(5):478–85

Lack of interaction between zidovudine and 4–methyl–amino–antipyrine, the active metabolite of metamizole, in human liver in vitro. Bacracheva N, et al. **Methods Find Exp Clin Pharmacol** 1995 Jun;17(5):299–301

Transport of the antiviral nucleoside analogs 3'–azido–3'–deoxythymidine and 2',3'–dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis oocytes. Yao SY, et al. **Mol Pharmacol** 1996 Aug;50(2):388–93

Passive and facilitative transport of nucleobases, nucleosides, and oligonucleotides—application to antiviral and other therapies. Brewster ME, et al. **NIDA Res Monogr** 1995; 154:61–85 (62 ref.)

Single dose and steady state pharmacokinetics of intravenous acyclovir in children undergoing bone marrow and liver transplant. Joshi P, et al. **Pediatr Infect Dis J** 1995 Aug; 14(8):717–9

Enhanced oral bioavailability of DDI after administration of 6–Cl–ddP, an adenosine deaminase–activated prodrug, to chronically catheterized rats. Anderson BD, et al. **Pharm Res** 1995 Aug;12(8):1126–33

Species dependent esterase activities for hydrolysis of an anti–HIV prodrug glycovir and bioavailability of active SC–48334. Cook CS, et al. **Pharm Res** 1995 Aug; 12(8):1158–64

Effects of gender, pregnancy, and anesthesia on the pharmacokinetics of zidovudine in rats. Huang CS, et al. **Pharm Res** 1995 Nov;12(11):1647–51

The effect of probenecid on the pharmacokinetics of zalcitabine in HIV–positive patients. Massarella JW, et al. **Pharm Res** 1996 Mar;13(3):449–52

The effect of food on pharmacokinetics of zalcitabine in HIV–positive patients. Nazareno LA, et al. **Pharm Res** 1995 Oct;12(10):1462–5

Renal disposition and drug interaction screening of (–)–2'–deoxy–3'–thiacytidine (3TC) in the isolated perfused rat kidney. Sweeney KR, et al. **Pharm Res** 1995 Dec; 12(12):1958–63

Iontophoresis enhances the transport of acyclovir through nude mouse skin by electrorepulsion and electroosmosis. Volpato NM, et al. **Pharm Res** 1995 Nov;12(11):1623–7

Pharmacokinetics of 1–(2–deoxy–2–fluoro–beta–L–arabinofuranosyl)–5–methyluracil (L–FMAU) in rats. Wright JD, et al. **Pharm Res** 1995 Sep;12(9):1350–3

Pharmacokinetic interaction between intravenous 2',3'–dideoxyinosine and pentamidine in rats. Yeh TK, et al. **Pharm Res** 1996 Apr;13(4):628–32

The effect of cimetidine and ranitidine administration with zidovudine. Fletcher CV, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):701–8

Biodistribution and virus inactivation efficacy of a silicon phthalocyanine in red blood cell concentrates as a function of delivery vehicle. Ben–Hur E, et al. **Photochem Photobiol** 1995 Sep;62(3):575–9

Subcellular distribution of hypericin in human cancer cells. Miskovsky P, et al. **Photochem Photobiol** 1995 Sep; 62(3):546–9

Effect of partial retinal destruction and gliosis on the intravitreal pharmacokinetics of HPMPC. Kim JW, et al. **Retina** 1995;15(6):513–7

[The pharmacokinetics of the glycyrrhizin and glycyrrhetic acid after intravenous administration of glycyrrhizin for the patients with chronic liver disease caused by type C hepatitis virus] Takahashi M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Dec;92(12):1929–36 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication. Nikolaeva L, et al. **Acta Virol** 1995 Dec;39(5–6):235–41

Inhibition of influenza virus protein synthesis by a plant preparation from Geranium sanguineum L. Serkedjieva J. **Acta Virol** 1995 Feb;39(1):5–10

Cytomegalovirus: genetics of drug resistance. Biron KK. **Adv Exp Med Biol** 1996;394:135–43 (43 ref.)

Saquinavir: an HIV proteinase inhibitor. Bragman K. **Adv Exp Med Biol** 1996;394:305–17 (25 ref.)

Antiviral drug resistance in herpes simplex virus. Coen DM. **Adv Exp Med Biol** 1996;394:49–57 (15 ref.)

In vivo selection of HIV–1 variants with reduced susceptibility to the protease inhibitor L–735,524 and related compounds. Emini EA, et al. **Adv Exp Med Biol** 1996;394:327–31 (8 ref.)

Delavirdine mesylate, a potent non–nucleoside HIV–1 reverse transcriptase inhibitor. Freimuth WW. **Adv Exp Med Biol** 1996;394:279–89 (42 ref.)

A preclinical and clinical overview of the nucleotide–based antiviral agent cidofovir (HPMPC). Lalezari JP, et al. **Adv Exp Med Biol** 1996;394:105–15 (26 ref.)

Promising anti–HIV compounds in preclinical or early clinical development. Litterst C. **Adv Exp Med Biol** 1996; 394:397–404 (16 ref.)

Inhibition of viral multiplication in acute and chronic stages of infection by ribozymes targeted against the polymerase gene of mouse hepatitis virus. Maeda A, et al. **Adv Exp Med Biol** 1995;380:399–404

Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Richman DD. **Adv Exp Med Biol** 1996; 394:383–95 (94 ref.)

Treatment of acyclovir–resistant herpes simplex and varicella zoster virus infections. Safrin S. **Adv Exp Med Biol** 1996; 394:59–66 (44 ref.)

Sorivudine: a potent inhibitor of varicella zoster virus replication. Whitley RJ. **Adv Exp Med Biol** 1996;394:41–4 (11 ref.)

Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals. Rice WG, et al. **Adv Pharmacol** 1995;33:389–438 (204 ref.)

The efficacy of nonoxynol–9 from an in vitro point of view [letter] Bourinbaiar AS, et al. **AIDS** 1996 May;10(5):558–9

HIV–1 group O sensitivity to antiretroviral drugs [letter] Descamps D, et al. **AIDS** 1995 Aug;9(8):977–8

Pentoxifylline inhibits acute HIV–1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor–kappa B activation. Navarro J, et al. **AIDS** 1996 May;10(5):469–75

Expression and characterization of CD4–IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. Allaway GP, et al. **AIDS Res Hum Retroviruses** 1995 May; 11(5):533–9

Low anticoagulant heparin retains anti–HIV type 1 activity in vitro. Coombe DR, et al. **AIDS Res Hum Retroviruses** 1995 Nov;11(11):1393–6

Interferon gamma stimulates cell–mediated transmission of HIV type 1 from abortively infected endothelial cells. Dianzani F, et al. **AIDS Res Hum Retroviruses** 1996 May 1;12(7):621–7

Inhibition of HIV type 1 Tat–mediated trans–activation by oncostatin M in HLtat cells. Esté JA, et al. **AIDS Res Hum Retroviruses** 1995 Nov;11(11):1355–8

Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'–azido–3'–deoxythymidine on HIV type 1 infection in vitro. Giacca M, et al. **AIDS Res Hum Retroviruses** 1996 May 20;12(8):677–82

Antivirals that target the amino–terminal domain of HIV type 1 glycoprotein 41. Gordon LM, et al. **AIDS Res Hum Retroviruses** 1995 Jun;11(6):677–86

Doxorubicin inhibits Tat–dependent transactivation of HIV type 1 LTR. Jeyaseelan R, et al. **AIDS Res Hum Retroviruses** 1996 May 1;12(7):569–76

The appearance of drug resistance–associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. Kaye S, et al. **AIDS Res Hum Retroviruses** 1995 Oct;11(10):1221–5

Anti–Tat MTT assay: a novel anti–HIV drug screening system using the viral regulatory network of replication. Kira T, et al. **AIDS Res Hum Retroviruses** 1995 Nov; 11(11):1359–66

Transmembrane P–glycoprotein (P–gp/P–170) in HIV infection: analysis of lymphocyte surface expression and drug–unrelated function. Lucia MB, et al. **AIDS Res Hum Retroviruses** 1995 Aug;11(8):893–901

Single basic amino acid substitutions at position 302 or 320 in the V3 domain of HIV type 1 are not sufficient to alter the antiviral activity of dextran sulfate and heparin. Okada T, et al. **AIDS Res Hum Retroviruses** 1995 May;11(5):571–5

ADA, a potential anti–HIV drug [letter] Vandevelde M, et al. **AIDS Res Hum Retroviruses** 1996 May 1;12(7):567–8

Antisense phosphorothioate oligodeoxynucleotides alter HIV type 1 replication in cultured human macrophages and peripheral blood mononuclear cells. Weichold FF, et al. **AIDS Res Hum Retroviruses** 1995 Jul;11(7):863–7

Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug–sensitive and resistant HIV type 1 strains. Zhu QY, et al. **AIDS Res Hum Retroviruses** 1996 Apr 10;12(6):507–17

Treatment of hepatitis B surface antigen carriers in the early stage of the infection using recombinant alpha–interferon with steroid priming. Guan R, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):535–40

Cytomegalovirus resistance to antiviral therapies. Drew WL. **Am J Health Syst Pharm** 1996 Apr 15;53(8 Suppl 2):S17–23

Use of a polyethylene glycol–peptide conjugate in a competition gel shift assay for screening potential antagonists of HIV–1 Tat protein binding to TAR RNA. Wang J, et al. **Anal Biochem** 1995 Dec 10;232(2):238–42

Structural mechanisms of HIV drug resistance. Erickson JW, et al. **Annu Rev Pharmacol Toxicol** 1996;36:545–71 (74 ref.)

Susceptibilities of several drug–resistant herpes simplex virus type 1 strains to alternative antiviral compounds. Andrei G, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1632–5

Activity of penciclovir against Epstein–Barr virus. Bacon TH, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1599–602

Efficacy of constant infusion of A–77003, an inhibitor of the human immunodeficiency virus type 1 (HIV–1) protease, in limiting acute HIV–1 infection in vitro. Bilello JA, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2523–7

SC–52151, a novel inhibitor of the human immunodeficiency virus protease. Bryant M, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2229–34

Structure–activity and cross–resistance evaluations of a series of human immunodeficiency virus type–1–specific compounds related to oxathiin carboxanilide. Buckheit RW Jr, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2718–27

NP–06: a novel anti–human immunodeficiency virus polypeptide produced by a Streptomyces species. Chokekijchai S, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2345–7

Anti–human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase. Fujihashi T, et al. **Antimicrob Agents Chemother** 1995 Sep; 39(9):2000–7

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross–resistance to 9–(2–phosphonylmethoxyethyl)adenine. Gu Z, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1888–91

Foscarnet alters antidiuretic hormone–mediated transport. Hoch BS, et al. **Antimicrob Agents Chemother** 1995 Sep; 39(9):2008–12

Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4–(2,6–dichlorophenyl)–1,2,5–thiadiazol–3–Y1 N,N–dialkylcarbamate derivatives. Ijichi K, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2337–40

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Kleim JP, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2253–7

Mode of action of (R)–9–[4–hydroxy–2–(hydroxymethyl)butyl]guanine against herpesviruses. Lowe DM, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1802–8

Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'–dideoxycytidine. Medlin HK, et al. **Antimicrob Agents Chemother** 1996 Apr; 40(4):953–7

Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Mendel DB, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):2120–2

Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)–(6–amino–9H–purin–9–yl)tetrahydro–2(S)–furanmethanol. Nair V, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1993–9

T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Ojwang JO, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2426–35

Inhibition of episomal hepatitis B virus DNA in vitro by 2,4–diamino–7–(2–deoxy–2–fluoro–beta–D–arabinofuranosyl)–pyrrolo[2,3–d]pyrimidine. Ojwang JO, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2570–3

Comparative evaluation of microplate enzyme–linked immunosorbent assay versus plaque reduction assay for antiviral susceptibility testing of herpes simplex virus isolates. Safrin S, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1017–9

Mechanism of inhibition of duck hepatitis B virus polymerase by (–)–beta–L–2',3'–dideoxy–3'–thiacytidine. Severini A, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1430–5

Antiviral effect in human cytomegalovirus–infected cells, pharmacokinetics, and intravitreal toxicology in rabbits of acyclovir diphosphate dimyristoylglycerol. Shakiba S, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1383–5

Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Shirasaka T, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2555-9

Inhibition of influenza virus transcription by 2'-deoxy-2'-fluoroguanosine. Tisdale M, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2454-8

Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease. Wolf DG, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2552-4

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Young SD, et al. **Antimicrob Agents Chemother** 1995 Dec;39(12):2602-5

Antiviral activity of RNA molecules containing self-releasing ribozymes targeted to lymphocytic choriomeningitis virus. Xing Z, et al. **Antisense Res Dev** 1995 Fall;5(3):203-12

Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Azad RF, et al. **Antiviral Res** 1995 Oct;28(2):101-11

Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Balzarini J, et al. **Antiviral Res** 1995 Jun;27(3):219-36

Anti-human cytomegalovirus activity and toxicity of sulfonated anthraquinones and anthraquinone derivatives. Barnard DL, et al. **Antiviral Res** 1995 Dec;28(4):317-29

Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Beutner KR. **Antiviral Res** 1995 Dec;28(4):281-90 (29 ref.)

The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection. Bridges CG, et al. **Antiviral Res** 1995 Aug; 27(4):325-34

Active compounds from Saussurea lappa Clarks that suppress hepatitis B virus surface antigen gene expression in human hepatoma cells. Chen HC, et al. **Antiviral Res** 1995 May; 27(1-2):99-109

In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI. Chokekijchai S, et al. **Antiviral Res** 1995 Sep;28(1):25-38

In vitro inhibition of human cytomegalovirus replication in human foreskin fibroblasts and endothelial cells by ascorbic acid 2-phosphate. Cinatl J, et al. **Antiviral Res** 1995 Aug; 27(4):405-18

Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. Clanton DJ, et al. **Antiviral Res** 1995 Aug;27(4):335-54

Antiviral activity of recombinant interferon-alpha on hepatitis A virus replication in human liver cells. Crance JM, et al. **Antiviral Res** 1995 Sep;28(1):69-80

Herpes simplex type 1:lacZ recombinant viruses. I. Characterization and application to defining the mechanisms of action of known antiherpes agents. Dicker IB, et al. **Antiviral Res** 1995 Nov;28(3):191-212

Herpes simplex type1:lacZ recombinant viruses. II. Microtiter plate-based colorimetric assays for the discovery of new antiherpes agents and the points at which such agents disrupt the viral replication cycle. Dicker IB, et al. **Antiviral Res** 1995 Nov;28(3):213-24

Propranolol suppresses reactivation of herpesvirus. Gebhardt BM, et al. **Antiviral Res** 1995 Jun;27(3):255-61

Role of trehalose dimycolate-induced interferon-alpha/beta in the restriction of encephalomyocarditis virus growth in vivo and in peritoneal macrophage cultures. Guillemard E, et al. **Antiviral Res** 1995 Oct;28(2):175-89

Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV. Hasegawa T, et al. **Antiviral Res** 1995 Jun;27(3):271-9

Modulation of alpha-interferon's antiviral and clinical effects by aspirin, acetaminophen, and prednisone in healthy volunteers. Hendrix CW, et al. **Antiviral Res** 1995 Oct; 28(2):121-31

In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice. Hollingshead M, et al. **Antiviral Res** 1995 Nov;28(3):265-79

Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2'- and 5'-positions of the sugar moiety. Ingate S, et al. **Antiviral Res** 1995 Jun;27(3):281-99

Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2',3'-dideoxy-3'-thiacytidine. Kavlick MF, et al. **Antiviral Res** 1995 Oct;28(2):133-46

Antiviral resistance--an emerging problem. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):365-8

Molecular mechanisms of antiviral resistance. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):369-401 (79 ref.)

Assays for antiviral drug resistance. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):403-13 (23 ref.)

Models of antiviral resistance. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):415-22 (23 ref.)

Antiviral resistance in clinical practice. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):423-38 (64 ref.)

Research initiatives in studies of antiviral resistance and consensus points and recommendations. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):439-52

Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro. Korba BE, et al. **Antiviral Res** 1995 Nov;28(3):225-42

Inhibition of the enteroviruses that cause acute hemorrhagic conjunctivitis (AHC) by benzimidazoles; enviroxime (LY 122772) and enviradone (LY 127123). Langford MP, et al. **Antiviral Res** 1995 Aug;27(4):355-65

Inhibition of HIV-1 in vitro by C-5 propyne phosphorothioate antisense to rev. Lund OS, et al. **Antiviral Res** 1995 Sep;28(1):81-91

4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus. McCauley JW, et al. **Antiviral Res** 1995 May; 27(1-2):179-86

Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus. Mar EC, et al. **Antiviral Res** 1995 Sep;28(1):1-11

Synthesis, antiviral activity and enzymatic phosphorylation of 9-phosphonopentenyl derivatives of guanine. Navé JF, et al. **Antiviral Res** 1995 Jun;27(3):301-16

Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells. Ochiai H, et al. **Antiviral Res** 1995 Aug;27(4):425-30

Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication. Palamara AT, et al. **Antiviral Res** 1995 Jun;27(3):237-53

Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Reymen D, et al. **Antiviral Res** 1995 Dec;28(4):343-57

Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Riddler SA, et al. **Antiviral Res** 1995 Jun;27(3):189-203 (48 ref.)

Antiviral activity of phosphonoformate on rotavirus transcription and replication. Rios M, et al. **Antiviral Res** 1995 May;27(1-2):71-83

A simple and rapid method for preliminary evaluation of in vivo efficacy of anti-HIV compounds in mice. Sato A, et al. **Antiviral Res** 1995 May;27(1-2):151-63

Analysis of drug-drug interactions: an overview. Shipman C Jr. **Antiviral Res** 1996 Jan;29(1):41-3

Inhibition of neurotropic mouse retrovirus replication in glial cells by synthetic oligo(2'-O-methyl)ribonucleoside phosphorothioates. Takase-Yoden S, et al. **Antiviral Res** 1995 Dec;28(4):359-68

Potent inhibition of human immunodeficiency virus by MDL 101028, a novel sulphonic acid polymer. Taylor DL, et al. **Antiviral Res** 1995 Oct;28(2):159-73

Inhibition of visna virus replication and cytopathic effect in sheep choroid plexus cell cultures by selected anti-HIV agents. Thormar H, et al. **Antiviral Res** 1995 May; 27(1-2):49-57

Antiviral properties of simple difunctionalized enols targeted to the HIV-1 protease. Vaillancourt M, et al. **Antiviral Res** 1995 Jun;27(3):205-18

Evaluation of the antiviral activity of N-(phosphonoacetyl)-L-aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats. Wyde PR, et al. **Antiviral Res** 1995 May;27(1-2):59-69

Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells. Xie H, et al. **Antiviral Res** 1995 Oct;28(2):113-20

Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Zhang H, et al. **Antiviral Res** 1995 Dec; 28(4):331-42

Efficacy of Coxiella burnetii and its chloroform-methanol residue (CMR) fraction against Rift Valley fever virus infection in mice. Zvilich M, et al. **Antiviral Res** 1995 May; 27(1-2):137-49

A time-related study of Brefeldin A effects in HSV-1 infected cultured human fibroblasts. Jensen HL, et al. **APMIS** 1995 Jul-Aug;103(7-8):530-9

Inactivation of human immunodeficiency virus type 1 reverse transcriptase by oltipraz: evidence for the formation of a stable adduct. Chavan SJ, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):143-52

Inhibition of neutrophil superoxide generation by hypericin, an antiretroviral agent. Nishiuchi T, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):335-42

Maintenance of replicative intermediates in ganciclovir-treated human cytomegalovirus-infected retinal glia. Burd EM, et al. **Arch Ophthalmol** 1996 Jul; 114(7):856-61

Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group. Jabs DA, et al. **Arch Ophthalmol** 1996 Jul;114(7):809-14

Synthesis, antitumoral and antiviral evaluation of halo- and demethyl-yatein derivatives. Medarde M, et al. **Arch Pharm (Weinheim)** 1995 Sep;328(9):640-4

Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Balzarini J, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):337-41

Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Balzarini J, et al. **Biochem Biophys Res Commun** 1996 Aug 14; 225(2):363-9

The activity of plant-derived antiretroviral proteins MAP30 and GAP31 against herpes simplex virus in vitro. Bourinbaiar AS, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):923-9

Inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by unmodified, phosphorothioated, and liposomally encapsulated oligonucleotides. Hatta T, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):341-6

Inhibition of vesicular stomatitis virus replication by epidermal growth factor in human epidermoid A-431 cells. Korutla L, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):670-4

In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. Moriya K, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):217-23

Inhibition of human immunodeficiency virus type 1 long terminal repeat-driven transcription by an in vivo metabolite of oltipraz: implications for antiretroviral therapy. Prochaska HJ, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):548-53

Antiviral effect of Sanicula europaea L. leaves extract on influenza virus-infected cells. Turan K, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):22-6

Synergistic binding of inhibitors to the protease from HIV type 1. Asante-Appiah E, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):113-7

The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase. Althaus IW, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):743-50

Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Bridges EG, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):731-6

Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Xiong X, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1563-7

Nucleoside spiroxiranes as suicide inhibitors of the human immunodeficiency virus. Bailey JM, et al. **Biochem Soc Trans** 1995 Nov;23(4):619S

Roles of oxygen and photoinduced acidification in the light-dependent antiviral activity of hypocrellin A. Fehr MJ, et al. **Biochemistry** 1995 Dec 5;34(48):15845-8

Extension of the polarity-dependent "switch phenomenon" of the gp120 binding domain as a target for antiviral chemotherapy. Graf von Stosch A, et al. **Biochemistry** 1996 Jan 16;35(2):411-7

Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Mazumder A, et al. **Biochemistry** 1995 Nov 21;34(46):15111-22

Inactivation of inosine 5'-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide 5'-monophosphate. Wang W, et al. **Biochemistry** 1996 Jan 9;35(1):95-101

Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity. Kamps JA, et al. **Biochim Biophys Acta** 1996 Jan 31;1278(2):183-90

The influence of merocyanine 540 and protoporphyrin on physicochemical properties of the erythrocyte membrane. Lagerberg JW, et al. **Biochim Biophys Acta** 1996 Jan 31; 1278(2):247-53

Zidovudine and dideoxynucleosides deplete wild-type mitochondrial DNA levels and increase deleted mitochondrial DNA levels in cultured Kearns-Sayre syndrome fibroblasts. Wang H, et al. **Biochim Biophys Acta** 1996 May 24;1316(1):51-9

Inhibitory effect of pyridobenzazoles on virus replication in vitro. Chiba T, et al. **Biol Pharm Bull** 1995 Aug; 18(8):1081-3

Novel assay system favorable for the study of cell-to-cell transmission of HIV-1 and its application to the evaluation of anti-HIV drugs. Inouye Y, et al. **Biol Pharm Bull** 1995 Jun;18(6):920-2

Structure-activity correlationship and strain specificity of polyoxometalates in anti-human immunodeficiency virus activity. Inouye Y, et al. **Biol Pharm Bull** 1995 Jul; 18(7):996-1000

Studies on the antiviral activity of protein kinase inhibitors against the replication of vesicular stomatitis virus. Kim YS, et al. **Biol Pharm Bull** 1995 Jun;18(6):895-9

Anti-AIDS agents--XIX. Neotripterifordin, a novel anti-HIV principle from Tripterygium wilfordii: isolation and structural elucidation. Chen K, et al. **Bioorg Med Chem** 1995 Oct;3(10):1345-8

2-amino-9-(3-azido-2,3-dideoxy-beta-D-erythro-pentofuranosyl)-6-substituted-9H-purines: synthesis and anti-HIV activity. Freeman GA, et al. **Bioorg Med Chem** 1995 Apr;3(4):447-58

Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus. Kim SG, et al. **Bioorg Med Chem** 1995 Jan;3(1):49-54

Synthesis and antiviral effects of 2-heteroaryl substituted adenosine and 8-heteroaryl substituted guanosine derivatives. Persson T, et al. **Bioorg Med Chem** 1995 Oct; 3(10):1377-82

Stereoselective synthesis, chemistry and antiviral evaluation

of 1-(2,3-dideoxy-3-C-hydroxymethyl-beta-D-threo-pentofuranosyl)thymine derivatives. Wengel J, et al. **Bioorg Med Chem** 1995 Sep;3(9):1223-9

Cystamine inhibits human immunodeficiency virus-1 replication in cord blood-derived mononuclear phagocytes and lymphocytes. Ho WZ, et al. **Blood** 1996 Aug 1; 88(3):928-33

In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells. Waddick KG, et al. **Blood** 1995 Dec 1;86(11):4228-33

Comparison of benzimidazole nucleosides and ganciclovir on the in vitro proliferation and colony formation of human bone marrow progenitor cells. Nassiri MR, et al. **Br J Haematol** 1996 May;93(2):273-9

Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Rainov NG, et al. **Cancer Gene Ther** 1996 Mar-Apr;3(2):99-106

Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Hamel W, et al. **Cancer Res** 1996 Jun 15;56(12):2697-702

HIV-1 Tat protein and its inhibitor Ro 24-7429 inhibit lymphocyte proliferation and induce apoptosis in peripheral blood mononuclear cells from healthy donors. Patki AH, et al. **Cell Immunol** 1996 Apr 10;169(1):40-6

Synthesis and anti-HIV activity of steroidal prodrugs of 3'-azido-3'-deoxythymidine (AZT). Balagopala MI, et al. **Cell Mol Biol (Noisy-le-grand)** 1995;41 Suppl 1:S1-7

Synthesis, activity and toxicity of novel macrocyclic ligands against HIV-1 in Jurkat and CEM-SS cell lines. Balogh-Nair V, et al. **Cell Mol Biol (Noisy-le-grand)** 1995; 41 Suppl 1:S9-14

Isolation of pyropheophorbide a from the leaves of Atalantia monophylla (ROXB.) CORR. (Rutaceae) as a possible antiviral active principle against herpes simplex virus type 2. Chansakaow S, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul;44(7):1415-7

Meisenheimer rearrangement of azetopyridoindoles. VIII. Synthesis and antiviral activities of 12-carbaeudistomin analogs. Kurihara T, et al. **Chem Pharm Bull (Tokyo)** 1996 May;44(5):900-8

Assay for antiviral activity of herbal extracts using their absorbed sera. Kurokawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Jun;44(6):1270-2

The inhibitory effect of the crude extract from a seaweed of Dygenea simplex C. Agardh on the in vitro cytopathic activity of HIV-1 and it's antigen production. Sekine H, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1580-4

Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity. Tamamura H, et al. **Chem Pharm Bull (Tokyo)** 1995 May; 43(5):853-8

Herpes simplex virus-inhibitory sulfated xylogalactans from the red seaweed Nothogenia fastigiata. Damonte EB, et al. **Chemotherapy** 1996 Jan-Feb;42(1):57-64

Duck hepatitis B virus model for screening of antiviral agents from medicinal herbs. Mi Z, et al. **Chin Med J (Engl)** 1995 Sep;108(9):660-4

The inhibitory effect of astragalus membranaceus on coxsackie B-3 virus RNA replication. Peng T, et al. **Chin Med Sci J** 1995 Sep;10(3):146-50

Clinical significance of drug resistance in human immunodeficiency virus. Richman DD. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S166-9 (26 ref.)

Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. Spector SA, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S170-3 (22 ref.)

Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Nieforth KA, et al. **Clin Pharmacol Ther** 1996 Jun;59(6):636-46

Studies on the suitability of alpha-hybrid interferon application in cattle. Straub OC. **Comp Immunol Microbiol Infect Dis** 1995 Sep;18(4):239-43

Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Haria M, et al. **Drugs** 1995 Nov;50(5):873-96 (149 ref.)

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. Back NK, et al. **EMBO J** 1996 Aug 1;15(15):4040-9

3'-Azido-3'-deoxythymidine inhibits erythroid-specific transcription factors in human erythroid K562 leukemia cells. Bridges EG, et al. **Eur J Haematol** 1996 Jan-Feb; 56(1-2):62-7

Comparative efficacy of antiviral drugs on human ocular fibroblasts. Cheng Q, et al. **Exp Eye Res** 1995 Oct; 61(4):461-7

Antiviral activities of anthraquinones, bianthrones and hypericin derivatives from lichens. Cohen PA, et al. **Experientia** 1996 Feb 15;52(2):180-3

Antimitotic and antiviral activities of Kelletinin A in HTLV-1 infected MT2 cells. Silvestri I, et al. **Experientia** 1995 Nov 15;51(11):1076-80

The cytostatic activity of 5-(1-azidovinyl)-2'-deoxyuridine (AzVDU) against herpes simplex virus thymidine kinase gene-transfected FM3A cells is due to inhibition of thymidylate synthase and enhanced by UV light (lambda = 254 nm) exposure. Balzarini J, et al. **FEBS Lett** 1995 Oct 2;373(1):41-4

An evaluation of the antioxidant and antiviral action of extracts of rosemary and Provençal herbs. Aruoma OI, et al. **Food Chem Toxicol** 1996 May;34(5):449-56

Effects of acute and short-term repeated application of fullerene C60 on agonist-induced responses in various tissues of guinea pig and rat. Satoh M, et al. **Gen Pharmacol** 1995 Nov;26(7):1533-8

Inhibition of HSV-1 proliferation by decoy phosphodiester oligonucleotides containing ICP4 recognition sequences. Clusel C, et al. **Gene Expr** 1995;4(6):301-9

Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Lee SW, et al. **Gene Ther** 1995 Aug;2(6):377-84

Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route. Fiume L, et al. **Hepatology** 1995 Oct; 22(4 Pt 1):1072-7

Inhibition of viral replication by genetically engineered mutants of the duck hepatitis B virus core protein. von Weizsäcker F, et al. **Hepatology** 1996 Aug;24(2):294-9

Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Zeuzem S, et al. **Hepatology** 1996 Feb; 23(2):366-71

Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Eastham JA, et al. **Hum Gene Ther** 1996 Mar 1;7(4):515-23

SPC3, a nontoxic peptide inhibitor of HIV infection [letter] Sabatier JM, et al. **In Vitro Cell Dev Biol Anim** 1995 Jun; 31(6):415-8

In vitro antiviral activities of sulfated polysaccharides from a marine microalga (Cochlodinium polykrikoides) against human immunodeficiency virus and other enveloped viruses. Hasui M, et al. **Int J Biol Macromol** 1995 Oct; 17(5):293-7

Methyl inosine monophosphate (MIMP) augments T-lymphocyte mitogen responses and reverses various immunosuppressants. Hadden EM, et al. **Int J Immunopharmacol** 1995 Sep;17(9):763-70

Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Kim JH, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):861-8

Effect of interferon-alpha on the steady-state levels of thymine, thymidine, guanine, and guanosine metabolites in herpes simplex virus-type 1-infected cells. O'Brien WJ, et al. **Intervirology** 1995;38(5):249-55

4th International Workshop on HIV Drug Resistance. Sardinia, Italy, July 6-9, 1995. Abstracts. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 3:S1-46

Drug resistance in cytomegalovirus: current knowledge and implications for patient management. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;12 Suppl 1:S1-22 (81 ref.)

Canventol inhibits HIV-1 replication by Tat-induced Tar-independent mechanism. Biswas DK, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):120-7

Anti-HIV potential of a new interferon, interferon-tau (trophoblastin). Dereuddre-Bosquet N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):241-6

The mutation frequency of feline immunodeficiency virus enhanced by 3'-azido-3'-deoxythymidine. LaCasse RA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):26-32

Viral resistance and the selection of antiretroviral combinations. Larder BA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S28-33 (28 ref.)

Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. Pauwels R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):211-21 (70 ref.)

In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol. St. Clair MH, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S83-91

Rapid screening of antiretroviral combinations. St Clair M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995; 10 Suppl 1:S24-7 (15 ref.)

Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5' end of human TK gene. Wu S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Jan 1;8(1):1-9

Karalicin, a new biologically active compound from Pseudomonas fluorescens/putida. II. Biological properties. Lampis G, et al. **J Antibiot (Tokyo)** 1996 Mar;49(3):263-6

Eulicin inhibits human immunodeficiency virus infection and replication. Nakamura M, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1362-3

Activity of penciclovir in antiviral assays against herpes simplex virus. Bacon TH, et al. **J Antimicrob Chemother** 1996 Feb;37(2):303-13

Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid. de Bony F, et al. **J Antimicrob Chemother** 1996 Feb;37(2):383-7

Characterization of antiviral activity of a sesquiterpene, triptofordin C-2. Hayashi K, et al. **J Antimicrob Chemother** 1996 Apr;37(4):759-68

Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay. Seki M, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1199-204

Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. Bishop JS, et al. **J Biol Chem** 1996 Mar 8;271(10):5698-703

Site-directed mutagenesis of Cys-15 and Cys-20 of pulmonary surfactant protein D. Expression of a trimeric protein with altered anti-viral properties. Brown-Augsburger P, et al. **J Biol Chem** 1996 Jun 7; 271(23):13724-30

Stoichiometry of 2',5'-oligoadenylate-induced dimerization of ribonuclease L. A sedimentation equilibrium study. Cole JL, et al. **J Biol Chem** 1996 Feb 23;271(8):3979-81

Thyroid hormone analogues potentiate the antiviral action of interferon-gamma by two mechanisms. Lin HY, et al. **J Cell Physiol** 1996 May;167(2):269-76

Disruption of herpes simplex virus ribonucleotide reductase quaternary structure by peptide inhibitors as a novel approach to antiviral therapy. Marcello A, et al. **J Chemother** 1995 Oct;7(5):403-5

Inhibition of HIV-1 replication by cyclopentenone prostaglandins in acutely infected human cells. Evidence for a transcriptional block. Rozera C, et al. **J Clin Invest** 1996 Apr 15;97(8):1795-803

Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. Eastman PS, et al. **J Clin Microbiol** 1995 Oct;33(10):2777-80

Structure-activity correlation study of HIV-1 inhibitors: electronic and molecular parameters. Hannongbua S, et al. **J Comput Aided Mol Des** 1996 Apr;10(2):145-52

Antiviral screening of British Columbian medicinal plants. McCutcheon AR, et al. **J Ethnopharmacol** 1995 Dec 1; 49(2):101-10

Antiviral activities of Nepalese medicinal plants. Taylor RS, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):157-63

Antibacterial effect of theaflavin, polyphenon 60 (Camellia sinensis) and Euphorbia hirta on Shigella spp.—a cell culture study. Vijaya K, et al. **J Ethnopharmacol** 1995 Dec 1;49(2):115-8

Screening of hundred Rwandese medicinal plants for antimicrobial and antiviral properties. Vlietinck AJ, et al. **J Ethnopharmacol** 1995 Apr;46(1):31-47

Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. Borman AM, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):419-26

Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC. Gu Z, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2601-5

Concurrent evolution of regions of the envelope and polymerase genes of human immunodeficiency virus type 1 during zidovudine (AZT) therapy. Sheehy N, et al. **J Gen Virol** 1996 May;77 (Pt 5):1071-81

CD4 down-modulation by ganglioside and phorbol ester inhibits human herpesvirus 7 infection. Yasukawa M, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2381-5

An antibody that binds domain 1 of CD4 inhibits replication of HIV-1, but not HTLV-I, in a CD4-positive/p56lck-negative HTLV-I-transformed cell line. Lemasson I, et al. **J Immunol** 1996 Jan 15; 156(2):859-65

Human immunodeficiency virus-induced cell death in cytokine-treated macrophages can be prevented by compounds that inhibit late stages of viral replication. Bergamini A, et al. **J Infect Dis** 1996 Jun;173(6):1367-78

In vitro inhibition of the replication of human immunodeficiency virus type 1 by beta-mercaptoethylamine (cysteamine). Bergamini A, et al. **J Infect Dis** 1996 Jul;174(1):214-8

Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease [letter; comment] Bilello JA, et al. **J Infect Dis** 1996 Jun;173(6):1524-6. Comment on: J Infect Dis 1995 Nov;172(5):1238-45.

Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. Boeckh M, et al. **J Infect Dis** 1995 Oct;172(4):939-43

Intracellular metabolism of zidovudine and stavudine in combination [letter] Hoggard P, et al. **J Infect Dis** 1996 Sep;174(3):671-2

Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. Klimov AI, et al. **J Infect Dis** 1995 Nov;172(5):1352-5

Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. Merrill DP, et al. **J Infect Dis** 1996 Feb;173(2):355-64

Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-gamma. Mikloska Z, et al. **J Infect Dis** 1996 Jan;173(1):7-17

Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and

genotypic characterization of sequential virus isolates. Smith IL, et al. **J Infect Dis** 1996 Jun;173(6):1481–4

Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. Thackray AM, et al. **J Infect Dis** 1996 Feb;173(2):291–9

Cloning and biologic activities of a bovine interferon–alpha isolated from the epithelium of a rotavirus–infected calf. Chaplin PJ, et al. **J Interferon Cytokine Res** 1996 Jan; 16(1):25–30

Priming with interferon–alpha 1 or interferon–alpha 2 enhances the production of both subtypes simultaneously. Fuchsberger N, et al. **J Interferon Cytokine Res** 1995 Jul; 15(7):637–9

Comparison of the in vitro host range of recombinant met–interferon–con1, interferon–alpha 2b, and interferon–beta [corrected] [published erratum appears in J Interferon Cytokine Res 1995 Sep;15(9):828] Hu CJ, et al. **J Interferon Cytokine Res** 1995 Mar;15(3):231–4

Potentiation by thyroxine of interferon–gamma–induced HLA–DR expression is protein kinase A– and C–dependent. Lin HY, et al. **J Interferon Cytokine Res** 1996 Jan;16(1):17–24

Inhibition of human immunodeficiency virus type 1 multiplication by transforming growth factor beta 1 and AZT in HIV–1–infected myeloid cells. McKiel V, et al. **J Interferon Cytokine Res** 1995 Oct;15(10):849–55

Antiviral activity of autocrine interferon–beta requires the presence of a functional interferon type I receptor. Rousseau V, et al. **J Interferon Cytokine Res** 1995 Sep; 15(9):785–9

Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus. Hirschman SZ, et al. **J Investig Med** 1996 Aug;44(6):347–51

Interferon–gamma inhibits HIV–induced invasiveness of monocytes. Dhawan S, et al. **J Leukoc Biol** 1995 Dec; 58(6):713–6

2–Sulfonyl–4–chloroanilino moiety: a potent pharmacophore for the anti–human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones. Artico M, et al. **J Med Chem** 1996 Jan 19;39(2):522–30

Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non–nucleoside HIV–1 reverse transcriptase inhibitors with antiviral activity. Campiani G, et al. **J Med Chem** 1996 Jul 5;39(14):2672–80

Quantitative structural activity relationship study of bis–tetraazacyclic compounds. A novel series of HIV–1 and HIV–2 inhibitors. Joao HC, et al. **J Med Chem** 1995 Sep 15;38(19):3865–73

Betulinic acid and dihydrobetulinic acid derivatives as potent anti–HIV agents. Kashiwada Y, et al. **J Med Chem** 1996 Mar 1;39(5):1016–7

Inhibitors of human immunodeficiency virus type 1 derived from gp41 transmembrane protein: structure–activity studies. Kazmierski WM, et al. **J Med Chem** 1996 Jul 5; 39(14):2681–9

Correlation of anti–HIV potency with lipophilicity in a series of cosalane analogs having normal alkenyl and phosphodiester chains as cholestane replacements. Keyes RF, et al. **J Med Chem** 1996 Jan 19;39(2):508–14

Aristeromycin–5'–carboxaldehyde: a potent inhibitor of S–adenosyl–L–homocysteine hydrolase. Liu S, et al. **J Med Chem** 1996 Jun 7;39(12):2347–53

Aryl phosphoramidate derivatives of d4T have improved anti–HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. McGuigan C, et al. **J Med Chem** 1996 Apr 12;39(8):1748–53

Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. Mazumder A, et al. **J Med Chem** 1996 Jun 21; 39(13):2472–81

Synthesis and biological evaluation of1',2'–seconucleo–5'–phosphonates. Racha S, et al. **J Med Chem** 1996 Mar 1; 39(5):1130–5

Synthesis and anti–herpes virus activity of 2'–deoxy–4'–thiopyrimidine nucleosides. Rahim SG, et al. **J Med Chem** 1996 Feb 2;39(3):789–95

Structure–activity relationships of the didemnins. Sakai R, et al. **J Med Chem** 1996 Jul 5;39(14):2819–34

New neplanocin analogues. 6. Synthesis and potent antiviral activity of 6'–homoneplanocin A1. Shuto S, et al. **J Med Chem** 1996 Jun 7;39(12):2392–9

Synthesis and antiviral activity of 2'–deoxy–4'–thio purine nucleosides. Van Draanen NA, et al. **J Med Chem** 1996 Jan 19;39(2):538–42

A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti–influenza drugs. von Itzstein M, et al. **J Med Chem** 1996 Jan 19; 39(2):388–91

Target structures for HIV–1 inactivation by methylene blue and light. Bachmann B, et al. **J Med Virol** 1995 Oct; 47(2):172–8

Tumor necrosis factor–alpha and interferon–gamma inhibit synergistically viral replication in hepatitis B virus–replicating cells. Kawanishi Y, et al. **J Med Virol** 1995 Nov;47(3):272–7

Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. Sarasini A, et al. **J Med Virol** 1995 Nov;47(3):237–44

Characterization of antisense RNA–mediated inhibition of SIV replication. Tung FY, et al. **J Med Virol** 1996 Apr; 48(4):321–5

Structural studies on human rhinovirus 14 drug–resistant compensation mutants. Hadfield AT, et al. **J Mol Biol** 1995 Oct 13;253(1):61–73

The action of pokeweed antiviral protein and ricin A–chain on mutants in the alpha–sarcin loop of Escherichia coli 23S ribosomal RNA. Marchant A, et al. **J Mol Biol** 1995 Dec 15;254(5):848–55

Synthesis and activity of piperazine–containing antirhinoviral agents and crystal structure of SDZ 880–061 bound to human rhinovirus 14. Oren DA, et al. **J Mol Biol** 1996 May 31;259(1):120–34

A novel basis of capsid stabilization by antiviral compounds. Phelps DK, et al. **J Mol Biol** 1995 Dec 8;254(4):544–51

Cultured human myocardial fibroblasts of pediatric origin: natural human interferon–alpha is more effective than recombinant interferon–alpha 2a in carrier–state coxsackievirus B3 replication. Heim A, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2199–208

Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV–1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. Neurath AR, et al. **J Mol Recognit** 1995 Sep–Oct;8(5):304–16

Anti–AIDS agents, 21. Triterpenoid saponins as anti–HIV principles from fruits of Gleditsia japonica and Gymnocladus chinensis, and a structure–activity correlation. Konoshima T, et al. **J Nat Prod** 1995 Sep; 58(9):1372–7

HIV inhibitory natural products. 26. Quinoline alkaloids from Euodia roxburghiana. McCormick JL, et al. **J Nat Prod** 1996 May;59(5):469–71

Curcumin—a natural herb with anti–HIV activity [letter] Jordan WC, et al. **J Natl Med Assoc** 1996 Jun;88(6):333

Anti–viral and immunomodulatory effects of interferon–alpha on cultured lymphocytes from patients with human T lymphotropic virus type I–associated myelopathy (HAM/TSP). Ijichi S, et al. **J Neuroimmunol** 1995 Sep;61(2):213–21

Biological and biochemical anti–human immunodeficiency virus activity of UC 38, a new non–nucleoside reverse transcriptase inhibitor. McMahon JB, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):298–305

Cationized hyperimmune immunoglobulins: pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus–infected human–peripheral blood lymphocytes–severe combined immune deficiency mice. Pardridge WM, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):246–52

Inactivation of viruses by chemically and photochemically generated singlet molecular oxygen. Müller–Breitkreutz K, et al. **J Photochem Photobiol B** 1995 Sep;30(1):63–70

Alteration of the expression of human estrogen receptor gene by distamycin. Bianchi N, et al. **J Steroid Biochem Mol Biol** 1995 Sep;54(5–6):211–5

Inhibition of mouse hepatitis virus multiplication by phosphorothioate analogues of oligodeoxynucleotides complementary to the leader RNA. Hayashi M, et al. **J Vet Med Sci** 1995 Dec;57(6):1081–3

Inhibition of viral multiplication in cells chronically infected with mouse hepatitis virus by antisense RNA against the polymerase gene. Maeda A, et al. **J Vet Med Sci** 1995 Jun; 57(3):563–5

Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo. Akarid K, et al. **J Virol** 1995 Nov;69(11):7001–5

Effects of 3'–deoxynucleoside 5'–triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus–strand strong–stop DNA. Arts EJ, et al. **J Virol** 1996 Feb;70(2):712–20

Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates. Bonneau AM, et al. **J Virol** 1996 Feb;70(2):787–93

Antiviral activity of alpha interferon in Sindbis virus–infected cells is restored by anti–E2 monoclonal antibody treatment. Després P, et al. **J Virol** 1995 Nov;69(11):7345–8

The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. de Vreese K, et al. **J Virol** 1996 Feb;70(2):689–96

The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin–binding drug SDZ NIM 811. Dorfman T, et al. **J Virol** 1996 Sep;70(9):3751–7

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. Doyon L, et al. **J Virol** 1996 Jun;70(6):3763–9

Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively. Gu Z, et al. **J Virol** 1996 Apr;70(4):2620–6

Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4–guanidino–Neu5Ac2en. Gubareva LV, et al. **J Virol** 1996 Mar;70(3):1818–27

Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. Harrigan PR, et al. **J Virol** 1996 Sep;70(9):5930–4

Sequence determinants of 3A–mediated resistance to enviroxime in rhinoviruses and enteroviruses. Heinz BA, et al. **J Virol** 1996 Jul;70(7):4854–7

Multidrug–resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. Iversen AK, et al. **J Virol** 1996 Feb;70(2):1086–90

Anti–human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. O'Brien WA, et al. **J Virol** 1996 May; 70(5):2825–31

(Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad–spectrum nonnucleoside reverse transcriptase inhibitors of drug–resistant isolates of human immunodeficiency virus type 1 (HIV–1) and select for drug–resistant variants of HIV–1IIIB with reduced replication phenotypes. Olmsted RA, et al. **J Virol** 1996 Jun;70(6):3698–705

Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single–chain variable fragments to inhibit early stages of the viral life cycle. Shaheen F, et al. **J Virol** 1996 Jun;70(6):3392–400

Characterization of inhibition of M2 ion channel activity by BL–1743, an inhibitor of influenza A virus. Tu Q, et al. **J Virol** 1996 Jul;70(7):4246–52

Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. Turpin JA, et al. **J Virol** 1996 Sep;70(9):6180–9

A blinded comparison of two methods of viral susceptibility testing: plaque reduction assay versus microplate in situ ELISA. Leahy BJ, et al. **J Virol Methods** 1996 Jan; 56(1):85–90

Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella–zoster virus to penciclovir and acyclovir. Standring–Cox R, et al. **J Virol Methods** 1996 Jan; 56(1):3–11

In vitro sensitivity of macropodid herpesvirus 2 to selected anti–herpetic compounds. Smith G. **J Wildl Dis** 1996 Jan; 32(1):117–20

A herpesvirus inhibitor from bovine whey [letter] Neurath AR, et al. **Lancet** 1996 Jun 15;347(9016):1703–4

Favorable pharmacodynamic features and superior anti–leukemic activity of B43 (anti–CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule. Myers DE, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):93–102

Inhibition of human immunodeficiency virus type 1 (HIV) gag gene expression by an antisense oligodeoxynucleotide phosphorothioate. Anazodo MI, et al. **Leukemia** 1995 Oct; 9 Suppl 1:S86–8

Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti–human immunodeficiency virus activity. Yang SS, et al. **Leukemia** 1995 Oct;9 Suppl 1:S75–85

Antiviral action of interferon–beta on Newcastle disease virus: selectivity to the hemagglutinin–neuraminidase gene expression. Yu Z, et al. **Med Microbiol Immunol (Berl)** 1995 May;184(1):45–52

Mutational analysis of DNA polymerase substrate recognition and subunit interactions using herpes simplex virus as prototype. Digard P, et al. **Methods Enzymol** 1995; 262:303–22

Compounds that target novel cellular components involved in HIV–1 transcription. Butera ST, et al. **Mol Med** 1995 Nov;1(7):758–67

Nuclear localization signal of HIV–1 as a novel target for therapeutic intervention. Dubrovsky L, et al. **Mol Med** 1995 Jan;1(2):217–30

Antiviral drugs from the nucleoside analog family block volume–activated chloride channels. Gschwentner M, et al. **Mol Med** 1995 May;1(4):407–17

Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC–781 and UC–82 as inhibitors of human immunodeficiency virus type 1 replication. Balzarini J, et al. **Mol Pharmacol** 1996 Aug;50(2):394–401

Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase. Mazumder A, et al. **Mol Pharmacol** 1996 Apr;49(4):621–8

Ligands of the antiestrogen–binding site are able to inhibit virion production of human immunodeficiency virus 1–infected lymphocytes. Mesange F, et al. **Mol Pharmacol** 1996 Jul;50(1):75–9

Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9–(2–phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines. Perno CF, et al. **Mol Pharmacol** 1996 Aug;50(2):359–66

Closing in on human immunodeficiency virus–1 [see comments] Mellors JW. **Nat Med** 1996 Mar;2(3):274–5 (23 ref.). Comment in: Nat Med 1996 May;2(5):490.

Japan's anti–AIDS drug arsenal slowly expands [news] Nathan R. **Nat Med** 1996 Jun;2(6):621

Bovine beta–lactoglobulin modified by 3–hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. Neurath AR, et al. **Nat Med** 1996 Feb;2(2):230–4

Nucleoside–analogue resistance involves the p66 subunit of HIV–1 RT. Boyer PL, et al. **Nat Struct Biol** 1996 Jul; 3(7):579–80

Regulation of the C3 production by gamma interferon from peripheral blood T cells in patients with membranoproliferative glomerulonephritis and poststreptococcal acute glomerulonephritis. Yan K, et al. **Nephron** 1996;72(4):623–8

The binding mode of drugs to the TAR RNA of HIV-1 studied by electric linear dichroism. Bailly C, et al. **Nucleic Acids Res** 1996 Apr 15;24(8):1460-4

A monoclonal antibody extends the half-life of an anti-HIV oligodeoxynucleotide and targets it to CD4+ cells. Morelli D, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4603-7

Use of digoxigenin-labeled RNA probe to test hepatitis A virus antiviral drugs. Cuyck-Gandré HV, et al. **Pathol Biol (Paris)** 1995 May;43(5):411-5

In vitro percutaneous absorption of arildone, a highly lipophilic drug, and the apparent no-effect of the penetration enhancer Azone in excised human skin. Baker EJ, et al. **Pharm Res** 1995 Jul;12(7):993-7

Does acyclovir increase serum lithium levels? Sylvester RK, et al. **Pharmacotherapy** 1996 May-Jun;16(3):466-8

Synthesis and biological activity of 1,2,4-triazinotriazinone derivatives. Abdel-Halim AM, et al. **Pharmazie** 1995 Nov; 50(11):726-9

Assessment of the anti-HIV activity of a pine cone isolate. Eberhardt TL, et al. **Planta Med** 1996 Feb;62(1):63-5

Anti-herpes virus activity of aporphine alkaloids. Montanha JA, et al. **Planta Med** 1995 Oct;61(5):419-24

Studies on the inhibitory effects of some acridone alkaloids on Epstein-Barr virus activation [letter] Takemura Y, et al. **Planta Med** 1995 Aug;61(4):366-8

Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Balzarini J, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7295-9

Stable triple helices formed by oligonucleotide N3'-->P5' phosphoramidates inhibit transcription elongation. Escudé C, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4365-9

Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Farnet CM, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3; 93(18):9742-7

Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans. Gnabre JN, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11239-43

Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants. Kleim JP, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):34-8

Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31. Lee-Huang S, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8818-22

Synthesis and targeted delivery of an azidothymidine homodinucleotide conferring protection to macrophages against retroviral infection. Magnani M, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4403-8

Isolation of virus-neutralizing RNAs from a large pool of random sequences. Pan W, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11509-13

Inhibitors of HIV-1 receptor that inhibit HIV integrase. Robinson WE Jr, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6326-31

The in vitro ejection of zinc from human immunodeficiency virus (HIV) type 1 nucleocapsid protein by disulfide benzamides with cellular anti-HIV activity. Tummino PJ, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):969-73

Chemical crosslinking of the subunits of HIV-1 reverse transcriptase. Debyser Z, et al. **Protein Sci** 1996 Feb; 5(2):278-86

Inhibition of in vitro HIV infection by trinitrophenyl-protein conjugates. Matsiota-Bernard P, et al. **Res Immunol** 1995 Feb;146(2):109-17

Inhibition of herpes simplex, rabies and rubella viruses by lectins with different specificities. Marchetti M, et al. **Res Virol** 1995 May-Jun;146(3):211-5

Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Rice WG, et al. **Science** 1995 Nov 17;270(5239):1194-7

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Wainberg MA, et al. **Science** 1996 Mar 1; 271(5253):1282-5

Statistical analysis of zidovudine (AZT) effect on CD4 cell counts in HIV disease. Mcneil AJ, et al. **Stat Med** 1996 Jan 15;15(1):75-92

Metallothionein synthesis induced by interferon alpha/beta in mice of various zinc status. Sato M, et al. **Tohoku J Exp Med** 1996 Mar;178(3):241-50

Antisense phosphorothioates as antivirals against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Matsukura M, et al. **Toxicol Lett** 1995 Dec; 82-83:435-8

Understanding the mechanism of action of the anti-influenza virus drug amantadine [letter] Pinto LH, et al. **Trends Microbiol** 1995 Jul;3(7):271

Heat stabilized, infectious poliovirus. Ofori-Anyinam O, et al. **Vaccine** 1995 Aug;13(11):983-6

Comparative antiviral effects of dsRNA on lower and higher vertebrates. Masycheva VI, et al. **Vet Res** 1995; 26(5-6):536-8

Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Blick TJ, et al. **Virology** 1995 Dec 20;214(2):475-84

Inhibition of HIV infection by pseudopeptides blocking viral envelope glycoprotein-mediated membrane fusion and cell death. Callebaut C, et al. **Virology** 1996 Apr 1;218(1):181-92

Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Gubareva LV, et al. **Virology** 1995 Oct 1;212(2):323-30

Suppression of influenza virus infection by an N-thioacetylneuraminic acid acrylamide copolymer resistant to neuraminidase. Itoh M, et al. **Virology** 1995 Oct 1;212(2):340-7

Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides. Lombardi S, et al. **Virology** 1996 Jun 15;220(2):274-84

Functional and molecular characterization of African swine fever virus mutants resistant to phosphonoacetic acid. Marques MI, et al. **Virology** 1995 Dec 1;214(1):72-81

Inhibition of HIV-1 in cell culture by synthetic humate analogues derived from hydroquinone: mechanism of inhibition. Schneider J, et al. **Virology** 1996 Apr 15; 218(2):389-95

Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Staschke KA, et al. **Virology** 1995 Dec 20;214(2):642-6

Reduction of human immunodeficiency virus production and cytopathic effects by inhibitors of the Na+/K+/2Cl- cotransporter. Voss TG, et al. **Virology** 1996 May 1; 219(1):291-4

Inhibition of human parainfluenza virus-3 replication by interferon and human MxA. Zhao H, et al. **Virology** 1996 Jun 15;220(2):330-8

[Study on asialoglycoprotein receptor mediated endocytosis of antiviral conjugate] Ju L, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):124-7 (Eng. Abstr.) **(Chi)**

[Anti-herpes simplex virus action of combined therapy with cyclocytidine and ganciclovir] Chen Z, et al. **Chung Hua Yen Ko Tsa Chih** 1996 Jan;32(1):25-8 (Eng. Abstr.) **(Chi)**

[Effect of Astragalus membranaceus on Ca2+ influx and coxsackie virus B3 RNA replication in cultured neonatal rat heart cells] Guo Q, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):483-5 (Eng. Abstr.) **(Chi)**

[Antiviral activity of tannin from the pericarp of Punica granatum L. against genital Herpes virus in vitro] Zhang J, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep; 20(9):556-8, 576, inside backcover (Eng. Abstr.) **(Chi)**

[Active antiviral agents against human cytomegalovirus and their use in pediatrics] Mazeron MC, et al. **Arch Pediatr** 1996;3 Suppl 1:309s-311s (12 ref.) **(Fre)**

[Use of cell culture for the research of cytotoxic and antiviral effects of a natural extract of Amaryllidaceae] Husson GP, et al. **C R Seances Soc Biol Fil** 1995;189(4):679-92 (Eng. Abstr.) **(Fre)**

[Protease inhibitors: a new class of anti-HIV substances (news)] **Dtsch Med Wochenschr** 1996 Aug 23; 121(34-35):A9-A10 **(Ger)**

[A new antiviral substance against AIDS is already tested by phase II trial (news)] Diehl M. **Dtsch Med Wochenschr** 1996 Jan 5;121(1-2):A21 **(Ger)**

[Update on the use of interferons in clinical practice] Lauta VM. **Clin Ter** 1995 Jun-Jul;146(6-7):393-448 (160 ref.) (Eng. Abstr.) **(Ita)**

[Genomic changes in the E2/NS1 region of HCV before and after IFN therapy] Higashi Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:923-9 **(Jpn)**

[Different effect of interferon on hepatitis C virus genomes using CAT expression system] Yanagi M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:936-43 **(Jpn)**

[Resistance of herpes simplex virus to acyclovir: laboratory and clinical aspects] Briazzhikova TS, et al. **Antibiot Khimioter** 1995 Nov-Dec;40(11-12):29-33 (Eng. Abstr.) **(Rus)**

[A new oxa-analog of myristic acid, suppressing replication of the human immunodeficiency virus] Vodovozova EL, et al. **Bioorg Khim** 1995 Sep;21(9):724-30 (Eng. Abstr.) **(Rus)**

[Inhibition of human immunodeficiency virus replication by anionic dyes] Iakubov LA, et al. **Dokl Akad Nauk** 1996 Apr;347(5):696-8 **(Rus)**

[Inhibition of Marburg virus reproduction by glycyrrhizinic acid and its derivatives] Pokrovskii AG, et al. **Dokl Akad Nauk** 1995 Oct;344(5):709-11 **(Rus)**

[Experimental use of a variant of the human immunodeficiency virus (HIV-1) with decreased sensitivity to 3'-azido-2',3'-dideoxythymidine and a study of its properties] Selimova LM, et al. **Dokl Akad Nauk** 1995 Oct; 344(4):562-4 **(Rus)**

[Mutant human gamma-interferon with increased antiviral activity] Tat'kov SI, et al. **Dokl Akad Nauk** 1996 Jan; 346(3):413-4 **(Rus)**

[Action of drugs based on native DNA against RNA and DNA containing viruses] Vainberg IP, et al. **Klin Med (Mosk)** 1995;73(6):3-5 **(Rus)**

[A model system for rapid screening of antiretroviral compounds] Shevelev AIa, et al. **Mol Biol (Mosk)** 1995 Sep-Oct;29(5):1114-25 **(Rus)**

[Anti-hemophilia drugs: from cryoprecipitate to factor VIII concentrates of high purity] Gutsalo AE, et al. **Ukr Biokhim Zh** 1995 Jan-Feb;67(1):3-13 (62 ref.) (Eng. Abstr.) **(Rus)**

[Mathematical modeling of the spread of influenza virus strains resistant to chemicals] Ivannikov IuG, et al. **Vestn Ross Akad Med Nauk** 1995;(9):41-3 (Eng. Abstr.) **(Rus)**

[The origin of resistance to chemicals of naturally occurring isolates of influenza A virus] Kozeletskaia KN, et al. **Vestn Ross Akad Med Nauk** 1995;(9):36-41 (Eng. Abstr.) **(Rus)**

[Antiviral properties of recombinant human lymphotoxin] Denisov AA, et al. **Vopr Virusol** 1995 Nov-Dec;40(6):277-9 (Eng. Abstr.) **(Rus)**

[Determination of the antiviral activity of a naturally occurring sulfated xylomannan under various experimental conditions] Pujol CA, et al. **Rev Argent Microbiol** 1995 Apr-Jun;27(2):91-8 (Eng. Abstr.) **(Spa)**

[Susceptibility of picornaviruses++ to an antiviral of plant origin (meliacin)] Wachsman MB, et al. **Rev Argent Microbiol** 1995 Jan-Mar;27(1):33-7 (Eng. Abstr.) **(Spa)**

POISONING

[Attempted suicide using massive doses of zidovudine (letter)] Pérez-Molina JA, et al. **Enferm Infecc Microbiol Clin** 1995 Oct;13(8):494-5 **(Spa)**

SUPPLY & DISTRIBUTION

French patients will get protease inhibitors [news] Gozlan M. **Lancet** 1996 Mar 23;347(9004):821

THERAPEUTIC USE

Relation between serum hepatitis C virus-RNA levels and efficacy of interferon-beta therapy. Minohara Y, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):530-3

Update on therapy of influenza and rhinovirus infections. Arruda E, et al. **Adv Exp Med Biol** 1996;394:175-87 (93 ref.)

Famciclovir: efficacy in zoster and issues in the assessment of pain. Boon RJ, et al. **Adv Exp Med Biol** 1996;394:17-31 (37 ref.)

Current clinical experience with nevirapine for HIV infection. Carr A, et al. **Adv Exp Med Biol** 1996; 394:299-304 (17 ref.)

Efficacy of combination antiretroviral therapy. Collier AC. **Adv Exp Med Biol** 1996;394:355-72 (100 ref.)

Subclinical shedding of HSV: its potential for reduction by antiviral therapy. Corey L, et al. **Adv Exp Med Biol** 1996; 394:11-6 (7 ref.)

Zidovudine: anno 1995. Danner SA. **Adv Exp Med Biol** 1996; 394:225-43 (114 ref.)

Oral ganciclovir for cytomegalovirus infections. Follansbee SE, et al. **Adv Exp Med Biol** 1996;394:93-103 (10 ref.)

Stavudine (d4T, Zerit). Friedland G, et al. **Adv Exp Med Biol** 1996;394:271-7 (21 ref.)

Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections. Jacobson MA. **Adv Exp Med Biol** 1996;394:85-92 (28 ref.)

The clinical use of didanosine. Kahn J. **Adv Exp Med Biol** 1996;394:245-56 (47 ref.)

Use of antiretroviral therapy in children and pregnant women. McKinney RE Jr. **Adv Exp Med Biol** 1996; 394:345-54 (22 ref.)

Management of genital herpes. Mertz GJ. **Adv Exp Med Biol** 1996;394:1-10 (30 ref.)

Management of respiratory syncytial virus infections. Mills J. **Adv Exp Med Biol** 1996;394:163-74 (59 ref.)

Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Richman DD. **Adv Exp Med Biol** 1996; 394:383-95 (94 ref.)

New initiatives in combination antiretroviral chemotherapy. Rooney JF, et al. **Adv Exp Med Biol** 1996;394:373-82 (29 ref.)

Treatment of acyclovir-resistant herpes simplex and varicella zoster virus infections. Safrin S. **Adv Exp Med Biol** 1996; 394:59-66 (44 ref.)

ddC (zalcitabine). Skowron G. **Adv Exp Med Biol** 1996; 394:257-69 (49 ref.)

Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Smiley ML, et al. **Adv Exp Med Biol** 1996;394:33-9 (23 ref.)

Therapy for chronic hepatitis B infection. Terrault NA, et al. **Adv Exp Med Biol** 1996;394:189-205 (129 ref.)

Controversies in initiating anti-retroviral therapy and in the use of combination therapies. Volberding PA. **Adv Exp Med Biol** 1996;394:333-43 (14 ref.)

Prophylaxis and treatment of CMV infections in transplantation. Zaia JA. **Adv Exp Med Biol** 1996; 394:117-34 (72 ref.)

Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. Bell JE, et al. **AIDS** 1996 May; 10(5):493-9

Sorivudine (BV-ara-U) for the treatment of complicated refractory varicella zoster virus infection in HIV-infected patients [letter] Burdge DR, et al. **AIDS** 1995 Jul;9(7):810-2

Management of cytomegalovirus disease. Danner SA. **AIDS** 1995 Dec;9 Suppl 2:S3-S8 (16 ref.)

Progressive multifocal leucoencephalopathy in AIDS: treatment with cytosine arabinoside [letter] Guarino M, et al. **AIDS** 1995 Jul;9(7):819-20

Phase I/II study of 3TC (lamivudine) in HIV-positive,

asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group. Ingrand D, et al. **AIDS** 1995 Dec;9(12):1323–9

The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. Jacobson MA, et al. **AIDS** 1995 Jul;9(7):727–34

Changing incidence of HIV-induced brain lesions in Oslo, 1983–1994: effects of zidovudine treatment. Maehlen J, et al. **AIDS** 1995 Oct;9(10):1165–9

Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. Roberts NA. **AIDS** 1995 Dec;9 Suppl 2:27–S32 (34 ref.)

Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. Schooley RT. **AIDS** 1995 Dec;9 Suppl 2:S15–S19 (21 ref.)

Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. Staszewski S, et al. **AIDS** 1996 May;10(5):F1–7

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). Stein DS, et al. **AIDS** 1996 May;10(5):485–92

Clinical experience with saquinavir. Vella S. **AIDS** 1995 Dec; 9 Suppl 2:S21–S25 (22 ref.)

Autocrine interferon-beta synthesis for gene therapy of HIV infection: increased resistance to HIV-1 in lymphocytes from healthy and HIV-infected individuals. Vieillard V, et al. **AIDS** 1995 Nov;9(11):1221–8

Zidovudine adherence among individuals with HIV infection. Muma RD, et al. **AIDS Care** 1995;7(4):439–47

New developments in antiretroviral drug therapy for HIV-1 infections. Johnson VA. **AIDS Clin Rev** 1995–96;:305–46 (106 ref.)

HIV viral load quantification, HIV resistance, and antiretroviral therapy. Katzenstein DA, et al. **AIDS Clin Rev** 1995–96;:277–303 (107 ref.)

Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. Freeman RC, et al. **AIDS Educ Prev** 1996 Feb;8(1):58–71

Hydroxyurea and AIDS: an old drug finds a new application? Lori F, et al. **AIDS Res Hum Retroviruses** 1995 Oct; 11(10):1149–51

Ganciclovir for cytomegalovirus infection [news] **Am Fam Physician** 1996 Mar;53(4):1441

Lamivudine as adjunct therapy in HIV [news] **Am Fam Physician** 1996 Feb 1;53(2):781–2

Ritonavir for advanced HIV infection [news] **Am Fam Physician** 1996 Jul;54(1):372, 374

Antiretroviral drug treatment for HIV/AIDS. Goldschmidt RH, et al. **Am Fam Physician** 1996 Aug;54(2):574–80, 587–8

Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Ikura Y, et al. **Am J Gastroenterol** 1996 Jul;91(7):1367–73

Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy. Jamal H, et al. **Am J Gastroenterol** 1996 May;91(5):1027–30

Interferon therapy for fulminant hepatitis associated with precore region mutation in hepatitis B virus carrier [letter] Omata F, et al. **Am J Gastroenterol** 1996 Aug;91(8):1673–5

alpha-Interferon retreatment of patients with chronic hepatitis C. Rabinovitz M, et al. **Am J Gastroenterol** 1996 Aug;91(8):1523–6

Treatment during primary HIV infection shows promise [news] **Am J Health Syst Pharm** 1995 Nov 1;52(21):2383–4

New nucleoside analogue, lamivudine, released for HIV therapy [news] **Am J Health Syst Pharm** 1996 Jan 15; 53(2):116

Current issues in the management of patients with cytomegalovirus infection. Flaherty JF Jr. **Am J Health Syst Pharm** 1996 Apr 15;53(8 Suppl 2):S3

Current and experimental therapeutic options for cytomegalovirus disease. Flaherty JF Jr. **Am J Health Syst Pharm** 1996 Apr 15;53(8 Suppl 2):S4–11

Current management of cytomegalovirus infection: treatment and prophylaxis. Hardy D. **Am J Health Syst Pharm** 1996 Apr 15;53(8 Suppl 2):S12–6; discussion S17

Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy. Mandanas RA, et al. **Am J Hematol** 1996 Feb;51(2):104–11

Variations in practice patterns: antiviral drug use in hospitalized patients with herpes infections. DesHarnais S, et al. **Am J Med Qual** 1996 Spring;11(1):33–42

Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. Desatnik HR, et al. **Am J Ophthalmol** 1996 Jul; 122(1):121–3

Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Bartlett JA, et al. **Ann Intern Med** 1996 Aug 1;125(3):161–72

Preemptive ganciclovir therapy in renal transplantation [letter] Brennan DC, et al. **Ann Intern Med** 1996 Apr 1; 124(7):693

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group. Chemello L, et al. **Ann Intern Med** 1996 Jun 15;124(12):1058–60

Ribavirin for chronic hepatitis C [letter] Chinitz MA. **Ann Intern Med** 1996 Oct 15;125(8):699

Hepatic hepatitis C virus RNA in chronic hepatitis C [letter; comment] Craxì A, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):72. Comment on: Ann Intern Med 1995 Apr 15;122(8):586–91.

Interferon for chronic hepatitis B [letter; comment] Evans AA, et al. **Ann Intern Med** 1996 Jan 15;124(2):276; discussion 277. Comment on: Ann Intern Med 1995 May 1;122(9):664–75.

Prophylaxis for occupational exposure to HIV. Gerberding JL. **Ann Intern Med** 1996 Sep 15;125(6):497–501 (31 ref.)

Viral dynamics of HIV: implications for drug development and therapeutic strategies. Havlir DV, et al. **Ann Intern Med** 1996 Jun 1;124(11):984–94 (112 ref.)

Treatment of cytomegalovirus retinitis in patients with AIDS [editorial; comment] Jabs DA. **Ann Intern Med** 1996 Jul 15;125(2):144–5. Comment on: Ann Intern Med 1996 Jul 15;125(2):98–103. Comment on: Ann Intern Med 1996 Jul 15;125(2):126–36.

Interferon for chronic hepatitis B [letter; comment] Koretz RL. **Ann Intern Med** 1996 Jan 15;124(2):276–7. Comment on: Ann Intern Med 1995 May 1;122(9):664–75.

Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report [see comments] Rahhal FM, et al. **Ann Intern Med** 1996 Jul 15;125(2):98–103. Comment in: Ann Intern Med 1996 Jul 15;125(2):144–5.

Effects of famiciclovir in acute herpes zoster [letter] Tirelli U. **Ann Intern Med** 1996 Apr 15;124(8):775

Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Whitley RJ, et al. **Ann Intern Med** 1996 Sep 1;125(5):376–83

Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients. Cohen P, et al. **Ann Med Interne (Paris)** 1996;147(2):81–6

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Jacobs LD, et al. **Ann Neurol** 1996 Mar;39(3):285–94

Use of zidovudine to prevent maternal transmission of HIV. Belgado BS, et al. **Ann Pharmacother** 1995 Dec; 29(12):1287–8

Failure of acyclovir sodium therapy in herpes simplex encephalitis. Gürses N, et al. **Ann Trop Paediatr** 1996 Jun; 16(2):173–5

Interferon response depends on viral transcription in human papillomavirus-containing lesions. Arany I, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2865–9

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Beutner KR, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1546–53

GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Ryan DM, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2583–4

Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Thackray AM, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):846–51

Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Wong JP, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2574–6

Consensus symposium on combined antiviral therapy. Lisbon, Portugal, July 25–27. **Antiviral Res** 1996 Jan;29(1):3–122 (0 ref.)

Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Biron F, et al. **Antiviral Res** 1996 Jan;29(1):111–3

Combination therapy with zidovudine, didanosine and saquinavir. Collier AC, et al. **Antiviral Res** 1996 Jan; 29(1):99

Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases. de Jong MD, et al. **Antiviral Res** 1996 Jan;29(1):5–29 (70 ref.)

Summary: antiviral treatment of hepatitis C virus. Dusheiko GM. **Antiviral Res** 1996 Jan;29(1):77–82 (30 ref.)

Combination antiviral therapy for respiratory virus infections. Hayden FG. **Antiviral Res** 1996 Jan;29(1):45–8

Role of animal models in selecting antiviral combinations for clinical studies. Kern ER. **Antiviral Res** 1996 Jan; 29(1):57–9

Antiviral activity of 9-[[(ethoxyhydroxyphosphinyl)-methoxy]methoxy] guanine against cytomegalovirus and herpes simplex virus. Kim HT, et al. **Antiviral Res** 1995 Nov;28(3):243–51

Combination therapy in primary HIV infection. Perrin L, et al. **Antiviral Res** 1996 Jan;29(1):87–9

CMV retinitis: ganciclovir/monoclonal antibody. Pollard RB. **Antiviral Res** 1996 Jan;29(1):73–5

D4T nucleoside combinations for HIV. Pollard RB. **Antiviral Res** 1996 Jan;29(1):101–4

The implications of drug resistance for strategies of combination antiviral chemotherapy. Richman DD. **Antiviral Res** 1996 Jan;29(1):31–3

Consensus symposium on combined antiviral therapy; overview of interferon and IL-2 combinations for the treatment of HIV infection. Sneller MC. **Antiviral Res** 1996 Jan;29(1):105–9

Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Tomai MA, et al. **Antiviral Res** 1995 Nov;28(3):253–64

Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Vella S, et al. **Antiviral Res** 1996 Jan;29(1):91–3

Herpetic trigeminal trophic syndrome. Treatment with acyclovir and sublesional triamcinolone. Shea CR, et al. **Arch Dermatol** 1996 Jun;132(6):613–4

Lymphoblastoid interferon alfa treatment in chronic hepatitis C. Iorio R, et al. **Arch Dis Child** 1996 Feb;74(2):152–6

Duration of the survival benefit of zidovudine therapy in HIV infection. Moore RD, et al. **Arch Intern Med** 1996 May 27;156(10):1073–7

A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Spruance SL, et al. **Arch Intern Med** 1996 Aug 12–26;156(15):1729–35

Event-related potentials in HIV infection: evidence for impact of antiretroviral treatment [letter] Evers S, et al. **Arch Neurol** 1996 Aug;53(8):715–6

Assessment of cytomegalovirus retinitis. Clinical evaluation vs centralized grading of fundus photographs. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. **Arch Ophthalmol** 1996 Jul; 114(7):791–805

Clinical vs photographic assessment of treatment of cytomegalovirus retinitis. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial Report 8. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. **Arch Ophthalmol** 1996 Jul;114(7):848–55

A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. The Herpetic Eye Disease Study Group. **Arch Ophthalmol** 1996 Sep;114(9):1065–72

Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. **Arch Ophthalmol** 1996 Jan; 114(1):23–33

Herpetic eye disease study. You can help [editorial] Dawson CR, et al. **Arch Ophthalmol** 1996 Jan;114(1):89–90 (8 ref.)

Serous retinal detachments in a patient with clinically resistant cytomegalovirus retinitis. Dodds EM, et al. **Arch Ophthalmol** 1996 Jul;114(7):896–7

Long-term, successful maintenance of bilateral cytomegalovirus retinitis using exclusively local therapy [letter] Duker JS, et al. **Arch Ophthalmol** 1996 Jul; 114(7):881–2

Treatment of cytomegalovirus retinitis with intraocular sustained-release ganciclovir implant [letter; comment] Friedberg DN. **Arch Ophthalmol** 1995 Nov;113(11):1354–5 . Comment on: Arch Ophthalmol 1994 Dec;112(12):1531–9.

Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Marx JL, et al. **Arch Ophthalmol** 1996 Jul;114(7):815–20

Delayed herpes zoster pseudodendrites. Polymerase chain reaction detection of viral DNA and a role for antiviral therapy. Pavan-Langston D, et al. **Arch Ophthalmol** 1995 Nov;113(11):1381–5

Endogenous bacterial endophthalmitis as a complication of intravenous therapy for cytomegalovirus retinopathy [letter] Tufail A, et al. **Arch Ophthalmol** 1996 Jul; 114(7):879–80

Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. Randolph AG, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):942–7

Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Conti DJ, et al. **Arch Surg** 1995 Nov;130(11):1217–21; discussion 1221–2

Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection. Emery S, et al. **Aust N Z J Med** 1995 Aug;25(4):344–9 (41 ref.)

Sustained-release intravitreal ganciclovir pellets in the treatment of cytomegalovirus retinitis in the acquired immunodeficiency syndrome [letter] Luckie A, et al. **Aust N Z J Ophthalmol** 1995 May;23(2):157–8

New strategies for treating AIDS. Sandstrom PA, et al. **Bioessays** 1996 May;18(5):343–6 (20 ref.)

Biological effect of active anti-IFN alpha immunization in HIV-infected patients. Fall LS, et al. **Biomed Pharmacother** 1995;49(9):422–8

New drugs—reports of new drugs recently approved by the FDA. Valacyclovir. Shinkai I, et al. **Bioorg Med Chem** 1996 Jan;4(1):1–2

Human HLA-specific T-cell clones with stable expression of a suicide gene: a possible tool to drive and control a graft-versus-host- graft-versus-leukemia reaction? Gallot G, et al. **Blood** 1996 Aug 1;88(3):1098–103

Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs. Humphrey RW, et al. **Blood** 1996 Jul 1;88(1):297–301

Effect of antiviral treatments on the bone marrow in murine aids. Brandi G, et al. **Blood Cells Mol Dis** 1995;21(2):109–18

Study shows two drugs are best for HIV infection [news]

Dillner L. **BMJ** 1995 Sep 30;311(7009):827
Antiviral drug resistance [editorial] Pillay D, et al. **BMJ** 1996 Aug 31;313(7056):503–4
Managing HIV disease after Delta [editorial] [see comments] Pinching AJ. **BMJ** 1996 Mar 2;312(7030):521–2. Comment in: **BMJ** 1996 Jun 15;312(7045):1542.
Acyclovir in recurrent herpes labialis [editorial] [see comments] Worrall G. **BMJ** 1996 Jan 6;312(7022):6. Comment in: **BMJ** 1996 Apr 13;312(7036):975.
Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group. Atkinson K, et al. **Bone Marrow Transplant** 1995 Sep;16(3):401–5
Successful treatment with ganciclovir of presumed Epstein-Barr meningo-encephalitis following bone marrow transplant. Dellemijn PL, et al. **Bone Marrow Transplant** 1995 Aug;16(2):311–2
Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Whimbey E, et al. **Bone Marrow Transplant** 1995 Sep; 16(3):393–9
Zidovudine therapy in HIV infection: which patients should be treated and when. Barry MG, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):107–10 (39 ref.)
Acyclovir-resistant chronic cutaneous herpes simplex in Wiskott-Aldrich syndrome. Modiano P, et al. **Br J Dermatol** 1995 Sep;133(3):475–8
Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Hoh HB, et al. **Br J Ophthalmol** 1996 Feb;80(2):140–3
Clinical evaluation of carbocyclic oxetanocin G eyedrops in the treatment of herpes simplex corneal ulcers. Shiota H, et al. **Br J Ophthalmol** 1996 May;80(5):413–5
A model for treatment strategy in the chemotherapy of AIDS. Kirschner D, et al. **Bull Math Biol** 1996 Mar; 58(2):376–90
Efficacy of four antiviral agents in the treatment of uncomplicated herpetic keratitis. Panda A, et al. **Can J Ophthalmol** 1995 Aug;30(5):256–8
Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time. Levine AM, et al. **Cancer** 1996 Aug 1; 78(3):517–26
In vitro and in vivo sensitivity of a non-mouse-adapted influenza A (Beijing) virus infection to amantadine and ribavirin. Sidwell RW, et al. **Chemotherapy** 1995 Nov-Dec; 41(6):455–61
Cytomegalovirus colitis in an immunocompetent old woman successfully treated with ganciclovir: a case report. Tsai HL, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Apr; 57(4):289–92
Parainfluenza virus respiratory infection after heart transplantation: successful treatment with ribavirin. Cobian L, et al. **Clin Infect Dis** 1995 Oct;21(4):1040–1
Foscarnet-resistant multidermatomal zoster in a patient with AIDS. Fillet AM, et al. **Clin Infect Dis** 1995 Nov; 21(5):1348–9
Use of famciclovir and valaciclovir in the treatment of viral keratitis [letter] Gatchel S. **Clin Infect Dis** 1996 May; 22(5):886
Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1. Park LP, et al. **Clin Infect Dis** 1995 Oct;21(4):930–7
The role of antiretroviral therapy in the management of HIV infection in women. Mofenson LM. **Clin Obstet Gynecol** 1996 Jun;39(2):361–85 (113 ref.)
The diagnosis and management of perinatal HIV infection. Nesheim SR. **Clin Obstet Gynecol** 1996 Jun;39(2):396–410 (84 ref.)
Therapeutic applications of alpha interferon for chronic viral hepatitis in pediatric patients. Kay MH, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):372–9 (50 ref.)
Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment. Malaguarnera M, et al. **Clin Ther** 1995 Jul-Aug;17(4):721–8
Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Sperber K, et al. **Clin Ther** 1995 Jul-Aug;17(4):622–36
Cytomegalovirus involving gastrointestinal tract in renal transplant recipients. Shrestha BM, et al. **Clin Transplant** 1996 Apr;10(2):170–5
Combined drugs may be better than zidovudine alone for immunocompromised adults infected with HIV-1. **Commun Dis Rep CDR Wkly** 1995 Oct 20;5(42):209
The treatment of multiple sclerosis: current and future. Polman CH, et al. **Curr Opin Neurol** 1995 Jun;8(3):200–9 (87 ref.)
Use of penciclovir and famciclovir in the management of genital herpes. Sacks SL. **Curr Probl Dermatol** 1996; 24:219–26 (34 ref.)
Aciclovir and its l-valyl ester, valaciclovir. Smiley ML, et al. **Curr Probl Dermatol** 1996;24:209–18 (56 ref.)
Therapeutic approaches to HIV infection based on virus structure and the host pathogen interaction. Pauza CD, et al. **Curr Top Microbiol Immunol** 1995;202:117–32 (94 ref.)
Acyclovir in the treatment of hand-foot-and-mouth disease. Shelley WB, et al. **Cutis** 1996 Apr;57(4):232–4
Recurrence rate of herpetic uveitis in patients on long-term oral acyclovir. Rodriguez A, et al. **Doc Ophthalmol** 1995; 90(4):331–40
Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Haria M, et al. **Drugs** 1995 Nov;50(5):873–96 (149 ref.)
Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Perry CM, et al. **Drugs** 1995 Aug;50(2):396–415 (64 ref.)
Antiviral therapy of acute herpes zoster in older patients. Herne K, et al. **Drugs Aging** 1996 Feb;8(2):97–112 (89 ref.)
Antiviral therapy in neonatal chronic lung disease. Giffin FJ, et al. **Early Hum Dev** 1995 Jun 21;42(2):97–109
Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration. Shimizu H, et al. **Endocr J** 1995 Aug; 42(4):551–6
Acyclovir prophylaxis of oral herpes virus during bone marrow transplantation. Epstein JB, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):158–62
Neopterin and beta 2-microglobulin as serum markers in a placebo-controlled anti-HIV therapy trial. Carstens J, et al. **Eur J Clin Chem Clin Biochem** 1995 Sep;33(9):559–62
Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients. Calderón EJ, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):512–9
Distribution of genotypes and response to alpha-interferon in patients with hepatitis C virus infection in Germany. Feucht HH, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):128–32
Oral acyclovir in herpes zoster ophthalmicus [letter; comment] Harding SP. **Eye** 1995;9 (Pt 3):390–2. Comment on: Eye 1994;8 (Pt 1):70–4.
Lamivudine: a magic bullet for chronic hepatitis B? Grimm I. **Gastroenterology** 1996 Jul;111(1):262–4
Local regression of breast tumors following intramammary ganciclovir administration in double transgenic mice expressing neu oncogene and herpes simplex virus thymidine kinase. Sacco MG, et al. **Gene Ther** 1995 Sep; 2(7):493–7
Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts. Armstrong DK, et al. **Genitourin Med** 1996 Apr;72(2):103–7
Systemically administered interferon alfa-2a prevents recurrence of condylomata acuminata following CO_2-laser ablation. The influence of the cyclic low-dose therapy regimen. Results of a multicentre double-blind placebo-controlled clinical trial [letter] Gross G, et al. **Genitourin Med** 1996 Feb;72(1):71
Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum. Monsonego J, et al. **Genitourin Med** 1996 Apr;72(2):111–4
Ups and downs—and ups in the antiviral therapy of HIV infection. Weller IV, et al. **Genitourin Med** 1996 Feb; 72(1):2–5 (24 ref.)
In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Tong XW, et al. **Gynecol Oncol** 1996 May;61(2):175–9
The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. Crystal S, et al. **Health Serv Res** 1995 Oct;30(4):593–614
Long-term effect of interferon alpha alone or after prednisone withdrawal in chronic hepatitis B. Interim report and review of the literature. Gonzalez-Mateos F, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):893–9 (25 ref.)
Interferon alpha treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation. Van Thiel DH, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):900–6
Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Van Thiel DH, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):907–12
gamma-Glutamyl transpeptidase as a response predictor when using alpha-interferon to treat hepatitis C. Van Thiel DH, et al. **Hepatogastroenterology** 1995 Nov-Dec; 42(6):888–92
A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C. Chayama K, et al. **Hepatology** 1996 May;23(5):953–7
Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C. Coverdale S, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1065–71
Hepatitis B virus precore/core variation and interferon therapy. Fattovich G, et al. **Hepatology** 1995 Nov; 22(5):1355–62
An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Féray C, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1084–9
Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Gish RG, et al. **Hepatology** 1996 Jan; 23(1):1–7
Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Gregorio GV, et al. **Hepatology** 1996 Apr;23(4):700–7
Liver-targeted antiviral nucleosides: enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo. Korba BA, et al. **Hepatology** 1996 May; 23(5):958–63
Expression of transforming growth factor alpha in the liver before and after interferon alfa therapy for chronic hepatitis B. Morimitsu Y, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1021–6
Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Todros L, et al. **Hepatology** 1995 Nov;22(5):1374–8
Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Yamada G, et al. **Hepatology** 1995 Nov;22(5):1351–4
Early treatment of herpes zoster. Tyring SK. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):137–44 (0 ref.)
alpha-Interferon treatment of patients with chronic fatigue syndrome. See DM, et al. **Immunol Invest** 1996 Jan-Mar; 25(1-2):153–64
Oral acyclovir in treatment of suspected herpes simplex encephalitis. Awasthi S, et al. **Indian Pediatr** 1995 Apr; 32(4):485–7
Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir. Jabs DA. **Infect Agents Dis** 1995 Sep;4(3):131–42 (63 ref.)
Herpes simplex virus resistance to acyclovir: clinical relevance. Pottage JC Jr, et al. **Infect Agents Dis** 1995 Sep; 4(3):115–24 (111 ref.)
Antiviral agents in dermatology: current status and future prospects. Memar OM, et al. **Int J Dermatol** 1995 Sep; 34(9):597–606 (98 ref.)
Benefit of oral zinc supplementation as an adjunct to zidovudine (AZT) therapy against opportunistic infections in AIDS. Mocchegiani E, et al. **Int J Immunopharmacol** 1995 Sep;17(9):719–27
Management of cytomegalovirus infection. The Jefferiss Wing Therapeutics and Protocols Group. Fisher M, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):313–9 (28 ref.)
Oral ganciclovir: a new option for patients with CMV retinitis [editorial] Fisher M, et al. **Int J STD AIDS** 1996 Jan-Feb;7(1):1–3 (19 ref.)
Intralesional interferon for the treatment of recalcitrant molluscum contagiosum in HIV antibody positive individuals—a preliminary report. Nelson MR, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):351–2
Antiviral chemotherapy in genital herpes simplex virus infections. Patel R, et al. **Int J STD AIDS** 1995 Sep-Oct; 6(5):320–8 (78 ref.)
Failure of antiretroviral therapy: role of viral and cellular factors. Cinatl J Jr, et al. **Intervirology** 1994;37(6):307–14 (76 ref.)
HIV treatment choice based on resistance patterns. Moyle G. **Intervirology** 1994;37(6):367–8
Efficacy of (S)-HPMPA against thymidine kinase-deficient herpes simplex virus-keratitis. Maudgal PC, et al. **Invest Ophthalmol Vis Sci** 1987 Feb;28(2):243–8
Combination Antiretroviral Therapy for HIV Infection. Proceedings of an international symposium. Berlin, Germany, March 25-26, 1995. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:v, S1–82
Clinical research and drug development of antivirals in HIV: an industry perspective. Carter SK. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S107–113
Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients. Cleland A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):6–18
Differences in participation in experimental drug trials among persons with AIDS. Diaz T, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 15;10(5):562–8
A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. Fischl MA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 1;11(4):379–84
Insights from monitoring the CPCRA didanosine/zalcitabine trial. Terry Beirn Community Programs for Clinical Research on AIDS. Fleming TR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S9–18
Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection. Frissen PH, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 15;12(5):482–8
Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. Godfried MH, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 15;10(5):531–9
Combination therapy from a clinician's perspective. Goebel FD. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995; 10 Suppl 1:S62–8 (38 ref.)
Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV

infection. Goldman AI, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Feb 1;11(2):161–9

Measuring viral load in the clinical setting. Harrigan R.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S34–40 (26 ref.)

Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model. Harvie P, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Aug 15;12(5):451–61

Studies of zidovudine in combination with didanosine and zalcitabine. Jablonowski H.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S52–6 (17 ref.)

Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC–PCR) assays compared. Kappes JC, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Oct 1;10(2):139–49

Survival effects of ZDV, ddI, and ddC in patients with CD4 < or = 50 cells/mm3. Kazempour K, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 2:S97–106

Therapeutic interventions in primary HIV infection. Kinloch-de Loës S, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S69–76 (44 ref.)

Triple combinations: present and future. Lange JM.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S77–82 (24 ref.)

Current HIV clinical trial design issues. Lange JM.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S47–51 (24 ref.)

Simulation of the San Francisco HIV epidemic: AZT a possible epidemiological modulator [letter] Lee L, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Oct 1;10(2):207–8

Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV. Mauss S, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Apr 15;11(5):469–77

Individualization of therapy using viral markers. Merigan T.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S41–6 (28 ref.)

Double-blind placebo-controlled pilot trial of acemannan in advanced human immunodeficiency virus disease. Montaner JS, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jun 1;12(2):153–7

Continuous low-dose interferon-alpha therapy for HIV-related immune thrombocytopenic purpura. Northfelt DW, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995 Jan 1;8(1):45–50

Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. Canadian HIV Trials Network A002 Study Group. Raboud JM, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 May 1;12(1):46–55

Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. Schooley RT, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 1;12(4):363–70

Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment. Simberkoff MS, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Feb 1;11(2):142–50

Inter-Company Collaboration Combination Trials. Clinical Trial Subcommittee of the Inter-Company Collaboration for AIDS Drug Development. Soo W, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 2:S92–6

Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: implications for secondary prevention efforts. Stall R, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Feb 1;11(2):151–60

Zidovudine and lamivudine: results of phase III studies. Staszewski S.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S57

HIV pathogenesis and treatment strategies. Vella S.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S20–3 (22 ref.)

A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS. Vella S, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Aug 15;12(5):462–9

Successful treatment of generalized lichen planus with recombinant interferon alfa-2b. Hildebrand A, et al.
J Am Acad Dermatol 1995 Nov;33(5 Pt 2):880–3

Didanosine (DDI) alone is now considered the first-line therapy for symptomatic children infected with the human immunodeficiency virus (HIV) [editorial]
J Am Osteopath Assoc 1996 Jun;96(6):339

Treatment options for chronic hepatitis C infection. James DG. **J Antimicrob Chemother** 1995 Oct;36(4):591–3 (19 ref.)

Zerit. Porche DJ. **J Assoc Nurses AIDS Care** 1995 Sep–Oct; 6(5):50–2

Oltipraz, a novel inhibitor of human immunodeficiency virus type 1 (HIV-1) replication. Prochaska HJ, et al.
J Cell Biochem Suppl 1995;22:117–25 (40 ref.)

Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. Ohmit SE, et al. **J Clin Epidemiol** 1996 Sep;49(9):963–7

Ganciclovir treatment of active hepatitis B virus infection in a heart transplant patient. Anand BS, et al.
J Clin Gastroenterol 1996 Mar;22(2):144–6

Famciclovir for the treatment of herpes zoster. Gordon A.
J Fam Pract 1996 Apr;42(4):350

Interferon therapy for patients more than 60 years of age with chronic hepatitis C. Horiike N, et al.
J Gastroenterol Hepatol 1995 May–Jun;10(3):246–9

Rise of plasma myeloperoxidase during interferon therapy. Nakamuta M, et al. **J Gastroenterol Hepatol** 1995 May–Jun; 10(3):277–80

Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: incidence and risk factors. Sheen IS, et al. **J Gastroenterol Hepatol** 1996 Feb;11(2):143–7

Treatment of hepatitis C virus in elderly persons with interferon alpha. Van Thiel DH, et al.
J Gerontol A Biol Sci Med Sci 1995 Nov;50(6):M330–3

New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin. Bizollon T, et al. **J Hepatol** 1995;23 Suppl 2:22–5

Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. Brillanti S, et al. **J Hepatol** 1995;23 Suppl 2:13–5; discussion 15–6

Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. Calleja JL, et al.
J Hepatol 1996 Mar;24(3):308–12

The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. Chemello L, et al. **J Hepatol** 1995;23 Suppl 2:8–12

Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. Guido M, et al. **J Hepatol** 1996 Mar; 24(3):301–7

Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population. Main J. **J Hepatol** 1995;23 Suppl 2:32–5; discussion 35–6 (18 ref.)

Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. Schvarcz R, et al. **J Hepatol** 1995;23 Suppl 2:17–21

Antiviral therapy for chronic hepatitis C viral infection. Sherlock S. **J Hepatol** 1995;23 Suppl 2:3–7 (31 ref.)

Introduction: combination antiviral therapy in chronic hepatitis C. Sherlock S. **J Hepatol** 1995;23 Suppl 2:1–2

Ganciclovir in cytomegalovirus retinitis [letter; comment] Huengsberg M, et al. **J Infect** 1995 Nov;31(3):247. Comment on: J Infect 1994 Nov;29(3):331–7.

Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group. Soriano V, et al. **J Infect** 1995 Jul; 31(1):9–13

Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs. Bravo FJ, et al. **J Infect Dis** 1996 Jan;173(1):1–6

Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected children. Chadwick EG, et al. **J Infect Dis** 1995 Dec;172(6):1475–9

Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. Cohen OJ, et al. **J Infect Dis** 1996 Apr;173(4):849–56

Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy [see comments] Demeter LM, et al. **J Infect Dis** 1995 Dec; 172(6):1480–5. Comment in: J Infect Dis 1996 Aug;174(2):448–9.

Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. Giacca M, et al. **J Infect Dis** 1996 Jul;174(1):204–9

Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. Glesby MJ, et al. **J Infect Dis** 1996 Jun;173(6):1477–80

A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. Haubrich RH, et al.
J Infect Dis 1995 Nov;172(5):1246–52

A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of > 500/mm3: AIDS Clinical Trials Group Protocol 208. Havlir D, et al. **J Infect Dis** 1995 Nov;172(5):1379–83

Once-weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome. Hodge WG, et al. **J Infect Dis** 1996 Aug;174(2):393–6

Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group. Imrie A, et al. **J Infect Dis** 1996 Jul;174(1):195–8

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. Kelleher AD, et al. **J Infect Dis** 1996 Feb;173(2):321–9

Hepatitis C virus genotypes 1 and 2 respond to interferon-alpha with different virologic kinetics. Kohara M, et al. **J Infect Dis** 1995 Oct;172(4):934–8

Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. Lewis LL, et al. **J Infect Dis** 1996 Jul; 174(1):16–25

Factors affecting treatment responses to interferon-alpha in chronic hepatitis C. Pawlotsky JM, et al. **J Infect Dis** 1996 Jul;174(1):1–7

Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. Ramachandran R, et al. **J Infect Dis** 1996 Apr; 173(4):1005–8

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. Schooley RT, et al. **J Infect Dis** 1996 Jun;173(6):1354–66

Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity. Skillman DR, et al. **J Infect Dis** 1996 May;173(5):1107–14

Acyclovir in human immunodeficiency virus patients [letter; comment] Stein DS, et al. **J Infect Dis** 1996 Feb; 173(2):504–7. Comment on: J Infect Dis 1995 Aug;172(2):346–52.

Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. Tynell E, et al. **J Infect Dis** 1996 Aug;174(2):324–31

Treatment of adult varicella with sorivudine: a randomized, placebo-controlled trial. Wallace MR, et al.
J Infect Dis 1996 Aug;174(2):249–55

Changes in biologic phenotype of human immunodeficiency virus during treatment of patients with didanosine. Zheng NN, et al. **J Infect Dis** 1996 May;173(5):1092–6

Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C. Hwang SJ, et al. **J Interferon Cytokine Res** 1995 Jul;15(7):611–6

Effect of topical interferon-beta on recurrence rates in genital herpes: a double-blind, placebo-controlled, randomized study. Ophir J, et al. **J Interferon Cytokine Res** 1995 Jul; 15(7):625–31

Further clinical studies of curdlan sulfate (CRDS)--an anti-HIV agent. Gordon M, et al. **J Med** 1995; 26(3–4):97–131

HCV replication in mononuclear cells stimulates anti-HCV-secreting B cells and reflects nonresponsiveness to interferon-alpha. Löhr HF, et al. **J Med Virol** 1995 Aug; 46(4):314–20

Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. Wutzler P, et al.
J Med Virol 1995 Jul;46(3):252–7

AIDS malignancy consortium plans first clinical trials.[news] McNeil C. **J Natl Cancer Inst** 1996 Mar 20;88(6):321

Neurophysiological evaluation of zidovudine in asymptomatic HIV-1 infection: a longitudinal placebo-controlled study. Baldeweg T, et al.
J Neurol Sci 1995 Oct;132(2):162–9

Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. Rosengren LE, et al. **J Neurol Sci** 1995 Nov;133(1–2):61–5

Intravenous ribavirin therapy for adenovirus gastroenteritis after bone marrow transplantation. Kapelushnik J, et al. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):110–2

Approaches to the development of novel inhibitors of hepatitis C virus replication. Clarke BE. **J Viral Hepat** 1995;2(1):1–8 (40 ref.)

Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225–02 Collaborative Group. Larder BA, et al.
J Virol 1996 Sep;70(9):5922–9

The in vivo antiviral activity of interleukin-12 is mediated by gamma interferon. Ozmen L, et al. **J Virol** 1995 Dec; 69(12):8147–50

From the Centers for Disease Control and Prevention. Update: provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV. **JAMA** 1996 Jul 10;276(2):90–2

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. Carpenter CC, et al. **JAMA** 1996 Jul 10;276(2):146–54 (109 ref.)

Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load [see comments] Dickover RE, et al. **JAMA** 1996 Feb 28;275(8):599–605. Comment in: JAMA 1996 Feb 28;275(8):640–1.

Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties [see comments] Fiscus SA, et al. **JAMA** 1996 May 15;275(19):1483–8. Comment in: JAMA 1996 May 15;275(19):1514–5. Comment in: JAMA 1996 Aug 21;276(7):527–8.

Safety and efficacy of lamivudine–zidovudine combination therapy in antiretroviral–naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. Katlama C, et al. **JAMA** 1996 Jul 10;276(2):118–25

From the Food and Drug Administration. Nightingale SL. **JAMA** 1995 Oct 11;274(14):1109

Patient–initiated, twice–daily oral famciclovir for early recurrent genital herpes. A randomized, double–blind multicenter trial. Canadian Famciclovir Study Group. Sacks SL, et al. **JAMA** 1996 Jul 3;276(1):44–9

Preventing perinatal HIV infection. How far have we come? [editorial; comment] Simonds RJ, et al. **JAMA** 1996 May 15;275(19):1514–5. Comment on: JAMA 1996 May 15;275(19):1483–8. Comment on: JAMA 1996 May 15;275(19):1504–6.

Safety and efficacy of lamivudine–zidovudine combination therapy in zidovudine–experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. Staszewski S, et al. **JAMA** 1996 Jul 10;276(2):111–7

Other AIDS drug regimens beat AZT alone, reduce clinical progression and mortality [news] Stephenson J. **JAMA** 1995 Oct 18;274(15):1183–4

New anti–HIV drugs and treatment strategies buoy AIDS researchers [news] Stephenson J. **JAMA** 1996 Feb 28; 275(8):579–80

New HIV drugs cast in supporting roles [news] Voelker R. **JAMA** 1996 Aug 28;276(8):585

Can researchers use new drugs to push HIV envelope to extinction? [news] Voelker R. **JAMA** 1996 Aug 14; 276(6):435–7

Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center [see comments] Wiznia AA, et al. **JAMA** 1996 May 15;275(19):1504–6. Comment in: JAMA 1996 May 15;275(19):1514–5.

Interferon and hepatocellular carcinoma [letter; comment] Andreone P, et al. **Lancet** 1996 Jan 20;347(8995):195. Comment on: Lancet 1995 Oct 21;346(8982):1051–5.

Combination superior to zidovudine in Delta trial [news] Choo V. **Lancet** 1995 Sep 30;346(8979):895

Interferon and hepatocellular carcinoma [letter; comment] Koretz RL. **Lancet** 1996 Jan 20;347(8995):194–5. Comment on: Lancet 1995 Oct 21;346(8982):1051–5.

Oral ganciclovir fails to prevent CMV in HIV trial [news] McCarthy M. **Lancet** 1995 Sep 30;346(8979):895

Drug prevents SIV infection [news] McCarthy M. **Lancet** 1995 Dec 2;346(8988):1482

HIV–associated respiratory diseases. Miller R. **Lancet** 1996 Aug 3;348(9023):307–12 (50 ref.)

Impact of treatment and prophylaxis on presentation and survival of patients with AIDS in Milan [letter] Monforte A, et al. **Lancet** 1995 Dec 2;346(8988):1488

FDA advised to license three anti–HIV agents [news] Nelson H. **Lancet** 1995 Nov 18;346(8986):1358

Protease inhibitors show promise in HIV infection [news] Nelson H. **Lancet** 1996 Feb 10;347(8998):383

Randomised trial of effects of interferon–alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis [see comments] Nishiguchi S, et al. **Lancet** 1995 Oct 21;346(8982):1051–5. Comment in: Lancet 1995 Oct 21;346(8982):1049–50. Comment in: Lancet 1996 Jan 20;347(8995):194–5. Comment in: Lancet 1996 Jan 20;347(8995):195.

Tackling liver cancer with interferon [comment] [published erratum appears in Lancet 1995 Dec 2;346(8988):1502] Schluger LK, et al. **Lancet** 1995 Oct 21;346(8982):1049–50 . Comment on: Lancet 1995 Oct 21;346(8982):1051–5.

Prevention of cytomegalovirus disease in transplant recipients [letter; comment] Snydman DR, et al. **Lancet** 1996 Jan 27; 347(8996):268–9. Comment on: Lancet 1995 Nov 25;346(8987):1380–1.

1–year follow–up of the use of hydroxycarbamide and didanosine in HIV infection [letter] Vila J, et al. **Lancet** 1996 Jul 20;348(9021):203–4

Transmission of HIV infection from mother to child [letter] Willocks L. **Lancet** 1996 Sep 14;348(9029):763–4

Prevention of cytomegalovirus disease in transplant recipients [see comments] Winston DJ. **Lancet** 1995 Nov 25; 346(8987):1380–1. Comment in: Lancet 1996 Jan 27;347(8996):268–9.

An adolescent with HTLV–1–associated adult T cell leukemia treated with interferon–alfa and zidovudine. Broniscer A, et al. **Leukemia** 1996 Jul;10(7):1244–8

Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype. Kanai K, et al. **Liver** 1995 Aug;15(4):185–8

Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV. Crowe S, et al. **Med J Aust** 1996 Mar 4;164(5):290–5 (20 ref.)

Managing HIV. Antiretroviral therapy. Fulcher D, et al. **Med J Aust** 1996 May 20;164(10):607 (0 ref.)

Hepatitis C: questions to be answered. Questions remain about virus transmission, the natural history of infection and the role of interferon in management [editorial; comment] Strasser SI. **Med J Aust** 1996 Feb 5;164(3):132–3 . Comment on: Med J Aust 1996 Feb 5;164(3):150–2.

Drugs for AIDS and associated infections. **Med Lett Drugs Ther** 1995 Oct 13;37(959):87–94

New drugs for HIV infection. **Med Lett Drugs Ther** 1996 Apr 12;38(972):35–7

Valacyclovir. **Med Lett Drugs Ther** 1996 Jan 5;38(965):3–4

Non–nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV–1) infections: strategies to overcome drug resistance development. de Clercq E. **Med Res Rev** 1996 Mar;16(2):125–57 (180 ref.)

U.S. prisoners' access to experimental HIV therapies. Collins A, et al. **Minn Med** 1995 Nov;78(11):45–8

Management of HIV infection. A 1995–96 overview for the clinician. Henry K. **Minn Med** 1995 Nov;78(11):17–24 (25 ref.)

Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. **MMWR Morb Mortal Wkly Rep** 1996 Jun 7;45(22):468–80

Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. **MMWR Morb Mortal Wkly Rep** 1996 May 3; 45(RR–5):1–24

Early treatment of HIV infection [letter; comment] Cates W Jr, et al. **N Engl J Med** 1995 Dec 28;333(26):1783. Comment on: N Engl J Med 1995 Aug 17;333(7):408–13.

Therapy for human immunodeficiency virus infection — what have we learned? [editorial; comment] Corey L, et al. **N Engl J Med** 1996 Oct 10;335(15):1142–4. Comment on: N Engl J Med 1996 Oct 10;335(15):1081–90. Comment on: N Engl J Med 1996 Oct 10;335(15):1091–8. Comment on: N Engl J Med 1996 Oct 10;335(15):1099–1106.

Ganciclovir. Crumpacker CS. **N Engl J Med** 1996 Sep 5; 335(10):721–9 (86 ref.)

A short–term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV–1 protease. European–Australian Collaborative Ritonavir Study Group. Danner SA, et al. **N Engl J Med** 1995 Dec 7; 333(23):1528–33

Viral load and response to treatment of HIV [letter; comment] De Gruttola V, et al. **N Engl J Med** 1996 Jun 20;334(25):1671–2; discussion 1672–3. Comment on: N Engl J Med 1996 Feb 15;334(7):426–31.

A preliminary trial of lamivudine for chronic hepatitis B infection [see comments] Dienstag JL, et al. **N Engl J Med** 1995 Dec 21;333(25):1657–61. Comment in: N Engl J Med 1995 Dec 21;333(25):1704–5.

Treatment with lamivudine, zidovudine, or both in HIV–positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party [see comments] Eron JJ, et al. **N Engl J Med** 1995 Dec 21; 333(25):1662–9. Comment in: N Engl J Med 1995 Dec 21;333(25):1704–5.

Early treatment of HIV infection [letter; comment] Fessel WJ. **N Engl J Med** 1995 Dec 28;333(26):1782; discussion 1783. Comment on: N Engl J Med 1995 Aug 17;333(7):450–1.

A trial comparing nucleoside monotherapy with combination therapy in HIV–infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team [see comments] Hammer SM, et al. **N Engl J Med** 1996 Oct 10;335(15):1081–90. Comment in: N Engl J Med 1996 Oct 10;335(15):1142–9.

Viral load and response to treatment of HIV [letter; comment] Ioannidis JP, et al. **N Engl J Med** 1996 Jun 20; 334(25):1671; discussion 1672–3. Comment on: N Engl J Med 1996 Feb 15;334(7):426–31.

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV–infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team [see comments] Katzenstein DA, et al. **N Engl J Med** 1996 Oct 10;335(15):1091–8. Comment in: N Engl J Med 1996 Oct 10;335(15):1142–9.

A preliminary study of ritonavir, an inhibitor of HIV–1 protease, to treat HIV–1 infection. Markowitz M, et al. **N Engl J Med** 1995 Dec 7;333(23):1534–9

A quarter–century of antiviral therapy [editorial; comment] Merigan TC. **N Engl J Med** 1995 Dec 21;333(25):1704–5 . Comment on: N Engl J Med 1995 Dec 21;333(25):1657–61. Comment on: N Engl J Med 1995 Dec 21;333(25):1662–9.

Long–term follow–up of HBeAg–positive patients treated with interferon alfa for chronic hepatitis B [see comments] Niederau C, et al. **N Engl J Med** 1996 May 30; 334(22):1422–7. Comment in: N Engl J Med 1996 May 30;334(22):1470–1.

Changes in plasma HIV–1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS [see comments] O'Brien WA, et al. **N Engl J Med** 1996 Feb 15; 334(7):426–31. Comment in: N Engl J Med 1996 Jun 20;334(25):1671; discussion 1672–3. Comment in: N Engl J Med 1996 Jun 20;334(25):1671–2; discussion 1672–3. Comment in: N Engl J Med 1996 Jun 20;334(25):1672; discussion 1672–3.

Interferon alfa and zidovudine in adult T–cell leukemia–lymphoma [letter; comment] Pagano JS. **N Engl J Med** 1995 Nov 9;333(19):1285–6. Comment on: N Engl J Med 1995 Jun 29;332(26):1744–8.

Zidovudine alone or in combination with didanosine or zalcitabine in HIV–infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS [see comments] Saravolatz LD, et al. **N Engl J Med** 1996 Oct 10;335(15):1099–106. Comment in: N Engl J Med 1996 Oct 10;335(15):1142–9.

Interferon alfa and zidovudine in adult T–cell leukemia–lymphoma. Lymphoma Study Group of the Japan Clinical Oncology Group [letter; comment] Tobinai K, et al. **N Engl J Med** 1995 Nov 9;333(19):1285; discussion 1286. Comment on: N Engl J Med 1995 Jun 29;332(26):1744–8.

Lack of sustained efficacy of interferon in patients with chronic hepatitis C [letter] Vento S, et al. **N Engl J Med** 1996 May 30;334(22):1479–80

Resolution of refractory AIDS–related mucosal candidiasis after initiation of didanosine plus saquinavir [letter] Zingman BS. **N Engl J Med** 1996 Jun 20;334(25):1674–5

Evaluation of alpha interferon for the treatment of chronic hepatitis B infection in Christchurch. Burt MJ, et al. **N Z Med J** 1996 May 10;109(1021):162–4

Immunocompromised patients, herpes zoster and acyclovir [letter] Elder M, et al. **N Z Med J** 1996 May 24; 109(1022):196

The reversal of Epstein Barr virus induced hepatosplenomegaly in 24 hours with inhibitors of xanthine oxidase and nitric oxide synthase [letter] Flavin–Koenig DF. **N Z Med J** 1996 Mar 22;109(1018):106–7

A fight to the death. Short N. **Nat Med** 1995 Feb;1(2):122–4

What direction for AIDS drug task force? [news] Steele FR. **Nat Med** 1995 Aug;1(8):725

Saquinavir: too early to market? [news] Steele FR. **Nat Med** 1996 Mar;2(3):257

Confusion reigns over compassionate use of AIDS drug [news] Tastemain C. **Nat Med** 1995 Oct;1(10):986

AZT combination trial shows positive results [news] **Nature** 1995 Sep 28;377(6547):277

Plants and AIDS [letter] Atta–ur–Rahman. **Nature** 1996 Sep 26;383(6598):294

'Beware of hype,' AIDS conference told [news] Macilwain C. **Nature** 1996 Jul 11;382(6587):101

Forum to advance trials for AIDS therapies [news] Macilwain C. **Nature** 1996 Aug 15;382(6592):566

Effect of human leukocyte alpha interferon on cryoglobulinaemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Gilli P, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):526–8

Membranoproliferative glomerulonephritis and hepatitis C: effects of interferon–alpha therapy on clinical outcome and histological pattern. Morosetti M, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):532–4

Recombinant alpha–interferon in renal allograft recipients with chronic hepatitis C. Ozgür O, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2104–6

Association between type II cryoglobulinemia and hepatitis C virus in a case treated with interferon–alpha [letter] Fukumoto S, et al. **Nephron** 1996;73(1):94–6

Genotype, serum level of HCV–RNA and response to interferon–alpha treatment in patients with chronic hepatitis C. Clarysse C, et al. **Neth J Med** 1995 Dec; 47(6):265–71

Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster. Boon RJ, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S76–7 (9 ref.)

Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS. Cohen BA. **Neurology** 1996 Feb;46(2):444–50

Sorivudine: a promising drug for the treatment of varicella–zoster virus infection. Whitley RJ. **Neurology** 1995 Dec;45(12 Suppl 8):S73–5 (10 ref.)

Absent inhibition of hepatitis B virus replication by azidothymidine in patients chronically coinfected by HIV–1 and HBV. Gallian P, et al. **New Microbiol** 1996 Apr;19(2):167–9

State of the art. Antiviral treatment of HIV infection. Bechtel–Boenning C. **Nurs Clin North Am** 1996 Mar; 31(1):1–13 (48 ref.)

Acyclovir suppression to prevent cesarean delivery after first–episode genital herpes. Scott LL, et al. **Obstet Gynecol** 1996 Jan;87(1):69–73

Cytomegalovirus optic neuritis: characteristics, therapy and survival. Mansor AM, et al. **Ophthalmologica** 1995; 209(5):260–6

Ganciclovir intraocular implant. A clinicopathologic study. Charles NC, et al. **Ophthalmology** 1996 Mar;103(3):416–21

New developments in the treatment of CMV retinitis [editorial; comment] Freeman WR. **Ophthalmology** 1996 Jul;103(7):999–1000. Comment on: Ophthalmology 1996 Jul;103(7):1078–83.

Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis [see comments] Rahhal FM, et al. **Ophthalmology** 1996 Jul;103(7):1078–83. Comment in: Ophthalmology 1996 Jul;103(7):999–1000.

Effect of interferon–alpha therapy in a patient with common variable immunodeficiency and chronic Epstein–Barr virus infection. Toraldo R, et al. **Pediatr Hematol Oncol** 1995 Sep–Oct;12(5):489–93

Intravenous ribavirin therapy for disseminated adenovirus infection. McCarthy AJ, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):1003–4

Perinatal herpes: current status and obstetric management strategies. Scott LL. **Pediatr Infect Dis J** 1995 Oct; 14(10):827–32; discussion 832–5 (73 ref.)

Cytomegalovirus infection in severe combined immunodeficiency: eradication with foscarnet. Walsh JE, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):911–2

Reassessment of the indications for ribavirin therapy in

respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases. **Pediatrics** 1996 Jan;97(1):137–40 (28 ref.)

Postexposure prophylaxis of varicella in children with leukemia by oral acyclovir [letter; comment] Ishida Y, et al. **Pediatrics** 1996 Jan;97(1):150–1. Comment on: Pediatrics 1993 Aug;92(2):219–22.

Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Kline MW, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):886–90

Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex. Burger DM, et al. **Pharm World Sci** 1995 Nov 24;17(6):218–21

Management of herpesvirus infections in the healthy host. Dudley MN. **Pharmacotherapy** 1995 Sep–Oct;15(5 Pt 2):43S–48S (31 ref.)

Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)

Prevention of facial herpetic infections after chemical peel and dermabrasion: new treatment strategies in the prophylaxis of patients undergoing procedures of the perioral area. Perkins SW, et al. **Plast Reconstr Surg** 1996 Sep;98(3):427–33; discussion 434–5

Why we should treat chronic viral hepatitis. King PD. **Postgrad Med** 1996 Sep;100(3):68–70, 73; discussion 73, 78 (13 ref.)

Chronic viral hepatitis and use of interferon. Whom are we treating? Koretz RL. **Postgrad Med** 1996 Sep;100(3):55–7, 61–2, 68 (11 ref.)

Combination antiretroviral therapy for the treatment of human immunodeficiency virus type–1 infection. Wilson CC, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):19–27 (85 ref.)

Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Herz AV, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7247–51

Long term follow–up and patterns of response of ALT in patients with chronic hepatitis NANB/C treated with recombinant interferon–alpha. da Silva LC, et al. **Rev Inst Med Trop Sao Paulo** 1995 May–Jun;37(3):239–43

Experience with stavudine (D4T). Friedland G. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:43–9; discussion 49–53

Antiretroviral therapy in the future. Friedland G. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:53–63; discussion 63–6

Augmentation of CD8 and CD4 lymphocytes subsets in AIDS infected children after treatment with a non–toxic chelating agents compound—Rodilemid. Dinu R, et al. **Rom J Intern Med** 1995 Jul–Dec;33(3–4):205–10

New developments in antiviral therapy for chronic hepatitis B infection. De Man RA, et al. **Scand J Gastroenterol Suppl** 1995;212:100–4 (26 ref.)

Chronic ulcerating acyclovir–resistant varicella zoster lesions in an AIDS patient. Bernhard P, et al. **Scand J Infect Dis** 1995;27(6):623–5

Combined alpha–interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Braconier JH, et al. **Scand J Infect Dis** 1995;27(4):325–9

Disseminated cytomegalovirus infection in an immunocompetent adult successfully treated with ganciclovir. López–Contreras J, et al. **Scand J Infect Dis** 1995;27(5):523–5

Efficacy of human leucocyte alpha–interferon treatment for chronic hepatitis C virus infection [corrected and republished in Scand J Infect Dis 1995;27(5):319–24] Weiland O, et al. **Scand J Infect Dis** 1995;27(4):319–24

Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy. Iberer F, et al. **Scand J Infect Dis Suppl** 1995;99:100–3

Update (1995) on clinical trials of antiviral therapy and prophylaxis for AIDS–related cytomegalovirus disease. Jacobson MA. **Scand J Infect Dis Suppl** 1995;99:96–9 (25 ref.)

HIV's Achilles' heel. Drugs and education are starting to slow the AIDS virus [news] Beardsley T. **Sci Am** 1996 Sep;275(3):16, 18

AIDS concerns [letter; comment] Blott KW. **Sci Am** 1996 Jan;274(1):10. Comment on: Sci Am 1995 Aug;273(2):58–65.

AIDS trials take on peer review [news] Cohen J. **Science** 1996 Jan 5;271(5245):20–1

AIDS conference. Chemokines share center stage with drug therapies [news] Cohen J. **Science** 1996 Jul 19; 273(5273):302–3

Results on new AIDS drugs bring cautious optimism [news] Cohen J. **Science** 1996 Feb 9;271(5250):755–6

Protease inhibitors: a tale of two companies [news] Cohen J. **Science** 1996 Jun 28;272(5270):1882–3

AIDS research. New drug shows promise in monkeys [news; comment] Cohen J. **Science** 1995 Nov 17;270(5239):1121–2 . Comment on: Science 1995 Nov 17;270(5239):1197–9.

AIDS task force fizzles out [news] Cohen J. **Science** 1996 Jan 26;271(5248):438–9

AZT trial in Thailand [letter; comment] Lallemant M, et al. **Science** 1995 Nov 10;270(5238):899–900. Comment on: Science 1995 Aug 4;269(5224):624–6.

AIDS researchers, activists fight crisis in clinical trials [news] Nowak R. **Science** 1995 Sep 22;269(5231):1666–7

HIV therapeutics. Richman DD. **Science** 1996 Jun 28; 272(5270):1886–8

Prevention of SIV infection in macaques by (R)–9–(2–phosphonylmethoxypropyl)adenine [see comments] Tsai CC, et al. **Science** 1995 Nov 17; 270(5239):1197–9. Comment in: Science 1995 Nov 17;270(5239):1121–2.

Anti–infective therapy for viral pneumonia. Mahmood W, et al. **Semin Respir Infect** 1995 Dec;10(4):270–81 (39 ref.)

A screening system for antiviral compounds against herpes simplex virus type 1 using the MTT method with L929 cells. Sudo K, et al. **Tohoku J Exp Med** 1995 Jul; 176(3):163–71

Regulatory issues of importance to developing anti–HIV therapeutics. Hastings KL. **Toxicol Pathol** 1996 May–Jun; 24(3):278–80

Definitions of cytomegalovirus disease after heart transplantation: antigenemia as a marker for antiviral therapy. Iberer F, et al. **Transpl Int** 1996;9(3):236–42

Prophylactic cytomegalovirus management strategies. Martin M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):23–7 (30 ref.)

Role of immunoglobulins and new antivirals in treatment of cytomegalovirus infection. Paya CV. **Transplant Proc** 1995 Oct;27(5 Suppl 1):28–30 (21 ref.)

A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Cattral MS, et al. **Transplantation** 1996 May 27;61(10):1483–8

Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus–free recipients of livers from seropositive donors. Grossi P, et al. **Transplantation** 1996 Jun 15; 61(11):1659–60

Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Wagner JA, et al. **Transplantation** 1995 Dec 27; 60(12):1473–7

Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes–, papova–, pox– and adenovirus) infections. De Clercq E. **Verh K Acad Geneeskd Belg** 1996;58(1):19–47; discussion 47–9

CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation. Iberer F, et al. **Wien Klin Wochenschr** 1995;107(23):718–22

Long–term treatment of diseased, FIV–seropositive field cats with azidothymidine (AZT). Hart S, et al. **Zentralbl Veterinarmed A** 1995 Aug;42(6):397–409

[Combination therapy of HIV (letter)] Gerstoft J, et al. **Ugeskr Laeger** 1996 Jan 8;158(2):175–6 (Dan)

[New medication for herpesvirus infections (editorial)] Vesikari T. **Duodecim** 1995;111(8):680, 683–4 (12 ref.) (Fin)

[Treatment of chronic viral hepatitis] Marcellin P, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 Mar–Apr; 32(2):85–7 (Fre)

[Ribavirin and mechanical ventilation (letter)] Hubert P. **Arch Pediatr** 1996 Feb;3(2):186 (Fre)

[Active antiviral agents against human cytomegalovirus and their use in pediatrics] Mazeron MC, et al. **Arch Pediatr** 1996;3 Suppl 1:309s–311s (12 ref.) (Fre)

[Compared efficiency of three strategies of management of chronic hepatitis C. Effect on the risk of cirrhosis 8 years after diagnosis] Michel P, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):47–54 (61 ref.) (Eng. Abstr.) (Fre)

[Predictive value of a rapid negativity of serum virus C viremia during treatment with interferon alpha in patients with chronic hepatitis C] Moulin V, et al. **Pathol Biol (Paris)** 1996 May;44(5):468–72 (Eng. Abstr.) (Fre)

[Anti–thyroid autoantibodies in hepatitis C. Thyroid function after interferon therapy in 4 patients] Broussard JF, et al. **Presse Med** 1995 Nov 18;24(35):1645–7 (Eng. Abstr.) (Fre)

[Vidarabine–interferon combination in patients with chronic viral hepatitis B of mutant form. Efficiency and tolerability during a pilot study (letter)] Durand M, et al. **Presse Med** 1996 Mar 16;25(9):459 (Fre)

[Current knowledge in the treatment of chronic hepatitis C] Pirotte J. **Rev Med Liege** 1995 Dec;50(12):501–4 (29 ref.) (Fre)

[Evaluation of side effects of interferon–alpha in 72 patients treated for chronic active hepatitis C] Duché A, et al. **Therapie** 1995 Sep–Oct;50(5):419–23 (Eng. Abstr.) (Fre)

[AIDS studies with didanosine and stavudine (news)] **Dtsch Med Wochenschr** 1996 May 31;121(22):A30 (Ger)

[New therapeutic strategies against HIV (news)] **Dtsch Med Wochenschr** 1996 Aug 23;121(34–35):A10 (Ger)

[HIV therapy with drug combinations (news)] Rass H. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):A36 (Ger)

[HIV: highly promising results with the new protease inhibitor (news)] Schenk M. **Dtsch Med Wochenschr** 1996 Aug 23;121(34–35):A35 (Ger)

[For the first time a combination of 2 protease inhibitors investigated (news)] Schenk M. **Dtsch Med Wochenschr** 1996 Aug 23;121(34–35):A36 (Ger)

[With interferon and zidovudine against therapy refractory T–cell leukemias (news)] Sauer H. **Fortschr Med** 1995 Dec 10;113(34):8 (Ger)

[New therapeutic possibilities in AIDS (editorial)] Heinzl S. **Med Monatsschr Pharm** 1996 May;19(5):121 (Ger)

[Antiretroviral therapy in HIV infection] Jablonowski H. **Med Monatsschr Pharm** 1996 Jul;19(7):196–205 (38 ref.) (Ger)

[New strategies in anti–HIV therapy––consequences for the neurologist?] Enzensberger W, et al. **Nervenarzt** 1996 Jun; 67(6):506–8 (2 ref.) (Ger)

[New treatments in HIV] Turner D, et al. **Harefuah** 1996 Apr 1;130(7):467–70 (32 ref.) (Heb)

[Acyclovir in the treatment of varicella in immunocompetent children] Catania S, et al. **Riv Eur Sci Med Farmacol** 1995 Jul–Aug;17(4):115–23 (Eng. Abstr.) (Ita)

[Long–term therapy in chronic hepatitis C with recombinant alpha interferon] Siciliano R, et al. **Riv Eur Sci Med Farmacol** 1994 May–Aug;16(3–4):73–8 (Eng. Abstr.) (Ita)

[Emergency drug therapy of meningoencephalitis] Kuzuhara S. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1837–42 (5 ref.) (Jpn)

[HCV–serotype and IFN response] Abe K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:959–64 (10 ref.) (Jpn)

[Changes of serum 2',5'–oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C] Daito K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:981–5 (16 ref.) (Jpn)

[HCV genotype as a predictor of response to IFN therapy in chronic hepatitis C] Ebata M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:954–8 (Jpn)

[Treatment of children with chronic hepatitis C with IFN] Fujisawa T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:841–6 (Jpn)

[Does interferon therapy on type C liver cirrhosis prevent the occurrence of hepatocellular carcinoma?] Harada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:754–8 (17 ref.) (Jpn)

[Clinical evaluation of positive– and negative–stranded HCV–RNAs in liver in relation to IFN therapy] Hino K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:949–53 (Jpn)

[Possibility and significance of interferon therapy for liver cirrhosis type C] Iwabuchi S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:746–53 (Jpn)

[Prediction of interferon therapy outcome by PCR–SSCP analysis of HCV 5' NCR] Kurihara C, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:326–32 (Jpn)

[Liver histology as a predictor of the response to interferon therapy] Okuno T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:975–80 (Jpn)

[Fluctuation of hepatitis C virus quasispecies with interferon treatment and interferon–resistant variants in hepatitis C virus 1b] Sakuma I, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:930–5 (9 ref.) (Jpn)

[HCV–RNA quantity of the serum] Sasaki Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:965–8 (Jpn)

[Change of HCV–RNA levels in liver tissue and interferon responsiveness in patients with chronic hepatitis C] Takeuchi M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:969–74 (Jpn)

[HCV–RNA of the hepatocytes of the complete responders with disappearance serum HCV–RNA after IFN treatment––using in situ hybridization] Terada M. **Nippon Rinsho** 1995 Sep;53 Suppl:944–8 (Jpn)

[Interferon therapy for acute hepatitis C: evaluation by HCV antibody, HCV genotypes and serum RNA titer] Toyama H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:521–7 (Jpn)

[Long–term follow up of histological changes in IFN–treated patients with chronic hepatitis C] Tsubota A. **Nippon Rinsho** 1995 Sep;53 Suppl:680–4 (Jpn)

[Criteria of IFN treatment for chronic hepatitis C] Yano M. **Nippon Rinsho** 1995 Sep;53 Suppl:986–90 (Jpn)

[Incidence of hepatocellular carcinoma in patients treated with interferon] Yokosuka O, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:805–9 (Jpn)

[Long–term prognosis of the interferon–treated patients with chronic hepatitis C] Yoshida H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:675–9 (Jpn)

[Chemotherapy with concomitant IFN treatment in three HBV carriers (mutant strain) with malignant lymphoma] Niitsu N, et al. **Rinsho Ketsueki** 1995 Aug;36(8):780–5 (Eng. Abstr.) (Jpn)

[Ganciclovir prophylaxis for cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation] Sakai R, et al. **Rinsho Ketsueki** 1996 Jan;37(1):14–21 (Eng. Abstr.) (Jpn)

[Chronic myelocytic leukemia associated with cytomegalovirus induced sialoadenitis after unrelated allogeneic bone marrow transplantation] Yoshida M, et al. **Rinsho Ketsueki** 1996 Jan;37(1):46–52 (Eng. Abstr.) (Jpn)

[Advances in the treatment of human immunodeficiency virus (HIV) infection (editorial)] Amato Neto V, et al. **Rev Assoc Med Bras** 1995 Mar–Apr;41(2):81–2 (Por)

[Policy of the Health Ministry on anti–retroviral therapy] del Bianco R. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:18–22 (Por)

[Anti–retroviral monotherapy with nucleoside analogues] de Mendonça JS. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:5–9 (Por)

[Resistance and combined use of anti–HIV drugs] Rosenthal C. **Rev Soc Bras Med Trop** 1995;28 Suppl 2:9–18 (Por)

[The beneficial effect of immunological and antiviral preparations in herpetic and papillomatosis infections] Topciu V, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995

Jul-Dec;40(3-4):257-60 **(Rum)**

[Action of para-aminobenzoic acid and its combination with acyclovir in herpetic infection] Akberova SI, et al. **Antibiot Khimioter** 1995 Oct;40(10):25-9 (Eng. Abstr.) **(Rus)**

[Treatment of experimental herpesvirus infection with nonsteroidal anti-inflammatory agents] Evstropov AN, et al. **Vopr Virusol** 1996 Mar-Apr;41(2):66-70 (Eng. Abstr.) **(Rus)**

[Thymus hormones in the treatment and prevention of flavivirus infection under experimental conditions] Liubimova NB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep-Oct; (5):105-8 (Eng. Abstr.) **(Rus)**

[Leukoregulin--a new possibility in the treatment of virus infections and malignant tumors] Bojić I. **Vojnosanit Pregl** 1994 Nov-Dec;51(6):540-2 (20 ref.) **(Scr)**

[Personal experience in the treatment of chronic viral hepatitis B with recombinant interferon B alfa-2] Nožić D, et al. **Vojnosanit Pregl** 1994 Jul-Aug;51(4):281-6 (Eng. Abstr.) **(Scr)**

[Varicella pneumonia in adults (letter)] Marti J, et al. **An Med Interna** 1995 Dec;12(12):618-9 **(Spa)**

[Present and future of the antiretroviral therapy (editorial)] Martinez-Vazquez JM, et al. **An Med Interna** 1996 Jan; 13(1):1-3 **(Spa)**

[Current status of the management of cytomegalovirus retinitis in patients with AIDS (editorial)] López-Cortés LF, et al. **Enferm Infecc Microbiol Clin** 1996 Mar; 14(3):137-41 **(Spa)**

[Longitudinal follow-up study of 64 children chronically infected with hepatitis B virus, treated and not treated with interferon] Vetencourt R, et al. **G E N** 1995 Jul-Sep; 49(3):227-33 (Eng. Abstr.) **(Spa)**

[Ribavirin treatment in patients with chronic hepatitis C refractory to interferon-alpha] Acero D, et al. **Gastroenterol Hepatol** 1996 May;19(5):243-6 (Eng. Abstr.) **(Spa)**

[Comparative study of the placenta from HIV+ mothers. Ultrastructural analysis] Villegas-Castrejon H, et al. **Ginecol Obstet Mex** 1996 Apr;64:167-76 (Eng. Abstr.) **(Spa)**

[Antiretroviral treatment against HIV (editorial)] González-Lahoz J, et al. **Med Clin (Barc)** 1995 Sep 30; 105(10):377-8 **(Spa)**

[Antiretroviral treatment against HIV (letter)] Pulido F, et al. **Med Clin (Barc)** 1996 May 25;106(20):798-9 **(Spa)**

[Comparison of 2 treatment strategies with prednisone and interferon in chronic hepatitis B] Gómez Camacho F, et al. **Rev Esp Enferm Dig** 1996 Mar;88(3):185-90 (Eng. Abstr.) **(Spa)**

[Periodical EEG pattern modifications in herpetic encephalitis treated with acyclovir] Benetó A, et al. **Rev Neurol** 1996 Jul;24(131):829-32 (Eng. Abstr.) **(Spa)**

[Alfa-2a interferon induces molecular remission in post-BMT relapse of chronic myelogenous leukaemia. Report of a case with loss of bcr-abl RNA] Casado LF, et al. **Sangre (Barc)** 1995 Oct;40(5):417-20 (Eng. Abstr.) **(Spa)**

[News about HIV. Combination therapy with new drugs gives hope] Sönnerborg A, et al. **Lakartidningen** 1996 Feb 7;93(6):451-2 **(Swe)**

TOXICITY

Intracellular activation and cytotoxicity of three different combinations of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. Palmer S, et al. **AIDS Res Hum Retroviruses** 1995 Oct;11(10):1227-33

Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir. Tong XW, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1611-7

Evaluation of retinal toxicity and efficacy of the anticytomegalovirus compound 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine. Besen G, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1485-8

Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Tjuvajev JG, et al. **Cancer Res** 1996 Sep 15;56(18):4087-95

Didanosine (ddI) and stavudine (d4T): absence of peripheral neurotoxicity in rabbits. Warner WA, et al. **Food Chem Toxicol** 1995 Dec;33(12):1047-50

Acute cardiotoxicity of the Anti-HIV dideoxynucleoside, F-ddA, in the rat. Donzanti BA, et al. **Fundam Appl Toxicol** 1995 Sep;27(2):167-76

Induction of thymic lymphoma in mice administered the dideoxynucleoside ddC. Sanders VM, et al. **Fundam Appl Toxicol** 1995 Sep;27(2):263-9

Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+) -cell depleted, athymic and NK-cell depleted SCID mice. Axelsson LG, et al. **Inflamm Res** 1996 Apr;45(4):181-91

Antibacterial effect of theaflavin, polyphenon 60 (Camellia sinensis) and Euphorbia hirta on Shigella spp.--a cell culture study. Vijaya K, et al. **J Ethnopharmacol** 1995 Dec 1;49(2):115-8

A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. Haubrich RH, et al. **J Infect Dis** 1995 Nov;172(5):1246-52

Ocular toxicity of iontophoretic foscarnet in rabbits. Yoshizumi MO, et al. **J Ocul Pharmacol Ther** 1995 Summer; 11(2):183-9

The NCI's AIDS antiviral drug screening program. Yang SS. **Leukemia** 1995 Oct;9 Suppl 1:S9-11

Destruction of human immunodeficiency-infected cells by ferrofluid particles manipulated by an external magnetic field: mechanical disruption and selective introduction of cytotoxic or antiretroviral substances into target cells. Peasley KW. **Med Hypotheses** 1996 Jan;46(1):5-12

Induction of micronuclei by low doses of azidothymidine (AZT). Dertinger SD, et al. **Mutat Res** 1996 Jul 5; 368(3-4):301-7

Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. Haynes P, et al. **Mutat Res** 1996 Jul 10;369(1-2):65-74

Mitochondrial toxicity of antiviral drugs. Lewis W, et al. **Nat Med** 1995 May;1(5):417-22 (66 ref.)

Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Lewis W, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3592-7

Effect of recombinant human hemoglobin on human bone marrow progenitor cells: protection and reversal of 3'-azido-3'-deoxythymidine-induced toxicity. Fowler DA, et al. **Toxicol Lett** 1996 Apr;85(1):55-62

ANTLERS

CHEMISTRY

Red deer antlers as biomonitors for lead contamination. Tataruch F. **Bull Environ Contam Toxicol** 1995 Sep; 55(3):332-7

GROWTH & DEVELOPMENT

Tissue differentiation and correlated changes in enzymatic activities during primary antler development in fallow deer (Dama dama). Szuwart T, et al. **Anat Rec** 1995 Dec; 243(4):413-20

Effects of castration on antler growth in fallow deer (Dama dama L.). Kierdorf U, et al. **J Exp Zool** 1995 Sep 1; 273(1):33-43

ANTRUM OF HIGHMORE see **MAXILLARY SINUS**

ANTRUM, PYLORIC see **PYLORIC ANTRUM**

ANTS

Pharaoh ant (Hymenoptera: Formicidae) colony development after consumption of pyriproxyfen baits. Vail KM, et al. **J Econ Entomol** 1995 Dec;88(6):1695-702

Imported fire ants--from medical nuisance to medical menace: new concerns for medical facilities in endemic areas [editorial] deShazo RD. **South Med J** 1995 Nov; 88(11):1181

CHEMISTRY

Antioxidant activity of Chinese ant extract preparations. Zhao Y, et al. **Acta Med Okayama** 1995 Dec;49(6):275-9

Separation of jumper ant (Myrmecia pilosula) venom allergens: a novel group of highly basic proteins. Donovan GR, et al. **Electrophoresis** 1995 May;16(5):804-10

GENETICS

Molecular cloning and characterization of the major allergen Myr p II from the venom of the jumper ant Myrmecia pilosula: Myr p I and Myr p II share a common protein leader sequence. Street MD, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1-2):87-97

FISH analysis of the telomere sequences of bulldog ants (Myrmecia: formicidae). Meyne J, et al. **Chromosoma** 1995 Oct;104(1):14-8

G-banding and chromosome condensation in the ant, Tapinoma nigerrimum. Lorite P, et al. **Chromosome Res** 1996 Jan;4(1):77-9

Mitochondrial DNA sequences reveal close relationships between social parasitic ants and their host species. Baur A, et al. **Curr Genet** 1995 Aug;28(3):242-7

Characterization of microsatellite loci in Formica lugubris B and their variability in other ant species. Chapuisat M. **Mol Ecol** 1996 Aug;5(4):599-601

Molecular phylogeny of Azteca ants (Hymenoptera:Formicidae) and the colonization of Cecropia trees. Ayala FJ, et al. **Mol Phylogenet Evol** 1996 Apr;5(2):423-8

IMMUNOLOGY

Hypersensitivity to fire ant venom [see comments] Stafford CT. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):87-95; quiz 96-9 (50 ref.). Comment in: Ann Allergy Asthma Immunol 1996 Aug;77(2):85.

Molecular cloning and characterization of the major allergen Myr p II from the venom of the jumper ant Myrmecia pilosula: Myr p I and Myr p II share a common protein leader sequence. Street MD, et al. **Biochim Biophys Acta** 1996 Feb 7;1305(1-2):87-97

Systemic reactions to the Samsum ant: an IgE-mediated hypersensitivity. Dib G, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):465-72

METABOLISM

Storage proteins in ants (Hymenoptera:Formicidae). Wheeler DE, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Sep;112(1):15-9 (41 ref.)

MICROBIOLOGY

Cellulose degradation by Leucocoprinus gongylophorus, the fungus cultured by the leaf-cutting ant Atta sexdens rubropilosa. Bacci M Jr, et al. **Antonie Van Leeuwenhoek** 1995;67(4):385-6

PARASITOLOGY

Mitochondrial DNA sequences reveal close relationships between social parasitic ants and their host species. Baur A, et al. **Curr Genet** 1995 Aug;28(3):242-7

PHYSIOLOGY

Effect of early illumination conditions on illumination preferences in the ant. Korczyńska J, et al. **Acta Neurobiol Exp (Warsz)** 1995;55(3):222

The continuing saga of imported fire ants: evolution before our eyes [editorial; comment] deShazo RD. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):85-6. Comment on: Ann Allergy Asthma Immunol 1996 Aug;77(2):87-95; quiz 96-9.

On the energetic cost of sociality. Fonck C, et al. **Physiol Behav** 1996 Apr-May;59(4-5):713-9

ANURA

ANATOMY & HISTOLOGY

Histological examination of the effects of corticosterone in larvae of the western toad, Bufo boreas (Anura: Bufonidae), and the Oriental fire-bellied toad, Bombina orientalis (Anura: Discoglossidae). Hayes TB. **J Morphol** 1995 Dec; 226(3):297-307

Distribution of cranial and rostral spinal nerves in tadpoles of the frog Discoglossus pictus (Discoglossidae). Schlosser G, et al. **J Morphol** 1995 Nov;226(2):189-212

Amphibian parathyroids: morphological and functional aspects. Srivastav AK, et al. **Microsc Res Tech** 1995 Oct 1;32(2):79-90 (113 ref.)

BLOOD

Effect of acute captivity stress on plasma concentrations of corticosterone and sex steroids in female whistling frogs, Litoria ewingi. Coddington EJ, et al. **Gen Comp Endocrinol** 1995 Oct;100(1):33-8

EMBRYOLOGY

Early cranial neural crest migration in the direct-developing frog, Eleutherodactylus coqui. Moury JD, et al. **Acta Anat (Basel)** 1995;153(4):243-53

The expression of Brachyury (T) during gastrulation in the marsupial frog Gastrotheca riobambae. del Pino EM. **Dev Biol** 1996 Jul 10;177(1):64-72

Cleavage arrest of early frog embryos by the G protein-activated protein kinase PAK I. Rooney RD, et al. **J Biol Chem** 1996 Aug 30;271(35):21498-504

Restrictions to floor plate induction by hedgehog and winged-helix genes in the neural tube of frog embryos. Ruiz i Altaba A, et al. **Mol Cell Neurosci** 1995 Apr; 6(2):106-21

Synergism between UV-B radiation and a pathogen magnifies amphibian embryo mortality in nature. Kiesecker JM, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21; 92(24):11049-52

[Division of a deformed green toad embryo] Kalabekov AL, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):462-3 **(Rus)**

GENETICS

Inheritance of allozyme loci in Bombina: one linkage group established. Szymura JM. **Biochem Genet** 1995 Jun; 33(5-6):167-72

Allozyme variation in populations of Pleurodema thaul (Lesson, 1826) (Anura; Leptodactylidae). Victoriano P, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Nov; 112(3):487-92

Strong expression of the calreticulin gene in the liver of Rana rugosa tadpoles, but not adult frogs. Yamamoto S, et al. **J Exp Zool** 1996 Aug 15;275(6):431-43

Hybridization between tetraploid and diploid species of treefrogs (Genus hyla). Mable BK, et al. **J Hered** 1995 Nov-Dec;86(6):432-40

Restrictions to floor plate induction by hedgehog and winged-helix genes in the neural tube of frog embryos. Ruiz i Altaba A, et al. **Mol Cell Neurosci** 1995 Apr; 6(2):106-21

Use of rRNA secondary structure in phylogenetic studies to identify homologous positions: an example of alignment and data presentation from the frogs. Kjer KM. **Mol Phylogenet Evol** 1995 Sep;4(3):314-30

GROWTH & DEVELOPMENT

Developmental regulation of the urea-cycle enzyme arginase in the direct developing frog Eleutherodactylus coqui. Callery EM, et al. **J Exp Zool** 1996 May 1;275(1):61-6

IMMUNOLOGY

Studies on transplantation immunity of the yellow-bellied toad Bombina variegata. Góralik E, et al.
Arch Immunol Ther Exp (Warsz) 1994;42(2):141-6

METABOLISM

Inheritance of allozyme loci in Bombina: one linkage group established. Szymura JM. **Biochem Genet** 1995 Jun; 33(5-6):167-72

Glycogen synthesis in amphibian oocytes: evidence for an indirect pathway. Kessi E, et al. **Biochem J** 1996 Apr 15; 315 (Pt 2):455-60

Localization of egg-surface carbohydrates and fertilization in Discoglossus pictus (Anura). Gualtieri R, et al.
Cell Tissue Res 1996 Feb;283(2):173-81

Freezing tolerance/intolerance and cryoprotectant synthesis in terrestrially overwintering anurans in the Great Plains, USA. Swanson DL, et al. **J Comp Physiol [B]** 1996; 166(2):110-9

BSTI, a trypsin inhibitor from skin secretions of Bombina bombina related to protease inhibitors of nematodes. Mignogna G, et al. **Protein Sci** 1996 Feb;5(2):357-62

A comparison of the positive- and negative-ion mass spectra of bio-active peptides from the dorsal secretion of the Australian red tree frog, Litoria rubella. Steinborner ST, et al. **Rapid Commun Mass Spectrom** 1996;10(10):1243-7

[Epibatidine--a nicotine-related, analgesic alkaloid from poison-dart frogs] Müller CE. **Pharm Unserer Zeit** 1996 Apr;25(2):85-92 (27 ref.) **(Ger)**

PARASITOLOGY

Karyotype analysis of anuran trypanosomes by pulsed-field gradient gel electrophoresis. Lun ZR, et al. **J Parasitol** 1995 Dec;81(6):1018-20

Gorgoderid trematodes (Digenea: Gorgoderidae) from the urinary bladder of frogs in Korea. Kim KH, et al.
Korean J Parasitol 1995 Jun;33(2):75-83

Parasitic disease in amphibians: control by the regulation of worm burdens. Tinsley RC. **Parasitology** 1995;111 Suppl:S153-78 (62 ref.)

PHYSIOLOGY

Nineteenth century research on naturally occurring cell death and related phenomena. Clarke PG, et al.
Anat Embryol (Berl) 1996 Feb;193(2):81-99 (143 ref.)

Alkaloids from frog skins: selective probes for ion channels and nicotinic receptors. Daly JW. **Braz J Med Biol Res** 1995 Oct;28(10):1033-42 (28 ref.)

Adverse effects of polluted continental water bodies in Chile on frog adrenergic synapse. Norris B, et al.
Bull Environ Contam Toxicol 1996 Oct;57(4):640-7

The separate and combined effects of harmonic structure, phase, and FM on female preferences in the barking treefrog (Hyla gratiosa). Bodnar DA.
J Comp Physiol [A] 1996 Feb;178(2):173-82

The kinematics and mechanism of prey capture in the African pig-nosed frog (Hemisus marmoratum): description of a radically divergent anuran tongue. Ritter D, et al.
J Exp Biol 1995 Sep;198 (Pt 9):2025-40

Do Australian desert frogs co-accumulate counteracting solutes with urea during aestivation? Withers PC, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1809-16

Mechanism of tongue protraction during prey capture in the spadefoot toad Spea multiplicata (Anura: Pelobatidae). O'Reilly SR, et al. **J Exp Zool** 1995 Nov 1;273(4):282-96

Multiple paternity in the red-eyed treefrog Agalychnis callidryas (Cope). d'Orgeix CA, et al. **Mol Ecol** 1995 Aug; 4(4):505-8

Selective phonotaxis by males in the Majorcan midwife toad. Bush SL, et al. **Proc R Soc Lond B Biol Sci** 1996 Jul 22; 263(1372):913-7

Molecular mechanisms of gustatory transduction in frog taste cells. Sato T, et al. **Prog Neurobiol** 1995 Jun;46(2-3):239-87 (100 ref.)

Modular organization of motor behavior in the frog's spinal cord. Bizzi E, et al. **Trends Neurosci** 1995 Oct;18(10):442-6 (30 ref.)

VIROLOGY

Three retroviral sequences in amphibians are distinct from those in mammals and birds. Tristem M, et al. **J Virol** 1996 Jul;70(7):4864-70

An erythrocytic virus of the Brazilian tree-frog, Phrynohyas venulosa. de Matos AP, et al. **Mem Inst Oswaldo Cruz** 1995 Sep-Oct;90(5):653-5

ANURIA

[Obstructive anuria. Thirty cases] Bennani S, et al.
Ann Urol (Paris) 1995;29(3):159-62 (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Severe renal vasoconstriction and anuria after intravenous urography in a patient with renal impairment. Arici M, et al. **Am J Kidney Dis** 1996 Sep;28(3):454-6

COMPLICATIONS

Nephrogenic metaplasia: long-term haemodialysis and anuria as potential risk factors and reversibility with renal transplantation. Thong W, et al.
Nephrol Dial Transplant 1995 Nov;10(11):2101-3

[Retroperitoneal fibrosis without dilatation of the upper urinary tract and non-obstructive anuria] Torrubia Romero FJ, et al. **Arch Esp Urol** 1996 Jan-Feb;49(1):69-72 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Obstructive anuria following fulguration of posterior urethral valves and Foley catheter drainage of the bladder. Sarkis P, et al. **Br J Urol** 1995 Nov;76(5):664-5

Ureteral endometriosis in a female patient presenting with single-kidney anuria. Kyriakidis A, et al. **Eur Urol** 1995; 28(2):175-6

Acute anuric renal failure related to oxalosis in identical twin infants. Mahmoud A, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):537-9

[Anuria following extracorporeal lithotripsy] Derevianko IM, et al. **Urol Nefrol (Mosk)** 1995 Jul-Aug;(4):27-9 (Eng. Abstr.) **(Rus)**

PARASITOLOGY

[Babesia canis human babesiosis causing a 40-day anuria (letter)] Marsaudon E, et al. **Ann Med Interne (Paris)** 1995; 146(6):451-2 **(Fre)**

RADIOGRAPHY

Reflex anuria. Huisman PM. **J Belge Radiol** 1995 Aug; 78(4):233

THERAPY

Lactate versus bicarbonate on-line hemofiltration: a comparative study. Marangoni R, et al. **Artif Organs** 1995 Jun;19(6):490-5

Long-term peritoneal dialysis in the absence of residual renal function [see comments] Jindal KK, et al.
Perit Dial Int 1996 Jan-Feb;16(1):78-81. Comment in: Perit Dial Int 1996 Jan-Feb;16(1):20-3.

Is peritoneal dialysis feasible once a large muscular patient becomes anuric? [editorial; comment] Twardowski ZJ, et al. **Perit Dial Int** 1996 Jan-Feb;16(1):20-3. Comment on: Perit Dial Int 1996 Jan-Feb;16(1):78-81.

ANUS

consider also terms at PROCT-

see related
PROCTOSCOPY

Squamous cell carcinoma complicating perianal hidradenitis suppurativa. Pérez-Diaz D, et al. **Int J Colorectal Dis** 1995; 10(4):225-8 (23 ref.)

The "guardians of the anus" and their practice. Viso L, et al. **Int J Colorectal Dis** 1995;10(4):229-31

[Anal migration of ventriculo-peritoneal shunt catheter. Apropos of 3 cases] Sami A, et al. **Neurochirurgie** 1995; 41(4):315-8 (25 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Absence of lambda immunoglobulin sequences on the supernumerary chromosome of the "cat eye" syndrome. Hough CA, et al. **Am J Med Genet** 1995 Sep 11; 58(3):277-81

Familial arhinia, choanal atresia, and microphthalmia. Thiele H, et al. **Am J Med Genet** 1996 May 3;63(1):310-3 (7 ref.)

Adults born with high anorectal atresia--how do they manage? Hassink EA, et al. **Dis Colon Rectum** 1996 Jun; 39(6):695-9

The Currarino syndrome--hereditary transmitted syndrome of anorectal, sacral and presacral anomalies. Case report and review of the literature. Köchling J, et al.
Eur J Pediatr Surg 1996 Apr;6(2):114-9 (35 ref.)

H-type anorectal malformations: incidence and clinical characteristics. Rintala RJ, et al. **J Pediatr Surg** 1996 Apr; 31(4):559-62

True complete diphallia. Zolfaghari A, et al.
Scand J Urol Nephrol 1995 Jun;29(2):233-5

[Urinary tract abnormalities associated with anorectal malformations] Tohda A, et al.
Nippon Hinyokika Gakkai Zasshi 1995 Aug;86(8):1388-93 (Eng. Abstr.) **(Jpn)**

[Electrical testing using the Myotest in the radical correction of anorectal defects in children] Kryvchenia DIu, et al. **Klin Khir** 1995;(6):46-7 **(Ukr)**

ANATOMY & HISTOLOGY

Presence and structure of anal and vaginal tonsils in the laboratory shrew (Suncus murinus). Kubo K, et al.
Anat Anz 1996 Jun;178(3):251-8

MRI of the anal sphincter. deSouza NM, et al.
J Comput Assist Tomogr 1995 Sep-Oct;19(5):745-51

The anogenital distance index, a predictor of the intrauterine position effects on reproduction in female house mice. Vandenbergh JG, et al. **Lab Anim Sci** 1995 Oct; 45(5):567-73

MRI of the anal canal: correlation with histologic examination. Van Beers BE, et al. **Magn Reson Imaging** 1996;14(2):151-6

Magnetic resonance imaging of the levator ani with anatomic correlation. Strohbehn K, et al. **Obstet Gynecol** 1996 Feb; 87(2):277-85

Anal sphincter complex: endoanal MR imaging of normal anatomy. Hussain SM, et al. **Radiology** 1995 Dec; 197(3):671-7

[Anal endosonography: the study technic and the correlations between the normal and echographic anatomy] Brunese L, et al. **Radiol Med (Torino)** 1996 Mar;91(3):253-7 (Eng. Abstr.) **(Ita)**

BLOOD SUPPLY

Ischaemic nature of anal fissure. Schouten WR, et al.
Br J Surg 1996 Jan;83(1):63-5

DRUG EFFECTS

Moderation of anal sphincter tone with nitric oxide agonists and antagonists. Hechtman HB, et al. **Arch Surg** 1996 Jul; 131(7):775-84

Force and intracellular Ca2+ during NANC-mediated relaxation of rat anococcygeus muscle and the effects of cyclopiazonic acid. Raymond GL, et al.
Clin Exp Pharmacol Physiol 1995 Oct;22(10):717-23

Absence of effect of nicotine on rectal sensation, rectal compliance, and anal sphincter pressures in healthy subjects. Kavin H, et al. **Dig Dis Sci** 1995 Oct; 40(10):2239-43

Effect of nifedipine on rectoanal motility. Chrysos E, et al. **Dis Colon Rectum** 1996 Feb;39(2):212-6

Effect of octreotide on anal pressure and rectal compliance. Rasmussen OO, et al. **Dis Colon Rectum** 1996 Jun; 39(6):624-7

Cyclic GMP relaxes the internal anal sphincter in Hirschsprung's disease. VanderWall KJ, et al.
J Pediatr Surg 1995 Jul;30(7):1013-5; discussion 1015-6

Heme oxygenase inhibitor zinc protoporphyrin IX causes an activation of nitric oxide synthase in the rabbit internal anal sphincter. Chakder S, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1376-82

INJURIES

External anal sphincter defects: correlation between pre-operative anal endosonography and intraoperative findings. Romano G, et al. **Br J Radiol** 1996 Jan;69(817):6-9

Endosonographic assessment of postpartum anal sphincter injury using a 120 degree sector scanner. Campbell DM, et al. **Clin Radiol** 1996 Aug;51(8):559-61

Unilateral pudendal neuropathy. Impact on outcome of anal sphincter repair. Sangwan YP, et al. **Dis Colon Rectum** 1996 Jun;39(6):686-9

Surgical treatment of traumatic cloaca. Venkatesh KS, et al. **Dis Colon Rectum** 1996 Jul;39(7):811-6

[Anal blood loss: remember the thermometer!] Siersema PD, et al. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):233-5 **(Dut)**

[Post-surgical or traumatic anal incontinences. Prospective study in 40 patients explorated by endorectal ultrasonography and electromyography] Aubert A, et al. **Gastroenterol Clin Biol** 1995 Jun-Jul;19(6-7):598-603 (Eng. Abstr.) **(Fre)**

[Manometric and clinical long-term outcome after grade III perineal rupture] Anthuber C, et al.
Gynakol Geburtshilfliche Rundsch 1995;35 Suppl 1:137-41 (Eng. Abstr.) **(Ger)**

[Technic of overlapping sphincter anal repair in the treatment of traumatic anal incontinence] Gangi S, et al.
Ann Ital Chir 1995 May-Jun;66(3):393-6 (Eng. Abstr.) **(Ita)**

[Diagnosis of anal sphincter injuries caused by delivery. Intra-anal ultrasound is a well-functioning method (see comments)] Fornell EU, et al. **Lakartidningen** 1996 May 29;93(22):2148-9. Comment in: Lakartidningen 1996 Jun 26;93(26-27):2494. **(Swe)**

INNERVATION

Comparative study of sensitive and vegetative innervation of external and internal anal sphincter muscles in different mammals. Panu R, et al. **Ital J Anat Embryol** 1995 Jul-Sep; 100(3):147-58

Inferior rectal nerve stimulation for anal sphincteric control: experimental study. Shafik A. **J Surg Res** 1995 Oct; 59(4):441-5

Electrical stimulation of sacral nerves for treatment of incontinence [letter; comment] Mander BJ, et al. **Lancet** 1996 Jan 6;347(8993):63-4. Comment on: Lancet 1995 Oct 28;346(8983):1124-7.

Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence [see comments] Matzel KE, et al. **Lancet** 1995 Oct 28;346(8983):1124-7. Comment in: Lancet 1996 Jan 6;347(8993):63-4.

Striated anal sphincter denervation in patients with progressive supranuclear palsy. Valldeoriola F, et al.
Mov Disord 1995 Sep;10(5):550-5

Quantitative assessment of anal canal sensation in patients undergoing low anterior resection for rectal cancer. Komatsu J, et al. **Surg Today** 1995;25(10):867-73

ANUS

PATHOLOGY

Endoanal coil in MR imaging of anal fistulas. Stoker J, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):360–2

High grade anal dysplasia in visually normal mucosa in homosexual men: seven cases. Surawicz CM, et al. **Am J Gastroenterol** 1995 Oct;90(10):1776–8

Genital findings in adolescent girls referred for suspected sexual abuse. Adams JA, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):850–7

Anal pathology in patients with Crohn's disease. Platell C, et al. **Aust N Z J Surg** 1996 Jan;66(1):5–9

High resolution magnetic resonance imaging of the anal sphincter using a dedicated endoanal coil. Comparison of magnetic resonance imaging with surgical findings. deSouza NM, et al. **Dis Colon Rectum** 1996 Aug; 39(8):926–34

Videoendoscopic anoscopy: a new technique for examining the anal canal. Lazas DJ, et al. **Gastrointest Endosc** 1995 Oct;42(4):351–4

High resolution magnetic resonance imaging of the anal sphincter using an internal coil. deSouza NM, et al. **Gut** 1995 Aug;37(2):284–7

Risk of dysplasia in anal condyloma. Metcalf AM, et al. **Surgery** 1995 Oct;118(4):724–6 (14 ref.)

[Complications of the surgical treatment of hemorrhoids and its therapy] Corno F, et al. **Ann Ital Chir** 1995 Nov–Dec; 66(6):813–6 (15 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Evidence for VIP-induced increase in NO production in myenteric neurons of opossum internal anal sphincter. Chakder S, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G492–7

Nerves that say NO: a new perspective on the human rectoanal inhibitory reflex. O'Kelly TJ. **Ann R Coll Surg Engl** 1996 Jan;78(1):31–8

Moderation of anal sphincter tone with nitric oxide agonists and antagonists. Hechtman HB, et al. **Arch Surg** 1996 Jul; 131(7):775–84

Patterns of anismus and the relation to biofeedback therapy. Park UC, et al. **Dis Colon Rectum** 1996 Jul;39(7):768–73

Long-term effect of vaginal deliveries on anorectal function in normal perimenopausal women. Ryhammer AM, et al. **Dis Colon Rectum** 1996 Aug;39(8):852–9

Latency measurement of rectoanal reflexes. Sangwan YP, et al. **Dis Colon Rectum** 1995 Dec;38(12):1281–5

The pressure area: a variable for the assessment of anal sphincter function. Hallböök O, et al. **Eur J Surg** 1995 Aug; 161(8):603–6

Anorectal and pelvic floor function. Relevance of continence, incontinence, and constipation. Sagar PM, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):163–82 (102 ref.)

Reflex interaction from the urinary bladder and the rectum on anal motility in the cat. Buntzen S, et al. **J Auton Nerv Syst** 1995 Jul 14;54(1):33–40

PHYSIOPATHOLOGY

Anorectal physiological parameters in chronic constipation of unknown aetiology (primary) and of cerebrovascular accidents—a preliminary report. Ho YH, et al. **Ann Acad Med Singapore** 1995 May;24(3):376–8

Investigation of anal function in patients with systemic sclerosis. Herrick AL, et al. **Ann Rheum Dis** 1996 Jun; 55(6):370–4

Sphincter function after transanal endoscopic microsurgical excision of rectal tumours. Hemingway D, et al. **Br J Surg** 1996 Jan;83(1):51–2

Flatus-related colorectal and anal motor events. Bassotti G, et al. **Dig Dis Sci** 1996 Feb;41(2):335–8

Level of highest mean resting pressure segment in the anal canal. A quantitative assessment of anal sphincter function. Goes RN, et al. **Dis Colon Rectum** 1996 Mar;39(3):289–93

Gradient of pressure and time between proximal anal canal and high-pressure zone during internal anal sphincter relaxation. Its role in the fecal continence mechanism. Goes RN, et al. **Dis Colon Rectum** 1995 Oct;38(10):1043–6

Patient selection is integral to the success of the electrically stimulated gracilis neosphincter [letter; comment] Mander BJ, et al. **Dis Colon Rectum** 1996 Jun;39(6):712–3. Comment on: Dis Colon Rectum 1995 Dec;38(12):1331–3.

Manometric asymmetry in the anal canal in controls and patients with fecal incontinence. Williams N, et al. **Dis Colon Rectum** 1995 Dec;38(12):1275–80

Fibre density in idiopathic ano-rectal incontinence. Dhaenens G, et al. **Electromyogr Clin Neurophysiol** 1995 Aug–Sep; 35(5):285–90

Anismus and biofeedback: who benefits? Siproudhis L, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):547–52

The perfect pelvic pouch—what makes the difference? Lewis WG, et al. **Gut** 1995 Oct;37(4):552–6

Relationship of symptoms in faecal incontinence to specific sphincter abnormalities. Engel AF, et al. **Int J Colorectal Dis** 1995;10(3):152–5

External anal sphincter electromyography in the differential diagnosis of parkinsonism [letter] Rodi Z, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):460–1

Anorectal function in fluctuating (on–off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography. Ashraf W, et al. **Mov Disord** 1995 Sep; 10(5):650–7

Simultaneous electromyography and manometry of the anal sphincters in parkinsonian patients: technical considerations [letter] Normand MM, et al. **Muscle Nerve** 1996 Jan; 19(1):110–1

[Anorectal manometry in hemorrhoidal disease] Girardi S, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):757–60 (17 ref.) (Eng. Abstr.) **(Ita)**

[When to combine internal sphincterotomy with hemorrhoidectomy] Lolli P, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):809–12 (Eng. Abstr.) **(Ita)**

[Anorectal manometry. Experience of 5 years] Morera C, et al. **G E N** 1995 Jul–Sep;49(3):212–7 (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

A retrospective study of the effects of pelvic irradiation for gynecological cancer on anorectal function. Yeoh E, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):1003–10

RADIOGRAPHY

Restorative proctocolectomy: morphological and functional study with coronal CT. Pizzamiglio M, et al. **Abdom Imaging** 1996 May–Jun;21(3):261–5

Proctographic features of anismus. Halligan S, et al. **Radiology** 1995 Dec;197(3):679–82

SURGERY

Stapled ileal pouch anal anastomoses are safer than handsewn anastomoses in patients with ulcerative colitis. Ziv Y, et al. **Am J Surg** 1996 Mar;171(3):320–3

Hypobaric spinal anaesthesia with bupivacaine (0.1%) gives selective sensory block for ano-rectal surgery. Maroof M, et al. **Can J Anaesth** 1995 Aug;42(8):691–4

Anal sphincter repair improves anorectal function and endosonographic image. A prospective clinical study. Felt-Bersma RJ, et al. **Dis Colon Rectum** 1996 Aug; 39(8):878–85

Simultaneous laparoscopic and transanal approach to rectal tumors [letter; comment] Goergen M, et al. **Dis Colon Rectum** 1996 Mar;39(3):358. Comment on: Dis Colon Rectum 1995 Mar;38(3):327–8.

Use of a suture holder facilitates transanal anastomosis. Hirata K, et al. **Dis Colon Rectum** 1996 Jun;39(6):700–1

Stimulated gracilis neosphincter—not as good as previously thought. Report of four cases [see comments] Korsgen S, et al. **Dis Colon Rectum** 1995 Dec;38(12):1331–3. Comment in: Dis Colon Rectum 1996 Jun;39(6):712–3.

Reconstruction with bilateral gluteus maximus myocutaneous rotation flap after wide local excision for perianal extramammary Paget's disease. Report of two cases. Murakami K, et al. **Dis Colon Rectum** 1996 Feb; 39(2):227–31

Long-term results of anterior levatorplasty for fecal incontinence. A retrospective study. Osterberg A, et al. **Dis Colon Rectum** 1996 Jun;39(6):671–4; discussion 674–5

Selective preservation of the anal transition zone in ileoanal pouch procedures. Pricolo VE, et al. **Dis Colon Rectum** 1996 Aug;39(8):871–7

Laparoscopic very low anterior resection and coloanal anastomosis using the pull-through technique. Ramos JR. **Dis Colon Rectum** 1995 Nov;38(11):1217–9

Long-term results of ileal pouch-anal anastomosis in patients with Crohn's disease. Sagar PM, et al. **Dis Colon Rectum** 1996 Aug;39(8):893–8

Unilateral pudendal neuropathy. Impact on outcome of anal sphincter repair. Sangwan YP, et al. **Dis Colon Rectum** 1996 Jun;39(6):686–9

Surgical treatment of traumatic cloaca. Venkatesh KS, et al. **Dis Colon Rectum** 1996 Jul;39(7):811–6

Effect of colectomy with ileo-anal anastomosis on the biliary lipids. Galatola G, et al. **Eur J Clin Invest** 1995 Jul; 25(7):534–8

Posterior sagittal anorectoplasty: functional results of primary and secondary operations in comparison to the pull-through method in anorectal malformations. Mulder W, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):170–3

Abdominoperineal excision of the rectum and anal canal with perineal colostomy. da Silva AL. **Eur J Surg** 1995 Oct; 161(10):761–4

Stapled ileal pouch-anal anastomosis with resection of the anal transition zone [see comments] Braun J, et al. **Int J Colorectal Dis** 1995;10(3):142–7. Comment in: Int J Colorectal Dis 1995;10(4):234.

Treatment of recurrent high anal fistula by total excision and primary sphincter reconstruction. Christiansen J, et al. **Int J Colorectal Dis** 1995;10(4):207–9

Stapled ileal pouch-anal anastomosis with resection of the anal transition zone [letter; comment] Thompson-Fawcett M, et al. **Int J Colorectal Dis** 1995;10(4):234. Comment on: Int J Colorectal Dis 1995;10(3):142–7.

Effect of some abdominal surgical operations on small bowel motility in humans: our experience. Bassotti G, et al. **J Clin Gastroenterol** 1995 Oct;21(3):211–6 (86 ref.)

Fecal incontinence after the surgical treatment of Hirschsprung disease. Catto-Smith AG, et al. **J Pediatr** 1995 Dec;127(6):954–7

Inverted U-pouch ileal reservoir: a technique for conversion of straight ileoanal pull-through. Prasad ML, et al. **J Pediatr Surg** 1995 Sep;30(9):1361–2

Mucosal proctectomy and colo-anal anastomosis as treatment of rectal atresia. Vaneerdeweg W, et al. **J Pediatr Surg** 1995 Dec;30(12):1722–3

A new guiding device for safer introduction of the blunt-ended stapler from the anus in low anterior anastomosis. Sadahiro S, et al. **J Surg Oncol** 1996 Aug; 62(4):298–9

Posterior urethral diverticula: a complication of surgery for high anorectal malformations. Vinnicombe SJ, et al. **Pediatr Radiol** 1996;26(2):120–6

Anal sphincter reconstruction with the gluteus maximus muscle: anatomic and physiologic considerations concerning conventional and dynamic gluteoplasty. Guelinckx PJ, et al. **Plast Reconstr Surg** 1996 Aug; 98(2):293–302; discussion 303–4

Sphincter preservation for low rectal carcinoma—the Durban experience. Desai Y, et al. **S Afr J Surg** 1995 Sep; 33(3):109–11

Anatomic basis of mesenteric elongation for ileo-anal anastomosis with J-shaped reservoir: comparison of two techniques of vascular section. Wind P, et al. **Surg Radiol Anat** 1996;18(1):11–6

Functional perineal colostomy with pudendal nerve anastomosis following anorectal resection: an experimental study. Sato T, et al. **Surgery** 1996 Jun;119(6):641–51

Rectal squamous mucosectomy and ileal anal pull-through procedures: single surgeon experience in 105 patients. Sitzmann JV, et al. **Surgery** 1995 Nov;118(5):797–802

[The transphincteric approach excision of rectal villous adenomas] Qiu H, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Mar;33(3):170–2 (Eng. Abstr.) **(Chi)**

[Treatment of rectal prolapse with elastic circling of the anus: Perspectives of utilization] Amar A, et al. **J Chir (Paris)** 1996 Jun;133(4):183–5 (Eng. Abstr.) **(Fre)**

[Dynamic graciloplasty, an effective approach to anal incontinence] Givel JC, et al. **Rev Med Suisse Romande** 1996 Jul;116(7):521–4 **(Fre)**

[Technic of overlapping sphincter anal repair in the treatment of traumatic anal incontinence] Gangi S, et al. **Ann Ital Chir** 1995 May–Jun;66(3):393–6 (Eng. Abstr.) **(Ita)**

[New operative procedure for genital prolapse—partial colpocleisis with extensive suture of levatores] Tsuji A, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1281–4 **(Jpn)**

[Colostomy in anal, rectal and sigmoid surgical pathology] Ruiz Healy F, et al. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S118–20 (Eng. Abstr.) **(Spa)**

[Electrical testing using the Myotest in the radical correction of anorectal defects in children] Kryvchenia DIu, et al. **Klin Khir** 1995;(6):46–7 **(Ukr)**

ULTRASONOGRAPHY

CT and anal endosonography in the evaluation of electrically stimulated neoanal sphincter: a preliminary report. Marano I, et al. **Abdom Imaging** 1996 Jul–Aug;21(4):353–6

Changes in the anal sphincter with age. An endosonographic study. Nielsen MB, et al. **Acta Radiol** 1996 May;37(3 Pt 1):357–61

Short communication: endoanal ultrasound during contraction of the anal sphincter—improved definition and diagnostic accuracy. Rieger NA, et al. **Br J Radiol** 1996 Jul;69(823):665–7

External anal sphincter defects: correlation between pre-operative anal endosonography and intraoperative findings. Romano G, et al. **Br J Radiol** 1996 Jan;69(817):6–9

Endosonographic assessment of postpartum anal sphincter injury using a 120 degree sector scanner. Campbell DM, et al. **Clin Radiol** 1996 Aug;51(8):559–61

Significance of anal canal ultrasound before sphincterotomy in multiparous women with anal fissure [letter] Reissman P. **Dis Colon Rectum** 1996 Sep;39(9):1060

Investigation of fecal incontinence with endoanal ultrasound. Rieger NA, et al. **Dis Colon Rectum** 1996 Aug;39(8):860–4

Anal endosonography in faecal incontinence [editorial] Bartram C. **Endoscopy** 1996 Feb;28(2):259–60 (26 ref.)

Anal sphincter defects in fecal incontinence: correlation between endosonography and surgery. Meyenberger C, et al. **Endoscopy** 1996 Feb;28(2):217–24

[Colloid cancer of the anus: value of anal ultrasonography and nuclear magnetic resonance imaging (letter)] De Parades V, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Oct;31(5):284–6 **(Fre)**

[Value of endo-anal ultrasonography in the assessment of anal incontinence] Roche B, et al. **Schweiz Med Wochenschr Suppl** 1996;79:64S–69s (Eng. Abstr.) **(Fre)**

[Anal endosonography: the study technic and the correlations between the normal and echographic anatomy] Brunese L, et al. **Radiol Med (Torino)** 1996 Mar;91(3):253–7 (Eng. Abstr.) **(Ita)**

ULTRASTRUCTURE

[Dolphin anal glands] Sokolov VE, et al. **Dokl Akad Nauk** 1995 Jun;342(6):823–6 **(Rus)**

VIROLOGY

Detection of Epstein–Barr virus DNA in anal scrapings from HIV-positive homosexual men. Näher H, et al. **Arch Dermatol Res** 1995;287(6):608–11

ANUS, ARTIFICIAL see **COLOSTOMY**

ANUS DISEASES

Clinical and serological manifestations of genital human papillomavirus infection. Wikström A. **Acta Derm Venereol Suppl (Stockh)** 1995;193:1–85

Effect of valvular heart diseases, migraine headaches, and perianal diseases on the risk of involvement in motor vehicle crashes. Lerman Y, et al. **J Trauma** 1995 Dec; 39(6):1058–62

Anorectal disorders. Five common causes of pain, itching, and bleeding. Metcalf A. **Postgrad Med** 1995 Nov; 98(5):81–4, 87–9, 92–4 (19 ref.)

[Evaluation of sexual abuse in an infant with condyloma acuminatum] Giryes H, et al. **Harefuah** 1995 Dec 15; 129(12):548–50, 615 (Eng. Abstr.) **(Heb)**

[Hemorrhoidal thrombosis and perianal hematoma: diagnosis and treatment] Delaini GG, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):783–5 (8 ref.) (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

[Ergotamine-induced anorectal lesions] Lamesch P, et al. **Chirurg** 1995 Aug;66(8):826–8 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Digital dilatation for relief of proctalgia fugax [letter; comment] Rockefeller R. **Am Fam Physician** 1996 Jul; 54(1):72. Comment on: Am Fam Physician 1995 Dec;52(8):2238–40.

Severe complications of perianal sepsis in patients with human immunodeficiency virus. Consten EC, et al. **Br J Surg** 1996 Jun;83(6):778–80

Anorectal surgery in human immunodeficiency virus-infected patients. Clinical outcome in relation to immune status. Consten EC, et al. **Dis Colon Rectum** 1995 Nov;38(11):1169–75

[Pelvic pain of proctological origin] Roche B, et al. **Schweiz Med Wochenschr** 1996 Feb 24;126(8):316–21 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Clinical aspects of genito-anal papillomavirus infection with a focus on when and how to investigate. von Krogh G. **Curr Probl Dermatol** 1996;24:140–50 (42 ref.)

Perianal Crohn's disease—is it all bad news? McKee RF, et al. **Dis Colon Rectum** 1996 Feb;39(2):136–42

Primary perianal actinomycosis. Posnik MR, et al. **Eur J Surg** 1996 Feb;162(2):153–4

[Daily aspects of proctology] Lewinson B. **Rev Med Brux** 1995 Jul–Aug;16(4):267–70 (Eng. Abstr.) **(Fre)**

[Anorectal problems in clinical practice] Voirol M, et al. **Rev Med Suisse Romande** 1996 Jul;116(7):531–5 **(Fre)**

[What is your diagnosis? Proctalgia fugax] Landolt M, et al. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1087–8 **(Ger)**

[Condylomata acuminata in children: a case report, update and management protocol] Níguez Carbonell JC, et al. **An Esp Pediatr** 1996 Mar;44(3):292–4 (20 ref.) **(Spa)**

DRUG THERAPY

Topical nitroglycerin therapy for anal fissures and ulcers [letter] Gorfine SR. **N Engl J Med** 1995 Oct 26; 333(17):1156–7

ETIOLOGY

Tolerance to different toilet paper preparations: toxicological and allergological aspects. Blecher P, et al. **Dermatology** 1995;191(4):299–304

Anal "epistaxis": exteriorization of rectal bleeding during colonoscopy [letter] Delpre G, et al. **Dig Dis Sci** 1995 Oct; 40(10):2293

Treatment of perianal infection following bone marrow transplantation. Cohen JS, et al. **Dis Colon Rectum** 1996 Sep;39(9):981–5

Faecal incontinence with transitory absence of anal contraction in two sexually or physically abused women. Berkelmans I, et al. **Eur J Gastroenterol Hepatol** 1996 Mar; 8(3):235–8

Recurrent perianal warts and anal carcinoma [letter] Joseph AT, et al. **Genitourin Med** 1996 Feb;72(1):69–70

Highly destructive perianal disease in children with Crohn's disease. Markowitz J, et al. **J Pediatr Gastroenterol Nutr** 1995 Aug;21(2):149–53

Myasthenia gravis presenting as uncontrollable flatus and urinary/fecal incontinence [letter] Berger AR, et al. **Muscle Nerve** 1996 Jan;19(1):113–4

Malignant retrorectal teratoma presenting as an infected perianal sinus. Haribhakti SP, et al. **Trop Gastroenterol** 1995 Apr–Jun;16(2):117–8

[Anal blood loss: remember the thermometer!] Siersema PD, et al. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):233–5 **(Dut)**

[Obstruction: a rare complication of congenital giant blue nevus] Martinot V, et al. **Arch Pediatr** 1995 Oct;2(10):980–3 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Anal and penile condylomas in HIV-negative and HIV-positive men: clinical, histological and virological characteristics correlated to therapeutic outcome. von Krogh G, et al. **Acta Derm Venereol** 1995 Nov;75(6):470–4

Perianal Crohn's disease in children and adolescents. Tolia V. **Am J Gastroenterol** 1996 May;91(5):922–6 (32 ref.)

Anal pathology in patients with Crohn's disease. Platell C, et al. **Aust N Z J Surg** 1996 Jan;66(1):5–9

High resolution magnetic resonance imaging of the anal sphincter using an internal coil. deSouza NM, et al. **Gut** 1995 Aug;37(2):284–7

Perianal lymphangioma circumscriptum mistaken for genital warts. Darmstadt GL. **Pediatrics** 1996 Sep;98(3 Pt 1):461–3 (18 ref.)

PHYSIOPATHOLOGY

Urge incontinence of faeces is a marker of severe external anal sphincter dysfunction. Gee AS, et al. **Br J Surg** 1995 Sep;82(9):1179–82

Clinical and physiological evaluation of anorectal eversion during restorative proctocolectomy. Williamson ME, et al. **Br J Surg** 1995 Oct;82(10):1391–4

SURGERY

The management of perianal diseases. Fazio VW, et al. **Adv Surg** 1996;29:59–78 (70 ref.)

Surgery for anal lesions in HIV-infected patients. Weiss EG, et al. **Ann Med** 1995 Aug;27(4):467–75 (44 ref.)

Perianal and anorectal conditions [see comments] Kumar D. **Br J Hosp Med** 1996 Apr 17–30;55(8):464–7. Comment in: Br J Hosp Med 1996 Apr 17–30;55(8):463.

Randomized comparison of agents for caudal anaesthesia in anal surgery. Adebamowo CA, et al. **Br J Surg** 1996 Mar; 83(3):364–5

Treatment of perianal infection following bone marrow transplantation. Cohen JS, et al. **Dis Colon Rectum** 1996 Sep;39(9):981–5

Anorectal surgery in human immunodeficiency virus-infected patients. Clinical outcome in relation to immune status. Consten EC, et al. **Dis Colon Rectum** 1995 Nov;38(11):1169–75

[Use of CO2 laser in the treatment of condylomata acuminata of the anogenital region in pregnant women] Woźniak J, et al. **Ginekol Pol** 1995 Feb;66(2):103–7 (Eng. Abstr.) **(Pol)**

THERAPY

Current therapy for recurrent and extensive anal warts. Congilosi SM, et al. **Dis Colon Rectum** 1995 Oct; 38(10):1101–7 (51 ref.)

Perianal Crohn's disease—is it all bad news? McKee RF, et al. **Dis Colon Rectum** 1996 Feb;39(2):136–42

Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts. Armstrong DK, et al. **Genitourin Med** 1996 Apr;72(2):103–7

Autoimplantation technique in the treatment of anogenital warts: a clinico-immunological study. Usman N, et al. **Int J STD AIDS** 1996 Jan–Feb;7(1):55–7

Is perianal sepsis adequately managed? The results of a five year audit at Royal Naval Hospital Haslar. Parker SJ, et al. **J R Nav Med Serv** 1995 Winter;80(3):148–51

ULTRASONOGRAPHY

Re: Anorectal inflammatory conditions [letter; comment] Jakab Z, et al. **Am J Gastroenterol** 1996 May;91(5):1057–8 . Comment on: Am J Gastroenterol 1995 Apr;90(4):574–8.

Anal endosonography in faecal incontinence [editorial] Bartram C. **Endoscopy** 1996 Feb;28(2):259–60 (26 ref.)

Anal sphincter defects in fecal incontinence: correlation between endosonography and surgery. Meyenberger C, et al. **Endoscopy** 1996 Feb;28(2):217–24

[Post-surgical or traumatic anal incontinences. Prospective study in 40 patients explorated by endorectal ultrasonography and electromyography] Aubert A, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):598–603 (Eng. Abstr.) **(Fre)**

[Ultrasound in anorectal diagnosis] Påhlman L, et al. **Lakartidningen** 1996 Feb 7;93(6):453–6 **(Swe)**

VIROLOGY

Anal and penile condylomas in HIV-negative and HIV-positive men: clinical, histological and virological characteristics correlated to therapeutic outcome. von Krogh G, et al. **Acta Derm Venereol** 1995 Nov;75(6):470–4

ANUS, IMPERFORATE

Urodynamic evaluation of an infant with complete bladder and colonic duplication, sacral dysgenesis, and an imperforate anus. Choo KL, et al. **Br J Urol** 1996 May; 77(5):749–50

COMPLICATIONS

Imperforate anus, bilateral hydronephrosis, bilateral undescended testes and pituitary hypoplasia: a variant of Hall–Pallister syndrome or a new syndrome. Cianfarani S, et al. **Acta Paediatr** 1995 Nov;84(11):1322–4

Duplication of appendix with segmental dilatation of the colon, myeloschisis and anal atresia. Rizalar R, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):112–3

Epidermolysis bullosa associated with pyloric, esophageal, and anal atresia: a case report. Cetinkurşun S, et al. **J Pediatr Surg** 1995 Oct;30(10):1477–8

Association of imperforate anus with occult spinal dysraphism. Tsakayannis DE, et al. **J Pediatr Surg** 1995 Jul;30(7):1010–2

Solitary crossed renal ectopia associated with unicornuate uterus, imperforate anus and congenital scoliosis. Eckford SD, et al. **J Urol** 1996 Jul;156(1):221

Spine evaluation in children with anorectal malformations. Beek FJ, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S28–32

Complex colon duplication mimicking an obstructed, non-functioning kidney in a newborn with imperforate anus and spinal dysraphism. Stylianos S, et al. **Pediatr Radiol** 1995;25(4):269–71

Associated urologic anomalies in low imperforate anus are capable of causing significant morbidity: a 15-year experience. Misra D, et al. **Urology** 1996 Aug;48(2):281–3

[Cryptorchidism in boys with anal atresia] Cortes D, et al. **Ugeskr Laeger** 1996 May 13;158(20):2845–8 (Eng. Abstr.) **(Dan)**

DIAGNOSIS

Pre-operative MRI of anorectal anomalies in the newborn period. McHugh K, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S33–6

MRI and radiographic findings in Currarino's triad. Pfluger T, et al. **Pediatr Radiol** 1996;26(8):524–7 (21 ref.)

Tethered cord and associated vertebral anomalies in children and infants with imperforate anus: evaluation with MR imaging and plain radiography. Long FR, et al. **Radiology** 1996 Aug;200(2):377–82

Tethered cord and associated anomalies in children and infants with imperforate anus: evaluation with MR imaging and plain radiography [editorial] Melhem ER. **Radiology** 1996 Aug;200(2):318–9

[The Townes-Brocks syndrome] Arroyo Carrera I, et al. **An Esp Pediatr** 1996 Apr;44(4):364–6 (18 ref.) **(Spa)**

GENETICS

Anal atresia and abdominal wall defect as unusual symptoms in EEC syndrome. De Smet L, et al. **Genet Couns** 1995; 6(2):127–30

PATHOLOGY

Innervation patterns of the rectal pouch and fistula in anorectal malformations: a preliminary report. Holschneider AM, et al. **J Pediatr Surg** 1996 Mar; 31(3):357–62

RADIOGRAPHY

The various types of anorectal fistula in male imperforate anus. Currarino G. **Pediatr Radiol** 1996;26(8):512–22; discussion 523 (35 ref.)

SURGERY

Posterior sagittal anorectoplasty: functional results of primary and secondary operations in comparison to the pull-through method in anorectal malformations. Mulder W, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):170–3

Sensation in the anal region and rectum after surgery for anorectal malformations. Nagashima M, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):167–9

Imperforate anus, malrotation and Hirschsprung's disease: a rare association. Poenaru D, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):187–9

Management of congenital anorectal malformations. Wakhlu AK. **Indian Pediatr** 1995 Nov;32(11):1239–42 (0 ref.)

Does posterior sagittal anorectoplasty in patients with high imperforate anus provide superior fecal continence? Bliss DP Jr, et al. **J Pediatr Surg** 1996 Jan;31(1):26–30; discussion 30–2

Male infertility after surgery for imperforate anus. Holt B, et al. **J Pediatr Surg** 1995 Dec;30(12):1677–9

Mucosal proctectomy and colo–anal anastomosis as treatment of rectal atresia. Vaneerdeweg W, et al. **J Pediatr Surg** 1995 Dec;30(12):1722–3

Coloplasty for congenital short colon. Wakhlu AK, et al. **J Pediatr Surg** 1996 Mar;31(3):344–8

[Surgery of atresia of the gastrointestinal tract] Joppich I, et al. **Chirurg** 1996 Jun;67(6):576–83 (10 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

The prenatal ultrasonographic visualization of imperforate anus in monoamniotic twins. Guzman ER, et al. **J Ultrasound Med** 1995 Jul;14(7):547–51

ANUS NEOPLASMS

[Anus cancer] Keldsen N, et al. **Ugeskr Laeger** 1996 Jul 8; 158(28):4073–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Cancer of the anal canal] Gérard JP, et al. **Bull Cancer Radiother** 1990;77(1):23–31 (41 ref.) **(Fre)**

[Anal cancer. A review] Tanum G. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1567–70 (31 ref.) (Eng. Abstr.) **(Nor)**

[Mucinous adenocarcinoma of the anal region. Study of 4 cases] Sacristán F, et al. **Rev Esp Enferm Dig** 1995 Sep; 87(9):677–80 (Eng. Abstr.) **(Spa)**

ANUS NEOPLASMS

COMPLICATIONS

Squamous cell carcinomas of the anus and infection with human papillomavirus in patients with AIDS. Muñoz-Jiménez F, et al. **Eur J Surg** 1996 Mar;162(3):251–3

Cloacogenic anal carcinoma presenting with humoral hypercalcemia: report of a case. Nobusawa S, et al. **Surg Today** 1995;25(11):970–3

CONGENITAL

Polypoid formations at the anal margin in infants less than two years old. Vanneuville G, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):164–6

DIAGNOSIS

[Colloid cancer of the anus: value of anal ultrasonography and nuclear magnetic resonance imaging (letter)] De Parades V, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Oct;31(5):284–6 **(Fre)**

[Anorectal tumor pathology and its diagnosis] De Vos A. **Rev Med Brux** 1995 Jul-Aug;16(4):271–3 (Eng. Abstr.) **(Fre)**

[Anorectal problems in clinical practice] Voirol M, et al. **Rev Med Suisse Romande** 1996 Jul;116(7):531–5 **(Fre)**

DRUG THERAPY

[Polyvisceral and multirecurrent lymphoma (letter)] Benhamou G, et al. **Presse Med** 1995 Dec 16–23;24(39):1909 **(Fre)**

[Medical treatment of 44 patients with anal canal carcinoma. Argentinian Intergroup for the treatment of gastrointestinal tumors (IATTGI)] Roca E, et al. **Medicina (B Aires)** 1995; 55(3):243–8 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Marital status in relation to Kaposi's sarcoma, non-Hodgkin's lymphoma, and anal cancer in the pre-AIDS era. Biggar RJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Feb 1;11(2):178–82

Risk of dysplasia in anal condyloma. Metcalf AM, et al. **Surgery** 1995 Oct;118(4):724–6 (14 ref.)

ETIOLOGY

Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. Critchlow CW, et al. **AIDS** 1995 Nov; 9(11):1255–62

Clinical presentation of minimally invasive and in situ squamous cell carcinoma of the anus in homosexual men. Forti RL, et al. **Clin Infect Dis** 1995 Sep;21(3):603–7

Anal carcinoma: a clinical approach to p53 and RB gene proteins. Tanum G, et al. **Oncology** 1996 Sep–Oct; 53(5):369–73

[Invasive anal carcinoma in a homosexual patient with HIV infection (letter)] Drobacheff C, et al. **Presse Med** 1995 Nov 4;24(33):1577 **(Fre)**

PATHOLOGY

Basal cell carcinoma of the anus. Butler WP. **Am J Gastroenterol** 1996 May;91(5):1043–4

High grade anal dysplasia in visually normal mucosa in homosexual men: seven cases. Surawicz CM, et al. **Am J Gastroenterol** 1995 Oct;90(10):1776–8

Pouch-anal cancer after restorative proctocolectomy for familial adenomatous polyposis. von Herbay A, et al. **Am J Surg Pathol** 1996 Aug;20(8):995–9

Patterns of recurrence in squamous cell carcinoma of the anal canal. Luna-Pérez P, et al. **Arch Med Res** 1995 Autumn;26(3):213–9 (20 ref.)

Milium-like syringoma in the perianal region. Higaki Y, et al. **Dermatology** 1995;191(3):249–51

Perianal lymphangioma circumscriptum mistaken for genital warts. Darmstadt GL. **Pediatrics** 1996 Sep;98(3 Pt 1):461–3 (18 ref.)

Intradural metastasis to the cauda equina from carcinoma of the anus. Cho DY, et al. **Spine** 1995 Nov 1;20(21):2341–4 (15 ref.)

RADIOGRAPHY

Bipedal lymphography in the management of carcinoma of the anal canal. Davey P, et al. **Br J Radiol** 1996 Jul; 69(823):632–5

Extramedullary plasmacytoma of anorectum: case report. Mutiso VM. **East Afr Med J** 1996 Feb;73(2):149–50

RADIOTHERAPY

Laparoscopic lateral ovarian transposition. Treissman MJ, et al. **Fertil Steril** 1996 Jun;65(6):1229–31

Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study. Martenson JA, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 1;35(4):745–9

[Interdisciplinary therapy of anal carcinoma] Döker R, et al. **Schweiz Rundsch Med Prax** 1995 Nov 21;84(47):1389–97 (43 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Methods to decrease the morbidity of abdominoperineal resection. Farid H, et al. **Am Surg** 1995 Dec;61(12):1061–4

Perineal wound closure with the rectus abdominis musculocutaneous flap after tumor ablation. de Haas WG, et al. **Ann Surg Oncol** 1995 Sep;2(5):400–6

Adenomatous polyps in the anal transitional zone after ileal pouch-anal anastomosis for familial adenomatous polyposis: treatment by transanal mucosectomy and ileal pouch advancement. Malassagne B, et al. **Br J Surg** 1995 Dec;82(12):1634

Outcome of restorative perineal graciloplasty with simultaneous excision of the anus and rectum for cancer. A ten-year experience with 81 patients. Cavina E. **Dis Colon Rectum** 1996 Feb;39(2):182–90

[Anorectal melanoma. Apropos of a distant recurrence (letter)] Benchellal ZA, et al. **Ann Chir** 1996;50(4):356 **(Fre)**

[Immediate vaginal reconstruction with a musculocutaneous flap from the gracilis muscle after extended abdomino-perineal resection] Sezeur A, et al. **Ann Chir** 1995;49(6):534–8 (Eng. Abstr.) **(Fre)**

[Value of inguinal lymph node excision in anorectal melanoma] Vorpahl U, et al. **Zentralbl Chir** 1996; 121(6):483–6 (Eng. Abstr.) **(Ger)**

[Primary malignant melanoma of the rectum] Zidan J, et al. **Harefuah** 1996 Feb 15;130(4):234–6; 296; 295 (Eng. Abstr.) **(Heb)**

THERAPY

Results of combined modality therapy for patients with anal cancer (E7283). An Eastern Cooperative Oncology Group study. Martenson JA, et al. **Cancer** 1995 Nov 15; 76(10):1731–6

Use of organ-sparing treatments varies internationally [news] Reynolds T. **J Natl Cancer Inst** 1995 Dec 20;87(24):1826–7

[Treatment of anus cancer (editorial)] Christiansen J, et al. **Ugeskr Laeger** 1996 Jul 8;158(28):4062 **(Dan)**

[Current treatment of cancers of the anal canal] Gérard JP, et al. **Ann Chir** 1995;49(5):363–8; discussion 368–72 (39 ref.) (Eng. Abstr.) **(Fre)**

[Anorectal malignant melanomas. Apropos of 5 cases. Review of the literature] Melhouf MM, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Sep;31(4):209–12 (Eng. Abstr.) **(Fre)**

[Anal cancer: current results of the EORTC and RTOG/ECOG studies] Grabenbauer GG. **Strahlenther Onkol** 1996 May;172(5):284–5 **(Ger)**

[Use of thermal radiochemotherapy in patients with anal epidermoid cancer] Knysh VI, et al. **Vestn Ross Akad Med Nauk** 1996;(3):23–5 (Eng. Abstr.) **(Rus)**

[First experience with thermoradiochemotherapy for patients with squamous cell carcinoma of the anal canal] Knysh VI, et al. **Vopr Onkol** 1996;42(3):79–81 **(Rus)**

ULTRASONOGRAPHY

[Ultrasound in anorectal diagnosis] Påhlman L, et al. **Lakartidningen** 1996 Feb 7;93(6):453–6 **(Swe)**

VETERINARY

[Clinical case. Cocker spaniel, female, 12 years old] Kessler M. **Tierarztl Prax** 1995 Oct;23(5):436, 521–4 **(Ger)**

VIROLOGY

Detection of human cytomegalovirus in female and male anogenital lesions with papillomavirus-associated dysplastic changes. Mougin C, et al. **Cancer Detect Prev** 1995;19(4):316–24

Study of human papillomavirus infection in patients with anal squamous carcinoma. Ramanujam PS, et al. **Dis Colon Rectum** 1996 Jan;39(1):37–9

ANUS PROLAPSE see **RECTAL PROLAPSE**

ANXIETY

Effect of music on ambulatory surgery patients' preoperative anxiety. Augustin P, et al. **AORN J** 1996 Apr;63(4):750, 753–8

The impact of parental presence on parental anxiety and satisfaction. Blesch P, et al. **AORN J** 1996 Apr;63(4):761–8

Gender differences in sexual desire: the effects of anger and anxiety. Beck JG, et al. **Arch Sex Behav** 1995 Dec; 24(6):595–612

A test of Martens, Vealey and Burton's theory of competitive anxiety. Prapavessis H, et al. **Aust J Sci Med Sport** 1996 Mar;28(1):24–9

Anxiety in women "at risk" of developing breast cancer. Thirlaway K, et al. **Br J Cancer** 1996 Jun;73(11):1422–4

Effect of age and magnesium administration on the performance of SHR in the elevated plus-maze. Oliveira GM, et al. **Braz J Med Biol Res** 1995 Mar;28(3):343–6

Is perinatal picrotoxin anxiogenic? Silva MR, et al. **Braz J Med Biol Res** 1995 Jun;28(6):663–6

Psychological impact of islet cell antibody screening for IDDM on children, adults, and their family members. Bennett Johnson S, et al. **Diabetes Care** 1995 Oct; 18(10):1370–2

Distress correlates with the degree of chest pain: a description of patients awaiting revascularisation [see comments] Bengtson A, et al. **Heart** 1996 Mar;75(3):257–60. Comment in: Heart 1996 Mar;75(3):221.

Uncertainty is an important symptom in patients awaiting revascularisation procedures [comment] Crisp AH. **Heart** 1996 Mar;75(3):221. Comment on: Heart 1996 Mar;75(3):257–60.

Effectiveness of individual and dyadic training protocols: the influence of trainee interaction anxiety. Arthur W Jr, et al. **Hum Factors** 1996 Mar;38(1):79–86

Psychologic predictors of duodenal ulcer healing. Levenstein S, et al. **J Clin Gastroenterol** 1996 Mar;22(2):84–9

How blood pressure in patients with non-insulin-dependent diabetes mellitus is influenced by stress. Okada S, et al. **J Int Med Res** 1995 Sep–Oct;23(5):377–80

The mildly abnormal cervical smear: patient anxiety and choice of management. Jones MH, et al. **J R Soc Med** 1996 May;89(5):257–60

Effect of anxiety on performance in multiple choice examination. Pamphlett R, et al. **Med Educ** 1995 Jul; 29(4):297–302

Anxiety and depression in general practice patients: prevalence and management. Harris MF, et al. **Med J Aust** 1996 May 6;164(9):526–9

Relations of goal orientations and expectations on multidimensional state anxiety. Newton M, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1107–12

Preferences for ethanol and diazepam in anxious individuals: an evaluation of the self-medication hypothesis. Chutuape MA, et al. **Psychopharmacology (Berl)** 1995 Sep; 121(1):91–103

Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics. Miczek KA, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):38–56 (161 ref.)

The effect of feedback on anxiety levels during ultrasound scanning for ovarian cancer. Tadmor OP, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):135–9

[Comparison of anxiety and pain in two procedures of hematopoietic stem cell collection: cytapheresis and bone marrow collection] Macquart-Moulin G, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):582–8 (Eng. Abstr.) **(Fre)**

BLOOD

[Hormonal markers of stress in acute cerebrovascular pathology] Miralles F, et al. **Rev Neurol** 1995 Sep–Oct; 23(123):979–82 (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Priming of experimental anxiety by repeated subthreshold GABA blockade in the rat amygdala. Sanders SK, et al. **Brain Res** 1995 Nov 20;699(2):250–9

Evidence for an anxiogenic action of AMPA receptor antagonists in the plus-maze test. Karcz-Kubicha M, et al. **Eur J Pharmacol** 1995 Jun 12;279(2–3):171–7

Rebound exacerbation of anxiety during prolonged tranquilizer ingestion [letter; comment] Cookson JC. **J R Soc Med** 1995 Sep;88(9):544. Comment on: J R Soc Med 1995 Feb;88(2):73–7.

Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Rodgers RJ, et al. **Pharmacol Biochem Behav** 1995 Dec; 52(4):805–13

Muscarinic antagonists are anxiogenic in rats tested in the black-white box. Smythe JW, et al. **Pharmacol Biochem Behav** 1996 May;54(1):57–63

Anxiolytic-like effects of yohimbine in the murine plus-maze: strain independence and evidence against alpha 2-adrenoceptor mediation. Cole JC, et al. **Psychopharmacology (Berl)** 1995 Apr;118(4):425–36

Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Privette TH, et al. **Psychopharmacology (Berl)** 1995 Apr;118(4):444–50

Anxiogenic activity of centrally administered scorpion (Mesobuthus tamulus) venom in rats. Bhattacharya SK. **Toxicon** 1995 Nov;33(11):1491–9

COMPLICATIONS

Is smoking associated with depression and anxiety in teenagers? Patton GC, et al. **Am J Public Health** 1996 Feb; 86(2):225–30

How can new behavioral knowledge and proven aids to treatment enter the teaching and practice of obstetrics? [comment] Good RS, et al. **Behav Med** 1995 Fall; 21(3):123–9. Comment on: Behav Med 1995 Fall;21(3):101–12. Comment on: Behav Med 1995 Fall;21(3):113–22.

Relationship of anxiety, stress, and psychosocial development to reproductive health [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):101–12 (110 ref.). Comment in: Behav Med 1995 Fall;21(3):123–9.

Treatment strategies for anxiety, stress, and developmental conflict during reproduction [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):113–22 (69 ref.). Comment in: Behav Med 1996 Fall;21(3):123–9.

Habitual coughing and its associations with asthma, anxiety, and gastroesophageal reflux. Lúdvíksdóttir D, et al. **Chest** 1996 May;109(5):1262–8

When mom or dad has cancer: II. Coping, cognitive appraisals, and psychological distress in children of cancer patients [see comments] Compas BE, et al.

Health Psychol 1996 May;15(3):167–75. Comment in: Health Psychol 1996 May;15(3):155–7.
Negative affect and self–report of physical symptoms: two longitudinal studies of older adults. Leventhal EA, et al. **Health Psychol** 1996 May;15(3):193–9
Are persons with nervous habit nervous? A preliminary examination of habit function in a nonreferred population. Woods DW, et al. **J Appl Behav Anal** 1996 Summer; 29(2):259–61
Anxiety and irritable bowel syndrome [letter; comment] [see comments] King TS, et al. **Lancet** 1996 Mar 2;347(9001):617 . Comment on: Lancet 1996 Jan 20;347(8995):150–3. Comment in: Lancet 1996 May 4;347(9010):1267.
Psychologic distress and low back pain. Evidence from a prospective study in the general population. Croft PR, et al. **Spine** 1995 Dec 15;20(24):2731–7

DIAGNOSIS

Anxiety, depression and worry in gastrointestinal cancer patients attending medical follow–up control visits. Nordin K, et al. **Acta Oncol** 1996;35(4):411–6
Physicians' fears about treating anxiety disorders [letter] Carswell TW Jr. **Am Fam Physician** 1996 Apr;53(5):1521
The Amsterdam Preoperative Anxiety and Information Scale (APAIS) [see comments] Moerman N, et al. **Anesth Analg** 1996 Mar;82(3):445–51. Comment in: Anesth Analg 1996 Mar;82(3):443–4.
Validation of a Portuguese version of the Beck Depression Inventory and the State–Trait Anxiety Inventory in Brazilian subjects. Gorenstein C, et al. **Braz J Med Biol Res** 1996 Apr;29(4):453–7
Phobic and anxiety conditions—diagnosis and therapy. Vlahova–Nikolova V, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):84
Structure of anxiety and the anxiety disorders: a hierarchical model. Zinbarg RE, et al. **J Abnorm Psychol** 1996 May; 105(2):181–93
Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler HR. **J Clin Psychiatry** 1996;57 Suppl 7:15–21; discussion 22–4 (60 ref.)
Depressive tendencies and susceptibility to anxiety: differential personality correlates. Kremen AM. **J Pers** 1996 Mar;64(1):209–42
Recognition and management of anxiety and depression in elderly patients [see comments] Martin LM, et al. **Mayo Clin Proc** 1995 Oct;70(10):999–1006 (09 ref.). Comment in: Mayo Clin Proc 1996 Apr;71(4):424.
Comparison of original and revised scoring systems for the Multiple Affect Adjective Check List. Jacobsen BS, et al. **Nurs Res** 1996 Jan–Feb;45(1):57–60
Anxiety in elderly hearing impaired persons. Andersson G, et al. **Percept Mot Skills** 1995 Oct;81(2):552–4
Relationships between scores on the motor activity anxiety test and the fear survey schedule. Bortoli L, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1192–4
Path analysis examining relationships among antecedents of anxiety, multidimensional state anxiety, and triathlon performance. Lane AM, et al. **Percept Mot Skills** 1995 Dec; 81(3 Pt 2):1255–66
Parent– and self–ratings of anxiety in children with mental retardation: agreement levels and test–retest reliability. Sarphare G, et al. **Res Dev Disabil** 1996 Jan–Feb; 17(1):27–39
[The expressions of anxiety in the elderly. Their diagnosis and therapy] Scapicchio PL. **Ann Ital Med Int** 1995 Oct; 10 Suppl:55S–57S (Eng. Abstr.) **(Ita)**
[New concepts relating to histochemistry of the serotonergic neural systems of the raphe nucleus] Villar MJ. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):293–300 (36 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Combination monoamine oxidase inhibitor and beta–blocker treatment of migraine, with anxiety and depression. Merikangas KR, et al. **Biol Psychiatry** 1995 Nov 1; 38(9):603–10
An imidazopyridine anxiolytic alters glucose tolerance in patients: a pilot investigation. Bottaï T, et al. **Clin Neuropharmacol** 1995 Feb;18(1):79–82
Flumazenil blocks the anxiolytic action of allopregnanolone. Fernández–Guasti A, et al. **Eur J Pharmacol** 1995 Jul 25; 281(1):113–5
Propranolol reduces the anxiety associated with day case surgery. Mealy K, et al. **Eur J Surg** 1996 Jan;162(1):11–4
Management of persistent anxiety and novel uses for anxiolytics. **J Clin Psychiatry** 1996;57 Suppl 7:3–95
Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler HR. **J Clin Psychiatry** 1996;57 Suppl 7:15–21; discussion 22–4 (60 ref.)
Corticotropin–releasing factor (CRF) antagonist [D–Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU–210 on defensive–withdrawal behavior in rats. Rodríguez de Fonseca F, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):56–64
Effects of valproate and lorazepam on experimental anxiety: tolerance, withdrawal, and role of clonidine. de Angelis L. **Pharmacol Biochem Behav** 1995 Oct;52(2):329–33
Failure of CCK receptor ligands to modify anxiety–related behavioural suppression in an operant conflict paradigm in rats. Charrier D, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):127–34
Effects of benzodiazepine receptor partial inverse agonists in the elevated plus maze test of anxiety in the rat. Cole BJ, et al. **Psychopharmacology (Berl)** 1995 Sep; 121(1):118–26
The anxiolytic–like activity of GR159897, a non–peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Walsh DM, et al. **Psychopharmacology (Berl)** 1995 Sep;121(2):186–91
Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety–related behavior in socially defeated rats. Liebsch G, et al. **Regul Pept** 1995 Oct 20; 59(2):229–39
[Comparison of the effectiveness of orally administered clorazepate dipotassium and nordiazepam on preoperative anxiety] Mielke L, et al. **Anaesthesiol Reanim** 1995; 20(6):144–8 (Eng. Abstr.) **(Ger)**
[The expressions of anxiety in the elderly. Their diagnosis and therapy] Scapicchio PL. **Ann Ital Med Int** 1995 Oct; 10 Suppl:55S–57S (Eng. Abstr.) **(Ita)**
[Behavioral effects of penicillin in experimental anxiety in rats] Kaluev AV, et al. **Biull Eksp Biol Med** 1995 Oct; 120(10):352–4 **(Rus)**
[Dependence of the strength of anxiolytic effect of tranquilizers on the level of anxiety in a conflict situation] Molodavkin GM, et al. **Biull Eksp Biol Med** 1996 Jan; 121(1):63–6 **(Rus)**
[Treatment of pain and anxiety in terminal oncologic patients in the Castilla–La Mancha community] Calles Gato MD, et al. **Aten Primaria** 1995 Sep 30;16(5):276–80 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Rat brain monoamine oxidase A and B inhibitory (tribulin) activity during drug withdrawal anxiety. Bhattacharya SK, et al. **Neurosci Lett** 1995 Oct 20;199(2):103–6

EPIDEMIOLOGY

Emotional reactions and colposcopy [letter] Magherini P, et al. **J Epidemiol Community Health** 1996 Feb;50(1):108–9
Is psychological wellbeing impaired in long–term survivors of breast cancer? Ellman R, et al. **J Med Screen** 1995; 2(1):5–9
A twin study of generalized anxiety disorder and major depression. Roy MA, et al. **Psychol Med** 1995 Sep; 25(5):1037–49
Psychology of computer use: XXXIX. Prevalence of computer anxiety in British managers and professionals. Bozionelos N. **Psychol Rep** 1996 Jun;78(3 Pt 1):995–1002
[Symptoms of anxiety and depression in adolescents] Essau CA, et al. **Prax Kinderpsychol Kinderpsychiatr** 1995 Oct; 44(8):322–8 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Pre–operative anxiety. Effect of early or late position on the operating list. Panda N, et al. **Anaesthesia** 1996 Apr; 51(4):344–6
Childhood bereavement [editorial] Black D. **BMJ** 1996 Jun 15;312(7045):1496
Creutzfeldt–Jakob disease and bovine spongiform encephalopathy. Scientists who inflame public anxieties must share responsibility for resulting panic [letter; comment] Fitzpatrick M. **BMJ** 1996 Apr 20;312(7037):1037 . Comment on: BMJ 1996 Mar 30;312(7034):790–1. Comment on: BMJ 1996 Mar 30;312(7034):791–3.
Telling patients there is nothing wrong [editorial; comment] Fitzpatrick R. **BMJ** 1996 Aug 10;313(7053):311–2. Comment on: BMJ 1996 Aug 10;313(7053):329–32.
Comparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: leukacytapheresis and bone marrow harvest. Auquier P, et al. **Bone Marrow Transplant** 1995 Oct;16(4):541–7
The psychological effects of breast screening in terms of patients' perceived health anxieties. Swanson V, et al. **Br J Clin Pract** 1996 Apr–May;50(3):129–35
The use of the Hospital Anxiety and Depression Scale (HADS) and the EORTC QLQ–C30 questionnaires to screen for treatable unmet needs in patients attending routinely for radiotherapy. Maher EJ, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:123–9
Symptom prevalence and worry about high voltage transmission lines. McMahan S, et al. **Environ Res** 1995 Aug;70(2):114–8
Psychic and social consequences of women in relation to memories of a stillborn child: a pilot study. Rådestad I, et al. **Gynecol Obstet Invest** 1996;41(3):194–8
Anxiety and depression after acute myocardial infarction. Crowe JM, et al. **Heart Lung** 1996 Mar–Apr;25(2):98–107
The effect of ward design on the well–being of post–operative patients. Pattison HM, et al. **J Adv Nurs** 1996 Apr;23(4):820–6
Sundown syndrome: etiology and management. Burney–Puckett M. **J Psychosoc Nurs Ment Health Serv** 1996 May;34(5):40–3 (15 ref.)
Psychiatric consequences of radical curative surgery for gastric cancer. Everitt NJ, et al. **J R Soc Med** 1995 Sep; 88(9):516–7
Needle wire localization for nonpalpable breast lesions: sensations, anxiety levels, and informational needs. Kelly P, et al. **Oncol Nurs Forum** 1996 May;23(4):639–45
Stress experienced while travelling without sight. Pfeiffer K. **Percept Mot Skills** 1995 Oct;81(2):411–7
An adolescent worried about his psoriasis. Poyner T, et al. **Practitioner** 1996 Feb;240(1559):69–76
Doctor–dependent changes in complaint–related cognitions and anxiety during medical consultations in functional abdominal complaints. Van Dulmen AM, et al. **Psychol Med** 1995 Sep;25(5):1011–8
Anxiety and panic in recreational scuba divers. Morgan WP. **Sports Med** 1995 Dec;20(6):398–421 (117 ref.)
Benefits of ethological analysis of behaviour [letter; comment] Dourish CT, et al. **Trends Pharmacol Sci** 1995 Aug;16(8):260–1. Comment on: Trends Pharmacol Sci 1995 Feb;16(2):33–6.
[Comparative study of the costs for two hematopoietic cell specimen collections: cytapheresis and bone marrow collection] Le Corroller AG, et al. **Rev Epidemiol Sante Publique** 1996 Apr;44(2):133–43 (Eng. Abstr.) **(Fre)**

GENETICS

Genetic analysis of anxiety–related behaviors and responses to benzodiazepine–related drugs in AXB and BXA recombinant inbred mouse strains. Mathis C, et al. **Behav Genet** 1995 Nov;25(6):557–68
Arm width and brightness modulation of spontaneous behaviour of two strains of mice tested in the elevated plus–maze. Lamberty Y, et al. **Physiol Behav** 1996 Mar; 59(3):439–44

HISTORY

[Anxiety in the language and in history] Barcia Goyanes JJ. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May–Jun;24(3):141–7 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Stress and the immune system in the etiology of anxiety and depression. Leonard BE, et al. **Pharmacol Biochem Behav** 1996 May;54(1):299–303 (74 ref.)

METABOLISM

Regulation of anxiety by GABAA receptors in the rat amygdala. Sanders SK, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):701–6
Cerebral tryptophan hydroxylase activity, and 5–HT1A receptor, 5–HT2A receptor, and 5–HT transporter binding in grouped and isolated Roman RHA and RLA rats: relationships with behaviours in two models of anxiety. Kulikov A, et al. **Psychopharmacology (Berl)** 1995 Oct; 121(3):385–95

NURSING

Assessment of anxiety in hospital patients. Shuldham CM, et al. **J Adv Nurs** 1995 Jul;22(1):87–93
Theoretical and practical considerations on the use of reassurance in the nursing management of anxious patients. Teasdale K. **J Adv Nurs** 1995 Jul;22(1):79–86 (61 ref.)

PHYSIOPATHOLOGY

Heart rate variability and preoperative anxiety. Sleigh JW, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1059–61
Cue–exposure to alcohol–associated stimuli reduces autonomic reactivity, but not craving and anxiety, in dependent drinkers. McCusker CG, et al. **Alcohol Alcohol** 1995 May;30(3):319–27
Preoperative gastric emptying. Effects of anxiety and oral carbohydrate administration. Nygren J, et al. **Ann Surg** 1995 Dec;222(6):728–34
Autonomic characteristics of generalized anxiety disorder and worry. Thayer JF, et al. **Biol Psychiatry** 1996 Feb 15; 39(4):255–66
Male Fischer 344 and Lewis rats display differences in locomotor reactivity, but not in anxiety–related behaviours: relationship with the hippocampal serotonergic system. Chaouloff F, et al. **Brain Res** 1995 Sep 25;693(1–2):169–78
Cholecystokinin and anxiety: promises and pitfalls. Rodgers RJ, et al. **Crit Rev Neurobiol** 1995;9(4):345–69 (202 ref.)
Comparative study of pre– and postsynaptic 5–HT1A receptor modulation of anxiety in two ethological animal tests. File SE, et al. **J Neurosci** 1996 Aug 1;16(15):4810–5
The relationships of anxiety and self–attention to running economy in competitive male distance runners. Martin JJ, et al. **J Sports Sci** 1995 Oct;13(5):371–6
Evaluation of animal welfare by the self–expression of an anxiety state. Carey MP, et al. **Lab Anim** 1995 Oct; 29(4):370–9
Effects of dietary alpha–linolenic acid deficiency on neuromuscular and cognitive functions in mice. Francès H, et al. **Life Sci** 1995;57(21):1935–47
Influence of eye orientation on pain as a function of anxiety. Honoré J, et al. **Pain** 1995 Nov;63(2):213–8
Cutaneous thresholds and anxiety: influence of eye orientation and lateral asymmetry. Naveteur J, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):707–16
Stress and the immune system in the etiology of anxiety and depression. Leonard BE, et al. **Pharmacol Biochem Behav** 1996 May;54(1):299–303 (74 ref.)
Acute stress markers in humans: response of plasma glucose,

cortisol and prolactin to two examinations differing in the anxiety they provoke. Armario A, et al. **Psychoneuroendocrinology** 1996 Jan;21(1):17–24

Cerebral tryptophan hydroxylase activity, and 5-HT1A receptor, 5-HT2A receptor, and 5-HT transporter binding in grouped and isolated Roman RHA and RLA rats: relationships with behaviours in two models of anxiety. Kulikov A, et al. **Psychopharmacology (Berl)** 1995 Oct; 121(3):385–95

[Selection of anxious mice by three-stage testing in a elevated cross maze] Lapin IP, et al. **Biull Eksp Biol Med** 1996 Mar; 121(3):355–6 **(Rus)**

[The dependence of the heart rhythm on anxiousness as a stable individual characteristic] Danilova NN, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul–Aug; 45(4):647–60 (Eng. Abstr.) **(Rus)**

[The bioelectrical correlates of the personality anxiousness of 2 strong types of higher nervous activity] Kalashnikova IG, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul–Aug;45(4):661–8 (Eng. Abstr.) **(Rus)**

[The role of the neurochemical mechanisms of the basolateral amygdaloid nucleus in anxiety states of different aversive origins] Talalaenko AN, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):184–7 **(Rus)**

PREVENTION & CONTROL

Effects of intraoperative progress reports on anxiety levels of surgical patients' family members. Leske JS. **Appl Nurs Res** 1995 Nov;8(4):169–73

Opening Pandora's box: the unpredictability of reassurance by a normal test result [see comments] McDonald IG, et al. **BMJ** 1996 Aug 10;313(7053):329–32. Comment in: BMJ 1996 Aug 10;313(7053):311–2.

Referral for x-ray [letter] Neal RD. **Br J Gen Pract** 1994 Sep;44(386):427–8

Information about diagnosis and prognosis related to anxiety and depression in children with cancer aged 8–16 years. Last BF, et al. **Eur J Cancer** 1996 Feb;32A(2):290–4

The effect of the amount of feedback on anxiety levels during ultrasound scanning. Zlotogorski Z, et al. **J Clin Ultrasound** 1996 Jan;24(1):21–4

Reducing the anxiety of children undergoing surgery: parental presence during anaesthetic induction. Cameron JA, et al. **J Paediatr Child Health** 1996 Feb;32(1):51–6

Premenstrual syndrome [letter; comment] Cohen SI. **Lancet** 1996 Jan 13;347(8994):122. Comment on: Lancet 1995 Dec 2;346(8988):1443–4.

[Diazepam eliminates the anxious state induced by amputation of the vibrissae (a model for assessing anxious behavior)] Kozlovskiĭ VL, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Sep–Oct; 45(5):1057–61 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Social physique anxiety, body esteem, and social anxiety in bodybuilders and self-reported anabolic steroid users. Schwerin MJ, et al. **Addict Behav** 1996 Jan–Feb;21(1):1–8

The Chinese Gender Role Stress scales. Factor structure and predictive validity. Tang CS, et al. **Behav Modif** 1996 Jul; 20(3):321–37

Origins of common fears: effects on severity, anxiety responses and memories of onset. Withers RD, et al. **Behav Res Ther** 1995 Nov;33(8):903–15

Visual ERPs evidence for enhanced processing of threatening information in anxious university students. Weinstein AM. **Biol Psychiatry** 1995 Jun 15;37(12):847–58

More than just a game: research developments and issues in competitive anxiety in sport. Jones G. **Br J Psychol** 1995 Nov;86 (Pt 4):449–78 (190 ref.)

Anxiety responses to maximal exercise testing. O'Connor PJ, et al. **Br J Sports Med** 1995 Jun;29(2):97–102

Anxiety induced by simulated public speaking and stroop color word test in healthy subjects: effects of different trait-anxiety levels. Palma SM, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2895–902

How schoolchildren propose to negotiate: the role of social withdrawal, social anxiety, and locus of control. Adalbjarnardottir S. **Child Dev** 1995 Dec;66(6):1739–51

Anxiety and the processing of emotionally threatening stimuli: distinctive patterns of selective attention among high- and low-test-anxious children. Vasey MW, et al. **Child Dev** 1996 Jun;67(3):1173–85

Only children and children with siblings in the People's Republic of China: levels of fear, anxiety, and depression. Yang B, et al. **Child Dev** 1995 Oct;66(5):1301–11

Life events as correlates of burden in spouse caregivers of persons with Alzheimer's disease. Russo J, et al. **Exp Aging Res** 1995 Jul–Sep;21(3):273–94

Personality change in dementia of the Alzheimer's type: relations to caregiver personality and burden. Welleford EA, et al. **Exp Aging Res** 1995 Jul–Sep;21(3):295–314

Processing of threat-related information by women with bulimic eating attitudes. Waller G, et al. **Int J Eat Disord** 1995 Sep;18(2):189–93

Anxiety, depression, and the anticipation of future positive and negative experiences. MacLeod AK, et al. **J Abnorm Psychol** 1996 May;105(2):286–9

Anxiety sensitivity, suffocation fear, and breath-holding duration as predictors of response to carbon dioxide challenge. McNally RJ, et al. **J Abnorm Psychol** 1996 Feb; 105(1):146–9

Anxiety and the use of strategies in the performance of a sentence-picture verification task. Richards A, et al. **J Abnorm Psychol** 1996 Feb;105(1):132–6

Effects of focus of attention on anxiety levels and social performance of individuals with social phobia. Woody SR. **J Abnorm Psychol** 1996 Feb;105(1):61–9

4.5 to 7 years: fearful behaviour, fears and worries. Stevenson-Hinde J, et al. **J Child Psychol Psychiatry** 1995 Sep;36(6):1027–38

Re: Spinal phobia: survey results of patient attitudes and preferences regarding anesthesia [letter] Parnass SM, et al. **J Clin Anesth** 1996 Jun;8(4):340

Depressed and anxious moods mediate relations among perceived socialization, self-focused attention, and dysfunctional attitudes. Oliver JM, et al. **J Clin Psychol** 1995 Nov;51(6):726–39

Stress and anxious-depressed symptoms among adolescents: searching for mechanisms of risk. Grant KE, et al. **J Consult Clin Psychol** 1995 Dec;63(6):1015–21

Maternal anxiety during pregnancy: effect on fetal behavior at 38 to 40 weeks of gestation. Groome LJ, et al. **J Dev Behav Pediatr** 1995 Dec;16(6):391–6

Training in early cancer detection and anxiety in adolescent males: a preliminary report. Weist MD, et al. **J Dev Behav Pediatr** 1996 Apr;17(2):98–9

Validation of the Radimer/Cornell measures of hunger and food insecurity. Kendall A, et al. **J Nutr** 1995 Nov; 125(11):2793–801

Effect of imagery on children's pain and anxiety during cardiac catheterization. Pederson C. **J Pediatr Nurs** 1995 Dec;10(6):365–74

Assessing filial maturity through the use of the Filial Anxiety Scale. Murray PD, et al. **J Psychol** 1995 Sep;129(5):519–29

The relationship of death anxiety with age and psychosocial maturity. Rasmussen CA, et al. **J Psychol** 1996 Mar; 130(2):141–4

A controlled study of anxiety and morbid cognitions at initial screening for human immunodeficiency virus (HIV) in a cohort of people with haemophilia. Jones QJ, et al. **J Psychosom Res** 1995 Jul;39(5):597–608

Passionate love and anxiety: a cross-generational study. Wang AY, et al. **J Soc Psychol** 1995 Aug;135(4):459–70

Public and private attributions to luck as a function of social anxiety. Whitehead GI 3rd, et al. **J Soc Psychol** 1995 Aug; 135(4):537–9

Hemisphere asymmetry and the processing of emotional words in anxiety. Richards A, et al. **Neuropsychologia** 1995 Jul;33(7):835–41

Children's preoperative coping and its effects on postoperative anxiety and return to normal activity. LaMontagne LL, et al. **Nurs Res** 1996 May-Jun;45(3):141–7

Affect in diabetic women during pregnancy and postpartum. York R, et al. **Nurs Res** 1996 Jan–Feb;45(1):54–6

Effects of positive attitude toward giving a speech on cardiovascular and subjective fear responses during speech in anxious subjects. Hu S, et al. **Percept Mot Skills** 1995 Oct;81(2):609–10

Effects of Intervention upon precompetition state anxiety in elite junior tennis players: the relevance of the matching hypothesis. Terry P, et al. **Percept Mot Skills** 1995 Aug; 81(1):287–96

Discriminant effectiveness of psychological state measures in predicting selection during field hockey trials. Terry PC, et al. **Percept Mot Skills** 1996 Apr;82(2):371–7

Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Cole JC, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):473–8

The influence of open arm ledges and maze experience in the elevated plus-maze. Fernandes C, et al. **Pharmacol Biochem Behav** 1996 May;54(1):31–40

Recent developments in anxiety, stress, and depression. File SE. **Pharmacol Biochem Behav** 1996 May;54(1):3–12 (156 ref.)

Behavioural and neurochemical responses of male and female chicks to cat odour. Fluck E, et al. **Pharmacol Biochem Behav** 1996 May;54(1):85–91

Role of 5-HT in stress, anxiety, and depression. Graeff FG, et al. **Pharmacol Biochem Behav** 1996 May;54(1):129–41 (112 ref.)

The elevated plus-maze is not sensitive to the effect of stressor controllability in rats. Grahn RE, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):565–70

Exploration and predation models of anxiety: evidence from laboratory and wild species. Hendrie CA, et al. **Pharmacol Biochem Behav** 1996 May;54(1):13–20 (56 ref.)

A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Hogg S. **Pharmacol Biochem Behav** 1996 May;54(1):21–30 (56 ref.)

Mineralocorticoid and glucocorticoid receptor antagonists in animal models of anxiety. Korte SM, et al. **Pharmacol Biochem Behav** 1996 May;54(1):261–7

Modulation of plus-maze behaviour in mice by the preferential D3-receptor agonist 7-OH-DPAT. Rodgers RJ, et al. **Pharmacol Biochem Behav** 1996 May;54(1):79–84

Plus-maze retest profile in mice: importance of initial stages of trail 1 and response to post-trail cholinergic receptor blockade. Rodgers RJ, et al. **Pharmacol Biochem Behav** 1996 May;54(1):41–50

Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Rodgers RJ, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):297–303

Abnormal behaviors in the stargazer rat are maladaptive, but not anxiety related. Brock JW, et al. **Physiol Behav** 1996 Apr-May;59(4–5):1011–4

Behavior of the Roman/Verh high- and low-avoidance rat lines in anxiety tests: relationship with defecation and self-grooming. Ferré P, et al. **Physiol Behav** 1995 Dec; 58(6):1209–13

Arm width and brightness modulation of spontaneous behaviour of two strains of mice tested in the elevated plus-maze. Lamberty Y, et al. **Physiol Behav** 1996 Mar; 59(3):439–44

Questions of parental anxiety [editorial; comment] Ferguson-Smith MA. **Prenat Diagn** 1995 Dec; 15(13):1209–13. Comment on: Prenat Diagn 1995 Dec;15(13):1215–26. Comment on: Prenat Diagn 1995 Dec;15(13):1227–40. Comment on: Prenat Diagn 1995 Dec;15(13):1241–57. Comment on: Prenat Diagn 1995 Dec;15(13):1275–95. Comment on: Prenat Diagn 1995 Dec;15(13):1297–302. Comment on: Prenat Diagn 1995 Dec;15(13):1303–11.

Psychological response to cervical screening. Bell S, et al. **Prev Med** 1995 Nov;24(6):610–6

Of creatures large and small: size anxiety, psychic size, shame, and the analytic situation. Kilborne B. **Psychoanal Q** 1995 Oct;64(4):672–90 (24 ref.)

An artist's defense against the fear of loss of creativity toward the end of life. Viederman M. **Psychoanal Q** 1995 Oct; 64(4):691–8

Doctor-assisted suicide: psychoanalysis of mass anxiety. Bracher M. **Psychoanal Rev** 1995 Oct;82(5):655–68; discussion 703–7

The relationship between suggestibility and anxiety among suspects detained at police stations. Gudjonsson GH, et al. **Psychol Med** 1995 Jul;25(4):875–8

Reconstruction and augmentation patients' reaction to the media coverage of silicone gel-filled implants: anxiety evaluated. Anderson RC, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1323–30

Smoking and trait anxiety. Farley J, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):858

The Multidimensional Perfectionism Scale: correlations with depression in college students with learning disabilities. Saddler CD, et al. **Psychol Rep** 1995 Oct;77(2):483–90

Performance anxiety among professional musicians in symphonic orchestras: a self-report study. van Kemenade JF, et al. **Psychol Rep** 1995 Oct;77(2):555–62

Anxiety: a potential predictor of vulnerability to the initiation of ethanol self-administration in rats. Spanagel R, et al. **Psychopharmacology (Berl)** 1995 Dec;122(4):369–73

Activation in novice and expert parachutists while jumping. Roth WT, et al. **Psychophysiology** 1996 Jan;33(1):63–72

Cardiovascular risk factors in depression. The role of anxiety and anger. Fava M, et al. **Psychosomatics** 1996 Jan–Feb; 37(1):31–7

[Anxiety and reconstructive surgery in children and adolescents] de Carmoy R. **Psychiatr Enfant** 1995; 38(1):141–202 (Eng. Abstr.) **(Fre)**

[Interaction of differential anxiety states with analytic cognitive style] Otto JH, et al. **Z Exp Psychol** 1995; 42(2):302–23 (Eng. Abstr.) **(Ger)**

[Breech presentation—information, anxiety and pattern of expectations of established obstetricians and pregnant patients. 2: Results of a survey of women with breech presentation] Fischer T, et al. **Z Geburtshilfe Neonatol** 1996 Mar-Apr;200(2):61–5 (Eng. Abstr.) **(Ger)**

[The relationship between work factors and psychiatric symptoms—a comparison between anxiety and depression] Tsukamoto K, et al. **Sangyo Eiseigaku Zasshi** 1995 Sep; 37(5):329–36 (Eng. Abstr.) **(Jpn)**

[Anxiety and depression in type II diabetics] Bundó Vidiella M, et al. **Aten Primaria** 1996 Jan;17(1):58–62 (Eng. Abstr.) **(Spa)**

THERAPY

The effect of humorous and musical distraction on preoperative anxiety. Gaberson KB. **AORN J** 1995 Nov; 62(5):784–8, 790–1

The efficacy of complaints management training in facilitating benzodiazepine withdrawal. Elsesser K, et al. **Behav Res Ther** 1996 Feb;34(2):149–56

The influence of personal message with music on anxiety and side effects associated with chemotherapy. Sabo CE, et al. **Cancer Nurs** 1996 Aug;19(4):283–9

Presurgical anxiety treated with cognitive behavioral therapy in a 13-year-old female with cleft lip and palate: a psychological case report. Whitehead TD, et al. **Cleft Palate Craniofac J** 1996 May;33(3):258–61

Phobic and anxiety conditions—diagnosis and therapy. Vlahova-Nikolova V, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):84

Anxiety and its control. Morse DR. **Int J Psychosom** 1995; 42(1–4):54–64 (40 ref.)

Eye movement desensitization of public-speaking anxiety: a partial dismantling. Foley T, et al. **J Behav Ther Exp Psychiatry** 1995 Dec;26(4):321–9

Eye movement desensitization and reprocessing in the treatment of test anxiety: a study of the effects of expectancy and eye movement. Gosselin P, et al. **J Behav Ther Exp Psychiatry** 1995 Dec;26(4):331–7

Sundown syndrome: etiology and management. Burney-Puckett M.

J Psychosoc Nurs Ment Health Serv 1996 May;34(5):40–3 (15 ref.)
Recognition and management of anxiety and depression in elderly patients [see comments] Martin LM, et al. **Mayo Clin Proc** 1995 Oct;70(10):999–1006 (09 ref.). Comment in: Mayo Clin Proc 1996 Apr;71(4):424.
[A study on the mechanism of anxiety reduction through training: a comparison and examination of the stress-model and the distraction-model] Ikezuki M, et al. **Shinrigaku Kenkyu** 1996 Apr;67(1):9–17 (Eng. Abstr.) **(Jpn)**

ANXIETY, CASTRATION

ETHNOLOGY

[Castration anxiety and oral envy in sexual relations. Analytic studies with ethnological observations] Gerlach A. **Psyche (Stuttg)** 1995 Sep-Oct;49(9–10):965–88 (Eng. Abstr.) **(Ger)**

ANXIETY, DENTAL see **DENTAL ANXIETY**

ANXIETY DISORDERS

Anxiety disorders in children and adolescents. Black B. **Curr Opin Pediatr** 1995 Aug;7(4):387–91 (32 ref.)
Common anxiety disorders in children and adolescents. Martini DR. **Curr Probl Pediatr** 1995 Oct;25(9):271–80 (54 ref.)
Serotonin receptors and their function in sleep, anxiety disorders and depression. Leonard BE. **Psychother Psychosom** 1996 Mar-Apr;65(2):66–75 (75 ref.)

CEREBROSPINAL FLUID

Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Fossey MD, et al. **Biol Psychiatry** 1996 Apr 15;39(8):703–7

CHEMICALLY INDUCED

Anxiety sensitivity [letter; comment] Fava GA. **Am J Psychiatry** 1996 Aug;153(8):1109–10. Comment on: Am J Psychiatry 1995 Aug;152(8):1156–60.
Functional anatomy of CCK-induced anxiety in normal volunteers [letter] Rauch SL, et al. **Am J Psychiatry** 1996 Sep;153(9):1238–9
Neurotoxicity related to the use of topical tretinoin (Retin-A). Bernstein AL, et al. **Ann Intern Med** 1996 Jan 15;124(2):227–8
Isatin, a putative anxiogenic endocoid, induces memory dysfunction in rats. Satyan KS, et al. **Indian J Exp Biol** 1995 Aug;33(8):576–9
Major depression and anxiety disorders associated with Norplant. Wagner KD. **J Clin Psychiatry** 1996 Apr; 57(4):152–7
Serotonin, psilocybin, and body dysmorphic disorder: a case report [letter] Hanes KR. **J Clin Psychopharmacol** 1996 Apr;16(2):188–9
Thioridazine withdrawal-induced behavioral deterioration treated with clonidine: two case reports. Sovner R. **Ment Retard** 1995 Aug;33(4):221–5

COMPLICATIONS

Psychiatric comorbidity: prevalence in methadone maintenance treatment. Milby JB, et al. **Am J Drug Alcohol Abuse** 1996 Feb;22(1):95–107
Relationship between ADHD and anxiety in boys: results from a family study. Perrin S, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug;35(8):988–96
Burning mouth syndrome: the relationship between the HAD scale and parafunctional habits. Paterson AJ, et al. **J Oral Pathol Med** 1995 Aug;24(7):289–92
The effect of anxiety and depression on completion/withdrawal status in patients admitted to substance abuse detoxification program. Araujo L, et al. **J Subst Abuse Treat** 1996 Jan-Feb;13(1):61–6
Psychiatric aspects of chronic pain. Eisendrath SJ. **Neurology** 1995 Dec;45(12 Suppl 9):S26–34; discussion S35–6 (36 ref.)
Feeling hopeless and helpless. When anxiety symptoms coexist with depressive disorder. Nesse RE. **Postgrad Med** 1996 Aug;100(2):163–6, 171–2, 175–7 (21 ref.)

DIAGNOSIS

Discriminant validity of the inventory to diagnose depression, lifetime version. Sakado K, et al. **Acta Psychiatr Scand** 1996 Apr;93(4):257–60
Can the Hospital Anxiety and Depression (HAD) Scale be used on Chinese elderly in general practice? Lam CL, et al. **Fam Pract** 1995 Jun;12(2):149–54
Psychiatric evaluation of physical rehabilitation patients. Aoki T, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):440–3
Anxiety in medically ill older patients: a review and update. Hocking LB, et al. **Int J Psychiatry Med** 1995;25(3):221–38 (74 ref.)
Tripartite structure of positive and negative affect, depression, and anxiety in child and adolescent psychiatric inpatients. Joiner TE Jr, et al. **J Abnorm Psychol** 1996 Aug; 105(3):401–9
Anxiety sensitivity and depression: how are they related? Taylor S, et al. **J Abnorm Psychol** 1996 Aug;105(3):474–9
Structure of anxiety and the anxiety disorders: a hierarchical model. Zinbarg RE, et al. **J Abnorm Psychol** 1996 May; 105(2):181–93
Personality dimensions in panic disorder and generalized anxiety disorder. Starcevic V, et al. **J Affect Disord** 1996 Apr 12;37(2–3):75–9
A self-report diagnostic measure of generalized anxiety disorder. Roemer L, et al. **J Behav Ther Exp Psychiatry** 1995 Dec;26(4):345–50
Anxiety and depressive symptom identification using the Duke Health Profile. Parkerson GR, et al. **J Clin Epidemiol** 1996 Jan;49(1):85–93
Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler HR. **J Clin Psychiatry** 1996;57 Suppl 7:15–21; discussion 22–4 (60 ref.)
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. Mintzer JE, et al. **J Clin Psychiatry** 1996;57 Suppl 7:55–63; discussion 73–5 (79 ref.)
Overview of generalized anxiety disorder in the elderly. Schneider LS. **J Clin Psychiatry** 1996;57 Suppl 7:34–45; discussion 52–4 (56 ref.)
The effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic. Tsuang D, et al. **J Clin Psychiatry** 1995 Dec;56(12):549–55
The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. Warshaw MG, et al. **J Clin Psychiatry** 1996 Apr;57(4):158–66
Sensitivity of clinically hospitalized adolescents' self-report measures to change over time. Nelson WM 3rd, et al. **J Clin Psychol** 1995 Nov;51(6):753–60
Measurement-induced improvement in anxiety: mean shifts with repeated assessment. Knowles ES, et al. **J Pers Soc Psychol** 1996 Aug;71(2):352–63
Examining comorbidity and posttraumatic stress disorder in a Vietnam veteran population using the MMPI-2. Weyermann AG, et al. **J Trauma Stress** 1996 Apr; 9(2):353–60
Trait and state anxiety before and after competitive performance. Halvari H, et al. **Percept Mot Skills** 1995 Dec; 81(3 Pt 2):1059–74
The structure of common psychiatric symptoms: how many dimensions of neurosis? Ormel J, et al. **Psychol Med** 1995 May;25(3):521–30
Procedural validity of the computerized version of the Composite International Diagnostic Interview (CIDI-Auto) in the anxiety disorders. Peters L, et al. **Psychol Med** 1995 Nov;25(6):1269–80
Scores of Brazilian University students on the Beck Depression and the State Trait Anxiety Inventories. Gorenstein C, et al. **Psychol Rep** 1995 Oct;77(2):635–41
Practice patterns in the diagnosis and treatment of anxiety and depression in the medically ill. A survey of psychiatrists. Epstein SA, et al. **Psychosomatics** 1996 Jul-Aug;37(4):356–67
Death anxiety, locus of control, and purpose in life of physicians. Their relationship to patient death notification. Viswanathan R. **Psychosomatics** 1996 Jul-Aug;37(4):339–45
[Anxious-excited depression: a mixed affective syndrome] Koukopoulos A, et al. **Encephale** 1995 Dec;21 Spec No 6:33–6 (21 ref.) (Eng. Abstr.) **(Fre)**
[Porphyria variegata. Apropos of a case] Virgili P, et al. **Encephale** 1995 Nov-Dec;21(6):467–71 (Eng. Abstr.) **(Fre)**
[Suicidal ideation in depressed patients with concomitant anxiety symptoms] Keller F. **Psychiatr Prax** 1996 May; 23(3):135–8 (Eng. Abstr.) **(Ger)**
[The "Patient Anxiety Seminar" as a graduate education program—effectiveness and use in general practice] Perkonigg A, et al. **Z Arztl Fortbild (Jena)** 1995 Aug; 89(4):370–7 (Eng. Abstr.) **(Ger)**
[Anxiety disorders in the elderly—diagnostic problems and therapeutic prospects] Boerner RJ. **Z Gerontol Geriatr** 1995 Nov-Dec;28(6):435–43 (48 ref.) (Eng. Abstr.) **(Ger)**
[Assessment of sexuality in patients diagnosed as having an anxiety attack-induced disorder (sexuality in patients with anxiety-induced disorder] Sanz-Carrillo C, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1994 May-Jun;22(3):131–6 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Azapirones: an alternative to benzodiazepines for anxiety. Cadieux RJ. **Am Fam Physician** 1996 May 15;53(7):2349–53 (23 ref.)
Hepatitis secondary to fluoxetine treatment [letter] Friedenberg FK, et al. **Am J Psychiatry** 1996 Apr; 153(4):580
Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disorders [letter] Papp LA, et al. **Am J Psychiatry** 1995 Oct;152(10):1531
Treatment of palilalia with trazodone [letter] Serra-Mestres J, et al. **Am J Psychiatry** 1996 Apr;153(4):580–1
Inappropriate guilt over benzodiazepine prescription [letter; comment] Reynolds RD. **Arch Fam Med** 1996 Jan;5(1):9 . Comment on: Arch Fam Med 1995 Jul;4(7):576.
The psychopharmacology of anxiety. Nutt DJ. **Br J Hosp Med** 1996 Feb 21-Mar 5;55(4):187–91 (19 ref.)
Setting the record straight [letter] Shandera R. **Can Fam Physician** 1996 May;42:852
Effects of alprazolam on glucose regulation in diabetes. Results of double-blind, placebo-controlled trial. Lustman PJ, et al. **Diabetes Care** 1995 Aug;18(8):1133–9
Guidelines on psychotropic drugs for the EC. Clinical investigation of medicinal products in the treatment of generalized anxiety disorder, panic disorder and obsessive-compulsive disorder. **Eur Neuropsychopharmacol** 1995 Jun;5(2):151–5
Acute confusion in a chronic benzodiazepine patient. Withdrawal-related nonconvulsive status epilepticus misdiagnosed as acute intoxication [letter] Primavera A, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):460–2
Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder. Mandos LA, et al. **Int Clin Psychopharmacol** 1995 Nov;10(4):251–6
Therapeutic efficacy of antidepressants in agitated anxious depression—a meta-analysis of moclobemide studies. Delini-Stula A, et al. **J Affect Disord** 1995 Oct 9; 35(1–2):21–30
International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: II. Pharmacotherapy of anxiety disorders. Uhlenhuth EH, et al. **J Affect Disord** 1995 Dec 18; 35(4):153–62
A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. Castaneda R, et al. **J Clin Psychiatry** 1996 May;57(5):207–12 (82 ref.)
Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler HR. **J Clin Psychiatry** 1996;57 Suppl 7:15–21; discussion 22–4 (60 ref.)
Benzodiazepine use in anxiety disordered patients with and without a history of alcoholism. Mueller TI, et al. **J Clin Psychiatry** 1996 Feb;57(2):83–9
The long-term management of generalized anxiety disorder: issues and dilemmas. Schweizer E, et al. **J Clin Psychiatry** 1996;57 Suppl 7:9–12; discussion 13–4 (45 ref.)
Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. Sramek JJ, et al. **J Clin Psychiatry** 1996 Jul;57(7):287–91
Epidemiology and psychopharmacology of anxiety in medical patients. Stoudemire A. **J Clin Psychiatry** 1996;57 Suppl 7:64–72; 73–5 (107 ref.)
The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. Zajecka JM. **J Clin Psychiatry** 1996;57 Suppl 2:10–4
A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. Adams JB, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):428–34
I have heard that buspirone regularly affects various blood tests. Is this so? Shader RI. **J Clin Psychopharmacol** 1996 Apr;16(2):194
Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Bourin M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):567–75
Test therapy in the treatment of generalized anxiety disorders with low dose fluspirilene. Wurthmann C, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Oct; 19(6):1049–60
Future directions in anxiolytic pharmacotherapy. Kunovac JL, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):895–909 (90 ref.)
Generalized anxiety disorder. Longitudinal course and pharmacologic treatment. Schweizer E. **Psychiatr Clin North Am** 1995 Dec;18(4):843–57 (76 ref.)
Prescription pattern of antidepressants in out-patient psychiatric practice. Munizza C, et al. **Psychol Med** 1995 Jul;25(4):771–8
International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: III. Clinical features affecting experts' therapeutic recommendations in anxiety disorders. Uhlenhuth EH, et al. **Psychopharmacol Bull** 1995; 31(2):289–96
[Treatment of generalized anxiety: new pharmacologic approaches] Boulenger JP. **Encephale** 1995 Nov-Dec; 21(6):459–66 (51 ref.) (Eng. Abstr.) **(Fre)**
[Differential pharmacologic therapy of generalized anxiety disorders—results of a study with 30 individual case experiments] Wurthmann C, et al. **Fortschr Neurol Psychiatr** 1995 Aug;63(8):303–9 (Eng. Abstr.) **(Ger)**
[Anxiety—compulsiveness—depression. Symposium, Mainz, 8 May 1993] **Nervenarzt** 1993 Sep;64(9 Suppl):1–12 **(Ger)**
[Pharmacotherapy of anxiety disorders] Bitter I. **Orv Hetil** 1995 Nov 5;136(45):2435–9 (19 ref.) (Eng. Abstr.) **(Hun)**

ECONOMICS

The treatment of common mental disorders by a community team based in primary care: a cost-effectiveness study. Goldberg D, et al. **Psychol Med** 1996 May;26(3):487–92

EPIDEMIOLOGY

Models of comorbidity for multifactorial disorders. Neale MC, et al. **Am J Hum Genet** 1995 Oct;57(4):935–53
Body dysmorphic disorder in patients with anxiety disorders

and major depression: a comorbidity study. Brawman-Mintzer O, et al. **Am J Psychiatry** 1995 Nov; 152(11):1665-7

Relationship between alcohol problems and anxiety disorders [letter; comment] Kushner MG. **Am J Psychiatry** 1996 Jan; 153(1):139-40. Comment on: Am J Psychiatry 1994 Dec;151(12):1723-34.

Attention deficit hyperactivity disorder and comorbid disorders: issues of overlapping symptoms. Milberger S, et al. **Am J Psychiatry** 1995 Dec;152(12):1793-9

Relationship of childhood anxiety to adult panic disorder: correlates and influence on course. Pollack MH, et al. **Am J Psychiatry** 1996 Mar;153(3):376-81

Childhood physical and sexual abuse in patients with anxiety disorders and in a community sample. Stein MB, et al. **Am J Psychiatry** 1996 Feb;153(2):275-7

Prevalence of comorbid anxiety disorders in primary care outpatients. Sherbourne CD, et al. **Arch Fam Med** 1996 Jan;5(1):27-34; discussion 35

Comorbidity of anxiety disorders and hypochondriasis considering different diagnostic systems. Bach M, et al. **Compr Psychiatry** 1996 Jan-Feb;37(1):62-7

Comorbidity of anxiety disorders in a multicenter anxiety study. Goisman RM, et al. **Compr Psychiatry** 1995 Jul-Aug; 36(4):303-11

Progress in the epidemiology of anxiety disorders. Eaton WW. **Epidemiol Rev** 1995;17(1):32-8 (55 ref.)

Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Schulz R, et al. **Gerontologist** 1995 Dec;35(6):771-91 (90 ref.)

Generalized anxiety disorder: issues in epidemiology. Brawman-Mintzer O, et al. **J Clin Psychiatry** 1996;57 Suppl 7:3-8 (29 ref.)

Generalized anxiety and mixed anxiety-depression: association with disability and health care utilization. Roy-Byrne PP. **J Clin Psychiatry** 1996;57 Suppl 7:86-91 (33 ref.)

Epidemiology and psychopharmacology of anxiety in medical patients. Stoudemire A. **J Clin Psychiatry** 1996;57 Suppl 7:64-72; 73-5 (107 ref.)

Comorbidity in the anxiety disorders: the use of a life-chart approach. Hunt C, et al. **J Psychiatr Res** 1995 Nov-Dec; 29(6):467-80

Patterns of anxiety and personality disorder comorbidity. Skodol AE, et al. **J Psychiatr Res** 1995 Sep-Oct; 29(5):361-74

Psychiatric disorders in relatives of probands with obsessive-compulsive disorder and co-morbid major depression or generalized anxiety. Black DW, et al. **Psychiatr Genet** 1995 Spring;5(1):37-41

Sex differences in depression: a role for preexisting anxiety. Breslau N, et al. **Psychiatry Res** 1995 Sep 8;58(1):1-12

Family psychiatric screening instruments for epidemiologic studies: pilot testing and validation. Lish JD, et al. **Psychiatry Res** 1995 Jul 28;57(2):169-80

Anxiety disorders lead mental ills in United States [news] **Public Health Rep** 1996 Jul-Aug;111(4):293-4

Identification of depression in a rural general practice. Strauss PR, et al. **S Afr Med J** 1995 Aug;85(8):755-9

Generalized anxiety disorder in stroke patients. A 3-year longitudinal study. Aström M. **Stroke** 1996 Feb;27(2):270-5

ETHNOLOGY

Mental health and health status of elderly Bengalis and Somalis in London. Silveira E, et al. **Age Ageing** 1995 Nov; 24(6):474-80

ETIOLOGY

Research on the treatment of sexually abused children: a review and recommendations. Finkelhor D, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1408-23 (76 ref.)

Affective disturbances in Alzheimer's disease. Bungener C, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1066-71

Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Coplan JD, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20; 93(4):1619-23

[Stress and anxiety] González de Rivera y Revuelta JL. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov-Dec;23(6):310-3 (33 ref.) (Eng. Abstr.) **(Spa)**

[Psychooncology: anxiety] Matias J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov-Dec;23(6):305-9 (26 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Familial vulnerability factors to post-traumatic stress disorder in male military veterans. Reich J, et al. **Acta Psychiatr Scand** 1996 Feb;93(2):105-12

Genetic factors in early separation anxiety: implications for the genesis of adult anxiety disorders. Silove D, et al. **Acta Psychiatr Scand** 1995 Jul;92(1):17-24

Relationship of genetically transmitted alpha EEG traits to anxiety disorders and alcoholism. Enoch MA, et al. **Am J Med Genet** 1995 Oct 9;60(5):400-8

Family psychiatric screening instruments for epidemiologic studies: pilot testing and validation. Lish JD, et al. **Psychiatry Res** 1995 Jul 28;57(2):169-80

HISTORY

[Daniel Paul Schreber, the illness of the Senate president] Peters UH. **Fortschr Neurol Psychiatr** 1995 Dec; 63(12):469-79 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

There's no such thing as the amygdala [editorial] Kirkpatrick B. **Biol Psychiatry** 1996 Mar 1;39(5):309-10

Autonomic characteristics of generalized anxiety disorder and worry. Thayer JF, et al. **Biol Psychiatry** 1996 Feb 15; 39(4):255-66

Anxiety disorders: the role of serotonin. Greist JH. **J Clin Psychiatry** 1996;57 Suppl 6:3-4

Serotonin receptor specificity in anxiety disorders. Lucki I. **J Clin Psychiatry** 1996;57 Suppl 6:5-10 (48 ref.)

Serotonin dysfunction disorders: a behavioral neurochemistry perspective. Petty F, et al. **J Clin Psychiatry** 1996;57 Suppl 8:11-6 (24 ref.)

Cholecystokinin in psychiatric research: a time for cautious excitement. Abelson JL. **J Psychiatr Res** 1995 Sep-Oct; 29(5):389-96 (60 ref.)

The neurobiology of anxiety disorders. Johnson MR, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):681-725 (152 ref.)

Relationship of generalized anxiety symptoms to urinary 5-hydroxyindoleacetic acid and vanillylmandelic acid. Garvey MJ, et al. **Psychiatry Res** 1995 Jun 29;57(1):1-5

PSYCHOLOGY

Family psychiatric histories in male patients with generalized anxiety disorder and major depressive disorder. Reich J. **Ann Clin Psychiatry** 1995 Jun;7(2):71-8

The effects of alcohol consumption on laboratory-induced panic and state anxiety. Kushner MG, et al. **Arch Gen Psychiatry** 1996 Mar;53(3):264-70

"If I feel anxious, there must be danger": ex-consequentia reasoning in inferring danger in anxiety disorders. Arntz A, et al. **Behav Res Ther** 1995 Nov;33(8):917-25

A follow-up study of cognitive bias in generalized anxiety disorder. Mogg K, et al. **Behav Res Ther** 1995 Nov; 33(8):927-35

Specificity of substance use in anxiety-disordered subjects. Goldenberg IM, et al. **Compr Psychiatry** 1995 Sep-Oct; 36(5):319-28

Family functioning in anxiety and eating disorders—a comparative study. Woodside DB, et al. **Compr Psychiatry** 1996 Mar-Apr;37(2):139-43

Anxiety and depression in general practitioners: associations with type of practice, fundholding, gender and other personal characteristics. Chambers R, et al. **Fam Pract** 1996 Apr;13(2):170-3

A troubled youth: relations with somatization, depression and anxiety in adulthood. Portegijs PJ, et al. **Fam Pract** 1996 Feb;13(1):1-11

The mental health pattern of migrants: is there a euphoric period followed by a mental health crisis? Pernice R, et al. **Int J Soc Psychiatry** 1996 Spring;42(1):18-27

Prevalence and improvement in psychopathology in opioid dependent patients participating in methadone maintenance. Musselman DL, et al. **J Addict Dis** 1995; 14(3):67-82

Mesial temporal lobe seizures presenting as anxiety disorders. Young GB, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):352-7

The effects of stress and coping upon the diagnostic intracavernous injection in men with erectile dysfunction. van der Borght W, et al. **J Psychosom Res** 1995 Oct; 39(7):865-73

Psychological adaptation of anxiety disorder patients following repeated exposure to emergency situation. Somer E, et al. **J Trauma Stress** 1996 Apr;9(2):207-21

Hyperventilation syndrome [letter] Naschitz JE, et al. **Lancet** 1996 Sep 14;348(9029):750

An ethologically based, stimulus and gender-sensitive nonhuman primate model for anxiety. Newman JD, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):677-85

Primate models of anxiety. Longitudinal perspectives. Coplan JD, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):727-43 (59 ref.)

The cultural context of anxiety disorders. Kirmayer LJ, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):503-21 (88 ref.)

Anxiety disorders of childhood. Implications for adult psychopathology. Pollock RA, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):745-66 (102 ref.)

The emotional Stroop task and psychopathology. Williams JM, et al. **Psychol Bull** 1996 Jul;120(1):3-24 (95 ref.)

[Social phobia] Oosterbaan DB, et al. **Ned Tijdschr Geneeskd** 1995 Dec 23;139(51):2649-52 **(Dut)**

[Compulsive clinical voyeurism: a special case of medical families] Biéder J. **Ann Med Psychol (Paris)** 1996 Jan; 154(1):67-9 **(Fre)**

[Anxious-depressive state and cognitive deficit in HIV infection] Silvestre D, et al. **Encephale** 1995 Jul-Aug; 21(4):285-8 (Eng. Abstr.) **(Fre)**

[Psychiatric emergencies and pregnancy] Rais M. **Rev Med Suisse Romande** 1996 Apr;116(4):291-4 **(Fre)**

[Anxiety syndrome in vertigo patients. A comparison of neuro-otologic findings in patients with and without anxiety] Aust G. **Laryngorhinootologie** 1995 Oct; 74(10):601-5 (Eng. Abstr.) **(Ger)**

[Psychoanalytic theory and therapy of neurotic anxieties] Thomä H. **Psyche (Stuttg)** 1995 Nov;49(11):1043-67 (Eng. Abstr.) **(Ger)**

[Are pathological (or vital) anxiety and common fear the same experiences? A controlled study] Ramos Brieva JA, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May-Jun;24(3):119-23 (Eng. Abstr.) **(Spa)**

[Assessment of sexuality in patients diagnosed as having an anxiety attack-induced disorder (sexuality in patients with anxiety-induced disorder] Sanz-Carrillo C, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1994 May-Jun;22(3):131-6 (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Regional cerebral blood flow in obsessive-compulsive disordered patients at rest. Differential correlates with obsessive-compulsive and anxious-avoidant dimensions. Lucey JV, et al. **Br J Psychiatry** 1995 Nov;167(5):629-34

REHABILITATION

The impact on unemployment of an intervention to increase recognition of previously untreated anxiety among primary care physicians. Yelin E, et al. **Soc Sci Med** 1996 Apr; 42(7):1069-75

THERAPY

Theoretical foundations of cognitive-behavior therapy for anxiety and depression. Brewin CR. **Annu Rev Psychol** 1996;47:33-57 (90 ref.)

Advances in the psychosocial treatment of anxiety disorders. Implications for national health care. Barlow DH, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):727-35 (117 ref.)

Parent and teacher reports of problem behaviors in child psychiatric inpatients: cross-informant correlations on admission and at 5-month follow-up. Sourander A, et al. **Child Psychiatry Hum Dev** 1995 Winter;26(2):85-95

The efficacy of psychosocial treatments in primary care. A review of randomized clinical trials. Brown C, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):414-24 (43 ref.)

Anxiety and its control. Morse DR. **Int J Psychosom** 1995; 42(1-4):54-64 (40 ref.)

Research on the treatment of sexually abused children: a review and recommendations. Finkelhor D, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1408-23 (76 ref.)

The relevance of the anxiety literature to research on eye movement desensitization [letter] Carrigan MH, et al. **J Behav Ther Exp Psychiatry** 1995 Dec;26(4):365-6

Issues in the transportability of treatment: the case of anxiety disorders in youths. Kendall PC, et al. **J Consult Clin Psychol** 1995 Oct;63(5):702-8 (60 ref.)

The interaction of the alliance and therapy microprocess: a sequential analysis. Sexton HC, et al. **J Consult Clin Psychol** 1996 Jun;64(3):471-80

Treatment of anxiety disorders of childhood. Albano AM, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):767-84 (90 ref.)

Cognitive-behavior therapy for generalized anxiety disorder. Harvey AG, et al. **Psychiatr Clin North Am** 1995 Dec; 18(4):859-70 (55 ref.)

Psychotherapeutic issues in long-term treatment of anxiety disorder patients. Shear MK. **Psychiatr Clin North Am** 1995 Dec;18(4):885-94 (90 ref.)

Anxiety in the elderly. Course and treatment. Sheikh JI, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):871-83 (90 ref.)

Practice patterns in the diagnosis and treatment of anxiety and depression in the medically ill. A survey of psychiatrists. Epstein SA, et al. **Psychosomatics** 1996 Jul-Aug;37(4):356-67

[Cognitive experimental approach to anxiety disorders] Azaïs F. **Encephale** 1995 Sep-Oct;21(5):597-607 (35 ref.) (Eng. Abstr.) **(Fre)**

[What psychotherapy to offer to anxious patients?] Bluchard S, et al. **Union Med Can** 1995 Nov;124(3):14-9 **(Fre)**

[Establishing a healing relationship in a nonverbal manner. Psychotherapy series, 13: Music therapy] Timmermann T. **Fortschr Med** 1996 May 30;114(15):14, 16 **(Ger)**

[Psychiatric treatment in another specialty clinic?] Schneider A, et al. **Psychiatr Prax** 1996 Mar;23(2):101 **(Ger)**

ANXIETY NEUROSES see **ANXIETY DISORDERS**

ANXIETY, SEPARATION

George Bernard Shaw's Pygmalion: a creative response to loss after early childhood trauma. Silvio JR. **J Am Acad Psychoanal** 1995 Summer;23(2):323-34

Animal behavior case of the month. Coprophagy, urination and defecation in the house, and general fearfulness in a dog. Taylor A, et al. **J Am Vet Med Assoc** 1996 Apr 1; 208(7):1026-8

COMPLICATIONS

Factors in the etiology and pathogenesis of panic disorder: revisiting the attachment-separation paradigm. Shear MK. **Am J Psychiatry** 1996 Jul;153(7 Suppl):125-36 (64 ref.)

Psychiatric comorbidity in children after the 1988 earthquake in Armenia. Goenjian AK, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1174-84

Emotional problems during youth as predictors of stature during early adulthood: results from a prospective epidemiologic study. Pine DS, et al. **Pediatrics** 1996 Jun; 97(6 Pt 1):856–63

DIAGNOSIS

Psychiatric comorbidity in children after the 1988 earthquake in Armenia. Goenjian AK, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1174–84

GENETICS

Genetic factors in early separation anxiety: implications for the genesis of adult anxiety disorders. Silove D, et al. **Acta Psychiatr Scand** 1995 Jul;92(1):17–24

PSYCHOLOGY

Crying in separated and non-separated newborns: sound spectrographic analysis. Michelsson K, et al. **Acta Paediatr** 1996 Apr;85(4):471–5

Attachment and separation in young children. Field T. **Annu Rev Psychol** 1996;47:541–61 (45 ref.)

Traits of separation anxiety in boys with gender identity disorder. Zucker KJ, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):791–8

Security of attachment in 8–12-year-olds: a revised version of the Separation Anxiety Test, its psychometric properties and clinical interpretation. Wright JC, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):757–74

Homesickness and the use of a camp infirmary: a preliminary report. Zimmerman DR, et al. **J Dev Behav Pediatr** 1995 Jun;16(3):187–91

Sodium depletion and maternal separation in the suckling rat increase its salt intake when adult. Leshem M, et al. **Physiol Behav** 1996 Jan;59(1):199–204

Repeated maternal separation of preweanling rats attenuates behavioral responses to primary and conditioned incentives in adulthood. Matthews K, et al. **Physiol Behav** 1996 Jan; 59(1):99–107

Mood changes in homesick persons during a holiday trip. A multiple case study. Van Tilburg MA, et al. **Psychother Psychosom** 1996 Mar–Apr;65(2):91–6

[Reflections on international adoption] Laurent A, et al. **Ann Med Psychol (Paris)** 1995 Oct;153(8):528–30; discussion 531 (2 ref.) (Eng. Abstr.) **(Fre)**

[Observation in day care centers for children and infants: reflection on the team role of the psychologist] Mauvais P. **Psychiatr Enfant** 1995;38(1):247–309 (Eng. Abstr.) **(Fre)**

[Case study of an anxious child] Popek L, et al. **Psychiatr Pol** 1995 Jul–Aug;29(4):479–89 (Eng. Abstr.) **(Pol)**

REHABILITATION

[Father-child hospitalization in the separation anxiety] Chabrol H, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Jul–Aug;23(4):223–6 (Eng. Abstr.) **(Spa)**

THERAPY

The role of free movement in separation-individuation. A study of paralysis. Rabenu P, et al. **Psychoanal Study Child** 1995;50:150–67

Helping foster children to mourn past relationships. Samuels SC. **Psychoanal Study Child** 1995;50:308–26

ANXIETY STATES, NEUROTIC see **ANXIETY DISORDERS**

ANXIOLYTIC AGENTS see **ANTI-ANXIETY AGENTS**

ANXIOLYTICS, BENZODIAZEPINE see **ANTI-ANXIETY AGENTS, BENZODIAZEPINE**

AORTA

see related
AORTOGRAPHY
CORONARY ARTERY BYPASS

Detection of ascending aorta thrombi with transesophageal echocardiography in patients with systemic embolization. Belkin RN, et al. **Am Heart J** 1995 Dec;130(6):1294–5

Usefulness of transesophageal echocardiography for positioning the intraaortic balloon pump in the operating room. Nishioka T, et al. **Am J Cardiol** 1996 Jan 1; 77(1):105–6

Laparoscopic radical hysterectomy (type III) with aortic and pelvic lymphadenectomy. Spirtos NM, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1763–7; discussion 1767–8

Management of intraaortic balloon entrapment. Fukushima Y, et al. **Ann Thorac Surg** 1995 Oct;60(4):1109–11

Perfadex is superior to Euro-Collins solution regarding 24-hour preservation of vascular function. Ingemansson R, et al. **Ann Thorac Surg** 1995 Nov;60(5):1210–4

An LDA and flow visualization study of pulsatile flow in an aortic bifurcation model. Naiki T, et al. **Biorheology** 1995 Jan–Feb;32(1):43–59

Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure. Wegner M, et al. **Cardiovasc Res** 1996 Jun; 31(6):891–8

Iatrogenic aorto-coronary venous fistula as a complication of coronary artery bypass surgery: patient report and review of the literature. Calkins JB Jr, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):55–9 (19 ref.)

Inflammatory aneurysm of the ascending aorta mimicking intramural hemorrhage [letter; comment] Federmann M, et al. **Circulation** 1996 Apr 1;93(7):1477–8. Comment on: Circulation 1995 Sep 15;92(6):1376–8. Comment on: Circulation 1995 Sep 15;92(6):1465–72.

Utilization of triple-lumen balloon catheter for occlusion of the ascending aorta during distal aortic arch surgery with hypothermic retrograde cerebral circulation technique through left thoracotomy. Okita Y, et al. **J Card Surg** 1995 Nov;10(6):699–702

Endovascular recanalization of the aorto-iliac segment: imaging and approaches. Criado FJ. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:51–7

Acquired aortopulmonary fistula in pseudoaneurysm of the aorta six years after a Bentall operation. Chevalier P, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1143–4

Traumatic aortopulmonary communication: clinicopathologic correlation. Wang TL, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1136–9

Aortic cannula velocimetry. Groom RC, et al. **Perfusion** 1995 May;10(3):183–8

[Displacement of the guidewire into the arterial system during machine-guided injection via a Y connector] Vogel H. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):166–7 (Ger)

[Atherosclerotic disease of the aorta: a source of thromboembolism] Gur H, et al. **Harefuah** 1996 Mar 1; 130(5):339–43 (34 ref.) **(Heb)**

[Hemoptysis due to aortopulmonary fistula: a case report of successful surgical treatment] Fukumura Y, et al. **Kyobu Geka** 1995 Nov;48(12):1046–9 (Eng. Abstr.) **(Jpn)**

[Clinico-pathological studies and problems on para-aortic lymph node dissection—D4 dissection] Kitamura M, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):302–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Traumatic anastomosis of the aorta and pulmonary artery] Panchenko VM, et al. **Klin Med (Mosk)** 1995;73(6):60 **(Rus)**

ABNORMALITIES

Morphologic features of the interrupted aortic arch in Chinese patients. Lee ML, et al. **Am J Cardiol** 1995 Nov 1;76(12):982–5

Hemangioma, supraumbilical midline raphé, and coarctation of the aorta with a right aortic arch: single causal entity? Kishnani P, et al. **Am J Med Genet** 1995 Oct 23;59(1):44–8

Hypoplasia of cushion ridges in the proximal outflow tract elicits formation of a right ventricle-to-aortic route in retinoic acid-induced complete transposition of the great arteries in the mouse: scanning electron microscopic observations of corrosion cast models. Nakajima Y, et al. **Anat Rec** 1996 May;245(1):76–82

Stenotic origin of an aberrant left subclavian artery from a right-sided aortic arch. A case report. Drnovsek V, et al. **Angiology** 1996 May;47(5):523–9

Avoiding hypoxemia during unifocalization. Mignosa C, et al. **Ann Thorac Surg** 1996 Feb;61(2):715–7

Aortico-left ventricular tunnel in fetuses and infants. Sousa-Uva M, et al. **Ann Thorac Surg** 1996 Jun; 61(6):1805–10

Echocardiographic-anatomical correlations in aorto-left ventricular tunnel. Cook AC, et al. **Br Heart J** 1995 Oct; 74(4):443–8

Anomalous aortic origin of the right coronary artery. An unusual cause of angina pectoris and its surgical correction. Tsang GM, et al. **Eur J Cardiothorac Surg** 1995;9(12):715–6

Increased nuchal translucency in trisomy 21 fetuses: relationship to narrowing of the aortic isthmus. Hyett J, et al. **Hum Reprod** 1995 Nov;10(11):3049–51

Embryological considerations on a multiple vascular anomaly in a child. Puzzolo D, et al. **Ital J Anat Embryol** 1995 Jul–Sep;100(3):125–33

One-stage repair of interrupted aortic arch, ventricular septal defect, and subaortic obstruction in the neonate: a novel approach. Luciani GB, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):348–58

Pulmonary atresia, intact ventricular septum, and major aortopulmonary collaterals: morphogenetic and surgical implications. Luciani GB, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):853–4

Unusual forms of tracheobronchial compression in infants with congenital heart disease. Robotin MC, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):415–23

Use of autogenous aortic and main pulmonary artery flaps for repair of anomalous origin of the right pulmonary artery from the ascending aorta. van Son JA, et al. **J Thorac Cardiovasc Surg** 1996 Mar;111(3):675–6

Unifocalization for pulmonary atresia with ventricular septal defect and major aortopulmonary collateral arteries. Yagihara T, et al. **J Thorac Cardiovasc Surg** 1996 Aug; 112(2):392–402

Gridlock, a localized heritable vascular patterning defect in the zebrafish [see comments] Weinstein BM, et al. **Nat Med** 1995 Nov;1(11):1143–7. Comment in: Nat Med 1995 Nov;1(11):1141–2.

Anomalous origin of coronary artery in association with aorticopulmonary window. D'Souza VJ, et al. **Pediatr Cardiol** 1996 Sep–Oct;17(5):316–8 (12 ref.)

Right aortic arch with retroesophageal left aberrant innominate artery. Moes CAF, et al. **Pediatr Cardiol** 1996 Nov–Dec;17(6):402–6

[Anomalous origin of the right pulmonary artery from the ascending aorta: a case report] Harada Y, et al. **Kyobu Geka** 1995 Oct;48(11):912–4 (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

Effect of hypertension on aortic root size and prevalence of aortic regurgitation. Kim M, et al. **Hypertension** 1996 Jul;28(1):47–52

The mechanical properties of fin whale arteries are explained by novel connective tissue designs. Gosline JM, et al. **J Exp Biol** 1996 Apr;199 (Pt 4):985–97

The position of the aorta in relation to the vertebra in patients with idiopathic thoracic scoliosis. Sevastik B, et al. **Surg Radiol Anat** 1996;18(1):51–6

[Magnetic resonance angiography of the origin of the supraaortic trunks: the tridimensional time-of-flight with single volume technique] Carriero A, et al. **Radiol Med (Torino)** 1996 Jun;91(6):743–6 (Eng. Abstr.) **(Ita)**

CHEMISTRY

Variability in cholesterol content in serum and aortic tissue in apolipoprotein E-deficient mice is comparable in inbred (129/Sv) and outbred (mixed 129/Sv and C57BL/6) mice [letter] van Ree JH, et al. **Atherosclerosis** 1995 Nov; 118(1):165–7

Cytochrome b-558 alpha-subunit cloning and expression in rat aortic smooth muscle cells. Fukui T, et al. **Biochim Biophys Acta** 1995 Oct 10;1231(3):215–9

Distribution of specific substance P binding sites in the heart and adjacent great vessels of the Wistar white rat. Walsh RJ, et al. **Cell Tissue Res** 1996 Jun;284(3):495–500

Platelet-derived growth factor-A mRNA expression in fetal, normal adult, and atherosclerotic human aortas. Analysis by competitive polymerase chain reaction. Murry CE, et al. **Circulation** 1996 Mar 15;93(6):1095–106

Concentration of soluble vascular cell adhesion molecule-1 (VCAM-1) correlated with expression of VCAM-1 mRNA in the human atherosclerotic aorta. Nakai K, et al. **Coron Artery Dis** 1995 Jun;6(6):497–502

Domain structure of heparan sulfates from bovine organs. Maccarana M, et al. **J Biol Chem** 1996 Jul 26; 271(30):17804–10

Comparison of ELISA and HPLC for the determination of desmosine or isodesmosine in aortic tissue elastin. Osakabe T, et al. **J Clin Lab Anal** 1995;9(5):293–6

Age-related changes in G proteins in rat aorta. Mader SL, et al. **J Gerontol A Biol Sci Med Sci** 1996 Mar;51(2):B111–6

Immunohistochemical localization of adrenomedullin in canine heart and aorta. Jougasaki M, et al. **Peptides** 1995; 16(4):773–5

[Evaluation of the toxic effects of cadmium on the body in light of research on the behavior of lipid compounds in aortic walls of animals] Grabowska-Maślanka H, et al. **Folia Med Cracov** 1994;35(1-4):39–44 (Eng. Abstr.) **(Pol)**

CYTOLOGY

Role of plasminogen activator inhibitor in the reciprocal regulation of bovine aortic endothelial and smooth muscle cell migration by TGF-beta 1. Petzelbauer E, et al. **Am J Pathol** 1996 Sep;149(3):923–31

Distribution of epithelioid cells in the wall of the chicken aorta and their functional role as chemoreceptors. Miyoshi M, et al. **Anat Rec** 1995 Jul;242(3):302–9

Tyrosine kinase is involved in angiotensin II-stimulated phospholipase D activation in aortic smooth muscle cells: function of Ca2+ influx. Suzuki A, et al. **Atherosclerosis** 1996 Mar;121(1):119–27

17 beta-Estradiol and smooth muscle cell proliferation in aortic cells of male and female rats. Espinosa E, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):8–14

Aorta-associated CD34+ hematopoietic cells in the early human embryo. Tavian M, et al. **Blood** 1996 Jan 1; 87(1):67–72

Elastic lamina growth in the developing mouse aorta. Davis EC. **J Histochem Cytochem** 1995 Nov;43(11):1115–23

Immunocytochemical study of the degradation of elastic fibers in a living extracellular matrix. Morris SM, et al. **J Histochem Cytochem** 1995 Nov;43(11):1145–53

Rat aortic smooth muscle cells become pericytes during angiogenesis in vitro. Nicosia RF, et al. **Lab Invest** 1995 Nov;73(5):658–66

Gap junctional communication in primary culture of cells derived from human aortic intima. Andreeva ER, et al. **Tissue Cell** 1995 Oct;27(5):591–7

Langhans cells of human arterial intima: uniform by stellate appearance but different by nature. Bobryshev YV, et al. **Tissue Cell** 1996 Apr;28(2):177–94

DRUG EFFECTS

Endothelium-dependent and -independent vasodilation of isolated rat aorta induced by caffeine. Hatano Y, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1679–84

Decreased sensitivity to vasoconstrictors in aortic rings after acute exposure to nitric oxide. Kanagy NL, et al.

Am J Physiol 1996 Jul;271(1 Pt 2):H253–60

Endothelin and nitric oxide release modulate aortic contraction to selected thrombin receptor agonists. Magazine HI, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1815–8

Mechanisms of action of isoflurane on contraction of rabbit conduit artery. Su JY. **Anesth Analg** 1996 Apr;82(4):837–42

Desflurane, sevoflurane, and isoflurane impair canine left ventricular–arterial coupling and mechanical efficiency. Hettrick DA, et al. **Anesthesiology** 1996 Aug;85(2):403–13

Effects of anesthetics and vasodilators on aortic input impedance [letter; comment] Prys-Roberts C, et al. **Anesthesiology** 1996 Feb;84(2):478–9. Comment on: Anesthesiology 1995 Aug;83(2):361–73.

Insulin does not disrupt actin microfilaments, microtubules, and in vitro aortic endothelial wound repair. Eshraghi S, et al. **Biochem Cell Biol** 1995 Jul–Aug;73(7–8):507–14

Tolerance to nitroglycerin in rabbit aorta. Investigating the involvement of the mu isozyme of glutathione S–transferases. Kenkare SR, et al. **Biochem Pharmacol** 1996 May 17;51(10):1357–63

In vitro characterization of a novel series of platelet–derived growth factor receptor tyrosine kinase inhibitors. Sawutz DG, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1631–8

Noradrenaline stimulation of high–affinity GTPase activity in membranes from rat aorta and caudal artery. Weber LP, et al. **Biochem Pharmacol** 1996 Aug 23;52(4):677–84

Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol–fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. Matsuo M, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):254–60

Mode of action of thrombin in the rabbit aorta. Godin D, et al. **Br J Pharmacol** 1995 Jul;115(6):903–8

Characterization of an alpha 1D–adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Kenny BA, et al. **Br J Pharmacol** 1995 Jul;115(6):981–6

Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta. Li Q, et al. **Br J Pharmacol** 1995 Dec;116(7):2963–70

The inhibitory effect of 3–amino–1,2,4–triazole on relaxation induced by hydroxylamine and sodium azide but not hydrogen peroxide or glyceryl trinitrate in rat aorta. Mian KB, et al. **Br J Pharmacol** 1995 Dec;116(8):3302–8

Differential sensitivity of basal and acetylcholine–stimulated activity of nitric oxide to destruction by superoxide anion in rat aorta. Mian KB, et al. **Br J Pharmacol** 1995 Jul;115(6):993–1000

Discrimination by the NO–trapping agent, carboxy–PTIO, between NO and the nitrergic transmitter but not between NO and EDRF. Rand MJ, et al. **Br J Pharmacol** 1995 Sep;116(2):1906–10

Analysis of the activity of alpha 1–adrenoceptor antagonists in rat aorta. Van der Graaf PH, et al. **Br J Pharmacol** 1996 May;118(2):299–310

Characterization of the vasorelaxant activity of tyramine and other phenylethylamines in rat aorta. Varma DR, et al. **Can J Physiol Pharmacol** 1995 Jun;73(6):742–6

Pharmacological investigation of signaling mechanisms contributing to phasic and tonic components of the contractile response of rat arteries to noradrenaline. Weber LP, et al. **Can J Physiol Pharmacol** 1995 May;73(5):594–601

Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. Breithaupt–Grögler K, et al. **Cardiovasc Drugs Ther** 1996 Mar;10(1):49–57

Decrease in Ca2+ sensitivity as a mechanism of hydrogen peroxide–induced relaxation of rabbit aorta. Iesaki T, et al. **Cardiovasc Res** 1996 May;31(5):820–5

alpha 1–Adrenoceptors on rabbit aortic smooth muscle cells in culture and in experimental intimal thickening. Manderson JA, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):912–8

Vasodilatory responses of isolated arteries of cirrhotic rats. Lee SS, et al. **Clin Sci (Colch)** 1995 Sep;89(3):227–32

Effects of an endurance training programme on the passive and noradrenaline–activated compliances of rat aorta. Koutsis G, et al. **Eur J Appl Physiol** 1995;71(2–3):173–9

Different alpha1–adrenoceptor subtypes mediate contraction in rabbit aorta and urethra. Auguet M, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):153–61

Characterization of a binding site for angiotensin IV on bovine aortic endothelial cells. Bernier SG, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):191–200

Effects of alpha–trinositol administered extra– and intracellularly (using liposomes) on rat aorta rings. Brailoiu E, et al. **Eur J Pharmacol** 1995 Aug 4;281(2):209–12

Hyporesponsiveness to nitrovasodilators in rat aorta incubated with endotoxin and L–arginine. Tsuchida S, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):251–4

Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gutierrez M, et al. **Gen Pharmacol** 1996 Jan;27(1):171–6

The effect of AL0671, a novel potassium channel opener, on potassium current in rat aortic smooth muscle cells. Matzno S, et al. **Gen Pharmacol** 1995 Oct;26(6):1327–34

Effects of angiotensin II infusion and inhibition of nitric oxide synthase on the rat aorta. Kato H, et al. **Hypertension** 1996 Aug;28(2):153–8

Doppler determined aortic acceleration after dipyridamole in the prediction of coronary artery disease. Dubrey S, et al. **Int J Cardiol** 1995 Aug;51(1):5–14

Short exposure to endotoxin increases the constriction induced by angiotensin II in rat aorta. Rasetti C, et al. **J Appl Physiol** 1995 Dec;79(6):2094–100

Effects of dicentrine on the mechanical properties of systemic arterial trees in dogs. Chang KC, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):169–76

Sustained inhibition of intimal thickening. In vitro and in vivo effects of polymeric beta–cyclodextrin sulfate. Bachinsky WB, et al. **J Clin Invest** 1995 Dec;96(6):2583–92

Effects of photodegradation products of nifedipine: the nitroso–derivative relaxes contractions of the rat aortic strip induced by norepinephrine and other agonists. Hayase N, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):813–21

Structure activity relationships of a series of buspirone analogs at alpha–1 adrenoceptors: further evidence that rat aorta alpha–1 adrenoceptors are of the alpha–1D–subtype. Saussy DL Jr, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):136–44

Evidence of a bradykinin B1 receptor in human ileum: pharmacological comparison to the rabbit aorta B1 receptor. Zuzack JS, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1337–43

Protamine–induced hypotension in heart operations: application of the concept of ventricular–arterial coupling. Oe M, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):462–71

Selective inhibition of inducible nitric oxide synthase by agmatine. Auguet M, et al. **Jpn J Pharmacol** 1995 Nov;69(3):285–7

Close correlation between nitric oxide (NO) formation from NO releasers and the biological activities of these agents in rats. Kita Y, et al. **Jpn J Pharmacol** 1995 Sep;69(1):69–74

Thymosin alpha 1 protects liver and aorta from oxidative damage in atherosclerotic rabbits. Gökkusu C, et al. **Life Sci** 1996;59(13):1059–67

Vibrio vulnificus hemolysin dilates rat thoracic aorta by activating guanylate cyclase. Kook H, et al. **Life Sci** 1996;59(3):PL41–7

Inhibition by triptoquinone–A of LPS– and IL–1 beta–primed induction of NO synthase in rat thoracic aorta. Moritoki H, et al. **Life Sci** 1996;59(3):PL49–54

Characteristics and possible mechanisms of low–Na+ induced contractions in rat aorta. Toma CP, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul;352(1):88–93

Effect of ACE inhibitors, calcium channel blockers and their combination on renal and extrarenal structures in renal failure. Amann K, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:33–8

Synthesis of two peptide scorpion toxins and their use to investigate the aortic tissue regulation. Tóth GK, et al. **Peptides** 1995;16(7):1167–72

Vasodilator effects of liriodenine and norushinsunine, two aporphine alkaloids isolated from Annona cherimolia, in rat aorta. Chuliá S, et al. **Pharmacology** 1995 Jun;50(6):380–7

Inhibition of adenosine deaminase activity of aortic endothelial cells by selected flavonoids. Melzig MF. **Planta Med** 1996 Feb;62(1):20–1

Effect of high potassium diets on the vascular and renal prostaglandin system in stroke–prone spontaneously hypertensive rats. Ishimitsu T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct;53(4):255–60

Low–dose aspirin does not attenuate platelet aggregation or atherosclerosis in miniature swine but decreases production of aortic wall prostacyclin. Smith MJ, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov;53(5):331–40

Relationship between contractile responses and cytosolic free calcium levels in response to phorbol ester (PMA) in isolated rat aorta. Kamata K, et al. **Res Commun Mol Pathol Pharmacol** 1995 Dec;90(3):423–6

Further characterization of antagonism by alpha 2–adrenoceptor agonists of contractions induced by alpha 1–adrenoceptor agonists. Nomura S, et al. **Res Commun Mol Pathol Pharmacol** 1996 Apr;92(1):31–42

Inhibition of alpha1–adrenoceptor–mediated contractions in isolated tail arteries and aorta of the rat by alpha2–adrenoceptor agonists. Nomura S, et al. **Res Commun Mol Pathol Pharmacol** 1995 Dec;90(3):307–20

Effects of adenosine tetraphosphate (ATPP) on vascular tone in the isolated rat aorta. Lee JW, et al. **Yonsei Med J** 1995 Dec;36(6):487–96

[Lipid peroxidation and protein glycosylation in the aorta of rabbits with alloxan diabetes during insulin correction] Khegai MD, et al. **Patol Fiziol Eksp Ter** 1995 Oct–Dec;(4):6–7 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Immunohistochemical evaluation of the developing outflow tract in the rat: achieving aortic to mitral fibrous continuity. Jackson M, et al. **Cardiovasc Res** 1995 Aug;30(2):262–9

Development of chicken aortic smooth muscle: expression of cytoskeletal and basement membrane proteins defines two distinct cell phenotypes emerging from a common lineage. Yablonka–Reuveni Z, et al. **Cell Mol Biol Res** 1995;41(4):241–9

Changes in blood flow velocity waveforms following fetal blood sampling. Zoppini C, et al. **Fetal Diagn Ther** 1995 Sep–Oct;10(5):315–21

Ultrastructural alterations caused by immunological reactions after intracardiac injection of allogeneic antibodies against blood group antigens: an experimental study using the in vitro whole–rat embryo culture. van der Zee DC, et al. **Teratology** 1995 Aug;52(2):57–70

ENZYMOLOGY

Human extracellular superoxide dismutase is a tetramer composed of two disulphide–linked dimers: a simplified, high–yield purification of extracellular superoxide dismutase. Oury TD, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):51–7

Hydrolysis of P2–purinoceptor agonists by a purified ectonucleotidase from the bovine aorta, the ATP–diphosphohydrolase. Picher M, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1453–60

Thrombin triggers the de novo expression of an inducible NO synthase in porcine aortic valve endothelial cells. De Meyer E, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):67–72

Regulation of Na+,K+–ATPase alpha–subunit expression by mechanical strain in aortic smooth muscle cells. Songu–Mize E, et al. **Hypertension** 1996 Mar;27(3 Pt 2):827–32

Phosphorylation of the inositol 1,4,5–trisphosphate receptor. Cyclic GMP–dependent protein kinase mediates cAMP and cGMP dependent phosphorylation in the intact rat aorta. Komalavilas P, et al. **J Biol Chem** 1996 Sep 6;271(36):21933–8

Isolation of active site peptides of lysyl oxidase. Kagan HM, et al. **Methods Enzymol** 1995;258:122–32

GROWTH & DEVELOPMENT

Age–related changes of aorta in Syrian hamsters of APA strain. Yamanouchi J, et al. **Histol Histopathol** 1995 Jul;10(3):703–8

Theoretical study of stress–modulated growth in the aorta. Taber LA, et al. **J Theor Biol** 1996 Jun 21;180(4):343–57

IMMUNOLOGY

Restricted usage of T–cell receptor Valpha–Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis. Seko Y, et al. **Circulation** 1996 May 15;93(10):1788–90

INJURIES

Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor–beta activity. Rasmussen LM, et al. **Am J Pathol** 1995 Oct;147(4):1041–8

Occult ascending aortic rupture in the presence of an air bag. Dunn JA, et al. **Ann Thorac Surg** 1996 Aug;62(2):577–8

Simultaneous repair of multiple traumatic aortic tears. Lancey RA, et al. **Ann Thorac Surg** 1995 Oct;60(4):1120–1

Transmediastinal gunshot wounds. A reconsideration of the role of aortography. Cornwell EE 3rd, et al. **Arch Surg** 1996 Sep;131(9):949–52; discussion 952–3

Effects of inflation pressure of balloon catheter on vascular injuries and subsequent development of intimal hyperplasia in rabbit aorta. Asada Y, et al. **Atherosclerosis** 1996 Mar;121(1):45–53

Imaging of traumatic aortic injury [letter; comment] Gordon AC, et al. **Clin Radiol** 1996 Feb;51(2):152. Comment on: Clin Radiol 1995 May;50(5):281–7.

Acute suprarenal aortogastric fistulae caused by gunshot wounds: the importance of early recognition in directing surgical strategy. Caldeira CC, et al. **J Trauma** 1996 May;40(5):838–9

Exclusion of aortic tear in the unstable trauma patient: the utility of transesophageal echocardiography. Cohn SM, et al. **J Trauma** 1995 Dec;39(6):1087–90

A prospective analysis of transesophageal echocardiography in the diagnosis of traumatic disruption of the aorta. Minard G, et al. **J Trauma** 1996 Feb;40(2):225–30

Acute repair of aorta–innominate vein fistulas. Roye GD, et al. **J Trauma** 1995 Oct;39(4):753–6 (12 ref.)

Effect of active oxygen species on intimal proliferation in rat aorta after arterial injury. Gong KW, et al. **J Vasc Res** 1996 Jan–Feb;33(1):42–6

Images in clinical medicine. Nail in the aorta. Felner JM. **N Engl J Med** 1996 Jan 25;334(4):239

Laparoscopy and major retroperitoneal vascular injuries (MRVI). Saville LE, et al. **Surg Endosc** 1995 Oct;9(10):1096–100

Blunt injury to the ascending aorta: three patterns of presentation. Prêtre R, et al. **Surgery** 1996 Jun;119(6):603–10

METABOLISM

Increased expression of 72–kd type IV collagenase (MMP–2) in human aortic atherosclerotic lesions. Li Z, et al. **Am J Pathol** 1996 Jan;148(1):121–8

Expression of NF–kappa B and I kappa B–alpha by aortic endothelium in an arterial injury model. Lindner V, et al. **Am J Pathol** 1996 Feb;148(2):427–38

cAMP evokes a rise in intracellular Na+ mediated by Na+ pump inhibition in rat aortic smooth muscle cells. Borin ML. **Am J Physiol** 1995 Oct;269(4 Pt 1):C884–91

Regulation of Ca(2+)–dependent nitric oxide synthase in bovine aortic endothelial cells. Buckley BJ, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C757–65

Hyperglycemia alters cytoplasmic Ca2+ responses to capacitative Ca2+ influx in rat aortic smooth muscle cells.

Rivera AA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1482–8

The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries. Farrell CL, et al. **Antisense Res Dev** 1995 Fall;5(3):175–83

An increased uptake of prothrombin, antithrombin, and fibrinogen by the rabbit balloon-deendothelialized aorta surface in vivo is maintained until reendothelialization is complete. Hatton MW, et al. **Arterioscler Thromb Vasc Biol** 1996 Sep;16(9):1147–55

Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Mukhin DN, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1607–15

Increased elastin-degrading activity and neointimal formation in porcine aortic organ culture. Reduction of both features with a serine proteinase inhibitor. Oho S, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2200–6

Selective increase in cholesterol at atherosclerosis-susceptible aortic sites after short-term cholesterol feeding. Schwenke DC. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1928–37

Two hypothetical proteins of human aortic adventitia, with Ig kappa, collagenous, and aromatic-rich motifs. Ozsvath KJ, et al. **Biochem Biophys Res Commun** 1996 Aug 14; 225(2):500–4

Differential gene expression of vascular natriuretic peptide receptor subtype in artery and vein. Yoshimoto T, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):535–9

Protease-susceptible sites and properties of fragments of aortic smooth-muscle myosin. King L, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):511–8

Primary structure of bovine aorta biglycan core protein deduced from cloned CDNA. Xu JH, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):263–72

Cloning and pharmacological characterization of a rabbit bradykinin B1 receptor. MacNeil T, et al. **Biochim Biophys Acta** 1995 Nov 7;1264(2):223–8

Changes in the pattern of distribution of von Willebrand factor in rat aortic endothelial cells following thrombin generation in vivo. Senis YA, et al. **Br J Haematol** 1996 Apr;93(1):195–203

The influence of aortic calcification on spinal bone mineral density in vitro. Hoshino H, et al. **Calcif Tissue Int** 1996 Jul;59(1):21–3

Decreased elastin synthesis in normal development and in long-term aortic organ and cell cultures is related to rapid and selective destabilization of mRNA for elastin. Johnson DJ, et al. **Circ Res** 1995 Dec;77(6):1107–13

Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Hamdan AD, et al. **Circulation** 1996 Mar 15;93(6):1073–8

Characterisation of inositol 1,4,5-trisphosphate binding sites in rabbit aortic smooth muscle. Murphy TV, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):145–50

Recycling of the 67-kDa elastin binding protein in arterial myocytes is imperative for secretion of tropoelastin. Hinek A, et al. **Exp Cell Res** 1995 Oct;220(2):312–24

Decreased interleukin-2 production by rat uterine artery, aorta and uterine tissues during pregnancy. Huleihel M, et al. **Hum Reprod** 1996 Jun;11(6):1337–42

Thromboxane A2 and vascular smooth muscle cell proliferation. Sachinidis A, et al. **Hypertension** 1995 Nov; 26(5):771–80

Prostacyclin synthesis elicited by endothelin-1 in rat aorta is mediated by an ETA receptor via influx of calcium and is independent of protein kinase C. Wright HM, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1035–40

Activation of heat shock transcription factor 1 in rat aorta in response to high blood pressure. Xu Q, et al. **Hypertension** 1996 Jul;28(1):53–7

A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. Eto M, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1104–7

The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type 1 complexes. Argraves KM, et al. **J Biol Chem** 1995 Nov 3;270(44):26550–7

Insulin-like growth factor-I (IGF-I) regulates IGF-binding protein-5 synthesis through transcriptional activation of the gene in aortic smooth muscle cells. Duan C, et al. **J Biol Chem** 1996 Feb 23;271(8):4280–8

Steroid-hormone regulation of myosin subunit expression in smooth and cardiac muscle. Calovini T, et al. **J Cell Biochem** 1995 Sep;59(1):69–78

Activation of heat shock protein (hsp)70 and proto-oncogene expression by alpha1 adrenergic agonist in rat aorta with age. Chin JH, et al. **J Clin Invest** 1996 May 15; 97(10):2316–23

Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid. Lindstedt L, et al. **J Clin Invest** 1996 May 15;97(10):2174–82

Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta. Nielsen LB, et al. **J Clin Invest** 1996 Jul 15;98(2):563–71

Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. Tschudi MR, et al. **J Clin Invest** 1996 Aug 15;98(4):899–905

Catabolism of rabbit prothrombin in rabbits: uptake of prothrombin by the aorta wall before and after a de-endothelializing injury in vivo. Hatton MW, et al. **J Lab Clin Med** 1995 Dec;126(6):521–9

Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. Ylitalo R, et al. **J Lab Clin Med** 1996 Feb;127(2):200–6

The expression of alpha 1 adrenoceptor subtypes changes with age in the rat aorta. Gurdal H, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1656–62

Regulation of L-arginine transport and nitric oxide release in superfused porcine aortic endothelial cells. Bogle RG, et al. **J Physiol (Lond)** 1996 Jan 1;490 (Pt 1):229–41

Regional differences in platelet-derived growth factor production by the canine aorta. Madura JA 2nd, et al. **J Vasc Res** 1996 Jan-Feb;33(1):53–61

Decreased PO2 and rabbit aortic smooth muscle mechanics. Moreland RS, et al. **J Vasc Res** 1995 Sep-Oct;32(5):313–9

Androstenedione increases thromboxane A2 receptors in human erythroleukemia cells. Zucker TP, et al. **Life Sci** 1996;58(8):683–90

Osteopontin is a constitutive component of normal elastic fibers in human skin and aorta. Baccarani-Contri M, et al. **Matrix Biol** 1995 Jul;14(7):553–60

Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta [see comments] Grainger DJ, et al. **Nat Med** 1995 Oct;1(10):1067–73. Comment in: Nat Med 1995 Oct;1(10):1001–1.

Free radicals, ceruloplasmin, and copper concentration in serum and aortic tissue in experimental atherosclerosis. Vlad M, et al. **Nutrition** 1995 Sep-Oct;11(5 Suppl):588–91

Lead alters growth and reduces angiotensin II receptor density of rat aortic smooth muscle cells. Carsia RV, et al. **Proc Soc Exp Biol Med** 1995 Nov;210(2):180–90

Effect of 1,25-dihydroxyvitamin D3 and diltiazem on tissue calcium in uremic rat. Inagaki O, et al. **Ren Fail** 1995 Nov; 17(6):651–7

[Interaction of a monoclonal antibody to P-selectin with activated platelets and endothelial cells. Heterogeneity of expressing P-selectin in human aorta endothelial cells] Byzova TV, et al. **Biokhimiia** 1995 Aug;60(8):1292–301 (Eng. Abstr.) **(Rus)**

[Immunocytochemical study to localize a scavenger receptor in human aorta smooth muscle cells] Nazarova VL, et al. **Biull Eksp Biol Med** 1995 Aug;120(8):195–8 **(Rus)**

PATHOLOGY

Sudden death while playing tennis due to a tear in ascending aorta (without dissection) and probable transient compression of the left main coronary artery. Comfort SR, et al. **Am J Cardiol** 1996 Aug 15;78(4):493–5

Estimation of aortic wall sclerosis in hypertension by use of carotid pulse tracing and cine magnetic resonance. Honda T, et al. **Angiology** 1996 Feb;47(2):157–63

Atrophy of the aortic media in giant cell arteritis. Petursdottir V, et al. **APMIS** 1996 Mar;104(3):191–8

Genetic determination of cartilaginous metaplasia in mouse aorta. Qiao JH, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2265–72

Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated. Aviram M, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):501–13

Probucol, but not MaxEPA fish oil, inhibits mononuclear cell adhesion to the aortic intima in the rat model of atherosclerosis. Barbeau ML, et al. **Biochem Cell Biol** 1995 May-Jun;73(5–6):283–8

Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Reidy MA, et al. **Circ Res** 1996 Mar;78(3):405–14

Proteoglycan alterations in the aortic intima-media of alloxan-diabetic rabbits: an ultrastructural and biochemical study. Richardson M, et al. **Exp Mol Pathol** 1995 Jun; 62(3):145–59

Fate of the native aorta after repair of acute type A dissection: a magnetic resonance imaging study. Moore NR, et al. **Heart** 1996 Jan;75(1):62–6

Structural changes and cyclic GMP content of the aorta after calcium antagonism or angiotensin converting enzyme inhibition in renovascular hypertensive rats. Véniant M, et al. **J Hypertens** 1995 Jul;13(7):731–7

Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. Tangirala RK, et al. **J Lipid Res** 1995 Nov; 36(11):2320–8

Diversity of the synthetic-state smooth-muscle cells proliferating in mechanically and hemodynamically injured rabbit arteries. Okamoto E, et al. **Lab Invest** 1996 Jan; 74(1):120–8

Cardiovascular hypertrophy and increased vascular contractile responsiveness following repeated cocaine administration in rabbits. Sutliff RL, et al. **Life Sci** 1996; 58(8):675–82

Magnetic resonance angiography of the aorta and renal arteries. Grist TM. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):253–69 (42 ref.)

Magnetic resonance of the heart and great vessels. de Roos A, et al. **Nat Med** 1995 Jul;1(7):711–3 (6 ref.)

Morphological fate and sequelae of human atherosclerosis: evaluation of immune mechanisms in atherogenesis through immunohistological and ultrastructural analysis. Shimokama T, et al. **Pathol Int** 1995 Nov;45(11):801–14

Magnetic resonance imaging demonstration of "remodeling" of the aorta following balloon angioplasty of discrete native coarctation. Weber HS, et al. **Pediatr Cardiol** 1996 May-Jun;17(3):184–8

Effect of MC1288, a vitamin D analogue, on lymphocyte proliferation in vitro and rat aortic allograft arteriosclerosis in vivo. Räisänen-Sokolowski A, et al. **Transplant Proc** 1996 Apr;28(2):919

The aortic width as an index of hypertension--how specific? Okeahialam BN. **West Afr J Med** 1995 Jul-Sep;14(3):165–8

[Annular ectasia of the aorta in a patient with acquired cutis laxa (letter)] Chavanon O, et al. **Presse Med** 1996 Feb 17; 25(6):261 **(Fre)**

[Magnetic resonance imaging in assessing the complications of cardiac surgery involving the ascending aorta] Fedriga E, et al. **Radiol Med (Torino)** 1995 Sep;90(3):238–43 (Eng. Abstr.) **(Ita)**

[Study of atherosclerosis regression in the elderly--central depression and its correlation to ulcerated plaques] Kakiuchi H, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jul; 32(7):503–10 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Determinants of stroke volume and systolic and diastolic aortic pressure. Stergiopulos N, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2050–9

Propofol alters left ventricular afterload as evaluated by aortic input impedance in dogs. Lowe D, et al. **Anesthesiology** 1996 Feb;84(2):368–76

Prostacyclin for spinal cord protection during aortic occlusion [letter] Katircioğlu SF, et al. **Ann Thorac Surg** 1996 Sep;62(3):950

Oxidized low-density lipoproteins facilitate leukocyte adhesion to aortic intima without affecting endothelium-dependent relaxation. Role of P-selectin. Mehta A, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov; 15(11):2076–83

Increased elastin-degrading activity and neointimal formation in porcine aortic organ culture. Reduction of both features with a serine proteinase inhibitor. Oho S, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2200–6

Review of non-invasive techniques of measuring aortic pressure through the use of ultrasound. Meyers MD, et al. **Biomed Sci Instrum** 1996;32:169–74

Development of an in-vitro circulatory system with known resistance and capacitance. Offerdahl CD, et al. **Biomed Sci Instrum** 1996;32:183–8

Analysis of the strain and stress distribution in the wall of the developing and mature rat aorta. Rachev A, et al. **Biorheology** 1995 Jul-Aug;32(4):473–85

Application of the principle of optical phase-contrast microscopy to velocity phase-encoded MRI of blood flow in the aorta. Dymond RC, et al. **Br J Radiol** 1996 May; 69(821):410–4

Inhibitory effects of insulin on cytosolic Ca2+ level and contraction in the rat aorta. Endothelium-dependent and -independent mechanisms. Han SZ, et al. **Circ Res** 1995 Oct;77(4):673–8

Effects of aortopulmonary collaterals on cerebral cooling and cerebral metabolic recovery after circulatory arrest. Kirshbom PM, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II490–4

Change in aortic end-systolic pressure by alterations in loading sequence and its relation to left ventricular isovolumic relaxation. Kohno F, et al. **Circulation** 1996 Jun 1;93(11):2080–7

The velocity distribution in the aortic annulus at different times during systole is mainly determined by the pattern of flow convergence in the left ventricular outflow tract--an experimental study using Doppler colour flow mapping. Zhou YQ, et al. **Clin Physiol** 1995 Nov; 15(6):597–610

A family history of NIDDM is associated with decreased aortic distensibility in normal healthy young adult subjects. Hopkins KD, et al. **Diabetes Care** 1996 May;19(5):501–3

Effects of an endurance training programme on the passive and noradrenaline-activated compliances of rat aorta. Koutsis G, et al. **Eur J Appl Physiol** 1995;71(2–3):173–9

Alpha 1-adrenoceptor-induced contractility in rat aorta is mediated by the alpha 1D subtype. Buckner SA, et al. **Eur J Pharmacol** 1996 Feb 22;297(3):241–8

Wave propagation in coupled left ventricle-arterial system. Implications for aortic pressure. Berger DS, et al. **Hypertension** 1996 May;27(5):1079–89

Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta. Berkenboom G, et al. **Hypertension** 1995 Nov;26(5):738–43

An aortic projection of lumbar paravertebral sympathetic neurons in the bullfrog. Thorne R, et al. **J Auton Nerv Syst** 1995 Dec 5;56(1–2):38–44

The mechanical properties of fin whale arteries are explained by novel connective tissue designs. Gosline JM, et al. **J Exp Biol** 1996 Apr;199 (Pt 4):985–97

Rectifying conductance substates in a large conductance Ca(2+)-activated K+ channel: evidence for a fluctuating barrier mechanism. Moss GW, et al. **J Gen Physiol** 1996 Jan;107(1):47–68

Measurement of regional aortic compliance by MR imaging: a study of reproducibility. Forbat SM, et al. **J Magn Reson Imaging** 1995 Nov-Dec;5(6):635-9

Reflex stimulation of aortic chemoreceptors through the stellate ganglion during hypoxia and hypotension in cats. Anand A. **J Physiol (Lond)** 1996 Mar 15;491 (Pt 3):853-8

Cytosolic calcium concentration in resting and stimulated endothelium of excised intact rat aorta. Usachev YM, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):309-17

Effect of age and sex on residual stress in the aorta. Saini A, et al. **J Vasc Res** 1995 Nov-Dec;32(6):398-405

Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides. Hollenberg MD, et al. **Mol Pharmacol** 1996 Feb; 49(2):229-33

Elastic properties of human aortas in relation to age and atherosclerosis: a structural model. Wuyts FL, et al. **Phys Med Biol** 1995 Oct;40(10):1577-97

Aortic pH oscillations in conscious humans and anaesthetised cats and rabbits. Cross BA, et al. **Respir Physiol** 1995 Oct; 102(1):51-62

Arterial Windkessels in marine mammals. Shadwick RE, et al. **Symp Soc Exp Biol** 1995;49:243-52

PHYSIOPATHOLOGY

Aortic thrombosis in a neonate with hereditary antithrombin III deficiency: successful outcome with thrombolytic and replacement treatment. Sánchez J, et al. **Acta Paediatr** 1996 Feb;85(2):245-7

Aortopulmonary collateral vessels and prolonged pleural effusions after modified Fontan procedures. Spicer RL, et al. **Am Heart J** 1996 Jun;131(6):1164-8

Hemodynamic correlates of spontaneous echo contrast in the descending aorta. Sukernik MR, et al. **Am J Cardiol** 1996 Jan 15;77(2):184-6

Evaluation of aortic distensibility in patients with coronary artery disease by use of cine magnetic resonance. Matsumoto Y, et al. **Angiology** 1996 Feb;47(2):149-55

Aortic-based therapy for cardiac arrest. Paradis NA. **Ann Emerg Med** 1996 May;27(5):563-8 (42 ref.)

Noninvasive assessment of cardiac function during exercise in patients with CHF or COPD: measurement of aortic bloodflow indices by continuous wave Doppler. Hux JE, et al. **Can J Cardiol** 1996 Jun;12(6):587-92

Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Benetos A, et al. **Circulation** 1996 Aug 15;94(4):698-703

Determining surgical indications for acute type B dissection based on enlargement of aortic diameter during the chronic phase. Kato M, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II107-12

Vascular dynamics in isolated systolic arterial hypertension. Meaney E, et al. **Clin Cardiol** 1995 Dec;18(12):721-5

Three-dimensional cross-sectional velocity distribution in the ascending aorta in cardiac patients. Kvitting P, et al. **Clin Physiol** 1996 May;16(3):239-58

Aortic distensibility in patients with cerebrovascular disease. Lehmann ED, et al. **Clin Sci (Colch)** 1995 Sep;89(3):247-53

Aortic distensibility measured by magnetic resonance imaging in patients with Marfan's syndrome [letter] Lehmann ED, et al. **Heart** 1996 Feb;75(2):214

Nitric oxide donor prevents hepatic and systemic perfusion decrease induced by endotoxin in anesthetized rabbits. Pastor CM, et al. **Hepatology** 1995 Nov;22(5):1547-53

L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Prevention by trandolapril and verapamil. Küng CF, et al. **Hypertension** 1995 Nov; 26(5):744-51

Role of prostaglandins in acetylcholine-induced contraction of aorta from spontaneously hypertensive and Wistar-Kyoto rats. Rapoport RM, et al. **Hypertension** 1996 Jul;28(1):64-75

Aortic stiffness and left ventricular mass in a rat model of isolated systolic hypertension. Tatchum-Talom R, et al. **Hypertension** 1995 Dec;26(6 Pt 1):963-70

The effect of aortic outflow on the quantification of mitral regurgitation by the flow convergence method. Hopmeyer J, et al. **J Am Soc Echocardiogr** 1996 Jan-Feb;9(1):44-57

Residual strain and local strain distributions in the rabbit atherosclerotic aorta. Matsumoto T, et al. **J Biomech** 1995 Oct;28(10):1207-17

Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement. Huang YT, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):535-41

Angiographic assessment of the stretch-recoil-gain relation after balloon coarctation angioplasty and its relation to late restenosis. Ino T, et al. **Jpn Circ J** 1996 Feb;60(2):102-7

Increased protection of the ischemic myocardium by decreased aortic pressure. Nakamura Y, et al. **Jpn Heart J** 1995 Nov;36(6):689-97 (34 ref.)

RADIATION EFFECTS

Theoretical analysis of magnetic field interactions with aortic blood flow. Kinouchi Y, et al. **Bioelectromagnetics** 1996; 17(1):21-32

RADIOGRAPHY see AORTOGRAPHY

SURGERY

Survival after resection and duodenocolostomy for massive mesenteric infarction after aortic surgery. Williams IM, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):69-70

Reducing aortic root bleeding [letter; comment] Baciewicz FA Jr. **Ann Thorac Surg** 1996 May;61(5):1587. Comment on: Ann Thorac Surg 1995 Oct;60(4):1130-1.

Technique for extraanatomic bypass in complex aortic coarctation. Barron DJ, et al. **Ann Thorac Surg** 1996 Jan; 61(1):241-4

Reducing bleeding after replacement of the aortic root [see comments] Bayfield MS, et al. **Ann Thorac Surg** 1995 Oct; 60(4):1130-1. Comment in: Ann Thorac Surg 1996 May;61(5):1587.

Modified pulmonary autograft aortic root replacement: the sinus obliteration technique. Black MD, et al. **Ann Thorac Surg** 1995 Nov;60(5):1434-6

Aortomyoplasty counterpulsation: experimental results and early clinical experience. Chachques JC, et al. **Ann Thorac Surg** 1996 Jan;61(1):420-5

Mismatch of aortotomy and saphenous vein graft size: a simple solution. John LC. **Ann Thorac Surg** 1996 Aug; 62(2):598-9

Hemostatic modification in aortic root replacement with composite graft [letter; comment] Khanna SK, et al. **Ann Thorac Surg** 1995 Oct;60(4):1161-2. Comment on: Ann Thorac Surg 1993 Apr;55(4):1027-9.

"Legs" technique for management of widely separated coronary arteries during ascending aortic repair. Mills NL, et al. **Ann Thorac Surg** 1996 Mar;61(3):869-74

Blalock-Taussig operation with an assist of venovenous extracorporeal membrane oxygenation. Miyamura H, et al. **Ann Thorac Surg** 1996 Aug;62(2):565-6

Recurrent cerebral vascular accidents are an indication for ascending aortic endarterectomy. Muehrcke DD, et al. **Ann Thorac Surg** 1996 May;61(5):1516-8

Isolated aortic coarctation in neonates and infants: results of resection and end-to-end anastomosis. Pfammatter JP, et al. **Ann Thorac Surg** 1996 Sep;62(3):778-82; discussion 782-3

Aortopulmonary fenestration with pulmonary artery septation for single ventricle and subaortic obstruction. Pridjian AK, et al. **Ann Thorac Surg** 1996 Mar; 61(3):997-1000

Comparative experimental study of cerebral protection during aortic arch reconstruction. Sakurada T, et al. **Ann Thorac Surg** 1996 May;61(5):1348-54

Dacron coronary graft obstruction after composite graft replacement of aortic root. Sekine S, et al. **Ann Thorac Surg** 1995 Oct;60(4):1123-5; discussion 1125-6

Totally laparoscopic aortobifemoral bypass grafting in an experimental model: description of technique with initial surgical results. Byrne J, et al. **Ann Vasc Surg** 1996 Mar; 10(2):156-65

An alternative approach to the Cabrol technique of aortic root replacement. Pascoe EA, et al. **Can J Surg** 1995 Dec; 38(6):550-1

Coarctation of the aorta. Repair with polytetrafluoroethylene patch aortoplasty. Backer CL, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II132-6 (37 ref.)

Anomalous origin of the right coronary artery from the pulmonary trunk: is surgical reimplantation into the aorta a method of choice? Kautzner J, et al. **Clin Cardiol** 1996 Mar;19(3):257-9

Aortic root replacement with a composite graft. Factors influencing immediate and long-term results. Bachet J, et al. **Eur J Cardiothorac Surg** 1996;10(3):207-13

Composite valve graft replacement of the ascending aorta and the aortic valve by a modified button technique: the influence of aortic pathology on early mortality and late survival. Biglioli P, et al. **Eur J Cardiothorac Surg** 1995; 9(9):483-90

A simple method to protect a fragile aorta [letter] Duda AM, et al. **J Card Surg** 1995 Sep;10(5):611-2

Aortic spoon-jaw clamp for aorto-saphenous vein anastomosis. Robicsek F. **J Card Surg** 1995 Sep;10(5):583-5

The incidence of significant pericardial effusion and tamponade following major aortic root surgery. Alkhulaifi AM, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):385-9

Coronary bypass after ascending aorta to femoral graft placement running head: CABG after ascending aorta-bifemoral graft. Cusimano RJ, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):161-3

Reconstruction of dilated aortic annulus using short tubular Dacron graft for aortic root replacement by aortic homograft--a solution for size mismatch. Kasegawa H, et al. **J Heart Valve Dis** 1996 Mar;5(2):178-80

Regurgitation through the morphologically pulmonary valve after additional aortopulmonary anastomosis. Uemura H, et al. **J Heart Valve Dis** 1995 Mar;4(2):176-81

Different types of sleeve anastomosis. Zhang L, et al. **J Reconstr Microsurg** 1995 Nov;11(6):461-5

Using dipyridamole-thallium imaging to reduce cardiac risk in aortic reconstruction. Erickson CA, et al. **J Surg Res** 1996 Feb 1;60(2):422-8

Endoluminal aortic grafting: a preliminary animal study of graft-healing. Harris EJ Jr, et al. **J Surg Res** 1996 Mar; 61(2):404-12

Studies of hypoxemic/reoxygenation injury: with aortic clamping. XIII. Interaction between oxygen tension and cardioplegic composition in limiting nitric oxide production and oxidant damage. Ihnken K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1274-86

Studies of hypoxemic/reoxygenation injury with aortic clamping: XI. Cardiac advantages of normoxemic versus hyperoxemic management during qardiopulmonary bypass. Ihnken K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1255-64

One-stage repair of interrupted aortic arch, ventricular septal defect, and subaortic obstruction in the neonate: a novel approach. Luciani GB, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):348-58

Studies of hypoxemic/reoxygenation injury: with aortic clamping. XII. Delay of cardiac reoxygenation damage in the presence of cyanosis: a new concept of controlled cardiac reoxygenation. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1265-73

Studies of hypoxemic/reoxygenation injury: with aortic clamping. X. Exogenous antioxidants to avoid nullification of the cardioprotective effects of blood cardioplegia. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1245-54

Modified surgical techniques for relief of aortic obstruction in [S,L,L] hearts with rudimentary right ventricle and restrictive bulboventricular foramen [see comments] van Son JA, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):909-15. Comment in: J Thorac Cardiovasc Surg 1996 Apr;111(4):904. Comment in: J Thorac Cardiovasc Surg 1996 Jun;111(6):1290-1.

Use of autogenous aortic and main pulmonary artery flaps for repair of anomalous origin of the right pulmonary artery from the ascending aorta. van Son JA, et al. **J Thorac Cardiovasc Surg** 1996 Mar;111(3):675-6

Redo aortic grafting after treatment of aortic graft infection. DiMuzio PJ, et al. **J Vasc Surg** 1996 Sep;24(3):328-35; discussion 336-7

Aortoscopy: a guidance system for endoluminal aortic surgery. Hill BB, et al. **J Vasc Surg** 1996 Sep;24(3):439-47; discussion 448

Comparison of axilofemoral and aortofemoral bypass for aortoiliac occlusive disease. Passman MA, et al. **J Vasc Surg** 1996 Feb;23(2):263-9; discussion 269-71

Limited thrombogenicity of low temperature, laser-welded vascular anastomoses. Self SB, et al. **Lasers Surg Med** 1996; 18(3):241-7

Continuous retrograde cerebral perfusion supplies substrates for brain metabolism during hypothermic circulatory arrest. Buket S, et al. **Perfusion** 1995 Jul;10(4):237-44

Experimental laparoscopic aortobifemoral bypass. Dion YM, et al. **Surg Endosc** 1995 Aug;9(8):894-7

[Treatment of prostheto-digestive using arterial allograft] Bahnini A, et al. **J Mal Vasc** 1996;21 Suppl A:167-70 (Eng. Abstr.) **(Fre)**

[Anomalous origin of the right pulmonary artery from the ascending aorta: a case report] Harada Y, et al. **Kyobu Geka** 1995 Oct;48(11):912-4 (Eng. Abstr.) **(Jpn)**

[A case report on concomitant graft replacement of the total aortic root and the transverse aortic arch for type A acute aortic dissection associated with annuloaortic ectasia] Kawaharada N, et al. **Kyobu Geka** 1996 Apr;49(4):312-4 (Eng. Abstr.) **(Jpn)**

[An evaluation of aortic root reconstruction using Carrel patch method with coronary anastomosis] Nakayama Y, et al. **Kyobu Geka** 1996 Jun;49(6):452-5 (Eng. Abstr.) **(Jpn)**

[Hemostatic mechanism associated with aprotinin during and after the extracorporeal circulation for cardiac and great vessel surgery] Takaori M, et al. **Masui** 1995 Dec; 44(12):1661-6 (Eng. Abstr.) **(Jpn)**

[Percutaneous placement of intraluminal stent-graft for aortic dissection: experimental study] Hashimoto M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Nov; 55(14):939-45 (Eng. Abstr.) **(Jpn)**

[Simultaneous aortic root and total arch graft replacement in a patient with aortitis syndrome] Sasaki A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):839-43 (Eng. Abstr.) **(Jpn)**

[Aortic root replacement employing Cabrol and Piehler techniques] Sekine S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):765-9 (Eng. Abstr.) **(Jpn)**

[Surgical treatment for Stanford type A acute aortic dissection] Suda H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1890-4 (Eng. Abstr.) **(Jpn)**

[Direct implantation of the left coronary artery in BWG syndrome--sparing the shortage of distance with pulmonary arterial wall] Tanaka K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1690-5 (Eng. Abstr.) **(Jpn)**

[Aorto-septal approach (modified Konno procedure). Surgical alternative in the management of diffuse aortic subvalvular stenosis] Ramírez Marroquín S, et al. **Arch Inst Cardiol Mex** 1996 Jan-Feb;66(1):51-4 (Eng. Abstr.) **(Spa)**

[Double transplantation of internal thoracic arteries in severe coronary artery disease and atherosclerosis of the ascending part and branches of the aorta] Olearchik AS. **Klin Khir** 1995;(7-8):41-3 **(Ukr)**

TRANSPLANTATION

Using aortic allograft material to treat mycotic aneurysms of the thoracic aorta [see comments] Knosalla C, et al. **Ann Thorac Surg** 1996 Apr;61(4):1146-52. Comment in: Ann Thorac Surg 1996 Apr;61(4):1053-4.

Successful conduit repair using aortic homograft in a

Jehovah's Witness child. Miyaji K, et al. **Ann Thorac Surg** 1996 Aug;62(2):590–1

Dissection of an allograft ascending aorta after aortic root replacement. Smith JA, et al. **Ann Thorac Surg** 1996 Mar; 61(3):1011–2

Triple drug immunosuppression significantly reduces aortic allograft arteriosclerosis in the rat. Lemström KB, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):553–64

Simultaneous aortorenal homograft transplantation: expanding the indications for renal and vascular replacement. Mestres CA, et al. **Br J Surg** 1996 Jul; 83(7):918

Experimental basis for autograft growth and viability. Kreitmann B, et al. **J Heart Valve Dis** 1995 Jul;4(4):379–83

Mycophenolate mofetil (MMF, RS–61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Räisänen–Sokolowski A, et al. **Transpl Immunol** 1995 Dec;3(4):342–51

Experimental transplant arteriosclerosis: inhibition by angiopeptin and low molecular weight heparin derivatives. Akyürek ML, et al. **Transplant Proc** 1995 Dec;27(6):3555–6

Effect of Neoral or cyclosporine on the development of chronic rejection in an aortic allograft rat model. Little DM, et al. **Transplant Proc** 1996 Apr;28(2):880–1

Effect of MC1288, a vitamin D analogue, on lymphocyte proliferation in vitro and rat aortic allograft arteriosclerosis in vivo. Räisänen–Sokolowski A, et al. **Transplant Proc** 1996 Apr;28(2):919

Reversibility of allograft arteriosclerosis after retransplantation to donor strain. Mennander A, et al. **Transplantation** 1996 Aug 27;62(4):526–9

Lack of effect of recombinant human superoxide dismutase on cold ischemia–induced arteriosclerosis in syngeneic rat aortic transplants. Myllärniemi M, et al. **Transplantation** 1996 Apr 15;61(7):1018–22

Inhibition of intimal hyperplasia in rat aortic allografts with cyclosporine. Stoltenberg RL, et al. **Transplantation** 1995 Nov 15;60(9):993–8

Immunosuppressive effects of leflunomide in experimental chronic vascular rejection. Swan SK, et al. **Transplantation** 1995 Oct 27;60(8):887–90

[Homograft replacement of aortic valve and ascending aorta] Brazão A, et al. **Rev Port Cardiol** 1996 Apr;15(4):295–300, 271 (Eng. Abstr.) **(Por)**

ULTRASONOGRAPHY

Initial experience with a steerable intravascular ultrasound catheter in the aorta and pulmonary artery. Görge G, et al. **Am J Card Imaging** 1995 Jul;9(3):180–4

Hemodynamic correlates of spontaneous echo contrast in the descending aorta. Sukernik MR, et al. **Am J Cardiol** 1996 Jan 15;77(2):184–6

Assessment of posterior aortic wall motion using echocardiogram in patients with atrial fibrillation. Nobuoka S, et al. **Clin Cardiol** 1996 Mar;19(3):221–4

Aortic root complications in Marfan's syndrome: identification of a lower risk group. Legget ME, et al. **Heart** 1996 Apr;75(4):389–95

Doppler determined aortic acceleration after dipyridamole in the prediction of coronary artery disease. Dubrey S, et al. **Int J Cardiol** 1995 Aug;51(1):5–14

Echocardiographic reference values for aortic root size: the Framingham Heart Study. Vasan RS, et al. **J Am Soc Echocardiogr** 1995 Nov–Dec;8(6):793–800

Exclusion of aortic tear in the unstable trauma patient: the utility of transesophageal echocardiography. Cohn SM, et al. **J Trauma** 1995 Dec;39(6):1087–90

Tissue characterization of arteries with 4 MHz ultrasound. Tobocman W, et al. **Ultrasonics** 1995 Jul;33(4):331–40

[Should Doppler echography in the diagnosis of the extra–cardiac sites of atherosclerosis be routine in patients with coronary disease? Apropos of 248 cases] Charon P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Nov;44(9):477–85 (Eng. Abstr.) **(Fre)**

[Doppler velocimetry in the umbilical, middle cerebral and aortic arteries, before and after cordocentesis] Chitrit Y, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):516–21 (Eng. Abstr.) **(Fre)**

[Estimating the peripheral vascular resistance of the aorta of fetal sheep by external Doppler ultrasound diagnosis] Rybakowski C, et al. **Gynakol Geburtshilfliche Rundsch** 1995;35 Suppl 1:152–6 (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

The structure and physical properties of invertebrate and primitive vertebrate arteries. Davison IG, et al. **J Exp Biol** 1995 Oct;198 (Pt 10):2185–96

Morphological fate and sequelae of human atherosclerosis: evaluation of immune mechanisms in atherogenesis through immunohistological and ultrastructural analysis. Shimokama T, et al. **Pathol Int** 1995 Nov;45(11):801–14

[Intercellular communication studied by using the gap junctions in a primary cell culture of human aortic intima] Andreeva ER, et al. **Tsitologiia** 1996;38(3):319–24 (Eng. Abstr.) **(Rus)**

AORTA, ABDOMINAL

Hepatic resection with vascular isolation and routine supraceliac aortic clamping. Stephen MS, et al. **Am J Surg** 1996 Mar;171(3):351–5

Balloon occlusion of the abdominal aorta during caesarean hysterectomy for placenta percreta. Paull JD, et al. **Anaesth Intensive Care** 1995 Dec;23(6):731–4

Abdominal aortic compression to treat circulatory collapse caused by severe pulmonary hypertension during liver transplantation. Gillies BS, et al. **Anesthesiology** 1996 Aug; 85(2):420–2

Importance of calcium in long–term preservation of the vasculature. Ingemansson R, et al. **Ann Thorac Surg** 1996 Apr;61(4):1158–62

Pathological case of the month. Idiopathic arterial calcification of infancy. Green DW, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):101–2

Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony–stimulating factor. Kawachi Y, et al. **Br J Haematol** 1996 Aug;94(2):413–6

Risk of compartment syndrome and aortic thrombosis following prolonged surgery in the Lloyd–Davies position. Harris SA, et al. **Br J Urol** 1996 May;77(5):752–3

Embolization of a high–output postnephrectomy aortocaval fistula with Gianturco coils and cyanoacrylate. Cekirge S, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):56–8

Hemodynamic improvement in hemorrhagic shock by aortic balloon occlusion and hypertonic saline solutions. Poli de Figueiredo LF, et al. **Cardiovasc Surg** 1995 Dec;3(6):679–86

Intrahepatic biliary dilatation with aortoarteritis. Kabra SK, et al. **Indian Pediatr** 1995 Jan;32(1):92–5

"Kissing–balloon" technique for abdominal aorta angioplasty. Initial results and long term outcome. Sagic D, et al. **Int Angiol** 1995 Dec;14(4):364–7

An unusual presentation of a ruptured abdominal aortic aneurysm. Haddad FS, et al. **J Accid Emerg Med** 1995 Sep; 12(3):220–1

Endovascular recanalization of the aorto–iliac segment: imaging and approaches. Criado FJ. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):51–7

Aortic pressure pain: clinical significance. Any relationship to the irritable bowel syndrome? Baert D, et al. **J Clin Gastroenterol** 1996 Mar;22(2):111–3

Percutaneous removal of a misplaced Palmaz stent with a coaxial snare technique. Hartnell GG, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):799–801

Primary leiomyosarcoma of the abdominal aorta. Malone MD, et al. **J Vasc Surg** 1996 Sep;24(3):487–93 (36 ref.)

Aortic and iliac stenoses: follow–up results of stent placement after insufficient balloon angioplasty in 118 cases. Vorwerk D, et al. **Radiology** 1996 Jan;198(1):45–8

Ureteroarterial fistula: case report and review of the literature. Batter SJ, et al. **Urology** 1996 Sep;48(3):481–9 (35 ref.)

[Hypoplasia of abdominal aorta, rare cause of hypertension in childhood] Durand I, et al. **Arch Pediatr** 1995 Dec; 2(12):1173–6 (Eng. Abstr.) **(Fre)**

[Surgery of abdominal aorta occlusion] Belov IuV, et al. **Khirurgiia (Mosk)** 1995;(6):3–5 (Eng. Abstr.) **(Rus)**

ABNORMALITIES

Abdominal aortic coarctation: CT, MRI, and angiographic correlation. Moresco KP, et al. **Comput Med Imaging Graph** 1995 Sep–Oct;19(5):427–30

An anomalous case of the gastro–splenic and the hepato–mesenteric trunks independently arising from the abdominal aorta. Harada H, et al. **Kurume Med J** 1996; 43(2):181–4

[A case of the three branches of the celiac trunk arising directly from the abdominal aorta] Higashi N, et al. **Kaibogaku Zasshi** 1995 Aug;70(4):349–52 (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

Carboxymethyl–dextran–gadolinium–DTPA as a blood–pool contrast agent for magnetic resonance angiography. Experimental study in rabbits. Loubeyre P, et al. **Invest Radiol** 1996 May;31(5):288–93

CHEMISTRY

Evidence for more extensive deposits of epitopes of oxidized low density lipoprotein in aortas of young people with elevated serum thiocyanate levels. PDAY Research Group. Scanlon CE, et al. **Atherosclerosis** 1996 Mar;121(1):23–33

Immunohistochemical localization of C–reactive protein–binding sites in human atherosclerotic aortic lesions by a modified streptavidin–biotin–staining method. Hatanaka K, et al. **Pathol Int** 1995 Sep;45(9):635–41

CYTOLOGY

Morphometrical changes of the arterial walls of main arteries from heart to the abdomino–inguinal mammary glands of rat from virgin through pregnancy, lactation and post–weaning. Awal MA, et al. **J Vet Med Sci** 1995 Apr; 57(2):251–6

DRUG EFFECTS

Lysophosphatidylcholine inhibits relaxation of rabbit abdominal aorta mediated by endothelium–derived nitric oxide and endothelium–derived hyperpolarizing factor independent of protein kinase C activation. Cowan CL, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec; 15(12):2290–7

EMBRYOLOGY

Flow and velocity waveform indices in the ovine fetal abdominal aorta with changes in behavioural state. Parkinson S, et al. **Reprod Fertil Dev** 1995;7(5):1299–304

INJURIES

Proliferating arterial smooth muscle cells after balloon injury express TNF–alpha but not interleukin–1 or basic fibroblast growth factor. Tanaka H, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):12–8

Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon–injured aortas in rabbits. Speidel CM, et al. **Circulation** 1995 Dec 1;92(11):3323–30

Abdominal aortic injury associated with transverse lumbar spine fracture—imaging findings. Reaney SM, et al. **Clin Radiol** 1995 Dec;50(12):834–8

Localization of [125I]endothelin–1 in injured aorta of rabbits. Kurata C, et al. **Eur J Pharmacol** 1995 Jul 1;293(2):109–14

Injuries of the abdominal aorta and inferior vena cava in association with thoracolumbar fractures: a lethal combination. Coimbra R, et al. **J Trauma** 1996 Sep; 41(3):533–5

Mortality and prognostic factors in penetrating injuries of the aorta. Demetriades D, et al. **J Trauma** 1996 May; 40(5):761–3

Blunt force injury of the abdominal aorta. Michaels AJ, et al. **J Trauma** 1996 Jul;41(1):105–9

Delayed rupture of the abdominal aorta in a child after a suspected handlebar injury. Tracy TF Jr, et al. **J Trauma** 1996 Jan;40(1):119–20

Insulin–like growth factor–I binding in injury–induced intimal hyperplasia of rabbit aorta. Sidway AN, et al. **J Vasc Surg** 1996 Feb;23(2):308–13

Traumatic abdominal pseudoaneurysm secondary to child abuse. Roche KJ, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S247–8

[Effect of antisense oligonucleotides on myo–intimal hyperplasia in a model of abdominal aortic injury in the rat] Chemla E, et al. **Arch Mal Coeur Vaiss** 1995 Mar; 88(3):381–9 (Eng. Abstr.) **(Fre)**

[Complication due to intraperitoneal dialysis catheter insertion] Majdan M, et al. **Pol Tyg Lek** 1996 Feb; 51(6–9):104–6 (Eng. Abstr.) **(Pol)**

INNERVATION

Chronic sensory denervation reduces thrombin–stimulated endothelin release from aortic endothelial cells. Milner P, et al. **Experientia** 1996 Mar 15;52(3):242–4

METABOLISM

Partial amino acid sequence of a novel 40–kDa human aortic protein, with vitronectin–like, fibrinogen–like, and calcium binding domains: aortic aneurysm–associated protein–40 (AAAP–40) [human MAGP–3, proposed] Xia S, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):36–9

Mechanisms of transmural heparin transport in the rat abdominal aorta after local vascular delivery. Lovich MA, et al. **Circ Res** 1995 Dec;77(6):1143–50

Different cholesterol deposition in aorta of Dahl salt–sensitive rats and spontaneously hypertensive rats fed a high–cholesterol diet. Yamaguchi Y, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S249–50

Localization of [125I]endothelin–1 in injured aorta of rabbits. Kurata C, et al. **Eur J Pharmacol** 1995 Jul 1;293(2):109–14

PATHOLOGY

Time–of–flight magnetic resonance angiography of aorta and renal arteries: state–of–the–art. Laissy JP, et al. **Eur J Radiol** 1996 Feb;21(3):201–11 (71 ref.)

Incidence and histologic characteristics of blebs in patients with abdominal aortic aneurysms. Hunter GC, et al. **J Vasc Surg** 1996 Jul;24(1):93–101

Human aorta: preliminary results with virtual endoscopy based on three–dimensional MR imaging data sets. Davis CP, et al. **Radiology** 1996 Apr;199(1):37–40

Breath–hold gadolinium–enhanced MR angiography of the abdominal aorta and its major branches. Prince MR, et al. **Radiology** 1995 Dec;197(3):785–92

Three–dimensional gadolinium–enhanced MR angiography for aortoiliac inflow assessment plus renal artery screening in a single breath hold. Snidow JJ, et al. **Radiology** 1996 Mar;198(3):725–32

[Isolated stenosing calcified lesions of the aorta] Sapoval M, et al. **J Radiol** 1995 Nov;76(11):1021–4 (10 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Regional differences in mechanical properties between major arteries—an experimental study in sheep. Mangell P, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):189–95

Non–invasive evaluation of abdominal aortic properties: lumped circuit model and estimation of its parameters. Morishita K, et al. **Med Biol Eng Comput** 1995 Sep; 33(5):699–703

Flow and velocity waveform indices in the ovine fetal abdominal aorta with changes in behavioural state. Parkinson S, et al. **Reprod Fertil Dev** 1995;7(5):1299–304

Acoustic generation of intra–arterial contrast boluses. Ivey JA, et al. **Ultrasound Med Biol** 1995;21(6):757–67

AORTA, ABDOMINAL

PHYSIOPATHOLOGY

Tensile strength and histological changes of abdominal aorta of malnourished rats. Yoshida WB, et al. **Cardiovasc Surg** 1995 Aug;3(4):437–9

Increased arterial stiffness in women, but not in men, with IDDM. Rydén Ahlgren A, et al. **Diabetologia** 1995 Sep; 38(9):1082–9

Is there a correlation between aortic Doppler velocimetric findings in diabetic pregnant women and fetal outcome? Reece EA, et al. **J Ultrasound Med** 1996 Jun;15(6):437–40

Effects of hypothyroidism and aortic construction on mitochondria during cardiac hypertrophy. Nishio ML, et al. **Med Sci Sports Exerc** 1995 Nov;27(11):1500–8

RADIOGRAPHY

Breath-hold ultrafast three-dimensional gadolinium-enhanced MR angiography of the aorta and the renal and other visceral abdominal arteries. Holland GA, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):971–81

Comparison of tailored and empiric scan delays for CT angiography of the abdomen. Sheiman RG, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):725–9

Radial artery approach for outpatient peripheral arteriography. al-Kutoubi A, et al. **Clin Radiol** 1996 Feb; 51(2):110–2

Interobserver variability in measuring the dimensions of the abdominal aorta: comparison of ultrasound and computed tomography. Jaakkola P, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):230–7

Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial. Fischbach R, et al. **Eur Radiol** 1996;6(1):9–13

SURGERY

Control of body temperature during abdominal aortic surgery. Gregorini P, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):187–90

Additive value of thallium single-photon emission computed tomography myocardial imaging for prediction of perioperative events in clinically selected high cardiac risk patients having abdominal aortic surgery. Vanzetto G, et al. **Am J Cardiol** 1996 Jan 15;77(2):143–8

The effects of supraceliac aortic clamping on the anticoagulant effects of heparin. Money SR, et al. **Am J Surg** 1996 Aug;172(2):155–7

A comparison of postoperative thrombotic potential following abdominal aortic surgery, carotid endarterectomy, and femoro-popliteal bypass. Gibbs NM, et al. **Anaesth Intensive Care** 1996 Feb;24(1):11–4

Laparoscopic aortofemoral bypass. Initial experience in an animal model. Ahn SS, et al. **Ann Surg** 1995 Nov; 222(5):677–83

Combined aortic and renal artery surgery. A contemporary experience. Benjamin ME, et al. **Ann Surg** 1996 May; 223(5):555–65; discussion 565–7

Endovascular grafting of abdominal aortic aneurysms. A preliminary study. Edwards WH Jr, et al. **Ann Surg** 1996 May;223(5):568–73; discussion 573–5

Bypass graft for complex forms of isthmic aortic coarctation in adults. Grinda JM, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1299–302

Do collagen-impregnated knitted Dacron grafts reduce the need for transfusion in infrarenal aortic reconstruction? Barral X, et al. **Ann Vasc Surg** 1995 Jul;9(4):339–43

Transperitoneal medial visceral rotation [letter] Deiparine MK, et al. **Ann Vasc Surg** 1995 Nov;9(6):607

Sequential distal anastomosis in aortofemoral bypass. Gewertz BL, et al. **Ann Vasc Surg** 1995 Nov;9(6):583–4

Differential effect of the retropleural and retroperitoneal environments on healing of the inner wall of porous fabric prostheses in the thoracic and abdominal aorta of the same dog. Hayashida N, et al. **Ann Vasc Surg** 1995 Jul; 9(4):369–77

Aortoiliac bypass in a renal transplant patient using a new technique. Jain KM, et al. **Ann Vasc Surg** 1995 Jul; 9(4):385–9

Delayed forced air warming prevents hypothermia during abdominal aortic surgery. Karayan J, et al. **Br J Anaesth** 1996 Mar;76(3):459–60

Preoperative inhibition of angiotensin-converting enzyme improves systemic and renal haemodynamic changes during aortic abdominal surgery. Licker M, et al. **Br J Anaesth** 1996 May;76(5):632–9

Assessment of subrenal banding of the abdominal aorta as a method of inducing cardiac hypertrophy in the guinea pig. Tweedie D, et al. **Cardioscience** 1995 Jun;6(2):115–9

Preservation of the pelvic circulation during infrarenal aortic surgery. Connolly JE, et al. **Cardiovasc Surg** 1996 Feb; 4(1):65–70 (46 ref.)

Role of vascular endoscopy in aortoiliac and femoropopliteal thromboendarterectomy. Kogel H, et al. **Cardiovasc Surg** 1996 Feb;4(1):93–6

Sequential aortofemoropopliteal/distal bypass for treatment of critical lower-limb ischaemia. Zukauskas G, et al. **Cardiovasc Surg** 1995 Dec;3(6):671–8

Serum phospholipases A2 after aortobifemoral reconstruction. Grönroos JM, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):271–4

The relationship between sigmoidal intramucosal pH and intestinal arterial occlusion during aortic reconstructive surgery. Klok T, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):304–7

Aortic graft infection with mycoplasma (Ureaplasma urealyticum). Levi N, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):374–5 (14 ref.)

Endovascular exclusion of juxtarenal anastomotic pseudoaneurysm. Lindblad B, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):116–8

The aortic polytetrafluoroethylene graft: further experience. Mohan CR, et al. **Eur J Vasc Endovasc Surg** 1996 Feb; 11(2):158–63

Popliteal-to-tibial bypass for acute leg ischemia complicating aortic reconstruction. Porcellini M, et al. **G Chir** 1996 Apr; 17(4):166–70

An experimental study of optimal parameters for bipolar electrocoagulation. Dilley AV, et al. **Gastrointest Endosc** 1995 Jul;42(1):27–30

Determinants of systolic pressure variation in patients ventilated after vascular surgery. Baeaussier M, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):547–51

Gasless videoendoscopic implantation of an aortobifemoral vascular prosthesis via a transperitoneal versus extraperitoneal approach: an experimental study [see comments] Bruns C, et al. **J Endovasc Surg** 1996 Aug; 3(3):290–6. Comment in: J Endovasc Surg 1996 Aug;3(3):297–8.

Endovascular stent-anchored aortic grafts: a comparison between self-expanding and balloon-expandable stents in minipigs. Lindh M, et al. **J Endovasc Surg** 1996 Aug; 3(3):284–9

Infrarenal aortic clamp hypertension is exacerbated by baroreceptor blockade. Giglia JS, et al. **J Surg Res** 1996 Aug;64(2):112–5

Effect of endoluminal PTFE graft placement on cell proliferation, PDGF secretion, and intimal hyperplasia. Ombrellaro MP, et al. **J Surg Res** 1996 Jun;63(1):110–4

Laparoscopic aortic surgery [letter; comment] Dion YM, et al. **J Vasc Surg** 1996 Mar;23(3):539. Comment on: J Vasc Surg 1995 Jul;22(1):73–9.

Durability of cross-femoral grafts after aortic graft infection: the fate of autogenous conduits. Jicha DL, et al. **J Vasc Surg** 1995 Oct;22(4):393–405; discussion 406–7

Development and comparison of transperitoneal and retroperitoneal approaches to laparoscopic-assisted aortofemoral bypass in a porcine model. Jones DB, et al. **J Vasc Surg** 1996 Mar;23(3):466–71

Preliminary experience with the Endovascular Technologies bifurcated endovascular aortic prosthesis in a calf model. Quiñones-Baldrich WJ, et al. **J Vasc Surg** 1995 Oct; 22(4):370–9; discussion 379–81

Growth factor production after polytetrafluoroethylene and vein arterial grafting: an experimental study. Sterpetti AV, et al. **J Vasc Surg** 1996 Mar;23(3):452–60

Clostridium septicum bacteremia associated with aortic graft infection. Upchurch GR Jr, et al. **J Vasc Surg** 1995 Oct; 22(4):493–5

Aortocaval fistula treated by aortic exclusion. Woolley DS, et al. **J Vasc Surg** 1995 Nov;22(5):639–42 (27 ref.)

Evaluation of low molecular weight heparin during and after aortic and carotid surgery: dose finding study. Alimi YS, et al. **Panminerva Med** 1996 Mar;38(1):15–21

Horseshoe kidney and aortic surgery. Wymenga LF, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):331–4 (10 ref.)

Videotunneler for minimal and direct access aortoiliac reconstructive surgery. Weber G, et al. **Surg Endosc** 1996 Aug;10(8):852–4

Healing characteristics of intraarterial stented grafts: effect of intraluminal position on prosthetic graft healing. Ombrellaro MP, et al. **Surgery** 1996 Jul;120(1):60–70

Postreperfusion syndrome in swine liver transplantation: comparison between orthotopic liver transplantation and total hepatectomy with portacaval shunt using aortic graft. Ishine N, et al. **Transplant Proc** 1996 Jun;28(3):1756–8

A pilot study of the effects of abdominal aortic cross clamping on metabolic gas exchange (short communication). Lind L. **Ups J Med Sci** 1995;100(2):165–7

Successful renal autotransplantation with Y-prosthetic aortic replacement in a patient with complete occlusion of abdominal aorta and renal artery. Yagisawa T, et al. **Urol Int** 1995;55(1):46–50

[A 10-year follow-up study of bypass operations with double-velour dacron in the aortoiliofemoral position] Andreev A. **Khirurgiia (Sofiia)** 1995;48(5):17–22 (Eng. Abstr.) **(Bul)**

[A comparative assessment of the results of end-to-end and end-to-side anastomoses in arterial reconstructions of the aorto-iliac segment] Zakhariev T, et al. **Khirurgiia (Sofiia)** 1995;48(1):37–42 (Eng. Abstr.) **(Bul)**

[Successful acute aortomesenteric bypass as a result of favorable circumstances] Jiříček M. **Rozhl Chir** 1995 Dec; 74(8):429–30 (Eng. Abstr.) **(Cze)**

[Surgery of infectious complications in prostheses in the abdominal aorta] Miler I, et al. **Rozhl Chir** 1995 Aug; 74(5):203–5 (Eng. Abstr.) **(Cze)**

[Prediction of respiratory complications after surgery of the abdominal aorta] Durand M, et al. **Can J Anaesth** 1995 Dec;42(12):1101–7 (Eng. Abstr.) **(Fre)**

[Treatment of prostheto-digestive fistulas using in situ prosthetic bypass] Fiorani P, et al. **J Mal Vasc** 1996;21 Suppl A:162–6 (Eng. Abstr.) **(Fre)**

[Intraoperative calorimetry in aortic bifurcation reconstruction] Balogh D, et al. **Anaesthesist** 1995 Aug; 44(8):552–7 (Eng. Abstr.) **(Ger)**

[Abdominal vascular and colonic pathology: the timing of combined treatment] Battisti G, et al. **G Chir** 1996 Apr; 17(4):175–7 (Eng. Abstr.) **(Ita)**

[Results of treating a late thrombosis in a vascular prosthesis after surgical repair of an aorto-femoral arterial segment with atherosclerosis] Cnotliwy M. **Ann Acad Med Stetin** 1994;40:145–58 (Eng. Abstr.) **(Pol)**

[A rare case of performance of simultaneous surgery in the reconstruction the aorto-iliac arterial segment in a patient with critical ischemia of the lower limbs] Gusak VK, et al. **Klin Khir** 1995;(7–8):45 **(Rus)**

[The radiculoischemia syndrome after prosthesis of the aorta] Zamiatin VV, et al. **Vestn Khir Im I I Grek** 1992 Mar; 148(3):335–7 **(Rus)**

TRANSPLANTATION

Identification of differentially expressed genes in rat aortic allograft vasculopathy. Chen J, et al. **Am J Pathol** 1996 Aug;149(2):597–611

Effect of temperature in long-term preservation of vascular endothelial and smooth muscle function. Ingemansson R, et al. **Ann Thorac Surg** 1996 May;61(5):1413–7

Does cyclosporin A have any effect on accelerated atherosclerosis in absence of graft rejection? Pathologic and morphometric evaluation in an experimental model. Bernucci P, et al. **J Heart Lung Transplant** 1995 Nov–Dec; 14(6 Pt 1):1187–96

JE gene expression in an animal model of acute arterial graft rejection. Isik FF, et al. **J Surg Res** 1996 Jan;60(1):224–31

Initial endothelial injury and cytomegalovirus infection accelerate the development of allograft arteriosclerosis. Li F, et al. **Transplant Proc** 1995 Dec;27(6):3552–4

[Our experience in the emergency treatment of secondary aortoenteric fistulae. The preliminary results of the use of aortic homografts] Novali C, et al. **Minerva Cardioangiol** 1996 Mar;44(3):87–94 (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Three-dimensional transabdominal ultrasound identification of aortic plaque. Webber JD, et al. **Am J Card Imaging** 1995 Oct;9(4):245–9

Interobserver variability in measuring the dimensions of the abdominal aorta: comparison of ultrasound and computed tomography. Jaakkola P, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):230–7

Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. Silverman DI, et al. **J Am Coll Cardiol** 1995 Oct;26(4):1062–7

ULTRASTRUCTURE

Histamine release from Weibel-Palade bodies of toad aortas induced by endothelin-1 and sarafotoxin-S6b. Doi Y, et al. **Anat Rec** 1995 Jul;242(3):374–82

AORTA, ASCENDING see **AORTA**

AORTA, DESCENDING see **AORTA, THORACIC**

AORTA, THORACIC

Neuroanesthesia adjunct therapy (mannitol and hyperventilation) is as effective as cerebrospinal fluid drainage for prevention of paraplegia after descending thoracic aortic cross-clamping in the dog. Mutch WA, et al. **Anesth Analg** 1995 Oct;81(4):800–5

A possible mechanism for the stimulation of metalloproteinase production in human aortic intimal smooth muscle cells by linoleic acid hydroperoxide. Arima N, et al. **Biochem Biophys Res Commun** 1996 Aug 5; 225(1):34–9

Heterogeneity of adenovirus-mediated gene transfer in cultured thoracic aorta and renal artery of rats. Yao A, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1046–50

Intraaortic mass after repair of an aortic dissection. Rosenzweig BP, et al. **J Am Soc Echocardiogr** 1996 Jan–Feb;9(1):100–3

Clinical value of aortic thermodilution monitoring of cardiac output in a small child after surgical correction of tetralogy of Fallot. Weyland A, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):435–7

Radiologic and manometric study of the gastroesophageal junction in dysphagia aortica. Sundaram U, et al. **J Clin Gastroenterol** 1995 Dec;21(4):275–8

Xanthine oxidase inactivation attenuates postocclusion shock after descending thoracic aorta occlusion and reperfusion in rabbits. Nielsen VG, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):715–22

Cine computed tomography for evaluation of tumors invasive to the thoracic aorta: seven clinical experiences. Ohtsuka T, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):190–2

ABNORMALITIES

Isolated innominate artery in asplenia syndrome with aortic atresia: newly recognized cardiovascular complex. Papagiannis J, et al. **Am Heart J** 1996 May;131(5):1042–4

Retroesophageal right subclavian artery originating from the aortic arch distal and dorsal to the left subclavian artery. Nakatani T, et al. **Anat Anz** 1996 Jun;178(3):269–71

Truncus arteriosus with total anomalous pulmonary venous return and interrupted arch. Berdjis F, et al. **Ann Thorac Surg** 1996 Jan;61(1):220–2

Aortic root replacement and extraanatomic bypass for interrupted aortic arch in an adult. Burton BJ, et al. **Ann Thorac Surg** 1995 Nov;60(5):1400–2

Vascular ring causing symptomatic tracheal compression in adulthood. Fadel E, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1411–3

Type B aortic dissection involving an isolated right-sided aortic arch. Masiello P, et al. **Ann Thorac Surg** 1996 Sep; 62(3):887–8

Growth potential in the new aortic arch after non-end-to-end repair of aortic arch interruption in infancy. Monro JL, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1212–6

Late development of esophageal compression from a vascular ring. Nicolosi AC, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1413–5

Right aortic arch with aberrant left subclavian artery: aneurysmal dilatation causing symptomatic compression of the right main bronchus in an adult. Patiniotis TC, et al. **Aust N Z J Surg** 1995 Sep;65(9):690–2 (9 ref.)

Aortic arch interruption associated with ruptured cerebral aneurysm. Hu WY, et al. **Can Assoc Radiol J** 1996 Feb; 47(1):20–3

The presentation of a double aortic arch in adulthood in association with congestive heart failure attributed to a previously silent aortic regurgitation. Nawa S, et al. **Cardiology** 1995;86(6):521–3

Interrupted aortic arch. Impact of subaortic stenosis on management and outcome. Jacobs ML, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II128–31

MRI of pseudocoarctation of the aorta: morphological and cine-MRI findings. Soler R, et al. **Comput Med Imaging Graph** 1995 Sep–Oct;19(5):431–4

Morphological change of the 5th aortic arch with tetralogy of Fallot and pulmonary atresia: echocardiographic and angiographic findings [letter] Kishkurno S, et al. **Eur Heart J** 1995 Dec;16(12):2010–1

Pulmonary artery banding is not contraindicated in double inlet left ventricle with transposition and aortic arch obstruction. Webber SA, et al. **Eur J Cardiothorac Surg** 1995;9(9):515–20

Aortoesophageal fistula and double aortic arch: two important points in management. Othersen HB Jr, et al. **J Pediatr Surg** 1996 Apr;31(4):594–5

Left aortic arch with right descending aorta and right ligamentum arteriosum associated with d-TGA and large VSD: surgical treatment of a rare form of vascular ring. Watanabe M, et al. **J Pediatr Surg** 1995 Sep;30(9):1363–5

Anterior translocation of the right pulmonary artery to prevent bronchovascular compression in a case of truncus arteriosus and type A interrupted aortic arch. Pretre R, et al. **J Thorac Cardiovasc Surg** 1996 Mar;111(3):672–4

Separate origins of the left internal and external carotid arteries directly from the aortic arch: duplex sonographic findings. Woodruff WW 3rd, et al. **J Ultrasound Med** 1995 Nov;14(11):867–9

Isolated persistent fifth aortic arch with right-sided aortic arch. Wu JR, et al. **Jpn Heart J** 1995 Nov;36(6):813–7

Interruption of aortic arch and hypoplastic left heart syndrome. Devloo-Blancquaert A, et al. **Pediatr Cardiol** 1995 Nov–Dec;16(6):304–8 (10 ref.)

Cutis marmorata telangiectatica congenita associated with a double aortic arch. O'Toole EA, et al. **Pediatr Dermatol** 1995 Dec;12(4):348–50

MR of right aortic arch with mirror-image branching and a left ligamentum arteriosum: an unusual cause of a vascular ring. Schlesinger AE, et al. **Pediatr Radiol** 1995;25(6):455–7

A case of the incomplete double aortic arch diagnosed in adulthood by MR imaging. Ito K, et al. **Radiat Med** 1995 Sep–Oct;13(5):263–7 (23 ref.)

Reconstruction of the aortic arches of a 28-day human embryo (stage 13) using the Born technique. Pillet JC, et al. **Surg Radiol Anat** 1995;17(2):129–32, 11–2 **(Eng, Fre)**

[The surgical correction of the right aortic arch with aberrant left subclavian artery and left ligamentum arteriosum—a rare case from clinical practice] Baev B, et al. **Khirurgiia (Sofiia)** 1995;48(1):48–50 (14 ref.) (Eng. Abstr.) **(Bul)**

[Diagnosis and treatment of interrupted aortic arch: report of 6 cases] Chen B, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul;33(7):433–4 (Eng. Abstr.) **(Chi)**

[Tactics and technique of primary correction of aortic arch interruption using a median sternotomy] Tláskal T, et al. **Rozhl Chir** 1995 May;74(4):188–92 (Eng. Abstr.) **(Cze)**

[Atresia of the aortic arch. A rare cause of asymmetrical arterial hypertension in adulthood] Heinrich U, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):719–22 (34 ref.) (Eng. Abstr.) **(Ger)**

[Clinical-therapeutic aspects and surgical treatment of aortic coarctation associated with hypoplasia of the aortic arch in less than 3-month-old patients] Patanè L, et al. **Pediatr Med Chir** 1995 Jul–Aug;17(4):323–6 (Eng. Abstr.) **(Ita)**

[A case of one stage-repair of interrupted aortic arch and ventricular septal defect in neonate using a separated cardiopulmonary bypass] Goto H, et al. **Kyobu Geka** 1995 Dec;48(13):1078–81 (Eng. Abstr.) **(Jpn)**

[Surgical management of vascular ring in 5 cases] Sakurai M, et al. **Kyobu Geka** 1995 Sep;48(10):841–4 (Eng. Abstr.) **(Jpn)**

[Reoperation for coarctation of the aorta and interrupted aortic arch] Hirai M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1657–63 (Eng. Abstr.) **(Jpn)**

[Bronchogenic carcinoma associated with right aortic arch and postaortic left brachiocephalic vein—report of a case] Kaneko Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1155–9 (Eng. Abstr.) **(Jpn)**

[Dissection of the pseudointima followed by lethal obstruction of the prosthetic graft—a case report] Ohuchi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec; 43(12):1963–6 (Eng. Abstr.) **(Jpn)**

[Axillo-iliac bypass grafting for reoperation of graft stenosis after aortic arch reconstruction of type B interruption of the aortic arch: two cases report] Tsukuda K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):212–5 (Eng. Abstr.) **(Jpn)**

[A successful palliative arterial switch operation with arch repair for tricuspid atresia with ventriculoarterial discordance, subaortic stenosis, coarctation, and aortic arch hypoplasia] Yamagishi M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1981–7 (Eng. Abstr.) **(Jpn)**

[A case of systemic arterial supply to the normal left basal segments with anomalous return of the left inferior pulmonary vein] Kuwahara T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):733–7 (Eng. Abstr.) **(Jpn)**

[A vascular ring as a rare cause of recurrent obstructive bronchitis in children] Najberg E, et al. **Pediatr Pol** 1995 Apr;70(4):363–6 (Eng. Abstr.) **(Pol)**

ANATOMY & HISTOLOGY

Effects of estrogen and progestin on aortic size and compliance in postmenopausal women. Giraud GD, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1708–17; discussion 1717–8

A modified aortic multiple-ring preparation for functional studies. Calderone V, et al. **J Pharmacol Toxicol Methods** 1996 Jun;35(3):131–8

Evaluation of ultrafast phase-contrast imaging in the thoracic aorta. Debatin JF, et al. **MAGMA** 1995 Jul;3(2):59–66

Improved MR images of arterial specimens by submersion in trichlorotrifluoroethane. Chu KC, et al. **Magn Reson Med** 1996 May;35(5):790–6

CHEMISTRY

High-resolution mapping of the frequency of lipid deposits in thoracic aortae from cholesterol-fed and heritable hyperlipidaemic rabbits [letter; comment] Forster BA, et al. **Atherosclerosis** 1996 Feb;120(1–2):249–53. Comment on: Atherosclerosis 1995 May;115(1):73–84.

Evidence for more extensive deposits of epitopes of oxidized low density lipoprotein in aortas of young people with elevated serum thiocyanate levels. PDAY Research Group. Scanlon CE, et al. **Atherosclerosis** 1996 Mar;121(1):23–33

Atherogenic change in the thoracic aorta of the senescence-accelerated mouse. Yagi K, et al. **Atherosclerosis** 1995 Dec;118(2):233–6

Delineation of endothelin receptor subtypes in rat and rabbit aortas. Shetty SS, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S310–3

Measurement by quantitative reverse transcription-polymerase chain reaction of the levels of tumor necrosis factor alpha mRNA in atherosclerotic arteries in Watanabe heritable hyperlipidemic rabbits. Lei X, et al. **Lab Invest** 1996 Jan;74(1):136–45

CYTOLOGY

Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of Vascular Dendritic Cells in athero-resistant and athero-prone areas of the normal aorta. Bobryshev YV, et al. **Arch Histol Cytol** 1995 Aug;58(3):307–22

Myoendothelial contacts in the human fetal aorta. Sosa-Melgarejo JA, et al. **Arch Med Res** 1995 Winter; 26(4):431–5

Erythropoietin induces Ca2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Morakkabati N, et al. **Exp Hematol** 1996 Feb;24(2):392–7

Morphometrical changes of the arterial walls of main arteries from heart to the abdomino-inguinal mammary glands of rat from virgin through pregnancy, lactation and post-weaning. Awal MA, et al. **J Vet Med Sci** 1995 Apr; 57(2):251–6

DRUG EFFECTS

Effects of estrogen and progestin on aortic size and compliance in postmenopausal women. Giraud GD, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1708–17; discussion 1717–8

Characterization of the effects of two new arginine/citrulline analogues on constitutive and inducible nitric oxide synthases in rat aorta. Joly GA, et al. **Br J Pharmacol** 1995 Jun;115(3):491–7

Regulation of kinin-induced contraction and DNA synthesis by inflammatory cytokines in the smooth muscle of the rabbit aorta. Levesque L, et al. **Br J Pharmacol** 1995 Sep; 116(1):1673–9

Effects of vitamin E deficiency on vasomotor activity and ultrastructural organisation of rat thoracic aorta. Rubino A, et al. **Br J Pharmacol** 1995 Jun;115(3):415–20

Immediate effects of intravenous cocaine on the thoracic aorta and coronary arteries. A transesophageal echocardiographic study. Eisenberg MJ, et al. **Chest** 1996 Jul;110(1):147–54

Time course of phorbol ester-induced contraction and protein kinase C activation in rat aorta. Bazan E, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):253–7

Effects of nifedipine and Bay K 8644 on myotropic responses in aortic rings of pregnant rats. Roy B, et al. **Eur J Pharmacol** 1995 Jun 23;280(1):1–9

Cardiovascular selectivity of 1,4-dihydropyridine derivatives, efonidipine (NZ-105), nicardipine and structure related compounds in isolated guinea-pig tissues. Masuda Y, et al. **Gen Pharmacol** 1995 Mar;26(2):339–45

Vasorelaxant effect of the analgesic clonixin on rat aorta. Morales MA, et al. **Gen Pharmacol** 1995 Mar;26(2):425–30

Role of endothelium in the vasodilating effect of progestins and androgens on the rat thoracic aorta. Perusquía M, et al. **Gen Pharmacol** 1996 Jan;27(1):181–5

Effects of angiotensin-converting enzyme inhibition versus beta-adrenergic blockade on aortic stiffness in essential hypertension. Savolainen A, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):99–104

Vasoactive effects of aqueous extracts from five Mexican medicinal plants on isolated rat aorta. Perusquía M, et al. **J Ethnopharmacol** 1995 Apr;46(1):63–9

Relaxant activity of three aporphine alkaloids from Annona cherimolia on isolated aorta of rat. Chuliá S, et al. **J Pharm Pharmacol** 1995 Aug;47(8):647–50

Testosterone causes direct relaxation of rat thoracic aorta. Costarella CE, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):34–9

Pharmacologic studies on the mechanism of melatonin-induced vasorelaxation in rat aorta. Weekley LB. **J Pineal Res** 1995 Oct;19(3):133–8

Acute or chronic exercise alters angiotensin II-induced contraction of rat aorta. Izawa T, et al. **Jpn J Physiol** 1995; 45(6):1093–100

[Effects of cyclosporine A on the reactivity of the aorta with regenerated endothelium in rats] Dagenais F, et al. **Ann Chir** 1995;49(8):694–9 (Eng. Abstr.) **(Fre)**

[In vitro endothelial dysfunction after cold storage: comparison with various preservative solutions] Dagenais F, et al. **Ann Chir** 1995;49(8):700–5 (Eng. Abstr.) **(Fre)**

[Effect of pentoxifylline on the vascular toxicity secondary to cyclosporine in rats] Latulippe JF, et al. **Ann Chir** 1995; 49(8):712–8 (Eng. Abstr.) **(Fre)**

[Effect of benzquercin on the connective tissue of lathyritic mice. Optic and electron microscopic study] Azzi G, et al. **Pathol Biol (Paris)** 1995 May;43(5):448–60 (Eng. Abstr.) **(Fre)**

[Differences between the effects of indorenate and other 5-HT1A agonists on the rabbit aorta] Castillo C, et al. **Arch Inst Cardiol Mex** 1995 Sep–Oct;65(5):395–402 (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Myoendothelial contacts in the human fetal aorta. Sosa-Melgarejo JA, et al. **Arch Med Res** 1995 Winter; 26(4):431–5

Expression of collagens and decorin during aortic arch artery development: implications for matrix pattern formation. Thieszen SL, et al. **Matrix Biol** 1995 Jul;14(7):573–82

Reconstruction of the aortic arches of a 28-day human embryo (stage 13) using the Born technique. Pillet JC, et al. **Surg Radiol Anat** 1995;17(2):129–32, 11–2 **(Eng, Fre)**

ENZYMOLOGY

Time course of phorbol ester-induced contraction and protein kinase C activation in rat aorta. Bazan E, et al. **Eur J Pharmacol** 1995 Aug 15;290(3):253–7

Expression and preferential inhibition of inducible nitric oxide synthase in aortas of endotoxemic rats. Weigert AL, et al. **J Am Soc Nephrol** 1995 Jun;5(12):2067–72

GROWTH & DEVELOPMENT

Growth potential in the new aortic arch after non-end-to-end repair of aortic arch interruption in infancy. Monro JL, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1212–6

IMMUNOLOGY

Relative importance of ischemic injury and immunological injury on the development of transplant arteriosclerosis in rabbit aortic allografts. Andersen HO, et al. **Transplantation** 1995 Oct 15;60(7):631–8

INJURIES

The CT appearance of aortic transection. Marotta R, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):647–51

Penetrating ulcer of the descending aorta mimicking a traumatic aortic laceration. Patel NH, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):20

The management of combined skeletal and arterial injuries of the lower extremity. Gates JD. **Am J Orthop** 1995 Sep; 24(9):674–80

Synergistic inhibitory effect of angiotensin-converting enzyme inhibitor and heparin on intimal hyperplasia after rat aorta injury. Park JS, et al. **Angiology** 1996 Jan; 47(1):9–14

Traumatic rupture of the descending thoracic aorta. Orend KH, et al. **Ann Ital Chir** 1996 Jan–Feb;67(1):21–3; discussion 23–5

Mortality and neurologic morbidity after repair of traumatic aortic disruption. Nocolosi AC, et al. **Ann Thorac Surg** 1996 Mar;61(3):875–8

Traumatic thoracic aortic rupture in the pediatric patient. Trachiotis GD, et al. **Ann Thorac Surg** 1996 Sep; 62(3):724–31; discussion 731–2

Percutaneous tamponade of inadvertent transthoracic catheterization of the aorta. Walser EM, et al. **Ann Thorac Surg** 1996 Sep;62(3):895–6

Blunt thoracic aortic trauma. A cost–utility approach for injury detection. Brasel KJ, et al. **Arch Surg** 1996 Jun; 131(6):619–25; discussion 625–6

Phenotypic heterogeneity of rat arterial smooth muscle cell clones. Implications for the development of experimental intimal thickening. Bochaton-Piallat ML, et al. **Arterioscler Thromb Vasc Biol** 1996 Jun;16(6):815–20

Traumatic aortic incompetence associated with transection of the thoracic aorta. Paone RF, et al. **Chest** 1996 Apr; 109(4):1118–9

Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. Nielsen LB, et al. **Circ Res** 1996 Apr; 78(4):615–26

Role of transesophageal echocardiography in the diagnosis and management of traumatic aortic disruption. Vignon P, et al. **Circulation** 1995 Nov 15;92(10):2959–68

Computed tomography of thoracic aortic trauma. Biquet JF, et al. **Eur Radiol** 1996;6(1):25–9

Blunt traumatic rupture of the thoracic aorta: an epidemiological perspective. Hill DA, et al. **J R Coll Surg Edinb** 1996 Apr;41(2):84–7

Helical CT angiography for traumatic aortic rupture: correlation with aortography and surgery in five cases. Schnyder P, et al. **J Thorac Imaging** 1996 Winter; 11(1):39–45

Mortality and prognostic factors in penetrating injuries of the aorta. Demetriades D, et al. **J Trauma** 1996 May; 40(5):761–3

Thoracic aorta injuries: management and outcome of 144 patients. Hunt JP, et al. **J Trauma** 1996 Apr;40(4):547–55; discussion 555–6

Routine transesophageal echocardiography for the diagnosis of aortic disruption in trauma patients without enlarged mediastinum. Vignon P, et al. **J Trauma** 1996 Mar; 40(3):422–7

Aortic transection secondary to rodeo injury. Tripp HF Jr, et al. **Mil Med** 1995 Aug;160(8):422–3

Traumatic aortic injury: diagnosis with contrast-enhanced thoracic CT—five-year experience at a major trauma center. Mirvis SE, et al. **Radiology** 1996 Aug;200(2):413–22

Acute traumatic rupture of the thoracic aorta. A comparison of techniques. Von Oppell UO, et al. **S Afr J Surg** 1996 Feb;34(1):19–24

Subintimal hematoma of the aorta after deceleration injury [letter; comment] Pezzella AT. **Tex Heart Inst J** 1996; 23(1):70–1. Comment on: Tex Heart Inst J 1995;22(3):268–70.

Blunt traumatic injury of the thoracic aorta following commercial airline crashes. Pezzella AT. **Tex Heart Inst J** 1996;23(1):65–7

Subintimal hematoma of the aorta after deceleration injury [see comments] Roughneen PT, et al. **Tex Heart Inst J** 1995;22(3):268–70. Comment in: Tex Heart Inst J 1996;23(1):70–1.

[Arterial embolism caused by penetration and migration of a bullet through the thoracic aorta] Todorić M, et al. **Vojnosanit Pregl** 1994 Jan–Feb;51(1):65–9 **(Scr)**

[Diagnostic role of the combination of computerized tomography and angiography in traumatic injuries of the thoracic aorta] Fava M, et al. **Rev Med Chil** 1995 Jul; 123(7):857–64 (Eng. Abstr.) **(Spa)**

METABOLISM

Effect of age on the pattern of short-term albumin uptake by the rabbit aortic wall near intercostal branch ostia. Sebkhi A, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb; 16(2):317–27

Visualization of the transport pathways of low density lipoproteins across the endothelial cells in the branched regions of rat arteries. Kao CH, et al. **Atherosclerosis** 1995 Jul;116(1):27–41

Differential labelings suggest two specific phospholipid subclass hydrolysis promoted by PDGF-BB in vascular smooth muscle cells. Comminges C, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):1008–13

Identification of a novel isoform of estrogen receptor, a potential inhibitor of estrogen action, in vascular smooth muscle cells. Inoue S, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):766–72

Hydrolysis of cyclic guanosine monophosphate and cyclic adenosine monophosphate by the penis and aorta of the diabetic rat. Miller MA, et al. **Br J Urol** 1996 Aug; 78(2):252–6

Effects of pressure-induced stretch and convection on low-density lipoprotein and albumin uptake in the rabbit aortic wall. Meyer G, et al. **Circ Res** 1996 Sep;79(3):532–40

Age-related changes in amounts and concentrations of collagen and elastin in normotensive human thoracic aorta. Cattell MA, et al. **Clin Chim Acta** 1996 Feb 9;245(1):73–84

Alteration in the release of endothelium-derived relaxing factors by alpha-adrenoceptor stimulation in the aorta of stroke-prone spontaneously hypertensive rats. Shimamura K, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S144–5

Interaction of 5-aminosalicylic acid with nitric oxide on rat aortic strips and human platelets. Pallapies D, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):145–9

Increased responsiveness and decreased expression of G proteins in deoxycorticosterone hypertension. Kanagy NL, et al. **Hypertension** 1996 Mar;27(3 Pt 2):740–5

Thrombin stimulates phosphorylation of insulin-like growth factor-1 receptor, insulin receptor substrate-1, and phospholipase C-gamma 1 in rat aortic smooth muscle cells. Rao GN, et al. **J Biol Chem** 1995 Nov 17; 270(46):27871–5

Natriuretic peptide receptors in the kidney and the ventral and dorsal aortae of the Atlantic hagfish Myxine glutinosa (Agnatha). Toop T, et al. **J Exp Biol** 1995 Sep;198 (Pt 9):1875–82

The role of increased nitric oxide in the vascular hyporeactivity to noradrenaline in long-term portal vein ligated rats. Michielsen PP, et al. **J Hepatol** 1995 Sep; 23(3):341–7

An ultrastructural and immunocytochemical study of thoracic aortic endothelium in aged Sprague-Dawley rats. Aliev G, et al. **J Submicrosc Cytol Pathol** 1995 Oct; 27(4):477–90

PATHOLOGY

Three-dimensional gadolinium-enhanced MR angiography of the thoracic aorta. Prince MR, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1387–97

Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Westermark P, et al. **Am J Pathol** 1995 Nov;147(5):1186–92

Deposition pattern of monocytes and fatty streak development in hypercholesterolemic rabbits. Back MR, et al. **Atherosclerosis** 1995 Jul;116(1):103–15

Three-dimensional time-of-flight MR angiography of the arch of aorta and its major branches: a comparative study with contrast angiography. Kumar S, et al. **Clin Radiol** 1996 Jan;51(1):18–21

Detection of abnormal aortic elastic properties in asymptomatic patients with Marfan syndrome by combined transoesophageal echocardiography and acoustic quantification. Franke A, et al. **Heart** 1996 Mar; 75(3):307–11

Pathologic leukocyte infiltration of the rabbit aorta confers a vasomotor effect to chemotactic peptides through cyclooxygenase-derived metabolites. Petitclerc E, et al. **J Immunol** 1996 May 1;156(9):3426–34

Effect of the antioxidant probucol on transplant arteriosclerosis in aorta-allografted rabbits. Andersen HO, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1561–71

MR imaging of the thoracic aorta. Flamm SD, et al. **Magn Reson Imaging Clin N Am** 1996 May;4(2):217–35 (54 ref.)

Magnetic resonance angiography of the thoracic aorta. Hartnell GG. **Magn Reson Imaging Clin N Am** 1993 Dec; 1(2):315–26 (47 ref.)

MR of right aortic arch [letter] Newman B. **Pediatr Radiol** 1996;26(5):367–9

Human aorta: preliminary results with virtual endoscopy based on three-dimensional MR imaging data sets. Davis CP, et al. **Radiology** 1996 Apr;199(1):37–40

[Calcified proliferation of the descending thoracic aorta] Fadel E, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):1039–42 (10 ref.) (Eng. Abstr.) **(Fre)**

[Analytical evaluation of compression and displacement of the esophagus and trachea due to right aortic arch with MR imaging] Ito K, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Feb; 56(3):89–93 (Eng. Abstr.) **(Jpn)**

[A case of non-small-cell primary lung cancer invading distal aortic arch and left subclavian artery] Tanaka K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Nov;43(11):1854–7 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Determinants of arterial stiffness in Chinese migrants to Australia. Dart AM, et al. **Atherosclerosis** 1995 Oct; 117(2):263–72

Abnormal activation of K+ channels underlies relaxation to bacterial lipopolysaccharide in rat aorta. Hall S, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):184–90

alpha-1-Adrenergic receptor stimulation causes arachidonic acid release through pertussis toxin-sensitive GTP-binding protein and JNK activation in rabbit aortic smooth muscle cells. Nishio E, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):277–82

Oxidative release of nitric oxide accounts for guanylyl cyclase stimulating, vasodilator and anti-platelet activity of Piloty's acid: a comparison with Angeli's salt. Zamora R, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):333–9

Noninvasive aortic pressure and flow measurement. Etemad ME, et al. **Biomed Sci Instrum** 1996;32:175–81

Comparison of rat aortic, carotid & femoral artery viscoelastic properties using harmonic analysis. Stinnett HO, et al. **Biomed Sci Instrum** 1996;32:189–96

Regulation of kinin-induced contraction and DNA synthesis by inflammatory cytokines in the smooth muscle of the rabbit aorta. Levesque L, et al. **Br J Pharmacol** 1995 Sep; 116(1):1673–9

Pressure-diameter relation of the human aorta. A new method of determination by the application of a special ultrasonic dimension catheter. Stefanadis C, et al. **Circulation** 1995 Oct 15;92(8):2210–9

Endothelium-dependent relaxation of rat thoracic aorta by amrinone-induced nitric oxide release. Mori K, et al. **Eur Heart J** 1996 Feb;17(2):308–16

Effect of sodium nitroprusside on cerebral haemodynamics during cross-clamping of the descending thoracic aorta in pigs. Strømholm T, et al. **Eur J Surg** 1996 Apr; 162(4):329–34

Effects of polysorbates and Cremophor EL on vascular responses in rat aorta. Zengil H, et al. **Experientia** 1995 Nov 15;51(11):1055–9

Alpha 1A-adrenoceptor subtype effectively increases Ca(2+)-sensitivity for contraction in rabbit thoracic aorta. Satoh M, et al. **Gen Pharmacol** 1995 Mar;26(2):357–62

Indigo carmine inhibits endothelium-dependent and -independent vasodilation. Chang KS, et al. **Hypertension** 1996 Feb;27(2):228–34

Large curvature effect on pulsatile entrance flow in a curved tube: model experiment simulating blood flow in an aortic arch. Naruse T, et al. **J Biomech Eng** 1996 May; 118(2):180–6

Phase-contrast echo-planar MR imaging: real-time quantification of flow and velocity patterns in the thoracic vessels induced by Valsalva's maneuver. Eichenberger AC, et al. **J Magn Reson Imaging** 1995 Nov–Dec;5(6):648–55

The origin and significance of secondary flows in the aortic arch. Black MM, et al. **J Med Eng Technol** 1995 Nov–Dec; 19(6):192–7

Heterogeneity of endothelium-dependent mechanisms in different rabbit arteries. Ferrer M, et al. **J Vasc Res** 1995 Sep–Oct;32(5):339–46

Acute or chronic exercise alters angiotensin II-induced contraction of rat aorta. Izawa T, et al. **Jpn J Physiol** 1995; 45(6):1093–100

Pencil excitation with interleaved fourier velocity encoding: NMR measurement of aortic distensibility. Hardy CJ, et al. **Magn Reson Med** 1996 Jun;35(6):814–9

PHYSIOPATHOLOGY

Detection of aortic plaques by transesophageal echocardiography in patients with ischemic stroke. Acartürk E, et al. **Acta Neurol Scand** 1995 Aug;92(2):170–2

Endothelial constitutive nitric oxide synthase protein and mRNA increased in rabbit atherosclerotic aorta despite impaired endothelium-dependent vascular relaxation. Kanazawa K, et al. **Am J Pathol** 1996 Jun;148(6):1949–56

Endothelial dysfunction in coronary vessels and thoracic aorta of rats exposed to cigarette smoke. Jorge PA, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):410–3

Comparison of the effects of hypercholesterolaemia on relaxation responses in aortas of spontaneously hypertensive rats and Dahl salt-sensitive rats. Kitagawa S, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S251–3

Chronic vitamin E treatment prevents defective endothelium-dependent relaxation in diabetic rat aorta. Keegan A, et al. **Diabetologia** 1995 Dec;38(12):1475–8

Effect of sodium nitroprusside on cardiac output during cross-clamping of the descending thoracic aorta in pigs. Aadahl P, et al. **Eur Surg Res** 1995;27(5):323–31

Validation of carotid artery tonometry as a means of estimating augmentation index of ascending aortic pressure. Chen CH, et al. **Hypertension** 1996 Feb;27(2):168–75

Association and cosegregation of stroke with impaired endothelium-dependent vasorelaxation in stroke prone, spontaneously hypertensive rats. Volpe M, et al. **J Clin Invest** 1996 Jul 15;98(2):256–61

Magnetic resonance velocity vector mapping of blood flow in thoracic aortic aneurysms and grafts. Bogren HG, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):704–14

Evaluation of the mechanism of endothelial dysfunction in the genetically-diabetic BB rat. Pieper GM, et al. **Life Sci** 1996;58(9):PL147–52

RADIATION EFFECTS

[Chemiluminescence and triboluminescence of the endothelium of the thoracic aorta in gamma-irradiated rabbits with experimental hypercholesterolemia] Orel VE, et al. **Radiats Biol Radioecol** 1996 Jan–Feb;36(1):82–7 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

CT aortography of thoracic aortic rupture. Gavant ML, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):955–61

Case report: imaging of Takayasu arteritis in the acute stage. Hayashi K, et al. **Br J Radiol** 1996 Feb;69(818):189–91

Technical note: inspiration or expiration? Reducing motion artefact in digital subtraction arch angiography of the extracranial carotid arteries. Withers DJ, et al. **Br J Radiol** 1995 Sep;68(813):1017–20

High level cross of the esophagus with the descending aorta in scoliosis: CT study. Takahashi K, et al.

J Comput Assist Tomogr 1996 May-Jun;20(3):460-4

Calcification of the ligamentum arteriosum in adults: CT features. Wimpfheimer O, et al.
J Comput Assist Tomogr 1996 Jan-Feb;20(1):34-7

[Exploration of the thoracic aorta, excluding the aortic valve] Douek P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):552-60 (12 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic role of the combination of computerized tomography and angiography in traumatic injuries of the thoracic aorta] Fava M, et al. **Rev Med Chil** 1995 Jul; 123(7):857-64 (Eng. Abstr.) **(Spa)**

SURGERY

Trimethaphan versus sodium nitroprusside for the control of proximal hypertension during thoracic aortic cross-clamping: the effects on spinal cord ischemia. Simpson JI, et al. **Anesth Analg** 1996 Jan;82(1):68-74

Is clamp and sew still viable for thoracic aortic resection? Mauney MC, et al. **Ann Surg** 1996 May;223(5):534-40; discussion 540-3

Selective cerebral perfusion technique during aortic arch repair in neonates. Asou T, et al. **Ann Thorac Surg** 1996 May;61(5):1546-8

Regional effects of aortomyoplasty in acute ischemia. Cardone JC, et al. **Ann Thorac Surg** 1996 Jan;61(1):426-9

Descending thoracic aortomyoplasty: a technique for clinical application. Flum DR, et al. **Ann Thorac Surg** 1996 Jan; 61(1):93-8

1988: The long-term success of skeletal muscle in aortic repair. Updated in 1995. Gardner TJ. **Ann Thorac Surg** 1995 Dec;60(6):1856

Bypass graft for complex forms of isthmic aortic coarctation in adults. Grinda JM, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1299-302

Late aneurysm after subclavian flap aortoplasty for coarctation of the aorta. Kino K, et al.
Ann Thorac Surg 1996 Apr;61(4):1262-4 (8 ref.)

Growth potential in the new aortic arch after non-end-to-end repair of aortic arch interruption in infancy. Monro JL, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1212-6

Mortality and neurologic morbidity after repair of traumatic aortic disruption. Nocolosi AC, et al. **Ann Thorac Surg** 1996 Mar;61(3):875-8

Reversed bevel technique for anastomosis at the aortic arch. Ravichandran PS, et al. **Ann Thorac Surg** 1996 Jan; 61(1):245-6

Effect of nitroglycerin on spinal cord ischemia after thoracic aortic cross-clamping. Simpson JI, et al.
Ann Thorac Surg 1996 Jan;61(1):113-7

Skeletal muscle ventricles in circulation: decreased incidence of rupture. Thomas GA, et al. **Ann Thorac Surg** 1996 Jan; 61(1):430-6

Resection of a thrombus floating in the aortic arch. Walther T, et al. **Ann Thorac Surg** 1996 Sep;62(3):899-901

Differential effect of the retropleural and retroperitoneal environments on healing of the inner wall of porous fabric prostheses in the thoracic and abdominal aorta of the same dog. Hayashida N, et al. **Ann Vasc Surg** 1995 Jul; 9(4):369-77

Polyvinylidene fluoride monofilament sutures: can they be used safely for long-term anastomoses in the thoracic aorta? Laroche G, et al. **Artif Organs** 1995 Nov;19(11):1190-9

Left atrial-aortic/femoral bypass with a centrifugal pump without systemic heparin during surgery on the descending aorta. Sander-Jensen K, et al. **Artif Organs** 1995 Jul; 19(7):774-6

Prosthetic graft infection in the descending thoracic aorta treated by extra-anatomic rerouting. Barnard SP, et al. **Cardiovasc Surg** 1995 Dec;3(6):703-5

Interrupted aortic arch. Impact of subaortic stenosis on management and outcome. Jacobs ML, et al.
Circulation 1995 Nov 1;92(9 Suppl):II128-31

Surgical treatment of aortic arch aneurysms using selective cerebral perfusion. Experience with 100 patients. Kazui T, et al. **Eur J Cardiothorac Surg** 1995;9(9):491-5

Pulmonary artery banding is not contraindicated in double inlet left ventricle with transposition and aortic arch obstruction. Webber SA, et al. **Eur J Cardiothorac Surg** 1995;9(9):515-20

An experimental study of optimal parameters for bipolar electrocoagulation. Dilley AV, et al.
Gastrointest Endosc 1995 Jul;42(1):27-30

Utilization of triple-lumen balloon catheter for occlusion of the ascending aorta during distal aortic arch surgery with hypothermic retrograde cerebral circulation technique through left thoracotomy. Okita Y, et al. **J Card Surg** 1995 Nov;10(6):699-702

Increased left ventricular contractility during cross-clamping of the descending thoracic aorta. Aakhus S, et al.
J Cardiothorac Vasc Anesth 1995 Oct;9(5):497-502

Isoflurane versus sodium nitroprusside for the control of proximal hypertension during thoracic aortic cross-clamping: effects on spinal cord ischemia. Simpson JI, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):491-6

Clinical experience with a collagen impregnated woven Dacron graft. Tolan M, et al.
J Cardiovasc Surg (Torino) 1995 Aug;36(4):323-7

Aprotinin use with hypothermic circulatory arrest for aortic valve and thoracic aortic surgery: renal function and early survival [see comments] Regragui IA, et al.
J Heart Valve Dis 1995 Nov;4(6):674-7. Comment in: J Heart Valve Dis 1995 Nov;4(6):669-73.

Left aortic arch with right descending aorta and right ligamentum arteriosum associated with d-TGA and large VSD: surgical treatment of a rare form of vascular ring. Watanabe M, et al. **J Pediatr Surg** 1995 Sep;30(9):1363-5

Isolated persistent fifth aortic arch with right-sided aortic arch. Wu JR, et al. **Jpn Heart J** 1995 Nov;36(6):813-7

Tracheomalacia before and after aortosternopexy: dynamic and quantitative assessment by electron-beam computed tomography with clinical correlation [see comments] Kao SC, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S187-93. Comment in: Pediatr Radiol 1995 Nov;25 Suppl 1:S197-8.

Repair of a ruptured aortic arch aneurysm complicated by postoperative paraplegia: report of a case. Hadama T, et al. **Surg Today** 1996;26(1):60-3

Transabdominal access to the thoracic aorta for aortofemoral bypass grafting. Tovar EA, et al. **Tex Heart Inst J** 1995; 22(3):255-7

[Diagnosis and treatment of interrupted aortic arch: report of 6 cases] Chen B, et al.
Chung Hua Wai Ko Tsa Chih 1995 Jul;33(7):433-4 (Eng. Abstr.) **(Chi)**

[Tactics and technique of primary correction of aortic arch interruption using a median sternotomy] Tláskal T, et al. **Rozhl Chir** 1995 May;74(4):188-92 (Eng. Abstr.) **(Cze)**

[Cerebral protection by selective cerebral perfusion during surgery on the aortic arch] Le Mee F, et al.
Arch Mal Coeur Vaiss 1995 Nov;88(11):1601-7 (Eng. Abstr.) **(Fre)**

[Revascularization of supra-aortic trunks from the femoral artery] Etienne G, et al. **Presse Med** 1995 Jul 1-8; 24(24):1124-6 (Eng. Abstr.) **(Fre)**

[Aortic valve reconstruction in ectasia of the aortic root and valve insufficiency] Schäfers HJ, et al. **Z Kardiol** 1996 Jun; 85(6):442-7 (Eng. Abstr.) **(Ger)**

[Prevention and therapy of prosthesis infections in the thoracic area] Haverich A, et al. **Zentralbl Chir** 1995; 120(8):630-4 (21 ref.) (Eng. Abstr.) **(Ger)**

[A case report on concomitant graft replacement of the total aortic root and the transverse aortic arch for type A acute aortic dissection associated with annuloaortic ectasia] Kawaharada N, et al. **Kyobu Geka** 1996 Apr;49(4):312-4 (Eng. Abstr.) **(Jpn)**

[Surgical results of total replacement of aortic root] Tsutsumi Y, et al. **Kyobu Geka** 1996 Mar;49(3):209-13 (Eng. Abstr.) **(Jpn)**

[Revascularization using vascular prosthesis in respiratory tract surgery] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):724-5 **(Jpn)**

[A case report of mediastinitis due to methicillin resistant Staphylococcus aureus after total aortic arch replacement] Asano S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):814-9 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Reoperation for coarctation of the aorta and interrupted aortic arch] Hirai M, et al.
Nippon Kyobu Geka Gakkai Zasshi 1995 Sep;43(9):1657-63 (Eng. Abstr.) **(Jpn)**

[Dissection of the pseudointima followed by lethal obstruction of the prosthetic graft—a case report] Ohuchi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec; 43(12):1963-6 (Eng. Abstr.) **(Jpn)**

[Acute type A aortic dissection after replacement of descending thoracic aorta for type B aortic dissection] Okada K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):848-52 (Eng. Abstr.) **(Jpn)**

[Simultaneous aortic root and total arch graft replacement in a patient with aortitis syndrome] Sasaki A, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Jun;44(6):839-43 (Eng. Abstr.) **(Jpn)**

[Comparison between retrograde cerebral perfusion and selective cerebral perfusion by intraoperative electroencepharogram] Sudo Y, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Feb;44(2):175-81 (Eng. Abstr.) **(Jpn)**

[Axillo-iliac bypass grafting for reoperation of graft stenosis after aortic arch reconstruction of type B interruption of the aortic arch: two cases report] Tsukuda K, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Feb;44(2):212-5 (Eng. Abstr.) **(Jpn)**

[A successful palliative arterial switch operation with arch repair for tricuspid atresia with ventriculoarterial discordance, subaortic stenosis, coarctation, and aortic arch hypoplasia] Yamagishi M, et al.
Nippon Kyobu Geka Gakkai Zasshi 1995 Dec;43(12):1981-7 (Eng. Abstr.) **(Jpn)**

[Palliative arterial switch] Caffarena Calvar JM, et al.
Rev Esp Cardiol 1996 Mar;49(3):229-32 (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

Importance of minor histocompatibility antigens in the development of allograft arteriosclerosis. Koulack J, et al.
Clin Immunol Immunopathol 1996 Sep;80(3 Pt 1):273-7

Total aortic arch replacement by a cryopreserved aortic homograft. Abad C, et al. **Eur J Cardiothorac Surg** 1995; 9(9):531-3

Effect of the antioxidant probucol on transplant arteriosclerosis in aorta-allografted rabbits. Andersen HO, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1561-71

Rat heart-aorta cluster transplantation: a novel model to study transplant rejection. D'Silva M, et al. **Transpl Int** 1995;8(4):298-306

Relative importance of ischemic injury and immunological injury on the development of transplant arteriosclerosis in rabbit aortic allografts. Andersen HO, et al.
Transplantation 1995 Oct 15;60(7):631-8

ULTRASONOGRAPHY

Spontaneous echocardiographic contrast in the thoracic aorta: factors associated with its occurrence and its association with embolic events. Finkelhor RS, et al.
Am Heart J 1995 Dec;130(6):1254-8

Preoperative intra-aortic ultrasonography to determine resectability in advanced oesophageal cancer. Akiyama S, et al. **Br J Surg** 1995 Dec;82(12):1671-4

Quantitative echocardiographic analysis of the aortic arch predicts outcome of balloon angioplasty of native coarctation of the aorta. Kaine SF, et al. **Circulation** 1996 Sep 1;94(5):1056-62

Images in cardiovascular medicine. Intra-aortic thrombus producing embolic arterial vascular disease. Lozano P, et al. **Circulation** 1996 Apr 1;93(7):1471

Pressure-diameter relation of the human aorta. A new method of determination by the application of a special ultrasonic dimension catheter. Stefanadis C, et al.
Circulation 1995 Oct 15;92(8):2210-9

Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. Silverman DI, et al.
J Am Coll Cardiol 1995 Oct;26(4):1062-7

Fetal arterial Doppler studies in twin-twin transfusion syndrome. Hecher K, et al. **J Ultrasound Med** 1995 Feb; 14(2):101-8

[Thrombus floating in the thoracic aorta revealed by mesenteric ischemia (letter)] Elian N, et al.
J Chir (Paris) 1996 May;133(3):146-7 **(Fre)**

[3-D echocardiography reconstruction of the thoracic aorta] von Hehn A. **Herz** 1995 Oct;20(5):340-7 (Eng. Abstr.) **(Ger)**

[The aortic arch as source of thromboembolism events--significance of echocardiography diagnosis] Gabelmann M, et al. **Z Kardiol** 1995 Sep;84(9):729-32 (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Calcified deposit formation in intimal thickenings of the human aorta. Bobryshev YV, et al. **Atherosclerosis** 1995 Nov;118(1):9-21

The role of proteoglycans in maintaining collagen fibril morphology. Dell'Orbo C, et al. **Histol Histopathol** 1995 Jul;10(3):583-8

An ultrastructural and immunocytochemical study of thoracic aortic endothelium in aged Sprague-Dawley rats. Aliev G, et al. **J Submicrosc Cytol Pathol** 1995 Oct; 27(4):477-90

[A quantitative analysis of the regional organizational characteristics of the aortic endotheliocyte layer in normotensive and spontaneously hypertensive rats] Gusev SA, et al. **Tsitologiia** 1996;38(2):119-28 (Eng. Abstr.) **(Rus)**

AORTIC ANEURYSM

Aortic aneurysm in heart transplant recipients. Muluk SC, et al. **J Vasc Surg** 1995 Dec;22(6):689-94; discussion 695-6

[Pathophysiology and clinical aspects of dissecting aortic aneurysms] Szabóová-Tomoriová E, et al. **Vnitr Lek** 1995 Jul;41(7):480-4 (36 ref.) (Eng. Abstr.) **(Slo)**

BLOOD

[Influence of acute aortic dissection, on platelet function second department of surgery, department of pharmacy: preliminary report] Moriyama Y, et al.
Nippon Geka Gakkai Zasshi 1995 Oct;96(10):725 **(Jpn)**

CHEMICALLY INDUCED

Intermittent cocaine use associated with recurrent dissection of the thoracic and abdominal aorta. Chang RA, et al.
Chest 1995 Dec;108(6):1758-62

COMPLICATIONS

Right ventricular obstruction in aortic dissection: a mechanism of hemodynamic collapse. Downey RJ, et al.
Ann Thorac Surg 1996 Mar;61(3):988-90

Intermittent hypoxia due to right atrial compression by an ascending aortic aneurysm. Savage EB, et al.
Ann Thorac Surg 1996 Aug;62(2):582-3

Lymphoplasmacytic aortitis and acute aortic dissection. An uncommon association. Faye-Petersen OM, et al.
Arch Pathol Lab Med 1996 Apr;120(4):402-4 (20 ref.)

Primary aortoesophageal fistula caused by an atherosclerotic thoracoabdominal aortic aneurysm: a case report and review of the literature. Hageman JH, et al.
Cardiovasc Surg 1995 Oct;3(5):495-9 (17 ref.)

Primary aortogastric fistula: a complication of ruptured aortic aneurysm. Lorimer JW, et al.
J Cardiovasc Surg (Torino) 1996 Aug;37(4):363-6

Acquired aortopulmonary fistula in pseudoaneurysm of the aorta six years after a Bentall operation. Chevalier P, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1143-4

Acute aortic dissection with intramural hematoma: possibility of transition to classic dissection or aneurysm. Ide K, et

al. **J Thorac Imaging** 1996 Winter;11(1):46–52

Subtotal rarefication of one aortic leaflet in a bicuspid aortic valve due to large aneurysm of left Valsalva's sinus. Cottogni M, et al. **Scand J Thorac Cardiovasc Surg** 1995; 29(2):87–90

[Dissecting aortic aneurysm combined with hepatorenal syndrome] Procházka J, et al. **Vnitr Lek** 1995 Jul; 41(7):462–6 (Eng. Abstr.) **(Cze)**

[Two case reports of Stanford type A acute aortic dissection complicated with thrombosed false lumen and saccular aneurysm formation] Jinno T, et al. **Kyobu Geka** 1995 Oct; 48(11):937–40 (Eng. Abstr.) **(Jpn)**

[The shock patients with the cardiac tamponade resulting from acute type A aortic dissection] Murata N, et al. **Kyobu Geka** 1996 Jun;49(6):460–3 (Eng. Abstr.) **(Jpn)**

[A successful repair of the aortic dissection (DeBakey type I) with ischemic complications of the kidney and lower extremities] Uwabe K, et al. **Kyobu Geka** 1995 Aug; 48(9):792–5 (Eng. Abstr.) **(Jpn)**

CONGENITAL

Congenital aneurysm of the sinus of Valsalva dissecting into the interventricular septum. Abad C. **Cardiovasc Surg** 1995 Oct;3(5):563–4

Morphometric features of ruptured congenital sinus of Valsalva aneurysm: implication for surgical treatment. van Son JA, et al. **J Cardiovasc Surg (Torino)** 1995 Oct; 36(5):433–6

DIAGNOSIS

Inflammatory aneurysm of the ascending aorta mimicking intramural hemorrhage [letter; comment] Federmann M, et al. **Circulation** 1996 Apr 1;93(7):1477–8. Comment on: Circulation 1995 Sep 15;92(6):1376–8. Comment on: Circulation 1995 Sep 15;92(6):1465–72.

Images in cardiovascular medicine. Saccular aortic aneurysm simulating pulmonary artery aneurysm. Fred HL, et al. **Circulation** 1996 Apr 15;93(8):1601

Acute dissection of the aorta: options for diagnostic imaging. Razavi M. **Cleve Clin J Med** 1995 Nov–Dec;62(6):360–5 (16 ref.)

Management of aortic dissection. Westaby S. **Curr Opin Cardiol** 1995 Sep;10(5):505–10 (17 ref.)

Sequential MR signal change of the thrombus in the false lumen of thrombosed aortic dissection. Kaminaga T, et al. **Magn Reson Imaging** 1995;13(6):773–9

[Multiplicity of clinical symptoms and manifestations of unruptured aneurysms of the sinus of Valsalva—3 case reports] Wiemer J, et al. **Z Kardiol** 1996 Apr;85(4):221–5 (Eng. Abstr.) **(Ger)**

[Diagnostic accuracy of transesophageal echocardiography in the diagnosis of aortic dissection: comparison with computerized axial tomography] Nicosia A, et al. **Cardiologia** 1995 May;40(5):329–39 (Eng. Abstr.) **(Ita)**

[Unusual clinical course of ruptured aortic aneurysms—reports of three cases (corrected and republished article originally printed in Pol Arch Med Wewn 1995 Jan;93(1):69–76)] Mitkowski P, et al. **Pol Arch Med Wewn** 1995 Feb;93(2):171–8 (Eng. Abstr.) **(Pol)**

[Unusual clinical course of ruptured aortic aneurysms—report of three cases] Mitkowski P, et al. **Pol Arch Med Wewn** 1995 Jan;93(1):69–76 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Thrombolytic drugs and acute aortic dissection [letter; comment] Menon V, et al. **Am Heart J** 1995 Dec; 130(6):1312–3. Comment on: Am Heart J 1994 Dec;128(6 Pt 1):1234–7.

[Medical treatment of aortic aneurysms using beta-blockers] Chakkour K, et al. **J Mal Vasc** 1995;20(4):288–9 (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Thoracic and thoracoabdominal aortic aneurysm and dissection: an investigation based on autopsy. Svensjö S, et al. **Br J Surg** 1996 Jan;83(1):68–71

Epidemiology of aortic aneurysm in the United States. Gillum RF. **J Clin Epidemiol** 1995 Nov;48(11):1289–98

ETHNOLOGY

Epidemiology of aortic aneurysm and peripheral vascular disease may show ethnic differences [letter; comment] Lip GY, et al. **BMJ** 1996 Jul 20;313(7050):173. Comment on: BMJ 1996 Apr 13;312(7036):948.

ETIOLOGY

Aortic aneurysms at the site of the repair of coarctation of the aorta: a review of 48 patients. Knyshov GV, et al. **Ann Thorac Surg** 1996 Mar;61(3):935–9

Dissection of an allograft ascending aorta after aortic root replacement. Smith JA, et al. **Ann Thorac Surg** 1996 Mar; 61(3):1011–2

Late development of dissecting aneurysm following balloon angioplasty of native aortic coarctation [see comments] Aydogan U, et al. **Cathet Cardiovasc Diagn** 1995 Nov; 36(3):226–9. Comment in: Cathet Cardiovasc Diagn 1995 Nov;36(3):230–1.

Aneurysm associated with balloon angioplasty of aortic coarctation: future prevention and treatment [editorial; comment] Ruiz CE, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):230–1. Comment on: Cathet Cardiovasc Diagn 1995 Nov;36(3):226–9.

Aortic dissection in a cardiac allograft recipient: a case report. Pak PH, et al. **J Heart Lung Transplant** 1995 Sep–Oct;14(5):1003–5

Vascular complications of total abdominal perfusion and aortic stop-flow infusion. Klein ES, et al. **J Surg Oncol** 1996 Jan;61(1):17–9

[Annular ectasia of the aorta in a patient with acquired cutis laxa (letter)] Chavanon O, et al. **Presse Med** 1996 Feb 17; 25(6):261 **(Fre)**

[A case of aortic dissection associated with congenital bicuspid aortic valve] Fujiyoshi K, et al. **Kyobu Geka** 1996 Jun;49(6):468–70 (Eng. Abstr.) **(Jpn)**

GENETICS

Familial aorto-cervicocephalic arterial dissections and congenitally bicuspid aortic valve. Schievink WI, et al. **Stroke** 1995 Oct;26(10):1935–40

HISTORY

Stenting for aortic aneurysm: an early report of a minimal access procedure. Miller SS. **Ann R Coll Surg Engl** 1995 Mar;77(2 Suppl):77–8

MICROBIOLOGY

Aspergillus terreus, an uncommon fungus causing aortic root abscess and pseudoaneurysm. Koshi G, et al. **Indian Heart J** 1995 May–Jun;47(3):265–7

Aortic aneurysm complicating bacterial endocarditis in childhood. Davis EA, et al. **J Paediatr Child Health** 1996 Feb;32(1):68–70

Melioidosis causing a mycotic aneurysm [letter] Steinmetz I, et al. **Lancet** 1996 Jun 1;347(9014):1564–5

MORTALITY

Contrasting epidemiology of aortic aneurysm and peripheral vascular disease in England and Wales [see comments] Coggon D, et al. **BMJ** 1996 Apr 13;312(7036):948. Comment in: BMJ 1996 Jul 20;313(7050):173.

PATHOLOGY

Aortic dissection in giant-cell arteritis. Liu G, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):160–71

[Case 3/95. Instituto do Coração do Hospital das Clinicas FMUSP (clinical conference)] **Arq Bras Cardiol** 1995 May; 64(5):469–74 **(Por)**

PHYSIOPATHOLOGY

Electrocardiographic abnormalities in patients with acute aortic dissection. Hirata K, et al. **Am J Cardiol** 1995 Dec 1;76(16):1207–12

RADIOGRAPHY

Syphilitic aortic aneurysm and squamous cell carcinoma of the penis: a case report. el-Gadi SM, et al. **Int J STD AIDS** 1995 Sep–Oct;6(5):356–60

[Circular dissection of the ascending aorta with intimo-intimal invagination. CT diagnosis of a rare form of aortic dissection] Hillemanns A, et al. **Radiologe** 1996 May;36(5):446–8 (Eng. Abstr.) **(Ger)**

[Late phase contrast enhanced-CT analysis of thrombosed type aortic dissection] Hayashi H, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(12):845–54 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Renal scintigraphy in the diagnosis of aortic dissection affecting the renal arteries. Gorenberg M, et al. **Clin Nucl Med** 1995 Sep;20(9):840–1

SURGERY

Endobronchial inflammatory polyp after thoracoabdominal aneurysm surgery: a late complication of use of a double-lumen endobronchial tube. Ikeda M, et al. **Anesthesiology** 1996 May;84(5):1234–6

Perioperative hepatic dysfunction in two patients during elective aortic aneurysm repair. Sprung J, et al. **Anesthesiology** 1995 Dec;83(6):1347–51

Aortic root replacement and extraanatomic bypass for interrupted aortic arch in an adult. Burton BJ, et al. **Ann Thorac Surg** 1995 Nov;60(5):1400–2

Embolization of biologic glue during repair of aortic dissection. Carrel T, et al. **Ann Thorac Surg** 1995 Oct; 60(4):1118–20

Reduced mortality and morbidity for ascending aortic aneurysm resection regardless of cause. Cohn LH, et al. **Ann Thorac Surg** 1996 Aug;62(2):463–8

Thoracoabdominal aortic aneurysms. Coselli JS. **Ann Thorac Surg** 1996 Jan;61(1):269–70

Operation for type A aortic dissection [letter] Lemole GM. **Ann Thorac Surg** 1995 Dec;60(6):1863–4

Embolization of biological glue after repair of acute aortic dissection [letter] Mastroroberto P, et al. **Ann Thorac Surg** 1996 Sep;62(3):946–7

"Legs" technique for management of widely separated coronary arteries during ascending aortic repair. Mills NL, et al. **Ann Thorac Surg** 1996 Mar;61(3):869–74

Acute aortic dissection in a patient with osteogenesis imperfecta [see comments] Moriyama Y, et al. **Ann Thorac Surg** 1995 Nov;60(5):1397–9 (8 ref.). Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Selective management of acute type B aortic dissection: long-term follow-up. Schor JS, et al. **Ann Thorac Surg** 1996 May;61(5):1339–41

Eradication of aortic infections with the use of cryopreserved arterial homografts. Vogt PR, et al. **Ann Thorac Surg** 1996 Sep;62(3):640–5

Acute aortic dissection as a complication of coronary artery surgery. Subramaniam P, et al. **Aust N Z J Surg** 1996 Jul; 66(7):498–500

Side-effect of endovascular grafting to treat aortic aneurysm. Norgren L, et al. **Br J Surg** 1996 Apr;83(4):520–1

Surgical management of aortic dissection during a 30-year period. Fann JI, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II113–21

Determining surgical indications for acute type B dissection based on enlargement of aortic diameter during the chronic phase. Kato M, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II107–12

Management of aortic dissection. Westaby S. **Curr Opin Cardiol** 1995 Sep;10(5):505–10 (17 ref.)

Aortic root replacement with a composite graft. Factors influencing immediate and long-term results. Bachet J, et al. **Eur J Cardiothorac Surg** 1996;10(3):207–13

The Marfan syndrome and the cardiovascular surgeon. Gott VL, et al. **Eur J Cardiothorac Surg** 1996;10(3):149–58

Surgical treatment of aortic arch aneurysms using selective cerebral perfusion. Experience with 100 patients. Kazui T, et al. **Eur J Cardiothorac Surg** 1995;9(9):491–5

Cryopreserved arterial homografts for in situ reconstruction of mycotic aneurysms and prosthetic graft infection. Vogt PR, et al. **Eur J Cardiothorac Surg** 1995;9(9):502–6

Intraaortic mass after repair of an aortic dissection. Rosenzweig BP, et al. **J Am Soc Echocardiogr** 1996 Jan–Feb;9(1):100–3

New technique for retrograde cerebral perfusion during arch aneurysm repair. Bartoccioni S, et al. **J Card Surg** 1995 Sep;10(5):592–3

Cardiopulmonary bypass in a post-lung-transplant patient. Cerza RF. **J Cardiothorac Vasc Anesth** 1996 Apr; 10(3):384–6

Combined use of aprotinin and a heparin-bonded cardiopulmonary bypass system for aortic aneurysm repair. Gallagher JM, et al. **J Cardiothorac Vasc Anesth** 1995 Dec; 9(6):728–30

Detection of cerebral malperfusion in chronic type "A" aortic dissection: the importance of bilateral arterial monitoring. Patla VR, et al. **J Cardiothorac Vasc Anesth** 1996 Apr; 10(3):378–9

Simultaneous Bentall's procedure and sternal turnover in a patient with Marfan syndrome. Chien HF, et al. **J Cardiovasc Surg (Torino)** 1995 Dec;36(6):559–62

Anterior patch aortic aneurysm model for the study of endoluminal grafts. Verbin C, et al. **J Invest Surg** 1995 Sep–Oct;8(5):381–8

Renal autotransplantation for aortic dissection in Marfan's syndrome. Thomson SD, et al. **J R Soc Med** 1995 Sep; 88(9):532P–533P

Aortic valve preservation in acute type A dissection: is it sound? von Segesser LK, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):381–90; discussion 390–1

Predictive factors for acute renal failure in thoracic and thoracoabdominal aortic aneurysm surgery. Safi HJ, et al. **J Vasc Surg** 1996 Sep;24(3):338–44; discussion 344–5

Preoperative disseminated intravascular coagulation (DIC) associated with aortic aneurysm—does it need to be corrected before surgery? Oba J, et al. **Surg Today** 1995; 25(12):1011–4

Surgical treatment of type A aortic dissections [letter; comment] Browdie DA, et al. **Tex Heart Inst J** 1996; 23(1):70. Comment on: Tex Heart Inst J 1995;22(3):250–3; discussion 253–4.

Surgical treatment of type A aortic dissections. Results with profound hypothermia and circulatory arrest [see comments] Ehrlich M, et al. **Tex Heart Inst J** 1995; 22(3):250–3; discussion 253–4. Comment in: Tex Heart Inst J 1996;23(1):70.

Correction of pectus excavatum combined with open heart surgery in a patient with Marfan's syndrome. Kalangos A, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):220–2

Fatal fungal infection of an ascending aortic graft. Wandschneider W, et al. **Thorac Cardiovasc Surg** 1995 Aug; 43(4):217–9

[Surgical treatment of ascending aortic dissecting aneurysm with Cabrol's operation in 3 patients] Yang C, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):561–2 (Eng. Abstr.) **(Chi)**

[Treatment of aortic aneurysm by endovascular prosthesis: conclusions and recommendations of the ANDEM (National Agency for Medical Development and Evaluation)] **Ann Cardiol Angeiol (Paris)** 1995 Jun–Aug; 44(6):310–2 **(Fre)**

[Coronary assessment and surgery for aortic aneurysm: systematic coronarography] Fabiani JN. **J Mal Vasc** 1996; 21 Suppl A:10–2 (Eng. Abstr.) **(Fre)**

[Presurgical evaluation of cerebral perfusion reserve in patients for cardiovascular surgery using 99mTc-ECD SPECT with diamox enhancement] Matsumura K, et al. **Kaku Igaku** 1996 Mar;33(3):223-31 (Eng. Abstr.) **(Jpn)**

[Surgical treatment for ascending aortic aneurysm using a transthoracic left ventricular venting] Emmoto T, et al. **Kyobu Geka** 1996 Feb;49(2):89-92; discussion 93-4 (Eng. Abstr.) **(Jpn)**

[Long-term results of Bentall and modified Bentall procedure in aortic root replacement] Ishibashi Y, et al. **Kyobu Geka** 1995 Oct;48(11):929-32 (Eng. Abstr.) **(Jpn)**

[Separate perfusion of upper and lower body under mild hypothermia during operation on the thoracoabdominal aorta] Ohmi M, et al. **Kyobu Geka** 1995 Aug;48(9):725-9; discussion 730-1 (Eng. Abstr.) **(Jpn)**

[Emergency surgical salvage for a type A early thrombosed aortic dissection complicated cardiac tamponade in a 80-year-old-patient] Ono Y, et al. **Kyobu Geka** 1996 Jun; 49(6):495-7 (Eng. Abstr.) **(Jpn)**

[Percutaneous placement of intraluminal stent-graft for aortic dissection: experimental study] Hashimoto M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Nov; 55(14):939-45 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of acute aortic dissections--a clinical study using a ringed intraluminal graft] Fujii H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1611-6 (Eng. Abstr.) **(Jpn)**

[Hiatal hernia incarceration during cardiopulmonary bypass in patient with acute aortic dissection--a case report] Hasegawa Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1680-3 (Eng. Abstr.) **(Jpn)**

[Acute aortic dissection with leg ischemia] Hata M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):499-504 (Eng. Abstr.) **(Jpn)**

[Successful treatment of an infected pseudoaneurysm of the ascending aorta with omental transfer--a case report] Inoue T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug; 43(8):1166-70 (Eng. Abstr.) **(Jpn)**

[Giant isolated extracadiac unruptured aneurysm of the right coronary sinus of valsalva--a case report] Mizushima T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb; 44(2):202-7 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Management of patients with closing aortic dissection] Moriyama Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1902-6 (Eng. Abstr.) **(Jpn)**

[Successful surgical treatment in a case of type IIIb acute aortic dissection complicated with acute myocardial infarction] Morota T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1972-6 (Eng. Abstr.) **(Jpn)**

[Acute type A aortic dissection after replacement of descending thoracic aorta for type B aortic dissection] Okada K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):848-52 (Eng. Abstr.) **(Jpn)**

[Factors affecting the occurrence of anastomotic leakage after graft replacement of type A aortic dissection] Sako H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct; 43(10):1736-40 (Eng. Abstr.) **(Jpn)**

[Surgical treatment for Stanford type A acute aortic dissection] Suda H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1890-4 (Eng. Abstr.) **(Jpn)**

[Renal autotransplantation for dissecting aneurysm] Takahashi A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1553-8 (Eng. Abstr.) **(Jpn)**

[Aortic dissection] Myhre HO, et al. **Tidsskr Nor Laegeforen** 1995 Sep 20;115(22):2754 **(Nor)**

[Aortic dissection. A 8-year material from health region 5] Myrmel T, et al. **Tidsskr Nor Laegeforen** 1995 Sep 20; 115(22):2773-6 (Eng. Abstr.) **(Nor)**

[Cerebrospinal fluid drainage to protect the spinal cord during surgical repair of thoracoabdominal aortic aneurysm] Maestre JM, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):378-82 (Eng. Abstr.) **(Spa)**

THERAPY

Cardiovascular shock. Rodgers KG. **Emerg Med Clin North Am** 1995 Nov;13(4):793-810 (61 ref.)

Endovascular repair of aortic aneurysms, arteriovenous fistulas, and false aneurysms. Parodi JC. **World J Surg** 1996 Jul-Aug;20(6):655-63

ULTRASONOGRAPHY

Pseudoaneurysm following aortic homograft: clinical implications? Oechslin E, et al. **Br Heart J** 1995 Dec; 74(6):645-9

Prolapse of an aortic dissection flap imaged by transoesophageal echocardiography. Richens T, et al. **Heart** 1996 Jan;75(1):34

Diagnosis of ascending aortic dissection by transesophageal echocardiography: utility of M-mode in recognizing artifacts. Evangelista A, et al. **J Am Coll Cardiol** 1996 Jan; 27(1):102-7

Accuracy of biplane and multiplane transesophageal echocardiography in diagnosis of typical acute aortic dissection and intramural hematoma. Keren A, et al. **J Am Coll Cardiol** 1996 Sep;28(3):627-36

Hypotension on initiation of cardiopulmonary bypass. Trunfio G. **J Cardiothorac Vasc Anesth** 1995 Aug; 9(4):469-70

[The main indications for transesophageal echocardiography] Lesbre JP. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):547-51 (21 ref.) (Eng. Abstr.) **(Fre)**

AORTIC ANEURYSM, ABDOMINAL

Management of descending aortic dissection. Orend KH, et al. **Ann Ital Chir** 1995 Nov-Dec;66(6):821-4 (8 ref.)

Pregnancy complicated by aortic dissection: caesarean delivery during extradural anaesthesia. Jayaram A, et al. **Br J Anaesth** 1995 Sep;75(3):358-60

Prospective evaluation of the Glasgow Aneurysm Score. Samy AK, et al. **J R Coll Surg Edinb** 1996 Apr;41(2):105-7

[Asymptomatic aneurysms of the abdominal aorta: in whom are they detected? When should a beta-blocker be prescribed? Who should have surgery and by which technique? (editorial)] Mellière D. **J Mal Vasc** 1995; 20(4):274-8 (12 ref.) (Fre)

[Localized dissection of the abdominal aorta. Diagnosis and surgical treatment] Esposito G, et al. **Minerva Chir** 1995 Jul-Aug;50(7-8):713-6 (Eng. Abstr.) **(Ita)**

BLOOD

Increased concentrations of cytokines and adhesion molecules in patients after repair of abdominal aortic aneurysm. Froon AH, et al. **Eur J Surg** 1996 Apr; 162(4):287-96

Intraoperative autotransfusion in aortic surgery: comparison of whole blood autotransfusion versus cell separation. Bartels C, et al. **J Vasc Surg** 1996 Jul;24(1):102-8

CLASSIFICATION

Morphological classification of abdominal aortic aneurysm in selection of patients for endovascular grafting. Schumacher H, et al. **Br J Surg** 1996 Jul;83(7):949-50

COMPLICATIONS

Transient dilatation of the abdominal aorta in an infant with Kawasaki disease associated with thrombocytopenia. Miyake T, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):521-5

Aortic aneurysm and dissection in giant cell arteritis [letter] Ginsburg R. **Ann Intern Med** 1996 Mar 15;124(6):615

Survival after aortic dissection in giant cell arteritis [letter] Richardson MP, et al. **Ann Rheum Dis** 1996 May; 55(5):332-3 (20 ref.)

Concurrent abdominal aortic aneurysm and urologic neoplasm: an argument for simultaneous intervention. Ginsberg DA, et al. **Ann Vasc Surg** 1995 Sep;9(5):428-33

Risk of rupture of large abdominal aortic aneurysms. Disagreement among vascular surgeons. Lederle FA. **Arch Intern Med** 1996 May 13;156(9):1007-9

Aortocaval fistula complicating abdominal aortic aneurysm: case report and literature review. Fenster MS, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):75-9

Case report: critical lower limb ischaemia due to aortic dissection relieved by percutaneous transfemoral fenestration. Cowling MG, et al. **Clin Radiol** 1995 Sep; 50(9):654-7

Vessel malformation in a patient with ADPKD: megadolichobasilar artery, abdominal aortic and iliac aneurysms. Stiasny B, et al. **Contrib Nephrol** 1995;115:182-4

Chronic contained rupture of an abdominal aortic aneurysm complicated by infection and femoral neuropathy. Case report. Aune S, et al. **Eur J Surg** 1995 Aug;161(8):613-4

Trash foot following injury: an unusual presentation of abdominal aortic aneurysm. Marsh SK, et al. **Injury** 1996 Jan;27(1):74-5

Escherichia coli infection of an abdominal aortic aneurysm. Khaira HS, et al. **J Infect** 1996 Mar;32(2):161-3 (14 ref.)

Primary aortoenteric fistula from a posttraumatic pseudoaneurysm. Napoli PJ, et al. **J Trauma** 1996 Jul; 41(1):149-52

Extracorporeal shock wave lithotripsy in 5 patients with aortic aneurysm [see comments] Deliveliotis C, et al. **J Urol** 1995 Nov;154(5):1671-2. Comment in: J Urol 1996 Jul;156(1):184.

Re: Extracorporeal shock wave lithotripsy in 5 patients with aortic aneurysm [letter; comment] Streem SB. **J Urol** 1996 Jul;156(1):184. Comment on: J Urol 1995 Nov;154(5):1671-2.

Congenital factor VII deficiency in a patient with an abdominal aortic aneurysm. Arroyo A, et al. **J Vasc Surg** 1996 Aug;24(2):288-90

Aortic dissection: percutaneous management of ischemic complications with endovascular stents and balloon fenestration. Slonim SM, et al. **J Vasc Surg** 1996 Feb; 23(2):241-51; discussion 251-3

In situ detection of frequent and active infection of human cytomegalovirus in inflammatory abdominal aortic aneurysms: possible pathogenic role in sustained chronic inflammatory reaction. Yonemitsu Y, et al. **Lab Invest** 1996 Apr;74(4):723-36

Chronic aortic dissection: presentation as acute renal failure. Manso C, et al. **Nephrol Dial Transplant** 1995;10(5):690-2

Aortic aneurysm in a four-year-old child with tuberous sclerosis. Tsukui A, et al. **Paediatr Anaesth** 1995;5(1):67-70

Direct erosion of lumbar spine by an abdominal aortic aneurysm, resulting in paraparesis: unusual presentation. Case report. Latif S, et al. **Paraplegia** 1995 Aug;33(8):480-1

Mural thrombi in abdominal aortic aneurysms: MR imaging characterization--useful before endovascular treatment? Castrucci M, et al. **Radiology** 1995 Oct;197(1):135-9

An unusual cause of back pain in a patient with an abdominal aortic aneurysm. A case report. Mason RJ, et al. **S Afr J Surg** 1995 Dec;33(4):167-9

Primary aortoenteric fistula. Barned H, et al. **West Indian Med J** 1995 Sep;44(3):93-5

[Coronary artery disease in patients with aortic abdominal aneurysm. Apropos of a consecutive series of 172 cases] Langanay T, et al. **Arch Mal Coeur Vaiss** 1996 Feb; 89(2):211-8 (30 ref.) (Eng. Abstr.) **(Fre)**

[[Aneurysm of the abdominal aorta and arteritis of the legs] Hassen-Khodja R, et al. **J Mal Vasc** 1995;20(4):301-4 (Eng. Abstr.) **(Fre)**

[Ureteral involvement in an inflammatory aneurysm of the abdominal aorta. (Apropos of a case. Review of the literature)] Soulié M, et al. **Prog Urol** 1995 Sep;5(4):590-5 (Eng. Abstr.) **(Fre)**

[Aortic dissection similar to giant cell arteritis: diagnostic difficulties and efficacy of steroid therapy] Cordioli E, et al. **Minerva Med** 1995 Jul-Aug;86(7-8):331-5 (Eng. Abstr.) **(Ita)**

[Arterial hypertension complicated by aortic dissection. Clinical analysis, results of conservative treatment] Grajek S, et al. **Przegl Lek** 1996;53(2):60-6 (Eng. Abstr.) **(Pol)**

[Inflammatory aorto-iliac aneurysm. A cause of extrinsic ureteral obstruction] García Díez F, et al. **Arch Esp Urol** 1995 Sep;48(7):750-3 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Temporary axillofemoral bypass: its use in high risk cardiac patients requiring urgent abdominal aneurysm repair. Lossing AG, et al. **Can J Cardiol** 1996 May;12(5):467-8

Abdominal aortic aneurysm. Rose WM 3rd, et al. **Compr Ther** 1995 Jul;21(7):339-43 (19 ref.)

Abdominal aortic aneurysms: assessment with gadolinium-enhanced time-of-flight coronal MR angiography (MRA). Laissy JP, et al. **Eur J Radiol** 1995 May;20(1):1-8

Idiopathic rupture of the iliac vein. Case report. Plate G, et al. **Eur J Surg** 1995 Aug;161(8):611-2

Primary dissection of the abdominal aorta. Satta J, et al. **Eur J Surg** 1995 Jul;161(7):527-9

Interobserver variability in measuring the dimensions of the abdominal aorta: comparison of ultrasound and computed tomography. Jaakkola P, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):230-7

Primary aortoenteric fistula: two new case reports and a review of 44 previously reported cases. Tareen AH, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):5-10 (34 ref.)

Chronic contained rupture of an aortic aneurysm mimicking infective spondylitis. Grevitt MP, et al. **Eur Spine J** 1996; 5(2):128-30

Clinical aspects and treatment of inflammatory abdominal aortic aneurysms. Pietri P, et al. **Int Angiol** 1995 Dec; 14(4):368-74

Comparison of magnetic resonance imaging methods for examinations of abdominal aortic aneurysms. Schick F, et al. **Invest Radiol** 1995 Oct;30(10):595-603

Aneurysmal form of aortoarteritis with aberrant right subclavian artery: diagnosis by Magnetic Resonance Angiography. Kumar S, et al. **Minerva Cardioangiol** 1995 Sep;43(9):375-8

[Detection of asymptomatic abdominal aorta in coronary disease patients having undergone coronarography] Hodara M, et al. **J Mal Vasc** 1995;20(4):279-84 (Eng. Abstr.) **(Fre)**

[Backache, claudicatio venosa and chronic diarrhea] Bertschinger P, et al. **Internist (Berl)** 1995 Dec; 36(12):1179-81 **(Ger)**

[Inflammatory aneurysm of the abdominal aorta] **Rontgenpraxis** 1995 Dec;48(12):340-1 **(Ger)**

[Aortocolic fistula as a rare complication of aorto-iliac aneurysms] Bruns C, et al. **Vasa** 1995;24(4):354-61 (Eng. Abstr.) **(Ger)**

[Atypical initial manifestation of Takayasu arteritis] Settmacher U, et al. **Zentralbl Chir** 1996;121(5):401-4 (Eng. Abstr.) **(Ger)**

[Evaluation of imaging methods used for diagnosis of abdominal aorta aneurysm] Pruszyński B, et al. **Pol Tyg Lek** 1995 Oct;50(40-44):60-3 **(Pol)**

DRUG THERAPY

Medical control of abdominal aortic aneurysm expansion rate [letter] Schneiderman J, et al. **J Vasc Surg** 1996 Aug; 24(2):297

ECONOMICS

Screening for abdominal aortic aneurysm: a computer assisted cost-utility analysis. St Leger AS, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):183-90

Private costs associated with abdominal aortic aneurysm screening: the importance of private travel and time costs [see comments] Bryan S, et al. **J Med Screen** 1995;2(2):62-6 . Comment in: J Med Screen 1995;2(2):61.

ENZYMOLOGY

Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. Sakalihasan N, et al. **J Vasc Surg** 1996 Jul; 24(1):127-33

AORTIC ANEURYSM, ABDOMINAL

EPIDEMIOLOGY

Aneurysms of the abdominal aorta in older adults. The Rotterdam Study. Pleumeekers HJ, et al. **Am J Epidemiol** 1995 Dec 15;142(12):1291–9

Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. Alcorn HG, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):963–70

Vascular emergencies: what's in season? Varty K, et al. **Cardiovasc Surg** 1995 Aug;3(4):409–11

Risk factors for abdominal aortic aneurysms in smokers. Franks PJ, et al. **Eur J Vasc Endovasc Surg** 1996 May; 11(4):487–92

Screening for abdominal aortic aneurysm and occlusive peripheral vascular disease in Japanese residents. Takei H, et al. **Surg Today** 1995;25(7):608–11

[Abdominal aortic aneurysm in the elderly] Mattace Raso F, et al. **Minerva Med** 1995 May;86(5):211–3 (Eng. Abstr.) **(Ita)**

[Prevalence of intraabdominal aneurysm in elderly patients] Molnar LJ, et al. **Rev Assoc Med Bras** 1995 Jan–Feb; 41(1):43–6 (Eng. Abstr.) **(Por)**

ETIOLOGY

Spinal cord injury increases the risk of abdominal aortic aneurysm. Gordon IL, et al. **Am Surg** 1996 Mar; 62(3):249–52

Aortic dissection in a 5–year old girl with Marfan's syndrome [letter] Ruiz ME, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):440–2 (14 ref.)

Aortic aneurysms in patients with autoimmune disorders treated with corticosteroids. Sato O, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):366–9 (17 ref.)

Current views on the pathogenesis of abdominal aortic aneurysms. Patel MI, et al. **J Am Coll Surg** 1995 Oct; 181(4):371–82 (152 ref.)

Abdominal aortic aneurysm associated with childhood sarcoidosis. Gedalia A, et al. **J Rheumatol** 1996 Apr; 23(4):757–9

A case of Pott's disease of the spine eroding into the suprarenal aorta. Hagino RT, et al. **J Vasc Surg** 1996 Sep; 24(3):482–6

Increased synthesis of matrix metalloproteinases by aortic smooth muscle cells is implicated in the etiopathogenesis of abdominal aortic aneurysms. Patel MI, et al. **J Vasc Surg** 1996 Jul;24(1):82–92

Does laminated intraluminal thrombus within abdominal aortic aneurysm cause anoxia of the aortic wall? [letter; comment] Vorp DA, et al. **J Vasc Surg** 1996 Mar; 23(3):540–1. Comment on: J Vasc Surg 1994 Oct;20(4):529–35; discussion 535–8.

The role of vitamin D3 in the aetiology of abdominal aortic aneurysms. Norman PE, et al. **Med Hypotheses** 1995 Jul; 45(1):17–20

Traumatic abdominal pseudoaneurysm secondary to child abuse. Roche KJ, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S247–8

Vascular and other serious infections with Mycobacterium bovis after bacillus of Calmette–Guérin therapy for bladder cancer. Hellinger WC, et al. **South Med J** 1995 Dec; 88(12):1212–6

[A case of ruptured thoracoabdominal aortic aneurysm complicated with high aortic occlusion] Satokawa H, et al. **Kyobu Geka** 1995 Nov;48(12):1053–6 (Eng. Abstr.) **(Jpn)**

[Etiology and pathogenesis of abdominal aortic aneurysms] Sukharev II, et al. **Klin Khir** 1995;(7–8):25–8 (32 ref.) **(Rus)**

GENETICS

Ultrasound screening of families with abdominal aortic aneurysm. Larcos G, et al. **Australas Radiol** 1995 Aug; 39(3):254–6

Unravelling the familial tendency to aneurysmal disease: popliteal aneurysm, hypertension and fibrillin genotype. MacSweeney ST, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):162–6

A clinicopathological study of familial abdominal aortic aneurysms. Origuchi N, et al. **Int Angiol** 1996 Mar; 15(1):26–32

[Familial risk of abdominal aortic aneurysm and its consequences for organization of selective detection] Limet R. **J Mal Vasc** 1995;20(4):285–7 (Eng. Abstr.) **(Fre)**

[Mode of genetic inheritance of abdominal aortic aneurysm: still no clear answers] Powell JT, et al. **Chirurg** 1995 Sep; 66(9):841–4 (21 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Features of autoimmunity in the abdominal aortic aneurysm. Gregory AK, et al. **Arch Surg** 1996 Jan;131(1):85–8

METABOLISM

Collagen, elastin and glycosaminoglycans in aortic aneurysms. Sobolewski K, et al. **Acta Biochim Pol** 1995; 42(3):301–7

Partial amino acid sequence of a novel 40–kDa human aortic protein, with vitronectin–like, fibrinogen–like, and calcium binding domains: aortic aneurysm–associated protein–40 (AAAP–40) [human MAGP–3, proposed] Xia S, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):36–9

Plasminogen activator and plasminogen activator inhibitor expression by normal and aneurysmal human aortic smooth muscle cells in culture. Louwrens HD, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):289–93

Alpha–1–antitrypsin deficiency in aneurysmal disease. St Jean P, et al. **Hum Hered** 1996 Mar–Apr;46(2):92–7

MICROBIOLOGY

Microbiological monitoring of aortic aneurysm sac contents during abdominal aneurysmectomy: results in 176 patients and review of the literature. Fourneau I, et al. **Acta Chir Belg** 1996 Jun;96(3):119–22 (14 ref.)

Infected aortic aneurysm and vertebral osteomyelitis after intravesical bacillus Calmette–Guérin therapy. Rozenblit A, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):711–3

A case of abdominal aortic aneurysm infected by Nocardia asteroides [letter] Bocchetti M, et al. **Biomed Pharmacother** 1996;50(1):36

Contained rupture of infected abdominal aortic aneurysm due to systemic candidiasis. Ikeda M, et al. **Cardiovasc Surg** 1995 Dec;3(6):711–4 (30 ref.)

Relevance of bacterial cultures of abdominal aortic aneurysm contents. van der Vliet JA, et al. **Surgery** 1996 Feb; 119(2):129–32

[Abdominal aortic aneurysm infected with Campylobacter fetus spp fetus. Report of a case and review of the literature] Kuzniec S, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep–Oct;50(5):284–8 (39 ref.) (Eng. Abstr.) **(Por)**

MORTALITY

A statewide, population–based time–series analysis of the outcome of ruptured abdominal aortic aneurysm. Rutledge R, et al. **Ann Surg** 1996 May;223(5):492–502; discussion 503–5

Perioperative mortality of elective abdominal aortic aneurysm surgery. A clinical prediction rule based on literature and individual patient data. Steyerberg EW, et al. **Arch Intern Med** 1995 Oct 9;155(18):1998–2004

The influence of age on operative mortality and long–term relative survival following emergency abdominal aortic aneurysm operations. Aune S, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):338–41

The potential of simple clinical information and electrocardiogram to predict mortality of primary elective abdominal aortic reconstruction. De Mol Van Otterloo JC, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):470–7

Decreased mortality of abdominal aortic aneurysms in a peripheral county. Lindholt JS, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):466–9

Trends in mortality and hospital morbidity due to abdominal aortic aneurysms. Millar WJ, et al. **Health Rep** 1995; 7(1):19–27, 21–30 **(Eng, Fre)**

Improvement in results of repair of type IV thoracoabdominal aortic aneurysms. Schwartz LB, et al. **J Vasc Surg** 1996 Jul;24(1):74–81

Influence of gender on cardiac risk and survival in patients with infrarenal aortic aneurysms. Starr JE, et al. **J Vasc Surg** 1996 May;23(5):870–80

Survival in thoracic or thoracoabdominal aortic aneurysm. Comparison between patients with or without surgical treatment. Myrmel T, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(3):105–9

Effect of the duration of symptoms, transport time, and length of emergency room stay on morbidity and mortality in patients with ruptured abdominal aortic aneurysms. Farooq MM, et al. **Surgery** 1996 Jan;119(1):9–14

[Abdominal aortic aneurysm in the county of Viborg. Mortality before and after the establishment of a specialized vascular surgery unit] Lindholt JS, et al. **Ugeskr Laeger** 1995 Dec 18;157(51):7146–8 (Eng. Abstr.) **(Dan)**

PATHOLOGY

Smooth muscle cell migration and proliferation is enhanced in abdominal aortic aneurysms. Patel MI, et al. **Aust N Z J Surg** 1996 May;66(5):305–8

A prospective study of anatomico–pathological changes in abdominal aortic aneurysms following endoluminal repair: is the aneurysmal process reversed? May J, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):11–7

Angiogenesis in abdominal aortic aneurysms. Thompson MM, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):464–9

Incidence and histologic characteristics of blebs in patients with abdominal aortic aneurysms. Hunter GC, et al. **J Vasc Surg** 1996 Jul;24(1):93–101

Intraluminal thrombus predicts rupture of an abdominal aortic aneurysm [letter] Satta J, et al. **J Vasc Surg** 1996 Apr;23(4):737–9

PHYSIOPATHOLOGY

Gastric intramucosal pH predicts outcome after surgery for ruptured abdominal aortic aneurysm. Maynard ND, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):201–6

Growth rate of infrarenal aortic aneurysms. Stonebridge PA, et al. **Eur J Vasc Endovasc Surg** 1996 Jan;11(1):70–3

The role of vitamin D3 in the aetiology of abdominal aortic aneurysms. Norman PE, et al. **Med Hypotheses** 1995 Jul; 45(1):17–20

Primary aortoenteric fistula. Barned H, et al. **West Indian Med J** 1995 Sep;44(3):93–5

[Electroconvulsive therapy and aortic aneurysm: apropos of a case] Atiar–Levy D, et al. **Encephale** 1995 Nov–Dec; 21(6):473–6 (Eng. Abstr.) **(Fre)**

[Preanesthetic evaluation of cardiovascular reserve in a patient with dilated cardiomyopathy] Oda T, et al. **Masui** 1996 Apr;45(4):491–5 (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Influence of screening on the incidence of ruptured abdominal aortic aneurysm: 5–year results of a randomized controlled study [letter; comment] Collin J. **Br J Surg** 1996 Jan;83(1):135. Comment on: Br J Surg 1995 Aug;82(8):1066–70.

Screening for abdominal aortic aneurysm in the Jeddah area, western Saudi Arabia. al–Zahrani HA, et al. **Cardiovasc Surg** 1996 Feb;4(1):87–92

Abdominal aortic aneurysm screening: an epidemiological point of view. Hak E, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):270–8 (115 ref.)

Screening for abdominal aneurysm. Henderson RG, et al. **J Fam Pract** 1996 Apr;42(4):350–1

Private costs associated with abdominal aortic aneurysm screening: the importance of private travel and time costs [see comments] Bryan S, et al. **J Med Screen** 1995;2(2):62–6 . Comment in: J Med Screen 1995;2(2):61.

Screening for aortic aneurysm: the surgical perspective. Harris P. **J Med Screen** 1994 Apr;1(2):106–9; discussion 115–6

Screening for abdominal aortic aneurysms. Law MR, et al. **J Med Screen** 1994 Apr;1(2):110–5; discussion 115–6

Opportunistic screening for abdominal aortic aneurysm [letter] Lewis M, et al. **J Med Screen** 1995;2(1):58–9

Accuracy of ultrasound in a screening programme for abdominal aortic aneurysms. Thomas PR, et al. **J Med Screen** 1994 Jan;1(1):3–6

Indomethacin prevents elastase–induced abdominal aortic aneurysms in the rat. Holmes DR, et al. **J Surg Res** 1996 Jun;63(1):305–9

Doxycycline inhibition of aneurysmal degeneration in an elastase–induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. Petrinec D, et al. **J Vasc Surg** 1996 Feb;23(2):336–46

Anti–CD 18 monoclonal antibody slows experimental aortic aneurysm expansion. Ricci MA, et al. **J Vasc Surg** 1996 Feb;23(2):301–7

RADIOGRAPHY

Gigantic aneurysm in the thoraco–abdominal aorta of an infant. Tsuji A, et al. **Acta Paediatr Jpn** 1996 Apr; 38(2):164–7

Inflammatory aneurysms of the abdominal aorta: CT findings. Arrivé L, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1481–4

Helical CT of abdominal aortic aneurysm [letter; comment] Hartnell GG. **AJR Am J Roentgenol** 1996 Aug;167(2):534–5 . Comment on: AJR Am J Roentgenol 1996 Feb;166(2):457.

Endovascular repair of abdominal aortic aneurysm: value of postoperative follow–up with helical CT. Rozenblit A, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1473–9

Helical CT of abdominal aortic aneurysm [see comments] Thoeni RF. **AJR Am J Roentgenol** 1996 Feb;166(2):457. Comment in: AJR Am J Roentgenol 1996 Aug;167(2):534–5.

Significance of radiological diagnosis for detection and staging of inflammatory abdominal aortic aneurysm. Bartels C, et al. **Cardiovasc Surg** 1995 Dec;3(6):665–70

Diagnostic imaging of Salmonella–related mycotic aneurysm of aorta by CT. Lee MH, et al. **Clin Imaging** 1996 Jan–Mar; 20(1):26–30

CT–angiography of abdominal aortic aneurysms after transfemoral endovascular aneurysm management. Balm R, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):182–8

Twice sealed–rupture of a small abdominal aortic aneurysm with unusual computed tomography findings. A case report. Ohtake H, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):249–50

Incidence and histologic characteristics of blebs in patients with abdominal aortic aneurysms. Hunter GC, et al. **J Vasc Surg** 1996 Jul;24(1):93–101

Computed tomography for ruptured abdominal aortic aneurysm? [letter; comment] Andros G. **N Engl J Med** 1996 May 9;334(19):1273. Comment on: N Engl J Med 1996 Jan 4;334(1):27.

Computed tomography for ruptured abdominal aortic aneurysm? [letter; comment] Eskind SJ. **N Engl J Med** 1996 May 9;334(19):1272–3. Comment on: N Engl J Med 1996 Jan 4;334(1):27.

Images in clinical medicine. Ruptured abdominal aortic aneurysm [see comments] Gervais DA, et al. **N Engl J Med** 1996 Jan 4;334(1):27. Comment in: N Engl J Med 1996 May 9;334(19):1272–3. Comment in: N Engl J Med 1996 May 9;334(19):1273.

Images in clinical medicine. Abdominal aortic aneurysm. Pasic M, et al. **N Engl J Med** 1996 Jan 4;334(1):26

Pre–operative computed tomography in abdominal aortic aneurysms. Fitzgerald EJ, et al. **Postgrad Med J** 1996 Aug; 72(850):484–6

Mural thrombi in abdominal aortic aneurysms: MR imaging characterization—useful before endovascular treatment? Castrucci M, et al. **Radiology** 1995 Oct;197(1):135–9

Draped aorta: CT sign of contained leak of aortic aneurysms. Halliday KE, et al. **Radiology** 1996 Apr;199(1):41–3

Infrarenal abdominal aortic aneurysms: implications of CT evaluation of size and configuration for placement of endovascular aortic grafts. Moritz JD, et al. **Radiology** 1996 Feb;198(2):463–6

Supra- and juxtarenal aneurysms of the abdominal aorta: preoperative assessment with thin-section spiral CT. Van Hoe L, et al. **Radiology** 1996 Feb;198(2):443–8

[Retroperitoneal vascular emergencies] Arrivé L, et al. **Ann Radiol (Paris)** 1996;39(2):78–88 (Eng. Abstr.) **(Fre)**

[A method of computer-assisted, 3-dimensional subtraction angiography using spiral roentgen computerized tomography] Englmeier KH, et al. **Radiologe** 1996 Apr; 36(4):360–4 (Eng. Abstr.) **(Ger)**

[CT angiography versus intra-arterial DSA in abdominal aortic aneurysms] Rieker O, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):17–23 (Eng. Abstr.) **(Ger)**

[Virtual CT endoscopy "Cruising Eye View": development and clinical applications] Hayashi H, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Feb; 56(3):135–6 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Rupture of abdominal aortic aneurysm demonstrated on Tc-99m RBC gastrointestinal bleeding study. DeArmas CR Jr, et al. **Clin Nucl Med** 1995 Oct;20(10):925–6

SURGERY

Cardiovascular responses to experimental infra-renal aortic cross-clamping. Modulating effects of isoflurane, sodium nitroprusside and milrinone. Seeman-Lodding H, et al. **Acta Anaesthesiol Scand** 1996 Apr;40(4):408–15

The persistent sciatic artery. A case report. Breek JC, et al. **Acta Chir Belg** 1995 Sep-Oct;95(5):241–2

Emergency aorto-iliac aneurysm surgery with low mortality and morbidity. Tobon Morales R, et al. **Acta Chir Belg** 1995 Sep-Oct;95(5):223–5

Abdominal wall hernias in patients with abdominal aortic aneurysmal versus aortoiliac occlusive disease. Hall KA, et al. **Am J Surg** 1995 Dec;170(6):572–5; discussion 575–6

In situ prosthetic graft replacement for mycotic thoracoabdominal aneurysms. Cordero JA Jr, et al. **Am Surg** 1996 Jan;62(1):35–9

Postoperative pulmonary complications and morbidity after abdominal aneurysmectomy: a comparison of postoperative epidural versus parenteral opioid analgesia. Major CP Jr, et al. **Am Surg** 1996 Jan;62(1):45–51

Colonic ischemia: the Achilles heel of ruptured aortic aneurysm repair. Piotrowski JJ, et al. **Am Surg** 1996 Jul; 62(7):557–60; discussion 560–1

Endovascular grafting for abdominal aortic aneurysms. Harris PL. **Ann R Coll Surg Engl** 1996 Jan;78(1 Suppl):23–4

Endovascular grafting of abdominal aortic aneurysms. A preliminary study. Edwards WH Jr, et al. **Ann Surg** 1996 May;223(5):568–73; discussion 573–5

Visceral ischemia and organ dysfunction after thoracoabdominal aortic aneurysm repair. A clinical and cost analysis. Harward TR, et al. **Ann Surg** 1996 Jun; 223(6):729–34; discussion 734–6

Technique of thoracoabdominal aneurysm repair. Acher CW, et al. **Ann Vasc Surg** 1995 Nov;9(6):585–95

Do collagen-impregnated knitted Dacron grafts reduce the need for transfusion in infrarenal aortic reconstruction? Barral X, et al. **Ann Vasc Surg** 1995 Jul;9(4):339–43

Internal iliac artery aneurysm following aortic reconstruction. Brings HA, et al. **Ann Vasc Surg** 1996 Jan; 10(1):59–62

Concurrent abdominal aortic aneurysm and urologic neoplasm: an argument for simultaneous intervention. Ginsberg DA, et al. **Ann Vasc Surg** 1995 Sep;9(5):428–33

Reduction of aneurysm pressure and wall stress after endovascular repair of abdominal aortic aneurysm in a canine model. Marston WA, et al. **Ann Vasc Surg** 1996 Mar;10(2):166–73

Nondissecting thoracoabdominal aortic aneurysms: Part I. Panneton JM, et al. **Ann Vasc Surg** 1995 Sep;9(5):503–14 (86 ref.)

Dissecting descending thoracic and thoracoabdominal aortic aneurysms: Part II. Panneton JM, et al. **Ann Vasc Surg** 1995 Nov;9(6):596–605 (56 ref.)

Ruptured abdominal aortic aneurysm: impact of comorbidity and postoperative complications on outcome. Panneton JM, et al. **Ann Vasc Surg** 1995 Nov;9(6):535–41

Use of left heart bypass in the surgical repair of thoracoabdominal aortic aneurysms. Schepens MA, et al. **Ann Vasc Surg** 1995 Jul;9(4):327–38

Retroperitoneal approach for repair of inflammatory aortic aneurysms. Todd GJ, et al. **Ann Vasc Surg** 1995 Nov; 9(6):525–34

Comparison of the utility of CT scans and intravascular ultrasound in endovascular aortic grafting. Verbin C, et al. **Ann Vasc Surg** 1995 Sep;9(5):434–40

Evaluation of dopexamine hydrochloride as a renoprotective agent during aortic surgery. Welch M, et al. **Ann Vasc Surg** 1995 Sep;9(5):488–92

Perioperative mortality of elective abdominal aortic aneurysm surgery. A clinical prediction rule based on literature and individual patient data. Steyerberg EW, et al. **Arch Intern Med** 1995 Oct 9;155(18):1998–2004

Sigmoid and gastric tonometry during infrarenal aortic aneurysm repair. Englund R, et al. **Aust N Z J Surg** 1996 Feb;66(2):88–90

Aortic stent surgery [letter; comment] Baranowski AP, et al. **Br J Anaesth** 1996 Jun;76(6):882–3. Comment on: Br J Anaesth 1995 Dec;75(6):779–81.

Anaesthetic implications of aortic stent surgery [see comments] Greiff JM, et al. **Br J Anaesth** 1995 Dec; 75(6):779–81. Comment in: Br J Anaesth 1996 Jun;76(6):882–3.

Antioxidant depletion during aortic aneurysm repair. Khaira HS, et al. **Br J Surg** 1996 Mar;83(3):401–3

Endovascular repair of abdominal aortic aneurysm: an initial experience. Nasim A, et al. **Br J Surg** 1996 Apr;83(4):516–9

Late failure of endoluminal abdominal aortic aneurysm repair due to continued aneurysm expansion. Nasim A, et al. **Br J Surg** 1996 Jun;83(6):810–1

Does concomitant aortic bypass and renal artery revascularization using the retroperitoneal approach increase perioperative risk? Darling RC 3rd, et al. **Cardiovasc Surg** 1995 Aug;3(4):421–3

Renal artery anomalies in patients with horseshoe or ectopic kidneys: the challenge of aortic reconstruction. de Virgilio C, et al. **Cardiovasc Surg** 1995 Aug;3(4):413–20

Acute ascending aortic dissection combined with chronic degenerative thoraco-abdominal aortic aneurysm [letter; comment] Abad C. **Eur J Cardiothorac Surg** 1995; 9(10):604–5. Comment on: Eur J Cardiothorac Surg 1994;8(11):616–8.

Simultaneous coronary bypass and abdominal aortic surgery in patients with severe coronary disease--indication and results. Autschbach R, et al. **Eur J Cardiothorac Surg** 1995; 9(12):678–83 discussion 683–4

Multilevel somatosensory evoked potentials (SEPs) for spinal cord monitoring in descending thoracic and thoraco-abdominal aortic surgery. Guérit JM, et al. **Eur J Cardiothorac Surg** 1996;10(2):93–103; discussion 103–4

Increased concentrations of cytokines and adhesion molecules in patients after repair of abdominal aortic aneurysm. Froon AH, et al. **Eur J Surg** 1996 Apr; 162(4):287–96

CT-angiography of abdominal aortic aneurysms after transfemoral endovascular aneurysm management. Balm R, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):182–8

Early experience with transfemoral endovascular aneurysm management (TEAM) in the treatment of aortic aneurysms. Balm R, et al. **Eur J Vasc Endovasc Surg** 1996 Feb; 11(2):214–20

Incidence and clinical presentation of bowel ischaemia after aortoiliac surgery--2930 operations from a population-based registry in Sweden. Björck M, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):139–44

The potential of simple clinical information and electrocardiogram to predict mortality of primary elective abdominal aortic reconstruction. De Mol Van Otterloo JC, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):470–7

Incisional hernias are more common in aneurysmal arterial disease. Holland AJ, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):196–200

Endovascular exclusion of juxtarenal anastomotic pseudoaneurysm. Lindblad B, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):116–8

Prevention of distal embolisation during abdominal aortic surgery. Ray SA, et al. **Eur J Vasc Endovasc Surg** 1996 Jan;11(1):121–2

Cerebral haemodynamics during thoracic- and thoracoabdominal aortic aneurysm repair. Saether OD, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):81–5

Thoracoabdominal aneurysms [letter; comment] Safi HJ. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):385. Comment on: Eur J Vasc Endovasc Surg 1995 Jan;9(1):112–3.

Biological responses differ considerably between endovascular and conventional aortic aneurysm surgery. Swartbol P, et al. **Eur J Vasc Endovasc Surg** 1996 Jul; 12(1):18–25

Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: a Joint Vascular Research Group study. Thompson JF, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):86–90

Oxygen free radical and cytokine generation during endovascular and conventional aneurysm repair. Thompson MM, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):70–5

A new animal model for abdominal aortic aneurysms:initial results using a multiple-wire stent. Whitbread T, et al. **Eur J Vasc Endovasc Surg** 1996 Jan;11(1):90–7

Clinical aspects and treatment of inflammatory abdominal aortic aneurysms. Pietri P, et al. **Int Angiol** 1995 Dec; 14(4):368–74

Laparoscopic aortic replacement in the porcine model: a feasibility study in preparation for laparoscopically assisted abdominal aortic aneurysm repair in humans. Chen MH, et al. **J Am Coll Surg** 1996 Aug;183(2):126–32

Computerized vectorcardiography for improved perioperative cardiac monitoring in vascular surgery. Gannedahl PE, et al. **J Am Coll Surg** 1996 Jun;182(6):530–6

A comparison of amrinone with sodium nitroprusside for control of hemodynamics during infrarenal abdominal aortic surgery. Dentz ME, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):486–90

Case 4--1995. Perioperative myocardial infarction in a patient undergoing abdominal aortic aneurysm resection: perioperative risk assessment [clinical conference] Fehr DM, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):452–9

Relationship between tissue ischemia and venous endothelin-1 during abdominal aortic aneurysm surgery. Fukuda S, et al. **J Cardiothorac Vasc Anesth** 1995 Oct; 9(5):510–4

Supraceliac, but not infrarenal, aortic cross-clamping upregulates neutrophil integrin CD11b. Hill GE, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):515–8

Optimal site for proximal and distal anastomoses in AAAs repair. Agus GB, et al. **J Cardiovasc Surg (Torino)** 1995 Oct;36(5):465–7

Protection by coenzyme Q10 of tissue reperfusion injury during abdominal aortic cross-clamping. Chello M, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):229–35

Ischemia of spinal cord following elective operative procedures of the infrarenal abdominal aorta. Dimakakos P, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):243–7

Incisional hernias: incidence following abdominal aortic aneurysm repair. Johnson B, et al. **J Cardiovasc Surg (Torino)** 1995 Oct;36(5):487–90

Surgical treatment of mesenteric infarction, thoracoabdominal aortic aneurysm, and proper hepatic aneurysm in a middle-aged woman with Takayasu's arteritis. Koyama M, et al. **J Cardiovasc Surg (Torino)** 1995 Aug;36(4):337–41

Chronic contained rupture of abdominal aortic aneurysms. Nonami Y, et al. **J Cardiovasc Surg (Torino)** 1996 Feb; 37(1):25–8

Long-term results and prognostic factors after repair of abdominal aortic aneurysm with concomitant malignancy. Onohara T, et al. **J Cardiovasc Surg (Torino)** 1996 Feb; 37(1):1–6

Dilation of gelatin-sealed knitted dacron prosthesis. Utoh J, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):343–4

Hospital volume, calendar age, and short term outcomes in patients undergoing repair of abdominal aortic aneurysms: the Ontario experience, 1988–92. Wen SW, et al. **J Epidemiol Community Health** 1996 Apr;50(2):207–13

Successful simultaneous resection and reconstruction of abdominal aortic aneurysm and esophageal cancer. Kuwano H, et al. **J Med** 1995;26(1–2):76–86

Using dipyridamole-thallium imaging to reduce cardiac risk in aortic reconstruction. Erickson CA, et al. **J Surg Res** 1996 Feb 1;60(2):422–8

Ischemic colitis complicating abdominal aortic aneurysm surgery in the U.S. veteran. Longo WE, et al. **J Surg Res** 1996 Feb 1;60(2):351–4

Intraoperative autotransfusion in aortic surgery: comparison of whole blood autotransfusion versus cell separation. Bartels C, et al. **J Vasc Surg** 1996 Jul;24(1):102–8

Hypothermia during aneurysm repair: the role of evaporation [letter; comment] Bascom J. **J Vasc Surg** 1996 Mar; 23(3):542. Comment on: J Vasc Surg 1995 Mar;21(3):392–400; discussion 400–2.

Results of endoluminal grafting in an experimental aortic aneurysm model. Eton D, et al. **J Vasc Surg** 1996 May; 23(5):819–29; discussion 829–31

Intraoperative salvage in patients undergoing elective abdominal aortic aneurysm repair: an analysis of cost and benefit. Goodnough LT, et al. **J Vasc Surg** 1996 Aug; 24(2):213–8

The risk of ischemic spinal cord injury in patients undergoing graft replacement for thoracoabdominal aortic aneurysms. Grabitz K, et al. **J Vasc Surg** 1996 Feb;23(2):230–40

Cardiac enzymes in the blood salvaged during abdominal aortic surgery [letter] Gregoretti S. **J Vasc Surg** 1996 Feb; 23(2):377–8

In situ repair of mycotic abdominal aortic aneurysms with rifampin-bonded gelatin-impregnated Dacron grafts: a preliminary case report. Gupta AK, et al. **J Vasc Surg** 1996 Sep;24(3):472–6

Ruptured abdominal aortic aneurysms: who should be offered surgery? Hardman DT, et al. **J Vasc Surg** 1996 Jan; 23(1):123–9

Pelvic radiation therapy as a risk factor for ischemic colitis complicating abdominal aortic reconstruction. Israeli D, et al. **J Vasc Surg** 1996 Apr;23(4):706–9

Abdominal aortic aneurysm repair in Veterans Affairs medical centers. Kazmers A, et al. **J Vasc Surg** 1996 Feb; 23(2):191–200

Ruptured abdominal aortic aneurysm: influence of intraoperative management on surgical outcome. Marty-Ané CH, et al. **J Vasc Surg** 1995 Dec;22(6):780–6

Transfemoral endovascular repair of abdominal aortic aneurysm: results of the North American EVT phase 1 trial. EVT Investigators. Moore WS, et al. **J Vasc Surg** 1996 Apr;23(4):543–53

Inflammatory abdominal aortic aneurysms: a case-control study. Nitecki SS, et al. **J Vasc Surg** 1996 May;23(5):860–8; discussion 868–9

Compression of the descending duodenum after reconstruction of infrarenal aortic aneurysm [letter] Rijken AM, et al. **J Vasc Surg** 1996 Jul;24(1):178–9

Cerebrospinal fluid drainage and distal aortic perfusion: reducing neurologic complications in repair of thoracoabdominal aortic aneurysm types I and II. Safi HJ, et al. **J Vasc Surg** 1996 Feb;23(2):223–8; discussion 229

Improvement in results of repair of type IV thoracoabdominal aortic aneurysms. Schwartz LB, et al. **J Vasc Surg** 1996 Jul;24(1):74–81

Historic control comparison of outcome for matched groups of patients undergoing endoluminal versus open repair of abdominal aortic aneurysms. White GH, et al.

J Vasc Surg 1996 Feb;23(2):201–11; discussion 211–2

Aortocaval fistula treated by aortic exclusion. Woolley DS, et al. **J Vasc Surg** 1995 Nov;22(5):639–42 (27 ref.)

Value of the staged segmental crossclamp to the aorta technique and reimplantation of intercostal arteries for the prevention of spinal complications associated with surgery for descending and thoraco–abdominal aortic aneurysms. Nakajima N, et al. **Jpn Heart J** 1996 May;37(3):275–84

Results of 50 consecutive aneurysmectomies for abdominal aortic aneurysms at a private specialist centre. Leong YP, et al. **Med J Malaysia** 1995 Dec;50(4):330–3

Aortic aneurysm in a four–year–old child with tuberous sclerosis. Tsukui A, et al. **Paediatr Anaesth** 1995;5(1):67–70

Graft replacement of the dissecting aneurysm originating in the suprarenal abdominal aorta. A case report. Urayama H, et al. **Panminerva Med** 1996 Mar;38(1):37–40

Abdominal aortic aneurysms: preliminary technical and clinical results with transfemoral placement of endovascular self–expanding stent–grafts [see comments] Blum U, et al. **Radiology** 1996 Jan;198(1):25–31. Comment in: Radiology 1996 Jan;198(1):14–6.

Stent–grafts for endovascular treatment of abdominal aortic aneurysms: how much do we really know? [editorial; comment] Hovsepian DM. **Radiology** 1996 Jan;198(1):14–6 . Comment on: Radiology 1996 Jan;198(1):25–31.

Infrarenal abdominal aortic aneurysms: implications of CT evaluation of size and configuration for placement of endovascular aortic grafts. Moritz JD, et al. **Radiology** 1996 Feb;198(2):463–6

Laparoscopic–assisted abdominal aortic aneurysm repair. Chen MH, et al. **Surg Endosc** 1995 Aug;9(8):905–7

Laparoscopic–assisted abdominal aortic aneurysm repair [letter] Hashmonai M, et al. **Surg Endosc** 1996 Jul; 10(7):780–1

Advantages of using the midline incision right retroperitoneal approach for abdominal aortic aneurysm repair. Endo M, et al. **Surg Today** 1996;26(1):1–4

Postoperative alteration in the size of Dacron vascular prostheses implanted in the infrarenal abdominal aorta. Igari T, et al. **Surg Today** 1995;25(7):605–7

Alterations in coagulation and fibrinolysis after surgery for aortic aneurysm. Oba J, et al. **Surg Today** 1995;25(6):532–5

Inflammatory reactions after vascular prosthesis implantation: a comparison of gelatin–sealed and unsealed Dacron prostheses. Utoh J, et al. **Surg Today** 1996;26(4):258–61

Orthotopic kidney autotransplantation to facilitate repair of a recurrent pararenal aortic aneurysm. AbuRahma AF, et al. **Surgery** 1996 Feb;119(2):230–4

Sociologic factors are major determinants of prolonged hospital stay after abdominal aneurysm repair. Kalman PG, et al. **Surgery** 1996 Jun;119(6):690–3

Relevance of bacterial cultures of abdominal aortic aneurysm contents. van der Vliet JA, et al. **Surgery** 1996 Feb; 119(2):129–32

Effects of differing rates of protamine reversal of heparin anticoagulation. Wakefield TW, et al. **Surgery** 1996 Feb; 119(2):123–8

Recovery of intraoperatively shed blood in aortoiliac surgery: comparison of cell washing with simple filtration. Trubel W, et al. **Thorac Cardiovasc Surg** 1995 Jun; 43(3):165–70

A pilot study of the effects of abdominal aortic cross clamping on metabolic gas exchange (short communication). Lind L. **Ups J Med Sci** 1995;100(2):165–7

Technique of radical cystectomy and simultaneous repair of an abdominal aortic aneurysm. Ginsberg DA, et al. **Urology** 1996 Jan;47(1):120–2

Simultaneous radical nephrectomy and repair of abdominal aortic aneurysm. Konety BR, et al. **Urology** 1996 Jun; 47(6):813–8

Intestinal ischemia following surgery for aorto–iliac disease. A review of 502 consecutive aortic reconstructions. Järvinen O, et al. **Vasa** 1996;25(2):148–55

[The results of resection treatment in infrarenal aneurysms of the abdominal aorta over the last 5 years (1989–1993)] Drenovski V, et al. **Khirurgiia (Sofiia)** 1995;48(1):29–33 (Eng. Abstr.) **(Bul)**

[Effects of platelet–rich plasma on hemostasis and transfusion requirement in vascular surgery] Godet G, et al. **Ann Fr Anesth Reanim** 1995;14(3):265–70 (Eng. Abstr.) **(Fre)**

[Evaluation of coronary risk in patients with subrenal abdominal aortic aneurysm] Eisenmann B, et al. **Chirurgie** 1994–95;120(12):96–9 (Eng. Abstr.) **(Fre)**

[Late complications of abdominal aortic prostheses: false aneurysms and aorta–digestive fistulas] Alimi Y, et al. **J Mal Vasc** 1995;20(3):172–6 (Eng. Abstr.) **(Fre)**

[Treatment of abdominal aortic aneurysms: importance of the bifurcated prosthesis] Batt M, et al. **J Mal Vasc** 1996; 21 Suppl A:53–7 (26 ref.) (Eng. Abstr.) **(Fre)**

[Patients operated on for aneurysms of the abdominal aorta: risk factors and survival] Becquemin JP, et al. **J Mal Vasc** 1995;20(4):296–300 (Eng. Abstr.) **(Fre)**

[Surgery for aneurysms of the subrenal abdominal aorta after the age of 70 years: survival and quality of life] Chakfe N, et al. **J Mal Vasc** 1995;20(4):313–6 (Eng. Abstr.) **(Fre)**

[Is it permissible to operate on an asymptomatic aneurysm of the abdominal aorta after the age of 80?] Cormier JM, et al. **J Mal Vasc** 1995;20(4):309–12 (Eng. Abstr.) **(Fre)**

[Morbidity and mortality after elective surgery of complicated aneurysms] Lacroix H, et al. **J Mal Vasc** 1996; 21 Suppl A:63–7 (Eng. Abstr.) **(Fre)**

[Treatment of abdominal aortic aneurysm: importance of the aorto–aortic tube?] Lagneau P, et al. **J Mal Vasc** 1996;21 Suppl A:48–52 (Eng. Abstr.) **(Fre)**

[Infrarenal aneurysm: traditional surgery] Limet R. **J Mal Vasc** 1996;21 Suppl A:58–62 (19 ref.) (Eng. Abstr.) **(Fre)**

[Preservation of masculine sexual functions after treatment for abdominal aortic aneurysms] Mellière D, et al. **J Mal Vasc** 1995;20(4):305–8 (Eng. Abstr.) **(Fre)**

[Endovascular treatment of aneurysms of the subrenal aorta using the Stentor endoprosthesis. Preliminary series] Mialhe C, et al. **J Mal Vasc** 1995;20(4):290–5 (Eng. Abstr.) **(Fre)**

[Coronary assessment and surgery for aortic aneurysm: a pragmatic attitude] Watelet J, et al. **J Mal Vasc** 1996;21 Suppl A:1–9 (Eng. Abstr.) **(Fre)**

[Surgery of thoracic and thoraco–abdominal aneurysms using deep hypothermia and cardiovascular arrest with continuous administration of blood cardioplegia] Grabenwöger M, et al. **Chirurg** 1995 Sep;66(9):878–82 (Eng. Abstr.) **(Ger)**

[Surgical treatment of infrarenal abdominal aortic aneurysm] Hagmüller GW, et al. **Chirurg** 1995 Sep;66(9):857–69 (38 ref.) (Eng. Abstr.) **(Ger)**

[Ischemic colitis after vascular surgery reconstruction of an abdominal aortic aneurysm] Kaiser MM, et al. **Chirurg** 1996 Apr;67(4):380–6 (30 ref.) (Eng. Abstr.) **(Ger)**

[Surgical treatment of thoraco–abdominal aneurysm. Indications and results] Sandmann W, et al. **Chirurg** 1995 Sep;66(9):845–56 (Eng. Abstr.) **(Ger)**

[Endoluminal therapy of infrarenal abdominal aortic aneurysms: a new interventional technique] Blum U, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jan;164(1):47–54 (Eng. Abstr.) **(Ger)**

[Intravascular therapy of aortic aneurysms: initial clinical results] Düber C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jan;164(1):55–61 (Eng. Abstr.) **(Ger)**

[Secondary stabilization of aortic bifurcation Chuter endoprostheses by implantation of self–expanding metal stents] Wendt G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jan;164(1):72–4 (Eng. Abstr.) **(Ger)**

[Chylous ascites, a rare complication of aortic surgery] Halloul Z, et al. **Vasa** 1995;24(4):377–81 (Eng. Abstr.) **(Ger)**

[Abdominal vascular and colonic pathology: the timing of combined treatment] Battisti G, et al. **G Chir** 1996 Apr; 17(4):175–7 (Eng. Abstr.) **(Ita)**

[Abdominal vascular and biliary pathology: timing of the combined treatment] Battisti G, et al. **G Chir** 1996 Mar; 17(3):111–4 (Eng. Abstr.) **(Ita)**

[Anastomotic pseudoaneurysm, true para–anastomotic aneurysm and recurrent aneurysm following surgery for abdominal aortic aneurysm. Is a unifying theory possible?] De Monti M, et al. **Minerva Cardioangiol** 1995 Sep; 43(9):367–73 (Eng. Abstr.) **(Ita)**

[Surgery of abdominal aortic aneurysm and concomitant disease of the digestive tract] Mattioli A, et al. **Minerva Chir** 1995 Sep;50(9):757–62 (Eng. Abstr.) **(Ita)**

[Surgery of abdominal aortic aneurysms in octogenarians. Critical remarks on indications for surgical intervention in different age groups] Pizzetti F, et al. **Recenti Prog Med** 1995 Nov;86(11):437–41 (Eng. Abstr.) **(Ita)**

[A case report of acute aortic dissection with aortic regurgitation and cardiac tamponade: intimal tear just above commissure of right coronary cusp and left coronary cusp] Kashiwagi J, et al. **Kyobu Geka** 1995 Nov; 48(12):1039–42 (Eng. Abstr.) **(Jpn)**

[A successfully treated case of thoracoabdominal aortic aneurysm complicated with the coagulation disorder] Ohsawa T, et al. **Kyobu Geka** 1995 Aug;48(9):776–80 (Eng. Abstr.) **(Jpn)**

[One stage operation for ischemic heart disease and abdominal aortic aneurysm with ascending aortic calcification] Uwabe K, et al. **Kyobu Geka** 1996 Jan; 49(1):73–5 (Eng. Abstr.) **(Jpn)**

[Problems in thoracic and abdominal aortic aneurysm surgery] Kawada S, et al. **Nippon Geka Gakkai Zasshi** 1995 Sep;96(9):612–3 **(Jpn)**

[Coronary artery disease in patients with abdominal aortic aneurysm] Tanaka H, et al. **Nippon Geka Gakkai Zasshi** 1995 Nov;96(11):773–8 (Eng. Abstr.) **(Jpn)**

[Treatment of patients with chronic dissecting aortic aneurysm (DeBakey type IIIb) presenting with compromised renal perfusion] Fuwa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct;43(10):1730–5 (Eng. Abstr.) **(Jpn)**

[A case report of bentall type operation for annuloaortic ectasia with anomalous origin of the right coronary artery complicated by aortic dissection] Hirai M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1044–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Surgery of thoracoabdominal aortic aneurysm associated with coronary artery disease] Okamoto H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1953–7 (Eng. Abstr.) **(Jpn)**

[Staged operation of multiple aortic aneurysms with myocardial infarction and stenosis of three coronary arteries] Shimoji M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct;43(10):1752–6 (Eng. Abstr.) **(Jpn)**

[Endovascular treatment of abdominal aortic aneurysms] Hatlinghus S, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28; 116(6):717–20 (Eng. Abstr.) **(Nor)**

[Results after surgical treatment of abdominal aortic aneurysm] Haug ES, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):493–6 (Eng. Abstr.) **(Nor)**

[Abdominal aortic aneurysms. A new therapeutic method] Solberg S. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):716 **(Nor)**

[Postoperative complications and mortality in abdominal aortic aneurysm surgery] Figueira A, et al. **Rev Esp Anestesiol Reanim** 1995 Dec;42(10):412–6 (Eng. Abstr.) **(Spa)**

THERAPY

Trash penis [letter; comment] Kumar U, et al. **Br J Urol** 1995 Dec;76(6):814. Comment on: Br J Urol 1995 May;75(5):675–6.

A safe, simple alternative for pressure reduction during aortic endograft deployment [comment] Diethrich EB. **J Endovasc Surg** 1996 Aug;3(3):275. Comment on: J Endovasc Surg 1996 Aug;3(3):270–2. Comment on: J Endovasc Surg 1996 Aug;3(3):273–4.

Adenosine–induced transient cardiac asystole enhances precise deployment of stent–grafts in the thoracic or abdominal aorta [see comments] Dorros G, et al. **J Endovasc Surg** 1996 Aug;3(3):270–2. Comment in: J Endovasc Surg 1996 Aug;3(3):275.

Transient asystole for aortic endograft deployment: a technique justified only in highly selected cases [see comments] White GH. **J Endovasc Surg** 1996 Aug; 3(3):273–4. Comment in: J Endovasc Surg 1996 Aug;3(3):275.

Selective management of abdominal aortic aneurysms in a prospective measurement program. Brown PM, et al. **J Vasc Surg** 1996 Feb;23(2):213–20; discussion 221–2

Intravascular stenting of traumatic abdominal aortic dissection. Marty–Ané CH, et al. **J Vasc Surg** 1996 Jan; 23(1):156–61 (13 ref.)

Aortoiliac aneurysms: management with endovascular stent–graft placement. Murphy KD, et al. **Radiology** 1996 Feb;198(2):473–80

Endovascular repair of abdominal aortic aneurysms using the EGS tube and bifurcated graft systems. Colburn MD, et al. **World J Surg** 1996 Jul–Aug;20(6):664–72 (44 ref.)

[Medical treatment of aortic abdominal aneurysms. Outstanding questions] Cacoub P, et al. **Presse Med** 1996 Apr 20;25(14):683–5 (15 ref.) (Eng. Abstr.) **(Fre)**

[Endovascular reconstruction of infrarenal abdominal aortic aneurysm] Allenberg JR, et al. **Chirurg** 1995 Sep; 66(9):870–7 (24 ref.) (Eng. Abstr.) **(Ger)**

[Transfemoral fenestration and stent implantation in aorto–iliac dissection] Farber A, et al. **Vasa** 1995; 24(4):389–91 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Long–term follow up of abdominal aortic aneurysm complicating Kawasaki disease: comparison of the effectiveness of different imaging methods. Fuyama Y, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):252–5

Safety of performing dobutamine stress echocardiography in patients with abdominal aortic aneurysm > or = 4 cm in diameter. Pellikka PA, et al. **Am J Cardiol** 1996 Feb 15;77(5):413–6

Emergency medicine physicians saving time with ultrasound. Durham B. **Am J Emerg Med** 1996 May;14(3):309–13

Ultrasound screening of families with abdominal aortic aneurysm. Larcos G, et al. **Australas Radiol** 1995 Aug; 39(3):254–6

Prognosis in elderly men with screening–detected abdominal aortic aneurysm. Ogren M, et al. **Eur J Vasc Endovasc Surg** 1996 Jan;11(1):42–7

Opportunistic screening for abdominal aortic aneurysm [letter] Lewis M, et al. **J Med Screen** 1995;2(1):58–9

Accuracy of ultrasound in a screening programme for abdominal aortic aneurysms. Thomas PR, et al. **J Med Screen** 1994 Jan;1(1):3–6

Pseudodissection of the abdominal aorta on color Doppler imaging. Crotty JM, et al. **J Ultrasound Med** 1995 Nov; 14(11):853–7

Screening for abdominal aortic aneurysms during lower extremity arterial evaluation in the vascular laboratory. Wolf YG, et al. **J Vasc Surg** 1995 Oct;22(4):417–21; discussion 421–3

[Color–coded duplex ultrasound in chronic dissecting abdominal aortic aneurysm. Differentiation between true and false aortic lumen with reference to the blood supply to larger abdominal arteries] Risse JH, et al. **Radiologe** 1995 Oct;35(10):759–66 (Eng. Abstr.) **(Ger)**

[Predictive value of ultrasonography in the study of aortic abdominal aneurysms] Politi U, et al. **Minerva Chir** 1995 May;50(5):489–91 (Eng. Abstr.) **(Ita)**

AORTIC ANEURYSM, RUPTURED see **AORTIC RUPTURE**

AORTIC ANEURYSM, THORACIC

Three–channeled aortic dissection. Ishikawa S, et al.

Ann Thorac Surg 1995 Dec;60(6):1816–8

COMPLICATIONS

Pseudocoarctation of the aorta complicated by saccular aneurysm: treatment by aortic arch replacement. Grigsby JL, et al. **Am Heart J** 1996 Jan;131(1):200–2

Aortic dissection with flap prolapse into the left ventricle. Rosenzweig BP, et al. **Am J Cardiol** 1996 Jan 15;77(2):214–6

Brain infarction caused by syphilitic aortic aneurysm. A case report. Nakane H, et al. **Angiology** 1996 Sep;47(9):911–7

Type B aortic dissection involving an isolated right-sided aortic arch. Masiello P, et al. **Ann Thorac Surg** 1996 Sep; 62(3):887–8

Right aortic arch with aberrant left subclavian artery: aneurysmal dilatation causing symptomatic compression of the right main bronchus in an adult. Patiniotis TC, et al. **Aust N Z J Surg** 1995 Sep;65(9):690–2 (9 ref.)

Left hilar mass with obstruction of the main bronchus due to localized pseudoaneurysm of the thoracic aorta. Lukanich JM, et al. **Can J Surg** 1996 Feb;39(1):63–6

Acute infectious mitroaortic endocarditis in association with acute aortic dissection. Surgical management of an unusual combination of diseases. Abad C. **Cardiovasc Surg** 1995 Dec;3(6):605–6

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)

Sudden death caused by retrograde aortic dissection during repair of a descending thoracic aneurysm. O'Connor CJ, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):380–3

Massive hemoptysis as a manifestation of fistulized thoracic aortic aneurysms into the bronchial tree. Julià-Serdà G, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):417–9

Radiologic and manometric study of the gastroesophageal junction in dysphagia aortica. Sundaram U, et al. **J Clin Gastroenterol** 1995 Dec;21(4):275–8

Aortic dissection presenting as a neurological emergency. Garrard P, et al. **J R Soc Med** 1996 May;89(5):271–2

Aortic dissection: percutaneous management of ischemic complications with endovascular stents and balloon fenestration. Slonim SM, et al. **J Vasc Surg** 1996 Feb; 23(2):241–51; discussion 251–3

Orthopnea due to an aneurysm of the thoracic aorta. Spiropoulos K, et al. **Respiration** 1995;62(3):174–6

Aneurysm of the left sinus of Valsalva. An unusual source of cerebral embolism. Stöllberger C, et al. **Stroke** 1996 Aug; 27(8):1424–6

[Thoracic aortic aneurysm with acute aortopulmonary fistula] Hagen T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jan;164(1):79–81 **(Ger)**

[A rare cause of recurrent upper gastrointestinal hemorrhage: aortoesophageal fistula in aneurysma spurium of the descending aorta] Weickert U, et al. **Z Gastroenterol** 1996 May;34(5):279–82 (Eng. Abstr.) **(Ger)**

[Aortic dissection similar to giant cell arteritis: diagnostic difficulties and efficacy of steroid therapy] Cordioli E, et al. **Minerva Med** 1995 Jul–Aug;86(7–8):331–5 (Eng. Abstr.) **(Ita)**

[A case report of tracheal stenosis due to true aortic arch aneurysm of retroesophageal right aortic arch associated with so called vascular ring-facial syndrome] Kameyama T, et al. **Kyobu Geka** 1995 Oct;48(11):945–7 (Eng. Abstr.) **(Jpn)**

[Asthma-like symptoms due to thoracic aneurysm] Nakano Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):200–3 (Eng. Abstr.) **(Jpn)**

[Arterial hypertension complicated by aortic dissection. Clinical analysis, results of conservative treatment] Grajek S, et al. **Przegl Lek** 1996;53(2):60–6 (Eng. Abstr.) **(Pol)**

[Coronary artery dissection without acute myocardial infarction] da Rocha AS, et al. **Arq Bras Cardiol** 1995 Jun; 64(6):557–8 (Eng. Abstr.) **(Por)**

DIAGNOSIS

Follow-up of chronic thoracic aortic dissection: comparison of transesophageal echocardiography and magnetic resonance imaging. Masani ND, et al. **Am Heart J** 1996 Jun;131(6):1156–63

Aortic dissection with flap prolapse into the left ventricle. Rosenzweig BP, et al. **Am J Cardiol** 1996 Jan 15;77(2):214–6

Detecting acute thoracic aortic dissection in the emergency department: time constraints and choice of the optimal diagnostic test [see comments] Sarasin FP, et al. **Ann Emerg Med** 1996 Sep;28(3):278–88. Comment in: Ann Emerg Med 1996 Sep;28(3):349–51.

Thoracic aortic dissection: ruling in and ruling out [editorial; comment] Wolfson AB, et al. **Ann Emerg Med** 1996 Sep; 28(3):349–51. Comment on: Ann Emerg Med 1996 Sep;28(3):278–88.

Evaluation of thoracic aortic dissection using breath-holding cine MRI. Sakuma H, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):45–50

Fast spoiled gradient-recalled MR imaging of thoracic aortic dissection: preliminary clinical experience at 1.5 T. Summers RM, et al. **Magn Reson Imaging** 1996;14(1):1–9

64-year-old woman with chest pain and presyncope. Poirier MK, et al. **Mayo Clin Proc** 1995 Nov;70(11):1087–90

Aortic dissection: a comparative study of diagnosis with spiral CT, multiplanar transesophageal echocardiography, and MR imaging. Sommer T, et al. **Radiology** 1996 May; 199(2):347–52

[Acute heart failure in a young man (clin conference)] Melin J. **Duodecim** 1994;110(2):161–6 **(Fin)**

[Exploration of the thoracic aorta, excluding the aortic valve] Douek P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):552–60 (12 ref.) (Eng. Abstr.) **(Fre)**

[Aortic dissection and pregnancy. Apropos of a case] Helms E, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):397–9 (Eng. Abstr.) **(Fre)**

[Aortic dissection. Symptoms with indications for surgery] Defraigne JO, et al. **Rev Med Liege** 1996 Jun;51(6):411–25 (49 ref.) **(Fre)**

[Intramural hemorrhage of the thoracic aorta as a precursor of dissection] Kodolitsch Y, et al. **Z Kardiol** 1995 Nov; 84(11):939–46 (Eng. Abstr.) **(Ger)**

[Aneurysmatic pathology of the thoracic aorta (editorial)] Biglioli P. **Cardiologia** 1995 Jul;40(7):461–3 **(Ita)**

[Total atrioventricular block as the primary clinical manifestation of undiagnosed aortic dissection] Lorenzoni R, et al. **G Ital Cardiol** 1995 Aug;25(8):1031–5 (12 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Aortic dissection in Taiwan. Liao WB, et al. **Jpn Heart J** 1995 Sep;36(5):639–45

ETIOLOGY

Aortic dissection complicating coronary angioplasty in cystic medial necrosis. Pande AK, et al. **Am Heart J** 1996 Jun; 131(6):1221–3

Late aneurysm after subclavian flap aortoplasty for coarctation of the aorta. Kino K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1262–4 (8 ref.)

Aortic dissection in a 5-year old girl with Marfan's syndrome [letter] Ruiz ME, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):440–2 (14 ref.)

Salmonella mycotic aneurysm of the aortic arch: case report and review. Meerkin D, et al. **Clin Infect Dis** 1995 Sep; 21(3):523–8 (32 ref.)

False aneurysm of the descending aorta due to penetrating injury. Ahat E, et al. **Injury** 1996 Apr;27(3):225–6

Acute aortic dissection after blunt chest trauma. Gammie JS, et al. **J Trauma** 1996 Jan;40(1):126–7

[Horton disease and aortic involvement (letter; comment)] Lévesque H, et al. **Presse Med** 1995 Oct 21;24(31):1447. Comment on: Presse Med 1995 May 27;24(19):915. **(Fre)**

[Aneurysm of the ascending aorta in tertiary syphilis] Rühlmann C, et al. **Dtsch Med Wochenschr** 1996 Apr 26; 121(17):550–5 (Eng. Abstr.) **(Ger)**

[A case of ruptured thoracoabdominal aortic aneurysm complicated with high aortic occlusion] Satokawa H, et al. **Kyobu Geka** 1995 Nov;48(12):1053–6 (Eng. Abstr.) **(Jpn)**

GENETICS

Iris flocculi and familial aortic dissection. Lewis RA, et al. **Arch Ophthalmol** 1995 Oct;113(10):1330–1

[Another case of dissecting aortic aneurysm with familial incidence] Conte MR, et al. **Cardiologia** 1992 Jul; 37(7):513–7 (19 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

[Depression of cellular immunity after aortic arch replacement] Nakamura M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):31–7 (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Double clostridial mycotic aneurysms of the aorta. Messa CA 3rd, et al. **Cardiovasc Surg** 1995 Dec;3(6):687–92 (28 ref.)

MORTALITY

Survival in thoracic or thoracoabdominal aortic aneurysm. Comparison between patients with or without surgical treatment. Myrmel T, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(3):105–9

PATHOLOGY

Four-barrel aortic dissection involving the ascending aorta. A case report. Ohte N, et al. **Angiology** 1995 Nov; 46(11):1059–62

Coronary artery dissection [letter; comment] Mooney EE, et al. **J Clin Pathol** 1996 May;49(5):437. Comment on: J Clin Pathol 1995 Aug;48(8):781–4.

Aortitis with dissection complicating systemic lupus erythematosus. Guard RW, et al. **Pathology** 1995 Jul; 27(3):224–8

PHYSIOPATHOLOGY

Magnetic resonance velocity vector mapping of blood flow in thoracic aortic aneurysms and grafts. Bogren HG, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):704–14

RADIOGRAPHY

Gigantic aneurysm in the thoraco-abdominal aorta of an infant. Tsuji A, et al. **Acta Paediatr Jpn** 1996 Apr; 38(2):164–7

Case quiz. Low VH. **Australas Radiol** 1995 Nov;39(4):415–6

The half-moon sign. A useful roentgen sign of saccular aneurysm of the aortic arch. Lin JS, et al. **Chest** 1996 Jan; 109(1):127–30

Diagnostic imaging of Salmonella-related mycotic aneurysm of aorta by CT. Lee MH, et al. **Clin Imaging** 1996 Jan–Mar; 20(1):26–30

Draped aorta: CT sign of contained leak of aortic aneurysms. Halliday KE, et al. **Radiology** 1996 Apr;199(1):41–3

MR imaging in the diagnosis of aortic dissection [letter; comment] Hartnell GG. **Radiology** 1995 Oct;197(1):314–5 . Comment on: Radiology 1995 Feb;194(2):331–6.

Thoracic aortic aneurysm and aortic dissection: new endoscopic mode for three-dimensional CT display of aorta. Kimura F, et al. **Radiology** 1996 Feb;198(2):573–8

[An opacity in the aorto-pulmonary window] Jougon J, et al. **Rev Pneumol Clin** 1996;52(1):26–8 **(Fre)**

[Aneurysm of the aortic arch] Criales Cortés JL. **Gac Med Mex** 1995 Sep–Dec;131(5–6):597–8 **(Spa)**

SURGERY

Pseudocoarctation of the aorta complicated by saccular aneurysm: treatment by aortic arch replacement. Grigsby JL, et al. **Am Heart J** 1996 Jan;131(1):200–2

In situ prosthetic graft replacement for mycotic thoracoabdominal aneurysms. Cordero JA Jr, et al. **Am Surg** 1996 Jan;62(1):35–9

Paraplegia, epidural analgesia, and thoracic aneurysmectomy [see comments] Fitzgibbon DR, et al. **Anesthesiology** 1995 Dec;83(6):1355–9. Comment in: Anesthesiology 1996 Jun;84(6):1519–20.

Visceral ischemia and organ dysfunction after thoracoabdominal aortic aneurysm repair. A clinical and cost analysis. Harward TR, et al. **Ann Surg** 1996 Jun; 223(6):729–34; discussion 734–6

Critical-illness polyneuropathy complicating cardiac operation. Alhan HC, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1237–9 (8 ref.)

Repeat cardiac operation in a patient with osteogenesis imperfecta [letter; comment] Cusimano RJ. **Ann Thorac Surg** 1996 Apr;61(4):1294. Comment on: Ann Thorac Surg 1995 Nov;60(5):1395–7. Comment on: Ann Thorac Surg 1995 Nov;60(5):1397–9. Comment on: Ann Thorac Surg 1995 Nov;60(5):1439–43.

Endovascular stent-grafting after arch aneurysm repair using the "elephant trunk". Fann JI, et al. **Ann Thorac Surg** 1995 Oct;60(4):1102–5

Using aortic allograft material to treat mycotic aneurysms of the thoracic aorta [see comments] Knosalla C, et al. **Ann Thorac Surg** 1996 Apr;61(4):1146–52. Comment in: Ann Thorac Surg 1996 Apr;61(4):1053–4.

Mycotic aneurysm of the aorta: evolving surgical concept [editorial; comment] Pasic M. **Ann Thorac Surg** 1996 Apr; 61(4):1053–4 (16 ref.). Comment on: Ann Thorac Surg 1996 Apr;61(4):1146–52.

Simplified technique for hemi-arch replacement during open distal anastomosis: the "calla" method. Sakamoto T, et al. **Ann Thorac Surg** 1996 Mar;61(3):1021–3

1988: Surgery of the descending thoracic aorta: spinal cord protection with the Gott shunt. Updated in 1995. Verdant A. **Ann Thorac Surg** 1995 Oct;60(4):1151–2

Aortoesophageal fistula after repair of descending aortic dissection. Wong RS, et al. **Ann Thorac Surg** 1996 Aug; 62(2):588–90

Technique of thoracoabdominal aneurysm repair. Acher CW, et al. **Ann Vasc Surg** 1995 Nov;9(6):585–95

Results of contemporary surgical treatment of descending thoracic aortic aneurysms: experience in 198 patients. Coselli JS, et al. **Ann Vasc Surg** 1996 Mar;10(2):131–7

Nondissecting thoracoabdominal aortic aneurysms: Part I. Panneton JM, et al. **Ann Vasc Surg** 1995 Sep;9(5):503–14 (86 ref.)

Dissecting descending thoracic and thoracoabdominal aortic aneurysms: Part II. Panneton JM, et al. **Ann Vasc Surg** 1995 Nov;9(6):596–605 (56 ref.)

Use of left heart bypass in the surgical repair of thoracoabdominal aortic aneurysms. Schepens MA, et al. **Ann Vasc Surg** 1995 Jul;9(4):327–38

Acute infectious mitroaortic endocarditis in association with acute aortic dissection. Surgical management of an unusual combination of diseases. Abad C. **Cardiovasc Surg** 1995 Dec;3(6):605–6

Prosthetic graft infection in the descending thoracic aorta treated by extra-anatomic rerouting. Barnard SP, et al. **Cardiovasc Surg** 1995 Dec;3(6):703–5

Descending thoracic aorta aneurysmectomy: left-left centrifugal pump versus simple clamping technique. Biglioli P, et al. **Cardiovasc Surg** 1995 Oct;3(5):511–8

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)

Acute ascending aortic dissection combined with chronic degenerative thoraco-abdominal aortic aneurysm [letter; comment] Abad C. **Eur J Cardiothorac Surg** 1995; 9(10):604–5. Comment on: Eur J Cardiothorac Surg 1994;8(11):616–8.

Multilevel somatosensory evoked potentials (SEPs) for spinal cord monitoring in descending thoracic and thoraco-abdominal aortic surgery. Guérit JM, et al. **Eur J Cardiothorac Surg** 1996;10(2):93–103; discussion 103–4

Medium-term results after surgery for aortic arch aneurysm

with hypothermic cerebral perfusion. Kitamura M, et al. **Eur J Cardiothorac Surg** 1995;9(12):697–700

Cerebral haemodynamics during thoracic- and thoracoabdominal aortic aneurysm repair. Saether OD, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):81–5

Thoracoabdominal aneurysms [letter; comment] Safi HJ. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):385. Comment on: Eur J Vasc Endovasc Surg 1995 Jan;9(1):112–3.

Fate of the native aorta after repair of acute type A dissection: a magnetic resonance imaging study. Moore NR, et al. **Heart** 1996 Jan;75(1):62–6

Transesophageal echocardiography in the diagnosis of thoracic saccular aortic aneurysm. The value of transesophageal echocardiography during the course of treatment. Hashimoto S, et al. **Int J Card Imaging** 1995 Dec;11(4):241–6

New technique for retrograde cerebral perfusion during arch aneurysm repair. Bartoccioni S, et al. **J Card Surg** 1995 Sep;10(5):592–3

Utilization of triple-lumen balloon catheter for occlusion of the ascending aorta during distal aortic arch surgery with hypothermic retrograde cerebral circulation technique through left thoracotomy. Okita Y, et al. **J Card Surg** 1995 Nov;10(6):699–702

Supraceliac, but not infrarenal, aortic cross-clamping upregulates neutrophil integrin CD11b. Hill GE, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):515–8

Anesthetic considerations for descending thoracic aortic surgery: Part 1. O'Connor CJ, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):581–8 (63 ref.)

Anesthetic considerations for descending thoracic aortic surgery: part II. O'Connor CJ, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):734–47 (126 ref.)

Loss of a right radial arterial pressure tracing during thoracic aortic aneurysm repair. Turnage WS, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):431–4

Surgical treatment of mesenteric infarction, thoracoabdominal aortic aneurysm, and proper hepatic aneurysm in a middle-aged woman with Takayasu's arteritis. Koyama M, et al. **J Cardiovasc Surg (Torino)** 1995 Aug;36(4):337–41

Surgical treatment of descending aortic aneurysm in a patient with syncopal attack. Matsuda K, et al. **J Cardiovasc Surg (Torino)** 1996 Feb;37(1):13–6

Endovascular covered stent repair of an intercostal artery patch dehiscence from a descending thoracic aortic aneurysm graft. Dorros G, et al. **J Endovasc Surg** 1996 Aug;3(3):299–305

Repair of aortic transection associated with ductal diverticular aneurysm. McKeown PP, et al. **J Pediatr Surg** 1995 Sep;30(9):1351–3

Endovascular stent-graft repair of thoracic aortic aneurysms. Mitchell RS, et al. **J Thorac Cardiovasc Surg** 1996 May; 111(5):1054–62

Retrograde perfusion through the superior vena cava perfuses the brain in human beings. Pagano D, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):270–2

Endovascular graft placement in experimental dissection of the thoracic aorta. Boudghène F, et al. **J Vasc Interv Radiol** 1995 Jul–Aug;6(4):501–7

The risk of ischemic spinal cord injury in patients undergoing graft replacement for thoracoabdominal aortic aneurysms. Grabitz K, et al. **J Vasc Surg** 1996 Feb;23(2):230–40

Cerebrospinal fluid drainage and distal aortic perfusion: reducing neurologic complications in repair of thoracoabdominal aortic aneurysm types I and II. Safi HJ, et al. **J Vasc Surg** 1996 Feb;23(2):223–8; discussion 229

Value of the staged segmental crossclamp to the aorta technique and reimplantation of intercostal arteries for the prevention of spinal complications associated with surgery for descending and thoraco-abdominal aortic aneurysms. Nakajima N, et al. **Jpn Heart J** 1996 May;37(3):275–84

Pathological study of implanted dacron grafts in surgery of thoracic aortic aneurysms. Urayama H, et al. **Minerva Cardioangiol** 1995 Jul–Aug;43(7–8):293–7

Single-stage replacement of the entire thoracic aorta via transverse thoracosternotomy. Detterbeck FC, et al. **South Med J** 1996 Mar;89(3):348–52

Repair of a ruptured aortic arch aneurysm complicated by postoperative paraplegia: report of a case. Hadama T, et al. **Surg Today** 1996;26(1):60–3

Alterations in coagulation and fibrinolysis after surgery for aortic aneurysm. Oba J, et al. **Surg Today** 1995;25(6):532–5

The sternocleidomastoid flap for treatment of a septic sternum defect. Maurer F, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):236–8

Transfemoral intraluminal stent graft implanted for thoracic aortic aneurysm. Pavčnik D, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):208–11

[The strategy and procedure in the surgical treatment of thoracic aortic aneurysms] Nachev G, et al. **Khirurgiia (Sofiia)** 1995;48(1):11–7 (Eng. Abstr.) **(Bul)**

[Surgery FOR annulo-dystrophic disease of the ascending aorta. Apropos of 203 cases] Guilmet D, et al. **Arch Mal Coeur Vaiss** 1996 Jan;89(1):19–25 (Eng. Abstr.) **(Fre)**

[Cerebral protection by selective cerebral perfusion during surgery on the aortic arch] Le Mee F, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1601–7 (Eng. Abstr.) **(Fre)**

[Surgery of thoracic and thoraco-abdominal aneurysms using deep hypothermia and cardiovascular arrest with continuous administration of blood cardioplegia] Grabenwöger M, et al. **Chirurg** 1995 Sep;66(9):878–82 (Eng. Abstr.) **(Ger)**

[Surgical treatment of thoraco-abdominal aneurysm. Indications and results] Sandmann W, et al. **Chirurg** 1995 Sep;66(9):845–56 (Eng. Abstr.) **(Ger)**

[Surgical treatment for ruptured aneurysm of distal arch or aortic arch: report of three cases] Gohra H, et al. **Kyobu Geka** 1996 Mar;49(3):206–8 (Eng. Abstr.) **(Jpn)**

[A case report of chronic sternal osteomyelitis after thoracic aortic aneurysmectomy] Ihaya A, et al. **Kyobu Geka** 1995 Nov;48(12):1065–7 (Eng. Abstr.) **(Jpn)**

[An approach to the emergency surgery for arch and/or ascending aortic aneurysm] Katoh T, et al. **Kyobu Geka** 1996 Jun;49(6):456–9 (Eng. Abstr.) **(Jpn)**

[A case report on concomitant graft replacement of the total aortic root and the transverse aortic arch for type A acute aortic dissection associated with annuloaortic ectasia] Kawaharada N, et al. **Kyobu Geka** 1996 Apr;49(4):312–4 (Eng. Abstr.) **(Jpn)**

[Aortic aneurysm complicated with coarctation of the aorta and Turner syndrome] Kusaba E, et al. **Kyobu Geka** 1995 Dec;48(13):1115–7 (Eng. Abstr.) **(Jpn)**

[Syphilitic thoracic aortic aneurysm with destruction of vertebral body, producing numbness of lower extremities and paraplegia] Miura M, et al. **Kyobu Geka** 1995 Oct; 48(11):953–6 (Eng. Abstr.) **(Jpn)**

[A case of type A acute aortic dissection successfully treated with a ringed intraluminal graft: a new technique of graft insertion] Mukohara N, et al. **Kyobu Geka** 1995 Sep; 48(10):857–60 (Eng. Abstr.) **(Jpn)**

[A successfully treated case of thoracoabdominal aortic aneurysm complicated with the coagulation disorder] Ohsawa T, et al. **Kyobu Geka** 1995 Aug;48(9):776–80 (Eng. Abstr.) **(Jpn)**

[Surgery for thoracic aortic aneurysm in the elderly patients with renal insufficiency and pulmonary disfunction] Sakakibara Y, et al. **Kyobu Geka** 1996 Jan;49(1):81–5 (Eng. Abstr.) **(Jpn)**

[A trial of antegrade perfusion to the lower half of the body with selective cerebral perfusion for repair of aortic arch aneurysm combined with atherosclerosis obliterance] Takagi H, et al. **Kyobu Geka** 1995 Sep;48(10):873–6 (Eng. Abstr.) **(Jpn)**

[A surgically treated case of ruptured true aortic arch aneurysm in association with Stanford type A chronic dissection] Takagi H, et al. **Kyobu Geka** 1996 Mar; 49(3):239–42 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of the true aortic arch aneurysm combined with coronary artery disease] Tanaka T, et al. **Kyobu Geka** 1995 Oct;48(11):899–902; discussion 902–4 (Eng. Abstr.) **(Jpn)**

[Problems in thoracic and abdominal aortic aneurysm surgery] Kawada S, et al. **Nippon Geka Gakkai Zasshi** 1995 Sep;96(9):612–3 **(Jpn)**

[The effectiveness of cerebrovascular complication prevention in single clamp coronary artery bypass surgery and non-clamping selective cerebral perfusion thoracic aorta aneurysm surgery] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):737–40 **(Jpn)**

[Selective cerebral perfusion during the surgery of thoracic aortic aneurysms in 139 cases] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):742–3 **(Jpn)**

[Incidence and prevention of cerebrovascular complications in thoracic aortic aneurysm surgery] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):744–6 **(Jpn)**

[An aortic valve-sparing operation (David's operation) for a patient with annulo-aortic ectasia (AAE) and aortic regurgitation (AR)—evaluation by intraoperative endoscopy] Furukawa K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):826–9 (Eng. Abstr.) **(Jpn)**

[Treatment of patients with chronic dissecting aortic aneurysm (DeBakey type IIIb) presenting with compromised renal perfusion] Fuwa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct;43(10):1730–5 (Eng. Abstr.) **(Jpn)**

[A report of surgical treatment for atherosclerotic aneurysm in the aortic arch associated with type III acute aortic dissection] Hara Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):516–8 (Eng. Abstr.) **(Jpn)**

[A comparison of changes of cerebrovascular oxygen saturation in retrograde and selective cerebral perfusion during aortic arch surgery] Higami T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec; 43(12):1919–23 (Eng. Abstr.) **(Jpn)**

[The treatment of patients with distal arch aneurysms—hypothermic circulatory arrest and left posterolateral exposure] Hirotani T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1115–9 (Eng. Abstr.) **(Jpn)**

[Single-stage surgery for annulo aortic ectasia, Stanford type-A aortic dissection and pectus excavatum in a patient with Marfan's syndrome] Ichikawa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):575–9 (Eng. Abstr.) **(Jpn)**

[Clinical experience with normothermic selective cerebral perfusion during graft replacement of ascending-arch-descending aortic aneurysms with annuloaortic ectasia] Kuniyoshi Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):19–24 (Eng. Abstr.) **(Jpn)**

[A case of visceral ischemia associated with acute type IIIb aortic dissection] Moizumi Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1023–7 (Eng. Abstr.) **(Jpn)**

[Graft replacement of a thoracic aneurysm and coronary artery bypass grafting using retrograde cerebral perfusion through left thoracotomy—a case report] Mukohara N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):74–7 (Eng. Abstr.) **(Jpn)**

[Replacement of descending thoracic aorta using open proximal anastomosis under hypothermic circulatory arrest] Murata S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):9–13 (Eng. Abstr.) **(Jpn)**

[Depression of cellular immunity after aortic arch replacement] Nakamura M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):31–7 (Eng. Abstr.) **(Jpn)**

[Selection of the surgical methods and surgical outcome of the distal arch aneurysm] Niinami H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec; 43(12):1936–41 (Eng. Abstr.) **(Jpn)**

[Successful surgical treatment for ruptured distal aortic arch aneurysm into lung] Ogino H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Nov; 43(11):1836–40 (Eng. Abstr.) **(Jpn)**

[Acute type A aortic dissection after replacement of descending thoracic aorta for type B aortic dissection] Okada K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):848–52 (Eng. Abstr.) **(Jpn)**

[Surgery of thoracoabdominal aortic aneurysm associated with coronary artery disease] Okamoto H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1953–7 (Eng. Abstr.) **(Jpn)**

[Dislodgement of the ringed-graft—a case report] Osaka K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug; 43(8):1182–6 (Eng. Abstr.) **(Jpn)**

[The graft replacement of the patient with aortic arch aneurysm and thrombosed aortic dissection] Sasaki A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug; 43(8):1191–4 (Eng. Abstr.) **(Jpn)**

[Staged operation of multiple aortic aneurysms with myocardial infarction and stenosis of three coronary arteries] Shimoji M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct;43(10):1752–6 (Eng. Abstr.) **(Jpn)**

[Successful graft replacement of a thoracic aortic aneurysm in a patient with Ehlers-Danlos syndrome] Takazawa A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Nov; 43(11):1850–3 (Eng. Abstr.) **(Jpn)**

[Replacement of the total thoracic aorta in a single stage using selective cerebral perfusion] Yanagiya A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct; 43(10):1778–82 (Eng. Abstr.) **(Jpn)**

[Tuberculous aneurysm of the descending aorta—successful surgical treatment] Fukuhara N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr;34(4):454–8 (Eng. Abstr.) **(Jpn)**

[Ischemic complications of dissecting aneurysm of the aorta. Treatment with percutaneous stents and fenestration] Nyman U, et al. **Lakartidningen** 1996 Feb 14;93(7):577–82 **(Swe)**

[Stent graft technique in thoracic aortic aneurysm. A new alternative to conventional surgery] Nyman U, et al. **Lakartidningen** 1996 Feb 14;93(7):584–8 **(Swe)**

THERAPY

Intracoronary stenting of a coronary occlusion resulting from an aortic dissection. Ikari Y, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):160–3

A safe, simple alternative for pressure reduction during aortic endograft deployment [comment] Diethrich EB. **J Endovasc Surg** 1996 Aug;3(3):275. Comment on: J Endovasc Surg 1996 Aug;3(3):270–2. Comment on: J Endovasc Surg 1996 Aug;3(3):273–4.

Adenosine-induced transient cardiac asystole enhances precise deployment of stent-grafts in the thoracic or abdominal aorta [see comments] Dorros G, et al. **J Endovasc Surg** 1996 Aug;3(3):270–2. Comment in: J Endovasc Surg 1996 Aug;3(3):275.

Transient asystole for aortic endograft deployment: a technique justified only in highly selected cases [see comments] White GH. **J Endovasc Surg** 1996 Aug; 3(3):273–4. Comment in: J Endovasc Surg 1996 Aug;3(3):275.

ULTRASONOGRAPHY

Diastolic flow across a ventricular septal defect: an invitation to a false diagnosis. Suskin N, et al. **Can J Cardiol** 1996 Apr;12(4):419–21

Intramural aortic haematoma following intra-aortic balloon counterpulsation. Documentation by transoesophageal echocardiography [letter] Vilacosta I, et al. **Eur Heart J** 1995 Dec;16(12):2015–6

Transesophageal echocardiography in the diagnosis of thoracic saccular aortic aneurysm. The value of transesophageal echocardiography during the course of

treatment. Hashimoto S, et al. **Int J Card Imaging** 1995 Dec;11(4):241–6

Transesophageal echocardiographic diagnosis of thoracic aortic dissection with the completely thrombosed false lumen: differentiation from true aortic aneurysm with mural thrombus. Nishino M, et al. **J Am Soc Echocardiogr** 1996 Jan–Feb;9(1):79–85

[Takayasu arteritis--a rare differential diagnosis in aortic dissection. A case report] Wildburg G, et al. **Z Kardiol** 1995 Dec;84(12):1033–8 (Eng. Abstr.) **(Ger)**

AORTIC ARCH see **AORTA, THORACIC**

AORTIC ARCH SYNDROMES

COMPLICATIONS

[Coronary arterial bypass grafting for angina pectoris suspected with aortitis syndrome: a case report] Nakamura N, et al. **Kyobu Geka** 1996 Jun;49(6):487–90 (Eng. Abstr.) **(Jpn)**

[Aortitis syndrome with left coronary ostial occlusion and aortic regurgitation: a case report] Osaka K, et al. **Kyobu Geka** 1995 Aug;48(9):789–91 (Eng. Abstr.) **(Jpn)**

[A case of Vogt–Koyanagi–Harada disease associated with aortitis syndrome] Kiriyama M, et al. **Nippon Ganka Gakkai Zasshi** 1996 Apr;100(4):326–31 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Right aortic arch and "isolated" left brachiocephalic arterial trunk. Fortuitous discovery in angiologic practice] Bouchet C, et al. **J Mal Vasc** 1995;20(3):224–6 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

[Relationship between postoperative prognosis and preoperative immunological factors in aortitis syndrome] Noji S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb; 44(2):149–54 (Eng. Abstr.) **(Jpn)**

SURGERY

[Cerebral protection by selective cerebral perfusion during surgery on the aortic arch] Le Mee F, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1601–7 (Eng. Abstr.) **(Fre)**

[Simultaneous aortic root and total arch graft replacement in a patient with aortitis syndrome] Sasaki A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):839–43 (Eng. Abstr.) **(Jpn)**

AORTIC BODIES

Pathologic quiz case 2. Vagal paraganglioma. Heartfield W, et al. **Arch Otolaryngol Head Neck Surg** 1996 Sep; 122(9):1013, 1015

Functioning glomus vagale tumor: report of case. Guiral H, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):227–30 (12 ref.)

EMBRYOLOGY

Evidence to support the distal vagal ganglion as the origin of C cells of the ultimobranchial gland in the chick. Kameda Y. **J Comp Neurol** 1995 Aug 14;359(1):1–14

PHYSIOPATHOLOGY

[Vasovagal syncope in 15-year-old girl] Gołąbek M, et al. **Pediatr Pol** 1996 May;71(5):477–9 (Eng. Abstr.) **(Pol)**

AORTIC COARCTATION

A pre-eclamptic with coarctation of the aorta. Matthews PC, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):358

Gridlock: a model for coarctation of the aorta? [comment] Towbin JA, et al. **Nat Med** 1995 Nov;1(11):1141–2. Comment on: Nat Med 1995 Nov;1(11):1143–7.

Gridlock, a localized heritable vascular patterning defect in the zebrafish [see comments] Weinstein BM, et al. **Nat Med** 1995 Nov;1(11):1143–7. Comment in: Nat Med 1995 Nov;1(11):1141–2.

COMPLICATIONS

Pseudocoarctation of the aorta complicated by saccular aneurysm: treatment by aortic arch replacement. Grigsby JL, et al. **Am Heart J** 1996 Jan;131(1):200–2

Losartan improves baroreflex control of heart rate of coarcted hypertensive rats. Santos CM, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H812–8

Takayasu's arteritis: the middle aortic syndrome. Pagni S, et al. **Am Surg** 1996 May;62(5):409–12

Aortic coarctation with two intercostal aneurysms, appearing radiographically as a subclavian aneurysm. A case report. Kelsay DE, et al. **Angiology** 1996 Jan;47(1):103–6

PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Frieden IJ, et al. **Arch Dermatol** 1996 Mar; 132(3):307–11

A pre-eclamptic with coarctation of the aorta. Matthews PC, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):358

Hypertensive response to acute aortic coarctation in chronic vasopressin deficient states. Fregoneze JB, et al. **Clin Exp Hypertens** 1995 Aug;17(6):977–88

Ebstein's anomaly with coarctation of the aorta--an unusual association. Salkar HR, et al. **Indian Heart J** 1996 May–Jun; 48(3):283–4 (7 ref.)

Coarctation of aorta and hereditary spherocytosis. Kaur K, et al. **J Assoc Physicians India** 1995 Sep;43(9):649

Decision making for the surgical management of aortic coarctation associated with ventricular septal defect. Brouwer RM, et al. **J Thorac Cardiovasc Surg** 1996 Jan; 111(1):168–75

Elevated arginine vasopressin and lowered atrial natriuretic factor associated with hypertension in coarctation of the aorta. Stewart JM, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):900–8

Left ventricular growth in a patient with critical coarctation of the aorta and hypoplastic left ventricle. Page DA, et al. **Pediatr Cardiol** 1995 Jul–Aug;16(4):176–8

[Hypoplasia of abdominal aorta, rare cause of hypertension in childhood] Durand I, et al. **Arch Pediatr** 1995 Dec; 2(12):1173–6 (Eng. Abstr.) **(Fre)**

[A successful palliative arterial switch operation with arch repair for tricuspid atresia with ventriculoarterial discordance, subaortic stenosis, coarctation, and aortic arch hypoplasia] Yamagishi M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1981–7 (Eng. Abstr.) **(Jpn)**

[Cholestasis in congenital heart diseases (hypoplastic left heart syndrome, aortic coarctation)] Konno T. **Ryoikibetsu Shokogun Shirizu** 1995;(7):571–3 (9 ref.) **(Jpn)**

[Diagnostic and therapeutic problems in a newborn with aortic coarctation, adrenal and intracranial hemorrhages and renal failure] Wróblewska-Kałużewska M, et al. **Pediatr Pol** 1995 Dec;70(12):1065–8 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Abdominal aortic coarctation: CT, MRI, and angiographic correlation. Moresco KP, et al. **Comput Med Imaging Graph** 1995 Sep–Oct;19(5):427–30

MRI of pseudocoarctation of the aorta: morphological and cine-MRI findings. Soler R, et al. **Comput Med Imaging Graph** 1995 Sep–Oct;19(5):431–4

Recent advances in the diagnosis and treatment of coarctation of the aorta. Hougen TJ, et al. **Curr Opin Cardiol** 1995 Sep;10(5):524–9 (19 ref.)

Biplane transoesophageal echocardiography, transthoracic Doppler, and magnetic resonance imaging in the assessment of coarctation of the aorta [see comments] Engvall J, et al. **Eur Heart J** 1995 Oct;16(10):1399–409. Comment in: Eur Heart J 1995 Oct;16(10):1315–6.

Imaging of aortic coarctation--difficult choices [editorial; comment] Sechtem U. **Eur Heart J** 1995 Oct;16(10):1315–6 . Comment on: Eur Heart J 1995 Oct;16(10):1399–409.

Magnetic resonance imaging demonstration of "remodeling" of the aorta following balloon angioplasty of discrete native coarctation. Weber HS, et al. **Pediatr Cardiol** 1996 May–Jun;17(3):184–8

Early diagnosis of coarctation of the aorta in children: a continuing dilemma. Ing FF, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):378–82

Stroke in a 24-year-old man. Chowdhury MM, et al. **Postgrad Med J** 1996 Apr;72(846):245–6

Atypical aortic coarctation and innominate artery stenosis associated with clubfoot and lower leg ischemia in an infant. Smith JC, et al. **Teratology** 1995 Dec;52(6):357–60

[Coarctation of the abdominal aorta] Karasch T, et al. **Dtsch Med Wochenschr** 1996 Feb 9;121(6):159–64 (35 ref.) (Eng. Abstr.) **(Ger)**

[Usefulness of nuclear magnetic resonance in the diagnosis of aortic coarctation and recoarctation] Albert Brotons D, et al. **Rev Esp Cardiol** 1995 Dec;48(12):807–11 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Acquired coarctation of the descending thoracic aorta. Ansari A, et al. **Tex Heart Inst J** 1996;23(1):68

GENETICS

Hemangioma, supraumbilical midline raphé, and coarctation of the aorta with a right aortic arch: single causal entity? Kishnani P, et al. **Am J Med Genet** 1995 Oct 23;59(1):44–8

The effect of aortic coarctation on expression of endothelin-1 and endothelin receptors in heart and lungs. Sirviö ML, et al. **Blood Press** 1995 Sep;4(5):320–3

Coarctation of the aorta and renal hypoplasia in a boy with Turner/Noonan surface anomalies and a 46,XY karyotype: a clinical model for the possible impairment of a putative lymphogenic gene(s) for Turner somatic stigmata. Hasegawa T, et al. **Hum Genet** 1996 May;97(5):564–7

MORTALITY

Surgical repair of coarctation of the aorta in neonates: factors affecting early mortality and re-coarctation. Wu JL, et al. **Cardiovasc Surg** 1995 Dec;3(6):573–8

PATHOLOGY

[Pathomorphological study of intraorgan arteries in patients with aortic coarctation] Litasova EE, et al. **Biull Eksp Biol Med** 1996 Mar;121(3):332–6 **(Rus)**

PHYSIOPATHOLOGY

Real-time comparison of pressure-predicted and Doppler-measured jet velocities distal to left-sided obstructions throughout systole. Zamora R, et al. **Am J Cardiol** 1995 Oct 15;76(11):853–5

Effect of chronic estradiol administration on the acute pressor response to aortic coarctation in conscious rats. Salgado MC, et al. **Braz J Med Biol Res** 1995 Aug;28(8):881–8

Peripheral blood flow responses to exercise after successful correction of coarctation of the aorta. Johnson D, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1719–24

[The evolution of the transmitral and transaortic gradient in aortic coarctation] da Silva AJ, et al. **Rev Port Cardiol** 1995 Oct;14(10):753–5 **(Por)**

[The right heart ventricle during hemodynamic overload of the left ventricle] Frolov VA, et al. **Patol Fiziol Eksp Ter** 1995 Jul–Sep;(3):26–31 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

[What is your diagnosis? Aortic isthmus stenosis] Braunschweig M. **Schweiz Rundsch Med Prax** 1996 Jul 2; 85(27–28):855–6 **(Ger)**

SURGERY

A postoperative follow-up study of infantile coarctation of the aorta. Abdulla S, et al. **Acta Paediatr Suppl** 1995 Aug; 410:69–73

Pseudocoarctation of the aorta complicated by saccular aneurysm: treatment by aortic arch replacement. Grigsby JL, et al. **Am Heart J** 1996 Jan;131(1):200–2

Feasibility and effectiveness of repeated balloon dilatation of restenosed congenital obstructions after previous balloon valvuloplasty/angioplasty. Rao PS, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):403–7

Percutaneous balloon dilatation of aortic coarctation in adults. deGiovanni JV, et al. **Am J Cardiol** 1996 Feb 15; 77(5):435–9

Technique for extraanatomic bypass in complex aortic coarctation. Barron DJ, et al. **Ann Thorac Surg** 1996 Jan; 61(1):241–4

Internal mammary artery atherosclerosis fifteen years after correction of aortic coarctation [letter] De Salazar AO, et al. **Ann Thorac Surg** 1996 Aug;62(2):629

Bypass graft for complex forms of isthmic aortic coarctation in adults. Grinda JM, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1299–302

Late aneurysm after subclavian flap aortoplasty for coarctation of the aorta. Kino K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1262–4 (8 ref.)

Aortic aneurysms at the site of the repair of coarctation of the aorta: a review of 48 patients. Knyshov GV, et al. **Ann Thorac Surg** 1996 Mar;61(3):935–9

Perioperative complications in combined aortic valve replacement and extraanatomic ascending–descending bypass. Pethig K, et al. **Ann Thorac Surg** 1996 Jun; 61(6):1724–6

Isolated aortic coarctation in neonates and infants: results of resection and end-to-end anastomosis. Pfammatter JP, et al. **Ann Thorac Surg** 1996 Sep;62(3):778–82; discussion 782–3

Coarctation repair using end-to-side anastomosis of descending aorta to proximal aortic arch. Rajasinghe HA, et al. **Ann Thorac Surg** 1996 Mar;61(3):840–4

Reoperation for recurrent aortic coarctation. Ralph-Edwards AC, et al. **Ann Thorac Surg** 1995 Nov;60(5):1303–7

Systemic obstruction in univentricular hearts: surgical options for neonates. Serraf A, et al. **Ann Thorac Surg** 1995 Oct; 60(4):970–6; discussion 976–7

Repair of coarctation of the aorta in adults: the fate of systolic hypertension. Wells WJ, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1168–71

Coarctation of the abdominal aorta. Bergamini TM, et al. **Ann Vasc Surg** 1995 Jul;9(4):352–6

Surgical repair of coarctation of the aorta in neonates: factors affecting early mortality and re-coarctation. Wu JL, et al. **Cardiovasc Surg** 1995 Dec;3(6):573–8

Coarctation of the aorta. Repair with polytetrafluoroethylene patch aortoplasty. Backer CL, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II132–6 (37 ref.)

Peripheral blood flow responses to exercise after successful correction of coarctation of the aorta. Johnson D, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1719–24

Aortic coarctation, aortic valvular stenosis, and coronary artery disease: combined one-stage surgical therapy operation. Bartoccioni S, et al. **J Card Surg** 1995 Sep; 10(5):594–6

Disappearance of signs of coarctation during dissection in a neonate--an unusual phenomenon [letter] Neema PK, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):444

Coarctation of the aorta in infants and neonates: results and assessment of prognostic variables. Demircin M, et al. **J Cardiovasc Surg (Torino)** 1995 Oct;36(5):459–64

Clinical experience with a collagen impregnated woven Dacron graft. Tolan M, et al. **J Cardiovasc Surg (Torino)** 1995 Aug;36(4):323–7

Unusual complication seven years after successful aortic recoarctation repair with a Dacron graft: acute thromboembolic leg ischemia caused by a mobile thrombus

at the distal suture line. Berzins R, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):842–4

Decision making for the surgical management of aortic coarctation associated with ventricular septal defect. Brouwer RM, et al. **J Thorac Cardiovasc Surg** 1996 Jan; 111(1):168–75

Doppler echocardiography during exercise to predict residual narrowing of the aorta after coarctation resection. Guenthard J, et al. **Pediatr Cardiol** 1996 Nov–Dec; 17(6):370–4

Ambulatory blood pressure in patients with occult recurrent coarctation of the aorta. Parrish MD, et al. **Pediatr Cardiol** 1995 Jul–Aug;16(4):166–71

Exercise-induced hypertension after corrective surgery for coarctation of the aorta. Sigurdardóttir LY, et al. **Pediatr Cardiol** 1996 Sep–Oct;17(5):301–7

[Clinical–therapeutic aspects and surgical treatment of aortic coarctation associated with hypoplasia of the aortic arch in less than 3–month–old patients] Patanè L, et al. **Pediatr Med Chir** 1995 Jul–Aug;17(4):323–6 (Eng. Abstr.) **(Ita)**

[Aortic aneurysm complicated with coarctation of the aorta and Turner syndrome] Kusaba E, et al. **Kyobu Geka** 1995 Dec;48(13):1115–7 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of congenital atypical coarctation of the aorta and postoperative management for hypertension] Ohno H, et al. **Kyobu Geka** 1995 Dec;48(13):1131–4 (Eng. Abstr.) **(Jpn)**

[Reoperation for coarctation of the aorta and interrupted aortic arch] Hirai M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1657–63 (Eng. Abstr.) **(Jpn)**

[Aortic coarctation and complex heart disease. Surgical treatment during the first year of life] Fiane AE, et al. **Tidsskr Nor Laegeforen** 1996 Aug 20;116(19):2310–2 (Eng. Abstr.) **(Nor)**

THERAPY

Should balloon angioplasty be used instead of surgery for native aortic coarctation? [editorial] Rao PS. **Br Heart J** 1995 Dec;74(6):578–9

Late development of dissecting aneurysm following balloon angioplasty of native aortic coarctation [see comments] Aydogan U, et al. **Cathet Cardiovasc Diagn** 1995 Nov; 36(3):226–9. Comment in: Cathet Cardiovasc Diagn 1995 Nov;36(3):230–1.

Interventional cardiac catheterization therapy for combined coarctation of the aorta and patent ductus arteriosus: successful outcome in two infants. Geggel RL, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):67–70; discussion 71

Acute cyanosis following balloon angioplasty of residual arch obstruction after the Norwood I operation. Recto MR, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):72–4

Aneurysm associated with balloon angioplasty of aortic coarctation: future prevention and treatment [editorial; comment] Ruiz CE, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):230–1. Comment on: Cathet Cardiovasc Diagn 1995 Nov;36(3):226–9.

Long–term effects of balloon coarctation angioplasty on arterial blood pressure in adolescent and adult patients. Schräder R, et al. **Cathet Cardiovasc Diagn** 1995 Nov; 36(3):220–5

Quantitative echocardiographic analysis of the aortic arch predicts outcome of balloon angioplasty of native coarctation of the aorta. Kaine SF, et al. **Circulation** 1996 Sep 1;94(5):1056–62

Recent advances in the diagnosis and treatment of coarctation of the aorta. Hougen TJ, et al. **Curr Opin Cardiol** 1995 Sep;10(5):524–9 (19 ref.)

Coarctation of the aorta: aortoplasty with Inoue balloon. Ramachandran P, et al. **Indian Heart J** 1996 May–Jun; 48(3):287–9 (11 ref.)

The various therapeutic approaches to aortic coarctation: is it fair to compare? [editorial; comment] Hanley FL. **J Am Coll Cardiol** 1996 Feb;27(2):471–2. Comment on: J Am Coll Cardiol 1996 Feb;27(2):462–70.

Five- to nine-year follow-up results of balloon angioplasty of native aortic coarctation in infants and children [see comments] Rao PS, et al. **J Am Coll Cardiol** 1996 Feb; 27(2):462–70. Comment in: J Am Coll Cardiol 1996 Feb;27(2):471–2.

Angiographic assessment of the stretch–recoil–gain relation after balloon coarctation angioplasty and its relation to late restenosis. Ino T, et al. **Jpn Circ J** 1996 Feb;60(2):102–7

Percutaneous transluminal balloon angioplasty of abdominal aortic coarctation in an infant. Adwani S, et al. **Pediatr Cardiol** 1996 Sep–Oct;17(5):346–8

Magnetic resonance imaging demonstration of "remodeling" of the aorta following balloon angioplasty of discrete native coarctation. Weber HS, et al. **Pediatr Cardiol** 1996 May–Jun;17(3):184–8

[The endovascular correction of aortic coarctation] Barkov ED, et al. **Vestn Khir Im I I Grek** 1992 Mar;148(3):265–72 (Eng. Abstr.) **(Rus)**

[Percutaneous transluminal angioplasty with a balloon catheter in native aortic coarctation: long–term experience] Palacios Rodríguez JM, et al. **Arch Inst Cardiol Mex** 1995 May–Jun;65(3):237–44 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Tardus–parvus Doppler signals in the renal arteries: a sign of pediatric thoracoabdominal aortic coarctations. McLeary MS, et al. **AJR Am J Roentgenol** 1996 Aug; 167(2):521–3

Intravascular ultrasound imaging of coarctation of the aorta: animal and human studies. Tong AD, et al. **Am J Card Imaging** 1995 Oct;9(4):250–6

AORTIC DISEASES

Diseases of the aorta, pulmonary, and peripheral vessels. **Curr Opin Cardiol** 1995 Sep;10(5):B120–5

Primary leiomyosarcoma of the abdominal aorta. Malone MD, et al. **J Vasc Surg** 1996 Sep;24(3):487–93 (36 ref.)

BLOOD

Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population–based study. Jie KS, et al. **Atherosclerosis** 1995 Jul;116(1):117–23

Intraoperative autotransfusion in aortic surgery: comparison of whole blood autotransfusion versus cell separation. Bartels C, et al. **J Vasc Surg** 1996 Jul;24(1):102–8

CHEMICALLY INDUCED

Fatal aortic thrombosis in a neonate during infusion of epsilon–aminocaproic acid. Hocker JR, et al. **J Pediatr Surg** 1995 Oct;30(10):1490–2

Aprotinin and aortic cannula thrombosis. Gitter R, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):537–8

COMPLICATIONS

Risk of catheter–related emboli in patients with atherosclerotic debris in the thoracic aorta. Karalis DG, et al. **Am Heart J** 1996 Jun;131(6):1149–55

Aortic dissection complicating coronary angioplasty in cystic medial necrosis. Pande AK, et al. **Am Heart J** 1996 Jun; 131(6):1221–3

Coronary artery discrete aneurysms, ectasia, and occlusive disease ane extensive arteriomegaly. Correlation, constellation, or coincidence? A case report. Gavaliatsis IP, et al. **Angiology** 1996 Jul;47(7):729–33

The proximal aorta: a source of stroke. Jones EF, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):207–20 (45 ref.)

Images in cardiovascular medicine. Intra–aortic thrombus producing embolic arterial vascular disease. Lozano P, et al. **Circulation** 1996 Apr 1;93(7):1471

Intramural aortic haematoma causing ischaemia of the spinal cord. Ferguson JD, et al. **Heart** 1996 May;75(5):533

Aortic atherosclerotic plaques as a source of systemic embolism. Khatibzadeh M, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):664–9

Aortic atheromatosis and risks of cerebral embolization. Barbut D, et al. **J Cardiothorac Vasc Anesth** 1996 Jan; 10(1):24–9; quiz 29–30 (72 ref.)

Massive hemoptysis as a manifestation of fistulized thoracic aortic aneurysms into the bronchial tree. Julià–Serdà G, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):417–9

Angiotensin II type–1 receptor antagonist as well as angiotensin converying enzyme inhibitor attenuates the development of heart failure in aortocaval fistula rats. Nishikimi T, et al. **Jpn Circ J** 1995 Nov;59(11):754–61

Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The French Study of Aortic Plaques in Stroke Group. **N Engl J Med** 1996 May 9; 334(19):1216–21

Reversible acute renal failure following aortic thrombosis inducing bilateral renal–artery occlusive disease. Le Goff C, et al. **Nephrol Dial Transplant** 1995;10(6):879–81

Successful renal autotransplantation with Y–prosthetic aortic replacement in a patient with complete occlusion of abdominal aorta and renal artery. Yagisawa T, et al. **Urol Int** 1995;55(1):46–50

[Aortoesophageal fistula. A rare cause of hematemesis] Pohlmann JT, et al. **Ugeskr Laeger** 1996 Aug 19; 158(34):4772–4 (Eng. Abstr.) **(Dan)**

[Dysphagia associated with aorto–cardiac compression on the distal esophagus: a rare event but not exceptional in the elderly] Tosato F, et al. **Minerva Chir** 1995 Sep; 50(9):773–7 (Eng. Abstr.) **(Ita)**

[A case of ruptured thoracoabdominal aortic aneurysm complicated with high aortic occlusion] Satokawa H, et al. **Kyobu Geka** 1995 Nov;48(12):1053–6 (Eng. Abstr.) **(Jpn)**

[Hemoptysis caused by aortobronchial fistula (letter)] Martín Zapatero E, et al. **Med Clin (Barc)** 1996 Mar 2;106(8):318–9 **(Spa)**

CONGENITAL

Pathological case of the month. Idiopathic arterial calcification of infancy. Green DW, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):101–2

Aortoesophageal fistula and double aortic arch: two important points in management. Othersen HB Jr, et al. **J Pediatr Surg** 1996 Apr;31(4):594–5

DIAGNOSIS

The many faces of aortoenteric fistulas. Antinori CH, et al. **Am Surg** 1996 May;62(5):344–9

Functional MR imaging of anomalies of the aorta. Schick F, et al. **Bildgebung** 1996 Jun;63(2):105–12

Postocclusive hyperaemic duplex scan: a new method of aortoiliac assessment [see comments] Currie IC, et al. **Br J Surg** 1995 Sep;82(9):1226–9. Comment in: Br J Surg 1996 Feb;83(2):280–1.

Inflammatory aneurysm of the ascending aorta mimicking intramural hemorrhage [letter; comment] Federmann M, et al. **Circulation** 1996 Apr 1;93(7):1477–8. Comment on: Circulation 1995 Sep 15;92(6):1376–8. Comment on: Circulation 1995 Sep 15;92(6):1465–72.

Novel biochemical diagnostic method for aortic dissection. Results of a prospective study using an immunoassay of smooth muscle myosin heavy chain. Suzuki T, et al. **Circulation** 1996 Mar 15;93(6):1244–9

Time–of–flight magnetic resonance angiography of aorta and renal arteries: state–of–the–art. Laissy JP, et al. **Eur J Radiol** 1996 Feb;21(3):201–11 (71 ref.)

Primary aortoenteric fistula: two new case reports and a review of 44 previously reported cases. Tareen AH, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):5–10 (34 ref.)

Vascular–enteric fistula: diagnosis by colonoscopy. Hamdani R, et al. **Gastrointest Endosc** 1995 Jul;42(1):80–1

Imaging the thoracic aorta [editorial] Reid JH. **Heart** 1996 Jul;76(1):3–5 (11 ref.)

Case in point. Aortic root abscess caused by Staphylococcus aureus. Greene GS. **Hosp Pract (Off Ed)** 1995 Sep 15; 30(9):29

Magnetic resonance imaging to study lesions of atherosclerosis in the hyperlipidemic rabbit aorta. Yuan C, et al. **Magn Reson Imaging** 1996;14(1):93–102

MR imaging of the thoracic aorta. Flamm SD, et al. **Magn Reson Imaging Clin N Am** 1996 May;4(2):217–35 (54 ref.)

Human aorta: preliminary results with virtual endoscopy based on three–dimensional MR imaging data sets. Davis CP, et al. **Radiology** 1996 Apr;199(1):37–40

[Diagnosis of secondary aortointestinal fistulae] Schantz V. **Ugeskr Laeger** 1996 Aug 19;158(34):4771–2 (Eng. Abstr.) **(Dan)**

[Angiosarcoma of the aorta—a case report] Düx M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):361–3 (8 ref.) **(Ger)**

[An intramural hematoma of the ascending aorta. The radiological trap] Bagnolesi P, et al. **Radiol Med (Torino)** 1995 Sep;90(3):317–20 (8 ref.) **(Ita)**

[Aortic intramural hematoma. An atypical pattern equivalent to aortic dissection] López–Mínguez JR, et al. **Rev Esp Cardiol** 1995 Sep;48(9):634–7 (Eng. Abstr.) **(Spa)**

[Identification of intramural aortic hematoma by transesophageal echocardiography] Vilacosta I, et al. **Rev Esp Cardiol** 1996 Mar;49(3):196–203 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol–lowering therapies in familial hypercholesterolemia. Tomochika Y, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):955–62

[Subacute thrombosis of the abdominal aorta with suprarenal involvement and successful treatment with pharmacomechanical fibrinolysis] Baštecký J, et al. **Vnitr Lek** 1995 Nov;41(11):777–82 (Eng. Abstr.) **(Cze)**

EPIDEMIOLOGY

Increased prevalence of aortic calcification in chronic pancreatitis. Gullo L, et al. **Am J Gastroenterol** 1996 Apr; 91(4):759–61

Secondary aortoenteric fistulae—changes from 1973 to 1993. Bergqvist D, et al. **Eur J Vasc Endovasc Surg** 1996 May; 11(4):425–8

The primary aortoenteric fistula in The Netherlands—the unpublished cases. Voorhoeve R, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):429–31

Predominance of aortic calcification as an atherosclerotic manifestation in women: the Reykjavik study. Danielsen R, et al. **J Clin Epidemiol** 1996 Mar;49(3):383–7

[Evolution of aortic atherosclerosis in specific European cities in the the 60's and 80's] Vikhert AM, et al. **Arkh Patol** 1995 Jul–Aug;57(4):72–5 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Renal infarction and thrombosis of the infrarenal aorta in a 35–year–old man with primary antiphospholipid syndrome. Poux JM, et al. **Am J Kidney Dis** 1996 May; 27(5):721–5 (20 ref.)

Aortoesophageal fistula after repair of descending aortic dissection. Wong RS, et al. **Ann Thorac Surg** 1996 Aug; 62(2):588–90

Relative resistance of the hamster to aortic atherosclerosis in spite of prolonged vitamin E deficiency and dietary hypercholesterolemia. Putative effect of increased HDL? Stein O, et al. **Biochim Biophys Acta** 1996 Jan 19; 1299(2):216–22

Severe arterial thrombosis in a congenitally factor VII deficient patient. Escoffre M, et al. **Br J Haematol** 1995 Nov;91(3):739–41

Primary aortoesophageal fistula caused by an atherosclerotic thoracoabdominal aortic aneurysm: a case report and review of the literature. Hageman JH, et al. **Cardiovasc Surg** 1995 Oct;3(5):495–9 (17 ref.)

Aortocaval fistula complicating abdominal aortic aneurysm: case report and literature review. Fenster MS, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):75–9

Intramural hematoma of the aorta caused by a penetrating atheromatous ulcer. Wann S, et al. **Clin Cardiol** 1996 May; 19(5):438–9

Oesophago–vascular fistulae secondary to benign peptic ulcer disease: a rare cause of fatal haemorrhage. Kenny PJ, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):370–1 (6 ref.)

Aortoduodenal fistula as an unusual and fatal manifestation of giant–cell arteritis. Lagrand WK, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):502–3

Reperfusion injury tourniquet syndrome caused by acute aortic occlusion due to embolism following pneumonectomy. Sonak RA, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):499–501

Aortobronchial fistula after correction of congenital cardiovascular abnormalities. Hiep–van Casteren SC, et al. **Eur Respir J** 1995 Oct;8(10):1796–8

Mycotic aortic aneurysm in patients who have lumbar vertebral osteomyelitis. A report of two cases. Rubery PT, et al. **J Bone Joint Surg Am** 1995 Nov;77(11):1729–32

Primary aortogastric fistula: a complication of ruptured aortic aneurysm. Lorimer JW, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):363–6

Aortocaval fistula secondary to mediastinitis. King M. **J Emerg Med** 1996 Jan–Feb;14(1):5–8

Acute aortic dissection with intramural hematoma: possibility of transition to classic dissection or aneurysm. Ide K, et al. **J Thorac Imaging** 1996 Winter;11(1):46–52

[Dissection of the interventricular septum with aorto–left ventricular communication due to infective endocarditis—report of a rare case] Yamauchi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):534–8 (Eng. Abstr.) **(Jpn)**

GENETICS

Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Groot PH, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):926–33

HISTORY

Postal diagnosis: breaking the bad news in the 17th century. Forrester J. **BMJ** 1995 Dec 23–30;311(7021):1694–6

METABOLISM

Increased expression of 72–kd type IV collagenase (MMP–2) in human aortic atherosclerotic lesions. Li Z, et al. **Am J Pathol** 1996 Jan;148(1):121–8

Effects of fish oil supplementation on atherosclerosis in different regions of the aorta of rabbits with diet–induced hypercholesterolaemia. Chen MF, et al. **Clin Sci (Colch)** 1995 Nov;89(5):497–504

Dietary effects of corn oil, oleic acid, perilla oil, and primrose oil on plasma and hepatic lipid level and atherosclerosis in Japanese quail. Sadi AM, et al. **Exp Anim** 1996 Jan; 45(1):55–62

Elevated levels of plasminogen–activator inhibitor type 1 in atherosclerotic aorta. Shireman PK, et al. **J Vasc Surg** 1996 May;23(5):810–7; discussion 817–8

MICROBIOLOGY

Aspergillus terreus, an uncommon fungus causing aortic root abscess and pseudoaneurysm. Koshi G, et al. **Indian Heart J** 1995 May–Jun;47(3):265–7

PATHOLOGY

Comparison of thickness and distensibility in the carotid artery and descending thoracic aorta: in vivo ultrasound assessment. Pearson AC, et al. **Am Heart J** 1996 Apr; 131(4):655–62

Pathological case of the month. Idiopathic arterial calcification of infancy. Green DW, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):101–2

Deposition pattern of monocytes and fatty streak development in hypercholesterolemic rabbits. Back MR, et al. **Atherosclerosis** 1995 Jul;116(1):103–15

Calcified deposit formation in intimal thickenings of the human aorta. Bobryshev YV, et al. **Atherosclerosis** 1995 Nov;118(1):9–21

High–resolution mapping of the frequency of lipid deposits in thoracic aortae from cholesterol–fed and heritable hyperlipidaemic rabbits [letter; comment] Forster BA, et al. **Atherosclerosis** 1996 Feb;120(1–2):249–53. Comment on: Atherosclerosis 1995 May;115(1):73–84.

Intraluminal thrombus predicts rupture of an abdominal aortic aneurysm [letter] Satta J, et al. **J Vasc Surg** 1996 Apr;23(4):737–9

[Calcified proliferation of the descending thoracic aorta] Fadel E, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):1039–42 (10 ref.) (Eng. Abstr.) **(Fre)**

[Analytical evaluation of compression and displacement of the esophagus and trachea due to right aortic arch with MR imaging] Ito K, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Feb; 56(3):89–93 (Eng. Abstr.) **(Jpn)**

[Study of atherosclerosis regression in the elderly—central depression and its correlation to ulcerated plaques] Kakiuchi H, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jul; 32(7):503–10 (Eng. Abstr.) **(Jpn)**

[Subpopulations of lymphocytes and monocytes/macrophages at the early stages of human aorta atherosclerosis] Zhdanov VS, et al. **Arkh Patol** 1995 Jul–Aug;57(4):67–71 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Endothelial dysfunction in the early stage of atherosclerosis precedes appearance of intimal lesions assessable with intravascular ultrasound. Mano T, et al. **Am Heart J** 1996 Feb;131(2):231–8

Comparison of thickness and distensibility in the carotid artery and descending thoracic aorta: in vivo ultrasound assessment. Pearson AC, et al. **Am Heart J** 1996 Apr; 131(4):655–62

Real–time comparison of pressure–predicted and Doppler–measured jet velocities distal to left–sided obstructions throughout systole. Zamora R, et al. **Am J Cardiol** 1995 Oct 15;76(11):853–5

Determination of wall shear stress in the aorta with the use of MR phase velocity mapping. Oshinski JN, et al. **J Magn Reson Imaging** 1995 Nov–Dec;5(6):640–7

PREVENTION & CONTROL

Cannula length and arch flow erosion [letter; comment] Groom RC, et al. **Ann Thorac Surg** 1996 Feb;61(2):773–4 . Comment on: Ann Thorac Surg 1995 Mar;59(3):710–2.

Triple drug immunosuppression significantly reduces aortic allograft arteriosclerosis in the rat. Lemström KB, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):553–64

RADIOGRAPHY

Spontaneous aortocaval fistula: CT findings with pathologic correlation. Quiroga S, et al. **Abdom Imaging** 1995 Sep–Oct; 20(5):466–9

Penetrating ulcer of the descending aorta mimicking a traumatic aortic laceration. Patel NH, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):20

Sequential helical CT angiography of aortoiliac disease. Raptopoulos V, et al. **AJR Am J Roentgenol** 1996 Jun; 166(6):1347–54

Angiographic demonstration of primary aorto–enteric fistula—a case report. Yeong KY. **Ann Acad Med Singapore** 1995 May;24(3):467–9

Mid–aortic syndrome presenting in childhood. Panayiotopoulos YP, et al. **Br J Surg** 1996 Feb;83(2):235–40

Radial artery approach for outpatient peripheral arteriography. al–Kutoubi A, et al. **Clin Radiol** 1996 Feb; 51(2):110–2

Aortic calcification and renal cysts demonstrated by CT in a teenager with Alagille syndrome. Pombo F, et al. **Pediatr Radiol** 1995;25(4):314–5

SURGERY

Aorto–iliac reconstruction without arteriography. Bodily K, et al. **Am J Surg** 1996 May;171(5):505–7

Abdominal wall hernias in patients with abdominal aortic aneurysmal versus aortoiliac occlusive disease. Hall KA, et al. **Am J Surg** 1995 Dec;170(6):572–5; discussion 575–6

The many faces of aortoenteric fistulas. Antinori CH, et al. **Am Surg** 1996 May;62(5):344–9

Surgical treatment of systemic atheroembolism from the thoracic aorta. Bojar RM, et al. **Ann Thorac Surg** 1996 May;61(5):1389–93

Vascular ring causing symptomatic tracheal compression in adulthood. Fadel E, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1411–3

Fringed valve prosthesis for aortic root abscess. Hayashi J, et al. **Ann Thorac Surg** 1996 Jul;62(1):262–4

Recurrent cerebral vascular accidents are an indication for ascending aortic endarterectomy. Muehrcke DD, et al. **Ann Thorac Surg** 1996 May;61(5):1516–8

Late development of esophageal compression from a vascular ring. Nicolosi AC, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1413–5

Endarterectomy for calcified porcelain aorta associated with aortic valve stenosis. Svensson LG, et al. **Ann Thorac Surg** 1996 Jan;61(1):149–52

Early clinical results of retrograde cerebral perfusion for aortic arch operations in Japan. Usui A, et al. **Ann Thorac Surg** 1996 Jul;62(1):94–103; discussion 103–4

Eradication of aortic infections with the use of cryopreserved arterial homografts. Vogt PR, et al. **Ann Thorac Surg** 1996 Sep;62(3):640–5

Successful salvage of aortoesophageal fistula caused by a fish bone. Yamada T, et al. **Ann Thorac Surg** 1996 Jun; 61(6):1843–5

Stenting without thrombolysis for aortoiliac occlusive disease: experience in 14 high–risk patients. Ballard JL, et al. **Ann Vasc Surg** 1995 Sep;9(5):453–8

Transperitoneal medial visceral rotation [letter] Deiparine MK, et al. **Ann Vasc Surg** 1995 Nov;9(6):607

Clinical and CT evaluation of a new stretch polytetrafluoroethylene aortic graft. Erdoes LS, et al. **Ann Vasc Surg** 1995 Sep;9(5):441–7

Aortic reconstruction in kidney transplant recipients. Panneton JM, et al. **Ann Vasc Surg** 1996 Mar;10(2):97–108 (44 ref.)

Blue toe syndrome from a "coral reef" aorta. Rosenberg GD, et al. **Ann Vasc Surg** 1995 Nov;9(6):561–4 (19 ref.)

Primary aortoenteric fistula: report of eight new cases and review of the literature. Voorhoeve R, et al. **Ann Vasc Surg** 1996 Jan;10(1):40–8 (76 ref.)

Evaluation of dopexamine hydrochloride as a renoprotective agent during aortic surgery. Welch M, et al. **Ann Vasc Surg** 1995 Sep;9(5):488–92

Rheological properties of commonly used plasma substitutes during preoperative normovolaemic acute haemodilution. Freyburger G, et al. **Br J Anaesth** 1996 Apr;76(4):519–25

Aortic prosthetic infection: 50 patients treated by radical or local surgery. Hannon RJ, et al. **Br J Surg** 1996 May; 83(5):654–8

Recurrent aortic infection: treatment by arterial homograft replacement. Nevelsteen A, et al. **Cardiovasc Surg** 1995 Aug;3(4):441–4

Spinal cord protection during surgical procedures on the descending thoracic and thoracoabdominal aorta: review of current techniques. Gharagozloo F, et al. **Chest** 1996 Mar;109(3):799–809 (98 ref.)

Simultaneous coronary bypass and abdominal aortic surgery in patients with severe coronary disease—indication and results. Autschbach R, et al. **Eur J Cardiothorac Surg** 1995; 9(12):678–83 discussion 683–4

Composite valve graft replacement of the ascending aorta and the aortic valve by a modified button technique: the influence of aortic pathology on early mortality and late survival. Biglioli P, et al. **Eur J Cardiothorac Surg** 1995; 9(9):483–90

Aortofemoral surgery and sexual function. Cormio L, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):453–7

Incisional hernias are more common in aneurysmal arterial disease. Holland AJ, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):196–200

Long–term results after open and semiclosed thrombendarterectomy for aortoiliac occlusive disease. Oertli D, et al. **Eur J Vasc Endovasc Surg** 1996 May; 11(4):432–6

Occlusion of vessels with posterior plaques. Barone GW, et al. **J Am Coll Surg** 1996 Jun;182(6):549–51

Surgical management of mobile aortic atheroma diagnosed by intraoperative transesophageal echocardiography [letter] Zenati M, et al. **J Card Surg** 1995 Sep;10(5):608–10

Protection by coenzyme Q10 of tissue reperfusion injury during abdominal aortic cross–clamping. Chello M, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):229–35

Ischemia of spinal cord following elective operative procedures of the infrarenal abdominal aorta. Dimakakos P, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):243–7

Acute suprarenal aortogastric fistulae caused by gunshot wounds: the importance of early recognition in directing surgical strategy. Caldeira CC, et al. **J Trauma** 1996 May; 40(5):838–9

Primary aortoenteric fistula from a posttraumatic pseudoaneurysm. Napoli PJ, et al. **J Trauma** 1996 Jul; 41(1):149–52

Intraoperative autotransfusion in aortic surgery: comparison of whole blood autotransfusion versus cell separation. Bartels C, et al. **J Vasc Surg** 1996 Jul;24(1):102–8

Cardiac enzymes in the blood salvaged during abdominal aortic surgery [letter] Gregoretti S. **J Vasc Surg** 1996 Feb; 23(2):377–8

Management and outcome of chronic atherosclerotic infrarenal aortic occlusion. Ligush J Jr, et al. **J Vasc Surg** 1996 Sep;24(3):394–404; discussion 404–5

Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive disease. Passman MA, et al. **J Vasc Surg** 1996 Feb;23(2):263–9; discussion 269–71

The treatment of focal aortic arch branch lesions with Palmaz stents. Queral LA, et al. **J Vasc Surg** 1996 Feb;23(2):368–75

Simplified, controlled limb reperfusion and simultaneous revascularization for acute aortic occlusion. Vogt PR, et al. **J Vasc Surg** 1996 Apr;23(4):730–3

Transabdominal access to the thoracic aorta for aortofemoral bypass grafting. Tovar EA, et al. **Tex Heart Inst J** 1995; 22(3):255–7

Prediction of early cardiac morbidity and mortality following aorto–iliac reconstruction: comparison between clinical scoring systems, echocardiography and dipyridamole–thallium scanning. Carrel T, et al. **Vasa** 1995; 24(4):362–7

Intestinal ischemia following surgery for aorto–iliac disease. A review of 502 consecutive aortic reconstructions. Järvinen O, et al. **Vasa** 1996;25(2):148–55

[Risk of development of false aneurysm and graft infection after aorta–femoral bypass graft. Retrospective study. Report of 211 cases] Aguiar ET, et al. **J Mal Vasc** 1996; 21(1):36–9 (Eng. Abstr.) **(Fre)**

[Late complications of abdominal aortic prostheses: false aneurysms and aorta–digestive fistulas] Alimi Y, et al. **J Mal Vasc** 1995;20(3):172–6 (Eng. Abstr.) **(Fre)**

[Emboligenic aortopathies. Cholesterol embolisms: surgical treatment] Fichelle JM, et al. **J Mal Vasc** 1996;21 Suppl A:100–12 (73 ref.) (Eng. Abstr.) **(Fre)**

[Selective indications of cardiac studies before aortic surgery] Alimi YS, et al. **Presse Med** 1995 Nov 11;24(34):1598–602 (Eng. Abstr.) **(Fre)**

[Paraplegia after surgical treatment of primary aorto–duodenal fistula] Picard E, et al. **Presse Med** 1996 Apr 13;25(13):621–3 (Eng. Abstr.) **(Fre)**

[Is preventive perioperative dopamine administration of value?] Bund M, et al. **Anaesthesiol Reanim** 1995; 20(3):76–81 (45 ref.) (Eng. Abstr.) **(Ger)**

[Our experience in the emergency treatment of secondary aortoenteric fistulae. The preliminary results of the use of aortic homografts] Novali C, et al. **Minerva Cardioangiol** 1996 Mar;44(3):87–94 (Eng. Abstr.) **(Ita)**

[Coronary artery bypass grafting in cases with the atherosclerotic ascending aorta] Bando M, et al. **Kyobu Geka** 1995 Oct;48(11):933–6 (Eng. Abstr.) **(Jpn)**

[Coronary artery bypass grafting surgery without cardiopulmonary bypass in a patient with calcified aorta] Noda H, et al. **Kyobu Geka** 1996 Feb;49(2):135–8 (Eng. Abstr.) **(Jpn)**

[One stage operation for ischemic heart disease and abdominal aortic aneurysm with ascending aortic calcification] Uwabe K, et al. **Kyobu Geka** 1996 Jan; 49(1):73–5 (Eng. Abstr.) **(Jpn)**

[Aortic root replacement employing Cabrol and Piehler techniques] Sekine S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):765–9 (Eng. Abstr.) **(Jpn)**

[Homograft replacement of aortic valve and ascending aorta] Brazão A, et al. **Rev Port Cardiol** 1996 Apr;15(4):295–300, 271 (Eng. Abstr.) **(Por)**

[Surgery of abdominal aorta occlusion] Belov IuV, et al. **Khirurgiia (Mosk)** 1995;(6):3–5 (Eng. Abstr.) **(Rus)**

[Double transplantation of internal thoracic arteries in severe coronary artery disease and atherosclerosis of the ascending part and branches of the aorta] Olearchik AS. **Klin Khir** 1995;(7–8):41–3 **(Ukr)**

THERAPY

Management of aortic intramural hematoma [editorial] Braverman AC, et al. **Curr Opin Cardiol** 1995 Sep; 10(5):501–4 (14 ref.)

Percutaneous transluminal angioplasty of the infrarenal aorta: initial outcome and long-term clinical and angiographic results. Hedeman Joosten PP, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):201–6

Covered stents for prevention of restenosis. Experimental and clinical results with different stent designs. Tepe G, et al. **Invest Radiol** 1996 Apr;31(4):223–9

Percutaneous treatment of aortoiliac atherosclerosis: a case report. Maynar M, et al. **J La State Med Soc** 1996 Jan; 148(1):24–7

Aortic balloon control of a traumatic aortoente.ic fistula after damage control laparotomy: a case report. Schwab CW, et al. **J Trauma** 1996 Jun;40(6):1021–3

Endovascular repair of aortoiliac occlusive disease. Marin ML, et al. **World J Surg** 1996 Jul–Aug;20(6):679–86

ULTRASONOGRAPHY

Endothelial dysfunction in the early stage of atherosclerosis precedes appearance of intimal lesions assessable with intravascular ultrasound. Mano T, et al. **Am Heart J** 1996 Feb;131(2):231–8

Three-dimensional transabdominal ultrasound identification of aortic plaque. Webber JD, et al. **Am J Card Imaging** 1995 Oct;9(4):245–9

Diagnosis of aortic intramural hematoma by intravascular ultrasound imaging. Alfonso F, et al. **Am J Cardiol** 1995 Oct 1;76(10):735–8

Absence of atherosclerotic lesions in the thoracic aorta indicates absence of significant coronary artery disease. Parthenakis F, et al. **Am J Cardiol** 1996 May 15; 77(12):1118–21 SERIALS SUBS JAF

Aorto-iliac reconstruction without arteriography. Bodily K, et al. **Am J Surg** 1996 May;171(5):505–7

Preoperative intra-aortic ultrasonography to determine resectability in advanced oesophageal cancer. Akiyama S, et al. **Br J Surg** 1995 Dec;82(12):1671–4

Postocclusive hyperaemic duplex scan: a new method of aortoiliac assessment [comment] Dodds SR. **Br J Surg** 1996 Feb;83(2):280–1. Comment on: Br J Surg 1995 Sep;82(9):1226–9.

Natural history of severe atheromatous disease of the thoracic aorta: a transesophageal echocardiographic study. Montgomery DH, et al. **J Am Coll Cardiol** 1996 Jan; 27(1):95–101

Surgical management of mobile aortic atheroma diagnosed by intraoperative transesophageal echocardiography [letter] Zenati M, et al. **J Card Surg** 1995 Sep;10(5):608–10

Detection of aortic emboli by transesophageal echocardiography during coronary artery bypass surgery. Yao FS, et al. **J Cardiothorac Vasc Anesth** 1996 Apr; 10(3):314–7

Aortic atheromas and acute ischemic stroke: a transesophageal echocardiographic study in an ethnically mixed population. Di Tullio MR, et al. **Neurology** 1996 Jun;46(6):1560–6

[3-D echocardiography reconstruction of the thoracic aorta] von Hehn A. **Herz** 1995 Oct;20(5):340–7 (Eng. Abstr.) **(Ger)**

[Cardiac impairment detected by echocardiography in patients with ankylosing spondylitis] Beňačka J, et al. **Vnitr Lek** 1995 Sep;41(9):613–7 (Eng. Abstr.) **(Slo)**

VETERINARY

A retrospective study of 100 cases of feline distal aortic thromboembolism: 1977–1993. Laste NJ, et al. **J Am Anim Hosp Assoc** 1995 Nov–Dec;31(6):492–500

Aortic thromboembolism associated with traumatic reticuloperitonitis in a downer cow. Du Preez ER, et al. **J S Afr Vet Assoc** 1995 Dec;66(4):254–5

AORTIC GLOMUS see **AORTIC BODIES**

AORTIC INCOMPETENCE see **AORTIC VALVE INSUFFICIENCY**

AORTIC REGURGITATION see **AORTIC VALVE INSUFFICIENCY**

AORTIC RUPTURE

Emergency! Thoracic aortic dissection. Ortiz AC. **Am J Nurs** 1996 Jun;96(6):50

Congenital aneurysm of the sinus of Valsalva dissecting into the interventricular septum. Abad C. **Cardiovasc Surg** 1995 Oct;3(5):563–4

COMPLICATIONS

Chest case of the day. Rupture of a sinus of Valsalva aneurysm into the right ventricle. Dee PM. **AJR Am J Roentgenol** 1996 Jul;167(1):234, 236–8

Sudden death while playing tennis due to a tear in ascending aorta (without dissection) and probable transient compression of the left main coronary artery. Comfort SR, et al. **Am J Cardiol** 1996 Aug 15;78(4):493–5

Valvuloplasty in traumatic aortic insufficiency due to subtotal tear of the intima. Miralles A, et al. **Ann Thorac Surg** 1995 Oct;60(4):1098–100

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)

Chronic contained rupture of an abdominal aortic aneurysm complicated by infection and femoral neuropathy. Case report. Aune S, et al. **Eur J Surg** 1995 Aug;161(8):613–4

[A rare cause of recurrent upper gastrointestinal hemorrhage: aortoesophageal fistula in aneurysma spurium of the descending aorta] Weickert U, et al. **Z Gastroenterol** 1996 May;34(5):279–82 (Eng. Abstr.) **(Ger)**

[Rupture of type A aortic dissection into right cardiac cavities] Salas Lobato A, et al. **Rev Esp Cardiol** 1996 Mar; 49(3):233–5 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Chest pain and aortic dissection [letter; comment] Bazarian JJ, et al. **Ann Emerg Med** 1995 Oct;26(4):526–7. Comment on: Ann Emerg Med 1995 Feb;25(2):274–99.

Blunt thoracic aortic trauma. A cost-utility approach for injury detection. Brasel KJ, et al. **Arch Surg** 1996 Jun; 131(6):619–25; discussion 625–6

Idiopathic rupture of the iliac vein. Case report. Plate G, et al. **Eur J Surg** 1995 Aug;161(8):611–2

Chronic contained rupture of an aortic aneurysm mimicking infective spondylitis. Grevitt MP, et al. **Eur Spine J** 1996; 5(2):128–30

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1–1996. A 69-year-old woman with severe, persistent congestive heart failure after treatment for bacteremia [clinical conference] **N Engl J Med** 1996 Jan 11;334(2):105–11

[Acute heart failure in a young man (clin conference)] Melin J. **Duodecim** 1994;110(2):161–6 **(Fin)**

[The perforation of a right-coronary sinus of Valsalva aneurysm into the right atrium] Elsner M, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1728–33 (38 ref.) (Eng. Abstr.) **(Ger)**

[Aortocolic fistula as a rare complication of aorto-iliac aneurysms] Bruns C, et al. **Vasa** 1995;24(4):354–61 (Eng. Abstr.) **(Ger)**

[Unusual clinical course of ruptured aortic aneurysms—report of three cases] Mitkowski P, et al. **Pol Arch Med Wewn** 1995 Jan;93(1):69–76 (Eng. Abstr.) **(Pol)**

[Unusual clinical course of ruptured aortic aneurysms—reports of three cases (corrected and republished article originally printed in Pol Arch Med Wewn 1995 Jan;93(1):69–76)] Mitkowski P, et al. **Pol Arch Med Wewn** 1995 Feb;93(2):171–8 (Eng. Abstr.) **(Pol)**

[Aortic intramural hematoma. An atypical pattern equivalent to aortic dissection] López-Mínguez JR, et al. **Rev Esp Cardiol** 1995 Sep;48(9):634–7 (Eng. Abstr.) **(Spa)**

ECONOMICS

Blunt thoracic aortic trauma. A cost-utility approach for injury detection. Brasel KJ, et al. **Arch Surg** 1996 Jun; 131(6):619–25; discussion 625–6

EPIDEMIOLOGY

Vascular emergencies: what's in season? Varty K, et al. **Cardiovasc Surg** 1995 Aug;3(4):409–11

ETIOLOGY

Occult ascending aortic rupture in the presence of an air bag. Dunn JA, et al. **Ann Thorac Surg** 1996 Aug;62(2):577–8

Traumatic thoracic aortic rupture in the pediatric patient. Trachiotis GD, et al. **Ann Thorac Surg** 1996 Sep; 62(3):724–31; discussion 731–2

Paravalvular aortic rupture causing angina following aortic valve replacement. Reddy ER, et al. **Cardiovasc Intervent Radiol** 1995 Sep–Oct;18(5):321–2

Rupture of the aorta due to a malpositioned tracheal cannula in a 4-month-old baby. Peres LC, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):175–9

Delayed rupture of the abdominal aorta in a child after a suspected handlebar injury. Tracy TF Jr, et al. **J Trauma** 1996 Jan;40(1):119–20

Blunt traumatic injury of the thoracic aorta following commercial airline crashes. Pezzella AT. **Tex Heart Inst J** 1996;23(1):65–7

Aortic dissection after aortic valve replacement. Report of a case with an aortocameral fistula. Tayama K, et al. **Thorac Cardiovasc Surg** 1995 Oct;43(5):299–301

MICROBIOLOGY

Contained rupture of infected abdominal aortic aneurysm due to systemic candidiasis. Ikeda M, et al. **Cardiovasc Surg** 1995 Dec;3(6):711–4 (30 ref.)

MORTALITY

A statewide, population-based time-series analysis of the outcome of ruptured abdominal aortic aneurysm. Rutledge R, et al. **Ann Surg** 1996 May;223(5):492–502; discussion 503–5

Effect of the duration of symptoms, transport time, and length of emergency room stay on morbidity and mortality in patients with ruptured abdominal aortic aneurysms. Farooq MM, et al. **Surgery** 1996 Jan;119(1):9–14

NURSING

Traumatic rupture of the descending thoracic aorta. Butler KL, et al. **AORN J** 1996 May;63(5):917–25 (32 ref.)

PATHOLOGY

Morphometric features of ruptured congenital sinus of Valsalva aneurysm: implication for surgical treatment. van Son JA, et al. **J Cardiovasc Surg (Torino)** 1995 Oct; 36(5):433–6

Intraluminal thrombus predicts rupture of an abdominal aortic aneurysm [letter] Satta J, et al. **J Vasc Surg** 1996 Apr;23(4):737–9

[A clinicopathological study of ruptured infectious aneurysms] Origuchi N, et al. **Nippon Ronen Igakkai Zasshi** 1995 Aug–Sep;32(8–9):553–9 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Gastric intramucosal pH predicts outcome after surgery for ruptured abdominal aortic aneurysm. Maynard ND, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):201–6

PREVENTION & CONTROL

Influence of screening on the incidence of ruptured abdominal aortic aneurysm: 5-year results of a randomized controlled study [letter; comment] Collin J. **Br J Surg** 1996 Jan;83(1):135. Comment on: Br J Surg 1995 Aug;82(8):1066–70.

Screening for aortic aneurysm: the surgical perspective. Harris P. **J Med Screen** 1994 Apr;1(2):106–9; discussion 115–6

Screening for abdominal aortic aneurysms. Law MR, et al. **J Med Screen** 1994 Apr;1(2):110–5; discussion 115–6

Accuracy of ultrasound in a screening programme for abdominal aortic aneurysms. Thomas PR, et al. **J Med Screen** 1994 Jan;1(1):3–6

RADIOGRAPHY

Chest case of the day. Rupture of a sinus of Valsalva aneurysm into the right ventricle. Dee PM. **AJR Am J Roentgenol** 1996 Jul;167(1):234, 236–8

CT aortography of thoracic aortic rupture. Gavant ML, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):955–61

Helical CT of abdominal aortic aneurysm [see comments] Thoeni RF. **AJR Am J Roentgenol** 1996 Feb;166(2):457. Comment in: AJR Am J Roentgenol 1996 Aug;167(2):534–5.

Mycotic aneurysm: a diagnostic challenge. Leo PJ, et al. **Am J Emerg Med** 1996 Jan;14(1):70–3

Fatal aortic rupture following balloon angioplasty of aortic restenosis in aortoarteritis. Sharma S, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):132–3

Twice sealed-rupture of a small abdominal aortic aneurysm with unusual computed tomography findings. A case report. Ohtake H, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):249–50

Helical CT angiography for traumatic aortic rupture: correlation with aortography and surgery in five cases. Schnyder P, et al. **J Thorac Imaging** 1996 Winter; 11(1):39–45

Combined repair of a traumatic rupture of the aorta and anterior stabilization of a thoracic spine fracture: a case report. Bakker FC, et al. **J Trauma** 1996 Jan;40(1):128–9

Computed tomography for ruptured abdominal aortic aneurysm? [letter; comment] Andros G. **N Engl J Med** 1996 May 9;334(19):1273. Comment on: N Engl J Med 1996 Jan 4;334(1):27.

Computed tomography for ruptured abdominal aortic

aneurysm? [letter; comment] Eskind SJ. **N Engl J Med** 1996 May 9;334(19):1272-3. Comment on: N Engl J Med 1996 Jan 4;334(1):27.

Images in clinical medicine. Ruptured abdominal aortic aneurysm [see comments] Gervais DA, et al. **N Engl J Med** 1996 Jan 4;334(1):27. Comment in: N Engl J Med 1996 May 9;334(19):1272-3. Comment in: N Engl J Med 1996 May 9;334(19):1273.

Blunt traumatic aortic rupture: detection with helical CT of the chest [see comments] Gavant ML, et al. **Radiology** 1995 Oct;197(1):125-33. Comment in: Radiology 1995 Oct;197(1):13-5.

Draped aorta: CT sign of contained leak of aortic aneurysms. Halliday KE, et al. **Radiology** 1996 Apr;199(1):41-3

Can helical CT replace aortography in thoracic trauma [editorial; comment] Trerotola SO. **Radiology** 1995 Oct; 197(1):13-5. Comment on: Radiology 1995 Oct;197(1):125-33.

[Retroperitoneal vascular emergencies] Arrivé L, et al. **Ann Radiol (Paris)** 1996;39(2):78-88 (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Rupture of abdominal aortic aneurysm demonstrated on Tc-99m RBC gastrointestinal bleeding study. DeArmas CR Jr, et al. **Clin Nucl Med** 1995 Oct;20(10):925-6

SURGERY

Colonic ischemia: the Achilles heel of ruptured aortic aneurysm repair. Piotrowski JJ, et al. **Am Surg** 1996 Jul; 62(7):557-60; discussion 560-1

Traumatic rupture of the descending thoracic aorta. Orend KH, et al. **Ann Ital Chir** 1996 Jan-Feb;67(1):21-3; discussion 23-5

Simultaneous repair of multiple traumatic aortic tears. Lancey RA, et al. **Ann Thorac Surg** 1995 Oct;60(4):1120-1

Traumatic rupture of the thoracic aorta during the second trimester of pregnancy. Lemermeyer G, et al. **Ann Thorac Surg** 1996 May;61(5):1541-3

Valvuloplasty in traumatic aortic insufficiency due to subtotal tear of the intima. Miralles A, et al. **Ann Thorac Surg** 1995 Oct;60(4):1098-100

Ruptured abdominal aortic aneurysm: impact of comorbidity and postoperative complications on outcome. Panneton JM, et al. **Ann Vasc Surg** 1995 Nov;9(6):535-41

Rupture of a dissecting thoracic aortic aneurysm into the pulmonary artery: successful surgical repair. Coselli JS, et al. **Cardiovasc Surg** 1995 Dec;3(6):697-701 (34 ref.)

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707-10 (17 ref.)

Endovascular exclusion of juxtarenal anastomotic pseudoaneurysm. Lindblad B, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):116-8

Geographical variations in the presentation of ruptured aneurysms of sinuses of valsalva: evaluation of surgical repair. Pannu HS, et al. **J Card Surg** 1995 Jul;10(4 Pt 1):316-24

Chronic contained rupture of abdominal aortic aneurysms. Nonami Y, et al. **J Cardiovasc Surg (Torino)** 1996 Feb; 37(1):25-8

Hospital volume, calendar age, and short term outcomes in patients undergoing repair of abdominal aortic aneurysms: the Ontario experience, 1988-92. Wen SW, et al. **J Epidemiol Community Health** 1996 Apr;50(2):207-13

Thoracic aorta injuries: management and outcome of 144 patients. Hunt JP, et al. **J Trauma** 1996 Apr;40(4):547-55; discussion 555-6

Ruptured abdominal aortic aneurysms: who should be offered surgery? Hardman DT, et al. **J Vasc Surg** 1996 Jan; 23(1):123-9

Ruptured abdominal aortic aneurysm: influence of intraoperative management on surgical outcome. Marty-Ané CH, et al. **J Vasc Surg** 1995 Dec;22(6):780-6

Aortocaval fistula treated by aortic exclusion. Woolley DS, et al. **J Vasc Surg** 1995 Nov;22(5):639-42 (27 ref.)

Acute traumatic rupture of the thoracic aorta. A comparison of techniques. Von Oppell UO, et al. **S Afr J Surg** 1996 Feb;34(1):19-24

Repair of a ruptured aortic arch aneurysm complicated by postoperative paraplegia: report of a case. Hadama T, et al. **Surg Today** 1996;26(1):60-3

Intestinal ischemia following surgery for aorto-iliac disease. A review of 502 consecutive aortic reconstructions. Järvinen O, et al. **Vasa** 1996;25(2):148-55

[Rupture of the sinus of Valsalva--the anesthesiological and resuscitation problems] Aleksandrov V, et al. **Khirurgiia (Sofiia)** 1995;48(1):87-9 (Eng. Abstr.) **(Bul)**

[Ischemic colitis after vascular surgery reconstruction of an abdominal aortic aneurysm] Kaiser MM, et al. **Chirurg** 1996 Apr;67(4):380-6 (30 ref.) (Eng. Abstr.) **(Ger)**

[Bacterial infections of the abdominal aorta] Knipping L, et al. **Chirurg** 1995 Sep;66(9):887-9 (Eng. Abstr.) **(Ger)**

[Chylous ascites, a rare complication of aortic surgery] Halloul Z, et al. **Vasa** 1995;24(4):377-81 (Eng. Abstr.) **(Ger)**

[Surgical treatment for ruptured aneurysm of distal arch or aortic arch: report of three cases] Gohra H, et al. **Kyobu Geka** 1996 Mar;49(3):206-8 (Eng. Abstr.) **(Jpn)**

[A case report of acute aortic dissection with aortic regurgitation and cardiac tamponade: intimal tear just above commissure of right coronary cusp and left coronary cusp] Kashiwagi J, et al. **Kyobu Geka** 1995 Nov; 48(12):1039-42 (Eng. Abstr.) **(Jpn)**

[An approach to the emergency surgery for arch and/or ascending aortic aneurysm] Katoh T, et al. **Kyobu Geka** 1996 Jun;49(6):456-9 (Eng. Abstr.) **(Jpn)**

[A surgical treatment of ruptured aortic dissection with non-opacified false lumen] Sakamoto Y, et al. **Kyobu Geka** 1995 Oct;48(11):957-9 (Eng. Abstr.) **(Jpn)**

[A surgically treated case of ruptured true aortic arch aneurysm in association with Stanford type A chronic dissection] Takagi H, et al. **Kyobu Geka** 1996 Mar; 49(3):239-42 (Eng. Abstr.) **(Jpn)**

[Rupture of dissecting aortic aneurysm associated with the right-sided aortic arch and anomalous course of the left brachiocephalic vein--a case report] Kanoh M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1086-91 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Successful surgical treatment for ruptured distal aortic arch aneurysm into lung] Ogino H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Nov; 43(11):1836-40 (Eng. Abstr.) **(Jpn)**

[Results after surgical treatment of abdominal aortic aneurysm] Haug ES, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):493-6 (Eng. Abstr.) **(Nor)**

[Abdominal aortic aneurysms. A new therapeutic method] Solberg S. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):716 **(Nor)**

ULTRASONOGRAPHY

Doppler echocardiographic characteristics of sinus of valsalva aneurysms. Xu Q, et al. **Am Heart J** 1995 Dec; 130(6):1265-9

Emergency medicine physicians saving time with ultrasound. Durham B. **Am J Emerg Med** 1996 May;14(3):309-13

Diastolic flow across a ventricular septal defect: an invitation to a false diagnosis. Suskin N, et al. **Can J Cardiol** 1996 Apr;12(4):419-21

Role of transesophageal echocardiography in the diagnosis and management of traumatic aortic disruption. Vignon P, et al. **Circulation** 1995 Nov 15;92(10):2959-68

Routine transesophageal echocardiography for the diagnosis of aortic disruption in trauma patients without enlarged mediastinum. Vignon P, et al. **J Trauma** 1996 Mar; 40(3):422-7

[Post-traumatic dissection of the aortic isthmus with favorable outcome without surgical treatment. Value of transesophageal echocardiography] Bourgeois M, et al. **Ann Fr Anesth Reanim** 1995;14(2):218-21 (16 ref.) (Eng. Abstr.) **(Fre)**

AORTIC SINUS see **SINUS OF VALSALVA**

AORTIC STENOSIS see **AORTIC VALVE STENOSIS**

AORTIC STENOSIS, SUPRAVALVULAR see **AORTIC VALVE STENOSIS**

AORTIC SUBVALVULAR STENOSIS

ETIOLOGY

Early changes in ventricular septal defect size and ventricular geometry in the single left ventricle after volume-unloading surgery. Donofrio MT, et al. **J Am Coll Cardiol** 1995 Oct;26(4):1008-15

"Acquired" subvalvular aortic stenosis after repair of several congenital cardiac defects. Tokel K, et al. **Turk J Pediatr** 1996 Apr-Jun;38(2):177-82

GENETICS

Familial bilateral blepharoptosis and subvalvular aortic stenosis. Bazopoulou-Kyrkanidou E, et al. **Genet Couns** 1995;6(3):227-32

SURGERY

Systemic obstruction in univentricular hearts: surgical options for neonates. Serraf A, et al. **Ann Thorac Surg** 1995 Oct; 60(4):970-6; discussion 976-7

Complication of intra-aortic balloon pumping in a pediatric patient. Van de Wal HJ, et al. **Eur J Cardiothorac Surg** 1995;9(10):602-3

Aortoventriculoplasty with the pulmonary autograft: the "Ross-Konno" procedure. Reddy VM, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):158-65; discussion 165-7

[Long-term outcome of subvalvular aortic stenoses. A comparative study in adults and children] Bernard Y, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):579-85 (Eng. Abstr.) **(Fre)**

[A modified Damus-Kaye-Stansel anastomosis for restrictive bulvoventricular foramen developed 5 years after Fontan procedure] Morishita A, et al. **Kyobu Geka** 1995 Dec; 48(13):1105-9 (Eng. Abstr.) **(Jpn)**

[A case of a univentricular heart developed subaortic stenosis after fontan operation] Kasahara S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):83-8 (Eng. Abstr.) **(Jpn)**

[Aorto-septal approach (modified Konno procedure). Surgical alternative in the management of diffuse aortic subvalvular stenosis] Ramírez Marroquín S, et al. **Arch Inst Cardiol Mex** 1996 Jan-Feb;66(1):51-4 (Eng. Abstr.) **(Spa)**

THERAPY

[Percutaneous dilatation of subaortic stenosis in an adult: a 3-year follow-up] Guillo P, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):407-10 (Eng. Abstr.) **(Fre)**

VETERINARY

Progression of subaortic stenosis detected by continuous wave Doppler echocardiography in a dog. Nakayama T, et al. **J Vet Intern Med** 1996 Mar-Apr;10(2):97-8

AORTIC VALVE

Left ventricular and aortic valve thrombosis caused by polycythemia rubra vera successfully treated with streptokinase. al-Saif S, et al. **Am Heart J** 1996 Feb; 131(2):397-9

Coronary artery obstruction caused by perivalvular abscess in aortic valve endocarditis. Schlaifer JD, et al. **Am Heart J** 1996 Feb;131(2):413-6 (8 ref.)

Total mechanical alternans in postoperative aortic valve replacement. Dal A, et al. **Anaesth Intensive Care** 1995 Aug; 23(4):513-4

Simplified technique for aortic annular enlargement during aortic valve replacement [letter; comment] Bortolotti U. **Ann Thorac Surg** 1996 May;61(5):1591-2. Comment on: Ann Thorac Surg 1995 Sep;60(3):701-4.

Comprehensive analysis of aortic valve vegetation with anyplane, paraplane, and three-dimensional echocardiography [letter] Kasprzak JD, et al. **Eur Heart J** 1996 Feb;17(2):318-20

Comparative study of the hydrodynamic function of six size 19 mm bileaflet heart valves. Fisher J. **Eur J Cardiothorac Surg** 1995;9(12):692-5 discussion 695-6

Giant blood cyst of the aortic valve. DeGroff C, et al. **J Am Soc Echocardiogr** 1995 Jul-Aug;8(4):543-5

Valvulitis involving a bioprosthetic valve in a patient with systemic lupus erythematosus. Gordon RJ, et al. **J Am Soc Echocardiogr** 1996 Jan-Feb;9(1):104-7

A rare complication of aortic valve endocarditis: diagnosis with transesophageal echocardiography. Winslow TM, et al. **J Am Soc Echocardiogr** 1995 Jul-Aug;8(4):546-50 (25 ref.)

Treatment of experimental rabbit infective endocarditis due to a multidrug-resistant Pseudomonas aeruginosa with high-dose ceftazidime alone and combined with amikacin or sulbactam or both. Xiong YQ, et al. **J Antimicrob Chemother** 1995 May;35(5):697-706

A three-dimensional, time-dependent analysis of flow through a bileaflet mechanical heart valve: comparison of experimental and numerical results. King MJ, et al. **J Biomech** 1996 May;29(5):609-18

Morphological comparison of mitral and aortic bioprostheses explanted from the same patient for primary tissue failure. Pansini S, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):291-4

Valve replacement with the CarboMedics bileaflet mechanical prosthesis: clinical results at midterm. Yamauchi M, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):285-9

Case report of Streptomyces endocarditis of a prosthetic aortic valve. Mossad SB, et al. **J Clin Microbiol** 1995 Dec; 33(12):3335-7

Preoperative echocardiographic prediction of small prosthesis size for aortic valve replacement. Bech-Hanssen O, et al. **J Heart Valve Dis** 1996 Mar;5(2):128-35

Thrombolytic therapy for left sided prosthetic heart valve thrombosis. Birdi I, et al. **J Heart Valve Dis** 1995 Mar; 4(2):154-9

Experience with the Edwards Prima stentless aortic bioprosthesis: a 2-year review. Dossche K, et al. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S85-8; discussion S88-9

Aortic root replacement with a cryopreserved aortic homograft in a patient with giant cell aortitis following two Bentall's type operations. Eishi K, et al. **J Heart Valve Dis** 1995 Sep;4(5):509-12

Porcine bioprosthetic valves prepared with permanent pre-dilation of the aortic root: a review. Fisher J. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S81-3; discussion S83-4 (14 ref.)

Transcranial Doppler ultrasound signals associated with prosthetic heart valves: an in vitro study. Mackay TG, et al. **J Heart Valve Dis** 1995 Jul;4(4):414-9

A comparison between glutaraldehyde and diepoxide-fixed stentless porcine aortic valves: biochemical and mechanical characterization and resistance to mineralization. Myers DJ, et al. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S98-101

Design and performance characteristics of the Pericarbon Stentless valve. Stacchino C, et al. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S102-5

Effects of storage temperature and fetal calf serum on the endothelium of porcine aortic valves. Feng XJ, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):218-30

Rifampicin antibiotic impregnation of the St. Jude Medical mechanical valve sewing ring: a weapon against endocarditis. French BG, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):248-52

Salmonella prosthetic valve endocarditis. Fukushima N, et

al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):840–2 (5 ref.)
Influence of the size of aortic valve prostheses on hemodynamics and change in left ventricular mass: implications for the surgical management of aortic stenosis. González-Juanatey JR, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):273–80
Listeria monocytogenes endocarditis in a patient with an aortic prosthetic valve. Castro Cabezas M, et al. **Neth J Med** 1996 Jan;48(1):15–7
Perforation of the right aortic valve cusp: complication of ventricular septal defect closure with a modified Rashkind umbrella. Vogel M, et al. **Pediatr Cardiol** 1996 Nov–Dec; 17(6):416–8
Risk of stroke in a cohort of 815 patients with calcification of the aortic valve with or without stenosis. Boon A, et al. **Stroke** 1996 May;27(5):847–51
[Comparative outcome of aortic valve endocarditis with or without annular abscess] Stchepinsky O, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):993–8 (Eng. Abstr.) **(Fre)**
[Infectious thyroiditis as initial manifestation of embolizing endocarditis of the aortic valve] Hofbauer LC, et al. **Dtsch Med Wochenschr** 1996 Mar 22;121(12):369–74 (Eng. Abstr.) **(Ger)**
[A case of infective aortic valve endocarditis with splenic abscess] Katayama Y, et al. **Kyobu Geka** 1996 Feb; 49(2):143–5 (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Calcific aortic valve stenosis and the congenitally bicuspid aortic valve: did Osler miss the link? [editorial] Mensah GA, et al. **Am J Cardiol** 1996 Feb 15;77(5):417–20
Collagen content in normal, pressure, and pressure-volume overloaded developing human hearts. Schwartz SM, et al. **Am J Cardiol** 1996 Apr 1;77(9):734–8
Familial congenital bicuspid aortic valve: a disorder of uncertain inheritance. Clementi M, et al. **Am J Med Genet** 1996 Apr 24;62(4):336–8
Fusion of valve cushions as a key factor in the formation of congenital bicuspid aortic valves in Syrian hamsters. Sans-Coma V, et al. **Anat Rec** 1996 Apr;244(4):490–8
Pulmonary autografts in patients with aortic annulus dysplasia. Elkins RC, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1141–5
Modified surgical palliation for a rare type of L-transposition with aortic atresia. Young JN, et al. **Ann Thorac Surg** 1995 Oct;60(4):1108–9
Images in cardiovascular medicine. Aortic valves. Shamrock, bileaflet, and lucky? Manning WJ, et al. **Circulation** 1995 Oct 15;92(8):2352
Isolated bicuspid aortic valve in a newborn with Down syndrome [letter] Aughton DJ, et al. **Clin Pediatr (Phila)** 1995 Nov;34(11):622
Rare cause of pure aortic regurgitation: congenital quadricuspid aortic valve [letter] Paemelaere JM, et al. **Eur Heart J** 1996 Apr;17(4):643–4
Congenital absence of aortic and pulmonary valve in a fetus with severe heart failure. Marek J, et al. **Heart** 1996 Jan; 75(1):98–100
Bicuspid aortic valves in hearts with other congenital heart disease. Duran AC, et al. **J Heart Valve Dis** 1995 Nov; 4(6):581–90
Morphologic determinants favoring surgical aortic valvuloplasty versus pulmonary autograft aortic valve replacement in children. van Son JA, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1149–56; discussion 1156–7
Subtotal rarefication of one aortic leaflet in a bicuspid aortic valve due to large aneurysm of left Valsalva's sinus. Cottogni M, et al. **Scand J Thorac Cardiovasc Surg** 1995; 29(2):87–90
Familial aorto-cervicocephalic arterial dissections and congenitally bicuspid aortic valve. Schievink WI, et al. **Stroke** 1995 Oct;26(10):1935–40
[A rare cause of pure isolated chronic aortic insufficiency: congenital quadricuspid aortic valve. Apropos of 2 cases] Paemelaere JM, et al. **Arch Mal Coeur Vaiss** 1996 Jan; 89(1):91–3 (Eng. Abstr.) **(Fre)**
[A case of aortic bicuspid valvular endocarditis with congenital left ventricular diverticulum] Kihara H, et al. **J Cardiol** 1995 Nov;26(5):299–303 (Eng. Abstr.) **(Jpn)**
[A case of aortic dissection associated with congenital bicuspid aortic valve] Fujiyoshi K, et al. **Kyobu Geka** 1996 Jun;49(6):468–70 (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

Effect of hypertension on aortic root size and prevalence of aortic regurgitation. Kim M, et al. **Hypertension** 1996 Jul;28(1):47–52

CHEMISTRY

Evidence for the presence of endothelin ETA receptors in endothelial cells in situ on the aortic side of porcine aortic valve. Nishimura J, et al. **Br J Pharmacol** 1995 Aug; 115(8):1369–76
A comparison of macroscopic lipid content within porcine pulmonary and aortic valves. Implications for bioprosthetic valves. Dunmore-Buyze J, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1756–61

DRUG EFFECTS

CPA induces a sustained increase in [Ca2+]i of endothelial cells in situ and relaxes porcine coronary artery. Higuchi Y, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2038–49

EMBRYOLOGY

Fusion of valve cushions as a key factor in the formation of congenital bicuspid aortic valves in Syrian hamsters. Sans-Coma V, et al. **Anat Rec** 1996 Apr;244(4):490–8

IMMUNOLOGY

The effect of cryopreservation on the immunogenicity of allogeneic cardiac valves. Ketheesan N, et al. **Cryobiology** 1996 Feb;33(1):41–53

INJURIES

Traumatic aortic incompetence associated with transection of the thoracic aorta. Paone RF, et al. **Chest** 1996 Apr; 109(4):1118–9
[Increased association of cardiac and thoracic vascular lesions after closed trauma of the thorax] Pretre R, et al. **Ann Chir** 1995;49(9):854–7 (Eng. Abstr.) **(Fre)**
[Traumatic aortic valve insufficiency] Nascimento J, et al. **Rev Port Cardiol** 1996 Feb;15(2):147–52, 101 (17 ref.) (Eng. Abstr.) **(Por)**

INNERVATION

Histopathologic studies of innervation of normal and prolapsed human mitral valves. Oki T, et al. **J Heart Valve Dis** 1995 Sep;4(5):496–502
Morphological study of vagal innervation in human semilunar valves using a histochemical method. Kawano H, et al. **Jpn Circ J** 1996 Jan;60(1):62–6

MICROBIOLOGY

Bartonella henselae endocarditis in an immunocompetent adult. Holmes AH, et al. **Clin Infect Dis** 1995 Oct; 21(4):1004–7
Use of the polymerase chain reaction and DNA sequencing for detection of Bartonella quintana in the aortic valve of a patient with culture-negative infective endocarditis. Jalava J, et al. **Clin Infect Dis** 1995 Oct;21(4):891–6
[Streptococcus bovis as the cause of combined endocarditis of the aortic, mitral and tricuspid valves] Friis EV, et al. **Ugeskr Laeger** 1995 Dec 11;157(50):7012–3 (Eng. Abstr.) **(Dan)**

PATHOLOGY

Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Gotoh T, et al. **Am J Cardiol** 1995 Nov 1;76(12):928–32
A prospective controlled evaluation of endoscopic detection of angiodysplasia and its association with aortic valve disease [see comments] Bhutani MS, et al. **Gastrointest Endosc** 1995 Nov;42(5):398–402. Comment in: Gastrointest Endosc 1995 Nov;42(5):491–3.
Demographic characteristics of patients undergoing aortic valve replacement for stenosis: relation to valve morphology. Davies MJ, et al. **Heart** 1996 Feb;75(2):174–8
Osseus metaplasia with functioning marrow in a calcified aortic valve [letter] Arumugam SB, et al. **J Card Surg** 1995 Sep;10(5):610–1
Anomalous origin of the left coronary artery from the dorsal aortic sinus and its relationship with aortic valve morphology in Syrian hamsters. Cardo M, et al. **J Comp Pathol** 1995 May;112(4):373–80
MR visualization of aortic valve vegetations. Caduff JH, et al. **J Comput Assist Tomogr** 1996 Jul–Aug;20(4):613–5
Pathological considerations in cryopreserved allograft heart valves. Schoen FJ, et al. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S72–5; discussion S75–6
[Asymptomatic endocarditis? Are consequent histological studies useful in valve surgery?] Zurbrügg HR, et al. **Swiss Surg Suppl** 1996;Suppl 1:23–6 (Eng. Abstr.) **(Ger)**
[Isolated aortic valve regurgitation due to degeneration of the valve leaflet--a clinical study] Moriyama Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):951–5 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Evaluation of the hemodynamic performance of stentless porcine aortic valves [letter; comment] Izzat MB, et al. **Ann Thorac Surg** 1995 Nov;60(5):1461. Comment on: Ann Thorac Surg 1995 Apr;59(4):857–62.
Low-field magnetic resonance imaging in the evaluation of mechanical and biological heart valve function. Di Cesare E, et al. **Eur J Radiol** 1995 Sep;20(3):224–8
Biomechanical and ultrastructural comparison of cryopreservation and a novel cellular extraction of porcine aortic valve leaflets. Courtman DW, et al. **J Biomed Mater Res** 1995 Dec;29(12):1507–16
Internal shear properties of fresh porcine aortic valve cusps: implications for normal valve function. Talman EA, et al. **J Heart Valve Dis** 1996 Mar;5(2):152–9

PHYSIOPATHOLOGY

Pressure gradients across bileaflet aortic valves by direct measurement and echocardiography. Laske A, et al. **Ann Thorac Surg** 1996 Jan;61(1):48–57
Extreme pulsus alternans presenting as 2:1 electromechanical dissociation. Rosenthal E. **Br Heart J** 1995 Dec;74(6):695
Abnormal systolic intraventricular flow velocities after valve replacement for aortic stenosis. Mechanisms, predictive factors, and prognostic significance. Bartunek J, et al. **Circulation** 1996 Feb 15;93(4):712–9
Measurement of aortic flow velocity during transesophageal echocardiography in the transgastric five-chamber view. Owen AN, et al. **J Am Soc Echocardiogr** 1995 Nov–Dec; 8(6):874–8
[The evolution of the transmitral and transaortic gradient in aortic coarctation] da Silva AJ, et al. **Rev Port Cardiol** 1995 Oct;14(10):753–5 **(Por)**

SURGERY

Recurrent syncope after successful aortic valve replacement. Sharma M, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):194–7
Aortic valve regurgitation after surgical versus percutaneous balloon valvotomy for congenital aortic valve stenosis. Justo RN, et al. **Am J Cardiol** 1996 Jun 15;77(15):1332–8
Effects of mitral and/or aortic valve replacement or repair on endothelium-dependent peripheral vasorelaxation and its relation to improvement in exercise capacity. Nakamura M, et al. **Am J Cardiol** 1996 Jan 1;77(1):98–102
Surgical treatment of aortic valve disease in the nineties with special emphasis on the use of the pulmonary autograft (Ross-operation). Pettersson G. **Ann Chir Gynaecol** 1995; 84(3):251–9 (10 ref.)
The last generation of pericardial valves in the aortic position: ten-year follow-up in 589 patients. Aupart MR, et al. **Ann Thorac Surg** 1996 Feb;61(2):615–20
Minimally invasive approach for aortic valve operations. Cosgrove DM 3rd, et al. **Ann Thorac Surg** 1996 Aug; 62(2):596–7
Pulmonary autograft reoperation: incidence and management. Elkins RC, et al. **Ann Thorac Surg** 1996 Aug; 62(2):450–5
Pulmonary autografts in patients with aortic annulus dysplasia. Elkins RC, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1141–5
Autologous tissue cardiac valve for aortic valve replacement: technical aspects and early results. Gross C, et al. **Ann Thorac Surg** 1996 Jun;61(6):1759–63
Aortic valve repair and replacement after balloon aortic valvuloplasty in children [see comments] Hawkins JA, et al. **Ann Thorac Surg** 1996 May;61(5):1355–8. Comment in: Ann Thorac Surg 1996 May;61(5):1297–8.
Aortic valve replacement in elderly patients: influence of concomitant coronary grafting on late survival. He GW, et al. **Ann Thorac Surg** 1996 Jun;61(6):1746–51
Safety of remote aortic valve replacement after prior coronary artery bypass grafting. Hoff SJ, et al. **Ann Thorac Surg** 1996 Jun;61(6):1689–91; discussion 1691–2
The aortic valve: to dilate, repair, or replace--that is the question [editorial; comment] Lamberti JJ. **Ann Thorac Surg** 1996 May;61(5):1297–8. Comment on: Ann Thorac Surg 1996 May;61(5):1355–8.
Valvuloplasty in traumatic aortic insufficiency due to subtotal tear of the intima. Miralles A, et al. **Ann Thorac Surg** 1995 Oct;60(4):1098–100
Mesenteric ischemia after a cardiac operation: conservative treatment with local vasodilation. Niederhäuser U, et al. **Ann Thorac Surg** 1996 Jun;61(6):1817–9
Right ventricular failure [letter; comment] Pessik CS, et al. **Ann Thorac Surg** 1996 Aug;62(2):630. Comment on: Ann Thorac Surg 1996 Feb;61(2):706–7.
Perioperative complications in combined aortic valve replacement and extraanatomic ascending-descending bypass. Pethig K, et al. **Ann Thorac Surg** 1996 Jun; 61(6):1724–6
Acute right ventricular failure during aortic valvular operation due to mechanical problem in the right coronary artery [see comments] Salerno TA, et al. **Ann Thorac Surg** 1996 Feb;61(2):706–7. Comment in: Ann Thorac Surg 1996 Aug;62(2):630.
Aortic root replacement with the pulmonary autograft in children with complex left heart obstruction. Starnes VA, et al. **Ann Thorac Surg** 1996 Aug;62(2):442–8; discussion 448–9
Time-related hemodynamic changes after aortic replacement with the freestyle stentless xenograft. Westaby S, et al. **Ann Thorac Surg** 1995 Dec;60(6):1633–8; discussion 1639
Doppler echocardiographic determination of geometric orifice areas in mechanical aortic valve prostheses. Henneke KH, et al. **Cardiology** 1995;86(6):508–13
Acute infectious mitroaortic endocarditis in association with acute aortic dissection. Surgical management of an unusual combination of diseases. Abad C. **Cardiovasc Surg** 1995 Dec;3(6):605–6
Surgical treatment for acute native aortic valvular infective endocarditis: long-term follow-up. Amrani M, et al. **Cardiovasc Surg** 1995 Dec;3(6):579–81
Efficacy of combined coronary revascularization and valve procedures in octogenarians. Adkins MS, et al. **Chest** 1995 Oct;108(4):927–31
Abnormal systolic intraventricular flow velocities after valve replacement for aortic stenosis. Mechanisms, predictive factors, and prognostic significance. Bartunek J, et al. **Circulation** 1996 Feb 15;93(4):712–9
Early and late mortality of patients undergoing aortic valve

replacement after previous coronary artery bypass graft surgery. Fighali SF, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II163–8

Early changes in regional and global left ventricular function after aortic valve replacement. Comparison of crystalloid, cold blood, and warm blood cardioplegias. Jin XY, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II155–62

Composite valve graft replacement of the ascending aorta and the aortic valve by a modified button technique: the influence of aortic pathology on early mortality and late survival. Biglioli P, et al. **Eur J Cardiothorac Surg** 1995; 9(9):483–90

Critical aortic stenosis in the neonate. Results of aortic commissurotomy. Cobanoglu A, et al. **Eur J Cardiothorac Surg** 1996;10(2):116–9

Is use of the pulmonary valve allograft justified as an aortic valve substitute? McCarthy JF, et al. **Eur J Cardiothorac Surg** 1996;10(2):105–8; discussion 109

Long-term results of aortic valve translocation for mycotic periannular abscess: comparative study of Danielson's original method and our threadless method. Endo M, et al. **Heart Vessels** 1995;10(6):318–22

Aortic and mitral annular remodeling using ultrasonic decalcification. Baumgartner F, et al. **Herz** 1996 Jun; 21(3):179–82

The role of transesophageal echocardiography during the Ross procedure. Azari DM, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):558–61

Long-term results after conservative aortic valve repair for aortic regurgitation with ventricular septal defect. Hisatomi K, et al. **J Cardiovasc Surg (Torino)** 1995 Dec;36(6):541–4

Intermittent aortic regurgitation following aortic valve replacement. Rumoroso JR, et al. **J Cardiovasc Surg (Torino)** 1995 Oct;36(5):443–5

Three years surgical and clinical experience with the Ross procedure in adults. Dossche K, et al. **J Heart Valve Dis** 1995 Jul;4(4):401–4

Porcine stentless aortic valve in re-replacements and acute aortic valve endocarditis. Gontijo BF, et al. **J Heart Valve Dis** 1995 Mar;4(2):171–5

Expanding indications for the Ross operation. Joyce F, et al. **J Heart Valve Dis** 1995 Jul;4(4):352–63

A technique to prevent bleeding after Ross procedure. Kumar AS, et al. **J Heart Valve Dis** 1995 Jul;4(4):405–6

Aortic valve replacement for aortic stenosis in 200 consecutive octogenarians. Logeais Y, et al. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S64–71

Preliminary experience with pulmonary autografts. Mazzucco A, et al. **J Heart Valve Dis** 1995 Jul;4(4):398–400

Aortic valve replacement with the Jyros bileaflet prosthetic valve; early echocardiographic and radiological evaluation. O'Keefe PA, et al. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S77–9; discussion 79–80

An appraisal of the Ross procedure [editorial] Oury JH. **J Heart Valve Dis** 1995 Jul;4(4):350–1

Mitral and aortic valve replacement using fresh unstented pulmonary and aortic homografts. Ozdogan ME, et al. **J Heart Valve Dis** 1996 Mar;5(2):181–5

Total aortic root replacement with pulmonary autografts: short term results in 45 consecutive patients. Prat AG, et al. **J Heart Valve Dis** 1995 Jul;4(4):368–73

Aprotinin use with hypothermic circulatory arrest for aortic valve and thoracic aortic surgery: renal function and early survival [see comments] Regragui IA, et al. **J Heart Valve Dis** 1995 Nov;4(6):674–7. Comment in: J Heart Valve Dis 1995 Nov;4(6):669–73.

Autograft aortic valve replacement with downsized pulmonary allograft for right ventricular outflow tract reconstruction. Sidiropoulos A, et al. **J Heart Valve Dis** 1996 Mar;5(2):176–7; discussion 174–5

Insertion of the pulmonary autograft as an inclusion cylinder—modifications to existing techniques. Skillington PD, et al. **J Heart Valve Dis** 1995 Jul;4(4):374–8

Narrowing of the aortic anulus in valve-sparing annuloaortic grafting. Eishi K, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):870–2

Aortic valve replacement in patients aged eighty years and older: early and long-term results. Gehlot A, et al. **J Thorac Cardiovasc Surg** 1996 May;111(5):1026–36

Aortic and aortic-mitral annular enlargement [letter; comment] Manouguian S, et al. **J Thorac Cardiovasc Surg** 1996 Jul;112(1):207. Comment on: J Thorac Cardiovasc Surg 1995 Apr;109(4):818–9.

Aortic valve replacement with a pulmonary autograft in infants with critical aortic stenosis. Südow G, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):433–6

Autologous tissue cardiac valve: implantation in children. Van de Wal HJ, et al. **J Thorac Cardiovasc Surg** 1996 Sep; 112(3):846–8

Aortic valve preservation in acute type A dissection: is it sound? von Segesser LK, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):381–90; discussion 390–1

Toronto stentless aortic valve replacement in elderly patients. van Nooten GJ, et al. **S Afr Med J** 1996 Apr;86 Suppl 2:C69–73

[The role of surgery in infectious endocarditis] Schoevaerdts JC. **Bull Mem Acad R Med Belg** 1995;150(10–11):430–8; discussion 438–41 (Eng. Abstr.) **(Fre)**

[Simultaneous heart valve implantation and coronary bypass following kidney transplantation] Alotti N, et al. **Orv Hetil** 1996 Apr 21;137(16):865–7 (Eng. Abstr.) **(Hun)**

[Surgical results of total replacement of aortic root] Tsutsumi Y, et al. **Kyobu Geka** 1996 Mar;49(3):209–13 (Eng. Abstr.) **(Jpn)**

[Different techniques in aortic valve valvuloplasty] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):714–6 **(Jpn)**

[An aortic valve-sparing operation (David's operation) for a patient with annulo-aortic ectasia (AAE) and aortic regurgitation (AR)—evaluation by intraoperative endoscopy] Furukawa K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):826–9 (Eng. Abstr.) **(Jpn)**

[Mitral and aortic annular enlargement for small mitral annulus after mitral annuloplasty] Minatoya K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1077–80 (Eng. Abstr.) **(Jpn)**

[Konno's operation for residual aortic stenosis following Nick's operation—a case report] Tsuji T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct; 43(10):1747–51 (Eng. Abstr.) **(Jpn)**

[Conservative surgery of the atrioventricular valves with a flexible and externally adjustable ring] Queiroz e Melo J, et al. **Rev Port Cardiol** 1995 Nov;14(11):873–5 **(Por)**

[Transthoracic and transesophageal echocardiographic study in aortic valve replacement with pulmonary valve autograft] Vargas-Barrón J. **Gac Med Mex** 1995 Mar–Apr; 131(2):133–8; discussion 138–40 (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

Ventricular outflow tract reconstructions with cryopreserved cardiac valve homografts. A single surgeon's 10-year experience. Hopkins RA, et al. **Ann Surg** 1996 May; 223(5):544–53; discussion 553–4

Effects of valve substitute on changes in left ventricular function and hypertrophy after aortic valve replacement. Jin XY, et al. **Ann Thorac Surg** 1996 Sep;62(3):683–90

Osteogenesis imperfecta and cardiovascular diseases [see comments] Wong RS, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1439–43 (36 ref.). Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

The effect of cryopreservation on the immunogenicity of allogeneic cardiac valves. Ketheesan N, et al. **Cryobiology** 1996 Feb;33(1):41–53

Right ventricular outflow reconstruction with homografts. Daenen W, et al. **Eur J Cardiothorac Surg** 1995;9(8):448–51; discussion 451–2

Free-hand sewn allografts, stentless (Prima Edwards) and stented (CESA) porcine bioprostheses. A comparative hemodynamic study. Dossche K, et al. **Eur J Cardiothorac Surg** 1995;9(10):562–6; discussion 566–7

Reconstruction of dilated aortic annulus using short tubular Dacron graft for aortic root replacement by aortic homograft—a solution for size mismatch. Kasegawa H, et al. **J Heart Valve Dis** 1996 Mar;5(2):178–80

Aortic and pulmonary homografts for right ventricular outflow tract reconstruction. Ross DN. **J Heart Valve Dis** 1995 Jul;4(4):396–7

Pathological considerations in cryopreserved allograft heart valves. Schoen FJ, et al. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S72–5; discussion S75–6

Use of larger sized aortic homograft conduits in right ventricular outflow tract reconstruction. Tam RK, et al. **J Heart Valve Dis** 1995 Nov;4(6):660–4

Performance of aortic and pulmonary homografts in the right ventricular outflow tract in children. Yankah AC, et al. **J Heart Valve Dis** 1995 Jul;4(4):392–5

Donor-specific cellular immune response against human cardiac valve allografts. Hoekstra F, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):281–6

Modified Fontan procedure for Ebstein's anomaly of the tricuspid valve—an alternative surgical approach preserving Ebstein's anatomy. Kaulitz R, et al. **Thorac Cardiovasc Surg** 1995 Oct;43(5):275–9

[Homograft replacement of aortic valve and ascending aorta] Brazão A, et al. **Rev Port Cardiol** 1996 Apr;15(4):295–300, 271 (Eng. Abstr.) **(Por)**

ULTRASONOGRAPHY

Doppler transesophageal echocardiographic determination of aortic valve area in adults with aortic stenosis. Stoddard MF, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):337–42

Value of multiplane transesophageal echocardiography in determining aortic valve area in aortic stenosis. Cormier B, et al. **Am J Cardiol** 1996 Apr 15;77(10):882–5

Evaluation of the hemodynamic performance of stentless porcine aortic valves [letter; comment] Izzat MB, et al. **Ann Thorac Surg** 1995 Nov;60(5):1461. Comment on: Ann Thorac Surg 1995 Apr;59(4):857–62.

Pressure gradients across bileaflet aortic valves by direct measurement and echocardiography. Laske A, et al. **Ann Thorac Surg** 1996 Jan;61(1):48–57

Images in cardiovascular medicine. Aortic valves. Shamrock, bileaflet, and lucky? Manning WJ, et al. **Circulation** 1995 Oct 15;92(8):2352

The role of transesophageal echocardiography during the Ross procedure. Azari DM, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):558–61

[Multidimensional transesophageal echocardiography in the determination of the orificial surface of aortic stenoses in adults. Apropos of 85 cases] Peltier M, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):332–8 (Eng. Abstr.) **(Fre)**

[Planar determination of the aortic valve area with transesophageal echocardiography with multiplanar probe in patients with aortic stenosis and insufficiency. Comparison with transthoracic Doppler echocardiography] Morelli S, et al. **G Ital Cardiol** 1995 Jul;25(7):851–7 (Eng. Abstr.) **(Ita)**

[Value and limitations of valve resistance in assessing prosthetic aortic valve function: clinical study using dobutamine stress doppler echocardiography] Okura H, et al. **J Cardiol** 1996 Jan;27(1):9–13 (Eng. Abstr.) **(Jpn)**

[Echocardiographic evaluation of the aortic and pulmonary valve areas in the newborn infant. Normal patterns] Lourenço A, et al. **Rev Port Cardiol** 1996 Mar;15(3):225–9, 182 (Eng. Abstr.) **(Por)**

ULTRASTRUCTURE

[The ultrastructure of the blood–air barrier and of the large (granular) epitheliocytes (type–2 alveolocytes) in patients with acquired defects and ischemic heart disease before and after surgical treatment] Goncharov IuV, et al. **Morfologiia** 1996;109(1):83–90 (Eng. Abstr.) **(Rus)**

AORTIC VALVE INCOMPETENCE see **AORTIC VALVE INSUFFICIENCY**

AORTIC VALVE INSUFFICIENCY

COMPLICATIONS

Aortic regurgitation progressing to aortic stenosis in antiphospholipid syndrome. Escalante A, et al. **Am Heart J** 1995 Oct;130(4):902–5

Multiple coronary thromboemboli complicating valvular heart disease and atrial fibrillation. Takenaka T, et al. **Am Heart J** 1996 Jan;131(1):194–6

Intensity of murmurs correlates with severity of valvular regurgitation. Desjardins VA, et al. **Am J Med** 1996 Feb; 100(2):149–56

Intraoperative TEE assessment of ventricular septal defect with aortic regurgitation. Leung MP, et al. **Ann Thorac Surg** 1996 Mar;61(3):854–60

The presentation of a double aortic arch in adulthood in association with congestive heart failure attributed to a previously silent aortic regurgitation. Nawa S, et al. **Cardiology** 1995;86(6):521–3

Angiodysplasia and aortic valve disease: let's close the book on this association [editorial; comment] Gostout CJ. **Gastrointest Endosc** 1995 Nov;42(5):491–3. Comment on: Gastrointest Endosc 1995 Nov;42(5):398–402.

Aortic regurgitation complicated by extreme left ventricular dilation: long-term outcome after surgical correction. Klodas E, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):670–7

Aortic regurgitation with extreme left ventricular dilation [letter] Miller GL. **J Am Coll Cardiol** 1996 Sep;28(3):798–9

[Follow-up study of Takayasu arteritis with aortic regurgitation] Morii S. **J Cardiol** 1995 Nov;26(5):293–8 (Eng. Abstr.) **(Jpn)**

[A case report of acute aortic dissection with aortic regurgitation and cardiac tamponade: intimal tear just above commissure of right coronary cusp and left coronary cusp] Kashiwagi J, et al. **Kyobu Geka** 1995 Nov; 48(12):1039–42 (Eng. Abstr.) **(Jpn)**

[A case report on concomitant graft replacement of the total aortic root and the transverse aortic arch for type A acute aortic dissection associated with annuloaortic ectasia] Kawaharada N, et al. **Kyobu Geka** 1996 Apr;49(4):312–4 (Eng. Abstr.) **(Jpn)**

[Clinical experience with normothermic selective cerebral perfusion during graft replacement of ascending-arch-descending aortic aneurysms with annuloaortic ectasia] Kuniyoshi Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):19–24 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Correlation of pediatric echocardiographic Doppler and catheter-derived valvar aortic stenosis gradients and the influence of aortic regurgitation. Wright SB, et al. **Am J Cardiol** 1996 Mar 15;77(8):663–5

Aortic valve insufficiency: changing concepts in diagnosis and management. Otto CM. **Cardiologia** 1996 Jun; 41(6):505–13 (41 ref.)

Comparative value of Doppler echocardiography and cardiac catheterization for management decision-making in patients with left-sided valvular regurgitation. Tribouilloy C, et al. **Eur Heart J** 1996 Feb;17(2):272–80

Magnetic resonance imaging of vascular changes in Takayasu arteritis. Hata A, et al. **Int J Cardiol** 1995 Nov 10; 52(1):45–52

[Chronic aortic valve insufficiency. The current status of its diagnosis and therapy] Hoppe UC, et al. **Dtsch Med Wochenschr** 1995 Dec 8;120(49):1709–13 (34 ref.) **(Ger)**

[ST segment depression during exertion as a marker of left ventricular dysfunction in patients with aortic insufficiency] Parreira L, et al. **Rev Port Cardiol** 1995 Oct;14(10):709–12 **(Por)**

DRUG THERAPY

Assessment of hemodynamic effects of

angiotensin-converting enzyme inhibitor therapy in chronic aortic regurgitation by using velocity-encoded cine magnetic resonance imaging. Globits S, et al. **Am Heart J** 1996 Feb;131(2):289-93

Medical treatment of chronic valvular regurgitation. Schön HR. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S170-4 (26 ref.)

EPIDEMIOLOGY

A prospective controlled evaluation of endoscopic detection of angiodysplasia and its association with aortic valve disease [see comments] Bhutani MS, et al. **Gastrointest Endosc** 1995 Nov;42(5):398-402. Comment in: Gastrointest Endosc 1995 Nov;42(5):491-3.

Effect of hypertension on aortic root size and prevalence of aortic regurgitation. Kim M, et al. **Hypertension** 1996 Jul;28(1):47-52

ETIOLOGY

Mitral and aortic insufficiency in polyarticular juvenile rheumatoid arthritis [letter] Karademir S, et al. **Acta Paediatr** 1996 Mar;85(3):380

Takayasu's arteritis with unstable angina and aortic insufficiency. Trazzera S, et al. **Am Heart J** 1995 Nov; 130(5):1122-4

Aortic valve regurgitation after surgical versus percutaneous balloon valvotomy for congenital aortic valve stenosis. Justo RN, et al. **Am J Cardiol** 1996 Jun 15;77(15):1332-8

Valvuloplasty in traumatic aortic insufficiency due to subtotal tear of the intima. Miralles A, et al. **Ann Thorac Surg** 1995 Oct;60(4):1098-100

Osteogenesis imperfecta and cardiovascular diseases [see comments] Wong RS, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1439-43 (36 ref.). Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Aortic valve regurgitation caused by blunt chest injury. Obadia JF, et al. **Br Heart J** 1995 Nov;74(5):545-7

Traumatic aortic incompetence associated with transection of the thoracic aorta. Paone RF, et al. **Chest** 1996 Apr; 109(4):1118-9

Acute aortic regurgitation caused by non-bacterial thrombotic endocarditis. Kardaras FG, et al. **Eur Heart J** 1995 Aug;16(8):1152-4

Rare cause of pure aortic regurgitation: congenital quadricuspid aortic valve [letter] Paemelaere JM, et al. **Eur Heart J** 1996 Apr;17(4):643-4

Intermittent aortic regurgitation following aortic valve replacement. Rumoroso JR, et al. **J Cardiovasc Surg (Torino)** 1995 Oct;36(5):443-5

Aortic valve replacement for aortic regurgitation due to Kawasaki disease. Report of two cases. Fukunaga S, et al. **J Heart Valve Dis** 1996 Mar;5(2):231-4

Perforation of the right aortic valve cusp: complication of ventricular septal defect closure with a modified Rashkind umbrella. Vogel M, et al. **Pediatr Cardiol** 1996 Nov-Dec; 17(6):416-8

Subtotal rarefication of one aortic leaflet in a bicuspid aortic valve due to large aneurysm of left Valsalva's sinus. Cottogni M, et al. **Scand J Thorac Cardiovasc Surg** 1995; 29(2):87-90

Aortic insufficiency and enterococcal endocarditis complicating systemic lupus erythematosus. Demircin M, et al. **Thorac Cardiovasc Surg** 1995 Oct;43(5):302-4

[Increased association of cardiac and thoracic vascular lesions after closed trauma of the thorax] Pretre R, et al. **Ann Chir** 1995;49(9):854-7 (Eng. Abstr.) **(Fre)**

[A rare cause of pure isolated chronic aortic insufficiency: congenital quadricuspid aortic valve. Apropos of 2 cases] Paemelaere JM, et al. **Arch Mal Coeur Vaiss** 1996 Jan; 89(1):91-3 (Eng. Abstr.) **(Fre)**

[Aortitis syndrome with left coronary ostial occlusion and aortic regurgitation: a case report] Osaka K, et al. **Kyobu Geka** 1995 Aug;48(9):789-91 (Eng. Abstr.) **(Jpn)**

[Traumatic aortic valve insufficiency] Nascimento J, et al. **Rev Port Cardiol** 1996 Feb;15(2):147-52, 101 (17 ref.) (Eng. Abstr.) **(Por)**

[Persistence of the left superior vena cava associated with aortic insufficiency: diagnostic and therapeutic considerations] Vicente Monmeneu J, et al. **Rev Esp Cardiol** 1996 Jan;49(1):77-80 (Eng. Abstr.) **(Spa)**

GENETICS

Acromicric dysplasia and geleophysic dysplasia: similarities and differences. Hennekam RC, et al. **Eur J Pediatr** 1996 Apr;155(4):311-4

IMMUNOLOGY

[Relationship between postoperative prognosis and preoperative immunological factors in aortitis syndrome] Noji S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb; 44(2):149-54 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Tortuosity of coronary arteries in chronic pressure and volume overload. Jakob M, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):25-31

PHYSIOPATHOLOGY

Combined rest and exercise electrocardiographic repolarization findings in relation to structural and functional abnormalities in asymptomatic aortic regurgitation. Chen J, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):343-7

Transesophageal Doppler echocardiographic assessment of left coronary blood flow velocity in chronic aortic regurgitation. Kisanuki A, et al. **Am Heart J** 1996 Jan; 131(1):101-6

Natural history and left ventricular response in chronic aortic regurgitation. Ishii K, et al. **Am J Cardiol** 1996 Aug 1; 78(3):357-61

Left ventricular function on exercise after surgical treatment of small aortic annuli. Kitamura M, et al. **Cardiovasc Surg** 1995 Dec;3(6):583-5

Effective regurgitant orifice area by the color Doppler flow convergence method for evaluating the severity of chronic aortic regurgitation. An animal study. Shiota T, et al. **Circulation** 1996 Feb 1;93(3):594-602

Coronary flow and left ventricular diastolic function in aortic regurgitation. Tamborini G, et al. **Coron Artery Dis** 1995 Aug;6(8):635-43

Paraprosthetic regurgitation in aortic prostheses: determination of the hemodynamic significance by pulsed Doppler examination of the subclavian artery flow. Omran H, et al. **J Heart Valve Dis** 1995 Mar;4(2):166-70

[The relationship between left ventricular function and the precipitation of symptoms in severe chronic aortic insufficiency (see comments)] Tarasoutchi F, et al. **Arq Bras Cardiol** 1995 Apr;64(4):301-9 (Eng. Abstr.). Comment in: Arq Bras Cardiol 1995 Apr;64(4):361-2. **(Por)**

[++Chronic aortic insufficiency. Physiopathological and clinical peculiarities (editorial)] Tarasoutchi F, et al. **Arq Bras Cardiol** 1995 May;64(5):417-8 **(Por)**

[Current aspects of hemodynamic compensation and surgical treatment in aortic valve diseases] Solov'ev GM, et al. **Vestn Ross Akad Med Nauk** 1995;(10):10-2 (Eng. Abstr.) **(Rus)**

RADIONUCLIDE IMAGING

[Radionuclide ejection fraction at rest and in exercise in chronic aortic insufficiency. Pre- and postoperative study in asymptomatic or paucisymptomatic patients] Jacques D, et al. **Arch Mal Coeur Vaiss** 1995 Sep;88(9):1301-6 (Eng. Abstr.) **(Fre)**

[Value and limits of exercise radionuclide ventriculography in chronic aortic insufficiency. Apropos of 47 operated cases] Pépin C, et al. **Arch Mal Coeur Vaiss** 1996 Jan; 89(1):69-75 (Eng. Abstr.) **(Fre)**

SURGERY

Insertion of an aortic and pulmonary homograft for simultaneous reconstruction of the left and right ventricular outflow tracts. A case report. Beyens T, et al. **Acta Chir Belg** 1995 Sep-Oct;95(5):237-40

Combined valve replacement and coronary bypass grafting in osteogenesis imperfecta [see comments] Almassi GH, et al. **Ann Thorac Surg** 1995 Nov;60(5):1395-7 (15 ref.). Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Aortic root replacement and extraanatomic bypass for interrupted aortic arch in an adult. Burton BJ, et al. **Ann Thorac Surg** 1995 Nov;60(5):1400-2

Ball valve (Smeloff-Cutter) aortic valve replacement without anticoagulation. Gometza B, et al. **Ann Thorac Surg** 1995 Nov;60(5):1312-6

Aortic valve repair and replacement after balloon aortic valvuloplasty in children [see comments] Hawkins JA, et al. **Ann Thorac Surg** 1996 May;61(5):1355-8. Comment in: Ann Thorac Surg 1996 May;61(5):1297-8.

Valvuloplasty in traumatic aortic insufficiency due to subtotal tear of the intima. Miralles A, et al. **Ann Thorac Surg** 1995 Oct;60(4):1098-100

Extending the limits of the Ross procedure. Reddy VM, et al. **Ann Thorac Surg** 1995 Dec;60(6 Suppl):S600-3

Pulmonary autograft in ventricular septal defect-aortic insufficiency complex. Schoof PH, et al. **Ann Thorac Surg** 1996 Mar;61(3):1005-6

Osteogenesis imperfecta and cardiovascular diseases [see comments] Wong RS, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1439-43 (36 ref.). Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Left ventricular function on exercise after surgical treatment of small aortic annuli. Kitamura M, et al. **Cardiovasc Surg** 1995 Dec;3(6):583-5

Aortic root replacement with a pulmonary autograft. Hokken RB, et al. **Eur J Cardiothorac Surg** 1995;9(7):378-83

Aortic regurgitation complicated by extreme left ventricular dilation: long-term outcome after surgical correction. Klodas E, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):670-7

Long-term results after conservative aortic valve repair for aortic regurgitation with ventricular septal defect. Hisatomi K, et al. **J Cardiovasc Surg (Torino)** 1995 Dec;36(6):541-4

Aortic root replacement with a cryopreserved aortic homograft in a patient with giant cell aortitis following two Bentall's type operations. Eishi K, et al. **J Heart Valve Dis** 1995 Sep;4(5):509-12

Aortic valve replacement for aortic regurgitation due to Kawasaki disease. Report of two cases. Fukunaga S, et al. **J Heart Valve Dis** 1996 Mar;5(2):231-4

Reconstruction of dilated aortic annulus using short tubular Dacron graft for aortic root replacement by aortic homograft--a solution for size mismatch. Kasegawa H, et al. **J Heart Valve Dis** 1996 Mar;5(2):178-80

The effect of left ventricular systolic function on long term survival in mitral and aortic regurgitation. Michel PL, et al. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S160-8; discussion S168-9

Morphologic determinants favoring surgical aortic valvuloplasty versus pulmonary autograft aortic valve replacement in children. van Son JA, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1149-56; discussion 1156-7

Correction of pectus excavatum combined with open heart surgery in a patient with Marfan's syndrome. Kalangos A, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):220-2

The sternocleidomastoid flap for treatment of a septic sternum defect. Maurer F, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):236-8

Aortic dissection after aortic valve replacement. Report of a case with an aortocameral fistula. Tayama K, et al. **Thorac Cardiovasc Surg** 1995 Oct;43(5):299-301

[Cesarean section in severe double valvular disease] Ilkjaer S, et al. **Ugeskr Laeger** 1996 Apr 29;158(18):2552-3 (Eng. Abstr.) **(Dan)**

[Asymptomatic endocarditis? Are consequent histological studies useful in valve surgery?] Zurbrügg HR, et al. **Swiss Surg Suppl** 1996;Suppl 1:23-6 (Eng. Abstr.) **(Ger)**

[Aortic valve reconstruction in ectasia of the aortic root and valve insufficiency] Schäfers HJ, et al. **Z Kardiol** 1996 Jun; 85(6):442-7 (Eng. Abstr.) **(Ger)**

[Combined valve repair for mitral-aortic insufficiency] Maisano F, et al. **G Ital Cardiol** 1995 Dec;25(12):1601-5 (Eng. Abstr.) **(Ita)**

[Left ventricular rupture following aortic and mitral valve replacement in a patient with osteogenesis imperfecta: a case report] Ichikawa H, et al. **Kyobu Geka** 1996 Apr; 49(4):294-6 (13 ref.) (Eng. Abstr.) **(Jpn)**

[A case of aortic valve rupture due to blunt chest trauma] Iriyama T, et al. **Kyobu Geka** 1995 Dec;48(13):1118-21 (Eng. Abstr.) **(Jpn)**

[Long-term results of Bentall and modified Bentall procedure in aortic root replacement] Ishibashi Y, et al. **Kyobu Geka** 1995 Oct;48(11):929-32 (Eng. Abstr.) **(Jpn)**

[Hemodynamic plus series of St. Jude medical valve prosthesis in aortic position: early clinical outcome and reconsideration of its application] Katsumata T, et al. **Kyobu Geka** 1996 Mar;49(3):194-8 (Eng. Abstr.) **(Jpn)**

[Case report of David's operation for annuloaortic ectasia and aortic regurgitation in a Marfan patient] Tamaki S, et al. **Kyobu Geka** 1996 Apr;49(4):270-3 (Eng. Abstr.) **(Jpn)**

[A successful repair of aortic regurgitation and right ventricular aneurysm long after correction of tetralogy of Fallot] Tambara K, et al. **Kyobu Geka** 1996 Feb;49(2):131-4 (Eng. Abstr.) **(Jpn)**

[Aortic valve replacement for rheumatoid aortic valve regurgitation] Uwabe K, et al. **Kyobu Geka** 1995 Sep; 48(10):869-72 (Eng. Abstr.) **(Jpn)**

[Simultaneous operation for annulo-aortic ectasia, mitral regurgitation, and tricuspid regurgitation in a patient with Marfan syndrome--report of a case] Akashi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1223-7 (Eng. Abstr.) **(Jpn)**

[An aortic valve-sparing operation (David's operation) for a patient with annulo-aortic ectasia (AAE) and aortic regurgitation (AR)--evaluation by intraoperative endoscopy] Furukawa K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):826-9 (Eng. Abstr.) **(Jpn)**

[A case report of bentall type operation for annuloaortic ectasia with anomalous origin of the right coronary artery complicated by aortic dissection] Hirai M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1044-9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Single-stage surgery for annulo aortic ectasia, Stanford type-A aortic dissection and pectus excavatum in a patient with Marfan's syndrome] Ichikawa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):575-9 (Eng. Abstr.) **(Jpn)**

[Isolated aortic valve regurgitation due to degeneration of the valve leaflet--a clinical study] Moriyama Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):951-5 (Eng. Abstr.) **(Jpn)**

[Open heart surgery in patients with systemic diseases requiring steroid treatment] Moro H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):493-8 (Eng. Abstr.) **(Jpn)**

[Surgical results of aortitis syndrome (Takayasu disease) combined with annuloaortic ectasia] Nakano H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1664-9 (Eng. Abstr.) **(Jpn)**

[A surgical case of infective endocarditis accompanied with immune complex glomerulonephritis] Ozaki T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1203-7 (Eng. Abstr.) **(Jpn)**

[Symptoms and ventricular dysfunction in chronic aortic insufficiency (editorial; comment)] Aloan L de A. **Arq Bras Cardiol** 1995 Apr;64(4):361-2. Comment on: Arq Bras Cardiol 1995 Apr;64(4):301-9. **(Por)**

[Current aspects of hemodynamic compensation and surgical treatment in aortic valve diseases] Solov'ev GM, et al. **Vestn Ross Akad Med Nauk** 1995;(10):10-2 (Eng. Abstr.) **(Rus)**

[Echocardiographic indicators of the surgical moment in chronic severe aortic insufficiency] Rosas Munive E. **Arch Inst Cardiol Mex** 1995 Jul–Aug;65(4):359–64 (22 ref.) **(Spa)**

THERAPY

Comparative value of Doppler echocardiography and cardiac catheterization for management decision–making in patients with left–sided valvular regurgitation. Tribouilloy C, et al. **Eur Heart J** 1996 Feb;17(2):272–80

Management of the parturient with severe aortic incompetence. Sheikh F, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):575–7

ULTRASONOGRAPHY

Assessment of aortic regurgitation by color flow and continuous–wave Doppler echocardiography. Dalal P, et al. **Am J Cardiol** 1996 Mar 15;77(8):661–3

Effective regurgitant orifice area by the color Doppler flow convergence method for evaluating the severity of chronic aortic regurgitation. An animal study. Shiota T, et al. **Circulation** 1996 Feb 1;93(3):594–602

Evaluation of aortic regurgitation with digitally determined color Doppler–imaged flow convergence acceleration: a quantitative study in sheep. Shiota T, et al. **J Am Coll Cardiol** 1996 Jan;27(1):203–10

Systolic aortic regurgitation: a hemodynamic challenge for the clinician. Kronzon I, et al. **J Am Soc Echocardiogr** 1995 Nov–Dec;8(6):941–3

[The quantification of valvular regurgitation. What new does echocardiography offer?] Mele D. **G Ital Cardiol** 1995 Sep; 25(9):1195–203 (54 ref.) **(Ita)**

[Planar determination of the aortic valve area with transesophageal echocardiography with multiplanar probe in patients with aortic stenosis and insufficiency. Comparison with transthoracic Doppler echocardiography] Morelli S, et al. **G Ital Cardiol** 1995 Jul;25(7):851–7 (Eng. Abstr.) **(Ita)**

VETERINARY

Acute and short–term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. The IMPROVE Study Group. **J Vet Intern Med** 1995 Jul–Aug;9(4):234–42

AORTIC VALVE PROLAPSE

SURGERY

Surgical management of ventricular septal defect with aortic valve prolapse: clinical considerations and results. Brauner R, et al. **Eur J Cardiothorac Surg** 1995;9(6):315–9

AORTIC VALVE STENOSIS

see related
CARDIOMYOPATHY, HYPERTROPHIC

Risk of stroke in a cohort of 815 patients with calcification of the aortic valve with or without stenosis. Boon A, et al. **Stroke** 1996 May;27(5):847–51

BLOOD

Decreased platelet function in aortic valve stenosis: high shear platelet activation then inactivation. O'Brien JR, et al. **Br Heart J** 1995 Dec;74(6):641–4

COMPLICATIONS

Aortic regurgitation progressing to aortic stenosis in antiphospholipid syndrome. Escalante A, et al. **Am Heart J** 1995 Oct;130(4):902–5

Normalization of left ventricular nonuniformity late after valve replacement for aortic stenosis. Villari B, et al. **Am J Cardiol** 1996 Jul 1;78(1):66–71

Endarterectomy for calcified porcelain aorta associated with aortic valve stenosis. Svensson LG, et al. **Ann Thorac Surg** 1996 Jan;61(1):149–52

Interrupted aortic arch. Impact of subaortic stenosis on management and outcome. Jacobs ML, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II128–31

Retinal artery embolization: a rare presentation of calcific aortic stenosis. Reimers CD, et al. **Clin Cardiol** 1996 Mar; 19(3):253–4

Angiodysplasia and aortic valve disease: let's close the book on this association [editorial; comment] Gostout CJ. **Gastrointest Endosc** 1995 Nov;42(5):491–3. Comment on: Gastrointest Endosc 1995 Nov;42(5):398–402.

Aortic stenosis in homozygous familial hypercholesterolaemia. Rallidis L, et al. **Heart** 1996 Jul; 76(1):84–5

Peripartum cardiomyopathy complicating severe aortic stenosis. Purcell IF, et al. **Int J Cardiol** 1995 Nov 24; 52(2):163–5; discussion 165–6

Subaortic stenosis in the spectrum of atrioventricular septal defects. Solutions may be complex and palliative. Van Arsdell GS, et al. **J Thorac Cardiovasc Surg** 1995 Nov; 110(5):1534–41; discussion 1541–2

Reversal of aortic stenosis, bleeding gastrointestinal angiodysplasia, and von Willebrand syndrome by aortic valve replacement [letter; comment] Anderson RP, et al. **Lancet** 1996 Mar 9;347(9002):689–90. Comment on: Lancet 1992 Jul 4;340(8810):35–7.

[A successful palliative arterial switch operation with arch repair for tricuspid atresia with ventriculoarterial discordance, subaortic stenosis, coarctation, and aortic arch hypoplasia] Yamagishi M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Dec;43(12):1981–7 (Eng. Abstr.) **(Jpn)**

[A case of Werner's syndrome associated with heart failure due aortic valve stenosis] Watanabe T, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):608–10 **(Jpn)**

[Angiodysplasia of the colon associated with aortic stenosis and renal insufficiency. Apropos of a case with massive digestive hemorrhage (letter)] Garcia Roman JM, et al. **An Med Interna** 1995 Dec;12(12):620–1 **(Spa)**

CONGENITAL

Aortic valve regurgitation after surgical versus percutaneous balloon valvotomy for congenital aortic valve stenosis. Justo RN, et al. **Am J Cardiol** 1996 Jun 15;77(15):1332–8

Effectiveness of balloon valvuloplasty in the young adult with congenital aortic stenosis. Sandhu SK, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):122–7

Critical aortic stenosis in the neonate. Results of aortic commissurotomy. Cobanoglu A, et al. **Eur J Cardiothorac Surg** 1996;10(2):116–9

Concurrent balloon dilatation of coexisting congenital pulmonary and aortic valve stenosis. Sharma S, et al. **Indian Heart J** 1996 Mar–Apr;48(2):169–70

[Surgical treatment of congenital aortic stenosis by aortoseptal approach] Mizuhara H, et al. **Kyobu Geka** 1995 Aug;48(9):768–72 (14 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Missed diagnosis of severe symptomatic aortic stenosis. Rispler S, et al. **Am J Cardiol** 1995 Oct 1;76(10):728–30

Accuracy of quantitation of aortic stenosis using femoral arterial recordings corrected for both temporal delay and systolic amplification. Vaitkus PT, et al. **Am J Cardiol** 1995 Oct 1;76(10):725–8

Correlation of pediatric echocardiographic Doppler and catheter–derived valvar aortic stenosis gradients and the influence of aortic regurgitation. Wright SB, et al. **Am J Cardiol** 1996 Mar 15;77(8):663–5

Effect of Doppler echocardiography on utilization of hemodynamic cardiac catheterization in the preoperative evaluation of aortic stenosis [see comments] Roger VL, et al. **Mayo Clin Proc** 1996 Feb;71(2):141–9. Comment in: Mayo Clin Proc 1996 Jul;71(7):721.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1–1996. A 69–year–old woman with severe, persistent congestive heart failure after treatment for bacteremia [clinical conference] **N Engl J Med** 1996 Jan 11;334(2):105–11

[Severe aortic stenosis without left–ventricular hypertrophy: associated variables and prognosis following aortic valve replacement] Seiler C, et al. **Schweiz Med Wochenschr** 1995 Dec 26;125(51–52):2502–5 (Eng. Abstr.) **(Ger)**

[Angiodysplasia of the right colon and aortic stenosis. A case report] Arcidiacono G, et al. **Minerva Cardioangiol** 1996 Apr;44(4):173–7 (25 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

A prospective controlled evaluation of endoscopic detection of angiodysplasia and its association with aortic valve disease [see comments] Bhutani MS, et al. **Gastrointest Endosc** 1995 Nov;42(5):398–402. Comment in: Gastrointest Endosc 1995 Nov;42(5):491–3.

ETIOLOGY

Radiation–induced cardiovascular dysfunction. Mittal S, et al. **Am J Cardiol** 1996 Jul 1;78(1):114–5

Noonan syndrome: structural abnormalities of the mitral valve causing subaortic obstruction. Marino B, et al. **Eur J Pediatr** 1995 Dec;154(12):949–52

Demographic characteristics of patients undergoing aortic valve replacement for stenosis: relation to valve morphology. Davies MJ, et al. **Heart** 1996 Feb;75(2):174–8

Left ventricular growth in a patient with critical coarctation of the aorta and hypoplastic left ventricle. Page DA, et al. **Pediatr Cardiol** 1995 Jul–Aug;16(4):176–8

GENETICS

A 30 kb deletion within the elastin gene results in familial supravalvular aortic stenosis. Olson TM, et al. **Hum Mol Genet** 1995 Sep;4(9):1677–9

Familial supravalvular aortic stenosis: a report of two brothers. Wu JR, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Feb; 12(2):128–31

HISTORY

Calcific aortic valve stenosis and the congenitally bicuspid aortic valve: did Osler miss the link? [editorial] Mensah GA, et al. **Am J Cardiol** 1996 Feb 15;77(5):417–20

METABOLISM

Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. O'Brien KD, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):523–32

A skeleton in the atherosclerosis closet [editorial; comment] Demer LL. **Circulation** 1995 Oct 15;92(8):2029–32. Comment on: Circulation 1995 Oct 15;92(8):2163–8.

Osteopontin is expressed in human aortic valvular lesions [see comments] O'Brien KD, et al. **Circulation** 1995 Oct 15;92(8):2163–8. Comment in: Circulation 1995 Oct 15;92(8):2029–32.

MORTALITY

Natural history of aortic valve stenosis of varying severity in the elderly. Iivanainen AM, et al. **Am J Cardiol** 1996 Jul 1;78(1):97–101

PATHOLOGY

Stenotic origin of an aberrant left subclavian artery from a right–sided aortic arch. A case report. Drnovsek V, et al. **Angiology** 1996 May;47(5):523–9

Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. O'Brien KD, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):523–32

Osseus metaplasia with functioning marrow in a calcified aortic valve [letter] Arumugam SB, et al. **J Card Surg** 1995 Sep;10(5):610–1

[Isolated stenosing calcified lesions of the aorta] Sapoval M, et al. **J Radiol** 1995 Nov;76(11):1021–4 (10 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Progression of valvular aortic stenosis in adults: literature review and clinical implications. Faggiano P, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):408–17 (77 ref.)

Gender differences in left ventricular function at rest and with exercise in asymptomatic aortic stenosis. Legget ME, et al. **Am Heart J** 1996 Jan;131(1):94–100

Left ventricular diastolic response to exercise in valvular aortic stenosis. Movsowitz C, et al. **Am J Cardiol** 1996 Feb 1;77(4):275–80

Abnormal systolic intraventricular flow velocities after valve replacement for aortic stenosis. Mechanisms, predictive factors, and prognostic significance. Bartunek J, et al. **Circulation** 1996 Feb 15;93(4):712–9

Sex–dependent differences in left ventricular function and structure in chronic pressure overload. Villari B, et al. **Eur Heart J** 1995 Oct;16(10):1410–9

Relation between symptoms and profiles of coronary artery blood flow velocities in patients with aortic valve stenosis: a study using transoesophageal Doppler echocardiography. Omran H, et al. **Heart** 1996 Apr;75(4):377–83

Early diastolic regional function of the hypertrophied left ventricle. Hayashida W, et al. **Int J Cardiol** 1996 Feb; 53(2):153–62

Left ventricular function in aortic stenosis: a clinical review. Roger VL. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S230–5 (49 ref.)

'Calcific degeneration of the aortic valve in old age: is the development of flow obstruction predictable?' [letter] Jolobe OM. **J Intern Med** 1996 Jul;240(1):43–4

Influence of stenotic valve geometry on measured pressure gradients and ventricular work: the relationship between morphology and flow. Cape EG, et al. **Pediatr Cardiol** 1996 May–Jun;17(3):155–62

[Differentiated evaluation of heart valve stenosis by expanded Bernoulli equation—in vitro studies of model stenoses] Wendt MO, et al. **Z Kardiol** 1995 Sep;84(9):686–93 (Eng. Abstr.) **(Ger)**

[Phasic flow velocity characteristics of the right coronary artery in patients with aortic stenosis: a Doppler guide wire study] Okura H, et al. **J Cardiol** 1996 May;27(5):255–9 (Eng. Abstr.) **(Jpn)**

[Current aspects of hemodynamic compensation and surgical treatment in aortic valve diseases] Solov'ev GM, et al. **Vestn Ross Akad Med Nauk** 1995;(10):10–2 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Pharmacological inhibition of restenosis: learning from experience. Shaw LA, et al. **Trends Pharmacol Sci** 1995 Dec;16(12):401–4 (36 ref.)

RADIOGRAPHY

Images in cardiovascular medicine. Calcific aortic stenosis and associated Lev's disease. Mueller RL, et al. **Circulation** 1995 Nov 15;92(10):3138

Myocardial perforation associated with the use of the Gensini ventriculography catheter. Davis GK, et al. **Int J Cardiol** 1996 Feb;53(2):103–6; discussion 107–8

RADIONUCLIDE IMAGING

Dipyridamole thallium–201 single–photon emission tomography in aortic stenosis: gender differences. Rask LP, et al. **Eur J Nucl Med** 1995 Oct;22(10):1155–62

AORTIC VALVE STENOSIS

SURGERY

Surgical commissurotomy of the aortic valve: outcome of open valvotomy in neonates with critical aortic stenosis. Gildein HP, et al. **Am Heart J** 1996 Apr;131(4):754–9

Normalization of left ventricular nonuniformity late after valve replacement for aortic stenosis. Villari B, et al. **Am J Cardiol** 1996 Jul 1;78(1):66–71

Modified pulmonary autograft aortic root replacement: the sinus obliteration technique. Black MD, et al. **Ann Thorac Surg** 1995 Nov;60(5):1434–6

Ross/Konno procedure for critical aortic stenosis in infancy. Calhoon JH, et al. **Ann Thorac Surg** 1995 Dec;60(6 Suppl):S597–9

Early in vivo experience with the Hemodynamic Plus St. Jude Medical heart valves in patients with narrowed aortic annulus. Carrel T, et al. **Ann Thorac Surg** 1996 May; 61(5):1418–22

Management of asymptomatic mild aortic stenosis during coronary artery operations. Fiore AC, et al. **Ann Thorac Surg** 1996 Jun;61(6):1693–7; discussion 1697–8

Effects of valve replacement on ventricular mechanics in mitral regurgitation and aortic stenosis. Harpole DH Jr, et al. **Ann Thorac Surg** 1996 Sep;62(3):756–61

Aortic valve repair and replacement after balloon aortic valvuloplasty in children [see comments] Hawkins JA, et al. **Ann Thorac Surg** 1996 May;61(5):1355–8. Comment in: Ann Thorac Surg 1996 May;61(5):1297–8.

Evaluation of the hemodynamic performance of small CarboMedics aortic prostheses using dobutamine-stress Doppler echocardiography. Izzat MB, et al. **Ann Thorac Surg** 1995 Oct;60(4):1048–52

The aortic valve: to dilate, repair, or replace—that is the question [editorial; comment] Lamberti JJ. **Ann Thorac Surg** 1996 May;61(5):1297–8. Comment on: Ann Thorac Surg 1996 May;61(5):1355–8.

Perioperative complications in combined aortic valve replacement and extraanatomic ascending–descending bypass. Pethig K, et al. **Ann Thorac Surg** 1996 Jun; 61(6):1724–6

Extending the limits of the Ross procedure. Reddy VM, et al. **Ann Thorac Surg** 1995 Dec;60(6 Suppl):S600–3

Indications for valve surgery in asymptomatic patients with aortic and mitral stenosis. Carabello BA. **Chest** 1995 Dec; 108(6):1678–82 (30 ref.)

Abnormal systolic intraventricular flow velocities after valve replacement for aortic stenosis. Mechanisms, predictive factors, and prognostic significance. Bartunek J, et al. **Circulation** 1996 Feb 15;93(4):712–9

Quality of life in octogenarians after valve replacement due to aortic stenosis. A prospective comparison with younger patients [see comments] Olsson M, et al. **Eur Heart J** 1996 Apr;17(4):583–9. Comment in: Eur Heart J 1996 Apr;17(4):496–7.

Critical aortic stenosis in the neonate. Results of aortic commissurotomy. Cobanoglu A, et al. **Eur J Cardiothorac Surg** 1996;10(2):116–9

Aortic root replacement with a pulmonary autograft. Hokken RB, et al. **Eur J Cardiothorac Surg** 1995;9(7):378–83

Complication of intra-aortic balloon pumping in a pediatric patient. Van de Wal HJ, et al. **Eur J Cardiothorac Surg** 1995;9(10):602–3

Prognosis of supravalve aortic stenosis in 81 patients in Liverpool (1960–1993). Kitchiner D, et al. **Heart** 1996 Apr; 75(4):396–402

Anecdotes in medicine: do they have value? [editorial] Parmley WW. **J Am Coll Cardiol** 1996 Sep;28(3):795

Aortic coarctation, aortic valvular stenosis, and coronary artery disease: combined one-stage surgical therapy operation. Bartoccioni S, et al. **J Card Surg** 1995 Sep; 10(5):594–6

Is surgery for aortic stenosis justified in patients over 75 years of age? Chocron S, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):255–9

Aortic valve replacement for aortic stenosis in 200 consecutive octogenarians. Logeais Y, et al. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S64–71

Long-term outcome of left ventricular dysfunction after surgery for severe aortic stenosis. Uwabe K, et al. **J Heart Valve Dis** 1995 Sep;4(5):503–7; discussion 507–8

Influence of the size of aortic valve prostheses on hemodynamics and change in left ventricular mass: implications for the surgical management of aortic stenosis. González-Juanatey JR, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):273–80

Aortoventriculoplasty with the pulmonary autograft: the "Ross-Konno" procedure. Reddy VM, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):158–65; discussion 165–7

Aortic valve replacement with a pulmonary autograft in infants with critical aortic stenosis. Südow G, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):433–6

Subaortic stenosis in the spectrum of atrioventricular septal defects. Solutions may be complex and palliative. Van Arsdell GS, et al. **J Thorac Cardiovasc Surg** 1995 Nov; 110(5):1534–41; discussion 1541–2

Morphologic determinants favoring surgical aortic valvuloplasty versus pulmonary autograft aortic valve replacement in children. van Son JA, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1149–56; discussion 1156–7

Effect of Doppler echocardiography on utilization of hemodynamic cardiac catheterization in the preoperative evaluation of aortic stenosis [see comments] Roger VL, et al. **Mayo Clin Proc** 1996 Feb;71(2):141–9. Comment in: Mayo Clin Proc 1996 Jul;71(7):721.

Fatal fungal infection of an ascending aortic graft. Wandschneider W, et al. **Thorac Cardiovasc Surg** 1995 Aug; 43(4):217–9

Which cardioplegia for the hypertrophied myocardium? A prospective clinical study of four preservation techniques. Bouchart F, et al. **Transplant Proc** 1995 Oct;27(5):2812–3

[Cesarean section in severe double valvular disease] Ilkjaer S, et al. **Ugeskr Laeger** 1996 Apr 29;158(18):2552–3 (Eng. Abstr.) **(Dan)**

[Long-term development of aortic valve stenosis surgically treated at an advanced stage] Eker A, et al. **Ann Chir** 1996; 50(5):374–80 (Eng. Abstr.) **(Fre)**

[Reoperation for aortic valve replacement after myocardial revascularization] Leprince P, et al. **Arch Mal Coeur Vaiss** 1996 Mar;89(3):335–9 (Eng. Abstr.) **(Fre)**

[Valvular replacement for aortic stenosis in octogenarians. Apropos of a consecutive series of 200 cases] Logeais Y, et al. **Arch Mal Coeur Vaiss** 1995 Feb;88(2):189–95 (30 ref.) (Eng. Abstr.) **(Fre)**

[Value and limitations of valve resistance in assessing prosthetic aortic valve function: clinical study using dobutamine stress doppler echocardiography] Okura H, et al. **J Cardiol** 1996 Jan;27(1):9–13 (Eng. Abstr.) **(Jpn)**

[Expedient technique of aortic annular enlargement in aortic valve replacement] Kusuhara K, et al. **Kyobu Geka** 1995 Nov;48(12):1006–8 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of congenital aortic stenosis by aortoseptal approach] Mizuhara H, et al. **Kyobu Geka** 1995 Aug;48(9):768–72 (14 ref.) (Eng. Abstr.) **(Jpn)**

[The long-term results of isolated aortic valve replacement with 19 mm prostheses] Nakamura T, et al. **Kyobu Geka** 1995 Sep;48(10):824–8 (Eng. Abstr.) **(Jpn)**

[Konno's operation for residual aortic stenosis following Nick's operation—a case report] Tsuji T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct; 43(10):1747–51 (Eng. Abstr.) **(Jpn)**

[Surgical results of aortic stenosis with or without left ventricular dysfunction—postoperative change of left ventricular function] Uwabe K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Oct;43(10):1710–5 (Eng. Abstr.) **(Jpn)**

[Current aspects of hemodynamic compensation and surgical treatment in aortic valve diseases] Solov'ev GM, et al. **Vestn Ross Akad Med Nauk** 1995;(10):10–2 (Eng. Abstr.) **(Rus)**

THERAPY

Right subscapular artery catheterization for balloon valvuloplasty of critical aortic stenosis in infants. Alekyan BG, et al. **Am J Cardiol** 1995 Nov 15;76(14):1049–52

Aortic valve regurgitation after surgical versus percutaneous balloon valvotomy for congenital aortic valve stenosis. Justo RN, et al. **Am J Cardiol** 1996 Jun 15;77(15):1332–8

Independent predictors of immediate results of percutaneous balloon aortic valvotomy in children. Valvuloplasty and Angioplasty of Congenital Anomalies (VACA) Registry Investigators. McCrindle BW. **Am J Cardiol** 1996 Feb 1; 77(4):286–93

How should we manage symptomatic aortic stenosis in the patient who is 80 or older? Sprigings DC, et al. **Br Heart J** 1995 Nov;74(5):481–4 (42 ref.)

An experimental study of intravascular stent in abdominal aorta of atherosclerotic miniature pigs. Huang J, et al. **Chin Med J (Engl)** 1995 Jul;108(7):497–500

Balloon aortic valvuloplasty in elderly patients at high risk for surgery, or inoperable. Immediate and mid-term results. Eltchaninoff H, et al. **Eur Heart J** 1995 Aug;16(8):1079–84

Percutaneous balloon valvuloplasty for concurrent mitral, aortic and tricuspid rheumatic stenosis. Sobrino N, et al. **Eur Heart J** 1995 May;16(5):711–3

Concurrent balloon dilatation of coexisting congenital pulmonary and aortic valve stenosis. Sharma S, et al. **Indian Heart J** 1996 Mar–Apr;48(2):169–70

"Kissing-balloon" technique for abdominal aorta angioplasty. Initial results and long term outcome. Sagic D, et al. **Int Angiol** 1995 Dec;14(4):364–7

Concurrent aortic and mitral balloon valvuloplasty by the retrograde non-transseptal technique. Bahl VK, et al. **Int J Cardiol** 1995 Nov 10;52(1):13–5

Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. Lieberman EB, et al. **J Am Coll Cardiol** 1995 Nov 15;26(6):1522–8

Midterm results of balloon dilation of congenital aortic stenosis: predictors of success. Moore P, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1257–63

Balloon expandable intravascular stent in infrarenal aortic stenosis. Kang EH. **Nebr Med J** 1995 Nov;80(11):329–31

Stepwise Inoue balloon catheter valvuloplasty for congenital aortic valve stenosis: comparison with standard balloon catheter technique. Ruzyllo W, et al. **Pediatr Cardiol** 1996 Jan–Feb;17(1):15–20

Percutaneous balloon aortic valvuloplasty in high-risk elderly patients. Park R, et al. **Wis Med J** 1995 Oct; 94(10):537–41

[Percutaneous valvotomy of aortic valve stenoses in children] Kachaner J, et al. **Arch Mal Coeur Vaiss** 1996 May; 89(5):525–31 (Eng. Abstr.) **(Fre)**

[Cardiology update—II] Trappe HJ. **Med Klin** 1995 Oct 15; 90(10):567–78 (139 ref.) **(Ger)**

[Aortic balloon valvuloplasty in critical aortic stenosis in the newborn and infants] Benito Bartolomé F, et al. **Rev Esp Cardiol** 1996 Apr;49(4):277–80 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Duplex sonography of the carotid arteries in patients with isolated aortic stenosis: imaging findings and relation to severity of stenosis. O'Boyle MK, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):197–202

Quantitative assessment of stenotic aortic valve area by using intracardiac echocardiography: in vitro validation and initial in vivo illustration. Jiang L, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):137–44

Doppler transesophageal echocardiographic determination of aortic valve area in adults with aortic stenosis. Stoddard MF, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):337–42

Value of multiplane transesophageal echocardiography in determining aortic valve area in aortic stenosis. Cormier B, et al. **Am J Cardiol** 1996 Apr 15;77(10):882–5

High reproducibility in the interpretation of intraoperative transesophageal echocardiographic evaluation of aortic atheromatous disease. Hartman GS, et al. **Anesth Analg** 1996 Mar;82(3):539–43

Mechanisms of regional ischaemic changes during dipyridamole echocardiography in patients with severe aortic valve stenosis and normal coronary arteries. Baroni M, et al. **Heart** 1996 May;75(5):492–7

Stenotic lesions. Wranne B, et al. **Heart** 1996 Jun;75(6 Suppl 2):36–42 (42 ref.)

Determination of aortic valve area in valvular aortic stenosis by direct measurement using intracardiac echocardiography: a comparison with the Gorlin and continuity equations. Foster GP, et al. **J Am Coll Cardiol** 1996 Feb;27(2):392–8

Duplex velocity characteristics of aortoiliac stenoses. de Smet AA, et al. **J Vasc Surg** 1996 Apr;23(4):628–36

Transesophageal color Doppler evaluation of obstructive lesions using the new "Quasar" technology. Fan P, et al. **Ultrasound Med Biol** 1995;21(8):1021–8

[Multidimensional transesophageal echocardiography in the determination of the orificial surface of aortic stenoses in adults. Apropos of 85 cases] Peltier M, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):332–8 (Eng. Abstr.) **(Fre)**

[Planar determination of the aortic valve area with transesophageal echocardiography with multiplanar probe in patients with aortic stenosis and insufficiency. Comparison with transthoracic Doppler echocardiography] Morelli S, et al. **G Ital Cardiol** 1995 Jul;25(7):851–7 (Eng. Abstr.) **(Ita)**

VETERINARY

Closed aortic valvotomy: a retrospective study in 15 dogs. Dhokarikar P, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct; 31(5):402–10

AORTICOPULMONARY SEPTAL DEFECT see **AORTOPULMONARY SEPTAL DEFECT**

AORTITIS

COMPLICATIONS

Lymphoplasmacytic aortitis and acute aortic dissection. An uncommon association. Faye-Petersen OM, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):402–4 (20 ref.)

Long term follow-up of percutaneous transluminal renal angioplasty with special reference to aorto-arteritis. Chatterjee SS, et al. **Indian Heart J** 1995 Mar–Apr; 47(2):120–4

Aortic root replacement with a cryopreserved aortic homograft in a patient with giant cell aortitis following two Bentall's type operations. Eishi K, et al. **J Heart Valve Dis** 1995 Sep;4(5):509–12

[Inflammatory aorto-iliac aneurysm. A cause of extrinsic ureteral obstruction] García Díez F, et al. **Arch Esp Urol** 1995 Sep;48(7):750–3 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Inflammatory aneurysm of the ascending aorta mimicking intramural hemorrhage [letter; comment] Federmann M, et al. **Circulation** 1996 Apr 1;93(7):1477–8. Comment on: Circulation 1995 Sep 15;92(6):1376–8. Comment on: Circulation 1995 Sep 15;92(6):1465–72.

Systemic lupus erythematosus with aortoarteritis. Menon J, et al. **Indian Pediatr** 1996 Mar;33(3):238–41

[Exploration of the thoracic aorta, excluding the aortic valve] Douek P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):552–60 (12 ref.) (Eng. Abstr.) **(Fre)**

[Inflammatory aneurysm of the abdominal aorta] **Rontgenpraxis** 1995 Dec;48(12):340–1 **(Ger)**

IMMUNOLOGY

[State of the immune system in patients with nonspecific aortoarteritis at the chronic stage] Sharapov NU, et al. **Klin Khir** 1995;(11–12):17–9 **(Rus)**

MICROBIOLOGY

Candida arteritis: are GI endoscopic procedures a source of vascular infections? Sailors DM, et al. **Am Surg** 1996 Jun; 62(6):472–7

Salmonella aortitis [letter] Lundgren JD, et al. **Clin Infect Dis** 1996 Apr;22(4):739–40

Primary Clostridium septicum aortitis: a rare cause of necrotizing suprarenal aortic infection. A case report and review of the literature. Sailors DM, et al. **J Vasc Surg** 1996 Apr;23(4):714–8 (24 ref.)

PATHOLOGY

Aortitis with dissection complicating systemic lupus erythematosus. Guard RW, et al. **Pathology** 1995 Jul; 27(3):224–8

PHYSIOPATHOLOGY

Multimodality evoked potentials in aortoarteritis. Varma AR, et al. **Electromyogr Clin Neurophysiol** 1995 Aug–Sep; 35(5):291–4

SURGERY

Retroperitoneal approach for repair of inflammatory aortic aneurysms. Todd GJ, et al. **Ann Vasc Surg** 1995 Nov; 9(6):525–34

Recurrent aortic infection: treatment by arterial homograft replacement. Nevelsteen A, et al. **Cardiovasc Surg** 1995 Aug;3(4):441–4

[Bacterial infections of the abdominal aorta] Knipping L, et al. **Chirurg** 1995 Sep;66(9):887–9 (Eng. Abstr.) **(Ger)**

THERAPY

Fatal aortic rupture following balloon angioplasty of aortic restenosis in aortoarteritis. Sharma S, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):132–3

AORTITIS SYNDROME see **AORTIC ARCH SYNDROMES**

AORTITIS, SYPHILITIC see **SYPHILIS, CARDIOVASCULAR**

AORTOCORONARY BYPASS see **CORONARY ARTERY BYPASS**

AORTOGRAPHY

Sequential helical CT angiography of aortoiliac disease. Raptopoulos V, et al. **AJR Am J Roentgenol** 1996 Jun; 166(6):1347–54

A comparison of iodixanol with iopamidol in aorto–femoral angiography. Verow P, et al. **Br J Radiol** 1995 Sep; 68(813):973–8

Fatal aortic rupture following balloon angioplasty of aortic restenosis in aortoarteritis. Sharma S, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):132–3

Images in cardiovascular medicine. Intra–aortic thrombus producing embolic arterial vascular disease. Lozano P, et al. **Circulation** 1996 Apr 1;93(7):1471

Abdominal aortic coarctation: CT, MRI, and angiographic correlation. Moresco KP, et al. **Comput Med Imaging Graph** 1995 Sep–Oct;19(5):427–30

Morphological change of the 5th aortic arch with tetralogy of Fallot and pulmonary atresia: echocardiographic and angiographic findings [letter] Kishkurno S, et al. **Eur Heart J** 1995 Dec;16(12):2010–1

Angiographic assessment of the stretch–recoil–gain relation after balloon coarctation angioplasty and its relation to late restenosis. Ino T, et al. **Jpn Circ J** 1996 Feb;60(2):102–7

Unusual subclavian steal: bidirectional and antegrade blood flow in the vertebral artery. Mirfakhraee M, et al. **Neuroradiology** 1995 Oct;37(7):503–11

Can helical CT replace aortography in thoracic trauma [editorial; comment] Trerotola SO. **Radiology** 1995 Oct; 197(1):13–5. Comment on: Radiology 1995 Oct;197(1):125–33.

[Circular dissection of the ascending aorta with intimo–intimal invagination. CT diagnosis of a rare form of aortic dissection] Hillemanns A, et al. **Radiologe** 1996 May;36(5):446–8 (Eng. Abstr.) **(Ger)**

[Dissection–like artifact on one–second scanning time CT] Nasu K, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Sep;55(11):727–31 (Eng. Abstr.) **(Jpn)**

ECONOMICS

Blunt thoracic aortic trauma. A cost–utility approach for injury detection. Brasel KJ, et al. **Arch Surg** 1996 Jun; 131(6):619–25; discussion 625–6

METHODS

Three–dimensional time–of–flight MR angiography of the arch of aorta and its major branches: a comparative study with contrast angiography. Kumar S, et al. **Clin Radiol** 1996 Jan;51(1):18–21

AORTOPULMONARY SEPTAL DEFECT

SURGERY

Surgical repair of d–transposition with aortopulmonary window: a case report. Marangi D, et al. **J Thorac Cardiovasc Surg** 1996 Mar;111(3):671–2 (9 ref.)

[Successful repair of distal type of aortopulmonary window by deep hypothermia with circulatory arrest] Fukuchi S, et al. **Kyobu Geka** 1995 Dec;48(13):1137–40 (Eng. Abstr.) **(Jpn)**

AOTINAE

The Santa Lucia strain of Plasmodium falciparum as a model for vaccine studies. II. Development of Aotus vociferans as a model for testing transmission–blocking vaccines. Collins WE, et al. **Am J Trop Med Hyg** 1996 Apr; 54(4):380–5

ANATOMY & HISTOLOGY

Ocular dominance columns in New World monkeys. Livingstone MS. **J Neurosci** 1996 Mar 15;16(6):2086–96

BLOOD

Peripheral blood eosinophilia in owl monkeys is associated with increased eosinophilopoiesis yet depressed recruitment kinetics to the Chemokine RANTES. Albert DL, et al. **Blood** 1996 Sep 1;88(5):1718–24

Hematologic values of the wild–caught karyotype V owl monkey (Aotus vociferans). Málaga CA, et al. **Lab Anim Sci** 1995 Oct;45(5):574–7

GENETICS

Mutations in S–cone pigment genes and the absence of colour vision in two species of nocturnal primate. Jacobs GH, et al. **Proc R Soc Lond B Biol Sci** 1996 Jun 22; 263(1371):705–10

PHYSIOLOGY

Mutations in S–cone pigment genes and the absence of colour vision in two species of nocturnal primate. Jacobs GH, et al. **Proc R Soc Lond B Biol Sci** 1996 Jun 22; 263(1371):705–10

AOTUS TRIVIRGATUS

BLOOD

Serum and urine biochemical diversity among adult wild–caught Aotus nancymae and Saimiri peruviensis. Weller RE, et al. **J Med Primatol** 1996 Jan;25(1):46–52

IMMUNOLOGY

Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Burghaus PA, et al. **Infect Immun** 1996 Sep;64(9):3614–9

PARASITOLOGY

The Santa Lucia strain of Plasmodium falciparum as a model for vaccine studies. I. Development in Aotus lemurinus griseimembra monkeys. Collins WE, et al. **Am J Trop Med Hyg** 1996 Apr;54(4):372–9

Sporozoite transmission of three strains of Plasmodium knowlesi to Aotus and Saimiri monkeys. Sullivan JS, et al. **J Parasitol** 1996 Apr;82(2):268–71

AP-1 ENHANCER-BINDING PROTEIN see **TRANSCRIPTION FACTOR AP-1**

APACHE

Mortality predicted by APACHE II. The effect of changes in physiological values and post–ICU hospital mortality. Goldhill DR, et al. **Anaesthesia** 1996 Aug;51(8):719–23

Health and activity after intensive care. Munn J, et al. **Anaesthesia** 1995 Dec;50(12):1017–21

Development of multiple organ dysfunction syndrome in critically ill patients with perforated viscus. Predictive value of APACHE severity scoring. Barie PS, et al. **Arch Surg** 1996 Jan;131(1):37–43

Correlation between Acute Physiology and Chronic Health Evaluation (APACHE) III score and immunological parameters in critically ill patients with sepsis. Rogy MA, et al. **Br J Surg** 1996 Mar;83(3):396–400

Comparison of APACHE II scoring in liver and kidney transplant recipients versus trauma and general surgical patients in a single intensive–care unit. Sawyer RG, et al. **Clin Transplant** 1995 Oct;9(5):401–5

Age as a component of severity of illness scoring [letter; comment] Barie PS, et al. **Crit Care Med** 1996 May;24(5):898–9

Mortality risk prediction in sepsis [letter; comment] Knaus WA. **Crit Care Med** 1995 Oct;23(10):1793–4. Comment on: Crit Care Med 1995 Feb;23(2):376–93.

Delta APACHE II for predicting course and outcome of nosocomial Staphylococcus aureus bacteremia and its relation to host defense. Yzerman EP, et al. **J Infect Dis** 1996 Apr;173(4):914–9

Severity of disease score as a predictor of mortality after caval filter insertion. McLoughlin RF, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):715–9

Comparative study of intensive care unit (ICU) performance. Livianu J, et al. **Medinfo** 1995;8 Pt 2:1052

Use of APACHE II classification to evaluate outcome and response to therapy in acute renal failure patients in a surgical intensive care unit. van Bommel EF, et al. **Ren Fail** 1995 Nov;17(6):731–42

The severity of disease measurements among Thai medical intensive care unit patients. Kiatboonsri S, et al. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):57–65

[Observed vs expected mortality in the emergency service of a general hospital. Evaluation by the APACHE II and multiple organ failure classification systems] Cabrales–Vargas N, et al. **Gac Med Mex** 1995 Mar–Apr; 131(2):149–55 (Eng. Abstr.) **(Spa)**

[Defects in the prediction of results by APACHE II. An analysis of the errors in predicting the mortality of patients in a critical state (letter; comment)] Rué Monné M, et al. **Med Clin (Barc)** 1995 Oct 7;105(11):436. Comment on: Med Clin (Barc) 1994 Apr 16;102(14):527–31. **(Spa)**

APAMIN

ANALOGS & DERIVATIVES

Photolabile derivatives of 125I–apamin: defining the structural criteria required for labeling high and low molecular mass polypeptides associated with small conductance Ca(2+)–activated K+ channels. Wadsworth JD, et al. **Biochemistry** 1996 Jun 18;35(24):7917–27

METABOLISM

Photolabile derivatives of 125I–apamin: defining the structural criteria required for labeling high and low molecular mass polypeptides associated with small conductance Ca(2+)–activated K+ channels. Wadsworth JD, et al. **Biochemistry** 1996 Jun 18;35(24):7917–27

Pharmacology of the high–affinity apamin receptor in rabbit heart. Schetz JA, et al. **Cardiovasc Res** 1995 Nov; 30(5):755–62

PHARMACOLOGY

Apamin, a selective SK potassium channel blocker, suppresses REM sleep without a compensatory rebound. Benington JH, et al. **Brain Res** 1995 Sep 18;692(1–2):86–92

Neural control of the expression of a Ca(2+)–activated K+ channel involved in the induction of myotonic–like characteristics. Ramírez BU, et al. **Cell Mol Neurobiol** 1996 Feb;16(1):39–49

Rat duodenum nitrergic–induced relaxations are cGMP–independent and apamin–sensitive. Martins SL, et al. **Eur J Pharmacol** 1995 Sep 25;284(3):265–70

Synthesis and pharmacological testing of dequalinium analogues as blockers of the apamin–sensitive Ca(2+)–activated K+ channel: variation of the length of the alkylene chain. Galanakis D, et al. **J Med Chem** 1996 Aug 30;39(18):3592–5

Apamin–sensitive K+ channels mediate an endothelium–dependent hyperpolarization in rabbit mesenteric arteries. Murphy ME, et al. **J Physiol (Lond)** 1995 Dec 15;489 (Pt 3):723–34

Characterization and regulation of apamin–binding K+ channels in skeletal muscle. Vigdor–Alboim S, et al. **Muscle Nerve** 1996 Mar;19(3):331–7

Modulation of Ca2+ oscillation and apamin–sensitive, Ca2+–activated K+ current in rat gonadotropes. Tse A, et al. **Pflugers Arch** 1995 Sep;430(5):645–52

TOXICITY

Compared toxicity of the potassium channel blockers, apamin and dendrotoxin. Lallement G, et al. **Toxicology** 1995 Dec 15;104(1–3):47–52

APATITES

Biodegradable ceramic–collagen composite implanted in rabbit tibiae. Suh H, et al. **ASAIO J** 1995 Jul–Sep; 41(3):M652–6

Apatite coated on organic polymers by biomimetic process: improvement in its adhesion to substrate by NaOH treatment. Tanahashi M, et al. **J Appl Biomater** 1994 Winter;5(4):339–47

Formation of apatite–collagen complexes. Doi Y, et al. **J Biomed Mater Res** 1996 May;31(1):43–9

Comparison of the release of growth hormone from hydroxyapatite, heat–treated hydroxyapatite, and fluoroapatite coatings on titanium. Downes S, et al. **J Biomed Mater Res** 1995 Sep;29(9):1053–60

Bone–bonding behavior under load–bearing conditions of an alumina ceramic implant incorporating beads coated with glass–ceramic containing apatite and wollastonite. Li ZL, et al. **J Biomed Mater Res** 1995 Sep;29(9):1081–8

Effect of crystallization on apatite–layer formation of bioactive glass 45S5. Peitl Filho O, et al. **J Biomed Mater Res** 1996 Apr;30(4):509–14

APATITES

ANALYSIS

Transitional structures in lamellar bone. Ziv V, et al. **Microsc Res Tech** 1996 Feb 1;33(2):203–13

[Analysis of deposits in calcific periarthritis] Hamada J. **Nippon Seikeigeka Gakkai Zasshi** 1995 Nov;69(11):1158–69 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Bonding strength of glass ionomers to dense synthetic hydroxyapatite and fluoroapatite ceramics. Li J, et al. **Acta Odontol Scand** 1996 Feb;54(1):19–23

Apatite formation on (2–x)CaO.x/3 M2O3 x 2SiO2 glasses (M = La, Y; 0 < or = x < or = 0.6) in a simulated body fluid. Fresa R, et al. **Biomaterials** 1995 Nov; 16(16):1249–53

Carbonate hydroxyapatite gel monolith formation and drying. Barralet JE, et al. **Biomed Mater Eng** 1996; 6(2):101–12

X-ray diffraction, electron microscopy, and Fourier transform infrared spectroscopy of apatite crystals isolated from chicken and bovine calcified cartilage. Kim H, et al. **Calcif Tissue Int** 1996 Jul;59(1):58–63

Synergistic effects of magnesium and carbonate on properties of biological and synthetic apatites. LeGeros RZ, et al. **Connect Tissue Res** 1995;33(1–3):203–9

Pyrolysis–gas chromatography of carbonate apatites used for sintering. Doi Y, et al. **J Biomed Mater Res** 1995 Nov; 29(11):1451–7

METABOLISM

The serum protein alpha2–HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. Schinke T, et al. **J Biol Chem** 1996 Aug 23; 271(34):20789–96

PHARMACOLOGY

Effect of calcium phosphate (Ca–P) coatings on trabecular bone response: a histological study. Caulier H, et al. **J Biomed Mater Res** 1995 Sep;29(9):1061–9

The effect of fluorhydroxyapatite–derived fluoride on acid production by streptococci. Guha–Chowdhury N, et al. **J Dent Res** 1995 Sep;74(9):1618–24

APAZONE

CHEMISTRY

Positive interference by azapropazone (Rheumox) in the measurement of total thyroxine using the Ciba–Corning ACS:180 immunoassay analyser. Smart JM, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):424–5

PHARMACOLOGY

Effects of azapropazone on pain–related brain activity in human subjects. Lötsch J, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):545–52

Lack of activity of azapropazone in the hot–plate test and in 5–HT1A and 5–HT2 receptor subtypes in rat brain membranes. Pini LA, et al. **Drugs Exp Clin Res** 1995; 21(5):181–6

THERAPEUTIC USE

Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study. Moral F, et al. **Clin Exp Rheumatol** 1995 Jul–Aug; 13(4):493–5

APC VIRUSES see **ADENOVIRUSES, HUMAN**

APE, BARBARY see **MACACA**

APE, BLACK see **MACACA**

APE, CELEBES see **MACACA**

APE DISEASES

DRUG THERAPY

A remembrance of Fred, the lowland gorilla. Atkinson JP. **Arthritis Rheum** 1996 Jun;39(6):891–3

MICROBIOLOGY

Mycobacterium tuberculosis infection in an orangutan (Pongo pygmaeus). Shin NS, et al. **J Vet Med Sci** 1995 Oct;57(5):951–3

PARASITOLOGY

The Nigerian I/CDC strain of Plasmodium ovale in chimpanzees. Morris CL, et al. **J Parasitol** 1996 Jun; 82(3):444–8

PHYSIOPATHOLOGY

Genetic analysis of serum alanine transaminase activity in normal and hepatitis C virus–infected chimpanzees: an application of research–oriented genetic management. Williams–Blangero S, et al. **Lab Anim Sci** 1996 Feb; 46(1):26–30

VIROLOGY

Complete sequencing of a gibbon hepatitis B virus genome reveals a unique genotype distantly related to the chimpanzee hepatitis B virus. Norder H, et al. **Virology** 1996 Apr 1;218(1):214–23

Sequence analysis of a highly divergent HIV–1–related lentivirus isolated from a wild captured chimpanzee. Vanden Haesevelde MM, et al. **Virology** 1996 Jul 15; 221(2):346–50

APERT SYNDROME see **ACROCEPHALOSYNDACTYLIA**

APES see **PONGIDAE**

APEU VIRUS see **BUNYAVIRUS**

APEX CARDIOGRAPHY see **KINETOCARDIOGRAPHY**

APGAR SCORE

Phenylephrine in treating maternal hypotension due to spinal anaesthesia for caesarean delivery: effects on neonatal catecholamine concentrations, acid base status and Apgar scores. LaPorta RF, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):901–5

Fetal effects of prophylactic ephedrine and maternal hypotension during regional anesthesia for cesarean section. Shearer VE, et al. **J Matern Fetal Med** 1996 Mar–Apr; 5(2):79–84

Understanding the Apgar score. Letko MD. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):299–303

Influence of acid–base status at birth and Apgar scores on survival in 500–1000–g infants. Gaudier FL, et al. **Obstet Gynecol** 1996 Feb;87(2):175–80

Use and abuse of the Apgar score. Committee on Fetus and Newborn, American Academy of Pediatrics, and Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. **Pediatrics** 1996 Jul; 98(1):141–2

[Administration of pethidine in labor with meconium contaminated amniotic fluid: effect on fetal outcome and respiratory disorders] Riehn A, et al. **Z Geburtshilfe Neonatol** 1995 May–Jun;199(3):103–6 (Eng. Abstr.) **(Ger)**

APHAKIA

GENETICS

Lens complementation system for the genetic analysis of growth, differentiation, and apoptosis in vivo. Liégeois NJ, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1303–7

APHAKIA, POSTCATARACT

COMPLICATIONS

Hydrogel intracorneal lenses in aphakic eyes. Steinert RF, et al. **Arch Ophthalmol** 1996 Feb;114(2):135–41

ETIOLOGY

Pediatric aphakic glaucoma: a study of 65 patients. Walton DS. **Trans Am Ophthalmol Soc** 1995;93:403–13; discussion 413–20

PATHOLOGY

Eye growth in the aphakic newborn rabbit. Kugelberg U, et al. **J Cataract Refract Surg** 1996 Apr;22(3):337–41

SURGERY

Differentiated treatment of secondary cataract following extracapsular cataract operation. Adank AM, et al. **Bull Soc Belge Ophtalmol** 1994;254:37–40 (18 ref.)

Epikeratophakia to correct traumatic aphakia after penetrating keratoplasty. Au YK, et al. **J Cataract Refract Surg** 1996 May;22(4):501–3

Transscleral fixation of posterior chamber intraocular lenses in the absence of capsular support. Helal M, et al. **J Cataract Refract Surg** 1996 Apr;22(3):347–51

Evaluation of the results of intraocular lens implantation in Egyptian children. Lucy SH, et al. **Metab Pediatr Syst Ophthalmol** 1994;17(1–4):14–8

[Sandwich intraocular lens implant: a concept for aphakia correction in children] Behrendt S, et al. **Klin Monatsbl Augenheilkd** 1995 Jul;207(1):42–5 (Eng. Abstr.) **(Ger)**

[Secondary intraocular lens implantation in aphakic eyes] Stankiewicz A, et al. **Klin Oczna** 1995 Jul–Sep; 97(7–8):225–6 (Eng. Abstr.) **(Pol)**

[Intraocular metallic crystalline lens for correction of aphakia] Aderikhin IV, et al. **Vestn Oftalmol** 1995 Jul–Sep; 111(3):4–7 (Eng. Abstr.) **(Rus)**

APHANIPTERA see **FLEAS**

APHASIA

see related **LANDAU–KLEFFNER SYNDROME**

The Academy of Aphasia Conference. San Diego, California, November 5, 1995. Abstracts. **Brain Lang** 1995 Oct; 51(1):1–226

Spared written naming of proper nouns: a case report. Cipolotti L, et al. **Memory** 1993 Dec;1(4):289–311

Selective preservation of a lexical category in aphasia: dissociations in comprehension of body parts and geographical place names following focal brain lesion. Goodglass H, et al. **Memory** 1993 Dec;1(4):313–28

Production of proper names: a clinical case study of the effects of phonemic cueing. Semenza C, et al. **Memory** 1993 Dec;1(4):265–80

Selective preservation of place names in an aphasic patient: a short report. Warrington EK, et al. **Memory** 1993 Dec; 1(4):281–8

COMPLICATIONS

What about aphasia? [letter] Gonzalez Rothi LJ. **ASHA** 1996 Winter;38(1):4

Issues arising in contemporary studies of disorders of syntactic processing in sentence comprehension in agrammatic patients. Caplan D. **Brain Lang** 1995 Sep; 50(3):325–38 (37 ref.)

On the relation between representational and processing models of asyntactic comprehension. Cornell TL. **Brain Lang** 1995 Sep;50(3):304–24 (19 ref.)

A time–based approach to agrammatic production. Kolk H. **Brain Lang** 1995 Sep;50(3):282–303 (53 ref.)

Aphasic naming: what matters? Nickels L, et al. **Neuropsychologia** 1995 Oct;33(10):1281–303

Aphasia, dichotic testing and defective hearing. Norrsell U, et al. **Scand J Rehabil Med** 1996 Mar;28(1):19–25

DIAGNOSIS

Syndromes of language dissolution in aging and dementia. Kirshner HS, et al. **Compr Ther** 1995 Sep;21(9):519–23 (30 ref.)

Frenchay Aphasia Screening Test: validity and comparability. Enderby P, et al. **Disabil Rehabil** 1996 May; 18(5):238–40

Acquired epileptiform opercular syndrome: a second case report, review of the literature, and comparison to the Landau–Kleffner syndrome. Shafrir Y, et al. **Epilepsia** 1995 Oct;36(10):1050–7 (32 ref.)

Profiling fluent aphasic spontaneous speech: a comparison of two methodologies. Edwards S. **Eur J Disord Commun** 1995;30(3):333–45

Characterising thematic role assignment in aphasic sentence production: procedures for elicited and spontaneous output. Whitworth A. **Eur J Disord Commun** 1995;30(3):384–99

Migraine with aura and functional psychosis: a rare differential diagnosis [letter] Stiefel FC, et al. **Gen Hosp Psychiatry** 1995 Sep;17(5):389–91

Refractory semantics in global aphasia: on semantic organisation and the access–storage distinction in neuropsychology. Forde E, et al. **Memory** 1995 Sep–Dec; 3(3–4):265–307

Study of unilateral hemisphere performance in children with developmental dysphasia. Duvelleroy–Hommet C, et al. **Neuropsychologia** 1995 Jul;33(7):823–34

Neuroradiological findings in primary progressive aphasia: CT MRI and cerebral perfusion SPECT. Sinnatamby R, et al. **Neuroradiology** 1996 Apr;38(3):232–8

ETIOLOGY

Aphasia in acute stroke: incidence, determinants, and recovery. Pedersen PM, et al. **Ann Neurol** 1995 Oct; 38(4):659–66

Aphasia in acute stroke: incidence, determinants, and recovery [letter] Wertz RT. **Ann Neurol** 1996 Jul; 40(1):129–30

Gesture laterality in aphasic and apraxic stroke patients. Foundas AL, et al. **Brain Cogn** 1995 Nov;29(2):204–13

Slowly progressive aphasia, a left temporal variant of probable Pick's disease: 15 years of follow–up. Kesler A, et al. **Isr J Med Sci** 1995 Oct;31(10):626–8

Global aphasia without hemiparesis. Agarwal V, et al. **J Assoc Physicians India** 1995 Apr;43(4):299

Progressive supranuclear palsy presenting with dynamic aphasia. Esmonde T, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):403–10

Acute aphasia complicating typhoid fever in an adult. Bansal AS, et al. **J Trop Med Hyg** 1995 Dec;98(6):392–4

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 8–1996. A 28–year–old woman with the rapid development of a major personality change and global aphasia [clinical conference] **N Engl J Med** 1996 Mar 14;334(11):715–20

Status epilepticus presenting as progressive dysphasia. Murchison JT, et al. **Neuroradiology** 1995 Aug;37(6):438–9

Kluver–Bucy syndrome following heat stroke in a 12–year–old girl. Pitt DC, et al. **Pediatr Neurol** 1995 Jul; 13(1):73–6

[Chronic subdural hematoma and transient neurologic deficiency (letter)] Hernette D, et al. **Ann Med Interne (Paris)** 1995;146(5):370–3 **(Fre)**

[An unusual autopsy case of corticobasal degeneration—with

special reference to clinicopathological differentiation from progressive supranuclear palsy and slowly progressive aphasia] Tsuchiya K, et al. **No To Shinkei** 1996 Jun; 48(6):559–65 (Eng. Abstr.) **(Jpn)**

HISTORY

The higher and lower in mental life: an essay on J. Hughlings Jackson and Freud. Goldstein RG.
J Am Psychoanal Assoc 1995;43(2):495–515

MORTALITY

Moderate head injuries in children as compared to other age groups, including the cases who had talked and deteriorated. Ceviker N, et al. **Acta Neurochir (Wien)** 1995; 133(3–4):116–21

NURSING

Silent voices. Stumpf MT. **Am J Nurs** 1995 Nov;95(11):72
Pediatric tool adapts to elderly patients [letter] Toth-Fisher C. **Am J Nurs** 1996 May;96(5):18

PHYSIOPATHOLOGY

Surgical approaches to tumors and epileptogenic zones close to Wernicke's area. Cukiert A, et al.
Arq Neuropsiquiatr 1995 Sep;53(3–B):587–91
Lexical–semantic event-related potential effects in patients with left hemisphere lesions and aphasia, and patients with right hemisphere lesions without aphasia. Hagoort P, et al. **Brain** 1996 Apr;119 (Pt 2):627–49
Word comprehension. The distinction between refractory and storage impairments. Warrington EK, et al. **Brain** 1996 Apr;119 (Pt 2):611–25
Tonal coarticulation in Thai after unilateral brain damage. Gandour J, et al. **Brain Lang** 1996 Mar;52(3):505–35
Phonological and lexical coding in verbal short-term memory and learning. Trojano L, et al. **Brain Lang** 1995 Nov;51(2):336–54
The role of the output phonological buffer in the control of speech timing: a single case study. Cohen L, et al. **Cortex** 1995 Sep;31(3):469–86
Modality specific naming and gesture disturbances: a case with optic aphasia, bilateral tactile aphasia, optic apraxia and tactile apraxia. Endo K, et al. **Cortex** 1996 Mar; 32(1):3–28
The representation of arithmetical facts: evidence from two rehabilitation studies. Girelli L, et al. **Cortex** 1996 Mar; 32(1):49–66
Perseveration in two aphasic patients. Papagno C, et al. **Cortex** 1996 Mar;32(1):67–82
Semantic processing without conscious understanding in a global aphasic: evidence from auditory event-related brain potentials. Revonsuo A, et al. **Cortex** 1996 Mar;32(1):29–48
Vestibular stimulation, spatial heminegleect and dysphasia, selective effects. Vallar G, et al. **Cortex** 1995 Sep; 31(3):589–93
Drawing to communicate: a case report of an adult with global aphasia. Ward-Lonergan JM, et al.
Eur J Disord Commun 1995;30(4):475–91
Defective imitation of gestures in patients with damage in the left or right hemispheres. Goldenberg G.
J Neurol Neurosurg Psychiatry 1996 Aug;61(2):176–80
Comparison of personalized cueing and provided cueing on the facilitation of verbal labeling by aphasic subjects. Freed DB, et al. **J Speech Hear Res** 1995 Oct;38(5):1081–90
Towards a unitary account of access dysphasia: a single case study. Cipolotti L, et al. **Memory** 1995 Sep–Dec; 3(3–4):309–32
Primary progressive aphasia and frontal lobe involvement [letter; comment] Bianchetti A, et al. **Neurology** 1996 Jan; 46(1):289–91. Comment on: Neurology 1994 Nov;44(11):2065–72.
Involvement of the healthy hemisphere in recovery from aphasia and motor deficit in patients with cortical ischemic infarction: a transcranial Doppler study. Silvestrini M, et al. **Neurology** 1995 Oct;45(10):1815–20
[Changes in regional cerebral blood flow in nondominant hemisphere during speech task in aphasics.: a PET activation study] Ohyama M, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):865–72 (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

A reverse length effect in dysphasic naming: when elephant is easier than ant. Best W. **Cortex** 1995 Dec;31(4):637–52 (50 ref.)
Consonant harmony as a compensatory mechanism in fluent aphasic speech. Kohn SE, et al. **Cortex** 1995 Dec; 31(4):747–56
Phonological errors in aphasic naming: comprehension, monitoring and lexicality. Nickels L, et al. **Cortex** 1995 Jun;31(2):209–37
Word specific impairments in naming and spelling but not reading. Orpwood L, et al. **Cortex** 1995 Jun;31(2):239–65
Words interact with colors in a globally aphasic patient: evidence from a Stroop–like task. Revonsuo A. **Cortex** 1995 Jun;31(2):377–86
Applying conversation analysis to aphasia: clinical implications and analytic issues. Perkins L.
Eur J Disord Commun 1995;30(3):372–83
Transposition of words as indicators of semantic state in aphasia. Goldfarb R. **Percept Mot Skills** 1996 Feb; 82(1):112–4
[Comparison between anomia with word comprehension difficulty and Gogi aphasia due to lobar atrophy] Yamada N, et al. **No To Shinkei** 1995 Nov;47(11):1059–67 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Role of the nondominant hemisphere and undamaged area during word repetition in poststroke aphasics. A PET activation study. Ohyama M, et al. **Stroke** 1996 May; 27(5):897–903

REHABILITATION

Vocational outcome of aphasic patients following severe traumatic brain injury. Gil M, et al. **Brain Inj** 1996 Jan; 10(1):39–45
Computerised augmentative communication devices for people with dysphasia: design and evaluation. Rostron A, et al. **Eur J Disord Commun** 1996;31(1):11–30
Recovery from aphasia. Farmer LJ.
J Miss State Med Assoc 1996 Aug;37(8):690–3 (52 ref.)

THERAPY

Aphasia in acute stroke: incidence, determinants, and recovery [letter] Wertz RT. **Ann Neurol** 1996 Jul; 40(1):129–30
What about aphasia? [letter] Gonzalez Rothi LJ. **ASHA** 1996 Winter;38(1):4
Aphasia therapy. Code C. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):157–9
What makes a therapy? Some parameters of therapeutic intervention in aphasia. Byng S, et al.
Eur J Disord Commun 1995;30(3):303–16
Drawing to communicate: a case report of an adult with global aphasia. Ward-Lonergan JM, et al.
Eur J Disord Commun 1995;30(4):475–91

APHASIA, ACQUIRED see **APHASIA**

APHASIA, ACQUIRED EPILEPTIC see **LANDAU-KLEFFNER SYNDROME**

APHASIA, AMNESIC see **ANOMIA**

APHASIA, ANOMIC see **ANOMIA**

APHASIA, BROCA

CLASSIFICATION

Varieties of progressive non-fluent aphasia. Cappa SF, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:243–8

COMPLICATIONS

The time course of syntactic activation during language processing: a model based on neuropsychological and neurophysiological data. Friederici AD. **Brain Lang** 1995 Sep;50(3):259–81 (61 ref.)
The breakdown of functional categories and the economy of derivation. Hagiwara H. **Brain Lang** 1995 Jul; 50(1):92–116 (50 ref.)
The elusive character of agrammatism. Kean ML.
Brain Lang 1995 Sep;50(3):369–84 (50 ref.)
Examining the empirical and linguistic bases of current theories of agrammatism. Mauner G. **Brain Lang** 1995 Sep; 50(3):339–68 (48 ref.)
Lexical properties, prosody, and syntax: implications for normal and disordered language. Shapiro LP, et al.
Brain Lang 1995 Aug;50(2):240–57
Syntactic processing in aphasia. Swinney D, et al.
Brain Lang 1995 Aug;50(2):225–39
Training sentence production in agrammatism: implications for normal and disordered language. Thompson CK, et al. **Brain Lang** 1995 Aug;50(2):201–24
Voice onset time production in French–speaking aphasics. Ryalls J, et al. **J Commun Disord** 1995 Sep;28(3):205–15

DIAGNOSIS

Impairments of discourse abilities and executive functions in traumatically brain-injured adults. Coelho CA, et al. **Brain Inj** 1995 Jul;9(5):471–7
Processing of number and gender inflections by French–speaking aphasics. Jakubowicz C, et al.
Brain Lang 1995 Nov;51(2):242–68
Variables and events in the syntax of agrammatic speech. Saddy JD. **Brain Lang** 1995 Aug;50(2):135–50

DRUG THERAPY

Bromocriptine is ineffective in the treatment of chronic nonfluent aphasia. Ozeren A, et al. **Acta Neurol Belg** 1995 Dec;95(4):235–8
Bromocriptine treatment of nonfluent aphasia. Gupta SR, et al. **Neurology** 1995 Dec;45(12):2170–3
A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia. Sabe L, et al.
Neurology 1995 Dec;45(12):2272–4

ETIOLOGY

Preserved speech abilities and compensation following prefrontal damage. Buckner RL, et al.
Proc Natl Acad Sci U S A 1996 Feb 6;93(3):1249–53
[Auditory comprehension in transcortical motor aphasia due to a medial lesions of the left frontal lobe] Otsuki M, et al. **No To Shinkei** 1995 Nov;47(11):1081–5 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Agrammatism in Spanish: a case study. Reznik M, et al.
Brain Lang 1995 Nov;51(2):355–68
Acquired aphasia in children [editorial] Rapin I.
J Child Neurol 1995 Jul;10(4):267–70 (24 ref.)
Comprehension of nonlexical categories in agrammatism. Milekić S, et al. **J Psycholinguist Res** 1995 Jul;24(4):299–311
Neuroanatomical correlates of category-specific semantic disorders: a critical survey. Gainotti G, et al. **Memory** 1995 Sep–Dec;3(3–4):247–64 (50 ref.)
Charting the progression in semantic dementia: implications for the organisation of semantic memory. Hodges JR, et al. **Memory** 1995 Sep–Dec;3(3–4):463–95
Investigating semantic memory impairments: the contribution of semantic priming. Moss HE, et al. **Memory** 1995 Sep–Dec;3(3–4):359–95
[Auditory comprehension in transcortical motor aphasia due to a medial lesions of the left frontal lobe] Otsuki M, et al. **No To Shinkei** 1995 Nov;47(11):1081–5 (Eng. Abstr.) **(Jpn)**
[Hemispheric functional specialization in motor aphasia. Neurophysiologic findings with computerized electroencephalographic brain mapping during musical and oral sound stimulation. Study of 2 cases] Muszkat M, et al. **Arq Neuropsiquiatr** 1995 Mar;53(1):88–93 (Eng. Abstr.) **(Por)**

PSYCHOLOGY

Profiling agrammatic spoken language: towards a government and binding framework. McEntee LJ, et al.
Eur J Disord Commun 1995;30(3):317–32

REHABILITATION

Melodic intonation therapy in the verbal decoding of aphasics. Popovici M. **Rom J Neurol Psychiatry** 1995 Jan–Mar;33(1):57–97

APHASIA, CONDUCTION

DIAGNOSIS

Levels of representation and units of access relevant to agrammatism. Kegl J. **Brain Lang** 1995 Aug;50(2):151–200

ETIOLOGY

"Semantic" conduction aphasia from a posterior insular cortex infarction. Marshall RS, et al. **J Neuroimaging** 1996 Jul; 6(3):189–91

APHASIA, EPILEPTIC, ACQUIRED see **LANDAU-KLEFFNER SYNDROME**

APHASIA, EXPRESSIVE see **APHASIA, BROCA**

APHASIA, FLUENT see **APHASIA, WERNICKE**

APHASIA, MOTOR see **APHASIA, BROCA**

APHASIA, NOMINAL see **ANOMIA**

APHASIA, NONFLUENT see **APHASIA, BROCA**

APHASIA, PRIMARY PROGRESSIVE

see related
ALZHEIMER'S DISEASE

DIAGNOSIS

[Progressive aphasia without dementia—the onset of an atrophic process of the brain] Kadykov AS, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1996;96(1):42–4 (11 ref.) (Eng. Abstr.) **(Rus)**

APHASIA, RECEPTIVE see **APHASIA, WERNICKE**

APHASIA, SENSORY see **APHASIA, WERNICKE**

APHASIA TESTS see **NEUROPSYCHOLOGICAL TESTS**

APHASIA, WERNICKE

COMPLICATIONS

Lexical properties, prosody, and syntax: implications for normal and disordered language. Shapiro LP, et al.
Brain Lang 1995 Aug;50(2):240–57
Voice onset time production in French–speaking aphasics. Ryalls J, et al. **J Commun Disord** 1995 Sep;28(3):205–15

DIAGNOSIS

Coherence violations and propositional usage in the narratives of fluent aphasics. Christiansen JA.
Brain Lang 1995 Nov;51(2):291–317

APHASIA, WERNICKE

Processing of number and gender inflections by French-speaking aphasics. Jakubowicz C, et al. **Brain Lang** 1995 Nov;51(2):242-68

Objects and properties: a study of the breakdown of semantic memory. Funnell E. **Memory** 1995 Sep-Dec;3(3-4):497-518

ETIOLOGY

[50-year-old patient with dyspnea, dizziness, palpitations and brief sensory aphasia] Hager A, et al. **Z Aratl Fortbild (Jena)** 1995 Dec;89(7):735-8 (Eng. Abstr.) **(Ger)**

[Anterior choroidal artery territory infarction with transcortical sensory aphasia after a neck clipping of left internal carotid artery aneurysms: a case report] Takei A, et al. **No Shinkei Geka** 1996 Jan;24(1):63-7 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Quantification of cortical atrophy in a case of progressive fluent aphasia. Harasty JA, et al. **Brain** 1996 Feb;119 (Pt 1):181-90

PHYSIOPATHOLOGY

Acquired aphasia in children [editorial] Rapin I. **J Child Neurol** 1995 Jul;10(4):267-70 (24 ref.)

Semantic neglect? [letter] Anderson B. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):349-50

Neuroanatomical correlates of category-specific semantic disorders: a critical survey. Gainotti G, et al. **Memory** 1995 Sep-Dec;3(3-4):247-64 (50 ref.)

PSYCHOLOGY

Quantification of cortical atrophy in a case of progressive fluent aphasia. Harasty JA, et al. **Brain** 1996 Feb;119 (Pt 1):181-90

REHABILITATION

Melodic intonation therapy in the verbal decoding of aphasics. Popovici M. **Rom J Neurol Psychiatry** 1995 Jan-Mar;33(1):57-97

APHERESIS see **BLOOD COMPONENT REMOVAL**

APHIDICOLIN

ADMINISTRATION & DOSAGE

Augmentation by aphidicolin of 1-beta-D-arabinofuranosylcytosine-induced c-jun and NF-kappa B activation in a human myeloid leukemia cell line: correlation with apoptosis. Kuwakado K, et al. **Leuk Res** 1995 Sep;19(9):645-50

ANALOGS & DERIVATIVES

Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta. Moynihan K, et al. **Cancer Chemother Pharmacol** 1996;38(4):349-54

PHARMACOLOGY

Increased expression of aphidicolin-induced common fragile sites in Tourette syndrome: the key to understand the genetics of comorbid phenotypes? Gericke GS, et al. **Am J Med Genet** 1996 Feb 16;67(1):25-30

Aphidicolin large-scale synchronization of rapidly dividing cell monolayers and the analysis of total histone and histone variant biosynthesis during the S and G2 phases of the HEp-2 cell cycle. Sourlingas TG, et al. **Anal Biochem** 1996 Feb 1;234(1):104-7

BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Yin DX, et al. **Cancer Res** 1995 Nov 1; 55(21):4922-8

Effect of aphidicolin on DNA synthesis in cultured human thyroid cells. Okugawa T, et al. **Exp Clin Endocrinol Diabetes** 1995;103(2):88-93

Precise localization of aphidicolin-induced breakpoints on the short arm of human chromosome 3. Paradee W, et al. **Genomics** 1995 May 20;27(2):358-61

A 350-kb cosmid contig in 3p14.2 that crosses the t(3;8) hereditary renal cell carcinoma translocation breakpoint and 17 aphidicolin-induced FRA3B breakpoints. Paradee W, et al. **Genomics** 1996 Jul 1;35(1):87-93

Live analysis of free centrosomes in normal and aphidicolin-treated Drosophila embryos. Debec A, et al. **J Cell Biol** 1996 Jul;134(1):103-15

Effects of cell-cycle-arrest agents on cleavage and development of mouse embryos. Samaké S, et al. **J Exp Zool** 1996 Feb 1;274(2):111-20

TOXICITY

Susceptibility of heterochromatin to aphidicolin-induced chromosomal breakage. Dominguez AM, et al. **Hum Genet** 1995 Nov;96(5):516-20

APHIDS

[A preliminary study on bioactivity of orange and tangerine peel extracts against aphis and mites] Fan Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Jul;20(7):397-8, 446 (Eng. Abstr.) **(Chi)**

CHEMISTRY

The aphid sex pheromone cyclopentanoids: synthesis in the elucidation of structure and biosynthetic pathways. Dawson GW, et al. **Bioorg Med Chem** 1996 Mar;4(3):351-61

ENZYMOLOGY

Changes in the methylation of amplified esterase DNA during loss and reselection of insecticide resistance in peach-potato aphids, Myzus persicae. Hick CA, et al. **Insect Biochem Mol Biol** 1996 Jan;26(1):41-7

Numerous transposed sequences of mitochondrial cytochrome oxidase I-II in aphids of the genus Sitobion (Hemiptera: Aphididae). Sunnucks P, et al. **Mol Biol Evol** 1996 Mar;13(3):510-24

GENETICS

Analysis of amplicons containing the esterase genes responsible for insecticide resistance in the peach-potato aphid Myzus persicae (Sulzer). Field LM, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):543-7

Numerous transposed sequences of mitochondrial cytochrome oxidase I-II in aphids of the genus Sitobion (Hemiptera: Aphididae). Sunnucks P, et al. **Mol Biol Evol** 1996 Mar;13(3):510-24

Spatial and temporal genetic variation in British field populations of the grain aphid Sitobion avenae (F.) (Hemiptera: Aphididae) studied using RAPD-PCR. De Barro PJ, et al. **Proc R Soc Lond B Biol Sci** 1995 Dec 22;262(1365):321-7

Molecular characterization of cyclic and obligate parthenogens in the aphid Rhopalosiphum padi (L.). Simon JC, et al. **Proc R Soc Lond B Biol Sci** 1996 Apr 22; 263(1369):481-6

GROWTH & DEVELOPMENT

Molecular characterization of cyclic and obligate parthenogens in the aphid Rhopalosiphum padi (L.). Simon JC, et al. **Proc R Soc Lond B Biol Sci** 1996 Apr 22; 263(1369):481-6

MICROBIOLOGY

Genetics, physiology, and evolutionary relationships of the genus Buchnera: intracellular symbionts of aphids. Baumann P, et al. **Annu Rev Microbiol** 1995;49:55-94 (179 ref.)

The endosymbiont (Buchnera sp.) of the aphid Diuraphis noxia contains plasmids consisting of trpEG and tandem repeats of trpEG pseudogenes. Lai CY, et al. **Appl Environ Microbiol** 1996 Feb;62(2):332-9

Cloning and characterization of the ribosomal protein genes in the spc operon of a prokaryotic endosymbiont of the pea aphid, Acyrthosiphon kondoi. Abe R, et al. **DNA Res** 1994;1(3):103-14

Phylogenetic position of yeast-like symbiont of Hamiltonaphis styraci (Homoptera, Aphididae) based on 18S rDNA sequence. Fukatsu T, et al. **Insect Biochem Mol Biol** 1996 Apr;26(4):383-8

The tryptophan biosynthetic pathway of aphid endosymbionts (Buchnera): genetics and evolution of plasmid-associated anthranilate synthase (trpEG) within the aphididae. Rouhbakhsh D, et al. **J Mol Evol** 1996 Apr; 42(4):414-21

PHYSIOLOGY

The evolution of soldiers in aphids. Stern DL, et al. **Biol Rev Camb Philos Soc** 1996 Feb;71(1):27-79 (166 ref.)

VIROLOGY

Ultrastructural study of acquisition and retention of potato leafroll luteovirus in the alimentary canal of its aphid vector, Myzus persicae Sulz. Garret A, et al. **Arch Virol** 1996;141(7):1279-92

Improved diagnosis of cowpea aphid-borne mosaic virus in Africa: significance for cowpea seed-indexing, breeding programs and potyvirus taxonomy. Huguenot C, et al. **Arch Virol** 1996;141(1):137-45

Loss of potyvirus transmissibility and helper-component activity correlate with non-retention of virions in aphid stylets. Wang RY, et al. **J Gen Virol** 1996 May;77 (Pt 5):861-7

Detection of potato leafroll virus in single aphids by the reverse transcription polymerase chain reaction and its potential epidemiological application. Singh RP, et al. **J Virol Methods** 1995 Sep;55(1):133-43

Aphid transmission and systemic plant infection determinants of barley yellow dwarf luteovirus-PAV are contained in the coat protein readthrough domain and 17-kDa protein, respectively. Chay CA, et al. **Virology** 1996 May 1; 219(1):57-65

Inhibition of viral aphid transmission by the N-terminus of the maize dwarf mosaic virus coat protein. Salomon R, et al. **Virology** 1995 Nov 10;213(2):676-9

Reason for non-aphid transmissibility in a strain of Kalanchoë mosaic potyvirus. Husted K. **Virus Genes** 1995;11(1):59-61

APHONIA

PSYCHOLOGY

Psychological processes in psychogenic voice disorder. Butcher P. **Eur J Disord Commun** 1995;30(4):467-74 (15 ref.)

THERAPY

Successful therapy for psychological aphonia [letter] Tsunoda K, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):119

APHORISMS AND PROVERBS

"Fischerisms" [editorial] South D. **J Miss State Med Assoc** 1996 May;37(5):583-6

Proverb interpretation to assess mental status. Lansinger T. **J Nurs Educ** 1995 Sep;34(6):290-1

APHRODISIACS

ADVERSE EFFECTS

Agranulocytosis associated with yohimbine use [letter] Siddiqui MA, et al. **Arch Intern Med** 1996 Jun 10; 156(11):1235-6, 1238

PHARMACOLOGY

Effect of ambrein, a major constituent of ambergris, on masculine sexual behavior in rats. Taha SA, et al. **Arch Int Pharmacodyn Ther** 1995 Mar-Apr;329(2):283-94

POISONING

Digoxinlike toxicity and death from a purported aphrodisiac [letter; comment] Pierach CA. **JAMA** 1996 Apr 3; 275(13):988. Comment on: JAMA 1995 Dec 20;274(23):1828-9.

Deaths associated with a purported aphrodisiac--New York City, February 1993-May 1995. **MMWR Morb Mortal Wkly Rep** 1995 Nov 24;44(46):853-5, 861

[Acute voluntary poisoning by inhalation of "poppers" (letter)] Badoual T, et al. **Presse Med** 1996 Feb 24;25(7):304 **(Fre)**

THERAPEUTIC USE

Treatment for potency problems with Afrodor 2000. Baumbusch F, et al. **Acta Chir Hung** 1995-96;35(1-2):87-92

APHTHAE see **STOMATITIS, APHTHOUS**

APHTHOVIRUS

CHEMISTRY

Structural comparison of two strains of foot-and-mouth disease virus subtype O1 and a laboratory antigenic variant, G67. Lea S, et al. **Structure** 1995 Jun 15;3(6):571-80

CLASSIFICATION

Equine rhinovirus 1 is more closely related to foot-and-mouth disease virus than to other picornaviruses. Li F, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):990-5

DRUG EFFECTS

Amitraz effects on foot-and-mouth disease virus in mammalian cells in vitro. D'Angelo M, et al. **Ecotoxicol Environ Saf** 1996 Mar;33(2):163-7

Alteration of the trypsin-sensitive antigenic site of foot-and-mouth disease virus following direct binding to an ELISA plate [letter] Pattnaik B, et al. **J Immunol Methods** 1996 Jun 10;192(1-2):195-7

ENZYMOLOGY

Identification of the active-site residues of the 3C proteinase of foot-and-mouth disease virus. Grubman MJ, et al. **Virology** 1995 Nov 10;213(2):581-9

Identification of critical amino acids within the foot-and-mouth disease virus leader protein, a cysteine protease. Roberts PJ, et al. **Virology** 1995 Oct 20; 213(1):140-6

[Nucleotide sequence of the RNA polymerase gene attenuated by a variant of foot-and-mouth disease virus and its comparison with the virulence of related variants of subtype A22] Lomakina NF, et al. **Mol Gen Mikrobiol Virusol** 1996 Jan-Mar;(1):35-40 (Eng. Abstr.) **(Rus)**

GENETICS

Detection of foot-and-mouth disease viral sequences in various fluids and tissues during persistence of the virus in cattle. Bergmann IE, et al. **Am J Vet Res** 1996 Feb; 57(2):134-7

Molecular epidemiology of foot-and-mouth disease (FMD) in Israel in 1994 and in other Middle-Eastern countries in the years 1992-1994. Stram Y, et al. **Arch Virol** 1995; 140(10):1791-7

Porcine polypyrimidine tract-binding protein stimulates

translation initiation at the internal ribosome entry site of foot-and-mouth-disease virus. Niepmann M. **FEBS Lett** 1996 Jun 10;388(1):39-42

Systematic replacement of amino acid residues within an Arg-Gly-Asp-containing loop of foot-and-mouth disease virus and effect on cell recognition. Mateu MG, et al. **J Biol Chem** 1996 May 31;271(22):12814-9

Recognition of the initiation codon for protein synthesis in foot-and-mouth disease virus RNA. Thomas AA, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):265-72

Identification of an essential region for internal initiation of translation in the aphthovirus internal ribosome entry site and implications for viral evolution. Martínez-Salas E, et al. **J Virol** 1996 Feb;70(2):992-8

High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site. Ramesh N, et al. **Nucleic Acids Res** 1996 Jul 15; 24(14):2697-700

Equine rhinovirus 1 is more closely related to foot-and-mouth disease virus than to other picornaviruses. Li F, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6; 93(3):990-5

Structural comparison of two strains of foot-and-mouth disease virus subtype O1 and a laboratory antigenic variant, G67. Lea S, et al. **Structure** 1995 Jun 15;3(6):571-80

A highly divergent antigenic site of foot-and-mouth disease virus retains its immunodominance. Borrego B, et al. **Viral Immunol** 1995;8(1):11-8

[Cloning fragments of the RNA polymerase gene of an attenuated variant of the foot-and-mouth disease virus A22] Lomakina NF, et al. **Mol Gen Mikrobiol Virusol** 1995 Apr-Jun;(2):33-6 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Liquid-phase blocking sandwich enzyme-linked immunosorbent assay for detection of antibodies against foot-and-mouth disease virus in water buffalo sera. Araújo JP, et al. **Am J Vet Res** 1996 Jun;57(6):840-3

In vitro synthesis of foot-and-mouth disease virus specific antibodies by porcine leukocytes. Rodríguez A, et al. **Arch Virol** 1995;140(9):1645-52

Investigation of an outbreak of foot-and-mouth disease in vaccinated dairy cattle in Thailand. Gleeson LJ, et al. **Aust Vet J** 1995 Jan;72(1):21-4

The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease. Kitching RP, et al. **Br Vet J** 1995 Jul-Aug; 151(4):379-89 (40 ref.)

Foot-and-mouth disease. Challenge of cattle after multiple vaccinations. Straub OC. **Comp Immunol Microbiol Infect Dis** 1995 Sep;18(4):253-7

The use of cyclophosphamide as an enhancer of the vaccine against foot-and-mouth disease. Portiansky EL, et al. **Experientia** 1996 Jun 15;52(6):605-7

A protective anti-peptide antibody against the immunodominant site of the A24 Cruzeiro strain of foot-and-mouth disease virus and its reactivity with other subtype viruses containing the same minimum binding sequence. Barnett PV, et al. **J Gen Virol** 1996 May;77 (Pt 5):1011-8

Recognition of foot-and-mouth disease virus and its capsid protein VP1 by bovine peripheral T lymphocytes. Garcia-Valcarcel M, et al. **J Gen Virol** 1996 Apr;77 (Pt 4):727-35

Antibody and host cell recognition of foot-and-mouth disease virus (serotype C) cleaved at the Arg-Gly-Asp (RGD) motif: a structural interpretation. Hernández J, et al. **J Gen Virol** 1996 Feb;77 (Pt 2):257-64

Alteration of the trypsin-sensitive antigenic site of foot-and-mouth disease virus following direct binding to an ELISA plate [letter] Pattnaik B, et al. **J Immunol Methods** 1996 Jun 10;192(1-2):195-7

Induced pocket to accommodate the cell attachment Arg-Gly-Asp motif in a neutralizing antibody against foot-and-mouth-disease virus. Verdaguer N, et al. **J Mol Biol** 1996 Feb 23;256(2):364-76

Sequence identification of antigenic variants in plaque isolates of foot-and-mouth disease virus. Meyer RF, et al. **J Virol Methods** 1995 Oct;55(2):281-3

Identification of native foot-and-mouth disease virus non-structural protein 2C as a serological indicator to differentiate infected from vaccinated livestock. Lubroth J, et al. **Res Vet Sci** 1995 Jul;59(1):70-8

Quantitative risk analysis applied to innocuity and potency tests on the oil-adjuvanted vaccine against foot and mouth disease in Argentina. Cané BG, et al. **Rev Sci Tech** 1995 Dec;14(4):1097-119 (5 ref.) **(Eng, Spa)**

Serological comparison of type A foot and mouth disease virus isolates from Thailand. Doughty WJ, et al. **Rev Sci Tech** 1995 Sep;14(3):547-55

Serological comparison of type Asia 1 foot and mouth disease virus isolates from Thailand. Doughty WJ, et al. **Rev Sci Tech** 1995 Sep;14(3):539-46

Selection of vaccine strains of foot and mouth disease virus for use in southern Africa. Fargeaud D. **Rev Sci Tech** 1995 Sep;14(3):521-38

Multiple-infected diagnostic specimens from foot and mouth disease endemic regions. Ferris NP, et al. **Rev Sci Tech** 1995 Sep;14(3):557-65

Absence of protein 2C from clarified foot-and-mouth disease virus vaccines provides the basis for distinguishing convalescent from vaccinated animals. Lubroth J, et al. **Vaccine** 1996 Apr;14(5):419-27

Isotype profiles induced in Balb/c mice during foot and mouth disease (FMD) virus infection or immunization with different FMD vaccine formulations. Pérez Filgueira DM, et al. **Vaccine** 1995 Jul;13(10):953-60

Assessment of foot and mouth disease vaccine potency by liquid-phase blocking ELISA: a proposal for an alternative to the challenge procedure in Argentina. Robiolo B, et al. **Vaccine** 1995 Oct;13(14):1346-52

Immune response of calves to foot-and-mouth disease virus vaccine emulsified with oil adjuvant. Strategies of vaccination. Späth EJ, et al. **Vaccine** 1995 Jul;13(10):909-14

Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines. Twomey T, et al. **Vaccine** 1995 Nov;13(16):1603-10

A highly divergent antigenic site of foot-and-mouth disease virus retains its immunodominance. Borrego B, et al. **Viral Immunol** 1995;8(1):11-8

A 10-amino-acid linear sequence of VP1 of foot and mouth disease virus containing B- and T-cell epitopes induces protection in mice. Zamorano P, et al. **Virology** 1995 Oct 1;212(2):614-21

[Mechanisms involved in the prolonged humoral immune response: behavior of aphthous fever virus] Wigdorovitz A, et al. **Rev Argent Microbiol** 1996 Jan-Mar;28(1):45-54 (45 ref.) (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Rapid and sensitive polymerase chain reaction based detection and typing of foot-and-mouth disease virus in clinical samples and cell culture isolates, combined with a simultaneous differentiation with other genomically and/or symptomatically related viruses. Vangrysperre W, et al. **Arch Virol** 1996;141(2):331-44

Assessment of variation in trypsin-sensitive neutralizable antigenic site of type O foot-and-mouth disease virus (FMDV) isolates using a Mab-binding inhibition assay [letter] Pattnaik B, et al. **J Immunol Methods** 1996 Jun 10; 192(1-2):191-3

Localization of foot and mouth disease virus RNA in tissue culture infected cells via in situ polymerase chain reaction. Prato Murphy ML, et al. **J Virol Methods** 1995 Aug; 54(2-3):173-8

Quantification of whole virus particles (146S) of foot-and-mouth disease virus in the presence of virus subunits (12S), using monoclonal antibodies in a sandwich ELISA. Crowther JR, et al. **Vaccine** 1995 Aug; 13(12):1064-75

Antigenic variants in a plaque-isolate of foot-and-mouth disease virus: implications for vaccine production. Piatti P, et al. **Vaccine** 1995;13(8):781-4 (23 ref.)

PATHOGENICITY

Virulence as a positive trait in viral persistence. Sáiz JC, et al. **J Virol** 1996 Sep;70(9):6410-3

PHYSIOLOGY

The persistence of foot-and-mouth disease virus on wool. McColl KA, et al. **Aust Vet J** 1995 Aug;72(8):286-92

Protective effect of lidocaine in the experimental foot-and-mouth disease pancreatitis. Portiansky EL, et al. **Experientia** 1995 Nov 15;51(11):1060-2

Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system. Abrams CC, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3089-98

Persistent infection of African buffalo (Syncerus caffer) with SAT-type foot-and-mouth disease viruses: rate of fixation of mutations, antigenic change and interspecies transmission. Vosloo W, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1457-67

Chimeric hepatitis B virus core particles as probes for studying peptide-integrin interactions. Chambers MA, et al. **J Virol** 1996 Jun;70(6):4045-52

Virulence as a positive trait in viral persistence. Sáiz JC, et al. **J Virol** 1996 Sep;70(9):6410-3

Foot and mouth disease virus replication in bovine skin Langerhans cells under in vitro conditions detected by RT-PCR. David D, et al. **Virus Genes** 1995;10(1):5-13

Susceptibility of llamas (Lama glama) to infection with foot-and-mouth-disease virus. Fondevila NA, et al. **Zentralbl Veterinarmed [B]** 1995 Dec;42(10):595-9

APICOECTOMY

Healing of apical periodontitis in dogs after apicoectomy and retrofilling with various filling materials. Trope M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):221-8

[Clinical and roentgenologic outcome evaluation after apicoectomy with zirconium oxide ceramic pins--a prospective study of 112 apicoectomy teeth] Schultze-Mosgau S, et al. **Fortschr Kiefer Gesichtschir** 1995;40:144-7 (Eng. Abstr.) (Ger)

METHODS

A 5 year audit of outcome of apicectomies carried out in a district general hospital [letter] [see comments] Beckett H, et al. **Ann R Coll Surg Engl** 1995 Nov;77(6):465. Comment in: Ann R Coll Surg Engl 1996 Jan;78(1):74.

Periodontal status following trapezoidal and semilunar flaps in apicectomy. Chindia ML, et al. **East Afr Med J** 1995 Sep;72(9):564-7

[Prospective comparative randomized study of tooth apex resection and orthograde root filling with Guttapercha and titanium pins] Gath HJ, et al. **Fortschr Kiefer Gesichtschir** 1995;40:142-3 (Eng. Abstr.) (Ger)

[Advantages of microsurgical apicoectomy and retro-preparation with ultrasound compared with current apicoectomy] Haas R, et al. **Fortschr Kiefer Gesichtschir** 1995;40:156-9 (Eng. Abstr.) (Ger)

[Results of follow-up after apicoectomy with 2 different root canal filling materials] Herzog U, et al. **Fortschr Kiefer Gesichtschir** 1995;40:150-2 (Eng. Abstr.) (Ger)

[Comparative studies with apicoectomy using various surgical techniques and filling materials] Reinhart E, et al. **Fortschr Kiefer Gesichtschir** 1995;40:152-6 (Eng. Abstr.) (Ger)

APICOMPLEXA

CHEMISTRY

Suppression of chemiluminescence of eastern oyster (Crassostrea virginica) hemocytes by the protozoan parasite Perkinsus marinus. Volety AK, et al. **Dev Comp Immunol** 1995 Mar-Apr;19(2):135-42

CLASSIFICATION

Phylogeny of the large extrachromosomal DNA of organisms in the phylum Apicomplexa. Egea N, et al. **J Eukaryot Microbiol** 1996 Mar-Apr;43(2):158

Phylogeny of the large extrachromosomal DNA of organisms in the phylum Apicomplexa. Egea N, et al. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):679-84

The genus Hepatozoon (Apicomplexa: Adeleina). Smith TG. **J Parasitol** 1996 Aug;82(4):565-85 (118 ref.)

GENETICS

Phylogeny of the large extrachromosomal DNA of organisms in the phylum Apicomplexa. Egea N, et al. **J Eukaryot Microbiol** 1995 Nov-Dec;42(6):679-84

IMMUNOLOGY

In vitro interaction of Perkinsus marinus merozoites with eastern and Pacific oyster hemocytes. La Peyre JF, et al. **Dev Comp Immunol** 1995 Jul-Aug;19(4):291-304

ISOLATION & PURIFICATION

Klossiella equi infection in horses; sporocyst stage identified in urine. Reppas GP, et al. **Aust Vet J** 1995 Aug;72(8):316-8

METABOLISM

Acute osmotic tolerance of cultured cells of the oyster pathogen Perkinsus marinus (Apicomplexa:Perkinsida). Burreson EM, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):575-82

PHYSIOLOGY

Parasitism of Aedes aegypti and Ae. albopictus (Diptera: Culicidae) by Ascogregarina spp. (Apicomplexa: Lecudinidae) in Florida. Blackmore MS, et al. **J Med Entomol** 1995 Nov;32(6):847-52

Hemosporid (Apicomplexa, Hematozoea, Hemosporida) community structure off pattern in wintering wild turkeys. Fedynich AM, et al. **J Wildl Dis** 1995 Jul;31(3):404-9

Histopathologic features of naturally occurring hepatozoonosis in wild martens (Martes melampus) in Japan. Yanai T, et al. **J Wildl Dis** 1995 Apr;31(2):233-7

APIS VENOMS see **BEE VENOMS**

APLASIA CUTIS CONGENITA see **ECTODERMAL DYSPLASIA**

APLYSIA

ANATOMY & HISTOLOGY

FMRFamide is endogenous to the Aplysia heart. Harris LL, et al. **Cell Tissue Res** 1995 Nov;282(2):331-41

CHEMISTRY

Aplysia limacina myoglobin cDNA cloning: an alternative mechanism of oxygen stabilization as studied by active-site mutagenesis. Cutruzzolà F, et al. **Biochem J** 1996 Feb 15; 314 (Pt 1):83-90

Primary structure of a new neuropeptide, cerebral peptide 2, purified from cerebral ganglia of Aplysia. Phares GA, et al. **Biochemistry** 1996 May 7;35(18):5921-7

The hemocyanin of the Californian black sea hare, Aplysia vaccaria Winkler. Herskovits TT, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Mar; 110(3):515-21

Structural analysis of a novel triphosphonoglycosphingolipid from the egg of the sea hare, Aplysia kurodai. Yamada S, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):794-9

APLYSIA

CYTOLOGY

The neuroendocrine bag cells of Aplysia: a model system for neural control of hormone secretion. Wayne NL. **J Endocrinol** 1995 Oct;147(1):1–4

ENZYMOLOGY

Stereochemistry of the Aplysia neuronal 12–lipoxygenase: specific potentiation of FMRFamide action by 12(S)–HPETE. Abe M, et al. **Brain Res** 1995 Jun 19; 683(2):200–8

Molecular cloning of prohormone convertase 1 from the atrial gland of Aplysia. Gorham EL, et al. **DNA Cell Biol** 1996 Apr;15(4):339–45

Phosphorylation of myosin regulatory light chains by the molluscan twitchin kinase. Heierhorst J, et al. **Eur J Biochem** 1995 Oct 15;233(2):426–31

Identification, purification, and characterization of the molecular forms of Aplysia californica peptidylglycine alpha–amidating enzyme. Boudreault A, et al. **J Neurochem** 1996 Jun;66(6):2596–605

Expression and characterization of Aplysia protein kinase C: a negative regulatory role for the E region. Sossin WS, et al. **J Neurosci** 1996 Jan;16(1):10–8

Crystallization of ADP–ribosyl cyclase from Aplysia californica. Pradas GS, et al. **Proteins** 1996 Jan;24(1):138–40

GENETICS

Primary structure of a new neuropeptide, cerebral peptide 2, purified from cerebral ganglia of Aplysia. Phares GA, et al. **Biochemistry** 1996 May 7;35(18):5921–7

Molecular cloning of prohormone convertase 1 from the atrial gland of Aplysia. Gorham EL, et al. **DNA Cell Biol** 1996 Apr;15(4):339–45

Molecular cloning of the defense factor in the albumen gland of the sea hare Aplysia kurodai. Takamatsu N, et al. **FEBS Lett** 1995 Dec 27;377(3):373–6

METABOLISM

Ag, a novel protein secreted from Aplysia glia. Lockhart ST, et al. **J Neurobiol** 1996 Jan;29(1):35–48

Axotomy induces a transient and localized elevation of the free intracellular calcium concentration to the millimolar range. Ziv NE, et al. **J Neurophysiol** 1995 Dec; 74(6):2625–37

Cloning and characterization of two related serotonergic receptors from the brain and the reproductive system of Aplysia that activate phospholipase C. Li XC, et al. **J Neurosci** 1995 Nov;15(11):7585–91

A syntaxin–related protein controls acetylcholine release by different mechanisms in Aplysia. Smirnova T, et al. **Neuroscience** 1995 Sep;68(1):125–33

PHYSIOLOGY

Alterations in the action potential of Aplysia neurons evoked by a phorbolester are mediated by protein kinase C. Papp A, et al. **Brain Res** 1995 Jun 26;684(1):107–11

Effects of temperature on reproductive neuroendocrine function in Aplysia californica. Wayne NL, et al. **Gen Comp Endocrinol** 1996 Jun;102(3):351–9

The use of a reversible transcription inhibitor, DRB, to investigate the involvement of specific proteins in the ocular circadian system of Aplysia. Koumenis C, et al. **J Biol Rhythms** 1996 Mar;11(1):45–56

Recovery of function, peripheral sensitization and sensory neurone activation by novel pathways following axonal injury in Aplysia californica. Dulin MF, et al. **J Exp Biol** 1995 Oct;198 (Pt 10):2055–66

Characterization and modulation of Na+ and Ca2+ currents underlying the action potential in bag cells of two species of Aplysia. Fieber LA. **J Exp Biol** 1995 Nov;198 (Pt 11):2337–47

Peripheral regeneration and central sprouting of sensory neurone axons in Aplysia californica following nerve injury. Steffensen I, et al. **J Exp Biol** 1995 Oct;198 (Pt 10):2067–78

Motor neuronal control of tail–directed and head–directed siphon responses in Aplysia californica. Hickie C, et al. **J Neurophysiol** 1995 Jul;74(1):307–21

Persistent activation of cAMP–dependent protein kinase by regulated proteolysis suggests a neuron–specific function of the ubiquitin system in Aplysia. Chain DG, et al. **J Neurosci** 1995 Nov;15(11):7592–603

Consequences and mechanisms of spike broadening of R20 cells in Aplysia californica. Ma M, et al. **J Neurosci** 1995 Oct;15(10):6720–34

Recovery of tail–elicited siphon–withdrawal reflex following unilateral axonal injury is associated with ipsi– and contralateral changes in gene expression in Aplysia californica. Noel F, et al. **J Neurosci** 1995 Oct; 15(10):6926–38

The biochemistry of learning and memory. Fagnou DD, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:279–86 (84 ref.)

Molecular enhancement of memory formation. Carew TJ. **Neuron** 1996 Jan;16(1):5–8 (24 ref.)

Evidence for synaptotagmin as an inhibitory clamp on synaptic vesicle release in Aplysia neurons. Martin KC, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21; 92(24):11307–11

Enhancement of sensorimotor connections by conditioning–related stimulation in Aplysia depends upon postsynaptic Ca2+. Murphy GG, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9931–6

APNEA

Apneic snout immersion in trained pigs elicits a "diving response". Schagatay E, et al. **Adv Exp Med Biol** 1995; 393:73–6

Breath holding spells in a very young infant [letter] Singh K. **Indian Pediatr** 1995 Apr;32(4):500

Severe pulmonary arterial hypertension during the apnea test for brain death. Nicolas F, et al. **Transplant Proc** 1996 Feb; 28(1):375

BLOOD

A model to describe the rate of oxyhaemoglobin desaturation during apnoea. Farmery AD, et al. **Br J Anaesth** 1996 Feb; 76(2):284–91

Duration of apnoea in anaesthetized children required for desaturation of haemoglobin to 95%: comparison of three different breathing gases. Kinouchi K, et al. **Paediatr Anaesth** 1995;5(2):115–9

CHEMICALLY INDUCED

Apnea and vomiting in an infant due to cocaine exposure. Okoruwa E, et al. **Iowa Med** 1995 Nov;85(11):449–50

Beta–endorphin may be a mediator of apnea induced by the laryngeal chemoreflex in piglets. Storm H, et al. **Pediatr Res** 1995 Aug;38(2):205–10

Comment on spinal–epidural anesthesia case report by Eldor et al [letter; comment] Camann W. **Reg Anesth** 1995 Sep–Oct;20(5):460–1. Comment on: Reg Anesth 1994 Nov–Dec;19(6):418–22.

COMPLICATIONS

Familial infantile apnea and immature beta oxidation. Iafolla AK, et al. **Pediatr Pulmonol** 1995 Sep;20(3):167–71

DIAGNOSIS

Apnoea detection: human performance and reliability of a computer algorithm. Macey PM, et al. **Acta Paediatr** 1995 Oct;84(10):1103–7

The least expensive diagnostic tool. Rosenberg NM, et al. **Pediatr Emerg Care** 1995 Dec;11(6):389–91

A computer algorithm for differentiating valid from distorted pulse oximeter waveforms in neonates. Adams JA, et al. **Pediatr Pulmonol** 1995 May;19(5):307–11

EPIDEMIOLOGY

Rotavirus infection and bradycardia–apnoea–episodes in the neonate. Riedel F, et al. **Eur J Pediatr** 1996 Jan; 155(1):36–40

ETIOLOGY

Phrenic nerve stimulation during transesophageal atrial pacing may cause apnea in spontaneously breathing patients [letter] Roth JV. **Anesth Analg** 1996 Sep;83(3):661

Apparent life threatening events and infant holding practices. Byard RW, et al. **Arch Dis Child** 1995 Dec;73(6):502–4

Apnoea and bradycardia during epileptic seizures: relation to sudden death in epilepsy. Nashef L, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):297–300

Environmental tobacco smoke exposure and gastroesophageal reflux in infants with apparent life–threatening events. Alaswad B, et al. **J Okla State Med Assoc** 1996 Jul;89(7):233–7

Images in clinical medicine. Periodic breathing in an infant with hydrocephalus. Marcus CL. **N Engl J Med** 1996 Jun 13;334(24):1577

Apparent life–threatening events in presumed healthy neonates during the first three days of life. Grylack LJ, et al. **Pediatrics** 1996 Mar;97(3):349–51

Apnea as a presenting sign of hydrocephalus. Nitahara J, et al. **Pediatrics** 1996 Apr;97(4):587–9

[Intra–alveolar hemorrhage. An uncommon accident in a breath holding diver] Boussuges A, et al. **Presse Med** 1995 Sep 2–9;24(25):1169–70 (Eng. Abstr.) **(Fre)**

GENETICS

Familial infantile apnea and immature beta oxidation. Iafolla AK, et al. **Pediatr Pulmonol** 1995 Sep;20(3):167–71

METABOLISM

Children's development effecting blood oxygen desaturation following apnea. Xue F, et al. **Chin Med J (Engl)** 1995 Jun;108(6):434–7

PATHOLOGY

A role for mast cells in adenosine A3 receptor–mediated hypotension in the rat. Hannon JP, et al. **Br J Pharmacol** 1995 Jul;115(6):945–52

Craniocervical stenosis and apnea spells in a 2–month–old baby with achondroplasia. Najjar JA, et al. **J Child Neurol** 1995 Nov;10(6):484–6

PHYSIOPATHOLOGY

The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. O'Donnell DE, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2005–13

A model of transient oscillatory pressure–flow relationships of canine airways. Suki B, et al. **Ann Biomed Eng** 1995 Sep–Oct;23(5):682–90

Relative contributions of voluntary apnoea, exposure to cold and face immersion in water to diving bradycardia in humans. Marsh N, et al. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):886–7

Improved understanding of respiratory control––implications for the treatment of apnoea. Lagercrantz H. **Eur J Pediatr** 1995;154(8 Suppl 3):S10–2

Immediate effects of arousal from sleep on cardiac autonomic outflow in the absence of breathing in dogs. Horner RL, et al. **J Appl Physiol** 1995 Jul;79(1):151–62

Acute systemic blood pressure elevation in obstructive and nonobstructive breath hold in primates. White SG, et al. **J Appl Physiol** 1995 Jul;79(1):324–30

Modulation of muscle sympathetic activity during spontaneous and artificial ventilation and apnoea in humans. Macefield VG, et al. **J Auton Nerv Syst** 1995 Jun 25; 53(2–3):137–47

Brainstem tubers presenting as disordered breathing in tuberous sclerosis complex. DiMario FJ Jr. **J Child Neurol** 1995 Sep;10(5):407–9

Breath–holding spells. Breningstall GN. **Pediatr Neurol** 1996 Feb;14(2):91–7 (35 ref.)

PREVENTION & CONTROL

Aminophylline versus caffeine citrate... [letter] Duc G, et al. **Acta Paediatr** 1995 Oct;84(10):1210; discussion 1099

[Metabolic, hormonal and nutritional effects of long–term theophylline therapy in preterm infants: a case–control study] Colonna F, et al. **Pediatr Med Chir** 1995 Jul–Aug; 17(4):345–8 (Eng. Abstr.) **(Ita)**

THERAPY

[The use of a laryngeal mask in a newborn infant with Nager acrofacial dysostosis] Nagahama H, et al. **Masui** 1995 Nov; 44(11):1555–8 (Eng. Abstr.) **(Jpn)**

APNEA, CENTRAL see **SLEEP APNEA SYNDROMES**

APNEA, OBSTRUCTIVE see **SLEEP APNEA SYNDROMES**

APNEA, SLEEP see **SLEEP APNEA SYNDROMES**

APO–A see **APOLIPOPROTEINS A**

APO A–I see **APOLIPOPROTEIN A–I**

APO A–II see **APOLIPOPROTEIN A–II**

APO–B see **APOLIPOPROTEINS B**

APO–C see **APOLIPOPROTEINS C**

APO–E see **APOLIPOPROTEINS E**

APO–1 ANTIGEN see **ANTIGENS, CD95**

APOCRINE GLANDS

see related
SWEATING

ANATOMY & HISTOLOGY

Morphology of the interdigital glands of a Formosan serow (Capricornis crispus swinhoei). Atoji Y, et al. **J Vet Med Sci** 1995 Oct;57(5):963–4

CYTOLOGY

Myoepithelial cells and innervation in the infraorbital gland of the Japanese serow (Capricornis crispus). Atoji Y, et al. **Eur J Morphol** 1995 Jul;33(3):237–46

Proliferating cells in human eccrine and apocrine sweat glands. Morimoto Y, et al. **J Histochem Cytochem** 1995 Dec;43(12):1217–21

INNERVATION

Myoepithelial cells and innervation in the infraorbital gland of the Japanese serow (Capricornis crispus). Atoji Y, et al. **Eur J Morphol** 1995 Jul;33(3):237–46

METABOLISM

Immunohistochemical localization of IL–1 alpha–, IL–1 beta–, IL–6– and TNF–alpha–like immunoreactivities in human apocrine glands. Ahmed AA, et al. **Arch Dermatol Res** 1995;287(8):764–6

PATHOLOGY

Apocrine carcinoma vs. apocrine metaplasia with atypia of the breast. Use of aspiration biopsy cytology. Yoshida K, et al. **Acta Cytol** 1996 Mar–Apr;40(2):247–51

An immunohistochemical study of lysozyme, CD–15 (Leu M1), and gross cystic disease fluid protein–15 in various skin tumors. Assessment of the specificity and sensitivity of markers of apocrine differentiation. Ansai S, et al.

Am J Dermatopathol 1995 Jun;17(3):249–55
Tubular apocrine adenoma with eccrine and apocrine immunophenotypes or papillary tubular adenoma? Tellechea O, et al. **Am J Dermatopathol** 1995 Oct; 17(5):499–505
Benign cutaneous adnexal tumors with combined folliculosebaceous, apocrine, and eccrine differentiation. Clinicopathologic and immunohistochemical study of eight cases [see comments] Wong TY, et al.
Am J Dermatopathol 1996 Apr;18(2):124–36. Comment in: Am J Dermatopathol 1996 Apr;18(2):103–9.
Histopathology of apocrine bromhidrosis. Bang YH, et al. **Plast Reconstr Surg** 1996 Aug;98(2):288–92

SECRETION

A human axillary odorant is carried by apolipoprotein D. Zeng C, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25; 93(13):6626–30

SURGERY

Surgical management of axillary bromidrosis--a modified skoog procedure by an axillary bipedicle flap approach. Wang HJ, et al. **Plast Reconstr Surg** 1996 Sep;98(3):524–9

APODEMUS see **MURIDAE**

APOENZYMES

CHEMISTRY

Flavinylation in wild-type trimethylamine dehydrogenase and differentially charged mutant enzymes: a study of the protein environment around the N1 of the flavin isoalloxazine. Mewies M, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):267–72
Acid-induced folding of yeast alcohol dehydrogenase under low pH conditions. Le WP, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):674–9
Structural analysis of human alpha-class glutathione transferase A1-1 in the apo-form and in complexes with ethacrynic acid and its glutathione conjugate. Cameron AD, et al. **Structure** 1995 Jul 15;3(7):717–27

GENETICS

Promoter elements of the PHR1 gene of Saccharomyces cerevisiae and their roles in the response to DNA damage. Sancar GB, et al. **Nucleic Acids Res** 1995 Nov 11; 23(21):4320–8

METABOLISM

Interaction of sheep liver apo-serine hydroxymethyltransferase with pyridoxal-5'-phosphate: a physicochemical, kinetic, and thermodynamic study. Brahatheeswaran B, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):363–72
Resolution of pyridoxal 5'-phosphate from O-acetylserine sulfhydrylase from Salmonella typhimurium and reconstitution of apoenzyme with cofactor and cofactor analogues as a probe of the cofactor binding site. Schnackerz KD, et al. **Arch Biochem Biophys** 1995 Dec 1;324(1):71–7
The reaction mechanism of copper amine oxidase: detection of intermediates by the use of substrates and inhibitors. Medda R, et al. **Biochemistry** 1995 Dec 19;34(50):16375–81
High-pressure-assisted reconstitution of recombinant chloroperoxidase. Zong Q, et al. **Biochemistry** 1995 Sep 26;34(38):12420–5

APOFERRITIN

BIOSYNTHESIS

Induction of ferritin synthesis in cells infected with Mengo virus. Mulvey MR, et al. **J Biol Chem** 1996 Apr 19; 271(16):9851–7

CHEMISTRY

Thermal stability of horse spleen apoferritin and human recombinant H apoferritin. Stefanini S, et al.
Arch Biochem Biophys 1996 Jan 1;325(1):58–64
Structural investigation of the complexation properties between horse spleen apoferritin and metalloporphyrins. Michaux MA, et al. **Proteins** 1996 Mar;24(3):314–21
Control of crystal forms of apoferritin by site-directed mutagenesis. Takeda S, et al. **Proteins** 1995 Dec; 23(4):548–56

GENETICS

Negative and positive elements in the promoter region of the human apoferritin L gene. D'Agostino P, et al.
Biochem Biophys Res Commun 1995 Oct 4;215(1):329–37

APOLIPOPROTEIN A-I

ADMINISTRATION & DOSAGE

Effects of intravenous infusion of lipid-free apo A-I in humans. Nanjee MN, et al.
Arterioscler Thromb Vasc Biol 1996 Sep;16(9):1203–14

ADVERSE EFFECTS

Apolipoprotein AI-derived pulmonary vascular amyloid in aged dogs. Roertgen KE, et al. **Am J Pathol** 1995 Nov; 147(5):1311–7

ANALYSIS

Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Asztalos BF, et al. **Biochim Biophys Acta** 1993 Sep 8; 1169(3):291–300
Comparison of apo A-I-containing subpopulations of dog plasma and prenodal peripheral lymph: evidence for alteration in subpopulations in the interstitial space. Asztalos BF, et al. **Biochim Biophys Acta** 1993 Sep 8; 1169(3):301–4
Reference intervals for plasma apolipoprotein A-1 determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study [see comments] Contois J, et al.
Clin Chem 1996 Apr;42(4):507–14. Comment in: Clin Chem 1996 Apr;42(4):489–91.
Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins. Park CT, et al. **J Biol Chem** 1996 Jul 26;271(30):18054–60

BIOSYNTHESIS

Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2). Jin FY, et al.
Arterioscler Thromb Vasc Biol 1996 Aug;16(8):1052–62
Human placental tissue expresses a novel 22.7 kDa apolipoprotein A-I-like protein. Richardson B, et al.
Biochemistry 1996 Jun 11;35(23):7580–5
Age-related changes in apolipoprotein A-I expression. Shah GN, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):277–82
Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Duverger N, et al. **Circulation** 1996 Aug 15;94(4):713–7
Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Berthou L, et al.
Eur J Biochem 1995 Aug 15;232(1):179–87
Transcriptional induction of rat liver apolipoprotein A-I gene expression by glucocorticoids requires the glucocorticoid receptor and a labile cell-specific protein. Saladin R, et al. **Eur J Biochem** 1996 Jul 15;239(2):451–9
Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI. Atger V, et al. **J Clin Invest** 1995 Dec; 96(6):2613–22
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. Berthou L, et al. **J Clin Invest** 1996 Jun 1; 97(11):2408–16
Copper deficiency increases hepatic apolipoprotein A-I synthesis and secretion but does not alter hepatic total cellular apolipoprotein A-I mRNA abundance in rats. Hoogeveen RC, et al. **J Nutr** 1995 Dec;125(12):2935–44
Expression of apolipoprotein A-I mRNA in normal intrahepatic biliary tree. Ohta T, et al. **Liver** 1996 Apr; 16(2):130–3
Copper deficiency increases total protein and apolipoprotein A-I synthesis in the rat small intestine. Wu JY, et al.
Proc Soc Exp Biol Med 1996 Sep;212(4):369–77

BLOOD

Apolipoprotein AI and apolipoprotein B containing particle analysis in normolipidemic hemodialyzed patients: evidence of free apolipoprotein E. Kandoussi AM, et al.
Am J Nephrol 1996;16(4):287–92
Low HDL cholesterol: what are the prospects of increasing it? [editorial] Ginsberg HN. **Ann Med** 1995 Jun;27(3):283–4
Serum concentrations of apolipoprotein A-I, apolipoprotein B, and lipoprotein(a) in a population sample. Leino A, et al. **Clin Chem** 1995 Nov;41(11):1633–6
Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease [letter] Kawano M, et al. **Clin Chim Acta** 1995 Aug 14;239(2):209–11
Cytochrome P450 and atherosclerosis [letter] Luoma P.
Clin Pharmacol Ther 1996 Apr;59(4):484
Serum lipid and lipoprotein metabolism after glucose ingestion in NIDDM and IGT patients.
Apolipoprotein-containing particles. Nagai T, et al.
Diabetes Care 1996 Apr;19(4):365–8
Capillary electrophoresis of human serum proteins and apolipoproteins. Lehmann R, et al. **Electrophoresis** 1995 Jun;16(6):998–1001
Identification of apolipoproteins A-I and B using high resolution electrophoresis on supported cellulose acetate. Cavalcanti S, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):275–9
Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. Steinmetz J, et al.
Eur J Clin Chem Clin Biochem 1995 Jun;33(6):337–42
Relationship of apolipoproteins AI, B and lipoprotein Lp(a) to hepatic function of liver recipients during the early post-transplant period. Armstrong VW, et al.
Eur J Clin Invest 1995 Jul;25(7):485–93
Development of monoclonal antibodies for the selective isolation of human plasma apolipoprotein A-containing particles. Calvo C, et al. **Hybridoma** 1995 Dec;14(6):603–8
Capillary electrophoresis, a rapid and sensitive method for routine analysis of apolipoprotein A-I in clinical samples. Liebich HM, et al. **J Chromatogr A** 1995 Nov 24; 717(1-2):25–31
Can genes prevent atherosclerosis? Hoeg JM. **JAMA** 1996 Sep 25;276(12):989–92
Plasma high-density lipoprotein cholesterol but not apolipoprotein A-I is a good correlate of the visceral obesity-insulin resistance dyslipidemic syndrome. Couillard C, et al. **Metabolism** 1996 Jul;45(7):882–8
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 16-1996. A 36-year-old woman with bilateral facial and hand weakness and impaired truncal sensation [clinical conference]
N Engl J Med 1996 May 23;334(21):1389–94
Apolipoproteins AI and B and plasma lipid values in well-treated diabetic patients from Romania. Dabelea D, et al. **Rom J Intern Med** 1995 Jul-Dec;33(3-4):249–56
The relation between the PST1 restriction fragment length polymorphism at the APO-AI locus and plasma APO-AI concentrations in marathon runners. Ziman MR, et al.
S Afr Med J 1995 Oct;85(10):1013–6
Hyperinsulinemia inhibits secretion of apo AI more efficiently than secretion of apoAII and apoE (insulin and secretion of apoproteins). Goldsztajn P, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:46–8
[Reduction of lipoproteins with apoAI but without apoAII (LpAI) in non-insulin-dependent diabetic patients] Barkia A, et al. **Ann Biol Clin (Paris)** 1996;54(2):83–6 (Eng. Abstr.) **(Fre)**
[Effect of plasma lipoproteins and apolipoprotein A-I on lipopolysaccharide-induced production of reactive oxygen metabolites by Kupffer cells of the rat] Usynin IF, et al. **Biokhimiia** 1996 Feb;61(2):260–5 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Phospholipid binding and lecithin-cholesterol acyltransferase activation properties of apolipoprotein A-I mutants. Holvoet P, et al. **Biochemistry** 1995 Oct 17;34(41):13334–42
Identification of a sequence of apolipoprotein A-I associated with the efflux of intracellular cholesterol to human serum and apolipoprotein A-I containing particles. Sviridov D, et al. **Biochemistry** 1996 Jan 9;35(1):189–96
Pre-beta HDL: structure and metabolism. Barrans A, et al.
Biochim Biophys Acta 1996 Apr 19;1300(2):73–85 (150 ref.)
Conformation of human serum apolipoprotein A-I(166–185) in the presence of sodium dodecyl sulfate or dodecylphosphocholine by 1H-NMR and CD. Evidence for specific peptide-SDS interactions. Wang G, et al.
Biochim Biophys Acta 1996 Jun 11;1301(3):174–84
Calorimetry of apolipoprotein-A1 binding to phosphatidylcholine-triolein-cholesterol emulsions. Derksen A, et al. **Biophys J** 1996 Jan;70(1):330–8
Branched synthetic constructs that mimic the physico-chemical properties of apolipoprotein AI in reconstituted high-density lipoproteins. Demoor L, et al.
Eur J Biochem 1996 Jul 1;239(1):74–84
Characterization of apolipoproteins B-100, AI and C from plasma lipoprotein in the goose, Anser anser. Evidence for a genetic polymorphism in ApoC-like apolipoproteins. Hermier D, et al. **Eur J Biochem** 1995 Dec 1;234(2):586–91
Apolipoprotein A-I conformation in reconstituted discoidal lipoproteins varying in phospholipid and cholesterol content. Bergeron J, et al. **J Biol Chem** 1995 Nov 17; 270(46):27429–38
Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability. Sparks DL, et al. **J Biol Chem** 1995 Nov 10;270(45):26910–7
Thermal unfolding of human high-density apolipoprotein A-1: implications for a lipid-free molten globular state. Gursky O, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2; 93(7):2991–5

DEFICIENCY

Case report: retinopathy and neuropathy associated with complete apolipoprotein A-I deficiency. Ng DS, et al.
Am J Med Sci 1996 Jul;312(1):30–3
Apolipoprotein A-I deficiency. Biochemical and metabolic characteristics. Ng DS, et al.
Arterioscler Thromb Vasc Biol 1995 Dec;15(12):2157–64
A new case of apoA-I deficiency showing codon 8 nonsense mutation of the apoA-I gene without evidence of coronary heart disease. Takata K, et al.
Arterioscler Thromb Vasc Biol 1995 Nov;15(11):1866–74
Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production [see comments] Plump AS, et al.
J Clin Invest 1996 Jun 1;97(11):2660–71. Comment in: J Clin Invest 1996 Jun 1;97(11):2405–6.

GENETICS

Apolipoprotein AI-CIII-AIV genetic polymorphisms and coronary heart disease in type 2 diabetes mellitus. Rigoli L, et al. **Acta Diabetol** 1995 Dec;32(4):251–6
Chronic vitamin A intake affects the expression of mRNA for apolipoprotein A-I, but not for nuclear retinoid receptors, in liver of young and aging Lewis rats.

APOLIPOPROTEIN A-I

Zolfaghari R, et al. **Arch Biochem Biophys** 1995 Nov 10; 323(2):258–64

Effects of a major gene for apolipoprotein A–I concentration are thyroid hormone dependent in Mexican Americans. Blangero J, et al. **Arterioscler Thromb Vasc Biol** 1996 Sep; 16(9):1177–83

G-->A substitution at position -75 of the apolipoprotein A–I gene promoter. Evidence against a direct effect on HDL cholesterol levels. Minnich A, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1740–5

Only the two end helixes of eight tandem amphipathic helical domains of human apo A–I have significant lipid affinity. Implications for HDL assembly. Palgunachari MN, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):328–38

SstI RFLP and hypertension as risk factors for extracoronary atherosclerosis in a male population of southern Italy. Pujia A, et al. **Artery** 1994;21(4):208–21

Selection of a gene for apolipoprotein A1 using autoantibodies from a patient with systemic lupus erythematosus. Merrill JT, et al. **Arthritis Rheum** 1995 Nov; 38(11):1655–9

9-cis-retinoic acid increases apolipoprotein AI secretion and mRNA expression in HepG2 cells. Haghpassand M, et al. **Atherosclerosis** 1995 Oct;117(2):199–207

Genetic control of apolipoprotein A–I distribution among HDL subclasses. Rainwater DL, et al. **Atherosclerosis** 1995 Dec;118(2):307–17

Identification of functional positive and negative thyroid hormone-responsive elements in the rat apolipoprotein AI promoter. Taylor AH, et al. **Biochemistry** 1996 Jun 25; 35(25):8281–8

Identification of two apolipoprotein variants, A–I Karatsu (Tyr 100-->His) and A–I Kurume (His 162-->Gln). Moriyama K, et al. **Clin Genet** 1996 Feb;49(2):79–84

Co-regulation of apo A–I, apo C–III and apo A–IV gene expression in human intestinal biopsies. Metzger S, et al. **Eur J Clin Invest** 1996 Jan;26(1):71–5

Transcriptional regulation of apolipoprotein A–I expression in Hep G2 cells by phorbol ester. Vandenbrouck Y, et al. **FEBS Lett** 1995 Nov 27;376(1–2):99–102

New MspI polymorphism at +83 bp of the human apolipoprotein AI gene: association with increased circulating high density lipoprotein cholesterol levels. Wang XL, et al. **Genet Epidemiol** 1996;13(1):1–10

Quantification of apolipoprotein A–I and B messenger RNA in heavy drinkers according to liver disease. Mathurin P, et al. **Hepatology** 1996 Jan;23(1):44–51

Evaluation of G-to-A substitution in the apolipoprotein A–I gene promoter as a determinant of high-density lipoprotein cholesterol level in subjects with and without cholesteryl ester transfer protein deficiency. Akita H, et al. **Hum Genet** 1995 Nov;96(5):521–6

Control of apolipoprotein AI gene expression through synergistic interactions between hepatocyte nuclear factors 3 and 4. Harnish DC, et al. **J Biol Chem** 1996 Jun 7; 271(23):13621–8

Binding specificity and modulation of the ApoA–I promoter activity by homo- and heterodimers of nuclear receptors. Tzameli I, et al. **J Biol Chem** 1996 Apr 5;271(14):8402–15

Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A–I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control. Wang N, et al. **J Biol Chem** 1996 Aug 30;271(35):21001–4

Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. Booth DR, et al. **J Clin Invest** 1996 Jun 15;97(12):2714–21

Polymorphisms at the 5'-end of the apolipoprotein AI gene and severity of coronary artery disease. Wang XL, et al. **J Clin Invest** 1996 Jul 15;98(2):372–7

Overexpression of human apolipoprotein A–I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis. Burkey BF, et al. **J Lipid Res** 1995 Jul;36(7):1463–73

Thyroid hormone influences conditional transcript elongation of the apolipoprotein A–I gene in rat liver. Lin-Lee YC, et al. **J Lipid Res** 1995 Jul;36(7):1586–94

Adaptive response of apolipoprotein A–I and A–IV mRNA in residual ileum after massive small bowel resection in rats. Sonoyama K, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Apr;41(2):253–64

Linkage mapping of the apolipoprotein A–I gene to bovine chromosome 15. Sundvold H, et al. **Mamm Genome** 1996 Jul;7(7):561

Mapping functional chicken genes: an alternative approach. Smith EJ, et al. **Poult Sci** 1996 May;75(5):642–7

A new apolipoprotein AI variant, Trp50Arg, causes hereditary amyloidosis. Booth DR, et al. **QJM** 1995 Oct; 88(10):695–702 (43 ref.)

The relation between the PST1 restriction fragment length polymorphism at the APO-AI locus and plasma APO-AI concentrations in marathon runners. Ziman MR, et al. **S Afr Med J** 1995 Oct;85(10):1013–6

[DNA polymorphisms of the apolipoprotein AI-CIII-AIV gene cluster in coronary artery disease] Dan Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Oct;75(10):584–7, 637 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Changes in epitope exposition of apolipoprotein A–I on the surface of high density lipoproteins after phospholipase A2 treatment. Menschikowski M, et al. **Atherosclerosis** 1995 Oct;117(2):159–67

Development of monoclonal antibodies for the selective isolation of human plasma apolipoprotein A–containing particles. Calvo C, et al. **Hybridoma** 1995 Dec;14(6):603–8

ISOLATION & PURIFICATION

Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Westermark P, et al. **Am J Pathol** 1995 Nov;147(5):1186–92

Elution of lipoprotein fractions containing apolipoproteins E and A–I in size exclusion on Superose 6 columns is sensitive to mobile phase pH and ionic strength. Westerlund J, et al. **J Chromatogr A** 1995 Dec 1;718(1):59–66

METABOLISM

Accumulation of HDL apolipoproteins accompanies abnormal cholesterol accumulation in Schnyder's corneal dystrophy. Gaynor PM, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):992–9

Only the two end helixes of eight tandem amphipathic helical domains of human apo A–I have significant lipid affinity. Implications for HDL assembly. Palgunachari MN, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):328–38

Lipoproteins containing apolipoprotein A–IV but not apolipoprotein A–I take up and esterify cell-derived cholesterol in plasma. von Eckardstein A, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1755–63

Detection of high density lipoprotein binding proteins with a new method using apolipoprotein AI-DNP as a ligand. Ma J, et al. **Biochem Biophys Res Commun** 1995 Nov 22; 216(3):801–7

Calcium-dependent binding of the plasma protein apolipoprotein A–I to two members of the annexin family. Brownawell AM, et al. **Biochemistry** 1996 May 28; 35(21):6839–45

Phospholipid binding and lecithin-cholesterol acyltransferase activation properties of apolipoprotein A–I mutants. Holvoet P, et al. **Biochemistry** 1995 Oct 17;34(41):13334–42

Identification of a sequence of apolipoprotein A–I associated with the efflux of intracellular cholesterol to human serum and apolipoprotein A–I containing particles. Sviridov D, et al. **Biochemistry** 1996 Jan 9;35(1):189–96

Pre-beta HDL: structure and metabolism. Barrans A, et al. **Biochim Biophys Acta** 1996 Apr 19;1300(2):73–85 (150 ref.)

Apolipoprotein A–I-containing lipoproteins and atherosclerosis. Leroy A, et al. **Curr Opin Lipidol** 1995 Oct; 6(5):281–5 (36 ref.)

Interaction between human amphipathic apolipoproteins and amyloid beta-peptide: surface plasmon resonance studies. Shuvaev VV, et al. **FEBS Lett** 1996 Mar 25;383(1–2):9–12

Binding of apolipoprotein A–I and acetaldehyde-modified apolipoprotein A–I to liver extracellular matrix. Paradis V, et al. **Hepatology** 1996 May;23(5):1232–8

Apolipoprotein-AI-containing particles and atherosclerosis. Fruchart JC, et al. **Isr J Med Sci** 1996 Jun;32(6):498–502

Regulation of cellular cholesterol efflux by lecithin:cholesterol acyltransferase reaction through nonspecific lipid exchange. Czarnecka H, et al. **J Biol Chem** 1996 Jan 26;271(4):2023–8

Effects of deletion of the carboxyl-terminal domain of ApoA–I or of its substitution with helices of ApoA–II on in vitro and in vivo lipoprotein association. Holvoet P, et al. **J Biol Chem** 1996 Aug 9;271(32):19395–401

Independent regulation of cholesterol incorporation into free apolipoprotein-mediated cellular lipid efflux in rat vascular smooth muscle cells. Li Q, et al. **J Biol Chem** 1995 Nov 3;270(44):26216–23

Lipoprotein association of human apolipoprotein E/A–I chimeras. Expression in transfected hepatoma cells. Thurberg BL, et al. **J Biol Chem** 1996 Mar 15; 271(11):6062–70

Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A–I catabolism is delayed in a gene dose-dependent manner. Brousseau ME, et al. **J Clin Invest** 1996 Apr 15; 97(8):1844–51

apo B gene knockout in mice results in embryonic lethality in homozygotes and neural tube defects, male infertility, and reduced HDL cholesterol ester and apo A–I transport rates in heterozygotes. Huang LS, et al. **J Clin Invest** 1995 Nov;96(5):2152–61

Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid. Lindstedt L, et al. **J Clin Invest** 1996 May 15;97(10):2174–82

Apolipoprotein A–I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production [see comments] Plump AS, et al. **J Clin Invest** 1996 Jun 1;97(11):2660–71. Comment in: J Clin Invest 1996 Jun 1;97(11):2405–6.

Finally, a noncontroversial role for Apo A–I in HDL-mediated cholesterol flux to cells [editorial; comment] Rothblat GH. **J Clin Invest** 1996 Jun 1; 97(11):2405–6. Comment on: J Clin Invest 1996 Jun 1;97(11):2660–71.

Efflux of intracellular versus plasma membrane cholesterol in HepG2 cells: different availability and regulation by apolipoprotein A–I. Sviridov D, et al. **J Lipid Res** 1995 Sep;36(9):1887–96

Association of synthetic peptide fragments of human apolipoprotein A–I with phospholipids. Vanloo B, et al. **J Lipid Res** 1995 Aug;36(8):1686–96

[Spectroscopic study of the mechanism of cholesterol interaction with apolipoproteins: a model of cholesterol-synthetic apolipoprotein A–I fragment] Klimov AN, et al. **Biokhimiia** 1995 Nov;60(11):1825–37 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Intravenous injection of rabbit apolipoprotein A–I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Miyazaki A, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov; 15(11):1882–8

Involvement of a cellular surface factor(s) in lipid-free apolipoprotein-mediated cellular cholesterol efflux. Li Q, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):227–34

Apolipoprotein A–I stimulates placental lactogen expression by human trophoblast cells. Handwerger S, et al. **Endocrinology** 1995 Dec;136(12):5555–60

HDL apolipoprotein A–I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice. Hayek T, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct; 33(10):721–5

Independent regulation of cholesterol incorporation into free apolipoprotein-mediated cellular lipid efflux in rat vascular smooth muscle cells. Li Q, et al. **J Biol Chem** 1995 Nov 3;270(44):26216–23

PHYSIOLOGY

Role of lecithin:cholesterol acyltransferase and apolipoprotein A–I in cholesterol esterification in lipoprotein-X in vitro. O K, et al. **J Lipid Res** 1995 Nov; 36(11):2344–54

SECRETION

9-cis-retinoic acid increases apolipoprotein AI secretion and mRNA expression in HepG2 cells. Haghpassand M, et al. **Atherosclerosis** 1995 Oct;117(2):199–207

Kinetic evidence for both a fast and a slow secretory pathway for apolipoprotein A–I in humans. Fisher WR, et al. **J Lipid Res** 1995 Jul;36(7):1618–28

Secretion of apolipoproteins A–I and B by HepG2 cells: regulation by substrates and metabolic inhibitors. Kempen HJ, et al. **J Lipid Res** 1995 Aug;36(8):1796–806

APOLIPOPROTEIN A-II

BIOSYNTHESIS

Regulation of rat liver apolipoprotein A–I, apolipoprotein A–II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Berthou L, et al. **Eur J Biochem** 1995 Aug 15;232(1):179–87

Transcriptional induction of rat liver apolipoprotein A–I gene expression by glucocorticoids requires the glucocorticoid receptor and a labile cell-specific protein. Saladin R, et al. **Eur J Biochem** 1996 Jul 15;239(2):451–9

Retinoids increase human apolipoprotein A–11 expression through activation of the retinoid X receptor but not the retinoic acid receptor. Vu-Dac N, et al. **Mol Cell Biol** 1996 Jul;16(7):3350–60

BLOOD

Decreased affinity of apolipoprotein AII to high-density lipoprotein in patients with transthyretin-related amyloidosis (Met30, Gln89, Pro36, and Thr34). Nakamura M, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):316–21

Consistent relationship between selenium and apolipoprotein A–II concentrations in the sera of fasting middle-aged male abstainers and regular consumers of alcohol. Koyama H, et al. **Biol Trace Elem Res** 1995 Oct;50(1):33–42

Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease [letter] Kawano M, et al. **Clin Chim Acta** 1995 Aug 14;239(2):209–11

Capillary electrophoresis of human serum proteins and apolipoproteins. Lehmann R, et al. **Electrophoresis** 1995 Jun;16(6):998–1001

Development of monoclonal antibodies for the selective isolation of human plasma apolipoprotein A–containing particles. Calvo C, et al. **Hybridoma** 1995 Dec;14(6):603–8

Contrasting in vivo effects of murine and human apolioprotein A–II. Gong EL, et al. **J Biol Chem** 1996 Mar 15;271(11):5984–7

Hyperinsulinemia inhibits secretion of apo AI more efficiently than secretion of apoAII and apoE (insulin and secretion of apoproteins). Goldsztajn P, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:46–8

GENETICS

Contrasting in vivo effects of murine and human apolioprotein A–II. Gong EL, et al. **J Biol Chem** 1996 Mar 15;271(11):5984–7

Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A–II. Marzal-Casacuberta A, et al. **J Biol Chem** 1996 Mar 22; 271(12):6720–8

Genetic factors in lipoprotein metabolism. Analysis of a genetic cross between inbred mouse strains NZB/BINJ and SM/J using a complete linkage map approach. Purcell-Huynh DA, et al. **J Clin Invest** 1995 Oct; 96(4):1845–58

Accelerated senile amyloidosis induced by amyloidogenic Apoa-II gene shortens the life span of mice but does not accelerate the rate of senescence. Higuchi K, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):B295–302

Involvement of intronic sequences in the transcriptional regulation of apolipoprotein B, E and A-II genes. Chartier FL, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:44–5

IMMUNOLOGY

Development of monoclonal antibodies for the selective isolation of human plasma apolipoprotein A-containing particles. Calvo C, et al. **Hybridoma** 1995 Dec;14(6):603–8

METABOLISM

Accumulation of HDL apolipoproteins accompanies abnormal cholesterol accumulation in Schnyder's corneal dystrophy. Gaynor PM, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):992–9

The molecular structure of apolipoprotein A-II modulates the capacity of HDL to promote cell cholesterol efflux. Bernini F, et al. **Biochim Biophys Acta** 1996 Jan 5; 1299(1):103–9

Interaction between human amphipathic apolipoproteins and amyloid beta-peptide: surface plasmon resonance studies. Shuvaev VV, et al. **FEBS Lett** 1996 Mar 25;383(1–2):9–12

Effects of deletion of the carboxyl-terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association. Holvoet P, et al. **J Biol Chem** 1996 Aug 9;271(32):19395–401

PHARMACOLOGY

Apolipoprotein A-II influences the substrate properties of human HDL2 and HDL3 for hepatic lipase. Mowri HO, et al. **Arterioscler Thromb Vasc Biol** 1996 Jun;16(6):755–62

SECRETION

Kinetic evidence for both a fast and a slow secretory pathway for apolipoprotein A-I in humans. Fisher WR, et al. **J Lipid Res** 1995 Jul;36(7):1618–28

APOLIPOPROTEINS

BIOSYNTHESIS

Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. Jamieson DG, et al. **Am J Pathol** 1995 Dec;147(6):1567–74

Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Mancini FP, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1911–6

Investigation of glucocorticoid modulation of apolipoprotein mRNA transcription. MacMahon MM, et al. **Biochem Soc Trans** 1996 Feb;24(1):117S

Soluble products of inflammatory reactions are not induced in children with asymptomatic Plasmodium falciparum infections. Jakobsen PH, et al. **Clin Exp Immunol** 1996 Jul; 105(1):69–73

The human lacrimal gland synthesizes apolipoprotein D mRNA in addition to tear prealbumin mRNA, both species encoding members of the lipocalin superfamily. Holzfeind P, et al. **Exp Eye Res** 1995 Oct;61(4):495–500

The murine gene encoding apolipoprotein D exhibits a unique expression pattern as compared to other species. Cofer S, et al. **Gene** 1996 Jun 1;171(2):261–3

Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1 alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells. Blais Y, et al. **Int J Cancer** 1995 Sep 15;62(6):732–7

Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of C-reactive protein and serum amyloid A in Hep3B cells. Drenth JP, et al. **J Immunol** 1996 Jul 1;157(1):400–4

Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. Harr SD, et al. **J Neurochem** 1996 Jun;66(6):2429–35

BLOOD

Plasma lipids, lipoproteins and apolipoproteins in hirsute women. Castelo-Branco C, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):261–5

Serum lipids and apolipoproteins from 1 to 15 years: changes with age and puberty, and relationships with diet, parental cholesterol and family history of ischaemic heart disease. Boulton TJ, et al. **Acta Paediatr** 1995 Oct;84(10):1113–8

Serum lipids and apolipoproteins in Spanish children and adolescents: a 5 year follow-up. Sanchez-Bayle M, et al. **Acta Paediatr** 1996 Mar;85(3):292–4

Lipoprotein (a) and apolipoprotein A-1 and B in schoolchildren whose grandparents had coronary and cerebrovascular events: a preliminary study of 12–13 year old Japanese children. Okada T, et al. **Acta Paediatr Jpn** 1995 Oct;37(5):582–7

Predictive value of lipid profile for salutary coronary angiographic changes in patients on a low-fat diet and physical exercise program. Niebauer J, et al. **Am J Cardiol** 1996 Jul 15;78(2):163–7

Cyclical variation of plasma lipids, apolipoproteins, and lipoprotein(a) during menstrual cycle of normal women. Tonolo G, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):E1101–5

Evaluation of common electrophoretic methods in determining the molecular weight of apolipoprotein(a) polymorphs. Furbee JW Jr, et al. **Anal Biochem** 1996 Feb 1;234(1):66–73

Downward blotting of proteins in a model based on apolipoprotein(a) phenotyping. Nagy B, et al. **Anal Biochem** 1995 Oct 10;231(1):40–5

Acute exposure to carbon monoxide does not affect plasma lipids, lipoproteins, and apolipoproteins. Leaf DA, et al. **Angiology** 1996 Apr;47(4):337–41

Apolipoproteins and gallstone disease [editorial] Juvonen T, et al. **Ann Med** 1995 Oct;27(5):507–8

Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine. Hasler-Rapacz J, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):137–43

Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apo E4. Muros M, et al. **Atherosclerosis** 1996 Mar;121(1):13–21

Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Duverger N, et al. **Circulation** 1996 Aug 15;94(4):713–7

Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias [editorial; comment] Sniderman AD, et al. **Clin Chem** 1996 Apr;42(4):489–91. Comment on: Clin Chem 1996 Apr;42(4):507–14. Comment on: Clin Chem 1996 Apr;42(4):515–23.

Distribution and characterization of apolipoproteins in Chrysemys picta plasma. Paolucci M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Mar; 110(3):583–8

Lipoprotein(a), apolipoprotein(a) polymorphism, and insulin treatment in type II diabetic patients [letter] Buscaglia P, et al. **Diabetes Care** 1995 Aug;18(8):1202–3

Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in the families of NIDDM patients. Hirata K, et al. **Diabetologia** 1995 Dec;38(12):1434–42

High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate. Saku K, et al. **Eur J Clin Pharmacol** 1995; 48(3–4):209–15

Effect of a new cyclical sequential postmenopausal HRT on lipoprotein, apoprotein and thrombophilia profile. Habiba M, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep; 62(1):89–94

Relations of body fat and fat distribution to the serum lipid, apolipoprotein and insulin concentrations of Samoan men and women. Galanis DJ, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19(10):731–8

The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. Hilbrands LB, et al. **J Am Soc Nephrol** 1995 Jun; 5(12):2073–81

Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. Kronenberg F, et al. **J Am Soc Nephrol** 1995 Jul; 6(1):110–20

Changes in serum lipids and apolipoproteins after exercise in men with high cholesterol: influence of intensity. Crouse SF, et al. **J Appl Physiol** 1995 Jul;79(1):279–86

Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. Hoeg JM, et al. **J Biol Chem** 1996 Feb 23;271(8):4396–402

Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin. Lijnen P, et al. **J Hum Hypertens** 1995 Jul;9(7):557–64

Relevance of body weight to apolipoprotein levels in Australian children. Wilcken DE, et al. **Med J Aust** 1996 Jan 1;164(1):22–5

Plasma levels of lipoproteins and apolipoproteins in congenital hypothyroidism: effects of L-thyroxine substitution therapy. Barbagallo CM, et al. **Metabolism** 1995 Oct;44(10):1283–7

Effect of plasma oncotic pressure on apolipoprotein levels in rats with Heymann nephritis. Kaysen GA, et al. **Miner Electrolyte Metab** 1996;22(1–3):31–8

Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Attman PO, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):63–9

Serum apolipoprotein profile of renal-transplant patients [letter] Segarra A, et al. **Nephron** 1995;70(2):264

Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients. Wheeler DC, et al. **Transpl Int** 1996;9(3):221–6

[Correlation analysis of lipids and apolipoproteins in plasma HDL, LDL and VLDL of normal subjects and endogenous hypertriglyceridemics] Fan P, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Jun;26(2):141–5 (Eng. Abstr.) **(Chi)**

[Apolipoproteins and their fractions] Koga S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:654–7 (14 ref.) **(Jpn)**

[An evaluation of a method for measuring apolipoproteins as a sensitive marker for estimating lipid metabolic disorder in a population at risk for essential arterial hypertension (EAH)] Azoicăi D, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jan-Mar; 40(1):41–5 **(Rum)**

CHEMISTRY

Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Kraft HG, et al. **Arterioscler Thromb Vasc Biol** 1996 Jun;16(6):713–9

Interaction of model class A1, class A2, and class Y amphipathic helical peptides with membranes. Mishra VK, et al. **Biochemistry** 1996 Aug 27;35(34):11210–20

Role of diacylglycerol and apolipophorin-III in regulation of physiochemical properties of the lipophorin surface: metabolic implications. Soulages JL, et al. **Biochemistry** 1996 Apr 23;35(16):5191–8

Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Marcovina SM, et al. **Clin Chem** 1996 Mar;42(3):436–9

Stationary phase expression of a novel Escherichia coli outer membrane lipoprotein and its relationship with mammalian apolipoprotein D. Implications for the origin of lipocalins. Bishop RE, et al. **J Biol Chem** 1995 Sep 29; 270(39):23097–103

Physical states of surface and core lipids in lipid emulsions and apolipoprotein binding to the emulsion surface. Saito H, et al. **J Biol Chem** 1996 Jun 28;271(26):15515–20

Determination of isotopic ratios of L-leucine and L-phenylalanine and their stable isotope labeled analogues in biological samples by gas chromatography/triple-stage quadrupole mass spectrometry. Schweer H, et al. **J Mass Spectrom** 1996 Jul;31(7):727–34

DRUG EFFECTS

High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate. Saku K, et al. **Eur J Clin Pharmacol** 1995; 48(3–4):209–15

GENETICS

Apolipoprotein polymorphism in Hungary. Császár A. **Acta Biomed Ateneo Parmense** 1995;66(3–4):169–74

Evaluation of common electrophoretic methods in determining the molecular weight of apolipoprotein(a) polymorphs. Furbee JW Jr, et al. **Anal Biochem** 1996 Feb 1;234(1):66–73

Molecular characterization of quail apolipoprotein very-low-density lipoprotein II: disulphide-bond-mediated dimerization is not essential for inhibition of lipoprotein lipase. MacLachlan I, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):599–604

Developmental regulation of expression of rabbit C-reactive protein and serum amyloid A genes. Rygg M, et al. **Biochim Biophys Acta** 1996 Jun 3;1307(1):89–96

In vitro characterization of an estrogen-regulated mRNA stabilizing activity in the avian liver. Ratnasabapathy R. **Cell Mol Biol Res** 1995;41(6):583–94

Five restriction fragment length polymorphisms of the APOA1-C3 gene and their influence on lipids and apolipoproteins in healthy Chinese. Saha N, et al. **Hum Hered** 1995 Nov-Dec;45(6):303–10

Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. Mancini FP, et al. **Hum Mol Genet** 1995 Sep;4(9):1535–42

Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long-range regulatory elements and factors in apolipoprotein gene regulation. Kardassis D, et al. **Hypertension** 1996 Apr;27(4):980–1008 (116 ref.)

The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a). Lawn RM, et al. **J Biol Chem** 1995 Oct 13;270(41):24004–9

Estrogen induces the assembly of a multiprotein messenger ribonucleoprotein complex on the 3'-untranslated region of chicken apolipoprotein II mRNA. Margot JB, et al. **J Biol Chem** 1996 Feb 23;271(8):4452–60

Transgenic mouse model for estrogen-regulated lipoprotein metabolism: studies on apoVLDL-II expression in transgenic mice. Zsigmond E, et al. **J Lipid Res** 1995 Jul; 36(7):1453–62

Is there a Finno-Ugrian suicide gene? [letter; comment] Császár A. **Lancet** 1996 Feb 10;347(8998):403. Comment on: Lancet 1995 Dec 16;346(8990):1632–3.

Wallaby serum amyloid A protein: cDNA cloning, sequence and evolutionary analysis. Uhlar CM, et al. **Scand J Immunol** 1996 Mar;43(3):271–6

Molecular basis of the interaction between LDL and recombinant apo(a). Helmhold M, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:36–8

[Apolipoprotein (a) polymorphism in relation to coronary heart disease in Chinese Han nationality] Qin S, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Oct;75(10):588–91, 637–8 (Eng. Abstr.) **(Chi)**

APOLIPOPROTEINS

IMMUNOLOGY

Bacterial lipoproteins may substitute for cytokines in the humoral immune response to T cell-independent type II antigens. Snapper CM, et al. **J Immunol** 1995 Dec 15; 155(12):5582–9

Role of beta 2-glycoprotein I in the anticardiolipin antibody affinity for phospholipid in autoimmune disease. Dueymes M, et al. **Lupus** 1995 Dec;4(6):477–81

Clinical significance of phospholipid-dependent anti-beta 2-glycoprotein I (beta 2-GPI) antibodies in systemic lupus erythematosus. Kaburaki J, et al. **Lupus** 1995 Dec; 4(6):472–6

Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Vaarala O, et al. **Thromb Haemost** 1996 Mar;75(3):456–9

[Anti-beta 2 glycoprotein 1 antibodies in idiopathic livedo reticularis] Aubry F, et al. **Ann Dermatol Venereol** 1995; 122(10):667–70 (Eng. Abstr.) **(Fre)**

METABOLISM

Lys and fibrinogen binding of wild-type (Trp72) and mutant (Arg72) human apo(a) kringle IV-10 expressed in E coli and CHO cells. Klezovitch O, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):392–8

Hepatic apolipoprotein and LDL receptor gene expression in the genetically hypercholesterolemic (RICO) rat. Felgines C, et al. **Atherosclerosis** 1995 Sep;117(1):15–24

The fibril forming region of the beta-amyloid precursor differs from that of the amyloid A precursor in its interaction with lipids. Liang JS, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):962–7

Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Gabel BR, et al. **Biochemistry** 1995 Dec 5;34(48):15777–84

Spectroscopic and lipid binding studies on the amino and carboxyl terminal fragments of Locusta migratoria apolipophorin III. Narayanaswami V, et al. **Biochemistry** 1995 Sep 19;34(37):11822–30

Chylomicron assembly and catabolism: role of apolipoproteins and receptors. Hussain MM, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):151–70 (313 ref.)

Synovial fluid lipids and apolipoproteins: a contemporary perspective. Prete PE, et al. **Biorheology** 1995 Jan-Feb; 32(1):1–16 (103 ref.)

Binding of beta 2 glycoprotein I to activated polystyrene and its recognition by human IgG autoantibodies. Keil LB, et al. **Biotechnol Appl Biochem** 1995 Dec;22 (Pt 3):305–13

Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo. Callow MJ, et al. **J Biol Chem** 1995 Oct 13;270(41):23914–7

Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes. Klezovitch O, et al. **J Clin Invest** 1996 Jul 1;98(1):185–91

Medium-term effects of betaxolol monotherapy and combination therapy with nitrendipine on lipoprotein and apolipoprotein metabolism in patients with mild to moderate essential hypertension. Saku K, et al. **J Hum Hypertens** 1996 Apr;10(4):263–8

A sensitive method to analyze in vitro secretion of lipoproteins: distribution of apolipoproteins is modulated by oleic acid in HepG2 cells. Benoist F, et al. **J Lipid Res** 1995 Oct;36(10):2243–50

Purification of the apolipoprotein B-67-containing low density lipoprotein particle and its affinity for the low density lipoprotein receptor. Welty FK, et al. **J Lipid Res** 1995 Dec;36(12):2622–9

Identification of a circulatory and oocytic avian apolipoprotein D. Vieira AV, et al. **Mol Reprod Dev** 1995 Dec;42(4):443–6

Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis [published erratum appears in Nat Med 1995 Jun;1(6):598] Palabrica TM, et al. **Nat Med** 1995 Mar;1(3):256–9

Renal lesion of type Ia glycogen storage disease: the glomerular size and renal localization of apolipoprotein. Yokoyama K, et al. **Nephron** 1995;70(3):348–52

Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). McCormick SP, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10147–51

A human axillary odorant is carried by apolipoprotein D. Zeng C, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25; 93(13):6626–30

Degradation of serum amyloid A in amyloid-susceptible and amyloid-resistant mouse strains. Elliott-Bryant R, et al. **Scand J Immunol** 1996 Sep;44(3):223–8

An altered form of apolipoprotein H binds hepatitis B virus surface antigen most efficiently. Mehdi H, et al. **Virology** 1996 Mar 1;217(1):58–66

Investigation of the association of intracellular apolipoprotein (a) with apolipoprotein B in human liver. Higgins JA, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:41–3

[Transport of cholesterol by high density lipoproteins from the standpoint of protein biochemistry] Titov VN. **Vopr Med Khim** 1995 May-Jun;41(3):2–8 (85 ref.) **(Rus)**

PHYSIOLOGY

Anticardiolipin antibodies in patients with pregnancy loss induce factor Xa production in the presence of beta 2-glycoprotein I. Ogasawara M, et al. **Am J Reprod Immunol** 1995 Nov;34(5):269–73

Beta 2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant. Brighton TA, et al. **Br J Haematol** 1996 Apr;93(1):185–94

URINE

Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). Mooser V, et al. **J Clin Invest** 1996 Feb 1;97(3):858–64

APOLIPOPROTEINS A

ANALYSIS

Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. O'Brien KD, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):523–32

Characterization of commercial antibodies for use in high resolution apo(a) phenotyping by immunoblot analysis. Gaw A, et al. **Clin Chim Acta** 1995 Aug 31;240(1):75–81

Immunoreactivity for apolipoprotein A-IV in tanycytes and astrocytes of rat brain. Fukagawa K, et al. **Neurosci Lett** 1995 Oct 13;199(1):17–20

BLOOD

Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. Johannsson G, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2142–50

Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Gault MH, et al. **Nephron** 1995;70(2):155–70

Apolipoprotein(a) concentrations in type 2 (non-insulin dependent) diabetic patients from Romania. Dabelea D, et al. **Rom J Intern Med** 1995 Jan-Jun;33(1-2):85–92

Apolipoprotein (a) concentrations in type 1 (insulin-dependent) diabetes mellitus. Serban V, et al. **Rom J Intern Med** 1995 Jan-Jun;33(1-2):77–83

CHEMISTRY

Crystal structures of apolipoprotein(a) kringle IV37 free and complexed with 6-aminohexanoic acid and with p-aminomethylbenzoic acid: existence of novel and expected binding modes. Mikol V, et al. **J Mol Biol** 1996 Mar 8;256(4):751–61

DRUG EFFECTS

Effect of immunosuppressive drug regime on cardiovascular risk profile following kidney transplantation. Murphy BG, et al. **Atherosclerosis** 1995 Aug;116(2):241–5

GENETICS

Apolipoprotein AI-CIII-AIV genetic polymorphisms and coronary heart disease in type 2 diabetes mellitus. Rigoli L, et al. **Acta Diabetol** 1995 Dec;32(4):251–6

SstI RFLP and hypertension as risk factors for extracoronary atherosclerosis in a male population of southern Italy. Pujia A, et al. **Artery** 1994;21(4):208–21

Genetic effect of apolipoprotein(a) and apolipoprotein E polymorphisms on plasma quantitative risk factors for coronary heart disease in American black women. Kamboh MI, et al. **Atherosclerosis** 1995 Sep;117(1):73–81

Intestinal expression of apolipoprotein A-IV and C-III is coordinately regulated by dietary lipid in newborn swine. Black DD, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):619–24

A TaqI polymorphism in a gene belonging to the human apoprotein(a)-plasminogen gene family on the telomeric region of chromosome 6 (6q26–27). Magnaghi P, et al. **Clin Genet** 1995 Jun;47(6):330

A recombination event in the closely linked plasminogen and apolipoprotein(a) gene loci. Magnaghi P, et al. **Clin Genet** 1995 Jun;47(6):285–9

Co-regulation of apo A-I, apo C-III and apo A-IV gene expression in human intestinal biopsies. Metzger S, et al. **Eur J Clin Invest** 1996 Jan;26(1):71–5

A unique pattern of apo(a) polymorphism in an isolated east Greenlandic Inuit (Eskimo) population. Klausen IC, et al. **Eur J Epidemiol** 1995 Oct;11(5):563–8

No association of apolipoprotein A-IV codon 347 and 360 variation with atherosclerosis and lipid transport in a sample of mixed hyperlipidemics. Carrejo MH, et al. **Genet Epidemiol** 1995;12(4):371–80

Polymorphisms of apolipoproteins A-IV and E in a Turkish population living in Germany. Malle E, et al. **Hum Genet** 1996 Sep;98(3):285–90

Ten allelic apolipoprotein[a] 5' flanking fragments exhibit comparable promoter activities in HepG2 cells. Bopp S, et al. **J Lipid Res** 1995 Aug;36(8):1721–8

Repression of fat-dependent intestinal apo A-IV mRNA abundance by medium chain triacylglycerols and proteins, and elevation by carbohydrates of fat-dependent apo A-IV transport in suckling rat pups. Satoh M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun;41(3):293–306

Adaptive response of apolipoprotein A-I and A-IV mRNA in residual ileum after massive small bowel resection in rats. Sonoyama K, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Apr;41(2):253–64

Two restriction fragment length polymorphisms at the apolipoprotein AIV (apoAIV) locus. Martin I, et al. **Mol Cell Probes** 1995 Oct;9(5):371–2

Differential transcriptional regulation of the apoAI gene by retinoic acid receptor homo- and heterodimers in yeast. Salerno AJ, et al. **Nucleic Acids Res** 1996 Feb 15; 24(4):566–72

Upregulation of apolipoprotein A-IV gene expression in residual ileum after massive small bowel resection requires the biliary secretion in rats. Sonoyama K, et al. **Proc Soc Exp Biol Med** 1996 Mar;211(3):273–80

Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Jürgens G, et al. **Stroke** 1995 Oct; 26(10):1841–8

[DNA polymorphisms of the apolipoprotein AI-CIII-AIV gene cluster in coronary artery disease] Dan Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Oct;75(10):584–7, 637 (Eng. Abstr.) **(Chi)**

METABOLISM

Determinants of lipoprotein(a) assembly: a study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Edelstein C, et al. **Biochemistry** 1995 Dec 19;34(50):16483–92

Activation of human plasma cholesteryl ester transfer protein by human apolipoprotein A-IV. Main LA, et al. **Biochim Biophys Acta** 1996 Mar 29;1300(1):17–24

Bimonthly update in lipidology: Nutrition. Roberts DC. **Curr Opin Lipidol** 1995 Oct;6(5):U117–20

Apolipoprotein A-IV: a circulating satiety signal produced by the small intestine. Tso P, et al. **Obes Res** 1995 Dec; 3 Suppl 5:689S–695S

PHARMACOLOGY

Mechanism of action of intracisternal apolipoprotein A-IV in inhibiting gastric acid secretion in rats. Okumura T, et al. **Gastroenterology** 1995 Nov;109(5):1583–8

PHYSIOLOGY

Secretion of biologically active human proapolipoprotein A-I in a baculovirus-insect cell system: protection from degradation by protease inhibitors. Pyle LE, et al. **J Lipid Res** 1995 Nov;36(11):2355–61

Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Duverger N, et al. **Science** 1996 Aug 16;273(5277):966–8

URINE

Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Kostner KM, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):905–11

APOLIPOPROTEINS B

[Cardiovascular study in Quebec: importance of apolipoprotein B and insulinemia in the risk evaluation for myocardial ischemia] Lamarche B, et al. **Union Med Can** 1995 Sep;124(2):17–21 **(Fre)**

ANALYSIS

Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. O'Brien KD, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):523–32

Lipoproteins containing apolipoprotein B isolated from patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia: identification and characterization. Aguie GA, et al. **Atherosclerosis** 1995 Dec;118(2):183–91

Apo B-containing lipoprotein particles in poorly controlled insulin-dependent diabetes. Igau B, et al. **Atherosclerosis** 1996 Feb;120(1-2):209–19

Binding of lipoprotein lipase to apolipoprotein B-containing lipoproteins. Carrero P, et al. **Biochim Biophys Acta** 1996 Jan 19;1299(2):198–206

A minimal model using stable isotopes to study the metabolism of apolipoprotein B-containing lipoproteins in humans. Maugeais C, et al. **Diabetes Metab** 1996 Feb; 22(1):57–63

[Alveolar adenoma of the lung. Immunohistochemical characterization of type II pneumocytes] Köppl H, et al. **Pathologe** 1996 Mar;17(2):150–3 (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Overexpression of human apolipoprotein B-100 in transgenic rabbits results in increased levels of LDL and decreased levels of HDL. Fan J, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1889–99

Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Mancini FP, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1911–6

Level of apolipoprotein B mRNA has an important effect

of the synthesis and secretion of apolipoprotein B-containing lipoproteins. Studies on transfected hepatoma cell lines expressing recombinant human apolipoprotein B. Selby SL, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov; 15(11):1900–10

Identification of trans-acting factors that interact with cis-acting elements present in the first nontranslated exon of the human apolipoprotein B gene. Chuang SS, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):553–62

The pattern of apolipoprotein B100 containing lipoprotein subclasses produced by the isolated visceral rat yolk sac depends on developmental stage and fatty acid availability. Plonné D, et al. **Biochim Biophys Acta** 1996 Jan 5; 1299(1):54–66

Synthesis and secretion of apolipoprotein B from cultured liver cells. Ginsberg HN. **Curr Opin Lipidol** 1995 Oct; 6(5):275–80

Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Cummings MH, et al. **Diabetologia** 1995 Aug;38(8):959–67

Dexamethasone enhanced by insulin, but not by thyroid hormones stimulates apolipoprotein B mRNA editing in cultured rat hepatocytes depending on the developmental stage. Lorentz A, et al. **FEBS Lett** 1996 Aug 5; 391(1–2):57–60

Endothelial cells synthesize and process apolipoprotein B. Sivaram P, et al. **J Biol Chem** 1996 Jun 21;271(25):15261–6

Overexpression of APOBEC-1 results in mooring sequence-dependent promiscuous RNA editing. Sowden M, et al. **J Biol Chem** 1996 Feb 9;271(6):3011–7

The microsomal triglyceride transfer protein facilitates assembly and secretion of apolipoprotein B-containing lipoproteins and decreases cotranslational degradation of apolipoprotein B in transfected COS-7 cells. Wang S, et al. **J Biol Chem** 1996 Jun 14;271(24):14124–33

Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif. Yamanaka S, et al. **J Biol Chem** 1996 May 10;271(19):11506–10

A genetic model for absent chylomicron formation: mice producing apolipoprotein B in the liver, but not in the intestine. Young SG, et al. **J Clin Invest** 1995 Dec; 96(6):2932–46

Apolipoprotein B RNA editing enzyme-deficient mice are viable despite alterations in lipoprotein metabolism. Morrison JR, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7154–9

An auxiliary factor containing a 240-kDa protein complex is involved in apolipoprotein B RNA editing. Schock D, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1097–102

BLOOD

Apolipoprotein AI and apolipoprotein B containing particle analysis in normolipidemic hemodialyzed patients: evidence of free apolipoprotein E. Kandoussi AM, et al. **Am J Nephrol** 1996;16(4):287–92

Dynamics of the fetal adrenal, cholesterol, and apolipoprotein B responses to antenatal betamethasone therapy. Parker CR Jr, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):562–5

Enzyme-linked immunosorbent assay for serum apolipoprotein B-100, a major triglyceride-transport protein in dairy cows. Yamamoto O, et al. **Am J Vet Res** 1995 Nov;56(11):1413–7

Influence of diets rich in saturated and omega-6 polyunsaturated fatty acids on the postprandial responses of apolipoproteins B-48, B-100, E, and lipids in triglyceride-rich lipoproteins. Bergeron N, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2111–21

Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Gaw A, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):236–49

Hypercholesterolemia with cholesterol-enriched LDL and normal levels of LDL-apolipoprotein B. Effects of the step I diet and bile acid sequestrants on the cholesterol content of LDL. Vega GL, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):517–22

Development of immunosorbents for apoB-containing lipoproteins apheresis. Pokrovsky SN, et al. **Artif Organs** 1995 Jun;19(6):500–5

Quantitation of apolipoprotein B-48 in triacylglycerol-rich lipoproteins by a specific enzyme-linked immunosorbent assay. Lovegrove JA, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):221–9

Restriction fragment length polymorphism of the apolipoprotein B gene and response to dietary fat and cholesterol. Abbey M, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:79G–85G

Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study [see comments] Contois JH, et al. **Clin Chem** 1996 Apr; 42(4):515–23. Comment in: Clin Chem 1996 Apr;42(4):489–91.

Serum concentrations of apolipoprotein A-I, apolipoprotein B, and lipoprotein(a) in a population sample. Leino A, et al. **Clin Chem** 1995 Nov;41(11):1633–6

The total apolipoprotein B/LDL-cholesterol ratio dose not predict LDL particle size. Tallis GA, et al. **Clin Chim Acta** 1995 Aug 31;240(1):63–73

Proteolysis of Japanese quail and chicken plasma apolipoprotein B and vitellogenin by cathepsin D: similarity of the resulting protein fragments with egg yolk polypeptides. Elkin RG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):191–6

Quantitative and qualitative derangement of apolipoprotein B-containing lipoproteins as a risk factor for diabetic macroangiopathy in nonobese NIDDM subjects. Harano Y, et al. **Diabetes** 1996 Jul;45 Suppl 3:S31–4

Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial. Purnell JQ, et al. **Diabetes** 1995 Oct;44(10):1218–26

Serum lipid and lipoprotein metabolism after glucose ingestion in NIDDM and IGT patients. Apolipoprotein-containing particles. Nagai T, et al. **Diabetes Care** 1996 Apr;19(4):365–8

Marine lipids normalize cholesteryl ester transfer in IDDM. Bagdade JD, et al. **Diabetologia** 1996 Apr;39(4):487–91

Identification of apolipoproteins A-I and B using high resolution electrophoresis on supported cellulose acetate. Cavalcanti S, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):275–9

Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. Steinmetz J, et al. **Eur J Clin Chem Clin Biochem** 1995 Jun;33(6):337–42

Relationship of apolipoproteins AI, B and lipoprotein Lp(a) to hepatic function of liver recipients during the early post-transplant period. Armstrong VW, et al. **Eur J Clin Invest** 1995 Jul;25(7):485–93

Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Watts GF, et al. **Eur J Clin Invest** 1995 Aug;25(8):559–67

Metabolic disruptions in the adipocyte-hepatocyte fatty acid axis as causes of HyperapoB. Sniderman AD, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S27–33 (68 ref.)

Increased proportion of plasma apoB-48 to apoB-100 in non-insulin-dependent diabetic rats: contribution of enhanced apoB mRNA editing in the liver. Yamane M, et al. **J Lipid Res** 1995 Aug;36(8):1676–85

ELISA quantitation of apolipoproteins in plasma lipoprotein fractions: ApoE in ApoB-containing lipoproteins (Lp B:E) and ApoB in ApoE-containing lipoproteins (Lp E:B). Yang CY, et al. **J Protein Chem** 1995 Oct;14(7):503–9

The relation of plasma triglyceride, apolipoprotein B, and high-density lipoprotein cholesterol to postheparin lipoprotein lipase activity is dependent on apolipoprotien E polymorphism. St-Amand J, et al. **Metabolism** 1996 Feb; 45(2):261–7

Apolipoprotein B independently predicts progression of very-low-level albuminuria in insulin-dependent diabetes mellitus. Watts GF, et al. **Metabolism** 1996 Sep; 45(9):1101–7

Why are lipids not predictive of cardiovascular death in the dialysis patient? Ritz E. **Miner Electrolyte Metab** 1996; 22(1–3):9–12 (25 ref.)

Apolipoproteins AI and B and plasma lipid values in well-treated diabetic patients from Romania. Dabelea D, et al. **Rom J Intern Med** 1995 Jul–Dec;33(3–4):249–56

Apolipoprotein B levels and related factors in a rural white South African community--the CORIS study. Coronary Risk Factor Study. Steyn K, et al. **S Afr Med J** 1996 Apr; 86(4):359–64

[Lipid metabolism parameters in patients with multi-infarct dementia and Alzheimer's type dementia] Sygitowicz G, et al. **Neurol Neurochir Pol** 1996 Mar–Apr;30(2):213–9; quiz 220 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Spectrophotometric method for determination of carbonyls in oxidatively modified apolipoprotein B of human low-density lipoproteins. Yan LJ, et al. **Anal Biochem** 1995 Jul 1;228(2):349–51

Elucidation of antioxidant activity of dihydrolipoic acid toward hydroxyl radical using a novel hydroxyl radical generator NP-III. Matsugo S, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):375–83

Characterization of apolipoproteins B-100, AI and C from plasma lipoprotein in the goose, Anser anser. Evidence for a genetic polymorphism in ApoC-like apolipoproteins. Hermier D, et al. **Eur J Biochem** 1995 Dec 1;234(2):586–91

Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo. Callow MJ, et al. **J Biol Chem** 1995 Oct 13;270(41):23914–7

The amino terminus of apolipoprotein B is necessary but not sufficient for microsomal triglyceride transfer protein responsiveness. Gretch DG, et al. **J Biol Chem** 1996 Apr 12;271(15):8682–91

Apolipoprotein B sequence requirements for hepatic very low density lipoprotein assembly. Evidence that hydrophobic sequences within apolipoprotein B48 mediate lipid recruitment. McLeod RS, et al. **J Biol Chem** 1996 Aug 2;271(31):18445–55

Immunoelectron microscopy of low density lipoproteins yields a ribbon and bow model for the conformation of apolipoprotein B on the lipoprotein surface. Chatterton JE, et al. **J Lipid Res** 1995 Sep;36(9):2027–37

Heterologous expression of apolipoprotein B carboxyl-terminal truncates: a model for the study of lipoprotein biogenesis. Patel SB, et al. **J Lipid Res** 1995 Oct;36(10):2090–103

Evidence that apoB-100 of low-density lipoproteins is a novel Src-related protein kinase. Guevara J Jr, et al. **J Protein Chem** 1995 Oct;14(7):627–31

Prediction of signal peptide functional properties: a study of the orientation and angle of insertion of yeast invertase mutants and human apolipoprotein B signal peptide variants. Talmud P, et al. **Protein Eng** 1996 Apr;9(4):317–21

[Conformation of apolipoprotein B-100--structure and functional classification of low density lipoproteins] Titov VN. **Biokhimiia** 1996 Jan;61(1):3–23 (93 ref.) (Eng. Abstr.) **(Rus)**

DEFICIENCY

Surfactant apoprotein B deficiency. Chetcuti PA, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F125–7 (30 ref.)

DRUG EFFECTS

Melatonin protects LDL from oxidation but does not prevent the apolipoprotein derivatization. Pieri C, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):256–60

GENETICS

Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Miserez AR, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1719–29

Familial defective apolipoprotein B-100 and myocardial infarction. The ECTIM study. Etude Cas-Témoins de l'Infarctus du Myocarde [letter] Brousseau T, et al. **Atherosclerosis** 1995 Aug;116(2):269–71

Apolipoprotein B (apo B) signal peptide length polymorphisms are associated with apo B, low density lipoprotein cholesterol, and glucose levels in Mexican Americans. Kammerer CM, et al. **Atherosclerosis** 1996 Feb; 120(1–2):37–45

Does the presence of the 3500 mutant apolipoprotein B-100 in low density lipoprotein particles affect their atherogenicity? Maher VM, et al. **Atherosclerosis** 1995 Nov; 118(1):105–10

Common variation in the gene for apolipoprotein B modulates postprandial lipoprotein metabolism: a hypothesis generating study. Peacock RE, et al. **Atherosclerosis** 1995 Jul;116(1):135–45

Apo B signal peptide insertion/deletion polymorphism is involved in postprandial lipoparticles' responses. Régis-Bailly A, et al. **Atherosclerosis** 1995 Nov; 118(1):23–34

DNA polymorphisms of the apoprotein B gene are associated with altered plasma lipoprotein concentrations but not with perceived risk of cardiovascular disease: European Atherosclerosis Research Study. Turner PR, et al. **Atherosclerosis** 1995 Aug;116(2):221–34

A novel single base deletion in the LDLR gene (211delG): Effect on serum lipid profiles and the influence of other genetic polymorphisms in the ACE, APOE and APOB genes. Ward AJ, et al. **Atherosclerosis** 1996 Feb; 120(1–2):83–91

Association of polymorphisms of the apolipoprotein B gene with coronary heart disease in Han Chinese. Ye P, et al. **Atherosclerosis** 1995 Sep;117(1):43–50

Transcriptional regulation of the apolipoprotein B-100 gene: identification of cis-acting elements in the first nontranslated exon of the human apolipoprotein B-100 gene. Chuang SS, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):394–404

Identification of trans-acting factors that interact with cis-acting elements present in the first nontranslated exon of the human apolipoprotein B gene. Chuang SS, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):553–62

In vitro reconstitution of apolipoprotein B RNA editing activity from recombinant APOBEC-1 and McArdle cell extracts. Yang Y, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):797–801

Modulation of hepatic apolipoprotein B, 3-hydroxy-3-methylglutaryl-CoA reductase and low-density lipoprotein receptor mRNA and plasma lipoprotein concentrations by defined dietary fats. Comparison of trimyristin, tripalmitin, tristearin and triolein. Bennett AJ, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):167–73

Restriction fragment length polymorphism of the apolipoprotein B gene and response to dietary fat and cholesterol. Abbey M, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:79G–85G

Genetic variation of apolipoprotein B can produce both low and high levels of apoB-containing lipoproteins in plasma. Schonfeld G. **Can J Cardiol** 1995 Oct;11 Suppl G:86G–92G (79 ref.)

Rapid typing of 4 VNTR loci, 3'ApoB, MCT118,St14 and YNZ22 by the polymerase chain reaction of a Greek sample. Lambropoulos AF, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):699–702

Identification and molecular analysis of two apoB gene mutations causing low plasma cholesterol levels. Welty FK, et al. **Circulation** 1995 Oct 15;92(8):2036–40

New methods for rapid detection of low-density lipoprotein receptor and apolipoprotein B gene mutations causing familial hypercholesterolemia. Minnich A, et al.

Clin Biochem 1995 Jun;28(3):277–84

Apolipoprotein B 3' hypervariable repeat genotype: association with plasma lipid concentration, coronary artery disease, and other restriction fragment polymorphisms. Wu JH, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):927–32

Rapid typing of variable number of tandem repeat locus in the human apolipoprotein B gene for DNA diagnosis of heart disease by polymerase chain reaction and capillary electrophoresis. Baba Y, et al. **Electrophoresis** 1995 Aug; 16(8):1437–40

Genotyping apolipoprotein B signal peptide insertion/deletion: a comparison of three methods. Glisic S, et al. **Electrophoresis** 1995 Jun;16(6):899–902

Comparison of German population data on the apoB–HVR locus with other Caucasian, Asian and black populations. Pöltl R, et al. **Forensic Sci Int** 1996 Jul 12;80(3):221–7

Distribution of ApoBII, MCT118 (D1S80), YNZ22 (D17S30), and COL2A1 Amp–FLPs (amplified fragment length polymorphisms) in Caucasoid population of Slovakia. Kádasi L, et al. **Gene Geogr** 1994 Aug;8(2):121–7

Polymorphism at VNTR locus 3 to the apolipoprotein B gene in a Tunisian population: difference from other ethnic groups. Buresi C, et al. **Genet Epidemiol** 1995;12(4):381–9

Apolipoprotein B gene DNA polymorphisms (EcoRI and MspI) and serum lipid levels in the Serbian healthy population: interaction of rare alleles and smoking and cholesterol levels. Glišić S, et al. **Genet Epidemiol** 1995; 12(5):499–508

Quantification of apolipoprotein A–I and B messenger RNA in heavy drinkers according to liver disease. Mathurin P, et al. **Hepatology** 1996 Jan;23(1):44–51

Association of apolipoprotein E but not B with Alzheimer's disease. Poduslo SE, et al. **Hum Genet** 1995 Nov; 96(5):597–600

Structural analysis of the minisatellite present at the 3' end of the human apolipoprotein B gene: new definition of the alleles and evolutionary implications. Buresi C, et al. **Hum Mol Genet** 1996 Jan;5(1):61–8

Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B–100. Benlian P, et al. **Hum Mutat** 1996;7(4):340–5

Targeted disruption of the mouse apobec–1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48. Hirano K, et al. **J Biol Chem** 1996 Apr 26;271(17):9887–90

Transgenic mice that overexpress mouse apolipoprotein B. Evidence that the DNA sequences controlling intestinal expression of the apolipoprotein B gene are distant from the structural gene. McCormick SP, et al. **J Biol Chem** 1996 May 17;271(20):11963–70

A genetic model for absent chylomicron formation: mice producing apolipoprotein B in the liver, but not in the intestine. Young SG, et al. **J Clin Invest** 1995 Dec; 96(6):2932–46

Ethanol modulates apolipoprotein B mRNA editing in the rat. Lau PP, et al. **J Lipid Res** 1995 Oct;36(10):2069–78

Increased proportion of plasma apoB–48 to apoB–100 in non–insulin–dependent diabetic rats: contribution of enhanced apoB mRNA editing in the liver. Yamane M, et al. **J Lipid Res** 1995 Aug;36(8):1676–85

Apolipoprotein B mRNA editing is preserved in the intestine and liver of zinc–deficient rats. Nassir F, et al. **J Nutr** 1996 Apr;126(4):860–4

The fld mutation maps near to but distinct from the Apob locus on mouse chromosome 12. Rowe LB, et al. **Mamm Genome** 1996 Jul;7(7):555–7

Regulation of hepatic apolipoprotein B RNA editing in the genetically obese Zucker rat. Phung TL, et al. **Metabolism** 1996 Sep;45(9):1056–8

The binding of apobec–1 to mammalian apo B RNA is stabilized by the presence of complementation factors which are required for post–transcriptional editing. Anant S, et al. **Nucleic Acids Symp Ser** 1995;(33):99–102

Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Farese RVJr, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6393–8

Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). McCormick SP, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10147–51

Proposed nomenclature for the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme: APOBEC–1 [letter] Davidson NO, et al. **RNA** 1995 Mar; 1(1):3

Determinants involved in regulating the proportion of edited apolipoprotein B RNAs. Sowden M, et al. **RNA** 1996 Mar; 2(3):274–88

Apolipoprotein B mRNA editing protein: a tool for dissecting lipoprotein metabolism and a potential therapeutic gene for hypercholesterolemia. Chan L, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:31–2 (16 ref.)

Involvement of intronic sequences in the transcriptional regulation of apolipoprotein B, E and A–II genes. Chartier FL, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:44–5

Genetics of hypercholesterolamemia: the detection of mutations in the apolipoprotein B gene using denaturing gradient gel electrophoresis. Gaffney D, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:19–20

Screening for mutations in the LDL receptor gene and apolipoprotein B–100 gene in 218 patients with severe hypercholesterolemia. Geisel J, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:14–5

Reconstitution of apoB mRNA editing in liver by gene–transfer as a potential approach for the treatment of severe forms of polygenic hypercholesterolemia—an outline of the rationale. Greeve J, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:27–30 (70 ref.)

A flow cytometric competition technique for measuring interaction of LDL with cellular LDL–receptors applied to patients with mutant (Arg3500—>Gln) apolipoprotein B. Heath F, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:21–4

Detection of the apolipoprotein B–100 arg(3500) > gl mutation in familial defective apoB–100 by temperature–gradient gel electrophoresis. Koch M, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:16–8

Receptor–ligand interactions in the hepatic uptake of chylomicron remnants studied with genetically manipulated mice. Redgrave TG, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:105–7

[Genetic variation in the apolipoprotein B gene] Vedie B, et al. **Ann Genet** 1995;38(4):187–201 (107 ref.) (Eng. Abstr.) **(Fre)**

[MED–PED: make early diagnosis—prevent early death] Kostner GM. **Wien Med Wochenschr** 1994; 144(12–13):317–9 (Eng. Abstr.) **(Ger)**

[Polymorphic variability of apolipoprotein B genes and insulin receptor in essential hypertension] Pisarska M. **Pol Arch Med Wewn** 1996 Mar;95(3):205–11 (Eng. Abstr.) **(Pol)**

[Analysis of allelic variants of the hypervariable locus of apolipoprotein B in Bashkir and Komi populations] Khusnutdinova EK, et al. **Genetika** 1995 Jul;31(7):995–1000 (Eng. Abstr.) **(Rus)**

[Allelic variants of apolipoproteins B and CII genes in patients with ischemic heart disease and in healthy persons from the Moscow population] Pogoda TV, et al. **Genetika** 1995 Jul;31(7):1001–9 (Eng. Abstr.) **(Rus)**

[Absence of DNA polymorphisms on the region of the APOV gene coding the proposed low density lipoprotein–binding domain of the ApoB–100 protein] Shevtsov SP. **Genetika** 1996 Feb;32(2):295–7 (Eng. Abstr.) **(Rus)**

[The relationship of apoB gene polymorphism to dyslipoproteinemia as the cause of atherosclerosis] Kravchenko NA. **Tsitol Genet** 1995 Jul–Aug;29(4):84–7 (33 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Accessibility of human apolipoprotein B–100 epitopes in insulin–dependent diabetes: relation with the surface lipid environment of atherogenic particles. Ziegler O, et al. **Diabetes Metab** 1996 Jun;22(3):179–84

Cloning and characterization of cDNAs coding for heavy and light chains of a monoclonal antibody (MabB23) specific for human plasma apolipoprotein B–100. Kwak JW, et al. **Gene** 1996 Mar 9;169(2):237–9

[The relationship between 4–hydroxynonenal–derived epitopes on apolipoprotein B and coronary heart disease] Chen Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Oct; 75(10):581–3, 637 (Eng. Abstr.) **(Chi)**

METABOLISM

Sensitive methods to study human apolipoprotein B metabolism using stable isotope–labeled amino acids. Demant T, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E1022–36

Hemoglobin induced apolipoprotein B crosslinking in low–density lipoprotein peroxidation. Miller YI, et al. **Arch Biochem Biophys** 1996 Feb 15;326(2):252–60

Selective recruitment of ApoB–48 for the assembly of VLDL in rat triacylglycerol–enriched hepatocytes. Coussons PJ, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):889–97

Homozygous familial hypobetalipoproteinemia. Increased LDL catabolism in hypobetalipoproteinemia due to a truncated apolipoprotein B species, apo B–87Padova. Gabelli C, et al. **Arterioscler Thromb Vasc Biol** 1996 Sep; 16(9):1189–96

Intracellular events in the assembly of very–low–density–lipoprotein lipids with apolipoprotein B in isolated rabbit hepatocytes. Cartwright IJ, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):897–907

Intracellular degradation in the regulation of secretion of apolipoprotein B–100 by rabbit hepatocytes. Cartwright IJ, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):977–84

Non–oxidative modification of native low–density lipoprotein by oxidized low–density lipoprotein. Yang M, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):377–80

Nonenzymic glycation of apolipoprotein B in patients with insulin– and noninsulin–dependent diabetes mellitus. Panteghini M, et al. **Clin Biochem** 1995 Dec;28(6):587–92

Cellular processing of apolipoprotein B–containing lipoproteins from young post–infarction patients and healthy controls. Tornvall P, et al. **Eur J Clin Invest** 1995 Sep;25(9):699–707

Formation of N–formylkynurenine suggests the involvement of apolipoprotein B–100 centered tryptophan radicals in the initiation of LDL lipid peroxidation. Giessauf A, et al. **FEBS Lett** 1996 Jul 1;389(2):136–40

Response of plasma ASP to a prolonged fast. Cianflone K, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19(9):604–9

Cellular metabolism of apoprotein–B containing lipoproteins: the role of apoproteins, heparan sulfate and cellular receptors. Sehayek E. **Isr J Med Sci** 1996 Jun;32(6):445–8

Role of acyl coenzyme A cholesterol acyltransferase in intrahepatic processing of apo B–lipoprotein in suncus. Nagayoshi A, et al. **J Biochem (Tokyo)** 1995 Aug; 118(2):259–64

In HepG2 cells, translocation, not degradation, determines the fate of the de novo synthesized apolipoprotein B. Bonnardel JA, et al. **J Biol Chem** 1995 Dec 1; 270(48):28892–6

Site–specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo. Callow MJ, et al. **J Biol Chem** 1995 Oct 13;270(41):23914–7

Biosynthesis of apolipoprotein B48–containing lipoproteins. Regulation by novel post–transcriptional mechanisms. Innerarity TL, et al. **J Biol Chem** 1996 Feb 2;271(5):2353–6 (78 ref.)

Members of the caudal family of homeodomain proteins repress transcription from the human apolipoprotein B promoter in intestinal cells. Lee SY, et al. **J Biol Chem** 1996 Jan 12;271(2):707–18

Apolipoprotein B sequence requirements for hepatic very low density lipoprotein assembly. Evidence that hydrophobic sequences within apolipoprotein B48 mediate lipid recruitment. McLeod RS, et al. **J Biol Chem** 1996 Aug 2;271(31):18445–55

Cell–surface expression of an amino–terminal fragment of apolipoprotein B increases lipoprotein lipase binding to cells. Pang L, et al. **J Biol Chem** 1996 Aug 9; 271(32):19518–23

Interactions between microsomal triglyceride transfer protein and apolipoprotein B within the endoplasmic reticulum in a heterologous expression system. Patel SB, et al. **J Biol Chem** 1996 Aug 2;271(31):18686–94

Brefeldin A reversibly inhibits the assembly of apoB containing lipoproteins in McA–RH7777 cells. Rustaeus S, et al. **J Biol Chem** 1995 Dec 1;270(48):28879–86

Degradation of apolipoprotein B in cultured rat hepatocytes occurs in a post–endoplasmic reticulum compartment. Wang CN, et al. **J Biol Chem** 1995 Oct 20;270(42):24924–31

Demonstration of a physical interaction between microsomal triglyceride transfer protein and apolipoprotein B during the assembly of ApoB–containing lipoproteins. Wu X, et al. **J Biol Chem** 1996 Apr 26;271(17):10277–81

Apoprotein B100, an inefficiently translocated secretory protein, is bound to the cytosolic chaperone, heat shock protein 70. Zhou M, et al. **J Biol Chem** 1995 Oct 20; 270(42):25220–4

Comparison of serine and hippurate as precursor equivalents during infusion of [15N]glycine for measurement of fractional synthetic rates of apolipoprotein B of very–low–density lipoprotein. Arends J, et al. **Metabolism** 1995 Oct;44(10):1253–8

Estrogen increases low–density lipoprotein receptor–independent catabolism of apolipoprotein B in hyperlipidemic rabbits. Colvin PL Jr. **Metabolism** 1996 Jul; 45(7):889–96

Intraperitoneal insulin infusion improves the depletion in choline–containing phospholipids of lipoprotein B particles in type I diabetic patients. Guerci B, et al. **Metabolism** 1996 Apr;45(4):430–4

Apolipoprotein E and B alleles in Parkinson's patients. Poduslo SE, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):145–7

Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). McCormick SP, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10147–51

Investigation of the association of intracellular apolipoprotein (a) with apolipoprotein B in human liver. Higgins JA, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:41–3

[Lipid metabolism parameters in patients with multi–infarct dementia and Alzheimer's type dementia] Sygitowicz G, et al. **Neurol Neurochir Pol** 1996 Mar–Apr;30(2):213–9; quiz 220 (Eng. Abstr.) **(Pol)**

[Conformation of apolipoprotein B–100—structure and functional classification of low density lipoproteins] Titov VN. **Biokhimiia** 1996 Jan;61(1):3–23 (93 ref.) (Eng. Abstr.) **(Rus)**

[Absence of DNA polymorphisms on the region of the APOV gene coding the proposed low density lipoprotein–binding domain of the ApoB–100 protein] Shevtsov SP. **Genetika** 1996 Feb;32(2):295–7 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Extracellular mast cell granules carry apolipoprotein B–100–containing lipoproteins into phagocytes in human arterial intima. Functional coupling of exocytosis and phagodytosis in neighboring cells. Kaartinen M, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):2047–54

apo B gene knockout in mice results in embryonic lethality in homozygotes and neural tube defects, male infertility, and reduced HDL cholesterol ester and apo A–I transport rates in heterozygotes. Huang LS, et al. **J Clin Invest** 1995 Nov;96(5):2152–61

[The mechanism of anti–insulin effect of apoprotein B] Panin LE, et al. **Vopr Med Khim** 1995 Nov–Dec;41(6):12–6 (Eng. Abstr.) **(Rus)**

SECRETION

Effects of saturated, mono–, and polyunsaturated fatty acids

on the secretion of apo B containing lipoproteins by Caco-2 cells. van Greevenbroek MM, et al. **Atherosclerosis** 1996 Mar;121(1):139-50

Chronic exogenous hyperinsulinaemia does not modify the acute inhibitory effect of insulin on the secretion of very-low-density lipoprotein triacylglycerol and apolipoprotein B in primary cultures of rat hepatocytes. Bourgeois CS, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):103-8

Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Sparks JD, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):567-74

The role of intracellular proteolysis in the regulation of apolipoprotein B secretion by rabbit hepatocytes. Cartwright IJ, et al. **Biochem Soc Trans** 1995 Aug; 23(3):413S

Synthesis and secretion of apolipoprotein B from cultured liver cells. Ginsberg HN. **Curr Opin Lipidol** 1995 Oct; 6(5):275-80

Factors affecting the regulation of apo B secretion by liver cells. Hahn SE, et al. **J Clin Lab Anal** 1995;9(6):431-49 (149 ref.)

Role of the neutral lipid accessible pool in the regulation of secretion of apoB-100 lipoprotein particles by HepG2 cells. Avramoglu RK, et al. **J Lipid Res** 1995 Dec; 36(12):2513-28

Secretion of apolipoproteins A-I and B by HepG2 cells: regulation by substrates and metabolic inhibitors. Kempen HJ, et al. **J Lipid Res** 1995 Aug;36(8):1796-806

APOLIPOPROTEINS C

ANALYSIS

[Alveolar adenoma of the lung. Immunohistochemical characterization of type II pneumocytes] Köppl H, et al. **Pathologe** 1996 Mar;17(2):150-3 (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Identification, characterization, cloning, and expression of apolipoprotein C-IV, a novel sialoglycoprotein of rabbit plasma lipoproteins. Zhang LH, et al. **J Biol Chem** 1996 Jan 19;271(3):1776-83

Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia [see comments] Li WW, et al. **J Clin Invest** 1995 Dec;96(6):2601-5. Comment in: J Clin Invest 1996 Dec;96(6):2546.

BLOOD

MDL 29311, a phenolic antioxidant, interferes with the interaction of apoC with VLDL: a possible explanation for its triglyceride-lowering effect. Sheetz MJ. **J Lipid Res** 1995 Dec;36(12):2609-21

Electrophoretic screening for human apolipoprotein C-II variants: repeated identification of apolipoprotein C-II(K19T). Wiebusch H, et al. **J Mol Med** 1995 Jul; 73(7):373-8

CHEMISTRY

Characterization of apolipoproteins B-100, AI and C from plasma lipoprotein in the goose, Anser anser. Evidence for a genetic polymorphism in ApoC-like apolipoproteins. Hermier D, et al. **Eur J Biochem** 1995 Dec 1;234(2):586-91

GENETICS

Apolipoprotein AI-CIII-AIV genetic polymorphisms and coronary heart disease in type 2 diabetes mellitus. Rigoli L, et al. **Acta Diabetol** 1995 Dec;32(4):251-6

Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Jong MC, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):934-40

Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Surguchov AP, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):941-7

SstI RFLP and hypertension as risk factors for extracoronary atherosclerosis in a male population of southern Italy. Pujia A, et al. **Artery** 1994;21(4):208-21

Intestinal expression of apolipoprotein A-IV and C-III is coordinately regulated by dietary lipid in newborn swine. Black DD, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):619-24

Single-strand conformational polymorphisms (SSCP): studies of the genetic polymorphisms of exon 4 of apolipoprotein C III. Beheshti I, et al. **Clin Biochem** 1995 Jun;28(3):303-7

Simple non-radioactive methods of analysis of polymorphic markers flanking human apolipoprotein C-III gene. Surguchov AP, et al. **Dis Markers** 1995 Aug;12(3):167-73

Construction and functional characterization of recombinant fusion proteins of human lipoprotein lipase and apolipoprotein CII. Hoffmann MM, et al. **Eur J Biochem** 1996 May 1;237(3):545-52

Co-regulation of apo A-I, apo C-III and apo A-IV gene expression in human intestinal biopsies. Metzger S, et al. **Eur J Clin Invest** 1996 Jan;26(1):71-5

Identification and characterization of a new human gene (APOC4) in the apolipoprotein E, C-I, and C-II gene locus. Allan CM, et al. **Genomics** 1995 Jul 20;28(2):291-300

Inactivation of Apoe and Apoc1 by two consecutive rounds of gene targeting: effects on mRNA expression levels of gene cluster members. van Ree JH, et al. **Hum Mol Genet** 1995 Aug;4(8):1403-9

Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia [see comments] Li WW, et al. **J Clin Invest** 1995 Dec;96(6):2601-5. Comment in: J Clin Invest 1996 Dec;96(6):2546.

Why there is an IRS [editorial; comment] O'Brien RM, et al. **J Clin Invest** 1995 Dec;96(6):2546. Comment on: J Clin Invest 1996 Dec;96(6):2601-5.

Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. Shachter NS, et al. **J Clin Invest** 1996 Aug 1;98(3):846-55

Electrophoretic screening for human apolipoprotein C-II variants: repeated identification of apolipoprotein C-II(K19T). Wiebusch H, et al. **J Mol Med** 1995 Jul; 73(7):373-8

Chromosomal assignment of the porcine gene for apolipoprotein C3 (APOC3) to chromosome 9 by somatic cell hybrids. Rettenberger G, et al. **Mamm Genome** 1996 Apr;7(4):322-3

Structure of the human apolipoprotein C-II gene promoter. Streicher R, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:49-50

[DNA polymorphisms of the apolipoprotein AI-CIII-AIV gene cluster in coronary artery disease] Dan Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Oct;75(10):584-7, 637 (Eng. Abstr.) **(Chi)**

[Allelic variants of apolipoproteins B and CII genes in patients with ischemic heart disease and in healthy persons from the Moscow population] Pogoda TV, et al. **Genetika** 1995 Jul;31(7):1001-9 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Isolation and characterization of recombinant human apolipoprotein C-II expressed in Escherichia coli. Wang CS, et al. **Biochim Biophys Acta** 1996 Aug 16; 1302(3):224-30

METABOLISM

Construction and functional characterization of recombinant fusion proteins of human lipoprotein lipase and apolipoprotein CII. Hoffmann MM, et al. **Eur J Biochem** 1996 May 1;237(3):545-52

Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. Haubenwallner S, et al. **J Lipid Res** 1995 Dec;36(12):2541-51

[The important role of apolipoprotein C-III in lipoprotein metabolism] Fruchart JC, et al. **C R Seances Soc Biol Fil** 1995;189(5):889-97 (30 ref.) (Eng. Abstr.) **(Fre)**

APOLIPOPROTEINS E

ADMINISTRATION & DOSAGE

From pseudocholinesterase to human immunodeficiency virus. Madhavankutty K, et al. **Med Hypotheses** 1995 Sep; 45(3):225-6

ANALYSIS

Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. O'Brien KD, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):523-32

Binding of lipoprotein lipase to apolipoprotein B-containing lipoproteins. Carrero P, et al. **Biochim Biophys Acta** 1996 Jan 19;1299(2):198-206

Immunohistochemical study on the deposition of apolipoprotein E in cerebral and islet amyloidoses in cynomolgus monkeys (Macaca fascicularis). Nakamura S, et al. **Exp Anim** 1996 Apr;45(2):199-203

Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils. Hall ED, et al. **Exp Neurol** 1995 Sep;135(1):17-27

Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: implications for Alzheimer's disease. Metzger RE, et al. **J Neuropathol Exp Neurol** 1996 Mar; 55(3):372-80

Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein [see comments] Polvikoski T, et al. **N Engl J Med** 1995 Nov 9;333(19):1242-7. Comment in: N Engl J Med 1995 Nov 9;333(19):1283-4. Comment in: N Engl J Med 1996 Feb 29;334(9):599-600.

BIOSYNTHESIS

Apolipoprotein E intrathecal synthesis is decreased in multiple sclerosis patients. Gaillard O, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):148-50

Apolipoprotein E is synthesized in the retina by Müller glial cells, secreted into the vitreous, and rapidly transported into the optic nerve by retinal ganglion cells. Amaratunga A, et al. **J Biol Chem** 1996 Mar 8;271(10):5628-32

Trans-repressor BEF-1 phosphorylation. A potential control mechanism for human ApoE gene regulation. Berg DT, et al. **J Biol Chem** 1996 Mar 1;271(9):4589-92

Cell surface proteoglycans modulate net synthesis and secretion of macrophage apolipoprotein E. Lucas M, et al. **J Biol Chem** 1996 Jun 7;271(23):13454-60

Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. Bellosta S, et al. **J Clin Invest** 1995 Nov;96(5):2170-9

Expression of mouse alpha-macroglobulins, lipoprotein receptor-related protein, LDL receptor, apolipoprotein E, and lipoprotein lipase in pregnancy. Overbergh L, et al. **J Lipid Res** 1995 Aug;36(8):1774-86

Discovery of a brain promoter from the human transferrin gene and its utilization for development of transgenic mice that express human apolipoprotein E alleles. Bowman BH, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12115-9

Cytochrome P450 1A1 promoter as a genetic switch for the regulatable and physiological expression of a plasma protein in transgenic mice. Smith JD, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11926-30

BLOOD

Intestinally derived lipoprotein particles in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia. Curtin A, et al. **Acta Diabetol** 1995 Dec;32(4):244-50

Apolipoprotein E in patients with dementia of the Alzheimer type and vascular dementia. Isoe K, et al. **Acta Neurol Scand** 1996 Feb-Mar;93(2-3):133-7

Effects of prospective, randomized cholesterol-lowering dietary intervention and apolipoprotein E phenotype on serum lipoprotein(a) concentrations of infants aged 7-24 mo. Routi T, et al. **Am J Clin Nutr** 1996 Mar;63(3):386-91

Apolipoprotein E phenotype modifies metabolic and hemodynamic abnormalities related to central obesity in women. Uusitupa MI, et al. **Am J Clin Nutr** 1996 Aug; 64(2):131-6

Apolipoprotein AI and apolipoprotein B containing particle analysis in normolipidemic hemodialyzed patients: evidence of free apolipoprotein E. Kandoussi AM, et al. **Am J Nephrol** 1996;16(4):287-92

Indirect sandwich enzyme-linked immunosorbent assay (ELISA) for plasma apolipoprotein E. Kee P, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):119-26

Influence of diets rich in saturated and omega-6 polyunsaturated fatty acids on the postprandial responses of apolipoproteins B-48, B-100, E, and lipids in triglyceride-rich lipoproteins. Bergeron N, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2111-21

Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Cohn JS, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):149-59

Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. Johannsson G, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2142-50

Lysosomal degradation and sorting of apolipoprotein E in macrophages. Deng J, et al. **J Lipid Res** 1995 Oct; 36(10):2129-40

SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. Lehtovirta M, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):644-9

Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease. Rösler N, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):452-4

ELISA quantitation of apolipoproteins in plasma lipoprotein fractions: ApoE in ApoB-containing lipoproteins (Lp B:E) and ApoB in ApoE-containing lipoproteins (Lp E:B). Yang CY, et al. **J Protein Chem** 1995 Oct;14(7):503-9

The effect of physical activity on serum total and low-density lipoprotein cholesterol concentrations varies with apolipoprotein E phenotype in male children and young adults: The Cardiovascular Risk in Young Finns Study. Taimela S, et al. **Metabolism** 1996 Jul;45(7):797-803

Regulation of the apolipoprotein E by dietary lipids occurs by transcriptional and post-transcriptional mechanisms. Srivastava RA. **Mol Cell Biochem** 1996 Feb 23; 155(2):153-62

ApoE as a prognostic factor for post-traumatic coma [letter; comment] Sorbi S, et al. **Nat Med** 1995 Sep;1(9):852. Comment on: Nat Med 1995 Feb;1(2):135-7.

Hyperinsulinemia inhibits secretion of apo AI more efficiently than secretion of apoAII and apoE (insulin and secretion of apoproteins). Goldsztajn P, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:46-8

Interaction of apo E-containing lipoproteins with the LDL-receptor-related protein, LRP. Harrach-Ruprecht B, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:122-3

The formation of large apo e-rich HDL particles in cholesterol-loaded rabbits in vivo. Skonner ER, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:145-6

[Genotyping of apolipoprotein E (alleles epsilon 2, epsilon 3 and epsilon 4) from capillary blood] Lagarde JP, et al. **Ann Biol Clin (Paris)** 1995;53(1-2):15-20 (Eng. Abstr.) **(Fre)**

APOLIPOPROTEINS E

CEREBROSPINAL FLUID

Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain. Pirttilä T, et al. **Arch Neurol** 1996 Feb;53(2):189–93

Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease. Rösler N, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):452–4

CHEMISTRY

Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease. Mahley RW, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:139–45 (24 ref.)

Monoclonal antibody against the polymorphic site distinguishes apolipoprotein E4 from other isoforms. Nukina N, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):467–72

Conformations of human apolipoprotein E(263–286) and E(267–289) in aqueous solutions of sodium dodecyl sulfate by CD and 1H NMR. Wang G, et al. **Biochemistry** 1996 Aug 13;35(32):10358–66

Apolipoprotein E2 (Arg–136—>Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia. Feussner G, et al. **Eur J Clin Invest** 1996 Jan;26(1):13–23

Molecular characterization of two monoclonal antibodies specific for the LDL receptor-binding site of human apolipoprotein E. Raffai R, et al. **J Lipid Res** 1995 Sep; 36(9):1905–18

DEFICIENCY

Accelerated atheromatous lesions in mouse hearts transplanted to apolipoprotein-E-deficient recipients. Russell PS, et al. **Am J Pathol** 1996 Jul;149(1):91–9

Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice [see comments] Zhou X, et al. **Am J Pathol** 1996 Aug;149(2):359–66. Comment in: Am J Pathol 1996 Aug;149(2):351–7.

Apolipoprotein E and the apolipoprotein E-deficient mouse. Plump AS, et al. **Annu Rev Nutr** 1995;15:495–518 (109 ref.)

Lymphocyte populations in atherosclerotic lesions of apoE -/- and LDL receptor -/- mice. Decreasing density with disease progression. Roselaar SE, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1013–8

Effect of the antioxidant N,N'-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. Tangirala RK, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1625–30

Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291—>Ser mutation in the human LPL gene. Zhang H, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct; 15(10):1695–703

Variability in cholesterol content in serum and aortic tissue in apolipoprotein E-deficient mice is comparable in inbred (129/Sv) and outbred (mixed 129/Sv and C57BL/6) mice [letter] van Ree JH, et al. **Atherosclerosis** 1995 Nov; 118(1):165–7

Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated. Aviram M, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):501–13

Altered lipid metabolism in apolipoprotein E-deficient mice does not affect cholesterol balance across the liver. Kuipers F, et al. **Hepatology** 1996 Jul;24(1):241–7

Intracellular localization and metabolism of chylomicron remnants in the livers of low density lipoprotein receptor-deficient mice and apoE-deficient mice. Evidence for slow metabolism via an alternative apoE-dependent pathway. Mortimer BC, et al. **J Biol Chem** 1995 Dec 1; 270(48):28767–76

Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. Palinski W, et al. **J Clin Invest** 1996 Aug 1;98(3):800–14

Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. Tangirala RK, et al. **J Lipid Res** 1995 Nov; 36(11):2320–8

Phosphorylation of tau protein is not affected in mice lacking apolipoprotein E. Mercken L, et al. **Neuroreport** 1995 Nov 27;6(17):2381–4

Derangement in stress response of apolipoprotein E-deficient mice. Gordon I, et al. **Neurosci Lett** 1996 Mar 15; 206(2–3):212–4

DRUG EFFECTS

The rat, a useful animal model for pharmacological studies on apolipoprotein E. Leininger-Muller B, et al. **Life Sci** 1996;58(6):455–67 (102 ref.)

GENETICS

Apolipoprotein E polymorphism, Alzheimer's disease and vascular dementia among elderly Finnish men. Stengård JH, et al. **Acta Neurol Scand** 1995 Oct;92(4):297–8

Apolipoprotein E genotype and neuropathological phenotype in two members of a German family with chromosome 14–linked early onset Alzheimer's disease. Egensperger R, et al. **Acta Neuropathol (Berl)** 1995;90(3):257–65

Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia. Martinoli MG, et al. **Acta Neuropathol (Berl)** 1995; 90(3):239–43

Apolipoprotein E allele frequencies in an Italian population: relation to age and lipid profile. Ruiu G, et al. **Aging (Milano)** 1995 Aug;7(4):185–9

Apolipoprotein epsilon 4 allele in Swedish twins and siblings with Alzheimer disease. Lannfelt L, et al. **Alzheimer Dis Assoc Disord** 1995 Fall;9(3):166–9

Associations between dietary factors and serum lipids by apolipoprotein E polymorphism. Marshall JA, et al. **Am J Clin Nutr** 1996 Jan;63(1):87–95

A 10-bp deletion in the apolipoprotein epsilon gene causing apolipoprotein E deficiency and severe type III hyperlipoproteinemia. Feussner G, et al. **Am J Hum Genet** 1996 Feb;58(2):281–91

Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Jarvik G, et al. **Am J Hum Genet** 1996 Jan;58(1):191–200

Gender difference in apolipoprotein E–associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Payami H, et al. **Am J Hum Genet** 1996 Apr;58(4):803–11

Evidence for major gene inheritance of Alzheimer disease in families of patients with and without apolipoprotein E epsilon 4. Rao VS, et al. **Am J Hum Genet** 1996 Sep; 59(3):664–75

Relative risk of Alzheimer disease and age–at–onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Tang MX, et al. **Am J Hum Genet** 1996 Mar; 58(3):574–84

Lipid metabolism and apolipoprotein E phenotypes in patients with xanthelasma. Ribera M, et al. **Am J Med** 1995 Nov;99(5):485–90

Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's Disease but is not causative. Bennett C, et al. **Am J Med Genet** 1995 Feb 27;60(1):1–6

Apolipoprotein E in the genetics and epidemiology of Alzheimer's disease. Hardy J. **Am J Med Genet** 1995 Oct 9;60(5):456–60

Impact of apolipoprotein E genotype variation on means, variances, and correlations of plasma lipid, lipoprotein, and apolipoprotein traits in octogenarians. Haviland MB, et al. **Am J Med Genet** 1995 Sep 25;58(4):315–31 (64 ref.)

Apolipoprotein E genotype in schizophrenia [letter] Joober R, et al. **Am J Med Genet** 1996 Apr 9;67(2):235

Apolipoprotein E–epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Premkumar DR, et al. **Am J Pathol** 1996 Jun;148(6):2083–95

Apolipoprotein E and epilepsy. Kilpatrick ES, et al. **Ann Clin Biochem** 1996 Mar;33 (Pt 2):146–7

Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease. Window on molecular epidemiology. Hyman BT, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:158–65 (27 ref.)

Apolipoprotein E alleles and brain vascular pathology in Alzheimer's disease. Kalaria RN, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:266–70

Apolipoprotein E polymorphism is associated with both senile plaque load and Alzheimer-type neurofibrillary tangle formation. März W, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:276–80

Amyloid beta-protein, APOE genotype and head injury. Nicoll JA, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:271–5 (9 ref.)

Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. Roses AD, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:146–57 (35 ref.)

ApoE2 allele, Down's syndrome, and dementia. Royston MC, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:255–9

Alzheimer's disease and apolipoprotein E in Italy. Sorbi S, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:260–5

Apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy [letter] Askanas V, et al. **Ann Neurol** 1996 Aug;40(2):264–5

High apolipoprotein E epsilon 4 allele frequency in age-related memory decline. Blesa R, et al. **Ann Neurol** 1996 Apr;39(4):548–51

No increased risk of the apolipoprotein E epsilon2 allele with early-onset Alzheimer's disease [letter] Corder EH, et al. **Ann Neurol** 1996 Mar;39(3):414–6

Apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives. Farrer LA, et al. **Ann Neurol** 1995 Nov; 38(5):797–808

Apolipoprotein E epsilon 4 in inclusion body myositis. Garlepp MJ, et al. **Ann Neurol** 1995 Dec;38(6):957–9

Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Gearing M, et al. **Ann Neurol** 1996 Mar;39(3):395–9

Apolipoprotein E and cognitive change in an elderly population. Hyman BT, et al. **Ann Neurol** 1996 Jul; 40(1):55–66

Apolipoprotein E epsilon 4 and fatal cerebral amyloid angiopathy associated with dementia pugilistica [letter] Jordan BD, et al. **Ann Neurol** 1995 Oct;38(4):698–9

Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view [letter; comment] Kakulas BA, et al. **Ann Neurol** 1995 Dec;38(6):966–7. Comment on: Ann Neurol 1995 Jul;38(1):2–4. Comment on: Ann Neurol 1995 Jul;38(1):6–14.

Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease [letter] Kamboh MI, et al. **Ann Neurol** 1995 Dec; 38(6):967–70

Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. Levy-Lahad E, et al. **Ann Neurol** 1995 Oct;38(4):678–80

High frequency of apolipoprotein E epsilon 2 in patients with cerebral hemorrhage due to cerebral amyloid angiopathy [letter; comment] Nicoll JA, et al. **Ann Neurol** 1996 May; 39(5):682–3. Comment on: Ann Neurol 1995 Feb;37(2):282. Comment on: Ann Neurol 1995 Aug;38(2):254–9.

Alzheimer's disease and apolipoprotein E–4 allele in an Amish population. Pericak-Vance MA, et al. **Ann Neurol** 1996 Jun;39(6):700–4

Apolipoprotein E genotype in elderly nondemented subjects without senile changes in the brain. Yamada M, et al. **Ann Neurol** 1996 Aug;40(2):243–5

Lack of an association between apolipoprotein E epsilon 4 and cerebral amyloid angiopathy in elderly Japanese [letter; comment] Yamada M, et al. **Ann Neurol** 1996 May; 39(5):683–4. Comment on: Ann Neurol 1995 Aug;38(2):254–9.

Apolipoprotein E alleles as risk factors in Alzheimer's disease. Roses AD. **Annu Rev Med** 1996;47:387–400 (66 ref.)

Distribution of apolipoprotein E genotypes in Asian Indians, Hungarians, and Papua New Guineans. Benkmann HG, et al. **Anthropol Anz** 1996 Mar;54(1):31–4

Apolipoprotein E genotype determines survival in the oldest old (85 years or older) who have good cognition. Corder EH, et al. **Arch Neurol** 1996 May;53(5):418–22

Medical education [letter] Menken M. **Arch Neurol** 1996 Mar; 53(3):215

Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. Seshadri S, et al. **Arch Neurol** 1995 Nov; 52(11):1074–9

Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Groot PH, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):926–33

Apolipoprotein E polymorphism and LDL size in a biethnic population. Haffner SM, et al. **Arterioscler Thromb Vasc Biol** 1996 Sep;16(9):1184–8

Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Jong MC, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):934–40

Apolipoprotein E polymorphism in American Indians and its relation to plasma lipoproteins and diabetes. The Strong Heart Study. Kataoka S, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):918–25

Apolipoprotein E polymorphism in middle-aged Belgian men: phenotype distribution and relation to serum lipids and lipoproteins. Braeckman L, et al. **Atherosclerosis** 1996 Feb;120(1–2):67–73

Genetic effect of apolipoprotein(a) and apolipoprotein E polymorphisms on plasma quantitative risk factors for coronary heart disease in American black women. Kamboh MI, et al. **Atherosclerosis** 1995 Sep;117(1):73–81

Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apo E4. Muros M, et al. **Atherosclerosis** 1996 Mar;121(1):13–21

A novel single base deletion in the LDLR gene (211delG): Effect on serum lipid profiles and the influence of other genetic polymorphisms in the ACE, APOE and APOB genes. Ward AJ, et al. **Atherosclerosis** 1996 Feb; 120(1–2):83–91

The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions. Egensperger R, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):484–6

Monoclonal antibody against the polymorphic site distinguishes apolipoprotein E4 from other isoforms. Nukina N, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):467–72

Effect of apolipoprotein E polymorphism on fasting retinyl palmitate level. Surguchov AP, et al. **Biochem Mol Med** 1995 Aug;55(2):156–7

Alzheimer's disease, herpes simplex virus type 1, cold sores and apolipoprotein E4. Lin WR, et al. **Biochem Soc Trans** 1995 Nov;23(4):594S

Characterization of a novel variant of apolipoprotein E, E2 Fukuoka (Arg–224 —> Gln) in a hyperlipidemic patient with xanthomatosis. Moriyama K, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):185–90

Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease. Norrman J, et al. **Br J Psychiatry** 1995 Oct;167(4):533–6

Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Bertrand P, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):174–8

Apolipoprotein E polymorphism and dietary plasma cholesterol response. Tikkanen M, et al. **Can J Cardiol** 1995

Oct;11 Suppl G:93G–96G (25 ref.)
Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty. van Bockxmeer FM, et al. **Circulation** 1995 Oct 15; 92(8):2066–71
High-throughput method for determination of apolipoprotein E genotypes with use of restriction digestion analysis by microplate array diagonal gel electrophoresis. Bolla MK, et al. **Clin Chem** 1995 Nov;41(11):1599–604
Improved procedure for eluting DNA from dried blood spots. Yang M, et al. **Clin Chem** 1996 Jul;42(7):1115–6
Lack of association of apolipoprotein E polymorphism with plasma Lp(a) levels in the Chinese. Heng CK, et al. **Clin Genet** 1995 Sep;48(3):113–9
Population frequency of apolipoprotein E5 (Glu3—>Lys) and E7 (Glu244—>Lys, Glu245—>Lys) variants in western Japan. Matsunaga A, et al. **Clin Genet** 1995 Aug; 48(2):93–9
Transgenic mouse and gene therapy. Harada K, et al. **Diabetes** 1996 Jul;45 Suppl 3:S129–32
Apolipoprotein E polymorphism and insulin levels in a biethnic population. Valdez R, et al. **Diabetes Care** 1995 Jul;18(7):992–1000
Phenotyping of apolipoprotein E using immobilized pH gradient gels for one-dimensional and two-dimensional separations. Golaz O, et al. **Electrophoresis** 1995 Jul; 16(7):1184–6
Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy. Nemeth A, et al. **Eur J Clin Chem Clin Biochem** 1995 Nov;33(11):799–804
Apolipoprotein E2 (Arg-136—>Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia. Feussner G, et al. **Eur J Clin Invest** 1996 Jan;26(1):13–23
Cerebrovascular amyloidosis in squirrel monkeys and rhesus monkeys: apolipoprotein E genotype. Morelli L, et al. **FEBS Lett** 1996 Jan 29;379(2):132–4
Underexpression of the apolipoprotein E2 and E4 alleles in the Greek Cypriot population of Cyprus. Cariolou MA, et al. **Genet Epidemiol** 1995;12(5):489–97 (29 ref.)
Dementia among elderly apolipoprotein E type 4/4 homozygotes: a prospective study. Ganguli M, et al. **Genet Epidemiol** 1995;12(3):309–11
Genotype–environment interaction: apolipoprotein E (ApoE) gene effects and age as an index of time and spatial context in the human. Zerba KE, et al. **Genetics** 1996 May; 143(1):463–78
Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of human alpha 1-antitrypsin in vivo. Okuyama T, et al. **Hum Gene Ther** 1996 Mar 20;7(5):637–45
Are men carrying the apolipoprotein epsilon 4– or epsilon 2 allele less fertile than epsilon 3 epsilon 3 genotypes? Gerdes LU, et al. **Hum Genet** 1996 Aug;98(2):239–42
Polymorphisms of apolipoproteins A–IV and E in a Turkish population living in Germany. Malle E, et al. **Hum Genet** 1996 Sep;98(3):285–90
Association of apolipoprotein E but not B with Alzheimer's disease. Poduslo SE, et al. **Hum Genet** 1995 Nov; 96(5):597–600
Genotypes with the apolipoprotein epsilon4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men. Stengård JH, et al. **Hum Genet** 1996 May;97(5):677–84
Inactivation of Apoe and Apoc1 by two consecutive rounds of gene targeting: effects on mRNA expression levels of gene cluster members. van Ree JH, et al. **Hum Mol Genet** 1995 Aug;4(8):1403–9
Polymorphism of the apolipoprotein E and angiotensin-converting enzyme genes in Japanese subjects with silent myocardial ischemia. Nakata Y, et al. **Hypertension** 1996 Jun;27(6):1205–9
Prevalence of dementia and distribution of ApoE alleles in Japanese centenarians: an almost-complete survey in Yamanashi Prefecture, Japan. Asada T, et al. **J Am Geriatr Soc** 1996 Feb;44(2):151–5
Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer's disease? [see comments] Nielson KA, et al. **J Am Geriatr Soc** 1996 Aug; 44(8):897–904. Comment in: J Am Geriatr Soc 1996 Aug;44(8):992–3.
Impact of sample selection on APOE epsilon 4 allele frequency: a comparison of two Alzheimer's disease samples. Tsuang D, et al. **J Am Geriatr Soc** 1996 Jun; 44(6):704–7
Temporal progression of hippocampal atrophy and apolipoprotein E gene in Alzheimer's disease [letter] Yamaguchi S, et al. **J Am Geriatr Soc** 1996 Feb;44(2):216–7
Atypical hyperlipidemia and nephropathy associated with apolipoprotein E homozygosity. Ellis D, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1170–7
Characterization of an upstream regulatory element of the human apolipoprotein E gene, and purification of its binding protein from the human placenta. Jo DW, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):915–22
Evolutionary duplication of a hepatic control region in the human apolipoprotein E gene locus. Identification of a second region that confers high level and liver-specific expression of the human apolipoprotein E gene in transgenic mice. Allan CM, et al. **J Biol Chem** 1995 Nov 3;270(44):26278–81
Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. Bellosta S, et al. **J Biol Chem** 1995 Nov 10;270(45):27063–71
Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein epsilon 4 allele. Bergeron N, et al. **J Clin Invest** 1996 Jan 1;97(1):65–72
Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma. Huang Y, et al. **J Clin Invest** 1995 Dec;96(6):2693–701
Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice. van Vlijmen BJ, et al. **J Clin Invest** 1996 Mar 1;97(5):1184–92
Genotyping of a patient homozygous for a rare apolipoprotein E1 [Gly127—>Asp; Arg158—>Cys] (Weisgraber allele). Iron A, et al. **J Inherit Metab Dis** 1995; 18(6):723–6
Apolipoprotein E epsilon 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers. St Clair D, et al. **J Med Genet** 1995 Aug;32(8):642–4
Diagnostic usefulness of apolipoprotein E epsilon 4 in the diagnosis of the dementias [letter] Frisoni GB, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):699–700
Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease. Ibarreta D, et al. **J Neurol Sci** 1995 Dec;134(1–2):146–9
Neuropathological evaluation and apolipoprotein E gene polymorphism analysis in diffuse Lewy body disease. Kawanishi C, et al. **J Neurol Sci** 1996 Mar;136(1–2):140–2
Apolipoprotein E and Alzheimer's disease. Stephens D. **J R Soc Health** 1996 Feb;116(1):41–3 (7 ref.)
Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. **JAMA** 1995 Nov 22–29;274(20):1627–9 (55 ref.)
Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group [see comments] **Lancet** 1996 Apr 20; 347(9008):1091–5 (77 ref.). Comment in: Lancet 1996 Apr 27;347(9009):1184–5. Comment in: Lancet 1996 Aug 3;348(9023):334.
Apolipoprotein E allele distribution in parents of Down's syndrome children. Avramopoulos D, et al. **Lancet** 1996 Mar 30;347(9005):862–5
APOE genotyping and Alzheimer's disease [letter; comment] Breitner JC. **Lancet** 1996 Apr 27;347(9009):1184–5. Comment on: Lancet 1996 Apr 20;347(9008):1091–5.
Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. al-Chalabi A, et al. **Lancet** 1996 Jan 20;347(8995):159–60
Apolipoprotein E–epsilon 4 gene dose [letter] Corder E, et al. **Lancet** 1995 Oct 7;346(8980):967–8
Attenuation of apolipoprotein E Epsilon4 allele gene dose in late age [letter; comment] Corder EH, et al. **Lancet** 1996 Feb 24;347(9000):542. Comment on: Lancet 1995 Nov 25;346(8987):1387–90.
Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample [see comments] Henderson AS, et al. **Lancet** 1995 Nov 25;346(8987):1387–90. Comment in: Lancet 1996 Feb 24;347(9000):542.
Apolipoprotein E genotyping in Alzheimer's disease [letter] Humphries S, et al. **Lancet** 1996 Jun 22;347(9017):1776
Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease [letter; comment] Kakulas BA, et al. **Lancet** 1996 Aug 17;348(9025):483. Comment on: Lancet 1996 Jul 13;348(9020):90–3.
Apolipoprotein E genotype and cerebral amyloid angiopathy [letter; comment] Kalaria RN, et al. **Lancet** 1995 Nov 25; 346(8987):1424. Comment on: Lancet 1995 Aug 26;346(8974):575.
Apolipoprotein E genotyping in Alzheimer's disease. The UK Alzheimer's Disease Genetic consortium [letter] Lovestone S, et al. **Lancet** 1996 Jun 22;347(9017):1775–6
Apolipoprotein E genotyping in Alzheimer's disease [letter] McKeith IG, et al. **Lancet** 1996 Jun 22;347(9017):1775
Alzheimer's disease, Down's syndrome, and chromosome segregation [letter] Potter H, et al. **Lancet** 1996 Jul 6; 348(9019):66
Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease [see comments] Saunders AM, et al. **Lancet** 1996 Jul 13;348(9020):90–3. Comment in: Lancet 1996 Aug 17;348(9025):483. Comment in: Lancet 1996 Aug 17;348(9025):483–4.
APOE genotyping in differential diagnosis of Alzheimer's disease [letter; comment] Slooter AJ, et al. **Lancet** 1996 Aug 3;348(9023):334. Comment on: Lancet 1996 Apr 20;347(9008):1091–5.
Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease [letter; comment] Smith AD, et al. **Lancet** 1996 Aug 17;348(9025):483–4. Comment on: Lancet 1996 Jul 13;348(9020):90–3.
Apolipoprotein E epsilon 4 in bulbar-onset motor neuron disease [letter] Smith RG, et al. **Lancet** 1996 Aug 3; 348(9023):334–5
Alzheimer's disease and apolipoprotein E genotype in Western Australia: an autopsy-verified series. Fabian VA, et al. **Med J Aust** 1996 Jul 15;165(2):77–80
Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: influence of apolipoprotein E polymorphism. Reznik Y, et al. **Metabolism** 1996 Jan;45(1):63–71
The relation of plasma triglyceride, apolipoprotein B, and high-density lipoprotein cholesterol to postheparin lipoprotein lipase activity is dependent on apolipoprotien E polymorphism. St-Amand J, et al. **Metabolism** 1996 Feb; 45(2):261–7
The effect of physical activity on serum total and low-density lipoprotein cholesterol concentrations varies with apolipoprotein E phenotype in male children and young adults: The Cardiovascular Risk in Young Finns Study. Taimela S, et al. **Metabolism** 1996 Jul;45(7):797–803
When a mind dies [editorial; comment] Campion EW. **N Engl J Med** 1996 Mar 21;334(12):791–2. Comment on: N Engl J Med 1996 Mar 21;334(12):745–51.
Molecular epidemiology of Alzheimer's disease [editorial; comment] Hyman BT, et al. **N Engl J Med** 1995 Nov 9; 333(19):1283–4. Comment on: N Engl J Med 1995 Nov 9;333(19):1242–7.
Apolipoprotein E and the neuropathology of dementia [letter; comment] Itoh Y, et al. **N Engl J Med** 1996 Feb 29; 334(9):599–600. Comment on: N Engl J Med 1995 Nov 9;333(19):1242–7.
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E [see comments] Reiman EM, et al. **N Engl J Med** 1996 Mar 21;334(12):752–8. Comment in: N Engl J Med 1996 Mar 21;334(12):792–4. Comment in: N Engl J Med 1996 Jul 18;335(3):207–8.
Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury [see comments] Nicoll JA, et al. **Nat Med** 1995 Feb;1(2):135–7 . Comment in: Nat Med 1995 Jul;1(7):603–4. Comment in: Nat Med 1995 Sep;1(9):852.
Head injury, amyloid beta and Alzheimer's disease [letter; comment] Roses AD, et al. **Nat Med** 1995 Jul;1(7):603–4 . Comment on: Nat Med 1995 Feb;1(2):135–7.
Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele. Heinonen O, et al. **Neurobiol Aging** 1995 Jul-Aug;16(4):505–13
Scopolamine-induced impairment as a potential predictor of Alzheimer's disease in individuals with Apolipoprotein E type 4 alleles. Pomara N, et al. **Neurochem Res** 1995 Dec; 20(12):1519–20
Apolipoprotein E genotype and Alzheimer's disease in an elderly Norwegian cohort. Benjamin R, et al. **Neurodegeneration** 1996 Mar;5(1):43–7
Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. Benjamin R, et al. **Neurodegeneration** 1995 Dec;4(4):443–8
A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Skoog I, et al. **Neurodegeneration** 1995 Dec;4(4):433–42
Apolipoprotein E allele in centenarians. Asada T, et al. **Neurology** 1996 May;46(5):1484
Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Bondi MW, et al. **Neurology** 1995 Dec;45(12):2203–6
A simple and efficient method for apolipoprotein E genotype determination. Chapman J, et al. **Neurology** 1996 May; 46(5):1484–5
Alzheimer's disease with and without coexisting Parkinson's disease changes: apolipoprotein E genotype and neuropathologic correlates. Gearing M, et al. **Neurology** 1995 Nov;45(11):1985–90
Epsilon 4 allele of apolipoprotein E increases risk of Alzheimer's disease in a Chinese population. Hong CJ, et al. **Neurology** 1996 Jun;46(6):1749–51
Apolipoprotein-epsilon4 and head trauma: Synergistic or additive risks? [letter; comment] Katzman R, et al. **Neurology** 1996 Mar;46(3):889–91. Comment on: Neurology 1995 Mar;45(3 Pt 1):555–7.
Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Lehtovirta M, et al. **Neurology** 1996 Feb; 46(2):413–9
Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese. Mak YT, et al. **Neurology** 1996 Jan; 46(1):146–9
A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele. Mui S, et al. **Neurology** 1996 Jul;47(1):196–201
Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Myers RH, et al. **Neurology** 1996 Mar;46(3):673–7
The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Olichney JM, et al. **Neurology** 1996 Jul;47(1):190–6
A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease. Ramachandran G, et al. **Neurology** 1996 Jul;47(1):256–9
A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory

impairment. Tierney MC, et al. **Neurology** 1996 Jan; 46(1):149–54

Apolipoprotein E gene expression in astrocytes: developmental pattern and regulation. Mouchel Y, et al. **Neuroreport** 1995 Dec 29;7(1):205–8

Increased acetylcholinesterase activity in the CSF of Alzheimer patients carrying apolipoprotein epsilon4 allele. Soininen H, et al. **Neuroreport** 1995 Dec 15;6(18):2518–20

Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia. Harrington CR, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):101–4

Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians. Morris CM, et al. **Neurosci Lett** 1995 Dec 1;201(1):45–7

Apolipoprotein E polymorphism and susceptibility to early- and late-onset sporadic Alzheimer's disease in Hokkaido, the northern part of Japan. Nunomura A, et al. **Neurosci Lett** 1996 Mar 8;206(1):17–20

A closely linked gene to apolipoprotein E may serve as an additional risk factor for Alzheimer's disease. Poduslo SE, et al. **Neurosci Lett** 1995 Dec 1;201(1):81–3

Apolipoprotein E (APOE) allele frequencies in late-onset sporadic Alzheimer's disease (AD), mixed dementia and vascular dementia: lack of association of epsilon 4 allele with AD in Italian octogenarian patients. Scacchi R, et al. **Neurosci Lett** 1995 Dec 15;201(3):231–4

Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Lehtovirta M, et al. **Neuroscience** 1995 Jul; 67(1):65–72

Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Nagy Z, et al. **Neuroscience** 1995 Dec; 69(3):757–61

Searching for a marker for Alzheimer's disease–Apo–E. Venarucci D, et al. **Panminerva Med** 1995 Jun;37(2):68–70

Discovery of a brain promoter from the human transferrin gene and its utilization for development of transgenic mice that express human apolipoprotein E alleles. Bowman BH, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12115–9

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Poirier J, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12260–4

Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. Basun H, et al. **Stroke** 1996 Aug;27(8):1310–5

Apolipoprotein E variants in ischemic stroke [letter; comment] Coria F, et al. **Stroke** 1995 Dec;26(12):2375–6. Comment on: Stroke 1992 Nov;23(11):1556–62.

Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Greenberg SM, et al. **Stroke** 1996 Aug; 27(8):1333–7

Influence of apolipoprotein E genotype on cerebral amyloid angiopathy in the elderly. Itoh Y, et al. **Stroke** 1996 Feb; 27(2):216–8

Rapid identification of ApoE alleles by multiple-single-strand conformation polymorphism (SSCP) analysis. Wilton S, et al. **Trends Genet** 1995 Sep; 11(9):341

Involvement of intronic sequences in the transcriptional regulation of apolipoprotein B, E and A–II genes. Chartier FL, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:44–5

Receptor-ligand interactions in the hepatic uptake of chylomicron remnants studied with genetically manipulated mice. Redgrave TG, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:105–7

Elevated levels of chylomicron- and VLDL-remnants leads to atherosclerosis in apoE transgenic mice. van Vlijmen BJ, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:113–5

[Apolipoprotein E polymorphism and Alzheimer disease] van der Weide J, et al. **Tijdschr Gerontol Geriatr** 1996 Apr; 27(2):73–7 (Eng. Abstr.) **(Dut)**

[Alzheimer's disease and the association of genetic polymorphism of apolipoprotein E and liquor beta protein in Finns] Lehtimäki T, et al. **Duodecim** 1995;111(5):401–7 **(Fin)**

[Apolipoprotein E polymorphism and serum cholesterol levels in Finnish children and adolescents] Lehtimäki T, et al. **Duodecim** 1994;110(14):1313–9 **(Fin)**

[Genotyping of apolipoprotein E (alleles epsilon 2, epsilon 3 and epsilon 4) from capillary blood] Lagarde JP, et al. **Ann Biol Clin (Paris)** 1995;53(1–2):15–20 (Eng. Abstr.) **(Fre)**

[Atheroma plaque and Apo E alleles] Venarucci D, et al. **Minerva Cardioangiol** 1996 Jan–Feb;44(1–2):15–8 (Eng. Abstr.) **(Ita)**

[Effect of apolipoprotein E phenotype on cerebrospinal fluid levels of tau in patients with dementia of Alzheimer type] Kanemaru K, et al. **Nippon Ronen Igakkai Zasshi** 1996 Feb; 33(2):120–1 **(Jpn)**

[Apolipoprotein E polymorphism in Alzheimer's disease] Shimohama S. **Nippon Ronen Igakkai Zasshi** 1996 Mar; 33(3):173–7 **(Jpn)**

IMMUNOLOGY

Allele epsilon 4 of apolipoprotein E shows a dose effect on age at onset of Pick disease. Farrer LA, et al. **Exp Neurol** 1995 Dec;136(2):162–70

Neurodegeneration in the central nervous system of apoE-deficient mice. Masliah E, et al. **Exp Neurol** 1995 Dec;136(2):107–22

Regional variation in the distribution of apolipoprotein E and A beta in Alzheimer's disease. Gearing M, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):833–41

ISOLATION & PURIFICATION

Elution of lipoprotein fractions containing apolipoproteins E and A–I in size exclusion on Superose 6 columns is sensitive to mobile phase pH and ionic strength. Westerlund J, et al. **J Chromatogr A** 1995 Dec 1;718(1):59–66

METABOLISM

Immunohistochemical study of apolipoprotein E in human cerebrovascular white matter lesions. Tomimoto H, et al. **Acta Neuropathol (Berl)** 1995;90(6):608–14

Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Gomez-Isla T, et al. **Ann Neurol** 1996 Jan;39(1):62–70

Accumulation of HDL apolipoproteins accompanies abnormal cholesterol accumulation in Schnyder's corneal dystrophy. Gaynor PM, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):992–9

Receptor pattern formation as a signal for the capture of lipoproteins. Mas-Oliva J, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):212–8

The role of lipoprotein lipase and apoprotein E in the recognition of chylomicrons and chylomicron remnants by cultured isolated mouse hepatocytes. Chang S, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):29–34

Uptake of apolipoprotein E-rich and apolipoprotein E-poor subfractions of high-density lipoprotein by liver membranes and HepG2 cells. Fragoso YD, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):611–5

Apolipoprotein E is increased in aged rat kidney. Chou SC, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):847–54

Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide A beta. Chan W, et al. **Biochemistry** 1996 Jun 4;35(22):7123–30

Developmental changes of apolipoprotein E immunoreactivity in Down syndrome brains. Arai Y, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):228–32

Apolipoprotein E polymorphism as a risk factor for vascular disease in diabetic patients. Boemi M, et al. **Diabetes Care** 1995 Apr;18(4):504–8

Differential binding of apolipoprotein E isoforms to tau and other cytoskeletal proteins. Fleming LM, et al. **Exp Neurol** 1996 Apr;138(2):252–60

Interaction between human amphipathic apolipoproteins and amyloid beta-peptide: surface plasmon resonance studies. Shuvaev VV, et al. **FEBS Lett** 1996 Mar 25;383(1–2):9–12

Very low density lipoprotein receptor binds apolipoprotein E2/2 as well as apolipoprotein E3/3. Takahashi S, et al. **FEBS Lett** 1996 May 20;386(2–3):197–200

The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. Argraves KM, et al. **J Biol Chem** 1995 Nov 3;270(44):26550–7

Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. Dong LM, et al. **J Biol Chem** 1996 Aug 9;271(32):19053–7

The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. Golabek AA, et al. **J Biol Chem** 1996 May 3;271(18):10602–6

Lipoprotein association of human apolipoprotein E/A–I chimeras. Expression in transfected hepatoma cells. Thurberg BL, et al. **J Biol Chem** 1996 Mar 15; 271(11):6062–70

Apolipoprotein E and low-density lipoprotein binding and internalization in primary cultures of rat astrocytes: isoform-specific alterations. Guillaume D, et al. **J Neurochem** 1996 Jun;66(6):2410–8

Crosslinking of apolipoprotein E by products of lipid peroxidation. Montine TJ, et al. **J Neuropathol Exp Neurol** 1996 Feb;55(2):202–10

Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Dong LM, et al. **Nat Struct Biol** 1996 Aug;3(8):718–22

ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. Huang DY, et al. **Neurosci Lett** 1995 Jun 16;192(3):209–12

The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype. Mann DM, et al. **Neurosci Lett** 1995 Aug 18; 196(1–2):105–8

Apolipoprotein E and B alleles in Parkinson's patients. Poduslo SE, et al. **Neurosci Lett** 1995 Jul 14;194(1–2):145–7

Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease. Salvatore M, et al. **Neurosci Lett** 1995 Oct 20; 199(2):95–8

ApoE immunoreactivity and microglial cells in Alzheimer's disease brain. Uchihara T, et al. **Neurosci Lett** 1995 Jul 28;195(1):5–8

Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Holtzman DM, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9480–4

[Alzheimer disease: hypotheses implicating apolipoproteins E] Blain H, et al. **Presse Med** 1996 May 4–11;25(16):763–8 (35 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Influence of purified apoprotein E on platelet activation induced by serotonin. Pfennig O, et al. **Am J Hematol** 1996 Aug;52(4):319–21

Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's beta-amyloid peptide in cultured vascular smooth muscle cells. Mazur-Kolecka B, et al. **Brain Res** 1995 Nov 6; 698(1–2):217–22

Apolipoprotein E and lipoprotein lipase co-ordinately enhance binding and uptake of chylomicrons by human hepatocytes. Mann WA, et al. **Eur J Clin Invest** 1995 Nov; 25(11):880–2

Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. Rensen PCN, et al. **J Biol Chem** 1996 Jun 21; 271(25):14791–9

Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Miyata M, et al. **Nat Genet** 1996 Sep;14(1):55–61

Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Woollett LA, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12500–4

Inhibition of ADP-induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion. Riddell DR, et al. **Thromb Res** 1995 Dec 15;80(6):499–508

PHYSIOLOGY

Apolipoprotein E, synaptic plasticity and Alzheimer's disease. Poirier J, et al. **Ann Med** 1995 Dec;27(6):663–70 (89 ref.)

Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Beffert U, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:166–74

Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease. Mahley RW, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:139–45 (24 ref.)

Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. Roses AD, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:146–57 (35 ref.)

Differential regulation of APP secretion by apolipoprotein E3 and E4. Wolozin BL, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:322–6

Apolipoprotein E and the apolipoprotein E-deficient mouse. Plump AS, et al. **Annu Rev Nutr** 1995;15:495–518 (109 ref.)

Interaction of apolipoprotein E with laminin increases neuronal adhesion and alters neurite morphology. Huang DY, et al. **Exp Neurol** 1995 Dec;136(2):251–7

Profound induction of hepatic cholesteryl ester transfer protein transgene expression in apolipoprotein E and low density lipoprotein receptor gene knockout mice. A novel mechanism signals changes in plasma cholesterol levels. Masucci-Magoulas L, et al. **J Clin Invest** 1996 Jan 1; 97(1):154–61

Apolipoprotein E and amyloidogenesis [editorial; comment] Castaño EM, et al. **Lab Invest** 1995 Oct;73(4):457–60. Comment on: Lab Invest 1995 Oct;73(4):469–75.

Association of apolipoprotein E with murine amyloid A protein amyloid [see comments] Kindy MS, et al. **Lab Invest** 1995 Oct;73(4):469–75. Comment in: Lab Invest 1995 Oct;73(4):457–60.

The rat, a useful animal model for pharmacological studies on apolipoprotein E. Leininger-Muller B, et al. **Life Sci** 1996;58(6):455–67 (102 ref.)

Phosphorylation of tau in apolipoprotein E-deficient mice. Genis I, et al. **Neurosci Lett** 1995 Oct 13;199(1):5–8

Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Gordon I, et al. **Neurosci Lett** 1995 Oct 13;199(1):1–4

[Isoform 4 of apolipoprotein E and Alzheimer disease. Specificity and clinical study] Mahieux F, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):231–9 (71 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. Bellosta S, et al. **J Biol Chem** 1995 Nov 10;270(45):27063–71

APOMORPHINE

ADMINISTRATION & DOSAGE

Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Sam E, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jan–Mar; 20(1):27–33

Sublingual apomorphine: a new pharmacological approach in Parkinson's disease? Montastruc JL, et al. **J Neural Transm Suppl** 1995;45:157–61

Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. van Laar T, et al. **Mov Disord** 1995 Jul; 10(4):433–9

[Treatment of motor fluctuations in Parkinson's disease with

subcutaneous injections of apomorphine] Merello M, et al. **Medicina (B Aires)** 1995;55(1):5-10 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Lipska BK, et al. **Biol Psychiatry** 1995 Aug 15;38(4):255-62

ANTAGONISTS & INHIBITORS

Intracerebroventricular injection of phospholipase A2 inhibits apomorphine-induced locomotion in rats. Brunner J, et al. **Psychiatry Res** 1995 Sep 29;58(2):165-9

DIAGNOSTIC USE

Psychotic and depressive symptoms in Parkinson's disease. A study of the growth hormone response to apomorphine. Mellers JD, et al. **Br J Psychiatry** 1995 Oct;167(4):522-6

The apomorphine test in gait disorders associated with parkinsonism. Linazasoro G. **Clin Neuropharmacol** 1996 Apr;19(2):171-6

Alcohol dependence, family history, and D2 dopamine receptor function as neuroendocrinologically assessed with apomorphine. Wiesbeck GA, et al. **Drug Alcohol Depend** 1995 Nov;40(1):49-53

Growth hormone response to apomorphine in panic disorder: comparison with major depression and normal controls. Pichot W, et al. **Eur Arch Psychiatry Clin Neurosci** 1995; 245(6):306-8

Changes in the amplitude of the N30 frontal component of SEPs during apomorphine test in parkinsonian patients. de Mari M, et al. **J Neural Transm Suppl** 1995;45:171-6

Effect of previous antidepressant therapy on the growth hormone response to apomorphine. Pitchot W, et al. **Neuropsychobiology** 1995;32(1):19-22

[Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease] Miranda M, et al. **Rev Med Chil** 1995 Mar;123(3):326-9 (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Sam E, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jan-Mar; 20(1):27-33

Pharmacokinetics of apomorphine in Parkinson's disease. Gancher S. **J Neural Transm Suppl** 1995;45:137-41 (21 ref.)

PHARMACOLOGY

Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Lipska BK, et al. **Biol Psychiatry** 1995 Aug 15;38(4):255-62

Administration of amphetamine does not increase the functional efficacy of dopaminergic grafts made in infancy. Abrous DN, et al. **Brain Res** 1996 Feb 5;708(1-2):21-8

Sensitization to apomorphine-induced rotational behavior in 6-OHDA-lesioned rats: effects of NMDA antagonists on drug response. Gancher S, et al. **Brain Res** 1995 Jun 5; 682(1-2):63-8

The hypothalamic paraventricular nucleus in two types of Wistar rats with different stress responses. I. Morphometric comparison. Mulders WH, et al. **Brain Res** 1995 Aug 14; 689(1):47-60

The hypothalamic paraventricular nucleus in two types of Wistar rats with different stress responses. II. Differential Fos-expression. Mulders WH, et al. **Brain Res** 1995 Aug 14;689(1):61-70

Effect of apomorphine on rat motor activity induced by fencamfamine and other indirect psychostimulant drugs. Aizenstein ML, et al. **Braz J Med Biol Res** 1995 Sep; 28(9):995-8

Effect of pimozide on the increase of muscarinic receptors caused by mazindol and apomorphine in the rat cerebral motor cortex. de-Sousa FC, et al. **Braz J Med Biol Res** 1995 Jan;28(1):113-9

Apomorphine can increase cutaneous inhibition of motor activity in Parkinson's disease. Clouston PD, et al. **Electroencephalogr Clin Neurophysiol** 1996 Feb;101(1):8-15

Divergent prolactin and pituitary-adrenal activity in rats selectively bred for different dopamine responsiveness. Rots NY, et al. **Endocrinology** 1996 May;137(5):1678-86

Growth hormone response to apomorphine in panic disorder: comparison with major depression and normal controls. Pichot W, et al. **Eur Arch Psychiatry Clin Neurosci** 1995; 245(6):306-8

Dopamine--glutamate--GABA interactions and ageing: studies in the striatum of the conscious rat. Porras A, et al. **Eur J Neurosci** 1995 Nov 1;7(11):2183-8

Induction of mating behavior by apomorphine in sexually sated rats. Mas M, et al. **Eur J Pharmacol** 1995 Jul 14; 280(3):331-4

Functional correlates of repeated administration of cocaine and apomorphine in the rat. Pontieri FE, et al. **Eur J Pharmacol** 1995 Sep 15;284(1-2):205-9

Apomorphine produced more yawning in Sprague-Dawley rats than in F344 rats: a pharmacological study. Tang AH, et al. **Eur J Pharmacol** 1995 Sep 15;284(1-2):13-8

Intrastriatal injection of opioid receptor agonists inhibits apomorphine-induced behavior in 6-hydroxydopamine-treated mice. Toyoshi T, et al. **Eur J Pharmacol** 1995 Dec 29;294(2-3):637-43

Reduction of apomorphine-induced rotational behaviour by subthalamic lesion in 6-OHDA lesioned rats is associated with a normalization of firing rate and discharge pattern of pars reticulata neurons. Burbaud P, et al. **Exp Brain Res** 1995;105(1):48-58

Effects of chronic lithium pretreatment on apomorphine-induced penile erection. Dehpour AR, et al. **Gen Pharmacol** 1995 Sep;26(5):1015-20

Effects of adenosine analogues on apomorphine-induced penile erection in rats. Sharifzadeh M, et al. **Gen Pharmacol** 1995 Dec;26(8):1785-90

Effects of adenosine drugs on apomorphine-induced licking in rats. Zarrindast MR, et al. **Gen Pharmacol** 1995 Sep; 26(5):1119-23

Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response. Maggio R, et al. **J Neural Transm Suppl** 1995;45:133-6 (22 ref.)

Injection of apomorphine--a test to predict individual different dopaminergic sensitivity? Surmann A, et al. **J Neural Transm Suppl** 1995;45:143-55

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. Colosimo C, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):634-7

The behavior of APO-SUS rats in animal models with construct validity for schizophrenia. Ellenbroek BA, et al. **J Neurosci** 1995 Nov;15(11):7604-11

Haloperidol and apomorphine differentially affect neuropeptidase activity. Waters SM, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):113-20

Inhibition by noncompetitive NMDA receptor antagonists of apomorphine-induced climbing behavior in mice. Kim HS, et al. **Life Sci** 1996;58(17):1397-402

Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats. Takeda N, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):589-90

Drug-induced circling preference in rats. Correlation with monoamine levels. Ali SF, et al. **Mol Neurobiol** 1995 Aug-Dec;11(1-3):145-54

Intrastriatal dopamine infusion reverses compensatory increases in D2-dopamine receptors in the 6-OHDA lesioned rat. Woiciechowsky C, et al. **Neurodegeneration** 1995 Jun;4(2):161-9

Effect of haloperidol and (-)-sulpiride on dopamine agonist-induced hypoactivity. Storey VJ, et al. **Neuropharmacology** 1995 Apr;34(4):449-55

Effects of acute treatment with dopaminergic drugs on open field behavior of adult monkeys treated with lead during the first year postpartum. Ferguson SA, et al. **Neurotoxicol Teratol** 1996 Mar-Apr;18(2):181-8

Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of parkinsonian tremor. Salamone J, et al. **Pharmacol Biochem Behav** 1996 Jan;53(1):179-83

Autosomal and Y chromosomal effects on the stereotyped response to apomorphine in wild house mice. Sluyter F, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):17-22

Frontal forebrain lesions: effects on the foraging and apomorphine pecking of pigeons. Wynne B, et al. **Physiol Behav** 1996 Apr-May;59(4-5):757-62

Multihormonal responses to apomorphine in mental illness. Mokrani MC, et al. **Psychoneuroendocrinology** 1995; 20(4):365-75

Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Lipska BK, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):35-43

Post-synaptic 5-HT1A receptor involvement in yawning and penile erections induced by apomorphine, physostigmine and mCPP in rats. Protais P, et al. **Psychopharmacology (Berl)** 1995 Aug;120(4):376-83

Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats. Swerdlow NR, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):27-34

Effects of single and repeated exposure to apomorphine on the acoustic startle reflex and its inhibition by a visual prepulse. Taylor MK, et al. **Psychopharmacology (Berl)** 1995 Jul;120(2):117-27

Sensitization to apomorphine in pigeons: unaffected by latent inhibition but still due to classical conditioning. Wynne B, et al. **Psychopharmacology (Berl)** 1995 Jun;119(4):414-20

[Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats] Minematsu N. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):247-52 (Eng. Abstr.) **(Jpn)**

[Apomorphine] Esteban Muñoz J. **Neurologia** 1995 Oct; 10(8):330-7 (55 ref.) **(Spa)**

THERAPEUTIC USE

Transcranial Doppler ultrasound in migraine and tension-type headache after apomorphine administration: double-blind crossover versus placebo study. Piccini P, et al. **Cephalalgia** 1995 Oct;15(5):399-403

Acute challenge with apomorphine in Huntington's disease: a double-blind study. Albanese A, et al. **Clin Neuropharmacol** 1995 Oct;18(5):427-34

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. Colosimo C, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):634-7

[Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease] Ferraz HB, et al. **Arq Neuropsiquiatr** 1995 Jun;53(2):245-51 (Eng. Abstr.) **(Por)**

APOPLEXY see CEREBROVASCULAR DISORDERS

APOPLEXY, PITUITARY see PITUITARY APOPLEXY

APOPROTEINS

ANALYSIS

Immunohistochemical distribution of surfactant apoproteins in hypoplastic lungs of nonimmunologic hydrops fetalis. Toki N, et al. **Hum Pathol** 1995 Nov;26(11):1252-9

BIOSYNTHESIS

Cloning and high-level expression of chicken apocytochrome c gene in Escherichia coli. Tong JC, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1187-95

The apparent coupling between synthesis and posttranslational modification of Escherichia coli acyl carrier protein is due to inhibition of amino acid biosynthesis. Keating DH, et al. **J Bacteriol** 1996 May; 178(9):2662-7

BLOOD

Fluorometric riboflavin titration in plasma by riboflavin-binding apoprotein as a method for vitamin B2 status assessment. Kodentsova VM, et al. **Ann Nutr Metab** 1995;39(6):355-60

[The relationships between apoprotein levels and body mass and atherogenic indices and sports activity in Aragonese schoolchildren] León Puy JF, et al. **An Esp Pediatr** 1996 Jul;45(1):21-4 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Differences in stability of recombinant apoaequorin within subcellular compartments. Badminton MN, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):950-7

Hydrophobic interaction and folding propensity of chicken heart apocytochrome c. Tong JC, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1177-86

Reaction of apoflavodoxin from Desulfovibrio vulgaris with 5,5'-dithio-bis-(2-nitrobenzoic acid). Logan CB, et al. **Biochem Soc Trans** 1996 Feb;24(1):30S

Pressure-induced perturbation of apomyoglobin structure: fluorescence studies on native and acidic compact forms. Bismuto E, et al. **Biochemistry** 1996 Jan 30;35(4):1173-8

Solution structure of rat apo-S100B(beta beta) as determined by NMR spectroscopy. Drohat AC, et al. **Biochemistry** 1996 Sep 10;35(36):11577-88

Design challenges for hemoproteins: the solution structure of apocytochrome b5. Falzone CJ, et al. **Biochemistry** 1996 May 28;35(21):6519-26

Characterization of the slow folding reactions of trp aporepressor from Escherichia coli by mutational analysis of prolines and catalysis by a peptidyl-prolyl isomerase. Mann CJ, et al. **Biochemistry** 1995 Nov 7;34(44):14573-80

Structural consequences of heme removal: molecular dynamics simulations of rat and bovine apocytochrome b5. Storch EM, et al. **Biochemistry** 1996 Sep 10; 35(36):11596-604

V92A mutation altered the folding propensity of chicken apocytochrome c and its interaction with phospholipids. Tong JC, et al. **Biochemistry** 1996 Jul 23;35(29):9460-8

Conformational heterogeneity of stability of apomyoglobin studied by hydrogen/deuterium exchange and electrospray ionization mass spectrometry. Wang F, et al. **Biochemistry** 1996 Apr 2;35(13):4069-78

Modified spectrophotometer for multi-dimensional circular dichroism/fluorescence data acquisition in titration experiments: application to the pH and guanidine-HCl induced unfolding of apomyoglobin. Ramsay G, et al. **Biophys J** 1995 Aug;69(2):701-7

Expression, lipoylation and structure determination of recombinant pea H-protein in Escherichia coli. Macherel D, et al. **Eur J Biochem** 1996 Feb 15;236(1):27-33

Reconstitution photoactive yellow protein from apoprotein and p-coumaric acid derivatives. Imamoto Y, et al. **FEBS Lett** 1995 Oct 30;374(2):157-60

Preparation of apolactoferrin with a very low iron saturation. Feng M, et al. **J Dairy Sci** 1995 Nov;78(11):2352-7

Time-resolved fluorescence studies of the molten globule state of apomyoglobin. Rischel C, et al. **J Mol Biol** 1996 Apr 12;257(4):877-85

Closure of a tyrosine/tryptophan aromatic gate leads to a compact fold in apo flavodoxin [letter] Genzor CG, et al. **Nat Struct Biol** 1996 Apr;3(4):329-32

Refolding and unfolding kinetics of the equilibrium folding intermediate of apomyoglobin. Jamin M, et al. **Nat Struct Biol** 1996 Jul;3(7):613-8

Packing interactions in the apomyglobin folding intermediate. Kay MS, et al. **Nat Struct Biol** 1996 May;3(5):439-45

How molten is the molten globule?[news] Ptitsyn O.

Nat Struct Biol 1996 Jun;3(6):488–90

Direct observation of fast protein folding: the initial collapse of apomyoglobin. Ballew RM, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5759–64

Structures of the apo- and the metal ion-activated forms of the diphtheria tox repressor from Corynebacterium diphtheriae. Schiering N, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9843–50

Pressure-induced perturbation of ANS-apomyoglobin complex: frequency domain fluorescence studies on native and acidic compact states. Bismuto E, et al. **Protein Sci** 1996 Jan;5(1):121–6

Dynamic structure of human serum transferrin from transient electric birefringence experiments. van Haeringen B, et al. **Proteins** 1995 Oct;23(2):233–40

The radius of gyration of an apomyoglobin folding intermediate. Eliezer D, et al. **Science** 1995 Oct 20; 270(5235):487–8

Similarity of a chromatic adaptation sensor to phytochrome and ethylene receptors. Kehoe DM, et al. **Science** 1996 Sep 6;273(5280):1409–12

Folding proteins caught in the act [news] Service RF. **Science** 1996 Jul 5;273(5271):29–30

GENETICS

Comparison of regional variability in lung-specific gene expression using a novel method for RNA isolation from lung subcompartments of rats and mice. Royce FH, et al. **Am J Pathol** 1996 Jun;148(6):1779–86

Cloning and high-level expression of chicken apocytochrome c gene in Escherichia coli. Tong JC, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1187–95

Dystroglycan mRNA expression during normal and mdx mouse embryogenesis: a comparison with utrophin and the apo-dystrophins. Schofield JN, et al. **Dev Dyn** 1995 Oct; 204(2):178–85

RNA editing of transcripts of the gene for apocytochrome b (cob) in rice mitochondria. Ito Y, et al. **Genes Genet Syst** 1996 Apr;71(2):85–9

Mutations affecting the mitochondrial genes encoding the cytochrome oxidase subunit I and apocytochrome b of Chlamydomonas reinhardtii. Colin M, et al. **Mol Gen Genet** 1995 Nov 15;249(2):179–84

Genetic mapping of mitochondrial markers by recombinational analysis in Chlamydomonas reinhardtii. Remacle C, et al. **Mol Gen Genet** 1995 Nov 15; 249(2):185–90

The moss, Physcomitrella patens, transformed with apoaequorin cDNA responds to cold shock, mechanical perturbation and pH with transient increases in cytoplasmic calcium. Russell AJ, et al. **Transgenic Res** 1996 May; 5(3):167–70

ISOLATION & PURIFICATION

Chlamyrhodopsin represents a new type of sensory photoreceptor. Deininger W, et al. **EMBO J** 1995 Dec 1;14(23):5849–58

METABOLISM

Kinetics and thermodynamics of the binding of riboflavin, riboflavin 5'-phosphate and riboflavin 3',5'-bisphosphate by apoflavodoxins. Pueyo JJ, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):855–61

Comparison of lipid aggregation and self-aggregation activities of pulmonary surfactant-associated protein A. Ruano ML, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):683–9

Hydrophobic interaction and folding propensity of chicken heart apocytochrome c. Tong JC, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1177–86

Cyanylation of the thiol of the cysteine of flavodoxin from Anabaena PCC 7119. Gallagher ME, et al. **Biochem Soc Trans** 1996 Feb;24(1):40S

Reaction of apoflavodoxin from Desulfovibrio vulgaris with 5,5'-dithio-bis-(2-nitrobenzoic acid). Logan CB, et al. **Biochem Soc Trans** 1996 Feb;24(1):30S

Assembly of light-harvesting chlorophyll a/b complex in vitro. Time-resolved fluorescence measurements. Booth PJ, et al. **Biochemistry** 1996 Apr 23;35(16):5103–8

The association rate constant for heme binding to globin is independent of protein structure. Hargrove MS, et al. **Biochemistry** 1996 Sep 3;35(35):11293–9

Metal ion interaction with urease and UreD-urease apoproteins. Park IS, et al. **Biochemistry** 1996 Apr 23; 35(16):5345–52

V92A mutation altered the folding propensity of chicken apocytochrome c and its interaction with phospholipids. Tong JC, et al. **Biochemistry** 1996 Jul 23;35(29):9460–8

A mechanism for iron uptake by transferrin. Pakdaman R, et al. **Eur J Biochem** 1996 Mar 15;236(3):922–31

Modification of a specific tyrosine enables tracing of the end-to-end distance during apomyoglobin folding. Rischel C, et al. **FEBS Lett** 1995 Oct 23;374(1):105–9

The apparent coupling between synthesis and posttranslational modification of Escherichia coli acyl carrier protein is due to inhibition of amino acid biosynthesis. Keating DH, et al. **J Bacteriol** 1996 May; 178(9):2662–7

Activation of SoxR-dependent transcription in vitro by noncatalytic or NifS-mediated assembly of [2Fe-2S] clusters into apo-SoxR. Hidalgo E, et al. **J Biol Chem** 1996 Mar 29;271(13):7269–72

Degradation of plastocyanin in copper-deficient Chlamydomonas reinhardtii. Evidence for a protease-susceptible conformation of the apoprotein and regulated proteolysis. Li HH, et al. **J Biol Chem** 1995 Oct 6;270(40):23504–10

Spectroscopic study of the interaction of aluminum ions with human transferrin. Tang S, et al. **J Inorg Biochem** 1995 Nov 15;60(3):175–85

PHARMACOLOGY

Uteroferrin induces lipid peroxidation in endometrial and conceptus microsomal membranes and is inhibited by apotransferrin, retinol binding protein, and the uteroferrin-associated proteins. Vallet JL. **Biol Reprod** 1995 Dec;53(6):1436–45

PHYSIOLOGY

Alterations of surfactant lipid turnover in silicosis: evidence of a role for surfactant-associated protein A (SP-A). Lesur O, et al. **Int J Exp Pathol** 1995 Aug;76(4):287–98

APOPTOSIS

see related
GERMINAL CENTER
NECROSIS

Accumulation and massive cell death of polymorphonuclear neutrophils in the developing bone marrow of the mouse: a histological study. Sasaki K, et al. **Acta Anat (Basel)** 1995; 153(2):111–8

Apoptosis in normal skin [letter] Hisa T, et al. **Acta Derm Venereol** 1995 Sep;75(5):412–3

Programmed cell death in brains of HIV-1-positive AIDS and pre-AIDS patients. An SF, et al. **Acta Neuropathol (Berl)** 1996;91(2):169–73

Both apoptosis and necrosis occur following intrastriatal administration of excitotoxins. Ferrer I, et al. **Acta Neuropathol (Berl)** 1995;90(5):504–10

T cell apoptosis as a consequence of chronic activation of the immune system in HIV infection. Gougeon ML. **Adv Exp Med Biol** 1995;374:121–7 (46 ref.)

Cell cycle-related protein kinases and T cell death. Lahti JM, et al. **Adv Exp Med Biol** 1995;376:247–58 (84 ref.)

Apoptosis during HIV infection. A cytopathic effect of HIV or an important host-defense mechanism against viruses in general? Martin SJ, et al. **Adv Exp Med Biol** 1995; 374:129–38 (46 ref.)

Programmed death of T cells in the course of HIV infection. Meyaard L, et al. **Adv Exp Med Biol** 1995;374:115–20 (27 ref.)

Mouse hepatitis virus-specific CD8+ cytotoxic T lymphocytes induce apoptosis in their target cells. Shibata S, et al. **Adv Exp Med Biol** 1995;380:109–11

Apoptosis of gamma/delta T cells in human ehrlichiosis. Caldwell CW, et al. **Am J Clin Pathol** 1996 May; 105(5):640–6

bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Diebold J, et al. **Am J Clin Pathol** 1996 Mar; 105(3):341–9

Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Björkerud S, et al. **Am J Pathol** 1996 Aug; 149(2):367–80

Biotin- or digoxigenin-conjugated nucleotides bind to matrix vesicles in atherosclerotic plaques. Kockx MM, et al. **Am J Pathol** 1996 Jun;148(6):1771–7

Quantitative in situ image analysis of apoptosis in well and poorly differentiated tumors from rat liver. Kong J, et al. **Am J Pathol** 1995 Dec;147(6):1626–32

Induction of apoptosis in endothelial cells treated with cholesterol oxides. Lizard G, et al. **Am J Pathol** 1996 May; 148(5):1625–38

Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Mooy CM, et al. **Am J Pathol** 1995 Oct;147(4):1097–104

Apoptosis during an early stage of nephrogenesis induces renal hypoplasia in bcl-2-deficient mice. Nagata M, et al. **Am J Pathol** 1996 May;148(5):1601–11

Photoreceptor apoptosis induced by a single systemic administration of N-methyl-N-nitrosourea in the rat retina. Nakajima M, et al. **Am J Pathol** 1996 Feb;148(2):631–41

Evidence of apoptotic cell death after experimental traumatic brain injury in the rat. Rink A, et al. **Am J Pathol** 1995 Dec;147(6):1575–83

Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Sharov VG, et al. **Am J Pathol** 1996 Jan;148(1):141–9

Absence of exogenous interleukin-4-induced apoptosis of gingival macrophages may contribute to chronic inflammation in periodontal diseases. Yamamoto M, et al. **Am J Pathol** 1996 Jan;148(1):331–9

Bleomycin induces apoptosis in human alveolar macrophages. Hamilton RF Jr, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):L318–25

Relationship between severity, necrosis, and apoptosis in five models of experimental acute pancreatitis. Kaiser AM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1295–304

TNF-alpha and IL-1 alpha induce mannose receptors and apoptosis in glomerular mesangial but not endothelial cells. Liu ZH, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1595–601

Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Uhal BD, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):L819–28

Eosinophil apoptosis and the resolution of airway inflammation in asthma. Woolley KL, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):237–43

A fluorometric assay for quantitating DNA strand breaks during apoptosis. Patel T, et al. **Anal Biochem** 1995 Aug 10;229(2):229–35

Detection of poly(ADP-ribose) polymerase and its apoptosis-specific fragment by a nonisotopic activity-western blot technique. Shah GM, et al. **Anal Biochem** 1995 Dec 10;232(2):251–4

Nineteenth century research on naturally occurring cell death and related phenomena. Clarke PG, et al. **Anat Embryol (Berl)** 1996 Feb;193(2):81–99 (143 ref.)

Macrophages during avian optic nerve development: relationship to cell death and differentiation into microglia. Moujahid A, et al. **Anat Embryol (Berl)** 1996 Feb; 193(2):131–44

Apoptosis and oxidative stress in the aging brain. Adams JD, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:135–51

Receptors that regulate T-cell susceptibility to apoptotic cell death. Boise LH, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:70–80 (32 ref.)

Lymphopoiesis, apoptosis, and immune amnesia. Donnenberg AD, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:213–26 (33 ref.)

Human blood and synovial fluid neutrophils cultured in vitro undergo programmed cell death which is promoted by the addition of synovial fluid. Bell AL, et al. **Ann Rheum Dis** 1995 Nov;54(11):910–5

Localisation of apoptosis and expression of apoptosis related proteins in the synovium of patients with rheumatoid arthritis. Sugiyama M, et al. **Ann Rheum Dis** 1996 Jul; 55(7):442–9

Oligonucleotides induce apoptosis restricted to the t(14;18) DHL-4 cell line. Morelli S, et al. **Anticancer Drug Des** 1996 Jan;11(1):1–14

Mutant H-ras overexpression inhibits drug and U.V. induced apoptosis. Fernandes RS, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1691–705

Apoptosis in human breast and gastrointestinal carcinomas. Detection in histological sections with monoclonal antibody to single-stranded DNA. Frankfurt OS, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1979–88

Two in situ labeling techniques reveal different patterns of DNA fragmentation during spontaneous apoptosis in vivo and induced apoptosis in vitro. Mundle SD, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):1895–904

Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review). Wu J. **Anticancer Res** 1996 Jul-Aug;16(4B):2233–9 (80 ref.)

Induction of Ley antigen by 5-aza-2'-deoxycytidine in association with differentiation and apoptosis in human pancreatic cancer cells. Yamada T, et al. **Anticancer Res** 1996 Mar-Apr;16(2):735–40

Apoptosis of mouse pancreatic acinar cells after duct ligation. Abe K, et al. **Arch Histol Cytol** 1995 Jun;58(2):221–9

Differential staining of DNA strand breaks in dying cells by non-radioactive in situ nick translation. Hashimoto S, et al. **Arch Histol Cytol** 1995 Jun;58(2):161–70

The ultrastructure, kinetics and intralobular distribution of apoptotic hepatocytes after portal branch ligation with special reference to their relationship to necrotic hepatocytes. Ikeda K, et al. **Arch Histol Cytol** 1995 Jun; 58(2):171–84

The fate of effete epithelial cells at the villus tips of the human small intestine. Shibahara T, et al. **Arch Histol Cytol** 1995 Jun;58(2):205–19

Multinucleated giant cells undergoing apoptosis in experimental autoimmune myocarditis. Suzuki K, et al. **Arch Histol Cytol** 1995 Jun;58(2):231–41

Apoptosis and heterophagy of medial edge epithelial cells of the secondary palatine shelves during fusion. Taniguchi K, et al. **Arch Histol Cytol** 1995 Jun;58(2):191–203

Apoptosis: The history and trends of its studies. Uchiyama Y. **Arch Histol Cytol** 1995 Jun;58(2):127–37 (73 ref.)

Apoptotic cells in the human endometrium and placental villi: pitfalls in applying the TUNEL method. Yasuda M, et al. **Arch Histol Cytol** 1995 Jun;58(2):185–90

Apoptosis of retinal ganglion cells in anterior ischemic optic neuropathy. Levin LA, et al. **Arch Ophthalmol** 1996 Apr; 114(4):488–91

Apoptotic photoreceptor cell death after traumatic retinal detachment in humans [letter] Sebag J, et al. **Arch Ophthalmol** 1996 Sep;114(9):1158–9

A histochemical study of apoptosis in the reduced ameloblasts of erupting mouse molars. Shibata S, et al. **Arch Oral Biol** 1995 Jul;40(7):677–80

The Gerhard Zbinden Memorial Lecture. Alteration of cell signalling in chemical toxicity. Nicotera P. **Arch Toxicol Suppl** 1996;18:3–11 (46 ref.)

Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Geng YJ, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):19–27

Apoptosis in thyroid tissue from patients with Hashimoto's thyroiditis. Kotani T, et al. **Autoimmunity** 1995;20(4):231–6

Molecular mechanisms of APO-1/Fas(CD95)-mediated apoptosis in tolerance and AIDS. Dhein J, et al.

Behring Inst Mitt 1995 Jun;(96):13–20 (37 ref.)
Immunocytochemical colocalization of clusterin in apoptotic photoreceptor cells in retinal degeneration slow rds mutant mouse retinas. Agarwal N, et al.
Biochem Biophys Res Commun 1996 Aug 5;225(1):84–91
Serum withdrawal induces apoptotic cell death in Ki-ras transformed but not in normal differentiated thyroid cells. di Jeso B, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):819–24
Activation of mitogen activated protein kinase in dolichyl phosphate-induced apoptosis in U937 cells. Dohi T, et al.
Biochem Biophys Res Commun 1996 Jul 5;224(1):87–91
Activation of cyclin E-dependent kinase by DNA-damage signals during apoptosis. Dou QP, et al.
Biochem Biophys Res Commun 1995 Sep 25;214(3):771–80
Specific inhibition of apoptosis after cerebral hypoxia–ischaemia by moderate post-insult hypothermia. Edwards AD, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1193–9
C-Fos is not essential for apoptosis. Gajate C, et al.
Biochem Biophys Res Commun 1996 Jan 5;218(1):267–72
Non-oxidative loss of glutathione in apoptosis via GSH extrusion. Ghibelli L, et al.
Biochem Biophys Res Commun 1995 Nov 2;216(1):313–20
Is polyamine decrease a common feature of apoptosis? Evidence from gamma rays- and heat shock-induced cell death. Grassilli E, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):708–14
Apoptosis of human kidney 293 cells is promoted by polymerized cadmium-metallothionein. Hamada T, et al.
Biochem Biophys Res Commun 1996 Feb 27;219(3):829–34
Consequences of p53 gene expression by adenovirus vector on cell cycle arrest and apoptosis in human aortic vascular smooth muscle cells. Katayose D, et al.
Biochem Biophys Res Commun 1995 Oct 13;215(2):446–51
Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. Kohno Y, et al. **Biochem Biophys Res Commun** 1996 Feb 27; 219(3):904–10
Relationship between susceptibility to apoptosis and Fas expression in peripheral blood T cells from uremic patients: a possible mechanism for lymphopenia in chronic renal failure. Matsumoto Y, et al.
Biochem Biophys Res Commun 1995 Oct 4;215(1):98–105
Increased intestinal Bak expression results in apoptosis. Moss SF, et al. **Biochem Biophys Res Commun** 1996 Jun 5; 223(1):199–203
Apoptosis in vascular smooth muscle cells: role of cell shrinkage. Orlov SN, et al.
Biochem Biophys Res Commun 1996 Apr 25;221(3):708–15
Induction of apoptosis reduces the severity of caerulein-induced pancreatitis in mice. Saluja A, et al.
Biochem Biophys Res Commun 1996 Mar 27;220(3):875–8
Role of c-jun in the inhibition of erythropoietin receptor-mediated apoptosis. Shimizu R, et al.
Biochem Biophys Res Commun 1996 May 6;222(1):1–6
Macrophage cytotoxicity against murine meth A sarcoma involves nitric oxide-mediated apoptosis. Sveinbjørnsson B, et al. **Biochem Biophys Res Commun** 1996 Jun 25; 223(3):643–9
The IGF-I receptor protects tumor cells from apoptosis induced by high concentrations of serum. Valentinis B, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):362–8
The novel regulatory mechanism of Fas system-mediated apoptosis in mesangial cells: implication to mesangial proliferative glomerulonephritis. Yasutomo K, et al.
Biochem Biophys Res Commun 1996 Feb 6;219(1):89–95
Regulation of the salvage pathway of deoxynucleotides synthesis in apoptosis induced by growth factor deprivation. Oliver FJ, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):421–5
Anti-oxidants and apoptosis. McGowan AJ, et al.
Biochem Soc Trans 1996 Feb;24(1):229–33 (35 ref.)
Type II transglutaminase expression in rabbit articular chondrocytes in culture: relation with cell differentiation, cell growth, cell adhesion and cell apoptosis. Borge L, et al. **Biochim Biophys Acta** 1996 Jun 13;1312(2):117–24
Increased p53 mRNA expression in liver and kidney apoptosis. Cummings MC. **Biochim Biophys Acta** 1996 Mar 1;1315(2):100–4
Programmed cell death: from development to disease. Meeting report. Hoeppner DJ, et al.
Biochim Biophys Acta 1996 Mar 18;1242(3):217–20
Activation of poly(ADP-ribose)polymerase in apoptotic human cells. Bernardi R, et al. **Biochimie** 1995;77(5):378–84
Out-of body experiences: cell-free cell death. Hengartner MO. **Bioessays** 1995 Jun;17(6):549–52 (16 ref.)
Cell-mediated cytotoxicity can be regulated by p53 tumor suppressor gene activity in vitro. Mahdi T, et al.
Biol Cell 1995;84(3):175–85
Induction of apoptosis in thymocytes: new evidence for an interaction of PKC and PKA pathways. Ojeda F, et al.
Biol Chem Hoppe Seyler 1995 Jun;376(6):389–93
Simultaneous detection of TDT-mediated dUTP-biotin nick end-labeling (TUNEL)-positive cells and multiple immunohistochemical markers in single tissue sections. Tornusciolo DR, et al. **Biotechniques** 1995 Nov;19(5):800–5
A monoclonal antibody recognizing CD43 (leukosialin) initiates apoptosis of human hematopoietic progenitor cells but not stem cells. Bažil V, et al. **Blood** 1996 Feb 15; 87(4):1272–81
Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL. Benito A, et al. **Blood** 1996 May 1;87(9):3837–43
Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy. Blankenberg FG, et al. **Blood** 1996 Mar 1;87(5):1951–6
Apoptosis in bone marrow of myelodysplastic syndrome patients [letter; comment] Bogdanović AD, et al. **Blood** 1996 Apr 1;87(7):3064. Comment on: Blood 1995 Jul 1;86(1):268–76.
Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Datta R, et al. **Blood** 1996 Sep 15;88(6):1936–43
Identification of the lineage of mature neutrophils and delineation of lipid body formation and apoptosis therein [letter; comment] Dvorak AM. **Blood** 1996 May 1; 87(9):4013–5. Comment on: Blood 1995 Nov 1;86(9):3341–52.
Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Estaquier J, et al. **Blood** 1996 Jun 15; 87(12):4959–66
Major histocompatibility complex class II-mediated inhibition of hematopoiesis in long-term marrow cultures involves apoptosis and is prevented by c-kit ligand [see comments] Hong DS, et al. **Blood** 1995 Nov 1;86(9):3341–52 . Comment in: Blood 1996 May 1;87(9):4013–5.
The Fanconi anemia complementation group C protein corrects DNA interstrand cross-link-specific apoptosis in HSC536N cells. Marathi UK, et al. **Blood** 1996 Sep 15; 88(6):2298–305
Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells. Mentz F, et al. **Blood** 1996 Sep 15;88(6):2172–82
The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Philpott NJ, et al.
Blood 1996 Mar 15;87(6):2244–51
Suppression of apoptosis during cytokine deprivation of 32D cells is not sufficient to induce complete granulocytic differentiation. Rodel JE, et al. **Blood** 1996 Feb 1; 87(3):858–64
CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. Schattner EJ, et al. **Blood** 1996 Aug 15;88(4):1375–82
Target cell-induced apoptosis of interleukin-2-activated human natural killer cells: roles of cell surface molecules and intracellular events. Yamauchi A, et al. **Blood** 1996 Jun 15;87(12):5127–35
CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Zupo S, et al. **Blood** 1996 Aug 15;88(4):1365–74
Comparative alterations in p53 expression and apoptosis in the irradiated rat small and large intestine. Arai T, et al.
Br J Cancer 1996 Aug;74(3):406–12
Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Reeve JG, et al. **Br J Cancer** 1996 May;73(10):1193–200
Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Paul C, et al. **Br J Dermatol** 1996 Apr;134(4):710–4
Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Amos TA, et al.
Br J Haematol 1995 Oct;91(2):387–93
Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Panayiotidis P, et al. **Br J Haematol** 1996 Jan; 92(1):97–103
In vivo induction of apoptosis in human lymphocytes by therapeutic fractionated total body irradiation. Delic J, et al. **Br J Radiol** 1995 Sep;68(813):997–1003
Calculation of the biological effect of fractionated radiotherapy: the importance of radiation-induced apoptosis. Olsen DR. **Br J Radiol** 1995 Nov;68(815):1230–6
Antigen presentation by astrocytes primes rat T lymphocytes for apoptotic cell death. A model for T-cell apoptosis in vivo. Gold R, et al. **Brain** 1996 Apr;119 (Pt 2):651–9
Apoptotic cell death of a temperature-sensitive central neuronal cell line. Hisanaga K, et al. **Brain Res** 1995 Jun 26;684(1):79–86
Apoptosis and DNA fragmentation as induced by tertiary butylhydroperoxide in the brain. Mukherjee SK, et al.
Brain Res Bull 1995;38(6):595–604
Apoptosis and oncosis in ocular disease. Heathcote JG.
Can J Ophthalmol 1995 Oct;30(6):298–300 (14 ref.)
Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Baretton GB, et al. **Cancer** 1996 Jan 15;77(2):255–64
Extensive apoptosis in ductal carcinoma in situ of the breast. Bodis S, et al. **Cancer** 1996 May 1;77(9):1831–5
Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins [letter; comment] Sinkovics JG. **Cancer** 1996 Jul 1;78(1):184–6. Comment on: Cancer 1995 Oct 15;76(8):1467–75.
Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Vollmers HP, et al. **Cancer** 1995 Aug 15;76(4):550–8
cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Ormerod MG, et al.
Cancer Chemother Pharmacol 1996;37(5):463–71
Apoptosis: inhibitor or instigator of carcinogenesis? Manning FC, et al. **Cancer Invest** 1996;14(5):455–65 (130 ref.)
Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Anthoney DA, et al.
Cancer Res 1996 Mar 15;56(6):1374–81
Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Chmura SJ, et al. **Cancer Res** 1996 Jun 15;56(12):2711–4
Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Demartis A, et al.
Cancer Res 1996 Sep 15;56(18):4213–8
Mch3, a novel human apoptotic cysteine protease highly related to CPP32. Fernandes-Alnemri T, et al.
Cancer Res 1995 Dec 15;55(24):6045–52
GADD153/CHOP, a DNA damage-inducible protein, reduced CAAT/enhancer binding protein activities and increased apoptosis in 32D c13 myeloid cells. Friedman AD. **Cancer Res** 1996 Jul 15;56(14):3250–6
Apoptotic death of human leukemic cells induced by vascular cells expressing nitric oxide synthase in response to gamma-interferon and tumor necrosis factor-alpha. Geng YJ, et al. **Cancer Res** 1996 Feb 15;56(4):866–74
Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Gomez-Manzano C, et al. **Cancer Res** 1996 Feb 15; 56(4):694–9
Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Hamel W, et al.
Cancer Res 1996 Jun 15;56(12):2697–702
Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. Han Z, et al.
Cancer Res 1996 Apr 1;56(7):1621–8
Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Isacson C, et al. **Cancer Res** 1996 Feb 15;56(4):669–74
Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Krajewski S, et al. **Cancer Res** 1996 Jun 15; 56(12):2849–55
Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacter pylori gastritis: effect of antibiotics and antioxidants. Mannick EE, et al. **Cancer Res** 1996 Jul 15; 56(14):3238–43
Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Mori S, et al. **Cancer Res** 1996 Apr 15;56(8):1874–9
Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells. Peled A, et al.
Cancer Res 1996 May 1;56(9):2148–56
Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Pizer ES, et al.
Cancer Res 1996 Jun 15;56(12):2745–7
Apoptosis in tumors and normal tissues induced by whole body hyperthermia in rats. Sakaguchi Y, et al.
Cancer Res 1995 Nov 15;55(22):5459–64
Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Shimizu S, et al. **Cancer Res** 1996 May 1;56(9):2161–6
Inhibition of neuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells. Tallett A, et al.
Cancer Res 1996 Sep 15;56(18):4255–63
Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: suppression of apoptosis with concomitant cell proliferation. Uhlmann EJ, et al. **Cancer Res** 1996 Jun 1;56(11):2506–9
Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Wang XW, et al. **Cancer Res** 1995 Dec 15; 55(24):6012–6
Cell proliferation and apoptosis during mammary carcinogenesis in pituitary isografted mice. Christov KT, et al. **Carcinogenesis** 1996 Aug;17(8):1741–6
Differential sensitivity to Ad5 E1B-21kD and Bcl-2 proteins of apoptin-induced versus p53-induced apoptosis. Zhuang SM, et al. **Carcinogenesis** 1995 Dec;16(12):2939–44
Signals for death and survival: a two-step mechanism for cavitation in the vertebrate embryo. Coucouvanis E, et al.
Cell 1995 Oct 20;83(2):279–87
A recessive mutant of the U937 cell line acquired resistance to anti-Fas and anti-p55 tumor necrosis factor receptor antibody-induced apoptosis. Noguchi K, et al.
Cell Growth Differ 1995 Oct;6(10):1271–7
Synergy between T cell Receptor and Fas (CD95/APO-1) signaling in mouse thymocyte death. Fisher GH, et al.
Cell Immunol 1996 Apr 10;169(1):99–106
Cell cycle progression out of G1 sensitizes primary-cultured nontransformed T cells to TCR-mediated apoptosis. Radvanyi LG, et al. **Cell Immunol** 1996 Jun 15; 170(2):260–73
A triplet of nuclease proteins (NP42–50) is activated in human Jurkat cells undergoing apoptosis. Zhang C, et al.
Cell Immunol 1995 Oct 15;165(2):161–7
Apoptosis of human embryonal carcinoma cells with in vitro differentiation. Yamada T, et al. **Cell Struct Funct** 1996

Feb;21(1):53–61

Apoptotic cell death in the rat adrenal gland: an in vivo and in vitro investigation. Carsia RV, et al. **Cell Tissue Res** 1996 Feb;283(2):247–54

Apoptosis in lactating and involuting mouse mammary tissue demonstrated by nick–end DNA labelling. Quarrie LH, et al. **Cell Tissue Res** 1995 Sep;281(3):413–9

Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Bennett MR, et al. **Circ Res** 1995 Dec; 77(6):1136–42

Apoptosis as a possible cause of gradual development of complete heart block and fatal arrhythmias associated with absence of the AV node, sinus node, and internodal pathways. James TN, et al. **Circulation** 1996 Apr 1; 93(7):1424–38

Apoptosis in human atherosclerosis and restenosis [letter; comment] Kockx M, et al. **Circulation** 1996 Jan 15; 93(2):394–5. Comment on: Circulation 1995 Jun 1;91(11):2703–11.

In vitro detection of apoptotic stimuli by use of the HL–60 myeloid leukemic cell line. Shellhaas JL, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):598–603

Inhibition of CD95 (Fas/Apo1)–mediated apoptosis by vaccinia virus WR. Heinkelein M, et al. **Clin Exp Immunol** 1996 Jan;103(1):8–14

An analysis of apoptosis in lymphoid organs and lupus disease in murine systemic lupus erythematosus (SLE). Ravirajan CT, et al. **Clin Exp Immunol** 1996 Aug;105(2):306–12

B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo–1/fas), diminished CD38 expression, and undergo enhanced apoptosis. Saxon A, et al. **Clin Exp Immunol** 1995 Oct;102(1):17–25

Apoptosis of T cells in multicentric Castleman's disease. Ishiyama T, et al. **Clin Immunol Immunopathol** 1996 Jun; 79(3):271–7

Apoptosis and its association with autoimmunity [editorial] George J, et al. **Clin Rheumatol** 1995 Sep;14(5):505–9 (29 ref.)

Programmed cell death in the anuran tadpole tail requires expression of a cell surface glycoprotein. Little GH, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Feb; 113(2):289–93

Role of apoptosis in the progression of glomerulosclerosis. Makino H, et al. **Contrib Nephrol** 1996;118:41–7 (30 ref.)

Glomerular capillary regeneration and endothelial cell apoptosis in both reversible and progressive models of glomerulonephritis. Shimizu A, et al. **Contrib Nephrol** 1996; 118:29–40

Expression of apoptosis–preventing Bcl–2 protein and –inducing Fas antigen in glomeruli of IgA nephropathy. Yoshimura A, et al. **Contrib Nephrol** 1996;118:48–53

Programmed cell death and cell transformation in craniofacial development. Shuler CF. **Crit Rev Oral Biol Med** 1995;6(3):202–17 (124 ref.)

Programmed cell death in the Drosophila central nervous system midline. Zhou L, et al. **Curr Biol** 1995 Jul 1; 5(7):784–90

Apoptosis–related fas antigen on memory T cells in aqueous humor of uveitis patients. Ohta K, et al. **Curr Eye Res** 1996 Mar;15(3):299–306

Apoptosis in brain–specific autoimmune disease. Bauer J, et al. **Curr Opin Immunol** 1995 Dec;7(6):839–43 (48 ref.)

The killer and the executioner: how apoptosis controls malignancy. Green DR, et al. **Curr Opin Immunol** 1995 Oct;7(5):694–703 (102 ref.)

Activation–induced death of mature T cells in the regulation of immune responses. Russell JH. **Curr Opin Immunol** 1995 Jun;7(3):382–8 (43 ref.)

Regulation of p53–dependent apoptosis by E1A and E1B. White E. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):34–58 (103 ref.)

Adaptation of the TdT assay for semi–quantitative flow cytometric detection of DNA strand breaks. Bromidge TJ, et al. **Cytometry** 1995 Jul 1;20(3):257–60

Measurement of apoptotic cells in peripheral blood. Carbonari M, et al. **Cytometry** 1995 Sep 15;22(3):161–7 (52 ref.)

Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells. Chapman RS, et al. **Cytometry** 1995 Jul 1;20(3):245–56

Factors affecting flow cytometric detection of apoptotic nuclei by DNA analysis. Elstein KH, et al. **Cytometry** 1995 Oct 1;21(2):170–6

Widespread programmed cell death in proliferative and postmitotic regions of the fetal cerebral cortex. Blaschke AJ, et al. **Development** 1996 Apr;122(4):1165–74

A group of genes required for maintenance of the amnioserosa tissue in Drosophila. Frank LH, et al. **Development** 1996 May;122(5):1343–52

Role of TGF beta s and BMPs as signals controlling the position of the digits and the areas of interdigital cell death in the developing chick limb autopod. Ganan Y, et al. **Development** 1996 Aug;122(8):2349–57

Contrasting effects of protein synthesis inhibition and of cyclic AMP on apoptosis in the developing retina. Rehen SK, et al. **Development** 1996 May;122(5):1439–48

Low bcl–2 expression and increased spontaneous apoptosis in T–lymphocytes from newly–diagnosed IDDM patients. Giordano C, et al. **Diabetologia** 1995 Aug;38(8):953–8

Defective expression of the apoptosis–inducing CD95 (Fas/APO–1) molecule on T and B cells in IDDM. Giordano C, et al. **Diabetologia** 1995 Dec;38(12):1449–54

Cytokine–induced apoptotic cell death in a mouse pancreatic beta–cell line: inhibition by Bcl–2. Iwahashi H, et al. **Diabetologia** 1996 May;39(5):530–6

Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Li W, et al. **Diabetologia** 1996 May;39(5):537–47

Spontaneous apoptosis in mouse F4N–S erythroleukemia cells induces a nonrandom fragmentation of DNA. Vodenicharov MD, et al. **DNA Cell Biol** 1996 Apr; 15(4):287–96

DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. Allday MJ, et al. **EMBO J** 1995 Oct 16;14(20):4994–5005

Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene–mediated apoptosis. Attardi LD, et al. **EMBO J** 1996 Jul 15;15(14):3693–701

T cells from baxalpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage–induced cell death in the absence of p53. gene product in. Brady HJ, et al. **EMBO J** 1996 Mar 15; 15(6):1221–30

Microfilament reorganization during apoptosis: the role of Gas2, a possible substrate for ICE–like proteases. Brancolini C, et al. **EMBO J** 1995 Nov 1;14(21):5179–90

A bacterial invasin induces macrophage apoptosis by binding directly to ICE. Chen Y, et al. **EMBO J** 1996 Aug 1; 15(15):3853–60

A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. Chittenden T, et al. **EMBO J** 1995 Nov 15;14(22):5589–96

Multiple pathways originate at the Fas/APO–1 (CD95) receptor: sequential involvement of phosphatidylcholine–specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. Cifone MG, et al. **EMBO J** 1995 Dec 1; 14(23):5859–68

Superoxide anion is a natural inhibitor of FAS–mediated cell death. Clément MV, et al. **EMBO J** 1996 Jan 15; 15(2):216–25

Cathepsin D protease mediates programmed cell death induced by interferon–gamma, Fas/APO–1 and TNF–alpha. Deiss LP, et al. **EMBO J** 1996 Aug 1; 15(15):3861–70

A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. Duckett CS, et al. **EMBO J** 1996 Jun 3;15(11):2685–94

Proteasomes play an essential role in thymocyte apoptosis. Grimm LM, et al. **EMBO J** 1996 Aug 1;15(15):3835–44

Cyclin D1 is an essential mediator of apoptotic neuronal cell death. Kranenburg O, et al. **EMBO J** 1996 Jan 2; 15(1):46–54

The ATP binding cassette transporter ABC1, is required for the engulfment of corpses generated by apoptotic cell death. Luciani MF, et al. **EMBO J** 1996 Jan 15;15(2):226–35

Cell–free reconstitution of Fas–, UV radiation– and ceramide–induced apoptosis. Martin SJ, et al. **EMBO J** 1995 Nov 1;14(21):5191–200

Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing Cu/Zn–superoxide dismutase: implications for Down syndrome. Peled–Kamar M, et al. **EMBO J** 1995 Oct 16; 14(20):4985–93

Specific loss of apoptotic but not cell–cycle arrest function in a human tumor derived p53 mutant. Rowan, S, et al. **EMBO J** 1996 Feb 15;15(4):827–38

Activation of cyclin–dependent kinases by Myc mediates induction of cyclin A, but not apoptosis. Rudolph B, et al. **EMBO J** 1996 Jun 17;15(12):3065–76

Involvement of the proteasome in the programmed cell death of NGF–deprived sympathetic neurons. Sadoul R, et al. **EMBO J** 1996 Aug 1;15(15):3845–52

DNA–dependent protein kinase catalytic subunit: a target for an ICE–like protease in apoptosis. Song Q, et al. **EMBO J** 1996 Jul 1;15(13):3238–46

Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle. Suzuki A, et al. **EMBO J** 1996 Jan 15;15(2):211–15

Targeting simian virus 40 T antigen to the osteoclast in transgenic mice causes osteoclast tumors and transformation and apoptosis of osteoclasts. Boyce BF, et al. **Endocrinology** 1995 Dec;136(12):5751–9

Hormonal regulation of apoptosis in early antral follicles: follicle–stimulating hormone as a major survival factor. Chun SY, et al. **Endocrinology** 1996 Apr;137(4):1447–56

Susceptibility of avian ovarian granulosa cells to apoptosis is dependent upon stage of follicle development and is related to endogenous levels of bcl–xlong gene expression. Johnson AL, et al. **Endocrinology** 1996 May;137(5):2059–66

Apoptosis contributes to the involution of beta cell mass in the post partum rat pancreas. Scaglia L, et al. **Endocrinology** 1995 Dec;136(12):5461–8

Different apoptotic pathways mediated by Fas and the tumor–necrosis–factor receptor. Cytosolic phospholipase A2 is not involved in Fas–mediated apoptosis. Enari M, et al. **Eur J Biochem** 1996 Mar 1;236(2):533–8

Apoptosis: molecular regulation of cell death. Hale AJ, et al. **Eur J Biochem** 1996 May 1;237(3):884

Apoptosis: molecular regulation of cell death. Hale AJ, et al. **Eur J Biochem** 1996 Feb 15;236(1):1–26 (380 ref.)

Stereospecific induction of apoptosis in U937 cells by N–octanoyl–sphingosine stereoisomers and N–octyl–sphingosine. The ceramide amide group is not required for apoptosis. Karasavvas N, et al. **Eur J Biochem** 1996 Mar 1;236(2):729–37

Proliferation and apoptosis in neuroblastoma: subdividing the mitosis–karyorrhexis index. Gestblom C, et al. **Eur J Cancer** 1995;31A(4):458–63

Apoptosis in normal epithelium, premalignant and malignant lesions of the oropharynx and oral cavity: a preliminary study. Birchall MA, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):380–3

Cell dynamics of undifferentiated carcinomas of the ovary. Immunohistochemical estimation of their growth fraction and apoptotic status. Kuwashima Y, et al. **Eur J Gynaecol Oncol** 1995;16(4):268–73

Monocytic differentiation and synthesis of proteins associated with apoptosis in human leukemia U–937 cells acquiring resistance to vincristine. Pantazis P, et al. **Eur J Haematol** 1996 Jul;57(1):79–86

Characterization of the tissue regression process in the uterus of older mice as apoptotic by the presence of Tp30, an isoform of terminin. Miller MM, et al. **Eur J Histochem** 1995;39(2):91–100

Bcl–2 delays macrophage engulfment of human B cells induced to undergo apoptosis. Flora PK, et al. **Eur J Immunol** 1996 Sep;26(9):2243–7

Clonal deletion of major histocompatibility complex class I–restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO–1/Fas) ligand. Müller KP, et al. **Eur J Immunol** 1995 Oct;25(10):2996–9

NMDA and kainate induce internucleosomal DNA cleavage associated with both apoptotic and necrotic cell death in the neonatal rat brain. van Lookeren Campagne M, et al. **Eur J Neurosci** 1995 Jul 1;7(7):1627–40

Epidermal growth factor prevents oxygen–triggered apoptosis and induces sustained signalling in cultured rat cerebral cortical neurons. Yamada M, et al. **Eur J Neurosci** 1995 Oct 1;7(10):2130–8

Monoclonal antibody to single–stranded DNA is a specific and sensitive cellular marker of apoptosis. Frankfurt OS, et al. **Exp Cell Res** 1996 Aug 1;226(2):387–97

SRB1, a class B scavenger receptor, recognizes both negatively charged liposomes and apoptotic cells. Fukasawa M, et al. **Exp Cell Res** 1996 Jan 10;222(1):246–50

Detection of apoptosis and DNA replication by differential labeling of DNA strand breaks with fluorochromes of different color. Li X, et al. **Exp Cell Res** 1996 Jan 10; 222(1):28–37

Expression of the integrin alpha 5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation. O'Brien V, et al. **Exp Cell Res** 1996 Apr 10; 224(1):208–13

Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells. Rusnak JM, et al. **Exp Cell Res** 1996 Apr 10;224(1):189–99

T cell apoptosis induced by interleukin–2 deprivation or transforming growth factor–beta 2: modulation by the phosphatase inhibitors okadaic acid and calyculin A. Weller M, et al. **Exp Cell Res** 1995 Dec;221(2):395–403

Multiple proteases are involved in thymocyte apoptosis. Zhivotovsky B, et al. **Exp Cell Res** 1995 Dec;221(2):404–12

Programmed cell death of retinal ganglion cells during experimental glaucoma. Garcia–Valenzuela E, et al. **Exp Eye Res** 1995 Jul;61(1):33–44

Calcimycin–induced lens epithelial cell apoptosis contributes to cataract formation. Li WC, et al. **Exp Eye Res** 1995 Jul;61(1):91–8

Epithelial injury induces keratocyte apoptosis: hypothesized role for the interleukin–1 system in the modulation of corneal tissue organization and wound healing. Wilson SE, et al. **Exp Eye Res** 1996 Apr;62(4):325–7

Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Philpott NJ, et al. **Exp Hematol** 1995 Dec;23(14):1642–8

Interferon–alpha–induced apoptosis in human erythroid progenitors. Tarumi T, et al. **Exp Hematol** 1995 Nov; 23(12):1310–8

Programmed cell death and its clearance in the developing mammalian kidney. Camp V, et al. **Exp Nephrol** 1996 Mar–Apr;4(2):105–11 (29 ref.)

Expression of apoptosis–related molecules in acute renal injury. Yoshimura A, et al. **Exp Nephrol** 1996 Jan–Feb; 4(1):15–8 (18 ref.)

Axotomy–induced apoptotic cell death of neonatal rat facial motoneurons: time course analysis and relation to NADPH–diaphorase activity. Rossiter JP, et al. **Exp Neurol** 1996 Mar;138(1):33–44

Intracellular calcium levels influence apoptosis in mature sensory neurons after trophic factor deprivation. Tong JX, et al. **Exp Neurol** 1996 Mar;138(1):45–52

Apoptosis occurs in granulosa cells but not cumulus cells in the atretic antral follicles in pig ovaries. Manabe N, et al. **Experientia** 1996 Jul 15;52(7):647–51

Choline deficiency induces apoptosis in SV40–immortalized CWSV–1 rat hepatocytes in culture. Albright CD, et al. **FASEB J** 1996 Mar;10(4):510–6

RAR and RXR selective ligands cooperatively induce apoptosis and neuronal differentiation in P19 embryonal

carcinoma cells. Horn V, et al. **FASEB J** 1996 Jul; 10(9):1071–7

Involvement of interleukin–1 beta–converting enzyme in apoptosis of bFGF–deprived murine aortic endothelial cells. Kondo S, et al. **FASEB J** 1996 Aug;10(10):1192–7

The biochemistry of programmed cell death. Kroemer G, et al. **FASEB J** 1995 Oct;9(13):1277–87 (84 ref.)

Tumor cell resistance to apoptosis due to a defect in the activation of sphingomyelinase and the 24 kDa apoptotic protease (AP24). Wright SC, et al. **FASEB J** 1996 Feb; 10(2):325–32

Role of retinoic acid and oxidative stress in embryonic stem cell death and neuronal differentiation. Castro–Obregón S, et al. **FEBS Lett** 1996 Feb 26;381(1–2):93–7

A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR–I and Fas. Chapman BS. **FEBS Lett** 1995 Oct 30;374(2):216–20

mtDNA–depleted U937 cells are sensitive to TNF and Fas–mediated cytotoxicity. Gamen S, et al. **FEBS Lett** 1995 Nov 27;376(1–2):15–8

Sequential activation of three distinct ICE–like activities in Fas–ligated Jurkat cells. Greidinger EL, et al. **FEBS Lett** 1996 Jul 29;390(3):299–303

The death domain motif found in Fas (Apo–1) and TNF receptor is present in proteins involved in apoptosis and axonal guidance. Hofmann K, et al. **FEBS Lett** 1995 Sep 11;371(3):321–3

Role of arachidonic acid metabolism in thymocyte apoptosis after irradiation. Korystov YN, et al. **FEBS Lett** 1996 Jun 17;388(2–3):238–41

Activin A–induced apoptosis is suppressed by BCL–2. Koseki T, et al. **FEBS Lett** 1995 Dec 4;376(3):247–50

Induction of apoptotic cell death by pancreatitis–associated ascitic fluid in Madin–Darby canine kidney cells. Nishikawa J, et al. **FEBS Lett** 1995 Oct 2;373(1):19–22

Prevention of necrosis and activation of apoptosis in oxidatively injured human myeloid leukemia U937 cells. Palomba L, et al. **FEBS Lett** 1996 Jul 15;390(1):91–4

Suppression of bcl–2 gene expression by sphingosine in the apoptosis of human leukemic HL–60 cells during phorbol ester–induced terminal differentiation. Sakakura C, et al. **FEBS Lett** 1996 Jan 29;379(2):177–80

Apoptosis, DNA damage and ubiquitin expression in normal and mdx muscle fibers after exercise. Sandri M, et al. **FEBS Lett** 1995 Oct 16;373(3):291–5

The SV40 T–antigen induces premature apoptotic mammary gland involution during late pregnancy in transgenic mice. Tzeng YJ, et al. **FEBS Lett** 1996 Feb 19;380(3):215–8

Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. Zamzami N, et al. **FEBS Lett** 1996 Apr 8;384(1):53–7

An ICE–like protease is a common mediator of apoptosis induced by diverse stimuli in human monocytic THP.1 cells. Zhu H, et al. **FEBS Lett** 1995 Oct 30;374(2):303–8

Induction of macrophage apoptosis by Bordetella pertussis adenylate cyclase–hemolysin. Khelef N, et al. **FEMS Microbiol Lett** 1995 Dec 1;134(1):27–32

Apoptosis as a function of ovarian reserve in women undergoing in vitro fertilization. Seifer DB, et al. **Fertil Steril** 1996 Oct;66(4):593–8

Apoptosis, programmed cell death in the central nervous system. Maślińska D, et al. **Folia Neuropathol** 1995; 33(2):69–76 (76 ref.)

Lens epithelial cell apoptosis is an early event in the development of UVB–induced cataract. Li WC, et al. **Free Radic Biol Med** 1996;20(3):301–11

Apoptosis and proliferation: the balance [letter; comment] Khosraviani K, et al. **Gastroenterology** 1996 Apr; 110(4):1323–4. Comment on: Gastroenterology 1995 Sep;109(3):994–8.

Apoptosis in the intestine [letter; comment] Moss SF, et al. **Gastroenterology** 1996 Aug;111(2):567–8. Comment on: Gastroenterology 1996 Apr;110(4):1238–43.

Apoptosis observed in peripheral T lymphocytes from patients with chronic hepatitis B. Nakamura K, et al. **Gastroenterology** 1996 Jul;111(1):156–64

Isolation of a novel mouse gene MA–3 that is induced upon programmed cell death. Shibahara K, et al. **Gene** 1995 Dec 12;166(2):297–301

The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53–inducible and death–promoting Bax protein. Han J, et al. **Genes Dev** 1996 Feb 15;10(4):461–77

The XPB and XPD DNA helicases are components of the p53–mediated apoptosis pathway. Wang XW, et al. **Genes Dev** 1996 May 15;10(10):1219–32

Programmed cell death in neurotumour cells involves the generation of ceramide. Wiesner DA, et al. **Glycoconj J** 1996 Apr;13(2):327–33

Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Mahida YR, et al. **Gut** 1996 Mar;38(3):337–47

In situ detection of enterocytic apoptosis in normal colonic mucosa and in familial adenomatous polyposis. Sträter J, et al. **Gut** 1995 Dec;37(6):819–25

Proliferation, apoptosis, and induction of hepatic transcription factors are characteristics of the early response of biliary epithelial (oval) cells to chemical carcinogens. Bisgaard HC, et al. **Hepatology** 1996 Jan; 23(1):62–70

Induction of rat liver parenchymal cell apoptosis by hepatic myofibroblasts via transforming growth factor beta. Gressner AM, et al. **Hepatology** 1996 Mar;23(3):571–81

Bacterial lipopolysaccharide antagonizes transforming growth factor beta 1–induced apoptosis in primary cultures of hepatocytes. Martín–Sanz P, et al. **Hepatology** 1996 May; 23(5):1200–7

The antiandrogen cyproterone acetate induces synthesis of transforming growth factor beta 1 in the parenchymal cells of the liver accompanied by an enhanced sensitivity to undergo apoptosis and necrosis without inflammation. Oberhammer F, et al. **Hepatology** 1996 Feb;23(2):329–37

Association between the apoptotic index and established prognostic parameters in endometrial adenocarcinoma. Heatley MK. **Histopathology** 1995 Nov;27(5):469–72

Interleukin–7 rescues human activated T lymphocytes from apoptosis induced by glucocorticoesteroids and regulates bcl–2 and CD25 expression. Hernández–Caselles T, et al. **Hum Immunol** 1995 Jul;43(3):181–9

Apoptosis in target organs of hypertension. Hamet P, et al. **Hypertension** 1995 Oct;26(4):642–8

A role for the orphan steroid receptor Nur77 in apoptosis accompanying antigen–induced negative selection. Calnan BJ, et al. **Immunity** 1995 Sep;3(3):273–82

The involvement of an ATP–gated ion channel, P(2X1), in thymocyte apoptosis. Chvatchko Y, et al. **Immunity** 1996 Sep;5(3):275–83

P2x purinoceptor is not important in thymocyte apoptosis. Jiang S, et al. **Immunol Lett** 1996 Mar;49(3):197–201

Exponential growth in apoptosis. Cohen JJ. **Immunol Today** 1995 Jul;16(7):346–8

Different pathways of in vitro ethanol–induced apoptosis in thymocytes and splenic T and B lymphocytes. Slukvin II, et al. **Immunopharmacology** 1995 Nov;31(1):43–57

Evidence for apoptosis of murine macrophages by Actinobacillus actinomycetemcomitans infection. Kato S, et al. **Infect Immun** 1995 Oct;63(10):3914–9

Plasmodium falciparum induces apoptosis in human mononuclear cells. Toure–Balde A, et al. **Infect Immun** 1996 Mar;64(3):744–50

Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Mogil RJ, et al. **Int Immunol** 1995 Sep;7(9):1451–8

Cross–linking of the TCR–CD3 complex with CD4, CD8 or LFA–1 induces an anti–apoptotic signal in thymocytes: the signal is canceled by FK506. Zhao Y, et al. **Int Immunol** 1995 Sep;7(9):1387–96

In–situ quantification of stage–specific apoptosis in the rat seminiferous epithelium: effects of short–term experimental cryptorchidism. Henriksén K, et al. **Int J Androl** 1995 Oct; 18(5):256–62

Demonstration of herpesvirus particles in apoptotic bodies of a brain lymphoma in an SIV–immunodeficient monkey [letter] De Mesquita R, et al. **Int J Cancer** 1995 Nov 3; 63(3):472–3

A novel anti–Thy–1 (CD90) monoclonal antibody induces apoptosis in mouse malignant T–lymphoma cells in spite of inducing bcl–2 expression. Fujita N, et al. **Int J Cancer** 1996 May 16;66(4):544–50

Tumor necrosis factor alpha is a powerful apoptotic inducer in lymphoid leukemic cells expressing the P–170 glycoprotein. Malorni W, et al. **Int J Cancer** 1996 Jul 17; 67(2):238–47

Apoptosis occurs more frequently in metastatic foci than in primary lesions of human colorectal carcinomas: analysis by terminal–deoxynucleotidyl–transferase–mediated dUTP–biotin nick end labeling. Tatebe S, et al. **Int J Cancer** 1996 Jan 17;65(2):173–7

Hyperthermia induces apoptosis in malignant fibrous histiocytoma cells in vitro. Yonezawa M, et al. **Int J Cancer** 1996 May 3;66(3):347–51

Growth factors and apoptosis in development. The role of insulin like growth factor I and TGFbeta1 in regulating cell growth and cell death in a human teratocarcinoma derived cell line. Granerus M, et al. **Int J Dev Biol** 1995 Oct;39(5):759–64

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Raza A, et al. **Int J Hematol** 1996 Jun;63(4):265–78 (52 ref.)

Increased c–fos expression associated with hyperthermia–induced apoptosis of a Burkitt lymphoma cell line. Cummings M. **Int J Radiat Biol** 1995 Dec; 68(6):687–92

Apoptosis, energy metabolism, and fraction of radiobiologically hypoxic cells: a study of human melanoma multicellular spheroids. Rofstad EK, et al. **Int J Radiat Biol** 1996 Sep;70(3):241–9

Apoptosis and downstaging after preoperative radiotherapy for muscle–invasive bladder cancer [see comments] Chyle V, et al. **Int J Radiat Oncol Biol Phys** 1996 May 1; 35(2):281–7. Comment in: Int J Radiat Oncol Biol Phys 1996 May 1;35(2):411–2.

Radiation–induced apoptosis: relevance to radiotherapy. Dewey WC, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):781–96 (78 ref.)

Translational research in bladder cancer [editorial; comment] Shipley WU. **Int J Radiat Oncol Biol Phys** 1996 May 1; 35(2):411–2. Comment on: Int J Radiat Oncol Biol Phys 1996 May 1;35(2):281–7.

Programmed cell death in development. Sanders EJ, et al. **Int Rev Cytol** 1995;163:105–73 (410 ref.)

The Fas–Fas ligand system and other modulators of apoptosis in the cornea. Wilson SE, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1582–92

Tissue transglutaminase in apoptosis of photoreceptor cells in rat retina. Zhang SR, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1793–9

Effects of human immunodeficiency virus type 1 infection on programmed cell death in the presence or absence of Bcl–2. Park IW, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Aug 1;12(4):321–8

Apoptosis is the mode of keratinocyte death in cutaneous graft–versus–host disease. Langley RG, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):187–90

DNA fragmentation induced in high–cell–density culture of primary rat hepatocytes is an active process dependent on energy availability, gene expression, and calmodulin. Maeda S, et al. **J Biochem (Tokyo)** 1995 Dec;118(6):1161–5

Phosphorylation of Bcl–2 protein and association with p21Ras in Ras–induced apoptosis. Chen CY, et al. **J Biol Chem** 1996 Feb 2;271(5):2376–9

FADD/MORT1 is a common mediator of CD95 (Fas/APO–1) and tumor necrosis factor receptor–induced apoptosis. Chinnaiyan AM, et al. **J Biol Chem** 1996 Mar 1;271(9):4961–5

Activation of the p21 pathway of growth arrest and apoptosis by the beta 4 integrin cytoplasmic domain. Clarke AS, et al. **J Biol Chem** 1995 Sep 29;270(39):22673–6

A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in Chinese hamster ovary cells. Cui Z, et al. **J Biol Chem** 1996 Jun 21;271(25):14668–71

An interleukin–1beta converting enzyme–like protease is a key component of Fas–mediated apoptosis. Darmon AJ, et al. **J Biol Chem** 1996 Sep 6;271(36):21699–702

Cleavage of CPP32 by granzyme B represents a critical role for granzyme B in the induction of target cell DNA fragmentation. Darmon AJ, et al. **J Biol Chem** 1996 Sep 6;271(36):21709–12

Double–stranded internucleosomal cleavage of apoptotic DNA is dependent on the degree of differentiation in muscle cells. Fimia GM, et al. **J Biol Chem** 1996 Jun 28; 271(26):15575–9

A peptide sequence from Bax that converts Bcl–2 into an activator of apoptosis. Hunter JJ, et al. **J Biol Chem** 1996 Apr 12;271(15):8521–4

Signal transduction pathways regulated by mitogen–activated/extracellular response kinase kinase kinase induce cell death. Johnson NL, et al. **J Biol Chem** 1996 Feb 9;271(6):3229–37

Cellular oxygen toxicity. Oxidant injury without apoptosis. Kazzaz JA, et al. **J Biol Chem** 1996 Jun 21;271(25):15182–6

Induction of apoptosis by the c–Myc helix–loop–helix/leucine zipper domain in mouse 3T3–L1 fibroblasts. Kohlhuber F, et al. **J Biol Chem** 1995 Dec 1; 270(48):28797–805

Suppression of apoptosis by dominant negative mutants of cyclin–dependent protein kinases. Meikrantz W, et al. **J Biol Chem** 1996 Apr 26;271(17):10205–9

Events in apoptosis. Acidification is downstream of protease activation and BCL–2 protection. Meisenholder GW, et al. **J Biol Chem** 1996 Jul 5;271(27):16260–2

Bcl–2 protects macrophages from nitric oxide–induced apoptosis. Messmer UK, et al. **J Biol Chem** 1996 Aug 16; 271(33):20192–7

Accumulation of sequence–specific RNA–binding proteins in the cytosol of activated T cells undergoing RNA degradation and apoptosis. Mondino A, et al. **J Biol Chem** 1995 Nov 3;270(44):26593–601

D4–GDI, a substrate of CPP32, is proteolyzed during Fas–induced apoptosis. Na S, et al. **J Biol Chem** 1996 May 10;271(19):11209–13

Dual roles of sphingolipids in signaling of the escape from and onset of apoptosis in a mouse cytotoxic T–cell line, CTLL–2. Nakamura S, et al. **J Biol Chem** 1996 Jan 19; 271(3):1255–7

Identification of a domain (155–183) on CD36 implicated in the phagocytosis of apoptotic neutrophils. Navazo MD, et al. **J Biol Chem** 1996 Jun 28;271(26):15381–5

The CED–3/ICE–like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. Orth K, et al. **J Biol Chem** 1996 Jul 12;271(28):16443–6

Systematic mutational analysis of the death domain of the tumor necrosis factor receptor 1–associated protein TRADD. Park A, et al. **J Biol Chem** 1996 Apr 19; 271(16):9858–62

Ordering the cell death pathway. Differential effects of BCL2, an interleukin–1–converting enzyme family protease inhibitor, and other survival agents on JNK activation in serum/nerve growth factor–deprived PC12 cells. Park DS, et al. **J Biol Chem** 1996 Sep 6;271(36):21898–905

The CD95 (APO–1/Fas) receptor activates NF–kappaB independently of its cytotoxic function. Ponton A, et al. **J Biol Chem** 1996 Apr 12;271(15):8991–5

CPP32/apopain is a key interleukin 1 beta converting enzyme–like protease involved in Fas–mediated apoptosis. Schlegel J, et al. **J Biol Chem** 1996 Jan 26;271(4):1841–4

Insulin–like growth factor–II is an autocrine survival factor for differentiating myoblasts. Stewart CE, et al. **J Biol Chem** 1996 May 10;271(19):11330–8

CrmA, a poxvirus–encoded serpin, inhibits cytotoxic T–lymphocyte–mediated apoptosis. Tewari M, et al. **J Biol Chem** 1995 Sep 29;270(39):22705–8

Localization of granzyme B in the nucleus. A putative role

in the mechanism of cytotoxic lymphocyte-mediated apoptosis. Trapani JA, et al. **J Biol Chem** 1996 Feb 23; 271(8):4127–33

Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. van den Dobbelsteen DJ, et al. **J Biol Chem** 1996 Jun 28; 271(26):15420–7

Identification and characterization of Ich-3, a member of the interleukin-1beta converting enzyme (ICE)/Ced-3 family and an upstream regulator of ICE. Wang S, et al. **J Biol Chem** 1996 Aug 23;271(34):20580–7

Poly(ADP-ribosyl)ation of histone H1 correlates with internucleosomal DNA fragmentation during apoptosis. Yoon YS, et al. **J Biol Chem** 1996 Apr 12;271(15):9129–34

Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. Zha H, et al. **J Biol Chem** 1996 Mar 29;271(13):7440–4

End labeling studies of fragmented DNA in the avian growth plate: evidence of apoptosis in terminally differentiated chondrocytes. Hatori M, et al. **J Bone Miner Res** 1995 Dec;10(12):1960–8

Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. Pulkkinen JO, et al. **J Cancer Res Clin Oncol** 1996;122(4):214–8

Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis. Grimm S, et al. **J Cell Biol** 1996 Jul;134(1):13–23

Thiol agents and Bcl-2 identify an alphavirus-induced apoptotic pathway that requires activation of the transcription factor NF-kappa B. Lin KI, et al. **J Cell Biol** 1995 Dec;131(5):1149–61

Bcl-2 inhibits retinoic acid-induced apoptosis during the neural differentiation of embryonal stem cells. Okazawa H, et al. **J Cell Biol** 1996 Mar;132(5):955–68

Programmed cell death during mammary tissue involution induced by weaning, litter removal, and milk stasis. Quarrie LH, et al. **J Cell Physiol** 1996 Sep;168(3):559–69

Interleukin-1 beta suppresses apoptosis in CD34 positive bone marrow cells through activation of the type I IL-1 receptor. Rodriguez C, et al. **J Cell Physiol** 1996 Feb; 166(2):387–96

Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death. Wu Y, et al. **J Cell Physiol** 1996 Sep;168(3):499–509

Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. Ongkeko W, et al. **J Cell Sci** 1995 Aug; 108 (Pt 8):2897–904

Apoptosis and necrosis after reversible focal ischemia: an in situ DNA fragmentation analysis. Charriaut-Marlangue C, et al. **J Cereb Blood Flow Metab** 1996 Mar;16(2):186–94

Very delayed infarction after mild focal cerebral ischemia: a role for apoptosis? Du C, et al. **J Cereb Blood Flow Metab** 1996 Mar;16(2):195–201

Cell turnover in normal cycling human ovary. Funayama Y, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):828–34

Evidence for atrophy and apoptosis in the prostates of men given finasteride. Rittmaster RS, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):814–9

Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice [see comments] Bargou RC, et al. **J Clin Invest** 1996 Jun 1;97(11):2651–9. Comment in: J Clin Invest 1996 Jun 1;97(11):2403–4.

Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis. Blume N, et al. **J Clin Invest** 1995 Nov;96(5):2227–35

Stretch-induced programmed myocyte cell death. Cheng W, et al. **J Clin Invest** 1995 Nov;96(5):2247–59

Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. de Vente JE, et al. **J Clin Invest** 1995 Oct; 96(4):1874–86

Preconditioning rabbit cardiomyocytes: role of pH, vacuolar proton ATPase, and apoptosis. Gottlieb RA, et al. **J Clin Invest** 1996 May 15;97(10):2391–8

Apoptotic depletion of CD4+ T cells in idiopathic CD4+ T lymphocytopenia. Laurence J, et al. **J Clin Invest** 1996 Feb 1;97(3):672–80

Balancing cell life and death: bax, apoptosis, and breast cancer [editorial; comment] Reed JC. **J Clin Invest** 1996 Jun 1;97(11):2403–4. Comment on: J Clin Invest 1996 Jun 1;97(11):2651–9.

Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. Sgonc R, et al. **J Clin Invest** 1996 Aug 1;98(3):785–92

Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. Strömblad S, et al. **J Clin Invest** 1996 Jul 15;98(2):426–33

Apoptosis in pressure overload-induced heart hypertrophy in the rat. Teiger E, et al. **J Clin Invest** 1996 Jun 15; 97(12):2891–7

Activation of the Fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways. Tsuyuki S, et al. **J Clin Invest** 1995 Dec; 96(6):2924–31

In situ end-labelling, light microscopic assessment and ultrastructure of apoptosis in lung carcinoma. Gaffney EF, et al. **J Clin Pathol** 1995 Nov;48(11):1017–21

Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma. Shoji Y, et al. **J Clin Pathol** 1996 Feb;49(2):134–8

Pronephric carcinoma: chromosomes of cells rescued from apoptosis by an oncogenic herpesvirus detected with a polymerase chain reaction. Carlson DL, et al. **J Comp Pathol** 1995 Oct;113(3):277–86

Apoptosis in chicken embryos induced by the infectious bursal disease virus. Vasconcelos AC, et al. **J Comp Pathol** 1995 May;112(4):327–38

Apoptosis identified by DNA fragmentation in epidermal neoplasms. Mori O, et al. **J Dermatol** 1995 Dec; 22(12):917–20

Induced luteal regression in the primate: evidence for apoptosis and changes in c-myc protein. Fraser HM, et al. **J Endocrinol** 1995 Oct;147(1):131–7

Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. Alexander-Miller MA, et al. **J Exp Med** 1996 Aug 1;184(2):485–92

Proteolysis and the biochemistry of life-or-death decisions [comment] Ashkenas J, et al. **J Exp Med** 1996 May 1; 183(5):1947–51 (34 ref.). Comment on: J Exp Med 1996 May 1;183(5):1957–64.

Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. Browning JL, et al. **J Exp Med** 1996 Mar 1;183(3):867–78

Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death [see comments] Casciola-Rosen L, et al. **J Exp Med** 1996 May 1;183(5):1957–64. Comment in: J Exp Med 1996 May 1;183(5):1947–51.

DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. Casciola-Rosen LA, et al. **J Exp Med** 1995 Dec 1; 182(6):1625–34

Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. Casiano CA, et al. **J Exp Med** 1996 Aug 1;184(2):765–70

HIV-induced apoptosis requires the CD4 receptor cytoplasmic tail and is accelerated by interaction of CD4 with p56lck. Corbeil J, et al. **J Exp Med** 1996 Jan 1; 183(1):39–48

Functional role of interleukin 1 beta (IL-1 beta) in IL-1 beta-converting enzyme-mediated apoptosis. Friedlander RM, et al. **J Exp Med** 1996 Aug 1;184(2):717–24

Fas ligation induces apoptosis of CD40-activated human B lymphocytes. Garrone P, et al. **J Exp Med** 1995 Nov 1; 182(5):1265–73

Bcl-XL displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. Grillot DA, et al. **J Exp Med** 1995 Dec 1;182(6):1973–83

In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. IV. Affinity-dependent, antigen-driven B cell apoptosis in germinal centers as a mechanism for maintaining self-tolerance. Han S, et al. **J Exp Med** 1995 Dec 1;182(6):1635–44

Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas-mediated apoptosis. Lagresle C, et al. **J Exp Med** 1996 Apr 1;183(4):1377–88

Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. Liles WC, et al. **J Exp Med** 1996 Aug 1;184(2):429–40

Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. Mazel S, et al. **J Exp Med** 1996 May 1;183(5):2219–26

Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. Merville P, et al. **J Exp Med** 1996 Jan 1;183(1):227–36

T-B cell interaction inhibits spontaneous apoptosis of mature lymphocytes in Bcl-2-deficient mice. Nakayama K, et al. **J Exp Med** 1995 Oct 1;182(4):1101–9

Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. Renno T, et al. **J Exp Med** 1996 Feb 1;183(2):431–7

Connections between signal transduction components and cellular responses initiated by antigen receptor on B lymphocytes [comment] Scheuermann RH, et al. **J Exp Med** 1995 Oct 1;182(4):903–6. Comment on: J Exp Med 1995 Oct 1;182(4):907–14.

A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. Süss G, et al. **J Exp Med** 1996 Apr 1;183(4):1789–96

Requirement of phospholipase C-gamma 2 activation in surface immunoglobulin M-induced B cell apoptosis [see comments] Takata M, et al. **J Exp Med** 1995 Oct 1; 182(4):907–14. Comment in: J Exp Med 1995 Oct 1;182(4):903–6.

A potential mechanism of "cross-talk" between the p55 tumor necrosis factor receptor and Fas/APO1: proteins binding to the death domains of the two receptors also bind to each other. Varfolomeev EE, et al. **J Exp Med** 1996 Mar 1;183(3):1271–5

Activation mediated by RP105 but not CD40 makes normal B cells susceptible to anti-IgM-induced apoptosis: a role for Fc receptor coligation. Yamashita Y, et al. **J Exp Med** 1996 Jul 1;184(1):113–20

Mitochondrial control of nuclear apoptosis [see comments] Zamzami N, et al. **J Exp Med** 1996 Apr 1;183(4):1533–44 . Comment in: J Exp Med 1996 Apr 1;183(4):1293–5.

Characterization of apoptosis-resistant antigen-specific T cells in vivo. Zhang L, et al. **J Exp Med** 1996 May 1; 183(5):2065–73

Inhibition of Nur77/Nurr1 leads to inefficient clonal deletion of self-reactive T cells. Zhou T, et al. **J Exp Med** 1996 Apr 1;183(4):1879–92

Apoptosis: a new mechanism of endothelial and Kupffer cell killing. Takei Y, et al. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S65–7

Experimental African swine fever: apoptosis of lymphocytes and virus replication in other cells. Gómez-Villamandos JC, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2399–405

Induction of apoptosis in epithelial cells by Epstein-Barr virus latent membrane protein 1. Lu JJ, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1883–92

In vivo induction of apoptosis by influenza virus. Mori I, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2869–73

Varicella-zoster virus induces apoptosis in cell culture. Sadzot-Delvaux C, et al. **J Gen Virol** 1995 Nov;76 (Pt 11):2875–9

Cell death induced by cytopathic bovine viral diarrhoea virus is mediated by apoptosis. Zhang G, et al. **J Gen Virol** 1996 Aug;77 (Pt 8):1677–81

Enhancement of TdT-mediated dUTP-biotin nick end-labeling (TUNEL) method using mung bean nuclease, a single-stranded DNA digestion enzyme. Umemura S, et al. **J Histochem Cytochem** 1996 Feb;44(2):125–32

Localization of apoptotic cells by direct immunogold detection of digoxigenin-labeled genomic DNA in semithin sections. Van Nassauw L, et al. **J Histochem Cytochem** 1996 Feb;44(2):183–5

Naive murine neonatal T cells undergo apoptosis in response to primary stimulation. Adkins B, et al. **J Immunol** 1996 Aug 15;157(4):1343–9

Intracellular signaling pathways involved in the induction of apoptosis in immature thymic T lymphocytes. Anderson KL, et al. **J Immunol** 1996 Jun 1;156(11):4083–91

CD95 (Fas/Apo-1)-induced apoptosis results in loss of glucose transporter function. Berridge MV, et al. **J Immunol** 1996 Jun 1;156(11):4092–9

Fas- and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF-beta 1. Cerwenka A, et al. **J Immunol** 1996 Jan 15;156(2):459–64

Oxygen radical production and thiol depletion are required for Ca(2+)-mediated endogenous endonuclease activation in apoptotic thymocytes. Fernandez A, et al. **J Immunol** 1995 Dec 1;155(11):5133–9

Antisense inhibition of vitamin D receptor expression induces apoptosis in monoblastoid U937 cells. Hewison M, et al. **J Immunol** 1996 Jun 1;156(11):4391–400

Functional glucocorticoid receptor expression is required for cAMP-mediated apoptosis in a human leukemic T cell line. Kiefer J, et al. **J Immunol** 1995 Nov 15;155(10):4525–8

Relation of oxidative stress and glutathione synthesis to CD95(Fas/APO-1)-mediated apoptosis of adult T cell leukemia cells. Kohno T, et al. **J Immunol** 1996 Jun 15; 156(12):4722–8

Inactivation of the small GTP binding protein Rho induces multinucleate cell formation and apoptosis in murine T lymphoma EL4. Moorman JP, et al. **J Immunol** 1996 Jun 1;156(11):4146–53

An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. Papoff G, et al. **J Immunol** 1996 Jun 15;156(12):4622–30

bcl-2 transgenic Lpr mice show profound enhancement of lymphadenopathy. Reap EA, et al. **J Immunol** 1995 Dec 1;155(11):5455–62

Listeria monocytogenes induces apoptosis of infected hepatocytes. Rogers HW, et al. **J Immunol** 1996 Jan 15; 156(2):679–84

CD95 engagement releases calcium from intracellular stores of long term activated, apoptosis-prone gammadelta T cells. Rovere P, et al. **J Immunol** 1996 Jun 15; 156(12):4631–7

Hematopoietic cell protein-tyrosine phosphatase-deficient motheaten mice exhibit T cell apoptosis defect. Su X, et al. **J Immunol** 1996 Jun 1;156(11):4198–208

Nonsecretory apoptotic killing by human NK cells. Vujanovic NL, et al. **J Immunol** 1996 Aug 1;157(3):1117–26

Flow cytometric ratio analysis of the Hoechst 33342 emission spectrum: multiparametric characterization of apoptotic lymphocytes. Chiu L, et al. **J Immunol Methods** 1996 Feb 5;189(2):157–71

A simplified method for the coordinate examination of apoptosis and surface phenotype of murine lymphocytes. Douglas RS, et al. **J Immunol Methods** 1995 Dec 27; 188(2):219–28

YOPRO-1 permits cytofluorometric analysis of programmed cell death (apoptosis) without interfering with cell viability. Idziorek T, et al. **J Immunol Methods** 1995 Sep 25; 185(2):249–58

Expression of biologically active mouse and human CD95/APO-1/Fas ligand in the baculovirus system. Mariani SM, et al. **J Immunol Methods** 1996 Jun 14; 193(1):63–70

Human T lymphocyte virus type I-induced myeloneuropathy in rats: implication of local activation of the pX and tumor necrosis factor-alpha genes in pathogenesis. Tomaru U, et al. **J Infect Dis** 1996 Aug;174(2):318–23

Interferon-gamma-dependent stimulation of Fas antigen in SV40-transformed human keratinocytes: modulation of the apoptotic process by protein kinase C. Takahashi H, et al. **J Invest Dermatol** 1995 Dec;105(6):810-5

Inhibition of apoptosis in polymorphonuclear neutrophils from burn patients. Chitnis D, et al. **J Leukoc Biol** 1996 Jun;59(6):835-9

The role of calcium in the regulation of apoptosis. McConkey DJ, et al. **J Leukoc Biol** 1996 Jun;59(6):775-83 (125 ref.)

Macrophage apoptosis in the absence of active interleukin-1 beta-converting enzyme. Nett-Fiordalisi M, et al. **J Leukoc Biol** 1995 Dec;58(6):717-24

Apoptosis of macrophages during the resulution of muscle inflammation. Tidball JG, et al. **J Leukoc Biol** 1996 Mar; 59(3):380-8

In-vivo induction of apoptosis in murine lymphocytes by bacterial lipopolysaccharides. Norimatsu M, et al. **J Med Microbiol** 1995 Oct;43(4):251-7

Apoptosis and DNA fragmentation in the bulbus cordis of the developing rat heart. Takeda K, et al. **J Mol Cell Cardiol** 1996 Jan;28(1):209-15

Elevated DNase I levels in human idiopathic dilated cardiomyopathy: an indicator of apoptosis? Yao M, et al. **J Mol Cell Cardiol** 1996 Jan;28(1):95-101

Ceramide induces apoptosis in cultured mesencephalic neurons. Brugg B, et al. **J Neurochem** 1996 Feb;66(2):733-9

Peroxynitrite-induced cytotoxicity in PC12 cells: evidence for an apoptotic mechanism differentially modulated by neurotrophic factors. Estévez AG, et al. **J Neurochem** 1995 Oct;65(4):1543-50

Apoptosis as the mechanism of neurodegeneration in Batten's disease. Lane SC, et al. **J Neurochem** 1996 Aug; 67(2):677-83

Metabolic and energetic changes during apoptosis in neural cells. Mills JC, et al. **J Neurochem** 1995 Oct;65(4):1721-30

Apoptosis and expression of Bcl-2 after compression trauma to rat spinal cord. Li GL, et al. **J Neuropathol Exp Neurol** 1996 Mar;55(3):280-9

Effect of postmortem interval on in situ end-labeling of DNA oligonucleosomes. Petito CK, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):761-5

H2O2 and nitric oxide-mediated oxidative stress induce apoptosis in rat skeletal muscle myoblasts. Stangel M, et al. **J Neuropathol Exp Neurol** 1996 Jan;55(1):36-43

Potassium deprivation-induced apoptosis of cerebellar granule neurons: a sequential requirement for new mRNA and protein synthesis, ICE-like protease activity, and reactive oxygen species. Schulz JB, et al. **J Neurosci** 1996 Aug 1;16(15):4696-706

Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. Ikemoto H, et al. **J Neurosurg** 1995 Dec;83(6):1008-16

Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury. Johnson EM JR, et al. **J Neurotrauma** 1995 Oct; 12(5):843-52 (102 ref.)

Apoptosis in the human liver during allograft rejection and end-stage liver disease. Afford SC, et al. **J Pathol** 1995 Aug;176(4):373-80

Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. Lipponen P, et al. **J Pathol** 1995 Sep; 177(1):49-55

Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. O'Brien BA, et al. **J Pathol** 1996 Feb;178(2):176-81

Low versus high cell turnover in diffusely growing non-Hodgkin's lymphomas. Spina D, et al. **J Pathol** 1995 Dec;177(4):335-41

Apoptosis of mouse MS-2 fibrosarcoma cells induced by photodynamic therapy with Zn (II)-phthalocyanine. Zhou C, et al. **J Photochem Photobiol B** 1996 May;33(3):219-23

Identification of male germ cells undergoing apoptosis in adult rats. Brinkworth MH, et al. **J Reprod Fertil** 1995 Sep;105(1):25-33

Response to Leydig cell apoptosis in the absence of testicular macrophages. Gaytan F, et al. **J Reprod Immunol** 1995 May;29(1):81-94

Follicular atresia as an apoptotic process: atresia-associated increase in the ovarian expression of the putative apoptotic marker sulfated glycoprotein-2. Hurwitz A, et al. **J Soc Gynecol Investig** 1996 Jul-Aug;3(4):199-208

Significance of spontaneous apoptosis during colorectal tumorigenesis. Koike M. **J Surg Oncol** 1996 Jun; 62(2):97-108

Is sepsis-induced apoptosis associated with macrophage dysfunction? Ayala A, et al. **J Trauma** 1996 Apr; 40(4):568-73; discussion 573-4

An African swine fever virus Bcl-2 homolog, 5-HL, suppresses apoptotic cell death. Afonso CL, et al. **J Virol** 1996 Jul;70(7):4858-63

Measles virus infection of thymic epithelium in the SCID-hu mouse leads to thymocyte apoptosis. Auwaerter PG, et al. **J Virol** 1996 Jun;70(6):3734-40

Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. Badley AD, et al. **J Virol** 1996 Jan;70(1):199-206

Apoptotic suppression by baculovirus P35 involves cleavage by and inhibition of a virus-induced CED-3/ICE-like protease. Bertin J, et al. **J Virol** 1996 Sep;70(9):6251-9

A rabbitpox virus serpin gene controls host range by inhibiting apoptosis in restrictive cells. Brooks MA, et al. **J Virol** 1995 Dec;69(12):7688-98

Human isolates of dengue type 1 virus induce apoptosis in mouse neuroblastoma cells. Desprès P, et al. **J Virol** 1996 Jun;70(6):4090-6

Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. Dobbelstein M, et al. **J Virol** 1996 Sep;70(9):6479-85

Resistance of chimpanzee T cells to human immunodeficiency virus type 1 Tat-enhanced oxidative stress and apoptosis. Ehret A, et al. **J Virol** 1996 Sep; 70(9):6502-7

Inactivated bovine herpesvirus 1 induces apoptotic cell death of mitogen-stimulated bovine peripheral blood mononuclear cells. Hanon E, et al. **J Virol** 1996 Jun; 70(6):4116-20

Alphavirus-induced apoptosis in mouse brains correlates with neurovirulence. Lewis J, et al. **J Virol** 1996 Mar; 70(3):1828-35

Adenovirus type 5 early region 4 is responsible for E1A-induced p53-independent apoptosis. Marcellus RC, et al. **J Virol** 1996 Sep;70(9):6207-15

The role of interleukin-10 in the inhibition of T-cell proliferation and apoptosis mediated by parainfluenza virus type 3. Sieg S, et al. **J Virol** 1996 Jul;70(7):4845-8

Open reading frame 5 of porcine reproductive and respiratory syndrome virus as a cause of virus-induced apoptosis. Suárez P, et al. **J Virol** 1996 May;70(5):2876-82

Temporal changes in chromatin, intracellular calcium, and poly(ADP-ribose) polymerase during Sindbis virus-induced apoptosis of neuroblastoma cells. Ubol S, et al. **J Virol** 1996 Apr;70(4):2215-20

Apoptosis is induced by N-myc expression in hepatocytes, a frequent event in hepadnavirus oncogenesis, and is blocked by insulin-like growth factor II. Ueda K, et al. **J Virol** 1996 Mar;70(3):1375-83

Insulin-like growth factor II blocks apoptosis of N-myc2-expressing woodchuck liver epithelial cells. Yang D, et al. **J Virol** 1996 Sep;70(9):6260-8

Induction of programmed death/apoptosis androgen-dependent mouse mammary tumor cell line (Shionogi Carcinoma 115) by androgen withdrawal. Furuya Y, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1159-65

Tumor necrosis factor-alpha gene transfer augments anti-Fas antibody-mediated apoptosis in human glioma cells. Mizuno M, et al. **Jpn J Cancer Res** 1996 May;87(5):543-7

Enhancement of Ca(2+)-dependent endonuclease activity in L1210 cells during apoptosis induced by 1-beta-D-arabinofuranosylcytosine: possible involvement of activating factor(s). Takauji R, et al. **Jpn J Cancer Res** 1995 Jul;86(7):677-84

Necrosis and apoptosis in neuroretina and pigment epithelium after diffuse photodynamic action in rats: a light and electron microscopic study. Büchi ER, et al. **Jpn J Ophthalmol** 1996;40(1):1-11

Significance of programmed cell death (apoptosis) in mammalian limb and palate development. Mori C. **Kaibogaku Zasshi** 1995 Dec;70(6):503-8 (12 ref.)

Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus [editorial] Tax WJ, et al. **Kidney Int** 1995 Sep;48(3):666-73 (88 ref.)

Enhanced expression of bcl-2 inhibits apoptosis in cultured human keratinocytes. Maeyama Y. **Kurume Med J** 1995; 42(4):291-7

Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Dong C, et al. **Lab Invest** 1996 May; 74(5):921-31

Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Greeno EW, et al. **Lab Invest** 1996 Aug;75(2):281-9

Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Kajstura J, et al. **Lab Invest** 1996 Jan;74(1):86-107

Myocyte nuclear mitotic division and programmed myocyte cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Liu Y, et al. **Lab Invest** 1995 Dec;73(6):771-87

Apoptosis in progressive crescentic glomerulonephritis. Shimizu A, et al. **Lab Invest** 1996 May;74(5):941-51

Age-dependent injury in human umbilical vein endothelial cells: relationship to apoptosis and correlation with a lack of A20 expression. Varani J, et al. **Lab Invest** 1995 Dec; 73(6):851-8

Programmed cell death in brains of HIV-1-positive pre-AIDS patients [letter] An SF, et al. **Lancet** 1995 Sep 30;346(8979):911-2

Regulation of transforming growth factor-beta 1-mediated apoptosis in head and neck squamous cell carcinoma. Duffey DC, et al. **Laryngoscope** 1996 Jul;106(7):889-94

Expressions of c-jun and p53 proteins in human middle ear cholesteatoma: relationship to keratinocyte proliferation, differentiation, and programmed cell death. Shinoda H, et al. **Laryngoscope** 1995 Nov;105(11):1232-7

Evaluation of cell death in EBV-transformed lymphocytes using agarose gel electrophoresis, light microscopy and electron microscopy. II. Induction of non-classic apoptosis ("para-apoptosis") by tritiated thymidine. Asher E, et al. **Leuk Lymphoma** 1995 Sep;19(1-2):107-19

Effect of anti-APO1 on spontaneous apoptosis of B cells in chronic lymphocytic leukaemia: the role of bcl-2 and interleukin 4. Mainou-Fowler T, et al. **Leuk Lymphoma** 1995 Oct;19(3-4):301-8

Apoptosis overview emphasizing the role of oxidative stress, DNA damage and signal-transduction pathways. Payne CM, et al. **Leuk Lymphoma** 1995 Sep;19(1-2):43-93 (720 ref.)

Evaluation of cell death in EBV-transformed lymphocytes using agarose gel electrophoresis, light microscopy and electron microscopy. I. Induction of classic apoptosis by the bile salt, sodium deoxycholate. Samaha HS, et al. **Leuk Lymphoma** 1995 Sep;19(1-2):95-105

In vivo radiosensitizing effects of recombinant interleukin 6 on radiation resistant BCL-1 B-lineage leukemia cells in a murine syngeneic bone marrow transplant model system. Waddick KG, et al. **Leuk Lymphoma** 1995 Sep; 19(1-2):121-8

Inhibition of human leukaemia 60 cell growth by S-D-lactoylglutathione in vitro. Mediation by metabolism to N-D-lactoylcysteine and induction of apoptosis. Edwards LG, et al. **Leuk Res** 1996 Jan;20(1):17-26

Stem cell factor and stromal cell co-culture prevent apoptosis in a subculture of the megakaryoblastic cell line, UT-7. Liesveld JL, et al. **Leuk Res** 1996 Jul;20(7):591-600

Apoptosis in myelodysplasia: a paradox or paradigm. Yoshida Y, et al. **Leuk Res** 1995 Dec;19(12):887-91 (31 ref.)

Resistance to apoptotic cell death in a drug resistant T cell leukaemia cell line. Geyp M, et al. **Leukemia** 1996 Mar; 10(3):447-55

Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Robertson LE, et al. **Leukemia** 1996 Mar; 10(3):456-9

Retroviral transduction of hematopoietic progenitor cells with mutant p53 promotes survival and proliferation, modifies differentiation potential and inhibits apoptosis. Shounan Y, et al. **Leukemia** 1996 Oct;10(10):1619-28

Apoptin, a protein encoded by chicken anemia virus, induces cell death in various human hematologic malignant cells in vitro. Zhuang SM, et al. **Leukemia** 1995 Oct;9 Suppl 1:S118-20

Apoptosis--the cell's silent exit. Bär PR. **Life Sci** 1996; 59(5-6):369-78 (45 ref.)

Roles of calcium in the regulation of apoptosis in HL-60 promyelocytic leukemia cells. Zhu WH, et al. **Life Sci** 1995; 57(23):2091-9

Modulation of antioxidant enzymes and programmed cell death by n-3 fatty acids. Fernandes G, et al. **Lipids** 1996 Mar;31 Suppl:S91-6

Polyamine involvement in the cell cycle, apoptosis, and autoimmunity. Brooks WH. **Med Hypotheses** 1995 May; 44(5):331-8

Apoptosis and HIV neuropathogenesis. Espey MG. **Med Hypotheses** 1995 Jun;44(6):536-8

The potential role of apoptosis (programmed cell death) in a chaotic determined carcinogenesis. Sedivy R. **Med Hypotheses** 1996 May;46(5):455-57

Can virus therapy of human cancer be improved by apoptosis induction? [published erratum appears in Med Hypotheses 1995 Sep;45(3):316] Sinkovics JG, et al. **Med Hypotheses** 1995 May;44(5):359-68 (72 ref.)

Apoptosis as a cause of death in chicken embryos inoculated with Newcastle disease virus. Lam KM, et al. **Microb Pathog** 1995 Sep;19(3):169-74

Cell proliferation and apoptosis in prostate cancer--correlation with pathologic stage? Brown C, et al. **Mod Pathol** 1996 Mar;9(3):205-9

Programmed cell death by default in embryonic cells, fibroblasts, and cancer cells. Ishizaki Y, et al. **Mol Biol Cell** 1995 Nov;6(11):1443-58

Delay of dimethylbenz[a]anthracene-induced mammary tumorigenesis in transgenic mice by apoptosis induced by an unusual mutant p53 protein. Li B, et al. **Mol Carcinog** 1995 Oct;14(2):75-83

mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Chen J, et al. **Mol Cell Biol** 1996 May;16(5):2445-52

Cytokines inhibit p53-mediated apoptosis but not p53-mediated G1 arrest. Lin Y, et al. **Mol Cell Biol** 1995 Nov;15(11):6045-54

Role of EGR-1 in thapsigargin-inducible apoptosis in the melanoma cell line A375-C6. Muthukkumar S, et al. **Mol Cell Biol** 1995 Nov;15(11):6262-72

Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Vartanian T, et al. **Mol Med** 1995 Nov;1(7):732-43

Apoptosis in vivo and in vitro: conflict or complementarity? Clarke AR, et al. **Mol Med Today** 1996 May;2(5):189-91

Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells. Beere HM, et al. **Mol Pharmacol** 1996 May; 49(5):842-51

Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells. Rusnak JM, et al. **Mol Pharmacol** 1996 Feb;49(2):244-52

Reversal of malignancy by the adenovirus E1a gene. Frisch SM. **Mutat Res** 1996 Feb 19;350(1):261-6 (31 ref.)

Apoptosis and multistage carcinogenesis in rat liver. Schulte-Hermann R, et al. **Mutat Res** 1995 Dec; 333(1-2):81-7 (43 ref.)

The beneficial effects of dietary restriction: reduced oxidative damage and enhanced apoptosis. Wachsman JT. **Mutat Res** 1996 Feb 19;350(1):25-34 (75 ref.)

Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract [see comments] Goldberg YP, et al. **Nat Genet** 1996 Aug; 13(4):442–9. Comment in: Nat Genet 1996 Aug;13(4):380–2.

Huntingtin: new marker along the road to death? [news; comment] Rosen A. **Nat Genet** 1996 Aug;13(4):380–2. Comment on: Nat Genet 1996 Aug;13(4):442–9.

Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Zeitlin S, et al. **Nat Genet** 1995 Oct;11(2):155–63

Cellular proofreading [comment] Brash DE. **Nat Med** 1996 May;2(5):525–6. Comment on: Nat Med 1996 May;2(5):577–80.

Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes [see comments] Finkel TH, et al. **Nat Med** 1995 Feb;1(2):129–34. Comment in: Nat Med 1995 Feb;1(2):118–20. Comment in: Nat Med 1995 May;1(5):386–7.

Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Friesen C, et al. **Nat Med** 1996 May;2(5):574–7

Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression [see comments] Holmgren L, et al. **Nat Med** 1995 Feb; 1(2):149–53. Comment in: Nat Med 1995 Feb;1(2):117–8.

Apoptosis and HIV disease [letter; comment] Lu W, et al. **Nat Med** 1995 May;1(5):386–7. Comment on: Nat Med 1995 Feb;1(2):129–34.

p53-dependent apoptosis suppresses radiation-induced teratogenesis [see comments] Norimura T, et al. **Nat Med** 1996 May;2(5):577–80. Comment in: Nat Med 1996 May;2(5):525–6.

Apoptosis in HIV infection [comment] Pantaleo G, et al. **Nat Med** 1995 Feb;1(2):118–20. Comment on: Nat Med 1995 Feb;1(2):129–34.

Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Zavazava N, et al. **Nat Med** 1996 Sep;2(9):1005–10

Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Busciglio J, et al. **Nature** 1995 Dec 21–28;378(6559):776–9

Historic apoptosis [letter] Clarke PG, et al. **Nature** 1995 Nov 16;378(6554):230

Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Darmon AJ, et al. **Nature** 1995 Oct 5;377(6548):446–8

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours [see comments] Graeber TG, et al. **Nature** 1996 Jan 4;379(6560):88–91. Comment in: Nature 1996 Jan 4;379(6560):19–20. Comment in: Nature 1996 Mar 14;380(6570):100.

X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Muchmore SW, et al. **Nature** 1996 May 23;381(6580):335–41

Spermiogenesis deficiency and germ-cell apoptosis in CREM-mutant mice. Nantel F, et al. **Nature** 1996 Mar 14;380(6570):159–62

Schwann cell apoptosis at developing neuromuscular junctions is regulated by glial growth factor. Trachtenberg JT, et al. **Nature** 1996 Jan 11;379(6561):174–7

Little difference [letter; comment] Wenger RH, et al. **Nature** 1996 Mar 14;380(6570):100. Comment on: Nature 1996 Jan 4;379(6560):88–91.

Induction of apoptosis in mature T cells by tumour necrosis factor. Zheng L, et al. **Nature** 1995 Sep 28;377(6547):348–51

Neuronal apoptosis in HIV infection in adults. Adle-Biassette H, et al. **Neuropathol Appl Neurobiol** 1995 Jun;21(3):218–27

Apoptotic neurons in brains from paediatric patients with HIV-1 encephalitis and progressive encephalopathy. Gelbard HA, et al. **Neuropathol Appl Neurobiol** 1995 Jun; 21(3):208–17

Apoptosis in amyotrophic lateral sclerosis is not restricted to motor neurons. Bcl-2 expression is increased in unaffected post-central gyrus. Troost D, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):498–504

A cautionary note on the use of the TUNEL stain to determine apoptosis. Charriaut-Marlangue C, et al. **Neuroreport** 1995 Dec 29;7(1):61–4

Phosphorylation of initiation factor 2 alpha subunit and apoptosis in Ca2+ ionophore-treated cultured neuronal cells. Alcázar A, et al. **Neurosci Lett** 1995 Dec 15; 201(3):215–8

p53 involves cytosine arabinoside-induced apoptosis in cultured cerebellar granule neurons. Enokido Y, et al. **Neurosci Lett** 1996 Jan 12;203(1):1–4

Detection of apoptosis in murine scrapie. Lucassen PJ, et al. **Neurosci Lett** 1995 Oct 6;198(3):185–8

Detection of apoptosis in weaver cerebellum by electron microscopic in situ end-labeling of fragmented DNA. Migheli A, et al. **Neurosci Lett** 1995 Oct 13;199(1):53–6

Apoptosis of neurons in the vestibular nuclei of adult mice results from prolonged change in the external environment. Mitchell IJ, et al. **Neurosci Lett** 1995 Oct 6;198(3):153–6

Apoptosis and cell proliferation in human neuroepithelial tumors. Schiffer D, et al. **Neurosci Lett** 1995 Aug 4; 195(2):81–4

Nerve growth factor withdrawal induces the apoptotic death of developing septal cholinergic neurons in vitro: protection by cyclic AMP analogue and high potassium. Kew JN, et al. **Neuroscience** 1996 Jan;70(2):329–39

Apoptosis induced by beta-N-oxalylamino-L-alanine on a motoneuron hybrid cell line. La Bella V, et al. **Neuroscience** 1996 Feb;70(4):1039–52

Apoptosis in substantia nigra following developmental hypoxic-ischemic injury. Oo TF, et al. **Neuroscience** 1995 Dec;69(3):893–901

Compensatory apoptosis in response to SV40 large T antigen expression in the liver. Allemand I, et al. **Oncogene** 1995 Dec 21;11(12):2583–90

The Gag-Myb-Ets fusion oncogene alters the apoptotic response and growth factor dependence of interleukin-3 dependent murine cells. Athanasiou M, et al. **Oncogene** 1996 Jan 18;12(2):337–44

Differential cell death in immortalized and non-immortalized cells at confluency. Brezden CB, et al. **Oncogene** 1996 Jan 4;12(1):201–6

Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Chen CY, et al. **Oncogene** 1995 Oct 19;11(8):1487–98

Induction of apoptosis by rho in NIH 3T3 cells requires two complementary signals. Ceramides function as a progression factor for apoptosis. Esteve P, et al. **Oncogene** 1995 Dec 21;11(12):2657–65

The transforming oncoproteins determine the mechanism by which p53 suppresses cell transformation: pRb-mediated growth arrest or apoptosis. Hansen R, et al. **Oncogene** 1995 Dec 21;11(12):2535–45

Resistance to Fas-mediated apoptosis in human hepatoma cells. Natoli G, et al. **Oncogene** 1995 Sep 21;11(6):1157–64

The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Okan I, et al. **Oncogene** 1995 Sep 21;11(6):1027–31

Fas-dependent apoptosis is impaired by SV40 T-antigen in transgenic liver. Rouquet N, et al. **Oncogene** 1995 Sep 21; 11(6):1061–7

Wild type p53 and c-myc co-operation in generating apoptosis of a rat hepatocellular carcinoma cell line (FAA-HTC1). Saito Y, et al. **Oncogene** 1995 Sep 21; 11(6):1013–8

Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Sheikh MS, et al. **Oncogene** 1995 Nov 2;11(9):1899–905

Minigemistocytic astrocytoma with frequent apoptoses: analysis of tumor growth. Higami Y, et al. **Pathol Int** 1995 Aug;45(8):610–5

Apoptosis in histiocytic necrotizing lymphadenitis. Liu Q, et al. **Pathol Int** 1995 Oct;45(10):729–34

Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Montironi R, et al. **Pathol Res Pract** 1995 Sep; 191(9):873–80

Could atherosclerosis originate from defective smooth muscle cell death (apoptosis)? Rembold C. **Perspect Biol Med** 1996 Spring;39(3):405–8

Identification, characterization, and purification of a tobacco endonuclease activity induced upon hypersensitive response cell death. Mittler R, et al. **Plant Cell** 1995 Nov; 7(11):1951–62

Possible contributions of mastocytosis, apoptosis, and hydrolysis in pathophysiology of randomized skin flaps in humans and guinea pigs. Ashoori F, et al. **Plast Reconstr Surg** 1996 Sep;98(3):491–501

Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the drosophila seven in absentia gene. Amson RB, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30; 93(9):3953–7

Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Casciola-Rosen L, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1624–9

bcl-2 overexpression reduces apoptotic photoreceptor cell death in three different retinal degenerations. Chen J, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7042–7

A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Clarke MF, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11024–8

Apoptosis of hemopoietic cells by the human granulocyte-macrophage colony-stimulating factor mutant E21R. Iversen PO, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2785–9

Neurotrophin 3 rescues neuronal precursors from apoptosis and promotes neuronal differentiation in the embryonic metanephric kidney. Karavanov A, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11279–83

Cleavage of actin by interleukin 1 beta-converting enzyme to reverse DNase I inhibition. Kayalar C, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2234–8

Platelet-derived growth factor induces apoptosis in growth-arrested murine fibroblasts. Kim HR, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9500–4

Human immunodeficiency virus 1 envelope-initiated G2-phase programmed cell death. Kolesnitchenko V, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11889–93

The herpes simplex virus major regulatory protein ICP4 blocks apoptosis induced by the virus or by hyperthermia. Leopardi R, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9583–7

Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. Liblau RS, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3031–6

Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Linette GP, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9545–52

Salmonella typhimurium invasion induces apoptosis in infected macrophages. Monack DM, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9833–8

Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bcl-2-independent regulator of apoptosis in human B-lineage lymphoma cells. Myers DE, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9575–9

Purification and cDNA cloning of a second apoptosis-related cysteine protease that cleaves and activates sterol regulatory element binding proteins. Pai JT, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5437–42

Proteolytic activation of the cell death protease Yama/CPP32 by granzyme B. Quan LT, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1972–6

Tumor dormancy and cell signaling: anti-mu-induced apoptosis in human B-lymphoma cells is not caused by an APO-1-APO-1 ligand interaction. Racila E, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2165–8

Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11. Sanchez Y, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2551–6

Disruption of RB/E2F-1 interaction by single point mutations in E2F-1 enhances S-phase entry and apoptosis. Shan B, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23; 93(2):679–84

Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. Strack PR, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9571–6

Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Takahashi A, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8395–400

Failure of programmed cell death and differentiation as causes of tumors: some simple mathematical models. Tomlinson IP, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11130–4

The molecular biology of apoptosis. Vaux DL, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2239–44 (125 ref.)

Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Wang HG, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7063–8

Apoptosis of nur77/N10-transgenic thymocytes involves the Fas/Fas ligand pathway. Weih F, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5533–8

Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. Weiss MJ, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9623–7

Angiotensin II type 2 receptor mediates programmed cell death. Yamada T, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):156–60

Bcl-2 interrupts the ceramide-mediated pathway of cell death. Zhang J, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5325–8

Control of tumor progression by maintenance of apoptosis. Bruchovsky N, et al. **Prostate Suppl** 1996;6:13–21 (27 ref.)

Radiation inactivation of human prostate cancer cells: the role of apoptosis. Algan O, et al. **Radiat Res** 1996 Sep; 146(3):267–75

Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Levine EL, et al. **Radiother Oncol** 1995 Oct;37(1):1–9

Gonadal cell apoptosis. Hsueh AJ, et al. **Recent Prog Horm Res** 1996;51:433–55; discussion 455–6 (66 ref.)

Programmed cell death in human breast cancer cells. McCloskey DE, et al. **Recent Prog Horm Res** 1996; 51:493–508 (60 ref.)

Cross-linking of cell surface receptors as a trigger or cell apoptosis and proliferation. Korystov YN. **Scanning Microsc** 1995 Sep;9(3):757–62 (55 ref.)

Comparison of DNA fragmentation and color thresholding for objective quantitation of apoptotic cells. Plymale DR, et al. **Scanning Microsc** 1995 Sep;9(3):833–42

The origin of programmed cell death. Ameisen JC. **Science** 1996 May 31;272(5266):1278–9 (11 ref.)

Oxidative stress and apoptosis in HIV infection [letter; comment] Baier-Bitterlich G, et al. **Science** 1996 Feb 2; 271(5249):582–3. Comment on: Science 1995 Aug 25;269(5227):1044–5.

Forging a path to cell death [news] Barinaga M. **Science** 1996 Aug 9;273(5276):735–7

Hierarchical control of lymphocyte survival. Boise LH, et al. **Science** 1996 Oct 4;274(5284):67–8 (17 ref.)

Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Bump NJ, et al. **Science** 1995 Sep 29;269(5232):1885–8

Fas ligand-induced apoptosis as a mechanism of immune privilege [see comments] Griffith TS, et al. **Science** 1995 Nov 17;270(5239):1189–92. Comment in: Science 1995 Nov 17;270(5239):1158–9.

Initiation of runaway cell death in an Arabidopsis mutant by extracellular superoxide. Jabs T, et al. **Science** 1996 Sep 27;273(5283):1853–6

Lymphocyte apoptosis: mediation by increased type 3 inositol

1,4,5-trisphosphate receptor. Khan AA, et al. **Science** 1996 Jul 26;273(5274):503-7

Programmed cell death [letter] Novak J. **Science** 1996 Oct 4;274(5284):20-1

Requirement of an ICE-like protease for induction of apoptosis and ceramide generation by REAPER. Pronk GJ, et al. **Science** 1996 Feb 9;271(5250):808-10

BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells. Uckun FM, et al. **Science** 1996 Aug 23;273(5278):1096-100

Interfering with apoptosis: Ca(2+)-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Vito P, et al. **Science** 1996 Jan 26;271(5248):521-5

Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Wang J, et al. **Science** 1996 Jul 19;273(5273):359-61

Cell killing by the Drosophila gene reaper. White K, et al. **Science** 1996 Feb 9;271(5250):805-7

Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Xia Z, et al. **Science** 1995 Nov 24; 270(5240):1326-31

Requirement for BMP signaling in interdigital apoptosis and scale formation. Zou H, et al. **Science** 1996 May 3; 272(5262):738-41

Sequential triggering of apoptosis, somatic mutation and isotype switch during germinal center development. Liu YJ, et al. **Semin Immunol** 1996 Jun;8(3):169-77 (51 ref.)

Relationships between B cell cytokine production in secondary lymphoid follicles and apoptosis of germinal center B lymphocytes. Pistoia V, et al. **Stem Cells (Dayt)** 1995 Sep;13(5):487-500 (105 ref.)

Zinc deficiency causes apoptosis but not cell cycle alterations in organogenesis-stage rat embryos: effect of varying duration of deficiency. Rogers JM, et al. **Teratology** 1995 Sep;52(3):149-59

Programmed cell death and N-acetoxy-2-acetylaminofluorene-induced apoptosis in the rat embryo. Thayer JM, et al. **Teratology** 1995 Jun; 51(6):418-29

Better dead than red. Evan IG. **Ther Immunol** 1994 Dec; 1(6):343-8 (80 ref.)

Mono-(2-ethylhexyl) phthalate rapidly alters both Sertoli cell vimentin filaments and germ cell apoptosis in young rat testes. Richburg JH, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):42-50

The role of nitric oxide in cell injury. Brüne B, et al. **Toxicol Lett** 1995 Dec;82-83:233-7 (20 ref.)

DNA degradation and proteolysis in thymocyte apoptosis. Fearnhead HO, et al. **Toxicol Lett** 1995 Dec;82-83:135-41

Role of active cell death (apoptosis) in multi-stage carcinogenesis. Schulte-Hermann R, et al. **Toxicol Lett** 1995 Dec;82-83:143-8 (20 ref.)

Signalling mechanisms and oxidative stress in apoptosis. Slater AF, et al. **Toxicol Lett** 1995 Dec;82-83:149-53 (24 ref.)

A toxicologic pathologist's view of apoptosis or I used to call it necrobiosis, but now I'm singing the apoptosis blues [see comments] Levin S. **Toxicol Pathol** 1995 Jul-Aug; 23(4):533-9 (34 ref.). Comment in: Toxicol Pathol 1995 Sep-Oct;23(5):617-21.

Role of Fas apoptosis and MHC genes in 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced immunotoxicity of T cells. Rhile MJ, et al. **Toxicology** 1996 Jun 17;110(1-3):153-67

Apoptosis in human kidney allografts. Matsuno T, et al. **Transplant Proc** 1996 Jun;28(3):1226-7

Activation of apoptosis during the reperfusion phase after rat liver ischemia. Sasaki H, et al. **Transplant Proc** 1996 Jun;28(3):1908-9

Human serum-induced porcine endothelial cell apoptosis--another pathway to xenograft rejection. Young DS, et al. **Transplant Proc** 1996 Apr;28(2):611-2

Apoptosis in the human allografted kidney. Analysis by terminal deoxynucleotidyl transferase-mediated DUTP-botin nick end labeling. Ito H, et al. **Transplantation** 1995 Oct 27;60(8):794-8

Apoptosis as a mechanism of cell death in liver allograft rejection [letter; comment] Searle JW, et al. **Transplantation** 1996 Jan 15;61(1):168-9. Comment on: Transplantation 1995 Feb 27;59(4):621-5.

Role of three cancer "master genes" p53, bcl2 and c-myc on the apoptotic process. Chiarugi V, et al. **Tumori** 1996 May-Jun;82(3):205-9 (57 ref.)

Role of apoptosis in biology and pathology: resistance to apoptosis in colon carcinogenesis. Payne CM, et al. **Ultrastruct Pathol** 1995 Jul-Aug;19(4):221-48 (246 ref.)

Apoptosis in chicken embryo fibroblasts caused by Newcastle disease virus. Lam KM. **Vet Microbiol** 1995 Dec; 47(3-4):357-63

Ultrastructure of multinucleated giant cell apoptosis in foreign-body granuloma. Honma T, et al. **Virchows Arch** 1996 Jun;428(3):165-76

Apoptosis in human gastric mucosa, chronic gastritis, dysplasia and carcinoma: analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labelling. Ishida M, et al. **Virchows Arch** 1996 Jul; 428(4-5):229-35

Apoptosis and cellular proliferation in oesophageal squamous cell carcinomas: differences between keratinizing and nonkeratinizing types. Ohbu M, et al. **Virchows Arch** 1995; 427(3):271-6

Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes. Macen JL, et al. **Virology** 1996 Apr 1;218(1):232-7

Induction of apoptotic DNA fragmentation by the infection of vesicular stomatitis virus. Koyama AH. **Virus Res** 1995 Aug;37(3):285-90

Effects of intracellular pH on apoptosis in HL-60 human leukemia cells. Park HJ. **Yonsei Med J** 1995 Dec; 36(6):473-9

[Apoptosis of tumor cells in lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity] Dong H, et al. **Chung Hua Chung Liu Tsa Chih** 1995 Jul; 17(4):245-8 (Eng. Abstr.) **(Chi)**

[Modulation of bcl-2 antisense RNA on programmed cell death of leukemic cell line] Chen X, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;76(2):112-5 (Eng. Abstr.) **(Chi)**

[Programmed neural cell death?] Langmeier M. **Cesk Fysiol** 1995 Dec;44(4):188-90 (26 ref.) (Eng. Abstr.) **(Cze)**

[The annual meeting of the American Association for Cancer Research (AACR), Toronto (Ontario), 18-22 May 1995] Méchali P, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):85-98 (Eng. Abstr.) **(Fre)**

[German Cancer Award 1996 (news)] **Dtsch Med Wochenschr** 1996 Mar 29;121(13):A8 **(Ger)**

[Apoptosis of T-helper cells is massively increased in AIDS] Weismann H. **Dtsch Med Wochenschr** 1996 Jan 26; 121(4):A14 **(Ger)**

[Significance of PUVA therapy for adult T-cell leukemia/lymphoma--PUVA therapy can induce apoptosis in leukemic cells] Takemori N, et al. **Hum Cell** 1995 Sep; 8(3):121-6 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of castration on apoptosis and transforming growth factor-beta 1 mRNA in the neonatal mouse seminal vesicles] Tanji N, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Nov;86(11):1660-5 (Eng. Abstr.) **(Jpn)**

[Anticancer agents and apoptosis] Fukuoka K, et al. **Nippon Rinsho** 1996 Jan;54(1):250-8 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Role of Fas system in apoptosis induced by hepatitis C virus infection] Mita E, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:198-202 (14 ref.) **(Jpn)**

[Immunohistochemical observation of Fas in the liver with chronic hepatitis C] Takatani M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:667-74 (23 ref.) **(Jpn)**

[Immunohistochemical observation of Fas in the liver of chronic hepatitis B and its ultrastructural localization] Takatani M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:234-40 (23 ref.) **(Jpn)**

[TUNEL method rarely revealed DNA fragmentation in chronic hepatitis C] Tanaka Y. **Nippon Rinsho** 1995 Sep; 53 Suppl:192-7 (17 ref.) **(Jpn)**

[Apoptosis: its molecular mechanisms and biological roles] Tanuma S. **Nippon Rinsho** 1995 Dec;53(12):3113-21 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Significance of apoptosis in hepatitis C and possible involvement of soluble factor in hepatocyte apoptosis] Torimoto Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:186-91 (16 ref.) **(Jpn)**

[Therapy of malignant brain tumors by using apoptosis] Kuchino Y. **No To Shinkei** 1995 Sep;47(9):829-34 (34 ref.) **(Jpn)**

[Apoptosis in autoimmune diseases] Kobayashi S, et al. **Ryumachi** 1995 Aug;35(4):712-25 (64 ref.) **(Jpn)**

[Lack of serum causes apoptosis of thymocytes not requiring protein synthesis and ATP generation] Gabaĭ VL, et al. **Biokhimiia** 1995 Aug;60(8):1201-8 (Eng. Abstr.) **(Rus)**

[Apoptosis in the African swine fever virus-swine mononuclear phagocyte system] Makarov VV. **Mol Gen Mikrobiol Virusol** 1995 Jul-Sep;(3):38-43 (Eng. Abstr.) **(Rus)**

[Activation of cell death in lymphocytes from individuals infected with HIV] Quirós E, et al. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):522-6 (Eng. Abstr.) **(Spa)**

[Evaluation of tumor response through of morphometric measurements. Quantification of apoptosis] Vargas F, et al. **G E N** 1995 Apr-Jun;49(2):161-4 (42 ref.) (Eng. Abstr.) **(Spa)**

[Apoptosis in the pathogenesis and treatment of disease] Benítez-Bribiesca L. **Gac Med Mex** 1995 Mar-Apr; 131(2):231-2 **(Spa)**

[Comment on 2 articles in Gaceta Médica de México (letter)] Espino Vela J. **Gac Med Mex** 1995 Sep-Dec;131(5-6):629 **(Spa)**

[Apoptosis and autoimmune diseases (editorial)] Font J, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):619-21 (37 ref.) **(Spa)**

DRUG EFFECTS

ICRF-193 modifies etoposide-induced apoptosis in thymocytes. Tanimoto C, et al. **Acta Med Okayama** 1995 Dec;49(6):281-6

Apoptotic process of cerebellar degeneration in experimental methylmercury intoxication of rats. Nagashima K, et al. **Acta Neuropathol (Berl)** 1996;91(1):72-7

Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection. Thomson AW, et al. **Adv Exp Med Biol** 1995;374:211-6 (46 ref.)

Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease? Ziv I, et al. **Adv Neurol** 1996;69:229-33 (26 ref.)

Effect of pre- or postnatal exposure to ethanol on the total number of neurons in the principal sensory nucleus of the trigeminal nerve: cell proliferation and neuronal death. Miller MW. **Alcohol Clin Exp Res** 1995 Oct;19(5):1359-63

Tumor necrosis factor-alpha-induced apoptosis in hepatocytes in long-term culture. Bour ES, et al. **Am J Pathol** 1996 Feb;148(2):485-95

Apoptosis is observed in mesothelial cells after exposure to crocidolite asbestos. BéruBé KA, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):141-7

Dimethyl sulfoxide-induced apoptosis in human leukemic U937 cells. Château MT, et al. **Anal Cell Pathol** 1996 Mar; 10(2):75-84

Apoptosis susceptibility of human carcinoma and leukemia cell lines to taxol. Relationship with cell cycle and drug concentration. Gangemi RM, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:550-4

Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line. Zhao R, et al. **Anticancer Drugs** 1995 Oct;6(5):657-68

Cell activation and death (apoptosis) induced by IL-2: ultrastructural evidence. Capelli E, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1775-80

Early stage monitoring of miltefosine induced apoptosis in KB cells by multinuclear NMR spectroscopy. Engelmann J, et al. **Anticancer Res** 1996 May-Jun;16(3B):1429-39

Transcatheter arterial embolization with cisplatin: apoptosis in VX2 tumour uterus transplants. Harima Y, et al. **Anticancer Res** 1996 Jan-Feb;16(1):193-9

Induction of programmed cell death (apoptosis) in human lymphoid leukemia cells by catechin compounds. Hibasami H, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1943-6

Cytotoxicity of antitumor agents toward cultured murine leukemia L1210 cells under a serum-deprived apoptotic condition. Kasamatsu T, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2597-600

Induction by 5-aza-2'-deoxycytidine, an inhibitor of DNA methylation, of Le(y) antigen, apoptosis and differentiation in human lung cancer cells. Saitoh F, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2137-43

Induction of DNA fragmentation by tannin- and lignin-related substances. Sakagami H, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2121-8

Induction of DNA fragmentation in human myelogenous leukaemic cell lines by phenothiazine-related compounds. Sakagami H, et al. **Anticancer Res** 1995 Nov-Dec; 15(6B):2533-40

The interaction between two antioxidants, sodium ascorbate and gallic acid: radical intensity and apoptosis induction. Sakagami H, et al. **Anticancer Res** 1996 May-Jun; 16(3A):1231-4

Apoptosis mediates the selective toxicity of caffeic acid phenethyl ester (CAPE) toward oncogene-transformed rat embryo fibroblast cells. Su ZZ, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):1841-8

Involvement of intracellular glutathione in induction of apoptosis by cisplatin in a human pharyngeal carcinoma cell line. Sugimoto C, et al. **Anticancer Res** 1996 Mar-Apr; 16(2):675-80

Nitric oxide (NO) in apoptotic versus necrotic RAW 264.7 macrophage cell death: the role of NO-donor exposure, NAD+ content, and p53 accumulation. Messmer UK, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):1-10

Apoptotic death of lymphocytes upon treatment with 2-chloro-2'-deoxyadenosine (2-CdA). Lassota P, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):17-23

Apoptotic inhibition of head and neck squamous cell carcinoma cells by tumor necrosis factor alpha. Briskin KB, et al. **Arch Otolaryngol Head Neck Surg** 1996 May; 122(5):559-63

Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts. Björkerud B, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):416-24

Inhibition of Fas antigen-mediated apoptosis of rheumatoid synovial cells in vitro by transforming growth factor beta 1. Kawakami A, et al. **Arthritis Rheum** 1996 Aug; 39(8):1267-76

The sigma receptor ligand, reduced haloperidol, induces apoptosis and increases intracellular-free calcium levels [Ca2+]i in colon and mammary adenocarcinoma cells. Brent PJ, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):219-26

Potentiation of sodium butyrate-induced apoptosis by vanadate in human promyelocytic leukemia cell line HL-60. Chang ST, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):594-601

Didemnin B induces cell death by apoptosis: the fastest induction of apoptosis ever described. Grubb DR, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1130-6

Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Imajoh-Ohmi S, et al. **Biochem Biophys Res Commun** 1995 Dec 26; 217(3):1070-7

Thiophosphate induces apoptosis in human leukemia cell lines. Jiang L, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):393-7

Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Kameda T, et al. **Biochem Biophys Res Commun** 1996 Mar 27;220(3):515–9

Augmentation of apoptosis in bronchial exuded rat eosinophils by cyclosporin A. Kitagaki K, et al. **Biochem Biophys Res Commun** 1996 May 6;222(1):71–7

Inhibitors of poly(ADP-ribose) polymerase block nitric oxide-induced apoptosis but not differentiation in human leukemia HL-60 cells. Kuo ML, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):502–8

The phosphatase inhibitor calyculin antagonizes the rapid initiation of apoptosis by photodynamic therapy. Luo Y, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):72–6

Phorbol esters attenuate the expression of p53 in cells treated with doxorubicin and protect TS-P53/K562 from apoptosis. Magnelli L, et al. **Biochem Biophys Res Commun** 1995 Oct 13;215(2):641–5

Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. Miquel K, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):869–76

Apoptosis in human hepatoma cell line induced by 4,5-didehydro geranylgeranoic acid (acyclic retinoid) via down-regulation of transforming growth factor-alpha. Nakamura N, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):100–4

Constitutively enhanced nbl expression is associated with the induction of internucleosomal DNA cleavage by actinomycin D. Naora H, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):258–64

Oxidized LDL induces apoptosis in cultured smooth muscle cells: a possible role for 7-ketocholesterol. Nishio E, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):413–8

Nitric oxide donor SNAP induces apoptosis in smooth muscle cells through cGMP-independent mechanism. Nishio E, et al. **Biochem Biophys Res Commun** 1996 Apr 5; 221(1):163–8

Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines. Okado A, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):219–24

Agents that elevate cAMP inhibit human neutrophil apoptosis. Rossi AG, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):892–9

Modulation of cell death pathways to apoptosis and necrosis of H2O2-treated rat thymocytes by lipocortin I. Sakamoto T, et al. **Biochem Biophys Res Commun** 1996 Mar 27; 220(3):643–7

Identification of the snake venom substance that induces apoptosis. Suhr SM, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):134–9

Dolichyl phosphate, a potent inducer of apoptosis in rat glioma C6 cells. Yasugi E, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):848–53

Calpain inhibitor-induced apoptosis in human prostate adenocarcinoma cells. Zhu W, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1130–7

Promotion of heat-induced apoptosis in FM3A cells by protease inhibitors. Zhu WG, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):924–31

Saikosaponin b2-induced apoptosis of cultured B16 melanoma cell line through down-regulation of PKC activity. Zong Z, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):480–5

A cleavage-site-directed inhibitor of interleukin-1 beta-converting enzyme-like proteases inhibits apoptosis in primary cultures of rat hepatocytes. Cain K, et al. **Biochem J** 1996 Feb 15;314 (Pt 1):27–32

Altered methional homoeostasis is associated with decreased apoptosis in BAF3 bcl2 murine lymphoid cells. Roch AM, et al. **Biochem J** 1996 Feb 1;313 (Pt 3):973–81

Role of phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in haemopoietic cells: phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signalling between interleukin-3 and granulocyte-macrophage colony stimulating factor. Scheid MP, et al. **Biochem J** 1995 Nov 15;312 (Pt 1):159–62

Apoptosis induction resulting from proteasome inhibition. Shinohara K, et al. **Biochem J** 1996 Jul 15;317 (Pt 2):385–8

Constitutive nuclear NF kappa B/rel DNA-binding activity of rat thymocytes is increased by stimuli that promote apoptosis, but not inhibited by pyrrolidine dithiocarbamate. Slater AF, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):833–8

Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32. Slee EA, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):21–4

prICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2. Smyth MJ, et al. **Biochem J** 1996 May 15;316 (Pt 1):25–8

Staurosporine-induced thymocyte apoptosis is inhibited by herbimycin A, a specific inhibitor of protein tyrosine kinase. Azuma Y, et al. **Biochem Mol Biol Int** 1995 Nov; 37(4):635–43

The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells. Hsieh TC, et al. **Biochem Mol Biol Int** 1995 Oct;37(3):499–506

Internucleosomal DNA cleavage in HeLa cells exposed to cisplatin. Maldonado V, et al. **Biochem Mol Biol Int** 1995 Nov;37(4):691–6

Cytokines and programmed cell death in burkitt lymphoma cells. Trubiani O, et al. **Biochem Mol Biol Int** 1995 Sep; 37(1):17–24

Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Hanif R, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):237–45

Effects of hemin on apoptosis, suppression of cytochrome c oxidase gene expression, and bone-marrow toxicity induced by doxorubicin (adriamycin). Papadopoulou LC, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):713–22

Ebselen inhibition of apoptosis by reduction of peroxides. Ramakrishnan N, et al. **Biochem Pharmacol** 1996 Jun 14; 51(11):1443–51

Azidothymidine induces apoptosis in mouse myeloma cell line Sp2/0. Sailaja G, et al. **Biochem Pharmacol** 1996 Sep 27;52(6):857–62

Evidence that gliotoxin enhances lymphocyte activation and induces apoptosis by effects on cyclic AMP levels. Sutton P, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2009–14

Inhibition of apoptosis by antioxidants in the human HL-60 leukemia cell line. Verhaegen S, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):1021–9

N-acetylcysteine protects lymphocytes from nitrogen mustard-induced apoptosis. Weltin D, et al. **Biochem Pharmacol** 1996 May 3;51(9):1123–9

Differential effects of phorbol ester on apoptosis in HL-60 promyelocytic leukemia cells. Zhu WH, et al. **Biochem Pharmacol** 1996 May 3;51(9):1229–36

Wortmannin enhances tumour necrosis factor alpha-stimulated neutrophil apoptosis. Murray J, et al. **Biochem Soc Trans** 1996 Feb;24(1):80S

Mechanism of apoptosis suppression by phorbol ester in IL-6-starved murine plasmacytomas: role of PKC modulation and cell cycle. Romanova LY, et al. **Biochemistry** 1996 Jul 30;35(30):9900–6

Clusterin gene expression in apoptotic MDCK cells is dependent on the apoptosis-inducing stimulus. Flach R, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):325–8

Spontaneous and glucocorticoid-induced apoptosis in human mature T lymphocytes. Brunetti M, et al. **Blood** 1995 Dec 1;86(11):4199–205

Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Chaouchi N, et al. **Blood** 1996 Feb 1; 87(3):1022–9

In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Chen GQ, et al. **Blood** 1996 Aug 1;88(3):1052–61

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptides (PACAP27) and PACAP38) protect CD4+CD8+ thymocytes from glucocorticoid-induced apoptosis. Delgado M, et al. **Blood** 1996 Jun 15;87(12):5152–61

The diadenosine polyphosphates Ap3A and Ap4A and adenosine triphosphate interact with granulocyte-macrophage colony-stimulating factor to delay neutrophil apoptosis: implications for neutrophil: platelet interactions during inflammation. Gasmi L, et al. **Blood** 1996 Apr 15;87(8):3442–9

Transforming growth factor-beta potently inhibits the viability-promoting activity of stem cell factor and other cytokines and induces apoptosis of primitive murine hematopoietic progenitor cells. Jacobsen FW, et al. **Blood** 1995 Oct 15;86(8):2957–66

Nerve growth factor prevents apoptosis of rat peritoneal mast cells through the trk proto-oncogene receptor. Kawamoto K, et al. **Blood** 1995 Dec 15;86(12):4638–44

Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Laurence J, et al. **Blood** 1996 Apr 15;87(8):3245–54

Glucocorticoids inhibit apoptosis of human neutrophils. Liles WC, et al. **Blood** 1995 Oct 15;86(8):3181–8

Transforming growth factor-beta 1 cooperates with anti-immunoglobulin for the induction of apoptosis in group I (biopsy-like) Burkitt lymphoma cell lines. MacDonald I, et al. **Blood** 1996 Feb 1;87(3):1147–54

Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Menzel T, et al. **Blood** 1996 Feb 1;87(3):1056–63

Inhibition of CD4 cross-linking-induced lymphocytes apoptosis by vesnarinone as a novel immunomodulating agent: vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion. Oyaizu N, et al. **Blood** 1996 Mar 15;87(6):2361–8

Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Silva M, et al. **Blood** 1996 Sep 1;88(5):1576–82

Target-induced death by apoptosis in human lymphokine-activated natural killer cells. Taga K, et al. **Blood** 1996 Mar 15;87(6):2411–8

Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Yanagida M, et al. **Blood** 1995 Nov 15; 86(10):3705–14

8-Chloro-cAMP induces apoptotic cell death in a human mammary carcinoma cell (MCF-7) line. Bøe R, et al. **Br J Cancer** 1995 Nov;72(5):1151–9

Citrus flavone tangeretin inhibits leukaemic HL-60 cell growth partially through induction of apoptosis with less cytotoxicity on normal lymphocytes. Hirano T, et al. **Br J Cancer** 1995 Dec;72(6):1380–8

Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-beta-D-arabinofuranosylcytosine. Horber DH, et al. **Br J Cancer** 1995 Nov;72(5):1067–73

Isolation and characterisation of Kasumi-1 human myeloid leukaemia cell line resistant to tumour necrosis factor alpha-induced apoptosis. Ido M, et al. **Br J Cancer** 1996 Feb;73(3):360–5

Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells. Kawamura KI, et al. **Br J Cancer** 1996 Jan;73(2):183–8

p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Malcomson RD, et al. **Br J Cancer** 1995 Oct; 72(4):952–7

Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505. Meikle I, et al. **Br J Cancer** 1996 Aug; 74(3):374–9

Apoptosis and necrosis induced with light and 5-aminolaevulinic acid-derived protoporphyrin IX. Noodt BB, et al. **Br J Cancer** 1996 Jul;74(1):22–9

Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells. Perry RR, et al. **Br J Cancer** 1995 Dec;72(6):1441–6

Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Bergamaschi G, et al. **Br J Haematol** 1996 Jun 2; 93(4):789–94

Inhibition of growth and induction of apoptosis by all-trans retinoic acid in lymphoid cell lines transfected with the PML/RAR alpha fusion gene. Maeda Y, et al. **Br J Haematol** 1996 Jun 2;93(4):973–6

Heparin induces apoptosis in human peripheral blood neutrophils. Manaster J, et al. **Br J Haematol** 1996 Jul; 94(1):48–52

Sodium butyrate delays neutrophil apoptosis: role of protein biosynthesis in neutrophil survival. Stringer RE, et al. **Br J Haematol** 1996 Jan;92(1):169–75

Cell death induced by beta-amyloid 1-40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosis. Le WD, et al. **Brain Res** 1995 Jul 17;686(1):49–60

Sodium butyrate induces aberrant tau phosphorylation and programmed cell death in human neuroblastoma cells. Nuydens R, et al. **Brain Res** 1995 Aug 7;688(1-2):86–94

Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Chang YF, et al. **Cancer** 1996 Jan 1;77(1):14–8

Transforming growth factor-beta 1 induces apoptosis in gastric cancer cells through a p53-independent pathway. Yamamoto M, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1628–33

Induction of apoptosis in MDA-231 cells by protein synthesis inhibitors is suppressed by multiple agents. Geier A, et al. **Cancer Invest** 1996;14(5):435–44

Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Büssing A, et al. **Cancer Lett** 1996 Jan 19;99(1):59–72

Tamoxifen and somatostatin affect tumours by inducing apoptosis. Candi E, et al. **Cancer Lett** 1995 Sep 4; 96(1):141–5

Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Frankfurt OS, et al. **Cancer Lett** 1995 Nov 6;97(2):149–54

Tirapazamine (SR 4233) interrupts cell cycle progression and induces apoptosis. Lin PS, et al. **Cancer Lett** 1996 Aug 2;105(2):249–55

Cytotoxic effects of sinococuline. Liu WK, et al. **Cancer Lett** 1996 Feb 6;99(2):217–24

Interphase and M-phase oral KB carcinoma cells are targetted in staurosporine-induced apoptosis. Swe M, et al. **Cancer Lett** 1996 Jul 12;104(2):145–52

Growth inhibition and apoptosis in human neuroblastoma SK-N-SH cells induced by hypericin, a potent inhibitor of protein kinase C. Zhang W, et al. **Cancer Lett** 1995 Sep 4;96(1):31–5

Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. Adam L, et al. **Cancer Res** 1995 Nov 15;55(22):5156–60

The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Bernhard EJ, et al. **Cancer Res** 1996 Apr 15;56(8):1727–30

Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Blagosklonny MV, et al. **Cancer Res** 1996 Apr 15;56(8):1851–4

Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Chresta CM, et al. **Cancer Res** 1996 Apr 15;56(8):1834–41

Potentiation of enediyne-induced apoptosis and differentiation by Bcl-2. Cortazzo M, et al. **Cancer Res**

1996 Mar 15;56(6):1199–203

Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro–transformed adenoma relative to adenoma relative to adenoma cell lines. Elder DJ, et al. **Cancer Res** 1996 May 15;56(10):2273–6

Reduced bile acid–induced apoptosis in "normal" colorectal mucosa: a potential biological marker for cancer risk. Garewal H, et al. **Cancer Res** 1996 Apr 1;56(7):1480–3

Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Haldar S, et al. **Cancer Res** 1996 Mar 15; 56(6):1253–5

Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Katoh O, et al. **Cancer Res** 1995 Dec 1; 55(23):5687–92

Interleukin–1 beta–converting enzyme mediates cisplatin–induced apoptosis in malignant glioma cells. Kondo S, et al. **Cancer Res** 1995 Dec 15;55(24):6166–71

Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl–2 to inhibit apoptosis without affecting clonogenic survival. Lock RB, et al. **Cancer Res** 1996 Sep 1;56(17):4006–12

Protease inhibitors induce specific changes in protein tyrosine phosphorylation that correlate with inhibition of apoptosis in myeloid cells. Lumelsky NL, et al. **Cancer Res** 1996 Sep 1;56(17):3909–14

Cell cycle–dependent tumor necrosis factor apoptosis. Shih SC, et al. **Cancer Res** 1996 Apr 1;56(7):1591–8

Both transforming growth factor–beta and substrate release are inducers of apoptosis in a human colon adenoma cell line. Wang CY, et al. **Cancer Res** 1995 Nov 1;55(21):5101–5

Influence of liver tumor promoters on apoptosis in rat hepatocytes induced by 2–acetylaminofluorene, ultraviolet light, or transforming growth factor beta 1. Worner W, et al. **Cancer Res** 1996 Mar 15;56(6):1272–8

BCL–2 expression delays drug–induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Yin DX, et al. **Cancer Res** 1995 Nov 1; 55(21):4922–8

Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. James NH, et al. **Carcinogenesis** 1996 Aug;17(8):1623–32

Dose dependence of phenobarbital promotion of preneoplastic hepatic lesions in F344 rats and B6C3F1 mice: effects on DNA synthesis and apoptosis. Kolaja KL, et al. **Carcinogenesis** 1996 May;17(5):947–54

Diallyl disulfide induces apoptosis of human colon tumor cells. Sundaram SG, et al. **Carcinogenesis** 1996 Apr; 17(4):669–73

Apoptotic and anti–proliferative effects of fumonisin B1 in human keratinocytes, fibroblasts, esophageal epithelial cells and hepatoma cells. Tolleson WH, et al. **Carcinogenesis** 1996 Feb;17(2):239–49

Induction of apoptotic program in cell–free extracts: requirement for dATP and cytochrome c. Liu X, et al. **Cell** 1996 Jul 12;86(1):147–57

Tyrphostin induces non–apoptotic programmed cell death in colon tumor cells. Szende B, et al. **Cell Biol Int** 1995 Nov;19(11):903–11

Apoptosis induced by protein kinase C inhibition in a neuroblastoma cell line. Behrens MM, et al. **Cell Growth Differ** 1995 Nov;6(11):1375–80

Induction of cell differentiation potentiates apoptosis triggered by prior exposure to DNA–damaging drugs. Bhatia U, et al. **Cell Growth Differ** 1995 Aug;6(8):937–44

Insulin regulates expression of c–fos and c–jun and suppresses apoptosis of lens epithelial cells. Rampalli AM, et al. **Cell Growth Differ** 1995 Aug;6(8):945–53

Expression of retinoic acid receptor beta mediates retinoic acid–induced growth arrest and apoptosis in breast cancer cells. Seewaldt VL, et al. **Cell Growth Differ** 1995 Sep; 6(9):1077–88

G1 cell cycle arrest and apoptosis are induced in NIH 3T3 cells by KN–93, an inhibitor of CaMK–II (the multifunctional Ca2+/CaM kinase). Tombes RM, et al. **Cell Growth Differ** 1995 Sep;6(9):1063–70

Apoptosis in 7–hydroxystaurosporine–treated T lymphoblasts correlates with activation of cyclin–dependent kinases 1 and 2. Wang Q, et al. **Cell Growth Differ** 1995 Aug; 6(8):927–36

HIV–1 Tat protein and its inhibitor Ro 24–7429 inhibit lymphocyte proliferation and induce apoptosis in peripheral blood mononuclear cells from healthy donors. Patki AH, et al. **Cell Immunol** 1996 Apr 10;169(1):40–6

Differential induction of programmed cell death in CD8+ and CD4+ T cells by the B subunit of cholera toxin. Yankelevich B, et al. **Cell Immunol** 1996 Mar 15; 168(2):229–34

Inhibition and down–regulation of poly(ADP–ribose) polymerase results in a marked resistance of HL–60 cells to various apoptosis–inducers. Tanaka Y, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Sep;41(6):771–81

Quinone–induced apoptosis in human colon adenocarcinoma cells via DT–diaphorase mediated bioactivation. Sun X, et al. **Chem Biol Interact** 1996 May 6;100(3):267–76

Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Lanza L, et al. **Clin Exp Immunol** 1996 Mar;103(3):482–90

Retinoic acid modulates the in vivo and in vitro growth of IL–6 autocrine human myeloma cell lines via induction of apoptosis. Levy Y, et al. **Clin Exp Immunol** 1996 Apr; 104(1):167–72

Neurotoxicity of beta–amyloid protein: cytochemical changes and apoptotic cell death investigated in organotypic cultures. Allen YS, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):370–1

Cisplatin–induced apoptosis in mouse proximal tubular cell line. Takeda M, et al. **Contrib Nephrol** 1996;118:24–8

Hypericin inhibits cell growth and induces apoptosis in retinal pigment epithelial cells: possible involvement of protein kinase C. Harris MS, et al. **Curr Eye Res** 1996 Mar; 15(3):255–62

Apoptosis in the developing tooth: association with an embryonic signaling center and suppression by EGF and FGF–4. Vaahtokari A, et al. **Development** 1996 Jan; 122(1):121–9

High–glucose–triggered apoptosis in cultured endothelial cells. Baumgartner–Parzer SM, et al. **Diabetes** 1995 Nov; 44(11):1323–7

Programmed cell death in sympathetic neurons: a study by two–dimensional polyacrylamide gel electrophoresis using computer image analysis. Amess B, et al. **Electrophoresis** 1995 Jul;16(7):1255–67

Daunorubicin–induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. Jaffrézou JP, et al. **EMBO J** 1996 May 15;15(10):2417–24

In vitro, follicle–stimulating hormone prevents apoptosis and stimulates deoxyribonucleic acid synthesis in the rat seminiferous epithelium in a stage–specific fashion. Henriksén K, et al. **Endocrinology** 1996 May;137(5):2141–9

N–cadherin–mediated cell contact inhibits granulosa cell apoptosis in a progesterone–independent manner. Peluso JJ, et al. **Endocrinology** 1996 Apr;137(4):1196–203

Cell cycle traverse in AHH–1 tk +/– human lymphoblastoid cells exposed to the chromosomal mutagen, m–amsa. Morris SM, et al. **Environ Mol Mutagen** 1996;27(1):10–8

Enhanced phosphorylation of nuclear 21–kDa and 34–kDa proteins in hepatoma cell death induced by tumor–necrosis factor–alpha. Masumi–Fukazawa A, et al. **Eur J Biochem** 1995 Aug 15;232(1):134–40

Human stem cell factor protects CD34 positive human myeloid leukaemia cells from chemotherapy–induced apoptosis [letter] Hassan HT, et al. **Eur J Cancer** 1995 Oct; 31A(11):1883–4

Apoptosis and chemotherapy resistance. Hickman JA. **Eur J Cancer** 1996 Jun;32A(6):921–6 (67 ref.)

Effect of intracellular acidity and ionomycin on apoptosis in HL–60 cells. Park HJ, et al. **Eur J Cancer** 1996 Mar; 32A(3):540–6

The short–chain fatty acid butyrate induces apoptosis in colorectal tumour cell lines. Hague A, et al. **Eur J Cancer Prev** 1995 Oct;4(5):359–64 (36 ref.)

Synergistic stimulatory effects of tumour necrosis factor alpha and interferon gamma on replication of human immunodeficiency virus type 1 and on apoptosis of HIV–1–infected host cells. Han X, et al. **Eur J Clin Invest** 1996 Apr;26(4):286–92

Nucleoside transporters, bcl–2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro. Petersen AJ, et al. **Eur J Haematol** 1996 Apr;56(4):213–20

Fas–mediated apoptosis is modulated by intracellular glutathione in human T cells. Chiba T, et al. **Eur J Immunol** 1996 May;26(5):1164–9

The role of oxygen in thymocyte apoptosis. McLaughlin KA, et al. **Eur J Immunol** 1996 May;26(5):1170–4

Differential susceptibility to monomeric HIV gp120–mediated apoptosis in antigen–activated CD4+ T cell populations. Tuosto L, et al. **Eur J Immunol** 1995 Oct; 25(10):2907–16

Ligation of either CD2 or CD28 rescues CD4+ T cells from HIV–gp120–induced apoptosis. Tuosto L, et al. **Eur J Immunol** 1995 Oct;25(10):2917–22

Inhibition of I–Ad–, but not Db–restricted peptide–induced thymic apoptosis by glucocorticoid receptor antagonist RU486 in T cell receptor transgenic mice. Xue Y, et al. **Eur J Immunol** 1996 Feb;26(2):428–34

Induction of p53–independent apoptosis by hygromycin B: suppression by Bcl–2 and adenovirus E1B 19–kDa protein. Chen G, et al. **Exp Cell Res** 1995 Nov;221(1):55–9

Different basal NAD levels determine opposite effects of poly(ADP–ribosyl)polymerase inhibitors on H2O2–induced apoptosis. Coppola S, et al. **Exp Cell Res** 1995 Dec;221(2):462–9

The increase in H2O2–induced apoptosis by ADP–ribosylation inhibitors is related to cell blebbing. Ghibelli L, et al. **Exp Cell Res** 1995 Dec;221(2):470–7

Effect of protease inhibitors on early events of apoptosis. Hara S, et al. **Exp Cell Res** 1996 Mar 15;223(2):372–84

Protection by ascorbate against apoptosis of thymocytes: implications of ascorbate–induced nonlethal oxidative stress and poly(ADP–ribosyl)ation. Maellaro E, et al. **Exp Cell Res** 1996 Jul 10;226(1):105–13

NF–kappaB activation by triphenyltin triggers apoptosis in HL–60 cells. Marinovich M, et al. **Exp Cell Res** 1996 Jul 10;226(1):98–104

TNF–alpha inhibits anti–IgM–mediated apoptosis in Ramos cells. Park E, et al. **Exp Cell Res** 1996 Jul 10;226(1):1–10

BCL–2 and MCL–1 expression in Chinese hamster ovary cells inhibits intracellular acidification and apoptosis induced by staurosporine. Reynolds JE, et al. **Exp Cell Res** 1996 Jun 15;225(2):430–6

Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Shiff SJ, et al. **Exp Cell Res** 1996 Jan 10; 222(1):179–88

Chemotherapeutic agent CPT–11 induces the new expression of the apoptosis initiator to the cytoplasm. Suzuki A, et al. **Exp Cell Res** 1996 Aug 25;227(1):154–9

A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM–2 mRNA levels in human prostate tumor xenografts. Wright PS, et al. **Exp Cell Res** 1996 Jan 10;222(1):54–60

The C–terminal cytoplasmic region of the granulocyte colony–stimulating factor receptor mediates apoptosis in maturation–incompetent murine myeloid cells. Dong F, et al. **Exp Hematol** 1996 Feb;24(2):214–20

Specific toxicity of tunicamycin in induction of programmed cell death of sympathetic neurons. Chang JY, et al. **Exp Neurol** 1996 Feb;137(2):201–11

Staurosporine–induced neuronal apoptosis. Koh JY, et al. **Exp Neurol** 1995 Oct;135(2):153–9

Induction of vanadium accumulation and nuclear sequestration causing cell suicide in human Chang liver cells. Sit KH, et al. **Experientia** 1996 Aug 15;52(8):778–85

Trolox inhibits apoptosis in irradiated MOLT–4 lymphocytes. McClain DE, et al. **FASEB J** 1995 Oct;9(13):1345–54

CPP32 inhibition prevents Fas–induced ceramide generation and apoptosis in human cells. Gamen S, et al. **FEBS Lett** 1996 Jul 22;390(2):232–7

Protease inhibitors block apoptosis at intermediate stages: a compared analysis of DNA fragmentation and apoptotic nuclear morphology. Ghibelli L, et al. **FEBS Lett** 1995 Dec 11;377(1):9–14

Protein tyrosine kinase inhibitors prevent didemnin B–induced apoptosis in HL–60 cells. Johnson KL, et al. **FEBS Lett** 1996 Mar 25;383(1–2):1–5

Nitric oxide induced poly(ADP–ribose) polymerase cleavage in RAW 264.7 macrophage apoptosis is blocked by Bcl–2. Messmer UK, et al. **FEBS Lett** 1996 Apr 15;384(2):162–6

Antioxidant inhibition of thymocyte apoptosis by dihydrolipoic acid. Bustamante J, et al. **Free Radic Biol Med** 1995 Sep;19(3):339–47

Lipopolysaccharide induced apoptosis of rat pancreatic acinar cells. Laine VJ, et al. **Gut** 1996 May;38(5):747–52

Sensitization of human ovarian tumor cells by subtoxic CDDP to anti–fas antibody–mediated cytotoxicity and apoptosis. Uslu R, et al. **Gynecol Oncol** 1996 Aug; 62(2):282–91

Purine analogs (fludarabine and 2–chlorodeoxyadenosine) as apoptosis–inducing drugs in CML therapy [letter] Martinelli G, et al. **Haematologica** 1996 May–Jun; 81(3):286–7

Apoptosis induction with purine analogs on freshly isolated chronic myeloid leukemia cells [letter] Zinzani PL, et al. **Haematologica** 1995 Jul–Aug;80(4):390–1

Transforming growth factor beta 1 increases the number of apoptotic bodies and decreases intracellular pH in isolated periportal and perivenular rat hepatocytes. Benedetti A, et al. **Hepatology** 1995 Nov;22(5):1488–98

The translational inhibitor cycloheximide represses growth factor depletion–induced apoptosis in an alb–SV40T transgenic rat liver cell line. Bulera SJ, et al. **Hepatology** 1996 Jun;23(6):1591–601

Transforming growth factor beta 1–induced cell death in preneoplastic foci of rat liver and sensitization by the antiestrogen tamoxifen. Müllauer L, et al. **Hepatology** 1996 Apr;23(4):840–7

The herbal medicine Inchin–ko–to inhibits liver cell apoptosis induced by transforming growth factor beta 1. Yamamoto M, et al. **Hepatology** 1996 Mar;23(3):552–9

Norepinephrine reverses the effects of activin A on DNA synthesis and apoptosis in cultured rat hepatocytes. Zhang YQ, et al. **Hepatology** 1996 Feb;23(2):288–93

Promoting apoptosis. Alison M. **Hum Exp Toxicol** 1995 Aug; 14(8):697–8

Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Fukuo K, et al. **Hypertension** 1996 Mar;27(3 Pt 2):823–6

TGF beta 1 inhibits NF–kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Arsura M, et al. **Immunity** 1996 Jul;5(1):31–40

A targeted glucocorticoid receptor antisense transgene increases thymocyte apoptosis and alters thymocyte development. King LB, et al. **Immunity** 1995 Nov; 3(5):647–56

Identification and characterization of a new member of the TNF family that induces apoptosis. Wiley SR, et al. **Immunity** 1995 Dec;3(6):673–82

Cycloheximide–induced apoptosis in Burkitt lymphoma (BJA–B) cells with and without Epstein–Barr virus infection. Ishii HH, et al. **Immunol Cell Biol** 1995 Oct; 73(5):463–8

Effects of N–acetyl–L–cysteine on T–cell apoptosis are not mediated by increased cellular glutathione. Jones DP, et al. **Immunol Lett** 1995 Mar;45(3):205–9

Modulation of drug–induced apoptosis in a human B–lymphoma cell line (HT58). Mihalik R, et al. **Immunol Lett** 1995 Nov;48(1):17–21

In vivo induction of apoptosis and immune responses in mice by administration of lipopolysaccharide from Porphyromonas gingivalis. Isogai E, et al. **Infect Immun** 1996 Apr;64(4):1461–6

H2O2 induces monocyte apoptosis and reduces viability of

Mycobacterium avium-M. intracellulare within cultured human monocytes. Laochumroonvorapong P, et al. **Infect Immun** 1996 Feb;64(2):452-9

Apoptotic cell death in the response of D-galactosamine-sensitized mice to lipopolysaccharide as an experimental endotoxic shock model. Morikawa, A, et al. **Infect Immun** 1996 Mar;64(3):734-8

Tumor necrosis factor-alpha up-regulates Bcl-2 expression and decreases calcium-dependent apoptosis in human B cell lines. Genestier L, et al. **Int Immunol** 1995 Apr; 7(4):533-40

Pleiotropic effects of Bcl-2 on transcription factors in T cells: potential role of NF-kappa B p50-p50 for the anti-apoptotic function of Bcl-2. Ivanov VN, et al. **Int Immunol** 1995 Nov;7(11):1709-20

Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. Basu A, et al. **Int J Cancer** 1995 Nov 15;63(4):597-603

Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-beta 1 and its type-I and type-II receptors. Landström M, et al. **Int J Cancer** 1996 Aug 7;67(4):573-9

Phorbol ester augments butyrate-induced apoptosis of colon cancer cells. McBain JA, et al. **Int J Cancer** 1996 Sep 4; 67(5):715-23

Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Ogretmen B, et al. **Int J Cancer** 1996 Sep 4;67(5):608-14

Wild-type p53-induced apoptosis in a Burkitt lymphoma cell line is inhibited by interferon gamma. Sangfelt O, et al. **Int J Cancer** 1996 Jul 3;67(1):106-12

Sphingosine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Sweeney EA, et al. **Int J Cancer** 1996 May 3;66(3):358-66

Modulation of growth and apoptosis response in PC-3 and LNCAP prostate-cancer cell lines by Fas. Takeuchi T, et al. **Int J Cancer** 1996 Sep 4;67(5):709-14

Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Wagener C, et al. **Int J Cancer** 1996 Jul 3;67(1):138-41

In vitro induction of apoptosis of developing brain cells by 5-azacytidine. Hossain MM, et al. **Int J Dev Neurosci** 1996 Feb;14(1):11-7

Thyroid hormone promotes BCL-2 expression and prevents apoptosis of early differentiating cerebellar granule neurons. Muller Y, et al. **Int J Dev Neurosci** 1995 Dec; 13(8):871-85

Cell proliferation and apoptosis in isoprenaline-induced sialosis in the rat submandibular glands. Chisholm DM, et al. **Int J Exp Pathol** 1995 Aug;76(4):263-9

Extracellular calcium is not required for gliotoxin or dexamethasone-induced DNA fragmentation: a reappraisal of the use of EGTA. Waring P, et al. **Int J Immunopharmacol** 1995 May;17(5):403-10

Radiosensitization of HL-60 human leukaemia cells by bryostatin-1 in the absence of increased DNA fragmentation or apoptotic cell death. Watson NC, et al. **Int J Radiat Biol** 1996 Feb;69(2):183-92

Autocrine feedback death and the regulation of mature T lymphocyte antigen responses. Lenardo MJ, et al. **Int Rev Immunol** 1995;13(2):115-34 (76 ref.)

13-cis retinoic acid inhibits growth of adult T cell leukemia cells and causes apoptosis; possible new indication for retinoid therapy [see comments] Maeda Y, et al. **Intern Med** 1996 Mar;35(3):180-4. Comment in: Intern Med 1996 Mar;35(3):167-8.

Adult T-cell leukemia: challenge for induction of apoptosis in leukemic cells [editorial; comment] Suzushima H, et al. **Intern Med** 1996 Mar;35(3):167-8. Comment on: Intern Med 1996 Mar;35(3):180-4.

Screening for apoptosis inducers in microbial products and induction of apoptosis by cytostatin. Yamazaki K, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1138-40

Identification of interleukin 1-induced apoptosis in rat islets using in situ specific labelling of fragmented DNA. Dunger A, et al. **J Autoimmun** 1996 Jun;9(3):309-13

Effects of protein tyrosine kinase inhibitors with different modes of action on topoisomerase activity and death of IL-2-dependent CTLL-2 cells. Azuma Y, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):312-8

The protective role of glutathione peroxidase in apoptosis induced by reactive oxygen species. Kayanoki Y, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):817-22

Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. Dickinson JL, et al. **J Biol Chem** 1995 Nov 17;270(46):27894-904

Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells. Fox JC, et al. **J Biol Chem** 1996 May 24;271(21):12578-84

Fibroblast growth factor-2 suppression of tumor necrosis factor alpha-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase. Gardner AM, et al. **J Biol Chem** 1996 Jun 14;271(24):14560-6

Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. Jarvis WD, et al. **J Biol Chem** 1996 Apr 5; 271(14):8275-84

Dithiocarbamates induce apoptosis in thymocytes by raising the intracellular level of redox-active copper. Nobel CI, et al. **J Biol Chem** 1995 Nov 3;270(44):26202-8

Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates. Sánchez A, et al. **J Biol Chem** 1996 Mar 29;271(13):7416-22

Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. Sawai H, et al. **J Biol Chem** 1995 Nov 10;270(45):27326-31

Disrupted signaling in a mutant J2E cell line that shows enhanced viability, but does not proliferate or differentiate, with erythropoietin. Tilbrook PA, et al. **J Biol Chem** 1996 Feb 16;271(7):3453-9

Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. Tsai JC, et al. **J Biol Chem** 1996 Feb 16;271(7):3667-70

The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. Watabe M, et al. **J Biol Chem** 1996 Jun 14;271(24):14067-72

Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Hughes DE, et al. **J Bone Miner Res** 1995 Oct;10(10):1478-87

Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells. Efferth T, et al. **J Cancer Res Clin Oncol** 1995;121(11):648-56

Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid. Inomata M, et al. **J Cancer Res Clin Oncol** 1995;121(12):729-38

Effect of pentoxifylline on apoptosis of cultured cells. Belloc F, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S71-4

Tamoxifen induces TGF-beta 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. Chen H, et al. **J Cell Biochem** 1996 Apr;61(1):9-17

Probing the molecular program of apoptosis by cancer chemopreventive agents. Fésüs L, et al. **J Cell Biochem Suppl** 1995;22:151-61 (49 ref.)

Calcium-cell cycle regulator, differentiator, killer, chemopreventor, and maybe, tumor promoter. Whitfield JF, et al. **J Cell Biochem Suppl** 1995;22:74-91 (38 ref.)

Role of Ced-3/ICE-family proteases in staurosporine-induced programmed cell death. Jacobsen MD, et al. **J Cell Biol** 1996 Jun;133(5):1041-51

Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. Morris EJ, et al. **J Cell Biol** 1996 Aug;134(3):757-70

Epidermal growth factor inhibits cytokine-induced apoptosis of primary human trophoblasts. Garcia-Lloret MI, et al. **J Cell Physiol** 1996 May;167(2):324-32

Concanavalin A induced apoptosis in fibroblasts: the role of cell surface carbohydrates in lectin mediated cytotoxicity. Kulkarni GV, et al. **J Cell Physiol** 1995 Oct; 165(1):119-33

Insulin-like growth factor I rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. Matthews CC, et al. **J Cell Physiol** 1996 Feb;166(2):323-31

Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. Selleri C, et al. **J Cell Physiol** 1995 Dec;165(3):538-46

Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120. Sekigawa I, et al. **J Clin Immunol** 1995 Nov;15(6):312-7

Nerve growth factor prevents apoptotic cell death in injured central cholinergic neurons. Wilcox BJ, et al. **J Comp Neurol** 1995 Sep 4;359(4):573-85

T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. Estaquier J, et al. **J Exp Med** 1995 Dec 1; 182(6):1759-67

Differential activation of a calcium-dependent endonuclease in human B lymphocytes. Role in ionomycin-induced apoptosis. Aagaard-Tillery KM, et al. **J Immunol** 1995 Oct 1;155(7):3297-307

Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. Abreu-Martin MT, et al. **J Immunol** 1995 Nov 1;155(9):4147-54

Bcl-2 expression inhibits prostaglandin E2-mediated apoptosis in B cell lymphomas. Brown DM, et al. **J Immunol** 1996 Aug 15;157(4):1359-70

Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. Hansson M, et al. **J Immunol** 1996 Jan 1;156(1):42-7

Acidic sphingomyelinase-generated ceramide is needed but not sufficient for TNF-induced apoptosis and nuclear factor-kappa B activation. Higuchi M, et al. **J Immunol** 1996 Jul 1;157(1):297-304

Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. McConkey DJ, et al. **J Immunol** 1996 Apr 1;156(7):2624-30

Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. Meagher LC, et al. **J Immunol** 1996 Jun 1;156(11):4422-8

Requirement for phosphatidylinositol 3'-kinase to protect hemopoietic progenitors against apoptosis depends upon the extracellular survival factor. Minshall C, et al. **J Immunol** 1996 Feb 1;156(3):939-47

IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis. Correlation with induction of Bcl-2. Mor F, et al. **J Immunol** 1996 Jan 15; 156(2):515-22

Cytokines suppress apoptosis independent of increases in reactive oxygen levels. Packham G, et al. **J Immunol** 1996 Apr 15;156(8):2792-800

IL-1 beta converting enzyme (ICE) is not required for apoptosis induced by lymphokine deprivation in an IL-2-dependent T cell line. Vasilakos JP, et al. **J Immunol** 1995 Oct 1;155(7):3433-42

The protein hydrolysate, Primatone RL, is a cost-effective multiple growth promoter of mammalian cell culture in serum-containing and serum-free media and displays anti-apoptosis properties. Schlaeger EJ. **J Immunol Methods** 1996 Aug 14;194(2):191-9

Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. van Rooijen N, et al. **J Immunol Methods** 1996 Jun 14; 193(1):93-9

Induction of apoptosis in B lineage cells by activin A derived from macrophages. Nishihara T, et al. **J Interferon Cytokine Res** 1995 Jun;15(6):509-16

Apoptosis. Kim IK. **J Korean Med Sci** 1995 Oct;10(5):307-13 (10 ref.)

Nicotine prolongs neutrophil survival by suppressing apoptosis. Aoshiba K, et al. **J Lab Clin Med** 1996 Feb; 127(2):186-94

Interleukin-6 suppression of neutrophil apoptosis is neutrophil concentration dependent. Biffl WL, et al. **J Leukoc Biol** 1995 Nov;58(5):582-4

Apoptotic cell death in activated monocytes following incorporation of clodronate-liposomes. Schmidt-Weber CB, et al. **J Leukoc Biol** 1996 Aug;60(2):230-44

Rapid killing of human neutrophils by the potent activator phorbol 12-myristate 13-acetate (PMA) accompanied by changes different from typical apoptosis or necrosis. Takei H, et al. **J Leukoc Biol** 1996 Feb;59(2):229-40

Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium-binding protein complex, calprotectin, derived from inflammatory peritoneal exudate cells. Yui S, et al. **J Leukoc Biol** 1995 Dec;58(6):650-8

Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog? [editorial; comment] Gelmann EP. **J Natl Cancer Inst** 1996 Mar 6;88(5):224-6. Comment on: J Natl Cancer Inst 1996 Mar 6;88(5):279-84.

Apoptosis provides new targets for chemotherapy [news] Holzman D. **J Natl Cancer Inst** 1996 Aug 21; 88(16):1098-100

Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines [see comments] Kalemkerian GP, et al. **J Natl Cancer Inst** 1995 Nov 15; 87(22):1674-80. Comment in: J Natl Cancer Inst 1995 Nov 15;87(22):1655-7.

Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells [see comments] Kang Y, et al. **J Natl Cancer Inst** 1996 Mar 6;88(5):279-84 . Comment in: J Natl Cancer Inst 1996 Mar 6;88(5):224-6.

Retinoids and apoptosis: implications for cancer chemoprevention and therapy [editorial; comment] Lotan R. **J Natl Cancer Inst** 1995 Nov 15;87(22):1655-7. Comment on: J Natl Cancer Inst 1995 Nov 15;87(22):1674-80.

Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. Milross CG, et al. **J Natl Cancer Inst** 1996 Sep 18;88(18):1308-14

Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. Robertson CN, et al. **J Natl Cancer Inst** 1996 Jul 3;88(13):908-17

Differential induction of immediate early gene proteins in cultured neurons by beta-amyloid (A beta): association of c-Jun with A beta-induced apoptosis. Anderson AJ, et al. **J Neurochem** 1995 Oct;65(4):1487-98

Cyanide-induced apoptosis and oxidative stress in differentiated PC12 cells. Mills EM, et al. **J Neurochem** 1996 Sep;67(3):1039-46

Staurosporine induces programmed cell death in embryonic neurons and activation of the ceramide pathway. Wiesner DA, et al. **J Neurochem** 1996 Apr;66(4):1418-25

Colony-stimulating factors regulate programmed cell death of rat microglia/brain macrophages in vitro. Gehrmann J. **J Neuroimmunol** 1995 Dec;63(1):55-61

Calcitonin gene-related peptide enhances apoptosis of thymocytes. Sakuta H, et al. **J Neuroimmunol** 1996 Jul; 67(2):103-9

Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. Farinelli SE, et al. **J Neurosci** 1996 Feb 1;16(3):1150-62

Removal of serum from primary cultures of cerebellar granule neurons induces oxidative stress and DNA fragmentation: protection with antioxidants and glutamate receptor antagonists. Atabay C, et al. **J Neurosci Res** 1996 Feb 15;43(4):465-75

Oxidized low density lipoproteins alter macrophage lipid uptake, apoptosis, viability and nitric oxide synthesis. Yang X, et al. **J Nutr** 1996 Apr;126(4 Suppl):1072S-5S

Apoptosis in human monocyte-macrophages exposed to oxidized low density lipoprotein. Hardwick SJ, et al. **J Pathol** 1996 Jul;179(3):294-302

Inorganic mercury chloride-induced apoptosis in the

cultured porcine renal cell line LLC-PK1.
Duncan-Achanzar KB, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1726-32

Induction of apoptosis in murine and human neuroblastoma cell lines by the enediyne natural product neocarzinostatin.
Hartsell TL, et al. **J Pharmacol Exp Ther** 1995 Oct; 275(1):479-85

An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture.
Ishitani R, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):447-54

Prostaglandin E2 induces apoptosis in resting immature and mature human lymphocytes: a c-Myc-dependent and Bcl-2-independent associated pathway.
Pica F, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1793-800

Induction of apoptosis by organotin compounds in vitro: neuronal protection with antisense oligonucleotides directed against stannin.
Thompson TA, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1201-16

Sodium nitroprusside-induced apoptotic cellular death via production of hydrogen peroxide in murine neuroblastoma N1E-115 cells.
Yamada M, et al. **J Pharmacol Toxicol Methods** 1996 Feb;35(1):11-7

The pineal neurohormone melatonin prevents in vivo and in vitro apoptosis in thymocytes.
Sainz RM, et al. **J Pineal Res** 1995 Nov;19(4):178-88

Lithium delays the radiation-induced apoptotic process in external granule cells of mouse cerebellum.
Inouye M, et al. **J Radiat Res (Tokyo)** 1995 Sep;36(3):203-8

Early alterations of apoptosis and cell proliferation in azoxymethane-initiated rat colonic epithelium.
Hirose Y, et al. **Jpn J Cancer Res** 1996 Jun;87(6):575-82

Apoptosis of HIV-infected cells following treatment with Sho-Saiko-to and its components.
Wu X, et al. **Jpn J Med Sci Biol** 1995 Apr;48(2):79-87

Thymic nurse cells as the site of thymocyte apoptosis and apoptotic cell clearance in the thymus of cyclophosphamide-treated mice.
Hiramine C, et al. **Lab Invest** 1996 Aug;75(2):185-201

Induction of atypical hyperplasia, apoptosis, and type II estrogen-binding sites in the ventral prostates of Noble rats treated with testosterone and pharmacologic doses of estradiol-17 beta.
Ho SM, et al. **Lab Invest** 1995 Sep; 73(3):356-65

Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation.
Orazi A, et al. **Lab Invest** 1996 Jul;75(1):33-42

Neutrophil apoptosis induced by proteolytic enzymes.
Trevani AS, et al. **Lab Invest** 1996 Mar;74(3):711-21

Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without stimulating proliferation.
Jewell AP, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):159-62

Bcl-2 expression and glucocorticoid-induced apoptosis of leukemic and lymphoma cells.
Smets LA, et al. **Leuk Lymphoma** 1996 Jan;20(3-4):199-205

Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis.
Anderson KM, et al. **Leuk Res** 1995 Nov; 19(11):789-801

Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside.
Bouffard DY, et al. **Leuk Res** 1995 Nov;19(11):849-56

Inhibition of human leukaemia 60 cell growth by S-D-lactoylglutathione in vitro. Mediation by metabolism to N-D-lactoylcysteine and induction of apoptosis.
Edwards LG, et al. **Leuk Res** 1996 Jan;20(1):17-26

Effect of methylglyoxal on human leukaemia 60 cell growth: modification of DNA G1 growth arrest and induction of apoptosis.
Kang Y, et al. **Leuk Res** 1996 May;20(5):397-405

Augmentation by aphidicolin of 1-beta-D-arabinofuranosylcytosine-induced c-jun and NF-kappa B activation in a human myeloid leukemia cell line: correlation with apoptosis.
Kuwakado K, et al. **Leuk Res** 1995 Sep;19(9):645-50

Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma.
Mohammad RM, et al. **Leuk Res** 1995 Sep;19(9):667-73

Retinoid-regulated expression of BCL-2 and tissue transglutaminase during the differentiation and apoptosis of human myeloid leukemia (HL-60) cells.
Nagy L, et al. **Leuk Res** 1996 Jun;20(6):499-505

Doppa induces cell death but not differentiation of U937 cells: evidence for the involvement of PKC-beta 1 in the regulation of apoptosis.
Pongracz J, et al. **Leuk Res** 1996 Apr;20(4):319-26

The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells.
Rowley PT, et al. **Leuk Res** 1996 Jun;20(6):473-80

pIXY321 protects against Ara-C or taxol-induced apoptosis and loss of clonogenic survival of normal human bone marrow progenitor cells.
Bhalla K, et al. **Leukemia** 1995 Nov;9(11):1851-6

In vitro treatment with retinoids or the topoisomerase inhibitor, VP-16, evidences different functional apoptotic pathways in acute promyelocytic leukemic cells.
Calabresse C, et al. **Leukemia** 1995 Dec;9(12):2049-57

Protection of human myeloid leukemic cells against doxorubicin-induced apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin 3.
Kaplinsky C, et al. **Leukemia** 1996 Mar; 10(3):460-5

Induction of apoptosis by cordycepin in ADA-inhibited TdT-positive leukemia cells.
Koç Y, et al. **Leukemia** 1996 Jun;10(6):1019-24

P53 and induction of apoptosis as a target for anticancer therapy.
Neubauer A, et al. **Leukemia** 1996 Jul;10 Suppl 3:S2-S4 (46 ref.)

Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study of paclitaxel.
Seiter K, et al. **Leukemia** 1995 Nov;9(11):1961-6

Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.
Tentori L, et al. **Leukemia** 1995 Nov; 9(11):1888-95

Role of serine and ICE-like proteases in induction of apoptosis by etoposide in human leukemia HL-60 cells.
Yoshida A, et al. **Leukemia** 1996 May;10(5):821-4

Protective action of isoquinolinesulfonamides in in vitro models of neuronal apoptosis.
Cagnoli CM, et al. **Life Sci** 1996;58(19):PL295-301

Potent growth inhibitory activity of a novel Ornithogalum cholestane glycoside on human cells: induction of apoptosis in promyelocytic leukemia HL-60 cells.
Hirano T, et al. **Life Sci** 1996;58(9):789-98

The requirement for and mobilization of calcium during induction by sodium ascorbate and by hydrogen peroxide of cell death.
Sakagami H, et al. **Life Sci** 1996;58(14):1131-8

Age related decline in cytokine induced nitric oxide synthase activation and apoptosis in cultured endothelial cells: minimal involvement of nitric oxide in the apoptosis.
Sato I, et al. **Mech Ageing Dev** 1995 Jun 30;81(1):27-36

Inhibition by bacterial lipopolysaccharide of spontaneous and TNF-alpha-induced human neutrophil apoptosis in vitro.
Hachiya O, et al. **Microbiol Immunol** 1995;39(9):715-23

Bleb formation and F-actin distribution during mitosis and tumor necrosis factor-induced apoptosis.
Laster SM, et al. **Microsc Res Tech** 1996 Jun 15;34(3):272-80

Activation of physiological cell death mechanisms by a necrosis-causing agent.
Vaux DL, et al. **Microsc Res Tech** 1996 Jun 15;34(3):259-66

Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells.
Ho YS, et al. **Mol Carcinog** 1996 May;16(1):20-31

Estrogen-induced apoptosis by inhibition of the erythroid transcription factor GATA-1.
Blobel GA, et al. **Mol Cell Biol** 1996 Apr;16(4):1687-94

Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells.
Liu Y, et al. **Mol Cell Biol** 1996 Mar; 16(3):1138-49

Induction of apoptosis by c-Fos protein.
Preston GA, et al. **Mol Cell Biol** 1996 Jan;16(1):211-8

Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes.
Hammes HP, et al. **Mol Med** 1995 Jul;1(5):527-34

Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway.
Woods CM, et al. **Mol Med** 1995 Jul;1(5):506-26

Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons.
Cavallaro S, et al. **Mol Pharmacol** 1996 Jul;50(1):60-6

Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.
Freemerman AJ, et al. **Mol Pharmacol** 1996 May; 49(5):788-95

Simultaneous evaluation of dexamethasone-induced apoptosis and micronuclei in rat primary spleen cell cultures.
Krishna G, et al. **Mutat Res** 1995 Nov; 332(1-2):1-8

Aspirin and colon cancer [letter; comment]
Goldberg Y. **N Engl J Med** 1996 Mar 21;334(12):800-1. Comment on: N Engl J Med 1995 Sep 7;333(10):609-14. Comment on: N Engl J Med 1995 Sep 7;333(10):656-8.

Inhibition by dexamethasone of human neutrophil apoptosis in vitro.
Kato T, et al. **Nat Immun** 1995 Apr;14(4):198-208

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis [see comments]
Wahl AF, et al. **Nat Med** 1996 Jan;2(1):72-9. Comment in: Nat Med 1996 Jul;2(7):724-5.

Intravenous fumonisin B1 induces cell proliferation and apoptosis in the rat.
Lim CW, et al. **Nat Toxins** 1996; 4(1):34-41

Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function.
Ankarcrona M, et al. **Neuron** 1995 Oct;15(4):961-73

GDNF reduces apoptosis in dopaminergic neurons in vitro.
Clarkson ED, et al. **Neuroreport** 1995 Dec 29;7(1):145-9

Cyclic AMP and pituitary adenylate cyclase-activating polypeptide (PACAP) prevent programmed cell death of cultured rat cerebellar granule cells.
Chang JY, et al. **Neurosci Lett** 1996 Mar 15;206(2-3):181-4

Nicotinamide as a precursor for NAD+ prevents apoptosis in the mouse brain induced by tertiary-butylhydroperoxide.
Klaidman LK, et al. **Neurosci Lett** 1996 Mar 8;206(1):5-8

Nitric oxide induces cultured cortical neuron apoptosis.
Palluy O, et al. **Neurosci Lett** 1996 Apr 12;208(1):1-4

Induction of apoptosis and secondary necrosis in rat dorsal root ganglion cell cultures by oxidized low density lipoprotein.
Papassotiropoulos A, et al. **Neurosci Lett** 1996 May 3;209(1):33-6

Insulin prevents apoptosis of external granular layer neurons in rat cerebellar slice cultures.
Tanaka M, et al. **Neurosci Lett** 1995 Oct 13;199(1):37-40

Tumor necrosis factor-alpha induces p53-dependent apoptosis in rat glioma cells.
Yin D, et al. **Neurosurgery** 1995 Oct;37(4):758-62; discussion 762-3

Retardation of chemical hypoxia-induced necrotic cell death by Bcl-2 and ICE inhibitors: possible involvement of common mediators in apoptotic and necrotic signal transductions.
Shimizu S, et al. **Oncogene** 1996 May 16; 12(10):2045-50

Ganciclovir-induced ablation non-proliferating thyrocytes expressing herpesvirus thymidine kinase occurs by p53-independent apoptosis.
Wallace H, et al. **Oncogene** 1996 Jul 4;13(1):55-61

Repression of apoptosis in human B-lymphoma cells by CD40-ligand and Bcl-2: relationship to the cell-cycle and role of the retinoblastoma protein.
Wang H, et al. **Oncogene** 1996 Jul 18;13(2):373-9

Induction of apoptosis by sodium butyrate in the human Y-79 retinoblastoma cell line.
Conway RM, et al. **Oncol Res** 1995;7(6):289-97

NSAIDs may prevent colon cancer through apoptosis, not anti-inflammatory effects [news]
Oncology (Huntingt) 1996 Apr;10(4):624

Apoptosis or necrosis following Photofrin photosensitization: influence of the incubation protocol.
Dellinger M. **Photochem Photobiol** 1996 Jul;64(1):182-7

PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes.
Johnson R, et al. **Photochem Photobiol** 1996 May;63(5):566-71

Kinetic analysis of apoptosis induction in human cell lines by UVA and 8-MOP.
Vowels BR, et al. **Photochem Photobiol** 1996 May;63(5):572-6

Constitutive overexpression of Cu/Zn superoxide dismutase exacerbates kainic acid-induced apoptosis of transgenic-Cu/Zn superoxide dismutase neurons.
Bar-Peled O, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8530-5

Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis.
Dou QP, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9019-23

Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway.
Gartenhaus RB, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):265-8

Differential effects of staphylococcal toxic shock syndrome toxin-1 on B cell apoptosis.
Hofer MF, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5425-30

Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons.
Ishitani R, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9937-41

Fumonisins and Alternaria alternata lycopersici toxins: sphinganine analog mycotoxins induce apoptosis in monkey kidney cells.
Wang W, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3461-5

Calcium, cell death, and tumor promotion.
Trump BF, et al. **Prog Clin Biol Res** 1995;391:121-31 (49 ref.)

Induction of apoptosis in prostatic tumor cell line DU145 by staurosporine, a potent inhibitor of protein kinases.
Zhang H, et al. **Prostate** 1996 Aug;29(2):69-76

Role of Fenton chemistry in thiol-induced toxicity and apoptosis.
Held KD, et al. **Radiat Res** 1996 May; 145(5):542-53 (81 ref.)

The biochemistry and molecular biology of glucocorticoid-induced apoptosis in the immune system.
Cidlowski JA, et al. **Recent Prog Horm Res** 1996;51:457-90; discussion 490-1 (161 ref.)

A novel function of haptoglobin: haptoglobin-haemoglobin complex induces apoptosis of hepatocarcinomatous Hep 3B cells.
Kim IK, et al. **Scand J Clin Lab Invest** 1995 Oct; 55(6):529-35

Histaminergic regulation of NK-cells: protection against monocyte-induced apoptosis.
Hansson M, et al. **Scand J Immunol** 1996 Aug;44(2):193-6

Apoptosis induced by microtubule disrupting drugs in normal murine thymocytes in vitro.
Bumbaširević V, et al. **Scanning Microsc** 1995 Jun;9(2):509-16; discussion 516-8

Induction of apoptosis by gemcitabine.
Huang P, et al. **Semin Oncol** 1995 Aug;22(4 Suppl 11):19-25

Felbamate protects CA1 neurons from apoptosis in a gerbil model of global ischemia.
Wasterlain CG, et al. **Stroke** 1996 Jul;27(7):1236-40

Thiol-mediated redox regulation of neutrophil apoptosis.
Watson RW, et al. **Surgery** 1996 Aug;120(2):150-7; discussion 157-8

Induction of apoptosis and cathepsin D in limbs exposed in vitro to an activated analog of cyclophosphamide.
Moallem SA, et al. **Teratology** 1995 Jul;52(1):3-14

Fate of germ cells in 2,5-hexanedione-induced testicular injury. II. Atrophy persists due to a reduced stem cell mass and ongoing apoptosis.
Allard EK, et al. **Toxicol Appl Pharmacol** 1996 Apr;137(2):149-56

Calcium channel blockers induce thymic apoptosis in vivo in rats.
Balakumaran A, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):122-7

Fate of germ cells in 2,5-hexanedione-induced testicular injury. I. Apoptosis is the mechanism of germ cell death.

Blanchard KT, et al. **Toxicol Appl Pharmacol** 1996 Apr; 137(2):141–8

4–Hydroxynonenal–induced cell death in murine alveolar macrophages. Li L, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):135–43

Dosing–induced stress causes hepatocyte apoptosis in rats primed by the rodent nongenotoxic hepatocarcinogen cyproterone acetate. Roberts RA, et al. **Toxicol Appl Pharmacol** 1995 Dec;135(2):192–9

Fluoranthene–induced apoptosis in murine T cell hybridomas is independent of the aromatic hydrocarbon receptor. Yamaguchi K, et al. **Toxicol Appl Pharmacol** 1996 Jul; 139(1):144–52

In vivo studies of cadmium–induced apoptosis in testicular tissue of the rat and its modulation by a chelating agent. Xu C, et al. **Toxicology** 1996 Jan 22;107(1):1–8

Induction of lymphocyte apoptosis and prolongation of allograft survival by FTY720. Suzuki S, et al. **Transplant Proc** 1996 Aug;28(4):2049–50

Fas antigen expression and apoptosis induction of in vitro cultured hepatocytes with high concentrations of cyclosporine A. Yokoyama I, et al. **Transplant Proc** 1996 Jun;28(3):1383–4

[Hormone–dependent cell death (editorial)] Tapanainen J. **Duodecim** 1994;110(10):933–5 (13 ref.) **(Fin)**

[In vitro induction of apoptosis in chronic lymphoid leukemia B lymphocytes by theophylline: therapeutic applications] Binet JL, et al. **Bull Acad Natl Med** 1995 Oct; 179(7):1379–91; discussion 1391–2 (Eng. Abstr.) **(Fre)**

[Induction of apoptosis, in vitro and in vivo, on colonic tumor cells of the rat after sodium butyrate treatment] Boisteau O, et al. **Bull Cancer (Paris)** 1996 Mar;83(3):197–204 (Eng. Abstr.) **(Fre)**

[Cisplatin resistance in a murine leukemia cell line associated with defect of apoptosis] Segal–Bendirdjian E, et al. **Bull Cancer (Paris)** 1996 May;83(5):371–8 (37 ref.) (Eng. Abstr.) **(Fre)**

[Apoptosis of human leukemic cells induced by topoisomerase I and II inhibitors] Solary E, et al. **Bull Cancer (Paris)** 1996 Mar;83(3):205–12 (Eng. Abstr.) **(Fre)**

[Pidotimod causes apoptotic cell death and inhibits the proliferative activity of YAC–1 tumor cells in vitro] Migliorati G, et al. **Drugs Exp Clin Res** 1993;19 Suppl:1–7 **(Ita)**

[On the novel differentiation–apoptosis inducers in tumor cells] Nakaya K. **Tanpakushitsu Kakusan Koso** 1996 Feb; 41(2):119–26 (38 ref.) **(Jpn)**

[Effect of calcium ions on cell death by apoptosis, induced by cytotoxic proteins from LAK cells] Sashenko LP, et al. **Doki Akad Nauk** 1995 Dec;345(6):827–9 **(Rus)**

GENETICS

Apoptosis in glial tumors as determined by in situ nonradioactive labeling of DNA breaks. Kordek R, et al. **Acta Neuropathol (Berl)** 1996;91(1):112–6

Apoptosis and bcl–2 protein expression in experimental alcoholic liver disease in the rat. Yacoub LK, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):854–9

Massive apoptosis detected by in situ DNA nick end labeling in neuroblastoma. Ikeda H, et al. **Am J Surg Pathol** 1996 Jun;20(6):649–55

Sequestration of mitotic (M–phase) chromosomes in autophagosomes: mitotic programmed cell death in human Chang liver cells induced by an $OH^{\bullet}$ burst from vanadyl(4). Sit KH, et al. **Anat Rec** 1996 May;245(1):1–8

Analysis of chromosome 5q13 genes in amyotrophic lateral sclerosis: homozygous NAIP deletion in a sporadic case. Jackson M, et al. **Ann Neurol** 1996 Jun;39(6):796–800

Early gene signalling–dependent and –independent induction of apoptosis in Ramos human B cells can be inhibited by over–expression of Bcl–2. Ning ZQ, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):23–9

Chromosomal localization of the human genes, CPP32, Mch2, Mch3, and Ich–1, involved in cellular apoptosis. Tino N, et al. **Biochem Biophys Res Commun** 1996 Aug 23;225(3):983–9

Cell death suffers a TKO. Osborne BA, et al. **Bioessays** 1995 Jun;17(6):557–9 (13 ref.)

Detection of apoptosis at the single–cell level by direct incorporation of fluorescein–dUTP in DNA strand breaks. Piqueras B, et al. **Biotechniques** 1996 Apr;20(4):634–40

Retroviral vector–mediated transfer of the tumor necrosis factor alpha gene into human cancer cells restores an apoptotic cell death program and induces a bystander–killing effect. Gillio Tos A, et al. **Blood** 1996 Mar 15;87(6):2486–95

Fanconi anemia genes act to suppress a cross–linker–inducible p53–independent apoptosis pathway in lymphoblastoid cell lines. Kruyt FA, et al. **Blood** 1996 Feb 1;87(3):938–48

A1, a Bcl–2 family member, prolongs cell survival and permits myeloid differentiation. Lin EY, et al. **Blood** 1996 Feb 1;87(3):983–92

Frequent expression of the cell death–inducing gene Bax in Reed–Sternberg cells of Hodgkin's disease. Rigal–Huguet F, et al. **Blood** 1996 Mar 15;87(6):2470–5

BCR–ABL does not prevent apoptotic death induced by human natural killer or lymphokine–activated killer cells. Roger R, et al. **Blood** 1996 Feb 1;87(3):1113–22

Activated abl oncogenes and apoptosis: differing responses of transformed myeloid progenitor cell lines. Zhu J, et al. **Blood** 1996 May 15;87(10):4368–75

Histochemical detection of intranuclear DNA fragmentation and its relation to the expression of bcl–2 oncoprotein in human prostatic cancer. Taniguchi J, et al. **Br J Urol** 1996 May;77(5):719–23

Programmed cell death in the dysmyelinating mutants. Skoff RP. **Brain Pathol** 1995 Jul;5(3):283–8

Apoptotic DNA fragmentation in the rat cerebral cortex induced by permanent middle cerebral artery occlusion. Linnik MD, et al. **Brain Res Mol Brain Res** 1995 Aug; 32(1):116–24

Programmed cell death and the gene behind spinal muscular atrophy. Robinson A. **Can Med Assoc J** 1995 Nov 15; 153(10):1459–62

Intracellular antibody against erbB–2 mediates targeted tumor cell eradication by apoptosis. Deshane J, et al. **Cancer Gene Ther** 1996 Mar–Apr;3(2):89–98

Apoptosis, cancer and the p53 tumour suppressor gene. Lee JM, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):149–61 (113 ref.)

Yttrium–90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis–related messenger RNA expression. DeNardo SJ, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5837s–5841s

bcl–xs gene therapy induces apoptosis of human mammary tumors in nude mice. Ealovega MW, et al. **Cancer Res** 1996 May 1;56(9):1965–9

Role of bcl–X(L) in the control of apoptosis in murine myeloma cells. Gauthier ER, et al. **Cancer Res** 1996 Mar 15;56(6):1451–6

Apoptosis–associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Marchetti P, et al. **Cancer Res** 1996 May 1;56(9):2033–8

Apoptotic response to oncogenic stimuli: cooperative and antagonistic interactions between c–myb and the growth suppressor p53. Sala A, et al. **Cancer Res** 1996 May 1; 56(9):1991–6

The genetics of programmed (apoptotic) cell death. Lin X, et al. **Cancer Surv** 1995;25:173–94 (101 ref.)

E2F–1 functions in mice to promote apoptosis and suppress proliferation. Field SJ, et al. **Cell** 1996 May 17;85(4):549–61

An alternatively spliced C. elegans ced–4 RNA encodes a novel cell death inhibitor. Shaham S, et al. **Cell** 1996 Jul 26;86(2):201–8

bcl–2 inhibits wild–type p53–triggered apoptosis but not G1 cell cycle arrest and transactivation of WAF1 and bax. Wang Y, et al. **Cell Growth Differ** 1995 Sep;6(9):1071–5

The olfactory system as a model for the analysis of the contribution of gene expression to programmed cell death. Hayward MD, et al. **Chem Senses** 1995 Apr;20(2):261–9 (100 ref.)

The genetics of programmed cell death in the nematode Caenorhabditis elegans. Horvitz HR, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:377–85 (56 ref.)

Apoptosis and the prognostic significance of p53 mutation. Lowe SW, et al. **Cold Spring Harb Symp Quant Biol** 1994; 59:419–26

Genetic instability and apoptotic cell death during neoplastic progression of v–myc–initiated B–cell lymphomas in the bursa of Fabricius. Neiman PE, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:509–15

p53–dependent apoptosis in vivo: impact of p53 inactivation on tumorigenesis. Symonds H, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:247–57

Apoptosis in carcinogenesis: the role of p53. Wyllie AH, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:403–9

Bcl–2 gene family and the regulation of programmed cell death. Yin XM, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:387–93 (46 ref.)

A member of the phylogenetically conserved CAD family of transcriptional regulators is dramatically up–regulated during the programmed cell death of skeletal muscle in the tobacco hawkmoth Manduca sexta. Sun D, et al. **Dev Biol** 1996 Feb 1;173(2):499–509

Imprinting of IGF2, insulin–dependent diabetes, immune function, and apoptosis: a hypothesis. Polychronakos C, et al. **Dev Genet** 1995;17(3):253–62

Programmed cell death in the absence of c–Fos and c–Jun. Roffler–Tarlov S, et al. **Development** 1996 Jan;122(1):1–9

Cell type–specific inhibition of p53–mediated apoptosis by mdm2. Haupt Y, et al. **EMBO J** 1996 Apr 1;15(7):1596–606

dad–1, an endogenous programmed cell death suppressor in Caenorhabditis elegans and vertebrates. Sugimoto A, et al. **EMBO J** 1995 Sep 15;14(18):4434–41

Expression of V642 APP mutant causes cellular apoptosis as Alzheimer trait–linked phenotype. Yamatsuji T, et al. **EMBO J** 1996 Feb 1;15(3):498–509

Identification of a cysteine protease closely related to interleukin–1 beta–converting enzyme. Faucheu C, et al. **Eur J Biochem** 1996 Feb 15;236(1):207–13

Studies of specific gene induction during apoptosis of cell lines conditionally immortalized by SV40. Guénal I, et al. **FEBS Lett** 1995 Nov 6;374(3):384–6

Ectopic E2F expression induces S phase and apoptosis in Drosophila imaginal discs. Asano M, et al. **Genes Dev** 1996 Jun 1;10(11):1422–32

Tissue–specific inactivation of p53 tumor suppression in the mouse. Bowman T, et al. **Genes Dev** 1996 Apr 1; 10(7):826–35

grim, a novel cell death gene in Drosophila. Chen P, et al. **Genes Dev** 1996 Jul 15;10(14):1773–82

Genetic determinants of p53–induced apoptosis and growth arrest. Polyak K, et al. **Genes Dev** 1996 Aug 1; 10(15):1945–52

Developing Caenorhabditis elegans neurons may contain both cell–death protective and killer activities. Shaham S, et al. **Genes Dev** 1996 Mar 1;10(5):578–91

Life, death, and the pursuit of apoptosis. White E. **Genes Dev** 1996 Jan 1;10(1):1–15 (191 ref.)

Assignment of DAP1 and DAPK––genes that positively mediate programmed cell death triggered by IFN–gamma––to chromosome regions 5p12.2 and 9q34.1, respectively. Feinstein E, et al. **Genomics** 1995 Sep 1; 29(1):305–7

Type 1 diabetes and the control of dexamethazone–induced apoptosis in mice maps to the same region on chromosome 6. Penha–Gonçalves C, et al. **Genomics** 1995 Aug 10; 28(3):398–404

Modification of tumor suppressor gene expression and induction of apoptosis in non–small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Roth JA. **Hum Gene Ther** 1996 May 20;7(8):1013–30

Molecular ordering of the cell death pathway. Bcl–2 and Bcl–xL function upstream of the CED–3–like apoptotic proteases. Chinnaiyan AM, et al. **J Biol Chem** 1996 Mar 1;271(9):4573–6

Anti–IgM–mediated regulation of c–myc and its possible relationship to apoptosis. Kaptein JS, et al. **J Biol Chem** 1996 Aug 2;271(31):18875–84

Molecular ordering of apoptotic mammalian CED–3/ICE–like proteases. Orth K, et al. **J Biol Chem** 1996 Aug 30;271(35):20977–80

An additional form of rat Bcl–x, Bcl–xbeta, generated by an unspliced RNA, promotes apoptosis in promyeloid cells. Shiraiwa N, et al. **J Biol Chem** 1996 May 31; 271(22):13258–65

Expression of the cell death–inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. Branet F, et al. **J Clin Endocrinol Metab** 1996 Jul; 81(7):2726–30

Human germinal center B cells express the apoptosis–inducing genes Fas, c–myc, P53, and Bax but not the survival gene bcl–2. Martinez–Valdez H, et al. **J Exp Med** 1996 Mar 1;183(3):971–7

Expression of the CTL–associated protein TIA–1 during murine embryogenesis. Lowin B, et al. **J Immunol** 1996 Aug 15;157(4):1448–54

Insertional mutagenesis affecting programmed cell death leads to thymic hyperplasia and altered thymopoiesis. Volkmann A, et al. **J Immunol** 1996 Jan 1;156(1):136–45

Induction of bcl–x by CD40 engagement rescues sIg–induced apoptosis in murine B cells. Wang Z, et al. **J Immunol** 1995 Oct 15;155(8):3722–5

Regulation of apoptosis by Bcl–2 and its related proteins: immunochemical challenges and therapeutic implications [editorial] Kernohan NM, et al. **J Pathol** 1996 May; 179(1):1–3

BCR–ABL: an anti–apoptosis gene in chronic myelogenous leukemia. Cotter TG. **Leuk Lymphoma** 1995 Jul; 18(3–4):231–6 (32 ref.)

The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia. Fernandes RS, et al. **Leukemia** 1996 Jun;10 Suppl 2:s17–21 (39 ref.)

Forced over–expression of the myeloid zinc finger gene MZF–1 inhibits apoptosis and promotes oncogenesis in interleukin–3–dependent FDCP.1 cells. Hromas R, et al. **Leukemia** 1996 Jun;10(6):1049–50

Apoptosis and proliferation of human hepatocellular carcinoma. Hino N, et al. **Liver** 1996 Apr;16(2):123–9

Evidence for transcriptional modulation but not acid phosphatase expression during programmed cell death in the colonial tunicate Botryllus schlosseri. Lauzon RJ, et al. **Microsc Res Tech** 1996 Jun 15;34(3):218–27

A mutant p53 that discriminates between p53–responsive genes cannot induce apoptosis. Friedlander P, et al. **Mol Cell Biol** 1996 Sep;16(9):4961–71

Functional dissection of the human Bc12 protein: sequence requirements for inhibition of apoptosis. Hunter JJ, et al. **Mol Cell Biol** 1996 Mar;16(3):877–83

Human chromosome 3 mediates growth arrest and suppression of apoptosis in microcell hybrids. Speevak MD, et al. **Mol Cell Biol** 1996 May;16(5):2214–25

Inhibition of c–myc expression induces apoptosis of WEHI 231 murine B cells. Wu M, et al. **Mol Cell Biol** 1996 Sep; 16(9):5015–25

A mouse Fas–associated protein with homology to the human Mort1/FADD protein is essential for Fas–induced apoptosis. Zhang J, et al. **Mol Cell Biol** 1996 Jun; 16(6):2756–63

Mammalian DNA damage–inducible genes associated with growth arrest and apoptosis. Smith ML, et al. **Mutat Res** 1996 Jun;340(2–3):109–24 (143 ref.)

Expanded polyglutamine in the Machado–Joseph disease protein induces cell death in vitro and in vivo. Ikeda H, et al. **Nat Genet** 1996 Jun;13(2):196–202

DNA damage, p53 and anticancer therapies. Milner J. **Nat Med** 1995 Sep;1(9):879–80 (8 ref.)

Transcriptional regulator of programmed cell death encoded by Caenorhabditis elegans gene ces–2. Metzstein MM, et al. **Nature** 1996 Aug 8;382(6591):545–7

Transcription. A fate worse than death [news] Thompson CB. **Nature** 1996 Aug 8;382(6591):492–3

A matter of life or death: is the Bcl–2 anti–apoptosis gene involved in neural plasticity in the olfactory system?

[comment] Getchell TV. **Neuroreport** 1995 Dec 29;7(1):9 . Comment on: Neuroreport 1995 Dec 29;7(1):197–200.
Ionizing radiation–induced apoptosis is associated with c–Jun expression and c–Jun/AP–1 activation in the developing cerebellum of the rat. Ferrer I, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):105–8
Quantitation of DNA fragmentation in apoptosis. Ioannou YA, et al. **Nucleic Acids Res** 1996 Mar 1;24(5):992–3
Deregulated messenger RNA expression during T cell apoptosis. Kerkhoff E, et al. **Nucleic Acids Res** 1995 Dec 11;23(23):4857–63
A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Algar EM, et al. **Oncogene** 1996 Mar 7;12(5):1005–14
Retinoblastoma protein inhibits IFN–gamma induced apoptosis. Berry DE, et al. **Oncogene** 1996 Apr 18; 12(8):1809–19
Targeted proteolysis of the focal adhesion kinase pp125 FAK during c–MYC–induced apoptosis is suppressed by integrin signalling. Crouch DH, et al. **Oncogene** 1996 Jun 20; 12(12):2689–96
Identification of a novel Bcl–2 related gene, BRAG–1, in human glioma. Das R, et al. **Oncogene** 1996 Mar 7; 12(5):947–51
The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl–2. Eliopoulos AG, et al. **Oncogene** 1995 Oct 5;11(7):1217–28
Activation of p21WAF1/Cip1 expression by a temperature–sensitive mutant of human p53 does not lead to apoptosis. Kobayashi T, et al. **Oncogene** 1995 Dec 7; 11(11):2311–6
Induction of c–myc mediated apoptosis in SV40–transformed rat fibroblasts. Lenahan MK, et al. **Oncogene** 1996 May 2;12(9):1847–54
Chromosome 22 complements apoptosis in Fas–and TNF–resistant mutant UK110 cells. Noguchi K, et al. **Oncogene** 1996 Jul 4;13(1):39–46
Comparative analysis of the structure and function of the chicken c–myc and v–myc genes: v–myc is a more potent inducer of cell proliferation and apoptosis than c–myc. Petropoulos CJ, et al. **Oncogene** 1996 Jun 20;12(12):2611–21
c–Myc induces apoptosis in epithelial cells by both p53–dependent and p53–independent mechanisms. Sakamuro D, et al. **Oncogene** 1995 Dec 7;11(11):2411–8
Bcl–XL protects cancer cells from p53–mediated apoptosis. Schott AF, et al. **Oncogene** 1995 Oct 5;11(7):1389–94
Induction of Fas–mediated apoptosis in p53–transfected human colon carcinoma cells. Tamura T, et al. **Oncogene** 1995 Nov 16;11(10):1939–46
Unmasking of a proliferation–restraining activity of the anti–apoptosis protein EBV BHRF1. Theodorakis P, et al. **Oncogene** 1996 Apr 18;12(8):1707–13
Induction of apoptosis by tamoxifen–activation of a p53–estrogen receptor fusion protein expressed in E1A and T24 H–ras transformed p53–/– mouse embryo fibroblasts. Vater CA, et al. **Oncogene** 1996 Aug 15;13(4):739–48
Abrogation of p53–induced G1 arrest by the HPV 16 E7 protein does not inhibit p53–induced apoptosis. Wang Y, et al. **Oncogene** 1996 Jun 20;12(12):2731–5
Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild–type p53. Yonish–Rouach E, et al. **Oncogene** 1995 Dec 7; 11(11):2197–205
Cell death in colorectal polyps as evaluated by in situ 3'–tailing reaction and its relationship to BCL–2 expression. Nakamura T, et al. **Pathol Int** 1995 Oct;45(10):721–8
Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Brinkmann U, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10427–31
Targeted gene disruption of Hsp70–2 results in failed meiosis, germ cell apoptosis, and male infertility. Dix DJ, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3264–8
Mutant cystic fibrosis transmembrane conductance regulator inhibits acidification and apoptosis in C127 cells: possible relevance to cystic fibrosis. Gottlieb RA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3587–91
Bc1–2 protects mice against fatal alphavirus encephalitis. Levine B, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):4810–5
A mutant p53 antagonizes the deregulated c–myc–mediated enhancement of apoptosis and decrease in leukemogenicity. Lotem J, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9672–6
Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor–associated factors. Uren AG, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):4974–8
Expression of galectin–3 modulates T–cell growth and apoptosis. Yang RY, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6737–42
Inhibition of apoptosis by overexpressing Bcl–2 enhances gene amplification by a mechanism independent of aphidicolin pretreatment. Yin DX, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3394–8
Pharmacia Biotech & Science prize. Grand prize winner. Life and death decisions: ced–9 and programmed cell death in Caenorhabditis elegans. Hengartner MO. **Science** 1995 Nov 10;270(5238):930–1
Cellular responses to DNA damage: cell–cycle checkpoints, apoptosis and the roles of p53 and ATM. Enoch T, et al. **Trends Biochem Sci** 1995 Oct;20(10):426–30 (45 ref.)
Detection of DNA strand breaks associated with apoptosis in human brain tumors. Nakagawa S, et al. **Virchows Arch** 1995;427(2):175–9
[The IGF–I receptor: a new antiproliferative marker?] Fehmann HC, et al. **Z Gastroenterol** 1995 Oct;33(10):630–1 (Ger)
[Analysis of a novel gene expressed in apoptotic T–cell hybridoma treated with dexamethasone] Sakazume S, et al. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):33–44 (Eng. Abstr.) (Jpn)
[Bcl–2 with anti–apoptotic activity] Katsumata M, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2062–73 (64 ref.) (Jpn)
[Regulation of apoptosis by products of the bcl–2 gene family] Miyawaki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Feb;41(2):127–35 (44 ref.) (Jpn)
[Apoptosis and its role in the mechanisms of growth regulation of tumor cells with multiple drug resistance (editorial)] Ralkhlin NT, et al. **Arkh Patol** 1996 Mar–Apr; 58(2):3–8 (Eng. Abstr.) (Rus)
[Apoptosis: molecular and cellular mechanisms] Umanskil SP. **Mol Biol (Mosk)** 1996 May–Jun;30(3):487–502 (153 ref.) (Rus)
[Oncogenes and suppressor genes: apoptosis mechanisms] Mezquita C. **Med Clin (Barc)** 1995 Sep 30;105(10):389–95 (53 ref.) (Spa)

IMMUNOLOGY

From cell activation to cell depletion. The programmed cell death hypothesis of AIDS pathogenesis. Ameisen JC. **Adv Exp Med Biol** 1995;374:139–63 (159 ref.)
The role of surface CD4 in HIV–induced apoptosis. Corbeil J, et al. **Adv Exp Med Biol** 1995;374:91–9 (59 ref.)
Amelioration of autoimmune reactions by antigen–induced apoptosis of T cells. McFarland HI, et al. **Adv Exp Med Biol** 1995;383:157–66
Autoimmunity, apoptosis defects and retroviruses. Mountz JD, et al. **Adv Exp Med Biol** 1995;374:183–201 (84 ref.)
Dendritic cells, apoptosis and murine retrovirus. Woods GM, et al. **Adv Exp Med Biol** 1995;378:493–6
Role of calmodulin in HIV–potentiated Fas–mediated apoptosis. Pan Z, et al. **Am J Pathol** 1996 Sep;149(3):903–10
Apoptosis in human alveolar macrophages is induced by endotoxin and is modulated by cytokines. Bingisser R, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):64–70
Response of testicular macrophages to EDS–induced Leydig cell death. Gaytan F, et al. **Andrologia** 1995 Sep–Oct; 27(5):259–65
Expression of apogens and engulfens during programmed cell death in the nervous system of the chick embryo. Takashita N, et al. **Arch Histol Cytol** 1995 Jun;58(2):243–8
Interleukin–6 delays neutrophil apoptosis. Biffl WL, et al. **Arch Surg** 1996 Jan;131(1):24–9; discussion 29–30
Target cell apoptosis induced by cytotoxic T cells and natural killer cells involves synergy between the pore–forming protein, perforin, and the serine protease, granzyme B. Trapani JA. **Aust N Z J Med** 1995 Dec;25(6):793–9 (63 ref.)
ErbB receptor activation, cell morphology changes, and apoptosis induced by anti–Her2 monoclonal antibodies. Kita Y, et al. **Biochem Biophys Res Commun** 1996 Sep 4; 226(1):59–69
Fas–mediated apoptosis in cultured human eosinophils. Druilhe A, et al. **Blood** 1996 Apr 1;87(7):2822–30
Antiphosphatidylserine antibodies in human immunodeficiency virus–1 patients with evidence of T–cell apoptosis and mediate antibody–dependent cellular cytotoxicity. Silvestris F, et al. **Blood** 1996 Jun 15; 87(12):5185–95
Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte–macrophage colony–stimulating factor. Walsh GM, et al. **Blood** 1996 Apr 1;87(7):2815–21
The Fas antigen is detected on immature B cells and the representative cell lines show Fas–mediated apoptosis. Nishiuchi R, et al. **Br J Haematol** 1996 Feb;92(2):302–7
Apoptosis as a cause of T–cell unresponsiveness in experimental Chagas' disease. Lopes MF, et al. **Braz J Med Biol Res** 1995 Aug;28(8):913–8 (35 ref.)
Acid sphingomyelinase–deficient human lymphoblasts and mice are defective in radiation–induced apoptosis. Santana P, et al. **Cell** 1996 Jul 26;86(2):189–99
Identification of a putative G protein–coupled receptor induced during activation–induced apoptosis of T cells. Choi JW, et al. **Cell Immunol** 1996 Feb 25;168(1):78–84
B cell lines from a subset of patients with common variable immunodeficiency undergo enhanced apoptosis associated with an increased display of CD95 (Apo–1/fas), diminished CD38 expression, and decreased IgG and IgA production. Guo BC, et al. **Cell Immunol** 1995 Nov;166(1):83–92
Soluble MHC II–peptide complexes induce antigen–specific apoptosis in T cells. Nag B, et al. **Cell Immunol** 1996 May 25;170(1):25–33
T cell receptor–independent apoptosis of thymocyte clones induced by a thymic epithelial cell line is mediated by steroids. Zilberman Y, et al. **Cell Immunol** 1996 May 25; 170(1):78–84
CD28 and apoptosis. Boise LH, et al. **Curr Opin Immunol** 1995 Oct;7(5):620–5 (49 ref.)
Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. Strasser A. **Curr Opin Immunol** 1995 Apr;7(2):228–34 (97 ref.)
Interleukin–2 receptor common gamma–chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti–apoptotic (bcl–2, bcl–xL) but not pro–apoptotic (bax, bcl–xS) gene expression. Akbar AN, et al. **Eur J Immunol** 1996 Feb;26(2):294–9
Mitochondrial perturbations define lymphocytes undergoing apoptotic depletion in vivo. Castedo M, et al. **Eur J Immunol** 1995 Dec;25(12):3277–84
Apoptotic death of lymphocytes in murine acquired immunodeficiency syndrome: involvement of Fas–Fas ligand interaction. Kanagawa O, et al. **Eur J Immunol** 1995 Sep;25(9):2421–7
Antibody–targeted superantigen therapy induces tumor–infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Litton MJ, et al. **Eur J Immunol** 1996 Jan;26(1):1–9
Mechanisms of peripheral T cell deletion: anergized T cells are Fas resistant but undergo proliferation–associated apoptosis. Miethke T, et al. **Eur J Immunol** 1996 Jul; 26(7):1459–67
Elucidation of the protein kinase C–dependent apoptosis pathway in distinct subsets of T lymphocytes in MRL–lpr/lpr mice. Ohkusu K, et al. **Eur J Immunol** 1995 Nov;25(11):3180–6
CD3–induced apoptosis of CD4+CD8+ thymocytes in the absence of clonotypic T cell antigen receptor. Tokoro Y, et al. **Eur J Immunol** 1996 May;26(5):1012–7
JNK, but not MAPK, activation is associated with Fas–mediated apoptosis in human T cells. Wilson DJ, et al. **Eur J Immunol** 1996 May;26(5):989–94
Croquemort, a novel Drosophila hemocyte/macrophage receptor that recognizes apoptotic cells. Franc NC, et al. **Immunity** 1996 May;4(5):431–43
CD95–induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Griffith TS, et al. **Immunity** 1996 Jul;5(1):7–16
ICE family proteases: mediators of all apoptotic cell death? Henkart PA. **Immunity** 1996 Mar;4(3):195–201 (52 ref.)
The roles of Fas/APO–1 (CD95) and TNF in antigen–induced programmed cell death in T cell receptor transgenic mice. Sytwu HK, et al. **Immunity** 1996 Jul; 5(1):17–30
The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Van Parijs L, et al. **Immunity** 1996 Mar;4(3):321–8
Apoptosis as a mechanism of lectin–dependent monocyte–mediated cytotoxicity. Dong HD, et al. **Immunol Invest** 1996 Jan–Mar;25(1–2):65–78
Acute Plasmodium falciparum infection is associated with increased percentages of apoptotic cells. Baldé AT, et al. **Immunol Lett** 1995 May;46(1–2):59–62
Induction and natural occurrence of serum nucleosomal DNA in autoimmune MRL/lpr/lpr mice: its relation to apoptosis in the thymus. Kanai Y, et al. **Immunol Lett** 1995 May;46(1–2):207–14
Apoptosis: the in vivo mechanism which mediates spontaneous AK–5 tumor regression. Khar A, et al. **Immunol Lett** 1995 May;46(1–2):165–8
Physical interaction with monocytes rescues human mature CD4+ T–cell lines from anti–CD3–induced apoptosis. Yamauchi Y, et al. **Immunol Lett** 1995 May;46(1–2):85–92
Fas bridging cell death and cytotoxicity: the reaper connection. Golstein P, et al. **Immunol Rev** 1995 Aug; 146:45–56 (58 ref.)
Nuclear changes in the cytotoxic T lymphocyte–induced model of apoptosis. Sellins KS, et al. **Immunol Rev** 1995 Aug;146:241–66 (104 ref.)
Granzyme B plays a critical role in cytotoxic lymphocyte–induced apoptosis. Shresta S, et al. **Immunol Rev** 1995 Aug;146:211–21 (32 ref.)
Modulation of superantigen–induced T–cell deletion by antibody anti–Pgp–1 (CD44). Ayroldi E, et al. **Immunology** 1996 Feb;87(2):191–7
Effects of antigen presentation on superantigen–induced apoptosis mediated by Fas/Fas ligand interactions in human T cells. Boshell M, et al. **Immunology** 1996 Apr; 87(4):586–92
Apoptosis is associated with reduced expression of complement regulatory molecules, adhesion molecules and other receptors on polymorphonuclear leucocytes: functional relevance and role in inflammation. Jones J, et al. **Immunology** 1995 Dec;86(4):651–60
Tyrosine phosphorylation participates in peripheral T–cell activation and programmed cell death in vivo. Migita K, et al. **Immunology** 1995 Aug;85(4):550–5
HIV–1 upregulates Fas ligand expression in CD4+ T cells in vitro and in vivo: association with Fas–mediated apoptosis and modulation by aurintricarboxylic acid. Mitra D, et al. **Immunology** 1996 Apr;87(4):581–5
Involvement of LFA–1/ICAM–2 adhesive interactions and PKC in activation–induced cell death following SEB rechallenge. Tchilian EZ, et al. **Immunology** 1996 Apr; 87(4):566–72
Mafosfamide induces DNA fragmentation and apoptosis in human T–lymphocytes. A possible mechanism of its immunosuppressive action. Pette M, et al. **Immunopharmacology** 1995 Jun;30(1):59–69
Trypanosoma cruzi–induced immunosuppression: selective triggering of CD4+ T–cell death by the T–cell receptor–CD3 pathway and not by the CD69 or Ly–6

activation pathway. Lopes MF, et al. **Infect Immun** 1996 May;64(5):1559–64

Regulation of CD95 (APO–1) expression and the induction of apoptosis in human T cells: changes in old age. Lechner H, et al. **Int Arch Allergy Immunol** 1996 Jul;110(3):238–43

APO–1 (CD95)–dependent and –independent antigen receptor–induced apoptosis in human T and B cell lines. Peter ME, et al. **Int Immunol** 1995 Nov;7(11):1873–7

Antigen–specific down–regulation of myelin basic protein–reactive T cells during spontaneous recovery from experimental autoimmune encephalomyelitis: further evidence of apoptotic deletion of autoreactive T cells in the central nervous system. Tabi Z, et al. **Int Immunol** 1995 Jun;7(6):967–73

Expression of Fas in B cells of the mouse germinal center and Fas–dependent killing of activated B cells. Watanabe D, et al. **Int Immunol** 1995 Dec;7(12):1949–56

Autocrine feedback death and the regulation of mature T lymphocyte antigen responses. Lenardo MJ, et al. **Int Rev Immunol** 1995;13(2):115–34 (76 ref.)

Anti–IgM–mediated regulation of c–myc and its possible relationship to apoptosis. Kaptein JS, et al. **J Biol Chem** 1996 Aug 2;271(31):18875–84

Loss of function of cytochrome c in Jurkat cells undergoing fas–mediated apoptosis. Krippner A, et al. **J Biol Chem** 1996 Aug 30;271(35):21629–36

Immune deficiency following thermal trauma is associated with apoptotic cell death. Teodorczyk–Injeyan JA, et al. **J Clin Immunol** 1995 Nov;15(6):318–28

Qualitative and quantitative contributions of the T cell receptor zeta chain to mature T cell apoptosis. Combadière B, et al. **J Exp Med** 1996 May 1;183(5):2109–17

Fc receptor off–signal in the B cell involves apoptosis. Ashman RF, et al. **J Immunol** 1996 Jul 1;157(1):5–11

Apoptosis associated with ex vivo down–regulation of Bcl–2 and up–regulation of Fas in potential cytotoxic CD8+ T lymphocytes during HIV infection. Boudet F, et al. **J Immunol** 1996 Mar 15;156(6):2282–93

Fas/Apo–1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas–mediated apoptosis. Cascino I, et al. **J Immunol** 1996 Jan 1; 156(1):13–7

Opposing roles of CD95 (Fas/APO–1) and CD40 in the death and rescue of human low density tonsillar B cells. Cleary AM, et al. **J Immunol** 1995 Oct 1;155(7):3329–37

Staphylococcal enterotoxin D functions as a human B cell superantigen by rescuing VH4–expressing B cells from apoptosis. Domiati–Saad R, et al. **J Immunol** 1996 May 15;156(10):3608–20

Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo–1) ligand–mediated cell death after activation in vitro versus in vivo. Ehl S, et al. **J Immunol** 1996 Apr 1;156(7):2357–60

Fc receptor–induced expression of Fas ligand on activated NK cells facilitates cell–mediated cytotoxicity and subsequent autocrine NK cell apoptosis. Eischen CM, et al. **J Immunol** 1996 Apr 15;156(8):2693–9

Uncoupling IL–2 production from apoptosis and TNF production by changing the signal through the TCR. Glickstein L, et al. **J Immunol** 1996 Mar 15;156(6):2062–7

Programmed cell death in peripheral lymphocytes from HIV–infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. Gougeon ML, et al. **J Immunol** 1996 May 1;156(9):3509–20

Stimulation of phosphatidylinositol turnover is a key event for Fas–dependent, activation–induced apoptosis in human T lymphocytes. Izquierdo M, et al. **J Immunol** 1996 Jul 1;157(1):21–8

Target–induced inactivation and cell death by apoptosis in a subset of human NK cells. Jewett A, et al. **J Immunol** 1996 Feb 1;156(3):907–15

An inducible lymphocyte nuclear Ca2+/Mg(2+)–dependent endonuclease associated with apoptosis. Khodarev NN, et al. **J Immunol** 1996 Feb 1;156(3):922–31

CD45 ligation induces programmed cell death in T and B lymphocytes. Klaus SJ, et al. **J Immunol** 1996 Apr 15; 156(8):2743–53

Resting B cells from New Zealand Black mice demonstrate a defect in apoptosis induction following surface IgM ligation. Kozono Y, et al. **J Immunol** 1996 Jun 1; 156(11):4498–503

IFN–gamma receptor–deficient mice are hypersensitive to the anti–CD3–induced cytokine release syndrome and thymocyte apoptosis. Protective role of endogenous nitric oxide. Matthys P, et al. **J Immunol** 1995 Oct 15; 155(8):3823–9

Bcl–2 blocks glucocorticoid– but not Fas– or activation–induced apoptosis in a T cell hybridoma. Memon SA, et al. **J Immunol** 1995 Nov 15;155(10):4644–52

Modulation of anti–IgM–induced B cell apoptosis by Bcl–xL and CD40 in WEHI–231 cells. Dissociation from cell cycle arrest and dependence on the avidity of the antibody–IgM receptor interaction. Merino R, et al. **J Immunol** 1995 Oct 15;155(8):3830–8

CD2–induced apoptosis in activated human peripheral T cells: a Fas–independent pathway that requires early protein tyrosine phosphorylation. Mollereau B, et al. **J Immunol** 1996 May 1;156(9):3184–90

CD28 costimulation inhibits TCR–induced apoptosis during a primary T cell response. Radvanyi LG, et al. **J Immunol** 1996 Mar 1;156(5):1788–98

CD40 expressed on thymic epithelial cells provides costimulation for proliferation but not for apoptosis of human thymocytes. Ruggiero G, et al. **J Immunol** 1996 May 15;156(10):3737–46

Cytotoxic effect of TNF and lymphotoxin on T lymphoblasts. Sarin A, et al. **J Immunol** 1995 Oct 15;155(8):3716–8

Maintenance of nuclear factor–kappa B/Rel and c–myc expression during CD40 ligand rescue of WEHI 231 early B cells from receptor–mediated apoptosis through modulation of I kappa B proteins. Schauer SL, et al. **J Immunol** 1996 Jul 1;157(1):81–6

T cells commit suicide, but B cells are murdered! Scott DW, et al. **J Immunol** 1996 Apr 1;156(7):2352–6 (42 ref.)

Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis. Activation–induced death can occur without Fas receptor. Tuček–Szabo CL, et al. **J Immunol** 1996 Jan 1;156(1):192–200

Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. Um HD, et al. **J Immunol** 1996 May 1;156(9):3469–77

Neutrophils undergo apoptosis following ingestion of Escherichia coli. Watson RW, et al. **J Immunol** 1996 May 15;156(10):3986–92

Costimulation of fibronectin receptor promotes Fc gamma R–mediated rescue of IL–3–dependent bone marrow–derived cells from apoptosis. Yoshikawa H, et al. **J Immunol** 1996 Mar 1;156(5):1832–40

Combined Hoechst 33342 and merocyanine 540 staining to examine murine B cell cycle stage, viability and apoptosis. Reid S, et al. **J Immunol Methods** 1996 Jun 10; 192(1–2):43–54

Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. Swanink CM, et al. **J Infect Dis** 1996 Feb;173(2):460–3

Anti–Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells. González–Cuadrado S, et al. **Kidney Int** 1996 Apr;49(4):1064–70

Expression of Fas antigen and Bcl–2 in human glomerulonephritis. Takemura T, et al. **Kidney Int** 1995 Dec;48(6):1886–92

Activation–induced apoptosis in Jurkat cells through a myc–independent mechanism. Ruiz–Ruiz MC, et al. **Mol Immunol** 1995 Sep;32(13):947–55

Correlation between the number of apoptotic cells and expression of the apoptosis–related antigens Fas, Le(y) and bcl–2 protein in non–Hodgkin's lymphomas. Aftabuddin M, et al. **Pathol Int** 1995 Jun;45(6):422–9

Apoptosis parallels lymphopoiesis in bone marrow transplantation and HIV disease. Donnenberg AD, et al. **Res Immunol** 1995 Jan;146(1):11–21

Cyclosporine–induced apoptosis in CD4+ T lymphocytes and computer–simulated analysis: modeling a treatment scenario for HIV infection. Huss R, et al. **Res Immunol** 1995 Feb;146(2):101–8 (32 ref.)

In vivo activation of T–cell induction into the primed phenotype and programmed cell death by staphylococcal enterotoxin B. Aroeira LS, et al. **Scand J Immunol** 1996 May;43(5):545–50

Decrease in cAMP levels promoted by CD48–CD2 interaction correlates with inhibition of apoptosis in B cells. Baixeras E, et al. **Scand J Immunol** 1996 Apr;43(4):406–12

Expression of apoptosis–inducing CD95 (Fas/Apo–1) on human beta–cells sorted by flow–cytometry and cultured in vitro. Stassi G, et al. **Transplant Proc** 1995 Dec; 27(6):3271–5

[Apoptosis (programmed cell death) in autoimmunity—autoimmunological aspect] George J, et al. **Harefuah** 1995 Nov 1;129(9):339–41 (27 ref.) **(Heb)**

PHYSIOLOGY

Mechanism of apoptosis in peripheral blood mononuclear cells of HIV–infected patients. Oyaizu N, et al. **Adv Exp Med Biol** 1995;374:101–14

Parkinson's disease. The apoptosis hypothesis. Stern G. **Adv Neurol** 1996;69:101–7 (29 ref.)

Costimulation of CD3/TcR complex with either integrin or nonintegrin ligands protects CD4+ allergen–specific T–cell clones from programmed cell death. Agea E, et al. **Allergy** 1995 Aug;50(8):677–82

Apoptosis is a major pathway responsible for the resolution of type II pneumocytes in acute lung injury. Bardales RH, et al. **Am J Pathol** 1996 Sep;149(3):845–52

In situ apoptosis assay for the detection of early acute myocardial infarction. Bardales RH, et al. **Am J Pathol** 1996 Sep;149(3):821–9

Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage. Guinee D Jr, et al. **Am J Pathol** 1996 Aug;149(2):531–8

Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Higaki K, et al. **Am J Pathol** 1996 Aug; 149(2):429–37

Cell fusion to study nuclear–cytoplasmic interactions in endothelial cell apoptosis. Polunovsky VA, et al. **Am J Pathol** 1996 Jul;149(1):115–28

Immunodetection of apoptosis–regulating proteins in lymphomas from patients with and without human immunodeficiency virus infection. Schlaifer D, et al. **Am J Pathol** 1996 Jul;149(1):177–85

Human monocyte–derived macrophage phagocytosis of senescent eosinophils undergoing apoptosis. Mediation by alpha v beta 3/CD36/thrombospondin recognition mechanism and lack of phlogistic response. Stern M, et al. **Am J Pathol** 1996 Sep;149(3):911–21

Immunodetection of histone epitopes correlates with early stages of apoptosis in activated human peripheral T lymphocytes. Zunino SJ, et al. **Am J Pathol** 1996 Aug; 149(2):653–63

Potential roles of apoptosis in viral pathogenesis. Collins M. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S20–4 (63 ref.)

Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms. Colombel M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:63–9 (20 ref.)

Neural apoptosis. Bredesen DE. **Ann Neurol** 1995 Dec; 38(6):839–51 (143 ref.)

Induction of Fas–mediated apoptosis on circulating lymphocytes by surgical stress. Oka M, et al. **Ann Surg** 1996 Apr;223(4):434–40

Apoptosis and necrosis occurring during different stages of primary and metastatic tumor growth of a rat mammary adenocarcinoma. Matsuda H, et al. **Anticancer Res** 1996 May–Jun;16(3A):1117–21

The involvement of macrophages and lymphocytes in the apoptosis of enterocytes. Iwanaga T. **Arch Histol Cytol** 1995 Jun;58(2):151–9 (38 ref.)

The process of apoptosis in follicular epithelial cells in the rabbit ovary, with special reference to involvement by macrophages. Kasuya K. **Arch Histol Cytol** 1995 Jun; 58(2):257–64

Apoptosis in the nervous system: morphological features, methods, pathology, and prevention. Lo AC, et al. **Arch Histol Cytol** 1995 Jun;58(2):139–49 (107 ref.)

Mechanisms of photoreceptor death in retinal degenerations. From the cell biology of the 1990s to the ophthalmology of the 21st century? Adler R. **Arch Ophthalmol** 1996 Jan; 114(1):79–83 (43 ref.)

Photoreceptor apoptosis in animal models. Implications for retinitis pigmentosa research [editorial] Wong F. **Arch Ophthalmol** 1995 Oct;113(10):1245–7 (24 ref.)

Monocyte apoptosis in patients with active lupus. Richardson BC, et al. **Arthritis Rheum** 1996 Aug;39(8):1432–4

Apoptosis in cell cultures induced by infectious bursal disease virus following in vitro infection. Tham KM, et al. **Avian Dis** 1996 Jan–Mar;40(1):109–13

Interferon–alpha primes macrophages for lipopolysaccharide–induced apoptosis. Adler B, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):921–7

Protein tyrosine kinases and phosphatases control apoptosis induced by extracellular adenosine 5'–triphosphate. Bronte V, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):344–51

Peroxynitrite causes apoptosis in rat thymocytes. Salgo MG, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):1111–8

Involvement of CD45 in dexamethasone– and heat shock–induced apoptosis of rat thymocytes. Troiano L, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):941–8

Induction of apoptosis by excessive polyamine accumulation in ornithine decarboxylase–overproducing L1210 cells. Poulin R, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):723–7

DNA fragmentation induced in lymphocytes by gamma irradiation or dexamethasone: inhibition by diethyldithiocarbamate (DTC), potentiated by zinc. Mathieu J, et al. **Biochem Mol Biol Int** 1995 Jul; 36(4):733–44

Role of CAS, a human homologue to the yeast chromosome segregation gene CSE1, in toxin and tumor necrosis factor mediated apoptosis. Brinkmann U, et al. **Biochemistry** 1996 May 28;35(21):6891–9

Relationship between arachidonate—phospholipid remodeling and apoptosis. Surette ME, et al. **Biochemistry** 1996 Jul 16;35(28):9187–96

Role of clusterin in cell adhesion during early phases of programmed cell death in P19 embryonic carcinoma cells. Fratelli M, et al. **Biochim Biophys Acta** 1996 Apr 24; 1311(2):71–6

Protein phosphorylation in apoptosis. Gjertsen BT, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):187–99 (309 ref.)

In vitro models for studying colorectal carcinogenesis: cellular and molecular events including APC and Rb cleavage in the control of proliferation, differentiation and apoptosis. Williams AC, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):F9–19 (91 ref.)

Effects of Na+/H+ antiport and intracellular pH in the regulation of HL–60 cell apoptosis. Zhu WH, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):122–8

Application of biotin, digoxigenin or fluorescein conjugated deoxynucleotides to label DNA strand breaks for analysis of cell proliferation and apoptosis using flow cytometry. Li X, et al. **Biotech Histochem** 1995 Sep;70(5):234–42

Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. Ayala A, et al. **Blood** 1996 May 15; 87(10):4261–75

Critical involvement of transmembrane tumor necrosis factor–alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Eissner G, et al. **Blood** 1995 Dec 1;86(11):4184–93

Involvement of nitric oxide in target–cell lysis and DNA fragmentation induced by murine natural killer cells. Filep JG, et al. **Blood** 1996 Jun 15;87(12):5136–43

Interleukin–8 induces the accumulation of B–cell chronic lymphocytic leukemia cells by prolonging survival in an

autocrine fashion. Francia di Celle P, et al. **Blood** 1996 May 15;87(10):4382–9

CD38–mediated growth suppression of B–cell progenitors requires activation of phosphatidylinositol 3–kinase and involves its association with the protein product of the c–cbl proto–oncogene. Kitanaka A, et al. **Blood** 1996 Jul 15;88(2):590–8

Fas receptor (CD95)–mediated apoptosis is induced in leukemic cells entering G1B compartment of the cell cycle. Komada Y, et al. **Blood** 1995 Nov 15;86(10):3848–60

Fas ligation induces apoptosis and Jun kinase activation independently of CD45 and Lck in human T cells. Latinis KM, et al. **Blood** 1996 Feb 1;87(3):871–5

Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self–antigen: implications for lymphomagenesis in acquired immunodeficiency syndrome. Roncella S, et al. **Blood** 1996 Jul 15; 88(2):599–608

Plasma cells induce apoptosis of pre–B cells by interacting with bone marrow stromal cells. Tsujimoto T, et al. **Blood** 1996 Apr 15;87(8):3375–83

The role of apoptosis in bispecific antibody–mediated T–cell cytotoxicity. Kroesen BJ, et al. **Br J Cancer** 1996 Mar; 73(6):721–7

Differences in resistance to 5–fluorouracil as a function of cell cycle delay and not apoptosis. Pickard M, et al. **Br J Cancer** 1995 Dec;72(6):1389–96

Susceptibility of AML cells to in vitro apoptosis correlates with heat shock protein 70 (hsp 70) expression. Chant ID, et al. **Br J Haematol** 1996 Jun 2;93(4):898–902

The CD4 receptor plays essential but distinct roles in HIV–1 infection and induction of apoptosis in primary bone marrow GPIIb/IIIa+ megakaryocytes and the HEL cell line. Zauli G, et al. **Br J Haematol** 1995 Oct;91(2):290–8

Neuronal cell death in scrapie–infected mice is due to apoptosis. Giese A, et al. **Brain Pathol** 1995 Jul;5(3):213–21

The microglial reaction in spinal cords of jimpy mice is related to apoptotic oligodendrocytes. Vela JM, et al. **Brain Res** 1996 Mar 11;712(1):134–42

The role of inducible transcription factors in apoptotic nerve cell death. Dragunow M, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):1–28 (374 ref.)

The CD4+ T–cell network and the cytokine profile after HIV–1 infection. Caterino–de–Araujo A. **Braz J Med Biol Res** 1995 Jan;28(1):2–6

Prognostic significance of proliferative and apoptotic fractions in low grade follicle center cell–derived non–Hodgkin's lymphomas. Czader M, et al. **Cancer** 1996 Mar 15;77(6):1180–8

Apoptotic cell death and its relationship to carcinogenesis in colorectal carcinoma. Tsujitani S, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1711–6

Intracellular ATP is required for actinomycin D–induced apoptotic cell death in HeLa cells. Chou CC, et al. **Cancer Lett** 1995 Sep 25;96(2):181–7

Apoptosis amd metastasis: a superior resistance of metastatic cancer cells to programmed cell death. Glinsky GV, et al. **Cancer Lett** 1996 Mar 19;101(1):43–51

Quantitative analysis of changes in cell proliferation and apoptosis during preneoplastic and neoplastic stages of hepatocarcinogenesis in rat. Kong J, et al. **Cancer Lett** 1996 Aug 2;105(2):241–8

Ha–ras oncogene expression abrogates a pH dependent endonuclease activity of apoptosis in normal rat kidney cells. Ostad M, et al. **Cancer Lett** 1996 Jan 2;98(2):175–82

Involvement of integrins in cell survival. Bates RC, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):191–203 (85 ref.)

Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta–converting enzyme–like protease as candidate. An B, et al. **Cancer Res** 1996 Feb 1;56(3):438–42

A soluble insulin–like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. D'Ambrosio C, et al. **Cancer Res** 1996 Sep 1;56(17):4013–20

bfl–1, a bcl–2 homologue, suppresses p53–induced apoptosis and exhibits potent cooperative transforming activity. D'Sa–Eipper C, et al. **Cancer Res** 1996 Sep 1; 56(17):3879–82

Deregulated apoptosis in ataxia telangiectasia: association with clinical stigmata and radiosensitivity. Duchaud E, et al. **Cancer Res** 1996 Mar 15;56(6):1400–4

Adenovirus–mediated transfer of a wild–type p53 gene and induction of apoptosis in cervical cancer. Hamada K, et al. **Cancer Res** 1996 Jul 1;56(13):3047–54

Involvement of CPP32/Yama(–like) proteases in Fas–mediated apoptosis. Hasegawa J, et al. **Cancer Res** 1996 Apr 15;56(8):1713–8

Expression of the Bcl–2 homologue Mcl–1 correlates with survival of peripheral blood B lymphocytes. Løvmo J, et al. **Cancer Res** 1996 Jan 1;56(1):40–3

p53–independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Shibata MA, et al. **Cancer Res** 1996 Jul 1;56(13):2998–3003

Hormone–induced apoptosis by Fas–nuclear receptor fusion proteins: novel biological tools for controlling apoptosis in vivo. Takebayashi H, et al. **Cancer Res** 1996 Sep 15; 56(18):4164–70

Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1–induced apoptosis. Tanaka S, et al. **Cancer Res** 1996 Aug 1;56(15):3391–4

Enhanced apoptosis predicts shortened survival in non–small cell lung carcinoma. Törmänen U, et al. **Cancer Res** 1995 Dec 1;55(23):5595–602

BCL–2 expression delays drug–induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Yin DX, et al. **Cancer Res** 1995 Nov 1; 55(21):4922–8

Involvement of MACH, a novel MORT1/FADD–interacting protease, in Fas/APO–1– and TNF receptor–induced cell death. Boldin MP, et al. **Cell** 1996 Jun 14;85(6):803–15

The product of par–4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Díaz–Meco MT, et al. **Cell** 1996 Sep 6; 86(5):777–86

A license to kill. Fraser A, et al. **Cell** 1996 Jun 14;85(6):781–4 (21 ref.)

Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death. Hay BA, et al. **Cell** 1995 Dec 29;83(7):1253–62

FLICE, a novel FADD–homologous ICE/CED–3–like protease, is recruited to the CD95 (Fas/APO–1) death––inducing signaling complex. Muzio M, et al. **Cell** 1996 Jun 14;85(6):817–27

Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis. Katayose D, et al. **Cell Growth Differ** 1995 Oct;6(10):1207–12

A secreted serine protease can induce apoptosis in Pam212 keratinocytes. Marthinuss J, et al. **Cell Growth Differ** 1995 Jul;6(7):807–16

Bcl–2 and thermotolerance cooperate in cell survival. Strasser A, et al. **Cell Growth Differ** 1995 Jul;6(7):799–805

Exposure to ornithine results in excessive accumulation of putrescine and apoptotic cell death in ornithine decarboxylase overproducing mouse myeloma cells. Tobias KE, et al. **Cell Growth Differ** 1995 Oct;6(10):1279–85

Inhibition of apoptosis and augmentation of lymphoproliferation in bcl–2 transgenic Fas/Fas ligand–defective mice. Tamura A, et al. **Cell Immunol** 1996 Mar 15;168(2):220–8

Suppression of glucocorticoid–induced thymocyte apoptosis by co–culture with thymic epithelial cells. Gao Y, et al. **Cell Mol Biol (Noisy–le–grand)** 1996 Mar;42(2):227–34

Thymosin beta–10 accelerates apoptosis. Hall AK. **Cell Mol Biol Res** 1995;41(3):167–80

Spontaneous germ cell death in the testis of the adult rat takes the form of apoptosis: re–evaluation of cell types that exhibit the ability to die during spermatogenesis. Blanco–Rodríguez J, et al. **Cell Prolif** 1996 Jan;29(1):13–31

Labelling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Li X, et al. **Cell Prolif** 1995 Nov;28(11):571–9

Immunolocalization of a gonadotropin–releasing hormone receptor site in murine endometrium that mediates apoptosis. Murdoch WJ. **Cell Tissue Res** 1995 Dec; 282(3):527–9

Thymocyte–directed enhancement of apoptosis via soluble factor(s) derived from a cortical and a medullary thymic epithelial cell line. Rinner I, et al. **Cell Tissue Res** 1996 May;284(2):327–30

Detection of apoptotic cells by selective precipitation of [3H]thymidine–labelled DNA. Patki AH, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):1–4

Hypothesis: apoptosis caused by cytotoxins represents a defensive response that evolved to combat intracellular pathogens. Vaux DL, et al. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):861–3

Sex hormones, proto–oncogene expression and apoptosis: their effects on rheumatoid synovial tissue. Cutolo M, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):87–94 (58 ref.)

Abnormal expression of apoptosis–related antigens, Fas and bcl–2, on circulating T–lymphocyte subsets in primary Sjögren's syndrome. Ichikawa Y, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):307–13

The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Mountz JD, et al. **Clin Immunol Immunopathol** 1996 Sep; 80(3 Pt 2):S2–14 (103 ref.)

Control of p53–dependent apoptosis by E1B, Bcl–2, and Ha–ras proteins. White E, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:395–402

Apoptosis. A sticky business. Häcker G, et al. **Curr Biol** 1995 Jun 1;5(6):622–4 (26 ref.)

Apoptosis and the cell cycle. Evan GI, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):825–34 (84 ref.)

Regulation of apoptosis by bcl–2 family proteins and its role in cancer and chemoresistance. Reed JC. **Curr Opin Oncol** 1995 Nov;7(6):541–6 (57 ref.)

Role of c–myc in myeloid differentiation, growth arrest and apoptosis. Hoffman B, et al. **Curr Top Microbiol Immunol** 1996;211:17–27 (51 ref.)

Nucleic acid dyes for detection of apoptosis in live cells. Frey T. **Cytometry** 1995 Nov 1;21(3):265–74

Kinetics of plasma membrane and mitochondrial alterations in cells undergoing apoptosis. Lizard G, et al. **Cytometry** 1995 Nov 1;21(3):275–83

Discrimination of apoptotic thymocytes by forward light scatter. Ormerod MG, et al. **Cytometry** 1995 Nov 1; 21(3):300–4

Chondrocyte apoptosis in endochondral ossification of chick sterna. Gibson GJ, et al. **Dev Dyn** 1995 Aug;203(4):468–76

Programmed cell death enhances uniformity in rat cerebral hemispheres. Zamenhof S, et al. **Dev Neurosci** 1995; 17(4):264–6

FGF suppresses apoptosis and induces differentiation of fibre cells in the mouse lens. Chow RL, et al. **Development** 1995 Dec;121(12):4383–93

Inhibition of testicular germ cell apoptosis and differentiation in mice misexpressing Bcl–2 in spermatogonia. Furuchi T, et al. **Development** 1996 Jun;122(6):1703–9

Two distinct phases of apoptosis in mammary gland involution: proteinase–independent and –dependent pathways. Lund LR, et al. **Development** 1996 Jan; 122(1):181–93

Reorganization of membrane contacts prior to apoptosis in the Drosophila retina: the role of the IrreC–rst protein. Reiter C, et al. **Development** 1996 Jun;122(6):1931–40

Apoptosis in the developing tooth: association with an embryonic signaling center and suppression by EGF and FGF–4. Vaahtokari A, et al. **Development** 1996 Jan; 122(1):121–9

Introduction to apoptosis. Salomon RN, et al. **Diagn Mol Pathol** 1995 Dec;4(4):235–8 (27 ref.)

Spatial, temporal and hormonal regulation of programmed muscle cell death during metamorphosis of the frog Xenopus laevis. Nishikawa A, et al. **Differentiation** 1995 Nov;59(4):207–14

Proteolytic activation of protein kinase C delta by an ICE–like protease in apoptotic cells. Emoto Y, et al. **EMBO J** 1995 Dec 15;14(24):6148–56

Apoptosis by a cytosolic extract from Fas–activated cells. Enari M, et al. **EMBO J** 1995 Nov 1;14(21):5201–8

WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. Englert C, et al. **EMBO J** 1995 Oct 2;14(19):4662–75

Cell type–specific inhibition of p53–mediated apoptosis by mdm2. Haupt Y, et al. **EMBO J** 1996 Apr 1;15(7):1596–606

Cytotoxicity–dependent APO–1 (Fas/CD95)–associated proteins form a death–inducing signaling complex (DISC) with the receptor. Kischkel FC, et al. **EMBO J** 1995 Nov 15;14(22):5579–88

The cytotoxic cell protease granzyme B initiates apoptosis in a cell–free system by proteolytic processing and activation of the ICE/CED–3 family protease, CPP32, via a novel two–step mechanism. Martin SJ, et al. **EMBO J** 1996 May 15;15(10):2407–16

NF–M (chicken C/EBP beta) induces eosinophilic differentiation and apoptosis in a hematopoietic progenitor cell line. Müller C, et al. **EMBO J** 1995 Dec 15; 14(24):6127–35

Bcl–2 and Fas/APO–1 regulate distinct pathways to lymphocyte apoptosis. Strasser A, et al. **EMBO J** 1995 Dec 15;14(24):6136–47

Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis. Wang X, et al. **EMBO J** 1996 Mar 1;15(5):1012–20

Interleukin–1 beta–converting enzyme–related proteases (IRPs) and mammalian cell death: dissociation of IRP–induced oligonucleosomal endonuclease activity from morphological apoptosis in granulosa cells of the ovarian follicle. Flaws JA, et al. **Endocrinology** 1995 Nov; 136(11):5042–53

Fas/APO–1/CD95 system as a mediator of granulosa cell apoptosis in ovarian follicle atresia. Hakuno N, et al. **Endocrinology** 1996 May;137(5):1938–48

Specific immunoneutralization of FSH leads to apoptotic cell death of the pachytene spermatocytes and spermatogonial cells in the rat. Shetty J, et al. **Endocrinology** 1996 May; 137(5):2179–82

New clues to cell death [news] **Environ Health Perspect** 1995 Dec;103(12):1084–5

Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell lines. De Laurenzi V, et al. **Eur J Cancer** 1995;31A(4):463–6

A decrease in intracellular glutathione concentration precedes the onset of apoptosis in murine thymocytes. Beaver JP, et al. **Eur J Cell Biol** 1995 Sep;68(1):47–54

Alterations in cytoskeletal and nuclear matrix–associated proteins during apoptosis. Tinnemans MM, et al. **Eur J Cell Biol** 1995 Sep;68(1):35–46

Pertussis toxin–sensitive GTP–binding proteins regulate activation–induced apoptotic cell death of human natural killer cells. Carracedo J, et al. **Eur J Immunol** 1995 Nov; 25(11):3094–9

Engagement of CD20 suppresses apoptosis in germinal center B cells. Holder M, et al. **Eur J Immunol** 1995 Nov; 25(11):3160–4

Apoptosis: programmed cell death in fetal development. Haanen C, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):129–33 (58 ref.)

Characterization of apoptotic phenomena induced by treatment with L–asparaginase in NIH3T3 cells. Bussolati O, et al. **Exp Cell Res** 1995 Oct;220(2):283–91

Programmed myocyte cell death affects the viable myocardium after infarction in rats. Cheng W, et al. **Exp Cell Res** 1996 Aug 1;226(2):316–27

Characterization of c–myc–transformed rat fibroblasts resistant to apoptosis induced ny growth factor deprivation. Dhanaraj, SN, et al. **Exp Cell Res** 1996 Apr 10;224(1):52–62

Multiple pathways for apoptotic nuclear fragmentation. Dini L, et al. **Exp Cell Res** 1996 Mar 15;223(2):340–7

Human Kupffer cell recognition and phagocytosis of apoptotic peripheral blood lymphocytes. Falasca L, et al. **Exp Cell Res** 1996 Apr 10;224(1):152–62

Reactive oxygen species act at both TGF-beta-dependent and -independent steps during induction of apoptosis of transformed cells by normal cells. Langer C, et al. **Exp Cell Res** 1996 Jan 10;222(1):117-24

Comparison of apoptosis signaling through T cell receptor, fas, and calcium ionophore. Maecker HT, et al. **Exp Cell Res** 1996 Jan 10;222(1):95-102

Analysis of events associated with serum deprivation-induced apoptosis in C3H/Sol8 muscle satellite cells. Mampuru LJ, et al. **Exp Cell Res** 1996 Aug 1; 226(2):372-80

Sizing highly fragmented DNA in individual apoptotic cells using the comet assay and a DNA crosslinking agent. Olive PL, et al. **Exp Cell Res** 1995 Nov;221(1):19-26

Heat shock proteins increase resistance to apoptosis. Samali A, et al. **Exp Cell Res** 1996 Feb 25;223(1):163-70

DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies. Shimizu T, et al. **Exp Cell Res** 1996 Aug 1;226(2):292-301

Behavior of nuclear matrix proteins during camptothecin-induced apoptosis in HL-60 human leukemia cells. Zweyer M, et al. **Exp Cell Res** 1995 Nov;221(1):27-40

Mast cell ontogeny and apoptosis. Metcalfe DD, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):227-30 (34 ref.)

The role of proteases during apoptosis. Patel T, et al. **FASEB J** 1996 Apr;10(5):587-97 (97 ref.)

Ligation of CD40 rescues Ramos-Burkitt lymphoma B cells from calcium ionophore- and antigen receptor-triggered apoptosis by inhibiting activation of the cysteine protease CPP32/Yama and cleavage of its substrate PARP. An S, et al. **FEBS Lett** 1996 May 20;386(2-3):115-22

Epidermal growth factor, but not hepatocyte growth factor, suppresses the apoptosis induced by transforming growth factor-beta in fetal hepatocytes in primary culture. Fabregat I, et al. **FEBS Lett** 1996 Apr 8;384(1):14-8

An interleukin-1 beta-converting enzyme-like protease is a common mediator of apoptosis in thymocytes. Fearnhead HO, et al. **FEBS Lett** 1995 Nov 20;375(3):283-8

Resistance of Ehrlich tumor cells to apoptosis can be due to accumulation of heat shock proteins. Gabai VL, et al. **FEBS Lett** 1995 Nov 13;375(1-2):21-6

Role of multiple cellular proteases in the execution of programmed cell death. Kumar S, et al. **FEBS Lett** 1995 Nov 20;375(3):169-73 (53 ref.)

Elevated cPLA2 levels as a mechanism by which the p70 TNF and p75 NGF receptors enhance apoptosis. MacEwan DJ. **FEBS Lett** 1996 Jan 22;379(1):77-81

Reactive oxygen intermediate(s) (ROI): common mediator(s) of poly(ADP-ribose)polymerase (PARP) cleavage and apoptosis. McGowan AJ, et al. **FEBS Lett** 1996 Sep 2; 392(3):299-303

Apoptosis is triggered by the cyclic AMP signalling pathway in renal mesangial cells. Mühl H, et al. **FEBS Lett** 1996 Mar 18;382(3):271-5

Characterisation of secondary metabolites associated with neutrophil apoptosis. Nunn AV, et al. **FEBS Lett** 1996 Sep 2;392(3):295-8

Control of apoptosis by the cellular ATP level. Richter C, et al. **FEBS Lett** 1996 Jan 8;378(2):107-10 (62 ref.)

Hydrogen peroxide in relation to proliferation and apoptosis in BHK-21 hamster fibroblasts. Burdon RH, et al. **Free Radic Res** 1996 Feb;24(2):81-93

Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist [see comments] Que FG, et al. **Gastroenterology** 1996 Apr;110(4):1238-43 (21 ref.). Comment in: Gastroenterology 1996 Aug;111(2):567-8.

Protein kinase C involvement in apoptosis. Lucas M, et al. **Gen Pharmacol** 1995 Sep;26(5):881-7 (70 ref.)

The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Xue D, et al. **Genes Dev** 1996 May 1;10(9):1073-83

Induction of gastric epithelial apoptosis by Helicobacter pylori. Moss SF, et al. **Gut** 1996 Apr;38(4):498-501

Necrosis and apoptosis in the gastrointestinal tract. Watson AJ. **Gut** 1995 Aug;37(2):165-7

The use of the digital cell image analysis of Feulgen-stained nuclei to detect apoptosis. Camby I, et al. **Histochem Cell Biol** 1995 Nov;104(5):407-14

DNA localization in nuclear fragments of apoptotic ameloblasts using anti-DNA immunoelectron microscopy: programmed cell death of ameloblasts. Nishikawa S, et al. **Histochem Cell Biol** 1995 Aug;104(2):151-9

The effects of formalin fixation on the detection of apoptosis in human brain by in situ end-labelling of DNA. Davison FD, et al. **Histochem J** 1995 Dec;27(12):983-8

Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis. Josefsson E, et al. **Immunology** 1996 May;88(1):140-6

Heat-shock protein expression on the membrane of T cells undergoing apoptosis. Poccia F, et al. **Immunology** 1996 May;88(1):6-12

Apoptosis in flat neoplasias of the colorectal mucosa. Rubio CA, et al. **In Vivo** 1995 May-Jun;9(3):173-6

ICAM-1 is required for T cell proliferation but not for anergy or apoptosis induced by Staphylococcus aureus enterotoxin B in vivo. Gonzalo JA, et al. **Int Immunol** 1995 Oct;7(10):1691-8

Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Cirielli C, et al. **Int J Cancer** 1995 Nov 27;63(5):673-9

The role of interleukin-10 (IL-10) in chronic B-lymphocytic leukemia: IL-10 prevents leukemic cells from apoptotic cell death. Kitabayashi A, et al. **Int J Hematol** 1995 Aug; 62(2):99-106

Expression of enhanced spontaneous and gamma-ray-induced apoptosis by lymphocytes of the wasted mouse. Woloschak GE, et al. **Int J Radiat Biol** 1996 Jan;69(1):47-55

Accelerated repopulation during fractionated irradiation of a murine ovarian carcinoma: downregulation of apoptosis as a possible mechanism. Thames HD, et al. **Int J Radiat Oncol Biol Phys** 1996 Jul 15;35(5):951-62

Apoptosis in the corneal epithelium. Ren H, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):1017-25

Photoreceptor cells in the vitiligo mouse die by apoptosis. TRPM-2/clusterin expression is increased in the neural retina and in the retinal pigment epithelium. Smith SB, et al. **Invest Ophthalmol Vis Sci** 1995 Oct;36(11):2193-201

Stimulation of the CD2 receptor pathway induces apoptosis in human T lymphotropic virus type I-infected cell lines. Guyot DJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Apr 1;11(4):317-25

A novel anti-apoptosis serum factor that down-regulates fas-mediated apoptosis. Kikuchi H, et al. **J Biochem (Tokyo)** 1995 May;117(5):936-9

A physical interaction between the cell death protein Fas and the tyrosine kinase p59fynT. Atkinson EA, et al. **J Biol Chem** 1996 Mar 15;271(11):5968-71

Casein kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis. Beyaert R, et al. **J Biol Chem** 1995 Oct 6;270(40):23293-9

Diminished cell proliferation associated with the death-protective activity of Bcl-2. Borner C. **J Biol Chem** 1996 May 31;271(22):12695-8

ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. Duan H, et al. **J Biol Chem** 1996 Jan 19; 271(3):1621-5

Activation of the CPP32 apoptotic protease by distinct signaling pathways with differential sensitivity to Bcl-xL. Erhardt P, et al. **J Biol Chem** 1996 Jul 26;271(30):17601-4

Lyn and Fgr protein-tyrosine kinases prevent apoptosis during retinoic acid-induced granulocytic differentiation of HL-60 cells. Katagiri K, et al. **J Biol Chem** 1996 May 10;271(19):11557-62

Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO-1- and staurosporine-induced cell death. Mehlen P, et al. **J Biol Chem** 1996 Jul 12;271(28):16510-4

The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis. Morana SJ, et al. **J Biol Chem** 1996 Jul 26;271(30):18263-71

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Pitti RM, et al. **J Biol Chem** 1996 May 31;271(22):12687-90

Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. Sawai H, et al. **J Biol Chem** 1995 Nov 10;270(45):27326-31

Apoptosis of colon cancer: comparison with Ki-67 proliferative activity and expression of p53. Takano Y, et al. **J Cancer Res Clin Oncol** 1996;122(3):166-70

Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implications for chemoprevention. Oridate N, et al. **J Cell Biochem Suppl** 1995;23:80-6

Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. Feng Z, et al. **J Cell Biol** 1995 Nov;131(4):1095-103

Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. French LE, et al. **J Cell Biol** 1996 Apr; 133(2):335-43

Control of adhesion-dependent cell survival by focal adhesion kinase. Frisch SM, et al. **J Cell Biol** 1996 Aug; 134(3):793-9

Early detachment of colon carcinoma cells during CD95(APO-1/Fas)-mediated apoptosis. I. De-adhesion from hyaluronate by shedding of CD44. Günthert AR, et al. **J Cell Biol** 1996 Aug;134(4):1089-96

Role of Ced-3/ICE-family proteases in staurosporine-induced programmed cell death. Jacobsen MD, et al. **J Cell Biol** 1996 Jun;133(5):1041-51

Induction of DNA synthesis and apoptosis in cardiac myocytes by E1A oncoprotein. Liu Y, et al. **J Cell Biol** 1996 Apr;133(2):325-34

Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. Rak J, et al. **J Cell Biol** 1995 Dec;131(6 Pt 1):1587-98

Constitutive expression of the machinery for programmed cell death. Weil M, et al. **J Cell Biol** 1996 Jun;133(5):1053-9

Regulation of apoptosis of interleukin 2-dependent mouse T-cell line by protein tyrosine phosphorylation and polyamines. Min A, et al. **J Cell Physiol** 1995 Dec; 165(3):615-23

Heat shock induction of apoptosis in promastigotes of the unicellular organism Leishmania (Leishmania) amazonensis. Moreira ME, et al. **J Cell Physiol** 1996 May;167(2):305-13

Suppression of apoptosis by v-ABL protein tyrosine kinase is associated with nuclear translocation and activation of protein kinase C in an interleukin-3-dependent haemopoietic cell line. Evans CA, et al. **J Cell Sci** 1995 Jul;108 (Pt 7):2591-8

Characterization of the execution phase of apoptosis in vitro using extracts from condemned-phase cells. Lazebnik YA, et al. **J Cell Sci Suppl** 1995;19:41-9

Role of apoptosis in HIV disease pathogenesis. Oyaizu N, et al. **J Clin Immunol** 1995 Sep;15(5):217-31 (165 ref.)

Role of transforming growth factor beta 1 on hepatic regeneration and apoptosis in liver diseases. Takiya S, et al. **J Clin Pathol** 1995 Dec;48(12):1093-7

In situ labeling of apoptotic cell death in the cerebral cortex and thalamus of rats during development. Spreafico R, et al. **J Comp Neurol** 1995 Dec 11;363(2):281-95

Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. Galle PR, et al. **J Exp Med** 1995 Nov 1;182(5):1223-30

Apoptosis: mitochondria resurrected? [comment] Henkart PA, et al. **J Exp Med** 1996 Apr 1;183(4):1293-5. Comment on: J Exp Med 1996 Apr 1;183(4):1533-44.

A novel function of CD40: induction of cell death in transformed cells. Hess S, et al. **J Exp Med** 1996 Jan 1; 183(1):159-67

Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. Martin SJ, et al. **J Exp Med** 1995 Nov 1;182(5):1545-56

Protection from anti-TCR/CD3-induced apoptosis in immature thymocytes by a signal through thymic shared antigen-1/stem cell antigen-2. Noda S, et al. **J Exp Med** 1996 May 1;183(5):2355-60

A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. Rodriguez I, et al. **J Exp Med** 1996 Mar 1;183(3):1031-6

CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. Schattner EJ, et al. **J Exp Med** 1995 Nov 1;182(5):1557-65

Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. Verhoven B, et al. **J Exp Med** 1995 Nov 1;182(5):1597-601

Biochemical pathways of apoptosis: nicotinamide adenine dinucleotide-deficient cells are resistant to tumor necrosis factor or ultraviolet light activation of the 24-kD apoptotic protease and DNA fragmentation. Wright SC, et al. **J Exp Med** 1996 Feb 1;183(2):463-71

Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. Yousefi S, et al. **J Exp Med** 1996 Apr 1;183(4):1407-14

Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. Anti-Ig down-regulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis. Choe J, et al. **J Immunol** 1996 Aug 1;157(3):1006-16

A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death. Lens SM, et al. **J Immunol** 1996 Jan 15;156(2):507-14

Regulation of apoptosis in neutrophils--Fas track to death? Liles WC, et al. **J Immunol** 1995 Oct 1;155(7):3289-91 (71 ref.)

B cells selected for apoptosis in the sheep ileal Peyer's patch have enhanced mutational diversity in the Ig V lambda light chain. Maybaum TA, et al. **J Immunol** 1996 Aug 15; 157(4):1474-84

Selective activation-induced apoptosis of peripheral T cells imposed by macrophages. A potential mechanism of antigen-specific peripheral lymphocyte deletion. Munn DH, et al. **J Immunol** 1996 Jan 15;156(2):523-32

Activation of the Na(+)/H(+) antiporter, Na+/HCO3(-)/CO3(2-) cotransporter, or Cl(-)/HCO3(-) exchanger in spontaneous thymocyte apoptosis. Tsao N, et al. **J Immunol** 1996 Aug 1;157(3):1107-16

Sequential changes of programmed cell death in developing fetal mouse limbs and its possible roles in limb morphogenesis. Kimura S, et al. **J Morphol** 1996 Sep; 229(3):337-46

Naturally occurring motoneuron cell death in rat upper respiratory tract motor nuclei: a histological, fast DiI and immunocytochemical study in the hypoglossal nucleus. Friedland DR, et al. **J Neurobiol** 1995 Aug;27(4):520-34

Activation of G proteins bidirectionally affects apoptosis of cultured cerebellar granule neurons. Yan GM, et al. **J Neurochem** 1995 Dec;65(6):2425-31

Apoptosis in ALS is not restricted to motoneurons: Bcl-2 expression is increased in post-central cortex, adjacent to the affected motor cortex. Troost D, et al. **J Neurol Sci** 1995 May;129 Suppl:79-80

Schwann cell apoptosis during normal development and after axonal degeneration induced by neurotoxins in the chick embryo. Ciutat D, et al. **J Neurosci** 1996 Jun 15; 16(12):3979-90

Increased production of 4 kDa amyloid beta peptide in serum deprived human primary neuron cultures: possible involvement of apoptosis. LeBlanc A. **J Neurosci** 1995 Dec; 15(12):7837-46

A timetable of events during programmed cell death induced

by trophic factor withdrawal from neuronal PC12 cells. Mesner PW, et al. **J Neurosci** 1995 Nov;15(11):7357–66

Targeted neocortical cell death in adult mice guides migration and differentiation of transplanted embryonic neurons. Sheen VL, et al. **J Neurosci** 1995 Dec; 15(12):8378–92

A novel type of programmed neuronal death in the cervical spinal cord of the chick embryo. Yaginuma H, et al. **J Neurosci** 1996 Jun 1;16(11):3685–703

Inhibition of lipid peroxidation attenuates axotomy–induced apoptotic degeneration of facial motor neurons in neonatal rats. Hall ED, et al. **J Neurosci Res** 1996 May 1;44(3):293–9

The association between cell proliferation and apoptosis: studies using the cell cycle–associated proteins Ki67 and DNA polymerase alpha. Coates PJ, et al. **J Pathol** 1996 Jan;178(1):71–7

Apoptosis of epithelial cells in vivo involves tissue transglutaminase upregulation. Cummings M. **J Pathol** 1996 Jul;179(3):288–93

Positive correlation between apoptotic and proliferative indices in gastrointestinal lymphomas of mucosa–associated lymphoid tissue (MALT). Du M, et al. **J Pathol** 1996 Apr; 178(4):379–84

Lupus in the Fas lane? Singh AK. **J R Coll Physicians Lond** 1995 Nov–Dec;29(6):475–8 (40 ref.)

Endothelial cell death in preovulatory ovine follicles: possible implication in the biomechanics of rupture. Murdoch WJ. **J Reprod Fertil** 1995 Sep;105(1):161–4

Interleukin–6 delays neutrophil apoptosis via a mechanism involving platelet–activating factor. Biffl WL, et al. **J Trauma** 1996 Apr;40(4):575–8; discussion 578–9

Tumor necrosis factor mediates apoptosis via Ca++/Mg++ dependent endonuclease with protein kinase C as a possible mechanism for cytokine resistance in human renal carcinoma cells. Woo KR, et al. **J Urol** 1996 May;155(5):1779–83

Apparent uncoupling of oncogenicity from fibroblast transformation and apoptosis in a mutant myc gene transduced by feline leukemia virus. Fulton R, et al. **J Virol** 1996 Feb;70(2):1154–62

Human cytomegalovirus IE1 and IE2 proteins block apoptosis. Zhu H, et al. **J Virol** 1995 Dec;69(12):7960–70

Apoptosis in gastric carcinomas and its association with cell proliferation and differentiation. Saegusa M, et al. **Jpn J Cancer Res** 1995 Aug;86(8):743–8

Apoptosis of monocytes cultured from long–term hemodialysis patients. Heidenreich S, et al. **Kidney Int** 1996 Mar;49(3):792–9

Insulin–like growth factor–I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Rubin R, et al. **Lab Invest** 1995 Sep;73(3):311–31 (274 ref.)

A multivariate study of non Hodgkin's lymphoma involving proliferation, apoptosis, bcl–2 and the microenvironment. Shetty V, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):273–9

A day in the life of the Bcl–2 protein: does the turnover rate of Bcl–2 serve as a biological clock for cellular lifespan regulation? Reed JC. **Leuk Res** 1996 Feb;20(2):109–11

The role of intracellular signalling pathways regulating thymocyte and leukemic T cell apoptosis. Conroy LA, et al. **Leukemia** 1996 Sep;10(9):1422–35 (205 ref.)

Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Lotem J, et al. **Leukemia** 1996 Jun;10(6):925–31 (131 ref.)

The endogenous estrogen metabolite 2–methoxyestradiol induces apoptotic neuronal cell death in vitro. Nakagawa–Yagi Y, et al. **Life Sci** 1996;58(17):1461–7

The requirement for and mobilization of calcium during induction by sodium ascorbate and by hydrogen peroxide of cell death. Sakagami H, et al. **Life Sci** 1996;58(14):1131–8

Con A cytotoxicity: a model for the study of key signaling steps leading to lymphocyte apoptosis in AIDS? Pitts OM. **Med Hypotheses** 1995 Sep;45(3):311–5

Programmed cell death during metamorphosis in the blow–fly Calliphora vomitoria. Bowen ID, et al. **Microsc Res Tech** 1996 Jun 15;34(3):202–17

Morphology and significance of programmed cell death in the developing limb bud of the vertebrate embryo. Hurle JM, et al. **Microsc Res Tech** 1996 Jun 15;34(3):236–46 (86 ref.)

Apoptosis of larval cells during amphibian metamorphosis. Ishizuya–Oka A. **Microsc Res Tech** 1996 Jun 15; 34(3):228–35 (73 ref.)

Hepatocyte death following transforming growth factor–beta 1 addition. Oberhammer F, et al. **Microsc Res Tech** 1996 Jun 15;34(3):247–58

Apoptotic morphology reflects mitotic–like aspects of physiological cell death and is independent of genome digestion. Odaka C, et al. **Microsc Res Tech** 1996 Jun 15; 34(3):267–71

Programmed cell death in the tobacco hornworm, Manduca sexta: alteration in protein synthesis. Zakeri Z, et al. **Microsc Res Tech** 1996 Jun 15;34(3):192–201

Regulation of p53–mediated apoptosis and cell cycle arrest by Steel factor. Abrahamson JL, et al. **Mol Cell Biol** 1995 Dec;15(12):6953–60

9–cis retinoic acid inhibition of activation–induced apoptosis is mediated via regulation of fas ligand and requires retinoic acid receptor and retinoid X receptor activation. Bissonnette RP, et al. **Mol Cell Biol** 1995 Oct; 15(10):5576–85

Structural and signaling requirements for BCR–ABL–mediated transformation and inhibition of apoptosis. Cortez D, et al. **Mol Cell Biol** 1995 Oct; 15(10):5531–41

A single tyrosine of the interleukin–9 (IL–9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL–9. Demoulin JB, et al. **Mol Cell Biol** 1996 Sep;16(9):4710–6

p53 plays a regulatory role in differentiation and apoptosis of central nervous system–associated cells. Eizenberg O, et al. **Mol Cell Biol** 1996 Sep;16(9):5178–85

E2F–1:DP–1 induces p53 and overrides survival factors to trigger apoptosis. Hiebert SW, et al. **Mol Cell Biol** 1995 Dec;15(12):6864–74

Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Ludwig RL, et al. **Mol Cell Biol** 1996 Sep;16(9):4952–60

The aromatic hydrocarbon receptor modulates the Hepa 1c1c7 cell cycle and differentiated state independently of dioxin. Ma Q, et al. **Mol Cell Biol** 1996 May;16(5):2144–50

Induction of apoptosis by c–Fos protein. Preston GA, et al. **Mol Cell Biol** 1996 Jan;16(1):211–8

A mouse Fas–associated protein with homology to the human Mort1/FADD protein is essential for Fas–induced apoptosis. Zhang J, et al. **Mol Cell Biol** 1996 Jun; 16(6):2756–63

Inhibition of cytotoxic T–lymphocyte–triggered apoptosis by target cell surface–coupled aprotinin. Wagner L, et al. **Mol Immunol** 1995 Aug;32(12):853–64

A role for GAPDH in apoptosis and neurodegeneration [letter; comment] Chuang DM, et al. **Nat Med** 1996 Jun; 2(6):609–10. Comment on: Nat Med 1996 Mar;2(3):267–9. Comment on: Nat Med 1996 Mar;2(3):347–50.

Bcl–2 protects from lethal hepatic apoptosis induced by an anti–Fas antibody in mice. Lacronique V, et al. **Nat Med** 1996 Jan;2(1):80–6

The three–dimensional structure of apopain/CPP32, a key mediator of apoptosis. Rotonda J, et al. **Nat Struct Biol** 1996 Jul;3(7):619–25

Increased T–cell apoptosis and terminal B–cell differentiation induced by inactivation of the Ets–1 proto–oncogene. Bories JC, et al. **Nature** 1995 Oct 19;377(6550):635–8

Bax–independent inhibition of apoptosis by Bcl–XL. Cheng EH, et al. **Nature** 1996 Feb 8;379(6565):554–6

Suppression of ceramide–mediated programmed cell death by sphingosine–1–phosphate. Cuvillier O, et al. **Nature** 1996 Jun 27;381(6585):800–3

Sequential activation of ICE–like and CPP32–like proteases during Fas–mediated apoptosis. Enari M, et al. **Nature** 1996 Apr 25;380(6576):723–6

Reversal of apoptosis by the leukaemia–associated E2A–HLF chimaeric transcription factor. Inaba T, et al. **Nature** 1996 Aug 8;382(6591):541–4

Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Liston P, et al. **Nature** 1996 Jan 25;379(6563):349–53

Apoptosis of T cells mediated by galectin–1. Perillo NL, et al. **Nature** 1995 Dec 14;378(6558):736–9

Requirement for ceramide–initiated SAPK/JNK signalling in stress–induced apoptosis. Verheij M, et al. **Nature** 1996 Mar 7;380(6569):75–9

Apoptosis: will cell death add life to nephrology? [editorial] Savill J. **Nephrol Dial Transplant** 1995 Nov;10(11):1977–9

Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl–2 and p53 proteins. Ellison DW, et al. **Neuropathol Appl Neurobiol** 1995 Aug;21(4):352–61

Function and expression of the Bcl–x gene in the developing and adult nervous system. Frankowski H, et al. **Neuroreport** 1995 Oct 2;6(14):1917–21

DNA fragmentation and activation of c–Jun in the cerebellum of mutant mice (weaver, Purkinje cell degeneration). Gillardon F, et al. **Neuroreport** 1995 Sep 11;6(13):1766–8

Amoeboid microglial response following X–ray–induced apoptosis in the neonatal rat brain. Ferrer I, et al. **Neurosci Lett** 1995 Jun 30;193(2):109–12

Flow cytometric analysis of serum deprivation–induced apoptosis of PC12 cells, with special reference to role of bcl–2. Satoh T, et al. **Neurosci Lett** 1995 Dec 8; 201(2):119–22

Apoptosis as a regulator of cell proliferation in the central posterior/prepacemaker nucleus of adult gymnotiform fish, Apteronotus leptorhynchus. Soutschek J, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):133–6

Glyceraldehyde–3–phosphate dehydrogenase is over–expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain. Sunaga K, et al. **Neurosci Lett** 1995 Nov 17;200(2):133–6

Apoptotic cell death in the cerebellum of mutant weaver and lurcher mice. Wüllner U, et al. **Neurosci Lett** 1995 Nov 17;200(2):109–12

Time course of axotomy–induced apoptotic cell death in facial motoneurons of neonatal wild type and bcl–2 transgenic mice. de Bilbao F, et al. **Neuroscience** 1996 Apr; 71(4):1111–9

Blockade of glutamate receptors unmasks neuronal apoptosis after oxygen–glucose deprivation in vitro. Gwag BJ, et al. **Neuroscience** 1995 Oct;68(3):615–9

Apoptosis in the human female reproductive tract. Spencer SJ, et al. **Obstet Gynecol Surv** 1996 May;51(5):314–23 (103 ref.)

Apoptosis in v–myc transformation of myelomonocytic cells and its modulation by CSF–1. Dolnikov A, et al. **Oncogene** 1996 Mar 21;12(6):1189–98

The retinoblastoma gene product inhibits TGF–beta1 induced apoptosis in primary rat hepatocytes and human HuH–7 hepatoma cells. Fan G, et al. **Oncogene** 1996 May 2;12(9):1909–19

Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53–regulated genes in colon carcinoma cells. Harwood FG, et al. **Oncogene** 1996 May 16;12(10):2057–67

Differential regulation of p53, c–Myc, Bcl–2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells. Jiang MC, et al. **Oncogene** 1996 Aug 1;13(3):609–16

Apoptosis suppression by bcl–2 is correlated with the regulation of nuclear and cytosolic Ca2+. Marin MC, et al. **Oncogene** 1996 Jun 6;12(11):2259–66

c–Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Packham G, et al. **Oncogene** 1996 Aug 1;13(3):461–9

p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis. Roemer K, et al. **Oncogene** 1996 May 16;12(10):2069–79

Expression of human immunodeficiency virus type I tat results in down–regulation of bcl–2 and induction of apoptosis in hematopoietic cells. Sastry KJ, et al. **Oncogene** 1996 Aug 1;13(3):487–93

Induction of apoptosis by the tumor suppressor protein BRCA1. Shao N, et al. **Oncogene** 1996 Jul 4;13(1):1–7

Retardation of chemical hypoxia–induced necrotic cell death by Bcl–2 and ICE inhibitors: possible involvement of common mediators in apoptotic and necrotic signal transductions. Shimizu S, et al. **Oncogene** 1996 May 16; 12(10):2045–50

Bcl–2 expression prevents activation of the ICE protease cascade. Shimizu S, et al. **Oncogene** 1996 Jun 6; 12(11):2251–7

Down regulation of Bcl–2 is the first step on Fas–mediated apoptosis of male reproductive tract. Suzuki A, et al. **Oncogene** 1996 Jul 4;13(1):31–7

Drug–induced apoptosis in B–cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl–2/bax proteins in drug resistance. Thomas A, et al. **Oncogene** 1996 Mar 7;12(5):1055–62

Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV–18 E6 through ubiquitin mediated degradation. Thomas M, et al. **Oncogene** 1996 Jul 18;13(2):265–73

Repression of apoptosis in human B–lymphoma cells by CD40–ligand and Bcl–2: relationship to the cell–cycle and role of the retinoblastoma protein. Wang H, et al. **Oncogene** 1996 Jul 18;13(2):373–9

Survival and death of prelymphomatous B–cells from N–myc/bcl–2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes. Zörnig M, et al. **Oncogene** 1995 Nov 16;11(10):2165–74

Redox signalling and the control of cell growth and death. Powis G, et al. **Pharmacol Ther** 1995;68(1):149–73 (240 ref.)

Ceramide: an intracellular mediator of apoptosis and growth suppression. Saba JD, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):233–40; discussion 240–1 (40 ref.)

Suppression of apoptosis by basement membrane requires three–dimensional tissue organization and withdrawal from the cell cycle. Boudreau N, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3509–13

A Fas–associated protein factor, FAF1, potentiates Fas–mediated apoptosis. Chu K, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11894–8

Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Gottlieb RA, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):654–8

Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Lazebnik YA, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9042–6

Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Tang DG, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5241–6

Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor–associated factors. Uren AG, et al. **Proc Natl Acad Sci U S A** 1996 May 14; 93(10):4974–8

Apoptosis in the developing CNS. Naruse I, et al. **Prog Neurobiol** 1995 Oct;47(2):135–55 (152 ref.)

Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Denmeade SR, et al. **Prostate** 1996 Apr;28(4):251–65 (94 ref.)

Photic injury triggers apoptosis of photoreceptor cells. Abler AS, et al. **Res Commun Mol Pathol Pharmacol** 1996 May; 92(2):177–89

Protein thiol modification and apoptotic cell death as cGMP–independent nitric oxide (NO) signaling pathways. Brüne B, et al. **Rev Physiol Biochem Pharmacol** 1996; 127:1–30 (105 ref.)

p53: DNA damage, DNA repair, and apoptosis. Götz C, et al. **Rev Physiol Biochem Pharmacol** 1996;127:65–95 (230 ref.)

Apoptosis: relevance to rheumatology. Tebib JG. **Rev Rhum Engl Ed** 1995 Nov;62(10):618–26 (52 ref.)

Apoptosis, I: General considerations. Oros A, et al.

APOPTOSIS

Rom J Morphol Embryol 1995 Jul-Dec;41(3-4):89-99 (56 ref.)

Cell death in the embryonic developing limb. Hurle JM, et al. **Scanning Microsc** 1995 Jun;9(2):519-33; discussion 533-4 (118 ref.)

Cell death in health and disease: the biology and regulation of apoptosis. Bellamy CO, et al. **Semin Cancer Biol** 1995 Feb;6(1):3-16 (126 ref.)

Induction of apoptosis by tumor suppressor genes and oncogenes. Canman CE, et al. **Semin Cancer Biol** 1995 Feb; 6(1):17-25 (90 ref.)

Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Eastman A. **Semin Cancer Biol** 1995 Feb;6(1):45-52 (69 ref.)

Implications of apoptotic cell death regulation in cancer therapy. McDonnell TJ, et al. **Semin Cancer Biol** 1995 Feb; 6(1):53-60 (80 ref.)

Induction of genes during apoptosis: examples from the immune system. Osborne BA. **Semin Cancer Biol** 1995 Feb; 6(1):27-33 (61 ref.)

Cyclin D1 induced apoptosis maintains the integrity of the G1/S checkpoint following ionizing radiation irradiation. Pardo FS, et al. **Somat Cell Mol Genet** 1996 Mar; 22(2):135-44

1995 STP Young Investigator Award recipient. Increased rate of apoptosis correlates with hepatocellular proliferation in Fischer-344 rats following long-term exposure to a mixture of groundwater contaminants. Constan AA, et al. **Toxicol Pathol** 1996 May-Jun; 24(3):315-22

The death domain: a module shared by proteins with diverse cellular functions [letter] Feinstein E, et al. **Trends Biochem Sci** 1995 Sep;20(9):342-4

Apoptosis and CD4+ lymphocyte depletion following feline immunodeficiency virus infection of a T-lymphocyte cell line. Johnson CM, et al. **Vet Pathol** 1996 Mar;33(2):195-203

Cell deletion by apoptosis during regression of rat parotid sialadenosis. Chisholm DM, et al. **Virchows Arch** 1995; 427(2):181-6

Demonstration of apoptosis in neuroblastoma and its relationship to tumour regression. Koizumi H, et al. **Virchows Arch** 1995;427(2):167-73

HIV-1 mediates rapid apoptosis of lymphocytes from human CD4 transgenic but not normal rabbits. Leno M, et al. **Virology** 1995 Nov 10;213(2):450-4

[Programmed neuronal cell death?] Langmeier M. **Cesk Fysiol** 1995 Dec;44(4):188-90 (Eng. Abstr.) **(Cze)**

[Signals for cellular selection for life and death by a new family of cytokines] Hintzen RQ, et al. **Ned Tijdschr Geneeskd** 1996 Jan 27;140(4):182-6 (29 ref.) **(Dut)**

[Cerebral ischemia: is cell death a type of apoptosis?] Charriaut-Marlangue C, et al. **Arch Pediatr** 1996;3 Suppl 1:245s-247s **(Fre)**

[Apoptosis--programmed cell death] Baumgartner-Parzer SM. **Wien Klin Wochenschr** 1996;108(11):311-20 (122 ref.) (Eng. Abstr.) **(Ger)**

[Apoptosis--programmed cell death--molecular aspect] Kaplinsky C, et al. **Harefuah** 1995 Nov 1;129(9):346-50 (53 ref.) **(Heb)**

[Apoptosis: cell do not die at random--biochemical aspect] Sela BA. **Harefuah** 1995 Nov 1;129(9):342-5 (27 ref.) **(Heb)**

[Fas antigen expression and apoptosis in liver tissues of patients with chronic hepatitis B] Mochizuki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:228-33 (17 ref.) **(Jpn)**

[Apoptosis and fulminant hepatitis] Sata M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:488-91 (18 ref.) **(Jpn)**

[Importance of programmed endothelial death in the formation of intraorgan vascular bed in human embryogenesis] Iarygin NE, et al. **Arkh Patol** 1995 Nov-Dec;57(6):39-44 (Eng. Abstr.) **(Rus)**

[The Fas/APO-1 antigen--a molecule mediating apoptosis] Baryshnikov AIu, et al. **Gematol Transfuziol** 1995 Nov-Dec;40(6):35-8 (28 ref.) **(Rus)**

[Morphology of apoptosis in normal and pathologic hematopoiesis] Pogorelov VM, et al. **Gematol Transfuziol** 1995 Sep-Oct;40(5):17-25 (61 ref.) **(Rus)**

RADIATION EFFECTS

Decreased DNA repair but normal apoptosis in ultraviolet-irradiated skin of p53-transgenic mice. Li G, et al. **Am J Pathol** 1996 Apr;148(4):1113-23

Measurement of apoptotic fragments in growing hair follicles following gamma-ray irradiation in mice. Kim TH, et al. **Anticancer Res** 1996 Jan-Feb;16(1):189-92

Radiation-induced apoptosis: effects of cell age and dose fractionation. Ling CC, et al. **Cancer Res** 1995 Nov 15; 55(22):5207-12

A radioresistant variant derived from a human neuroblastoma cell line is less prone to radiation-induced apoptosis. Russell J, et al. **Cancer Res** 1995 Nov 1;55(21):4915-21

Apoptosis induced by X-irradiation of rec-myc cells is postmitotic and not predicted by the time after irradiation or behavior of sister cells. Vidair CA, et al. **Cancer Res** 1996 Sep 15;56(18):4116-8

Influence of liver tumor promoters on apoptosis in rat hepatocytes induced by 2-acetylaminofluorene, ultraviolet light, or transforming growth factor beta 1. Worner W, et al. **Cancer Res** 1996 Mar 15;56(6):1272-8

UVB irradiation of human-derived peripheral blood lymphocytes induces apoptosis but not T-cell anergy: additive effects with various immunosuppressive agents. Yaron I, et al. **Cell Immunol** 1996 Mar 15;168(2):258-66

Early and late G2 arrest of cells undergoing radiation-induced apoptosis or micronucleation. Abend M, et al. **Cell Prolif** 1996 Feb;29(2):101-13

Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. Zhai S, et al. **Exp Cell Res** 1996 May 1;224(2):335-43

Radiation-induced apoptosis in normal and pre-neoplastic mammary glands in vivo: significance of gland differentiation and p53 status. Meyn RE, et al. **Int J Cancer** 1996 Feb 8;65(4):466-72

Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Sakakura C, et al. **Int J Cancer** 1996 Jul 3;67(1):101-5

Expression and localization of clusterin mRNA in the small and large intestine of the irradiated rat: its relationship with apoptosis. Arai T, et al. **Int J Radiat Biol** 1996 May; 69(5):547-53

Reducing the radiation-induced G2 delay causes HeLa cells to undergo apoptosis instead of mitotic death. Bernhard EJ, et al. **Int J Radiat Biol** 1996 May;69(5):575-84

RBE of fast neutrons for apoptosis in mouse thymocytes. Warenius HM, et al. **Int J Radiat Biol** 1995 Dec;68(6):625-9

Expression of enhanced spontaneous and gamma-ray-induced apoptosis by lymphocytes of the wasted mouse. Woloschak GE, et al. **Int J Radiat Biol** 1996 Jan;69(1):47-55

Syk and Lyn are involved in radiation-induced signaling, but inactivation of Syk or Lyn alone is not sufficient to prevent radiation-induced apoptosis. Yang C, et al. **J Biochem (Tokyo)** 1995 Jul;118(1):33-8

Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in gamma radiation-induced apoptosis. Chen YR, et al. **J Biol Chem** 1996 Jan 12;271(2):631-4

Radiation-induced apoptosis is differentially regulated in primary B cells from normal mice and mice with the CBA/N X-linked immunodeficiency. Woodland RT, et al. **J Immunol** 1995 Oct 1;155(7):3453-63

Lithium delays the radiation-induced apoptotic process in external granule cells of mouse cerebellum. Inouye M, et al. **J Radiat Res (Tokyo)** 1995 Sep;36(3):203-8

P53 and induction of apoptosis as a target for anticancer therapy. Neubauer A, et al. **Leukemia** 1996 Jul;10 Suppl 3:S2-S4 (46 ref.)

Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation. Han Z, et al. **Mol Cell Biol** 1995 Nov;15(11):5849-57

Ionizing radiation-induced apoptosis is associated with c-Jun expression and c-Jun/AP-1 activation in the developing cerebellum of the rat. Ferrer I, et al. **Neurosci Lett** 1995 Dec 29;202(1-2):105-8

Gamma-radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo. Kitada S, et al. **Oncogene** 1996 Jan 4;12(1):187-92

Blockage of RNA polymerase as a possible trigger for u.v. light-induced apoptosis. Ljungman M, et al. **Oncogene** 1996 Aug 15;13(4):823-31

Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: influence of H-ras on the G2 delay. McKenna WG, et al. **Oncogene** 1996 Jan 18; 12(2):237-45

Effect of cell cycle stage, dose rate and repair of sublethal damage on radiation-induced apoptosis in F9 teratocarcinoma cells. Langley RE, et al. **Radiat Res** 1995 Oct;144(1):90-6

Comments on "Radiation-induced apoptosis in HL60 cells: oxygen effect, relationship between apoptosis and loss of clonogenicity, and dependence of time to apoptosis on radiation dose" by Hopcia et al. (Radiat. Res. 145, 315-323, 1996) [letter] Makepeace CM, et al. **Radiat Res** 1996 Jul; 146(1):116-9

Apoptosis and delayed expression of c-jun and c-fos after gamma irradiation of Jurkat T cells. Syljuåsen RG, et al. **Radiat Res** 1996 Sep;146(3):276-82

An equation for the dose response of radiation-induced apoptosis [letter; comment] Bistrović M, et al. **Radiother Oncol** 1995 May;35(2):165-6. Comment on: Radiother Oncol 1994 Oct;33(1):17-22.

Time course of radiation-induced apoptosis in the adult rat spinal cord. Li YQ, et al. **Radiother Oncol** 1996 Apr; 39(1):35-42

Spontaneous and induced apoptosis after whole body radiation exposure: experimental approaches. Observations in radio-induced thymic lymphomagenesis. Humblet C, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:129-35

Apoptosis and the assessment of radiation injury. Vincent PC. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:153-64 (129 ref.)

Radiation-induced apoptosis in thymocytes: pH sensitization. Ojeda F, et al. **Z Naturforsch [C]** 1996 May-Jun; 51(5-6):432-4

[Gene transfer and radiotherapy] Bourhis J, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):107-13 (43 ref.) (Eng. Abstr.) **(Fre)**

[The biological significance and clinical prospects of apoptosis within the parameters of radiotherapy response (editorial)] Tordiglione M, et al. **Radiol Med (Torino)** 1996 Mar;91(3):286-91 (44 ref.) **(Ita)**

[Immunohistochemical study of radiation-induced apoptosis and oncogenes] Hasegawa M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Sep; 55(11):779-80 (Eng. Abstr.) **(Jpn)**

[Development of apoptosis induced by whole-body irradiation in murine liver] Terashima M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Aug; 55(9):700-2 (Eng. Abstr.) **(Jpn)**

APORPHINES

CHEMISTRY

N-[18F]-fluoroalkylation of noraporphines: microwave versus thermal treatment. Zijlstra S, et al. **Eur J Morphol** 1995 Apr;33(2):154-7

PHARMACOLOGY

Cytoprotective and antioxidant effects of boldine on tert-butyl hydroperoxide-induced damage to isolated hepatocytes. Bannach R, et al. **Cell Biol Toxicol** 1996 Apr; 12(2):89-100

Effects of dicentrine on the mechanical properties of systemic arterial trees in dogs. Chang KC, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):169-76

Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance. Chen G, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1271-7

Vasodilator effects of liriodenine and norushinsunine, two aporphine alkaloids isolated from Annona cherimolia, in rat aorta. Chuliá S, et al. **Pharmacology** 1995 Jun; 50(6):380-7

Antiplatelet and vasorelaxing actions of some aporphinoids. Chen KS, et al. **Planta Med** 1996 Apr;62(2):133-6

Lipoxygenase inhibition and antioxidant properties of protoberberine and aporphine alkaloids isolated from Mahonia aquifolium [letter] Mišík V, et al. **Planta Med** 1995 Aug;61(4):372-3

Anti-herpes virus activity of aporphine alkaloids. Montanha JA, et al. **Planta Med** 1995 Oct;61(5):419-24

THERAPEUTIC USE

Renin-angiotensin system in the antihypertensive effect of isoteoline in spontaneously hypertensive rats. Markov M, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S368-70

APPARATUS AND INSTRUMENTS see **EQUIPMENT AND SUPPLIES**

APPENDECTOMY

Appendiceal stump abscess. Filippi de la Palavesa MM, et al. **Abdom Imaging** 1996 Jan-Feb;21(1):65-6

MALTectomy (appendectomy/tonsillectomy) does not influence the occurrence or mode of presentation of adult celiac disease. O'Gorman P, et al. **Am J Gastroenterol** 1996 Apr;91(4):723-5

The long-term outcome after negative appendix operation. Miettinen P, et al. **Ann Chir Gynaecol** 1995;84(3):267-70

Acute appendicitis: does removal of a normal appendix matter, what is the value of diagnostic accuracy and is surgical delay important? [letter; comment] Cuschieri RJ, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):73. Comment on: Ann R Coll Surg Engl 1995 Sep;77(5):358-63.

Acute appendicitis: does removal of a normal appendix matter, what is the value of diagnostic accuracy and is surgical delay important? [see comments] Walker SJ, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):358-63. Comment in: Ann R Coll Surg Engl 1996 Jan;78(1):73.

Laparoscopy during pregnancy. Curet MJ, et al. **Arch Surg** 1996 May;131(5):546-50; discussion 550-1

Early discharge after open appendicectomy. Lord RV, et al. **Aust N Z J Surg** 1996 Jun;66(6):361-5

Appendiceal mass: interval appendicectomy should not be the rule. Adalla SA. **Br J Clin Pract** 1996 Apr-May; 50(3):168-9

Operative viva G. Meckel's diverticulum. Parks RW, et al. **Br J Hosp Med** 1996 Feb 21-Mar 5;55(4):176-7

'Residual' appendicitis following incomplete laparoscopic appendicectomy. Milne AA, et al. **Br J Surg** 1996 Feb; 83(2):217

Laparoscopic appendectomy: a review of 95 consecutive suspected cases of appendicitis. Karim SS, et al. **Can J Surg** 1995 Oct;38(5):449-53

Medical treatment of postappendectomy intraperitoneal abscesses in children. Héloury Y, et al. **Eur J Pediatr Surg** 1995 Jun;5(3):149-51

Acute appendicitis. How many uncorrect diagnosis? A clinical and histological evaluation of 124 cases treated with emergency procedure. Covarelli P, et al. **G Chir** 1996 May; 17(5):276-8

Use of laparoscopy in the treatment of acute and chronic right lower quadrant pain [see comments] Morfesis FA, et al. **J Ky Med Assoc** 1996 Jan;94(1):16-21. Comment in: J Ky Med Assoc 1996 Apr;94(4):160.

Bilateral ureteral obstruction after appendectomy in children. Hugen CA, et al. **J Pediatr Surg** 1995 Dec;30(12):1666-7

Early patient discharge following appendicectomy: safety and feasibility. Salam IM, et al. **J R Coll Surg Edinb** 1995

Oct;40(5):300–2
Is a histologically normal appendix following emergency appendicectomy alway normal? [see comments] Wang Y, et al. **Lancet** 1996 Apr 20;347(9008):1076–9. Comment in: Lancet 1996 Jul 13;348(9020):126–7.
Laparoscopic versus open appendectomy. Williams MD, et al. **South Med J** 1996 Jul;89(7):668–74
Laparoscopic appendectomy and the management of gynecologic pathologic conditions found at laparoscopy for presumed appendicitis. Apelgren KN, et al. **Surg Clin North Am** 1996 Jun;76(3):469–82 (47 ref.)
Intraperitoneal fluid collection after laparoscopic appendectomy. Sonographic analysis in asymptomatic patients. Sales JP, et al. **Surg Endosc** 1995 Jul;9(7):805–6
Intraabdominal abscesses following laparoscopic and open appendectomies. Tang E, et al. **Surg Endosc** 1996 Mar; 10(3):327–8
Laparoscopy not recommended for routine appendectomy in men: results of a prospective randomized study. Mutter D, et al. **Surgery** 1996 Jul;120(1):71–4
[Recommendations and medical references 1996] **Ann Chir** 1996;50(2):182–8 **(Fre)**
["Open" versus laparoscopic appendectomy] Ablassmaier B, et al. **Chirurg** 1996 May;67(5):522–5; discussion 522 (Eng. Abstr.) **(Ger)**
[Laparoscopic versus conventional appendectomy: a prospective randomized study] Henle KP, et al. **Chirurg** 1996 May;67(5):526–30; discussion 522 (Eng. Abstr.) **(Ger)**
[Ultrasound diagnosis of acute appendicitis—possibilities and limits of the method—results of prospective and retrospective clinical studies] Uebel P, et al. **Ultraschall Med** 1996 Jun;17(3):100–5 (Eng. Abstr.) **(Ger)**
[The perforation of the cecum by a fecalith following appendectomy] Cherniavskiĭ AV, et al. **Vestn Khir Im I I Grek** 1992 Nov–Dec;149(11–12):370–1 **(Rus)**
[Postappendectomy vascular complications in childhood] Díez García R, et al. **An Esp Pediatr** 1996 Mar;44(3):270–2 (19 ref.) **(Spa)**
[Pathology of the cecal appendix in our country. An analysis of 936 surgical specimens of appendectomy] Ross E, et al. **G E N** 1995 Apr–Jun;49(2):140–4 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Pelvic abscess following laparoscopic appendicectomy [letter] Frizelle FA, et al. **Ann R Coll Surg Engl** 1995 Nov; 77(6):467–8
Pelvic abscess following laparoscopic appendicectomy [letter] Taylor RS. **Ann R Coll Surg Engl** 1995 Nov; 77(6):468
Left scrotal abscess complicating laparoscopic appendicectomy. Kollias J, et al. **Aust N Z J Surg** 1996 Aug;66(8):568–9
Pitfalls in nonrandomized outcomes studies. The case of incidental appendectomy with open cholecystectomy. Wen SW, et al. **JAMA** 1995 Dec 6;274(21):1687–91
[Does laparoscopic treatment of abdominal infections generate bacteremias? Prospective study: 75 cases] Benoit J, et al. **J Chir (Paris)** 1995 Dec;132(12):472–7 (Eng. Abstr.) **(Fre)**
[Post-appendectomy fistulas of the cecum. Apropos of 22 cases] Genier F, et al. **J Chir (Paris)** 1995 Oct;132(10):393–8 (17 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of surgical wound infections after appendectomy: intravenous versus rectal metronidazole] Anselmi M, et al. **Rev Med Chil** 1995 Aug;123(8):961–6 (Eng. Abstr.) **(Spa)**

ECONOMICS

Cost-effective evaluation and management of the acute abdomen. Gill BD, et al. **Surg Clin North Am** 1996 Feb; 76(1):71–82 (13 ref.)

INSTRUMENTATION

Laparoscopic appendectomy [letter] Pelosi MA, et al. **J Laparoendosc Surg** 1995 Dec;5(6):419–21

METHODS

A clinical outcome and cost analysis of laparoscopic versus open appendectomy. McCahill LE, et al. **Am J Surg** 1996 May;171(5):533–7
Randomized, single-blinded trial of laparoscopic versus open appendectomy in children: effects on postoperative analgesia. Lejus C, et al. **Anesthesiology** 1996 Apr; 84(4):801–6
Laparoscopic appendicectomy: a trainee's perspective [see comments] Botha AJ, et al. **Ann R Coll Surg Engl** 1995 Jul;77(4):259–62. Comment in: Ann R Coll Surg Engl 1996 Jan;78(1):71–2.
Laparoscopic appendicectomy: a trainee's perspective [letter; comment] Meshikhes AW, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):71–2. Comment on: Ann R Coll Surg Engl 1995 Jul;77(4):259–62.
Laparoscopic appendectomy for complicated appendicitis. Frazee RC, et al. **Arch Surg** 1996 May;131(5):509–11; discussion 511–3
A prospective trial of open versus laparoscopic appendicectomy. Sayed Hassen AH, et al. **Aust N Z J Surg** 1996 Mar;66(3):178–80
Residual appendicitis following incomplete laparoscopic appendectomy [letter] Somerville PG, et al. **Br J Surg** 1996 Jun;83(6):869
Incidental appendicectomy for the long mobile appendix. Wheeler JM, et al. **Br J Surg** 1996 Apr;83(4):498
Laparoscopic appendectomy. A comparison with open appendectomy. Kluiber RM, et al. **Dis Colon Rectum** 1996 Sep;39(9):1008–11
Laparoscopic appendicectomy in the management of acute lower gastrointestinal bleeding. So JB, et al. **Gastrointest Endosc** 1995 Nov;42(5):488–9
Complete two-handed laparoscopic appendectomy: report of 100 cases. Chao C, et al. **J Formos Med Assoc** 1995 Nov;94(11):679–82
Laparoscopic surgery in pregnancy: report on two cases. Posta CG. **J Laparoendosc Surg** 1995 Jun;5(3):203–5
Laparoscopic procedure for suspected appendicitis. A prospective study in 283 consecutive patients. Bouillot JL, et al. **Surg Endosc** 1995 Sep;9(9):957–60
Laparoscopic bipolar strip-tease appendicectomy. A new endosurgical technique. Tan HL, et al. **Surg Endosc** 1995 Dec;9(12):1301–3
Laparoscopic and open appendectomies [letter; comment] Pelosi M, et al. **Surg Laparosc Endosc** 1995 Dec;5(6):492–3 . Comment on: Surg Laparosc Endosc 1994 Aug;4(4):272–6.
Laparoscopic versus open appendectomy: prospective randomized trial. Hansen JB, et al. **World J Surg** 1996 Jan; 20(1):17–20; discussion 21
Subcuticular skin closure as a standard approach to emergency appendectomy in children: prospective clinical trial. Serour F, et al. **World J Surg** 1996 Jan;20(1):38–42
[A modified technic in laparoscopy-assisted appendectomy—a transumbilical approach through a single port] Kala Z, et al. **Rozhl Chir** 1996 Jan;75(1):15–8 (Eng. Abstr.) **(Cze)**
[Does laparoscopic treatment of abdominal infections generate bacteremias (editorial)] Benoit J, et al. **G Chir** 1996 May;17(5):225–30 **(Fre)**
[Impact of celioscopic surgery in general and digestive system surgery] Johanet H, et al. **J Chir (Paris)** 1995 Nov; 132(11):434–7 (Eng. Abstr.) **(Fre)**
[Laparoscopy for appendicular syndromes in young women. Results of a prospective study] Sfairi A, et al. **J Chir (Paris)** 1995 Aug–Sep;132(8–9):333–5 (Eng. Abstr.) **(Fre)**
[Mucocele of the appendix: value of excision by celioscopy] Sfairi A, et al. **J Chir (Paris)** 1995 Oct;132(10):403–5 (Eng. Abstr.) **(Fre)**
[Advantages of laparoscopic appendectomy] Näf R, et al. **Rev Med Suisse Romande** 1996 Jul;116(7):537–40 **(Fre)**
[A case of traditional appendectomy changed to laparoscopic surgery] Cagnazzo A, et al. **Ann Ital Chir** 1996 Jan–Feb; 67(1):109–10 (Eng. Abstr.) **(Ita)**
[Laparoscopic appendectomy in acute appendicitis] Kulik IaP, et al. **Vestn Khir Im I I Grek** 1995;154(2):34–6 (Eng. Abstr.) **(Rus)**

STANDARDS

Audit of paediatric appendicectomy results. Wright JE. **J Qual Clin Pract** 1995 Dec;15(4):235–7

STATISTICS & NUMERICAL DATA

Analysis of 8651 appendicectomies in England and Wales during 1992 [letter; comment] Corder AP. **Br J Surg** 1995 Dec;82(12):1699. Comment on: Br J Surg 1995 Jul;82(7):933.
Acute appendicitis in Ethiopia. Kotisso B, et al. **East Afr Med J** 1996 Apr;73(4):251–2
Appendectomy and tonsillectomy in patients with inflammatory bowel disease. Smithson JE, et al. **J Clin Gastroenterol** 1995 Dec;21(4):283–6
Emergency appendicectomy and meat consumption in the UK. Appleby P, et al. **J Epidemiol Community Health** 1995 Dec;49(6):594–6

APPENDICEAL NEOPLASMS

see related
PSEUDOMYXOMA PERITONEI

A half century of experience with carcinoid tumors in children. Corpron CA, et al. **Am J Surg** 1995 Dec; 170(6):606–8
Appendicular adenocarcinoma [letter; comment] Rodriguez-Sanjuan JC. **Ann Surg** 1995 Dec;222(6):765–6. Comment on: Ann Surg 1995 Feb;221(2):202.
Appendiceal mucocele with concomitant colonic cancer. Report of two cases. Fujiwara T, et al. **Dis Colon Rectum** 1996 Feb;39(2):232–6

COMPLICATIONS

Appendicular adenocarcinoma leading to appendiculo-vesical fistula. Rahman SI, et al. **Br J Urol** 1996 Aug;78(2):305–6
Recovery from severe osteoporosis following cure from ectopic ACTH syndrome caused by an appendix carcinoid. Dobnig H, et al. **J Intern Med** 1996 Apr;239(4):365–9
Primary adenocarcinoma of the appendix. Hartley JE, et al. **J R Soc Med** 1996 Feb;89(2):111P–3P
Incidental mucinous cystadenocarcinoma of the appendix. Lee J, et al. **Postgrad Med J** 1996 Jan;72(843):55–6
[Adenocarcinoma of the appendix. A propos of a case complicated by double local and parietal recurrence] de Souza N, et al. **J Chir (Paris)** 1996 Jun;133(4):159–61 (10 ref.) (Eng. Abstr.) **(Fre)**
[A case of carcinomatous peritonitis for which combination therapy of 5-FU, leucovorin and cisplatin was effective] Okabe T, et al. **Gan To Kagaku Ryoho** 1996 Feb; 23(3):349–53 (Eng. Abstr.) **(Jpn)**
[Villous adenoma of the appendix caused acute appendicitis] Guliás Piñeiro A, et al. **Rev Esp Enferm Dig** 1996 Jun; 88(6):435–7 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Adenomatous polyposis coli presenting as adenocarcinoma of the appendix. Parker GM, et al. **Am J Gastroenterol** 1996 Apr;91(4):801–2
A case of retroperitoneal pseudomyxoma. Baba Y, et al. **Radiat Med** 1995 Sep–Oct;13(5):247–9
Venous hemangioma of the mesoappendix: report of a case and a brief review of the Japanese literature. Hanatate F, et al. **Surg Today** 1995;25(11):962–4 (8 ref.)
[Clinical and cytogenetic observations on carcinoid tumors] Angelescu N, et al. **Chirurgia (Bucur)** 1995;44(1):21–6 **(Rum)**
[Psoas abscess as initial manifestation of appendiceal tumor (letter)] Tabet J, et al. **Med Clin (Barc)** 1996 Apr 13; 106(14):556–7 **(Spa)**

DRUG THERAPY

Prognostic implications of chemoresistance-sensitivity assays for colorectal and appendiceal cancer. Fernandez-Trigo V, et al. **Am J Clin Oncol** 1995 Oct;18(5):454–60

GENETICS

Genetic analysis of synchronous mucinous tumors of the ovary and appendix. Chuaqui RF, et al. **Hum Pathol** 1996 Feb;27(2):165–71

PATHOLOGY

Fine needle aspiration cytology of appendiceal mucinous cystadenoma: a case report. Zuzarte JC, et al. **Acta Cytol** 1996 Mar–Apr;40(2):327–30
Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations. Cuatrecasas M, et al. **Am J Surg Pathol** 1996 Jun;20(6):739–46
Peritoneal carcinomatosis [letter; comment] Noguchi M. **Ann Surg** 1995 Dec;222(6):760–1. Comment on: Ann Surg 1995 Feb;221(2):124–32.
Epithelial noncarcinoid tumors and tumor-like lesions of the appendix [letter] Carr NJ, et al. **Cancer** 1995 Dec 1; 76(11):2383–4
Colonoscopic appearance of an adenocarcinoid of the vermiform appendix. Jiménez-Pérez FJ, et al. **Endoscopy** 1996 Feb;28(2):270
Combined goblet cell carcinoid and mucinous cystadenoma of the appendix. al-Talib RK, et al. **J Clin Pathol** 1995 Sep;48(9):869–70
Intussusception of the appendix: a report of three cases with different clinical and pathologic features. Sakaguchi N, et al. **Pathol Int** 1995 Oct;45(10):757–61
Carcinoid tumors of the appendix [letter] Gutiérrez MC, et al. **Pediatr Pathol Lab Med** 1995 Jul–Aug;15(4):641–2
Appendiceal mucinous cystadenoma associated with pseudomyxoma peritonei and multicystic peritoneal mesothelioma: report of a case. Kusuyama T, et al. **Surg Today** 1995;25(8):745–9
Rare metastases of signet ring cell carcinomas to the scrotum: report of two cases. Niesel T, et al. **Urology** 1996 May; 47(5):769–71
[A case of goblet cell carcinoid of the appendix] Kamada T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May; 93(5):367–72 (16 ref.) **(Jpn)**

RADIOGRAPHY

Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. Jacquet P, et al. **J Am Coll Surg** 1995 Dec;181(6):530–8

SECONDARY

Acute appendicitis secondary to metastatic nasopharyngeal carcinoma. Hsu KL, et al. **J Surg Oncol** 1995 Oct; 60(2):131–2
[Metastasis of rectal cancer into the appendix in association with acute destructive appendicitis] Shpizel' RS. **Klin Khir** 1995;(7–8):33 **(Rus)**

SURGERY

Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. Jacquet P, et al. **J Am Coll Surg** 1995 Dec;181(6):530–8
Appendiceal intussusception due to an appendiceal malignant polyp—an association in a patient with Peutz-Jeghers syndrome: report of a case. Miyahara M, et al. **Surg Today** 1995;25(9):834–7

APPENDICEAL NEOPLASMS

ULTRASONOGRAPHY

Lymphoma of the appendix: sonographic findings [letter] Krepel VM, et al. **AJR Am J Roentgenol** 1996 Jul; 167(1):286

APPENDICITIS

Perforated appendicitis: past and future controversies. Blewett CJ, et al. **Semin Pediatr Surg** 1995 Nov;4(4):234–8 (34 ref.)

BLOOD

C-reactive protein in the diagnosis of acute appendicitis [letter] Chen SC, et al. **Am J Emerg Med** 1996 Jan; 14(1):101–3

Accuracy of serum C-reactive protein measurements in diagnosis of acute appendicitis compared with surgeon's clinical impression. Gurleyik E, et al. **Dis Colon Rectum** 1995 Dec;38(12):1270–4

COMPLICATIONS

Delay in presentation accounts for the majority of inflamed appendices [letter; comment] Franz MG, et al. **Ann Surg** 1996 Jan;223(1):105–6. Comment on: Ann Surg 1995 Mar;221(3):278–81.

Granulomatous appendicitis in acute myeloblastic leukemia: expanding the clinicopathologic spectrum of invasive candidiasis. Moyana TN, et al. **Arch Pathol Lab Med** 1996 Feb;120(2):203–5

Management of complicated appendicitis. A rational approach based on clinical course. Keller MS, et al. **Arch Surg** 1996 Mar;131(3):261–4

Acute appendicitis presenting with surgical emphysema and pneumomediastinum. McCahy P, et al. **Br J Clin Pract** 1995 Jul–Aug;49(4):217–8

Appendicovesical fistula. Athanassopoulos A, et al. **Int Urol Nephrol** 1995;27(6):705–8 (9 ref.)

Spontaneous drainage of an appendiceal abscess into an orthotopic neobladder. Petrus C, et al. **J Urol** 1996 Jun; 155(6):2028

[A case of gangrenous appendicitis complicated by an anaerobic gas infection in the retroperitoneal space and right thigh] Iarūmov N, et al. **Khirurgiia (Sofiia)** 1995; 48(5):72–3 **(Bul)**

[Does laparoscopic treatment of abdominal infections generate bacteremias? Prospective study: 75 cases] Benoit J, et al. **J Chir (Paris)** 1995 Dec;132(12):472–7 (Eng. Abstr.) **(Fre)**

[Metastasis of rectal cancer into the appendix in association with acute destructive appendicitis] Shpizel' RS. **Klin Khir** 1995;(7–8):33 **(Rus)**

[Acute appendicitis and necrosis of the ileum in strangulated femoral hernia in an aged patient] Stavitskiĭ VV. **Klin Khir** 1995;(4):52 **(Rus)**

[Subphrenic abscess in retrocecal appendicitis in children] Gumerov AA, et al. **Vestn Khir Im I I Grek** 1992 Mar; 148(3):317–9 **(Rus)**

DIAGNOSIS

Early childhood appendicitis is still a difficult diagnosis. Paajanen H, et al. **Acta Paediatr** 1996 Apr;85(4):459–62

The myth of the fecalith. Maenza RL, et al. **Am J Emerg Med** 1996 Jul;14(4):394–7

The long-term outcome after negative appendix operation. Miettinen P, et al. **Ann Chir Gynaecol** 1995;84(3):267–70

Acute appendicitis: does removal of a normal appendix matter, what is the value of diagnostic accuracy and is surgical delay important? [letter; comment] Cuschieri RJ, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):73. Comment on: Ann R Coll Surg Engl 1995 Sep;77(5):358–63.

Assessment of peritonism in appendicitis. Golledge J, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):11–4

Assessment of peritonism in appendicitis [letter] Guy RJ, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):234–5

Assessment of peritonism in appendicitis [letter] Hamer DB. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):234

Assessment of peritonism in appendicitis [letter] Thomson H. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):234

Role of the primary care provider in expediting care of children with acute appendicitis. Chande VT, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):703–6

Appendiceal mass: interval appendicectomy should not be the rule. Adalla SA. **Br J Clin Pract** 1996 Apr–May; 50(3):168–9

Recent advances in the diagnosis and treatment of acute appendicitis. Calder JD, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):129–33 (24 ref.)

Combination of skin temperature and a single white cell count does not improve diagnostic accuracy in acute appendicitis. Middleton SB, et al. **Br J Surg** 1996 Apr;83(4):499

Nothing new on appendicitis [letter; comment] Girotti MJ, et al. **Can Med Assoc J** 1995 Oct 1;153(7):888, 890. Comment on: Can Med Assoc J 1995 May 15;152(10):1617–26.

Six cases in which mesenteric lymphadenitis due to non-typhi Salmonella caused an appendicitis-like syndrome [letter] García-Corbeira P, et al. **Clin Infect Dis** 1995 Jul; 21(1):231–2

Accuracy of serum C-reactive protein measurements in diagnosis of acute appendicitis compared with surgeon's clinical impression. Gurleyik E, et al. **Dis Colon Rectum** 1995 Dec;38(12):1270–4

Rebound tenderness in the clinical diagnosis of acute appendicitis [letter] Adwok JA. **East Afr Med J** 1995 Aug; 72(8):544

Value of rebound tenderness in acute appendicitis. Alshehri MY, et al. **East Afr Med J** 1995 Aug;72(8):504–6

Colonoscopic diagnosis and treatment of acute appendicitis. Said M, et al. **Eur J Gastroenterol Hepatol** 1995 Jun; 7(6):569–71

"Acute appendicitis" of neurosurgical origin. Shoshan Y, et al. **Eur J Surg** 1996 Apr;162(4):343–5

Influence of white cell count on surgical decision making in patients with abdominal pain in the right lower quadrant. Vermeulen B, et al. **Eur J Surg** 1995 Jul;161(7):483–6

Acute appendicitis. How many uncorrect diagnosis? A clinical and histological evaluation of 124 cases treated with emergency procedure. Covarelli P, et al. **G Chir** 1996 May; 17(5):276–8

Comparison of different neural network algorithms in the diagnosis of acute appendicitis. Pesonen E, et al. **Int J Biomed Comput** 1996 Jan;40(3):227–33

Clinical and laboratory findings in acute appendicitis in the elderly. Elangovan S. **J Am Board Fam Pract** 1996 Mar–Apr;9(2):75–8

Idiopathic granulomatous appendicitis. Report of five cases, one of which presented as migratory arthritis. Naschitz JE, et al. **J Clin Gastroenterol** 1995 Dec;21(4):290–4

Acute appendicitis mistaken as acute rejection in renal transplant recipients. Talwalkar NC, et al. **J Postgrad Med** 1994 Jan–Mar;40(1):39–40

Right-sided low inguinal pain in young women. Kumar S. **J R Coll Surg Edinb** 1996 Apr;41(2):93–4

Unusual course of the gonadal vein: a case report of postpartum ovarian vein thrombosis mimicking acute appendicitis clinically and sonographically. Adkins J, et al. **J Ultrasound Med** 1996 May;15(5):409–12

The role of imaging in diagnosis of acute appendicitis. Brake D, et al. **Kans Med** 1995 Fall;96(3):130–2, 129

70-year-old man with abdominal pain amd weight loss. Vlahakis NE, et al. **Mayo Clin Proc** 1996 Jun;71(6):601–4

Epiploic appendicitis: ultrasound and CT characteristics. Rutten MJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):264–5 (6 ref.)

Rectal examinations and appendicitis malpractice claims [letter] Fink S. **South Med J** 1995 Dec;88(12):1279

Laparoscopic appendectomy and the management of gynecologic pathologic conditions found at laparoscopy for presumed appendicitis. Apelgren KN, et al. **Surg Clin North Am** 1996 Jun;76(3):469–82 (47 ref.)

Loss prevention case of the month. Difficult diagnosis. Avery JK. **Tenn Med** 1996 Jul;89(7):244–5

Acute appendicitis in young children in the Belfast urban area: 1985–1992. Wilson D, et al. **Ulster Med J** 1994 Apr; 63(1):3–7

[Laparoscopy in suspected acute appendicitis. Experiences with the first 233 laparoscopies at a university hospital department] Pedersen AG, et al. **Ugeskr Laeger** 1996 Apr 22;158(17):2377–80 (Eng. Abstr.) **(Dan)**

[Acute left-side appendicitis: diagnostic contribution of tomodensitometry] Nisolle JF, et al. **Arch Pediatr** 1996 Jan; 3(1):47–50 (Eng. Abstr.) **(Fre)**

[Management of patients with pain in the right iliac fossa and human immunodeficiency virus infection] Barthod F, et al. **J Chir (Paris)** 1996 Jan;133(1):12–5 (Eng. Abstr.) **(Fre)**

[Appendicitis and pregnancy. Seven case reports] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):411–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[Role of CT in the evaluation of patients with painful symptoms located in the lower right abdominal quadrant] Gualdi GF, et al. **Clin Ter** 1995 Aug–Sep;146(8–9):519–28 (Eng. Abstr.) **(Ita)**

[Appendicitis (letter; comment)] Stagnaro S, et al. **Minerva Med** 1996 Apr;87(4):183–4. Comment on: Minerva Med 1995 Mar;86(3):93–6. **(Ita)**

[Acute abdomen in pregnancy. Diagnosis of surgical causes] Bøe HA, et al. **Tidsskr Nor Laegeforen** 1996 Feb 20; 116(5):600–3 (Eng. Abstr.) **(Nor)**

[Difficulty in diagnosing acute appendicitis in a nursing infant] Makarova MA. **Klin Khir** 1995;(6):44–5 **(Rus)**

[Crohn's disease and symptoms of appendicitis] Pechan J, et al. **Bratisl Lek Listy** 1996 Jan;97(1):28–30 (Eng. Abstr.) **(Slo)**

[Perforated appendicitis in children: evaluation of delayed diagnosis] Santini I, et al. **P R Health Sci J** 1995 Dec; 14(4):263–7 **(Spa)**

[Idiopathic granulomatous appendicitis or Crohn's disease confined to the appendix?] De Fuenmayor Valera ML, et al. **Rev Esp Enferm Dig** 1995 Dec;87(12):885–8 (Eng. Abstr.) **(Spa)**

[More penalties without reason by the disciplinary board. Criticism against the handling of appendicitis] Andersson R. **Lakartidningen** 1996 Jun 26;93(26–27):2524–5 **(Swe)**

[Acute pelvic phlebothrombosis simulating acute appendicitis] Zubenko OV, et al. **Klin Khir** 1995;(7–8):30–1 **(Ukr)**

DRUG THERAPY

Prophylactic antibiotics in uncomplicated appendicitis during childhood—a prospective randomised study. Söderquist-Elinder C, et al. **Eur J Pediatr Surg** 1995 Oct; 5(5):282–5

Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. Berne TV, et al. **J Am Coll Surg** 1996 May; 182(5):403–7

Preoperative administration of antibiotics in patients with suspected acute appendicitis. Murao Y, et al. **Surg Today** 1996;26(5):314–22

EPIDEMIOLOGY

Analysis of 8651 appendicectomies in England and Wales during 1992 [letter; comment] Corder AP. **Br J Surg** 1995 Dec;82(12):1699. Comment on: Br J Surg 1995 Jul;82(7):933.

Appendicitis: an African perspective. Walker AR, et al. **J R Soc Med** 1995 Nov;88(11):616–9 (53 ref.)

ETHNOLOGY

Acute appendicitis among black South Africans. Fulton J, et al. **S Afr J Surg** 1995 Dec;33(4):165–6

ETIOLOGY

Extraluminal appendicolith in perforating appendicitis [letter] Lin BH, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1499

Acute appendicitis following abdominal trauma. Serour F, et al. **Arch Surg** 1996 Jul;131(7):785–6

The retrocaecal appendix appears to be less prone to infection [letter] Sarela A. **Br J Surg** 1996 Jun;83(6):867–8

Clusters of acute appendicitis: further evidence for an infectious aetiology. Andersson R, et al. **Int J Epidemiol** 1995 Aug;24(4):829–33

Entrapment of the appendix and the fallopian tube in peritoneal dialysis catheters in two children. Borghol M, et al. **J Pediatr Surg** 1996 Mar;31(3):427–9

Foreign-body appendicitis. Sukhotnik I, et al. **J Pediatr Surg** 1995 Oct;30(10):1515–6

Primary adenocarcinoma of the appendix. Hartley JE, et al. **J R Soc Med** 1996 Feb;89(2):111P–3P

Acute appendicitis secondary to metastatic nasopharyngeal carcinoma. Hsu KL, et al. **J Surg Oncol** 1995 Oct; 60(2):131–2

Endometriosis of the appendix with decidual polyp formation: a rare cause of acute appendicitis during pregnancy. Silvestrini IE, et al. **P R Health Sci J** 1995 Sep;14(3):223–5

[Acute appendicitis in a patient with fibroma of the cecum] Kurguzov OP, et al. **Khirurgiia (Mosk)** 1995;(5):72–3 **(Rus)**

[Villous adenoma of the appendix caused acute appendicitis] Guliás Piñeiro A, et al. **Rev Esp Enferm Dig** 1996 Jun; 88(6):435–7 (Eng. Abstr.) **(Spa)**

GENETICS

Simultaneous acute appendicitis in monozygotic twins: coincidence or genetic? Gurbuz AT, et al. **Am Surg** 1996 May;62(5):407–8 (6 ref.)

METABOLISM

Plasminogen activator inhibitor-2 expression in inflamed appendix. Whawell SA, et al. **Histopathology** 1995 Jul; 27(1):75–8

Peritoneal interleukin-8 in acute appendicitis. Zeillemaker AM, et al. **J Surg Res** 1996 May;62(2):273–7

The activity of granulocyte alpha-amylase in acute appendicitis. Zakrzewska I, et al. **Rocz Akad Med Bialymst** 1994;39:81–5

MICROBIOLOGY

Appendicitis due to Mycobacterium avium complex in a patient with AIDS [letter] Domingo P, et al. **Arch Intern Med** 1996 May 27;156(10):1114

Granulomatous appendicitis in acute myeloblastic leukemia: expanding the clinicopathologic spectrum of invasive candidiasis. Moyana TN, et al. **Arch Pathol Lab Med** 1996 Feb;120(2):203–5

Appendicitis due to Mycobacterium avium complex in an adolescent infected with the human immunodeficiency virus [letter] Livingston RA, et al. **Clin Infect Dis** 1995 Jun;20(6):1579–80

PARASITOLOGY

Appendiceal colic caused by Enterobius vermicularis. Zoorob RJ. **J Am Board Fam Pract** 1996 Jan–Feb;9(1):57–9

PATHOLOGY

The retrocaecal appendix appears to be less prone to infection. Varshney S, et al. **Br J Surg** 1996 Feb;83(2):223–4

Appendicitis in Dar es Salaam, histological pattern. Mbembati NA, et al. **Cent Afr J Med** 1996 Mar;42(3):68–70

Is a histologically normal appendix following emergency appendicectomy alway normal? [see comments] Wang Y, et al. **Lancet** 1996 Apr 20;347(9008):1076–9. Comment in: Lancet 1996 Jul 13;348(9020):126–7.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10–1996. A 36-year-old man with right-lower-quadrant pain of two years' duration [clinical conference] **N Engl J Med** 1996 Mar 28; 334(13):849–54

[The ultrastructure of the epithelial endocrinocytes of the appendiceal mucosa in appendicitis patients] Kostiukevich SV. **Tsitologiia** 1996;38(2):115–8 (Eng. Abstr.) **(Rus)**

[Morphological analysis of reaction of the neuroendocrine apparatus of the appendix in different forms of appendicitis] Popovich IuL. **Klin Khir** 1995;(4):31–3 **(Ukr)**

RADIOGRAPHY

Plain radiography for diagnosis of gastrointestinal perforation in immune-compromised children—is it enough? Gilad E, et al. **Med Pediatr Oncol** 1995 Dec;25(6):470–2

[Laparoscopy for appendicular syndromes in young women. Results of a prospective study] Sfairi A, et al. **J Chir (Paris)** 1995 Aug-Sep;132(8–9):333–5 (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Failure of technetium-99m hexamethylpropylene amine oxime leukocyte scintigraphy in the evaluation of children with suspected appendicitis. Kanegaye JT, et al. **Pediatr Emerg Care** 1995 Oct;11(5):285–90

SURGERY

A clinical outcome and cost analysis of laparoscopic versus open appendectomy. McCahill LE, et al. **Am J Surg** 1996 May;171(5):533–7

A four-year experience with laparoscopy in the management of appendicitis. Panton ON, et al. **Am J Surg** 1996 May; 171(5):538–41

The long-term outcome after negative appendix operation. Miettinen P, et al. **Ann Chir Gynaecol** 1995;84(3):267–70

Acute appendicitis: does removal of a normal appendix matter, what is the value of diagnostic accuracy and is surgical delay important? [see comments] Walker SJ, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):358–63. Comment in: Ann R Coll Surg Engl 1996 Jan;78(1):73.

Laparoscopic appendectomy for complicated appendicitis. Frazee RC, et al. **Arch Surg** 1996 May;131(5):509–11; discussion 511–3

Pregnancies complicated by acute appendicitis. To WW, et al. **Aust N Z J Surg** 1995 Nov;65(11):799–803

Scrotal suppuration after appendicitis [letter] Pal KM. **Br J Clin Pract** 1995 Sep-Oct;49(5):279–80

Operative viva G. Meckel's diverticulum. Parks RW, et al. **Br J Hosp Med** 1996 Feb 21-Mar 5;55(4):176–7

'Residual' appendicitis following incomplete laparoscopic appendicectomy. Milne AA, et al. **Br J Surg** 1996 Feb; 83(2):217

Acute right iliac fossa pain in acquired immunodeficiency: a comparison between patients with and without acquired immune deficiency syndrome. Savioz D, et al. **Br J Surg** 1996 May;83(5):644–6

Residual appendicitis following incomplete laparoscopic appendectomy [letter] Somerville PG, et al. **Br J Surg** 1996 Jun;83(6):869

Laparoscopic appendectomy: a review of 95 consecutive suspected cases of appendicitis. Karim SS, et al. **Can J Surg** 1995 Oct;38(5):449–53

Acute appendicitis in Ethiopia. Kotisso B, et al. **East Afr Med J** 1996 Apr;73(4):251–2

Timing of antibiotic treatment in non-perforated gangrenous appendicitis. Almqvist P, et al. **Eur J Surg** 1995 Jun; 161(6):431–3

Laparoscopic surgery in pregnancy: report on two cases. Posta CG. **J Laparoendosc Surg** 1995 Jun;5(3):203–5

Bilateral ureteral obstruction after appendectomy in children. Hugen CA, et al. **J Pediatr Surg** 1995 Dec;30(12):1666–7

Early patient discharge following appendicectomy: safety and feasibility. Salam IM, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):300–2

Laparoscopic procedure for suspected appendicitis. A prospective study in 283 consecutive patients. Bouillot JL, et al. **Surg Endosc** 1995 Sep;9(9):957–60

Preoperative administration of antibiotics in patients with suspected acute appendicitis. Murao Y, et al. **Surg Today** 1996;26(5):314–22

Laparoscopic versus open appendectomy: prospective randomized trial. Hansen JB, et al. **World J Surg** 1996 Jan; 20(1):17–20; discussion 21

[Acute appendicitis: a serious disease in the elderly] Vermeulen MI, et al. **Ned Tijdschr Geneeskd** 1995 Aug 12;139(32):1635–8 (Eng. Abstr.) **(Dut)**

[Abdominal surgical emergencies in human immunodeficiency virus (HIV) infected patients. Apropos of 34 cases] Hammoud R, et al. **Ann Chir** 1995;49(10):922–7 (Eng. Abstr.) **(Fre)**

[Appendicitis and pregnancy. Seven case reports] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):411–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[Indications for celioscopic surgery in children (editorial)] Heloury Y. **Presse Med** 1995 Oct 14;24(30):1374–5 (9 ref.) **(Fre)**

[Acute appendicitis in patients over 70 years of age] Sfairi A, et al. **Presse Med** 1996 Apr 27;25(15):707–10 (Eng. Abstr.) **(Fre)**

["Open" versus laparoscopic appendectomy] Ablassmaier B, et al. **Chirurg** 1996 May;67(5):522–5; discussion 522 (Eng. Abstr.) **(Ger)**

[Laparoscopic versus conventional appendectomy: a prospective randomized study] Henle KP, et al. **Chirurg** 1996 May;67(5):526–30; discussion 522 (Eng. Abstr.) **(Ger)**

[A case of primary salpinx cancer—diagnostic difficulties] Błoch P, et al. **Ginekol Pol** 1995 Nov;66(11):646–8 (Eng. Abstr.) **(Pol)**

[A rare case of appendicitis in pregnancy] Dębniak B, et al. **Ginekol Pol** 1996 Jan;67(1):37–9 (Eng. Abstr.) **(Pol)**

[Endolymphatic therapy in the treatment of patients with acute appendicitis] Komarov NV, et al. **Klin Khir** 1996; (1):18–20 **(Rus)**

[Laparoscopic appendectomy in acute appendicitis] Kulik IaP, et al. **Vestn Khir Im I I Grek** 1995;154(2):34–6 (Eng. Abstr.) **(Rus)**

[Acute phlegmonous appendicitis in a patient with a strangulated diaphragmatic hernia] Levina ZI. **Vestn Khir Im I I Grek** 1992 Feb;148(2):170–1 **(Rus)**

THERAPY

Role of the primary care provider in expediting care of children with acute appendicitis. Chande VT, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):703–6

Management of complicated appendicitis. A rational approach based on clinical course. Keller MS, et al. **Arch Surg** 1996 Mar;131(3):261–4

Recent advances in the diagnosis and treatment of acute appendicitis. Calder JD, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):129–33 (24 ref.)

Randomized controlled trial of appendicectomy versus antibiotic therapy for acute appendicitis [letter; comment] Ozgüc H, et al. **Br J Surg** 1995 Sep;82(9):1284. Comment on: Br J Surg 1995 Feb;82(2):166–9.

Colonoscopic diagnosis and treatment of acute appendicitis. Said M, et al. **Eur J Gastroenterol Hepatol** 1995 Jun; 7(6):569–71

[Endolymphatic therapy in the treatment of patients with acute appendicitis] Komarov NV, et al. **Klin Khir** 1996; (1):53 **(Rus)**

ULTRASONOGRAPHY

Ultrasonography to evaluate adults for appendicitis: decision making based on meta-analysis and probabilistic reasoning. Orr RK, et al. **Acad Emerg Med** 1995 Jul;2(7):644–50

Laboratory aid and ultrasonography in the diagnosis of appendicitis in children. Ko YS, et al. **Acta Paediatr Sin** 1995 Nov-Dec;36(6):415–9

Appendicitis in children and young adults: Doppler sonographic-pathologic correlation. Patriquin HB, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):629–33

Sonographic differential diagnosis of right lower quadrant pain other than appendicitis. Jain KA, et al. **Clin Imaging** 1996 Jan-Mar;20(1):12–6

Ultrasound in the differential diagnosis of appendicitis. Simonovský V. **Clin Radiol** 1995 Nov;50(11):768–73

Subhepatic appendix with fecalith mimicking acute cholecystitis with gallstone. Patel NR, et al. **J Clin Ultrasound** 1996 Jan;24(1):45–7

Degenerated uterine leiomyoma mimicking acute appendicitis: sonographic diagnosis. Yacoe ME, et al. **J Clin Ultrasound** 1995 Oct;23(8):473–5

Ultrasonography as an adjunct in the diagnosis of acute appendicitis: a 4-year experience. Ramachandran P, et al. **J Pediatr Surg** 1996 Jan;31(1):164–7; discussion 167–9

Focal appendicitis confined to the tip: diagnosis at US. Lim HK, et al. **Radiology** 1996 Sep;200(3):799–801

Ultrasonography in the management of acute appendicitis. Rossi P, et al. **Surg Endosc** 1996 Jun;10(6):619–21

[Value of ultrasound in diagnosis of acute appendicitis] Zoller WG, et al. **Bildgebung** 1996 Jun;63(2):78–82 (38 ref.) (Eng. Abstr.) **(Ger)**

[Ultrasound diagnosis of acute appendicitis—possibilities and limits of the method—results of prospective and retrospective clinical studies] Uebel P, et al. **Ultraschall Med** 1996 Jun;17(3):100–5 (Eng. Abstr.) **(Ger)**

APPENDIX

see related
APPENDECTOMY

Appendiceal mucocele: sonographic and MR imaging findings [letter] Koga H, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1552

Intussusception of the appendix due to endometriosis. Panzer S, et al. **Am J Gastroenterol** 1995 Oct;90(10):1892–3

Appendiceal endometriosis presenting as massive lower intestinal hemorrhage [see comments] Shome GP, et al. **Am J Gastroenterol** 1995 Oct;90(10):1881–3. Comment in: Am J Gastroenterol 1996 Jun;91(6):1280–1.

Appendiceal mass. interval appendicectomy should not be the rule. Adalla SA. **Br J Clin Pract** 1996 Apr-May; 50(3):168–9

Drain-site herniation of the appendix. O'Riordan DC, et al. **Br J Surg** 1995 Dec;82(12):1628

Incidental appendicectomy for the long mobile appendix. Wheeler JM, et al. **Br J Surg** 1996 Apr;83(4):498

A simple device in the prevention of recurrent appendico-umbilical stenosis. Köhl U, et al. **Br J Urol** 1996 Apr;77(4):603–4

Colonic carcinoma presenting as an appendiceal abscess in a young woman. Ramsay JA, et al. **Can J Surg** 1996 Feb; 39(1):53–6

Elective interval laparoscopic management for periappendiceal abscess. Hsia CY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Jul;56(1):52–7

Intestinal stricturing as a late presentation of appendiceal abscess. Tasker AD, et al. **Clin Radiol** 1995 Sep;50(9):644–6

Laparoscopic appendicectomy in the management of acute lower gastrointestinal bleeding. So JB, et al. **Gastrointest Endosc** 1995 Nov;42(5):488–9

Appendicovesical fistula. Athanassopoulos A, et al. **Int Urol Nephrol** 1995;27(6):705–8 (9 ref.)

Foreign-body appendicitis. Sukhotnik I, et al. **J Pediatr Surg** 1995 Oct;30(10):1515–6

Foreign bodies of dental origin in the appendix. Mellor TK, et al. **J R Army Med Corps** 1995 Oct;141(3):174–6 (25 ref.)

External abdominal hernia of mucocele of the appendix in drain-tube removal site. Bacchin P, et al. **Radiol Med (Torino)** 1995 Dec;90(6):827–9 (13 ref.)

Appendical fistulae formation as a complication of primary Crohn's disease prior to surgical management: report of a case. Morita H, et al. **Surg Today** 1996;26(5):340–4

[Invagination of vermiform appendix in an asymptomatic adult: a case report] Hsiaw C, et al. **Chang Keng I Hsueh** 1995 Sep;18(3):301–4 (Eng. Abstr.) **(Chi)**

[Calculosis of the appendix: report of a case] Troiani F, et al. **G Chir** 1995 Jun-Jul;16(6–7):293–6 **(Ita)**

[Appendiceal mucocele: diagnosis by echography, spiral computed tomography and magnetic resonance] Bertolotto M, et al. **Radiol Med (Torino)** 1995 Dec;90(6):829–32 (6 ref.) **(Ita)**

[Current possibilities in the diagnosis and treatment of appendiceal mucocele] Fedorov VD, et al. **Khirurgiia (Mosk)** 1996;(1):27–8 (10 ref.) (Eng. Abstr.) **(Rus)**

[Idiopathic granulomatous appendicitis or Crohn's disease confined to the appendix?] De Fuenmayor Valera ML, et al. **Rev Esp Enferm Dig** 1995 Dec;87(12):885–8 (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Duplication of appendix with segmental dilatation of the colon, myeloschisis and anal atresia. Rizalar R, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):112–3

Delayed separation of an appendix-containing umbilical stump. Borgna-Pignatti C, et al. **J Pediatr Surg** 1995 Dec; 30(12):1717–8

Clinical presentation of rare appendiculo-omphalic anomalies. Zaidenstein L, et al. **J Pediatr Surg** 1995 Dec; 30(12):1702–3

[Acute left-side appendicitis: diagnostic contribution of tomodensitometry] Nisolle JF, et al. **Arch Pediatr** 1996 Jan; 3(1):47–50 (Eng. Abstr.) **(Fre)**

[Absence of the appendix] Kalyshev IuG, et al. **Klin Khir** 1995;(7–8):49 **(Rus)**

[Rare anomalies in the development of the appendix] Drino E, et al. **Acta Chir Iugosl** 1991;38(1):103–11 (Eng. Abstr.) **(Ser)**

BLOOD SUPPLY

Venous hemangioma of the mesoappendix: report of a case and a brief review of the Japanese literature. Hanatate F, et al. **Surg Today** 1995;25(11):962–4 (8 ref.)

Strangulation of the appendix in a femoral hernia sac. Weir CD, et al. **Ulster Med J** 1994 Apr;63(1):114–5

CHEMISTRY

Is a histologically normal appendix following emergency appendicectomy alway normal? [see comments] Wang Y, et al. **Lancet** 1996 Apr 20;347(9008):1076–9. Comment in: Lancet 1996 Jul 13;348(9020):126–7.

CYTOLOGY

Microdissected domes from gut-associated lymphoid tissues: a model of M cell transepithelial transport in vitro. Kabok Z, et al. **Adv Exp Med Biol** 1995;371A:235–8

IMMUNOLOGY

Expression of VLA-4 and L-selectin in human gut-associated lymphoid tissue (GALT). Farstad IN, et al. **Adv Exp Med Biol** 1995;371A:91–6

INNERVATION

[Morphological analysis of reaction of the neuroendocrine apparatus of the appendix in different forms of appendicitis] Popovich IuL. **Klin Khir** 1995;(4):31–3 **(Ukr)**

MICROBIOLOGY

Appendicectomy [letter; comment] Puylaert JB. **Lancet** 1996 Jul 13;348(9020):126–7. Comment on: Lancet 1996 Apr 20;347(9008):1076–9.

PATHOLOGY

Fine needle aspiration cytology of appendiceal mucinous cystadenoma: a case report. Zuzarte JC, et al. **Acta Cytol** 1996 Mar-Apr;40(2):327–30

The retrocaecal appendix appears to be less prone to infection. Varshney S, et al. **Br J Surg** 1996 Feb;83(2):223–4

Laparoscopic removal of an abdominal pregnancy adherent to the appendix after ovulation induction with human menopausal gonadotrophin. Ben-Rafael Z, et al. **Hum Reprod** 1995 Jul;10(7):1804–5

APPENDIX

Idiopathic granulomatous appendicitis. Report of five cases, one of which presented as migratory arthritis. Naschitz JE, et al. **J Clin Gastroenterol** 1995 Dec;21(4):290–4
Intussusception of the appendix: a report of three cases with different clinical and pathologic features. Sakaguchi N, et al. **Pathol Int** 1995 Oct;45(10):757–61
[Pathology of the cecal appendix in our country. An analysis of 936 surgical specimens of appendectomy] Ross E, et al. **G E N** 1995 Apr–Jun;49(2):140–4 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Appendiceal colic in children: a true clinical entity? Gorenstin A, et al. **J Am Coll Surg** 1996 Mar;182(3):246–50
Role of appendix in the development of inflammatory bowel disease in TCR–alpha mutant mice. Mizoguchi A, et al. **J Exp Med** 1996 Aug 1;184(2):707–15

RADIOGRAPHY

Epiploic appendicitis: ultrasound and CT characteristics. Rutten MJ, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Mar;164(3):264–5 (6 ref.)
[Mucocele of the appendix: value of excision by celioscopy] Sfairi A, et al. **J Chir (Paris)** 1995 Oct;132(10):403–5 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Epiploic appendicitis: ultrasound and CT characteristics. Rutten MJ, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Mar;164(3):264–5 (6 ref.)

ULTRASTRUCTURE

[The ultrastructure of the epithelial endocrinocytes of the appendiceal mucosa in appendicitis patients] Kostiukevich SV. **Tsitologiia** 1996;38(2):115–8 (Eng. Abstr.) **(Rus)**
[The ultrastructure of the epithelial endocrinocytes of the appendiceal mucosa in the human fetus] Kostiukevich SV. **Tsitologiia** 1995;37(3):187–92 (Eng. Abstr.) **(Rus)**

APPETITE

see related

APPETITE DEPRESSANTS

Immediate acceptance of minerals and HCl by calcium–deprived rats: brief exposure tests. Coldwell SE, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R11–7
Food and general neophobia in Swedish families: parent–child comparisons and relationships with serving specific foods. Koivisto UK, et al. **Appetite** 1996 Apr; 26(2):107–18
Regulation of angiotensinogen gene expression in the rat forebrain by adrenal steroids and relation to salt appetite. Riftina F, et al. **Brain Res Mol Brain Res** 1995 Nov; 33(2):201–8
Food craving during the menstrual cycle and its relationship to stress, happiness of relationship and depression; a preliminary enquiry. Dye L, et al. **J Affect Disord** 1995 Jun 8;34(3):157–64
The effect of KT/V(urea) on nitrogen appearance and appetite in peritoneal dialysis. Lynn RI, et al.
Perit Dial Int 1995;15(5 Suppl):S50–2
[Regulation of food intake and appetite: overview] Aou S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:13–8 (23 ref.) **(Jpn)**

DRUG EFFECTS

Effects of amylin on appetite regulation and memory. Morley JE, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1042–6 (60 ref.)
Resistant starch has little effect on appetite, food intake and insulin secretion of healthy young men. de Roos N, et al. **Eur J Clin Nutr** 1995 Jul;49(7):532–41
Fenfluramine's appetite suppression and serotonin neurotoxicity are separable. McCann UD, et al.
Eur J Pharmacol 1995 Sep 5;283(1–3):R5–7
Effect of sucrose and sweeteners on appetite and energy intake. Blundell JE, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 2:S12–7 (46 ref.)
Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced–stage non–hormone–sensitive cancer: a placebo–controlled multicenter study. Simons JP, et al. **J Clin Oncol** 1996 Apr; 14(4):1077–84
Role of peripheral angiotensin in salt appetite of the sodium–deplete rat. Thunhorst RL.
Neurosci Biobehav Rev 1996;20(1):101–6 (33 ref.)
Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Levin N, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1726–30
Appetite–suppressing effects of urocortin, a CRF–related neuropeptide. Spina M, et al. **Science** 1996 Sep 13; 273(5281):1561–4
Circadian anorectic effects of peripherally administered amylin in rats. Lutz TA, et al. **Z Ernahrungswiss** 1995 Sep; 34(3):214–9

PHYSIOLOGY

Acceptance of minerals and other compounds by calcium–deprived rats: 24–h tests. Coldwell SE, et al.
Am J Physiol 1996 Jul;271(1 Pt 2):R1–10
Effects of weight and energy content of preloads on subsequent appetite and food intake. de Graaf C, et al.
Appetite 1996 Apr;26(2):139–51
Impact of peritoneal absorption of glucose on appetite, protein catabolism and survival in CAPD patients. Davies SJ, et al. **Clin Nephrol** 1996 Mar;45(3):194–8
Techniques for the experimental measurement of human eating behaviour and food intake: a practical guide. Hill AJ, et al. **Int J Obes Relat Metab Disord** 1995 Jun; 19(6):361–75 (91 ref.)
Determinants of postprandial appetite sensations: macronutrient intake and glucose metabolism. Raben A, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20(2):161–9
Macronutrient effects on appetite. Stubbs RJ.
Int J Obes Relat Metab Disord 1995 Nov;19 Suppl 5:S11–9 (54 ref.)
Delaying the introduction of complementary food until 6 months does not affect appetite or mother's report of food acceptance of breast–fed infants from 6 to 12 months in a low income, Honduran population. Cohen RJ, et al.
J Nutr 1995 Nov;125(11):2787–92
The association of thirst, sodium appetite and vasopressin release with c–fos expression in the forebrain of the rat after intracerebroventricular injection of angiotensin II, angiotensin–(1–7) or carbachol. Mahon JM, et al.
Neuroscience 1995 Nov;69(1):199–208
Sympathetic nervous system influences salt appetite in four strains of rats. Bourjeili N, et al. **Physiol Behav** 1995 Sep; 58(3):437–43
Food intake and the menstrual cycle: a retrospective analysis, with implications for appetite research. Buffenstein R, et al. **Physiol Behav** 1995 Dec;58(6):1067–77 (142 ref.)
Behaviorally conditioned anorexia: role of gastric emptying and prostaglandins. Exton MS, et al. **Physiol Behav** 1995 Sep;58(3):471–6
Effect of peptide YY (PYY) on food–associated conflict. Hagan MM, et al. **Physiol Behav** 1995 Oct;58(4):731–5
[Progress in research on the central mechanism of feeding behavior—neuronal network] Oomura Y, et al.
Nippon Rinsho 1995 Jun;53 Suppl:585–96 (20 ref.) **(Jpn)**
[Role of cytokines in regulation of food intake and appetite] Shimizu H. **Nippon Rinsho** 1995 Jun;53 Suppl:58–63 (39 ref.) **(Jpn)**

APPETITE DEPRESSANTS

Tolerance to appetite suppression induced by peptidoglycan. Biberstine KJ, et al. **Infect Immun** 1996 Sep;64(9):3641–5
Cytokines and feeding suppression: an integrative view from neurologic to molecular levels. Plata–Salamán CR.
Nutrition 1995 Sep–Oct;11(5 Suppl):674–7 (26 ref.)

ADVERSE EFFECTS

Dilated cardiomyopathy associated with chronic consumption of phendimetrazine. Rostagno C, et al.
Am Heart J 1996 Feb;131(2):407–9
Phenylpropanolamine and associated myocardial injury. Leo PJ, et al. **Ann Emerg Med** 1996 Sep;28(3):359–62
Appetite suppressants and primary pulmonary hypertension in the United Kingdom. Thomas SH, et al. **Br Heart J** 1995 Dec;74(6):660–3
Urticarial vasculitis induced by centrally acting appetite suppressants [letter] Papadavid E, et al. **Br J Dermatol** 1996 May;134(5):990–1
A toxic reaction from combining fluoxetine and phentermine [letter] Bostwick JM, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):189–90
Appetite–suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group [see comments] Abenhaim L, et al. **N Engl J Med** 1996 Aug 29;335(9):609–16. Comment in: N Engl J Med 1996 Aug 29;335(9):659–60.
Bilateral acute angle–closure glaucoma after dexfenfluramine treatment. Denis P, et al. **Ophthalmologica** 1995; 209(4):223–4
[Iatrogenic pulmonary artery hypertension] Weitzenblum E, et al. **Rev Mal Respir** 1996;13(2):133–9 (32 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. Gross AS, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):311–7
Contribution to characterization of anorectic protein similar to satietin from urine. Maletinská L, et al.
Pharmacol Biochem Behav 1995 Dec;52(4):715–21

PHARMACOKINETICS

N–docosahexaenoyl, 3 hydroxytyramine: a dopaminergic compound that penetrates the blood–brain barrier and suppresses appetite. Shashoua VE, et al. **Life Sci** 1996; 58(16):1347–57

PHARMACOLOGY

Long–term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss. Breum L, et al. **Int J Obes Relat Metab Disord** 1996 Feb; 20(2):147–53
Dexfenfluramine inhibits catecholamine stimulated in vitro lipolysis in human fat cells. Richter WO, et al.
Int J Obes Relat Metab Disord 1995 Jul;19(7):503–5
Devazepide reverses the anorexic effect of simmondsin in the rat. Cokelaere MM, et al. **J Endocrinol** 1995 Dec; 147(3):473–7
Ciclazindol inhibits ATP–sensitive K+ channels and stimulates insulin secretion in CR1–G1 insulin–secreting cells. Lee K, et al. **Mol Pharmacol** 1996 Apr;49(4):715–20
Hepatic vagus does not mediate IL–1 alpha induced anorexia. Laviano A, et al. **Neuroreport** 1995 Jul 10;6(10):1394–6
Biological actions of drugs affecting serotonin and eating. Garattini S. **Obes Res** 1995 Nov;3 Suppl 4:463S–470S (65 ref.)
Metergoline potentiates natural feeding and antagonizes the anorectic action of medical hypothalamic 5–hydroxytryptamine. Currie PJ, et al.
Pharmacol Biochem Behav 1996 Apr;53(4):1023–8
Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus–maze. Rodgers RJ, et al. **Pharmacol Biochem Behav** 1995 Dec; 52(4):805–13
Effect of amphetamine on behavior maintained by sucrose: interaction of reinforcement schedule and food restriction. Slawecki CJ, et al. **Pharmacol Biochem Behav** 1996 Jul; 54(3):595–600
Effect of amphetamine on human macronutrient intake. Foltin RW, et al. **Physiol Behav** 1995 Nov;58(5):899–907
Influence of social dominance on self–stimulation behavior in male golden hamsters. Kureta Y, et al.
Physiol Behav 1996 Apr–May;59(4–5):621–4
Effects of systemic phenylpropanolamine and fenfluramine on serotonin activity within rat paraventricular hypothalamus. McMahon LR, et al. **Physiol Behav** 1996 Jan;59(1):63–9
Effect of dexfenfluramine on metabolic and neurochemical measures in restraint–stressed ob/ob mice. Rowland NE, et al. **Physiol Behav** 1995 Oct;58(4):749–54
Appetite–suppressing effects of urocortin, a CRF–related neuropeptide. Spina M, et al. **Science** 1996 Sep 13; 273(5281):1561–4

POISONING

Adverse events associated with ephedrine–containing products—Texas, December 1993–September 1995.
MMWR Morb Mortal Wkly Rep 1996 Aug 16; 45(32):689–93

STANDARDS

Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. Spring B, et al.
Am J Clin Nutr 1995 Dec;62(6):1181–7

THERAPEUTIC USE

Diethylpropion pharmacotherapeutic adjuvant therapy for inpatient treatment of cocaine dependence: a test of the cocaine–agonist hypothesis. Alim TN, et al.
Clin Neuropharmacol 1995 Apr;18(2):183–95
Appetite suppressants as adjuncts in the treatment of obesity. Elks ML. **J Fam Pract** 1996 Mar;42(3):287–92 (57 ref.)
From the Food and Drug Administration. Nightingale SL.
JAMA 1996 Jul 3;276(1):14
Pantothenic acid as a weight–reducing agent: fasting without hunger, weakness and ketosis. Leung LH.
Med Hypotheses 1995 May;44(5):403–5
Pharmacotherapy for obesity — do the benefits outweigh the risks? [editorial; comment] Manson JE, et al.
N Engl J Med 1996 Aug 29;335(9):659–60. Comment on: N Engl J Med 1996 Aug 29;335(9):609–16.
Conflicts of interest—editorialists respond [letter; comment] Manson JE, et al. **N Engl J Med** 1996 Oct 3;335(14):1064–5 . Comment on: N Engl J Med 1996 Oct 3;335(14):1055–6.
Anorexic medications to treat obesity [letter] Donckers SW.
Nurse Pract 1996 Apr;21(4):13–4
Dexfenfluramine and abdominal visceral fat [editorial; comment] Bouchard C. **Obes Res** 1996 Jan;4(1):77–9. Comment on: Obes Res 1996 Jan;4(1):1–7.
Clinical studies with dexfenfluramine: from past to future. Guy–Grand B. **Obes Res** 1995 Nov;3 Suppl 4:491S–496S (34 ref.)
Clinical studies with mazindol. Inoue S. **Obes Res** 1995 Nov; 3 Suppl 4:549S–552S (11 ref.)
Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM [see comments] Marks SJ, et al. **Obes Res** 1996 Jan;4(1):1–7 . Comment in: Obes Res 1996 Jan;4(1):77–9.
Sibutramine: a novel new agent for obesity treatment. Ryan DH, et al. **Obes Res** 1995 Nov;3 Suppl 4:553S–559S (29 ref.)
Effects of mazindol in two patients with Prader–Willi syndrome. Itoh M, et al. **Pediatr Neurol** 1995 Nov; 13(4):349–51
Somatometric and hormonal effects of dexfenfluramine. Sonka J, et al. **Sb Lek** 1995;96(4):299–301
[Anorexics in the treatment of eating disorders] Faltus F, et al. **Ceska Slov Psychiatr** 1995 Nov;91(5):291–8 (47 ref.) **(Cze)**
[Drug treatment of obesity] Meinders AE, et al.
Ned Tijdschr Geneeskd 1996 Aug 10;140(32):1632–4 (22

ref.) **(Dut)**

[Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice] Geyer G, et al. **Acta Med Austriaca** 1995;22(5):95–101; 104–9 (Eng. Abstr.) **(Ger)**

[The treatment of the obese non–insulin–dependent patient with d–fenfluramine] Daniele E, et al. **Clin Ter** 1996 Apr; 147(4):199–204 (Eng. Abstr.) **(Ita)**

[Therapy of obesity using appetite depressants] Ikeda Y. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1290–4 (4 ref.) **(Jpn)**

[Effectiveness of serotonergic agonists in the treatment of obese patients] Mendoza Espejo R, et al. **Aten Primaria** 1995 Oct 15;16(6):364–6 (Eng. Abstr.) **(Spa)**

[Anorexigenic drugs in the treatment of obesity] Maiz A, et al. **Rev Med Chil** 1995 May;123(5):637–40 (Eng. Abstr.) **(Spa)**

TOXICITY

Antioxidant defense in rat brain after chronic treatment with anorectic drugs. D'Almeida V, et al. **Toxicol Lett** 1995 Nov 15;81(2–3):101–5

APPETITE DISORDERS see **EATING DISORDERS**

APPETITE REGULATION

Cognitive factors in the dietary response of restrained and unrestrained eaters to manipulation of the fat content of a dish. Chapelot D, et al. **Appetite** 1995 Oct;25(2):155–75

Meal pattern during the transient hypophagia of rats switched from a high fat to a high carbohydrate diet. Del Prete E, et al. **Appetite** 1995 Oct;25(2):133–41

Consistency of liking and appropriateness ratings and their relation to consumption in a product test of ice cream. Lähteenmäki L, et al. **Appetite** 1995 Oct;25(2):189–97

Restrained eating and dieting: replication of their divergent effects on eating regulation. Lowe MR. **Appetite** 1995 Oct; 25(2):115–8

Food preferences and desire to eat in anorexia and bulimia nervosa. Stoner SA, et al. **Int J Eat Disord** 1996 Jan; 19(1):13–22

Neural control of dieting [letter; comment] Spedding M, et al. **Nature** 1996 Apr 11;380(6574):488. Comment on: Nature 1995 Apr 6;374(6522):542–6.

Cytokines and feeding suppression: an integrative view from neurologic to molecular levels. Plata–Salamán CR. **Nutrition** 1995 Sep–Oct;11(5 Suppl):674–7 (26 ref.)

[Etiology and physiopathology of obesity: mechanism of appetite control] Inokuchi T. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1221–5 (5 ref.) **(Jpn)**

DRUG EFFECTS

Replacement of dietary fat with sucrose polyester: effects on energy intake and appetite control in nonobese males. Cotton JR, et al. **Am J Clin Nutr** 1996 Jun;63(6):891–6

Dehydroepiandrosterone and macronutrient selection by obese Zucker rats (fa/fa). Svec F, et al. **Appetite** 1995 Oct; 25(2):143–54

Fat substitution and food intake: effect of replacing fat with sucrose polyester at lunch or evening meals. Cotton JR, et al. **Br J Nutr** 1996 Apr;75(4):545–56

Effects of cisapride on gastric emptying of oil and aqueous meal components, hunger, and fullness. Jones KL, et al. **Gut** 1996 Mar;38(3):310–5

PHYSIOLOGY

Excitotoxic lesions of the parabrachial nuclei prevent conditioned taste aversions and sodium appetite in rats. Scalera G, et al. **Behav Neurosci** 1995 Oct;109(5):997–1008

An analysis of excessive running in the development of activity anorexia. Beneke WM, et al. **Physiol Behav** 1995 Sep;58(3):451–7

[Cyclic enteral nutrition] Hébuterne X, et al. **Presse Med** 1996 Feb 10;25(5):202–6 (30 ref.) (Eng. Abstr.) **(Fre)**

APPETITE SUPPRESSANTS see **APPETITE DEPRESSANTS**

APPETITIVE BEHAVIOR

see related
CEREMONIAL

Potential stock differences in the social behavior of rats in a situation of restricted access to food. Helder R, et al. **Behav Genet** 1995 Sep;25(5):483–7

Overt orienting in the rat: parametric studies of cued detection of visual targets. Bushnell PJ. **Behav Neurosci** 1995 Dec;109(6):1095–105

Computational and entrainment models of circadian food–anticipatory activity: evidence from non–24–hr feeding schedules. Mistlberger RE, et al. **Behav Neurosci** 1995 Aug;109(4):790–8

Measures of cocaine–seeking behavior using a multiple schedule of food and drug self–administration in rats. Weissenborn R, et al. **Drug Alcohol Depend** 1995 Jun; 38(3):237–46

Chaser (Csr), a new gene affecting larval foraging behavior in Drosophila melanogaster. Pereira HS, et al. **Genetics** 1995 Sep;141(1):263–70

Patterns of individual diet choice and efficiency of foraging in wedge–capped capuchin monkeys (Cebus olivaceus). Fragaszy DM, et al. **J Comp Psychol** 1995 Dec; 109(4):339–48

Concurrent–schedule performance in dairy cows: persistent undermatching. Foster TM, et al. **J Exp Anal Behav** 1996 Jan;65(1):57–80

Procrastination by pigeons: preference for larger, more delayed work requirements. Mazur JE. **J Exp Anal Behav** 1996 Jan;65(1):159–71

Choice with certain and uncertain reinforcers in an adjusting–delay procedure. Mazur JE. **J Exp Anal Behav** 1996 Jul;66(1):63–73

Effects of food–pellet size on rate, latency, and topography of autoshaped key pecks and gapes in pigeons. Ploog BO, et al. **J Exp Anal Behav** 1996 Jan;65(1):21–35

Representing within–session response rates proportionally and entirely. Schaal DW. **J Exp Anal Behav** 1996 Jul; 66(1):135–41

Decremental carryover effects of sucrose ingestion in the negative anticipatory contrast procedure in rats. Timberlake W, et al. **J Exp Psychol Anim Behav Process** 1995 Oct;21(4):304–17

Short–term evaluation of a foraging device for non–human primates. Holmes SN, et al. **Lab Anim** 1995 Oct;29(4):364–9

Effects of delay of reinforcement with reduction of confinement in the goal–box and elimination of handling immediately following runway traversal. Calef RS, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1147–51

DRUG EFFECTS

Specific effects of idazoxan in a distraction task: evidence that endogenous norepinephrine plays a role in selective attention in rats. Bunsey MD, et al. **Behav Neurosci** 1995 Oct;109(5):903–11

Cocaine and food deprivation: effects on food–reinforced fixed–ratio performance in pigeons. Hughes CE, et al. **J Exp Anal Behav** 1996 Jan;65(1):145–58

Nicotine as a discriminative stimulus: a neurobiobehavioral approach to studying central cholinergic mechanisms. Rosecrans JA. **J Subst Abuse** 1989;1(3):287–300

Blockade of the discriminative stimulus effects of gamma–hydroxybutyric acid (GHB) by the GHB receptor antagonist NCS–382. Colombo G, et al. **Physiol Behav** 1995 Sep;58(3):587–90

Methotrexate does not interfere with an appetitive Pavlovian conditioning task in Sprague–Dawley rats. Stock HS, et al. **Physiol Behav** 1995 Nov;58(5):969–73

PHYSIOLOGY

Acquisition, retention, and extinction of operant discriminations in rats with nucleus basalis magnocellularis lesions. Butt AE, et al. **Behav Neurosci** 1995 Aug; 109(4):699–713

Temporal integration in self–stimulation: a paradox lost? Fouriezos G. **Behav Neurosci** 1995 Oct;109(5):965–71

Spatial learning and memory as a function of age in the dog. Head E, et al. **Behav Neurosci** 1995 Oct;109(5):851–8

The NMDA antagonist MK–801 affects nonspatial learning in preweanling rats. Highfield DA, et al. **Behav Neurosci** 1996 Apr;110(2):300–4

Dissociations between appetitive and consummatory responses by pharmacological manipulations of reward–relevant brain regions. Ikemoto S, et al. **Behav Neurosci** 1996 Apr;110(2):331–45

HemiParkinson analogue rats display active support in good limbs versus passive support in bad limbs on a skilled reaching task of variable height. Miklyaeva EI, et al. **Behav Neurosci** 1996 Feb;110(1):117–25

Functional differences between the prelimbic and anterior cingulate regions of the rat prefrontal cortex. Seamans JK, et al. **Behav Neurosci** 1995 Dec;109(6):1063–73

Differences in hippocampal volume among food storing corvids. Basil JA, et al. **Brain Behav Evol** 1996;47(3):156–64

Instrumental learning in toads (Bufo arenarum): reinforcer magnitude and the medial pallium. Papini MR, et al. **Brain Behav Evol** 1995;46(2):61–71

Preferential activation of midbrain dopamine neurons by appetitive rather than aversive stimuli. Mirenowicz J, et al. **Nature** 1996 Feb 1;379(6564):449–51

Patterns of feeding and behaviour in horses recovering from dysautonomia (grass sickness). Doxey DL, et al. **Vet Rec** 1995 Aug 19;137(8):181–3

APPLE see **FRUIT**

APPOINTMENTS AND SCHEDULES

Pre–operative anxiety. Effect of early or late position on the operating list. Panda N, et al. **Anaesthesia** 1996 Apr; 51(4):344–6

Decreases in anesthesia–controlled time cannot permit one additional surgical operation to be reliably scheduled during the workday [see comments] Dexter F, et al. **Anesth Analg** 1995 Dec;81(6):1263–8. Comment in: Anesth Analg 1996 Jul;83(1):194.

Flexible coordination allows more cases [letter; comment] Johnstone RE. **Anesth Analg** 1996 Jul;83(1):194. Comment on: Anesth Analg 1995 Dec;81(6):1263–8.

Clinic follow–up from the emergency department: do patients show up? Murray MJ, et al. **Ann Emerg Med** 1996 Jan; 27(1):56–8

Application of prediction levels to OR scheduling. Dexter F. **AORN J** 1996 Mar;63(3):607–15

Patient characteristics affecting attendance at general outpatient clinics. McClure RJ, et al. **Arch Dis Child** 1996 Feb;74(2):121–5

Noncompliance with scheduled revisits to a pediatric emergency department. Scarfone RJ, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):948–53

A randomised controlled trial comparing two schedules of antenatal visits: the antenatal care project [see comments] Sikorski J, et al. **BMJ** 1996 Mar 2;312(7030):546–53. Comment in: BMJ 1996 Mar 2;312(7030):524–5. Comment in: BMJ 1996 Jul 20;313(7050):167; discussion 169. Comment in: BMJ 1996 Jul 20;313(7050):167–8; discussion 169. Comment in: BMJ 1996 Jul 20;313(7050):168; discussion 169.

Reducing patient waiting times through quality assurance methods in La Troncal, Ecuador. Hermida J, et al. **Bull Pan Am Health Organ** 1996 Jun;30(2):118–24

Validation of an algorithm for oral anticoagulant dosing and appointment scheduling. Vadher BD, et al. **Clin Lab Haematol** 1995 Dec;17(4):339–45

Case manager follow–up to failed appointments and subsequent service utilization. Blank MB, et al. **Community Ment Health J** 1996 Feb;32(1):23–31

Diurnal non–stress test variations in healthy term fetuses. A call for evening appointments for fetal testing. Petrikovsky BM, et al. **Early Hum Dev** 1996 Feb 23;44(2):127–30

An audit of medical paediatric out–patient appointments and letters. Brown DC, et al. **Health Bull (Edinb)** 1995 Sep; 53(5):269–73

Customer service. Timeliness is next to godliness. Appleby C. **Hosp Health Netw** 1996 Aug 5;70(15):40

An audit study of defaulters of regular psychiatric outpatient appointments in Hong Kong. Pang AH, et al. **Int J Soc Psychiatry** 1995 Summer;41(2):103–7

Short or long consultations? Primary care nurses' considerations in making appointments with general practitioners. Andersson SO, et al. **J Adv Nurs** 1995 Oct; 22(4):759–68

Managed delay for coronary artery bypass graft surgery: the experience at one Canadian center. Cox JL, et al. **J Am Coll Cardiol** 1996 May;27(6):1365–73

Telephone planning: the key to improved patient service and reduced stress. de St. Georges JM. **J Am Dent Assoc** 1995 Oct;126(10):1434–7

Risk factors for appointment failures in a geriatric outpatient clinic [letter] Martin AI. **J Am Geriatr Soc** 1995 Dec; 43(12):1446–7

Resource management in dental practice. Ringenberg T. **J Dent Educ** 1996 Jan;60(1):24–7

Physician ability to predict appointment–keeping behavior of prenatal patients. Feierabend RH. **J Fam Pract** 1996 May;42(5):482–6

Effects of an appointment reminder call on patient show rates. Gariti P, et al. **J Subst Abuse Treat** 1995 May–Jun; 12(3):207–12

Waiting times for non–urgent specialist appointments [letter; comment] Rogers JH, et al. **Med J Aust** 1995 Sep 18; 163(6):336. Comment on: Med J Aust 1995 Jun 19;162(12):648–9.

A surgical process management tool. Blake J, et al. **Medinfo** 1995;8 Pt 1:527–31

Dynamic systems analysis for better hospital bed operation: using time series model. Kim MK. **Medinfo** 1995;8 Pt 1:532–6

Waiting in the emergency department. Havill JH, et al. **N Z Med J** 1996 May 10;109(1021):159–61

Follow–up appointment compliance of discharged patients from a pediatric emergency department [letter] Polacek TL, et al. **Nurse Pract** 1996 Mar;21(3):150, 152–3

The impact of mailing fecal occult blood test kits on return rate in a community cancer screening center. Mahon SM. **Oncol Nurs Forum** 1995 Sep;22(8):1259–63

Patient impatience can cost your practice business. Bernet PM. **Pa Med** 1995 Nov;98(11):40

Charging for missed sessions: ethical problem or straw person? [comment] Fay A. **Psychol Rep** 1996 Jun;78(3 Pt 1):924–6. Comment on: Psychol Rep 1996 Jun;78(3 Pt 1):881–2.

Ethical implications of charging for missed sessions. Fay A. **Psychol Rep** 1995 Dec;77(3 Pt 2):1251–9

Revisiting fee policies [see comments] Herron WG. **Psychol Rep** 1996 Jun;78(3 Pt 1):881–2. Comment in: Psychol Rep 1996 Jun;78(3 Pt 1):924–6.

Client characteristics associated with not keeping appointments for public health nursing home visits. Josten LE, et al. **Public Health Nurs** 1995 Oct;12(5):305–11

A quality assurance manager's perspective on in–life inspections. Streeton RL Jr. **Qual Assur** 1995 Jun; 4(2):117–9

Acuity scheduling systems: a case study in radiology. Maddala T. **Radiol Technol** 1996 May–Jun;67(5):415–20

[Prior appointment, profile of the patient and accessibility] Gómez–Calcerrada D, et al. **Aten Primaria** 1996 Mar 15; 17(4):288–91 (Eng. Abstr.) **(Spa)**

[Causes of non–compliance and associated factors in non–attendance of scheduled consultation] Sánchez Muñoz C, et al. **Aten Primaria** 1996 Jan;17(1):34–8 (Eng. Abstr.) **(Spa)**

APPROPRIATENESS REVIEW see **REGIONAL HEALTH PLANNING**

APRAXIA

CHEMICALLY INDUCED

Intranasal butorphanol-induced apraxia reversed by naloxone. Gora-Harper ML, et al. **Pharmacotherapy** 1995 Nov-Dec;15(6):798-800

COMPLICATIONS

[Characterization of gestural disorders in primary progressive apraxia: diagnostic and nosographic contribution] Habib M, et al. **Rev Neurol (Paris)** 1995 Oct;151(10):541-51 (29 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Progressive apraxia in clinically discordant monozygotic twins. Caselli RJ, et al. **Arch Neurol** 1995 Oct; 52(10):1004-10

The basal ganglia and apraxia. Pramstaller PP, et al. **Brain** 1996 Feb;119 (Pt 1):319-40 (105 ref.)

Diagonistic dyspraxia. Clinical characteristics, responsible lesion and possible underlying mechanism. Tanaka Y, et al. **Brain** 1996 Jun;119 (Pt 3):859-73 (75 ref.)

Acquired epileptiform opercular syndrome: a second case report, review of the literature, and comparison to the Landau-Kleffner syndrome. Shafrir Y, et al. **Epilepsia** 1995 Oct;36(10):1050-7 (32 ref.)

Sensorimotor learning in ideomotor apraxia. Motomura N, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1123-9

An investigation of a method of simplified scoring for the Kaufman Hand Movements test as a measure of limb apraxia. Neiman MR, et al. **Percept Mot Skills** 1996 Feb; 82(1):267-71

[Anosognosia, 2)anosodiaphoria] Matsumine H, et al. **No To Shinkei** 1995 Dec;47(12):1196-7 **(Jpn)**

DRUG THERAPY

Botulinum A toxin for the so-called apraxia of lid opening. Lepore V, et al. **Mov Disord** 1995 Jul;10(4):525-6

ETIOLOGY

The basal ganglia and apraxia. Pramstaller PP, et al. **Brain** 1996 Feb;119 (Pt 1):319-40 (105 ref.)

Gesture laterality in aphasic and apraxic stroke patients. Foundas AL, et al. **Brain Cogn** 1995 Nov;29(2):204-13

Eyelid "apraxia" in patients with motor neuron disease. Abe K, et al. **J Neurol Neurosurg Psychiatry** 1995 Dec; 59(6):629-32

[Progressive severity of left unilateral apraxia in 2 cases of Alzheimer disease] Ceccaldi M, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):240-6 (36 ref.) (Eng. Abstr.) **(Fre)**

[Anarthria, progressive apraxia and extrapyramidal syndrome: an uncommon clinical form of corticobasal degeneration? A case studied by HMPAO Tc99m single-photon emission tomography] Fayet G, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):247-50 (14 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Congenital ocular motor apraxia with torsional oscillations: a case report. Russo PA, et al. **Optom Vis Sci** 1995 Dec; 72(12):925-30

Congenital ocular motor apraxia in two siblings. Gürer YK, et al. **Pediatr Neurol** 1995 Oct;13(3):261-2

HISTORY

The black hole in Charley Toorop's "The three generations": a neuro-iconographic analysis and reconstruction. Lakke JP. **Clin Neurol Neurosurg** 1995 Aug;97(3):269-76

PHYSIOPATHOLOGY

Autosomal dominant rolandic epilepsy and speech dyspraxia: a new syndrome with anticipation. Scheffer IE, et al. **Ann Neurol** 1995 Oct;38(4):633-42

Intermittent horizontal saccade failure ('ocular motor apraxia') in children. Harris CM, et al. **Br J Ophthalmol** 1996 Feb;80(2):151-8

Subcortical origin of visuomotor apraxia. Classen J, et al. **Brain** 1995 Dec;118 (Pt 6):1365-74

Diagonistic dyspraxia. Clinical characteristics, responsible lesion and possible underlying mechanism. Tanaka Y, et al. **Brain** 1996 Jun;119 (Pt 3):859-73 (75 ref.)

Modality specific naming and gesture disturbances: a case with optic aphasia, bilateral tactile aphasia, optic apraxia and tactile apraxia. Endo K, et al. **Cortex** 1996 Mar; 32(1):3-28

Human motor planning, motor programming, and use of new task-relevant information with different apraxic syndromes. Platz T, et al. **Eur J Neurosci** 1995 Jul 1;7(7):1536-47

Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening [letter; comment] Jankovic J. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):704. Comment on: J Neurol Neurosurg Psychiatry 1995 Sep;59(3):309-11.

Apraxia of lid opening [letter; comment] Jankovic J. **Mov Disord** 1995 Sep;10(5):686-7. Comment on: Mov Disord 1994 Nov;9(6):610-5.

Visual evoked potentials in children with developmental coordination disorder. Mon-Williams MA, et al. **Ophthalmic Physiol Opt** 1996 Mar;16(2):178-83

Congenital ocular motor apraxia in two siblings. Gürer YK, et al. **Pediatr Neurol** 1995 Oct;13(3):261-2

[Pathophysiology underlying apraxia in corticobasal degeneration] Hashimoto R, et al. **No To Shinkei** 1996 Jun; 48(6):513-20 **(Jpn)**

THERAPY

Using electropalatography to treat severe acquired apraxia of speech. Howard S, et al. **Eur J Disord Commun** 1995; 30(2):246-55

APRICOT see **FRUIT**

APRINDINE

BLOOD

[Disopyramide, mexiletine, aprindine] Suzuki M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:989-93 (25 ref.) **(Jpn)**

APROCARB

Dominance of insecticide resistance presents a plastic response. Bourguet D, et al. **Genetics** 1996 May; 143(1):407-16

Development of malathion resistance in Culex quinquefasciatus Say (Diptera: Culicidae). Gopalan N, et al. **Indian J Med Res** 1996 Feb;103:84-90

TOXICITY

Sister chromatid exchange in human lymphocytes induced by propoxur following plant activation by Vicia faba. Gómez-Arroyo S, et al. **Environ Mol Mutagen** 1995; 26(4):324-30

APROTININ

ADMINISTRATION & DOSAGE

Continuous small-dose aprotinin controls fibrinolysis during orthotopic liver transplantation. Marcel RJ, et al. **Anesth Analg** 1996 Jun;82(6):1122-5

Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children. Seghaye MC, et al. **Ann Thorac Surg** 1996 Apr;61(4):1205-11

A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Levy JH, et al. **Circulation** 1995 Oct 15;92(8):2236-44

Efficacy and safety of a blood conservation program including low-dose aprotinin in routine myocardial revascularization. Schönberger JP, et al. **J Cardiovasc Surg (Torino)** 1996 Feb;37(1):35-44

Recombinant aprotinin in coronary artery bypass graft operations. Green D, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):963-70

Low-dose and high-dose aprotinin improve hemostasis in coronary operations. Speekenbrink RG, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):523-30

[Hemostatic mechanism associated with aprotinin during and after the extracorporeal circulation for cardiac and great vessel surgery] Takaori M, et al. **Masui** 1995 Dec; 44(12):1661-6 (Eng. Abstr.) **(Jpn)**

[The preventive role of large doses of aprotinin in decreasing the degree of metabolic disorders during aortocoronary bypass operations] Dement'eva II, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):55-8 (Eng. Abstr.) **(Rus)**

[Experience in the use of lymphatic infusion preparations in multimodal treatment of patients with giant lung abscess] Opanasenko NS. **Klin Khir** 1996;(1):25-7 **(Rus)**

ADVERSE EFFECTS

A perspective on aprotinin [comment] Cooper BE. **Ann Pharmacother** 1996 Apr;30(4):407-8. Comment on: Ann Pharmacother 1996 Apr;30(4):[illegible]-80.

Safety of repeat aprotinin administration for LVAD recipients undergoing cardiac transplantation. Goldstein DJ, et al. **Ann Thorac Surg** 1996 Feb;61(2):692-5

Aprotinin in staged heart transplantation: anaphylactic potential of repeated exposure [letter; comment] Martinelli L, et al. **Ann Thorac Surg** 1996 Apr;61(4):1288-9. Comment on: Ann Thorac Surg 1995 May;59(5):1063-7; discussion 1068.

Aprotinin therapy [letter; comment] Thorpe CM, et al. **Br J Anaesth** 1995 Aug;75(2):246. Comment on: Br J Anaesth 1994 Dec;73(6):734-7.

Anaphylactic reaction to aprotinin [letter] Ceriana P, et al. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):477-8

Aprotinin and aortic cannula thrombosis. Gitter R, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):537-8

ANALOGS & DERIVATIVES

Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties. Stassen JM, et al. **Thromb Haemost** 1995 Aug;74(2):646-54

Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo. Stassen JM, et al. **Thromb Haemost** 1995 Aug;74(2):655-9

CHEMISTRY

Expression, purification and functional characterisation of a Kunitz-type module from chicken type VI collagen. Bearz A, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):1050-5

Identification and isolation of the bactericidal domains in the proteinase inhibitor aprotinin. Pellegrini A, et al. **Biochem Biophys Res Commun** 1996 May 15;222(2):559-65

Dynamic structure of a highly ordered beta-sheet molten globule: multiple conformations with a stable core. Barbar E, et al. **Biochemistry** 1995 Sep 12;34(36):1142-34

Salt effects on the amide hydrogen exchange of bovine pancreatic trypsin inhibitor. Christoffersen M, et al. **Biochemistry** 1996 Feb 20;35(7):2309-15

Effects of trifluoroethanol on the conformations of peptides representing the entire sequence of bovine pancreatic trypsin inhibitor. Kemmink J, et al. **Biochemistry** 1995 Oct 3;34(39):12630-5

Iterative optimization of high-affinity proteases inhibitors using phage display. 1. Plasmin. Markland W, et al. **Biochemistry** 1996 Jun 18;35(24):8045-57

Extensive nonrandom structure in reduced and unfolded bovine pancreatic trypsin inhibitor. Pan H, et al. **Biochemistry** 1995 Oct 31;34(43):13974-81

Pressure-tuning the conformation of bovine pancreatic trypsin inhibitor studied by Fourier-transform infrared spectroscopy. Goossens K, et al. **Eur J Biochem** 1996 Feb 15;236(1):254-62

The roles of partly folded intermediates in protein folding. Creighton TE, et al. **FASEB J** 1996 Jan;10(1):110-8 (55 ref.)

Biotinylated aprotinin: a versatile probe for the detection of serine proteinases on western blots. Melrose J, et al. **Int J Biochem Cell Biol** 1995 Sep;27(9):891-904

Enhanced plasmin inhibition by a reactive center lysine mutant of the Kunitz-type protease inhibitor domain of the amyloid beta-protein precursor. Van Nostrand WE, et al. **J Biol Chem** 1995 Sep 29;270(39):22827-30

Fluctuation and cross-correlation analysis of protein motions observed in nanosecond molecular dynamics simulations. Hünenberger PH, et al. **J Mol Biol** 1995 Sep 29; 252(4):492-503

Thermodynamic stability effects of single peptide bond hydrolysis in protein inhibitors of serine proteinases. Krokoszyńska I, et al. **J Mol Biol** 1996 Mar 8; 256(4):793-802

A third native one-disulphide intermediate in the folding of bovine pancreatic trypsin inhibitor. Dadlez M, et al. **Nat Struct Biol** 1995 Aug;2(8):674-9

Using buried water molecules to explore the energy landscape of proteins. Denisov VP, et al. **Nat Struct Biol** 1996 Jun;3(6):505-9

A kinetic explanation for the rearrangement pathway of BPTI folding. Weissman JS, et al. **Nat Struct Biol** 1995 Dec;2(12):1123-30

A simple algorithm for the calculation of multiple site titration curves. Karshikoff A. **Protein Eng** 1995 Mar; 8(3):243-8

Conformational sampling by NMR solution structures calculated with the program DIANA evaluated by comparison with long-time molecular dynamics calculations in explicit water. Berndt KD, et al. **Proteins** 1996 Mar;24(3):304-13

Structure and internal dynamics of the bovine pancreatic trypsin inhibitor in aqueous solution from long-time molecular dynamics simulations. Brunne RM, et al. **Proteins** 1995 Sep;23(1):49-62

Protein conformational landscapes: energy minimization and clustering of a long molecular dynamics trajectory. Troyer JM, et al. **Proteins** 1995 Sep;23(1):97-110

DIAGNOSTIC USE

Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Aprile C, et al. **Eur J Nucl Med** 1995 Dec;22(12):1393-401

ECONOMICS

Cost/benefit analysis of pharmacologic hemostasis. Harmon DE. **Ann Thorac Surg** 1996 Feb;61(2 Suppl):S21-5; discussion S33-4

GENETICS

cDNA cloning and primary structure of tryptase from bovine mast cells, and evidence for the expression of bovine pancreatic trypsin inhibitor mRNA in the same cells. Pallaoro M, et al. **Eur J Biochem** 1996 Apr 1;237(1):100-5

Multicopy overexpression of bovine pancreatic trypsin inhibitor saturates the protein folding and secretory capacity of Saccharomyces cerevisiae. Parekh R, et al. **Protein Expr Purif** 1995 Aug;6(4):537-45

IMMUNOLOGY

Routine intraoperative application of high-dose aprotinin in

open heart surgery in adults: antibody formation after first exposure. Pfannschmidt J, et al. **Curr Med Res Opin** 1995; 13(5):282–4

METABOLISM

Role of an aprotinin-sensitive protease in the activation of Ca(2+)-ATPase by superoxide radical (O2-.) in microsomes of pulmonary vascular smooth muscle. Chakraborti T, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):885–90

Alanine point-mutations in the reactive region of bovine pancreatic trypsin inhibitor: effects on the kinetics and thermodynamics of binding to beta-trypsin and alpha-chymotrypsin. Castro MJ, et al. **Biochemistry** 1996 Sep 3;35(35):11435–46

PHARMACOKINETICS

Kinetic mechanism of the inhibition of human urinary kallikrein by basic pancreatic trypsin inhibitor. Miranda TL, et al. **Braz J Med Biol Res** 1995 May;28(5):505–12

PHARMACOLOGY

Serine proteinase inhibitors influence the stability of tropoelastin mRNA in neonatal rat lung fibroblast cultures. McGowan SE, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):L376–85

Procoagulant action of aprotinin [letter; comment] Alston TA. **Anesth Analg** 1996 Jun;82(6):1305–6. Comment on: Anesth Analg 1995 Nov;81(5):919–24.

Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro. Despotis GJ, et al. **Anesth Analg** 1996 Jun;82(6):1126–31

Aprotinin [see comments] Robert S, et al.
Ann Pharmacother 1996 Apr;30(4):372–80 (68 ref.). Comment in: Ann Pharmacother 1996 Apr;30(4):407–8.

Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Feindt PR, et al.
Ann Thorac Surg 1995 Oct;60(4):1076–80

Identification and isolation of the bactericidal domains in the proteinase inhibitor aprotinin. Pellegrini A, et al.
Biochem Biophys Res Commun 1996 May 15;222(2):559–65

Inhibition of human pancreatic proteinases by mucus proteinase inhibitor, eglin c and aprotinin. Belorgey D, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):555–60

Inhibition of human leukocyte and porcine pancreatic elastase by homologues of bovine pancreatic trypsin inhibitor. Kraunsoe JA, et al. **Biochemistry** 1996 Jul 16;35(28):9090–6

Effects of aprotinin on renal function in chronic hypoxic rats. Chen CF, et al. **Chin J Physiol** 1995;38(1):23–6

Different modes of inhibition of human adenovirus proteinase, probably a cysteine proteinase, by bovine pancreatic trypsin inhibitor. Brown MT, et al.
FEBS Lett 1996 Jun 17;388(2–3):233–7

Aprotinin inhibits unspecific degradation of collagen in rat and human pancreas. López JM, et al. **Int J Pancreatol** 1996 Feb;19(1):55–60

Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display. Dennis MS, et al. **J Biol Chem** 1995 Oct 27;270(43):25411–7

Analysis of aprotinin on the mean arterial pressure, carotid artery blood flow, and hindlimb vascular resistance in the live rat, and pulmonary vascular resistance in the isolated perfused rat lung. Jahr JS, et al. **J Med** 1995;26(1–2):31–42

Protease activation in the porcine pancreatic allograft during preservation. Jönsson P, et al. **Pancreas** 1995 Oct; 11(3):256–60

[Comparison of effects of aprotinin and tranexamic acid on blood loss in heart surgery] Corbeau JJ, et al.
Ann Fr Anesth Reanim 1995;14(2):154–61 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Inhibition of cytotoxic T-lymphocyte-triggered apoptosis by target cell surface-coupled aprotinin. Wagner L, et al.
Mol Immunol 1995 Aug;32(12):853–64

THERAPEUTIC USE

Aprotinin prolongs whole blood activated partial thromboplastin time but not whole blood prothrombin time in patients undergoing cardiac surgery [see comments] Despotis GJ, et al. **Anesth Analg** 1995 Nov;81(5):919–24. Comment in: Anesth Analg 1996 Jun;82(6):1305–6. Comment in: Anesth Analg 1996 Aug;83(2):433.

Aprotinin administration and disseminated intravascular coagulation [letter; comment] Ramsay MA.
Anesth Analg 1996 Aug;83(2):433. Comment on: Anesth Analg 1995 Feb;80(2):349–52.

Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Dietrich W, et al. **Anesthesiology** 1995 Oct;83(4):679–89; discussion 29A–30A

Topical aprotinin in cardiac operations: a note of caution [letter] Çiçek S, et al. **Ann Thorac Surg** 1996 Mar; 61(3):1039–40

Topical aprotinin in cardiac operations [letter; comment] Çiçek S. **Ann Thorac Surg** 1995 Oct;60(4):1155. Comment on: Ann Thorac Surg 1994 Sep;58(3):778–81.

Postoperative aprotinin: effect on blood loss and transfusion requirements in cardiac operations. Çiçek S, et al.
Ann Thorac Surg 1996 May;61(5):1372–6

Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting. Jansen PG, et al.
Ann Thorac Surg 1996 May;61(5):1363–6

Genetically engineered serine protease inhibitor for hemostasis after cardiac operations. Ohri SK, et al.
Ann Thorac Surg 1996 Apr;61(4):1223–30

Aprotinin in children undergoing repair of congenital heart defects. Penkoske PA, et al. **Ann Thorac Surg** 1995 Dec; 60(6 Suppl):S529–32

Defining the role of aprotinin in heart transplantation. Prendergast TW, et al. **Ann Thorac Surg** 1996 Sep; 62(3):670–4

Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. Primack C, et al. **Ann Thorac Surg** 1996 Apr;61(4):1188–93

Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass. Terrell MR, et al.
Ann Thorac Surg 1996 Aug;62(2):506–11

Aprotinin during liver transplantation [letter; comment] Lentschener C, et al. **Br J Anaesth** 1996 Jun;76(6):882. Comment on: Br J Anaesth 1995 Dec;75(6):747–51.

Improved haemodynamic stability with administration of aprotinin during orthotopic liver transplantation [see comments] Milroy SJ, et al. **Br J Anaesth** 1995 Dec; 75(6):747–51. Comment in: Br J Anaesth 1996 Jun;76(5):882.

Aprotinin employment in patients with acute leukaemia to prevent haemorrhage during pulmonary aspergillosis [letter] Pagano L, et al. **Br J Haematol** 1996 Jul;94(1):210–1

Aprotinin in patients having coronary artery bypass graft surgery. Royston D. **Curr Opin Cardiol** 1995 Nov; 10(6):591–6 (50 ref.)

Aprotinin prevents the development of the trauma-induced multiple organ failure in a chronic sheep model. Dwenger A, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar; 34(3):207–14

Platelet composition and function in patients undergoing cardiopulmonary bypass for heart surgery. Bertolino G, et al. **Haematologica** 1996 Mar-Apr;81(2):116–20

Combined use of aprotinin and a heparin-bonded cardiopulmonary bypass system for aortic aneurysm repair. Gallagher JM, et al. **J Cardiothorac Vasc Anesth** 1995 Dec; 9(6):728–30

Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. Menichetti A, et al.
J Cardiovasc Surg (Torino) 1996 Aug;37(4):401–7

Antifibrinolytic therapy: treat whom and with what? [letter] Horrow JC. **J Clin Anesth** 1995 Dec;7(8):690

Is aprotinin safe when used in the context of profound hypothermia and circulatory arrest? A literary review [comment] Hornick P, et al. **J Heart Valve Dis** 1995 Nov; 4(6):669–73 (60 ref.). Comment on: J Heart Valve Dis 1995 Nov;4(6):674–7.

Aprotinin use with hypothermic circulatory arrest for aortic valve and thoracic aortic surgery: renal function and early survival [see comments] Regragui IA, et al.
J Heart Valve Dis 1995 Nov;4(6):674–7. Comment in: J Heart Valve Dis 1995 Nov;4(6):669–73.

Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study. Casas JI, et al.
J Thorac Cardiovasc Surg 1995 Oct;110(4 Pt 1):1107–17

Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest. Goldstein DJ, et al.
J Thorac Cardiovasc Surg 1995 Dec;110(6):1615–21; discussion 1621–2

Clotting and fibrinolytic disturbance during lung transplantation: effect of low-dose aprotinin. Groningen Lung Transplant Group. Gu YJ, et al.
J Thorac Cardiovasc Surg 1996 Sep;112(3):599–606

Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. Hill GE, et al. **J Thorac Cardiovasc Surg** 1995 Dec; 110(6):1658–62

Aprotinin use in patients with dialysis-dependent renal failure undergoing cardiac operations. Lemmer JH Jr, et al.
J Thorac Cardiovasc Surg 1996 Jul;112(1):192–4

Effect of antiproteolytic drugs: epsilon-aminocaproic acid (EACA) and aprotinin on experimental anti-GBM nephritis. Hruby Z, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):32–9

Hyperoncotic dextran and systemic aprotinin in necrotizing rodent pancreatitis. Huch K, et al.
Scand J Gastroenterol 1995 Aug;30(8):812–6

Tachocomb used in endoscopic surgery. Scheyer M, et al. **Surg Endosc** 1996 May;10(5):501–3

Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass. Spannagl M, et al. **Thromb Haemost** 1995 May;73(5):825–8

Gelatin use impairs platelet adhesion during cardiac surgery. Tabuchi N, et al. **Thromb Haemost** 1995 Dec;74(6):1447–51

[Fibrinolytic inhibitors and prevention of bleeding in cardiac valve surgery. Comparison of tranexamic acid and high dose aprotinin] Boughenou F, et al.
Arch Mal Coeur Vaiss 1995 Mar;88(3):363–70 (Eng. Abstr.) **(Fre)**

[Aprotinin in the control of surgical hemorrhage] Rocha E, et al. **Med Clin (Barc)** 1996 Mar 2;106(8):307–16 (161 ref.) **(Spa)**

[Aprotinin reduces intraoperative bleeding during spinal arthrodesis interventions (letter)] Llau JV, et al.
Rev Esp Anestesiol Reanim 1996 Mar;43(3):118 **(Spa)**

[Use of aprotinin in cardiovascular surgery] Colorio C, et al. **Sangre (Barc)** 1995 Jun;40(3):207–11 (34 ref.) **(Spa)**

TOXICITY

Examination of the biological safety of a drug derived from mammalian organs. Hübner GE, et al.
Arzneimittelforschung 1996 Jun;46(6):657–61

APSAC see **ANISTREPLASE**

APTITUDE

Prediction of students' USMLE step 2 performances based on premedical credentials related to verbal skills. Roth KS, et al. **Acad Med** 1996 Feb;71(2):176–80

Models of spouse similarity: applications to fluid ability measured in twins and their spouses. Reynolds CA, et al. **Behav Genet** 1996 Mar;26(2):73–88

The development of perceptual completion abilities: infants' perception of stationary, partially occluded objects. Craton LG. **Child Dev** 1996 Jun;67(3):890–904

Development of an aspect of executive control: development of the abilities to remember what I said and to "do as I say, not as I do". Diamond A, et al. **Dev Psychobiol** 1996 May;29(4):315–34

A preliminary study of factors that influence children's sense of competence to manage their asthma. Miles A, et al.
J Asthma 1995;32(6):437–44

The abilities of a musical savant and his family. Young RL, et al. **J Autism Dev Disord** 1995 Jun;25(3):231–48

Savants, segments, art and autism. Pring L, et al.
J Child Psychol Psychiatry 1995 Sep;36(6):1065–76

The fluid and crystallized abilities of white, black, and Hispanic adolescents and adults, both with and without an education covariate. Kaufman AS, et al.
J Clin Psychol 1995 Sep;51(5):636–47

The relevance of Vygotsky's theory of the "zone of proximal development" to the assessment of children with intellectual disabilities. Rutland AF, et al. **J Intellect Disabil Res** 1996 Apr;40 (Pt 2):151–8

Two longitudinal studies of the abilities of people with Down's syndrome. Shepperdson B.
J Intellect Disabil Res 1995 Oct;39 (Pt 5):419–31

Development and validation of the State Hope Scale. Snyder CR, et al. **J Pers Soc Psychol** 1996 Feb;70(2):321–35

Effect of instruction on perceived physical ability and exercise adherence. Cain RE. **Percept Mot Skills** 1996 Apr; 82(2):494

Computerized information retrieval: individual differences in the use of spatial vs nonspatial navigational information. Westerman SJ. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):771–86

Perspective production in a savant autistic draughtsman. Mottron L, et al. **Psychol Med** 1995 May;25(3):639–48

Set-shifting aptitude in Parkinson's disease: external versus internal cues. Hsieh S, et al. **Psychol Rep** 1995 Aug; 77(1):339–49

[The cytoarchitectonic characteristics of the speech center of the brain in gifted people in the plan to study individual variability of human brain structure] Bogolepova IN.
Morfologiia 1994 Apr-Jun;106(4–6):31–8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Talents and disorders: relationships among handedness, sex, and college major. Martino G, et al. **Brain Cogn** 1995 Oct; 29(1):66–84

Is there really a syndrome involving the co-occurrence of neurodevelopmental disorder talent, non-right handedness and immune disorder among children? Flannery KA, et al. **Cortex** 1995 Sep;31(3):503–15

APTITUDE TESTS

Prediction and qualitative assessment of five- and six-year-old children's reading: a longitudinal study. Stuart M. **Br J Educ Psychol** 1995 Sep;65 (Pt 3):287–96

Academic little league [editorial; comment] Slack WV.
MD Comput 1995 Sep-Oct;12(5):325–6, 329. Comment on: MD Comput 1995 Sep-Oct;12(5):363–72.

Measurement of intelligence: misplaced trust and the lure of prophecy [see comments] Slack WV. **MD Comput** 1995 Sep-Oct;12(5):363–72 (127 ref.). Comment in: MD Comput 1995 Sep-Oct;12(5):325–6, 329.

[Academic performance in the 1st year and its relationship with admission variables in medical schools. Comparative study] García RE. **Rev Med Chil** 1995 Jan;123(1):28–36 (Eng. Abstr.) **(Spa)**

APUD CELLS

CYTOLOGY

[The histotopography of the endocrinocytes in the rectal epithelium of hens in ontogeny] Ivanova OV.
Morfologiia 1995;108(1):76–8 (Eng. Abstr.) **(Rus)**

APUD CELLS

ULTRASTRUCTURE

[Current methods for studying the functional morphology of apud cells] Iuzhakov VV, et al. **Arkh Patol** 1996 Mar-Apr;58(2):21-8 (37 ref.) (Eng. Abstr.) **(Rus)**

[The ultrastructure of the epithelial endocrinocytes of the appendiceal mucosa in the human fetus] Kostiukevich SV. **Tsitologiia** 1995;37(3):187-92 (Eng. Abstr.) **(Rus)**

APUDOMA

see related
MULTIPLE ENDOCRINE NEOPLASIA

CLASSIFICATION

[The systematization of APUD tumors] Liubenov T, et al. **Khirurgiia (Sofiia)** 1995;48(5):15-6 (Eng. Abstr.) **(Bul)**

DIAGNOSIS

Cartinoid tumor of the middle ear and mastoid. Himi T, et al. **Auris Nasus Larynx** 1995;22(2):128-33 (21 ref.)

[A case from practice (342). Neuroendocrine tumor of the anterior mediastinum. Atypical nevocellular nevus] Eichmann MM, et al. **Schweiz Rundsch Med Prax** 1996 Feb 13;85(7):208-10 **(Ger)**

PATHOLOGY

Cartinoid tumor of the middle ear and mastoid. Himi T, et al. **Auris Nasus Larynx** 1995;22(2):128-33 (21 ref.)

[Endocrine-cell stomach tumors] Derizhanova IS, et al. **Arkh Patol** 1995 Jul-Aug;57(4):16-20 (Eng. Abstr.) **(Rus)**

[Apudoma of the prostate] Serezhin BS. **Arkh Patol** 1995 Sep-Oct;57(5):57-63 (Eng. Abstr.) **(Rus)**

APURINIC ACID

CHEMISTRY

Formation of 8-nitroguanine in DNA treated with peroxynitrite in vitro and its rapid removal from DNA by depurination. Yermilov V, et al. **FEBS Lett** 1995 Dec 4;376(3):207-10

APYRASE

ANALYSIS

Solubilization and characterization of an ATP diphosphohydrolase (EC 3.6.1.5) from rat brain synaptic plasma membranes. Battastini AM, et al. **Biochem Mol Biol Int** 1995 Oct;37(2):209-19

Autoradiography-based cytochemical detection of ecto-ATPase, ecto-ADPase, 5'-nucleotidase, and extracellular adenosine production, employing 141Ce3+ as a capturing agent. Culic O, et al. **Histochem J** 1995 Jul; 27(7):555-64

ANTAGONISTS & INHIBITORS

Inhibition of ATP-diphosphohydrolase(apyrase) of Torpedo electric organ by 5'-p-fluorosulfonylbenzoyladenosine. Marti E, et al. **Biochim Biophys Acta** 1996 Jun 13; 1282(1):17-24

DRUG EFFECTS

The increased endotoxin-sensitivity of pregnant rats, as reflected by glomerular ecto-ADP-ase activity, is not dependent on the presence of decidual cells. Faas MM, et al. **Placenta** 1996 Mar-Apr;17(2-3):185-8

GENETICS

The Apyrase gene of the vector mosquito, Aedes aegypti, is expressed specifically in the adult female salivary glands. Smartt CT, et al. **Exp Parasitol** 1995 Nov;81(3):239-48

ISOLATION & PURIFICATION

Purification and cloning of a soluble ATP-diphosphohydrolase (apyrase) from potato tubers (Solanum tuberosum). Handa M, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):916-23

Purification of pancreas type-I ATP diphosphohydrolase and identification by affinity labelling with the 5'-p-fluorosulphonylbenzoyladenosine ATP analogue. Sévigny J, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):351-6

Purification and properties of human placental ATP diphosphohydrolase. Christoforidis S, et al. **Eur J Biochem** 1995 Nov 15;234(1):66-74

Partial purification and immunohistochemical localization of ATP diphosphohydrolase from Schistosoma mansoni. Immunological cross-reactivities with potato apyrase and Toxoplasma gondii nucleoside triphosphate hydrolase. Vasconcelos EG, et al. **J Biol Chem** 1996 Sep 6; 271(36):22139-45

METABOLISM

Purification of pancreas type-I ATP diphosphohydrolase and identification by affinity labelling with the 5'-p-fluorosulphonylbenzoyladenosine ATP analogue. Sévigny J, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):351-6

Hydrolysis of P2-purinoceptor agonists by a purified ectonucleotidase from the bovine aorta, the ATP-diphosphohydrolase. Picher M, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1453-60

Human placental ATP diphosphohydrolase is a highly N-glycosylated plasma membrane enzyme. Christoforidis S, et al. **Biochim Biophys Acta** 1996 Jul 25;1282(2):257-62

ATP diphosphohydrolase activity in synaptosomes from cerebral cortex of rats subjected to chemically induced phenylketonuria. Wyse AT, et al. **Braz J Med Biol Res** 1995 Jun;28(6):643-9

Comparative studies on animal and plant apyrases (ATP diphosphohydrolase EC 3.6.1.5) with application of immunological techniques and various ATPase inhibitors. Komoszyński MA. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):581-91

Characterization of ATP-diphosphohydrolase from rat mammary gland. Alvarez A, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):75-9

ATP-diphosphohydrolase activity in rat renal microvillar membranes and vascular tissue. Sandoval S, et al. **Int J Biochem Cell Biol** 1996 May;28(5):591-9

Partial purification and immunohistochemical localization of ATP diphosphohydrolase from Schistosoma mansoni. Immunological cross-reactivities with potato apyrase and Toxoplasma gondii nucleoside triphosphate hydrolase. Vasconcelos EG, et al. **J Biol Chem** 1996 Sep 6; 271(36):22139-45

CD39 is an ecto-(Ca2+,Mg2+)-apyrase. Wang TF, et al. **J Biol Chem** 1996 Apr 26;271(17):9898-901

An in vitro method for evaluating vascular endothelial ADPase activity. Caprino L, et al. **J Pharmacol Toxicol Methods** 1996 Jun;35(3):153-7

Salivary apyrase in New World blackflies (Diptera: Simuliidae) and its relationship to onchocerciasis vector status. Cupp MS, et al. **Med Vet Entomol** 1995 Jul; 9(3):325-30

Apyrase activity and adenosine diphosphate induced platelet aggregation inhibition by the salivary gland proteins of Culicoides variipennis, the North American vector of bluetongue viruses. Pérez de León AA, et al. **Vet Parasitol** 1996 Feb;61(3-4):327-38

PHYSIOLOGY

Apyrases (ATP diphosphohydrolases, EC 3.6.1.5): function and relationship to ATPases. Komoszyński M, et al. **Biochim Biophys Acta** 1996 Feb 2;1310(2):233-41 (91 ref.)

AQUACULTURE

Transgenic fish in aquaculture and developmental biology. Gong Z, et al. **Curr Top Dev Biol** 1995;30:177-214 (174 ref.)

Well-being of zoo and aquarium animals explored [news] Boyce J. **J Am Vet Med Assoc** 1995 Oct 1;207(7):832, 837

Washington's Aquatic Animal Health Program: serving needs of growing industry and educating [news] [see comments] Gustafsson BK. **J Am Vet Med Assoc** 1995 Oct 1; 207(7):830-1. Comment in: J Am Vet Med Assoc 1995 Dec 15;207(12):1543-4. Comment in: J Am Vet Med Assoc 1996 May 15;208(10):1625.

Proponent of training in aquatic animal health [letter; comment] [see comments] Jack SW. **J Am Vet Med Assoc** 1995 Dec 15;207(12):1543-4. Comment on: J Am Vet Med Assoc 1995 Oct 1;207(7):830-1. Comment in: J Am Vet Med Assoc 1996 May 15;208(10):1625.

More thoughts on veterinarians' role in aquatic animal health [letter; comment] Karreman GA. **J Am Vet Med Assoc** 1996 May 15;208(10):1625. Comment on: J Am Vet Med Assoc 1995 Oct 1;207(7):830-1. Comment on: J Am Vet Med Assoc 1995 Dec 15;207(12):1543-4. Comment on: J Am Vet Med Assoc 1996 Feb 1;208(3):338. Comment on: J Am Vet Med Assoc 1996 Apr 1;208(7):1016.

AVMA/Practice Group perspectives: use of drug labels in the prescription of antimicrobial therapy. Representing the Aquaculture and Seafood Safety Advisory Committee (ASSAC). Stoskopf MK. **J Am Vet Med Assoc** 1995 Oct 1;207(7):889-9; discussion 890-4

More on fish anatomy [letter; comment] [see comments] Waterstrat PR. **J Am Vet Med Assoc** 1996 Apr 1; 208(7):1016. Comment on: J Am Vet Med Assoc 1996 Feb 1;208(3):338. Comment in: J Am Vet Med Assoc 1996 May 15;208(10):1625.

Prescription of veterinary drugs in fish farming [letter] Grave K, et al. **Vet Rec** 1995 Jul 8;137(2):51-2

Nervous mortality syndrome in farmed Atlantic salmon. Rodger HD, et al. **Vet Rec** 1995 Dec 9;137(24):616-7

Preliminary findings of ophthalmological abnormalities in farmed halibut. Williams DL, et al. **Vet Rec** 1995 Jun 17; 136(24):610-2

STANDARDS

Care of fish in biological research. Klontz GW. **J Anim Sci** 1995 Nov;73(11):3485-92 (24 ref.)

Disinfection in aquaculture. Torgersen Y, et al. **Rev Sci Tech** 1995 Jun;14(2):419-34 (39 ref.)

TRENDS

Future of biotechnology-based control of disease in marine invertebrates. Mialhe E, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):275-83

AQUAREOVIRUS see **REOVIRIDAE**

AQUEDUCT OF SYLVIUS see **CEREBRAL AQUEDUCT**

AQUEOUS HUMOR

CHEMISTRY

IgG, albumin and total IgG index in the aqueous humour of eyes with pseudoexfoliation syndrome. Moreno-Montañés J, et al. **Acta Ophthalmol Scand** 1995 Jun;73(3):249-51

Aqueous humour and cerebrospinal fluid collected at necropsy as indicators of ante mortem serum 3-OH butyrate concentration in pregnant sheep. Scott PR, et al. **Br Vet J** 1995 Jul-Aug;151(4):459-61

Simultaneous measurement of reduced and oxidized glutathione in human aqueous humor and cataracts by electrochemical detection. Chakrapani B, et al. **Ophthalmic Res** 1995;27 Suppl 1:69-77

Field diagnosis of nitrite poisoning in cattle by testing aqueous humour samples with urine test strips. Montgomery JF, et al. **Vet Rec** 1995 Dec 2;137(23):593-4

CYTOLOGY

Leukemic glaucoma: the effects on outflow facility of chronic lymphocytic leukemia lymphocytes. Schuman JS, et al. **Exp Eye Res** 1995 Nov;61(5):609-17

DRUG EFFECTS

Effects of brimonidine on aqueous humor dynamics in human eyes. Toris CB, et al. **Arch Ophthalmol** 1995 Dec; 113(12):1514-7

Effect of daily topical ethacrynic acid on aqueous humor dynamics in monkeys. Croft MA, et al. **Curr Eye Res** 1995 Sep;14(9):777-81

Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. Toris CB, et al. **Exp Eye Res** 1995 Dec;61(6):649-57

[Effect of mitomycin C on aqueous humor flow after trabeculectomy] Diestelhorst M, et al. **Ophthalmologe** 1995 Aug;92(4):542-5 (Eng. Abstr.) **(Ger)**

[Comparison between local and systemic administration of cyclosporin A on the effective level in conjunctiva, aqueous humor and serum] Pfau B, et al. **Ophthalmologe** 1995 Dec; 92(6):833-9 (Eng. Abstr.) **(Ger)**

[Effects of amosulalol hydrochloride on intraocular pressure and aqueous humor dynamics in the rabbit eye] Taniguchi T, et al. **Nippon Ganka Gakkai Zasshi** 1996 Apr; 100(4):279-83 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Vitreous and aqueous humors contain a latent proteinase activity that abolishes IGF binding to specific IGF binding proteins. Moshyedi P, et al. **Curr Eye Res** 1995 Jul; 14(7):555-61

Matrix metalloproteinases and their inhibitors in aqueous humor. Huang SH, et al. **Exp Eye Res** 1996 May; 62(5):481-90

IMMUNOLOGY

Comparison of methods for estimation of Toxoplasma gondii-specific antibody production in the aqueous humor of cats. Hill SL, et al. **Am J Vet Res** 1995 Sep;56(9):1181-7

Apoptosis-related fas antigen on memory T cells in aqueous humor of uveitis patients. Ohta K, et al. **Curr Eye Res** 1996 Mar;15(3):299-306

METABOLISM

Selenium concentrations in serum, lens and aqueous humour of patients with senile cataract. Karaküçük S, et al. **Acta Ophthalmol Scand** 1995 Aug;73(4):329-32

Intraocular levels of methotrexate after intravenous administration. de Smet MD, et al. **Am J Ophthalmol** 1996 Apr;121(4):442-4

Collagen metabolism in human aqueous humor from primary open-angle glaucoma. Decreased degradation and increased biosynthesis play a role in its pathogenesis. González-Avila G, et al. **Arch Ophthalmol** 1995 Oct; 113(10):1319-23

Mitomycin-C concentration in human ocular aqueous humor after topical administration during trabeculectomy. Rump AF, et al. **Arzneimittelforschung** 1995 Dec;45(12):1329-30

Collagen synthesis activity in the aqueous humour of eyes with glaucoma surgery: a pilot study. Tuulonen A, et al. **Br J Ophthalmol** 1996 Jan;80(1):74-7

Penetration of [3H] tiazofurin into guinea pig eye by a saturable mechanism. Redžić ZB, et al. **Eur J Ophthalmol** 1995 Apr-Jun;5(2):131-5

Pathway of albumin into the anterior chamber [letter; comment] Freddo TF, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Oct;233(10):662-5 . Comment on: Graefes Arch Clin Exp Ophthalmol 1994 Apr;232(4):242-51.

Aqueous flare in eyes with senile disciform macular degeneration: correlation with clinical stage and area of neovascular membrane. Kubota T, et al.

Graefes Arch Clin Exp Ophthalmol 1996 May;234(5):285–7
Immunohistochemical evaluation of the integrity of the blood–aqueous barrier in normal and rubeotic human eyes. Küchle M, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Jul;233(7):414–20
Indomethacin and epinephrine effects on outflow facility and cyclic adenosine monophosphate formation in monkeys. Crawford KS, et al. **Invest Ophthalmol Vis Sci** 1996 Jun; 37(7):1348–59
Contrast–enhanced magnetic resonance imaging confirmation of an anterior protein pathway in normal rabbit eyes. Kolodny NH, et al. **Invest Ophthalmol Vis Sci** 1996 Jul; 37(8):1602–7
Dexamethasone–cyclodextrin–polymer co–complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Kristinsson JK, et al.
Invest Ophthalmol Vis Sci 1996 May;37(6):1199–203
Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Rabiah PK, et al.
Invest Ophthalmol Vis Sci 1996 Mar;37(4):613–8
Effect of cataract surgery on aqueous turnover and blood–aqueous barrier. Kondo T, et al.
J Cataract Refract Surg 1995 Nov;21(6):706–9
Identification of a neuropeptide and neuropeptide–processing enzymes in aqueous humor confers neuroendocrine features to the human ocular ciliary epithelium. Ortego J, et al. **J Neurochem** 1996 Feb;66(2):787–96
Ocular concentrations of mitomycin C after extraocular application in rabbits. Mietz H, et al.
J Ocul Pharmacol Ther 1995 Spring;11(1):49–55
Availability of 0.3% ofloxacin ointment and solution in human conjunctiva and aqueous humor. Tang–Liu D, et al. **J Ocul Pharmacol Ther** 1995 Spring;11(1):57–63
Corticosteroid suppression of trauma–induced hyaluronan in rabbit cornea and aqueous. Molander N, et al.
J Refract Surg 1995 Jul–Aug;11(4):260–6
Effects of BQ–123, an ETA recepter–selective antagonist, on changes of intraocular pressure, blood–aqueous barrier and aqueous prostaglandin concentrations caused by endothelin–1 in rabbit. Haque MS, et al.
Jpn J Ophthalmol 1996;40(1):26–32
Penetration of topical 0.3% ciprofloxacin into human aqueous humor. Kalayci D, et al. **Ophthalmic Surg Lasers** 1996 Jan; 27(1):21–4
[Vascular endothelial growth factor in the aqueous humor in diabetic retinopathy and other diseases of the retina (letter; comment)] Pfeiffer A. **Dtsch Med Wochenschr** 1995 Oct 20;120(42):1453. Comment on: Dtsch Med Wochenschr 1995 Jun 2;120(22):819. **(Ger)**
[Fluconazole level in aqueous humor after oral drug administration in humans] Aust R, et al. **Ophthalmologe** 1995 Dec;92(6):829–32 (Eng. Abstr.) **(Ger)**
[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis] Sato H, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jul;100(7):513–9 (Eng. Abstr.) **(Jpn)**
[Biochemical changes in lens, aqueous humor and vitreous body and effects of aldose reductase inhibitor (TAT) on rats with experimental diabetes] Saito H.
Nippon Ika Daigaku Zasshi 1995 Aug;62(4):339–50 (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Anterior chamber fluid cultures following phacoemulsification and posterior chamber lens implantation. Gimbel HV, et al. **Ophthalmic Surg Lasers** 1996 Feb;27(2):121–6
[Search for bacterial contamination of the aqueous humor during cataract surgery with and without local antibiotic prophylaxis] Saint–Blancat P, et al. **J Fr Ophtalmol** 1995; 18(11):650–5 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Aging effects on accommodation and outflow facility responses to pilocarpine in humans. Croft MA, et al.
Arch Ophthalmol 1996 May;114(5):586–92
A study of aqueous humor dynamics in keratoconus. Goodman WT, et al. **Exp Eye Res** 1996 Jan;62(1):95–9
The effects of sleep on circulating catecholamines and aqueous flow in human subjects. Maus TL, et al.
Exp Eye Res 1996 Apr;62(4):351–8
The significance of ascorbate in the aqueous humour protection against UV–A and UV–B. Ringvold A.
Exp Eye Res 1996 Mar;62(3):261–4
Regulation of outflow rate and resistance in the perfused anterior segment of the bovine eye. Wiederholt M, et al. **Exp Eye Res** 1995 Aug;61(2):223–34
Posterior drainage of intraocular fluid: an experimental approach on bovine cadaver eyes. Rezai KA, et al.
Ger J Ophthalmol 1995 Sep;4(5):275–8
Outflow characteristics of isolated anterior segments of human eyes. Dijkstra BG, et al.
Invest Ophthalmol Vis Sci 1996 Sep;37(10):2015–21
Migration of cultured bovine trabecular meshwork cells to aqueous humor and constituents. Hogg P, et al.
Invest Ophthalmol Vis Sci 1995 Nov;36(12):2449–60
Serum effects on aqueous outflow during anterior chamber perfusion in monkeys. Kee C, et al.
Invest Ophthalmol Vis Sci 1996 Aug;37(9):1840–8
Inhibition of transforming growth factor–beta–induced cataractous changes in lens explants by ocular media and alpha 2–macroglobulin. Schulz MW, et al.
Invest Ophthalmol Vis Sci 1996 Jul;37(8):1509–19
Crosslinked poly(1–vinyl–2–pyrrolidinone) as a vitreous substitute. Hong Y, et al. **J Biomed Mater Res** 1996 Apr; 30(4):441–8
Morphology of the aqueous outflow pathway. Gong H, et al. **Microsc Res Tech** 1996 Mar 1;33(4):336–67 (76 ref.)
Transscleral flow of aqueous humor: an in vitro experiment. Ayyala RS, et al. **Ophthalmic Surg Lasers** 1996 Jan; 27(1):66–9

SECRETION

Aqueous shunts: single–plate Molteno vs ACTSEB. Kim DM, et al. **Acta Ophthalmol Scand** 1995 Jun;73(3):277–80
Effects of timolol, terbutaline and forskolin on IOP, aqueous humour formation and ciliary cyclic AMP levels in the bovine eye. Shahidullah M, et al. **Curr Eye Res** 1995 Jul; 14(7):519–28
Modeling the effects of anterior chamber fluid viscosities on intraocular pressure following glaucoma filtering surgery. Fankhauser F, et al. **Graefes Arch Clin Exp Ophthalmol** 1995 Nov;233(11):737–41
Corneal endothelial permeability and aqueous humor flow using a standard protocol. van Best JA, et al.
Graefes Arch Clin Exp Ophthalmol 1995 Sep;233(9):582–91
Retroperfusion studies of the aqueous outflow system. Part 2: Studies in human eyes. Ethier CR, et al.
Invest Ophthalmol Vis Sci 1995 Nov;36(12):2466–75
Topically applied hydralazine: effects on systemic cardiovascular parameters, blood–aqueous barrier, and aqueous humor dynamics in normotensive humans. Larsson LI, et al. **J Ocul Pharmacol Ther** 1995 Summer;11(2):145–56
A family with a syndrome of ectopia lentis, spontaneous filtering blebs, and craniofacial dysmorphism. Shawaf S, et al. **Ophthalmic Genet** 1995 Dec;16(4):163–9
A technique to evaluate fluid flow in glaucoma shunts. Latina MA. **Ophthalmic Surg Lasers** 1995 Nov–Dec;26(6):576–8
Combined corticosteroid and catecholamine stimulation of aqueous humor flow. Jacob E, et al. **Ophthalmology** 1996 Aug;103(8):1303–8

VIROLOGY

Serologic and polymerase chain reaction analysis of intraocular fluids in the diagnosis of infectious uveitis. de Boer JH, et al. **Am J Ophthalmol** 1996 Jun;121(6):650–8
Inhibition of PCR by aqueous and vitreous fluids. Wiedbrauk DL, et al. **J Clin Microbiol** 1995 Oct;33(10):2643–6

AQUEOUS SHUNTS see **MOLTENO IMPLANTS**

ARA–A see **VIDARABINE**

ARA–AMP see **VIDARABINE PHOSPHATE**

ARA–C see **CYTARABINE**

ARA–CTP see **ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE**

ARA–U see **ARABINOFURANOSYLURACIL**

ARAB WORLD

Child maltreatment as perceived by Arab students of social science in the West Bank. Haj–Yahia MM, et al.
Child Abuse Negl 1995 Oct;19(10):1209–19

ARABIDOPSIS

CHEMISTRY

Characterization of an acyl–CoA–binding protein from Arabidopsis thaliana. Engeseth NJ, et al.
Arch Biochem Biophys 1996 Jul 1;331(1):55–62
Experimental manipulation of gamma–tubulin distribution in Arabidopsis using anti–microtubule drugs. Liu B, et al.
Cell Motil Cytoskeleton 1995;31(2):113–29
Functional expression of the plant K+ channel KAT1 in insect cells. Marten I, et al. **FEBS Lett** 1996 Feb 19; 380(3):229–32
Analysis of the H(+)–ATPase and other proteins of the Arabidopsis plasma membrane. Schaller GE, et al.
Methods Cell Biol 1995;50:129–48
Isolation of a new mitotic–like cyclin from Arabidopsis: complementation of a yeast cyclin mutant with a plant cyclin. Day IS, et al. **Plant Mol Biol** 1996 Feb;30(3):565–75
Evidence that plant K+ channel proteins have two different types of subunits. Tang H, et al. **Plant Physiol** 1995 Sep; 109(1):327–30
Dimerization specificity of Arabidopsis MADS domain homeotic proteins APETALA1, APETALA3, PISTILLATA, and AGAMOUS. Riechmann JL, et al.
Proc Natl Acad Sci U S A 1996 May 14;93(10):4793–8
Substitution of L–fucose by L–galactose in cell walls of Arabidopsis mur1. Zablackis E, et al. **Science** 1996 Jun 21; 272(5269):1808–10

CYTOLOGY

Epidermal fate map of the Arabidopsis shoot meristem. Schnittger A, et al. **Dev Biol** 1996 May 1;175(2):248–55
The homeobox gene GLABRA2 is required for position–dependent cell differentiation in the root epidermis of Arabidopsis thaliana. Masucci JD, et al. **Development** 1996 Apr;122(4):1253–60
Cellular localization of the Ca2+ binding TCH3 protein of Arabidopsis. Antosiewicz DM, et al. **Plant J** 1995 Nov; 8(5):623–36
A protocol for obtaining embryogenic cell lines from Arabidopsis. Pillon E, et al. **Plant J** 1996 Apr;9(4):573–7
Initiation of runaway cell death in an Arabidopsis mutant by extracellular superoxide. Jabs T, et al. **Science** 1996 Sep 27;273(5283):1853–6

DRUG EFFECTS

Benzothiadiazole induces disease resistance in Arabidopsis by activation of the systemic acquired resistance signal transduction pathway. Lawton KA, et al. **Plant J** 1996 Jul; 10(1):71–82
Differential regulation of trichome formation on the adaxial and abaxial leaf surfaces by gibberellins and photoperiod in Arabidopsis thaliana (L.) Heynh. Chien JC, et al.
Plant Physiol 1996 Aug;111(4):1321–8
Differential accumulation of antioxidant mRNAs in Arabidopsis thaliana exposed to ozone. Conklin PL, et al.
Plant Physiol 1995 Sep;109(1):203–12
Ozone–induced responses in Arabidopsis thaliana: the role of salicylic acid in the accumulation of defense–related transcripts and induced resistance. Sharma YK, et al.
Proc Natl Acad Sci U S A 1996 May 14;93(10):5099–104
The ethylene signal transduction pathway in Arabidopsis: an emerging paradigm? Chang C. **Trends Biochem Sci** 1996 Apr;21(4):129–33 (35 ref.)

EMBRYOLOGY

The COP9 complex, a novel multisubunit nuclear regulator involved in light control of a plant developmental switch. Chamovitz DA, et al. **Cell** 1996 Jul 12;86(1):115–21
Cytokinesis in the Arabidopsis embryo involves the syntaxin–related KNOLLE gene product. Lukowitz W, et al. **Cell** 1996 Jan 12;84(1):61–71
Pattern formation in the Arabidopsis embryo: a genetic perspective. Jürgens G, et al.
Philos Trans R Soc Lond B Biol Sci 1995 Oct 30; 350(1331):19–25 (38 ref.)

ENZYMOLOGY

cis–regulatory elements of the peroxidase gene in Arabidopsis thaliana involved in root–specific expression and responsiveness to high–salt stress. Wanapu C, et al.
Ann N Y Acad Sci 1996 May 15;782:107–14
Functional expression of uridine 5'–diphospho–glucose 4–epimerase (EC 5.1.3.2) from Arabidopsis thaliana in Saccharomyces cerevisiae and Escherichia coli. Dörmann P, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):27–34
Adenosine–5'–triphosphate–sulfurylase from Arabidopsis thaliana and Escherichia coli are functionally equivalent but structurally and kinetically divergent: nucleotide sequence of two adenosine–5'–triphosphate–sulfurylase cDNAs from Arabidopsis thaliana and analysis of a recombinant enzyme. Murillo M, et al.
Arch Biochem Biophys 1995 Oct 20;323(1):195–204
Molecular and functional studies of copper amine oxidase from Arabidopsis thaliana. Møller SG, et al.
Biochem Soc Trans 1995 Nov;23(4):630S
A cDNA clone from Arabidopsis thaliana encoding plastidic ferredoxin: sulfite reductase. Brühl A, et al.
Biochim Biophys Acta 1996 Jul 18;1295(2):119–24
Arabidopsis thaliana cDNA isolated by functional complementation shows homology to serine/threonine protein kinases. Covic L, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):125–9
Characterization of an Arabidopsis thaliana cDNA encoding an S–adenosylmethionine–sensitive threonine synthase. Threonine synthase from higher plants. Curien G, et al.
FEBS Lett 1996 Jul 15;390(1):85–90
Generation of active oxygen in elicited cells of Arabidopsis thaliana is mediated by a NADPH oxidase–like enzyme. Desikan R, et al. **FEBS Lett** 1996 Mar 11;382(1–2):213–7
Transformation of Saccharomyces cerevisiae with a cDNA encoding a sterol C–methyltransferase from Arabidopsis thaliana results in the synthesis of 24–ethyl sterols. Husselstein T, et al. **FEBS Lett** 1996 Feb 26;381(1–2):87–92
Isolation and characterization of a cDNA encoding a sulfate transporter from Arabidopsis thaliana. Takahashi H, et al.
FEBS Lett 1996 Aug 26;392(2):95–9
A 14–kDa Arabidopsis thaliana RNA polymerase III subunit contains two alpha–motifs flanked by a highly charged C terminus. Larkin RM, et al. **Gene** 1996 Jun 26;172(2):211–5
The mitochondrial pyruvate dehydrogenase complex: nucleotide and deduced amino–acid sequences of a cDNA encoding the Arabidopsis thaliana E1 alpha–subunit. Luethy MH, et al. **Gene** 1995 Oct 27;164(2):251–4
Clustered genes within the genome of Arabidopsis thaliana encoding pectin methylesterase–like enzymes. Richard L, et al. **Gene** 1996 May 8;170(2):207–11
Arabidopsis thaliana NADPH oxidoreductase homologs confer tolerance of yeasts toward the thiol–oxidizing drug diamide. Babiychuk E, et al. **J Biol Chem** 1995 Nov 3; 270(44):26224–31
Arabidopsis thaliana contains two differentially expressed farnesyl–diphosphate synthase genes. Cunillera N, et al.
J Biol Chem 1996 Mar 29;271(13):7774–80

Inhibition of ubiquitin-mediated proteolysis by the Arabidopsis 26 S protease subunit S5a. Deveraux Q, et al. **J Biol Chem** 1995 Dec 15;270(50):29660-3

Cloning by metabolic interference in yeast and enzymatic characterization of Arabidopsis thaliana sterol delta 7-reductase. Lecain E, et al. **J Biol Chem** 1996 May 3; 271(18):10866-73

Cloning of a cDNA encoded by a member of the Arabidopsis thaliana ATP sulfurylase multigene family. Expression studies in yeast and in relation to plant sulfur nutrition. Logan HM, et al. **J Biol Chem** 1996 May 24; 271(21):12227-33

Association between 36- and 13.6-kDa alpha-like subunits of Arabidopsis thaliana RNA polymerase II. Ulmasov T, et al. **J Biol Chem** 1996 Mar 1;271(9):5085-94

Three-dimensional structure of glutathione S-transferase from Arabidopsis thaliana at 2.2 A resolution: structural characterization of herbicide-conjugating plant glutathione S-transferases and a novel active site architecture. Reinemer P, et al. **J Mol Biol** 1996 Jan 19;255(2):289-309

Analysis of the H(+)-ATPase and other proteins of the Arabidopsis plasma membrane. Schaller GE, et al. **Methods Cell Biol** 1995;50:129-48

A chlorophyll synthetase gene from Arabidopsis thaliana. Gaubier P, et al. **Mol Gen Genet** 1995 Nov 1;249(1):58-64

Arabidopsis thaliana tryptophan synthase alpha: gene cloning, expression, and subunit interaction. Radwanski ER, et al. **Mol Gen Genet** 1995 Oct 25;248(6):657-67

The circadian clock gates expression of two Arabidopsis catalase genes to distinct and opposite circadian phases. Zhong HH, et al. **Mol Gen Genet** 1996 May 23; 251(2):196-203

The same Arabidopsis gene encodes both cytosolic and mitochondrial alanyl-tRNA synthetases. Mireau H, et al. **Plant Cell** 1996 Jun;8(6):1027-39

Identification in vitro of a post-translational regulatory site in the hinge 1 region of Arabidopsis nitrate reductase. Su W, et al. **Plant Cell** 1996 Mar;8(3):519-27

Arabidopsis TCH4, regulated by hormones and the environment, encodes a xyloglucan endotransglycosylase. Xu W, et al. **Plant Cell** 1995 Oct;7(10):1555-67

The sequence and expression of the gamma-VPE gene, one member of a family of three genes for vacuolar processing enzymes in Arabidopsis thaliana. Kinoshita T, et al. **Plant Cell Physiol** 1995 Dec;36(8):1555-62

FLP recombinase in transgenic plants: constitutive activity in stably transformed tobacco and generation of marked cell clones in Arabidopsis. Kilby NJ, et al. **Plant J** 1995 Nov;8(5):637-52

The use of an alternative promoter in the Arabidopsis thaliana HMG1 gene generates an mRNA that encodes a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase isoform with an extended N-terminal region. Lumbreras V, et al. **Plant J** 1995 Oct;8(4):541-9

Distinct roles for light-dependent NADPH:protochlorophyllide oxidoreductases (POR) A and B during greening in higher plants. Runge S, et al. **Plant J** 1996 Apr;9(4):513-23

Transgenic tobacco plants expressing the Arabidopsis thaliana nitrilase II enzyme. Schmidt RC, et al. **Plant J** 1996 May;9(5):683-91

A second form of adenine phosphoribosyltransferase in Arabidopsis thaliana with relative specificity towards cytokinins. Schnorr KM, et al. **Plant J** 1996 Jun;9(6):891-8

Molecular cloning of a cDNA encoding diacylglycerol kinase (DGK) in Arabidopsis thaliana. Katagiri T, et al. **Plant Mol Biol** 1996 Feb;30(3):647-53

Expression of Arabidopsis cytosolic ascorbate peroxidase gene in response to ozone or sulfur dioxide. Kubo A, et al. **Plant Mol Biol** 1995 Nov;29(3):479-89

A second and differentially expressed glutamyl-tRNA reductase gene from Arabidopsis thaliana. Kumar AM, et al. **Plant Mol Biol** 1996 Feb;30(3):419-26

Molecular cloning of a sulfotransferase in Arabidopsis thaliana and regulation during development and in response to infection with pathogenic bacteria. Lacomme C, et al. **Plant Mol Biol** 1996 Mar;30(5):995-1008

Tissue-specific and light-responsive regulation of the promoter region of the Arabidopsis thaliana chloroplast omega-3 fatty acid desaturase gene (FAD7). Nishiuchi T, et al. **Plant Mol Biol** 1995 Nov;29(3):599-609

Members of two gene families encoding ubiquitin-conjugating enzymes, AtUBC1-3 and AtUBC4-6, from Arabidopsis thaliana are differentially expressed. Thoma S, et al. **Plant Mol Biol** 1996 Jun; 31(3):493-505

Differential accumulation of the transcripts of 22 novel protein kinase genes in Arabidopsis thaliana. Thümmler F, et al. **Plant Mol Biol** 1995 Nov;29(3):551-65

Molecular cloning and characterization of the cDNA coding for the biotin-containing subunit of the chloroplastic acetyl-coenzyme A carboxylase. Choi JK, et al. **Plant Physiol** 1995 Oct;109(2):619-25

Abscisic acid induces the alcohol dehydrogenase gene in Arabidopsis. de Bruxelles GL, et al. **Plant Physiol** 1996 Jun;111(2):381-91

Multiple isoforms of Arabidopsis casein kinase I combine conserved catalytic domains with variable carboxyl-terminal extensions. Klimczak LJ, et al. **Plant Physiol** 1995 Oct;109(2):687-96

Light suppresses 3-Hydroxy-3-methylglutaryl coenzyme A reductase gene expression in Arabidopsis thaliana. Learned RM. **Plant Physiol** 1996 Feb;110(2):645-55

Analysis of flavanone 3-hydroxylase in Arabidopsis seedlings. Coordinate regulation with chalcone synthase and chalcone isomerase. Pelletier MK, et al. **Plant Physiol** 1996 May;111(1):339-45

Ultraviolet-B- and ozone-induced biochemical changes in antioxidant enzymes of Arabidopsis thaliana. Rao MV, et al. **Plant Physiol** 1996 Jan;110(1):125-36

Insect cell expression of recombinant imidazoleglycerolphosphate dehydratase of Arabidopsis and wheat and inhibition by triazole herbicides. Tada S, et al. **Plant Physiol** 1995 Sep;109(1):153-9

Regulation of Arabidopsis thaliana (L.) Heynh Arginine decarboxylase by potassium deficiency stress. Watson MB, et al. **Plant Physiol** 1996 Aug;111(4):1077-83

Ferulate-5-hydroxylase from Arabidopsis thaliana defines a new family of cytochrome P450-dependent monooxygenases. Meyer K, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6869-74

A protein farnesyl transferase involved in abscisic acid signal transduction in Arabidopsis. Cutler S, et al. **Science** 1996 Aug 30;273(5279):1239-41

GENETICS

cis-regulatory elements of the peroxidase gene in Arabidopsis thaliana involved in root-specific expression and responsiveness to high-salt stress. Wanapu C, et al. **Ann N Y Acad Sci** 1996 May 15;782:107-14

Characterization of a ferritin mRNA from Arabidopsis thaliana accumulated in response to iron through an oxidative pathway independent of abscisic acid. Gaymard F, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):67-73

Molecular and functional studies of copper amine oxidase from Arabidopsis thaliana. Møller SG, et al. **Biochem Soc Trans** 1995 Nov;23(4):630S

Molecular cloning and sequencing of a nuclear gene encoding tRNA(Gln) (UUG) from Arabidopsis thaliana. Akama K. **Biochim Biophys Acta** 1996 Jun 7;1307(2):127-8

A cDNA clone from Arabidopsis thaliana encoding plastidic ferredoxin: sulfite reductase. Brühl A, et al. **Biochim Biophys Acta** 1996 Jul 18;1295(2):119-24

Arabidopsis thaliana cDNA isolated by functional complementation shows homology to serine/threonine protein kinases. Covic L, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):125-9

Mutations of Arabidopsis thaliana pre-tRNA(Tyr) affecting pseudouridylation of U35. Szweykowska-Kulinska Z, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):87-92

Biotin synthesis in higher plants: isolation of a cDNA encoding Arabidopsis thaliana bioB-gene product equivalent by functional complementation of a biotin auxotroph mutant bioB105 of Escherichia coli K12. Baldet P, et al. **C R Acad Sci III** 1996 Feb;319(2):99-106

Epigenetic control of an endogenous gene family is revealed by a novel blue fluorescent mutant of Arabidopsis. Bender J, et al. **Cell** 1995 Dec 1;83(5):725-34

The SCARECROW gene regulates an asymmetric cell division that is essential for generating the radial organization of the Arabidopsis root. Di Laurenzio L, et al. **Cell** 1996 Aug 9;86(3):423-33

HOOKLESS1, an ethylene response gene, is required for differential cell elongation in the Arabidopsis hypocotyl. Lehman A, et al. **Cell** 1996 Apr 19;85(2):183-94

The BELL1 gene encodes a homeodomain protein involved in pattern formation in the Arabidopsis ovule primordium. Reiser L, et al. **Cell** 1995 Dec 1;83(5):735-42

Brassinosteroids rescue the deficiency of CYP90, a cytochrome P450, controlling cell elongation and de-etiolation in Arabidopsis. Szekeres M, et al. **Cell** 1996 Apr 19;85(2):171-82

Floral chromosomes of Arabidopsis thaliana for detecting low-copy DNA sequences by fluorescence in situ hybridization. Murata M, et al. **Chromosoma** 1995 Oct; 104(1):39-43

Characterization of the nuclear gene encoding chloroplast ribosomal protein S13 from Arabidopsis thaliana. Kumar R, et al. **Curr Genet** 1995 Sep;28(4):346-52

Identification and characterization of the Arabidopsis thaliana chloroplast DNA region containing the genes psbA, trnH and rps19'. Liere K, et al. **Curr Genet** 1995 Jul;28(2):128-30

Transgene inactivation in Arabidopsis thaliana. Scheid OM. **Curr Top Microbiol Immunol** 1995;197:29-42 (57 ref.)

The expression of the Athb-8 homeobox gene is restricted to provascular cells in Arabidopsis thaliana. Baima S, et al. **Development** 1995 Dec;121(12):4171-82

LOP1: a gene involved in auxin transport and vascular patterning in Arabidopsis. Carland FM, et al. **Development** 1996 Jun;122(6):1811-9

The CLAVATA and SHOOT MERISTEMLESS loci competitively regulate meristem activity in Arabidopsis. Clark SE, et al. **Development** 1996 May;122(5):1567-75

Procuste1 mutants identify two distinct genetic pathways controlling hypocotyl cell elongation, respectively in dark- and light-grown Arabidopsis seedlings. Desnos T, et al. **Development** 1996 Feb;122(2):683-93

An altered body plan is conferred on Arabidopsis plants carrying dominant alleles of two genes. Grbić B, et al. **Development** 1996 Aug;122(8):2395-2403

The Arabidopsis homeotic genes APETALA3 and PISTILLATA are sufficient to provide the B class organ identity function. Krizek BA, et al. **Development** 1996 Jan; 122(1):11-22

The WUSCHEL gene is required for shoot and floral meristem integrity in Arabidopsis. Laux T, et al. **Development** 1996 Jan;122(1):87-96

The REVOLUTA gene is necessary for apical meristem development and for limiting cell divisions in the leaves and stems of Arabidopsis thaliana. Talbert PB, et al. **Development** 1995 Sep;121(9):2723-35

Two independent and polarized processes of cell elongation regulate leaf blade expansion in Arabidopsis thaliana (L.) Heynh. Tsuge T, et al. **Development** 1996 May; 122(5):1589-600

Structural analysis of a recA-like gene in the genome of Arabidopsis thaliana. Sato S, et al. **DNA Res** 1995; 2(2):89-93

The higher plant Arabidopsis thaliana encodes a functional CDC48 homologue which is highly expressed in dividing and expanding cells. Feiler HS, et al. **EMBO J** 1995 Nov 15;14(22):5626-37

A mutation in protein phosphatase 2A regulatory subunit A affects auxin transport in Arabidopsis. Garbers C, et al. **EMBO J** 1996 May 1;15(9):2115-24

Multiple regions of the Arabidopsis SAUR-AC1 gene control transcript abundance: the 3' untranslated region functions as an mRNA instability determinant. Gil P, et al. **EMBO J** 1996 Apr 1;15(7):1678-86

Molecular identification of zeaxanthin epoxidase of Nicotiana plumbaginifolia, a gene involved in abscisic acid biosynthesis and corresponding to the ABA locus of Arabidopsis thaliana. Marin E, et al. **EMBO J** 1996 May 15;15(10):2331-42

Combinatorial interplay of promoter elements constitutes the minimal determinants for light and developmental control of gene expression in Arabidopsis. Puente P, et al. **EMBO J** 1996 Jul 15;15(14):3732-43

Cloning of Arabidopsis thaliana glutathione synthetase (GSH2) by functional complementation of a yeast gsh2 mutant. Ullmann P, et al. **Eur J Biochem** 1996 Mar 1; 236(2):662-9

Molecular characterization of an Arabidopsis thaliana cDNA encoding a novel putative adenylate translocator of higher plants. Kampfenkel K, et al. **FEBS Lett** 1995 Nov 6; 374(3):351-5

Isolation of an ion channel gene from Arabidopsis thaliana using the H5 signature sequence from voltage-dependent K+ channels. Ketchum KA, et al. **FEBS Lett** 1996 Jan 2;378(1):19-26

An Arabidopsis thaliana cDNA encoding PS II-X, a 4.1 kDa component of photosystem II: a bipartite presequence mediates SecA/delta pH-independent targeting into thylakoids. Kim SJ, et al. **FEBS Lett** 1996 Jul 22; 390(2):175-8

A novel myb-related gene from Arabidopsis thaliana. Li SF, et al. **FEBS Lett** 1996 Jan 29;379(2):117-21

Characterisation of an Arabidopsis thaliana cDNA encoding glutathione synthetase. Rawlins MR, et al. **FEBS Lett** 1995 Nov 27;376(1-2):81-6

Promoter and expression studies on an Arabidopsis thaliana dehydrin gene. Rouse DT, et al. **FEBS Lett** 1996 Mar 4; 381(3):252-6

Isolation, characterization, and chromosomal location of a gene encoding the delta 1-pyrroline-5-carboxylate synthetase in Arabidopsis thaliana. Savouré A, et al. **FEBS Lett** 1995 Sep 18;372(1):13-9

Transfer of rps10 from the mitochondrion to the nucleus in Arabidopsis thaliana: evidence for RNA-mediated transfer and exon shuffling at the integration site. Wischmann C, et al. **FEBS Lett** 1995 Oct 30;374(2):152-6

The first intron of the Arabidopsis thaliana gene coding for elongation factor 1 beta contains an enhancer-like element. Gidekel M, et al. **Gene** 1996 May 8;170(2):201-6

Structure of the gene encoding nitrilase 1 from Arabidopsis thaliana. Hillebrand H, et al. **Gene** 1996 May 8; 170(2):197-200

Characterization of two members (ACS1 and ACS3) of the 1-aminocyclopropane-1-carboxylate synthase gene family of Arabidopsis thaliana. Liang X, et al. **Gene** 1995 Dec 29;167(1-2):17-24

The mitochondrial pyruvate dehydrogenase complex: nucleotide and deduced amino-acid sequences of a cDNA encoding the Arabidopsis thaliana E1 alpha-subunit. Luethy MH, et al. **Gene** 1995 Oct 27;164(2):251-4

Isolation and characterization of a cDNA encoding Arabidopsis thaliana 3-hydroxy-3-methylglutaryl-coenzyme A synthase. Montamat F, et al. **Gene** 1995 Dec 29;167(1-2):197-201

Arabidopsis expresses two genes that encode polypeptides similar to the yeast RNA polymerase I and III AC40 subunit. Ulmasov T, et al. **Gene** 1995 Dec 29;167(1-2):203-7

Nuclear localization of the Arabidopsis APETALA3 and PISTILLATA homeotic gene products depends on their simultaneous expression. McGonigle B, et al. **Genes Dev** 1996 Jul 15;10(14):1812-21

Radiation-sensitive mutants of Arabidopsis thaliana. Jenkins ME, et al. **Genetics** 1995 Jun;140(2):725-32

Genome-wide high-resolution mapping by recurrent intermating using Arabidopsis thaliana as a model. Liu SC, et al. **Genetics** 1996 Jan;142(1):247-58

A physical map of chromosome 2 of Arabidopsis thaliana. Zachgo EA, et al. **Genome Res** 1996 Jan;6(1):19-25

Arabidopsis thaliana contains two differentially expressed farnesyl-diphosphate synthase genes. Cunillera N, et al.

J Biol Chem 1996 Mar 29;271(13):7774–80

A cell wall–associated, receptor–like protein kinase. He ZH, et al. **J Biol Chem** 1996 Aug 16;271(33):19789–93

Two classes of plant cDNA clones differentially complement yeast calcineurin mutants and increase salt tolerance of wild–type yeast. Lippuner V, et al. **J Biol Chem** 1996 May 31;271(22):12859–66

The Arabidopsis thaliana UBC7/13/14 genes encode a family of multiubiquitin chain–forming E2 enzymes. van Nocker S, et al. **J Biol Chem** 1996 May 24;271(21):12150–8

arc6, an extreme chloroplast division mutant of Arabidopsis also alters proplastid proliferation and morphology in shoot and root apices. Robertson EJ, et al. **J Cell Sci** 1995 Sep; 108 (Pt 9):2937–44

Increased resistance to extracellular cation block by mutation of the pore domain of the Arabidopsis inward–rectifying K+ channel KAT1. Ichida AM, et al. **J Membr Biol** 1996 May;151(1):53–62

Characterization of an Arabidopsis thaliana gene that defines a new class of putative plant receptor kinases with an extracellular lectin–like domain. Hervé C, et al. **J Mol Biol** 1996 May 24;258(5):778–88

Gene expression in plant cell cultures under continuous blue light irradiation of high intensity. Kaldenhoff R. **J Photochem Photobiol B** 1995 Dec;31(3):97–100 (35 ref.)

Molecular methods for isolation of signal transduction pathway mutants. Chory J, et al. **Methods Cell Biol** 1995; 49:441–54 (16 ref.)

High–frequency and efficient Agrobacterium–mediated transformation of Arabidopsis thaliana ecotypes "C24" and "Landsberg erecta" using Agrobacterium tumefaciens. Barghchi M. **Methods Mol Biol** 1995;44:135–47

Agrobacterium–mediated transformation of Arabidopsis thaliana. Application in T–DNA tagging. Topping JF, et al. **Methods Mol Biol** 1995;49:63–76 (26 ref.)

Intra– and interspecific variation of the alcohol dehydrogenase locus region in wild plants Arabis gemmifera and Arabidopsis thaliana [letter] Miyashita NT, et al. **Mol Biol Evol** 1996 Feb;13(2):433–6

Molecular analysis of the Arabidopsis pattern formation of gene GNOM: gene structure and intragenic complementation. Busch M, et al. **Mol Gen Genet** 1996 Apr 10;250(6):681–91

Binding specificity and tissue–specific expression pattern of the Arabidopsis bZIP transcription factor TGA2. de Pater S, et al. **Mol Gen Genet** 1996 Feb 5;250(2):237–9

A chlorophyll synthetase gene from Arabidopsis thaliana. Gaubier P, et al. **Mol Gen Genet** 1995 Nov 1;249(1):58–64

Characterisation of a new allele of pale cress and its role in greening in Arabidopsis thaliana. Grevelding C, et al. **Mol Gen Genet** 1996 Jul 19;251(5):532–41

Mapping of the nucleolus organizer region on chromosome 4 in Arabidopsis thaliana. Haberer G, et al. **Mol Gen Genet** 1996 Jan 15;250(1):123–8

Novel GUS expression patterns following transposition of an enhancer trap Ds element in Arabidopsis. Klimyuk VI, et al. **Mol Gen Genet** 1995 Dec 10;249(4):357–65

Developmental and tissue–specific regulation of the gene for the wheat basic/leucine zipper protein HBP–1a(17) in transgenic Arabidopsis plants. Mikami K, et al. **Mol Gen Genet** 1995 Sep 20;248(5):573–82

Complementation of an Arabidopsis thaliana biotin auxotroph with an Escherichia coli biotin biosynthetic gene. Patton DA, et al. **Mol Gen Genet** 1996 Jun 12;251(3):261–6

The tef1 box, a ubiquitous cis–acting element involved in the activation of plant genes that are highly expressed in cycling cells. Regad F, et al. **Mol Gen Genet** 1995 Oct 25;248(6):703–11

Genetic and physical mapping in Brassica diploid species of a gene cluster defined in Arabidopsis thaliana. Sadowski J, et al. **Mol Gen Genet** 1996 Jun 12;251(3):298–306

Transgenic Arabidopsis tester lines with dominant marker genes. Van Lijsebettens M, et al. **Mol Gen Genet** 1996 Jun 12;251(3):365–72

Structure, organization and expression of the metallothionein gene family in Arabidopsis. Zhou J, et al. **Mol Gen Genet** 1995 Aug 21;248(3):318–28

Identification of a new Arabidopsis disease resistance locus, RPs4, and cloning of the corresponding avirulence gene, avrRps4, from Pseudomonas syringae pv. pisi. Hinsch M, et al. **Mol Plant Microbe Interact** 1996 Jan;9(1):55–61

Phenotypic and genotypic variation in the interaction between Arabidopsis thaliana and Albugo candida. Holub EB, et al. **Mol Plant Microbe Interact** 1995 Nov–Dec; 8(6):916–28

Four Arabidopsis RPP loci controlling resistance to the Noco2 isolate of Peronospora parasitica map to regions known to contain other RPP recognition specificities. Reignault P, et al. **Mol Plant Microbe Interact** 1996 Aug; 9(6):464–73

A disease resistance gene in Arabidopsis with specificity for the avrPph3 gene of Pseudomonas syringae pv. phaseolicola. Simonich MT, et al. **Mol Plant Microbe Interact** 1995 Jul–Aug;8(4):637–40

First plant genome sequencing planned [news] Kramer D. **Nature** 1996 Sep 19;383(6597):208

A member of the KNOTTED class of homeodomain proteins encoded by the STM gene of Arabidopsis. Long JA, et al. **Nature** 1996 Jan 4;379(6560):66–9

A gene triggering flower formation in Arabidopsis [see comments] Mandel MA, et al. **Nature** 1995 Oct 12; 377(6549):522–4. Comment in: Nature 1995 Oct 12;377(6549):482.

Role of SUPERMAN in maintaining Arabidopsis floral whorl boundaries. Sakai H, et al. **Nature** 1995 Nov 9; 378(6553):199–203

Cleaning the GenBank Arabidopsis thaliana data set. Korning PG, et al. **Nucleic Acids Res** 1996 Jan 15;24(2):316–20

DNA–binding properties of Arabidopsis MADS domain homeotic proteins APETALA1, APETALA3, PISTILLATA and AGAMOUS. Riechmann JL, et al. **Nucleic Acids Res** 1996 Aug 15;24(16):3134–41

Identification and distribution of seven classes of middle–repetitive DNA in the Arabidopsis thaliana genome. Thompson HL, et al. **Nucleic Acids Res** 1996 Aug 1;24(15):3017–22

Another heritage from the RNA world: self–excision of intron sequence from nuclear pre–tRNAs. Weber U, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2212–9

Regulation of flowering time: Arabidopsis as a model system to study genes that promote or delay flowering. Coupland G. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):27–34 (54 ref.)

Genetic analysis of a seedling stress response to ethylene in Arabidopsis. Roman G, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):75–81 (48 ref.)

Conserved expression of the Arabidopsis ACT1 and ACT 3 actin subclass in organ primordia and mature pollen. An YQ, et al. **Plant Cell** 1996 Jan;8(1):15–30

Ectopic expression of the Arabidopsis transcriptional activator Athb–1 alters leaf cell fate in tobacco. Aoyama T, et al. **Plant Cell** 1995 Nov;7(11):1773–85

Superroot, a recessive mutation in Arabidopsis, confers auxin overproduction. Boerjan W, et al. **Plant Cell** 1995 Sep; 7(9):1405–19

Arabidopsis in Madison: genes and phenotypes spread like weeds. Chasan R. **Plant Cell** 1995 Nov;7(11):1737–48 (34 ref.)

Isolation and characterization of an Arabidopsis mutant deficient in the thylakoid lipid digalactosyl diacylglycerol. Dörmann P, et al. **Plant Cell** 1995 Nov;7(11):1801–10

Expression of the Pseudomonas syringae avirulence protein AvrB in plant cells alleviates its dependence on the hypersensitive response and pathogenicity (Hrp) secretion system in eliciting genotype–specific hypersensitive cell death [see comments] Gopalan S, et al. **Plant Cell** 1996 Jul;8(7):1095–105. Comment in: Plant Cell 1996 Jul;8(7):1091–3.

DNA binding properties of two Arabidopsis MADS domain proteins: binding consensus and dimer formation. Huang H, et al. **Plant Cell** 1996 Jan;8(1):81–94

Conservation of floral homeotic gene function between Arabidopsis and antirrhinum. Irish VF, et al. **Plant Cell** 1995 Oct;7(10):1635–44

The Arabidopsis AGL8 MADS box gene is expressed in inflorescence meristems and is negatively regulated by APETALA1. Mandel MA, et al. **Plant Cell** 1995 Nov; 7(11):1763–71

A nuclear mutant of Arabidopsis with impaired stability on distinct transcripts of the plastid psbB, psbD/C, ndhH, and ndhC operons. Meurer J, et al. **Plant Cell** 1996 Jul; 8(7):1193–207

The same Arabidopsis gene encodes both cytosolic and mitochondrial alanyl–tRNA synthetases. Mireau H, et al. **Plant Cell** 1996 Jun;8(6):1027–39

Isolation of Arabidopsis genes that differentiate between resistance responses mediated by the RPS2 and RPM1 disease resistance genes. Reuber TL, et al. **Plant Cell** 1996 Feb;8(2):241–9

Genetic separation of third and fourth whorl functions of AGAMOUS. Sieburth LE, et al. **Plant Cell** 1995 Aug; 7(8):1249–58

Calmodulin isoforms differentially enhance the binding of cauliflower nuclear proteins and recombinant TGA3 to a region derived from the Arabidopsis Cam–3 promoter. Szymanski DB, et al. **Plant Cell** 1996 Jun;8(6):1069–77

The Arabidopsis ERECTA gene encodes a putative receptor protein kinase with extracellular leucine–rich repeats. Torii KU, et al. **Plant Cell** 1996 Apr;8(4):735–46

Analysis of the role of 5' and 3' flanking sequence elements upon in vivo expression of the plant tRNATrp genes. Ulmasov B, et al. **Plant Cell** 1995 Oct;7(10):1723–34

The Arabidopsis Adh gene exhibits diverse nucleosome arrangements within a small DNase I–sensitive domain. Vega–Palas MA, et al. **Plant Cell** 1995 Nov;7(11):1923–32

A Dissociation insertion causes a semidominant mutation that increases expression of TINY, an Arabidopsis gene related to APETALA2. Wilson K, et al. **Plant Cell** 1996 Apr; 8(4):659–71

Arabidopsis TCH4, regulated by hormones and the environment, encodes a xyloglucan endotransglycosylase. Xu W, et al. **Plant Cell** 1995 Oct;7(10):1555–67

Effects of sulfate concentrations on the expression of a soybean seed storage protein gene and its reversibility in transgenic Arabidopsis thaliana. Hirai MY, et al. **Plant Cell Physiol** 1995 Oct;36(7):1331–9

Touch–inducible genes for calmodulin and a calmodulin–related protein are located in tandem on a chromosome of Arabidopsis thaliana. Ito T, et al. **Plant Cell Physiol** 1995 Oct;36(7):1369–73

Genomic organization of 251 kDa acetyl–CoA carboxylase genes in Arabidopsis: tandem gene duplication has made two differentially expressed isozymes. Yanai Y, et al. **Plant Cell Physiol** 1995 Jul;36(5):779–87

Mutations throughout an Arabidopsis blue–light photoreceptor impair blue–light–responsive anthocyanin accumulation and inhibition of hypocotyl elongation. Ahmad M, et al. **Plant J** 1995 Nov;8(5):653–8

Strong, constitutive expression of the Arabidopsis ACT2/ACT8 actin subclass in vegetative tissues. An YQ, et al. **Plant J** 1996 Jul;10(1):107–21

Use of Ac as an insertional mutagen in Arabidopsis. Bhatt AM, et al. **Plant J** 1996 Jun;9(6):935–45

Further progress towards a catalogue of all Arabidopsis genes: analysis of a set of 5000 non–redundant ESTs. Cooke R, et al. **Plant J** 1996 Jan;9(1):101–24

The CIC library: a large insert YAC library for genome mapping in Arabidopsis thaliana. Creusot F, et al. **Plant J** 1995 Nov;8(5):763–70

The minimal ribosomal RNA gene promoter of Arabidopsis thaliana includes a critical element at the transcription initiation site. Doelling JH, et al. **Plant J** 1995 Nov; 8(5):683–92

An Arabidopsis mutant deficient in sterol biosynthesis: heterologous complementation by ERG 3 encoding a delta 7–sterol–C–5–desaturase from yeast. Gachotte D, et al. **Plant J** 1995 Sep;8(3):407–16

Identification of genes required for pollen–stigma recognition in Arabidopsis thaliana. Hülskamp M, et al. **Plant J** 1995 Nov;8(5):703–14

Isolation of Arabidopsis mutants altered in the light–regulation of chalcone synthase gene expression using a transgenic screening approach. Jackson JA, et al. **Plant J** 1995 Sep;8(3):369–80

mCCG methylation in angiosperms. Jeddeloh JA, et al. **Plant J** 1996 May;9(5):579–86

FLP recombinase in transgenic plants: constitutive activity in stably transformed tobacco and generation of marked cell clones in Arabidopsis. Kilby NJ, et al. **Plant J** 1995 Nov;8(5):637–52

Two dominant photomorphogenic mutations of Arabidopsis thaliana identified as suppressor mutations of hy2. Kim BC, et al. **Plant J** 1996 Apr;9(4):441–56

Construction of an equalized cDNA library from Arabidopsis thaliana. Kohchi T, et al. **Plant J** 1995 Nov;8(5):771–6

Comparative mapping in Arabidopsis and Brassica, fine scale genome collinearity and congruence of genes controlling flowering time. Lagercrantz U, et al. **Plant J** 1996 Jan; 9(1):13–20

Isolation of two novel myb–like genes from Arabidopsis and studies on the DNA–binding properties of their products. Li SF, et al. **Plant J** 1995 Dec;8(6):963–72

Efficient isolation and mapping of Arabidopsis thaliana T–DNA insert junctions by thermal asymmetric interlaced PCR. Liu YG, et al. **Plant J** 1995 Sep;8(3):457–63

The use of an alternative promoter in the Arabidopsis thaliana HMG1 gene generates an mRNA that encodes a novel 3–hydroxy–3–methylglutaryl coenzyme A reductase isoform with an extended N–terminal region. Lumbreras V, et al. **Plant J** 1995 Oct;8(4):541–9

Sequence–based identification of T–DNA insertion mutations in Arabidopsis: actin mutants act2–1 and act4–1. McKinney EC, et al. **Plant J** 1995 Oct;8(4):613–22

CLA1, a novel gene required for chloroplast development, is highly conserved in evolution. Mandel MA, et al. **Plant J** 1996 May;9(5):649–58

Detailed description of four YAC contigs representing 17 Mb of chromosome 4 of Arabidopsis thaliana ecotype Columbia. Schmidt R, et al. **Plant J** 1996 May;9(5):755–65

Analysis of Arabidopsis mutants deficient in flavonoid biosynthesis. Shirley BW, et al. **Plant J** 1995 Nov; 8(5):659–71

Molybdenum co–factor biosynthesis: the Arabidopsis thaliana cDNA cnx1 encodes a multifunctional two–domain protein homologous to a mammalian neuroprotein, the insect protein Cinnamon and three Escherichia coli proteins. Stallmeyer B, et al. **Plant J** 1995 Nov;8(5):751–62

Organization and expression of the gene coding for the potassium transport system AKT1 of Arabidopsis thaliana. Basset M, et al. **Plant Mol Biol** 1995 Dec;29(5):947–58

A promoter identified in the 3' end of the Ac transposon can be activated by cis–acting elements in transgenic Arabidopsis lines. Cocherel S, et al. **Plant Mol Biol** 1996 Feb;30(3):539–51

Characterization of DNA sequences encoding a novel isoform of the 55 kDa B regulatory subunit of the type 2A protein serine/threonine phosphatase of Arabidopsis thaliana. Corum JW 3rd, et al. **Plant Mol Biol** 1996 May; 31(2):419–27

Isolation of a cDNA encoding a novel GTP–binding protein of Arabidopsis thaliana. Dombrowski JE, et al. **Plant Mol Biol** 1995 Sep;28(6):1121–6

Two closely related cDNAs encoding starch branching enzyme from Arabidopsis thaliana. Fisher DK, et al. **Plant Mol Biol** 1996 Jan;30(1):97–108

Isolation of an Arabidopsis homologue of the maize homeobox Knotted–1 gene. Granger CL, et al. **Plant Mol Biol** 1996 May;31(2):373–8

Comparison of different constitutive and inducible promoters for the overexpression of transgenes in Arabidopsis thaliana. Holtorf S, et al. **Plant Mol Biol** 1995 Nov; 29(4):637–46

Expression of three members of the calcium–dependent protein kinase gene family in Arabidopsis thaliana. Hong Y, et al. **Plant Mol Biol** 1996 Mar;30(6):1259–75

Characterization of eight new members of the calmodulin-like domain protein kinase gene family from Arabidopsis thaliana. Hrabak EM, et al. **Plant Mol Biol** 1996 May;31(2):405-12

Homologues of a vacuolar processing enzyme that are expressed in different organs in Arabidopsis thaliana. Kinoshita T, et al. **Plant Mol Biol** 1995 Oct;29(1):81-9

Two new oleosin isoforms with altered expression patterns in seeds of the Arabidopsis mutant fus3. Kirik V, et al. **Plant Mol Biol** 1996 May;31(2):413-7

Isolation, expression, and evolution of the gene encoding mitochondrial elongation factor Tu in Arabidopsis thaliana. Kuhlman P, et al. **Plant Mol Biol** 1995 Dec;29(5):1057-70

Cloning, molecular and functional characterization of Arabidopsis thaliana allene oxide synthase (CYP 74), the first enzyme of the octadecanoid pathway to jasmonates. Laudert D, et al. **Plant Mol Biol** 1996 May;31(2):323-35

Thi1, a thiamine biosynthetic gene in Arabidopsis thaliana, complements bacterial defects in DNA repair. Machado CR, et al. **Plant Mol Biol** 1996 Jun;31(3):585-93

Molecular characterization of the gene coding for GPRP, a class of proteins rich in glycine and proline interacting with membranes in Arabidopsis thaliana. Marty I, et al. **Plant Mol Biol** 1996 Feb;30(3):625-36

A distinctly regulated protein repair L-isoaspartylmethyltransferase from Arabidopsis thaliana. Mudgett MB, et al. **Plant Mol Biol** 1996 Feb;30(4):723-37

Tissue-specific and light-responsive regulation of the promoter region of the Arabidopsis thaliana chloroplast omega-3 fatty acid desaturase gene (FAD7). Nishiuchi T, et al. **Plant Mol Biol** 1995 Nov;29(3):599-609

A senescence-associated gene of Arabidopsis thaliana is distinctively regulated during natur.. and artificially induced leaf senescence. Oh SA, et al. **Plant Mol Biol** 1996 Feb;30(4):739-54

Athila, a new retroelement from Arabidopsis thaliana. Pélissier T, et al. **Plant Mol Biol** 1995 Nov;29(3):441-52

Several distinct genes encode nearly identical to 16 kDa proteolipids of the vacuolar H(+)-ATPase from Arabidopsis thaliana. Perera IY, et al. **Plant Mol Biol** 1995 Oct;29(2):227-44

Cloning of an Arabidopsis thaliana cDNA encoding cystathionine beta-lyase by functional complementation in Escherichia coli. Ravanel S, et al. **Plant Mol Biol** 1995 Nov;29(4):875-82

Cloning and characterization of an Arabidopsis thaliana cDNA clone encoding an organellar isoform of serine acetyltransferase. Roberts MA, et al. **Plant Mol Biol** 1996 Mar;30(5):1041-9

Expression of the type 2 metallothionein-like gene MT2 from Arabidopsis thaliana in Zn(2+)-metallothionein-deficient Synechococcus PCC 7942: putative role for MT2 in Zn2+ metabolism. Robinson NJ, et al. **Plant Mol Biol** 1996 Mar; 30(6):1169-79

Isolation of a novel Arabidopsis ozone-induced cDNA by differential display. Sharma YK, et al. **Plant Mol Biol** 1995 Oct;29(1):91-8

The GATA-binding protein CGF-1 is closely related to GT-1. Teakle GR, et al. **Plant Mol Biol** 1995 Dec; 29(6):1253-66

Members of two gene families encoding ubiquitin-conjugating enzymes, AtUBC1-3 and AtUBC4-6, from Arabidopsis thaliana are differentially expressed. Thoma S, et al. **Plant Mol Biol** 1996 Jun; 31(3):493-505

Analysis of Arabidopsis cDNA that shows homology to the tomato E8 cDNA. Trentmann SM, et al. **Plant Mol Biol** 1995 Oct;29(1):161-6

Isolation and characterization of an auxin-inducible glutathione S-transferase gene of Arabidopsis thaliana. van der Kop DA, et al. **Plant Mol Biol** 1996 Feb;30(4):839-44

Structure and organization of two closely related low-temperature-induced dhn/lea/rab-like genes in Arabidopsis thaliana L. Heynh. Welin BV, et al. **Plant Mol Biol** 1995 Oct;29(2):391-5

Cloning of a cDNA encoding the 21.2 kDa oleosin isoform from Arabidopsis thaliana and a study of its expression in a mutant defective in diacylglycerol acyltransferase activity. Zou J, et al. **Plant Mol Biol** 1996 May;31(2):429-33

Multiple genes, tissue specificity, and expression-dependent modulationcontribute to the functional diversity of potassium channels in Arabidopsis thaliana. Cao Y, et al. **Plant Physiol** 1995 Nov;109(3):1093-106

Functional expression of the extraplastidial Arabidopsis thaliana oleate desaturase gene (FAD2) in Saccharomyces cerevisiae. Covello PS, et al. **Plant Physiol** 1996 May; 111(1):223-6

Abscisic acid induces the alcohol dehydrogenase gene in Arabidopsis. de Bruxelles GL, et al. **Plant Physiol** 1996 Jun;111(2):381-91

A metal-accumulator mutant of Arabidopsis thaliana. Delhaize E. **Plant Physiol** 1996 Jul;111(3):849-55

An Arabidopsis thaliana thionin gene is inducible via a signal transduction pathway different from that for pathogenesis-related proteins. Epple P, et al. **Plant Physiol** 1995 Nov;109(3):813-20

A putative Mg chelatase subunit from Arabidopsis thaliana cv C24. Sequence and transcript analysis of the gene, import of the protein into chloroplasts, and in situ localization of the transcript and protein. Gibson LC, et al. **Plant Physiol** 1996 May;111(1):61-71

Purification and properties of Arabidopsis thaliana COR (cold-regulated) gene polypeptides COR15am and COR6.6 expressed in Escherichia coli. Gilmour SJ, et al. **Plant Physiol** 1996 May;111(1):293-9

The Arabidopsis profilin gene family. Evidence for an ancient split between constitutive and pollen-specific profilin genes. Huang S, et al. **Plant Physiol** 1996 May; 111(1):115-26

Arabidopsis mutants lacking phenolic sunscreens exhibit enhanced ultraviolet-B injury and oxidative damage. Landry LG, et al. **Plant Physiol** 1995 Dec;109(4):1159-66

The Arabidopsis thaliana trp5 mutant has a feedback-resistant anthranilate synthase and elevated soluble tryptophan. Li J, et al. **Plant Physiol** 1996 Jan;110(1):51-9

Comparison of metallothionein gene expression and nonprotein thiols in ten Arabidopsis ecotypes. Correlation with copper tolerance. Murphy A, et al. **Plant Physiol** 1995 Nov;109(3):945-54

Expression of an Arabidopsis potassium channel gene in guard cells. Nakamura RL, et al. **Plant Physiol** 1995 Oct; 109(2):371-4

Cold-shock regulation of the Arabidopsis TCH genes and the effects of modulating intracellular calcium levels. Polisensky DH, et al. **Plant Physiol** 1996 Aug;111(4):1271-9

Arabidopsis thaliana sku mutant seedlings show exaggerated surface-dependent alteration in root growth vector. Rutherford R, et al. **Plant Physiol** 1996 Aug;111(4):987-98

Cloning of a second Arabidopsis peptide transport gene. Song W, et al. **Plant Physiol** 1996 Jan;110(1):171-8

Insect cell expression of recombinant imidazoleglycerolphosphate dehydratase of Arabidopsis and wheat and inhibition by triazole herbicides. Tada S, et al. **Plant Physiol** 1995 Sep;109(1):153-9

Evidence that plant K+ channel proteins have two different types of subunits. Tang H, et al. **Plant Physiol** 1995 Sep; 109(1):327-30

Effects of COR6.6 and COR15am polypeptides encoded by COR (cold-regulated) genes of Arabidopsis thaliana on the freeze-induced fusion and leakage of liposomes. Uemura M, et al. **Plant Physiol** 1996 May;111(1):313-27

Copper-sensitive mutant of Arabidopsis thaliana. van Vliet C, et al. **Plant Physiol** 1995 Nov;109(3):871-8

Effects of COR6.6 and COR15am polypeptides encoded by COR (cold-regulated) genes of Arabidopsis thaliana on dehydration-induced phase transitions of phospholipid membranes. Webb MS, et al. **Plant Physiol** 1996 May; 111(1):301-12

Sensitivity to abscisic acid of guard-cell K+ channels is suppressed by abi1-1, a mutant Arabidopsis gene encoding a putative protein phosphatase. Armstrong F, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9520-4

A computer-based systematic survey reveals the predominance of small inverted-repeat elements in wild-type rice genes. Bureau TE, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8524-9

Environmental stress sensitivity of an ascorbic acid-deficient Arabidopsis mutant. Conklin PL, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9970-4

Reduced DNA methylation in Arabidopsis thaliana results in abnormal plant development. Finnegan EJ, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8449-54

The genome of Arabidopsis thaliana. Goodman HM, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10831-5 (64 ref.)

CAX1, an H+/Ca2+ antiporter from Arabidopsis. Hirschi KD, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6; 93(16):8782-6

Characterization of Arabidopsis thaliana cDNAs that render yeasts tolerant toward the thiol-oxidizing drug diamide. Kushnir S, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10580-4

Arabidopsis mutant analysis and gene regulation define a nonredundant role for glutamate dehydrogenase in nitrogen assimilation. Melo-Oliveira R, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4718-23

Ferulate-5-hydroxylase from Arabidopsis thaliana defines a new family of cytochrome P450-dependent monooxygenases. Meyer K, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6869-74

A change of ploidy can modify epigenetic silencing. Mittelsten Scheid O, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7114-9

A gene encoding a mitogen-activated protein kinase kinase kinase is induced simultaneously with genes for a mitogen-activated protein kinase and an S6 ribosomal protein kinase by touch, cold, and water stress in Arabidopsis thaliana. Mizoguchi T, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):765-9

Mercuric ion reduction and resistance in transgenic Arabidopsis thaliana plants expressing a modified bacterial merA gene. Rugh CL, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3182-7

Ozone-induced responses in Arabidopsis thaliana: the role of salicylic acid in the accumulation of defense-related transcripts and induced resistance. Sharma YK, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5099-104

Two Arabidopsis cyclin promoters mediate distinctive transcriptional oscillation in synchronized tobacco BY-2 cells. Shaul O, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4868-72

Arabidopsis mutants deficient in T-DNA integration. Sonti RV, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5; 92(25):11786-90

Arabidopsis MBP1 gene encodes a conserved ubiquitin recognition component of the 26S proteasome. van Nocker S, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):856-60

The PR5K receptor protein kinase from Arabidopsis thaliana is structurally related to a family of plant defense proteins. Wang X, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19; 93(6):2598-602

Arabidopsis AUX1 gene: a permease-like regulator of root gravitropism. Bennett MJ, et al. **Science** 1996 Aug 16; 273(5277):948-50

Ethylene insensitivity conferred by Arabidopsis ERS gene. Hua J, et al. **Science** 1995 Sep 22;269(5231):1712-4

First global sequencing effort begins [news] Kaiser J. **Science** 1996 Oct 4;274(5284):30

Chemical shackles for genes? [news; comment] Pennisi E. **Science** 1996 Aug 2;273(5275):574-5. Comment on: Science 1996 Aug 2;273(5275):654-7.

Demethylation-induced developmental pleiotropy in Arabidopsis [see comments] Ronemus MJ, et al. **Science** 1996 Aug 2;273(5275):654-7. Comment in: Science 1996 Aug 2;273(5275):574-5.

Probing flowers' genetic past [news] Roush W. **Science** 1996 Sep 6;273(5280):1339

Quantitative monitoring of gene expression patterns with a complementary DNA microarray [see comments] Schena M, et al. **Science** 1995 Oct 20;270(5235):467-70. Comment in: Science 1995 Oct 20;270(5235):368-9, 371.

Physical map and organization of Arabidopsis thaliana chromosome 4. Schmidt R, et al. **Science** 1995 Oct 20; 270(5235):480-3

GROWTH & DEVELOPMENT

Initiation patterns of flower and floral organ development in Arabidopsis thaliana. Bossinger G, et al. **Development** 1996 Apr;122(4):1093-102

Procuste1 mutants identify two distinct genetic pathways controlling hypocotyl cell elongation, respectively in dark- and light-grown Arabidopsis seedlings. Desnos T, et al. **Development** 1996 Feb;122(2):683-93

Clonal analysis of the late flowering fca mutant of Arabidopsis thaliana: cell fate and cell autonomy. Furner IJ, et al. **Development** 1996 Mar;122(3):1041-50

The Arabidopsis homeotic genes APETALA3 and PISTILLATA are sufficient to provide the B class organ identity function. Krizek BA, et al. **Development** 1996 Jan; 122(1):11-22

The control of trichome spacing and number in Arabidopsis. Larkin JC, et al. **Development** 1996 Mar;122(3):997-1005

Formation of lateral root meristems is a two-stage process. Laskowski MJ, et al. **Development** 1995 Oct; 121(10):3303-10

The WUSCHEL gene is required for shoot and floral meristem integrity in Arabidopsis. Laux T, et al. **Development** 1996 Jan;122(1):87-96

Mutations in the PERIANTHIA gene of Arabidopsis specifically alter floral organ number and initiation pattern. Running MP, et al. **Development** 1996 Apr;122(4):1261-9

A developmental switch sufficient for flower initiation in diverse plants [see comments] Weigel D, et al. **Nature** 1995 Oct 12;377(6549):495-500. Comment in: Nature 1995 Oct 12;377(6549):482.

Signal-transduction pathways controlling light-regulated development in Arabidopsis. Chory J, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):59-65 (62 ref.)

Conserved expression of the Arabidopsis ACT1 and ACT 3 actin subclass in organ primordia and mature pollen. An YQ, et al. **Plant Cell** 1996 Jan;8(1):15-30

Parallels between UNUSUAL FLORAL ORGANS and FIMBRIATA, genes controlling flower development in Arabidopsis and Antirrhinum. Ingram GC, et al. **Plant Cell** 1995 Sep;7(9):1501-10

Diverse roles for MADS box genes in Arabidopsis development. Rounsley SD, et al. **Plant Cell** 1995 Aug; 7(8):1259-69

Effects of gibberellins on seed germination of phytochrome-deficient mutants of Arabidopsis thaliana. Yang YY, et al. **Plant Cell Physiol** 1995 Oct;36(7):1205-11

Specification of chimeric flowering shoots in wild-type Arabidopsis. Hempel FD, et al. **Plant J** 1995 Nov; 8(5):725-31

Arabidopsis mutants with a reduced seed dormancy. Léon-Kloosterziel KM, et al. **Plant Physiol** 1996 Jan; 110(1):233-40

A role for brassinosteroids in light-dependent development of Arabidopsis [see comments] Li J, et al. **Science** 1996 Apr 19;272(5260):398-401. Comment in: Science 1996 Apr 19;272(5260):370-1.

Chemical shackles for genes? [news; comment] Pennisi E. **Science** 1996 Aug 2;273(5275):574-5. Comment on: Science 1996 Aug 2;273(5275):654-7.

Demethylation-induced developmental pleiotropy in Arabidopsis [see comments] Ronemus MJ, et al. **Science** 1996 Aug 2;273(5275):654-7. Comment in: Science 1996 Aug 2;273(5275):574-5.

Green light for steroid hormones [comment] Russell DW. **Science** 1996 Apr 19;272(5260):370-1 (7 ref.). Comment on: Science 1996 Apr 19;272(5260):398-401.

METABOLISM

Construction of gene expression system in cultured tobacco

cells. Shinmyo A, et al. **Ann N Y Acad Sci** 1996 May 15; 782:97–106

Differential stimulation of NAD kinase and binding of peptide substrates by wild–type and mutant plant calmodulin isoforms. Liao B, et al.
Arch Biochem Biophys 1996 Mar 1;327(1):53–60

Transfer of rps19 to the nucleus involves the gain of an RNP–binding motif which may functionally replace RPS13 in Arabidopsis mitochondria. Sánchez H, et al.
EMBO J 1996 May 1;15(9):2138–49

An Arabidopsis thaliana cDNA encoding PS II–X, a 4.1 kDa component of photosystem II: a bipartite presequence mediates SecA/delta pH–independent targeting into thylakoids. Kim SJ, et al. **FEBS Lett** 1996 Jul 22; 390(2):175–8

Promoter and expression studies on an Arabidopsis thaliana dehydrin gene. Rouse DT, et al. **FEBS Lett** 1996 Mar 4; 381(3):252–6

Identification of an Arabidopsis thaliana cDNA encoding a HSP70–related protein belonging to the HSP110/SSE1 subfamily. Storozhenko S, et al. **FEBS Lett** 1996 Jul 15; 390(1):113–8

Nuclear localization of the Arabidopsis APETALA3 and PISTILLATA homeotic gene products depends on their simultaneous expression. McGonigle B, et al. **Genes Dev** 1996 Jul 15;10(14):1812–21

Molecular characterization of a putative Arabidopsis thaliana copper transporter and its yeast homologue. Kampfenkel K, et al. **J Biol Chem** 1995 Nov 24;270(47):28479–86

Characterization and subcellular localization of a small GTP–binding protein (Ara–4) from Arabidopsis: conditional expression under control of the promoter of the gene for heat–shock protein HSP81–1. Ueda T, et al. **Mol Gen Genet** 1996 Mar 20;250(5):533–9

Evidence for proteolytic processing of tobacco mosaic virus movement protein in Arabidopsis thaliana. Hughes RK, et al. **Mol Plant Microbe Interact** 1995 Sep–Oct;8(5):658–65

Isoiation and characterization of an Arabidopsis mutant deficient in the thylakoid lipid digalactosyl diacylglycerol. Dörmann P, et al. **Plant Cell** 1995 Nov;7(11):1801–10

Transcription factor veracity: is GBF3 responsible for ABA–regulated expression of Arabidopsis Adh? Lu G, et al. **Plant Cell** 1996 May;8(5):847–57

A nuclear mutant of Arabidopsis with impaired stability on distinct transcripts of the plastid psbB, psbD/C, ndhH, and ndhC operons. Meurer J, et al. **Plant Cell** 1996 Jul; 8(7):1193–207

An Arabidopsis mutant deficient in sterol biosynthesis: heterologous complementation by ERG 3 encoding a delta 7–sterol–C–5–desaturase from yeast. Gachotte D, et al.
Plant J 1995 Sep;8(3):407–16

AtJ1, a mitochondrial homologue of the Escherichia coli DnaJ protein. Kroczynska B, et al. **Plant Mol Biol** 1996 Jun;31(3):619–29

Thi1, a thiamine biosynthetic gene in Arabidopsis thaliana, complements bacterial defects in DNA repair. Machado CR, et al. **Plant Mol Biol** 1996 Jun;31(3):585–93

Activity of the yeast FLP recombinase in Arabidopsis. Sonti RV, et al. **Plant Mol Biol** 1995 Sep;28(6):1127–32

Deviating T–DNA transfer from Agrobacterium tumefaciens to plants. van der Graaff E, et al. **Plant Mol Biol** 1996 Jun;31(3):677–81

Effect of volatile methyl jasmonate on the oxylipin pathway in tobacco, cucumber, and arabidopsis. Avdiushko S, et al. **Plant Physiol** 1995 Dec;109(4):1227–30

Coi1–dependent expression of an Arabidopsis vegetative storage protein in flowers and siliques and in response to coronatine or methyl jasmonate. Benedetti CE, et al.
Plant Physiol 1995 Oct;109(2):567–72

Differential accumulation of antioxidant mRNAs in Arabidopsis thaliana exposed to ozone. Conklin PL, et al.
Plant Physiol 1995 Sep;109(1):203–12

A metal–accumulator mutant of Arabidopsis thaliana. Delhaize E. **Plant Physiol** 1996 Jul;111(3):849–55

Quantification of free plus conjugated indoleacetic acid in arabidopsis requires correction for the nonenzymatic conversion of indolic nitriles. Ljić N, et al.
Plant Physiol 1996 Jul;111(3):781–8

Expression of an Arabidopsis potassium channel gene in guard cells. Nakamura RL, et al. **Plant Physiol** 1995 Oct; 109(2):371–4

Transgenic AEQUORIN reveals organ–specific cytosolic Ca2+ responses to anoxia and Arabidopsis thaliana seedlings. Sedbrook JC, et al. **Plant Physiol** 1996 May; 111(1):243–57

Structural requirements of oleosin domains for subcellular targeting to the oil body. van Rooijen GJ, et al.
Plant Physiol 1995 Dec;109(4):1353–61

The impact of alteration of polyunsaturated fatty acid levels on C6–aldehyde formation of Arabidopsis thaliana leaves. Zhuang H, et al. **Plant Physiol** 1996 Jul;111(3):805–12

A novel iron–regulated metal transporter from plants identified by functional expression in yeast. Eide D, et al.
Proc Natl Acad Sci U S A 1996 May 28;93(11):5624–8

Seed and vascular expression of a high–affinity transporter for cationic amino acids in Arabidopsis. Frommer WB, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12036–40

Arabidopsis mutant analysis and gene regulation define a nonredundant role for glutamate dehydrogenase in nitrogen assimilation. Melo–Oliveira R, et al.
Proc Natl Acad Sci U S A 1996 May 14;93(10):4718–23

Mercuric ion reduction and resistance in transgenic Arabidopsis thaliana plants expressing a modified bacterial merA gene. Rugh CL, et al.
Proc Natl Acad Sci U S A 1996 Apr 16;93(8):3182–7

Environmental and developmental signals modulate proline homeostasis: evidence for a negative transcriptional regulator. Verbruggen N, et al.
Proc Natl Acad Sci U S A 1996 Aug 6;93(16):8787–91

Circadian oscillations of cytosolic and chloroplastic free calcium in plants. Johnson CH, et al. **Science** 1995 Sep 29;269(5232):1863–5

Ethylene–binding sites generated in yeast expressing the Arabidopsis ETR1 gene [see comments] Schaller GE, et al. **Science** 1995 Dec 15;270(5243):1809–11. Comment in: Science 1995 Dec 15;270(5243):1774.

MICROBIOLOGY

Phenotypic and genotypic variation in the interaction between Arabidopsis thaliana and Albugo candida. Holub EB, et al. **Mol Plant Microbe Interact** 1995 Nov–Dec; 8(6):916–28

Systemic acquired resistance in Arabidopsis requires salicylic acid but not ethylene. Lawton K, et al.
Mol Plant Microbe Interact 1995 Nov–Dec;8(6):863–70

A disease resistance gene in Arabidopsis with specificity for the avrPph3 gene of Pseudomonas syringae pv. phaseolicola. Simonich MT, et al.
Mol Plant Microbe Interact 1995 Jul–Aug;8(4):637–40

PHYSIOLOGY

Plant morphogenesis. Life on a different plane. Lloyd C.
Curr Biol 1995 Oct 1;5(10):1085–7 (9 ref.)

Four Arabidopsis thaliana 14–3–3 protein isoforms can complement the lethal yeast bmh1 bmh2 double disruption. van Heusden GP, et al. **FEBS Lett** 1996 Aug 12; 391(3):252–6

Reaction norms of Arabidopsis IV. Relationships between plasticity and fitness. Pigliucci M, et al. **Heredity** 1996 May; 76 (Pt 5):427–36

Identification of strong modifications in cation selectivity in an Arabidopsis inward rectifying potassium channel by mutant selection in yeast. Uozumi N, et al.
J Biol Chem 1995 Oct 13;270(41):24276–81

QTL analysis of flowering time in Arabidopsis thaliana. Clarke JH, et al. **Mol Gen Genet** 1995 Aug 21;248(3):278–86

Interaction of FLC and late–flowering mutations in Arabidopsis thaliana. Sanda SL, et al. **Mol Gen Genet** 1996 Apr 24;251(1):69–74

Rooting the meristem [news; comment] Jürgens G.
Nature 1995 Nov 2;378(6552):16. Comment on: Nature 1995 Nov 2;378(6552):62–5.

Cell fate in the Arabidopsis root meristem determined by directional signalling [see comments] van den Berg C, et al. **Nature** 1995 Nov 2;378(6552):62–5. Comment in: Nature 1995 Nov 2;378(6552):16.

Far–red light blocks greening of Arabidopsis seedlings via a phytochrome A–mediated change in plastid development. Barnes SA, et al. **Plant Cell** 1996 Apr;8(4):601–15

A null mutation in the first enzyme of flavonoid biosynthesis does not affect male fertility in Arabidopsis. Burbulis IE, et al. **Plant Cell** 1996 Jun;8(6):1013–25

The regulator of MAT2 (ROM2) protein binds to early maturation promoters and represses PvALF–activated transcription. Chern MS, et al. **Plant Cell** 1996 Feb; 8(2):305–21

Characterization of a new vacuolar membrane aquaporin sensitive to mercury at a unique site. Daniels MJ, et al.
Plant Cell 1996 Apr;8(4):587–99

AINTEGUMENTA, an APETALA2–like gene of Arabidopsis with pleiotropic roles in ovule development and floral organ growth. Elliott RC, et al. **Plant Cell** 1996 Feb;8(2):155–68

The AINTEGUMENTA gene of Arabidopsis required for ovule and female gametophyte development is related to the floral homeotic gene APETALA2. Klucher KM, et al. **Plant Cell** 1996 Feb;8(2):137–53

Cold calcium signaling in Arabidopsis involves two cellular pools and a change in calcium signature after acclimation. Knight H, et al. **Plant Cell** 1996 Mar;8(3):489–503

Functional domains of the floral regulator AGAMOUS: characterization of the DNA binding domain and analysis of dominant negative mutations. Mizukami Y, et al.
Plant Cell 1996 May;8(5):831–45

Design in Arabidopsis thaliana of a synchronous system of floral induction by one long day. Corbesier L, et al.
Plant J 1996 Jun;9(6):947–52

Benzothiadiazole induces disease resistance in Arabidopsis by activation of the systemic acquired resistance signal transduction pathway. Lawton KA, et al. **Plant J** 1996 Jul; 10(1):71–82

Derepression of the activity of genetically engineered heat shock factor causes constitutive synthesis of heat shock proteins and increased thermotolerance in transgenic Arabidopsis. Lee JH, et al. **Plant J** 1995 Oct;8(4):603–12

Ethylene is a positive regulator of root hair development in Arabidopsis thaliana. Tanimoto M, et al. **Plant J** 1995 Dec;8(6):943–8

A role for arabinogalactan–proteins in plant cell expansion: evidence from studies on the interaction of beta–glucosyl Yariv reagent with seedlings of Arabidopsis thaliana. Willats WG, et al. **Plant J** 1996 Jun;9(6):919–25

The Arabidopsis XET–related gene family: environmental and hormonal regulation of expression. Xu W, et al.
Plant J 1996 Jun;9(6):879–89

A brassinosteroid–insensitive mutant in Arabidopsis thaliana exhibits multiple defects in growth and development. Clouse SD, et al. **Plant Physiol** 1996 Jul;111(3):671–8

The arabidopsis ACT7 actin gene is expressed in rapidly developing tissues and responds to several external stimuli. McDowell JM, et al. **Plant Physiol** 1996 Jul;111(3):699–711

Phytochrome A regulates red–light induction of phototropic enhancement in Arabidopsis. Parks BM, et al.
Plant Physiol 1996 Jan;110(1):155–62

Isolation of mutations affecting the development of freezing tolerance in Arabidopsis thaliana (L.) Heynh. Warren G, et al. **Plant Physiol** 1996 Aug;111(4):1011–9

A chloroplast lipoxygenase is required for wour d–induced jasmonic acid accumulation in Arabidopsis. Bell E, et al.
Proc Natl Acad Sci U S A 1995 Sep 12;92(19):8675–9

Mapping the protein regions responsible for the functional specificities of the Arabidopsis MADS domain organ–identity proteins. Krizek BA, et al.
Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4063–70

Chromophore–bearing NH2–terminal domains of phytochromes A and B determine their photosensory specificity and differential light lability. Wagner D, et al.
Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4011–5

Genetic and environmental control of flowering time in Arabidopsis. Coupland G. **Trends Genet** 1995 Oct; 11(10):393–7 (38 ref.)

RADIATION EFFECTS

The influence of photosynthetically active radiation on the effects of ultraviolet–B radiation on Arabidopsis thaliana. Berkelsar EJ, et al. **Photochem Photobiol** 1996 Jul; 64(1):110–6

An apparatus for studying rapid electrophysiological responses to light demonstrated on Arabidopsis leaves. Spalding EP. **Photochem Photobiol** 1995 Nov;62(5):934–9

Mutations throughout an Arabidopsis blue–light photoreceptor impair blue–light–responsive anthocyanin accumulation and inhibition of hypocotyl elongation. Ahmad M, et al. **Plant J** 1995 Nov;8(5):653–8

Differential regulation of trichome formation on the adaxial and abaxial leaf surfaces by gibberellins and photoperiod in Arabidopsis thaliana (L.) Heynh. Chien JC, et al.
Plant Physiol 1996 Aug;111(4):1321–8

Arabidopsis mutants lacking phenolic sunscreens exhibit enhanced ultraviolet–B injury and oxidative damage. Landry LG, et al. **Plant Physiol** 1995 Dec;109(4):1159–66

[The genetic consequences of the radioactive contamination of populations of Arabidopsis thaliana growing in a 30–kilometer area of the accident at the Chernobyl Atomic Electric Power Station] Abramov VI, et al.
Radiats Biol Radioecol 1995 Sep–Oct;35(5):676–89 (Eng. Abstr.) **(Rus)**

[Effects of chronic effects of lead nitrate and ionizing radiation on mutagenesis in Arabidopsis Thaliana (L.) Heynh] Kriukov VI, et al. **Radiats Biol Radioecol** 1996 Mar–Apr;36(2):209–18 (Eng. Abstr.) **(Rus)**

VIROLOGY

Open reading frames of turnip crinkle virus involved in satellite symptom expression and incompatibility with Arabidopsis thaliana ecotype Dijon. Oh JW, et al.
Mol Plant Microbe Interact 1995 Nov–Dec;8(6):979–87

Nucleotide sequence of Chinese rape mosaic virus (oilseed rape mosaic virus), a crucifer tobamovirus infectious on Arabidopsis thaliana. Aguilar I, et al. **Plant Mol Biol** 1996 Jan;30(1):191–7

ARABIDOPSIS THALIANA see **ARABIDOPSIS**

ARABINOFURANOSYLADENINE see **VIDARABINE**

ARABINOFURANOSYLADENINE MONOPHOSPHATE see **VIDARABINE PHOSPHATE**

ARABINOFURANOSYLCYTOSINE see **CYTARABINE**

ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE

ANALYSIS

A new sensitive method for determination of intracellular 1–beta–D–arabinofuranosylcytosine 5'–triphosphate content in human materials in vivo. Yamauchi T, et al.
Cancer Res 1996 Apr 15;56(8):1800–4

PHARMACOKINETICS

Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia. Boos J, et al.
Med Pediatr Oncol 1996 Jun;26(6):397–404

ARABINOFURANOSYLNUCLEOSIDES see **ARABINONUCLEOSIDES**

ARABINOFURANOSYLNUCLEOTIDES see **ARABINONUCLEOTIDES**

ARABINOFURANOSYLURACIL

ANALOGS & DERIVATIVES

Sorivudine: a potent inhibitor of varicella zoster virus replication. Whitley RJ. **Adv Exp Med Biol** 1996;394:41–4 (11 ref.)

Sorivudine (BV–ara–U) for the treatment of complicated refractory varicella zoster virus infection in HIV–infected patients [letter] Burdge DR, et al. **AIDS** 1995 Jul;9(7):810–2

Successful treatment of sorivudine–related agranulocytosis with granulocyte–colony stimulating factor [letter] Sato H, et al. **Am J Hematol** 1995 Nov;50(3):227

Hydrocephalus induction in mice infected with herpes simplex virus type 2 after antiviral treatment. Schinazi RF, et al. **Antiviral Res** 1995 Dec;28(4):291–302

Inhibition of Epstein–Barr virus replication by a novel L–nucleoside, 2'–fluoro–5–methyl–beta–L–arabinofuranosyluracil. Yao GQ, et al. **Biochem Pharmacol** 1996 Apr 12;51(7):941–7

Inhibition of dihydropyrimidine dehydrogenase by 5–propynyluracil, a metabolite of the anti–varicella zoster virus agent netivudine. Peck R, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):22–31

Treatment of adult varicella with sorivudine: a randomized, placebo–controlled trial. Wallace MR, et al. **J Infect Dis** 1996 Aug;174(2):249–55

Severe toxicity of fialuridine (FIAU) [letter; comment] Josephson L. **N Engl J Med** 1996 Apr 25;334(17):1135–6; discussion 1137–8. Comment on: N Engl J Med 1995 Oct 26;333(17):1099–105.

Severe toxicity of fialuridine (FIAU) [letter; comment] Lewis W, et al. **N Engl J Med** 1996 Apr 25;334(17):1136; discussion 1137–8. Comment on: N Engl J Med 1995 Oct 26;333(17):1099–105. Comment on: N Engl J Med 1995 Oct 26;333(17):1146–8.

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B [see comments] McKenzie R, et al. **N Engl J Med** 1995 Oct 26;333(17):1099–105. Comment in: N Engl J Med 1995 Oct 26;333(17):1146–8. Comment in: N Engl J Med 1996 Apr 25;334(17):1135; discussion 1137–8. Comment in: N Engl J Med 1996 Apr 25;334(17):1135–6; discussion 1137–8. Comment in: N Engl J Med 1996 Apr 25;334(17):1136; discussion 1137–8. Comment in: N Engl J Med 1996 Apr 25;334(17):1136–7; discussion 1137–8.

Severe toxicity of fialuridine (FIAU) [letter; comment] Prince AM. **N Engl J Med** 1996 Apr 25;334(17):1136; discussion 1137–8. Comment on: N Engl J Med 1995 Oct 26;333(17):1099–105.

Mitochondrial toxicity––new adverse drug effects [editorial; comment] [see comments] Swartz MN. **N Engl J Med** 1995 Oct 26;333(17):1146–8. Comment on: N Engl J Med 1995 Oct 26;333(17):1099–105. Comment in: N Engl J Med 1996 Apr 25;334(17):1136; discussion 1137–8.

Sorivudine: a promising drug for the treatment of varicella–zoster virus infection. Whitley RJ. **Neurology** 1995 Dec;45(12 Suppl 8):S73–5 (10 ref.)

Synthesis of 2'–fluoro–5–[11C]–methyl–1–beta–D–arabinofuranosyluracil ([11C]–FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Conti PS, et al. **Nucl Med Biol** 1995 Aug; 22(6):783–9

Pharmacokinetics of 1–(2–deoxy–2–fluoro–beta–L–arabinofuranosyl)–5–methyluracil (L–FMAU) in rats. Wright JD, et al. **Pharm Res** 1995 Sep;12(9):1350–3

Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Lewis W, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3592–7

ARABINONUCLEOSIDES

CHEMICAL SYNTHESIS

Synthesis and antiproliferative and antiviral activity of 2'–deoxy–2'–fluoroarabinofuranosyl analogs of the nucleoside antibiotics toyocamycin and sangivamycin. Krawczyk SH, et al. **J Med Chem** 1995 Sep 29; 38(20):4106–14

Structure––activity relationships of 1–(2–Deoxy–2–fluoro–beta–L–arabinofuranosyl)pyrimidine nucleosides as anti–hepatitis B virus agents. Ma T, et al. **J Med Chem** 1996 Jul 5;39(14):2835–43

METABOLISM

Kinetics and metabolism of 2–chloro–2'–deoxyadenosine and 2–chloro–2'–arabino–fluoro–2'–deoxyadenosine in the isolated perfused rat liver. Albertioni F, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jul–Sep; 20(3):225–32

PHARMACOLOGY

Inhibition of episomal hepatitis B virus DNA in vitro by 2,4–diamino–7–(2–deoxy–2–fluoro–beta–D–arabinofuranosyl)–pyrrolo[2,3–d]pyrimidine. Ojwang JO, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2570–3

Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2–chloro–9–(2–deoxy–2–fluoro–beta–D–arabinofuranosyl) adenine. Xie KC, et al. **Cancer Res** 1996 Jul 1;56(13):3030–7

ARABINONUCLEOTIDES

CHEMISTRY

Purine arabinonucleoside 5'–triphosphates with substituents at 2' position as substrates for DNA polymerases. Sharkin YA, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):1041–8

METABOLISM

Purine arabinonucleoside 5'–triphosphates with substituents at 2' position as substrates for DNA polymerases. Sharkin YA, et al. **Biochem Mol Biol Int** 1995 Apr;35(5):1041–8

[Purine arabinonucleoside–5'–triphosphates with substituents in the 2'–position as DNA polymerase substrates] Sharkin IuA, et al. **Mol Biol (Mosk)** 1995 Jul–Aug;29(4):918–29 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

The effects of cytosine arabinoside on RNA–primed DNA synthesis by DNA polymerase alpha–primase. Harrington C, et al. **J Biol Chem** 1995 Nov 3;270(44):26664–9

THERAPEUTIC USE

Characteristic antitumor activity of cytarabine ocfosfate against human colorectal adenocarcinoma xenografts in nude mice. Koga K, et al. **Cancer Chemother Pharmacol** 1995;36(6):459–62

ARABINOSE

ANALOGS & DERIVATIVES

Lipopolysaccharides of polymyxin B–resistant mutants of Escherichia coli are extensively substituted by 2–aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Nummila K, et al. **Mol Microbiol** 1995 Apr; 16(2):271–8

BIOSYNTHESIS

Biosynthetic origin of mycobacterial cell wall arabinosyl residues. Scherman M, et al. **J Bacteriol** 1995 Dec; 177(24):7125–30

METABOLISM

Screening for L–arabinose fermenting yeasts. Dien BS, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:233–42

ARABINOSYLADENINE see **VIDARABINE**

ARABINOSYLCYTOSINE see **CYTARABINE**

ARABINOSYLCYTOSINE TRIPHOSPHATE see **ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE**

ARABINOSYLURACIL see **ARABINOFURANOSYLURACIL**

ARABS

see related

ISLAM

Ritual female genital surgery among Bedouin in Israel. Asali A, et al. **Arch Sex Behav** 1995 Oct;24(5):571–5

Differences in cord serum retinol concentrations by ethnic origin in the Negev (southern Israel). Gorodischer R, et al. **Early Hum Dev** 1995 Jun 21;42(2):123–30

The incidence of birthmarks in Israeli neonates. Kahana M, et al. **Int J Dermatol** 1995 Oct;34(10):704–6

Paget's disease of bone in Negev Bedouin: report of two cases. Lowenthal MN, et al. **Isr J Med Sci** 1995 Oct; 31(10):628–9

Generalised obesity and regional adiposity in adult white and migrant Muslim males from Pakistan in Peterborough. Bose K. **J R Soc Health** 1996 Jun;116(3):161–7

Teaching sex education in the Arab sector in Israel: an approach for working with a traditional population. Oz S. **J Sex Marital Ther** 1996 Spring;22(1):54–62

Diabetes, obesity and hypertension in urban and rural people of bedouin origin in the United Arab Emirates. el Mugamer IT, et al. **J Trop Med Hyg** 1995 Dec;98(6):407–15

Tackling mental illness: roles for old and new disciplines. al–Krenawi A, et al. **World Health Forum** 1996;17(3):246–8

[The frequency of ABO blood groups and the expression of group antigens and isohemagglutinins in Syrian Arabs] Sakharov RS, et al. **Sud Med Ekspert** 1996 Apr–Jun; 39(2):34–6 (Eng. Abstr.) **(Rus)**

GENETICS

The genetics of traditional living: Y–chromosomal and mitochondrial lineages in the Sinai Peninsula [letter] Salem AH, et al. **Am J Hum Genet** 1996 Sep;59(3):741–3

An autosomal recessive nonsyndromic–hearing–loss locus identified by DNA pooling using two inbred Bedouin kindreds. Scott DA, et al. **Am J Hum Genet** 1996 Aug; 59(2):385–91

Clinical features and studies of erythropoiesis in Israeli Bedouins with congenital dyserythropoietic anemia type I. Tamary H, et al. **Blood** 1996 Mar 1;87(5):1763–70

Population data on the PCR–based loci LDLR GYPA, HBGG, D7S8, Gc, HLA–DQA1, and D1S80 from Arabs from Dubai. Alkhayat A, et al. **Forensic Sci Int** 1996 Jul 31;81(1):29–34

The frequency of 14 beta–thalassemia mutations in the Arab populations. el–Hazmi MA, et al. **Hemoglobin** 1995; 19(6):353–60

Arab population data on the PCR–based loci: HLA–DQA1, LDLR, GYPA, HBGG, D7S8, Gc, and D1S80. Hayes JM, et al. **J Forensic Sci** 1995 Sep;40(5):888–92

PSYCHOLOGY

Spatial and temporal locations in child Jordanian Arabic. Khanji R, et al. **Percept Mot Skills** 1996 Apr;82(2):675–82

Factorial structure of the Arabic Children's Depression Inventory among Kuwaiti subjects. Abdel–Khalek AM. **Psychol Rep** 1996 Jun;78(3 Pt 1):963–7

STATISTICS & NUMERICAL DATA

Obesity among Jewish and Bedouin secondary school students in the Negev, Israel. Pilpel D, et al. **Public Health Rev** 1995;23(3):253–62

ARACHIDONATE 5–LIPOXYGENASE

ANALYSIS

Colocalization of cytosolic phospholipase A2, 5–lipoxygenase, and 5–lipoxygenase–activating protein at the nuclear membrane of A23187–stimulated human neutrophils. Pouliot M, et al. **Eur J Biochem** 1996 May 15;238(1):250–8

ANTAGONISTS & INHIBITORS

Effect of chronic 5–lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Fischer AR, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1203–7

A novel 5–lipoxygenase inhibitor prevents gallstone formation in a lithogenic prairie dog model. Kam DM, et al. **Am Surg** 1996 Jul;62(7):551–5; discussion 555–6

Non–steroidal anti–inflammatory agents, Part 19. E–2–pyrrolizin–5–yl acrylic acids as potent dual or selective inhibitors of bovine cyclooxygenase and 5–lipoxygenase. Dannhardt G, et al. **Arch Pharm (Weinheim)** 1995 Sep;328(9):681–6

Nephrotic syndrome associated with N–hydroxyureas, inhibitors of 5–lipoxygenase. Read NG, et al. **Arch Toxicol** 1995;69(7):480–90

Hydroxylamine analogs of 2,6–di–t–butylphenols: dual inhibitors of cyclooxygenase and 5–lipoxygenase or selective 5–lipoxygenase inhibitors. Kramer JB, et al. **Bioorg Med Chem** 1995 Apr;3(4):403–10

Synthesis of a novel dual inhibitor of thromboxane A2 synthetase and 5–lipoxygenase (E3040) via the direct coupling reaction of hydroquinone with 3–pyridinecarboxaldehyde. Komatsu Y, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct;43(10):1614–6

Oxidative inactivation of human 5–lipoxygenase in phosphatidylcholine vesicles. De Carolis E, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):416–23

Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Chung KF. **Eur Respir J** 1995 Jul;8(7):1203–13 (117 ref.)

Competitive inhibition of the 5–lipoxygenase–catalysed linoleate oxidation by arachidonic and 5–hydroperoxy–eicosatetraenoic acids. Mirzoeva OK, et al. **FEBS Lett** 1995 Dec 27;377(3):306–8

Inhibition of 5–lipoxygenase promotes the regeneration of the liver after partial hepatectomy in normal and icteric rats. Urade M, et al. **Hepatology** 1996 Mar;23(3):544–8

A controlled trial of the effect of the 5–lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. Kane GC, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):646–54

(R)–(+)–N–[3–[5–[(4–fluorophenyl)methyl]–2–thienyl]–1–methyl– 2–propynyl]–N–hydroxyurea (ABT–761), a second–generation 5–lipoxygenase inhibitor. Brooks CD, et al. **J Med Chem** 1995 Nov 24;38(24):4768–75

Chiral dioxolane inhibitors of leukotriene biosynthesis: structure–activity relationships and syntheses using asymmetric dihydroxylation. Crawley GC, et al. **J Med Chem** 1995 Sep 29;38(20):3951–6

Thiopyranol[2,3,4–c,d]indoles as inhibitors of 5–lipoxygenase, 5–lipoxygenase–activating protein, and leukotriene C4 synthase. Hutchinson JH, et al. **J Med Chem** 1995 Oct 27; 38(22):4538–47

Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5–lipoxygenase. Malamas MS, et al. **J Med Chem** 1996 Jan 5;39(1):237–45

Different biliary excretion systems for glucuronide and sulfate of a model compound; study using Eisai hyperbilirubinemic rats. Takenaka O, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1362–9

Selective inhibitors of 5–lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Anderson KM, et al. **Leuk Res** 1995 Nov; 19(11):789–801

Insights into IgE–mediated lung inflammation derived from

a study employing a 5-lipoxygenase inhibitor. Kane GC, et al. **Prostaglandins** 1995 Jul;50(1):1-18

Inhibition of endotoxin-induced microvascular leakage by a platelet-activating factor antagonist and 5-lipoxygenase inhibitor. Klabunde RE, et al. **Shock** 1995 Nov;4(5):368-72

BIOSYNTHESIS

Interleukin-3 regulates development of the 5-lipoxygenase/leukotriene C4 synthase pathway in mouse mast cells. Murakami M, et al. **J Biol Chem** 1995 Sep 29; 270(39):22653-6

Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. Avis IM, et al. **J Clin Invest** 1996 Feb 1;97(3):806-13

Lymphocytes stimulate expression of 5-lipoxygenase and its activating protein in monocytes in vitro via granulocyte macrophage colony-stimulating factor and interleukin 3. Ring WL, et al. **J Clin Invest** 1996 Mar 1;97(5):1293-301

BLOOD

The suppression of 5-lipoxygenation of arachidonic acid in human polymorphonuclear leucocytes by the 15-lipoxygenase product (15S)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid: structure-activity relationship and mechanism of action. Petrich K, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):911-6

CHEMISTRY

Competitive binding assay of src homology domain 3 interactions between 5-lipoxygenase and growth factor receptor binding protein 2. VanderNoot VA, et al. **Anal Biochem** 1995 Sep 1;230(1):108-14

Characterization of the arachidonate and ATP binding sites of human 5-lipoxygenase using photoaffinity labeling and enzyme immobilization. Falgueyret JP, et al. **Biochemistry** 1995 Oct 17;34(41):13603-11

GENETICS

Lipoxygenase products and expression of 5-lipoxygenase and 5-lipoxygenase-activating protein in human cultured synovial cells. Bonnet C, et al. **Prostaglandins** 1995 Sep; 50(3):127-35

METABOLISM

Inhibition of mitogen-activated protein kinase kinase blocks activation and redistribution of 5-lipoxygenase in HL-60 cells. Lepley RA, et al. **Arch Biochem Biophys** 1996 Jul 1;331(1):141-4

Characterization of the arachidonate and ATP binding sites of human 5-lipoxygenase using photoaffinity labeling and enzyme immobilization. Falgueyret JP, et al. **Biochemistry** 1995 Oct 17;34(41):13603-11

Evidence for the involvement of 5-lipoxygenase products in the regulation of the expression of the proenkephalin gene in cultured astroglial cells. Mamot C, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):79-86

Studies on the regulation and localization of 5-lipoxygenase in human B-lymphocytes. Jakobsson PJ, et al. **Eur J Biochem** 1995 Aug 15;232(1):37-46

Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis. Keicher U, et al. **Eur J Clin Invest** 1995 Dec;25(12):915-9

Colonic microvascular integrity in acute endotoxaemia: interactions between constitutive nitric oxide and 5-lipoxygenase products. László F, et al. **Eur J Pharmacol** 1995 Apr 24;277(2-3):R1-3

Leukotriene A4, and not leukotriene B4, is the main 5-lipoxygenase metabolite released by bovine leukocytes. Sala A, et al. **FEBS Lett** 1996 Jun 17;388(2-3):94-8

Tyrosine kinase activity modulates catalysis and translocation of cellular 5-lipoxygenase. Lepley RA, et al. **J Biol Chem** 1996 Mar 15;271(11):6179-84

5-Lipoxygenase products modulate the activity of the 85-kDa phospholipase A2 in human neutrophils. Wijkander J, et al. **J Biol Chem** 1995 Nov 3;270(44):26543-9

Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. Voelkel NF, et al. **J Clin Invest** 1996 Jun 1;97(11):2491-8

Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. Wilborn J, et al. **J Clin Invest** 1996 Apr 15;97(8):1827-36

Mechanisms of platelet-activating factor-induced lipid body formation: requisite roles for 5-lipoxygenase and de novo protein synthesis in the compartmentalization of neutrophil lipids. Bozza PT, et al. **J Exp Med** 1996 Apr 1; 183(4):1515-25

5(S),15(S)-dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. Chavis C, et al. **J Exp Med** 1996 Apr 1;183(4):1633-43

5-Lipoxygenase metabolism in alveolar macrophages from subjects infected with the human immunodeficiency virus. Coffey MJ, et al. **J Immunol** 1996 Jul 1;157(1):393-9

Arachidonate 5-lipoxygenase. Rådmark O. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):171-84 (58 ref.)

The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationship. Carlberg C, et al. **J Pineal Res** 1995 May;18(4):171-8 (51 ref.)

PHYSIOLOGY

Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Fischer AR, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1203-7

Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling. Lammers CH, et al. **J Neurochem** 1996 Jan; 66(1):147-52

ARACHIDONATE 12-LIPOXYGENASE

ANALYSIS

Arachidonate 12-lipoxygenase in porcine anterior pituitary cells: its localization and possible function in gonadotrophs. Ikawa H, et al. **J Endocrinol** 1996 Jan;148(1):33-41

ANTAGONISTS & INHIBITORS

Inactivation of mouse epidermal 12-lipoxygenase by anthralin--implications for the role of oxygen radicals. Müller K, et al. **Biochem Pharmacol** 1996 May 3; 51(9):1173-9

Novel 10-substituted antipsoriatic anthrones as inhibitors of epidermal 12-lipoxygenase and lipid peroxidation in membranes. Müller K, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):2077-83

Suicide inactivation of porcine leukocyte 12-lipoxygenase associated with its incorporation of 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid derivative. Kishimoto K, et al. **Biochim Biophys Acta** 1996 Mar 29;1300(1):56-62

BIOSYNTHESIS

Down-regulation of epidermal growth factor-induced 12-lipoxygenase expression by glucocorticoids in human epidermoid carcinoma A431 cells. Chang WC, et al. **Biochem Pharmacol** 1995 Sep 28;50(7):947-52

Human mononuclear cells express 12-LX: coordinated mRNA regulation with 5-LX and FLAP genes. Kaminski WE, et al. **Blood** 1996 Jan 1;87(1):331-40

Interleukin-1 beta regulates the expression of a leukocyte type of 12-lipoxygenase in rat islets and RIN m5F cells. Bleich D, et al. **Endocrinology** 1995 Dec;136(12):5736-44

BLOOD

A colorimetric method for the determination of lipoxygenase activity suitable for use in a high throughput assay format. Waslidge NB, et al. **Anal Biochem** 1995 Nov 1;231(2):354-8

CHEMISTRY

Arachidonate 12-lipoxygenase. Yoshimoto T, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):195-212 (128 ref.)

GENETICS

A TaqI polymorphism at the porcine arachidonate 12-lipoxygenase (ALOX12) locus. Coscelli MB, et al. **Anim Genet** 1995 Dec;26(6):446-7

Lipoxygenase mRNA in cultured human epidermal and oral keratinocytes. Zhao H, et al. **J Lipid Res** 1995 Nov; 36(11):2444-9

METABOLISM

Stereochemistry of the Aplysia neuronal 12-lipoxygenase: specific potentiation of FMRFamide action by 12(S)-HPETE. Abe M, et al. **Brain Res** 1995 Jun 19; 683(2):200-8

Tonic inhibition of renin secretion by the 12 lipoxygenase pathway: augmentation by high salt intake. Stern N, et al. **Endocrinology** 1996 May;137(5):1878-84

Interleukin-1 enhances pancreatic islet arachidonic acid 12-lipoxygenase product generation by increasing substrate availability through a nitric oxide-dependent mechanism. Ma Z, et al. **J Biol Chem** 1996 Jan 12;271(2):1029-42

A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. Antonipillai I, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1940-5

Lipoxin biosynthesis and actions: role of the human platelet LX-synthase. Serhan CN, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):293-306 (41 ref.)

Arachidonate 12-lipoxygenase. Yoshimoto T, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):195-212 (128 ref.)

12-Lipoxygenase isoenzymes in mouse skin tumor development. Krieg P, et al. **Mol Carcinog** 1995 Oct; 14(2):118-29

Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Tang DG, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5241-6

Conversion of human 15-lipoxygenase to an efficient 12-lipoxygenase: the side-chain geometry of amino acids 417 and 418 determine positional specificity. Sloane DL, et al. **Protein Eng** 1995 Mar;8(3):275-82

Characterization of arachidonic acid metabolites through the 12-lipoxygenase pathway in human epidermis by high-performance liquid chromatography and gas chromatography/mass spectrometry. Antón R, et al. **Rapid Commun Mass Spectrom** 1995;Spec No:S169-82

Characterization of arachidonate 12-lipoxygenase found in the liver of mongrel dog and its immunohistochemical localization in neutrophils. Reddy GR, et al. **Tokushima J Exp Med** 1995 Jul;42(1-2):27-35

ARACHIDONATE 15-LIPOXYGENASE

ANTAGONISTS & INHIBITORS

[Effect of 1,25-dihydroxyvitamin D3 on 15-lipoxygenase activity] Bondarenko LB, et al. **Vopr Med Khim** 1995 May-Jun;41(3):29-31 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Regulation of 15-lipoxygenase expression in lung epithelial cells by interleukin-4. Brinckmann R, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):305-12

Induction of 15-lipoxygenase mRNA and protein in early atherosclerotic lesions. Hiltunen T, et al. **Circulation** 1995 Dec 1;92(11):3297-303

Transgenic rabbits with the integrated human 15-lipoxygenase gene driven by a lysozyme promoter: macrophage-specific expression and variable positional specificity of the transgenic enzyme. Shen J, et al. **FASEB J** 1995 Dec;9(15):1623-31

GENETICS

Transient overexpression of human 15-lipoxygenase in aortic endothelial cells enhances tumor necrosis factor-induced vascular cell adhesion molecule-1 gene expression. Wölle J, et al. **Biochem Biophys Res Commun** 1996 Mar 18; 220(2):310-4

Arachidonate 15-lipoxygenase. Kühn H, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):157-70 (72 ref.)

Lipoxygenase mRNA in cultured human epidermal and oral keratinocytes. Zhao H, et al. **J Lipid Res** 1995 Nov; 36(11):2444-9

Tissue-specific regulation of the rabbit 15-lipoxygenase gene in erythroid cells by a transcriptional silencer. O'Prey J, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3664-72

Conversion of human 15-lipoxygenase to an efficient 12-lipoxygenase: the side-chain geometry of amino acids 417 and 418 determine positional specificity. Sloane DL, et al. **Protein Eng** 1995 Mar;8(3):275-82

METABOLISM

Leukotrienes and 15-lipoxygenase products in glomerulonephritis. Badr KF. **Adv Nephrol Necker Hosp** 1995;24:19-31 (58 ref.)

The suppression of 5-lipoxygenation of arachidonic acid in human polymorphonuclear leucocytes by the 15-lipoxygenase product (15S)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid: structure-activity relationship and mechanism of action. Petrich K, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):911-6

Role of lipid hydroperoxides in the activation of 15-lipoxygenase. Jones GD, et al. **Biochemistry** 1996 Jun 4;35(22):7197-203

15-lipoxygenase metabolite(s) of arachidonic acid mediates adrenocorticotropin action in bovine adrenal steroidogenesis. Yamazaki T, et al. **Endocrinology** 1996 Jul; 137(7):2670-5

Nitric oxide oxidises a ferrous mammalian lipoxygenase to a pre-activated ferric species. Wiesner R, et al. **FEBS Lett** 1996 Jul 8;389(3):229-32

The selenoenzyme phospholipid hydroperoxide glutathione peroxidase controls the activity of the 15-lipoxygenase with complex substrates and preserves the specificity of the oxygenation products. Schnurr K, et al. **J Biol Chem** 1996 Mar 1;271(9):4653-8

Arachidonate 15-lipoxygenase. Kühn H, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):157-70 (72 ref.)

Lipoperoxides in LDL incubated with fibroblasts that overexpress 15-lipoxygenase. Ezaki M, et al. **J Lipid Res** 1995 Sep;36(9):1996-2004

Conversion of human 15-lipoxygenase to an efficient 12-lipoxygenase: the side-chain geometry of amino acids 417 and 418 determine positional specificity. Sloane DL, et al. **Protein Eng** 1995 Mar;8(3):275-82

PHARMACOLOGY

Lipoxygenase treatment render low-density lipoprotein susceptible to Cu2+-catalysed oxidation. Lass A, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):577-85

ARACHIDONATE LIPOXYGENASES

GENETICS

Purification and molecular cloning of an 8R-lipoxygenase from the coral Plexaura homomalla reveal the related primary structures of R- and S-lipoxygenases. Brash AR, et al. **J Biol Chem** 1996 Aug 23;271(34):20949-57

ARACHIDONIC ACID

ADMINISTRATION & DOSAGE

Feeding formula without arachidonic acid and docosahexaenoic acid has no effect on preferential looking acuity or recognition memory in healthy full-term infants at 9 mo of age. Innis SM, et al. **Am J Clin Nutr** 1996 Jul; 64(1):40–6

Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults. Innis SM, et al. **Am J Clin Nutr** 1996 Aug;64(2):159–67

Effects of a low birthweight infant formula containing human milk levels of docosahexaenoic and arachidonic acids. Koletzko B, et al. **J Pediatr Gastroenterol Nutr** 1995 Aug; 21(2):200–8

Arachidonic acid supply and metabolism in human infants born at full term. Koletzko B, et al. **Lipids** 1996 Jan; 31(1):79–83

ADVERSE EFFECTS

Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid–induced inflammation and indomethacin–induced gastric ulceration. Langenbach R, et al. **Cell** 1995 Nov 3;83(3):483–92

ANALOGS & DERIVATIVES see ARACHIDONIC ACIDS

ANALYSIS

Long-chain polyunsaturated fatty acid content in Dutch preterm breast milk; differences in the concentrations of docosahexaenoic acid and arachidonic acid due to length of gestation. Beijers RJ, et al. **Early Hum Dev** 1996 Mar 22;44(3):215–23

Age- and dietary-related distributions of hepatic arachidonic and docosahexaenoic acid in early infancy. Farquharson J, et al. **Pediatr Res** 1995 Sep;38(3):361–5

Distribution of arachidonic, eicosapentaenoic, docosahexaenoic and related fatty acids in ovine endometrial phospholipids in late gestation and labor. Zhang Q, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Sep; 53(3):201–9

ANTAGONISTS & INHIBITORS

Estrogens protect against hydrogen peroxide and arachidonic acid induced DNA damage. Tang M, et al. **Biochim Biophys Acta** 1996 Jan 19;1299(2):155–9

Effect of inhibitors of arachidonic acid metabolism on corneal reepithelialization in the rat. Gupta AG, et al. **Exp Eye Res** 1993 Jun;56(6):701–8

Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Ondrey FG, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):129–34

Activation of phospholipase D by prostaglandin F2 alpha in rat luteal cells and effects of inhibitors of arachidonic acid metabolism. Yamamoto H, et al. **Prostaglandins** 1995 Oct;50(4):201–11

BIOSYNTHESIS

Indomethacin, esculetin and nordihydroguaiaretic acid modify arachidonate biosynthesis in rat adrenocortical cells. de Gómez Dumm NT, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(3):155–64

Activation of cytosolic phospholipase A2 in permeabilized human neutrophils. Bauldry SA, et al. **Biochim Biophys Acta** 1996 Jan 19;1299(2):223–34

Linoleic acid esterified in low density lipoprotein serves as substrate for increased arachidonic acid synthesis in differentiating monocytic cells. Hrboticky N, et al. **Biochim Biophys Acta** 1996 Aug 16;1302(3):199–206

Effects of AMPA receptor modulators on the production of arachidonic acid from striatal neurons. Petitet F, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):143–51

Cytosolic phospholipase A2 is phosphorylated in collagen- and thrombin-stimulated human platelets independent of protein kinase C and mitogen-activated protein kinase. Börsch-Haubold AG, et al. **J Biol Chem** 1995 Oct 27; 270(43):25885–92

Arachidonic and docosahexaenoic acids are biosynthesized from their 18-carbon precursors in human infants. Salem N Jr, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):49–54

BLOOD

Arachidonic acid metabolites in acute myocardial infarction. Takase B, et al. **Angiology** 1996 Jul;47(7):649–61

Stability of plasma nonesterified arachidonate in healthy individuals in fasting and nonfasting states. Hallaq Y, et al. **Clin Chem** 1996 May;42(5):771–3

Human cytomegalovirus–induced immunosuppression. Relationship to tumor necrosis factor–dependent release of arachidonic acid and prostaglandin E2 in human monocytes. Nokta MA, et al. **J Clin Invest** 1996 Jun 1; 97(11):2635–41

Arachidonic acid status of human infants: influence of gestational age at birth and diets with very long chain n-3 and n-6 fatty acids. Carlson SE. **J Nutr** 1996 Apr;126(4 Suppl):1092S–8S

Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Adams PB, et al. **Lipids** 1996 Mar;31 Suppl:S157–61

[Essential fatty acids and prematurity: a triple experimental approach] Descomps B, et al. **C R Seances Soc Biol Fil** 1995;189(5):781–96 (Eng. Abstr.) **(Fre)**

[Preparations affecting arachidonic acid metabolism in the thrombocytes in the treatment of ischemic heart disease] Liusov VA, et al. **Eksp Klin Farmakol** 1995 Jul–Aug; 58(4):76–9 **(Rus)**

CHEMISTRY

The isoprostanes. Current knowledge and directions for future research. Morrow JD, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):1–9 (54 ref.)

Lipofuscin-like pigments by autoxidation of polyunsaturated fatty acids in the presence of amine neurotransmitters: the role of malondialdehyde. d'Ischia M, et al. **Biochim Biophys Acta** 1996 Aug 13;1290(3):319–26

The hemifusion intermediate and its conversion to complete fusion: regulation by membrane composition. Chernomordik L, et al. **Biophys J** 1995 Sep;69(3):922–9

Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. Bhattacharyya DK, et al. **J Biol Chem** 1996 Jan 26;271(4):2179–84

Visible light-sensitized oxidation of arachidonic acid in the presence of inperatorin. Fukui Y, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun;41(3):387–93

Phospholipid molecular species with eicosapentaenoic acid (20:5(n-3)) are less stable than species with arachidonic acid (20:4(n-6)) in isolated rat liver cells. Woldseth B, et al. **Scand J Clin Lab Invest** 1995 Oct;55(6):513–22

METABOLISM

Radiodetoxified endotoxin-induced tolerance. Effect on endotoxin lethality and macrophage arachidonic acid metabolism. Bertók L, et al. **Acta Microbiol Immunol Hung** 1995;42(4):409–18

Acute hypoxia modulates arachidonic acid metabolism in cat carotid bodies. Role of dopamine. Strosznajder RP. **Acta Neurobiol Exp (Warsz)** 1996;56(2):535–43

Arachidonic acid transfer across the human red cell membrane by a specific transport system. Bojesen IN, et al. **Acta Physiol Scand** 1995 Jun;154(2):253–67

Epidermal growth factor increases phosphoinositide turnover and intracellular free calcium in an immortalized human myometrial cell line independent of the arachidonic acid metabolic pathway. Anwer K, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):676–81

Endothelin and PDGF enhance arachidonic acid release and DNA synthesis in vascular smooth muscle cells. Irons CE, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1642–6

Enhanced arachidonic acid metabolism in alveolar macrophages from wheezy infants. Modulation by dexamethasone. Azevedo I, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1208–14

Preparation of 13C-labeled polyunsaturated fatty acids by an arachidonic acid–producing fungus Mortierella alpina 1S-4. Kawashima H, et al. **Anal Biochem** 1995 Aug 10; 229(2):317–22

Relative activities of retrovirally expressed murine prostaglandin synthase-1 and -2 depend on source of arachidonic acid. Chulada PC, et al. **Arch Biochem Biophys** 1996 Jun 15;330(2):301–13

Influence of calcium on arachidonic acid mobilization by murine resident peritoneal macrophages. Lloret S, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):251–7

Alteration of arachidonate levels in tick salivary glands by dietary modification of host blood lipids. Madden RD, et al. **Arch Insect Biochem Physiol** 1996;31(1):53–72

Role of cytosolic phospholipase A2 in arachidonic acid release of rat-liver macrophages: regulation by Ca2+ and phosphorylation. Ambs P, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):189–95

Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Engelhardt G, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):29–38

Meloxicam: influence on arachidonic acid metabolism. Part I. In vitro findings. Engelhardt G, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):21–8

Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride]. Shivachar AC, et al. **Biochem Pharmacol** 1996 Mar 8;51(5):669–76

Characterization of the arachidonate and ATP binding sites of human 5-lipoxygenase using photoaffinity labeling and enzyme immobilization. Falgueyret JP, et al. **Biochemistry** 1995 Oct 17;34(41):13603–11

Relationship between arachidonate--phospholipid remodeling and apoptosis. Surette ME, et al. **Biochemistry** 1996 Jul 16;35(28):9187–96

Control of arachidonate levels within inflammatory cells. Chilton FH, et al. **Biochim Biophys Acta** 1996 Jan 5; 1299(1):1–15 (139 ref.)

Neutrophil release of arachidonic acid, oxidants, and proteinases: causally related or independent. Ely EW, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):135–44

Regulation of bradykinin-stimulated phospholipase C and arachidonic acid release by protein kinase A in MDCK-D1 cells. Kennedy CR, et al. **Biochim Biophys Acta** 1995 Sep 14;1258(2):206–14

Novel metabolic pathways for linoleic and arachidonic acid metabolism. Moghaddam M, et al. **Biochim Biophys Acta** 1996 Aug 13;1290(3):327–39

Changes in arachidonic acid metabolism and the aggregation of polymorphonuclear leukocytes in rats with streptozotocin-induced diabetes. Nakagawa Y, et al. **Biochim Biophys Acta** 1996 Mar 1;1315(2):145–51

Comparison of acceptor and donor substrates in the CoA-independent transacylase reaction in human neutrophils. Nixon AB, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):187–96

Acetylated low density lipoprotein inhibits the incorporation of arachidonic acid in phospholipids with a concomitant increase of cholesterol arachidonate in rat peritoneal macrophages. Pollaud C, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):211–9

Metabolism of arachidonic acid by canine polymorphonuclear leukocytes synthesis of lipoxygenase and omega-oxidized metabolites. Rosolowsky M, et al. **Biochim Biophys Acta** 1996 Apr 19;1300(2):143–50

Arachidonate mobilization is coupled to depletion of intracellular calcium stores and influx of extracellular calcium in differentiated U937 cells. Rzigalinski BA, et al. **Biochim Biophys Acta** 1996 Feb 16;1299(3):342–52

Arachidonic acid metabolism and cell proliferation in rat mammary carcinoma cells treated with indomethacin. Tripathi SC, et al. **Biochim Biophys Acta** 1996 May 24; 1316(1):5–7

15-Hydroperoxyeicosapentaenoic acid inhibits arachidonic acid metabolism in rabbit platelets more potently than eicosapentaenoic acid. Tsunomori M, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):171–6

Hexachlorocyclohexanes affect the arachidonic acid release from phosphatidylinositol but not from other phospholipid classes in tubular cell cultures. Puente-Fraga JC, et al. **Biosci Rep** 1995 Aug;15(4):191–9

Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation. Izaki S, et al. **Br J Dermatol** 1996 Jun;134(6):1060–4

Eicosanoids are produced by microglia, not by astrocytes, in rat glial cell cultures. Matsuo M, et al. **Brain Res** 1995 Jul 10;685(1-2):201–4

Release of arachidonic acid via Ca2+ increase stimulated by pyrophosphonucleotides and bradykinin in mammary tumour cells. Enomoto K, et al. **Cell Biochem Funct** 1995 Dec;13(4):279–86

Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross-talk of calcium, protein kinase C (PKC), and arachidonic acid. Naor Z, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):527–44 (142 ref.)

Signal transduction pathways leading to arachidonic acid release from neutrophilic HL-60 cells. The involvement of G protein, protein kinase C and phospholipase A2. Buhl WJ, et al. **Cell Signal** 1995 May;7(4):351–64

Adenosine receptor activation potentiates phosphoinositide hydrolysis and arachidonic acid release in DDT1-MF2 cells: putative interrelations. Schachter JB, et al. **Cell Signal** 1995 Sep;7(7):659–68

Stimulation of arachidonic acid mobilization by adherence of resident peritoneal macrophages to plastic substrate. Lloret S, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Mar;113(3):403–8

Arachidonic acid metabolism in intestinal hypothermic preservation injury. Mangino MJ, et al. **Cryobiology** 1996 Aug;33(4):404–12

Products of ozonized arachidonic acid potentiate the formation of DNA single strand breaks in cultured human lung cells. Kozumbo WJ, et al. **Environ Mol Mutagen** 1996; 27(3):185–95

The incorporation of arachidonic acid into triacylglycerol in P388D1 macrophage-like cells. Balsinde J, et al. **Eur J Biochem** 1996 Feb 1;235(3):480–5

Involvement of an arachidonic-acid-dependent pathway in the interferon-beta-mediated expression of C202 gene in Ehrlich-ascites-tumor cells. Toniato E, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):91–6

The coat protein gp120 of HIV-1 inhibits astrocyte uptake of excitatory amino acids via macrophage arachidonic acid. Dreyer EB, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2502–7

Exposure to gp120 of HIV-1 induces an increased release of arachidonic acid in rat primary neuronal cell culture followed by NMDA receptor-mediated neurotoxicity. Ushijima H, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1353–9

Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells. Hichami A, et al. **Eur J Pharmacol** 1995 Oct 15;291(2):91–7

Effect of inhibitors of arachidonic acid metabolism on corneal reepithelialization in the rat. Gupta AG, et al. **Exp Eye Res** 1993 Jun;56(6):701–8

Stimulation of synaptosomal free radical production by fatty acids: relation to esterification and to degree of unsaturation. Bondy SC, et al. **FEBS Lett** 1995 Nov 13; 375(1-2):53–5

Role of arachidonic acid metabolism in thymocyte apoptosis after irradiation. Korystov YN, et al. **FEBS Lett** 1996 Jun 17;388(2-3):238–41

Arachidonic acid release: an in vitro alternative for dermal irritancy testing. DeLeo VA, et al. **Food Chem Toxicol** 1996 Feb;34(2):167–76

Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Bieglmayer C, et al. **Gynecol Endocrinol** 1995 Dec;9(4):307–12

Role of endothelium–derived metabolites of arachidonic acid in enhanced pulmonary artery contractions in female rabbits. Pfister SL, et al. **Hypertension** 1996 Jan;27(1):43–8

Effect of chloroquine on arachidonic acid pathway in isolated mast cells. Drábiková K, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S13–4

Conversion of endogenous arachidonic acid to 5,15–diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. Thomas E, et al. **Inflamm Res** 1995 Mar;44(3):121–4

Regulation of arachidonic acid metabolism, aromatase activity and growth in human breast cancer cells by interleukin–1beta and phorbol ester: dissociation of a mediatory role for prostaglandin E2 in the autocrine control of cell function. Hughes R, et al. **Int J Cancer** 1996 Sep 4;67(5):684–9

Time course and concentration dependence of the incorporation of deuterated/tritiated arachidonic acid and derived fatty acids in THP–1 cell lipids. Risé P, et al. **Ital J Biochem** 1995 Jul–Aug;44(4):169–82

Alterations in arachidonic acid metabolism in mouse mast cells induced to undergo maturation in vitro in response to stem cell factor. Samet JM, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1329–41

Cyclooxygenase–1 and –2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. Karim S, et al. **J Biol Chem** 1996 May 17;271(20):12042–8

Arachidonic acid activates the noncapacitative entry of Ca2+ during [Ca2+]i oscillations. Shuttleworth TJ. **J Biol Chem** 1996 Sep 6;271(36):21720–5

Molecular cloning of a novel human diacylglycerol kinase highly selective for arachidonate–containing substrates. Tang W, et al. **J Biol Chem** 1996 Apr 26;271(17):10237–41

Estrogen pretreatment increases arachidonic acid release by bradykinin stimulated normal human osteoblast–like cells. Cissel DS, et al. **J Cell Biochem** 1996 Feb;60(2):260–70

Homologous desensitization of ATP–stimulated mitogenesis: mechanism involves desensitization of arachidonic acid release and cAMP elevation but not the activation of protein kinase A. Huang NN, et al. **J Cell Physiol** 1995 Dec;165(3):667–75

Enhancement of stress–induced synthesis of hsp27 and alpha B crystallin by modulators of the arachidonic acid cascade. Ito H, et al. **J Cell Physiol** 1996 Feb;166(2):332–9

Inhibition of the arachidonic acid pathway prevents induction of IL–8 mRNA by phorbol ester and changes the release of IL–8 from HL 60 cells: differential inhibition of induced expression of IL–8, TNF–alpha, IL–1 alpha, and IL–1 beta. Meier RW, et al. **J Cell Physiol** 1995 Oct;165(1):62–70

Arachidonic acid release from NIH 3T3 cells by group–I phospholipase A2: involvement of a receptor–mediated mechanism. Xing M, et al. **J Cell Physiol** 1995 Dec; 165(3):566–75

Subcellular localization of docosahexaenoic acid and arachidonic acid omega–hydroxylation activity in the brain, liver and colonic adenocarcinoma. Yamane M, et al. **J Chromatogr A** 1996 Apr 12;730(1–2):91–8

Migration of human inflammatory cells into the lung results in the remodeling of arachidonic acid into a triglyceride pool. Triggiani M, et al. **J Exp Med** 1995 Nov 1; 182(5):1181–90

Role of changes in renal hemodynamics and P–450 metabolites of arachidonic acid in the reversal of one–kidney, one clip hypertension. Zou AP, et al. **J Hypertens** 1995 May;13(5):557–66

Microtubule–active agents mimic lipopolysaccharides in priming macrophages for enhanced arachidonic acid metabolism. Veis N, et al. **J Inflamm** 1996;46(2):106–13

Priming of human peripheral blood mononuclear cells with lipopolysaccharides for enhanced arachidonic acid release and leukotriene synthesis. Surette ME, et al. **J Leukoc Biol** 1996 May;59(5):709–15

Inhibition of platelet type II phospholipase A2 by an acylamino phospholipid does not alter arachidonate liberation. Gaigé B, et al. **J Lipid Mediat Cell Signal** 1995 May;11(3):281–93

Regulation of calcium influx and catecholamine secretion in chromaffin cells by a cytochrome P450 metabolite of arachidonic acid. Hildebrandt E, et al. **J Lipid Res** 1995 Dec;36(12):2599–608

Metabolism of deuterium–labeled linoleic, 6,9,12–octadecatrienoic, 8,11,14–eicosatrienoic, and arachidonic acids in the rat. Luthria DL, et al. **J Lipid Res** 1995 Sep;36(9):1897–904

Possible evidence that the herbal medicine shakuyaku–kanzo–to decreases prostaglandin levels through suppressing arachidonate turnover in endometrium. Imai A, et al. **J Med** 1995;26(3–4):163–74

Time–dependent increase in release of arachidonic acid following passive avoidance training in the day–old chick. Clements MP, et al. **J Neurochem** 1996 Sep;67(3):1317–23

Endothelin–1 increases arachidonic acid release in C6 glioma cells through a potassium–modulated influx of calcium. Dunican DJ, et al. **J Neurochem** 1996 Aug;67(2):830–7

Functional coupling of the delta–, mu–, and kappa–opioid receptors to mitogen–activated protein kinase and arachidonate release in Chinese hamster ovary cells. Fukuda K, et al. **J Neurochem** 1996 Sep;67(3):1309–16

Preferential in vivo incorporation of [3H]arachidonic acid from blood in rat brain synaptosomal fractions before and after cholinergic stimulation. Jones CR, et al. **J Neurochem** 1996 Aug;67(2):822–9

Changes in arachidonic acid levels and formation and in lipid synthesis in the human neuroblastoma SK–N–BE during retinoic acid–induced differentiation. Petroni A, et al. **J Neurochem** 1996 Aug;67(2):549–56

Glutamate release evoked by glutamate receptor agonists in cultured chick retina cells: modulation by arachidonic acid. Duarte CB, et al. **J Neurosci Res** 1996 May 15;44(4):363–73

The role of specific eicosanoids in mediating the acute narcotic effects of ethanol. Elmer GI, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):308–15

Arachidonic acid cascade and stimulation of acetylcholine release by human recombinant interleukin–1 beta in guinea pig ileum. Mameya S, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):319–24

SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock. Marshall LA, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1254–62

Arachidonic acid and diacylglycerol release associated with inhibition of myosin light chain dephosphorylation in rabbit smooth muscle. Gong MC, et al. **J Physiol (Lond)** 1995 Jul 1;486 (Pt 1):113–22

Stimulation of arachidonic acid release from thyroid phospholipids. Stelmach H, et al. **J Physiol Pharmacol** 1995 Dec;46(4):439–46

Preferential esterification of arachidonic acid into ethanolamine phospholipids in epithelial cells from ovine endometrium. Tamby JP, et al. **J Reprod Fertil** 1996 May; 107(1):23–30

The effect of trinitrobenzene sulfonic acid (TNB) on colonocyte arachidonic acid metabolism. Stratton MD, et al. **J Surg Res** 1996 Feb 1;60(2):375–8

Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Ondrey FG, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):129–34

Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Dehmlow C, et al. **Life Sci** 1996;58(18):1591–600

Low concentrations of nonsteroidal anti–inflammatory drugs affect cell functions. Sergeeva MG, et al. **Life Sci** 1995 Mar 10;56(16):PL313–9

Arachidonic acid supply and metabolism in human infants born at full term. Koletzko B, et al. **Lipids** 1996 Jan; 31(1):79–83

Arachidonic acid maldistribution in obesity. Phinney SD. **Lipids** 1996 Mar;31 Suppl:S271–4 (14 ref.)

Losses of arachidonic acid in rat liver after alcohol inhalation. Salem N Jr, et al. **Lipids** 1996 Mar;31 Suppl:S153–6

Effect of dietary alpha–linolenic acid intake on incorporation of docosahexaenoic and arachidonic acids into plasma phospholipids of term infants. Sauerwald TU, et al. **Lipids** 1996 Mar;31 Suppl:S131–5

Arachidonic acid metabolites and glucocorticoid regulatory mechanism in cultured porcine tracheal smooth muscle cells. Tanaka H, et al. **Lung** 1995;173(6):347–61

Characterization of arachidonic–acid–metabolizing enzymes in adult Schistisoma mansoni. Abdel Baset H, et al. **Mol Biochem Parasitol** 1995 Jul;73(1–2):31–41

Clearance and metabolism of arachidonic acid by C6 glioma cells and astrocytes. Staub F, et al. **Neurochem Res** 1995 Dec;20(12):1449–56

Regulation of FFA by the acyltransferase pathway in focal cerebral ischemia–reperfusion. Zhang JP, et al. **Neurochem Res** 1995 Nov;20(11):1279–86

Lipoxygenase products and expression of 5–lipoxygenase and 5–lipoxygenase–activating protein in human cultured synovial cells. Bonnet C, et al. **Prostaglandins** 1995 Sep; 50(3):127–35

Hyperglycemia promotes elevated generation of TXA2 in isolated rat uteri. Jawerbaum A, et al. **Prostaglandins** 1995 Jul;50(1):47–56

Amplification of arachidonic acid metabolism in rat liver cells (the C–9 cell–line) by tosyl–L–phenylalanine chloromethyl ketone and phenylmethyl–sulfonyl fluoride. Levine L. **Prostaglandins** 1995 Aug;50(2):89–101

Age–related increased 14C–arachidonic acid uptake by platelets in normal subjects. Canal J, et al. **Rev Esp Fisiol** 1995 Mar;51(1):37–41

Metabolism of orally fed [3H]–eicosapentaenoic and [14C]–arachidonic acid in essential fatty acid–deficient rats. Nilsson A, et al. **Scand J Clin Lab Invest** 1996 May; 56(3):219–27

Effects of noradrenaline and dopamine infusions on arachidonic acid metabolism in man. Kerttula T, et al. **Thromb Res** 1995 Oct 15;80(2):169–78

Characterization of arachidonate 12–lipoxygenase found in the liver of mongrel dog and its immunohistochemical localization in neutrophils. Reddy GR, et al. **Tokushima J Exp Med** 1995 Jul;42(1–2):27–35

[Levels of different metabolites of arachidonic acid in synovial fluid of patients with arthrosis or rheumatoid arthritis] Grignani G, et al. **Minerva Med** 1996 Mar; 87(3):75–9 (Eng. Abstr.) **(Ita)**

[The role of arachidonic acid cycle enzymes in platelet activation by low density lipoproteins] Vlasova II, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):376–9 **(Rus)**

[Features of biosynthesis of (14C)–arachidonic acid metabolites in metastasizing tumors] Kudriavtsev IA, et al. **Dokl Akad Nauk** 1996 Feb;346(6):822–4 **(Rus)**

[Effect of inhibitors of lipoxygenase oxidation of arachidonic acid and phenofluorazole on rat thymocyte cytoplasmic pH and on the change of this parameter induced by concanavalin A] Astashkin EN, et al. **Dokl Akad Nauk SSSR** 1992;325(4):869–73 **(Rus)**

[Role of metabolic arachidonic acid cascade and prostaglandin E2 in the pathogenesis of immunodeficiency in traumatic shock and acute hemorrhage] Pavlovskii MP, et al. **Klin Khir** 1995;(4):35–8 (62 ref.) **(Ukr)**

[Mechanisms of the early effect of biologically active hydroxysterols: calcitriol and ecdysterone. Modulation of intracellular pools of arachidonic acid and products of its oxidative metabolism] Kotsiuruba AV, et al. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):45–52 (Eng. Abstr.) **(Ukr)**

PHARMACOKINETICS

Arachidonic acid metabolism and intracellular calcium concentration in inflammatory bowel disease. Schmidt C, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):865–9

PHARMACOLOGY

Arachidonic acid stimulates protein tyrosine phosphorylation in vascular cells. Buckley BJ, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1489–95

Afferent arteriolar response to arachidonic acid: involvement of metabolic pathways. Imig JD, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F87–93

Dual effects of arachidonic acid on ATP–sensitive K+ current of coronary smooth muscle cells. Xu X, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H1957–62

Inhibitory effects of arachidonic acid (20:4,n–6) and its monohydroperoxy– and hydroxy–metabolites on procoagulant activity in endothelial cells. Bates EJ, et al. **Atherosclerosis** 1995 Jul;116(1):125–33

Arachidonic acid potentiates ACh receptor currents by protein kinase C activation but not by receptor phosphorylation. Ikeuchi Y, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):716–21

Arachidonic acid and lipoxygenase products stimulate protein kinase C beta mRNA levels in pituitary alpha T3–1 cell line: role in gonadotropin–releasing hormone action. Shraga–Levine Z, et al. **Biochem J** 1996 Jun ;,316 (Pt 2):667–70

Effect of pyridoxal–5'–phosphate on aggregation of platelets from stored human concentrates induced by arachidonic acid. Nolan ML, et al. **Biochem Soc Trans** 1996 Feb; 24(1):95S

Synergistic induction of acyl–CoA oxidase activity, an indicator of peroxisome proliferation, by arachidonic acid and retinoic acid in Morris hepatoma 7800C1 cells. Sohlenius AK, et al. **Biochim Biophys Acta** 1995 Oct 5; 1258(3):257–64

Arachidonic acid induces c–jun gene expression in stromal cells stimulated by interleukin–1 and tumor necrosis factor–alpha: evidence for a tyrosine–kinase–dependent process. Rizzo MT, et al. **Blood** 1995 Oct 15;86(8):2967–75

Mucosa–dependent muscarinic liberation of prostaglandins from rat isolated trachea. Brunn G, et al. **Br J Pharmacol** 1995 Oct;116(3):1991–8

Modulation of calcium channel currents by arachidonic acid in single smooth muscle cells from vas deferens of the guinea–pig. Nagano N, et al. **Br J Pharmacol** 1995 Sep; 116(2):1887–93

Suppression of evoked IPSPs by arachidonic acid and prostaglandin F2 alpha. Owens J Jr, et al. **Brain Res** 1995 Sep 11;691(1–2):223–8

Arachidonic acid disrupts calcium dynamics in neonatal rat cardiac myocytes. Hoffmann P, et al. **Cardiovasc Res** 1995 Dec;30(6):889–98

Unsaturated fatty acids synergistically enhance glucocorticoid–induced gene expression. Vallette G, et al. **Cell Signal** 1995 May;7(4):319–23

Interaction of arachidonic acid with ligand binding sites of the N–methyl–D–aspartate receptor in rat hippocampal membranes. Yeh GC, et al. **Chin J Physiol** 1995; 38(2):117–23

Vasodilatation to arachidonic acid in humans. An insight into endogenous prostanoids and effects of aspirin. Bhagat K, et al. **Circulation** 1995 Oct 15;92(8):2113–8

Actions of arachidonic acid on erythrocyte membrane Rb permeability. Dwight JF, et al. **Clin Chim Acta** 1995 Jul 14;238(2):187–97

Selective suppression of endothelial cell activation by arachidonic acid. Stuhlmeier KM, et al. **Eur J Immunol** 1996 Jul;26(7):1417–23

Pre–incubation of synaptosomes with arachidonic acid potentiates inhibition of [3H]D–aspartate transport. Lundy DF, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):273–9

The suppression by lipopolysaccharide of cytochrome P450–dependent renal vasodilation in the rat is mediated by nitric oxide. Oyekan AO. **Eur J Pharmacol** 1995 Apr 24;277(2–3):123–32

Arachidonic acid activatable electrogenic H+ transport in the absence of cytochrome b558 in human T lymphocytes. Káldi K, et al. **FEBS Lett** 1996 Feb 26;381(1–2):156–60

Competitive inhibition of the 5-lipoxygenase-catalysed linoleate oxidation by arachidonic and 5-hydroperoxy-eicosatetraenoic acids. Mirzoeva OK, et al. **FEBS Lett** 1995 Dec 27;377(3):306-8

21-aminosteroid and 2-(aminomethyl)chromans inhibition of arachidonic acid-induced lipid peroxidation and permeability enhancement in bovine brain microvessel endothelial cell monolayers. Shi F, et al. **Free Radic Biol Med** 1995 Sep;19(3):349-57

Modulation of prostaglandin synthesis in mammalian sperm acrosome reaction. Breitbart H, et al. **Hum Reprod** 1995 Aug;10(8):2079-84

Reduced pulmonary artery vasoconstriction in methacholine in cholesterol-fed rabbits. Pfister SL, et al. **Hypertension** 1996 Mar;27(3 Pt 2):804-10

Arachidonate and related unsaturated fatty acids selectively inactivate the guanine nucleotide-binding regulatory protein, Gz. Glick J, et al. **J Biol Chem** 1996 Feb 9; 271(6):2949-54

Ca2+ pools and cell growth: arachidonic acid induces recovery of cells growth-arrested by Ca2+ pool depletion. Graber MN, et al. **J Biol Chem** 1996 Jan 12;271(2):883-8

Activation of phospholipase C-gamma by the concerted action of tau proteins and arachidonic acid. Hwang SC, et al. **J Biol Chem** 1996 Aug 2;271(31):18342-9

Regulation of GLUT4 gene expression by arachidonic acid. Evidence for multiple pathways, one of which requires oxidation to prostaglandin E2. Long SD, et al. **J Biol Chem** 1996 Jan 12;271(2):1138-44

Mechanism of inhibition by arachidonic acid of the catalytic activity of Ras GTPase-activating proteins. Sermon BA, et al. **J Biol Chem** 1996 Jan 19;271(3):1566-72

Effect of arachidonic acid on activity of the apical K+ channel in the thick ascending limb of the rat kidney. Wang W, et al. **J Gen Physiol** 1995 Oct;106(4):727-43

Modulation of neuronal calcium channels by arachidonic acid and related substances. Schmitt H, et al. **J Membr Biol** 1995 Jun;145(3):233-44

Modulation of ryanodine binding to the cardiac Ca2+ release channel by arachidonic acid. Uehara A, et al. **J Mol Cell Cardiol** 1996 Jan;28(1):43-51

Arachidonic acid and oleoylacetylglycerol induce a synergistic facilitation of Ca(2+)-dependent glutamate release from hippocampal mossy fiber nerve endings. Zhang L, et al. **J Neurochem** 1996 Jan;66(1):177-85

Inhibition of the Kv4 (Shal) family of transient K+ currents by arachidonic acid. Villarroel A, et al. **J Neurosci** 1996 Feb 1;16(3):1016-25

Inhibition of the Kv4 (Shal) family of transient K+ currents by arachidonic acid. Villarroel A, et al. **J Neurosci** 1996 Apr 15;16(8):2522-32

Biological effects of dietary arachidonic acid. Introduction. German JB, et al. **J Nutr** 1996 Apr;126(4 Suppl):1076S-80S

Is dietary arachidonic acid necessary for feline reproduction? Pawlosky RJ, et al. **J Nutr** 1996 Apr;126(4 Suppl):1081S-5S

Short-term diets rich in arachidonic acid influence plasma phospholipid polyunsaturated fatty acid levels and prostacyclin and thromboxane production in humans. Sinclair AJ, et al. **J Nutr** 1996 Apr;126(4 Suppl):1110S-4S

Antagonistic effects of dietary arachidonic acid and n-3 polyunsaturated fatty acids. Whelan J. **J Nutr** 1996 Apr; 126(4 Suppl):1086S-91S (35 ref.)

Arachidonic acid protects against hypoxic injury in rat proximal tubules. Alkhunaizi AM, et al. **Kidney Int** 1996 Mar;49(3):620-5

Retinal fatty acids of piglets fed docosahexaenoic and arachidonic acids from microbial sources. Craig-Schmidt MC, et al. **Lipids** 1996 Jan;31(1):53-9

Effects of different polyunsaturated fatty acids on growth-related early gene expression and cell growth. Sellmayer A, et al. **Lipids** 1996 Mar;31 Suppl:S37-40

Effects of indomethacin and arachidonic acid on sister chromatid exchange induction by styrene and styrene-7,8-oxide. Lee SH, et al. **Mutat Res** 1995 Oct; 348(2):93-9

Effects of indomethacin and arachidonic acid on sister chromatid exchange induction by styrene and styrene-7,8-oxide. Lee SH, et al. **Mutat Res** 1995 Dec; 348(4):175-81

Arachidonic acid-induced hormone release in somatotropes: involvement of calcium. Roudbaraki MM, et al. **Neuroendocrinology** 1996 Mar;63(3):244-56

Hippocampal long-term depression: arachidonic acid as a potential retrograde messenger. Bolshakov VY, et al. **Neuropharmacology** 1995 Nov;34(11):1581-7

Arachidonic acid and lysophosphatidylcholine modulate excitatory transmitter amino acid release from the rat cerebral cortex. O'Regan MH, et al. **Neurosci Lett** 1995 Jun 30;193(2):85-8

Interactions between large and small luteal cells collected during the mid- or late-luteal stages of the bovine oestrous cycle. Del Vecchio RP, et al. **Reprod Fertil Dev** 1995; 7(1):35-40

[The modulation of cellular ion channel activity by arachidonic acid, its metabolic products and other fatty acids] Krutetskaia ZI, et al. **Tsitologiia** 1995;37(1-2):5-65 (241 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

The role of arachidonic acid in the secretion of the amyloid precursor protein (APP). Emmerling MR, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:310-5

Augmentation of TNF cytotoxicity by protein kinase C inhibitors: role of arachidonic acid and manganese superoxide dismutase. Prezioso JA, et al. **Cytokine** 1995 Aug;7(6):517-25

Mediators of arachidonic acid-induced relaxation of bovine coronary artery. Pratt PF, et al. **Hypertension** 1996 Jul; 28(1):76-82

Relationship of arachidonic acid release to porcine coronary artery relaxation. Weintraub NL, et al. **Hypertension** 1995 Oct;26(4):684-90

Beta 1 integrins signal lipid second messengers required during cell adhesion. Auer KL, et al. **Mol Biol Cell** 1995 Oct;6(10):1305-13

Arachidonic acid as a neurotoxic and neurotrophic substance. Katsuki H, et al. **Prog Neurobiol** 1995 Aug;46(6):607-36 (345 ref.)

Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. Di Marzo V. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):239-54 (183 ref.)

Lindane-induced elimination of gap junctional communication in rat uterine myocytes is mediated by an arachidonic acid-sensitive cAMP-independent mechanism. Criswell KA, et al. **Toxicol Appl Pharmacol** 1995 Nov; 135(1):127-38

[Reactive oxygen species and arachidonic acid metabolites of polymorphonuclear leukocytes] Döring G, et al. **Immun Infekt** 1995 Oct;23(5):148-57 (163 ref.) (Eng. Abstr.) **(Ger)**

SECRETION

A novel diterpenoid labdane from Sideritis javalambrensis inhibits eicosanoid generation from stimulated macrophages but enhances arachidonate release. Pang L, et al. **Biochem Pharmacol** 1996 Mar 22;51(6):863-8

Characterisation of cytosolic phospholipase A2 as mediator of the enhanced arachidonic acid release from dimethyl sulphoxide differentiated U937 cells. Withnall MT, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1893-902

Protein kinase C activation precedes arachidonic acid release during IgG-mediated phagocytosis. Karimi K, et al. **J Immunol** 1995 Dec 15;155(12):5786-94

ATP receptor-mediated increase of Ca ionophore-stimulated arachidonic acid release from PC12 pheochromocytoma cells. Murayama T, et al. **Jpn J Pharmacol** 1995 Sep; 69(1):43-51

Role of hydroxyl radical in the stimulation of arachidonic acid release caused by H2O2 in pulmonary smooth muscle cells: protective effect of anion channel blocker. Chakraborti S, et al. **Mol Cell Biochem** 1995 May 24; 146(2):91-8

Neuromedin B stimulates arachidonic acid release, c-fos gene expression, and the growth of C6 glioma cells. Moody TW, et al. **Peptides** 1995;16(6):1133-40

TOXICITY

Preclinical evaluation of single-cell oils that are highly enriched with arachidonic acid and docosahexaenoic acid. Boswell K, et al. **Food Chem Toxicol** 1996 Jul;34(7):585-93

Arachidonate has protumor-promoting action that is inhibited by linoleate in mouse skin carcinogenesis. Fischer SM, et al. **J Nutr** 1996 Apr;126(4 Suppl):1099S-1104S

Arachidonic acid as a neurotoxic and neurotrophic substance. Katsuki H, et al. **Prog Neurobiol** 1995 Aug;46(6):607-36 (345 ref.)

ARACHIDONIC ACIDS

[Anandamide: an endogenous cannabinoid receptor agonist] Ueda N. **Seikagaku** 1995 Aug;67(8):1036-40 (19 ref.) **(Jpn)**

[Anandamide: a marijuana-like compound produced in animal tissues] Ueda N, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2329-39 (59 ref.) **(Jpn)**

ANALYSIS

The arachidonic acid content of the Australian diet is lower than previously estimated. Mann NJ, et al. **J Nutr** 1995 Oct;125(10):2528-35

Brain cannabinoids in chocolate [letter] di Tomaso E, et al. **Nature** 1996 Aug 22;382(6593):677-8

Characterization of arachidonic acid metabolites through the 12-lipoxygenase pathway in human epidermis by high-performance liquid chromatography and gas chromatography/mass spectrometry. Antón R, et al. **Rapid Commun Mass Spectrom** 1995;Spec No:S169-82

BIOSYNTHESIS

Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: involvement of Ca(2+)-dependent transacylase and phosphodiesterase activities. Sugiura T, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):113-7

Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Di Marzo V, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):977-84

5(S),15(S)-dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. Chavis C, et al. **J Exp Med** 1996 Apr 1;183(4):1633-43

Estimation of arachidonic acid synthesis in full term neonates using natural variation of 13C content. Demmelmair H, et al. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):31-6

BLOOD

Lipid peroxidation, prostacyclin and thromboxane A2 in pigs depleted of vitamin E and selenium and supplemented with linseed oil. Nolan MR, et al. **Br J Nutr** 1995 Sep; 74(3):369-80

Docosahexaenoic and arachidonic acid content of serum and red blood cell membrane phospholipids of preterm infants fed breast milk, standard formula or formula supplemented with n-3 and n-6 long-chain polyunsaturated fatty acids. Boehm G, et al. **Eur J Pediatr** 1996 May;155(5):410-6

Parameters of respiratory burst and arachidonic acid metabolism in polymorphonuclear granulocytes from patients with various thyroid diseases. Szabó J, et al. **Exp Clin Endocrinol Diabetes** 1996;104(2):172-6

Influence of systemic cyclooxygenase inhibition with single-dose aspisol on kinetics of arachidonic acid metabolites in the venous effluate of transplanted kidney grafts in humans. Storck M, et al. **Transplant Proc** 1996 Feb;28(1):312-3

CHEMICAL SYNTHESIS

Synthesis and cannabinoid receptor binding activity of conjugated triene anandamide, a novel eicosanoid. Wise ML, et al. **Experientia** 1996 Jan 16;52(1):88-92

CHEMISTRY

Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. Thomas BF, et al. **J Med Chem** 1996 Jan 19;39(2):471-9

Hydroxypropyl-beta-cyclodextrin increases aqueous solubility and stability of anandamide. Jarho P, et al. **Life Sci** 1996;58(10):PL 181-5

Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines. Fontana A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):301-8

METABOLISM

Arachidonic acid metabolites and sinonasal polyposis. I. Possible prognostic value. Klapan I, et al. **Am J Otolaryngol** 1995 Nov-Dec;16(6):396-402

Biogenesis and metabolic fate of docosahexaenoic and arachidonic acids in rat uterine stromal cells in culture. Pageaux JF, et al. **Arch Biochem Biophys** 1996 Mar 1; 327(1):142-50

Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. Hampson AJ, et al. **Biochim Biophys Acta** 1995 Nov 16; 1259(2):173-9

Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis. Keicher U, et al. **Eur J Clin Invest** 1995 Dec;25(12):915-9

Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. Schmid PC, et al. **FEBS Lett** 1995 Nov 13; 375(1-2):117-20

Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue. Kempe K, et al. **J Biol Chem** 1996 Jul 19;271(29):17287-95

Purification of a lysophospholipase from bovine brain that selectively deacylates arachidonoyl-substituted lysophosphatidylcholine. Pete MJ, et al. **J Biol Chem** 1996 Jul 26;271(30):18114-21

Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. Ueda N, et al. **J Biol Chem** 1995 Oct 6;270(40):23823-7

Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells. VanRollins M, et al. **J Biol Chem** 1996 Jun 14;271(24):14001-9

Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils. Powell WS, et al. **J Immunol** 1996 Jan 1;156(1):336-42

The Molecular Biology of the Arachidonate Cascade. Symposium proceedings. Kyoto, Japan, December 5-7, 1993. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):iii, 83-448

Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. Faas FH, et al. **J Urol** 1996 Jul;156(1):243-8

The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Paria BC, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9460-4

Discordance between macrophage arachidonate metabolic phenotype and the expression of cytosolic phospholipase A2 and cyclooxygenase. Dolecki GJ, et al. **Prostaglandins** 1995 Jun;49(6):397-414

Role of interferon-alpha in arachidonic acid metabolism by

the rat uteri from spayed animals: effect of 17 beta-estradiol. Motta AB, et al.
Prostaglandins Leukot Essent Fatty Acids 1995 Oct; 53(4):267-71

Cytosolic phospholipase A2 and cyclooxygenase-2 mediate release and metabolism of arachidonic acid in tumor necrosis factor-alpha-primed cultured intestinal epithelial cells (INT 407). Gustafson-Svärd C, et al.
Scand J Gastroenterol 1995 Oct;30(10):1000-7

[Effects of selenium and vitamin E on arachidonic acid metabolism in experimental myocardial ischaemia] Liu W, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Sep; 29(5):279-82 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Evidence that iodolactones are the mediators of growth inhibition by iodine on the thyroid. Gärtner R, et al.
Acta Med Austriaca 1996;23(1-2):47-51 (34 ref.)

Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Ellis EF, et al.
Am J Physiol 1995 Dec;269(6 Pt 2):H1859-64

A specific inhibitor of cytosolic phospholipase A2 activity, AACOCF3, inhibits glucose-induced insulin secretion from isolated rat islets. Loweth AC, et al.
Biochem Biophys Res Commun 1996 Jan 17;218(2):423-7

Anandamide, an endogenous cannabinomimetic substance, modulates rat brain protein kinase C in vitro. De Petrocellis L, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1127-33

Effects of anandamide on hepatic fatty acid metabolism. Guzmán M, et al. **Biochem Pharmacol** 1995 Sep 7; 50(6):885-8

Inhibition of collagen-induced platelet activation by arachidonyl trifluoromethyl ketone. McNicol A, et al.
Biochem Pharmacol 1995 Nov 27;50(11):1795-802

Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride]. Shivachar AC, et al.
Biochem Pharmacol 1996 Mar 8;51(5):669-76

Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Lio YC, et al. **Biochim Biophys Acta** 1996 Jul 12;1302(1):55-60

Anandamides: tolerance and cross-tolerance to delta 9-tetrahydrocannabinol. Fride E. **Brain Res** 1995 Oct 30; 697(1-2):83-90

Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Pate DW, et al.
Curr Eye Res 1995 Sep;14(9):791-7

15-lipoxygenase metabolite(s) of arachidonic acid mediates adrenocorticotropin action in bovine adrenal steroidogenesis. Yamazaki T, et al. **Endocrinology** 1996 Jul; 137(7):2670-5

Chemotactic 5-oxo-icosatetraenoic acids activate a unique pattern of neutrophil responses. Analysis of phospholipid metabolism, intracellular Ca2+ transients, actin reorganization, superoxide-anion production and receptor up-regulation. Norgauer J, et al. **Eur J Biochem** 1996 Mar 15;236(3):1003-9

Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Barg J, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):145-52

Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Varga K, et al.
Eur J Pharmacol 1995 May 24;278(3):279-83

5-Oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway. O'Flaherty JT, et al. **J Biol Chem** 1996 Jul 26;271(30):17821-8

5-Lipoxygenase products modulate the activity of the 85-kDa phospholipase A2 in human neutrophils. Wijkander J, et al. **J Biol Chem** 1995 Nov 3;270(44):26543-9

5-Oxo-eicosatetraenoate is a broadly active, eosinophil-selective stimulus for human granulocytes. O'Flaherty JT, et al. **J Immunol** 1996 Jul 1;157(1):336-42

Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils. Powell WS, et al. **J Immunol** 1996 Jan 1;156(1):336-42

Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. Lee M, et al.
J Pharmacol Exp Ther 1995 Nov;275(2):529-36

Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand. Romero J, et al. **Life Sci** 1996;58(15):1249-57

Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Terranova JP, et al.
Naunyn Schmiedebergs Arch Pharmacol 1995 Nov; 352(5):576-9

Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Vela G, et al. **Neuropharmacology** 1995 Jun;34(6):665-8

Long-term synaptic transformation of hippocampal CA1 gamma-aminobutyric acid synapses and the effect of anandamide. Collin C, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10167-71

The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Skaper SD, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):3984-9

Arachidonic acid inhibits hCG-stimulated progesterone production by corpora lutea of primates: potential mechanism of action. Ciereszko RE, et al.
Prostaglandins 1995 Aug;50(2):103-19

Regulation of a neuronal form of focal adhesion kinase by anandamide. Derkinderen P, et al. **Science** 1996 Sep 20; 273(5282):1719-22

SECRETION

Vasoactive intestinal peptide increases the liberation of arachidonate from anterior pituitary cells in vitro. Judd AM. **Life Sci** 1995;57(18):1641-6

ARACHIS see **PEANUTS**

ARACHNID VECTORS

The spread of tick-borne borreliosis in West Africa and its relationship to sub-Saharan drought. Trape JF, et al.
Am J Trop Med Hyg 1996 Mar;54(3):289-93

Photo quiz. Rocky Mountain Spotted Fever. Cox GM, et al. **Clin Infect Dis** 1995 Aug;21(2):315, 429

Ixodid ticks collected at the Faculty of Veterinary Science, Onderstepoort, from dogs diagnosed with Babesia canis infection. Horak IG. **J S Afr Vet Assoc** 1995 Sep; 66(3):170-1

Mites as vectors for scrapie [letter] Wisniewski HM, et al. **Lancet** 1996 Apr 20;347(9008):1114

Recent acquisitions on tick and tick-borne disease resistance in N'dama (Bos taurus) and Gobra zebu (Bos indicus) cattle. Mattioli RC, et al. **Parassitologia** 1995 Apr;37(1):63-7 (40 ref.)

Use of participatory rural appraisal (PRA) tools for investigating tick ecology and tick-borne disease in Somaliland. Catley AP, et al. **Trop Anim Health Prod** 1996 Feb;28(1):91-8

[Tick-transmitted arbovirus in Maghreb] Chastel C, et al. **Bull Soc Pathol Exot** 1995;88(3):81-5 (Eng. Abstr.) **(Fre)**

[The role of ticks in the epidemiology of Lyme borreliosis] Wegner Z, et al. **Przegl Epidemiol** 1995;49(3):245-50 (33 ref.) (Eng. Abstr.) **(Pol)**

[The role of ticks occurring in Poland in the epidemiology of transmitted diseases] Wegner Z. **Wiad Parazytol** 1995; 41(3):305-19 (Eng. Abstr.) **(Pol)**

[The activity of cyfluthrin and cypermethrin-based preparations against the vector of the causative agent of tick-borne relapsing fever] Vasil'ev IS, et al.
Med Parazitol (Mosk) 1995 Apr-Jun;(2):8-12 (Eng. Abstr.) **(Rus)**

[The interrelationships of ixodid ticks (Ixodidae) with the causative agents of transmissible vertebrate infections] Balashov IuS. **Parazitologiia** 1995 Sep-Oct;29(5):337-52 (90 ref.) (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Prevalence of ticks in relation to their role as vector of Borrelia burgdorferi under autochthone conditions. Gupta SK, et al. **Appl Parasitol** 1995 May;36(2):97-106

IMMUNOLOGY

Dermacentor andersoni: salivary gland proteins suppressing T-lymphocyte responses to concanavalin A in vitro. Bergman DK, et al. **Exp Parasitol** 1995 Nov;81(3):262-71

[The probable utilization of the protective properties of the vector's saliva by the causative agents of specifically tick-borne infections] Alekseev AN, et al. **Parazitologiia** 1995 May-Jun;29(3):154-8 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Short report: density of Lyme disease spirochetes within deer ticks collected from zoonotic sites. Brunet LR, et al.
Am J Trop Med Hyg 1995 Sep;53(3):300-2

Evidence implicating nymphal Ixodes pacificus (Acari: ixodidae) in the epidemiology of Lyme disease in California. Clover JR, et al. **Am J Trop Med Hyg** 1995 Sep;53(3):237-40

Growth and migration of Borrelia burgdorferi in Ixodes ticks during blood feeding. De Silva AM, et al.
Am J Trop Med Hyg 1995 Oct;53(4):397-404

Ability of experimentally infected chickens to infect ticks with the Lyme disease spirochete, Borrelia burgdorferi. Piesman J, et al. **Am J Trop Med Hyg** 1996 Mar;54(3):294-8

The first isolation of Borrelia burgdorferi from Ixodes ricinus (Acari, Ixodidae) ticks in Poland. Dąbrowski J, et al.
Bull Inst Marit Trop Med Gdynia 1993-94;44-45(1-4):61-4

Occurrence of Borrelia spirochaetes in ticks (Acari, Ixodidae) collected in the forest areas in Olsztyn province (north central Poland). Wegner Z, et al.
Bull Inst Marit Trop Med Gdynia 1993-94;44-45(1-4):51-9

Prevalence of Lyme borrelia in ticks in Bratislava, Slovak Republic. Drgonová M, et al.
Cent Eur J Public Health 1995 Aug;3(3):134-7

Laboratory reared Amblyomma hebraeum and Amblyomma variegatum ticks differ in their susceptibility to infection with Cowdria ruminantium. Mahan SM, et al.
Epidemiol Infect 1995 Oct;115(2):345-53

Prevalence of ticks infected with Francisella tularensis in natural foci of tularemia in western Slovakia. Guryčová D, et al. **Eur J Epidemiol** 1995 Aug;11(4):469-74

Differential spirochetal infectivities to vector ticks of mice chronically infected by the agent of Lyme disease. Shih CM, et al. **J Clin Microbiol** 1995 Dec;33(12):3164-8

Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. de Silva AM, et al. **J Exp Med** 1996 Jan 1;183(1):271-5

Identification of an uncultivable Borrelia species in the hard tick Amblyomma americanum: possible agent of a Lyme disease-like illness. Barbour AG, et al. **J Infect Dis** 1996 Feb;173(2):403-9

Suppression of acute Ixodes scapularis-induced Borrelia burgdorferi infection using tumor necrosis factor-alpha, interleukin-2, and interferon-gamma. Zeidner N, et al.
J Infect Dis 1996 Jan;173(1):187-95

Is the small mammal (Clethrionomys glareolus) or the tick vector (Ixodes ricinus) the primary overwintering reservoir for the Lyme borreliosis spirochete in Sweden? Tälleklint L, et al. **J Wildl Dis** 1995 Oct;31(4):537-40

The effect of infection with Lyme disease spirochetes (Borrelia burgdorferi) on the phototaxis, activity, and questing height of the tick vector Ixodes scapularis. Lefcort H, et al. **Parasitology** 1996 Aug;113 (Pt 2):97-103

[The probable utilization of the protective properties of the vector's saliva by the causative agents of specifically tick-borne infections] Alekseev AN, et al. **Parazitologiia** 1995 May-Jun;29(3):154-8 (Eng. Abstr.) **(Rus)**

[The frequency of generalized infection in adult fasting ticks of the genus Ixodes in foci of borreliosis in Russia and the USA] Moskvitina GG, et al. **Parazitologiia** 1995 Sep-Oct;29(5):353-60 (Eng. Abstr.) **(Rus)**

PARASITOLOGY

Population dynamics of Theileria sergenti in persistently infected cattle and vector ticks analysed by a polymerase chain reaction. Kubota S, et al. **Parasitology** 1996 May;112 (Pt 5):437-42

PHYSIOLOGY

Risk of human exposure to vector ticks (Acari: Ixodidae) in a heavily used recreational area in northern California. Lane RS. **Am J Trop Med Hyg** 1996 Aug;55(2):165-73

Nocturnal questing by adult blacklegged ticks, Ixodes scapularis (Acari: Ixodidae). Durden LA, et al.
J Parasitol 1996 Feb;82(1):174-5

Refeeding activity of immature ticks of Ixodes persulcatus and transmission of Lyme disease spirochete by partially fed larvae. Nakao M, et al. **J Parasitol** 1996 Aug; 82(4):669-72

Propagation of the tick Amblyomma variegatum in the Caribbean. Barré N, et al. **Rev Sci Tech** 1995 Sep; 14(3):841-55

VIROLOGY

Amblyomma variegatum (Acari: Ixodidae): mechanism and control of arbovirus secretion in tick saliva. Kaufman WR, et al. **Exp Parasitol** 1996 Apr;82(3):316-23

Variation in parameters affecting risk of human disease due to TBE virus. Korenberg EI, et al.
Folia Parasitol (Praha) 1995;42(4):307-12

Persistence and transmission of tick-borne viruses: Ixodes ricinus and louping-ill virus in red grouse populations. Hudson PJ, et al. **Parasitology** 1995;111 Suppl:S49-58 (27 ref.)

ARACHNID VENOMS see **SPIDER VENOMS**

ARACHNIDISM

Scorpion envenomation [editorial] Sofer S.
Intensive Care Med 1995 Aug;21(8):626-8 (20 ref.)

Spider bites [see comments] Blackman JR.
J Am Board Fam Pract 1995 Jul-Aug;8(4):288-94 (35 ref.)
. Comment in: J Am Board Fam Pract 1995 Nov-Dec;8(6):503.

Spider bites [letter] Watkins-Colwell GJ.
J Am Board Fam Pract 1996 Jan-Feb;9(1):71

A comparative study of severe scorpion envenomation in children caused by Tityus bahiensis and Tityus serrulatus. Bucaretchi F, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jul-Aug;37(4):331-6

[Scorpion stings in children. Saudi Arabian experience] el Aminn EO, et al. **Arch Pediatr** 1995 Aug;2(8):766-73 (64 ref.) (Eng. Abstr.) **(Fre)**

[Scorpion bites in southern France: experience at the poison-control centre of Marseilles (letter)] De Haro L, et al. **Presse Med** 1996 Apr 6;25(12):600 **(Fre)**

[Black widow spider (Latrodectus tredecimguttatus) bite. Presentation of 12 cases] Díez García F, et al.
Med Clin (Barc) 1996 Mar 9;106(9):344-6 (Eng. Abstr.) **(Spa)**

BLOOD

Standardization of an enzyme linked immunosorbent assay (ELISA) for detecting circulating toxic venom antigens in patients stung by the scorpion Tityus serrulatus. de Rezende NA, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jan-Feb;37(1):71-4

ARACHNIDISM

COMPLICATIONS

Black widow spider bite in a child. Reeves JA, et al. **Am J Emerg Med** 1996 Sep;14(5):469–71 (17 ref.)

Chronic relapsing pancreatitis from a scorpion sting in Trinidad. George Angus LD, et al. **Ann Trop Paediatr** 1995 Dec;15(4):285–9 (18 ref.)

Life–threatening hemolysis following a brown recluse spider bite. Leung LK, et al. **J Tenn Med Assoc** 1995 Oct; 88(10):396–7

Cardiac involvement and scorpion envenomation in children. Das S, et al. **J Trop Pediatr** 1995 Dec;41(6):338–40

DIAGNOSIS

Bite to the left leg. Necrotic ulcer from a brown recluse spider bite. Walker JS, et al. **Acad Emerg Med** 1995 Mar; 2(3):223; 231; 234–7

Chronic relapsing pancreatitis from a scorpion sting in Trinidad. George Angus LD, et al. **Ann Trop Paediatr** 1995 Dec;15(4):285–9 (18 ref.)

Spider bite reactions. Carbonaro PA, et al. **Cutis** 1995 Nov; 56(5):256–9 (36 ref.)

DRUG THERAPY

Use of dantrolene in experimental scorpion envenomation by Androctonus australis hector [letter] Guieu R, et al. **Arch Toxicol** 1995;69(8):575–7

Treatment of black widow spider envenomation [letter; comment] Miller TA. **J Am Board Fam Pract** 1995 Nov–Dec;8(6):503. Comment on: J Am Board Fam Pract 1995 Jul–Aug;8(4):288–94.

EPIDEMIOLOGY

From the Centers for Disease Control and Prevention. Necrotic arachnidism—Pacific Northwest, 1988–1996. **JAMA** 1996 Jun 26;275(24):1870–1

Necrotic arachnidism—Pacific Northwest, 1988–1996. **MMWR Morb Mortal Wkly Rep** 1996 May 31;45(21):433–6

[Retrospective study on Latrodectus stings in Bahia, Brazil] Lira–da–Silva RM, et al. **Rev Soc Bras Med Trop** 1995 Jul–Sep;28(3):205–10 (Eng. Abstr.) **(Por)**

ETIOLOGY

Injection of a whole black widow spider. Bush SP, et al. **Ann Emerg Med** 1996 Apr;27(4):532–3

IMMUNOLOGY

Interleukin–6 release following scorpion sting in children. Sofer S, et al. **Toxicon** 1996 Mar;34(3):389–92

PHYSIOPATHOLOGY

Assessment of left ventricular function in severe scorpion envenomation: combined hemodynamic and echo–Doppler study. Abroug F, et al. **Intensive Care Med** 1995 Aug; 21(8):629–35

Scorpion envenomation in children in southern India. Das S, et al. **J Trop Med Hyg** 1995 Oct;98(5):306–8

THERAPY

Efficacy of widow spider antivenin [letter; comment] Pearl JM. **Ann Emerg Med** 1996 Feb;27(2):273. Comment on: Ann Emerg Med 1994 Dec;24(6):1198–9. Comment on: Ann Emerg Med 1995 Sep;26(3):393–4.

Delayed but effective treatment of red–back spider envenomation [letter] Wells CL, et al. **Med J Aust** 1996 Apr 1;164(7):447

Brown recluse spider envenomation of the eyelid: an animal model. Cole HP 3rd, et al. **Ophthal Plast Reconstr Surg** 1995 Sep;11(3):153–64

ARACHNODACTYLY see MARFAN SYNDROME

ARACHNOID

MR of leptomeningeal melanosis in children. Byrd SE, et al. **Eur J Radiol** 1995 Jul;20(2):93–9

BLOOD SUPPLY

Experimental deposition of Alzheimer amyloid beta–protein in canine leptomeningeal vessels. Prior R, et al. **Neuroreport** 1995 Sep 11;6(13):1747–51

IMMUNOLOGY

HLA–DR expression on arachnoid cells. A role in the fibrotic inflammation surrounding nerve roots in spondylotic cervical myelopathy. Frank E. **Spine** 1995 Oct 1; 20(19):2093–6

INJURIES

Sudden onset of subarachnoid block after subdural catheterization: a case of arachnoid rupture? Elliott DW, et al. **Br J Anaesth** 1996 Feb;76(2):322–4

PATHOLOGY

Subarachnoid haemorrhage induced proliferation of leptomeningeal cells and deposition of extracellular matrices in the arachnoid granulations and subarachnoid space. Immunhistochemical study. Motohashi O, et al. **Acta Neurochir (Wien)** 1995;136(1–2):88–91

Arachnoid granulations in the transverse and sigmoid sinuses: CT, MR, and MR angiographic appearance of a normal anatomic variation. Roche J, et al. **AJNR Am J Neuroradiol** 1996 Apr;17(4):677–83

Sarcomatosis of leptomeninges, brain and spinal cord coexisting with von Recklinghausen's neurofibromatosis. A case report and review of the literature. Słowiński J, et al. **Folia Neuropathol** 1995;33(3):135–40

Magnetic resonance imaging of syrinx associated with intramedullary metastases and leptomeningeal disease. Phuphanich S, et al. **J Neuroimaging** 1996 Apr;6(2):115–7

The natural history of arachnoid cysts: endoscopic and cine–mode MRI evidence of a slit–valve mechanism. Santamarta D, et al. **Minim Invasive Neurosurg** 1995 Dec; 38(4):133–7 (28 ref.)

Ossification of the lumbosacral dura and arachnoid following spinal cord trauma. Case report. Bell RB, et al. **Paraplegia** 1995 Sep;33(9):543–6

RADIATION EFFECTS

Treatment of diffuse leptomeningeal malignancy by intrathecal injection of 131I radioimmunoconjugates. Kemshead JT, et al. **Recent Results Cancer Res** 1996; 141:145–58

ARACHNOID CYSTS

Gradual resolution of an arachnoid cyst after spontaneous rupture into the subdural space. Case report. Rakier A, et al. **J Neurosurg** 1995 Dec;83(6):1085–6

Craniospinal arachnoid cyst: case report] Fukushima Y, et al. **No Shinkei Geka** 1996 Jan;24(1):75–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

[Type I glutaric acidity with arachnoidal cysts] Artigas J, et al. **Rev Neurol** 1995 Jan–Feb;23(119):153–6 (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Spinal arachnoid cyst developing after surgical treatment of a ruptured vertebral artery aneurysm: a possible complication of topical use of fibrin glue. Case report. Taguchi Y, et al. **J Neurosurg** 1996 Mar;84(3):526–9

COMPLICATIONS

Isosexual precocious puberty in a boy with meningomyelocele and cerebral arachnoid cyst. Kumar A, et al. **Indian Pediatr** 1995 Jan;32(1):101–3

Fluctuating hemiparesis caused by a quadrigeminal arachnoid cyst: case report. Wong CW, et al. **Surg Neurol** 1996 Feb; 45(2):193–5

[Spinal intradural arachnoid cyst associated with enlarged filum terminale] Hirano A, et al. **No Shinkei Geka** 1995 Nov;23(11):1011–5 (Eng. Abstr.) **(Jpn)**

[A case of a thoracic extradural arachnoid cyst presenting with slowly progressive muscle weakness in the right upper and lower limbs] Inoue H, et al. **Rinsho Shinkeigaku** 1996 Jan;36(1):47–51 (Eng. Abstr.) **(Jpn)**

[Unusual association of Kallmann syndrome and arachnoid cyst of the middle fossa. Report of a case] Fernandes YB, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3–B):662–6 (Eng. Abstr.) **(Por)**

DIAGNOSIS

Petrous apex arachnoid cyst: radiographic confusion with primary cholesteatoma. Cheung SW, et al. **Am J Otol** 1995 Sep;16(5):690–4

Posterior fossa cystic lesions—magnetic resonance imaging manifestations. Tan EC, et al. **Brain Dev** 1995 Nov–Dec; 17(6):418–24

Reduced GABAA receptor density contralateral to a potentially epileptogenic MRI abnormality in a patient with complex partial seizures. Kuwert T, et al. **Eur J Nucl Med** 1996 Jan;23(1):95–8

Isosexual precocious puberty in a boy with meningomyelocele and cerebral arachnoid cyst. Kumar A, et al. **Indian Pediatr** 1995 Jan;32(1):101–3

Large arachnoid cyst. Mondal T, et al. **Indian Pediatr** 1995 Aug;32(8):927–9 (12 ref.)

The natural history of arachnoid cysts: endoscopic and cine–mode MRI evidence of a slit–valve mechanism. Santamarta D, et al. **Minim Invasive Neurosurg** 1995 Dec; 38(4):133–7 (28 ref.)

Cine–magnetic resonance imaging evaluation of communication between middle cranial fossa arachnoid cysts and cisterns. Eguchi T, et al. **Neurol Med Chir (Tokyo)** 1996 Jun;36(6):353–7

An unusual spinal intradural arachnoid cyst. Slavotinek JP, et al. **Neuroradiology** 1996 Feb;38(2):152–4

Intradiploic arachnoid cyst presenting as a frontal sinus mass. Tsue TT, et al. **Otolaryngol Head Neck Surg** 1996 Jan; 114(1):110–2

Fluctuating hemiparesis caused by a quadrigeminal arachnoid cyst: case report. Wong CW, et al. **Surg Neurol** 1996 Feb; 45(2):193–5

[The radiological findings in surgically and conservatively treated intracranial arachnoid cysts] Ernst S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):29–35 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Posttraumatic spinal subarachnoid cyst. Coffin CM, et al. **Eur Radiol** 1996;6(4):523–5

Intracranial cysts in autosomal dominant polycystic kidney disease. Schievink WI, et al. **J Neurosurg** 1995 Dec; 83(6):1004–7

GENETICS

Absence/hypoplasia of tibia, polydactyly, retrocerebellar arachnoid cyst, and other anomalies: an autosomal recessive disorder. Holmes LB, et al. **J Med Genet** 1995 Nov; 32(11):896–900 (29 ref.)

PATHOLOGY

Cine–mode magnetic resonance imaging of a thoracic intradural arachnoid cyst: case report. Fujimura M, et al. **Surg Neurol** 1996 Jun;45(6):533–6

PHYSIOPATHOLOGY

Unusual lesions of the internal auditory canal. Bohrer PS, et al. **Am J Otol** 1996 Jan;17(1):143–9

The natural history of arachnoid cysts: endoscopic and cine–mode MRI evidence of a slit–valve mechanism. Santamarta D, et al. **Minim Invasive Neurosurg** 1995 Dec; 38(4):133–7 (28 ref.)

RADIOGRAPHY

Arachnoid cyst and chronic subdural haematoma in a child with osteogenesis imperfecta type III resulting from the substitution of glycine 1006 by alanine in the pro alpha 2(I) chain of type I procollagen. Cole WG, et al. **J Med Genet** 1996 Mar;33(3):193–6

SURGERY

Symptomatic intraventricular arachnoid cyst in an elderly man. Koga H, et al. **Acta Neurochir (Wien)** 1995; 137(1–2):113–7

Arachnoid cyst within the fourth ventricle—a case report. Nadkarni T, et al. **Br J Neurosurg** 1995;9(5):675–8 (10 ref.)

Percutaneous endoscopic treatment of suprasellar arachnoid cysts: ventriculocystostomy or ventriculocystocisternostomy? Technical note. Decq P, et al. **J Neurosurg** 1996 Apr;84(4):696–701

Cystplastic cyst–subarachnoid shunt procedure for arachnoid cyst of the middle cranial fossa—technical note. Takeuchi T, et al. **Neurol Med Chir (Tokyo)** 1996 Jun;36(6):396–9 (7 ref.)

Arachnoid cysts: does surgery improve epileptic seizures and headaches? Koch CA, et al. **Neurosurg Rev** 1995; 18(3):173–81 (37 ref.)

Burr hole neuroendoscopic fenestration of quadrigeminal cistern arachnoid cyst: technical case report. Ruge JR, et al. **Neurosurgery** 1996 Apr;38(4):830–7 (32 ref.)

Surgical options in the treatment of interhemispheric arachnoid cysts. Caldarelli M, et al. **Surg Neurol** 1996 Sep; 46(3):212–21

New surgical treatment of middle fossa arachnoid cyst. Shigemori M, et al. **Surg Neurol** 1996 Feb;45(2):189–92

[Arachnoid cysts of the middle cranial fossa in children. A review of 75 cases, 47 of which have been operated in a comparative study between membranectomy with opening of cisterns and cystoperitoneal shunt] Lena G, et al. **Neurochirurgie** 1996;42(1):29–34 (Eng. Abstr.) **(Fre)**

[Intracranial arachnoid cyst in pediatric age] Cagnoni G, et al. **Pediatr Med Chir** 1996 Jan–Feb;18(1):85–90 (Eng. Abstr.) **(Ita)**

[Intrasellar arachnoid cyst: a case report] Tanaka Y, et al. **No Shinkei Geka** 1995 Sep;23(9):801–6 (Eng. Abstr.) **(Jpn)**

[A case of a thoracic extradural arachnoid cyst presenting with slowly progressive muscle weakness in the right upper and lower limbs] Inoue H, et al. **Rinsho Shinkeigaku** 1996 Jan;36(1):47–51 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Posterior fossa arachnoid cyst: an in utero mimicker of Dandy–Walker malformation. Estroff JA, et al. **J Ultrasound Med** 1995 Oct;14(10):787–90

[The ultrasonic diagnosis in utero of fetal arachnoid cysts] Ruseva R, et al. **Akush Ginekol (Sofiia)** 1994;33(2):43–4 **(Bul)**

ARACHNOIDITIS

DIAGNOSIS

Postcontrast MRI of cranial meninges: leptomeningitis versus pachymeningitis. Kioumehr F, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):713–20

Laminectomy–induced arachnoradiculitis: a postoperative serial MRI study. Matsui H, et al. **Neuroradiology** 1995 Nov;37(8):660–6

RADIOGRAPHY

[The clinical characteristics of rhinosinusogenic diffuse cerebral arachnoiditis located predominantly in the anterior cranial fossa] Gushchin AN.

Zh Nevropatol Psikhiatr Im S S Korsakova 1995;95(2):23–6 (Eng. Abstr.) **(Rus)**

THERAPY

Neurosurgical care of spinal epidural, subdural, and intramedullary abscesses and arachnoiditis. Martin RJ, et al. **Orthop Clin North Am** 1996 Jan;27(1):125–36 (72 ref.)

ARANEID VENOMS see **SPIDER VENOMS**

ARAURIDINE see **ARABINOFURANOSYLURACIL**

ARBITRATING see **NEGOTIATING**

ARBOVIRUS, GROUP B see **FLAVIVIRUS**

ARBOVIRUS INFECTIONS

[Arbovirus infections, hemorrhagic fever with renal syndrome and Astrakhan fever in the southeastern region of the Russian Federation] Butenko AM, et al. **Med Parazitol (Mosk)** 1995 Jul–Sep;(3):58–60 **(Rus)**

EPIDEMIOLOGY

Arboviruses causing neurological disorders in the central nervous system. Dobler G. **Arch Virol Suppl** 1996;11:33–40 (18 ref.)

Arboviruses as imported disease agents: the need for increased awareness. Gubler DJ. **Arch Virol Suppl** 1996; 11:21–32 (29 ref.)

From the Centers for Disease Control and Prevention. Arboviral disease—United States, 1994. **JAMA** 1995 Oct 11;274(14):1110–2

Arbovirus surveillance. **Wkly Epidemiol Rec** 1995 Nov 17; 70(46):329–31 **(Eng, Fre)**

ETIOLOGY

Arboviruses and the central nervous system. Griffin DE. **Springer Semin Immunopathol** 1995;17(2–3):121–32 (79 ref.)

IMMUNOLOGY

Phenotypic changes in Langerhans' cells after infection with arboviruses: a role in the immune response to epidermally acquired viral infection? Johnston LJ, et al. **J Virol** 1996 Jul;70(7):4761–6

Arboviruses and the central nervous system. Griffin DE. **Springer Semin Immunopathol** 1995;17(2–3):121–32 (79 ref.)

PREVENTION & CONTROL

[Major results of the study of arbovirus infections in the Soviet Union, conducted under the supervision of A.A. Smorodintsev] Il'enko VI. **Tr Inst Im Pastera** 1992;67:33–44 **(Rus)**

TRANSMISSION

Arboviruses causing neurological disorders in the central nervous system. Dobler G. **Arch Virol Suppl** 1996;11:33–40 (18 ref.)

Travel-related vector-borne virus infections in Germany. Schwarz TF, et al. **Arch Virol Suppl** 1996;11:57–65

Australian arboviruses: at what risk New Zealand? [editorial] Weinstein P, et al. **Aust N Z J Med** 1995 Dec;25(6):666–9 (19 ref.)

The virtual absence of Culicoides imicola (Diptera: Ceratopogonidae) in a light-trap survey of the colder, high-lying area of the eastern Orange Free State, South Africa, and implications for the transmission of arboviruses. Venter GJ, et al. **Onderstepoort J Vet Res** 1994 Dec; 61(4):327–40

[Tick-transmitted arbovirus in Maghreb] Chastel C, et al. **Bull Soc Pathol Exot** 1995;88(3):81–5 (Eng. Abstr.) **(Fre)**

VETERINARY

The dispersal of Culicoides brevitarsis in eastern New South Wales and associations with the occurrences of arbovirus infections in cattle. Bishop AL, et al. **Aust Vet J** 1996 May; 73(5):174–8

Australian–Indonesian collaboration in veterinary arbovirology—a review. Daniels PW, et al. **Vet Microbiol** 1995 Sep;46(1–3):151–74 (108 ref.)

Veterinary arbovirus vectors in Australia—a retrospective. Muller MJ. **Vet Microbiol** 1995 Sep;46(1–3):101–16 (67 ref.)

Influences of vector biology on transmission of arboviruses and outbreaks of disease: the Culicoides brevitarsis model. Murray MD. **Vet Microbiol** 1995 Sep;46(1–3):91–9

ARBOVIRUSES

see related
BUNYAVIRIDAE
FLAVIVIRIDAE
REOVIRIDAE
TOGAVIRIDAE

The role of Aedes albopictus as an arbovirus vector. Mitchell CJ. **Parassitologia** 1995 Dec;37(2–3):109–13 (17 ref.)

Arbovirus surveillance in Italy. Verani P, et al. **Parassitologia** 1995 Dec;37(2–3):105–8 (19 ref.)

Australian–Indonesian collaboration in veterinary arbovirology—a review. Daniels PW, et al. **Vet Microbiol** 1995 Sep;46(1–3):151–74 (108 ref.)

CLASSIFICATION

Arboviruses as imported disease agents: the need for increased awareness. Gubler DJ. **Arch Virol Suppl** 1996; 11:21–32 (29 ref.)

IMMUNOLOGY

Phenotypic changes in Langerhans' cells after infection with arboviruses: a role in the immune response to epidermally acquired viral infection? Johnston LJ, et al. **J Virol** 1996 Jul;70(7):4761–6

ISOLATION & PURIFICATION

Arbovirus surveillance in Iowa, USA, during the flood of 1993. Gilliland TM, et al. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 1):157–61

Veterinary arbovirus vectors in Australia—a retrospective. Muller MJ. **Vet Microbiol** 1995 Sep;46(1–3):101–16 (67 ref.)

[Mosquito-borne arboviruses in the Baikal region] L'vov SD, et al. **Vopr Virusol** 1995 Jul–Aug;40(4):170–2 (Eng. Abstr.) **(Rus)**

PATHOGENICITY

Arboviruses causing neurological disorders in the central nervous system. Dobler G. **Arch Virol Suppl** 1996;11:33–40 (18 ref.)

[Mosquitoes—arbovirus vectors] Tarasov VV. **Med Parazitol (Mosk)** 1995 Apr–Jun;(2):40–6 **(Rus)**

ARBOVIRUSES, GROUP A see **ALPHAVIRUS**

ARBUTIN

PHARMACOLOGY

Arbutin inhibits PLA2 in partially hydrated model systems. Oliver AE, et al. **Biochim Biophys Acta** 1996 Jul 12; 1302(1):69–78

Arbutin: mechanism of its depigmenting action in human melanocyte culture. Maeda K, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):765–9

ARC see **AIDS-RELATED COMPLEX**

ARCHAEA see **ARCHAEOBACTERIA**

ARCHAEBACTERIA see **ARCHAEOBACTERIA**

ARCHAEOBACTERIA

A hot topic: the origin of hyperthermophiles. Forterre P. **Cell** 1996 Jun 14;85(6):789–92 (20 ref.)

The third form of life [news] Gray MW. **Nature** 1996 Sep 26;383(6598):299–300

CHEMISTRY

1H NMR investigation of the electronic and molecular structure of the four-iron cluster ferredoxin from the hyperthermophile Pyrococcus furiosus. Identification of Asp 14 as a cluster ligand in each of the four redox states. Calzolai L, et al. **Biochemistry** 1995 Sep 12;34(36):11373–84

Molecular model of the solution structure for the paramagnetic four-iron ferredoxin from the hyperthermophilic archaeon Thermococcus litoralis. Wang PL, et al. **Biochemistry** 1996 Sep 3;35(35):11319–28

A gene, han1A, encoding an archaeal histone-like protein from the Thermococcus species AN1: homology with eukaryal histone consensus sequences and the implications for delineation of the histone fold. Ronimus RS, et al. **Biochim Biophys Acta** 1996 Jun 3;1307(1):1–7

Archaebacterial lipid models: stable liposomes from 1-alkyl-2-phytanyl-sn-glycero-3-phosphocholines. Yamauchi K, et al. **Biochim Biophys Acta** 1996 Sep 4; 1283(2):163–9

Extreme resistance to thermally induced DNA backbone breaks in the hyperthermophilic archaeon Pyrococcus furiosus. Peak MJ, et al. **J Bacteriol** 1995 Nov; 177(21):6316–8

Hyperthermostable surface layer protein tetrabrachion from the archaebacterium Staphylothermus marinus: evidence for the presence of a right-handed coiled coil derived from the primary structure. Peters J, et al. **J Mol Biol** 1996 Apr 19;257(5):1031–41

The N-terminal domain of TFIIB from Pyrococcus furiosus forms a zinc ribbon [letter] Zhu W, et al. **Nat Struct Biol** 1996 Feb;3(2):122–4

CLASSIFICATION

Natronococcus amylolyticus sp. nov., a haloalkaliphilic archaeon. Kanal H, et al. **Int J Syst Bacteriol** 1995 Oct; 45(4):762–6

Halobaculum gomorrense gen. nov., sp. nov., a novel extremely halophilic archaeon from the Dead Sea. Oren A, et al. **Int J Syst Bacteriol** 1995 Oct;45(4):747–54

Picrophilus gen. nov., fam. nov.: a novel aerobic, heterotrophic, thermoacidophilic genus and family comprising archaea capable of growth around pH 0. Schleper C, et al. **J Bacteriol** 1995 Dec;177(24):7050–9

Archaeal–eubacterial mergers in the origin of Eukarya: phylogenetic classification of life. Margulis L. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1071–6

DRUG EFFECTS

Differential antibiotic sensitivity determined by the large ribosomal subunit in thermophilic archaea. Ruggero D, et al. **J Bacteriol** 1996 Jun;178(11):3396–8

ENZYMOLOGY

Cloning, sequencing, and expression of a xylanase gene from the extreme thermophile Dictyoglomus thermophilum Rt46B.1 and activity of the enzyme on fiber-bound substrate. Gibbs MD, et al. **Appl Environ Microbiol** 1995 Dec;61(12):4403–8

Isolation and characterization of a heat-stable pullulanase from the hyperthermophilic archaeon Pyrococcus woesei after cloning and expression of its gene in Escherichia coli. Rüdiger A, et al. **Appl Environ Microbiol** 1995 Feb; 61(2):567–75

A eubacterial Mycobacterium tuberculosis tRNA synthetase is eukaryote-like and resistant to a eubacterial-specific antisynthetase drug. Sassanfar M, et al. **Biochemistry** 1996 Aug 6;35(31):9995–10003

Halolysin R4, a serine proteinase from the halophilic archaeon Haloferax mediterranei; gene cloning, expression and structural studies. Kamekura M, et al. **Biochim Biophys Acta** 1996 May 23;1294(2):159–67

Properties and stabilization of an extracellular alpha-glucosidase from the extremely thermophilic archaebacteria Thermococcus strain AN1: enzyme activity at 130 degrees C. Piller K, et al. **Biochim Biophys Acta** 1996 Jan 4;1292(1):197–205

Refolding pathway and association intermediates of glutamate dehydrogenase from the hyperthermophile Pyrococcus furiosus. Consalvi V, et al. **Eur J Biochem** 1996 Aug 1;239(3):679–85

Dimeric 3-phosphoglycerate kinases from hyperthermophilic Archaea. Cloning, sequencing and expression of the 3-phosphoglycerate kinase gene of Pyrococcus woesei in Escherichia coli and characterization of the protein. Structural and functional comparison with the 3-phosphoglycerate kinase of Methanothermus fervidus. Hess D, et al. **Eur J Biochem** 1995 Oct 1;233(1):227–37

Purification and characterization of carbamoyl-phosphate synthetase from the deep-sea hyperthermophilic archaebacterium Pyrococcus abyssi. Purcarea C, et al. **Eur J Biochem** 1996 Feb 15;236(1):189–99

Purification and characterization of phosphoenolpyruvate carboxylase from the hyperthermophilic archaeon Methanothermus sociabilis. Sako Y, et al. **FEBS Lett** 1996 Aug 26;392(2):148–52

Glyceraldehyde-3-phosphate dehydrogenase from Thermotoga maritima: strategies of protein stabilization. Jaenicke R. **FEMS Microbiol Rev** 1996 May;18(2–3):215–24 (33 ref.)

Insights into the molecular basis of thermal stability from the structure determination of Pyrococcus furiosus glutamate dehydrogenase. Rice DW, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):105–17 (43 ref.)

The amino-acid sequence similarity of plant glutamate dehydrogenase to the extremophilic archaeal enzyme conforms to its stress-related function. Syntichaki KM, et al. **Gene** 1996 Feb 2;168(1):87–92

Sequence, expression in Escherichia coli, and analysis of the gene encoding a novel intracellular protease (PfpI) from the hyperthermophilic archaeon Pyrococcus furiosus. Halio SB, et al. **J Bacteriol** 1996 May;178(9):2605–12

Dihydrolipoamide dehydrogenase from the halophilic archaeon Haloferax volcanii: homologous overexpression of the cloned gene. Jolley KA, et al. **J Bacteriol** 1996 Jun; 178(11):3044–8

Molecular and phylogenetic characterization of pyruvate and 2-ketoisovalerate ferredoxin oxidoreductases from Pyrococcus furiosus and pyruvate ferredoxin oxidoreductase from Thermotoga maritima. Kletzin A, et al. **J Bacteriol** 1996 Jan;178(1):248–57

Molybdenum and vanadium do not replace tungsten in the catalytically active forms of the three tungstoenzymes in the hyperthermophilic archaeon Pyrococcus furiosus. Mukund S, et al. **J Bacteriol** 1996 Jan;178(1):163–7

Characterization of the celB gene coding for beta-glucosidase from the hyperthermophilic archaeon Pyrococcus furiosus and its expression and site-directed mutation in Escherichia coli. Voorhorst WG, et al. **J Bacteriol** 1995 Dec; 177(24):7105–11

Properties of glutamate dehydrogenase and its involvement in alanine production in a hyperthermophilic archaeon, Thermococcus profundus. Kobayashi T, et al. **J Biochem (Tokyo)** 1995 Sep;118(3):587–92

Purification and characterization of a novel ADP-dependent glucokinase from the hyperthermophilic archaeon Pyrococcus furiosus. Kengen SW, et al. **J Biol Chem** 1995 Dec 22;270(51):30453–7

Archaebacterial DNA polymerases tightly bind uracil-containing DNA. Lasken RS, et al. **J Biol Chem** 1996 Jul 26;271(30):17692–6

Isolation and characterization of the hyperthermostable serine protease, pyrolysin, and its gene from the hyperthermophilic archaeon Pyrococcus furiosus. Voorhorst WG, et al. **J Biol Chem** 1996 Aug 23;

271(34):20426–31

Gene for aspartate racemase from the sulfur-dependent hyperthermophilic archaeum, Desulfurococcus strain SY. Yohda M, et al. **J Biol Chem** 1996 Sep 6;271(36):22017–21

The adenylosuccinate synthetase from the hyperthermophilic archaeon Pyrococcus species displays unusual structural features. Bouyoub A, et al. **J Mol Biol** 1996 Aug 16; 261(2):144–54

Cloning of thermostable DNA polymerases from hyperthermophilic marine Archaea with emphasis on Thermococcus sp. 9 degrees N-7 and mutations affecting 3'-5' exonuclease activity. Southworth MW, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5281–5

Crystallization and preliminary crystallographic analysis of an amylopullulanase from the hyperthermophilic archaeon Pyrococcus woesei. Knapp S, et al. **Proteins** 1995 Dec; 23(4):595–7

The structure of Pyrococcus furiosus glutamate dehydrogenase reveals a key role for ion-pair networks in maintaining enzyme stability at extreme temperatures. Yip KS, et al. **Structure** 1995 Nov 15;3(11):1147–58

GENETICS

Isolation and characterization of a heat-stable pullulanase from the hyperthermophilic archaeon Pyrococcus woesei after cloning and expression of its gene in Escherichia coli. Rüdiger A, et al. **Appl Environ Microbiol** 1995 Feb; 61(2):567–75

A gene, han1A, encoding an archaeal histone-like protein from the Thermococcus species AN1: homology with eukaryal histone consensus sequences and the implications for delineation of the histone fold. Ronimus RS, et al. **Biochim Biophys Acta** 1996 Jun 3;1307(1):1–7

Dimeric 3-phosphoglycerate kinases from hyperthermophilic Archaea. Cloning, sequencing and expression of the 3-phosphoglycerate kinase gene of Pyrococcus woesei in Escherichia coli and characterization of the protein. Structural and functional comparison with the 3-phosphoglycerate kinase of Methanothermus fervidus. Hess D, et al. **Eur J Biochem** 1995 Oct 1;233(1):227–37

General vectors for archaeal hyperthermophiles: strategies based on a mobile intron and a plasmid. Aagaard C, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):93–104 (38 ref.)

The unique DNA topology and DNA topoisomerases of hyperthermophilic archaea. Forterre P, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):237–48 (47 ref.)

Archaeal transcription factors and their role in transcription initiation. Thomm M. **FEMS Microbiol Rev** 1996 May; 18(2–3):159–71 (64 ref.)

Viruses, plasmids and other genetic elements of thermophilic and hyperthermophilic Archaea. Zillig W, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):225–36 (28 ref.)

A putative SOS repair gene (dinF-like) in a hyperthermophilic archaeon. Bouyoub A, et al. **Gene** 1995 Dec 29;167(1–2):147–9

The 3-phosphoglycerate kinase of the hyperthermophilic archaeum Pyrococcus woesei produced in Escherichia coli: loss of heat resistance due to internal translation initiation and its restoration by site-directed mutagenesis. Hess D, et al. **Gene** 1996 Jun 12;172(1):121–4

Aspartyl-tRNA synthetase of the hyperthermophilic archaeon Pyrococcus sp. KOD1 has a chimerical structure of eukaryotic and bacterial enzymes. Imanaka T, et al. **Gene** 1995 Oct 16;164(1):153–6

An abnormally acidic TATA-binding protein from a hyperthermophilic archaeon. Rashid N, et al. **Gene** 1995 Dec 1;166(1):139–43

Sequence of plasmid pGT5 from the archaeon Pyrococcus abyssi: evidence for rolling-circle replication in a hyperthermophile. Erauso G, et al. **J Bacteriol** 1996 Jun; 178(11):3232–7

Conserved sequence elements involved in regulation of ribosomal protein gene expression in halophilic archaea. Shimmin LC, et al. **J Bacteriol** 1996 Aug;178(15):4737–41

Characterization of uncultivated prokaryotes: isolation and analysis of a 40-kilobase-pair genome fragment from a planktonic marine archaeon. Stein JL, et al. **J Bacteriol** 1996 Feb;178(3):591–9

Comparative analysis of ribonuclease P RNA structure in Archaea. Haas ES, et al. **Nucleic Acids Res** 1996 Apr 1; 24(7):1252–9

A cell-free transcription system for the hyperthermophilic archaeon Pyrococcus furiosus. Hethke C, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2369–76

recA-like genes from three archaean species with putative protein products similar to Rad51 and Dmc1 proteins of the yeast Saccharomyces cerevisiae. Sandler SJ, et al. **Nucleic Acids Res** 1996 Jun 1;24(11):2125–32

An archaebacterial homologue of the essential eubacterial cell division protein FtsZ. Baumann P, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6726–30

Archaeal ubiquity. Stein JL, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6228–30 (13 ref.)

Citrate synthase from the hyperthermophilic Archaeon, Pyrococcus furiosus. Muir JM, et al. **Protein Eng** 1995 Jun; 8(6):583–92

Transcription: new insights from studies on Archaea. Baumann P, et al. **Trends Genet** 1995 Jul;11(7):279–83 (43 ref.)

ISOLATION & PURIFICATION

A psychrophilic crenarchaeon inhabits a marine sponge: Cenarchaeum symbiosum gen. nov., sp. nov. Preston CM, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6241–6

METABOLISM

L-alanine production from glucose fermentation by hyperthermophilic members of the domains bacteria and Archaea: a remnant of an ancestral metabolism? Ravot G, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2657–9

Thermococcus alcaliphilus sp. nov., a new hyperthermophilic archaeum growing on polysulfide at alkaline pH. Keller M, et al. **Arch Microbiol** 1995 Dec;164(6):390–5

Protein splicing: evidence for an N-O acyl rearrangement as the initial step in the splicing process. Shao Y, et al. **Biochemistry** 1996 Mar 26;35(12):3810–5

Light-driven chloride ion transport by halorhodopsin from Natronobacterium pharaonis. 1. The photochemical cycle. Váró G, et al. **Biochemistry** 1995 Nov 7;34(44):14490–9

Light-driven chloride ion transport by halorhodopsin from Natronobacterium pharaonis. 2. Chloride release and uptake, protein conformation change, and thermodynamics. Váró G, et al. **Biochemistry** 1995 Nov 7;34(44):14500–7

Respiratory chains of archaea and extremophiles. Schäfer G, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):16–20 (39 ref.)

Histones and chromatin structure in hyperthermophilic Archaea. Grayling RA, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):203–13 (29 ref.)

On the origin of respiration: electron transport proteins from archaea to man. Schäfer G, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):173–88 (55 ref.)

Characterization of 2-ketoisovalerate ferredoxin oxidoreductase, a new and reversible coenzyme A-dependent enzyme involved in peptide fermentation by hyperthermophilic archaea. Heider J, et al. **J Bacteriol** 1996 Feb;178(3):780–7

High-affinity maltose/trehalose transport system in the hyperthermophilic archaeon Thermococcus litoralis. Xavier KB, et al. **J Bacteriol** 1996 Aug;178(16):4773–7

1H NMR investigation of the secondary structure, tertiary contacts and cluster environment of the four-iron ferredoxin from the hyperthermophilic archaeon Thermococcus litoralis. Donaire A, et al. **J Biomol NMR** 1996 Jan;7(1):35–47

Evolution of energetic metabolism: the respiration-early hypothesis. Castresana J, et al. **Trends Biochem Sci** 1995 Nov;20(11):443–8

[Halophilic archaea flagella: biochemical and genetic analysis] Serganova IS, et al. **Biokhimiia** 1995 Aug; 60(8):1261–7 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Modeling and measuring the elastic properties of an archaeal surface, the sheath of Methanospirillum hungatei, and the implication of methane production. Xu W, et al. **J Bacteriol** 1996 Jun;178(11):3106–12

Functional compartmentalization in bacteria and archaea. A hypothetical interface between cytoplasmic membrane and cytoplasm. Mayer F, et al. **Naturwissenschaften** 1996 Jan; 83(1):36–9

ULTRASTRUCTURE

Functional compartmentalization in bacteria and archaea. A hypothetical interface between cytoplasmic membrane and cytoplasm. Mayer F, et al. **Naturwissenschaften** 1996 Jan; 83(1):36–9

VIROLOGY

Viruses, plasmids and other genetic elements of thermophilic and hyperthermophilic Archaea. Zillig W, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):225–36 (28 ref.)

ARCHAEOLOGY

An improved method for estimating original mineral contents in excavated bone using sulfur. Yamada M, et al. **Biol Trace Elem Res** 1996 May;52(2):155–61

California social climbers: low water prompts high status [news] Fischman J. **Science** 1996 May 10;272(5263):811–2

[Ancient DNA] Ueda S. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):733–7 (19 ref.) **(Jpn)**

METHODS

The retrieval of ancient human DNA sequences. Handt O, et al. **Am J Hum Genet** 1996 Aug;59(2):368–76

Mineral-bound noncollagenous proteins in archaeological human skeletons. Freundorfer S, et al. **Electrophoresis** 1995 May;16(5):817–9

DNA damage and DNA sequence retrieval from ancient tissues. Höss M, et al. **Nucleic Acids Res** 1996 Apr 1; 24(7):1304–7

Interisland and interarchipelago transfer of stone tools in prehistoric Polynesia. Weisler MI, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1381–5

ARCHENTERON see **GASTRULA**

ARCHITECTURAL ACCESSIBILITY

Home access modifications: effects on community visits by people with physical disabilities. White GW, et al. **J Appl Behav Anal** 1995 Winter;28(4):457–63

LEGISLATION & JURISPRUDENCE

Does the architectural design of burn centers comply with the Americans with Disabilities Act? Kirby DL, et al. **J Burn Care Rehabil** 1996 Mar-Apr;17(2):156–60; discussion 155

Responses within nonfederal hospitals in Pennsylvania to the Americans with Disabilities Act of 1990. Jones DL, et al. **Phys Ther** 1996 Jan;76(1):49–60

[Greater mobility in Europe—current European developments for barrier-free transportation] Bonk R, et al. **Rehabilitation (Stuttg)** 1995 Nov;34(4):219–22 (Eng. Abstr.) **(Ger)**

[European meeting of the ICTA Commission of RI, June 1995 in Tallin, Estland] Bühler C, et al. **Rehabilitation (Stuttg)** 1995 Nov;34(4):226–7 **(Ger)**

ARCHITECTURE

see related
HEALTH FACILITY PLANNING

ARCHIVES

The need to preserve historical material [letter] Berridge V. **Addiction** 1995 Dec;90(12):1683

Guardians of the wax ... and the patient [editorial] Mills SE, et al. **Am J Clin Pathol** 1995 Oct;104(4):365–7

Feasibility of using decades-old archival tissues in molecular oncology/epidemiology. Iwamoto KS, et al. **Am J Pathol** 1996 Aug;149(2):399–406

Problems and suggested solutions in creating an archive of clinical trials data to permit later meta-analysis: an example of methotrexate trials in rheumatoid arthritis. Chernoff MC, et al. **Control Clin Trials** 1995 Oct;16(5):342–55

'Et in arcadia ego...?' Some notes on methodological issues in the use of psychoanalytic documents and archives. Steiner R. **Int J Psychoanal** 1995 Aug;76 (Pt 4):739–58

Necropsy as a research method. UK Cancer Family Study Group [letter] Steel CM. **Lancet** 1995 Nov 18; 346(8986):1368–9

The Wellcome Tropical Medicine Resource: 19th century principles, 21st century technology, and distance learning with global horizons. Young RA. **Trans R Soc Trop Med Hyg** 1995 Sep-Oct;89(5):465–6

[Archiving of pathologic-anatomic findings in bone diseases and bone neoplasms in individual databanks. Experiences of a new enterprise with applicable outcome] Delling G. **Pathologe** 1996 Jan;17(1):83–5 (Eng. Abstr.) **(Ger)**

ARCUATE NUCLEUS

ANATOMY & HISTOLOGY

[It is incorrect to talk in absolute terms about the site of the arcuate nucleus (letter)] Lehmann A. **Lakartidningen** 1996 Mar 20;93(12):1108 **(Swe)**

DRUG EFFECTS

Central administration of 8-OH-DPAT and mCPP stimulates prolactin secretion in ovariectomized, estrogen-treated rats: lack of an effect on tuberoinfundibular dopaminergic neuron activity. Pan JT, et al. **Life Sci** 1996;58(14):1189–94

Leptin, the obese gene product, rapidly modulates synaptic transmission in the hypothalamus. Glaum SR, et al. **Mol Pharmacol** 1996 Aug;50(2):230–5

Hypercorticism induces neurotensin mRNA in rat periventricular hypothalamus. Nicot A, et al. **Neuroreport** 1995 Nov 13;6(16):2158–60

Glutamate stimulation of arcuate nucleus inhibits responses of subfornical organ neurons to plasma hypernatremia and angiotensin II. Rosas-Arellano MP, et al. **Neurosci Lett** 1995 Oct 6;198(3):201–4

ENZYMOLOGY

Short-photoperiod exposure reduces L-aromatic-amino-acid decarboxylase immunostaining in the arcuate nucleus and median eminence of male Syrian hamsters. Krajnak K, et al. **Brain Res** 1996 Mar 11;712(1):95–101

Effects of dehydroepiandrosterone (DHEA) on pituitary prolactin and arcuate nucleus neuron tyrosine hydroxylase mRNA levels in the rat. Garcia de Yebenes E, et al. **J Neuroendocrinol** 1995 Aug;7(8):589–95

Melatonin increases the in situ activity of tyrosine hydroxylase in the mediobasal hypothalamus of male Syrian hamsters. Alexiuk NA, et al. **Life Sci** 1996;59(8):687–94

METABOLISM

Release into ventriculo-cisternal perfusate of beta-endorphin- and Met-enkephalin-immunoreactivity: effects of electrical stimulation in the arcuate nucleus and periaqueductal gray of the rat. Bach FW, et al. **Brain Res** 1995 Sep 4;690(2):167–76

Cyclic and age-related changes in norepinephrine concentrations in the medial preoptic area and arcuate nucleus. Mohankumar PS, et al. **Brain Res Bull** 1995;

38(6):561–4
Growth hormone receptor gene is expressed in neuropeptide Y neurons in hypothalamic arcuate nucleus of rats. Kamegai J, et al. **Endocrinology** 1996 May;137(5):2109–12
Disinhibition from opioid influence augments hypothalamic neuropeptide Y (NPY) gene expression and pituitary luteinizing hormone release: effects of NPY messenger ribonucleic acid antisense oligodeoxynucleotides. Xu B, et al. **Endocrinology** 1996 Jan;137(1):78–84
GH-deficient dw/dw rats and lit/lit mice show increased Fos expression in the hypothalamic arcuate nucleus following systemic injection of GH-releasing peptide-6. Dickson SL, et al. **J Endocrinol** 1995 Sep;146(3):519–26
Differential effects of estrogen and progesterone on levels of POMC mRNA levels in the arcuate nucleus: relationship to the timing of LH surge release. Petersen SL, et al. **J Neuroendocrinol** 1993 Dec;5(6):643–8
Gonadal steroid hormone regulation of proopiomelanocortin gene expression in arcuate neurons that innervate the medial preoptic area of the rat. Cheung S, et al. **Neuroendocrinology** 1995 Sep;62(3):283–92
Induction of c-fos mRNA in the arcuate nucleus of normal and mutant growth hormone-deficient mice by a synthetic non-peptidyl growth hormone secretagogue. Sirinathsinghji DJ, et al. **Neuroreport** 1995 Oct 23; 6(15):1989–92
Neuropeptide Y, the hypothalamus, and diabetes: insights into the central control of metabolism. Frankish HM, et al. **Peptides** 1995;16(4):757–71 (154 ref.)
NPY mRNA and peptide immunoreactivity in the arcuate nucleus are increased by osmotic stimuli: correlation with dehydration anorexia. O'Shea RD, et al. **Peptides** 1995; 16(6):1117–25

PATHOLOGY

Commentary on morphologic variations of the external arcuate nucleus in infants dying of SIDS: a preliminary report, J. Forensic Sci., Vol. 39, No. 4, July 1994, pp.1076–1083 [letter; comment] Koehler SA. **J Forensic Sci** 1995 Jul;40(4):531–2. Comment on: J Forensic Sci 1994 Jul;39(4):1076–83.

PHYSIOLOGY

Identification of target cells for growth hormone's action in the arcuate nucleus. Burton KA, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):E716–22
Naltrexone induces arcuate nucleus neuropeptide Y gene expression in the rat. Kotz CM, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R289–94
Sexual dimorphism in secretion of hypothalamic gonadotropin-releasing hormone and norepinephrine after coitus in rabbits. Yang S, et al. **Endocrinology** 1996 Jul; 137(7):2683–93
Arcuate nucleus neurons that project to the hypothalamic paraventricular nucleus: neuropeptidergic identity and consequences of adrenalectomy on mRNA levels in the rat. Baker RA, et al. **J Comp Neurol** 1995 Aug 7; 358(4):518–30
Effects of the synthesized growth hormone releasing peptide, KP-102, on growth hormone release in sodium glutamate monohydrate-treated low growth rats. Nakagawa T, et al. **Life Sci** 1996;59(9):705–12
[Effects of lesion or stimulation of pituitary gland and hypothalamic arcuate nucleus on pain modulation in rats] Chen QL, et al. **Sheng Li Hsueh Pao** 1995 Oct;47(5):505–9 (Eng. Abstr.) **(Chi)**
[Inhibitory effects of hypothalamic arcuate nucleus or anterior pituitary stimulation on the nociceptive responses of thalamic parafascicular neurons] Jiao YY, et al. **Sheng Li Hsueh Pao** 1995 Oct;47(5):423–8 (Eng. Abstr.) **(Chi)**
[Effect of microinjection of sodium giutamate and glycine into ventrolateral nucleus of tractus solitarius on the evoked potentials of arcuatus nucleus in rabbits] Liu SX, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):343–8 (Eng. Abstr.) **(Chi)**
[Leptin and obesity—an error (letter)] Lehmann A. **Lakartidningen** 1996 Feb 28;93(9):761, 763 **(Swe)**

PHYSIOPATHOLOGY

alpha-2-Adrenergic activation of proopiomelanocortin-containing neurons in the arcuate nucleus causes opioid-mediated hypotension and bradycardia. Li SJ, et al. **Neuroendocrinology** 1996 Mar; 63(3):275–83

ARCUS SENILIS

COMPLICATIONS

Epithelial iron line in juvenile corneal arcus lipoides. Jünemann A, et al. **Cornea** 1995 Sep;14(5):540–2

ARDS, HUMAN see **RESPIRATORY DISTRESS SYNDROME, ADULT**

AREAWIDE PLANNING see **REGIONAL HEALTH PLANNING**

ARECA

Betel-quid and tobacco chewing among the United Kingdom's Bangladeshi community. Bedi R. **Br J Cancer** 1996 Sep;74 Suppl 29:S73–7
Betel-quid and tobacco chewing among the United Kingdom's Bangladeshi community. Bedi R. **Br J Cancer Suppl** 1996 Sep;29:S73–7
High prevalence of expression of p53 oncoprotein in oral carcinomas from India associated with betel and tobacco chewing. Kuttan NA, et al. **Eur J Cancer B Oral Oncol** 1995 May;31B(3):169–73
Effect of orally administered betel leaf (Piper betle Linn.) on digestive enzymes of pancreas and intestinal mucosa and on bile production in rats. Prabhu MS, et al. **Indian J Exp Biol** 1995 Oct;33(10):752–6
Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. Ko YC, et al. **J Oral Pathol Med** 1995 Nov;24(10):450–3
Increased lysyl oxidase activity in fibroblasts cultured from oral submucous fibrosis associated with betel nut chewing in Taiwan. Ma RH, et al. **J Oral Pathol Med** 1995 Oct; 24(9):407–12
Oral cancer and precancer related to betel and miang chewing in Thailand: a review. Reichart PA. **J Oral Pathol Med** 1995 Jul;24(6):241–3 (17 ref.)
Prevalence and related risk factors of betel quid chewing by adolescent students in southern Taiwan. Yang MS, et al. **J Oral Pathol Med** 1996 Feb;25(2):69–71
Sympathetic response to betel chewing. Chu NS. **J Psychoactive Drugs** 1995 Apr-Jun;27(2):183–6
A comparative clinico-pathological study of oral submucous fibrosis in habitual chewers of pan masala and betelquid. Babu S, et al. **J Toxicol Clin Toxicol** 1996;34(3):317–22
Oral fibrosis among teenagers chewing tobacco, areca nut, and Pan masala [letter] Babu S, et al. **Lancet** 1996 Sep 7; 348(9028):692
Mutual interactions among ingredients of betel quid in inducing genotoxicity on Chinese hamster ovary cells. Lee CH, et al. **Mutat Res** 1996 Feb;367(2):99–104
Oxidative damage to DNA induced by areca nut extract. Liu TY, et al. **Mutat Res** 1996 Jan;367(1):25–31
The mutagenicities of alkaloids and N-nitrosoguvacoline from betel quid. Wang CK, et al. **Mutat Res** 1996 Aug 8;360(3):165–71
Betel chewing increases the skin temperature: effects of atropine and propranolol. Chu NS. **Neurosci Lett** 1995 Jul 14;194(1-2):130–2
Evaluation of the modifying influence of arecanut on the garlic-modulated hepatic detoxication system enzymes, sulfhydryl content, and lipid peroxidation in mice. Singh A, et al. **Teratog Carcinog Mutagen** 1995;15(3):127–34
Modulatory influence of arecanut on the mouse hepatic xenobiotic detoxication system and skin papillomagenesis. Singh A, et al. **Teratog Carcinog Mutagen** 1995;15(3):135–46

ARECOLINE

ADMINISTRATION & DOSAGE

Neuroendocrine responses to intravenous infusion of arecoline in patients with Alzheimer's disease. Asthana S, et al. **Psychoneuroendocrinology** 1995;20(6):623–36

ANALOGS & DERIVATIVES

Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats. Whiteaker P, et al. **Br J Pharmacol** 1995 Oct;116(3):2097–105
Minimal arecaidine concentrations showing a promotion effect during DMBA-induced hamster cheek pouch carcinogenesis. Lin LM, et al. **J Oral Pathol Med** 1996 Feb;25(2):65–8
In vitro production of interleukin-6 by human gingival, normal buccal mucosa, and oral submucous fibrosis fibroblasts treated with betel-nut alkaloids. Chen CC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Nov; 11(11):604–14

CHEMISTRY

1,2,5-Thiadiazole derivatives of arecoline stimulate M1 receptors coupled to phosphoinositide turnover. Periyasamy S, et al. **Brain Res** 1995 Sep 25;693(1-2):118–23

PHARMACOLOGY

Preferential in vivo incorporation of [3H]arachidonic acid from blood in rat brain synaptosomal fractions before and after cholinergic stimulation. Jones CR, et al. **J Neurochem** 1996 Aug;67(2):822–9
In vitro production of interleukin-6 by human gingival, normal buccal mucosa, and oral submucous fibrosis fibroblasts treated with betel-nut alkaloids. Chen CC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Nov; 11(11):604–14

TOXICITY

Mutual interactions among ingredients of betel quid in inducing genotoxicity on Chinese hamster ovary cells. Lee CH, et al. **Mutat Res** 1996 Feb;367(2):99–104

ARENAVIRIDAE INFECTIONS

VETERINARY

Experimental reproduction of severe hypoglycemia and spiking mortality syndrome using field-derived and embryo-passaged preparations. Davis JF, et al. **Avian Dis** 1996 Jan-Mar;40(1):158–72

ARENAVIRUS

Experimental infection of guinea pigs with Venezuelan hemorrhagic fever virus (Guanarito): a model of human disease. Hall WC, et al. **Am J Trop Med Hyg** 1996 Jul; 55(1):81–8

ISOLATION & PURIFICATION

Prevalence of antibodies to arenaviruses in rodents from the southern and western United States: evidence for an arenavirus associated with the genus Neotoma. Kosoy MY, et al. **Am J Trop Med Hyg** 1996 Jun;54(6):570–6
Oliveros virus: a novel arenavirus from Argentina. Bowen MD, et al. **Virology** 1996 Mar 1;217(1):362–6

ARENAVIRUS INFECTIONS see **ARENAVIRIDAE INFECTIONS**

ARGENTAFFIN CELLS see **ENTEROCHROMAFFIN CELLS**

ARGENTAFFIN SYSTEM see **CHROMAFFIN SYSTEM**

ARGENTAFFINOMA see **CARCINOID TUMOR**

ARGINASE

ANALYSIS

Separation of arginase isoforms by capillary zone electrophoresis and isoelectric focusing in density gradient column. Pedrosa MM, et al. **Electrophoresis** 1995 Apr; 16(4):659–69

ANTAGONISTS & INHIBITORS

Computer-aided comparison of the inhibition of arginase and nitric oxide synthase in macrophages by amino acids not related to arginine. Hrabák A, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Feb; 113(2):375–81
The inhibitory effect of nitrite, a stable product of nitric oxide (NO) formation, on arginase. Hrabák A, et al. **FEBS Lett** 1996 Jul 22;390(2):203–6

BIOSYNTHESIS

Developmental regulation of the urea-cycle enzyme arginase in the direct developing frog Eleutherodactylus coqui. Callery EM, et al. **J Exp Zool** 1996 May 1;275(1):61–6

BLOOD

[Arginase] Ikemoto M. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:198–201 (9 ref.) **(Jpn)**

CHEMISTRY

Chemical modification and inactivation of rat liver arginase by N-bromosuccinimide: reaction with His141. Daghigh F, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):107–12
Comparative properties of arginases. Jenkinson CP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 May; 114(1):107–32 (270 ref.)
The cloning, expression and crystallisation of a thermostable arginase. Bewley MC, et al. **FEBS Lett** 1996 May 20; 386(2-3):215–8

DEFICIENCY

Neurological deterioration in patients with urea cycle disorders under valproate therapy—a cause for concern [letter] Sewell AC, et al. **Eur J Pediatr** 1995 Jul; 154(7):593–4

GENETICS

Evidence for sltA1 as a salt-sensitive allele of the arginase gene (agaA) in the ascomycete Aspergillus nidulans. Clement DJ, et al. **Curr Genet** 1996 Apr;29(5):462–7
CCAAT/enhancer-binding protein beta (C/EBP beta) binds and activates while hepatocyte nuclear factor-4 (HNF-4) does not bind but represses the liver-type arginase promoter. Chowdhury S, et al. **Eur J Biochem** 1996 Mar 1;236(2):500–9
Amiloride toxicity in the fission yeast Schizosaccharomyces pombe is released by thiamine and mutations in the thiamine-repressible gene car1. Niederberger C, et al. **Gene** 1996 May 24;171(1):119–22
The delayed glucocorticoid-responsive and hepatoma cell-selective enhancer of the rat arginase gene is located around intron 7. Gotoh T, et al. **J Biochem (Tokyo)** 1995 May;117(5):1138

METABOLISM

Myometrial arginase activity increases with advancing

pregnancy in the guinea pig. Weiner CP, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):779–82

Chemical modification and inactivation of rat liver arginase by N-bromosuccinimide: reaction with His141. Daghigh F, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):107–12

Interaction of arginase with metal ions: studies of the enzyme from human liver and comparison with other arginases. Carvajal N, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Sep; 112(1):153–9

Hormonal and nutritional modulation of hepatic arginase activity in growing cattle. Elsasser TH, et al. **Domest Anim Endocrinol** 1996 May;13(3):219–28

Immunohistochemical study of arginase in cancer of the stomach. Wu CW, et al. **Virchows Arch** 1996 Aug; 428(6):325–31

PHYSIOLOGY

Comparative properties of arginases. Jenkinson CP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 May; 114(1):107–32 (270 ref.)

SECRETION

L-arginine deficiency and hemodynamic changes as a result of arginase efflux following orthotopic liver transplantation. Längle F, et al. **Transplant Proc** 1995 Oct; 27(5):2872–3

ARGININE

Phenotypic expressions of a Gly 154Arg mutation in type II collagen in two unrelated patients with spondyloepimetaphyseal dysplasia (SEMD). Kaitila I, et al. **Am J Med Genet** 1996 May 3;63(1):111–22

Retinitis punctata albescens associated with the Arg135Trp mutation in the rhodopsin gene. Souied E, et al. **Am J Ophthalmol** 1996 Jan;121(1):19–25

Arg519–Cys mutation in COL2A1: evidence for multiple founders. Bleasel JF, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:215–8

Characterization of recombinant human collagen II with Arg519–to–Cys substitution. Fertala A, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:251–3

Inhibition of the reconstituted mitochondrial oxoglutarate carrier by arginine–specific reagents. Stipani I, et al. **Arch Biochem Biophys** 1996 Jul 1;331(1):48–54

Evidence that the PTH receptor binding site on PTHrP(1–34) can hinge at Arg19/Arg20. Barden JA, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):431–6

A family of novel DNA–binding nuclear proteins having polypyrimidine tract–binding motif and arginine/serine–rich motif. Matsushima Y, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):427–33

A newly identified GPI–anchored arginine–specific ADP–ribosyltransferase activity in chicken spleen. Tsuchiya M, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):760–4

Probing the active site residues in aromatic donor oxidation in horseradish peroxidase: involvement of an arginine and a tyrosine residue in aromatic donor binding. Adak S, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):985–91

Heparin binding to platelet factor–4. An NMR and site–directed mutagenesis study: arginine residues are crucial for binding. Mayo KH, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):357–65

Purification and characterization of a secreted arginine–specific dibasic cleaving enzyme from EL–4 cells. Csuhai E, et al. **Biochemistry** 1995 Sep 26;34(38):12411–9

Fructose–1,6–bisphosphatase: arginine–22 is involved in stabilization of the T allosteric state. Lu G, et al. **Biochemistry** 1995 Oct 17;34(41):13272–7

Structure–function analysis of the mammalian DNA polymerase beta active site: role of aspartic acid 256, arginine 254, and arginine 258 in nucleotidyl transfer. Menge KL, et al. **Biochemistry** 1995 Dec 12; 34(49):15934–42

Electron paramagnetic resonance spectroscopy of the heme domain of inducible nitric oxide synthase: binding of ligands at the arginine site induces changes in the heme ligation geometry. Salerno JC, et al. **Biochemistry** 1996 Jun 18; 35(24):7626–30

Importance of two buried salt bridges in the stability and folding pathway of barnase. Tissot AC, et al. **Biochemistry** 1996 May 28;35(21):6786–94

Active site–directed thrombin inhibitors—II. Studies related to arginine/guanidine bioisosteres. St Laurent DR, et al. **Bioorg Med Chem** 1995 Aug;3(8):1145–56

Computer–aided comparison of the inhibition of arginase and nitric oxide synthase in macrophages by amino acids not related to arginine. Hrabák A, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Feb; 113(2):375–81

No association between the Gly971Arg variant of the insulin receptor substrate 1 gene and NIDDM in the Taiwanese population. Chuang LM, et al. **Diabetes Care** 1996 May; 19(5):446–9

Malignant familial hypertrophic cardiomyopathy in a family with a 453Arg—>Cys mutation in the beta–myosin heavy chain gene: coexistence of sudden death and end–stage heart failure. Ko YL, et al. **Hum Genet** 1996 May; 97(5):585–90

Scanning of the Wiskott–Aldrich syndrome (WAS) gene: identification of 18 novel alterations including a possible mutation hotspot at Arg86 resulting in thrombocytopenia, a mild WAS phenotype. Kwan SP, et al. **Hum Mol Genet** 1995 Oct;4(10):1995–8

Role of arginine 38 in horseradish peroxidase. A critical residue for substrate binding and catalysis. Rodriguez–Lopez JN, et al. **J Biol Chem** 1996 Feb 23; 271(8):4023–30

Arginine at positions 13 or 70–71 in pocket 4 of HLA–DRB1 alleles is associated with susceptibility to tuberculoid leprosy. Zerva L, et al. **J Exp Med** 1996 Mar 1; 183(3):829–36

Arginine–164–tryptophan substitution in connexin32 associated with X linked dominant Charcot–Marie–Tooth disease. Oterino A, et al. **J Med Genet** 1996 May; 33(5):413–5

The C–terminal domain of the largest subunit of RNA polymerase II interacts with a novel set of serine/arginine–rich proteins. Yuryev A, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6975–80

Macular dystrophy associated with monogenic Arg172Trp mutation of the peripherin/RDS gene in a Japanese family. Nakazawa M, et al. **Retina** 1995;15(6):518–23

New proteins related to the Ser–Arg family of splicing factors. Blencowe BJ, et al. **RNA** 1995 Oct;1(8):852–65

ADMINISTRATION & DOSAGE

Urea cycle intermediate kinetics and nitrate excretion at normal and "therapeutic" intakes of arginine in humans. Beaumier L, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E884–96

High doses of dietary arginine during repletion impair weight gain and increase infectious mortality in protein–malnourished mice. Peck MD, et al. **Br J Nutr** 1995 Dec;74(6):787–95

Nutritional pharmacology and malignant disease: a therapeutic modality in patients with cancer. Heys SD, et al. **Br J Surg** 1996 May;83(5):608–19 (135 ref.)

Dietary L–arginine attenuates blood pressure in mineralocorticoid–salt hypertensive rats. Laurant P, et al. **Clin Exp Hypertens** 1995 Oct;17(7):1009–24

Renal response to L–arginine in salt–sensitive patients with essential hypertension. Higashi Y, et al. **Hypertension** 1996 Mar;27(3 Pt 2):643–8

L–arginine restores dilator responses of the basilar artery to acetylcholine during chronic hypertension. Kitazono T, et al. **Hypertension** 1996 Apr;27(4):893–6

Dietary supplementation with L–arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. Chin–Dusting JP, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1207–13

Studies of hypoxemic/reoxygenation injury: without aortic clamping. V. Role of the L–arginine–nitric oxide pathway: the nitric oxide paradox. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1200–11

Suppression of intimal hyperplasia in experimental vein grafts by oral l–arginine supplementation and single ex vivo immersion in deferoxamine manganese. Davis MG, et al. **J Vasc Surg** 1996 Mar;23(3):410–20

Dietary supplementation with L–arginine limits cell proliferation in the remnant glomerulus. Ingram A, et al. **Kidney Int** 1995 Dec;48(6):1857–65

Decreased tumor incidence and increased survival by one year oral low dose arginine supplementation in the mouse. Lubec B, et al. **Life Sci** 1996;58(25):2317–25

L–arginine has no effect on erythropoietin–induced hypertension in the excision remnant kidney model [letter] Poux JM, et al. **Nephrol Dial Transplant** 1996 Feb; 11(2):397–8

L–arginine and salt sensitivity [letter] Coruzzi P, et al. **Nephron** 1996;72(2):335

[Role of lactose, arginine and lysine combination in fracture healing (an experimental study)] Fini M, et al. **Ann Ital Chir** 1996 Jan–Feb;67(1):77–82; discussion 82–3 (Eng. Abstr.) **(Ita)**

[Experimental osteoporosis caused by estrogen deficiency in rats. Role of a lactose, L–arginine and L–lysine combination in the prevention and therapy] Fini M, et al. **Minerva Med** 1996 Mar;87(3):81–8 (Eng. Abstr.) **(Ita)**

[Comparative study of arginine and glutamine supplements in malnourished surgical patients] Morais AA, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep–Oct; 50(5):276–9 (Eng. Abstr.) **(Por)**

ADVERSE EFFECTS

[Basic amino acid, L–arginine aggravates ischemia–reperfusion injury] Takeuchi K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):155–61 (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

Renal and haemodynamic effects of nitric oxide blockade in a Wistar assay rat during high pressure cross–circulation of an isolated denervated kidney. Bergström G, et al. **Acta Physiol Scand** 1995 Jun;154(2):241–52

The NO synthase inhibitor L–NNA depresses neurohypophysial vasopressin but not its precursor amidating enzymes in salt–loaded rats. Skujins A, et al. **Acta Physiol Scand** 1995 Nov;155(3):243–50

Oral administration of the nitric oxide biosynthesis inhibitor, N–nitro–L–arginine methyl ester (L–NAME), causes hypertension, but not glucose intolerance or insulin resistance, in rats. Swislocki A, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 1):1009–14

Preterm birth in rats produced by the synergistic action of a nitric oxide inhibitor (NG–nitro–L–arginine methyl ester) and an antiprogestin (onapristone). Yallampalli C, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):207–12

Insulin resistance after hypertension induced by the nitric oxide synthesis inhibitor L–NMMA in rats. Baron AD, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):E709–15

Induction of NG–monomethyl–L–arginine uptake: a mechanism for differential inhibition of NO synthases? Bogle RG, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C750–6

Determinants of renal vasoconstriction after systemic inhibition of nitric oxide synthesis in rats. Brand–Schieber E, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1203–7

Evidence for VIP–induced increase in NO production in myenteric neurons of opossum internal anal sphincter. Chakder S, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G492–7

Interaction between nitric oxide and prostaglandin E2 pathways in pregnant rat uteri. Dong YL, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E471–6

Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Faraci FM, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1522–7

Nitric oxide: a modulator for the epidermal growth factor receptor expression in developing ovarian granulosa cells. Hattori M, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C812–8

Toxic dilatation of colon in a rat model of colitis is linked to an inducible form of nitric oxide synthase. Mourelle M, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G425–30

L–NNA suppresses cerebrovascular response and evoked potentials during somatosensory stimulation in rats. Ngai AC, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1803–10

Nitric oxide is necessary for a switch from stationary to locomoting phenotype in epithelial cells. Noiri E, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C794–802

Effect of L–NMMA, cromakalim, and glibenclamide on cerebral blood flow in hypercapnia and hypoxia. Reid JM, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H916–22

Effect of L–NAME on pressure–flow relationships in isolated rabbit lungs: role of red blood cells. Sprague RS, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):H1941–8

Endogenous nitric oxide is decreased in asthmatic patients by an inhibitor of inducible nitric oxide synthase. Yates DH, et al. **Am J Respir Crit Care Med** 1996 Jul; 154(1):247–50

Direct measurement of crosslinks, pyridinoline, deoxypyridinoline, and pentosidine, in the hydrolysate of tissues using high–performance liquid chromatography. Takahashi M, et al. **Anal Biochem** 1995 Dec 10; 232(2):158–62

Chronic treatment with nitric oxide synthase (NOS) inhibitor profoundly reduces cerebellar NOS activity and cyclic guanosine monophosphate but does not modify minimum alveolar anesthetic concentration. Adachi T, et al. **Anesth Analg** 1995 Oct;81(4):862–5

Effect of the inhibitor of nitric oxide synthase, NG–nitro–L–arginine methyl ester, on cerebral and myocardial blood flows during hypoxia in the awake dog. Audibert G, et al. **Anesth Analg** 1995 Nov;81(5):945–51

Cardiac and regional hemodynamic interactions between halothane and nitric oxide synthase activity in dogs. Chelly JE, et al. **Anesthesiology** 1996 Jul;85(1):142–9

In squid axons phosphoarginine plays a key role in modulating Na–Ca exchange fluxes at micromolar [Ca2+]i. DiPolo R, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:199–207

Inactivation of nitric oxide synthase isoforms by diaminoguanidine and NG–amino–L–arginine. Wolff DJ, et al. **Arch Biochem Biophys** 1996 Jan 15;325(2):227–34

Inhibition of endothelium–derived relaxing factor in A6 cells. Mountian I, et al. **Arch Physiol Biochem** 1995 Aug; 103(4):445–9

Elevated L–arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L–arginine in hypercholesterolemic rabbits. Bode–Böger SM, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):598–603

Effects of the nitric oxide synthase inhibitor N omega nitro–L–arginine methyl ester on electrical activity and ion channels of mouse pancreatic B cells. Krippeit–Drews P, et al. **Biochem Biophys Res Commun** 1996 Jul 5; 224(1):199–205

Interleukin–12 gene–expression of macrophages is regulated by nitric oxide. Rothe H, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):159–63

Advanced Maillard reaction and crosslinking of corneal collagen in diabetes. Sady C, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):793–7

Nitric oxide relaxes rabbit corpus cavernosum smooth muscle via a potassium–conductive pathway. Seftel AD, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):382–7

Modulation of heme oxygenase activity in rat brain and spleen by inhibitors and donors of nitric oxide. Willis D, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):1152–6

Oxidative denitrification of N omega–hydroxy–L–arginine by the superoxide radical anion. Everett SA, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):17–21

Regulation of the mouse inducible–type nitric oxide synthase gene promoter by interferon–gamma, bacterial

lipopolysaccharide and NG-monomethyl-L-arginine. Weisz A, et al. **Biochem J** 1996 May 15;316 (Pt 1):209-15

Reduction of cis-platinum induced nephrotoxicity by zinc histidine complex : the possible implication of nitric oxide. Srivastava RC, et al. **Biochem Mol Biol Int** 1995 Jul; 36(4):855-62

Transport of nitric oxide synthase inhibitors through cationic amino acid carriers in human erythrocytes. Forray MI, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):1963-8

Brain cell membrane Na+,K(+)-ATPase activity after inhibition of cerebral nitric oxide synthase by intravenous NG-nitro-L-arginine in newborn piglets. Groenendaal F, et al. **Biol Neonate** 1995;68(6):419-25

NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice. Orucevic A, et al. **Br J Cancer** 1996 Jan;73(2):189-96

Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226. Abounader R, et al. **Br J Pharmacol** 1995 Oct;116(4):2245-50

Attenuation by creatine of myocardial metabolic stress in Brattleboro rats caused by chronic inhibition of nitric oxide synthase. Constantin-Teodosiu D, et al. **Br J Pharmacol** 1995 Dec;116(8):3288-92

Reduction by NG-nitro-L-arginine methyl ester (L-NAME) of antigen-induced nasal airway plasma extravasation in human subjects in vivo. Dear JW, et al. **Br J Pharmacol** 1995 Sep;116(2):1720-2

The effect of endotoxin on sympathetic responses in the rat isolated perfused mesenteric bed; involvement of nitric oxide and cyclo-oxygenase products. Fatehi-Hassanabad Z, et al. **Br J Pharmacol** 1995 Dec;116(8):3316-22

Cerebrovascular responsiveness to NG-nitro-L-arginine methyl ester in spontaneously diabetic rats. Fouyas IP, et al. **Br J Pharmacol** 1996 May;118(2):243-8

Effects of the non-peptide, non-selective endothelin antagonist, bosentan, on regional haemodynamic responses to NG-monomethyl-L-arginine in conscious rats. Gardiner SM, et al. **Br J Pharmacol** 1996 May;118(2):352-4

Enhancement of the haemodynamic effects of NG-monomethyl-L-arginine by transforming growth factor-beta 1 in conscious, normal, but not endotoxaemic, rats. Gardiner SM, et al. **Br J Pharmacol** 1995 Dec; 116(7):3042-8

Alterations of insulin response to different beta cell secretagogues and pancreatic vascular resistance induced by N omega-nitro-L-arginine methyl ester. Gross R, et al. **Br J Pharmacol** 1995 Oct;116(3):1965-72

Cerebrovascular consequences of repeated exposure to NG-nitro-L-arginine methyl ester. Kelly PA, et al. **Br J Pharmacol** 1995 Nov;116(6):2771-7

Endothelium-dependent relaxations in sheep pulmonary arteries and veins: resistance to block by NG-nitro-L-arginine in pulmonary hypertension. Kemp BK, et al. **Br J Pharmacol** 1995 Nov;116(5):2457-67

Study of NO and VIP as non-adrenergic non-cholinergic neurotransmitters in the pig gastric fundus. Lefebvre RA, et al. **Br J Pharmacol** 1995 Oct;116(3):2017-26

Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226. Lundberg JM, et al. **Br J Pharmacol** 1995 Dec; 116(7):2971-82

Loss of NADPH-diaphorase containing neurones after reversible focal ischaemia in rats delayed by L-NAME. Margaill I, et al. **Br J Pharmacol** 1995 Nov;116(5):2344-5

Role of nitric oxide in the development of tolerance and sensitization to behavioural effects of phencyclidine in mice. Noda Y, et al. **Br J Pharmacol** 1996 Apr; 117(7):1579-85

Deficient nitric oxide responsible for reduced nerve blood flow in diabetic rats: effects of L-NAME, L-arginine, sodium nitroprusside and evening primrose oil. Omawari N, et al. **Br J Pharmacol** 1996 May;118(1):186-90

Effect of NG-nitro-L-arginine methylester (L-NAME) on functional and biochemical alpha 1-adrenoceptor-mediated responses in rat blood vessels. Tabernero A, et al. **Br J Pharmacol** 1996 Feb;117(4):757-63

The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Thiemermann C, et al. **Br J Pharmacol** 1995 Dec;116(7):2845-51

Nitric oxide, an enteric nonadrenergic-noncholinergic relaxant transmitter: evidence using phosphodiesterase V and nitric oxide synthase inhibition. Williams SJ, et al. **Br J Pharmacol** 1995 Sep;116(2):1789-96

NANC neurotransmission in lamina propria of the rabbit urethra: regulation by different subsets of calcium channels. Zygmunt PK, et al. **Br J Pharmacol** 1995 Jul;115(6):1020-6

Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery. Zygmunt PM, et al. **Br J Pharmacol** 1996 Apr; 117(7):1600-6

Manipulation of the L-arginine-nitric oxide pathway in experimental colitis. Neilly PJ, et al. **Br J Surg** 1995 Sep; 82(9):1188-91

Pulmonary artery pressure during exercise in the horse after inhibition of nitric oxide synthase. Mills PC, et al. **Br Vet J** 1996 Mar;152(2):119-22

N omega-nitro-L-arginine methyl ester interferes with pentylenetetrazol-induced kindling and has no effect on changes in glutamate binding. Becker A, et al. **Brain Res** 1995 Aug 7;688(1-2):230-32

Nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester decreases ischemic damage in reversible focal cerebral ischemia in hyperglycemic rats. Quast MJ, et al. **Brain Res** 1995 Apr 24;677(2):204-12

Nitro-L-arginine augments the endothelin-1 content of cerebrospinal fluid induced by cerebral ischemia. Spatz M, et al. **Brain Res** 1995 Jun 26;684(1):99-102

Nitric oxide synthase inhibitor blocks light-induced phase shifts of the circadian activity rhythm, but not c-fos expression in the suprachiasmatic nucleus of the Syrian hamster. Weber ET, et al. **Brain Res** 1995 Sep 18; 692(1-2):137-42

Chronic administration of L-NAME in drinking water alters working memory in rats. Cobb BL, et al. **Brain Res Bull** 1995;38(2):203-7

Exaggerated Bezold-Jarisch reflex in the hypertension induced by inhibition of nitric oxide synthesis. Araújo MT, et al. **Braz J Med Biol Res** 1995 Sep;28(9):1009-12

Effects of N(g)-methyl-L-arginine, an inhibitor of nitric oxide synthesis, on interleukin-2-induced capillary leakage and antitumor responses in healthy and tumor-bearing mice. Orucevic A, et al. **Cancer Immunol Immunother** 1996 Jan;42(1):38-46

Effects of nitric oxide synthase inhibition on the muscle blood flow response to exercise in rats with heart failure. Hirai T, et al. **Cardiovasc Res** 1995 Sep;30(3):469-76

L-NMMA blocks carbachol-induced increases in cGMP levels but not decreases in tension in the presence of forskolin in rabbit papillary muscles. Hui J, et al. **Cardiovasc Res** 1995 Sep;30(3):372-6

Basilar arterial construction caused by intracisternal NG-nitro-L-arginine in anesthetized monkeys. Okamura T, et al. **Cardiovasc Res** 1995 Nov;30(5):663-7

Contrasting effects of blockade of nitric oxide formation on resistance and conductance coronary vessels in conscious dogs. Parent R, et al. **Cardiovasc Res** 1996 Apr;31(4):555-67

Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischaemia-reperfusion injury. Schulz R, et al. **Cardiovasc Res** 1995 Sep;30(3):432-9

Vascular acetylcholine response during chronic NO synthase inhibition: in vivo versus in vitro. Zanchi A, et al. **Cardiovasc Res** 1995 Jul;30(1):122-9

Effects of N(G)-Nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, on IL-2-induced LAK cell generation in vivo and in vitro in healthy and tumor-bearing mice. Orucevic A, et al. **Cell Immunol** 1996 Apr 10;169(1):125-32

Lactam-conformationally restricted analogs of N alpha-arylsulfonyl arginine amide: design, synthesis and inhibitory activity toward thrombin and related enzymes. Okayama T, et al. **Chem Pharm Bull (Tokyo)** 1995 Oct; 43(10):1683-91

beta-Adrenoceptor activates endothelium-dependent release of nitric oxide in rat aorta. Zheng XF, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):385-90

Effects of NO modulation on cardiac arrhythmias in the rat isolated heart. Pabla R, et al. **Circ Res** 1995 Nov; 77(5):984-92

Lysophosphatidylcholine inhibits endothelium-dependent hyperpolarization and N omega-nitro-L-arginine/indomethacin-resistant endothelium-dependent relaxation in the porcine coronary artery. Eizawa H, et al. **Circulation** 1995 Dec 15; 92(12):3520-6

Altered serotonin receptor subtypes mediate coronary microvascular hyperreactivity in pigs with chronic inhibition of nitric oxide synthesis. Kadokami T, et al. **Circulation** 1996 Jul 15;94(2):182-9

Direct quantification of pentosidine in urine and serum by HPLC with column switching. Takahashi M, et al. **Clin Chem** 1996 Sep;42(9):1439-44

Changes of endothelial functions in the coronary artery after chronic nitroarginine feeding. Kajimoto N, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S154-6

Nitric oxide inhibition does not prevent the hypotensive response to increased renal perfusion in rabbits. Thomas CJ, et al. **Clin Exp Pharmacol Physiol** 1995 May; 22(5):345-51

Comparison of responses to aminoguanidine and N omega-nitro-L-arginine methyl ester in the rat aorta. Yen MH, et al. **Clin Exp Pharmacol Physiol** 1995 Sep; 22(9):641-5

Superficial hand vein responses to NG-monomethyl-L-arginine in post-partum and non-pregnant women. Ford GA, et al. **Clin Sci (Colch)** 1996 Jun;90(6):493-7

Nitric oxide synthase inhibition versus norepinephrine for the treatment of hyperdynamic sepsis in sheep. Booke M, et al. **Crit Care Med** 1996 May;24(5):835-44

Evidence of a glycemic threshold for the formation of pentosidine in diabetic dog lens but not in collagen. Nagaraj RH, et al. **Diabetes** 1996 May;45(5):587-94

The insulin-induced increase of guanosine-3',5'-cyclic monophosphate in human platelets is mediated by nitric oxide. Trovati M, et al. **Diabetes** 1996 Jun;45(6):768-70

Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Cameron NE, et al. **Diabetologia** 1996 Feb;39(2):172-82

Effects of chronic nitric oxide synthase inhibition in cold-restraint and ethanol-induced gastric mucosal damage in rats. Qiu BS, et al. **Digestion** 1996;57(1):60-6

Sound-evoked electrocortical desynchronization is inhibited by N omega-nitro-L-arginine methyl ester microinfused into the inferior colliculi in rats. Iannone M, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jul;99(1):57-62

Nitric oxide regulates peroxisomal enzyme activities. Kremser K, et al. **Eur J Clin Chem Clin Biochem** 1995 Nov;33(11):763-74

Implication of a nitric oxide synthase mechanism in the action of substance P: L-NAME blocks thermal hyperalgesia induced by endogenous and exogenous substance P in the rat. Radhakrishnan V, et al. **Eur J Neurosci** 1995 Sep 1; 7(9):1920-5

Nitric oxide and sensory afferent neurones modulate the protective effects of low-dose endotoxin on rat gastric mucosal damage. Barrachina D, et al. **Eur J Pharmacol** 1995 Jul 14;280(3):339-42

In vivo metabolites of N omega-nitro-L-arginine methyl ester: methanol and N omega-nitro-L-arginine. Brouillet E, et al. **Eur J Pharmacol** 1995 Dec 7;293(4):487-90

NG-nitro-L-arginine methyl ester protects against lipid peroxidation in the gerbil following cerebral ischaemia. Caldwell M, et al. **Eur J Pharmacol** 1995 Oct 16; 285(2):203-6

Labeling of neuropeptide Y receptors in SK-N-MC cells using the novel, nonpeptide Y1 receptor-selective antagonist [3H]BIBP3226. Entzeroth M, et al. **Eur J Pharmacol** 1995 May 24;278(3):239-42

Leukotrienes mediate tracheal hyperresponsiveness after nitric oxide synthesis inhibition. Folkerts G, et al. **Eur J Pharmacol** 1995 Oct 16;285(2):R1-2

Evidence for the involvement of nitric oxide in the antinociceptive effect of ketorolac. Granados-Soto V, et al. **Eur J Pharmacol** 1995 Apr 24;277(2-3):281-4

Colonic microvascular integrity in acute endotoxaemia: interactions between constitutive nitric oxide and 5-lipoxygenase products. László F, et al. **Eur J Pharmacol** 1995 Apr 24;277(2-3):R1-3

Neuropeptide Y accounts for sympathetic vasoconstriction in guinea-pig vena cava: evidence using BIBP 3226 and 3435. Malmstrom RE, et al. **Eur J Pharmacol** 1995 Dec 29;294(2-3):661-8

Effect of chronic nitric oxide synthesis inhibition on the inflammatory responses induced by carrageenin in rats. Medeiros MV, et al. **Eur J Pharmacol** 1995 Oct 16; 285(2):109-14

Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis. Moreno H Jr, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):93-6

Involvement of neurohumoral factors in the pressor mechanism of NG-nitro-L-arginine. Nakahara T, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):49-56

Nitric oxide modulation of Ca2+ responses in cow tracheal epithelium. Sakai A, et al. **Eur J Pharmacol** 1995 Nov 30; 291(3):375-9

L-N6-(1-iminoethyl)-lysine potently inhibits inducible nitric oxide synthase and is superior to NG-monomethyl-arginine in vitro and in vivo. Stenger S, et al. **Eur J Pharmacol** 1995 Dec 29;294(2-3):703-12

L-Arginine reverses the abolition of hypovolaemic decompensation by N-nitro-L-arginine methyl ester and naloxone in conscious rabbits. Ventura S, et al. **Eur J Pharmacol** 1995 Dec 29;294(2-3):369-75

N-nitro-L-arginine methyl ester blocks the decompensatory phase of acute hypovolaemia in conscious rabbits by a brainstem mechanism. Ventura S, et al. **Eur J Pharmacol** 1995 Apr 24;277(2-3):265-9

Comparison of the effects of aminoguanidine and N omega-nitro-L-arginine methyl ester on the multiple organ dysfunction caused by endotoxaemia in the rat. Wu CC, et al. **Eur J Pharmacol** 1996 Apr 4;300(1-2):99-104

Nitric oxide synthase inhibitors exert differential time-dependent effects on LPS-induced uveitis. Allen JB, et al. **Exp Eye Res** 1996 Jan;62(1):21-8

N-monomethyl-arginine and nicotinamide prevent streptozotocin-induced double strand DNA break formation in pancreatic rat islets. Bedoya FJ, et al. **Experientia** 1996 Apr 15;52(4):344-7

Nitric oxide synthase inhibitors protect rat retina against ischemic injury. Geyer O, et al. **FEBS Lett** 1995 Nov 6; 374(3):399-402

beta-Glucosylarginine: a new glucose-protein bond in a self-glucosylating protein from sweet corn. Singh DG, et al. **FEBS Lett** 1995 Nov 27;376(1-2):61-4

Mucus and alkali secretion in the rat duodenum: effects of indomethacin, N omega-nitro-L-arginine, and luminal acid. Sababi M, et al. **Gastroenterology** 1995 Nov; 109(5):1526-34

Attenuation of tolerance to, and physical dependence on, morphine in the rat by inhibition of nitric oxide synthase. Bhargava HN. **Gen Pharmacol** 1995 Sep;26(5):1049-53

Decrease in sensitisation rate and intestinal anaphylactic response after nitric oxide synthase inhibition in a food hypersensitivity model. Fargeas MJ, et al. **Gut** 1996 Apr; 38(4):598-602

Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity [letter] Neilly PJ, et al. **Gut** 1996 Mar;38(3):475

Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Rachmilewitz D, et al. **Gut** 1995 Aug;37(2):247-55

Inhibition of nitric oxide synthesis in the forearm arterial bed of patients with advanced cirrhosis. Campillo B, et al. **Hepatology** 1995 Nov;22(5):1423–9

L–arginine minimizes reperfusion injury in a low–flow, reflow model of liver perfusion. Jones SM, et al. **Hepatology** 1996 Jul;24(1):163–8

Endothelin and vascular reactivity in cirrhosis. Sieber CC. **Hepatology** 1995 Nov;22(5):1609–11

Pre–eclampsia–like conditions produced by nitric oxide inhibition: effects of L–arginine, D–arginine and steroid hormones. Buhimschi I, et al. **Hum Reprod** 1995 Oct; 10(10):2723–30

Preglomerular sudanophilia in L–NAME hypertensive rats. Involvement of endothelin. Bouriquet N, et al. **Hypertension** 1996 Mar;27(3 Pt 1):382–91

Role of renal nerves in mediating the hypertensive effects of nitric oxide synthesis inhibition. Granger J, et al. **Hypertension** 1996 Mar;27(3 Pt 2):613–8

Effects of angiotensin II infusion and inhibition of nitric oxide synthase on the rat aorta. Kato H, et al. **Hypertension** 1996 Aug;28(2):153–8

Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Numaguchi K, et al. **Hypertension** 1995 Dec;26(6 Pt 1):957–62

ACE inhibition prevents and reverses L–NAME–exacerbated nephrosclerosis in spontaneously hypertensive rats. Ono H, et al. **Hypertension** 1996 Feb;27(2):176–83

Effects of long–term nitric oxide synthesis inhibition on plasma volume expansion and fetal growth in the pregnant rat. Salas SP, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1019–23

Role of nitric oxide in modulating the vasoconstrictor actions of angiotensin II in preglomerular and postglomerular vessels in dogs. Schnackenberg CG, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1024–9

Vascular structure and expression of endothelin–1 gene in L–NAME–treated spontaneously hypertensive rats. Sventek P, et al. **Hypertension** 1996 Jan;27(1):49–55

Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade. Yamada SS, et al. **Hypertension** 1996 May; 27(5):1165–72

Inhibition of nitric oxide synthase reduces Sephadex–induced oedema formation in the rat lung: dependence on intact adrenal function. Andersson SE, et al. **Inflamm Res** 1995 Oct;44(10):418–22

Degradation of bovine cartilage proteoglycan in vitro is enhanced by inhibition of nitric oxide synthase. Hanglow AC, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S151–2

Effects of iloprost, a stable prostacyclin analog, and its combination with NW–nitro–L–arginine on early events following lipopolysaccharide injection: observations in the hamster cheek pouch microcirculation. Bouskela E, et al. **Int J Microcirc Clin Exp** 1995 Jul–Aug;15(4):170–80

Administration of a nitric oxide synthase inhibitor does not suppress low–dose streptozotocin–induced diabetes in mice. Papaccio G, et al. **Int J Pancreatol** 1995 Feb;17(1):63–8

Effect of nitric oxide synthase inhibition on blood flow after retinal ischemia in cats. Ostwald P, et al. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2396–403

Flow–mediated vasodilation of human epicardial coronary arteries: effect of inhibition of nitric oxide synthesis. Shiode N, et al. **J Am Coll Cardiol** 1996 Feb;27(2):304–10

Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. Qiu C, et al. **J Am Soc Nephrol** 1995 Nov;6(5):1476–81

Alpha 2–adrenoceptors determine the response to nitric oxide inhibition in the rat glomerulus and proximal tubule. Thomson SC, et al. **J Am Soc Nephrol** 1995 Nov; 6(5):1482–90

L–arginine–related responses to pressure and vasoactive agents in monocrotaline–treated rat pulmonary arteries. Madden JA, et al. **J Appl Physiol** 1995 Aug;79(2):589–93

In vitro responses of lung arteries to acute hypoxia after NO synthase blockade or chronic hypoxia. Teng GQ, et al. **J Appl Physiol** 1995 Sep;79(3):763–70

Involvement of nitric oxide in the smooth muscle tone of the isolated canine spleen and the responses to acetylcholine and substance P. Grassi–Kassisse DM, et al. **J Auton Pharmacol** 1996 Feb;16(1):35–40

The conjugal transfer system of Agrobacterium tumefaciens octopine–type Ti plasmids is closely related to the transfer system of an IncP plasmid and distantly related to Ti plasmid vir genes. Alt–Mörbe J, et al. **J Bacteriol** 1996 Jul;178(14):4248–57

Identification of Agrobacterium tumefaciens genes that direct the complete catabolism of octopine. Cho K, et al. **J Bacteriol** 1996 Apr;178(7):1872–80

The tra region of the nopaline–type Ti plasmid is a chimera with elements related to the transfer systems of RSF1010, RP4, and F. Farrand SK, et al. **J Bacteriol** 1996 Jul; 178(14):4233–47

N(omega)–phosphoarginine phosphatase (17 kDa) and alkaline phosphatase as protein arginine phosphatases. Kumon A, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):719–24

Inhibition of ecto–5'–nucleotidase by nitric oxide donors. Implications in renal epithelial cells. Siegfried G, et al. **J Biol Chem** 1996 Mar 1;271(9):4659–64

Do ETA receptors participate in the hemodynamic and renal effects of chronic nitric oxide blockade? Fujihara CK, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S462–5

Endothelium–derived nitric oxide does not modulate metabolic coronary vasodilation induced by tachycardia in dogs. Katsuda Y, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):437–44

Effect of nitric oxide synthase inhibition on bleeding time in humans. Simon DI, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):339–42

Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro–L–arginine. Huang Z, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):981–7

Nitric oxide synthase inhibition by L–NAME prevents brain acidosis during focal cerebral ischemia in rabbits. Regli L, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):988–95

Neuronal damage following intraspinal injection of a nitric oxide synthase inhibitor in the rat. Yezierski RP, et al. **J Cereb Blood Flow Metab** 1996 Sep;16(5):996–1004

NG–monomethyl–L–arginine inhibits the blood flow but not the insulin–like response of forearm muscle to IGF– I: possible role of nitric oxide in muscle protein synthesis. Fryburg DA. **J Clin Invest** 1996 Mar 1;97(5):1319–28

Angiotensin II–induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase. Hou J, et al. **J Clin Invest** 1995 Nov;96(5):2469–77

Regulation of blood pressure by nitroxidergic nerve. Toda N. **J Diabetes Complications** 1995 Oct–Dec;9(4):200–2 (21 ref.)

Thrombin inhibitors based on ketone derivatives of arginine and lysine. Jones DM, et al. **J Enzym Inhib** 1995;9(1):43–60

Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse. Vodovotz Y, et al. **J Exp Med** 1996 May 1;183(5):2337–42

L–arginine and endogenous nitric oxide protect the gastric mucosa from endothelin–1–induced gastric ulcers in rats. Lazaratos S, et al. **J Gastroenterol** 1995 Oct;30(5):578–84

Dose–dependent effects of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertension in conscious rats. Pilette C, et al. **J Gastroenterol Hepatol** 1996 Jan;11(1):1–6

The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis. Forrest EH, et al. **J Hepatol** 1995 Sep;23(3):254–8

Vascular structure in hypertension induced by NG–nitro–L–arginine methyl ester: methodological considerations for studies of small arteries in hypertension—reply [letter; comment] Dunn WR, et al. **J Hypertens** 1995 Oct;13(10):1217–21. Comment on: J Hypertens 1995 Aug;13(8):817–21.

Vascular structure in NG–nitro–L–arginine methyl ester–induced hypertension: methodological considerations for studies of small arteries in hypertension [editorial] [see comments] Schiffrin EL. **J Hypertens** 1995 Aug; 13(8):817–21 (40 ref.). Comment in: J Hypertens 1995 Oct;13(10):1217–21.

Vascular reactivity and flow–pressure curve in isolated kidneys from rats with N–nitro–L–arginine methyl ester–induced hypertension. Vargas F, et al. **J Hypertens** 1996 Mar;14(3):373–9

NG–nitro–L–arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin–2–induced capillary leak syndrome in healthy mice. Orucevic A, et al. **J Immunother Emphasis Tumor Immunol** 1995 Nov; 18(4):210–20

Inhibitors of nitric oxide synthase in human skin. Goldsmith PC, et al. **J Invest Dermatol** 1996 Jan;106(1):113–8

Kinetics, pharmacology, and autoradiographic distribution of L–[3H]nitroarginine binding sites in rat cerebellum. Rao VL, et al. **J Neurochem** 1996 Feb;66(2):701–9

L–[3H]nitroarginine and L–[3H]arginine uptake into rat cerebellar synaptosomes: kinetics and pharmacology. Rao VL, et al. **J Neurochem** 1996 Sep;67(3):1275–81

The role of nitric oxide and sulphydryls in gastric mucosal protection induced by sodium cromoglycate in rats. Ali AT. **J Pharm Pharmacol** 1995 Sep;47(9):739–43

Effects of chronic nitric oxide synthase inhibition on TNB–induced colitis in rats. Pfeiffer CJ, et al. **J Pharm Pharmacol** 1995 Oct;47(10):827–32

Variable effects of L–arginine analogs on L–arginine–nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. Chen LY, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):253–7

Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. Doods HN, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):136–42

NG–nitro–L–arginine methyl ester attenuates the maintenance and expression of methamphetamine–induced behavioral sensitization and enhancement of striatal dopamine release. Inoue H, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1424–30

The angiotensin receptor antagonist 2–ethoxy–1–[[2'–(1H–tetrazol–5–yl) biphenyl–4–yl]methyl]–1H–benzimidazole–7–carboxylic acid (CV11974) attenuates the tubuloglomerular feedback response during NO synthase blockade in rats. Kawata T, et al. **J Pharmacol Exp Ther** 1996 May;277(2):572–7

Inhibition of cerebral neurogenic vasodilation by L–glutamine and nitric oxide synthase inhibitors and its reversal by L–citrulline. Lee TJ, et al. **J Pharmacol Exp Ther** 1996 Feb;276(2):353–8

Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226. Wieland HA, et al. **J Pharmacol Exp Ther** 1995 Oct;275(1):143–9

Phosphoarginine stimulation of Na(+)–Ca2+ exchange in squid axons—a new pathway for metabolic regulation? DiPolo R, et al. **J Physiol (Lond)** 1995 Aug 15;487 (Pt 1):57–66

Regional difference in the distribution of L–NAME–sensitive and –insensitive NANC relaxations in cat airway. Takahashi N, et al. **J Physiol (Lond)** 1995 Nov 1;488 (Pt 3):709–20

Nitric oxide synthase inhibition and the uterotrophic response to oestrogen in immature rats. Rao VS, et al. **J Reprod Fertil** 1995 Nov;105(2):303–6

Effects of NG–nitro–L–arginine on alpha–agonists–induced contraction of aortae from Wistar Kyoto rats and stroke–prone spontaneously hypertensive rats. Matsuda K, et al. **J Smooth Muscle Res** 1995 Apr;31(2):51–60

Tumor cell nitric oxide inhibits cell growth in vitro, but stimulates tumorigenesis and experimental lung metastasis in vivo. Edwards P, et al. **J Surg Res** 1996 Jun;63(1):49–52

VEGF improves myocardial blood flow but produces EDRF–mediated hypotension in porcine hearts. Hariawala MD, et al. **J Surg Res** 1996 Jun;63(1):77–82

Inhibition of NO synthase prevents acute collateral artery dilation in the rat hindlimb. Unthank JL, et al. **J Surg Res** 1996 Mar;61(2):463–8

The role of N omega–nitro–L–arginine in modulation of pulmonary vascular tone in the maturing newborn pig. Domkowski PW, et al. **J Thorac Cardiovasc Surg** 1995 Nov; 110(5):1486–92

Cerebral metabolic recovery from deep hypothermic circulatory arrest after treatment with arginine and nitro–arginine methyl ester. Hiramatsu T, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):698–707

Studies of hypoxemic/reoxygenation injury: without aortic clamping. V. Role of the L–arginine–nitric oxide pathway: the nitric oxide paradox. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1200–11

Regulation of renin release is impaired after nitric oxide inhibition. Chatziantoniou C, et al. **Kidney Int** 1996 Mar; 49(3):626–33

Peritoneal dialysis solutions reverse the hemodynamic effects of nitric oxide synthesis inhibitors. White R, et al. **Kidney Int** 1995 Dec;48(6):1986–93

Randomised double–blind placebo–controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin–induced asthma. Ricciardolo FL, et al. **Lancet** 1996 Aug 10;348(9024):374–7

Nitric oxide: a mediator of endotoxin–induced middle ear effusions. Ball SS, et al. **Laryngoscope** 1996 Aug; 106(8):1021–7

Effects of L–name on endothelin–1–induced barrel–rolling in periaqueductal gray area of rats. D'Amico M, et al. **Life Sci** 1995;57(22):PL357–60

Nitro containing L–arginine analogs interfere with assays for nitrate and nitrite. Greenberg SS, et al. **Life Sci** 1995; 57(21):1949–61

The nitric oxide synthase inhibitor NW–nitro–L–arginine methylester attenuates brain catalase activity in vitro. Rotzinger S, et al. **Life Sci** 1995 Mar 10;56(16):1321–4

NG–methyl–L–arginine and somatostatin decrease glucose and insulin and block endothelin–1 (ET–1)–induced insulin release but not ET–1–induced hypoglycemia. Zimmerman RS, et al. **Metabolism** 1995 Dec;44(12):1532–5

Effects L–NG–nitro arginine methyl ester (L–NAME), L–NG–monomethyl arginine (L–NMMA) and L–arginine on the antinociceptive effects of morphine in mice. Dambisya YM, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):577–82

Capillary reperfusion after L–arginine, L–NMMA, and L–NNA treatment in cheek pouch microvasculature. Bertuglia S, et al. **Microvasc Res** 1995 Sep;50(2):162–74

Ti plasmid–encoded octopine and nopaline catabolism in Agrobacterium: specificities of the LysR–type regulators OccR and NocR, and protein–induced DNA bending. Kreusch D, et al. **Mol Gen Genet** 1995 Nov 1;249(1):102–10

Cocaine kindling in mice. Responses to N–methyl–D,L–aspartate (NMDLA) and L–arginine. Itzhak Y. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):217–22

Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. Sautel M, et al. **Mol Pharmacol** 1996 Aug;50(2):285–92

Evidence against a role of nitric oxide in the indirect negative inotropic–effect of M–cholinoceptor stimulation in human ventricular myocardium. Kilter H, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):308–12

Plasma advanced glycosylation end–products in maintenance haemodialysis patients. Odetti P, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2110–3

NG–nitro–L–arginine methyl ester causes glomerular nitrite production in long–term incubations [letter] Rivas–Cabañero L, et al. **Nephron** 1996;73(1):97–8

Effect of NG–nitro–L–arginine methyl ester on nephrotoxicity induced by gentamicin in rats. Rivas–Cabañero L, et al. **Nephron** 1995;71(2):203–7

A nitric oxide synthase inhibitor impairs memory storage in mice. Baratti CM, et al. **Neurobiol Learn Mem** 1996 May; 65(3):197–201

L–nitroarginine reduces hippocampal mediation of place learning in the rat. Mogensen J, et al. **Neurobiol Learn Mem** 1995 Jul;64(1):17–24

Inhibition of nitric oxide synthase attenuates osmotic thirst in the rat. Kannan H, et al. **Neurobiology (Bp)** 1995; 3(3–4):363–70

Inhibition of nitric oxide synthase in the hypothalamus blocks the increase in plasma prolactin induced by intraventricular injection of interleukin-1 alpha in the rat. Rettori V, et al. **Neuroimmunomodulation** 1994 Mar-Apr;1(2):116-20

Inhibition of nitric oxide synthase impairs a distinct form of long-term memory in the honeybee, Apis mellifera. Müller U. **Neuron** 1996 Mar;16(3):541-9

Substantial regional and hemispheric differences in brain nitric oxide synthase (NOS) inhibition following intracerebroventricular administration of N omega-nitro-L-arginine (L-NA) and its methyl ester (L-NAME). Salter M, et al. **Neuropharmacology** 1995 Jun; 34(6):639-49

Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Pasternak GW, et al. **Neuropsychopharmacology** 1995 Dec;13(4):309-13 (24 ref.)

Role of hippocampal NO in the acquisition and consolidation of inhibitory avoidance learning. Bernabeu R, et al. **Neuroreport** 1995 Jul 31;6(11):1498-1500

Localization of NO synthase in rat brain by [3H]L-NG-nitro-arginine autoradiography. Burazin TC, et al. **Neuroreport** 1995 Oct 2;6(14):1842-4

Synergistic effect of intrastriatal co-administration of L-NAME and quinolinic acid. Galasso JM, et al. **Neuroreport** 1995 Jul 31;6(11):1505-8

Nitric oxide synthase inhibition decreases pontine acetylcholine release. Leonard TO, et al. **Neuroreport** 1995 Jul 31;6(11):1525-9

L-NOARG, an inhibitor of nitric oxide synthase, induces catalepsy in mice. Marras RA, et al. **Neuroreport** 1995 Dec 29;7(1):158-60

NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthase, increases extracellular GABA in the striatum of the freely moving rat. Semba J, et al. **Neuroreport** 1995 Jul 10;6(10):1426-8

Inhibition of nitric oxide synthase causes anxiolytic-like behaviour in an elevated plus-maze. Volke V, et al. **Neuroreport** 1995 Jul 10;6(10):1413-6

Hypothalamic blood flow remains unaltered following chronic nitric oxide synthase blockade in rats. Benyó Z, et al. **Neurosci Lett** 1995 Sep 29;198(2):127-30

Nitric oxide synthase inhibitor facilitates focal seizures induced by aminopyridine in rat. Boda B, et al. **Neurosci Lett** 1996 May 3;209(1):37-40

Application of [3H]L-N(G)-nitro-arginine labelling to measure cerebellar nitric oxide synthase in patients with schizophrenia. Doyle CA, et al. **Neurosci Lett** 1995 Dec 29;202(1-2):49-52

Effect of spinal infusion of L-NAME, a nitric oxide synthase inhibitor, on spinal tolerance and dependence induced by chronic intrathecal morphine in the rat. Dunbar S, et al. **Neurosci Lett** 1996 Mar 22;207(1):33-6

Possible modulation of auditory middle latency responses by nitric oxide in the inferior colliculus of anaesthetized rats. Grassi C, et al. **Neurosci Lett** 1995 Aug 25;196(3):213-7

Intraventricular administration of nitric oxide synthase inhibitors prevents delayed neuronal death in gerbil hippocampal CA1 neurons. Kohno K, et al. **Neurosci Lett** 1995 Oct 13;199(1):65-8

Role of the L-arginine-nitric oxide pathway in the basal hydroxyl radical production in the striatum of awake rats as measured by brain microdialysis. Lancelot E, et al. **Neurosci Lett** 1995 Dec 29;202(1-2):21-4

L-NAME, an inhibitor of nitric oxide synthase, blocks the established allodynia induced by intrathecal administration of prostaglandin E2. Minami T, et al. **Neurosci Lett** 1995 Dec 15;201(3):239-42

Nitric oxide synthase inhibitor blocks acetylcholine induced increase in brain blood flow in rainbow trout. Söderström V, et al. **Neurosci Lett** 1995 Sep 15;197(3):191-4

Inhibitors of nitric oxide synthase and the opioid withdrawal syndrome. London ED, et al. **NIDA Res Monogr** 1995; 147:170-81 (26 ref.)

L-NAME reduces infarct volume in a filament model of transient middle cerebral artery occlusion in the rat pup. Ashwal S, et al. **Pediatr Res** 1995 Nov;38(5):652-6

Experimental neuronal injury in the newborn lamb: a comparison of N-methyl-D-aspartic acid receptor blockade and nitric oxide synthesis inhibition on lesion size and cerebral hyperemia. Taylor GA, et al. **Pediatr Res** 1995 Nov;38(5):644-51

Perinatal nitric oxide synthase inhibition retards neonatal growth by inducing hypertrophic pyloric stenosis in rats. Voelker CA, et al. **Pediatr Res** 1995 Nov;38(5):768-74

NG-nitro-L-arginine methyl ester and alpha-methyl-L-ornithine inhibit kyotorphin synthetase from rat brain. Kawabata A, et al. **Peptides** 1995; 16(7):1317-9

A nitric oxide synthase inhibitor delays the formation of learning-related neural activity in the cerebellar interpositus nucleus during rabbit eyelid conditioning. Allen MT, et al. **Pharmacol Biochem Behav** 1996 Jan; 53(1):147-53

Nitric oxide synthesis inhibition attenuates morphine-induced place preference. Kivastik T, et al. **Pharmacol Biochem Behav** 1996 Apr;53(4):1013-5

Failure of intrabulbar and peripheral administration of N omega-nitro-L-arginine to prevent the formation of an olfactory memory in mice. Okere CO, et al. **Physiol Behav** 1995 Aug;58(2):387-91

Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Miyata T, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2353-8

Longevity and the genetic determination of collagen glycoxidation kinetics in mammalian senescence. Sell DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):485-90

A nitric oxide synthesis inhibitor decreased prostaglandin production in rat mesenteric vasculature. Soma M, et al. **Prostaglandins** 1996 Mar;51(3):225-32

Nitric oxide synthesis inhibition enhances bupivacaine cardiotoxicity. Heavner JE, et al. **Reg Anesth** 1996 May-Jun;21(3):243-8

Nitric oxide synthase inhibition and acute renal ischemia: effect on systemic hemodynamics and mortality. Atanasova I, et al. **Ren Fail** 1995 Jul;17(4):389-403

Effect of asymmetric dimethyl arginine on nitric oxide synthase activity in normal and pre-eclamptic placentae. King RG, et al. **Reprod Fertil Dev** 1995;7(6):1581-4

Role of nitric oxide in motility and secretion of the feline hepatobiliary tract. Thune A, et al. **Scand J Gastroenterol** 1995 Jul;30(7):715-20

Plasma pentosidine levels in uremic patients before and after hemodialysis. Takahashi M, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):131-4

A selective inhibitor of inducible in nitric oxide synthase prolongs survival in a rat model of bacterial peritonitis: comparison with two nonselective strategies. Aranow JS, et al. **Shock** 1996 Feb;5(2):116-21

Inhibition of nitric oxide synthase during hemorrhagic shock increases hepatic injury. Harbrecht BG, et al. **Shock** 1995 Nov;4(5):332-7

Nitric oxide synthase inhibition is detrimental to cardiac function and promotes bronchospasm in anaphylaxis in rabbits. Mitsuhata H, et al. **Shock** 1995 Aug;4(2):143-8

Effects of nitric oxide synthase inhibition on regional hemodynamics and oxygen transport in endotoxic dogs. Walker TA, et al. **Shock** 1995 Dec;4(6):415-20

Glutamate-induced disruption of the blood-brain barrier in rats. Role of nitric oxide. Mayhan WG, et al. **Stroke** 1996 May;27(5):965-9; discussion 970

Structure and function of the rat basilar artery during chronic nitric oxide synthase inhibition. Moreau P, et al. **Stroke** 1995 Oct;26(10):1922-8; discussion 1928-9

Time-dependent inhibition of oxotremorine-induced cerebral hyperemia by N omega-nitro-L-arginine in cats. Tietjen CS, et al. **Stroke** 1995 Nov;26(11):2160-5

Preventive effect of N(G)-nitro-L-arginine against L-cysteine-induced seizures in mice. Yamamoto H. **Toxicol Lett** 1996 Jan;84(1):1-5

[Clinical studies of a caries-defense varnish containing sialin-like material] He H, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 May; 30(3):175-7 **(Chi)**

[Hemodynamic effects of sub-chronic NO synthase inhibition in conscious dogs: role of EDRF/NO in muscular exertion] Puybasset L, et al. **Arch Mal Coeur Vaiss** 1995 Aug; 88(8):1217-21 (Eng. Abstr.) **(Fre)**

[Effects of L-arginine and its functional antagonist N-nitro-L-arginine on behavior] Dubynin VA, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):465-8 **(Rus)**

ANALYSIS

Arginine-239 in the beta subunit is at or near the active site of bovine pyruvate dehydrogenase. Eswaran D, et al. **Biochim Biophys Acta** 1995 Oct 25;1252(2):203-8

Simultaneous determination of cefepime and L-arginine in injections by second-derivative spectrophotometry. Ródenas V, et al. **J Pharm Biomed Anal** 1995 Aug; 13(9):1095-9

Reaction of 3-deoxypentosulose with N-methyl- and N,N-dimethylguanidine as model reagents for protein-bound arginine and for creatine. Sopio R, et al. **Z Lebensm Unters Forsch** 1995 Oct;201(4):381-6

ANTAGONISTS & INHIBITORS

Manipulation of the L-arginine-nitric oxide pathway in experimental colitis. Neilly PJ, et al. **Br J Surg** 1995 Sep; 82(9):1188-91

BIOSYNTHESIS

Hypoxia inhibits L-arginine synthesis from L-citrulline in porcine pulmonary artery endothelial cells. Su Y, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):L581-7

Genes and enzymes of the acetyl cycle of arginine biosynthesis in Corynebacterium glutamicum: enzyme evolution in the early steps of the arginine pathway. Sakanyan V, et al. **Microbiology** 1996 Jan;142 (Pt 1):99-108

Implication of a repression system, homologous to those of other bacteria, in the control of arginine biosynthesis genes in Streptomyces coelicolor. Soutar A, et al. **Mol Gen Genet** 1996 May 23;251(2):245-51

BLOOD

Kinetics of plasma arginine and leucine in pediatric burn patients. Yu YM, et al. **Am J Clin Nutr** 1996 Jul;64(1):60-6

Relations among arginine, citrulline, ornithine, and leucine kinetics in adult burn patients. Yu YM, et al. **Am J Clin Nutr** 1995 Nov;62(5):960-8

Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. Chen LY, et al. **Circulation** 1996 May 1;93(9):1740-6

Neurological deterioration in patients with urea cycle disorders under valproate therapy--a cause for concern [letter] Sewell AC, et al. **Eur J Pediatr** 1995 Jul; 154(7):593-4

Calcium alpha-ketoglutarate administration to malnourished hemodialysis patients improves plasma arginine concentrations. Riedel E, et al. **Miner Electrolyte Metab** 1996;22(1-3):119-22

L-arginine deficiency and hemodynamic changes as a result of arginase efflux following orthotopic liver transplantation. Längle F, et al. **Transplant Proc** 1995 Oct; 27(5):2872-3

CHEMISTRY

Stability of ceftazidime (with arginine) in an elastomeric infusion device. Bednar DA, et al. **Am J Health Syst Pharm** 1995 Sep 1;52(17):1912-4

Determination of amino acid isotope ratios by electrospray ionization-mass spectrometry. Goshe MB, et al. **Anal Biochem** 1995 Nov 1;231(2):387-92

Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. Fromm JR, et al. **Arch Biochem Biophys** 1995 Nov 10; 323(2):279-87

Differential modulation of binding loop flexibility and stability by Arg50 and Arg52 in Cucurbita maxima trypsin inhibitor-V deduced by trypsin-catalyzed hydrolysis and NMR spectroscopy. Cai M, et al. **Biochemistry** 1996 Apr 16;35(15):4784-94

Use of designed metal-binding sites to study helix proximity in the lactose permease of Escherichia coli. 2. Proximity of helix IX (Arg302) with helix X (His322 and Glu325). He MM, et al. **Biochemistry** 1995 Dec 5;34(48):15667-70

DNA polymerase beta: pre-steady-state kinetic analysis and roles of arginine-283 in catalysis and fidelity. Werneburg BG, et al. **Biochemistry** 1996 Jun 4;35(22):7041-50

Improved method for converting an unmodified peptide to an energy-transfer substrate for a proteinase. Geoghegan KF. **Bioconjug Chem** 1996 May-Jun;7(3):385-91

Isomerization of the Xaa-Pro peptide bond induced by ionic interactions of arginine. Tsikaris V, et al. **Biopolymers** 1996 Jun;38(6):673-82

Point mutation of a conserved arginine (104) to lysine introduces hypersensitivity to inhibition by glyphosate in the 5-enolpyruvylshikimate-3-phosphate synthase of Bacillus subtilis. Selvapandiyan A, et al. **FEBS Lett** 1995 Oct 30;374(2):253-6

The sensitivity of AMPA-selective glutamate receptor channels to pentobarbital is determined by a single amino acid residue of the alpha 2 subunit. Yamakura T, et al. **FEBS Lett** 1995 Nov 6;374(3):412-4

Precolumn fluorescence derivatization of the antagonist [Arg6,D-Trp7,9,MePhe8]-substance P[6-11] with benzoin in high-performance liquid chromatography and selective detection of arginine-containing fragments in its degradation products. Cui H, et al. **J Chromatogr A** 1996 Jun 7;736(1-2):91-6

Interaction of the lipoprotein lipase asparagine 291-->serine mutation with body mass index determines elevated plasma triacylglycerol concentrations: a study in hyperlipidemic subjects, myocardial infarction survivors, and healthy adults. Fisher RM, et al. **J Lipid Res** 1995 Oct; 36(10):2104-12

Evidence for essential arginine residues at the active sites of maize branching enzymes. Cao H, et al. **J Protein Chem** 1996 Apr;15(3):291-304

The post-translational incorporation of arginine into a beta-amyloid peptide increases the probability of alpha-helix formation. Bongiovanni G, et al. **Neuroreport** 1995 Dec 29;7(1):326-8

Identification of arginine 331 as an important active site residue in the class II fructose-1,6-bisphosphate aldolase of Escherichia coli. Qamar S, et al. **Protein Sci** 1996 Jan; 5(1):154-61

The effect of deamination and/or blocking arginine residues on the molecular assembly of acid-extracted rat tail tendon collagen. Hu XW, et al. **Tissue Cell** 1996 Apr;28(2):215-22

DEFICIENCY

L-arginine depletion inhibits glomerular nitric oxide synthesis and exacerbates rat nephrotoxic nephritis. Waddington S, et al. **Kidney Int** 1996 Apr;49(4):1090-6

L-arginine deficiency and hemodynamic changes as a result of arginase efflux following orthotopic liver transplantation. Längle F, et al. **Transplant Proc** 1995 Oct; 27(5):2872-3

DIAGNOSTIC USE

New approach to the diagnosis of growth hormone deficiency in adults. Ghigo E, et al. **Eur J Endocrinol** 1996 Mar;134(3):352-6

DRUG EFFECTS

Effects of high energy phosphates and L-arginine on the electrical parameters of ischemic-reperfused rat skeletal muscle fibers. Tricarico D, et al. **Eur J Pharmacol** 1995 Dec 4;287(1):17-25

Protein kinases and phosphatases that act on histidine, lysine, or arginine residues in eukaryotic proteins: a possible regulator of the mitogen-activated protein kinase cascade. Matthews HR. **Pharmacol Ther** 1995;67(3):323-50 (154 ref.)

GENETICS

Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Aparicio C, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):467-72

The dominant beta-thalassaemia in a Spanish family is due to a frameshift that introduces an extra CGG codon (= arginine) at the 5' end of the second exon. Arjona SN, et al. **Br J Haematol** 1996 Jun 2;93(4):841-4

Arterial and venous thrombosis in two Italian families with the factor V Arg506-->Gln mutation. Montaruli B, et al. **Eur J Haematol** 1996 Jul;57(1):96-100

Overexpression of an mRNA dependent on rare codons inhibits protein synthesis and cell growth. Zahn K. **J Bacteriol** 1996 May;178(10):2926-33

Effect of Lys-->Arg mutation on the thermal stability of Cu,Zn superoxide dismutase: influence on the monomer-dimer equilibrium. Folcarelli S, et al. **Protein Eng** 1996 Apr;9(4):323-5

Activated protein C resistance in ischemic stroke not due to factor V arginine506-->glutamine mutation. Fisher M, et al. **Stroke** 1996 Jul;27(7):1163-6

Prothrombin Molise I: documentation of a second incidence of replacement of a critical Arg near the active site. James HL, et al. **Thromb Res** 1995 Nov 15;80(4):363-6

[Arg506 --> Gln mutation of coagulation factor V (factor V Leiden) and transient cerebral ischemia at a young age in 3 members of the same family] Moia M, et al. **Ann Ital Med Int** 1996 Jan-Mar;11(1):17-9 (Eng. Abstr.) **(Ita)**

[Identification of Arg-135-Leu mutation in the rhodopsin gene in a family with autosomal dominant retinitis pigmentosa] Reig C, et al. **Med Clin (Barc)** 1996 Feb 17; 106(6):219-21 (Eng. Abstr.) **(Spa)**

METABOLISM

Sources of arginine for induced nitric oxide synthesis in the isolated perfused liver. Pastor CM, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G861-6

Arginine synthesis in enterocytes of neonatal pigs. Wu G, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R621-9

Detection of arginine-ADP-ribosylated protein using recombinant ADP-ribosylarginine hydrolase. Ohno T, et al. **Anal Biochem** 1995 Oct 10;231(1):115-22

Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Bode-Böger SM, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):598-603

Substitution of glycine for arginine-213 in extracellular-superoxide dismutase impairs affinity for heparin and endothelial cell surface. Adachi T, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):235-9

Involvement of an arginyl residue in the nucleotide-binding site of Ca(2+)-ATPase from sarcoplasmic reticulum as seen by reaction with phenylglyoxal. Corbalán-García S, et al. **Biochem J** 1996 Aug 15;318 (Pt 1):179-85

Binding of intermediate, product, and substrate analogs to neuronal nitric oxide synthase: ferriheme is sensitive to ligand-specific effects in the L-arginine binding site. Salerno JC, et al. **Biochemistry** 1996 Sep 10;35(36):11839-45

Arginine-binding RNAs resembling TAR identified by in vitro selection. Tao J, et al. **Biochemistry** 1996 Feb 20; 35(7):2229-38

Metabolism of L-arginine through polyamine and nitric oxide synthase pathways in proliferative or differentiated human colon carcinoma cells. Blachier F, et al. **Biochim Biophys Acta** 1995 Sep 21;1268(3):255-62

Towards the localization of the essential arginine residues in the band 3 protein of human red blood cell membranes. Böhm R, et al. **Biochim Biophys Acta** 1996 Apr 26; 1280(2):238-42

Arginine uptake through a novel cationic amino acid:K+ symporter, System R+, in brush border membrane vesicles from larval Manduca sexta midgut. Liu Z, et al. **Biochim Biophys Acta** 1996 Jun 13;1282(1):25-31

Protein kinase C-dependent regulation of L-arginine transport activity in Caco-2 intestinal cells. Pan M, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):27-32

Relevance of the arginine transport activity to the nitric oxide synthesis in mouse peritoneal macrophages stimulated with bacterial lipopolysaccharide. Shibazaki T, et al. **Biochim Biophys Acta** 1996 May 28;1311(3):150-4

Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Azuma H, et al. **Br J Pharmacol** 1995 Jul;115(6):1001-4

Induction of L-arginine transport and nitric oxide synthase in vascular smooth muscle cells: synergistic actions of pro-inflammatory cytokines and bacterial lipopolysaccharide. Wileman SM, et al. **Br J Pharmacol** 1995 Dec;116(8):3243-50

Differential regulation of L-arginine transport and nitric oxide production by vascular smooth muscle and endothelium. Durante W, et al. **Circ Res** 1996 Jun; 78(6):1075-82

Involvement of oxidative and L-arginine-NO pathways in the neurotoxicity of drugs of abuse in vitro. Cerruti C, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):381-2

Identification of two novel arginine binding DNAs. Harada K, et al. **EMBO J** 1995 Dec 1;14(23):5798-811

NMR detection of arginine-ligand interactions in complexes of Lactobacillus casei dihydrofolate reductase. Gargaro AR, et al. **Eur J Biochem** 1996 Jun 1;238(2):435-9

High and low affinity transport of L-arginine in rat brain synaptosomes. Tan CH, et al. **Experientia** 1995 Nov 15; 51(11):1052-4

Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: structure studies of a cysteine thiolate-liganded heme protein that hydroxylates L-arginine to produce NO. as a cellular signal. Masters BS, et al. **FASEB J** 1996 Apr;10(5):552-8 (70 ref.)

Quantification of DNA damage and repair in amino acid auxotrophs and UV-sensitive mutants of Aspergillus nidulans using an ELISA. Donnelly E, et al. **FEBS Lett** 1995 Dec 18;377(2):118-22

Arginine-427 in the Na+/glucose cotransporter (SGLT1) is involved in trafficking to the plasma membrane. Lostao MP, et al. **FEBS Lett** 1995 Dec 18;377(2):181-4

beta-Glucosylarginine: a new glucose-protein bond in a self-glucosylating protein from sweet corn. Singh DG, et al. **FEBS Lett** 1995 Nov 27;376(1-2):61-4

Nitric oxide exposure and sulfhydryl modulation alter L-arginine transport in cultured pulmonary artery endothelial cells. Patel JM, et al. **Free Radic Biol Med** 1996; 20(5):629-37

Inducible nitric oxide synthase in the cardiovascular system [editorial] Bhagat K, et al. **Heart** 1996 Mar;75(3):218-20

Arginine consumption as a monitor of mycoplasma infection of cultured cells [letter] Capiaumont J, et al. **In Vitro Cell Dev Biol Anim** 1995 Jul-Aug;31(7):497-8

Basic amino acid transport in plasma membrane vesicles of Penicillium chrysogenum. Hillenga DJ, et al. **J Bacteriol** 1996 Jul;178(14):3991-5

Fermentative arginine degradation in Halobacterium salinarium (formerly Halobacterium halobium): genes, gene products, and transcripts of the arcRACB gene cluster. Ruepp A, et al. **J Bacteriol** 1996 Aug;178(16):4942-7

Catalytic role of an arginine residue in the highly conserved and unique sequence of phosphoenolpyruvate carboxylase. Yano M, et al. **J Biochem (Tokyo)** 1995 Jun;117(6):1196-200

Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. Dong LM, et al. **J Biol Chem** 1996 Aug 9;271(32):19053-7

A large DNA-binding nuclear protein with RNA recognition motif and serine/arginine-rich domain. Inagaki H, et al. **J Biol Chem** 1996 May 24;271(21):12525-31

Characterization by electron paramagnetic resonance of the interactions of L-arginine and L-thiocitrulline with the heme cofactor region of nitric oxide synthase. Salerno JC, et al. **J Biol Chem** 1995 Nov 17;270(46):27423-8

Cytokines and insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes. Regulation of L-arginine transport and no production by CAT-1, CAT-2A, and CAT-2B. Simmons WW, et al. **J Biol Chem** 1996 May 17;271(20):11694-702

Role of Arg112 of cytochrome p450cam in the electron transfer from reduced putidaredoxin. Analyses with site-directed mutants. Unno M, et al. **J Biol Chem** 1996 Jul 26;271(30):17869-74

Acute hypoxia increases intracellular L-arginine content in cultured porcine pulmonary artery endothelial cells. Su Y, et al. **J Cell Physiol** 1996 May;167(2):349-53

Agmatine, a bioactive metabolite of arginine. Production, degradation, and functional effects in the kidney of the rat. Lortie MJ, et al. **J Clin Invest** 1996 Jan 15;97(2):413-20

The DNA-binding domain of the hexameric arginine repressor. Grandori R, et al. **J Mol Biol** 1995 Nov 24; 254(2):150-62

Structure of the oligomerization and L-arginine binding domain of the arginine repressor of Escherichia coli. Van Duyne GD, et al. **J Mol Biol** 1996 Feb 23;256(2):377-91

Variable effects of L-arginine analogs on L-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. Chen LY, et al. **J Pharmacol Exp Ther** 1996 Jan;276(1):253-7

Regulation of L-arginine transport and nitric oxide release in superfused porcine aortic endothelial cells. Bogle RG, et al. **J Physiol (Lond)** 1996 Jan 1;490 (Pt 1):229-41

Activation of L-arginine transport (system y+) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells. Sobrevia L, et al. **J Physiol (Lond)** 1996 Feb 1;490 (Pt 3):775-81

Diabetes-induced activation of system y+ and nitric oxide synthase in human endothelial cells: association with membrane hyperpolarization. Sobrevia L, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):183-92

Inflammatory mediators stimulate arginine transport and arginine-derived nitric oxide production in a murine breast cancer cell line. Cendan JC, et al. **J Surg Res** 1996 Feb 1;60(2):284-8

Dietary modulation of amino acid transport in rat and human liver. Espat NJ, et al. **J Surg Res** 1996 Jun;63(1):263-8

Nitric oxide, sepsis, and arginine metabolism. Kelly E, et al. **JPEN J Parenter Enteral Nutr** 1995 May-Jun; 19(3):234-8 (52 ref.)

Lipopolysaccharide and tumor necrosis factor stimulate lung microvascular arginine uptake, a response attenuated by dexamethasone. Pan M, et al. **JPEN J Parenter Enteral Nutr** 1996 Jan-Feb;20(1):50-5

L-arginine depletion inhibits glomerular nitric oxide synthesis and exacerbates rat nephrotoxic nephritis. Waddington S, et al. **Kidney Int** 1996 Apr;49(4):1090-6

Correlation between inhibition of growth and arginine transport of Leishmania donovani promastigotes in vitro by diamidines. Kandpal M, et al. **Life Sci** 1996; 59(7):PL75-80

Binding-protein-dependent arginine transport in Pasteurella haemolytica. Caskey LS, et al. **Microbiology** 1996 Jul;142 (Pt 7):1739-47

L-arginine transport and metabolism in Giardia intestinalis support its position as a transition between the prokaryotic and eukaryotic kingdoms. Knodler LA, et al. **Microbiology** 1995 Sep;141 (Pt 9):2063-70

Proline is biosynthesized from arginine in Staphylococcus aureus. Townsend DE, et al. **Microbiology** 1996 Jun;142 (Pt 6):1491-7

Kinetics and molecular characteristics of arginine transport by Leishmania donovani promastigotes. Kandpal M, et al. **Mol Biochem Parasitol** 1995 May;71(2):193-201

Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions. Weng Z, et al. **Mol Cell Biol** 1995 Oct;15(10):5627-34

A binding site for activation by the Bacillus subtilis AhrC protein, a repressor/activator of arginine metabolism. Klingel U, et al. **Mol Gen Genet** 1995 Aug 21;248(3):329-40

An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Bianchi M, et al. **Mol Med** 1995 Mar;1(3):254-66

A third periplasmic transport system for L-arginine in Escherichia coli: molecular characterization of the artPIQMJ genes, arginine binding and transport. Wissenbach U, et al. **Mol Microbiol** 1995 Aug;17(4):675-86

RNA aptamers that bind L-arginine with sub-micromolar dissociation constants and high enantioselectivity. Geiger A, et al. **Nucleic Acids Res** 1996 Mar 15;24(6):1029-36

Interaction between nutrition, interleukins, and the NO-arginine system [editorial; comment] Roth E. **Nutrition** 1996 Feb;12(2):129-30. Comment on: Nutrition 1996 Feb;12(2):89-90.

Whole body arginine metabolism and nitric oxide synthesis in newborns with persistent pulmonary hypertension. Castillo L, et al. **Pediatr Res** 1995 Jul;38(1):17-24

Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Xia Y, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6770-4

Structural basis of ligand discrimination by two related RNA aptamers resolved by NMR spectroscopy. Yang Y, et al. **Science** 1996 May 31;272(5266):1343-7

The L-arginine/nitric oxide pathway--biological properties and therapeutic applications. Neilly PJ, et al. **Ulster Med J** 1994 Oct;63(2):193-200 (67 ref.)

Further definition of the sequence and position requirements of the arginine control element that mediates repression and induction by arginine in Saccharomyces cerevisiae. Crabeel M, et al. **Yeast** 1995 Nov;11(14):1367-80

[The L-arginine/nitric oxide metabolic pathway. Its physiopathology and clinical implications] Mengozzi G, et al. **Ann Ital Med Int** 1996 Jan-Mar;11(1):46-51 (48 ref.) (Eng. Abstr.) **(Ita)**

[CCl4 as an inducer of L-arginine-dependent NO synthesis] Kovalenko OA, et al. **Biull Eksp Biol Med** 1996 Apr; 121(4):414-6 **(Rus)**

[The deamination of L-arginine and the synthesis of active nitrogen compounds in Yersinia pestis] Valentsev VE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep-Oct; (5):48-51 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Hypoxia inhibits L-arginine uptake by pulmonary artery endothelial cells. Block ER, et al. **Am J Physiol** 1995 Nov; 269(5 Pt 1):L574-80

L-[3H]nitroarginine and L-[3H]arginine uptake into rat cerebellar synaptosomes: kinetics and pharmacology. Rao VL, et al. **J Neurochem** 1996 Sep;67(3):1275-81

PHARMACOLOGY

Relationship between insulin responses to D-glucose and to L-arginine in women with a history of gestational diabetes. Alvarsson M, et al. **Acta Diabetol** 1995 Jun;32(2):86-91

Effects of L-arginine on utero-placental circulation in growth-retarded fetuses. Neri I, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):208-12

Pancreatic somatostatin-14 and somatostatin-25 release in rainbow trout is stimulated by glucose and arginine. Eilertson CD, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1017-23

Effect of L-arginine on metabolic recovery of the ischemic myocardium. Carrier M, et al. **Ann Thorac Surg** 1996 Jun; 61(6):1651-7

Effects of endothelin-1 and L-arginine after cold ischemia in lamb hearts. Hiramatsu T, et al. **Ann Thorac Surg** 1996 Jan;61(1):36-40; discussion 40-1

Moderation of anal sphincter tone with nitric oxide agonists and antagonists. Hechtman HB, et al. **Arch Surg** 1996 Jul; 131(7):775-84

Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Böger RH, et al. **Atherosclerosis** 1995 Oct;117(2):273–84

Reduction of nitric oxide synthase activity in human neutrophils by oxidized low-density lipoproteins. Reversal of the effect of oxidized low-density lipoproteins by high-density lipoproteins and L-arginine. Mehta JL, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1181–5

Attenuation of adrenomedullin-induced renal vasodilatation by NG-nitro L-arginine but not glibenclamide. Miura K, et al. **Br J Pharmacol** 1995 Jul;115(6):917–24

Deficient nitric oxide responsible for reduced nerve blood flow in diabetic rats: effects of L-NAME, L-arginine, sodium nitroprusside and evening primrose oil. Omawari N, et al. **Br J Pharmacol** 1996 May;118(1):186–90

L-arginine ameliorates cerebral blood flow and metabolism and decreases infarct volume in rats with cerebral ischemia. He Z, et al. **Brain Res** 1995 Nov 20;699(2):208–13

L-arginine reverses low coronary reflow and enhances postischaemic recovery of cardiac mechanical function. Amrani M, et al. **Cardiovasc Res** 1995 Aug;30(2):200–4

Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischaemia-reperfusion injury. Schulz R, et al. **Cardiovasc Res** 1995 Sep;30(3):432–9

The hypotensive effect of L-arginine is associated with increased expired nitric oxide in humans. Mehta S, et al. **Chest** 1996 Jun;109(6):1550–5

L-arginine-induced conducted signals alter upstream arteriolar responsivity to L-arginine. Frame MD, et al. **Circ Res** 1995 Oct;77(4):695–701

Effects of NO modulation on cardiac arrhythmias in the rat isolated heart. Pabla R, et al. **Circ Res** 1995 Nov; 77(5):984–92

Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Egashira K, et al. **Circulation** 1996 Jul 15;94(2):130–4

Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine. Procopio M, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):665–9

Vascular and hormonal responses to arginine: provision of substrate for nitric oxide or non-specific effect? MacAllister RJ, et al. **Clin Sci (Colch)** 1995 Aug; 89(2):183–90

Nitric oxide in streptozotocin-induced diabetes mellitus in rats. Maree A, et al. **Clin Sci (Colch)** 1996 May;90(5):379–84

L-arginine/nitric oxide amplifies the magnitude and duration of the luteinizing hormone surge induced by estrogen: involvement of neuropeptide Y. Bonavera JJ, et al. **Endocrinology** 1996 May;137(5):1956–62

Nitric oxide regulates peroxisomal enzyme activities. Kremser K, et al. **Eur J Clin Chem Clin Biochem** 1995 Nov;33(11):763–74

Arginine, lysine and ornithine as vasodilators in the forearm of man. Rhodes P, et al. **Eur J Clin Invest** 1996 Apr; 26(4):325–31

Mechanisms mediating NG-nitro-L-arginine methyl ester-induced hypophagia in mice. Hui SC, et al. **Eur J Pharmacol** 1995 Sep 5;283(1-3):141–50

Rolipram increases cyclic GMP content in L-arginine-treated cultured bovine aortic endothelial cells. Kessler T, et al. **Eur J Pharmacol** 1995 Jul 18;290(2):163–7

Hyporesponsiveness to nitrovasodilators in rat aorta incubated with endotoxin and L-arginine. Tsuchida S, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):251–4

L-Arginine reverses the abolition of hypovolaemic decompensation by N-nitro-L-arginine methyl ester and naloxone in conscious rabbits. Ventura S, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):369–75

Luteinizing hormone pulse frequency is increased by arginine infusion in prepubertal sheep. Recabarren SE, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):72–7

A UV-induced mutation in neurospora that affects translational regulation in response to arginine. Freitag M, et al. **Genetics** 1996 Jan;142(1):117–27

L-arginine minimizes reperfusion injury in a low-flow, reflow model of liver perfusion. Jones SM, et al. **Hepatology** 1996 Jul;24(1):163–8

Systemic hypotension and diuresis by L-arginine in cirrhotic patients with ascites: role of nitric oxide. Tajiri K, et al. **Hepatology** 1995 Nov;22(5):1430–5

Pre-eclampsia-like conditions produced by nitric oxide inhibition: effects of L-arginine, D-arginine and steroid hormones. Buhimschi I, et al. **Hum Reprod** 1995 Oct; 10(10):2723–30

Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Matsuoka H, et al. **Hypertension** 1996 Jan;27(1):14–8

Contrasting effect of antihypertensive treatment on the renal response to L-arginine. Mimran A, et al. **Hypertension** 1995 Dec;26(6 Pt 1):937–41

L-arginine prevents corticotropin-induced increases in blood pressure in the rat. Turner SW, et al. **Hypertension** 1996 Feb;27(2):184–9

Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. Adams MR, et al. **J Am Coll Cardiol** 1995 Oct; 26(4):1054–61

Effect of arginine and ornithine infusions on luteinizing hormone secretion in prepubertal ewes. Recabarren SE, et al. **J Anim Sci** 1996 Jan;74(1):162–6

Effect of cold exposure on profiles of metabolic and endocrine responses and on responses to feeding and arginine injection in sheep. Sano H, et al. **J Anim Sci** 1995 Jul;73(7):2054–62

Role of an upstream open reading frame in mediating arginine-specific translational control in Neurospora crassa. Luo Z, et al. **J Bacteriol** 1996 Apr;178(8):2172–7

Acute effect of L-arginine on hemodynamics and vascular capacitance in the canine pacing model of heart failure. Ogilvie RI, et al. **J Cardiovasc Pharmacol** 1995 Sep; 26(3):407–13

Supplemental L-arginine HCl augments bacterial phagocytosis in human polymorphonuclear leukocytes. Moffat FL Jr, et al. **J Cell Physiol** 1996 Jul;168(1):26–33

L-Arginine does not restore dilatation of the basilar artery during diabetes mellitus. Mayhan WG, et al. **J Cereb Blood Flow Metab** 1996 May;16(3):500–6

In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose. Maccario M, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3774–8

Direct detrimental effects of L-arginine upon ischemia—reperfusion injury to myocardium. Takeuchi K, et al. **J Mol Cell Cardiol** 1995 Jul;27(7):1405–14

Ocular hypotensive effects of L-arginine and its derivatives and their actions on ocular blood flow. Chiou GC, et al. **J Ocul Pharmacol Ther** 1995 Spring;11(1):1–10

Improvement of retinal functions after ischemia with L-arginine and its derivatives. Liu SX, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):261–5

Nitric oxide synthase inhibition and the uterotrophic response to oestrogen in immature rats. Rao VS, et al. **J Reprod Fertil** 1995 Nov;105(2):303–6

Metabolic effects of arginine in a healthy elderly population. Hurson M, et al. **JPEN J Parenter Enteral Nutr** 1995 May-Jun;19(3):227–30

The effect of intravenous infusion of L-arginine, glycine and D-lysine on urinary calcium excretion in the rat. Singh HJ. **Jpn J Physiol** 1995;45(2):327–36

Hindquarter vasodilation after intracisternal injection of D-arginine in the conscious rat. Takemoto Y. **Jpn J Physiol** 1995;45(5):759–69

Inhibition by triptoquinone-A of LPS- and IL-1 beta-primed induction of NO synthase in rat thoracic aorta. Moritoki H, et al. **Life Sci** 1996;59(3):PL49–54

The effects of arginine administration on the levels of arginine, other amino acids and related amino compounds in the plasma, heart, aorta, vena cava, bronchi and pancreas of the rat. Noeh FM, et al. **Life Sci** 1996;58(8):PL131–8

Differential beta-cell response to glucose, glucagon, and arginine during progression to type I (insulin-dependent) diabetes mellitus. Chaillous L, et al. **Metabolism** 1996 Mar; 45(3):306–14

Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity. Maccario M, et al. **Metabolism** 1996 Mar;45(3):342–6

Effects L-NG-nitro arginine methyl ester (L-NAME), L-NG-monomethyl arginine (L-NMMA) and L-arginine on the antinociceptive effects of morphine in mice. Dambisya YM, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17(9):577–82

Capillary reperfusion after L-arginine, L-NMMA, and L-NNA treatment in cheek pouch microvasculature. Bertuglia S, et al. **Microvasc Res** 1995 Sep;50(2):162–74

Influence of nitric oxide on renal function in toxic acute renal failure in the rat. Schramm L, et al. **Miner Electrolyte Metab** 1996;22(1-3):168–77

Nitric oxide—a retrograde messenger for carbon monoxide signaling in ischemic heart. Maulik N, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1-2):75–86

Cocaine kindling in mice. Responses to N-methyl-D,L-aspartate (NMDLA) and L-arginine. Itzhak Y. **Mol Neurobiol** 1995 Aug-Dec;11(1-3):217–22

Effects of arginine-lysine mixture, glucose and ATP on the autonomic outflows to the thymus and spleen. Niijima A, et al. **Neurobiology (Bp)** 1995;3(3-4):299–307

Arginine-supplemented diets inhibit endotoxin-induced bacterial translocation in mice. Adjei AA, et al. **Nutrition** 1995 Jul-Aug;11(4):371–4

Impact of the L-arginine/nitric oxide system in pregnancy. Neri I, et al. **Obstet Gynecol Surv** 1995 Dec;50(12):851–8 (64 ref.)

Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans. Larsson H, et al. **Pancreas** 1995 Aug;11(2):201–5

Stimulation of growth hormone secretion in children with X-linked hypophosphatemia. Seikaly MG, et al. **Pediatr Nephrol** 1995 Dec;9(6):751–2

Differential effects of deltorphin on arginine and galanin-induced growth hormone secretion in healthy man. degli Uberti EC, et al. **Regul Pept** 1995 Jul 21;58(1-2):41–6

Induction of L-arginine-dependent production of nitric oxide in bovine monocytes by interferon gamma and lipopolysaccharide. Zhao BY, et al. **Res Vet Sci** 1996 Mar; 60(2):190–2

Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Zhang F, et al. **Stroke** 1996 Feb;27(2):317–23

Effect of L-arginine on renal blood flow in normal subjects and patients with hypoxic chronic obstructive pulmonary disease. Howes TQ, et al. **Thorax** 1996 May;51(5):516–9

Involvement of the L-arginine-nitric oxide synthase pathway in the relaxant responses of the rat isolated anococcygeus muscle to a scorpion (Leiurus quinquestriatus quinquestriatus) venom. Gwee MC, et al. **Toxicon** 1995 Sep; 33(9):1141–50

L-arginine restores suppressed acetylcholine-induced endothelium-dependent vascular relaxation in cyclosporine A-treated rats. Kim HS, et al. **Transplant Proc** 1996 Jun; 28(3):1372–4

L-arginine can attenuate warm ischemic injury in the rat kidney and nitric oxide production in the preserved kidney. Kin S, et al. **Transplant Proc** 1996 Jun;28(3):1889–90

Cytoprotective effect of nitric oxide on ischemia-reperfusion injury in rat kidneys. Negita M, et al. **Transplant Proc** 1996 Jun;28(3):1904–5

Protection against hepatic ischemia/reperfusion injury by exogenous L-arginine. Shiraishi M, et al. **Transplant Proc** 1996 Jun;28(3):1887–8

[Effect of feeding protected arginine on food intake, milk yield and growth hormone and amino acid levels in blood plasma of cows during the summer feeding period with grass] Kirchgessner M, et al. **Arch Tierernahr** 1993; 45(1):57–69 (Eng. Abstr.) **(Ger)**

[Effects of L-arginine and its functional antagonist N-nitro-L-arginine on behavior] Dubynin VA, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):465–8 **(Rus)**

PHYSIOLOGY

Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells. Bani D, et al. **Cancer Res** 1995 Nov 15;55(22):5272–5

L-arginine and pancreatic islet blood flow in anesthetized rats. Svensson AM, et al. **Experientia** 1996 Mar 15; 52(3):239–41

Site-directed mutagenesis of two conserved charged amino acids in the N-terminal region of alpha subunit of E. coli-F(0)F(1). Hase B, et al. **FEBS Lett** 1996 Mar 11; 382(1-2):171–4

Possible involvement of the L-arginine-nitric oxide pathway in the modulation of stress-induced analgesia. Haulică I, et al. **Funct Neurol** 1995 Jul-Oct;10(4–5):169–73

Endotoxin-induced L-arginine pathway produces nitric oxide and modulates the Ca2+-activated K+ channel in cultured human dermal papilla cells. Nameda Y, et al. **J Invest Dermatol** 1996 Feb;106(2):342–5

Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. Cockcroft JR, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1067–71

The importance of Arg40 and 45 in the mitogenic activity and structural stability of basic fibroblast growth factor: effects of acidic amino acid substitutions. Arakawa T, et al. **J Protein Chem** 1995 Jul;14(5):263–74

Evidence that the L-arginine pathway plays a role in the regulation of pumping activity in bovine mesenteric lymphatic vessels. Eisenhoffer J, et al. **Microvasc Res** 1995 Sep;50(2):249–59

[Studies concerning the relaxant effects of the L-arginine-nitric oxide system.] Haulică I, et al. **Rom J Physiol** 1993 Jul-Dec;30(3-4):131–7 **(Fre)**

[Leishmania-macrophage interactions: role of cytokines and molecules co-involved in killing] Faliero SM, et al. **Parassitologia** 1995 Apr;37(1):5–15 (126 ref.) (Eng. Abstr.) **(Ita)**

[The bioregulatory system L-arginine—nitric oxide] Markov KhM. **Patol Fiziol Eksp Ter** 1996 Jan-Mar;(1):34–9 (76 ref.) **(Rus)**

THERAPEUTIC USE

L-arginine decreases infarct size in rats exposed to environmental tobacco smoke. Zhu B, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):91–100

L-arginine reduces endothelial inflammation and myocardial stunning during ischemia/reperfusion. Engelman DT, et al. **Ann Thorac Surg** 1995 Nov;60(5):1275–81

Effect of L-arginine cardioplegia on recovery of neonatal lamb hearts after 2 hours of cold ischemia. Hiramatsu T, et al. **Ann Thorac Surg** 1995 Nov;60(5):1187–92

Regression or progression. Dependency on vascular nitric oxide. Candipan RC, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):44–50

Acute supplementation with the nitric oxide precursor L-arginine does not improve cardiovascular performance in patients with hypercholesterolemia. Wennmalm A, et al. **Atherosclerosis** 1995 Dec;118(2):223–31

L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Bode-Böger SM, et al. **Circulation** 1996 Jan 1;93(1):85–90

Healing of chronic gastric ulcerations by L-arginine. Role of nitric oxide, prostaglandins, gastrin and polyamines. Brzozowski T, et al. **Digestion** 1995;56(6):463–71

Beneficial effects of L-arginine on intestinal epithelial restitution after ischemic damage in rats. Raul F, et al. **Digestion** 1995;56(5):400–5

Effects of lysine-arginine association on immune functions in patients with recurrent infections. Azzarà A, et al. **Drugs Exp Clin Res** 1995;21(2):71–8

Immunoglobulin G can cross-react with glucagon antisera and cause a spuriously high plasma immunoreactive glucagon level. Hattori N, et al. **Endocr J** 1995 Aug;

42(4):455–60
Pressor, renal and endocrine effects of L-arginine in essential hypertensives. Pedrinelli R, et al. **Eur J Clin Pharmacol** 1995;48(3–4):195–201
The role of arginine, indomethacin and kallikrein in the treatment of oligoasthenospermia. Aydin S, et al. **Int Urol Nephrol** 1995;27(2):199–202
Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. Koifman B, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1251–6
Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. Clarkson P, et al. **J Clin Invest** 1996 Apr 15;97(8):1989–94
Cerebral metabolic recovery from deep hypothermic circulatory arrest after treatment with arginine and nitro-arginine methyl ester. Hiramatsu T, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):698–707
The L-arginine/nitric oxide pathway—biological properties and therapeutic applications. Neilly PJ, et al. **Ulster Med J** 1994 Oct;63(2):193–200 (67 ref.)
Treatment of ammonia intoxication in rats through the use of amino acids from the urea cycle. Ortolani EL, et al. **Vet Hum Toxicol** 1995 Jun;37(3):217–20
Effects of growth factors and L-arginine on ischemic skin flaps in rats. Walls CM, et al. **Vet Surg** 1995 Nov–Dec; 24(6):484–91

TOXICITY

Effect of dietary arginine on urinary nitrate excretion in germ-free rats. Rowland IR, et al. **Food Chem Toxicol** 1996 Jun;34(6):555–8

ARGININE CARBOXYPEPTIDASE

BLOOD

Human plasma carboxypeptidase N; stability of enzyme activity following collection. McCleave MJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):42S

CHEMISTRY

Human plasma carboxypeptidase N; stability of enzyme activity following collection. McCleave MJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):42S

DRUG EFFECTS

[The effect of diazepam on the activity of carboxypeptidase N and the angiotensin-converting enzyme in sections of the brain of rats with differing normal emotionality and in emotional stress] Nikishin NN, et al. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):108–13 (Eng. Abstr.) **(Rus)**
[The effect of the intraperitoneal administration of a physiological solution on rat behavior in the "open field" test and on the activity of the enzymes participating in neuropeptide metabolism] Vernigora AN, et al. **Fiziol Zh Im I M Sechenova** 1995 Dec;81(12):121–5 **(Rus)**

METABOLISM

Removal of Arg141 from the alpha chain of human hemoglobin by carboxypeptidases N and M. Michel B, et al. **Circ Res** 1996 Apr;78(4):635–42
[Effect of captopril and reserpine on the activity of certain neuropeptide metabolism enzymes] Gengin MT, et al. **Vopr Med Khim** 1995 Sep–Oct;41(5):37–9 (Eng. Abstr.) **(Rus)**

URINE

Significance of renal kininases in patients with Cushing's syndrome. Shimamoto K, et al. **Clin Exp Hypertens** 1995 Nov;17(8):1173–82
Significance of renal kininases in patients with primary aldosteronism. Ura N, et al. **Clin Exp Hypertens** 1995 Oct; 17(7):1049–58

ARGININE KINASE

CHEMISTRY

Denaturation and urea gradient gel electrophoresis of arginine kinase: evidence for a collapsed-state conformation. France RM, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):93–9

ARGININE OXYTOCIN see **VASOTOCIN**

ARGININE-SPECIFIC TRNA see **RNA, TRANSFER, ARG**

ARGININE VASOPRESSIN see **ARGIPRESSIN**

ARGININE VASOTOCIN see **VASOTOCIN**

ARGININOSUCCINASE see **ARGININOSUCCINATE LYASE**

ARGININOSUCCINATE LYASE

ANALYSIS

Intracellular localization of the mRNAs of argininosuccinate synthetase and argininosuccinate lyase around liver mitochondria, visualized by high-resolution in situ reverse transcription-polymerase chain reaction. Cohen NS. **J Cell Biochem** 1996 Apr;61(1):81–96

BIOSYNTHESIS

Coinduction of nitric oxide synthase, argininosuccinate synthetase, and argininosuccinate lyase in lipopolysaccharide-treated rats. RNA blot, immunoblot, and immunohistochemical analyses. Nagasaki A, et al. **J Biol Chem** 1996 Feb 2;271(5):2658–62

BLOOD

Determination of argininosuccinate lyase in human serum by ion-pair reversed phase liquid chromatography. Canepari S, et al. **Biomed Chromatogr** 1995 Jul–Aug;9(4):171–4

CHEMISTRY

Characterization and enzyme activity of argininosuccinate lyase/delta-crystallin of the embryonic duck lens. Piatigorsky J, et al. **Biochim Biophys Acta** 1996 Jul 18; 1295(2):158–64
delta-Crystallin is more thermostable than mammalian argininosuccinate lyase [letter]. Voorter CE, et al. **Exp Eye Res** 1993 Jun;56(6):733–5
Preparation of recombinant argininosuccinate synthetase and argininosuccinate lyase: expression of the enzymes in rat tissues. Yu Y, et al. **J Biochem (Tokyo)** 1995 May; 117(5):952–7

DEFICIENCY

Sodium citrate supplementation in inborn argininosuccinate lyase deficiency: a study in a 5-year-old patient under total parenteral nutrition. Renner C, et al. **Eur J Pediatr** 1995 Nov;154(11):909–14

GENETICS

Effect of lipopolysaccharide treatment in vivo on tissue expression of argininosuccinate synthetase and argininosuccinate lyase mRNAs: relationship to nitric oxide synthase. Hattori Y, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):148–53
Glucocorticoid-dependent induction of the mRNA coding for argininosuccinate lyase in cultured fetal rat hepatocytes. Renouf S, et al. **Biol Neonate** 1995;68(3):221–8

METABOLISM

Characterization and enzyme activity of argininosuccinate lyase/delta-crystallin of the embryonic duck lens. Piatigorsky J, et al. **Biochim Biophys Acta** 1996 Jul 18; 1295(2):158–64
Preparation of recombinant argininosuccinate synthetase and argininosuccinate lyase: expression of the enzymes in rat tissues. Yu Y, et al. **J Biochem (Tokyo)** 1995 May; 117(5):952–7

ARGININOSUCCINATE SYNTHETASE

ANALYSIS

Intracellular localization of the mRNAs of argininosuccinate synthetase and argininosuccinate lyase around liver mitochondria, visualized by high-resolution in situ reverse transcription-polymerase chain reaction. Cohen NS. **J Cell Biochem** 1996 Apr;61(1):81–96

BIOSYNTHESIS

A cohort of supporting metabolic enzymes is coinduced with nitric oxide synthase in human tumor cell lines. Nussler AK, et al. **Cancer Lett** 1996 May 15;103(1):79–84
Glutamine increases argininosuccinate synthetase mRNA levels in rat hepatocytes. The involvement of cell swelling. Quillard M, et al. **Eur J Biochem** 1996 Feb 15;236(1):56–9
Coinduction of nitric oxide synthase, argininosuccinate synthetase, and argininosuccinate lyase in lipopolysaccharide-treated rats. RNA blot, immunoblot, and immunohistochemical analyses. Nagasaki A, et al. **J Biol Chem** 1996 Feb 2;271(5):2658–62

BLOOD

[Argininosuccinate synthetase (ASS)] Miura T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:415–8 (7 ref.) **(Jpn)**

CHEMISTRY

Preparation of recombinant argininosuccinate synthetase and argininosuccinate lyase: expression of the enzymes in rat tissues. Yu Y, et al. **J Biochem (Tokyo)** 1995 May; 117(5):952–7

DEFICIENCY

Pancreatic secretory trypsin inhibitor gene is highly expressed in the liver of adult-onset type II citrullinemia. Kobayashi K, et al. **FEBS Lett** 1995 Sep 18;372(1):69–73
Type II citrullinemia associated with neutropenia. Kamiya Y, et al. **Intern Med** 1995 Jul;34(7):679–82
Long-term survival of patients with argininosuccinate synthetase deficiency. Maestri NE, et al. **J Pediatr** 1995 Dec;127(6):929–35

GENETICS

Effect of lipopolysaccharide treatment in vivo on tissue expression of argininosuccinate synthetase and argininosuccinate lyase mRNAs: relationship to nitric oxide synthase. Hattori Y, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):148–53
Characterization of human wild-type and mutant argininosuccinate synthetase proteins expressed in bacterial cells. Shaheen N, et al. **Enzyme Protein** 1994–95; 48(5–6):251–64
Nature and frequency of mutations in the argininosuccinate synthetase gene that cause classical citrullinemia. Kobayashi K, et al. **Hum Genet** 1995 Oct;96(4):454–63

METABOLISM

Preparation of recombinant argininosuccinate synthetase and argininosuccinate lyase: expression of the enzymes in rat tissues. Yu Y, et al. **J Biochem (Tokyo)** 1995 May; 117(5):952–7

ARGINYL T RNA SYNTHETASE

BIOSYNTHESIS

Cloning and characterization of cDNA encoding a human arginyl-tRNA synthetase. Girjes AA, et al. **Gene** 1995 Oct 27;164(2):347–50

GENETICS

Cloning and characterization of cDNA encoding a human arginyl-tRNA synthetase. Girjes AA, et al. **Gene** 1995 Oct 27;164(2):347–50

ARGIPRESSIN

ADMINISTRATION & DOSAGE

During acute hypercapnia vasopressin inhibits an angiotensin drive to ventilation in conscious dogs. Walker JK, et al. **J Appl Physiol** 1995 Sep;79(3):786–94

ANALOGS & DERIVATIVES

The effect of vasopressin analogue [d(CH2)5(1),Tyr(Me)2]AVP on memory process in rats with experimental amnesia. Car H, et al. **Acta Neurobiol Exp (Warsz)** 1995;55(3):207–11
Inhibition of the vasopressin-enhancing effect on memory retrieval and relearning by a vasopressin V1 receptor antagonist in mice. Alescio-Lautier B, et al. **Eur J Pharmacol** 1995 Dec 29;294(2–3):763–70
Theoretical conformational analysis of three vasopressin antagonists with a modified cyclohexyl ring in the first thioacid residue. Kaźmierkiewicz R, et al. **Int J Pept Protein Res** 1995 May;45(5):451–8
Vasopressin anti-idiotypic antibody staining in the rat brain: colocalization with [35S] [pGlu4, Cyt6]AVP(4–9) binding sites. Jurzak M, et al. **J Neuroendocrinol** 1993 Oct; 5(5):523–31

ANALYSIS

Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Purba JS, et al. **Arch Gen Psychiatry** 1996 Feb;53(2):137–43
Ontogeny of arginine vasopressin-like immunoreactivity in the Brazilian opossum brain. Iqbal J, et al. **Brain Res Dev Brain Res** 1995 Oct 27;89(1):11–32
Neurogenesis of the sexually dimorphic vasopressin cells of the bed nucleus of the stria terminalis and amygdala of rats. al-Shamma HA, et al. **J Neurobiol** 1996 Jan;29(1):91–8
Analysis of the peptide content of the locust vasopressin-like immunoreactive (VPLI) neurons. Baines RA, et al. **Peptides** 1995;16(5):799–807

ANTAGONISTS & INHIBITORS

Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. Akerlund M, et al. **Adv Exp Med Biol** 1995; 395:595–600 (32 ref.)
Potent inhibitory effect of SR 49059, an orally active non-peptide vasopressin V1a receptor antagonist, on human arterial coronary bypass graft. Liu JJ, et al. **Clin Sci (Colch)** 1995 Nov;89(5):481–5

BIOSYNTHESIS

Production of hybrid oxytocin/vasopressin precursors and accumulation of oxytocin precursors in the rough endoplasmic reticulum of rat magnocellular neurons. Morris JF, et al. **Adv Exp Med Biol** 1995;395:49–58
Effect of hypoosmolality on the abundance, poly(A) tail length and axonal targeting of arginine vasopressin and oxytocin mRNAs in rat hypothalamic magnocellular neurons. Svane PC, et al. **FEBS Lett** 1995 Oct 2;373(1):35–8

BLOOD

Role of plasma vasopressin in changes of water balance accompanying acute alcohol intoxication. Taivainen H, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):759–62

Plasma arginine vasopressin response to hypertonic saline infusion in Alzheimer disease. Peskind ER, et al. **Alzheimer Dis Assoc Disord** 1995 Winter;9(4):238–42

Hemodynamic and hormonal responses to atrial distension in the ovine fetus. Jaekle RK, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):694–701

Reflex control of vasopressin during hemorrhage in hypertensive rabbits. Courneya CA, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1570–7

Effect of water restriction during adaptation to a low-sodium diet in man. Sutters M, et al. **Clin Sci (Colch)** 1995 Sep; 89(3):305–10

Roles of the suprachiasmatic nucleus and vasoactive intestinal peptide in the response of plasma arginine vasopressin to osmotic challenge. Nagai N, et al. **Endocrinology** 1996 Feb; 137(2):504–7

Influence of alcohol on the hydromineral hormone responses to exercise in a warm environment. Saini J, et al. **Eur J Appl Physiol** 1995;72(1–2):32–6

Plasma levels of beta-endorphin, leucine enkephalin and arginine vasopressin in patients with essential hypertension and the effects of clonidine. Zheng X, et al. **Int J Cardiol** 1995 Oct;51(3):233–44

Raised plasma arginine vasopressin concentrations during cluster headache attacks. Franceschini R, et al. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):381–3

Elevated arginine vasopressin and lowered atrial natriuretic factor associated with hypertension in coarctation of the aorta. Stewart JM, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):900–8

Elevated arginine vasopressin levels in squamous cell cancer of the head and neck. Talmi YP, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):317–21

Failure of arginine-vasopressin and other pressor hormones to increase in severe recurrent dialysis hypotension [see comments] Friess U, et al. **Nephrol Dial Transplant** 1995; 10(8):1421–7. Comment in: Nephrol Dial Transplant 1996 Feb;11(2):402–3.

Failure of AVP and other pressor hormones to increase in severe recurrent dialysis hypotension [letter; comment] Zoccali C, et al. **Nephrol Dial Transplant** 1996 Feb; 11(2):402–3. Comment on: Nephrol Dial Transplant 1995;10(8):1421–7.

[Participation of atrial natriuretic peptide (hANP) levels and arginine vasopressin (AVP) in aged persons with nocturia] Kikuchi Y. **Nippon Hinyokika Gakkai Zasshi** 1995 Nov; 86(11):1651–9 (Eng. Abstr.) **(Jpn)**

CEREBROSPINAL FLUID

Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma. Peskind ER, et al. **Biol Psychiatry** 1995 Oct 15; 38(8):532–8

Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. Pitts AF, et al. **Biol Psychiatry** 1995 Sep 1;38(5):330–5

CHEMISTRY

Exploration of the conformational space of oxytocin and arginine-vasopressin using the electrostatically driven Monte Carlo and molecular dynamics methods. Liwo A, et al. **Biopolymers** 1996 Feb;38(2):157–75

Theoretical conformational analysis of three vasopressin antagonists with a modified cyclohexyl ring in the first thioacid residue. Kaźmierkiewicz R, et al. **Int J Pept Protein Res** 1995 May;45(5):451–8

The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. Mouillac B, et al. **J Biol Chem** 1995 Oct 27; 270(43):25771–7

DEFICIENCY

Hypertensive response to acute aortic coarctation in chronic vasopressin deficient states. Fregoneze JB, et al. **Clin Exp Hypertens** 1995 Aug;17(6):977–88

GENETICS

Identification of 13 new mutations in the vasopressin-neurophysin II gene in 17 kindreds with familial autosomal dominant neurohypophyseal diabetes insipidus. Rittig S, et al. **Am J Hum Genet** 1996 Jan; 58(1):107–17

Photoperiodic exposure and time of day modulate the expression of arginine vasopressin mRNA and vasoactive intestinal peptide mRNA in the suprachiasmatic nuclei of Siberian hamsters. Duncan MJ, et al. **Brain Res Mol Brain Res** 1995 Sep;32(2):181–6

A novel point mutation in the translation initiation codon of the pre-pro-vasopressin-neurophysin II gene: cosegregation with morphological abnormalities and clinical symptoms in autosomal dominant neurohypophyseal diabetes insipidus. Rutishauser J, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):192–8

A new type of familial central diabetes insipidus caused by a single base substitution in the neurophysin II coding region of the vasopressin gene. Ueta Y, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1787–90

Thymic vasopressin (AVP) transgene expression in rats: a model for the study of thymic AVP hyper-expression in T cell differentiation. Jessop DS, et al. **J Neuroimmunol** 1995 Oct;62(1):85–90

METABOLISM

Strategies for cell biological studies in oxytocinergic neurons. Gainer H, et al. **Adv Exp Med Biol** 1995;395:1–8 (58 ref.)

Histoautoradiographic detection of oxytocin- and vasopressin-binding sites in the amygdala of the rat. Veinante P, et al. **Adv Exp Med Biol** 1995;395:347–8

Differential expression of vasopressin receptor binding in the hypothalamus during lactation in golden hamsters. Delville Y, et al. **Brain Res** 1995 Aug 14;689(1):147–50

Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus. Tsukaguchi H, et al. **J Clin Invest** 1995 Oct;96(4):2043–50

Vasopressin anti-idiotypic antibody staining in the rat brain: colocalization with [35S] [pGlu4, Cyt6]AVP(4–9) binding sites. Jurzak M, et al. **J Neuroendocrinol** 1993 Oct; 5(5):523–31

Lithium induced polyuria and renal vasopressin receptor density. Hensen J, et al. **Nephrol Dial Transplant** 1996 Apr; 11(4):622–7

Nongenomic effect of glucocorticoid on the release of arginine vasopressin from hypothalamic slices in rats. Liu X, et al. **Neuroendocrinology** 1995 Dec;62(6):628–33

Increase in the septal vasopressin content by prolyl endopeptidase inhibitors in rats. Miura N, et al. **Neurosci Lett** 1995 Aug 18;196(1–2):128–30

Evidence for regulatory mechanisms maintaining testosterone-dependent AVP concentrations in terminal regions. Magnusson K, et al. **Peptides** 1996;17(2):263–8

Initiating and responsible enzyme of arginine vasopressin degradation in human placenta and pregnancy serum. Mizutani S, et al. **Regul Pept** 1995 Nov 10;59(3):371–8

[Effect of electrical stimulation of afferent renal nerve on arterial blood pressure, heart rate and vasopressin in rabbits] Lu M, et al. **Sheng Li Hsueh Pao** 1995 Oct;47(5):471–7 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Effect of the non-peptide, vasopressin V1a receptor antagonist, SR 49059 and its enantiomer, SR 49770, on isolated human myometrium. Bossmar T, et al. **Acta Obstet Gynecol Scand** 1996 Jul;75(6):516–9

Subcellular mechanisms of angiotensin II and arginine vasopressin activation of area postrema neurons. Consolim-Colombo FM, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R34–41

PGE2 reverses AVP inhibition of HCO3- absorption in rat MTAL by activation of protein kinase C. Good DW. **Am J Physiol** 1996 Jun;270(6 Pt 2):F978–85

Quantitation of aquaporin-2 abundance in microdissected collecting ducts: axial distribution and control by AVP. Kishore BK, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F62–70

Extracellular nucleotide receptor inhibits AVP-stimulated water permeability in inner medullary collecting duct. Kishore BK, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):F863–9

Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. Lee B, et al. **Am J Physiol** 1995 Dec; 269(6 Pt 1):E1095–100

Adenosine inhibits arginine vasopressin-stimulated chloride secretion in a mouse IMCD cell line (mIMCD-K2). Moyer BD, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):F884–91

Effect of vasopressin on baroreflex control of lumbar sympathetic nerve activity and hindquarter resistance. Scheuer DA, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H1963–71

Extracellular chloride regulates mesangial cell calcium response to vasopressor peptides. Stevanovic ZS, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F21–9

The effects of halothane on arginine-vasopressin-induced Ca2+ mobilization from the intracellular stores and the receptor-mediated Ca2+ entry from the extracellular space in single cultured smooth muscle cells of rat aorta. Fujihara H, et al. **Anesth Analg** 1996 Sep;83(3):584–90

Coupling between [arginine8]-vasopressin-activated increases in protein tyrosine phosphorylation and cellular calcium in A7r5 aortic smooth muscle cells. Kaplan N, et al. **Arch Biochem Biophys** 1996 Feb 15;326(2):271–80

Phosphatidylinositol 3-kinase is involved in TRE-dependent gene expression in response to arginine vasopressin. Nishioka N, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):1037–42

Establishment of vasopressin-responsive early proximal tubular cell lines derived from transgenic mice harboring temperature-sensitive simian virus 40 large T-antigen gene. Takeda M, et al. **Biochem Mol Biol Int** 1995 Oct; 37(3):507–15

Independent induction of morphological transformation of CHO cells by receptor-activated cyclic AMP synthesis or by receptor-operated calcium influx. Singer-Lahat D, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):495–502

Potentiation of the intracellular Ca2+ response to arginine vasopressin by increased cytosolic-free Mg2+ in rat vascular smooth muscle cells. Yoshimura M, et al. **Biochim Biophys Acta** 1996 Jun 13;1312(2):151–7

Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans. Pietrowsky R, et al. **Biol Psychiatry** 1996 Mar 1; 39(5):332–40

Physiologic concentrations of arginine vasopressin activate human platelets in vitro. Wun T, et al. **Br J Haematol** 1996 Mar;92(4):968–72

Characterization of arginine vasopressin actions in human uterine artery: lack of role of the vascular endothelium. Jovanović A, et al. **Br J Pharmacol** 1995 Aug; 115(7):1295–301

Effects of intrahypothalamic morphine and its interactions with oxytocin and vasopressin during food intake in rats. Gulati K, et al. **Brain Res** 1995 Aug 28;690(1):99–103

Effects of central administration of arginine-vasopressin on aversive memory retrieval. Kumar KB, et al. **Brain Res** 1995 Nov 20;699(2):293–6

Human cytomegalovirus modulates the Ca2+ response to vasopressin and ATP in fibroblast cultures. Himpens B, et al. **Cell Calcium** 1995 Aug;18(2):111–9

Vasopressin stimulates Ca2+ spiking activity in A7r5 vascular smooth muscle cells via activation of phospholipase A2. Byron KL. **Circ Res** 1996 May; 78(5):813–20

Effect of arginine vasopressin on regional adrenal blood flow and plasma cortisol concentration in fetal sheep. Carter AM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct; 62(2):235–9

[Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists. Bax WA, et al. **Eur J Pharmacol** 1995 Oct 16; 285(2):199–202

Peripheral injection of arginine8-vasopressin increases Fos in specific brain areas. Wu PH, et al. **Eur J Pharmacol** 1995 Aug 15;281(3):263–9

Thermoregulatory activity of sodium nitroprusside and arginine vasopressin. Gągało IT, et al. **Gen Pharmacol** 1995 Mar;26(2):393–7

Protein kinase C modulation of cardiomyocyte angiotensin II and vasopressin receptor desensitization. Zhang M, et al. **Hypertension** 1996 Feb;27(2):269–75

Stimulation of mitogen-activated protein kinase and Na+/H+ exchanger in human platelets. Differential effect of phorbol ester and vasopressin. Aharonovitz O, et al. **J Biol Chem** 1996 Jul 12;271(28):16494–9

Effects of vasopressin and aldosterone on the lateral mobility of epithelial Na+ channels in A6 renal epithelial cells. Smith PR, et al. **J Membr Biol** 1995 Sep;147(2):195–205

Development of alcohol tolerance in the rat after a single exposure to combined treatment with arginine8-vasopressin and ethanol. Wu PH, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1283–91

OPC-21268 antagonizes arginine vasopressin-induced vasoconstrictor response in the spinally-anesthetized dog. Chihara T, et al. **Jpn J Pharmacol** 1995 Jul;68(3):345–7

Vasopressin V1-receptor stimulation produces a positive inotropic response without affecting pHi in guinea pig papillary muscles. Yamaguchi H, et al. **Jpn J Pharmacol** 1995 Jun;68(2):217–21

AVP inhibits EGF-stimulated MAP kinase cascade in Madin-Darby canine kidney cells. Yamada T, et al. **Kidney Int** 1995 Sep;48(3):745–52

Effect of indomethacin on the CRH- and VP-induced pituitary-adrenocortical response during social stress. Bugajski J, et al. **Life Sci** 1996;58(5):PL 67–72

V2-receptor blockade enhances pressor response to vasopressin: gender difference. Wang YX, et al. **Life Sci** 1996;59(8):695–703

Hypothalamic-pituitary-adrenal axis activity and its relationship to the autonomic nervous system in women with visceral and subcutaneous obesity: effects of the corticotropin-releasing factor/arginine-vasopressin test and of stress. Pasquali R, et al. **Metabolism** 1996 Mar; 45(3):351–6

Effect of atrial natriuretic factor on vasopressin-stimulated cyclic AMP accumulation in papillary collecting tubule [letter] Appel RG, et al. **Nephron** 1995;71(3):369–70

Calcium responses of isolated, immunocytochemically identified rat pinealocytes to noradrenergic, cholinergic and vasopressinergic stimulations. Schomerus C, et al. **Neurochem Int** 1995 Aug;27(2):163–75

Arginine vasopressin stimulates 32P labeling of phosphoinositides in rat pineal gland. Novotná R, et al. **Neurosci Lett** 1995 Sep 1;197(1):49–52

Vasopressin effects on lung liquid volume in fetal sheep. Cummings JJ, et al. **Pediatr Res** 1995 Jul;38(1):30–5

Changes in amino acid levels in rat plasma, cisternal cerebrospinal fluid, and brain tissue induced by intravenously infused arginine-vasopressin. Reichel A, et al. **Peptides** 1995;16(5):965–71

Enhancement of NGF gene expression in rat brain by the memory-enhancing peptide AVP(4–8). Zhou AW, et al. **Peptides** 1995;16(4):581–6

Modulation of the effect of arginine-vasopressin on water and ion transport in the newt early distal tubule and frog urinary bladder by V1-antagonists. Goncharevskaya OA, et al. **Pflugers Arch** 1995 Oct;430(6):1004–11

Arginine vasopressin mediates the chloroquine induced increase in renal sodium excretion. Musabayane CT, et al.

Trop Med Int Health 1996 Aug;1(4):542–50

[Vasopressin facilitates aortic baroreceptor activity in the rat] Ma XY, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):394–400 (Eng. Abstr.) **(Chi)**

[The role of protein kinase C and muscarinic cholinoreceptors in vasopressin-stimulated water transport] Bagrov IaIu, et al. **Eksp Klin Farmakol** 1995 Jul–Aug;58(4):33–5 (Eng. Abstr.) **(Rus)**

[The comparative physiological characteristics of the regulating effect of vasopressin on higher nervous activity in mammals in an ascending order] Sollertinskaia TN. **Fiziol Zh Im I M Sechenova** 1996 Feb;82(2):20–31 (Eng. Abstr.) **(Rus)**

[The ultrastructural characteristics of the epithelial cells in the frog bladder under the action of vasopressin and in a vasopressin-independent increase in permeability for water] Komissarchik IaIu, et al. **Tsitologiia** 1996; 38(1):14–21 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Cerebral oedema after subarachnoid haemorrhage. Pathogenetic significance of vasopressin. László FA, et al. **Acta Neurochir (Wien)** 1995;133(3–4):122–33

Renal cortical and medullary blood flow responses during water restriction: role of vasopressin. Franchini KG, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1257–64

Regulation of bioactive and immunoreactive ACTH secretion by CRF and AVP in sheep fetuses. Zehnder TJ, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):E1076–82

Activation of calcium-sensitive potassium channels in L6 skeletal myocytes by arginine vasopressin requires extracellular calcium. Gosling M, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1163–8

Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant-induced arthritis. Chowdrey HS, et al. **Br J Pharmacol** 1995 Nov; 116(5):2417–24

Corticotropin-releasing factor, vasopressin, and prostaglandins mediate, and nitric oxide restrains, the hypothalamic-pituitary-adrenal response to acute local inflammation in the rat. Turnbull AV, et al. **Endocrinology** 1996 Feb;137(2):455–63

Urinary excretion of aquaporin-2 in humans: a potential marker of collecting duct responsiveness to vasopressin. Elliot S, et al. **J Am Soc Nephrol** 1996 Mar;7(3):403–9

kappa-Opioid agonist, U50,488H, stimulates ovine fetal pituitary-adrenal function via hypothalamic arginine-vasopressin and corticotrophin-releasing factor. Taylor CC, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):877–84

The role of vasopressin, somatostatin and GABA in febrile convulsion in rat pups. Nagaki S, et al. **Life Sci** 1996; 58(24):2233–42

Protein tyrosine phosphorylation in cardiovascular system. Srivastava AK. **Mol Cell Biochem** 1995 Aug–Sep; 149–150:87–94 (90 ref.)

In vivo evidence that arginine vasopressin is involved in the adrenocorticotropin response induced by interleukin-6 but not by tumor necrosis factor-alpha in the rat. Kageyama K, et al. **Neuroimmunomodulation** 1995 May–Jun; 2(3):137–40

The role of arginine vasopressin in interleukin-1 beta-induced adrenocorticotropin secretion in the rat. Sasaki S, et al. **Neuroimmunomodulation** 1995 May–Jun; 2(3):134–6

Altered alertness of vasopressin-secreting transgenic mice. Miller M, et al. **Peptides** 1995;16(8):1329–33

[Neurohormonal factors in heart failure. II] Cosín Aguilar J, et al. **Rev Esp Cardiol** 1996 May;49(5):317–27 (47 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

Neuroendocrine and cardiovascular effects of serotonin: selective role of brain angiotensin on vasopressin. Saydoff JA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E513–21

Body temperature modification of osmotically induced vasopressin secretion and thirst in humans. Takamata A, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):R874–80

Membrane-mediated inhibition of corticosterone on the release of arginine vasopressin from rat hypothalamic slices. Liu X, et al. **Brain Res** 1995 Dec 15;704(1):19–22

The effect of naloxone administration on the secretion of corticotropin-releasing hormone, arginine vasopressin, and adrenocorticotropin in unperturbed horses. Alexander SL, et al. **Endocrinology** 1995 Nov;136(11):5139–47

Centrally administered neuropeptide FF inhibits arginine vasopressin release in conscious rats. Arima H, et al. **Endocrinology** 1996 May;137(5):1523–9

Influence of residual C-peptide secretion on the arginine vasopressin response to hypoglycaemia and metoclopramide in insulin-dependent diabetes. Chiodera P, et al. **Eur J Clin Invest** 1995 Aug;25(8):568–73

Association of arginine vasopressin-secreting cell, steroid-secreting cell, adrenal and islet cell antibodies in a patient presenting with central diabetes insipidus, empty sella, subclinical adrenocortical failure and impaired glucose tolerance. De Bellis A, et al. **Horm Res** 1995; 44(3):142–6

Hyponatremia and osmoregulation of vasopressin secretion in patients with intracranial bleeding. Kamoi K, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2906–11

Inferior petrosal sinus sampling in healthy subjects reveals a unilateral corticotropin-releasing hormone-induced arginine vasopressin release associated with ipsilateral adrenocorticotropin secretion. Kalogeras KT, et al. **J Clin Invest** 1996 May 1;97(9):2045–50

Development of concentration thresholds for fetal swallowing and arginine vasopressin stimulation in the preterm ovine fetus. Kullama LK, et al. **J Matern Fetal Med** 1996 Mar–Apr;5(2):51–7

Vasopressin, atrial natriuretic factor and renal water homeostasis in premature newborn infants with respiratory distress syndrome. Ronconi M, et al. **J Perinat Med** 1995; 23(4):307–14

Effects of intravenously infused pituitary adenylate cyclase-activating polypeptide on arginine vasopressin and oxytocin secretion in man. Chiodera P, et al. **Neuroreport** 1995 Jul 31;6(11):1490–2

THERAPEUTIC USE

Platelet response to vasopressin in preeclampsia [letter] van der Post J, et al. **Am J Obstet Gynecol** 1995 Dec; 173(6):1897–8

ARGIPRESTOCIN see **VASOTOCIN**

ARGON

Argon laser revision stapedectomy. Horn KL, et al. **Am J Otol** 1994 May;15(3):383–8

A comparison of argon, carbon dioxide, and nitrogen in a broiler killing system. Poole GH, et al. **Poult Sci** 1995 Jul; 74(7):1218–23

[Non-contact argon gas coagulation in flexible endoscopy of the gastrointestinal tract: in vitro studies and initial clinical experiences] Johanns W, et al. **Z Gastroenterol** 1995 Dec;33(12):694–700 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Adhesion and proliferation of cultured human aortic smooth muscle cells on polystyrene implanted with N+, F+ and Ar+ ions: correlation with polymer surface polarity and carbonization. Bačáková L, et al. **Biomaterials** 1996 Jun; 17(11):1121–6

The adsorption of argon, krypton, and xenon on activated charcoal. Underhill DW. **Health Phys** 1996 Aug; 71(2):160–6

ARGYRIA

ETIOLOGY

[General argyria caused by administration of tobacco-withdrawal tablets containing silver acetate] Van Garsse L, et al. **Ned Tijdschr Geneeskd** 1995 Dec 23; 139(51):2658–61 (Eng. Abstr.) **(Dut)**

PATHOLOGY

Asymptomatic blue nevus-like macule. Diagnosis: localized argyria. Espinal ML, et al. **Arch Dermatol** 1996 Apr; 132(4):461, 464

[Light microscope and energy dispersive X-ray analysis of amalgam pigmentation] Wu Q, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 May; 30(3):140–2, 191 (Eng. Abstr.) **(Chi)**

ARHINENCEPHALY see **HOLOPROSENCEPHALY**

ARM

see related
FORELIMB

Perforating granuloma annulare and HIV [letter] Núñez M, et al. **Acta Derm Venereol** 1995 Sep;75(5):407

Toxic shock syndrome in a male secondary to myositis of the arm. Klonis E. **Anaesth Intensive Care** 1995 Jun; 23(3):361–3

The anthroform biorobotic arm: a system for the study of spinal circuits. Hannaford B, et al. **Ann Biomed Eng** 1995 Jul–Aug;23(4):399–408

Multiple painful blue nodules. Multiple glomus tumors (glomangiomas). Yen A, et al. **Arch Dermatol** 1996 Jun; 132(6):704–5, 707–8

Focused review: postmastectomy lymphedema. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S74–80 (55 ref.)

Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment [see comments] Sorkin P, et al. **Arch Surg** 1995 Oct;130(10):1079–84. Comment in: Arch Surg 1996 Feb;131(2):220.

Physiological responses to asynchronous and synchronous arm-cranking exercise. Hopman MT, et al. **Eur J Appl Physiol** 1995;72(1–2):111–4

Bilateral brachial plexopathy following hyperabduction of arms. Mukherji JD, et al. **J Assoc Physicians India** 1995 Aug;43(8):580–1

Perioperative compartment syndrome. A report of four cases. Seiler JG 3rd, et al. **J Bone Joint Surg Am** 1996 Apr; 78(4):600–2

Classification systems of soft tissue disorders of the neck and upper limb: do they satisfy methodological guidelines? Buchbinder R, et al. **J Clin Epidemiol** 1996 Feb;49(2):141–9 (76 ref.)

Opportunistic mycotic infections of the upper limb. A review. al-Qattan MM. **J Hand Surg [Br]** 1996 Apr;21(2):148–50 (21 ref.)

Mucormycosis of the upper limb. al-Qattan MM, et al. **J Hand Surg [Br]** 1996 Apr;21(2):261–2

Computer simulation of the upper extremities. Buford WL Jr, et al. **J Hand Ther** 1995 Apr–Jun;8(2):167–74 (33 ref.)

On the heterogeneity of neurogenic facioscapulohumeral muscular atrophy [letter; comment] Kaneko K, et al. **Muscle Nerve** 1996 Apr;19(4):533–5. Comment on: Muscle Nerve 1995;2:S96–7.

Vasospasm causing a cold hemiplegic arm. Wanklyn P, et al. **Postgrad Med J** 1995 Sep;71(839):559–60

Early-stage breast cancer: arm edema after wide excision and breast irradiation. Kiel KD, et al. **Radiology** 1996 Jan; 198(1):279–83

Sleep-related periodic arm movement [letter] Yokota T, et al. **Sleep** 1995 Oct;18(8):707–8

Prevalence and associated features of the cold hemiplegic arm. Wanklyn P, et al. **Stroke** 1995 Oct;26(10):1867–70

Lymphangiosarcoma in a chronic lymphedematous limb: a case report. Lasa MV, et al. **Tumori** 1995 Sep–Oct; 81(5):381–2

["The withered arm". A multifocal motor neuropathy and considerations in differential diagnosis] Andersen B, et al. **Ugeskr Laeger** 1996 Jul 29;158(31):4390–4 (Eng. Abstr.) **(Dan)**

[Lesions of the hand and upper limb in children with linear scleroderma. Therapeutic approach in two cases] Duport G, et al. **Ann Chir Main Memb Super** 1996;15(1):5–10 (Eng. Abstr.) **(Fre)**

[Polyalgetic syndrome of the upper limbs following intensive and prolonged use of a computer keyboard (letter)] Hamonet C, et al. **Presse Med** 1995 Oct 7;24(29):1358 **(Fre)**

[Treatment of primary hyperhidrosis of the upper limbs by transthoracic endoscopic sympathectomy] Lesèche G, et al. **Presse Med** 1995 Nov 4;24(33):1569–73 (36 ref.) (Eng. Abstr.) **(Fre)**

[Outcome of various inpatient lymph drainage procedures] Herpertz U. **Z Lymphol** 1996 Jun;20(1):27–30 (Eng. Abstr.) **(Ger)**

[Sequelae of manipulation of the postmastectomy arm] Klimaschewski H. **Z Lymphol** 1996 Jun;20(1):43–5 **(Ger)**

[Gigantic arm lymphedema] Rüger K. **Z Lymphol** 1995 Aug; 19(1):12–5 (Eng. Abstr.) **(Ger)**

[Malignant neuroectodermal tumor of the arm in a 15-year-old girl successfully treated with chemo- and radiotherapy] Armata J, et al. **Pediatr Pol** 1995 Nov; 70(11):977–9 (Eng. Abstr.) **(Pol)**

[Diagnostic method in occupational vegetative trophic dysfunction of upper limb muscles] Rastopina EI, et al. **Med Tr Prom Ekol** 1995;(7):33–6 (Eng. Abstr.) **(Rus)**

ABNORMALITIES

Epidemiological analysis of the association of congenital diaphragmatic hernia with upper-limb deficiencies: a primary polytopic developmental field defect. Martínez-Frías ML. **Am J Med Genet** 1996 Mar 1; 62(1):68–70

Residents' corner. Answer to case of the month #33. Holt-Oram syndrome. Sykes AM, et al. **Can Assoc Radiol J** 1995 Oct;46(5):398–400

Phocomelia, ectrodactyly, skull defect and urinary system anomaly: Schinzel-phocomelia syndrome? Evliyaoğlu N, et al. **Clin Genet** 1996 Feb;49(2):70–3

Hepatoblastoma associated with congenital hemihypertrophy. Rattan KN, et al. **Indian Pediatr** 1995 Dec;32(12):1308–9

Right upper limb bud triplication and polythelia, left sided hemihypertrophy and congenital hip dislocation, facial dysmorphism, congenital heart disease, and scoliosis: disorganisation-like spectrum or patterning gene defect? Sabry MA, et al. **J Med Genet** 1995 Jul;32(7):555–6

[Upper limb lengthening. 47 clinical cases] Pajardi G. **Ann Chir Main Memb Super** 1995;14(4–5):218–23 (Eng. Abstr.) **(Fre)**

[Schizencephaly and upper limb malformation] Humbertclaude V, et al. **Arch Pediatr** 1996 Apr;3(4):357–9 (Eng. Abstr.) **(Fre)**

[Malformations of the extremities. The therapeutic approach (letter)] Minguella Solá J. **An Esp Pediatr** 1996 Jan; 44(1):83–4 **(Spa)**

ANATOMY & HISTOLOGY

An unusual origin for the accessory head of biceps brachii muscle. Sargon MF, et al. **Clin Anat** 1996;9(3):160–2

Arm span as measurement of response to GH treatment [letter] Rotenstein D. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3432

Gantzer's muscle. An anatomical study of the accessory head of the flexor pollicis longus muscle. al-Qattan MM. **J Hand Surg [Br]** 1996 Apr;21(2):269–70

Using middle upper arm circumference to assess severe adult malnutrition during famine. Collins S. **JAMA** 1996 Aug 7;276(5):391–5

A study of the fasciocutaneous vascularisation of the arm. Surgical applications. Le Huec JC, et al. **Surg Radiol Anat** 1995;17(2):121–8, 8–10 **(Eng, Fre)**

BLOOD SUPPLY

Coronary artery steal and bilateral stenting of subclavian artery [letter] Ozşarlak O, et al. **AJR Am J Roentgenol** 1996 Apr;166(4):996

Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Fishbane S, et al. **Am J Kidney Dis** 1996 May;27(5):668–72

Pressure wave propagation in a multibranched model of the human upper limb. Karamanoglu M, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1363–9

Simultaneous ipsilateral and contralateral measurements of vasomotion in conduit arteries of human upper limbs. Porret CA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):H1852–8

The role of paradoxical arterial emboli of the extremities. AbuRahma AF, et al. **Am J Surg** 1996 Aug;172(2):214–7

Long-term follow-up of bypasses to the brachial artery across the shoulder joint. Jain KM, et al. **Am J Surg** 1996 Aug;172(2):127–9

Upper and lower limb blood pressures during general anaesthesia [comment] Howat DD. **Anaesthesia** 1995 Oct; 50(10):918. Comment on: Anaesthesia 1995 Jun;50(6):553–5.

The relationship between arm–ankle pressure difference and peak systolic velocity in patients with stenotic lower extremity vein grafts. Papanicolaou G, et al. **Ann Vasc Surg** 1995 Nov;9(6):554–60

Three year follow-up of a case of giant cell arteritis presenting with a chronic cough and upper limb ischaemic symptoms. Rischmueller M, et al. **Br J Rheumatol** 1996 Aug;35(8):800–2

Upper extremity thromboembolism after axillary–axillary bypass grafting. McLafferty RB, et al. **Cardiovasc Surg** 1996 Feb;4(1):111–3

Case report: upper extremity ischaemia secondary to ergotamine poisoning. Voyvodic F, et al. **Clin Radiol** 1996 Aug;51(8):589–91

Critical limb ischemia after accidental subcutaneous infusion of sulprostone. de Koning YW, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):171–3

Surgical management of brachioaxillary–subclavian vein occlusion. Sottiurai VS, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):225–9

Factors associated with early failure of arteriovenous fistulae for haemodialysis access. Wong V, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):207–13

An anatomical study and ontogenetic explanation of 23 cases with variations in the main pattern of the human brachio–antebrachial arteries. Rodríguez–Baeza A, et al. **J Anat** 1995 Oct;187 (Pt 2):473–9

Management of large high-flow arteriovenous malformations of the shoulder and upper extremity with transcatheter embolotherapy. Dickey KW, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):765–73

Percutaneous use of the Fogarty adherent clot catheter. Trerotola SO, et al. **J Vasc Interv Radiol** 1995 Jul–Aug; 6(4):578–80

Results of a policy with arm veins used as the first alternative to an unavailable ipsilateral greater saphenous vein for infrainguinal bypass. Hölzenbein TJ, et al. **J Vasc Surg** 1996 Jan;23(1):130–40

Intra-arterial iloprost for limb ischaemia [letter] Motz E, et al. **Lancet** 1995 Nov 11;346(8985):1295

Acute ischemia of an upper limb as the first manifestation of hydroxyapatite crystal deposition disease [letter] Micheau V, et al. **Rev Rhum Engl Ed** 1995 Jul–Sep; 62(7–8):536–7

The upper arm arterio–venous fistula—an alternative for vascular access in haemodialysis. Gade J, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):121–4

Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin). Monreal M, et al. **Thromb Haemost** 1996 Feb;75(2):251–3

[Personal experience with establishment of arteriovenous anastomoses for dialysis using blood vessels in the cubital fossa] Utikal P, et al. **Rozhl Chir** 1996 Feb;75(2):83–7 (Eng. Abstr.) **(Cze)**

[Complications caused by patient positioning in unidentified "thoracic outlet syndrome"] Peterson T, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):516–8 (Eng. Abstr.) **(Ger)**

[Peripheral vascular injuries in polytrauma] Richter A, et al. **Unfallchirurg** 1995 Sep;98(9):464–7 (Eng. Abstr.) **(Ger)**

[Vascular traumatic lesions in childhood and adolescence] Bettili G, et al. **Minerva Cardioangiol** 1996 Apr;44(4):155–60 (Eng. Abstr.) **(Ita)**

[Evaluation of the usefulness of stress tests in diagnosis of thoracic outlet syndrome with upper limb ischemia] Kwiatkowska W. **Przegl Lek** 1995;52(8):388–91 (Eng. Abstr.) **(Pol)**

[Surgical treatment of complicated arterial forms of thoracic outlet syndrome] Driuk NF, et al. **Klin Khir** 1995; (11–12):13–5 **(Rus)**

[Deep venous thrombosis of the upper limb. A prospective study of the central venous catheter as an etiologic factor and clinical and subclinical incidence of pulmonary thromboembolism] Gelonch J, et al. **Nutr Hosp** 1991 May–Jun;6(3):161–71 (Eng. Abstr.) **(Spa)**

GROWTH & DEVELOPMENT

Correlations among height, leg length and arm span in growing Korean children. Yun DJ, et al. **Ann Hum Biol** 1995 Sep–Oct;22(5):443–58

Increased limb lengths in patients with shortened spines due to tuberculosis in early childhood. Krishna M, et al. **Spine** 1996 May 1;21(9):1045–7

INJURIES see ARM INJURIES

INNERVATION

Tourniquet paralysis in microsurgery. Landi A, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):89–93

Intercostal nerve transfer to restore upper extremity functions after brachial plexus injury. Nagano A, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):42–5

Focal upper limb demyelinating neuropathy. Thomas PK, et al. **Brain** 1996 Jun;119 (Pt 3):765–74

Electrically evoked long-latency responses in human forearm, arm and shoulder muscles. Logullo F, et al. **Electromyogr Clin Neurophysiol** 1995 Aug–Sep; 35(5):273–80

Upper-limb dystonia secondary to a midbrain hemorrhage [letter] Esteban Muñoz J, et al. **Mov Disord** 1996 Jan; 11(1):96–9

Chronic progressive monomelic sensory neuropathy. Yuen EC. **Neurology** 1996 Mar;46(3):850

Reconstruction of tonic vibration reflex in the biceps brachii reinnervated by transferred intercostal nerves in patients with brachial plexus injury. Sai K, et al. **Neurosci Lett** 1996 Mar 8;206(1):1–4

Metabolic activity pattern in the motor and somatosensory cortex of monkeys performing a visually guided reaching task with one forelimb. Dalezios Y, et al. **Neuroscience** 1996 May;72(2):325–33

Clinical syndromes associated with disproportionate weakness of the upper versus the lower extremities after cervical spinal cord injury. Levi AD, et al. **Neurosurgery** 1996 Jan;38(1):179–83; discussion 183–5

Bypass coaptation procedures for cervical nerve root avulsion. Yamada S, et al. **Neurosurgery** 1996 Jun; 38(6):1145–51; discussion 1151–2

Clinical diagnosis of peripheral nerve compression in the upper extremity. Anto C, et al. **Orthop Clin North Am** 1996 Apr;27(2):227–36 (31 ref.)

Electrodiagnosis in compression neuropathies of the upper extremities. de Araujo MP. **Orthop Clin North Am** 1996 Apr;27(2):237–44 (50 ref.)

Dynamics and pathophysiology of nerve compression in the upper extremity. Delfiner JS. **Orthop Clin North Am** 1996 Apr;27(2):219–26 (25 ref.)

Persistence of symptoms after surgical release of compressive neuropathies and subsequent management. Idler RS. **Orthop Clin North Am** 1996 Apr;27(2):409–16 (21 ref.)

Differential diagnosis and pitfalls in electrodiagnostic studies and special tests for diagnosing compressive neuropathies. Kaufman MA. **Orthop Clin North Am** 1996 Apr; 27(2):245–52 (32 ref.)

Unusual compressive neuropathies of the upper limb. Osterman AL, et al. **Orthop Clin North Am** 1996 Apr; 27(2):389–408 (116 ref.)

Multiple compression neuropathies and the double-crush syndrome. Simpson RL, et al. **Orthop Clin North Am** 1996 Apr;27(2):381–8 (59 ref.)

Surgical anatomy of the radial nerve in the arm: practical considerations of the branching patterns to the triceps brachii. Stanescu S, et al. **Orthopedics** 1996 Apr;19(4):311–5

Selective block of the brachialis motor point. An anatomic investigation of musculocutaneous nerve branching. Buchanan TS, et al. **Reg Anesth** 1996 Mar–Apr;21(2):89–92

[A case from practice (344). Neuralgic shoulder amyotrophy or plexus neuritis] Burckhardt B. **Schweiz Rundsch Med Prax** 1996 Mar 12;85(11):348–50 **(Ger)**

[Several functional and diagnostic criteria in the evaluation of the state of the neuromuscular function of arms of workers exposed to the effects of local vibration] Ermakova GA, et al. **Med Tr Prom Ekol** 1995;(10):23–6 (Eng. Abstr.) **(Rus)**

[The use of physical factors in the combined treatment of traumatic damages to the nerve trunks of the extremities] Danda VA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):21–5 (Eng. Abstr.) **(Rus)**

[Sympathetic denervation of an extremity as a presentation form of apical lung cancer] Campero M, et al. **Rev Med Chil** 1995 May;123(5):624–7 (Eng. Abstr.) **(Spa)**

PATHOLOGY

Self-administered examination versus conventional medical examination of the musculoskeletal system in the neck, shoulders, and upper limbs. The Stockholm MUSIC I Study Group. Toomingas A, et al. **J Clin Epidemiol** 1995 Dec;48(12):1473–83

Upper extremity atrophy associated with a giant congenital melanocytic nevus. Skidmore RA, et al. **Pediatr Dermatol** 1995 Sep;12(3):272–4

Infantile myofibromatosis. Chateil JF, et al. **Skeletal Radiol** 1995 Nov;24(8):629–32

PHYSIOLOGY

Isolated effects of peripheral arm and central body cooling on arm performance. Giesbrecht GG, et al. **Aviat Space Environ Med** 1995 Oct;66(10):968–75

Metabolic and ventilatory response pattern to arm elevation in patients with COPD and healthy age-matched subjects. Baarends EM, et al. **Eur Respir J** 1995 Aug;8(8):1345–51

The stability of precision grip forces during cyclic arm movements with a hand-held load. Flanagan JR, et al. **Exp Brain Res** 1995;105(3):455–64

Luminance neurons in the pretectal olivary nucleus mediate the pupillary light reflex in the rhesus monkey. Gamlin PD, et al. **Exp Brain Res** 1995;106(1):169–76

Grasping component alterations and limb transport. Timmann D, et al. **Exp Brain Res** 1996 Mar;108(3):486–92

Stability properties of human reaching movements. Won J, et al. **Exp Brain Res** 1995;107(1):125–36

Three-dimensional kinematics of wheelchair propulsion. Rao SS, et al. **IEEE Trans Rehabil Eng** 1996 Sep;4(3):152–60

The effect of beta-adrenergic blockade on non-esterified fatty acid uptake of exercising skeletal muscle during arm cranking. Schrauwen P, et al. **Int J Sports Med** 1995 Oct; 16(7):439–44

Normal range of motion of the joints of the upper extremity in male subjects, with special reference to side. Günal I, et al. **J Bone Joint Surg Am** 1996 Sep;78(9):1401–4

Postural and synergic control for three-dimensional movements of reaching and grasping. Desmurget M, et al. **J Neurophysiol** 1995 Aug;74(2):905–10

Pallidal neuron activity during sequential arm movements. Mushiake H, et al. **J Neurophysiol** 1995 Dec;74(6):2754–8

Directional variation of spatial and temporal characteristics of limb movements made by monkeys in a two-dimensional work space. Turner RS, et al. **J Neurophysiol** 1995 Aug; 74(2):684–97

The role of upper limb segment rotations in the development of racket-head speed in the squash forehand. Elliott B, et al. **J Sports Sci** 1996 Apr;14(2):159–65

Measurement of upper extremity orientation by video stereometry system. Peterson B, et al. **Med Biol Eng Comput** 1996 Mar;34(2):149–54

Acute effects of vibration from a chipping hammer and a grinder on the hand–arm system. Kihlberg S, et al. **Occup Environ Med** 1995 Nov;52(11):731–7

Calf blood pressure: clinical implications and correlations with arm blood pressure in infants and young children. Crapanzano MS, et al. **Pediatrics** 1996 Feb;97(2):220–4

Visual stability with goal-directed eye and arm movements toward a target displaced during saccadic suppression. Blouin J, et al. **Psychol Res** 1995;58(3):169–76

Equilibrium-point control hypothesis examined by measured arm stiffness during multijoint movement [see comments] Gomi H, et al. **Science** 1996 Apr 5;272(5258):117–20. Comment in: Science 1996 Apr 5;272(5258):32–3.

Tilting against a major theory of movement control [news; comment] Pennisi E. **Science** 1996 Apr 5;272(5258):32–3. Comment on: Science 1996 Apr 5;272(5258):117–20.

Current issues in directional motor control [see comments] Georgopoulos AP. **Trends Neurosci** 1995 Nov; 18(11):506–10 (63 ref.). Comment in: Trends Neurosci 1996 Apr;19(4):137–8.

[Temperature gradients of the upper and lower extremities in healthy people according to the results of radiothermometry studies] Obukhova AA, et al. **Fiziol Cheloveka** 1995 Nov–Dec;21(6):157–9 **(Rus)**

PHYSIOPATHOLOGY

The performance of rapid arm movements in Parkinson's disease. A review. Agostino R, et al. **Adv Neurol** 1996; 69:135–46 (61 ref.)

Strength in Parkinson's disease: relationship to rate of force generation and clinical status. Corcos DM, et al. **Ann Neurol** 1996 Jan;39(1):79–88

Standing balance during internally produced perturbations in subjects with hemiplegia: validation of the balance scale. Stevenson TJ, et al. **Arch Phys Med Rehabil** 1996 Jul; 77(7):656–62

Single-joint rapid arm movements in normal subjects and in patients with motor disorders. Berardelli A, et al. **Brain** 1996 Apr;119 (Pt 2):661–74 (78 ref.)

Interjoint coordination during pointing movements is disrupted in spastic hemiparesis. Levin MF. **Brain** 1996 Feb; 119 (Pt 1):281–93

Kinematics of initiating a two-joint arm movement in patients with cerebellar ataxia. Massaquoi S, et al. **Can J Neurol Sci** 1996 Feb;23(1):3–14

The effects of the saddle seat on seated postural control and upper-extremity movement in children with cerebral palsy. Reid DT. **Dev Med Child Neurol** 1996 Sep;38(9):805–15

Contralateral and ipsilateral EMG responses to transcranial magnetic stimulation during recovery of arm and hand function after stroke. Turton A, et al. **Electroencephalogr Clin Neurophysiol** 1996 Aug; 101(4):316–28

Effect of arm cranking exercise on skin blood flow of lower limb in people with injuries to the spinal cord. Muraki S, et al. **Eur J Appl Physiol** 1995;71(1):28–32

Function of the upper extremities in hereditary multiple exostoses. Stanton RP, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):568–73

Use of botulinum toxin in stroke patients with severe upper

limb spasticity. Bhakta BB, et al.
J Neurol Neurosurg Psychiatry 1996 Jul;61(1):30–5
Adaptation motor learning of arm movements in patients with cerebellar disease. Deuschl G, et al.
J Neurol Neurosurg Psychiatry 1996 May;60(5):515–9
The effect of trunk support on performance during arm ergometry in patients with cervical cord injuries. Klefbeck B, et al. **Paraplegia** 1996 Mar;34(3):167–72
The effects of neurodevelopmental treatment versus practice on the reaching of children with spastic cerebral palsy. Fetters L, et al. **Phys Ther** 1996 Apr;76(4):346–58
[Motor initiation difficulty of right upper extremity induced by tactile–stimulation after infarction in the left anterior cerebral artery territory] Otsuki M, et al.
Rinsho Shinkeigaku 1996 Jan;36(1):1–6 (Eng. Abstr.) **(Jpn)**
[Mobilization and stretching one more time (letter)] Ersson B. **Lakartidningen** 1996 Feb 14;93(7):555–6 **(Swe)**

RADIATION EFFECTS

Upper limb disease in women treated for breast cancer [see comments] Sainsbury R. **Lancet** 1995 Dec 2;346(8988):1444 . Comment in: Lancet 1996 Feb 17;347(8999):473.

RADIOGRAPHY

Residents' corner. Answer to case of the month #33. Holt–Oram syndrome. Sykes AM, et al.
Can Assoc Radiol J 1995 Oct;46(5):398–400

RADIONUCLIDE IMAGING

Extraosseous uptake of 99mtechnetium phosphate in an extremity. Ozalp E, et al. **Semin Nucl Med** 1995 Oct; 25(4):352–4

SURGERY

Limb salvage surgery with microsurgical reconstruction for the treatment of musculoskeletal tumours involving the upper extremity. Kumta SM, et al.
Ann Acad Med Singapore 1995 Jul;24(4 Suppl):8–14
Quantitative evaluation of tourniquet leak during i.v. regional anaesthesia of the upper and lower limbs in human volunteers. Hoffmann AC, et al. **Br J Anaesth** 1995 Sep; 75(3):269–73
The long–term outcome of upper limb amputees treated at a rehabilitation centre in Sydney, Australia. Jones LE, et al. **Disabil Rehabil** 1995 Nov–Dec;17(8):437–42
Major limb amputation in adults, Zaria, Nigeria. Yakubu A, et al. **J R Coll Surg Edinb** 1996 Apr;41(2):102–4
Amputation of a useless limb. Pearce RL, et al.
Med J Aust 1996 Apr 1;164(7):407–8
Transient axillary–upper inner arm subcutaneous fibrous banding following transaxillary subpectoral endoscopic breast augmentation [letter] Maximovich SP.
Plast Reconstr Surg 1996 May;97(6):1304–5
[Surgery of soft tissue sarcoma (with the exception of the retroperitoneum)] Stöckle E, et al. **Ann Chir** 1996; 50(3):263–75 (85 ref.) (Eng. Abstr.) **(Fre)**
[1984–1994: Ten years of skin flaps. Development of transfer techniques. New methods of autoplasty described during this period] Martin D. **Ann Chir Plast Esthet** 1995 Oct; 40(5):527–82 (126 ref.) (Eng. Abstr.) **(Fre)**

ARM ERGOMETRY TEST see **EXERCISE TEST**

ARM INJURIES

Upper extremity injuries in young athletes. Ireland ML, et al. **Clin Sports Med** 1995 Jul;14(3):533–69 (101 ref.)
Upper extremity disorders: a literature review to determine work–relatedness. Vender MI, et al. **J Hand Surg [Am]** 1995 Jul;20(4):534–41 (79 ref.)
Work–related upper–extremity disorders and work disability: clinical and psychosocial presentation. Himmelstein JS, et al. **J Occup Environ Med** 1995 Nov;37(11):1278–86
[Bloodless avulsion of the upper limb] Nechiporenko PI. **Klin Khir** 1995;(11–12):47–8 **(Rus)**

COMPLICATIONS

Diagnostic approach to reflex sympathetic dystrophy after fracture: radiography or bone scintigraphy?
Todorović–Tirnanić M, et al. **Eur J Nucl Med** 1995 Oct; 22(10):1187–93
Osseous overgrowth after amputation in adolescents and children. O'Neal ML, et al. **J Pediatr Orthop** 1996 Jan–Feb; 16(1):78–84

DIAGNOSIS

Common upper–extremity injuries. Lillegard WA, et al.
Arch Fam Med 1996 Mar;5(3):159–68 (40 ref.)
Cumulative trauma disorders of the upper limbs in workers on an agricultural farm. Raffi GB, et al.
Arh Hig Rada Toksikol 1996 Mar;47(1):19–23

EPIDEMIOLOGY

Upper–extremity impairment in young children. Schutzman SA, et al. **Ann Emerg Med** 1995 Oct;26(4):474–9
The epidemiology and management of upper limb peripheral nerve injuries in modern practice. McAllister RM, et al. **J Hand Surg [Br]** 1996 Feb;21(1):4–13
Alpine skiing injuries. A nine–year study. Davidson TM, et al. **West J Med** 1996 Apr;164(4):310–4
[Vascular traumatic lesions in childhood and adolescence] Bettili G, et al. **Minerva Cardioangiol** 1996 Apr;44(4):155–60 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Auger injuries in the Wimmera region 1987–95. Read KO, et al. **Aust N Z J Surg** 1996 Apr;66(4):229–30
Sports–specific injuries. Plancher KD, et al.
Clin Sports Med 1996 Apr;15(2):207–18 (16 ref.)
'Sand–blaster' injuries. Amir A, et al. **Injury** 1996 Apr; 27(3):223–4
A wonderful dog–master story [letter] Hakansson BO.
Trop Doct 1996 Apr;26(2):88
[Hand and arm vibration syndrome caused by mechanical screw driver] Kákosy T, et al. **Orv Hetil** 1995 Nov 12; 136(46):2507–9 (Eng. Abstr.) **(Hun)**

MICROBIOLOGY

[The wound microflora of patients with gunshot injuries to the extremities during a mass hospitalization] Men'shikov DD, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr;(2):17–20 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Computer–assisted evaluation of hand and arm function after thermal injury. Harvey KD, et al. **J Burn Care Rehabil** 1996 Mar–Apr;17(2):176–80; discussion 175
Rupture of an anomalous tendon slip as a cause of forearm pain. O'Hara JJ, et al. **J Hand Surg [Br]** 1995 Dec; 20(6):791–3
[Unidimensionality of a functional measure for patient with an injured upper limb] Luquet C, et al.
Rev Epidemiol Sante Publique 1996 Jun;44(3):248–61 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Psychosocial consequences of upper limb injury. Paterson MC, et al. **J Hand Surg [Br]** 1995 Dec;20(6):776–81

RADIOGRAPHY

Agreement in the interpretation of extremity radiographs of injured children and adolescents. Minnes BG, et al.
Acad Emerg Med 1995 Sep;2(9):826–30
Should accident and emergency nurses request radiographs? Results of a multicentre evaluation. Thurston J, et al.
J Accid Emerg Med 1996 Mar;13(2):86–9

REHABILITATION

Bilateral musculocutaneous nerve palsy. A case report. Kuhlman KA, et al. **Am J Phys Med Rehabil** 1996 May–Jun;75(3):227–31
Controlled active mobilization following surgical repair of the avulsed radial attachment of the biceps brachii muscle: a case report. Hurov JR. **J Orthop Sports Phys Ther** 1996 Jun;23(6):382–7
Occupational handicap in victims of limb injuries. Magalhaes T, et al. **Med Law** 1996;15(1):135–41
[The use of physical factors in the combined treatment of traumatic damages to the nerve trunks of the extremities] Danda VA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):21–5 (Eng. Abstr.) **(Rus)**
[Experience with physiotherapy in a posttraumatic neurodystrophic syndrome of the extremities] Landa VA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec; (6):21–4 (Eng. Abstr.) **(Rus)**

SURGERY

The role of microsurgery and free tissue transfer in the reconstruction of the paediatric upper extremity. Kay S, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):113–23 (50 ref.)
A preliminary report of tissue preservation with University of Wisconsin cold storage solution in major limb replantation. Kour AK, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):37–41
Tourniquet paralysis in microsurgery. Landi A, et al.
Ann Acad Med Singapore 1995 Jul;24(4 Suppl):89–93
Major limb replantation: a Thai experience. Patradul A, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):82–8
Brachioradialis muscle flap: clinical anatomy and use in soft–tissue reconstruction of the elbow. Rohrich RJ, et al. **Ann Plast Surg** 1995 Jul;35(1):70–6
Salvage of extensively burned upper limbs by a pedicled latissimus dorsi flap. Delay E, et al. **Burns** 1995 Sep; 21(6):449–52
Repair of chronic distal biceps brachii tendon rupture using free autogenous semitendinosus tendon. Hang DW, et al. **Clin Orthop** 1996 Feb;(323):188–91
The application of the limited contact dynamic compression plate in the upper extremity: an analysis of 114 consecutive cases. McKee MD, et al. **Injury** 1995 Dec;26(10):661–6
Vascular trauma of the upper limb and associated nerve injuries. Shaw AD, et al. **Injury** 1995 Oct;26(8):515–8
Upper arm fasciotomy. A new approach. Maginn P, et al. **J Hand Surg [Br]** 1996 Feb;21(1):59–62
Traumatic plastic deformity of an adult forearm: case report and literature review. Simonian PT, et al.
J Orthop Trauma 1996;10(3):213–5 (12 ref.)
Effective management of osteomyelitis after grade III open fractures. Monsivais JJ. **J South Orthop Assoc** 1996 Spring; 5(1):30–6
Arterial gunshot injuries of the extremities: a South African experience. Degiannis E, et al. **J Trauma** 1995 Sep; 39(3):570–5
Is immediate decompression of high voltage electrical injuries to the upper extremity always necessary? Mann R, et al. **J Trauma** 1996 Apr;40(4):584–7; discussion 587–9
Functional soft–tissue coverage in skeletonizing injuries of the upper extremity using the ipsilateral latissimus dorsi myocutaneous flap. Germann G, et al.
Plast Reconstr Surg 1995 Oct;96(5):1130–5
Treatment for self–inflicted laceration scars [letter] Papanastasiou S. **Plast Reconstr Surg** 1995 Dec;96(7):1754
[Upper limb lengthening. 47 clinical cases] Pajardi G.
Ann Chir Main Memb Super 1995;14(4–5):218–23 (Eng. Abstr.) **(Fre)**
[Rupture of the distal tendon of the biceps brachialis: apropos of 43 cases] Catonné Y, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(2):163–72 (17 ref.) (Eng. Abstr.) **(Fre)**
[Surgical treatment of the rupture of the inferior tendon of the biceps. Apropos of 6 cases] Gennari JM, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(2):173–7 (Eng. Abstr.) **(Fre)**
[Peripheral vascular injuries in polytrauma] Richter A, et al. **Unfallchirurg** 1995 Sep;98(9):464–7 (Eng. Abstr.) **(Ger)**
[Proximal humerus shaft fracture as a complication after keyhole–plasty. A case report] Friedel R, et al.
Unfallchirurgie 1995 Aug;21(4):198–201 (Eng. Abstr.) **(Ger)**
[Muscle incoordination phenomena after surgical management of proximal rupture of the biceps tendon] Schmidt I, et al. **Unfallchirurgie** 1995 Oct;21(5):227–32 (Eng. Abstr.) **(Ger)**
[Long–term results of surgical and conservative treatment of ruptures of the long biceps tendon] Zimmer–Amrhein S, et al. **Zentralbl Chir** 1996;121(5):394–400 (Eng. Abstr.) **(Ger)**

THERAPY

Common upper–extremity injuries. Lillegard WA, et al.
Arch Fam Med 1996 Mar;5(3):159–68 (40 ref.)

ULTRASONOGRAPHY

[Ultrasound of extremity lesions caused by birth trauma] Riebel T, et al. **Ultraschall Med** 1995 Aug;16(4):196–9 (Eng. Abstr.) **(Ger)**

ARMADILLOS

Antibodies to St. Louis encephalitis virus in armadillos from southern Florida. Day JF, et al. **J Wildl Dis** 1995 Jan; 31(1):10–4

ANATOMY & HISTOLOGY

New and peculiar cytoplasmic membranous bodies in the acinar cells of the harderian gland of the armadillo Chaetophractus villosus. Aldana Marcos HJ, et al.
Biocell 1995 Aug;19(2):85–93
Ultrastructure of normal armadillo epidermis. Zhou HM, et al. **Int J Lepr Other Mycobact Dis** 1996 Jun;64(2):159–65

IMMUNOLOGY

Immune response of armadillos (Dasypus novemcinctus). I. Use of lectins to identify lymphocyte subpopulations and to evaluate cell proliferation. Santos–Argumedo L, et al.
Int J Lepr Other Mycobact Dis 1995 Dec;63(4):546–51

MICROBIOLOGY

Evolution of lymphocyte populations in armadillos (Dasypus novemcinctus) inoculated with M. leprae. Guerra–Infante F, et al. **Int J Lepr Other Mycobact Dis** 1996 Jun; 64(2):152–8
Radiometric procedure for detecting a cultivable Mycobacterium in Mycobacterium leprae–infected armadillo tissue [letter] Harris EB, et al.
Int J Lepr Other Mycobact Dis 1996 Mar;64(1):82–4
Infection of distal peripheral nerves by M. leprae in infected armadillos; an experimental model of nerve involvement in leprosy. Scollard DM, et al.
Int J Lepr Other Mycobact Dis 1996 Jun;64(2):146–51
Paracoccidioides brasiliensis. A mycologic and immunochemical study of a sample isolated from an armadillo (Dasipus novencinctus). Vidal MS, et al.
Rev Inst Med Trop Sao Paulo 1995 Jan–Feb;37(1):43–9

PARASITOLOGY

Nematodes of armadillos in Paraguay: a description of a new species Aspidodera esperanzae (Nematoda: Aspidoderidae). Fujita O, et al. **J Parasitol** 1995 Dec;81(6):936–41
Prevalence and identity of Sarcocystis infections in armadillos (Dasypus novemcinctus). Lindsay DS, et al.
J Parasitol 1996 Jun;82(3):518–20

PHYSIOLOGY

Decrease of body temperature in armadillos experimentally covered by soil. Casanave EB, et al. **Arch Physiol Biochem** 1995 Apr;103(1):29-32

Bradycardia in armadillos experimentally covered with soil. Casanave EB, et al. **Arch Physiol Biochem** 1995 Apr; 103(1):51-3

ARMED FORCES PERSONNEL see MILITARY PERSONNEL

ARMIN

PHARMACOLOGY

[Change in the non-specific anti-infection resistance of the body exposed to cholinergic stimulation] Zabrodskiĭ PF. **Biull Eksp Biol Med** 1995 Aug;120(8):164-6 **(Rus)**

[The effect of armin on neuromuscular transmission in the frog against a background of hexadecamethonium action] Grigor'ev VM. **Fiziol Zh Im I M Sechenova** 1995 Jul; 81(7):27-32 (Eng. Abstr.) **(Rus)**

ARNOLD-CHIARI DEFORMITY

Arnold-chiari malformation in pregnancy. Semple DA, et al. **Anaesthesia** 1996 Jun;51(6):580-2

Apneic spells in a patient with myelomeningocele without Chiari type II malformation--case report. Nishimura T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):876-81

COMPLICATIONS

Surgical decompression of Chiari I malformation for isolated progressive sensorineural hearing loss. Johnson GD, et al. **Am J Otol** 1994 Sep;15(5):634-8

Pulsatile tinnitus associated with congenital central nervous system malformations. Wiggs WJ Jr, et al. **Am J Otol** 1996 Mar;17(2):241-4

Type I Chiari deformity presenting with profound sinus bradycardia: case report and literature review. Selmi F, et al. **Br J Neurosurg** 1995;9(4):543-5

Spontaneous intracranial hypotension: headache with a reversible Arnold-Chiari malformation. Kasner SE, et al. **Headache** 1995 Oct;35(9):557-9

Sudden death and Chiari malformations [letter; comment] Rocker GM, et al. **Intensive Care Med** 1995 Jul;21(7):621 . Comment on: Intensive Care Med 1993;19(2):73-4.

Multiple lentigines (Leopard) syndrome with Chiara I malformation. Agha A, et al. **J Dermatol** 1995 Jul; 22(7):520-3

Spontaneous intracranial hypotension [letter; comment] Schievink WI, et al. **J Neurosurg** 1996 Jan;84(1):151-2. Comment on: J Neurosurg 1995 Sep;83(3):556-8.

Isolated sleep apnea due to Chiari type I malformation and syringomyelia. Shiihara T, et al. **Pediatr Neurol** 1995 Oct; 13(3):266-7

[Chiari "malformation" in Crouzon syndrome] Cinalli G, et al. **Arch Pediatr** 1996 May;3(5):433-9 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Esophageal dysphagia as the sole symptom in type I Chiari malformation. Elta GH, et al. **Dig Dis Sci** 1996 Mar; 41(3):512-5 (11 ref.)

Scoliosis as the first sign of a cystic spinal cord lesion. Samuelsson L, et al. **Eur Spine J** 1995;4(5):284-90 (41 ref.)

Adult Arnold-Chiari malformation: a postpartum case presentation. O'Reilly SA, et al. **J Am Osteopath Assoc** 1995 Oct;95(10):607-9

Progressive dysphagia due to adult Chiari I malformation mimicking amyotrophic lateral sclerosis [letter] Ikusaka M, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):357-8

Special imaging casebook. Chiari II malformation. Herman TE, et al. **J Perinatol** 1995 Sep-Oct;15(5):434-5

De novo Chiari-I malformation in infants demonstrated by sequential magnetic resonance imaging scans. Report of two cases. Amin-Hanjani S, et al. **Pediatr Neurosurg** 1995; 22(6):299-302

Syringomyelia and chiari malformation presenting as scoliosis in cystic fibrosis. Rusakow LS, et al. **Pediatr Pulmonol** 1995 May;19(5):317-8 (10 ref.)

[A case of the clinical manifestation of the Arnold-Chiari syndrome in middle age] Rabinovich SS. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(2):91-2 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Acquired Chiari-I malformation and hydromyelia secondary to a giant craniopharyngioma. Lee M, et al. **Pediatr Neurosurg** 1995;22(5):251-4

[Syringomyelia, scoliosis and idiopathic Arnold-Chiari malformations: a common etiology] Royo-Salvador MB. **Rev Neurol** 1996 Aug;24(132):937-59 (119 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Significance of chronic tonsillar herniation in sudden death. James DS. **Forensic Sci Int** 1995 Oct 30;75(2-3):217-23

[Histopathological analysis of herniated cerebellar tonsils resected from the patients with Chiari type I malformation with syringomyelia] Koga H, et al. **No To Shinkei** 1995 Nov;47(11):1075-9 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Evaluation of the autonomic cardiovascular response in Arnold-Chiari deformities and cough syncope syndrome. Ireland PD, et al. **Arch Neurol** 1996 Jun;53(6):526-31

SURGERY

Surgical decompression of Chiari I malformation for isolated progressive sensorineural hearing loss. Johnson GD, et al. **Am J Otol** 1994 Sep;15(5):634-8

Posterior fossa decompression for Chiari I deformity, including resection of the cerebellar tonsils. Fischer EG. **Childs Nerv Syst** 1995 Nov;11(11):625-9

Chiari complex in children--neuroradiological diagnosis, neurosurgical treatment and proposal of a new classification (312 cases). Cama A, et al. **Eur J Pediatr Surg** 1995 Dec; 5 Suppl 1:35-8

Spontaneous regeneration of the foramen magnum after decompressive suboccipital craniectomy in Chiari malformation: case report. Aoki N, et al. **Neurosurgery** 1995 Aug;37(2):340-2

Posterior fossa volume and response to suboccipital decompression in patients with Chiari I malformation. Badie B, et al. **Neurosurgery** 1995 Aug;37(2):214-8

Chiari I malformation: classification and management. Bindal AK, et al. **Neurosurgery** 1995 Dec;37(6):1069-74

Surgical indication and results of foramen magnum decompression versus syringosubarachnoid shunting for syringomyelia associated with Chiari I malformation. Hida K, et al. **Neurosurgery** 1995 Oct;37(4):673-8; discussion 678-9 (33 ref.)

The effect of early craniocervical decompression on functional outcome in neonates and young infants with myelodysplasia and symptomatic Chiari II malformations: results from a prospective series. Pollack IF, et al. **Neurosurgery** 1996 Apr;38(4):703-10; discussion 710

"Conservative" cranio-cervical decompression in the treatment of syringomyelia-Chiari I complex. A prospective study of 20 adult cases. Di Lorenzo N, et al. **Spine** 1995 Dec 1;20(23):2479-83

ULTRASONOGRAPHY

[The ultrasonic diagnosis of the Arnold-Chiari malformation in young infants] Blagodatskiĭ MD, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(2):87-90 **(Rus)**

AROCLORS

ADVERSE EFFECTS

Xenoestrogens alter mammary gland differentiation and cell proliferation in the rat. Brown NM, et al. **Environ Health Perspect** 1995 Jul-Aug;103(7-8):708-13

ANALYSIS

A rapid method for determination of Aroclor 1260 in cattle adipose tissue. Kumar Y, et al. **J Environ Sci Health B** 1996 Sep;31(5):1001-13

METABOLISM

Photodegradation of Aroclor 1254 using simulated sunlight and various sensitizers. Lin Y, et al. **Bull Environ Contam Toxicol** 1996 Apr;56(4):566-70

The presence of glass beads or Triton X-100 in the medium enhances the aerobic dechlorination of Aroclor 1221 in Pseudomonas sp. CPE1 culture. Fava F. **Chemosphere** 1996 Apr;32(8):1469-75

Aroclor 1221 aerobic dechlorination by a bacterial co-culture: role of chlorobenzoic acid degrading bacteria in the process. Fava F. **Chemosphere** 1996 Apr; 32(8):1477-83

Female rhesus monkeys dosed with Aroclor 1254: analysis of polychlorinated biphenyl congeners in dam's milk and in the blood of dams and their offspring before, during, and after gestation. Mes J, et al. **J Anal Toxicol** 1995 Jul-Aug;19(4):209-17

PHARMACOKINETICS

Transfer of PCBs via lactation simultaneously induces the expression of P450 isoenzymes and the protooncogenes c-Ha-ras and c-raf in neonates. Borlak JT, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):517-29

PHARMACOLOGY

Transfer of PCBs via lactation simultaneously induces the expression of P450 isoenzymes and the protooncogenes c-Ha-ras and c-raf in neonates. Borlak JT, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):517-29

Structure-dependent induction of CYP2B by polychlorinated biphenyl congeners in female Sprague-Dawley rats. Connor K, et al. **Biochem Pharmacol** 1995 Nov 27; 50(11):1913-20

Human liver S-9 metabolic activation: proficiency in cytogenetic assays and comparison with phenobarbital/beta-naphthoflavone or aroclor 1254 induced rat S-9. Johnson TE, et al. **Environ Mol Mutagen** 1996;28(1):51-9

Influence of Aroclor 1254, phenobarbital, beta-naphthoflavone, and ethanol pretreatment on the biotransformation of cyclophosphamide in male and female rats. Sessink PJ, et al. **Toxicology** 1996 Aug 16; 112(2):141-50

TOXICITY

Effects on PCBs on liver ultrastructure and monooxygenase activities in Japanese quail. Stouvenakers N, et al. **Bull Environ Contam Toxicol** 1996 May;56(5):839-46

Promotion of N-nitrosodiethylamine-initiated hepatocellular tumors and hepatoblastomas by 2,3,7,8-tetrachlorodibenzo-p-dioxin or Aroclor 1254 in C57BL/6, DBA/2, and B6D2F1 mice. Beebe LE, et al. **Cancer Res** 1995 Nov 1;55(21):4875-80

P450 induction by Aroclor 1254 and 3,3',4,4'-tetrachlorobiphenyl in cultured hepatocytes from rat, quail and man: interspecies comparison. Dubois M, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jan;113(1):51-9

Evaluation of phenobarbital/beta-naphthoflavone as an alternative S9-induction regime to Aroclor 1254 in the rat for use in in vitro genotoxicity assays. Callander RD, et al. **Mutagenesis** 1995 Nov;10(6):517-22

Embryotoxicity of polychlorinated biphenyls (PCBS) for preimplantation embryos. Lindenau A, et al. **Reprod Toxicol** 1996 May-Jun;10(3):227-30

Neonatal polychlorinated biphenyl treatment increases adult testis size and sperm production in the rat. Cooke PS, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):112-7

Developmental exposure to polychlorinated biphenyls (Aroclor 1254) reduces circulating thyroid hormone concentrations and causes hearing deficits in rats. Goldey ES, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):77-88

Modulation by iron of hepatic microsomal and nuclear cytochrome P450, and cytosolic glutathione S-transferase and peroxidase in C57BL/10ScSn mice induced with polychlorinated biphenyls (Aroclor 1254). Madra S, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):79-86

Alterations in rat brain thyroid hormone status following pre- and postnatal exposure to polychlorinated biphenyls (Aroclor 1254). Morse DC, et al. **Toxicol Appl Pharmacol** 1996 Feb;136(2):269-79

Suppression of pulmonary P4502b and induction of hepatic, intestinal and kidney P4501a-1 and 1a-2 in the Ah-responsive and non-responsive mouse by Aroclor 1254. Beebe LE, et al. **Xenobiotica** 1995 Jun;25(6):541-51

AROMATASE

ANALYSIS

Granulosa-cumulus-corona expansion and aromatase localization in preovulatory follicles in superovulated heifers. Laurincik J, et al. **Acta Vet Scand** 1996;37(1):99-107

Aromatase in human common epithelial ovarian neoplasms. Kaga K, et al. **Am J Pathol** 1996 Jul;149(1):45-51

Immunohistochemical localization of estrogen receptors within aromatase-immunoreactive neurons in the fetal and neonatal rat brain. Tsuruo Y, et al. **Anat Embryol (Berl)** 1996 Feb;193(2):115-21

Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours. Kitawaki J, et al. **Anticancer Res** 1996 Jan-Feb;16(1):91-7

Rooster testicular germ cells and epididymal sperm contain P450 aromatase. Kwon S, et al. **Biol Reprod** 1995 Dec; 53(6):1259-64

Sperm, a source of estrogen. Hess RA, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:59-62 (41 ref.)

Aromatase in breast cancer tissue--localization and relationship with reproductive status of patients. Berstein LM, et al. **J Cancer Res Clin Oncol** 1996;122(8):495-8

ANTAGONISTS & INHIBITORS

Aromatase inhibitors: current status. Ibrahim NK, et al. **Am J Clin Oncol** 1995 Oct;18(5):407-17 (142 ref.)

Effects of 3-[N-(2-chlorobenzyl)amino]-6-(1H-imidazol-1-yl) pyridazine dihydrochloride on various aromatase enzyme systems and experimental breast cancer. Bandoh K, et al. **Arzneimittelforschung** 1995 Aug;45(8):897-900

Insulin-like growth factor I inhibits aromatization induced by follice-stimulating hormone in rat sertoli cell culture. Rappaport MS, et al. **Biol Reprod** 1996 Feb;54(2):446-52

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. Bonnefoi HR, et al. **Br J Cancer** 1996 Feb;73(4):539-42

Aromatase inhibitors--where are we now? [editorial] Miller WR. **Br J Cancer** 1996 Feb;73(4):415-7

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Yates RA, et al. **Br J Cancer** 1996 Feb;73(4):543-8

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Zilembo N, et al. **Br J Cancer** 1995 Oct;72(4):1007-12

Estrogen-induction of dendritic spines in ventromedial hypothalamus and hippocampus: effects of neonatal

aromatase blockade and adult GDX. Lewis C, et al. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):91–5

Aromatase inhibition with 4–OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Murray R, et al. **Breast Cancer Res Treat** 1995 Sep;35(3):249–53

Aromatization of androgens is important for skeletal maintenance of aged male rats. Vanderschueren D, et al. **Calcif Tissue Int** 1996 Sep;59(3):179–83

Inhibition of aromatase activity and growth suppression by 4–methoxy–4–androstene–3,17–dione in an androgen sensitive human prostatic carcinoma cell line. Block JL, et al. **Cancer Lett** 1996 Mar 29;101(2):143–8

Binding characteristics of seven inhibitors of human aromatase: a site–directed mutagenesis study. Kao YC, et al. **Cancer Res** 1996 Aug 1;56(15):3451–60

Aromatase inhibitors: synthesis, biological activity, and structure of 1,2–imidazolylmethylcyclopentanol derivatives. Kato A, et al. **Chem Pharm Bull (Tokyo)** 1995 Dec;43(12):2152–8

The synthesis of 19–norandrostenedione from dehydroepiandrosterone in equine placenta is inhibited by aromatase inhibitors 4–hydroxyandrostenedione and fadrozole. Moslemi S, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):613–8

New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity [editorial; comment] Castiglione–Gertsch M. **Eur J Cancer** 1996 Mar; 32A(3):393–5. Comment on: Eur J Cancer 1996 Mar;32A(3):404–12.

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer [see comments] Jonat W, et al. **Eur J Cancer** 1996 Mar;32A(3):404–12. Comment in: Eur J Cancer 1996 Mar;32A(3):393–5.

Effect of the peroxisome proliferator, ammonium perfluorooctanoate (C8), on hepatic aromatase activity in adult male Crl:CD BR (CD) rats. Liu RC, et al. **Fundam Appl Toxicol** 1996 Apr;30(2):220–8

Making males from females: the effects of aromatase inhibitors on a parthenogenetic species of whiptail lizard. Wennstrom KL, et al. **Gen Comp Endocrinol** 1995 Sep; 99(3):316–22

Anti–androgen effects of the aromatase inhibitor, atamestane. Shao TC, et al. **J Androl** 1995 Mar–Apr;16(2):100–7

A new aromatase inhibitor, FR901537. I. Taxonomy, fermentation, isolation, physiochemical characteristics and biological activities. Oohata N, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):757–62

A new aromatase inhibitor, FR901537. II. Pharmacological and antitumor effects. Oohata N, et al. **J Antibiot (Tokyo)** 1995 Aug;48(8):763–7

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. Buzdar A, et al. **J Clin Oncol** 1996 Jul;14(7):2000–11

Comparative molecular field analysis of non–steroidal aromatase inhibitors related to fadrozole. Recanatini M. **J Comput Aided Mol Des** 1996 Feb;10(1):74–82

Evaluation of 6,7–aziridinyl steroids and related compounds as inhibitors of aromatase (P–450arom). Njar VC, et al. **J Enzym Inhib** 1995;9(3):195–202

Presence of aromatase inhibitors in cycads. Kowalska MT, et al. **J Ethnopharmacol** 1995 Jul 28;47(3):113–6

Structure–activity relationships of a new family of steroidal aromatase inhibitors. 1. Synthesis and evaluation of a series of analogs related to 19–[(methylthio)methyl]androstenedione (RU54115). Lesuisse D, et al. **J Med Chem** 1996 Feb 2;39(3):757–72

Probing the hydrophobic pocket of the active site of aromatase with 4–phenoxy–7 alpha–(phenylthio)–4–androstene–3,17–dione. Liu XP, et al. **J Med Chem** 1995 Sep 29;38(20):4135–8

Time–dependent inactivation of aromatase by 6–alkylandrosta–1,4–diene–3,17–diones. Effects of length and configuration of 6–alkyl group. Numazawa M, et al. **J Med Chem** 1996 Mar 1;39(5):1033–8

Synthesis and structure–activity relationships of 6–substituted androst–4–ene analogs as aromatase inhibitors. Numazawa M, et al. **J Med Chem** 1996 May 24;39(11):2245–52

Tetrahydronaphthalenes: influence of heterocyclic substituents on inhibition of steroid enzymes P450 arom and P450 17. Wächter GA, et al. **J Med Chem** 1996 Feb 16;39(4):834–41

Imidazole derivatives of pyrrolidonic and piperidonic as potential inhibitors of human placental aromatase in vitro. Baroudi M, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1–2):73–7

The potent and selective inhibition of estrogen production by non–steroidal aromatase inhibitor, YM511. Kudoh M, et al. **J Steroid Biochem Mol Biol** 1995 Sep;54(5–6):265–71

A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. Lønning PE, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(3–4):409–12

Effects of flavonoids on aromatase activity, an in vitro study. Pelissero C, et al. **J Steroid Biochem Mol Biol** 1996 Feb; 57(3–4):215–23

Blockade of estrogen synthesis with an aromatase inhibitor affects luteal function of the pseudopregnant rat. Shetty G, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(3–4):347–53

Nitric oxide inhibits aromatase activity: mechanisms of action. Snyder GD, et al. **J Steroid Biochem Mol Biol** 1996 Apr;58(1):63–9

Anastrozole for metastatic breast cancer. **Med Lett Drugs Ther** 1996 Jul 5;38(978):61–2

Activity of formestane in de novo tamoxifen–resistant patients with metastatic breast cancer. Noberasco C, et al. **Oncology** 1995 Nov–Dec;52(6):454–7

Inhibition of aromatase. Banting L. **Prog Med Chem** 1996; 33:147–84 (151 ref.)

Effect of aromatase inhibitor, TZA–2209, on the prostate of androstenedione–treated castrated dogs: changes in prostate volume and histopathological findings. Suzuki K, et al. **Prostate** 1996 May;28(5):328–37

Aromatase inhibitors: effect of ring A and ring B unsaturation on aromatase inhibition by 4–thiosubstituted derivatives of 4–androstene–3,17–dione. Abul–Hajj YJ, et al. **Steroids** 1995 May;60(5):423–7

Further studies on 6–alkylandrost–4–ene–3,17–diones as aromatase inhibitors: elongation of the 6–alkyl chain. Numazawa M, et al. **Steroids** 1995 Aug;60(8):506–11

[Introduction of a new aromatase inhibitor fadrozole hydrochloride hydsate] Tsukagoshi S. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1991–7 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

The alternative exons 1 of the mouse aromatase cytochrome P–450 gene. Honda S, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):145–50

Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Lu Q, et al. **Endocrinology** 1996 Jul;137(7):3061–8

Inhibition of aromatase expression by a psoralen–linked triplex–forming oligonucleotide targeted to a coding sequence. Macaulay VM, et al. **FEBS Lett** 1995 Sep 25; 372(2–3):222–8

Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells. Zhou D, et al. **J Biol Chem** 1996 Jun 21; 271(25):15194–202

Molecular and epidemiological analyses of abnormal expression of aromatase in breast cancer. Harada N, et al. **Pharmacogenetics** 1995;5 Spec No:S59–64

CHEMISTRY

A three–dimensional model of aromatase cytochrome P450. Graham–Lorence S, et al. **Protein Sci** 1995 Jun; 4(6):1065–80

DEFICIENCY

Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. Morishima A, et al. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3689–98

DRUG EFFECTS

Modulation of aromatase activity by growth factors in an androgen sensitive human prostate cancer cell line, LNCaP. Block JL, et al. **Cancer Lett** 1996 Apr 19;102(1–2):167–72

GENETICS

Relationship between adipose stromal–vascular cells and adipocytes in human adipose tissue. O'Brien SN, et al. **Anal Quant Cytol Histol** 1996 Apr;18(2):137–43

Sheep gene mapping: assignment of ALDOB, CYP19, WT and SOX2 by somatic cell hybrid analysis. Payen E, et al. **Anim Genet** 1995 Oct;26(5):331–3

The alternative exons 1 of the mouse aromatase cytochrome P–450 gene. Honda S, et al. **Biochim Biophys Acta** 1996 Mar 1;1305(3):145–50

Functional aromatase expression in porcine adrenal gland and testis. Conley AJ, et al. **Biol Reprod** 1996 Feb;54(2):497–505

Demonstration of tissue–specific promoters in nonprimate species that express aromatase P450 in placentae. Hinshelwood MM, et al. **Biol Reprod** 1995 Nov; 53(5):1151–9

Ontogeny of aromatase messenger ribonucleic acid and aromatase activity in the rat midbrain. Raab H, et al. **Brain Res Mol Brain Res** 1995 Dec 28;34(2):333–6

Overexpression of int–5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Tekmal RR, et al. **Cancer Res** 1996 Jul 15;56(14):3180–5

Molecular cloning of cytochrome P450 aromatase complementary deoxyribonucleic acid from periimplantation porcine and equine blastocysts identifies multiple novel 5'–untranslated exons expressed in embryos, endometrium, and placenta. Choi I, et al. **Endocrinology** 1996 Apr;137(4):1457–67

Structure and promoter analysis of the cytochrome P–450 aromatase gene of the teleost fish, medaka (Oryzias latipes). Tanaka M, et al. **J Biochem (Tokyo)** 1995 Apr;117(4):719–25

Regulation of placenta–specific expression of the aromatase cytochrome P–450 gene. Involvement of the trophoblast–specific element binding protein. Yamada K, et al. **J Biol Chem** 1995 Oct 20;270(42):25064–9

Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. Morishima A, et al. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3689–98

Aromatase expression in endometriosis. Noble LS, et al. **J Clin Endocrinol Metab** 1996 Jan;81(1):174–9

An atlas of aromatase mRNA expression in the zebra finch brain. Shen P, et al. **J Comp Neurol** 1995 Sep 11; 360(1):172–84

Identification and characterization of transcriptional regulatory elements of the human aromatase cytochrome P450 gene (CYP19). Toda K, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):151–9 (22 ref.)

Analysis of the expression and the first exon of aromatase mRNA in monkey brain. Yamada–Mouri N, et al. **J Steroid Biochem Mol Biol** 1995 Oct;55(1):17–23

Aromatase gene is amplified in MCF–7 human breast cancer cells. Zhou D, et al. **J Steroid Biochem Mol Biol** 1993 Aug; 46(2):147–53

Functional ovarian and placental isoforms of porcine aromatase. Corbin CJ, et al. **Mol Cell Endocrinol** 1995 Aug 30;113(1):29–37

Quantitative detection of alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in aromatase–expressing human cells by competitive RT–PCR. Agarwal VR, et al. **Mol Cell Probes** 1995 Dec; 9(6):453–64

Characteristics of triplex–directed photoadduct formation by psoralen–linked oligodeoxynucleotides. Bates PJ, et al. **Nucleic Acids Res** 1995 Nov 11;23(21):4283–9

Molecular and epidemiological analyses of abnormal expression of aromatase in breast cancer. Harada N, et al. **Pharmacogenetics** 1995;5 Spec No:S59–64

METABOLISM

Aromatization of [4–14C]testosterone to [14C]estradiol–17 beta by testicular tissue from male–to–female transsexuals on estrogen therapy. Gunasegaram R, et al. **Arch Androl** 1995 Sep–Oct;35(2):127–33

Conformational analysis of 19–oxygenated steroids with a 4–ene or 2,4–diene structure, potential intermediates of aromatase reaction, with semiempirical molecular orbital PM3 calculations. Numazawa M, et al. **Biol Pharm Bull** 1995 May;18(5):782–4

Expression of estrogen receptor in the facial nucleus is suppressed by estradiol, but not by testosterone, indicating a lack of requirement for aromatization. Orikasa C, et al. **Brain Res** 1995 Sep 25;693(1–2):112–7

Modulation of aromatase activity by growth factors in an androgen sensitive human prostate cancer cell line, LNCaP. Block JL, et al. **Cancer Lett** 1996 Apr 19;102(1–2):167–72

Characterization of oviductal aromatase in the northern leopard frog, Rana pipiens. Kobayashi F, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):653–7

1,25–Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Tanaka S, et al. **Endocrinology** 1996 May;137(5):1860–9

3 beta–hydroxysteroid dehydrogenase/isomerase and aromatase activity in primary cultures of developing zebra finch telencephalon: dehydroepiandrosterone as substrate for synthesis of androstenedione and estrogens. Vanson A, et al. **Gen Comp Endocrinol** 1996 Jun;102(3):342–50

Effects of epidermal growth factor, transforming growth factor alpha and androstenedione on follicular growth and aromatization in culture. Almahbobi G, et al. **Hum Reprod** 1995 Oct;10(10):2767–72

Time–dependent effects of transforming growth factor alpha on aromatase activity in human granulosa cells. Harlow CR, et al. **Hum Reprod** 1995 Oct;10(10):2554–9

Regulation of arachidonic acid metabolism, aromatase activity and growth in human breast cancer cells by interleukin–1beta and phorbol ester: dissociation of a mediatory role for prostaglandin E2 in the autocrine control of cell function. Hughes R, et al. **Int J Cancer** 1996 Sep 4;67(5):684–9

Aromatase expression in human germinomas with possible biological effects. O'Marcaigh AS, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3763–6

Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre– and postmenopausal breast cancer patients. Pasqualini JR, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1460–4

Aromatase activity and interleukin–6 production by normal and malignant breast tissues. Purohit A, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):3052–8

Human testicular aromatase: clinical experience [letter; comment] Valenta LJ. **J Clin Endocrinol Metab** 1995 Oct; 80(10):3098–9. Comment on: J Clin Endocrinol Metab 1995 Jun;80(6):1941–7.

Aromatase expression in a feminizing adrenocortical tumor. Young J, et al. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3173–6

Possible mechanism for the first response to short captivity stress in the water frog, Rana esculenta. Gobbetti A, et al. **J Endocrinol** 1996 Feb;148(2):233–9

Why so much oestriol? A comparison of the aromatisation

of androstenedione and 16 alpha-hydroxyandrostenedione when incubated alone or together with human placental microsomes. Othman YS, et al. **J Endocrinol** 1996 Mar; 148(3):399–407

IL-6sR: release from MCF-7 breast cancer cells and role in regulating peripheral oestrogen synthesis. Singh A, et al. **J Endocrinol** 1995 Nov;147(2):R9–12

Immunocytochemical and biochemical evidence for aromatase in neurons of the retina, optic tectum and retinotectal pathways in goldfish. Gelinas D, et al. **J Neuroendocrinol** 1993 Dec;5(6):635–41

Dietary zinc deficiency alters 5 alpha-reduction and aromatization of testosterone and androgen and estrogen receptors in rat liver. Om AS, et al. **J Nutr** 1996 Apr; 126(4):842–8

Effects of testosterone and its metabolites on aromatase-immunoreactive cells in the quail brain: relationship with the activation of male reproductive behavior. Balthazart J, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):185–200 (125 ref.)

Expression and regulation of aromatase and 17 beta-hydroxysteroid dehydrogenase type 4 in human THP 1 leukemia cells. Jakob F, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(5–6):555–63

Possible involvement of microfilaments in the regulation of Sertoli cell aromatase activity. Meroni SB, et al. **Mol Cell Endocrinol** 1995 Jul;112(1):69–75

Presence of estrogen receptors in aromatase-immunoreactive neurons in the mouse brain. Tsuruo Y, et al. **Neurosci Lett** 1995 Jul 28;195(1):49–52

[Aromatase activity in breast cancer tissue: the role of a cellular substrate] Bershtein LM, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):410–3 **(Rus)**

PHYSIOLOGY

Prostaglandin E2-9-ketoreductase and prostaglandin F2 alpha activate brain aromatase to induce courtship in the male crested newt, Triturus carnifex. Gobbetti A, et al. **Horm Behav** 1995 Jun;29(2):267–77

The control and biological importance of intratumoural aromatase in breast cancer. Dowsett M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):145–50 (22 ref.)

Regulation of sex-specific formation of oestrogen in brain development: endogenous inhibitors of aromatase. Hutchison JB, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):201–7 (37 ref.)

AROMATIC AMINO ACID DECARBOXYLASES

ANALYSIS

Elevated aromatic-L-amino acid decarboxylase in human carcinoid tumors. Gilbert JA, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):845–50

Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Arai R, et al. **Brain Res** 1996 Jan 8;706(1):177–9

Short-photoperiod exposure reduces L-aromatic-amino-acid decarboxylase immunostaining in the arcuate nucleus and median eminence of male Syrian hamsters. Krajnak K, et al. **Brain Res** 1996 Mar 11;712(1):95–101

Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine. Mura A, et al. **Brain Res** 1995 Dec 15;704(1):51–60

BIOSYNTHESIS

Amphetamine and vigabatrin down regulate aromatic L-amino acid decarboxylase mRNA levels. Buckland PR, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):69–76

Gene expression of aromatic L-amino acid decarboxylase mRNA in the kidney of normotensive and hypertensive rats. Sanada H, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S179–81

Tissue-specific expression of the nonneuronal promoter of the aromatic L-amino acid decarboxylase gene is regulated by hepatocyte nuclear factor 1. Aguanno A, et al. **J Biol Chem** 1996 Feb 23;271(8):4528–38

Alternative splicing in the coding region of human aromatic L-amino acid decarboxylase mRNA. Chang YT, et al. **Neurosci Lett** 1996 Jan 5;202(3):157–60

BLOOD

Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease. Boomsma F, et al. **Life Sci** 1995;57(19):1753–9

GENETICS

Tissue-specific expression of the nonneuronal promoter of the aromatic L-amino acid decarboxylase gene is regulated by hepatocyte nuclear factor 1. Aguanno A, et al. **J Biol Chem** 1996 Feb 23;271(8):4528–38

Cultured human keratinocytes as a peripheral source of mRNA for tyrosine hydroxylase and aromatic L-amino acid decarboxylase. Chang YT, et al. **J Inherit Metab Dis** 1996;19(2):239–42

Analysis of the neuronal promoter of the rat aromatic L-amino acid decarboxylase gene. Aguanno A, et al. **J Neurochem** 1995 Nov;65(5):1944–54

Alternate promoters in the rat aromatic L-amino acid decarboxylase gene for neuronal and nonneuronal expression: an in situ hybridization study. Jahng JW, et al. **J Neurochem** 1996 Jan;66(1):14–9

The human aromatic L-amino acid decarboxylase gene can be alternatively spliced to generate unique protein isoforms. O'Malley KL, et al. **J Neurochem** 1995 Dec;65(6):2409–16

Alternative splicing in the coding region of human aromatic L-amino acid decarboxylase mRNA. Chang YT, et al. **Neurosci Lett** 1996 Jan 5;202(3):157–60

Overexpression of a tryptophan decarboxylase cDNA in Catharanthus roseus crown gall calluses results in increased tryptamine levels but not in increased terpenoid indole alkaloid production. Goddijn OJ, et al. **Transgenic Res** 1995 Sep;4(5):315–23

IMMUNOLOGY

Aromatic-L-amino-acid decarboxylase, a pyridoxal phosphate-dependent enzyme, is a beta-cell autoantigen. Rorsman F, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8626–9

METABOLISM

Progesterone receptor immunoreactivity in aromatic L-amino acid decarboxylase-containing neurons of the guinea pig hypothalamus and preoptic area. Warembourg M, et al. **J Comp Neurol** 1996 Apr 15;367(4):477–90

In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. Bergström M, et al. **J Nucl Med** 1996 Jan;37(1):32–7

Aromatic L-amino acid decarboxylase modulation and Parkinson's disease. Neff NH, et al. **Prog Brain Res** 1995; 106:91–7 (39 ref.)

Immunocytochemical colocalizations of serotonin, aromatic L-amino acid decarboxylase and polypeptide hormones in A- and PP-cells of the chicken endocrine pancreas. Takayanagi M, et al. **Tissue Cell** 1995 Aug;27(4):439–46

AROUSAL

Overlapping stage models and reaction time additivity: effects of the activation equation. Miller J, et al. **Acta Psychol (Amst)** 1995 Nov;90(1–3):11–28

The availability versus the use of partial information: multiple levels of selective processing between perception and action. Smid HG, et al. **Acta Psychol (Amst)** 1995 Nov; 90(1–3):145–62

The effect of type A personality on physiological arousal while playing computer games. Griffiths MD, et al. **Addict Behav** 1995 Jul-Aug;20(4):543–8

Simulations of circadian system and vigilance during space missions. Achermann P, et al. **Adv Space Biol Med** 1996; 5:201–12

Failure to find postshock increases in ethanol preference. Fidler TL, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):110–21

Replication and extended analysis of behavior state, environmental events, and related variables among individuals with profound disabilities. Guess D, et al. **Am J Ment Retard** 1995 Jul;100(1):36–51

Electrodermal orienting activity in children with Down syndrome. Martinez-Selva JM, et al. **Am J Ment Retard** 1995 Jul;100(1):51–8

Arousal and cardiorespiratory responses to hypoxia in Prader-Willi syndrome. Arens R, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):283–7

The effect of sleep fragmentation on daytime function. Martin SE, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1328–32

Time-course of stepwise CPAP titration. Behavior of respiratory and neurological variables. Montserrat JM, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1854–9

Attachment and separation in young children. Field T. **Annu Rev Psychol** 1996;47:541–61 (45 ref.)

Sex differences in cardiovascular reactivity as a function of the appraised gender relevance of the stressor. Lash SJ, et al. **Behav Med** 1995 Summer;21(2):86–94

Overt orienting in the rat: parametric studies of cued detection of visual targets. Bushnell PJ. **Behav Neurosci** 1995 Dec;109(6):1095–105

Postconditioning isolation disrupts contextual conditioning: an experimental analysis. Rudy JW. **Behav Neurosci** 1996 Apr;110(2):238–46

"If I feel anxious, there must be danger": ex-consequentia reasoning in inferring danger in anxiety disorders. Arntz A, et al. **Behav Res Ther** 1995 Nov;33(8):917–25

Aetiology of spider phobia: classificatory differences between two origins instruments. Kirkby KC, et al. **Behav Res Ther** 1995 Nov;33(8):955–8

Experimental manipulations of responsibility: an analogue test for models of obsessive-compulsive disorder. Ladouceur R, et al. **Behav Res Ther** 1995 Nov;33(8):937–46

Change in danger cognitions in agoraphobia and social phobia during treatment. Poulton RG, et al. **Behav Res Ther** 1996 May-Jun;34(5–6):413–21

Cognition-behaviour links in the persistence of panic. Salkovskis PM, et al. **Behav Res Ther** 1996 May-Jun; 34(5–6):453–8

Stability of catastrophic cognitions in panic disorder. Zoellner LA, et al. **Behav Res Ther** 1996 May-Jun; 34(5–6):399–402

Delayed startle sensitization distinguishes rats exposed to one or three stress sessions: further evidence toward an animal model of PTSD. Servatius RJ, et al. **Biol Psychiatry** 1995 Oct 15;38(8):539–46

Psychological and cardiovascular predictors of anaesthesia induction, operative and post-operative complications in minor gynaecological surgery. Abbott J, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):613–25

Aversive stimulation by staff and violence by psychiatric patients. Whittington R, et al. **Br J Clin Psychol** 1996 Feb; 35 (Pt 1):11–20

Sleep apnea impairs the arousal response to airway occlusion [see comments] Berry RB, et al. **Chest** 1996 Jun; 109(6):1490–6. Comment in: Chest 1996 Jun;109(6):1417–9.

The effects of work intensity on adolescent mental health, achievement, and behavioral adjustment: new evidence from a prospective study. Mortimer JT, et al. **Child Dev** 1996 Jun;67(3):1243–61

Anxiety and the processing of emotionally threatening stimuli: distinctive patterns of selective attention among high- and low-test-anxious children. Vasey MW, et al. **Child Dev** 1996 Jun;67(3):1173–85

Infant affective reactions to the resumption of maternal interaction after the still-face. Weinberg MK, et al. **Child Dev** 1996 Jun;67(3):905–14

Auditory startle response during exposure to war stress. Shalev AY, et al. **Compr Psychiatry** 1996 Mar-Apr; 37(2):134–8

A novel demonstration of enhanced memory associated with emotional arousal. Cahill L, et al. **Conscious Cogn** 1995 Dec;4(4):410–21

Asymmetry of finger temperature and early behavior. Kagan J, et al. **Dev Psychobiol** 1995 Dec;28(8):443–51

Social context and sensation seeking: gender differences in college student drinking motivations. Beck KH, et al. **Int J Addict** 1995 Jul;30(9):1101–15

Smoking cessation leads to reduced stress, but why? Parrott AC. **Int J Addict** 1995 Sep;30(11):1509–16 (17 ref.)

Inability to dehypnotize--implications for management: a brief communication. Gravitz MA. **Int J Clin Exp Hypn** 1995 Oct;43(4):369–74

Trait factors, state effects, and hypnotizability. Kumar VK, et al. **Int J Clin Exp Hypn** 1996 Jul;44(3):232–49

The Pavlovian "principle of strength". Windholz G. **Integr Physiol Behav Sci** 1995 Jul-Sep;30(3):228–36

Expectations about arousal and nocturnal panic. Craske MG, et al. **J Abnorm Psychol** 1995 Nov;104(4):567–75

Cognitive biases in generalized social phobia. Foa EB, et al. **J Abnorm Psychol** 1996 Aug;105(3):433–9

Tripartite structure of positive and negative affect, depression, and anxiety in child and adolescent psychiatric inpatients. Joiner TE Jr, et al. **J Abnorm Psychol** 1996 Aug; 105(3):401–9

Anxiety sensitivity, suffocation fear, and breath-holding duration as predictors of response to carbon dioxide challenge. McNally RJ, et al. **J Abnorm Psychol** 1996 Feb; 105(1):146–9

Anxiety and the use of strategies in the performance of a sentence-picture verification task. Richards A, et al. **J Abnorm Psychol** 1996 Feb;105(1):132–6

Anxiety sensitivity and depression: how are they related? Taylor S, et al. **J Abnorm Psychol** 1996 Aug;105(3):474–9

Effects of focus of attention on anxiety levels and social performance of individuals with social phobia. Woody SR. **J Abnorm Psychol** 1996 Feb;105(1):61–9

Prevailing mood, mood changes and dreams in bipolar disorder. Beauchemin KM, et al. **J Affect Disord** 1995 Oct 9;35(1–2):41–9

Sensation-seeking and emotional disturbances in depression: relationships and evolution. Carton S, et al. **J Affect Disord** 1995 Jun 8;34(3):219–25

Retardation of mentation in depressives: Posner's covert orientation of visual attention test. Smith MJ, et al. **J Affect Disord** 1995 Dec 13;35(3):107–15

Psychophysiological detection through the guilty knowledge technique: effects of mental countermeasures. Ben-Shakhar G, et al. **J Appl Psychol** 1996 Jun;81(3):273–81

On the origin of eye movement desensitization [comment] Rosen GM. **J Behav Ther Exp Psychiatry** 1995 Jun; 26(2):121–2. Comment on: J Behav Ther Exp Psychiatry 1989 Sep;20(3):211–7.

The relationship of various measures of time urgency to indices of physical health. Wright L, et al. **J Clin Psychol** 1995 Sep;51(5):610–4

Laboratory studies of antipredator behavior in the Mongolian gerbil (Meriones unguiculatus): factors affecting response attenuation with repeated presentations. Ellard CG. **J Comp Psychol** 1996 Jun;110(2):155–63

Assessment of danger to themselves and their infants by rhesus macaque (Macaca mulatta) mothers. Maestripieri D. **J Comp Psychol** 1995 Dec;109(4):416–20

Early auditory experience and the ontogeny of alarm-call discrimination in Belding's ground squirrels (Spermophilus beldingi). Mateo JM. **J Comp Psychol** 1996 Jun; 110(2):115–24

The relationship between vivid description, emotional arousal, and in-session resolution of problematic reactions.

Watson JC. **J Consult Clin Psychol** 1996 Jun;64(3):459–64

Behavioral variability in SHR and WKY rats as a function of rearing environment and reinforcement contingency. Hunziker MH, et al. **J Exp Anal Behav** 1996 Jan; 65(1):129–44

Habituation of the orienting response to stimuli of different functional values in 4-month old infants. Malcuit G, et al. **J Exp Child Psychol** 1996 Jul;62(2):272–91

Role of stimulus ambiguity in conditional learning. de Brugada I, et al. **J Exp Psychol Anim Behav Process** 1995 Oct;21(4):275–84

Impact of shock on pain reactivity: I. Whether hypo- or hyperalgesia is observed depends on how pain reactivity is tested. Illich PA, et al.
J Exp Psychol Anim Behav Process 1995 Oct;21(4):331–47

Affect intensity and individual differences in informational style. Larsen RJ, et al. **J Pers** 1996 Mar;64(1):185–207

Variability in automatic activation as an unobtrusive measure of racial attitudes: a bona fide pipeline? Fazio RH, et al. **J Pers Soc Psychol** 1995 Dec;69(6):1013–27

Effects of adult attachment and presence of romantic partners on physiological responses to stress. Feeney BC, et al. **J Pers Soc Psychol** 1996 Feb;70(2):255–70

Social evaluation and cardiovascular response: an active coping approach. Wright RA, et al. **J Pers Soc Psychol** 1995 Sep;69(3):530–43

Does high 'action-proneness' make people more vulnerable to chronic fatigue syndrome? A controlled psychometric study. Van Houdenhove B, et al. **J Psychosom Res** 1995 Jul;39(5):633–40

Stress and alcohol: the moderating effect of chronic stress on the acute stress—intoxication relationship. Breslin FC, et al. **J Stud Alcohol** 1995 Sep;56(5):546–52

Stress, smoking, and the cardiovascular system. Pomerleau OF, et al. **J Subst Abuse** 1989;1(3):331–43 (50 ref.)

Stress and arousal in deployment of a combat support hospital. Hall DP Jr, et al. **Mil Med** 1995 Nov; 160(11):581–3

Age and stress history effects on spatial performance in a swim task in Fischer-344 rats. Mabry TR, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):1–10

Habituation and sensitization of the acoustic startle response in rats: amplitude, threshold, and latency measures. Pilz PKD, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):67–79

Sustained arousal and attention after traumatic brain injury. Whyte J, et al. **Neuropsychologia** 1995 Jul;33(7):797–813

Pain in infancy: individual differences. Axia G, et al. **Percept Mot Skills** 1995 Aug;81(1):142

Motor performance of schizophrenics after mellow and frenetic antecedent music. Chambliss C, et al. **Percept Mot Skills** 1996 Feb;82(1):153–4

Observation of response strategies in cycling time trials. DeFrancesco C, et al. **Percept Mot Skills** 1995 Aug; 81(1):299–304

Stimulus-driven or autonomous shift or attention? Hsieh S. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1187–99

Reactivity in extroverts and introverts. Hunt AE, et al. **Percept Mot Skills** 1996 Apr;82(2):526

Instantaneous change in sleep stage with noise of a passing truck. Kawada T, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):1031–40

Relations among heart rate, immediate memory, and time estimation under two different instructions. Osato E, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):831–42

Temporal delays in incorporation of events into dreams [see comments] Powell RA, et al. **Percept Mot Skills** 1995 Aug; 81(1):95–104. Comment in: Percept Mot Skills 1996 Feb;82(1):88–90.

Temporal consistency and stability of three scales for measuring stress in adults. Rossini ED, et al. **Percept Mot Skills** 1996 Apr;82(2):588–90

Zero effect of crowding on arousal and performance: on 'proving' the null hypothesis. Rousseau F, et al. **Percept Mot Skills** 1995 Aug;81(1):72–4

Enhancement of randomness by flotation rest (restricted environmental stimulation technique). Sakata S, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):999–1010

Scores on sensation seeking as a predictor of sexual activities among homosexuals. Schroth ML. **Percept Mot Skills** 1996 Apr;82(2):657–8

Discriminant effectiveness of psychological state measures in predicting performance outcome in karate competition. Terry PC, et al. **Percept Mot Skills** 1995 Aug;81(1):275–86

Physiological sensations of initial smoking in the development of regular smoking behavior. Wang MQ, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1131–4

Analysis by gender and Visual Imagery Reactivity of conventional and imagery Rorschach. Yanovski A, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1319–40

Predicting perceptual defense. York MW, et al. **Percept Mot Skills** 1996 Feb;82(1):185–6

Cognitive and psychophysiological correlates of positive, negative, and disorganized symptoms in the schizophrenia spectrum. Brekke JS, et al. **Psychiatry Res** 1995 Aug 28; 57(3):241–50

Antidepressant responses and changes in visual adaptation after sleep deprivation. Sokolski KN, et al. **Psychiatry Res** 1995 Aug 28;57(3):197–207

Effects of delay of reinforcement with reduction of confinement in the goal-box and elimination of handling immediately following runway traversal. Calef RS, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1147–51

Pupil dilation as a measure of processing load in simultaneous interpretation and other language tasks. Hyönä J, et al. **Q J Exp Psychol A** 1995 Aug;48(3):598–612

Sleep and arousal in adolescents and adults with nocturnal enuresis. Hunsballe JM, et al. **Scand J Urol Nephrol Suppl** 1995;173:59–60; discussion 60–1

Seizures and arousals from sleep—which comes first? Malow BA, et al. **Sleep** 1995 Nov;18(9):783–6

[Early attachment experiences and behavioral problems in young children in a social and cognitive test situation] Ziegenhain U, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Mar-Apr;45(3-4):95–102 (Eng. Abstr.) **(Ger)**

[Modification of performance by activation in the elderly] Hüppe M, et al. **Z Exp Psychol** 1996;43(1):69–84 (Eng. Abstr.) **(Ger)**

[Hypopnea according to various definitions and coexisting arousal response in patients with sleep-disordered breathing] Nakano H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep;33(9):981–7 (Eng. Abstr.) **(Jpn)**

[The morphometric characteristics of the serotonin-producing cells of the intestines in the red-cheeked suslik during its spontaneous arousal] Dubinin EV, et al. **Morfologiia** 1994 Jul-Dec;107(7-12):111–9 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Predictors for altering caffeine consumption during stress. Ratliff-Crain J, et al. **Addict Behav** 1995 Jul-Aug; 20(4):509–16

Measuring cocaine effect expectancies among therapeutic community inpatients. Schafer J, et al. **Addict Behav** 1996 Mar-Apr;21(2):205–10

Influence of CGS 8216 on some acute effects of ethanol. Kotlińska J, et al. **Alcohol Alcohol** 1995 Sep;30(5):601–5

Low-dose effect of ethanol on locomotor activity induced by activation of the mesolimbic system. Milton GV, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):768–76

Mutations affecting sensitivity to ethanol in the nematode, Caenorhabditis elegans. Morgan PG, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1423–9

Alcohol reactions in subjects of European descent: effects on alcohol use and on physical and psychomotor responses to alcohol. Whitfield JB, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):81–6

Effects of hostility on alcohol stress-response-dampening. Zeichner A, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):977–83

Concentrations of desflurane and propofol that suppress response to command in humans. Chortkoff BS, et al. **Anesth Analg** 1995 Oct;81(4):737–43

Improved arousal and initiation following tricyclic antidepressant use in severe brain injury. Reinhard DL, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):80–3

Amphetamine-induced conditioned activity in rats: comparison with novelty-induced activity and role of the basolateral amygdala. Ahmed SH, et al. **Behav Neurosci** 1995 Aug;109(4):723–33

Stress controllability influences the ataxic properties of both ethanol and midazolam in the rat. Drugan RC, et al. **Behav Neurosci** 1996 Apr;110(2):360–7

Clonidine antagonizes the aversive effects of opiate withdrawal and the rewarding effects of morphine only in opiate withdrawn rats. Nader K, et al. **Behav Neurosci** 1996 Apr;110(2):389–400

Classical conditioning in the fetal rat: reinforcing properties of dynorphin A (1-13). Varlinskaya EI, et al. **Behav Neurosci** 1996 Feb;110(1):154–67

Cocaine enhances the expression of fear-potentiated startle: evaluation of state-dependent extinction and the shock-sensitization of acoustic startle. Willick ML, et al. **Behav Neurosci** 1995 Oct;109(5):929–38

Thyrotropin-releasing hormone: a potential comparator for the panicogenic effects of pentagastrin and CCK? [letter; comment] Coupland N, et al. **Biol Psychiatry** 1996 Mar 15;39(6):465–6. Comment on: Biol Psychiatry 1994 Jul 15;36(2):73–83.

Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Goddard AW, et al. **Biol Psychiatry** 1995 Jul 15;38(2):74–85

Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Strassman RJ, et al. **Biol Psychiatry** 1996 May 1;39(9):784–95

SSRI and sympathomimetic interaction [letter] Blue P. **Br J Psychiatry** 1996 May;168(5):653

Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Cheskin LJ, et al. **Drug Alcohol Depend** 1995 Aug;39(2):151–4

Carbamazepine and cocaine-cue reactivity. Hersh D, et al. **Drug Alcohol Depend** 1995 Oct;39(3):213–21

Pharmacologically induced changes in arousal: effects on behavioral and electrophysiologic measures of alertness and attention. Oken BS, et al. **Electroencephalogr Clin Neurophysiol** 1995 Nov; 95(5):359–71

Diazepam blocks fear-potentiated startle in humans. Patrick CJ, et al. **J Abnorm Psychol** 1996 Feb;105(1):89–96

Synergistic anticholinergic and antiserotonergic effects in humans. Meador KJ, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):611–21

The effect of heavy social drinking on recall and event-related potentials. Nichols JM, et al. **J Stud Alcohol** 1996 Mar;57(2):125–35

Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Santucci V, et al. **Life Sci** 1996;58(6):PL103–10

Algorithm helps healthcare practitioners manage opioid-induced sedation. Skalla K. **Oncol Nurs Forum** 1996 Apr;23(3):542–3

Effect of dexfenfluramine on metabolic and neurochemical measures in restraint-stressed ob/ob mice. Rowland NE, et al. **Physiol Behav** 1995 Oct;58(4):749–54

Antimanic drugs stabilize hamster circadian rhythms. Klemfuss H, et al. **Psychiatry Res** 1995 Aug 28;57(3):215–22

Type I and type II schizophrenia: relations between tonic electrodermal activity and clinical ratings before and after haloperidol treatment. Maina G, et al. **Psychiatry Res** 1995 Jun 29;57(1):49–56

Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Waddington JL, et al. **Psychol Med** 1995 Jul;25(4):849–57

Chronic psychiatric patients' use of caffeine: pharmacological effects and mechanisms. Kruger A. **Psychol Rep** 1996 Jun; 78(3 Pt 1):915–23 (50 ref.)

Comparison of the effects of nicotine on a fixed rate and a subject-paced version of the rapid information processing task. Baldinger B, et al. **Psychopharmacology (Berl)** 1995 Oct;121(3):396–400

Habituation of orienting reaction in therapy-resistant partial epilepsy. Rogozea R, et al. **Rom J Neurol Psychiatry** 1995 Jan-Mar;33(1):7–27

[EEG changes during propofol-alfentanil-nitrous oxide anesthesia] Arndt VM, et al. **Anaesthesiol Reanim** 1995; 20(5):126–33 (Eng. Abstr.) **(Ger)**

[Plasma catecholamine level and clinical parameters—quality criteria for premedication in childhood] Burkhardt U, et al. **Anaesthesiol Reanim** 1995;20(4):88–96 (Eng. Abstr.) **(Ger)**

[Comparison of various methods of anesthesia by plasma catecholamine determination] Hertel VG, et al. **Anaesthesiol Reanim** 1995;20(5):116–25 (Eng. Abstr.) **(Ger)**

[Intraoperative awareness and auditory evoked potentials] Schwender D, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S46–51 (30 ref.) (Eng. Abstr.) **(Ger)**

[Clonidine increases the anesthetic effectiveness of thiopental] Tonner PH, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):357–60 (Eng. Abstr.) **(Ger)**

[Rates of awakening, circulatory parameters and side-effects with sevoflurane and enflurane. An open, randomized, comparative phase III study] Wiesner G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):290–6 (Eng. Abstr.) **(Ger)**

[Vigilance-decreasing effects of 2 plant-derived sedatives] Gerhard U, et al. **Schweiz Rundsch Med Prax** 1996 Apr 9;85(15):473–81 (Eng. Abstr.) **(Ger)**

GENETICS

A simple auditory oddball task in young adult males at high risk for alcoholism. Ramachandran G, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):9–15

Genetic analysis of the relationships between behavioral and neuroendocrine traits in Roman High and Low Avoidance rat lines. Castanon N, et al. **Behav Genet** 1995 Jul; 25(4):371–84

Selective breeding for extremes in open-field activity of mice entails a differentiation of hippocampal mossy fibers. Hausheer-Zarmakupi Z, et al. **Behav Genet** 1996 Mar; 26(2):167–76

A multivariate genetic analysis of sensation seeking. Koopmans JR, et al. **Behav Genet** 1995 Jul;25(4):349–56

Genetic analysis of anxiety-related behaviors and responses to benzodiazepine-related drugs in AXB and BXA recombinant inbred mouse strains. Mathis C, et al. **Behav Genet** 1995 Nov;25(6):557–68

Quantitative trait loci associated with the behavioral response of B x D recombinant inbred mice to restraint stress: a preliminary communication. Tarricone BJ, et al. **Behav Genet** 1995 Sep;25(5):489–95

Genetic analysis of the corticosterone response to ethanol in BXD recombinant inbred mice. Roberts AJ, et al. **Behav Neurosci** 1995 Dec;109(6):1199–208

Salivary cortisol responses and the risk for substance abuse in prepubertal boys. Moss HB, et al. **Biol Psychiatry** 1995 Oct 15;38(8):547–55

Developmental and genetic influences on the P50 sensory gating phenotype. Myles-Worsley M, et al. **Biol Psychiatry** 1996 Feb 15;39(4):289–95

Spectral analysis of EEG from families. Eischen SE, et al. **Biol Psychol** 1995 Aug;41(1):61–8

Evoked potentials in subjects at risk for Alzheimer's disease. Boutros N, et al. **Psychiatry Res** 1995 Jun 29;57(1):57–63

Parental history of hypertension, sodium loading, and cardiovascular response to stress. Miller SB, et al. **Psychosom Med** 1995 Jul-Aug;57(4):381–9

PHYSIOLOGY

Sympathetic skin response in Parkinson's disease. Hirashima F, et al. **Acta Neurol Scand** 1996 Feb-Mar;93(2-3):127–32

Clinical and electrophysiological findings in the Tullio phenomenon. Bronstein AM, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:209–11

The role of neuroimaging in the discovery of processing stages. A review. Mulder G, et al. **Acta Psychol (Amst)** 1995 Nov;90(1–3):63–79 (66 ref.)

Bisecting RT with lateralized readiness potentials: precue effects of LRP onset. OosmanA, et al. **Acta Psychol (Amst)** 1995 Nov;90(1–3):111–27

The temporal selectivity of additive factor effects on the reaction process revealed in ERP component latencies. Smulders FT, et al. **Acta Psychol (Amst)** 1995 Nov; 90(1–3):97–109

The role of autonomic arousal in problem gambling. Sharpe L, et al. **Addiction** 1995 Nov;90(11):1529–40

Corticotropin–releasing hormone involvement in stressor–induced alterations in sleep and in the regulation of waking. Opp MR. **Adv Neuroimmunol** 1995;5(2):127–43 (100 ref.)

Test–retest precision of functional MR in sensory and motor task activation. Yetkin FZ, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):95–8

Cue–exposure to alcohol–associated stimuli reduces autonomic reactivity, but not craving and anxiety, in dependent drinkers. McCusker CG, et al. **Alcohol Alcohol** 1995 May;30(3):319–27

Delayed P3A in abstinent elderly male chronic alcoholics. Biggins CA, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):1032–42

Auditory event–related potentials in fetal alcohol syndrome and Down's syndrome children. Kaneko WM, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):35–42

Fetal ethanol exposure: hypothalamic–pituitary–adrenal and beta–endorphin responses to repeated stress. Weinberg J, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):122–31

Event–related potentials and information processing in infants with and without Down syndrome. Karrer R, et al. **Am J Ment Retard** 1995 Sep;100(2):146–59

High autonomic arousal and electrodermal orienting at age 15 years as protective factors against criminal behavior at age 29 years. Raine A, et al. **Am J Psychiatry** 1995 Nov; 152(11):1595–600

Movement arousals and sleep–related disordered breathing in adults. Collard P, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):454–9

Brain imaging and cognitive neuroscience. Toward strong inference in attributing function to structure. Sarter M, et al. **Am Psychol** 1996 Jan;51(1):13–21 (75 ref.)

Acute pain and central nervous system arousal do not restore impaired hypoxic ventilatory response during sevoflurane sedation. Sarton E, et al. **Anesthesiology** 1996 Aug; 85(2):295–303

Effects of postnatal stimulation on the passive avoidance behaviour of young rats. Gschanes A, et al. **Behav Brain Res** 1995 Oct;70(2):191–6

Lateralization and stress responses in mice: interindividual differences in the association of brain, neuroendocrine, and immune responses. Neveu PJ. **Behav Genet** 1996 Jul; 26(4):373–7

Relationship of anxiety, stress, and psychosocial development to reproductive health [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):101–12 (110 ref.). Comment in: Behav Med 1995 Fall;21(3):123–9.

A time–structured analysis of hypothalamically induced increases in self–grooming and activity in the rat. Bressers WM, et al. **Behav Neurosci** 1995 Dec;109(6):1158–71

Effects of lesions to amygdala, ventral subiculum, medial prefrontal cortex, and nucleus accumbens on the reaction to novelty: implication for limbic–striatal interactions. Burns LH, et al. **Behav Neurosci** 1996 Feb;110(1):60–73

Conditioned diminution of the unconditioned response in rabbit eyeblink conditioning: identifying neural substrates in the cerebellum and brainstem. Canli T, et al. **Behav Neurosci** 1995 Oct;109(5):874–92

The isolation and companion comfort responses of 7– and 3–day–old rat pups are modulated by drugs active at the opioid receptor. Carden SE, et al. **Behav Neurosci** 1996 Apr;110(2):324–30

Fear–potentiated startle and electrically evoked startle mediated by synapses in rostrolateral midbrain. Frankland PW, et al. **Behav Neurosci** 1995 Aug;109(4):669–80

The physiology of social conflict in rats: what is particularly stressful? Haller J, et al. **Behav Neurosci** 1996 Apr; 110(2):353–9

Effects of peripherally administered corticotropin–releasing factor (CRF) and a CRF antagonist: does peripheral CRF activity mediate behavior of guinea pig pups during isolation? Hennessy MB, et al. **Behav Neurosci** 1995 Dec; 109(6):1137–45

Prepulse inhibition in the rat is regulated by ventral and caudodorsal striato–pallidal circuitry. Kodsi MH, et al. **Behav Neurosci** 1995 Oct;109(5):912–28

Stimulus–elicited behavior in rapid eye movement sleep without atonia. Morrison AR, et al. **Behav Neurosci** 1995 Oct;109(5):972–9

Poststimulation excitability of ventral pallidum self–stimulation neurons. Panagis G, et al. **Behav Neurosci** 1995 Aug;109(4):777–81

Effects of exposure to stressors of varying predictability on adrenal function in rats. Pitman DL, et al. **Behav Neurosci** 1995 Aug;109(4):767–76

Hyperexcitability: exaggerated fear–potentiated startle produced by partial amygdala kindling. Rosen JB, et al. **Behav Neurosci** 1996 Feb;110(1):43–50

Amygdala central nucleus lesions attenuate acoustic startle stimulus–evoked heart rate changes in rats. Young BJ, et al. **Behav Neurosci** 1996 Apr;110(2):228–37

Effects of sleep deprivation on spontaneous eye blink rate and alpha EEG power. Barbato G, et al. **Biol Psychiatry** 1995 Sep 1;38(5):340–1

Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Castellanos FX, et al. **Biol Psychiatry** 1996 Jan 1;39(1):33–41

Plasma neurotransmitters, blood pressure, and heart rate during supine–resting, orthostasis, and moderate exercise conditions in major depressed patients. Lechin F, et al. **Biol Psychiatry** 1995 Aug 1;38(3):166–73

Nocturnal/daytime urine noradrenergic measures and sleep in combat–related PTSD. Mellman TA, et al. **Biol Psychiatry** 1995 Aug 1;38(3):174–9

Quantitative EEG in never–treated schizophrenic patients. Omori M, et al. **Biol Psychiatry** 1995 Sep 1;38(5):305–9

Autonomic characteristics of generalized anxiety disorder and worry. Thayer JF, et al. **Biol Psychiatry** 1996 Feb 15; 39(4):255–66

Prolactin and cortisol responses to fenfluramine challenge in mania. Yatham LN. **Biol Psychiatry** 1996 Feb 15; 39(4):285–8

Hemoconcentration and stress: a review of physiological mechanisms and relevance for cardiovascular disease risk. Allen MT, et al. **Biol Psychol** 1995 Aug;41(1):1–27 (125 ref.)

Psychophysiological stress effects from the combination of night–shift work and noise. Boucsein W, et al. **Biol Psychol** 1996 Feb 5;42(3):301–22

Psychophysiological responses to changes in workload during simulated air traffic control. Brookings JB, et al. **Biol Psychol** 1996 Feb 5;42(3):361–77

Concentrations of sodium, potassium and cortisol in saliva, and self–reported chronic work stress factors. Burton RF, et al. **Biol Psychol** 1996 Feb 5;42(3):425–38

Psychophysiology and adaptive automation. Byrne EA, et al. **Biol Psychol** 1996 Feb 5;42(3):249–68 (75 ref.)

Visceral perception, anhedonia, and emotion. Ferguson ML, et al. **Biol Psychol** 1996 Jan 5;42(1–2):131–45

Work–physiological synchronization as a determinant of performance in repetitive computer work. Henning RA, et al. **Biol Psychol** 1996 Feb 5;42(3):269–86

Working with new technologies: hormone excretion as an indicator for sustained arousal. A pilot study. Korunka C, et al. **Biol Psychol** 1996 Feb 5;42(3):439–52

Electrooculographic and performance indices of fatigue during simulated flight. Morris TL, et al. **Biol Psychol** 1996 Feb 5;42(3):343–60

Occupational stress and strain of female students: results of physiological, behavioral, and psychological monitoring. Myrtek M, et al. **Biol Psychol** 1996 Feb 5;42(3):379–91

Perception of emotions in everyday life: studies with patients and normals. Myrtek M, et al. **Biol Psychol** 1996 Jan 5; 42(1–2):147–64

Psychophysiological assessment of human reliability in a simulated complex system. Rau R. **Biol Psychol** 1996 Feb 5;42(3):287–300

Intra–individual patterns of hormonal and affective adaptation to work demands: an n = 2 study of junior doctors. Robert G, et al. **Biol Psychol** 1996 Feb 5; 42(3):393–411

Symptom reporting in asthma patients and insulin–dependent diabetics. Schandry R, et al. **Biol Psychol** 1996 Jan 5; 42(1–2):231–44

Event–related brain potentials and the processing of cardiac activity. Schandry R, et al. **Biol Psychol** 1996 Jan 5; 42(1–2):75–85

Physiological indices of workload in a simulated flight task. Veltman JA, et al. **Biol Psychol** 1996 Feb 5;42(3):323–42

Effects of work demands on immunoglobulin A and cortisol in air traffic controllers. Zeier H, et al. **Biol Psychol** 1996 Feb 5;42(3):413–23

Classification of veterans with post–traumatic stress disorder using visual brain evoked P3s to traumatic stimuli. Attias J, et al. **Br J Psychiatry** 1996 Jan;168(1):110–5

Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Frith CD, et al. **Br J Psychiatry** 1995 Sep;167(3):343–9

Influence of level of identification with a group and physiological arousal on perceived intergroup complexity. Wann DL, et al. **Br J Soc Psychol** 1995 Sep;34 (Pt 3):223–35

Constructing arousal profiles for vegetative state patients—a preliminary report. Wilson SL, et al. **Brain Inj** 1996 Feb; 10(2):105–13

Tension headache [editorial; comment] Bogduk N. **Cephalalgia** 1996 Apr;16(2):77–8. Comment on: Cephalalgia 1996 Apr;16(2):97–103.

Pattern reversal visual evoked potentials in children with migraine or tension–type headache [see comments] Rossi LN, et al. **Cephalalgia** 1996 Apr;16(2):104–6. Comment in: Cephalalgia 1996 Apr;16(2):78.

Temperament and craniofacial variation in the first two years. Arcus D, et al. **Child Dev** 1995 Oct;66(5):1529–40

Sex differences in neonatal stress reactivity. Davis M, et al. **Child Dev** 1995 Feb;66(1):14–27

Neonatal stress reactivity: predictions to later emotional temperament. Gunnar MR, et al. **Child Dev** 1995 Feb; 66(1):1–13

Dampening of adrenocortical responses during infancy: normative changes and individual differences. Gunnar MR, et al. **Child Dev** 1996 Jun;67(3):877–89

Primary (idiopathic) generalized epilepsy and underlying mechanisms. Niedermeyer E. **Clin Electroencephalogr** 1996 Jan;27(1):1–21 (147 ref.)

Dyshormia revisited: generalized seizures and arousal. Nowack WJ. **Clin Electroencephalogr** 1996 Jan;27(1):22–5

P300 latency: abnormal in sleep apnea with somnolence and idiopathic hypersomnia, but normal in narcolepsy. Sangal RB, et al. **Clin Electroencephalogr** 1995 Jul;26(3):146–53

Psychosensorial and related phenomena in panic disorder and in temporal lobe epilepsy. Toni C, et al. **Compr Psychiatry** 1996 Mar–Apr;37(2):125–33

Electrodermal activity (EDA) and suicidal behavior [see comments] Wolfersdorf M, et al. **Crisis** 1996;17(2):69–77. Comment in: Crisis 1996;17(2):50.

Plasma cortisol and vocalization responses of postweaning age guinea pigs to maternal and sibling separation: evidence for filial attachment after weaning. Hennessy MB, et al. **Dev Psychobiol** 1995 Mar;28(2):103–15

Stability and change in cortisol and behavioral response to stress during the first 18 months of life. Lewis M, et al. **Dev Psychobiol** 1995 Dec;28(8):419–28

Psychophysiological correlates of infant temperament: stability of behavior and autonomic patterning from 5 to 18 months. Stifter CA, et al. **Dev Psychobiol** 1996 May; 29(4):379–91

Alerting effects on choice reaction time and the photic eyeblink reflex. Low KA, et al. **Electroencephalogr Clin Neurophysiol** 1996 May; 98(5):385–93

Clinical application of automatic integrative interpretation of awake background EEG: quantitative interpretation, report making, and detection of artifacts and reduced vigilance level. Nakamura M, et al. **Electroencephalogr Clin Neurophysiol** 1996 Feb; 98(2):103–12

Fast Fourier transform analysis of the masseter muscle EMG during reaction to a warning signal. Nakajima I. **Electromyogr Clin Neurophysiol** 1995 Aug–Sep;35(5):281–4

Surface electromyography as a tool to study the head rest comfort in cars. Lamotte T, et al. **Ergonomics** 1996 May; 39(5):781–96

Remote cortical dysfunction as a possible cause of subcortical neglect? A regional cerebral blood flow study. Hublet C, et al. **Eur Neurol** 1995;35(5):254–8

Possible involvement of the L–arginine–nitric oxide pathway in the modulation of stress–induced analgesia. Haulică I, et al. **Funct Neurol** 1995 Jul–Oct;10(4–5):169–73

Physiological response in healthy subjects and in patients after myocardial infarction, elicited by a new computerised version of the Raven Coloured PM 47 as a mental stress test. Pruneti CA, et al. **Funct Neurol** 1995 Jul–Oct; 10(4–5):195–201

Stressors, including social conflict, decrease plasma prolactin in male golden hamsters. Huhman KL, et al. **Horm Behav** 1995 Dec;29(4):581–92

Social effects and circadian rhythms in squirrel monkey pituitary–adrenal activity. Lyons DM, et al. **Horm Behav** 1995 Jun;29(2):177–90

Anticipatory blood pressure response to exercise predicts future high blood pressure in middle–aged men. Everson SA, et al. **Hypertension** 1996 May;27(5):1059–64

Smoking and EEG power spectra: effects of differences in arousal seeking. Cook MR, et al. **Int J Psychophysiol** 1995 Apr;19(3):247–56

Blocking and unconditioned response diminution in human classical autonomic conditioning. Kimmel HD, et al. **Integr Physiol Behav Sci** 1996 Jan–Mar;31(1):18–43

Event–related brain potentials elicited by rhyming and non–rhyming pictures differentiate subgroups of reading disabled adolescents. McPherson WB, et al. **Integr Physiol Behav Sci** 1996 Jan–Mar;31(1):3–17

Discrete, patterned and purposeful adaptive physiological adjustments integrated by forebrain influences. Wolf S. **Integr Physiol Behav Sci** 1995 Jul–Sep;30(3):190–9 (21 ref.)

Forebrain involvement in fatal cardiac arrhythmia. Wolf S. **Integr Physiol Behav Sci** 1995 Jul–Sep;30(3):215–25

Sociotropy, autonomy, and dysphoric emotional responses to specific classes of stress: a psychophysiological evaluation. Allen NB, et al. **J Abnorm Psychol** 1996 Feb; 105(1):25–33

Effect of psychological stress on airway impedance in individuals with asthma and panic disorder. Carr RE, et al. **J Abnorm Psychol** 1996 Feb;105(1):137–41

Biological challenge manipulation of PCO2 levels: a test of Klein's (1993) suffocation alarm theory of panic. Schmidt NB, et al. **J Abnorm Psychol** 1996 Aug;105(3):446–54

Immediate effects of arousal from sleep on cardiac autonomic outflow in the absence of breathing in dogs. Horner RL, et al. **J Appl Physiol** 1995 Jul;79(1):151–62

Effect of inspiratory pressure support on the arousal response to CO2 in sleeping dogs. Kim WS, et al. **J Appl Physiol** 1995 Nov;79(5):1419–25

Family history of hypertension and vasovagal symptoms during blood donation. Ditto B, et al. **J Behav Med** 1995 Aug;18(4):331–40

Assessment of the cardiovascular effects of stress. Engler MB, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):51–63 (85 ref.)

Dynamic neuroimaging of brain function. Simpson GV, et

al. **J Clin Neurophysiol** 1995 Sep;12(5):432–49 (65 ref.)
Endogenous event-related potentials in term and preterm infants. Tokioka AB, et al. **J Clin Neurophysiol** 1995 Sep; 12(5):468–75
Event-related potentials during delayed recognition of Wechsler Memory Scale-R paired associate learning. Holamon B, et al. **J Clin Psychol** 1995 May;51(3):391–5
Cortical localization of human sustained attention: detection with functional MR using a visual vigilance paradigm. Lewin JS, et al. **J Comput Assist Tomogr** 1996 Sep–Oct; 20(5):695–701
Relaxation training and opioid inhibition of blood pressure response to stress. McCubbin JA, et al. **J Consult Clin Psychol** 1996 Jun;64(3):593–601
Partial advance information and response preparation: inferences from the lateralized readiness potential. Leuthold H, et al. **J Exp Psychol Gen** 1996 Sep;125(3):307–23
Explicit and implicit learning of event sequences: evidence from event-related brain potentials. Eimer M, et al. **J Exp Psychol Learn Mem Cogn** 1996 Jul;22(4):970–87
Does peace prevent homosexuality? Schmidt G, et al. **J Homosex** 1995;28(3–4):269–75
Identified octopaminergic neurons provide an arousal mechanism in the locust brain. Bacon JP, et al. **J Neurophysiol** 1995 Dec;74(6):2739–43
Lateralization of prefrontal activation during internal mental calculation: a functional magnetic resonance imaging study. Burbaud P, et al. **J Neurophysiol** 1995 Nov;74(5):2194–200
Effects of auditory stimuli on intracranial pressure and cerebral perfusion pressure in traumatic brain injury. Schinner KM, et al. **J Neurosci Nurs** 1995 Dec;27(6):348–54
Individual differences in repressive-defensiveness predict basal salivary cortisol levels. Brown LL, et al. **J Pers Soc Psychol** 1996 Feb;70(2):362–71
Individual differences in cardiac sympathetic control predict endocrine and immune responses to acute psychological stress. Uchino BN, et al. **J Pers Soc Psychol** 1995 Oct; 69(4):736–43
Cardiac autonomic function during sleep of never-depressed borderline subjects: a pilot study. Battaglia M, et al. **J Psychiatr Res** 1995 Sep–Oct;29(5):397–405
Psychophysiological aspects of autistic disorders: overview. Murray JB. **J Psychol** 1996 Mar;130(2):145–58 (95 ref.)
Labor experience, maternal mood and cortisol and catecholamine levels in low-risk primiparous women. Mahomed K, et al. **J Psychosom Obstet Gynaecol** 1995 Dec; 16(4):181–6
Self-reported stressors, symptom complaints and psychobiological functioning I: Cardiovascular stress reactivity. Vingerhoets AJ, et al. **J Psychosom Res** 1996 Feb;40(2):177–90
Self-reported stressors, symptom complaints and psychobiological functioning–II: Psychoneuroendocrine variables. Vingerhoets AJ, et al. **J Psychosom Res** 1996 Feb;40(2):191–203
Auditory P3 event related potentials (ERP) and brainstem auditory evoked responses (BAER) after spinal cord injury in humans. Ament PA, et al. **J Spinal Cord Med** 1995 Jul; 18(3):208–15
Role of estradiol in alcohol intake and alcohol-related behaviors. Hilakivi-Clarke L. **J Stud Alcohol** 1996 Mar; 57(2):162–70
Influence of arousal and attention on the control of postural sway. Maki BE, et al. **J Vestib Res** 1996 Jan–Feb;6(1):53–9
Lipid peroxidation in lung of rat stressed by immobilization: effects of vitamin E supplementation. Kovacheva S, et al. **Lung** 1995;173(4):255–63
Click-evoked vestibulocollic reflexes in torticollis. Colebatch JG, et al. **Mov Disord** 1995 Jul;10(4):455–9
Enhancement of antibody production by a learning paradigm. Alvarez-Borda B, et al. **Neurobiol Learn Mem** 1995 Sep; 64(2):103–5
Influence of separate and combined septal and amygdala lesions on memory, acoustic startle, anxiety, and locomotor activity in rats. Decker MW, et al. **Neurobiol Learn Mem** 1995 Sep;64(2):156–68
Age-related changes in plasma catecholamine and glucose responses of F-344 rats to a single footshock as used in inhibitory avoidance training. Mabry TR, et al. **Neurobiol Learn Mem** 1995 Sep;64(2):146–55
Physiological activation of a cortical network during performance of the Wisconsin Card Sorting Test: a positron emission tomography study. Berman KF, et al. **Neuropsychologia** 1995 Aug;33(8):1027–46
Changes in alertness are a principal component of variance in the EEG spectrum. Makeig S, et al. **Neuroreport** 1995 Dec 29;7(1):213–6
Abnormal response to exercise, face immersion, and isoproterenol in children with the long QT syndrome. Katagiri-Kawade M, et al. **Pacing Clin Electrophysiol** 1995 Dec;18(12 Pt 1):2128–34
Autonomic dysfunction in newly diagnosed insulin-dependent diabetes mellitus children. Verrotti A, et al. **Pediatr Neurol** 1996 Jan;14(1):49–52
Effects of abdominal and thoracic breathing upon multiple-site electromyography and peripheral skin temperature. Boyer BA, et al. **Percept Mot Skills** 1995 Aug; 81(1):3–14
Brain-emitted event-related potentials recorded during rapid decision-making may be useful in monitoring the neuropathogenesis of the human immunodeficiency virus (HIV). Linnville SE. **Percept Mot Skills** 1995 Aug; 81(1):209–10
Cutaneous thresholds and anxiety: influence of eye orientation and lateral asymmetry. Naveteur J, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):707–16
Human EEG responses to classical music and simulated white noise: effects of a musical loudness component on consciousness. Ogata S. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):779–90
A study of physiological response during emotional imaging. Yogo Y, et al. **Percept Mot Skills** 1995 Aug;81(1):43–9
Circannual changes in the duration of the immobility response of rats in the forced swim test. Abel EL. **Physiol Behav** 1995 Sep;58(3):591–3
Sympathetic nervous system influences salt appetite in four strains of rats. Bourjeili N, et al. **Physiol Behav** 1995 Sep; 58(3):437–43
Emotional hyperthermia and performance in humans. Briese E. **Physiol Behav** 1995 Sep;58(3):615–8
Analysis of the possible altering function of the septal organ in rats: a lesional and behavioral study. Giannetti N, et al. **Physiol Behav** 1995 Nov;58(5):837–45
The pedunculopontine nucleus--auditory input, arousal and pathophysiology. Reese NB, et al. **Prog Neurobiol** 1995 Oct;47(2):105–33 (365 ref.)
Single-word auditory stimulation and regional cerebral blood flow as studied by SPECT. Beversdorf D, et al. **Psychiatry Res** 1995 Sep 29;61(3):181–9
Schizophrenic auditory hallucinations are associated with increased regional cerebral blood flow during verbal memory activation in a study using single photon emission computed tomography. Busatto GF, et al. **Psychiatry Res** 1995 Nov 10;61(4):255–64
A controlled positron emission tomography study of obsessive and neutral auditory stimulation in obsessive-compulsive disorder with checking rituals. Cottraux J, et al. **Psychiatry Res** 1996 Mar 29; 60(2–3):101–12
Numbers of preceding nontargets differentially affect responses to targets in normal volunteers and patients with schizophrenia: a study of event-related potentials. Gonsalvez CJ, et al. **Psychiatry Res** 1995 Sep 8;58(1):69–75
Regional differentiation of cortical activity in schizophrenia: a complementary approach to conventional analysis of regional cerebral blood flow. Hook S, et al. **Psychiatry Res** 1995 Aug 8;61(2):85–93
Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormones, and cortisol in schizophrenia. Rao ML, et al. **Psychiatry Res** 1995 Jun 29;57(1):21–39
Abnormal saccadic distractibility in patients with schizophrenia: a 99mTc-HMPAO SPET study. Crawford TJ, et al. **Psychol Med** 1996 Mar;26(2):265–77
Aberrant interhemispheric alpha coherence on electroencephalography in schizophrenic patients during activation tasks. Morrison-Stewart SL, et al. **Psychol Med** 1996 May;26(3):605–12
Neurofunctional mechanisms in autism. Waterhouse L, et al. **Psychol Rev** 1996 Jul;103(3):457–89 (280 ref.)
Acute stress markers in humans: response of plasma glucose, cortisol and prolactin to two examinations differing in the anxiety they provoke. Armario A, et al. **Psychoneuroendocrinology** 1996 Jan;21(1):17–24
Chronic social stress produces reductions in available splenic type II corticosteroid receptor binding and plasma corticosteroid binding globulin levels. Spencer RL, et al. **Psychoneuroendocrinology** 1996 Jan;21(1):95–109
Epidermal cell proliferative activity assessed by proliferating cell nuclear antigen (PCNA) decreases following immobilization-induced stress in male Syrian hamsters. Tsuchiya T, et al. **Psychoneuroendocrinology** 1996 Jan; 21(1):111–7
Predicting sleep latency from the three-process model of alertness regulation. Akerstedt T, et al. **Psychophysiology** 1996 Jul;33(4):385–9
Determinants of subjective experience of sexual arousal in women: feedback from genital arousal and erotic stimulus content. Laan E, et al. **Psychophysiology** 1995 Sep; 32(5):444–51
Assessment of female sexual arousal: response specificity and construct validity. Laan E, et al. **Psychophysiology** 1995 Sep;32(5):476–85
Self-efficacy as a moderator of perceived control effects on cardiovascular reactivity: is enhanced control always beneficial? Gerin W, et al. **Psychosom Med** 1995 Jul–Aug; 57(4):390–7
Gender differences in patterns of dynamic cardiovascular regulation. Lawler KA, et al. **Psychosom Med** 1995 Jul–Aug;57(4):357–65
Power spectral analysis of heart rate variability in healthy young women during the normal menstrual cycle. Sato N, et al. **Psychosom Med** 1995 Jul–Aug;57(4):331–5
Relationships between thyroid hormones and symptoms in combat-related posttraumatic stress disorder. Wang S, et al. **Psychosom Med** 1995 Jul–Aug;57(4):398–402
Information processing during eye tracking as revealed by event-related potentials in schizophrenics, alcoholics, and healthy controls. Kathmann N, et al. **Schizophr Res** 1995 Aug 1;16(2):145–56
Glucose metabolic correlates of continuous performance test performance in adults with a history of infantile autism, schizophrenics, and controls. Siegel BV Jr, et al. **Schizophr Res** 1995 Sep;17(1):85–94
Arousal: revisiting the reticular activating system [comment] Steriade M. **Science** 1996 Apr 12;272(5259):225–6 (14 ref.) . Comment on: Science 1996 Apr 12;272(5259):271–4. Comment on: Science 1996 Apr 12;272(5259):274–7.
Slow wave sleep and cyclic alternating pattern (CAP) in HIV-infected asymptomatic men. Ferini-Strambi L, et al. **Sleep** 1995 Jul;18(6):446–50
Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. Szymusiak R. **Sleep** 1995 Jul; 18(6):478–500 (181 ref.)
Psychosocial and behavioral factors associated with serum lipids in university students. Undén AL, et al. **Soc Sci Med** 1995 Oct;41(7):915–22
[Electrodermal reactivity in schizophrenic women with so-called basic symptoms] Wolfersdorf M, et al. **Fortschr Neurol Psychiatr** 1995 Sep;63(9):363–7 (Eng. Abstr.) **(Ger)**
[Cerebral activation studies with PET and fMRT, clinical relevance?] Brandt T. **Nervenarzt** 1995 Dec;66(12):942–5 **(Ger)**
[Sympathetic skin response in Parkinson syndrome] Jost WH, et al. **Nervenarzt** 1995 Oct;66(10):777–80 (Eng. Abstr.) **(Ger)**
[Intracranial blood flow parameters in cerebral functional changes and cognitive cerebral performance] Klingelhöfer J, et al. **Nervenarzt** 1996 Apr;67(4):283–93 (Eng. Abstr.) **(Ger)**
[Psychobiology of motivation and organization of psychological aspects from the viewpoint of a hierarchical model] Gedo JE. **Psyche (Stuttg)** 1996 May;50(5):386–406 (Eng. Abstr.) **(Ger)**
[Approximation of sleep duration and sleep efficiency using actography] Wallner F, et al. **Wien Med Wochenschr** 1995; 145(17–18):497–8 (Eng. Abstr.) **(Ger)**
[Psychological stress and neuronal plasticity. An expanded model of the stress reaction process as the basis for understand central nervous system adaptation processes] Huether G, et al. **Z Psychosom Med Psychoanal** 1996; 42(2):107–27 (70 ref.) (Eng. Abstr.) **(Ger)**

RADIATION EFFECTS

Detrimental influence of bright light exposure on alertness, performance, and mood in the early morning. Daurat A, et al. **Neurophysiol Clin** 1996;26(1):8–14

ARRHENOBLASTOMA see **ANDROBLASTOMA**

ARRHYTHMIA

see related
ANTI-ARRHYTHMIA AGENTS
ELECTRIC COUNTERSHOCK

LEOPARD syndrome associated with steatocystoma multiplex and hyperelastic skin. Report of a Japanese case [letter] Mochizuki-Osawa M, et al. **Acta Derm Venereol** 1995 Jul;75(4):323–4
Arrhythmias. **Curr Opin Cardiol** 1996 Jan;11(1):B1–23
Cesarean delivery for intrapartum fetal heart rate abnormalities: incorporating survey data into clinical judgment. Skupski DW, et al. **Obstet Gynecol** 1996 Jul; 88(1):60–4
[Arrhythmia after surgery for congenital cardiopathies. What studies? What treatment?] Friedli B. **Arch Mal Coeur Vaiss** 1996 Mar;89(3):351–7 (Eng. Abstr.) **(Fre)**

BLOOD

[Environmental medicine evaluation of increased blood levels of hazardous materials in cardiac arrhythmias] Letzel S. **Dtsch Med Wochenschr** 1996 May 10;121(19):641–2 **(Ger)**

CHEMICALLY INDUCED

Cardiac electrophysiology, arrhythmogenic mechanisms and roentgen contrast media. Jacobsen EA, et al. **Acta Radiol Suppl** 1995;399:105–14 (60 ref.)
ST segment elevations without myocardial infarction in a patient on clozapine [letter] Ketch J, et al. **Am J Emerg Med** 1996 Jan;14(1):111–2
Proarrhythmic and antiarrhythmic actions of ion channel blockers on arrhythmias in the heart: model study. Chay TR. **Am J Physiol** 1996 Jul;271(1 Pt 2):H329–56
Cardiac effects of standard-dose halofantrine therapy. Matson PA, et al. **Am J Trop Med Hyg** 1996 Mar; 54(3):229–31
Sevoflurane is equivalent to isoflurane for attenuating bupivacaine-induced arrhythmias and seizures in rats. Fukuda H, et al. **Anesth Analg** 1996 Sep;83(3):570–3
Do diuretics cause heart disease? [letter; comment] Shivkumar K, et al. **Ann Intern Med** 1995 Dec 1; 123(11):891–2. Comment on: Ann Intern Med 1995 Feb 1;122(3):223–6.
Urban ectopy in the mountains: carbon monoxide exposure at high altitude. Leaf DA, et al. **Arch Environ Health** 1996 Jul–Aug;51(4):283–90
Arrhythmias in organophosphate poisoning: effect of atropine and bispyridinium oximes. Worek F, et al. **Arch Int Pharmacodyn Ther** 1995 May–Jun;329(3):418–35
Persistent electrocardiographic changes after flecainide overdose. Greig J, et al. **Br J Clin Pract** 1995 Jul–Aug; 49(4):218–9
Arrhythmogenic effects of combined orally administered

theophylline and albuterol in patients with chronic obstructive pulmonary disease. Cukier A, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2869–77

What have clinical trials taught us about proarrhythmia? Skanes AC, et al. **Can J Cardiol** 1996 Apr;12 Suppl B:20B–26B (39 ref.)

ECG changes in pediatric patients on tricyclic antidepressants, desipramine, and imipramine. Johnson A, et al. **Can J Psychiatry** 1996 Mar;41(2):102–6

Fulminant malignant arrythmia and multiorgan failure in acute arsenic poisoning [letter] Civantos DP, et al. **Chest** 1995 Dec;108(6):1774–5

Arrhythmogenic action of thrombin during myocardial reperfusion via release of inositol 1,4,5–triphosphate. Jacobsen AN, et al. **Circulation** 1996 Jan 1;93(1):23–6

Risk of selected serious cardiac events among new users of antihistamines. Staffa JA, et al. **Clin Ther** 1995 Nov–Dec; 17(6):1062–77

Cisapride–induced dysrhythmia in a pediatric patient receiving extracorporeal life support. Pettignano R, et al. **Crit Care Med** 1996 Jul;24(7):1268–71

Proarrhythmic effects of a quinidine analog in dogs with chronic A–V block. Chézalviel–Guilbert F, et al. **Fundam Clin Pharmacol** 1995;9(3):240–7

Decreased R–R variation: a criterium for overdosage of tricyclic psychotropic drugs. Rechlin T. **Intensive Care Med** 1995 Jul;21(7):598–601

Cardiac arrhythmia in a child receiving pericyazine [letter] Jaworowsky S, et al. **Isr J Psychiatry Relat Sci** 1995; 32(4):299–300

Resolved: cardiac arrhythmias make desipramine an unacceptable choice in children. Werry JS, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1239–45; discussion 1245–8

Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Hohnloser SH, et al. **J Am Coll Cardiol** 1995 Oct;26(4):852–8

Efficacy and proarrhythmia of oral sotalol in pediatric patients. Pfammatter JP, et al. **J Am Coll Cardiol** 1995 Oct; 26(4):1002–7

Use of astemizole in a large group practice. Craig TJ, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):352–4

Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. Hohnloser SH, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):920–36 (102 ref.)

Electrophysiological and arrhythmogenic effects of the histamine type 1–receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance. Adamantidis MM, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):319–27

Rilmenidine prevents epinephrine–induced arrhythmias in halothane–anesthetized dogs. Mammoto T, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S40–3

Cardiovascular safety in depressed patients: focus on venlafaxine. Feighner JP. **J Clin Psychiatry** 1995 Dec; 56(12):574–9 (44 ref.)

Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis. Chay TR. **J Electrocardiol** 1995;28 Suppl:191–7

Endogenous adenosine reduces depression of cardiac function induced by beta–adrenergic stimulation during low flow perfusion. Fenton RA, et al. **J Mol Cell Cardiol** 1995 Oct; 27(10):2373–83

Chloral hydrate toxicity from oral and intravenous administration. Sing K, et al. **J Toxicol Clin Toxicol** 1996; 34(1):101–6

Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. Haruno A, et al. **Jpn J Pharmacol** 1995 May;68(1):95–102

QT prolongation on the standard dose of astemizole [letter; comment] Gowardman J. **N Z Med J** 1996 Feb 9; 109(1015):38. Comment on: N Z Med J 1995 Nov 24;108(1012):488–91.

Cardiac arrhythmia in a child after the usual dose of chloral hydrate [letter] Rokicki W. **Pediatr Cardiol** 1996 Nov–Dec; 17(6):419–20

Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Tisdale JE, et al. **Prog Cardiovasc Dis** 1995 Sep–Oct;38(2):167–80 (104 ref.)

QT–interval prolongation with Ecstasy [letter] Drake WM, et al. **S Afr Med J** 1996 Feb;86(2):180–1

Drug interactions associated with terfenadine and related nonsedating antihistamines. Zechnich AD, et al. **West J Med** 1996 Jan;164(1):68–9

[Severe acute buflomedil poisoning] Piriou V, et al. **Ann Fr Anesth Reanim** 1995;14(5):432–4 (Eng. Abstr.) **(Fre)**

[Prolonged QT interval and cardiac toxicity due to halofantrine (letter)] Fourcade L, et al. **Med Trop (Mars)** 1995;55(2):182–3 **(Fre)**

[Intraventricular arrhythmia after propoxyphene poisoning (letter)] Staikowsky F, et al. **Presse Med** 1995 Sep 2–9; 24(25):1179 **(Fre)**

[Proarrhythmic effects of anti–arrhythmia agents] Scanu P, et al. **Rev Med Interne** 1995;16(8):602–7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Effects of psychopharmacologic therapy on heart rate variation] Rechlin T. **Nervenarzt** 1995 Sep;66(9):678–85 (Eng. Abstr.) **(Ger)**

["Arrhythmica" or: history, extent and practical consequences of pro–arrhythmia effects] Gertsch M. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):566–75 (13 ref.) (Eng. Abstr.) **(Ger)**

[Chloral hydrate—is it safe?] Paret G, et al. **Harefuah** 1996 Jan 1;130(1):14–5, 71 (Eng. Abstr.) **(Heb)**

[A case of arrhythmogenic effects of quinidine, digoxin and finoptin combination] Nesterov IuI, et al. **Klin Med (Mosk)** 1995;73(4):86–7 **(Rus)**

CLASSIFICATION

PEHO or PEHO–like syndrome? Chitty LS, et al. **Clin Dysmorphol** 1996 Apr;5(2):143–52

Classification of arrhythmic events in ambulatory electrocardiogram, using artificial neural networks. Silipo R, et al. **Comput Biomed Res** 1995 Aug;28(4):305–18

Classification of cardiac arrhythmias using fuzzy ARTMAP. Ham FM, et al. **IEEE Trans Biomed Eng** 1996 Apr; 43(4):425–30

Type and significance of fetal arrhythmias. Rane HS, et al. **Indian Heart J** 1996 Jan–Feb;48(1):40–4

[The syndromal principle in the diagnosis and construction of a working classification of cardiac arrhythmias] Lipnitskiĭ TN, et al. **Lik Sprava** 1995 May–Jun;(5–6):69–72 **(Rus)**

COMPLICATIONS

Circadian variation in sudden cardiac death: effects of age, sex, and initial cardiac rhythm. Thakur RK, et al. **Ann Emerg Med** 1996 Jan;27(1):29–34

A newly recognized autosomal dominant limb girdle muscular dystrophy with cardiac involvement. van der Kooi AJ, et al. **Ann Neurol** 1996 May;39(5):636–42

Somatized psychiatric disorder presenting as palpitations. Barsky AJ, et al. **Arch Intern Med** 1996 May 27; 156(10):1102–8

Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy. Slade AK, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:37–49 (74 ref.)

Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology. Epstein AE, et al. **Circulation** 1996 Sep 1;94(5):1147–66

Torsade de pointes and T–wave alternans in a patient with brainstem hemorrhage. Chao CL, et al. **Int J Cardiol** 1995 Sep;51(2):199–201

Advanced clinical monitoring: similar scenario discrimination. Cordova MJ, et al. **Medinfo** 1995;8 Pt 2:880–4

[Complete arrhythmia, caused by atrial fibrillation, causing ischemic cerebral vascular accident following acute alcoholic intoxication in a young subject (letter)] Rosolacci T, et al. **Presse Med** 1995 Dec 16–23;24(39):1911 **(Fre)**

DIAGNOSIS

Bystander vs EMS first–responder CPR: initial rhythm and outcome in witnessed nonmonitored out–of–hospital cardiac arrest [see comments] Swor RA, et al. **Acad Emerg Med** 1995 Jun;2(6):494–8. Comment in: Acad Emerg Med 1995 Jun;2(6):474–6.

Persistent atrial standstill documented over a 22–year period. Bensaid J. **Am Heart J** 1996 Feb;131(2):404–7

Lack of proarrhythmia as assessed by Holter monitor after atrial radiofrequency ablation of supraventricular tachycardia in children. Johnson TB, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):120–4

Electrocardiograms of Wolff–Parkinson–White syndrome simulating other conditions. Wang K, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):152–5

Comparison of four methods of assessing heart rate variability in patients with heart failure. Woo MA, et al. **Am J Crit Care** 1996 Jan;5(1):34–41

Evaluation and outcomes of patients with palpitations. Weber BE, et al. **Am J Med** 1996 Feb;100(2):138–48

Cardiac event recorders yield more diagnoses and are more cost–effective than 48–hour Holter monitoring in patients with palpitations. A controlled clinical trial. Kinlay S, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):16–20

Diaphragmatic herniation of the large bowel associated with unusual clinical and electrocardiographic presentation. Kounis NG, et al. **Br J Clin Pract** 1996 Jan–Feb;50(1):54–5

Comparison of the diagnostic yield of Holter versus transtelephonic monitoring. Kus T, et al. **Can J Cardiol** 1995 Nov;11(10):891–4

Ventricular arrhythmias and athlete's heart. Role of signal–averaged electrocardiography. Biffi A, et al. **Eur Heart J** 1996 Apr;17(4):557–63

Influence of coronary artery bypass grafting on ventricular late potentials as a predictive factor for ventricular arrhythmias during short– and long–term follow–up. Frielingsdorf J, et al. **Eur Heart J** 1995 May;16(5):660–6

Genetic design of optimum linear and nonlinear QRS detectors. Poli R, et al. **IEEE Trans Biomed Eng** 1995 Nov; 42(11):1137–41

Late rhythm abnormalities after surgical repair of tetralogy of Fallot: noninvasive and invasive evaluation. Saxena A, et al. **Indian Heart J** 1995 May–Jun;47(3):223–6

Signal–averaged electrocardiography in myotonic dystrophy. Fragola PV, et al. **Int J Cardiol** 1995 Jun 2;50(1):61–8

Fractal dimension predicts arrhythmia recurrence in patients being treated for life–threatening ventricular arrhythmias. ESVEM Investigators. Karagounis LA, et al. **J Electrocardiol** 1995;28 Suppl:71–3

Predictors of persistent palpitations and continued medical utilization. Barsky AJ, et al. **J Fam Pract** 1996 May; 42(5):465–72

Computer–assisted instruction of arrhythmia for MS–windows. Takeuchi A, et al. **Medinfo** 1995;8 Pt 2:1230

Uncertain value of electronic fetal monitoring in predicting cerebral palsy [see comments] Nelson KB, et al. **N Engl J Med** 1996 Mar 7;334(10):613–8. Comment in: N Engl J Med 1996 Mar 7;334(10):659–60. Comment in: N Engl J Med 1996 Jul 25;335(4):287; discussion 288. Comment in: N Engl J Med 1996 Jul 25;335(4):287–8.

A critical appraisal of quantitative spectro–temporal analysis of the signal–averaged ECG: predicting arrhythmic events after myocardial infarction. Bloomfield DM, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):768–77

A client/server system for remote diagnosis of cardiac arrhythmias. Tong DA, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:601–5

Electrophysiologic study in chronic Chagas' heart disease. Scanavacca M, et al. **Rev Paul Med** 1995 Mar–Apr; 113(2):841–50 (45 ref.)

The role of ECG monitoring during bronchoscopy in lung cancer patients. Vasic N. **Support Care Cancer** 1995 Nov; 3(6):402–8

[Localization value of intra–esophageal atrial pacing by modified digitus medius proportional unit] Huang SL, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun; 15(6):341–2 (Eng. Abstr.) **(Chi)**

[Arrhythmogenic right ventricular disease on a young peasant] Wang L, et al. **J Tongji Med Univ** 1995;15(3):162–6 (Eng. Abstr.) **(Ger)**

[Ventricular arrhythmias: diagnosis and drug therapy] Schüpfer C, et al. **Schweiz Rundsch Med Prax** 1996 May 14;85(20):647–54 (40 ref.) (Eng. Abstr.) **(Ger)**

[Clinical value of intracavitary electrograms stored by implantable automatic defibrillator in patients resuscitated after cardiac arrest] Auricchio A, et al. **Cardiologia** 1995 Jan;40(1):31–9 (Eng. Abstr.) **(Ita)**

[Electrocardiogram in pre–excitation] Oreto G, et al. **G Ital Cardiol** 1996 Mar;26(3):303–22 (55 ref.) **(Ita)**

[Arrhythmias in the aged: prevalence and correlation with symptoms] Baratta L, et al. **Recenti Prog Med** 1996 Mar; 87(3):96–101 (Eng. Abstr.) **(Ita)**

[XXI International Congress of Electrocardiology 3–7 July 1994, Yokkohama, Japan] Jagielski J. **Pol Arch Med Wewn** 1995 Jan;93(1):88–91 **(Pol)**

[Holter electrocardiography en pediatric cardiology: preliminary experience] Ferreira J, et al. **Rev Port Cardiol** 1996 Jan;15(1):27–33 (Eng. Abstr.) **(Por)**

[The combined use of the cardiointervalogram and 24–hour ECG monitoring in analyzing heart rhythm disorders] Nedostup AV, et al. **Ter Arkh** 1995;67(9):66–9 (Eng. Abstr.) **(Rus)**

[The work capacity expertise of motor vehicle drivers suffering from IHD with rhythm disorders and the possibilities for their social and vocational rehabilitation] Petrov MN, et al. **Ter Arkh** 1995;67(9):21–3 (Eng. Abstr.) **(Rus)**

[The diagnosis of disorders of heart rhythm and conductivity in patients with mitral valve prolapse] Antukh EA. **Voen Med Zh** 1996 Apr;317(4):22–3 **(Rus)**

[Analysis of arrhythmias using Holter electrocardiographic monitoring in patients with ventricular preexcitation] Jurkovičová O, et al. **Bratisl Lek Listy** 1995 Aug; 96(8):420–9 (Eng. Abstr.) **(Slo)**

[Level of agreement in the interpretation of electrocardiograms] Moreno Castillo A, et al. **Aten Primaria** 1995 Sep 15;16(4):187–91 (Eng. Abstr.) **(Spa)**

[Myocardial structure and study of arrhythmias during ambulatory electrocardiographic monitoring in mild essential hypertension] Pose–Reino A, et al. **Med Clin (Barc)** 1996 Jan 13;106(1):7–10 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Antiarrhythmic effects of magnesium sulphate. Report of three cases. Knudsen K, et al. **Acta Anaesthesiol Scand** 1995 Aug;39(6):850–4

Successful heart failure therapy is effective antiarrhythmia therapy [editorial] Khosla S, et al. **Am Heart J** 1996 May; 131(5):1048–50 (23 ref.)

Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. Hopson JR, et al. **Am J Cardiol** 1996 Jan 25;77(3):72A–82A

From first class to third class: recent upheaval in antiarrhythmic therapy—lessons from clinical trials. Lazzara R. **Am J Cardiol** 1996 Aug 29;78(4A):28–33

Theoretical aspect of effective antiarrhythmic therapy: ventricular arrhythmia and drugs that prolong action potential duration (APD) [letter] Mkparu FO. **Am J Cardiol** 1995 Oct 15;76(11):856

Introduction: a new age in the pharmacologic therapy of cardiac arrhythmias. Singh BN, et al. **Am J Cardiol** 1996

Aug 29;78(4A):1-3

Lanthanum provides cardioprotection by modulating Na(+)-Ca2+ exchange. Maulik N, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:546-50

The cardiac ion channels: relevance to management of arrhythmias. Roden DM, et al. **Annu Rev Med** 1996; 47:135-48 (66 ref.)

Arrhythmias in organophosphate poisoning: effect of atropine and bispyridinium oximes. Worek F, et al. **Arch Int Pharmacodyn Ther** 1995 May-Jun;329(3):418-35

Is there a need for new antiarrhythmic drugs? Roden DM. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:13-8 (36 ref.)

Proarrhythmic complications of sotalol [editorial; comment] Campbell TJ. **Aust N Z J Med** 1996 Apr;26(2):147-8. Comment on: Aust N Z J Med 1996 Apr;26(2):167-70.

Heart rate variability in left ventricular hypertrophy [letter; comment] Sanderson JE, et al. **Br Heart J** 1995 Dec; 74(6):702. Comment on: Br Heart J 1995 Feb;73(2):139-44.

Assessment of arrhythmias after myocardial infarction in the post-CAST era. Camm AJ, et al. **Can J Cardiol** 1996 Apr; 12 Suppl B:9B-19B; discussion 27B-28B (106 ref.)

Adverse drug reactions and drug substitution in an arrhythmia clinic. Sadek I, et al. **Can J Cardiol** 1995 Dec; 11(11):1001-4

ESVEM tells us what we don't know [letter] Anderson KP, et al. **Circulation** 1995 Nov 15;92(10):3144

Guidelines for the use of propafenone in treating supraventricular arrhythmias. Kishore AG, et al. **Drugs** 1995 Aug;50(2):250-62 (73 ref.)

Should post-infarction asymptomatic ventricular arrhythmias be treated? Campbell RW. **Eur Heart J** 1995 Jul;16 Suppl E:46-8 (37 ref.)

Consequences of the Sicilian Gambit. Rosen MR. **Eur Heart J** 1995 Aug;16 Suppl G:32-6

Should post-infarction asymptomatic ventricular arrhythmias be treated? The need for caution. Sleight P. **Eur Heart J** 1995 Jul;16 Suppl E:49 (29 ref.)

Measurement of serum amiodarone and desethylamiodarone by HPLC: its usefulness in the follow-up of arrhythmic patients treated with amiodarone. Manfredi C, et al. **Int J Clin Pharmacol Res** 1995;15(2):87-93

Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients. Masuhara K, et al. **Int J Clin Pharmacol Res** 1995; 15(3):103-13

Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. Perry JC, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1246-50

Efficacy and proarrhythmia of oral sotalol in pediatric patients. Pfammatter JP, et al. **J Am Coll Cardiol** 1995 Oct; 26(4):1002-7

Magnesium in cardiovascular therapy [letter] Joshi PP. **J Assoc Physicians India** 1995 Oct;43(10):724-5

Magnesium and heart [editorial; comment] Mehta PJ, et al. **J Assoc Physicians India** 1995 Aug;43(8):527-8. Comment on: J Assoc Physicians India 1995 Aug;43(8):529-31.

Propafenone: an effective agent for the management of supraventricular arrhythmias. Grant AO. **J Cardiovasc Electrophysiol** 1996 Apr;7(4):353-64 (74 ref.)

Cardiac arrhythmias and antiarrhythmic drugs: recent advances in our understanding of mechanism. Rosen MR. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):868-79 (40 ref.)

Acute antiarrhythmic effects of intravenously administered amiodarone on canine ventricular arrhythmia. Awaji T, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):869-78

Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. Finance O, et al. **J Cardiovasc Pharmacol** 1995 Oct;26(4):570-6

SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. Manning AS, et al. **J Cardiovasc Pharmacol** 1995 Sep; 26(3):453-61

The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. Billman GE, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1517-26

Differential efficacy of the class III agent MK-499 against programmed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction. Lynch JJ Jr, et al. **J Pharmacol Exp Ther** 1996 May;277(2):671-8

Treatment of cardiac membrane stabilizing dysrhythmias [letter; comment] Kulling PE. **J Toxicol Clin Toxicol** 1996; 34(1):131-4. Comment on: J Toxicol Clin Toxicol 1995;33(2):179-83.

Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. Haruno A, et al. **Jpn J Pharmacol** 1995 May;68(1):95-102

The SWORD of Damocles. Sanderson J. **Lancet** 1996 Jul 6;348(9019):2-3

Drugs for cardiac arrhythmias. **Med Lett Drugs Ther** 1996 Aug 30;38(982):75-82

Phosphodiesterase inhibition and Ca2+ sensitization. Ravens U, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):245-9 (21 ref.)

Antiarrhythmic and anti-ischemic properties of calcium-channel antagonists. Apostolakos MJ, et al. **New Horiz** 1996 Feb;4(1):45-57 (94 ref.)

Effects of platelet-activating factor antagonists WEB 2086 and BN 50730 on digoxin-induced arrhythmias. Cakici I, et al. **Pharmacol Toxicol** 1995 Jun;76(6):343-7

Trilinolein reduces infarct size and suppresses ventricular arrhythmias in rats subjected to coronary ligation. Chan P, et al. **Pharmacology** 1995 Aug;51(2):118-26

Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia. Brooks RR, et al. **Proc Soc Exp Biol Med** 1996 May;212(1):84-93

Medical treatment of cardiac arrhythmias in Chagas' heart disease. de Paola AA, et al. **Rev Paul Med** 1995 Mar-Apr; 113(2):858-61 (29 ref.)

[Importance of programmed ventricular stimulation in the evaluation of proarrhythmic effects of orally administered anti-arrhythmia agents] Pleskot M, et al. **Vnitr Lek** 1995 Sep;41(9):581-5 (Eng. Abstr.) **(Cze)**

[Anti-arrhythmic therapy and cardiac failure] Cosnay P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:35-41 (44 ref.) (Eng. Abstr.) **(Fre)**

[Use of current anti-arrhythmia agents in pediatric cardiology] Massin M. **Rev Med Liege** 1995 Dec; 50(12):505-9 (40 ref.) **(Fre)**

["Sicilian gambit": basic principles and strategies of anti-arrhythmia therapy. Satellite symposium of the 15th Congress of the European Society for Cardiology, Barcelona, 30 August 1992] **Internist (Berl)** 1993 Jan;34(1 Suppl [sizilian]):1-20 **(Ger)**

[Ventricular arrhythmias: diagnosis and drug therapy] Schüpfer C, et al. **Schweiz Rundsch Med Prax** 1996 May 14;85(20):647-54 (40 ref.) (Eng. Abstr.) **(Ger)**

[Clinical use of intravenous amiodarone for supraventricular arrhythmias] Assadi S, et al. **Harefuah** 1995 Dec 15; 129(12):583-6 (24 ref.) **(Heb)**

[Current clinical interest in monitoring digoxinemia] Salerno L, et al. **Clin Ter** 1995 Dec;146(12):775-9 (Eng. Abstr.) **(Ita)**

[Therapy of arrhythmias in hypertrophic cardiomyopathy] Rapezzi C, et al. **G Ital Cardiol** 1995 Nov;25(11):1443-6 **(Ita)**

[Emergency drug therapy of arrhythmia] Mitamura H. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1804-9 (5 ref.) **(Jpn)**

[The effect of treatment with propafenone, metoprolol and amiodarone on lymphocyte sodium efflux and level of cAMP in serum] Kosmala W. **Pol Arch Med Wewn** 1995 Jul;94(1):14-20 (Eng. Abstr.) **(Pol)**

[Antiarrhythmic drug effectiveness. Proposal for a new approach based on pharmacological hourly effects] Maia IG, et al. **Arq Bras Cardiol** 1995 Jun;64(6):525-31 (Eng. Abstr.) **(Por)**

[An experimental study of the pharmacological activity of opiate receptor ligands on models of adrenaline-induced arrhythmias] Lishmanov IuB, et al. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):26-8 (Eng. Abstr.) **(Rus)**

[Tactics of treatment of patients with arrhythmia] Glezer MG, et al. **Klin Med (Mosk)** 1995;73(4):13-7 (0 ref.) **(Rus)**

[Pharmacologic control of reperfusion dysrhythmias] Kovács P, et al. **Ceska Slov Farm** 1995 Oct;44(5):257-60 (Eng. Abstr.) **(Slo)**

ECONOMICS

Cost-effectiveness in clinical cardiology. II. Preventive strategies and arrhythmia therapies. Simmons J, et al. **Chest** 1996 Jul;110(1):256-62

EPIDEMIOLOGY

Twenty-four-hour ambulatory electrocardiography in elderly subjects: prevalence of various arrhythmias and prognostic implications (report from the Bronx Longitudinal Aging Study). Frishman WH, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):297-302

Blood pressure influences the occurrence of complex ventricular arrhythmia in hemodialysis patients. De Lima JJ, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1200-3

[Arrhythmias in the aged: prevalence and correlation with symptoms] Baratta L, et al. **Recenti Prog Med** 1996 Mar; 87(3):96-101 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Electrocardiographic abnormalities in patients receiving hemodialysis. Abe S, et al. **Am Heart J** 1996 Jun; 131(6):1137-44

Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. Bayés-Genís A, et al. **Am J Cardiol** 1995 Nov 2; 76(13):54D-59D (53 ref.)

QT dispersion and arrhythmic events in idiopathic dilated cardiomyopathy. Grimm W, et al. **Am J Cardiol** 1996 Aug 15;78(4):458-61

Effect of age on postmyocardial infarction ventricular arrhythmias (Holter Registry data from CAST I and CAST II). Cardiovascular Arrhythmia Suppression Trials. Josephson RA, et al. **Am J Cardiol** 1995 Oct 1;76(10):710-3

Cardiac trauma: an unusual cause of dysrhythmias and electrocardiographic changes during laparoscopic Nissen fundoplication. Swide CE, et al. **Anesthesiology** 1996 Jul; 85(1):209-11

Low-voltage electrical injury [letter; comment] Bailey B, et al. **Ann Emerg Med** 1996 Jul;28(1):103. Comment on: Ann Emerg Med 1995 Nov;26(5):604-8.

Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias. Harpole DH, et al. **Ann Thorac Surg** 1996 Mar;61(3):977-82

Atrial arrhythmias and pacing after orthotopic heart transplantation: bicaval versus standard atrial anastomosis. Grant SC, et al. **Br Heart J** 1995 Aug;74(2):149-53

Assessment of arrhythmias after myocardial infarction in the post-CAST era. Camm AJ, et al. **Can J Cardiol** 1996 Apr; 12 Suppl B:9B-19B; discussion 27B-28B (106 ref.)

The contribution of neutrophils to reperfusion arrhythmias and a possible role for antiadhesive pharmacological substances. Dhein S, et al. **Cardiovasc Res** 1995 Dec; 30(6):881-8

Mechanosensitive connective tissue: potential influence on heart rhythm. Kohl P, et al. **Cardiovasc Res** 1996 Jul; 32(1):62-8 (63 ref.)

Mechano-electric feedback [editorial] Lab MJ, et al. **Cardiovasc Res** 1996 Jul;32(1):1-2

Effects of mechano-electrical feedback: potential arrhythmogenic influence in patients with congestive heart failure. Reiter MJ. **Cardiovasc Res** 1996 Jul;32(1):44-51 (44 ref.)

Importance of a non-dominant right coronary artery occlusion presenting as sudden cardiac death with prolonged right ventricular dysfunction and malignant arrhythmias. Karim MA, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):257-61

Relationship of early postoperative dysrhythmias and long-term outcome after resection of non-small cell lung cancer. Amar D, et al. **Chest** 1996 Aug;110(2):437-9

Atypical electromechanical dissociation in a patient with recurrent pulmonary embolism. Chirillo F, et al. **Chest** 1996 Feb;109(2):562-3

Cellular and ionic basis of arrhythmias in postinfarction remodeled ventricular myocardium. Qin D, et al. **Circ Res** 1996 Sep;79(3):461-73

Chronic treatment with carbachol sensitizes the myocardium to cAMP-induced arrhythmia. Eschenhagen T, et al. **Circulation** 1996 Feb 15;93(4):763-71

Apoptosis as a possible cause of gradual development of complete heart block and fatal arrhythmias associated with absence of the AV node, sinus node, and internodal pathways. James TN, et al. **Circulation** 1996 Apr 1; 93(7):1424-38

New insights into myocardial arrhythmogenesis: distribution of gap-junctional coupling in normal, ischaemic and hypertrophied human hearts. Peters NS. **Clin Sci (Colch)** 1996 Jun;90(6):447-52 (56 ref.)

Risk stratification for malignant arrhythmic events in patients with an acute myocardial infarction: role of an open infarct-related artery and the signal-averaged ECG. Hermosillo AG, et al. **Coron Artery Dis** 1995 Dec; 6(12):973-83

QT dispersion and heart rate variability [editorial; comment] Bayés de Luna A, et al. **Eur Heart J** 1996 Feb;17(2):165-6 . Comment on: Eur Heart J 1996 Feb;17(2):258-63.

QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy [see comments] Fei L, et al. **Eur Heart J** 1996 Feb;17(2):258-63. Comment in: Eur Heart J 1996 Feb;17(2):165-6.

Autonomic, ischaemic, circadian and rhythmic factors as causes of the spontaneous variability of ventricular arrhythmias. Janssen MJ, et al. **Eur Heart J** 1995 May; 16(5):674-81

Chloroethylclonidine increases the incidence of lethal arrhythmias during coronary occlusion in anesthetized dogs. Geller JC, et al. **Eur J Pharmacol** 1995 Dec 29; 294(2-3):423-8

Palpitations and lightheadedness in a 42-year-old man. Larry JA, et al. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):24O, 24S

GABAergic and glutaminergic modulation of centrally evoked arrhythmias in rats. Crambes A, et al. **Hypertension** 1996 Jan;27(1):148-54

Late rhythm abnormalities after surgical repair of tetralogy of Fallot: noninvasive and invasive evaluation. Saxena A, et al. **Indian Heart J** 1995 May-Jun;47(3):223-6

Electrocardiographic changes in elderly patients during small bowel enema. Zavras GM, et al. **Invest Radiol** 1996 May; 31(5):256-60

Mechanoelectrical feedback: maturation of a concept. Lerman BB. **J Cardiovasc Electrophysiol** 1996 Jan;7(1):17-9

Sinusoidal fetal heart rate pattern during chemotherapy in a pregnant woman with acute myelogenous leukemia. Hsu KF, et al. **J Formos Med Assoc** 1995 Sep;94(9):562-5

Thromboembolism associated with junctional escape rhythm and atrial standstill after orthotopic heart transplantation. Koller-Strametz J, et al. **J Heart Lung Transplant** 1995 Sep-Oct;14(5):999-1002

Relation between age, left ventricular mass and ventricular arrhythmias in patients with hypertension. Ferrara N, et al. **J Hum Hypertens** 1995 Jul;9(7):581-7

Heart rate variability before sudden blood pressure elevations or complex cardiac arrhythmias in phaeochromocytoma. Dabrowska B, et al. **J Hypertens** 1996 Jan;10(1):43-50

Low magnesium enhances the pro-arrhythmic effect of low potassium in the hypertrophied rat heart but not in the normal rat heart. Evans SJ, et al. **J Hypertens** 1996 May;

14(5):635–44

Structural and non-structural disease underlying high-risk cardiac arrhythmias relevant to sports medicine. Rossi L. **J Sports Med Phys Fitness** 1995 Jun;35(2):79–86 (29 ref.)

Staged operation to Fontan increases the incidence of sinoatrial node dysfunction. Manning PB, et al. **J Thorac Cardiovasc Surg** 1996 Apr;111(4):833–9; discussion 839–40

Histamine liberation related to cardiopulmonary bypass in children: possible relation to transient postoperative arrhythmias. Seghaye MC, et al. **J Thorac Cardiovasc Surg** 1996 May;111(5):971–81

Glucose is arrhythmogenic in the anoxic-reoxygenated embryonic chick heart. Tran L, et al. **Pediatr Res** 1996 May;39(5):766–73

Identifying the causes of syncope and palpitations. Burn S, et al. **Practitioner** 1995 Nov;239(1556):666–9 (3 ref.)

Arrhythmias induced by exercise in athletes and others. McGovern BA, et al. **S Afr Med J** 1996 Apr;86 Suppl 2:C78–82 (22 ref.)

[Ventricular arrhythmias and arterial hypertension] Dorobantu M, et al. **Ann Cardiol Angeiol (Paris)** 1996 May; 45(5):291–5 (23 ref.) (Eng. Abstr.) **(Fre)**

[Do arrhythmias after infarction deter patients from smoking?] Pochmalicki G, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jan;45(1):5–11 (Eng. Abstr.) **(Fre)**

[Wandering pacemaker (letter)] Wiel E, et al. **Ann Fr Anesth Reanim** 1996;15(3):390–1 **(Fre)**

[Outcome of arrhythmogenic right ventricular dysplasia. Apropos of 4 cases] Fontaine G, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):973–9 (12 ref.) (Eng. Abstr.) **(Fre)**

[Influence of post-infarction myocardial revascularization on the prevalence of delayed potentials] Lomama E, et al. **Arch Mal Coeur Vaiss** 1995 Sep;88(9):1267–72 (29 ref.) (Eng. Abstr.) **(Fre)**

[Supervision after an electrical accident] Gonska BD. **Dtsch Med Wochenschr** 1996 Aug 16;121(33):1032 **(Ger)**

[Could C- and D-network mobile phones endanger patients with pacemakers? (see comments)] Hofgärtner F, et al. **Dtsch Med Wochenschr** 1996 May 17;121(20):646–52 (Eng. Abstr.). Comment in: Dtsch Med Wochenschr 1996 May 17;121(20):645. **(Ger)**

[Holiday heart syndrome] Rau T, et al. **Dtsch Med Wochenschr** 1996 Sep 6;121(36):1108 **(Ger)**

[Arrhythmogenic right ventricular disease on a young peasant] Wang L, et al. **J Tongji Med Univ** 1995;15(3):162–6 (Eng. Abstr.) **(Ger)**

[Complex partial seizures as cause of transient cardiac arrhythmia] Wilder-Smith E, et al. **Schweiz Med Wochenschr** 1995 Nov 18;125(46):2237–43 (Eng. Abstr.) **(Ger)**

[Transient pacemaker dysfunction and spontaneous arrhythmias in symptomatic and asymptomatic patients with ventricular demand pacemakers] Brandes A, et al. **Z Kardiol** 1996 Apr;85(4):237–47 (Eng. Abstr.) **(Ger)**

[Dispersion of ventricular recovery time as a new marker of arrhythmogenic risk] Ducceschi V, et al. **Cardiologia** 1995 May;40(5):355–60 **(Ita)**

[Excess of histamine as a possible cause of cardiac arrhythmias] Marra L, et al. **Clin Ter** 1996 Mar;147(3):145–7 (10 ref.) (Eng. Abstr.) **(Ita)**

[Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine] Mondillo S, et al. **Clin Ter** 1995 Dec;146(12):769–74 (Eng. Abstr.) **(Ita)**

[Arrhythmogenic dysplasia of the right ventricle: diagnostic problems] Bettini R, et al. **G Ital Cardiol** 1995 Nov; 25(11):1479–84 **(Ita)**

[Cardiac dysrhythmias related to extracorporeal shock wave lithotripsy using a piezoelectric lithotriptor in patients with kidney stones] Kataoka H. **J Cardiol** 1995 Sep;26(3):185–91 (Eng. Abstr.) **(Jpn)**

[A case of various cardiac disorders due to interferon-alpha] Kawada Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):276–8 **(Jpn)**

[Arrhythmias in patients with mitral valve prolapse] Kitliński M, et al. **Folia Med Cracov** 1994;35(1–4):61–7 (Eng. Abstr.) **(Pol)**

[Cardiotoxic effect of the herec-TNF alpha preparation given intravenously to patients with advanced neoplasms] Muc M, et al. **Przegl Lek** 1996;53(2):78–82 (Eng. Abstr.) **(Pol)**

[Chronic Chagas cardiopathy as a model for an insight on the pathogenesis of arrhythmogenic right ventricular cardiomyopathy (editorial)] Rossi MA. **Arq Bras Cardiol** 1995 Jul;65(1):3–5 (39 ref.) **(Por)**

[Cardiovascular impact of alcoholism] Faintuch JJ. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jan-Feb;50(1):76–9 (47 ref.) (Eng. Abstr.) **(Por)**

[A comparative analysis of rhythm and conduction disorders in patients with dilated cardiomyopathy and chronic myocarditis] Naumov VG, et al. **Ter Arkh** 1995;67(9):63–6 (Eng. Abstr.) **(Rus)**

[Cardiac arrhythmias and ionic hypomagnesemia during liver transplantation (letter)] Acosta F, et al. **Med Clin (Barc)** 1996 Feb 10;106(5):196–7 **(Spa)**

GENETICS

Identical twins with arrhythmogenic right ventricular dysplasia. Hiraoka E, et al. **Am J Cardiol** 1995 Nov 15; 76(14):1099–100

A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42–q43. Rampazzo A, et al. **Hum Mol Genet** 1995 Nov; 4(11):2151–4

Molecular genetic insights into cardiovascular disease. Keating MT, et al. **Science** 1996 May 3;272(5262):681–5 (33 ref.)

HISTORY

Beethoven's final illness [letter; comment] Lüderitz B. **Lancet** 1996 Mar 16;347(9003):766. Comment on: Lancet 1996 Jan 20;347(8995):167–70.

[Discovery of the pacemaker and heart conduction system in mammals. Fantasy and truth] Ehrlich W. **Z Kardiol** 1995 Dec;84(12):963–70 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

High prevalence of antibodies against beta 1- and beta 2-adrenoceptors in patients with primary electrical cardiac abnormalities. Chiale PA, et al. **J Am Coll Cardiol** 1995 Oct;26(4):864–9

METABOLISM

A symposium: progress in hypertensive heart disease: microangiopathy, molecular and cellular biology, cardiac arrhythmias, and heart failure. February 23–24, 1995, Bilbao, Spain. Proceedings. **Am J Cardiol** 1995 Nov 2; 76(13):1D–63D

Infarct limitation of the second window of protection in a conscious rabbit model. Yang XM, et al. **Cardiovasc Res** 1996 May;31(5):777–83

Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients. Masuhara K, et al. **Int J Clin Pharmacol Res** 1995; 15(3):103–13

Effects of selective alpha 1A-adrenoceptor antagonists on reperfusion arrhythmias in isolated rat hearts. Yasutake M, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):173–80

MORTALITY

Classification of death in antiarrhythmia trials. Epstein AE, et al. **J Am Coll Cardiol** 1996 Feb;27(2):433–42

Smoking cessation and arrhythmic death: the CAST experience. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Peters RW, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1287–92

Toward vital status sweeps: a case history in sequential monitoring. Hallstrom A, et al. **Stat Med** 1995 Sep 15; 14(17):1927–31

PATHOLOGY

Endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy [editorial] Angelini A, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):203–6 (35 ref.)

Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Basso C, et al. **Circulation** 1996 Sep 1;94(5):983–91

Brief, intermediate and prolonged ischemia in the isolated crystalloid perfused rat heart: relationship between susceptibility to arrhythmias and degree of ultrastructural injury. Ravingerova T, et al. **J Mol Cell Cardiol** 1995 Sep; 27(9):1937–51

[Morphologic analysis of arrhythmogenic and non-arrhythmogenic zones of subendocardial areas of the heart in patients with rhythm disorders] Bokeriiai LA, et al. **Arkh Patol** 1995 Jul-Aug;57(4):51–6 (Eng. Abstr.) **(Rus)**

[Fever, dyspnea and palpitations in a 53-year-old woman (clinical conference)] Raventós A, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):69–74 **(Spa)**

PHYSIOPATHOLOGY

Ambulatory blood pressure and cardiac rhythm disturbances in elderly hypertensives: relation to left ventricular mass and filling pattern. Colivicchi F, et al. **Age Ageing** 1996 Mar;25(2):155–8

Characterization of spontaneous recurrent ventricular arrhythmias detected by electrogram-storing defibrillators in sudden cardiac death survivors with no inducible ventricular arrhythmias at baseline electrophysiologic testing. Zaim S, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):274–9

Evidence favoring the hypothesis that ventricular arrhythmias have prognostic significance in left ventricular hypertrophy secondary to systemic hypertension. Almendral J, et al. **Am J Cardiol** 1995 Nov 2; 76(13):60D–63D (27 ref.)

Cellular electrophysiologic basis of cardiac arrhythmias. Boyden PA. **Am J Cardiol** 1996 Aug 29;78(4A):4–11

Relation of ventricular size and function to heart failure status and ventricular dysrhythmia in patients with severe left ventricular dysfunction. Koilpillai C, et al. **Am J Cardiol** 1996 Mar 15;77(8):606–11

Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates. Roden DM. **Am J Cardiol** 1996 Aug 29;78(4A):12–6

Cardiac dysrhythmia during sleep in the critically ill: a pilot study. Richards KC, et al. **Am J Crit Care** 1996 Jan; 5(1):26–33

Proarrhythmic and antiarrhythmic actions of ion channel blockers on arrhythmias in the heart: model study. Chay TR. **Am J Physiol** 1996 Jul;271(1 Pt 2):H329–56

Functional roles of sodium-calcium exchange in normal and abnormal cardiac rhythm. Noble D, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:480–8 (17 ref.)

Neurobiology of arrhythmias in children prenatally exposed to cocaine [letter] Friedman EH. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1178–9

Inhibition of adenosine deaminase and administration of adenosine increase hypoxia induced ventricular ectopy. Leone RJ Jr, et al. **Basic Res Cardiol** 1995 May-Jun; 90(3):234–9

Wavelet formation in excitable cardiac tissue: the role of wavefront-obstacle interactions in initiating high-frequency fibrillatory-like arrhythmias. Starobin JM, et al. **Biophys J** 1996 Feb;70(2):581–94

Relation between QT and RR intervals in patients with bradyarrhythmias. Ishida S, et al. **Br Heart J** 1995 Aug; 74(2):159–62

Extreme pulsus alternans presenting as 2:1 electromechanical dissociation. Rosenthal E. **Br Heart J** 1995 Dec;74(6):695

Right sided pulsus alternans: a neglected phenomenon [editorial] Morpurgo M, et al. **Cardiologia** 1995 Nov; 40(11):803–6

Reduced beat-to-beat changes of heart rate: an important risk factor after acute myocardial infarction. Reinhardt L, et al. **Cardiology** 1996 Mar-Apr;87(2):104–11

Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion. Aidonidis I, et al. **Cardiovasc Drugs Ther** 1995 Aug; 9(4):555–63

Effect of magnesium on ischemic and reperfusion arrhythmias in a canine model with diminished collateral blood flow. Euler DE. **Cardiovasc Drugs Ther** 1995 Aug;9(4):565–71

Mechano-electrical feedback in ventricular myocardium. Franz MR. **Cardiovasc Res** 1996 Jul;32(1):15–24 (40 ref.)

Sympathomimetic modulation of load-dependent changes in the action potential duration in the in situ porcine heart. Horner SM, et al. **Cardiovasc Res** 1996 Jul;32(1):148–57

Electrical alternans and the onset of rate-induced pulsus alternans during acute regional ischaemia in the anaesthetised pig heart. Murphy CF, et al. **Cardiovasc Res** 1996 Jul;32(1):138–47

Restraint stress changes heart sensitivity to arrhythmogenic drugs. Sun AY, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Sep;16(5):455–9

Effects of NO modulation on cardiac arrhythmias in the rat isolated heart. Pabla R, et al. **Circ Res** 1995 Nov; 77(5):984–92

Combining monophasic action potential recordings with pacing to demonstrate delayed afterdepolarizations and triggered arrhythmias in the intact heart. Value of diastolic slope. de Groot SH, et al. **Circulation** 1995 Nov 1; 92(9):2697–704

QT dispersion and heart rate variability [editorial; comment] Bayés de Luna A, et al. **Eur Heart J** 1996 Feb;17(2):165–6 . Comment on: Eur Heart J 1996 Feb;17(2):258–63.

Sudden cardiac death, circadian rhythms and defibrillators [editorial; comment] Boyle NG, et al. **Eur Heart J** 1995 Sep;16(9):1162–4. Comment on: Eur Heart J 1995 Sep;16(9):1231–3.

At what time are implantable defibrillator shocks delivered? Evidence for individual circadian variance in sudden cardiac death [see comments] d'Avila A, et al. **Eur Heart J** 1995 Sep;16(9):1231–3. Comment in: Eur Heart J 1995 Sep;16(9):1162–4.

Athletes and arrhythmias: clinical considerations and perspectives. Josephson ME, et al. **Eur Heart J** 1996 Apr; 17(4):498–505 (47 ref.)

Comparison and combination of late potentials and spectral turbulence analysis to predict arrhythmic events after myocardial infarction in the Post-Infarction Late Potential (PILP) Study. Mäkijärvi M, et al. **Eur Heart J** 1995 May; 16(5):651–9

Apical hypertrophy associated with rapid T wave inversion on the electrocardiogram. Yamanari H, et al. **Heart Vessels** 1995;10(4):221–4

GABAergic and glutaminergic modulation of centrally evoked arrhythmias in rats. Crambes A, et al. **Hypertension** 1996 Jan;27(1):148–54

Association of reduced PR-AC interval with ventricular early potentials in dilated cardiomyopathy. Fujimoto S, et al. **Int J Cardiol** 1995 Jun 30;50(2):167–73

Forebrain involvement in fatal cardiac arrhythmia. Wolf S. **Integr Physiol Behav Sci** 1995 Jul-Sep;30(3):215–25

Resolved: cardiac arrhythmias make desipramine an unacceptable choice in children. Werry JS, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1239–45; discussion 1245–8

Triggered activity as a mechanism for inherited ventricular arrhythmias in German shepherd Dogs. Gilmour RF Jr, et al. **J Am Coll Cardiol** 1996 May;27(6):1526–33

The relation of emotional behavior to plasma catecholamines, cortisol and ventricular arrhythmia. Kojima K, et al. **J Auton Nerv Syst** 1995 Oct 5;55(1–2):57–64

High arrythmogenesis during early reperfusion of ischaemic myocardium: participation of oxygen free radicals.

Ravingerova T, et al. **J Basic Clin Physiol Pharmacol** 1993 Oct-Dec;4(4):335-46

Reperfusion-induced arrhythmias in isolated rat heart: an index of cellular damage or viability of cardiomyocytes? Tribulova N, et al. **J Basic Clin Physiol Pharmacol** 1993 Oct-Dec;4(4):321-34

Cardiac arrhythmias and antiarrhythmic drugs: recent advances in our understanding of mechanism. Rosen MR. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):868-79 (40 ref.)

Why do exercise-induced ventricular arrhythmias increase with age? Role of M-mode echocardiographic aging changes. Mayuga R, et al.
J Gerontol A Biol Sci Med Sci 1996 Jan;51(1):M23-8

Increased incidence of chronotropic incompetence in older donor hearts. Chau EM, et al. **J Heart Lung Transplant** 1995 Jul-Aug;14(4):743-8

Heart rate variability before sudden blood pressure elevations or complex cardiac arrhythmias in phaeochromocytoma. Dabrowska B, et al. **J Hypertens** 1996 Jan;10(1):43-50

Electrophysiologic and proarrhythmogenic effects of therapeutic and toxic doses of imipramine: a study with high resolution ventricular epicardial mapping in rabbit hearts. Robert E, et al. **J Pharmacol Exp Ther** 1996 Jul; 278(1):170-8

Fast anatomical imaging of the heart and assessment of myocardial perfusion with arrhythmia insensitive magnetization preparation. Tsekos NV, et al.
Magn Reson Med 1995 Oct;34(4):530-6

Model of rate-dependent property in myocardial tissues as a useful algorithm for the PC-based arrhythmia generator. Ikeda N, et al. **Medinfo** 1995;8 Pt 1:729-32

Effects of cromakalim or glibenclamide on arrhythmias and dispersion of refractoriness in chronically infarcted in anesthetized dogs. D'Alonzo AJ, et al.
Naunyn Schmiedebergs Arch Pharmacol 1995 Aug; 352(2):222-8

Clinical application of a microcomputer system for analysis of monophasic action potentials. Yuan S, et al.
Pacing Clin Electrophysiol 1996 Mar;19(3):297-308

Electrogram patterns associated with successful radiofrequency ablation of accessory pathways in children. Schwartz SM, et al. **Pediatr Cardiol** 1996 May-Jun; 17(3):137-42

Age, altitude, and arrhythmia. Alexander JK.
Tex Heart Inst J 1995;22(4):308-16 (69 ref.)

Use of a 64 channel computerized cardiac mapping system in arrhythmia surgery. Chang BC, et al. **Yonsei Med J** 1995 Sep;36(4):378-85

[Prognostic significance of impaired intra-and infra-bundle of His conduction in the heart] Pleskot M, et al.
Cas Lek Cesk 1996 May 15;135(10):308-12 (Eng. Abstr.) **(Cze)**

[Sudden cardiac death: definition, mechanisms and risk factors] Evéquoz D, et al. **Schweiz Rundsch Med Prax** 1996 Feb 13;85(7):188-96 (56 ref.) (Eng. Abstr.) **(Fre)**

[Rhythmology in clinical practice (editorial)] Fuhrer J, et al. **Schweiz Rundsch Med Prax** 1996 Apr 30;85(18):581-3 **(Ger)**

[Assessment of ventricular arrhythmias] Osswald S, et al. **Schweiz Rundsch Med Prax** 1996 Feb 13;85(7):179-87 (48 ref.) (Eng. Abstr.) **(Ger)**

[Electrocardiographic examinations after orthotopic heart transplantation] Kriehuber E. **Wien Med Wochenschr** 1995; 145(21):587-94 (Eng. Abstr.) **(Ger)**

[Assessment of dispersion++ of ventricular recovery in patients with chronic obstructive pulmonary disease] Sarubbi B, et al. **Cardiologia** 1995 Apr;40(4):247-51 (Eng. Abstr.) **(Ita)**

[Relationship between ventricular arrhythmia and cardiac function in Chagas disease] Barretto AC, et al.
Arq Bras Cardiol 1995 Jun;64(6):533-5 (Eng. Abstr.) **(Por)**

[Indications for electrophysiological studies and catheter ablation of cardiac arrhythmias. Recommendations of the Department of Arrhythmias and Clinical Electrophysiology of the Brazilian Society of Cardiology] Sosa EA, et al. **Arq Bras Cardiol** 1995 Feb;64(2):149-51 (1 ref.) **(Por)**

[The relationship between heart rate variability, clinical and coronary angiographic parameters, ventricular function, arrhythmia profile and late potentials in patients with a recent myocardial infarct] Brizida L, et al.
Rev Port Cardiol 1995 Nov;14(11):799-803 **(Por)**

[Participation of endogenous mu- and delta-opiate receptor agonists in mechanisms of the anti-arrhythmia effect of adaptation] Maslov LN, et al. **Biull Eksp Biol Med** 1996 Jan;121(1):24-5 **(Rus)**

[The role of cholinergic regulation of the heart in the protective antiarrhythmic effect of adaptation to continuous moderate stress] Pshennikova MG, et al.
Biull Eksp Biol Med 1995 Jul;120(7):36-9 **(Rus)**

[The prostanoid system in patients with disordered heart rhythm] Bobrov VA, et al. **Ter Arkh** 1995;67(8):68-71 (69 ref.) **(Rus)**

PREVENTION & CONTROL

Supplemental oxygen during endoscopic variceal ligation: effects on arterial oxygenation and cardiac arrhythmia. Iwao T, et al. **Am J Gastroenterol** 1995 Dec;90(12):2186-90

Suppression of reperfusion arrhythmia by ischemic preconditioning in the rat: is it mediated by the adenosine receptor, prostaglandin, or bradykinin receptor? Miura T, et al. **Basic Res Cardiol** 1995 May-Jun;90(3):240-6

Protection by cimetidine, but not ranitidine, implies that H2 receptors do not mediate arrhythmogenesis in a rat model of regional ischaemia and reperfusion in vitro. Banning MM, et al. **Cardiovasc Res** 1995 Nov;30(5):705-10

Anti-arrhythmic protection by ischaemic preconditioning in isolated rat hearts is not due to depletion of endogenous catecholamines. Lawson CS, et al. **Cardiovasc Res** 1996 Apr;31(4):655-62

Interrelationship between magnesium and potassium in preventing myocardial ischemia-reperfusion arrhythmia. Xiang S, et al. **Chin Med J (Engl)** 1996 Apr;109(4):282-5

Clinical trial enrollers vs. nonenrollers: the Cardiac Arrhythmia Suppression Trial (CAST) Recruitment and Enrollment Assessment in Clinical Trials (REACT) project. Gorkin L, et al. **Control Clin Trials** 1996 Feb; 17(1):46-59

Management and prophylaxis of life-threatening arrhythmias--recent achievements. Andresen D, et al.
Eur Heart J 1995 Aug;16 Suppl G:20-3 (24 ref.)

Effects of MCI-154, a new cardiotonic Ca2+ sensitizer, on ventricular arrhythmias and membrane ionic currents. Eto K, et al. **Eur J Pharmacol** 1996 Mar 18;298(3):247-56

The cardiovascular protective role of docosahexaenoic acid. McLennan P, et al. **Eur J Pharmacol** 1996 Apr 4; 300(1-2):83-9

Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Liu YH, et al.
Hypertension 1996 Jan;27(1):7-13

Protective effects of All-trans-retinoic acid against cardiac arrhythmias induced by isoproterenol, lysophosphatidylcholine or ischemia and reperfusion. Kang JX, et al. **J Cardiovasc Pharmacol** 1995 Dec;26(6):943-8

Rilmenidine prevents epinephrine-induced arrhythmias in halothane-anesthetized dogs. Mammoto T, et al.
J Cardiovasc Pharmacol 1995;26 Suppl 2:S40-3

Interleukin 1 alpha-induced expression of manganous superoxide dismutase reduces myocardial reperfusion injury in the rat. Nogae C, et al. **J Mol Cell Cardiol** 1995 Oct;27(10):2091-9

Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats. Pepe S, et al. **J Nutr** 1996 Jan; 126(1):34-42

Saralasin suppresses arrhythmias in an isolated guinea pig ventricular free wall model of simulated ischemia and reperfusion. Thomas GP, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1379-86

The use of ungating with the Medstone lithotriptor. Cass AS. **J Urol** 1996 Sep;156(3):896-8 (15 ref.)

Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists? Stevenson WG, et al. **JAMA** 1996 Aug 14;276(6):481-5

Vitamin E and coronary heart disease [letter] Walsh GP. **Lancet** 1996 Jun 15;347(9016):1690-1

Electrophysiological, rate dependent, and autonomic effects of the class III antiarrhythmic almokalant after myocardial infarction in the pig. Tuininga YS, et al.
Pacing Clin Electrophysiol 1996 May;19(5):802-10

Effects of captopril on ischaemia-reperfusion-induced arrhythmias in an in vivo rat model. Olmez E, et al.
Pharmacol Res 1995 Jul-Aug;32(1-2):37-41

Reduced incidence of cardiac arrhythmias after orthotopic heart transplantation with direct bicaval anastomosis. Forni A, et al. **Transplant Proc** 1996 Feb;28(1):289-92

[Effects of guan-fu base a on experimental cardiac arrhythmias and myocardial contractility] Dong YL, et al.
Yao Hsueh Hsueh Pao 1995;30(8):577-82 (Eng. Abstr.) **(Chi)**

[The high risk cardiac patient in anesthesia] Francke A.
Anaesthesiol Reanim 1996;21(2):32-42 (89 ref.) (Eng. Abstr.) **(Ger)**

[Stratification of arrhythmia risk and therapeutic options in survivors of acute myocardial infarction] Arós Borau F, et al. **Rev Esp Cardiol** 1996 Mar;49(3):157-65 (85 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

The quality of life of patients with life-threatening arrhythmias. Arteaga WJ, et al. **Arch Intern Med** 1995 Oct 23;155(19):2086-91

Somatized psychiatric disorder presenting as palpitations. Barsky AJ, et al. **Arch Intern Med** 1996 May 27; 156(10):1102-8

RADIONUCLIDE IMAGING

Evaluation of radionuclide angiography in diagnosis of arrhythmogenic right ventricular cardiomyopathy. Le Guludec D, et al. **J Am Coll Cardiol** 1995 Nov 15; 26(6):1476-83

REHABILITATION

Cardiac rehabilitation/exercise in patients with implantable cardioverter defibrillators. Friedman AW, et al.
J Natl Med Assoc 1996 Jun;88(6):374-8

[The work capacity expertise of motor vehicle drivers suffering from IHD with rhythm disorders and the possibilities for their social and vocational rehabilitation] Petrov MN, et al. **Ter Arkh** 1995;67(9):21-3 (Eng. Abstr.) **(Rus)**

SURGERY

Guidance of radiofrequency catheter ablation by transesophageal echocardiography in children with palliated single ventricle. Drant SE, et al.
Am J Cardiol 1995 Dec 15;76(17):1311-2

Treatment of arrhythmias by radiofrequency ablation. De Giovanni JV. **Arch Dis Child** 1995 Nov;73(5):385-7 (18 ref.)

Radiofrequency ablation of arrhythmias in the pediatric patient. Moak JP. **Curr Opin Cardiol** 1996 Jan;11(1):81-92 (47 ref.)

Application of ultrasound energy for intracardiac ablation of arrhythmias [see comments] He DS, et al.
Eur Heart J 1995 Jul;16(7):961-6. Comment in: Eur Heart J 1995 Jul;16(7):875-6.

Reasons for prolonged or failed attempts at radiofrequency catheter ablation of accessory pathways. Morady F, et al.
J Am Coll Cardiol 1996 Mar 1;27(3):683-9

ACC/AHA Task Force Report. Guidelines for Clinical Intracardiac Electrophysiological and Catheter Ablation Procedures. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on Clinical Intracardiac Electrophysiologic and Catheter Ablation Procedures). Developed in collaboration with the North American Society of Pacing and Electrophysiology.
J Cardiovasc Electrophysiol 1995 Aug;6(8):652-79

Future ablation concepts of tachyarrhythmias. Chen SA, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 1):852-62 (99 ref.)

Delayed effects of radiofrequency energy: mechanisms and clinical implications. Fenelon G, et al.
Pacing Clin Electrophysiol 1996 Apr;19(4 Pt 1):484-9 (31 ref.)

Estimation of temperature during radiofrequency catheter ablation using impedance measurements. Hartung WM, et al. **Pacing Clin Electrophysiol** 1995 Nov;18(11):2017-21

NASPE Survey on Catheter Ablation. Scheinman MM.
Pacing Clin Electrophysiol 1995 Aug;18(8):1474-8

Use of a 64 channel computerized cardiac mapping system in arrhythmia surgery. Chang BC, et al. **Yonsei Med J** 1995 Sep;36(4):378-85

[Radiofrequency ablation of the atrioventricular accessory pathways. Value of unipolar and bipolar recordings] Aliot E, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:89-97 (35 ref.) (Eng. Abstr.) **(Fre)**

[Mid-term outcome of escape rhythm after radiofrequency ablation of the atrioventricular junction] Deharo JC, et al.
Arch Mal Coeur Vaiss 1996 Mar;89(3):319-24 (Eng. Abstr.) **(Fre)**

[Role of power and temperature monitoring in radiofrequency ablation] Halimi F, et al.
Arch Mal Coeur Vaiss 1996 Feb;89(2):243-8 (Eng. Abstr.) **(Fre)**

[Radiofrequency ablation: physical bases and principles] Lavergne T, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:57-63 (35 ref.) (Eng. Abstr.) **(Fre)**

[Biophysical basis and cardiac lesions caused by different techniques of cardiac arrhythmia ablation] Lévy S.
Arch Mal Coeur Vaiss 1995 Oct;88(10):1465-9 (28 ref.) (Eng. Abstr.) **(Fre)**

[Ablation of arrhythmia disorders: endocavitary catheter surgery. 2 decades of cardia electrophysiology] Fontaine G. **Bull Mem Acad R Med Belg** 1995;150(10-11):380-414 (33 ref.) **(Fre)**

[The organizational and technical aspects of transcatheter ablation in cardiac arrhythmias. A document of the Gruppo Italiano di Aritmologia with a contribution of the Assoziazione Italiana di Cardiostimolazione under the aegis of the Società Italiana di Cardiologia and of the Associazione Nazionale Medici Cardiologi Ospedalieri]
Cardiologia 1995 Aug;40(8):593-609 **(Ita)**

[The organizational aspects and technics of catheter ablation in cardiac arrhythmias. Associazione Nazionale Medici Cardiologi Ospedalieri] **G Ital Cardiol** 1995 Aug; 25(8):1083-102 **(Ita)**

[Radiofrequency ablation of heart arrhythmias. Results in the first 150 patients treated at the Arrhythmia center in Oslo] Gjesdal K, et al. **Tidsskr Nor Laegeforen** 1995 Nov 30; 115(29):3606-11 (Eng. Abstr.) **(Nor)**

[Electrophysiological study and cardiac arrhythmia ablation using radiofrequency] de Paola AA. **Arq Bras Cardiol** 1995 Jun;64(6):585 **(Por)**

[Indications for electrophysiological studies and catheter ablation of cardiac arrhythmias. Recommendations of the Department of Arrhythmias and Clinical Electrophysiology of the Brazilian Society of Cardiology] Sosa EA, et al. **Arq Bras Cardiol** 1995 Feb;64(2):149-51 (1 ref.) **(Por)**

THERAPY

Drug therapy versus implantation of a cardiac defibrillator for the treatment of malignant arrhythmias in left ventricular dysfunction [editorial] Mannino MM, et al.
Am Heart J 1996 Jun;131(6):1251-9 (44 ref.)

Treatment of arrhythmias during pregnancy. Page RL.
Am Heart J 1995 Oct;130(4):871-6 (50 ref.)

Long-term outcome in patients with pacemakers following the Fontan operation. Fishberger SB, et al.
Am J Cardiol 1996 Apr 15;77(10):887-9

Prospective trials of implantable cardioverter defibrillators

versus drugs: are they addressing the right question? [editorial] Josephson M, et al. **Am J Cardiol** 1996 Apr 15; 77(10):859–63 (29 ref.)

Transesophageal atrial pacing combined with dual-chamber pacing [letter] Broka SM, et al. **Anesthesiology** 1996 Feb; 84(2):472

The implantable cardioverter defibrillator: modern implantation techniques and their impact on outcomes. Luceri RM, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:129–33

New generations of implantable pacemaker defibrillators for ventricular and atrial tachyarrhythmias. Saksena S, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:149–54

Cost-effectiveness in clinical cardiology. II. Preventive strategies and arrhythmia therapies. Simmons J, et al. **Chest** 1996 Jul;110(1):256–62

Interactions between antiarrhythmic drugs and implantable cardioverter-defibrillators. Dougherty AH. **Curr Opin Cardiol** 1996 Jan;11(1):2–8 (25 ref.)

Radiofrequency ablation--what is left? Zipes DP. **Eur Heart J** 1995 Aug;16 Suppl G:24–7 (13 ref.)

Issues in cardiac pacing: optimising pacemaker therapy [editorial] Gambhir DS. **Indian Heart J** 1996 Mar-Apr; 48(2):115–7 (32 ref.)

Classification of death in antiarrhythmia trials. Epstein AE, et al. **J Am Coll Cardiol** 1996 Feb;27(2):433–42

Changing Perspectives in Cardiac Arrhythmia Control: Agents, Techniques, Goals, and Outcomes. Symposium proceedings. Dallas, Texas, November 13, 1994. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):865–978

Drugs versus devices: contemporary practice in light of contemporary trials. Epstein AE. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):937–41 (32 ref.)

Mechanisms and therapy of complex arrhythmias in pediatric patients. Saul JP, et al. **J Cardiovasc Electrophysiol** 1995 Dec;6(12):1129–48 (146 ref.)

Implantation of transvenous implantable cardioverter-defibrillator by electrophysiologists: one-year experience. Tung RT, et al. **Kans Med** 1995 Fall; 96(3):121–4, 116

Radiofrequency catheter ablation for treatment of cardiac arrhythmias. **Med Lett Drugs Ther** 1996 Apr 26; 38(973):40–2

Nonpharmacological therapy for malignant ventricular arrhythmias: implantable defibrillator trials. Saksena S, et al. **Prog Cardiovasc Dis** 1996 May-Jun;38(6):429–44 (90 ref.)

New devices are helping transform coronary care [news] Wickelgren I. **Science** 1996 May 3;272(5262):668–70

[Influence of changing Ca++ concentration in neiguan (PC 6) on the effect of acupuncture treating experimental arrhythmia of rabbits] Zhang Y, et al. **Chen Tzu Yen Chiu** 1995;20(2):63–7 (Eng. Abstr.) **(Chi)**

[To treat a cardiac arrest or to count ventricular arrhythmias? (editorial)] Toivonen L, et al. **Duodecim** 1994;110(9):857–9 (15 ref.) **(Fin)**

[International symposium on treatment of cardiac arrhythmia. Current trends. Lille, France, November 2-3, 1995] **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:11–154 **(Fre)**

[Automatic implantable defibrillator and antiarrhythmic surgery in ischemic cardiopathies. Apropos of 53 cases] Fleurant E, et al. **Arch Mal Coeur Vaiss** 1995 Nov; 88(11):1627–34 (Eng. Abstr.) **(Fre)**

[Observations on the implantable automatic defibrillator] Slama R. **Bull Mem Acad R Med Belg** 1994; 149(8–11):383–7; discussion 387–8 (Eng. Abstr.) **(Fre)**

[Long term drug therapy for the prevention of recurrence in atrial fibrillation] Newman D, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:21A–26A (43 ref.) **(Fre)**

[Driving of a motor vehicle after implantation of a cardioverter-defibrillator in malignant heart rhythm disorders. Criteria for the medical assessment of driving fitness in Europe] Lüderitz B, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):119–23 (Eng. Abstr.) **(Ger)**

[Current pacemaker treatment and technology] Candinas R, et al. **Schweiz Rundsch Med Prax** 1996 May 14; 85(20):663–70 (24 ref.) (Eng. Abstr.) **(Ger)**

[Low pacing thresholds of ventricular pacemaker leads: not a marker for large R-wave amplitudes and high impedance values] Schuchert A, et al. **Z Kardiol** 1995 Dec;84(12):971–6 (Eng. Abstr.) **(Ger)**

[Management of patients with sustained ventricular arrhythmia: anti-arrhythmia agents or defibrillator?] Cappato R, et al. **Cardiologia** 1996 Feb;41(2):95–105 (75 ref.) **(Ita)**

[Treatment of supraventricular tachyarrhythmias: drugs or ablation?] Chimienti M, et al. **G Ital Cardiol** 1996 Feb; 26(2):213–26 (80 ref.) **(Ita)**

[Treatment of arrhythmia] Hayakawa K. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1512–6 (5 ref.) **(Jpn)**

[Biophysical basis and clinical use of catheter guided electric high frequency ablation in treatment of cardiac arrhythmias] Stanke A. **Pol Tyg Lek** 1995 Sep; 50(36–39):90–4 (35 ref.) **(Pol)**

[Recommendations of the Department of Arrhythmia and Clinical Electrophysiology (DAEC) of the Brazilian Cardiology Society on indications for permanent pacemaker implantation, choice of stimulation mode, and indications for automatic cardioverter-defibrillator implantation] Sosa EA, et al. **Arq Bras Cardiol** 1995 Jun; 64(6):579–83 **(Por)**

[The achievements of cardiac electrotherapy] Schaldach M. **Vestn Khir Im I I Grek** 1995;154(2):95–105 **(Rus)**

[Treatment of cardiac arrhythmias during pregnancy] Rodríguez Blanco VM, et al. **Med Clin (Barc)** 1996 Jun 1;107(1):29–36 (125 ref.) **(Spa)**

ULTRASONOGRAPHY

Fetal arrhythmias: intrauterine diagnosis, treatment and prognosis. Maeno Y, et al. **Acta Paediatr Jpn** 1995 Aug; 37(4):431–6

Guidance of radiofrequency catheter ablation by transesophageal echocardiography in children with palliated single ventricle. Drant SE, et al. **Am J Cardiol** 1995 Dec 15;76(17):1311–2

In vivo and in vitro studies on the mechanism and clinical significance of spontaneous echocardiographic contrast in patients with atrial dysrhythmias. Castello R, et al. **Prog Cardiovasc Dis** 1996 Jul-Aug;39(1):47–56 (65 ref.)

[Clinical significance of fetal cardiac arrhythmias] Räsänen J, et al. **Duodecim** 1994;110(6):575–83 **(Fin)**

VETERINARY

ECG of the month. Grubb TL, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):349–51

[Sedation and anesthesia in dogs and cats with cardiovascular disease. II. Anesthesia planning with respect to pathophysiology, heart arrhythmia] Skarda RT, et al. **Schweiz Arch Tierheilkd** 1995;137(12):543–51 (Eng. Abstr.) **(Ger)**

[ECG abnormalities in Airedale terriers] Amberger C, et al. **Tierarztl Prax** 1996 Jun;24(3):278–83 (Eng. Abstr.) **(Ger)**

ARRHYTHMIA, SINUS

Postural effect on respiratory sinus arrhythmia with various respiratory frequencies. Kobayashi H. **Appl Human Sci** 1996 Mar;15(2):87–91

CHEMICALLY INDUCED

[Sinus bradyarrhythmia during administration of all-trans retinoic acid in a patient with acute promyelocytic leukemia] Maruhashi K, et al. **Rinsho Ketsueki** 1996 May; 37(5):443–7 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Ambulatory measurement of respiratory sinus arrhythmia and respiration rate. de Geus EJ, et al. **Biol Psychol** 1995 Nov 16;41(3):205–27

[Automatic regulation of sinus rhythm in patients with migraine] Rozentryt P, et al. **Neurol Neurochir Pol** 1995 Nov-Dec;29(6):889–900 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Bradycardia after heart transplantation: reversal with theophylline. Bertolet BD, et al. **J Am Coll Cardiol** 1996 Aug;28(2):396–9

[Restoration of the sinus rhythm in atrial fibrillation] Talajic M, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:27A–34A (83 ref.) **(Fre)**

ETIOLOGY

Ventilator-associated sinus arrhythmia in a preterm neonate--an indicator for a mature autonomic nervous system? Zernikow B, et al. **Acta Paediatr** 1996 Apr; 85(4):505–7

Persistent atrial mechanical dysfunction after spontaneous conversion of chronic atrial fibrillation to sinus rhythm. Kahn ZU, et al. **Am Heart J** 1996 Mar;131(3):606–8 (14 ref.)

[Variability of sinus rhythm and cardiac failure] Daillet E, et al. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):551–3 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Determinants of respiratory sinus arrhythmia in the vagotomized rabbit. Perlini S, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H909–15

Respiratory sinus arrhythmia. A phenomenon improving pulmonary gas exchange and circulatory efficiency. Hayano J, et al. **Circulation** 1996 Aug 15;94(4):842–7

Respiratory sinus arrhythmia and central respiratory drive in humans. Al-Ani M, et al. **Clin Sci (Colch)** 1996 Mar; 90(3):235–41

Modulation of respiratory sinus arrhythmia by breathing pattern. Haggenmiller C, et al. **Clin Sci (Colch)** 1996;91 Suppl:40–2

[Mathematical model of "respiratory sinus arrhythmia"] Schiek M, et al. **Wien Med Wochenschr** 1995; 145(17–18):492–4 (Eng. Abstr.) **(Ger)**

[Circadian rhythms in the spectrum of heart rate variability] Schubert E, et al. **Wien Med Wochenschr** 1995; 145(17–18):460–2 (Eng. Abstr.) **(Ger)**

[Automatic regulation of sinus rhythm in patients with migraine] Rozentryt P, et al. **Neurol Neurochir Pol** 1995 Nov-Dec;29(6):889–900 (Eng. Abstr.) **(Pol)**

[The dynamics of cardiac vagal sinus arrhythmia in cats under the action of met-enkephalin] Pokrovskiĭ VM, et al. **Fiziol Zh Im I M Sechenova** 1995 Jul;81(7):69–73 (Eng. Abstr.) **(Rus)**

[Can permanent sinus arrhythmia in conscious dogs be suppressed with anesthesia?] Bernadič M, et al. **Bratisl Lek Listy** 1996 May;97(5):273–8 (Eng. Abstr.) **(Slo)**

VETERINARY

ECG of the month. Respiratory sinus arrhythmia and wandering pacemaker in a cat. Rishniw M, et al. **J Am Vet Med Assoc** 1996 Jun 1;208(11):1811–2

ARSENATES

METABOLISM

Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium. Huang RN, et al. **Toxicol Appl Pharmacol** 1996 Feb;136(2):243–9

Inorganic pentavalent arsenic methylation by rats: effect of concentration and dichromate. Gonzalez MJ, et al. **Vet Hum Toxicol** 1995 Oct;37(5):409–13

PHARMACOLOGY

Effects of copper-chrome-arsenate (CCA) components on PCP degradation by Arthrobacter strain ATCC 33790. Edgehill RU. **Bull Environ Contam Toxicol** 1996 Aug; 57(2):258–63

TOXICITY

Arsenic and chromium enhance transformation of bovine papillomavirus DNA-transfected C3H/10T1/2 cells. Kowalski LA, et al. **Cancer Lett** 1996 May 15;103(1):65–9

Time-dependent porphyric response in mice subchronically exposed to arsenic. García-Vargas G, et al. **Hum Exp Toxicol** 1995 Jun;14(6):475–83

Developmental toxicity of inorganic arsenic in whole embryo: culture oxidation state, dose, time, and gestational age dependence. Tabocova S, et al. **Toxicol Appl Pharmacol** 1996 Jun;138(2):298–307

Effect of trivalent and pentavalent arsenic in causing chromosome alterations in cultured Chinese hamster ovary (CHO) cells. Kochhar TS, et al. **Toxicol Lett** 1996 Jan; 84(1):37–42

ARSENAZO III

CHEMISTRY

Detection and quantitation of gadolinium chelates in human serum and urine by high-performance liquid chromatography and post-column derivatization of gadolinium with Arsenazo III. Hvattum E, et al. **J Pharm Biomed Anal** 1995 Jun;13(7):927–32

ARSENIC

Controlling for time-since-hire in occupational studies using internal comparisons and cumulative exposure. Arrighi HM, et al. **Epidemiology** 1995 Jul;6(4):415–8

ADVERSE EFFECTS

Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Chen CJ, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):504–10

Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Tseng CH, et al. **Atherosclerosis** 1996 Feb;120(1–2):125–33

Contact hypersensitivity to arsenic in a crystal factory worker. Barbaud A, et al. **Contact Dermatitis** 1995 Oct; 33(4):272–3

Arsenic in Dermatology. Maloney ME. **Dermatol Surg** 1996 Mar;22(3):301–4 (31 ref.)

Risk and revisionism in arsenic cancer risk assessment. Mushak P, et al. **Environ Health Perspect** 1995 Jul-Aug; 103(7–8):684–9

Abnormal peripheral microcirculation in seemingly normal subjects living in blackfoot-disease-hyperendemic villages in Taiwan. Tseng CH, et al. **Int J Microcirc Clin Exp** 1995 Jan-Feb;15(1):21–7

A retrospective lung cancer mortality study of people exposed to insoluble arsenic and radon. Liu YT, et al. **Lung Cancer** 1996 Mar;14 Suppl 1:S137–48

Controlling the healthy worker survivor effect: an example of arsenic exposure and respiratory cancer. Arrighi HM, et al. **Occup Environ Med** 1996 Jul;53(7):455–62

Diabetes mellitus and arsenic exposure: a second look at case-control data from a Swedish copper smelter. Rahman M, et al. **Occup Environ Med** 1995 Nov;52(11):773–4

Significance of exposure assessment to analysis of cancer risk from inorganic arsenic in drinking water in Taiwan. Brown KG, et al. **Risk Anal** 1995 Aug;15(4):475–84

Diabetes mellitus among Swedish art glass workers--an effect of arsenic exposure? Rahman M, et al. **Scand J Work Environ Health** 1996 Apr;22(2):146–9

[A study on the relationship between drinking water with high arsenic content and incidence of malignant tumour in Heihe Village, western part of Huhehot, Inner Mongolia] Luo FJ, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1995 Oct;

16(5):289–91 (Eng. Abstr.) **(Chi)**

ANALYSIS

Determination of arsenic, cadmium and lead in porcine and bovine kidneys by electrothermal atomic absorption spectrometry. Soares ME, et al. **Analyst** 1995 Sep; 120(9):2367–70

Distribution of arsenic and sulphate in the vicinity of Ashanti goldmine at Obuasi, Ghana. Golow AA, et al. **Bull Environ Contam Toxicol** 1996 May;56(5):703–10

Arsenic levels in soil of a town polluted 35 years ago (Nakajo, Japan). Nakadaira H, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):650–7

Determination of arsenic in blood and stomach contents by inductively coupled plasma/mass spectrometry (ICP/MS). Tanaka T, et al. **Forensic Sci Int** 1996 Jul 31;81(1):43–50

Arsenic adulteration in Indian tobacco. Narang AP, et al. **Indian J Med Sci** 1995 Mar;49(3):55–7

Multi-element detection of organometals by supercritical fluid chromatography with inductively coupled plasma mass spectrometric detection. Kumar UT, et al. **J Chromatogr Sci** 1995 Nov;33(11):606–10

[The assessment of arsenic exposure in copper smelting] Tsolova S, et al. **Probl Khig** 1995;20:128–38 (Eng. Abstr.) **(Bul)**

[Effect of unprepared and calcined magnetitum of arsenic solubility in boiling water extracts] Tie B, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):278–80, 318 (Eng. Abstr.) **(Chi)**

[Analysis of poisonous trace elements in huangwu gongmitai] Zhu T, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 May; 20(5):285–6, 319 (Eng. Abstr.) **(Chi)**

[Arsenic, lead and cadmium in home-made preserves of fruit and vegetables from previous years. 2. Climbing beans since the harvest year 1913] Boppel B. **Z Lebensm Unters Forsch** 1995 Jul;201(1):12–3 (Eng. Abstr.) **(Ger)**

[Arsenic, lead and cadmium in home-made preserves of fruits and vegetables from previous years. 3. Peaches since the harvest year 1931] Boppel B. **Z Lebensm Unters Forsch** 1995 Jul;201(1):14–6 (Eng. Abstr.) **(Ger)**

[Duplicate study on the dietary intake of some metals/metalloids by children in Germany. I. Arsenic and mercury] Wilhelm M, et al. **Zentralbl Hyg Umweltmed** 1995 Jun;197(5):345–56 (Eng. Abstr.) **(Ger)**

[Arsenic (As)] Sakai T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:846–9 (9 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

[Protective effects of sodium selenite and selenomethionine on genotoxicity to human peripheral lymphocytes induced by arsenic] Hu G, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1996 Jan;30(1):26–9 (Eng. Abstr.) **(Chi)**

BLOOD

Accumulation of arsenic species in serum of patients with chronic renal disease. Zhang X, et al. **Clin Chem** 1996 Aug; 42(8 Pt 1):1231–7

METABOLISM

Effect of DMPS and various adsorbents on the arsenic excretion in guinea-pigs after injection with As2O3. Reichl FX, et al. **Arch Toxicol** 1995;69(10):712–7

Study of distribution and interaction of arsenic and selenium in rat thyroid. Glattre E, et al. **Biol Trace Elem Res** 1995 Aug–Sep;49(2–3):177–86

Mono- and dimethylation of arsenic in rat liver cytosol in vitro. Styblo M, et al. **Chem Biol Interact** 1996 Jan 5; 99(1–3):147–64

A unique metabolism of inorganic arsenic in native Andean women. Vahter M, et al. **Eur J Pharmacol** 1995 Dec 7; 293(4):455–62

Interactions of rat red blood cell sulfhydryls with arsenate and arsenite. Winski SL, et al. **J Toxicol Environ Health** 1995 Nov;46(3):379–97

Comparative in vitro methylation of trivalent and pentavalent arsenicals. Styblo M, et al. **Toxicol Appl Pharmacol** 1995 Dec;135(2):172–8

Efflux-mediated resistance to arsenicals in arsenic-resistant and -hypersensitive Chinese hamster cells. Wang Z, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):112–9

Inorganic pentavalent arsenic methylation by rats: effect of concentration and dichromate. Gonzalez MJ, et al. **Vet Hum Toxicol** 1995 Oct;37(5):409–13

PHARMACOKINETICS

A physiologically based pharmacokinetic model for arsenic exposure. I. Development in hamsters and rabbits. Mann S, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):8–22

PHARMACOLOGY

The arsenical resistance operon of IncN plasmid R46. Bruhn DF, et al. **FEMS Microbiol Lett** 1996 Jun 1;139(2–3):149–53

Efflux-mediated resistance to arsenicals in arsenic-resistant and -hypersensitive Chinese hamster cells. Wang Z, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):112–9

POISONING

Mees' lines: A clue for the diagnosis of arsenic poisoning [letter] Quecedo E, et al. **Arch Dermatol** 1996 Mar; 132(3):349–50

Fulminant malignant arrythmia and multiorgan failure in acute arsenic poisoning [letter] Civantos DP, et al. **Chest** 1995 Dec;108(6):1774–5

Elevated incidence of childhood leukemia in Woburn, Massachusetts: NIEHS Superfund Basic Research Program searches for causes. Durant JL, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:93–8

An unhappily married man with thick soles [see comments] Navarro B, et al. **Lancet** 1996 Jun 8;347(9015):1596. Comment in: Lancet 1996 Jul 27;348(9022):276.

All is not what it seems [letter; comment] Sataline L. **Lancet** 1996 Jul 27;348(9022):276. Comment on: Lancet 1996 Jun 8;347(9015):1596.

Arsenic poisoning after a barbecue [letter] Geschke AM, et al. **Med J Aust** 1996 Sep 2;165(5):296

Teat licking in dairy cattle [letter] Lawson RB. **Vet Rec** 1996 Apr 27;138(17):424

[Acute arsenic poisoning] Johansen JB, et al. **Ugeskr Laeger** 1996 Jul 15;158(29):4201–2 (Eng. Abstr.) **(Dan)**

TOXICITY

An insect model for assessing arsenic toxicity: arsenic elevated glutathione content in the Musca domestica and Trichoplusia ni. Zaman K, et al. **Bull Environ Contam Toxicol** 1995 Dec;55(6):845–52

Role of arsenic as a reproductive toxin with particular attention to neural tube defects. Shalat SL, et al. **J Toxicol Environ Health** 1996 Jun 28;48(3):253–72 (130 ref.)

Assessment of a possible genotoxic environmental risk in sheep bred on grounds with strongly elevated contents of mercury, arsenic and antimony. Gebel T, et al. **Mutat Res** 1996 Jul 5;368(3–4):267–74

Implications of arsenic genotoxicity for dose response of carcinogenic effects. Rudel R, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):87–105 (55 ref.)

URINE

Geographical and temporal differences in the urinary excretion of inorganic arsenic: a Belgian population study. Buchet JP, et al. **Occup Environ Med** 1996 May;53(5):320–7

Arsenic burden among children in industrial areas of eastern Germany. Trepka MJ, et al. **Sci Total Environ** 1996 Feb 9;180(2):95–105

An attempt to explain interindividual variability in 24-h urinary excretion of inorganic arsenic metabolites by C57 BL/6J mice. Telolahy P, et al. **Toxicology** 1995 Nov 30; 103(2):105–12

ARSENIC COMPOUNDS see **ARSENICALS**

ARSENICALS

ADVERSE EFFECTS

Numerous erythematous truncal plaques. Multiple basal cell carcinomas associated with arsenic ingestion. Mowad CM, et al. **Arch Dermatol** 1996 Sep;132(9):1105–6, 1108–9

Generalized contact dermatitis from acetarsone. Sasseville D, et al. **Contact Dermatitis** 1995 Dec;33(6):431–2

Use of the fluorescent micronucleus assay to detect the genotoxic effects of radiation and arsenic exposure in exfoliated human epithelial cells. Moore LE, et al. **Environ Mol Mutagen** 1996;27(3):176–84

Effects of multiple gallium arsenide exposure on some biochemical alterations in rat brain [letter] Flora SJ, et al. **Ind Health** 1994;32(4):247–52

ANALYSIS

Identification of methylated metabolites of inorganic arsenic by thin-layer chromatography. Stýblo M, et al. **J Chromatogr B Biomed Appl** 1995 Jun 9;668(1):21–9

ANTAGONISTS & INHIBITORS

Antidotal efficacy of newly synthesized dimercaptosuccinic acid (DMSA) monoesters in experimental arsenic poisoning in mice. Kreppel H, et al. **Fundam Appl Toxicol** 1995 Jul; 26(2):239–45

BLOOD

Time dependence of accumulation and binding of inorganic and organic arsenic species in rabbit erythrocytes. Delnomdedieu M, et al. **Chem Biol Interact** 1995 Oct 20; 98(1):69–83

A unique metabolism of inorganic arsenic in native Andean women. Vahter M, et al. **Eur J Pharmacol** 1995 Dec 7; 293(4):455–62

CHEMISTRY

Involvement of vicinal dithiols in differential regulation of fMLP and phorbol ester-activated phospholipase D in stimulated human neutrophils. Planat V, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):847–53

METABOLISM

Arsenite release on enzymic transformation of arsonomethyl substrate analogues: a potentially lethal synthesis by glycerol-3-phosphate dehydrogenase. Mutenda EK, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):983–8

Binding of phenylarsenoxide to Arg-tRNA protein transferase is independent of vicinal thiols. Li J, et al. **Biochemistry** 1995 Dec 5;34(48):15829–37

Enzymatic methylation of arsenic compounds: assay, partial purification, and properties of arsenite methyltransferase and monomethylarsonic acid methyltransferase of rabbit liver. Zakharyan R, et al. **Chem Res Toxicol** 1995 Dec; 8(8):1029–38

Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. Carter NS, et al. **J Biol Chem** 1995 Nov 24; 270(47):28153–7

Reactions of arsine with hemoglobin. Hatlelid KM, et al. **J Toxicol Environ Health** 1996 Feb 9;47(2):145–57

Comparative in vitro methylation of trivalent and pentavalent arsenicals. Styblo M, et al. **Toxicol Appl Pharmacol** 1995 Dec;135(2):172–8

PHARMACOLOGY

Characterisation of cloned lines of Trypanosoma brucei expressing stable resistance to MelCy and suramin. Scott AG, et al. **Acta Trop** 1996 Feb;60(4):251–62

Phenylarsine oxide and vanadate: apparent paradox of inhibition of protein phosphotyrosine phosphatases in rat adipocytes. Li J, et al. **Biochim Biophys Acta** 1996 Jul 24; 1312(3):223–30

Effect of phenylarsine oxide on the fission yeast Schizosaccharomyces pombe cell cycle. Oustrin ML, et al. **Biochimie** 1995;77(4):279–87

In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Chen GQ, et al. **Blood** 1996 Aug 1;88(3):1052–61

Effects of the protein tyrosine phosphatase inhibitor phenylarsine oxide on excision-activated calcium channels in Lymnaea neurons. Pafford CM, et al. **Cell Calcium** 1995 Nov;18(5):400–10

Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. Carter NS, et al. **J Biol Chem** 1995 Nov 24; 270(47):28153–7

The role of arsenic-thiol interactions in metalloregulation of the ars operon. Shi W, et al. **J Biol Chem** 1996 Apr 19;271(16):9291–7

Differential susceptibility of filarial and human erythrocyte glutathione reductase to inhibition by the trivalent organic arsenical melarsen oxide. Müller S, et al. **Mol Biochem Parasitol** 1995 May;71(2):211–9

POISONING

The use of haemodialysis and 2,3 propanesulphonate (DMPS) to manage acute oral poisoning by lethal dose of arsenic trioxide. Kruszewska S, et al. **Int J Occup Med Environ Health** 1996;9(2):111–5

Arsine toxicity: chemical and mechanistic implications. Klimecki WT, et al. **J Toxicol Environ Health** 1995 Dec; 46(4):399–409 (49 ref.)

Toxic little black pills [letter] McAnulty JM, et al. **Med J Aust** 1996 Jul 1;165(1):62

Chelation of organoarsenate with dimercaptosuccinic acid. Shum S, et al. **Vet Hum Toxicol** 1995 Jun;37(3):239–42

THERAPEUTIC USE

Evaluation of the efficacy of melarsenoxyde cysteamine (Cymelarsan) in treatment of camels experimentally infected with Trypanosoma evansi using antigen trapping enzyme-linked immunosorbent assay. Nyang'ao JM, et al. **J Vet Pharmacol Ther** 1995 Dec;18(6):468–70

Preliminary efficacy trial of Cymelarsan in mice artificially infected with Trypanosoma brucei brucei isolated from a dog in Zambia. Syakalima M, et al. **Jpn J Vet Res** 1995 Sep;43(2):93–7

Ancient remedy performs new tricks [news] Mervis J. **Science** 1996 Aug 2;273(5275):578

Anti-nematode activity of sixteen compounds against Trichinella spiralis in mice--a possible new screen for macrofilaricides. Surin J. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):128–34

TOXICITY

Influence of glucose on the toxicity of oxophenylarsine in MDCK cells. Liebl B, et al. **Arch Toxicol** 1995;69(6):421–4

Effect of DMPS and various adsorbents on the arsenic excretion in guinea-pigs after injection with As2O3. Reichl FX, et al. **Arch Toxicol** 1995;69(10):712–7

Chronic toxicity of indium arsenide and indium phosphide to the lungs of hamsters. Tanaka A, et al. **Fukuoka Igaku Zasshi** 1996 May;87(5):108–15

Is ingested inorganic arsenic a "threshold" carcinogen? Abernathy CO, et al. **Fundam Appl Toxicol** 1996 Feb; 29(2):168–75 (59 ref.)

Antidotal efficacy of newly synthesized dimercaptosuccinic

acid (DMSA) monoesters in experimental arsenic poisoning in mice. Kreppel H, et al. **Fundam Appl Toxicol** 1995 Jul; 26(2):239–45
Reversal of oxophenylarsine-induced inhibition of glucose uptake in MDCK cells. Liebl B, et al. **Fundam Appl Toxicol** 1995 Aug;27(1):1–8
Subchronic toxicity evaluation of lewisite in rats. Sasser LB, et al. **J Toxicol Environ Health** 1996 Mar;47(4):321–34
Trypanosoma evansi: measurement of pyruvate production as an indicator of the drug sensitivity of isolates in vitro. Sutherland DV, et al. **Trop Med Parasitol** 1995 Jun; 46(2):93–8
[Isolation and characterization of bacterial strains resistant to arsenical compounds] Pimenov EV, et al. **Mikrobiologiia** 1996 Mar–Apr;65(2):214–8 **(Rus)**

ARSENITES

METABOLISM

Arsenite release on enzymic transformation of arsonomethyl substrate analogues: a potentially lethal synthesis by glycerol-3-phosphate dehydrogenase. Mutenda EK, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):983–8
Enzymatic methylation of arsenic compounds: assay, partial purification, and properties of arsenite methyltransferase and monomethylarsonic acid methyltransferase of rabbit liver. Zakharyan R, et al. **Chem Res Toxicol** 1995 Dec; 8(8):1029–38
Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium. Huang RN, et al. **Toxicol Appl Pharmacol** 1996 Feb;136(2):243–9
Efflux-mediated resistance to arsenicals in arsenic-resistant and -hypersensitive Chinese hamster cells. Wang Z, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):112–9

PHARMACOKINETICS

Soft metal thiol chemistry is not involved in the transport of arsenite by the Ars pump. Chen Y, et al. **J Bacteriol** 1996 Feb;178(3):911–3
An attempt to explain interindividual variability in 24-h urinary excretion of inorganic arsenic metabolites by C57 BL/6J mice. Telolahy P, et al. **Toxicology** 1995 Nov 30; 103(2):105–12

PHARMACOLOGY

Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. Ishikawa T, et al. **J Biol Chem** 1996 Jun 21;271(25):14981–8
The role of arsenic-thiol interactions in metalloregulation of the ars operon. Shi W, et al. **J Biol Chem** 1996 Apr 19;271(16):9291–7
Sensitization to x-rays by sodium arsenite or heat in normal cells and in cells with an induced tolerance for heat and arsenite. van Rijn J, et al. **Radiat Environ Biophys** 1995 Aug;34(3):169–75
Effects of monoisoamyl meso-2,3-dimercaptosuccinate on arsenite-induced maternal and developmental toxicity in mice. Domingo JL, et al. **Res Commun Mol Pathol Pharmacol** 1995 Sep; 89(3):389–400

TOXICITY

Modulation of cellular antioxidant defense activities by sodium arsenite in human fibroblasts. Lee TC, et al. **Arch Toxicol** 1995;69(7):498–504
Arsenite, but not cadmium, induces ornithine decarboxylase and heme oxygenase activity in rat liver: relevance to arsenic carcinogenesis. Brown JL, et al. **Cancer Lett** 1996 Jan 2;98(2):227–31
Arsenic and chromium enhance transformation of bovine papillomavirus DNA-transfected C3H/10T1/2 cells. Kowalski LA, et al. **Cancer Lett** 1996 May 15;103(1):65–9
Effect of arsenic and cadmium on the persistence of mutagen-induced DNA lesions in human cells. Hartmann A, et al. **Environ Mol Mutagen** 1996;27(2):98–104
Time-dependent porphyric response in mice subchronically exposed to arsenic. García-Vargas G, et al. **Hum Exp Toxicol** 1995 Jun;14(6):475–83
Lowering extracellular calcium content protects cells from arsenite-induced killing and micronuclei formation. Liu YC, et al. **Mutagenesis** 1996 Jan;11(1):75–8
Squalene inhibits sodium arsenite-induced sister chromatid exchanges and micronuclei in Chinese hamster ovary-K1 cells. Fan SR, et al. **Mutat Res** 1996 Jul 5;368(3-4):165–9
Dietary garlic extract in modifying clastogenic effects of inorganic arsenic in mice: two-generation studies. RoyChoudhury A, et al. **Mutat Res** 1996 Apr 4; 359(3):165–70
Developmental toxicity of inorganic arsenic in whole embryo: culture oxidation state, dose, time, and gestational age dependence. Tabocova S, et al. **Toxicol Appl Pharmacol** 1996 Jun;138(2):298–307
Efflux-mediated resistance to arsenicals in arsenic-resistant and -hypersensitive Chinese hamster cells. Wang Z, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):112–9
Effect of trivalent and pentavalent arsenic in causing chromosome alterations in cultured Chinese hamster ovary (CHO) cells. Kochhar TS, et al. **Toxicol Lett** 1996 Jan; 84(1):37–42
Sodium arsenite and heat shock induce stress proteins in precision-cut rat liver slices. Wijeweera JB, et al. **Toxicology** 1995 Dec 15;104(1-3):35–45

ARSON see **FIRESETTING BEHAVIOR**

ART

see related
ANATOMY, ARTISTIC
MEDICAL ILLUSTRATION
MEDICINE IN ART

The clock drawing test as a cognitive screening tool for elderly patients in an acute-care hospital. Ben-Yehuda A, et al. **Aging (Milano)** 1995 Jun;7(3):188–90
Artistic expressions of illness. Soffa VM. **Altern Ther Health Med** 1996 May;2(3):63–6
Medicine--a healing or a dying art? Smith BH, et al. **Br J Gen Pract** 1996 Apr;46(405):249–51
A painting that changed by my life [letter] Ward SJ. **Br J Hosp Med** 1995 Oct 4–17;54(7):354
A creative art centre for adults with developmental disabilities. Katz E. **Disabil Rehabil** 1996 May;18(5):261–4
The development of visual preferences in art-trained and non-art-trained schoolchildren. Bezruczko N, et al. **Genet Soc Gen Psychol Monogr** 1996 May;122(2):179–96
Pediatric headaches: what do the children want? Lewis DW, et al. **Headache** 1996 Apr;36(4):224–30
Savants, segments, art and autism. Pring L, et al. **J Child Psychol Psychiatry** 1995 Sep;36(6):1065–76
Intellectual evaluations of children using human figure drawings: an empirical investigation of two methods. Abell SC, et al. **J Clin Psychol** 1996 Jan;52(1):67–74
Art and science, culture and dental research [editorial] Newman HN. **J Dent Res** 1996 Jan;75(1):526–7
Symbolic immunity and flexibility in preschoolers' human figure drawings. Boyatzis CJ, et al. **J Genet Psychol** 1995 Sep;156(3):293–302
Altars to the hand: art and belief in southern Nigeria [editorial] Horan AL. **J Hand Ther** 1996 Jan-Mar;9(1):2–5
1994 Molecular Graphics Art Show and Video Show. Goodsell DS, et al. **J Mol Graph** 1995 Aug;13(4):223–41
Arts courses for students and clinicians [letter; comment] Jarrett P. **Lancet** 1996 Jul 27;348(9022):271. Comment on: Lancet 1996 Jun 1;347(9014):1499–500.
Epilepsy and art [letter] Malcolm SJ. **Med J Aust** 1996 Jul 1;165(1):64
Quantification of essential tremor in writing and drawing. Elble RJ, et al. **Mov Disord** 1996 Jan;11(1):70–8
Learning improved by arts training [letter] Gardiner MF, et al. **Nature** 1996 May 23;381(6580):284
Are perception and memory for faces influenced by a specific age at onset factor in Parkinson's disease? Haeske-Dewick HC. **Neuropsychologia** 1996 Apr;34(4):315–20
Evidence for a global scanpath strategy in viewing abstract compared with realistic images. Zangemeister WH, et al. **Neuropsychologia** 1995 Aug;33(8):1009–25
Gender, gender role, and drawing skill. Sappington J, et al. **Percept Mot Skills** 1996 Feb;82(1):283–8
What hinders accurate depiction of projective shape? Reith E, et al. **Perception** 1995;24(9):995–1010
Crumb: whereof one should not speak. Greenberg HR. **Psychoanal Rev** 1995 Dec;82(6):936–40
The vital role of adaptive grandiosity in artistic creativity. Wolson P. **Psychoanal Rev** 1995 Aug;82(4):577–97
Perspective production in a savant autistic draughtsman. Mottron L, et al. **Psychol Med** 1995 May;25(3):639–48
Children's drawings and attachment to pets. Kidd AH, et al. **Psychol Rep** 1995 Aug;77(1):235–41
Aesthetic properties of pictorial perception. Takahashi S. **Psychol Rev** 1995 Oct;102(4):671–83
Pointillism and science [editorial] Dimsdale JE. **Psychosom Med** 1996 Jan-Feb;58(1):1
Curie-point pyrolysis-gas chromatography/mass spectrometry in the art field. 2--The characterization of proteinaceous binders. Carbini M, et al. **Rapid Commun Mass Spectrom** 1996;10(10):1240–2
The visual arts in Northern Ireland hospitals. Cromie H. **Ulster Med J** 1995 Oct;64(2):164–71
[White walls for black holes: essay on graffiti psychopathology] Catheline-Antipoff N, et al. **Psychiatr Enfant** 1995;38(2):625–53 (16 ref.) (Eng. Abstr.) **(Fre)**
[Is beauty a measurable concept in medicine? (editorial)] Honigmann K. **Schweiz Rundsch Med Prax** 1995 Nov 14; 84(46):1333–4 **(Ger)**
[Relationship between physicians and art] Hankiss J. **Orv Hetil** 1996 Feb 11;137(6):306–10 **(Hun)**

HISTORY

Vincent van Gogh's birthday. Arnold WN. **Pharos** 1995 Fall; 58(4):28–32
[Goya, a cyclothymic genius] Alonso Fernández F. **An R Acad Nac Med (Madr)** 1995;112(4):771–83; discussion 783–7 **(Spa)**

ART THERAPY

Participation of children with autism and nondisabled peers in a cooperatively structured community art program. Schleien SJ, et al. **J Autism Dev Disord** 1995 Aug; 25(4):397–413
[Art therapy as an assisting psychotherapeutic method for adolescents] Skowron J, et al. **Psychiatr Pol** 1996 Mar–Apr; 30(2):247–54 (Eng. Abstr.) **(Pol)**
[Art psychotherapy solves psychosomatic disorders] Wilhelmson B. **Lakartidningen** 1996 May 8;93(19):1851 **(Swe)**

METHODS

Video Respite: an innovative resource for family, professional caregivers, and persons with dementia. Lund DA, et al. **Gerontologist** 1995 Oct;35(5):683–7

ORGANIZATION & ADMINISTRATION

Womanspirit: a journey into healing through art in breast cancer. Predeger E. **ANS Adv Nurs Sci** 1996 Mar; 18(3):48–58

ART-TRS GENE PROTEIN, HIV see **GENE PRODUCTS, REV**

ART-TRS GENES see **GENES, REV**

ARTEMIA

DRUG EFFECTS

Comparative sensitivity of three age classes of Artemia salina larvae to several phenolic compounds. Barahona MV, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):271–8
Toxicity of Fusarium sambucinum Fuckel sensu lato to brine shrimp. Schmidt R, et al. **Mycopathologia** 1995;129(3):173–5

EMBRYOLOGY

Mitochondrial differentiation during the early development of the brine shrimp Artemia franciscana. Vallejo CG, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):505–10

ENZYMOLOGY

Purification and characterization of Artemia 2',3'-cyclic nucleotide 3'-phosphodiesterase. Díaz AR, et al. **Biochim Biophys Acta** 1996 Jun 4;1290(2):135–40
Specific ADP-ribose pyrophosphatase from Artemia cysts and rat liver: effects of nitroprusside, fluoride and ionic strength. Fernández A, et al. **Biochim Biophys Acta** 1996 May 21;1290(1):121–7
Potential role in development of the major cysteine protease in larvae of the brine shrimp Artemia franciscana. Warner AH, et al. **Cell Tissue Res** 1995 Oct;282(1):21–31
Valyl-tRNA synthetase from Artemia. Purification and association with elongation factor 1. Brandsma M, et al. **Eur J Biochem** 1995 Oct 1;233(1):277–82
Thermal stability of Artemia HGPRT: effect of substrates on inactivation kinetics. Montero C, et al. **Int J Biol Macromol** 1996 Jun;18(4):255–62
Tissue-specific expression of two Artemia franciscana sarco/endoplasmic reticulum Ca-ATPase isoforms. Escalante R, et al. **J Histochem Cytochem** 1996 Apr; 44(4):321–5

GENETICS

Tissue-specific alternative promoters regulate the expression of the two sarco/endoplasmic reticulum Ca-ATPase isoforms from Artemia franciscana. Escalante R, et al. **DNA Cell Biol** 1995 Oct;14(10):893–900
Evolutionary history of introns in a multidomain globin gene. Jellie AM, et al. **J Mol Evol** 1996 Jun;42(6):641–7

METABOLISM

Accumulation and depuration of DDTs in the food chain from Artemia to brook trout (Salvelinus fontinalis). Wang JS, et al. **Bull Environ Contam Toxicol** 1996 Jun; 56(6):888–95
Acute depression of mitochondrial protein synthesis during anoxia: contributions of oxygen sensing, matrix acidification, and redox state. Kwast KE, et al. **J Biol Chem** 1996 Mar 29;271(13):7313–9

PARASITOLOGY

Gammarus pulex (L.) feeding bioassay--effects of parasitism. Pascoe D, et al. **Bull Environ Contam Toxicol** 1995 Oct; 55(4):629–32

ARTERIAL CATHETERIZATION, PERIPHERAL see **CATHETERIZATION, PERIPHERAL**

ARTERIAL LINES see **CATHETERS, INDWELLING**

ARTERIAL OBSTRUCTIVE DISEASES see **ARTERIAL OCCLUSIVE DISEASES**

ARTERIAL OCCLUSIVE DISEASES

Catheter-directed thrombolysis: an annotated bibliography and selected references (1990–1994). Dykes TA, et al. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):126S–133S
Popliteal artery entrapment syndrome. Anatomic and embryologic bases, diagnostic and therapeutic considerations following a series of 15 cases with a review of the literature. Rosset E, et al. **Surg Radiol Anat** 1995;

17(2):161–9, 23–7 (89 ref.) **(Eng, Fre)**

BLOOD

Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease [see comments] Fermo I, et al. **Ann Intern Med** 1995 Nov 15; 123(10):747–53. Comment in: Ann Intern Med 1996 Sep 1;125(5):419–20.

Lipoprotein(a) and general risk factors in patients with angiographically assessed peripheral arterial disease. Prior M, et al. **Int Angiol** 1995 Dec;14(4):357–63

Leukocyte activation study during occlusive arterial disease of the lower limb: effect of pentoxifylline infusion. Fossat C, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S96–100

Hemostatic disorders associated with arterial hypertension and peripheral arterial disease. Trifiletti A, et al. **J Cardiovasc Surg (Torino)** 1995 Oct;36(5):483–5

Increased serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease. Burgmann H, et al. **J Clin Pathol** 1996 Jun;49(6):508–10

Homocysteine: an independent risk factor associated with coronary disease and other arterial occlusive diseases in adults. Drown DJ. **Prog Cardiovasc Nurs** 1995 Fall; 10(4):37–8

Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Lee AJ, et al. **Thromb Haemost** 1995 Sep; 74(3):828–32

Blood coagulation and fibrinolysis activation during sudden arterial occlusion of lower extremities—an association with ischemia and patient outcome. Peltonen S, et al. **Thromb Haemost** 1995 Dec;74(6):1442–6

CHEMICALLY INDUCED

Bromocriptine and postpartum cerebral angiopathy: a causal relationship? Comabella M, et al. **Neurology** 1996 Jun; 46(6):1754–6

CLASSIFICATION

[Clinical-functional classification of combined occlusive lesions of the arterial system] Konstantinov BA, et al. **Khirurgiia (Mosk)** 1995;(5):50–3 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Aneurysms of the pancreaticoduodenal artery associated with occlusion of the celiac artery. Uher P, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):470–3 (22 ref.)

Physician recognition of hypercholesterolemia in patients undergoing peripheral and carotid artery revascularization. Aspry KE, et al. **Am J Prev Med** 1995 Sep–Oct; 11(5):336–41

Brain ischemia following bilateral carotid occlusion during development of hypertension in young spontaneously hypertensive rats—importance of morphologic changes of the arteries of the circle of Willis. Kusuda K, et al. **Angiology** 1996 May;47(5):455–65

The early effects of intravenous L-propionyl carnitine on ulcerative trophic lesions of the lower limbs in arteriopathic patients: a controlled randomized study. Persico G, et al. **Drugs Exp Clin Res** 1995;21(5):187–98

Brainstem ischemic damage following occlusion of the blood vessels in the rat's posterior cerebral circulation. Inui H, et al. **Eur Arch Otorhinolaryngol** 1996;253(3):176–81

Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus. Belch JJ, et al. **Int Angiol** 1995 Dec;14(4):385–8

The microcirculatory effects of peripheral sympathectomy. Koman LA, et al. **J Hand Surg [Am]** 1995 Sep;20(5):709–17

Evidence of misery perfusion and risk for recurrent stroke in major cerebral arterial occlusive diseases from PET. Yamauchi H, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):18–25

Ruptured aneurysm of the middle meningeal artery associated with occlusion of the posterior cerebral artery. Case report. Ushikoshi S, et al. **J Neurosurg** 1996 Feb;84(2):269–71

Essential hypertension: could the basic defect be in blood supply of vasomotor centre? Garg VK, et al. **Med Hypotheses** 1995 Sep;45(3):287–91

Traumatic occlusion of one limb of an intracranial arterial fenestration: an uncommon cause of stroke. Schievink WI, et al. **Neurology** 1996 Jul;47(1):277–8

Permanent occlusion of bilateral internal carotid arteries produces cognitive deficits in two learning behavior tasks. Watanabe H, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Feb; 16(1):19–24

Age and carotid artery occlusive disease are important determinants of cerebral blood flow changes after antihypertensive therapy. Fagan SC, et al. **Pharmacotherapy** 1995 Sep–Oct;15(5):573–8

Subacute mucormycosis with secondary internal carotid occlusion: clinical and MR findings. Casanova B, et al. **Rev Neurol** 1995 May–Jun;23(121):682–4

A model to predict the histopathology of human stroke using diffusion and T2-weighted magnetic resonance imaging [see comments] Welch KM, et al. **Stroke** 1995 Nov; 26(11):1983–9. Comment in: Stroke 1996 Jul;27(7):1254–6.

Induced hypertension during ischemia reduces infarct area after temporary middle cerebral artery occlusion in rats. Chileuitt L, et al. **Surg Neurol** 1996 Sep;46(3):229–34

Interruption of pulmonary arterial flow with inadequate ventilation leads to pulmonary infection. Urano, et al. **Virchows Arch** 1996 Mar;427(6):607–12

[Preventive treatment of cerebrovascular accidents of arterial origin] Castillo V, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):159–63 (33 ref.) (Eng. Abstr.) **(Fre)**

[A case of ruptured thoracoabdominal aortic aneurysm complicated with high aortic occlusion] Satokawa H, et al. **Kyobu Geka** 1995 Nov;48(12):1053–6 (Eng. Abstr.) **(Jpn)**

[Three cases of hyperkalemia after reperfusion associated with revascularization for massive acute arterial occlusions] Arakura A, et al. **Masui** 1996 Mar;45(3):340–4 (Eng. Abstr.) **(Jpn)**

[Monocular photopsia preceding with neovascular glaucoma due to internal carotid artery occlusion; a case report] Urushitani M, et al. **Rinsho Shinkeigaku** 1996 Mar; 36(3):481–4 (Eng. Abstr.) **(Jpn)**

CONGENITAL

Endovascular stents in children under 1 year of age: acute impact and late results. Hatai Y, et al. **Br Heart J** 1995 Dec;74(6):689–95 (16 ref.)

DIAGNOSIS

Cardiac-gated MR angiography of the entire lower extremity: a prospective comparison with conventional angiography. Glickerman DJ, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):445–51

Diagnosis and treatment of an ophthalmic artery occlusion during an intralesional injection of corticosteroid into an eyelid capillary hemangioma. Egbert JE, et al. **Am J Ophthalmol** 1996 Jun;121(6):638–42

Assessment of noninvasive lower extremity arterial testing versus pulse exam. Kazmers A, et al. **Am Surg** 1996 Apr; 62(4):315–9

Comparison of whole-body thallium imaging with transcutaneous PO2 in studying regional blood supply in patients with peripheral arterial occlusive disease. Liu Y, et al. **Angiology** 1996 Sep;47(9):879–86

Diagnosis of arterial disease of the lower extremities with duplex ultrasonography. Koelemay MJ, et al. **Br J Surg** 1996 Mar;83(3):404–9 (48 ref.)

Case report: low femoral artery puncture: a cause of diagnostic error. Murray JG, et al. **Clin Radiol** 1996 Jul; 51(7):515–7

Large vessel vasculitis without temporal artery involvement: isolated form of giant cell arteritis? Lambert M, et al. **Clin Rheumatol** 1996 Mar;15(2):174–80

Spinal claudication versus arterial claudication. Maher M, et al. **Ir J Med Sci** 1996 Apr–Jun;165(2):118–20

Basilar and distal vertebral artery occlusive disease: correlation of MR imaging and MR angiography. Seynaeve P, et al. **J Belge Radiol** 1996 Apr;79(2):61–7

High resolution, magnetization transfer saturation, variable flip angle, time-of-flight MRA in the detection of intracranial vascular stenoses. Dagirmanjian A, et al. **J Comput Assist Tomogr** 1995 Sep–Oct;19(5):700–6

Carotid and vertebral artery occlusion after blunt cervical injury: the role of MR angiography in early diagnosis. Bok AP, et al. **J Trauma** 1996 Jun;40(6):968–72

Value of toe pulse waves in addition to systolic pressures in the assessment of the severity of peripheral arterial disease and critical limb ischemia. Carter SA, et al. **J Vasc Surg** 1996 Aug;24(2):258–65

The relative contributions of carotid duplex scanning, magnetic resonance angiography, and cerebral arteriography to clinical decisionmaking: a prospective study in patients with carotid occlusive disease. Erdoes LS, et al. **J Vasc Surg** 1996 May;23(5):950–6

Use of magnetic resonance angiography for the preoperative evaluation of patients with infrainguinal arterial occlusive disease. Hoch JR, et al. **J Vasc Surg** 1996 May; 23(5):792–800; discussion 801

Acute effects of exercise on muscle MRI in peripheral arterial occlusive disease. Yoshioka H, et al. **Magn Reson Imaging** 1995;13(5):651–9

Bio-acoustic signals from stenotic tube flow: state of the art and perspectives for future methodological development. Ask P, et al. **Med Biol Eng Comput** 1995 Sep;33(5):669–75 (29 ref.)

Velocity profile distribution along an arterial vessel: way to improve detection of stenotic sites. Cavalcanti S, et al. **Med Biol Eng Comput** 1995 May;33(3):247–51

Cepstrum analysis of reflected pressure waves in stenosed arteries. Roffeh Y, et al. **Med Biol Eng Comput** 1996 Mar; 34(2):175–80

Variability of magnetic resonance angiography and computed tomography angiography in grading middle cerebral artery stenosis. Wong KS, et al. **Stroke** 1996 Jun;27(6):1084–7

The ocular ischemic syndrome in carotid artery occlusive disease: ophthalmic color Doppler flow velocity and electroretinographic changes following carotid artery reconstruction. Story JL, et al. **Surg Neurol** 1995 Dec; 44(6):534–5

Cystic adventitial disease of the popliteal artery—a case of young boy. Ishibashi S, et al. **Tohoku J Exp Med** 1995 Jul;176(3):173–80 (20 ref.)

Thermodiffusion as a novel method for continuous monitoring of the hepatic microcirculation after liver transplantation. Klar E, et al. **Transplant Proc** 1995 Oct; 27(5):2610–2

[Hydrostatic toe pressure measurement: a noninvasive screening method in the diagnosis of arterial occlusive diseases in diabetics and nondiabetics] Sambraus HW. **Dtsch Med Wochenschr** 1996 Mar 22;121(12):364–8 (Eng. Abstr.) **(Ger)**

[Angiology update] Ranke C, et al. **Med Klin** 1995 Aug 15; 90(8):467–79 (129 ref.) **(Ger)**

DRUG THERAPY

Factors predicting the outcome of intraarterial thrombolysis in peripheral arterial and graft occlusions. Sandbaek G, et al. **Acta Radiol** 1996 May;37(3 Pt 1):299–304

Minimally invasive management of acute superior mesenteric artery occlusion: combined urokinase and laparoscopic therapy. Regan F, et al. **Am J Gastroenterol** 1996 May; 91(5):1019–21

Thrombolysis in extremital arteries—indications and methods. Wellander E, et al. **Ann Chir Gynaecol** 1995; 84(4):341–8 (74 ref.)

Occlusive thrombosis in the femoral artery of the rabbit: a pharmacological model for evaluating antiplatelet and anticoagulant agents. Sugidachi A, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):57–64

Dosage and timing of Photofrin for photodynamic therapy of intimal hyperplasia. Hsiang YN, et al. **Cardiovasc Surg** 1995 Oct;3(5):489–94

Antithrombotic therapy in peripheral arterial occlusive disease. Clagett GP, et al. **Chest** 1995 Oct;108(4 Suppl):431S–443S (193 ref.)

L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Bode-Böger SM, et al. **Circulation** 1996 Jan 1;93(1):85–90

Thrombolytic therapy for acute arterial occlusion. Ouriel K. **Curr Opin Gen Surg** 1994;:257–64 (39 ref.)

Peripheral arterial occlusions: local low-dose thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA). Hess H, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):97–104

Pharmacologic approaches to the treatment of atherosclerotic arterial obstruction. Capron L. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S40–3 (15 ref.)

Prevention studies with pentoxifylline: new clinical projects. Eugène-Jolchine I, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S143–6 (29 ref.)

The impact of thrombolytic therapy on arterial and graft occlusions: a critical analysis. Bhatnagar PK, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):105–12

The promise of new genetically engineered plasminogen activators. Cutler D, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):3S–7S (16 ref.)

Technical determinants of success in catheter-directed thrombolysis for peripheral arterial occlusions. Kandarpa K. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):55S–61S (54 ref.)

Drug variables in thrombolytic therapy. Meyerovitz MF. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):62S–65S (34 ref.)

Thrombolytic therapy compared with mechanical recanalization in non-acute peripheral arterial occlusions: a randomized trial. Meyerovitz MF, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):775–81

Thrombolysis and angioplasty of chronic iliac artery occlusions. Motarjeme A, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):66S–72S

Randomized comparison of thrombolysis and surgery. TOPAS Investigators. Thrombolysis or Peripheral Arterial Surgery. Ouriel K. **J Vasc Interv Radiol** 1995 Nov–Dec; 6(6 Pt 2 Su):83S

Surgery versus thrombolytic therapy in the management of peripheral arterial occlusions. Ouriel K. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):48S–54S (42 ref.)

Thrombolysis of lower extremity embolic occlusions: a study of the results of the STAR Registry [see comments] Huettl EA, et al. **Radiology** 1995 Oct;197(1):141–5. Comment in: Radiology 1996 Apr;199(1):288–9.

The role of thrombolysis in the management of acute arterial occlusions of the lower limb. Browning NG, et al. **S Afr J Surg** 1995 Dec;33(4):170–4 (52 ref.)

Time dependency of the acetazolamide effect on cerebral hemodynamics in patients with chronic occlusive cerebral arteries. Early steal phenomenon demonstrated by [15O]H2O positron emission tomography. Kuwabara Y, et al. **Stroke** 1995 Oct;26(10):1825–9

Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke. Correlations of outcome with clinical and radiological data. Trouillas P, et al. **Stroke** 1996 May;27(5):882–90

Thrombolytic therapy: overview of results in major vascular occlusions. Marder VJ. **Thromb Haemost** 1995 Jul; 74(1):101–5 (60 ref.)

[Thrombolytic therapy in arterial disorders other than myocardial infarction] Verstraete M. **Arch Mal Coeur Vaiss** 1996 Jan;89(1):77–82 (47 ref.) (Eng. Abstr.) **(Fre)**

[Acute carotid occlusion: thrombolytic treatment] Maiza D, et al. **J Mal Vasc** 1996;21 Suppl A:83–9 (10 ref.) (Eng. Abstr.) **(Fre)**

[Platelet antiaggregants and atheromatous arteriopathy of the lower limbs] Lévesque H, et al. **Rev Med Interne** 1996; 17(2):163–8 (47 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic efficiency of of pulsed spray lysis in peripheral arterial occlusions] Roeren T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jun;164(6):489–95 (Eng. Abstr.) **(Ger)**

[Are beta-blockers generally contraindicated in patients with peripheral arterial occlusive disease?] Schweizer J, et al. **Z Kardiol** 1996 Mar;85(3):193–7 (Eng. Abstr.) **(Ger)**

[Clinical experience in patients with chronic peripheral obliterating arteriopathy: defibrotide versus definite molecular weight heparan sulfate (MW 7500–15000 dalton)] Michelini S, et al. **Minerva Cardioangiol** 1996 Jan–Feb; 44(1–2):33–7 (Eng. Abstr.) **(Ita)**

[Early reperfusion as a rationale from of therapy in ischemic stroke] Garcia JH. **Rev Neurol** 1995 Sep–Oct; 23(123):1067–73 (40 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Pharmacoeconomic considerations in peripheral arterial thrombolytic therapy. Kaul AF. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):104S–110S

Cost-efficacy issues in the treatment of peripheral vascular disease: primary amputation or revascularization for limb-threatening ischemia. Perler BA. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):111S–115S (28 ref.)

Clinical economics and noncoronary vascular disease. Schwartz JS. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):116S–124S (16 ref.)

EPIDEMIOLOGY

Screening for abdominal aortic aneurysm and occlusive peripheral vascular disease in Japanese residents. Takei H, et al. **Surg Today** 1995;25(7):608–11

ETIOLOGY

Obstruction of the proximal pulmonary artery branches after banding of the pulmonary trunk. Hiraishi S, et al. **Am J Cardiol** 1995 Oct 15;76(11):842–6

Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis. A nonhuman primate model of restenosis. Geary RL, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):34–43

Percutaneous extraluminal (subintimal) recanalization of a brachial artery occlusion following cardiac catheterization. Bolia A, et al. **Cardiovasc Intervent Radiol** 1996 May–Jun; 19(3):184–6

Pulmonary vein thrombosis and peripheral embolization. Garcia MJ, et al. **Chest** 1996 Mar;109(3):846–7

Images in cardiovascular medicine. Intra-aortic thrombus producing embolic arterial vascular disease. Lozano P, et al. **Circulation** 1996 Apr 1;93(7):1471

Association of below-knee atherosclerosis to medial arterial calcification in diabetes mellitus. Chantelau E, et al. **Diabetes Res Clin Pract** 1995 Sep;29(3):169–72

Reperfusion injury tourniquet syndrome caused by acute aortic occlusion due to embolism following pneumonectomy. Sonak RA, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):499–501

Vascular injury following closed proximal tibial fracture: beware the extension injury. Housden PL, et al. **Injury** 1995 Dec;26(10):698–701

Human homocysteine catabolism: three major pathways and their relevance to development of arterial occlusive disease. Dudman NP, et al. **J Nutr** 1996 Apr;126(4 Suppl):1295S–300S

Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases. Malinow MR. **J Nutr** 1996 Apr;126(4 Suppl):1238S–43S (38 ref.)

Homocysteine, vitamins and arterial occlusive disease: an overview. Rosenberg IH. **J Nutr** 1996 Apr;126(4 Suppl):1235S–7S (26 ref.)

Arterial lesions in Behçet's disease. A study in 25 patients. Lê Thi Huong D, et al. **J Rheumatol** 1995 Nov; 22(11):2103–13

A serious vascular complication of internal fixation of a tibial plateau fracture: a cautionary tale from which several lessons can be learned. Rawes ML, et al. **J Trauma** 1996 Feb;40(2):323–5

Thrombophilia, homocystinuria, and mutation of the factor V gene [letter; comment] D'Angelo A, et al. **N Engl J Med** 1996 Jul 25;335(4):289; discussion 290. Comment on: N Engl J Med 1996 Mar 21;334(12):763–8.

Traumatic occlusion of the anterior cerebral artery—case report. Ishibashi A, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):882–5 (7 ref.)

Subclavian artery compression from a chest tube after thoracotomy in a premature infant. Fowler CL. **Pediatr Radiol** 1995;25(6):458–9

Retinal detachment in acute systemic hypertension. **Retina** 1995;15(6):524–6

Maintenance treatment of diabetic patients, associating arterial obstructive tibio-peroneal disease. Wolosker N, et al. **Rev Paul Med** 1995 Jan–Feb;113(1):701–5

Radial artery occlusion in primary antiphospholipid syndrome after aortic valve replacement [letter] Asherson RA, et al. **S Afr Med J** 1995 Oct;85(10):1042

Nylon monofilament for intraluminal middle cerebral artery occlusion in rats [letter; comment] Rabb CH. **Stroke** 1996 Jan;27(1):151. Comment on: Stroke 1995 Sep;26(9):1655–7; discussion 1658.

[Arterial stenosis after radiotherapy] Piedbois P, et al. **Bull Cancer Radiother** 1990;77(1):3–13 (89 ref.) (Eng. Abstr.) **(Fre)**

[Diabetic arteriopathy of the lower limbs] Cormier JM, et al. **Chirurgie** 1996;121(2):133–6 (Eng. Abstr.) **(Fre)**

[Local vascular complications after iatrogenic femoral artery puncture] Fruhwirth J, et al. **Wien Klin Wochenschr** 1996; 108(7):196–200 (Eng. Abstr.) **(Ger)**

[Smoking and peripheral vascular disorders] Stammler F, et al. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):459–66 (12 ref.) (Eng. Abstr.) **(Ger)**

[Hypothenar hammer syndrome] Mertens R, et al. **Rev Med Chil** 1995 Mar;123(3):345–9 (Eng. Abstr.) **(Spa)**

METABOLISM

Flow threshold for enhanced phorbol ester binding in the ischemic gerbil brain. Tanaka K, et al. **Neurochem Res** 1995 Sep;20(9):1007–12

L-NAME reduces infarct volume in a filament model of transient middle cerebral artery occlusion in the rat pup. Ashwal S, et al. **Pediatr Res** 1995 Nov;38(5):652–6

Sequential studies of severely hypometabolic tissue volumes after permanent middle cerebral artery occlusion. A positron emission tomographic investigation in anesthetized baboons. Touzani O, et al. **Stroke** 1995 Nov;26(11):2112–9

PATHOLOGY

Secondary thalamic lesions after ligation of the middle cerebral artery: an ultrastructural study. Nordborg C, et al. **Acta Neuropathol (Berl)** 1996;91(1):61–6

Intracerebral vascular occlusion in familial erythrophagocytic lymphohistiocytosis: a case report of two siblings. Takano T, et al. **Acta Neuropathol (Berl)** 1995; 90(5):532–8

Collagen-encapsulated coagulation necrosis in cerebral infarcts: a pathological study. Yamazaki M, et al. **Acta Neuropathol (Berl)** 1996;91(1):47–52

Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Garcia JH, et al. **Am J Pathol** 1995 Nov; 147(5):1477–86

Preliminary reports on morphological and ultrastructural changes in the corpora cavernosa of the rat after chronic arterial obstruction. Siracusano S, et al. **Arch Esp Urol** 1996 Mar;49(2):191–5

Mesenteric ischaemia: a multidisciplinary approach. Bradbury AW, et al. **Br J Surg** 1995 Nov;82(11):1446–59 (224 ref.)

Transition from ischemic neuronal necrosis to infarction in repeated ischemia. Hanyu S, et al. **Brain Res** 1995 Jul 17; 686(1):44–8

Cytokine therapy for arterial restenosis: inhibition of neointimal hyperplasia by gamma-interferon. Castronuovo JJ Jr, et al. **Cardiovasc Surg** 1995 Oct;3(5):463–8

CT and MRI of intracavernous carotid artery aneurysm with occlusion of the cervical internal carotid artery. Holemans JA, et al. **J Comput Assist Tomogr** 1995 Nov–Dec; 19(6):1006–7

Progression of atrophy of the corpus callosum with deterioration of cerebral cortical oxygen metabolism after carotid artery occlusion: a follow up study with MRI and PET. Yamauchi H, et al. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):420–6

Iliac artery patency before and immediately after percutaneous transluminal angioplasty: assessment with time-of-flight MR angiography. Laissy JP, et al. **Radiology** 1995 Nov;197(2):455–9

Depiction of infarct frequency distribution by computer-assisted image mapping in rat brains with middle cerebral artery occlusion. Comparison of photothrombotic and intraluminal suture models. Zhao W, et al. **Stroke** 1996 Jun;27(6):1112–7

[Giant cell arteritis—a rare cause of severe arterial occlusive disease of the leg arteries] von Bierbrauer A, et al. **Med Klin** 1995 Sep 15;90(9):547–53 **(Ger)**

[The time of severe acute ischemia as a risk factor in the restoration of the circulation in the ischemic extremity in embolisms of the major arteries] Ivashchenko VV. **Vestn Khir Im I I Grek** 1992 Feb;148(2):165–9 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Doppler study of the ophthalmic artery in patients with carotid occlusive disease. Kerty E, et al. **Acta Neurol Scand** 1995 Aug;92(2):173–7

Intermittent calf and foot compression increases lower extremity blood flow. Eze AR, et al. **Am J Surg** 1996 Aug; 172(2):130–4; discussion 135

An open-ended-pattern coronary circulation: demonstration of its potential "self-cure" role in obstructive coronary artery disease. A case report. Antonellis J, et al. **Angiology** 1996 May;47(5):507–10

Orthostatic vasoconstrictor response in patients with occlusive arterial disease assessed by laser Doppler flux and transcutaneous oximetry. Caspary LA, et al. **Angiology** 1996 Feb;47(2):165–73

Do-it-yourself femoropopliteal bypass. Fox AD, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):392–4

Local hemodynamic changes during transient middle cerebral artery occlusion and recirculation in the rat: a [14C]iodoantipyrine autoradiographic study. Takagi K, et al. **Brain Res** 1995 Sep 11;691(1–2):160–8

Theoretical modelling of the release rate of low-density lipoproteins and their breakdown products at arterial stenoses. Deng X, et al. **Clin Invest Med** 1996 Apr; 19(2):83–91

Relation of haemostatic, fibrinolytic, and rheological variables to the angiographic extent of peripheral arterial occlusive disease. Woodburn KR, et al. **Int Angiol** 1995 Dec;14(4):346–52

Microcirculation and CVI: vogue or heart of the matter? What lessons from peripheral arterial occlusive disease of lower limbs? Becker F. **J Cardiovasc Surg (Torino)** 1995 Aug;36(4):379–80

Continuous time estimation as a behavioural index of human cerebral ischaemia during temporary occlusion of the internal carotid artery. Lazar RM, et al. **J Neurol Neurosurg Psychiatry** 1996 May;60(5):559–63

The correlation of ankle oscillometric blood pressures and segmental pulse volumes to Doppler systolic pressures in arterial occlusive disease. Lee BY, et al. **J Vasc Surg** 1996 Jan;23(1):116–22

Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Kawai H, et al. **Jpn J Pharmacol** 1995 Oct;69(2):143–8

Effects of monoionic and nonionic radiographic contrast media on cutaneous microcirculation in patients with peripheral arterial occlusive disease. Franzeck UK, et al. **Microvasc Res** 1995 Jul;50(1):18–24

Neurocritical care for acute ischemic stroke. Hund E, et al. **Neurol Clin** 1995 Aug;13(3):511–27 (87 ref.)

Monophosphoryl lipid A preserves myocardial contractile function following multiple, brief periods of coronary occlusion in dogs. Yao Z, et al. **Pharmacology** 1995 Sep; 51(3):152–9

Relationship between testicular morphology and sperm production following ischaemia in the ram. Markey CM, et al. **Reprod Fertil Dev** 1995;7(1):119–28

Vasomotor reactivity and pattern of collateral blood flow in severe occlusive carotid artery disease. Müller M, et al. **Stroke** 1996 Feb;27(2):296–9

Simplified model of krypton laser-induced thrombotic distal middle cerebral artery occlusion in spontaneously hypertensive rats. Yao H, et al. **Stroke** 1996 Feb;27(2):333–6

Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Zhang F, et al. **Stroke** 1996 Feb;27(2):317–23

Doppler velocity ratio measurements evaluated in a phantom model of multiple arterial disease. Allard L, et al. **Ultrasound Med Biol** 1995;21(4):471–80

Parameter mapping for the detection of disturbed blood flow. Ferrara KW, et al. **Ultrasound Med Biol** 1995;21(4):517–25

[Bilateral occlusion of the internal carotid arteries. Analysis of a series of 19 patients] Catala M, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):648–56 (Eng. Abstr.) **(Fre)**

[Temporal threshold for middle cerebral artery infarction] Calandre L, et al. **Neurologia** 1995 Oct;10(8):313–8 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Effects of CD11b/18 monoclonal antibody on rats with permanent middle cerebral artery occlusion. Garcia JH, et al. **Am J Pathol** 1996 Jan;148(1):241–8

Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Miyazawa K, et al. **Atherosclerosis** 1995 Dec;118(2):213–21

Are low-molecular-weight heparins useful for the prophylaxis and treatment of arterial thrombi? Samama CM, et al. **Haemostasis** 1996;26 Suppl 2:57–64

Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). Berger PB, et al. **J Am Coll Cardiol** 1996 Jan;27(1):1–7

Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis. Stalnikowicz-Darvasi R. **J Clin Gastroenterol** 1995 Jul;21(1):13–6 (20 ref.)

[Risk predictors and risk-adjusted prevention in peripheral arterial occlusive diseases] Rieger H. **Internist (Berl)** 1995 Sep;36(9):902–8 (30 ref.) **(Ger)**

PSYCHOLOGY

[Quality of life in peripheral arterial occlusive disease. Multicenter study of quality of life characteristics with a newly developed disease-specific questionnaire] Heidrich H, et al. **Med Klin** 1995 Dec 15;90(12):693–7 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Intraarterial pressure measurements during angiographic evaluation of peripheral vascular disease: techniques, interpretation, applications, and limitations. Kinney TB, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):277–84 (44 ref.)

Sequential helical CT angiography of aortoiliac disease. Raptopoulos V, et al. **AJR Am J Roentgenol** 1996 Jun;

166(6):1347–54

Prospective comparison of CT angiography of the legs with intraarterial digital subtraction angiography. Rieker O, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):269–76

Case of the month: a pulmonary embolus, or what? Uberoi R, et al. **Br J Radiol** 1996 Jun;69(822):575–6

Radial artery approach for outpatient peripheral arteriography. al-Kutoubi A, et al. **Clin Radiol** 1996 Feb; 51(2):110–2

Cost-effectiveness of colour duplex sonography compared with angiography of the pelvis and lower limb. Geitung JT, et al. **Eur Radiol** 1996;6(4):481–4

Lipoprotein(a) and general risk factors in patients with angiographically assessed peripheral arterial disease. Prior M, et al. **Int Angiol** 1995 Dec;14(4):357–63

Relation of haemostatic, fibrinolytic, and rheological variables to the angiographic extent of peripheral arterial occlusive disease. Woodburn KR, et al. **Int Angiol** 1995 Dec;14(4):346–52

Moyamoya disease and beta-thalassemia. Mukherjee A. **J Assoc Physicians India** 1995 Oct;43(10):710–1

A patient with MELAS and arterial occlusive findings on cerebral angiography. Ito J, et al. **J Child Neurol** 1995 Jul; 10(4):337–9

CT and MRI of intracavernous carotid artery aneurysm with occlusion of the cervical internal carotid artery. Holemans JA, et al. **J Comput Assist Tomogr** 1995 Nov–Dec; 19(6):1006–7

Spiral computed tomography angiography in the assessment of middle cerebral artery occlusive disease. Wong KS, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):537–9

[Intraarterial digital subtraction angiography (i.a. DSA) of the lower limb using fine needle technique] Koch JA, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Dec;163(6):515–22 (Eng. Abstr.) **(Ger)**

[2-D-time-of-flight MR angiography of the peripheral blood vessels. Experimental and clinical studies on value of this method in arterial occlusive diseases] Vosshenrich R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jan;164(1):25–30 (Eng. Abstr.) **(Ger)**

[A woman with diffuse problems in her legs and back. Suspect obstruction of the pelvic vasculature!] Wahlberg E, et al. **Lakartidningen** 1996 Jan 24;93(4):252–4 **(Swe)**

RADIONUCLIDE IMAGING

Demonstration of popliteal artery entrapment on leg muscle scintigraphy [letter; comment] Allen MJ, et al. **Clin Radiol** 1995 Dec;50(12):881–2. Comment on: Clin Radiol 1995 Jun;50(6):404–8.

The significance of increased 111indium platelet accumulation at post-angioplasty sites. Nyamekye I, et al. **Clin Radiol** 1996 Jul;51(7):507–10

Progression of atrophy of the corpus callosum with deterioration of cerebral cortical oxygen metabolism after carotid artery occlusion: a follow up study with MRI and PET. Yamauchi H, et al. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):420–6

Sequential studies of severely hypometabolic tissue volumes after permanent middle cerebral artery occlusion. A positron emission tomographic investigation in anesthetized baboons. Touzani O, et al. **Stroke** 1995 Nov;26(11):2112–9

REHABILITATION

[Results of kinesis therapy in patients with diabetic macroangiopathy of the lower extremities] Ponikowska I, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):16–8 (Eng. Abstr.) **(Pol)**

SURGERY

Endovascular stents and stented grafts for the treatment of aneurysms and other arterial lesions. Marin ML, et al. **Adv Surg** 1996;29:93–109 (50 ref.)

The role of composite sequential bypass in the treatment of multilevel infrainguinal arterial occlusive disease. Alexander JJ, et al. **Am J Surg** 1996 Aug;172(2):118–22

Aorto-iliac reconstruction without arteriography. Bodily K, et al. **Am J Surg** 1996 May;171(5):505–7

Management and outcome of infrapopliteal arterial graft infections with distal graft involvement. Calligaro KD, et al. **Am J Surg** 1996 Aug;172(2):178–80

Abdominal wall hernias in patients with abdominal aortic aneurysmal versus aortoiliac occlusive disease. Hall KA, et al. **Am J Surg** 1995 Dec;170(6):572–5; discussion 575–6

Long-term follow-up of bypasses to the brachial artery across the shoulder joint. Jain KM, et al. **Am J Surg** 1996 Aug;172(2):127–9

Pelvic revascularization by direct hypogastric artery reconstruction. Johansen K. **Am J Surg** 1996 May; 171(5):456–9

Outcomes and resource utilization in a managed care setting for lower extremity vein bypass grafts. Maini BS, et al. **Am J Surg** 1996 Aug;172(2):113–6; discussion 117

Prosthetic-vein composite graft with remote popliteal arteriovenous fistula. Sladen JG, et al. **Am J Surg** 1996 Aug;172(2):123–6

Circulatory arrest in a reoperation for brachiocephalic arterial occlusive disease. Bastounis EA, et al. **Ann Thorac Surg** 1996 Apr;61(4):1259–61 (7 ref.)

Stenting without thrombolysis for aortoiliac occlusive disease: experience in 14 high-risk patients. Ballard JL, et al. **Ann Vasc Surg** 1995 Sep;9(5):453–8

Do collagen-impregnated knitted Dacron grafts reduce the need for transfusion in infrarenal aortic reconstruction? Barral X, et al. **Ann Vasc Surg** 1995 Jul;9(4):339–43

Transluminal recanalization of occluded iliac arteries: a surgical experience. Cardon JM, et al. **Ann Vasc Surg** 1995; 9 Suppl:S54–61

Sequential distal anastomosis in aortofemoral bypass. Gewertz BL, et al. **Ann Vasc Surg** 1995 Nov;9(6):583–4

Cryopreserved arterial allografts for limb salvage in the absence of suitable saphenous vein: two-year results in 20 cases. Gournier JP, et al. **Ann Vasc Surg** 1995;9 Suppl:S7–14

Aortoiliac bypass in a renal transplant patient using a new technique. Jain KM, et al. **Ann Vasc Surg** 1995 Jul; 9(4):385–9

The occluded renal artery: an ongoing surgical challenge. Jordan WD Jr, et al. **Ann Vasc Surg** 1995 Jul;9(4):344–51

Evaluation of dopexamine hydrochloride as a renoprotective agent during aortic surgery. Welch M, et al. **Ann Vasc Surg** 1995 Sep;9(5):488–92

Recurrent aortic infection: treatment by arterial homograft replacement. Nevelsteen A, et al. **Cardiovasc Surg** 1995 Aug;3(4):441–4

The present status of endoluminal stented grafts for the treatment of aneurysms, traumatic injuries and arterial occlusions. Veith FJ, et al. **Cardiovasc Surg** 1996 Feb; 4(1):3–7 (30 ref.)

Sequential aortofemoropopliteal/distal bypass for treatment of critical lower-limb ischaemia. Zukauskas G, et al. **Cardiovasc Surg** 1995 Dec;3(6):671–8

Technical report: Recanalisation of all three infrapopliteal arteries by subintimal angioplasty. Nydahl S, et al. **Clin Radiol** 1996 May;51(5):366–7

Simultaneous coronary bypass and abdominal aortic surgery in patients with severe coronary disease--indication and results. Autschbach R, et al. **Eur J Cardiothorac Surg** 1995; 9(12):678–83 discussion 683–4

Serum phospholipases A2 after aortobifemoral reconstruction. Grönroos JM, et al. **Eur J Clin Chem Clin Biochem** 1995 May;33(5):271–4

The crossover femoropopliteal bypass: a useful option for unilaterial iliofemoral occlusive disease. Chalmers RT, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):330–4

Aortofemoral surgery and sexual function. Cormio L, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):453–7

The influence of gender on the outcome of arterial procedures in the lower extremity. Enzler MA, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):446–52

Endovascular remote endarterectomy in femoropopliteal occlusive disease: one-year clinical experience with the ring strip cutter device. Ho GH, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):105–12

Incisional hernias are more common in aneurysmal arterial disease. Holland AJ, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):196–200

Combined vascular reconstruction and microvascular muscle flap transfer for salvage of ischaemic legs with major tissue loss and wound complications. Lepäntalo M, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):65–9

Natural history of infrainguinal vein bypass stenoses: early lesions increase the risk of thrombosis. Nielsen TG. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):60–4

Long-term results after open and semiclosed thrombendarterectomy for aortoiliac occlusive disease. Oertli D, et al. **Eur J Vasc Endovasc Surg** 1996 May; 11(4):432–6

A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. Sculpher M, et al. **Int J Technol Assess Health Care** 1996 Winter;12(1):104–25

Protection by coenzyme Q10 of tissue reperfusion injury during abdominal aortic cross-clamping. Chello M, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):229–35

Ischemia of spinal cord following elective operative procedures of the infrarenal abdominal aorta. Dimakakos P, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):243–7

Endovascular remote endarterectomy in femoropopliteal long segmental occlusive disease. A new surgical technique illustrated and preliminary results using a ring strip cutter device. Moll FL, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:39–40

Endovascular remote endarterectomy in femoropopliteal long segmental occlusive disease. A new surgical technique illustrated and preliminary results using a ring strip cutter device. Moll FL, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):39–40

Nd:Yag laser-assisted balloon angioplasty of superficial femoral artery occlusions in a diabetic population. Field CK, et al. **J Diabetes Complications** 1995 Jul–Sep;9(3):186–9

The role of angioplasty and stenting in the treatment of occlusive lesions of supra-aortic trunks. Criado FJ, et al. **J Mal Vasc** 1996;21 Suppl A:132–8

Using dipyridamole-thallium imaging to reduce cardiac risk in aortic reconstruction. Erickson CA, et al. **J Surg Res** 1996 Feb 1;60(2):422–8

Epidural regional hypothermia for prevention of paraplegia after aortic occlusion: experimental evaluation in a rabbit model. Gonzalez-Fajardo J, et al. **J Vasc Surg** 1996 Mar; 23(3):446–52

Cardiac enzymes in the blood salvaged during abdominal aortic surgery [letter] Gregoretti S. **J Vasc Surg** 1996 Feb; 23(2):377–8

Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive disease. Passman MA, et al. **J Vasc Surg** 1996 Feb;23(2):263–9; discussion 269–71

Does donor iliac artery percutaneous transluminal angioplasty or stent placement influence the results of femorofemoral bypass? Analysis of 70 consecutive cases with long-term follow-up. Perler BA, et al. **J Vasc Surg** 1996 Sep;24(3):363–9; discussion 369–70

Simplified, controlled limb reperfusion and simultaneous revascularization for acute aortic occlusion. Vogt PR, et al. **J Vasc Surg** 1996 Apr;23(4):730–3

Acute cerebellar edema following intra-arterial tissue plasminogen activator thrombolysis for basilar artery occlusion--case report. Matsumoto K, et al. **Neurol Med Chir (Tokyo)** 1996 Jul;36(7):455–7

Aortic and iliac stenoses: follow-up results of stent placement after insufficient balloon angioplasty in 118 cases. Vorwerk D, et al. **Radiology** 1996 Jan;198(1):45–8

Videotunneler for minimal and direct access aortoiliac reconstructive surgery. Weber G, et al. **Surg Endosc** 1996 Aug;10(8):852–4

Long-term follow-up of the Palmaz stent for iliac occlusive disease. Cikrit DF, et al. **Surgery** 1995 Oct;118(4):608–13; discussion 613–4

Intestinal ischemia following surgery for aorto-iliac disease. A review of 502 consecutive aortic reconstructions. Järvinen O, et al. **Ann Chir Gynaecol** 1996;25(2):148–55

Current status of [illegible]rectomy for peripheral arterial occlusive dise[illegible]an SS, et al. **World J Surg** 1996 Jul–Aug;20(6):6[illegible]43 (45 ref.)

[Surgical treatment in patients with diabetic macroangiopathy] Kirilova K, et al. **Khirurgiia (Sofiia)** 1995;48(1):18–22 (Eng. Abstr.) **(Bul)**

[Amputation and arterial reconstruction in peripheral occlusive arterial diseases in Denmark 1977–1993] Seidelin CM, et al. **Ugeskr Laeger** 1995 Oct 23;157(43):5985–8 (Eng. Abstr.) **(Dan)**

[Arteriopathies of the lower limbs and lesions of the renal arteries] Lacombe M. **Chirurgie** 1996;121(2):121–6 (Eng. Abstr.) **(Fre)**

[Current status of reconstructive surgery of the sub-inguinal artery] Testart J, et al. **Chirurgie** 1994–95;120(10):582–8 (55 ref.) (Eng. Abstr.) **(Fre)**

[Risk of development of false aneurysm and graft infection after aorta-femoral bypass graft. Retrospective study. Report of 211 cases] Aguiar ET, et al. **J Mal Vasc** 1996; 21(1):36–9 (Eng. Abstr.) **(Fre)**

-Emergency surgical treatment of acute carotid occlusion- Streichenberger R, et al. **J Mal Vasc** 1996;21 Suppl A:90–6 (Eng. Abstr.) **(Fre)**

[Revascularization of supra-aortic trunks from the femoral artery] Etienne G, et al. **Presse Med** 1995 Jul 1–8; 24(24):1124–6 (Eng. Abstr.) **(Fre)**

[Microvascular flap surgery in arterial occlusive disease] Stober R. **Handchir Mikrochir Plast Chir** 1995 Nov; 27(6):292–6 (Eng. Abstr.) **(Ger)**

[Quality assurance in peripheral vascular surgery] Enzler MA. **Swiss Surg** 1995;Suppl 1:1–29 **(Ger)**

[Initial clinical results in the treatment of peripheral arterial occlusive diseases using new percutaneous atherectomy equipment (REDHA-CUT)] Redha F, et al. **Swiss Surg** 1996;(3):102–4 (Eng. Abstr.) **(Ger)**

[Foot salvage in diabetic gangrene] Jung V. **Zentralbl Chir** 1996;121(5):387–92; discussion 392–3 (Eng. Abstr.) **(Ger)**

[Reconstruction of isolated lower leg arteriovenous occlusions in the critical foot ischemia stage--assessment of current status] Kiechle V, et al. **Zentralbl Chir** 1996; 121(5):380–6 (Eng. Abstr.) **(Ger)**

[Femoro-popliteal bypass with reversed saphenous vein. Experience in a General Surgery Department] Falco E, et al. **Minerva Chir** 1995 Oct;50(10):883–8 (Eng. Abstr.) **(Ita)**

[Three cases of hyperkalemia after reperfusion associated with revascularization for massive acute arterial occlusions] Arakura A, et al. **Masui** 1996 Mar;45(3):340–4 (Eng. Abstr.) **(Jpn)**

[Lymphatic complications after lower limb vascular surgery] Haaverstad R, et al. **Tidsskr Nor Laegeforen** 1996 Jun 20; 116(16):1886–8 (Eng. Abstr.) **(Nor)**

[Surgery of abdominal aorta occlusion] Belov IuV, et al. **Khirurgiia (Mosk)** 1995;(6):3–5 (Eng. Abstr.) **(Rus)**

[Method of cascade shunting in the treatment of femoral-popliteal segment occlusion] Sergeev OA. **Klin Khir** 1995;(11–12):42–3 **(Rus)**

[Amputations in patients with arterial obliterating diseases] Lebedev LV, et al. **Vestn Khir Im I I Grek** 1995; 154(3):88–90 **(Rus)**

[The short bypass in the treatment of popliteal artery occlusion] Prochotský A, et al. **Bratisl Lek Listy** 1995 Sep; 96(9):499–502 (Eng. Abstr.) **(Slo)**

[Early reperfusion as a rationale from of therapy in ischemic stroke] Garcia JH. **Rev Neurol** 1995 Sep–Oct; 23(123):1067–73 (40 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Self-expandable stents for the treatment of iliac artery obstructive lesions: long-term success and prognostic factors. Sapoval MR, et al. **AJR Am J Roentgenol** 1996 May;166(5):1173–9

Diagnosis and treatment of an ophthalmic artery occlusion during an intralesional injection of corticosteroid into an eyelid capillary hemangioma. Egbert JE, et al. **Am J Ophthalmol** 1996 Jun;121(6):638–42

Infection of endovascular stents in a swine model. Thibodeaux LC, et al. **Am J Surg** 1996 Aug;172(2):151–4

The results of arterial thrombolysis. Kroese AJ, et al. **Ann Chir Gynaecol** 1995;84(4):350–3 (17 ref.)

Oxygen inhalation in nonhypoxic sickle cell patients during vaso-occlusive crisis [letter] Khoury H, et al. **Blood** 1995 Nov 15;86(10):3998

Blood flow in the lower limb after balloon angioplasty of the superficial femoral artery. Hussain ST, et al. **Br J Surg** 1996 Jun;83(6):791–5

Re: Comparison of efficacy in crossing femoropopliteal artery occlusions with movable core and hydrophilic guidewires [letter; comment] Hartnell GG. **Cardiovasc Intervent Radiol** 1995 Jul–Aug;18(4):274–5. Comment on: Cardiovasc Intervent Radiol 1994 Nov–Dec;17(6):319–22.

Magnetic resonance angiography of intravascular endoprostheses: investigation of three devices. Laissy JP, et al. **Cardiovasc Intervent Radiol** 1995 Nov–Dec; 18(6):360–6

Percutaneous transluminal angioplasty of an innominate artery occlusion. Watura R, et al. **Cardiovasc Intervent Radiol** 1995 Nov–Dec;18(6):396–8

Ankle–arm index, angiography, and duplex ultrasonography after recanalization of occlusions in femoropopliteal arteries: comparison of long–term results. Winter–Warnars HAO, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug; 19(4):234–8

Anterograde perfusion in acute limb ischemia secondary to vascular occlusive cardiopulmonary support. Jaski BE, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):373–6

Use of a snare–loop device as an adjunct to Palmaz stent placement. Sapoval MR, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):269–71

Peripheral artery recanalization in humans using balloon and laser angioplasty. Barbeau GR, et al. **Clin Cardiol** 1996 Mar; 19(3):232–8

Case report: pulmonary arterial obstruction caused by recurrent tumour treated with endovascular stenting. Chan O, et al. **Clin Radiol** 1996 Mar;51(3):228–9

Case report: percutaneous transluminal angioplasty of irradiation induced bilateral subclavian artery occlusions. Hinchcliffe M, et al. **Clin Radiol** 1995 Nov;50(11):804–7

Percutaneous revascularization in peripheral arterial disease. Rosenfield K, et al. **Curr Probl Cardiol** 1996 Jan;21(1):7–93 (228 ref.)

The value of duplex surveillance after endovascular intervention for femoropopliteal obstructive disease. Tielbeek AV, et al. **Eur J Vasc Endovasc Surg** 1996 Aug; 12(2):145–50

Percutaneous transluminal angioplasty of subclavian stenosis to improve inflow to internal mammary coronary arterial grafts. Wallis F, et al. **Eur Radiol** 1996;6(2):220–3

Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Kubota Y, et al. **Invest Radiol** 1995 Sep;30(9):532–7

Endovascular recanalization of the aorto–iliac segment: imaging and approaches. Criado FJ. **J Cardiovasc Surg (Torino)** 1996 Jun;37 Suppl 1:51–7

The ideal guidance imaging system for endovascular interventions. Verbin CS, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):5–9

Percutaneous endovascular covered stenting of a distal superficial femoral artery occlusion. Goodwin AT, et al. **J R Soc Med** 1995 Aug;88(8):477P–478P

Recombinant tissue plasminogen activator for the treatment of lower extremity peripheral vascular occlusive disease. Bero CJ, et al. **J Vasc Interv Radiol** 1995 Jul–Aug; 6(4):571–7

Interventionalists' guide to the patient's experience of lower extremity arterial occlusive disease. McDaniel MD, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):30S–35S (27 ref.)

Thrombolytic therapy compared with mechanical recanalization in non–acute peripheral arterial occlusions: a randomized trial. Meyerovitz MF, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):775–81

Regarding "should percutaneous transluminal angioplasty be recommended for treatment of infrageniculate popliteal artery or tibioperoneal trunk stenosis?" [letter] Bell PR, et al. **J Vasc Surg** 1996 Aug;24(2):298–9

Iliac artery stenoses after percutaneous transluminal angioplasty: follow–up with duplex ultrasonography. Spijkerboer AM, et al. **J Vasc Surg** 1996 Apr;23(4):691–7

Should percutaneous transluminal angioplasty be recommended for treatment of infrageniculate popliteal artery or tibioperoneal trunk stenosis? Treiman GS, et al. **J Vasc Surg** 1995 Oct;22(4):457–63; discussion 464–5

Femoropopliteal artery: initial and 6–month results of color duplex US–guided percutaneous transluminal angioplasty [see comments] Katzenschlager R, et al. **Radiology** 1996 May;199(2):331–4. Comment in: Radiology 1996 May;199(2):317–8.

Iliac artery patency before and immediately after percutaneous transluminal angioplasty: assessment with time–of–flight MR angiography. Laissy JP, et al. **Radiology** 1995 Nov;197(2):455–9

Femoropopliteal angioplasty with US guidance: an example of a niche market [editorial; comment] Polak JF. **Radiology** 1996 May;199(2):317–8. Comment on: Radiology 1996 May;199(2):331–4.

Outcome of percutaneous intervention in iliac artery stents. Sapoval MR, et al. **Radiology** 1996 Feb;198(2):481–6

Late reobstruction in iliac arterial stents: percutaneous treatment. Vorwerk D, et al. **Radiology** 1995 Nov; 197(2):479–83

Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Brandt T, et al. **Stroke** 1996 May;27(5):875–81

Outcome in patients with acute basilar artery occlusion requiring mechanical ventilation. Wijdicks EF, et al. **Stroke** 1996 Aug;27(8):1301–3

The influence of surgical insults on restenosis after transluminal balloon angioplasty. Yasuhara H, et al. **Surg Today** 1995;25(10):897–900

Economic implications of thrombolysis or operation as the initial treatment modality in acute peripheral arterial occlusion. Ouriel K, et al. **Surgery** 1995 Nov;118(5):810–4

Successful stenting of a pulmonary arterial stenosis after a single lung transplant. Ferretti G, et al. **Thorax** 1995 Sep; 50(9):1011–2; discussion 1016–7

Indications and results of arterial stents for occlusive disease. Ahn SS, et al. **World J Surg** 1996 Jul–Aug;20(6):644–8 (29 ref.)

Indications and results of balloon angioplasty for arterial occlusive lesions. Kalman PG, et al. **World J Surg** 1996 Jul–Aug;20(6):630–4

Endovascular repair of aortoiliac occlusive disease. Marin ML, et al. **World J Surg** 1996 Jul–Aug;20(6):679–86

[The use of continuous epidural analgesia in the combined treatment of chronic arterial obstruction in the lower extremities] Chernaev V, et al. **Khirurgiia (Sofiia)** 1995; 48(1):90–6 (Eng. Abstr.) **(Bul)**

[Angioplasty for subclavian artery stenosis: report of two cases] Fang BR, et al. **J Formos Med Assoc** 1995 Jun;94 Suppl 1:S50–3 (Eng. Abstr.) **(Chi)**

[Percutaneous intentional extraluminal recanalization of the femoropopliteal artery. Initial experiences and results] Vandenbosch G, et al. **J Belge Radiol** 1996 Jun;79(3):129–32 (Eng. Abstr.) **(Dut)**

[Angiology update] Ranke C, et al. **Med Klin** 1996 Apr 1; 91 Suppl 1:140–52 (129 ref.) **(Ger)**

[Percutaneous transluminal angioplasty (PTA) of isolated crural arterial stenoses in critical arterial occlusive disease] Häuser H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):238–43 (Eng. Abstr.) **(Ger)**

[Arterial stenting versus vascular replacement] Mahler F. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2074–9 (Eng. Abstr.) **(Ger)**

[Physical training and low–dose heparin–calcium in patients suffering from chronic obliterating arteriopathy of the lower limbs with intermittent claudication] Cina G, et al. **Minerva Cardioangiol** 1996 Apr;44(4):179–85 (Eng. Abstr.) **(Ita)**

[Spinal electrostimulation in the treatment of advanced chronic obliterating arteriopathies] Visconti W, et al. **Minerva Cardioangiol** 1996 Jan–Feb;44(1–2):19–27 (Eng. Abstr.) **(Ita)**

[Angioplasty, surgical, or clinical treatment. Therapeutic options for obstructive coronary artery disease (editorial)] Hueb WA, et al. **Arq Bras Cardiol** 1995 Jul;65(1):7–10 (28 ref.) **(Por)**

[Percutaneous transluminal angioplasty. An efficient alternative in the treatment of peripheral obstructive arteriopathy] Kisileczky N, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul–Aug; 50(4):185–8 (Eng. Abstr.) **(Por)**

[Electric stimulation of the spinal cord in diffuse occlusive lesions of peripheral arteries] Claeys L, et al. **Khirurgiia (Mosk)** 1995;(5):57–61 **(Rus)**

[Stimulation of tissue lymphatic drainage in the treatment of patients with arterial diseases] Kungurtsev VV, et al. **Khirurgiia (Mosk)** 1996;(1):42–5 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Doppler study of the ophthalmic artery in patients with carotid occlusive disease. Kerty E, et al. **Acta Neurol Scand** 1995 Aug;92(2):173–7

Diagnosis of middle cerebral artery occlusion with transcranial color–coded real–time sonography. Kimura K, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):895–9

Aorto–iliac reconstruction without arteriography. Bodily K, et al. **Am J Surg** 1996 May;171(5):505–7

Doppler assessment of physiological stenosis at the bifurcation of the main pulmonary artery: a cause of functional murmur in neonates. So BH, et al. **Biol Neonate** 1996;69(4):243–8

Diagnosis of arterial disease of the lower extremities with duplex ultrasonography [letter] Whiteley M. **Br J Surg** 1996 Jun;83(6):867

Relative fasting hypoinsulinaemia and ultrasonically measured early arterial disease in type 2 diabetes. The SENDCAP Study Group, St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention Study. Elkeles RS, et al. **Diabet Med** 1996 Mar;13(3):247–53

Detection of sub–critical arterial stenoses by hyperaemic Doppler. Currie IC, et al. **Eur J Vasc Endovasc Surg** 1996 Jan;11(1):29–35

The value of duplex surveillance after endovascular intervention for femoropopliteal obstructive disease. Tielbeek AV, et al. **Eur J Vasc Endovasc Surg** 1996 Aug; 12(2):145–50

Cost–effectiveness of colour duplex sonography compared with angiography of the pelvis and lower limb. Geitung JT, et al. **Eur Radiol** 1996;6(4):481–4

Iso–osmotic bowel preparation improves the accuracy of iliac artery colour flow duplex examination. Whiteley MS, et al. **J R Soc Med** 1995 Nov;88(11):657P–660P

Duplex velocity characteristics of aortoiliac stenoses. de Smet AA, et al. **J Vasc Surg** 1996 Apr;23(4):628–36

The physiological and clinical significance of nonlinear TCD waveform analysis in occlusive cerebrovascular disease. Visée HF, et al. **Neurol Res** 1995 Oct;17(5):384–8

Femoropopliteal artery: initial and 6–month results of color duplex US–guided percutaneous transluminal angioplasty [see comments] Katzenschlager R, et al. **Radiology** 1996 May;199(2):331–4. Comment in: Radiology 1996 May;199(2):317–8.

Femoropopliteal angioplasty with US guidance: an example of a niche market [editorial; comment] Polak JF. **Radiology** 1996 May;199(2):317–8. Comment on: Radiology 1996 May;199(2):331–4.

Color–coded transcranial duplex sonography in a patient with transient stenosis of the middle cerebral artery due to bacterial meningitis [letter; comment] Büttner T, et al. **Stroke** 1996 May;27(5):1006–7. Comment on: Stroke 1995 Aug;26(8):1399–403.

Detection of microembolic signals in patients with middle cerebral artery stenosis by means of a bigate probe. A pilot study. Nabavi DG, et al. **Stroke** 1996 Aug;27(8):1347–9

Can transcranial Doppler really detect reduced cerebral perfusion states? Sugimori H, et al. **Stroke** 1995 Nov; 26(11):2053–60

Parameter mapping for the detection of disturbed blood flow. Ferrara KW, et al. **Ultrasound Med Biol** 1995;21(4):517–25

[Determining the degree of stenosis of peripheral arteries. Hemodynamic and ultrasound principles] Neuerburg–Heusler D, et al. **Vasa** 1996;25(2):109–13 (Eng. Abstr.) **(Ger)**

ARTERIES

see related
ANGIOGRAPHY
ENDARTERECTOMY

Persistent median artery in carpal tunnel syndrome. Lisanti M, et al. **Acta Orthop Belg** 1995;61(4):315–8

Respiratory compensation, as evidenced by a declining arterial and end–tidal PCO2, is attenuated during fast ramp exercise functions. Scheuermann BW, et al. **Adv Exp Med Biol** 1995;393:137–42

Phase–coupling of arterial blood gas oscillations and ventilatory kinetics during exercise in humans. Phase coupling and the exercise hyperpnoea. Ward SA, et al. **Adv Exp Med Biol** 1995;393:219–24

Determination of ammonia in ear–lobe capillary blood is an alternative to arterial blood ammonia. Huizenga JR, et al. **Clin Chim Acta** 1995 Jul 31;239(1):65–70

Arterial blood ammonia during orthotopic liver transplantation as an indicator of waste elimination by the new liver [letter] Huizenga JR, et al. **Clin Chim Acta** 1995 Jul 31;239(1):103–6

Relationship between arterial and end–tidal carbon dioxide pressure during controlled ventilation in porcine neonates. Sakamoto H, et al. **Exp Anim** 1996 Apr;45(2):195–8

Evaluation of cryopreserved arteries as alternative small vessel prostheses. Nataf P, et al. **Int J Artif Organs** 1995 Apr;18(4):197–202

Effect of ambient temperature on arterial pressure variability during sleep in the rat. Sei H, et al. **J Sleep Res** 1996 Mar; 5(1):37–41

Structural quantification and bifurcation symmetry in arterial tree models generated by constrained constructive optimization. Schreiner W, et al. **J Theor Biol** 1996 May 21;180(2):161–74

Method for cryopreserving human arteries: 1H NMR spectroscopy for measuring the kinetics of permeation and ice–forming tendency of cryoprotective agents. Eugene M, et al. **Transplant Proc** 1996 Feb;28(1):345

ABNORMALITIES

The persistent sciatic artery. A case report. Breek JC, et al. **Acta Chir Belg** 1995 Sep–Oct;95(5):241–2

PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Frieden IJ, et al. **Arch Dermatol** 1996 Mar; 132(3):307–11

Aneurysm of a congenitally persistent sciatic artery presenting as a soft–tissue mass of the buttock. A case report. Benevenia J, et al. **J Bone Joint Surg Am** 1995 Nov; 77(11):1724–8 (33 ref.)

A rare case of the double thyroid ima artery. Sannomiya T, et al. **Kurume Med J** 1996;43(2):177–80

Absence of three regular thyroid arteries replaced by an unusual lowest thyroid artery (A. thyroidea ima): a case report. Moriggl B, et al. **Surg Radiol Anat** 1996;18(2):147–50

ANATOMY & HISTOLOGY

Variations in the branching of the internal pudendal artery in the ischioanal fossa. Fronhöfer G, et al. **Anat Anz** 1996 Apr;178(2):133–5

Classification of the vascular patterns of the thoracic limb muscles of cats. Ocal MK, et al. **Anat Anz** 1996 Jan;

178(1):83–9

Arterial vascularization of the abdominal and pelvic regions in the degu, Octodon degus (Rodentia, Octodontidae). Ventura J, et al. **Anat Anz** 1996 Jun;178(3):285–91

Morphology of isolated small arteries from patients with essential hypertension. Aalkjaer C, et al. **Blood Press Suppl** 1995;2:113–6 (33 ref.)

Corona mortis. Incidence and location. Tornetta P 3rd, et al. **Clin Orthop** 1996 Aug;(329):97–101

Adventitia as a target for intravascular local drug delivery [editorial] Huehns TY, et al. **Heart** 1996 Jun;75(6):537–8

Fabrication of vascular replicas from magnetic resonance images. Friedman MH, et al. **J Biomech Eng** 1995 Aug; 117(3):364–6

Proportions and structure of contacting and non-contacting varicosities in the perivascular plexus of the rat tail artery. Luff SE, et al. **J Comp Neurol** 1995 Oct 30;361(4):699–709

The influence of optimization target selection on the structure of arterial tree models generated by constrained constructive optimization. Schreiner W, et al. **J Gen Physiol** 1995 Oct;106(4):583–99 (34 ref.)

John Evelyn's tables of veins and arteries: a rediscovered letter. Aspin RK. **Med Hist** 1995 Oct;39(4):493–9

A persistent median artery causing carpal tunnel syndrome in a patient with chronic renal failure: case report. Feldkamp MM, et al. **Neurosurgery** 1995 Jul;37(1):140–3

The arterial blood supply of the pancreas: a review. III. The inferior pancreaticoduodenal artery. An anatomical review and a radiological study. Bertelli E, et al. **Surg Radiol Anat** 1996;18(2):67–74 (42 ref.)

The artery of the sinuatrial node: anatomic considerations based on 45 injection-dissections of the heart. Sow ML, et al. **Surg Radiol Anat** 1996;18(2):103–9

[The arteries of the stomach] Sow ML, et al. **Bull Assoc Anat (Nancy)** 1995 Jun;79(245):33–40 (Eng. Abstr.) **(Fre)**

[Arterial vascularization of the sinoatrial and atrioventricular node (preliminary study apropos of 15 anatomic parts] Ndiaye M, et al. **Dakar Med** 1994;39(1):1–4 (Eng. Abstr.) **(Fre)**

[Variability of the course of the uterine artery and its branches within the broad ligament and vascularization of uterine walls depending on a woman's age in light of anatomical, radiologic and microangiographic studies] Pilarczyk K. **Ann Acad Med Stetin** 1995;41:43–55 (Eng. Abstr.) **(Pol)**

[The structure of the arteries and the hemodynamic characteristics in the area of the ostia of efferent vessels] Gansburgskii AN. **Morfologiia** 1995;108(1):82–91 (112 ref.) **(Rus)**

CHEMISTRY

Compositional and structural alterations of arterial glycosaminoglycans associated with the complications brought about by thalassemia major. A case report. Cardoso LE, et al. **Angiology** 1996 Feb;47(2):175–83

A method for the assessment of hypoxia in the arterial wall, with potential application in vivo. Björnheden T, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):178–85

Tissue concentrations of endothelins and functional effects of endothelin-receptor activation in human arteries and veins. Holm P, et al. **J Thorac Cardiovasc Surg** 1996 Aug; 112(2):264–72

SM-20 is a novel 40-kd protein whose expression in the arterial wall is restricted to smooth muscle. Wax SD, et al. **Lab Invest** 1996 Apr;74(4):797–808

CYTOLOGY

Lipoprotein(a) stimulates the proliferation of cultured human arterial smooth muscle cells through two pathways. Miyata M, et al. **FEBS Lett** 1995 Dec 27;377(3):493–6

Effect of histologic preparation on the cross-sectional area of arterial rings. Dobrin PB. **J Surg Res** 1996 Mar; 61(2):413–5

Morphometrical changes of the arterial walls of main arteries from heart to the abdomino-inguinal mammary glands of rat from virgin through pregnancy, lactation and post-weaning. Awal MA, et al. **J Vet Med Sci** 1995 Apr; 57(2):251–6

DRUG EFFECTS

Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. Sihm I, et al. **Blood Press** 1995 Jul;4(4):241–8

Morphology of isolated small arteries from patients with essential hypertension. Aalkjaer C, et al. **Blood Press Suppl** 1995;2:113–6 (33 ref.)

Effect of phosphodiesterase inhibitors on human arteries in vitro. Vroom MB, et al. **Br J Anaesth** 1996 Jan;76(1):122–9

Characterization of arginine vasopressin actions in human uterine artery: lack of role of the vascular endothelium. Jovanović A, et al. **Br J Pharmacol** 1995 Aug; 115(7):1295–301

Rhythmic relaxations of active tension in the rabbit large arteries induced by a combination of cyclopiazonic acid and Bay K 8644. Omote M, et al. **Br J Pharmacol** 1996 May;118(2):233–6

Endothelial modulation of vasoconstrictor responses to endothelin-1 in human placental stem villi small arteries. Sabry S, et al. **Br J Pharmacol** 1995 Jul;115(6):1038–42

Effect of NG-nitro-L-arginine methylester (L-NAME) on functional and biochemical alpha 1-adrenoceptor-mediated responses in rat blood vessels. Tabernero A, et al. **Br J Pharmacol** 1996 Feb;117(4):757–63

Enhanced contractile responses of arteries from streptozotocin diabetic rats to sodium fluoride. Weber LP, et al. **Br J Pharmacol** 1996 May;118(1):115–22

Elastase in the prevention of arterial aging and the treatment of atherosclerosis. Ooyama T, et al. **Ciba Found Symp** 1995; 192:307–17; discussion 318–20 (36 ref.)

Alpha 1-adrenoceptors mediating contraction in arteries of normotensive and spontaneously hypertensive rats are of the alpha 1D or alpha 1A subtypes. Villalobos-Molina R, et al. **Eur J Pharmacol** 1996 Mar 18;298(3):257–63

Effects of atrial natriuretic peptide and cyclic guanosine monophosphate on isolated human myometrial arteries preconstricted by endothelin-1. Kublickiene KR, et al. **Gynecol Obstet Invest** 1995;40(3):190–4

Comparison of the effect of dopamine in primate arteries and veins. Okamura T, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S35–7 (19 ref.)

Effect of antihypertensive therapy on small artery structure in hypertensive patients [letter; comment] Schiffrin EL. **Hypertension** 1995 Oct;26(4):716–8. Comment on: Hypertension 1995 Apr;25(4 Pt 1):474–81.

Is median thoracic artery a target organ artery for estradiol and progesterone? A comparison with uterine artery. Guis F, et al. **J Assist Reprod Genet** 1995 Aug;12(7):399–405

Effects of dicentrine on the mechanical properties of systemic arterial trees in dogs. Chang KC, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):169–76

Vascular structure in hypertension induced by NG-nitro-L-arginine methyl ester: methodological considerations for studies of small arteries in hypertension--reply [letter; comment] Dunn WR, et al. **J Hypertens** 1995 Oct;13(10):1217–21. Comment on: J Hypertens 1995 Aug;13(8):817–21.

The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. Kool MJ, et al. **J Hypertens** 1995 Aug;13(8):839–48

A comparison of the effect of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism on the structural changes associated with hypertension in rat small arteries. Shaw LM, et al. **J Hypertens** 1995 Oct; 13(10):1135–43

Thiocyanate induces vasoconstriction in rat-tail artery primed with norepinephrine. Engström KG, et al. **J Lab Clin Med** 1996 Apr;127(4):391–400

Conformationally biased analogs of human C5a mediate changes in vascular permeability. Kawatsu R, et al. **J Pharmacol Exp Ther** 1996 Jul;278(1):432–40

Intervessel (arteries and veins) and heart/vessel selectivities of therapeutically used calcium entry blockers: variable, vessel-dependent indexes. Magnon M, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1157–66

Vasorelaxing effect of S-nitrosocaptopril on dog coronary arteries: no cross-tolerance with nitroglycerin. Matsumoto T, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1247–53

A-4, a tertiary amine analog of HC-3, lowers arterial pressure in spontaneously hypertensive rats. Ozkutlu U, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1352–8

Two different endothelin B receptor subtypes mediate contraction of the rabbit saphenous vein. Nishiyama M, et al. **Jpn J Pharmacol** 1995 Jul;68(3):235–43

Direct effects of fentanyl on canine coronary artery rings. Introna RP, et al. **Life Sci** 1995 Mar 3;56(15):1265–73

Possible involvement of endothelial leukotrienes in acetylcholine-induced contraction in rabbit coronary artery. Jino H, et al. **Life Sci** 1996;59(12):961–7

Tyrosine kinase inhibition suppresses angiotensin contraction in hypertensive and normotensive small resistance arteries. Malloy LG, et al. **Life Sci** 1996;58(19):PL317–24

Effects of streptozotocin-induced diabetes and insulin treatment on substance P of the rat arterial wall. Markle RA, et al. **Life Sci** 1996;58(14):1123–9

Smoking and impaired endothelium-dependent dilatation [letter; comment] Migliacci R, et al. **N Engl J Med** 1996 Jun 20;334(25):1674. Comment on: N Engl J Med 1996 Jan 18;334(3):150–4.

Characteristics of contractile 5-HT receptors in isolated human omental arteries: presence of 5-HT1 and 5-HT2 receptors. Wallerstedt SM, et al. **Pharmacol Toxicol** 1996 Jan;78(1):50–4

Characteristics of DQ2511-induced relaxation in isolated dog, monkey and human arteries. Okamura T, et al. **Pharmacology** 1995 Jun;50(6):370–9

Inhibition of alpha1-adrenoceptor-mediated contractions in isolated tail arteries and aorta of the rat by alpha2-adrenoceptor agonists. Nomura S, et al. **Res Commun Mol Pathol Pharmacol** 1995 Dec;90(3):307–20

Further characterization of antagonism by alpha 2-adrenoceptor agonists of contractions induced by alpha 1-adrenoceptor agonists. Nomura S, et al. **Res Commun Mol Pathol Pharmacol** 1996 Apr;92(1):31–42

[Arterial wall: a new pharmacological and therapeutic target?] Laurent S, et al. **Therapie** 1995 Jul-Aug; 50(4):387–98 (73 ref.) (Eng. Abstr.) **(Fre)**

[The pharmacological rationale for the development of a calcium antagonist in the prevention of damage to the arterial wall] Paoletti R. **Ann Ital Med Int** 1995 Oct;10 Suppl:73S **(Ita)**

EMBRYOLOGY

Development and degeneration of the arterial system in the mesonephros and metanephros of chicken embryos. Carretero A, et al. **Anat Rec** 1995 Sep;243(1):120–8

Formation of the arterial media during vascular development. Thayer JM, et al. **Cell Mol Biol Res** 1995;41(4):251–62 (100 ref.)

Topography of the "vitreous structures" (tractus; membranelles) with respect to the layers of embryonal blood vessels. Pau H. **Graefes Arch Clin Exp Ophthalmol** 1996 Mar; 234(3):199–204

GROWTH & DEVELOPMENT

Developmental remodeling of the internal elastic lamina of rabbit arteries: effect of blood flow. Wong LC, et al. **Circ Res** 1996 May;78(5):799–805

INJURIES

Injury of a medial sacral vessel during lumbar laminectomy. Kiev J, et al. **Ann Vasc Surg** 1996 Jan;10(1):63–5

A morphological study of the long-term repair process in experimentally stretched but unruptured arteries and veins. Mitchell GM, et al. **Br J Plast Surg** 1996 Jan;49(1):34–40

Regional expression of natriuretic peptide receptors during the formation of arterial neointima in the rabbit. Brown J, et al. **Circ Res** 1995 Nov;77(5):906–18

Reduction of intimal hyperplasia by naroparcil, a 4-methylumbelliferyl beta-D-xyloside analogue, after arterial injury in the hypercholesterolemic rabbit. Steg PG, et al. **Circ Res** 1995 Nov;77(5):919–26

Peripheral vascular injury. Flynn TC. **Curr Opin Gen Surg** 1994;:30–4 (41 ref.)

Absence of avascular necrosis of the humeral head after post-traumatic rupture of the anterior and posterior humeral circumflex arteries. A case report. Gerber C, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1256–9

Closed vascular injury of the finger. Giddins GE, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):325–7

Reconstruction of major arteries of lower extremities after war injuries. Long-term follow up. Lovric Z, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):223–7

Arterial gunshot injuries of the extremities: a South African experience. Degiannis E, et al. **J Trauma** 1995 Sep; 39(3):570–5

Early resuscitation with low-volume PolyDCLHb is effective in the treatment of shock induced by penetrating vascular injury. Leppäniemi A, et al. **J Trauma** 1996 Feb; 40(2):242–8

[Fractures and blood vessels] Strobbe LJ, et al. **Ned Tijdschr Geneeskd** 1996 Feb 17;140(7):345–7 **(Dut)**

[Vascular injuries in war] Radonic V, et al. **Chirurg** 1995 Sep;66(9):883–6 (Eng. Abstr.) **(Ger)**

[Peripheral vascular injuries in polytrauma] Richter A, et al. **Unfallchirurg** 1995 Sep;98(9):464–7 (Eng. Abstr.) **(Ger)**

[Vascular traumatic lesions in childhood and adolescence] Bettili G, et al. **Minerva Cardioangiol** 1996 Apr;44(4):155–60 (Eng. Abstr.) **(Ita)**

INNERVATION

ANG II receptor blockade and arterial baroreflex regulation of renal nerve activity in cardiac failure. DiBona GF, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1189–96

Angiotensin II modulates arterial baroreflex function via a central alpha 1-adrenoceptor mechanism in rabbits. Nishida Y, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1009–16

Enhanced sympathetic neurotransmission in the tail artery of 1,3-dipropyl-8-sulphophenylxanthine (DPSPX)-treated rats. Karoon P, et al. **Br J Pharmacol** 1995 Sep; 116(2):1918–22

Heterogeneity of neurogenic responses in intra- and extrameningeal arteries of dogs. Kohno Y, et al. **Br J Pharmacol** 1995 Nov;116(6):2557–62

The autonomic nervous system and the regulation of arterial tone in migraine. Thomsen LL, et al. **Clin Auton Res** 1995 Oct;5(5):243–50 (111 ref.)

Immunohistochemical study of the existence and coexistence of catecholamine synthesizing enzymes and some neuropeptides in perivascular nerve fibres of the main thoraco-cranial arteries in the pig. Sienkiewicz W, et al. **Folia Histochem Cytobiol** 1995;33(2):59–67

Enhanced vascular neuropeptide Y-immunoreactive innervation in two hypertensive rat strains. Fan XM, et al. **Hypertension** 1995 Nov;26(5):758–63

Regulation of blood pressure by nitroxidergic nerve. Toda N. **J Diabetes Complications** 1995 Oct-Dec;9(4):200–2 (21 ref.)

METABOLISM

Macrovascular dopamine release. Kraschinski S, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1244–9

Activation of adenylyl cyclase downregulates sodium/calcium exchanger of arterial myocytes. Smith L, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1379–84

Balloon catheterization induced arterial expression of embryonic fibronectins. Dubin D, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1958–67

Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Hoshiga M, et al. **Circ Res** 1995 Dec;

77(6):1129–35

Increased calcium sequestration by sarcoplasmic reticulum in small muscular arteries in young spontaneously hypertensive rats. Toyoda Y, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S223–4

Regional differences of endogenous ATP release in rabbit arteries. Ishii R, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Mar;113(3):387–91

Structure of cholesterol–containing particles accumulating in atherosclerotic lesions and the mechanisms of their derivation. Hoff HF, et al. **Curr Opin Lipidol** 1995 Oct; 6(5):317–25 (91 ref.)

The SM 22 promoter directs tissue–specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice. Moessler H, et al. **Development** 1996 Aug;122(8):2415–25

Metal ion release from mechanically–disrupted human arterial wall. Implications for the development of atherosclerosis. Evans PJ, et al. **Free Radic Res** 1995 Nov; 23(5):465–9

A scavenger that really scavenges is better in the liver than in the artery. Cooper AD. **Hepatology** 1996 Apr; 23(4):929–30

Decreased interleukin–2 production by rat uterine artery, aorta and uterine tissues during pregnancy. Huleihel M, et al. **Hum Reprod** 1996 Jun;11(6):1337–42

Natriuretic peptide receptors in human artery and vein and rabbit vein graft. Ikeda T, et al. **Hypertension** 1996 Mar; 27(3 Pt 2):833–7

Effects of papaverine and vasointestinal polypeptide on penile and vascular cAMP and cGMP in control and diabetic animals: an in vitro study. Miller MA, et al. **Int J Impot Res** 1995 Jun;7(2):91–100

Pentoxifylline selectivity inhibits tumor necrosis factor synthesis in the arterial wall. Bernard C, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S30–3

The regulation of pH in resistance arteries from spontaneously hypertensive and Wistar–Kyoto rats: the effect of bicarbonate. Scuteri A, et al. **J Hypertens** 1995 May;13(5):523–8

Calcium channel activation mobilizes calcium from a restricted pericellular region surrounding canine coronary artery smooth muscle cells. Wheeler–Clark ES, et al. **J Pharmacol Exp Ther** 1995 Sep;274(3):1493–506

Serotonin stimulates rapid increase of inositol 1,4,5–trisphosphate in ovine uterine artery: correlation with contractile state. Zhang L, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):576–83

Thrombin activity on dissected and anastomosed human arteries. Johnson PC, et al. **J Surg Res** 1996 Jan;60(1):193–8

Participation of endogenous noradrenaline in the release of ATP by high potassium in the rat caudal artery. Shinozuka K, et al. **Jpn J Pharmacol** 1995 May;68(1):125–7

Effects of streptozotocin–induced diabetes and insulin treatment on substance P of the rat arterial wall. Markle RA, et al. **Life Sci** 1996;58(14):1123–9

Effect of pressure on transmural fluid flow in different de–endothelialised arteries. Dhar P, et al. **Med Biol Eng Comput** 1996 Mar;34(2):155–9

DQ–2511, having an antiulcer action, elicits vasodilation through an increase in cyclic GMP contents in rat arteries. Hatanaka S, et al. **Pharmacology** 1995 Sep;51(3):174–9

Isradipine increases vascular prostaglandin I2–formation while the thromboxane B2–synthesis is diminished. Kritz H, et al. **Thromb Res** 1995 Dec 15;80(6):483–9

MICROBIOLOGY

Chlamydia linked to atherosclerosis [news] Mlot C. **Science** 1996 Jun 7;272(5267):1422

PATHOLOGY

MR angiography of abdominal and peripheral arteries. Techniques and clinical applications. Ekelund L, et al. **Acta Radiol** 1996 Jan;37(1):3–13 (109 ref.)

The relation between peripheral vascular structure, left ventricular hypertrophy, and ambulatory blood pressure in essential hypertension. Sihm I, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 1):987–96

Correlation between the presence of an immature smooth muscle cell population in tunica media and the development of atherosclerotic lesion. A study on different–sized rabbit arteries from cholesterol–fed and Watanabe heritable hyperlipemic rabbits. Giuriato L, et al. **Atherosclerosis** 1995 Jul;116(1):77–92

Arterial grafts for coronary artery surgery. Wandschneider W, et al. **Cardiovasc Surg** 1995 Oct;3(5):525–7

Proliferative response of smooth muscle cells after experimental balloon angioplasty [letter; comment] Hanke H. **Circulation** 1996 Jan 1;93(1):202. Comment on: Circulation 1995 Apr 1;91(7):2049–57.

Changes in various tissues in the arterial wall of spontaneously hypertensive rats. Saito N, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S126–8

Effects of chronic treatment with carvedilol on abnormalities of endothelium–dependent relaxation and structure of endothelium in resistance arteries of SHRSP. Sasaki F, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S329–30

Smooth muscle cell proliferation in the arterial intima after stretch injury: relationship between the severity of stretching and intima hyperplasia in New Zealand white rabbits. Sakamoto H, et al. **Exp Anim** 1996 Jan;45(1):89–93

Metal ion release from mechanically–disrupted human arterial wall. Implications for the development of atherosclerosis. Evans PJ, et al. **Free Radic Res** 1995 Nov; 23(5):465–9

Arterial elements and perisinusoidal cells in borderline hepatocellular nodules and small hepatocellular carcinomas. Terada T, et al. **Histopathology** 1995 Oct; 27(4):333–9

Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Isner JM, et al. **Hum Gene Ther** 1996 May 20;7(8):959–88

Effect of antihypertensive therapy on small artery structure in hypertensive patients [letter; comment] Schiffrin EL. **Hypertension** 1995 Oct;26(4):716–8. Comment on: Hypertension 1995 Apr;25(4 Pt 1):474–81.

Contributions of vascular tone and structure to elastic properties of a medium–sized artery. Weber R, et al. **Hypertension** 1996 Mar;27(3 Pt 2):816–22

Uremic small–artery disease with medial calcification and intimal hyperplasia (so–called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. Hafner J, et al. **J Am Acad Dermatol** 1995 Dec;33(6):954–62 (61 ref.)

Numerical investigation and prediction of atherogenic sites in branching arteries. Lei M, et al. **J Biomech Eng** 1995 Aug;117(3):350–7

Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I–converting enzyme inhibitor. Schiffrin EL. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S13–8

Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries. Simari RD, et al. **J Clin Invest** 1996 Jul 1;98(1):225–35

Histological changes in vessels used for microvascular reconstruction in the head and neck. Shibahara T, et al. **J Craniomaxillofac Surg** 1996 Feb;24(1):24–8

Structural changes of large conduit arteries in hypertension. Safar ME, et al. **J Hypertens** 1996 May;14(5):545–55 (67 ref.)

Vascular structure in NG–nitro–L–arginine methyl ester–induced hypertension: methodological considerations for studies of small arteries in hypertension [editorial] [see comments] Schiffrin EL. **J Hypertens** 1995 Aug; 13(8):817–21 (40 ref.). Comment in: J Hypertens 1995 Oct;13(10):1217–21.

Thrombogenicity of the human arterial wall after interventional thermal injury. Post MJ, et al. **J Vasc Res** 1996 Mar–Apr;33(2):156–63

Neonatal Escherichia coli infection and segmental arterial necrosis: similarity to edema disease of weanling swine. de Chadarévian JP, et al. **Mod Pathol** 1995 May;8(4):446–9

[Arterial wall: a new pharmacological and therapeutic target?] Laurent S, et al. **Therapie** 1995 Jul–Aug; 50(4):387–98 (73 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Effects of endothelin–1 and the ETA receptor antagonist BQ–123 on resistance arteries from normal pregnant and preeclamptic women. Wolff K, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):432–8 (34 ref.)

Effects of aging per se on arterial stiffness: systemic and regional compliance in beagles. Haidet GC, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):319–27

Arterial baroreflex sensitivity assessed from phase IV of the Valsalva maneuver. Kautzner J, et al. **Am J Cardiol** 1996 Sep 1;78(5):575–9

Memory of arterial receptor activation involves reduced [Ca2+]i and desensitization of cross bridges to [Ca2+]i. Ratz PH, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1402–7

Diastolic time: an important determinant of regional arterial blood flow. Saupe KW, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H973–9

Scatter in input impedance spectrum may result from the elastic nonlinearity of the arterial wall. Stergiopulos N, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1490–5

Arterial wave propagation phenomena, ventricular work, and power dissipation. Berger DS, et al. **Ann Biomed Eng** 1995 Nov–Dec;23(6):804–11

Pressure peaking in pulsatile flow through arterial tree structures. Duan B, et al. **Ann Biomed Eng** 1995 Nov–Dec; 23(6):794–803

Triiodothyronine optimizes sheep ventriculoarterial coupling for work efficiency. DiPierro FV, et al. **Ann Thorac Surg** 1996 Sep;62(3):662–9

Kinetics of nitric oxide liberation by 3,4–dihydro–1,2–diazete 1,2–dioxides and their vasodilatory properties in vitro and in vivo. Utepbergenov DI, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):1023–32

Measurement of oscillatory flow pressure gradient in an elastic artery model. Cohen MI, et al. **Biorheology** 1995 Jul–Aug;32(4):459–71

Non–invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Sorensen KE, et al. **Br Heart J** 1995 Sep;74(3):247–53

Electrical activity in rat tail artery during asynchronous activation of postganglionic nerve terminals by ciguatoxin–1. Brock JA, et al. **Br J Pharmacol** 1995 Oct; 116(4):2213–20

On the pressure and flow–rate distributions in tree–like and arterial–venous networks. Mayer S. **Bull Math Biol** 1996 Jul;58(4):753–85

Differential effects of pressure and flow on DNA and protein synthesis and on fibronectin expression by arteries in a novel organ culture system. Bardy N, et al. **Circ Res** 1995 Oct;77(4):684–94

NO flow helps clear murky waters? [editorial; comment] Davies PF. **Circ Res** 1996 May;78(5):945–6. Comment on: Circ Res 1996 May;78(5):750–8.

Developmental remodeling of the internal elastic lamina of rabbit arteries: effect of blood flow. Wong LC, et al. **Circ Res** 1996 May;78(5):799–805

Design and representation of multivariate patient–based reference regions for arterial pH, PCO2 and base excess values. Hekking M, et al. **Clin Biochem** 1995 Dec; 28(6):581–5

Vascular reactivity of arterial coronary artery bypass grafts—implications for their performance. Dzimiri N, et al. **Clin Cardiol** 1996 Mar;19(3):165–71 (63 ref.)

Evaluation of arterial compliance in humans. Giannattasio C, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):347–62 (23 ref.)

Baroreceptors in the carotid sinus contribute to arterial baroreceptor reflexes in normotensive rats. Ohta H, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S62–3

Applied recording force and noninvasive arterial pulses. Driscoll MD, et al. **Clin Invest Med** 1995 Oct;18(5):370–9

Definitions of cardiac/ventricular and vascular/arterial compliance are different [letter] Lehmann ED, et al. **Clin Sci (Colch)** 1996 Feb;90(2):143–6

Mechanics of the arterial wall: review and directions. Humphrey JD. **Crit Rev Biomed Eng** 1995;23(1–2):1–162 (512 ref.)

Active and passive reaction of large arterial vessels to sublingual test with nitroglycerin. Mazhbich BI, et al. **Eur J Appl Physiol** 1995;72(1–2):67–70

Does lowering of cholesterol levels influence functional properties of large arteries? Kool M, et al. **Eur J Clin Pharmacol** 1995;48(3–4):217–23

Superoxide anion and endothelial regulation of arterial tone. Katusic ZS. **Free Radic Biol Med** 1996;20(3):443–8 (52 ref.)

Wave propagation in coupled left ventricle–arterial system. Implications for aortic pressure. Berger DS, et al. **Hypertension** 1996 May;27(5):1079–89

Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects. Jamerson KA, et al. **Hypertension** 1996 Apr;27(4):854–8

Reactive hyperemia unmasks reduced compliance of cutaneous arteries in essential hypertension. Heron E, et al. **J Appl Physiol** 1995 Aug;79(2):498–505

Effects of exercise training on responses of peripheral and visceral arteries in swine. McAllister RM, et al. **J Appl Physiol** 1996 Jan;80(1):216–25

Estimation of arterial PCO2 in the elderly. St Croix CM, et al. **J Appl Physiol** 1995 Dec;79(6):2086–93

Theoretical study of dynamics of arterial wall remodeling in response to changes in blood pressure. Rachev A, et al. **J Biomech** 1996 May;29(5):635–42

Particle volumetric residence time calculations in arterial geometries. Kunov MJ, et al. **J Biomech Eng** 1996 May; 118(2):158–64

Modeling interstitial flow in an artery wall allows estimation of wall shear stress on smooth muscle cells. Wang DM, et al. **J Biomech Eng** 1995 Aug;117(3):358–63

Upregulation of a non–ETA receptor in human arteries in vitro. Adner M, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S314–6

Differences in nitric oxide production in porcine resistance arteries and epicardial conduit coronary arteries. Xu XP, et al. **J Cell Physiol** 1996 Sep;168(3):539–48

Blood vessel adaptation to gravity in a semi–arboreal snake. Conklin DJ, et al. **J Comp Physiol [B]** 1996;165(7):518–26

Facilitation of the arterial baroreflex by the preoptic area in anaesthetized rats. Inui K, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):521–31

Hypothalamic modulation of the arterial chemoreceptor reflex in the anaesthetized cat: role of the nucleus tractus solitarii. Silva–Carvalho L, et al. **J Physiol (Lond)** 1995 Sep 15;487 (Pt 3):751–60

Maternal right hypogastric artery blood flow during normal pregnancy and 6 weeks postpartum. Veille JC, et al. **J Soc Gynecol Investig** 1996 Jul–Aug;3(4):191–8

Impedance and wave reflection in arterial system: simulation with geometrically tapered T–tubes. Chang KC, et al. **Med Biol Eng Comput** 1995 Sep;33(5):652–60

In vivo measurement of arterial pre–tension. Green SI, et al. **Med Biol Eng Comput** 1995 Nov;33(6):826–9

Flow in catheterised curved artery. Jayaraman G, et al. **Med Biol Eng Comput** 1995 Sep;33(5):720–4

Real–time measurement of pulse wave velocity from arterial pressure waveforms. Ramsey MW, et al. **Med Biol Eng Comput** 1995 Sep;33(5):636–42

Paracrine functions of the coronary vascular endothelium. Fleming I, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):137–45 (49 ref.)

Optimization of hemodynamic energy expenditure in the arterial system. Monos E, et al. **Obes Res** 1995 Dec;3 Suppl 5:811S–818S

Melatonin receptors potentiate contractile responses to adrenergic nerve stimulation in rat caudal artery. Duckles SP, et al. **Proc West Pharmacol Soc** 1995;38:101–2

High Reynolds number flow in tubes of complex geometry with application to wall shear stress in arteries. Pedley TJ.

Symp Soc Exp Biol 1995;49:219–41

Quantification of blood flow patterns in human vessels by magnetic resonance imaging. Botnar R, et al. **Technol Health Care** 1996 Apr;4(1):97–112

Mathematical modeling of arterial blood flow and correlation to atherosclerosis. Perktold K, et al. **Technol Health Care** 1995 Dec;3(3):139–51

Forward and backward waves in the arterial system: nonlinear separation using Riemann invariants. Pythoud F, et al. **Technol Health Care** 1995 Dec;3(3):201–7

Sound stimulation-induced vasomotor reflex in the central artery of the rabbit ear. Takeoka M, et al. **Tohoku J Exp Med** 1996 Feb;178(2):101–11

Volumetric blood flow measurement by simultaneous Doppler signal and B-mode image processing: a feasibility study. Willink R, et al. **Ultrasound Med Biol** 1995; 21(4):481–92

[Color Doppler sonography of peripheral and cerebral fetal vessels in comparison as prognostic criterion in predicting intrauterine distress] Mai R, et al. **Z Geburtshilfe Neonatol** 1996 Jan–Feb;200(1):25–9 (Eng. Abstr.) **(Ger)**

[Humoral factor(s), circulating in the blood of spontaneously hypertensive rats, increase vascular tone and decrease the constrictor response of the isolated rat tail artery, caused by stimulation of sympathetic fibers of the vascular wall] Medvedeva NA, et al. **Biull Eksp Biol Med** 1996 Apr; 121(4):380–2 **(Rus)**

[The dependence of ortho- and antiorthostatic hemodynamic reactions on the initial (controllable) tonus of the arterial vessels in rats] Osadchii TI, et al. **Fiziol Zh Im I M Sechenova** 1995 Sep;81(9):111–26 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Variable response of the peripheral circulation to acetylcholine in patients with coronary artery disease. Testa M, et al. **Am J Cardiol** 1996 Jan 15;77(2):149–53

Effect of aging and hypertension on contractility of resistance arteries: modulation by endothelial factors. Lang MG, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H837–44

Ca(2+)-dependent K+ current in arterial smooth muscle cells from aldosterone-salt hypertensive rats. Liu Y, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1246–57

Hypertension and peripheral arterial hemodynamics. Milio G, et al. **Angiology** 1995 Dec;46(12):1069–74

Arterial and cardiac changes in hypertension in the elderly. Asmar R, et al. **Blood Press** 1995;Suppl 3:31–7 (48 ref.)

Enhanced contractile responses of arteries from streptozotocin diabetic rats to sodium fluoride. Weber LP, et al. **Br J Pharmacol** 1996 May;118(1):115–22

Pathophysiology of smooth muscle in hypertension. Lee RM, et al. **Can J Physiol Pharmacol** 1995 May;73(5):574–84 (103 ref.)

The autonomic nervous system and the regulation of arterial tone in migraine. Thomsen LL, et al. **Clin Auton Res** 1995 Oct;5(5):243–50 (111 ref.)

Vessel wall properties of large arteries in uncomplicated IDDM. Kool MJ, et al. **Diabetes Care** 1995 May; 18(5):618–24

Non-invasive assessment of unstimulated forearm arterial compliance in human subjects. Impaired vasoreactivity in hypercholesterolaemia. Baldassarre D, et al. **Eur J Clin Invest** 1995 Nov;25(11):859–66

Exaggerated effects of progestogen on uterine artery pulsatility index in Turner's syndrome patients receiving hormone replacement therapy. Biljan MM, et al. **Fertil Steril** 1995 Dec;64(6):1104–8

Endothelin and vascular reactivity in cirrhosis. Sieber CC. **Hepatology** 1995 Nov;22(5):1609–11

Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. Chin-Dusting JP, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1207–13

Influence of the arterial blood pressure and nonhemodynamic factors on regional arterial wall properties in moderate essential hypertension. Duprez DA, et al. **J Hum Hypertens** 1996 Apr;10(4):251–6

Arterial spontaneous rhythmic contractile activity in humans and rats: spectral analysis and regulatory mechanisms. Rizzoni D, et al. **J Hypertens** 1995 Sep;13(9):1043–52

[The vascular changes in arterial hypertension] Ponte E, et al. **Minerva Med** 1995 Sep;86(9):357–65 (60 ref.) (Eng. Abstr.) **(Ita)**

[Compliance of the arterial system in sportsmen] Karpman VL, et al. **Fiziol Cheloveka** 1995 Sep–Oct;21(5):144–9 **(Rus)**

RADIATION EFFECTS

[Arterial stenosis after radiotherapy] Piedbois P, et al. **Bull Cancer Radiother** 1990;77(1):3–13 (89 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY see ANGIOGRAPHY

SURGERY

Porcine gastroepiploic artery as an in vitro experimental model to study vasodilators in microsurgery. Kim DC, et al. **Ann Plast Surg** 1996 May;36(5):502–7

Compliance and formation of distal anastomotic intimal hyperplasia in Dacron mesh tube constricted veins used as arterial bypass grafts. Trubel W, et al. **ASAIO J** 1994 Jul–Sep;40(3):M273–8

Longitudinal forces acting at side-to-end and end-to-side anastomoses when a knitted polyester arterial prosthesis is implanted in the dog. Dadgar L, et al. **J Invest Surg** 1995 May–Jun;8(3):163–78

Mechanical evaluation of anastomotic tension and patency in arteries. Zhang F, et al. **J Reconstr Microsurg** 1996 Feb; 12(2):121–6

Tissue factor and its inhibition at the human microvascular anastomosis. Dumanian GA, et al. **J Surg Res** 1996 Jan; 60(1):263–9

Thrombin activity on dissected and anastomosed human arteries. Johnson PC, et al. **J Surg Res** 1996 Jan;60(1):193–8

Arterial gunshot injuries of the extremities: a South African experience. Degiannis E, et al. **J Trauma** 1995 Sep; 39(3):570–5

Study on microvascular anastomosis of arteries with absorbable polyglyconate suture. Huang GK, et al. **Microsurgery** 1995;16(7):505–9

Vascular complications after free tissue transfer. Rieck B, et al. **Microsurgery** 1995;16(6):400–3

Telescoping and glue technique in vein grafts for arterial defects. Saitoh S, et al. **Plast Reconstr Surg** 1995 Nov; 96(6):1401–8

Prospective study of wound complications in continuous infrainguinal incisions after lower limb arterial reconstruction: incidence, risk factors, and cost. Kent KC, et al. **Surgery** 1996 Apr;119(4):378–83

Reconstruction of the gastroduodenal artery in pancreatic transplantation. Han DJ. **Transplant Proc** 1996 Jun; 28(3):1727–8

[The role of transplanted vein graft in arterial reconstruction] Patrone P, et al. **Minerva Chir** 1995 Jul–Aug;50(7–8):673–9 (Eng. Abstr.) **(Ita)**

[The St. Jude biopolymeric graft in reconstruction of peripheral arteries] Lotina S, et al. **Acta Chir Iugosl** 1990; 37(2):269–78 (Eng. Abstr.) **(Scc)**

[Arterial surgery of the extremities without angiography. A simpler preoperative survey with color doppler] Karacagil S, et al. **Lakartidningen** 1995 Oct 4;92(40):3692–3 **(Swe)**

TRANSPLANTATION

Transfer of vessels in the management of thumb and ring avulsion injuries. Adani R, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):51–7

Eradication of aortic infections with the use of cryopreserved arterial homografts. Vogt PR, et al. **Ann Thorac Surg** 1996 Sep;62(3):640–5

Cryopreserved arterial allografts for limb salvage in the absence of suitable saphenous vein: two-year results in 20 cases. Gournier JP, et al. **Ann Vasc Surg** 1995;9 Suppl:S7–14

Recurrent aortic infection: treatment by arterial homograft replacement. Nevelsteen A, et al. **Cardiovasc Surg** 1995 Aug;3(4):441–4

Arterial grafts for coronary artery surgery. Wandschneider W, et al. **Cardiovasc Surg** 1995 Oct;3(5):525–7

Vascular reactivity of arterial coronary artery bypass grafts—implications for their performance. Dzimiri N, et al. **Clin Cardiol** 1996 Mar;19(3):165–71 (63 ref.)

Arterial and venous conduits for coronary artery bypass. A current review. Cooper GJ, et al. **Eur J Cardiothorac Surg** 1996;10(2):129–40 (197 ref.)

Technical aspects and late functional results of gastroepiploic bypass grafting (400 cases). Jegaden O, et al. **Eur J Cardiothorac Surg** 1995;9(10):575–80; discussion 581

Cryopreaserved arterial homografts for in situ reconstruction of mycotic aneurysms and prosthetic graft infection. Vogt PR, et al. **Eur J Cardiothorac Surg** 1995;9(9):502–6

Cyclosporin A delays the presentation of intimal hyperplasia in an experimental model of arterial autograft. Bellón JM, et al. **Eur Surg Res** 1996;28(1):39–48

Assessment of cyclosporine A-induced ultrastructural changes in vascular wall using an experimental arterial autograft model. Buján J, et al. **Histol Histopathol** 1995 Jul;10(3):567–76

The comparison of vascular reactivities of arterial and venous grafts to vasodilators: management of graft spasm. Üydeş-Doğan BS, et al. **Int J Cardiol** 1996 Feb; 53(2):137–45

A long term follow-up of one of the first arterial homografts. Hardaway RM. **J Cardiovasc Surg (Torino)** 1995 Oct; 36(5):491–2

Effects of competitive blood flow on arterial graft patency and diameter. Medium-term postoperative follow-up. Hashimoto H, et al. **J Thorac Cardiovasc Surg** 1996 Feb; 111(2):399–407

Arteries from human beings are less infectible by Staphylococcus aureus than polytetrafluoroethylene in an aortic dog model. Koskas F, et al. **J Vasc Surg** 1996 Mar; 23(3):472–6

Defining the role of the radial artery. Barner HB. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):3–9

Current status of the inferior epigastric artery. Buche M, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):10–4 (19 ref.)

Complete revascularization with three or more arterial conduits. Calafiore AM, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):15–23

Optimal use of the gastroepiploic artery. Suma H. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):24–8

Complete revascularization with internal thoracic artery grafts. Tector AJ, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):29–41 (67 ref.)

[Experience of the exclusive use of arteries in myocardial revascularization] Galrinho A, et al. **Rev Port Cardiol** 1995 Oct;14(10):681–9 (Eng. Abstr.) **(Por)**

ULTRASONOGRAPHY

Assessment of arterial invasion in pancreatic cancer using color Doppler ultrasonography. Tomiyama T, et al. **Am J Gastroenterol** 1996 Jul;91(7):1410–6

Arterial wall thickness measurements by B mode ultrasonography in patients with Takayasu's arteritis. Raninen RO, et al. **Ann Rheum Dis** 1996 Jul;55(7):461–5

Doppler colour flow analysis of uterine and ovarian arteries prior to and after surgery for tubal sterilization: a prospective study. Geber S, et al. **Hum Reprod** 1996 Jun; 11(6):1195–8

Assessment of arterial distensibility by automatic pulse wave velocity measurement [letter; comment] Lehmann ED, et al. **Hypertension** 1996 May;27(5):1188–91. Comment on: Hypertension 1995 Sep;26(3):485–90.

A transputer-based physiological signal processing system. Part 1—System design. Cowan DM, et al. **Med Eng Phys** 1995 Sep;17(6):403–9

Duplex ultrasonography to diagnose failing arterial prosthetic grafts. Calligaro KD, et al. **Surgery** 1996 Sep;120(3):455–9

Intravascular ultrasound image subtraction: a contrast enhancing technique to facilitate automatic three-dimensional visualization of the arterial lumen. Pasterkamp G, et al. **Ultrasound Med Biol** 1995;21(7):913–8

Volumetric blood flow measurement by simultaneous Doppler signal and B-mode image processing: a feasibility study. Willink R, et al. **Ultrasound Med Biol** 1995; 21(4):481–92

[Echographic and velocimetric aspects of arteriopathies in the diabetic] Niang EH, et al. **Dakar Med** 1994;39(1):37–42 (Eng. Abstr.) **(Fre)**

[Evaluation of blood flow in uterine arteries in patients with cancer of the cervix uteri using transvaginal color doppler ultrasonography] Szpurek D, et al. **Ginekol Pol** 1995 Sep; 66(9):529–32 (Eng. Abstr.) **(Pol)**

ULTRASTRUCTURE

A morphological study of the long-term repair process in experimentally stretched but unruptured arteries and veins. Mitchell GM, et al. **Br J Plast Surg** 1996 Jan;49(1):34–40

Thymic vascular system of the European common frog, Rana temporaria: a scanning electron-microscopic study of vascular casts. Miodoński AJ, et al. **Cell Tissue Res** 1995 Sep;281(3):543–9

Assessment of cyclosporine A-induced ultrastructural changes in vascular wall using an experimental arterial autograft model. Buján J, et al. **Histol Histopathol** 1995 Jul;10(3):567–76

ARTERIO-ARTERIAL FISTULA

COMPLICATIONS

Coronary artery fistula to bronchial artery on contralateral side of coronary atherosclerosis and myocardial insufficiency. A case report. Wandwi WB, et al. **Angiology** 1996 Feb;47(2):211–3

Late complications in traumatic coronary artery fistula: report of a case requiring surgical repair after 8 years. Shimabukuro M, et al. **Cardiology** 1996 Jan–Feb;87(1):86–9

Bilateral coronary arterio-cameral fistulae in a case of tetralogy of Fallot. Patil CV, et al. **Indian Heart J** 1996 Mar–Apr;48(2):175–7

A surgically-treated case of left atrial myxoma complicating coronary artery fistula. Sasaki Y, et al. **Jpn Heart J** 1995 Nov;36(6):825–8

[Hemoptysis due to aortopulmonary fistula: a case report of successful surgical treatment] Fukumura Y, et al. **Kyobu Geka** 1995 Nov;48(12):1046–9 (Eng. Abstr.) **(Jpn)**

CONGENITAL

Congenital coronary artery fistulae arising from bilateral coronary arteries and emptying into both pulmonary artery and left ventricle: a rare presentation. Nawa S, et al. **Cardiology** 1996 May–Jun;87(3):263–6

[A quantitative evaluation of coronary steal phenomenon in coronary artery-pulmonary artery fistula: case report] Okeie K, et al. **J Cardiol** 1995 Nov;26(5):305–12 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Traumatic aortopulmonary communication: clinicopathologic correlation. Wang TL, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1136–9

ETIOLOGY

Coronary-pulmonary steal syndrome. Najm HK, et al. **Ann Thorac Surg** 1996 Jul;62(1):264–5 (7 ref.)

Rupture of a dissecting thoracic aortic aneurysm into the pulmonary artery: successful surgical repair. Coselli JS, et al. **Cardiovasc Surg** 1995 Dec;3(6):697–701 (34 ref.)

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)

Acquired aortopulmonary fistula in pseudoaneurysm of the aorta six years after a Bentall operation. Chevalier P, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):1143–4
[Thoracic aortic aneurysm with acute aortopulmonary fistula] Hagen T, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Jan;164(1):79–81 **(Ger)**

PATHOLOGY

Multiple fistulas between coronary and pulmonary arteries. Van Dam DW, et al. **Eur J Cardiothorac Surg** 1995; 9(12):707–8 (10 ref.)
Extrarenal anastomoses of intrarenal fetal arteries with the arteries of surrounding structures. Kosinski H.
Folia Morphol (Warsz) 1995;54(3):173–80

PHYSIOPATHOLOGY

Transverse sinus dural fistula: combined surgical and endovascular approach: a case report. Misra M, et al.
Surg Neurol 1996 Aug;46(2):129–34
[A quantitative evaluation of coronary steal phenomenon in coronary artery–pulmonary artery fistula: case report] Okeie K, et al. **J Cardiol** 1995 Nov;26(5):305–12 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Case report: bronchial to coronary artery anastomosis—a potential hazard in bronchial artery embolization. Van den Berg JC, et al. **Br J Radiol** 1996 Jun;69(822):570–2

SURGERY

Rupture of a dissecting thoracic aortic aneurysm into the pulmonary artery: successful surgical repair. Coselli JS, et al. **Cardiovasc Surg** 1995 Dec;3(6):697–701 (34 ref.)
Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)
Transverse sinus dural fistula: combined surgical and endovascular approach: a case report. Misra M, et al.
Surg Neurol 1996 Aug;46(2):129–34
[An operative case of bilateral coronary arteries fistulae to pulmonary artery associated with a giant saccular aneurysm] Kawaharada N, et al. **Kyobu Geka** 1996 Mar; 49(3):220–3 (Eng. Abstr.) **(Jpn)**
[Surgical treatment of coronary artery fistulas] Yasuda T, et al. **Kyobu Geka** 1995 Aug;48(9):763–7 (Eng. Abstr.) **(Jpn)**

THERAPY

Coil embolization of a coronary fistula in a post–transplant patient. Furniss SS, et al. **Eur Heart J** 1995 Aug; 16(8):1147–8

ULTRASONOGRAPHY

Multiplane transesophageal echocardiography in the diagnosis of congenital coronary artery fistula. Lin FC, et al. **Am Heart J** 1995 Dec;130(6):1236–44

ARTERIOGRAPHY see **ANGIOGRAPHY**

ARTERIOHEPATIC DYSPLASIA see **ALAGILLE SYNDROME**

ARTERIOLES

ANATOMY & HISTOLOGY

[Architecture and fine structure of the terminal blood vessels in the marginal papillae of the tongue in newborn piglets] Schlechta C, et al. **Anat Anz** 1996 Apr;178(2):137–43 (Eng. Abstr.) **(Ger)**

CYTOLOGY

Differential contractile response of cultured microvascular pericytes to vasoactive agents. Murphy DD, et al.
Microcirculation 1994 Jul;1(2):121–8

DRUG EFFECTS

Afferent arteriolar response to arachidonic acid: involvement of metabolic pathways. Imig JD, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F87–93
Effect of endopeptidase-24.11 inhibitors and C-ANP receptor ligand on responses evoked in arterioles of rat cremaster muscle by atrial natriuretic peptide. Peyroux J, et al. **Br J Pharmacol** 1995 Dec;116(8):3117–24
L-arginine-induced conducted signals alter upstream arteriolar responsivity to L-arginine. Frame MD, et al.
Circ Res 1995 Oct;77(4):695–701
Adenosine-induced vasoconstriction in vivo. Role of the mast cell and A3 adenosine receptor. Shepherd RK, et al.
Circ Res 1996 Apr;78(4):627–34
Pharmacological characterization of purinoceptor-mediated constriction of submucosal arterioles in guinea pig ileum. Galligan JJ, et al. **J Pharmacol Exp Ther** 1995 Sep; 274(3):1425–30
Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy. Young BA, et al.
Kidney Int 1995 Aug;48(2):431–8
Short-term exposure to lipopolysaccharide is associated with microvascular contractile dysfunction in vivo. Gao XP, et al. **Life Sci** 1995 Mar 3;56(15):1243–9
Acute effects of ethanol on responses of cerebral arterioles. Mayhan WG, et al. **Stroke** 1995 Nov;26(11):2097–101; discussion 2102

INNERVATION

Sensory nerves play an efferent role in the function of the arterioles, but not the dilator muscle, of the rat iris. Hill CE, et al. **J Auton Nerv Syst** 1996 Apr 20;58(1–2):89–100

METABOLISM

pO2 measurements in arteriolar networks. Torres Filho IP, et al. **Microvasc Res** 1996 Mar;51(2):202–12
Arteriolar contribution to microcirculatory CO2/O2 exchange. Ye GF, et al. **Microvasc Res** 1995 Nov; 50(3):338–59
Differential regulation of cytosolic calcium between afferent arteriol ar smooth muscle cells from mouse kidney. Scholz H, et al. **Pflugers Arch** 1995 Nov;431(1):46–51

PATHOLOGY

Insulin induces medial hypertrophy of myocardial arterioles in rats. Zimlichman R, et al. **Am J Hypertens** 1995 Sep; 8(9):915–20
Effects of lisinopril on the structure of renal arterioles. Notoya M, et al. **Hypertension** 1996 Mar;27(3 Pt 1):364–70
Intestinal fibrosis and vascular remodeling in ten horses and two ponies. Schultheiss PC, et al. **J Vet Diagn Invest** 1995 Oct;7(4):575–8
[Microcirculatory system of paired hamster cheek pouches after blood loss and replacement] Mikhaĭlichenko LA.
Biull Eksp Biol Med 1996 Jan;121(1):30–2 **(Rus)**

PHYSIOLOGY

Ratiometric measurement of endothelial depolarization in arterioles with a potential-sensitive dye. Beach JM, et al.
Am J Physiol 1996 Jun;270(6 Pt 2):H2216–27
Flow-dependent arteriolar dilation in normotensive rats fed low- or high-salt diets. Boegehold MA. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1407–14
Role of myosin phosphorylation and [Ca2+]i in myogenic reactivity and arteriolar tone. Zou H, et al.
Am J Physiol 1995 Nov;269(5 Pt 2):H1590–6
Chaotic oscillations in microvessel arterial networks. Cavalcanti S, et al. **Ann Biomed Eng** 1996 Jan–Feb; 24(1):37–47
Antisense evidence for two functionally active forms of nitric oxide synthase in brain microvascular endothelium. Rosenblum WI, et al. **Biochem Biophys Res Commun** 1996 Jul 16;224(2):535–43
Differential sensitivity of venular and arteriolar alpha-adrenergic receptor constriction to inhibition by hypoxia. Role of receptor subtype and coupling heterogeneity. Leech CJ, et al. **Circ Res** 1996 Jun; 78(6):1064–74
Divergent mechanisms of ATP-sensitive K+ channel-induced vasodilation in renal afferent and efferent arterioles. Evidence of L-type Ca2+ channel-dependent and -independent actions of pinacidil. Reslerova M, et al.
Circ Res 1995 Dec;77(6):1114–20
Mechanisms of action of atrial natriuretic factor and C-type natriuretic peptide. Amin J, et al. **Hypertension** 1996 Mar; 27(3 Pt 2):684–7
20-HETE requires increased vascular tone to constrict rabbit afferent arterioles. Arima S, et al. **Hypertension** 1996 Mar; 27(3 Pt 2):781–5
Effects of increased pulse pressure on cerebral arterioles. Baumbach GL. **Hypertension** 1996 Feb;27(2):159–67
Biomechanical model for the myogenic response in the microcirculation: Part I—Formulation and initial testing. Lee S, et al. **J Biomech Eng** 1996 May;118(2):145–51
Biomechanical model for the myogenic response in the microcirculation: Part II—Experimental evaluation in rat cremaster muscle. Lee S, et al. **J Biomech Eng** 1996 May; 118(2):152–7
Oxygen radicals do not play a role in arteriolar dilation during cortical spreading depression. Meng W, et al.
J Cereb Blood Flow Metab 1996 Jan;16(1):175–9
Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles. Tamaki T, et al. **Kidney Int** 1996 Mar; 49(3):722–9
The mechanics of arteriole-tissue interaction. Guilford WH, et al. **Microvasc Res** 1995 Sep;50(2):260–87
Does luminal release of EDRF contribute to downstream microvascular tone? Klotz KF, et al. **Pflugers Arch** 1995 Oct;430(6):978–83
Involvement of specific macrophage-lineage cells surrounding arterioles in barrier and scavenger function in brain cortex. Mato M, et al.
Proc Natl Acad Sci U S A 1996 Apr 16;93(8):3269–74
Impaired pial arteriolar reactivity to hypercapnia during hyperammonemia depends on glutamine synthesis. Hirata T, et al. **Stroke** 1996 Apr;27(4):729–36

PHYSIOPATHOLOGY

Influence of NaCl concentration at the macula densa on angiotensin II-induced constriction of the afferent arteriole. Ren YL, et al. **Hypertension** 1996 Mar;27(3 Pt 2):649–52
Arteriolar reactivity of endotoxin-tolerant rats after hemorrhage and reinfusion. Baker CH, et al. **Shock** 1995 Dec;4(6):455–60
[Vascular remodeling] Lombardo M, et al. **G Ital Cardiol** 1995 Nov;25(11):1475–8 **(Ita)**

ULTRASTRUCTURE

Ultrastructure of rat pulmonary arterioles after neonatal exposure to hypoxia and subsequent relief and treatment with monocrotaline. King AP, et al. **J Pathol** 1995 Sep; 177(1):71–81
A circumferential stress–growth rule predicts arcade arteriole formation in a network model. Price RJ, et al.
Microcirculation 1995 May;2(1):41–51

ARTERIOSCLEROSIS

see related
DIET, ATHEROGENIC

[Progress on diagnosis and therapy of diabetic angiopathies] Haranou Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):562–7 (12 ref.) **(Jpn)**

BLOOD

Plasma viscosity increase with progression of peripheral arterial atherosclerotic disease. Poredoš P, et al.
Angiology 1996 Mar;47(3):253–9
TGF-beta: implications for human vascular disease. Metcalfe JC, et al. **J Hum Hypertens** 1995 Aug;9(8):679
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes [see comments] Boushey CJ, et al.
JAMA 1995 Oct 4;274(13):1049–57. Comment in: JAMA 1996 Mar 6;275(9):681; discussion 682–3. Comment in: JAMA 1996 Mar 6;275(9):681–2; discussion 682–3. Comment in: JAMA 1996 Mar 6;275(9):682–3.

COMPLICATIONS

Vascular risk factors and arteriosclerotic disease in idiopathic normal-pressure hydrocephalus of the elderly. Krauss JK, et al. **Stroke** 1996 Jan;27(1):24–9
[The prognosis for the development of ischemic disorders of the cerebral circulation in persons with an asymptomatic course of atherosclerotic occlusive lesions of the major arteries of the head] Pyshkina LI, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1995;95(2):9–14 **(Rus)**

DIAGNOSIS

[Digital subtraction angiography and duplex scanning in the multimodal diagnosis of carotid artery pathology] Bragina LK, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Jan–Mar;(1):16–9 **(Rus)**

DRUG THERAPY

A prescreening system for potential antiproliferative agents: implications for local treatment strategies of postangioplasty restenosis. Voisard R, et al.
Int J Cardiol 1995 Aug;51(1):15–28
Decrease of urine protein after treatment with probucol in patients with mild glomerulonephritis and arteriolosclerosis [letter] Ogawa M, et al. **Nephron** 1995;70(3):376–7
[A free radical mechanism for inhibition of arteriosclerosis development with calcium antagonists] Andrzejak R, et al. **Postepy Hig Med Dosw** 1995;49(5):645–59 (87 ref.) (Eng. Abstr.) **(Pol)**
[Fenofibrate and arteriosclerosis. The new developments of the last 5 years (editorial)] Millán Núñez Cortés J, et al.
Rev Clin Esp 1995 Dec;195(12):817–9 (46 ref.) **(Spa)**

EPIDEMIOLOGY

[Unidentified arteriopathy: an epidemiological study. The preliminary results] Baggio E, et al.
Minerva Cardioangiol 1996 Mar;44(3):75–9 (Eng. Abstr.) **(Ita)**
[The Mediterranean diet in the prevention of arteriosclerosis] Jossa F, et al. **Recenti Prog Med** 1996 Apr;87(4):175–81 (Eng. Abstr.) **(Ita)**
[Use of epidemiological data to predict the occurrence of arteriosclerotic diseases in urban residents] Suzuki K.
Nippon Ronen Igakkai Zasshi 1996 May;33(5):360–70 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid [editorial; comment] Motulsky AG.
Am J Hum Genet 1996 Jan;58(1):17–20 (28 ref.). Comment on: Am J Hum Genet 1996 Jan;58(1):35–41.
Alcohol intake as a risk factor for peripheral arterial disease in the general population in the Edinburgh Artery Study. Jepson RG, et al. **Eur J Epidemiol** 1995 Feb;11(1):9–14
Adhesion molecules and cell surface receptors in the heart transplant-associated arteriosclerosis. Hinek A.
Folia Histochem Cytobiol 1996;34(1):3–19 (140 ref.)
Homocysteine as a risk factor for arteriosclerosis. Kuritzky L. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):37, 41 (5 ref.)
Vascular risk factors for atherosclerotic plaque progression in carotid artery. Delcker A, et al. **Int Angiol** 1995 Dec; 14(4):339–45

Influence of vein valves in the development of arteriosclerosis in venoarterial grafts in the rabbit. Chaux A, et al. **J Thorac Cardiovasc Surg** 1995 Nov;110(5):1381–9; discussion 1389–90

Experimental transplant arteriosclerosis: inhibition by angiopeptin and low molecular weight heparin derivatives. Akyürek ML, et al. **Transplant Proc** 1995 Dec;27(6):3555–6

Initial endothelial injury and cytomegalovirus infection accelerate the development of allograft arteriosclerosis. Li F, et al. **Transplant Proc** 1995 Dec;27(6):3552–4

Relative importance of ischemic injury and immunological injury on the development of transplant arteriosclerosis in rabbit aortic allografts. Andersen HO, et al. **Transplantation** 1995 Oct 15;60(7):631–8

[Familial combined hyperlipidemia with particularly severe and premature arteriosclerotic lesions. Description of a case] Brocchieri A, et al. **Minerva Med** 1996 May; 87(5):237–42 (Eng. Abstr.) **(Ita)**

[Study on serial changes in blood pressure, obesity and blood chemistry and cardiovascular disease in the long-term hospitalized patients with sequela of acute carbon monoxide poisoning] Hatama S. **Fukuoka Igaku Zasshi** 1995 Dec; 86(12):443–57 (Eng. Abstr.) **(Jpn)**

[Insulin resistance and arteriosclerosis] Matsuzawa Y. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1579–82 (8 ref.) **(Jpn)**

[Homocysteine—an independent risk factor of premature vascular disease] Mansoor MA, et al. **Tidsskr Nor Laegeforen** 1996 May 30;116(14):1663–7 (41 ref.) **(Nor)**

[Free radicals and their importance in medicine] Andrzejak R, et al. **Postepy Hig Med Dosw** 1995;49(4):531–49 (89 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Importance of minor histocompatibility antigens in the development of allograft arteriosclerosis. Koulack J, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):273–7

Increased antibody titers against mycobacterial heat-shock protein 65 in patients with vasculitis and arteriosclerosis. Gruber R, et al. **Int Arch Allergy Immunol** 1996 May; 110(1):95–8

Immunologic basis of transplant-associated arteriosclerosis. Shi C, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30; 93(9):4051–6

Expression of CD11b and ICAM-1 in an in vivo model of transplant arteriosclerosis. Akyürek ML, et al. **Transpl Immunol** 1995 Jun;3(2):107–13

Reversibility of allograft arteriosclerosis after retransplantation to donor strain. Mennander A, et al. **Transplantation** 1996 Aug 27;62(4):526–9

METABOLISM

Carotid atherosclerosis. Immunocytochemical analysis of the vascular and cellular composition in endarterectomies. Milei J, et al. **Cardiologia** 1996 Jun;41(6):535–42

Effects of fish oil supplementation on atherosclerosis in different regions of the aorta of rabbits with diet-induced hypercholesterolaemia. Chen MF, et al. **Clin Sci (Colch)** 1995 Nov;89(5):497–504

Adhesion molecules and cell surface receptors in the heart transplant-associated arteriosclerosis. Hinek A. **Folia Histochem Cytobiol** 1996;34(1):3–19 (140 ref.)

PATHOLOGY

Localized adhesion of monocytes to human atherosclerotic plaques demonstrated in vitro: implications for atherogenesis. Poston RN, et al. **Am J Pathol** 1996 Jul; 149(1):73–80

Migration behavior of human smooth muscle cells cultivated from restenotic and primary lesions. Brandl R, et al. **Angiology** 1995 Nov;46(11):973–80

Extracellular mast cell granules carry apolipoprotein B-100-containing lipoproteins into phagocytes in human arterial intima. Functional coupling of exocytosis and phagodytosis in neighboring cells. Kaartinen M, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):2047–54

Mononuclear leukocytes invade rabbit arterial intima during thickening formation via CD18-and VLA-4-dependent mechanisms and stimulate smooth muscle migration. Kling D, et al. **Circ Res** 1995 Dec;77(6):1121–8

1,3 Butadiene, a vapor phase component of environmental tobacco smoke, accelerates arteriosclerotic plaque development. Penn A, et al. **Circulation** 1996 Feb 1; 93(3):552–7

Association between the extent of sclerotic changes in iliac arteries and long-term prognosis in patients with ischemic heart disease. Maruyama T, et al. **J Cardiol** 1996 Jul; 28(1):33–9

Effect of the antioxidant probucol on transplant arteriosclerosis in aorta-allografted rabbits. Andersen HO, et al. **J Mol Cell Cardiol** 1995 Aug;27(8):1561–71

[An autopsy case of "diffuse neurofibrillary tangles with calcification", multiple infarctions and hyaline arteriosclerosis] Arai T, et al. **No To Shinkei** 1996 Jan; 48(1):69–76 (26 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Endothelins as cardiovascular peptides. Levin ER. **Am J Nephrol** 1996;16(3):246–51 (64 ref.)

Non-Newtonian flow of blood in an arteriosclerotic blood vessel with rigid permeable walls. Das B, et al. **J Theor Biol** 1995 Jul 7;175(1):1–11

[Arteriosclerosis and osteoporosis (editorial)] Laroche M. **Presse Med** 1996 Jan 20;25(2):52–4 (Eng. Abstr.) **(Fre)**

[Molecular medicine and gene therapy as exemplified with arteriosclerosis and restenosis] Lüscher TF, et al. **Schweiz Med Wochenschr** 1995 Nov 4;125(44):2107–21 (112 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Dominant social status and contraceptive hormone treatment inhibit atherogenesis in premenopausal monkeys. Kaplan JR, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec; 15(12):2094–100

Triple drug immunosuppression significantly reduces aortic allograft arteriosclerosis in the rat. Lemström KB, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):553–64

Oestradiol inhibition of vascular myointimal proliferation following immune, chemical and mechanical injury. Foegh ML, et al. **Ciba Found Symp** 1995;191:139–45; discussion 145–9 (19 ref.)

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes [see comments] Boushey CJ, et al. **JAMA** 1995 Oct 4;274(13):1049–57. Comment in: JAMA 1996 Mar 6;275(9):681; discussion 682–3. Comment in: JAMA 1996 Mar 6;275(9):681–2; discussion 682–3. Comment in: JAMA 1996 Mar 6;275(9):682–3.

Experimental transplant arteriosclerosis: inhibition by angiopeptin and low molecular weight heparin derivatives. Akyürek ML, et al. **Transplant Proc** 1995 Dec;27(6):3555–6

Effect of MC1288, a vitamin D analogue, on lymphocyte proliferation in vitro and rat aortic allograft arteriosclerosis in vivo. Räisänen-Sokolowski A, et al. **Transplant Proc** 1996 Apr;28(2):919

Lack of effect of recombinant human superoxide dismutase on cold ischemia-induced arteriosclerosis in syngeneic rat aortic transplants. Myllärniemi M, et al. **Transplantation** 1996 Apr 15;61(7):1018–22

[Overview—suppression effect of essential trace elements on arteriosclerotic development and it's mechanism] Saito N. **Nippon Rinsho** 1996 Jan;54(1):59–66 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Prophylactic and correcting effect of polyethylene oxide Polyox WSR-301 in experimental lipoidosis in rats] Sokolova IA, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):587–9 **(Rus)**

RADIOGRAPHY

[Clinical usefulness of helical-scanning CT for the evaluation of arteriosclerotic carotid lesions] Nomura M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(12):878–84 (Eng. Abstr.) **(Jpn)**

SURGERY

Rotational atherectomy with a new device: initial clinical experience. Kjellgren O, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):459–66

Results of vascular reconstructions for atherosclerotic arterial occlusive disease of the lower limbs in young adults. van Goor H, et al. **Eur J Vasc Endovasc Surg** 1995 Oct; 10(3):323–6

A randomized trial of transcutaneous extraction atherectomy in femoral arteries: intravascular ultrasound observations. Nakamura S, et al. **J Clin Ultrasound** 1995 Oct;23(8):461–71

Horseshoe kidney and aortic surgery. Wymenga LF, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):331–4 (10 ref.)

Current status of atherectomy for peripheral arterial occlusive disease. Ahn SS, et al. **World J Surg** 1996 Jul-Aug;20(6):635–43 (45 ref.)

[Arterial wall texture after uncomplicated endarterectomy] Bürrig KF, et al. **Pathologe** 1995 Sep;16(5):336–41 (49 ref.) (Eng. Abstr.) **(Ger)**

[The outcomes of reconstructive-reparative operations in atherosclerotic lesions of the femoral-popliteal segment] Veretenin VA, et al. **Voen Med Zh** 1995 Aug;(8):37–41 **(Rus)**

THERAPY

A prescreening system for potential antiproliferative agents: implications for local treatment strategies of postangioplasty restenosis. Voisard R, et al. **Int J Cardiol** 1995 Aug;51(1):15–28

Covered stents for prevention of restenosis. Experimental and clinical results with different stent designs. Tepe G, et al. **Invest Radiol** 1996 Apr;31(4):223–9

Phenol lumbar sympathetic block in diabetic lower limb ischemia. Mashiah A, et al. **J Cardiovasc Risk** 1995 Oct; 2(5):467–9

Increased serum level of total homocysteine in CAPD patients despite fish oil therapy. Holdt B, et al. **Perit Dial Int** 1996;16 Suppl 1:S246–9

Prediction of cure of hypertension in atherosclerotic renal artery stenosis. Barri YM, et al. **South Med J** 1996 Jul; 89(7):679–83

Concern about safety of carotid angioplasty [letter; comment] Roubin GS, et al. **Stroke** 1996 Jun;27(6):1130–1. Comment on: Stroke 1996 Feb;27(2):197–8.

[Molecular medicine and gene therapy as exemplified with arteriosclerosis and restenosis] Lüscher TF, et al. **Schweiz Med Wochenschr** 1995 Nov 4;125(44):2107–21 (112 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of atherosclerotic occlusion of blood vessels] Genik SM. **Klin Khir** 1995;(7-8):28–30 (36 ref.) **(Ukr)**

ULTRASONOGRAPHY

A randomized trial of transcutaneous extraction atherectomy in femoral arteries: intravascular ultrasound observations. Nakamura S, et al. **J Clin Ultrasound** 1995 Oct;23(8):461–71

VIROLOGY

Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Lemström K, et al. **Circulation** 1995 Nov 1;92(9):2594–604

Virally induced arteriosclerosis: increased life expectancy? Kaunitz H. **Med Hypotheses** 1995 Oct;45(4):335–8

ARTERIOSCLEROSIS, CORONARY see **CORONARY ARTERIOSCLEROSIS**

ARTERIOSCLEROSIS OBLITERANS

COMPLICATIONS

A rare case of arteriosclerosis obliterans without prominent risk factors complicated by idiopathic thrombocytopenic purpura. A case report. Yamagishi S, et al. **Angiology** 1996 Apr;47(4):413–7

DIAGNOSIS

The clinical features and treatment of arteriosclerosis obliterans with diabetes. Tsushima N, et al. **Diabetes** 1996 Jul;45 Suppl 3:S101–4

Arteriosclerosis obliterans. Diagnostic and nonoperative treatment options. Ku A, et al. **Postgrad Med** 1995 Nov; 98(5):203–4, 207–10, 212 (29 ref.)

MRA imaging of arterial patency in undialyzed uremic patients with arteriosclerosis obliterans. Owada A, et al. **Ren Fail** 1995 Nov;17(6):743–50

[Identification and rehabilitation of high-risk patients in the prevention of atherosclerotic ulceration] Cujić M, et al. **Med Pregl** 1996;49(3-4):137–40 (Eng. Abstr.) **(Scr)**

DRUG THERAPY

Improved skin blood flow and cutaneous temperature in the foot of a patient with arteriosclerosis obliterans by vasopressin V1 antagonist (OPC21268). A case report. Toba K, et al. **Angiology** 1995 Nov;46(11):1027–33

ETIOLOGY

Acute arterial obliteration: a new feature of the POEMS syndrome? Lesprit P, et al. **Medicine (Baltimore)** 1996 Jul; 75(4):226–32 (45 ref.)

IMMUNOLOGY

Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerosis obliterans. Uno H, et al. **Atherosclerosis** 1995 Jul;116(1):93–102

PATHOLOGY

Observation of atherosclerotic lesions by an intravascular microscope in patients with arteriosclerosis obliterans. Uchida Y, et al. **Am Heart J** 1995 Nov;130(5):1114–9

PHYSIOPATHOLOGY

Doppler spectral analysis of blood flow velocities in common femoral artery: age-related changes in healthy subjects and characteristics of abnormal hemodynamics in obstructive arterial disease. Nomura K, et al. **Radiat Med** 1996 Jan-Feb; 14(1):13–7

RADIONUCLIDE IMAGING

[Usefulness of the 201TlCl exercise leg perfusion scintigraphy inarteriosclerosis obliterans (ASO)—with evaluation of leg perfusion comparing before and after PTA] Kijima T, et al. **Kaku Igaku** 1995 Sep;32(9):935–41 (Eng. Abstr.) **(Jpn)**

SURGERY

Early results of a reinforced biosynthetic ovine collagen vascular prosthesis for small arterial reconstruction. Yoshida H, et al. **Surg Today** 1996;26(4):262–6

THERAPY

National study of obliterative arterial disease of the lower limbs involving general practitioners in France: Artemio study. Vray M, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S51–7

Arteriosclerosis obliterans. Diagnostic and nonoperative treatment options. Ku A, et al. **Postgrad Med** 1995 Nov; 98(5):203–4, 207–10, 212 (29 ref.)

[Hemosorption in the treatment of patients with severe forms of chronic arterial insufficiency of the lower limbs] Akhtamov DA. **Anesteziol Reanimatol** 1995 Sep-Oct;

(5):37–8 **(Rus)**

ARTERIOSCLEROTIC DEMENTIA see **DEMENTIA, VASCULAR**

ARTERIOVENOUS ANASTOMOSIS

ANATOMY & HISTOLOGY

The structure, innervation and location of arteriovenous anastomoses in the equine foot. Molyneux GS, et al. **Equine Vet J** 1994 Jul;26(4):305–12

INNERVATION

The structure, innervation and location of arteriovenous anastomoses in the equine foot. Molyneux GS, et al. **Equine Vet J** 1994 Jul;26(4):305–12

PHYSIOLOGY

Heat–washout: a new method for measuring cutaneous blood flow rate in areas with and without arteriovenous anastomoses. Midttun M, et al. **Clin Physiol** 1996 May; 16(3):259–74

Blood flow rate in arteriovenous anastomoses and capillaries in thumb, first toe, ear lobe, and nose. Midttun M, et al. **Clin Physiol** 1996 May;16(3):275–89

Short–term hemodynamic changes in episcleral arteriovenous anastomoses correlate with venous pressure and IOP changes in the albino rabbit. Funk RH, et al. **Curr Eye Res** 1996 Jan;15(1):87–93

Arteriovenous anastomoses and the thermoregulatory shift between cutaneous vasoconstrictor and vasodilator reflexes. Krogstad AL, et al. **J Auton Nerv Syst** 1995 Jun 25;53(2–3):215–22

PHYSIOPATHOLOGY

Maintenance of adequate hemodialysis access. Prevention of neointimal hyperplasia. Taber TE, et al. **ASAIO J** 1995 Oct–Dec;41(4):842–6

Gastric microcirculatory disturbance and behaviour of leucocytes after thermal injury: intravital observation of arteriovenous shunting channels in the gastric submucosal layer. Yoshida M, et al. **J Gastroenterol Hepatol** 1995 Jul–Aug;10(4):365–70

Anomalous internal carotid artery–anterior cerebral artery anastomosis associated with fenestration and cerebral aneurysm. Fujimura M, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):229–33 (26 ref.)

SURGERY

[The selection of cervical vessels recipients in reconstructive surgery of head and neck with free flaps] Llorente Pendas JL, et al. **Acta Otorrinolaringol Esp** 1995 Jul–Aug; 46(4):273–7 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Ultrasound diagnosis of portocaval anastomosis in infants––a report of eight cases. Farrant P, et al. **Br J Radiol** 1996 May;69(821):389–93

Identification of arteriovenous anastomoses by duplex ultrasound. Implications for the treatment of varicose veins. Kanter A, et al. **Dermatol Surg** 1995 Oct;21(10):885–9

ULTRASTRUCTURE

Scanning electron microscopic study of episcleral arteriovenous anastomoses in the owl and cynomolgus monkey. Funk RH, et al. **Curr Eye Res** 1996 Mar; 15(3):321–7

ARTERIOVENOUS ANEURYSM see **ARTERIOVENOUS FISTULA**

ARTERIOVENOUS FISTULA

see related
ARTERIOVENOUS MALFORMATIONS

Pulmonary arteriovenous malformation [letter; comment] Dieter RA Jr. **Angiology** 1995 Oct;46(10):969–71. Comment on: Angiology 1994 May;45(5):399–404.

The upper arm arterio–venous fistula––an alternative for vascular access in haemodialysis. Gade J, et al. **Scand J Urol Nephrol** 1995 Jun;29(2):121–4

Ureteroarterial fistula: case report and review of the literature. Batter SJ, et al. **Urology** 1996 Sep;48(3):481–9 (35 ref.)

[Intrahepatic arterioportal shunt and arteriovenous shunt] Nagayama K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):210–3 (21 ref.) **(Jpn)**

[Intrahepatic arteriovenous fistula] Toshima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):207–9 (23 ref.) **(Jpn)**

BLOOD

Carotid–cavernous fistula and jugular venous oxygen saturation [letter] Dujovny M, et al. **J Neurosurg** 1996 Apr; 84(4):713

CLASSIFICATION

Classification of spontaneous dural arteriovenous fistulas [editorial; comment] **Acta Radiol** 1995 Nov;36(6):581. Comment on: Acta Radiol 1995 Nov;36(6):582–92.

Classification of spontaneous dural arteriovenous fistulas with regard to their pathogenesis [see comments] Mironov A. **Acta Radiol** 1995 Nov;36(6):582–92. Comment in: Acta Radiol 1995 Nov;36(6):581.

COMPLICATIONS

Rapidly progressive portal hypertension 23 years after post–traumatic arterioportal fistula of the liver. Kayser S, et al. **Am J Gastroenterol** 1996 Jul;91(7):1442–6 (30 ref.)

High–output cardiac failure due to excessive shunting in a hemodialysis access fistula: an easily overlooked diagnosis. Engelberts I, et al. **Am J Nephrol** 1995;15(4):323–6

Decompression of the occluded subclavian vein in the patient with ipsilateral threatened access by transposition of the internal jugular vein. Gertler JP. **ASAIO J** 1995 Oct–Dec; 41(4):896–8

Venous stasis orbitopathy: a clinical and echographic study. Atta HR, et al. **Br J Ophthalmol** 1996 Feb;80(2):129–34

An unusual case of priapism in a child: diagnosis and treatment. Jameson JS, et al. **Br J Urol** 1996 Mar; 77(3):462–3

Posttraumatic high–flow priapism treated by N–butyl–cyanoacrylate embolization. Numan F, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):278–80 (22 ref.)

Renovascular hypertension caused by traumatic arteriovenous fistula. Lu E, et al. **Chin Med J (Engl)** 1996 Mar;109(3):249–51

Splenic arteriovenous fistula. A rare lesion causing bleeding esophageal varices, ascites, and diarrhea. Galler G, et al. **Dig Dis Sci** 1996 Apr;41(4):816–9

Retinal arteriovenous communication in retinitis pigmentosa with Refsum's disease–like findings. Abu el–Asrar AM, et al. **Doc Ophthalmol** 1995;89(4):313–20

Splenic aneurysm with arteriovenous fistula. A case report. Kelekis D, et al. **Hepatogastroenterology** 1995 Jul–Aug; 42(4):352–5

Long–term observation of a case of pulmonary arteriovenous fistula with pulmonary hypertension. Yoshida F, et al. **Intern Med** 1995 Jun;34(6):574–6

Aneurysm of a branch of the subclavian artery with multiple arteriovenous fistulae. Egami J, et al. **J Cardiovasc Surg (Torino)** 1996 Aug;37(4):355–7

Brain abscesses: the lung connection. Finkelstein R, et al. **J Intern Med** 1996 Jul;240(1):33–6

A cervical dural arteriovenous fistula in a patient presenting with radiculopathy. Case report. Kohno M, et al. **J Neurosurg** 1996 Jan;84(1):119–23 (26 ref.)

Angiotensin II type–1 receptor antagonist as well as angiotensin converying enzyme inhibitor attenuates the development of heart failure in aortocaval fistula rats. Nishikimi T, et al. **Jpn Circ J** 1995 Nov;59(11):754–61

Concurrent acute angle–closure glaucoma, choroidal detachment and exudative retinal detachment in a patient with spontaneous carotid cavernous fistula. Fujitani A, et al. **Ophthalmologica** 1995;209(4):220–2

Innominate artery enlargement in congenital arteriovenous fistula with subsequent tracheal compression and stridor. Döhlemann C, et al. **Pediatr Cardiol** 1995 Nov–Dec; 16(6):287–90 (17 ref.)

Three cases of spontaneous direct carotid cavernous fistulas associated with Ehlers–Danlos syndrome type IV. Debrun GM, et al. **Surg Neurol** 1996 Sep;46(3):247–52

Diarrhea, massive ascites, and portal hypertension: rare case of a splenic arterio–venous fistula. Strassburg CP, et al. **Z Gastroenterol** 1996 Apr;34(4):243–9

[Unusual spontaneous dural cavernous sinus fistula between right external carotid artery and left cavernous sinus––a case report] Chen JY, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Mar; 12(3):193–6 (Eng. Abstr.) **(Chi)**

[Spinal dural arteriovenous fistula: a treatable cause of loss of strength in the legs] Canta LR, et al. **Ned Tijdschr Geneeskd** 1995 Dec 23;139(51):2655–8 (Eng. Abstr.) **(Dut)**

[Progressive paraparesis] Kuopio AM, et al. **Duodecim** 1995; 111(5):435–8 **(Fin)**

[Portal hypertension with hepatic–portal fistula on a cirrhotic liver] Gailleton R, et al. **Ann Chir** 1996;50(3):276–8 (Eng. Abstr.) **(Fre)**

[A rare cause of neurologic bladder: arteriovenous dural fistula with venous epidural drainage] Punga–Maole ML, et al. **Prog Urol** 1995 Dec;5(6):1001–8 (32 ref.) (Eng. Abstr.) **(Fre)**

[High flow priapism following a straddle–injury–induced arteriocavernosal fistula: a case report] Kuwahara M, et al. **Hinyokika Kiyo** 1995 Aug;41(8):625–8 (Eng. Abstr.) **(Jpn)**

[A case of Rendu–Osler–Weber syndrome and pulmonary arteriovenous fistula] Nomura M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep; 33(9):1009–12 (Eng. Abstr.) **(Jpn)**

[A case of spinal dural arteriovenous fistula associated with normal pressure hydrocephalus] Masuo O, et al. **No Shinkei Geka** 1995 Sep;23(9):825–8 (Eng. Abstr.) **(Jpn)**

[A case of spontaneous arteriovenous fistula presenting as the partial oculomotor nerve palsy] Nagata E, et al. **Rinsho Shinkeigaku** 1995 Jul;35(7):808–10 (Eng. Abstr.) **(Jpn)**

CONGENITAL

Transcatheter embolization in treatment of congenital coronary artery aneurysm. Chen MF, et al. **Am Heart J** 1996 Feb;131(2):396–7

Use of interlocking detachable coils in embolization of coronary arteriovenous fistulas. Qureshi SA, et al. **Am J Cardiol** 1996 Jul 1;78(1):110–3

Anterior cranial fossa dural arteriovenous fistula with a varix mimicking an anterior communicating artery aneurysm. Ogawa T, et al. **Neuroradiology** 1996 Apr;38(3):252–3

Innominate artery enlargement in congenital arteriovenous fistula with subsequent tracheal compression and stridor. Döhlemann C, et al. **Pediatr Cardiol** 1995 Nov–Dec; 16(6):287–90 (17 ref.)

Congenital hepatoportal arteriovenous fistula [letter; comment] Stringer MD, et al. **Surgery** 1996 Feb; 119(2):235–6. Comment on: Surgery 1995 Feb;117(2):170–4.

[Arteriovenous malformations with aneurysms of the great vein of Galen] Mraček Z. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(1 Suppl):67–73 (Eng. Abstr.) **(Cze)**

[Pulmonary arteriovenous fistula. A rare cause of dyspnea and cyanosis in an adult] Fourcade L, et al. **Arch Mal Coeur Vaiss** 1996 Jan;89(1):103–6 (Eng. Abstr.) **(Fre)**

[Pulmonary arteriovenous fistulae and brain abscesses: a report of 2 cases treated by embolization and a review of the literature] Ricci P, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):497–501 (24 ref.) **(Ita)**

[Pain, paresthesias and loss of strength in the lower limbs in a 45–year–old woman (clinical conference)] Barraquer–Bordas L, et al. **Med Clin (Barc)** 1996 Mar 9; 106(9):347–53 **(Spa)**

DIAGNOSIS

Spinal dural arteriovenous fistulas: evaluation with MR angiography. Bowen BC, et al. **AJNR Am J Neuroradiol** 1995 Nov–Dec;16(10):2029–43

Paraspinal arteriovenous fistula with perimedullary venous drainage. Cognard C, et al. **AJNR Am J Neuroradiol** 1995 Nov–Dec;16(10):2044–8

Spinal dural arteriovenous fistulas: MR and myelographic findings. Gilbertson JR, et al. **AJNR Am J Neuroradiol** 1995 Nov–Dec;16(10):2049–57

Fistula of the posterior communicating artery and cavernous sinus. Kinugasa K, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1626–8

Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelium detachments. Kuhn D, et al. **Arch Ophthalmol** 1995 Nov;113(11):1392–8

An unusual case of vascular abnormality mimicking a lateral meniscal cyst. Vergis A, et al. **Arthroscopy** 1995 Oct; 11(5):616–9

Early discovery of a traumatic carotid–cavernous sinus fistula by jugular venous oxygen saturation monitoring. Case report. Calon B, et al. **J Neurosurg** 1995 Nov;83(5):910–1

MR imaging and MR angiography in the diagnosis of dural arteriovenous fistulas. Panasci DJ, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):493–508 (32 ref.)

Carotid–cavernous fistula mimicking Graves' eye disease. Oestreicher JH, et al. **Ophthal Plast Reconstr Surg** 1995 Dec;11(4):238–44

Dural arteriovenous fistulas of superior sagittal sinus: case report and review of literature. Kurl S, et al. **Surg Neurol** 1996 Mar;45(3):250–5 (23 ref.)

Spinal giant intradural perimedullary arteriovenous fistula: clinical and neuroradiological study in one case with review of literature. Nagashima C, et al. **Surg Neurol** 1996 Jun;45(6):524–31; discussion 531–2 (18 ref.)

[Rare association of a coronary fistula with a fusiform aneurysm of the superior vena cava: diagnosis via transesophageal echocardiography and MRI] Ritter M, et al. **Schweiz Rundsch Med Prax** 1995 Sep 26;84(39):1068–70 (Eng. Abstr.) **(Ger)**

[Evaluation by proton magnetic resonance spectroscopy of carotid–cavernous fistula with cortical venous drainage] Uno M, et al. **No Shinkei Geka** 1995 Oct;23(10):927–33 (Eng. Abstr.) **(Jpn)**

[A case of spontaneous arteriovenous fistula presenting as the partial oculomotor nerve palsy] Nagata E, et al. **Rinsho Shinkeigaku** 1995 Jul;35(7):808–10 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure. Wegner M, et al. **Cardiovasc Res** 1996 Jun; 31(6):891–8

ETIOLOGY

Carotid–jugular arteriovenous fistula: a complication of temporary hemodialysis catheter. el–Shahawy MA, et al. **Am J Nephrol** 1995;15(4):332–6 (51 ref.)

Iatrogenic vertebrojugular arteriovenous fistula. Stock U, et al. **Anaesthesia** 1996 Jul;51(7):687–8

Do–it–yourself femoropopliteal bypass. Fox AD, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):392–4

Arteriovenous fistulae complicating orthopaedic procedures. Ward AS, et al. **Aust N Z J Surg** 1995 Dec;65(12):905–7 (20 ref.)

Selective embolization of bilateral arterial cavernous fistulas for posttraumatic penile arterial priapism. Lazinger M, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):281–4

Iatrogenic aorto–coronary venous fistula as a complication of coronary artery bypass surgery: patient report and review of the literature. Calkins JB Jr, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):55–9 (19 ref.)

Aortocaval fistula complicating abdominal aortic aneurysm: case report and literature review. Fenster MS, et al. **Cathet Cardiovasc Diagn** 1996 May;38(1):75–9

Development of pulmonary arteriovenous fistulae in children after cavopulmonary shunt. Bernstein HS, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II309–14

Iatrogenic AV-fistula treated by a graft–covered self–expandable stent. Brunkwall J, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):243–5

Endovascular graft placement for a symptomatic iatrogenic peroneal arteriovenous fistula. Spark JI, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):496–8

Cavernous sinus–carotid fistula: a complication of maxillofacial injury. Nocini P, et al. **Int J Oral Maxillofac Surg** 1995 Aug;24(4):276–8

Pulmonary arteriovenous fistula associated with unequal branching of the pulmonary artery system. Morimoto S, et al. **Intern Med** 1995 Oct;34(10):1019–22

Arteriovenous fistula after fibular osteotomy leading to recurrent haemarthroses in a total knee replacement. Haddad FS, et al. **J Bone Joint Surg Br** 1996 May; 78(3):458–60

Peroneal arteriovenous fistula as a complication of above–knee femoropopliteal polytetrafluorethylene graft thrombectomy with the Fogarty catheter. Acín F, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):113–5

Aortocaval fistula secondary to mediastinitis. King M. **J Emerg Med** 1996 Jan–Feb;14(1):5–8

Dural arteriovenous fistula of the posterior fossa developing after surgical occlusion of the sigmoid sinus. Report of five cases. Sakaki T, et al. **J Neurosurg** 1996 Jan;84(1):113–8

Traumatic renal arteriovenous fistula in a 3–year–old girl, successfully treated by percutaneous transluminal embolization. van der Zee JA, et al. **J Pediatr Surg** 1995 Oct;30(10):1513–4

Steal phenomenon in a traumatic carotid–cavernous fistula. Iida K, et al. **J Trauma** 1995 Nov;39(5):1015–7

Color Doppler sonographic study of an iatrogenic fistula between the common carotid artery and internal jugular vein. Chen YW, et al. **J Ultrasound Med** 1995 Oct; 14(10):777–80

Transient arteriovenous fistulae after transrectal prostate biopsy: diagnosis with color Doppler ultrasonography. Wachsberg RH, et al. **J Ultrasound Med** 1996 Jan; 15(1):57–61

Symptomatic intrarenal arteriovenous fistula detected 25 years after percutaneous renal biopsy. Alcázar R, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1346–8

Transplant nephrectomy for a large AV fistula following renal biopsy [letter] Mansy H, et al. **Nephron** 1995; 71(4):481–2

Fulminant development of pulmonary arteriovenous fistulas in an infant after total cavopulmonary shunt. Bernstein HS, et al. **Pediatr Cardiol** 1996 Jan–Feb;17(1):46–50

Formation of a fatal arterioportal fistula following needle liver biopsy in a child with a living–related liver transplant: report of a case. Otobe Y, et al. **Surg Today** 1995; 25(10):916–9

[Arteriovenous and arterial–digestive system fistulas complicating isolated iliac aneurysm] Chambon JP, et al. **J Chir (Paris)** 1995 Oct;132(10):371–4 (Eng. Abstr.) **(Fre)**

[Vascular complications of lumbar disk surgery. Report of two cases and review of the literature on 122 cases] Pillet JC, et al. **J Mal Vasc** 1995;20(3):219–23 (85 ref.) (Eng. Abstr.) **(Fre)**

[Arteriovenous fistula with cardiac insufficiency disclosing kidney cancer] Jan N, et al. **Rev Med Interne** 1996; 17(4):329–32 (30 ref.) (Eng. Abstr.) **(Fre)**

[Local vascular complications after iatrogenic femoral artery puncture] Fruhwirth J, et al. **Wien Klin Wochenschr** 1996; 108(7):196–200 (Eng. Abstr.) **(Ger)**

[An arteriovenous fistula in an unusual site] Kasper AS, et al. **Zentralbl Chir** 1995;120(8):657–9 (Eng. Abstr.) **(Ger)**

[Arteriovenous fistula as a complication of percutaneous renal biopsy] Lund–Sørensen N, et al. **Tidsskr Nor Laegeforen** 1995 Nov 30;115(29):3625–6 (Eng. Abstr.) **(Nor)**

GENETICS

Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin? Berg JN, et al. **J Med Genet** 1996 Mar;33(3):256–7

PATHOLOGY

Carotid–cavernous sinus fistula and aneurysmal rupture associated with fibromuscular dysplasia. A case report. Hirai T, et al. **Acta Radiol** 1996 Jan;37(1):49–51 (8 ref.)

A puzzling accidental intraoperative finding: an arteriovenous fistula? [letter] Hayes A, et al. **Anesth Analg** 1996 Mar;82(3):674–5

MRI/myelographic localization of fistulous tract in spinal dural arteriovenous malformations prior to arteriography. Chen CJ, et al. **J Comput Assist Tomogr** 1995 Nov–Dec; 19(6):893–6

Ultrastructure of the afferent arteries of experimental femoral arteriovenous fistulae in rabbits. Jones GT, et al. **Pathology** 1995 Oct;27(4):333–8

[The nerve cells of the hemispheric cerebral cortex in an extracranial arterial shunt] Fateev IN. **Morfologiia** 1995; 108(2):25–7 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Advantage of monitoring skin vibration as an index of arteriovenous fistular blood flow. Aoki T, et al. **Artif Organs** 1996 Mar;20(3):277–9

How do AV fistulae lose function? The roles of haemodynamics, vascular remodelling, and intimal hyperplasia [editorial] Hehrlein C. **Nephrol Dial Transplant** 1995;10(8):1287–90

The effects of a carotid–jugular fistula on cerebral blood flow in the cat: an experimental study in the chronic period. Tokiwa K, et al. **Neurol Res** 1995 Aug;17(4):297–300

[Paradoxical aggravation of carotid cavernous fistula] Muraine M, et al. **J Fr Ophtalmol** 1996;19(1):51–4 (12 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Spontaneous aortocaval fistula: CT findings with pathologic correlation. Quiroga S, et al. **Abdom Imaging** 1995 Sep–Oct; 20(5):466–9

Spontaneous disappearance of a spinal dural arteriovenous fistula. Meder JF, et al. **AJNR Am J Neuroradiol** 1995 Nov–Dec;16(10):2058–62

Acquired carotid–cavernous fistula caused by traumatic intracavernous rupture of an embryonic anastomosis. Mironov A. **AJNR Am J Neuroradiol** 1995 Sep; 16(8):1629–32

Fistula between a posterior communicating artery aneurysm and the cavernous sinus. Tytle TL, et al. **AJNR Am J Neuroradiol** 1995 Oct;16(9):1808–10

A serpiginous intradural filling defect on a lumbar myelogram could be identified as a spinal dural arteriovenous fistula or a spinal arteriovenous malformation. Moran CJ. **AJR Am J Roentgenol** 1995 Nov;165(5):1300–1

Traumatic aneurysms and arteriovenous fistulas of intracranial vessels associated with penetrating head injuries occurring during war: principles and pitfalls in diagnosis and management. A survey of 31 cases and review of the literature. Amirjamshidi A, et al. **J Neurosurg** 1996 May;84(5):769–80

Anterior cranial fossa dural arteriovenous fistula with a varix mimicking an anterior communicating artery aneurysm. Ogawa T, et al. **Neuroradiology** 1996 Apr;38(3):252–3

Venopelvic fistula: a rare complication of hyperalimentation. Aihara T, et al. **Pediatr Radiol** 1996;26(3):198–9

Traumatic aneurysm and arteriovenous fistula of the splenic artery. Oğuzkurt L, et al. **Pediatr Radiol** 1996;26(3):195–7

Angiographic workup of a carotid cavernous sinus fistula (CCF) or what information does the interventionalist need for treatment? [see comments] Debrun GM. **Surg Neurol** 1995 Jul;44(1):75–9 (18 ref.). Comment in: Surg Neurol 1996 Aug;46(2):193.

Untreated arteriovenous fistula after World War II trauma. Schneider M, et al. **Vasa** 1996;25(2):174–9

[A case of post–traumatic arteriovenous fistula of the subclavian artery] Nakano H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):754–8 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Diagnostic angioscintigraphic evaluation of malignant hepatic tumors before catheter embolization: determination of shunt, flow distribution, and reflux. Walser RH, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):77–81

Tc–99m MAA total–body imaging to detect intrapulmonary right–to–left shunts and to evaluate the therapeutic effect in pulmonary arteriovenous shunts. Lu G, et al. **Clin Nucl Med** 1996 Mar;21(3):197–202

SURGERY

Evolution of different therapeutic strategies in the treatment of cranial dural arteriovenous fistulas—report of 30 cases. Bavinzski G, et al. **Acta Neurochir (Wien)** 1996;138(2):132–8

Spinal dural arteriovenous fistulas: a plea for neurosurgical treatment. Huffmann BC, et al. **Acta Neurochir (Wien)** 1995; 135(1–2):44–51

Direct approach to intracranial vertebral arteriovenous fistula. Case report. Morimoto T, et al. **Acta Neurochir (Wien)** 1995;137(1–2):98–101

Successful repair of a massive coronary arteriovenous fistula in a 68–year–old man. Phillips WS, et al. **Ann Thorac Surg** 1996 Mar;61(3):984–6

Iliac arteriovenous fistula following lumbar disc surgery treated by percutaneous endoluminal stent grafting. McCarter DH, et al. **Br J Surg** 1996 Jun;83(6):796–7

Iatrogenic AV-fistula treated by a graft–covered self–expandable stent. Brunkwall J, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):243–5

Splenic arteriovenous fistula. Brothers TE, et al. **Int Surg** 1995 Apr–Jun;80(2):189–94 (90 ref.)

Hemodilution in complicated high velocity vascular injuries of limbs. Mackay Z, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):217–21

Endovascular surgical approach to intracranial vascular diseases. Higashida RT, et al. **J Endovasc Surg** 1996 May; 3(2):146–57 (57 ref.)

Surgical interruption of leptomeningeal drainage as treatment for intracranial dural arteriovenous fistulas without dural sinus drainage. Collice M, et al. **J Neurosurg** 1996 May; 84(5):810–7

Acute repair of aorta–innominate vein fistulas. Roye GD, et al. **J Trauma** 1995 Oct;39(4):753–6 (12 ref.)

Endovascular stent–graft repair of common iliac artery–to–inferior vena cava fistula. Zajko AB, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):803–6

Aortocaval fistula treated by aortic exclusion. Woolley DS, et al. **J Vasc Surg** 1995 Nov;22(5):639–42 (27 ref.)

Access to the cavernous sinus through the vertebral artery: technical case report. Debrun GM, et al. **Neurosurgery** 1995 Jul;37(1):144–6; discussion 146–7

Postsurgical development of dural arteriovenous malformations after transpetrosal and transtentorial operations: case report. Sasaki T, et al. **Neurosurgery** 1995 Oct;37(4):820–4; discussion 824–5 (14 ref.)

Surgical treatment of an enormous aneurysmal portahepatic venous fistula: report of a case. Miyauchi A, et al. **Surg Today** 1995;25(9):855–8 (11 ref.)

Congenital hepatoportal arteriovenous fistula [letter; comment] Stringer MD, et al. **Surgery** 1996 Feb; 119(2):235–6. Comment on: Surgery 1995 Feb;117(2):170–4.

[Surgical treatment of carotid–cavernous fistulas. A description of open surgical techniques in the treatment of carotid–cavernous fistula with preserved normal flow in the internal carotid artery] Poulsgård L, et al. **Ugeskr Laeger** 1995 Nov 27;157(48):6725–8 (Eng. Abstr.) **(Dan)**

[A case of pulmonary arteriovenous fistula failed in transcatheter embolization and followed by emergency operation] Masaoka T, et al. **Kyobu Geka** 1995 Oct; 48(11):941–4 (Eng. Abstr.) **(Jpn)**

[Posterior fossa dural arteriovenous fistula with progressive disorder of cerebellar circulation; case report] Niki Y, et al. **No Shinkei Geka** 1996 May;24(5):455–8 (Eng. Abstr.) **(Jpn)**

[Embolization of carotid–cavernous fistulae. Technique and results of surgery] Dowżenko A, et al. **Pol Tyg Lek** 1995 Oct;50(40–44):26–8 (Eng. Abstr.) **(Pol)**

[Surgery for the repair of renal arteriovenous fistula and its hemodynamic impact] Aguilar C, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):386–8 (Eng. Abstr.) **(Spa)**

THERAPY

Transcranial cerebral oximetry and carotid cavernous fistula occlusion. Technical note. Dujovny M, et al. **Acta Neurochir (Wien)** 1995;133(1–2):83–6

Type D dural carotid–cavernous fistula. Results of combined treatment with irradiation and particulate embolization. Hasuo K, et al. **Acta Radiol** 1996 May;37(3 Pt 1):294–8

Percutaneous superselective coil–embolization of intrarenal arteriovenous fistulas. Case reports. Husstedt H, et al. **Acta Radiol** 1996 Jul;37(4):539–41

Traumatic bilateral carotid–cavernous fistulas treated with detachable balloon. A case report. Kim JK, et al. **Acta Radiol** 1996 Jan;37(1):46–8 (6 ref.)

Experimental arteriovenous fistulas: treatment with porous metallic stents [see comments] Geremia G, et al. **AJNR Am J Neuroradiol** 1995 Nov–Dec;16(10):1965–73. Comment in: AJNR Am J Neuroradiol 1995 Nov–Dec;16(10):1974–6.

The use of stents in endovascular intervention [comment] Jungreis CA. **AJNR Am J Neuroradiol** 1995 Nov–Dec; 16(10):1974–6. Comment on: AJNR Am J Neuroradiol 1995 Nov–Dec;16(10):1953–63. Comment on: AJNR Am J Neuroradiol 1995 Nov–Dec;16(10):1953–63. Comment on: AJNR Am J Neuroradiol 1995 Nov–Dec;16(10):1965–73.

Percutaneous closure of an arteriovenous iliac fistula with a Cragg endoluminal graft. Allgayer B, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):673–4

High–flow priapism in a child: treatment with superselective embolization. Stock KW, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):290–2

Use of interlocking detachable coils in embolization of coronary arteriovenous fistulas. Qureshi SA, et al. **Am J Cardiol** 1996 Jul 1;78(1):110–3

Management of cavernous sinus–dural fistulas. Indications and techniques for primary embolization via the superior ophthalmic vein [see comments] Goldberg RA, et al. **Arch Ophthalmol** 1996 Jun;114(6):707–14. Comment in: Arch Ophthalmol 1996 Jun;114(6):750.

Techniques and surgical approach for transvenous embolization [editorial; comment] Kupersmith M. **Arch Ophthalmol** 1996 Jun;114(6):750. Comment on: Arch Ophthalmol 1996 Jun;114(6):707–14.

Transvenous approach to salvage incomplete arterial embolization of compound traumatic arteriovenous fistulae. Ben–Menachem Y. **Cardiovasc Intervent Radiol** 1995 Nov–Dec;18(6):391–5

Embolization of a high–output postnephrectomy aortocaval fistula with Gianturco coils and cyanoacrylate. Cekirge S, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):56–8

Selective embolization of bilateral arterial cavernous fistulas for posttraumatic penile arterial priapism. Lazinger M, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):281–4

Posttraumatic high-flow priapism treated by N-butyl-cyanoacrylate embolization. Numan F, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):278-80 (22 ref.)

Percutaneous endoluminal stent-graft repair of an old traumatic femoral arteriovenous fistula. Uflacker R, et al. **Cardiovasc Intervent Radiol** 1996 Mar-Apr;19(2):120-2

Endovascular graft placement for a symptomatic iatrogenic peroneal arteriovenous fistula. Spark JI, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):496-8

Arteriovenous fistula of the internal mammary artery (combat injury): transcatheter intravascular coil occlusion Radanović B, et al. **Eur Radiol** 1996;6(2):236-8

Angiographic embolization of intrahepatic arterioportal fistula. Taourel P, et al. **Eur Radiol** 1996;6(4):510-3

Arteriovenous fistulae complicating central venous catheterization: value of endovascular treatment based on a series of seven cases. Ricolfi F, et al. **Intensive Care Med** 1995 Dec;21(12):1043-7

Long-term results in direct carotid-cavernous fistulas after treatment with detachable balloons. Lewis AI, et al. **J Neurosurg** 1996 Mar;84(3):400-4

The role of radiosurgery and particulate embolization in the treatment of dural arteriovenous fistulas. Link MJ, et al. **J Neurosurg** 1996 May;84(5):804-9

Treatment of carotid-cavernous sinus fistulas using a superior ophthalmic vein approach. Miller NR, et al. **J Neurosurg** 1995 Nov;83(5):838-42

Traumatic renal arteriovenous fistula in a 3-year-old girl, successfully treated by percutaneous transluminal embolization. van der Zee JA, et al. **J Pediatr Surg** 1995 Oct;30(10):1513-4

Percutaneous transcatheter embolization of coronary arteriovenous fistulas. Harris WO, et al. **Mayo Clin Proc** 1996 Jan;71(1):37-42

Interventional neuroradiology of the head and neck. Hurst RW. **Neuroimaging Clin N Am** 1996 May;6(2):473-95 (38 ref.)

Percutaneous transvenous embolisation of iatrogenic vertebral arteriovenous fistula. Fukao S, et al. **Neuroradiology** 1995 Jul;37(5):400-2

Management of 100 consecutive direct carotid-cavernous fistulas: results of treatment with detachable balloons [letter; comment] Parkinson D. **Neurosurgery** 1995 Aug; 37(2):357. Comment on: Neurosurgery 1995 Feb;36(2):239-44; discussion 244-5.

Cerebral dural arteriovenous fistulas: percutaneous transvenous embolization. Urtasun F, et al. **Radiology** 1996 Apr;199(1):209-17

Hepatic arterioportal fistulas: surgical ligation of embolization? [letter; comment] Tarazov PG. **Surgery** 1996 Feb;119(2):237. Comment on: Surgery 1995 Feb;117(2):170-4.

Transcatheter embolization of a residual congenital coronary arteriovenous fistula with a detachable balloon; superiority of interventional cardiology? Aydoğan U, et al. **Turk J Pediatr** 1996 Apr-Jun;38(2):245-51

Endovascular repair of aortic aneurysms, arteriovenous fistulas, and false aneurysms. Parodi JC. **World J Surg** 1996 Jul-Aug;20(6):655-63

[Dural fistula of the cavernous sinus. Treatment through an intravenous approach apropos of 4 cases] Courtheoux P, et al. **J Neuroradiol** 1995 Dec;22(4):301-8 (Eng. Abstr.) **(Fre)**

[Dural fistula of the cavernous sinus. Clinical and angiographic aspects. Results of particulate intravascular treatment] Sonier CB, et al. **J Neuroradiol** 1995 Dec; 22(4):289-300 (Eng. Abstr.) **(Fre)**

[Pulmonary arteriovenous fistulae and brain abscesses: a report of 2 cases treated by embolization and a review of the literature] Ricci P, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):497-501 (24 ref.) **(Ita)**

[Fatal outcome after hepatic artery embolization in spontaneous arterioportal fistula in a patient with liver cirrhosis] Tarazov PG. **Vestn Rentgenol Radiol** 1996 Jan-Feb;(1):47-8 **(Rus)**

[Therapeutic strategy in vascular changes. New methods for a small group of patients difficult to treat] Risberg B, et al. **Lakartidningen** 1996 Feb 28;93(9):779-82 **(Swe)**

ULTRASONOGRAPHY

Usefulness of ultrasonography in operation for pulmonary arteriovenous fistula. Sugita M, et al. **Ann Thorac Surg** 1996 Jun;61(6):1821-3

Color Doppler sonographic study of an iatrogenic fistula between the common carotid artery and internal jugular vein. Chen YW, et al. **J Ultrasound Med** 1995 Oct; 14(10):777-80

Sonographic diagnosis of arteriovenous fistula in pancreas transplant. Keener TS, et al. **J Ultrasound Med** 1995 Feb; 14(2):149-52

Transient arteriovenous fistulae after transrectal prostate biopsy: diagnosis with color Doppler ultrasonography. Wachsberg RH, et al. **J Ultrasound Med** 1996 Jan; 15(1):57-61

Use of pulsed Doppler ultrasound in detecting renal arteriovenous fistula. Ha SK, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2150-2

Transvenous hemodynamic assessment of arteriovenous malformations and fistulas. Preliminary clinical experience in Doppler guidewire monitoring of embolotherapy. Murayama Y, et al. **Stroke** 1996 Aug;27(8):1358-64

VETERINARY

Technetium 99m sulfur colloid scintigraphy to evaluate reticuloendothelial system function in dogs with portasystemic shunts. Koblik PD, et al. **J Vet Intern Med** 1995 Nov-Dec;9(6):374-80

ARTERIOVENOUS HEMOFILTRATION see **HEMOFILTRATION**

ARTERIOVENOUS MALFORMATIONS

see related
ANGIOMATOSIS
ARTERIOVENOUS FISTULA
HEMANGIOMA

Multiple and massive arteriovenous malformations in pregnancy. Geary M, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):147-50

Hepatic vascular anomalies in infancy: a twenty-seven-year experience. Boon LM, et al. **J Pediatr** 1996 Sep; 129(3):346-54 (52 ref.)

Venoarterial connections in visceral heterotaxy [letter] Anderson RH, et al. **J Thorac Cardiovasc Surg** 1996 May; 111(5):1106-9

Modern management of spinal and spinal cord vascular lesions. Meisel HJ, et al. **Minim Invasive Neurosurg** 1995 Dec;38(4):138-45

Multiple arteriovenous malformations of spinal cord and brain in a child. Tsurushima H, et al. **Pediatr Neurosurg** 1995;23(3):166-70

[Arteriovenous malformation of the superior mesenteric artery with secondary portal hypertension] Múgica F, et al. **Gastroenterol Hepatol** 1995 Oct;18(8):420-4 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Bleeding from polypoid colonic arteriovenous malformations. Koziara FJ, et al. **Am J Gastroenterol** 1996 Mar;91(3):584-6 (6 ref.)

Neonatal pulmonary arteriovenous malformation [letter] Trivedi K, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jan;74(1):F80

Cerebral venous malformation complicated by spontaneous thrombosis. Kim P, et al. **Childs Nerv Syst** 1996 Mar; 12(3):172-5

Congenital pelvic arteriovenous malformation: a rare cause of sciatica. Vos LD, et al. **Clin Neurol Neurosurg** 1995 Aug; 97(3):229-32

Combined malformation of the Vein of Galen and of spinal vessels: endovascular embolization. Hammen A, et al. **Clin Neuropathol** 1995 Jul-Aug;14(4):233-6 (15 ref.)

Congenital pelvic arteriovenous malformation with massive vaginal bleeding [letter] Kushtagi P, et al. **Int J Gynaecol Obstet** 1996 Jan;52(1):71-2

Ruptured type III cervical spinal cord arteriovenous malformation as a cause of acute quadriparesis. Singhal AB, et al. **J Assoc Physicians India** 1995 Aug;43(8):565-6

Massive lower gastrointestinal bleeding due to 'Dieulafoy's vascular malformation' of the jejunum: case report. Goins WA, et al. **J Natl Med Assoc** 1995 Oct;87(10):766-70 (27 ref.)

[Congenital arterio-venous malformations: an unusual cause of heart failure at birth and during the first months of life] Favilli S, et al. **G Ital Cardiol** 1995 Jul;25(7):885-90 (Eng. Abstr.) **(Ita)**

[Dieulafoy ulcer associated with acute drug-induced gastritis: a rare case] Reddavid M, et al. **Minerva Chir** 1995 May; 50(5):515-7 (Eng. Abstr.) **(Ita)**

[A case of arteriovenous malformation of the ileum complicated with decompensated liver cirrhosis: effective case of home parenteral nutrition for intestinal bleeding] Fukushima M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov;92(11):1871-5 (15 ref.) **(Jpn)**

[A case of multiple vascular malformations of brain and liver] Czochra M, et al. **Neurol Neurochir Pol** 1995 Sep-Oct; 29(5):787-93 (Eng. Abstr.) **(Pol)**

[Back pain caused by pelvic vascular malformation] Suárez Muñoz J, et al. **Neurologia** 1995 Nov;10(9):380 **(Spa)**

[Pseudoaneurysm of galen's vein secondary to cerebral arterio-venous malformations] Benito-León J, et al. **Rev Neurol** 1996 Jun;24(130):720-2 **(Spa)**

DIAGNOSIS

Spinal dural arteriovenous fistulas: MR and myelographic findings. Gilbertson JR, et al. **AJNR Am J Neuroradiol** 1995 Nov-Dec;16(10):2049-57

Posttreatment MR findings in spinal dural arteriovenous malformations. Willinsky RA, et al. **AJNR Am J Neuroradiol** 1995 Nov-Dec;16(10):2063-71

Diagnostic dilemma of an intramedullary vascular malformation. A case report. Dinakar I, et al. **Angiology** 1995 Nov;46(11):1063-8

Arteriovenous malformation of the esophagus disguised as a leiomyoma. Konstantakos AK, et al. **Ann Thorac Surg** 1995 Dec;60(6):1798-800

Imaging quiz case 2. Arteriovenous malformation (AVM) of the buccal fat pad. Cullen MM, et al. **Arch Otolaryngol Head Neck Surg** 1996 May; 122(5):571-573

Initially migraine-like manifestation of a ruptured spinal arteriovenous malformation. Maggioni F, et al. **Cephalalgia** 1995 Jun;15(3):237-40

Cerebral venous malformation complicated by spontaneous thrombosis. Kim P, et al. **Childs Nerv Syst** 1996 Mar; 12(3):172-5

Diagnosis of spinal arteriovenous malformations by MRI at 1.0 T. Hojer C, et al. **Clin Imaging** 1996 Apr-Jun; 20(2):79-84

Spontaneous pulsatile tinnitus secondary to a dural malformation not visualized by magnetic resonance angiography. Koenigsberg RA. **Clin Imaging** 1996 Apr-Jun;20(2):95-8

Spinal arteriovenous malformation presenting as meningitis. Lowe DW, et al. **Dev Med Child Neurol** 1996 Jun; 38(6):549-53

Cervical spinal arteriovenous malformation. Geusens E, et al. **J Belge Radiol** 1995 Jun;78(3):184-5

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 34-1995. A 77-year old woman with 17 years of gastrointestinal bleeding [clinical conference] **N Engl J Med** 1995 Nov 9;333(19):1273-9

Hereditary hemorrhagic telangiectasia [letter; comment] Kjeldsen AD, et al. **N Engl J Med** 1996 Feb 1;334(5):331-2 . Comment on: N Engl J Med 1995 Oct 5;333(14):918-24.

Hereditary hemorrhagic telangiectasia [letter; comment] Shovlin CL, et al. **N Engl J Med** 1996 Feb 1;334(5):330-1; discussion 331-2. Comment on: N Engl J Med 1995 Oct 5;333(14):918-24.

Magnetic resonance angiography of cerebral arteriovenous malformations. Abe T, et al. **Neurol Med Chir (Tokyo)** 1995 Aug;35(8):580-3

Arteriovenous malformation with auricular hypertrophy. Kojima Y, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Jul-Aug;57(4):224-7

Nitric oxide in the management of persistent pulmonary hypertension of the newborn--an unusual cause of failure. Jerwood DC, et al. **Paediatr Anaesth** 1995;5(3):193-5

Newborn with congenital arteriovenous fistulas of the abdominal wall complicated by a ductus arteriosus aneurysm. Akita H, et al. **Pediatr Cardiol** 1995 Sep-Oct; 16(5):235-8

Left innominate vein compression by a brachiocephalic artery anomaly. Moes CA, et al. **Pediatr Cardiol** 1995 Nov-Dec; 16(6):291-3 (7 ref.)

Magnetic resonance venography of congenital vascular malformations of the extremities. Laor T, et al. **Pediatr Radiol** 1996;26(6):371-80

Large diffuse arteriovenous malformation affecting the right cerebral and cerebellar hemispheres: case report. Sagoh M, et al. **Surg Neurol** 1996 Aug;46(2):122-7; discussion 127-8

Magnetic resonance imaging of vascular lesions of the scrotum and penis. Forstner R, et al. **Urology** 1995 Oct; 46(4):581-3

[Lower limb pain and leaping progressive paraparesis (clinical conference)] Jokelainen M. **Duodecim** 1994; 110(6):622-9 **(Fin)**

[Pulmonary arteriovenous malformation causing an abnormally high hemoglobin concentration] Parpala T, et al. **Duodecim** 1994;110(11):1076-8 **(Fin)**

[Arteriovenous malformations, a diagnostic responsibility of the dentist] Gravel JF, et al. **J Can Dent Assoc** 1995 Dec; 61(12):1068, 1071-3 **(Fre)**

[Angiodysplasia of the large intestine in children] Krivchenia DIu, et al. **Klin Khir** 1995;(6):13-5 **(Rus)**

[Multiple arteriovenous malformations of the brain, spinal cord, kidneys and peripheral vessels] Okladnikov GI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(2):93-5 **(Rus)**

[Cerebral arterio-venous malformations in children under 10 years] Marzo ME, et al. **Rev Neurol** 1996 May; 24(129):558-61 (Eng. Abstr.) **(Spa)**

ETIOLOGY

[A case of dural AVM detected after STA-MCA anastomosis] Igase K, et al. **No Shinkei Geka** 1996 Jan; 24(1):81-5 (Eng. Abstr.) **(Jpn)**

GENETICS

[Familial venous dysplasia and lymphedema] Weissleder H, et al. **Z Lymphol** 1996 Jun;20(1):36-9 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Congenital absence of portal venous system associated with a large inferior mesenteric-caval shunt: a case report. Komatsu S, et al. **Hepatogastroenterology** 1995 Jul; 42(3):286-90 (17 ref.)

Arteriovenous malformation of the bronchial artery showing endobronchial protrusion. Soda H, et al. **Intern Med** 1995 Aug;34(8):797-800

Diffuse pulmonary arteriovenous malformation in a child with polysplenia syndrome. Kapur S, et al. **Pediatr Pathol Lab Med** 1995 May-Jun;15(3):463-8

PHYSIOPATHOLOGY

The use of xenon-133 for measurement of blood flow through systemic arteriovenous malformations before and after therapeutic embolization. Kennedy AM, et al.

Br J Radiol 1995 Aug;68(812):844–9

Recovery after surgery of the spinal N24 SEP in dural arteriovenous malformation of the dorsal cord. Valeriani M, et al. **Electroencephalogr Clin Neurophysiol** 1995 Sep; 96(5):479–82

Spinal dural arteriovenous malformations. Intraoperative evoked potential evidence for pathophysiology. A case report. Stecker MM, et al. **Spine** 1996 Feb 15;21(4):512–5

Transvenous hemodynamic assessment of experimental arteriovenous malformations. Doppler guidewire monitoring of embolotherapy in a swine model. Murayama Y, et al. **Stroke** 1996 Aug;27(8):1365–72

Temporal lobe arteriovenous malformations: surgical management and outcome. Malik GM, et al. **Surg Neurol** 1996 Aug;46(2):106–14; discussion 114–5

Successful removal of cryptic arteriovenous malformation located at the upper ventral pons via subtemporal transtentorial approach. Nagata K, et al. **Surg Neurol** 1996 Aug;46(2):116–21

Large diffuse arteriovenous malformation affecting the right cerebral and cerebellar hemispheres: case report. Sagoh M, et al. **Surg Neurol** 1996 Aug;46(2):122–7; discussion 127–8

[Embolization of AVM's of thoracic spinal cord with histoacryl glue] Radek A, et al. **Neurol Neurochir Pol** 1996 Mar–Apr;30(2):333–45 (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

A serpiginous intradural filling defect on a lumbar myelogram could be identified as a spinal dural arteriovenous fistula or a spinal arteriovenous malformation. Moran CJ. **AJR Am J Roentgenol** 1995 Nov;165(5):1300–1

Pulmonary arteriovenous malformation. Suchin CR, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):648

Bronchial arteriovenous malformation in a child with hemoptysis. A case report. Sharifi M, et al. **Angiology** 1996 Feb;47(2):203–9

Microvascular anatomy of dural arteriovenous abnormalities of the spine: a microangiographic study. McCutcheon IE, et al. **J Neurosurg** 1996 Feb;84(2):215–20

Correlating angiograms with CT/MRI scans for radiosurgery. Popescu GF, et al. **Minim Invasive Neurosurg** 1995 Sep;38(3):105–11

Pitfall of superselective catheterization by 3F catheter for spinal arteriovenous malformation. Sato M, et al. **Radiat Med** 1995 Sep–Oct;13(5):259–61

Normal and abnormal vascular structures that simulate neoplasms on chest radiographs: clues to the diagnosis. Cole TJ, et al. **Radiographics** 1995 Jul;15(4):867–91 (23 ref.)

Pediatric great vessel anomalies: initial clinical experience with spiral CT angiography. Hopkins KL, et al. **Radiology** 1996 Sep;200(3):811–5

Renal arteriovenous malformations masquerading as renal cell carcinoma. Vasavada SP, et al. **Urology** 1995 Nov; 46(5):716–21

[Spiral CT for detection of heart valve disease with complex postoperative changes] Becker C, et al. **Radiologe** 1996 Apr; 36(4):365–7 **(Ger)**

RADIONUCLIDE IMAGING

Tc-99m MAA total-body imaging to detect intrapulmonary right-to-left shunts and to evaluate the therapeutic effect in pulmonary arteriovenous shunts. Lu G, et al. **Clin Nucl Med** 1996 Mar;21(3):197–202

Pulmonary arteriovenous malformation diagnosed with radionuclide angiography. Unal SN, et al. **Clin Nucl Med** 1995 Dec;20(12):1097–9

SURGERY

Per-operative use of a balloon-occluding arterial catheter in renal arteriovenous malformation. Kumar U, et al. **Br J Urol** 1996 Feb;77(2):312–3

A case of pulmonary arteriovenous malformation in a patient with brain abscess successfully treated with video-assisted thoracoscopic resection. Watanabe N, et al. **Chest** 1995 Dec;108(6):1724–7

Aortobronchial fistula after correction of congenital cardiovascular abnormalities. Hiep-van Casteren SC, et al. **Eur Respir J** 1995 Oct;8(10):1796–8

Laparoscopic appendicectomy in the management of acute lower gastrointestinal bleeding. So JB, et al. **Gastrointest Endosc** 1995 Nov;42(5):488–9

Hepatic artery ligation for hepatic vascular tumors with arteriovenous and arterioportal venous shunts in the newborn: successful management of two cases and review of the literature. Hazebroek FW, et al. **J Pediatr Surg** 1995 Aug;30(8):1127–30 (15 ref.)

Correlating angiograms with CT/MRI scans for radiosurgery. Popescu GF, et al. **Minim Invasive Neurosurg** 1995 Sep;38(3):105–11

Surgical removal of giant basal ganglia arteriovenous malformations through the extended transsylvian approach following preoperative embolization--two case reports. Mizoi K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec; 35(12):869–75

Treatment of scalp arteriovenous malformation. Nagasaka S, et al. **Neurosurgery** 1996 Apr;38(4):671–7; discussion 677

Salvage of an amputated ear temporarily lodged in a forearm. Schiavon M, et al. **Plast Reconstr Surg** 1995 Dec; 96(7):1698–701

Temporal lobe arteriovenous malformations: surgical management and outcome. Malik GM, et al. **Surg Neurol** 1996 Aug;46(2):106–14; discussion 114–5

Successful removal of cryptic arteriovenous malformation located at the upper ventral pons via subtemporal transtentorial approach. Nagata K, et al. **Surg Neurol** 1996 Aug;46(2):116–21

What is your general approach to the management of brain stem AVMs? Samson D, et al. **Surg Neurol** 1995 Aug; 44(2):107–8

Argon and YAG laser photocoagulation and excision of hemangiomas and vascular malformations of the nose. Apfelberg DB. **West J Med** 1995 Aug;163(2):122–7

[Surgical treatment of superficial vascular malformations. Indications for tissue expansion] Laurian C, et al. **J Mal Vasc** 1996;21(1):31–5 (Eng. Abstr.) **(Fre)**

[Dieulafoy lesions (letter)] Herrero RG, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):493 **(Spa)**

[The endoscopic Nd-YAG laser treatment of the "watermelon stomach"] Meroño E, et al. **Rev Clin Esp** 1996 May;196(5):302–5 (Eng. Abstr.) **(Spa)**

[Cerebral arterio-venous malformations in children under 10 years] Marzo ME, et al. **Rev Neurol** 1996 May; 24(129):558–61 (Eng. Abstr.) **(Spa)**

THERAPY

Successful conservative management of congenital pelvic arteriovenous malformation. Chao AS, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):185–8

Venous sac embolization of pulmonary arteriovenous malformations in two patients. Coley SC, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):452–4

Pulmonary arteriovenous malformations: results of treatment with coil embolization in 53 patients. Dutton JA, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1119–25

Successful combination endoscopic therapy for duodenal Dieulafoy's lesion [letter] Steinert D, et al. **Am J Gastroenterol** 1996 Apr;91(4):818–9

General anesthesia in a child with a dynamic, vascular anterior mediastinal mass. Furst SR, et al. **Anesthesiology** 1996 Apr;84(4):976–9

Successful management of pelvic arteriovenous malformation by repeated particulate intra-arterial embolization [letter; comment] Jackson JE. **Br J Urol** 1996 Jan;77(1):171. Comment on: Br J Urol 1995 Jun;75(6):805–6.

Systemic supply to a pulmonary arteriovenous malformation: potential explanation for recurrence. Wispelaere JFD, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):285–7

How I do it. Arteriovenous malformation management. Yakes WF, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):65–71

Unusual complications after embolization of a pulmonary arteriovenous malformation. Haitjema T, et al. **Chest** 1996 May;109(5):1401–4

Haemodynamics and gas exchange before and after coil embolization of pulmonary arteriovenous malformations. Andrivet P, et al. **Eur Respir J** 1995 Jul;8(7):1228–30

Giant vascular malformation of the face in a premature infant: complete resolution by embolization. Lopez-Gutierrez JC, et al. **J Pediatr Surg** 1995 Oct;30(10):1519–20

Management of large high-flow arteriovenous malformations of the shoulder and upper extremity with transcatheter embolotherapy. Dickey KW, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):765–73

Surgical removal of giant basal ganglia arteriovenous malformations through the extended transsylvian approach following preoperative embolization--two case reports. Mizoi K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec; 35(12):869–75

Hemodynamic evaluation of spinal arteriovenous malformations before and after embolization--preliminary report. Touho H, et al. **Neurol Med Chir (Tokyo)** 1995 Jul; 35(7):445–9

Embolisation of pulmonary arteriovenous malformations: results and follow up in 32 patients [see comments] Haitjema TJ, et al. **Thorax** 1995 Jul;50(7):719–23. Comment in: Thorax 1995 Jul;50(7):707–8.

Pulmonary arteriovenous malformations [editorial; comment] Robertson RJ, et al. **Thorax** 1995 Jul;50(7):707–8. Comment on: Thorax 1995 Jul;50(7):719–23.

[What to do in a 60-year-old HIV-positive woman with a cerebral arteriovenous malformation? Decision analysis (letter; comment)] Wolbers JG. **Ned Tijdschr Geneeskd** 1996 Feb 17;140(7):386–7. Comment on: Ned Tijdschr Geneeskd 1995 Nov 18;139(46):2362–9. **(Dut)**

[Transcatheter embolization in 39 cases of hyperactive arteriovenous malformation] Marchianò AV, et al. **Radiol Med (Torino)** 1996 Apr;91(4):440–6 (Eng. Abstr.) **(Ita)**

[Embolization of congenital pulmonary arteriovenous malformations] Kolbenstvedt A, et al. **Tidsskr Nor Laegeforen** 1996 Jun 20;116(16):1883–5 (Eng. Abstr.) **(Nor)**

[Embolization of AVM's of thoracic spinal cord with histoacryl glue] Radek A, et al. **Neurol Neurochir Pol** 1996 Mar–Apr;30(2):333–45 (Eng. Abstr.) **(Pol)**

[A patient with Rendu-Osler-Weber disease and pulmonary arteriovenous malformations treated satisfactorily by embolization] Martín Díaz E, et al. **Arch Bronconeumol** 1996 Jun-Jul;32(6):307–9 (12 ref.) (Eng. Abstr.) **(Spa)**

[Therapeutic strategy in vascular changes. New methods for a small group of patients difficult to treat] Risberg B, et al. **Lakartidningen** 1996 Feb 28;93(9):779–82 **(Swe)**

ULTRASONOGRAPHY

Pancreatic arteriovenous malformation with duodenal ulcer. Demonstration by color Doppler ultrasonography. Tano S, et al. **Dig Dis Sci** 1996 Jun;41(6):1232–7

Transvenous hemodynamic assessment of arteriovenous malformations and fistulas. Preliminary clinical experience in Doppler guidewire monitoring of embolotherapy. Murayama Y, et al. **Stroke** 1996 Aug;27(8):1358–64

Transcranial Doppler ultrasonography and transesophageal echocardiography in the investigation of pulmonary arteriovenous malformation in a patient with hereditary hemorrhagic telangiectasia presenting with stroke. Yeung M, et al. **Stroke** 1995 Oct;26(10):1941–4

Prenatal sonographic diagnosis of a vein of Galen aneurysm: relevance of associated malformations for timing and mode of delivery. Dören M, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):287–9

Prenatal diagnosis of cerebral arteriovenous malformation using color Doppler ultrasonography: case report and review of the literature. Sepulveda W, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):282–6 (30 ref.)

[A case of pancreatic arteriovenous malformation--understanding of its pathophysiology with a color Doppler ultrasonography] Imano E, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct; 92(10):1799–803 **(Jpn)**

ARTERIOVENOUS MALFORMATIONS, CEREBRAL see **CEREBRAL ARTERIOVENOUS MALFORMATIONS**

ARTERIOVENOUS SHUNT, SURGICAL

Effect of access recirculation on the modeled urea distribution volume. Daugirdas JT, et al. **Am J Kidney Dis** 1996 Apr;27(4):512–8

Candida infection of the arteriovenous fistula used for hemodialysis. Nguyen MH, et al. **Am J Kidney Dis** 1996 Apr;27(4):596–8 (8 ref.)

The effects of hemodialysis on platelet deposition in prosthetic graft fistulas. Windus DW, et al. **Am J Kidney Dis** 1995 Oct;26(4):614–21

The arteriovenous fistula for hemodialysis access: gold standard or archaic relic? Leapman SB, et al. **Am Surg** 1996 Aug;62(8):652–6; discussion 656–7

Reverse jugular flow in a case of thrombosis of the brachiocephalic vein with an artificial arteriovenous fistula. Chen YW, et al. **Angiology** 1996 Jul;47(7):699–702

Right-to-left veno-arterial shunting for right-sided circulatory failure. Slater JP, et al. **Ann Thorac Surg** 1995 Oct;60(4):978–84; discussion 985

Prevention of platelet adhesion on polysulfone porous catheter by saline solution perfusion, II. Ex vivo and in vivo investigation. Khang G, et al. **Biomed Mater Eng** 1996; 6(2):123–34

Arterialised venous groin flap: case report. Sakai S. **Br J Plast Surg** 1996 Mar;49(2):90–2

Puncture of stents implanted into veins and arteriovenous fistulas: an experimental study. Schürmann K, et al. **Cardiovasc Intervent Radiol** 1995 Nov–Dec;18(6):383–90

Creation of a controlled venoarterial shunt. A surgical intervention for right-side circulatory failure. Slater JP, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II467–71

Lung perfusion scintigram in a patient with tetralogy of Fallot and a unidirectional Glenn shunt. A case report. McLeary MS, et al. **Clin Nucl Med** 1995 Jul;20(7):647–8

Factors affecting the lifespan of autologous and synthetic arteriovenous access routes for haemodialysis. Lazarides MK, et al. **Eur J Surg** 1996 Apr;162(4):297–301

Effects of increased pulse pressure on cerebral arterioles. Baumbach GL. **Hypertension** 1996 Feb;27(2):159–67

Patterns of atherosclerotic occlusive disease of lower leg and pedal arteries in hypertensive patients undergoing infrainguinal bypass procedures. Karacagil S, et al. **Int Angiol** 1996 Mar;15(1):57–60

Electrophysiological monitoring for selective shunting during carotid endarterectomy. Fiori L, et al. **J Neurosurg Anesthesiol** 1995 Jul;7(3):168–73

Surgery versus thrombolytic therapy in the management of peripheral arterial occlusions. Ouriel K. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):48S–54S (42 ref.)

Percutaneous use of the Fogarty adherent clot catheter. Trerotola SO, et al. **J Vasc Interv Radiol** 1995 Jul–Aug; 6(4):578–80

Simple percutaneous arteriovenous graft ligation [letter] Sottiurai VS, et al. **J Vasc Surg** 1996 Jul;24(1):175–6

Hemodynamic consequences of Cimino fistulas studied with finger pressure measurements during fistula compression. Bos WJ, et al. **Kidney Int** 1995 Nov;48(5):1641–5

The cerebral function monitor (CFM) is a useful addition to a bilateral carotid artery, vein graft model. Toner CC, et al. **Lab Anim** 1995 Oct;29(4):427–31

Magnetic resonance angiography of dialysis access shunts: initial results. Waldman GJ, et al. **Magn Reson Imaging** 1996;14(2):197–200

Revascularization of occluded haemodialysis fistulae with the Hydrolyser thrombectomy catheter: description of the technique and report of six cases. Pattynama PM, et al. **Nephrol Dial Transplant** 1995;10(7):1224–7

Posterior interosseous nerve palsy after brachiocephalic

arteriovenous fistula construction: report of two cases. Sawin PD, et al. **Neurosurgery** 1995 Sep;37(3):537–9; discussion 539–40

Perfusion technique for treatment of right heart failure. Beck JR, et al. **Perfusion** 1995 Sep;10(5):323–6

Great toe–to–hand transfer nourished by arterial inflow through the venous system. Iglesias M, et al. **Plast Reconstr Surg** 1996 Apr;97(5):1024–6

Renal hemodynamic response to the creation of vascular access in patients with end–stage renal disease. Crowley ST, et al. **Ren Fail** 1995 Sep;17(5):589–93

Lessons from vascular access procedures for hemodialysis. Shaffer D. **Surg Oncol Clin N Am** 1995 Jul;4(3):537–48 (70 ref.)

Experience with arteriovenous fistulae for hemodialysis. Moray G, et al. **Transplant Proc** 1996 Aug;28(4):2341–2

Follow–up results of synthetic vascular grafts in children undergoing hemodialysis. Nayir A, et al. **Turk J Pediatr** 1995 Jul–Sep;37(3):223–8

[Can distal vein arterialization be beneficial for the diabetic foot with necrosis?] Lengua F. **Chirurgie** 1994–95; 120(13):143–52 (Eng. Abstr.) **(Fre)**

[Initial experiences with dilatation of dialysis shunts with color–coded duplex ultrasonography monitoring] Wittenberg G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jan;164(1):38–41 (Eng. Abstr.) **(Ger)**

[Foot salvage in diabetic gangrene] Jung V. **Zentralbl Chir** 1996;121(5):387–92; discussion 392–3 (Eng. Abstr.) **(Ger)**

[Results of revision and new operation in arteriovenous shunt complications] Schumann M, et al. **Zentralbl Chir** 1996; 121(5):376–9 (Eng. Abstr.) **(Ger)**

[An experimental study of blood supply to the bile duct under arterio–portal shunting] Munemura T. **Hokkaido Igaku Zasshi** 1995 Jul;70(4):591–608 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Pulse oximeter analysis of peripheral cyanosis distal to an AV fistula. Pesola GR, et al. **Am J Emerg Med** 1996 May; 14(3):268–9

Utilization of inpatient and outpatient resources for the management of hemodialysis access complications. Rocco MV, et al. **Am J Kidney Dis** 1996 Aug;28(2):250–6

Results and complications of arteriovenous access dialysis grafts in the lower extremity: a five year review. Taylor SM, et al. **Am Surg** 1996 Mar;62(3):188–91

Prolongation of hemodialysis access survival with elective revision. Sands JJ, et al. **Clin Nephrol** 1995 Nov; 44(5):329–33

Factors associated with early failure of arteriovenous fistulae for haemodialysis access. Wong V, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):207–13

The treatment of hand ischemia by arterial ligation and upper extremity bypass after angioaccess surgery. Katz S, et al. **J Am Coll Surg** 1996 Sep;183(3):239–42

Tenascin: a potential role in human arteriovenous PTFE graft failure. Chen C, et al. **J Surg Res** 1996 Feb 1;60(2):409–16

Pulmonary embolism following hemodialysis access thrombolysis/thrombectomy. Swan TL, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):683–6

Recombinant tissue plasminogen activator (rt–PA) as first–line therapy for declotting of haemodialysis access. Andriani M, et al. **Nephrol Dial Transplant** 1995; 10(9):1714–9

Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula. Erdem Y, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1299–305

Chronic venous occlusions in haemodialysis shunts: efficacy of percutaneous treatment. Vorwerk D, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1869–73

Fatal Salmonella typhimurium infection of a vascular graft in an infant. Juneja R, et al. **Pediatr Cardiol** 1996 Sep–Oct; 17(5):330–1

Mechanical thrombolysis for the treatment of thrombosed hemodialysis access grafts. Beathard GA, et al. **Radiology** 1996 Sep;200(3):711–6

Thrombosed hemodialysis grafts [letter] Günther RW. **Radiology** 1996 Mar;198(3):908–9

Detection and treatment of dysfunctional hemodialysis access grafts: effect of a surveillance program on graft patency and the incidence of thrombosis. Safa AA, et al. **Radiology** 1996 Jun;199(3):653–7

Pulmonary emboli from pulse–spray and mechanical thrombolysis: evaluation with an animal dialysis–graft model. Trerotola SO, et al. **Radiology** 1996 Jul; 200(1):169–76

The effect of a pancreatic allograft distal arteriovenous fistula on islet hormone secretions. Fiedor P, et al. **Transplant Proc** 1995 Dec;27(6):3280–1

[Surgical complications of vascular procedures in hemodialysis therapy] Simek S. **Sb Lek** 1995;96(1):27–34 (Eng. Abstr.) **(Cze)**

ECONOMICS

Cost–efficacy issues in the treatment of peripheral vascular disease: primary amputation or revascularization for limb–threatening ischemia. Perler BA. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):111S–115S (28 ref.)

INSTRUMENTATION

A Corethane/polyester composite vascular prosthesis for vascular access. Comparison with expanded polytetrafluoroethylene grafts in a canine model. Wilson GJ, et al. **ASAIO J** 1995 Jul–Sep;41(3):M728–34

A method to trim multilayered polytetrafluoroethylene grafts. Gelbfish GA, et al. **J Am Coll Surg** 1996 Jun; 182(6):552–4

METHODS

Superficial repositioning of the artery for chronic hemodialysis: indications and prognosis. Yasunaga C, et al. **Am J Kidney Dis** 1995 Oct;26(4):602–6

A new method of creating an arteriovenous graft access. Benedetti E, et al. **Am J Surg** 1996 Mar;171(3):369–70

1988: Surgery of the descending thoracic aorta: spinal cord protection with the Gott shunt. Updated in 1995. Verdant A. **Ann Thorac Surg** 1995 Oct;60(4):1151–2

Bidirectional Glenn. Is accessory pulmonary blood flow good or bad? Mainwaring RD, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II294–7

Saphenous vein forearm grafts and gortex thigh grafts as alternative forms of vascular access. Bhandari S, et al. **Clin Nephrol** 1995 Nov;44(5):325–8

The Gracz arteriovenous fistula evaluated. Results of the brachiocephalic elbow fistula in haemodialysis angio–access. Bender MH, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):294–7

Interposition vein cuffs [editorial] Harris P, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):257–9 (11 ref.)

Refinements of the in situ vein bypass: towards a more "closed" technique. van Dijk LC, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):136–8

An alternative technique to create end–of–vein to side–of–artery fistula for angioaccess. Katsumata T, et al. **J Am Coll Surg** 1996 Jan;182(1):69–70

Contemporary vascular access surgery for chronic haemodialysis. Koo Seen Lin LC, et al. **J R Coll Surg Edinb** 1996 Jun;41(3):164–9 (75 ref.)

Augmentation of pulmonary blood flow with an axillary arteriovenous fistula after a cavopulmonary shunt. Magee A, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):176–80

Percutaneous creation of arteriovenous hemodialysis grafts: work in progress. Trerotola SO, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):675–81

Improved method to create the common ostium variant of the distal arteriovenous fistula for enhancing crural prosthetic graft patency. Dardik H, et al. **J Vasc Surg** 1996 Aug;24(2):240–8

Axillary grafts for difficult hemodialysis access. McCann RL. **J Vasc Surg** 1996 Sep;24(3):457–61; discussion 461–2

Relevance of the ulnaris fistula as a dialysis shunt. Cetto C, et al. **Nephrol Dial Transplant** 1995;10(6):877–8

Subclavian artery to right atrium haemodialysis bridge graft for superior vena caval occlusion. Mickley V. **Nephrol Dial Transplant** 1996 Jul;11(7):1361–2

The salvage of a degloved hand skin flap by arteriovenous shunting. Hsu WM, et al. **Plast Reconstr Surg** 1996 Jul; 98(i):146–50

Successful management of portal hypertension following artificial arterioportal shunting: report of a case. Ko S, et al. **Surg Today** 1995;25(6):557–9

Upper arm arteriovenous fistula for chronic hemodialysis: 20 years later. Dagher FJ. **Transplant Proc** 1996 Aug; 28(4):2325–7 (12 ref.)

[Establishment of arteriovenous anastomoses with interposition of ePTFE (Goretex) prostheses] Bachleda P, et al. **Rozhl Chir** 1996 Jan;75(1):26–30 (Eng. Abstr.) **(Cze)**

[Personal experience with establishment of arteriovenous anastomoses for dialysis using blood vessels in the cubital fossa] Utíkal P, et al. **Rozhl Chir** 1996 Feb;75(2):83–7 (Eng. Abstr.) **(Cze)**

[Indications and clinical experiences with the use of central shunts for chronic hemodialysis] Settmacher U, et al. **Zentralbl Chir** 1995;120(12):969–73 (Eng. Abstr.) **(Ger)**

ARTERITIS

Magnetic resonance imaging of the brain in nonarteritic ischemic optic neuropathy. Arnold AC, et al. **J Neuroophthalmol** 1995 Sep;15(3):158–60

COMPLICATIONS

Intrahepatic biliary dilatation with aortoarteritis. Kabra SK, et al. **Indian Pediatr** 1995 Jan;32(1):92–5

[[Aneurysm of the abdominal aorta and arteritis of the legs] Hassen–Khodja R, et al. **J Mal Vasc** 1995;20(4):301–4 (Eng. Abstr.) **(Fre)**

[An autopsy case of segmental mediolytic arteritis (SMA) accompanied with microscopic polyarteritis nodosa] Ito MR, et al. **Ryumachi** 1995 Aug;35(4):693–8 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Inflammatory aorto–iliac aneurysm. A cause of extrinsic ureteral obstruction] García Díez F, et al. **Arch Esp Urol** 1995 Sep;48(7):750–3 (Eng. Abstr.) **(Spa)**

[Cerebrovascular diseases and non–infectious inflammatory arteriopathies] Vivancos F, et al. **Rev Neurol** 1995;23 Suppl 1:S22–32 (84 ref.) **(Spa)**

DIAGNOSIS

Pan–nephritis (glomerulonephritis, arteriolitis, and tubulointerstitial nephritis) associated with predominant mesangial C1q deposition and hypocomplementemia: a variant type of C1q nephropathy? Imai H, et al. **Am J Kidney Dis** 1996 Apr;27(4):583–7 (15 ref.)

A change in ocular involvement in a patient suffering from ankylosing spondylitis and Behçet's disease. Beiran I, et al. **Eur J Ophthalmol** 1995 Jul–Sep;5(3):192–4

Optic neuropathy, headache, and diplopia with MRI suggestive of cerebral arteritis in relapsing polychondritis. Massry GG, et al. **J Neuroophthalmol** 1995 Sep;15(3):171–5

Bilateral multiple arterial aneurysms. Schatz H. **Retina** 1995; 15(4):348–9; discussion 349–50

[Granulomatous vasculitis of the CNS as a complication of herpes zoster ophthalmicus] Terborg C, et al. **Fortschr Neurol Psychiatr** 1995 Oct;63(10):383–7 (Eng. Abstr.) **(Ger)**

ETIOLOGY

The induction of cardioangitis by Lactobacillus casei cell wall in mice. I. The cytokine production from murine macrophages by Lactobacillus casei cell wall extract. Okitsu–Negishi S, et al. **Clin Immunol Immunopathol** 1996 Jan;78(1):30–40

Destructive allograft fungal arteritis following simultaneous pancreas–kidney transplantation. Ciancio G, et al. **Transplantation** 1996 Apr 27;61(8):1172–5

[Cerebral arteritis in AIDS. Demonstration with MRA in 2 patients] Brunereau L, et al. **J Radiol** 1996 May; 77(5):367–71 (Eng. Abstr.) **(Fre)**

[Diffuse panbronchiolitis with P–ANCA–positive arteritis and necrotizing glomerulitis] Saku N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr;34(4):434–8 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Interferon–gamma–producing T cells in giant cell vasculitis represent a minority of tissue–infiltrating cells and are located distant from the site of pathology. Wagner AD, et al. **Am J Pathol** 1996 Jun;148(6):1925–33

MICROBIOLOGY

Infection of endovascular stents in a swine model. Thibodeaux LC, et al. **Am J Surg** 1996 Aug;172(2):151–4

Candida arteritis: are GI endoscopic procedures a source of vascular infections? Sailors DM, et al. **Am Surg** 1996 Jun; 62(6):472–7

PATHOLOGY

[Segmental mediolytic arteriopathy] Ludvíková M, et al. **Cesk Patol** 1995 Dec;31(4):125–8 (Eng. Abstr.) **(Cze)**

PHYSIOPATHOLOGY

Multimodality evoked potentials in aortoarteritis. Varma AR, et al. **Electromyogr Clin Neurophysiol** 1995 Aug–Sep; 35(5):291–4

[Cerebrovascular diseases and non–infectious inflammatory arteriopathies] Vivancos F, et al. **Rev Neurol** 1995;23 Suppl 1:S22–32 (84 ref.) **(Spa)**

ULTRASONOGRAPHY

[Ultrasound diagnosis, follow–up and therapy of cystic degeneration of the adventitia. 2 case reports and review of the literature] Schäberle W, et al. **Ultraschall Med** 1996 Jun;17(3):131–7 (39 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Lingual arteritis, multifocal meningoencephalitis, and uveitis induced by barley spikelet clusters in a two–year–old heifer. Sorden SD, et al. **Can Vet J** 1996 Apr;37(4):227–9

ARTERITIS, TAKAYASU'S see **TAKAYASU'S ARTERITIS**

ARTERITIS, TEMPORAL see **TEMPORAL ARTERITIS**

ARTERITIS VIRUS, EQUINE

Clinical features of the 1992 outbreak of equine viral arteritis in Spain. Monreal L, et al. **Equine Vet J** 1995 Jul; 27(4):301–4

Sexual and in–contact transmission of asinine strain of equine arteritis virus among donkeys. Paweska JT, et al. **J Clin Microbiol** 1995 Dec;33(12):3296–9

Equine viral arteritis [letter] Paweska JT. **J S Afr Vet Assoc** 1995 Sep;66(3):111–2

Equine viral arteritis with abortions: serological and virological evidence in Germany. Eichhorn W, et al. **Zentralbl Veterinarmed [B]** 1995 Nov;42(9):573–6

ENZYMOLOGY

The arterivirus nsp4 protease is the prototype of a novel group of chymotrypsin–like enzymes, the 3C–like serine proteases. Snijder EJ, et al. **J Biol Chem** 1996 Mar 1; 271(9):4864–71

GENETICS

Equine arteritis virus subgenomic mRNA synthesis: analysis

of leader-body junctions and replicative-form RNAs. den Boon JA, et al. **J Virol** 1996 Jul;70(7):4291–8
Phylogenetic analysis of open reading frame 5 of field isolates of equine arteritis virus and identification of conserved and nonconserved regions in the GL envelope glycoprotein. Balasuriya UB, et al. **Virology** 1995 Dec 20;214(2):690–7
Equine arteritis virus subgenomic RNA transcription: UV inactivation and translation inhibition studies. Den Boon JA, et al. **Virology** 1995 Nov 10;213(2):364–72

IMMUNOLOGY

Immunoperoxidase histochemistry as a diagnostic tool for detection of equine arteritis virus antigen in formalin fixed tissues. Lopez JW, et al. **Equine Vet J** 1996 Jan;28(1):77–9
Comparison of equine arteritis virus isolates using neutralizing monoclonal antibodies and identification of sequence changes in GL associated with neutralization resistance. Glaser AL, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2223–33
Development and evaluation of an ELISA using recombinant fusion protein to detect the presence of host antibody to equine arteritis virus. Chirnside ED, et al. **J Virol Methods** 1995 Jul;54(1):1–13

ISOLATION & PURIFICATION

Histopathological and immunofluorescent studies on transplacental infection in experimentally induced abortion by equine arteritis virus. Wada R, et al. **Zentralbl Veterinarmed [B]** 1996 Apr;43(2):65–74

ARTERIVIRUS

CHEMISTRY

Structural polypeptides of the American (VR-2332) strain of porcine reproductive and respiratory syndrome virus. Bautista EM, et al. **Arch Virol** 1996;141(7):1357–65

CLASSIFICATION

Isolation of a distinct serotype of porcine reproductive and respiratory syndrome (PRRS) virus in Ontario. Gagnon CA, et al. **Can Vet J** 1995 Dec;36(12):777–8

GENETICS

Pathogenesis of plaque variants of porcine reproductive and respiratory syndrome virus in pregnant sows. Park BK, et al. **Am J Vet Res** 1996 Mar;57(3):320–3
Genetic variation in porcine reproductive and respiratory syndrome virus isolates in the midwestern United States. Kapur V, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1271–6
A nested set of six or seven subgenomic mRNAs is formed in cells infected with different isolates of porcine reproductive and respiratory syndrome virus. Meng XJ, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1265–70
Sequence comparison of open reading frames 2 to 5 of low and high virulence United States isolates of porcine reproductive and respiratory syndrome virus. Meng XJ, et al. **J Gen Virol** 1995 Dec;76 (Pt 12):3181–8
Proteins encoded by open reading frames 3 and 4 of the genome of Lelystad virus (Arteriviridae) are structural proteins of the virion. van Nieuwstadt AP, et al. **J Virol** 1996 Jul;70(7):4767–72

IMMUNOLOGY

Kinetics of humoral immune response to the major structural proteins of the porcine reproductive and respiratory syndrome virus. Loemba HD, et al. **Arch Virol** 1996; 141(3–4):751–61
Antigenic comparison of Canadian and US isolates of porcine reproductive and respiratory syndrome virus using monoclonal antibodies to the nucleocapsid protein. Magar R, et al. **Can J Vet Res** 1995 Jul;59(3):232–4
Assessment of seropositivity to porcine reproductive and respiratory syndrome (PRRS) virus in swine herds in Ontario—1978 to 1982. Carman S, et al. **Can Vet J** 1995 Dec;36(12):776–7
Comparative serology of porcine reproductive and respiratory syndrome in eight European laboratories, using immunoperoxidase monolayer assay and enzyme-linked immunosorbent assay. Drew TW. **Rev Sci Tech** 1995 Sep; 14(3):761–75
Comparison of a commercial ELISA and an immunoperoxidase monolayer assay to detect antibodies directed against porcine respiratory and reproductive syndrome virus. Nodelijk G, et al. **Vet Microbiol** 1996 Apr; 49(3–4):285–95
Comparison of the antigen distribution of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Halbur PG, et al. **Vet Pathol** 1996 Mar;33(2):159–70
Antibody-dependent enhancement (ADE) of porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs. Yoon KJ, et al. **Viral Immunol** 1996; 9(1):51–63

ISOLATION & PURIFICATION

An ELISA for porcine reproductive and respiratory syndrome: production of antigen of high quality. Cho HJ, et al. **Can J Vet Res** 1996 Apr;60(2):89–93
Isolation of a distinct serotype of porcine reproductive and respiratory syndrome (PRRS) virus in Ontario. Gagnon CA, et al. **Can Vet J** 1995 Dec;36(12):777–8
Nucleocapsid protein N of Lelystad virus: expression by recombinant baculovirus, immunological properties, and suitability for detection of serum antibodies. Meulenberg JJ, et al. **Clin Diagn Lab Immunol** 1995 Nov;2(6):652–6
Evaluation of the persistence of porcine reproductive and respiratory syndrome virus in pig carcases. Magar R, et al. **Vet Rec** 1995 Nov 25;137(22):559–61

METABOLISM

Intracellular synthesis, processing, and transport of proteins encoded by ORFs 5 to 7 of porcine reproductive and respiratory syndrome virus. Mardassi H, et al. **Virology** 1996 Jul 1;221(1):98–112

PATHOGENICITY

Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Halbur PG, et al. **Vet Pathol** 1995 Nov;32(6):648–60

PHYSIOLOGY

Comparison among strains of porcine reproductive and respiratory syndrome virus for their ability to cause reproductive failure. Mengeling WL, et al. **Am J Vet Res** 1996 Jun;57(6):834–9
Stability of porcine reproductive and respiratory syndrome virus in the presence of fomites commonly found on farms. Pirtle EC, et al. **J Am Vet Med Assoc** 1996 Feb 1; 208(3):390–2
Open reading frame 5 of porcine reproductive and respiratory syndrome virus as a cause of virus-induced apoptosis. Suárez P, et al. **J Virol** 1996 May;70(5):2876–82
[Significance of PRRS virus infections for respiratory tract infections in swine—a literature review] Beilage EG. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec;102(12):457–69 (127 ref.) (Eng. Abstr.) **(Ger)**

ARTERIVIRUS INFECTIONS

IMMUNOLOGY

Kinetics of humoral immune response to the major structural proteins of the porcine reproductive and respiratory syndrome virus. Loemba HD, et al. **Arch Virol** 1996; 141(3–4):751–61
Lactate dehydrogenase-elevating virus: an ideal persistent virus? Plagemann PG, et al. **Springer Semin Immunopathol** 1995;17(2–3):167–86 (78 ref.)

VETERINARY

Comparison among strains of porcine reproductive and respiratory syndrome virus for their ability to cause reproductive failure. Mengeling WL, et al. **Am J Vet Res** 1996 Jun;57(6):834–9
Pathogenesis of plaque variants of porcine reproductive and respiratory syndrome virus in pregnant sows. Park BK, et al. **Am J Vet Res** 1996 Mar;57(3):320–3
An ELISA for porcine reproductive and respiratory syndrome: production of antigen of high quality. Cho HJ, et al. **Can J Vet Res** 1996 Apr;60(2):89–93
Pathogenesis of in utero infection in porcine fetuses with porcine reproductive and respiratory syndrome virus. Lager KM, et al. **Can J Vet Res** 1995 Jul;59(3):187–92
Antibody production and blastogenic response in pigs experimentally infected with porcine reproductive and respiratory syndrome virus. Vézina SA, et al. **Can J Vet Res** 1996 Apr;60(2):94–9
Assessment of seropositivity to porcine reproductive and respiratory syndrome (PRRS) virus in swine herds in Ontario—1978 to 1982. Carman S, et al. **Can Vet J** 1995 Dec;36(12):776–7
Isolation of a distinct serotype of porcine reproductive and respiratory syndrome (PRRS) virus in Ontario. Gagnon CA, et al. **Can Vet J** 1995 Dec;36(12):777–8
Immunoperoxidase histochemistry as a diagnostic tool for detection of equine arteritis virus antigen in formalin fixed tissues. Lopez JW, et al. **Equine Vet J** 1996 Jan;28(1):77–9
Clinical features of the 1992 outbreak of equine viral arteritis in Spain. Monreal L, et al. **Equine Vet J** 1995 Jul; 27(4):301–4
Sexual and in-contact transmission of asinine strain of equine arteritis virus among donkeys. Paweska JT, et al. **J Clin Microbiol** 1995 Dec;33(12):3296–9
Genetic variation in porcine reproductive and respiratory syndrome virus isolates in the midwestern United States. Kapur V, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1271–6
A nested set of six or seven subgenomic mRNAs is formed in cells infected with different isolates of porcine reproductive and respiratory syndrome virus. Meng XJ, et al. **J Gen Virol** 1996 Jun;77 (Pt 6):1265–70
Equine viral arteritis [letter] Paweska JT. **J S Afr Vet Assoc** 1995 Sep;66(3):111–2
Persistence of porcine reproductive and respiratory syndrome virus in serum and semen of adult boars. Christopher-Hennings J, et al. **J Vet Diagn Invest** 1995 Oct;7(4):456–64
Comparison of immunogold silver staining (IGSS) with two immunoperoxidase staining systems for the detection of porcine reproductive and respiratory syndrome virus (PRRSV) antigens in formalin-fixed tissues. Larochelle R, et al. **J Vet Diagn Invest** 1995 Oct;7(4):540–3
Evaluation of an indirect fluorescent IgM antibody test for the detection of pigs with recent infection of porcine reproductive and respiratory syndrome virus. Park BK, et al. **J Vet Diagn Invest** 1995 Oct;7(4):544–6
Mycoplasma hyorhinis infection levels in lungs of piglets with porcine reproductive and respiratory syndrome (PRRS). Kobayashi H, et al. **J Vet Med Sci** 1996 Feb;58(2):109–13
Comparative serology of porcine reproductive and respiratory syndrome in eight European laboratories, using immunoperoxidase monolayer assay and enzyme-linked immunosorbent assay. Drew TW. **Rev Sci Tech** 1995 Sep; 14(3):761–75
Comparison of a commercial ELISA and an immunoperoxidase monolayer assay to detect antibodies directed against porcine respiratory and reproductive syndrome virus. Nodelijk G, et al. **Vet Microbiol** 1996 Apr; 49(3–4):285–95
Porcine reproductive and respiratory syndrome virus does not exacerbate Mycoplasma hyopneumoniae infection in young pigs. Van Alstine WG, et al. **Vet Microbiol** 1996 Apr;49(3–4):297–303
Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Halbur PG, et al. **Vet Pathol** 1995 Nov;32(6):648–60
Pathogenesis of porcine reproductive and respiratory syndrome virus infection in gnotobiotic pigs. Rossow KD, et al. **Vet Pathol** 1995 Jul;32(4):361–73
Improved performance of a large pig complex after sequential nursery depopulation. Dee SA, et al. **Vet Rec** 1996 Jan 13;138(2):31–4
Effect of post-coital intrauterine inoculation of porcine reproductive and respiratory syndrome virus on conception in gilts. Lager KM, et al. **Vet Rec** 1996 Mar 9;138(10):227–8
Evaluation of the persistence of porcine reproductive and respiratory syndrome virus in pig carcases. Magar R, et al. **Vet Rec** 1995 Nov 25;137(22):559–61
Antibody-dependent enhancement (ADE) of porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs. Yoon KJ, et al. **Viral Immunol** 1996; 9(1):51–63
Equine viral arteritis with abortions: serological and virological evidence in Germany. Eichhorn W, et al. **Zentralbl Veterinarmed [B]** 1995 Nov;42(9):573–6
Histopathological and immunofluorescent studies on transplacental infection in experimentally induced abortion by equine arteritis virus. Wada R, et al. **Zentralbl Veterinarmed [B]** 1996 Apr;43(2):65–74
[Significance of PRRS virus infections for respiratory tract infections in swine—a literature review] Beilage EG. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec;102(12):457–69 (127 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Lactate dehydrogenase-elevating virus: an ideal persistent virus? Plagemann PG, et al. **Springer Semin Immunopathol** 1995;17(2–3):167–86 (78 ref.)

ARTHRALGIA

CHEMICALLY INDUCED

Polyarthralgia associated with prazosin use [letter] Bell A, et al. **Ann Pharmacother** 1995 Sep;29(9):937

COMPLICATIONS

A diabetic man with left shoulder pain. Caprio FJ. **Tenn Med** 1996 Jul;89(7):252–3
[The Schnitzler syndrome as a cause of recurrent fever of unknown origin] Winckelmann G, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):860–4 (14 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Medial ankle pain after lateral ligament rupture. van Dijk CN, et al. **J Bone Joint Surg Br** 1996 Jul;78(4):562–7
An approach to the diagnosis of chronic wrist pain. Hodgson SP, et al. **J R Coll Surg Edinb** 1995 Dec;40(6):407–10
[The value of MRI in the evaluation of lesions of the supraspinous muscle. Multicentric retrospective study of 66 records] Vander Maren C, et al. **Acta Orthop Belg** 1995; 61 Suppl 1:8–13 **(Fre)**
[Magnetic resonance in the study of the painful shoulder. The surgical comparison in 30 consecutive cases] Della Sala SW, et al. **Radiol Med (Torino)** 1996 Apr;91(4):348–55 (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Intra-articular guanethidine injection for resistant shoulder pain: a preliminary double blind study of a novel approach. Gado K, et al. **Ann Rheum Dis** 1996 Mar;55(3):199–201
[Topical capsaicin and joint pain: a therapeutic break-through?] Gratton N, et al. **Union Med Can** 1995 Mar;124(1):2–4 (17 ref.) **(Fre)**
[Clinical trial comparing a new NSAID with 2 different dosages and diclofenac in patients with arthralgia in acute phase] Alicicco E, et al. **Clin Ter** 1995 Oct;146(10):595–601

(Eng. Abstr.) (Ita)

EPIDEMIOLOGY

Prevalence of chronic knee pain in children and adolescents in northern Finland. Vähäsarja V. **Acta Paediatr** 1995 Jul; 84(7):803–5

ETIOLOGY

A rational approach to the diagnosis of arthritis. Litman K. **Am Fam Physician** 1996 Mar;53(4):1295–300, 1305–6, 1309–10

Arthralgia as the initial manifestation of malignant lymphoma [letter] Ando T, et al. **Am J Hematol** 1995 Oct;50(2):152

Chronic fatigue, arthralgia, and malaise. Gompels MM, et al. **Ann Rheum Dis** 1996 Aug;55(8):502–3

The discriminating value of serum lactate dehydrogenase levels in children with malignant neoplasms presenting as joint pain. Wallendal M, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):70–3

Dorsal defect of the patella: an uncommon cause of knee pain. Narváez J, et al. **Arthritis Rheum** 1996 Jul; 39(7):1244–5

Ankle pain and swelling in a 24-year-old woman [clinical conference] Chivers FS, et al. **Clin Orthop** 1996 Feb; (323):338–40, 343–4

'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Dwarakanath AD, et al. **Gut** 1995 Oct;37(4):585–8

Cryoglobulinemia: recent findings in cutaneous and extracutaneous manifestations. Davis MD, et al. **Int J Dermatol** 1996 Apr;35(4):240–8 (50 ref.)

Shoulder pain after a stroke. Jespersen HF, et al. **Int J Rehabil Res** 1995 Sep;18(3):273–6

Comparison of the findings of triple-injection cinearthrography of the wrist with those of arthroscopy. Weiss AP, et al. **J Bone Joint Surg Am** 1996 Mar; 78(3):348–56

Shoulder pain in long-term haemodialysis patients. A clinical study of 166 patients. Konishiike T, et al. **J Bone Joint Surg Br** 1996 Jul;78(4):601–5

Successful treatment of severe arthralgia associated with palmoplantar pustulosis with low-dose oral cyclosporine A. Yamamoto T, et al. **J Dermatol** 1995 Jul;22(7):512–4

The Valenti procedure for hallux limitus/rigidus [letter] Oloff L. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):178–9; discussion 180–1

Osteoid osteoma in the differential diagnosis of persistent joint pain. Georgoulis AD, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(2):125–8

Learning from the Japanese Registry: how will we prevent long-term complications? Niigata Research Programme for beta 2-M Removal Membrane. Aoike I, et al. **Nephrol Dial Transplant** 1995;10 Suppl 7:7–15

[Clinical judgment and decision making in practice. A patient with joint symptoms (clinical conference)] Stehouwer CD, et al. **Ned Tijdschr Geneeskd** 1996 Aug 17;140(33):1675–9 (Dut)

[A case from practice (340). Transient regional osteoporosis of the right knee] Festini V. **Schweiz Rundsch Med Prax** 1996 Jan 16;85(3):68–9 (Ger)

[A case from practice (337). Psoriasis vulgaris, Hallopeau's continuous suppurative acrodermatitis. Psoriatic arthropathy. Chronic alcoholism with personality changes, polyneuropathy, hepatopathy. Cardiomyopathy with chronic atrial fibrillation, thrombocytopathy, macrocytosis] Widmer A. **Schweiz Rundsch Med Prax** 1995 Nov 28; 84(48):1435 (Ger)

[Hip pain as only symptom of extensive phlebothrombosis] Ekkernkamp M, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep–Oct;133(5):456–9 (Eng. Abstr.) (Ger)

IMMUNOLOGY

Arthropathy, leucopenia and recurrent infection associated with a TcR gamma delta population. Hodges E, et al. **Br J Rheumatol** 1995 Oct;34(10):978–83

MICROBIOLOGY

Microbiological investigation of polyarthralgia. Jones JW, et al. **J Clin Pathol** 1995 Aug;48(8):777–9

[Differential diagnosis of post-infection arthralgias] Landgraf S. **Dtsch Med Wochenschr** 1995 Oct 13;120(41):1414–5 (Ger)

PATHOLOGY

[Diarrhea, a constitutional syndrome and arthralgias] Gisbert JP, et al. **Rev Clin Esp** 1995 Sep;195(9):657–8 (Spa)

RADIOGRAPHY

Surgeons' decision making in patients with chronic wrist pain: role of bilateral three-compartment wrist arthrography—prospective study. Yin Y, et al. **Radiology** 1996 Sep;200(3):829–32

[Climacteric arthralgia and hand arthrosis] Holzer G, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):653–6 (Eng. Abstr.) (Ger)

RADIONUCLIDE IMAGING

Technetium-99m labelled human immunoglobulin scintigraphy predicts rheumatoid arthritis in patients with arthralgia. de Bois MH, et al. **Scand J Rheumatol** 1996; 25(3):155–8

SURGERY

[Painful extensor digitorum brevis] Kuhlmann JN, et al. **Acta Orthop Belg** 1996 Jun;62(2):100–2 (Eng. Abstr.) (Fre)

[Magnetic resonance in the study of the painful shoulder. The surgical comparison in 30 consecutive cases] Della Sala SW, et al. **Radiol Med (Torino)** 1996 Apr;91(4):348–55 (Eng. Abstr.) (Ita)

THERAPY

The clinical course of shoulder pain: prospective cohort study in primary care. Primary Care Rheumatology Society Shoulder Study Group. Croft P, et al. **BMJ** 1996 Sep 7; 313(7057):601–2

Effectiveness of new push/pull hemodiafiltration for arthralgia in long-term hemodialysis patients. Shinzato T, et al. **Contrib Nephrol** 1995;112:111–8

Pulsed ultrasound treatment of the painful shoulder a randomized, double-blind, placebo-controlled study. Nykänen M. **Scand J Rehabil Med** 1995 Jun;27(2):105–8

[Conservative therapy of shoulder pain] Tilscher H. **Wien Med Wochenschr** 1996;146(6–7):138–42 (4 ref.) (Eng. Abstr.) (Ger)

ARTHRITIS

Human blood and synovial fluid neutrophils cultured in vitro undergo programmed cell death which is promoted by the addition of synovial fluid. Bell AL, et al. **Ann Rheum Dis** 1995 Nov;54(11):910–5

Translation and validation of arthritis outcome measures into Spanish. González VM, et al. **Arthritis Rheum** 1995 Oct; 38(10):1429–46

Barriers to return to work among persons unemployed due to arthritis and musculoskeletal disorders. Straaton KV, et al. **Arthritis Rheum** 1996 Jan;39(1):101–9

Single-blind randomized controlled trial of an educational booklet for patients with chronic arthritis. Maggs FM, et al. **Br J Rheumatol** 1996 Aug;35(8):775–7

Soluble forms of P-selectin and intercellular adhesion molecule-3 in synovial fluids. Hosaka S, et al. **Clin Immunol Immunopathol** 1996 Mar;78(3):276–82

Spondyloarthropathies. **Curr Opin Rheumatol** 1995 Jul; 7(4):B62–6

Predictors of motor vehicle crashes in a dementia clinic population: the role of gender and arthritis [letter] Tuokko H, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1444–5

HLA-DQ8 transgenic mice are highly susceptible to collagen-induced arthritis: a novel model for human polyarthritis. Nabozny GH, et al. **J Exp Med** 1996 Jan 1;183(1):27–37

Spondyloarthropathies of childhood. Cabral DA, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1051–70 (73 ref.)

Rapid destructive arthritis of the shoulder. Nguyen VD. **Skeletal Radiol** 1996 Feb;25(2):107–12 (44 ref.)

[Recurrent arthritis in a child. A rare manifestation of Wilson's disease] Olsen BS, et al. **Ugeskr Laeger** 1996 Jul 22;158(30):4305–6 (Eng. Abstr.) (Dan)

[Monoarthritis] Scutellari PN, et al. **Radiol Med (Torino)** 1995 Dec;90(6):689–98 (48 ref.) (Eng. Abstr.) (Ita)

BLOOD

[Blood prolactin under the effect of protirelin in spondylarthropathies. Treatment trial of 4 cases of reactive arthritis and 2 cases of psoriatic arthritis with bromocriptine] Eulry F, et al. **Ann Med Interne (Paris)** 1996;147(1):15–9 (Eng. Abstr.) (Fre)

CHEMICALLY INDUCED

Silicone gels as adjuvants. Effects on humoral and cell-mediated immune responses. Naim JO, et al. **Adv Exp Med Biol** 1995;383:1–6

Severe migratory polyarthritis following in vivo CAMPATH-1G. Varadi G, et al. **Bone Marrow Transplant** 1995 Dec;16(6):843–5

Intermittent polyarthritis due to propylthiouracil. Tosun M, et al. **Clin Rheumatol** 1995 Sep;14(5):574–5

Calcium pyrophosphate crystal deposition disease and other crystal deposition diseases. Fam AG. **Curr Opin Rheumatol** 1995 Jul;7(4):364–8 (32 ref.)

Induction of arthritis in mice and rats by potassium peroxochromate and assessment of disease activity by whole blood chemiluminescence and 99mpertechnetate-imaging. Miesel R, et al. **Free Radic Res** 1995 Sep;23(3):213–27

Type II collagen-induced arthritis in the diabetic-resistant biobreeding rat: inflammatory and histopathological features of joint pathology and effects of antiinflammatory and antirheumatic drugs on this chronic arthritic process. Smith RJ, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1801–13

Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Flory CM, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):754–8

[Polyarthritis during treatment with interferon-alpha. 2 cases (letter)] Carli P, et al. **Presse Med** 1995 Nov 25;24(36):1709 (Fre)

CLASSIFICATION

Are we making the most of the Stanford Health Assessment Questionnaire? Tennant A, et al. **Br J Rheumatol** 1996 Jun; 35(6):574–8

Proposal for the development of classification criteria for idiopathic arthritides of childhood [see comments] Fink CW. **J Rheumatol** 1995 Aug;22(8):1566–9. Comment in: J Rheumatol 1995 Aug;22(8):1445–5.

Classification criteria for childhood arthritic diseases [editorial; comment] Hochberg MC. **J Rheumatol** 1995 Aug;22(8):1445–6. Comment on: J Rheumatol 1995 Aug;22(8):1566–9.

Clinical and genetic evidence that juvenile arthritis is not a single disease. Fink CW, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1155–69 (68 ref.)

COMPLICATIONS

Haemochromatosis associated with arthritis and hypopituitarism. Wilkinson H. **Ann Clin Biochem** 1996 Mar; 33 (Pt 2):171–3

Cross-cultural adaptation of a brief outcome questionnaire for Spanish-speaking arthritis patients. Escalante A, et al. **Arthritis Rheum** 1996 Jan;39(1):93–100

Pyoderma gangrenosum in association with undifferentiated seronegative spondylarthropathy. Olivieri I, et al. **Arthritis Rheum** 1996 Jun;39(6):1062–5

Arthropathic pityriasis rubra pilaris [letter] Fiallo P, et al. **Br J Dermatol** 1996 Jun;134(6):1154–5

Skin nodules in palmar fasciitis and polyarthritis associated with carcinoma [letter; comment] Kyriazis NC. **Br J Dermatol** 1995 Aug;133(2):341–2. Comment on: Br J Dermatol 1993 Feb;128(2):194–202.

Arthritis associated with monoclonal gammapathy: clinical characteristics. Jorgensen C, et al. **Br J Rheumatol** 1996 Mar;35(3):241–3 (14 ref.)

The mystery of one red ear. Lance JW. **Clin Exp Neurol** 1994;31:13–8

An unusual case of mixed sclerosing bone dystrophy presenting with morning stiffness and joint swelling in childhood: a case report. Foeldvari I, et al. **Clin Exp Rheumatol** 1995 Jul–Aug;13(4):525–8 (19 ref.)

Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study. Moral F, et al. **Clin Exp Rheumatol** 1995 Jul–Aug; 13(4):493–5

Sacroiliitis in sarcoidosis: case reports and review of the literature. Kötter I, et al. **Clin Rheumatol** 1995 Nov; 14(6):695–700 (29 ref.)

Enteropathic arthritis, Whipple's disease, juvenile spondyloarthropathy, uveitis, and SAPHO syndrome. Leirisalo-Repo M. **Curr Opin Rheumatol** 1995 Jul; 7(4):284–9

Adult celiac disease is frequently associated with sacroiliitis. Usai P, et al. **Dig Dis Sci** 1995 Sep;40(9):1906–8

Interstitial granulomatous dermatitis with arthritis. Long D, et al. **J Am Acad Dermatol** 1996 Jun;34(6):957–61

Immunological parameters in leprosy patients with and without arthritis. Pal S, et al. **J Indian Med Assoc** 1995 Jul;93(7):266–7

Arthritis not immobilization causes bone loss in the carrageenan injection model of inflammatory arthritis. Bogoch ER, et al. **J Orthop Res** 1995 Sep;13(5):777–82

Polymyositis, arthritis, and proteinuria in a patient with adult celiac disease. Evron E, et al. **J Rheumatol** 1996 Apr; 23(4):782–3

Rheumatoid papules in a patient with acquired immune deficiency syndrome and symmetric polyarthritis. Golden BD, et al. **J Rheumatol** 1996 Apr;23(4):760–2

Detection of plantar tenosynovitis of the forefoot by ultrasound in patients with early arthritis. Koski JM. **Scand J Rheumatol** 1995;24(5):312–3

Familial Pelger-Huet anomaly accompanied by tuberculosis and complicated by acute polyarthritis. Suzuki N, et al. **Scand J Rheumatol** 1995;24(5):319–20

[Crouzon's syndrome, arthritis and crural ulcers] Alušík S. **Vnitr Lek** 1996 Jan;42(1):23–5 (Eng. Abstr.) (Cze)

[Acute febrile polyarthritis and prolonged inflammatory syndrome in a patient with acute hepatitis A (letter)] Castera L, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):847–8 (Fre)

[Changes in the gastrointestinal system of children with inflammatory systemic connective tissue diseases] Rutkowska-Sak L, et al. **Pediatr Pol** 1995 Mar;70(3):235–41 (Eng. Abstr.) (Pol)

[Primary generalized tuberculosis in children with lesions of the osteoarticular system] Vatutina VV. **Probl Tuberk** 1995; (5):52–3 (Rus)

[Arthropathy associated with parvovirus B19 infection (letter; comment)] Holgado S, et al. **Med Clin (Barc)** 1996 Mar 16;106(10):399. Comment on: Med Clin (Barc) 1995 Jan 14;104(1):22–4. (Spa)

[Multiple pseudocystic spondylodiscitis in oligoarthritis of unknown origin (letter)] Ros S, et al. **Med Clin (Barc)** 1996 Feb 24;106(7):279 (Spa)

DIAGNOSIS

A rational approach to the diagnosis of arthritis. Litman K. **Am Fam Physician** 1996 Mar;53(4):1295–300, 1305–6,

1309–10
Tuberculous arthritis of the knee presenting as a meniscal tear. Furia JP, et al. **Am J Orthop** 1996 Feb;25(2):138–42
Biologic markers of arthritis. Scher DM, et al. **Am J Orthop** 1996 Apr;25(4):263–72 (69 ref.)
The semeiology of arthritis: discriminating between patients on the basis of their symptoms. Helliwell PS. **Ann Rheum Dis** 1995 Nov;54(11):924–6
Destructive large joint arthritis [letter; comment] Richards AJ. **Ann Rheum Dis** 1996 Jan;55(1):78. Comment on: Ann Rheum Dis 1995 Aug;54(8):626–7.
The diagnostic challenge of acute polyarthritis. Wamuo IA, et al. **Ann Rheum Dis** 1996 May;55(5):284–5
A new case of polyarthritis as a presenting sign of non–Hodgkin's lymphoma [letter; comment] Mínguez C, et al. **Br J Rheumatol** 1995 Aug;34(8):794–5. Comment on: Br J Rheumatol 1994 Jan;33(1):79–84.
Fat suppressed contrast enhanced MR imaging in the assessment of sacroiliitis. Wittram C, et al. **Clin Radiol** 1996 Aug;51(8):554–8
Pyogenic sacro–iliitis, a rare cause of peripartum pelvic pain. Engelsbel S, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):125–6
Posterolateral arthritis of the knee. Stubbs BT. **J Arthroplasty** 1995 Aug;10(4):427–32
A comparison of MR and CT in suspected sacroiliitis. Wittram C, et al. **J Comput Assist Tomogr** 1996 Jan–Feb; 20(1):68–72
Intra–articular osteoid osteoma of the humerus with synovitis simulating chronic monoarthritis of the elbow in a recreational tennis player. Sanchis–Alfonso V, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(1):45–6
Modified birdcage coils for targeted imaging. Gasson J, et al. **Magn Reson Imaging** 1995;13(7):1003–12
Magnetic resonance imaging of arthritides affecting the shoulder. Ferraro FA, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):157–70 (76 ref.)
Comparison between scintigraphy with polyclonal immunoglobulin (99Tcm–HIG) and physical examination in polyarthritic disease. Vesterskiöld L, et al. **Scand J Rheumatol** 1996;25(3):159–63
[Diagnosis and course of early arthritis; study in a specialized clinic for early arthritis] Speyer I, et al. **Ned Tijdschr Geneeskd** 1996 Apr 20;140(16):882–5 (Eng. Abstr.) **(Dut)**
[A case from practice (341). 1. HLA–B27–negative ankylosing spondylitis (Bechterew's disease)—sacroiliitis, right–sided leg length shortening of about 1 cm, left convex thoracic scoliosis. 2. Chronic bronchitis—chronic nicotine abuse of about 10–pack year. 3. Normochromic, normocytic anemia at time of diagnosis] Lorz W. **Schweiz Rundsch Med Prax** 1996 Jan 30;85(5):133–6 **(Ger)**
[The shoulder joint—diagnostic imaging] Imhof H, et al. **Wien Med Wochenschr** 1996;146(6–7):116–20 (24 ref.) (Eng. Abstr.) **(Ger)**
[Lésniowski–Crohn disease and ulcerative colitis in the pediatric clinic of rheumatology] Rutkowska–Sak L. **Pediatr Pol** 1995 Mar;70(3):231–4 (Eng. Abstr.) **(Pol)**
[Jaccoud's arthropathy] Shostak NA. **Ter Arkh** 1995; 67(11):80–3 (26 ref.) (Eng. Abstr.) **(Rus)**
[Reiter's disease as the source of errors in the diagnosis of traumatic arthritis] Il'in II, et al. **Vestn Khir Im I I Grek** 1995;154(2):74–6 **(Rus)**
[Immunoglobulin E and beta 2–microglobulin in the blood serum and synovial fluid of patients with rheumatoid arthritis, arthrosis deformans and traumatic arthritis] Nefko IeM, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):127–9 **(Ukr)**

DIET THERAPY

Diet and arthritis. Cleland LG, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):771–85 (43 ref.)

DRUG THERAPY

The effect on joint fluid concentration of neuropeptide Y by intra–articular injection of glucocorticoid in temporomandibular joint arthritis. Alstergren P, et al. **Acta Odontol Scand** 1996 Feb;54(1):1–7
The anti–inflammatory effects of Chinese crude drug prescriptions on experimental arthritis. Lin CC, et al. **Am J Chin Med** 1995;23(2):145–52
Somatostatin–induced modulation of inflammation in experimental arthritis. Matucci–Cerinic M, et al. **Arthritis Rheum** 1995 Nov;38(11):1687–93
The antiinflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis. Ornstein MH, et al. **Arthritis Rheum** 1996 Jan; 39(1):157–61
Oral administration of type II collagen suppresses non–specifically induced chronic arthritis in rats. Yoshino S. **Biomed Pharmacother** 1996;50(1):24–8
Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non–steroidal anti–inflammatory drugs. Smith G, et al. **Br J Rheumatol** 1996 May;35(5):458–62
The effects of interleukin–1 receptor antagonist on oxidant–induced arthritis in mice. Miesel R, et al. **Clin Exp Rheumatol** 1995 Sep–Oct;13(5):595–601
Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study. Moral F, et al. **Clin Exp Rheumatol** 1995 Jul–Aug; 13(4):493–5
Experience with low–dose methotrexate: toxicity, tolerability and effect on conventional patterns of drug therapy for inflammatory arthritis. Nisar M, et al. **Clin Rheumatol** 1995 Sep;14(5):544–50
Enteropathic arthritis, Whipple's disease, juvenile spondyloarthropathy, uveitis, and SAPHO syndrome. Leirisalo–Repo M. **Curr Opin Rheumatol** 1995 Jul; 7(4):284–9
Arthrotec, diclofenac and ibuprofen in general practice. Kiff PS, et al. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):31–8
A review on the strategies for the development and application of new anti–arthritic agents. Lewis AJ, et al. **Immunopharmacol Immunotoxicol** 1995 Nov;17(4):607–63 (272 ref.)
CT–guided intraarticular corticosteroid injection into the sacroiliac joints in patients with spondyloarthropathy: indication and follow–up with contrast–enhanced MRI. Bollow M, et al. **J Comput Assist Tomogr** 1996 Jul–Aug; 20(4):512–21
Oral administration of an immunodominant human collagen peptide modulates collagen–induced arthritis. Khare SD, et al. **J Immunol** 1995 Oct 1;155(7):3653–9
Isradipine, a calcium–channel antagonist, has immunosuppressor activity on T lymphocytes from peripheral blood and synovial fluid from patients with autoimmune arthritis. Guillen C, et al. **J Immunother Emphasis Tumor Immunol** 1995 Jul; 18(1):66–74
Type II collagen–induced arthritis in the diabetic–resistant biobreeding rat: inflammatory and histopathological features of joint pathology and effects of antiinflammatory and antirheumatic drugs on this chronic arthritic process. Smith RJ, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1801–13
Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. Braun J, et al. **J Rheumatol** 1996 Apr;23(4):659–64
Sensory denervation with capsaicin attenuates inflammation and nociception in arthritic rats. Cruwys SC, et al. **Neurosci Lett** 1995 Jul 7;193(3):205–7
Availability of over–the–counter drugs for arthritis in Sao Paulo, Brazil. Ferraz MB, et al. **Soc Sci Med** 1996 Apr; 42(8):1129–31
[Cortisone injection into the sacroiliac joint] Bellaïche L. **Ann Radiol (Paris)** 1995;38(4):192–5 (Eng. Abstr.) **(Fre)**
[Intra–articular morphine versus steroid administration to the acutely painful joint in gonarthrosis and arthritis (letter)] Stein A, et al. **Dtsch Med Wochenschr** 1996 Feb 23; 121(8):255 **(Ger)**

ENZYMOLOGY

Proteinases and inhibitors. Cawston TE. **Br Med Bull** 1995 Apr;51(2):385–401 (65 ref.)
Phospholipase A2 inhibitors: a challenge for the future. Berenbaum F. **Rev Rhum Engl Ed** 1995 Jun;62(6):409–14 (45 ref.)

EPIDEMIOLOGY

Predictive factors of severity of spondyloarthropathy in North Africa. Claudepierre P, et al. **Br J Rheumatol** 1995 Dec;34(12):1139–45
Factors associated with prevalent self–reported arthritis and other rheumatic conditions—United States, 1989–1991. **MMWR Morb Mortal Wkly Rep** 1996 Jun 14;45(23):487–91
Absence of an association between rubella vaccination and arthritis in underimmune postpartum women. Slater PE, et al. **Vaccine** 1995 Nov;13(16):1529–32

ETHNOLOGY

Prevalence and impact of arthritis by race and ethnicity—United States, 1989–1991. **MMWR Morb Mortal Wkly Rep** 1996 May 10;45(18):373–8

ETIOLOGY

Arthritis and hypergammaglobulinemic purpura in hypersensitivity pneumonitis. Oosterkamp HM, et al. **Am J Med** 1996 Apr;100(4):478–9
Crystal–induced arthritis: an overview. Schumacher HR. **Am J Med** 1996 Feb 26;100(2A):46S–52S (22 ref.)
Subcutaneous nodules in a patient with polyarthritis. Le CH, et al. **Ann Rheum Dis** 1995 Oct;54(10):796–7
Possible role of inducible nitric oxide synthase in articular chondrocytes in the pathogenesis of arthritic swelling [letter; comment] [see comments] Ahlqvist J, et al. **Arthritis Rheum** 1995 Oct;38(10):1529–31. Comment on: Arthritis Rheum 1993 Aug;36(8):1036–44. Comment in: Arthritis Rheum 1996 Jun;39(6):1071–2.
Possible role of bone marrow fat in the development of an inflammatory response to sickled erythrocytes: comment on the article by Mann and Schumacher [letter; comment] McCarty DJ, et al. **Arthritis Rheum** 1995 Sep;38(9):1349–50 . Comment on: Arthritis Rheum 1995 Feb;38(2):284–7.
Subcutaneous fat necrosis following traumatic pancreatitis. Lee MS, et al. **Australas J Dermatol** 1995 Nov;36(4):196–8
Identification of a cyanogen bromide fragment of porcine type II collagen capable of modulating collagen arthritis in B10.RIII (H–2r) mice. Nabozny GH, et al. **Autoimmunity** 1995;20(1):39–49
Altered development of collagen induced arthritis in T cell receptor V beta congenic B10.RIII mice. Nabozny GH, et al. **Autoimmunity** 1995;20(1):51–8
Human models: Whipple's disease, coeliac disease and jejunoileal bypass. Utsinger PD, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):77–103 (129 ref.)
Arthritis in scleroderma. Misra R, et al. **Br J Rheumatol** 1995 Sep;34(9):831–7
Chronic polyarthritis and graft–versus–host disease [letter] Naranjo–Hernández A, et al. **Br J Rheumatol** 1996 Mar; 35(3):297–8
Acute reactive polyarthritis after intravesical bacillus Calmette–Guèrin instillation. Hammadeh MY, et al. **Br J Urol** 1995 Dec;76(6):811–2
Role of mast cells in arthritis. Arnason JA, et al. **Chem Immunol** 1995;62:204–38 (279 ref.)
Cytotoxic T lymphocytes specific for murine type II collagen do not trigger arthritis in B10 mice. Gao XM, et al. **Clin Exp Immunol** 1996 Jan;103(1):89–93
Successful induction of severe destructive arthritis by the transfer of in vitro–activated synovial fluid T cells from patients with rheumatoid arthritis (RA) in severe combined immunodeficient (SCID) mice. Sakata A, et al. **Clin Exp Immunol** 1996 May;104(2):247–54
Erosive polyarthritis as presenting manifestation of Wegener's granulomatosis. ter Borg EJ, et al. **Clin Rheumatol** 1995 Sep;14(5):551–3
The adolescent with arthritis. Lindsley CB. **Compr Ther** 1996 Jan;22(1):48–51 (7 ref.)
Metabolic and endocrine disease and arthritis. Matteucci BM. **Curr Opin Rheumatol** 1995 Jul;7(4):356–8 (8 ref.)
Induction of type II collagen arthritis in the DA rat using silicone gel as adjuvant. Naim JO, et al. **Curr Top Microbiol Immunol** 1996;210:103–11
A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Taylor GA, et al. **Immunity** 1996 May;4(5):445–54
Different effect of cyclosporin A on arthritides induced by a muramyl dipeptide analogue or the complete adjuvant in rats. Sugawara T, et al. **Int J Exp Pathol** 1995 Jun; 76(3):191–9
Collagen–induced arthritis in CD4– or CD8–deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen–induced arthritis. Tada Y, et al. **J Immunol** 1996 Jun 1;156(11):4520–6
Femoral anteversion in arthritis of the knee [letter; comment] Bernstein RM. **J Pediatr Orthop** 1995 Sep–Oct;15(5):700. Comment on: J Pediatr Orthop 1994 Sep–Oct;14(5):608–10.
Symptomatic unilateral sacroiliitis in systemic lupus erythematosus [letter] Lee SS. **Lupus** 1995 Aug;4(4):328–9
Chronic arthropathy and rectal bleeding in a long–term haemodialysis patient. Zingraff J, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2153–5
Acute polyarthritis after BCG–therapy for bladder carcinoma in a patient with ankylosing spondylitis. Thepot C, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):459–61
Our experience with Lyme arthritis. Szechiński J, et al. **Rocz Akad Med Bialymst** 1996;41(1):69–77
Acute sarcoid arthritis: a favourable outcome? A retrospective survey of 49 patients with review of the literature. Gran JT, et al. **Scand J Rheumatol** 1996; 25(2):70–3 (23 ref.)
[Parvovirus B19 infection. New physiopathological approaches] Labau E, et al. **Presse Med** 1996 Feb 3; 25(4):162–6 (26 ref.) (Eng. Abstr.) **(Fre)**
[Paraneoplastic seropositive polyarthritis (letter)] Olive P, et al. **Rev Med Interne** 1995;16(11):865 **(Fre)**
[Rheumatic involvement in Hansen's disease] Cossermelli–Messina W, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Mar–Apr; 50(2):107–10 (50 ref.) (Eng. Abstr.) **(Por)**

GENETICS

Genes and arthritis. Wordsworth P. **Br Med Bull** 1995 Apr; 51(2):249–66 (63 ref.)
A genome scan localizes five non–MHC loci controlling collagen–induced arthritis in rats. Remmers EF, et al. **Nat Genet** 1996 Sep;14(1):82–5
[Blau syndrome or familial form of sarcoidosis with onset during infancy] Moraillon I, et al. **Ann Dermatol Venereol** 1996;123(1):29–30 (Eng. Abstr.) **(Fre)**

HISTORY

'Arthritis' in Byzantium (AD 324–1453): unknown information from non–medical literary sources. Lascaratos J. **Ann Rheum Dis** 1995 Dec;54(12):951–7
Did the model for Polyphemus have acromegalic arthritis? [letter] Denko CW. **J Rheumatol** 1995 Nov;22(11):2191–2
William Musgrave's (1655–1721) system of arthritides. Did it include rheumatoid arthritis? Hansen SE. **Scand J Rheumatol** 1995;24(5):274–8

IMMUNOLOGY

Defective dendritic cell (DC) function in a HLA–B27 transgenic rat model of spondyloarthropathy (SpA). Stagg

AJ, et al. **Adv Exp Med Biol** 1995;378:557-9
Improved isolation of dendritic cells in chronic arthritic joints reveals no B7 (CD80) surface expression. Summers KL, et al. **Adv Exp Med Biol** 1995;378:561-3
Nitric oxide in inflammation and immune response. Moilanen E, et al. **Ann Med** 1995 Jun;27(3):359-67 (119 ref.)
Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. Gelpi C, et al. **Arthritis Rheum** 1996 Apr;39(4):692-7
Type XI and II collagen-induced arthritis in rats: characterization of inbred strains of rats for arthritis-susceptibility and immune-responsiveness to type XI and II collagen. Cremer MA, et al. **Autoimmunity** 1995; 20(3):153-61
Animal models of intestinal and joint inflammation. Sartor RB, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):55-76 (54 ref.)
Antineutrophil cytoplasmic antibodies in inflammatory arthritis--potential for misdiagnosis? Helsloot J, et al. **Br J Rheumatol** 1995 Sep;34(9):820-4
Cytotoxic T lymphocytes specific for murine type II collagen do not trigger arthritis in B10 mice. Gao XM, et al. **Clin Exp Immunol** 1996 Jan;103(1):89-93
Crohn's disease (CD) patients suffering from peripheral arthritis or ankylosing spondylitis reveal restricted T cell receptor V beta regions in different temporal phases of disease. Lügering N, et al. **Clin Exp Immunol** 1996 Aug; 105(2):278-84
Successful induction of severe destructive arthritis by the transfer of in vitro-activated synovial fluid T cells from patients with rheumatoid arthritis (RA) in severe combined immunodeficient (SCID) mice. Sakata A, et al. **Clin Exp Immunol** 1996 May;104(2):247-54
Superantigen-mediated proliferation and cytotoxicity of T cells isolated from the inflammatory tissues and peripheral blood of arthritis patients. Li S, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):278-87
Variable-region gene family usage for type II collagen autoantibodies in arthritis-susceptible DBA/1 mice. Ye XJ, et al. **Clin Immunol Immunopathol** 1996 Mar;78(3):263-75
Role of HLA-B27 in spondyloarthropathies. Khare SD, et al. **Curr Top Microbiol Immunol** 1996;206:85-100 (77 ref.)
H2-A polymorphism contributes to H2-Ebeta-mediated protection in collagen-induced arthritis. Gonzalez-Gay MA, et al. **Immunogenetics** 1996;44(5):377-84
Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo. Leroux JY, et al. **J Clin Invest** 1996 Feb 1;97(3):621-32
Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. Otani K, et al. **J Immunol** 1996 May 1; 156(9):3558-62
"The good, the bad, and the ugly." The role of chemokines in models of human disease. Strieter RM, et al. **J Immunol** 1996 May 15;156(10):3583-6 (33 ref.)
Collagen-induced arthritis in CD4- or CD8-deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis. Tada Y, et al. **J Immunol** 1996 Jun 1;156(11):4520-6
Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. Georgopoulos S, et al. **J Inflamm** 1996;46(2):86-97
Autoimmune arthritis caused by Candida septic arthritis. Rovinsky D, et al. **J Shoulder Elbow Surg** 1995 Nov-Dec; 4(6):472-6
Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations. Schultz DR, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):143-59 (120 ref.)
[Joint and systemic manifestations related to type 2 anti-mitochondrial antibodies] Dhôte R, et al. **Ann Med Interne (Paris)** 1995;146(8):536-40 (31 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Hyaluronan in inflammatory joint disease. Laurent TC, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:116-20 (39 ref.)
Synovial fluid and serum concentrations of aminoterminal propeptide of type III procollagen in healthy volunteers and patients with joint disease. Sharif M, et al. **Ann Rheum Dis** 1996 Jan;55(1):47-51
Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with osteoarthritis or rheumatoid arthritis. Takahashi M, et al. **Ann Rheum Dis** 1996 May; 55(5):324-7
The synthesis of collagenase, gelatinase-A (72 kDa) and -B (95 kDa), and TIMP-1 and -2 by human osteoblasts from normal and arthritic bone. Meikle MC, et al. **Bone** 1995 Sep;17(3):255-60
Calcitonin gene related peptide gene expression in collagen-induced arthritis. Weihe E, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1015-9
Expression of mammalian 60-kD heat shock protein in the joints of mice with pristane-induced arthritis. Barker RN, et al. **Clin Exp Immunol** 1996 Jan;103(1):83-8
Oil-induced arthritis in DA rats: tissue distribution of arthritogenic 14C-labelled hexadecane. Kleinau S, et al. **Int J Immunopharmacol** 1995 May;17(5):393-401
Lipopolysaccharide binding protein as a marker of inflammation in synovial fluid of patients with arthritis: correlation with interleukin 6 and C-reactive protein. Heumann D, et al. **J Rheumatol** 1995 Jul;22(7):1224-9
Adhesion molecule in untreated inflammatory arthritis. Mulherin DM, et al. **QJM** 1996 Mar;89(3):195-203
The accuracy of MRI-determined synovial membrane and joint effusion volumes in arthritis. A comparison of pre- and post-aspiration volumes. Ostergaard M, et al. **Scand J Rheumatol** 1995;24(5):305-11

MICROBIOLOGY

Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. Rath HC, et al. **J Clin Invest** 1996 Aug 15;98(4):945-53

MORTALITY

Rheumatoid factor, chronic arthritis and mortality. Heliövaara M, et al. **Ann Rheum Dis** 1995 Oct;54(10):811-4

PATHOLOGY

Animal models of intestinal and joint inflammation. Sartor RB, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):55-76 (54 ref.)
Joints count: a review of old and new articular indices of joint inflammation [editorial] Thompson PW, et al. **Br J Rheumatol** 1995 Nov;34(11):1003-7
Radiographic assessment of the trapezial space before and after ligament reconstruction and tendon interposition arthroplasty. Kadiyala RK, et al. **J Hand Surg [Br]** 1996 Apr;21(2):177-81

PHYSIOPATHOLOGY

Cerebral mechanisms operating in the presence and absence of inflammatory pain. Jones AK, et al. **Ann Rheum Dis** 1996 Jul;55(7):411-20 (83 ref.)
More on vasodilatation, joint swelling, and nitric oxide [letter; comment] Ahlqvist J. **Arthritis Rheum** 1996 Jun; 39(6):1071-2. Comment on: Arthritis Rheum 1995 Oct;38(10):1529-31.
Neurogenic influences on contralateral responses during experimental rat monoarthritis. Kidd BL, et al. **Brain Res** 1995 Aug 7;688(1-2):72-6
Involvement of H1 receptors in the central antinociceptive effect of histamine: pharmacological dissection by electrophysiological analysis. Braga PC, et al. **Experientia** 1996 Jan 16;52(1):60-5
The relationship of joint symptoms with exercise performance in older adults. Coleman EA, et al. **J Am Geriatr Soc** 1996 Jan;44(1):14-21
Bisphosphonate (pamidronate/APD) prevents arthritis-induced loss of fracture toughness in the rabbit femoral diaphysis. Bellingham CM, et al. **J Orthop Res** 1995 Nov;13(6):876-80
[Capsaicin for arthritic pain] Niv D, et al. **Harefuah** 1996 Mar 15;130(6):415-20 (43 ref.) **(Heb)**

PREVENTION & CONTROL

A single intra-articular injection of liposomally conjugated methotrexate suppresses joint inflammation in rat antigen-induced arthritis. Williams AS, et al. **Br J Rheumatol** 1996 Aug;35(8):719-24
Oxpentifylline inhibits tumor necrosis factor-alpha mRNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats. Kiely PD, et al. **Eur J Immunol** 1995 Oct;25(10):2899-906
Immunization with T cell receptor V beta chain peptides deletes pathogenic T cells and prevents the induction of collagen-induced arthritis in mice. Haqqi TM, et al. **J Clin Invest** 1996 Jun 15;97(12):2849-58
Vaccination with a recombinant V alpha domain of a TCR prevents the development of collagen-induced arthritis. Rosloniec EF, et al. **J Immunol** 1995 Nov 1;155(9):4504-11

PSYCHOLOGY

Activity participation and well-being among older people with arthritis. Zimmer Z, et al. **Gerontologist** 1995 Aug; 35(4):463-71
The effect of arthritis on the quality of life in hereditary hemochromatosis. Adams PC, et al. **J Rheumatol** 1996 Apr; 23(4):707-10
Development and initial validation of a scale to measure self-efficacy beliefs in patients with chronic pain. Anderson KO, et al. **Pain** 1995 Oct;63(1):77-84
Evaluation of a Swedish version of the arthritis self-efficacy scale in people with fibromyalgia. Lomi C, et al. **Scand J Rheumatol** 1995;24(5):282-7

RADIOGRAPHY

Asymptomatic sacroiliitis in inflammatory bowel disease. Assessment by computed tomography. McEniff N, et al. **Clin Imaging** 1995 Oct-Dec;19(4):258-62
A comparison of MR and CT in suspected sacroiliitis. Wittram C, et al. **J Comput Assist Tomogr** 1996 Jan-Feb; 20(1):68-72
Metastatic adenocarcinoma mimicking unilateral sacroiliitis. Humphrey SM, et al. **J Rheumatol** 1995 May;22(5):970-2
[Computed tomography of the sacroiliac joints] Miquel A, et al. **Ann Radiol (Paris)** 1995;38(4):177-85 (28 ref.) **(Fre)**

RADIONUCLIDE IMAGING

Significance of sacroiliac index in diagnostics of seronegative spondyloarthropathies. Pavlića L, et al. **Med Pregl** 1993; 46 Suppl 1:45-7

RADIOTHERAPY

A survey of radiation synovectomy in Europe, 1991-1993. Clunie G, et al. **Eur J Nucl Med** 1995 Sep;22(9):970-6

REHABILITATION

Assistive devices used by home-based elderly persons with arthritis. Mann WC, et al. **Am J Occup Ther** 1995 Sep; 49(8):810-20

SURGERY

The Harris-Galante cementless femoral component: poor results in 57 hips followed for 3 years. de Nies F, et al. **Acta Orthop Scand** 1996 Apr;67(2):122-4
Polyethylene wear in Scanhip arthroplasty with a 22 or 32 mm head: 62 matched patients followed for 7-9 years. Kesteris U, et al. **Acta Orthop Scand** 1996 Apr;67(2):125-7
Pain reduction after anteromedial displacement of the tibial tuberosity: 5-year follow-up in 21 knees with patellofomoral arthrosis. Sakai N, et al. **Acta Orthop Scand** 1996 Feb;67(1):13-5
Treatment of painful basal joint arthritis of the thumb [letter] Hough G 3rd. **Am J Orthop** 1995 Oct;24(10):790
Femoral head bone grafting for reconstruction of the acetabular wall in dysplastic hip replacement. Hartwig CH, et al. **Arch Orthop Trauma Surg** 1995;114(5):269-73
Evolution of the quadriceps snip. Garvin KL, et al. **Clin Orthop** 1995 Dec;(321):131-7
Ankle arthrodesis: results after the miniarthrotomy technique. Paremain GD, et al. **Foot Ankle Int** 1996 May;17(5):247-52
Surgical treatment of arthritic valgus knee: femoral supracondylar osteotomy or knee replacement? Berruto M, et al. **Ital J Orthop Traumatol** 1993;19(1):33-41
First carpometacarpal joint arthritis. A comparison of two arthroplasty techniques. Livesey JP, et al. **J Hand Surg [Br]** 1996 Apr;21(2):182-8
Results of scaphotrapeziotrapezoid fusion for isolated idiopathic arthritis. Srinivasan VB, et al. **J Hand Surg [Br]** 1996 Jun;21(3):378-80
Complications of office based arthroscopy of the knee. Szachnowski P, et al. **J Rheumatol** 1995 Sep;22(9):1722-5
Significance of laser treatment in arthroscopic therapy of degenerative gonarthritis. A prospective, randomised clinical study and experimental research. Grifka J, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):88-93
Arthroscopic treatment of the flexed arthritic knee in active middle-aged patients. Puddu G, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):73-5
Results of surgical correction of kyphotic deformities of the spine in ankylosing spondylitis on the basis of the modified arthritis impact measurement scales. Halm H, et al. **Spine** 1995 Jul 15;20(14):1612-9
[Laser-assisted induction of arthrosis] Raunest J, et al. **Orthopade** 1996 Feb;25(1):10-6 (Eng. Abstr.) **(Ger)**

THERAPY

Progress toward the treatment of arthritis by gene therapy. Evans CH, et al. **Ann Med** 1995 Oct;27(5):543-6
Successful application of high dose intravenous immunoglobulins in Sjögren's syndrome associated arthritis [letter] Zeuner RA, et al. **Ann Rheum Dis** 1995 Nov; 54(11):936
Psycho-educational interventions in the treatment of arthritis. Hawley DJ. **Baillieres Clin Rheumatol** 1995 Nov; 9(4):803-23 (46 ref.)
Home exercises and out-patient hydrotherapy [letter; comment] Becker BE. **Br J Rheumatol** 1995 Oct; 34(10):991-2. Comment on: Br J Rheumatol 1993 Sep;32(9):812-5.
The role of the rheumatology nurse practitioner in primary care: an experiment in the further education of the practice nurse. Grahame R, et al. **Br J Rheumatol** 1996 Jun; 35(6):581-8
Patient education: treatment or nice extra [editorial] Lorig K. **Br J Rheumatol** 1995 Aug;34(8):703-4
Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. Otani K, et al. **J Immunol** 1996 May 1; 156(9):3558-62
Gene therapy and arthritis [editorial] Doherty PJ. **J Rheumatol** 1995 Jul;22(7):1220-3
Effects of continuous passive motion and immobilization on synovitis and cartilage degradation in antigen induced arthritis. Kim HK, et al. **J Rheumatol** 1995 Sep; 22(9):1714-21
Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Mikecz K, et al. **Nat Med** 1995 Jun;1(6):558-63
[Experimental bases for photodynamic laser therapy in chronic polyarthritis] Hendrich C, et al. **Orthopade** 1996 Feb;25(1):30-6 (Eng. Abstr.) **(Ger)**
[Conservative therapy of shoulder pain] Tilscher H. **Wien Med Wochenschr** 1996;146(6-7):138-42 (4 ref.) (Eng. Abstr.) **(Ger)**
[The measurement of outcomes in chronic pathology. Its application to arthritis] Zeni L. **Minerva Med** 1995 May; 86(5):215-22 (35 ref.) **(Ita)**

ARTHRITIS

ULTRASONOGRAPHY

[Ultrasound examination of the shoulder joint] Lick-Schiffer W. **Wien Med Wochenschr** 1996;146(6-7):121-3 (11 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Hyaluronate and large molecular weight proteoglycans in synovial fluid from horses with various arthritides. Tulamo RM, et al. **Am J Vet Res** 1996 Jun;57(6):932-7

Induction of intra-articular tumour necrosis factor during acute inflammatory responses in equine arthritis [see comments] Billinghurst RC, et al. **Equine Vet J** 1995 May; 27(3):208-16. Comment in: Equine Vet J 1995 May;27(3):160-1.

Comparison of polysulphated glycosaminoglycan and sodium hyaluronate with placebo in treatment of traumatic arthritis in horses. Gaustad G, et al. **Equine Vet J** 1995 Sep; 27(5):356-62

Tumour necrosis factor, equine arthritis and clinical research [editorial; comment] May SA. **Equine Vet J** 1995 May; 27(3):160-1. Comment on: Equine Vet J 1995 May;27(3):208-16.

Femoral head and neck excision in a dog that had previously undergone contralateral hind limb amputation. Carpenter LG, et al. **J Am Vet Med Assoc** 1996 Mar 1;208(5):695-6

Is there an epidemic/epizootic of spondyloarthropathy in baboons? [letter] Rothschild BM, et al. **J Med Primatol** 1996 Jan;25(1):69-70

VIROLOGY

Polymyositis, arthritis, and uveitis in a macaque experimentally infected with human T lymphotropic virus type I. Beilke MA, et al. **Arthritis Rheum** 1996 Apr; 39(4):610-5

Mosquito-borne viruses and epidemic polyarthritis. Mackenzie JS, et al. **Med J Aust** 1996 Jan 15;164(2):90-3 (21 ref.)

ARTHRITIS, ADJUVANT

BLOOD

Metallothionein induction in cultured rat hepatocytes by arthritic rat serum, activated macrophages, interleukin-6, interleukin-11 and leukaemia inhibitory factor. Coyle P, et al. **Inflamm Res** 1995 Nov;44(11):475-81

[The relationship between antipyrine kinetics, the seromucoid content and the xanthine oxidase activity in the plasma of rats with acute and chronic inflammation] Lutsevich AN, et al. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):51-5 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Intra-articular injection of stromelysin into rabbit knees as a model to evaluate matrix metalloprotease inhibitors. Goldberg RL, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S115-6

COMPLICATIONS

Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. McCafferty DM, et al. **Gastroenterology** 1995 Oct;109(4):1173-80

[Action of sodium oxybutyrate in pain syndromes] Daniloova EI, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):395-8 **(Rus)**

DIAGNOSIS

A quantitative one-dimensional magnetic resonance imaging technique in adjuvant arthritis: the assessment of disease progression and indomethacin efficacy. Borah B, et al. **J Rheumatol** 1995 May;22(5):855-62

DRUG THERAPY

Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Multiparameter analysis of disease magnetic resonance imaging and bone mineral density measurements. Bradbeer JN, et al. **Arthritis Rheum** 1996 Mar;39(3):504-14

Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Kinne RW, et al. **Arthritis Rheum** 1995 Dec;38(12):1777-90

Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Walmsley M, et al. **Arthritis Rheum** 1996 Mar;39(3):495-503

The effect of minocycline in rat models of inflammatory arthritis: correlation of arthritis suppression with enhanced T cell calcium flux. Sewell KL, et al. **Cell Immunol** 1996 Feb 1;167(2):195-204

A synthetic 10-kD heat shock protein (hsp10) from Mycobacterium tuberculosis modulates adjuvant arthritis. Ragno S, et al. **Clin Exp Immunol** 1996 Mar;103(3):384-90

Therapeutic effects of estradiol benzoate on development of collagen-induced arthritis (CIA) in the Lewis rat are mediated via suppression of the humoral response against denatured collagen type II (CII). Waksman Y, et al. **Clin Exp Immunol** 1996 Mar;103(3):376-83

Differential effects of methotrexate and liposomally conjugated methotrexate in rat adjuvant-induced arthritis. Williams AS, et al. **Clin Exp Immunol** 1995 Dec; 102(3):560-5

Inhibitory properties of triethylphosphine goldlupinylsulfide in adjuvant-induced arthritis in rats. Ghia M, et al. **Farmaco** 1995 Sep;50(9):601-4

Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. Engelhardt G, et al. **Inflamm Res** 1995 Dec; 44(12):548-55

Effect of clodronate on established collagen-induced arthritis in rats. Osterman T, et al. **Inflamm Res** 1995 Jun; 44(6):258-63

The influence of a peptide sequence from PF-4 (CT-112) on type II collagen-induced arthritis in mice. Wooley PH, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S125-6

Combined treatment with ren-shen-yang-rong-tang (Japanese name: ninjin-youei-to) plus prednisolone on adjuvant-induced arthritis in Lewis rat. Harigai E, et al. **Int J Immunopharmacol** 1995 May;17(5):411-8

Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis. Ueno M, et al. **Int J Immunopharmacol** 1995 Jul;17(7):597-603

Antiinflammatory activity of a Ghanaian antiarthritic herbal preparation: III. Kweifio-Okai G, et al. **J Ethnopharmacol** 1995 Apr;46(1):7-15

Effect of oleanolic acid on complement in adjuvant- and carrageenan-induced inflammation in rats. Kapil A, et al. **J Pharm Pharmacol** 1995 Jul;47(7):585-7

Tenidap and flurbiprofen enhance uptake of matrix metalloproteinase inhibitor 4-dedimethylaminotetracycline in inflamed joints of adjuvant arthritic rats. Leung MK, et al. **J Rheumatol** 1995 Sep;22(9):1726-31

Anti-inflammatory effect of flurbiprofen tape applied percutaneously to rats with adjuvant-induced arthritis. Uchida S, et al. **Jpn J Pharmacol** 1995 Sep;69(1):37-41

Neuropeptide Y- and vasoactive intestinal polypeptide-like immunoreactivity in adjuvant arthritis: effects of capsaicin treatment. Ahmed M, et al. **Neuropeptides** 1995 Jul; 29(1):33-43

ENZYMOLOGY

Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Kang RY, et al. **Br J Rheumatol** 1996 Aug;35(8):711-8

ETIOLOGY

Arthritis in mice induced by a single immunisation with collagen. Kato F, et al. **Ann Rheum Dis** 1996 Aug; 55(8):535-9

Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Mauri C, et al. **Eur J Immunol** 1996 Jul;26(7):1511-8

Induction of type II collagen arthritis in the DA rat using silicone gels and oils as adjuvant. Naim JO, et al. **J Autoimmun** 1995 Oct;8(5):751-61

GENETICS

Restricted expression of T cell receptor V beta and lymphokine genes in arthritic joints of a TCR V beta a (H-2q) mouse strain-BUB/BnJ-with collagen-induced arthritis. Haqqi TM, et al. **Autoimmunity** 1995;20(3):163-70

HLA-DQ8 transgenic mice are highly susceptible to collagen-induced arthritis: a novel model for human polyarthritis. Nabozny GH, et al. **J Exp Med** 1996 Jan 1;183(1):27-37

Adrenal medullary grafts suppress c-fos induction in spinal neurons of arthritic rats. Sagen J, et al. **Neurosci Lett** 1995 Jun 16;192(3):181-4

IMMUNOLOGY

Tolerance to an arthritogenic T-cell epitope of HSP65 and the regulation of experimental arthritis. Prakken BJ, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:425-6

Arthritis: animal models of oral tolerance. Staines NA, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:297-305 (14 ref.)

Polyarthritis in the rat: effects of tolerance and sensitization to the bacterial extract OM-89 with a possible mode of action. Willis D, et al. **Br J Rheumatol** 1995 Dec; 34(12):1135-8

Treatment with an anti-CD4 monoclonal antibody strongly ameliorates established rat adjuvant arthritis. Pelegrí C, et al. **Clin Exp Immunol** 1996 Feb;103(2):273-8

Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Staines NA, et al. **Clin Exp Immunol** 1996 Mar;103(3):368-75

Therapeutic effects of estradiol benzoate on development of collagen-induced arthritis (CIA) in the Lewis rat are mediated via suppression of the humoral response against denatured collagen type II (CII). Waksman Y, et al. **Clin Exp Immunol** 1996 Mar;103(3):376-83

High doses of interleukin-12 inhibit the development of joint disease in DBA/1 mice immunized with type II collagen in complete Freund's adjuvant. Hess H, et al. **Eur J Immunol** 1996 Jan;26(1):187-91

Identification and characterization of a major tolerogenic T-cell epitope of type II collagen that suppresses arthritis in B10.RIII mice. Miyahara H, et al. **Immunology** 1995 Sep; 86(1):110-5

Immunomodulating effects of the new anti-rheumatic drug tenidap on collagen-induced arthritis. Matsushita I, et al. **Int J Immunopharmacol** 1995 Mar;17(3):213-9

Systemic versus cartilage-specific expression of a type II collagen-specific T-cell epitope determines the level of tolerance and susceptibility to arthritis. Malmström V, et al. **Proc Natl Acad Sci U S A** 1996 Apr 30;93(9):4480-5

METABOLISM

Local expression of corticotropin-releasing hormone in inflammatory arthritis. Crofford LJ, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:459-71 (63 ref.)

IL-1 has no direct role in the IGF-1 non-responsive state during experimentally induced arthritis in mouse knee joints. Verschure PJ, et al. **Ann Rheum Dis** 1995 Dec; 54(12):976-82

Cellular adhesion molecules in rat adjuvant arthritis. Halloran MM, et al. **Arthritis Rheum** 1996 May;39(5):810-9

Significant changes in neuropeptide concentrations in the brain of normotensive (WKY) and spontaneously hypertensive (SHR) rats following knee joint monoarthritis. Bileviciute I, et al. **Brain Res** 1995 Dec 15;704(1):71-8

Chronic arthritis increases tyrosine hydroxylase mRNA levels in the pontine noradrenergic cell groups. Cho HJ, et al. **Brain Res** 1995 Oct 9;695(1):96-9

The effect of a unilateral inflammation at the rat's ankle joint on the expression of preprotachykinin-A mRNA and preprosomatostatin mRNA in dorsal root ganglion cells--a study using non-radioactive in situ hybridization. Hanesch U, et al. **Brain Res** 1995 Nov 27;700(1-2):279-84

Beta 2-microglobulin has a strong affinity to bone marrow and synovium: an experimental study. Ono K, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S10-3

Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Mauri C, et al. **Eur J Immunol** 1996 Jul;26(7):1511-8

Beta-adrenergic receptor regulation of macrophage-derived tumor necrosis factor-alpha production from rats with experimental arthritis. Chou RC, et al. **J Neuroimmunol** 1996 Jun;67(1):7-16

Induction of transcription factor AP2 mRNA expression in rat primary afferent neurons during acute inflammation. Donaldson LF, et al. **Neurosci Lett** 1995 Aug 25; 196(3):181-4

Expression of mu- and kappa-, but not delta-, opioid receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats. Maekawa K, et al. **Pain** 1996 Feb; 64(2):365-71

Effects of surgical denervation on substance P and calcitonin gene-related peptide in adjuvant arthritis. Ahmed M, et al. **Peptides** 1995;16(4):569-79

Effects of ankle joint inflammation on the proportion of calcitonin gene-related peptide (CGRP)-immunopositive perikarya in dorsal root ganglia. Hanesch U, et al. **Prog Brain Res** 1995;104:339-47 (72 ref.)

PATHOLOGY

Depletion of gamma/delta T cells does not prevent or ameliorate, but rather aggravates, rat adjuvant arthritis. Pelegrí C, et al. **Arthritis Rheum** 1996 Feb;39(2):204-15

Reinnervation of post-arthritic joints in the rat. da Silva JA, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):43-51

Effects of a protein kinase C inhibitor (PKCI) on the development of adjuvant-induced arthritis (AA) in rats. DiMartino M, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S123-4

Alteration of spleen lymphocyte populations in rats with arthritis induced by muramyl dipeptide analogue or complete adjuvant. Sugawara T, et al. **Int J Tissue React** 1995;17(1):5-13

Visualisation of subchondral erosion in rat monoarticular arthritis by magnetic resonance imaging. Carpenter TA, et al. **Skeletal Radiol** 1995 Jul;24(5):341-9

PHYSIOPATHOLOGY

Depletion of gamma/delta T cells does not prevent or ameliorate, but rather aggravates, rat adjuvant arthritis. Pelegrí C, et al. **Arthritis Rheum** 1996 Feb;39(2):204-15

Changes in urinary deoxypyridinoline level and vertebral bone mass in the development of adjuvant-induced arthritis in rats. Segawa Y, et al. **Bone** 1995 Jul;17(1):57-62

Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant-induced arthritis. Chowdrey HS, et al. **Br J Pharmacol** 1995 Nov; 116(5):2417-24

The role of endogenous serotonin in adjuvant-induced arthritis in the rat. Harbuz MS, et al. **Br J Rheumatol** 1996 Feb;35(2):112-6

Biphasic changes in behavioral, endocrine, and sympathetic systems in adjuvant arthritis in Lewis rats. Tanaka H, et al. **Brain Res Bull** 1996;39(1):33-7

Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. Anderson GD, et al. **J Clin Invest** 1996 Jun 1;97(11):2672-9

Rat blood neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal inflammation. Issekutz TB, et al. **J Exp Med** 1996 May 1;183(5):2175-84

The alpha 4-integrin supports leukocyte rolling and adhesion in chronically inflamed postcapillary venules in vivo. Johnston B, et al. **J Exp Med** 1996 May 1;183(5):1995-2006

Application of 6-hydroxydopamine into the fatpads surrounding the draining lymph nodes exacerbates adjuvant-induced arthritis. Lorton D, et al. **J Neuroimmunol** 1996 Feb;64(2):103–13

Neuropeptide gene expression and capsaicin-sensitive primary afferents: maintenance and spread of adjuvant arthritis in the rat. Donaldson LF, et al. **J Physiol (Lond)** 1995 Jul 15;486 (Pt 2):473–82

Supraspinal influences on the facilitation of rat nociceptive reflexes induced by carrageenan monoarthritis. Herrero JF, et al. **Neurosci Lett** 1996 May 3;209(1):21–4

PREVENTION & CONTROL

Tolerance to an arthritogenic T-cell epitope of HSP65 and the regulation of experimental arthritis. Prakken BJ, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:425–6

A protective role for testosterone in adjuvant-induced arthritis. Harbuz MS, et al. **Br J Rheumatol** 1995 Dec; 34(12):1117–22

Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Oliver SJ, et al. **Cell Immunol** 1995 Dec;166(2):196–206

Administration of a nondepleting anti-CD4 monoclonal antibody (W3/25) prevents adjuvant arthritis, even upon rechallenge: parallel administration of a depleting anti-CD8 monoclonal antibody (OX8) does not modify the effect of W3/25. Pelegrí C, et al. **Cell Immunol** 1995 Oct 15; 165(2):177–82

Prevention of adjuvant arthritis in Lewis rats by neonatal bacille Calmette-Guerin (BCG) infection. Esaguy N, et al. **Clin Exp Immunol** 1996 Apr;104(1):103–7

Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184–198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Staines NA, et al. **Clin Exp Immunol** 1996 Mar;103(3):368–75

Effects of oral administration of type I interferon on adjuvant arthritis in rats. Yoshino S. **Comp Immunol Microbiol Infect Dis** 1996 Feb;19(2):133–8

High doses of interleukin-12 inhibit the development of joint disease in DBA/1 mice immunized with type II collagen in complete Freund's adjuvant. Hess H, et al. **Eur J Immunol** 1996 Jan;26(1):187–91

Suppression of rat adjuvant arthritis by some acyclic nucleotide analogs. Zídek A, et al. **Eur J Pharmacol** 1995 Nov 24;286(3):307–10

The preventive effect of oral administration of type I interferon on collagen-induced arthritis in rats. Yoshino S. **Exp Mol Pathol** 1995 Apr;62(2):123–30

Inhibition of rats adjuvant arthritis by a bradykinin antagonist Hoe 140 and its influence on kallikreins. Sharma JN, et al. **Gen Pharmacol** 1996 Jan;27(1):133–6

Transfer of type II collagen-induced arthritis from DBA/1 to severe combined immunodeficiency mice can be prevented by blockade of Mac-1. Taylor PC, et al. **Immunology** 1996 Jun;88(2):315–21

Effects of a protein kinase C inhibitor (PKCI) on the development of adjuvant-induced arthritis (AA) in rats. DiMartino M, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S123–4

Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: the regulation of lymph node cell populations and cytokine production. Haynes DR, et al. **Inflamm Res** 1996 Apr;45(4):159–65

Expression of an ovalbumin-specific V beta 8.2 TCR transgene inhibits collagen arthritis in B10.Q mice. Nabozny GH, et al. **Int Immunol** 1995 Aug;7(8):1279–86

Effect of high lipid diet and allopurinol on the development of experimentally induced arthritis in rats. Yossif AM, et al. **Pharmacology** 1995 Sep;51(3):160–4

RADIONUCLIDE IMAGING

Macrophage targeting with technetium-99m labelled J001 acylated poly-galactoside for scintigraphy of inflammation: optimization and assessment of imaging specificity in experimental arthritis. Miot-Noirault E, et al. **Eur J Nucl Med** 1996 Jan;23(1):61–8

In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. Breeman WA, et al. **J Nucl Med** 1996 Jan;37(1):108–17

Rat adjuvant arthritis: imaging with technetium-99m-anti-CD4 Fab' fragments. Kinne RW, et al. **J Nucl Med** 1995 Dec;36(12):2268–75

99Tcm-HIG accumulates in the synovial tissue of rats with adjuvant arthritis by binding to extracellular matrix proteins. de Bois MH, et al. **Nucl Med Commun** 1996 Jan; 17(1):54–9

RADIOTHERAPY

Rhenium-188 sulphur colloid as a radiation synovectomy agent. Wang SJ, et al. **Eur J Nucl Med** 1995 Jun;22(6):505–7

THERAPY

Influence of various forms of dialyzable leukocyte extracts on rat adjuvant arthritis. Stančiková M, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):295–9

Anti-CD4 monoclonal antibodies suppress murine collagen-induced arthritis only at the time of primary immunisation. Williams RO, et al. **Cell Immunol** 1996 Jun 15;170(2):291–5

A 71-kD heat shock protein (hsp) from Mycobacterium tuberculosis has modulatory effects on experimental rat arthritis. Kingston AE, et al. **Clin Exp Immunol** 1996 Jan; 103(1):77–82

Treatment of arthritis in Lewis rats by a monoclonal antibody against alpha beta T cell receptor: differential sensitivity of Yersinia-induced arthritis versus adjuvant arthritis. Gaede K, et al. **Clin Immunol Immunopathol** 1995 Dec; 77(3):339–48

Retrovirus mediated in vivo gene transfer to synovium in bacterial cell wall-induced arthritis in rats. Makarov SS, et al. **Gene Ther** 1995 Aug;2(6):424–8

Adjuvant arthritis in Lewis rats can be suppressed by immunoglobulins from arthritis-resistant strains. Ulmansky R, et al. **Isr J Med Sci** 1996 Jan;32(1):40–3

Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice. Fujisawa K, et al. **J Clin Invest** 1996 Jul 15;98(2):271–8

Attenuation of pain-related hyperventilation in adjuvant arthritic rats with adrenal medullary transplants in the spinal subarachnoid space. Wang H, et al. **Pain** 1995 Dec; 63(3):313–20

Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Makarov SS, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):402–6

Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-alpha 4 antibody in adjuvant arthritis. Barbadillo C, et al. **Springer Semin Immunopathol** 1995;16(4):427–36 (59 ref.)

ARTHRITIS, BACTERIAL see **ARTHRITIS, INFECTIOUS**

ARTHRITIS, DEGENERATIVE see **OSTEOARTHRITIS**

ARTHRITIS-ENCEPHALITIS VIRUS, CAPRINE

Prevalence, spread and control of caprine arthritis-encephalitis virus in dairy goat herds in New South Wales. Greenwood PL, et al. **Aust Vet J** 1995 Sep; 72(9):341–5

Changes in serum antioxidant concentrations during infection with caprine lentivirus. Mdurvwa EG, et al. **Cell Mol Biol (Noisy-le-grand)** 1995;41 Suppl 1:S65–72

Selected models of HIV-induced neurological disease. Narayan O, et al. **Curr Top Microbiol Immunol** 1995; 202:151–66 (61 ref.)

GENETICS

Two species of Rev proteins, with distinct N termini, are expressed by caprine arthritis encephalitis virus. Gazit A, et al. **J Virol** 1996 Apr;70(4):2674–7

Activation of caprine arthritis-encephalitis virus long terminal repeat by gamma interferon. Tong-Starksen SE, et al. **J Virol** 1996 Jan;70(1):595–9

Genetic and antigenic characterization of caev (caprine arthritis-encephalitis virus) recombinant transmembrane protein. Rosati S, et al. **Vet Microbiol** 1995 Aug; 45(4):363–70

IMMUNOLOGY

A long term study of goats naturally infected with caprine arthritis-encephalitis virus. Hanson J, et al. **Acta Vet Scand** 1996;37(1):31–9

Serologic diagnosis of caprine arthritis-encephalitis by ELISA with two recombinant proteins in a parallel testing format. Clavijo A, et al. **J Immunoassay** 1995 Nov; 16(4):419–36

ISOLATION & PURIFICATION

Bacterial expression of the caprine arthritis-encephalitis virus gag and env proteins and their use in enzyme-linked immunosorbent assay. Clavijo A, et al. **Am J Vet Res** 1995 Jul;56(7):841–8

-PCR for the detection of lentiviruses from small ruminants-Zanoni RG, et al. **Schweiz Arch Tierheilkd** 1996;138(2):93–8 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Replication properties of dUTPase-deficient mutants of caprine and ovine lentiviruses. Turelli P, et al. **J Virol** 1996 Feb;70(2):1213–7

ARTHRITIS, GOUTY

COMPLICATIONS

Gouty arthritis in nodal osteoarthritis. Fam AG, et al. **J Rheumatol** 1996 Apr;23(4):684–9

Bilateral carpal tunnel syndrome secondary to tophaceous compression of the median nerves. Tsai CY, et al. **Scand J Rheumatol** 1996;25(2):107–8

DIAGNOSIS

Gout in the cervical spine: MR pattern mimicking diskovertebral infection. Duprez TP, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):151–3

Clinics in diagnostic imaging (2). Juvenile gouty arthropathy with associated nephropathy. Lam PW, et al. **Singapore Med J** 1995 Feb;36(1):85–7

[Gouty arthritis in women. The clinical picture in 13 newly diagnosed cases] Slot O. **Ugeskr Laeger** 1996 Mar 4; 158(10):1366–8 (Eng. Abstr.) **(Dan)**

[A case from practice (349). Calcium-pyrophosphate arthropathy with acute pseudogout and involvement of the large joints with bilateral preference of wrist joint and knee joint] Dubach M. **Schweiz Rundsch Med Prax** 1996 May 14;85(20):671–3 **(Ger)**

[Polyarticular gout--change in the clinical picture?] Becker-Capeller D, et al. **Z Arztl Fortbild (Jena)** 1996 May; 90(3):227–31 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

The anti-inflammatory and anti-hyperuricemic effects of Chinese herbal formula danggui-nian-tong-tang on acute gouty arthritis: a comparative study with indomethacin and allopurinol. Chou CT, et al. **Am J Chin Med** 1995; 23(3–4):261–71

Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Shrestha M, et al. **Ann Emerg Med** 1995 Dec;26(6):682–6

Should patients with interval gout be treated with urate lowering drugs? [editorial; comment] Fam AG. **J Rheumatol** 1995 Sep;22(9):1621–3. Comment on: J Rheumatol 1995 Sep;22(9):1618–20.

A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. Ferraz MB, et al. **J Rheumatol** 1995 May;22(5):908–14

ETIOLOGY

Picture of the month. Glycogen storage disease type Ia (von Gierke disease) complicated by gouty arthritis and xanthomatosis. Hou JW, et al. **Arch Pediatr Adolesc Med** 1996 Feb;150(2):219–20

Gouty arthritis in a patient with Ivemark syndrome [letter] Bhattacharjee M, et al. **South Med J** 1996 Aug;89(8):834–5

[Hyperuricemia] Gröbner W, et al. **Urologe A** 1996 May; 35(3):263–77 (13 ref.) **(Ger)**

PATHOLOGY

Case in point. Tophaceous gout. Fred HL. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):27

PSYCHOLOGY

[Pain and pain perception in the elderly from the viewpoint of rheumatology] Nehen HG. **Z Gerontol Geriatr** 1995 Sep-Oct;28(5):335–8 (10 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Gouty arthropathy of the acromioclavicular joint. Blotter RH, et al. **Am J Orthop** 1995 Nov;24(11):859–60

Computed tomography of the knee joint as an indicator of intraarticular tophi in gout. Gerster JC, et al. **Arthritis Rheum** 1996 Aug;39(8):1406–9

RADIONUCLIDE IMAGING

Three-phase skeletal scintigraphy in gouty arthritis: an example of potential diagnostic pitfalls in radiopharmaceutical imaging of the extremities for infection. Pickhardt PJ, et al. **Clin Nucl Med** 1996 Jan; 21(1):33–9

ARTHRITIS, INFECTIOUS

Pyogenic infection of the sacroiliac joint. McGaughey I. **Aust N Z J Surg** 1996 May;66(5):282–6

Fungal arthritis. A review. Hansen BL, et al. **Scand J Rheumatol** 1995;24(4):248–50 (34 ref.)

BLOOD

Serum-mediated resolution of Lyme arthritis in mice. Barthold SW, et al. **Lab Invest** 1996 Jan;74(1):57–67

COMPLICATIONS

Ureaplasma urealyticum destructive septic polyarthritis revealing a common variable immunodeficiency. Puéchal X, et al. **Arthritis Rheum** 1995 Oct;38(10):1524–6

Septic arthritis in osteoarthritic hips. Knight DJ, et al. **BMJ** 1996 Jul 6;313(7048):40–1

Lancefield group C streptococcal arthritis and osteomyelitis [letter] Yoho RM, et al. **J Am Podiatr Med Assoc** 1995 Oct;85(10):561–4

Septic arthritis associated with brachial plexus neuropathy. A case report. Gabriel SR, et al. **J Bone Joint Surg Am** 1996 Jan;78(1):103–5

Poststreptococcal reactive arthritis mimicking acute septic arthritis: a hospital-based study. Birdi N, et al. **J Pediatr Orthop** 1995 Sep-Oct;15(5):661–5

Emphysematous septic arthritis: case report and review of the literature. Roy R, et al. **J Rheumatol** 1995 Sep; 22(9):1776–8 (29 ref.)

An avoidable complication of septic arthritis. Atkinson K. **J Tenn Med Assoc** 1996 Jan;89(1):16–7

Salmonella arthritis in a patient with severe lupus nephritis and thalassemia minor [letter] Krumme B, et al.

Nephron 1995;71(4):465–7

Manubrio–sternal joint sepsis in rheumatoid arthritis [letter] Wright GD, et al. **Postgrad Med J** 1995 Jul;71(837):443–4

Fatigue fracture of the sacral bone associated with septic arthritis of the symphysis pubis. Albertsen AM, et al. **Skeletal Radiol** 1995 Nov;24(8):605–7

DIAGNOSIS

Osteomyelitis and septic arthritis in children: guidelines for the use of imaging [letter; comment] Wysoki M, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):725. Comment on: AJR Am J Roentgenol 1995 Aug;165(2):399–403.

Scintigraphic techniques for delineation of infection and inflammation. Oyen WJ, et al. **Br J Hosp Med** 1995 Jul 12–Aug 15;54(2–3):75–80

Painful knees associated with a septic focus. Averns HL, et al. **Br J Rheumatol** 1995 Sep;34(9):862–4

Suppurative knee arthritis following acute osteomyelitis of the femur detected by magnetic resonance. Itokazu M, et al. **Chin Med J (Engl)** 1995 Sep;108(9):704–7

A case of Tbc oligoarthritis with negative cultures: early diagnosis using CT–scan and in situ hybridization [letter] Iliopoulos A, et al. **Clin Exp Rheumatol** 1995 May–Jun; 13(3):414–5

Needle arthroscopy: a new frontier in rheumatology. Panchal P, et al. **Compr Ther** 1996 Jan;22(1):44–7 (14 ref.)

Viral arthritis: the lessons of parvovirus B19. Mangi RJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):65–72 (7 ref.)

Septic arthritis and bilateral endogenous endophthalmitis associated with percutaneous transluminal coronary angioplasty [letter] Siddiqui MA, et al. **J Am Geriatr Soc** 1996 Apr;44(4):476–7

D–lactic acid in synovial fluid. A rapid diagnostic test for bacterial synovitis. Gratacós J, et al. **J Rheumatol** 1995 Aug;22(8):1504–8

Septic arthritis due to Mycobacterium marinum [letter; comment] Patel S, et al. **J Rheumatol** 1995 Aug; 22(8):1607–8. Comment on: J Rheumatol 1994 May;21(5):957–60.

Hip pain in a patient with an earlier fall. Falen SW, et al. **J South Orthop Assoc** 1995 Summer;4(2):124–7

Arthritis without grains caused by Pseudallescheria boydii. Ginter G, et al. **Mycoses** 1995 Sep–Oct;38(9–10):369–71

Septic arthritis in a lumbar facet joint: a rare cause of an epidural abscess. Heenan SD, et al. **Neuroradiology** 1995 Aug;37(6):462–4

Pediatric bone and joint infections. Diagnosis and antimicrobial management. Sonnen GM, et al. **Pediatr Clin North Am** 1996 Aug;43(4):933–47 (30 ref.)

Septic arthritis. Brower AC. **Radiol Clin North Am** 1996 Mar; 34(2):293–309, x (19 ref.)

Gadolinium–DTPA–enhanced magnetic resonance imaging of musculoskeletal infectious processes. Hopkins KL, et al. **Skeletal Radiol** 1995 Jul;24(5):325–30

[Lyme arthritis: the joint lesions in Lyme borreliosis in the USA] Steere AC. **Ter Arkh** 1995;67(11):43–5 (Eng. Abstr.) **(Rus)**

[The clinical instrumental characteristics of the locomotor involvement in patients who have had Lyme disease] Ushakova MA, et al. **Ter Arkh** 1995;67(11):45–9 (Eng. Abstr.) **(Rus)**

[Juvenile chronic arthritis (JCA) or chronic arthropathy due to parvovirus B19?] Andreu Alapont E, et al. **An Esp Pediatr** 1996 Feb;44(2):157–8 (14 ref.) **(Spa)**

[The osteoarticular manifestations associated with parvovirus B19 infection in the course of an infectious outbreak (letter; comment)] Cáliz Cáliz R, et al. **Med Clin (Barc)** 1995 Oct 21;105(13):517. Comment on: Med Clin (Barc) 1995 Jan 14;104(1):22–4. **(Spa)**

[Bacterial sacroileitis. Clinical findinds and clinical course in 9 cases] Durlach RA, et al. **Medicina (B Aires)** 1995; 55(2):106–10 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G. Tissi L, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1938–47

Use of itraconazole for treatment of sporotrichosis involving a knee prosthesis [letter] DeHart DJ. **Clin Infect Dis** 1995 Aug;21(2):450

Chondroprotective effect of betamethasone in lapine pyogenic arthritis. Stricker SJ, et al. **J Pediatr Orthop** 1996 Mar–Apr;16(2):231–6

Amelioration of antigen induced arthritis in rabbits treated with a secreted viral serine proteinase inhibitor. Maksymowych WP, et al. **J Rheumatol** 1996 May; 23(5):878–82

Atypical presentation of systematic nocardiosis and successful treatment with meropenem. Velasco N, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):709–10

The neuropeptide alpha–melanocyte–stimulating hormone inhibits experimental arthritis in rats. Ceriani G, et al. **Neuroimmunomodulation** 1994 Jan;1(1):28–32

Pediatric bone and joint infections. Diagnosis and antimicrobial management. Sonnen GM, et al. **Pediatr Clin North Am** 1996 Aug;43(4):933–47 (30 ref.)

Infectious arthritis: tailoring initial treatment to clinical findings. Stimmler MM. **Postgrad Med** 1996 Apr; 99(4):127–31, 135–9

EPIDEMIOLOGY

Risk factors for septic arthritis in patients with joint disease. A prospective study. Kaandorp CJ, et al. **Arthritis Rheum** 1995 Dec;38(12):1819–25

Peripheral pyogenic arthritis. A study of one hundred seventy–nine cases. Le Dantec L, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):103–10

Salmonella septic arthritis in Zambian children. Lavy CB, et al. **Trop Doct** 1995 Oct;25(4):163–6

[Septic arthritis in newborns and infants—clinical epidemiology] Lejman T, et al. **Chir Narzadow Ruchu Ortop Pol** 1995;60(5):409–13 (Eng. Abstr.) **(Pol)**

[Osteoarticular infections by Salmonella non–typhi] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1995 Aug–Sep; 13(7):406–10 (30 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Sternoclavicular septic arthritis in a patient with end–stage liver disease. Guerra C, et al. **Ann Emerg Med** 1996 Feb; 27(2):264–6

Pyomyositis and septic arthritis due to Bacteroides fragilis in an immunocompetent patient. Calvo–Alén J, et al. **Clin Infect Dis** 1995 Nov;21(5):1344

Bacteroides fragilis arthritis following cesarean section. Failla DM, et al. **Clin Infect Dis** 1995 Nov;21(5):1341–2

Enterococcal arthritis: case report and review. Raymond NJ, et al. **Clin Infect Dis** 1995 Sep;21(3):516–22 (54 ref.)

Bone and joint infections in patients with infective endocarditis: review of a 4–year experience. Sapico FL, et al. **Clin Infect Dis** 1996 May;22(5):783–7

Long term evaluation of septic arthritis in hemophilic patients. Gilbert MS, et al. **Clin Orthop** 1996 Jul;(328):54–9

Arthritis in Israeli spotted fever. Klein M, et al. **Clin Rheumatol** 1995 Sep;14(5):580–1

Early postsplenectomy arthritis caused by penicillin–resistant Streptococcus pneumoniae. Merle–Melet M, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):159–60 (7 ref.)

Chronic septic arthritis and osteomyelitis in a prosthetic knee joint due to Clostridium difficile. Pron B, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):599–601

Preferential induction of septic arthritis and mortality by superantigen–producing staphylococci. Bremell T, et al. **Infect Immun** 1995 Oct;63(10):4185–7

Role of intercellular adhesion molecule 1 in pathogenesis of staphylococcal arthritis and in host defense against staphylococcal bacteremia. Verdrengh M, et al. **Infect Immun** 1996 Jul;64(7):2804–7

Association of lysogenic bacteriophage MAV1 with virulence of Mycoplasma arthritidis. Voelker LL, et al. **Infect Immun** 1995 Oct;63(10):4016–23

Vitamin A deficiency predisposes to Staphylococcus aureus infection. Wiedermann U, et al. **Infect Immun** 1996 Jan; 64(1):209–14

Septic arthritis caused by an unusual type of Haemophilus influenzae. Glatman–Freedman A, et al. **J Infect** 1996 Mar; 32(2):143–5

Septic arthritis secondary to toothpick penetration [letter] Leung MJ, et al. **Med J Aust** 1996 Jan 1;164(1):56

Acute gonococcal sacro–iliitis—a case report. Deshmukh RG. **Med J Malaysia** 1995 Dec;50(4):411–4

Musculoskeletal manifestations of brucellosis: a study of 90 cases in Israel. Zaks N, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):97–102

Orthopedic implications of tuberculosis. Cesario TC. **West J Med** 1995 Dec;163(6):565

Staphylococcus aureus septic arthritis in patients on hemodialysis treatment. Slaughter S, et al. **West J Med** 1995 Aug;163(2):128–32

[Systemic fat necrosis and septic arthritis in acute pancreatitis] Reijnierse JE, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):31–4 (Eng. Abstr.) **(Dut)**

[Anatomo–clinical conference. Hôpital Cochin. Case No 3 – 1995. Apropos of destructive oligoarthritis] Mariette X, et al. **Ann Med Interne (Paris)** 1995;146(5):310–5 **(Fre)**

[Pneumococcal cellulitis, secondary septic arthritis (letter)] Lalin P, et al. **Presse Med** 1996 Jan 6–13;25(1):38 **(Fre)**

[Pneumococcal septic arthritis in HIV infection] Trivalle C, et al. **Presse Med** 1995 Nov 4;24(33):1566–8 (13 ref.) (Eng. Abstr.) **(Fre)**

[Parasitic arthritis: a case report] Di Pietro A, et al. **Pediatr Med Chir** 1996 Mar–Apr;18(2):211–2 (Eng. Abstr.) **(Ita)**

[Septic arthritis caused by Salmonella enteritidis in systemic lupus erythematosus] Gomez Rodriguez N, et al. **An Med Interna** 1996 Jan;13(1):27–30 (Eng. Abstr.) **(Spa)**

[Chronic meningococcemia: a rare cause of migratory arthritis (letter)] Sopeña B, et al. **An Med Interna** 1996 Apr; 13(4):206–7 **(Spa)**

IMMUNOLOGY

Effect of HLA type and hypocomplementaemia on the expression of parvovirus arthritis: one year follow up of an outbreak. Gendi NS, et al. **Ann Rheum Dis** 1996 Jan; 55(1):63–5

Yersinia–associated arthritis in rats: effect of 65 kDa heat shock protein, bovine serum albumin and incomplete Freund's adjuvant. Gripenberg–Lerche C, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):321–5

Infectious arthritis and immune dysfunction. **Curr Opin Rheumatol** 1995 Jul;7(4):B66–73

Chondrocyte–peripheral blood mononuclear cell interactions: the role of ICAM–1. Horner A, et al. **Immunology** 1995 Dec;86(4):584–90

Involvement of CD4+ T lymphocytes in induction of severe destructive Lyme arthritis in inbred LSH hamsters. Lim LC, et al. **Infect Immun** 1995 Dec;63(12):4818–25

Pathogen antigen– and superantigen–reactive synovial fluid T cells in reactive arthritis. Lahesmaa R, et al. **J Infect Dis** 1995 Nov;172(5):1290–7

METABOLISM

In situ hybridization analysis of synovial and systemic cytokine messenger RNA expression in superantigen–mediated Staphylococcus aureus arthritis. Zhao YX, et al. **Arthritis Rheum** 1996 Jun;39(6):959–67

Insulin–like growth factor I and its binding proteins 3 and 4 are increased in Human inflammatory synovial fluid. Kanety H, et al. **J Rheumatol** 1996 May;23(5):815–8

MICROBIOLOGY

Septic arthritis of the shoulder due to Streptococcus agalactiae. García S, et al. **Acta Orthop Belg** 1996 Mar; 62(1):66–8

Mycobacterium kansasii septic arthritis in a patient with acquired immunodeficiency syndrome. García Vivar ML, et al. **Arthritis Rheum** 1996 May;39(5):881–2

Loosening of a revision total hip replacement in a 60–year–old woman with longstanding rheumatoid arthritis [clinical conference] Gravallese EM, et al. **Arthritis Rheum** 1995 Sep;38(9):1315–24

Molecular detection of bacterial DNA in venereal–associated arthritis. Li F, et al. **Arthritis Rheum** 1996 Jun;39(6):950–8

C. albicans septic arthritis in a patient with AIDS. Smith NA, et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):270–1

Enterococcal arthritis with avascular necrosis in a lupus patient. Markov G, et al. **Br J Rheumatol** 1996 Jun; 35(6):595–7 (11 ref.)

Dermacase. Gonococcemia. Enta T. **Can Fam Physician** 1995 Aug;41:1300; 1311

Invasive staphylococcal infections complicating percutaneous transluminal coronary angioplasty: three cases and review. Cleveland KO, et al. **Clin Infect Dis** 1995 Jul;21(1):93–6 (17 ref.)

Joint infections due to Listeria monocytogenes: case report and review. Ellis LC, et al. **Clin Infect Dis** 1995 Jun; 20(6):1548–50 (15 ref.)

Moraxella nonliquefaciens septic arthritis in a patient undergoing hemodialysis. Johnson DW, et al. **Clin Infect Dis** 1995 Oct;21(4):1039–40

Bacterial arthritis. Goldenberg DL. **Curr Opin Rheumatol** 1995 Jul;7(4):310–4 (44 ref.)

Localization of viable bacteria and bacterial antigens in arthritic joints of Erysipelothrix rhusiopathiae–infected pigs. Franz B, et al. **FEMS Immunol Med Microbiol** 1995 Oct;12(2):137–42

Absolute identification of muramic acid, at trace levels, in human septic synovial fluids in vivo and absence in aseptic fluids. Fox A, et al. **Infect Immun** 1996 Sep;64(9):3911–5

An ospA frame shift, identified from DNA in Lyme arthritis synovial fluid, results in an outer surface protein A that does not bind protective antibodies. Fikrig E, et al. **J Immunol** 1995 Dec 15;155(12):5700–4

Impact of interferon–gamma receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis. Zhao YX, et al. **J Immunol** 1995 Dec 15; 155(12):5736–42

Salmonella septic arthritis of the shoulder in Zambian children. Lavy CB, et al. **J R Coll Surg Edinb** 1996 Jun; 41(3):197–9

Autoimmune arthritis caused by Candida septic arthritis. Rovinsky D, et al. **J Shoulder Elbow Surg** 1995 Nov–Dec; 4(6):472–6

Bacteroides fragilis infection of a knee prosthesis after haemorrhoidectomy [letter] Pattison RM, et al. **Lancet** 1995 Oct 21;346(8982):1097

Septic arthritis and osteomyelitis caused by penicillin and cephalosporin–resistant Streptococcus pneumoniae in a children's hospital. Abbasi S, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):78–83

Unusual radiological manifestations of Lemierre's syndrome: a case report. Goyal M, et al. **Pediatr Radiol** 1995 Nov; 25 Suppl 1:S105–6

Migratory polyarthritis associated with Plesiomonas shigelloides infection. Gupta S. **Scand J Rheumatol** 1995; 24(5):323–5

Listeria monocytogenes arthritis of several joints. Ukkonen HJ, et al. **Scand J Rheumatol** 1995;24(6):392–4

[Meningococcal arthritis] Mader R. **Harefuah** 1995 Sep; 129(5–6):214–6 (26 ref.) **(Heb)**

[Staphylococcus saprophyticus isolated in blood cultures from normal–weight newborn infants with septic arthritis] Codiță U, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Apr–Jun;40(2):153–7 (Eng. Abstr.) **(Rum)**

[Coxofemoral infectious arthritis caused by Candida albicans in an HIV seropositive patient (letter)] Rodríguez–Escudero MJ, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):63–4 **(Spa)**

PATHOLOGY

Suppression of pannus-like extension of synovial cells by lipid-derivatized chondroitin sulphate: in vitro and in vivo studies using Escherichia coli-induced arthritic rabbits. Sugiura N, et al. **Int J Exp Pathol** 1995 Oct;76(5):369-79

Limited TCR V beta usage of infiltrating T cells in synovial tissues from patients with HTLV-I associated arthropathy. Ohshima K, et al. **Pathol Res Pract** 1995 Mar;191(2):148-55

Cartilage destruction in septic arthritis--electron microscopy and historical considerations. Gauger M, et al. **Z Rheumatol** 1995 Jul-Aug;54(4):241-9

PHYSIOPATHOLOGY

Manifestations of Chlamydia induced arthritis in patients with silent versus symptomatic urogenital chlamydial infection. Wollenhaupt J, et al. **Clin Exp Rheumatol** 1995 Jul-Aug; 13(4):453-8

PREVENTION & CONTROL

Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. Edwards CK 3rd, et al. **J Immunol** 1996 Aug 15;157(4):1758-72

RADIOGRAPHY

Unusual radiological manifestations of Lemierre's syndrome: a case report. Goyal M, et al. **Pediatr Radiol** 1995 Nov; 25 Suppl 1:S105-6

HIV arthritis. Eustace SJ, et al. **Radiol Clin North Am** 1996 Mar;34(2):450-3 (46 ref.)

Lyme arthropathy. Eustace SJ, et al. **Radiol Clin North Am** 1996 Mar;34(2):454-5 (22 ref.)

[Computed tomography of the sacroiliac joints] Miquel A, et al. **Ann Radiol (Paris)** 1995;38(4):177-85 (28 ref.) **(Fre)**

RADIONUCLIDE IMAGING

Tc-99m nanocolloid and Tc-99m MDP three-phase bone imaging in osteomyelitis and septic arthritis. A comparative study. Mudun A, et al. **Clin Nucl Med** 1995 Sep;20(9):772-8

SURGERY

Long-term outcome of 42 knees with chronic infection after total knee arthroplasty. Bose WJ, et al. **Clin Orthop** 1995 Oct;(319):285-96

Total knee arthroplasty in tuberculous arthritis. Su JY, et al. **Clin Orthop** 1996 Feb;(323):181-7

Acute flexor tenosynovitis in association with Clostridium difficile infection: a case report. Wright TW, et al. **J Hand Surg [Am]** 1996 Mar;21(2):304-6

[Candida arthritis of the knee joint caused by penetrating injury] Schnider A, et al. **Chirurg** 1995 Nov;66(11):1162-4 (Eng. Abstr.) **(Ger)**

[Systematic revision--a contribution to the treatment strategy of early infection in trauma surgery] Eyssel M, et al. **Unfallchirurgie** 1996 Jun;22(3):139-42 (Eng. Abstr.) **(Ger)**

THERAPY

Treatment of arthritis in Lewis rats by a monoclonal antibody against alpha beta T cell receptor: differential sensitivity of Yersinia-induced arthritis versus adjuvant arthritis. Gaede K, et al. **Clin Immunol Immunopathol** 1995 Dec; 77(3):339-48

Hip pain in a patient with an earlier fall. Falen SW, et al. **J South Orthop Assoc** 1995 Summer;4(2):124-7

Serum-mediated resolution of Lyme arthritis in mice. Barthold SW, et al. **Lab Invest** 1996 Jan;74(1):57-67

ULTRASONOGRAPHY

Septic arthritis of the elbow in children: the role of sonography. Lim-Dunham JE, et al. **Pediatr Radiol** 1995; 25(7):556-9

VETERINARY

Importance of Staphylococcus hyicus ssp hyicus as a cause of arthritis in pigs up to 12 weeks of age. Hill BD, et al. **Aust Vet J** 1996 May;73(5):179-81

Changes in serum antioxidant concentrations during infection with caprine lentivirus. Mdurvwa EG, et al. **Cell Mol Biol (Noisy-le-grand)** 1995;41 Suppl 1:S65-72

Mycoplasma bovis-associated pneumonia and arthritis complicated with pyogranulomatous tenosynovitis in calves. Adegboye DS, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):647-9

Use of antimicrobial-impregnated polymethyl methacrylate beads for treatment of chronic, refractory septic arthritis and osteomyelitis of the digit in a bull. Trostle SS, et al. **J Am Vet Med Assoc** 1996 Feb 1;208(3):404-7

Mycoplasma-associated polyarthritis in farmed crocodiles (Crocodylus niloticus) in Zimbabwe. Mohan K, et al. **Onderstepoort J Vet Res** 1995 Mar;62(1):45-9

Surgical management of digit disorders in cattle. Desrochers A, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):277-98 (45 ref.)

Arthroscopy in food animal practice. Gaughan EM. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):233-47 (11 ref.)

Orthopedic conditions of small ruminants. Llama, sheep, goat, and deer. Kaneps AJ. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):211-31 (51 ref.)

Immunohistochemical detection of lymphocyte subpopulations in the tarsal joints of chickens with experimental viral arthritis. Pertile TL, et al. **Vet Pathol** 1996 May;33(3):303-10

Idiopathic infective arthritis of the coxofemoral joint in a mature horse. Clegg PD. **Vet Rec** 1995 Oct 28; 137(18):460-4

[Septic arthritis of the pastern in cattle--clinical, radiological and sonographic findings and treatment] Kofler J. **Berl Munch Tierarztl Wochenschr** 1995 Aug;108(8):281-9 (Eng. Abstr.) **(Ger)**

VIROLOGY

Viral arthritis including HIV. Naides SJ. **Curr Opin Rheumatol** 1995 Jul;7(4):337-42 (36 ref.)

Viral arthritis: the lessons of parvovirus B19. Mangi RJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):65-72 (7 ref.)

Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis. Linn ML, et al. **J Gen Virol** 1996 Mar;77 (Pt 3):407-11

Herpes viruses in multicase families with rheumatoid arthritis. Newkirk MM, et al. **J Rheumatol** 1995 Nov;22(11):2055-61

[Virus-induced arthritis (editorial; comment)] Kalden JR. **Z Rheumatol** 1995 Nov-Dec;54(6):389-90. Comment on: Z Rheumatol 1995 Nov-Dec;54(6):391-404. **(Ger)**

[Virus-associated arthritis (see comments)] Saal JG. **Z Rheumatol** 1995 Nov-Dec;54(6):391-404 (148 ref.) (Eng. Abstr.). Comment in: Z Rheumatol 1995 Nov-Dec;54(6):389-90. **(Ger)**

ARTHRITIS, JUVENILE CHRONIC see **ARTHRITIS, JUVENILE RHEUMATOID**

ARTHRITIS, JUVENILE RHEUMATOID

Nutritional status in active juvenile chronic arthritis not treated with steroids. Strano CG, et al. **Acta Paediatr** 1995 Sep;84(9):1010-3

Childhood leukemia mimicking juvenile rheumatoid arthritis. Tsai MJ, et al. **Acta Paediatr Sin** 1995 Jul-Aug;36(4):274-8

Young adults with arthritis: meeting their transitional needs [see comments] Chamberlain MA, et al. **Br J Rheumatol** 1996 Jan;35(1):84-90. Comment in: Br J Rheumatol 1996 Jan;35(1):80-3.

Juvenile rheumatoid arthritis: current concepts and practice. Arnason JA, et al. **J Pediatr Ophthalmol Strabismus** 1995 Nov-Dec;32(6):383-5 (25 ref.)

The school experience of children with arthritis. Coping in the 1990s and transition into adulthood. Spencer CH, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1285-98 (25 ref.)

[Juvenile chronic arthritis in children] Zgradić I. **Med Pregl** 1995;48(1-2):19-23 (13 ref.) (Eng. Abstr.) **(Ser)**

BLOOD

Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Gattorno M, et al. **Ann Rheum Dis** 1996 Apr;55(4):243-7

Significance of cytokine measurements in patients with juvenile rheumatoid arthritis: comment on the article by Mangge et al [letter; comment] Canvin JM, et al. **Arthritis Rheum** 1995 Oct;38(10):1531-2. Comment on: Arthritis Rheum 1995 Feb;38(2):211-20.

Superoxide dismutase and lipid-bound sialic acid in sera from children with cancers and juvenile chronic arthritis. Maneva A, et al. **Eur J Cancer Prev** 1995 Oct;4(5):429-35

Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. De Benedetti F, et al. **J Rheumatol** 1995 Aug;22(8):1581-5

Elevated serum prolactin levels in children with juvenile rheumatoid arthritis and antinuclear antibody seropositivity. McMurray RW, et al. **J Rheumatol** 1995 Aug;22(8):1577-80

Biochemical analysis of ferritin subunits in sera from adult Still's disease patients. Higashi S, et al. **Rheumatol Int** 1995; 15(2):45-50

CLASSIFICATION

Proposal for the development of classification criteria for idiopathic arthritides of childhood [see comments] Fink CW. **J Rheumatol** 1995 Aug;22(8):1566-9. Comment in: J Rheumatol 1995 Aug;22(8):1445-5.

Classification criteria for childhood arthritic diseases [editorial; comment] Hochberg MC. **J Rheumatol** 1995 Aug;22(8):1445-6. Comment on: J Rheumatol 1995 Aug;22(8):1566-9.

Proposal for classification criteria for idiopathic arthritides of childhood [letter] Malleson P. **J Rheumatol** 1996 May; 23(5):942; discussion 942-3

Proposal for classification criteria for idiopathic arthritides of childhood [letter] Miller JJ 3rd. **J Rheumatol** 1996 May; 23(5):943; discussion 943-4

COMPLICATIONS

Mitral and aortic insufficiency in polyarticular juvenile rheumatoid arthritis [letter] Karademir S, et al. **Acta Paediatr** 1996 Mar;85(3):380

Intraocular lens implantation in patients with juvenile rheumatoid arthritis-associated uveitis: an unresolved management issue [editorial; comment] Holland GN. **Am J Ophthalmol** 1996 Aug;122(2):255-7 (10 ref.). Comment on: Am J Ophthalmol 1996 Aug;122(2):161-70.

Intraocular lens implantation in patients with juvenile rheumatoid arthritis [see comments] Probst LE, et al. **Am J Ophthalmol** 1996 Aug;122(2):161-70 (24 ref.). Comment in: Am J Ophthalmol 1996 Aug;122(2):255-7.

Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Cazzola M, et al. **Blood** 1996 Jun 1;87(11):4824-30

Managing the complications of childhood arthritis [letter; comment] Southwood T. **BMJ** 1995 Sep 23; 311(7008):810-1. Comment on: BMJ 1995 Aug 26;311(7004):569.

Antibodies against retinal S-antigen in patients with juvenile chronic arthritis-associated uveitis [letter] Edelsten C, et al. **Br J Rheumatol** 1996 Jan;35(1):101-2

Successful management of reactive haemophagocytic syndrome in systemic-onset juvenile chronic arthritis [letter] Fishman D, et al. **Br J Rheumatol** 1995 Sep; 34(9):888

Correlates of disablement in polyarticular juvenile chronic arthritis--a cross-sectional study. van der Net J, et al. **Br J Rheumatol** 1996 Jan;35(1):91-100

Juvenile rheumatoid arthritis and uveitis: minimizing the blinding complications. Ceisler EJ, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):91-107

Juvenile rheumatoid arthritis and renal amyloidosis (case report). Kavukçu S, et al. **Int Urol Nephrol** 1995; 27(3):251-6

The primary role of steroids on the osteoporosis in juvenile rheumatoid patients evaluated by dual energy X-ray absorptiometry. Falcini F, et al. **J Endocrinol Invest** 1996 Mar;19(3):165-9

Prevalence of celiac disease in patients with juvenile chronic arthritis. Lepore L, et al. **J Pediatr** 1996 Aug;129(2):311-3

Bone mineral metabolism in children with juvenile rheumatoid arthritis. Cassidy JT, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1017-33 (117 ref.)

Clinical quiz. Differential diagnosis of a patient with Wegener's granulomatosis. Becker N, et al. **Pediatr Nephrol** 1995 Dec;9(6):785-7

Retroperitoneal fibrosis and juvenile rheumatoid arthritis. Tsai TC, et al. **Pediatr Nephrol** 1996 Apr;10(2):208-9

Pain in children with juvenile rheumatoid arthritis: a descriptive study. Abu-Saad HH, et al. **Pediatr Res** 1995 Aug;38(2):194-7

Physical therapy management of the subluxated wrist in children with arthritis. Barden W, et al. **Phys Ther** 1995 Oct;75(10):879-85

Synovial cysts of the hips in seronegative arthritis. Iversen JK, et al. **Skeletal Radiol** 1996 May;25(4):396-9

DIAGNOSIS

Childhood leukemia mimicking juvenile rheumatoid arthritis. Tsai MJ, et al. **Acta Paediatr Sin** 1995 Jul-Aug;36(4):274-8

Elevated serum ferritin levels: associated diseases and clinical significance [letter; comment] Naranjo-Hernandez A. **Am J Med** 1996 Jul;101(1):121; discussion 122. Comment on: Am J Med 1995 Jun;98(6):566-71.

Parvovirus infection mimicking a systematic onset of juvenile chronic arthritis (Still's disease) [letter] Rodrigo de Liria C, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):105-6

Juvenile chronic arthritis of the hip: value of contrast-enhanced MR imaging. Murray JG, et al. **Clin Radiol** 1996 Feb;51(2):99-102

Childhood leukemia mimicking arthritis. Needleman M. **J Am Board Fam Pract** 1996 Jan-Feb;9(1):56

Evaluation of disease activity by laboratory tests in juvenile rheumatoid arthritis. Martinez-Cordero E, et al. **J Investig Allergol Clin Immunol** 1995 Jul-Aug;5(4):216-20

Juvenile spondyloarthropathies: clinical manifestations and medical imaging. Azouz EM, et al. **Skeletal Radiol** 1995 Aug;24(6):399-408 (64 ref.)

Juvenile rheumatoid arthritis: cervical spine involvement and MRI in early diagnosis. Oren B, et al. **Turk J Pediatr** 1996 Apr-Jun;38(2):189-94

[Juvenile chronic arthritis (JCA) or chronic arthropathy due to parvovirus B19?] Andreu Alapont E, et al. **An Esp Pediatr** 1996 Feb;44(2):157-8 (14 ref.) **(Spa)**

[Antinuclear antibodies and juvenile chronic rheumatoid arthritis (editorial)] Modesto Caballero C. **An Esp Pediatr** 1996 Apr;44(4):305-9 (33 ref.) **(Spa)**

DRUG THERAPY

Increased risk of leukaemia in patients with juvenile chronic arthritis treated with chlorambucil. Kauppi MJ, et al. **Acta Paediatr** 1996 Feb;85(2):248-50

Sulphasalazine desensitization in a paediatric patient with juvenile chronic arthritis. Kümmerle-Deschner J, et al. **Acta Paediatr** 1995 Aug;84(8):952-4

Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials. Ruperto N, et al. **Ann Rheum Dis** 1996 Jan;55(1):73-5

Early treatment of systemic onset juvenile chronic arthritis with low-dose cyclosporin A [letter] Gattorno M, et al.

Clin Exp Rheumatol 1995 May-Jun;13(3):409-10

Juvenile rheumatoid arthritis [letter; comment] Freis PC. **J Am Board Fam Pract** 1995 Jul-Aug;8(4):341-2. Comment on: J Am Board Fam Pract 1995 Jan-Feb;8(1):46-8.

Liver biopsy findings in patients with juvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapy. Kugathasan S, et al. **J Pediatr** 1996 Jan;128(1):149-51

Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. Muzaffer MA, et al. **J Pediatr** 1996 May;128(5 Pt 1):698-700

Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. Ravelli A, et al. **J Pediatr** 1996 Feb;128(2):275-8

Influence of food on the bioavailability of oral methotrexate in children. Dupuis LL, et al. **J Rheumatol** 1995 Aug; 22(8):1570-3

Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. Ravelli A, et al. **J Rheumatol** 1995 Aug; 22(8):1574-6

Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a followup study. Uziel Y, et al. **J Rheumatol** 1996 May;23(5):910-8

Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future. Giannini EH, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1099-125 (89 ref.)

[Can indomethacin prolong arthritis?] Savolainen A, et al. **Duodecim** 1995;111(3):257-9 **(Fin)**

ENZYMOLOGY

Augmented plasma and tissue kallikrein like activity in synovial fluid of patients with inflammatory articular diseases. Volpe-Júnior N, et al. **Inflamm Res** 1996 Apr; 45(4):198-202

EPIDEMIOLOGY

Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993. Is the epidemiology changing? Peterson LS, et al. **Arthritis Rheum** 1996 Aug;39(8):1385-90

Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. Yamaguchi A, et al. **Arthritis Rheum** 1995 Nov;38(11):1672-7

Prevalence of juvenile chronic arthritis in a population of 12-year-old children in urban Australia. Manners PJ, et al. **Pediatrics** 1996 Jul;98(1):84-90

GENETICS

Juvenile rheumatoid arthritis and spondyloarthropathies. Lindsley CB. **Curr Opin Rheumatol** 1995 Sep;7(5):425-9 (46 ref.)

Immunoprinting excludes many potential susceptibility genes as predisposing to early onset pauciarticular juvenile chronic arthritis except HLA class II and TNF. Epplen C, et al. **Eur J Immunogenet** 1995 Aug;22(4):311-22

Interaction between HLA-DR and HLA-DP, and between HLA and interleukin 1 alpha in juvenile rheumatoid arthritis indicates heterogeneity of pathogenic mechanisms of the disease. Ploski R, et al. **Hum Immunol** 1995 Apr; 42(4):343-7

Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis. Pryhuber KG, et al. **J Rheumatol** 1996 Apr;23(4):747-52

IMMUNOLOGY

Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Knipping E, et al. **Arthritis Rheum** 1995 Dec;38(12):1735-7

Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. Yamaguchi A, et al. **Arthritis Rheum** 1995 Nov;38(11):1672-7

Presence of multiple anti-phospholipid antibody specificities in a pediatric population. Beaman KD, et al. **Autoimmunity** 1995;21(2):99-106

Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome. Gattorno M, et al. **Br J Rheumatol** 1995 Sep;34(9):873-81

The relationship between exposed galactose and N-acetylglucosamine residues on IgG in rheumatoid arthritis (RA), juvenile chronic arthritis (JCA) and Sjögren's syndrome (SS). Bond A, et al. **Clin Exp Immunol** 1996 Jul;105(1):99-103

Incidence of anti Hsp 90 and 70 antibodies in children with SLE, juvenile dermatomyositis and juvenile chronic arthritis. Conroy SE, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):99-104

Immune complexes from sera of patients with juvenile rheumatoid arthritis reveal novel 40 and 60 kd bands. Moore TL, et al. **Clin Exp Rheumatol** 1995 Sep-Oct; 13(5):667-72

Juvenile rheumatoid arthritis and spondyloarthropathies. Lindsley CB. **Curr Opin Rheumatol** 1995 Sep;7(5):425-9 (46 ref.)

Serologic subtyping of HLA-DR8 by means of the cytotoxic human monoclonal antibody 5643. Viken HD, et al. **Hum Immunol** 1995 Jul;43(3):200-6

Cellular immune responses of patients with juvenile chronic arthritis to retinal antigens and their synthetic peptides. Gupta D, et al. **Immunol Res** 1996;15(1):74-83

Immunopathogenesis of juvenile rheumatoid arthritis: role of T cells and MHC. Sakkas LI, et al. **Immunol Res** 1995; 14(3):218-36 (179 ref.)

Development and histologic characterizations of an animal model of antigen-induced arthritis of the juvenile rabbit temporomandibular joint. Kapila S, et al. **J Dent Res** 1995 Dec;74(12):1870-9

Patterns of T lymphocyte clonal expansion in HLA-typed patients with juvenile rheumatoid arthritis. Thompson SD, et al. **J Rheumatol** 1995 Jul;22(7):1356-64

Autoantibodies to IL-1 alpha in sera from umbilical cords, children, and adults, and from patients with juvenile chronic arthritis. Müller K, et al. **Scand J Rheumatol** 1996; 25(3):164-7

Antibodies against oxidised low-density lipoprotein in juvenile chronic arthritis. Savolainen A, et al. **Scand J Rheumatol** 1995;24(4):209-11

[Three cases with juvenile rheumatoid arthritis who showed hypocomplementemia related to disease activity] Wada Y, et al. **Ryumachi** 1996 Feb;36(1):50-7 (Eng. Abstr.) **(Jpn)**

METABOLISM

Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Pepmueller PH, et al. **Arthritis Rheum** 1996 May;39(5):746-57

PATHOLOGY

Lesions of the mandibular condyle in juvenile chronic arthritis. Pearson MH, et al. **Br J Orthod** 1996 Feb; 23(1):49-56

Abnormal muscle MRI in a patient with systemic juvenile arthritis. Miller ML, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S107-8

Correlation of some cytomorphological and ultrastructural modifications of synovial fluid in juvenile chronic arthritis. Ciobanu A, et al. **Rom J Morphol Embryol** 1995 Jul-Dec; 41(3-4):111-5

PHYSIOPATHOLOGY

Tumor necrosis factor receptor p75 correlates better than p55 with disease activity in juvenile rheumatoid arthritis: comment on the article by Mangge et al [letter; comment] Gattorno M, et al. **Arthritis Rheum** 1996 May;39(5):883-4 . Comment on: Arthritis Rheum 1995 Feb;38(2):211-20.

Correlates of disablement in polyarticular juvenile chronic arthritis--a cross-sectional study. van der Net J, et al. **Br J Rheumatol** 1996 Jan;35(1):91-100

Dentofacial growth in orthodontically treated and untreated children with juvenile chronic arthritis (JCA). A comparison with Angle Class II division 1 subjects. Kjellberg H, et al. **Eur J Orthod** 1995 Oct;17(5):357-73

Condylar condition and mandibular growth during early functional treatment of children with juvenile chronic arthritis. Pedersen TK, et al. **Eur J Orthod** 1995 Oct; 17(5):385-94

Bite force and temporomandibular disorder in juvenile chronic arthritis. Wenneberg B, et al. **J Oral Rehabil** 1995 Aug;22(8):633-41

PSYCHOLOGY

General and segmental reduced pain thresholds in juvenile chronic arthritis. Hogeweg JA, et al. **Pain** 1995 Jul; 62(1):11-7

RADIOGRAPHY

[Bone density in children and adolescents with rheumatic diseases. Preliminary results of selective measurement of trabecular and cortical bone using peripheral computerized tomography] Lettgen B, et al. **Klin Padiatr** 1996 May-Jun; 208(3):114-7 (Eng. Abstr.) **(Ger)**

SURGERY

Fracture of the femoral head after ceramic-on-polyethylene total hip arthroplasty. Callaway GH, et al. **J Arthroplasty** 1995 Dec;10(6):855-9

Noncemented femoral components in total hip arthroplasty for patients with rheumatoid arthritis. Walker KR, et al. **Minn Med** 1996 Jul;79(7):27-31

THERAPY

Treatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two children. Horneff G, et al. **Ann Rheum Dis** 1995 Oct;54(10):846-9

A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Barnett ML, et al. **Arthritis Rheum** 1996 Apr;39(4):623-8

Use of intravenous immune globulin in the therapy of children with rheumatological diseases. Roifman CM. **J Clin Immunol** 1995 Nov;15(6 Suppl):42S-51S (10 ref.)

Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group. Giannini EH, et al. **J Rheumatol** 1996 May;23(5):919-24

ULTRASONOGRAPHY

Hypertrophic bursopathy of the subacromial-subdeltoid bursa in juvenile rheumatoid arthritis: sonographic appearance. Ruhoy MK, et al. **Pediatr Radiol** 1996; 26(5):353-5

ARTHRITIS, POSTINFECTIOUS see **ARTHRITIS, REACTIVE**

ARTHRITIS, PSORIATIC

[Management of psoriatic arthritis] Abu-Shakra M, et al. **Harefuah** 1996 Feb 15;130(4):283-7 (53 ref.) **(Heb)**

BLOOD

Elevated levels of corticotrophin-releasing factor binding protein in the blood of patients suffering from arthritis and septicaemia and the presence of novel ligands in synovial fluid. Woods RJ, et al. **Br J Rheumatol** 1996 Feb; 35(2):120-4

Increased serum level of interleukin-6 in patients with psoriatic arthritis and thrombocytosis. Yasumoto S, et al. **J Dermatol** 1995 Oct;22(10):718-22

CHEMICALLY INDUCED

Psoriatic arthropathy after BCG immunotherapy for bladder carcinoma [letter] Queiro R, et al. **Br J Rheumatol** 1995 Nov;34(11):1097

CLASSIFICATION

Psoriatic arthritis. New types, new treatments [editorial] Ruzicka T. **Arch Dermatol** 1996 Feb;132(2):215-9 (47 ref.)

COMPLICATIONS

Psoriatic onycho-pachydermo-periostitis. A variant of psoriatic distal interphalangeal arthritis? Boisseau-Garsaud AM, et al. **Arch Dermatol** 1996 Feb;132(2):176-80 (22 ref.)

Rheological analysis of peripheral blood neutrophils in a patient with cutaneous and arthropathic psoriasis accompanying hypopyon-iridocyclitis. Iijima S, et al. **Australas J Dermatol** 1996 May;37 Suppl 1:S40-1

Secondary amyloidosis complicating arthropathic psoriasis. Tsuda S, et al. **Clin Exp Dermatol** 1996 Mar;21(2):141-4

Bilateral Baker's cyst in a patient with psoriatic arthritis of pediatric onset [letter] Lepore L, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):109-10

Rapidly progressive seronegative spondylarthropathy with atlantodental subluxation in a patient with moderately advanced HIV infection. Schewe CK, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):83-5

Vertical asymmetry of the mandibular ramus and condylar heights measured with a new method from dental panoramic radiographs in patients with psoriatic arthritis. Mattila M, et al. **J Oral Rehabil** 1995 Oct;22(10):741-5

Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis? [letter] Masson C, et al. **J Rheumatol** 1995 Nov;22(11):2191

Prevalence of psoriatic arthritis in Italian psoriatic patients. Salvarani C, et al. **J Rheumatol** 1995 Aug;22(8):1499-503

Odontoid fracture and C1-C2 subluxation in psoriatic cervical spondyloarthropathy. A case report. Sosner J, et al. **Spine** 1996 Feb 15;21(4):519-21 (6 ref.)

[Arthritis and pustulosis palmoplantaris] Moe AT, et al. **Ugeskr Laeger** 1996 Apr 1;158(14):1984-5 (Eng. Abstr.) **(Dan)**

[A case from practice (337). Psoriasis vulgaris, Hallopeau's continuous suppurative acrodermatitis. Psoriatic arthropathy. Chronic alcoholism with personality changes, polyneuropathy, hepatopathy. Cardiomyopathy with chronic atrial fibrillation, thrombocytopathy, macrocytosis] Widmer A. **Schweiz Rundsch Med Prax** 1995 Nov 28; 84(48):1435 **(Ger)**

[Reflexions on the Tietze syndrome. Clinical contribution] Pappalardo A, et al. **Clin Ter** 1995 Nov;146(11):675-82 (32 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Osteoarticular manifestations of pustulosis palmaris et plantaris and of psoriasis: two distinct entities. Mejjad O, et al. **Ann Rheum Dis** 1996 Mar;55(3):177-80

The myriad faces of psoriatic arthritis. Rothschild BM. **Compr Ther** 1996 Mar;22(3):165-8 (15 ref.)

Seronegative spondyloarthropathies. El-Khoury GY, et al. **Radiol Clin North Am** 1996 Mar;34(2):343-57, xi (56 ref.)

Juvenile spondyloarthropathies: clinical manifestations and medical imaging. Azouz EM, et al. **Skeletal Radiol** 1995 Aug;24(6):399-408 (64 ref.)

DRUG THERAPY

Psoriatic arthritis. New types, new treatments [editorial] Ruzicka T. **Arch Dermatol** 1996 Feb;132(2):215-9 (47 ref.)

Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report. Eibschutz B, et al. **Arthritis Rheum** 1995 Nov;38(11):1604-9

Sulfasalazine in psoriatic arthritis: a new or established indication? [letter] Goupille P, et al. **Arthritis Rheum** 1996 Apr;39(4):711-2

Hazards of low dose methotrexate [editorial] Conaghan PG, et al. **Aust N Z J Med** 1995 Dec;25(6):670-3 (30 ref.)

Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment. Gómez-Vaquero C, et al. **Br J Rheumatol** 1996 Jun;35(6):564–7

Quantitative assessment of synovial inflammation by dynamic gadolinium-enhanced magnetic resonance imaging. A study of the effect of intra-articular methylprednisolone on the rate of early synovial enhancement. Ostergaard M, et al. **Br J Rheumatol** 1996 Jan;35(1):50–9

Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Leeb BF, et al. **Clin Exp Rheumatol** 1995 Jul–Aug;13(4):459–63

Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Spadaro A, et al. **Clin Exp Rheumatol** 1995 Sep–Oct; 13(5):589–93

Constrictive bronchiolitis obliterans following gold therapy for psoriatic arthritis. Schwartzman KJ, et al. **Eur Respir J** 1995 Dec;8(12):2191–3

Sulfasalazine: a definitively efficient treatment for psoriatic arthritis [letter] Goupille P, et al. **J Rheumatol** 1996 Apr; 23(4):791–2

Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. Gupta AK, et al. **J Rheumatol** 1995 May;22(5):894–8

The second course of gold. Klinkhoff AV, et al. **J Rheumatol** 1995 Sep;22(9):1655–6

Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis? [letter] Masson C, et al. **J Rheumatol** 1995 Nov;22(11):2191

Therapeutic efficacy of bromocriptine in psoriatic arthritis (two case-reports) [letter] Eulry F, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):607–8

[Treatment of rheumatoid psoriasis with bromocriptine] Eulry F, et al. **Presse Med** 1995 Nov 18;24(35):1642–4 (Eng. Abstr.) **(Fre)**

[Chloroquine in the treatment of psoriatic arthritis] Jajić Z, et al. **Reumatizam** 1995;42(2):7–9 (Eng. Abstr.) **(Scr)**

ETIOLOGY

Posttraumatic reflex sympathetic dystrophy and psoriatic arthritis [letter; comment] Goupille P, et al. **J Rheumatol** 1995 Nov;22(11):2188–9. Comment on: J Rheumatol 1995 Apr;22(4):783–5.

[Post-traumatic psoriatic arthritis. 2 cases] Thomachot B, et al. **Presse Med** 1996 Jan 6–13;25(1):21–4 (13 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Pitzalis C, et al. **Arthritis Rheum** 1996 Jan;39(1):137–45

The antiperinuclear factor in spondylarthropathies [letter] Muñoz-Fernández S, et al. **Br J Rheumatol** 1996 Aug; 35(8):804–5

Psoriatic arthritis. Winchester R. **Dermatol Clin** 1995 Oct; 13(4):779–92 (11 ref.)

METABOLISM

The volume of synovial fluid effusion in psoriatic arthritis [letter] Punzi L, et al. **Clin Exp Rheumatol** 1995 Jul–Aug; 13(4):535–6

PATHOLOGY

Dry taps and what to do about them: a pictorial essay on failed arthrocentesis of the knee. Roberts WN, et al. **Am J Med** 1996 Apr;100(4):461–4

Distinctive radiological features of small hand joints in rheumatoid arthritis and seronegative spondyloarthritis demonstrated by contrast-enhanced (Gd-DTPA) magnetic resonance imaging. Jevtic V, et al. **Skeletal Radiol** 1995 Jul;24(5):351–5

PHYSIOPATHOLOGY

Expression and function of CD80 and CD86 costimulator molecules on synovial dendritic cells in chronic arthritis. Summers KL, et al. **Arthritis Rheum** 1996 Aug; 39(8):1287–91

A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Husted JA, et al. **Clin Exp Rheumatol** 1995 Jul–Aug;13(4):439–43

Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. Blackmore MG, et al. **J Rheumatol** 1995 May;22(5):886–93

[Problems in psoriatic rheumatism in 1996] Kahn MF. **Schweiz Med Wochenschr Suppl** 1996;80:5S **(Fre)**

PSYCHOLOGY

[Various personality traits of patients with psoriatic arthropathy] Giordano N, et al. **Minerva Med** 1996 Jun; 87(6):283–7 (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Case in point. Psoriatic spondyloarthropathy. Ansari A, et al. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):16D

HIV arthritis. Eustace SJ, et al. **Radiol Clin North Am** 1996 Mar;34(2):450–3 (46 ref.)

RADIONUCLIDE IMAGING

[Psoriatic osteoarthropathy and bone scintigraphy] Holzmann H, et al. **Hautarzt** 1996 Jun;47(6):427–31 (19 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

[The therapeutic use of physical factors in the combined therapy of patients with psoriatic arthritis] Grigor'eva VD, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec; (6):48–52 (51 ref.) **(Rus)**

SURGERY

Arthroscopic synovectomy in rheumatoid and psoriatic knee joint synovitis: long-term outcome. Fiocco U, et al. **Br J Rheumatol** 1996 May;35(5):463–70

ULTRASONOGRAPHY

Long-term sonographic follow-up of rheumatoid and psoriatic proliferative knee joint synovitis. Fiocco U, et al. **Br J Rheumatol** 1996 Feb;35(2):155–63

[Routine hip ultrasonography in inflammatory rheumatoid diseases. Results in 119 consecutive patients of a rheumatism clinic] Keitel R, et al. **Fortschr Med** 1996 Jan 20;114(1–2):23–6 (Eng. Abstr.) **(Ger)**

ARTHRITIS, REACTIVE

see related

REITER'S DISEASE

Third International Workshop on Reactive Arthritis. 23–26 September 1995, Berlin, Germany. Report and abstracts. Kingsley G, et al. **Ann Rheum Dis** 1996 Aug;55(8):564–84

[Tropical reactive arthritis] Jeandel P. **Med Trop (Mars)** 1995; 55(4):325–8 (0 ref.) **(Fre)**

[Reactive arthritis] del Pino J. **An Med Interna** 1995 Oct; 12(10):469–71 (44 ref.) **(Spa)**

CHEMICALLY INDUCED

[Formaldehyde in the occupational environment. A possible cause of chemically induced reactive arthritis] Tilsted D, et al. **Ugeskr Laeger** 1996 Aug 5;158(32):4525–7 (Eng. Abstr.) **(Dan)**

COMPLICATIONS

Poststreptococcal reactive arthritis mimicking acute septic arthritis: a hospital-based study. Birdi N, et al. **J Pediatr Orthop** 1995 Sep–Oct;15(5):661–5

DIAGNOSIS

Reactive arthritis, diagnosis and treatment: a review. Nordstrom DC. **Acta Orthop Scand** 1996 Apr;67(2):196–201 (42 ref.)

The value of isotype determination of serum antibodies against Chlamydia for the diagnosis of Chlamydia reactive arthritis. Bas S, et al. **Br J Rheumatol** 1996 Jun;35(6):542–7

Reactive arthritis: urogenital swab culture is the only useful diagnostic method for the detection of the arthritogenic infection in extra-articularly asymptomatic patients with undifferentiated oligoarthritis. Erlacher L, et al. **Br J Rheumatol** 1995 Sep;34(9):838–42

Prediction of diagnosis in acute and subacute oligoarthritis of unknown origin. Kvien TK, et al. **Br J Rheumatol** 1996 Apr;35(4):359–63

An unusual case of restrictive cardiomyopathy in a patient with reactive arthritis caused by Staphylococcus epidermidis [letter] Mondillo S, et al. **Eur Heart J** 1996 Jan;17(1):152–3

Reactive arthritis [letter; comment] Vasey FB, et al. **J Fla Med Assoc** 1995 Oct;82(10):703–4. Comment on: J Fla Med Assoc 1995 Jun;82(6):411–4.

Reactive arthritis after an insect bite--suspect the unsuspected [letter] Branley J, et al. **Med J Aust** 1996 Apr 1;164(7):447–8

[Diagnostic evaluation of suspected reactive arthritis] Glennås A, et al. **Tidsskr Nor Laegeforen** 1995 Sep 10; 115(21):2656–8 (Eng. Abstr.) **(Nor)**

DRUG THERAPY

Reactive arthritis, diagnosis and treatment: a review. Nordstrom DC. **Acta Orthop Scand** 1996 Apr;67(2):196–201 (42 ref.)

Epidemiologic, clinical, and therapeutic aspects of reactive arthritis and ankylosing spondylitis. Toivanen A, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):279–83 (53 ref.)

EPIDEMIOLOGY

Reactive arthritis in patients attending an urban sexually transmitted diseases clinic. Rich E, et al. **Arthritis Rheum** 1996 Jul;39(7):1172–7

Reactive arthritis: characteristics in southern New Zealand. Highton J, et al. **N Z Med J** 1996 Mar 22;109(1018):93–5

ETIOLOGY

Rocky Mountain spotted fever presenting with acute monarticular arthritis. Sundy JS, et al. **Arthritis Rheum** 1996 Jan;39(1):175–6

The pathogenetic role of HLA-B27. Feltkamp TE, et al. **Immunol Today** 1996 Jan;17(1):5–7 (4 ref.)

Poststreptococcal reactive arthritis, clinical course, and outcome in 6 adult patients. Gutiérrez-Ureña S, et al. **J Rheumatol** 1995 Sep;22(9):1710–3

[Relationship between intestinal inflammation and arthritis] Helenius P, et al. **Duodecim** 1994;110(1):19–26 (36 ref.) **(Fin)**

[Reactive arthritis] Hitzelhammer J, et al. **Hautarzt** 1996 Jun; 47(6):479–87; quiz 485–6 (37 ref.) **(Ger)**

GENETICS

Oncogene expression in synovial fluid cells in reactive and early rheumatoid arthritis: a brief report. Roivainen A, et al. **Br J Rheumatol** 1995 Sep;34(9):805–8

TAP1 and TAP2 polymorphism in HLA-B27-positive subpopulations: no allelic differences in ankylosing spondylitis and reactive arthritis. Westman P, et al. **Hum Immunol** 1995 Dec;44(4):236–42

IMMUNOLOGY

A comparative study of HLA genes in HLA-B27 positive ankylosing spondylitis and HLA-B27 positive peripheral reactive arthritis. Westman P, et al. **Arthritis Rheum** 1996 Jun;39(6):943–9

Aetiological agents and immune mechanisms in enterogenic reactive arthritis. Sieper J, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):105–21 (83 ref.)

Synovial fluid and serum antibodies against Chlamydia in different forms of arthritis: intra-articular IgA production in Chlamydia sexually acquired reactive arthritis. Bas S, et al. **Br J Rheumatol** 1996 Jun;35(6):548–52

Comparative microbicidal activity of synovial fluid on arthritogenic organisms. Inman RD, et al. **Clin Exp Immunol** 1996 Apr;104(1):80–5

HLA frequencies in HLA-B27 negative patients with reactive arthritis. Laivoranta S, et al. **Clin Exp Rheumatol** 1995 Sep–Oct;13(5):637–40

Etiopathogenesis of reactive arthritis and ankylosing spondylitis. Careless DJ, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):290–8 (70 ref.)

Epidemiologic, clinical, and therapeutic aspects of reactive arthritis and ankylosing spondylitis. Toivanen A, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):279–83 (53 ref.)

TAP1 and TAP2 polymorphism in HLA-B27-positive subpopulations: no allelic differences in ankylosing spondylitis and reactive arthritis. Westman P, et al. **Hum Immunol** 1995 Dec;44(4):236–42

Cross-reactivity between Borrelia burgdorferi and "arthrogenic" bacteria in sera from patients with reactive arthritis. Sobieszczańska B, et al. **Rocz Akad Med Bialymst** 1996;41(1):90–5

HLA-B27-restricted cytotoxic T lymphocyte responses to arthritogenic enterobacteria or self-antigens are dominated by closely related TCRBV gene segments. A study in patients with reactive arthritis. Duchmann R, et al. **Scand J Immunol** 1996 Jan;43(1):101–8

Expression of MHC class II molecules on human monocytes is regulated independently from each other after phagocytosis of bacteria. Wuorela M, et al. **Scand J Immunol** 1996 Jan;43(1):39–46

MICROBIOLOGY

Alteration of Chlamydia trachomatis biologic behavior in synovial membranes. Suppression of surface antigen production in reactive arthritis and Reiter's syndrome. Nanagara R, et al. **Arthritis Rheum** 1995 Oct;38(10):1410–7

Aetiological agents and immune mechanisms in enterogenic reactive arthritis. Sieper J, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):105–21 (83 ref.)

Search for infective agents in undifferentiated oligoarthritis in Papua New Guinea [letter] Humphries J, et al. **Br J Rheumatol** 1996 May;35(5):492–3

Reactive arthritis-associated bacteria can stimulate lymphocyte proliferation in non-exposed individuals and newborns. Chieco-Bianchi F, et al. **Clin Exp Immunol** 1995 Dec;102(3):551–9

Etiopathogenesis of reactive arthritis and ankylosing spondylitis. Careless DJ, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):290–8 (70 ref.)

Idiopathic granulomatous appendicitis. Report of five cases, one of which presented as migratory arthritis. Naschitz JE, et al. **J Clin Gastroenterol** 1995 Dec;21(4):290–4

Reactive arthritis as a complication of Campylobacter lari enteritis [letter] Goudswaard J, et al. **J Infect** 1995 Sep; 31(2):171

Role of YadA in Yersinia-enterocolitica-induced reactive arthritis: a hypothesis [letter] Skurnik M. **Trends Microbiol** 1995 Aug;3(8):318–9

[Sterno-clavicular arthritis in patients without known risk factors (letter)] Quesada Rubio R, et al. **An Med Interna** 1995 Oct;12(10):514–5 **(Spa)**

[Reactive arthritis caused by Yersinia enterocolitica and Chlamydia trachomatis] Sánchez Burson J, et al. **An Med Interna** 1995 Oct;12(10):472–6 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. Zhang Y, et al. **Arthritis Rheum** 1996 Jul;39(7):1238–43

ARTHRITIS, REACTIVE

VETERINARY

Development of reactive arthritis and resistance to erythromycin and rifampin in a foal during treatment for Rhodococcus equi pneumonia. Kenney DG, et al. **Equine Vet J** 1994 May;26(3):246–8

VIROLOGY

[Parvovirus B19—a ubiquitous, little know virus. From erythema infectiosum and arthropathy to chronic anemia] Frickhofen N. **Fortschr Med** 1995 Sep 10;113(25):351–3 **(Ger)**

ARTHRITIS, RHEUMATIC, ACUTE see **RHEUMATIC FEVER**

ARTHRITIS, RHEUMATOID

Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Belcher C, et al. **Ann Rheum Dis** 1996 Apr;55(4):230–6

Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Jorgensen C, et al. **Ann Rheum Dis** 1996 Feb;55(2):94–8

Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with osteoarthritis or rheumatoid arthritis. Takahashi M, et al. **Ann Rheum Dis** 1996 May; 55(5):324–7

Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Marok R, et al. **Arthritis Rheum** 1996 Apr;39(4):583–91

Patient education: treatment or nice extra. The British experience [letter] Curson D, et al. **Br J Rheumatol** 1996 Aug;35(8):805–7

Evaluation of a Dutch version of the AIMS2 for patients with rheumatoid arthritis. Riemsma RP, et al. **Br J Rheumatol** 1996 Aug;35(8):755–60

Antibodies to four gram-negative bacteria in rheumatoid arthritis which share sequences with the rheumatoid arthritis susceptibility motif. Tiwana H, et al. **Br J Rheumatol** 1996 Jun;35(6):592–4

Prognostic markers in rheumatoid arthritis and classification of antirheumatic therapies. Choy EH, et al. **Drugs** 1995;50 Suppl 1:15–25 (73 ref.)

Rheumatoid arthritis in the elderly. Prevalence and optimal management. van Schaardenburg D. **Drugs Aging** 1995 Jul; 7(1):30–7 (57 ref.)

Perioperative management of the rheumatoid patient. Haynie RL, et al. **J Foot Ankle Surg** 1996 Mar-Apr;35(2):94–100 (74 ref.)

Influenza vaccination in rheumatoid arthritis [letter; comment] Cimmino MA, et al. **J Rheumatol** 1995 Sep; 22(9):1802–3. Comment on: J Rheumatol 1994 Jul;21(7):1203–6.

Perioperative management of rheumatoid arthritis. Areas of concern for primary care physicians. Lyssy KJ, et al. **Postgrad Med** 1996 Feb;99(2):191–4, 199–201, 205–6 (27 ref.)

Eicosanoids in rheumatoid arthritis. Sperling RI. **Rheum Dis Clin North Am** 1995 Aug;21(3):741–58 (84 ref.)

Quantitative photometrical assessment of iron deposits in synovial membranes in different joint diseases. Fritz P, et al. **Rheumatol Int** 1996;15(5):211–6

[Human leukocyte antigen (HLA) and the related diseases] Mizuki N, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2091–103 (12 ref.) **(Jpn)**

[Chronic rheumatoid arthritis model mice transgenic for the HTLV-I tax gene] Iwakura Y. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2074–82 (33 ref.) **(Jpn)**

BLOOD

Megakaryocyte-related interleukins in reactive thrombocytosis versus autonomous thrombocythemia. Haznedaroğlu IC, et al. **Acta Haematol** 1996;95(2):107–11

Folic acid and methotrexate in rheumatoid arthritis [letter; comment] Kavanaugh A, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):73; discussion 74. Comment on: Ann Intern Med 1994 Dec 1;121(11):833–41.

Some nutritional parameters in patients with rheumatoid arthritis. Lamour A, et al. **Ann Med Interne (Paris)** 1995; 146(6):409–12

Increased type I collagen degradation is associated with a need for total joint replacement surgery in rheumatoid arthritis [letter] Aman S, et al. **Ann Rheum Dis** 1996 Feb; 55(2):147

Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Choy EH, et al. **Arthritis Rheum** 1996 Jan;39(1):52–6

Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Youings A, et al. **Biochem J** 1996 Mar 1;314 (Pt 2):621–30

Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Blann AD, et al. **Br J Rheumatol** 1995 Sep;34(9):814–9

Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Maillefert JF, et al. **Br J Rheumatol** 1996 May;35(5):430–5

In vitro duodenal iron uptake and serum and mucosal iron protein levels, with special reference to rheumatoid arthritis. Raja KB, et al. **Br J Rheumatol** 1995 Nov; 34(11):1041–7

Lymphocyte reactivity to Clostridium perfringens antigens and toxoid in patients with arthritis [letter] Ström H, et al. **Br J Rheumatol** 1995 Nov;34(11):1095–6

sIL-2R levels in rheumatoid arthritis: poor correlation with clinical activity is due in part to disease duration. Tebib JG, et al. **Br J Rheumatol** 1995 Nov;34(11):1037–40

Elevated levels of corticotrophin-releasing factor binding protein in the blood of patients suffering from arthritis and septicaemia and the presence of novel ligands in synovial fluid. Woods RJ, et al. **Br J Rheumatol** 1996 Feb; 35(2):120–4

Increased numbers of CD5+ B cells and T cell receptor (TCR) gamma delta+ T cells are associated with younger age of onset in rheumatoid arthritis (RA). Hassan J, et al. **Clin Exp Immunol** 1996 Mar;103(3):353–6

The role of interleukin-8 and other cytokines in the pathogenesis of Felty's syndrome. Meliconi R, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):285–91

Serum erythropoietin and transferrin receptor levels in patients with rheumatoid arthritis. Noé G, et al. **Clin Exp Rheumatol** 1995 Jul-Aug;13(4):445–51

Lipid profile and anticardiolipin antibodies in rheumatoid arthritis [letter] Seriolo B, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):406–7

Sera of patients with rheumatoid arthritis contain antibodies to recombinant human T-lymphotrophic virus type I/II envelope glycoprotein p21. Starkebaum G, et al. **Clin Immunol Immunopathol** 1996 May;79(2):182–8

The effect of auranofin and sulphasalazine therapy on circulating levels of interleukin 6 in rheumatoid arthritis patients. Crilly A, et al. **Clin Rheumatol** 1995 Sep; 14(5):561–5

Does methotrexate affect serum level of IgA-alpha-1 antitrypsin complex in early rheumatoid arthritis? Lacki JK, et al. **Clin Rheumatol** 1995 Sep;14(5):566–9

Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Müller K, et al. **Clin Rheumatol** 1995 Jul;14(4):397–400

Soluble interleukin-2-receptor and interleukin-6 changes during low-dose methotrexate treatment in rheumatoid arthritis [letter] Spadaro A, et al. **Clin Rheumatol** 1996 Mar; 15(2):218–9

T-cell receptor variable region of the beta-chain gene use in peripheral blood and multiple synovial membranes during rheumatoid arthritis. Alam A, et al. **Hum Immunol** 1995 Apr;42(4):331–9

Blood polymorphonuclear leukocyte migratory activities during rheumatoid arthritis. Egger G, et al. **Inflammation** 1995 Dec;19(6):651–67

Day-to-day variation in iron status indexes is similar for most measures in elderly women with and without rheumatoid arthritis. Lammi-Keefe CJ, et al. **J Am Diet Assoc** 1996 Mar;96(3):247–51

Upregulated expression of IL-4 receptors and increased levels of IL-4 in rheumatoid arthritis patients. Rivas D, et al. **J Autoimmun** 1995 Aug;8(4):587–600

Rheumatoid factor avidity in patients with rheumatoid arthritis: identification of pathogenic RFs which correlate with disease parameters and with the gal(0) glycoform of IgG. Newkirk MM, et al. **J Clin Immunol** 1995 Sep; 15(5):250–7

Predictive significance of rheumatoid factor [letter; comment] Aho K, et al. **J Rheumatol** 1995 Nov; 22(11):2186–7. Comment on: J Rheumatol 1995 Mar;22(3):570–1.

Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids [see comments] Gudbjörnsson B, et al. **J Rheumatol** 1996 Apr;23(4):596–602 . Comment in: J Rheumatol 1996 Apr;23(4):577–81.

Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Weinberg AD, et al. **Nat Med** 1996 Feb; 2(2):183–9

Expression of neutrophil activation markers and neutrophil adhesion to chondrocytes in rheumatoid arthritis patients: relationship with disease activity. De Clerck LS, et al. **Res Immunol** 1995 Feb;146(2):81–7

Lipoprotein(a) in relation to acute phase reaction in patients with rheumatoid arthritis and polymyalgia rheumatica. Wållberg-Jonsson S, et al. **Scand J Clin Lab Invest** 1995 Jul;55(4):309–15

Biological markers of rheumatoid arthritis: do they help in evaluating and following patients? Wollheim FA. **Schweiz Med Wochenschr Suppl** 1996;80:18S–19S

Altered fatty acid, cholesterol and Na+/K+ ATPase activity in erythrocyte membrane of rheumatoid arthritis patients. Masoom-Yasinzai M. **Z Naturforsch [C]** 1996 May-Jun;51(5-6):401–3

[A study of relation between rheumatoid arthritis (RA) and blood stasis--the effect of acupuncture promoting blood circulation to remove blood stasis] Sun Z. **Chen Tzu Yen Chiu** 1995;20(2):71–5 (Eng. Abstr.) **(Chi)**

[Levels of endogenous plasma cortisol in patients with rheumatoid arthritis and other diffuse connective tissue diseases] Kučera M, et al. **Vnitr Lek** 1995 Jul;41(7):449–53 (Eng. Abstr.) **(Cze)**

[Concentration of serum sulphydryl groups in patients with rheumatoid arthritis dependent on age and duration of disease] Janiszewski M, et al. **Wiad Lek** 1994 Sep; 47(17-18):654–8 (Eng. Abstr.) **(Pol)**

[The effect of an antimalarial agent (chloroquine) on acute phase reactants in patients with rheumatoid arthritis] Jajić Z, et al. **Reumatizam** 1994;41(2):5–7 (Eng. Abstr.) **(Scr)**

CHEMICALLY INDUCED

Controversy of oral contraceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity. Pladevall-Vila M, et al. **Am J Epidemiol** 1996 Jul 1;144(1):1–14

G-CSF and exacerbation of rheumatoid arthritis [letter; comment] Stricker RB, et al. **Am J Med** 1996 Jun; 100(6):665–6. Comment on: Am J Med 1995 Jun;98(6):589–91.

Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Joosten LA, et al. **Arthritis Rheum** 1996 May; 39(5):797–809

Rheumatoid arthritis exacerbation by G-CSF treatment for bucillamine-induced agranulocytosis [letter] Nakashima H, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):677–9

Downregulation of silicone-induced chronic arthritis by gastric administration of type II collagen. Yoshino S. **Immunopharmacology** 1995 Nov;31(1):103–8

CLASSIFICATION

What is meant by 'rheumatoid'? [letter] Lagier R. **Ann Rheum Dis** 1996 Jun;55(6):403

What is rheumatoid arthritis? Symmons DP. **Br Med Bull** 1995 Apr;51(2):243–8 (13 ref.)

Construct validation of the ACR 1991 revised criteria for global functional status in rheumatoid arthritis. Stucki G, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):349–52

How many types of patients meet classification criteria? [letter; comment] Adebajo AO, et al. **J Rheumatol** 1995 Jul;22(7):1434–5; discussion 1435–6. Comment on: J Rheumatol 1994 Aug;21(8):1385–9.

How many types of patients meet classification criteria? [letter; comment] Roth SH. **J Rheumatol** 1995 Jul; 22(7):1435; discussion 1435–6. Comment on: J Rheumatol 1994 Aug;21(8):1385–9.

COMPLICATIONS

Agranulocytosis in rheumatoid arthritis associated with long-term flucloxacillin for staphylococcal osteomyelitis. Burton IE, et al. **Acta Haematol** 1995;94(4):196–8

Cervical spine instability in rheumatoid arthritis [letter] Sced A, et al. **Anaesth Intensive Care** 1996 Feb;24(1):127

Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Cortet B, et al. **Ann Rheum Dis** 1995 Oct;54(10):815–9

Chest pain in patients with rheumatoid arthritis. Martin JC, et al. **Ann Rheum Dis** 1996 Mar;55(3):152–3

Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Peel NF, et al. **Ann Rheum Dis** 1995 Oct;54(10):801–6

Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Peeters HR, et al. **Ann Rheum Dis** 1996 Mar;55(3):162–8

Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Voskuyl AE, et al. **Ann Rheum Dis** 1996 Mar;55(3):190–2

Isolated nail fold vasculitis in rheumatoid arthritis. Watts RA, et al. **Ann Rheum Dis** 1995 Nov;54(11):927–9

Rheumatoid arthritis preceding the onset of polyarticular tophaceous gout [letter] Zonana-Nacach A, et al. **Ann Rheum Dis** 1996 Jul;55(7):489–90 (25 ref.)

Erythematous papules in a patient with rheumatoid arthritis. Rheumatoid neutrophilic dermatitis (RND). Harkaway K, et al. **Arch Dermatol** 1995 Oct;131(10):1196, 1199–200

Accidental injury is a serious risk in children with typical absence epilepsy. Wirrell EC, et al. **Arch Neurol** 1996 Sep; 53(9):929–32

The relationship between rheumatoid arthritis and the acquired immunodeficiency syndrome: comment on the article by Ornstein et al [letter; comment] Adebajo AO, et al. **Arthritis Rheum** 1996 Aug;39(8):1437–9. Comment on: Arthritis Rheum 1995 Nov;38(11):1701–6.

Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Fries JF, et al. **Arthritis Rheum** 1996 Apr;39(4):616–22

The coexistence of systemic sclerosis and rheumatoid arthritis in five patients. Clinical and immunogenetic features suggest a distinct entity. Horiki T, et al. **Arthritis Rheum** 1996 Jan;39(1):152–6 (15 ref.)

Progressive joint destruction in a human immunodeficiency virus-infected patient with rheumatoid arthritis. Müller-Ladner U, et al. **Arthritis Rheum** 1995 Sep; 38(9):1328–32

A reexamination of the relationship between active rheumatoid arthritis and the acquired immunodeficiency syndrome [see comments] Ornstein MH, et al. **Arthritis Rheum** 1995 Nov;38(11):1701–6. Comment in: Arthritis Rheum 1996 Aug;39(8):1437–9.

Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Puéchal X, et al. **Arthritis Rheum** 1995 Nov;38(11):1618-29

Epstein-Barr virus clonality in lymphomas occurring in patients with rheumatoid arthritis. van de Rijn M, et al. **Arthritis Rheum** 1996 Apr;39(4):638-42

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. van Gestel AM, et al. **Arthritis Rheum** 1996 Jan; 39(1):34-40

The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Voskuyl AE, et al. **Arthritis Rheum** 1996 Feb;39(2):266-71

Acute laryngeal obstruction in rheumatoid arthritis [see comments] Bossingham DH, et al. **BMJ** 1996 Feb 3; 312(7026):295-6. Comment in: BMJ 1996 May 11;312(7040):1227.

Stridor in rheumatoid arthritis may be caused by laryngeal amyloidosis [letter; comment] Watkinson JC. **BMJ** 1996 May 11;312(7040):1227. Comment on: BMJ 1996 Feb 3;312(7026):295-6.

A stiff collar for the treatment of rheumatoid atlantoaxial subluxation. Kauppi M, et al. **Br J Rheumatol** 1996 Aug; 35(8):771-4

A study of the role of parvovirus B19 in rheumatoid arthritis [see comments] Kerr JR, et al. **Br J Rheumatol** 1995 Sep; 34(9):809-13. Comment in: Br J Rheumatol 1996 May;35(5):494.

Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Kobayashi H, et al. **Br J Rheumatol** 1996 Jan;35(1):44-9

Proteinaceous lymphadenopathy in a patient with known rheumatoid arthritis--case report and review of the literature. al Rikabi AC, et al. **Br J Rheumatol** 1995 Nov; 34(11):1087-9

Atlanto-occipital subluxation in rheumatoid arthritis demonstrated by magnetic resonance imaging. Romanowski CA, et al. **Br J Rheumatol** 1995 Aug; 34(8):787-9

Raynaud's phenomenon in rheumatoid arthritis. Saraux A, et al. **Br J Rheumatol** 1996 Aug;35(8):752-4

Hyper-IgM syndrome associated with rheumatoid arthritis: report of RA in a patient with primary impaired CD40 pathway. Sibilia J, et al. **Br J Rheumatol** 1996 Mar; 35(3):282-4

Correlates of functional disability in early rheumatoid arthritis: a cross-sectional study of 706 patients in four European countries. Smedstad LM, et al. **Br J Rheumatol** 1996 Aug;35(8):746-51

A patient with rheumatoid arthritis and microscopic polyarteritis [letter] Steuer A, et al. **Br J Rheumatol** 1995 Dec;34(12):1185-6

Neutrophilic dermatosis in association with rheumatoid arthritis. Hughes JR, et al. **Clin Exp Dermatol** 1995 Mar; 20(2):168-70

Osteoporosis in rheumatoid arthritis. Dequeker J, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S21-6 (60 ref.)

Brown-Sequard syndrome as a presenting symptom of cervical myelopathy in a rheumatoid arthritis patient [letter] Elkayam O, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):673-4

Gliadin immune reactivity in patients with rheumatoid arthritis. Paimela L, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):603-7

Treatment of osteoporosis of rheumatoid arthritis [letter] Cantatore FP, et al. **Clin Rheumatol** 1995 Sep;14(5):594-5

Osteoporosis in rheumatoid arthritis: effect of disease activity. Celiker R, et al. **Clin Rheumatol** 1995 Jul;14(4):429-33

Facioscapulohumeral dystrophy with myositis associated with rheumatoid arthritis. Coelho PC, et al. **Clin Rheumatol** 1996 Mar;15(2):185-8

Prevalence of metacarpal osteopenia in young rheumatoid arthritis patients. Kalla AA, et al. **Clin Rheumatol** 1995 Nov;14(6):617-25

Lymphatic obstruction in rheumatoid arthritis. Sant SM, et al. **Clin Rheumatol** 1995 Jul;14(4):445-50

Mutilating rheumatoid arthritis associated with sarcoidosis: a case report. Takashita M, et al. **Clin Rheumatol** 1995 Sep; 14(5):576-9

Coexisting rheumatoid arthritis and ankylosing spondylitis discussion of 3 cases with review of the literature. Toussirot E, et al. **Clin Rheumatol** 1995 Sep;14(5):554-60 (27 ref.)

Pyoderma gangrenosum with hepatopancreatic manifestations in a patient with rheumatoid arthritis. Hastier P, et al. **Dig Dis Sci** 1996 Mar;41(3):594-7 (9 ref.)

The underestimated long term medical and economic consequences of rheumatoid arthritis. Pincus T. **Drugs** 1995; 50 Suppl 1:1-14 (80 ref.)

Imaging of pulmonary disease in rheumatoid arthritis using J001X scintigraphy: preliminary results. Goupille P, et al. **Eur J Nucl Med** 1995 Dec;22(12):1411-5

Extensor tendon ruptures in rheumatoid arthritis. Williamson SC, et al. **Hand Clin** 1995 Aug;11(3):449-59 (21 ref.)

Case in point. Scleromalacia perforans. Olivero JJ. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):99

Rheumatoid neutrophilic dermatitis. Hassab-el-Naby HM, et al. **Int J Dermatol** 1996 Mar;35(3):207-8 (6 ref.)

Long-term results following digital flexor tenosynovectomy in rheumatoid arthritis. Wheen DJ, et al. **J Hand Surg [Am]** 1995 Sep;20(5):790-4

Complete palmar dislocation of the lunate in rheumatoid arthritis. Avascularity without avascular changes. Arner M, et al. **J Hand Surg [Br]** 1996 Jun;21(3):384-7

Palmar bands in rheumatoid arthritis and other chronic conditions of the upper limb. Elliot D, et al. **J Hand Surg [Br]** 1996 Jun;21(3):369-74

Frequency of cervical spine involvement in rheumatoid arthritis. Rajangam K, et al. **J Indian Med Assoc** 1995 Apr; 93(4):138-9, 137

Inner ear involvement in rheumatoid arthritis: a prospective clinical study. Kastanioudakis I, et al. **J Laryngol Otol** 1995 Aug;109(8):713-8

Anterior dissection of popliteal cyst causing anterior compartment syndrome. Hammoudeh M, et al. **J Rheumatol** 1995 Jul;22(7):1377-9

Pathogenetic mechanism and prevalence of the stable atlantoaxial subluxation in rheumatoid arthritis. Kauppi M, et al. **J Rheumatol** 1996 May;23(5):831-4

Absence of an association of rheumatoid arthritis and diffuse idiopathic skeletal hyperostosis: a case-control study. Mata S, et al. **J Rheumatol** 1995 Nov;22(11):2062-4

Trends in hospitalizations for gastrointestinal bleeding among patients with rheumatoid arthritis in Rochester, Minnesota, 1950-1991. Matteson EL, et al. **J Rheumatol** 1995 Aug; 22(8):1471-7

Intravenous cyclophosphamide pulses in the treatment of pyoderma gangrenosum associated with rheumatoid arthritis [letter; comment] Nordstrom D. **J Rheumatol** 1995 May;22(5):1000-1. Comment on: J Rheumatol 1994 Jul;21(7):1352-6.

Treatment of progressive rheumatoid interstitial lung disease with cyclosporine. Puttick MP, et al. **J Rheumatol** 1995 Nov;22(11):2163-5

Diffuse interstitial pulmonary amyloidosis in rheumatoid arthritis. Sumiya M, et al. **J Rheumatol** 1996 May; 23(5):933-6

Catastrophic antiphospholipid syndrome with fatal acute course in rheumatoid arthritis. Voisin L, et al. **J Rheumatol** 1995 Aug;22(8):1586-8

Relapsing polychondritis associated with rheumatoid arthritis. Hussain T, et al. **JPMA J Pak Med Assoc** 1995 Sep;45(9):249-50

Rheumatoid arthritis. The multiple pathways to chronic synovitis [editorial] Zvaifler NJ. **Lab Invest** 1995 Sep; 73(3):307-10

Chronic eosinophilic pneumonia in rheumatoid arthritis. Papiris SA, et al. **Monaldi Arch Chest Dis** 1995 Oct; 50(5):360-2

Disseminated cutaneous infection due to Mycobacterium chelonae in a patient with rheumatoid arthritis, amyloidosis, and renal failure. Forslund T, et al. **Nephrol Dial Transplant** 1995;10(7):1234-6

Rheumatoid arthritis associated with membranous nephropathy and IgA nephritis with necrotizing lesions. Irie F, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1338-41 (28 ref.)

A rare case of sarcoidosis with rheumatoid arthritis. Yutani Y, et al. **Osaka City Med J** 1995 Dec;41(2):85-9

Manubrio-sternal joint sepsis in rheumatoid arthritis [letter] Wright GD, et al. **Postgrad Med J** 1995 Jul;71(837):443-4

An autopsy case of diffuse panbronchiolitis accompanying rheumatoid arthritis. Sugiyama Y, et al. **Respir Med** 1996 Mar;90(3):175-7

Cilioretinal artery occlusion in sickle cell trait and rheumatoid arthritis. Kachmaryk MM, et al. **Retina** 1995; 15(6):501-4

A case of rheumatoid arthritis with lumbar spine involvement. Biasi D, et al. **Rheumatol Int** 1995;15(3):125-6

Esophageal motility disorder in a patient with rheumatoid arthritis [letter] Ozoran K, et al. **Rheumatol Int** 1996; 15(6):255-7

Relationships between measurements of impairment, disability, pain, and disease activity in rheumatoid arthritis patients with shoulder problems. Boström C, et al. **Scand J Rheumatol** 1995;24(6):352-9

Listeria monocytogenes arthritis of several joints. Ukkonen HJ, et al. **Scand J Rheumatol** 1995;24(6):392-4

Peripheral ulcerative keratitis in the setting of rheumatoid arthritis: treatment with immunosuppressive therapy. Jifi-Bahlool H, et al. **Semin Arthritis Rheum** 1995 Aug; 25(1):67-73

Lipoprotein (a) and anticardiolipin antibodies as risk factors for vascular disease in rheumatoid arthritis [letter; comment] Seriolo B, et al. **Thromb Haemost** 1995 Aug; 74(2):799-800. Comment on: Thromb Haemost 1994 Apr;71(4):424-7. Comment on: Thromb Haemost 1994 Oct;72(4):563-6.

[Rheumatoid pericarditis: correlation with immunologic parameters] Alušík S, et al. **Vnitr Lek** 1995 Nov; 41(11):764-6 (Eng. Abstr.) **(Cze)**

[Microalbuminuria in rheumatoid arthritis] Nordin H, et al. **Ugeskr Laeger** 1996 May 27;158(22):3141-3 (Eng. Abstr.) **(Dan)**

[Pleuropulmonary manifestations of rheumatoid arthritis] Crestani B, et al. **Presse Med** 1996 May 18;25(17):807-12 (25 ref.) (Eng. Abstr.) **(Fre)**

[Association of pyoderma gangrenosum with hepato-pancreatic involvement in rheumatoid polyarthritis (letter)] Ferrazzi V, et al. **Rev Med Interne** 1996;17(3):266-7 **(Fre)**

[Association of polymyositis and rheumatoid arthritis. Apropos of a new case not related to drug ingestion] Jardin H, et al. **Rev Med Interne** 1996;17(4):321-4 (27 ref.) (Eng. Abstr.) **(Fre)**

[Generalized osteoporosis in chronic polyarthritis--pathomechanisms and treatment approaches] Ringe JD. **Z Rheumatol** 1996 May-Jun;55(3):149-57 (49 ref.) (Eng. Abstr.) **(Ger)**

[Loculated pericardial effusion leading to functional tricuspid stenosis in a case of rheumatoid arthritis] Galli CA, et al. **Cardiologia** 1995 Sep;40(9):685-8 (11 ref.) (Eng. Abstr.) **(Ita)**

[Recurrent rheumatism and idiopathic osteoporosis in young adults. Coincidence or association?] Giordano N, et al. **Clin Ter** 1995 Dec;146(12):811-7 (16 ref.) (Eng. Abstr.) **(Ita)**

[Aortic valve replacement for rheumatoid aortic valve regurgitation] Uwabe K, et al. **Kyobu Geka** 1995 Sep; 48(10):869-72 (Eng. Abstr.) **(Jpn)**

[Case report: rheumatoid arthritis complicated by chronic myelogenous leukemia treated with interferon] Abe T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):70-5 (Eng. Abstr.) **(Jpn)**

[A case of Sjögren's syndrome with rheumatoid arthritis manifesting transverse myelitis with antineuronal antibody] Fujimoto Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):76-82 (Eng. Abstr.) **(Jpn)**

[A case of rheumatoid arthritis associated with multiple myeloma] Inoue F, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):94-9 (10 ref.) (Eng. Abstr.) **(Jpn)**

[A young woman with rheumatoid arthritis who rapidly developed secondary amyloidosis] Tanimoto K, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):83-9 (Eng. Abstr.) **(Jpn)**

[Immunohistochemical study of fibrosis and S-100 protein-positive cells in idiopathic pulmonary fibrosis and in interstitial pneumonia associated with rheumatoid arthritis] Yoshinouchi T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):9-15 (Eng. Abstr.) **(Jpn)**

[Acute myeloid leukemia (M1) following chemotherapy for Ki-1 lymphoma complicated with rheumatoid arthritis] Yoshida K, et al. **Rinsho Ketsueki** 1995 Dec;36(12):1365-71 (Eng. Abstr.) **(Jpn)**

[Detection of myocardial lesions by dipyridamole thallium-201 scintigraphy in patients with rheumatoid arthritis] Momose S. **Ryumachi** 1995 Jun;35(3):559-65 (Eng. Abstr.) **(Jpn)**

[Clinical characteristics and genetic background of secondary amyloidosis associated with rheumatoid arthritis in Japanese] Nakai H, et al. **Ryumachi** 1996 Feb;36(1):25-33 (Eng. Abstr.) **(Jpn)**

[IgG rheumatoid factor in rheumatoid arthritis with interstitial lung disease] Sakaida H. **Ryumachi** 1995 Aug; 35(4):671-7 (Eng. Abstr.) **(Jpn)**

[Corticosteroid therapy and aseptic bone necrosis in patients with rheumatoid arthritis] Tsurko VV, et al. **Ter Arkh** 1995; 67(7):71-4 (Eng. Abstr.) **(Rus)**

[Rheumatoid arthritis and ankylosing spondylitis] Jajić Z, et al. **Reumatizam** 1995;42(1):15-7 (Eng. Abstr.) **(Scr)**

[Changes in thyroid function in systemic lupus erythematosus, progressive systemic sclerosis and rheumatoid arthritis] Sram K, et al. **Reumatizam** 1994; 41(2):1-4 (Eng. Abstr.) **(Scr)**

[Acute ischemia of the lower limb in a patient with temporal arteritis and rheumatoid arthritis, carrier of anticardiolipin antibodies] Rodríguez Gómez M, et al. **An Med Interna** 1995 Oct;12(10):492-4 (Eng. Abstr.) **(Spa)**

[Effects of Sjögren's syndrome on pulmonary function impairment in patients with rheumatoid arthritis] Supervía A, et al. **An Med Interna** 1996 Apr;13(4):160-2 (Eng. Abstr.) **(Spa)**

[Bilateral pleural effusion and rheumatoid arthritis. Diagnostic value of pleural fluid cytology] Jareño Esteban J, et al. **Arch Bronconeumol** 1996 Mar;32(3):145-7 (Eng. Abstr.) **(Spa)**

[Seronegative rheumatoid arthritis and neuropathy as paraneoplastic phenomena in a case of chronic myelomonocytic leukemia (letter)] Calvo Villas JM, et al. **Sangre (Barc)** 1995 Oct;40(5):437-8 **(Spa)**

DIAGNOSIS

Crowned dens syndrome: a manifestation of hydroxy-apatite rheumatism. Malca SA, et al. **Acta Neurochir (Wien)** 1995; 135(3-4):126-30 (21 ref.)

Painful ankle region in rheumatoid arthritis. Analysis of soft-tissue changes with ultrasonography and MR imaging. Lehtinen A, et al. **Acta Radiol** 1996 Jul;37(4):572-7

Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Visser H, et al. **Ann Rheum Dis** 1996 Mar;55(3):157-61

Quantification of rheumatoid synovitis by magnetic resonance imaging. Gaffney K, et al. **Arthritis Rheum** 1995 Nov;38(11):1610-7

Specificity of antiperinuclear factor for rheumatoid arthritis in rheumatoid factor-positive sera. Berthelot JM, et al. **Br J Rheumatol** 1995 Aug;34(8):716-20

Stability of health status measurement in rheumatoid arthritis. Geenen R, et al. **Br J Rheumatol** 1995 Dec;34(12):1162-6

The value of HLA-B27 typing in the diagnosis of early, oligosymptomatic spondylarthropathies [letter; comment] Olajos A, et al. **Br J Rheumatol** 1996 Feb;35(2):192. Comment on: Br J Rheumatol 1995 Apr;34(4):301-3.

Long-term outcomes in rheumatoid arthritis. Pincus T. **Br J Rheumatol** 1995 Nov;34 Suppl 2:59-73 (77 ref.)

Needle arthroscopy [editorial] Reece R, et al. **Br J Rheumatol** 1995 Dec;34(12):1102-4 (18 ref.)

Short-term outcomes in recent-onset rheumatoid arthritis. Young A. **Br J Rheumatol** 1995 Nov;34 Suppl 2:79-86 (34 ref.)

Managing early presentation of rheumatoid arthritis. Systematic overview. Glazier R. **Can Fam Physician** 1996 May;42:913-22 (85 ref.)

Cytidine deaminase may be a useful marker in differentiating elderly onset rheumatoid arthritis from polymyalgia rheumatica/giant cell arteritis [see comments] Kassimos D, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):641-4. Comment in: Clin Exp Rheumatol 1995 Sep-Oct;13(5):571-2.

Paleopathology, its character and contribution to understanding and distinguishing among rheumatologic diseases: perspectives on rheumatoid arthritis and spondyloarthropathy. Rothschild BM. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):657-62 (31 ref.)

Cytidine deaminase--a new differential tool distinguishing elderly onset rheumatoid arthritis from polymyalgia rheumatica? [editorial; comment] Williams RC Jr. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):571-2. Comment on: Clin Exp Rheumatol 1995 Sep-Oct;13(5):641-4.

Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Gruber BL, et al. **Clin Immunol Immunopathol** 1996 Feb; 78(2):161-71

Magnetic resonance imaging of the wrist in rheumatoid arthritis: comparison with other inflammatory joint diseases and control subjects. Tonolli-Serabian I, et al. **Clin Rheumatol** 1996 Mar;15(2):137-42

Needle arthroscopy: a new frontier in rheumatology. Panchal P, et al. **Compr Ther** 1996 Jan;22(1):44-7 (14 ref.)

Immunoglobulin G galactosylation deficiency determined by isoelectric focusing and lectin affinoblotting in differential diagnosis of rheumatoid arthritis. Kötz K, et al. **Electrophoresis** 1996 Mar;17(3):533-4

Cryoglobulinaemia masquerading as rheumatoid vasculitis: the retina provides the clue [letter] Talks SJ, et al. **Eye** 1996;10 (Pt 3):399-402

Evaluation and treatment of the rheumatoid wrist. Terrono AL, et al. **Instr Course Lect** 1996;45:15-26 (64 ref.)

Presentation of chronic myelogenous leukemia as a rheumatoid syndrome--MRT-diagnosed chloroma. Tamm I, et al. **Leukemia** 1996 Jun;10(6):1072-4

Magnetic resonance imaging of rheumatoid arthritis. Winalski CS, et al. **Radiol Clin North Am** 1996 Mar;34(2):243-58, x (59 ref.)

Early-stage rheumatoid arthritis: diagnostic accuracy of MR imaging. Sugimoto H, et al. **Radiology** 1996 Jan; 198(1):185-92

The value of the ACR 1987 criteria in very early rheumatoid arthritis. Kaarela K, et al. **Scand J Rheumatol** 1995; 24(5):279-81

Scoring of synovial membrane hypertrophy and bone erosions by MR imaging in clinically active and inactive rheumatoid arthritis of the wrist. Ostergaard M, et al. **Scand J Rheumatol** 1995;24(4):212-8

The cervical spine in rheumatoid arthritis: relationship between neurologic signs and morphology of MR imaging and radiographs. Reijnierse M, et al. **Skeletal Radiol** 1996 Feb;25(2):113-8

[The diagnostic significance of rheumatoid factors in patients with early rheumatoid arthritis] Chen L. **Chung Hua Nei Ko Tsa Chih** 1995 Jul;34(7):449-51 (Eng. Abstr.) **(Chi)**

[Clinical judgment and decision making in practice. A patient with joint symptoms (clinical conference)] Stehouwer CD, et al. **Ned Tijdschr Geneeskd** 1996 Aug 17;140(33):1675-9 **(Dut)**

[Diagnosis of rheumatoid arthritis] Sieper J, et al. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):523-6 (9 ref.) **(Ger)**

[Assessment of disease course in chronic rheumatoid arthritis: new quantitative dimensions for clinical practice] Stucki G, et al. **Schweiz Med Wochenschr** 1995 Oct 21; 125(42):2003-14 (39 ref.) (Eng. Abstr.) **(Ger)**

[Therapy refractory atypical polyarthritis and cryoglobulinemia in a patient with colon carcinoma and palliative intestinal bypass. Differential diagnosis: carcinoma-polyarthritis or bypass arthritis] Kanzler S, et al. **Z Gastroenterol** 1995 Aug;33(8):449-53 (Eng. Abstr.) **(Ger)**

[Comparison of rheumatoid test procedures--value and critical interpretation of sensitivity and specificity and their effect on pre-test and post-test probability] Aupperle KR, et al. **Z Rheumatol** 1996 May-Jun;55(3):158-67 (Eng. Abstr.) **(Ger)**

[RS3PE syndrome. A new rheumatic inflammatory syndrome in advanced age] Pittau E, et al. **Clin Ter** 1995 Nov; 146(11):663-73 (35 ref.) (Eng. Abstr.) **(Ita)**

[Usefulness of the determination of C reactive protein and other acute phase proteins in rheumatoid arthritis] Galeazzi M, et al. **Recenti Prog Med** 1995 Nov;86(11):456-62 (40 ref.) (Eng. Abstr.) **(Ita)**

[Clinical significance of IgG rheumatoid factor in patients with rheumatoid arthritis] Naka T, et al. **Ryumachi** 1995 Jun;35(3):530-7 (Eng. Abstr.) **(Jpn)**

[The relationship between genotypes of HLA-DRB1 alleles and progression of bony destruction changes of rheumatoid arthritis] Toda Y, et al. **Ryumachi** 1995 Jun;35(3):514-20 (Eng. Abstr.) **(Jpn)**

[Antibodies to skeletal muscle myofibrillar proteins in the diagnosis of rheumatoid arthritis] Zborovskiĭ AB, et al. **Ter Arkh** 1995;67(8):54-6 (Eng. Abstr.) **(Rus)**

[Rheumatoid arthritis in the cricoarytenoid joint] Jajić I, et al. **Reumatizam** 1994;41(2):13-4 (Eng. Abstr.) **(Scr)**

[Rheumatoid arthritis and celiac disease: a chance association? (letter)] Mota Vargas R, et al. **An Med Interna** 1996 May;13(5):252-3 **(Spa)**

[Immunoglobulin E and beta 2-microglobulin in the blood serum and synovial fluid of patients with rheumatoid arthritis, arthrosis deformans and traumatic arthritis] Nelko IeM, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):127-9 **(Ukr)**

DIET THERAPY

Validation of a meta-analysis: the effects of fish oil in rheumatoid arthritis. Fortin PR, et al. **J Clin Epidemiol** 1995 Nov;48(11):1379-90

DRUG THERAPY

Flare-up at contact allergy sites in a gold-treated rheumatic patient. Möller H, et al. **Acta Derm Venereol** 1996 Jan; 76(1):55-8

Rheumatoid arthritis--changing theories and treatment modalities. van de Putte LB, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:10-3 (13 ref.)

Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities. Blackburn WD. **Am J Med** 1996 Feb 26;100(2A):24S-30S (47 ref.)

Serious adverse events with low-dose, long-term corticosteroid therapy in rheumatoid arthritis [letter; comment] Roger L. **Am J Med** 1995 Dec;99(6):692-4. Comment on: Am J Med 1994 Feb;96(2):115-23.

Cyclosporine dosing for RA [letter; comment] Redford TW, et al. **Am Pharm** 1995 Mar;NS35(3):5. Comment on: Am Pharm 1994 Nov;NS34(11):31-7, 41-2.

Folic acid and methotrexate in rheumatoid arthritis [letter; comment] Cooper BA. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):73; discussion 74. Comment on: Ann Intern Med 1994 Dec 1;121(11):833-41.

Misoprostol and gastrointestinal complications in patients taking nonsteroidal anti-inflammatory drugs for rheumatoid arthritis [letter; comment] Grossman CM. **Ann Intern Med** 1996 May 15;124(10):926-7. Comment on: Ann Intern Med 1995 Aug 15;123(4):241-9.

Misoprostol and gastrointestinal complications in patients taking nonsteroidal anti-inflammatory drugs for rheumatoid arthritis [letter; comment] Hammer HF. **Ann Intern Med** 1996 May 15;124(10):927. Comment on: Ann Intern Med 1995 Aug 15;123(4):241-9.

Folic acid and methotrexate in rheumatoid arthritis [letter; comment] Kavanaugh A, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):73; discussion 74. Comment on: Ann Intern Med 1994 Dec 1;121(11):833-41.

Misoprostol and gastrointestinal complications in patients taking nonsteroidal anti-inflammatory drugs for rheumatoid arthritis [letter; comment] Madhok R, et al. **Ann Intern Med** 1996 May 15;124(10):926; discussion 927 . Comment on: Ann Intern Med 1995 Aug 15;123(4):241-9.

Folic acid and methotrexate in rheumatoid arthritis [letter; comment] Shiroky JB. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):73-4. Comment on: Ann Intern Med 1994 Dec 1;121(11):833-41.

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial [see comments] van der Heide A, et al. **Ann Intern Med** 1996 Apr 15;124(8):699-707. Comment in: Ann Intern Med 1996 Apr 15;124(8):773-4.

Rheumatoid arthritis: treat now, not later! [editorial; comment] Weinblatt ME. **Ann Intern Med** 1996 Apr 15; 124(8):773-4. Comment on: Ann Intern Med 1996 Apr 15;124(8):699-707.

Misoprostol and gastrointestinal complications in patients taking nonsteroidal anti-inflammatory drugs for rheumatoid arthritis [letter; comment] Wendel TD. **Ann Intern Med** 1996 May 15;124(10):926; discussion 927 . Comment on: Ann Intern Med 1995 Aug 15;123(4):241-9.

Rheumatoid arthritis and the drop in tolerance to foods: elimination diets and the reestablishment of tolerance by low-dose diluted food. Gianfranceschi P, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:379-81

Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Alarcón GS, et al. **Ann Rheum Dis** 1995 Sep;54(9):708-12

Specific drugs for a complex disease: can there be a magic bullet against rheumatoid arthritis? Barthel HR, et al. **Ann Rheum Dis** 1995 Dec;54(12):948-50

A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Bendix G, et al. **Ann Rheum Dis** 1996 Mar;55(3):169-76

Tenidap: not just another NSAID? Canvin JM, et al. **Ann Rheum Dis** 1996 Feb;55(2):79-82 (29 ref.)

Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients. De La Mata J, et al. **Ann Rheum Dis** 1995 Nov;54(11):881-5

Early rheumatoid arthritis: time to aim for remission? Emery P, et al. **Ann Rheum Dis** 1995 Dec;54(12):944-7

Economic evaluation in rheumatology: a necessity for clinical studies. Griffiths B, et al. **Ann Rheum Dis** 1995 Nov; 54(11):863-4

Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Hassan W. **Ann Rheum Dis** 1996 May; 55(5):273-5

Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Lems WF, et al. **Ann Rheum Dis** 1996 May; 55(5):288-93

Low dose desensitisation does not reduce the toxicity of sulphasalazine in rheumatoid arthritis. McInnes IB, et al. **Ann Rheum Dis** 1996 May;55(5):328-30

Effect of gold treatment on cytokine expression in synovium [letter; comment] Smith MD. **Ann Rheum Dis** 1995 Sep; 54(9):779. Comment on: Ann Rheum Dis 1994 May;53(5):315-22.

Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Zonneveld IM, et al. **Arch Dermatol** 1996 Feb; 132(2):184-7

Oral heparin in the treatment of rheumatoid arthritis. Imiela J, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(5-6):313-5

Influence of gold salts treatment on the serum concentration of IL-1 and IL-2 in patients with rheumatoid arthritis. Lewandowicz J, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(3-4):195-8

Resolution of a soft-tissue sarcoma in a patient with rheumatoid arthritis after discontinuation of azathioprine therapy. Csuka ME, et al. **Arch Intern Med** 1996 Jul 22; 156(14):1573-6

Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Singh G, et al. **Arch Intern Med** 1996 Jul 22;156(14):1530-6

Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. **Arthritis Rheum** 1996 May;39(5):723-31

Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Bachman TR, et al. **Arthritis Rheum** 1996 Feb;39(2):325-9

Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone [see comments] Blackburn WD Jr, et al. **Arthritis Rheum** 1995 Oct;38(10):1447-56. Comment in: Arthritis Rheum 1996 Jul;39(7):1263-4.

Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Blanco R, et al. **Arthritis Rheum** 1996 Jun;39(6):1016-20 (19 ref.)

Cytomegalovirus in methotrexate-treated rheumatoid arthritis patients: comment on the concise communication by Aglas et al [letter] Bowman S, et al. **Arthritis Rheum** 1995 Dec;38(12):1861-2

Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial. Buchbinder R, et al. **Arthritis Rheum** 1995 Nov;38(11):1568-80

Nonsteroidal antiinflammatory drug-induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis. Davies NM, et al. **Arthritis Rheum** 1996 Feb; 39(2):321-4 (15 ref.)

Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Eggelmeijer F, et al. **Arthritis Rheum** 1996 Mar;39(3):396-402

The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Emkey RD, et al. **Arthritis Rheum** 1996 Feb;39(2):277-82

The total cost of drug therapy for rheumatoid arthritis: comment on the article by Prashker and Meenan [letter] Feinberg HL. **Arthritis Rheum** 1995 Dec;38(12):1862-3

N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot study. Gravallese EM, et al. **Arthritis Rheum** 1996 Jun;39(6):1021-6

Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Gutierrez-Ureña S, et al. **Arthritis Rheum** 1996 Feb;39(2):272-6

Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables. Kremer JM, et al. **Arthritis Rheum** 1995 Sep;38(9):1194-203

Results of controlled study of combination therapy with azathioprine and methotrexate in the treatment of rheumatoid arthritis revisited: comment on the article by Willkens et al [letter] McCarty DJ. **Arthritis Rheum** 1996 Aug;39(8):1436-7

Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year followup. McKendry RJ, et al. **Arthritis Rheum** 1996 Jul; 39(7):1246-53

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study.

Mladenovic V, et al. **Arthritis Rheum** 1995 Nov; 38(11):1595–603

Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension. Moreland LW, et al. **Arthritis Rheum** 1995 Sep; 38(9):1177–86

Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Möttönen T, et al. **Arthritis Rheum** 1996 Jun;39(6):996–1005

Tenidap in rheumatoid arthritis: comment on the article by Blackburn et al [letter; comment] Pruzanski W, et al. **Arthritis Rheum** 1996 Jul;39(7):1263–4. Comment on: Arthritis Rheum 1995 Oct;38(10):1447–56.

Healing phenomena of erosive changes in rheumatoid arthritis patients undergoing disease-modifying antirheumatic drug therapy. Rau R, et al. **Arthritis Rheum** 1996 Jan;39(1):162–8

Long-term treatment with every-other-week methotrexate in rheumatoid arthritis patients with sustained disease improvement: comment on the article by Kremer et al [letter] Roth SH. **Arthritis Rheum** 1995 Dec;38(12):1865–6

Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Shapiro DL, et al. **Arthritis Rheum** 1995 Dec;38(12):1851–4 (24 ref.)

Toxicity of combination therapies in rheumatoid arthritis: comment on the article by Willkens et al [letter] Stein CM. **Arthritis Rheum** 1996 Aug;39(8):1435–7

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. van Gestel AM, et al. **Arthritis Rheum** 1996 Jan; 39(1):34–40

Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Willkens RF, et al. **Arthritis Rheum** 1995 Dec;38(12):1799–806

Neutrophil trafficking into inflamed joints in patients with rheumatoid arthritis, and the effects of methylprednisolone. Youssef PP, et al. **Arthritis Rheum** 1996 Feb;39(2):216–25

Innovative treatment approaches for rheumatoid arthritis. Combination therapy. Borigini MJ, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):689–710 (61 ref.)

Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. Furst DE. **Baillieres Clin Rheumatol** 1995 Nov;9(4):711–29 (41 ref.)

Antimicrobial therapy for rheumatoid arthritis. Kloppenburg M, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):759–69 (89 ref.)

Innovative treatment approaches for rheumatoid arthritis. New cyclo-oxygenase and cytokine inhibitors. Richardson CE, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):731–58 (73 ref.)

The epidemiology of drug treatment failure in rheumatoid arthritis. Wolfe F. **Baillieres Clin Rheumatol** 1995 Nov; 9(4):619–32 (40 ref.)

Side-effects of drugs used in the treatment of rheumatoid arthritis. Evans PJ, et al. **Biochem Soc Symp** 1995; 61:195–207 (49 ref.)

The role of corticosteroids in rheumatoid arthritis [editorial] Byron M. **Br J Hosp Med** 1996 Mar 6-19;55(5):235–6

Radical Intervention in Early Rheumatoid Arthritis. The Case for Enteric-Coated Sulphasalazine, Methotrexate and Combination Regimes. Proceedings of a workshop. Camogli, Italy, September 1994. **Br J Rheumatol** 1995 Nov; 34 Suppl 2:1–112

Infertility may sometimes be associated with NSAID consumption. Akil M, et al. **Br J Rheumatol** 1996 Jan; 35(1):76–8

Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Barrera P, et al. **Br J Rheumatol** 1995 Aug; 34(8):747–55

An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Bevis PJ, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:56–60

Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Beyeler C, et al. **Br J Rheumatol** 1996 May;35(5):446–52

Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Bologna C, et al. **Br J Rheumatol** 1996 May;35(5):453–7

Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease [letter] Borg AA. **Br J Rheumatol** 1995 Nov;34(11):1097–8

Clinical efficacy of sulphasalazine—a review. Capell HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:35–9 (30 ref.)

A randomized double-blind controlled trial of sulphasalazine combined with pulses of methylprednisolone or placebo in the treatment of rheumatoid arthritis. Ciconelli RM, et al. **Br J Rheumatol** 1996 Feb;35(2):150–4

Are slow-acting anti-rheumatic drugs monitored too often? An audit of current clinical practice. Comer M, et al. **Br J Rheumatol** 1995 Oct;34(10):966–70

Folate supplementation and methotrexate. Dijkmans BA. **Br J Rheumatol** 1995 Dec;34(12):1172–4 (22 ref.)

Safety of meloxicam: a global analysis of clinical trials. Distel M, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:68–77

Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Emery P. **Br J Rheumatol** 1995 Nov;34 Suppl 2:87–90 (16 ref.)

How and when should combination therapy be used? The role of an anchor drug. Farr M, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:100–3 (38 ref.)

Rational disease-modifying anti-rheumatic drug (DMARD) therapy: is it possible? [editorial] Furst DE. **Br J Rheumatol** 1996 Aug;35(8):707–8

Rheumatoid arthritis and heparin [letter] Gaffney A, et al. **Br J Rheumatol** 1996 Aug;35(8):808–9

Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Ghozlan PR, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:51–5

Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions. Haagsma CJ, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:104–8 (30 ref.)

A randomized trial of testosterone therapy in males with rheumatoid arthritis. Hall GM, et al. **Br J Rheumatol** 1996 Jun;35(6):568–73

Combination therapy with sulphasalazine and azathioprine [letter] Helliwell PS. **Br J Rheumatol** 1996 May;35(5):493–4

Neurological side effects in two patients receiving gold injections for rheumatoid arthritis. Hill C, et al. **Br J Rheumatol** 1995 Oct;34(10):989–90

Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Hilliquin P, et al. **Br J Rheumatol** 1996 May;35(5):441–5

A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Huskisson EC, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:29–34

CAMPATH-1H in rheumatoid arthritis—an intravenous dose-ranging study. Isaacs JD, et al. **Br J Rheumatol** 1996 Mar;35(3):231–40

Use of contrast enhanced MRI in the assessment of therapeutic response to a disease-modifying antirheumatic drug. Case study of a patient with rheumatoid arthritis—6- and 24-month follow up. Jevtic V, et al. **Br J Rheumatol** 1995 Oct;34(10):956–9

An audit of methotrexate and folic acid for rheumatoid arthritis. Experience from a teaching centre. Jobanputra P, et al. **Br J Rheumatol** 1995 Oct;34(10):971–5

Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Jones M, et al. **Br J Rheumatol** 1996 Aug;35(8):738–45

Sulphasalazine-induced systemic lupus erythematosus in a patient with rheumatoid arthritis [letter; comment] Khattak FH, et al. **Br J Rheumatol** 1996 Jan;35(1):104. Comment on: Br J Rheumatol 1995 May;34(5):435–9.

Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis. Kremer JM. **Br J Rheumatol** 1995 Nov;34 Suppl 2:26–9 (37 ref.)

Neurological signs in RA patients receiving gold [letter] Machtey I. **Br J Rheumatol** 1996 Aug;35(8):804

Corticosteroids in the management of rheumatoid arthritis [editorial] Morrison E, et al. **Br J Rheumatol** 1996 Jan; 35(1):2–4

Quantitative assessment of synovial inflammation by dynamic gadolinium-enhanced magnetic resonance imaging. A study of the effect of intra-articular methylprednisolone on the rate of early synovial enhancement. Ostergaard M, et al. **Br J Rheumatol** 1996 Jan;35(1):50–9

Clinical trial design for evaluating combination therapies. Paulus HE. **Br J Rheumatol** 1995 Nov;34 Suppl 2:92–5 (26 ref.)

A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Reginster JY, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:17–21

Re: Audit of shared care between hospital and general practice in the management of rheumatoid arthritis [letter; comment] Richards AJ. **Br J Rheumatol** 1996 Apr;35(4):398 . Comment on: Br J Rheumatol 1995 Jul;34(7):673–6.

Adverse events in methotrexate-treated rheumatoid arthritis patients. Sandoval DM, et al. **Br J Rheumatol** 1995 Nov; 34 Suppl 2:49–56 (76 ref.)

Combination of sulphasalazine and methotrexate in the management of rheumatoid arthritis—view based on personal clinical experience. Shiroky JB. **Br J Rheumatol** 1995 Nov;34 Suppl 2:109–12

Sulphasalazine: mechanism of action in rheumatoid arthritis. Smedegård G, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:7–15 (133 ref.)

Tenidap versus diclofenac in rheumatoid arthritis [letter; comment] Swaak AJ. **Br J Rheumatol** 1996 Jun;35(6):602 . Comment on: Br J Rheumatol 1995 Jun;34(6):554–63.

Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis. van Riel PL, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:40–2

Efficacy of methotrexate in rheumatoid arthritis. Weinblatt ME. **Br J Rheumatol** 1995 Nov;34 Suppl 2:43–8 (49 ref.)

Methotrexate in rheumatoid arthritis: toxicity issues [editorial] Weinblatt ME. **Br J Rheumatol** 1996 May; 35(5):403–5 (27 ref.)

Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritis. Williams HJ. **Br J Rheumatol** 1995 Nov;34 Suppl 2:96–9 (34 ref.)

A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Wojtulewski JA, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:22–8

How do second-line agents work? Choy E, et al. **Br Med Bull** 1995 Apr;51(2):472–92 (124 ref.)

Mechanisms of the effects of methotrexate. Cronstein BN, et al. **Bull Rheum Dis** 1996 Aug;45(5):6–8

Cyclosporine in the treatment of rheumatoid arthritis. Stein CM. **Bull Rheum Dis** 1995 Nov;44(7):1–4 (11 ref.)

Dermacase. Fixed drug eruption. Enta T. **Can Fam Physician** 1996 Jun;42:1099, 1101

Methotrexate in rheumatoid arthritis: when NSAIDs fail. Flynn JA, et al. **Cleve Clin J Med** 1995 Nov-Dec; 62(6):351–9 (92 ref.)

Correlation between methotrexate pharmacokinetic parameters, and clinical and biological status in rheumatoid arthritis patients. Bologna C, et al. **Clin Exp Rheumatol** 1995 Jul-Aug;13(4):465–70

Treatment of early rheumatoid arthritis: a review of current and future concepts and therapy [see comments] Dawes PT, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):381–94 (87 ref.). Comment in: Clin Exp Rheumatol 1996 Jan-Feb;14(1):106.

Aggressive therapy for rheumatoid arthritis. Kahn MF. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S31–4 (26 ref.)

Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Leeb BF, et al. **Clin Exp Rheumatol** 1995 Jul-Aug;13(4):459–63

Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Lems WF, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):293–7

A perspective on anti-cytokine and anti-T cell-directed therapies in rheumatoid arthritis. Maini RN. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S35–40 (40 ref.)

Rheumatoid arthritis: new trends in therapy. van de Putte LB, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S27–30 (11 ref.)

Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Stein CM, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):47–51

Mechanism of action of cyclosporin in rheumatoid arthritis. Bentin J. **Clin Rheumatol** 1995 Sep;14 Suppl 2:22–5 (50 ref.)

The clinical and immunological effects of cyclosporin A on patients with rheumatoid arthritis. Chang DM, et al. **Clin Rheumatol** 1995 Sep;14(5):537–43

The effect of auranofin and sulphasalazine therapy on circulating levels of interleukin 6 in rheumatoid arthritis patients. Crilly A, et al. **Clin Rheumatol** 1995 Sep; 14(5):561–5

A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis. Farr M, et al. **Clin Rheumatol** 1995 Sep;14(5):531–6

Cyclosporine in rheumatoid arthritis: an overview. Førre O. **Clin Rheumatol** 1995 Sep;14 Suppl 2:33–6 (20 ref.)

Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Franck H, et al. **Clin Rheumatol** 1996 Mar;15(2):163–7

Prognostic factors for the outcome of methotrexate treatment in rheumatoid arthritis. Kolarz G, et al. **Clin Rheumatol** 1995 Sep;14(5):515–8

Does methotrexate affect serum level of IgA-alpha-1 antitrypsin complex in early rheumatoid arthritis? Lacki JK, et al. **Clin Rheumatol** 1995 Sep;14(5):566–9

Clinical implications of patients' knowledge. Mahmud T, et al. **Clin Rheumatol** 1995 Nov;14(6):627–30

The use of Sandimmun (cyclosporin A) in severe refractory rheumatoid arthritis: the Belgian experience. Malaise MG, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 2:26–32

Anti-inflammatory efficacy of Melothria madraspatana in active rheumatoid arthritis [letter] Ramakrishanamacharya CH, et al. **Clin Rheumatol** 1996 Mar;15(2):214–5

Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy. Salaffi F, et al. **Clin Rheumatol** 1995 Jul;14(4):458–63

Soluble interleukin-2-receptor and interleukin-6 changes during low-dose methotrexate treatment in rheumatoid arthritis [letter] Spadaro A, et al. **Clin Rheumatol** 1996 Mar; 15(2):218–9

Guidelines for the use of cyclosporine in rheumatoid arthritis. Tugwell P, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 2:37–41

Assessment of salsalate, a nonacetylated salicylate, in the treatment of patients with arthritis. Atkinson MH, et al. **Clin Ther** 1995 Sep-Oct;17(5):827–37

A multi-centre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. Pasero G, et al. **Curr Med Res Opin** 1995;13(6):305–15

Management of adverse effects of disease-modifying antirheumatic drugs. Wijnands MJ, et al. **Drug Saf** 1995 Oct;13(4):219–27 (31 ref.)

Methotrexate for rheumatoid arthritis. **Drug Ther Bull** 1995 Mar;33(3):17–9 (31 ref.)

Safety aspects of cyclosporin in rheumatoid arthritis. Dijkmans BA. **Drugs** 1995;50 Suppl 1:41–7 (37 ref.)

Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis [published erratum appears in Drugs 1995 Oct;50(4):625] Rains CP, et al. **Drugs** 1995 Jul;50(1):137–56 (134 ref.)

Clinical use of cyclosporin in rheumatoid arthritis. Richardson C, et al. **Drugs** 1995;50 Suppl 1:26–36 (53 ref.)

International consensus recommendations on cyclosporin use in rheumatoid arthritis. Tugwell P. **Drugs** 1995;50 Suppl 1:48–56 (32 ref.)

Combination therapy with cyclosporin in rheumatoid arthritis. Yocum DE. **Drugs** 1995;50 Suppl 1:37–40 (20 ref.)

Pharmacological intervention in older patients with rheumatoid arthritis. Quality of life aspects. Bendtsen P, et al. **Drugs Aging** 1995 Nov;7(5):338–46 (55 ref.)

Disease-modifying antirheumatic drugs. Potential effects in older patients. Gardner G, et al. **Drugs Aging** 1995 Dec; 7(6):420–37 (43 ref.)

Low dose corticosteroids in early rheumatoid arthritis. Can these drugs slow disease progression? Kirwan JR, et al. **Drugs Aging** 1996 Mar;8(3):157–61 (16 ref.)

Somatostatin 14 and joint inflammation: evidence for intraarticular efficacy of prolonged administration in rheumatoid arthritis. Fioravanti A, et al. **Drugs Exp Clin Res** 1995;21(3):97–103

Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis. Awni WM, et al. **Eur J Clin Pharmacol** 1995; 48(2):155–60

Novel synthetic retinoic acid inhibits rat collagen arthritis and differentially affects serum immunoglobulin subclass levels. Kuwabara K, et al. **FEBS Lett** 1996 Jan 8; 378(2):153–6

Is a pound of prevention worth an ounce of cure? Fennerty MB. **Gastroenterology** 1996 Mar;110(3):958–60

Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment. Brett SJ, et al. **Int Immunol** 1996 Mar;8(3):325–34

Intra-articular somatostatin 14 reduces synovial thickness in rheumatoid arthritis: an ultrasonographic study. Coari G, et al. **Int J Clin Pharmacol Res** 1995;15(1):27–32

Nephrogenic diabetes insipidus induced by lobenzarit disodium treatment in patients with rheumatoid arthritis. Sakane N, et al. **Intern Med** 1996 Feb;35(2):119–22 (17 ref.)

Minocycline in rheumatoid arthritis. Langevitz P, et al. **Isr J Med Sci** 1996 May;32(5):327–30 (33 ref.)

Could aspirin/NSAID treatment preserve independence and decrease the need for institutionalization of older rheumatoid arthritis patients [letter] Leibovitz A, et al. **J Am Geriatr Soc** 1996 Feb;44(2):216

Nodulosis during methotrexate therapy for rheumatoid arthritis. Das SK, et al. **J Assoc Physicians India** 1995 Sep; 43(9):651

Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Salloum E, et al. **J Clin Oncol** 1996 Jun;14(6):1943–9 (56 ref.)

Advances and issues in the pharmacotherapy of rheumatoid arthritis. Dahl SL. **J Clin Pharm Ther** 1995 Jun; 20(3):131–47 (77 ref.)

A case of drug eruption caused by the crude drug Boi (Sinomenium stem/Sinomeni caulis et Rhizoma). Okuda T, et al. **J Dermatol** 1995 Oct;22(10):795–800

Pancytopenia related eosinophilia in rheumatoid arthritis: a specific methotrexate phenomenon? Bruyn GA, et al. **J Rheumatol** 1995 Jul;22(7):1373–6

How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions [letter] Cheatum DE. **J Rheumatol** 1996 May;23(5):944

What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? Criswell LA, et al. **J Rheumatol** 1995 May;22(5):829–35

A preliminary evaluation of hydroxyurea for the treatment of rheumatoid arthritis. Ehrlich LS, et al. **J Rheumatol** 1995 Sep;22(9):1646–50

Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. Hilliquin P, et al. **J Rheumatol** 1995 Sep;22(9):1651–4

The second course of gold. Klinkhoff AV, et al. **J Rheumatol** 1995 Sep;22(9):1655–6

How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions. Klinkhoff AV, et al. **J Rheumatol** 1995 Sep;22(9):1657–9

Treatment of rheumatoid joint inflammation with intrasynovial triamcinolone hexacetonide. McCarty DJ, et al. **J Rheumatol** 1995 Sep;22(9):1631–5

Combination drug therapy of seropositive rheumatoid arthritis [see comments] McCarty DJ, et al. **J Rheumatol** 1995 Sep;22(9):1636–45. Comment in: J Rheumatol 1995 Sep;22(9):1611–7.

Neurogenic influences in arthritis: potential modification by capsaicin [editorial] Matucci Cerinic M, et al. **J Rheumatol** 1995 Aug;22(8):1447–9 (27 ref.)

What is the best source of useful data on the treatment of rheumatoid arthritis: clinical trials, clinical observations, or clinical protocols? [editorial; comment] Pincus T, et al. **J Rheumatol** 1995 Sep;22(9):1611–7. Comment on: J Rheumatol 1995 Sep;22(9):1636–45.

Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis—a double blind study. Rao UR, et al. **J Rheumatol** 1995 Jul;22(7):1235–40

Assessment of radiographic abnormalities in rheumatoid arthritis: what have we accomplished and where should we go from here? Sharp JT. **J Rheumatol** 1995 Sep; 22(9):1787–91 (48 ref.)

Accelerated nodulosis, pleural effusion, and pericardial tamponade during methotrexate therapy [letter; comment] Smith MD. **J Rheumatol** 1995 Jul;22(7):1439. Comment on: J Rheumatol 1994 May;21(5):934–7.

Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. Suarez-Almazor ME, et al. **J Rheumatol** 1995 May;22(5):836–43

Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. van der Veen MJ, et al. **J Rheumatol** 1995 Sep;22(9):1766–8 (20 ref.)

Radiographic progression in rheumatoid arthritis: results of 3 comparative trials. van Riel PL, et al. **J Rheumatol** 1995 Sep;22(9):1797–9

Pulse methylprednisolone in rheumatoid arthritis: effects on peripheral blood and synovial fluid neutrophil surface phenotype. Youssef P, et al. **J Rheumatol** 1995 Nov; 22(11):2065–71

Long-term therapy for rheumatoid arthritis [comment] Gómez-Reino JJ. **Lancet** 1996 Feb 10;347(8998):343–4. Comment on: Lancet 1996 Feb 10;347(8998):347–52.

Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis [see comments] ten Wolde S, et al. **Lancet** 1996 Feb 10;347(8998):347–52. Comment in: Lancet 1996 Feb 10;347(8998):343–4.

Safe prescribing of methotrexate for rheumatoid arthritis [letter] Kirkham BW. **Med J Aust** 1995 Sep 4;163(5):278

Mysteclin V in the treatment of rheumatoid arthritis [letter] Laidlaw CD. **Med J Aust** 1996 Apr 15;164(8):512

Epstein-Barr virus and lymphoproliferation in methotrexate-treated rheumatoid arthritis. Thomason RW, et al. **Mod Pathol** 1996 Mar;9(3):261–6

Glucocorticoids and joint destruction in rheumatoid arthritis [letter; comment] Deodhar AA, et al. **N Engl J Med** 1995 Dec 7;333(23):1569–70. Comment on: N Engl J Med 1995 Jul 20;333(3):142–6.

Glucocorticoids and joint destruction in rheumatoid arthritis [letter; comment] Fries JF, et al. **N Engl J Med** 1995 Dec 7;333(23):1569; discussion 1570. Comment on: N Engl J Med 1995 Jul 20;333(3):142–6.

Cyclosporine and methotrexate for severe rheumatoid arthritis [letter; comment] Malleson P. **N Engl J Med** 1995 Dec 7;333(23):1567; discussion 1568–9. Comment on: N Engl J Med 1995 Jul 20;333(3):137–41.

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. O'Dell JR, et al. **N Engl J Med** 1996 May 16;334(20):1287–91

Glucocorticoids and joint destruction in rheumatoid arthritis [letter; comment] Porter D. **N Engl J Med** 1995 Dec 7; 333(23):1569; discussion 1570. Comment on: N Engl J Med 1995 Jul 20;333(3):142–6.

Cyclosporine and methotrexate for severe rheumatoid arthritis [letter; comment] Rosh JR, et al. **N Engl J Med** 1995 Dec 7;333(23):1567–8; discussion 1568–9. Comment on: N Engl J Med 1995 Jul 20;333(3):137–41.

Treatment of rheumatoid arthritis [letter] Schinagl EF, et al. **N Engl J Med** 1996 Sep 12;335(11):822; discussion 822–3

Cyclosporine and methotrexate for severe rheumatoid arthritis [letter; comment] Schlesinger N, et al. **N Engl J Med** 1995 Dec 7;333(23):1567; discussion 1568–9. Comment on: N Engl J Med 1995 Jul 20;333(3):137–41.

Cyclosporine and methotrexate for severe rheumatoid arthritis [letter; comment] Steinberg AD. **N Engl J Med** 1995 Dec 7;333(23):1567; discussion 1568–9. Comment on: N Engl J Med 1995 Jul 20;333(3):137–41.

Treatment of rheumatoid arthritis [letter] Stohl W, et al. **N Engl J Med** 1996 Sep 12;335(11):821–2; discussion 821–2

Cyclosporine and methotrexate for severe rheumatoid arthritis [letter; comment] Storb R, et al. **N Engl J Med** 1995 Dec 7;333(23):1568; discussion 1568–9. Comment on: N Engl J Med 1995 Jul 20;333(3):137–41.

Cyclosporine and methotrexate for severe rheumatoid arthritis [letter; comment] van de Rijn M, et al. **N Engl J Med** 1995 Dec 7;333(23):1568; discussion 1568–9. Comment on: N Engl J Med 1995 Jul 20;333(3):137–41.

Treatment of rheumatoid arthritis [letter] Zurier RB, et al. **N Engl J Med** 1996 Sep 12;335(11):822; discussion 822–3

Treating rheumatoid arthritis with clotrimazole [letter; comment] Panayi GS. **Nat Med** 1995 Oct;1(10):977–8. Comment on: Nat Med 1995 Jun;1(6):534–40.

Non-coeliac sprue possibly related to methotrexate in a rheumatoid arthritis patient. Houtman PM, et al. **Neth J Med** 1995 Sep;47(3):113–6

Interaction of indometacin farnesil, a new nonsteroidal antiinflammatory drug with peripheral blood mononuclear cells from patients with rheumatoid arthritis. Hirohata S, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr; 19(2):136–44

Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Wang Y, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8955–9

The facts about methotrexate in rheumatoid arthritis [editorial; comment] Bannwarth B, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep;62(7–8):471–3. Comment on: Rev Rhum Engl Ed 1995 Jul-Sep;62(7–8):477–86.

Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths) [see comments] Berthelot JM, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep;62(7–8):477–86 (108 ref.). Comment in: Rev Rhum Engl Ed 1995 Jul-Sep;62(7–8):471–3.

Polyradiculoneuropathy induced by gold therapy [letter] Navaux F, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):467

Low-dose glucocorticoid therapy in rheumatoid arthritis. Trèves R. **Rev Rhum Engl Ed** 1995 Nov;62(10):611–7 (40 ref.)

The changing face of therapy for rheumatoid arthritis. Kremer JM. **Rheum Dis Clin North Am** 1995 Aug; 21(3):845–52 (34 ref.)

Investigational agents for rheumatoid arthritis. Merkel PA, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):779–96 (85 ref.)

Rheumatoid arthritis. Outcome measures. Paulus HE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):605–18 (52 ref.)

Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals. Trentham DE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):817–34 (58 ref.)

Cyclosporine in rheumatoid arthritis. Yocum DE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):835–44 (57 ref.)

D-penicillamine and gold salt treatments were complicated by myasthenia and pemphigus, respectively, in the same patient with rheumatoid arthritis. Ciompi ML, et al. **Rheumatol Int** 1995;15(3):95–7

The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. Kornasoff D, et al. **Rheumatol Int** 1996;15(6):225–30

Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. Martín-Mola E, et al. **Rheumatol Int** 1995;15(3):111–6

Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Schnabel A, et al. **Rheumatol Int** 1996;15(5):195–200

Plasma viscosity in the monitoring of therapy in rheumatoid arthritis patients. Gudmundsson M, et al. **Scand J Rheumatol** 1995;24(4):219–24

Comparison of intramuscular gold and sulphasalazine in the treatment of early rheumatoid arthritis. A one year prospective study. Peltomaa R, et al. **Scand J Rheumatol** 1995;24(6):330–5

Effects of methotrexate, sulphasalazine and aurothiomalate on polymorphonuclear leucocytes in rheumatoid arthritis. Storgaard M, et al. **Scand J Rheumatol** 1996;25(3):168–73

Magnetic resonance imaging of the femoral head to detect avascular necrosis in active rheumatoid arthritis treated with methylprednisolone pulse therapy. van Vugt RM, et al. **Scand J Rheumatol** 1996;25(2):74–6

Review of clinical trials and benefit/risk ratio of meloxicam. Barner A. **Scand J Rheumatol Suppl** 1996;102:29–37 (15 ref.)

Clinical implications of selective cyclooxygenase-2 inhibition. Emery P. **Scand J Rheumatol Suppl** 1996; 102:23–8

Outcome measures in rheumatoid arthritis. Stucki G, et al. **Schweiz Med Wochenschr Suppl** 1996;80:14S–17S

Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Kavanaugh A, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):297–307

Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis. Rothman D, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):87–96 (75 ref.)

Major infection during methotrexate treatment for rheumatoid arthritis [letter] Schnabel A, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):357–9

[Cyclosporin A in the treatment of refractory rheumatoid arthritis] Trnavský K. **Cas Lek Cesk** 1995 Nov 15; 134(22):731–4 (Eng. Abstr.) **(Cze)**

[Subcutaneous self-administration of methotrexate in rheumatoid arthritis (letter)] Huisman AM, et al. **Ned Tijdschr Geneeskd** 1996 Jul 27;140(30):1564–5 **(Dut)**

[Methotrexate; fatal dosage errors due to inattention] Vesseur J, et al. **Ned Tijdschr Geneeskd** 1996 Jul 27;140(30):1533–5 **(Dut)**

[Towards more individualized parenteral gold therapy (editorial)] Kaarela K, et al. **Duodecim** 1994;110(11):1046–7 (14 ref.) **(Fin)**

[Cutaneous pseudolymphoma during treatment of rheumatoid polyarthritis with low-dose methotrexate] Delaporte E, et al. **Ann Dermatol Venereol** 1995;122(8):521–5 (33 ref.) (Eng. Abstr.) **(Fre)**

[Combination regimens in rheumatoid arthritis (editorial)] Bologna C, et al. **Presse Med** 1996 Jun 1;25(19):876–8 (Eng. Abstr.) **(Fre)**

[Methotrexate in rheumatology: a therapeutic revolution] Kaye O, et al. **Rev Med Liege** 1995 Nov;50(11):453–7 (10 ref.) **(Fre)**

[Methotrexate treatment of rheumatoid arthritis] Beyeler C. **Schweiz Med Wochenschr** 1996 Apr 27;126(17):703–12 (61 ref.) (Eng. Abstr.) **(Ger)**

[Felty syndrome: a therapy-resistant variant of chronic rheumatoid arthritis? 2 case reports and literature review] Brücker R, et al. **Schweiz Rundsch Med Prax** 1996 Apr 16;85(16):534–40 (38 ref.) (Eng. Abstr.) **(Ger)**

[Cutaneous side-effects of nonsteroidal anti-inflammatory drugs (NSAID)] Gebhardt M, et al. **Z Rheumatol** 1995

Nov-Dec;54(6):405-12 (49 ref.) (Eng. Abstr.) (Ger)
[Treatment of rheumatoid arthritis of senile onset with methotrexate] Biasi D, et al. **Recenti Prog Med** 1995 Dec; 86(12):472-5 (Eng. Abstr.) (Ita)
[A case of rheumatoid arthritis complicated with salazosulfapyridine-induced aplastic anemia] Suwa A, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb; 18(1):116-22 (Eng. Abstr.) (Jpn)
[Prognosis and outcome of rheumatoid arthritis. Influence of anti-rheumatic therapy on natural course of disease and objectives in daily treatment] Fujimori J, et al. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):396-400 (8 ref.) (Jpn)
[Prognosis and outcome of rheumatoid arthritis--10 to 16 years of anti-rheumatic therapy] Fujimori J, et al. **Ryumachi** 1995 Jun;35(3):543-51 (Eng. Abstr.) (Jpn)
[A case of rheumatoid arthritis with malignant lymphoma taking methotrexate] Hayakawa M, et al. **Ryumachi** 1995 Aug;35(4):678-82 (23 ref.) (Eng. Abstr.) (Jpn)
[Methotrexate and salazosulfapyridine in the long-term treatment of rheumatoid arthritis] Ichikawa Y, et al. **Ryumachi** 1995 Aug;35(4):663-70 (Eng. Abstr.) (Jpn)
[Bucillamin induced lung injury in rheumatoid arthritis] Inokuma S, et al. **Ryumachi** 1996 Feb;36(1):34-42 (Eng. Abstr.) (Jpn)
[A long-term clinical analysis of the rheumatoid patients treated by a combination of GST and CCA] Minami M, et al. **Ryumachi** 1995 Oct;35(5):780-91 (Eng. Abstr.) (Jpn)
[Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for malignant rheumatoid arthritis] Okuda Y, et al. **Ryumachi** 1995 Aug;35(4):699-704 (18 ref.) (Eng. Abstr.) (Jpn)
[Disease-modifying drugs in rheumatoid arthritis. Duration of treatment and reasons for withdrawal] Grefslie H, et al. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):958-62 (32 ref.) (Eng. Abstr.) (Nor)
[Development of standards by the Norwegian Society of Rheumatology. Control of disease modifying drugs] Kvien TK, et al. **Tidsskr Nor Laegeforen** 1996 Aug 20; 116(19):2315-8 (Eng. Abstr.) (Nor)
[Overdose of methotrexate with a fatal outcome in a patient with rheumatoid arthritis] Porawska W. **Pol Arch Med Wewn** 1995 Apr;93(4):346-50 (Eng. Abstr.) (Pol)
[Assessment of the possibility of using the photodynamic effect in rheumatology] Tauraltis VA, et al. **Biofizika** 1992 Mar-Apr;37(2):345-51 (Eng. Abstr.) (Rus)
[The effect of basic therapy on the morphological picture of the rectal mucosa in patients with rheumatoid arthritis] Frizen BN, et al. **Ter Arkh** 1995;67(11):76-80 (Eng. Abstr.) (Rus)
[Myokimia induced by gold salts (see comments)] Garrido JA, et al. **Neurologia** 1995 Jun-Jul;10(6):235-7 (Eng. Abstr.) . Comment in: Neurologia 1996 Feb;11(2):85-6. (Spa)
[Treatment with cyclosporine of refractory rheumatoid arthritis] Massardo L, et al. **Rev Med Chil** 1995 Feb; 123(2):215-24 (Eng. Abstr.) (Spa)

ECONOMICS

Evaluation of two interventions to reduce the ancillary costs of outpatient care for rheumatoid arthritis. Katz JN, et al. **Arthritis Rheum** 1996 Jan;39(1):177-8
Health economics as an aspect of health outcome: basic principles and application in rheumatoid arthritis [letter; comment] Dawson JK, et al. **Br J Rheumatol** 1996 May; 35(5):494. Comment on: Br J Rheumatol 1995 Aug;34(8):774-80.
The cost of rheumatoid arthritis. McIntosh E. **Br J Rheumatol** 1996 Aug;35(8):781-90
Treatment of rheumatoid arthritis--does it affect society's cost for the disease? Magnusson S. **Br J Rheumatol** 1996 Aug;35(8):791-5
The underestimated long term medical and economic consequences of rheumatoid arthritis. Pincus T. **Drugs** 1995; 50 Suppl 1:1-14 (80 ref.)
A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. Anis AH, et al. **J Rheumatol** 1996 Apr; 23(4):609-16
Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Kavanaugh A, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):297-307

ENZYMOLOGY

Beta 1,4-galactosyltransferase variations in rheumatoid arthritis. Alavi A, et al. **Adv Exp Med Biol** 1995;376:185-92 (35 ref.)
Bone alkaline phosphatase in rheumatic diseases. Beyeler C, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):379-84
Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Beyeler C, et al. **Ann Rheum Dis** 1996 Jan;55(1):66-8
Impaired activity of protease inhibitors towards neutrophil elastase bound to human articular cartilage. Kawabata K, et al. **Ann Rheum Dis** 1996 Apr;55(4):248-52
Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Maeda S, et al. **Ann Rheum Dis** 1995 Dec;54(12):970-5
Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Kang RY, et al. **Br J Rheumatol** 1996 Aug;35(8):711-8
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Ronday HK, et al. **Br J Rheumatol** 1996 May; 35(5):416-23
Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Stein CM, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):47-51
Evaluation of beta 1,4-galactosyltransferase in rheumatoid arthritis and its role in the glycosylation network associated with this disease. Alavi A, et al. **Glycoconj J** 1995 Jun; 12(3):206-10 (35 ref.)
Augmented plasma and tissue kallikrein like activity in synovial fluid of patients with inflammatory articular diseases. Volpe-Júnior N, et al. **Inflamm Res** 1996 Apr; 45(4):198-202
Low serum creatine kinase activity is associated with muscle weakness in patients with rheumatoid arthritis. Stucki G, et al. **J Rheumatol** 1996 Apr;23(4):603-8
Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. Wernicke D, et al. **J Rheumatol** 1996 Apr;23(4):590-5
Neurone-specific enolase levels in pleural effusions in patients with rheumatoid arthritis. Nyberg P, et al. **Thorax** 1996 Jan;51(1):92-4
Histamine-stimulated production of matrix metalloproteinase 1 by human rheumatoid synovial fibroblasts is mediated by histamine H1-receptors. Zenmyo M, et al. **Virchows Arch** 1995;427(4):437-44
[The effect of antibodies to erythrocyte superoxide dismutase on its activity in the blood of rheumatoid arthritis patients] Gontar' IP, et al. **Biull Eksp Biol Med** 1995 Oct; 120(10):391-3 (Rus)

EPIDEMIOLOGY

Occurrence of rheumatoid arthritis is not increased in the first degree relatives of a population based inception cohort of inflammatory polyarthritis. Jones MA, et al. **Ann Rheum Dis** 1996 Feb;55(2):89-93
Gender, paid work, and symptoms of emotional distress in rheumatoid arthritis patients. Fifield J, et al. **Arthritis Rheum** 1996 Mar;39(3):427-35
Serum cholesterol and risk of rheumatoid arthritis in a cohort of 52 800 men and women. Heliövaara M, et al. **Br J Rheumatol** 1996 Mar;35(3):255-7
The epidemiology of hip osteoarthritis and rheumatoid arthritis in the Orient. Lau EM, et al. **Clin Orthop** 1996 Feb;(323):81-90 (67 ref.)
The expression of rheumatoid arthritis in Saudi Arabia. Alballa SR. **Clin Rheumatol** 1995 Nov;14(6):641-5
Epidemiology of rheumatoid arthritis. Alarcón GS. **Rheum Dis Clin North Am** 1995 Aug;21(3):589-604 (144 ref.)
Clinical expression of rheumatoid arthritis in Chilean patients. Massardo L, et al. **Semin Arthritis Rheum** 1995 Dec; 25(3):203-13
[The mode of onset of rheumatoid arthritis and seasonal variations] Grazio S, et al. **Reumatizam** 1995;42(2):1-6 (Eng. Abstr.) (Ser)

ETHNOLOGY

Expression of rheumatoid arthritis in two ethnic Jewish Israeli groups. Amit M, et al. **Ann Rheum Dis** 1996 Jan; 55(1):69-72
Racial variation in rheumatoid arthritis [letter] James WH. **Ann Rheum Dis** 1996 Apr;55(4):272
Severity of rheumatoid arthritis in Greek versus English patients: comment on the article by Drosos et al [letter; comment] Christodoulou D. **Arthritis Rheum** 1995 Sep; 38(9):1344-5. Comment on: Arthritis Rheum 1992 Jul;35(7):745-8.
Does rheumatoid arthritis exist in the indigenous Australian Aboriginal population? [letter] Douglas WA. **Med J Aust** 1996 Feb 5;164(3):191-2
Does rheumatoid arthritis exist in the indigenous Australian aboriginal population? [letter] Roberts-Thomson PJ. **Med J Aust** 1995 Oct 16;163(8):444-5

ETIOLOGY

Rheumatoid arthritis: pathogenesis and early recognition. Pope RM. **Am J Med** 1996 Feb 26;100(2A):3S-9S (53 ref.)
Why the gender difference in susceptibility to rheumatoid arthritis? [editorial] Brennan P, et al. **Ann Rheum Dis** 1995 Sep;54(9):694-5
Role of androgens in the aetiology of rheumatoid arthritis [letter] Brennan P, et al. **Ann Rheum Dis** 1996 Jun;55(6):404
Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Silman AJ, et al. **Arthritis Rheum** 1996 May; 39(5):732-5
Innovative treatment approaches for rheumatoid arthritis. T-cell regulation. Choy EH, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):653-71 (76 ref.)
Hormonal control of rheumatoid inflammation. Panayi GS. **Br Med Bull** 1995 Apr;51(2):462-71 (34 ref.)
Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Maini RN, et al. **Immunol Rev** 1995 Apr;144:195-223 (112 ref.)
Orthotopic implantation of inflamed synovial tissue from RA patients induces a characteristic arthritis in immunodeficient (SCID) mice. Sack U, et al. **J Autoimmun** 1996 Feb;9(1):51-8
The estrogen connection: the etiological relationship between diabetes, cancer, rheumatoid arthritis and psychiatric disorders. Holden RJ. **Med Hypotheses** 1995 Aug; 45(2):169-89 (162 ref.)
Rheumatoid arthritis: are pets implicated in its etiology? Bond C, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):308-17
[Polyarthritis and neutropenia associated with activated clone T CD8 proliferation without large granulous lymphocytes: a new entity different from Felty's syndrome? (letter)] Amiot F, et al. **Ann Med Interne (Paris)** 1996;147(1):61-2 (Fre)

GENETICS

Collagen arthritis in T cell receptor congenic mice. A unique approach to study the role of T cell receptor genotypes in autoimmune arthritis. Nabozny GH, et al. **Adv Exp Med Biol** 1995;383:99-104 (20 ref.)
Age, sex, and the familial risk of rheumatoid arthritis. Kwoh CK, et al. **Am J Epidemiol** 1996 Jul 1;144(1):15-24
Sex influences on the penetrance of HLA shared-epitope genotypes for rheumatoid arthritis. Meyer JM, et al. **Am J Hum Genet** 1996 Feb;58(2):371-83
Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Mulcahy B, et al. **Am J Hum Genet** 1996 Sep;59(3):676-83
Constitutive expression of c-fos and c-jun, overexpression of ets-2, and reduced expression of metastasis suppressor gene nm23-H1 in rheumatoid arthritis. Dooley S, et al. **Ann Rheum Dis** 1996 May;55(5):298-304
Associations of HLA-DRB and -DQB genes with two and five year outcome in rheumatoid arthritis. Eberhardt K, et al. **Ann Rheum Dis** 1996 Jan;55(1):34-9
Associations of HLA-DRB and HLA-DRQ genes with two and five year outcomes in rheumatoid arthritis [letter] Grennan DM, et al. **Ann Rheum Dis** 1996 Jul;55(7):489
Occurrence of rheumatoid arthritis is not increased in the first degree relatives of a population based inception cohort of inflammatory polyarthritis. Jones MA, et al. **Ann Rheum Dis** 1996 Feb;55(2):89-93
Further evidence for genetic anticipation in familial rheumatoid arthritis. McDermott E, et al. **Ann Rheum Dis** 1996 Jul;55(7):475-7
Should patients with recent onset rheumatoid arthritis be offered genetic screening? Symmons DP, et al. **Ann Rheum Dis** 1996 Jul;55(7):407-10 (25 ref.)
Role of hydrophobic amino acids at position 74 of DRB1 chain in rheumatoid arthritis. Cerná M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):139-44 (40 ref.)
The genotypic distribution of shared-epitope DRB1 alleles suggests a recessive mode of inheritance of the rheumatoid arthritis disease-susceptibility gene. Evans TI, et al. **Arthritis Rheum** 1995 Dec;38(12):1754-61
Limited heterogeneity of rearranged T cell receptor V alpha and V beta transcripts in synovial fluid T cells in early stages of rheumatoid arthritis. Fischer DC, et al. **Arthritis Rheum** 1996 Mar;39(3):454-62
T-cell receptor polymorphisms in Tlingit Indians with rheumatoid arthritis. Charmley P, et al. **Autoimmunity** 1994; 19(4):247-51
Absence of correlation between IL-1 alpha intron 6 polymorphism and rheumatoid arthritis. Bailly S, et al. **Br J Rheumatol** 1995 Dec;34(12):1123-6
Oncogene expression in synovial fluid cells in reactive and early rheumatoid arthritis: a brief report. Roivainen A, et al. **Br J Rheumatol** 1995 Sep;34(9):805-8
Genetic epidemiology of rheumatoid disease. Ollier WE, et al. **Br Med Bull** 1995 Apr;51(2):267-85 (102 ref.)
Analysis of V kappa genes in rheumatoid arthritis (RA) synovial B lymphocytes provides evidence for both polyclonal activation and antigen-driven selection. Moyes SP, et al. **Clin Exp Immunol** 1996 Jul;105(1):89-98
Rheumatoid arthritis in Greece: clinical, serological and genetic considerations. Drosos AA, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S7-12 (48 ref.)
TAP2D is associated with HLA-B44 and DR4 and may contribute to rheumatoid arthritis and Felty's syndrome susceptibility. Hillarby MC, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):67-70
Positive and negative association of HLA-DR genotypes with Japanese rheumatoid arthritis. Takeuchi F, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):17-22
Allele-specific quantification of TNFA transcripts in rheumatoid arthritis. Brinkman BM, et al. **Hum Genet** 1996 Jun;97(6):813-8
Proliferation enhancement by spontaneous multiplication of chromosome 7 in rheumatic synovial cells in vitro. Ermis A, et al. **Hum Genet** 1995 Dec;96(6):651-4
T-cell receptor variable region of the beta-chain gene use in peripheral blood and multiple synovial membranes during rheumatoid arthritis. Alam A, et al. **Hum Immunol** 1995 Apr;42(4):331-9
HLA-DRB1 genotyping in patients with rheumatoid arthritis in Taiwan. Yen JH, et al. **J Rheumatol** 1995 Aug; 22(8):1450-4
Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin? Brennan P, et al. **Lancet** 1996 Jul 13;348(9020):106-9 (40 ref.)
HLA-DR4 and HLA-DR10 motifs that carry susceptibility

to rheumatoid arthritis bind 70-kD heat shock proteins. Auger I, et al. **Nat Med** 1996 Mar;2(3):306–10

Immune response of HLA-DQ8 transgenic mice to peptides from the third hypervariable region of HLA-DRB1 correlates with predisposition to rheumatoid arthritis. Zanelli E, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5; 93(5):1814–9

Oncogenes in rheumatoid arthritis. Müller-Ladner U, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):675–90 (97 ref.)

Expression of a multidrug resistance gene in human rheumatoid synovium. Jorgensen C, et al. **Rheumatol Int** 1995;15(2):83–6

Differential expression of cytokine genes in CD27-positive and -negative CD4 lymphocyte subsets from healthy humans and rheumatoid arthritis patients. Stonâns I, et al. **Rheumatol Int** 1996;15(6):249–54

Polymorphism in the LMP2 and LMP7 genes and adult rheumatoid arthritis: no relationship with disease susceptibility or outcome. Maksymowych WP, et al. **Tissue Antigens** 1995 Aug;46(2):136–9

[Allelic variations of DPB1, DQA1, DQB1 and DRB1 and rheumatoid arthritis: further genetic and statistical considerations] Morozzi G, et al. **Ann Ital Med Int** 1995 Jul–Sep;10(3):171–4 (Eng. Abstr.) **(Ita)**

[Gene scanning discovers the regions of MS and RA] Orn P. **Lakartidningen** 1996 Feb 14;93(7):575–6 **(Swe)**

HISTORY

William Musgrave's (1655–1721) system of arthritides. Did it include rheumatoid arthritis? Hansen SE. **Scand J Rheumatol** 1995;24(5):274–8

Rheumatoid arthritis in an Icelandic textbook from 1782. Jónsson H, et al. **Scand J Rheumatol** 1996;25(3):134–7

IMMUNOLOGY

Adherence of rheumatoid lymphocytes to endothelium of lamina propria. Kadioglu A, et al. **Adv Exp Med Biol** 1995; 371A:171–3

Significance and molecular basis for IgG glycosylation changes in rheumatoid arthritis. Rademacher TW, et al. **Adv Exp Med Biol** 1995;376:193–204 (52 ref.)

Localizations of regulatory proteins of complement components on RA synovial tissues--especially germinal centers. Sato T, et al. **Adv Exp Med Biol** 1995;378:313–5

Autoregulation of Tcr V region epitopes in autoimmune disease. Schluter SF, et al. **Adv Exp Med Biol** 1995; 383:231–6

G-CSF and exacerbation of rheumatoid arthritis [letter; comment] Stricker RB, et al. **Am J Med** 1996 Jun; 100(6):665–6. Comment on: Am J Med 1995 Jun;98(6):589–91.

Analysis of immunoglobulin gamma heavy chains from rheumatoid arthritis synovium. Evidence of antigen-driven selection. Bridges SL Jr, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:450–2

Immunomodulatory mechanisms mediated by sex hormones in rheumatoid arthritis. Cutolo M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:237–51 (75 ref.)

TNF alpha is an effective therapeutic target for rheumatoid arthritis. Feldmann M, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:272–8 (20 ref.)

Rheumatoid arthritis and the drop in tolerance to foods: elimination diets and the reestablishment of tolerance by low-dose diluted food. Gianfranceschi P, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:379–81

In situ hybridization analysis of immunoglobulin VH gene family expression in rheumatoid arthritis. Rundle CH, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:453–6

V-gene repertoire and hypermutation of rheumatoid factors produced in rheumatoid synovial inflammation and immunized healthy donors. Thompson KM, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:440–9

Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. Trentham DE. **Ann N Y Acad Sci** 1996 Feb 13; 778:306–14 (15 ref.)

Increased serum and synovial fluid antibodies to immunoselected peptides in patients with rheumatoid arthritis. Dybwad A, et al. **Ann Rheum Dis** 1996 Jul; 55(7):437–41

Differences in oxidative response of subpopulations of neutrophils from healthy subjects and patients with rheumatoid arthritis. Eggleton P, et al. **Ann Rheum Dis** 1995 Nov;54(11):916–23

Cellular immunity to cartilage aggrecan core protein in patients with rheumatoid arthritis and non-arthritic controls. Goodstone NJ, et al. **Ann Rheum Dis** 1996 Jan; 55(1):40–6

Predominance of HLA-DRB1*0405 in Korean patients with rheumatoid arthritis. Kim HY, et al. **Ann Rheum Dis** 1995 Dec;54(12):988–90

Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis. Nakajima A, et al. **Ann Rheum Dis** 1996 Apr;55(4):237–42

Determination of IgA- and IgM-rheumatoid factors in patients with rheumatoid arthritis with and without nephropathy. Nakano M, et al. **Ann Rheum Dis** 1996 Aug; 55(8):520–4

Increased levels of serum IgM antibody to staphylococcal enterotoxin B in patients with rheumatoid arthritis. Origuchi T, et al. **Ann Rheum Dis** 1995 Sep;54(9):713–20

Clinical significance of antibodies against oxidised low density lipoprotein in early RA [letter] Paimela L, et al. **Ann Rheum Dis** 1996 Aug;55(8):558–9

Human leucocyte antigen typing in rheumatoid arthritis/polymyositis overlap syndrome [letter] Sharma A, et al. **Ann Rheum Dis** 1995 Sep;54(9):780–1

Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Tetlow LC, et al. **Ann Rheum Dis** 1995 Nov;54(11):896–903

Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4. van Roon JA, et al. **Ann Rheum Dis** 1995 Oct;54(10):836–40

Contrasting effect of oral and intravenous cyclophosphamide treatment on phenotypes of human peripheral blood lymphocytes. Lacki JK, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):291–4

Lymphocyte phenotype studies of rheumatoid arthritis patients treated with methotrexate. Lacki JK, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):287–90

High seroprevalence of anti-HTLV-I antibody in rheumatoid arthritis. Eguchi K, et al. **Arthritis Rheum** 1996 Mar;39(3):463–6

Association of tumor necrosis factor microsatellite polymorphisms with HLA-DRB1*04-bearing haplotypes in rheumatoid arthritis patients. Hajeer AH, et al. **Arthritis Rheum** 1996 Jul;39(7):1109–14

Accelerated generation of CD14+ monocyte-lineage cells from the bone marrow of rheumatoid arthritis patients. Hirohata S, et al. **Arthritis Rheum** 1996 May;39(5):836–43

High frequencies of identical T cell clonotypes in synovial tissues of rheumatoid arthritis patients suggest the occurrence of common antigen-driven immune responses. Ikeda Y, et al. **Arthritis Rheum** 1996 Mar;39(3):446–53

Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Isomaki P, et al. **Arthritis Rheum** 1996 Mar;39(3):386–95

Enrichment of differentiated CD45RBdim,CD27- memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Kohem CL, et al. **Arthritis Rheum** 1996 May;39(5):844–54

Elevated levels of the soluble form of bone marrow stromal cell antigen 1 in the sera of patients with severe rheumatoid arthritis. Lee BO, et al. **Arthritis Rheum** 1996 Apr; 39(4):629–37

The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Liu MF, et al. **Arthritis Rheum** 1996 Jan;39(1):110–4

Antibodies to synovial antigens in recent-onset rheumatoid arthritis. McColl GJ, et al. **Arthritis Rheum** 1995 Oct; 38(10):1418–28

Synergy between T cell receptor beta gene polymorphism and HLA-DR4 in susceptibility to rheumatoid arthritis. Mu H, et al. **Arthritis Rheum** 1996 Jun;39(6):931–7

Terminal differentiation of spontaneous rheumatoid factor-secreting B cells from rheumatoid arthritis patients depends on endogenous interleukin-10. Perez L, et al. **Arthritis Rheum** 1995 Dec;38(12):1771–6

Rheumatoid arthritis in a United States Public Health Service Hospital in Oklahoma: serologic manifestations in rheumatoid arthritis vary among tribal groups. Scofield RH, et al. **Arthritis Rheum** 1996 Feb;39(2):283–6

Polymerase chain reaction-based genotyping of the constant segment of immunoglobulin kappa shows weak or no association with rheumatoid arthritis. Singh R, et al. **Arthritis Rheum** 1995 Oct;38(10):1526–7

Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis. Thomas R, et al. **Arthritis Rheum** 1996 Feb;39(2):183–90 (85 ref.)

CD80 expression in rheumatoid arthritis: comment on the article by Ranheim and Kipps [letter] Thomas R, et al. **Arthritis Rheum** 1995 Dec;38(12):1863–5

Responsiveness of human T lymphocytes to bacterial superantigens presented by cultured rheumatoid arthritis synoviocytes. Tsai C, et al. **Arthritis Rheum** 1996 Jan; 39(1):125–36

Oligoclonal T cell proliferation in patients with rheumatoid arthritis and their unaffected siblings. Waase I, et al. **Arthritis Rheum** 1996 Jun;39(6):904–13

Oral tolerance: mechanisms and possible role in inflammatory joint diseases. Kagnoff MF. **Baillieres Clin Rheumatol** 1996 Feb;10(1):41–54 (71 ref.)

Fas antigen expression on synovial cells was down-regulated by interleukin 1 beta. Tsuboi M, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):280–5

Relationship between levels of IgG and IgM and IgM rhematoid factor in human sera. Arrar L, et al. **Biochem Soc Trans** 1995 Aug;23(3):475S

Heat-shock proteins (Hsps)-reactive T-cells in inflammatory disease. Bell CG. **Biochem Soc Trans** 1996 Feb;24(1):84S

Do heat-shock proteins (Hsps)65-reactive lymphocytes in rheumatoid arthritis, Hashimoto's thyroiditis & systemic lupus erythematosus implicate Hsp65 in autoimmunity? Bell CG. **Biochem Soc Trans** 1996 Feb;24(1):85S

Natural ligand motifs of closely related HLA-DR4 molecules predict features of rheumatoid arthritis associated peptides. Friede T, et al. **Biochim Biophys Acta** 1996 Jun 7; 1316(2):85–101

Seronegative arthritis mailbase discussion group [letter] Archer JR. **Br J Rheumatol** 1995 Dec;34(12):1185

Differential expression of the costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid synovial tissue. Balsa A, et al. **Br J Rheumatol** 1996 Jan;35(1):33–7

Antineutrophil cytoplasmic antibodies in rheumatoid arthritis patients. de Bandt M, et al. **Br J Rheumatol** 1996 Jan; 35(1):38–43

Changes in glycosylation of IgG during fasting in patients with rheumatoid arthritis. Kjeldsen-Kragh J, et al. **Br J Rheumatol** 1996 Feb;35(2):117–9

Agalactosyl IgG in aggregates from the rheumatoid joint. Leader KA, et al. **Br J Rheumatol** 1996 Apr;35(4):335–41

Interference by IgM rheumatoid factor on ELISA for antibodies to mycobacterial 65 kDa heat shock protein in rheumatoid arthritis [letter; comment] Lim KK, et al. **Br J Rheumatol** 1996 Mar;35(3):300–1. Comment on: Br J Rheumatol 1995 Jul;34(7):610–5.

Presence of bacterial flora-derived antigen in synovial tissue macrophages and dendritic cells. Melief MJ, et al. **Br J Rheumatol** 1995 Dec;34(12):1112–6

Prognostic value of quantitative measurement of rheumatoid factor in early rheumatoid arthritis. Paimela L, et al. **Br J Rheumatol** 1995 Dec;34(12):1146–50

Pregnancy, schizophrenia and rheumatoid arthritis [letter; comment] Rafter GW. **Br J Rheumatol** 1996 Jun;35(6):603 . Comment on: Br J Rheumatol 1995 Jan;34(1):1–3.

Anti-ganglioside antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy. Salih AM, et al. **Br J Rheumatol** 1996 Aug;35(8):725–31

T cell receptor usage in rheumatoid arthritis. Lanchbury JS, et al. **Br Med Bull** 1995 Apr;51(2):346–58 (62 ref.)

The role of T-lymphocytes in rheumatoid arthritis. Salmon M, et al. **Br Med Bull** 1995 Apr;51(2):332–45 (51 ref.)

Immunology of systemic rheumatoid disease. Snowden N, et al. **Br Med Bull** 1995 Apr;51(2):437–48 (50 ref.)

Role of antigen presenting cells in rheumatoid arthritis. Viner NJ. **Br Med Bull** 1995 Apr;51(2):359–67 (40 ref.)

Rheumatoid arthritis. Feldmann M, et al. **Cell** 1996 May 3; 85(3):307–10 (35 ref.)

The relationship between exposed galactose and N-acetylglucosamine residues on IgG in rheumatoid arthritis (RA), juvenile chronic arthritis (JCA) and Sjögren's syndrome (SS). Bond A, et al. **Clin Exp Immunol** 1996 Jul;105(1):99–103

Characterization of altered calcium signalling in T lymphocytes from patients with rheumatoid arthritis (RA). Carruthers DM, et al. **Clin Exp Immunol** 1996 Aug; 105(2):291–6

High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Gerli R, et al. **Clin Exp Immunol** 1995 Dec;102(3):547–50

Changes in the phenotype of monocytes/macrophages and expression of cytokine mRNA in peripheral blood and synovial fluid of patients with rheumatoid arthritis. Highton J, et al. **Clin Exp Immunol** 1995 Dec;102(3):541–6

The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast. Migita K, et al. **Clin Exp Immunol** 1996 Apr;104(1):86–91

Analysis of V kappa genes in rheumatoid arthritis (RA) synovial B lymphocytes provides evidence for both polyclonal activation and antigen-driven selection. Moyes SP, et al. **Clin Exp Immunol** 1996 Jul;105(1):89–98

Successful induction of severe destructive arthritis by the transfer of in vitro-activated synovial fluid T cells from patients with rheumatoid arthritis (RA) in severe combined immunodeficient (SCID) mice. Sakata A, et al. **Clin Exp Immunol** 1996 May;104(2):247–54

Antiperinuclear factor isotypes in rheumatoid arthritis [letter; comment] Borg AA. **Clin Exp Rheumatol** 1995 Jul–Aug; 13(4):529–31. Comment on: Clin Exp Rheumatol 1994 Nov–Dec;12(6):615–9.

Autoimmune connective tissue disease, chronic polyarthritides and B cell expansion: risks and perspectives with immunosuppressive drugs. Ferraccioli GF, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S71–80 (100 ref.)

Humoral immunity and glycosylation abnormalities in rheumatoid arthritis. Isenberg DA. **Clin Exp Rheumatol** 1995 Sep–Oct;13 Suppl 12:S17–20 (18 ref.)

Antiperinuclear factor isotypes in rheumatoid arthritis [letter; comment] Muñoz-Fernández S, et al. **Clin Exp Rheumatol** 1995 Jul–Aug;13(4):529; discussion 530–1. Comment on: Clin Exp Rheumatol 1994 Nov–Dec;12(6):615–9.

Gliadin immune reactivity in patients with rheumatoid arthritis. Paimela L, et al. **Clin Exp Rheumatol** 1995 Sep–Oct;13(5):603–7

CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis. Gerli R, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):31–7

IL-8/NAP-1 is the major T-cell chemoattractant in synovial tissues of rheumatoid arthritis. Nishiura H, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):179–84

Sera of patients with rheumatoid arthritis contain antibodies to recombinant human T-lymphotrophic virus type I/II envelope glycoprotein p21. Starkebaum G, et al. **Clin Immunol Immunopathol** 1996 May;79(2):182–8

Expression of the activation antigen CD27 in rheumatoid arthritis. Tak PP, et al. **Clin Immunol Immunopathol** 1996 Aug;80(2):129–38

Immunologic mechanisms in common rheumatologic

diseases. Miller-Blair DJ, et al. **Clin Orthop** 1996 May; (326):43-54 (28 ref.)

B lymphocytes and humoral immune responses in rheumatoid arthritis. De Clerck LS. **Clin Rheumatol** 1995 Sep;14 Suppl 2:14-8 (56 ref.)

Complement-activating properties of IgM rheumatoid factors reacting with IgG subclasses. Sato Y, et al. **Clin Rheumatol** 1995 Jul;14(4):425-8

Comparative epitope mapping of antibodies to collagen in women with silicone breast implants, systemic lupus erythematosus and rheumatoid arthritis. Rowley MJ, et al. **Curr Top Microbiol Immunol** 1996;210:307-16

Cytokine production by SV40-transformed adherent synovial cells from rheumatoid arthritis patients. Shimozato O, et al. **Cytokine** 1996 Jan;8(1):99-105

Detection of immunoglobulin G glycosylation changes in patients with rheumatoid arthritis by means of isoelectric focusing and lectin-affinoblotting. Hänsler M, et al. **Electrophoresis** 1995 May;16(5):811-2

Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Butler DM, et al. **Eur Cytokine Netw** 1995 Jul-Dec;6(4):225-30

The B lymphocyte in rheumatoid arthritis: analysis of rearranged V kappa genes from B cells infiltrating the synovial membrane. Gause A, et al. **Eur J Immunol** 1995 Oct;25(10):2775-82

Role of tumor necrosis factor-alpha in the regulation of activated synovial T cell growth: down-regulation of synovial T cells in rheumatoid arthritis patients. Lai NS, et al. **Eur J Immunol** 1995 Dec;25(12):3243-8

HLA-associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent-onset insulin-dependent diabetes mellitus. Roep BO, et al. **Eur J Immunol** 1996 Jun;26(6):1285-9

The C1q binding activity of IgG is modified in vitro by reactive oxygen species: implications for rheumatoid arthritis. Griffiths HR, et al. **FEBS Lett** 1996 Jun 17; 388(2-3):161-4

Expansion of large granular lymphocyte subsets in Wiskott-Aldrich syndrome. Plebani A, et al. **Haematologica** 1995 Nov-Dec;80(6):521-5

Efficient immortalization of rheumatoid synovial tissue B-lymphocytes. A comparison between the techniques of electric field-induced and PEG fusion. Krenn V, et al. **Hum Antibodies Hybridomas** 1995;6(2):47-51

Comparison of anti-TNF alpha autoantibodies in plasma and from EBV transformed lymphocytes of autoimmune and normal individuals. Tsuchiyama L, et al. **Hum Antibodies Hybridomas** 1995;6(2):73-6

Mycobacterium tuberculosis antigen, interleukin 2 and interleukin 2 inhibitor in patients with rheumatoid arthritis. Wu CH, et al. **Immunol Invest** 1995 Nov;24(6):957-64

Therapeutic regulation of T cells in rheumatoid arthritis. Breedveld FC, et al. **Immunol Rev** 1995 Apr;144:5-16 (48 ref.)

Agalactosyl IgG and beta-1,4-galactosyltransferase gene expression in rheumatoid arthritis patients and in the arthritis-prone MRL lpr/lpr mouse. Jeddi PA, et al. **Immunology** 1996 Apr;87(4):654-9

Synovial fibroblasts as accessory cells for staphylococcal enterotoxin-mediated T-cell activation. Kraft M, et al. **Immunology** 1995 Jul;85(3):461-6

Evidence for monoclonal expansion of synovial T cells bearing V alpha 2.1/V beta 5.5 gene segments and recognizing a synthetic peptide that shares homology with a number of putative autoantigens. Ostenstad B, et al. **Immunology** 1995 Oct;86(2):168-75

The collagen-like component of the complement system, C1q, is recognized by 7 S autoantibodies and is functionally impaired in synovial fluids of patients with rheumatoid arthritis. Trinder PK, et al. **Immunology** 1996 Mar; 87(3):355-61

Downregulation of silicone-induced chronic arthritis by gastric administration of type II collagen. Yoshino S. **Immunopharmacology** 1995 Nov;31(1):103-8

HLA class-I and class-II antigen association in rheumatoid arthritis at Varanasi, India. Agrawal V, et al. **Indian J Pathol Microbiol** 1996 Jan;39(1):19-25

Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment. Brett SJ, et al. **Int Immunol** 1996 Mar;8(3):325-34

Purification of recombinant human Hsp60: use of a GroEL-free preparation to assess autoimmunity in rheumatoid arthritis. Handley HH, et al. **J Autoimmun** 1995 Oct;8(5):659-73

Identification of clonally expanded T cells in rheumatoid arthritis using a sequence enrichment nuclease assay. González-Quintial R, et al. **J Clin Invest** 1996 Mar 1; 97(5):1335-43

CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. Schmidt D, et al. **J Clin Invest** 1996 May 1;97(9):2027-37

Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids. Wang F, et al. **J Exp Med** 1995 Dec 1; 182(6):1825-31

Persistence of dominant T cell clones in synovial tissues during rheumatoid arthritis. Alam A, et al. **J Immunol** 1996 May 1;156(9):3480-5

Contribution of IL-1, CD14, and CD13 in the increased IL-6 production induced by in vitro monocyte-synoviocyte interactions. Chomarat P, et al. **J Immunol** 1995 Oct 1; 155(7):3645-52

Biochemical characterization and microsequencing of a 205-kDa synovial protein stimulatory for T cells and reactive with rheumatoid factor containing sera. Hain NA, et al. **J Immunol** 1996 Aug 15;157(4):1773-80

Oligoclonality of V beta 3 TCR chains in the CD8+ T cell population of rheumatoid arthritis patients. Hingorani R, et al. **J Immunol** 1996 Jan 15;156(2):852-8

Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles. Kirschmann DA, et al. **J Immunol** 1995 Dec 15; 155(12):5655-62

T cells bound by vascular cell adhesion molecule-1/CD106 in synovial fluid in rheumatoid arthritis: inhibitory role of soluble vascular cell adhesion molecule-1 in T cell activation. Kitani A, et al. **J Immunol** 1996 Mar 15; 156(6):2300-8

Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. Schulze-Koops H, et al. **J Immunol** 1995 Nov 15;155(10):5029-37

IgM rheumatoid factors react with human class I HLA molecules. Williams RC Jr, et al. **J Immunol** 1996 Feb 15; 156(4):1684-94

High avidity state of leukocyte function-associated antigen-1 on rheumatoid synovial fluid T lymphocytes. Yokota A, et al. **J Immunol** 1995 Oct 15;155(8):4118-24

Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis. Zack DJ, et al. **J Immunol** 1995 Nov 15;155(10):5057-63

Prevalence of antikeratin antibodies in Greek patients with rheumatoid arthritis. A clinical, serologic, and immunogenetic study. Boki KA, et al. **J Rheumatol** 1995 Nov;22(11):2046-8

Occurrence of antineutrophil cytoplasmic and antineutrophil (peri)nuclear antibodies in rheumatoid arthritis. Bosch X, et al. **J Rheumatol** 1995 Nov;22(11):2038-45

Incidence, target antigens, and clinical implications of antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Braun MG, et al. **J Rheumatol** 1996 May; 23(5):826-30

High levels of antibodies to annexins V and VI in patients with rheumatoid arthritis. Dubois T, et al. **J Rheumatol** 1995 Jul;22(7):1230-4

CD4+ T cell inducible immunoregulatory cytokine response in rheumatoid arthritis. al-Janadi N, et al. **J Rheumatol** 1996 May;23(5):809-14

Antigen binding differences between secreted and cell surface expressed rheumatoid factor derived from inflamed synovium. Kenny TP, et al. **J Rheumatol** 1996 May; 23(5):819-25

HLA-DR1, DR4, and DRB1 disease related subtypes in rheumatoid arthritis. Association with susceptibility but not severity in a city wide community based study. Suarez-Almazor ME, et al. **J Rheumatol** 1995 Nov; 22(11):2027-33

Monocyte-macrophage antigen expression on chondrocytes. Summers KL, et al. **J Rheumatol** 1995 Jul;22(7):1326-34

HLA-DPB1 polymorphism in patients with rheumatoid arthritis in Taiwan. Yen JH, et al. **J Rheumatol** 1995 Nov; 22(11):2034-7

Rheumatoid arthritis. The multiple pathways to chronic synovitis [editorial] Zvaifler NJ. **Lab Invest** 1995 Sep; 73(3):307-10

Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids. Kremer JM. **Lipids** 1996 Mar;31 Suppl:S243-7 (50 ref.)

Low occurrence of arthritic manifestations in patients with pulmonary tuberculosis. T cell subsets and humoral studies. Dlugovitzky D, et al. **Mem Inst Oswaldo Cruz** 1995 Sep-Oct;90(5):623-8

VH3-21 B cells escape from a state of tolerance in rheumatoid arthritis and secrete rheumatoid factor. He X, et al. **Mol Med** 1995 Nov;1(7):768-80

Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Albani S, et al. **Nat Med** 1995 May;1(5):448-52

HLA-DR4 and HLA-DR10 motifs that carry susceptibility to rheumatoid arthritis bind 70-kD heat shock proteins. Auger I, et al. **Nat Med** 1996 Mar;2(3):306-10

Agalactosyl IgG and mannose-binding proteins: biochemical nicety or pathophysiological paradigm? [comment] Ezekowitz RA. **Nat Med** 1995 Mar;1(3):207-8. Comment on: Nat Med 1995 Mar;1(3):237-43.

The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. McInnes IB, et al. **Nat Med** 1996 Feb;2(2):175-82

Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein [see comments] Malhotra R, et al. **Nat Med** 1995 Mar;1(3):237-43. Comment in: Nat Med 1995 Mar;1(3):207-8.

Shock revelations about HLA-DR4 — a shortcut to rheumatoid arthritis? Ollier B. **Nat Med** 1996 Mar; 2(3):279-80

The anticytokine neuropeptide alpha-melanocyte-stimulating hormone in synovial fluid of patients with rheumatic diseases: comparisons with other anticytokine molecules. Catania A, et al. **Neuroimmunomodulation** 1994 Sep-Oct;1(5):321-8

Detection of T cell receptors in early rheumatoid arthritis synovial tissue. Ramanujam T, et al. **Pathobiology** 1995; 63(2):100-8

Prospects of immunotherapy for rheumatoid arthritis. 't Hart BA, et al. **Pharm World Sci** 1995 Nov 24;17(6):178-85 (112 ref.)

Short communication: selective placental transport of maternal IgG to the fetus. Williams PJ, et al. **Placenta** 1995 Dec;16(8):749-56

Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Schröder AE, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):221-5

T-cell repertoires in healthy and diseased human tissues analysed by T-cell receptor beta-chain CDR3 size determination: evidence for oligoclonal expansions in tumours and inflammatory diseases. Even J, et al. **Res Immunol** 1995 Feb;146(2):65-80

Membranoproliferative glomerulonephritis, p-antineutrophil cytoplasmic antibodies, and rheumatoid arthritis. Report of a case. Constantin A, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):141-4

Autoimmunity. Insights provided by the SCID mouse model. Jorgensen C, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep; 62(7-8):519-24 (38 ref.)

T cells in rheumatoid arthritis. Paradigms and facts. Goronzy JJ, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):655-74 (102 ref.)

IgM rheumatoid factor estimation by ELISA in seronegative rheumatoid arthritis before and after IgM fractionation: does seronegative RA exist? Dabadghao S, et al. **Rheumatol Int** 1996;15(5):189-93

The specificity of the anti-Proteus antibody response in tissue-typed rheumatoid arthritis (RA) patients from Brest. Fielder M, et al. **Rheumatol Int** 1995;15(2):79-82

The levels of memory (CD45RA-, RO+) CD4+ and CD8+ peripheral blood T-lymphocytes correlate with IgM rheumatoid factors in rheumatoid arthritis. Neidhart M, et al. **Rheumatol Int** 1996;15(5):201-9

Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study. Röther E, et al. **Rheumatol Int** 1996;15(6):231-7

Tenidap, but not nonsteroidal anti-inflammatory drugs, inhibits T-cell proliferation and cytokine induction. Dolhain RJ, et al. **Scand J Immunol** 1995 Dec;42(6):686-93

Expression of the mucosal lymphocyte integrin alpha E beta 7 and its ligand E-cadherin in the synovium of patients with rheumatoid arthritis. Trollmo C, et al. **Scand J Immunol** 1996 Sep;44(3):293-8

Cytokine autoantibodies in rheumatoid arthritis. Hansen MB, et al. **Scand J Rheumatol** 1995;24(4):197-203

Raised IgA rheumatoid factor (RF) but not IgM RF or IgG RF is associated with extra-articular manifestations in rheumatoid arthritis. Jónsson T, et al. **Scand J Rheumatol** 1995;24(6):372-5

Clinical expression of rheumatoid arthritis in Chilean patients. Massardo L, et al. **Semin Arthritis Rheum** 1995 Dec; 25(3):203-13

[Antikeratin antibodies: another specific antibodies in rheumatoid arthritis patients] Zhou Z, et al. **Chung Hua Nei Ko Tsa Chih** 1995 May;34(5):330-2 (Eng. Abstr.) **(Chi)**

[HLA-DR molecular typing: diagnostic and prognostic value in beginning rheumatoid arthritis] Guerne PA. **Schweiz Med Wochenschr Suppl** 1996;80:12S-13S **(Fre)**

[Vaccination against influenza in patients with rheumatoid arthritis: clinical and antibody response] Francioni C, et al. **Recenti Prog Med** 1996 Apr;87(4):145-9 (Eng. Abstr.) **(Ita)**

[The effect of antibodies to erythrocyte superoxide dismutase on its activity in the blood of rheumatoid arthritis patients] Gontar' IP, et al. **Biull Eksp Biol Med** 1995 Oct; 120(10):391-3 **(Rus)**

METABOLISM

Aggrecan degradation in osteoarthritis and rheumatoid arthritis. Lark MW, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:92-7 (31 ref.)

Local expression of corticotropin-releasing hormone in inflammatory arthritis. Crofford LJ, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:459-71 (63 ref.)

Differential distribution of annexins-I, -II, -IV, and -VI in synovium. Goulding NJ, et al. **Ann Rheum Dis** 1995 Oct; 54(10):841-5

Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis. Hakala M, et al. **Ann Rheum Dis** 1995 Nov;54(11):886-90

Signalling through neutrophil Fc gamma RIII, Fc gamma RII, and CD59 is not impaired in active rheumatoid arthritis. Jones J, et al. **Ann Rheum Dis** 1996 May; 55(5):294-7

Interleukin-1 expression by neutrophils in rheumatoid arthritis. Quayle JA, et al. **Ann Rheum Dis** 1995 Nov;

54(11):930–3
Interleukin–4 inhibits prostaglandin E2 production by freshly prepared adherent rheumatoid synovial cells via inhibition of biosynthesis and gene expression of cyclo–oxygenase II but not of cyclo–oxygenase I. Sugiyama E, et al. **Ann Rheum Dis** 1996 Jun;55(6):375–82
Interleukin 10 inhibits interleukin 6 production and acute phase response in rheumatoid arthritis. Łącki JK, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(1):11–4
Expression and functional expansion of fibroblast growth factor receptor T cells in rheumatoid synovium and peripheral blood of patients with rheumatoid arthritis. Byrd V, et al. **Arthritis Rheum** 1996 Jun;39(6):914–22
Longitudinal study of hand bone densitometry in rheumatoid arthritis. Deodhar AA, et al. **Arthritis Rheum** 1995 Sep; 38(9):1204–10
Elevated nitric oxide production in rheumatoid arthritis. Detection using the fasting urinary nitrate:creatinine ratio. Grabowski PS, et al. **Arthritis Rheum** 1996 Apr;39(4):643–7
Nuclear factor–kappa B in rheumatoid synovium. Localization of p50 and p65. Handel ML, et al. **Arthritis Rheum** 1995 Dec;38(12):1762–70
Expression of activation markers of the rheumatoid arthritis synovial membrane: comment on the article by Qu et al [letter; comment] Kinne RW, et al. **Arthritis Rheum** 1995 Sep;38(9):1346–8. Comment on: Arthritis Rheum 1994 Feb;37(2):212–20.
Enhancement of SPARC (osteonectin) synthesis in arthritic cartilage. Increased levels in synovial fluids from patients with rheumatoid arthritis and regulation by growth factors and cytokines in chondrocyte cultures. Nakamura S, et al. **Arthritis Rheum** 1996 Apr;39(4):539–51
Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor alpha. Rall LC, et al. **Arthritis Rheum** 1996 Jul;39(7):1115–24
High DNA–binding activity of transcription factor NF–kappa B in synovial membranes of patients with rheumatoid arthritis. Asahara H, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):827–32
Chromatographic investigation of the glycosylation pattern of alpha–1–acid glycoprotein secreted by the HepG2 cell line; a putative model for inflammation? Elliott HG, et al. **Biomed Chromatogr** 1995 Sep–Oct;9(5):199–204
Synovial fluid lipids and apolipoproteins: a contemporary perspective. Prete PE, et al. **Biorheology** 1995 Jan–Feb; 32(1):1–16 (103 ref.)
The effects of age and gender on the pharmacokinetics of tenidap sodium in patients with rheumatoid arthritis and osteoarthritis. Caldwell JR, et al. **Br J Clin Pharmacol** 1995; 39 Suppl 1:3S–9S
Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Barrera P, et al. **Br J Rheumatol** 1995 Aug; 34(8):747–55
Increased expression of interferon (IFN)–gamma together with IFN–gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis. Dolhain RJ, et al. **Br J Rheumatol** 1996 Jan; 35(1):24–32
Practical clinical pharmacology and drug interactions of low–dose methotrexate therapy in rheumatoid arthritis. Furst DE. **Br J Rheumatol** 1995 Nov;34 Suppl 2:20–5 (50 ref.)
Endogenous opioid tone in patients with rheumatoid arthritis. Kassimos D, et al. **Br J Rheumatol** 1996 May;35(5):436–40
Changes in glycosylation of IgG during fasting in patients with rheumatoid arthritis. Kjeldsen–Kragh J, et al. **Br J Rheumatol** 1996 Feb;35(2):117–9
Overexpression of proto–oncogene bcl–2 in rheumatoid synovium [letter] Liang HY, et al. **Br J Rheumatol** 1996 Aug;35(8):803–4
In vitro duodenal iron uptake and serum and mucosal iron protein levels, with special reference to rheumatoid arthritis. Raja KB, et al. **Br J Rheumatol** 1995 Nov; 34(11):1041–7
The effects of joint washout and steroid injection compared with either joint washout or steroid injection alone in rheumatoid knee effusion. Srinivasan A, et al. **Br J Rheumatol** 1995 Aug;34(8):771–3
Cytokine expression in chronic inflammatory disease. Brennan FM, et al. **Br Med Bull** 1995 Apr;51(2):368–84 (60 ref.)
Hypoxia, oxidative stress and rheumatoid arthritis. Mapp PI, et al. **Br Med Bull** 1995 Apr;51(2):419–36 (43 ref.)
Alterations in neurokinin 1 receptor gene expression in models of pain and inflammation. Krause JE, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):854–9 (49 ref.)
Expression of interferon–gamma (IFN–gamma), IL–10, IL–12 and transforming growth factor–beta (TGF–beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Bucht A, et al. **Clin Exp Immunol** 1996 Mar;103(3):357–67
Sex hormones, proto–oncogene expression and apoptosis: their effects on rheumatoid synovial tissue. Cutolo M, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):87–94 (58 ref.)
Decreased levels of a soluble form of the human adhesion receptor CD58 (LFA–3) in sera and synovial fluids of patients with rheumatoid arthritis. Hoffmann JC, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):23–9
Humoral immunity and glycosylation abnormalities in rheumatoid arthritis. Isenberg DA. **Clin Exp Rheumatol** 1995 Sep–Oct;13 Suppl 12:S17–20 (18 ref.)
Interleukin–10 in rheumatoid arthritis. Lapadula G, et al. **Clin Exp Rheumatol** 1995 Sep–Oct;13(5):629–32
Biochemical markers of joint damage: is there any hope? Wollheim FA. **Clin Exp Rheumatol** 1995 Sep–Oct;13 Suppl 12:S3–5 (21 ref.)
Macrophage inflammatory protein–1 beta: a C–C chemokine in osteoarthritis. Koch AE, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):307–14
Expression of adhesion molecules in early rheumatoid synovial tissue. Tak PP, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):236–42
The mechanism of autoantibody formation to cartilage in rheumatoid arthritis: possible cross–reaction of antibodies to dietary collagens with autologous type II collagen. Terato K, et al. **Clin Immunol Immunopathol** 1996 May; 79(2):142–54
Cytokines in rheumatoid arthritis. Houssiau FA. **Clin Rheumatol** 1995 Sep;14 Suppl 2:10–3 (21 ref.)
Resident joint tissues, rather than infiltrating neutrophils and monocytes, are the predominant sources of TNF–alpha in zymosan–induced arthritis. Pettipher ER, et al. **Cytokine** 1996 Feb;8(2):130–3
Role of tumor necrosis factor–alpha and platelet–activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Lupia E, et al. **Eur J Immunol** 1996 Aug;26(8):1690–4
Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin–1: a potential mechanism for inflammatory angiogenesis. Ben–Av P, et al. **FEBS Lett** 1995 Sep 18;372(1):83–7
Production of PAF–acether by synovial fluid neutrophils in rheumatoid arthritis. Hilliquin P, et al. **Inflamm Res** 1995 Aug;44(8):313–6
Plasma and synovial fluid interleukin–1, interleukin–6 and substance P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal anti inflammatory drugs indomethacin, diclofenac and naproxen. Sacerdote P, et al. **Inflamm Res** 1995 Nov;44(11):486–90
Conversion of endogenous arachidonic acid to 5,15–diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. Thomas E, et al. **Inflamm Res** 1995 Mar;44(3):121–4
Glycobiology: 'the function of sugar in the IgG molecule'. Dwek RA, et al. **J Anat** 1995 Oct;187 (Pt 2):279–92
Monocyte chemotactic factor in rheumatoid arthritis synovial tissue. Probably a cross–linked derivative of S19 ribosomal protein. Nishiura H, et al. **J Biol Chem** 1996 Jan 12; 271(2):878–82
Androgen and estrogen receptors are present in primary cultures of human synovial macrophages. Cutolo M, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):820–7
Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. Sakurai H, et al. **J Clin Invest** 1995 Nov;96(5):2357–63
Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. Williams LM, et al. **J Clin Invest** 1996 Jun 15; 97(12):2833–41
Structural restriction in the heavy chain CDR3 of human rheumatoid factors. Børretzen M, et al. **J Immunol** 1995 Oct 1;155(7):3630–7
Growth–related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis. Koch AE, et al. **J Immunol** 1995 Oct 1;155(7):3660–6
Leukemia inhibitory factor induces leukocyte infiltration and cartilage proteoglycan degradation in goat joints. Carroll GJ, et al. **J Interferon Cytokine Res** 1995 Jun;15(6):567–73
Interleukin–1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit. Arner EC, et al. **J Rheumatol** 1995 Jul;22(7):1338–46
Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. Lafforgue P, et al. **J Rheumatol** 1995 May; 22(5):844–9
Inorganic pyrophosphate generation from adenosine triphosphate by cell–free human synovial fluid. Park W, et al. **J Rheumatol** 1996 Apr;23(4):665–71
Induction of release of secretory nonpancreatic phospholipase A2 from human articular chondrocytes. Pruzanski W, et al. **J Rheumatol** 1995 Nov;22(11):2114–9
Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. Sugiyama E, et al. **J Rheumatol** 1995 Nov;22(11):2020–6
Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Qu Z, et al. **Lab Invest** 1995 Sep;73(3):339–46
NMR studies on human, pathologically changed synovial fluids: role of hypochlorous acid. Schiller J, et al. **Magn Reson Med** 1996 Jun;35(6):848–53
Duodenal mucosal ferritin in rheumatoid arthritis: implications for anaemia of chronic disease. O'Toole PA, et al. **QJM** 1996 Jul;89(7):509–14
Impact of using stored cells for immunofluorescence detection of antiperinuclear factor on sensitivity of the method for the diagnosis of rheumatoid arthritis. Berthelot JM, et al. **Rev Rhum Engl Ed** 1995 Jul–Sep;62(7–8):507–12
Production of TNF by monocytes of patients with early rheumatoid arthritis is increased. Leirisalo–Repo M, et al. **Scand J Rheumatol** 1995;24(6):366–71
Cytokines in rheumatoid arthritis. Localization in arthritic joint tissue and regulation in vitro. Deleuran BW. **Scand J Rheumatol Suppl** 1996;104:1–34
Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. Edno L, et al. **Ther Drug Monit** 1996 Apr;18(2):128–34
In situ hybridization of stromelysin mRNA in the synovial biopsies from rheumatoid arthritis. Sawai T, et al. **Tohoku J Exp Med** 1996 Mar;178(3):315–30
[Levels of different metabolites of arachidonic acid in synovial fluid of patients with arthrosis or rheumatoid arthritis] Grignani G, et al. **Minerva Med** 1996 Mar; 87(3):75–9 (Eng. Abstr.) **(Ita)**
[Matrix metalloproteinase (MMP–9) in patients with rheumatoid arthritis] Seki M, et al. **Ryumachi** 1995 Oct; 35(5):792–801 (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Role of enteric bacteria in the pathogenesis of rheumatoid arthritis: evidence for antibodies to enterobacterial common antigens in rheumatoid sera and synovial fluids. Aoki S, et al. **Ann Rheum Dis** 1996 Jun;55(6):363–9
Mycoplasma fermentans in joints of patients with rheumatoid arthritis and other joint disorders [letter] Sohaeverbeke T, et al. **Lancet** 1996 May 18;347(9012):1418
Major infection during methotrexate treatment for rheumatoid arthritis [letter] Schnabel A, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):357–9
Immortalized B–lymphocytes from rheumatoid synovial tissue show specificity for bacterial HSP 60. Krenn V, et al. **Virchows Arch** 1996 Feb;427(5):511–8

MORTALITY

The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Voskuyl AE, et al. **Arthritis Rheum** 1996 Feb;39(2):266–71
Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Jones M, et al. **Br J Rheumatol** 1996 Aug;35(8):738–45
Mortality in rheumatoid arthritis: do age and gender make a difference? Anderson ST. **Semin Arthritis Rheum** 1996 Apr;25(5):291–6 (18 ref.)
Mortality in rheumatoid arthritis. Myllykangas–Luosujärvi RA, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):193–202 (65 ref.)

PATHOLOGY

Shoulder destruction in rheumatoid arthritis. Classification and prognostic signs in 83 patients followed 5–23 years. Hirooka A, et al. **Acta Orthop Scand** 1996 Jun;67(3):258–63
Dry taps and what to do about them: a pictorial essay on failed arthrocentesis of the knee. Roberts WN, et al. **Am J Med** 1996 Apr;100(4):461–4
Is rheumatoid arthritis a failure of B cell death in synovium? Edwards JC, et al. **Ann Rheum Dis** 1995 Sep;54(9):696–700 (37 ref.)
Localisation of apoptosis and expression of apoptosis related proteins in the synovium of patients with rheumatoid arthritis. Sugiyama M, et al. **Ann Rheum Dis** 1996 Jul; 55(7):442–9
Eosinophils are an insignificant cellular component of rheumatoid synovium in patients with late stage disease: comparative distributions with mast cells and macrophages. Tetlow LC, et al. **Ann Rheum Dis** 1996 Aug;55(8):548–51
The CD69 activation pathway in rheumatoid arthritis synovial fluid T cells. Hernández–García C, et al. **Arthritis Rheum** 1996 Aug;39(8):1277–86
Accelerated generation of CD14+ monocyte–lineage cells from the bone marrow of rheumatoid arthritis patients. Hirohata S, et al. **Arthritis Rheum** 1996 May;39(5):836–43
Fibroblast adhesion to articular cartilage [letter; comment] Jasin HE. **Arthritis Rheum** 1996 Jun;39(6):1072–3. Comment on: Arthritis Rheum 1995 Nov;38(11):1694–700.
Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. Jendro MC, et al. **Arthritis Rheum** 1995 Sep;38(9):1242–51
Expression of activation markers of the rheumatoid arthritis synovial membrane: comment on the article by Qu et al [letter; comment] Kinne RW, et al. **Arthritis Rheum** 1995 Sep;38(9):1346–8. Comment on: Arthritis Rheum 1994 Feb;37(2):212–20.
Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long–term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables. Kremer JM, et al. **Arthritis Rheum** 1995 Sep;38(9):1194–203
Rheumatoid synovial fibroblast adhesion to human articular cartilage. Enhancement by neutrophil proteases [see comments] McCurdy L, et al. **Arthritis Rheum** 1995 Nov; 38(11):1694–700. Comment in: Arthritis Rheum 1996 Jun;39(6):1072–3.
Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Mulherin D, et al. **Arthritis Rheum** 1996 Jan;39(1):115–24
Progressive joint destruction in a human immunodeficiency virus–infected patient with rheumatoid arthritis. Müller–Ladner U, et al. **Arthritis Rheum** 1995 Sep;

38(9):1328–32

Course of gut inflammation in spondylarthropathies and therapeutic consequences. Mielants H, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):147–64 (75 ref.)

A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. Brennan P, et al. **BMJ** 1996 Aug 24;313(7055):471–6

CD69 on synovial T cells in rheumatoid arthritis correlates with disease activity [letter] Iannone F, et al. **Br J Rheumatol** 1996 Apr;35(4):397

Adhesion of rheumatoid lymphocytes to mucosal endothelium: the gut revisited. Kadioglu A, et al. **Br J Rheumatol** 1996 Mar;35(3):218–25

In vitro effects of methotrexate on human articular cartilage and bone-derived osteoblasts. van der Veen MJ, et al. **Br J Rheumatol** 1996 Apr;35(4):342–9

The anatomy of the rheumatoid lesion. Palmer DG. **Br Med Bull** 1995 Apr;51(2):286–95 (45 ref.)

An ultrastructural study of glomerular basement membrane in rheumatoid arthritis patients with urinary abnormalities. Saito T, et al. **Clin Nephrol** 1995 Jun;43(6):360–7

A one-day double-labelling technique for tissue specimens: immunogold-silver staining for in situ hybridization combined with alkaline phosphatase-anti-alkaline phosphatase (APAAP) immunohistochemistry for antigens. Müller-Ladner U, et al. **Histochem J** 1996 Feb;28(2):133–4

Production of PAF-acether by synovial fluid neutrophils in rheumatoid arthritis. Hilliquin P, et al. **Inflamm Res** 1995 Aug;44(8):313–6

Blood monocytes in rheumatoid arthritis are highly adherent to cultured endothelium. Mazure G, et al. **Int Arch Allergy Immunol** 1995 Nov;108(3):211–23

Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid joints. Mima T, et al. **J Clin Invest** 1995 Oct; 96(4):1746–58

Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium. Thomas R, et al. **J Immunol** 1996 Apr 15;156(8):3074–86

Mononuclear cell (MNC) subtypes in osteoarthritis synovial fluid. Comparison with MNC subtypes in rheumatoid arthritis synovial fluid. Fort JG, et al. **J Rheumatol** 1995 Jul;22(7):1335–7

Analysis of junctional sequences of T cell receptor gamma chain transcripts in gamma delta T cells from rheumatoid synovial fluid. Kageyama Y, et al. **J Rheumatol** 1995 May; 22(5):812–6

Cartilage destruction via the synovial fluid in rheumatoid arthritis [letter; comment] Mohr W. **J Rheumatol** 1995 Jul; 22(7):1436–8. Comment on: J Rheumatol 1994 Oct;21(10):1796–801.

Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. Nagashima M, et al. **J Rheumatol** 1995 Sep;22(9):1624–30

Fibronectin induces protease dependent focal matrix depletion and cell overlap in cultured rheumatoid synoviocytes. Wang AZ, et al. **J Rheumatol** 1995 May; 22(5):817–28

Noninvasive 3D MR microscopy as a tool in pharmacological research: application to a model of rheumatoid arthritis. Beckmann N, et al. **Magn Reson Imaging** 1995;13(7):1013–7

Images in clinical medicine. Cholesterol crystals. DeMarco PJ, et al. **N Engl J Med** 1995 Nov 16;333(20):1325

Role of adhesion molecules in the pathogenesis of rheumatoid arthritis. Liao HX, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):715–40 (150 ref.)

The neutrophil in rheumatoid arthritis. Pillinger MH, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):691–714 (135 ref.)

Immunohistochemical analysis of proliferating and antigen-presenting cells in rheumatoid synovial tissue. Krenn V, et al. **Rheumatol Int** 1996;15(6):239–47

Predictive value of rheumatoid factor isotypes for radiological progression in patients with rheumatoid arthritis [letter; comment] Valdimarsson H, et al. **Scand J Rheumatol** 1996;25(3):189–90. Comment on: Scand J Rheumatol 1995;24(3):146–53.

Distinctive radiological features of small hand joints in rheumatoid arthritis and seronegative spondyloarthritis demonstrated by contrast-enhanced (Gd-DTPA) magnetic resonance imaging. Jevtic V, et al. **Skeletal Radiol** 1995 Jul;24(5):351–5

[Involvement of the shoulder in rheumatoid arthritis] Rombouts JJ, et al. **Acta Orthop Belg** 1995;61 Suppl 1:84–92 (Eng. Abstr.) **(Fre)**

[The effect of basic therapy on the morphological picture of the rectal mucosa in patients with rheumatoid arthritis] Frizen BN, et al. **Ter Arkh** 1995;67(11):76–80 (Eng. Abstr.) **(Rus)**

[The detection of secondary amyloidosis in rheumatoid arthritis by aspiration biopsy of the subcutaneous fatty tissue] Päi S, et al. **Ter Arkh** 1995;67(11):73–5 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Bone loss of the radius in rheumatoid arthritis. Comparison between 34 patients and 40 controls. Toyoda T, et al. **Acta Orthop Scand** 1996 Jun;67(3):269–73

Differential release of molecular markers in joint disease. Saxne T. **Acta Orthop Scand Suppl** 1995 Oct;266:80–3 (29 ref.)

Should the MHAQ ever be used? [letter] Serrano MA, et al. **Ann Rheum Dis** 1996 Apr;55(4):271–2

Predictors of joint damage in rheumatoid arthritis. Wollheim FA. **APMIS** 1996 Feb;104(2):81–93 (103 ref.)

Serum pro-matrix metalloproteinase 3 in rheumatoid arthritis: a reflection of local or systemic inflammation? [letter; comment] Cheung NT, et al. **Arthritis Rheum** 1996 May; 39(5):884–6. Comment on: Arthritis Rheum 1995 Aug;38(8):1031–9.

Severity of rheumatoid arthritis in Greek versus English patients: comment on the article by Drosos et al [letter; comment] Christodoulou D. **Arthritis Rheum** 1995 Sep; 38(9):1344–5. Comment on: Arthritis Rheum 1992 Jul;35(7):745–8.

The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Emkey RD, et al. **Arthritis Rheum** 1996 Feb;39(2):277–82

Inhibition of Fas antigen-mediated apoptosis of rheumatoid synovial cells in vitro by transforming growth factor beta 1. Kawakami A, et al. **Arthritis Rheum** 1996 Aug; 39(8):1267–76

Predictors of work disability in rheumatoid arthritis patients. A five-year followup. Reisine S, et al. **Arthritis Rheum** 1995 Nov;38(11):1630–7

Expression and function of CD80 and CD86 costimulator molecules on synovial dendritic cells in chronic arthritis. Summers KL, et al. **Arthritis Rheum** 1996 Aug; 39(8):1287–91

Neutrophil trafficking into inflamed joints in patients with rheumatoid arthritis, and the effects of methylprednisolone. Youssef PP, et al. **Arthritis Rheum** 1996 Feb;39(2):216–25

Tyrosine phosphorylation in inflammatory neutrophils. Lloyds D, et al. **Biochem Soc Trans** 1996 Feb;24(1):79S

Methodological problems in comparing the severity of rheumatoid arthritis between populations. Ali-Gombe A, et al. **Br J Rheumatol** 1995 Aug;34(8):781–4 (27 ref.)

Advice to car drivers with rheumatoid arthritis [letter] Dawson JK, et al. **Br J Rheumatol** 1995 Aug;34(8):796–7

Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Deodhar AA, et al. **Br J Rheumatol** 1996 Apr;35(4):309–22 (88 ref.)

Bone resorption by tartrate-resistant acid phosphatase-positive multinuclear cells isolated from rheumatoid synovium. Fujikawa Y, et al. **Br J Rheumatol** 1996 Mar;35(3):213–7

Lymphatic function in inflammatory arthritis [letter; comment] Kiely PD, et al. **Br J Rheumatol** 1996 Apr; 35(4):396. Comment on: Br J Rheumatol 1995 Jul;34(7):689–91.

Peripheral bone mass measurements--is there any clinical value in rheumatoid arthritis? [editorial] Reid DM, et al. **Br J Rheumatol** 1996 Feb;35(2):109–10

Why does an inflammation in the joint hurt? [editorial] Schaible HG. **Br J Rheumatol** 1996 May;35(5):405–6 (11 ref.)

Comparison of the validity and reliability of self-reported articular indices. Stucki G, et al. **Br J Rheumatol** 1995 Aug; 34(8):760–6

Anterior pituitary function in patients with newly diagnosed rheumatoid arthritis. Templ E, et al. **Br J Rheumatol** 1996 Apr;35(4):350–6

Discordance between objective and subjective assessment of functional ability of patients with rheumatoid arthritis. van den Ende CH, et al. **Br J Rheumatol** 1995 Oct;34(10):951–5

In-patient treatment for active rheumatoid arthritis: clinical course and predictors of improvement. Vliet Vlieland TP, et al. **Br J Rheumatol** 1995 Sep;34(9):847–53

Knee laxity in patients with osteoarthritis and rheumatoid arthritis. Wada M, et al. **Br J Rheumatol** 1996 Jun; 35(6):560–3

Quality of life in rheumatoid arthritis: a case-control study in patients living in northern Norway. Bekkelund SI, et al. **Clin Exp Rheumatol** 1995 Jul-Aug;13(4):471–5

Correlation between methotrexate pharmacokinetic parameters, and clinical and biological status in rheumatoid arthritis patients. Bologna C, et al. **Clin Exp Rheumatol** 1995 Jul-Aug;13(4):465–70

Rheumatoid arthritis in Greece: clinical, serological and genetic considerations. Drosos AA, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S7–12 (48 ref.)

Pro- and antiinflammatory cytokine balance in rheumatoid arthritis. Miossec P. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S13–6 (16 ref.)

Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis. Shin H, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):225–33

The clinical and immunological effects of cyclosporin A on patients with rheumatoid arthritis. Chang DM, et al. **Clin Rheumatol** 1995 Sep;14(5):537–43

The role of T cells in rheumatoid arthritis. De Keyser F, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 2:5–9 (21 ref.)

The use of Sandimmun (cyclosporin A) in severe refractory rheumatoid arthritis: the Belgian experience. Malaise MG, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 2:26–32

Prognostic factors of severe rheumatoid arthritis. Westhovens R. **Clin Rheumatol** 1995 Sep;14 Suppl 2:19–21 (24 ref.)

24-h ECG monitoring in patients with rheumatoid arthritis. Tlustochowicz W, et al. **Eur Heart J** 1995 Jun;16(6):848–51

Echo-Doppler left ventricular filling abnormalities in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Corrao S, et al. **Eur J Clin Invest** 1996 Apr;26(4):293–7

Kinematics of the distal radioulnar joint in rheumatoid arthritis: an in vivo study using centrode analysis. Weiler PJ, et al. **J Hand Surg [Am]** 1995 Nov;20(6):937–43

Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. Szekanecz Z, et al. **J Investig Med** 1996 Apr;44(4):124–35 (164 ref.)

The role of chemokines in inflammatory joint disease. Kunkel SL, et al. **J Leukoc Biol** 1996 Jan;59(1):6–12 (26 ref.)

A Grip Ability Test for use in rheumatology practice. Dellhag B, et al. **J Rheumatol** 1995 Aug;22(8):1559–65

Functional status assessment of physical impairment in a community based population with rheumatoid arthritis: severely incapacitated patients are rare. Hakala M, et al. **J Rheumatol** 1996 Apr;23(4):617–23

Percentile curve reference charts of physical function: rheumatoid arthritis population. Lassere M, et al. **J Rheumatol** 1995 Jul;22(7):1241–6

Hypothalamic-pituitary-adrenal-glucocorticoid axis function in rheumatoid arthritis [editorial; comment] Masi AT, et al. **J Rheumatol** 1996 Apr;23(4):577–81 (19 ref.). Comment on: J Rheumatol 1996 Apr;23(4):596–602.

Sex hormone status and bone mineral density in men with rheumatoid arthritis. Mateo L, et al. **J Rheumatol** 1995 Aug; 22(8):1455–60

Is it possible to predict the first year extent of pain and disability for patients with rheumatoid arthritis? van der Heide A, et al. **J Rheumatol** 1995 Aug;22(8):1466–70

Determinants of hand function in patients with rheumatoid arthritis. Vliet Vlieland TP, et al. **J Rheumatol** 1996 May; 23(5):835–40

Effects of mirthful laughter on neuroendocrine and immune systems in patients with rheumatoid arthritis [letter] Yoshino S, et al. **J Rheumatol** 1996 Apr;23(4):793–4

Physical fitness in children with juvenile rheumatoid arthritis and other chronic pediatric illnesses. Singsen BH. **Pediatr Clin North Am** 1995 Oct;42(5):1035–50 (61 ref.)

On the belief that arthritis pain is related to the weather. Redelmeier DA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2895–6

A study of ovarian function in rheumatoid arthritis. Flaisler F, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):549–54

Rheumatic pains of previously undiagnosed diabetic subjects. Qiao Q, et al. **Scand J Rheumatol** 1995;24(4):234–7

Chemiluminescence responses and chemotaxis of monocytes from patients with early rheumatoid arthritis. Repo H, et al. **Scand J Rheumatol** 1996;25(2):92–6

Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. Masi AT, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):1–27 (166 ref.)

[Kidney function problems in rheumatoid arthritis] Nordin H, et al. **Ugeskr Laeger** 1996 May 27;158(22):3137–40 (40 ref.) (Eng. Abstr.) **(Dan)**

[Functional study of Swanson's metacarpophalangeal arthroplasties in rheumatoid arthritis] Vézina P, et al. **Ann Chir** 1995;49(8):775–8 (Eng. Abstr.) **(Fre)**

[Prognostic factors in early inflammatory arthritis] Combe B. **Rev Med Interne** 1996;17(3):224–30 (67 ref.) (Eng. Abstr.) **(Fre)**

[Fracture threshhold of rheumatoid arthritis patients] Miyamoto S, et al. **Ryumachi** 1995 Jun;35(3):538–42 (Eng. Abstr.) **(Jpn)**

[Bone mineral density of the radius in patients with rheumatoid arthritis measured by dual energy X-ray absorptiometry] Miyata M, et al. **Ryumachi** 1995 Jun; 35(3):521–9 (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Pasero G, et al. **Arthritis Rheum** 1996 Jun;39(6):1006–15

The preventive effect of oral administration of type I interferon on collagen-induced arthritis in rats. Yoshino S. **Exp Mol Pathol** 1995 Apr;62(2):123–30

Validity and reproducibility of self-administered joint counts. A prospective longitudinal followup study in patients with rheumatoid arthritis. Prevoo ML, et al. **J Rheumatol** 1996 May;23(5):841–5 .

PSYCHOLOGY

Personality and stress: an exploratory comparison of rheumatoid arthritis and osteoarthritis. Latman NS, et al. **Arch Phys Med Rehabil** 1996 Aug;77(8):796–800

Gender, paid work, and symptoms of emotional distress in rheumatoid arthritis patients. Fifield J, et al. **Arthritis Rheum** 1996 Mar;39(3):427–35

Effects of stress management on clinical outcomes in rheumatoid arthritis. Parker JC, et al. **Arthritis Rheum** 1995 Dec;38(12):1807–18

Arthritis and perceptions of quality of life: an examination of positive and negative affect in rheumatoid arthritis patients. Zautra AJ, et al. **Health Psychol** 1995 Sep; 14(5):399–408

The moderating effect of demographic variables on coping effectiveness. Spitzer A, et al. **J Adv Nurs** 1995 Sep; 22(3):578–85

Social support: how does it really work? Spitzer A, et al.

J Adv Nurs 1995 Nov;22(5):850–4

Life events and the onset of rheumatoid arthritis [letter; comment] **James WH. J Psychosom Res** 1995 May; 39(4):507–8. Comment on: J Psychosom Res 1994 Nov;38(8):837–47.

On the belief that arthritis pain is related to the weather. **Redelmeier DA, et al. Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2895–6

Outcome measures in rheumatoid arthritis. **Stucki G, et al. Schweiz Med Wochenschr Suppl** 1996;80:14S–17S

[Pain and pain perception in the elderly from the viewpoint of rheumatology] **Nehen HG. Z Gerontol Geriatr** 1995 Sep–Oct;28(5):335–8 (10 ref.) (Eng. Abstr.) **(Ger)**

[Coping with the illness by patients with chronic polyarthritis. Forms of coping and therapeutic implications] **Csef H, et al. Z Rheumatol** 1995 Sep–Oct;54(5):310–8 (Eng. Abstr.) **(Ger)**

[Coping with stress and rheumatoid factor—a comparative study] **Mur E, et al. Z Rheumatol** 1995 Sep–Oct; 54(5):319–23 (Eng. Abstr.) **(Ger)**

[Various personality traits of patients with psoriatic arthropathy] **Giordano N, et al. Minerva Med** 1996 Jun; 87(6):283–7 (Eng. Abstr.) **(Ita)**

[Quality of life, subjective health status and health and life satisfaction in rheumatoid arthritis] **Sato H, et al. Nippon Koshu Eisei Zasshi** 1995 Sep;42(9):743–54 (Eng. Abstr.) **(Jpn)**

[Spontaneous use of active and passive coping strategies for pain in patients with rheumatoid arthritis] **Sebro B, et al. Reumatizam** 1993;40(1):1–4 (Eng. Abstr.) **(Scr)**

RADIOGRAPHY

The radiology of rheumatoid arthritis. **Brown JH, et al. Am Fam Physician** 1995 Oct;52(5):1372–80 (04 ref.)

Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. **van der Heide A, et al. Arthritis Rheum** 1995 Oct;38(10):1466–74

Joint erosions and patients with early rheumatoid arthritis. **van der Heijde DM. Br J Rheumatol** 1995 Nov;34 Suppl 2:74–8 (31 ref.)

Pre-operative cervical spine radiography in rheumatoid arthritis [letter; comment] **Baylis RJ, et al. Clin Radiol** 1996 Apr;51(4):307. Comment on: Clin Radiol 1995 Mar;50(3):157–9.

Pre-operative cervical spine radiography in rheumatoid arthritis [letter; comment] **Frater RA. Clin Radiol** 1996 Jan; 51(1):77. Comment on: Clin Radiol 1995 Mar;50(3):157–9.

Radiographic evaluation of the upper cervical spine in rheumatoid arthritis: a retrospective analysis. **Kuhr M, et al. Eur Spine J** 1996;5(2):107–11 (30 ref.)

The validity of radiography as outcome measure in rheumatoid arthritis. **Boers M. J Rheumatol** 1995 Sep; 22(9):1783–6 (18 ref.)

Monitoring radiographic changes in early rheumatoid arthritis [editorial] **Paulus HE, et al. J Rheumatol** 1996 May; 23(5):801–5

Attempts to apply curve fitting models to the analysis of progression of radiographic damage in rheumatoid arthritis are laudable, but are the results believable? [letter; comment] **Plant MJ, et al. J Rheumatol** 1995 Sep; 22(9):1800–2. Comment on: J Rheumatol 1994 Sep;21(9):1589–90. Comment on: J Rheumatol 1995 Sep;21(9):1626–30.

Assessment of radiographic abnormalities in rheumatoid arthritis: what have we accomplished and where should we go from here? **Sharp JT. J Rheumatol** 1995 Sep; 22(9):1787–91 (48 ref.)

Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). **van der Heijde DM, et al. J Rheumatol** 1995 Sep; 22(9):1792–6

Radiographic progression in rheumatoid arthritis: results of 3 comparative trials. **van Riel PL, et al. J Rheumatol** 1995 Sep;22(9):1797–9

Radiographic changes in the temporomandibular joint in patients with generalized osteoarthritis and rheumatoid arthritis. **Gynther GW, et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):613–8

Scoring radiographic abnormalities in rheumatoid arthritis. **Sharp JT. Radiol Clin North Am** 1996 Mar;34(2):233–41, x (66 ref.)

[New approaches to computer-assisted diagnosis of rheumatologic diseases] **Boegl K, et al. Radiologe** 1995 Sep; 35(9):604–10 (Eng. Abstr.) **(Ger)**

[Even jaw-joint can be affected by rheumatoid arthritis (letter)] **Westermark A. Lakartidningen** 1996 Apr 3; 93(14):1315 **(Swe)**

RADIONUCLIDE IMAGING

Use of a radiolabeled monoclonal antibody against E-selectin for imaging of endothelial activation in rheumatoid arthritis. **Chapman PT, et al. Arthritis Rheum** 1996 Aug; 39(8):1371–5

New agents for scintigraphy in rheumatoid arthritis. **de Bois MH, et al. Eur J Nucl Med** 1995 Nov;22(11):1339–46 (73 ref.)

Technetium-99m labelled polyclonal human IgG scintigraphy before and 26 weeks after initiation of parenteral gold treatment in patients with rheumatoid arthritis. **de Bois MH, et al. J Rheumatol** 1995 Aug; 22(8):1461–5

Evaluation of disease activity in rheumatoid arthritis and other arthritides using 99mtechnetium labeled nonspecific human immunoglobulin. **Jamar F, et al. J Rheumatol** 1995 May;22(5):850–4

Technetium-99m labelled human immunoglobulin scintigraphy predicts rheumatoid arthritis in patients with arthralgia. **de Bois MH, et al. Scand J Rheumatol** 1996; 25(3):155–8

RADIOTHERAPY

Beta-particle dosimetry in radiation synovectomy. **Johnson LS, et al. Eur J Nucl Med** 1995 Sep;22(9):977–88

Treatment of rheumatoid arthritis with radionuclide combination. **Andjelković Z, et al. Med Pregl** 1993;46 Suppl 1:48–50

REHABILITATION

Therapeutic monoclonal antibodies. **Choy EH, et al. Br J Rheumatol** 1995 Aug;34(8):707–15 (64 ref.)

Effectiveness of minimally supervised home aerobic training in patients with systemic rheumatic disease. **Daltroy LH, et al. Br J Rheumatol** 1995 Nov;34(11):1064–9

Sequential occupational dexterity assessment (SODA): a new test to measure hand disability. **van Lankveld W, et al. J Hand Ther** 1996 Jan–Mar;9(1):27–32

[Rheumatoid arthritis: general practice searches for effective healing methods (interview by Elisabeth B. Moosmann)] **Peter HH. Fortschr Med** 1996 Jan 20;114(1–2):20–1 **(Ger)**

[Rheumatoid arthritis and quality of life] **Kawai S. Ryumachi** 1995 Jun;35(3):609–20 (43 ref.) **(Jpn)**

[Rehabilitation in rheumatoid arthritis (RA) patients—assessment of effects of rehabilitation based on activities of daily living (ADL)] **Konno T, et al. Ryumachi** 1995 Jun;35(3):595–9 (Eng. Abstr.) **(Jpn)**

[The validity and reliability of a Japanese version of Arthritis Impact Measurement Scales in patients with rheumatoid arthritis] **Sato H, et al. Ryumachi** 1995 Jun;35(3):566–74 (Eng. Abstr.) **(Jpn)**

SURGERY

Relationship between retention of the posterior cruciate ligament and postoperative flexion in total knee arthroplasty. **Yokoyama Y, et al. Acta Med Okayama** 1995 Dec;49(6):295–300

Occipito-cervical fixation in rheumatoid arthritis—an analysis of surgical risk factors in 163 patients. **Zygmunt SC, et al. Acta Neurochir (Wien)** 1995;135(1–2):25–31

Late results of the Souter-Strathclyde total elbow prosthesis in rheumatoid arthritis. 6/19 implants loose after 5 years. **Sjödén GO, et al. Acta Orthop Scand** 1995 Oct;66(5):391–4

Cervical spine surgery in patients with rheumatoid arthritis: an appraisal. **McRorie ER, et al. Ann Rheum Dis** 1996 Feb; 55(2):99–104

Outcome analysis of total knee-replacements in patients with rheumatoid arthritis versus osteoarthritis. **Elke R, et al. Arch Orthop Trauma Surg** 1995;114(6):330–4

Loosening of a revision total hip replacement in a 60-year-old woman with longstanding rheumatoid arthritis [clinical conference] **Gravallese EM, et al. Arthritis Rheum** 1995 Sep;38(9):1315–24

In the rheumatoid patient: surgery to the cervical spine. **Casey AT, et al. Br J Rheumatol** 1995 Nov;34(11):1079–86 (48 ref.)

Arthroscopic synovectomy in rheumatoid and psoriatic knee joint synovitis: long-term outcome. **Fiocco U, et al. Br J Rheumatol** 1996 May;35(5):463–70

Arthroscopic ankle arthrodesis in rheumatoid arthritis. **Turan I, et al. Clin Orthop** 1995 Nov;(320):110–4

Evaluation and treatment of the rheumatoid wrist. **Terrono AL, et al. Instr Course Lect** 1996;45:15–26 (64 ref.)

Long-term results of total knee arthroplasty in class 3 and 4 rheumatoid arthritis. **Rodriguez JA, et al. J Arthroplasty** 1996 Feb;11(2):141–5

Cementless total knee arthroplasty in rheumatoid arthritis. A report on 51 AGC knees followed for 54 months. **Schrøder HM, et al. J Arthroplasty** 1996 Jan;11(1):18–23

Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis. **Spinner RJ, et al. J Arthroplasty** 1996 Feb;11(2):217–22 (46 ref.)

Prophylaxis against deep venous thrombosis after total knee arthroplasty. Pneumatic plantar compression and aspirin compared with aspirin alone. **Westrich GH, et al. J Bone Joint Surg Am** 1996 Jun;78(6):826–34

Revision of failed total elbow arthroplasty. **Dent CM, et al. J Bone Joint Surg Br** 1995 Sep;77(5):691–5

Extensile posterior approach to the ankle. **Hayes AG, et al. J Bone Joint Surg Br** 1996 May;78(3):468–70

Short-term complications of the lateral approach for non-constrained elbow replacement. Follow-up of 50 rheumatoid elbows. **Ljung P, et al. J Bone Joint Surg Br** 1995 Nov;77(6):937–42

Resection arthroplasty of the forefoot in rheumatoid arthritis cases. **Broeng L, et al. J Foot Ankle Surg** 1995 Nov–Dec; 34(6):534–6

Matched hemiresection interposition arthroplasty of the distal radioulnar joint. **Bain GI, et al. J Hand Surg [Am]** 1995 Nov;20(6):944–50

Salvage of the failed Darrach procedure. **Kleinman WB, et al. J Hand Surg [Am]** 1995 Nov;20(6):951–8

Excision of the distal ulna in rheumatoid arthritis. Is the price too high? **Nanchahal J, et al. J Hand Surg [Br]** 1996 Apr; 21(2):189–96

Resection arthroplasty of the metacarpophalangeal joints in rheumatoid arthritis. Results after more than 15 years. **Rüther W, et al. J Hand Surg [Br]** 1995 Oct;20(5):707–15

Early active mobilization after tendon transfers using mesh reinforced suture techniques. **Silfverskiöld KL, et al. J Hand Surg [Br]** 1995 Jun;20(3):291–300

Interposition arthroplasty of the elbow with rheumatoid arthritis. **Ljung P, et al. J Shoulder Elbow Surg** 1996 Mar–Apr;5(2 Pt 1):81–5

Surgery on the rheumatoid cervical spine for the non-ambulant myelopathic patient-too much, too late? [see comments] **Casey AT, et al. Lancet** 1996 Apr 13; 347(9007):1004–7. Comment in: Lancet 1996 Apr 13;347(9007):984–5.

Noncemented femoral components in total hip arthroplasty for patients with rheumatoid arthritis. **Walker KR, et al. Minn Med** 1996 Jul;79(7):27–31

Long-term results of forefoot arthroplasty in patients with rheumatoid arthritis. **Patsalis T, et al. Orthopedics** 1996 May;19(5):439–47 (48 ref.)

Arthroscopic knee joint synovectomy in the treatment of early stages of rheumatoid arthritis. **Latosiewicz R, et al. Rocz Akad Med Bialymst** 1994;39:25–30

Arthrodesis in rheumatoid arthritis using absorbable screws and rods. **Juutilainen T, et al. Scand J Rheumatol** 1995; 24(4):228–33

Surgical management of cervical rheumatoid problems. **Crockard HA. Spine** 1995 Dec 1;20(23):2584–90 (40 ref.)

[Rupture of the flexor tendons after partial arthrodesis of carpus in the rheumatoid wrist] **Fourastier J. Ann Chir Main Memb Super** 1995;14(4–5):224–8 (Eng. Abstr.) **(Fre)**

[Shoulder prosthesis] **Rev Chir Orthop Reparatrice Appar Mot** 1995;81 Suppl 2:73–133 **(Fre)**

[Guépar's total radio-carpal prosthesis in the surgery of the rheumatoid wrist. Apropos of 72 cases reviewed] **Fourastier J, et al. Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):108–15 (Eng. Abstr.) **(Fre)**

[Synovectomy of the knee joint in rheumatoid arthritis. Follow-up studies] **Fritsch E, et al. Fortschr Med** 1995 Dec 10;113(34):487–9 (Eng. Abstr.) **(Ger)**

[Arthrodesis of the rheumatoid wrist] **Flügel M. Orthopade** 1996 Apr;25(2):126–8 (Eng. Abstr.) **(Ger)**

[Rheumatoid orthopedics and endoprosthetics of the shoulder joint] **Schwägerl W, et al. Wien Med Wochenschr** 1996; 146(6–7):124–9 (31 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of supracondylar femoral fracture proximal to a knee joint endoprosthesis by retrograde interlocking nailing] **Ostermann PA, et al. Zentralbl Chir** 1995; 120(9):731–3 (Eng. Abstr.) **(Ger)**

THERAPY

A 3-year follow-up of temporomandibular disorders in rheumatoid arthritis and ankylosing spondylitis. **Tegelberg A, et al. Acta Odontol Scand** 1996 Feb;54(1):14–8

TNF alpha is an effective therapeutic target for rheumatoid arthritis. **Feldmann M, et al. Ann N Y Acad Sci** 1995 Sep 7;766:272–8 (20 ref.)

Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. **Trentham DE. Ann N Y Acad Sci** 1996 Feb 13; 778:306–14 (15 ref.)

Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. **Arthritis Rheum** 1996 May; 39(5):713–22

Workshop on chronic pain, pain control, and patient outcomes in rheumatoid arthritis and osteoarthritis. **Bellamy N, et al. Arthritis Rheum** 1996 Mar;39(3):357–62 (26 ref.)

Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. **Campion GV, et al. Arthritis Rheum** 1996 Jul; 39(7):1092–101

Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. **Choy EH, et al. Arthritis Rheum** 1996 Jan;39(1):52–6

Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. **Drevlow BE, et al. Arthritis Rheum** 1996 Feb;39(2):257–65

Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. **Jendro MC, et al. Arthritis Rheum** 1995 Sep;38(9):1242–51

Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. **Joosten LA, et al. Arthritis Rheum** 1996 May; 39(5):797–809

Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. **Kanik KS, et al. Arthritis Rheum** 1996 Jun;39(6):1027–9

Health outcomes of two telephone interventions for patients

with rheumatoid arthritis or osteoarthritis. Maisiak R, et al. **Arthritis Rheum** 1996 Aug;39(8):1391–9

Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH–1H administered by daily subcutaneous injection. Matteson EL, et al. **Arthritis Rheum** 1995 Sep;38(9):1187–93

Double–blind, placebo–controlled multicenter trial using chimeric monoclonal anti–CD4 antibody, cM–T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Moreland LW, et al. **Arthritis Rheum** 1995 Nov;38(11):1581–8

A double–blind, placebo–controlled study of anti–CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Olsen NJ, et al. **Arthritis Rheum** 1996 Jul;39(7):1102–8

Deactivation of vascular endothelium by monoclonal anti–tumor necrosis factor alpha antibody in rheumatoid arthritis. Paleolog EM, et al. **Arthritis Rheum** 1996 Jul; 39(7):1082–91

The effect of progressive resistance training in rheumatoid arthritis. Increased strength without changes in energy balance or body composition. Rall LC, et al. **Arthritis Rheum** 1996 Mar;39(3):415–26

Oral type II collagen treatment in early rheumatoid arthritis. A double–blind, placebo–controlled, randomized trial. Sieper J, et al. **Arthritis Rheum** 1996 Jan;39(1):41–51

Synovial tissue responses following treatment of rheumatoid arthritis with the humanized monoclonal antibody CAMPATH–1H [letter; comment] Soriano ER, et al. **Arthritis Rheum** 1996 Jan;39(1):181–2. Comment on: Arthritis Rheum 1995 Feb;38(2):254–8.

Reduction of synovial inflammation after anti–CD4 monoclonal antibody treatment in early rheumatoid arthritis. Tak PP, et al. **Arthritis Rheum** 1995 Oct; 38(10):1457–65

Decrease in cellularity and expression of adhesion molecules by anti–tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Tak PP, et al. **Arthritis Rheum** 1996 Jul;39(7):1077–81

American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis: comment on the article by Felson et al [letter; comment] van Gestel A, et al. **Arthritis Rheum** 1996 Mar;39(3):535–7. Comment on: Arthritis Rheum 1995 Jun;38(6):727–35.

Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin–10 and interleukin–4. van Roon JA, et al. **Arthritis Rheum** 1996 May;39(5):829–35

CAMPATH–1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose–escalation study. Weinblatt ME, et al. **Arthritis Rheum** 1995 Nov;38(11):1589–94

Innovative treatment approaches for rheumatoid arthritis. T–cell regulation. Choy EH, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):653–71 (76 ref.)

Anti–cytokine therapy in rheumatoid arthritis. Elliott MJ, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):633–52 (81 ref.)

Course of gut inflammation in spondylarthropathies and therapeutic consequences. Mielants H, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):147–64 (75 ref.)

Innovative treatment approaches for rheumatoid arthritis. Issues in clinical trials of biological agents. Strand V. **Baillieres Clin Rheumatol** 1995 Nov;9(4):825–35 (38 ref.)

Decreases in health care resource utilization in patients with rheumatoid arthritis following a cognitive behavioral intervention. Young LD, et al. **Biofeedback Self Regul** 1995 Sep;20(3):259–68

Measuring outcome in rheumatoid arthritis—which measures are suitable for routine clinical use? [letter; comment] Blake DR. **Br J Rheumatol** 1996 Mar;35(3):301. Comment on: Br J Rheumatol 1995 Sep;34(9):802–4.

Health economics as an aspect of health outcome: basic principles and application in rheumatoid arthritis [see comments] Lambert CM, et al. **Br J Rheumatol** 1995 Aug; 34(8):774–80 (49 ref.). Comment in: Br J Rheumatol 1996 May;35(5):494.

Treatment of rheumatoid arthritis—does it affect society's cost for the disease? Magnusson S. **Br J Rheumatol** 1996 Aug;35(8):791–5

Measuring outcome in rheumatoid arthritis—which measures are suitable for routine clinical use? [editorial] [see comments] Symmons DP. **Br J Rheumatol** 1995 Sep; 34(9):802–4. Comment in: Br J Rheumatol 1996 Mar;35(3):301.

In–patient treatment for active rheumatoid arthritis: clinical course and predictors of improvement. Vliet Vlieland TP, et al. **Br J Rheumatol** 1995 Sep;34(9):847–53

A randomized clinical trial of in–patient multidisciplinary treatment versus routine out–patient care in active rheumatoid arthritis. Vliet Vlieland TP, et al. **Br J Rheumatol** 1996 May;35(5):475–82

Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives. Chernajovsky Y, et al. **Br Med Bull** 1995 Apr;51(2):503–16 (41 ref.)

Managing early presentation of rheumatoid arthritis. Systematic overview. Glazier R. **Can Fam Physician** 1996 May;42:913–22 (85 ref.)

Comment on the treatment of early rheumatoid arthritis [letter; comment] Ibkhatra SA, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):106. Comment on: Clin Exp Rheumatol 1995 May–Jun;13(3):381–94.

Therapeutic regulation of T cells in rheumatoid arthritis. Breedveld FC, et al. **Immunol Rev** 1995 Apr;144:5–16 (48 ref.)

Monoclonal anti–TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Maini RN, et al. **Immunol Rev** 1995 Apr;144:195–223 (112 ref.)

Repopulation of blood lymphocyte sub–populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH–1H. Brett S, et al. **Immunology** 1996 May;88(1):13–9

Impacts of foot orthoses on pain and disability in rheumatoid arthritics. Conrad KJ, et al. **J Clin Epidemiol** 1996 Jan; 49(1):1–7

In vivo blockade of TNF–alpha by intravenous infusion of a chimeric monoclonal TNF–alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. Lorenz HM, et al. **J Immunol** 1996 Feb 15;156(4):1646–53

Clinically important change in rheumatoid arthritis [letter] Geenen R, et al. **J Rheumatol** 1996 Apr;23(4):786–8

Health care utilization and outcomes among persons with rheumatoid arthritis in fee–for–service and prepaid group practice settings. Yelin EH, et al. **JAMA** 1996 Oct 2; 276(13):1048–53

Conservative treatment for rheumatoid cervical spine [letter] Kauppi M. **Lancet** 1996 Jun 15;347(9016):1695

Orthoses for rheumatoid feet: does it matter what's underfoot? Marks MB, et al. **Lancet** 1996 Jun 15; 347(9016):1639

Marked amelioration of established collagen–induced arthritis by treatment with antibodies to CD23 in vivo. Plater–Zyberk C, et al. **Nat Med** 1995 Aug;1(8):781–5

Prospects of immunotherapy for rheumatoid arthritis. 't Hart BA, et al. **Pharm World Sci** 1995 Nov 24;17(6):178–85 (112 ref.)

Biologic interventions in rheumatoid arthritis. Cush JJ, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):797–816 (74 ref.)

Marine and botanical lipids as immunomodulatory and therapeutic agents in the treatment of rheumatoid arthritis. DeLuca P, et al. **Rheum Dis Clin North Am** 1995 Aug; 21(3):759–77 (91 ref.)

Assessment of long–term outcomes of rheumatoid arthritis. How choices of measures and study designs may lead to apparently different conclusions. Pincus T. **Rheum Dis Clin North Am** 1995 Aug;21(3):619–54 (112 ref.)

Improvement in rheumatoid arthritis following application of an extracorporeal granulotrap column, G–1. Fujimori J, et al. **Rheumatol Int** 1996;15(5):175–80

Intra–articular administration of polyclonal immunoglobulin G in rheumatoid arthritis. A double–blind, placebo–controlled pilot study. Bagge E, et al. **Scand J Rheumatol** 1996;25(3):174–6

Treatment of rheumatoid arthritis with biologics. Panayi GS. **Schweiz Med Wochenschr Suppl** 1996;80:22S–23S

Combination therapy of severe rheumatoid arthritis at an early stage of the disease. Tugwell P, et al. **Schweiz Med Wochenschr Suppl** 1996;80:20S–21S

Anti–integrin immunotherapy in rheumatoid arthritis: protective effect of anti–alpha 4 antibody in adjuvant arthritis. Barbadillo C, et al. **Springer Semin Immunopathol** 1995;16(4):427–36 (59 ref.)

Effective anticoagulation by argatroban during immunoadsorption therapy for malignant rheumatoid arthritis with a high polymorphonuclear leukocyte elastase level. Suzuki S, et al. **Thromb Res** 1995 Oct 1;80(1):93–8

[A study of relation between rheumatoid arthritis (RA) and blood stasis—the effect of acupuncture promoting blood circulation to remove blood stasis] Sun Z. **Chen Tzu Yen Chiu** 1995;20(2):71–5 (Eng. Abstr.) **(Chi)**

[Immunotherapy in rheumatoid arthritis; current status] Breedveld FC, et al. **Ned Tijdschr Geneeskd** 1996 Jun 15; 140(24):1255–9 (30 ref.) **(Dut)**

[Therapy of rheumatoid arthritis] Sieper J, et al. **Dtsch Med Wochenschr** 1996 Apr 26;121(17):563–7 (12 ref.) **(Ger)**

[Rheumatism: a too long pathway to adequate therapy. Experiences of a physician as rheumatism patient] Genth–Stolzenburg S. **Fortschr Med** 1996 Jan 20; 114(1–2):19 **(Ger)**

[Treatment strategy for rheumatoid arthritis (editorial)] Mackiewicz S. **Pol Arch Med Wewn** 1995 Mar; 93(3):197–202 **(Pol)**

[Effect of T–activin and irradiation with a helium–neon laser on the status of the interleukin–2–dependent component of the proliferative response of mononuclear cells in rheumatoid arthritis] Parnes Ela, et al. **Fiziol Cheloveka** 1995 Jul–Aug;21(4):143–9 **(Rus)**

[The combined intensive therapy of rheumatoid arthritis with systemic manifestations] Oliunin IuA, et al. **Ter Arkh** 1995; 67(8):59–62 (Eng. Abstr.) **(Rus)**

[Altered T–cells against rheumatoid arthritis. Markers as tools for early prognosis] Orn P. **Lakartidningen** 1996 Feb 14;93(7):570–3 **(Swe)**

[The combined use of diprospan and laser irradiation of the joints in rheumatoid arthritis patients] Lysenko HI, et al. **Lik Sprava** 1995 May–Jun;(5–6):77–80 (Eng. Abstr.) **(Ukr)**

ULTRASONOGRAPHY

Long–term sonographic follow–up of rheumatoid and psoriatic proliferative knee joint synovitis. Fiocco U, et al. **Br J Rheumatol** 1996 Feb;35(2):155–63

Baker's cyst in rheumatoid arthritis: an ultrasonographic study with a high resolution technique. Andonopoulos AP, et al. **Clin Exp Rheumatol** 1995 Sep–Oct;13(5):633–6

Ultrasonography is a nonspecific method in the evaluation of joints. Kauppi M, et al. **Clin Rheumatol** 1996 Mar; 15(2):181–4

Intra–articular somatostatin 14 reduces synovial thickness in rheumatoid arthritis: an ultrasonographic study. Coari G, et al. **Int J Clin Pharmacol Res** 1995;15(1):27–32

Ultrasonographic imaging of the hand and wrist in rheumatoid arthritis. Lund PJ, et al. **Skeletal Radiol** 1995 Nov;24(8):591–6

[Routine hip ultrasonography in inflammatory rheumatoid diseases. Results in 119 consecutive patients of a rheumatism clinic] Keitel R, et al. **Fortschr Med** 1996 Jan 20;114(1–2):23–6 (Eng. Abstr.) **(Ger)**

URINE

Urinary glucaric acid excretion in rheumatoid arthritis: influence of disease activity and disease modifying drugs. Addyman R, et al. **Ann Rheum Dis** 1996 Jul;55(7):478–81

Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone. Stichtenoth DO, et al. **Ann Rheum Dis** 1995 Oct; 54(10):820–4

Receiver operating characteristic analysis of urinary pyridinium cross–links in arthritis [letter] Takahashi M, et al. **Br J Rheumatol** 1995 Aug;34(8):792–3

VIROLOGY

High prevalence of arthropathy in HTLV–I carriers on a Japanese island. Motokawa S, et al. **Ann Rheum Dis** 1996 Mar;55(3):193–5

Parvovirus B19 in rheumatoid arthritis: comment on the article by Kerr et al [letter; comment] Nikkari S, et al. **Br J Rheumatol** 1996 May;35(5):494. Comment on: Br J Rheumatol 1995 Sep;34(9):809–13.

Human T–cell leukemia virus type I tax transactivates the interleukin–6 gene in human rheumatoid synovial cells. Mori N, et al. **J Rheumatol** 1995 Nov;22(11):2049–54

Herpes viruses in multicase families with rheumatoid arthritis. Newkirk MM, et al. **J Rheumatol** 1995 Nov;22(11):2055–61

Epstein–Barr virus and lymphoproliferation in methotrexate–treated rheumatoid arthritis. Thomason RW, et al. **Mod Pathol** 1996 Mar;9(3):261–6

ARTHRITIS, SEPTIC see **ARTHRITIS, INFECTIOUS**

ARTHRITIS, VIRAL see **ARTHRITIS, INFECTIOUS**

ARTHROBACTER

CLASSIFICATION

Reclassification of Micrococcus agilis (Ali–Cohen 1889) to the genus Arthrobacter as Arthrobacter agilis comb. nov. and emendation of the genus Arthrobacter. Koch C, et al. **Int J Syst Bacteriol** 1995 Oct;45(4):837–9

DRUG EFFECTS

Effects of copper–chrome–arsenate (CCA) components on PCP degradation by Arthrobacter strain ATCC 33790. Edgehill RU. **Bull Environ Contam Toxicol** 1996 Aug; 57(2):258–63

ENZYMOLOGY

Cloning, nucleotide sequencing, and expression of an opine dehydrogenase gene from Arthrobacter sp. strain 1C. Dairi T, et al. **Appl Environ Microbiol** 1995 Aug;61(8):3169–71

Analysis of interaction between the Arthrobacter sarcosine oxidase and the coenzyme flavin adenine dinucleotide by site–directed mutagenesis. Nishiya Y, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2405–10

Stereoselective production of (+)–trans–chrysanthemic acid by a microbial esterase: cloning, nucleotide sequence, and overexpression of the esterase gene of Arthrobacter globiformis in Escherichia coli. Nishizawa M, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3208–15

Manganese(II)–dependent extradiol–cleaving catechol dioxygenase from Arthrobacter globiformis CM–2. Whiting AK, et al. **Biochemistry** 1996 Jan 9;35(1):160–70

Quinaldine 4–oxidase from Arthrobacter sp. Rü61a, a versatile procaryotic molybdenum–containing hydroxylase active towards N–containing heterocyclic compounds and aromatic aldehydes. Stephan I, et al. **Eur J Biochem** 1996 Feb 15;236(1):155–62

Purification and characterization of the 3–ketosteroid–delta 1–dehydrogenase of Arthrobacter simplex produced in Streptomyces lividans. Choi KP, et al. **J Biochem (Tokyo)** 1995 May;117(5):1043–9

Biosynthesis of topa quinone cofactor in bacterial amine oxidases. Solvent origin of C–2 oxygen determined by Raman spectroscopy. Nakamura N, et al. **J Biol Chem** 1996 Mar 1;271(9):4718–24

GENETICS

Cloning, nucleotide sequencing, and expression of an opine dehydrogenase gene from Arthrobacter sp. strain 1C. Dairi T, et al. **Appl Environ Microbiol** 1995 Aug;61(8):3169–71

Stereoselective production of (+)–trans–chrysanthemic acid

by a microbial esterase: cloning, nucleotide sequence, and overexpression of the esterase gene of Arthrobacter globiformis in Escherichia coli. Nishizawa M, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3208–15

A pAO1–encoded molybdopterin cofactor gene (moaA) of Arthrobacter nicotinovorans: characterization and site–directed mutagenesis of the encoded protein. Menéndez C, et al. **Arch Microbiol** 1995 Aug;164(2):142–51

Cloning and sequencing of trehalose biosynthesis genes from Arthrobacter sp. Q36. Maruta K, et al. **Biochim Biophys Acta** 1996 Feb 9;1289(1):10–3

METABOLISM

Degradation of iprodione by a soil Arthrobacter–like strain. Athiel P, et al. **Appl Environ Microbiol** 1995 Sep; 61(9):3216–20

Analysis of interaction between the Arthrobacter sarcosine oxidase and the coenzyme flavin adenine dinucleotide by site–directed mutagenesis. Nishiya Y, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2405–10

MoaA of Arthrobacter nicotinovorans pAO1 involved in Mo–pterin cofactor synthesis is an Fe–S protein. Menéndez C, et al. **FEBS Lett** 1996 Aug 5;391(1–2):101–3

PHYSIOLOGY

Cold shock and cold acclimation proteins in the psychrotrophic bacterium Arthrobacter globiformis SI55. Berger F, et al. **J Bacteriol** 1996 Jun;178(11):2999–3007

VIROLOGY

Genetic characterization of site–specific integration functions of phi AAU2 infecting "Arthrobacter aureus" C70. Le Marrec C, et al. **J Bacteriol** 1996 Apr;178(7):1996–2004

ARTHRODERMA see **ASCOMYCETES**

ARTHRODESIS

Intraarticular foot and ankle injections to identify source of pain before arthrodesis. Khoury NJ, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):669–73

Arthrodesis after infected knee arthroplasty using long arthrodesis nail. A report of five cases. Jørgensen PS, et al. **Am J Knee Surg** 1995 Summer;8(3):110–3

Partial arthrodeses of the wrist. Marcuzzi A, et al. **Chir Organi Mov** 1995 Apr–Jun;80(2):157–69 **(Eng, Ita)**

Influence of arthrodeses on kinematics of the axially loaded ankle complex during dorsiflexion/plantarflexion. Hintermann B, et al. **Foot Ankle Int** 1995 Oct;16(10):633–6

Tibiocalcaneal arthrodesis. Mann RA, et al. **Foot Ankle Int** 1995 Jul;16(7):401–5

Selective hindfoot arthrodesis for the treatment of adult acquired flatfoot deformity: an in vitro study. O'Malley MJ, et al. **Foot Ankle Int** 1995 Jul;16(7):411–7

Triple arthrodesis for diabetic peritalar neuroarthropathy. Tisdel CL, et al. **Foot Ankle Int** 1995 Jun;16(6):332–8

Total hip arthroplasty for arthrodesed hips. 5- to 13-year results. Reikerås O, et al. **J Arthroplasty** 1995 Aug; 10(4):529–31

Mid–tarsal and tarsometatarsal arthrodesis for primary degenerative osteoarthrosis or osteoarthrosis after trauma. Mann RA, et al. **J Bone Joint Surg Am** 1996 Sep; 78(9):1376–85

Extracorporeal life support in the operative treatment of progressive kyphoscoliosis. A case report. Newton PO, et al. **J Bone Joint Surg Am** 1996 Feb;78(2):281–3

Results of scaphotrapeziotrapezoid fusion for isolated idiopathic arthritis. Srinivasan VB, et al. **J Hand Surg [Br]** 1996 Jun;21(3):378–80

Function after amputation, arthrodesis, or arthroplasty for tumors about the shoulder. Kneisl JS. **J South Orthop Assoc** 1995 Fall;4(3):228–36 (36 ref.)

Chronic volar dislocation of the metacarpophalangeal joint of the thumb: a case report and review of the literature. Tung TC, et al. **J Trauma** 1996 Sep;41(3):561–4

Hip fusion in young adults. Barnhardt T, et al. **Orthopedics** 1996 Apr;19(4):303–6

ADVERSE EFFECTS

Stress fracture of the tibia following extensive hindfoot and ankle arthrodesis: a report of three cases. Mitchell JR, et al. **Foot Ankle Int** 1995 Jul;16(7):445–8

Upper extremity function after wrist arthrodesis. Weiss AC, et al. **J Hand Surg [Am]** 1995 Sep;20(5):813–7

Intermediate follow–up of a simple method of hip arthrodesis in adolescent patients. Benaroch TE, et al. **J Pediatr Orthop** 1996 Jan–Feb;16(1):30–6

[Rupture of the flexor tendons after partial arthrodesis of carpus in the rheumatoid wrist] Fourastier J. **Ann Chir Main Memb Super** 1995;14(4–5):224–8 (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Anatomic structures at risk: combined subtalar and ankle arthrodesis with a retrograde intramedullary rod. Pochatko DJ, et al. **Foot Ankle Int** 1995 Sep;16(9):542–7

Wrist arthrodesis using a dynamic compression plate. O'Bierne J, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):700–4

Bioabsorbable rods and pins for fixation of metacarpophalangeal arthrodesis of the thumb. Voche P, et al. **J Hand Surg [Am]** 1995 Nov;20(6):1032–6

METHODS

Primary arthrodesis of the injured knee: still a solution in 1995? A case report. Deldycke J, et al. **Acta Chir Belg** 1995 Nov–Dec;95(6):284–8

Knee arthrodesis with a unilateral external fixator. Hessmann M, et al. **Acta Chir Belg** 1996 Jun;96(3):123–7

Pantalar fusion for correction of painful equinus after traumatic Chopart's amputation--a report of 2 cases. Persson BM, et al. **Acta Orthop Scand** 1996 Jun;67(3):300–2

Arthrodesis for traumatic flat foot. Tarsometatarsal and medial longitudinal arch fusion by inlay grafting, 11 feet followed for 1.5 years. Petje G, et al. **Acta Orthop Scand** 1996 Aug;67(4):359–63

Medial compartment arthrosis of the knee. Dearborn JT, et al. **Am J Orthop** 1996 Jan;25(1):18–26 (64 ref.)

Complications of 50 consecutive limited wrist fusions by a single surgeon. Brown RE, et al. **Ann Plast Surg** 1995 Jul; 35(1):46–53

Technique and clinical evaluation of arthroscopic ankle arthrodesis. Corso SJ, et al. **Arthroscopy** 1995 Oct; 11(5):585–90

Arthroscopic ankle arthrodesis in rheumatoid arthritis. Turan I, et al. **Clin Orthop** 1995 Nov;(320):110–4

Knee arthrodesis in the treatment of failed total knee replacement. Vlasak R, et al. **Clin Orthop** 1995 Dec; (321):138–44

Bone grafting in foot surgery. Donley BG, et al. **Foot Ankle Int** 1996 Apr;17(4):242

Triple arthrodesis with lateral column lengthening for treatment of severe planovalgus deformity. Horton GA, et al. **Foot Ankle Int** 1995 Jul;16(7):395–400

Treatment of symptomatic hammertoe with a proximal interphalangeal joint arthrodesis. Lehman DE, et al. **Foot Ankle Int** 1995 Sep;16(9):535–41

Retrograde intramedullary nailing for ankle arthrodesis. Moore TJ, et al. **Foot Ankle Int** 1995 Jul;16(7):433–6

Ankle arthrodesis: results after the miniarthrotomy technique. Paremain GD, et al. **Foot Ankle Int** 1996 May;17(5):247–52

Triple arthrodesis for diabetic peritalar neuropathy [letter] Sanders LJ. **Foot Ankle Int** 1995 Dec;16(12):809

Silastic single–stem implants in the treatment of hallux rigidus [letter] Swanson AB. **Foot Ankle Int** 1995 Dec;16(12):809

Iatrogenic hallux varus surgical procedure: a study of 14 cases. Tourné Y, et al. **Foot Ankle Int** 1995 Aug; 16(8):457–63

Osteonecrosis of the talus: treatment by hindfoot fusion. Urquhart MW, et al. **Foot Ankle Int** 1996 May;17(5):275–82

Arthrodesis of the ankle with a free vascularized autogenous bone graft. Reconstruction of segmental loss of bone secondary to osteomyelitis, tumor, or trauma. Bishop AT, et al. **J Bone Joint Surg Am** 1995 Dec;77(12):1867–75

Arthrodesis of the wrist for post–traumatic disorders. Hastings H 2nd, et al. **J Bone Joint Surg Am** 1996 Jun; 78(6):897–902

Resection arthrodesis of the knee with an intercalary allograft. Weiner SD, et al. **J Bone Joint Surg Am** 1996 Feb;78(2):185–92

Extensile posterior approach to the ankle. Hayes AG, et al. **J Bone Joint Surg Br** 1996 May;78(3):468–70

Buried Kirschner wire fixation in digital fusion [letter] Blustein SM, et al. **J Foot Ankle Surg** 1996 Mar–Apr; 35(2):184–5

Buried Kirschner wire fixation in digital fusion. Creighton RE, et al. **J Foot Ankle Surg** 1995 Nov–Dec;34(6):567–70; discussion 595

Review of Elmslie's triple arthrodesis for post–polio pes calcaneovalgus deformity. Faraj AA. **J Foot Ankle Surg** 1995 May–Jun;34(3):319–21

Talonavicular joint arthrodesis for paralytic post poliomyelitis forefoot instability. Faraj AA. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):166–8

Ankle and subtalar fusion utilizing a tricortical bone graft, bone stimulator, and external fixator after avascular necrosis of the talus. Janis L, et al. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):120–6; discussion 188–9

Tibiofibular arthrodesis for malunion of the talocrural joint. Loder BG, et al. **J Foot Ankle Surg** 1995 May–Jun; 34(3):283–8 (8 ref.)

Midcarpal arthrodesis. Siegel JM, et al. **J Hand Surg [Am]** 1996 Mar;21(2):179–82

Motion–preserving procedures in the treatment of scapholunate advanced collapse wrist: proximal row carpectomy versus four–corner arthrodesis. Wyrick JD, et al. **J Hand Surg [Am]** 1995 Nov;20(6):965–70

Lunotriquetral arthrodesis. A controversial procedure. Sennwald GR, et al. **J Hand Surg [Br]** 1995 Dec; 20(6):755–60

Long–term follow–up of joint stabilization procedures in the treatment of fixed deformities of feet in leprosy. Ebenezer M, et al. **Lepr Rev** 1996 Jun;67(2):126–34

Valgus tilting of the ankle joint after subtalar (hindfoot) fusion: complication or natural progression of valgus hindfoot deformity? Fitzgibbons TC. **Orthopedics** 1996 May;19(5):415–23

Bone graft in hindfoot arthrodesis: allograft vs autograft. McGarvey WC, et al. **Orthopedics** 1996 May;19(5):389–94

The miniarthrotomy technique of ankle arthrodesis: a cadaver study of operative vascular compromise and early clinical results. Miller SD, et al. **Orthopedics** 1996 May; 19(5):425–30

Arthrodesis in rheumatoid arthritis using absorbable screws and rods. Juutilainen T, et al. **Scand J Rheumatol** 1995; 24(4):228–33

[The role of glenohumeral arthrodesis compared to prosthetic arthroplasty of the shoulder] Lemaire R, et al. **Acta Orthop Belg** 1995;61 Suppl 1:135–40 **(Fre)**

[Absorbable osteosynthesis: experimental and clinical approach in surgery of the hand] Merle M, et al. **Bull Mem Acad R Med Belg** 1994;149(8–11):329–39; discussion 339–42 (Eng. Abstr.) **(Fre)**

[Stabilization of the hindfoot by talonavicular arthrodesis. Results apropos of 50 cases] Asencio G, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(8):691–701 (Eng. Abstr.) **(Fre)**

[Arthrodesis of the ankle under arthroscopy. Apropos of 10 cases reviewed after a year] Bonnin M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(2):128–35 (Eng. Abstr.) **(Fre)**

[Congenital convex talus. Methods and results of a single–stage surgical correction] Daumas L, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(6):527–37 (Eng. Abstr.) **(Fre)**

[The foot in hereditary motor and sensory neuropathies in children] Ghanem I, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):152–60 (Eng. Abstr.) **(Fre)**

[Subtalar dislocations. Apropos of 35 cases] Jarde O, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(1):42–48 (Eng. Abstr.) **(Fre)**

[Arthrodesis of the ankle joint] Bauer G, et al. **Orthopade** 1996 Apr;25(2):158–65 (74 ref.) (Eng. Abstr.) **(Ger)**

[Arthrodesis of the rheumatoid wrist] Flügel M. **Orthopade** 1996 Apr;25(2):126–8 (Eng. Abstr.) **(Ger)**

[Primary arthrodesis of the knee joint] Gossé F, et al. **Orthopade** 1996 Apr;25(2):146–52 (27 ref.) (Eng. Abstr.) **(Ger)**

[Elbow arthrodesis and its alternative] Hahn MP, et al. **Orthopade** 1996 Apr;25(2):112–20 (70 ref.) (Eng. Abstr.) **(Ger)**

[Arthrodesis of the wrist in arthritis] Knopp W, et al. **Orthopade** 1996 Apr;25(2):121–5 (23 ref.) (Eng. Abstr.) **(Ger)**

[Arthrodesis following revision of a knee endoprosthesis. Literature review 1984–1994] Kohn D, et al. **Orthopade** 1996 Apr;25(2):153–7 (27 ref.) (Eng. Abstr.) **(Ger)**

[Biomechanics of arthrodesis of the ‚major joints of the extremities] Kummer B. **Orthopade** 1996 Apr;25(2):99–103 (Eng. Abstr.) **(Ger)**

[Arthrodesis of the shoulder joint] Reichelt A. **Orthopade** 1996 Apr;25(2):104–11 (61 ref.) (Eng. Abstr.) **(Ger)**

[New technique for a hip arthrodesis using an anterior approach and a ventral plate] Siebenrock KA, et al. **Orthopade** 1996 Apr;25(2):140–5 (Eng. Abstr.) **(Ger)**

[Screw arthrodesis of the ankle joint. Technique and outcome] Thermann H, et al. **Orthopade** 1996 Apr; 25(2):166–76 (55 ref.) (Eng. Abstr.) **(Ger)**

[Hip joint arthrodesis using the cobra plate. Indication, technique, outcome] Wagner M, et al. **Orthopade** 1996 Apr; 25(2):129–39 (69 ref.) (Eng. Abstr.) **(Ger)**

[Arthrodesis (editorial)] Wirth CJ, et al. **Orthopade** 1996 Apr; 25(2):95 **(Ger)**

[Significance of arthrodeses] Wirth CJ, et al. **Orthopade** 1996 Apr;25(2):96–8 **(Ger)**

[Hindfoot arthrodesis] Wülker N, et al. **Orthopade** 1996 Apr; 25(2):177–86 (57 ref.) (Eng. Abstr.) **(Ger)**

[Arthrodesis of the metatarsophalangeal joint of the large toe] Wülker N. **Orthopade** 1996 Apr;25(2):187–93 (28 ref.) (Eng. Abstr.) **(Ger)**

[Post–traumatic shoulder arthrodeses--indications, technique, results] Dávid A, et al. **Unfallchirurg** 1995 Nov; 98(11):566–9 (Eng. Abstr.) **(Ger)**

[Biomechanical study of the initial stability of various arthrodesis methods for the upper ankle joint] Pommer A, et al. **Unfallchirurg** 1995 Oct;98(10):535–9 (Eng. Abstr.) **(Ger)**

VETERINARY

Use of sodium monoiodoacetate to fuse the distal hock joints in horses. Sammut EB, et al. **Aust Vet J** 1995 Jan;72(1):25–8

Resolution of lameness associated with Scottish fold osteodystrophy following bilateral ostectomies and pantarsal arthrodeses: a case report. Mathews KG, et al. **J Am Anim Hosp Assoc** 1995 Jul–Aug;31(4):280–8

ARTHROGRAPHY

Prognostic significance of posterior subtalar joint arthrography following fractures of the calcaneus. Matsui Y, et al. **Arch Orthop Trauma Surg** 1995;114(5):257–9

Arthrographic evaluation of developmental dysplasia of the hip. Outcome prediction. Liu JS, et al. **Clin Orthop** 1996 May;(326):229–37

Optimizing joint–imaging: (CT)–arthrography. Obermann WR. **Eur Radiol** 1996;6(3):275–83 (8 ref.)

Digital subtraction shoulder arthrography in determining site and size of rotator cuff tear. Farin PU, et al. **Invest Radiol** 1995 Sep;30(9):544–7

Revised arthrographic index of deformity for Perthes' disease. Shigeno Y, et al. **J Pediatr Orthop B** 1996 Winter; 5(1):44–7

Monitoring radiographic changes in early rheumatoid arthritis [editorial] Paulus HE, et al. **J Rheumatol** 1996 May;

23(5):801-5
Cinearthrography of the Bankart lesion and anterior capsule elongation. Hata Y, et al. **J Shoulder Elbow Surg** 1996 Mar-Apr;5(2 Pt 1):124-31
Tibial attachment area of the anterior cruciate ligament in the extended knee position. Anatomy and cryosections in vitro complemented by magnetic resonance arthrography in vivo. Stäubli HU, et al.
Knee Surg Sports Traumatol Arthrosc 1994;2(3):138-46
Three-compartment wrist arthrography: direct comparison of digital subtraction with nonsubtraction images. Yin Y, et al. **Radiology** 1995 Oct;197(1):287-90
Proximal tibiofibular joint: a radiographic and computed tomographic study. Sugita T, et al. **Tohoku J Exp Med** 1995 May;176(1):35-44
[Bone and digitalization] Leblanc G, et al.
Ann Radiol (Paris) 1995;38(5):297-303 **(Fre)**
[Bone and criteria of choice of a CT apparatus] Leblanc G, et al. **Ann Radiol (Paris)** 1995;38(5):304-9 **(Fre)**
[Results of sutures of the internal meniscus associated with reconstruction of the anterior cruciate ligament in chronic knee joint instability. Apropos of 42 cases, 30 of them controlled by arthrography] Lerat JL, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(6):514-26 (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Scoring radiographic abnormalities in rheumatoid arthritis. Sharp JT. **Radiol Clin North Am** 1996 Mar;34(2):233-41, x (66 ref.)

INSTRUMENTATION

[Arthrography of the wrist joint in acute trauma] Grechenig W, et al. **Unfallchirurg** 1996 Apr;99(4):260-6 (Eng. Abstr.) **(Ger)**

METHODS

Corrected sagittal tomography of the temporomandibular joint. Influence of errors in film and patient positioning on linear and angular measurements. Panmekiate S, et al. **Acta Odontol Scand** 1995 Aug;53(4):264-9
Knee joint space width measurement: an experimental study of the influence of radiographic procedure and joint positioning. Ravaud P, et al. **Br J Rheumatol** 1996 Aug; 35(8):761-6
Aspiration arthrography of the hip joint. Its uses and limitations in revision hip surgery. Mulcahy DM, et al. **J Arthroplasty** 1996 Jan;11(1):64-8
Comparison of the findings of triple-injection cinearthrography of the wrist with those of arthroscopy. Weiss AP, et al. **J Bone Joint Surg Am** 1996 Mar; 78(3):348-56
Quantitative microfocal radiography detects changes in OA knee joint space width in patients in placebo controlled trial of NSAID therapy [see comments] Buckland-Wright JC, et al. **J Rheumatol** 1995 May;22(5):937-43. Comment in: J Rheumatol 1995 May;22(5):807-8.
Temporomandibular joint imaging: a comparative study of diagnostic accuracy for the detection of bone change with biplanar multidirectional tomography and panoramic images. Ludlow JB, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Dec;80(6):735-43
C1-2 arthrography. Chevrot A, et al. **Skeletal Radiol** 1995 Aug;24(6):425-9
[The puncture of the knee] Wybier M, et al.
Ann Radiol (Paris) 1995;38(5):284-6 (Eng. Abstr.) **(Fre)**
[Functional and anatomical results after surgical treatment of ruptures of the rotator cuff. 1: Preoperative functional and anatomical evaluation of ruptures of the rotator cuff] Gazielly DF, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(1):8-16 (Eng. Abstr.) **(Fre)**
[Double-contrast tomographic arthrography and double-contrast CT arthrography in rotator cuff lesions] Wirth W. **Orthopade** 1995 Nov;24(6):483-90 (Eng. Abstr.) **(Ger)**

ARTHROGRYPOSIS

The myopathic variety of arthrogryposis multiplex congenita. Padma MV, et al. **J Assoc Physicians India** 1995 Apr; 43(4):291-2
Lethal arthrogryposis multiplex congenital (fetal akinesia deformation sequence, FADS). Porter HJ.
Pediatr Pathol Lab Med 1995 Jul-Aug;15(4):617-37 (96 ref.)

COMPLICATIONS

Epileptic seizures, arthrogryposis, and migrational brain disorders: a syndrome? [letter; comment] Veggiotti P, et al. **Acta Neurol Scand** 1995 Jun;91(6):518-9. Comment on: Acta Neurol Scand 1994 Oct;90(4):232-40.
Medial-approach open reduction of hip dislocation in amyoplasia-type arthrogryposis. Szöke G, et al.
J Pediatr Orthop 1996 Jan-Feb;16(1):127-30
Arthrogryposis multiplex congenita and bilateral parietal polymicrogyria in association with the intrauterine death of a twin. Baker EM, et al. **Neuropediatrics** 1996 Feb; 27(1):54-6
[A child with hyperpyrexia syndrome and multiple-organ failure caused by an orthopedic corset (letter)] van Wouwe JP. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1739-40 **(Dut)**

ETIOLOGY

Arthrogryposis associated with unsuccessful attempts at termination of pregnancy. Hall JG. **Am J Med Genet** 1996 May 3;63(1):293-300 (40 ref.)

GENETICS

Distal arthrogryposis type IIB: further clinical delineation and 54-year follow-up of an index case. Friedman BD, et al. **Am J Med Genet** 1995 Aug 28;58(2):125-7
Arthrogryposis, renal dysfunction and cholestasis syndrome: report of five patients from three Italian families. Di Rocco M, et al. **Eur J Pediatr** 1995 Oct;154(10):835-9 (8 ref.)
A gene for a severe lethal form of X-linked arthrogryposis (X-linked infantile spinal muscular atrophy) maps to human chromosome Xp11.3-q11.2. Kobayashi H, et al.
Hum Mol Genet 1995 Jul;4(7):1213-6
Epilepsy in the Freeman Sheldon syndrome. Sackey A, et al. **J Child Neurol** 1995 Jul;10(4):335-7

HISTORY

Arthrogryposis multiplex congenita, AD 1156. Gordon EC. **Dev Med Child Neurol** 1996 Jan;38(1):80-3

PATHOLOGY

Incidence of maxillofacial involvement in arthrogryposis multiplex congenita. Steinberg B, et al.
J Oral Maxillofac Surg 1996 Aug;54(8):956-9

SURGERY

Distal femoral extension osteotomy for knee flexion contracture in patients with arthrogryposis. DelBello DA, et al. **J Pediatr Orthop** 1996 Jan-Feb;16(1):122-6
[Bilateral biceps replacement-plasty by transposition of the latissimus dorsi muscle in arthrogryposis multiplex congenita. A case report] Mailänder P, et al.
Handchir Mikrochir Plast Chir 1996 Mar;28(2):59-63 (Eng. Abstr.) **(Ger)**

THERAPY

Amyoplasia, the most common type of arthrogryposis: the potential for good outcome. Sells JM, et al. **Pediatrics** 1996 Feb;97(2):225-31

ULTRASONOGRAPHY

Ultrasound diagnosis of the Pena Shokeir phenotype at 14 weeks of pregnancy. Ajayi RA, et al. **Prenat Diagn** 1995 Aug;15(8):762-4
Prenatal findings in generalized amyoplasia. Sepulveda W, et al. **Prenat Diagn** 1995 Jul;15(7):660-4

ARTHROMYODYSPLASIA, CONGENITAL see **ARTHROGRYPOSIS**

ARTHROPATHY, NEUROGENIC

CHEMICALLY INDUCED

A reappraisal of quinolone tolerability. The experience of their musculoskeletal adverse effects. Hayem G, et al.
Drug Saf 1995 Dec;13(6):338-42

COMPLICATIONS

Neuropathic arthropathy of the spine in diabetes. Phillips S, et al. **Diabetes Care** 1995 Jun;18(6):867-9
Treatment of a pleural effusion due to Charcot's arthropathy. Linder SH. **South Med J** 1995 Nov;88(11):1179-80

DIAGNOSIS

Neuroarthropathy: an overuse injury of the shoulder in quadriplegia. Barber DB, et al. **J Spinal Cord Med** 1996 Jan;19(1):9-11
A hot ankle. Steuer A, et al. **Lancet** 1996 Mar 2;347(9001):586

ETIOLOGY

Asymptomatic big toe changes in diabetic patients with early Charcot knees--a report of 2 cases. Tani Y, et al.
Acta Orthop Scand 1996 Jun;67(3):302-4
Charcot arthropathy following digital replantation. Vanderhooft E, et al. **J Hand Surg [Am]** 1995 Jul; 20(4):683-6
Development of a 'Charcot-like joint' in tophaceous gout. Laversuch CJ, et al. **J R Soc Med** 1995 Dec;88(12):713p-5p

PHYSIOPATHOLOGY

Neurogenic influences on contralateral responses during experimental rat monoarthritis. Kidd BL, et al.
Brain Res 1995 Aug 7;688(1-2):72-6
The Charcot joint in diabetes. Klenerman L. **Diabet Med** 1996;13 Suppl 1:S52-4 (11 ref.)

RADIOGRAPHY

Imaging features of dissecting neuropathic joints. Peh WC, et al. **Australas Radiol** 1995 Aug;39(3):249-53

RADIONUCLIDE IMAGING

Differentiation of infected from noninfected rapidly progressive neuropathic osteoarthropathy [letter; comment] Miles K. **J Nucl Med** 1996 Apr;37(4):706. Comment on: J Nucl Med 1995 Aug;36(8):1427-8.

SURGERY

Triple arthrodesis for diabetic peritalar neuropathy [letter] Sanders LJ. **Foot Ankle Int** 1995 Dec;16(12):809
Silastic single-stem implants in the treatment of hallux rigidus [letter] Swanson AB. **Foot Ankle Int** 1995 Dec;16(12):809
Triple arthrodesis for diabetic peritalar neuroarthropathy. Tisdel CL, et al. **Foot Ankle Int** 1995 Jun;16(6):332-8
Surgical management of lumbar neuropathic spinal arthropathy (Charcot joint) after traumatic thoracic paraplegia: report of two cases. Arnold PM, et al.
J Spinal Disord 1995 Oct;8(5):357-62

THERAPY

The Charcot joint in diabetes. Klenerman L. **Diabet Med** 1996;13 Suppl 1:S52-4 (11 ref.)

ARTHROPLASTY

Choice of anaesthetic regimen influences haemodynamic response to cemented arthroplasty. Guest CB, et al.
Can J Anaesth 1995 Oct;42(10):928-36
Cylindrical cemented ankle arthroplasty: a prospective series with long-term follow-up. Kofoed H. **Foot Ankle Int** 1995 Aug;16(8):474-9
Cytokine and coagulation characteristics of retrieved blood after arthroplasty. Kristiansson M, et al.
Intensive Care Med 1995 Dec;21(12):989-95
The change in serum protein concentration in response to the stress of total joint surgery: a comparison of older versus younger patients. Puskarich-May CL, et al.
J Am Geriatr Soc 1996 May;44(5):555-8
The predictors of surgical procedure and the effects on functional recovery in elderly with subcapital fractures. Young Y, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul; 51(4):M158-64
Ulnar buttress arthroplasty for reconstruction after resection of the distal ulna for giant cell tumour. Hashizume H, et al. **J Hand Surg [Br]** 1996 Apr;21(2):213-5
Scapho-trapezoid arthritis. A cause of residual pain after arthroplasty of the trapezio-metacarpal joint. Irwin AS, et al. **J Hand Surg [Br]** 1995 Jun;20(3):346-52
Partial trapeziectomy and interpositional arthroplasty for trapeziometacarpal osteoarthritis of the thumb. Menon J. **J Hand Surg [Br]** 1995 Oct;20(5):700-6
Resection arthroplasty of the metacarpophalangeal joints in rheumatoid arthritis. Results after more than 15 years. Rüther W, et al. **J Hand Surg [Br]** 1995 Oct;20(5):707-15
Bone formation and bone resorption in failed total joint arthroplasties: histomorphometric analysis with histochemical and immunohistochemical technique. Kadoya Y, et al. **J Orthop Res** 1996 May;14(3):473-82
Adaptive finite element modeling of long-term polyethylene wear in total hip arthroplasty. Maxian TA, et al.
J Orthop Res 1996 Jul;14(4):668-75
Function after amputation, arthrodesis, or arthroplasty for tumors about the shoulder. Kneisl JS.
J South Orthop Assoc 1995 Fall;4(3):228-36 (36 ref.)
Patch-grafting for regional femoral bone loss in cementless revision hip arthroplasty. Hussell JG, et al.
S Afr J Surg 1995 Dec;33(4):179-83

ADVERSE EFFECTS

Clinical image: silicone synovitis. Kenik J.
Arthritis Rheum 1995 Oct;38(10):1523
Rate of degeneration of human acetabular cartilage after hemiarthroplasty [letter; comment] Blasier RB.
J Bone Joint Surg Am 1996 Apr;78(4):635. Comment on: J Bone Joint Surg Am 1995 Jun;77(6):877-82.
Arthroscopic osteochondral autograft transplantation in anterior cruciate ligament reconstruction: a preliminary clinical study. Bobić V.
Knee Surg Sports Traumatol Arthrosc 1996;3(4):262-4
The weight-bearing knee after anterior cruciate ligament rupture. An in vitro biomechanical study. Bonnin M, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):245-51
The tendon defect after anterior cruciate ligament reconstruction using the midthird patellar tendon--a problem for the patellofemoral joint? Breitfuss H, et al.
Knee Surg Sports Traumatol Arthrosc 1996;3(4):194-8
Recurrent acute hemarthrosis after anterior cruciate ligament reconstruction. Report of an unusual complication and a review of the literature. Friederich NF, et al.
Knee Surg Sports Traumatol Arthrosc 1996;3(4):215-8
Arthroscopic portals: the importance of blade selection. Sochart DH, et al.
Knee Surg Sports Traumatol Arthrosc 1996;3(4):209-10
Effect of pretension in reconstructions of the anterior cruciate ligament with a Dacron prosthesis. A retrospective study. van Heerwaarden RJ, et al.
Knee Surg Sports Traumatol Arthrosc 1996;3(4):202-8
Temperature changes in the knee joint during arthroscopic surgery. Zaffagnini S, et al.

ARTHROPLASTY

Knee Surg Sports Traumatol Arthrosc 1996;3(4):199–201

HISTORY

Historical overview of operations for anterior cruciate ligament rupture. Dandy DJ.
Knee Surg Sports Traumatol Arthrosc 1996;3(4):256–61

INSTRUMENTATION

Preliminary results of an absorbable interference screw. Barber FA, et al. **Arthroscopy** 1995 Oct;11(5):537–48

Comparison of pullout strength for seven- and nine-millimeter diameter interference screw size as used in anterior cruciate ligament reconstruction. Shapiro JD, et al. **Arthroscopy** 1995 Oct;11(5):596–9

Arthroscopic portals: the importance of blade selection. Sochart DH, et al.
Knee Surg Sports Traumatol Arthrosc 1996;3(4):209–10

METHODS

Autoarthroplasty of knee cartilage defects by osteoperiosteal grafts. Korkala OL, et al. **Arch Orthop Trauma Surg** 1995; 114(5):253–6

Anterior cruciate ligament reconstruction: endoscopic versus two-incision technique [letter; comment] Jenny JY. **Arthroscopy** 1995 Aug;11(4):513–5. Comment on: Arthroscopy 1994 Oct;10(5):502–12.

Endoscopic anterior cruciate ligament reconstruction: modified technique and radiographic review. O'Donnell JB, et al. **Arthroscopy** 1995 Oct;11(5):577–84

Subcapital fracture of a congenitally dislocated hip: revival of Girdlestone resection arthroplasty. Taha AM.
Bull Hosp Jt Dis 1995;54(1):35–42 (100 ref.)

Girdlestone arthroplasty for loosening of the total hip prosthesis: evaluation and results. Scalvi A, et al.
Chir Organi Mov 1995 Jul–Aug;80(3):279–85

Early migration of femoral components revised with impacted cancellous allografts and cement. A preliminary report of five patients. Franzén H, et al.
J Bone Joint Surg Br 1995 Nov;77(6):862–4

Resection arthroplasty of the forefoot in rheumatoid arthritis cases. Broeng L, et al. **J Foot Ankle Surg** 1995 Nov–Dec; 34(6):534–6

The Cosentino modification for tendon interpositional arthroplasty. Cosentino GL. **J Foot Ank'e Surg** 1995 Sep–Oct;34(5):501–8

The Valenti procedure for hallux limitus/rigidus. Saxena A. **J Foot Ankle Surg** 1995 Sep–Oct;34(5):485–8; discussion 511

Matched hemiresection interposition arthroplasty of the distal radioulnar joint. Bain GI, et al. **J Hand Surg [Am]** 1995 Nov;20(6):944–50

Stabilized resection arthroplasty by an anterior approach in trapeziometacarpal arthritis: results and surgical technique. Le Viet D, et al. **J Hand Surg [Am]** 1996 Mar;21(2):194–201

Basal joint arthritis: trapeziectomy with ligament reconstruction and tendon interposition arthroplasty. Lins RE, et al. **J Hand Surg [Am]** 1996 Mar;21(2):202–9

Radiographic assessment of the trapezial space before and after ligament reconstruction and tendon interposition arthroplasty. Kadiyala RK, et al. **J Hand Surg [Br]** 1996 Apr;21(2):177–81

First carpometacarpal joint arthritis. A comparison of two arthroplasty techniques. Livesey JP, et al.
J Hand Surg [Br] 1996 Apr;21(2):182–8

Interposition arthroplasty of the elbow with rheumatoid arthritis. Ljung P, et al. **J Shoulder Elbow Surg** 1996 Mar–Apr;5(2 Pt 1):81–5

Chondral damage and age depress the long-term prognosis after partial meniscectomy. A 12- to 15-year follow-up study. Maletius W, et al.
Knee Surg Sports Traumatol Arthrosc 1996;3(4):211–4

Long-term results of forefoot arthroplasty in patients with rheumatoid arthritis. Patsalis T, et al. **Orthopedics** 1996 May;19(5):439–47 (48 ref.)

[Outcome of hip shelf arthroplasty in adults after a minimum of 15 years of follow-up. Long term results and analysis of failures of 56 dysplastic hips] Migaud H, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(8):716–23 (Eng. Abstr.) **(Fre)**

[Hallux rigidus operated on by Keller and Brandes method: radiological parameters of success and prognosis] Breitenseher MJ, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Jun;164(6):483–8 (Eng. Abstr.) **(Ger)**

REHABILITATION

Effect of an alternative flexion splinting protocol on mid-joint ROM [letter] Groth G, et al. **J Hand Ther** 1996 Jan–Mar;9(1):68–9

VETERINARY

In favor of shelf arthroplasty in some dogs [letter] Whittick WG. **J Am Vet Med Assoc** 1996 Aug 1;209(3):542–3

ARTHROPLASTY, REPLACEMENT see **JOINT PROSTHESIS**

ARTHROPLASTY, REPLACEMENT, HIP see **HIP PROSTHESIS**

ARTHROPLASTY, REPLACEMENT, KNEE see **KNEE PROSTHESIS**

ARTHROPOD-BORNE VIRUSES see **ARBOVIRUSES**

ARTHROPOD VECTORS

Assessment of arthropod vectors of infectious diseases in areas of U.S. troop deployment in the Persian Gulf. Cope SE, et al. **Am J Trop Med Hyg** 1996 Jan;54(1):49–53

[Human diffusion of arthropod disease vectors throughout the world] Mouchet J, et al. **Sante** 1995 Sep–Oct;5(5):293–8 (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Multivariate morphometric discrimination of nymphal and adult forms of the blacklegged tick (Acari: Ixodidae), a principal vector of the agent of Lyme disease in eastern North America. Hutcheson HJ, et al. **J Med Entomol** 1995 Nov;32(6):827–42

CLASSIFICATION

Classification of human parasites, vectors, and similar organisms. Garcia LS. **Clin Infect Dis** 1995 Aug;21(2):281–2

MICROBIOLOGY

Infestation of rodents with larval Ixodes ricinus (Acari: Ixodidae) is an important factor in the transmission cycle of Borrelia burgdorferi s.l. in German woodlands. Kurtenbach K, et al. **J Med Entomol** 1995 Nov; 32(6):807–17

Prevalence of Borrelia burgdorferi sensu lato infection in Ixodes ricinus in Sweden. Gustafson R, et al.
Scand J Infect Dis 1995;27(6):597–601

[Lyme borreliosis: epidemiologic and etiopathogenic aspects] Oteo-Revuelta JA, et al. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):550–5 (53 ref.) **(Spa)**

PARASITOLOGY

Decline of urinary schistosomiasis in Kurmuk town, western Ethio-Sudanese border, Ethiopia. Birrie H, et al.
Ethiop Med J 1996 Jan;34(1):47–9

Colonization of irrigation canals by Bulinus abyssinicus and upsurge of urinary schistosomiasis in the middle Awash Valley of Ethiopia. Bizuneh A, et al. **Ethiop Med J** 1995 Oct;33(4):259–63

Cypria reptans (Crustacea: Ostracoda) as an intermediate host of Neoechinorhynchus rutili (Acanthocephala: Eoacanthocephala) in Italy. Dezfuli BS. **J Parasitol** 1996 Jun;82(3):503–5

PHYSIOLOGY

Blood-feeding arthropods: live syringes or invertebrate pharmacologists? Ribeiro JM. **Infect Agents Dis** 1995 Sep; 4(3):143–52 (100 ref.)

VIROLOGY

Importance of localized skin infection in tick-borne encephalitis virus transmission. Labuda M, et al.
Virology 1996 May 15;219(2):357–66

ARTHROPOD VENOMS

ADMINISTRATION & DOSAGE

Discontinuing venom immunotherapy: outcome after five years. Golden DB, et al. **J Allergy Clin Immunol** 1996 Feb; 97(2):579–87

IMMUNOLOGY

[Diagnosis of allergy to venom of Hymenoptera (editorial)] Nittner-Marszalska M, et al. **Pneumonol Alergol Pol** 1995; 63(9–10):479–83 **(Pol)**

[Immunotherapy in patients allergic to hymenoptera venom] Lorente Toledano F, et al.
Allergol Immunopathol (Madr) 1996;24 Suppl 1:84–92 **(Spa)**

ISOLATION & PURIFICATION

Purification and characterization of a paralytic polypeptide from larvae of Myrmeleon bore. Matsuda K, et al.
Biochem Biophys Res Commun 1995 Oct 4;215(1):167–71

THERAPEUTIC USE

Venom immunotherapy modulates interleukin-4 and interferon-gamma messenger RNA expression of peripheral T lymphocytes. Akoum H, et al. **Immunology** 1996 Apr;87(4):593–8

ARTHROPODS

A new risk of occupational disease: allergic asthma and rhinoconjunctivitis in persons working with beneficial arthropods. Cipolla C, et al.
Int Arch Occup Environ Health 1996;68(2):133–5

Helminth and arthropod parasites of experimentally introduced whooping cranes in Florida. Spalding MG, et al. **J Wildl Dis** 1996 Jan;32(1):44–50

[Porocephalosis, a little known parasitosis, literature review and a Congolese case report] Faisy C, et al.
Med Trop (Mars) 1995;55(3):258–62 (26 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Central projections of Tömösváry's organ in Lithobius forficatus (Chilopoda, Lithobiidae). Petykó Z, et al.
Cell Tissue Res 1996 Feb;283(2):331–4

Inductive signals. Revolving vertebrates. Jones CM, et al. **Curr Biol** 1995 Jun 1;5(6):574–6 (16 ref.)

Pentastomid parasites of the family Sebekidae Fain, 1961 in west African dwarf crocodiles Osteolaemus tetraspis Cope, 1851 from the Congo, with a description of Alofia parva n. sp. Riley J, et al. **Onderstepoort J Vet Res** 1995 Sep; 62(3):151–62

DRUG EFFECTS

Biomonitoring of anticholinesterase pesticides in the soil: usefulness of soil Collembola. Chakravorty PP, et al.
Biomed Environ Sci 1995 Sep;8(3):232–9

Sublethal sensitivity index as an ecotoxicity parameter measuring energy allocation under toxicant stress: application to cadmium in soil arthropods. Crommentuijn T, et al. **Ecotoxicol Environ Saf** 1995 Aug;31(3):192–200

EMBRYOLOGY

The evolution of arthropod segmentation: insights from comparisons of gene expression patterns. Patel NH.
Dev Suppl 1994;:201–7 (34 ref.)

GENETICS

The evolving role of Hox genes in arthropods. Akam M, et al. **Dev Suppl** 1994;:209–15 (62 ref.)

Common origin of arthropod tyrosinase, arthropod hemocyanin, insect hexamerin, and dipteran arylphorin receptor. Burmester T, et al. **J Mol Evol** 1996 Jun; 42(6):713–28

The sequence, organization, and evolution of the Locusta migratoria mitochondrial genome. Flook PK, et al.
J Mol Evol 1995 Dec;41(6):928–41

First molecular evidence for the existence of a Tardigrada + Arthropoda clade. Giribet G, et al. **Mol Biol Evol** 1996 Jan;13(1):76–84

Limb development. Gene ties arthropods together [news; comment] Roush W. **Science** 1995 Nov 24;270(5240):1297 . Comment on: Science 1995 Nov 24;270(5240):1363–6.

GROWTH & DEVELOPMENT

Parasites of domestic and wild animals in South Africa. XXXIV. Arthropod parasites of nyalas in north-eastern KwaZulu-Natal. Horak IG, et al.
Onderstepoort J Vet Res 1995 Sep;62(3):171–9

The development of crustacean limbs and the evolution of arthropods [see comments] Panganiban G, et al. **Science** 1995 Nov 24;270(5240):1363–6. Comment in: Science 1995 Nov 24;270(5240):1297.

MICROBIOLOGY

Attachment of non-culturable toxigenic Vibrio cholerae O1 and non-O1 and Aeromonas spp. to the aquatic arthropod Gerris spinolae and plants in the River Ganga, Varanasi. Shukla BN, et al. **FEMS Immunol Med Microbiol** 1995 Oct; 12(2):113–20

Molecular evidence for a close relative of the arthropod endosymbiont Wolbachia in a filarial worm. Sironi M, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):223–7

PHYSIOLOGY

Blood-feeding arthropods: live syringes or invertebrate pharmacologists? Ribeiro JM. **Infect Agents Dis** 1995 Sep; 4(3):143–52 (100 ref.)

Arthropod succession on exposed rabbit carrion in Alexandria, Egypt. Tantawi TI, et al. **J Med Entomol** 1996 Jul;33(4):566–80

The double spermatogenesis in Scutigera coleoptrata (Myriapoda, Chilopoda): macro- and microspermatocyte growth. Prunescu CC, et al. **Zygote** 1995 May;3(2):171–6

ARTHROSCOPY

Fat-suppressed three-dimensional spoiled gradient-echo MR imaging of hyaline cartilage defects in the knee: comparison with standard MR imaging and arthroscopy. Disler DG, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):127–32

MRI versus arthroscopy in evaluating knee meniscal pathology. Hutchinson CH, et al. **Am J Knee Surg** 1995 Summer;8(3):93–6

Arthroscopic lateral portals revisited. A cadaveric study of the safe zones. Bennett WF, et al. **Am J Orthop** 1995 Jul; 24(7):546–51

Long-term results of arthroscopic meniscal repair. An analysis of isolated tears. Eggli S, et al.
Am J Sports Med 1995 Nov–Dec;23(6):715–20

Arthroscopic findings after shoulder dislocation. Hintermann B, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):545–51

Paradoxical phenomena of the McMurray test. An arthroscopic investigation. Kim SJ, et al.
Am J Sports Med 1996 Jan–Feb;24(1):83–7

Arthroscopic anterior labral reconstruction using a

transglenoid suture technique. Results in active-duty military patients. Mologne TS, et al. **Am J Sports Med** 1996 May-Jun;24(3):268-74

Arthroscopic treatment of osteoarthritis of the knee: a prospective, randomized, placebo-controlled trial. Results of a pilot study. Moseley JB Jr, et al. **Am J Sports Med** 1996 Jan-Feb;24(1):28-34

Assessment of recovery following day-case arthroscopy. A comparison between propofol and isoflurane-based anaesthesia. Gupta A, et al. **Anaesthesia** 1995 Nov; 50(11):937-42

Postarthroscopic meniscus repair analgesia with intraarticular ketorolac or morphine. Reuben SS, et al. **Anesth Analg** 1996 May;82(5):1036-9

Outcome and clinical signs of arthroscopically graded patellar chondromalacia with or without lateral release. Korkala OL, et al. **Ann Chir Gynaecol** 1995;84(3):276-9

Arthroscopic bioabsorbable tack stabilization of initial anterior shoulder dislocations: a preliminary report. Arciero RA, et al. **Arthroscopy** 1995 Aug;11(4):410-7

Arthroscopy of symptomatic total knee replacements. Bae DK, et al. **Arthroscopy** 1995 Dec;11(6):664-71

The arthroscopic appearance of lipoma arborescens of the knee. Blais RE, et al. **Arthroscopy** 1995 Oct;11(5):623-7

An intermeniscal fibrous band in a recreational runner. Butler JP, et al. **Arthroscopy** 1995 Dec;11(6):735-7 (16 ref.)

Hip arthroscopy: an anatomic study of portal placement and relationship to the extra-articular structures. Byrd JW, et al. **Arthroscopy** 1995 Aug;11(4):418-23

Technique and clinical evaluation of arthroscopic ankle arthrodesis. Corso SJ, et al. **Arthroscopy** 1995 Oct; 11(5):585-90

Aspects of coracoacromial ligament anatomy of interest to the arthroscopic surgeon. Edelson JG, et al. **Arthroscopy** 1995 Dec;11(6):715-9

Suprascapular nerve entrapment by ganglion cysts: a report of six cases with arthroscopic findings and review of the literature. Fehrman DA, et al. **Arthroscopy** 1995 Dec; 11(6):727-34 (47 ref.)

Coracoacromial ligament: a comparative arthroscopic and anatomic study. Gallino M, et al. **Arthroscopy** 1995 Oct; 11(5):564-7

Osteonecrosis of the knee following laser-assisted arthroscopic surgery: a report of six cases. Garino JP, et al. **Arthroscopy** 1995 Aug;11(4):467-74

Endoscopic therapy in epicondylitis radialis humeri. Grifka J, et al. **Arthroscopy** 1995 Dec;11(6):743-8

Arthroscopic proximal patella realignment and stabilization. Henry JE, et al. **Arthroscopy** 1995 Aug;11(4):424-5

Arthroscopic subacromial decompression with and without the Holmium:YAG-laser. A prospective comparative study. Imhoff A, et al. **Arthroscopy** 1995 Oct;11(5):549-56

Insertion-site anatomy of the human menisci: gross, arthroscopic, and topographical anatomy as a basis for meniscal transplantation. Johnson DL, et al. **Arthroscopy** 1995 Aug;11(4):386-94

A ring-shaped lateral meniscus. Kim SJ, et al. **Arthroscopy** 1995 Dec;11(6):738-9

Arthroscopy for limitation of motion of the elbow. Kim SJ, et al. **Arthroscopy** 1995 Dec;11(6):680-3

Initial failure strength of open and arthroscopic Bankart repairs. McEleney ET, et al. **Arthroscopy** 1995 Aug; 11(4):426-31

Delayed hypersensitivity rash to the knee after injection of arthroscopy portals with bupivacine (Marcaine) [letter; comment] Magsamen BF. **Arthroscopy** 1995 Aug; 11(4):512-3. Comment on: Arthroscopy 1994 Jun;10(3):305-8.

Patellar tendon graft harvesting using horizontal incisions for anterior cruciate ligament reconstruction. Mishra AK, et al. **Arthroscopy** 1995 Dec;11(6):749-52

The relationship between subacromial space pressure, blood pressure, and visual clarity during arthroscopic subacromial decompression. Morrison DS, et al. **Arthroscopy** 1995 Oct; 11(5):557-60

The arthroscopic knot technique for fracture of the tibia in children [letter; comment] Müezzinoğlu US. **Arthroscopy** 1995 Aug;11(4):511-2. Comment on: Arthroscopy 1994 Dec;10(6):698-9.

Endoscopic anterior cruciate ligament reconstruction: modified technique and radiographic review. O'Donnell JB, et al. **Arthroscopy** 1995 Oct;11(5):577-84

Arthroscopic debridement for the osteoarthritic ankle. Ogilvie-Harris DJ, et al. **Arthroscopy** 1995 Aug;11(4):433-6

Arthroscopic treatment for posterior impingement in degenerative arthritis of the elbow. Ogilvie-Harris DJ, et al. **Arthroscopy** 1995 Aug;11(4):437-43

Bilateral hypoplastic lateral meniscus. Ohana N, et al. **Arthroscopy** 1995 Dec;11(6):740-2

Arthroscopic repair for a flap tear of the posterior horn of the lateral meniscus adjacent to its tibial insertion. Shino K, et al. **Arthroscopy** 1995 Aug;11(4):495-8

Arthroscopy of the elbow: anatomy, portal sites, and a description of the proximal lateral portal. Stothers K, et al. **Arthroscopy** 1995 Aug;11(4):449-57

Redislocation with a bony bankart lesion after arthroscopic Bankart repair. Thal R, et al. **Arthroscopy** 1995 Dec; 11(6):720-2

Comparison of intraarticular bupivacaine with the addition of morphine or fentanyl for analgesia after arthroscopic surgery. Uysalel A, et al. **Arthroscopy** 1995 Dec;11(6):660-3

Arthroscopic-assisted reduction of distal radius fractures. Wolfe SW, et al. **Arthroscopy** 1995 Dec;11(6):706-14

Arthroscopic Bankart suture repair for recurrent traumatic unidirectional anterior shoulder dislocations. Youssef JA, et al. **Arthroscopy** 1995 Oct;11(5):561-3

Needle arthroscopy [editorial] Reece R, et al. **Br J Rheumatol** 1995 Dec;34(12):1102-4 (18 ref.)

Diagnostic accuracy of CT scan in intra-articular lesions of the knee (arthroscopic confirmation of 100 cases). Gagliardi S, et al. **Chir Organi Mov** 1995 Jul-Aug;80(3):301-7

Hip arthroscopy for posttraumatic loose fragments in the young active adult: three case reports. Byrd JW. **Clin J Sport Med** 1996 Apr;6(2):129-33; discussion 133-4

Arthroscopy of the elbow. Baker CL, et al. **Clin Sports Med** 1996 Apr;15(2):261-81 (32 ref.)

The role of arthroscopy in athletic injuries of the wrist. Savoie FH 3rd, et al. **Clin Sports Med** 1996 Apr; 15(2):219-33 (12 ref.)

Virtual reality arthroscopy training simulator. Ziegler R, et al. **Comput Biol Med** 1995 Mar;25(2):193-203

Arthroscopy in the diagnostics and treatment of non-acute knee disorders in children. Vähäsarja V, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):25-8

Knee arthroscopy under local anaesthesia: results and evaluation of patients' satisfaction. Iossifidis A. **Injury** 1996 Jan;27(1):43-4

Diagnostic and therapeutic ankle arthroscopy. Harrington P, et al. **Ir J Med Sci** 1996 Apr-Jun;165(2):121-4

Osteoarthritis, the hazard of living longer: arthroscopy vs. conservative treatment. Israeli A, et al. **Isr J Med Sci** 1996 Feb;32(2):121-2

Arthroscopically assisted reconstruction of the anterior cruciate ligament. A prospective randomized analysis of three techniques. O'Neill DB. **J Bone Joint Surg Am** 1996 Jun;78(6):803-13

Intraligamentous ganglion cysts of the anterior cruciate ligament: MR findings with clinical and arthroscopic correlations. Do-Dai DD, et al. **J Comput Assist Tomogr** 1996 Jan-Feb;20(1):80-4

Arthroscopy of the calcaneocuboid and talonavicular joints. Oloff L, et al. **J Foot Ankle Surg** 1996 Mar-Apr; 35(2):101-8; discussion 186-7

The value of wrist arthroscopy. An evaluation of 129 cases. De Smet L, et al. **J Hand Surg [Br]** 1996 Apr;21(2):210-2

Transforaminal arthroscopic decompression of lateral recess stenosis. Kambin P, et al. **J Neurosurg** 1996 Mar;84(3):462-7

Prospective comparison of arthroscopy and arthrocentesis for temporomandibular joint disorders. Fridrich KL, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):816-20; discussion 821

Arthroscopic diagnosis and treatment of temporomandibular joint synovial chondromatosis: report of a case. Miyamoto H, et al. **J Oral Maxillofac Surg** 1996 May;54(5):629-31

Recovery of muscle strength following arthroscopic meniscectomy. Matthews P, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):18-26

Arthroscopic evaluation of chondropathy in osteoarthritis of the knee [see comments] Ayral X, et al. **J Rheumatol** 1996 Apr;23(4):698-706. Comment in: J Rheumatol 1996 Apr;23(4):582-5.

Arthroscopic treatment of adhesive capsulitis. Segmüller HE, et al. **J Shoulder Elbow Surg** 1995 Nov-Dec;4(6):403-8

Arthroscopic debridement for osteoarthritis of the knee: a seven years follow-up study. Su JY, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Dec; 11(12):667-72

Arthroscopic Bankart procedures for anterior shoulder instability. A review of the literature. el Akad AM, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):113-22 (61 ref.)

Is intra-articular pethidine an alternative to local anaesthetics in arthroscopy? A double-blind study comparing prilocaine with pethidine. Ekblom A, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3-4):189-94

The importance of arthroscopy in sports injuries in children and adolescents. Haus J, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(1):34-8

Arthroscopy in patients with knee endoprostheses. Jerosch J, et al. **Knee Surg Sports Traumatol Arthrosc** 1993; 1(3-4):218-22

Arthroscopic surgery of the hip: current status. Norman-Taylor FH, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):255-8 (23 ref.)

Short-term treatment outcome study for the management of temporomandibular joint closed lock. A comparison of arthrocentesis to nonsurgical therapy and arthroscopic lysis and lavage. Murakami K, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Sep;80(3):253-7

Carpal tunnel syndrome. Etiology and endoscopic treatment. Akelman E, et al. **Orthop Clin North Am** 1995 Oct; 26(4):769-78

Arthroscopic anatomy of the elbow. Andrews JR, et al. **Orthop Clin North Am** 1995 Oct;26(4):671-7

Arthroscopic anatomy of the wrist. Bettinger PC, et al. **Orthop Clin North Am** 1995 Oct;26(4):707-19

Arthroscopy of the acromioclavicular joint. Corso SJ, et al. **Orthop Clin North Am** 1995 Oct;26(4):661-70

Arthroscopic reduction and internal fixation of distal radius fractures. Culp RW, et al. **Orthop Clin North Am** 1995 Oct; 26(4):739-48

Arthroscopic treatment of triangular fibrocartilage tears. Gan BS, et al. **Orthop Clin North Am** 1995 Oct;26(4):721-9

Arthroscopic treatment of impingement syndrome. Green A. **Orthop Clin North Am** 1995 Oct;26(4):631-41

Arthroscopic removal of loose bodies of the elbow. Greis PE, et al. **Orthop Clin North Am** 1995 Oct;26(4):679-89

Arthroscopic anatomy of the shoulder. Hulstyn MJ, et al. **Orthop Clin North Am** 1995 Oct;26(4):597-612

Arthroscopic evaluation and treatment of shoulder instability. Jahnke AH Jr, et al. **Orthop Clin North Am** 1995 Oct; 26(4):613-30

Arthroscopy of the distal radioulnar joint. Leibovic SJ, et al. **Orthop Clin North Am** 1995 Oct;26(4):755-7

Arthroscopic treatment for osteoarthritis of the elbow. O'Driscoll SW. **Orthop Clin North Am** 1995 Oct; 26(4):691-706

Arthroscopy for carpal instability. Savoie FH 3rd, et al. **Orthop Clin North Am** 1995 Oct;26(4):731-8

Diagnostic imaging and arthroscopy for chronic wrist pain. Weiss AP, et al. **Orthop Clin North Am** 1995 Oct; 26(4):759-67

Stabilization of the fractured scaphoid under arthroscopic control. Whipple TL. **Orthop Clin North Am** 1995 Oct; 26(4):749-54

Arthroscopic evaluation and treatment of the rotator cuff. Yamaguchi K, et al. **Orthop Clin North Am** 1995 Oct; 26(4):643-59

The role of hip arthroscopy in the diagnosis and treatment of hip disease. McCarthy JC, et al. **Orthopedics** 1995 Aug; 18(8):753-6

Transcutaneous electric nerve stimulation (TENS) during distension shoulder arthrography: a controlled trial. Morgan B, et al. **Pain** 1996 Feb;64(2):265-7

A regional anesthetic technique for ankle arthroscopy [letter] Hannenberg AA. **Reg Anesth** 1995 Jul-Aug;20(4):357-8

Intra-articular morphine and bupivacaine for pain relief after therapeutic arthroscopic knee surgery. Chan ST. **Singapore Med J** 1995 Feb;36(1):35-7

Rehabilitation following arthroscopic meniscectomy. St-Pierre DM. **Sports Med** 1995 Nov;20(5):338-47 (147 ref.)

Arthroscopic subacromial decompression for the shoulder impingement syndrome. McMahon PJ, et al. **West J Med** 1995 Dec;163(6):566-7

[Study of a protocol of intra-articular analgesia after arthroscopy of the knee] Dalger JM, et al. **Cah Anesthesiol** 1996;44(1):97-100 (Eng. Abstr.) **(Fre)**

[Arthrodesis of the ankle under arthroscopy. Apropos of 10 cases reviewed after a year] Bonnin M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(2):128-35 (Eng. Abstr.) **(Fre)**

[Prevention of thrombosis with fraxiparin 0.3 after arthroscopic interventions] Holland K, et al. **Fortschr Med** 1995 Aug 20;113(22-23):335-6 (Eng. Abstr.) **(Ger)**

[Agee endoscopic decompression of the median nerve: prospective study with comparison to open decompression] Benedetti VR, et al. **Handchir Mikrochir Plast Chir** 1996 May;28(3):151-5 (Eng. Abstr.) **(Ger)**

[2 1/2 years experience with endoscopic carpal tunnel release] Mascharka Z. **Handchir Mikrochir Plast Chir** 1996 May;28(3):138-42 (Eng. Abstr.) **(Ger)**

[Complications of endoscopic carpal tunnel operations] Piza-Katzer H, et al. **Handchir Mikrochir Plast Chir** 1996 May;28(3):156-9 (Eng. Abstr.) **(Ger)**

[Shoulder arthroscopy using the holmium-YAG laser method. State of the art 1994] Fanton GS. **Orthopade** 1996 Feb;25(1):79-83 (Eng. Abstr.) **(Ger)**

[Arthroscopic management of recurrent anterior shoulder dislocation by combining a labrum suture with antero-inferior holmium:YAG laser capsular shrinkage] Hardy P, et al. **Orthopade** 1996 Feb;25(1):91-3 (Eng. Abstr.) **(Ger)**

[Arthroscopic holmium-YAG laser compared to conventional procedures on the knee joint. 2-year results of a randomized prospective study] Lübbers C, et al. **Orthopade** 1996 Feb;25(1):64-72 (35 ref.) (Eng. Abstr.) **(Ger)**

[Use of laser in arthroscopy of the ankle. Indications, method, first results] Zangger P, et al. **Orthopade** 1996 Feb; 25(1):73-8 (Eng. Abstr.) **(Ger)**

[Differential indications for so-called "lateral release" in treatment of chondropathia patellae] Schultz W, et al. **Sportverletz Sportschaden** 1996 Mar;10(1):13-8 (Eng. Abstr.) **(Ger)**

[Arthroscopic shoulder surgery] Okamura K. **Hokkaido Igaku Zasshi** 1995 May;70(3):375-81 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Current advances and future direction of arthroscopic surgery for disorders in the knee joint] Yasuda K. **Hokkaido Igaku Zasshi** 1995 May;70(3):383-9 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Medial patellar plica of the knee in MR examination and arthroscopy] Kruczyński J, et al. **Chir Narzadow Ruchu Ortop Pol** 1995;60(4):313-7 (Eng. Abstr.) **(Pol)**

[Lateral release of the patella. II. Arthroscopic technique of subcutaneous lateral release, complications] Latosiewicz R. **Chir Narzadow Ruchu Ortop Pol** 1994;59(3):235-8 (19 ref.) (Eng. Abstr.) **(Pol)**

[Treatment of gonarthrosis with arthroscopic abrasion] Hašpl M, et al. **Lijec Vjesn** 1995 Sep-Oct;117(9-10):236-40 (Eng. Abstr.) **(Scr)**

[Chronic knee instability--arthroscopic analysis] Nikolić D. **Vojnosanit Pregl** 1995 Mar-Apr;52(2):122-7 (Eng. Abstr.) **(Scr)**

ADVERSE EFFECTS

Femoral nerve palsy after arthroscopic surgery with an infusion pump irrigation system. A report of three cases. DiStefano VJ, et al. **Am J Orthop** 1996 Feb;25(2):145-8

Deltoid and supraspinatus muscle pressures following various arthroscopic shoulder procedures. Carr CF, et al. **Arthroscopy** 1995 Aug;11(4):401-3

An experimental assessment of the risk of compartment syndrome during knee arthroscopy. Ekman EF, et al. **Arthroscopy** 1996 Apr;12(2):193-9

Neurological complications of ankle arthroscopy. Ferkel RD, et al. **Arthroscopy** 1996 Apr;12(2):200-8

Complications in hip arthroscopy. Funke EL, et al. **Arthroscopy** 1996 Apr;12(2):156-9

Dermatitis complicating saphenous nerve injury after arthroscopic debridement of a medial meniscal cyst. Logue EJ 3rd, et al. **Arthroscopy** 1996 Apr;12(2):228-31

Periarticular heterotopic ossification: a complication of arthroscopic anterior cruciate ligament reconstruction using a two-incision technique. Ogilvie-Harris DJ, et al. **Arthroscopy** 1995 Dec;11(6):676-9

Popliteal artery injury complicating arthroscopic meniscectomy. Potter D, et al. **Arthroscopy** 1995 Dec; 11(6):723-6

Osteonecrosis of the knee following arthroscopic laser meniscectomy. Rozbruch SR, et al. **Arthroscopy** 1996 Apr; 12(2):245-50

Fatal pulmonary embolus after knee arthroscopy. Rozencwaig R, et al. **Arthroscopy** 1996 Apr;12(2):240-1

Shoulder arthroscopy and nerve injury: pitfalls and prevention. Stanish WD, et al. **Arthroscopy** 1995 Aug; 11(4):458-66

Incidence of deep vein thrombosis after arthroscopic knee surgery: a prospective study. Williams JS Jr, et al. **Arthroscopy** 1995 Dec;11(6):701-5

Injury to infrapatellar branch of saphenous nerve in arthroscopic knee surgery. Mochida H, et al. **Clin Orthop** 1995 Nov;(320):88-94

Popliteal artery pseudoaneurysm revealed by deep vein thrombosis after arthroscopic meniscectomy. Guermazi A, et al. **Eur Radiol** 1996;6(2):217-9

Persistent synovial fistula after arthroscopy: is titanium synovitis a risk factor? Li PL, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):322-3

Complications following arthroscopy of the temporomandibular joint: analysis covering a 10-year period (451 arthroscopies). Carls FR, et al. **J Craniomaxillofac Surg** 1996 Feb;24(1):12-5

Complications of office based arthroscopy of the knee. Szachnowski P, et al. **J Rheumatol** 1995 Sep;22(9):1722-5

Cutaneous nerve lesions of the shoulder and arm after arthroscopic shoulder surgery. Segmüller HE, et al. **J Shoulder Elbow Surg** 1995 Jul-Aug;4(4):254-8

Pseudoaneurysm of the descending genicular artery after arthroscopic meniscectomy: report of a case. Tozzi A, et al. **J Trauma** 1996 Aug;41(2):340-1

Neural and vascular complications of arthroscopic meniscal surgery. Bernard M, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(1):14-8

Complication during arthroscopy. Avery JK. **Tenn Med** 1996 May;89(5):161-2

INSTRUMENTATION

Single-portal endoscopic carpal tunnel release: agee carpal tunnel release system. Elmaraghy MW, et al. **Ann Plast Surg** 1996 Mar;36(3):286-91

Distraction for ankle arthroscopy. Casteleyn PP, et al. **Arthroscopy** 1995 Oct;11(5):633-4

The all-inside meniscal suture technique using new instruments. Maruyama M. **Arthroscopy** 1996 Apr; 12(2):256-8

Fluid pump systems for arthroscopy: a comparison of pressure control versus pressure and flow control. Ogilvie-Harris DJ, et al. **Arthroscopy** 1995 Oct;11(5):591-5

Needle arthroscopy: a new frontier in rheumatology. Panchal P, et al. **Compr Ther** 1996 Jan;22(1):44-7 (14 ref.)

Arthroscopic treatment of acute complete thumb metacarpophalangeal ulnar collateral ligament tears. Ryu J, et al. **J Hand Surg [Am]** 1995 Nov;20(6):1037-42

Kirschner wire fixation through anatomic snuffbox [letter; comment] Whipple TL, et al. **J Hand Surg [Am]** 1996 Mar; 21(2):322-3. Comment on: J Hand Surg [Am] 1995 Jan;20(1):57-62.

Suturing of the meniscus using the Nottingham needle and Ti-cron suture. Fleetcroft JP. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3-4):217

Problems with the sterilisation and the maintenance of sterility of arthroscopic instruments: a comparison of different types of camera drapes. Herzberg W. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3-4):223-5

[Problems in treating carpal tunnel syndrome (editorial)] Brüser P. **Handchir Mikrochir Plast Chir** 1996 May; 28(3):117-9 **(Ger)**

[Choice of procedure in therapy of distal median nerve compression syndrome] Frick A, et al. **Handchir Mikrochir Plast Chir** 1996 May;28(3):147-50 (Eng. Abstr.) **(Ger)**

[Technique, results and risks of endoscopic carpal tunnel release] Kröpfl A, et al. **Handchir Mikrochir Plast Chir** 1996 May;28(3):120-7 (Eng. Abstr.) **(Ger)**

[Agee endoscopic operation of carpal tunnel syndrome in comparison with open surgical technique] Schäfer W, et al. **Handchir Mikrochir Plast Chir** 1996 May;28(3):143-6 (Eng. Abstr.) **(Ger)**

[Carpal tunnel syndrome. A comparison of endoscopic and open surgical treatment] Skorpik G, et al. **Handchir Mikrochir Plast Chir** 1996 May;28(3):133-7 (Eng. Abstr.) **(Ger)**

[Endoscopic operation or conventional open surgical technique in carpal tunnel syndrome: a prospective comparative study] Stark B, et al. **Handchir Mikrochir Plast Chir** 1996 May;28(3):128-32 (Eng. Abstr.) **(Ger)**

[Computerized tomography assisted follow-up of arthroscopic implantation of hydroxylapatite implants in fractures of the head of the tibial. Preliminary results of CT-controlled quantitative evaluation of healing and foreign body reaction to calcium hydroxyapatite implants] Liebig T, et al. **Rontgenpraxis** 1996 Jun;49(6):141-4 **(Ger)**

[Critical considerations in arthroscopic stabilization of the unstable shoulder joint] Jerosch J. **Sportverletz Sportschaden** 1996 Mar;10(1):1-12 (93 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic approaches to reconstruction of the cruciate ligament: refresher course] Kohn D. **Sportverletz Sportschaden** 1995 Dec;9(4):A31-42 (0 ref.) **(Ger)**

[Intraoperative EMG recording in stimulation of the glenohumeral joint capsule] Jerosch J, et al. **Unfallchirurg** 1995 Nov;98(11):580-5 (Eng. Abstr.) **(Ger)**

[Initial experiences with hip joint arthroscopy. Report based on 2 cases] Wallenböck E, et al. **Wien Klin Wochenschr** 1995;107(19):582-4 (Eng. Abstr.) **(Ger)**

[Arthroscopy and arthroscopic surgery of the shoulder joint] Landsiedl F. **Wien Med Wochenschr** 1996;146(6-7):146-8 (18 ref.) (Eng. Abstr.) **(Ger)**

[The value of wrist joint arthroscopy in injuries] Bickert B, et al. **Zentralbl Chir** 1995;120(12):927-33 (Eng. Abstr.) **(Ger)**

METHODS

Arthroscopic treatment of triangular fibrocartilage complex lesions of the wrist. De Smet L, et al. **Acta Orthop Belg** 1996 Mar;62(1):8-13

Arthroscopic assessment of the medial collateral ligament complex of the elbow. Field LD, et al. **Am J Sports Med** 1995 Jul-Aug;23(4):396-400

Lateral traction during shoulder arthroscopy: its effect on tissue perfusion measured by pulse oximetry. Hennrikus WL, et al. **Am J Sports Med** 1995 Jul-Aug;23(4):444-6

Anaesthesia for day-care arthroscopy. A comparison between desflurane and isoflurane. Gupta A, et al. **Anaesthesia** 1996 Jan;51(1):56-62

Arthroscopic subacromial decompression with and without the Holmium: YAG-laser [letter] Brillhart AT. **Arthroscopy** 1996 Apr;12(2):263-4

Anterior-inferior (5 o'clock) portal for shoulder arthroscopy. Davidson PA, et al. **Arthroscopy** 1995 Oct;11(5):519-25

Hip arthroscopy utilizing the supine position [letter] Dorfmann H, et al. **Arthroscopy** 1996 Apr;12(2):264-7

Arthroscopic treatment of rotator cuff tear and greater tuberosity fracture nonunion. Gartsman GM, et al. **Arthroscopy** 1996 Apr;12(2):242-4

Results of isolated meniscal repair evaluated by second-look arthroscopy. Horibe S, et al. **Arthroscopy** 1996 Apr; 12(2):150-5

Arthroscopic reduction and internal fixation of a displaced intraarticular lateral femoral condyle fracture of the knee. McCarthy JJ, et al. **Arthroscopy** 1996 Apr;12(2):224-7

Arthroscopic management of recurrent anterior dislocation of the shoulder: analysis of technical modifications on the Caspari procedure. Marcacci M, et al. **Arthroscopy** 1996 Apr;12(2):144-9

Arthroscopically assisted tibial plateau fracture management: a modified method. Müezzinoğlu US, et al. **Arthroscopy** 1995 Aug;11(4):506-9

Arthroscopic arthrolysis for flexion contracture following intraarticular reconstruction of the anterior cruciate ligament. Reider B, et al. **Arthroscopy** 1996 Apr; 12(2):165-73

Arthroscopic shoulder surgery with three different laser systems: an evaluation of laser applications. Vangsness CT Jr, et al. **Arthroscopy** 1995 Dec;11(6):696-700

Simple and safe arthroscopic placement and removal of cannulated screw and washer for fixation of tibial avulsion fracture of the anterior cruciate ligament. Veselko M, et al. **Arthroscopy** 1996 Apr;12(2):259-62

Comparison between open and arthroscopic acromioplasties: evaluation of absenteeism [see comments] Kinnard P, et al. **Can J Surg** 1996 Feb;39(1):21-3. Comment in: Can J Surg 1996 Jun;39(3):254.

Open versus arthroscopic acromioplasty [letter; comment] O'Driscoll SW. **Can J Surg** 1996 Jun;39(3):254. Comment on: Can J Surg 1996 Feb;39(1):21-3.

Arthroscopically assisted reduction of intraarticular distal radial fractures. Geissler WB, et al. **Clin Orthop** 1996 Jun; (327):125-34

The resistant frozen shoulder. Manipulation versus arthroscopic release. Ogilvie-Harris DJ, et al. **Clin Orthop** 1995 Oct;(319):238-48

Arthroscopic ankle arthrodesis in rheumatoid arthritis. Turan I, et al. **Clin Orthop** 1995 Nov;(320):110-4

Arthroscopy of the subtalar joint: establishing a medial portal. Mekhail AO, et al. **Foot Ankle Int** 1995 Jul;16(7):427-32

Arthroscopic evaluation of acute initial shoulder dislocations. Baker CL Jr. **Instr Course Lect** 1996;45:83-9

Outpatient ACL surgery: a review of safety, practicality, and economy. Malek MM, et al. **Instr Course Lect** 1996; 45:281-6

Intraoperative complications of arthroscopically assisted ACL reconstruction using patellar tendon autograft. Malek MM, et al. **Instr Course Lect** 1996;45:297-302

Comparison of the findings of triple-injection cinearthrography of the wrist with those of arthroscopy. Weiss AP, et al. **J Bone Joint Surg Am** 1996 Mar; 78(3):348-56

An arthroscopic technique for the reduction and fixation of tibial-eminence fractures. Mah JY, et al. **J Pediatr Orthop** 1996 Jan-Feb;16(1):119-21

The case for a simple method of grading osteoarthritis severity at arthroscopy [editorial; comment] Marshall KW. **J Rheumatol** 1996 Apr;23(4):582-5 (24 ref.). Comment on: J Rheumatol 1996 Apr;23(4):698-706.

Tibial plateau fractures: the arthroscopic option. Bobic V, et al. **Knee Surg Sports Traumatol Arthrosc** 1993; 1(3-4):239-42 (23 ref.)

Arthroscopic resection of the acromioclavicular joint (ARAC). Jerosch J, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(3-4):209-15

Microendoscopy of the synovial vasculature in the rabbit knee joint. Funk RH, et al. **Microvasc Res** 1995 Jul; 50(1):45-55

[Clinical and anatomic results of a series of 20 rotator cuff ruptures treated with endoscopic stapler] Gleyze P, et al. **Acta Orthop Belg** 1995;61 Suppl 1:32-6 **(Fre)**

[Arthroscopy of the wrist: diagnostic and therapeutic contribution] Wachtl SW, et al. **Int Orthop** 1995; 19(6):339-45 (Eng. Abstr.) **(Fre)**

[Arthroscopy of the knee joint. Conclusions and recommendations] **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):175-86 (0 ref.) **(Fre)**

[Surgical treatment of carpal tunnel syndrome: a comparison between long and short incision and endoscopic release] Richter VM, et al. **Handchir Mikrochir Plast Chir** 1996 May;28(3):160-6 (Eng. Abstr.) **(Ger)**

[Arthroscopic treatment possibilities of the rotator cuff] Landsiedl F. **Orthopade** 1995 Nov;24(6):529-40 (80 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic resection of the shoulder joint (Mumford operation)] Jerosch J, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep-Oct;133(5):432-6 (Eng. Abstr.) **(Ger)**

[Lateral release of the patella. I--Diagnostics, indications] Latosiewicz R. **Chir Narzadow Ruchu Ortop Pol** 1994; 59(3):231-4 (19 ref.) (Eng. Abstr.) **(Pol)**

TRENDS

[Ambulatory surgery in orthopedics--nothing new! (comment)] Hipp E, et al. **Fortschr Med** 1995 Jul 20; 113(20-21):310. Comment on: Fortschr Med 1995 Jul 20;113(20-21):307-9. **(Ger)**

[Ambulatory operations in orthopedics (see comments)] Roth P. **Fortschr Med** 1995 Jul 20;113(20-21):307-9 (Eng. Abstr.) . Comment in: Fortschr Med 1995 Jul 20;113(20-21):310. **(Ger)**

UTILIZATION

[The prospects for using knee joint arthroscopy in military hospitals] Rikun OV, et al. **Voen Med Zh** 1996 Mar; 317(3):34-7, 80 (Eng. Abstr.) **(Rus)**

VETERINARY

Arthroscopy in food animal practice. Gaughan EM. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):233-47 (11 ref.)

Arthroscopy in the diagnosis and treatment of front leg lameness. van Bree H, et al. **Vet Q** 1995 Apr;17 Suppl 1:S32-4 (0 ref.)

Removal of chip fractures of the femoral trochlear ridges of three horses by arthroscopy. Montesso F, et al. **Vet Rec** 1995 Jul 22;137(4):94-6

Comparison of arthroscopy and arthrotomy for the treatment of osteochondritic lesions in the femoropatellar joint of horses. Vatistas NJ, et al. **Vet Rec** 1995 Dec 16; 137(25):629-32

[Arthroscopic studies of the stifle of dogs] Fehr M, et al. **Tierarztl Prax** 1996 Apr;24(2):137-43 (Eng. Abstr.) **(Ger)**

ARTHUS PHENOMENON see **ARTHUS REACTION**

ARTHUS REACTION

IMMUNOLOGY

ICAM-1 mediates leukocyte-endothelium adhesive interactions in the reversed passive Arthus reaction. Smith RJ, et al. **J Leukoc Biol** 1996 Mar;59(3):333-40

PHYSIOPATHOLOGY

The role of ICAM-1 in the reverse passive Arthus reaction induced pleurisy in the rat. Fielding LE, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S213-4

The role of CD11/CD18 integrins in the reverse passive Arthus reaction in rat dermal tissue. Rote WE, et al. **J Leukoc Biol** 1996 Feb;59(2):254-61

ARTICULATION DISORDERS

Listeners' reactions to misarticulation: a methodological investigation. Small LH, et al. **Percept Mot Skills** 1995 Oct; 81(2):504-6

COMPLICATIONS

Phonatory and articulatory changes associated with increased vocal intensity in Parkinson disease: a case study. Dromey C, et al. **J Speech Hear Res** 1995 Aug;38(4):751-64

Speech dysfunction in early Parkinson's disease. Stewart C, et al. **Mov Disord** 1995 Sep;10(5):562-5

DIAGNOSIS

Diadochokinetic rate in persons with traumatic brain injury. Blumberger J, et al. **Brain Inj** 1995 Nov-Dec;9(8):797-804

Results of systematic speech sound monitoring in children with cleft palate. Ainoda N, et al. **Folia Phoniatr Logop** 1996;48(2):86-91

Simultaneous evaluation of articulatory velopharyngeal function under different dynamic conditions with EMA and videoendoscopy. Engelke W, et al. **Folia Phoniatr Logop** 1996;48(2):65-77

Relationships between measures of phonological performance in preterm children. Holdgrafer G. **Percept Mot Skills** 1995 Aug;81(1):41-2

Relationships among language domains in preterm children. Holdgrafer G. **Percept Mot Skills** 1995 Aug;81(1):305-6

Phonetic and phonological aspects of English affricate production in children with speech disorders. Hardcastle WJ, et al. **Phonetica** 1995;52(3):242-50

[Language development in children with cleft palate] Schönweiler B, et al. **Folia Phoniatr Logop** 1996;48(2):92-7 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Premature loss of the maxillary primary incisors: effect on speech production. Gable TO, et al. **ASDC J Dent Child** 1995 May-Jun;62(3):173-9

Speech error patterns in Cantonese-speaking children with cleft palate. Stokes SF, et al. **Eur J Disord Commun** 1996; 31(1):45-64

Associations among different orofacial dysfunctions in 9-11-year-olds. Pahkala R, et al. **Eur J Orthod** 1995 Dec; 17(6):497-503

Effect of method of cleft palate repair on the quality of speech at the age of 6 years. Haapanen ML. **Scand J Plast Reconstr Surg Hand Surg** 1995 Sep; 29(3):245-50

[Anarthria, progressive apraxia and extrapyramidal syndrome: an uncommon clinical form of corticobasal degeneration? A case studied by HMPAO Tc99m single-photon emission tomography] Fayet G, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):247-50 (14 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Familial aggregation of phonological disorders: results from a 28-year follow-up. Felsenfeld S, et al. **J Speech Hear Res** 1995 Oct;38(5):1091-107

PHYSIOPATHOLOGY

The role of the output phonological buffer in the control of speech timing: a single case study. Cohen L, et al. **Cortex** 1995 Sep;31(3):469-86

Early otitis media and phonological development at age 2 years. Abraham SS, et al. **Laryngoscope** 1996 Jun; 106(6):727-32

PSYCHOLOGY

Consequences of a motor programming deficit for rehearsal and written sentence comprehension. Martin RC, et al. **Q J Exp Psychol A** 1995 Aug;48(3):536-72

SURGERY

[Basic principles for indications in phonosurgery] Friedrich G. **Laryngorhinootologie** 1995 Nov;74(11):663-5 (24 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Electropalatography treatment in an adult with late repair of cleft palate. Whitehill TL, et al. **Cleft Palate Craniofac J** 1996 Mar;33(2):160-8

Surgical correction of velopharyngeal insufficiency with and without compensatory articulation. Pamplona M, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1-2):53-9

Electropalatography in the treatment of articulation/phonological disorders. Dagenais PA. **J Commun Disord** 1995 Dec;28(4):303-29

Visual feedback in treatment of residual phonological disorders. Ruscello DM. **J Commun Disord** 1995 Dec; 28(4):279-302

Speech appliances in the treatment of phonological disorders. Ruscello DM. **J Commun Disord** 1995 Dec;28(4):331-53

ARTICULATORS see **DENTAL ARTICULATORS**

ARTIFACTS

Reduction of peristaltic artifacts on magnetic resonance imaging of the abdomen: a comparative evaluation of three drugs. Martí-Bonmatí L, et al. **Abdom Imaging** 1996 Jul-Aug;21(4):309-13

Intracytoplasmic "negative images" in Gaucher cells [letter] Ferrara G. **Acta Cytol** 1996 Jul-Aug;40(4):848-9

Use of an enhanced gradient system for diffusion MR imaging with motion-artifact reduction. Brockstedt S, et al. **Acta Radiol** 1995 Nov;36(6):662-70

Artifacts in chest radiographs with a third-generation computed radiography system. Volpe JP, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):653-7

Magnetic deflection forces from atrial septal defect and patent ductus arteriosus-occluding devices, stents, and coils used in pediatric-aged patients. Strouse PJ, et al. **Am J Cardiol** 1996 Aug 15;78(4):490-1

Spurious automated white cell count with Coulter STKS in the myelodysplastic syndromes suggests the presence of a red cell membrane defect [letter] Elghetany MT, et al. **Am J Hematol** 1996 May;52(1):69

Transcutaneous electrical nerve stimulator-induced electrocardiogram artifact. A brief report. Sliwa JA, et al. **Am J Phys Med Rehabil** 1996 Jul-Aug;75(4):307-9

Effects of electrocardiograph frequency filters on P-QRS-T amplitudes of the feline electrocardiogram. Schrope DP, et al. **Am J Vet Res** 1995 Nov;56(11):1534-40

Common methodological problems and artifacts associated with studies of myocardial stunning in vivo. Bolli R. **Basic Res Cardiol** 1995 Jul-Aug;90(4):257-62 (13 ref.)

Adenosine 5'-(gamma-thiotriphosphate): an ATP analog that should be used with caution in muscle contraction studies. Resetar AM, et al. **Biochemistry** 1995 Dec 12; 34(49):16039-45

Electromagnetic interference testing of somatosensory and near-infrared devices used in the microgravity and hospital environments. Macnab AJ, et al. **Biomed Instrum Technol** 1996 May-Jun;30(3):236-42

Immunofluorescent artifacts due to the pH of antifading mounting media. Swartz DJ, et al. **Biotechniques** 1996 Mar; 20(3):398-400

Discriminating PCR artifacts using directed heteroduplex analysis (DHDA). Tang J, et al. **Biotechniques** 1995 Dec; 19(6):902-5

The value of flow cytometric analysis of platelet glycoprotein expression of CD34+ cells measured under conditions that prevent P-selectin-mediated binding of platelets. Dercksen MW, et al. **Blood** 1995 Nov 15;86(10):3771-82

Novel CBFB-MYH11 fusion transcripts or reverse transcription-polymerase chain reaction artifacts? [letter; comment] van der Reijden BA, et al. **Blood** 1996 Mar 15; 87(6):2605. Comment on: Blood 1995 Sep 15;86(6):2449-50.

Panoramic radiographs [letter] [see comments] Shaw R. **Br Dent J** 1996 Jan 6;180(1):9. Comment in: Br Dent J 1996 May 11;180(9):327.

Nasal supernumeries? [letter; comment] Tighe J. **Br Dent J** 1996 May 11;180(9):327. Comment on: Br Dent J 1996 Jan 6;180(1):9.

Avoiding artefacts in oral biopsies: the punch biopsy versus the incisional biopsy. Moule I, et al. **Br J Oral Maxillofac Surg** 1995 Aug;33(4):244-7

Immunoblotting studies on artifactual contamination of enamel homogenates by albumin and other proteins. Chen WY, et al. **Calcif Tissue Int** 1995 Aug;57(2):145-51

Observation and prevention of an artefactual formation of oxidized DNA bases and nucleosides in the GC-EIMS method. Douki T, et al. **Carcinogenesis** 1996 Feb; 17(2):347-53

Magnetic resonance angiography of intravascular endoprostheses: investigation of three devices. Laissy JP, et al. **Cardiovasc Intervent Radiol** 1995 Nov-Dec; 18(6):360-6

Risk of overestimation of free malondialdehyde in perfused rat hearts due to homogenization artifacts. Verbunt RJ, et al. **Cardiovasc Res** 1996 Apr;31(4):603-6

Experimental bias in the evaluation of the cellular transient expression in DNA co-transfection experiments. Bergeron D, et al. **Cell Mol Biol Res** 1995;41(3):155-9

Cerebrospinal fluid flow artifact. A possible pitfall on fast-spin-echo MR imaging of the spine simulating intradural pathology. Larsen DW, et al. **Clin Imaging** 1996 Apr-Jun;20(2):140-2

Bone scan injection artifacts. Andrich MP, et al. **Clin Nucl Med** 1996 Mar;21(3):260-2

Artifacts caused by nonionic contrast media and a portacath on a dual-energy x-ray absorptiometry whole-body composition study. Andrich MP, et al. **Clin Nucl Med** 1996 May;21(5):407-8

Incorporation of right ventricular counts as a bullseye artifact. Cecil MP, et al. **Clin Nucl Med** 1995 Aug; 20(8):688-90

ANC schemes for the enhancement of EEG signals in the presence of EOG artifacts. Sadasivan PK, et al. **Comput Biomed Res** 1996 Feb;29(1):27-40

Autofluorescence correction for fluorescence in situ hybridization. Szöllösi J, et al. **Cytometry** 1995 Aug 1; 20(4):356-61

Influence of cytotoxicity on test results in the L5178Y TK+/- mouse lymphoma assay. Oberly TJ, et al. **Environ Mol Mutagen** 1996;27(1):75-8

Flow cytometric measurement of DNA S-phase in human bone marrow cells: correcting for peripheral blood contamination. Abrahamsen JF, et al. **Eur J Haematol** 1996 Mar;56(3):138-47

Spotting hot microwave problems [editorial] Marani E. **Eur J Morphol** 1995 Apr;33(2):149-53

Two-dimensional coronary MRA: limitations and artifacts. Duerinckx AJ, et al. **Eur Radiol** 1996;6(3):312-25

Comparative histomorphology between isoproterenol-induced early lesions and postmortem artifacts in the rat heart. Kemi M, et al. **Exp Anim** 1995 Jul;44(3):245-9

Studies on sarcolemma components may be misleading due to inadequate recovery [comment] Hansen O, et al. **FEBS Lett** 1996 Apr 15;384(2):203-5. Comment on: FEBS Lett 1995 Dec 4;376(3):211-5.

Reactions of nitric oxide and peroxynitrite with organic molecules and ferrihorseradish peroxidase: interference with the determination of hydrogen peroxide. Ischiropoulos H, et al. **Free Radic Biol Med** 1996; 20(3):373-81

Location-dependent artifact for no measurement using multiwell plates. Snell JC, et al. **Free Radic Biol Med** 1996; 20(3):361-3

Template secondary structure can increase the error frequency of the DNA polymerase from Thermus aquaticus. Loewen PC, et al. **Gene** 1995 Oct 16;164(1):59-63

Reduction of mispriming in amplification reactions with restricted PCR. Puskás LG, et al. **Genome Res** 1995 Oct; 5(3):309-11

Approach to genotyping errors caused by nontemplated nucleotide addition by Taq DNA polymerase. Smith JR, et al. **Genome Res** 1995 Oct;5(3):312-7

Signal-to-noise ratio enhancement of cardiac late potentials using ensemble correlation. Atarius R, et al. **IEEE Trans Biomed Eng** 1995 Nov;42(11):1132-7

Reduced order Kalman filtering for the enhancement of respiratory sounds. Charleston S, et al. **IEEE Trans Biomed Eng** 1996 Apr;43(4):421-4

A new double modeling approach for dynamic cardiac PET studies using noise and spillover contaminated LV measurements. Feng D, et al. **IEEE Trans Biomed Eng** 1996 Mar;43(3):319-27

Noise and neuronal populations conspire to encode simple waveforms reliably. Parnas BR. **IEEE Trans Biomed Eng** 1996 Mar;43(3):313-8

Elimination of AC interference in electrocardiogram using IIR notch filter with transient suppression. Pei SC, et al. **IEEE Trans Biomed Eng** 1995 Nov;42(11):1128-32

Reduction of motion artifacts using a two-frequency impedance plethysmograph and adaptive filtering. Rosell J, et al. **IEEE Trans Biomed Eng** 1995 Oct;42(10):1044-8

Calculation of the signal-to-noise ratio for simple surface coils and arrays of coils. Wang J, et al. **IEEE Trans Biomed Eng** 1995 Sep;42(9):908-17

The effect of noise and high-pass filtering on the estimation of mean blood velocity using wide and narrow ultrasound beams. Willink RD, et al. **IEEE Trans Biomed Eng** 1996 Mar;43(3):229-37

Immunoglobulin Inhibiting Reagent: evaluation of a new method for eliminating spurious elevations in CA125 caused by HAMA. Nicholson S, et al. **Int J Biol Markers** 1996 Jan-Mar;11(1):46-9

Allelic dropout caused by allele-specific amplification failure in single-cell PCR of the cystic fibrosis delta F508 deletion. Dreesen JC, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):112-4

Polymerase chain reaction amplification specificity: incidence of allele dropout using different DNA preparation methods for heterozygous single cells. Gitlin SA, et al. **J Assist Reprod Genet** 1996 Feb;13(2):107-11

Reduction in signal overlap results in increased FISH efficiency: implications for preimplantation genetic diagnosis. Munné S, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):149-56

Reduced allele dropout in single-cell analysis for preimplantation genetic diagnosis of cystic fibrosis. Ray PF, et al. **J Assist Reprod Genet** 1996 Feb;13(2):104-6

Allele dropout in sequential PCR and FISH analysis of single cells (cell recycling). Rechitsky S, et al. **J Assist Reprod Genet** 1996 Feb;13(2):115-24

Abnormal central venous pressure tracing. Eller EB, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):775-6

Interference in a pulse oximeter from a nerve stimulator. Block FE Jr, et al. **J Clin Monit** 1995 Nov;11(6):392-3

Clinical evaluation of a method for automatic detection and removal of artifacts in auditory evoked potential monitoring. de Beer NA, et al. **J Clin Monit** 1995 Nov; 11(6):381-91

Non-neoplastic glandular structures in bone marrow: a technical artefact. McCluggage WG, et al. **J Clin Pathol** 1995 Dec;48(12):1141-2

Review of artifacts associated with transrectal ultrasound: understanding, recognition, and prevention of misinterpretation. Hulsmans FJ, et al. **J Clin Ultrasound** 1995 Oct;23(8):483-94 (21 ref.)

Artifacts and thresholding in X-ray CT of a cortical bone and titanium composite. Sutherland CJ, et al. **J Comput Assist Tomogr** 1996 May-Jun;20(3):496-503

The "pituitary pseudoaneurysm" artefact with 3D TOF MRA of the circle of Willis. Uberoi R, et al. **J Comput Assist Tomogr** 1995 Sep-Oct;19(5):822-3

Effect of noise in maximum likelihood analysis of late potentials. Sörnmo L, et al. **J Electrocardiol** 1995;28 Suppl:50-3

Artefact in forensic medicine: pseudo-rodent activity. Patel F. **J Forensic Sci** 1995 Jul;40(4):706-7

Artifacts in functional magnetic resonance imaging from gaseous oxygen. Bates S, et al. **J Magn Reson Imaging** 1995 Jul-Aug;5(4):443-5

Ex vivo evaluation of ferromagnetism, heating, and artifacts of breast tissue expanders exposed to a 1.5-T MR system. Fagan LL, et al. **J Magn Reson Imaging** 1995 Sep-Oct; 5(5):614-6

MR imaging and vascular access ports: ex vivo evaluation of ferromagnetism, heating, and artifacts at 1.5 T. Shellock FG, et al. **J Magn Reson Imaging** 1995 Jul-Aug;5(4):481-4

A segmented K-space velocity mapping protocol for quantification of renal artery blood flow during breath-holding. Thomsen C, et al. **J Magn Reson Imaging** 1995 Jul-Aug;5(4):393-401

Single breath-hold volumetric imaging of the heart using magnetization-prepared 3-dimensional segmented echo planar imaging. Wielopolski PA, et al. **J Magn Reson Imaging** 1995 Jul-Aug;5(4):403-9

False evidence of carotid stenosis on magnetic resonance angiography caused by surgical clips. Bertorini TE, et al. **J Neuroimaging** 1995 Oct;5(4):206-8

A Monte Carlo investigation of artifacts caused by liver uptake in single-photon emission computed tomography perfusion imaging with technetium 99m-labeled agents. King MA, et al. **J Nucl Cardiol** 1996 Jan-Feb;3(1):18-29

The "hurricane sign": evidence of patient motion artifact on cardiac single-photon emission computed tomographic imaging. Sorrell V, et al. **J Nucl Cardiol** 1996 Jan-Feb; 3(1):86-8

Preventing patient motion during tomographic myocardial perfusion imaging. Cooper JA, et al. **J Nucl Med** 1995 Nov; 36(11):2001-5

A recipe for the preparation of a rodent food that eliminates chlorophyll-based tissue fluorescence [news] Holmes H, et al. **J Photochem Photobiol B** 1995 Aug;29(2-3):199

Radiographic artifacts. Kirberger RM, et al. **J S Afr Vet Assoc** 1995 Jun;66(2):85-94 (8 ref.)

Pseudodissection of the abdominal aorta on color Doppler imaging. Crotty JM, et al. **J Ultrasound Med** 1995 Nov; 14(11):853-7

The two-tone testis due to refractive shadowing of the intratesticular artery. Nicolaou S, et al. **J Ultrasound Med** 1995 Dec;14(12):963-5

Increased renal function in kidneys with ureteropelvic junction obstruction: fact or artifact? Assessment by quantitative single photon emission computerized tomography of dimercapto-succinic acid uptake by the kidneys. Groshar D, et al. **J Urol** 1996 Mar;155(3):844-6

Accurate velocity mapping with FAcE. Maier SE, et al. **Magn Reson Imaging** 1996;14(2):163-71

Locally focused MRI. Cao Y, et al. **Magn Reson Med** 1995 Dec;34(6):858-67

Multiple breath-hold averaging (MBA) method for increased SNR in abdominal MRI. Feinberg DA, et al. **Magn Reson Med** 1995 Dec;34(6):905-9

Movement-related effects in fMRI time-series. Friston KJ, et al. **Magn Reson Med** 1996 Mar;35(3):346-55

The Rician distribution of noisy MRI data. Gudbjartsson H, et al. **Magn Reson Med** 1995 Dec;34(6):910-4

Removal of lipid artifacts in 1H spectroscopic imaging by data extrapolation. Haupt CI, et al. **Magn Reson Med** 1996 May;35(5):678-87

A forward-subtraction procedure for removing hyperfine artifacts in electron paramagnetic resonance imaging. Kuppusamy P, et al. **Magn Reson Med** 1996 Mar; 35(3):316-22

Retrospective estimation and correction of physiological artifacts in fMRI by direct extraction of physiological activity from MR data. Le TH, et al. **Magn Reson Med** 1996 Mar;35(3):290-8

Phase-encode reordering to minimize errors caused by motion. Macgowan CK, et al. **Magn Reson Med** 1996 Mar; 35(3):391-8

Velocity encoding using ghost artifacts. Madore B, et al. **Magn Reson Med** 1996 Jun;35(6):887-94

The diminishing variance algorithm for real-time reduction of motion artifacts in MRI. Sachs TS, et al. **Magn Reson Med** 1995 Sep;34(3):412-22

Correction of motional artifacts in diffusion-weighted images using a reference phase map. Ulug AM, et al. **Magn Reson Med** 1995 Sep;34(3):476-80

Reduction of phase error ghosting artifacts in thin slice fast spin-echo imaging. Wan X, et al. **Magn Reson Med** 1995 Oct;34(4):632-8

Error in MR volumetric flow measurements due to ordered phase encoding in the presence of flow varying with respiration. Wolf RL, et al. **Magn Reson Med** 1995 Sep; 34(3):470-5

Discrimination between artefacts and contractions in pressure signals from the gastrointestinal tract by pattern recognition method. Andersen MB, et al. **Med Biol Eng Comput** 1996 Mar;34(2):127-32

Pathological specimens of rat temporal bone--comparison between different fixative solution. Sano M, et al. **Med J Osaka Univ** 1993 Sep;41-42(1-4):17-22

Correction of motion artifacts in linogram and projection reconstruction MRI using geometry and consistency constraints. Gai N, et al. **Med Phys** 1996 Feb;23(2):251-62

The frequency of chimeric molecules as a consequence of PCR co-amplification of 16S rRNA genes from different bacterial species. Wang GC, et al. **Microbiology** 1996 May; 142 (Pt 5):1107-14

A new method of bipolymerase sequencing prevents "stop-bands". Austin CC. **Mol Biotechnol** 1995 Aug; 4(1):100-1

Functional MRI: are we all moving towards artifactual conclusions? Or fMRI fact or fancy? Weisskoff RM. **NMR Biomed** 1995 May;8(3):101-3 (10 ref.)

Cardioverter discharges following sensing of electrical artifact due to fluid penetration in the connector port. Hief C, et al. **Pacing Clin Electrophysiol** 1995 Aug;18(8):1589-91

MR imaging artifacts that simulate disease: how to recognize and eliminate them. Arena L, et al. **Radiographics** 1995 Nov;15(6):1373-94

Three-dimensional spiral CT during arterial portography: comparison of three rendering techniques. Heath DG, et al. **Radiographics** 1995 Jul;15(4):1001-11

The AAPM/RSNA physics tutorial for residents. Introduction to emission CT. Madsen MT. **Radiographics** 1995 Jul;15(4):975-91

The case of the corrugated coif. **Radiol Technol** 1995 Jul-Aug;66(6):396

The case of the repetitious ripple. Martin NJ. **Radiol Technol** 1995 Nov-Dec;67(2):168

Just bending the rule. Martin NJ. **Radiol Technol** 1996 Mar-Apr;67(4):346

Power Doppler US in synovitis: reality or artifact? [letter] Cardinal E, et al. **Radiology** 1996 Sep;200(3):868-9

Color Doppler twinkling artifact in hyperechoic regions. Rahmouni A, et al. **Radiology** 1996 Apr;199(1):269-71

Central intraluminal saturation stripe on MR angiograms of curved vessels: simulation, phantom, and clinical analysis. Saloner D, et al. **Radiology** 1996 Mar;198(3):733-9

False-positive activated protein C (APC) sensitivity ratio caused by freezing and by contamination of plasma with platelets [letter] Shizuka R, et al. **Thromb Res** 1995 Apr 15;78(2):189-90

Effects of stenosis on transit-time ultrasound measurements of blood flow. Gordon IL. **Ultrasound Med Biol** 1995; 21(5):623-33

Correction of intrinsic spectral broadening errors in Doppler peak velocity measurements made with phased sector and linear array transducers. Winkler AJ, et al. **Ultrasound Med Biol** 1995;21(8):1029-35

[Online recording of monitor data. The artifact problem] Petry A. **Anaesthesist** 1995 Dec;44(12):818-25 (Eng. Abstr.) **(Ger)**

[The reduction of ferromagnetic artifacts by using a fast-spin-echo sequence in the postoperative assessment of degenerative diseases of the cervical spine] Scarabino T, et al. **Radiol Med (Torino)** 1996 Mar;91(3):174-6 (Eng. Abstr.) **(Ita)**

[Dissection-like artifact on one-second scanning time CT] Nasu K, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Sep;55(11):727-31 (Eng. Abstr.) **(Jpn)**

[A device for the artifact-free lead take-off of brain electrical activity in exposure to a UHF field in free-ranging rats] Vorob'ev VV, et al. **Fiziol Zh Im I M Sechenova** 1995 Jan;81(1):141-3 **(Rus)**

[Pseudocystic pulmonary images] Schoendorff J, et al. **Rev Clin Esp** 1996 Feb;196(2):127-8 **(Spa)**

ARTIFICIAL INSEMINATION see **INSEMINATION, ARTIFICIAL**

ARTIFICIAL INTELLIGENCE

see related
NEURAL NETWORKS (COMPUTER)

Differences in knowledge representations of experienced and inexperienced clinicians as captured by repertory grids. Murphy GC, et al. **Acad Med** 1996 Jan;71(1 Suppl):S16-8

Reasoning in expert system ONE for vertigo work-up. Kentala E, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:207-8

Evaluation of a knowledge-based system providing ventilatory management and decision for extubation. Dojat M, et al. **Am J Respir Crit Care Med** 1996 Mar; 153(3):997-1004

Knowledge-guided segmentation and morphometric analysis of colorectal dysplasia. Hamilton PW, et al. **Anal Quant Cytol Histol** 1995 Jun;17(3):172-82

Types of planning: can artificial intelligence yield insights into prefrontal function? Hendler JA. **Ann N Y Acad Sci** 1995 Dec 15;769:265-76 (45 ref.)

Architectures for intelligent systems based on reusable components [editorial] Musen MA, et al. **Artif Intell Med** 1995 Jun;7(3):189-99

Model-based diagnosis of brain disorders: a prototype framework. Siregar P, et al. **Artif Intell Med** 1995 Aug; 7(4):315-42

A theoretical approach to artificial intelligence systems in medicine. Spyropoulos B, et al. **Artif Intell Med** 1995 Oct; 7(5):455-65

Situated clinical cognition. Timpka T. **Artif Intell Med** 1995 Oct;7(5):387-94

Ontology-based configuration of problem-solving methods and generation of knowledge-acquisition tools: application of PROTEGE-II to protocol-based decision support. Tu SW, et al. **Artif Intell Med** 1995 Jun;7(3):257-89

A case study in ontology library construction. van Heijst G, et al. **Artif Intell Med** 1995 Jun;7(3):227-55

Use of artificial intelligence in analytical systems for the clinical laboratory. Place JF, et al. **Clin Biochem** 1995 Aug; 28(4):373-89 (84 ref.)

Virtual reality and telepresence for military medicine. Satava RM. **Comput Biol Med** 1995 Mar;25(2):229-36

Vision-based object registration for real-time image overlay. Uenohara M, et al. **Comput Biol Med** 1995 Mar; 25(2):249-60

Effective domain-dependent reuse in medical knowledge bases. Dojat M, et al. **Comput Biomed Res** 1995 Dec; 28(6):403-32 (53 ref.)

Parallel processing of chemical information in a local area network--II. A parallel cross-validation procedure for artificial neural networks. Derks EP, et al. **Comput Chem** 1996 Aug;20(4):439-48

Artificial intelligence programming with LabVIEW: genetic algorithms for instrumentation control and optimization. Moore JH. **Comput Methods Programs Biomed** 1995 Jun; 47(1):73-9

The development of automated client responses for computerized clinical simulation testing. Krawczak J, et al. **Comput Nurs** 1995 Nov-Dec;13(6):295-300

How reliable is computerized assessment of readability? Mailloux SL, et al. **Comput Nurs** 1995 Sep-Oct;13(5):221-5

Utilization of laboratory resources: developments in knowledge-based ordering systems. Boon-Falleur L, et al. **Int J Biomed Comput** 1995 Sep;40(1):17-30

Database techniques for biological materials & methods. Baclawski K, et al. **Ismb** 1993;1:21-8

The induction of rules for predicting chemical carcinogenesis in rodents. Bahler D, et al. **Ismb** 1993;1:29-37

SENEX: a CLOS/CLIM application for molecular pathology. Ball SS, et al. **Ismb** 1993;1:38-46

Toward multistrategy parallel and distributed learning in sequence analysis. Chan PK, et al. **Ismb** 1993;1:65-73

Protein topology prediction through parallel constraint logic programming. Clark DA, et al. **Ismb** 1993;1:83-91

Knowledge-based generation of machine learning experiments: learning with DNA crystallography data. Cohen D, et al. **Ismb** 1993;1:92-100

Representation for discovery of protein motifs. Conklin D, et al. **Ismb** 1993;1:101-8

A modular learning environment for protein modeling. Gracy J, et al. **Ismb** 1993;1:145-53

Integrating order and distance relationships from heterogeneous maps. Graves M. **Ismb** 1993;1:154-62

Inference of order in genetic systems. Guidi JN, et al. **Ismb** 1993;1:163-71

Finding relevant biomolecular features. Hunter L, et al. **Ismb** 1993;1:190-7

Constructive induction and protein tertiary structure prediction. Ioerger TR, et al. **Ismb** 1993;1:198-206

Protein secondary structure prediction using two-level case-based reasoning. Leng B, et al. **Ismb** 1993;1:251-9

Prediction of primate splice junction gene sequences with a cooperative knowledge acquisition system. Mephu Nguifo E, et al. **Ismb** 1993;1:292-300

A service-oriented information sources database for the biological sciences. Springer GK, et al. **Ismb** 1993;1:380-6

Towards an intelligent system for the automatic assignment of domains in globular proteins. Sternberg MJ, et al. **Ismb** 1995;3:376-83

Transmembrane segment prediction from protein sequence data. Weiss SM, et al. **Ismb** 1993;1:420-8

Molecular diversity in chemical databases: comparison of medicinal chemistry knowledge bases and databases of commercially available compounds. Cummins DJ, et al. **J Chem Inf Comput Sci** 1996 Jul-Aug;36(4):750-63

A knowledge-based approach to deconvolve the water component in in vivo proton MR spectroscopy. Saeed N. **J Comput Assist Tomogr** 1995 Sep-Oct;19(5):830-7

Integrated access to metabolic and genomic data. Karp PD, et al. **J Comput Biol** 1996 Spring;3(1):191-212

Protein secondary structure prediction using two-level case-based reasoning. Leng B, et al. **J Comput Biol** 1994 Spring;1(1):25-38

A knowledge-based system for diagnosis of mastitis problems at the herd level. 1. Concepts. Hogeveen H, et al. **J Dairy Sci** 1995 Jul;78(7):1430-40

A knowledge-based system for diagnosis of mastitis problems at the herd level. 2. Machine milking. Hogeveen H, et al. **J Dairy Sci** 1995 Jul;78(7):1441-55

The acquisition and validation of removable partial denture design knowledge. I. Methodology and overview. Davenport JC, et al. **J Oral Rehabil** 1996 Mar;23(3):152-7

The use of artificial intelligence in the analysis of sports performance: a review of applications in human gait analysis and future directions for sports biomechanics. Lapham AC, et al. **J Sports Sci** 1995 Jun;13(3):229-37 (38 ref.)

Vascular applications of telepresence surgery: initial feasibility studies in swine. Bowersox JC, et al. **J Vasc Surg** 1996 Feb;23(2):281-7

Alan Turing: the machine, the enigma, and the test [editorial] Bleich HL. **MD Comput** 1995 Sep-Oct;12(5):330, 333-4
Hycones: a hybrid approach to designing decision support systems. Leão BD, et al. **MD Comput** 1996 Mar-Apr; 13(2):160-4
Development of a knowledge-based electronic patient record. Safran C, et al. **MD Comput** 1996 Jan-Feb; 13(1):46-54, 63
Lecture to the London Mathematical Society on 20 February 1947. 1986 [classical article] Turing AM. **MD Comput** 1995 Sep-Oct;12(5):390-7
Performance of a neural network trained to make third-molar treatment-planning decisions. Brickley MR, et al. **Med Decis Making** 1996 Apr-Jun;16(2):153-60
A case-based assistant for diagnosis and analysis of dysmorphic syndromes. Evans CD. **Med Inf (Lond)** 1995 Apr-Jun;20(2):121-31
Use of neural networks in medical expert systems. Likothanassis SD, et al. **Med Inf (Lond)** 1995 Oct-Dec; 20(4):349-57
Computerized knowledge bases in primary health care: a curse or a blessing for health promotion, prevention and patient quality?. Alendahl K, et al. **Medinfo** 1995;8 Pt 2:917-21
Temporal reasoning abstractions in QMR. Aliferis CF, et al. **Medinfo** 1995;8 Pt 1:847-51
Machine learning to support diagnostics in the domain of asymptomatic liver disease. Babic A, et al. **Medinfo** 1995; 8 Pt 1:809-13
Third generation electronic medical record knowledge based perspectives. Balkányi L, et al. **Medinfo** 1995;8 Pt 1:257-60
Description and advantages of an index-driven medical knowledge base. Bishop CW, et al. **Medinfo** 1995;8 Pt 2:952
An integrated system to represent and manage medical knowledge. Fiore M, et al. **Medinfo** 1995;8 Pt 2:931-3
Cognitive design for sharing medical knowledge models. Gangemi A, et al. **Medinfo** 1995;8 Pt 1:85-9
Information, intelligence, and interface: the pillars of a successful medical information system. Hadzikadic M, et al. **Medinfo** 1995;8 Pt 2:1589
Computer-aided clinical laboratory diagnosis in conjunction with the electronic medical textbook. Kawamata F, et al. **Medinfo** 1995;8 Pt 2:955
An object-oriented model for the integration of knowledge-based systems. Mann G. **Medinfo** 1995;8 Pt 2:938-42
Integrated development of a knowledge-based CPR system for quality assurance in diabetes outpatient clinics. Moser W, et al. **Medinfo** 1995;8 Pt 1:236-9
A diagnostic workstation for neoplastic bone marrow diseases: evaluation on 526 cases. Nguyen D, et al. **Medinfo** 1995;8 Pt 1:771-5
ICOHR: intelligent computer based oral health record. Peterson LC, et al. **Medinfo** 1995;8 Pt 2:1709
Adaptation and abstraction as steps towards case-based reasoning in the real medical world: case-based selection strategies for antibiotics therapy. Schmidt R, et al. **Medinfo** 1995;8 Pt 2:947-51
Knowledge-based temporal abstraction in diabetes therapy. Shahar Y, et al. **Medinfo** 1995;8 Pt 1:852-6
Terminological reference of a knowledge-based system: the data dictionary. Stausberg J, et al. **Medinfo** 1995;8 Pt 1:157-61
Problems of knowledge acquisition automation in medical expert systems. Stempczyńska J, et al. **Medinfo** 1995;8 Pt 1:857-60 (9 ref.)
Induction of expert system rules based on rough sets and resampling methods. Tsumoto S, et al. **Medinfo** 1995;8 Pt 1:861-5
Smart Classification System (SmaCS): design, implementation, and application for congenital heart disease terminology. van den Heuvel F, et al. **Medinfo** 1995; 8 Pt 1:167-71
Enormous knowledge base of disease diagnosis criteria. Xiao ZH, et al. **Medinfo** 1995;8 Pt 2:956
A new and cheap medical examination system with artificial intelligence. Zhang X, et al. **Medinfo** 1995;8 Pt 2:1702
A model for medical knowledge representation application to the analysis of descriptive pathology reports. Smart JF, et al. **Methods Inf Med** 1995 Sep;34(4):352-60
Hints. Abu-Mostafa YS. **Neural Comput** 1995 Jul;7(4):639-71 (34 ref.)
Learning and generalization in radial basis function networks. Freeman JA, et al. **Neural Comput** 1995 Sep;7(5):1000-20
Consciousness: perspectives from symbolic and connectionist AI. Bechtel W. **Neuropsychologia** 1995 Sep;33(9):1075-86 (37 ref.)
Reviewing the Behavioral Science Knowledge Base on Technology Transfer. Proceedings of a meeting. November 17-18, 1993. **NIDA Res Monogr** 1995;155:1-289
Reviewing the behavioral science knowledge base on technology transfer. Introduction. Backer TE, et al. **NIDA Res Monogr** 1995;155:1-20 (23 ref.)
Assessing and enhancing readiness for change: implications for technology transfer. Backer TE. **NIDA Res Monogr** 1995;155:21-41 (40 ref.)
The use of misclassification costs to learn rule-based decision support models for cost-effective hospital admission strategies. Ambrosino R, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:304-8
Structured knowledge representation: an improved methodology for communication of hospital policy. Guterman JJ, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:733-6
Concept formation vs. logistic regression: predicting death in trauma patients. Hadzikadic M, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:198-202
Medical decision support: experience with implementing the Arden Syntax at the Columbia-Presbyterian Medical Center. Jenders RA, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:169-73
Representing hospital events as complex conditionals. Kuperman GJ, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:137-41
Assessing the behavioral impact of a diagnostic decision support system. Li YC, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:805-9
A rational reconstruction of INTERNIST-I using PROTEGE-II. Musen MA, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:289-93
An object-oriented, knowledge-based system for cardiovascular rehabilitation--phase II. Ryder RM, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:280-3
Real time monitoring in the control theory paradigm. Séroussi B, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:761-5
Using intermediate states to improve the ability of the Arden Syntax to implement care plans and reuse knowledge. Sherman EH, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:238-42
Knowledge discovery in clinical databases based on variable precision rough set model. Tsumoto S, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:270-4
Evaluation of a belief-network-based reminder system that learns from utility feedback. Wagner MM, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:666-72
Computers and psychiatry. Greist JH. **Psychiatr Serv** 1995 Oct;46(10):989-91
Image representations for visual learning. Beymer D, et al. **Science** 1996 Jun 28;272(5270):1905-9 (61 ref.)
New directions for health: towards a knowledge base for public health action. Dean K, et al. **Soc Sci Med** 1996 Mar; 42(5):745-50
Toxicity estimation by chemical substructure analysis: the TOX II program. Klopman G, et al. **Toxicol Lett** 1995 Sep;79(1-3):145-55 (14 ref.)
[Analytic design and clinical application of an intelligent control system for pharmacotherapy with insulin--2] Peters A, et al. **Biomed Tech (Berl)** 1996 Mar;41(3):42-53 (Eng. Abstr.) **(Ger)**
[MEDRISK--an expert system for medical risk assessment] Mayer-Ohly E, et al. **Versicherungsmedizin** 1995 Oct 1; 47(5):170-7 (Eng. Abstr.) **(Ger)**
[An approach for planning hospital menus using a knowledge-based system] Schaeffler V, et al. **Z Ernahrungswiss** 1995 Sep;34(3):236-9 (Eng. Abstr.) **(Ger)**
[Computer-oracle-brain] Majer U. **Zentralbl Neurochir** 1995; 56(4):193-5 (Eng. Abstr.) **(Ger)**
[Artificial intelligence and its medical applications] Armoni A, et al. **Harefuah** 1996 Feb 1;130(3):185-90 (34 ref.) **(Heb)**
[Biological versus artificial intelligence: a critical approach] Sanvito WL. **Arq Neuropsiquiatr** 1995 Sep;53(3-A):361-8 (Eng. Abstr.) **(Por)**

ARTIFICIAL LIMBS

Chopart prosthesis and semirigid foot orthosis in traumatic forefoot amputation. Comparative gait analysis. Hirsch G, et al. **Am J Phys Med Rehabil** 1996 Jul-Aug;75(4):283-91
Combined free flap, Ilizarov lengthening and prosthetic fitting in the reconstruction of a proximal forearm amputation--a case report. Kour AK, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):135-7
The anthroform biorobotic arm: a system for the study of spinal circuits. Hannaford B, et al. **Ann Biomed Eng** 1995 Jul-Aug;23(4):399-408
Aeromedical certification of a pilot with bi-lateral prosthetic hands--a case report. Ospina EM, et al. **Aviat Space Environ Med** 1996 May;67(5):491-3
Mobility after amputation of a lower limb [letter] Kulkarni JR. **BMJ** 1995 Dec 16;311(7020):1643-4
Automated hexahedral mesh generation from biomedical image data: applications in limb prosthetics. Zachariah SG, et al. **IEEE Trans Rehabil Eng** 1996 Jun;4(2):91-102
Biomechanical basis of choosing the rational mass and its distribution throughout the lower limb prosthesis segments. Farber BS, et al. **J Rehabil Res Dev** 1995 Nov;32(4):325-36
An above-knee prosthesis with a system of energy recovery: a technical note. Farber BS, et al. **J Rehabil Res Dev** 1995 Nov;32(4):337-48
The prediction of metabolic energy expenditure during gait from mechanical energy of the limb: a preliminary study. Foerster SA, et al. **J Rehabil Res Dev** 1995 May; 32(2):128-34
Volumetric determinations with CAD/CAM in prosthetics and orthotics: errors of measurement. Lilja M, et al. **J Rehabil Res Dev** 1995 May;32(2):141-8
The effect of prosthetic alignment on relative limb loading in persons with trans-tibial amputation: a preliminary report. Pinzur MS, et al. **J Rehabil Res Dev** 1995 Nov; 32(4):373-7
Gait initiation of persons with below-knee amputation: the characterization and comparison of force profiles. Rossi SA, et al. **J Rehabil Res Dev** 1995 May;32(2):120-7
The effect of five prosthetic feet on the gait and loading of the sound limb in dysvascular below-knee amputees. Snyder RD, et al. **J Rehabil Res Dev** 1995 Nov;32(4):309-15
Energy expenditure during ambulation in dysvascular and traumatic below-knee amputees: a comparison of five prosthetic feet. Torburn L, et al. **J Rehabil Res Dev** 1995 May;32(2):111-9
Design methodology for a multifunctional hand prosthesis. Vinet R, et al. **J Rehabil Res Dev** 1995 Nov;32(4):316-24
Interface mechanics in external prosthetics: review of interface stress measurement techniques. Sanders JE. **Med Biol Eng Comput** 1995 Jul;33(4):509-16 (41 ref.)
Perspectives on the role of afferent signals in control of motor neuroprostheses. Johnson KO, et al. **Med Eng Phys** 1995 Oct;17(7):481-96 (99 ref.)
Development of a non-linear finite element modelling of the below-knee prosthetic socket interface. Zhang M, et al. **Med Eng Phys** 1995 Dec;17(8):559-66
Amputation surgery and prostheses. Rodriguez RP. **Orthop Clin North Am** 1996 Jul;27(3):525-39 (59 ref.)
The influence of lower-extremity muscle force on gait characteristics in individuals with below-knee amputations secondary to vascular disease. Powers CM, et al. **Phys Ther** 1996 Apr;76(4):369-77; discussion 378-85
Driving appliances for upper limb amputees. Verrall T, et al. **Prosthet Orthot Int** 1995 Aug;19(2):124-7
Energy cost during ambulation in transfemoral amputees: a knee joint with a mechanical swing phase control vs a knee joint with a pneumatic swing phase control. Boonstra AM, et al. **Scand J Rehabil Med** 1995 Jun;27(2):77-81
[Integrated gait analysis: a complex expert system approach to detailed data evaluation] Mainka C, et al. **Biomed Tech (Berl)** 1995 Dec;40(12):363-71 (Eng. Abstr.) **(Ger)**
[The treatment and prosthesis after an interilioabdominal amputation for sarcomas of the bones and soft tissues] Trishkin VA, et al. **Vestn Khir Im I I Grek** 1995;154(2):53-6 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

[Diagnostic methods of detection of early degenerative changes in the lumbo-coccygeal triangle in relation to the use of prostheses] MatanovićB, et al. **Reumatizam** 1993; 40(1):11-4 (Eng. Abstr.) **(Scr)**

INSTRUMENTATION

Adaptive filtering of the electromyographic signal for prosthetic control and force estimation. Park E, et al. **IEEE Trans Biomed Eng** 1995 Oct;42(10):1048-52

REHABILITATION

Rehabilitation in limb deficiency. 3. The geriatric amputee. Andrews KL. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S14-7 (41 ref.)
Rehabilitation in limb deficiency. 1. Gait and motion analysis. Czerniecki JM. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S3-8 (41 ref.)
Rehabilitation in limb deficiency. 4. Limb amputation. Esquenazi A, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S18-28 (42 ref.)
Rehabilitation in limb deficiency. 2. The pediatric amputee. Jain S. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S9-13 (42 ref.)

UTILIZATION

Prosthetic usage in major upper extremity amputations. Wright TW, et al. **J Hand Surg [Am]** 1995 Jul;20(4):619-22

ARTIFICIAL ORGANS

Xth World Congress of the International Society for Artificial Organs in conjunction with the International Faculty for Artificial Organs. Taipei, November 14-18, 1995. Abstracts. **Artif Organs** 1995 Oct;19(10):957-1109
Reconstruction of liver tissue in vitro: geometry of characteristic flat bed, hollow fiber, and spouted bed bioreactors with reference to the in vivo liver. Bader A, et al. **Artif Organs** 1995 Sep;19(9):941-50
Functional stability of porcine hepatocyte spheroids in various culture systems under 100% porcine and human plasma conditions. Sakai Y, et al. **Artif Organs** 1996 Jan; 20(1):56-60
A gait-powered autologous battery charging system for artificial organs. Antaki JF, et al. **ASAIO J** 1995 Jul-Sep; 41(3):M588-95
Feasibility studies for a photosynthetic artificial lung. Optimization of parameters affecting photosynthesis. Basu S, et al. **ASAIO J** 1994 Jul-Sep;40(3):M743-6
A two layer model for the effects of blood contact on membrane transport in artificial organs. Boyd RF, et al. **ASAIO J** 1994 Jul-Sep;40(3):M864-9
200 cases with a new breathing pacemaker dispel myths about diaphragm pacing. Dobelle WH, et al. **ASAIO J** 1994 Jul-Sep;40(3):M244-52
The development of an implantable artificial lung. Fazzalari FL, et al. **ASAIO J** 1994 Jul-Sep;40(3):M728-31
An artificial gill system for oxygen uptake from water using perfluorooctylbromide. Haramoto H, et al. **ASAIO J** 1994

Jul-Sep;40(3):M803-7
Effects of blood phase oscillation on gas transfer in a microporous intravascular lung. High KM, et al. **ASAIO J** 1994 Jul-Sep;40(3):M735-9
A new apparatus for chronic observation of the microcirculation in situ to evaluate artificial organ performance. Imachi K, et al. **ASAIO J** 1994 Jul-Sep; 40(3):M757-61
Performance evaluation of implantable artificial organs by sound spectrum analysis. Lee SH, et al. **ASAIO J** 1994 Jul-Sep;40(3):M762-6
A dynamic intravascular artificial lung. Makarewicz AJ, et al. **ASAIO J** 1994 Jul-Sep;40(3):M747-50
A pumping artificial lung. Makarewicz AJ, et al. **ASAIO J** 1994 Jul-Sep;40(3):M518-21
An artificial esophagus consisting of cultured human esophageal epithelial cells, polyglycolic acid mesh, and collagen. Sato M, et al. **ASAIO J** 1994 Jul-Sep; 40(3):M389-92
Small intrapulmonary artery lung prototypes: design, construction, and in vitro water testing. Snider MT, et al. **ASAIO J** 1994 Jul-Sep;40(3):M533-9
Primary or established liver cells for a hybrid liver? Comparison of metabolic features. Stange J, et al. **ASAIO J** 1995 Jul-Sep;41(3):M310-5
Relationship between stenting time and regeneration of neoesophageal submucosal tissue. Takimoto Y, et al. **ASAIO J** 1994 Jul-Sep;40(3):M793-7
Long-term cardiopulmonary support with a composite artificial heart-lung system. Tatsumi E, et al. **ASAIO J** 1995 Jul-Sep;41(3):M557-60
Design and evaluation of a new, low pressure loss, implantable artificial lung. Vaslef SN, et al. **ASAIO J** 1994 Jul-Sep;40(3):M522-6
Experimental study of bioactive polyurethane sponge as an artificial trachea. Yanagi M, et al. **ASAIO J** 1994 Jul-Sep; 40(3):M412-8
Preclinical trial of a bioartificial liver support system in a porcine fulminant hepatic failure model. Sheil AG, et al. **Aust N Z J Surg** 1996 Aug;66(8):547-52
Implantable biohybrid artificial organs. Colton CK. **Cell Transplant** 1995 Jul-Aug;4(4):415-36 (72 ref.)
Use of mammalian liver cells for artificial liver support. Jauregui HO, et al. **Cell Transplant** 1996 May-Jun; 5(3):353-67 (130 ref.)
XXIInd European Society for Artificial Organs (ESAO) Congress. Berlin, Germany, 19-21 October 1995. Abstracts. **Int J Artif Organs** 1995 Aug;18(8):417-84
Mass transfer limitations to the performance of membrane bioartificial liver support devices. Catapano G. **Int J Artif Organs** 1996 Jan;19(1):18-35 (70 ref.)
Hybrid liver support [editorial] Gerlach J. **Int J Artif Organs** 1996 Jan;19(1):1-2 (8 ref.)
Assessment of bioartificial liver support in acute liver failure. Hughes RD, et al. **Int J Artif Organs** 1996 Jan;19(1):3-6 (18 ref.)
Matrix-induced liver cell aggregates (MILCA) for bioartificial liver use. Kong LB, et al. **Int J Artif Organs** 1996 Jan;19(1):72-8
Blood platelet activation and membrane glycoprotein changes during extracorporeal life support (ECLS). In vitro studies. Mellgren K, et al. **Int J Artif Organs** 1995 Jun; 18(6):315-21
Role of transport proteins in bioartificial liver assist systems. Mitzner S, et al. **Int J Artif Organs** 1996 Jan;19(1):49-52 (6 ref.)
Hepatocyte encapsulation--initial intentions and new aspects for its use in bioartificial liver support. Stange J, et al. **Int J Artif Organs** 1996 Jan;19(1):45-8 (26 ref.)
Cell sources for bioartificial liver support. Stange J, et al. **Int J Artif Organs** 1996 Jan;19(1):14-7 (25 ref.)
Plasma separation for artificial liver support. LePage EB, et al. **J Clin Apheresis** 1995;10(2):70-5
Functional activity of isolated pig hepatocytes attached to different extracellular matrix substrates. Implication for application of pig hepatocytes in a bioartificial liver. te Velde AA, et al. **J Hepatol** 1995 Aug;23(2):184-92
Designer tissues take hold [news] [published erratum appears in Science 1995 Nov 3;270(5237):721] Service RF. **Science** 1995 Oct 13;270(5234):230-2
Hepatic support strategies. Chen S, et al. **Transplant Proc** 1996 Aug;28(4):2036-8
Long survival of xenografted bioartificial pancreas with a mesh-reinforced polyvinyl alcohol hydrogel bag employing a B-cell line (MIN6). Hayashi H, et al. **Transplant Proc** 1996 Jun;28(3):1428-9
Tissue engineering of a bioartificial kidney: a universal donor organ. Humes HD. **Transplant Proc** 1996 Aug;28(4):2032-5 (24 ref.)
Metabolic aspects of cultured hepatocytes for use in a bioartificial liver support system. Waring MA, et al. **Transplant Proc** 1995 Dec;27(6):3572-3
Is a clinical application of hybrid liver support systems limited by an initial disorder in cellular amino acid and alpha-keto acid metabolism, rather than by later gradual loss of primary hepatocyte function? Gerlach JC, et al. **Transplantation** 1996 Jul 27;62(2):224-8
Neointimized Gore-Tex graft for ureteral prosthesis in the dog. Peters JJ, et al. **Urology** 1996 Sep;48(3):379-82
[Pulmonary (side)effects of extracorporeal therapy procedures] Kolb G. **Wien Klin Wochenschr Suppl** 1996; 1:15-20 (42 ref.) **(Ger)**
[Activation of blood coagulation in extracorporeal circulation] Nowak G. **Wien Klin Wochenschr Suppl** 1996; 1:9-14 (28 ref.) **(Ger)**
[Clinical aspects of biocompatibility] Schiffl H, et al. **Wien Klin Wochenschr Suppl** 1996;1:4-8 (27 ref.) **(Ger)**
[An artificial liver on its way to clinical reality?] Thasler WE, et al. **Zentralbl Chir** 1995;120(8):614-23 (82 ref.) (Eng. Abstr.) **(Ger)**
[Pressure changes in the renal pelvis of the dogs in response to a sudden rise in intravesical pressure, examined in the presence of resico ureteral reflux with artificial ureter and/or pelvis] Noro K, et al. **J Smooth Muscle Res** 1996 Feb;32(1):9-16 (Eng. Abstr.) **(Jpn)**
[Treatment of hepatic insufficiency with hepatocyte transplantation and the bioartificial liver] Bojić I. **Vojnosanit Pregl** 1995 May-Jun;52(3):267-70 **(Scr)**

STANDARDS

Who wins in medical lawsuits? [editorial] Glueck J. **Artif Organs** 1995 Aug;19(8):791
Function of culturing monolayer hepatocytes by collagen gel coating and coculture with nonparenchymal cells. Koike M, et al. **Artif Organs** 1996 Feb;20(2):186-92
Development of a bioartificial liver with sandwiched-cultured hepatocytes between two collagen gel layers. Taguchi K, et al. **Artif Organs** 1996 Feb; 20(2):178-85
Effect of ELAD liver support on plasma HGF and TGF-beta 1 in acute liver failure. Miwa Y, et al. **Int J Artif Organs** 1996 Apr;19(4):240-4

TRENDS

Artificial liver. Evolution and future perspectives. Rozga J, et al. **ASAIO J** 1995 Oct-Dec;41(4):831-7 (58 ref.)
The future of artificial organs [editorial] Gurland HJ, et al. **Int J Artif Organs** 1995 Feb;18(2):64-8 (10 ref.)

ARTIFICIAL SKIN see **SKIN, ARTIFICIAL**

ARTIFICIAL SWEETENERS see **SWEETENING AGENTS**

ARTIFICIAL TEARS see **OPHTHALMIC SOLUTIONS**

ARTIFICIAL VENTRICLE see **HEART-ASSIST DEVICES**

ARTIODACTYLA

GENETICS

Differences in the distribution and nature of the interstitial telomeric (TTAGGG)n sequences in the chromosomes of the Giraffidae, okapai (Okapia johnstoni), and giraffe (Giraffa camelopardalis): evidence for ancestral telomeres at the okapi polymorphic rob(5;26) fusion site. Vermeesch JR, et al. **Cytogenet Cell Genet** 1996;72(4):310-5
Pseudogenes in ribonuclease evolution: a source of new biomacromolecular function? Trabesinger-Ruef N, et al. **FEBS Lett** 1996 Mar 18;382(3):319-22
Evolutionary histories of highly repeated DNA families among the Artiodactyla (Mammalia). Modi WS, et al. **J Mol Evol** 1996 Mar;42(3):337-49
Porcine SINE-associated microsatellite markers: evidence for new artiodactyl SINEs. Alexander LJ, et al. **Mamm Genome** 1995 Jul;6(7):464-8
Phylogenetic position of cetaceans relative to artiodactyls: reanalysis of mitochondrial and nuclear sequences. Hasegawa M, et al. **Mol Biol Evol** 1996 May;13(5):710-7

PARASITOLOGY

ITS2 ribosomal RNA indicates Schistosoma hippopotami is a distinct species. Després L, et al. **Int J Parasitol** 1995 Dec;25(12):1509-14
Coccidia of the collared peccary (Tayassu tajacu) in southern Texas with descriptions of three new species of Eimeria (Apicomplexa: Eimeriidae). Wilber PG, et al. **J Parasitol** 1996 Aug;82(4):624-9

VIROLOGY

Morbillivirus infections in wildlife (in relation to their population biology and disease control in domestic animals). Anderson EC. **Vet Microbiol** 1995 May; 44(2-4):319-32

ARVICOLINAE see **MICROTINAE**

ARVICOLINES see **MICROTINAE**

ARYL HYDROCARBON HYDROXYLASES

BIOSYNTHESIS

Relationship between CYP1A enzyme activities and protein levels in rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. DeVito MJ, et al. **J Toxicol Environ Health** 1996 Mar;47(4):379-94

DRUG EFFECTS

Effects of polychlorinated dibenzo-p-dioxin and dibenzofuran congeners in human lymphoblastoid cells on aryl hydrocarbon hydroxylase activity. Kiyohara C, et al. **Chemosphere** 1995 Oct;31(7):3673-80

GENETICS

Mutagenesis study of Asp-290 in cytochrome P450 2B11 using a fusion protein with rat NADPH-cytochrome P450 reductase. Harlow GR, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):85-92
New anthracycline metabolites produced by the aklavinone 11-hydroxylase gene in Streptomyces galilaeus ATCC 31133. Kim HS, et al. **J Antibiot (Tokyo)** 1996 Apr; 49(4):355-60

ISOLATION & PURIFICATION

Purification and properties of a new beta-naphthoflavone inducible cytochrome P-450, aryl hydrocarbon hydroxylase from rat kidney. Ohgiya N, et al. **Biochim Biophys Acta** 1996 Feb 9;1289(1):122-30

METABOLISM

Role of residue 480 in substrate specificity of cytochrome P450 2B5 and 2B11. Liu J, et al. **Arch Biochem Biophys** 1996 Mar 1;327(1):167-73
Dioxins, furans and AHH-active PCB congeners in eggs of two gull species from the western Mediterranean. Pastor D, et al. **Chemosphere** 1995 Sep;31(6):3397-411
New anthracycline metabolites produced by the aklavinone 11-hydroxylase gene in Streptomyces galilaeus ATCC 31133. Kim HS, et al. **J Antibiot (Tokyo)** 1996 Apr; 49(4):355-60
The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Kiyohara C, et al. **Jpn J Cancer Res** 1996 Jan;87(1):18-24

ARYL HYDROCARBON RECEPTORS see **RECEPTORS, ARYL HYDROCARBON**

ARYLAMIDASES see **AMINO ACID NAPHTHYLAMIDASES**

ARYLAMINE ACETYLASES see **ARYLAMINE ACETYLTRANSFERASES**

ARYLAMINE ACETYLTRANSFERASES

ANALYSIS

Evidence for the lack of hepatic N-acetyltransferase in suncus (Suncus murinus). Nakura H, et al. **Biochem Pharmacol** 1995 Oct 12;50(8):1165-70
N-acetyltransferase activity in the quail (Coturnix coturnix jap) duodenum. Hong GX, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):251-5
Identification of arylamine N-acetyltransferase activity in the bovine lens. Gaudet SJ, et al. **Curr Eye Res** 1995 Oct; 14(10):873-7
N-acetyltransferase, hydroxyindole-O-methyltransferase and melatonin in the optic lobes of the giant tiger shrimp Penaeus monodon. Withyachumnarnkul B, et al. **J Pineal Res** 1995 May;18(4):217-21

ANTAGONISTS & INHIBITORS

Sinusoidal 50-Hz magnetic fields depress rat pineal NAT activity and serum melatonin. Role of duration and intensity of exposure. Selmaoui B, et al. **Life Sci** 1995; 57(14):1351-8

BIOSYNTHESIS

Melatonin synthesis: analysis of the more than 150-fold nocturnal increase in serotonin N-acetyltransferase messenger ribonucleic acid in the rat pineal gland. Roseboom PH, et al. **Endocrinology** 1996 Jul;137(7):3033-45

DRUG EFFECTS

Possible involvement of D4-like dopamine receptor in regulation of serotonin N-acetyltransferase activity in duck retina. Zawilska JB, et al. **Pol J Pharmacol** 1995 Jul-Aug; 47(4):345-8

GENETICS

Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Doll MA, et al. **Anal Biochem** 1995 Nov 1;231(2):413-20
The association of polymorphic N-acetyltransferase (NAT2) with breast cancer risk. Ambrosone CB, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:250-2
Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1•10 allele with higher N-acetylation activity in bladder and colon tissue. Bell DA, et al. **Cancer Res** 1995 Nov 15;55(22):5226-9
Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Brockmöller J, et al. **Cancer Res** 1996 Sep 1;56(17):3915-25
Homozygous rapid arylamine N-acetyltransferase (NAT2)

genotype as a susceptibility factor for lung cancer. Cascorbi I, et al. **Cancer Res** 1996 Sep 1;56(17):3961-6
Acetylator genotype (NAT2)-dependent formation of aberrant crypts in congenic Syrian hamsters administered 3,2'-dimethyl-4-aminobiphenyl. Feng Y, et al. **Cancer Res** 1996 Feb 1;56(3):527-31
Metabolic polymorphisms and cancer susceptibility. Smith G, et al. **Cancer Surv** 1995;25:27-65 (249 ref.)
GSTM1 and NAT2 genotypes and urinary mutagens in coke oven workers. Gabbani G, et al. **Carcinogenesis** 1996 Aug; 17(8):1677-81
Environmental air pollution and DNA adducts in Copenhagen bus drivers--effect of GSTM1 and NAT2 genotypes on adduct levels. Nielsen PS, et al. **Carcinogenesis** 1996 May;17(5):1021-7
Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk. Spurr NK, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1864-9
N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Kaufmann GR, et al. **Clin Pharmacol Ther** 1996 Jul;60(1):62-7
Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Mrozikiewicz PM, et al. **Clin Pharmacol Ther** 1996 Apr;59(4):376-82
Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. Nebert DW, et al. **DNA Cell Biol** 1996 Apr;15(4):273-80 (96 ref.)
Arylamine N-acetyltransferases. Expression in Escherichia coli, purification, and substrate specificities of recombinant hamster monomorphic and polymorphic isozymes. Wagner CR, et al. **Drug Metab Dispos** 1996 Feb;24(2):245-53
More on adducts and addicts. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Coggon D. **Hum Exp Toxicol** 1995 Jun;14(6):538-9
A competitive enzyme linked immunosorbent assay for the determination of N-acetyltransferase (NAT2) phenotypes. Wong P, et al. **J Pharm Biomed Anal** 1995 Aug; 13(9):1079-86
Diet, acetylator phenotype, and risk of colorectal neoplasia. Roberts-Thomson IC, et al. **Lancet** 1996 May 18; 347(9012):1372-4
aarD, a Providencia stuartii homologue of cydD: role in 2'-N-acetyltransferase expression, cell morphology and growth in the presence of an extracellular factor. Macinga DR, et al. **Mol Microbiol** 1996 Feb;19(3):511-20
Diurnal variation in mRNA encoding serotonin N-acetyltransferase in pineal gland. Borjigin J, et al. **Nature** 1995 Dec 21-28;378(6559):783-5
Cloning, sequencing and expression of NAT1 and NAT2 encoding genes from rapid and slow acetylator inbred rats. Doll MA, et al. **Pharmacogenetics** 1995 Aug;5(4):247-51
Cloning, expression, and functional characterization of rapid and slow acetylator polymorphic N-acetyl-transferase encoding genes of the Syrian hamster. Ferguson RJ, et al. **Pharmacogenetics** 1996 Feb;6(1):55-66
Lung cancer and mutations at the polymorphic NAT2 gene locus. Martínez C, et al. **Pharmacogenetics** 1995 Aug; 5(4):207-14
A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Wolkenstein P, et al. **Pharmacogenetics** 1995 Aug;5(4):255-8
Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays. Zhao B, et al. **Pharmacogenetics** 1995 Oct;5(5):275-80
The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers. Rothman N, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5084-9
Pineal serotonin N-acetyltransferase: expression cloning and molecular analysis. Coon SL, et al. **Science** 1995 Dec 8; 270(5242):1681-3

ISOLATION & PURIFICATION

Isolation and characterization of an arylalkylamine N-acetyltransferase from Drosophila melanogaster. Hintermann E, et al. **FEBS Lett** 1995 Nov 13; 375(1-2):148-50

METABOLISM

N-acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. Sadrieh N, et al. **Cancer Res** 1996 Jun 15;56(12):2683-7
Human N-acetylation of benzidine: role of NAT1 and NAT2. Zenser TV, et al. **Cancer Res** 1996 Sep 1;56(17):3941-7
Recombinant rat and hamster N-acetyltransferases-1 and -2: relative rates of N-acetylation of arylamines and N,O-acyltransfer with arylhydroxamic acids. Jones RF, et al. **Carcinogenesis** 1996 Aug;17(8):1729-33
Kinetics of acetyl coenzyme A:arylamine N-acetyltransferase from rapid and slow acetylator frog tissues. Ho CC, et al. **Drug Metab Dispos** 1996 Feb;24(2):137-41
Isolation and characterization of an arylalkylamine N-acetyltransferase from Drosophila melanogaster. Hintermann E, et al. **FEBS Lett** 1995 Nov 13; 375(1-2):148-50
A possible relationship between N-acetyltransferase and folate metabolism. Sim E, et al. **Hum Exp Toxicol** 1995 Aug;14(8):696-7
N-acetyltransferase activity--a susceptibility factor in human bladder carcinogenesis. Dewan A, et al. **Indian J Cancer** 1995 Mar;32(1):15-9
(+)-N-allylnormetazocine enhances N-acetyltransferase activity and melatonin synthesis: preliminary evidence for a functional role of sigma receptors in the rat pineal gland. Steardo L, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):845-9
Light-induced suppression of nocturnal serotonin N-acetyltransferase activity in chick pineal gland and retina: a wavelength comparison. Zawilska JB, et al. **J Pineal Res** 1995 Sep;19(2):87-92
Melatonin and arylalkylamine N-acetyltransferase activity in the silkworm, Bombyx mori. Itoh MT, et al. **Mol Cell Endocrinol** 1995 Nov 30;115(1):59-64
Melatonin biosynthesis in photoreceptor-enriched chick retinal cell cultures: role of cyclic AMP in the K(+)-evoked, Ca(2+)-dependent induction of serotonin N-acetyltransferase activity. Gan J, et al. **Neurochem Int** 1995 Aug;27(2):147-55
Arylamine and arylalkylamine N-acetyltransferases in retina, pineal gland, brain and liver of chicks: a comparative study. Nowak JZ, et al. **Neurochem Int** 1995 Sep;27(3):285-97
Differences in arylalkylamine N-acetyltransferase activity between inflammatory disease-susceptible Lewis and -resistant Fischer rats. Mastorakos G, et al. **Neuroendocrinology** 1995 Jul;62(1):71-8
Characterization of the arylalkylamine N-acetyltransferase in Onchocerca volvulus. Aisien SO, et al. **Parasitol Res** 1996;82(4):369-71
Partial characterization of serotonin N - acetyltransferases from northern pike (Esox lucius, L.) pineal organ and retina: effects of temperature. Falcón J, et al. **Pflugers Arch** 1996 Jul;432(3):386-93
The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers. Rothman N, et al. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):5084-9
Mercapturic acid formation in cultured opossum kidney cells. Golenhofen N, et al. **Ren Physiol Biochem** 1995 Jul-Aug; 18(4):191-7

PHARMACOLOGY

N-Acetyltransferase mechanism for alpha-melanocyte stimulating hormone regulation in rat ageing. Cangemi L, et al. **Neurosci Lett** 1995 Dec 1;201(1):65-8

PHYSIOLOGY

Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Badawi AF, et al. **Cancer Res** 1995 Nov 15; 55(22):5230-7

URINE

N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients. Ishizu S, et al. **Jpn J Cancer Res** 1995 Dec;86(12):1179-81

ARYLSULFATASE A see **CEREBROSIDE-SULFATASE**

ARYLSULFATASE B see **CHONDRO-4-SULFATASE**

ARYLSULFATASES

ANALYSIS

[Arylsulfatase] Tajima Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:392-5 (21 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Regulation and inhibition of steroid sulfatase activity in breast cancer. Purohit A, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:40-9 (28 ref.)
Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate. Purohit A, et al. **Biochemistry** 1995 Sep 12;34(36):11508-14
Reversal of scopolamine induced amnesia in rats by the steroid sulfatase inhibitor estrone-3-O-sulfamate. Li PK, et al. **Brain Res Cogn Brain Res** 1995 Oct;2(4):251-4
In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Purohit A, et al. **Int J Cancer** 1995 Sep 27;63(1):106-11

BIOSYNTHESIS

Cloning and expression of the mouse pseudoautosomal steroid sulphatase gene (Sts). Salido EC, et al. **Nat Genet** 1996 May;13(1):83-6

CHEMISTRY

The evolutionary conservation of a novel protein modification, the conversion of cysteine to serinesemialdehyde in arylsulfatase from Volvox carteri. Selmer T, et al. **Eur J Biochem** 1996 Jun 1;238(2):341-5

DEFICIENCY

X-linked ichthyosis without STS deficiency: clinical, genetical, and molecular studies. Robledo R, et al. **Am J Med Genet** 1995 Nov 6;59(2):143-8
Metachromatic leucodystrophy (MLD) in a patient with a constitutional ring chromosome 22. Coulter-Mackie MB, et al. **J Med Genet** 1995 Oct;32(10):787-91

DIAGNOSTIC USE

Enzymatic determination of serum 3 alpha-sulfated bile acids concentration with bile acid 3 alpha-sulfate sulfohydrolase. Kato T, et al. **Dig Dis Sci** 1996 Aug;41(8):1564-70

GENETICS

A study of the steroid sulfatase gene in families with X-linked ichthyosis using polymerase chain reaction. Nomura K, et al. **Acta Derm Venereol** 1995 Sep;75(5):340-2
X-linked ichthyosis without STS deficiency: clinical, genetical, and molecular studies. Robledo R, et al. **Am J Med Genet** 1995 Nov 6;59(2):143-8
The biochemical identification of carrier state in mothers of sporadic cases of X-linked recessive ichthyosis. Cuevas-Covarrubias SA, et al. **Genet Couns** 1995;6(2):103-7
Molecular cloning and site-specific mutagenesis of a gene involved in arylsulfatase production in Campylobacter jejuni. Yao R, et al. **J Bacteriol** 1996 Jun;178(11):3335-8
Arylsulphatase from Alteromonas carrageenovora. Barbeyron T, et al. **Microbiology** 1995 Nov;141 (Pt 11):2897-904
Cloning and expression of the mouse pseudoautosomal steroid sulphatase gene (Sts). Salido EC, et al. **Nat Genet** 1996 May;13(1):83-6
Characterization of the promoter region of human steroid sulfatase: a gene which escapes X inactivation. Li XM, et al. **Somat Cell Mol Genet** 1996 Mar;22(2):105-17
Steroid sulfatase and the Y chromosome hypertensive locus of the spontaneously hypertensive rat. Johnson ML, et al. **Steroids** 1995 Oct;60(10):681-5

METABOLISM

Regulation and inhibition of steroid sulfatase activity in breast cancer. Purohit A, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:40-9 (28 ref.)
Effect of breast cyst fluid on oestrone sulphatase activity in MCF-7 breast cancer cells. Erbas H, et al. **Anticancer Res** 1996 Mar-Apr;16(2):833-6

ARYLSULFATE SULFOHYDROLASES see **ARYLSULFATASES**

ARYLSULFONATES

Fluorescence of eosinophil leucocyte granules induced by 1-hydroxy-3,6,8-pyrenetrisulfonate. Visualization of differences in protein isoelectric points. Trigoso CI, et al. **Histochem Cell Biol** 1995 Jul;104(1):69-73

ARYLSULFONIC ACIDS

New efficient sulfurizing reagents for the preparation of oligodeoxyribonucleotide phosphorothioate analogues. Efimov VA, et al. **Nucleic Acids Res** 1995 Oct 25; 23(20):4029-33

ARYLSULFOTRANSFERASE

ANTAGONISTS & INHIBITORS

Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention. Eaton EA, et al. **Drug Metab Dispos** 1996 Feb;24(2):232-7
Preparation and characterization of anti-peptide antibodies directed against human phenol and hydroxysteroid sulphotransferases. Sharp S, et al. **J Pharmacol Toxicol Methods** 1995 Oct;34(2):89-95

BIOSYNTHESIS

Bacterial expression and kinetic characterization of the human monoamine-sulfating form of phenol sulfotransferase. Ganguly TC, et al. **Drug Metab Dispos** 1995 Sep;23(9):945-50
Human phenol sulfotransferase STP2 gene: molecular cloning, structural characterization, and chromosomal localization. Her C, et al. **Genomics** 1996 May 1; 33(3):409-20
Retinoic acid inhibits hydrocortisone-stimulated expression of phenol sulfotransferase in bovine bronchial epithelial cells. Beckmann JD, et al. **J Cell Physiol** 1996 Feb; 166(2):281-7

BLOOD

Human platelet sulfotransferase shows seasonal rhythms. Marazziti D, et al. **Chronobiol Int** 1995 Apr;12(2):100-5

CHEMISTRY

Structure of sea-urchin arylsufatransferase. Yamada K, et al. **Eur J Biochem** 1996 Mar 15;236(3):1038-9

GENETICS

Characterization of bovine tracheobronchial phenol sulphotransferase cDNA and detection of mRNA

regulation by cortisol. Schauss SJ, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):209–17

Human phenol sulfotransferase STP2 gene: molecular cloning, structural characterization, and chromosomal localization. Her C, et al. **Genomics** 1996 May 1; 33(3):409–20

cDNA cloning and expression of a new form of human aryl sulfotransferase. Zhu X, et al. **Int J Biochem Cell Biol** 1996 May;28(5):565–71

Primary structures and properties of two related forms of aryl sulfotransferases in human liver. Ozawa S, et al. **Pharmacogenetics** 1995;5 Spec No:S135–40

ISOLATION & PURIFICATION

Purification and reaction mechanism of arylsulfate sulfotransferase from Haemophilus K–12, a mouse intestinal bacterium. Lee NS, et al. **J Biochem (Tokyo)** 1995 Oct; 118(4):796–801

METABOLISM

Zonal distribution of sulfotransferase for phenol in olfactory sustentacular cells. Miyawaki A, et al. **EMBO J** 1996 May 1;15(9):2050–5

Reduced platelet phenolsulphotransferase activity towards dopamine and 5–hydroxytryptamine in migraine. Jones AL, et al. **Eur J Clin Pharmacol** 1995;49(1–2):109–14

Photoaffinity labeling of human recombinant sulfotransferases with 2–azidoadenosine 3',5'–[5'–32P]bisphosphate. Radominska A, et al. **J Biol Chem** 1996 Feb 9;271(6):3195–9

ARYTENOID CARTILAGE

Airway obstruction due to arytenoid prolapse in two children [letter] Turner GD, et al. **Anaesthesia** 1996 Aug;51(8):796

Acute laryngeal obstruction in rheumatoid arthritis [see comments] Bossingham DH, et al. **BMJ** 1996 Feb 3; 312(7026):295–6. Comment in: BMJ 1996 May 11;312(7040):1227.

INJURIES

Arytenoid dislocation. Faries PL, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):160–2 (9 ref.)

[Intubation trauma of the larynx—a literature review with special reference to arytenoid cartilage dislocation (see comments)] Rieger A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):281–7 (37 ref.) (Eng. Abstr.). Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Jun;31(5):279–80. **(Ger)**

PATHOLOGY

Unexpected death in a horse with arytenoid chondritis and perilaryngeal lesions. France MP, et al. **Aust Vet J** 1995 Sep;72(9):351–2

[Laser resection of the vocal cord growth of the arytenoid cartilage in the treatment of contact ulcer] Szmeja Z, et al. **Otolaryngol Pol** 1995;49(4):311–3 (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Acquired airway obstruction caused by hypertrophic mucosa of the arytenoids and aryepiglottic folds. Nonomura N, et al. **Am J Otolaryngol** 1996 Jan–Feb;17(1):71–4

Postintubation arytenoid subluxation. Talmi YP, et al. **Ann Otol Rhinol Laryngol** 1996 May;105(5):384–90

SURGERY

Subtotal carbon dioxide laser arytenoidectomy by endoscopic approach for treatment of bilateral cord immobility in adduction. Remacle M, et al. **Ann Otol Rhinol Laryngol** 1996 Jun;105(6):438–45

Evaluation of partial arytenoidectomy as a treatment for equine laryngeal hemiplegia [see comments] Lumsden JM, et al. **Equine Vet J** 1994 Mar;26(2):125–9. Comment in: Equine Vet J 1994 Mar;26(2):92–3.

A comparison of type I thyroplasty and arytenoid adduction. Bielamowicz S, et al. **J Voice** 1995 Dec;9(4):466–72

[Laser resection of the vocal cord growth of the arytenoid cartilage in the treatment of contact ulcer] Szmeja Z, et al. **Otolaryngol Pol** 1995;49(4):311–3 (Eng. Abstr.) **(Pol)**

AS IF PERSONALITY see **PERSONALITY DISORDERS**

ASBESTOS

Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Thoracoscopic and mineralogic study. Boutin C, et al. **Am J Respir Crit Care Med** 1996 Jan; 153(1):444–9

A study of personal and area airborne asbestos concentrations during asbestos abatement: a statistical evaluation of fibre concentration data. Lange JH, et al. **Ann Occup Hyg** 1996 Aug;40(4):449–66

Deposition of inhaled asbestos and man–made mineral fibres in the respiratory tract. Morgan A. **Ann Occup Hyg** 1995 Oct;39(5):747–58 (40 ref.)

Airborne fibre concentrations and lung burden compared to the tumour response in rats and humans exposed to asbestos. Rödelsperger K, et al. **Ann Occup Hyg** 1995 Oct; 39(5):715–25 (27 ref.)

Asbestos contamination in paraffin tissue blocks [letter; comment] Longo WE. **Arch Pathol Lab Med** 1996 Mar; 120(3):225–6. Comment on: Arch Pathol Lab Med 1995 Jun;119(6):528–32.

French minister promises action to clean up asbestos [news] Dorozynski A. **BMJ** 1995 Oct 7;311(7010):898

Malignant tumours of the gastrointestinal tract in an area with an asbestos–cement plant. Sarić M, et al. **Cancer Lett** 1996 Jun 5;103(2):191–9

Clara cell protein (CC–16) and surfactant–associated protein A (SP–A) in asbestos–exposed workers. Lesur O, et al. **Chest** 1996 Feb;109(2):467–74

Occupational exposure to dusts containing asbestos and chronic airways disease. Zejda JE. **Int J Occup Med Environ Health** 1996;9(2):117–25 (50 ref.)

ADVERSE EFFECTS

Malignant peritoneal mesothelioma. Case report and review of the literature. Watteeuw G, et al. **Acta Clin Belg** 1995; 50(4):222–6 (18 ref.)

Occupational respiratory cancer and exposure to asbestos: a case–control study in a cohort of workers in the electricity and gas industry. Imbernon E, et al. **Am J Ind Med** 1995 Sep;28(3):339–52

Mortality among maintenance employees potentially exposed to asbestos in a refinery and petrochemical plant. Tsai SP, et al. **Am J Ind Med** 1996 Jan;29(1):89–98

Asbestos–induced visceral pleural fibrosis reduces pulmonary compliance. Valkila EH, et al. **Am J Ind Med** 1995 Sep; 28(3):363–72

Cancer of the lung, pleura, larynx and pharynx in an area with an asbestos–cement plant. Curin K, et al. **Arh Hig Rada Toksikol** 1995 Sep;46(3):289–300

Distant health effects of using asbestos in shipyards and in co–operating plants. Renke W, et al. **Bull Inst Marit Trop Med Gdynia** 1993–94;44–45(1–4):5–11

Asbestos–related cancer [letter; comment] Genits JF. **CA Cancer J Clin** 1996 Jul–Aug;46(4):254–5. Comment on: CA Cancer J Clin 1996 Mar–Apr;46(2):67–9.

Carcinogens and the workplace [letter; comment] Hawkins R. **CA Cancer J Clin** 1996 Jul–Aug;46(4):255–6. Comment on: CA Cancer J Clin 1996 Mar–Apr;46(2):70–92.

A molecular and epidemiological study on bladder cancer: p53 mutations, tobacco smoking, and occupational exposure to asbestos. Kannio A, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jan;5(1):33–9

Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Wang X, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul–Aug; 4(5):543–8

Mechanisms of carcinogenesis and clinical features of asbestos–associated cancers. Mossman BT, et al. **Cancer Invest** 1996;14(5):466–80 (126 ref.)

In vitro biological effects of clay minerals advised as substitutes for asbestos. Governa M, et al. **Cell Biol Toxicol** 1995 Oct;11(5):237–49

Longitudinal pattern of reported respiratory symptoms and accelerated ventilatory loss in asbestos–exposed workers. Brodkin CA, et al. **Chest** 1996 Jan;109(1):120–6

Expression of genes coding for growth factors in experimental pneumoconiosis. Morris GF, et al. **Chest** 1996 Mar;109(3 Suppl):45S–49S (55 ref.)

Case report: asbestos related pericardial disease. Cooper M, et al. **Clin Radiol** 1996 Sep;51(9):656–7

Asbestos: facts and fiction [letter] Mossman BT. **Environ Health Perspect** 1994 May;102(5):424–6 (20 ref.)

Asbestos–related diseases and asbestos types used in the former GDR. Sturm W, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):173–8

Consequences of long–lasting asbestos–exposure: peripheral blood parameters in shipyard workers with and without asbestosis. Trošić I, et al. **Exp Toxicol Pathol** 1995 May; 47(2–3):212–6

Effects of smoking on respiratory function and exercise performance in asbestos workers. Wang X, et al. **Ind Health** 1995;33(4):173–80

The correlation of chest radiograph and pulmonary function tests in asbestos miners and millers. Dave SK, et al. **Indian J Chest Dis Allied Sci** 1996 Apr–Jun;38(2):81–9

The mesothelial cell and its role in asbestos–induced pleural injury. Kuwahara M, et al. **Int J Exp Pathol** 1995 Jun; 76(3):163–70 (58 ref.)

The origin and development of the asbestos Threshold Limit Value: scientific indifference and corporate influence. Egilman DS, et al. **Int J Health Serv** 1995;25(4):667–96 (98 ref.)

The lack of causality between asbestos and colorectal cancer. Weiss W. **J Occup Environ Med** 1995 Dec;37(12):1364–73

Asbestos exposure and asbestosis [letter; comment] Black JA. **J R Soc Med** 1996 Apr;89(4):240. Comment on: J R Soc Med 1995 Dec;88(12):669–71.

Mesothelioma: is asbestos exposure the only cause? [letter] Gun RT. **Med J Aust** 1995 Sep 18;163(6):334–5

Mesothelioma: is asbestos exposure the only cause? [letter; comment] Kilpatrick DJ. **Med J Aust** 1995 Oct 2;163(7):392 . Comment on: Med J Aust 1995 Apr 17;162(8):429–31. Comment on: Med J Aust 1995 Jul 17;163(2):105–6.

Asbestos and cancer. Albin M, et al. **Med Lav** 1995 May–Jun; 86(3):259–62

Recent data on cancer due to asbestos in Sweden. Englund A. **Med Lav** 1995 Sep–Oct;86(5):435–9

The use of asbestos in Japan and China and malignancy related findings. Frank AL. **Med Lav** 1995 Sep–Oct; 86(5):457–60

Asbestos mineralogic analysis as indicator of carcinogenic risk. Frank AL. **Med Lav** 1995 Sep–Oct;86(5):490–5

Asbestos and cancer in Finland. Huuskonen MS, et al. **Med Lav** 1995 Sep–Oct;86(5):426–34

Mesotheliomas following exposure to asbestos used in railroads: 130 Italian cases. Maltoni C, et al. **Med Lav** 1995 Sep–Oct;86(5):461–77

Mesotheliomas following exposure to asbestos used in sugar refineries: report of 12 Italian cases. Maltoni C, et al. **Med Lav** 1995 Sep–Oct;86(5):478–83

European multicentric case control study on risk for mesothelioma after non–occupational (domestic and environmental) exposure to asbestos. Mollo F, et al. **Med Lav** 1995 Sep–Oct;86(5):496–500

Recent data on cancer due to asbestos in the U.S.A. and Denmark. Nicholson WJ, et al. **Med Lav** 1995 Sep–Oct; 86(5):393–410

Ignored occupational risks of asbestos mesotheliomas. Pinto C, et al. **Med Lav** 1995 Sep–Oct;86(5):484–9

Recent data on cancer due to asbestos in Germany. Rösler JA, et al. **Med Lav** 1995 Sep–Oct;86(5):440–8

Malignant mesothelioma associated with low pulmonary tissue asbestos burdens: a light and scanning electron microscopic analysis of 18 cases. Srebro SH, et al. **Mod Pathol** 1995 Aug;8(6):614–21

Survival in cohorts of asbestos cement workers and controls. Albin M, et al. **Occup Environ Med** 1996 Feb;53(2):87–93

Lung cancer in asbestos cement workers in Denmark. Raffn E, et al. **Occup Environ Med** 1996 Jun;53(6):399–402

Vermiculite: a review of the mineralogy and health effects of vermiculite exploitation. Addison J. **Regul Toxicol Pharmacol** 1995 Jun;21(3):397–405 (74 ref.)

Pleural mesothelioma with non–Hodgkin's lymphoma [letter] Hughes P, et al. **Thorax** 1995 Aug;50(8):915

A case study in avoiding a deadly legacy in developing countries. Lemen RA, et al. **Toxicol Ind Health** 1994 Jan–Apr;10(1–2):59–87 (210 ref.)

[Epidemiology of malignant pleural mesothelioma in the Nantes–Saint Nazaire region. Course in 1956–1992] Chailleux E, et al. **Rev Mal Respir** 1995;12(4):353–7 (Eng. Abstr.) **(Fre)**

[Are artificial mineral fibers harmful to health and unsuitable for asbestos substitute?] Rüegger M. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):961–6 (Eng. Abstr.) **(Ger)**

[Malignant peritoneal mesothelioma: its relation to asbestos] Pentimone F, et al. **Minerva Med** 1995 Oct;86(10):439–43 (38 ref.) (Eng. Abstr.) **(Ita)**

[Epidemiologic survey of pleural plaques among inhabitants of Matsubase exposed to asbestos] Hiraoka T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr; 34(4):385–91 (Eng. Abstr.) **(Jpn)**

[Exposure to asbestos and levels of selected tumor biomarkers] Krajewska B, et al. **Med Pr** 1996;47(2):89–96 (Eng. Abstr.) **(Pol)**

[Sanitary–hygienic regulations of the utilization of asbestos production waste in railway facilities] Shterengartz RIa, et al. **Gig Sanit** 1995 Sep–Oct;(5):55–7 (Eng. Abstr.) **(Rus)**

[Adverse effects of ergot alkaloids. An important differential diagnosis from asbestos–induced pleuritis] Blomqvist A, et al. **Lakartidningen** 1996 May 29;93(22):2163–4 **(Swe)**

ANALYSIS

A laboratory method for generation of replicate filter samples of asbestos fibers in air. Skogstad A, et al. **Am Ind Hyg Assoc J** 1996 Aug;57(8):741–5

Asbestos exposure and ovarian fiber burden. Heller DS, et al. **Am J Ind Med** 1996 May;29(5):435–9

The use of a new static device based on the collection of the thoracic fraction for the assessment of the airborne concentration of asbestos fibres by transmission electron microscopy. Kauffer E, et al. **Ann Occup Hyg** 1996 Jun; 40(3):311–9

Evaluation of lift and passive sampling methods during asbestos abatement activities. Lange JH, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):325–31

A total sample preparation method for the measurement of airborne asbestos and other fibers by optical and electron microscopy. Kohyama N, et al. **Ind Health** 1996; 34(3):185–203

Asbestos mineralogic analysis as indicator of carcinogenic risk. Frank AL. **Med Lav** 1995 Sep–Oct;86(5):490–5

Pulmonary asbestos bodies and asbestos fibers as indicators of exposure. Karjalainen A, et al. **Scand J Work Environ Health** 1996 Feb;22(1):34–8

[Occupational exposure to asbestos in removal and protective treatment of roof coverings] Maino A, et al. **Med Lav** 1995 Nov–Dec;86(6):546–554 (Eng. Abstr.) **(Ita)**

[Exposure to mineral fibers in selected ceramics plants] Woźniak H, et al. **Med Pr** 1995;46(4):327–36 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Vermiculite: a review of the mineralogy and health effects of vermiculite exploitation. Addison J. **Regul Toxicol Pharmacol** 1995 Jun;21(3):397–405 (74 ref.)

[Relationship between the physiochemical properties of asbestos and pulmonary fibrosis] Wrzaszczyk B, et al.

Med Pr 1996;47(4):401–9 (39 ref.) (Eng. Abstr.) **(Pol)**

HISTORY

[The diffusion of information on the carcinogenicity of asbestos in the Italian scientific community before 1965] Carnevale F, et al. **Med Lav** 1995 Jul–Aug;86(4):295–302 (Eng. Abstr.) **(Ita)**

TOXICITY

Up-regulated expression of transforming growth factor-alpha in the bronchiolar-alveolar duct regions of asbestos-exposed rats. Liu JY, et al. **Am J Pathol** 1996 Jul; 149(1):205–17

Participation of nitric oxide and iron in the oxidation of DNA in asbestos-treated human lung epithelial cells. Chao CC, et al. **Arch Biochem Biophys** 1996 Feb 1;326(1):152–7

Mesothelioma, asbestos, and reported history of cancer in first-degree relatives. Heineman EF, et al. **Cancer** 1996 Feb 1;77(3):549–54

Role of fibre characteristics on cytotoxicity and induction of anaphase/telophase aberrations in rat pleural mesothelial cells in vitro: correlations with in vivo animal findings. Yegles M, et al. **Carcinogenesis** 1995 Nov;16(11):2751–8

Synthesis of poly(ADP-ribose) in asbestos treated rat pleural mesothelial cells in culture. Dong HY, et al. **Mutat Res** 1995 Oct;331(2):197–204

Increased neutrophil adherence to endothelial cells exposed to asbestos. Treadwell MD, et al.
Toxicol Appl Pharmacol 1996 Jul;139(1):62–70

ASBESTOS, AMOSITE

ADVERSE EFFECTS

Enhancement of the macrophage oxidative burst by immunoglobulin coating of respirable fibers: fiber-specific differences between asbestos and man-made fibers. Hill IM, et al. **Exp Lung Res** 1996 Mar–Apr;22(2):133–48

METABOLISM

Bromo-deoxyuridine (BRDU) uptake in the lungs of rats inhaling amosite asbestos or vitreous fibres at equal airborne fibre concentrations. Donaldson K, et al.
Exp Toxicol Pathol 1995 May;47(2–3):207–11

PHARMACOLOGY

Effects of cigarette smoke and asbestos on airway, vascular and mesothelial cell proliferation. Sekhon H, et al.
Int J Exp Pathol 1995 Dec;76(6):411–8

TOXICITY

Effect of long and short fibre amosite asbestos on in vitro TNF production by rat alveolar macrophages: the modifying effect of lipopolysaccharide. Dogra S, et al.
Ind Health 1995;33(3):131–41

Cytogenetic and pathogenic effects of long and short amosite asbestos. Donaldson K, et al. **J Pathol** 1995 Nov; 177(3):303–7

Phytic acid, an iron chelator, attenuates pulmonary inflammation and fibrosis in rats after intratracheal instillation of asbestos. Kamp DW, et al. **Toxicol Pathol** 1995 Nov–Dec;23(6):689–95

ASBESTOS, AMPHIBOLE

ADVERSE EFFECTS

The amphibole hypothesis of asbestos-related cancer—gone but not forgotten [editorial] Cullen MR.
Am J Public Health 1996 Feb;86(2):158–9

Occupational exposure to chrysotile asbestos and cancer risk: a review of the amphibole hypothesis. Stayner LT, et al. **Am J Public Health** 1996 Feb;86(2):179–86 (72 ref.)

[Potential role of environmental and domestic exposure to tremolite in pleural cancer in New Caledonia] Goldberg P, et al. **Rev Epidemiol Sante Publique** 1995;43(5):444–50 (Eng. Abstr.) **(Fre)**

TOXICITY

In vivo studies on genotoxicity and cogenotoxicity of ingested UICC anthophyllite asbestos. Varga C, et al.
Cancer Lett 1996 Aug 2;105(2):181–5

ASBESTOS, CROCIDOLITE

Alveolar macrophage cytokine and growth factor production in a rat model of crocidolite-induced pulmonary inflammation and fibrosis. Driscoll KE, et al.
J Toxicol Environ Health 1995 Oct;46(2):155–69

ADVERSE EFFECTS

Studies on genotoxicity of orally administered crocidolite asbestos in rats: implications for ingested asbestos induced carcinogenesis. Varga C, et al. **Anticancer Res** 1996 Mar–Apr;16(2):811–4

Malignant mesothelioma in Pilbara Aborigines. Musk AW, et al. **Aust J Public Health** 1995 Oct;19(5):520–2 (10 ref.)

Chrysotile and crocidolite asbestos in Israel: uses, exposures and risks. Richter ED, et al. **Med Lav** 1995 Sep–Oct; 86(5):449–56

Exposure to crocidolite and the incidence of different histological types of lung cancer. de Klerk NH, et al.
Occup Environ Med 1996 Mar;53(3):157–9

Occupational and environmental mesotheliomas due to crocidolite mining activities in Wittenoom, Western Australia. Rogers A, et al.
Scand J Work Environ Health 1995 Aug;21(4):259–64

ANALYSIS

Asbestos bodies in lung tissue following exposure to crocidolite. Williams V, et al. **Am J Ind Med** 1995 Oct; 28(4):489–95

METABOLISM

Vitronectin enhances internalization of crocidolite asbestos by rabbit pleural mesothelial cells via the integrin alpha v beta 5. Boylan AM, et al. **J Clin Invest** 1995 Oct; 96(4):1987–2001

PHARMACOKINETICS

Biopersistence of man-made vitreous fibers and crocidolite asbestos in the rat lung following inhalation. Hesterberg TW, et al. **Fundam Appl Toxicol** 1996 Feb;29(2):269–79

PHARMACOLOGY

Apoptosis is observed in mesothelial cells after exposure to crocidolite asbestos. BéruBé KA, et al.
Am J Respir Cell Mol Biol 1996 Jul;15(1):141–7

TOXICITY

Fibre-induced lipid peroxidation leads to DNA adduct formation in Salmonella typhimurium TA104 and rat lung fibroblasts. Howden PJ, et al. **Carcinogenesis** 1996 Mar; 17(3):413–9

Comparative proliferative and histopathologic changes in rat lungs after inhalation of chrysotile or crocidolite asbestos. BéruBé KA, et al. **Toxicol Appl Pharmacol** 1996 Mar; 137(1):67–74

Short-term crocidolite inhalation studies in mice: validation of an inhalation chamber. Rihn B, et al. **Toxicology** 1996 May 17;109(2–3):147–56

ASBESTOS, SERPENTINE

Pollution and its control in asbestos milling processes in India. Mukherjee AK, et al. **Ind Health** 1996;34(1):35–43

ADVERSE EFFECTS

Occupational exposure to chrysotile asbestos and cancer risk: a review of the amphibole hypothesis. Stayner LT, et al. **Am J Public Health** 1996 Feb;86(2):179–86 (72 ref.)

Chrysotile asbestos induces PDGF-A chain-dependent proliferation in human and rat lung fibroblasts in vitro. Lasky JA, et al. **Chest** 1996 Mar;109(3 Suppl):26S–28S

Chrysotile and crocidolite asbestos in Israel: uses, exposures and risks. Richter ED, et al. **Med Lav** 1995 Sep–Oct; 86(5):449–56

ANALYSIS

An individual with a majority of ferruginous bodies formed on chrysotile cores. Levin JL, et al.
Arch Environ Health 1995 Nov–Dec;50(6):462–5

Release of asbestos fibers during casting ring liner manipulation. Davis DR. **J Prosthet Dent** 1995 Sep; 74(3):294–8

PHARMACOLOGY

[Lipid peroxidation in the presence of inorganic compounds. Relation to oxidative stress mechanisms] Fournier J, et al. **C R Seances Soc Biol Fil** 1995;189(3):429–42 (36 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Fibre-induced lipid peroxidation leads to DNA adduct formation in Salmonella typhimurium TA104 and rat lung fibroblasts. Howden PJ, et al. **Carcinogenesis** 1996 Mar; 17(3):413–9

Distinctive profile of alveolar macrophage-derived cytokine release induced by fibrogenic and nonfibrogenic mineral dusts. Lemaire I, et al. **J Toxicol Environ Health** 1996 Apr 5;47(5):465–78

Comparative proliferative and histopathologic changes in rat lungs after inhalation of chrysotile or crocidolite asbestos. BéruBé KA, et al. **Toxicol Appl Pharmacol** 1996 Mar; 137(1):67–74

[Comparison of toxic effects of brucite and aluminium-treated chrysotile on macrophage] Guo C, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul; 29(4):219–21 (Eng. Abstr.) **(Chi)**

ASBESTOSIS

Asbestos bodies in lung tissue following exposure to crocidolite. Williams V, et al. **Am J Ind Med** 1995 Oct; 28(4):489–95

Asbestos-related bilateral diffuse pleural thickening: natural history of radiographic and lung function abnormalities. Yates DH, et al. **Am J Respir Crit Care Med** 1996 Jan; 153(1):301–6

Asbestos exposure and asbestosis: clarifying terminology and avoiding confusion [see comments] Woodard PK, et al. **J R Soc Med** 1995 Dec;88(12):669–71 (19 ref.). Comment in: J R Soc Med 1996 Apr;89(4):240.

Medical and public health approaches to asbestos disease. Frank AL. **Mt Sinai J Med** 1995 Oct;62(5):401–5

New developments in asbestos-related pleural disease. Rudd RM. **Thorax** 1996 Feb;51(2):210–6 (59 ref.)

[Liability in occupational asbestosis and its harmful sequelae] Kurajica L, et al. **Arh Hig Rada Toksikol** 1995 Dec; 46(4):451–7 (Eng. Abstr.) **(Scr)**

BLOOD

The molecular epidemiology of oncoproteins. Serum p53 protein in patients with asbestosis. Hemminki K, et al.
Chest 1996 Mar;109(3 Suppl):22S–26S

Serum oncoproteins in asbestosis patients. Partanen R, et al.
Clin Chem 1995 Dec;41(12 Pt 2):1844–7

Consequences of long-lasting asbestos-exposure: peripheral blood parameters in shipyard workers with and without asbestosis. Trošić I, et al. **Exp Toxicol Pathol** 1995 May; 47(2–3):212–6

CLASSIFICATION

Asbestos exposure and asbestosis [letter; comment] Black JA. **J R Soc Med** 1996 Apr;89(4):240. Comment on: J R Soc Med 1995 Dec;88(12):669–71.

COMPLICATIONS

Carcinosarcoma of lung associated with asbestosis. Farrell DJ, et al. **Histopathology** 1995 Nov;27(5):484–6

The association of occupational asbestos dust exposure and laryngeal carcinoma [see comments] Kraus T, et al.
Isr J Med Sci 1995 Sep;31(9):540–8 (76 ref.). Comment in: Isr J Med Sci 1995 Sep;31(9):563–4.

Lung cancer latency and asbestos liability. Mustacchi P.
J Leg Med 1996 Jun;17(2):277–300

[Asbestos-associated cancer as an occupational disease] Leino T, et al. **Duodecim** 1994;110(18):1713–7 **(Fin)**

DIAGNOSIS

Mesothelioma as a risk indicator of asbestos exposure: the role of the pathologist. Zampi G, et al. **Med Lav** 1995 Sep–Oct;86(5):389–92

[Standardization of diagnostic criteria for occupational asbestosis of the lungs and lung parenchyma] Vujović M. **Arh Hig Rada Toksikol** 1995 Dec;46(4):445–9 (Eng. Abstr.) **(Scr)**

[Criteria for diagnosis of occupational asbestosis of the pulmonary parenchyma and pleura] Zavalić M, et al.
Arh Hig Rada Toksikol 1995 Dec;46(4):433–44 (Eng. Abstr.) **(Scr)**

EPIDEMIOLOGY

Asbestos-related diseases and asbestos types used in the former GDR. Sturm W, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):173–8

Updating the epidemiology of asbestos disease. Symposium proceedings. Carpi, Italy, October 30, 1994. **Med Lav** 1995 Sep–Oct;86(5):388–500

Asbestos and cancer in Finland. Huuskonen MS, et al.
Med Lav 1995 Sep–Oct;86(5):426–34

Asbestos related disease in the United States. Lemen RA.
Med Lav 1995 Sep–Oct;86(5):411–25

Occupational and environmental mesotheliomas due to crocidolite mining activities in Wittenoom, Western Australia. Rogers A, et al.
Scand J Work Environ Health 1995 Aug;21(4):259–64

[Epidemiologic survey of pleural plaques among inhabitants of Matsubase exposed to asbestos] Hiraoka T, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1996 Apr; 34(4):385–91 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

The use of asbestos in Japan and China and malignancy related findings. Frank AL. **Med Lav** 1995 Sep–Oct; 86(5):457–60

Chrysotile and crocidolite asbestos in Israel: uses, exposures and risks. Richter ED, et al. **Med Lav** 1995 Sep–Oct; 86(5):449–56

[Occupational exposure to asbestos in removal and protective treatment of roof coverings] Maino A, et al. **Med Lav** 1995 Nov–Dec;86(6):546–554 (Eng. Abstr.) **(Ita)**

[Sanitary-hygienic regulations of the utilization of asbestos production waste in railway facilities] Shterengartz RIa, et al. **Gig Sanit** 1995 Sep–Oct;(5):55–7 (Eng. Abstr.) **(Rus)**

GENETICS

Asbestos and mesothelioma: genetic lessons from a tragedy [comment] Knudson A. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10819–20 (21 ref.). Comment on: Proc Natl Acad Sci U S A 1995 Nov 21;92(24):10854–8.

HISTORY

Mesotheliomas all: long before their time [editorial] Logan JS, et al. **Ulster Med J** 1996 May;65(1):1–2

ASBESTOSIS

IMMUNOLOGY

Alveolar macrophage cytokine and growth factor production in a rat model of crocidolite-induced pulmonary inflammation and fibrosis. Driscoll KE, et al. **J Toxicol Environ Health** 1995 Oct;46(2):155–69

[Study on correlation between chest X-P course findings and change in antinuclear antibody in asbestos plant employees] Tamura M, et al. **Sangyo Eiseigaku Zasshi** 1996 May; 38(3):138–41 (Eng. Abstr.) **(Jpn)**

METABOLISM

Clara cell protein (CC-16) and surfactant-associated protein A (SP-A) in asbestos-exposed workers. Lesur O, et al. **Chest** 1996 Feb;109(2):467–74

Oxidized BAL fluid proteins in patients with interstitial lung diseases. Lenz AG, et al. **Eur Respir J** 1996 Feb;9(2):307–12

Elevated interleukin-8 in the alveolitis of individuals with asbestos exposure. Broser M, et al. **Int Arch Occup Environ Health** 1996;68(2):109–14

MORTALITY

Differences in occupational mortality from pleural cancer, peritoneal cancer, and asbestosis. Coggon D, et al. **Occup Environ Med** 1995 Nov;52(11):775–7

PATHOLOGY

Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Thoracoscopic and mineralogic study. Boutin C, et al. **Am J Respir Crit Care Med** 1996 Jan; 153(1):444–9

Causes of pulmonary impairment in asbestos-exposed individuals with diffuse pleural thickening. Kee ST, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):789–93

Autopsy evaluation of asbestos exposure: retrospective study of 135 cases with quantitation of ferruginous bodies in digested lung tissue. King JA, et al. **South Med J** 1996 Apr;89(4):380–5

Phytic acid, an iron chelator, attenuates pulmonary inflammation and fibrosis in rats after intratracheal instillation of asbestos. Kamp DW, et al. **Toxicol Pathol** 1995 Nov-Dec;23(6):689–95

PHYSIOPATHOLOGY

Lung function and respiratory symptoms related to changes in smoking habits in asbestos-exposed subjects. Waage HP, et al. **J Occup Environ Med** 1996 Feb;38(2):178–83

PREVENTION & CONTROL

Finnish Institute of Occupational Health Asbestos Program 1987–1992. Huuskonen MS, et al. **Am J Ind Med** 1995 Jul; 28(1):123–42

The use of a new static device based on the collection of the thoracic fraction for the assessment of the airborne concentration of asbestos fibres by transmission electron microscopy. Kauffer E, et al. **Ann Occup Hyg** 1996 Jun; 40(3):311–9

Phytic acid, an iron chelator, attenuates pulmonary inflammation and fibrosis in rats after intratracheal instillation of asbestos. Kamp DW, et al. **Toxicol Pathol** 1995 Nov-Dec;23(6):689–95

RADIOGRAPHY

Clinical problem-solving: diverted by the chief complaint [letter] Anderson K. **N Engl J Med** 1995 Nov 23; 333(21):1425

[Longitudinal study of radiologic anomalies in subjects working in asbestos-insulated buildings] Pierre N, et al. **Rev Epidemiol Sante Publique** 1995;43(5):432–43 (Eng. Abstr.) **(Fre)**

[Study on correlation between chest X-P course findings and change in antinuclear antibody in asbestos plant employees] Tamura M, et al. **Sangyo Eiseigaku Zasshi** 1996 May; 38(3):138–41 (Eng. Abstr.) **(Jpn)**

ASCARIASIS

Biliary ascariasis. A case report. Sarihan H, et al. **Turk J Pediatr** 1995 Oct-Dec;37(4):399–402

[Hepatic ascariasis] Nakasaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):58–60 (16 ref.) **(Jpn)**

[Intragallbladder ascariasis] Nakazawa O, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):464–7 (11 ref.) **(Jpn)**

[Biliopancreatic ascariasis: an infrequent disease in our environment] de la Cruz Alvarez J, et al. **Gastroenterol Hepatol** 1996 Apr;19(4):210–2 (Eng. Abstr.) **(Spa)**

[Unusual ingestion of a nasogastric tube by Ascaris lumbricoides] Bustamante-Sarabia J, et al. **Rev Gastroenterol Mex** 1996 Jan-Mar;61(1):38–42 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Ascaris lumbricoides infestation as a cause of intestinal obstruction in children: experience with 87 cases. Villamizar E, et al. **J Pediatr Surg** 1996 Jan;31(1):201–4; discussion 204–5

Can Ascaris suum cause visceral larva migrans? [letter] Petithory JC. **Lancet** 1996 Sep 7;348(9028):689

Effect of removing Ascaris on the growth of Guatemalan schoolchildren. Watkins WE, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):871–6

Ascaris and Trichuris do not contribute to growth retardation in primary school children. Lai KP, et al. **Southeast Asian J Trop Med Public Health** 1995 Jun; 26(2):322–8

[Surgical complications of intestinal ascariasis] Yousri B, et al. **J Chir (Paris)** 1995 Oct;132(10):399–402 (Eng. Abstr.) **(Fre)**

[Cholecystolithiasis with ascariasis] Shibayama K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):391–3 (19 ref.) **(Jpn)**

[Acute pancreatitis caused by Ascaris lumbricoides in acute renal failure: case report] Morović-Vergles J, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:87–8 (Eng. Abstr.) **(Scr)**

DIAGNOSIS

Acute pancreatitis caused by biliary ascaris in pregnancy. Asrat T, et al. **J Perinatol** 1995 Jul-Aug;15(4):330–2 (15 ref.)

Index of suspicion. Case 1. Toxocara canis and Ascaris infection with lead poisoning] Kidd J, et al. **Pediatr Rev** 1995 Nov;16(11):433, 434

[A case of unilateral eyelid edema in ascariasis] Stawowski R, et al. **Klin Oczna** 1995 Nov-Dec;97(11–12):346–7 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Vitamin A status of Indonesian children infected with Ascaris lumbricoides after dosing with vitamin A supplements and albendazole. Tanumihardjo SA, et al. **J Nutr** 1996 Feb; 126(2):451–7

Selective treatment and targeted chemotherapy: effect on prevalence and intensity of infection for two intestinal helminths in Nepalese children. Curtale F. **Panminerva Med** 1995 Dec;37(4):214–9

Effect of removing Ascaris on the growth of Guatemalan schoolchildren. Watkins WE, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):871–6

The effect of targeted chemotherapy against ascariasis on the height of children in rural Myanmar. Hlaing T. **Trans R Soc Trop Med Hyg** 1994 Jul-Aug;88(4):433

The effects of deworming on indicators of school performance in Guatemala. Watkins WE, et al. **Trans R Soc Trop Med Hyg** 1996 Mar-Apr;90(2):156–61

EPIDEMIOLOGY

Ascaris lumbricoides infection and environmental risk factors in an urban African setting. Tshikuka JG, et al. **Ann Trop Med Parasitol** 1995 Oct;89(5):505–14

Epidemiology of human hookworm and Ascaris lumbricoides infestations in rural Gambia. Palmer DR, et al. **East Afr Med J** 1995 Aug;72(8):527–30

Intensity of infection and reinfection rate of A. lumbricoides in a rural farming village, Dembia district, northwest Ethiopia. Dagnew M, et al. **Ethiop Med J** 1995 Oct; 33(4):243–9

Ascaris lumbricoides aggregation in relation to child growth status, delayed cutaneous hypersensitivity, and plant anthelmintic use in Madagascar. Kightlinger LK, et al. **J Parasitol** 1996 Feb;82(1):25–33

Intestinal helminths and xerophthalmia in Nepal. A case-control study. Curtale F, et al. **J Trop Pediatr** 1995 Dec;41(6):334–7

An outbreak of visceral larva migrans due to Ascaris suum in Kyushu, Japan [letter] Maruyama H, et al. **Lancet** 1996 Jun 22;347(9017):1766–7

Estimating the number of multiple-species geohelminth infections in human communities. Booth M, et al. **Parasitology** 1995 Dec;111 (Pt 5):645–53

Helminth infections, morbidity indicators and schistosomiasis treatment history in three villages, Dongting Lake region, PR China. Booth M, et al. **Trop Med Int Health** 1996 Aug; 1(4):464–74

[The effect of different factors on the epidemic process in ascariasis (exemplified by Tula Province)] Oshevskaia ZA. **Med Parazitol (Mosk)** 1995 Jul-Sep;(3):28–31 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Effect of mercury on the immune response and mean intensity of Ascaris suum infection in guinea pigs. Borošková Z, et al. **J Helminthol** 1995 Sep;69(3):187–94

Antibody isotype responses to antigens of Ascaris lumbricoides in a case-control study of persistently heavily infected Bangladeshi children. Palmer DR, et al. **Parasitology** 1995 Sep;111 (Pt 3):385–93

Nutritional status and the IgE response against Ascaris lumbricoides in children from a tropical slum. Hagel I, et al. **Trans R Soc Trop Med Hyg** 1995 Sep-Oct;89(5):562–5

[The effect of copper on immune responses in guinea pigs with experimental ascariasis] Borošková Z, et al. **Vet Med (Praha)** 1996 Jan;41(1):13–8 (Eng. Abstr.) **(Slo)**

PARASITOLOGY

Endoscopic treatment of biliary ascariasis. Report of a case. Valgaeren G, et al. **Acta Clin Belg** 1996;51(2):97–100

Ascariasis of the kidney. Taylor KL. **Pediatr Pathol Lab Med** 1995 Jul-Aug;15(4):609–15

PATHOLOGY

Ascariasis of the kidney. Taylor KL. **Pediatr Pathol Lab Med** 1995 Jul-Aug;15(4):609–15

[Interstitial nephritis with acute renal failure in Ascaris lumbricoides infection] Meister P, et al. **Pathologe** 1995 Nov;16(6):434–8 (16 ref.) (Eng. Abstr.) **(Ger)**

[A histological and electron microscopic study of the kidneys in migrating ascariasis] Chebyshev NV, et al. **Med Parazitol (Mosk)** 1996 Jan-Mar;(1):37–40 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

A cost-effectiveness analysis of anthelminthic intervention for community control of soil-transmitted helminth infection: levamisole and Ascaris lumbricoides. Holland CV, et al. **J Parasitol** 1996 Aug;82(4):527–30

Targeted anthelminthic treatment of school children: effect of frequency of application on the intensity of Ascaris lumbricoides infection in children from rural Nigerian villages. Holland CV, et al. **Parasitology** 1996 Jul;113 (Pt 1):87–95

RADIOGRAPHY

CT diagnosis of intestinal ascariasis. Hommeyer SC, et al. **Abdom Imaging** 1995 Jul-Aug;20(4):315–6

CT identification of ascaris in the biliary tract. Rocha M de S, et al. **Abdom Imaging** 1995 Jul-Aug;20(4):317–9

SURGERY

Surgical management of worm volvulus. Madiba TE, et al. **S Afr J Surg** 1996 Feb;34(1):33–5; discussion 35–6

ULTRASONOGRAPHY

Ultrasound in the diagnosis of gallbladder ascariasis. Filice C, et al. **Abdom Imaging** 1995 Jul-Aug;20(4):320–2

Residents' corner: Answer to case of the month #37. Hepatic ascariasis. Clark T, et al. **Can Assoc Radiol J** 1996 Jun; 47(3):220–2

Sonography of hepatobiliary ascariasis. Ali M, et al. **J Clin Ultrasound** 1996 Jun;24(5):235–41

Biliary ascariasis: ultrasound diagnosis. Mehta P, et al. **J Clin Ultrasound** 1995 Oct;23(8):500–1

Ultrasonographic diagnosis of intestinal ascariasis. Ozmen MN, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S171–2

VETERINARY

Comparison of two methods for recovering migrating Ascaris suum larvae from the liver and lungs of pigs. Slotved HC, et al. **J Parasitol** 1996 Aug;82(4):612–5

The effect of two types of diet on populations of Ascaris suum and Oesophagostomum dentatum in experimentally infected pigs. Petkevicius S, et al. **Parasitology** 1995 Sep; 111 (Pt 3):395–401

Study on a new egg count technique for Macracanthorhynchus hirudinaceus and Ascaris suum. Dangjin L. **Vet Parasitol** 1996 Jan;61(1–2):113–7

The distribution of Parascaris equorum eggs in the soil profile of bare paddocks in some Norwegian studs. Ihler CF. **Vet Res Commun** 1995;19(6):495–501

ASCARIDIA

Content of some microelements in chickens with ascaridiasis under combined drug treatment. Damyanova A, et al. **Parasitol Res** 1995;81(7):549–52

ENZYMOLOGY

Purification and characterization of prostaglandin-H E-isomerase, a sigma-class glutathione S-transferase, from Ascaridia galli. Meyer DJ, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):223–7

METABOLISM

A novel membrane glycoprotein involved in ascidian hemocyte aggregation and phagocytosis. Takahashi H, et al. **Eur J Biochem** 1995 Nov 1;233(3):778–83

PHYSIOLOGY

Ascaridia dissimilis larval migration associated with enteritis and low market weights in meat turkeys. Willoughby DH, et al. **Avian Dis** 1995 Oct-Dec;39(4):837–43

ASCARIDIA GALLI see **ASCARIDIA**

ASCARIDIASIS

DRUG THERAPY

Content of some microelements in chickens with ascaridiasis under combined drug treatment. Damyanova A, et al. **Parasitol Res** 1995;81(7):549–52

METABOLISM

Content of some microelements in chickens with ascaridiasis under combined drug treatment. Damyanova A, et al.

Parasitol Res 1995;81(7):549–52

VETERINARY

Ascaridia dissimilis larval migration associated with enteritis and low market weights in meat turkeys. Willoughby DH, et al. **Avian Dis** 1995 Oct–Dec;39(4):837–43

[Activity of alpha-amylase, trypsin and lipase in pancreas and duodenal contents of Ascaridia galli infected chickens fed with various proteins] Zółtowska K, et al. **Wiad Parazytol** 1995;41(2):217–20 (Eng. Abstr.) **(Pol)**

[The influence of various levels of carotene and protein in the diet on the index of invasion and digestive enzyme activity in chickens infected with Ascaridia galli] Zółtowska K, et al. **Wiad Parazytol** 1996;42(1):65–9 (Eng. Abstr.) **(Pol)**

ASCARIDIDA

CHEMISTRY

Comparative SDS-page protein patterns of four ascaridid nematodes. Ashour AA, et al. **J Egypt Soc Parasitol** 1995 Dec;25(3):761–7

DRUG EFFECTS

[Structural disorders in the tissues of nematodes of the suborder Ascaridata after exposure to anthelmintics] Bogoiavlenskiĭ IuK, et al. **Med Parazitol (Mosk)** 1995 Apr–Jun;(2):19–27 (30 ref.) (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Nucleolar cycle and localization of NORs in early embryos of Parascaris univalens. González-García JM, et al. **Chromosoma** 1995 Dec;104(4):287–97

ISOLATION & PURIFICATION

Ocular larva migrans and histopathological lesions in mice experimentally infected with Baylisascaris transfuga embryonated eggs. Papini R, et al. **Vet Parasitol** 1996 Feb; 61(3–4):315–20

PHYSIOLOGY

Egg deposition of the intestinal nematode Heterakis spumosa: stimulation by soluble colon factors of mice. Harder A, et al. **J Parasitol** 1995 Oct;81(5):733–5

ASCARIDIDA INFECTIONS

PARASITOLOGY

Egg deposition of the intestinal nematode Heterakis spumosa: stimulation by soluble colon factors of mice. Harder A, et al. **J Parasitol** 1995 Oct;81(5):733–5

The life cycle of Contracaecum osculatum (Rudolphi, 1802) sensu stricto (Nematoda, Ascaridoidea, Anisakidae) in view of experimental infections. Køie M, et al. **Parasitol Res** 1995;81(6):481–9

[Parasitologic significance of the alteration of the causative Anisakidae worm and of the Pseudoterranova decipiens female immature adult worm, casting off the cuticles, and excreted from human in Kanazawa City] Ishikura H, et al. **Hokkaido Igaku Zasshi** 1995 Sep;70(5):667–85 (48 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Ocular larva migrans and histopathological lesions in mice experimentally infected with Baylisascaris transfuga embryonated eggs. Papini R, et al. **Vet Parasitol** 1996 Feb; 61(3–4):315–20

PHYSIOPATHOLOGY

Ocular larva migrans and histopathological lesions in mice experimentally infected with Baylisascaris transfuga embryonated eggs. Papini R, et al. **Vet Parasitol** 1996 Feb; 61(3–4):315–20

VETERINARY

Encephalitic nematodiasis in a Douglas squirrel and a rock dove ascribed to Baylisascaris procyonis. Coates JW, et al. **Can Vet J** 1995 Sep;36(9):566–9

Efficacy of six anthelmintics against luminal stages of Baylisascaris procyonis in naturally infected raccoons (Procyon lotor). Bauer C, et al. **Vet Parasitol** 1995 Nov; 60(1–2):155–9

Dose titration of moxidectin oral gel against migrating Strongylus vulgaris and Parascaris equorum larvae in pony foals. Monahan CM, et al. **Vet Parasitol** 1995 Nov; 60(1–2):103–10

ASCARIDOIDEA

Encephalitic nematodiasis in a Douglas squirrel and a rock dove ascribed to Baylisascaris procyonis. Coates JW, et al. **Can Vet J** 1995 Sep;36(9):566–9

Visceral larva migrans induced eosinophilic cardiac pseudotumor: a cause of sudden death in a child. Boschetti A, et al. **J Forensic Sci** 1995 Nov;40(6):1097–9 (12 ref.)

[Parasitologic significance of the alteration of the causative Anisakidae worm and of the Pseudoterranova decipiens female immature adult worm, casting off the cuticles, and excreted from human in Kanazawa City] Ishikura H, et al. **Hokkaido Igaku Zasshi** 1995 Sep;70(5):667–85 (48 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Distribution of cobalt in parasitic helminths. Chowdhury N, et al. **J Helminthol** 1995 Sep;69(3):259–61

DRUG EFFECTS

Dose titration of moxidectin oral gel against migrating Strongylus vulgaris and Parascaris equorum larvae in pony foals. Monahan CM, et al. **Vet Parasitol** 1995 Nov; 60(1–2):103–10

GROWTH & DEVELOPMENT

The life cycle of Contracaecum osculatum (Rudolphi, 1802) sensu stricto (Nematoda, Ascaridoidea, Anisakidae) in view of experimental infections. Køie M, et al. **Parasitol Res** 1995;81(6):481–9

ISOLATION & PURIFICATION

The amphipod Gammarus fossarum as a natural true intermediate host of the nematode Raphidascaris acus. Moravec F. **J Parasitol** 1996 Aug;82(4):668–9

Larval anisakids (Nematoda: Ascaridoidea) in horse mackerel (Trachurus trachurus) from the fish market in Granada (Spain). Adroher FJ, et al. **Parasitol Res** 1996;82(3):253–6

Larval anisakids (Nematoda:Ascaridoidea) in horse mackerel (Trachurus trachurus) from the fish market in Granada, Spain. Adroher FJ, et al. **Parasitol Res** 1996;82(4):319–22

ASCARIS

CYTOLOGY

Reconstitution in vitro of the motile apparatus from the amoeboid sperm of Ascaris shows that filament assembly and bundling move membranes. Italiano JE Jr, et al. **Cell** 1996 Jan 12;84(1):105–14

EMBRYOLOGY

Basic fibroblast growth factor induces notochord formation and the expression of As-T, a Brachyury homolog, during ascidian embryogenesis. Nakatani Y, et al. **Development** 1996 Jul;122(7):2023–31

Posterior end mark, a novel maternal gene encoding a localized factor in the ascidian embryo. Yoshida S, et al. **Development** 1996 Jul;122(7):2005–12

GENETICS

Cloning of a cDNA encoding the small subunit of cytochrome b558 (cybS) of mitochondrial fumarate reductase (complex II) from adult Ascaris suum. Saruta F, et al. **Biochim Biophys Acta** 1996 Aug 7;1276(1):1–5

Are mitochondria inherited paternally in Ascaris? Anderson TJ, et al. **Int J Parasitol** 1995 Aug;25(8):1001–4

Multiple requirements for nematode spliced leader RNP function in trans-splicing. Denker JA, et al. **RNA** 1996 Aug;2(8):746–55

IMMUNOLOGY

Methacholine-induced histamine liberation during airway challenge tests in Ascaris skin-sensitive sheep. Marek W, et al. **Respiration** 1995;62(6):322–30

ISOLATION & PURIFICATION

The distribution of Parascaris equorum eggs in the soil profile of bare paddocks in some Norwegian studs. Ihler CF. **Vet Res Commun** 1995;19(6):495–501

[Ascaris volvulus] Sánchez Jarquín MR, et al. **Cir Pediatr** 1995 Jul;8(3):130–1 (Eng. Abstr.) **(Spa)**

METABOLISM

Hydrogen bonding of tyrosine B10 to heme-bound oxygen in Ascaris hemoglobin. Direct evidence from UV resonance Raman spectroscopy. Huang S, et al. **J Biol Chem** 1996 Jan 12;271(2):958–62

A selective Ascaris acetylcholine receptor antagonist: 1,1-dimethyl-4-(2-quinolyl)-piperazinium iodide. Navarrete A, et al. **Proc West Pharmacol Soc** 1995;38:35–6

BSTI, a trypsin inhibitor from skin secretions of Bombina bombina related to protease inhibitors of nematodes. Mignogna G, et al. **Protein Sci** 1996 Feb;5(2):357–62

ASCARIS LUMBRICOIDES

CT diagnosis of intestinal ascariasis. Hommeyer SC, et al. **Abdom Imaging** 1995 Jul–Aug;20(4):315–6

Ascaris lumbricoides infection and environmental risk factors in an urban African setting. Tshikuka JG, et al. **Ann Trop Med Parasitol** 1995 Oct;89(5):505–14

Residents' corner: Answer to case of the month #37. Hepatic ascariasis. Clark T, et al. **Can Assoc Radiol J** 1996 Jun; 47(3):220–2

Epidemiology of human hookworm and Ascaris lumbricoides infestations in rural Gambia. Palmer DR, et al. **East Afr Med J** 1995 Aug;72(8):527–30

Intensity of infection and reinfection rate of A. lumbricoides in a rural farming village, Dembia district, northwest Ethiopia. Dagnew M, et al. **Ethiop Med J** 1995 Oct; 33(4):243–9

A cost-effectiveness analysis of anthelminthic intervention for community control of soil-transmitted helminth infection: levamisole and Ascaris lumbricoides. Holland CV, et al. **J Parasitol** 1996 Aug;82(4):527–30

Intestinal helminths and xerophthalmia in Nepal. A case-control study. Curtale F, et al. **J Trop Pediatr** 1995 Dec;41(6):334–7

Selective treatment and targeted chemotherapy: effect on prevalence and intensity of infection for two intestinal helminths in Nepalese children. Curtale F. **Panminerva Med** 1995 Dec;37(4):214–9

Targeted anthelminthic treatment of school children: effect of frequency of application on the intensity of Ascaris lumbricoides infection in children from rural Nigerian villages. Holland CV, et al. **Parasitology** 1996 Jul;113 (Pt 1):87–95

Ultrasonographic diagnosis of intestinal ascariasis. Ozmen MN, et al. **Pediatr Radiol** 1995 Nov;25 Suppl 1:S171–2

The effects of deworming on indicators of school performance in Guatemala. Watkins WE, et al. **Trans R Soc Trop Med Hyg** 1996 Mar–Apr;90(2):156–61

Helminth infections, morbidity indicators and schistosomiasis treatment history in three villages, Dongting Lake region, PR China. Booth M, et al. **Trop Med Int Health** 1996 Aug; 1(4):464–74

[Interstitial nephritis with acute renal failure in Ascaris lumbricoides infection] Meister P, et al. **Pathologe** 1995 Nov;16(6):434–8 (16 ref.) (Eng. Abstr.) **(Ger)**

[Acute pancreatitis caused by Ascaris lumbricoides in acute renal failure: case report] Morović-Vergles J, et al. **Lijec Vjesn** 1995 Jun;117 Suppl 2:87–8 (Eng. Abstr.) **(Scr)**

[Biliopancreatic ascariasis: an infrequent disease in our environment] de la Cruz Alvarez J, et al. **Gastroenterol Hepatol** 1996 Apr;19(4):210–2 (Eng. Abstr.) **(Spa)**

[Unusual ingestion of a nasogastric tube by Ascaris lumbricoides] Bustamante-Sarabia J, et al. **Rev Gastroenterol Mex** 1996 Jan–Mar;61(1):38–42 (Eng. Abstr.) **(Spa)**

[Intestinal obstruction caused by Ascaris lumbricoides. A rare condition to be considered] Gustafsson M, et al. **Lakartidningen** 1996 Jun 5;93(23):2254–5 **(Swe)**

CYTOLOGY

Worm sperm and advances in cell locomotion. Theriot JA. **Cell** 1996 Jan 12;84(1):1–4 (18 ref.)

GENETICS

R4, a non-LTR retrotransposon specific to the large subunit rRNA genes of nematodes. Burke WD, et al. **Nucleic Acids Res** 1995 Nov 25;23(22):4628–34

Most mRNAs in the nematode Ascaris lumbricoides are trans-spliced: a role for spliced leader addition in translational efficiency. Maroney PA, et al. **RNA** 1995 Sep; 1(7):714–23

Direct analysis of nematode cis- and trans-spliceosomes: a functional role for U5 snRNA in spliced leader addition trans-splicing and the identification of novel Sm snRNPs. Maroney PA, et al. **RNA** 1996 Aug;2(8):735–45

U6 snRNA function in nuclear pre-mRNA splicing: a phosphorothioate interference analysis of the U6 phosphate backbone. Yu YT, et al. **RNA** 1995 Mar;1(1):46–54

GROWTH & DEVELOPMENT

Ascaris lumbricoides aggregation in relation to child growth status, delayed cutaneous hypersensitivity, and plant anthelmintic use in Madagascar. Kightlinger LK, et al. **J Parasitol** 1996 Feb;82(1):25–33

IMMUNOLOGY

Antibody isotype responses to antigens of Ascaris lumbricoides in a case-control study of persistently heavily infected Bangladeshi children. Palmer DR, et al. **Parasitology** 1995 Sep;111 (Pt 3):385–93

Nutritional status and the IgE response against Ascaris lumbricoides in children from a tropical slum. Hagel I, et al. **Trans R Soc Trop Med Hyg** 1995 Sep–Oct;89(5):562–5

ISOLATION & PURIFICATION

Vitamin A status of Indonesian children infected with Ascaris lumbricoides after dosing with vitamin A supplements and albendazole. Tanumihardjo SA, et al. **J Nutr** 1996 Feb; 126(2):451–7

Acute pancreatitis caused by biliary ascaris in pregnancy. Asrat T, et al. **J Perinatol** 1995 Jul–Aug;15(4):330–2 (15 ref.)

PHYSIOLOGY

Viability of Ascaris suum, Ascaris lumbricoides and Trichuris muris eggs to alkaline pH and different temperatures. Ghiglietti R, et al. **Parassitologia** 1995 Dec;37(2–3):229–32

ASCARIS SUUM

The effect of two types of diet on populations of Ascaris

suum and Oesophagostomum dentatum in experimentally infected pigs. Petkevicius S, et al. **Parasitology** 1995 Sep; 111 (Pt 3):395–401

[The effect of copper on immune responses in guinea pigs with experimental ascariasis] Borošková Z, et al. **Vet Med (Praha)** 1996 Jan;41(1):13–8 (Eng. Abstr.) **(Slo)**

CHEMISTRY

Purification and molecular characterization of a novel b5-type cytochrome of the parasitic nematode, Ascaris suum. Yu Y, et al. **Arch Biochem Biophys** 1996 Apr 1; 328(1):165–72

Structural characterization of a novel glycoinositolphospholipid from the parasitic nematode, Ascaris suum. Sugita M, et al. **Biochim Biophys Acta** 1996 Aug 16;1302(3):185–92

Neuronal localization of serotonin in the nematode Ascaris suum. Johnson CD, et al. **J Comp Neurol** 1996 Apr 8; 367(3):352–60

The motile major sperm protein (MSP) from Ascaris suum is a symmetric dimer in solution. Haaf A, et al. **J Mol Biol** 1996 Jul 12;260(2):251–60

DRUG EFFECTS

Ascaris suum: ultrastructural effect of in vitro albendazole therapy. Magambo JK. **East Afr Med J** 1996 Feb; 73(2):140–2

The action of serotonin and the nematode neuropeptide KSAYMRFamide on the pharyngeal muscle of the parasitic nematode, Ascaris suum. Brownlee DJ, et al. **Parasitology** 1995 Sep;111 (Pt 3):379–84

Anthelmintic properties of alpha-sanshool from Zanthoxylum liebmannianum. Navarrete A, et al. **Planta Med** 1996 Jun;62(3):250–1

ENZYMOLOGY

A pH-dependent allosteric transition in Ascaris suum phosphofructokinase distinct from that observed with fructose 2,6-bisphosphate. Rao GS, et al. **Arch Biochem Biophys** 1995 Oct 1;322(2):410–6

Isotope partitioning with Ascaris suum phosphofructokinase is consistent with an ordered kinetic mechanism. Gibson GE, et al. **Biochemistry** 1996 Apr 30;35(17):5451–7

Comparison of the substrate specificities of cAMP-dependent protein kinase from bovine heart and Ascaris suum muscle. Treptau T, et al. **Biol Chem Hoppe Seyler** 1996 Mar; 377(3):203–9

A carboxylesterase from the parasitic nematode Ascaris suum homologous to the intestinal-specific ges-1 esterase of Caenorhabditis elegans. Azzaria M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov; 109(2–3):225–36

The catalytic subunit of cAMP-dependent protein kinase from Ascaris suum. The cloning and structure of a novel subtype of protein kinase A. Jung S, et al. **Eur J Biochem** 1995 Aug 15;232(1):111–7

Identification of a novel dihydrolipoyl dehydrogenase-binding protein in the pyruvate dehydrogenase complex of the anaerobic parasitic nematode, Ascaris suum. Klingbeil MM, et al. **J Biol Chem** 1996 Mar 8;271(10):5451–7

Purification and characterization of gamma-glutamylcysteine synthetase from Ascaris suum. Hussein AS, et al. **Mol Biochem Parasitol** 1995 Jun;72(1–2):57–64

NADPH diaphorase activity in peptidergic neurones of the parasitic nematode, Ascaris suum. Bascal ZA, et al. **Parasitology** 1996 Jan;112 (Pt 1):125–34

Identification and properties of a neuropeptide-degrading endopeptidase (neprilysin) of Ascaris suum muscle. Sajid M, et al. **Parasitology** 1995 Dec;111 (Pt 5):599–608

GENETICS

A newly formed telomere in Ascaris suum does not exert a telomere position effect on a nearby gene. Huang YJ, et al. **Mol Cell Biol** 1996 Jan;16(1):130–4

Preparation of biologically active Ascaris suum mitochondrial tRNAMet with a TV-replacement loop by ligation of chemically synthesized RNA fragments. Ohtsuki T, et al. **Nucleic Acids Res** 1996 Feb 15;24(4):662–7

IMMUNOLOGY

Production of a monoclonal dinitrophenyl-specific rat IgE and establishment of an IgE capture ELISA for estimating the concentration of rat IgE antibodies to dinitrophenyl-Ascaris suum. Hanashiro K, et al. **Int Arch Allergy Immunol** 1996 Aug;110(4):371–9

ISOLATION & PURIFICATION

Comparison of two methods for recovering migrating Ascaris suum larvae from the liver and lungs of pigs. Slotved HC, et al. **J Parasitol** 1996 Aug;82(4):612–5

An outbreak of visceral larva migrans due to Ascaris suum in Kyushu, Japan [letter] Maruyama H, et al. **Lancet** 1996 Jun 22;347(9017):1766–7

Study on a new egg count technique for Macracanthorhynchus hirudinaceus and Ascaris suum. Dangjin L. **Vet Parasitol** 1996 Jan;61(1–2):113–7

METABOLISM

A Cl channel in Ascaris suum selectivity conducts dicarboxylic anion product of glucose fermentation and suggests a role in removal of waste organic anions. Valkanov MA, et al. **J Membr Biol** 1995 Nov;148(1):41–9

Inhibition of glutathione synthesis of Ascaris suum by buthionine sulfoximine. Hussein AS, et al. **Parasitol Res** 1996;82(4):372–4

Actions of neurotoxins (bungarotoxins, neosurugatoxin and lophotoxins) on insect and nematode nicotinic acetylcholine receptors. Tornøe C, et al. **Toxicon** 1995 Apr;33(4):411–24 (61 ref.)

PATHOGENICITY

Can Ascaris suum cause visceral larva migrans? [letter] Petithory JC. **Lancet** 1996 Sep 7;348(9028):689

PHYSIOLOGY

Survival of salmonellas and Ascaris suum eggs in a thermophilic biogas plant. Plym-Forshell L. **Acta Vet Scand** 1995;36(1):79–85

Nitric oxide mediates the inhibitory effects of SDPNFLRFamide, a nematode FMRFamide-related neuropeptide, in Ascaris suum. Bowman JW, et al. **J Neurophysiol** 1995 Nov;74(5):1880–8

Cell biology of nematode sperm. L'Hernault SW, et al. **Methods Cell Biol** 1995;48:273–301 (38 ref.)

Effects of pH on a high conductance Ca-dependent chloride channel: a patch-clamp study in Ascaris suum. Robertson AP, et al. **Parasitology** 1996 Aug;113 (Pt 2):191–8

Viability of Ascaris suum, Ascaris lumbricoides and Trichuris muris eggs to alkaline pH and different temperatures. Ghiglietti R, et al. **Parassitologia** 1995 Dec;37(2–3):229–32

Use of a polyurethane carrier for assessing the survival of helminth eggs in liquid biological sludges. Plachý P, et al. **Vet Med (Praha)** 1995 Oct;40(10):323–6

ULTRASTRUCTURE

Ascaris suum: ultrastructural effect of in vitro albendazole therapy. Magambo JK. **East Afr Med J** 1996 Feb; 73(2):140–2

ASCAROIDEA see **ASCARIDOIDEA**

ASCHELMINTHES see **HELMINTHS**

ASCHOFF BODIES see **RHEUMATIC NODULE**

ASCITES

Pelvic endometriosis mimicking advanced ovarian cancer: presentation with pleural effusion, ascites, and elevated serum CA 125 level. Myers TJ, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):966–7

Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice. Zhang SY, et al. **Blood** 1996 Apr 15;87(8):3404–9

Malignant ascites. Parsons SL, et al. **Br J Surg** 1996 Jan; 83(1):6–14 (92 ref.)

[Fluid retention in cirrhosis] Henriksen JH. **Ugeskr Laeger** 1995 Nov 27;157(48):6733–4 **(Dan)**

[Reliability of bioelectric impedance analysis as a method of nutritional monitoring in cirrhosis with ascites] Cabré E, et al. **Gastroenterol Hepatol** 1995 Aug–Sep;18(7):359–65 (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

[Therapy-induced formation of ascites and pleural effusion during initial chemotherapy in a patient with non-Hodgkin's lymphoma. Ascites and pleural effusion during initial chemotherapy] Gruhn B, et al. **Klin Padiatr** 1995 Nov–Dec;207(6):317–20 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

PEG in a patient with ascites and varices [letter] Kynci JA, et al. **Gastrointest Endosc** 1995 Jul;42(1):100–1

Ovarian hemangioma associated with concomitant stromal luteinization and ascites. Yamawaki T, et al. **Gynecol Oncol** 1996 Jun;61(3):438–41 (13 ref.)

Acute hemoperitoneum in an alcoholic man with ascites. Bhutani MS. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):16G

Image-guided percutaneous hepatic biopsy: effect of ascites on the complication rate. Little AF, et al. **Radiology** 1996 Apr;199(1):79–83

Relationship among volume of paracentesis, portal blood flow and renal resistive index, evaluated by duplex Doppler ultrasonography in cirrhosis with tense ascites. Caruso G, et al. **Recenti Prog Med** 1996 Apr;87(4):164–6

[Incidence of spontaneous bacterial peritonitis in cirrhotic patients with ascites. A two-year prospective study] Osztrogonácz H, et al. **Orv Hetil** 1996 Jan 28;137(4):179–82 (Eng. Abstr.) **(Hun)**

[Diagnostic aspects of spontaneous bacterial peritonitis in hepatic cirrhosis with ascites] Breda A, et al. **Minerva Gastroenterol Dietol** 1995 Sep;41(3):227–30 (Eng. Abstr.) **(Ita)**

[A case of hemolytic uremic syndrome accompanied by massive proteinuria and ascites] Ookawara S, et al. **Nippon Jinzo Gakkai Shi** 1996 Feb;38(2):98–102 (Eng. Abstr.) **(Jpn)**

[Scrotal digestion caused by pancreatic ascites] Martínez Bengoechea JJ, et al. **Actas Urol Esp** 1995 Apr;19(4):320–1 (Eng. Abstr.) **(Spa)**

CONGENITAL

An unusual cause of congenital ascites. Puvabanditsin S, et al. **Acta Paediatr** 1995 Jul;84(7):829–30

DIAGNOSIS

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Arroyo V, et al. **Hepatology** 1996 Jan;23(1):164–76 (119 ref.)

Bile ascites. Chaturvedi A, et al. **Indian Pediatr** 1995 Feb; 32(2):251–3 (6 ref.)

Diagnosing ascites: value of ascitic fluid total protein, albumin, cholesterol, their ratios, serum-ascites albumin and cholesterol gradient. Gupta R, et al. **J Gastroenterol Hepatol** 1995 May–Jun;10(3):295–9

Fetal ascites and oligohydramnios: prenatal diagnosis of a sialic acid storage disease (index case). Poulain P, et al. **Prenat Diagn** 1995 Sep;15(9):864–7

[Diagnosis of neoplastic ascites: combined use of albumin gradient between serum and ascites and cholesterol in ascitic fluid] Sartori M, et al. **Recenti Prog Med** 1996 Feb; 87(2):75–7 **(Ita)**

[Diagnosis of ascites--malignant or benign etiology? (letter)] Adamsen S, et al. **Lakartidningen** 1996 May 15;93(20):1932 **(Swe)**

[Ascites--a diagnostic and therapeutic challenge] Castedal M, et al. **Lakartidningen** 1996 Feb 28;93(9):784–8 **(Swe)**

DRUG THERAPY

MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Leonessa F, et al. **Br J Cancer** 1996 Jan;73(2):154–61

Peripheral natural killer cell activity and intraperitoneal soluble p55 tumor necrosis factor receptor in patients with malignant ascites: two possible indicators for response to intraperitoneal combined tumor necrosis factor alpha and interferon gamma treatment. Ott MG, et al. **Cancer Immunol Immunother** 1996 Jan;42(1):31–7

Ascites free-water dynamics in decompensated cirrhosis: effects of acute and chronic frusemide treatment [see comments] Milani A, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):763–7. Comment in: Eur J Gastroenterol Hepatol 1995 Aug;7(8):749–51.

Rapid resolution of chylous ascites after liver transplantation using somatostatin analog and total parenteral nutrition. Shapiro AM, et al. **Transplantation** 1996 May 15; 61(9):1410–1

[Predictive analysis of the response to treatment with diuretics of patients with liver cirrhosis and ascites] Del Val A, et al. **Rev Esp Enferm Dig** 1995 Dec;87(12):859–64 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Purification and characterization of an AP endonuclease/DNA 3' repair diesterase from mouse ascites sarcoma cells. Sarker AH, et al. **Biochim Biophys Acta** 1995 Dec 14;1245(3):299–304

ETIOLOGY

An unusual cause of congenital ascites. Puvabanditsin S, et al. **Acta Paediatr** 1995 Jul;84(7):829–30

Pancreatic ascites in children. D'Cruz AJ, et al. **Acta Paediatr Jpn** 1995 Oct;37(5):630–3

Evaluation and initial management of patients with ascites. Lipsky MS, et al. **Am Fam Physician** 1996 Sep 15; 54(4):1327–33 (18 ref.)

Prognosis assessment of cirrhotic patients with refractory ascites treated with a peritoneovenous shunt [see comments] Guardiola J, et al. **Am J Gastroenterol** 1995 Dec;90(12):2097–102. Comment in: Am J Gastroenterol 1995 Dec;90(12):2086–9.

Idiopathic dialysis ascites in the nineties: resolution after renal transplantation. Melero M, et al. **Am J Kidney Dis** 1995 Oct;26(4):668–70

Xerocytosis with concomitant intrauterine ascites: first description and therapeutic approach [letter] Entezami M, et al. **Blood** 1996 Jun 15;87(12):5392–3

Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Nador RG, et al. **Blood** 1996 Jul 15; 88(2):645–56

Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease. Seber A, et al. **Bone Marrow Transplant** 1996 Feb;17(2):207–11 (28 ref.)

Acute ascites with blunt cardiac rupture. Dagenais F, et al. **Can J Cardiol** 1996 Jan;12(1):86–8 (12 ref.)

Previously unrecognized intrapericardial hematoma leading to refractory abdominal ascites. Meleca MJ, et al. **Chest** 1995 Dec;108(6):1747–8

Spontaneous bacterial peritonitis complicating malignancy-related ascites [letter] Bac DV, et al. **Dig Dis Sci** 1996 Jan;41(1):131–2

Ascites, pleural, and pericardial effusions in acute pancreatitis. A prospective study of incidence, natural

history, and prognostic role. Maringhini A, et al. **Dig Dis Sci** 1996 May;41(5):848–52

Eosinophilic gastroenteritis presenting as ascites and splenomegaly. Santos J, et al. **Eur J Gastroenterol Hepatol** 1995 Jul;7(7):675–8

Malignant ascites: a 2–year review from a teaching hospital. Parsons SL, et al. **Eur J Surg Oncol** 1996 Jun;22(3):237–9

The prognostic implication of ascites in advanced–stage ovarian cancer. Puls LE, et al. **Gynecol Oncol** 1996 Apr; 61(1):109–12

Hepatic venoocclusive disease as a complication of whole abdominopelvic irradiation and treatment with the transjuglar intrahepatic portosystemic shunt: case report and literature review. Shen–Gunther J, et al. **Gynecol Oncol** 1996 May;61(2):282–6 (25 ref.)

Biliary ascites caused by perforation of choledochal cyst. Sarin YK, et al. **Indian Pediatr** 1995 Jul;32(7):815–7

Idiopathic colonic phlebitis with massive ascites. Matsunaga I, et al. **Intern Med** 1995 Aug;34(8):776–81

Adult T cell leukemia clinically manifested with ascites and pleural effusion. Saburi Y, et al. **Intern Med** 1995 Aug; 34(8):815–8

Ascitic fluid analysis—the yet new investigation [editorial; comment] Menon VP, et al. **J Assoc Physicians India** 1995 Nov;43(11):743–4. Comment on: J Assoc Physicians India 1995 Nov;43(11):745–7.

Ascitic fluid cholesterol in malignant and tubercular ascites [see comments] Sood A, et al. **J Assoc Physicians India** 1995 Nov;43(11):745–7. Comment in: J Assoc Physicians India 1995 Nov;43(11):743–4.

Cirrhosis: ascites and hepatorenal syndrome. Recent advances in pathogenesis. Henriksen JH. **J Hepatol** 1995; 23 Suppl 1:25–30 (74 ref.)

Endometriosis with a pleural effusion and ascites. Report of a case treated with nafarelin acetate. Shek Y, et al. **J Reprod Med** 1995 Jul;40(7):540–2

Ascitic fluid protein concentration [letter; comment] Cronin CC, et al. **Lancet** 1996 Mar 16;347(9003):772–3. Comment on: Lancet 1996 Jan 20;347(8995):197.

Endomyocardial fibrosis: why is there striking ascites with little or no peripheral oedema? [letter] [see comments] Freers J, et al. **Lancet** 1996 Jan 20;347(8995):197. Comment in: Lancet 1996 Mar 16;347(9003):772–3.

High interleukin–6 production within the peritoneal cavity in decompensated cirrhosis and malignancy–related ascites. Bac DJ, et al. **Liver** 1995 Oct;15(5):265–70

Primary ascites as the presenting feature of systemic lupus erythematosus: response to cyclosporin therapy. Hernández Pérez J, et al. **Nephrol Dial Transplant** 1995;10(8):1451–3

A dialysis patient with fatigue and ascites. Wizemann V, et al. **Nephrol Dial Transplant** 1995;10(9):1778–9

Ascites due to endometriosis. Spitzer M, et al. **Obstet Gynecol Surv** 1995 Aug;50(8):628–31 (17 ref.)

Transient fetal ascites associated with Down's syndrome [letter] Duncan KA, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):227

Diarrhea, massive ascites, and portal hypertension: rare case of a splenic arterio–venous fistula. Strassburg CP, et al. **Z Gastroenterol** 1996 Apr;34(4):243–9

[Ascites, hydrothorax and ovarian tumor: Meigs' syndrome in a patient with small ovaries and increased CA 125 level (published erratum appears in Ned Tijdschr Geneeskd 1995 Dec 30;139(52):2768)] Cober–Tromp HA, et al. **Ned Tijdschr Geneeskd** 1995 Nov 4;139(44):2262–5 (Eng. Abstr.) **(Dut)**

[For safety's sake] Leppäniemi A. **Duodecim** 1994; 110(14):1340–2 **(Fin)**

[Lymphocytic ascites revealing systemic mastocytosis] Essner C, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):948–51 (23 ref.) (Eng. Abstr.) **(Fre)**

[Urinary ascites: response to the letter of J.–F. Blanc et al] Lachaux A, et al. **Gastroenterol Clin Biol** 1995 Aug–Sep; 19(8–9):732 **(Fre)**

[Diagnosis and therapy of ascites] Frick E, et al. **Internist (Berl)** 1995 Aug;36(8):853–65 (0 ref.) **(Ger)**

[24–year–old patient with acute abdomen and ascites] Lessing P, et al. **Internist (Berl)** 1995 Oct;36(10):995–8 **(Ger)**

[23–year–old patient with abdominal pain, hepatosplenomegaly, ascites and leg edema] Oswald M, et al. **Internist (Berl)** 1995 Sep;36(9):912–7 **(Ger)**

[Ascites with a blind spot] Warsitz T, et al. **Med Klin** 1995 Nov 15;90(11):634–6 **(Ger)**

[Complications in a patient with a jejuno–peritoneal shunt by the Le Veen technique] Fulgente R, et al. **Chir Ital** 1994;46(6):71–2 (Eng. Abstr.) **(Ita)**

[A case of systemic lupus erythematosus with pleural effusion, ascites and pericardial effusion] Koyama K, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):614–6 **(Jpn)**

[Massive ascites as an initial sign, plasmacytoma of the cervical supine, and hyperammonemic consciousness disturbance in a patient with biclonal type multiple myeloma] Ohmoto A, et al. **Rinsho Ketsueki** 1996 Apr; 37(4):346–51 (Eng. Abstr.) **(Jpn)**

[Pancreatic ascites] Jasiński A, et al. **Pol Arch Med Wewn** 1995 Mar;93(3):253–5 (Eng. Abstr.) **(Pol)**

[Acute pancreatitis complicated by pancreatic ascites. Diagnostic and therapeutic difficulties] Wereszczyńska–Siemiątkowska U, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):369–74 (Eng. Abstr.) **(Pol)**

[Ascites caused by portal hypertension in a patient with chronic myelomonocytic leukemia] Pamplona J, et al. **Rev Esp Enferm Dig** 1996 Feb;88(2):151–3 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Autoantibodies against p53 are not increased in human ascites and pleural effusions. Munker R, et al. **Cancer Immunol Immunother** 1996 Mar;42(3):200–1

Low protein concentration in cirrhotic ascites is related to low ascitic concentrations of immunoglobulins G and A. García–Díaz M, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):963–9

Survivability and leucocyte migration inhibition in mice immunized with cryotreated ascites fibrosarcoma cells using different freeze–thaw cycles. Roy A, et al. **Indian J Exp Biol** 1995 Jul;33(7):485–8

Nitric oxide synthesis contributes to IL–2–induced antitumor responses against intraperitoneal Meth A tumor. Yim CY, et al. **J Immunol** 1995 Nov 1;155(9):4382–90

[Cellular immune response in tuberculosis: analysis of T–lymphocytes and their subsets, B–lymphocytes and natural cytotoxic cells in different tuberculosis states and body fluids] Montes Santiago J, et al. **Rev Clin Esp** 1996 Apr;196(4):223–7 (Eng. Abstr.) **(Spa)**

METABOLISM

Human chorionic gonadotropin–beta in the differentiation of malignancy–related and nonmalignant ascites. Gerbes AL, et al. **Digestion** 1996;57(2):113–7

Massive ascitic fluid loss and coagulation disturbances after liver transplantation [see comments] Gane E, et al. **Gastroenterology** 1995 Nov;109(5):1631–8. Comment in: Gastroenterology 1996 Aug;111(2):564–5.

Levels of soluble intercellular adhesion molecule 1, eicosanoids and cytokines in ascites of patients with liver cirrhosis, peritoneal cancer and spontaneous bacterial peritonitis. Pruimboom WM, et al. **Int J Immunopharmacol** 1995 May;17(5):375–84

mRNA levels of nm23 in murine ascites hepatoma (H22) clones with different lymphatic metastatic potential. Jiang XP, et al. **J Cancer Res Clin Oncol** 1996;122(1):55–8

Evaluation of hollow fiber bioreactors as an alternative to murine ascites production for small scale monoclonal antibody production. Jackson LR, et al. **J Immunol Methods** 1996 Feb 5;189(2):217–31

In vitro NMR proton T1 measurements in peritoneal ascites. Yilmaz A, et al. **Phys Med Biol** 1996 Mar;41(3):539–49

MICROBIOLOGY

Plant bacterial spores, active systemically as a separate entity, play a significant role in human illnesses such as cancer, granulomas, AIDS, and milky white abdominal ascites that currently defies recognition. White MW. **Med Hypotheses** 1995 Jun;44(6):493–503

[Septic ascites: a rare post–operative complication] La Torre F, et al. **G Chir** 1995 Nov–Dec;16(11–12):507–9 (Eng. Abstr.) **(Ita)**

MORTALITY

High mortality after abdominal operation in patients with large–volume malignant ascites. Yazdi GP, et al. **J Surg Oncol** 1996 Jun;62(2):93–6

PATHOLOGY

Waldenstrom's macroglobulinemia transformed into immunoblastic lymphoma presenting with malignant ascites [letter] Marinella MA, et al. **Am J Hematol** 1996 Mar; 51(3):249–50

A possible role of TGF–beta in the formation of malignant effusions. Ikubo A, et al. **Clin Immunol Immunopathol** 1995 Oct;77(1):27–32

Peritoneal fibrosis in cirrhotics treated with peritoneovenous shunting for ascites. An autopsy study with clinical correlations. Stanley MM, et al. **Dig Dis Sci** 1996 Mar; 41(3):571–7

Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas. Alama A, et al. **Gynecol Oncol** 1996 Jul;62(1):82–8

Effects of KW–3902, an adenosine A1–receptor antagonist, on ascites volume in puromycin aminonucleoside (PAN)–induced nephrotic rats. Kusaka H, et al. **Jpn J Pharmacol** 1995 Jun;68(2):213–6

PHYSIOPATHOLOGY

Ascites and its effects upon respiratory muscle loading and work of breathing. Rosado M, et al. **Crit Care Med** 1996 Mar;24(3):538–40 (22 ref.)

IL–6 secretion by human peritoneal mesothelial and ovarian cancer cells. Offner FA, et al. **Cytokine** 1995 Aug; 7(6):542–7

Ascites formation and dynamics in cirrhotic patients [comment] Gentilini P. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):749–51. Comment on: Eur J Gastroenterol Hepatol 1995 Aug;7(8):763–7.

Ascites free–water dynamics in decompensated cirrhosis: effects of acute and chronic frusemide treatment [see comments] Milani A, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):763–7. Comment in: Eur J Gastroenterol Hepatol 1995 Aug;7(8):749–51.

Induction of apoptotic cell death by pancreatitis–associated ascitic fluid in Madin–Darby canine kidney cells. Nishikawa J, et al. **FEBS Lett** 1995 Oct 2;373(1):19–22

Systemic hypotension and diuresis by L–arginine in cirrhotic patients with ascites: role of nitric oxide. Tajiri K, et al. **Hepatology** 1995 Nov;22(5):1430–5

Ascites and hepatorenal syndrome: pathophysiology and management. Roberts LR, et al. **Mayo Clin Proc** 1996 Sep; 71(9):874–81 (37 ref.)

Effects of ascites and body position on gas exchange in patients with cirrhosis. Chang SC, et al. **Proc Natl Sci Counc Repub China B** 1995 Jul;19(3):143–50

[Effects of experimental ascites on diaphragm strength] De Vito EL, et al. **Medicina (B Aires)** 1995;55(3):218–24 (Eng. Abstr.) **(Spa)**

[Influence of liver cirrhosis with and without ascites on ventilatory mechanics] Ordiales Fernández JJ, et al. **Rev Esp Enferm Dig** 1995 Dec;87(12):853–7 (Eng. Abstr.) **(Spa)**

[Study of arterial blood gases in liver cirrhosis with and without ascites] Ordiales Fernández JJ, et al. **Rev Esp Enferm Dig** 1996 Mar;88(3):197–201 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Enhancing ascites: an aid to CT diagnosis. Wise SW, et al. **Abdom Imaging** 1996 Jan–Feb;21(1):67–8

SURGERY

Prognosis assessment of cirrhotic patients with refractory ascites treated with a peritoneovenous shunt [see comments] Guardiola J, et al. **Am J Gastroenterol** 1995 Dec;90(12):2097–102. Comment in: Am J Gastroenterol 1995 Dec;90(12):2086–9.

Hemorrhagic complications of large volume abdominal paracentesis. Webster ST, et al. **Am J Gastroenterol** 1996 Feb;91(2):366–8

Peritoneovenous shunting in cirrhosis: its role in the management of refractory ascites in the 1990s [editorial; comment] Wong F, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2086–9 (39 ref.). Comment on: Am J Gastroenterol 1995 Dec;90(12):2097–102.

Hemodynamic effects of peritoneovenous shunts in hemodialysis patients with ascites. Greenberg S, et al. **Am J Kidney Dis** 1996 Sep;28(3):387–94

Pancreatic pseudocysts, ascites, and fistulas. Yeo CJ. **Curr Opin Gen Surg** 1994;:173–8 (36 ref.)

Temporary use of peritoneovenous shunting for treatment of tense ascites following a Whipple procedure. Takahashi T, et al. **Dig Dis Sci** 1995 Sep;40(9):1946–50

Tips for the treatment of refractory ascites. Siuta M, et al. **Gastroenterology** 1996 Mar;110(3):956–8

Transjugular intrahepatic portosystemic shunt: is it the ultimate solution for refractory ascites? Wong F, et al. **Hepatology** 1995 Nov;22(5):1613–5

Large–volume paracentesis in the treatment of cirrhotic patients with refractory ascites. The role of postparacentesis plasma volume expansion. Forouzandeh B, et al. **J Clin Gastroenterol** 1996 Apr;22(3):207–10 (51 ref.)

High mortality after abdominal operation in patients with large–volume malignant ascites. Yazdi GP, et al. **J Surg Oncol** 1996 Jun;62(2):93–6

Severe ascites: efficacy of the transjugular intrahepatic portosystemic shunt in treatment. Crenshaw WB, et al. **Radiology** 1996 Jul;200(1):185–92

[Peritoneojugular shunt in the treatment of idiopathic ascites in the hemodialyzed patient: a clinical case] Massari R, et al. **Chir Ital** 1995;47(1):55–6 (Eng. Abstr.) **(Ita)**

[Surgical treatment of refractory ascites with peritoneovenous shunt] Massari R, et al. **Chir Ital** 1995; 47(1):57–0 (14 ref.) (Eng. Abstr.) **(Ita)**

[A case of refractory ascites successfully treated with transjugular intrahepatic portosystemic shunt] Kanazawa H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May; 93(5):373–6 **(Jpn)**

[The preoperative preparation of patients with liver cirrhosis complicated by a drug–resistant form of ascites] Pozdniakov AV. **Vestn Khir Im I I Grek** 1992 Nov–Dec; 149(11–12):383–4 **(Rus)**

THERAPY

Evaluation and initial management of patients with ascites. Lipsky MS, et al. **Am Fam Physician** 1996 Sep 15; 54(4):1327–33 (18 ref.)

Iatrogenic incarceration of umbilical hernia in cirrhotic patients with ascites. Chu KM, et al. **Am J Gastroenterol** 1995 Nov;90(11):2058–9

Comparison of the Caldwell needle/cannula with Angiocath needle in large volume paracentesis. Shaheen NJ, et al. **Am J Gastroenterol** 1996 Sep;91(9):1731–3

Intraperitoneal infusion of recombinant human tumor necrosis factor and mitoxantrone in neoplastic ascites: a feasibility study. Del Mastro L, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2207–12

Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK–432 plus IL–2 in gastric cancer patients. Yamaguchi Y, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2201–6

Transjugular insertion of biliary stents (TIBS) in two patients

with malignant obstruction, ascites, and coagulopathy. Amygdalos MA, et al. **Cardiovasc Intervent Radiol** 1996 Mar–Apr;19(2):107–9

Management of ascites and pleural effusions in ovarian hyperstimulation syndrome [letter; comment] Aboulghar M, et al. **Fertil Steril** 1995 Dec;64(6):1228–9. Comment on: Fertil Steril 1995 May;63(5):1114–7.

Continuous ascitic recirculation in severe ovarian hyperstimulation syndrome. Beck DH, et al. **Intensive Care Med** 1995 Jul;21(7):590–3

Drainage of tense ascites in children after cardiac surgery. Baden HP, et al. **J Cardiothorac Vasc Anesth** 1995 Dec; 9(6):720–1

Ascites and hepatorenal syndrome: pathophysiology and management. Roberts LR, et al. **Mayo Clin Proc** 1996 Sep; 71(9):874–81 (37 ref.)

Aspiration of fetal pleural effusions or ascites may improve neonatal resuscitation. Cardwell MS. **South Med J** 1996 Feb;89(2):177–8

[The treatment of ascites: a medical controversy?] Luthi F, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):507–8 **(Fre)**

[Reinfusion ascites therapy: considerations after a year's experience] Russo GE, et al. **Riv Eur Sci Med Farmacol** 1994 May–Aug;16(3–4):79–83 (Eng. Abstr.) **(Ita)**

[Intraperitoneal use of human tumor necrosis factor (hrTNFalfa) in patients with ascites during advanced neoplastic disease] Muc-Wierzgoń M, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):357–61 (Eng. Abstr.) **(Pol)**

[Paracentesis associated to dextran–70 in the treatment of ascites in patients with chronic liver diseases: a randomized therapeutic study] Cotrim HP, et al. **Arq Gastroenterol** 1994 Oct–Dec;31(4):123–9 (Eng. Abstr.) **(Por)**

[Treatment of ascites: looking for the good and the inexpensive (editorial)] Rosa H. **Arq Gastroenterol** 1994 Oct–Dec;31(4):123–4 **(Por)**

ULTRASONOGRAPHY

Spontaneous intrauterine remission of fetal ascites in one identical twin. Report of a case with ultrasound evaluation. Chen FP, et al. **J Reprod Med** 1995 Sep;40(9):655–8

The origin of ascites in prune belly syndrome—early sonographic evidence [letter] Fried S, et al. **Prenat Diagn** 1995 Sep;15(9):876–7

Fetal echocardiography guidelines to predict survival of fetuses with ascites. Respondek M, et al. **Ultrasound Obstet Gynecol** 1996 Apr;7(4):256–61

VETERINARY

Experimental reduction of eggshell conductance during incubation. I. effect on the susceptibility to ascites syndrome. Odom TW, et al. **Avian Dis** 1995 Oct–Dec; 39(4):821–9

Ascites and hepatic cirrhosis in a cockatiel (Nymphicus hollandicus). Battison AL, et al. **J Am Anim Hosp Assoc** 1996 May–Jun;32(3):237–42

Cystic, peritoneal mesothelioma in a dog. DiPinto MN, et al. **J Am Anim Hosp Assoc** 1995 Sep–Oct;31(5):385–9

Does pulmonary hypertension syndrome (ascites) occur more frequently in broilers medicated with monensin? Chapman ME, et al. **Poult Sci** 1995 Oct;74(10):1591–6

Pulmonary arteriole hypertrophy in broilers with pulmonary hypertension syndrome (ascites). Enkvetchakul B, et al. **Poult Sci** 1995 Oct;74(10):1677–82

Heritability of ascites and the ratio of right to total ventricle weight in broiler breeder male lines. Lubritz DL, et al. **Poult Sci** 1995 Jul;74(7):1237–41

Hematocrit values and mortality from ascites in cold-stressed broilers from parents selected by hematocrit. Shlosberg A, et al. **Poult Sci** 1996 Jan;75(1):1–5

Bronchodilator, oxygen level, and temperature effects on ascites incidence in broiler chickens. Vanhooser SL, et al. **Poult Sci** 1995 Oct;74(10):1586–90

Ascites syndrome in a turkey reared above 2000 metres [letter] Duff JP, et al. **Vet Rec** 1995 Sep 16;137(12):300

[Ascites as a result of peritoneal mesotheliomas in a horse] Harps O, et al. **Tierarztl Prax** 1996 Jun;24(3):270–4 (Eng. Abstr.) **(Ger)**

ASCITES, CHYLOUS see **CHYLOPERITONEUM**

ASCITES, GELATINOUS see **PSEUDOMYXOMA PERITONEI**

ASCITES SHUNT, PERITONEOVENOUS see **PERITONEOVENOUS SHUNT**

ASCITIC FLUID

see related
PERITONEAL LAVAGE

Rusty peritoneal dialysis fluid after intravenous administration of iron dextran. Carter TB, et al. **Am J Kidney Dis** 1996 Jan;27(1):147–50

Post dialysis fluid (CAPD) increases 3H cholesterol efflux from human skin fibroblasts. Killalea AG, et al. **Biochem Soc Trans** 1996 Feb;24(1):116S

Diagnosis, prevention and management of ovarian hyperstimulation syndrome [letter; comment] Beck DH, et al. **Br J Obstet Gynaecol** 1996 May;103(5):490. Comment on: Br J Obstet Gynaecol 1995 Oct;102(10):767–72.

A severe case of ovarian hyperstimulation syndrome: 65 liters of ascites aspirated in an on-going IVF–ET twin pregnancy. Bar-Hava I, et al. **Gynecol Endocrinol** 1995 Dec;9(4):295–8

Non-machinery-based system for cell-free, concentrated autogenous ascitic fluid reinfusion. Katoh S, et al. **Int J Artif Organs** 1995 Jul;18(7):399–406

[Reinfusion ascites therapy: considerations after a year's experience] Russo GE, et al. **Riv Eur Sci Med Farmacol** 1994 May–Aug;16(3–4):79–83 (Eng. Abstr.) **(Ita)**

CHEMISTRY

Immunocytes and cell-mediated immunity in the pathology of reproduction. Nouza K, et al. **Adv Exp Med Biol** 1995; 371A:373–7

MCP-1 levels are elevated in peritonitis fluid from CAPD patients due to secretion by peritoneal macrophages. Sach M, et al. **Adv Perit Dial** 1995;11:19–23

Increased levels of human hepatocyte growth factor in serum and peritoneal fluid after partial hepatectomy. Kimura F, et al. **Am J Gastroenterol** 1996 Jan;91(1):116–21

Folate receptor in malignant effusions of ovarian carcinoma. Holm J, et al. **APMIS** 1995 Sep;103(9):663–70

Effect of an pyruvate-based peritoneal dialysis solution on the pH of a residual peritoneal dialysis fluid. Ing TS, et al. **Artif Organs** 1996 Mar;20(3):264–6

Validation of a commercial human fibronectin assay for use in dogs and cats. Hirschberger J, et al. **Aust Vet J** 1996 May;73(5):196–7

Free fatty acid analysis in ascitic fluid improves diagnosis in malignant abdominal tumors. Greco AV, et al. **Clin Chim Acta** 1995 Jul 31;239(1):13–22

Detection of nucleosome-IgG immune complexes in ascites from mice transplanted with anti-DNA antibody-secreting hybridomas and in plasma from MRL-lpr/lpr mice. Fournié GJ. **Clin Exp Immunol** 1996 May;104(2):236–40

Interleukin-6 and soluble interleukin-6 receptor in peritoneal fluid and serum of patients with endometriosis. Schröder W, et al. **Clin Exp Obstet Gynecol** 1996;23(1):10–4

Measurement of human chorionic gonadotropin-related immunoreactivity in serum, ascites and tumour cysts of patients with gynaecologic malignancies. Grossmann M, et al. **Eur J Clin Invest** 1995 Nov;25(11):867–73

Image analysis of cellular DNA content in peritoneal fluid of patients with ovarian tumors of low malignant potential and invasive epithelial ovarian cancer. Guidozzi F, et al. **Gynecol Oncol** 1996 May;61(2):204–9

Identification of biologically active inhibin in the peritoneal fluid of women. Billiar RB, et al. **J Assist Reprod Genet** 1995 Jan;12(1):55–60

Ascitic fluid analysis—the yet new investigation [editorial; comment] Menon VP, et al. **J Assoc Physicians India** 1995 Nov;43(11):743–4. Comment on: J Assoc Physicians India 1995 Nov;43(11):745–7.

Ascitic fluid cholesterol in malignant and tubercular ascites [see comments] Sood A, et al. **J Assoc Physicians India** 1995 Nov;43(11):745–7. Comment in: J Assoc Physicians India 1995 Nov;43(11):743–4.

Diagnosing ascites: value of ascitic fluid total protein, albumin, cholesterol, their ratios, serum-ascites albumin and cholesterol gradient. Gupta R, et al. **J Gastroenterol Hepatol** 1995 May–Jun;10(3):295–9

High interleukin-6 production within the peritoneal cavity in decompensated cirrhosis and malignancy-related ascites. Bac DJ, et al. **Liver** 1995 Oct;15(5):265–70

Immunolocalization of 91 kDa ascitic protein in the human placenta. Kami K, et al. **Okajimas Folia Anat Jpn** 1995 Oct;72(4):227–34

The fibrinolytic system in human ascites. Bugø L, et al. **Scand J Gastroenterol** 1995 Nov;30(11):1101–7

[Immunologic factors in the serum and peritoneal fluid in women after laparoscopy. I. Nonspecific factors] Ulčová-Gallová Z, et al. **Ceska Gynekol** 1996 Feb; 61(1):23–7 (Eng. Abstr.) **(Cze)**

[Diagnosis of neoplastic ascites: combined use of albumin gradient between serum and ascites and cholesterol in ascitic fluid] Sartori M, et al. **Recenti Prog Med** 1996 Feb; 87(2):75–7 **(Ita)**

[Spontaneous bacterial peritonitis in liver cirrhosis. What tests to perform on the ascitic fluid?] Tincani E, et al. **Recenti Prog Med** 1996 Apr;87(4):150–3 (Eng. Abstr.) **(Ita)**

[Evaluation of peritoneal fluid in women with endometriosis] Skrzypczak J, et al. **Ginekol Pol** 1995 Aug;66(8):444–50 (Eng. Abstr.) **(Pol)**

[Examination of 17 beta-estradiol and progesterone levels in peritoneal fluid and blood serum of women with endometriosis] Skrzypczak J, et al. **Ginekol Pol** 1995 Sep; 66(9):523–8 (Eng. Abstr.) **(Pol)**

[Ascitic fluid: benignancy and malignancy parameters] Fluixá Carrascosa F, et al. **Rev Esp Enferm Dig** 1996 Jan; 88(1):35–8 (28 ref.) **(Spa)**

[Endoscopic and clinical parameters in assessing th degree of portal hypertension: the value of the serum-ascitic fluid albumin gradient] Torres E, et al. **Rev Gastroenterol Peru** 1996 Jan–Apr;16(1):20–6 (Eng. Abstr.) **(Spa)**

[Diagnosis of ascites—malignant or benign etiology? (letter)] Adamsen S, et al. **Lakartidningen** 1996 May 15;93(20):1932 **(Swe)**

CYTOLOGY

Peritoneal fluid cytology in advanced mucinous cystadenocarcinoma of the pancreas. Centeno BA, et al. **Acta Cytol** 1996 Mar–Apr;40(2):191–5

Detection of perforin in human peritoneal fluid T-lymphocytes. Hameed A, et al. **Acta Cytol** 1996 May–Jun;40(3):401–7

Comparative analyses of peritoneal fluid from calves and adult cattle. Anderson DE, et al. **Am J Vet Res** 1995 Aug; 56(8):973–6

Characterization of cellular components in the peritoneal fluid and in the endometrial tissue of women with endometriosis. Kamiński K, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(5–6):247–52

Ascitic fluid analysis—the yet new investigation [editorial; comment] Menon VP, et al. **J Assoc Physicians India** 1995 Nov;43(11):743–4. Comment on: J Assoc Physicians India 1995 Nov;43(11):745–7.

Effects of FMLP and LPS on [Ca2+]i of peritoneal exudate polymorphonuclear leukocytes following onset of inflammation. Qu J, et al. **J Periodontal Res** 1995 May; 30(3):153–8

Multiparameter flow cytometric DNA analysis of effusions: a prospective study of 36 cases compared with routine cytology and immunohistochemistry. Joseph MG, et al. **Mod Pathol** 1995 Aug;8(6):686–93

Activation of the peritoneal mast cells and eosinophils in untreated hemorrhagic shock in rats. Dębek W, et al. **Rocz Akad Med Bialymst** 1995;40(1):105–21

[Oncologic diagnosis of serous effusions in body cavities (cytologic study and evaluation of cholesterol and carcinoembryonic antigen levels)] Gulyás M, et al. **Orv Hetil** 1995 Nov 5;136(45):2453–8 (Eng. Abstr.) **(Hun)**

[Evaluation of intraoperative peritoneal cytology and intraperitoneal chemotherapy using CDDP combined with MMC for gastric carcinomatous peritonitis] Kitamura M, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1523–6 (Eng. Abstr.) **(Jpn)**

[Postcoital test evaluated in peritoneal fluid] Radwan J, et al. **Ginekol Pol** 1995 Apr;66(4):228–30 (Eng. Abstr.) **(Pol)**

[A test for sperm cell survival in peritoneal fluid] Radwan J, et al. **Ginekol Pol** 1995 Jun;66(6):340–3 (Eng. Abstr.) **(Pol)**

[The diagnostic value of cytology in children on continuous ambulatory peritoneal dialysis (CAPD)] Sieniawska M, et al. **Pol Arch Med Wewn** 1995 Mar;93(3):216–21 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

[Development of 5-fluorouracil incorporated in microspheres for peritoneal carcinomatosis—animal experiments] Hagiwara A, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1638–40 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

High levels of proteolytic enzymes in the ascitic fluid and plasma of rats bearing the Yoshida AH-130 hepatoma. Isidoro C, et al. **Invasion Metastasis** 1995;15(3–4):116–24

The potent anti-Staphylococcus aureus activity of a sterile rabbit inflammatory fluid is due to a 14-kD phospholipase A2. Weinrauch Y, et al. **J Clin Invest** 1996 Jan 1;97(1):250–7

[Pharmacological and biochemical investigation of intracavital fluorinated pyrimidine chemotherapy] Shibata H, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1613–5 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Value of ascitic fibronectin and cholesterol concentration in the differentiation between malignancy-related and non-malignant ascites. Archimandritis A, et al. **Ann Med Interne (Paris)** 1996;147(3):145–50

GENETICS

FISH in the evaluation of pleural and ascitic fluids. Chen Z, et al. **Cancer Genet Cytogenet** 1995 Oct 15;84(2):116–9

IMMUNOLOGY

IL-1 beta, TNF-alpha, and IL-2 in peritoneal fluid and macrophage-conditioned media of women with endometriosis. Keenan JA, et al. **Am J Reprod Immunol** 1995 Dec;34(6):381–5

Inflammatory response in peritoneal exudate and plasma of patients undergoing planned relaparotomy for severe secondary peritonitis. Holzheimer RG, et al. **Arch Surg** 1995 Dec;130(12):1314–9; discussion 1319–20

Ascitic fluid-associated lymphocytes in patients with metastatic ovarian cancer. Analysis of lymphocyte subsets and of phenotypical changes induced by "in vitro". Loiudice L, et al. **Eur J Gynaecol Oncol** 1995;16(4):301–6

No evidence of the hook effect in peritoneal fluid CA 125 measurement using immunoenzymatic second generation assays: comparison with immunoradiometric assays. Barbati A, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep; 62(1):69–73

PELs and the perforin and granzyme independent mechanism

of CTL-mediated lysis. Berke G. **Immunol Rev** 1995 Aug; 146:21-31 (52 ref.)

Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC. Mantovani G, et al. **J Mol Med** 1995 Aug;73(8):409-16

Continuous ambulatory peritoneal dialysis impairs T lymphocyte selection in the peritoneum. Fricke H, et al. **Kidney Int** 1996 May;49(5):1386-95

Inhibition of Con A-induced lymphocyte proliferation by peritoneal exudate of Toxoplasma gondii-infected mice. Nam HW, et al. **Korean J Parasitol** 1995 Sep;33(3):195-200

[The significance of immune island appeared in pleural and peritoneal effusion] Zhou D, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Apr; 18(2):77-9, 127 (Eng. Abstr.) **(Chi)**

-Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma- Radke J, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):83-7 (Eng. Abstr.) **(Ger)**

[Clinical effects and immunological analysis of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion of gastric carcinoma] Hazama S, et al. **Gan To Kagaku Ryoho** 1995 Sep; 22(11):1595-7 (Eng. Abstr.) **(Jpn)**

METABOLISM

Serum CA-125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation. Bastani B, et al. **Am J Nephrol** 1995;15(6):468-72

Intraperitoneal fluid volume changes during peritoneal dialysis in the rat: indicator dilution vs. volumetric measurements. Zakaria ER, et al. **Blood Purif** 1995; 13(5):255-70

Peritoneal and systemic cytokine response to laparotomy. Badia JM, et al. **Br J Surg** 1996 Mar;83(3):347-8

Epidermal growth factor and basic fibroblast growth factor in peritoneal fluid of women with endometriosis. Huang JC, et al. **Fertil Steril** 1996 May;65(5):931-4

Endometriosis and polycystic ovary syndrome: enhanced stimulatory effect of peritoneal fluid on progesterone release from human granulosa-lutein cells. Whitehead SA, et al. **Fertil Steril** 1996 Sep;66(3):487-9

Massive ascitic fluid loss after liver transplantation [letter; comment] John TG, et al. **Gastroenterology** 1996 Aug; 111(2):564-5. Comment on: Gastroenterology 1995 Nov;109(5):1631-8.

Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. McLaren J, et al. **Hum Reprod** 1996 Jan; 11(1):220-3

Peritoneal interleukin-8 in acute appendicitis. Zeillemaker AM, et al. **J Surg Res** 1996 May;62(2):273-7

Measurement of peritoneal fluid handling in children on continuous ambulatory peritoneal dialysis using dextran 70. Reddingius RE, et al. **Nephrol Dial Transplant** 1995; 10(6):866-70

Measurement of hydrostatic intraperitoneal pressure: a necessary routine test in peritoneal dialysis. Durand PY, et al. **Perit Dial Int** 1996;16 Suppl 1:S84-7

Role of diaphragmatic, visceral, and parietal pathways in peritoneal fluid absorption in rat peritoneal dialysis. Kumano K, et al. **Perit Dial Int** 1996;16 Suppl 1:S80-3

Relationship between prostaglandin in peritoneal fluid and pelvic venous congestion after sterilization. Ruifang W, et al. **Prostaglandins** 1996 Feb;51(2):161-7

Increase in the peritoneal antioxidative potential in experimental hemorrhagic shock. Dębek W, et al. **Rocz Akad Med Bialymst** 1995;40(1):122-8

Luminol-chemiluminescence in free peritoneal cells in hemorrhagic shock in rats treated with PAF-receptor-antagonist BN 52021. Dębek W, et al. **Rocz Akad Med Bialymst** 1995;40(1):129-37

[Significance of tumor necrosis factor alpha (TNF-alpha) in endometriosis] Küpker W, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):239-42 (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

[Isolation of Bilophila wadsworthia from peritoneal fluid of a patient with an infected Douglas pouch] Sawamura H, et al. **Kansenshogaku Zasshi** 1995 Oct;69(10):1162-3 **(Jpn)**

PATHOLOGY

Effusion cytology of hepatocellular carcinoma. Falconieri G, et al. **Acta Cytol** 1995 Sep-Oct;39(5):893-7

Quality control of immunocytochemical staining of effusions using a standardized method of cell processing. Kuenen-Boumeester V, et al. **Acta Cytol** 1996 May-Jun; 40(3):475-9

Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serious effusions. Lee JS, et al. **Acta Cytol** 1996 Jul-Aug; 40(4):631-6

Cytology of Langerhans cell histiocytosis in effusions: a case report. Nagaoka S, et al. **Acta Cytol** 1996 May-Jun; 40(3):563-6

Peritoneal exfoliative cytology and Ki-ras mutational analysis in patients with pancreatic adenocarcinoma. Rall CJ, et al. **Cancer Lett** 1995 Nov 6;97(2):203-11

Differential expression of jackfruit-lectin-specific glycoconjugates in metastatic adenocarcinoma and reactive mesothelial cells-a diagnostic aid in effusion cytology. Sujathan K, et al. **J Cancer Res Clin Oncol** 1996; 122(7):433-6

Rapid chromosome analysis and prenatal diagnosis using fluid from the cystic hygroma, hydrothorax and isolated ascites: new source for chromosome analysis. Yang YH, et al. **J Obstet Gynaecol** 1995 Oct;21(5):443-50

Ascitic positive cytology and intraperitoneal metastasis in ovarian dysgerminoma. Mandai M, et al. **J Obstet Gynaecol Res** 1996 Feb;22(1):89-94

Establishment of AIDS-related lymphoma cell lines from lymphomatous effusions. Gaidano G, et al. **Leukemia** 1996 Jul;10(7):1237-40

[Dynamics of level of peritoneal exudate cellular elements in BALB/c mice infected with Coxsackie virus A13] Bocharov EF, et al. **Biull Eksp Biol Med** 1995 Jul; 120(7):75-7 **(Rus)**

PHYSIOPATHOLOGY

Influence of changes in peritoneal fluid on body-composition measurements by dual-energy X-ray absorptiometry in patients receiving continuous ambulatory peritoneal dialysis. Woodrow G, et al. **Am J Clin Nutr** 1996 Aug; 64(2):237-41

The effect of peritoneal fluid from patients with endometriosis on human sperm function in vitro. Aeby TC, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1779-83; discussion 1783-5

Effect of peritoneal fluid from infertile women with endometriosis on ionophore-stimulated acrosome loss. Tasdemir M, et al. **Hum Reprod** 1995 Sep;10(9):2419-22

Cell free ascitic fluid prevents loss of cell surface sialic acid from Zajdela Ascitic Hepatoma cells in culture. Jain N, et al. **Indian J Biochem Biophys** 1995 Jun;32(3):113-8

PREVENTION & CONTROL

[Pseudomembranous colitis probably caused by Clostridium difficile: first case appeared during preventive treatment of infection of ascitic fluid with norfloxacin (letter)] Tordjman R, et al. **Gastroenterol Clin Biol** 1995 May; 19(5):545-6 **(Fre)**

[Complications in the intraperitoneal chemotherapy with the implantable intraperitoneal port and the strategy for the prevention of the complication] Maruyama M, et al. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1469-72 (Eng. Abstr.) **(Jpn)**

THERAPY

Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo. Kitsuki H, et al. **Clin Immunol Immunopathol** 1996 Mar; 78(3):283-90

Successful outcome of severe ovarian hyperstimulation syndrome (OHSS) with 27 liters of ascitic fluid removed by paracentesis. Grochowski D, et al. **J Assist Reprod Genet** 1995 Jul;12(6):394-6

ULTRASONOGRAPHY

Trauma ultrasound workshop improves physician detection of peritoneal and pericardial fluid. Ali J, et al. **J Surg Res** 1996 Jun;63(1):275-9

Quantitative sensitivity of ultrasound in detecting free intraperitoneal fluid [letter; comment] Lentz KA, et al. **J Trauma** 1996 Jun;40(6):1052-4. Comment on: J Trauma 1995 Aug;39(2):375-80.

Sonographic detection of the pelvic peritoneal fluid [letter; comment] Kaufmann RC. **J Ultrasound Med** 1995 Sep; 14(9):698. Comment on: J Ultrasound Med 1995 Mar;14(3):205-9.

VETERINARY

Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases. Collatos C, et al. **J Am Vet Med Assoc** 1995 Aug 15;207(4):465-70

Validation of the determination of the activity of adenosine deaminase in the body effusions of cats. Hirschberger J, et al. **Res Vet Sci** 1995 Nov;59(3):226-9

VIROLOGY

Cytodiagnosis of parvovirus B19 infection from ascites fluid of hydrops fetalis: report of a case. Iwa N, et al. **Diagn Cytopathol** 1995 Aug;13(2):139-41

Evidence of hepatitis C virus infection in peritoneal fluid but not in dialysate and ultrafiltrate or hemofiltrate [letter] Gladziwa U, et al. **Nephron** 1995;71(1):98

ASCOMYCETES

CHEMISTRY

Structural investigation of cell-wall polysaccharides from Neosartorya: relationships with their putative anamorphs of Aspergillus. Leal JA, et al. **Carbohydr Res** 1995 Aug 25;273(2):255-62

Potent inhibitors of cysteine proteases from the marine fungus Microascus longirostris. Yu CM, et al. **J Antibiot (Tokyo)** 1996 Apr;49(4):395-7

[Physicochemical properties of a beta-glucan from Sclerotinia sclerotiorum] Liu R, et al. **Wei Sheng Wu Hsueh Pao** 1995 Apr;35(2):103-8 (Eng. Abstr.) **(Chi)**

CLASSIFICATION

Ascomycetous yeast communities of marine invertebrates in a southeast Brazilian mangrove ecosystem. de Araujo FV, et al. **Antonie Van Leeuwenhoek** 1995 Aug;68(2):91-9

Phylogenetic position of yeast-like symbiont of Hamiltonaphis styraci (Homoptera, Aphididae) based on 18S rDNA sequence. Fukatsu T, et al. **Insect Biochem Mol Biol** 1996 Apr;26(4):383-8

CYTOLOGY

[Light and electron microscopic studies on the sporogenesis of Sphaerospora molnari in the gill lamellas of carp (Cyprinus carpio)] Kaup FJ, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jun;108(6):206-14 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Cloning and targeted disruption of enpg-1, encoding the major in vitro extracellular endopolygalacturonase of the chestnut blight fungus, Cryphonectria parasitica. Gao S, et al. **Appl Environ Microbiol** 1996 Jun;62(6):1984-90

Characterization of a multigene family encoding an endopolygalacturonase in Sclerotinia sclerotiorum. Fraissinet-Tachet L, et al. **Curr Genet** 1995 Dec;29(1):96-9

Characterization of the cleavage specificity of a subtilisin-like serine proteinase from Ophiostoma piceae by liquid chromatography/mass spectrometry and tandem MS. Abraham LD, et al. **FEBS Lett** 1995 Oct 30;374(2):208-10

Characterization and disruption of a gene in the maize pathogen Cochliobolus carbonum encoding a cellulase lacking a cellulose binding domain and hinge region. Sposato P, et al. **Mol Plant Microbe Interact** 1995 Jul-Aug; 8(4):602-9

Purification, cloning and characterization of two xylanases from Magnaporthe grisea, the rice blast fungus. Wu SC, et al. **Mol Plant Microbe Interact** 1995 Jul-Aug;8(4):506-14

[Evaluation of the cellulolytic capacity of Ascobolus furfuraceus (Fungi, Ascomycotina)] Mercuri OA, et al. **Rev Argent Microbiol** 1995 Jul-Sep;27(3):130-8 (Eng. Abstr.) **(Spa)**

[Endoglucanase production in 4 species of the genus Saccobolus] Ramos AM, et al. **Rev Argent Microbiol** 1996 Apr-Jun;28(2):55-62 (Eng. Abstr.) **(Spa)**

[Kinetics of xylanase and cellulase production by Ascobolus gamundii (Fungi, Ascomycotina)] Sivori AS, et al. **Rev Argent Microbiol** 1996 Jan-Mar;28(1):9-15 (Eng. Abstr.) **(Spa)**

GENETICS

Comparison of fungi within the Gaeumannomyces-Phialophora complex by analysis of ribosomal DNA sequences. Bryan GT, et al. **Appl Environ Microbiol** 1995 Feb;61(2):681-9

Cloning and targeted disruption of enpg-1, encoding the major in vitro extracellular endopolygalacturonase of the chestnut blight fungus, Cryphonectria parasitica. Gao S, et al. **Appl Environ Microbiol** 1996 Jun;62(6):1984-90

A microsatellite marker for studying the ecology and diversity of fungal endophytes (Epichloë spp.) in grasses. Groppe K, et al. **Appl Environ Microbiol** 1995 Nov; 61(11):3943-9

DNA polymorphism in morels: complete sequences of the internal transcribed spacer of genes coding for rRNA in Morchella esculenta (yellow morel) and Morchella conica (black morel). Wipf D, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3541-3

Detection of additional restriction fragment length polymorphisms among the weakly virulent (nonaggressive) and highly virulent (aggressive) isolates of Leptosphaeria maculans. Patterson NA, et al. **Can J Microbiol** 1995 Dec; 41(12):1135-41

Nucleotide-sequence analysis indicates that a DNA plasmid in a diseased isolate of Ophiostoma novo-ulmi is derived by recombination between two long repeat sequences in the mitochondrial large subunit ribosomal RNA gene. Abu-Amero SN, et al. **Curr Genet** 1995 Jun;28(1):54-9

Physical and genetic map of the mitochondrial genome of Cryphonectria parasitica Ep155. Bell JA, et al. **Curr Genet** 1996 Jun;30(1):34-43

Biolistic transformation of the obligate plant pathogenic fungus, Erysiphe graminis f.sp. hordei. Christiansen SK, et al. **Curr Genet** 1995 Dec;29(1):100-2

Inheritance of chromosome-length polymorphisms in Ophiostoma ulmi (sensu lato). Dewar K, et al. **Curr Genet** 1995 May;27(6):541-9

Molecular karyotype of the phytopathogenic fungus Sclerotinia sclerotiorum. Fraissinet-Tachet L, et al. **Curr Genet** 1996 Apr;29(5):496-501

Characterization of a multigene family encoding an endopolygalacturonase in Sclerotinia sclerotiorum.

Fraissinet-Tachet L, et al. **Curr Genet** 1995 Dec;29(1):96-9
A small insertion in the SSU rDNA of the lichen fungus Arthonia lapidicola is a degenerate group-I intron. Grube M, et al. **Curr Genet** 1996 May;29(6):582-6
Sequence diversity and unusual variability at the het-c locus involved in vegetative incompatibility in the fungus Podospora anserina. Saupe S, et al. **Curr Genet** 1995 Apr; 27(5):466-71
Transformation of Sordaria macrospora to hygromycin B resistance: characterization of transformants by electrophoretic karyotyping and tetrad analysis. Walz M, et al. **Curr Genet** 1995 Dec;29(1):88-95
Deletion of the Cochliobolus heterostrophus mating-type (MAT) locus promotes the function of MAT transgenes. Wirsel S, et al. **Curr Genet** 1996 Feb;29(3):241-9
MIP: an epigenetic gene silencing process in Ascobolus immersus. Rossignol JL, et al.
Curr Top Microbiol Immunol 1995;197:179-91 (32 ref.)
Phylogenetic resolution of Morchella, Verpa, and Disciotis [Pezizales: Morchellaceae] based on restriction enzyme analysis of the 28S ribosomal RNA gene. Bunyard BA, et al. **Exp Mycol** 1995 Sep;19(3):223-33
Phylogenetic ordinal placement based on rDNA sequences of the freshwater genera Ophioceras and Pseudohalonectria. Chen W, et al. **Exp Mycol** 1995 Sep; 19(3):191-201
Chitin synthase homologs in three ectomycorrhizal truffles. Lanfranco L, et al. **FEMS Microbiol Lett** 1995 Dec 1; 134(1):109-14
Genetic differentiation in the rice blast fungus revealed by the distribution of the Fosbury retrotransposon. Shull V, et al. **Fungal Genet Biol** 1996 Mar;20(1):59-69
Isolation and characterization of two novel genes expressed in germinating conidia of the obligate biotroph Erysiphe graminis f.sp. hordei. Justesen A, et al. **Gene** 1996 Apr 17; 170(1):131-5
An additional copy of the adenylate cyclase-encoding gene relieves developmental defects produced by a mutation in a vegetative incompatibility-controlling gene in Podospora anserina. Loubradou G, et al. **Gene** 1996 Apr 17; 170(1):119-23
Cloning and sequence of the Ascobolus immersus S-adenosyl-L-methionine synthetase-encoding gene. Mautino MR, et al. **Gene** 1996 Apr 17;170(1):155-6
Identification of peptide synthetase-encoding genes from filamentous fungi producing host-selective phytotoxins or analogs. Nikolskaya AN, et al. **Gene** 1995 Nov 20; 165(2):207-11
A gene responsible for vegetative incompatibility in the fungus Podospora anserina encodes a protein with a GTP-binding motif and G beta homologous domain. Saupe S, et al. **Gene** 1995 Aug 30;162(1):135-9
Sexual reproduction plays a major role in the genetic structure of populations of the fungus Mycosphaerella graminicola. Chen RS, et al. **Genetics** 1996 Apr; 142(4):1119-27
Inheritance of mitochondrial DNA and plasmids in the ascomycetous fungus, Epichloë typhina. Chung KR, et al. **Genetics** 1996 Jan;142(1):259-65
Isolation of the Ascobolus immersus spore color gene b2 and study in single cells of gene silencing by methylation induced premeiotically. Colot V, et al. **Genetics** 1995 Dec; 141(4):1299-314
Genetic and physical mapping of telomeres in the rice blast fungus, Magnaporthe grisea. Farman ML, et al.
Genetics 1995 Jun;140(2):479-92
Altered mating-type identity in the fungus Podospora anserina leads to selfish nuclei, uniparental progeny, and haploid meiosis. Zickler D, et al. **Genetics** 1995 Jun; 140(2):493-503
Non-locus-specific polygenes giving responses to selection for gene conversion frequencies in Ascobolus immersus. Zwolinski SA, et al. **Genetics** 1995 Aug;140(4):1277-87
Genome comparisons in the yeastlike fungal genus Galactomyces Redhead et Malloch. Smith MT, et al.
Int J Syst Bacteriol 1995 Oct;45(4):826-31
Genetic homogeneity of Trichophyton mentagrophytes var. interdigitale isolated from geographically distant regions. Mochizuki T, et al. **J Med Vet Mycol** 1996 Mar-Apr; 34(2):139-43
Natural plasmids of filamentous fungi. Griffiths AJ.
Microbiol Rev 1995 Dec;59(4):673-85 (102 ref.)
Loculoascomycete origins and evolution of filamentous ascomycete morphology based on 18S rRNA gene sequence data. Berbee ML. **Mol Biol Evol** 1996 Mar; 13(3):462-70
A common group I intron between a plant parasitic fungus and its host. Niahida H, et al. **Mol Biol Evol** 1995 Sep; 12(5):883-6
Methylation of DNA repeats of decreasing sizes in Ascobolus immersus. Goyon C, et al. **Mol Cell Biol** 1996 Jun; 16(6):3054-65
MAGGY, a retrotransposon in the genome of the rice blast fungus Magnaporthe grisea. Farman ML, et al.
Mol Gen Genet 1996 Jul 26;251(6):665-74
The Magnaporthe grisea DNA fingerprinting probe MGR586 contains the 3' end of an inverted repeat transposon. Farman ML, et al. **Mol Gen Genet** 1996 Jul 26; 251(6):675-81
NUT1, a major nitrogen regulatory gene in Magnaporthe grisea, is dispensable for pathogenicity. Froeliger EH, et al. **Mol Gen Genet** 1996 Jul 26;251(6):647-56
Cloning and characterization of the eapB and eapC genes of Cryphonectria parasitica encoding two new acid proteinases, and disruption of eapC. Jara P, et al.
Mol Gen Genet 1996 Jan 15;250(1):97-105
Characterization of the transcript of a new class of retroposon-type repetitive element cloned from the powdery mildew fungus, Erysiphe graminis. Wei YD, et al. **Mol Gen Genet** 1996 Mar 7;250(4):477-82
MPG1, a gene encoding a fungal hydrophobin of Magnaporthe grisea, is involved in surface recognition. Beckerman JL, et al. **Mol Plant Microbe Interact** 1996 Aug; 9(6):450-6
The PWL host specificity gene family in the blast fungus Magnaporthe grisea. Kang S, et al.
Mol Plant Microbe Interact 1995 Nov-Dec;8(6):939-48
A competitive polymerase chain reaction to quantify DNA of Leptosphaeria maculans during blackleg development in oilseed rape. Mahuku GS, et al.
Mol Plant Microbe Interact 1995 Sep-Oct;8(5):761-7
Three extracellular proteases from Cochliobolus carbonum: cloning and targeted disruption of ALP1. Murphy JM, et al. **Mol Plant Microbe Interact** 1996 May;9(4):290-7
Characterization and disruption of a gene in the maize pathogen Cochliobolus carbonum encoding a cellulase lacking a cellulose binding domain and hinge region. Sposato P, et al. **Mol Plant Microbe Interact** 1995 Jul-Aug; 8(4):602-9
Purification, cloning and characterization of two xylanases from Magnaporthe grisea, the rice blast fungus. Wu SC, et al. **Mol Plant Microbe Interact** 1995 Jul-Aug;8(4):506-14
Telomere length does not change during senescence of the ascomycete Podospora anserina. Schwartz T, et al.
Mutat Res 1996 May;316(5-6):193-9
Contribution of ultra-short invasive elements to the evolution of the mitochondrial genome in the genus Podospora. Koll F, et al. **Nucleic Acids Res** 1996 May 1;24(9):1734-41
Chromosomal organization of TOX2, a complex locus controlling host-selective toxin biosynthesis in Cochliobolus carbonum. Ahn JH, et al. **Plant Cell** 1996 May;8(5):887-97
Identification, cloning, and characterization of PWL2, a gene for host species specificity in the rice blast fungus. Sweigard JA, et al. **Plant Cell** 1995 Aug;7(8):1221-33
Mg-SINE: a short interspersed nuclear element from the rice blast fungus, Magnaporthe grisea. Kachroo P, et al.
Proc Natl Acad Sci U S A 1995 Nov 21;92(24):11125-9

GROWTH & DEVELOPMENT

A method for selecting Trichoderma strains antagonistic against Sclerotinia minor. Naár Z, et al. **Microbiol Res** 1995 Sep;150(3):239-46
[Advances in the study on artificial cultivation of Cordyceps sinensis] Yin D, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Dec;20(12):707-9, inside back cover (29 ref.) **(Chi)**
[Effect of light and glucose on the apothecial development of Iodophanus carneus (Fungi, Ascomycotina)] Diorio LA. **Rev Argent Microbiol** 1996 Apr-Jun;28(2):63-72 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Molecular phylogeny of the fungi of the Iceman's grass clothing. Rollo F, et al. **Curr Genet** 1995 Aug;28(3):289-97
Use of RAPD analysis for in situ identification of Ascosphaera aggregata and Ascosphaera larvis in larval cadavers of the alfalfa leafcutting bee, Megachile rotundata. Lu R, et al. **J Invertebr Pathol** 1996 Jul;68(1):78-83
A statistical evaluation of the occurrence of keratinolytic fungi in the sediments of two dam reservoirs. Ulfig K.
Rocz Panstw Zakl Hig 1995;46(1):81-9

METABOLISM

New metabolites with nematicidal and antimicrobial activities from the ascomycete Lachnum papyraceum (Karst.) Karst. VIII. Isolation, structure determination and biological activities of minor metabolites structurally related to mycorrhizin A. Shan R, et al. **J Antibiot (Tokyo)** 1996 May; 49(5):447-52

PHYSIOLOGY

The fine structure of ascospore shape and development in Ceratocystis fimbriata. de Beer C, et al.
Antonie Van Leeuwenhoek 1995;67(4):325-32
Fruiting studies in species of Capronia (Herpotrichiellaceae). Untereiner WA. **Antonie Van Leeuwenhoek** 1995 Jul; 68(1):3-17
Temperature-dependent dimorphism of the yeast Arxula adeninivorans Ls3. Wartmann T, et al.
Antonie Van Leeuwenhoek 1995 Oct;68(3):215-23
Steroid hormone signalling system and fungi. Zakelj-Mavrič M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec;112(4):637-42 (69 ref.)
Induction of longevity by cytoplasmic transfer of a linear plasmid in Podospora anserina. Hermanns J, et al.
Curr Genet 1996 Feb;29(3):250-6
An asexual fungus has the potential for sexual development. Sharon A, et al. **Mol Gen Genet** 1996 Apr 24;251(1):60-8
[Light and electron microscopic studies on the sporogenesis of Sphaerospora molnari in the gill lamellas of carp (Cyprinus carpio)] Kaup FJ, et al.
Berl Munch Tierarztl Wochenschr 1995 Jun;108(6):206-14 (Eng. Abstr.) **(Ger)**

RADIATION EFFECTS

[Development of Iodophanus carneus under different types of light] Diorio LA, et al. **Rev Argent Microbiol** 1995 Apr-Jun;27(2):71-9 (Eng. Abstr.) **(Spa)**

VIROLOGY

Transcriptional repression of specific host genes by the mycovirus Cryphonectria hypovirus 1. Kazmierczak P, et al. **J Virol** 1996 Feb;70(2):1137-42
Induction of a Cryphonectria parasitica cellobiohydrolase I gene is suppressed by hypovirus infection and regulated by a GTP-binding-protein-linked signaling pathway involved in fungal pathogenesis. Wang P, et al.
Proc Natl Acad Sci U S A 1995 Dec 5;92(25):11529-33

ASCORBASE see **ASCORBATE OXIDASE**

ASCORBATE OXIDASE

CHEMISTRY

A heme-containing ascorbate oxidase from Pleurotus ostreatus. Kim YR, et al. **J Biol Chem** 1996 Feb 9; 271(6):3105-11

GENETICS

cDNA cloning and gene expression of ascorbate oxidase in tobacco. Kato N, et al. **Plant Mol Biol** 1996 Feb;30(4):833-7

METABOLISM

Pulmonary oxygen toxicity in mice is characterized by alterations in ascorbate redox status. Rusakow LS, et al.
J Appl Physiol 1995 Nov;79(5):1769-76
A heme-containing ascorbate oxidase from Pleurotus ostreatus. Kim YR, et al. **J Biol Chem** 1996 Feb 9; 271(6):3105-11

ASCORBIC ACID

The effect of simple hypothermic preservation with Trolox and ascorbate on lipid peroxidation in dog kidneys. McAnulty JF, et al. **Cryobiology** 1996 Apr;33(2):217-25
Oxidation of caffeine and related methylxanthines in ascorbate and polyphenol-driven Fenton-type oxidations. Stadler RH, et al. **Free Radic Res** 1996 Mar;24(3):225-10
Vitamin C and human health--a review of recent data relevant to human requirements. Weber P, et al.
Int J Vitam Nutr Res 1996;66(1):19-30 (107 ref.)
Quantitation of the reactive oxygen species generated by the UVA irradiation of ascorbic acid-glycated lens proteins. Linetsky M, et al. **Photochem Photobiol** 1996 May; 63(5):649-55
Catalytic metals, ascorbate and free radicals: combinations to avoid. Buettner GR, et al. **Radiat Res** 1996 May; 145(5):532-41 (79 ref.)
[A comment on vitamin C (letter)] Cohn H.
Ugeskr Laeger 1996 Jul 1;158(27):3952-3 **(Dan)**
[Substitution of ascorbic acid for potassium bromide in the making of French bread] Corrales X, et al.
Arch Latinoam Nutr 1993 Sep;43(3):234-40 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Considerations of the scientific substantiation for antioxidant vitamins and beta-carotene in disease prevention. Blumberg JB. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1521S-1526S (59 ref.)
Evidence from cancer intervention and biomarker studies and the development of biochemical markers. Bowen PE, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1403S-1409S (54 ref.)
Epidemiologic evidence for vitamin C and vitamin E in cancer prevention. Byers T, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1385S-1392S
Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Hennekens CH, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1377S-1380S (26 ref.)
Determination of optimal vitamin C requirements in humans. Levine M, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1347S-1356S (137 ref.)
Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Losonczy KG, et al. **Am J Clin Nutr** 1996 Aug; 64(2):190-6
Relations among aging, antioxidant status, and cataract. Taylor A, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1439S-1447S (80 ref.)
Dietary vitamin C and beta-carotene and risk of death in middle-aged men. The Western Electric Study. Pandey DK, et al. **Am J Epidemiol** 1995 Dec 15;142(12):1269-78
A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group [see comments] Manson JE, et al. **Ann Epidemiol** 1995 Jul;5(4):261-9. Comment in: Ann Epidemiol 1995 Jul;5(4):333-5.
Effect of different levels of an ascorbic acid and tea mixture

on nonheme iron absorption from a typical Tunisian meal fed to healthy rats. Hamdaouui M, et al. **Ann Nutr Metab** 1995;39(5):310–6

Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? McAlindon TE, et al. **Arthritis Rheum** 1996 Apr; 39(4):648–56

Role of ascorbate in protection by nitecapone against cardiac ischemia–reperfusion injury. Haramaki N, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):839–43

An N-of-1 trial for treatment of hyperemesis gravidarum. Magee LA, et al. **Br J Obstet Gynaecol** 1996 May; 103(5):478–80

Vitamin C as placebo [letter; comment] Ball DR. **Can J Anaesth** 1995 Aug;42(8):750–1. Comment on: Can J Anaesth 1994 Dec;41(12):1166–71.

Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Kurbacher CM, et al. **Cancer Lett** 1996 Jun 5;103(2):183–9

Dietary antioxidants and carotid artery wall thickness. The ARIC Study. Atherosclerosis Risk in Communities Study. Kritchevsky SB, et al. **Circulation** 1995 Oct 15; 92(8):2142–50

A new gastric ulcer model in rats produced by ferrous iron and ascorbic acid injection. Naito Y, et al. **Digestion** 1995; 56(6):472–8

Serum antioxidant potential, and lipoprotein oxidation in female smokers following vitamin C supplementation. Mulholland CW, et al. **Int J Food Sci Nutr** 1996 May; 47(3):227–31

Comparison of two levels of vitamin C supplementation on antioxidant vitamin status in elderly institutionalized subjects. Birlouez-Aragon I, et al. **Int J Vitam Nutr Res** 1995;65(4):261–6

Liver ascorbate and glutathione disulfide levels in guinea pigs are affected by dietary ascorbate intake and the type of diet. Netke S, et al. **Int J Vitam Nutr Res** 1995;65(3):187–92

Dietary intakes of energy and water-soluble vitamins in different categories of aging. van der Wielen RP, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jan;51(1):B100–7

Long-term low ascorbic acid intake reduces bone mass in guinea pigs. Kipp DE, et al. **J Nutr** 1996 Aug;126(8):2044–9

High phosphatidylcholine hydroperoxide level in plasma of guinea pigs with low and excess supplementation of ascorbic acid. Kinoshita M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Feb;42(1):35–46

Glutathione deficiency as a complication of methylmalonic acidemia: response to high doses of ascorbate. Treacy E, et al. **J Pediatr** 1996 Sep;129(3):445–8

A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. Curhan GC, et al. **J Urol** 1996 Jun;155(6):1847–51

A pilot study for a randomized controlled trial to prevent gastric cancer in high-risk Japanese population: study design and feasibility evaluation. Tsugane S, et al. **Jpn J Cancer Res** 1996 Jul;87(7):676–9

Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women [see comments] Kushi LH, et al. **N Engl J Med** 1996 May 2;334(18):1156–62. Comment in: N Engl J Med 1996 May 2;334(18):1189–90.

Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Gastaldello K, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:44–7

Effects of supplemental ascorbic acid on the performance of broiler chickens exposed to multiple concurrent stressors. McKee JS, et al. **Poult Sci** 1995 Nov; 74(11):1772–85

Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Levine M, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3704–9

[Vitamin C and disease (letter)] Cohn H. **Ugeskr Laeger** 1996 Apr 8;158(15):2139 **(Dan)**

[Vitamin C and cancer (letter)] Feddersen S. **Ugeskr Laeger** 1996 Jul 1;158(27):3953–4 **(Dan)**

[Old wine in new bottles: the "promille-killer" Party Plus] Schmidt V, et al. **Blutalkohol** 1995 Sep;32(5):241–53 (Eng. Abstr.) **(Ger)**

[Antioxidative vitamins and cataracts in the elderly] Heseker H. **Z Ernahrungswiss** 1995 Sep;34(3):167–76 (68 ref.) (Eng. Abstr.) **(Ger)**

[Optic neuritis and vitamin C] Ichibe Y, et al. **Nippon Ganka Gakkai Zasshi** 1996 May;100(5):381–7 (Eng. Abstr.) **(Jpn)**

[Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of the consumption of food with an elevated content of this vitamin] Núñez Martín C, et al. **Nutr Hosp** 1995 Nov-Dec;10(6):368–72 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Safety of antioxidant vitamins and beta-carotene. Diplock AT. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1510S–1516S (56 ref.)

Urethral "discharge" from megadose ascorbic acid [letter] Kamien M. **Med J Aust** 1996 May 6;164(9):575

[Delusion and sleep deprivation] Devillières P, et al. **Encephale** 1996 May-Jun;22(3):229–31 (Eng. Abstr.) **(Fre)**

ANALOGS & DERIVATIVES

In vitro inhibition of human cytomegalovirus replication in human foreskin fibroblasts and endothelial cells by ascorbic acid 2-phosphate. Cinatl J, et al. **Antiviral Res** 1995 Aug; 27(4):405–18

Inhibitory effect of sodium 5,6-benzylidene ascorbate (SBA) on the elevation of melanin biosynthesis induced by ultraviolet-A (UV-A) light in cultured B-16 melanoma cells. Kojima S, et al. **Biol Pharm Bull** 1995 Aug; 18(8):1076–80

Inhibition of hepatocellular carcinoma development and erythrocyte polyamine levels in ODS rats fed on 3'-methyl-4-dimethylaminoazobenzene by hemicalcium ascorbate, 2-O-octadecylascorbic acid, and ascorbyl palmitate. Shimpo K, et al. **Cancer Detect Prev** 1996; 20(2):137–45

Differential susceptibility of epidermal keratinocytes and neuroblastoma cells to cytotoxicity of ultraviolet-B light irradiation prevented by the oxygen radical-scavenger ascorbate-2-phosphate but not by ascorbate. Kanatate T, et al. **Cell Mol Biol Res** 1995;41(6):561–7

Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. Kameyama K, et al. **J Am Acad Dermatol** 1996 Jan; 34(1):29–33

The reduction of membrane-bound dopamine beta-monooxygenase in resealed chromaffin granule ghosts. Is intragranular ascorbic acid a mediator for extragranular reducing equivalents? Wimalasena K, et al. **J Biol Chem** 1995 Nov 17;270(46):27516–24

Promotive action of acylated ascorbate on cellular DNA synthesis and growth at low doses in contrast to inhibitory action at high doses or upon combination with hyperthermia. Kageyama K, et al. **J Cancer Res Clin Oncol** 1996;122(1):41–4

Ascorbate polyphosphate is a bioavailable vitamin C source in juvenile rainbow trout: tissue saturation and compartmentalization model. Matusiewicz M, et al. **J Nutr** 1995 Dec;125(12):3055–61

In situ intestinal absorption of 2-O-alpha-D-glucopyranosyl-L-ascorbic acid in guinea pigs. Wakamiya H, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Apr;41(2):265–72

Protective effect of magnesium-L-ascorbyl-2 phosphate against skin damage induced by UVB irradiation. Kobayashi S, et al. **Photochem Photobiol** 1996 Jul; 64(1):224–8

Ascorbic acid is essential for the release of insulin from scorbutic guinea pig pancreatic islets. Wells WW, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11869–73

ANALYSIS

Carotenoids, vitamins C and E, and mortality in an elderly population. Sahyoun NR, et al. **Am J Epidemiol** 1996 Sep 1;144(5):501–11

Analysis of ascorbate in plant tissues by high-performance capillary zone electrophoresis. Davey MW, et al. **Anal Biochem** 1996 Jul 15;239(1):8–19

Characterization of carbon paste electrodes in vitro for simultaneous amperometric measurement of changes in oxygen and ascorbic acid concentrations in vivo. Lowry JP, et al. **Analyst** 1996 Jun;121(6):761–6

Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. Suarna C, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1616–24

Carbon fibre micro-electrode and in vitro or in brain slices voltammetric measurement of ascorbate, catechol and indole oxidation signals: influence of temperature and physiological media. Crespi F. **Biosens Bioelectron** 1996; 11(8):743–9

Comparative determination of ascorbic acid in bass (Morone lebrax) liver by HPLC and DNPH methods. Otles S. **Int J Food Sci Nutr** 1995 Aug;46(3):229–32

Simultaneous determination of ascorbic, dehydroascorbic, isoascorbic, and dehydroisoascorbic acids in meat-based food products by liquid chromatography with postcolumn fluorescence detection: a method extension. Ali MS, et al. **J AOAC Int** 1996 May-Jun;79(3):803–8

Spin trapping endogenous radicals in MC-1010 cells: evidence for hydroxyl radical and carbon-centered ascorbyl radical adducts. Bernofsky C, et al. **Mol Cell Biochem** 1995 Jul 19;148(2):155–64

[Ascorbic acid concentrations in ruminal fluid and in blood of cattle and sheep] Hatipoglu F, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Aug;102(8):321–3 (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Transgenic expression of L-gulono-gamma-lactone oxidase in medaka (Oryzias latipes), a teleost fish that lacks this enzyme necessary for L-ascorbic acid biosynthesis. Toyohara H, et al. **Biochem Biophys Res Commun** 1996 Jun 25;223(3):650–3

Ascorbate synthesis-dependent glutathione consumption in mouse liver. Bánhegyi G, et al. **FEBS Lett** 1996 Feb 26; 381(1-2):39–41

Glutathione depletion induces glycogenolysis dependent ascorbate synthesis in isolated murine hepatocytes. Braun L, et al. **FEBS Lett** 1996 Jun 17;388(2-3):173–6

[Measurement of radical in irradiated experimental tumor: direct detection of ascorbate radical in mice using ESR] Isoda H, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Sep;55(11):769–73 (Eng. Abstr.) **(Jpn)**

BLOOD

Dietary intake, plasma levels of antioxidant vitamins, and oxidative stress in relation to coronary artery disease in elderly subjects. Singh RB, et al. **Am J Cardiol** 1995 Dec 15;76(17):1233–8

Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill patients. Schorah CJ, et al. **Am J Clin Nutr** 1996 May;63(5):760–5

Determination of ascorbic acid and dehydroascorbic acid in plasma by high-performance liquid chromatography with coulometric detection—are they reliable biomarkers of oxidative stress? Lykkesfeldt J, et al. **Anal Biochem** 1995 Aug 10;229(2):329–35

Peroxynitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals. Vásquez-Vivar J, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):869–76

Ascorbic acid concentrations in umbilical cord veins and arteries of preterm and term newborns. Guajardo L, et al. **Biol Neonate** 1995;68(1):1–9

Effect of smoking cessation on plasma ascorbic acid concentration. Lykkesfeldt J, et al. **BMJ** 1996 Jul 13; 313(7049):91

Stability of ascorbic acid, carotenoids, retinol, and tocopherols in plasma stored at -70 degrees C for 4 years. Comstock GW, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul-Aug; 4(5):505–7

An automated, specific, spectrophotometric method for measuring ascorbic acid in plasma (EFTSA). Benzie IF. **Clin Biochem** 1996 Apr;29(2):111–6

Measurement of ascorbic acid in human plasma and serum: stability, intralaboratory repeatability, and interlaboratory reproducibility. Margolis SA, et al. **Clin Chem** 1996 Aug; 42(8 Pt 1):1257–62

Leukocyte lipid peroxidation, superoxide dismutase, glutathione peroxidase and serum and leukocyte vitamin C levels of patients with type II diabetes mellitus. Akkuş I, et al. **Clin Chim Acta** 1996 Jan 31;244(2):221–7

The effect of ascorbic acid on the measurement of total cholesterol and triglycerides: possible artefactual lowering in individuals with high plasma concentration of ascorbic acid. Benzie IF, et al. **Clin Chim Acta** 1995 Aug 14; 239(2):185–90

The vitamin C connection [letter] Cheraskin E. **Diabet Med** 1995 Aug;12(8):724–5

Plasma ascorbic acid concentrations in the Republic of Karelia, Russia and in North Karelia, Finland. Matilainen T, et al. **Eur J Clin Nutr** 1996 Feb;50(2):115–20

Plasma concentrations of carotenoids and antioxidant vitamins in Scottish males: influences of smoking. Ross MA, et al. **Eur J Clin Nutr** 1995 Nov;49(11):861–5

Levels of antioxidant nutrients in plasma and low density lipoproteins: a human volunteer supplementation study. Calzada C, et al. **Free Radic Res** 1995 Nov;23(5):489–503

Serum beta-carotene, vitamin E, vitamin C and malondialdehyde levels in several types of cancer. Torun M, et al. **J Clin Pharm Ther** 1995 Oct;20(5):259–63

Vitamin C status and blood pressure. Ness AR, et al. **J Hypertens** 1996 Apr;14(4):503–8

Plasma ascorbic acid concentrations are related to cardiovascular risk factors in African-Americans. Toohey L, et al. **J Nutr** 1996 Jan;126(1):121–8

Decrease of serum ascorbic acid concentrations in patients with diabetic macroangiopathy. Nagano S, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Feb;42(1):1–9

Serum carotene, vitamin A, and vitamin C levels in breast cancer and cancer of the uterine cervix. Ramaswamy G, et al. **Nutr Cancer** 1996;25(2):173–7

Effect of diet on growth and plasma ascorbic acid in chicks. Kratzer FH, et al. **Poult Sci** 1996 Jan;75(1):82–9

Iron, ascorbate and copper status of Sowetan Blacks with calcific chronic pancreatitis. Segal I, et al. **QJM** 1996 Jan; 89(1):45–53

[Relationship between serum micronutrients and precancerous gastric lesions] Zhang L, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul; 29(4):198–201 (Eng. Abstr.) **(Chi)**

[Vitamin C (ascorbic acid)] Hashizume N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:709–11 (2 ref.) **(Jpn)**

[The vitamin allowance of the adult population of the Russian Federation and its changes in 1983–1993. 1. Vitamins C, E, A and carotene] Spirichev VB, et al. **Vopr Pitan** 1995; (4):5–12 (Eng. Abstr.) **(Rus)**

[Serum levels of vitamins A, C and E in the population of Slovakia] Babinská K, et al. **Bratisl Lek Listy** 1995 Aug; 96(8):430–4 (Eng. Abstr.) **(Slo)**

[Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of the consumption of food with an elevated content of this vitamin] Núñez Martín C, et al. **Nutr Hosp** 1995 Nov-Dec;10(6):368–72 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Determination of rate constants for rapid peroxidase reactions. Goodwin DC, et al. **Anal Biochem** 1995 Nov 1;231(2):333–8

Kinetics and mechanisms of hypochlorous acid reactions. Folkes LK, et al. **Arch Biochem Biophys** 1995 Oct 20; 323(1):120–6

Stopped–flow kinetic study of the reaction of ascorbic acid with peroxynitrite. Squadrito GL, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):53–9

NO–redox paradox: direct oxidation of alpha–tocopherol and alpha–tocopherol–mediated oxidation of ascorbate. Gorbunov NV, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):835–41

Characterisation of novel indenoindoles. Part II. Redox–recycling with ascorbate. Björquist P, et al. **Biochem Pharmacol** 1996 May 17;51(10):1403–10

DNA–drug interaction. The effects of vitamin C on the solution structure of Calf–thymus DNA studied by FTIR and laser Raman difference spectroscopy. Neault JF, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):387–97

DEFICIENCY see ASCORBIC ACID DEFICIENCY

HISTORY

[Albert Szent–Györgyi and flavonoid research] Gábor M. **Orv Hetil** 1996 Jan 14;137(2):83–4 **(Hun)**

METABOLISM

Simultaneous amperometric measurement of ascorbate and catecholamine secretion from individual bovine adrenal medullary cells. Cahill PS, et al. **Anal Chem** 1995 Aug 1; 67(15):2599–605

The effect of iron on metabolism of vitamin C in chickens. Nagórna–Stasiak B, et al. **Arch Vet Pol** 1994;34(1–2):99–106

One–electron oxidation of ergothioneine and analogues investigated by pulse radiolysis: redox reaction involving ergothioneine and vitamin C. Asmus KD, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):625–9

Proposed role for a combination of citric acid and ascorbic acid in the production of dietary iron overload: a fundamental cause of disease. Crawford RD. **Biochem Mol Med** 1995 Feb;54(1):1–11 (77 ref.)

Oxidation of vitamin E, vitamin C, and thiols in rat brain synaptosomes by peroxynitrite. Vatassery GT. **Biochem Pharmacol** 1996 Aug 23;52(4):579–86

Ascorbic acid recycling enhances the antioxidant reserve of human erythrocytes. May JM, et al. **Biochemistry** 1995 Oct 3;34(39):12721–8

Ascorbate is the major electron donor for a transmembrane oxidoreductase of human erythrocytes. May JM, et al. **Biochim Biophys Acta** 1995 Sep 13;1238(2):127–36

Endocrine regulation of ascorbic acid transport and secretion in luteal cells. Musicki B, et al. **Biol Reprod** 1996 Feb; 54(2):399–406

A kinetic study of the coupled iron–ceruloplasmin catalyzed oxidation of ascorbate in the presence of albumin. Løvstad RA. **Biometals** 1995 Oct;8(4):328–31

Dosing time with ascorbic acid and nitrate, gum and tobacco chewing, fasting, and other factors affecting N–nitrosoproline formation in healthy subjects taking proline with a standard meal. Mirvish SS, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov; 4(7):775–82

Ascorbic acid may protect against human gastric cancer by scavenging mucosal oxygen radicals. Drake IM, et al. **Carcinogenesis** 1996 Mar;17(3):559–62

The reductive conversion of chromium (VI) by ascorbate gives rise to apurinic/apyrimidinic sites in isolated DNA. da Cruz Fresco P, et al. **Chem Res Toxicol** 1995 Sep; 8(6):884–90

The transport of vitamin C in the isolated human near–term placenta. Rybakowski C, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):107–14

Dietary restriction delays cataract and reduces ascorbate levels in Emory mice. Taylor A, et al. **Exp Eye Res** 1995 Jul;61(1):55–62

Gluconeogenesis from ascorbic acid: ascorbate recycling in isolated murine hepatocytes. Braun L, et al. **FEBS Lett** 1996 Jul 22;390(2):183–6

Role of ascorbic acid in the metabolism of S–nitroso–glutathione. Kashiba–Iwatsuki M, et al. **FEBS Lett** 1996 Jul 1;389(2):149–52

Ascorbate is the natural substrate for plant peroxidases. Mehlhorn H, et al. **FEBS Lett** 1996 Jan 15;378(3):203–6

Oxidation of ascorbic acid by lipoxygenase: effect of selected chemicals. Roy P, et al. **Food Chem Toxicol** 1996 Jun; 34(6):563–70

Whole body X–ray irradiation to mice decreases ascorbic acid concentration in bone marrow: comparison between ascorbic acid and vitamin E. Umegaki K, et al. **Free Radic Biol Med** 1995 Oct;19(4):493–7

Kinetics of the competitive degradation of deoxyribose and other molecules by hydroxyl radicals produced by the Fenton reaction in the presence of ascorbic acid. Zhao MJ, et al. **Free Radic Res** 1995 Sep;23(3):229–43

Ascorbic acid and total vitamin C concentrations in plasma, gastric juice, and gastrointestinal mucosa: effects of gastritis and oral supplementation. Waring AJ, et al. **Gut** 1996 Feb; 38(2):171–6

Exercise training generates ascorbate free radical in rat heart. Somani SM, et al. **Indian J Physiol Pharmacol** 1995 Oct; 39(4):323–9

Detection of an increase in ascorbate radical in an irradiated experimental tumour system using ESR. Isoda H, et al. **Int J Radiat Biol** 1995 Oct;68(4):467–73

Liver ascorbate and glutathione disulfide levels in guinea pigs are affected by dietary ascorbate intake and the type of diet. Netke S, et al. **Int J Vitam Nutr Res** 1995;65(3):187–92

Ascorbic acid and glucose oxidation by ultraviolet A–generated oxygen free radicals. Giangiacomo A, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1549–56

alpha–Lipoic acid dependent regeneration of ascorbic acid from dehydroascorbic acid in rat liver mitochondria. Xu DP, et al. **J Bioenerg Biomembr** 1996 Feb;28(1):77–85

Selective oxidative modification and affinity cleavage of pigeon liver malic enzyme by the Cu(2+)–ascorbate system. Chou WY, et al. **J Biol Chem** 1995 Oct 27; 270(43):25935–41

Interaction of ascorbate and alpha–tocopherol in resealed human erythrocyte ghosts. Transmembrane electron transfer and protection from lipid peroxidation. May JM, et al. **J Biol Chem** 1996 May 3;271(18):10577–82

Resolution of the facilitated transport of dehydroascorbic acid from its intracellular accumulation as ascorbic acid. Vera JC, et al. **J Biol Chem** 1995 Oct 6;270(40):23706–12

The reduction of membrane–bound dopamine beta–monooxygenase in resealed chromaffin granule ghosts. Is intragranular ascorbic acid a mediator for extragranular reducing equivalents? Wimalasena K, et al. **J Biol Chem** 1995 Nov 17;270(46):27516–24

Effects of physical exercise and aging on ascorbic acid and superoxide anion levels in peritoneal macrophages from mice and guinea pigs. De la Fuente M, et al. **J Comp Physiol [B]** 1995;165(4):315–9

Ascorbate–stimulated lipid peroxidation in human brain is dependent on iron but not on hydroxyl radical. Andorn AC, et al. **J Neurochem** 1996 Aug;67(2):717–22

Inhibitory action of palytoxin on ascorbic acid transport into cultured bovine adrenal chromaffin cells. Morita K, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):996–1001

Endotoxin depletes ascorbate in the guinea pig heart. Protective effects of vitamins C and E against oxidative stress. Rojas C, et al. **Life Sci** 1996;59(8):649–57

In vitro oxidation of vitamins C and E, cholesterol, and thiols in rat brain synaptosomes. Vatassery GT. **Lipids** 1995 Nov; 30(11):1007–13

The nitric oxide/ascorbate cycle: how neurones may control their own oxygen supply. Millar J. **Med Hypotheses** 1995 Jul;45(1):21–6 (65 ref.)

Protective effect of seminal plasma proteins on the degradation of ascorbic acid. Liu L, et al. **Mol Cell Biochem** 1995 Jul 5;148(1):59–66

In vitro oxidation of vitamin E, vitamin C, thiols and cholesterol in rat brain mitochondria incubated with free radicals. Vatassery GT, et al. **Neurochem Int** 1995 May; 26(5):527–35

Gender differences in cerebral ascorbate levels and ascorbate loss in ischemia. Ferris DC, et al. **Neuroreport** 1995 Jul 31;6(11):1485–9

Environmental stress sensitivity of an ascorbic acid–deficient Arabidopsis mutant. Conklin PL, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9970–4

PHARMACOKINETICS

The uptake of ascorbic acid into human umbilical vein endothelial cells and its effect on oxidant insult. Ek A, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1339–46

Measurement of ascorbic acid kinetics in man using stable isotopes and gas chromatography/mass spectrometry. Bluck LJ, et al. **J Mass Spectrom** 1996 Jul;31(7):741–8

Ascorbate polyphosphate is a bioavailable vitamin C source in juvenile rainbow trout: tissue saturation and compartmentalization model. Matusiewicz M, et al. **J Nutr** 1995 Dec;125(12):3055–61

The mechanism of uptake of ascorbic acid into osteoblasts and leukocytes. Wolf G. **Nutr Rev** 1996 May;54(5):150–2 (12 ref.)

Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Levine M, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3704–9

PHARMACOLOGY

Manganese absorption in humans: the effect of phytic acid and ascorbic acid in soy formula. Davidsson L, et al. **Am J Clin Nutr** 1995 Nov;62(5):984–7

Influence of combined antioxidant nutrient intakes on their plasma concentrations in an elderly population. Jacques PF, et al. **Am J Clin Nutr** 1995 Dec;62(6):1228–33

Interaction among vitamin C, vitamin E, and beta–carotene. Niki E, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1322S–1326S

Vitamins E and C, beta–carotene, and other carotenoids as antioxidants. Sies H, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1315S–1321S (87 ref.)

Damage to DNA by cadmium or nickel in the presence of ascorbate. Littlefield NA, et al. **Ann Clin Lab Sci** 1995 Nov–Dec;25(6):485–92

Copper malabsorption after intestinal resection in rats. Effects of cholecalciferol and ascorbic acid. Hartiti S, et al. **Ann Nutr Metab** 1995;39(4):227–33

Effect of vitamin C on plasma lipids. Howard PA, et al. **Ann Pharmacother** 1995 Nov;29(11):1129–36 (58 ref.)

The interaction between two antioxidants, sodium ascorbate and gallic acid: radical intensity and apoptosis induction. Sakagami H, et al. **Anticancer Res** 1996 May–Jun; 16(3A):1231–4

Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Taper HS, et al. **Anticancer Res** 1996 Jan–Feb;16(1):499–503

Topical treatment of recurrent mucocutaneous herpes with ascorbic acid–containing solution. Hovi T, et al. **Antiviral Res** 1995 Jun;27(3):263–70

Chromate–induced chromium(V) formation in live mice and its control by cellular antioxidants: an L–band electron paramagnetic resonance study. Liu KJ, et al. **Arch Biochem Biophys** 1995 Oct 20;323(1):33–9

Beta–glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Shioi A, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):2003–9

Differing alpha–tocopherol oxidative lability and ascorbic acid sparing effects in buoyant and dense LDL. Tribble DL, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov; 15(11):2025–31

One electron reduction of vanadate(V) to oxovanadium(IV) by low–molecular–weight biocomponents like saccharides and ascorbic acid: effect of oxovanadium(IV) complexes on pUC18 DNA and on lipid peroxidation in isolated rat hepatocytes. Sreedhara A, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):115–20

Mitochondria–bound hexokinase from rabbit reticulocytes is resistant to the inactivation induced by Fe(II)/ascorbate. Stocchi V, et al. **Biochem Mol Biol Int** 1995 Apr; 35(5):1133–42

Inhibition of lipid peroxidation in low–density lipoprotein by the flavonoid myrigalone B and ascorbic acid. Mathiesen L, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1719–25

The effect of antioxidant supplementation on the oxidant–induced stress response in human lymphocytes. Brennan LA, et al. **Biochem Soc Trans** 1996 Feb;24(1):75S

Iron–ascorbate–phospholipid mediated modification of low density lipoprotein. Greenspan P, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):242–8

Inactivation of cholinesterase by ascorbic acid in the presence of cupric ions: a possible mechanism for the inactivation of an enzyme by the metal–catalyzed oxidation system. Kanazawa H, et al. **Biol Pharm Bull** 1995 Sep;18(9):1179–83

Olfactory ensheathing cells do not require L–ascorbic acid in vitro to assemble a basal lamina or to myelinate dorsal root ganglion neurites. Devon R, et al. **Brain Res** 1995 Aug 7;688(1–2):223–9

Ascorbate potentiates amphetamine–induced conditioned place preference and forebrain dopamine release in rats. Pierce RC, et al. **Brain Res** 1995 Aug 7;688(1–2):21–6

Lack of inhibitory effects of beta–carotene, vitamin C, vitamin E and selenium on development of ductular adenocarcinomas in exocrine pancreas of hamsters. Appel MJ, et al. **Cancer Lett** 1996 Jun 5;103(2):157–62

Induction of NAD(P)H:quinone reductase by vitamins A, E and C in Colo205 colon cancer cells. Wang W, et al. **Cancer Lett** 1995 Nov 27;98(1):63–9

Antioxidants inhibit the enhancement of malignant cell transformation induced by 2,3,7,8–tetrachlorodibenzo–p–dioxin. Wölfle D, et al. **Carcinogenesis** 1996 Jun;17(6):1273–8

Differential susceptibility of epidermal keratinocytes and neuroblastoma cells to cytotoxicity of ultraviolet–B light irradiation prevented by the oxygen radical–scavenger ascorbate–2–phosphate but not by ascorbate. Kanatate T, et al. **Cell Mol Biol Res** 1995;41(6):561–7

Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Levine GN, et al. **Circulation** 1996 Mar 15;93(6):1107–13

Induction of ovalbumin mRNA by ascorbic acid in primary cultures of tubular gland cells of the chicken oviduct. Muramatsu T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Oct; 112(2):209–16

Comparative cytoprotection of cultured corneal endothelial cells by water–soluble antioxidants against free–radical damage. Zeng LH, et al. **Cornea** 1995 Sep;14(5):509–14

Vitamin C reduces cytochalasin D cataractogenesis. Kilic F, et al. **Curr Eye Res** 1995 Oct;14(10):943–9

Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. Kowluru RA, et al. **Diabetes** 1996 Sep;45(9):1233–7

Experimental and clinical studies on the reduction of erythrocyte sorbitol–glucose ratios by ascorbic acid in diabetes mellitus. Wang H, et al. **Diabetes Res Clin Pract** 1995 Apr;28(1):1–8

Effects of cyclosporine A on the rat liver and kidney protein pattern, and the influence of vitamin E and C coadministration. Benito B, et al. **Electrophoresis** 1995 Jul; 16(7):1273–83

Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell lines. De Laurenzi V, et al. **Eur J Cancer** 1995;31A(4):463–6

Retinoic acid–induced heparin binding (RIHB, chicken midkine) factor expression by cultured chondrocytes is strongly enhanced by ascorbic acid. Castagnola P, et al. **Eur J Cell Biol** 1996 Apr;69(4):387–91

Influence of vitamin C on the absorption and first pass metabolism of propranolol. Gonzalez JP, et al. **Eur J Clin Pharmacol** 1995;48(3–4):295–7

Protection by ascorbate against apoptosis of thymocytes: implications of ascorbate–induced nonlethal oxidative stress and poly(ADP–ribosyl)ation. Maellaro E, et al.

Exp Cell Res 1996 Jul 10;226(1):105–13

Ascorbic acid protects against male infertility in a teleost fish. Dabrowski K, et al. **Experientia** 1996 Feb 15; 52(2):97–100

Mobilization of iron from cellular ferritin by ascorbic acid in neuroblastoma SK–N–SH cells: an EPR study. Baader SL, et al. **FEBS Lett** 1996 Feb 26;381(1–2):131–4

Depletion of cellular iron by bps and ascorbate: effect on toxicity of adriamycin. Nyayapati S, et al. **Free Radic Biol Med** 1996;20(3):319–29

Oxidative stress in acidic conditions increases the production of inositol phosphates in chick retinal cells in culture. Rego AC, et al. **Free Radic Biol Med** 1996;20(2):175–87

Human cytochrome P450's are pro–oxidants in iron/ascorbate–initiated microsomal lipid peroxidation. Lambert N, et al. **Free Radic Res** 1996 Mar;24(3):177–85

Effects of methylene blue and ascorbate on transmembrane potential in frog skeletal muscle. Nánási PP, et al. **Gen Pharmacol** 1995 Oct;26(6):1307–11

Iron ascorbate–stimulated lipid peroxidation in vitro. Why is the method controversial? Laszczyca P, et al. **Gen Physiol Biophys** 1995 Feb;14(1):3–18

Effects of aging and antioxidants on glucose transport in rat adipocytes. Moustafa SA, et al. **Gerontology** 1995; 41(6):301–7

Correlations between lipid peroxide and glutathione levels in vitamin C supplemented fasting guinea pigs. Kaplan B. **Horm Metab Res** 1995 Sep;27(9):419–20

A possible mechanism for initiation of lipid peroxidation by ascorbate in rat liver microsomes. Casalino E, et al. **Int J Biochem Cell Biol** 1996 Feb;28(2):137–49

Repair of semi–oxidized 3,5–diiodotyrosine: radiation chemical studies in the presence of oxygen, ascorbate and superoxide anion. Das TN. **Int J Radiat Biol** 1996 Jul; 70(1):7–13

Human plasma patterns during 14 days ingestion of vitamin E, beta–carotene, ascorbic acid, and their various combinations. Baker H, et al. **J Am Coll Nutr** 1996 Apr; 15(2):159–63

Ascorbic acid induces a favorable lipoprotein profile in women. Gatto LM, et al. **J Am Coll Nutr** 1996 Apr; 15(2):154–8

Effect of ascorbic acid supplementation during the inhalation exposure of guinea–pigs to industrial dust on bronchoalveolar lavage and pulmonary enzymes. Kováčiková Z, et al. **J Appl Toxicol** 1995 Jul–Aug; 15(4):321–4

Regulation of BPAG2 (180 kDa) gene expression in spontaneously transformed murine keratinocytes: tissue distribution, modulation during cell adhesion, and up–regulation by ascorbic acid. Tajima S, et al. **J Biochem (Tokyo)** 1995 Oct;118(4):734–7

The reduction of membrane–bound dopamine beta–monooxygenase in resealed chromaffin granule ghosts. Is intragranular ascorbic acid a mediator for extragranular reducing equivalents? Wimalasena K, et al. **J Biol Chem** 1995 Nov 17;270(46):27516–24

Effects of high–dose vitamin C administration on bacterial translocation and lung neutrophil sequestration in burned mice. Zapata–Sirvent RL, et al. **J Burn Care Rehabil** 1995 Jul–Aug;16(4):422–8

Vitamin C improves endothelium–dependent vasodilation in patients with non–insulin–dependent diabetes mellitus. Ting HH, et al. **J Clin Invest** 1996 Jan 1;97(1):22–8

Effects of supplemental vitamins E and C on the immune responses of calves. Hidiroglou M, et al. **J Dairy Sci** 1995 Jul;78(7):1578–83

Ascorbic acid preferentially enhances type I and III collagen gene transcription in human skin fibroblasts. Tajima S, et al. **J Dermatol Sci** 1996 Mar;11(3):250–3

Phospholipase A2 activity in vitro cultured cells—influence of ascorbate supplementation. Stoll KE, et al. **J Lipid Mediat Cell Signal** 1995 May;11(3):261–6

Activity of ionotropic glutamate receptors in retinal cells: effect of ascorbate/Fe(2+)–induced oxidative stress. Agostinho P, et al. **J Neurochem** 1996 Sep;67(3):1153–63

Prevention of radiolysis of monoclonal antibody during labeling. Chakrabarti MC, et al. **J Nucl Med** 1996 Aug; 37(8):1384–8

Prooxidant effects of antioxidant vitamins. Introduction. Herbert V. **J Nutr** 1996 Apr;126(4 Suppl):1197S–200S

Vitamin C–driven free radical generation from iron. Herbert V, et al. **J Nutr** 1996 Apr;126(4 Suppl):1213S–20S (61 ref.)

The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. Schwartz JL. **J Nutr** 1996 Apr;126(4 Suppl):1221S–7S (42 ref.)

Inhibitory effect of ascorbate on cell growth: relation to catalase activity. Nemoto S, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Apr;42(2):77–85

Hydrogen peroxide mediates the killing of U937 tumor cells elicited by pharmacologically attainable concentrations of ascorbic acid: cell death prevention by extracellular catalase or catalase from cocultured erythrocytes or fibroblasts. Sestili P, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1719–25

Alteration of bone status with ascorbic acid deficiency in ODS (osteogenic disorder Shionogi) rats. Togari A, et al. **Jpn J Pharmacol** 1995 Jul;68(3):255–61

Accumulation of tropoelastin by a short–term ascorbic acid treatment in the culture medium of aortic smooth muscle cells in vitro. Tajima S, et al. **Keio J Med** 1995 Dec; 44(4):140–5

Interaction of ascorbic acid with the neurotoxic effects of NMDA and sodium nitroprusside. Bell JA, et al. **Life Sci** 1995;58(4):367–71

Endotoxin depletes ascorbate in the guinea pig heart. Protective effects of vitamins C and E against oxidative stress. Rojas C, et al. **Life Sci** 1996;59(8):649–57

Salivary excretory index—quantification of the ascorbic acid response in dynamic radionuclide sialography. Han R, et al. **Med Pregl** 1993;46 Suppl 1:54–5

Protective effects of alpha–hederin, chlorophyllin and ascorbic acid towards the induction of micronuclei by doxorubicin in cultured human lymphocytes. Amara–Mokrane YA, et al. **Mutagenesis** 1996 Mar; 11(2):161–7

Ameliorating effect of vitamin C on murine sperm toxicity induced by three pesticides (endosulfan, phosphamidon and mancozeb). Khan PK, et al. **Mutagenesis** 1996 Jan; 11(1):33–6

Effect of intake of exogenous vitamins C, E and beta–carotene on the antioxidative status in kidneys of rats with streptozotocin–induced diabetes. Mekiňová D, et al. **Nahrung** 1995;39(4):257–61

Tolerance to nitrates and simultaneous upregulation of platelet activity prevented by enhancing antioxidant state. Bassenge E, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Feb; 353(3):363–7

Reduced enzymatic antioxidant defense mechanism in kidney tissues from gentamicin–treated guinea pigs: effects of vitamins E and C. Kavutcu M, et al. **Nephron** 1996; 72(2):269–74

The effects of ascorbic acid and oxiracetam on scopolamine–induced amnesia in a habituation test in aged mice. de Angelis L, et al. **Neurobiol Learn Mem** 1995 Sep; 64(2):119–24

Influence of lipid peroxidation on [3H]ketanserin binding to 5–HT2 prefrontal cortex receptors. Rego AC, et al. **Neurochem Int** 1995 Dec;27(6):489–96

Modulation of N–methyl–D–aspartate receptor activity by oxidative stress conditions in chick retinal cells. Agostinho P, et al. **Neurosci Lett** 1995 Oct 6;198(3):193–6

Effect of ascorbic acid on hyperoxic rat astrocytes. Sharma P. **Neuroscience** 1996 May;72(2):391–7

Ascorbate effect on cytokine stimulation of HIV production. Harakeh S, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):684–7

On the biologic significance of vitamin C interaction with ceruloplasmin [editorial; comment] Jacob RA. **Nutrition** 1996 Feb;12(2):126–7. Comment on: Nutrition 1996 Feb;12(2):83–8.

Evidence for an action of araboascorbic acid on dopaminergic pathways of the corpus striatum. Dorris RL. **Pharmacol Biochem Behav** 1995 Sep;52(1):241–3

The effect of high–dose ascorbate supplementation on plasma lipoprotein(a) levels in patients with premature coronary heart disease. Bostom AG, et al. **Pharmacotherapy** 1995 Jul–Aug;15(4):458–64

Ascorbic acid glycation of lens proteins produces UVA sensitizers similar to those in human lens. Ortwerth BJ, et al. **Photochem Photobiol** 1995 Sep;62(3):454–62

Scanning electron microscopy and transmission electron microscopy aspects of synergistic antitumor activity of vitamin C – vitamin K3 combinations against human prostatic carcinoma cells. Gilloteaux J, et al. **Scanning Microsc** 1995 Mar;9(1):159–73

Plasma ascorbate protects coagulation factors against photooxidation. Parkkinen J, et al. **Thromb Haemost** 1996 Feb;75(2):292–7

Cytotoxicity of unsaturated metabolites of valproic acid and protection by vitamins C and E in glutathione–depleted rat hepatocytes. Jurima–Romet M, et al. **Toxicology** 1996 Aug 1;112(1):69–85

Antioxidant agents and colorectal carcinogenesis: role of beta–carotene, vitamin E and vitamin C. Pappalardo G, et al. **Tumori** 1996 Jan–Feb;82(1):6–11 (88 ref.)

The effect of graded ascorbic acid intake on the activity of GSH–Px in the liver of female guinea pigs. Kováciková Z, et al. **Z Ernahrungswiss** 1995 Sep;34(3):220–3

[Effect of heparin and ascorbic acid on growth behavior of cultivated corneal epithelial cells of the rabbit] Knorr M, et al. **Ophthalmologe** 1996 Jun;93(3):275–8 (Eng. Abstr.) (Ger)

[Evaluation of daunorubicin nephrotoxicity and effect of tocopherol and ascorbic acid on lesions induced in rat kidneys. I. Histologic, histochemical and biochemical studies] Skomra D, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:181–8 (Eng. Abstr.) (Pol)

[Evaluation of daunorubicin nephrotoxicity and effect of tocopherol and ascorbic acid on lesions induced in rat kidneys. II. Ultrastructural studies of kidney glomeruli] Skomra D, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:189–94 (Eng. Abstr.) (Pol)

[The effect of intravenous ascorbic acid on urinary 17–hydroxysteroid excretion at an early stage of cerebral stroke] Nadgrodkiewicz K. **Neurol Neurochir Pol** 1996 Jan–Feb;30(1):49–56 (Eng. Abstr.) (Pol)

[Kinetics of Fe2+–induced lipid peroxidation in liposomes in the presence of ascorbic acid. Concentrated effects of Fe2+ ions] Dremina ES, et al. **Biofizika** 1995 Mar–Apr; 40(2):335–41 (Eng. Abstr.) (Rus)

[Comparative study of the kinetics of phospholipid liposome peroxidation, induced by hypochlorite and in the Fe2+ + ascorbate system] Panasenko OM, et al. **Biofizika** 1996 Mar–Apr;41(2):334–41 (Eng. Abstr.) (Rus)

[The effect of paracetamol and its combinations with acetylsalicylic and ascorbic acids on lipid peroxidation processes in the rat liver] Chaika LA, et al. **Eksp Klin Farmakol** 1996 Jan–Feb;59(1):43–6 (Eng. Abstr.) (Rus)

[A comparative study of the anabolic action of ecdysten, leveton and Prime Plus, preparations of plant origin] Gadzhieva RM, et al. **Eksp Klin Farmakol** 1995 Sep–Oct; 58(5):46–8 (Eng. Abstr.) (Rus)

[The anticlastogenic effect of ascorbic acid in relation to the damages induced in human lymphocytes by the photomutagenic action of 8–methoxypsoralen and by ammonium molybdate] Makedonov GP, et al. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):726–9 (Eng. Abstr.) (Rus)

PHYSIOLOGY

The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data [see comments] Jha P, et al. **Ann Intern Med** 1995 Dec 1; 123(11):860–72 (55 ref.). Comment in: Ann Intern Med 1995 Dec 1;123(11):887.

Effect of vitamin E, vitamin C and beta–carotene on LDL oxidation and atherosclerosis. Jialal I, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:97G–103G (97 ref.)

Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Weber C, et al. **Circulation** 1996 Apr 15;93(8):1488–92

The significance of ascorbate in the aqueous humour protection against UV–A and UV–B. Ringvold A. **Exp Eye Res** 1996 Mar;62(3):261–4

Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids. Rock CL, et al. **J Am Diet Assoc** 1996 Jul;96(7):693–702; quiz 703–4 (128 ref.)

The role of ascorbate in brain: therapeutic implications [editorial] Smythies JR. **J R Soc Med** 1996 May;89(5):241

Lipid peroxidation in brain: interactions of L–DOPA/dopamine with ascorbate and iron [published erratum appears in Neurodegeneration 1995 Sep;4(3):347] Li CL, et al. **Neurodegeneration** 1995 Jun;4(2):147–53

SECRETION

Endocrine regulation of ascorbic acid transport and secretion in luteal cells. Musicki B, et al. **Biol Reprod** 1996 Feb; 54(2):399–406

THERAPEUTIC USE

Posatirelin for the treatment of late–onset Alzheimer's disease: a double–blind multicentre study vs citicoline and ascorbic acid. Parnetti L, et al. **Acta Neurol Scand** 1995 Aug;92(2):135–40

Effects of antioxidant vitamins C and E on signal–averaged electrocardiogram in acute myocardial infarction. Chamiec T, et al. **Am J Cardiol** 1996 Feb 1;77(4):237–41

Intake of vitamins A, C, and E and postmenopausal breast cancer. The Iowa Women's Health Study. Kushi LH, et al. **Am J Epidemiol** 1996 Jul 15;144(2):165–74

Antioxidants and cardiovascular disease: why do we still not have the answers? [editorial; comment] Chalmers TC. **Ann Intern Med** 1995 Dec 1;123(11):887. Comment on: Ann Intern Med 1995 Dec 1;123(11):860–72.

Magnesium and ascorbic acid supplementation in diabetes mellitus. Eriksson J, et al. **Ann Nutr Metab** 1995; 39(4):217–23

Symptomatic response to ascorbic acid. Pradeep JK, et al. **Br J Urol** 1996 Feb;77(2):319–20

Supplementation with vitamins C and E suppresses leukocyte oxygen free radical production in patients with myocardial infarction. Herbaczyńska–Cedro K, et al. **Eur Heart J** 1995 Aug;16(8):1044–9

Vitamin C and the genesis of autoimmune disease and allergy (review). Kodama M, et al. **In Vivo** 1995 May–Jun; 9(3):231–8 (38 ref.)

Correction of anemia and iron deficiency in vegetarians by administration of ascorbic acid. Sharma DC, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):403–6

Ascorbic acid and gastrointestinal cancer. Cohen M, et al. **J Am Coll Nutr** 1995 Dec;14(6):565–78 (136 ref.)

Epidemiologic studies of antioxidants and cancer in humans. Flagg EW, et al. **J Am Coll Nutr** 1995 Oct;14(5):419–27 (88 ref.)

Metabolic benefits deriving from chronic vitamin C supplementation in aged non–insulin dependent diabetics. Paolisso G, et al. **J Am Coll Nutr** 1995 Aug;14(4):387–92

Hemodynamic effects of delayed initiation of antioxidant therapy (beginning two hours after burn) in extensive third–degree burns. Tanaka H, et al. **J Burn Care Rehabil** 1995 Nov–Dec;16(6):610–5

Randomized clinical trial of ascorbic acid in the treatment of pressure ulcers. ter Riet G, et al. **J Clin Epidemiol** 1995 Dec;48(12):1453–60

Vitamin C for the treatment of recurrent furunculosis in patients with imparied neutrophil functions. Levy R, et al. **J Infect Dis** 1996 Jun;173(6):1502–5

Vitamin C, smoking and SIDS [letter] Cheraskin E. **J R Soc Health** 1995 Oct;115(5):332

Ascorbate administration to normal and cholesterol–fed rats

inhibits in vitro TBARS formation in serum and liver homogenates. Santillo M, et al. **Life Sci** 1996;58(14):1101–8

Proline, ascorbic acid, or thioredoxin affect jaundice and mortality in Long Evans cinnamon rats. Hawkins RL, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):509–15

[A study on the value of vitamin C in treating skeletal fluorosis] Shangguan C, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Nov;34(11):761–3 (Eng. Abstr.) **(Chi)**

[Protective effects of vitamins C and E in hypoxia] Schreiber M, et al. **Sb Lek** 1995;96(2):163–6 **(Cze)**

[Cancer and vitamin C (letter)] Plum P. **Ugeskr Laeger** 1996 Jan 1;158(1):66–7 **(Dan)**

[The modifying effect of long-term administration of ascorbic acid with drinking water on asbestos-induced pleural carcinogenesis in Wistar rats] Stadnikova NM, et al. **Vopr Onkol** 1996;42(1):85–8 (Eng. Abstr.) **(Rus)**

[Treatment of complicated Parkinson disease with a solution of levodopa-carbidopa and ascorbic acid] Linazasoro G, et al. **Neurologia** 1995 Jun-Jul;10(6):220–3 (Eng. Abstr.) **(Spa)**

[Results of preoperative autotransfusion with ferrous ascorbate prophylaxis in orthopedic surgery patients] Guinea JM, et al. **Sangre (Barc)** 1996 Feb;41(1):25–8 (Eng. Abstr.) **(Spa)**

TOXICITY

Effect of the type of serum in the medium on sodium ascorbate-induced cytotoxicity. Sakagami H, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1937–41

Effects of sodium ascorbate, sodium saccharin and ammonium chloride on the male rat urinary bladder. Cohen SM, et al. **Carcinogenesis** 1995 Nov;16(11):2743–50

Evaluation of the micronucleus test in vitro using Chinese hamster cells: results of four chemicals weakly positive in the in vivo micronucleus test. Miller BM, et al. **Environ Mol Mutagen** 1995;26(3):240–7

Ascorbic acid is not clastogenic and does not modify the effect of extended low-dose-rate gamma-irradiation in mouse bone marrow. Abramsson-Zetterberg L. **Int J Radiat Biol** 1996 Jul;70(1):77–81

The requirement for and mobilization of calcium during induction by sodium ascorbate and by hydrogen peroxide of cell death. Sakagami H, et al. **Life Sci** 1996;58(14):1131–8

Sustained levels of ascorbic acid are toxic and immunosuppressive for human T cells. Eylar E, et al. **P R Health Sci J** 1996 Mar;15(1):21–6

ASCORBIC ACID DEFICIENCY

see related
SCURVY

COMPLICATIONS

Vitamin C status, cervico-vaginal infection and premature rupture of amniotic membranes. Casanueva E, et al. **Arch Med Res** 1995;26 Spec No:S149–52

[Incidence of scurvy in Hungary today] Kapocsi J. **Orv Hetil** 1996 May 5;137(18):971–3 (Eng. Abstr.) **(Hun)**

[Effect of vitamin E and vitamin C deficiency on the development of alcoholic liver diseases] Goto Y. **Arukoru Kenkyuto Yakubutsu Ison** 1996 Apr;31(2):177–92 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Effect of marginal ascorbic acid deficiency on saliva level of cortisol in the guinea pig. Enwonwu CO, et al. **Arch Oral Biol** 1995 Aug;40(8):737–42

METABOLISM

Ascorbate depletion prevents aldosterone stimulation by sodium deficiency in the guinea pig. Redmann A, et al. **Eur J Endocrinol** 1995 Oct;133(4):499–506

Renal handling of carnitine in experimental vitamin C deficiency. Rebouche CJ. **Metabolism** 1995 Dec; 44(12):1639–43

Ascorbic acid is essential for the release of insulin from scorbutic guinea pig pancreatic islets. Wells WW, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11869–73

PATHOLOGY

Morphological and biochemical changes in lenses of guinea pigs after vitamin-C-deficient diet and UV-B radiation. Malik A, et al. **Ophthalmic Res** 1995;27(4):189–96

URINE

Marked increase in urinary excretion of nitrate and N-nitrosothioproline in the osteogenic disordered syndrome rats, lacking ascorbic acid biosynthesis, by administration of lipopolysaccharide and thioproline. Tsuda M, et al. **Carcinogenesis** 1995 Nov;16(11):2653–7

VETERINARY

Utilization of the bone/liver alkaline phosphatase activity ratio in blood plasma as an indicator of ascorbate deficiency in salmonid fish. Matusiewicz M, et al. **Proc Soc Exp Biol Med** 1996 May;212(1):44–51

ASCORBINO DEHYDROGENASE see **ASCORBATE OXIDASE**

ASEPSIS

Procedures of lumbar puncture in paediatrics [letter; comment] Perkins V. **Br J Hosp Med** 1995 Oct 18–31; 54(8):414. Comment on: Br J Hosp Med 1995 Mar 15–Apr 4;53(6):273–4.

Aseptic technique in needle EMG: common sense and common practice [letter] Capazzoli NJ. **Muscle Nerve** 1996 Apr;19(4):538

Propofol and postoperative infections [letter; comment] Grounds RM. **N Engl J Med** 1995 Nov 30;333(22):1506; discussion 1507. Comment on: N Engl J Med 1995 Jul 20;333(3):147–54.

Propofol and postoperative infections [letter; comment] Kolbitsch C, et al. **N Engl J Med** 1995 Nov 30; 333(22):1506–7. Comment on: N Engl J Med 1995 Jul 20;333(3):147–54.

Developing a collaborative community partnership program in medical asepsis with tattoo studios. Bechtel GA, et al. **Public Health Nurs** 1995 Oct;12(5):348–52

METHODS

A clinical trial on the prevention of catheter-related sepsis using a new hub model. Segura M, et al. **Ann Surg** 1996 Apr;223(4):363–9

An examination of nurses' practices when performing aseptic technique for wound dressings. Bree-Williams FJ, et al. **J Adv Nurs** 1996 Jan;23(1):48–54

STANDARDS

PDA comments on USP in-process revision <1116> microbiological evaluation of clean rooms and other controlled environments. Parenteral Drug Association. **PDA J Pharm Sci Technol** 1995 Nov-Dec;49(6):264–6

Regulatory aspects of isolation/barrier technology. Lyda JC. **PDA J Pharm Sci Technol** 1995 Nov-Dec;49(6):300–4

ASIALIA see **XEROSTOMIA**

ASIALOGANGLIOSIDES see **GLYCOSPHINGOLIPIDS**

ASIALOGLYCOPROTEINS

Fate of DNA targeted to hepatocytes by asialoglycoprotein polylysine conjugates. Wu GW, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):211–7

ADMINISTRATION & DOSAGE

A hepatocyte-targeted conjugate capable of delivering biologically active colchicine in vitro. Plourde R, et al. **Bioconjug Chem** 1996 Jan-Feb;7(1):131–7

ANALYSIS

Picogram detection levels of asialofetuin via the carbohydrate moieties using the light addressable potentiometric sensor. Dill K, et al. **Glycoconj J** 1995 Oct;12(5):660–3

CHEMISTRY

Picogram detection levels of asialofetuin via the carbohydrate moieties using the light addressable potentiometric sensor. Dill K, et al. **Glycoconj J** 1995 Oct;12(5):660–3

DIAGNOSTIC USE

An organotypical in vitro model of the liver parenchyma for uptake studies of diagnostic MR receptor agents. Bader A, et al. **Magn Reson Imaging** 1995;13(7):991–1002

GENETICS

Molecular cloning and expression of cDNA encoding human macrophage C-type lectin. Its unique carbohydrate binding specificity for Tn antigen. Suzuki N, et al. **J Immunol** 1996 Jan 1;156(1):128–35

METABOLISM

Interactions of gelatinases with soluble and immobilized fetuin and asialofetuin. Ochieng J, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):250–5

Inhibition of asialoglycoprotein endocytosis and degradation in rat hepatocytes by protein phosphatase inhibitors. Holen I, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):317–26

The differences in structural specificity for recognition and binding between asialoglycoprotein receptors of liver and macrophages. Ozaki K, et al. **Glycoconj J** 1995 Jun; 12(3):268–74

The major subunit of the asialoglycoprotein receptor is expressed on the hepatocellular surface in mice lacking the minor receptor subunit. Braun JR, et al. **J Biol Chem** 1996 Aug 30;271(35):21160–6

Selective sugar binding to the carbohydrate recognition domains of the rat hepatic and macrophage asialoglycoprotein receptors. Iobst ST, et al. **J Biol Chem** 1996 Mar 22;271(12):6686–93

Decreased binding of asialoglycoproteins to hepatocytes from ethanol-fed rats. Consequence of both impaired synthesis and inactivation of the asialoglycoprotein receptor. Tworek BL, et al. **J Biol Chem** 1996 Feb 2;271(5):2531–8

Interaction of native and asialo rat sublingual glycoproteins with lectins. Wu AM, et al. **Life Sci** 1995;57(20):1841–52

An organotypical in vitro model of the liver parenchyma for uptake studies of diagnostic MR receptor agents. Bader A, et al. **Magn Reson Imaging** 1995;13(7):991–1002

[Establishment of in vitro model for HBV infection via asialoglycoprotein receptor] Neda H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:121–4 (15 ref.) **(Jpn)**

[HCV gene transfected animal using receptor mediated gene delivery] Yamamoto M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:107–11 **(Jpn)**

[Elimination of asialoorosomucoid and its catabolism in liver of rats with toxic CCl4-induced cirrhosis] Pupyshev AB, et al. **Patol Fiziol Eksp Ter** 1995 Oct-Dec;(4):38–40 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

[Participation of sialic acid residue in the fibrinogen-fibrin conversion by thrombin] Akihama S, et al. **Yakugaku Zasshi** 1995 Jul;115(7):537–42 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

A role of asialoglycoproteins for plasma-membrane-induced inhibition of the switching from alpha 1 to beta subtypes in adrenergic response during primary culture of rat hepatocytes. Kajiyama Y, et al. **Biochem J** 1996 Jun 15; 316 (Pt 3):743–9

ASIAN AMERICANS

Voices of Korean-American students. Park EJ. **Adolescence** 1995 Winter;30(120):945–53

Pregnancy outcomes of US-born and foreign-born Japanese Americans. Alexander GR, et al. **Am J Public Health** 1996 Jun;86(6):820–4

Use of Chinese therapies among Chinese patients seeking emergency department care. Pearl WS, et al. **Ann Emerg Med** 1995 Dec;26(6):735–8

Characteristics associated with rapid decline in forced expiratory volume. Burchfiel CM, et al. **Ann Epidemiol** 1996 May;6(3):217–27

The incidence of non-Hodgkin's lymphoma and its histologic subtypes in Asian migrants to the United States and their descendants. Herrinton LJ, et al. **Cancer Causes Control** 1996 Mar;7(2):224–30

Liver cancer in Asian migrants to the United States and their descendants [see comments] Rosenblatt KA, et al. **Cancer Causes Control** 1996 May;7(3):345–50. Comment in: Cancer Causes Control 1996 MAY;7(3):299–301.

Thyroid cancer incidence in Asian migrants to the United States and their descendants. Rossing MA, et al. **Cancer Causes Control** 1995 Sep;6(5):439–44

Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Wu AH, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct-Nov;4(7):735–41

Attitudes toward use of nursing homes and home care in older Japanese-Americans. McCormick WC, et al. **J Am Geriatr Soc** 1996 Jul;44(7):769–77

Hepatitis B and C virus serologies among Japanese Americans with hepatocellular carcinoma. Nomura A, et al. **J Infect Dis** 1996 Jun;173(6):1474–6

Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study [see comments] White L, et al. **JAMA** 1996 Sep 25;276(12):955–60. Comment in: JAMA 1996 Sep 25;276(12):993–5.

Asian American and Pacific islander health: a paradigm for minority health. Yoon E, et al. **JAMA** 1996 Mar 6; 275(9):736–7

A program to increase breast and cervical cancer screening for Cambodian women in a midwestern community. Kelly AW, et al. **Mayo Clin Proc** 1996 May;71(5):437–44

Providing culturally competent health care to Hmong patients. Gervais KG. **Minn Med** 1996 May;79(5):49–51

Developing preventive health programs for recent immigrants. A case study of cancer screening for Vietnamese women in Olmsted County, Minnesota. Tosomeen AH, et al. **Minn Med** 1996 May;79(5):46–8

Health status of Asian Pacific Americans in Missouri. Kwon IW, et al. **Mo Med** 1995 Oct;92(10):648–52

Drug abuse prevention research concerns in Asian and Pacific Islander populations. Kuramoto FH. **NIDA Res Monogr** 1994;139:249–72 (13 ref.)

Increased risk of placenta previa among women of Asian origin. Taylor VM, et al. **Obstet Gynecol** 1995 Nov; 86(5):805–8

Relation of height and weight to the regional variations in bone mass among Japanese-American men and women. Davis JW, et al. **Osteoporos Int** 1995;5(4):234–8

Prevention in practice. Ethnic groups. Millar J, et al. **Prim Care** 1995 Dec;22(4):713–30 (27 ref.)

Cultural differences in attitudes, values, and beliefs about osteoporosis in first and second generation Japanese-American women. Matsumoto D, et al. **Women Health** 1995;23(4):39–56

EDUCATION

Multiethnic experiences enhance nursing students' learning. Williamson E, et al. **J Community Health Nurs** 1996;

13(2):73-81 (Dut)

GENETICS

Acute effects of alcohol on P300 in Asians with different ALDH2 genotypes. Wall TL, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):617-22

HISTORY

Sewers and scapegoats: spatial metaphors of smallpox in nineteenth century San Francisco. Craddock S. **Soc Sci Med** 1995 Oct;41(7):957-68

PSYCHOLOGY

Cultural orientation and psychological well-being in Chinese Americans. Ying YW. **Am J Community Psychol** 1995 Dec; 23(6):893-911

A comparative study of Vietnamese Amerasians, their non-Amerasian siblings, and unrelated, like-aged Vietnamese immigrants. McKelvey RS, et al. **Am J Psychiatry** 1996 Apr;153(4):561-3

Multiple forms of stress in Cambodian adolescent refugees. Sack WH, et al. **Child Dev** 1996 Feb;67(1):107-16

Taiwanese love styles and their association with self-esteem and relationship quality. Cho W, et al. **Genet Soc Gen Psychol Monogr** 1995 Aug;121(3):281-309

Sociocultural influences on eating attitudes and behaviors, body image, and psychological functioning: a comparison of African-American, Asian-American, and Caucasian college women. Akan GE, et al. **Int J Eat Disord** 1995 Sep;18(2):181-7

Case study: sex reassignment in a teenage girl. Reiner WG. **J Am Acad Child Adolesc Psychiatry** 1996 Jun; 35(6):799-803

Propensity for seeking counseling services: a comparison of Asian and American undergraduates. Lippincott JA, et al. **J Am Coll Health** 1995 Mar;43(5):201-4

Inner sanctum. Ta K. **Minn Med** 1996 Jan;79(1):6-7, 56

Precepts and practices: researching identity formation among Indian Hindu adolescents in the United States. Miller BD. **New Dir Child Dev** 1995 Spring;(67):71-85

Patients from Japan and physician-patient communication [letter; comment] Uyeda RY. **West J Med** 1995 Nov; 163(5):487. Comment on: West J Med 1995 Jul;163(1):36-9.

STATISTICS & NUMERICAL DATA

Differences in Asian and white drinking: consumption level, drinking contexts, and expectancies. O'Hare T. **Addict Behav** 1995 Mar-Apr;20(2):261-6

Cystic fibrosis in Asian Indians. Powers CA, et al. **Arch Pediatr Adolesc Med** 1996 May;150(5):554-5

Latino, Asian, and black segregation in U.S. metropolitan areas: are multiethnic metros different? Frey WH, et al. **Demography** 1996 Feb;33(1):35-50

Picture imperfect: hidden problems among Asian Pacific islander elderly. Tanjasiri SP, et al. **Gerontologist** 1995 Dec; 35(6):753-60 (65 ref.)

High uric acid: a metabolic marker of coronary heart disease among alcohol abstainers. Iribarren C, et al. **J Clin Epidemiol** 1996 Jun;49(6):673-8

Re: Educational attainment and racial differences in cigarette smoking [letter] Jenkins CN. **J Natl Cancer Inst** 1996 Jun 19;88(12):840-2

Are Asian/Pacific Islander American women represented in women's health research? [letter] Yi JK. **Womens Health Issues** 1996 Jul-Aug;6(4):237-8

ASIATIC COBRA see **COBRA**

ASIATIC RACE see **MONGOLOID RACE**

ASP see **VIPERIDAE**

ASPA CEMENT see **GLASS IONOMER CEMENTS**

ASPARAGINASE

ADMINISTRATION & DOSAGE

Biological characterization of L-asparaginase liposomal formulations. Gaspar MM, et al. **Cancer Chemother Pharmacol** 1996;38(4):373-7

[Long-term infusion of L-asparaginase--an alternative to intramuscular injection?] Rodriguez T, et al. **Klin Padiatr** 1995 Jul-Aug;207(4):207-10 (Eng. Abstr.) (Ger)

ADVERSE EFFECTS

Effects of Erwinia-asparaginase on the coagulation system. Carlsson H, et al. **Eur J Haematol** 1995 Nov;55(5):289-93

Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Nowak-Göttl U, et al. **Eur J Haematol** 1996 Jan-Feb;56(1-2):35-8

Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy [see comments] Nowak-Göttl U, et al. **Haematologica** 1995 Sep-Oct; 80(5):451-3. Comment in: Haematologica 1996 Mar-Apr;81(2):191.

[Tumor lysis syndrome in a dog] Piek CJ, et al. **Tijdschr Diergeneeskd** 1996 Feb 1;121(3):64-6 (Eng. Abstr.)

ANALYSIS

L-aspartate aminotransferase and L-asparaginase in rat lymph node: a histoenzymological and immunohistochemical study. Gragera RR, et al. **Eur J Histochem** 1995;39(3):195-200

CHEMISTRY

A covalently bound catalytic intermediate in Escherichia coli asparaginase: crystal structure of a Thr-89-Val mutant. Palm GJ, et al. **FEBS Lett** 1996 Jul 22;390(2):211-6

METABOLISM

Immobilization of L-asparaginase into a biocompatible poly(ethylene glycol)-albumin hydrogel: I: Preparation and in vitro characterization. Jean-François J, et al. **Biotechnol Appl Biochem** 1996 Jun;23 (Pt 3):221-6

Guinea pig serum L-asparaginase: purification, and immunological relationship to liver L-asparaginase and serum L-asparaginases in other mammals. Zhang N, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):607-12

Asparaginase decreases clotting factors in vitro: a possible pitfall? Nowak-Göttl U, et al. **Int J Clin Lab Res** 1995; 25(3):146-8

PHARMACOLOGY

Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells. Kravtzoff R, et al. **Eur J Clin Pharmacol** 1996;49(6):465-70

Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells. Bussolati O, et al. **Exp Cell Res** 1995 Oct;220(2):283-91

THERAPEUTIC USE

Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Nowak-Göttl U, et al. **Haematologica** 1996 Mar-Apr; 81(2):127-31

Management of L-asparaginase induced prothrombotic state in acute lymphoblastic leukemia [letter; comment] Parma M, et al. **Haematologica** 1996 Mar-Apr;81(2):191. Comment on: Haematologica 1995 Sep-Oct;80(5):451-3.

ASPARAGINE

Asparagine 229 mutants of thymidylate synthase catalyze the methylation of 3-methyl-2'-deoxyuridine 5'-monophosphate. Costi PM, et al. **Biochemistry** 1996 Apr 2;35(13):3944-9

Identification of Asn289 as a ligand binding site in the rat thyrotropin-releasing hormone (THR) receptor as determined by complementary modifications in the ligand and receptor: a new model for THR binding. Han B, et al. **Biochemistry** 1995 Oct 17;34(41):13412-22

Contributions of asparagine at alpha 97 to the cooperative oxygenation process of hemoglobin. Kim HW, et al. **Biochemistry** 1996 May 28;35(21):6620-7

Alliinase (alliin lyase) from garlic (Alliium sativum) is glycosylated at ASN146 and forms a complex with a garlic mannose-specific lectin. Rabinkov A, et al. **Glycoconj J** 1995 Oct;12(5):690-8

Protein conformational changes during the bacteriorhodopsin photocycle. A Fourier transform infrared/resonance Raman study of the alkaline form of the mutant Asp-85-->Asn. Nilsson A, et al. **J Biol Chem** 1995 Dec 15;270(50):29746-51

Deletion of Asn281 in the alpha-subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization. Desbois-Mouthon C, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):719-27

Kinetic and structural consequences of replacing the aspartate bridge by asparagine in the catalytic metal triad of Escherichia coli alkaline phosphatase. Tibbitts TT, et al. **J Mol Biol** 1996 Apr 5;257(3):700-15

ANALOGS & DERIVATIVES

Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155. Garone L, et al. **Biochemistry** 1996 Jul 9;35(27):8881-9

ANALYSIS

Serial lectin affinity chromatography demonstrates altered asparagine-linked sugar chain structures of gamma-glutamyltransferase in human renal cell carcinoma. Yoshida K, et al. **J Chromatogr B Biomed Appl** 1995 Oct 6;672(1):45-51

BIOSYNTHESIS

Molecular cloning and characterisation of asparagine synthetase from Lotus japonicus: dynamics of asparagine synthesis in N-sufficient conditions. Waterhouse RN, et al. **Plant Mol Biol** 1996 Mar;30(5):883-97

CHEMISTRY

Functional properties of the histidine-aspartate ion pair of flavocytochrome b2 (L-lactate dehydrogenase): substitution of Asp282 with asparagine. Gondry M, et al. **Biochemistry** 1996 Jul 2;35(26):8587-94

Looking for residues involved in the muscle acylphosphatase catalytic mechanism and structural stabilization: role of Asn41, Thr42, and Thr46. Taddei N, et al. **Biochemistry** 1996 Jun 4;35(22):7077-83

The role of the asparagine-linked oligosaccharides of the alpha-subunit in human thyrotropin bioactivity. Fares FA, et al. **Endocrinology** 1996 Feb;137(2):555-60

Oligosaccharide mapping reveals hormone-specific glycosylation patterns on equine gonadotropin alpha-subunit Asn56. Gotschall RR, et al. **Endocrinology** 1996 Jun;137(6):2543-57

Separation of asparagine-linked oligosaccharides by high-pH anion-exchange chromatography with pulsed amperometric detection: empirical relationships between oligosaccharide structure and chromatographic retention [letter] Rohrer JS. **Glycobiology** 1995 Jun;5(4):359-60

Asn102 of the gonadotropin-releasing hormone receptor is a critical determinant of potency for agonists containing C-terminal glycinamide. Davidson JS, et al. **J Biol Chem** 1996 Jun 28;271(26):15510-4

Deamidation in proteins: the crystal structure of bovine pancreatic ribonuclease with an isoaspartyl residue at position 67. Capasso S, et al. **J Mol Biol** 1996 Apr 5; 257(3):492-6

GENETICS

Versatility of heme coordination demonstrated in a fungal peroxidase. Absorption and resonance Raman studies of Coprinus cinereus peroxidase and the Asp245-->Asn mutant at various pH values. Smulevich G, et al. **Biochemistry** 1996 Aug 13;35(32):10576-85

Effects of Asn318 and Asp87Asn318 mutations on signal transduction by the gonadotropin-releasing hormone receptor and receptor regulation. Awara WM, et al. **Endocrinology** 1996 Feb;137(2):655-62

The mutation Asp69-->Ser affects the chaperone-like activity of alpha A-crystallin. Smulders RH, et al. **Eur J Biochem** 1995 Sep 15;232(3):834-8

A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. Reymer PW, et al. **Hum Mol Genet** 1995 Sep;4(9):1543-9

Discrepant sequence at codon 57 of DQB1: implication on HLA typing of "Asp 57" in I.D.D.M. [letter] Smith S, et al. **Tissue Antigens** 1995 Jul;46(1):71-2

IMMUNOLOGY

CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. Chen W, et al. **J Immunol** 1996 Aug 1;157(3):1000-5

METABOLISM

Evidence that Asn542 of neprilysin (EC 3.4.24.11) is involved in binding of the P2' residue of substrates and inhibitors. Dion N, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):623-7

Asp 46 can substitute Asp 96 as the Schiff base proton donor in bacteriorhodopsin. Coleman M, et al. **Biochemistry** 1995 Nov 28;34(47):15599-606

Asparagine-linked glycosylation: specificity and function of oligosaccharyl transferase. Imperiali B, et al. **Bioorg Med Chem** 1995 Dec;3(12):1565-78 (86 ref.)

Mobilization of glutamine and asparagine in mouse kidney during Ehrlich cell carcinoma development. Quesada AR, et al. **Cancer Lett** 1996 Jul 19;105(1):29-32

Complex asparagine-linked oligosaccharides in Mgat1-null embryos. Campbell RM, et al. **Glycobiology** 1995 Jul; 5(5):535-43

Characterization of asparagine-linked oligosaccharides on a mouse submandibular mucin. Denny PC, et al. **Glycobiology** 1995 Sep;5(6):589-97

Affinity, specificity, and kinetics of the interaction of the SHC phosphotyrosine binding domain with asparagine-X-X-phosphotyrosine motifs of growth factor receptors. Laminet AA, et al. **J Biol Chem** 1996 Jan 5; 271(1):264-9

The binding of propranolol at 5-hydroxytryptamine1D beta T355N mutant receptors may involve formation of two hydrogen bonds to asparagine. Glennon RA, et al. **Mol Pharmacol** 1996 Jan;49(1):198-206

tRNA-dependent asparagine formation. Curnow AW, et al. **Nature** 1996 Aug 15;382(6592):589-90

Asn-tRNA in Lactobacillus bulgaricus is formed by asparaginylation of tRNA and not by transamidation of Asp-tRNA. Kim SI, et al. **Nucleic Acids Res** 1996 Jul 15; 24(14):2648-51

PHARMACOLOGY

L-glutamine and L-asparagine stimulate ODC activity and proliferation in a porcine jejunal enterocyte line. Kandil HM, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):G591-9

Expression of asparagine synthetase mRNA through asparagine independent signal transduction pathway that might involve protein kinase C in BALB3T3 cells. Chiyo T, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):1929-35

Membrane Ca2+ fluxes in rat hepatoma cells exposed to a supraphysiological concentration of asparagine. Wong PC, et al. **Biochem Mol Biol Int** 1995 May;35(6):1161-7

ASPARAGINE

Ultrastructural and immunocytochemical characterization of autophagic vacuoles in isolated hepatocytes: effects of vinblastine and asparagine on vacuole distributions. Fengsrud M, et al. **Exp Cell Res** 1995 Dec;221(2):504–19

Nitrogen-source-induced activation of neutral trehalase in Schizosaccharomyces pombe and Pachysolen tannophilus: role of cAMP as second messenger. Soto T, et al. **FEMS Microbiol Lett** 1995 Oct 15;132(3):229–32

PHYSIOLOGY

EcoRI variant N199H has enhanced specific activity. Kim JJ, et al. **Gene** 1996 May 24;171(1):129–30

ASPARAGINE-SPECIFIC TRNA see **RNA, TRANSFER, ASN**

ASPARAGINE SYNTHASE see **ASPARTATE-AMMONIA LIGASE**

ASPARTAME

ADVERSE EFFECTS

Aspartame as a cause of allergic reactions, including anaphylaxis [letter; comment] Roberts HJ. **Arch Intern Med** 1996 May 13;156(9):1027–8. Comment on: Arch Intern Med 1995 Sep 11;155(16):1749–54.

Lactose intolerance [letter; comment] Roberts HJ. **N Engl J Med** 1995 Nov 16;333(20):1359. Comment on: N Engl J Med 1995 Jul 6;333(1):1–4.

ANALYSIS

[Use of HPLC technique for determination of aspartame and acesulfam-K in processed fruit products] Szymczyk K, et al. **Rocz Panstw Zakl Hig** 1995;46(4):373–81 (Eng. Abstr.) **(Pol)**

CHEMISTRY

An Equiratio Mixture Model for non-additive components: a case study for aspartame/acesulfame-K mixtures. Schifferstein HN. **Chem Senses** 1996 Feb;21(1):1–11

PHARMACOKINETICS

Aspartame pharmacokinetics – the effect of ageing. Puthrasingam S, et al. **Age Ageing** 1996 May;25(3):217–20

PHARMACOLOGY

Erythrocyte L-aspartyl-L-phenylalanine hydrolase activity and plasma phenylalanine and aspartate concentrations in children consuming diets high in aspartame. Stegink LD, et al. **Am J Clin Nutr** 1995 Dec;62(6):1206–11

Evolution of the sweetness receptor in primates. I. Why does alitame taste sweet in all prosimians and simians, and aspartame only in Old World simians? Glaser D, et al. **Chem Senses** 1995 Oct;20(5):573–84

Prediction of sweetness intensity for equiratio aspartame/sucrose mixtures. Schifferstein HN. **Chem Senses** 1995 Apr;20(2):211–9

The effect of sweeteners on perceived viscosity. Theunissen MJ, et al. **Chem Senses** 1995 Aug;20(4):441–50

Prevention of nephrotoxicity of ochratoxin A, a food contaminant. Creppy EE, et al. **Toxicol Lett** 1995 Dec; 82–83:869–77 (54 ref.)

ASPARTATE AMINOTRANSFERASE

ANALYSIS

L-aspartate aminotransferase and L-asparaginase in rat lymph node: a histoenzymological and immunohistochemical study. Gragera RR, et al. **Eur J Histochem** 1995;39(3):195–200

A multicenter clinical trial of PerioGard in distinguishing between diseased and healthy periodontal sites. (I). Study design, methodology and therapeutic outcome. Persson GR, et al. **J Clin Periodontol** 1995 Oct;22(10):794–803

BLOOD

Elevated serum liver enzyme concentrations during ritodrine therapy. Shen O, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):183–4

Severe preeclampsia with fulminant and extreme elevation of aspartate aminotransferase and lactate dehydrogenase levels: high risk for maternal death. Catanzarite VA, et al. **Am J Perinatol** 1995 Sep;12(5):310–3

The pathogenesis of decreased aspartate aminotransferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency. Ono K, et al. **Clin Nephrol** 1995 Jun;43(6):405–8

Aminotransferase activities in mouse, Mus domesticus, erythrocytes separated according to age. Westrick JA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov;109(2–3):489–97

Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors. Kwan D, et al. **Dig Dis Sci** 1995 Sep;40(9):1951–5

Effect of oestrogen/gestagen replacement therapy on liver enzymes in patients with Ullrich–Turner syndrome. Wemme H, et al. **Eur J Pediatr** 1995 Oct;154(10):807–10

Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Yasuda K, et al. **Gastroenterology** 1995 Oct;109(4):1295–300

Increased levels of alcohol markers (gamma GT, MCV, ASAT, ALAT) in older patients are not related to high alcohol intake [letter] Mowé M, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1136–7

A preliminary report on the prognostic value of selected diagnostic enzymes among certain malignant and schistosomal malignant patients. Ahmed SA. **J Egypt Soc Parasitol** 1995 Dec;25(3):659–76

Evaluation of serum lipid profile and cardiac enzyme changes in cerebrovascular accidents. Aggarwal SP, et al. **J Indian Med Assoc** 1995 Sep;93(9):331–2

Elevation of ALT to AST ratio in patients with enteroviral myocarditis. Kanda T, et al. **J Med** 1995;26(3–4):153–62

Dietary wheat gluten alleviates the elevation of serum transaminase activities in D-galactosamine-injected rats. Manabe A, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Apr; 42(2):121–32

Effect of weight reduction on serum transaminase activities in children with simple obesity [letter; comment] Tazawa Y, et al. **J Pediatr** 1996 Apr;128(4):587–8. Comment on: J Pediatr 1994 Aug;125(2):239–41.

Unexplained high activity of aspartate aminotransferase (EC 2.6.1.1): a case report. de Jonge N, et al. **Neth J Med** 1996 Jun;48(6):224–6

Comparison of acute hepatocellular proliferating cell nuclear antigen labeling indices and growth fractions, p34cdc2 kinases, and serum enzymes in carbon tetrachloride-treated rats. Monticello TM, et al. **Toxicol Pathol** 1995 Jul–Aug; 23(4):439–46

[Alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamate dehydrogenase (GLDH), alkaline phosphatase (AP) and gamma-glutamyltransferase (GGP) in intestinal diseases of dogs] Dodurka T, et al. **Berl Munch Tierarztl Wochenschr** 1995 Jul;108(7):244–8 (Eng. Abstr.) **(Ger)**

[Expert consultation. Prolonged elevation of transaminase concentration] Ramadori G. **Leber Magen Darm** 1996 Mar; 26(2):114 **(Ger)**

[Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] Miura Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:266–71 (12 ref.) **(Jpn)**

CHEMISTRY

Use of protease sensitivity to probe the conformations of newly synthesised mutant forms of mitochondrial aspartate aminotransferase. Azzariti A, et al. **Biochem Biophys Res Commun** 1995 Oct 24;215(3):800–7

Rationalisation of the C-S lyase activity of aspartate amino transferase. Teesdale-Spittle PH, et al. **Biochem Soc Trans** 1996 Feb;24(1):141S

Crystal structures and solution studies of oxime adducts of mitochondrial aspartate aminotransferase. Marković-Housley Z, et al. **Eur J Biochem** 1996 Mar 15; 236(3):1025–32

Structural features of the precursor to mitochondrial aspartate aminotransferase responsible for binding to hsp70. Lain B, et al. **J Biol Chem** 1995 Oct 20;270(42):24732–9

Probes for analysis of stability of different variants of aspartate aminotransferase. Martinez-Carrion M, et al. **Methods Enzymol** 1995;259:590–608

Redesign of the substrate specificity of Escherichia coli aspartate aminotransferase to that of Escherichia coli tyrosine aminotransferase by homology modeling and site-directed mutagenesis. Onuffer JJ, et al. **Protein Sci** 1995 Sep;4(9):1750–7

[Changes in the conformation of a cofactor in the complex of aspartate aminotransferase with D-aspartate] Kochkina VM, et al. **Mol Biol (Mosk)** 1995 Sep–Oct;29(5):1168–71 **(Rus)**

GENETICS

The roles of Tyr70 and Tyr225 in aspartate aminotransferase assessed by analysing the effects of mutations on the multiple reactions of the substrate analogue serine o-sulphate. Birolo L, et al. **Eur J Biochem** 1995 Sep 15; 232(3):859–64

Pyridoxal 5'-phosphate modulates expression of cytosolic aspartate aminotransferase gene by inactivation of glucocorticoid receptor. Oka T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Jun;41(3):363–75

METABOLISM

Changes in enzyme levels in hypertensive heart tissue. Atlante A, et al. **Biochem Mol Biol Int** 1995 Nov; 37(5):983–90

Substrate accessibility to cytosolic aspartate aminotransferase improves posthypoxic recovery of isolated rat heart. Pisarenko OI, et al. **Biochem Mol Med** 1995 Aug; 55(2):138–48

Rationalisation of the C-S lyase activity of aspartate amino transferase. Teesdale-Spittle PH, et al. **Biochem Soc Trans** 1996 Feb;24(1):141S

Examining the structural and chemical flexibility of the active site base, Lys-258, of Escherichia coli aspartate aminotransferase by replacement with unnatural amino acids. Gloss LM, et al. **Biochemistry** 1995 Sep 26; 34(38):12323–32

The reaction catalyzed by Escherichia coli aspartate aminotransferase has multiple partially rate-determining steps, while that catalyzed by the Y225F mutant is dominated by ketimine hydrolysis. Goldberg JM, et al. **Biochemistry** 1996 Apr 23;35(16):5280–91

Effects of mebendazole, albendazole and praziquantel on alanine aminotransferase and aspartate aminotransferase of Echinococcus granulosus cyst wall harbored in mice. Xiao S, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):107–10

The roles of Tyr70 and Tyr225 in aspartate aminotransferase assessed by analysing the effects of mutations on the multiple reactions of the substrate analogue serine o-sulphate. Birolo L, et al. **Eur J Biochem** 1995 Sep 15; 232(3):859–64

Changing the reaction specificity of a pyridoxal-5'-phosphate-dependent enzyme. Graber R, et al. **Eur J Biochem** 1995 Sep 1;232(2):686–90

Crystal structures and solution studies of oxime adducts of mitochondrial aspartate aminotransferase. Marković-Housley Z, et al. **Eur J Biochem** 1996 Mar 15; 236(3):1025–32

Differential effects of molecular chaperones on refolding of homologous proteins. Widmann M, et al. **FEBS Lett** 1995 Dec 27;377(3):481–4

The effect of prostaglandin E1 on liver adenine nucleotides and cytoplasmic enzymes in a porcine model of normothermic hepatic ischemia. Helling TS, et al. **Hepatology** 1995 Nov;22(5):1554–9

3T3 fibroblasts transfected with a cDNA for mitochondrial aspartate aminotransferase express plasma membrane fatty acid-binding protein and saturable fatty acid uptake. Isola LM, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9866–70

The use of natural and unnatural amino acid substrates to define the substrate specificity differences of Escherichia coli aspartate and tyrosine aminotransferases. Onuffer JJ, et al. **Protein Sci** 1995 Sep;4(9):1743–9

Redesign of the substrate specificity of Escherichia coli aspartate aminotransferase to that of Escherichia coli tyrosine aminotransferase by homology modeling and site-directed mutagenesis. Onuffer JJ, et al. **Protein Sci** 1995 Sep;4(9):1750–7

[Aspartate aminotransferase of the human cerebellar cortex] Kalinichenko SG, et al. **Tsitologiia** 1995;37(9–10):910–4 (Eng. Abstr.) **(Rus)**

SECRETION

The influence of antagonists of poly(ADP-ribose) metabolism on acetaminophen hepatotoxicity. Kröger H, et al. **Gen Pharmacol** 1996 Jan;27(1):167–70

ASPARTATE AMINOTRANSFERASE ISOENZYMES see **ASPARTATE AMINOTRANSFERASE**

ASPARTATE AMINOTRANSFERASE ISOZYMES see **ASPARTATE AMINOTRANSFERASE**

ASPARTATE-AMMONIA LIGASE

BIOSYNTHESIS

Sugar regulation of harvest-related genes in asparagus. Davies KM, et al. **Plant Physiol** 1996 Jul;111(3):877–83

CHEMISTRY

Mapping the aspartic acid binding site of Escherichia coli asparagine synthetase B using substrate analogs. Parr IB, et al. **J Med Chem** 1996 Jun 7;39(12):2367–78

GENETICS

Expression of asparagine synthetase mRNA through asparagine independent signal transduction pathway that might involve protein kinase C in BALB3T3 cells. Chiyo T, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):1929–35

Lactobacillus bulgaricus asparagine synthetase and asparaginyl-tRNA synthetase: coregulation by transcription antitermination? Kim SI, et al. **J Bacteriol** 1996 Apr;178(8):2459–61

Metabolic regulation of asparagine synthetase gene expression in maize (Zea mays L.) root tips. Chevalier C, et al. **Plant J** 1996 Jan;9(1):1–11

Molecular cloning and characterisation of asparagine synthetase from Lotus japonicus: dynamics of asparagine synthesis in N-sufficient conditions. Waterhouse RN, et al. **Plant Mol Biol** 1996 Mar;30(5):883–97

METABOLISM

Glutamic acid gamma-monohydroxamate and hydroxylamine are alternate substrates for Escherichia coli asparagine synthetase B. Boehlein SK, et al. **Biochemistry** 1996 Mar 5;35(9):3031–7

Probing the mechanism of nitrogen transfer in Escherichia coli asparagine synthetase by using heavy atom isotope effects. Stoker PW, et al. **Biochemistry** 1996 Mar 5; 35(9):3024–30

ASPARTATE CARBAMOYLTRANSFERASE

ANTAGONISTS & INHIBITORS

Effects of lipids on nucleotide inhibition of wheat-germ aspartate transcarbamoylase: evidence of an additional level of control? Khan A, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):669-73

Identification of the binding site for the allosteric inactivator UTP in mammalian CPS II. Zhu LM, et al. **Biochem Soc Trans** 1995 Nov;23(4):620S

BIOSYNTHESIS

Molecular cloning of a human cDNA encoding a trifunctional enzyme of carbamoyl-phosphate synthetase-aspartate transcarbamoylase-dihydroorotase in de Novo pyrimidine synthesis. Iwahana H, et al. **Biochem Biophys Res Commun** 1996 Feb 6;219(1):249-55

CHEMISTRY

Unlike the quaternary structure transition, the tertiary structure change of the 240s loop in allosteric aspartate transcarbamylase requires active site saturation by substrate for completion. Fetler L, et al. **Biochemistry** 1995 Dec 5; 34(48):15654-60

A bifunctional fusion protein containing the maltose-binding polypeptide and the catalytic chain of aspartate transcarbamoylase: assembly, oligomers, and domains. Yang YR, et al. **Biophys Chem** 1996 Apr 16;59(3):289-97

Effects of assembly and mutations outside the active site on the functional pH dependence of Escherichia coli aspartate transcarbamylase. Yuan X, et al. **J Biol Chem** 1996 Jan 19;271(3):1285-94

Analysis of the low frequency normal modes of the T-state of aspartate transcarbamylase. Thomas A, et al. **J Mol Biol** 1996 Apr 19;257(5):1070-87

Analysis of the low-frequency normal modes of the R state of aspartate transcarbamylase and a comparison with the T state modes. Thomas A, et al. **J Mol Biol** 1996 Aug 23;261(3):490-506

Thermodynamic approaches to understanding aspartate transcarbamylase. Allewell NM, et al. **Methods Enzymol** 1995;259:608-28

A reappraisal of the diversity and class distribution of aspartate transcarbamoylases in gram-negative bacteria. Kenny MJ, et al. **Microbiology** 1996 Jul;142 (Pt 7):1873-9

Structural similarity between ornithine and aspartate transcarbamoylases of Escherichia coli: characterization of the active site and evidence for an interdomain carboxy-terminal helix in ornithine transcarbamoylase. Murata LB, et al. **Protein Sci** 1996 Apr;5(4):709-18

Structural similarity between ornithine and aspartate transcarbamoylases of Escherichia coli: implications for domain switching. Murata LB, et al. **Protein Sci** 1996 Apr; 5(4):719-28

CLASSIFICATION

A reappraisal of the diversity and class distribution of aspartate transcarbamoylases in gram-negative bacteria. Kenny MJ, et al. **Microbiology** 1996 Jul;142 (Pt 7):1873-9

GENETICS

Overexpression of cyclin D1 enhances gene amplification. Zhou P, et al. **Cancer Res** 1996 Jan 1;56(1):36-9

As in Saccharomyces cerevisiae, aspartate transcarbamoylase is assembled on a multifunctional protein including a dihydroorotase-like cryptic domain in Schizosaccharomyces pombe. Lollier M, et al. **Curr Genet** 1995 Jul;28(2):138-49

Overexpression and purification of the trimeric aspartate transcarbamoylase from Bacillus subtilis. Baker DP, et al. **Protein Expr Purif** 1995 Oct;6(5):679-84

An early gene of the Chlorella virus PBCV-1 encodes a functional aspartate transcarbamylase. Landstein D, et al. **Virology** 1996 Jul 1;221(1):151-8

ISOLATION & PURIFICATION

Overexpression and purification of the trimeric aspartate transcarbamoylase from Bacillus subtilis. Baker DP, et al. **Protein Expr Purif** 1995 Oct;6(5):679-84

METABOLISM

Identification of the binding site for the allosteric inactivator UTP in mammalian CPS II. Zhu LM, et al. **Biochem Soc Trans** 1995 Nov;23(4):620S

Effects of assembly and mutations outside the active site on the functional pH dependence of Escherichia coli aspartate transcarbamylase. Yuan X, et al. **J Biol Chem** 1996 Jan 19;271(3):1285-94

Thermodynamic approaches to understanding aspartate transcarbamylase. Allewell NM, et al. **Methods Enzymol** 1995;259:608-28

ASPARTATE KINASE

GENETICS

Sequence of the Bacillus stearothermophilus gene encoding aspartokinase II. Cantoni R, et al. **Gene** 1996 Feb 22; 169(1):135-6

METABOLISM

[Aspartate kinase from the cyanobacteriium Plectonema boryanum infected with the cyanophage LPP-3] Perepelitsa SI, et al. **Ukr Biokhim Zh** 1995 Jan-Feb; 67(1):46-51 (Eng. Abstr.) **(Rus)**

ASPARTATE TRANSCARBAMYLASE see **ASPARTATE CARBAMOYLTRANSFERASE**

ASPARTIC ACID

Mutation of an aspartate at position 63 in the human platelet-activating factor receptor augments binding affinity but abolishes G-protein-coupling and inositol phosphate production. Parent JL, et al. **Biochem Biophys Res Commun** 1996 Feb 27;219(3):968-75

Phosphofructo-1-kinase: role of charge neutralization in the active site. Zheng RL, et al. **Biochem Biophys Res Commun** 1995 Sep 25;214(3):765-70

Measuring the strength of side-chain hydrogen bonds in peptide helices: the Gln.Asp (i, i + 4) interaction. Huyghues-Despointes BM, et al. **Biochemistry** 1995 Oct 17;34(41):13267-71

Direct measurement of the aspartic acid 26 pKa for reduced Escherichia coli thioredoxin by 13C NMR. Jeng MF, et al. **Biochemistry** 1996 Jan 9;35(1):1-6

Structure-function analysis of the mammalian DNA polymerase beta active site: role of aspartic acid 256, arginine 254, and arginine 258 in nucleotidyl transfer. Menge KL, et al. **Biochemistry** 1995 Dec 12; 34(49):15934-42

Asp76 is the Schiff base counterion and proton acceptor in the proton-translocating form of sensory rhodopsin I. Rath P, et al. **Biochemistry** 1996 May 28;35(21):6690-6

A linkage of the pKa's of asp-85 and glu-204 forms part of the reprotonation switch of bacteriorhodopsin. Richter HT, et al. **Biochemistry** 1996 Apr 2;35(13):4054-62

D38 is an essential part of the proton translocation pathway in bacteriorhodopsin. Riesle J, et al. **Biochemistry** 1996 May 28;35(21):6635-43

Probing the functional role of two conserved active site aspartates in mouse adenosine deaminase. Sideraki V, et al. **Biochemistry** 1996 Jun 18;35(24):7862-72

Importance of two buried salt bridges in the stability and folding pathway of barnase. Tissot AC, et al. **Biochemistry** 1996 May 28;35(21):6786-94

Identification of an active acidic residue in the catalytic site of beta-hexosaminidase. Tse R, et al. **Biochemistry** 1996 Jun 11;35(23):7599-607

Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Wang YX, et al. **Biochemistry** 1996 Aug 6;35(31):9945-50

Asp537 and Asp812 in bacteriophage T7 RNA polymerase as metal ion-binding sites studied by EPR, flow-dialysis, and transcription. Woody AY, et al. **Biochemistry** 1996 Jan 9;35(1):144-52

A phosphotransferase activity of the Bacillus subtilis sporulation protein Spo0F that employs phosphoramidate substrates. Zapf JW, et al. **Biochemistry** 1996 Mar 5; 35(9):2926-33

Characterization of the mutant visual pigment responsible for congenital night blindness: a biochemical and Fourier-transform infrared spectroscopy study. Zvyaga TA, et al. **Biochemistry** 1996 Jun 11;35(23):7536-45

Identification of an aspartic acid residue in the beta subunit which is essential for catalysis and proton pumping by transhydrogenase from Escherichia coli. Meuller J, et al. **Biochim Biophys Acta** 1996 Mar 28;1273(3):191-4

HLA-DQ beta 1 typing and non-Asp57 alleles in the aborigine population of Senegal. Chauffert M, et al. **Diabetes Care** 1995 May;18(5):677-80

The catalytic site of chloroplastic NADP-dependent malate dehydrogenase contains a His/Asp pair. Lemaire M, et al. **Eur J Biochem** 1996 Mar 15;236(3):947-52

Asp-59 is not important for the catalytic activity of the restriction endonuclease EcoRI. Grabowski G, et al. **FEBS Lett** 1996 Feb 26;381(1-2):106-10

Cloning the cDNA of human PWP2, which encodes a protein with WD repeats and maps to 21q22.3. Lalioti MD, et al. **Genomics** 1996 Jul 15;35(2):321-7

Epidermolysis bullosa simplex (Weber-Cockayne) associated with a novel missense mutation of Asp328 to Val in Linker 12 domain of keratin 5. Matsuki M, et al. **Hum Mol Genet** 1995 Oct;4(10):1999-2000

Mutants in the putative nucleotide-binding region of the plasma membrane Ca(2+)-pump. A reduction in activity due to slow dephosphorylation. Adamo HP, et al. **J Biol Chem** 1995 Dec 15;270(50):30111-4

Asp333, Asp495, and His523 form the catalytic triad of rat soluble epoxide hydrolase. Arand M, et al. **J Biol Chem** 1996 Feb 23;271(8):4223-9

An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase. McAllister-Lucas LM, et al. **J Biol Chem** 1995 Dec 22;270(51):30671-9

Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase. Moriyama Y, et al. **J Biol Chem** 1996 Feb 16;271(7):3347-50

Protein conformational changes during the bacteriorhodopsin photocycle. A Fourier transform infrared/resonance Raman study of the alkaline form of the mutant Asp-85-->Asn. Nilsson A, et al. **J Biol Chem** 1995 Dec 15;270(50):29746-51

Site-directed mutagenesis of human lysyl hydroxylase expressed in insect cells. Identification of histidine residues and an aspartic acid residue critical for catalytic activity. Pirskanen A, et al. **J Biol Chem** 1996 Apr 19; 271(16):9398-402

Characterization of a potential catalytic residue, Asp-133, in the high affinity ATP-binding site of Escherichia coli SecA, translocation ATPase. Sato K, et al. **J Biol Chem** 1996 Jul 19;271(29):17439-44

Kinetic and structural consequences of replacing the aspartate bridge by asparagine in the catalytic metal triad of Escherichia coli alkaline phosphatase. Tibbitts TT, et al. **J Mol Biol** 1996 Apr 5;257(3):700-15

Role of the conserved histidine and aspartic acid residues in activity and stabilization of human gelatinase B: an example of matrix metalloproteinases. Pourmotabbed T, et al. **J Protein Chem** 1995 Oct;14(7):527-35

An aspartic acid at amino acid 108 is required to rescue infectious virus after transfection of a poliovirus cDNA containing a CGDD but not SGDD amino acid motif in 3Dpol. Walker DE, et al. **J Virol** 1995 Dec;69(12):8173-7

Analysis of the NH2-terminal 87th amino acid of Escherichia coli GyrA in quinolone-resistance. Yonezawa M, et al. **Microbiol Immunol** 1995;39(7):517-20

The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Befort K, et al. **Mol Pharmacol** 1996 Feb;49(2):216-23

ANALOGS & DERIVATIVES

MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. Brown MS, et al. **AJNR Am J Neuroradiol** 1995 Nov-Dec;16(10):2013-20

Proton magnetic resonance spectroscopy in children with temporal lobe epilepsy. Cross JH, et al. **Ann Neurol** 1996 Jan;39(1):107-13

Evaluation of the antiviral activity of N-(phosphonoacetyl)-L-aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats. Wyde PR, et al. **Antiviral Res** 1995 May;27(1-2):59-69

Synthesis and dopamine receptor binding studies of homochiral 8-aminopyrido[1,2-a]indoles. Gmeiner P, et al. **Arch Pharm (Weinheim)** 1995 Jul-Aug;328(7-8):626-8

Tumorigenicity and gene amplification potentials of cyclin D1-overexpressing NIH3T3 cells. Asano K, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1169-76

The transport of acidic amino acids and their analogues across monolayers of human intestinal absorptive (Caco-2) cells in vitro. Nicklin PL, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):176-86

2-Naphthalenesulphanyl-L-aspartyl-2-(phenethyl) amide (2-NAP) and food intake in rats: evidence that endogenous peripheral CCK does not play a major role as a satiety factor. Ebenezer IS, et al. **Br J Pharmacol** 1995 Nov; 116(5):2371-4

N-acetylaspartate as an acetyl source in the nervous system. Mehta V, et al. **Brain Res Mol Brain Res** 1995 Jul; 31(1-2):151-7

Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside. Hageboutros A, et al. **Cancer Chemother Pharmacol** 1996;37(3):229-34

Separate pathways for p53 induction by ionizing radiation and N-(phosphonoacetyl)-L-aspartate. Chen CY, et al. **Cancer Res** 1996 Aug 15;56(16):3659-62

Analogue of aspartate and glutamate active at synapses are attractants for Escherichia coli. Lake EM, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):283-8

Magnetic resonance spectroscopic findings in patients with subcortical ischemic stroke. Lai ML, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Jul;56(1):31-5

Radiation-induced changes in human brain metabolites as studied by 1H nuclear magnetic resonance spectroscopy in vivo. Usenius T, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):719-24

PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells. Yang JL, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 15;34(5):1073-9

Neuronal dysfunction in patients with closed head injury evaluated by in vivo 1H magnetic resonance spectroscopy. Choe BY, et al. **Invest Radiol** 1995 Aug;30(8):502-6

Cytosine deaminase gene as a positive selection marker. Wei K, et al. **J Biol Chem** 1996 Feb 16;271(7):3812-6

N-acetylaspartate complexes with calcium and lanthanide ions. Rubin Y, et al. **J Inorg Biochem** 1995 Oct;60(1):31-43

Time dependence of N-acetyl-aspartate, lactate, and pyruvate concentrations following spinal cord injury. Falconer JC, et al. **J Neurochem** 1996 Feb;66(2):717-22

Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. Moffett JR, et al. **J Neurocytol** 1995 Jun;24(6):409-33

In vivo microdialysis and gas chromatography/mass spectrometry for studies on release of

N-acetylaspartylglutamate and N-acetylaspartate in rat brain hypothalamus. Lin SN, et al. **J Neurosci Methods** 1995 Nov;62(1-2):199-205

Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. Noordhuis P, et al. **Leuk Res** 1996 Feb;20(2):127-34

N-acetylaspartate and epilepsy. Gadian DG. **Magn Reson Imaging** 1995;13(8):1193-5

Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of the epileptic human brain. Petroff OA, et al. **Magn Reson Imaging** 1995;13(8):1197-211

Reversible decreases in N-acetylaspartate after acute brain injury. De Stefano N, et al. **Magn Reson Med** 1995 Nov; 34(5):721-7

Localised proton magnetic resonance spectroscopy in X-linked adrenoleukodystrophy. Confort-Gouny S, et al. **Neuroradiology** 1995 Oct;37(7):568-75

1H and 31P magnetic resonance spectroscopic imaging of white matter signal hyperintensity areas in elderly subjects. Constans JM, et al. **Neuroradiology** 1995 Nov;37(8):615-23

The effect of N-acetylaspartate on the intracellular free calcium concentration in NTera2-neurons. Rubin Y, et al. **Neurosci Lett** 1995 Oct 6;198(3):209-12

Mapping of lactate and N-acetyl-L-aspartate predicts infarction during acute focal ischemia: in vivo 1H magnetic resonance spectroscopy in rats. Higuchi T, et al. **Neurosurgery** 1996 Jan;38(1):121-9; discussion 129-30

Reduced N-acetylaspartate in the brain observed on in vivo proton magnetic resonance spectroscopy in patients with mental retardation. Hashimoto T, et al. **Pediatr Neurol** 1995 Oct;13(3):205-8

[N-acetyl-aspartate abnormalities in internal-temporal epileptic foci using proton magnetic resonance spectroscopy] Giroud M, et al. **Rev Neurol (Paris)** 1995 Jun-Jul;151(6-7):404-9 (28 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Identification of a critical aspartate residue in transmembrane domain three necessary for the binding of somatostatin to the somatostatin receptor SSTR2. Strnad J, et al. **Biochem Biophys Res Commun** 1995 Nov 22;216(3):913-21

Presence of D-aspartate and D-glutamate in tumor proteins. Fisher GH, et al. **Cancer Biochem Biophys** 1995 Nov; 15(2):79-82

Distribution of aspartate and glutamate in the nucleus of the solitary tract of the lamb. Sweazey RD. **Exp Brain Res** 1995;105(2):241-53

Identification of osteocalcin as a permanent aging constituent of the bone matrix: basis for an accurate age at death determination. Ritz S, et al. **Forensic Sci Int** 1996 Jan 12; 77(1-2):13-26

D-aspartate in the male and female reproductive system of Octopus vulgaris lam. D'Aniello A, et al. **Gen Comp Endocrinol** 1995 Oct;100(1):69-72

Estimation of chronologic age using the aspartic acid racemization method. II. On human cortical bone. Pfeiffer H, et al. **Int J Legal Med** 1995;108(1):24-6

ANTAGONISTS & INHIBITORS

Cysteamine and naloxone attenuate aspartic acid-induced depression of ventilation. Schlenker EH, et al. **Physiol Behav** 1996 Apr-May;59(4-5):709-12

BIOSYNTHESIS

Molecular aging of tubulin: accumulation of isoaspartyl sites in vitro and in vivo. Najbauer J, et al. **Biochemistry** 1996 Apr 23;35(16):5183-90

A novel silent posttranslational mechanism converts methionine to aspartate in hemoglobin Bristol (beta 67[E11] Val-Met->Asp). Rees DC, et al. **Blood** 1996 Jul 1; 88(1):341-8

BLOOD

Erythrocyte L-aspartyl-L-phenylalanine hydrolase activity and plasma phenylalanine and aspartate concentrations in children consuming diets high in aspartame. Stegink LD, et al. **Am J Clin Nutr** 1995 Dec;62(6):1206-11

CEREBROSPINAL FLUID

Inhibitory and excitatory amino acids in cerebrospinal fluid of neurolathyrism patients, a highly prevalent motorneurone disease. Khan JK, et al. **Acta Neurol Scand** 1995 Jun;91(6):506-10

CSF excitatory amino acids and severity of illness in Alzheimer's disease. Csernansky JG, et al. **Neurology** 1996 Jun;46(6):1715-20

CHEMISTRY

Enzymatic synthesis of the N-glycosidic bond by beta-aspartylation of glycosylamines. Mononen I, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):510-3

Identification of Asp 549 as the catalytic nucleophile of glycogen-debranching enzyme via trapping of the glycosyl-enzyme intermediate. Braun C, et al. **Biochemistry** 1996 Apr 30;35(17):5458-63

1H NMR investigation of the electronic and molecular structure of the four-iron cluster ferredoxin from the hyperthermophile Pyrococcus furiosus. Identification of Asp 14 as a cluster ligand in each of the four redox states. Calzolai L, et al. **Biochemistry** 1995 Sep 12;34(36):11373-84

Use of designed metal-binding sites to study helix proximity in the lactose permease of Escherichia coli. 1. Proximity of helix VII (Asp237 and Asp240) with helices X (Lys319) and XI (Lys358). He MM, et al. **Biochemistry** 1995 Dec 5;34(48):15661-6

Probing the function of Asp128 in the lower molecular weight protein-tyrosine phosphatase-catalyzed reaction. A pre-steady-state and steady-state kinetic investigation. Wu L, et al. **Biochemistry** 1996 Apr 30;35(17):5426-34

Estimation of age from dentin by utilizing the racemization of aspartic acid: influence of pH. Ohtani S. **Forensic Sci Int** 1995 Oct 30;75(2-3):181-7

Estimation of chronologic age using the aspartic acid racemization method. I. On human rib cartilage. Pfeiffer H, et al. **Int J Legal Med** 1995;108(1):19-23

Age estimation in biopsy specimens of dentin. Ritz S, et al. **Int J Legal Med** 1995;108(3):135-9

Unequivocal identification of Asp-214 as the catalytic nucleophile of Saccharomyces cerevisiae alpha-glucosidase using 5-fluoro glycosyl fluorides. McCarter JD, et al. **J Biol Chem** 1996 Mar 22;271(12):6889-94

Studies on age estimation using racemization of aspartic acid in cementum. Ohtani S. **J Forensic Sci** 1995 Sep;40(5):805-7

Protein selectivity in immobilized metal affinity chromatography based on the surface accessibility of aspartic and glutamic acid residues. Zachariou M, et al. **J Protein Chem** 1995 Aug;14(6):419-30

[Changes in the conformation of a cofactor in the complex of aspartate aminotransferase with D-aspartate] Kochkina VM, et al. **Mol Biol (Mosk)** 1995 Sep-Oct;29(5):1168-71 **(Rus)**

GENETICS

Versatility of heme coordination demonstrated in a fungal peroxidase. Absorption and resonance Raman studies of Coprinus cinereus peroxidase and the Asp245-->Asn mutant at various pH values. Smulevich G, et al. **Biochemistry** 1996 Aug 13;35(32):10576-85

Mutation of the catalytic site Asp177 to Glu177 in human pancreatic lipase produces an active lipase with increased sensitivity to proteases. Lowe ME. **Biochim Biophys Acta** 1996 Jul 26;1302(2):177-83

Effects of Asn318 and Asp87Asn318 mutations on signal transduction by the gonadotropin-releasing hormone receptor and receptor regulation. Awara WM, et al. **Endocrinology** 1996 Feb;137(2):655-62

Association between toluene diisocyanate-induced asthma and DQB1 markers: a possible role for aspartic acid at position 57. Balboni A, et al. **Eur Respir J** 1996 Feb; 9(2):207-10

Critical effects on catalytic function produced by amino acid substitutions at Asp804 and Asp808 of the alpha1 isoform of Na,K-ATPase. Van Huysse JW, et al. **FEBS Lett** 1996 Jul 1;389(2):179-85

A mutation in which alanine 128 Is replaced by aspartic acid abolishes dimerization of the b-subunit of the F0F1-ATPase from Escherichia coli. Howitt SM, et al. **J Biol Chem** 1996 Mar 22;271(12):7038-42

Modification of the pH profile and tetrabenazine sensitivity of rat VMAT1 by replacement of aspartate 404 with glutamate. Steiner-Mordoch S, et al. **J Biol Chem** 1996 May 31;271(22):13048-54

METABOLISM

Similar localization of immunoreactive glutamate and aspartate in the pineal organ and retina of various nonmammalian vertebrates. Vigh B, et al. **Acta Biol Hung** 1995;46(1):99-106

Enhancement of 3[H]D-aspartate release during ischemia like conditions in rat hippocampal slices: source of excitatory amino acids. Zabłocka B, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):63-70

Estimation of age from dentin by using the racemization reaction of aspartic acid. Ohtani S. **Am J Forensic Med Pathol** 1995 Jun;16(2):158-61

Tissue Factor residue Asp44 regulates catalytic function of the bound proteinase Factor VIIa. Kelly CR, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):145-51

Functional properties of the histidine-aspartate ion pair of flavocytochrome b2 (L-lactate dehydrogenase): substitution of Asp282 with asparagine. Gondry M, et al. **Biochemistry** 1996 Jul 2;35(26):8587-94

Insights into the catalytic mechanism and active-site environment of Comamonas testosteroni delta 5-3-ketosteroid isomerase as revealed by site-directed mutagenesis of the catalytic base aspartate-38. Holman CM, et al. **Biochemistry** 1995 Oct 31;34(43):14245-53

Aspartate 74 as a primary determinant in acetylcholinesterase governing specificity to cationic organophosphonates. Hosea NA, et al. **Biochemistry** 1996 Aug 20; 35(33):10995-1004

Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase. Kaushik N, et al. **Biochemistry** 1996 Sep 10; 35(36):11536-46

Mitochondrial phosphate transport protein. replacements of glutamic, aspartic, and histidine residues affect transport and protein conformation and point to a coupled proton transport path. Phelps A, et al. **Biochemistry** 1996 Aug 20; 35(33):10757-62

NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT1A antagonist. Dijk SN, et al. **Br J Pharmacol** 1995 Aug;115(7):1169-74

The effect of the desglycinyl metabolite of remacemide hydrochloride (FPL 12495AA) and dizocilpine (MK-801) on endogenous amino acid release from mouse cortex. Srinivasan J, et al. **Br J Pharmacol** 1995 Dec;116(8):3087-92

Adenosine modulates methylmercuric chloride (MeHgCl)-induced D-aspartate release from neonatal rat primary astrocyte cultures. Aschner M, et al. **Brain Res** 1995 Aug 14;689(1):1-8

Cocaine increases extraneuronal levels of aspartate and glutamate in the nucleus accumbens. Smith JA, et al. **Brain Res** 1995 Jun 19;683(2):264-9

Glucagon-like peptide-1(7-36)amide induces the release of aspartic acid and glutamine by the ventromedial hypothalamus of the conscious rat. Calvo JC, et al. **Brain Res Bull** 1995;38(5):435-9

Retrograde labeling of retinal ganglion cells and brain neuronal subsets by [3H]-D-aspartate injection in the Syrian hamster hypothalamus. De Vries MJ, et al. **Brain Res Bull** 1995;38(4):349-54

The entry of acidic amino acids into brain and CSF during development, using in situ perfusion in the rat. al-Sarraf H, et al. **Brain Res Dev Brain Res** 1995 Dec 21; 90(1-2):151-8

Aspartic acid residue 124 in the third transmembrane domain of the somatostatin receptor subtype 3 is essential for somatostatin-14 binding. Nehring RB, et al. **DNA Cell Biol** 1995 Nov;14(11):939-44

Anatomical distribution and postnatal changes in endogenous free D-aspartate and D-serine in rat brain and periphery. Hashimoto A, et al. **Eur J Neurosci** 1995 Aug 1; 7(8):1657-63

Pre-incubation of synaptosomes with arachidonic acid potentiates inhibition of [3H]D-aspartate transport. Lundy DF, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):273-9

The functional role of the binding site aspartate in muscarinic acetylcholine receptors, probed by site-directed mutagenesis. Page KM, et al. **Eur J Pharmacol** 1995 May 26;289(3):429-37

Role of the conserved aspartate and phenylalanine residues in prokaryotic and mitochondrial elongation factor Ts in guanine nucleotide exchange. Zhang Y, et al. **FEBS Lett** 1996 Aug 12;391(3):330-2

Age-related changes in D-aspartic acid of rat teeth. Ohtani S, et al. **Growth Dev Aging** 1995 Spring-Summer; 59(1-2):55-61

Changes in D-aspartic acid in human deciduous teeth with age from 1-20 years. Ohtani S, et al. **Growth Dev Aging** 1996 Spring;60(1):1-6

Immunocytochemical localization of aspartate and glutamate in the peripheral vestibular system. Harper A, et al. **Hear Res** 1995 Jun;86(1-2):171-82

Enzymatic properties of mutant forms of RNase Rh from Rhizopus niveus as to Asp51. Ohgi K, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):548-52

Exchange of aspartate and alanine. Mechanism for development of a proton-motive force in bacteria. Abe K, et al. **J Biol Chem** 1996 Feb 9;271(6):3079-84

Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. Ellis SW, et al. **J Biol Chem** 1995 Dec 8;270(49):29055-8

Effect on substrate binding of an alteration at the conserved aspartic acid- 162 in herpes simplex virus type 1 thymidine kinase. Black ME, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1521-7

Mapping the aspartic acid binding site of Escherichia coli asparagine synthetase B using substrate analogs. Parr IB, et al. **J Med Chem** 1996 Jun 7;39(12):2367-78

Age-related changes in the uptake and release of glutamate and aspartate in the mouse brain. Saransaari P, et al. **Mech Ageing Dev** 1995 Jul 14;81(2-3):61-71

The release of glutamate and aspartate from rat brain synaptosomes in response to domoic acid (amnesic shellfish toxin) and kainic acid. Brown JA, et al. **Mol Cell Biochem** 1995 Oct 4;151(1):49-54

Characterization of an Na(+)-dependent glutamate/aspartate transporter from cultured Bergmann glia. Ruiz M, et al. **Neuroreport** 1995 Oct 23;6(15):2041-4

Nitric oxide regulates excitatory amino acid release in a biphasic manner in freely moving rats. Segieth J, et al. **Neurosci Lett** 1995 Nov 17;200(2):101-4

N-acetylaspartate in neuropsychiatric disorders. Tsai G, et al. **Prog Neurobiol** 1995 Aug;46(5):531-40 (178 ref.)

The role of aspartate-235 in the binding of cations to an artificial cavity at the radical site of cytochrome c peroxidase. Fitzgerald MM, et al. **Protein Sci** 1995 Sep; 4(9):1844-50

Roles of Glu 349 and Asp 352 in membrane insertion and translocation by diphtheria toxin. Kaul P, et al. **Protein Sci** 1996 Apr;5(4):687-92

New mutations and phenotypes associated with glutamate and aspartate transport in Chinese hamster ovary (CHO-K1) cells. Igo RP Jr, et al. **Somat Cell Mol Genet** 1996 Mar;22(2):87-103

PHARMACOKINETICS

Volume-activated release of D-aspartate from human

placental tissue [letter] Shennan DB, et al. **Placenta** 1996 Mar-Apr;17(2-3):189-90

PHARMACOLOGY

Synthesis and dopamine receptor binding studies of homochiral 8-aminopyrido[1,2-a]indoles. Gmeiner P, et al. **Arch Pharm (Weinheim)** 1995 Jul-Aug;328(7-8):626-8

Substrate accessibility to cytosolic aspartate aminotransferase improves posthypoxic recovery of isolated rat heart. Pisarenko OI, et al. **Biochem Mol Med** 1995 Aug; 55(2):138-48

Analogue of aspartate and glutamate active at synapses are attractants for Escherichia coli. Lake EM, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):283-8

Aspartate and glutamate modulation of growth hormone secretion in the pig: possible site of action. Barb CR, et al. **Domest Anim Endocrinol** 1996 Jan;13(1):81-90

Intracoronary magnesium is not protective against acute reperfusion injury in the regional ischaemic-reperfused dog heart. Schlack W, et al. **Eur J Clin Invest** 1995 Jul; 25(7):501-9

The effect of light history on the aspartate-isolated fast-PIII responses of the albino rat retina. Reiser MA, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):221-9

Role of aspartate in ischemic spinal cord damage. Ogata T, et al. **J Orthop Res** 1996 May;14(3):504-10

Involvement of D-aspartic acid in the synthesis of testosterone in rat testes. D'Aniello A, et al. **Life Sci** 1996; 59(2):97-104

Different effects of three high-dose oral calcium salts on acid-base metabolism, plasma electrolytes and urine parameters of rats. Classen HG, et al. **Methods Find Exp Clin Pharmacol** 1995 Sep;17(7):437-42

Both electrolytic and excitotoxic lesions of nucleus accumbens disrupt latent inhibition of learning in rats. Tai CT, et al. **Neurobiol Learn Mem** 1995 Jul;64(1):36-48

Functional geometry of amino acid sensitive membrane of layer V neurons in the guinea-pig neocortex in vitro. Mednikova YS, et al. **Neuroscience** 1995 Nov;69(1):115-23

N-acetylaspartate in neuropsychiatric disorders. Tsai G, et al. **Prog Neurobiol** 1995 Aug;46(5):531-40 (178 ref.)

Selective activation of calcium permeability by aspartate in Purkinje cells. Yuzaki M, et al. **Science** 1996 Aug 23; 273(5278):1112-4

[Psychopharmacological properties of three magnesium salts: pidolate, lactate and aspartate] Teste JF, et al. **Ann Pharm Fr** 1995;53(4):176-83 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Site-directed mutagenesis of two conserved charged amino acids in the N-terminal region of alpha subunit of E. coli-F(0)F(1). Hase B, et al. **FEBS Lett** 1996 Mar 11; 382(1-2):171-4

Molecular determinants of external barium block in Shaker potassium channels. Hurst RS, et al. **FEBS Lett** 1996 Jun 10;388(1):59-65

Asp-285 of the metal-tetracycline/H+ antiporter of Escherichia coli is essential for substrate binding. Kimura T, et al. **FEBS Lett** 1996 Jun 10;388(1):50-2

Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions. Weng Z, et al. **Mol Cell Biol** 1995 Oct;15(10):5627-34

Intracerebral microdialysis of glutamate and aspartate in two vascular territories after aneurysmal subarachnoid hemorrhage. Säveland H, et al. **Neurosurgery** 1996 Jan; 38(1):12-9; discussion 19-20

N-acetylaspartate in neuropsychiatric disorders. Tsai G, et al. **Prog Neurobiol** 1995 Aug;46(5):531-40 (178 ref.)

SECRETION

Arachidonic acid and lysophosphatidylcholine modulate excitatory transmitter amino acid release from the rat cerebral cortex. O'Regan MH, et al. **Neurosci Lett** 1995 Jun 30;193(2):85-8

Lidocaine reduces the hypoxia-induced release of an excitatory amino acid analog from rat striatal slices in superfusion. Díaz L, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):943-53

THERAPEUTIC USE

Temperature-dependent cardioprotection of exogenous substrates in long-term heart preservation with continuous perfusion: twenty-four-hour preservation of isolated rat heart with St. Thomas' Hospital solution containing glucose, insulin, and aspartate. Shimada Y, et al. **J Heart Lung Transplant** 1996 May;15(5):485-95

Studies of hypoxemic/reoxygenation injury: without aortic clamping. VIII. Counteraction of oxidant damage by exogenous glutamate and aspartate. Morita K, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1228-34

TOXICITY

Mineralization of the globus pallidus following excitotoxic lesions of the basal forebrain. Stewart GR, et al. **Brain Res** 1995 Oct 9;695(1):81-7

Toxicology of cupric salts in honeybees. I. Hormesis effects of organic derivatives on lethality parameters. Bounias M, et al. **Ecotoxicol Environ Saf** 1995 Jul;31(2):127-32

ASPARTIC ACID-SPECIFIC TRNA see RNA, TRANSFER, ASP

ASPARTIC PROTEINASES

[Biosynthetic mechanism of endothelins with various physiological and physiopathological significance--structure and function of endothelin converting enzyme] Takayanagi R. **Fukuoka Igaku Zasshi** 1995 Sep;86(9):362-6 (3 ref.) **(Jpn)**

ANALYSIS

Cathepsin E expressed in pancreatic cancer. Azuma T, et al. **Adv Exp Med Biol** 1995;362:363-6

Co-expression of endothelin-1 and endothelin-converting enzyme-1 in patients with chronic rhinitis. Furukawa K, et al. **Am J Respir Cell Mol Biol** 1996 Mar;14(3):248-53

The use of antibodies for characterization and quantification of a recombinant protein. Sabater M, et al. **Ann N Y Acad Sci** 1996 May 15;782:462-77

Localization of rat endothelin-converting enzyme to vascular endothelial cells and some secretory cells. Takahashi M, et al. **Biochem J** 1995 Oct 15;311 (Pt 2):657-65

Expression of ECE and related membrane peptidases in the EA.hy926 cell line. Walkden BJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S59-60

ANTAGONISTS & INHIBITORS

Inhibition and entrapment of aspartic proteinases by alpha 2-macroglobulin. Athauda SB, et al. **Adv Exp Med Biol** 1995;362:305-13

Guinea pig Clara cells secrete endothelin 1 through a phosphoramidon-sensitive pathway. Laporte J, et al. **Am J Respir Cell Mol Biol** 1996 Apr;14(4):356-62

Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis. Goldman RC, et al. **Infect Agents Dis** 1995 Dec;4(4):228-47 (120 ref.)

Peptidyl substrates containing unnatural amino acid at the P'1 position are potent inhibitors of prohormone convertases. Basak A, et al. **Int J Pept Protein Res** 1995 Sep-Oct;46(3-4):228-37

WS75624 A and B, new endothelin converting enzyme inhibitors isolated from Saccharothrix sp. No. 75624. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. Tsurumi Y, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1066-72

WS75624 A and B, new endothelin converting enzyme inhibitors isolated from Saccharothrix sp. No. 75624. II. Structure elucidation of WS75624 A and B. Yoshimura S, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1073-5

[Phe22]-big endothelin-1[19-37]: a new and potent inhibitor of the endothelin-converting enzyme. Claing A, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S72-4

S 17162 is a novel selective inhibitor of big ET-1 responses in the rat. Descombes JJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S61-4

Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme. Kukkola PJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S65-8

Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11. Trapani AJ, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S69-71

Thermodynamic mapping of the inhibitor site of the aspartic protease endothiapepsin. Gómez J, et al. **J Mol Biol** 1995 Sep 22;252(3):337-50

Halistanol disulfate B, a novel sulfated sterol from the sponge Pachastrella sp.: inhibitor of endothelin converting enzyme. Patil AD, et al. **J Nat Prod** 1996 Jun;59(6):606-8

[Synthetic inhibitors targeting serine and aspartic acid proteases] Reboud-Ravaux MC, et al. **J Pharm Belg** 1996 May-Jun;51(3):161-4 (44 ref.) (Eng. Abstr.) (Fre)

BIOSYNTHESIS

Aspartic proteinases from the human malaria parasite Plasmodium falciparum. Berry C, et al. **Adv Exp Med Biol** 1995;362:511-8

Plant aspartic proteinases from Cynara cardunculus spp. flavescens cv. cardoon; nucleotide sequence of a cDNA encoding cyprosin and its organ-specific expression. Cordeiro MC, et al. **Adv Exp Med Biol** 1995;362:367-72

Expression and secretion of recombinant aspartic proteinases by Bacillus brevis. Hayashi T, et al. **Adv Exp Med Biol** 1995;362:589-96

Expression in E. coli of Aspergillus niger var. macrosporus proteinase A, a non-pepsin type acid proteinase. Kagami N, et al. **Adv Exp Med Biol** 1995;362:597-603

Candida albicans aspartic proteinase: cDNA cloning and comparison among strains. Murayama SY, et al. **Adv Exp Med Biol** 1995;362:573-6

Glycoproteins of the aspartyl proteinase gene family secreted by the developing placenta. Roberts RM, et al. **Adv Exp Med Biol** 1995;362:231-40

Molecular cloning and sequence analysis of a gene encoding an aspartic proteinase from Aspergillus oryzae. Takeuchi M, et al. **Adv Exp Med Biol** 1995;362:577-80

Mathematical modeling of proteinase A overproduction by Saccharomyces cerevisiae. Grøn S, et al. **Ann N Y Acad Sci** 1996 May 15;782:350-62

Endothelin-1 production and endothelin converting enzyme expression by guinea pig airway epithelial cells. Shima H, et al. **Biochem Mol Biol Int** 1995 Nov;37(5):1001-10

Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Wang X, et al. **Circ Res** 1996 Feb;78(2):322-8

Glucose-regulated translational control of proinsulin biosynthesis with that of the proinsulin endopeptidases PC2 and PC3 in the insulin-producing MIN6 cell line. Skelly RH, et al. **Diabetes** 1996 Jan;45(1):37-43

Molecular cloning of prohormone convertase 1 from the atrial gland of Aplysia. Gorham EL, et al. **DNA Cell Biol** 1996 Apr;15(4):339-45

Rice aspartic proteinase, oryzasin, expressed during seed ripening and germination, has a gene organization distinct from those of animal and microbial aspartic proteinases. Asakura T, et al. **Eur J Biochem** 1995 Aug 15;232(1):77-83

Degradation of Rhizopus niveus aspartic proteinase-I with mutated prosequences occurs in the endoplasmic reticulum of Saccharomyces cerevisiae. Fukuda R, et al. **J Biol Chem** 1996 Jun 14;271(24):14252-5

Expression pattern of aspartic proteinase antigens in aspergilli. Reichard U, et al. **Mycoses** 1996 Mar-Apr; 39(3-4):99-101

Expression of antisense PC1 in stably transfected RIN5F cells significantly reduces CCK 8 biosynthesis. Yoon JY, et al. **Regul Pept** 1995 Oct 20;59(2):221-7

CHEMICAL SYNTHESIS

Breaking the shackles of the genetic code: engineering retroviral proteases through total chemical synthesis. Kent SB, et al. **Adv Exp Med Biol** 1995;362:425-38

CHEMISTRY

Comparisons of the three-dimensional structures, specificities and glycosylation of renins, yeast proteinase A and cathepsin D. Aguilar CF, et al. **Adv Exp Med Biol** 1995; 362:155-66

A new way of looking at aspartic proteinase structures: a comparison of pepsin structure to other aspartic proteinases in the near active site region. Andreeva NS, et al. **Adv Exp Med Biol** 1995;362:19-32

Characteristics of YAP3, a new prohormone processing aspartic protease from S. cerevisiae. Azaryan AV, et al. **Adv Exp Med Biol** 1995;362:569-72

Aspartic proteinases from the human malaria parasite Plasmodium falciparum. Berry C, et al. **Adv Exp Med Biol** 1995;362:511-8

Aspartic proteinases (cyprosins) from Cynara cardunculus spp. Flavescens cv. cardoon; purification, characterisation, and tissue-specific expression. Brodelius PE, et al. **Adv Exp Med Biol** 1995;362:255-66

Computer simulation and analysis of the reaction pathway for the decomposition of the hydrated peptide bond in aspartic proteases. Cachau RE, et al. **Adv Exp Med Biol** 1995;362:461-5

Identification of amino acid residues of the retroviral aspartic proteinases important for substrate specificity and catalytic efficiency. Cameron CE, et al. **Adv Exp Med Biol** 1995; 362:399-406

Comparison of the active site specificity of the aspartic proteinases based on a systematic series of peptide substrates. Dunn BM, et al. **Adv Exp Med Biol** 1995;362:1-9

Structure of human cathepsin D: comparison of inhibitor binding and subdomain displacement with other aspartic proteases. Erickson JW, et al. **Adv Exp Med Biol** 1995; 362:181-92

Comparative investigations on pig gastric proteases and their zymogens. Foltmann B, et al. **Adv Exp Med Biol** 1995; 362:41-51

Molecular modeling of the structure of FIV protease. Gustchina A. **Adv Exp Med Biol** 1995;362:479-84

Aspergillus niger var. macrosporus proteinase B. cDNA cloning, expression, and activation of the proenzyme. Inoue H, et al. **Adv Exp Med Biol** 1995;362:581-7

Expression in E. coli of Aspergillus niger var. macrosporus proteinase A, a non-pepsin type acid proteinase. Kagami N, et al. **Adv Exp Med Biol** 1995;362:597-603

Breaking the shackles of the genetic code: engineering retroviral proteases through total chemical synthesis. Kent SB, et al. **Adv Exp Med Biol** 1995;362:425-38

Structure and possible function of aspartic proteinases in barley and other plants. Kervinen J, et al. **Adv Exp Med Biol** 1995;362:241-54 (72 ref.)

Conformation analysis of non-pepsin-type acid proteinase A from the fungus Aspergillus niger by NMR. Kojima M, et al. **Adv Exp Med Biol** 1995;362:611-5

Site-directed mutagenesis of rhizopuspepsin: an analysis of unique specificity. Lowther WT, et al. **Adv Exp Med Biol** 1995;362:555-8

Pepstatin-insensitive carboxyl proteinases. Oda K, et al. **Adv Exp Med Biol** 1995;362:529-42

Activities of precursor and tethered dimer forms of HIV proteinase. Phylip LH, et al. **Adv Exp Med Biol** 1995; 362:467-72

The three-dimensional X-ray crystal structure of the aspartic proteinase native to Trichoderma reesei complexed with

a renin inhibitor CP-80794. Pitts JE, et al. **Adv Exp Med Biol** 1995;362:543–7

X-ray crystallographic study of a non-pepsin-type acid proteinase, Aspergillus niger proteinase A. Sasaki H, et al. **Adv Exp Med Biol** 1995;362:605–9

A quantum mechanical model of the hydration and acidity of the active site in aspartic proteases. Topol IA, et al. **Adv Exp Med Biol** 1995;362:549–54

Rat endothelin-converting enzyme-1 forms a dimer through Cys412 with a similar catalytic mechanism and a distinct substrate binding mechanism compared with neutral endopeptidase-24.11. Shimada K, et al. **Biochem J** 1996 May 1;315 (Pt 3):863–7

Effect of irreversibility on the thermodynamic characterization of the thermal denaturation of Aspergillus saitoi acid proteinase. Tello-Solis SR, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):969–74

Molecular modeling of the active site of endothelin-converting enzyme. Sansom CE, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S75–7

Purification and characterization of an extracellular aspartic proteinase from Aspergillus fumigatus. Reichard U, et al. **J Med Vet Mycol** 1995 Jul-Aug;33(4):279

pH-dependent denaturation of extracellular aspartic proteinases from Candida species. Wagner T, et al. **J Med Vet Mycol** 1995 Jul-Aug;33(4):275–8

Thermodynamic mapping of the inhibitor site of the aspartic protease endothiapepsin. Gómez J, et al. **J Mol Biol** 1995 Sep 22;252(3):337–50

Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Abad-Zapatero C, et al. **Protein Sci** 1996 Apr;5(4):640–52

A theoretical study of torsional flexibility in the active site of aspartic proteinases: implications for catalysis. Beveridge A. **Proteins** 1996 Mar;24(3):322–34

New database [letter] Vondrasek J, et al. **Science** 1996 Apr 19;272(5260):337–8

The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Cutfield SM, et al. **Structure** 1995 Nov 15;3(11):1261–71

DRUG EFFECTS

Role of endothelin-converting enzyme in the systemic hemodynamics and regional circulatory effects of proendothelin-1 (1–38) and diaspirin cross-linked hemoglobin in rats. Gulati A, et al. **J Lab Clin Med** 1995 Dec;126(6):559–70

[Comparison of the effects of fenticonazole and econazole on the aspartic proteinase secreted by Candida albicans] De Bernardis F, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):163–5 (Eng. Abstr.) **(Fre)**

GENETICS

Candida albicans aspartic proteinase: cDNA cloning and comparison among strains. Murayama SY, et al. **Adv Exp Med Biol** 1995;362:573–6

Molecular cloning and sequence analysis of a gene encoding an aspartic proteinase from Aspergillus oryzae. Takeuchi M, et al. **Adv Exp Med Biol** 1995;362:577–80

Fine mapping of the human endothelin-converting enzyme gene by fluorescent in situ hybridization and radiation hybrids. Albertin G, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):682–7

Specific co-ordinated regulation of PC3 and PC2 gene expression with that of preproinsulin in insulin-producing beta TC3 cells. Schuppin GT, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):259–68

Characterization of multiple prohormone convertase PC1/3 transcripts in porcine ovary. Dai G, et al. **Biochim Biophys Acta** 1995 Oct 17;1264(1):1–6

Human endothelin converting enzyme gene (ECE1) mapped to chromosomal region 1p36.1. Matsuoka R, et al. **Cytogenet Cell Genet** 1996;72(4):322–4

Human prohormone convertase 3 gene: exon-intron organization and molecular scanning for mutations in Japanese subjects with NIDDM. Ohagi S, et al. **Diabetes** 1996 Jul;45(7):897–901

Rice aspartic proteinase, oryzasin, expressed during seed ripening and germination, has a gene organization distinct from those of animal and microbial aspartic proteinases. Asakura T, et al. **Eur J Biochem** 1995 Aug 15;232(1):77–83

Molecular cloning and sequencing of the gene encoding an extracellular aspartic proteinase from Aspergillus fumigatus. Reichard U, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):69–74

Molecular cloning of the cDNA and gene for an elastinolytic aspartic proteinase from Aspergillus fumigatus and evidence of its secretion by the fungus during invasion of the host lung. Lee JD, et al. **Infect Immun** 1995 Oct; 63(10):3796–803

Cloning and characterization of the Schistosoma japonicum aspartic proteinase involved in hemoglobin degradation. Becker MM, et al. **J Biol Chem** 1995 Oct 13; 270(41):24496–501

Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). Valdenaire O, et al. **J Biol Chem** 1995 Dec 15;270(50):29794–8

Temporal expression of ECE-1, ET-1, ET-3, ETA, and ETB receptor mRNAs after balloon angioplasty in the rat. Wang X, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S22–5

Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles. Wu X, et al. **J Virol** 1996 Jun; 70(6):3378–84

Linkage mapping of the endothelin-converting enzyme gene (Ednce) to rat chromosome 5. Deng AY, et al. **Mamm Genome** 1995 Oct;6(10):759–60

Cloning and characterization of the eapB and eapC genes of Cryphonectria parasitica encoding two new acid proteinases, and disruption of eapC. Jara P, et al. **Mol Gen Genet** 1996 Jan 15;250(1):97–105

IMMUNOLOGY

Isolation and characterization of a clone encoding a major allergen (Bla g Bd90K) involved in IgE-mediated cockroach hypersensitivity. Helm R, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):172–80

ISOLATION & PURIFICATION

Inhibition and entrapment of aspartic proteinases by alpha 2-macroglobulin. Athauda SB, et al. **Adv Exp Med Biol** 1995;362:305–13

Cardosin A and B, aspartic proteases from the flowers of cardoon. Faro C, et al. **Adv Exp Med Biol** 1995;362:373–7

Purification and characterization of an acid proteinase from Dirofilaria immitis worms. Sato K, et al. **Adv Exp Med Biol** 1995;362:299–304

Purification, characterization and partial amino acid sequencing of two new aspartic proteinases from fresh flowers of Cynara cardunculus L. Veríssimo P, et al. **Eur J Biochem** 1996 Feb 1;235(3):762–8

Isolation and characterization of a clone encoding a major allergen (Bla g Bd90K) involved in IgE-mediated cockroach hypersensitivity. Helm R, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):172–80

Isolation of a renin-like enzyme from the leech Theromyzon tessulatum. Laurent V, et al. **Peptides** 1995;16(8):1351–8

[Molecules of the family of aspartic proteinases in the placenta of ruminants: hormones or proteins?] Beckers JF, et al. **Bull Mem Acad R Med Belg** 1994;149(8–11):355–64; discussion 364–7 (Eng. Abstr.) **(Fre)**

METABOLISM

Characteristics of YAP3, a new prohormone processing aspartic protease from S. cerevisiae. Azaryan AV, et al. **Adv Exp Med Biol** 1995;362:569–72

Aspartic proteinases (cyprosins) from Cynara cardunculus spp. Flavescens cv. cardoon; purification, characterisation, and tissue-specific expression. Brodelius PE, et al. **Adv Exp Med Biol** 1995;362:255–66

Processing, purification, and kinetic characterization of the Gag-Pol encoded retroviral proteinase of myeloblastosis associated virus expressed in E. coli. Brynda J, et al. **Adv Exp Med Biol** 1995;362:485–8

Computer simulation and analysis of the reaction pathway for the decomposition of the hydrated peptide bond in aspartic proteases. Cachau RE, et al. **Adv Exp Med Biol** 1995;362:461–5

Identification of amino acid residues of the retroviral aspartic proteinases important for substrate specificity and catalytic efficiency. Cameron CE, et al. **Adv Exp Med Biol** 1995; 362:399–406

Comparison of the active site specificity of the aspartic proteinases based on a systematic series of peptide substrates. Dunn BM, et al. **Adv Exp Med Biol** 1995;362:1–9

Cardosin A and B, aspartic proteases from the flowers of cardoon. Faro C, et al. **Adv Exp Med Biol** 1995;362:373–7

Extracellular aspartic proteinases from Candida yeasts. Fusek M, et al. **Adv Exp Med Biol** 1995;362:489–500

Structure and possible function of aspartic proteinases in barley and other plants. Kervinen J, et al. **Adv Exp Med Biol** 1995;362:241–54 (72 ref.)

Site-directed mutagenesis of rhizopuspepsin: an analysis of unique specificity. Lowther WT, et al. **Adv Exp Med Biol** 1995;362:555–8

A novel intracellular acid proteinase from the plasmodia of a true slime mold, Physarum polycephalum. Murakami-Murofushi K, et al. **Adv Exp Med Biol** 1995; 362:565–8

Pepstatin-insensitive carboxyl proteinases. Oda K, et al. **Adv Exp Med Biol** 1995;362:529–42

Activities of precursor and tethered dimer forms of HIV proteinase. Phylip LH, et al. **Adv Exp Med Biol** 1995; 362:467–72

The three-dimensional X-ray crystal structure of the aspartic proteinase native to Trichoderma reesei complexed with a renin inhibitor CP-80794. Pitts JE, et al. **Adv Exp Med Biol** 1995;362:543–7

Purification and characterization of an acid proteinase from Dirofilaria immitis worms. Sato K, et al. **Adv Exp Med Biol** 1995;362:299–304

A quantum mechanical model of the hydration and acidity of the active site in aspartic proteases. Topol IA, et al. **Adv Exp Med Biol** 1995;362:549–54

Functional aspects of cathepsin E: is it an embryonic or fetal type of aspartic proteinase? Yonezawa S, et al. **Adv Exp Med Biol** 1995;362:345–8

Proenkephalin-processing enzymes in chromaffin granules: model for neuropeptide biosynthesis. Hook VY, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:121–33 (22 ref.)

The processing proteases prohormone thiol protease, PC1/3 and PC2, and 70-kDa aspartic proteinase show preferences among proenkephalin, proneuropeptide Y, and proopiomelanocortin substrates. Hook VY, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):107–14

Chromaffin granule aspartic proteinase processes recombinant proopiomelanocortin (POMC). Azaryan AV, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):937–44

Endothelin-converting enzyme: substrate specificity and inhibition by novel analogs of phosphoramidon. Keller PM, et al. **Biochem Biophys Res Commun** 1996 Jun 14; 223(2):372–8

Downregulation of prohormone convertase-1 by a phorbol ester. Udupi V, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):495–500

Rat endothelin-converting enzyme-1 forms a dimer through Cys412 with a similar catalytic mechanism and a distinct substrate binding mechanism compared with neutral endopeptidase-24.11. Shimada K, et al. **Biochem J** 1996 May 1;315 (Pt 3):863–7

Molecular pharmacology of endothelin converting enzymes. Turner AJ, et al. **Biochem Pharmacol** 1996 Jan 26; 51(2):91–102 (127 ref.)

The role of prohormone convertases in insulin biosynthesis: evidence for inherited defects in their action in man and experimental animals. Steiner DF, et al. **Diabetes Metab** 1996 Apr;22(2):94–104 (72 ref.)

Yeast aspartic protease 3 (Yap3) prefers substrates with basic residues in the P2, P1 and P2' positions. Ledgerwood EC, et al. **FEBS Lett** 1996 Mar 25;383(1–2):67–71

A removable spacer peptide in an alpha-factor-leader/insulin precursor fusion protein improves processing and concomitant yield of the insulin precursor in Saccharomyces cerevisiae. Kjeldsen T, et al. **Gene** 1996 Apr 17;170(1):107–12

Cloning and characterization of the Schistosoma japonicum aspartic proteinase involved in hemoglobin degradation. Becker MM, et al. **J Biol Chem** 1995 Oct 13; 270(41):24496–501

Specificity and kinetic studies on the cleavage of various prohormone mono- and paired-basic residue sites by yeast aspartic protease 3. Cawley NX, et al. **J Biol Chem** 1996 Feb 23;271(8):4168–76

Degradation of Rhizopus niveus aspartic proteinase-I with mutated prosequences occurs in the endoplasmic reticulum of Saccharomyces cerevisiae. Fukuda R, et al. **J Biol Chem** 1996 Jun 14;271(24):14252–5

Furin, PC1/3, and/or PC6A process rabbit, but not human, pro-lactase-phlorizin hydrolase to the 180-kDa intermediate. Keller P, et al. **J Biol Chem** 1995 Oct 27; 270(43):25722–8

Programming the Rous sarcoma virus protease to cleave new substrate sequences. Ridky TW, et al. **J Biol Chem** 1996 May 3;271(18):10538–44

Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. Rouillé Y, et al. **J Biol Chem** 1995 Nov 3;270(44):26488–96

Characterization of a vacuolar protease in Neurospora crassa and the use of gene RIPing to generate protease-deficient strains. Vázquez-Laslop N, et al. **J Biol Chem** 1996 Sep 6;271(36):21944–9

Multiple pathways for vacuolar sorting of yeast proteinase A. Westphal V, et al. **J Biol Chem** 1996 May 17; 271(20):11865–70

Localization and biochemical characterization of endothelin-converting enzyme. Barnes K, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S37–9

Characterization of endothelin receptors and endothelin-converting enzyme activity in the rabbit lung. Gratton JP, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S88–90

Characterization of the endothelin-converting enzyme in guinea pig upper bronchus. Lebel N, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S81–3

Characteristics of the chromaffin granule aspartic proteinase involved in proenkephalin processing. Azaryan AV, et al. **J Neurochem** 1995 Oct;65(4):1771–9

Pro-thyrotropin-releasing hormone processing by recombinant PC1. Nillni EA, et al. **J Neurochem** 1995 Dec; 65(6):2462–72

Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein. Konvalinka J, et al. **J Virol** 1995 Nov;69(11):7264–8

Fluorescence polarization assay for endothelin-converting enzymes. Hazan S, et al. **Peptides** 1995;16(5):833–6

Shared functions in vivo of a glycosyl-phosphatidylinositol-linked aspartyl protease, Mkc7, and the proprotein processing protease Kex2 in yeast. Komano H, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10752–6

A theoretical study of torsional flexibility in the active site of aspartic proteinases: implications for catalysis. Beveridge A. **Proteins** 1996 Mar;24(3):322–34

Proteolytic activity of purified avian sarcoma and leukemia virus NC-PR protein expressed in Escherichia coli. Séllos-Moura M, et al. **Virology** 1996 Jul 15;221(2):335–45

PHARMACOLOGY

Effect of pregnancy-specific protein B on luteal cell progesterone, prostaglandin, and oxytocin production

during two stages of the bovine estrous cycle. Del Vecchio RP, et al. **J Anim Sci** 1995 Sep;73(9):2662–8
Bovine luteal cell production in vitro of prostaglandin E2, oxytocin and progesterone in response to pregnancy-specific protein B and prostaglandin F2 alpha. Del Vecchio RP, et al. **J Reprod Fertil** 1996 May; 107(1):131–6
Prostaglandin F2 alpha, progesterone and oxytocin production by cultured bovine luteal cells treated with prostaglandin E2 and pregnancy-specific protein B. Del Vecchio RP, et al. **Prostaglandins** 1995 Sep;50(3):137–50

PHYSIOLOGY

Proceedings of the 5th International Conference on Aspartic Proteinases. Kawashimacho, Gifu Prefecture, Japan, September 19–24, 1993. **Adv Exp Med Biol** 1995;362:v–xxi, 1–629
Mutational analysis of PC1 (SPC3) in PC12 cells. 66-kDa PC1 is fully functional. Zhou Y, et al. **J Biol Chem** 1995 Oct 20;270(42):24702–6
The role of Candida albicans secreted aspartic proteinase in the development of candidoses. Hoegl L, et al. **J Mol Med** 1996 Mar;74(3):135–42 (71 ref.)

SECRETION

Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. De Bernardis F, et al. **Infect Immun** 1996 Feb;64(2):466–71
[Comparison of the effects of fenticonazole and econazole on the aspartic proteinase secreted by Candida albicans] De Bernardis F, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):163–5 (Eng. Abstr.) **(Fre)**

ASPARTOKINASE see **ASPARTATE KINASE**

ASPARTOKINASE HOMOSERINE DEHYDROGENASE

METABOLISM

Homocysteine antagonism of nitric oxide-related cytostasis in Salmonella typhimurium. De Groote MA, et al. **Science** 1996 Apr 19;272(5260):414–7

ASPARTYL PROTEINASES see **ASPARTIC PROTEINASES**

ASPARTYL T RNA SYNTHETASE

GENETICS

Aspartyl-tRNA synthetase of the hyperthermophilic archaeon Pyrococcus sp. KOD1 has a chimerical structure of eukaryotic and bacterial enzymes. Imanaka T, et al. **Gene** 1995 Oct 16;164(1):153–6

METABOLISM

Identity of prokaryotic and eukaryotic tRNA(Asp) for aminoacylation by aspartyl-tRNA synthetase from Thermus thermophilus. Becker HD, et al. **Biochemistry** 1996 Jun 11;35(23):7447–58

ASPARTYLGLUCOSAMINIDASE see **ASPARTYLGLUCOSYLAMINASE**

ASPARTYLGLUCOSYLAMINASE

CHEMISTRY

Enzymatic synthesis of the N-glycosidic bond by beta-aspartylation of glycosylamines. Mononen I, et al. **Biochem Biophys Res Commun** 1996 Jan 17;218(2):510–3
A sting in the (N-terminal) tail [news] Artymiuk PJ. **Nat Struct Biol** 1995 Dec;2(12):1035–7
Three-dimensional structure of human lysosomal aspartylglucosaminidase. Oinonen C, et al. **Nat Struct Biol** 1995 Dec;2(12):1102–8

DEFICIENCY

Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer. Enomaa N, et al. **Hum Gene Ther** 1995 Jun;6(6):723–31
[Contribution of ion exchange chromatography of amino acids to the diagnosis of aspartylglucosaminuria (letter)] Candito M, et al. **Ann Biol Clin (Paris)** 1995;53(3):145–6 **(Fre)**

GENETICS

Molecular cloning, chromosomal assignment, and expression of the mouse aspartylglucosaminidase gene. Tenhunen K, et al. **Genomics** 1995 Nov 20;30(2):244–50
Single base deletion in exon 7 of the glycosylasparaginase gene causes a mild form of aspartylglycosaminuria in a patient of Mauritian origin. Park H, et al. **J Inherit Metab Dis** 1996;19(1):76–83
[Aspartylglucosaminuria: a point mutation as a cause of mental defect] Ikonen E, et al. **Duodecim** 1994; 110(7):667–73 (21 ref.) **(Fin)**

METABOLISM

Glycosylation and phosphorylation of lysosomal glycosylasparaginase. Park H, et al. **Arch Biochem Biophys** 1996 Apr 1;328(1):73–7
Functional analyses of active site residues of human lysosomal aspartylglucosaminidase: implications for catalytic mechanism and autocatalytic activation. Tikkanen R, et al. **EMBO J** 1996 Jun 17;15(12):2954–60
Activation of glycosylasparaginase. Formation of active N-terminal threonine by intramolecular autoproteolysis. Guan C, et al. **J Biol Chem** 1996 Jan 19;271(3):1732–7
Primary folding of aspartylglucosaminidase. Significance of disulfide bridges and evidence of early multimerization. Riikonen A, et al. **J Biol Chem** 1996 Aug 30; 271(35):21340–4

ULTRASTRUCTURE

A sting in the (N-terminal) tail [news] Artymiuk PJ. **Nat Struct Biol** 1995 Dec;2(12):1035–7

ASPARTYLGLUCOSYLAMINE DEASPARTYLASE see **ASPARTYLGLUCOSYLAMINASE**

ASPARTYLGLYCOSAMINE AMIDOHYDROLASE see **ASPARTYLGLUCOSYLAMINASE**

ASPARTYLPHENYLALANINE METHYL ESTER see **ASPARTAME**

ASPERGILLOSIS

Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. Roilides E, et al. **J Med Vet Mycol** 1996 Jan–Feb;34(1):63–9
Case records of the Department of Medicine University of Mississippi Medical Center. Acute panniculitis secondary to fungal infection, most likely Aspergillus species [clinical conference] Guynes RD, et al. **J Miss State Med Assoc** 1996 Jun;37(6):610–5
Chronic bilateral suppurative otitis media caused by Aspergillus terreus. Tiwari S, et al. **Mycoses** 1995 Jul–Aug; 38(7–8):297–300
Aspergillus peritonitis in peritoneal dialysis [letter] Tanis BC, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):752
Aspergillus peritonitis in peritoneal dialysis: case report and a review of the literature [see comments] Tanis BC, et al. **Nephrol Dial Transplant** 1995;10(7):1240–3. Comment in: Nephrol Dial Transplant 1995;10(7):1124–5.
Spinal epidural abscess due to Aspergillus infection of the vertebrae: report of 3 cases. Dubbeld P, et al. **Neth J Med** 1996 Jan;48(1):18–23
Parasellar Aspergillus granuloma extending from the sphenoid sinus: report of two cases. Kurita H, et al. **Surg Neurol** 1995 Nov;44(5):489–94
Renal abscess due to Aspergillus fumigatus in a patient with the acquired immunodeficiency syndrome. Segarra J, et al. **Urol Int** 1995;55(1):60–2
[Hepatic aspergillosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):43–4 (5 ref.) **(Jpn)**
[Aspergillus tracheobronchitis in a patient with AIDS (letter)] Arizcorreta Yarza A, et al. **Med Clin (Barc)** 1995 Nov 25;105(18):717 **(Spa)**

BLOOD

Plasma (1-->3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. Miyazaki T, et al. **J Clin Microbiol** 1995 Dec;33(12):3115–8

CHEMICALLY INDUCED

Invasive aspergillosis: a life-threatening complication of short-term steroid treatment. Conesa D, et al. **Ann Pharmacother** 1995 Dec;29(12):1235–7

COMPLICATIONS

Aspergillus sinusitis in patients with AIDS: report of three cases and review. Teh W, et al. **Clin Infect Dis** 1995 Sep; 21(3):529–35 (46 ref.)
Aspergillosis of the muscle in a woman with sarcoidosis and CD4+ T lymphocytopenia. Viallard JF, et al. **Clin Infect Dis** 1995 Nov;21(5):1345–6
Catheter-related cutaneous aspergillosis complicated by fungemia and fatal pulmonary infection in an HIV-positive patient with acute lymphocytic leukemia. Girmenia C, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):524–6
Clusterlike headache. A case of sphenoidal aspergilloma. Zanchin G, et al. **Headache** 1995 Sep;35(8):494–7 (20 ref.)
Syndrome of the anterior spinal artery as the primary manifestation of aspergillosis. Pfausler B, et al. **Infection** 1995 Jul–Aug;23(4):240–2
Aspergillus aneurysm of the middle cerebral artery causing a fatal subarachnoid hemorrhage. Suzuki K, et al. **Intern Med** 1995 Jun;34(6):550–3
Aspergillus flavus meningitis and pontine hemorrhage in an older patient [letter] Adunsky A, et al. **J Am Geriatr Soc** 1996 Jun;44(6):739–40
Aspergillosis in immunocompromised children with acute myeloid leukemia and bone marrow aplasia. Report of two cases. de Aquino MZ, et al. **Rev Inst Med Trop Sao Paulo** 1994 Sep–Oct;36(5):465–9
Pulmonary aspergilloma complicating Wegener's granulomatosis [letter] Le Thi Huong D, et al. **Scand J Rheumatol** 1995;24(4):260
Tuberculosis and invasive pulmonary aspergillosis in a young woman with a myelodysplastic syndrome. Kueh YK, et al. **Singapore Med J** 1995 Feb;36(1):107–9
Invasive aspergilloma of the frontal base causing internal carotid artery occlusion. Satoh H, et al. **Surg Neurol** 1995 Nov;44(5):483–8 (30 ref.)
Commentary: unusual manifestations of aspergillosis [comment] Denning DW. **Thorax** 1995 Jul;50(7):812–3 (23 ref.). Comment on: Thorax 1995 Jul;50(7):805–6. Comment on: Thorax 1995 Jul;50(7):807–8. Comment on: Thorax 1995 Jul;50(7):809–10. Comment on: Thorax 1995 Jul;50(7):810–1.
Colonisation with Aspergillus of an intralobar pulmonary sequestration [see comments] Freixinet J, et al. **Thorax** 1995 Jul;50(7):810–1. Comment in: Thorax 1995 Jul;50(7):812–3.
Aspergillus laryngotracheobronchitis presenting as stridor in a patient with peripheral T cell lymphoma. Kuo PH, et al. **Thorax** 1996 Aug;51(8):869–70
Three cases of pulmonary aspergilloma in adult patients with cystic fibrosis [see comments] Maguire CP, et al. **Thorax** 1995 Jul;50(7):805–6. Comment in: Thorax 1995 Jul;50(7):812–3.
Pseudomembranous necrotising bronchial aspergillosis complicating chronic airways limitation [see comments] Nicholson AG, et al. **Thorax** 1995 Jul;50(7):807–8. Comment in: Thorax 1995 Jul;50(7):812–3.
Topical treatment of life threatening haemoptysis from aspergillomas. Rumbak M, et al. **Thorax** 1996 Mar; 51(3):253–5
[Chronic necrotizing pulmonary aspergillosis complicated by pneumothorax] Kobashi Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb;34(2):210–5 (Eng. Abstr.) **(Jpn)**
[Invasive pulmonary aspergillosis in a patient with acute leukemia--the role of neutrophil elastase in in cavity formation] Oe H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr; 34(4):459–64 (Eng. Abstr.) **(Jpn)**
[Cavernous changes as a result of pulmonary tissue hyperreactivity to Aspergillus fumigatus infection] Krakówka P, et al. **Pneumonol Pol** 1990 Nov–Dec; 58(11–12):624–8 (Eng. Abstr.) **(Pol)**
[Invasive pulmonary aspergillosis associated with influenza virus] Alba D, et al. **An Med Interna** 1996 Jan;13(1):34–6 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Primary Aspergillus osteomyelitis in the tibia of an immunosuppressed man. Sonin AH, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1277–9
Serodiagnosis and monitoring of Aspergillus infections after lung transplantation. Tomee JF, et al. **Ann Intern Med** 1996 Aug 1;125(3):197–201
Retained sponge after thoracotomy that mimicked aspergilloma. Nomori H, et al. **Ann Thorac Surg** 1996 May; 61(5):1535–6
Invasive Aspergillus sinusitis in pediatric bone marrow transplant patients. Evaluation and management. Choi SS, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct; 121(10):1188–92
Diagnosis and management of invasive aspergillosis. Denning DW. **Curr Clin Top Infect Dis** 1996;16:277–99 (41 ref.)
Tools and trends in the detection of Aspergillus fumigatus. Latgé JP. **Curr Top Med Mycol** 1995;6:245–81 (137 ref.)
Immunoblotting patterns in the serodiagnosis of aspergilloma: antibody response to the 90kDa Aspergillus fumigatus antigen. López-Medrano R, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):146–52
Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Sulahian A, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):139–45
Aspergillus infections: problems in diagnosis and treatment. Andriole VT. **Infect Agents Dis** 1996 Jan;5(1):47–54 (74 ref.)
Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. Verweij PE, et al. **J Clin Microbiol** 1995 Dec;33(12):3150–3
Recurrent aspergilloma of the frontoethmoid sinus in a non-immunocompromised patient. Tierney P, et al. **J R Soc Med** 1996 Mar;89(3):165P–6P
Western blot analysis of cerebrospinal fluid for detection of Aspergillus antigens. Ray P, et al. **Mycopathologia** 1995 Aug;131(2):103–6
Evaluation of eight antibody tests and one antigen test for the diagnosis of invasive aspergillosis. Kappe R, et al. **Mycoses** 1996 Jan–Feb;39(1–2):13–23
Peritoneal aspergillosis--pitfalls in the diagnosis of a rare disease [editorial; comment] Geiss HK. **Nephrol Dial Transplant** 1995;10(7):1124–5. Comment on: Nephrol Dial Transplant 1995;10(7):1240–3.
Pulmonary aspergillosis: early diagnosis improves survival. von Eiff M, et al. **Respiration** 1995;62(6):341–7
Aspergillosis of the sphenoid sinus: presentation as a pituitary mass and postoperative gallium-67 imaging. Parker KM, et al. **Surg Neurol** 1996 Apr;45(4):354–8

[A case report of invasive pulmonary aspergillosis which could not be saved in spite of making an early diagnosis] Niki Y, et al. **Kansenshogaku Zasshi** 1995 Nov; 69(11):1307–11 (Eng. Abstr.) **(Jpn)**

[Diagnosis of pulmonary aspergillosis in cases with cavity as sequela of tuberculosis] Saeki A, et al. **Kekkaku** 1996 Jun;71(6):407–13 (Eng. Abstr.) **(Jpn)**

[Pulmonary aspergillosis in patients with disseminated processes in the lungs] Vlasenko SIu, et al. **Ter Arkh** 1996; 68(3):80–3 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Bioavailability of itraconazole from oral liquids in question [letter] Villarreal JD, et al. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1707–8

Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis. Allendoerfer R, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1345–8

Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Denning DW, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1809–14

Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Kurtz MB, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1784–9

In vitro and in vivo antifungal activities of DU–6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Nakajima R, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1517–21

Refractory pulmonary aspergillosis: compassionate trial with terbinafine. Schiraldi GF, et al. **Br J Dermatol** 1996 Jun; 134 Suppl 46:25–9: discussion 39–40

Aprotinin employment in patients with acute leukaemia to prevent haemorrhage during pulmonary aspergillosis [letter] Pagano L, et al. **Br J Haematol** 1996 Jul;94(1):210–1

Osteomyelitis of sacral spine caused by aspergillus versicolor with neurologic deficits. Liu Z, et al. **Chin Med J (Engl)** 1995 Jun;108(6):472–5

The use of collagen shields impregnated with amphotericin B to treat Aspergillus keratomycosis. Mendicute J, et al. **CLAO J** 1995 Oct;21(4):252–5

Deposition of amphotericin B aerosols in pulmonary aspergilloma. Diot P, et al. **Eur Respir J** 1995 Aug; 8(8):1263–8

Aspergillus infections: problems in diagnosis and treatment. Andriole VT. **Infect Agents Dis** 1996 Jan;5(1):47–54 (74 ref.)

Efficacy of oral saperconazole in systemic murine aspergillosis. Hanson LH, et al. **J Med Vet Mycol** 1995 Sep–Oct;33(5):311–7

Aspergillus flavus mycetoma and epidural abscess successfully treated with itraconazole. Witzig RS, et al. **J Med Vet Mycol** 1996 Mar–Apr;34(2):133–7

Endoscopic instillation of fungicide to treat aspergilloma [letter] Guleria R, et al. **Lancet** 1996 Aug 31;348(9027):621

Terbinafine in the treatment of non–immunocompromised compassionate cases of bronchopulmonary aspergillosis. Schiraldi GF, et al. **Mycoses** 1996 Jan–Feb;39(1–2):5–12

The role of surgery and itraconazole in Aspergillus peritonitis in CAPD [letter] Kitiyakara C, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1498

Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony–stimulating factor, and surgery: report of five cases. Dornbusch HJ, et al. **Pediatr Hematol Oncol** 1995 Nov–Dec;12(6):577–86

Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Purcell IF, et al. **Thorax** 1995 Dec;50(12):1321–3

Treatment of pulmonary aspergilloma in cystic fibrosis by percutaneous instillation of amphotericin B via indwelling catheter [see comments] Ryan PJ, et al. **Thorax** 1995 Jul; 50(7):809–10. Comment in: Thorax 1995 Jul;50(7):812–3.

Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Marks WH, et al. **Transplantation** 1996 Jun 27; 61(12):1771–4 (8 ref.)

[Palliative percutaneous treatment under x–ray computed tomographic control of inoperable pulmonary aspergilloma. Apropos of 30 cases] Giron J, et al. **Rev Mal Respir** 1995;12(6):593–9 (Eng. Abstr.) **(Fre)**

[Curative antifungal treatment of invasive pulmonary aspergillosis] Andrès E, et al. **Rev Pneumol Clin** 1995; 51(4):228–31 (31 ref.) (Eng. Abstr.) **(Fre)**

[A case of itraconazole–induced hypokalemia with pulmonary aspergilloma] Yamamoto T, et al. **Kansenshogaku Zasshi** 1995 Dec;69(12):1413–7 (Eng. Abstr.) **(Jpn)**

[Chronic necrotizing pulmonary aspergillosis treated with itraconazole and inhaled amphotericin B] Sato A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1141–5 (Eng. Abstr.) **(Jpn)**

[Treatment of patients with pulmonary aspergilloma with itraconazole] Wierzbicka M, et al. **Pneumonol Alergol Pol** 1996;64(1–2):59–63 (Eng. Abstr.) **(Pol)**

[Pulmonary aspergillosis and itraconazole (letter)] Serrano–Heranz R, et al. **Arch Bronconeumol** 1995 Aug–Sep;31(7):372–3 **(Spa)**

EPIDEMIOLOGY

An outbreak of cutaneous aspergillosis in a tertiary–care hospital. Bryce EA, et al. **Infect Control Hosp Epidemiol** 1996 Mar;17(3):170–2

Molecular epidemiology of apparent outbreak of invasive aspergillosis in a hematology ward. Leenders A, et al. **J Clin Microbiol** 1996 Feb;34(2):345–51

Kitchens as a source of Aspergillus niger infection. Loudon KW, et al. **J Hosp Infect** 1996 Mar;32(3):191–8

Nosocomial outbreak of Aspergillus fumigatus infection among patients in a renal unit? Sessa A, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1322–4

ETIOLOGY

Aspergillus fumigatus scleritis. Rodriguez–Ares MT, et al. **Acta Ophthalmol Scand** 1995 Oct;73(5):467–9

Aspergillus endophthalmitis after sutureless cataract surgery. Oxford KW, et al. **Am J Ophthalmol** 1995 Oct;120(4):534–5

Unusual cause of lethal pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Pittet D, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):541–4

Bilateral orbital involvement with massive allergic fungal sinusitis [letter] Chang WJ, et al. **Arch Ophthalmol** 1996 Jun;114(6):767–8

Do not drink mate. An additional source of infection in South American neutropenic patients [letter] Kusminsky G, et al. **Bone Marrow Transplant** 1996 Jan;17(1):127

Chronic sinusitis [letter; comment] Odell E, et al. **Br Dent J** 1995 Nov 11;179(9):327. Comment on: Br Dent J 1995 Jul 22;179(2):64–8.

Hickman catheter–associated primary cutaneous aspergillosis in a patient with the acquired immunodeficiency syndrome. Romero LS, et al. **Int J Dermatol** 1995 Aug;34(8):551–3

Asymptomatic aspergillosis of the maxillary sinus associated with foreign body of endodontic origin. Report of a case. Kobayashi A. **Int J Oral Maxillofac Surg** 1995 Jun; 24(3):243–4

Aspergillus and lung transplantation. Yeldandi V, et al. **J Heart Lung Transplant** 1995 Sep–Oct;14(5):883–90

Central venous catheter infection by Aspergillus fumigatus in a patient with B–type non–Hodgkin lymphoma. Berner R, et al. **Med Pediatr Oncol** 1996 Sep;27(3):202–4

Peracute disseminated fatal Aspergillus fumigatus sepsis as a complication of corticoid–treated systemic lupus erythematosus. Nenoff P, et al. **Mycoses** 1995 Nov–Dec; 38(11–12):467–71 (21 ref.)

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14–1996. A 66–year–old woman with toxic epidermal necrolysis and a fatal course [clinical conference] **N Engl J Med** 1996 May 9; 334(19):1254–61

Aspergillus endophthalmitis. An unrecognized endemic disease in orthotopic liver transplantation. Hunt KE, et al. **Ophthalmology** 1996 May;103(5):757–67 (65 ref.)

Scanning electron microscopy studies of peritoneal catheter in CAPD peritonitis due to Aspergillus fumigatus. Park SB, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):81–3

Pulmonary aspergillosis complicating ankylosing spondylitis. Zizzo G, et al. **Radiol Med (Torino)** 1996 Jun;91(6):817–8

Fatal fungal infection of an ascending aortic graft. Wandschneider W, et al. **Thorac Cardiovasc Surg** 1995 Aug; 43(4):217–9

Incidence and significance of Aspergillus cultures following liver and kidney transplantation. Brown RS Jr, et al. **Transplantation** 1996 Feb 27;61(4):666–9

Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Marks WH, et al. **Transplantation** 1996 Jun 27; 61(12):1771–4 (8 ref.)

[Chronic septic granulomatosis revealed by neonatal pulmonary aspergillosis] Mouy R, et al. **Arch Pediatr** 1995 Sep;2(9):861–4 (Eng. Abstr.) **(Fre)**

[Disseminated aspergillosis with pulmonary and cardiac localization in an HIV–infected patient] Escamilla R, et al. **Rev Mal Respir** 1995;12(4):380–2 (Eng. Abstr.) **(Fre)**

[Invasive pulmonary aspergillosis and influenza virus infection in patients with chronic bronchitis? (letter)] Bulpa P, et al. **Rev Pneumol Clin** 1995;51(5):300–1 **(Fre)**

[A case of bronchial asthma complicated by mycosis] Andronova NV, et al. **Ter Arkh** 1995;67(11):33–5 (7 ref.) **(Rus)**

IMMUNOLOGY

Specific IgG4 responses during chronic and transient antigen exposure in aspergillosis. Tomee JF, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1952–7

Arthropathy, leucopenia and recurrent infection associated with a TcR gamma delta population. Hodges E, et al. **Br J Rheumatol** 1995 Oct;34(10):978–83

Aspergillus fumigatus antigens. López–Medrano R, et al. **Microbiology** 1995 Oct;141 (Pt 10):2699–704

[Extralobar sequestration presenting increased serum CA19–9 and associated with lung aspergillosis—an unusual case] Kugai T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):565–9 (Eng. Abstr.) **(Jpn)**

METABOLISM

False–positive antineutrophil cytoplasmic antibody in aspergillosis with oxalosis [letter; comment] Nakajima M, et al. **Arch Pathol Lab Med** 1996 May;120(5):425–6. Comment on: Arch Pathol Lab Med 1995 Jun;119(6):558–61.

Production of cytokines by alveolar and peritoneal macrophages stimulated by Aspergillus fumigatus conidia or hyphae. Taramelli D, et al. **J Med Vet Mycol** 1996 Jan–Feb;34(1):49–56

MICROBIOLOGY

Renal aspergilloma due to Aspergillus flavus. Khan ZU, et al. **Clin Infect Dis** 1995 Jul;21(1):210–2

Fungal aerobiology: how, when and where? Hay RJ, et al. **J Hosp Infect** 1995 Jun;30 Suppl:352–7

[A case of invasive pulmonary aspergillosis accompanied with Aspergillus meningitis] Akutsu K, et al. **Kansenshogaku Zasshi** 1996 Jun;70(6):637–41 (Eng. Abstr.) **(Jpn)**

[A high concentration of itraconazole in an aspergilloma] Niwa H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):67–70 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

The use of respiratory–tract cultures in the diagnosis of invasive pulmonary aspergillosis. Horvath JA, et al. **Am J Med** 1996 Feb;100(2):171–8

Pathological features of invasive oral aspergillosis in patients with hematologic malignancies. Myoken Y, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):263–70

Invasive aspergillosis of the larynx in AIDS. Kingdom TT, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):135–7

Aspergillus sinusitis: clinical aspects and treatment outcomes. Min YG, et al. **Otolaryngol Head Neck Surg** 1996 Jul; 115(1):49–52

[Metastatic aspergillus panniculitis in blast transformation of a myelodysplastic syndrome and agranulocytosis] Skaria AM, et al. **Hautarzt** 1995 Aug;46(8):579–81 (Eng. Abstr.) **(Ger)**

[A case of aspergilloma in a adenocarcinoma cavity in a patient with a history of pulmonary tuberculosis] Nalepa P. **Pneumonol Alergol Pol** 1995;63(9–10):553–5 **(Pol)**

[Morphofunctional description of protective cell reactions in aspergillosis] Khmel'nitski i OK, et al. **Arkh Patol** 1995 Nov–Dec;57(6):31–5 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Behre GF, et al. **Ann Hematol** 1995 Dec;71(6):287–91

Aspergillosis prior to bone marrow transplantation. Infectious Diseases Working Party of the EBMT and the EORTC Invasive Fungal Infections Cooperative Group [letter] Cordonnier C, et al. **Bone Marrow Transplant** 1995 Aug; 16(2):323–4

Interferon–gamma and tumor necrosis factor–alpha protect mice from invasive aspergillosis. Nagai H, et al. **J Infect Dis** 1995 Dec;172(6):1554–60

RADIOGRAPHY

A 41–year–old Guyanese woman is admitted to a hospital with severe hemoptysis. Macari M, et al. **Clin Imaging** 1995 Jul–Sep;19(3):218–20

CT manifestations of pulmonary aspergillosis. Logan PM, et al. **Crit Rev Diagn Imaging** 1996 Feb;37(1):1–37 (43 ref.)

Radiodense concretions in maxillary sinus aspergillosis: pathogenesis and the role of CT densitometry. Lenglinger FX, et al. **Eur Radiol** 1996;6(3):375–9

Acute nephritis by Aspergillus in a patient with AIDS. Munõz–Bustillo E, et al. **Nephrol Dial Transplant** 1996 Jan; 11(1):194–6

Aspergillosis of the paranasal sinuses. A case report and radiographic review. Falworth MS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):255–60

Varied radiologic appearances of pulmonary aspergillosis. Thompson BH, et al. **Radiographics** 1995 Nov; 15(6):1273–84 (36 ref.)

Aspergillus infection of the neck with an extradural component: an unusual presentation. Lin MB, et al. **Singapore Med J** 1995 Dec;36(6):678–81

[Paranasal sinus mycetoma with orbital involvement in a patient with AIDS] Busch M, et al. **Bildgebung** 1995 Sep; 62(3):199–201 (Eng. Abstr.) **(Ger)**

[Invasive aspergillosis in the hematologic patient: the usefulness of computed tomographic and high–resolution computed tomographic studies] Sergiacomi G, et al. **Radiol Med (Torino)** 1996 Apr;91(4):377–84 (Eng. Abstr.) **(Ita)**

SURGERY

The role of surgery and itraconazole in Aspergillus peritonitis in CAPD [letter] Kitiyakara C, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1498

[Aspergilus nasal sinusitis endoscopic surgery] Wang D, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995; 30(3):169–70 (Eng. Abstr.) **(Chi)**

[Emergency lung resections for invasive aspergillosis in neutropenic patients] Bernard A, et al. **Ann Chir** 1995; 49(9):849–53 (Eng. Abstr.) **(Fre)**

[INfection of the orbits from the oromandibular surgery viewpoint] Schwenzer N, et al. **Fortschr Kiefer Gesichtschir** 1996;41:38–43 **(Ger)**

THERAPY

Clinical conference on management dilemmas. An expanding right upper lobe cavity [clinical conference] Schnader J, et al. **Chest** 1996 Mar;109(3):829–35

Diagnosis and management of invasive aspergillosis. Denning DW. **Curr Clin Top Infect Dis** 1996;16:277–99 (41 ref.)

[Isolated invasive sphenoid aspergillosis] Delevaux I, et al. **Presse Med** 1996 Apr 6;25(12):587–9 (Eng. Abstr.) **(Fre)**

TRANSMISSION

Transmission of invasive aspergillosis from a subclinically infected donor to three different organ transplant recipients. Keating MR, et al. **Chest** 1996 Apr; 109(4):1119–24

Fungal aerobiology: how, when and where? Hay RJ, et al. **J Hosp Infect** 1995 Jun;30 Suppl:352–7

Kitchens as a source of Aspergillus niger infection. Loudon KW, et al. **J Hosp Infect** 1996 Mar;32(3):191–8

Aspergillosis in immunocompromised paediatric patients: associations with building hygiene, design, and indoor air. Anderson K, et al. **Thorax** 1996 Mar;51(3):256–61

VETERINARY

Long-term survival of four dogs with disseminated Aspergillus terreus infection treated with itraconazole. Kelly SE, et al. **Aust Vet J** 1995 Aug;72(8):311–3

Bronchopulmonary and disseminated granulomatous disease associated with Aspergillus fumigatus and Candida species infection in a golden retriever. Clercx C, et al. **J Am Anim Hosp Assoc** 1996 Mar–Apr;32(2):139–45

Subcutaneous mycetoma-like granuloma in a horse caused by Aspergillus versicolor. Keegan KG, et al. **J Vet Diagn Invest** 1995 Oct;7(4):564–7

Maternal transfer of anti-Aspergillus spp. immunoglobulins in African black-footed penguins (Spheniscus demersus). Graczyk TK, et al. **J Wildl Dis** 1995 Oct;31(4):545–9

Aspergillus spp. seropositivity in New Zealand penguins. Graczyk TK, et al. **Mycopathologia** 1995 Sep;131(3):179–84

Mycotic osteomyelitis in a dog following nasal aspergillosis. Moore AH, et al. **Vet Rec** 1995 Sep 30;137(14):349–50

Distribution of topical agents in the frontal sinuses and nasal cavity of dogs: comparison between current protocols for treatment of nasal aspergillosis and a new noninvasive technique. Richardson EF, et al. **Vet Surg** 1995 Nov–Dec; 24(6):476–83

[A case of acute disseminated pneumomycosis in a cow] Pusterla N, et al. **Schweiz Arch Tierheilkd** 1996; 138(4):189–94 (Eng. Abstr.) **(Ger)**

ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY

COMPLICATIONS

Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Becker JW, et al. **Chest** 1996 Jun;109(6):1536–40

Aspergillosis in acute myelogenous leukemia. Knapp R, et al. **Int Arch Allergy Immunol** 1996 Feb;109(2):115

Saprophytic mycosis with pulmonary echinococcosis. Date A, et al. **J Trop Med Hyg** 1995 Dec;98(6):416–8

Aspergillary bronchopneumonia: an unusual cause of atelectasis and asphyxia in a leukemic patient. Velloso ED, et al. **Rev Paul Med** 1994 Oct–Dec;112(4):639–41

DIAGNOSIS

Allergic bronchopulmonary aspergillosis presenting with cough variant asthma and identifiable source of Aspergillus fumigatus. Krasnick J, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):344–6

Multifactorial immunologic lung disease: a case report. Krasnick J, et al. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):239–41

Problems with skin testing in patients with allergic bronchopulmonary aspergillosis. Schwartz HJ. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):533–5

Improved diagnosis of allergic bronchopulmonary aspergillosis with gp66 (formerly antigen 7) of Aspergillus fumigatus for specific IgE detection. Little SA, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):55–63

[Invasive aspergillosis in intensive care (see comments)] Le Conte P, et al. **Ann Fr Anesth Reanim** 1995;14(2):198–208 (78 ref.) (Eng. Abstr.). Comment in: Ann Fr Anesth Reanim 1995;14(5):454–6. **(Fre)**

[Pulmonary aspergillosis. Report of 8 children] Castañeda-Ramos SA, et al. **Gac Med Mex** 1995 May–Jun; 131(3):343–8 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Quandary about treatment of aspergillomas persists. Kauffman CA. **Lancet** 1996 Jun 15;347(9016):1640

Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Caras WE, et al. **Mayo Clin Proc** 1996 Jan;71(1):25–30

ETIOLOGY

Aspergillus infection in single and double lung transplant recipients. Westney GE, et al. **Transplantation** 1996 Mar 27;61(6):915–9

[Invasive aspergillosis during resuscitation (comment)] Coronel B, et al. **Ann Fr Anesth Reanim** 1995;14(5):454–5 (13 ref.). Comment on: Ann Fr Anesth Reanim 1995;14(2):198–208. **(Fre)**

[Bronchopulmonary aspergillosis and mucoviscidosis] Baculard A, et al. **Rev Pneumol Clin** 1995;51(3):160–3 (29 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Miller PW, et al. **Am J Hum Genet** 1996 Jul; 59(1):45–51

IMMUNOLOGY

Specific IgG4 responses during chronic and transient antigen exposure in aspergillosis. Tomee JF, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1952–7

T cell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis. Chauhan B, et al. **J Clin Invest** 1996 May 15;97(10):2324–31

MICROBIOLOGY

Aspergillus culture filtrates and sputum sols from patients with pulmonary aspergillosis cause damage to human respiratory ciliated epithelium in vitro. Amitani R, et al. **Eur Respir J** 1995 Oct;8(10):1681–7

[Development of infection with Aspergillus flavus in woman being treated for allergic pulmonary Aspergillosis caused by Aspergillus fumigatus] Yamamoto K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1099–104 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Tumor necrosis factor-alpha and interleukin-1 alpha expression in a murine model of allergic bronchopulmonary aspergillosis. Chu HW, et al. **Lab Anim Sci** 1996 Feb; 46(1):42–7

Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Caras WE, et al. **Mayo Clin Proc** 1996 Jan;71(1):25–30

RADIOGRAPHY

Aspergillosis in acute myelogenous leukemia. Knapp R, et al. **Int Arch Allergy Immunol** 1996 Feb;109(2):115

ASPERGILLUS

Fungal aerobiology: how, when and where? Hay RJ, et al. **J Hosp Infect** 1995 Jun;30 Suppl:352–7

Chronic bilateral suppurative otitis media caused by Aspergillus terreus. Tiwari S, et al. **Mycoses** 1995 Jul–Aug; 38(7–8):297–300

Effects of Aspergillus sulphureus mycotoxins on Cryptococcus neoformans. Vidotto V, et al. **Mycoses** 1996 Mar–Apr;39(3–4):129–33

Aspergillus infection in single and double lung transplant recipients. Westney GE, et al. **Transplantation** 1996 Mar 27;61(6):915–9

CHEMISTRY

Physiological and biochemical changes induced by osmolality in halotolerant aspergilli. Mahdy HM, et al. **Acta Microbiol Pol** 1996;45(1):55–65

Characterization of the antifungal protein secreted by the mould Aspergillus giganteus. Lacadena J, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):273–81

Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Sulahian A, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):139–45

The ribosome-inactivating protein restrictocin deters insect feeding on Aspergillus restrictus. Brandhorst T, et al. **Microbiology** 1996 Jun;142 (Pt 6):1551–6

[Production and characterization of sterigmatocystin] Lou J, et al. **Wei Sheng Wu Hsueh Pao** 1995 Oct;35(5):358–63 (Eng. Abstr.) **(Chi)**

[A high concentration of itraconazole in an aspergilloma] Niwa H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):67–70 (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Single-strand conformation polymorphism analysis of PCR-amplified ribosomal DNA internal transcribed spacers to differentiate species of Aspergillus section Flavi. Kumeda Y, et al. **Appl Environ Microbiol** 1996 Aug; 62(8):2947–52

Epidemiology of fungal infections: the promise of molecular typing. Pfaller MA. **Clin Infect Dis** 1995 Jun;20(6):1535–9 (61 ref.)

RES-1149-1 and -2, novel non-peptidic endothelin type B receptor antagonists produced by Aspergillus sp. I. Taxonomy of producing strain, fermentation, isolation, and physico-chemical and biological properties. Ogawa T, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):1–5

Molecular typing of Aspergillus species. Birch M, et al. **J Hosp Infect** 1995 Jun;30 Suppl:339–51 (43 ref.)

Use of UV photography to identify aflatoxin-producing strains of Aspergillus flavus and A. parasiticus. Cvetnic Z, et al. **Z Lebensm Unters Forsch** 1995 Oct;201(4):399–401

DRUG EFFECTS

Fungistatic and fungicidal activity of east African medicinal plants. Fabry W, et al. **Mycoses** 1996 Jan–Feb;39(1–2):67–70

Zinc and aspergillus [letter; comment] Beck-Mannagetta J. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):138–40. Comment on: Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Jan;79(1):82–7.

Amphotericin B. Abadi J. **Pediatr Rev** 1995 Oct;16(10):363–4

ENZYMOLOGY

Molecular characterization of an Aspergillus parasiticus dehydrogenase gene, norA, located on the aflatoxin biosynthesis gene cluster. Cary JW, et al. **Appl Environ Microbiol** 1996 Feb;62(2):360–6

Functional analysis of the threonine- and serine-rich Gp-I domain of glucoamylase I from Aspergillus awamori var. kawachi. Semimaru T, et al. **Appl Environ Microbiol** 1995 Aug;61(8):2885–90

Effect of irreversibility on the thermodynamic characterization of the thermal denaturation of Aspergillus saitoi acid proteinase. Tello-Solis SR, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):969–74

Purification and characterization of versicolorin B synthase from Aspergillus parasiticus. Catalysis of the stereodifferentiating cyclization in aflatoxin biosynthesis essential to DNA interaction. McGuire SM, et al. **Biochemistry** 1996 Sep 3;35(35):11470–86

Functional and structural roles of the highly conserved Trp120 loop region of glucoamylase from Aspergillus awamori. Natarajan S, et al. **Biochemistry** 1996 Mar 5; 35(9):3050–8

Implication of tryptophan and histidine in the active site of endo-polygalacturonase from Aspergillus ustus: elucidation of the reaction mechanism. Rao MN, et al. **Biochim Biophys Acta** 1996 Sep 5;1296(2):167–73

Characterization of the Aspergillus parasiticus niaD and niiA gene cluster. Chang PK, et al. **Curr Genet** 1996 Jun; 30(1):68–75

Commentary on: 'Thermostability of beta-xylosidase from Aspergillus sydowii MG49' by M. Gowda and G. Nanda, FEBS Letters 330, 275–278 (1993) [comment] Ananthapadmanaban D. **FEBS Lett** 1996 May 6;385(3):244 . Comment on: FEBS Lett 1993 Sep 20;330(3):275–8.

Inversion of configuration during hydrolysis of alpha-1,4-galacturonidic linkage by three Aspergillus polygalacturonases. Biely P, et al. **FEBS Lett** 1996 Mar 18;382(3):249–55

An essential tyrosine residue of Aspergillus polygalacturonase. Stratilová E, et al. **FEBS Lett** 1996 Mar 11;382(1–2):164–6

Comparison of the omtA genes encoding O-methyltransferases involved in aflatoxin biosynthesis from Aspergillus parasiticus and A. flavus. Yu J, et al. **Gene** 1995 Sep 22;163(1):121–5

Studies on glucoamylase produced from Aspergillus awamori (NRRL-3112) and their effect on saccharification of potato starch. Kumar Soni S, et al. **Indian J Exp Biol** 1995 Dec; 33(12):957–61

The Cu,Zn superoxide dismutases of Aspergillus flavus, Aspergillus niger, Aspergillus nidulans, and Aspergillus terreus: purification and biochemical comparison with the Aspergillus fumigatus Cu,Zn superoxide dismutase. Holdom MD, et al. **Infect Immun** 1996 Aug;64(8):3326–32

Molecular cloning and characterization of a rhamnogalacturonan acetylesterase from Aspergillus aculeatus. Synergism between rhamnogalacturonan degrading enzymes. Kauppinen S, et al. **J Biol Chem** 1995 Nov 10;270(45):27172–8

Isolation and characterization of the versicolorin B synthase gene from Aspergillus parasiticus. Expansion of the aflatoxin b1 biosynthetic gene cluster. Silva JC, et al. **J Biol Chem** 1996 Jun 7;271(23):13600–8

The Aspergillus parasiticus polyketide synthase gene pksA, a homolog of Aspergillus nidulans wA, is required for aflatoxin B1 biosynthesis. Chang PK, et al. **Mol Gen Genet** 1995 Aug 21;248(3):270–7

Rhamnogalacturonase B from Aspergillus aculeatus is a rhamnogalacturonan alpha-L-rhamnopyranosyl-(1-->4)-alpha-D-galactopyranosyluronide lyase. Mutter M, et al. **Plant Physiol** 1996 Jan;110(1):73–7

Identification and elimination by site-directed mutagenesis of thermolabile aspartyl bonds in Aspergillus awamori glucoamylase. Chen HM, et al. **Protein Eng** 1995 Jun; 8(6):575–82

GENETICS

Allocation of random amplified polymorphic DNA markers and enzyme activities to Aspergillus nidulans and Aspergillus tetrazonus chromosomes. Varga J, et al. **Antonie Van Leeuwenhoek** 1995 Oct;68(3):245–51

Molecular characterization of an Aspergillus parasiticus dehydrogenase gene, norA, located on the aflatoxin biosynthesis gene cluster. Cary JW, et al. **Appl Environ Microbiol** 1996 Feb;62(2):360–6

Analysis of heterologous protein production in defined recombinant Aspergillus awamori strains. Gouka RJ, et al. **Appl Environ Microbiol** 1996 Jun;62(6):1951–7

Structure and function of fas-1A, a gene encoding a putative

fatty acid synthetase directly involved in aflatoxin biosynthesis in Aspergillus parasiticus. Mahanti N, et al. **Appl Environ Microbiol** 1996 Jan;62(1):191–5

Molecular cloning and nucleotide sequence of the 1,2–alpha–D–mannosidase gene, msdS, from Aspergillus saitoi and expression of the gene in yeast cells. Inoue T, et al. **Biochim Biophys Acta** 1995 Dec 6;1253(2):141–5

Characterization of the Aspergillus parasiticus niaD and niiA gene cluster. Chang PK, et al. **Curr Genet** 1996 Jun; 30(1):68–75

Cloning and expression of an Aspergillus kawachii endo–1,4–beta–xylanase gene in Saccharomyces cerevisiae. Crous JM, et al. **Curr Genet** 1995 Oct;28(5):467–73

A novel strategy for the isolation of defined pyrG mutants and the development of a site–specific integration system for Aspergillus awamori. Gouka RJ, et al. **Curr Genet** 1995 May;27(6):536–40

Cloning and sequencing of cellulase cDNA from Aspergillus kawachii and its expression in Saccharomyces cerevisiae. Sakamoto S, et al. **Curr Genet** 1995 Apr;27(5):435–9

Comparison of the omtA genes encoding O–methyltransferases involved in aflatoxin biosynthesis from Aspergillus parasiticus and A. flavus. Yu J, et al. **Gene** 1995 Sep 22;163(1):121–5

Characterization of the polyketide synthase gene (pksL1) required for aflatoxin biosynthesis in Aspergillus parasiticus. Feng GH, et al. **J Bacteriol** 1995 Nov; 177(21):6246–54

Molecular cloning and characterization of a rhamnogalacturonan acetylesterase from Aspergillus aculeatus. Synergism between rhamnogalacturonan degrading enzymes. Kauppinen S, et al. **J Biol Chem** 1995 Nov 10;270(45):27172–8

Isolation and characterization of the versicolorin B synthase gene from Aspergillus parasiticus. Expansion of the aflatoxin b1 biosynthetic gene cluster. Silva JC, et al. **J Biol Chem** 1996 Jun 7;271(23):13600–8

Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. Verweij PE, et al. **J Clin Microbiol** 1995 Dec;33(12):3150–3

The Aspergillus parasiticus polyketide synthase gene pksA, a homolog of Aspergillus nidulans wA, is required for aflatoxin B1 biosynthesis. Chang PK, et al. **Mol Gen Genet** 1995 Aug 21;248(3):270–7

GROWTH & DEVELOPMENT

Evaluation of surface disinfection procedures for enumerating fungi in foods: a collaborative study. Andrews S. **Int J Food Microbiol** 1996 Apr;29(2–3):177–84

IMMUNOLOGY

Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. Verweij PE, et al. **J Clin Microbiol** 1995 Dec;33(12):3150–3

Comparison of the antimicrobial activity of deactivated human macrophages challenged with Aspergillus fumigatus and Listeria monocytogenes. Meier–Ososky I, et al. **J Infect Dis** 1996 Sep;174(3):651–4

Maternal transfer of anti–Aspergillus spp. immunoglobulins in African black–footed penguins (Spheniscus demersus). Graczyk TK, et al. **J Wildl Dis** 1995 Oct;31(4):545–9

Western blot analysis of cerebrospinal fluid for detection of Aspergillus antigens. Ray P, et al. **Mycopathologia** 1995 Aug;131(2):103–6

[Anaphylactic reaction to Aspergillus] Drouet M, et al. **Allerg Immunol (Paris)** 1996 Mar;28(3):88–9 (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

Osteomyelitis of sacral spine caused by aspergillus versicolor with neurologic deficits. Liu Z, et al. **Chin Med J (Engl)** 1995 Jun;108(6):472–5

Invasive fungal sinusitis in the immunocompromised pediatric patient. Lansford BK, et al. **Ear Nose Throat J** 1995 Aug; 74(8):566–73

Aspergillus terreus, an uncommon fungus causing aortic root abscess and pseudoaneurysm. Koshi G, et al. **Indian Heart J** 1995 May–Jun;47(3):265–7

Subcutaneous mycetoma–like granuloma in a horse caused by Aspergillus versicolor. Keegan KG, et al. **J Vet Diagn Invest** 1995 Oct;7(4):564–7

Aspergillus peritonitis in peritoneal dialysis [letter] Tanis BC, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):752

Positive cultures around breast prostheses [letter; comment] Niazi ZB, et al. **Plast Reconstr Surg** 1996 Jul;98(1):186. Comment on: Plast Reconstr Surg 1995 Oct;96(5):1125–9.

METABOLISM

Analysis of heterologous protein production in defined recombinant Aspergillus awamori strains. Gouka RJ, et al. **Appl Environ Microbiol** 1996 Jun;62(6):1951–7

Effect of aerobic pretreatment with Aspergillus terreus on the anaerobic digestion of olive–mill wastewater. Borja R, et al. **Biotechnol Appl Biochem** 1995 Oct;22 (Pt 2):233–46

Expression of an Erwinia pectate lyase in three species of Aspergillus. Bartling S, et al. **Curr Genet** 1996 Apr; 29(5):474–81

Clavin, a type–1 ribosome–inactivating protein from Aspergillus clavatus IFO 8605. cDNA isolation, heterologous expression, biochemical and biological characterization of the recombinant protein. Parente D, et al. **Eur J Biochem** 1996 Jul 15;239(2):272–80

Aspergillus culture filtrates and sputum sols from patients with pulmonary aspergillosis cause damage to human respiratory ciliated epithelium in vitro. Amitani R, et al. **Eur Respir J** 1995 Oct;8(10):1681–7

Micellar electrokinetic capillary chromatography of fungal metabolites. Resolution optimized by experimental design. Nielsen MS, et al. **J Chromatogr A** 1996 Jan 19; 721(2):337–44

Mode and extent of degradation of adenosine and guanosine by extracts of Aspergillus terricola. Elshafei AM, et al. **Microbiol Res** 1995 Sep;150(3):291–5

Aflatoxin–producing potential of Aspergillus flavus and Aspergillus parasiticus isolated from samples of smoked–dried meat. Cvetnić Z, et al. **Nahrung** 1995; 39(4):302–7

Use of UV photography to identify aflatoxin–producing strains of Aspergillus flavus and A. parasiticus. Cvetnić Z, et al. **Z Lebensm Unters Forsch** 1995 Oct;201(4):399–401

[Test for the effects of mutagenic toxic fungal metabolites originating from municipal landfill sites] Bubak A, et al. **Med Pr** 1996;47(2):133–41 (Eng. Abstr.) **(Pol)**

PATHOGENICITY

A case of allergic aspergillus sinusitis with acute onset. Ito A, et al. **Auris Nasus Larynx** 1995;22(3):197–9

PHYSIOLOGY

Physiological and biochemical changes induced by osmolality in halotolerant aspergilli. Mahdy HM, et al. **Acta Microbiol Pol** 1996;45(1):55–65

Loss of meiosis in Aspergillus. Geiser DM, et al. **Mol Biol Evol** 1996 Jul;13(6):809–17

ULTRASTRUCTURE

Characterization of experimentally induced, nonaflatoxigenic variant strains of Aspergillus parasiticus. Kale SP, et al. **Appl Environ Microbiol** 1996 Sep;62(9):3399–404

ASPERGILLUS FLAVUS

see related

AFLATOXINS

Aspergillus flavus meningitis and pontine hemorrhage in an older patient [letter] Adunsky A, et al. **J Am Geriatr Soc** 1996 Jun;44(6):739–40

Aspergillus flavus mycetoma and epidural abscess successfully treated with itraconazole. Witzig RS, et al. **J Med Vet Mycol** 1996 Mar–Apr;34(2):133–7

Recurrent aspergilloma of the frontoethmoid sinus in a non–immunocompromised patient. Tierney P, et al. **J R Soc Med** 1996 Mar;89(3):165P–6P

Fatal fungal infection of an ascending aortic graft. Wandschneider W, et al. **Thorac Cardiovasc Surg** 1995 Aug; 43(4):217–9

[Metastatic aspergillus panniculitis in blast transformation of a myelodysplastic syndrome and agranulocytosis] Skaria AM, et al. **Hautarzt** 1995 Aug;46(8):579–81 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Effects of some insect growth regulators on growth of Aspergillus flavus and its productivity of aflatoxin B1 and lipids. el–Refai IM, et al. **Food Addit Contam** 1995 Jul–Aug; 12(4):585–90

The plant growth regulator methyl jasmonate inhibits aflatoxin production by Aspergillus flavus. Goodrich–Tanrikulu M, et al. **Microbiology** 1995 Nov;141 (Pt 11):2831–7

ENZYMOLOGY

Isolation and characterization of polygalacturonase genes (pecA and pecB) from Aspergillus flavus. Whitehead MP, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3316–22

Acid phosphatase synthesis in Aspergillus flavus. Famurewa O, et al. **Folia Microbiol (Praha)** 1994;39(6):475–80

Cloning and characterization of the cDNAs and genes (mep20) encoding homologous metalloproteinases from Aspergillus flavus and A. fumigatus. Ramesh MV, et al. **Gene** 1995 Nov 7;165(1):121–5

Disruption of the serine proteinase gene (sep) in Aspergillus flavus leads to a compensatory increase in the expression of a metalloproteinase gene (mep20). Ramesh MV, et al. **J Bacteriol** 1996 Jul;178(13):3899–907

Expression of elastinolytic activity among isolates in Aspergillus section flavi. Mellon JE, et al. **Mycopathologia** 1995 Aug;131(2):115–20

GENETICS

Isolation and characterization of polygalacturonase genes (pecA and pecB) from Aspergillus flavus. Whitehead MP, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3316–22

Molecular characterization of the afl–1 locus in Aspergillus flavus. Woloshuk CP, et al. **Appl Environ Microbiol** 1995 Aug;61(8):3019–23

Conservation of structure and function of the aflatoxin regulatory gene aflR from Aspergillus nidulans and A. flavus. Yu JH, et al. **Curr Genet** 1996 May;29(6):549–55

IMMUNOLOGY

Monoclonal antibodies against a 97–kilodalton antigen from Aspergillus flavus. Hetherington SV, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):63–7

ISOLATION & PURIFICATION

Renal aspergilloma due to Aspergillus flavus. Khan ZU, et al. **Clin Infect Dis** 1995 Jul;21(1):210–2

A survey of aflatoxins and aflatoxigenic Aspergillus flavus in corn–based products from the Spanish market. Sanchis V, et al. **Microbiol Res** 1995 Nov;150(4):437–40

[Development of infection with Aspergillus flavus in woman being treated for allergic pulmonary Aspergillosis caused by Aspergillus fumigatus] Yamamoto K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1099–104 (Eng. Abstr.) **(Jpn)**

METABOLISM

Kojic acid production from cocoa juice by Aspergillus flavus entrapped in calcium alginate. el–Sharkawy SH. **Boll Chim Farm** 1995 Jun;134(6):316–9

Effects of some insect growth regulators on growth of Aspergillus flavus and its productivity of aflatoxin B1 and lipids. el–Refai IM, et al. **Food Addit Contam** 1995 Jul–Aug; 12(4):585–90

Aflatoxin contamination of sorghum seeds during storage under controlled conditions. Mukherjee K, et al. **Int J Med Microbiol Virol Parasitol Infect Dis** 1995 Apr; 282(3):237–43

Effects of maize weevils (Coleoptera: Curculionidae) on production of aflatoxin B1 by Aspergillus flavus in stored corn. Beti JA, et al. **J Econ Entomol** 1995 Dec; 88(6):1776–82

Use of UV photography to identify aflatoxin–producing strains of Aspergillus flavus and A. parasiticus. Cvetnić Z, et al. **Z Lebensm Unters Forsch** 1995 Oct;201(4):399–401

[Relationship between aflatoxin and sclerotia production in aspergillus flavus] Wang Z, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1996 Jan;30(1):14–6 (Eng. Abstr.) **(Chi)**

[The effect of Aspergillus flavus metabolites on the development of experimental Klebsiella pneumonia] Bondarenko VM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec; (6):23–4 **(Rus)**

PHYSIOLOGY

The plant growth regulator methyl jasmonate inhibits aflatoxin production by Aspergillus flavus. Goodrich–Tanrikulu M, et al. **Microbiology** 1995 Nov;141 (Pt 11):2831–7

Expression pattern of aspartic proteinase antigens in aspergilli. Reichard U, et al. **Mycoses** 1996 Mar–Apr; 39(3–4):99–101

ASPERGILLUS FUMIGATUS

Refractory pulmonary aspergillosis: compassionate trial with terbinafine. Schiraldi GF, et al. **Br J Dermatol** 1996 Jun; 134 Suppl 46:25–9: discussion 39–40

Transmission of invasive aspergillosis from a subclinically infected donor to three different organ transplant recipients. Keating MR, et al. **Chest** 1996 Apr; 109(4):1119–24

Aspergillosis of the muscle in a woman with sarcoidosis and CD4+ T lymphocytopenia. Viallard JF, et al. **Clin Infect Dis** 1995 Nov;21(5):1345–6

Tools and trends in the detection of Aspergillus fumigatus. Latgé JP. **Curr Top Med Mycol** 1995;6:245–81 (137 ref.)

Hickman catheter–associated primary cutaneous aspergillosis in a patient with the acquired immunodeficiency syndrome. Romero LS, et al. **Int J Dermatol** 1995 Aug;34(8):551–3

Bronchopulmonary and disseminated granulomatous disease associated with Aspergillus fumigatus and Candida species infection in a golden retriever. Clercx C, et al. **J Am Anim Hosp Assoc** 1996 Mar–Apr;32(2):139–45

Central venous catheter infection by Aspergillus fumigatus in a patient with B–type non–Hodgkin lymphoma. Berner R, et al. **Med Pediatr Oncol** 1996 Sep;27(3):202–4

Peracute disseminated fatal Aspergillus fumigatus sepsis as a complication of corticoid–treated systemic lupus erythematosus. Nenoff P, et al. **Mycoses** 1995 Nov–Dec; 38(11–12):467–71 (21 ref.)

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14–1996. A 66–year–old woman with toxic epidermal necrolysis and a fatal course [clinical conference] **N Engl J Med** 1996 May 9; 334(19):1254–61

Nosocomial outbreak of Aspergillus fumigatus infection among patients in a renal unit? Sessa A, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1322–4

Invasive aspergillosis of the larynx in AIDS. Kingdom TT, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):135–7

Scanning electron microscopy studies of peritoneal catheter in CAPD peritonitis due to Aspergillus fumigatus. Park

SB, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):81–3

Aspergillosis in immunocompromised paediatric patients: associations with building hygiene, design, and indoor air. Anderson K, et al. **Thorax** 1996 Mar;51(3):256–61

Colonisation with Aspergillus of an intralobar pulmonary sequestration [see comments] Freixinet J, et al. **Thorax** 1995 Jul;50(7):810–1. Comment in: Thorax 1995 Jul;50(7):812–3.

Aspergillus laryngotracheobronchitis presenting as stridor in a patient with peripheral T cell lymphoma. Kuo PH, et al. **Thorax** 1996 Aug;51(8):869–70

Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Purcell IF, et al. **Thorax** 1995 Dec;50(12):1321–3

Renal abscess due to Aspergillus fumigatus in a patient with the acquired immunodeficiency syndrome. Segarra J, et al. **Urol Int** 1995;55(1):60–2

[Chronic septic granulomatosis revealed by neonatal pulmonary aspergillosis] Mouy R, et al. **Arch Pediatr** 1995 Sep;2(9):861–4 (Eng. Abstr.) **(Fre)**

[INfection of the orbits from the oromandibular surgery viewpoint] Schwenzer N, et al. **Fortschr Kiefer Gesichtschir** 1996;41:38–43 **(Ger)**

[A case of acute disseminated pneumomycosis in a cow] Pusterla N, et al. **Schweiz Arch Tierheilkd** 1996; 138(4):189–94 (Eng. Abstr.) **(Ger)**

[A case of itraconazole-induced hypokalemia with pulmonary aspergilloma] Yamamoto T, et al. **Kansenshogaku Zasshi** 1995 Dec;69(12):1413–7 (Eng. Abstr.) **(Jpn)**

[Extralobar sequestration presenting increased serum CA19–9 and associated with lung aspergillosis—an unusual case] Kugai T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):565–9 (Eng. Abstr.) **(Jpn)**

[Pulmonary aspergillosis in patients with disseminated processes in the lungs] Vlasenko Slu, et al. **Ter Arkh** 1996; 68(3):80–3 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Chitin assay in aspergillus fumigatus. Kopeček P. **Acta Univ Palacki Olomuc Fac Med** 1994;138:17–8

The isolation, purification and identification of fumitremorgin B produced by Aspergillus fumigatus. Liu J, et al. **Biomed Environ Sci** 1996 Mar;9(1):1–11

Structural investigation of cell-wall polysaccharides from Neosartorya: relationships with their putative anamorphs of Aspergillus. Leal JA, et al. **Carbohydr Res** 1995 Aug 25;273(2):255–62

Inhibition of the alveolar macrophage oxidative burst by a diffusible component from the surface of the spores of the fungus Aspergillus fumigatus. Slight J, et al. **Thorax** 1996 Apr;51(4):389–96

CLASSIFICATION

Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of Aspergillus fumigatus. Anderson MJ, et al. **J Clin Microbiol** 1996 Jan;34(1):87–93

Comparison of three typing methods for clinical and environmental isolates of Aspergillus fumigatus [letter; comment] Loudon KW, et al. **J Clin Microbiol** 1995 Dec; 33(12):3362–3. Comment on: J Clin Microbiol 1995 Jun;33(6):1596–601.

Phenotypic and genotypic analysis of variability in Aspergillus fumigatus. Rinyu E, et al. **J Clin Microbiol** 1995 Oct;33(10):2567–75

Use of phenotypic and genotypic fingerprinting methods in the strain identification of Aspergillus fumigatus. Rath PM, et al. **Mycoses** 1995 Nov–Dec;38(11–12):429–34

DRUG EFFECTS

Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis. Allendoerfer R, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1345–8

In vitro and in vivo antifungal activities of DU–6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Nakajima R, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1517–21

Ultrastructural alterations produced by sertaconazole on several opportunistic pathogenic fungi. Figueras MJ, et al. **J Med Vet Mycol** 1995 Nov–Dec;33(6):395–401

Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. Roilides E, et al. **J Med Vet Mycol** 1996 Jan–Feb;34(1):63–9

Effects of tunicamycin on glycoprotein antigens of Aspergillus fumigatus. Hearn VM, et al. **Microbios** 1996; 85(345):239–50

ENZYMOLOGY

Inhibition of Aspergillus serine proteinase by Streptomyces subtilisin inhibitor and high-level expression of this inhibitor in Pichia pastoris. Markaryan A, et al. **Biochem Biophys Res Commun** 1996 Mar 18;220(2):372–6

Selection of multiple disruption events in Aspergillus fumigatus using the orotidine-5'-decarboxylase gene, pyrG, as a unique transformation marker. d'Enfert C. **Curr Genet** 1996 Jun;30(1):76–82

Cloning and characterization of the cDNAs and genes (mep20) encoding homologous metalloproteinases from Aspergillus flavus and A. fumigatus. Ramesh MV, et al. **Gene** 1995 Nov 7;165(1):121–5

Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Birch M, et al. **Infect Immun** 1996 Mar;64(3):751–5

Molecular cloning of the cDNA and gene for an elastinolytic aspartic proteinase from Aspergillus fumigatus and evidence of its secretion by the fungus during invasion of the host lung. Lee JD, et al. **Infect Immun** 1995 Oct; 63(10):3796–803

Specific inhibition of mature fungal serine proteinases and metalloproteinases by their propeptides. Markaryan A, et al. **J Bacteriol** 1996 Apr;178(8):2211–5

Purification and characterization of an extracellular aspartic proteinase from Aspergillus fumigatus. Reichard U, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):279

GENETICS

Selection of multiple disruption events in Aspergillus fumigatus using the orotidine-5'-decarboxylase gene, pyrG, as a unique transformation marker. d'Enfert C. **Curr Genet** 1996 Jun;30(1):76–82

Molecular cloning and sequencing of the gene encoding an extracellular aspartic proteinase from Aspergillus fumigatus. Reichard U, et al. **FEMS Microbiol Lett** 1995 Jul 15;130(1):69–74

Cloning Aspergillus fumigatus allergens by the pJuFo filamentous phage display system. Crameri R, et al. **Int Arch Allergy Immunol** 1996 May;110(1):41–5

Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of Aspergillus fumigatus. Anderson MJ, et al. **J Clin Microbiol** 1996 Jan;34(1):87–93

Use of phenotypic and genotypic fingerprinting methods in the strain identification of Aspergillus fumigatus. Rath PM, et al. **Mycoses** 1995 Nov–Dec;38(11–12):429–34

Afut1, a retrotransposon-like element from Aspergillus fumigatus. Neuveglise C, et al. **Nucleic Acids Res** 1996 Apr 15;24(8):1428–34

A rapid method for the isolation of genomic DNA from Aspergillus fumigatus. Bir N, et al. **Prep Biochem** 1995 Nov; 25(4):171–81

[Aspergillus fumigatus: from saprophytism to virulence. Phenotypic and genotypic biodiversity] Grillot R, et al. **Ann Pharm Fr** 1996;54(2):68–72 (21 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Aspergillus fumigatus somatic antigens: comparison between two methods of preparation and immunochemical characterization. Madrenys-Brunet N, et al. **Allergol Immunopathol (Madr)** 1995 Jul–Aug;23(4):164–70

Inhibition of the transcription factors NF-kappa B and AP-1 underlies loss of cytokine gene expression in rat alveolar macrophages treated with a diffusible product from the spores of Aspergillus fumigatus. Nicholson WJ, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):88–96

Specific IgG4 responses during chronic and transient antigen exposure in aspergillosis. Tomee JF, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1952–7

Serodiagnosis and monitoring of Aspergillus infections after lung transplantation. Tomee JF, et al. **Ann Intern Med** 1996 Aug 1;125(3):197–201

A 12-year longitudinal study of Aspergillus sensitivity in patients with cystic fibrosis. Hutcheson PS, et al. **Chest** 1996 Aug;110(2):363–6

Immunoblotting patterns in the serodiagnosis of aspergilloma: antibody response to the 90kDa Aspergillus fumigatus antigen. López-Medrano R, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):146–52

Suppressive effects of Aspergillus fumigatus culture filtrates on human alveolar macrophages and polymorphonuclear leucocytes. Murayama T, et al. **Eur Respir J** 1996 Feb; 9(2):293–300

An immunodominant 90-kilodalton Aspergillus fumigatus antigen is the subunit of a catalase. López-Medrano R, et al. **Infect Immun** 1995 Dec;63(12):4774–80

Cross-reactivity between Aspergillus fumigatus and Penicillium. Brouwer J. **Int Arch Allergy Immunol** 1996 Jun;110(2):166–73

Cloning Aspergillus fumigatus allergens by the pJuFo filamentous phage display system. Crameri R, et al. **Int Arch Allergy Immunol** 1996 May;110(1):41–5

Improved diagnosis of allergic bronchopulmonary aspergillosis with gp66 (formerly antigen 7) of Aspergillus fumigatus for specific IgE detection. Little SA, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):55–63

Humoral and cell-mediated autoimmunity in allergy to Aspergillus fumigatus. Crameri R, et al. **J Exp Med** 1996 Jul 1;184(1):265–70

A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanil ide (XTT). Meshulam T, et al. **J Infect Dis** 1995 Oct;172(4):1153–6

Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. Roilides E, et al. **J Infect Dis** 1995 Oct;172(4):1028–34

Aspergillus fumigatus antigens. López-Medrano R, et al. **Microbiology** 1995 Oct;141 (Pt 10):2699–704

Aspergillus fumigatus peptides differentially express Th1 and Th2 cytokines. Kurup VP, et al. **Peptides** 1996;17(2):183–90

ISOLATION & PURIFICATION

Aspergillus fumigatus scleritis. Rodriguez-Ares MT, et al. **Acta Ophthalmol Scand** 1995 Oct;73(5):467–9

Fungal pneumonia: the predominant lung infection causing death in children undergoing bone marrow transplantation. Heurlin N, et al. **Acta Paediatr** 1996 Feb;85(2):168–72

Unusual cause of lethal pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Pittet D, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):541–4

Allergic bronchopulmonary aspergillosis presenting with cough variant asthma and identifiable source of Aspergillus fumigatus. Krasnick J, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):344–6

[Development of infection with Aspergillus flavus in woman being treated for allergic pulmonary Aspergillosis caused by Aspergillus fumigatus] Yamamoto K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1099–104 (Eng. Abstr.) **(Jpn)**

[Cavernous changes as a result of pulmonary tissue hyperreactivity to Aspergillus fumigatus infection] Krakówka P, et al. **Pneumonol Pol** 1990 Nov–Dec; 58(11–12):624–8 (Eng. Abstr.) **(Pol)**

METABOLISM

Binding of human fibronectin to Aspergillus fumigatus conidia. Peñalver MC, et al. **Infect Immun** 1996 Apr; 64(4):1146–53

Tryprostatins A and B, novel mammalian cell cycle inhibitors produced by Aspergillus fumigatus [letter] Cui CB, et al. **J Antibiot (Tokyo)** 1995 Nov;48(11):1382–4

GERI-BP002-A, novel inhibitor of acyl-CoA: cholesterol acyltransferase produced by Aspergillus fumigatus F93. Kim YK, et al. **J Antibiot (Tokyo)** 1996 Jan;49(1):31–6

Cell wall protein and glycoprotein constituents of Aspergillus fumigatus that bind to polystyrene may be responsible for the cell surface hydrophobicity of the mycelium. Peñalver MC, et al. **Microbiology** 1996 Jul;142 (Pt 7):1597–604

PATHOGENICITY

The search for virulence determinants in Aspergillus fumigatus. Bouchara JP, et al. **Trends Microbiol** 1995 Aug; 3(8):327–30 (25 ref.)

[Aspergillus fumigatus: from saprophytism to virulence. Phenotypic and genotypic biodiversity] Grillot R, et al. **Ann Pharm Fr** 1996;54(2):68–72 (21 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Cell surface properties of Aspergillus fumigatus conidia: correlation between adherence, agglutination, and rearrangements of the cell wall. Tronchin G, et al. **Can J Microbiol** 1995 Aug;41(8):714–21

Production of cytokines by alveolar and peritoneal macrophages stimulated by Aspergillus fumigatus conidia or hyphae. Taramelli D, et al. **J Med Vet Mycol** 1996 Jan–Feb;34(1):49–56

Expression pattern of aspartic proteinase antigens in aspergilli. Reichard U, et al. **Mycoses** 1996 Mar–Apr; 39(3–4):99–101

ULTRASTRUCTURE

Cell surface properties of Aspergillus fumigatus conidia: correlation between adherence, agglutination, and rearrangements of the cell wall. Tronchin G, et al. **Can J Microbiol** 1995 Aug;41(8):714–21

ASPERGILLUS NIDULANS

CHEMISTRY

Ethanol utilization regulatory protein: profile alignments give no evidence of origin through aldehyde and alcohol dehydrogenase gene fusion. Nicholas HB Jr, et al. **Protein Sci** 1995 Dec;4(12):2621–4

CYTOLOGY

Cell cycle regulation in Aspergillus by two protein kinases. Osmani SA, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):633–41 (127 ref.)

sepB: an Aspergillus nidulans gene involved in chromosome segregation and the initiation of cytokinesis. Harris SD, et al. **EMBO J** 1995 Nov 1;14(21):5244–57

Two S-phase checkpoint systems, one involving the function of both BIME and Tyr15 phosphorylation of p34cdc2, inhibit NIMA and prevent premature mitosis. Ye XS, et al. **EMBO J** 1996 Jul 15;15(14):3599–610

Characterization and localization of the cytoplasmic dynein heavy chain in Aspergillus nidulans. Xiang X, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9890–4

DRUG EFFECTS

Screening of medicinal plants for induction of somatic segregation activity in Aspergillus nidulans. Ramos Ruiz A, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):123–7

A study of the structural basis of the ability of chlorinated alkanes and alkenes to induce aneuploidy and toxicity in

the mold Aspergillus nidulans. Rosenkranz HS, et al. **Mutat Res** 1996 Jul 22;354(2):183–93

ENZYMOLOGY

stcS, a putative P-450 monooxygenase, is required for the conversion of versicolorin A to sterigmatocystin in Aspergillus nidulans. Keller NP, et al. **Appl Environ Microbiol** 1995 Oct;61(10):3628–32

Molecular cloning and expression in Saccharomyces cerevisiae of two Aspergillus nidulans xylanase genes. Pérez-Gonzalez JA, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2179–82

Purification and partial characterization of the high and low molecular weight form (S- and F-form) of invertase secreted by Aspergillus nidulans. Chen JS, et al. **Biochim Biophys Acta** 1996 Sep 5;1296(2):207–18

Regulation of folate-dependent enzyme levels in Aspergillus nidulans: studies with regulatory mutants. Lewandowska I, et al. **Biochim Biophys Acta** 1996 May 21;1290(1):89–94

Purification and characterization of mitochondrial ribonuclease P from Aspergillus nidulans. Lee YC, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):289–96

The RNA component of mitochondrial ribonuclease P from Aspergillus nidulans. Lee YC, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):297–303

Regulation of beta-glucosidase biosynthesis in Aspergillus nidulans. Lee J, et al. **FEMS Microbiol Lett** 1996 Jan 1; 135(1):79–84

Structure-function analysis of the proline permease (PRNB) of the filamentous fungus Aspergillus nidulans. Tazebay U, et al. **Folia Microbiol (Praha)** 1994;39(6):551

Role of tryptophans in substrate binding and catalysis by DNA photolyase. Kim ST, et al. **Methods Enzymol** 1995; 258:319–43

Substrate specificity of nine NAD(+)-dependent alcohol dehydrogenases in Aspergillus nidulans. Sealy-Lewis HM, et al. **Microbiology** 1995 Sep;141 (Pt 9):2295–300

Mutations affecting extracellular protease production in the filamentous fungus Aspergillus nidulans. Katz ME, et al. **Mol Gen Genet** 1996 Apr 10;250(6):715–24

GENETICS

Allocation of random amplified polymorphic DNA markers and enzyme activities to Aspergillus nidulans and Aspergillus tetrazonus chromosomes. Varga J, et al. **Antonie Van Leeuwenhoek** 1995 Oct;68(3):245–51

Molecular cloning and expression in Saccharomyces cerevisiae of two Aspergillus nidulans xylanase genes. Pérez-Gonzalez JA, et al. **Appl Environ Microbiol** 1996 Jun;62(6):2179–82

Does gene palB regulate the transcription or the post-translational modification of Pi-repressible phosphatases of Aspergillus nidulans? Maccheroni Júnior W, et al. **Braz J Med Biol Res** 1995 Jan;28(1):31–8

Transformation of Aspergillus nidulans by RNA from rat macrophages stimulated with lipopolysaccharide. Zucchi TM, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Mar; 42(2):235–40

Recombinational stability of replicating plasmids in Aspergillus nidulans during transformation, vegetative growth and sexual reproduction. Aleksenko AY, et al. **Curr Genet** 1995 Jun;28(1):87–93

Evidence for sltA1 as a salt-sensitive allele of the arginase gene (agaA) in the ascomycete Aspergillus nidulans. Clement DJ, et al. **Curr Genet** 1996 Apr;29(5):462–7

Wild chromosomal variants in Aspergillus nidulans. Geiser DM, et al. **Curr Genet** 1996 Feb;29(3):293–300

catA, a new Aspergillus nidulans gene encoding a developmentally regulated catalase. Navarro RE, et al. **Curr Genet** 1996 Mar;29(4):352–9

Characterization of the ugatA gene of Ustilago maydis, isolated by homology to the gatA gene of Aspergillus nidulans. Straffon MJ, et al. **Curr Genet** 1996 Mar; 29(4):360–9

Conservation of structure and function of the aflatoxin regulatory gene aflR from Aspergillus nidulans and A. flavus. Yu JH, et al. **Curr Genet** 1996 May;29(6):549–55

sepB: an Aspergillus nidulans gene involved in chromosome segregation and the initiation of cytokinesis. Harris SD, et al. **EMBO J** 1995 Nov 1;14(21):5244–57

Nitrogen metabolite signalling involves the C-terminus and the GATA domain of the Aspergillus transcription factor AREA and the 3' untranslated region of its mRNA. Platt A, et al. **EMBO J** 1996 Jun 3;15(11):2791–801

The RNA component of mitochondrial ribonuclease P from Aspergillus nidulans. Lee YC, et al. **Eur J Biochem** 1996 Jan 15;235(1–2):297–303

The Aspergillus nidulans penicillin-biosynthesis gene aat (penDE) is controlled by a CCAAT-containing DNA element. Litzka O, et al. **Eur J Biochem** 1996 Jun 15; 238(3):675–82

Quantification of DNA damage and repair in amino acid auxotrophs and UV-sensitive mutants of Aspergillus nidulans using an ELISA. Donnelly E, et al. **FEBS Lett** 1995 Dec 18;377(2):118–22

Quantitative analysis of gene expression in sexual structures of Aspergillus nidulans by sequencing of 3'-directed cDNA clones. Lee DW, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):71–6

Characterisation of the Aspergillus nidulans frA1 mutant: hexose phosphorylation and apparent lack of involvement of hexokinase in glucose repression. Ruijter GJ, et al. **FEMS Microbiol Lett** 1996 Jun 1;139(2–3):223–28

Genetic and molecular characterisation of purine permease genes of Aspergillus nidulans reveals a novel family of transporters conserved in prokaryotes and eukaryotes. Diallinas G, et al. **Folia Microbiol (Praha)** 1994;39(6):513–4

Mitochondrial inheritance in Aspergillus nidulans. Coenen A, et al. **Genet Res** 1996 Apr;67(2):93–100

Suppression and enhancement of the Aspergillus nidulans medusa mutation by altered dosage of the bristle and stunted genes. Busby TM, et al. **Genetics** 1996 May; 143(1):155–63

Extragenic suppressors of nudC3, a mutation that blocks nuclear migration in Aspergillus nidulans. Chiu YH, et al. **Genetics** 1995 Oct;141(2):453–64

An alpha tubulin mutation suppresses nuclear migration mutations in Aspergillus nidulans. Willins DA, et al. **Genetics** 1995 Dec;141(4):1287–98

Identification of a major cis-acting DNA element controlling the bidirectionally transcribed penicillin biosynthesis genes acvA (pcbAB) and ipnA (pcbC) of Aspergillus nidulans. Bergh KT, et al. **J Bacteriol** 1996 Jul;178(13):3908–16

The tamA gene of Aspergillus nidulans contains a putative zinc cluster motif which is not required for gene function. Davis MA, et al. **J Bacteriol** 1996 Jun;178(11):3406–9

Isolation of a gene involved in 1,3-beta-glucan synthesis in Aspergillus nidulans and purification of the corresponding protein. Kelly R, et al. **J Bacteriol** 1996 Aug; 178(15):4381–91

A lacZ reporter fusion method for the genetic analysis of regulatory mutations in pathways of fungal secondary metabolism and its application to the Aspergillus nidulans penicillin pathway. Pérez-Esteban B, et al. **J Bacteriol** 1995 Nov;177(21):6069–76

The Aspergillus nidulans bimE (blocked-in-mitosis) gene encodes multiple cell cycle functions involved in mitotic checkpoint control and mitosis. James SW, et al. **J Cell Sci** 1995 Nov;108 (Pt 11):3485–99

Screening of medicinal plants for induction of somatic segregation activity in Aspergillus nidulans. Ramos Ruiz A, et al. **J Ethnopharmacol** 1996 Jul 5;52(3):123–7

The QUTA activator and QUTR repressor proteins of Aspergillus nidulans interact to regulate transcription of the quinate utilization pathway genes. Lamb HK, et al. **Microbiology** 1996 Jun;142 (Pt 6):1477–90

Domain structure and function within the QUTA protein of Aspergillus nidulans: implications for the control of transcription. Levesley I, et al. **Microbiology** 1996 Jan;142 (Pt 1):87–98

A pre-induction sporulation gene from Aspergillus nidulans. Lewis C, et al. **Microbiology** 1995 Aug;141 (Pt 8):1821–8

An extreme creA mutation in Aspergillus nidulans has severe effects on D-glucose utilization. van der Veen P, et al. **Microbiology** 1995 Sep;141 (Pt 9):2301–6

The intergenic region between the divergently transcribed niiA and niaD genes of Aspergillus nidulans contains multiple NirA binding sites which act bidirectionally. Punt PJ, et al. **Mol Cell Biol** 1995 Oct;15(10):5688–99

Analysis of the regulation of the Aspergillus nidulans penicillin biosynthesis gene aat (penDE), which encodes acyl coenzyme A:6-aminopenicillanic acid acyltransferase. Litzka O, et al. **Mol Gen Genet** 1995 Dec 15;249(5):557–69

The Aspergillus nidulans genes chsA and chsD encode chitin synthases which have redundant functions in conidia formation. Motoyama T, et al. **Mol Gen Genet** 1996 Jun 24;251(4):442–50

The hapC gene of Aspergillus nidulans is involved in the expression of CCAAT-containing promoters. Papagiannopoulos P, et al. **Mol Gen Genet** 1996 Jun 24; 251(4):412–21

Mutational analysis of the C-terminal region of AREA, the transcription factor mediating nitrogen metabolite repression in Aspergillus nidulans. Platt A, et al. **Mol Gen Genet** 1996 Jan 15;250(1):106–14

The plasmid replicator AMA1 in Aspergillus nidulans in an inverted duplication of a low-copy-number dispersed genomic repeat. Aleksenko A, et al. **Mol Microbiol** 1996 Feb;19(3):565–74

Translational initiation competence, 'leaky scanning' and translational reinitiation in areA mRNA of Aspergillus nidulans. Arst HN Jr, et al. **Mol Microbiol** 1996 Mar; 19(5):1019–24

Mutational analysis reveals dispensability of the N-terminal region of the Aspergillus transcription factor mediating nitrogen metabolite repression. Langdon T, et al. **Mol Microbiol** 1995 Sep;17(5):877–88

Twenty-five coregulated transcripts define a sterigmatocystin gene cluster in Aspergillus nidulans. Brown DW, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1418–22

Fungal metabolic model for human type I hereditary tyrosinaemia. Fernández-Cañón JM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9132–6

METABOLISM

Control of metabolic flux through the quinate pathway in Aspergillus nidulans. Wheeler KA, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):195–205

Molecular characterisation of meaB, a novel gene affecting nitrogen metabolite repression in Aspergillus nidulans. Polley SD, et al. **FEBS Lett** 1996 Jun 17;388(2–3):200–5

Post-transcriptional control and kinetic characterization of proline transport in germinating conidiospores of Aspergillus nidulans. Tazebay UH, et al. **FEMS Microbiol Lett** 1995 Oct 1;132(1–2):27–37

Isolation of a gene involved in 1,3-beta-glucan synthesis in Aspergillus nidulans and purification of the corresponding protein. Kelly R, et al. **J Bacteriol** 1996 Aug; 178(15):4381–91

Signaling of ambient pH in Aspergillus involves a cysteine protease. Denison SH, et al. **J Biol Chem** 1995 Dec 1; 270(48):28519–22

Mutational analysis reveals dispensability of the N-terminal region of the Aspergillus transcription factor mediating nitrogen metabolite repression. Langdon T, et al. **Mol Microbiol** 1995 Sep;17(5):877–88

Fungal metabolic model for human type I hereditary tyrosinaemia. Fernández-Cañón JM, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26;92(20):9132–6

PHYSIOLOGY

Cell cycle. The NIMA kinase joins forces with Cdc2. Fry AM, et al. **Curr Biol** 1995 Oct 1;5(10):1122–5 (16 ref.)

FluG and flbA function interdependently to initiate conidiophore development in Aspergillus nidulans through brlA beta activation. Lee BN, et al. **EMBO J** 1996 Jan 15;15(2):299–309

Biosynthetic pathways of glycerol accumulation under salt stress in Aspergillus nidulans. Redkar RJ, et al. **Exp Mycol** 1995 Dec;19(4):241–6

ASPERGILLUS NIGER

Do not drink mate. An additional source of infection in South American neutropenic patients [letter] Kusminsky G, et al. **Bone Marrow Transplant** 1996 Jan;17(1):127

The efficacy of an enzymic cocktail and a fungal mycelium in dephosphorylating corn-soybean meal-based feeds fed to growing turkeys. Zyła K, et al. **Poult Sci** 1996 Mar; 75(3):381–7

[A case of bronchial asthma complicated by mycosis] Andronova NV, et al. **Ter Arkh** 1995;67(11):33–5 (7 ref.) **(Rus)**

CHEMISTRY

Purification and characterization of copper-metallothionein from Aspergillus niger by affinity chromatography. Goetghebeur M, et al. **Biotechnol Appl Biochem** 1995 Dec; 22 (Pt 3):315–25

DRUG EFFECTS

[Cyclosporin A and the permeability of the cytoplasmic membrane in Aspergillus niger] Sazykin IuO, et al. **Antibiot Khimioter** 1995 Oct;40(10):19–24 (Eng. Abstr.) **(Rus)**

[Ultrastructural study of the action of cyclosporine on cells of the fungus Aspergillus niger] Sazykin IuO, et al. **Antibiot Khimioter** 1995 Nov-Dec;40(11–12):34–9 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Influence of medium components and metabolic inhibitors on glucose oxidase production by Aspergillus niger mycelium. Gromada A, et al. **Acta Microbiol Pol** 1996; 45(1):37–43

Aspergillus niger var. macrosporus proteinase B. cDNA cloning, expression, and activation of the proenzyme. Inoue H, et al. **Adv Exp Med Biol** 1995;362:581–7

Expression in E. coli of Aspergillus niger var. macrosporus proteinase A, a non-pepsin type acid proteinase. Kagami N, et al. **Adv Exp Med Biol** 1995;362:597–603

Conformation analysis of non-pepsin-type acid proteinase A from the fungus Aspergillus niger by NMR. Kojima M, et al. **Adv Exp Med Biol** 1995;362:611–5

X-ray crystallographic study of a non-pepsin-type acid proteinase, Aspergillus niger proteinase A. Sasaki H, et al. **Adv Exp Med Biol** 1995;362:605–9

Production, characterization and application of the cellulase-free xylanase from Aspergillus niger. Qy Y, et al. **Appl Biochem Biotechnol** 1996 Spring;57–58:375–81

Half-site reactivity with p-nitrophenylhydrazine and subunit separation of the dimeric copper-containing amine oxidase from Aspergillus niger. Frébort I, et al. **Biochem Mol Biol Int** 1995 Aug;36(6):1207–16

Spectrophotometric assay for superoxide dismutase based on the nitroblue tetrazolium reduction by glucose-glucose oxidase. Nagi MN, et al. **Biochem Mol Biol Int** 1995 Jul; 36(3):633–8

Participation of a proton-translocating plasma membrane ATPase, acid phosphatase and alkaline phosphatase in ATP degradation by Aspergillus niger extracts. Elzainy TA, et al. **Biochim Biophys Acta** 1995 Oct 4;1239(1):91–7

Two amine oxidases from Aspergillus niger AKU 3302 contain topa quinone as the cofactor: unusual cofactor link to the glutamyl residue occurs only at one of the enzymes. Frébort I, et al. **Biochim Biophys Acta** 1996 Jun 7; 1295(1):59–72

Reversible inhibition and irreversible inactivation of catalase in presence of hydrogen peroxide. Lardinois OM, et al. **Biochim Biophys Acta** 1996 Jul 18;1295(2):222–38

Purification and characterization of a novel esterase induced by growth of Aspergillus niger on sugar-beet pulp. Kroon

PA, et al. **Biotechnol Appl Biochem** 1996 Jun;23 (Pt 3):255–62

Release of ferulic acid from sugar-beet pulp by using arabinanase, arabinofuranosidase and an esterase from Aspergillus niger. Kroon PA, et al. **Biotechnol Appl Biochem** 1996 Jun;23 (Pt 3):263–7

Chemoenzymatic synthesis of 6 omega-S-alpha-D-glucopyranosyl-6 omega-thiomaltooligosaccharides: their binding to Aspergillus niger glucoamylase G1 and its starch-binding domain. Apparu C, et al. **Carbohydr Res** 1995 Nov 22; 277(2):313–20

Two distinct quinoprotein amine oxidases are induced by n-butylamine in the mycelia of Aspergillus niger AKU 3302. Purification, characterization, cDNA cloning and sequencing. Frébort I, et al. **Eur J Biochem** 1996 Apr 1; 237(1):255–65

1H and 15N assignments and secondary structure of the starch-binding domain of glucoamylase from Aspergillus niger. Jacks AJ, et al. **Eur J Biochem** 1995 Oct 15; 233(2):568–78

Expression in Aspergillus niger of the starch-binding domain of glucoamylase. Comparison with the proteolytically produced starch-binding domain. Le Gal-Coëffet MF, et al. **Eur J Biochem** 1995 Oct 15;233(2):561–7

Inversion of configuration during hydrolysis of alpha-1,4-galacturonidic linkage by three Aspergillus polygalacturonases. Biely P, et al. **FEBS Lett** 1996 Mar 18;382(3):249–55

Trehalose-6-phosphate synthase A affects citrate accumulation by Aspergillus niger under conditions of high glycolytic flux. Arisan-Atac I, et al. **FEMS Microbiol Lett** 1996 Jun 15;140(1):77–83

Phytase from Aspergillus niger. Volfová O, et al. **Folia Microbiol (Praha)** 1994;39(6):481–4

Preliminary characterization of a new exo-beta-(1,4)-galactanase with transferase activity. Bonnin E, et al. **Int J Biol Macromol** 1995 Dec;17(6):345–51

Production of feruloyl/rho-coumaroyl esterase activity by Penicillium expansum, Penicillium brevicompactum and Aspergillus niger. Donaghy JA, et al. **J Appl Bacteriol** 1995 Dec;79(6):657–62

Differential scanning calorimetric studies on the domain structure of Aspergillus glucoamylase. Tanaka A, et al. **J Biochem (Tokyo)** 1995 May;117(5):1024–8

Inhibition of copper/quinoprotein amine oxidases from Aspergillus niger by benzophenanthridine alkaloids. Luhová L, et al. **J Enzym Inhib** 1995;9(4):295–302

Solution structure of the granular starch binding domain of glucoamylase from Aspergillus niger by nuclear magnetic resonance spectroscopy. Sorimachi K, et al. **J Mol Biol** 1996 Jun 28;259(5):970–87

Dietary Aspergillus niger phytase increases iron absorption in humans. Sandberg AS, et al. **J Nutr** 1996 Feb; 126(2):476–80

Utilization of water hyacinth cellulose for production of cellobiase-rich preparation by Aspergillus niger 1. Ismail AM, et al. **Microbios** 1995;83(336):191–8

Cloning and characterisation of genes (pkc1 and pkcA) encoding protein kinase C homologues from Trichoderma reesei and Aspergillus niger. Morawetz R, et al. **Mol Gen Genet** 1996 Jan 15;250(1):17–28

Regulation of acid phosphatases in an Aspergillus niger pacC disruption strain. van den Hombergh JP, et al. **Mol Gen Genet** 1996 Jul 19;251(5):542–50

Stable accumulation of Aspergillus niger phytase in transgenic tobacco leaves. Verwoerd TC, et al. **Plant Physiol** 1995 Dec;109(4):1199–205

Identification and elimination by site-directed mutagenesis of thermolabile aspartyl bonds in Aspergillus awamori glucoamylase. Chen HM, et al. **Protein Eng** 1995 Jun; 8(6):575–82

[Effect of a supplemental Aspergillus niger phytase on the utilization of plant phosphorus by rainbow trout (Oncorhynchus mykiss)] Rodehutscord M, et al. **Arch Tierernahr** 1995;48(1–2):211–9 (Eng. Abstr.) **(Ger)**

GENETICS

Identification and cloning of a mobile transposon from Aspergillus niger var. awamori. Amutan M, et al. **Curr Genet** 1996 Apr;29(5):468–73

New protease mutants in Aspergillus niger result in strongly reduced in vitro degradation of target proteins; genetical and biochemical characterization of seven complementation groups. van den Hombergh JP, et al. **Curr Genet** 1995 Sep;28(4):299–308

Cloning and characterization of three Aspergillus niger promoters. Luo X. **Gene** 1995 Sep 22;163(1):127–31

The Aspergillus niger (ficuum) aphA gene encodes a pH 6.0-optimum acid phosphatase. Mullaney EJ, et al. **Gene** 1995 Aug 30;162(1):117–21

Nucleotide sequence of the Aspergillus niger srpA gene. Thompson SA, et al. **Gene** 1995 Dec 29;167(1–2):337–8

The isolation of Ant1, a transposable element from Aspergillus niger. Glayzer DC, et al. **Mol Gen Genet** 1995 Dec 10;249(4):432–8

Identification, cloning and analysis of the Aspergillus niger gene pacC, a wide domain regulatory gene responsive to ambient pH. MacCabe AP, et al. **Mol Gen Genet** 1996 Feb 25;250(3):367–74

GROWTH & DEVELOPMENT

Fungal growth within a silicone tissue expander: case report. Coady MS, et al. **Br J Plast Surg** 1995 Sep;48(6):428–30

Lysis and biological control of Aspergillus niger by Bacillus subtilis AF 1. Podile AR, et al. **Can J Microbiol** 1996 Jun; 42(6):533–8

ISOLATION & PURIFICATION

Kitchens as a source of Aspergillus niger infection. Loudon KW, et al. **J Hosp Infect** 1996 Mar;32(3):191–8

METABOLISM

Organic acid production by Aspergillus niger in recycling culture analyzed by capillary electrophoresis. Schrickx JM, et al. **Anal Biochem** 1995 Oct 10;231(1):175–81

Lysis and biological control of Aspergillus niger by Bacillus subtilis AF 1. Podile AR, et al. **Can J Microbiol** 1996 Jun; 42(6):533–8

Polyol pools in Aspergillus niger. Witteveen CF, et al. **FEMS Microbiol Lett** 1995 Dec 1;134(1):57–62

Effect of fermentation conditions on the production of citric acid from cheese whey by Aspergillus niger. el-Samragy YA, et al. **Int J Food Microbiol** 1996 Apr;29(2-3):411–6

PHYSIOLOGY

Expression pattern of aspartic proteinase antigens in aspergilli. Reichard U, et al. **Mycoses** 1996 Mar-Apr; 39(3-4):99–101

ASPERGILLUS NUCLEASE S1

S1 mapping using single-stranded DNA probes. Viville S, et al. **Methods Mol Biol** 1996;58:147–53

CHEMISTRY

S1 nuclease: immunoaffinity purification and evidence for the proximity of cysteine 25 to the substrate binding site. Gite S, et al. **J Mol Recognit** 1995 Sep-Oct;8(5):281–9

DIAGNOSTIC USE

S1 nuclease protection assay using streptavidin dynabeads-purified single-stranded DNA. Cammas FM, et al. **Anal Biochem** 1996 Apr 5;236(1):182–4

GENETICS

The roles of CRE, TRE, and TRE-adjacent S1 nuclease sensitive element in the regulation of tyrosine hydroxylase gene promoter activity by angiotensin II. Kim EL, et al. **J Neurochem** 1996 Jul;67(1):26–36

ISOLATION & PURIFICATION

S1 nuclease: immunoaffinity purification and evidence for the proximity of cysteine 25 to the substrate binding site. Gite S, et al. **J Mol Recognit** 1995 Sep-Oct;8(5):281–9

METABOLISM

Induction of double-strand breaks by S1 nuclease, mung bean nuclease and nuclease P1 in DNA containing abasic sites and nicks. Chaudhry MA, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):3805–9

Hairpin opening by single-strand-specific nucleases. Kabotyanski EB, et al. **Nucleic Acids Res** 1995 Oct 11; 23(19):3872–81

Linker histones affect patterns of digestion of supercoiled plasmids by single-strand-specific nucleases. Ivanchenko M, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6970–4

PHARMACOLOGY

An S1 nuclease mapping method for detection of low abundance transcripts. Flouriot G, et al. **Anal Biochem** 1996 May 15;237(1):159–61

ASPERGILLUS OCHRACEUS

METABOLISM

Metabolites of ochratoxins in rat urine and in a culture of Aspergillus ochraceus. Xiao H, et al. **Appl Environ Microbiol** 1996 Feb;62(2):648–55

ASPERGILLUS ORYZAE

ENZYMOLOGY

Molecular cloning and sequence analysis of a gene encoding an aspartic proteinase from Aspergillus oryzae. Takeuchi M, et al. **Adv Exp Med Biol** 1995;362:577–80

Identification of the active-site peptide of 2,3-dihydroxybenzoic acid decarboxylase from Aspergillus oryzae. Santha R, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):191–200

Glycosidase-catalysed oligosaccharide synthesis: preparation of N-acetylchitooligosaccharides using the beta-N-acetylhexosaminidase of Aspergillus oryzae. Singh S, et al. **Carbohydr Res** 1995 Dec 27;279:293–305

Enzymatic synthesis of 2-acetamido-4-O-(2-acetamido-2-deoxy-beta-D-galactopyranosyl)-2-deoxy-D-glucopyranose and 2-acetamido-6-O-(2-acetamido-2-deoxy-beta-D-galactopyranosyl)-2-deoxy-D-glucopyranose catalysed by the beta-N-acetylhexosaminidase from Aspergillus oryzae. Singh S, et al. **Carbohydr Res** 1995 Dec 27;279:321–5

Safety evaluation of a lipase expressed in Aspergillus oryzae. Greenough RJ, et al. **Food Chem Toxicol** 1996 Feb; 34(2):161–6

Induction and repression of alpha-amylase production in batch and continuous cultures of Aspergillus oryzae. Mørkeberg R, et al. **Microbiology** 1995 Oct;141 (Pt 10):2449–54

GENETICS

Gene transfer by electroporation of filamentous fungi. Kapoor M. **Methods Mol Biol** 1995;47:279–89

PHYSIOLOGY

Effects of Saccharomyces cerevisiae and Aspergillus oryzae cultures on ruminal fermentation in dairy cows. Yoon IK, et al. **J Dairy Sci** 1996 Mar;79(3):411–7

The effect of Saccharomyces cerevisiae and Aspergillus oryzae on fermentations in the rumen of faunated and defaunated sheep; protozoal and probiotic interactions. Mathieu F, et al. **Reprod Nutr Dev** 1996;36(3):271–87

ASPHYXIA

Free-flow waterbeds are potentially deadly to infants [letter; comment] Bass M. **Med J Aust** 1995 Sep 18;163(6):335–6 . Comment on: Med J Aust 1995 Apr 3;162(7):391–2.

Degrees of violence and blood spattering associated with manual and ligature strangulation: a retrospective study. Cartwright AJ. **Med Sci Law** 1995 Oct;35(4):294–302

Dangerous atmospheres: IH concerns in confined spaces. Johnson LF. **Occup Health Saf** 1996 May;65(5):43–4, 47

BLOOD

The hemodynamic and arterial blood gas response to asphyxiation: a canine model of pulseless electrical activity. DeBehnke DJ, et al. **Resuscitation** 1995 Oct;30(2):169–75

CHEMICALLY INDUCED

On an accident by liquid nitrogen--histological changes of skin in cold. Tabata N, et al. **Forensic Sci Int** 1995 Nov 30;76(1):61–7

Death due to asphyxia linked to antipsychotic drugs. Jitsufuchi N, et al. **Nippon Hoigaku Zasshi** 1995 Aug; 49(4):255–9

COMPLICATIONS

End-tidal carbon dioxide changes during cardiopulmonary resuscitation after experimental asphyxial cardiac arrest. Bhende MS, et al. **Am J Emerg Med** 1996 Jul;14(4):349–50

Bilateral opercular syndrome: an unusual complication of perinatal difficulties. Koeda T, et al. **Brain Dev** 1995 May-Jun;17(3):193–5

Outcome model of asphyxial cardiac arrest in rats. Katz L, et al. **J Cereb Blood Flow Metab** 1995 Nov;15(6):1032–9

Focal peliosis hepatis, a sequela of asphyxial death? Selby DM, et al. **Pediatr Pathol Lab Med** 1995 Jul-Aug; 15(4):589–96

On-site triage of avalanche victims with asystole by the emergency doctor. Brugger H, et al. **Resuscitation** 1996 Feb;31(1):11–6

CONGENITAL see ASPHYXIA NEONATORUM

DIAGNOSIS

Re: Auto-erotic asphyxial death [letter; comment] Cooper AJ. **Can J Psychiatry** 1995 Aug;40(6):363–4. Comment on: Can J Psychiatry 1994 Apr;39(3):157–60.

ENZYMOLOGY

The effect of post-asphyxial reoxygenation with 21% vs. 100% oxygen on Na+,K(+)-ATPase activity in striatum of newborn piglets. Goplerud JM, et al. **Brain Res** 1995 Oct 23;696(1-2):161–4

EPIDEMIOLOGY

Epidemiology of Munchausen syndrome by proxy, non-accidental poisoning, and non-accidental suffocation. McClure RJ, et al. **Arch Dis Child** 1996 Jul;75(1):57–61

Review: autoerotic asphyxiation in the United States [retracted in J Forensic Sci 1995 Nov;40(6):932] Uva JL. **J Forensic Sci** 1995 Jul;40(4):574–81 (76 ref.)

Death by hanging in Western Australia. Cooke CT, et al. **Pathology** 1995 Jul;27(3):268–72

ETIOLOGY

A potential danger of bedclothes covering the face. Campbell AJ, et al. **Acta Paediatr** 1996 Mar;85(3):281–4

Plasma cell granuloma of the larynx as a cause of sudden asphyxial death. Fonseca CA, et al. **Am J Forensic Med Pathol** 1995 Sep;16(3):243–5

Suffocation from use of modified gas mask. Howard JD. **Am J Forensic Med Pathol** 1995 Jun;16(2):140–1

Agitated delirium versus positional asphyxia [letter;

comment] Karch SB, et al. **Ann Emerg Med** 1995 Dec; 26(6):760–1. Comment on: Ann Emerg Med 1995 May;25(5):710–2.

Two hours in the life of a government medical officer [see comments] Cave FM. **Aust Fam Physician** 1995 Sep; 24(9):1765. Comment in: Aust Fam Physician 1995 Nov;24(11):2146.

A case of death by physical restraint: new lessons from a photograph. Miles S. **J Am Geriatr Soc** 1996 Mar; 44(3):291–2

Accidental death or sudden infant death syndrome? Beal SM, et al. **J Paediatr Child Health** 1995 Aug;31(4):269–71

Auto-erotic asphyxiation: three case reports. Cooper AJ. **J Sex Marital Ther** 1996 Spring;22(1):47–53

Accidental infant death and stroller-prams. Byard RW, et al. **Med J Aust** 1996 Aug 5;165(3):140–1

[Asphyxia caused by flippos (letter)] Bataille MR. **Ned Tijdschr Geneeskd** 1996 Aug 17;140(33):1704 **(Dut)**

METABOLISM

The role of cerebral microvessels in the elimination of histamine released during postasphyxial reperfusion in newborn piglets. Kovács J, et al. **Neurosci Lett** 1995 Jul 28;195(1):25–8

MICROBIOLOGY

Aspergillary bronchopneumonia: an unusual cause of atelectasis and asphyxia in a leukemic patient. Velloso ED, et al. **Rev Paul Med** 1994 Oct-Dec;112(4):639–41

PATHOLOGY

Hanging in an automobile: a report on a unique case history. Durso S, et al. **Am J Forensic Med Pathol** 1995 Dec; 16(4):352–4

Immunohistochemical characterization of alveolar macrophages and pulmonary giant cells in fatal asphyxia. Grellner W, et al. **Forensic Sci Int** 1996 Jun 14;79(3):205–13

Autopsy cases among patients with mental disorders: an unusual case of asphyxia caused by the iron roller of a garbage truck. Hayase T, et al. **J Forensic Sci** 1995 Sep; 40(5):896–9

[The value of various lung changes in death by strangulation] Grellner W, et al. **Arch Kriminol** 1995 Jul-Aug; 196(1-2):38–45 (Eng. Abstr.) **(Ger)**

[Suicidal hanging or homicide? On the criminal significance of "professional knots"] Hausmann R, et al. **Arch Kriminol** 1995 Jul-Aug;196(1-2):12–7 (Eng. Abstr.) **(Ger)**

[Unusual findings in death by hanging—reconstruction of capacity for action] Ortmann C, et al. **Arch Kriminol** 1996 Mar-Apr;197(3-4):104–10 (Eng. Abstr.) **(Ger)**

[Homicide by strangulation with a lasso sling] Yamamoto K, et al. **Arch Kriminol** 1995 Jul-Aug;196(1-2):6–11 (Eng. Abstr.) **(Ger)**

[Forensic medical expertise in manual strangulations] Podporinova EE. **Sud Med Ekspert** 1996 Jan-Mar;39(1):6–9 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Suffocation and related problems. Suzuki T. **Forensic Sci Int** 1996 Jun 28;80(1-2):71–8 (12 ref.)

Effects of static lung inflation on sympathetic activity in human muscle nerves at rest and during asphyxia. Macefield VG, et al. **J Auton Nerv Syst** 1995 Jun 25; 53(2-3):148–56

Decreased respiratory tolerance from intermittent asphyxia in rat sucklings. Atakent YS, et al. **J Perinatol** 1995 Jul-Aug;15(4):310–3

Circulatory responses to acute asphyxia in intact and chemodenervated fetal sheep near term. Jensen A, et al. **Reprod Fertil Dev** 1995;7(5):1351–9

The hemodynamic and arterial blood gas response to asphyxiation: a canine model of pulseless electrical activity. DeBehnke DJ, et al. **Resuscitation** 1995 Oct;30(2):169–75

PSYCHOLOGY

Panic attacks: Klein's false suffocation alarm, Taylor and Rachman's data, and Ley's dyspneic-fear theory [letter; comment] Ley R. **Arch Gen Psychiatry** 1996 Jan;53(1):83–5 . Comment on: Arch Gen Psychiatry 1993 Apr;50(4):306–17.

Anxiety sensitivity, suffocation fear, and breath-holding duration as predictors of response to carbon dioxide challenge. McNally RJ, et al. **J Abnorm Psychol** 1996 Feb; 105(1):146–9

ASPHYXIA NEONATORUM

BLOOD

Nucleated red blood cells: a marker for fetal asphyxia? Phelan JP, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1380–4

Prolactin and growth hormone in perinatal asphyxia. Varvarigou A, et al. **Biol Neonate** 1996;69(2):76–83

Reduced iron-associated antioxidants in premature newborns suffering intracerebral hemorrhage. Lackmann GM, et al. **Free Radic Biol Med** 1996;20(3):407–9

Umbilical venous guanosine 3',5'-cyclic phosphate (cGMP) concentration increases in asphyxiated newborns. Itoh H, et al. **Reprod Fertil Dev** 1995;7(6):1515–9

[Analysis of mean differences for acid-base balance parameters in blood from umbilical arteries and veins of newborns with perinatal hypoxemia] Grudzińska M, et al. **Ginekol Pol** 1995 Apr;66(4):198–204 (Eng. Abstr.) **(Pol)**

CEREBROSPINAL FLUID

Creatine kinase isoenzyme BB concentrations in cerebrospinal fluid in asphyxiated preterm neonates. Talvik T, et al. **Acta Paediatr** 1995 Oct;84(10):1183–7

Monoamine neurotransmitters and metabolites in the cerebrospinal fluid following perinatal asphyxia. Blennow M, et al. **Biol Neonate** 1995;67(6):407–13

Concerning the paper of Blennow et al. Monoamine neurotransmitters and metabolites in the cerebrospinal fluid following perinatal asphyxia [letter] Bódis J, et al. **Biol Neonate** 1996;69(1):36

COMPLICATIONS

Early [18F]FDG positron emission tomography in infants with hypoxic-ischaemic encephalopathy shows hypermetabolism during the postasphyctic period. Blennow M, et al. **Acta Paediatr** 1995 Nov;84(11):1289–95

Profound asphyxia in the premature infant: imaging findings. Barkovich AJ, et al. **AJNR Am J Neuroradiol** 1995 Oct; 16(9):1837–46

Multiple nuchal cord entanglements and intrapartum complications. Larson JD, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1228–31

Of policies and palsies [letter; comment] Perkins RP. **Am J Obstet Gynecol** 1996 Feb;174(2):798–9. Comment on: Am J Obstet Gynecol 1995 Jun;172(6):1830–4; discussion 1834–6.

Long-term effect of perinatal and postnatal asphyxia on developing human auditory brainstem responses: brainstem impairment. Jiang ZD, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1-2):111–27

Long-term effect of perinatal and postnatal asphyxia on developing human auditory brainstem responses: peripheral hearing loss. Jiang ZD. **Int J Pediatr Otorhinolaryngol** 1995 Nov;33(3):225–38

Multiple organ involvement in perinatal asphyxia. Martín-Ancel A, et al. **J Pediatr** 1995 Nov;127(5):786–93

Nonoliguric and oliguric acute renal failure in asphyxiated term neonates. Karlowicz MG, et al. **Pediatr Nephrol** 1995 Dec;9(6):718–22

Early prediction of the development of microcephaly after hypoxic-ischemic encephalopathy in the full-term newborn [letter; comment] Badawi N, et al. **Pediatrics** 1996 Jan;97(1):151–2. Comment on: Pediatrics 1994 May;93(5):703–7.

Can asphyxiated infants at risk for neonatal seizures be rapidly identified by current high-risk markers? Perlman JM, et al. **Pediatrics** 1996 Apr;97(4):456–62

[Cerebral palsy and perinatal asphyxia in full term newborn infants] Bréart G, et al. **Arch Pediatr** 1996 Jan;3(1):70–4 (15 ref.) (Eng. Abstr.) **(Fre)**

[Perinatal risk factors and motor deficiency due to cerebral palsy] Rumeau-Rouquette C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):119–23 (24 ref.) (Eng. Abstr.) **(Fre)**

-Brain damage in infancy: mostly not intrapartum. On the etiology of mental and neurologic handicaps- Largo RH, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S71–80 (18 ref.) **(Ger)**

-Neonatal asphyxia as the cause of brain damage in children?- Schneider H. **Arch Gynecol Obstet** 1995;256 Suppl:S32–42 (75 ref.) (Eng. Abstr.) **(Ger)**

[Decision of the Pfalz superior court in Zweibrücken 16 May 1994, Az: 7 U 211/91 (LG Landau in Pfalz, 2 0 498/86)] Ehlers AP. **Z Geburtshilfe Neonatol** 1995 Nov-Dec; 199(6):262–4 **(Ger)**

[Prognostic indicators of neurological sequelae in perinatal asphyxia: state of the art] González de Dios J. **Rev Neurol** 1995 Mar-Apr;23(120):351–62 (194 ref.) **(Spa)**

[Perinatal asphyxia, hypoxic-ischemic encephalopathy and neurological sequelae in full-term newborns. II. Description and interrelation] González de Dios J, et al. **Rev Neurol** 1996 Aug;24(132):969–76 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Nucleated red blood cells: a marker for fetal asphyxia? Phelan JP, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1380–4

Understanding the Apgar score. Letko MD. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):299–303

Clinical, neurophysiologic, and neuropathological features of an infant with brain damage of total asphyxia type (Myers). Natsume J, et al. **Pediatr Neurol** 1995 Jul;13(1):61–4

[Contribution of electroencephalography to the diagnosis and prognosis of perinatal asphyxia in full-term neonates] d'Allest AM, et al. **Arch Pediatr** 1996;3 Suppl 1:254s–256s **(Fre)**

[Nuclear magnetic resonance spectroscopy: methodology and applications to the study of asphyxia neonatorum] Barantin L, et al. **Neurophysiol Clin** 1995;25(3):115–29 (56 ref.) (Eng. Abstr.) **(Fre)**

[Clinical results of pulse oximetry sub partu for measuring fetal arterial oxygen saturation] Butterwegge M, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):634–41 (Eng. Abstr.) **(Ger)**

[Intensive monitoring of the fetus sub partu—value and false interpretation] Saling E. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):628–33 (18 ref.) (Eng. Abstr.) **(Ger)**

[Erythropoietin as a biochemical parameter for fetal hypoxia] Fahnenstich H, et al. **Klin Padiatr** 1995 Nov-Dec; 207(6):326–30 (Eng. Abstr.) **(Ger)**

[Significance of intrapartum hypoxia for cerebral long-term morbidity] Schneider H. **Z Geburtshilfe Neonatol** 1996 Mar-Apr;200(2):43–9 (47 ref.) (Eng. Abstr.) **(Ger)**

[Perinatal asphyxia, hypoxic-ischemic encephalopathy and neurological sequelae in full-term newborns. II. Description and interrelation] González de Dios J, et al. **Rev Neurol** 1996 Aug;24(132):969–76 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Acute effects of two different doses of magnesium sulphate in infants with birth asphyxia. Levene M, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F174–7

EPIDEMIOLOGY

[Perinatal asphyxia, hypoxic-ischemic encephalopathy and neurological sequelae in full-term newborns: an epidemiological study (1)] Gónzalez de Dios J, et al. **Rev Neurol** 1996 Jul;24(131):812–9 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Asphyxiating thoracic dystrophy. Umakumaran P, et al. **Indian Pediatr** 1995 Mar;32(3):357–9

The predictive value of elevation in specific serum enzymes for subsequent development of hypoxic-ischemic encephalopathy or intraventricular hemorrhage in full-term and premature asphyxiated newborns. Lackmann GM, et al. **Neuropediatrics** 1995 Aug;26(4):192–8

-Perinatal asphyxia of the neonate at term- Fawer CL. **Arch Gynecol Obstet** 1995;256 Suppl:S61–70 (13 ref.) **(Fre)**

[Limits of assistant liability in delivery by an assisting physician in residency] Bebong B, et al. **Geburtshilfe Frauenheilkd** 1995 Aug;55(8):M90–1 **(Ger)**

[Incidence of fetal macrosomia: maternal and fetal morbidity] Rodríguez-Rojas RR, et al. **Ginecol Obstet Mex** 1996 Jun; 64:247–50 (Eng. Abstr.) **(Spa)**

[Pulmonary hypoplasia of the newborn infant in a pregnancy complicated with ovular premature rupture and oligohydramnios] Aspillaga C, et al. **Rev Chil Obstet Ginecol** 1995;60(2):131–4 (Eng. Abstr.) **(Spa)**

METABOLISM

Nicotine treatment counteracts perinatal asphyxia-induced changes in the mesostriatal/limbic dopamine systems and in motor behaviour in the four-week-old male rat. Chen Y, et al. **Neuroscience** 1995 Sep;68(2):531–8

Cerebral metabolism within 18 hours of birth asphyxia: a proton magnetic resonance spectroscopy study. Hanrahan JD, et al. **Pediatr Res** 1996 Apr;39(4 Pt 1):584–90

The effect of asphyxia on the pharmacokinetics of ceftazidime in the term newborn. Van Den Anker JN, et al. **Pediatr Res** 1995 Nov;38(5):808–11

[Findings in cerebral proton spin resonance spectroscopy in newborn infants with asphyxia, and psychomotor development] Groenendaal F, et al. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):255–9 (Eng. Abstr.) **(Dut)**

[Exploration of brain metabolism and hemodynamics in perinatal asphyxia in full-term neonates] Saliba E, et al. **Arch Pediatr** 1996;3 Suppl 1:248s–250s (9 ref.) **(Fre)**

MORTALITY

Birth asphyxia: incidence, clinical course and outcome in a Swedish population. Thornberg E, et al. **Acta Paediatr** 1995 Aug;84(8):927–32

PATHOLOGY

Neuronal death after perinatal asphyxia. de Haan HH, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):123–7 (46 ref.)

Differential involvement of the brain in neonatal asphyxia: a pathogenic explanation. Sheth RD, et al. **J Child Neurol** 1995 Nov;10(6):464–6

PHYSIOPATHOLOGY

Cerebral and ventilatory depression during hypoxia in anaesthetized newborn guinea-pigs. Yuan SZ, et al. **Acta Paediatr** 1995 Dec;84(12):1409–13

Local vascular CO2 reactivity in the infant brain assessed by functional MRI. Toft PB, et al. **Pediatr Radiol** 1995; 25(6):420–4

[Pathophysiology of perinatal asphyxia and brain damage (see comments)] de Haan HH. **Ned Tijdschr Geneeskd** 1995 Aug 19;139(33):1673–6. Comment in: Ned Tijdschr Geneeskd 1995 Nov 18;139(46):2391–2. **(Dut)**

[Pathophysiology of perinatal asphyxia and brain damage (letter; comment)] Groenendaal F. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2391–2. Comment on: Ned Tijdschr Geneeskd 1995 Aug 19;139(33):1673–6. **(Dut)**

[Exploration of brain metabolism and hemodynamics in perinatal asphyxia in full-term neonates] Saliba E, et al. **Arch Pediatr** 1996;3 Suppl 1:248s–250s (9 ref.) **(Fre)**

[Variations in renal hemodynamics during acute renal insufficiency in anoxic neonates] Proverbio MR, et al. **Pediatr Med Chir** 1996 Jan–Feb;18(1):33–5 (Eng. Abstr.) **(Ita)**

[Perinatal brain injury in infants with depressed EEG activities immediately after birth] Hayakawa F, et al. **No To Hattatsu** 1996 Jan;28(1):48–52 (Eng. Abstr.) **(Jpn)**

[Perinatal asphyxia, hypoxic–ischemic encephalopathy and neurological sequelae in full–term newborns: an epidemiological study (1)] Gónzalez de Dios J, et al. **Rev Neurol** 1996 Jul;24(131):812–9 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

[Progresses in pediatrics in China, 1995] Hu Y. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):751–2 (0 ref.) **(Chi)**

THERAPY

[First aid and resuscitation of newborn infants—techniques, indications and risks] Ritzerfeld S, et al. **Z Geburtshilfe Neonatol** 1995 Sep–Oct;199(5):199–202 **(Ger)**

ULTRASONOGRAPHY

[Subpartal diagnosis of umbilical cord encirclement using color–coded Doppler ultrasonography and correlation with cardiotocographic changes during labor] Funk A, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):623–7 (Eng. Abstr.) **(Ger)**

[Variations in cerebral blood flow in various states of severe neonatal hypoxic–ischemic encephalopathy] González de Dios J, et al. **Rev Neurol** 1995 May–Jun;23(121):639–43 (Eng. Abstr.) **(Spa)**

URINE

Neonatal urinary uric acid/creatinine [correction of ceratinine] ratio as an additional marker of perinatal asphyxia. Bader D, et al. **Eur J Pediatr** 1995 Sep; 154(9):747–9

ASPICULARIASIS see **OXYURIASIS**

ASPIDIUM see **PLANTS, MEDICINAL**

ASPIRATION

Recognition and management of hot liquid aspiration in children. Sheridan RL. **Ann Emerg Med** 1996 Jan; 27(1):89–91

Gastroesophageal reflux–induced bronchoconstriction. Is microaspiration a factor? [see comments] Harding SM, et al. **Chest** 1995 Nov;108(5):1220–7. Comment in: Chest 1995 Nov;108(5):1186–7. Comment in: Chest 1995 Nov;108(5):1187–8.

Straight pin aspiration in young women. Shabb B, et al. **J Trauma** 1996 May;40(5):827–8

Turban pin aspiration syndrome: a new form of foreign body aspiration. Uçan ES, et al. **Respir Med** 1996 Aug; 90(7):427–8

[Milk microaspiration as a cause of recurrent bronchial obstruction in infants] Chiappero M, et al. **Allergol Immunopathol (Madr)** 1995 Sep–Oct;23(5):207–10 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Effects of non–REM sleep on the response of respiratory output to varying inspiratory flow. Georgopoulos D, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1624–30

Circle systems with a coaxial inspiratory limb. Investigation with a lung model. Cook LB, et al. **Anaesthesia** 1996 Mar; 51(3):247–54

Respiration of amniotic fluid in near–term foetal rabbit. Haddad B, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):247–50

Scintigraphic quantification of aspiration reduction with the Passy–Muir valve. Stachler RJ, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):231–4

Relief of distress of breathholding: separate effects of expiration and inspiration. Flume PA, et al. **Respir Physiol** 1995 Jul;101(1):41–6

ASPIRATION BIOPSY see **BIOPSY, NEEDLE**

ASPIRATION LIPECTOMY see **LIPECTOMY**

ASPIRATION, MECHANICAL see **SUCTION**

ASPIRATION, MECONIUM see **MECONIUM ASPIRATION**

ASPIRATION OF GASTRIC CONTENTS see **PNEUMONIA, ASPIRATION**

ASPIRATION PNEUMONIA see **PNEUMONIA, ASPIRATION**

ASPIRATIONS (PSYCHOLOGY)

Ethnicity, family achievement syndrome, and adolescents' aspirations: Rosen's framework revisited. Marjoribanks K. **J Genet Psychol** 1996 Sep;157(3):349–59

Effects of failure on subsequent performance: the importance of self–defining goals. Brunstein JC, et al. **J Pers Soc Psychol** 1996 Feb;70(2):395–407

Identity in three cohorts of midlife women. Helson R, et al. **J Pers Soc Psychol** 1995 Sep;69(3):544–57

Personal goals of young social drop–outs. Salmela–Aro K, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1184–6

Birth order, family environment, and young adults' occupational aspirations. Marjoribanks K. **Psychol Rep** 1995 Oct;77(2):626–8

ASPIRIN

Calculation of van't Hoff enthalpy associated with aspirin–induced change in liposomal membrane anisotropy. De S, et al. **Phys Med Biol** 1996 Mar;41(3):383–6

ADMINISTRATION & DOSAGE

Patterns of aspirin use in middle–aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Shahar E, et al. **Am Heart J** 1996 May;131(5):915–22 (37 ref.)

Effects of low–dose aspirin therapy on plasma levels of polyunsaturated fatty acids: a preliminary investigation. McCoy MC, et al. **Am J Perinatol** 1995 Sep;12(5):371–4

Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self–report and microelectronic monitoring. Burney KD, et al. **Arch Fam Med** 1996 May;5(5):297–300

Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Eisenberg MJ, et al. **Arch Intern Med** 1996 Jul 22;156(14):1506–10 (34 ref.)

Diagnosis and management of migraine. Low dose aspirin may be used for prophylaxis [letter] Nelson–Piercy C, et al. **BMJ** 1996 Sep 14;313(7058):691–2

ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré–eclampsia com Aspirina) Collaborative Group [see comments] **Br J Obstet Gynaecol** 1996 Jan; 103(1):39–47. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):719–20.

ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women [letter; comment] Goffinet F, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):719–20. Comment on: Br J Obstet Gynaecol 1996 Jan;103(1):39–47.

Aspirin and other nonsteroidal anti–inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Martínez ME, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov; 4(7):703–7

Aspirin and other platelet–active drugs. The relationship among dose, effectiveness, and side effects. Hirsh J, et al. **Chest** 1995 Oct;108(4 Suppl):247S–257S (148 ref.)

The effect of low dose aspirin on the platelet function in patients with acute myocardial infarction (AMI). Jin L, et al. **Chin Med J (Engl)** 1995 Oct;108(10):783

A prospective randomized placebo–controlled trial of low–dose aspirin for prevention of intra–uterine growth retardation. Wang Z, et al. **Chin Med J (Engl)** 1996 Mar; 109(3):238–42

Second European Stroke Prevention Study [news] Ferguson JJ. **Circulation** 1996 Feb 1;93(3):399

The protective dose of the potent GPIIb/IIIa antagonist SC–54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. Frederick LG, et al. **Circulation** 1996 Jan 1; 93(1):129–34

Low–molecular–weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Gent M, et al. **Circulation** 1996 Jan 1;93(1):80–4

Randomized comparison of aspirin and phenprocoumon for prevention of right–sided thromboembolic complications associated with transvenous defibrillation leads. Jung W, et al. **Eur Heart J** 1995 Jul;16(7):986–92

Antiphospholipid antibodies, low–dose aspirin and pregnancy losses [letter] Balasch J, et al. **Hum Reprod** 1996 May; 11(5):1140–1

Low–dose aspirin and recurrent miscarriage [letter] Christiansen OB. **Hum Reprod** 1995 Nov;10(11):3077–9

Dose of prophylactic aspirin in IHD and body weight [letter] Kumar H. **J Assoc Physicians India** 1995 Aug;43(8):586

Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase. McAdam B, et al. **J Pharmacol Exp Ther** 1996 May;277(2):559–64

Adjusted–dose warfarin versus low–intensity, fixed–dose warfarin plus aspirin for high–risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. **Lancet** 1996 Sep 7; 348(9028):633–8

Aspirin and the risk of colorectal cancer in women [letter; comment] Morgan G. **N Engl J Med** 1996 Jan 11; 334(2):119–20; discussion 121. Comment on: N Engl J Med 1995 Sep 7;333(10):609–14. Comment on: N Engl J Med 1995 Sep 7;333(10):656–8.

Optimal oral anticoagulation for patients with mechanical heart valves [letter; comment] von Schacky C. **N Engl J Med** 1995 Nov 30;333(22):1504–5. Comment on: N Engl J Med 1995 Jul 6;333(1):11–7.

Topical acetylsalicylic, salicylic acid and indomethacin suppress pain from experimental tissue acidosis in human skin. Steen KH, et al. **Pain** 1995 Sep;62(3):339–47

Low–dose aspirin does not attenuate platelet aggregation or atherosclerosis in miniature swine but decreases production of aortic wall prostacyclin. Smith MJ, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):331–40

Success of audit in reducing the time taken to administer thrombolysis and aspirin in patients with acute myocardial infarction. Currie P, et al. **Scott Med J** 1994 Aug; 39(4):120–2

[Acetylsalicylic acid matrices for use in stomatology] Rabišková M. **Ceska Slov Farm** 1996 May;45(3):123–4 (Eng. Abstr.) **(Cze)**

[Acetylsalicylic acid in acute and postherpetic neuralgia should no be dissolved in chloroform] van Horssen N. **Ned Tijdschr Geneeskd** 1995 Aug 12;139(32):1657 **(Dut)**

[What dose of aspirin should be prescribed in patients with coronary disease?] Montalescot G, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):469–72 (Eng. Abstr.) **(Fre)**

[The prophylactic taking of low doses of acetylsalicylic acid and the risk of ulcer hemorrhage] **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1759 **(Ger)**

[Acetylsalicylic acid as free radical scavenger. An argument for increased dosages in acute and preventive therapy of vascular diseases] Kuhn W, et al. **Fortschr Med** 1995 Nov 30;113(33):483–4 **(Ger)**

–Is prevention of pre–eclampsia with low dosage aspirin possible? Critical assessment of available studies– Lippert TH, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):88–92 (23 ref.) (Eng. Abstr.) **(Ger)**

[Comments on the contribution by B. Noll. Aspirin and heparin in acute myocardial infarct (letter)] Möckel M, et al. **Internist (Berl)** 1995 Nov;36(11):1101–4 **(Ger)**

[High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia] Hartmann A. **Nervenarzt** 1995 Dec;66(12):886–9; discussion 885 (18 ref.) (Eng. Abstr.) **(Ger)**

[Aspirin dosage for prevention of cerebral infarct: arguments for low dosage] Hennerici MG, et al. **Nervenarzt** 1995 Dec; 66(12):890–4; discussion 885 (38 ref.) (Eng. Abstr.) **(Ger)**

[Administration of acetylsalicylic acid and risk of colorectal adenoma and carcinoma] Möhler M, et al. **Z Gastroenterol** 1995 Aug;33(8):470–1 **(Ger)**

[Response to the letter by K. Schrör on: Prevention of reinfarction with 100 mg or 30 mg ASS daily (letter; comment)] Förster W. **Z Kardiol** 1995 Dec;84(12):1043. Comment on: Z Kardiol 1995 Jun;84(6):496–8. **(Ger)**

[Response to the editorial by J. C. Frölich: Aspirin—yes, but 30 mg?? (letter; comment)] Förster W. **Z Kardiol** 1995 Dec;84(12):1044–5. Comment on: Z Kardiol 1995 May;84(5):344–7. **(Ger)**

[Response to the letter by W. Förster on: prevention of reinfarction with 100 mg or 30 mg aspirin daily (letter)] Schrör K. **Z Kardiol** 1996 May;85(5):357 **(Ger)**

[The effect of subgingival irrigation with acetylsalicylate on the polymorphonuclear leukocyte count in periodontal pockets of medium depth] Paolantonio M, et al. **Minerva Stomatol** 1995 Jun;44(6):265–71 (Eng. Abstr.) **(Ita)**

[Significance of combined use of anticoagulants and antiplatelet agents in the early stage after prosthetic valve replacement] Toyohira H, et al. **Kyobu Geka** 1995 Aug; 48(9):749–55 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Drug–related segmental colitis: angiographic findings. Morin B, et al. **Abdom Imaging** 1995 Nov–Dec;20(6):529–30

Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population–based case–control study. Steineck G, et al. **Acta Oncol** 1995; 34(6):741–8

Phenomenology, pathogenesis, diagnosis and treatment of aspirin–sensitive rhinosinusitis. Schapowal AG, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):235–50 (0 ref.)

Tolerability of imidazole salycilate in aspirin–sensitive patients. Senna GE, et al. **Allergy Proc** 1995 Sep–Oct; 16(5):251–4

Analgesic nephropathy. Proceedings of a symposium. June 1995. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S1–70

Does aspirin cause acute or chronic renal failure in experimental animals and in humans? D'Agati V. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S24–9 (34 ref.)

Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti–inflammatory agents. Matzke GR. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S63–70 (38 ref.)

Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease [see comments] Greenberg PD, et al. **Am J Med** 1996 Jun; 100(6):598–604. Comment in: Am J Med 1996 Jun;100(6):596–7.

Aspirin use and fecal occult blood testing [editorial; comment] Marks RD. **Am J Med** 1996 Jun;100(6):596–7. Comment on: Am J Med 1996 Jun;100(6):598–604.

Inflammatory cell populations in bronchial biopsies from aspirin–sensitive asthmatic subjects. Nasser SM, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):90–6

Inhaled PGE2 prevents aspirin–induced bronchoconstriction

and urinary LTE4 excretion in aspirin-sensitive asthma. Sestini P, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):572-5

Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Szczeklik A, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):567-71

Autoimmune phenomena in bronchial asthma with special reference to aspirin intolerance. Szczeklik A, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1753-6

Spinal haematoma and central neural blockade [letter] Knowles P, et al. **Anaesthesia** 1996 Aug;51(8):803

Complications of cutaneous surgery in patients who are taking warfarin, aspirin, or nonsteroidal anti-inflammatory drugs. Otley CC, et al. **Arch Dermatol** 1996 Feb; 132(2):161-6

The changing clinical pattern of Reye's syndrome 1982-1990. Hardie RM, et al. **Arch Dis Child** 1996 May;74(5):400-5

Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. **Arch Intern Med** 1996 Feb 26;156(4):409-16

Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapy. Blackshear JL, et al. **Arch Intern Med** 1996 Mar 25;156(6):658-60

Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Beving H, et al. **Blood Coagul Fibrinolysis** 1996 Jan;7(1):80-4

Is aspirin safe for patients with heart failure? Cleland JG, et al. **Br Heart J** 1995 Sep;74(3):215-9 (53 ref.)

Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. **Br J Obstet Gynaecol** 1995 Nov;102(11):861-8

A comparison of intravenous and inhalational maintenance anaesthesia for endoscopic procedures in the aspirin intolerance syndrome. Novak-Jankovič V, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):345-9

Aspirin increases tissue oedema after skeletal muscle ischaemia and reperfusion. Braithwaite BD, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):76-80

Increased gastroduodenal concentrations of transforming growth factor alpha in adaptation to aspirin in monkeys and rats. Romano M, et al. **Gastroenterology** 1996 May; 110(5):1448-55

Effect of allopurinol, sulphasalazine, and vitamin C on aspirin induced gastroduodenal injury in human volunteers. McAlindon ME, et al. **Gut** 1996 Apr;38(4):518-24

Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial. Slattery J, et al. **Gut** 1995 Oct;37(4):509-11

Release of sulfidoleukotrienes in vitro: its relevance in the diagnosis of pseudoallergy to acetylsalicylic acid. Czech W, et al. **Inflamm Res** 1995 Jul;44(7):291-5

Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. Bar Dayan Y, et al. **Isr J Med Sci** 1996 May;32(5):288-91

Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. O'Sullivan S, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):421-32

Aspirin or acetaminophen? A comparison from data collected by the Spanish Drug Monitoring System. Carvajal A, et al. **J Clin Epidemiol** 1996 Feb;49(2):255-61

Reversible prolonged skin bleeding time in acute gastrointestinal bleeding presumed due to NSAIDs. Day JP, et al. **J Clin Gastroenterol** 1996 Mar;22(2):96-103

Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis. Stalnikowicz-Darvasi R. **J Clin Gastroenterol** 1995 Jul;21(1):13-6 (20 ref.)

Correlation between transmucosal potential difference and morphological damage during aspirin injury of gastric mucosa in rats. Cook GA, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):264-9

The value of C1 esterase inhibitor in patients with aspirin-sensitive urticaria. Grzelewska-Rzymowska I, et al. **J Investig Allergol Clin Immunol** 1995 Sep-Oct; 5(5):272-5

Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. Matsubara T, et al. **J Pediatr** 1996 May;128(5 Pt 1):701-3

Aspirin for frail elderly stroke patients? [letter] McGonigal G. **J R Coll Physicians Lond** 1996 Mar-Apr;30(2):187

Hemostatic function of aspirin-treated platelets vulnerable to cardiopulmonary bypass. Altered shear-induced pathway. Tabuchi N, et al. **J Thorac Cardiovasc Surg** 1995 Sep;110(3):813-8

Aspirin and the risk of colorectal cancer in women [letter; comment] Kaufmann HJ. **N Engl J Med** 1996 Jan 11; 334(2):120; discussion 121-2. Comment on: N Engl J Med 1995 Sep 7;333(10):656-8.

Aspirin, salicylate and gastrointestinal injury [letter; comment] Fernández AG, et al. **Nat Med** 1995 Jul; 1(7):602-3. Comment on: Nat Med 1995 Feb;1(2):154-8.

Menthol and aspirin-induced asthma [letter] Kawane H. **Respir Med** 1996 Apr;90(4):247-9

Aspirin, a silent risk factor in urology. Zhu JP, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):369-74 (64 ref.)

Reye's syndrome and the use of aspirin. Smith TC. **Scott Med J** 1996 Feb;41(1):4-9

Is there a link between acute spinal epidural hematoma and aspirin? Heye N. **Spine** 1995 Sep 1;20(17):1931-2

Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts [editorial; comment] Barnett HJ, et al. **Stroke** 1996 Apr;27(4):588-92 (60 ref.). Comment on: Stroke 1996 Apr;27(4):756-60.

Platelet disorders in uraemia before and after haemodialysis under the influence of low dose aspirin. Tschugguel W, et al. **Thromb Res** 1995 Nov 1;80(3):225-33

[Acute pancreatitis--induced by 5-aminosalicylic acid or an extraintestinal manifestation of ulcerative colitis?] Petersen HH, et al. **Ugeskr Laeger** 1995 Sep 25;157(39):5400-1 (Eng. Abstr.) **(Dan)**

[Importance of the leukotriene C4 liberation test for the diagnosis of drug allergy (preliminary results)] Sainte-Laudy J, et al. **Allerg Immunol (Paris)** 1996 Feb; 28(2):44-7 (Eng. Abstr.) **(Fre)**

[Rectal stenosis following prolonged use of suppositories of acetylsalicylic acid and paracetamol. Correction by perineal approach (letter)] Catheline JM, et al. **Ann Chir** 1995;49(6):551 **(Fre)**

[Acetylsalicylic acid as an augmentation factor in food allergy] Möller R, et al. **Hautarzt** 1996 Apr;47(4):281-3 (Eng. Abstr.) **(Ger)**

[Nonsteroidal antirheumatic drugs and acetylsalicylic acid: adverse effects distal to the duodenum] Gut A, et al. **Schweiz Med Wochenschr** 1996 Apr 13;126(15):616-25 (95 ref.) (Eng. Abstr.) **(Ger)**

[An adult case of rice-induced asthma with aspirin idiosyncrasy] Owan I, et al. **Arerugi** 1995 Jul;44(7):708-10 **(Jpn)**

[Serum phospholipase A2 activity in patients with aspirin-induced asthma] Toyoshima M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):691-4 (Eng. Abstr.) **(Jpn)**

[Aspirin-induced asthma] Sakakibara H. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):227-33 (5 ref.) **(Jpn)**

[Sensitivity to acetylsalicylic acid] Elverland HH. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):754-6 (22 ref.) (Eng. Abstr.) **(Nor)**

[The influence of misoprostol on post-aspirin bronchoconstriction in patients with aspirin sensitive asthma] Szmidt M, et al. **Pneumonol Alergol Pol** 1995; 63(9-10):544-52 (Eng. Abstr.) **(Pol)**

ANALOGS & DERIVATIVES

2-bromoacetoxybenzoic acid, a brominated aspirin analog. Loll PJ, et al. **Acta Crystallogr C** 1996 Feb 15;52 (Pt 2):375-7

Inhaled lysine acetylsalicylate (L-ASA) attenuates histamine-induced bronchoconstriction in asthma. Crimi N, et al. **Allergy** 1996 Mar;51(3):157-63

Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. Swan SK, et al. **Am J Kidney Dis** 1995 Dec;26(6):918-23

Role of NO mechanism in cardiovascular effects of diaspirin cross-linked hemoglobin in anesthetized rats. Sharma AC, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1379-88

Effect of oncotic pressure of diaspirin cross-linked hemoglobin (DCLHb) on brain injury after temporary focal cerebral ischemia in rats. Cole DJ, et al. **Anesth Analg** 1996 Aug;83(2):342-7

Diaspirin cross-linked hemoglobin does not increase brain oxygen consumption during hypothermic cardiopulmonary bypass in rabbits. Hindman BJ, et al. **Anesthesiology** 1995 Dec;83(6):1302-11

Diaspirin crosslinked hemoglobin (DCLHb) attenuates bacterial translocation in rats. Schultz SC, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(6):647-64

Metabolic fate of the new antithrombotic agent aspalatone in rats. In vivo and in vitro study. Suh DY, et al. **Arzneimittelforschung** 1995 Oct;45(10):1071-4

Role of endothelin in the cardiovascular effects of diaspirin crosslinked and stroma reduced hemoglobin. Gulati A, et al. **Crit Care Med** 1996 Jan;24(1):137-47

Anti-nociception induced by systemic or PAG-microinjected lysine-acetylsalicylate in rats. Effects on tail-flick related activity of medullary off- and on-cells. Tortorici V, et al. **Eur J Neurosci** 1995 Sep 1;7(9):1857-65

Inhaled lysine acetylsalicylate (L-ASA) attenuates the bronchoconstrictor response to adenosine 5'-monophosphate (AMP) in asthmatic subjects. Crimi N, et al. **Eur Respir J** 1995 Jun;8(6):905-12

Comparison of effects of calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers. Murray FE, et al. **Gut** 1996 Jan;38(1):11-4

Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. Wallace JL, et al. **J Clin Invest** 1995 Dec;96(6):2711-8

Role of endothelin-converting enzyme in the systemic hemodynamics and regional circulatory effects of proendothelin-1 (1-38) and diaspirin cross-linked hemoglobin in rats. Gulati A, et al. **J Lab Clin Med** 1995 Dec;126(6):559-70

Diaspirin cross-linked hemoglobin is efficacious in gut resuscitation as measured by a GI tract optode. Frankel HL, et al. **J Trauma** 1996 Feb;40(2):231-40; discussion 241

Early resuscitation with low-volume PolyDCLHb is effective in the treatment of shock induced by penetrating vascular injury. Leppäniemi A, et al. **J Trauma** 1996 Feb; 40(2):242-8

The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Tfelt-Hansen P, et al. **Lancet** 1995 Oct 7; 346(8980):923-6

Effect of diaspirin crosslinked and stroma-reduced hemoglobin on mean arterial pressure and endothelin-1 concentration in rats. Gulati A, et al. **Life Sci** 1995 Mar 17;56(17):1433-42

Closing in on a stomach-sparing aspirin substitute [news] Service RF. **Science** 1996 Sep 20;273(5282):1660

The effects of diaspirin cross-linked hemoglobin in sepsis. Mourelatos MG, et al. **Shock** 1996 Feb;5(2):141-8

Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid. Minuz P, et al. **Thromb Res** 1995 Dec 1;80(5):367-76

Influence of systemic cyclooxygenase inhibition with single-dose aspisol on kinetics of arachidonic acid metabolites in the venous effluate of transplanted kidney grafts in humans. Storck M, et al. **Transplant Proc** 1996 Feb;28(1):312-3

[Liver cirrhosis and granulomatous hepatitis after prolonged ingestion of lysine acetylsalicylate] D'Abrigeon G, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):944-7 (Eng. Abstr.) **(Fre)**

[Postoperative analgesia in herniated disk surgery. Comparative study of diclofenac , lysine acetylsalicylate, and ketorolac] Izquierdo E, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):316-9 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Importance of glass transition temperature in accelerated stability testing of amorphous solids: case study using a lyophilized aspirin formulation [letter] Duddu SP, et al. **J Pharm Sci** 1996 Mar;85(3):345-7

Effects of solid-state processing on water vapor sorption by aspirin [letter] Hancock BC, et al. **J Pharm Sci** 1996 Feb; 85(2):246-8

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase [see comments] Loll PJ, et al. **Nat Struct Biol** 1995 Aug; 2(8):637-43. Comment in: Nat Struct Biol 1995 Aug;2(8):605-6.

CONTRAINDICATIONS

Aspirin is a hazard for vitreoretinal surgery [letter] Elaxel CJ, et al. **Br J Ophthalmol** 1996 May;80(5):486

[Is thrombocytopenia in primary antiphospholipid syndrome a contraindication for aspirin? (letter)] Durand JM, et al. **Presse Med** 1996 May 25;25(18):863 **(Fre)**

DIAGNOSTIC USE

Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Hilsden RJ, et al. **Gastroenterology** 1996 May;110(5):1395-403

Aspirin, salicylate, sulfite and tartrazine induced bronchoconstriction. Safe doses and case definition in epidemiological studies. Corder EH, et al. **J Clin Epidemiol** 1995 Oct;48(10):1269-75

Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Nasser S, et al. **Thorax** 1996 Jan; 51(1):64-70

HISTORY

[Aspirin, an always current drug] Van Cauwenberge H. **Rev Med Liege** 1996 Jan;51(1):7-18 (29 ref.) **(Fre)**

IMMUNOLOGY

Oral aspirin and ibuprofen increase cytokine-induced synthesis of IL-1 beta and of tumour necrosis factor-alpha ex vivo. Endres S, et al. **Immunology** 1996 Feb;87(2):264-70

Hydrocortisone sodium succinate does not cross-react with aspirin in aspirin-sensitive patients with asthma. Feigenbaum BA, et al. **J Allergy Clin Immunol** 1995 Oct; 96(4):545-8

Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. Settipane RA, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):480-5

METABOLISM

Aspirin-DNA interaction studied by FTIR and laser Raman difference spectroscopy. Neault JF, et al. **FEBS Lett** 1996 Mar 11;382(1-2):26-30

Comparison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site. Wennogle LP, et al. **FEBS Lett** 1995 Sep 11;371(3):315-20

Protein binding of acetylsalicylic acid and salicylic acid in porcine and human serum. Lee S, et al. **Vet Hum Toxicol** 1995 Jun;37(3):224-5

PHARMACOKINETICS

A deconvolution method for estimating the first-pass metabolism of orally administered drugs. Yamashita F, et al. **Biol Pharm Bull** 1995 Dec;18(12):1787-9

Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma

relative to adenoma relative to adenoma cell lines. Elder DJ, et al. **Cancer Res** 1996 May 15;56(10):2273–6

Pharmacokinetic interactions of alcohol and acetylsalicylic acid. Melander O, et al. **Eur J Clin Pharmacol** 1995; 48(2):151–3

PHARMACOLOGY

The effect of aspirin and indomethacin on prostacyclin and thromboxane production by placental tissue incubated with immunoglobulin G fractions from patients with lupus anticoagulant. Peaceman AM, et al.
Am J Obstet Gynecol 1995 Nov;173(5):1391–6

Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects. Kubacka RT, et al. **Ann Pharmacother** 1996 Jan;30(1):20–6

Modulation of alpha-interferon's antiviral and clinical effects by aspirin, acetaminophen, and prednisone in healthy volunteers. Hendrix CW, et al. **Antiviral Res** 1995 Oct; 28(2):121–31

Thyromimetic action of the peroxisome proliferators clofibrate, perfluorooctanoic acid, and acetylsalicylic acid includes changes in mRNA levels for certain genes involved in mitochondrial biogenesis. Cai Y, et al.
Arch Biochem Biophys 1996 Jan 1;325(1):107–12

Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Szczeklik A, et al.
Arterioscler Thromb Vasc Biol 1996 Aug;16(8):948–54

Suppression of the hypersensitive response in potato by acetyl salicylic acid. Lee M, et al.
Biochem Biophys Res Commun 1996 May 15;222(2):309–11

Glycation-induced inactivation of malate dehydrogenase protection by aspirin and a lens molecular chaperone, alpha-crystallin. Heath MM, et al.
Biochim Biophys Acta 1996 Apr 12;1315(3):176–84

Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. Endoh T, et al. **Carcinogenesis** 1996 Mar; 17(3):467–75

Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Rao KV, et al. **Carcinogenesis** 1996 Jul; 17(7):1435–8

Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside. Negrescu EV, et al. **Cardiovasc Drugs Ther** 1995 Aug; 9(4):619–29

Reduced red cell deformability associated with blood flow and platelet activation: improved by dipyridamole alone or combined with aspirin. Bozzo J, et al.
Cardiovasc Res 1995 Nov;30(5):725–30

Salicylate or aspirin inhibits the induction of the inducible nitric oxide synthase in rat cardiac fibroblasts. Farivar RS, et al. **Circ Res** 1996 May;78(5):759–68

Vasodilatation to arachidonic acid in humans. An insight into endogenous prostanoids and effects of aspirin. Bhagat K, et al. **Circulation** 1995 Oct 15;92(8):2113–8

Effects of inhaled nitric oxide compared with aspirin on platelet function in vivo in healthy subjects. Albert J, et al. **Clin Sci (Colch)** 1996 Aug;91(2):225–31

NSAID-induced delay in gastric ulcer healing is not associated with decreased epithelial cell proliferation in rats. Penney AG, et al. **Dig Dis Sci** 1995 Dec; 40(12):2684–93

Antiplatelet drugs. A comparative review. Schrör K.
Drugs 1995 Jul;50(1):7–28 (189 ref.)

Aspirin renders the oesophageal mucosa more permeable to acid and pepsin. Lanas AI, et al.
Eur J Gastroenterol Hepatol 1995 Nov;7(11):1065–72

Chronopharmacological study of acetylsalicylic acid in mice. Ohdo S, et al. **Eur J Pharmacol** 1995 Jul 1;293(2):151–7

Mitochondrial alterations induced by aspirin in rat hepatocytes expressing mitochondrially targeted green fluorescent protein (mtGFP). Venerando R, et al.
FEBS Lett 1996 Mar 18;382(3):256–60

Effects of acetylsalicylic acid (aspirin) and naproxen sodium (naproxen) on ovulation, prostaglandin, and progesterone production in the rabbit. Zanagnolo V, et al.
Fertil Steril 1996 May;65(5):1036–43

Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. D'Andrea G, et al. **Funct Neurol** 1995 Mar-Apr;10(2):91–8

Aspirin-induced conformational changes in platelet membrane in subjects with stroke. Hasan M, et al.
Gerontology 1995;41(4):212–9

Gastric adaptation to injury by repeated doses of aspirin strengthens mucosal defence against subsequent exposure to various strong irritants in rats. Brzozowski T, et al.
Gut 1995 Dec;37(6):749–57

Comparison of effects of calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers. Murray FE, et al. **Gut** 1996 Jan;38(1):11–4

Vascular thromboxane formation in hemostasis mechanism: correlation between bleeding time and vascular TXB2 in a patient with congenital platelet cyclo-oxygenase deficiency. Fuse I, et al. **Int J Hematol** 1996 Jun; 63(4):317–24

Post-prandial thermogenesis with ephedrine, caffeine and aspirin in lean, pre-disposed obese and obese women. Horton TJ, et al. **Int J Obes Relat Metab Disord** 1996 Feb; 20(2):91–7

Hepatic oxidative stress and related defenses during treatment of mice with acetylsalicylic acid and other peroxisome proliferators. Cai Y, et al. **J Biochem Toxicol** 1995 Apr; 10(2):87–94

Aspirin inhibits collagen-induced platelet serotonin release, as measured by microbore high-performance liquid chromatography with electrochemical detection. Tsai TH, et al. **J Chromatogr B Biomed Appl** 1995 Jul 21;669(2):404–7

Aspirin inhibition of naloxone-induced luteinizing hormone secretion in man. Conte D, et al.
J Clin Endocrinol Metab 1996 May;81(5):1772–5

Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. Wallace JL, et al.
J Clin Invest 1995 Dec;96(6):2711–8

Early ultrastructural changes of antral mucosa with aspirin in the absence of Helicobacter pylori. McCarthy CJ, et al. **J Clin Pathol** 1995 Nov;48(11):994–7

Novel actions of aspirin and sodium salicylate: discordant effects on nitric oxide synthesis and induction of nitric oxide synthase mRNA in a murine macrophage cell line. Kepka-Lenhart D, et al. **J Leukoc Biol** 1996 Jun; 59(6):840–6

Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat. Kalkman EA, et al.
J Mol Cell Cardiol 1995 Nov;27(11):2483–94

Effect of KBT-3022, a new diphenylthiazole derivative, on platelet functions. Yokota K, et al. **J Pharm Pharmacol** 1995 Sep;47(9):768–74

Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. Arlen RR, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1649–58

Effects of intravenous nonsteroidal antiinflammatory drugs on a C-fiber reflex elicited by a wide range of stimulus intensities in the rat. Bustamante D, et al.
J Pharmacol Exp Ther 1996 Mar;276(3):1232–43

Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban. Kawamura M, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):502–10

Zwitterionic phospholipids enhance aspirin's therapeutic activity, as demonstrated in rodent model systems. Lichtenberger LM, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1221–7

Is aspirin, as used for antithrombosis, an emotion-modulating agent? Ketterer MW, et al. **J Psychosom Res** 1996 Jan; 40(1):53–8

Effect of single and repeated doses of a new nitroderivative of acetylsalicylic acid on platelet TXA2 production in rats. Cuzzolin L, et al. **Life Sci** 1996;58(11):PL207–10

Influence of butibufen on enzyme activity and lysosomal stabilization ex vivo: a comparative study with hydrocortisone and acetylsalicylic acid. Alamo C, et al.
Methods Find Exp Clin Pharmacol 1995 Jun;17(5):303–10

Aspirin--now we can see it. Allen KN. **Nat Med** 1995 Sep; 1(9):882–3 (13 ref.)

Aspirin and inflammation [editorial; comment]
Nat Struct Biol 1995 Aug;2(8):605–6. Comment on: Nat Struct Biol 1995 Aug;2(8):637–47.

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase [see comments] Loll PJ, et al. **Nat Struct Biol** 1995 Aug; 2(8):637–43. Comment in: Nat Struct Biol 1995 Aug;2(8):605–6.

Influence of acetylsalicylic acid and metabolites on DU-145 prostatic cancer cell proliferation. Viljoen TC, et al.
Oncology 1995 Nov-Dec;52(6):465–9

Aspirin and acetaminophen reduced both Fos expression in rat lumbar spinal cord and inflammatory signs produced by carrageenin inflammation. Honoré P, et al. **Pain** 1995 Dec;63(3):365–75

Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Clària J, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10;92(21):9475–9

Binding of estradiol to whole prostatic DU-145 cells in the presence and absence of tamoxifen and acetylsalicylic acid. Viljoen TC, et al. **Prostate** 1995 Sep;27(3):160–5

The effect of sodium salicylate and aspirin on NF-kappa B [letter; comment] Frantz B, et al. **Science** 1995 Dec 22; 270(5244):2017–9. Comment on: Science 1994 Aug 12;265(5174):956–9.

Aspirin as a free radical scavenger: consequences for therapy of cerebrovascular ischemia [letter] Kuhn W, et al.
Stroke 1995 Oct;26(10):1959–60

A prostacyclin-sparing effect of indobufen vs. aspirin. De Caterina R, et al. **Thromb Haemost** 1996 Mar;75(3):510–4

[Effects of low dose aspirin on platelet function and prostaglandins metabolism in systemic and coronary circulation in patients with ischemia heart disease] Liu H, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):595–8 (Eng. Abstr.) **(Chi)**

[Comparison of the effects of ketorolac and aspirin on hemostasis in the rabbit] Samama CM, et al.
Ann Fr Anesth Reanim 1995;14(5):393–8 (Eng. Abstr.) **(Fre)**

[Effect of acetylsalicylic acid on platelet aggregation and capillary bleeding in healthy cats] Hart S, et al.
DTW Dtsch Tierarztl Wochenschr 1995 Dec;102(12):476–80 (Eng. Abstr.) **(Ger)**

[High levels of cholesterol and lipoprotein (A) in serum decreases the inhibitory effect of aspirin on generation of thrombin] Szczeklik A, et al. **Pol Arch Med Wewn** 1995 Jun;93(6):483–9 (Eng. Abstr.) **(Pol)**

[The effect of salicylates on the toxicity of GABAlytics for mice] Golovko AI, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):619–20 **(Rus)**

[The effect of paracetamol and its combinations with acetylsalicylic and ascorbic acids on lipid peroxidation processes in the rat liver] Chalka LA, et al.
Eksp Klin Farmakol 1996 Jan-Feb;59(1):43–6 (Eng. Abstr.) **(Rus)**

[The effect of aspirin on the contingent negative wave in healthy subjects] Vein AM, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1995;95(4):45–6 (Eng. Abstr.) **(Rus)**

[Erythrocytes modulate the anti-aggregation effect of aspirin and dipyridamole. Study under static conditions and in a flow system] Bozzo J, et al. **Sangre (Barc)** 1996 Feb; 41(1):13–8 (Eng. Abstr.) **(Spa)**

POISONING

Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model [see comments] Johnson D, et al. **Ann Emerg Med** 1995 Nov; 26(5):569–74. Comment in: Ann Emerg Med 1996 May;27(5):672–3.

Transient myocardial dysfunction in a child with salicylate toxicity. Ralston ME, et al. **J Emerg Med** 1995 Sep-Oct; 13(5):657–9

Salicylate poisoning: two-dimensional J-resolved NMR urinalysis. Maschke S, et al. **NMR Biomed** 1995 Feb; 8(1):19–24

[Cerebral infarct in chronic acetylsalicylic acid poisoning] Treib J, et al. **Nervenarzt** 1996 Apr;67(4):333–4 (Eng. Abstr.) **(Ger)**

[Treatment of acute poisoning caused by carbamazepine, digoxin, and acetylsalicylic acid, with repeated doses of activated charcoal] Montoya-Cabrera MA, et al.
Gac Med Mex 1995 May-Jun;131(3):349–54 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. O'Connor CM, et al.
Am J Cardiol 1996 Apr 15;77(10):791–7

Intracoronary stenting without intravascular ultrasound guidance followed by antiplatelet therapy with aspirin alone in selected patients. Roy PR, et al. **Am J Cardiol** 1996 May 15;77(12):1105–7

Effects of aspirin on status of thrombin generation in atrial fibrillation. Yamamoto K, et al. **Am J Cardiol** 1996 Mar 1;77(7):528–30

Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Steiner M, et al.
Am J Clin Nutr 1995 Dec;62(6 Suppl):1381S–1384S

Aspirin use and cognitive function in the elderly. Stürmer T, et al. **Am J Epidemiol** 1996 Apr 1;143(7):683–91

Therapeutic uses of aspirin in renal diseases. Winchester JF.
Am J Kidney Dis 1996 Jul;28(1 Suppl 1):S20–3 (44 ref.)

The angiotensin sensitivity test and low-dose aspirin are ineffective methods to predict and prevent hypertensive disorders in nulliparous pregnancy. Kyle PM, et al.
Am J Obstet Gynecol 1995 Sep;173(3 Pt 1):865–72

The effect of low-dose aspirin on pregnancies complicated by elevated human chorionic gonadotropin levels. Wenstrom KD, et al. **Am J Obstet Gynecol** 1995 Oct; 173(4):1292–6

The effect of aspirin on the visual outcome of nonarteritic anterior ischemic optic neuropathy. Botelho PJ, et al.
Am J Ophthalmol 1996 Apr;121(4):450–1

Low-dose aspirin therapy and placental pathology in women with poor prior pregnancy outcomes. Cusick W, et al.
Am J Reprod Immunol 1995 Sep;34(3):141–7

A randomized trial of E5510 versus aspirin in patients with transient ischemic attacks. The Japanese E5510 TIA study-1 (JETS-1) Group. Maruyama S, et al. **Angiology** 1995 Nov;46(11):999–1008

Aspirin for asymptomatic carotid artery stenosis [letter; comment] Browner WS. **Ann Intern Med** 1996 Sep 1; 125(5):420; discussion 420–1. Comment on: Ann Intern Med 1995 Nov 1;123(9):649–55.

Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group [comment] [see comments] Côté R, et al. **Ann Intern Med** 1995 Nov 1; 123(9):649–55. Comment on: Ann Intern Med 1995 Nov 1;123(9):720–2. Comment on: Ann Intern Med 1995 Nov 1;123(9):729. Comment in: Ann Intern Med 1995 Nov 1;123(9):720–2. Comment in: Ann Intern Med 1995 Nov 1;123(9):723–5. Comment in: Ann Intern Med 1996 Sep 1;125(5):420; discussion 420–1. Comment in: Ann Intern Med 1996 Sep 1;125(5):420–1.

Aspirin for asymptomatic carotid artery stenosis [letter; comment] Creutzig A, et al. **Ann Intern Med** 1996 Sep 1;125(5):420–1. Comment on: Ann Intern Med 1995 Nov 1;123(9):649–55.

Aspirin for asymptomatic carotid artery stenosis [letter; comment] Hart RG, et al. **Ann Intern Med** 1996 Sep 1; 125(5):420; discussion 420–1. Comment on: Ann Intern Med

1995 Nov 1;123(9):649–55.

Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes [see comments] Krumholz HM, et al. **Ann Intern Med** 1996 Feb 1;124(3):292–8. Comment in: Ann Intern Med 1996 Feb 1;124(3):335–8.

Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Nicolau DP, et al. **Antimicrob Agents Chemother** 1995 Aug; 39(8):1748–51

Aspirin treatment and increased generation of cysteinyl leukotrienes in Kawasaki disease [letter; comment] Shimizu T, et al. **Arch Dis Child** 1996 Jan;74(1):90–1. Comment on: Arch Dis Child 1995 Jun;72(6):526–7.

The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Gage BF, et al. **Arch Intern Med** 1996 Sep 9;156(16):1829–36

Antiplatelet therapy and the prevention of thrombosis. Rodgers A, et al. **Aust N Z J Med** 1996 Apr;26(2):210–5 (19 ref.)

The pharmacological prevention of pre-eclampsia. Dekker GA. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):509–28 (109 ref.)

Use of aspirin in secondary prevention of coronary heart disease is rising [letter; comment] Carney AJ, et al. **BMJ** 1996 Mar 30;312(7034):846. Comment on: BMJ 1995 Dec 2;311(7018):1504.

Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Collins R, et al. **BMJ** 1996 Sep 14;313(7058):652–9

Audit suggests that use of aspirin is rising in coronary heart disease [letter] [see comments] King R, et al. **BMJ** 1995 Dec 2;311(7018):1504. Comment in: BMJ 1996 Mar 30;312(7034):846.

ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. Lip GY, et al. **BMJ** 1996 Jan 6;312(7022):45–9 (0 ref.)

Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. Rodgers A, et al. **BMJ** 1996 Jul 20;313(7050):147

Increasing prescription of drugs for secondary prevention of myocardial infarction. Authors' recommendations are too restrictive [letter; comment] Sapsford RJ, et al. **BMJ** 1996 Jan 27;312(7025):252. Comment on: BMJ 1995 Oct 7;311(7010):917–8.

Increasing prescription of drugs for secondary prevention after myocardial infarction [see comments] Smith J, et al. **BMJ** 1995 Oct 7;311(7010):917–8. Comment in: BMJ 1996 Jan 27;312(7025):252.

Which diabetic patients should be taking aspirin? [editorial] Yudkin JS. **BMJ** 1995 Sep 9;311(7006):641–2

Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. Lip GY, et al. **Br J Clin Pharmacol** 1996 May; 41(5):369–79 (83 ref.)

Aspirin in acute myocardial infarction [letter] Bradshaw C, et al. **Br J Gen Pract** 1996 Apr;46(405):255

Aspirin and acute myocardial infarction: clarifying the message [editorial] [see comments] Deeks J, et al. **Br J Gen Pract** 1995 Aug;45(397):395–6. Comment in: Br J Gen Pract 1995 Oct;45(399):565.

Aspirin and acute myocardial infarction [letter; comment] Johnson N, et al. **Br J Gen Pract** 1995 Oct;45(399):565. Comment on: Br J Gen Pract 1995 Aug;45(397):395–6.

Acute myocardial infarction [letter] Moher M. **Br J Gen Pract** 1995 Aug;45(397):444–5

Prediction of pre-eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin [see comments] Bower SJ, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):625–9 . Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):599–602.

Where next for prophylaxis against pre-eclampsia? [see comments] Pipkin FB, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):603–7. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):599–602.

Aspirin improves the outcome of intra-arterial thrombolysis with tissue plasminogen activator. Thrombolysis Study Group. Braithwaite BD, et al. **Br J Surg** 1995 Oct; 82(10):1357–8

Antithrombotic therapy in atrial fibrillation. Turpie AG, et al. **Can Fam Physician** 1996 Jul;42:1341–5 (16 ref.)

Aspirin and reduced risk of esophageal carcinoma. Funkhouser EM, et al. **Cancer** 1995 Oct 1;76(7):1116–9

G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. DuBois RN, et al. **Cancer Res** 1996 Feb 15; 56(4):733–7

Platelets and platelet inhibitors in acute myocardial infarction. Kamat SG, et al. **Cardiol Clin** 1995 Aug; 13(3):435–47 (139 ref.)

Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis. Chen LY, et al. **Cardiovasc Res** 1995 Dec;30(6):866–74

Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Nebe J, et al. **Cephalalgia** 1995 Dec;15(6):531–5

Aspirin—friend or fiend? [letter] Mendis BL. **Ceylon Med J** 1996 Jun;41(2):76–7

A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Hall P, et al. **Circulation** 1996 Jan 15;93(2):215–22

Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Hung J, et al. **Circulation** 1995 Nov 1;92(9):2432–6

Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. Krumholz HM, et al. **Circulation** 1995 Nov 15; 92(10):2841–7

Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries. Maalej N, et al. **Circulation** 1996 Mar 15; 93(6):1201–5

Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin. Mruk JS, et al. **Circulation** 1996 Feb 15;93(4):792–9

Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Savage MP, et al. **Circulation** 1995 Dec 1;92(11):3194–200

Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Lotke PA, et al. **Clin Orthop** 1996 Mar; (324):251–8

Intranasal lysine aspirin in recurrent nasal polyposis. Scadding GK, et al. **Clin Otolaryngol** 1995 Dec;20(6):561–3

Aspirin augmentation of the efficacy of thrombolysis. O'Donnell CJ, et al. **Coron Artery Dis** 1995 Dec;6(12):936–9 (23 ref.)

Long-term aspirin in the prevention of cardiovascular disorders. Recent developments and variations on a theme. Catella-Lawson F, et al. **Drug Saf** 1995 Aug;13(2):69–75 (53 ref.)

Aspirin for primary prevention of coronary disease. Fuster V, et al. **Eur Heart J** 1995 Jul;16 Suppl E:16–20 (23 ref.)

Aspirin and myocardial infarction: is one positive study enough? Verheugt FW. **Eur Heart J** 1995 Jul;16 Suppl E:13–5

The protocol for a European double-blind trial of aspirin and resistant starch in familial adenomatous polyposis: the CAPP study. Concerted Action Polyposis Prevention. Burn J, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1385–6

Uterine Doppler wave form and the prediction of the recurrence of pre-eclampsia and intra-uterine growth retardation in patients treated with low-dose aspirin. Haddad B, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):179–83

Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. D'Andrea G, et al. **Funct Neurol** 1995 Mar-Apr;10(2):91–8

Anticoagulation: risks and benefits in atrial fibrillation. Fiore LD. **Geriatrics** 1996 Jun;51(6):22–4, 27–8, 31 (37 ref.)

Is aspirin safe in heart failure? more data [letter] Cleland JG, et al. **Heart** 1996 Apr;75(4):426

Is aspirin safe for patients with heart failure? [letter] Jolobe OM. **Heart** 1996 Feb;75(2):214

Prevention of post-surgical adhesion formation using aspirin in a rodent model: a preliminary report. Golan A, et al. **Hum Reprod** 1995 Jul;10(7):1797–800

Pharmacologic treatment for myocardial infarction: role of aspirin [letter] Bhatt S. **Indian Heart J** 1995 May-Jun; 47(3):283

Incomplete aspirin desensitization in an aspirin-sensitive asthmatic. Rothe T, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):298–300

Aspirin, interleukin-3 and the antiphospholipid syndrome. Fishman P, et al. **Isr J Med Sci** 1996 Jan;32(1):13–7

Marked reduction in long-term cardiac deaths with aspirin after a coronary event. Multicenter Myocardial Ischemia Research Group. Goldstein RE, et al. **J Am Coll Cardiol** 1996 Aug;28(2):326–30

Immunosuppressive therapy prevents recurrent pericarditis. Marcolongo R, et al. **J Am Coll Cardiol** 1995 Nov 1; 26(5):1276–9

Could aspirin/NSAID treatment preserve independence and decrease the need for institutionalization of older rheumatoid arthritis patients [letter] Leibovitz A, et al. **J Am Geriatr Soc** 1996 Feb;44(2):216

Effect of aspirin treatment on plasma levels of keto PGF 1 alpha and thromboxane B2. Madan ZM, et al. **J Assoc Physicians India** 1995 Sep;43(9):597–9

More uses of known drugs [editorial] Mehta PJ, et al. **J Assoc Physicians India** 1995 Sep;43(9):595

Prophylaxis against deep venous thrombosis after total knee arthroplasty. Pneumatic plantar compression and aspirin compared with aspirin alone. Westrich GH, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):826–34

Efficacy of systemically administered acetylsalicylic acid plus scaling on periodontal health and elastase-alpha 1-proteinase inhibitor in gingival crevicular fluid. Flemmig TF, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):153–9

Adjunctive supragingival irrigation with acetylsalicylic acid in periodontal supportive therapy. Flemmig TF, et al. **J Clin Periodontol** 1995 Jun;22(6):427–33

Treating unstable angina. Strickland C, et al. **J Fam Pract** 1995 Dec;41(6):603–4

Prospective study of regular aspirin use and the risk of breast cancer [see comments] Egan KM, et al. **J Natl Cancer Inst** 1996 Jul 17;88(14):988–93. Comment in: J Natl Cancer Inst 1996 Jul 17;88(14):941–2.

Aspirin and breast cancer: no surprises yet [editorial; comment] Rosenberg L. **J Natl Cancer Inst** 1996 Jul 17; 88(14):941–2. Comment on: J Natl Cancer Inst 1996 Jul 17;88(14):988–93.

Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):371–6

Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. Algra A, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb;60(2):197–9

Growth inhibition of rat glioma cells in vitro and in vivo by aspirin. Aas AT, et al. **J Neurooncol** 1995;24(2):171–80

Low-dose aspirin and prednisone treatment of pregnancy loss caused by lupus anticoagulants. Harger JH, et al. **J Perinatol** 1995 Nov-Dec;15(6):463–9

A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin. Schumacher WA, et al. **J Pharmacol Toxicol Methods** 1996 Feb;35(1):3–10

Is aspirin, as used for antithrombosis, an emotion-modulating agent? Ketterer MW, et al. **J Psychosom Res** 1996 Jan; 40(1):53–8

Aspirin-mouthwash relieves pain of oral lesions. Angirish A. **J R Soc Health** 1996 Apr;116(2):105–6

Aspirin for prevention of myocardial infarction. Mirvis DM. **J Tenn Med Assoc** 1995 Oct;88(10):392–4

Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation [see comments] Gage BF, et al. **JAMA** 1995 Dec 20; 274(23):1839–45. Comment in: JAMA 1996 Mar 27;275(12):909; discussion 910.

Cost-effectiveness of stroke prophylaxis for nonvalvular atrial fibrillation [letter; comment] Kan BD, et al. **JAMA** 1996 Mar 27;275(12):909; discussion 910. Comment on: JAMA 1995 Dec 20;274(23):1839–45.

Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. Oler A, et al. **JAMA** 1996 Sep 11;276(10):811–5

Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group [see comments] **Lancet** 1996 Mar 2;347(9001):561–8. Comment in: Lancet 1996 Apr 27;347(9009):1191. Comment in: Lancet 1996 May 4;347(9010):1263.

Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial—Italy (MAST-I) Group [comment] [see comments] **Lancet** 1995 Dec 9; 346(8989):1509–14. Comment on: Lancet 1995 Dec 9;346(8989):1504. Comment on: Lancet 1995 Dec 9;346(8989):1504–5. Comment in: Lancet 1996 Feb 10;347(8998):391; discussion 393. Comment in: Lancet 1996 Feb 10;347(8998):391–2; discussion 393. Comment in: Lancet 1996 Feb 10;347(8998):392; discussion 393. Comment in: Lancet 1996 Feb 10;347(8998):392–3.

Multicentre Acute Stroke Trial—Italy [letter; comment] Barer D. **Lancet** 1996 Feb 10;347(8998):391–2; discussion 393. Comment on: Lancet 1995 Dec 9;346(8989):1504. Comment on: Lancet 1995 Dec 9;346(8989):1504–5. Comment on: Lancet 1995 Dec 9;346(8989):1509–14.

Multicentre Acute Stroke Trial—Italy [letter; comment] Carolei A, et al. **Lancet** 1996 Feb 10;347(8998):392; discussion 393. Comment on: Lancet 1995 Dec 9;346(8989):1509–14. Comment on: Lancet 1995 Dec 9;346(8989):1515.

Are aspirin and other non-steroidal anti-inflammatory drugs effective in the prevention and treatment of colorectal cancer? [letter] Elder DJ, et al. **Lancet** 1996 Aug 17; 348(9025):485

Multicentre Acute Stroke Trial—Italy [letter; comment] Muir KW. **Lancet** 1996 Feb 10;347(8998):391; discussion 393. Comment on: Lancet 1995 Dec 9;346(8989):1504–5. Comment on: Lancet 1995 Dec 9;346(8989):1509–14.

Multicentre Acute Stroke Trial—Italy [letter; comment] Rothwell P. **Lancet** 1996 Feb 10;347(8998):392–3. Comment on: Lancet 1995 Dec 9;346(8989):1509–14.

Failure of aspirin and diltiazem to prevent the formation of acute coronary thrombi in dogs. Morishima Y, et al. **Methods Find Exp Clin Pharmacol** 1995 May;17(4):273–7

Low-molecular-weight heparin for the treatment of acute ischemic stroke [letter; comment] Bloom JM. **N Engl J Med** 1996 May 23;334(21):1407. Comment on: N Engl J Med 1995 Dec 14;333(24):1588–93.

Aspirin and the risk of colorectal cancer in women [letter; comment] Johnson KA, et al. **N Engl J Med** 1996 Jan 11; 334(2):119; discussion 121. Comment on: N Engl J Med 1995 Sep 7;333(10):609–14.

Aspirin and the risk of colorectal cancer in women [letter; comment] Roychowdhury DF. **N Engl J Med** 1996 Jan 11;334(2):120; discussion 121. Comment on: N Engl J Med 1995 Sep 7;333(10):609–14. Comment on: N Engl J Med 1995 Sep 7;333(10):656–8.

Aspirin and the risk of colorectal cancer in women [letter; comment] Schuler M. **N Engl J Med** 1996 Jan 11; 334(2):121–2. Comment on: N Engl J Med 1995 Sep 7;333(10):609–14. Comment on: N Engl J Med 1995 Sep 7;333(10):656–8.

Aspirin and the risk of colorectal cancer in women [letter; comment] van Bodegraven AA, et al. **N Engl J Med** 1996 Jan 11;334(2):120; discussion 121–2. Comment on: N Engl J Med 1995 Sep 7;333(10):609–14. Comment on: N Engl J Med 1995 Sep 7;333(10):656–8.

Aspirin and coronary disease [letter] Vogel RA. **N Engl J Med** 1996 Oct 10;335(15):1161–2

Comparison of aspirin with a thromboxane antagonist for patients with prolonged chest pain and ST segment

depression. Norris RM, et al. **N Z Med J** 1996 Jul 26; 109(1026):278–80

Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Miller VT, et al. **Neurology** 1996 Jan;46(1):238–40

Reversible dementia and chorea in a young woman with the lupus anticoagulant. Van Horn G, et al. **Neurology** 1996 Jun;46(6):1599–603

A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow. Morris JM, et al. **Obstet Gynecol** 1996 Jan;87(1):74–8

Aspirin versus indomethacin treatment of patent ductus arteriosus in preterm infants with respiratory distress syndrome. van Overmeire B, et al. **Pediatr Res** 1995 Dec; 38(6):886–91

The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Durongpisitkul K, et al. **Pediatrics** 1995 Dec;96(6):1057–61

Long-term aspirin therapy for hepatopulmonary syndrome. Song JY, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):917–20

Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Van Marter LJ, et al. **Pediatrics** 1996 May;97(5):658–63

Low-dose aspirin does not attenuate platelet aggregation or atherosclerosis in miniature swine but decreases production of aortic wall prostacyclin. Smith MJ, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):331–40

Accommodative amplitudes in the Early Treatment Diabetic Retinopathy Study. Braun CI, et al. **Retina** 1995; 15(4):275–81

The use of aspirin and opiates by Dumfries and Galloway general practitioners in the management of acute myocardial infarction. Strachan DA, et al. **Scott Med J** 1995 Oct;40(5):151–2

Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts [editorial; comment] Barnett HJ, et al. **Stroke** 1996 Apr;27(4):588–92 (60 ref.). Comment on: Stroke 1996 Apr;27(4):756–60.

Interobserver agreement in the classification of stroke in the physicians' health study. Berger K, et al. **Stroke** 1996 Feb; 27(2):238–42

Aspirin wars: the optimal dose of aspirin prevent stroke [editorial; comment] Hart RG, et al. **Stroke** 1996 Apr; 27(4):585–7 (45 ref.). Comment on: Stroke 1996 Apr;27(4):756–60.

Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? [see comments] Patrono C, et al. **Stroke** 1996 Apr;27(4):756–60 (36 ref.). Comment in: Stroke 1996 Apr;27(4):585–7. Comment in: Stroke 1996 Apr;27(4):588–92.

Susac's syndrome: improvement with combined antiplatelet and calcium antagonist therapy [letter] Wildemann B, et al. **Stroke** 1996 Jan;27(1):149–51

Oral anticoagulant treatment with and without aspirin. Altman R, et al. **Thromb Haemost** 1995 Jul;74(1):506–10 (37 ref.)

Antiplatelet therapy with aspirin: from clinical trials to practice. Goodnight SH. **Thromb Haemost** 1995 Jul; 74(1):401–5 (64 ref.)

Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Mitusch R, et al. **Thromb Haemost** 1996 Feb;75(2):219–23

Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin. Szczeklik A. **Thromb Haemost** 1995 Jul;74(1):77–80 (34 ref.)

Experimental thrombosis model induced by free radicals. Application to aspirin and other different substances. Jourdan A, et al. **Thromb Res** 1995 Jul 1;79(1):109–23

Another antithrombotic action of aspirin. O'Brien JR, et al. **Thromb Res** 1995 Oct 15;80(2):185–8

The role of coumadin and aspirin in atrial fibrillation. Hutter AM Jr. **Trans Am Clin Climatol Assoc** 1995;107:79–85; discussion 85–6 (17 ref.)

Warfarin sodium or aspirin therapy to prevent stroke in nonrheumatic atrial fibrillation. Answered and unanswered questions [editorial; comment] Stratton JR. **West J Med** 1995 Aug;163(2):177–9. Comment on: West J Med 1995 Aug;163(2):145–57.

[A rat middle cerebral artery thrombosis model for evaluation of thrombolytic and antithrombotic agents] Liu XG, et al. **Yao Hsueh Hsueh Pao** 1995;30(9):662–7 (Eng. Abstr.) **(Chi)**

[TIA... An aspirin? (letter)] van 't Veer WJ. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):631–2 **(Dut)**

[Treatments of ischemic cardiopathies (IC) and modalities of prescription of aspirin in the three French MONICA centers in 1990] Cambou JP, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):578–86 (Eng. Abstr.) **(Fre)**

[Anticoagulation in cardiology] Meier B. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):567–77 (53 ref.) (Eng. Abstr.) **(Fre)**

[Antithrombotic treatment of atrial fibrillation] Connelly SJ, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:14A–18A (13 ref.) **(Fre)**

[Can nitrogen monoxide replace aspirin in the prevention of preeclampsia?] Ohl J, et al. **Contracept Fertil Sex** 1996 Apr;24(4):259–61 (16 ref.) **(Fre)**

[Should nitrogen monoxide replace aspirin in the prevention of preeclampsia?] Uzan S, et al. **Contracept Fertil Sex** 1996 Apr;24(4):262–3 **(Fre)**

[Uterine velocimetry and vascular pregnancy pathologies prevented with low-dose aspirin] Haddad B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):396–404 (51 ref.) (Eng. Abstr.) **(Fre)**

[Aspirin during pregnancy. Indications and modalities of prescription after the publication of the later trials] Uzan S, et al. **Presse Med** 1996 Jan 6–13;25(1):31–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[2nd European study on secondary prevention of stroke (ESPS 2). Respective roles of acetylsalicylic acid, dipyridamole and their combination] Franck G. **Rev Med Liege** 1995 Nov;50(11):491 **(Fre)**

[Effectiveness of fixed analgesic combinations exemplified by thomapyrin] Aicher B, et al. **Wien Klin Wochenschr** 1996;108(8):219–33 (104 ref.) (Eng. Abstr.) **(Ger)**

[Low doses of acetylsalicylic acid effectively inhibits thrombocyte aggregation after ischemic stroke] Oláh L, et al. **Orv Hetil** 1996 Mar 3;137(9):455–9 (Eng. Abstr.) **(Hun)**

[Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity] Guazzi M, et al. **Cardiologia** 1996 Jun;41(6):527–33 (Eng. Abstr.) **(Ita)**

[The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?] Cimminiello C, et al. **G Ital Cardiol** 1995 Sep;25(9):1187–93 (36 ref.) (Eng. Abstr.) **(Ita)**

[Contemporary opinions on the use of aspirin, heparin and thrombolytic therapy in unstable angina pectoris--pathogenetic findings versus results of many clinical tests] Popiel M, et al. **Przegl Lek** 1996;53(1):33–40 (40 ref.) (Eng. Abstr.) **(Pol)**

[Atrial fibrillation due to non-valvular causes: indications for antithrombotic therapy] Codinach Huix P. **Med Clin (Barc)** 1996 Apr 20;106(15):586–9 (25 ref.) **(Spa)**

[Acetyl-salicylic acid and trifusal in the prevention of atherothrombotic stroke] Alvarez Sabín J. **Rev Neurol** 1995 Sep-Oct;23(123):1091–5 (36 ref.) **(Spa)**

[Antiaggregant treatment for cerebral ischemia: ticlopidine versus aspirin] Rey A, et al. **Rev Neurol** 1996 Feb; 24(126):214–8 (Eng. Abstr.) **(Spa)**

[Antiphospholipid antibodies in women with habitual abortions. Treatment with prednisone and acetylsalicylic acid during pregnancy] Marco P, et al. **Sangre (Barc)** 1995 Oct;40(5):389–92 (Eng. Abstr.) **(Spa)**

TOXICITY

Re: Gastrointestinal blood loss with low-dose aspirin [letter; comment] Petroski D. **Am J Gastroenterol** 1995 Nov; 90(11):2071. Comment on: Am J Gastroenterol 1995 Apr;90(4):581–5.

Acetaminophen/aspirin mixtures: experimental data. Porter GA. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S30–3 (11 ref.)

Role of neutrophil-mediated inflammation in aspirin-induced gastric mucosal injury. Yoshida N, et al. **Dig Dis Sci** 1995 Nov;40(11):2300–4

Anti-ulcerogenic evaluation of the methanolic extracts of some indigenous medicinal plants of Pakistan in aspirin-ulcerated rats. Akhtar AH, et al. **J Ethnopharmacol** 1995 Apr;46(1):1–6

Gastric adaptation to aspirin and stress enhances gastric mucosal resistance against the damage by strong irritants. Brzozowski T, et al. **Scand J Gastroenterol** 1996 Feb; 31(2):118–25

Aspirin-alcohol interaction in the production of cleft palate and limb malformations in the TO mouse. Padmanabhan R, et al. **Teratology** 1995 Jun;51(6):404–17

Induction of hepatic cytochrome P4502E1 in rats by acetylsalicylic acid or sodium salicylate. Damme B, et al. **Toxicology** 1996 Jan 8;106(1–3):99–103

URINE

Salicylate poisoning: two-dimensional J-resolved NMR urinalysis. Maschke S, et al. **NMR Biomed** 1995 Feb; 8(1):19–24

ASPIRIN-LIKE AGENTS see **ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL**

ASSAULTIVE BEHAVIOR see **VIOLENCE**

ASSERTIVENESS

Social skills training for young adolescents: symbolic and behavioral components. Thompson KL, et al. **Adolescence** 1995 Fall;30(119):724–34

Assertiveness [letter; comment] Christian D, et al. **J Adv Nurs** 1995 Jul;22(1):198–9. Comment on: J Adv Nurs 1995 Feb;21(2):356–63.

Statistics [letter; comment] Walker JM. **J Adv Nurs** 1995 Jul; 22(1):198–9. Comment on: J Adv Nurs 1995 Feb;21(2):356–63.

Compulsive eating, obsessive thoughts of food, and their relation to assertiveness and depression in women. Ghiz L, et al. **J Clin Psychol** 1995 Jul;51(4):491–9

Combining behavioral therapy and pharmacotherapy for smoking cessation: an update. Hughes JR. **NIDA Res Monogr** 1995;150:92–109

Combining pharmacotherapy with psychotherapy for substance abusers with borderline personality disorder: strategies for enhancing compliance. Linehan MM. **NIDA Res Monogr** 1995;150:129–42

Memory and social skill in schizophrenia: the role of gender. Mueser KT, et al. **Psychiatry Res** 1995 Jul 28;57(2):141–53

Further validation of the Self-Defeating Personality Scale. McCutcheon LE. **Psychol Rep** 1995 Jun;76(3 Pt 2):1135–8

Self-defeating personality and depression: a closer look. Schill T, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1167–70

[Cognitive distortion in the affirmation of self. Various observations] Masson A, et al. **Rev Med Liege** 1995 Sep; 50(9):390–5 (21 ref.) **(Fre)**

[Effects of intimacy and familiarity on self-assertive strategy in interpersonal conflicts among preschool children] Yamamoto A. **Shinrigaku Kenkyu** 1995 Aug;66(3):205–12 (Eng. Abstr.) **(Jpn)**

ASSESSMENT, EDUCATIONAL see **EDUCATIONAL MEASUREMENT**

ASSESSMENT OF HEALTH CARE NEEDS see **HEALTH SERVICES NEEDS AND DEMAND**

ASSESSMENT, RISK see **RISK ASSESSMENT**

ASSIMILATION see **ACCULTURATION**

ASSISTED CIRCULATION

see related
HEART-ASSIST DEVICES

Aortomyoplasty counterpulsation: experimental results and early clinical experience. Chachques JC, et al. **Ann Thorac Surg** 1996 Jan;61(1):420–5

Descending thoracic aortomyoplasty: a technique for clinical application. Flum DR, et al. **Ann Thorac Surg** 1996 Jan; 61(1):93–8

Cardiac transplantation after mechanical circulatory support: a Canadian perspective. Masters RG, et al. **Ann Thorac Surg** 1996 Jun;61(6):1734–9

Mechanical circulatory assistance in paediatric patients with cardiac failure. Khan A, et al. **Cardiovasc Surg** 1996 Feb; 4(1):43–9

[A successful circulatory assist in acute left heart failure after a rapid two-stage arterial switch operation] Jung E, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Aug;43(8):1160–5 (Eng. Abstr.) **(Jpn)**

[Changes in indicators of brain metabolism in heart surgery patients under normal and hypothermic perfusion] Mierbekov EM, et al. **Anesteziol Reanimatol** 1996 Mar-Apr;(2):59–62 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

An approach to reducing hemolysis in an axial-flow blood pump. Anai H, et al. **ASAIO J** 1995 Jul-Sep;41(3):M771–4

Mechanisms of red blood cell trauma in assisted circulation. Rheologic similarities of red blood cell transformations due to natural aging and mechanical stress. Kameneva MV, et al. **ASAIO J** 1995 Jul-Sep;41(3):M457–60

Circulatory assist techniques after cardiomyoplasty. Determinants for clinical outcome and later consequences. Mesana TG, et al. **ASAIO J** 1995 Jul-Sep;41(3):M469–72

Acute phase responses of vasoactive hormones to non pulsatile systemic circulation. Tatsumi E, et al. **ASAIO J** 1995 Jul-Sep;41(3):M460–5

How does the sympathetic nervous system behave during non pulsatile circulation? Toda K, et al. **ASAIO J** 1995 Jul-Sep;41(3):M465–8

Reduction of haemorrhagic complications during mechanically assisted circulation with the use of a multi-system anticoagulation protocol. Glauber M, et al. **Int J Artif Organs** 1995 Oct;18(10):649–55

INSTRUMENTATION

An approach to reducing hemolysis in an axial-flow blood pump. Anai H, et al. **ASAIO J** 1995 Jul-Sep;41(3):M771–4

A high capacity transcutaneous energy transmission system. Phillips RP. **ASAIO J** 1995 Jul-Sep;41(3):M259–62

Development and clinical application of a next generation implantable echocardiography probe for monitoring cardiac function under assisted circulation after open heart surgery. Yuzu R, et al. **ASAIO J** 1994 Jul-Sep; 40(3):M482–5

Cardiovascular applications of biomaterials and implants--an overview. Black MM. **J Med Eng Technol** 1995 Sep-Oct; 19(5):151–7

METHODS

Atrial cannulation for left ventricular assistance: superiority of the dome approach. Jett GK. **Ann Thorac Surg** 1996 Mar;61(3):1014–5

Right-to-left veno-arterial shunting for right-sided circulatory failure. Slater JP, et al. **Ann Thorac Surg** 1995 Oct;60(4):978–84; discussion 985

Circulatory assist techniques after cardiomyoplasty. Determinants for clinical outcome and later consequences. Mesana TG, et al. **ASAIO J** 1995 Jul-Sep;41(3):M469–72

[Circulatory support. I. Indications and description of

systems] Defraigne JO, et al. **Rev Med Liege** 1996 Apr; 51(4):295–306 (0 ref.) **(Fre)**

[Separate perfusion of upper and lower body under mild hypothermia during operation on the thoracoabdominal aorta] Ohmi M, et al. **Kyobu Geka** 1995 Aug;48(9):725–9; discussion 730–1 (Eng. Abstr.) **(Jpn)**

STANDARDS

Seal-less centrifugal blood pump with magnetically suspended rotor: rot-a-flot. Mendler N, et al. **Artif Organs** 1995 Jul;19(7):620–4

ASSISTED SUICIDE see **SUICIDE, ASSISTED**

ASSOCIATED VIRUSES see **SATELLITE VIRUSES**

ASSOCIATION

see related
WORD ASSOCIATION TESTS

Spontaneous mnemonic strategies used by older and younger adults to remember proper names. Brooks JO 3rd, et al. **Memory** 1993 Dec;1(4):393–407

Naming faces and naming names: exploring an interactive activation model of person recognition. Burton AM, et al. **Memory** 1993 Dec;1(4):457–80 (26 ref.)

Association as a cause of dating bias. Kemp S. **Memory** 1996 Mar;4(2):131–43

Priming effects in prospective memory. Mäntylä T. **Memory** 1993 Sep;1(3):203–18

Repetition priming and proper name processing. Do common names and proper names prime each other? Valentine T, et al. **Memory** 1993 Dec;1(4):329–49

ASSOCIATION, FREE see **FREE ASSOCIATION**

ASSOCIATION LEARNING

Selective influences of age and speed on associative memory. Salthouse TA. **Am J Psychol** 1995 Fall;108(3):381–96

Postconditioning isolation disrupts contextual conditioning: an experimental analysis. Rudy JW. **Behav Neurosci** 1996 Apr;110(2):238–46

The CS–US interval and taste aversion learning: a brief look. Schafe GE, et al. **Behav Neurosci** 1995 Aug;109(4):799–802

Infants' forgetting of correlated attributes and object recognition. Bhatt RS, et al. **Child Dev** 1996 Feb; 67(1):172–87

The Pavlovian "principle of strength". Windholz G. **Integr Physiol Behav Sci** 1995 Jul–Sep;30(3):228–36

Higher-order behavior classes: contingencies, beliefs, and verbal behavior [comment] Catania AC. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):191–200 (60 ref.). Comment on: J Behav Ther Exp Psychiatry 1995 Sep;26(3):179–90.

Naming stimulus equivalence, and conditioned hearing. Dugdale N. **J Exp Anal Behav** 1996 Jan;65(1):272–4

Developing a theory of derived stimulus relations. Hayes SC. **J Exp Anal Behav** 1996 Jan;65(1):309–11

Naming as a facilitator of discrimination. McIlvane WJ, et al. **J Exp Anal Behav** 1996 Jan;65(1):267–72

Naming and equivalence relations. Saunders KJ, et al. **J Exp Anal Behav** 1996 Jan;65(1):304–8

Naming is not (necessary for) stimulus equivalence. Saunders RR, et al. **J Exp Anal Behav** 1996 Jan;65(1):312–4

On the experimental analysis of naming and the formation of stimulus classes. Stromer R. **J Exp Anal Behav** 1996 Jan;65(1):250–2

Second-order excitation mediated by a backward conditioned inhibitor. Barnet RC, et al. **J Exp Psychol Anim Behav Process** 1996 Jul;22(3):279–96

Sign tracking versus goal tracking in the sexual conditioning of male Japanese quail (Coturnix japonica). Burns M, et al. **J Exp Psychol Anim Behav Process** 1996 Jul; 22(3):297–306

Effect of relative stimulus validity: learning or performance deficit? Cole RP, et al. **J Exp Psychol Anim Behav Process** 1995 Oct;21(4):293–303

Role of stimulus ambiguity in conditional learning. de Brugada I, et al. **J Exp Psychol Anim Behav Process** 1995 Oct;21(4):275–84

Effect of US signal value on blocking of a CS–US association. Goddard MJ. **J Exp Psychol Anim Behav Process** 1996 Jul;22(3):258–64

Impact of shock on pain reactivity: II. Evidence for enhanced pain. King TE, et al. **J Exp Psychol Anim Behav Process** 1996 Jul;22(3):265–78

Pavlovian aversive context conditioning using carbon dioxide as the unconditional stimulus. Mongeluzi DL, et al. **J Exp Psychol Anim Behav Process** 1996 Jul;22(3):244–57

A constructive-associative model of the contextual dependence of unidimensional similarity. Wedell DH. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):634–61

Category-based predictions: influence of uncertainty and feature associations. Ross BH, et al. **J Exp Psychol Learn Mem Cogn** 1996 May;22(3):736–53

The effects of category distinctiveness and stimulus relations on young children's use of retrieval clustering strategies. Nida RE, et al. **J Gen Psychol** 1995 Oct;122(4):345–53

A note on adults' color-emotion associations. Hemphill M. **J Genet Psychol** 1996 Sep;157(3):275–80

Savings in relearning: II. On the formation of behavior-based trait associations and inferences. Carlston DE, et al. **J Pers Soc Psychol** 1995 Sep;69(3):420–35

Probing sensory and associative semantics for animals and objects in normal subjects. Laws KR, et al. **Memory** 1995 Sep–Dec;3(3–4):397–408

Associative spread as a mediating variable in the generation effect. Widner RL Jr. **Memory** 1995 Mar;3(1):1–19

Patterns of functional damage in neural network models of associative memory. Ruppin E, et al. **Neural Comput** 1995 Sep;7(5):1105–27

Differential effects of aging on memory for content and context: a meta-analysis. Spencer WD, et al. **Psychol Aging** 1995 Dec;10(4):527–39

On the mechanisms of plasticity in young and older adults after instruction in the method of loci: evidence for an amplification model. Verhaeghen P, et al. **Psychol Aging** 1996 Mar;11(1):164–78

An associative interpretation of the indirect McCollough effect. Eissenberg T, et al. **Q J Exp Psychol B** 1995 Aug; 48(3):262–86

Associative learning in schizophrenia: a comment to Carroll (1995) [letter; comment] Hemsley DR. **Schizophr Res** 1995 Nov;17(3):287–8. Comment on: Schizophr Res 1995 May;15(3):299–301.

Analyses of adult age differences in associative learning. Salthouse TA, et al. **Z Psychol Z Angew Psychol** 1995; 203(4):351–60

DRUG EFFECTS

Acute ethanol impairs spatial memory but not stimulus/response memory in the rat. Matthews DB, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):902–9

Area postrema mediates the formation of rapid, conditioned palatability shifts in lithium-treated rats. Eckel LA, et al. **Behav Neurosci** 1996 Feb;110(1):202–12

Scopolamine selectively disrupts the acquisition of contextual fear conditioning in rats. Anagnostaras SG, et al. **Neurobiol Learn Mem** 1995 Nov;64(3):191–4

PHYSIOLOGY

Molecular approaches to conditioned taste aversion. Houpt TA. **Appetite** 1995 Jun;24(3):259

Olfactory-visual associative learning in monkeys depends on intrahemispheric olfactory-visual interaction. Parker A, et al. **Behav Neurosci** 1995 Dec;109(6):1045–51

Effects of lesions of the associative parietal cortex on the acquisition and use of spatial memory in egocentric and allocentric navigation tasks in the rat. Save E, et al. **Behav Neurosci** 1996 Feb;110(1):74–85

The role of the rat hippocampal system in several effects of context in extinction. Wilson A, et al. **Behav Neurosci** 1995 Oct;109(5):828–36

Acquisition of conditioned inhibition in rats is impaired by ablation of serotoninergic pathways. Lister S, et al. **Eur J Neurosci** 1996 Feb;8(2):415–23

The nucleus accumbens in monkeys (Macaca fascicularis). III. Reversal learning. Stern CE, et al. **Exp Brain Res** 1995; 106(2):239–47

Configural association theory and the hippocampal formation: an appraisal and reconfiguration. Rudy JW, et al. **Hippocampus** 1995;5(5):375–89 (80 ref.)

Blocking and unconditioned response diminution in human classical autonomic conditioning. Kimmel HD, et al. **Integr Physiol Behav Sci** 1996 Jan–Mar;31(1):18–43

Impaired avoidance learning after closed-head injury: dissociation between two tasks due to classical conditioning. Kosmidis MH, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):622–33

Latent inhibition: a neural network approach. Schmajuk NA, et al. **J Exp Psychol Anim Behav Process** 1996 Jul; 22(3):321–49

Neuroanatomical and functional specificity of the basolateral amygdaloid nucleus in taste-potentiated odor aversion. Ferry B, et al. **Neurobiol Learn Mem** 1995 Sep;64(2):169–80

Functional brain maps of retrieval mode and recovery of episodic information [see comments] Nyberg L, et al. **Neuroreport** 1995 Dec 29;7(1):249–52. Comment in: Neuroreport 1995 Dec 29;7(1):9–10.

Neuronal responsiveness to various sensory stimuli, and associative learning in the rat amygdala. Uwano T, et al. **Neuroscience** 1995 Sep;68(2):339–61

[The participation of the glutaminergic input of the nucleus accumbens in regulating the synaptic release of dopamine during associative learning] Saul'skaia NB, et al. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):45–54 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Failure to produce taste-aversion learning in rats exposed to static electric fields and air ions. Creim JA, et al. **Bioelectromagnetics** 1995;16(5):301–6

ASTASIA-ABASIA see **CONVERSION DISORDER**

ASTATINE

Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide. Garg PK, et al. **Nucl Med Biol** 1995 May;22(4):467–73

THERAPEUTIC USE

[211At]methylene blue for targeted radiotherapy of human melanoma xenografts: dose fractionation in the treatment of cutaneous tumours. Link EM, et al. **Eur J Cancer** 1996 Jun;32A(7):1240–7

TOXICITY

Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis. McLendon RE, et al. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):69–80

ASTEMIZOLE

ADMINISTRATION & DOSAGE

[Comparative assessment of astemizole-pseudoephedrine and loratadine-pseudoephedrine in children with allergic rhinitis] Paz Martinez D, et al. **Rev Alerg Mex** 1995 Nov–Dec;42(6):105–9 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Comparison of efficacy, safety, and skin test inhibition of cetirizine and astemizole. Berkowitz RB, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):363–8

Terfenadine, astemizole, and ebastine produce QTc interval prolongation in an experimental model predictive of adverse clinical ECG effects [letter] Hey JA, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):476

Cardiac actions of antihistamines. Woosley RL. **Annu Rev Pharmacol Toxicol** 1996;36:233–52 (73 ref.)

Risk of selected serious cardiac events among new users of antihistamines. Staffa JA, et al. **Clin Ther** 1995 Nov–Dec; 17(6):1062–77

Use of astemizole in a large group practice. Craig TJ, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):352–4

Re: Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates [letter; comment] Kurokawa M, et al. **J Natl Cancer Inst** 1995 Nov 1;87(21):1638–9. Comment on: J Natl Cancer Inst 1994 May 18;86(10):770–5.

QT prolongation on the standard dose of astemizole [letter; comment] Gowardman J. **N Z Med J** 1996 Feb 9; 109(1015):38. Comment on: N Z Med J 1995 Nov 24;108(1012):488–91.

Drug interactions associated with terfenadine and related nonsedating antihistamines. Zechnich AD, et al. **West J Med** 1996 Jan;164(1):68–9

ANALYSIS

Colorimetric determination of astemizole in bulk and in its pharmaceutical dosage forms using flow injection. Alwarthan AA, et al. **J Pharm Biomed Anal** 1996 Mar; 14(5):579–82

PHARMACOLOGY

Perinatal astemizole exposure in the rat throughout gestation: long-term behavioral and anatomic effects associated with reproduction. Almeida RG, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jun;114(2):123–7

Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. Suessbrich H, et al. **FEBS Lett** 1996 Apr 29; 385(1–2):77–80

Comparison of the effects of astemizole/pseudoephedrine and triprolidine/pseudoephedrine on CNS activity and psychomotor function. Stanley N, et al. **Int Clin Psychopharmacol** 1996 Mar;11(1):31–6

Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance. Adamantidis MM, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):319–27

THERAPEUTIC USE

Tilarin in combination with astemizole. Bukstein DA, et al. **Allergy** 1996;51(28 Suppl):20–7

Comparison of efficacy, safety, and skin test inhibition of cetirizine and astemizole. Berkowitz RB, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):363–8

Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis. Bernstein DI, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):749–55

Astemizole in combination with pseudoephedrine in the treatment of seasonal allergic rhinitis. Simola M, et al. **Rhinology** 1996 Mar;34(1):21–3

TOXICITY

Carcinogenicity studies of astemizole in mice and rats. Benze J, et al. **Cancer Res** 1995 Dec 1;55(23):5589–94

ASTHENIA

see related
NEURASTHENIA

EPIDEMIOLOGY

Persons found in their homes helpless or dead [see comments]

Gurley RJ, et al. **N Engl J Med** 1996 Jun 27;334(26):1710–6 . Comment in: N Engl J Med 1996 Jun 27;334(26):1738–9.

ETIOLOGY

Asthenia: an important symptom in cancer patients. Morant R. **Cancer Treat Rev** 1996 Jan;22 Suppl A:117–22

PARASITOLOGY

Unusual neurological presentation of dipylidiasis in a child. Cirioni O, et al. **Eur J Pediatr** 1996 Jan;155(1):67

ASTHENOPIA

EPIDEMIOLOGY

Is there a typical VDT patient? A demographic analysis. Salibello C, et al. **J Am Optom Assoc** 1995 Aug; 66(8):479–83

[Risk factors for asthenopia among computer terminal operators] Sánchez-Román FR, et al. **Salud Publica Mex** 1996 May-Jun;38(3):189–96 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Analysis of ocular surface area for comfortable VDT workstation layout. Sotoyama M, et al. **Ergonomics** 1996 Jun;39(6):877–84

[Rapid eye fatigue—causes and therapy] Thaller-Antlanger H. **Ther Umsch** 1996 Jan;53(1):25–30 (Eng. Abstr.) **(Ger)**

[Eye-strain symptoms after work with a computer screen] Trusiewicz D, et al. **Klin Oczna** 1995 Nov-Dec; 97(11–12):343–5 (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Viewing distance variation and related ophthalmological changes in office activities with and without VDUs. Piccoli B, et al. **Ergonomics** 1996 May;39(5):719–28

Optometric correlates of Meares-Irlen syndrome: a matched group study. Evans BJ, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):481–7

PREVENTION & CONTROL

Visual comfort in VDT workstation design. Taptagaporn S, et al. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):84–8

A preliminary investigation into the aetiology of Meares-Irlen syndrome. Evans BJ, et al. **Ophthalmic Physiol Opt** 1996 Jul;16(4):286–96

THERAPY

[Rapid eye fatigue—causes and therapy] Thaller-Antlanger H. **Ther Umsch** 1996 Jan;53(1):25–30 (Eng. Abstr.) **(Ger)**

ASTHMA

see related
ANTI-ASTHMATIC AGENTS

INTERASMA 95. Poznan, Poland, 30 August–2 September 1995. Abstracts. **Allerg Immunol (Paris)** 1995 Sep; 27(7):216–70

Risk factors for asthmatic patients requiring intubation: A comprehensive review. LeSon S, et al. **Allergol Immunopathol (Madr)** 1995 Sep-Oct;23(5):235–47 (133 ref.)

Asthma: The important questions, part 3. Report of a workshop. Paros, Greece, June 1995. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S1–32

Asthma knowledge, attitudes, and quality of life in adolescents [see comments] Gibson PG, et al. **Arch Dis Child** 1995 Oct;73(4):321–6. Comment in: Arch Dis Child 1996 Apr;74(4):367.

Asthma, enuresis, and chronic illness: long term impact on height. Power C, et al. **Arch Dis Child** 1995 Oct; 73(4):298–304

Occupational health: undefined, under reported, and uncompensated. Prescribed diseases yield substantial compensation [letter; comment] Wilkinson J. **BMJ** 1995 Sep 9;311(7006):691. Comment on: BMJ 1995 May 20;310(6990):1299–300.

Asthma 1995. Willis's "terrible disease". Owen G. **Can Fam Physician** 1995 Nov;41:1951, 1953–4

Asthma, employment status, and disability among adults treated by pulmonary and allergy specialists. Blanc PD, et al. **Chest** 1996 Mar;109(3):688–96

Asthma in infants and small children. Brugman SM, et al. **Clin Chest Med** 1995 Dec;16(4):637–56 (242 ref.)

Problems in the phenotypic assessment of asthma. Weiss ST. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:12–4; discussion 17–8 (4 ref.)

Is there a specific phenotype for asthma? Woolcock AJ, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:3–7; discussion 17–8

The young athlete with chronic disease. Small E, et al. **Clin Sports Med** 1995 Jul;14(3):709–26 (144 ref.)

Current concepts of fatal asthma. Igwebe T, et al. **Compr Ther** 1995 Aug;21(8):407–12 (44 ref.)

Quality of life measurement in asthma [editorial; comment] Jones PW. **Eur Respir J** 1995 Jun;8(6):885–7. Comment on: Eur Respir J 1995 Jun;8(6):888–98.

Relationships of self-esteem and efficacy to psychological distress in mothers of children with chronic physical illnesses. Silver EJ, et al. **Health Psychol** 1995 Jul; 14(4):333–40

Knowledge of asthma among parents of asthmatic children. Lal A, et al. **Indian Pediatr** 1995 Jun;32(6):649–55

Allergic-type adverse reactions to low osmolality contrast media in patients with a history of allergy or asthma. Simon MR. **Invest Radiol** 1995 May;30(5):285–90

Asthma in the pregnant adolescent: a review. Shulman V, et al. **J Adolesc Health** 1996 Mar;18(3):168–76 (89 ref.)

52nd Annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI). New Orleans, Louisiana, March 15–20, 1996. Abstracts. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 3):183–576

Allergy versus asthma as the focus of the subspecialty. Platts-Mills TA, et al. **J Allergy Clin Immunol** 1996 Mar; 97(3):865–8

Internet for the allergist. Bell T. **J Asthma** 1996;33(3):143–8 (6 ref.)

Development of a clinical asthma score for use in hospitalized children between 1 and 5 years of age. Parkin PC, et al. **J Clin Epidemiol** 1996 Aug;49(8):821–5

The impact of a summer asthma camp experience on asthma education and morbidity in children. Sorrells VD, et al. **J Fam Pract** 1995 Nov;41(5):465–8

What is asthma? An update on the mechanisms. O'Byrne PM. **J Investig Allergol Clin Immunol** 1995 Jan-Feb; 5(1):6–11 (39 ref.)

Effect of bronchial asthma on the course of pregnancy, labour and perinatal outcome. Jana N, et al. **J Obstet Gynaecol** 1995 Jun;21(3):227–32

An update of GEPOR project activity. Donner CF, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):228–9

Patients' interest in educational programmes on asthma. Moscato G, et al. **Monaldi Arch Chest Dis** 1995 Aug; 50(4):319–22

From pathophysiological mechanisms to pharmacological treatment of childhood asthma. Barnes PJ. **Pediatr Pulmonol Suppl** 1995;11:40–1

Natural history of childhood asthma. Landau LI. **Pediatr Pulmonol Suppl** 1995;11:30–1

The risk of anesthesia in the asthmatic child. Pradal M, et al. **Pediatr Pulmonol Suppl** 1995;11:51–2

Chronic asthma: an update. Kemper KJ. **Pediatr Rev** 1996 Apr;17(4):111–8 (18 ref.)

Asthma and chronic bronchitis: similarities and differences [editorial] Bousquet J, et al. **Respir Med** 1996 Apr; 90(4):187–90

Management of childhood and adolescent asthma. 1994 consensus. South African Childhood Asthma Working Group. **S Afr Med J** 1994 Dec;84(12):862–6

Is optimal management of childhood asthma achievable in South Africa? [letter] Morris A. **S Afr Med J** 1994 Dec; 84(12):869–70

Developing outcome measures for ambulatory care—an application to asthma and diabetes. McColl E, et al. **Soc Sci Med** 1995 Nov;41(10):1339–48

Childhood asthma: what is it and where is it going? [editorial] Christie G, et al. **Thorax** 1995 Oct;50(10):1027–30 (81 ref.)

Adolescent asthma. Introduction. Pérez-Yarza EG. **Thorax** 1996 Jan;51 Suppl 1:S1

Prognostic factors for the outcome of childhood asthma in adolescence. Roorda RJ. **Thorax** 1996 Jan;51 Suppl 1:S7–12 (98 ref.)

Overview of diisocyanate occupational asthma. Bernstein JA. **Toxicology** 1996 Jul 17;111(1-3):181–9 (24 ref.)

[The clinical scoring system for predicting the risk of intraoperative and postoperative bronchospasm] Harada J, et al. **Masui** 1995 Oct;44(10):1415–20 (Eng. Abstr.) **(Jpn)**

[Concept and definition of asthma] Adachi M, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):163–7 (9 ref.) **(Jpn)**

[Recent trends in the treatment and physiopathology of bronchial asthma] Inoue H. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):449–53 (6 ref.) **(Jpn)**

[Inflammatory mediators in asthma] Ota K. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):178–83 (5 ref.) **(Jpn)**

[Evaluation of the course of pregnancy and the newborn state in women with bronchial asthma] Wszelaki-Lass E, et al. **Ginekol Pol** 1995 Dec;66(12):670–3 (Eng. Abstr.) **(Pol)**

[Child asthma in 1996] Ojeda Casas JA. **Allergol Immunopathol (Madr)** 1996;24 Suppl 1:104–17 (30 ref.) **(Spa)**

[Asthma and pregnancy] Gazca Aguilar A, et al. **Ginecol Obstet Mex** 1995 Nov;63:460–6 (Eng. Abstr.) **(Spa)**

[Bronchial hyperreactivity and occupational asthma (editorial)] Peces-Barba Romero G, et al. **Rev Clin Esp** 1996 Mar;196(3):143–4 **(Spa)**

BLOOD

Effects of "systemic" budesonide concentrations on in vitro allergen-induced activation of blood mononuclear cells isolated from asthmatic patients. Oddera S, et al. **Allergy** 1995 May;50(5):397–404

Circulating leukocyte adhesion molecules in stable asthma and nonobstructive chronic bronchitis. Riise GC, et al. **Allergy** 1995 Aug;50(8):693–8

Associations of blood group-related antigens to FEV1, wheezing, and asthma. Kauffmann F, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):76–82

Increased levels of free serotonin in plasma of symptomatic asthmatic patients. Lechin F, et al. **Ann Allergy Asthma Immunol** 1996 Sep;77(3):245–53

Comparison of serum and plasma leukotriene B4 levels in normal and asthmatic subjects. Seggev JS, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):365–8

Serum eosinophil cationic protein measurements in monitoring pulmonary inflammation in asthma [letter] Brand PL. **Arch Dis Child** 1996 Jul;75(1):88

Clinical value of monitoring eosinophil activity in asthma. Koller DY, et al. **Arch Dis Child** 1995 Nov;73(5):413–7

Plasma interleukin-3 and interleukin-4 concentrations in Turkish asthmatic children [letter] Kutukculer N, et al. **Arch Dis Child** 1995 Oct;73(4):378–9

Blood eosinophil counts and arterial oxygen tension in acute asthma. Spallarossa D, et al. **Arch Dis Child** 1995 Oct; 73(4):333–7

Effect of hydrocortisone treatment on oxygen metabolism and phagocytosis of peripheral blood neutrophils in asthmatic patients, sensitive and resistant to glucocorticosteroid therapy. Jankowska R, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(5–6):383–6

In vivo effect of prednisolone on release of leukotriene C4 in eosinophils obtained from asthmatic patients. Shindo K, et al. **Biochem Biophys Res Commun** 1995 Sep 25; 214(3):869–74

Plasma thrombospondin levels in sheep with allergic asthma. Huang S-W, et al. **Chest** 1996 Jun;109(6):1614–7

Soluble intercellular adhesion molecule 1 (ICAM-1) antigen in sera of bronchial asthmatics. Shiota Y, et al. **Chest** 1996 Jan;109(1):94–9

Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma [see comments] Ulrik CS. **Clin Exp Allergy** 1995 Sep;25(9):820–7. Comment in: Clin Exp Allergy 1995 Sep;25(9):795–8.

Glucocorticoids induced down-regulation of glucocorticoid receptor mRNA expression in asthma. Vachier I, et al. **Clin Exp Immunol** 1996 Feb;103(2):311–5

Blood eosinophil leukotriene C4 production in asthma of different severities. Laviolette M, et al. **Eur Respir J** 1995 Sep;8(9):1465–72

Effect of glucose on the respiratory burst of circulating neutrophils from asthmatics. Lin X, et al. **Exp Mol Pathol** 1995 Feb;62(1):1–11

The effect of high-dose inhaled budesonide on lipid profile in asthmatic patients. Yavuz O, et al. **Gen Pharmacol** 1996 Jan;27(1):89–90

Pediatric asthma—a correlation of clinical treatment and oxygen saturation. Cook T, et al. **Hawaii Med J** 1995 Jul; 54(7):665–8

Evidence for an increased intracellular free calcium concentration in platelets of bronchial asthma patients. Kuroda S, et al. **Intern Med** 1995 Aug;34(8):722–7

Serum eosinophilic cationic protein as a marker of disease activity in chronic asthma [letter; comment] Chanarin N, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):705–6 . Comment on: J Allergy Clin Immunol 1995 Jan;95(1 Pt 1):23–8.

Lipoprotein levels in elderly patients with asthma. Cardiovascular Health Study Research Group. Enright PL, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):467–9

Increased adhesion to vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 of eosinophils from patients with asthma. Håkansson L, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):941–50

Compartmentalization of eosinophil granulocyte-macrophage colony-stimulating factor expression in patients with asthma. Sullivan S, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):966–76

Decreased adrenal sex steroid levels in the absence of glucocorticoid suppression in postmenopausal asthmatic women. Weinstein RE, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):1–8

Increased hypodense eosinophils after activation with PAF-acether and calcium ionophore in asthmatic subjects. Agrawal DK, et al. **J Asthma** 1996;33(4):213–9

Serum levels of soluble interleukin-2 receptor in asthma patients. Motojima S, et al. **J Asthma** 1995;32(2):151–8

Increased spontaneous production and generation of superoxide anion by blood neutrophils in patients with asthma. Teramoto S, et al. **J Asthma** 1996;33(3):149–55

Effect of two beta 2-agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis. Giustina A, et al. **J Endocrinol Invest** 1995 Dec;18(11):847–52

Undetectable interferon-alpha serum levels in a patient with atopic dermatitis. Dolen JG, et al. **J Interferon Cytokine Res** 1995 Nov;15(11):973–5

Intracellular (polymorphonuclear) magnesium content in patients with bronchial asthma between attacks. Fantidis P, et al. **J R Soc Med** 1995 Aug;88(8):441–5

Individual time-courses of ECP and EPX during allergen provocation tests in asthmatic children. Kleinau I, et al. **Pediatr Allergy Immunol** 1995 May;6(2):109–18

C-reactive protein in acute pulmonary exacerbations of patients with cystic fibrosis. Friesen CA, et al. **Pediatr Pulmonol** 1995 Oct;20(4):215–9

Pattern of cytokine production by T cells from adolescents with asthma in remission, after stimulation with Dermatophagoides farinae antigen. Noma T, et al.

Pediatr Res 1995 Aug;38(2):187–93

Plasma atrial natriuretic peptide during spontaneous bronchoconstriction in asthmatics. Robichaud A, et al. **Peptides** 1995;16(4):653–6

[Plasma endothelin 1 and its clinical evaluation in asthma] Sun R, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Jun; 18(3):161–3, 190–1 (Eng. Abstr.) **(Chi)**

[Immediate suppression of endogenous cortisol secretion after single oral administration of 6-alpha-methylprednisolone] Hampe S, et al. **Wien Med Wochenschr** 1995; 145(17–18):501–2 (Eng. Abstr.) **(Ger)**

[Eosinophil activation markers in status asthmaticus] Nagy L, et al. **Orv Hetil** 1996 Jan 21;137(3):121–4 (Eng. Abstr.) **(Hun)**

[Eosinophil cationic protein in serum from adults with asthma and with chronic obstructive pulmonary disease] Yoshizawa A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):24–9 (Eng. Abstr.) **(Jpn)**

[Comparative study of the effect of carbon dioxide on the generation of active forms of oxygen by leukocytes in health and in bronchial asthma] Kogan AKh, et al. **Patol Fiziol Eksp Ter** 1995 Jul–Sep;(3):34–40 (Eng. Abstr.) **(Rus)**

[Changes in the lipid composition of the blood serum lipoproteins during the hormonal treatment of patients with bronchial asthma] Lizenko MV, et al. **Ter Arkh** 1995; 67(11):35–8 (Eng. Abstr.) **(Rus)**

[An analysis of DNA reparative synthesis in the lymphocytes of bronchial asthma patients] Soliev AK, et al. **Tsitologiia** 1995;37(5–6):465–9 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Effect of ethanol on airway caliber and nonspecific bronchial responsiveness in patients with alcohol-induced asthma. Myou S, et al. **Allergy** 1996 Jan;51(1):52–5

Occupational asthma caused by FD&C blue dye no. 2. Miller ME, et al. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):31–4

Acute health effects of exposure to high levels of air pollution in eastern Europe. Peters A, et al. **Am J Epidemiol** 1996 Sep 15;144(6):570–81

Endotoxin exposure-response in a fiberglass manufacturing facility. Milton DK, et al. **Am J Ind Med** 1996 Jan; 29(1):3–13

Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Sestini P, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):572–5

Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Szczeklik A, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):567–71

Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. A prospective cohort study. Troisi RJ, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1183–8

Inhalation challenge effects of perfume scent strips in patients with asthma. Kumar P, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):429–33

An outbreak of naphthalene di-isocyanate-induced asthma in a plastics factory. Fuortes LJ, et al. **Arch Environ Health** 1995 Sep–Oct;50(5):337–40

Impact of environmental pollution on respiratory sensitization and asthma. Kimber I. **Arch Toxicol Suppl** 1996;18:34–48 (85 ref.)

Reactive airways dysfunction syndrome. Alberts WM, et al. **Chest** 1996 Jun;109(6):1618–26 (72 ref.)

Isolated late asthmatic reaction after exposure to a high-molecular-weight occupational agent, subtilisin. Lemière C, et al. **Chest** 1996 Sep;110(3):823–4

Pickled onion-induced asthma: a model of sulfite-sensitive asthma? [see comments] Gastaminza G, et al. **Clin Exp Allergy** 1995 Aug;25(8):698–703. Comment in: Clin Exp Allergy 1995 Aug;25(8):680–1.

Sulfite sensitivity [editorial; comment] Peroni DG, et al. **Clin Exp Allergy** 1995 Aug;25(8):680–1. Comment on: Clin Exp Allergy 1995 Aug;25(8):698–703.

Effect of ozone exposure on maximal airway narrowing in non-asthmatic and asthmatic subjects. Hiltermann TJ, et al. **Clin Sci (Colch)** 1995 Dec;89(6):619–24

Contact dermatitis and asthma from sodium metabisulfite in a photographic technician. Jacobs MC, et al. **Contact Dermatitis** 1995 Jul;33(1):65–6

Asthma and the beta 2-agonist controversy: much ado about something. Lieberman JS, et al. **Del Med J** 1995 Dec; 67(12):624–8 (28 ref.)

Air toxics and asthma: impacts and end points. Eschenbacher WL, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:209–11

Association between toluene diisocyanate-induced asthma and DQB1 markers: a possible role for aspartic acid at position 57. Balboni A, et al. **Eur Respir J** 1996 Feb; 9(2):207–10

Occupational asthma due to ceftazidime. Stenton SC, et al. **Eur Respir J** 1995 Aug;8(8):1421–3

Occupational asthma caused by natural rubber latex. Vandenplas O. **Eur Respir J** 1995 Nov;8(11):1957–65 (80 ref.)

Outdoor air pollution and asthma. **Food Chem Toxicol** 1996 Mar;34(3):318–9

Early reaction type allergies and diseases of the respiratory passages in employees from persulphate production. Wrbitzky R, et al. **Int Arch Occup Environ Health** 1995; 67(6):413–7

Fatal asthma during inhalation challenge [letter] Baum CG. **J Allergy Clin Immunol** 1996 Jul;98(1):239

Skin test responses to latex in an allergy and asthma clinic. Hadjiliadis D, et al. **J Allergy Clin Immunol** 1995 Sep; 96(3):431–2

Fatal asthma attack associated with inhalation of nebulized distilled water. Marino JT. **J Allergy Clin Immunol** 1996 Jul;98(1):239

Chronic respiratory symptoms associated with estimated long-term ambient concentrations of fine particulates less than 2.5 microns in aerodynamic diameter (PM2.5) and other air pollutants. Abbey DE, et al. **J Expo Anal Environ Epidemiol** 1995 Apr–Jun;5(2):137–59

Cobalt-induced occupational asthma associated with systemic illness. Baik JJ, et al. **J Korean Med Sci** 1995 Jun; 10(3):200–4

Occupational asthma induced by ethylene oxide [letter] Verraes S, et al. **Lancet** 1995 Nov 25;346(8987):1434–5

Occupational asthma due to isocyanates. Baur X. **Lung** 1996; 174(1):23–30 (50 ref.)

Asthma due to isocyanates: a mail survey in a 1% sample of furniture workers in the Veneto region, Italy. Mastrangelo G, et al. **Med Lav** 1995 Nov–Dec;86(6):503–10

Asthma death induced by ibuprofen [see comments] Antonicelli L, et al. **Monaldi Arch Chest Dis** 1995 Aug; 50(4):276–8. Comment in: Monaldi Arch Chest Dis 1995 Aug;50(4):256–7.

Asthma following royal jelly [letter] Harwood M, et al. **N Z Med J** 1996 Aug 23;109(1028):325

Physiological wheezing [letter] Parkinson P. **N Z Med J** 1995 Sep 22;108(1008):392

Epidemiological study of hard metal asthma. Kusaka Y, et al. **Occup Environ Med** 1996 Mar;53(3):188–93

Decreased ventilatory function in hard metal workers. Kusaka Y, et al. **Occup Environ Med** 1996 Mar;53(3):194–9

A cross sectional study of chemical industry workers with occupational exposure to persulphates. Merget R, et al. **Occup Environ Med** 1996 Jun;53(6):422–6

Asthma caused by topical application of ketorolac. Sitenga GL, et al. **Ophthalmology** 1996 Jun;103(6):890–2

Menthol and aspirin-induced asthma [letter] Kawane H. **Respir Med** 1996 Apr;90(4):247–9

Occupational asthma due to chloramine-T solution. Kujala VM, et al. **Respir Med** 1995 Nov;89(10):693–5

Occupational asthma due to latex in a hospital administrative employee. Vandenplas O, et al. **Thorax** 1996 Apr; 51(4):452–3

Increase in non-specific bronchial hyperresponsiveness as an early marker of bronchial response to occupational agents during specific inhalation challenges. Vandenplas O, et al. **Thorax** 1996 May;51(5):472–8

Characterization of histamine releasing factors in diisocyanate-induced occupational asthma. Lummus ZL, et al. **Toxicology** 1996 Jul 17;111(1–3):191–206

[Asthma, rhinitis and urticaria following occupational exposure to cyanoacrylate glues] Kopferschmit-Kubler MC, et al. **Rev Mal Respir** 1996 Jul;13(3):305–7 (Eng. Abstr.) **(Fre)**

[Chronic course of reactive bronchial dysfunction syndrome. Apropos of 6 further cases] Rivoire B, et al. **Rev Mal Respir** 1995;12(5):471–7 (Eng. Abstr.) **(Fre)**

[Solvent emissions in a school building after using a construction moisture protection substance] Bent S, et al. **Gesundheitswesen** 1996 Apr;58(4):234–6 (Eng. Abstr.) **(Ger)**

[Occupational asthma: definition—epidemiology—etiologic substances—prognosis—prevention—diagnosis—expert assessment aspects] Merget R, et al. **Pneumologie** 1996 May; 50(5):356–63 (83 ref.) **(Ger)**

[Drug-induced asthma] Gani F, et al. **Recenti Prog Med** 1996 Jan;87(1):31–40 (30 ref.) **(Ita)**

[Persistent reactive airway dysfunction syndrome after exposure to chromate] Nagasaka Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):759–64 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Serum phospholipase A2 activity in patients with aspirin-induced asthma] Toyoshima M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):691–4 (Eng. Abstr.) **(Jpn)**

[Aspirin-induced asthma] Sakakibara H. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):227–33 (5 ref.) **(Jpn)**

[Bronchial asthma with inflammation of the nose mucous membrane induced by occupational exposure to methyl methacrylate in a dental technician] Wittczak T, et al. **Med Pr** 1996;47(3):259–66 (Eng. Abstr.) **(Pol)**

CLASSIFICATION

Correlation between the clinical classification of bronchial asthma severity and the methacholine test in children. Albornoz C, et al. **J Investig Allergol Clin Immunol** 1995 Nov–Dec;5(6):322–4

COMPLICATIONS

Sinusitis and asthma: associations, influences and principles of management. Halpern GM. **Allergol Immunopathol (Madr)** 1995 Jul–Aug;23(4):171–81 (60 ref.)

Pseudoasthma in a case of asthma. Imam AP, et al. **Allergol Immunopathol (Madr)** 1995 Mar–Apr;23(2):96–100

Maternal asthma and idiopathic preterm labor. Kramer MS, et al. **Am J Epidemiol** 1995 Nov 15;142(10):1078–88

Rhinovirus inhalation causes long-lasting excessive airway narrowing in response to methacholine in asthmatic subjects in vivo. Cheung D, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1490–6

Management of sinusitis in the asthmatic patient. Senior BA, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):6–15; quiz 15–9 (47 ref.)

Diagnosis and management of migraine. Care needs to be taken with treatment [letter] Lock J, et al. **BMJ** 1996 Sep 14;313(7058):691; discussion 691–2

Surgical therapy for Wolff-Parkinson-White syndrome in patients with bronchial asthma. Ohtake H, et al. **Cardiovasc Surg** 1996 Feb;4(1):53–6

Prevalence of gastroesophageal reflux symptoms in asthma. Field SK, et al. **Chest** 1996 Feb;109(2):316–22

Asthma deaths confounded by substance abuse. An assessment of fatal asthma. Levenson T, et al. **Chest** 1996 Sep;110(3):604–10

Habitual coughing and its associations with asthma, anxiety, and gastroesophageal reflux. Lúdvíksdóttir D, et al. **Chest** 1996 May;109(5):1262–8

Dyspnea doesn't always signify bronchial asthma [letter; comment] Rizzo S. **Chest** 1996 Feb;109(2):588–9. Comment on: Chest 1995 Feb;107(2):569–70.

Atopic status in patients with brittle and non-brittle asthma: a case-control study. Miles J, et al. **Clin Exp Allergy** 1995 Nov;25(11):1074–82

Mechanisms of increased airway microvascular permeability: role in airway inflammation and obstruction. Goldie RG, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul; 22(6–7):387–96 (88 ref.)

Low measured auto-positive end-expiratory pressure during mechanical ventilation of patients with severe asthma: hidden auto-positive end-expiratory pressure [see comments] Leatherman JW, et al. **Crit Care Med** 1996 Mar; 24(3):541–6. Comment in: Crit Care Med 1996 Mar;24(3):379–80.

Fever and leucocytosis accompanying asthmatic reactions due to occupational agents: frequency and associated factors. Lemière C, et al. **Eur Respir J** 1996 Mar; 9(3):517–23

Cytokine concentrations in sputum of asthmatic patients. Konno S, et al. **Int Arch Allergy Immunol** 1996 Jan; 109(1):73–8

The assessment of dyspnea in bronchial asthma. Subratty AH. **Int J Clin Pharmacol Ther** 1995 Jul;33(7):394–6

Do patients with severe asthma run an increased risk from ischaemic heart disease? Torén K, et al. **Int J Epidemiol** 1996 Jun;25(3):617–20

Amphotericin B: emergency challenge in a neutropenic, asthmatic patient with fungal sepsis. Kemp SF, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):425–7

Asthma and its association with cardiovascular disease in the elderly. The Cardiovascular Health Study Research Group. Enright PL, et al. **J Asthma** 1996;33(1):45–53

Hypopigmented skin lesions associated with atopic dermatitis in asthma. Nader-Djalal N, et al. **J Asthma** 1996; 33(4):231–8

The accuracy of environmental tobacco smoke exposure measures among asthmatic children. Emerson JA, et al. **J Clin Epidemiol** 1995 Oct;48(10):1251–9

Three cases of primary biliary cirrhosis associated with bronchial asthma. Terasaki S, et al. **J Gastroenterol** 1995 Oct;30(5):667–71

Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. Teran LM, et al. **J Immunol** 1996 Aug 15;157(4):1806–12

Eosinophilic gastroenteritis associated with food allergy and bronchial asthma. Park HS, et al. **J Korean Med Sci** 1995 Jun;10(3):216–9

Asthma of the back [letter] Thompson EN. **Pain** 1995 Jun; 61(3):493–4

Cough and asthma in children. Newson T, et al. **Pediatr Ann** 1996 Mar;25(3):156–8, 161 (29 ref.)

Retropharyngeal air accumulation as a complication of pneumomediastinum and a cause of airway obstruction in asthma. Cohn RC, et al. **Pediatr Emerg Care** 1995 Oct; 11(5):298–9

Use of fiberoptic bronchoscopy in asthmatic children with lung collapse. Barbato A, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):253–5 (9 ref.)

Hopkins syndrome: T2-weighted high intensity of anterior horn on spinal MR imaging. Arita J, et al. **Pediatr Neurol** 1995 Oct;13(3):263–5 (15 ref.)

Gastroesophageal reflux is chronologically correlated with coughing but not with wheezing in children with bronchial asthma and gastroesophageal reflux symptoms [letter] Tomomasa T, et al. **Pediatr Pulmonol** 1995 Sep;20(3):193–4

Pathophysiology and mechanisms of gastroesophageal reflux in childhood asthma. Malfroot A, et al. **Pediatr Pulmonol Suppl** 1995;11:55–6

Management of GER in childhood asthma. Orenstein SR. **Pediatr Pulmonol Suppl** 1995;11:57–8

Cor pulmonale due to untreated asthma in a young woman with coexistent anorexia nervosa. Wilson GE, et al. **Respir Med** 1995 Oct;89(9):631–3

Effect of acute hyperoxia on the bronchodilator response to salbutamol in stable asthmatic patients. Dagg KD, et

al. **Thorax** 1996 Aug;51(8):853–4

Assessment of food chemical intolerance in adult asthmatic subjects. Hodge L, et al. **Thorax** 1996 Aug;51(8):805–9

[Complications of an asthma crisis] Delafosse C, et al. **Rev Mal Respir** 1996 Jul;13(3):313–5 **(Fre)**

[Bronchial asthma complicated by myasthenia gravis] Akiba Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr; 34(4):449–53 (Eng. Abstr.) **(Jpn)**

[Swyer–James syndrome with bronchial asthma and recurrent spontaneous pneumothorax] Koura T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun;34(6):731–6 (Eng. Abstr.) **(Jpn)**

[A case of bronchial asthma complicated by mycosis] Andronova NV, et al. **Ter Arkh** 1995;67(11):33–5 (7 ref.) **(Rus)**

[Psychoautonomic disorders in bronchial asthma patients] Ubaĭdullaev AM, et al. **Ter Arkh** 1996;68(3):44–7 (Eng. Abstr.) **(Rus)**

[Preanesthetic study revealing an endobronchial foreign body in an asthmatic patient (letter)] Pérez–Torres MC, et al. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):115–7 **(Spa)**

DIAGNOSIS

Influence of breathing pattern on transcutaneous oxygen and carbon dioxide tension during histamine provocation in children with bronchial asthma. Holmgren D, et al. **Acta Paediatr** 1996 Feb;85(2):177–82

Asthma treatment in schoolchildren: lung function in different therapeutic groups. Korppi M, et al. **Acta Paediatr** 1996 Feb;85(2):190–4

Occupational hypersensitivity to sesame seeds. Alday E, et al. **Allergy** 1996 Jan;51(1):69–70

Statement on self–monitoring of peak expiratory flow in the investigation of occupational asthma. Subcommittee on Occupational Allergy of the European Academy of Allergology and Clinical Immunology. Moscato G, et al. **Allergy** 1995 Sep;50(9):711–7

Asthma: diagnosis and management. Shuttari MF. **Am Fam Physician** 1995 Dec;52(8):2225–35

Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid–phase measurements. Pizzichini E, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):308–17

Diagnostic complexity in a patient with asthma, pulmonary infiltrates, and eosinophilia [clinical conference] Backman KS, et al. **Ann Allergy Asthma Immunol** 1995 Nov; 75(5):391–400

New onset dyspnea with reversible airway obstruction in a 70–year–old man [clinical conference] Hermanoff MH, et al. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):475–80

Allergic bronchopulmonary aspergillosis presenting with cough variant asthma and identifiable source of Aspergillus fumigatus. Krasnick J, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):344–6

Multifactorial immunologic lung disease: a case report. Krasnick J, et al. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):239–41

Persistent sinusitis and refractory asthma in a 10–year–old boy [clinical conference] Kwong KY, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):21–6

Clinical evaluation of asthma. Li JT, et al. **Ann Allergy Asthma Immunol** 1996 Jan;76(1):1–13; quiz 13–5 (86 ref.)

Statement on self–monitoring of peak expiratory flows in the investigation of occupational asthma. Subcommittee on Occupational Allergy of European Academy of Allergy and Clinical Immunology, American Academy of Allergy and Immunology, European Respiratory Society, American College of Allergy, Asthma and Immunology. Moscato G, et al. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):233–8

Going beyond the National Asthma Education Program guidelines for the diagnosis and management of asthma: critical need for outcomes assessment [editorial] Stempel DA, et al. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):457–60

A 24–year–old female with new onset of shortness of breath and non–productive cough. Torres C. **Aviat Space Environ Med** 1995 Aug;66(8):795–6

Use of a postal questionnaire to estimate the likely under–diagnosis of asthma–like illness in adults. Frank P, et al. **Br J Gen Pract** 1996 May;46(406):295–97

Diagnosis of asthma and chronic obstructive pulmonary disease in general practice. Van Schayck CP. **Br J Gen Pract** 1996 Mar;46(404):193–7

Emergency management of acute adult asthma. Grunfeld AF, et al. **Can Fam Physician** 1995 Nov;41:1909–16 (42 ref.)

Asthma and chronic bronchitis. Can family physicians predict rates of progression? van Schayck CP, et al. **Can Fam Physician** 1995 Nov;41:1868–76

Eucapnic voluntary hyperventilation as a bronchoprovocation technique: development of a standarized dosing schedule in asthmatics. Argyros GJ, et al. **Chest** 1996 Jun;109(6):1520–4

Bronchoprovocation tests in the diagnosis of isocyanate–induced asthma. Banks DE, et al. **Chest** 1996 May;109(5):1370–9

Assessment of asthma in the workplace. ACCP consensus statement. American College of Chest Physicians. Chan–Yeung M. **Chest** 1995 Oct;108(4):1084–117 (159 ref.)

Interpretation of eucapnic voluntary hyperventilation in the diagnosis of asthma. Hurwitz KM, et al. **Chest** 1995 Nov; 108(5):1240–5

Prior diagnosis and treatment of patients with normal results of methacholine challenge and unexplained respiratory symptoms. Joyce DP, et al. **Chest** 1996 Mar;109(3):697–701

Parents' evaluations of wheezing in their children with asthma. Lee H, et al. **Chest** 1996 Jan;109(1):91–3

Vocal cord dysfunction syndrome and "steroid–dependent" asthmatics [letter; comment] Pacht ER, et al. **Chest** 1995 Dec;108(6):1772–3. Comment on: Chest 1995 Mar;107(3):817–25.

Physiologic diagnosis and function in asthma. Cherniack RM. **Clin Chest Med** 1995 Dec;16(4):567–81 (17 ref.)

Occupational asthma. Diagnosis, management, and prevention. Newman LS. **Clin Chest Med** 1995 Dec; 16(4):621–36 (187 ref.)

Evaluation of atopy through an expert system: description of the database. Ray P, et al. **Clin Exp Allergy** 1995 Nov; 25(11):1067–73

Relationship of daytime asthma symptom frequency to morning peak expiratory flow. Atherton HA, et al. **Eur Respir J** 1996 Feb;9(2):232–6

Methacholine challenge does not affect bronchoalveolar fluid cell number and many indices of cell function in asthma. Kraft M, et al. **Eur Respir J** 1995 Nov;8(11):1966–71

Eosinophil cationic protein and tidal flow volume loops in children 0–2 years of age. Lødrup Carlsen KC, et al. **Eur Respir J** 1995 Jul;8(7):1148–54

Frequency of nocturnal symptoms in asthmatic children attending a hospital out–patient clinic. Meijer GG, et al. **Eur Respir J** 1995 Dec;8(12):2076–80

Psychogenic vocal cord dysfunction simulating bronchial asthma. Mobeireek A, et al. **Eur Respir J** 1995 Nov; 8(11):1978–81

Comparing methods for assessing bronchial responsiveness in children: single step cold air challenge, multiple step cold air challenge, and histamine provocation. Modl M, et al. **Eur Respir J** 1995 Oct;8(10):1742–7

Statement on self–monitoring of peak expiratory flows in the investigation of occupational asthma. Subcommittee on Occupational Allergy of the European Academy of Allergology and Clinical Immunology. American Academy of Allergy and Clinical Immunology. European Respiratory Society. American College of Allergy, Asthma and Immunology. Moscato G, et al. **Eur Respir J** 1995 Sep;8(9):1605–10

Outcome of wheeze in childhood: the influence of atopy. Ross S, et al. **Eur Respir J** 1995 Dec;8(12):2081–7

Increased IgE—diagnostic value of the index in children with bronchial obstruction. Klinkanova M, et al. **Folia Med (Plovdiv)** 1995;37(4A Suppl):54

Late–onset asthma: making the diagnosis, choosing drug therapy. Sherman CB. **Geriatrics** 1995 Dec;50(12):24–6, 29–30, 33 (22 ref.)

Managing the patient with intractable asthma. Martin RJ. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):61–4, 69–74, 79–80

Validation of questionnaire and bronchial hyperresponsiveness against respiratory physician assessment in the diagnosis of asthma. Jenkins MA, et al. **Int J Epidemiol** 1996 Jun;25(3):609–16

No confirmation of Geschwind's hypothesis of associations between reading disability, immune disorders, and motor preference in ADHD. Biederman J, et al. **J Abnorm Child Psychol** 1995 Oct;23(5):545–52

Practice parameters for the diagnosis and treatment of asthma. Joint Task Force on Practice Parameters, representing the American Academy of Allergy Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 2):707–870

Early childhood respiratory symptoms and the subsequent diagnosis of asthma. Dodge R, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):48–54

Do subjects investigated for occupational asthma through serial peak expiratory flow measurements falsify their results? Malo JL, et al. **J Allergy Clin Immunol** 1995 Nov; 96(5 Pt 1):601–7

Diagnosis of soybean–induced asthma. Morell F, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):320–4

Statement on self–monitoring of peak expiratory flows in the investigation of occupational asthma. Subcommittee on Occupational Allergy of European Academy of Allergy and Clinical Immunology. Moscato G, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):295–301

Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing patients with symptomatic from patients with asymptomatic allergy to common aeroallergens. Pastorello EA, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):580–7

Cross refractoriness between bradykinin and hypertonic saline challenges in asthma. Rajakulasingam K, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):502–9

Bronchogenic carcinoma masquerading as bronchial asthma. Singh B, et al. **J Assoc Physicians India** 1995 Aug;43(8):579

Comparison between incremental and single–dose allergen administration in bronchial provocation tests. Wasserfallen JB, et al. **J Asthma** 1996;33(3):169–78

Vocal cord dysfunction. A syndrome that mimics asthma. Moran MG. **J Cardpulm Rehabil** 1996 Mar–Apr;16(2):91–2

Condensed expirate nitrite as a home marker for acute asthma [letter] Hunt J, et al. **Lancet** 1995 Nov 4;346(8984):1235–6

Neural networks [letter; comment] Lane V, et al. **Lancet** 1995 Dec 2;346(8988):1501. Comment on: Lancet 1995 Oct 28;346(8983):1135–8.

Methacholine inhaled challenge: study of correlation among different indices expressing the result. Clini E, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):194–8

Potential problems in peak expiratory flow data used to diagnose occupational asthma. Miller MR. **Occup Med (Oxf)** 1996 Jun;46(3):239–41

Hypertonic saline challenge in an adult epidemiological survey. Rabone SJ, et al. **Occup Med (Oxf)** 1996 Jun; 46(3):177–85

Assessment of respiratory distress in the asthmatic child: when should we be concerned? Gayle MO, et al. **Pediatr Ann** 1996 Mar;25(3):128–35

Cough and asthma in children. Newson T, et al. **Pediatr Ann** 1996 Mar;25(3):156–8, 161 (29 ref.)

Clinical diagnosis of infant asthma. Boner AL, et al. **Pediatr Pulmonol Suppl** 1995;11:36–7

Assessing nocturnal asthma in children. Menardo JL. **Pediatr Pulmonol Suppl** 1995;11:38–9

Steroids and asthma [letter] DeMasi JM. **Pediatrics** 1996 Jul; 98(1):169; discussion 169–70

Automated identification of episodes of asthma exacerbation for quality measurement in a computer–based medical record. Aronow DB, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:309–13

Paediatric endobronchial leiomyoma mimicking asthma. Olgun N, et al. **Respir Med** 1995 Sep;89(8):581–2

Occupational lung disease. 8. The diagnosis of occupational asthma from serial measurements of lung function at and away from work. Bright P, et al. **Thorax** 1996 Aug; 51(8):857–63 (49 ref.)

Development of OASYS–2: a system for the analysis of serial measurement of peak expiratory flow in workers with suspected occupational asthma. Gannon PF, et al. **Thorax** 1996 May;51(5):484–9

Interrelationships between diagnosed asthma, asthma–like symptoms, and abnormal airway behaviour in adolescence: the Odense Schoolchild Study. Siersted HC, et al. **Thorax** 1996 May;51(5):503–509

[Acute asthma outside hospital. The predictive value of pulse oximetry in manifestation of respiratory insufficiency] Guldager H, et al. **Ugeskr Laeger** 1995 Nov 20; 157(47):6583–5 (Eng. Abstr.) **(Dan)**

[Eosinophil count in asthma. A marker of disease activity in intrinsic and extrinsic asthma] Ulrik CS. **Ugeskr Laeger** 1996 Jun 17;158(25):3612–6 (Eng. Abstr.) **(Dan)**

[Extrinsic and intrinsic asthma from childhood to early adult age. A 10–year follow–up] Ulrik CS, et al. **Ugeskr Laeger** 1996 Jun 17;158(25):3617–21 (Eng. Abstr.) **(Dan)**

[Diagnosis of bronchial asthma and chronic obstructive lung disease by the family physician (letter; comment)] Geijer RM, et al. **Ned Tijdschr Geneeskd** 1995 Dec 2; 139(48):2512–3. Comment on: Ned Tijdschr Geneeskd 1995 Sep 30;139(39):1966–71. **(Dut)**

[Diagnosis of bronchial asthma and chronic obstructive lung disease by the family physician. Ad hoc consensus group 'Diagnosis of asthma/chronic obstructive lung disease by the family physician' (see comments)] van Schayck CP. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1966–71 (22 ref.). Comment in: Ned Tijdschr Geneeskd 1995 Dec 2;139(48):2512–3. **(Dut)**

[Asthma in children] Dutau G. **Rev Pneumol Clin** 1996; 52(2):111–6 (5 ref.) (Eng. Abstr.) **(Fre)**

[Serum IgE, atopy, bronchial reactivity: details on female patients] Vellutini M, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):119–21 **(Ita)**

[Atopy, asthma and the judgement of preemployment fitness] Innocenti A. **Med Lav** 1995 Jul–Aug;86(4):303–8 (36 ref.) (Eng. Abstr.) **(Ita)**

[pH–metric parameters potentially predictive of asthmatic symptomatology: clinical and statistical research] Ponticelli A, et al. **Pediatr Med Chir** 1995 Nov–Dec;17(6):513–4 (Eng. Abstr.) **(Ita)**

[Nasal smear cytology in bronchial asthma: correlation of appearance and numbers of nasal smear mast cells, eosinophils or basophils and serum IgE antibodies to house dust mite in patients with bronchial asthma] Hirano K, et al. **Arerugi** 1995 Sep;44(9):1117–24 (Eng. Abstr.) **(Jpn)**

[Asthma–like symptoms due to thoracic aneurysm] Nakano Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):200–3 (Eng. Abstr.) **(Jpn)**

[Diagnosis of bronchial asthma] Nakagawa T. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):194–8 (5 ref.) **(Jpn)**

[Assessment of skin reactivity in patients with bronchial asthma undergoing non–specific immunotherapy] Faber M, et al. **Pneumonol Alergol Pol** 1995;63(9–10):516–20 **(Pol)**

[Asthma and chronic obstructive pulmonary disease. Similarities and differences] Pierzchala W. **Pneumonol Alergol Pol** 1995;63(5–6):332–5 (24 ref.) **(Pol)**

[Significance of exposure tests in diagnosis of occupational asthma] Kuś L, et al. **Pneumonol Pol** 1990 Jul–Aug; 58(7–8):370–3 (Eng. Abstr.) **(Pol)**

[Differences and similarities between asthma and chronic obstructive pulmonary diseases (editorial)] Pierzchala W. **Pol Arch Med Wewn** 1995 Apr;93(4):273–81 **(Pol)**

[Bronchoconstriction symptoms mimicking bronchial

asthma—report of two cases] Rogala B, et al. **Przegl Lek** 1995;52(8):403–4 (Eng. Abstr.) **(Pol)**

[A phonogramic study of expiratory wheezing in the asthmatic patient] Bueso A, et al. **Arch Bronconeumol** 1995 Dec;31(10):501–6 (Eng. Abstr.) **(Spa)**

[Usefulness of maximal expiratory flow in the diagnosis of occupational asthma (letter)] Gutiérrez Vall de Cabres V, et al. **Aten Primaria** 1995 Sep 30;16(5):294–5 **(Spa)**

DIET THERAPY

Dietary fish oil and airways obstruction. Britton J. **Thorax** 1995 Sep;50 Suppl 1:S11–5 (28 ref.)

[Is a fish oil enriched diet therapeutically beneficial?] Machura E, et al. **Pediatr Pol** 1995 Jul;70(7):597–602 (23 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis. Osmond MH, et al. **Acad Emerg Med** 1995 Jul;2(7):651–6

Asthma treatment in schoolchildren: lung function in different therapeutic groups. Korppi M, et al. **Acta Paediatr** 1996 Feb;85(2):190–4

Linear growth of very young asthmatic children treated with high-dose nebulized budesonide. Reid A, et al. **Acta Paediatr** 1996 Apr;85(4):421–4

Intermittent treatment with inhaled steroids for deterioration of asthma due to upper respiratory tract infections. Svedmyr J, et al. **Acta Paediatr** 1995 Aug;84(8):884–8

Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers. Wennergren G, et al. **Acta Paediatr** 1996 Feb;85(2):183–9

Modern treatment of asthma in children. Zeffren BS, et al. **Adv Pediatr** 1996;43:423–68 (214 ref.)

Inhaled steroids treatment and withdrawal in asthmatic children. Farrero E, et al. **Allergol Immunopathol (Madr)** 1995 Jul–Aug;23(4):182–8

Cyclosporin in steroid dependent asthma. Mungan D, et al. **Allergol Immunopathol (Madr)** 1995 Sep–Oct;23(5):202–6

The first 20 minutes after a single dose of inhaled salmeterol in asthmatic children. Barbato A, et al. **Allergy** 1995 Jun; 50(6):506–10

A double-blind, placebo-controlled comparison of sodium cromoglycate and ketotifen in the treatment of childhood asthma. Croce J, et al. **Allergy** 1995 Jun;50(6):524–7

A 4-week comparison of salmeterol and terbutaline in adult asthma. Hermansson BA, et al. **Allergy** 1995 Jul;50(7):551–8

Do inhaled steroids have similar efficacy? A case of bronchial asthma suggesting different efficacy of inhaled glucocorticosteroids. Larsen BB, et al. **Allergy** 1995 Jul; 50(7):600–3

Anticholinergic antimuscarinic agents in the treatment of airways bronchoconstriction in children. Martinati LC, et al. **Allergy** 1996 Jan;51(1):2–7 (33 ref.)

B2 agonists and their safety in the treatment of asthma. Fireman P. **Allergy Proc** 1995 Sep–Oct;16(5):235–9 (22 ref.)

Nebulized fenoterol versus i.v. aminophylline treatment of acute severe asthma [letter] Pan JF, et al. **Am J Emerg Med** 1995 Nov;13(6):677–80

Metered-dose inhaler technique of patients in an urban ED: prevalence of incorrect technique and attempt at education. Shrestha M, et al. **Am J Emerg Med** 1996 Jul;14(4):380–4

Re: "Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy: the Washington, DC, Dilated Cardiomyopathy Study" [letter] Lanes SF, et al. **Am J Epidemiol** 1996 Sep 1;144(5):528–9

Helping patients manage asthma. Brock P. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2662, 2666

Inadequate outpatient medical therapy for patients with asthma admitted to two urban hospitals [see comments] Hartert TV, et al. **Am J Med** 1996 Apr;100(4):386–94. Comment in: Am J Med 1996 Apr;100(4):381–2.

Isoetharine versus albuterol for acute asthma: greater immediate effect, but more side effects. Shrestha M, et al. **Am J Med** 1996 Mar;100(3):323–7

Comprehensive long-term management program for asthma: effect on outcomes in adult African-Americans. Kelso TM, et al. **Am J Med Sci** 1996 Jun;311(6):272–80

Asthma treatment in pregnancy: a randomized controlled study. Wendel PJ, et al. **Am J Obstet Gynecol** 1996 Jul; 175(1):150–4

Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo. Autio P, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1172–5

Glucocorticoid resistance in asthma. Barnes PJ, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 2):S125–40 (231 ref.)

Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Bentley AM, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):551–6

Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Busse WW, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):122–7

Rebound airway obstruction and responsiveness after cessation of terbutaline: effects of budesonide. de Jong JW, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):70–5

Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Diamant Z, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1790–5

The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Inman MD, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):65–9

The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antagonist, on neurokinin A-induced bronchoconstriction in asthmatics. Joos GF, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1781–4

Inhaled nitric oxide. A bronchodilator in mild asthmatics with methacholine-induced bronchospasm. Kacmarek RM, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):128–35

Is the time for steroids in treatment of asthma over? [letter] Kanwar BA, et al. **Am J Respir Crit Care Med** 1996 Sep; 154(3 Pt 1):823–4

Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Kharitonov SA, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):454–7

The effect of nedocromil sodium on childhood asthma during the viral season. König P, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1879–86

Hypothalamic-pituitary-adrenal axis in corticosteroid-resistant bronchial asthma. Lane SJ, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):557–60

A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma. Leblanc P, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):324–8

Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Lock SH, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):509–14

Influence of inhaled steroids on recovery from occupational asthma after cessation of exposure: an 18-month double-blind crossover study. Malo JL, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):953–60

Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma. Martinati LC, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):232–6

Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. Meijer GG, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1887–92

Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Noonan M, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1467–73

Single, high-dose intramuscular triamcinolone acetonide versus weekly oral methotrexate in life-threatening asthma: a double-blind study [see comments] Ogirala RG, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1461–6 . Comment in: Am J Respir Crit Care Med 1996 Jun;153(6 Pt 1):1989–90.

Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Pedersen B, et al. **Am J Respir Crit Care Med** 1996 May; 153(5):1519–29

Can steroids cause asthma to remit? Pedersen S. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S31–2 (16 ref.)

How do steroids work? Schleimer RP. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S28–30 (34 ref.)

Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Szczeklik A, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):567–71

Inhaled beclomethasone dipropionate and growth in children with mild asthma [letter; comment] Turpeinen M, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1726. Comment on: Am J Respir Crit Care Med 1995 Jun;151(6):1715–9.

Single, high dose intramuscular triamcinolone acetonide versus weekly oral methotrexate in life-threatening asthma: a double blind study [letter; comment] Vervloet D, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1989–90 . Comment on: Am J Respir Crit Care Med 1995 Nov;152(5 Pt 1):1461–6.

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Woolcock A, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1481–8

Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Yates DH, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1170–4

APhA sample protocol for chronic management of asthma. American Pharmaceutical Association Respiratory Disease Panelists and Reviewers. **Am Pharm** 1995 Nov; NS35(11):30–5

The role of the pharmacist in improving asthma care. National Asthma Education and Prevention Program. **Am Pharm** 1995 Nov;NS35(11):24–9

Asthma management can save lives. Williams DM. **Am Pharm** 1995 Nov;NS35(11):3

Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Aaronson DW. **Ann Allergy Asthma Immunol** 1996 May;76(5):440–6

Motivation for participation in clinical trials of drugs for the treatment of asthma, seasonal allergic rhinitis, and perennial nonallergic rhinitis. Aby JS, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):348–54

Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma. Bierman CW, et al. **Ann Allergy Asthma Immunol** 1996 Jan; 76(1):27–35

Development of a scale to measure children's metered-dose inhaler and spacer technique. Boccuti L, et al. **Ann Allergy Asthma Immunol** 1996 Sep;77(3):217–21

Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma. Bousquet J, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):189–94

Controlled-release theophylline inhibits early morning airway obstruction and hyperresponsiveness in asthmatic subjects. Crescioli S, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):106–10

Efficacy of once daily extended-release theophylline in decreasing the use of inhaled beta 2-agonists in stable, mild-to-moderate asthma patients. Edwards TB, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):409–16

Lack of effect of loratadine on moderate to severe asthma. Ekström T, et al. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):287–9

Fluticasone propionate compared with theophylline for mild-to-moderate asthma. Galant SP, et al. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):112–8

Adrenal suppression among asthmatic children receiving chronic therapy with inhaled corticosteroid with and without spacer device. Goldberg S, et al. **Ann Allergy Asthma Immunol** 1996 Mar;76(3):234–8

The role of theophylline in the treatment of asthma [editorial] Kamada AK, et al. **Ann Allergy Asthma Immunol** 1996 Jul; 77(1):1–3 (47 ref.)

Inhaled steroids in acute asthma [letter] Kao NL. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):214

Anti-inflammatory effects of theophylline: modulation of cytokine production. Mascali JJ, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):34–8

Minor symptoms are not predictive of elevated theophylline levels in adults on chronic therapy. Melamed J, et al. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):516–20

Safety of salmeterol in the maintenance treatment of asthma [see comments] Nathan RA, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):243–8. Comment in: Ann Allergy Asthma Immunol 1995 Sep;75(3):209–11.

How patients determine when to replace their metered-dose inhalers. Ogren RA, et al. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):485–9

Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. Okamoto LJ, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):455–61

High beta-agonist users in five HMOs: implications beyond high beta-agonist use [editorial] Pearlman DS. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):125–7

Asthma peak flow diary improves care [letter] Plaut TF. **Ann Allergy Asthma Immunol** 1996 May;76(5):476–8

Physicians' metered dose inhaler technique after a single teaching session. Resnick DJ, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):145–8

Role of theophylline in asthma [letter] Rivington RN. **Ann Allergy Asthma Immunol** 1996 Jun;76(6):542–3

Salmeterol xinafoate in children on high dose inhaled steroids. Russell G, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):423–8

Eosinophil activity reflects clinical status in patients with asthma before and during a prednisolone course. Skedinger M, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):250–5

Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children. Skoner DP, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):462–8

Leukotriene inhibitors and antagonists in asthma. Spector SL. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):463–70, 473; quiz 473–4 (78 ref.)

Trends in asthma therapy in the United States: 1965–1992. Terr AI, et al. **Ann Allergy Asthma Immunol** 1996 Mar; 76(3):273–81

Osteoporosis in steroid-dependent asthma. Villareal MS, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):369–72

Salmeterol for the treatment of asthma [editorial; comment] Weinberger M. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):209–11 (26 ref.). Comment on: Ann Allergy Asthma Immunol 1995 Sep;75(3):243–8.

Randomized, double-blind, placebo-controlled trial of intravenous ketamine in acute asthma. Howton JC, et al. **Ann Emerg Med** 1996 Feb;27(2):170–5

Using metered-dose inhalers [letter; comment] Moore KA. **Ann Emerg Med** 1996 Feb;27(2):271–2. Comment on: Ann Emerg Med 1995 Sep;26(3):308–11.

Prospective, randomized trial of epinephrine, metaproterenol, and both in the prehospital treatment of asthma in the adult patient. Quadrel M, et al. **Ann Emerg Med** 1995 Oct; 26(4):469–73

Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Scarfone RJ, et al. **Ann Emerg Med** 1995 Oct;26(4):480–6

Molecular mechanisms of antiasthma therapy. Barnes PJ. **Ann Med** 1995 Oct;27(5):531–5 (35 ref.)

Comment: steroid treatment of mild chronic asthma [letter; comment] Grigg CF. **Ann Pharmacother** 1995 Nov; 29(11):1170, 1173. Comment on: Ann Pharmacother 1994 Nov;28(11):1285–9.

Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate. Birkebaek NH, et al. **Arch Dis Child** 1995 Dec;73(6):524–7

Nedocromil in the outpatient management of asthma. Keenan

JM, et al. **Arch Fam Med** 1995 Oct;4(10):835–42; discussion 843

Effect of hydrocortisone treatment on oxygen metabolism and phagocytosis of peripheral blood neutrophils in asthmatic patients, sensitive and resistant to glucocorticosteroid therapy. Jankowska R, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(5–6):383–6

Long–and short–acting beta 2–adrenergic agonists. Effects on airway function in patients with asthma. Busse WW. **Arch Intern Med** 1996 Jul 22;156(14):1514–20 (63 ref.)

Testosterone treatment of men treated with glucocorticoids [editorial; comment] Odell WD. **Arch Intern Med** 1996 Jun 10;156(11):1133–4. Comment on: Arch Intern Med 1996 Jun 10;156(11):1173–7.

Oral prednisone as a risk factor for infections in children with asthma. Grant CC, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):58–63

Factors associated with prolonged hospitalization of children with asthma [letter; comment] Needles CF. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1401. Comment on: Arch Pediatr Adolesc Med 1995 Mar;149(3):276–9.

The modulatory effect of antigen– and PAF–induced asthmatic reaction by aerosol administration of OKY–046 in guinea pigs. Tsai JJ, et al. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):87–93

Effect of inhaled corticosteroids on bronchial hyperresponsiveness in patients with mild asthma. Wongtim S, et al. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):81–5

Asthma management and mode of acquisition of inhaled bronchodilators. Comino EJ, et al. **Aust N Z J Med** 1995 Oct;25(5):496–502

Drug delivery in asthma: a comparison of spacers with a jet nebuliser. Gibson PG, et al. **Aust N Z J Med** 1995 Aug; 25(4):324–9

Beta–2 agonists in asthma—the Thoracic Society of Australia and New Zealand. Wilson J, et al. **Aust N Z J Med** 1995 Aug;25(4):358–61 (39 ref.)

Influence of ethnic group on asthma treatment in children in 1990–1: national cross sectional study. Duran–Tauleria E, et al. **BMJ** 1996 Jul 20;313(7050):148–52

Prescribing and hospital admissions for asthma in east London. Griffiths C, et al. **BMJ** 1996 Feb 24; 312(7029):481–2

Treatment of children with asthma. Entrust parents with "crisis pack" of steroids [letter; comment] Speight N. **BMJ** 1995 Sep 23;311(7008):810. Comment on: BMJ 1995 Jun 10;310(6993):1522–7.

Characteristics of general practices that prescribe appropriately for asthma. Sturdy P, et al. **BMJ** 1995 Dec 9;311(7019):1547–8

Review of prescribed treatment for children with asthma in 1990 [see comments] Warner JO. **BMJ** 1995 Sep 9; 311(7006):663–6. Comment in: BMJ 1995 Dec 16;311(7020):1644–5; discussion 1645. Comment in: BMJ 1995 Dec 16;311(7020):1645.

Are young adults with asthma treated sufficiently with inhaled steroids? A population–based study of prescription data from 1991 and 1994. Gaist D, et al. **Br J Clin Pharmacol** 1996 Apr;41(4):285–9

Dose–response relationship and time–course of the effect of inhaled magnesium sulphate on airflow in normal and asthmatic subjects. Hill J, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):539–44

Drugs affecting the leukotriene pathway in asthma. Barnes NC, et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):262–6 (55 ref.)

Patient perception of the diskus inhaler: a comparison with the turbuhaler inhaler. Schlaeppi M, et al. **Br J Clin Pract** 1996 Jan–Feb;50(1):14–9

Eformoterol and bronchial hyperresponsiveness in mild asthma. Chung KF. **Br J Clin Pract Symp Suppl** 1995 Sep; 81:14–5

The place of long–acting beta 2 agonists in primary care. Stott PC. **Br J Clin Pract Symp Suppl** 1995 Sep;81:20–1

Continuous eformoterol and beta 2–receptor responsiveness. Sussman HS. **Br J Clin Pract Symp Suppl** 1995 Sep;81:16–7

Cardiovascular and metabolic effects of eformoterol in adults. Till MD. **Br J Clin Pract Symp Suppl** 1995 Sep;81:2–3

Efficient inhaler devices [letter] Cragg DK. **Br J Gen Pract** 1996 Mar;46(404):199

Inhaler devices for patients with asthma [letter] Fitzmaurice D, et al. **Br J Gen Pract** 1996 Mar;46(404):199–200

Optimizing inhaled drug delivery in patients with asthma. Jackson C, et al. **Br J Gen Pract** 1995 Dec;45(401):683–7 (35 ref.)

Drug delivery in asthma. Smith C. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):33–4

Glucocorticosteroid treatment of asthma. Bai TR. **Can Fam Physician** 1995 Nov;41:1921–7 (25 ref.)

Withdrawal of corticosteroid therapy after acute asthma attacks. **Can Med Assoc J** 1995 Nov 15;153(10):1471, 1473 **(Eng, Fre)**

Misuse of asthma–medication inhalers [letter; comment] Belda A. **Can Med Assoc J** 1995 Oct 15;153(8):1069. Comment on: Can Med Assoc J 1995 Jun 15;152(12):1961.

Recent trends in the use of inhaled beta 2–adrenergic agonists and inhaled corticosteroids in Saskatchewan. Habbick B, et al. **Can Med Assoc J** 1995 Nov 15;153(10):1437–43

Choose better device to treat asthma and put on a happy face [letter] Newhouse MT. **Can Med Assoc J** 1996 Aug 15;155(4):369

Rapid onset of tolerance to the bronchoprotective effect of salmeterol [see comments] Bhagat R, et al. **Chest** 1995 Nov; 108(5):1235–9. Comment in: Chest 1996 Jul;110(1):305–6. Comment in: Chest 1996 Jul;110(1):306.

Goals of asthma management. A step–care approach. Bone RC. **Chest** 1996 Apr;109(4):1056–65 (60 ref.)

Determination of post–salbutamol methacholine dose shift [letter] Cockcroft DW, et al. **Chest** 1996 Aug;110(2):579–80

Loss of bronchoprotection with salmeterol [letter; comment] D'Urzo AD. **Chest** 1996 Jul;110(1):306. Comment on: Chest 1995 Nov;108(5):1235–9.

Survey of asthma practice among emergency physicians [see comments] Emerman CL, et al. **Chest** 1996 Mar; 109(3):708–12. Comment in: Chest 1996 Mar;109(3):594–5.

Magnesium saga [letter; comment] Kanwar B, et al. **Chest** 1996 May;109(5):1411–2. Comment on: Chest 1995 Jun;107(6):1576–81.

A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma. Karpel JP, et al. **Chest** 1996 Sep;110(3):611–6

Cumulative dose–response study of non–CFC propellant HFA 134a salbutamol sulfate metered–dose inhaler in patients with asthma. Kleerup EC, et al. **Chest** 1996 Mar; 109(3):702–7

Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Newhouse MT, et al. **Chest** 1996 Sep;110(3):595–603

Vocal cord dysfunction syndrome and "steroid–dependent" asthmatics [letter; comment] Pacht ER, et al. **Chest** 1995 Dec;108(6):1772–3. Comment on: Chest 1995 Mar;107(3):817–25.

A 1–year comparison of turbuhaler vs pressurized metered–dose inhaler in asthmatic patients. Pauwels RA, et al. **Chest** 1996 Jul;110(1):53–7

Heliox therapy for acute vocal cord dysfunction [letter; comment] Reisner C, et al. **Chest** 1995 Nov;108(5):1477. Comment on: Chest 1995 Mar;107(3):757–60.

Guidelines in need of guidance [editorial; comment] Sarwar A, et al. **Chest** 1996 Mar;109(3):594–5. Comment on: Chest 1996 Mar;109(3):708–12.

Effect of early vs late intervention with inhaled corticosteroids in asthma [see comments] Selroos O, et al. **Chest** 1995 Nov;108(5):1228–34. Comment in: Chest 1995 Nov;108(5):1188–90.

Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults. Shrestha M, et al. **Chest** 1996 Jul;110(1):42–7

Asthma mortality and beta–agonists [letter; comment] Skorodin MS. **Chest** 1995 Dec;108(6):1768. Comment on: Chest 1995 Apr;107(4):1116–24.

Unusual etiology of cough in a woman with asthma. Sorhage F, et al. **Chest** 1996 Sep;110(3):852–4

When should inhaled corticosteroids be started for asthma? [editorial; comment] Tarpy R, et al. **Chest** 1995 Nov; 108(5):1188–90. Comment on: Chest 1995 Nov;108(5):1228–34.

Treat patients who have nocturnal asthma with anti–inflammatory drugs first [letter; comment] Wempe JB, et al. **Chest** 1996 Apr;109(4):1130. Comment on: Chest 1995 Feb;107(2):406–12.

Controversies involving inhaled beta–agonists and inhaled corticosteroids in the treatment of asthma. Fahy JV, et al. **Clin Chest Med** 1995 Dec;16(4):715–33 (145 ref.)

Childhood asthma. Older children and adolescents. Gern JE, et al. **Clin Chest Med** 1995 Dec;16(4):657–70 (99 ref.)

Chronobiology and chronotherapy of asthma. Pincus DJ, et al. **Clin Chest Med** 1995 Dec;16(4):699–713 (62 ref.)

Nonstandard and potential future therapies for asthma. Rennard SI, et al. **Clin Chest Med** 1995 Dec;16(4):735–44 (79 ref.)

Asthma mechanisms, determinants of severity and treatment: the role of nedocromil sodium. Report of a workshop held in Whistler, British Columbia, Canada, 18–19 May 1995. Barnes PJ, et al. **Clin Exp Allergy** 1995 Aug;25(8):771–87 (146 ref.)

Anti–inflammatory effects of long–acting beta–agonists in asthma [editorial] Bradding P. **Clin Exp Allergy** 1995 Oct; 25(10):912–4 (36 ref.)

Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics. Di Lorenzo G, et al. **Clin Exp Allergy** 1995 Oct;25(10):951–6

Eosinophil cationic protein (ECP) and eosinophil protein X (EPX) concentrations in serum and bronchial lavage fluid in asthma. Effect of prednisolone treatment. Robinson DS, et al. **Clin Exp Allergy** 1995 Nov;25(11):1118–27

Bioassay of steroids [letter; comment] Stempel DA. **Clin Pharmacol Ther** 1996 Apr;59(4):482–3. Comment on: Clin Pharmacol Ther 1995 Apr;57(4):455–60.

Influence of treatment with beclomethasone, cromoglycate and theophylline on perception of bronchoconstriction in patients with bronchial asthma. Higgs CM, et al. **Clin Sci (Colch)** 1996 Mar;90(3):227–34

Efficacy and safety of mepyramine–theophylline–acetate in the treatment of asthmatic crisis in children. Sienra–Monge JJ, et al. **Clin Ther** 1995 Jul–Aug;17(4):708–20

Bronchodilator therapy in the management of acute asthma. Moan MJ, et al. **Compr Ther** 1995 Aug;21(8):421–7 (39 ref.)

Albuterol delivery by metered–dose inhaler in a mechanically ventilated pediatric lung model. Garner SS, et al. **Crit Care Med** 1996 May;24(5):870–4

Urodilatin (ularitide, INN): a potent bronchodilator in asthmatic subjects. Flüge T, et al. **Eur J Clin Invest** 1995 Oct;25(10):728–36

Efficacy and safety of salmeterol in childhood asthma. Lenney W, et al. **Eur J Pediatr** 1995 Dec;154(12):983–90

Theophylline and selective phosphodiesterase inhibitors as anti–inflammatory drugs in the treatment of bronchial asthma. Banner KH, et al. **Eur Respir J** 1995 Jun; 8(6):996–1000 (50 ref.)

The psychological factors associated with poor compliance with treatment in asthma. Bosley CM, et al. **Eur Respir J** 1995 Jun;8(6):899–904

Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group. Boyd G. **Eur Respir J** 1995 Sep; 8(9):1494–8

High dose and low dose systematic corticosteroids are equally efficient in acute severe asthma [letter; comment] Carter E. **Eur Respir J** 1995 Aug;8(8):1435. Comment on: Eur Respir J 1995 Jan;8(1):22–7.

Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Chung KF. **Eur Respir J** 1995 Jul;8(7):1203–13 (117 ref.)

Inhaled lysine acetylsalicylate (L–ASA) attenuates the bronchoconstrictor response to adenosine 5'–monophosphate (AMP) in asthmatic subjects. Crimi N, et al. **Eur Respir J** 1995 Jun;8(6):905–12

Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze. Freezer NJ, et al. **Eur Respir J** 1995 Sep;8(9):1488–93

Prostanoids and cough response to capsaicin in asthma and chronic bronchitis. Fujimura M, et al. **Eur Respir J** 1995 Sep;8(9):1499–505

Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered–dose inhaler (P–MDI) [letter] Fuller RW, et al. **Eur Respir J** 1995 Dec;8(12):2194–5

Airway and lung elastic fibre is not reduced in asthma nor in asthmatics following corticosteroid treatment. Godfrey RW, et al. **Eur Respir J** 1995 Jun;8(6):922–7

Low–dose theophylline modulates T–lymphocyte activation in allergen–challenged asthmatics. Jaffar ZH, et al. **Eur Respir J** 1996 Mar;9(3):456–62

Preventive therapy for asthma in children; a 9–year experience in eastern Finland. Korppi M, et al. **Eur Respir J** 1995 Aug;8(8):1318–20

Inflammatory bronchial polyps associated with asthma: resolution with inhaled corticosteroid. Niimi A, et al. **Eur Respir J** 1995 Jul;8(7):1237–9

Treatment of steroid–dependent bronchial asthma with cyclosporin. Nizankowska E, et al. **Eur Respir J** 1995 Jul; 8(7):1091–9

Effect of salmeterol compared with beclomethasone on allergen–induced asthmatic and inflammatory responses. Pizzichini MM, et al. **Eur Respir J** 1996 Mar;9(3):449–55

Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency and association with adrenal function. Roy A, et al. **Eur Respir J** 1996 Feb;9(2):226–31

Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life [see comments] Rutten–van Mölken MP, et al. **Eur Respir J** 1995 Jun;8(6):888–98. Comment in: Eur Respir J 1995 Jun;8(6):885–7.

FK506 and cyclosporin A inhibit granulocyte/macrophage colony–stimulating factor production by mononuclear cells in asthma. Sano T, et al. **Eur Respir J** 1995 Sep;8(9):1473–8

PDE isoenzymes as targets for anti–asthma drugs. Schudt C, et al. **Eur Respir J** 1995 Jul;8(7):1179–83 (18 ref.)

Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Smith EC, et al. **Eur Respir J** 1995 Jul;8(7):1214–21

Reduced dose salbutamol in comparison with standard dosage for symptom relief in asthma. Yates DH, et al. **Eur Respir J** 1995 Nov;8(11):1847–51

Treatment of mild asthma with inhaled corticosteroids: is discontinuation of therapy possible? van Grunsven PM, et al. **Fam Med** 1996 Jan;28(1):46–51

Effects of instruction by practice assistants on inhaler technique and respiratory symptoms of patients. A controlled randomized videotaped intervention study. Verver S, et al. **Fam Pract** 1996 Feb;13(1):35–40

Late–onset asthma: making the diagnosis, choosing drug therapy. Sherman CB. **Geriatrics** 1995 Dec;50(12):24–6, 29–30, 33 (22 ref.)

Pediatric asthma—a correlation of clinical treatment and oxygen saturation. Cook T, et al. **Hawaii Med J** 1995 Jul; 54(7):665–8

Managing the patient with intractable asthma. Martin RJ. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):61–4, 69–74, 79–80

Helping patients live with asthma. Rachelefsky GS. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):51–6, 59–64 (14 ref.)

MDIS and spacers in management of asthma. Bhadoria DP, et al. **Indian J Med Sci** 1995 May;49(5):123–6

Steroids in acute asthma: oral or nebulized? Singhi S. **Indian Pediatr** 1996 Mar;33(3):262–3

Cetirizine reduces ICAM–1 on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite–allergic asthma. Fasce L, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):272–6

Effect of azelastine on endotoxin–induced airway hyperresponsiveness in mice. Konno S, et al. **Int Arch Allergy Immunol** 1995 Nov;108(3):292–7

Incomplete aspirin desensitization in an aspirin-sensitive asthmatic. Rothe T, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):298–300

A controlled trial of nebulized salbutamol and adrenaline in acute severe asthma. Abroug F, et al. **Intensive Care Med** 1995 Jan;21(1):18–23

Importance of the inhaler mouthpiece cover [letter] O'Donnell JJ, et al. **Intensive Care Med** 1995 Aug;21(8):698

An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine–Asthma Study Group. **J Allergy Clin Immunol** 1996 Jun;97(6):1218–24

The effect of inhaled albuterol in moderate to severe asthma. Apter AJ, et al. **J Allergy Clin Immunol** 1996 Aug; 98(2):295–301

Molecular mechanisms of steroid action in asthma. Barnes PJ. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):159–68 (74 ref.)

Effect of solution and suspension type aerosol of formoterol on tremor response and airways in patients with asthma. Bauer K, et al. **J Allergy Clin Immunol** 1995 Oct; 96(4):495–501

A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. Bernstein IL, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):317–24

Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. Bhagat R, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):47–52

Try using binoculars [letter; comment] Costello J, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):1014–7. Comment on: J Allergy Clin Immunol 1995 Mar;95(3):641–51.

Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. de Blic J, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):14–20

Trial of a "credit card" asthma self-management plan in a high-risk group of patients with asthma. D'Souza W, et al. **J Allergy Clin Immunol** 1996 May;97(5):1085–92

Hydrocortisone sodium succinate does not cross-react with aspirin in aspirin-sensitive patients with asthma. Feigenbaum BA, et al. **J Allergy Clin Immunol** 1995 Oct; 96(4):545–8

Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. Hanania NA, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):571–9

Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. Holgate ST, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):1–13 (89 ref.)

Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. Johnson M. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):169–76 (26 ref.)

Theophylline: potential antiinflammatory effects in nocturnal asthma. Kraft M, et al. **J Allergy Clin Immunol** 1996 Jun; 97(6):1242–6

Theophylline's effect on neutrophil function and the late asthmatic response. Kraft M, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):251–7

Remodeling of asthmatic airways by glucocorticosteroids. Laitinen LA, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):153–8 (22 ref.)

Effects of nedocromil sodium in steroid-resistant asthma: a randomized controlled trial. Marin JM, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):602–10

Anaphylaxis to 6-alpha-methylprednisolone in an eight-year-old child. Moreno-Ancillo A, et al. **J Allergy Clin Immunol** 1996 May;97(5):1169–71

Cetirizine in patients with seasonal rhinitis and concomitant asthma [letter; comment] Nieman RB. **J Allergy Clin Immunol** 1996 Feb;97(2):716–7. Comment on: J Allergy Clin Immunol 1995 May;95(5 Pt 1):923–32.

The effects of prednisolone on the cutaneous tuberculin response in patients with corticosteroid-resistant bronchial asthma. Sousa AR, et al. **J Allergy Clin Immunol** 1996 Feb; 97(2):698–706

Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. Verberne AA, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):938–46

Normal diurnal variation in serum cortisol concentration in asthmatic children treated with inhaled budesonide. Volovitz B, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):874–8

Clinical use of inhaled corticosteroids in asthma. Wasserfallen JB, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):177–82 (41 ref.)

Decrease in hospitalization for treatment of childhood asthma with increased use of antiinflammatory treatment, despite an increase in prevalence of asthma. Wennergren G, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):742–8

Improving inhaler therapy compliance in asthmatics [letter] Bedi RS. **J Assoc Physicians India** 1995 Aug;43(8):585

High dose hydrocortisone therapy complicating acute severe asthma [letter] Mehta S. **J Assoc Physicians India** 1995 Sep; 43(9):658

Theophylline—down but not yet out [editorial; comment] Ahrens RC. **J Asthma** 1995;32(2):85–7. Comment on: J Asthma 1995;32(2):89–95.

Compliance with asthma therapy: a case for shared responsibility [editorial; comment] Bender B, et al. **J Asthma** 1996;33(4):199–202. Comment on: J Asthma 1996;33(4):203–11.

Comparison of Diskus inhaler, a new multidose powder inhaler, with Diskhaler inhaler for the delivery of salmeterol to asthmatic patients. Canadian Study Group. Boulet LP, et al. **J Asthma** 1995;32(6):429–36

Duration of action of a single dose of azelastine in patients with chronic asthma. Chervinsky P, et al. **J Asthma** 1995; 32(2):141–5

Medication compliance and asthma: overlooking the trees because of the forest [see comments] Creer TL, et al. **J Asthma** 1996;33(4):203–11 (45 ref.). Comment in: J Asthma 1996;33(4):199–202.

Acute asthma: treatment and outcome of 2000 consecutive pediatric emergency room visits in Doha, Qatar. Dawod ST, et al. **J Asthma** 1996;33(2):131–5

Two new roles for theophylline in the asthmatic? [see comments] Jenne JW. **J Asthma** 1995;32(2):89–95 (56 ref.) . Comment in: J Asthma 1995;32(2):85–7.

Inhaled corticosteroids: benefits and risks [see comments] Robinson DS, et al. **J Asthma** 1996;33(1):5–16 (103 ref.). Comment in: J Asthma 1996;33(1):1–3.

Inhaled corticosteroids in asthma—star wars [editorial; comment] Sachs MI. **J Asthma** 1996;33(1):1–3. Comment on: J Asthma 1996;33(1):5–16.

Long-acting inhaled beta agonists [see comments] Tilles SA, et al. **J Asthma** 1995;32(6):397–404 (51 ref.). Comment in: J Asthma 1995;32(6):395–6.

Treatment of nocturnal asthma by addition of oral slow-release albuterol to standard treatment in stable asthma patients. Van Keimpema AR, et al. **J Asthma** 1996; 33(2):119–24

A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. Wasserman SI, et al. **J Asthma** 1996;33(4):265–74

Long-acting inhaled beta agonists in the treatment of bronchial asthma [editorial; comment] Wellman JJ. **J Asthma** 1995;32(6):395–6. Comment on: J Asthma 1995;32(6):397–404.

Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. Mann RD, et al. **J Clin Epidemiol** 1996 Feb;49(2):247–50

Use of an automated prescription database to identify individuals with asthma. Osborne ML, et al. **J Clin Epidemiol** 1995 Nov;48(11):1393–7

Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. Feoktistov I, et al. **J Clin Invest** 1995 Oct;96(4):1979–86

In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma. Turner CR, et al. **J Clin Invest** 1996 Jan 15;97(2):381–7

Nontapering versus tapering prednisone in acute exacerbations of asthma: a pilot trial. Verbeek PR, et al. **J Emerg Med** 1995 Sep-Oct;13(5):715–9

Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. Adcock IM, et al. **J Exp Med** 1995 Dec 1;182(6):1951–8

Self-management of asthma. Bramson R. **J Fam Pract** 1996 Jul;43(1):21–2

C pneumoniae in adult asthma [comment] Ebell MH. **J Fam Pract** 1995 Oct;41(4):405–6. Comment on: J Fam Pract 1995 Oct;41(4):345–51.

Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial [see comments] Hahn DL. **J Fam Pract** 1995 Oct;41(4):345–51. Comment in: J Fam Pract 1995 Oct;41(4):405–6. Comment in: J Fam Pract 1996 Mar;42(3):307–8.

MDI with spacer vs nebulizer in pediatric asthma. Shaughnessy AF, et al. **J Fam Pract** 1996 Jan;42(1):29–30

Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group. Sheffer AL, et al. **J Fam Pract** 1996 Apr; 42(4):369–75

Antibiotic treatment of asthma [letter; comment] Thom D. **J Fam Pract** 1996 Mar;42(3):307–8. Comment on: J Fam Pract 1995 Oct;41(4):345–51.

Differences in utilization of asthma drugs between two neighbouring Swedish provinces: relation to treatment in individuals with airway disease. Larsson L, et al. **J Intern Med** 1995 Oct;238(4):307–16

Effect of paper spacer (spader) in conjunction with procaterol metered dose inhaler in the treatment of acute asthma. Charoenratanakul S, et al. **J Med Assoc Thai** 1996 Mar;79(3):149–53

Aftercare for participants in clinical research: ethical considerations in an asthma drug trial. Harth SC, et al. **J Med Ethics** 1995 Aug;21(4):225–8

Use of ipratropium for severe asthma [letter; comment] Osmond MH, et al. **J Pediatr** 1995 Nov;127(5):842. Comment on: J Pediatr 1995 Apr;126(4):639–45.

Pneumocystis carinii pneumonia associated with inhaled corticosteroids in an immunocompetent child with asthma. Sy ML, et al. **J Pediatr** 1995 Dec;127(6):1000–2

Paradoxical bronchoconstriction with salbutamol [letter] Wheatley G, et al. **J R Army Med Corps** 1995 Jun; 141(2):113

Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate. Packe GE, et al. **J R Coll Physicians Lond** 1996 Mar-Apr;30(2):128–32

The effects on prescribing patterns and costs of having a special interest in asthma [see comments] Jones KP, et al. **J R Soc Med** 1995 Oct;88(10):570–5. Comment in: J R Soc Med 1996 Apr;89(4):238.

Prescribing patterns and costs [letter; comment] Sturdy P, et al. **J R Soc Med** 1996 Apr;89(4):238. Comment on: J R Soc Med 1995 Oct;88(10):570–5.

Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. Israel E, et al. **JAMA** 1996 Mar 27;275(12):931–6

Effects of NIP-502 on antigen-induced bronchial responses and allergic reactions in animal models. Yamamoto A, et al. **Jpn J Pharmacol** 1995 May;68(1):47–55

Bronchodilation subsensitivity to salbutamol after salmeterol [letter; comment] Barnes N. **Lancet** 1995 Oct 7; 346(8980):968; discussion 968–9. Comment on: Lancet 1995 Jul 22;346(8969):201–6.

Comparison of non-chlorofluorocarbon-containing salbutamol and conventional inhaler [letter] Desager KN, et al. **Lancet** 1996 Jul 20;348(9021):200–1

Aerosol inhalation before reading age [letter] Faurisson F, et al. **Lancet** 1995 Nov 11;346(8985):1298

Evaluation of oral anti-allergic drugs in Japan [letter] Hayashi K, et al. **Lancet** 1996 Feb 17;347(8999):477

Zileuton. McGill KA, et al. **Lancet** 1996 Aug 24; 348(9026):519–24 (38 ref.)

Bronchodilation subsensitivity to salbutamol after salmeterol [letter; comment] Ng HW. **Lancet** 1995 Oct 7; 346(8980):968; discussion 968–9. Comment on: Lancet 1995 Jul 22;346(8969):201–6.

Salbutamol in the treatment of asthma [letter] Perrin-Fayolle M. **Lancet** 1995 Oct 21;346(8982):1101

Randomised double-blind placebo-controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin-induced asthma. Ricciardolo FL, et al. **Lancet** 1996 Aug 10;348(9024):374–7

Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Todd G, et al. **Lancet** 1996 Jul 6;348(9019):27–9

Bronchodilation subsensitivity to salbutamol after salmeterol [letter] Weinberger M. **Lancet** 1995 Oct 7;346(8980):968–9

Effect of fluticasone on growth in children with asthma [letter] Whitaker K, et al. **Lancet** 1996 Jul 6;348(9019):63–4

Short term effect of methotrexate in severe steroid-dependent asthma. Kanzow G, et al. **Lung** 1995;173(4):223–31

Effects of corticosteroid inhalation therapy on the deposition pattern of Tc-99m human serum albumin radioaerosols in asthma. Kao CH, et al. **Lung** 1995;173(5):291–6

Effect of nebulized lidocaine on severe glucocorticoid-dependent asthma. Hunt LW, et al. **Mayo Clin Proc** 1996 Apr;71(4):361–8

Outpatient asthma management. Cockcroft DW, et al. **Med Clin North Am** 1996 Jul;80(4):701–18 (60 ref.)

A mechanism for masking receptors with particular application to asthma. Hills BA. **Med Hypotheses** 1996 Jan; 46(1):33–41

Pharmaceutical Benefits Advisory Committee: some questions answered [letter] Bandouvakis J. **Med J Aust** 1996 Jan 1;164(1):51–2

The Chocuhaler: sweet deliverance in asthma management. Hayden MJ, et al. **Med J Aust** 1995 Dec 4–18; 163(11–12):587–8

Fluticasone propionate for chronic asthma. **Med Lett Drugs Ther** 1996 Sep 13;38(983):83–4

Effect of inhaled nedocromil sodium therapy on blood gas changes in children challenged with ultrasonically nebulized distilled water. A comparison of 8 mg versus 16 mg daily dose. Oggiano N, et al. **Minerva Pediatr** 1995 Oct;47(10):427–31

Methotrexate in the treatment of systemic glucocorticoid-dependent severe persistent asthma: a word of caution. Fabbri L, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):130–7 (118 ref.)

Paradoxical bronchospasm and cutaneous rash after metered-dose inhaled bronchodilators. Facchini G, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):201–3

Anti-inflammatory treatment of asthma in children. What strategy is appropriate? Frazier CA. **N C Med J** 1995 Dec; 56(12):616–8 (15 ref.)

Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network [see comments] Drazen JM, et al. **N Engl J Med** 1996 Sep 19;335(12):841–7. Comment in: N Engl J Med 1996 Sep 19;335(12):886–8.

Inhaled beta 2-agonists in the treatment of asthma [editorial; comment] O'Byrne PM, et al. **N Engl J Med** 1996 Sep 19;335(12):886–8. Comment on: N Engl J Med 1996 Sep 19;335(12):841–7.

Theophylline in asthma. Weinberger M, et al. **N Engl J Med** 1996 May 23;334(21):1380–8 (100 ref.)

A pilot study to investigate the pulmonary effects of digoxin in patients with asthma. Ayson M, et al. **N Z Med J** 1996 Feb 9;109(1015):36–7

Update on spacer devices in childhood asthma. Leversha AM, et al. **N Z Med J** 1996 Mar 8;109(1017):76–8

A cornucopia of drug discovery? [letter; comment] Persson C. **Nat Med** 1996 Jan;2(1):5–6. Comment on: Nat Med 1995 Nov;1(11):1122–5.

Influence of budesonide on the response to inhaled terbutaline in children with mild asthma. Fuglsang G, et al. **Pediatr Allergy Immunol** 1995 May;6(2):103–8

Use of magnesium sulfate in asthma in childhood. Monem GF, et al. **Pediatr Ann** 1996 Mar;25(3):136, 139–44 (52 ref.)

Prehospital management of asthmatic children [letter;

comment] Perry RF, et al. **Pediatr Emerg Care** 1996 Feb; 12(1):71–2. Comment on: Pediatr Emerg Care 1995 Aug;11(4):217–9.

Intratracheal administration of phosphodiesterase III inhibitor attenuates bronchoconstriction in cats: a preliminary report. Hu H, et al. **Pediatr Pulmonol** 1995 Jun; 19(6):360–4

Short–term and long–term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. König P, et al. **Pediatr Pulmonol** 1995 Oct;20(4):205–14

Treatment of severe asthma in childhood. Cropp GJ. **Pediatr Pulmonol Suppl** 1995;11:49–50

Behavioral side effects of medications used to treat asthma and allergic rhinitis. Milgrom H, et al. **Pediatr Rev** 1995 Sep;16(9):333–5; quiz 336 (21 ref.)

Advances in the management of acute asthma in children. Murphy SJ, et al. **Pediatr Rev** 1996 Jul;17(7):227–34; quiz 235

Quality improvement: an ACQIP exercise on the management of acute asthma—Part 2. Smith–Ross S, et al. **Pediatr Rev** 1995 Aug;16(8):311–5

Beta2–adrenergic agents in asthma. Turcios NL. **Pediatr Rev** 1996 Mar;17(3):103–4

Hypoglycemia and cortisol deficiency associated with low–dose corticosteroid therapy for asthma. Carrel AL, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):921–4

Steroids and asthma [letter] DeMasi JM. **Pediatrics** 1996 Jul; 98(1):169; discussion 169–70

Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Park CL, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):196–200

Steroids and asthma [letter] Van Ditzhuyzen O, et al. **Pediatrics** 1996 Jul;98(1):169; discussion 169–70

Steroids and asthma [letter] Weinberger M. **Pediatrics** 1996 Jul;98(1):168–9; discussion 169–70

The use of beta 2–adrenoceptor agonists in the treatment of bronchial asthma. Svedmyr N, et al. **Pharmacol Toxicol** 1996 Jan;78(1):3–11 (94 ref.)

beta–Adrenoceptor agonists in future asthma therapy. Ullman A. **Pharmacol Toxicol** 1995;77 Suppl 3:36–9

Cost comparison of beta 2–agonist bronchodilators used in the treatment of asthma. Nightingale CH. **Pharmacotherapy** 1995 Sep–Oct;15(5):677–81

Asthma. Specific preventive strategies. Morris RJ. **Postgrad Med** 1996 Aug;100(2):105–6, 109–12, 118 passim (21 ref.)

Aerosol delivery systems for bronchial asthma. Ariyananda PL, et al. **Postgrad Med J** 1996 Mar;72(845):151–6 (60 ref.)

Effect of zatebradine, a novel 'sinus node inhibitor', on pulmonary function compared to placebo. Maesen FP, et al. **Pulm Pharmacol** 1994 Dec;7(6):349–55

Bronchodilating effects of natriuretic and vasorelaxant peptides compared to salbutamol in asthmatics. Flüge T, et al. **Regul Pept** 1995 Nov 10;59(3):357–70

Inhaled glucocorticoids: new developments relevant to updating of the asthma management guidelines. Barnes PJ. **Respir Med** 1996 Aug;90(7):379–84 (44 ref.)

Asthma management and morbidity in Australian general practice: the relationship between patient and doctor estimates. Bauman A, et al. **Respir Med** 1995 Nov; 89(10):665–72

Fluticasone propionate—an update on preclinical and clinical experience. Fuller R, et al. **Respir Med** 1995 Sep;89 Suppl A:3–18 (59 ref.)

Assessment of the continued supervision and asthma management knowledge of patients possessing home nebulizers. Gregson RK, et al. **Respir Med** 1995 Aug; 89(7):487–93

Management of acute asthma attacks associated with respiratory tract infection: a postal survey of general practitioners in the U.K. Jones K, et al. **Respir Med** 1996 Aug;90(7):419–25

Comparison of four–times–a–day and twice–a–day dosing regimens in subjects requiring 1200 micrograms or less of budesonide to control mild to moderate asthma. Malo JL, et al. **Respir Med** 1995 Sep;89(8):537–43

Effect of inhaled beclomethasone on serum markers of collagen metabolism in postmenopausal asthmatic women. Puolijoki H, et al. **Respir Med** 1996 Jul;90(6):339–42

Effect of menthol vapour on airway hyperresponsiveness in patients with mild asthma. Tamaoki J, et al. **Respir Med** 1995 Aug;89(7):503–4

Relative efficacy of hydrocortisone and methylprednisolone in acute severe asthma. Hall CM, et al. **S Afr Med J** 1995 Nov;85(11):1153–6

Theophylline in asthma—no longer the bad egg in the basket! [letter] Morris A. **S Afr Med J** 1995 Nov;85(11):1189

Relative efficacy of hydrocortisone and methylprednisolone in acute severe asthma [letter] Straughan JL. **S Afr Med J** 1996 Mar;86(3):273

Home nebuliser use in children with asthma in two Scottish Health Board Areas. Madge PJ, et al. **Scott Med J** 1995 Oct;40(5):141–3

Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide (ANP). Angus RM, et al. **Thorax** 1996 Jan; 51(1):71–4

Emergency treatment of asthma [letter; comment] Barry PW, et al. **Thorax** 1995 Jul;50(7):814. Comment on: Thorax 1995 Jan;50(1):1–2. Comment on: Thorax 1995 Jan;50(1):79–80.

Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Bootsma GP, et al. **Thorax** 1995 Oct;50(10):1044–50

Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Clark DJ, et al. **Thorax** 1996 Mar;51(3):262–6

Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? Dent G, et al. **Thorax** 1996 Jun; 51(6):647–9 (12 ref.)

Compliance with inhaled asthma medication in preschool children. Gibson NA, et al. **Thorax** 1995 Dec;50(12):1274–9

Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol. Grove A, et al. **Thorax** 1996 Jun;51(6):585–9

Beta 2 adrenoceptor polymorphisms: are they clinically important? [editorial] Hall IP. **Thorax** 1996 Apr;51(4):351–3

Validation of an asthma quality of life diary in a clinical trial. Hyland ME, et al. **Thorax** 1995 Jul;50(7):724–30

Potential effects of correction of inaccuracies of the mini–Wright peak expiratory flow meter on the use of an asthma self–management plan. Miles JF, et al. **Thorax** 1996 Apr;51(4):403–6

Fatal varicella zoster infection in a severe steroid dependent asthmatic patient receiving methotrexate [see comments] Morice AH, et al. **Thorax** 1995 Nov;50(11):1221–2. Comment in: Thorax 1995 Nov;50(11):1222–3.

Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Sont JK, et al. **Thorax** 1996 May;51(5):496–502

Acute asthma during pregnancy. Stenius–Aarniala BS, et al. **Thorax** 1996 Apr;51(4):411–4

Comparison of three inhaled non–steroidal anti–inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5'–monophosphate challenge in asthma. Wang M, et al. **Thorax** 1996 Aug;51(8):799–804

Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma. Weiner P, et al. **Thorax** 1995 Dec;50(12):1270–3

Inhalation therapy with magnesium sulfate and salbutamol sulfate in bronchial asthma. Meral A, et al. **Turk J Pediatr** 1996 Apr–Jun;38(2):169–75

Long–acting beta 2–agonists and their role in asthma management. Galant SP. **West J Med** 1995 Oct;163(4):372

Steroid–resistant asthma. Leung DY. **West J Med** 1995 Oct; 163(4):367–8

Caution with inhaled corticosteroids in childhood asthma. Welch MJ. **West J Med** 1995 Oct;163(4):371–2

[Treating steroids dependent asthmatic patients with high dose beclomethasone dipropionate aerosol] Dong J, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Jun; 18(3):152–4, 190 (Eng. Abstr.) (Chi)

[Fluticasone propionate—a new inhalation steroid for the treatment of bronchial asthma] Lange P, et al. **Ugeskr Laeger** 1996 Jan 22;158(4):439–44 (Dan)

[Salmeterol improves the control of disease in patients with moderate asthma. A comparative study of inhaled salmeterol 50 mg and salbutamol depot tablets 8 mg, both administered twice daily] Ringbaek TJ, et al. **Ugeskr Laeger** 1996 Jul 1;158(27):3940–3 (Eng. Abstr.) (Dan)

[Treatment of asthma; are there still questions? (letter; comment)] Ponsioen BP. **Ned Tijdschr Geneeskd** 1996 Mar 2;140(9):508–9. Comment on: Ned Tijdschr Geneeskd 1996 Jan 13;140(2):72–7. (Dut)

[When are bronchodilator agents sufficient in asthma/chronic obstructive lung disease? (letter; comment)] Ponsioen BP. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2390–1. Comment on: Ned Tijdschr Geneeskd 1995 Aug 5;139(31):1580–3. (Dut)

[Inhalation therapy in young children with asthma] Roorda RJ. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2548–51 (43 ref.) (Dut)

[Treatment of asthma; are there still questions? (see comments)] van Schayck CP. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):72–7 (47 ref.). Comment in: Ned Tijdschr Geneeskd 1996 Mar 2;140(9):508–9. (Dut)

[Beta–2 adrenergic receptor agonists in asthma treatment] Haahtela T, et al. **Duodecim** 1995;111(8):744–8 (28 ref.) (Fin)

[Who needs an adder bite treatment kit in winter time?] Hietarinta M, et al. **Duodecim** 1994;110(6):585–7 (Fin)

[Growth retardation in an asthmatic child] Saha MT, et al. **Duodecim** 1995;111(5):444–6 (Fin)

[Comparative study of the acceptability of Tilade Syncroner and Tilade Standard by mildly asthmatic patients. Syncroner Trial Research Group] Pujet JC, et al. **Allerg Immunol (Paris)** 1995 Dec;27(10):377–83 (Eng. Abstr.) (Fre)

[Hypersensitivity syndrome caused by dapsone. Transient circulating clone T] Bocquet H, et al. **Ann Dermatol Venereol** 1995;122(8):514–6 (14 ref.) (Eng. Abstr.) (Fre)

[Nebulization for basic treatment of asthma in adults] Demoly P, et al. **Presse Med** 1996 May 25;25(18):857–62 (39 ref.) (Eng. Abstr.) (Fre)

[Asthma and corticotherapy (editorial)] Michel FB, et al. **Presse Med** 1996 Mar 16;25(9):436–7 (Eng. Abstr.) (Fre)

[Inhalation treatment: glucocorticoids] Aubert JD. **Rev Med Suisse Romande** 1996 May;116(5):329–33 (20 ref.) (Fre)

[Asthma in children: practical aspects of inhalation techniques] Barazzone C. **Rev Med Suisse Romande** 1996 Feb;116(2):111–2 (Fre)

[Inhaled corticotherapy in asthma: when should it be started and how to stop?] Aubier M. **Rev Pneumol Clin** 1996; 52(2):145–9 (19 ref.) (Eng. Abstr.) (Fre)

[Functional contribution of inhalation spacers in the treatment of asthma] el Kamel A, et al. **Rev Pneumol Clin** 1995;51(2):73–5 (Eng. Abstr.) (Fre)

[Primum non nocere: inhaled corticoids] Lacronique J. **Rev Pneumol Clin** 1996;52(2):137–43 (81 ref.) (Eng. Abstr.) (Fre)

[Corticoid resistance in asthma] Perrin–Fayolle M, et al. **Rev Pneumol Clin** 1996;52(2):150–8 (43 ref.) (Eng. Abstr.) (Fre)

[Modes of administration of beta agonists in asthma] Salmeron S, et al. **Rev Pneumol Clin** 1996;52(2):119–27 (76 ref.) (Eng. Abstr.) (Fre)

[Leukotriene blockade in asthma—a new anti–inflammatory therapeutic principle] Griese M, et al. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):845–51 (61 ref.) (Ger)

[Cyclosporin in severe steroid–requiring bronchial asthma] Klein RM, et al. **Dtsch Med Wochenschr** 1995 Oct 6; 120(40):1349–55 (Eng. Abstr.) (Ger)

[Gastroesophageal reflux and bronchial asthma (letter)] Müller–Lissner S. **Dtsch Med Wochenschr** 1996 Aug 2; 121(31–32):1000–1 (11 ref.) (Ger)

[Beta 2–sympathomimetic drugs] Criée CP, et al. **Internist (Berl)** 1995 Sep;36(9):918–23 (28 ref.) (Ger)

[Asthma therapy with topically active steroids] Matthys H. **Internist (Berl)** 1995 Oct;36(10):1005–9 (21 ref.) (Ger)

[Limitations of current treatment of asthma: possibilities for new treatment forms] Wilkens H, et al. **Med Klin** 1996 May 15;91(5):302–7 (55 ref.) (Ger)

[Reactivation of tuberculosis by use of inhaled steroid (letter)] Kropp R. **Pneumologie** 1995 Dec;49(12):704 (Ger)

[Therapy–resistant asthma: causes and therapy] Rothe TB, et al. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1118–24 (Eng. Abstr.) (Ger)

[Safety and side effects of inhalant steroid therapy in children with bronchial asthma] Schöni MH. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1108–13 (37 ref.) (Eng. Abstr.) (Ger)

[Chronopharmacology of reversible airway obstruction] Haen E. **Wien Med Wochenschr** 1995;145(17–18):439–45 (38 ref.) (Eng. Abstr.) (Ger)

[Beta–2 agonists, exposure to allergens and bronchial hyperreactivity in children with allergic asthma] Piacentini GL, et al. **Pediatr Med Chir** 1995 Nov–Dec;17(6):515–7 (Eng. Abstr.) (Ita)

[Effects of inhaled beclomethasone on height growth and bone metabolism in children with asthma] Inoue T, et al. **Arerugi** 1995 Jul;44(7):678–84 (Eng. Abstr.) (Jpn)

[On the studies and treatments of asthma, and their future] Ito K. **Arerugi** 1996 Jun;45(6):533–41 (10 ref.) (Jpn)

[A comparison of two delivery methods on the bronchodilator effects of beta 2–stimulant] Kishida M, et al. **Arerugi** 1996 Jun;45(6):542–5 (Eng. Abstr.) (Jpn)

[Early effects of intravenous steroid therapy on cell recruitment in sputum of chronic asthmatics] Maeda Y, et al. **Arerugi** 1995 Sep;44(9):1111–6 (Eng. Abstr.) (Jpn)

[Effect of dosing schedule on efficacy of corticosteroid inhalation in chronic asthma] Suzuki R, et al. **Arerugi** 1995 Jul;44(7):685–91 (Eng. Abstr.) (Jpn)

[Inhaled beclomethasone in long–term management of asthma: optimal dose and optimal duration of treatment] Kudo K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep;33(9):956–65 (Eng. Abstr.) (Jpn)

[Anti–allergic agent therapy of asthma] Fujimura M. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):216–21 (5 ref.) (Jpn)

[Steroid inhalation therapy of asthma] Hozawa S. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):205–9 (5 ref.) (Jpn)

[Emergency drug therapy of bronchial asthma] Inoue H. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1791–7 (8 ref.) (Jpn)

[Therapy of asthma using bronchodilator agents—special reference to adrenergic beta 2–receptor agonists] Kurosawa M, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10; 85(2):210–5 (5 ref.) (Jpn)

[Steroid inhalation therapy of bronchial asthma] Makino S. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2085–90 (9 ref.) (Jpn)

[Recent view on drug therapy of bronchial asthma] Mano K. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):417–22 (9 ref.) (Jpn)

[Pharmacological studies on KW–4679, an antiallergic drug. (1): Inhibitory effect on passive cutaneous anaphylaxis (PCA) and experimental asthma in rats and guinea pigs] Ishii H, et al. **Nippon Yakurigaku Zasshi** 1995 Oct; 106(4):289–98 (Eng. Abstr.) (Jpn)

[Effect of loratadine, selective antagonist of histamine H1 receptors, on histamine–induced bronchoconstriction] Cieslewicz G, et al. **Pneumonol Alergol Pol** 1995; 63(5–6):281–5 (Eng. Abstr.) (Pol)

[Chemotactic serum activity for neutrophils and eosinophils and spontaneous production of histamine releasing factor in patients with seasonal bronchial asthma treated with nedocromil sodium] Grzelewska–Rzymowska I, et al. **Pneumonol Alergol Pol** 1996;64(3–4):132–40 (Eng. Abstr.) (Pol)

[A trial of ipratropium bromide dose optimalization in

patients with atopic asthma] Karwat K. **Pneumonol Alergol Pol** 1995;63(9–10):539–43 (Eng. Abstr.) **(Pol)**

[Long-term corticosteroid therapy as a risk factor of osteoporosis in patients with asthma and chronic bronchitis] Kolaczkowska M, et al. **Pneumonol Alergol Pol** 1996; 64(3–4):196–203 (Eng. Abstr.) **(Pol)**

[Production of selected cytokines by monocytes (IL–1 beta, IL–6) and lymphocytes (IL–2, IL–4) in peripheral blood of patients with nonallergic bronchial asthma treated with Broncho-Vaxom] Moniuszko T, et al. **Pneumonol Alergol Pol** 1995;63 Suppl 2:66–70 (Eng. Abstr.) **(Pol)**

[Effect of Ribomunyl therapy on production of selected cytokines by mononuclear peripheral blood cells in nonatopic bronchial asthma] Moniuszko T, et al. **Pneumonol Alergol Pol** 1995;63 Suppl 2:71–5 (Eng. Abstr.) **(Pol)**

[Efficacy of flunisolide in treatment of patients with bronchial asthma] Romański B, et al. **Pneumonol Alergol Pol** 1995; 63(9–10):527–31 (Eng. Abstr.) **(Pol)**

[Effect of flunisolide on exacerbation of clinical symptoms, spirometric parameters, consumption of B2-adrenergic drugs and levels of cortisol and ECP in serum of patients with bronchial asthma] Siergiejko Z, et al. **Pneumonol Alergol Pol** 1995;63 Suppl 2:76–82 (Eng. Abstr.) **(Pol)**

[The influence of misoprostol on post-aspirin bronchoconstriction in patients with aspirin sensitive asthma] Szmidt M, et al. **Pneumonol Alergol Pol** 1995; 63(9–10):544–52 (Eng. Abstr.) **(Pol)**

[The role of long-acting beta-mimetics in patients with chronic bronchial spasm and bronchial asthma] Chazan R, et al. **Pol Arch Med Wewn** 1995 Jul;94(1):59–63 (47 ref.) **(Pol)**

[The treatment of bronchial asthma with powdered salbutamol and powdered beclomethasone dipropionate] Basacopol A, et al. **Pneumoftiziologia** 1995 Jan–Jun; 44(1–2):25–8 (Eng. Abstr.) **(Rum)**

[Aevit and glutamic acid in the treatment of patients with bronchial asthma] Daniliak IG, et al. **Klin Med (Mosk)** 1995; 73(5):50–3 (Eng. Abstr.) **(Rus)**

[Treatment with thymogen and myelopid of patients with bronchial asthma] Zoloedov VI, et al. **Klin Med (Mosk)** 1995;73(6):43–5 (Eng. Abstr.) **(Rus)**

[A comparative evaluation of the efficacy of immunocorrection in children with bronchial asthma living in ecologically contrasted regions] Trishina SV, et al. **Lik Sprava** 1995 Jul–Aug;(7–8):59–61 (Eng. Abstr.) **(Rus)**

[Cardiac monitoring in bronchial asthma patients taking salben] Kakhnovskii IM, et al. **Ter Arkh** 1996;68(3):50–2 **(Rus)**

[Changes in the lipid composition of the blood serum lipoproteins during the hormonal treatment of patients with bronchial asthma] Lizenko MV, et al. **Ter Arkh** 1995; 67(11):35–8 (Eng. Abstr.) **(Rus)**

[The effect of the Russian inhalant glucocorticosteroid budesonide on bronchial inflammation and hyperreactivity during the long-term treatment of bronchial asthma patients] Sutochnikova OA, et al. **Ter Arkh** 1996; 68(3):48–50 (Eng. Abstr.) **(Rus)**

[Broncholytic agents in the treatment of bronchial asthma] Tkachenko Iulia, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):13–6 (38 ref.) **(Rus)**

[Comparative study] of beclomethasone and budesonide, with same posology (400 micrograms every 12 hours), in the control of cortico-dependent intrinsic asthma] Hernández J, et al. **Allergol Immunopathol (Madr)** 1995 Sep–Oct; 23(5):193–201 (Eng. Abstr.) **(Spa)**

[The excretion of free cortisol in the urine in healthy children and in asthmatics treated with long-term inhaled glucocorticoids] Gónzalez Pérez-Yarza E, et al. **An Esp Pediatr** 1996 Jun;44(6):531–6 (Eng. Abstr.) **(Spa)**

[The risk from inhaled glucocorticoids in childhood asthma (letter)] Ferrer López P. **Arch Bronconeumol** 1995 Aug–Sep;31(7):371 **(Spa)**

[Trends in the pharmacotherapy of chronic airflow obstruction in Argentina: 1983–1990 (letter; comment)] Quadrelli SA, et al. **Medicina (B Aires)** 1995;55(1):88–90. Comment on: Medicina (B Aires) 1994;54(2):103–9. **(Spa)**

[Comparative study of the effectiveness of 2 oral corticoids in the control of severe crisis of bronchial asthma: deflazacort and prednisone] Chapela R. **Rev Alerg Mex** 1995 Jul–Aug;42(4):64–8 (Eng. Abstr.) **(Spa)**

[The use of steroids in asthmatic children] Meza Morales A, et al. **Rev Alerg Mex** 1995 Jul–Aug;42(4):74–7 (19 ref.) (Eng. Abstr.) **(Spa)**

[Why is one ACTH-preparation worse than another in asthma? (letter)] Kjellson L. **Lakartidningen** 1996 Aug 7; 93(32–33):2726 **(Swe)**

[Asthma symptoms and anti-asthma drugs in 4 Scandinavian countries] Janson C, et al. **Nord Med** 1996 May; 111(5):147–50 (Eng. Abstr.) **(Swe)**

ECONOMICS

Protocol therapy for acute asthma: therapeutic benefits and cost savings. McFadden ER Jr, et al. **Am J Med** 1995 Dec; 99(6):651–61

National Asthma Education and Prevention Program working group report on the financing of asthma care. Billings J, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 2):S119–30

National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. Sullivan S, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 2):S84–95

An intervention program to reduce the hospitalization cost of asthmatic patients requiring intubation. Doan T, et al. **Ann Allergy Asthma Immunol** 1996 Jun;76(6):513–8

Drug utilization evaluation identifies costs associated with high use of beta-adrenergic agonists. Stempel DA, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):153–8

Efficacy and cost effectiveness of inhaled steroids in asthma in a developing country: an epilogue [letter] Perera BJ. **Arch Dis Child** 1995 Nov;73(5):482

Use of a pharmacy and medical claims database to document cost centers for 1993 annual asthma expenditures. Stempel DA, et al. **Arch Fam Med** 1996 Jan;5(1):36–40

Direct and indirect costs of asthma in Canada, 1990 [see comments] Krahn MD, et al. **Can Med Assoc J** 1996 Mar 15;154(6):821–31. Comment in: Can Med Assoc J 1996 Mar 15;154(6):841–3.

Understanding the costs of asthma: the next step [editorial; comment] Weiss KB, et al. **Can Med Assoc J** 1996 Mar 15;154(6):841–3. Comment on: Can Med Assoc J 1996 Mar 15;154(6):821–31.

An economic evaluation of short-term inpatient rehabilitation for children with severe asthma. Weinstein AG, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):264–73

The cost of childhood asthma to Australian families. Toelle BG, et al. **Pediatr Pulmonol** 1995 Jun;19(6):330–5

Cost comparison of beta 2-agonist bronchodilators used in the treatment of asthma. Nightingale CH. **Pharmacotherapy** 1995 Sep–Oct;15(5):677–81

A cost comparison of beta 2-agonist bronchodilators is not a cost-effectiveness comparison. Rickard K, et al. **Pharmacotherapy** 1996 May–Jun;16(3):484–5; discussion 486–7

[Bronchial asthma—a cost of illness analysis] Nowak D, et al. **Pneumologie** 1996 May;50(5):364–71 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Induction of nitric oxide synthase in a model of allergic occupational asthma. Yan ZQ, et al. **Allergy** 1995 Sep; 50(9):760–4

Is mast cell activation during asthmatic reaction reflected in the circulation? Mędrala W, et al. **J Investig Allergol Clin Immunol** 1995 Nov–Dec;5(6):343–6

[Serum phospholipase A2 activity in patients with aspirin-induced asthma] Toyoshima M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):691–4 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Prevalence of and factors associated with childhood asthma in Hong Kong. Lau YL, et al. **Acta Paediatr** 1995 Jul; 84(7):820–2

Epidemiology of bronchial asthma in children in Olomouc district. Kopřiva F, et al. **Acta Univ Palacki Olomuc Fac Med** 1994;138:33–4

Prevalence of asthma and asthma symptoms in a general population sample from northern Italy. European Community Respiratory Health Survey—Italy. **Allergy** 1995 Sep;50(9):755–9

Allergen avoidance in infancy and allergy at 4 years of age. Hide DW, et al. **Allergy** 1996 Feb;51(2):89–93

Prevalence of bronchial asthma in schoolchildren in Oslo, Norway. Comparison of data obtained in 1993 and 1981. Skjønsberg OH, et al. **Allergy** 1995 Oct;50(10):806–10

The problem of asthma in the Ukraine. Markov A. **Allergy Proc** 1995 Sep–Oct;16(5):269–73

Prevalence and predictors of asthma in working groups in British Columbia. Siracusa A, et al. **Am J Ind Med** 1995 Sep;28(3):411–23

Airways responsiveness, wheeze onset, and recurrent asthma episodes in young adolescents. The East Boston Childhood Respiratory Disease Cohort. Carey VJ, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):356–61

The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Johnston SL, et al. **Am J Respir Crit Care Med** 1996 Sep; 154(3 Pt 1):654–60

Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. A prospective cohort study. Troisi RJ, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1183–8

Childhood asthma in Qatar. Dawod ST, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):360–4

Prevalence and severity of asthma, rhinitis, and eczema in Singapore schoolchildren. Goh DY, et al. **Arch Dis Child** 1996 Feb;74(2):131–5

Persistent nocturnal cough in childhood: a population based study. Ninan TK, et al. **Arch Dis Child** 1995 Nov; 73(5):403–7

A comparison of admission patterns of childhood asthma in 1982 and 1992. Visitsunthorn N, et al. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):123–8

Readmissions to hospital: the contribution of morbidity data to the evaluation of asthma management. Rushworth RL, et al. **Aust J Public Health** 1995 Aug;19(4):363–7

Asthma epidemics and air pollution. Epidemic of asthma was not associated with episode of air pollution [letter] Anderson HR, et al. **BMJ** 1996 Jun 22;312(7046):1606–7

A major outbreak of asthma associated with a thunderstorm: experience of accident and emergency departments and patients' characteristics. Thames Regions Accident and Emergency Trainees Association [see comments] Davidson AC, et al. **BMJ** 1996 Mar 9;312(7031):601–4. Comment in: BMJ 1996 Mar 9;312(7031):590–1.

Asthma epidemics and air pollution. Upper respiratory tract infection and fall in atmospheric temperature may lead to attacks of childhood asthma [letter; comment] Hawker J, et al. **BMJ** 1996 Jun 22;312(7046):1606. Comment on: BMJ 1996 Mar 9;312(7031):590–1.

Do people living near inner city main roads have more asthma needing treatment? Case control study [see comments] Livingstone AE, et al. **BMJ** 1996 Mar 16; 312(7032):676–7. Comment in: BMJ 1996 Mar 16;312(7032):649–50.

Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. Strachan DP, et al. **BMJ** 1996 May 11;312(7040):1195–9

Prevalence of asthma and COPD in general practice in 1992: has it changed since 1977? Tirimanna PR, et al. **Br J Gen Pract** 1996 May;46(406):277–81

Occupational asthma in a community-based survey of adult asthma. Blanc PD, et al. **Chest** 1996 Mar;109(3 Suppl):56S–57S

Occupation and asthma. Through a glass, darkly [editorial; comment] Blanc PD. **Chest** 1996 Jul;110(1):3–5. Comment on: Chest 1996 Jul;110(1):58–61.

Epidemiologic methods for the study of occupational asthma. Current problems and solutions. Cullen MR. **Chest** 1996 Mar;109(3 Suppl):51S–54S (28 ref.)

Incidence of occupational asthma and persistent asthma in young adults has increased in Finland [see comments] Reijula K, et al. **Chest** 1996 Jul;110(1):58–61. Comment in: Chest 1996 Jul;110(1):3–5.

Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren between 1979 and 1991 [see comments] Aberg N, et al. **Clin Exp Allergy** 1995 Sep;25(9):815–9. Comment in: Clin Exp Allergy 1995 Sep;25(9):791–4.

EGEA (Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy)—design issues. EGEA Co-operative Group. Kauffmann F, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:19–22

Asthma epidemiology in the Far East. Lai CK, et al. **Clin Exp Allergy** 1996 Jan;26(1):5–12 (47 ref.)

Asthma genetics studies in Western Australia. Le Souëf PN. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:26–8 (10 ref.)

Dutch approach to the study of the genetics of asthma. Panhuysen CI, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:35–8

Genetics of asthma: University of Toronto. The University of Toronto Genetics of Asthma Research Group. Slutsky AS, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:33–4

Time trends in asthma and allergy: ten questions, fewer answers [editorial; comment] Strachan DP. **Clin Exp Allergy** 1995 Sep;25(9):791–4 (30 ref.). Comment on: Clin Exp Allergy 1995 Sep;25(9):815–9.

Collaborative study on the genetics of asthma in Germany. Wjst M, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:23–5

An epidemiologic study of bronchial asthma and smoking. Flodin U, et al. **Epidemiology** 1995 Sep;6(5):503–5

Asthmatic risk factors and bronchial reactivity in non-diagnosed asthmatic adults. Lebowitz MD, et al. **Eur J Epidemiol** 1995 Oct;11(5):541–8

Wheeze in preschool children: who is followed-up, who is treated and who is hospitalized? Luyt DK, et al. **Eur Respir J** 1995 Oct;8(10):1736–41

Prevalence and characteristics of children with chronic respiratory symptoms in eastern Finland. Timonen KL, et al. **Eur Respir J** 1995 Jul;8(7):1155–60

Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance. Van Ganse E, et al. **Eur Respir J** 1995 Nov;8(11):1856–60

Growing out of asthma. Chugh K. **Indian Pediatr** 1995 Jun; 32(6):719–21

Quality of housing and allergy to cockroaches in the Dominican Republic. Barnes KC, et al. **Int Arch Allergy Immunol** 1996 Jan;109(1):68–72

Mite allergens did not cause asthma epidemics in Barcelona, Spain. Codina R, et al. **J Allergy Clin Immunol** 1996 Jul; 98(1):236–8

Mite allergen (Der p 1) concentration in houses and its relation to the presence and severity of asthma in a population of Sydney schoolchildren. Marks GB, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):441–8

Decrease in hospitalization for treatment of childhood asthma with increased use of antiinflammatory treatment, despite an increase in prevalence of asthma. Wennergren G, et al. **J Allergy Clin Immunol** 1996 Mar;97(3):742–8

The prevalence of asthma and respiratory symptoms among young adults: is it increasing in Australia? Abramson M, et al. **J Asthma** 1996;33(3):189–96

An epidemiological investigation into nocturnal asthma. Chhabra SK. **J Asthma** 1995;32(2):147–50

Current prevalence of asthma-related symptoms in San Diego's predominantly Hispanic inner-city children. Christiansen SC, et al. **J Asthma** 1996;33(1):17–26

Asthma and its association with cardiovascular disease in the

elderly. The Cardiovascular Health Study Research Group. Enright PL, et al. **J Asthma** 1996;33(1):45–53

Risk factors for intubation of adult asthmatic patients. LeSon S, et al. **J Asthma** 1995;32(2):97–104

Risk of preschool asthma: incidence, hospitalization, recurrence, and readmission probability. Schaubel D, et al. **J Asthma** 1996;33(2):97–103

Effectiveness of a specialized asthma clinic in reducing asthma morbidity in an inner–city minority population. Sperber K, et al. **J Asthma** 1995;32(5):335–43

Characteristics of hospitalization for asthma among persons less than 35 years of age in Chicago. Targonski PV, et al. **J Asthma** 1995;32(5):365–72

A computer–assisted telephone interview technique for assessment of asthma morbidity and drug use in adult asthma. Anie KA, et al. **J Clin Epidemiol** 1996 Jun; 49(6):653–6

Asthma and ambient air pollution in Helsinki. Pönkä A, et al. **J Epidemiol Community Health** 1996 Apr;50 Suppl 1:s59–62

Towards a better understanding of childhood asthma. Van Asperen PP. **J Paediatr Child Health** 1995 Aug;31(4):272–5 (36 ref.)

The challenge of asthma: Lancet conference 1997 [editorial] **Lancet** 1996 Jul 27;348(9022):207

Allergy to laboratory animals among animal handlers. Bryant DH, et al. **Med J Aust** 1995 Oct 16;163(8):415–8

Asthma management in eastern Australia, 1990 and 1993 [see comments] Comino EJ, et al. **Med J Aust** 1996 Apr 1; 164(7):403–6. Comment in: Med J Aust 1996 Apr 1;164(7):391–3.

Consumption of oily fish and childhood asthma risk [see comments] Hodge L, et al. **Med J Aust** 1996 Feb 5; 164(3):137–40. Comment in: Med J Aust 1996 Feb 5;164(3):135–6.

Asthma and atopy in four rural Australian aboriginal communities. Veale AJ, et al. **Med J Aust** 1996 Aug 19; 165(4):192–6

The prevalence of asthma [letter] McQueen EG. **N Z Med J** 1995 Oct 27;108(1010):443

Feasibility study of respiratory questionnaire and peak flow recordings in autobody shop workers exposed to isocyanate–containing spray paint: observations and limitations. Cullen MR, et al. **Occup Med (Oxf)** 1996 Jun; 46(3):197–204

Time trends in acute childhood asthma in Basque Country, Spain. Benito J, et al. **Pediatr Pulmonol** 1995 Sep; 20(3):184–8

Characteristics of near–fatal asthma in childhood. Martin AJ, et al. **Pediatr Pulmonol** 1995 Jul;20(1):1–8

A cohort study on childhood asthma admissions and readmissions. To T, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):191–5

Prevalence of self–reported asthma symptoms in a French elderly sample. Nejjari C, et al. **Respir Med** 1996 Aug; 90(7):401–8

Prevalence of asthma and asthma–like symptoms in three French cities. Neukirch F, et al. **Respir Med** 1995 Nov; 89(10):685–92

Prevalence of asthma in young cross–country skiers in central Scandinavia: differences between Norway and Sweden. Sue–Chu M, et al. **Respir Med** 1996 Feb;90(2):99–105

The use of children's medical records to predict the risk of asthma attack. Neville RG, et al. **Scott Med J** 1995 Oct; 40(5):138–40

Short–term association between air pollution and emergency room visits for asthma in Barcelona. Castellsague J, et al. **Thorax** 1995 Oct;50(10):1051–6

Asthma, airways responsiveness and air pollution in two contrasting districts of northern England. Devereux G, et al. **Thorax** 1996 Feb;51(2):169–74

Descriptive study of cough, wheeze and school absence in childhood. Doull IJ, et al. **Thorax** 1996 Jun;51(6):630–1

Asthma and other pulmonary diseases in former elite athletes. Kujala UM, et al. **Thorax** 1996 Mar;51(3):288–92

Occupational asthma: measures of frequency from four countries. Meredith S, et al. **Thorax** 1996 Apr;51(4):435–40

Trends in the prevalence of asthma in Scottish and English primary school children 1982–92. Rona RJ, et al. **Thorax** 1995 Sep;50(9):992–3

Effect of readmissions on increasing hospital admissions for asthma in children. Senthilselvan A. **Thorax** 1995 Sep; 50(9):934–6

Repeaters count: a sentinel method for asthma outbreaks. Barcelona Soybean–Asthma Group. Soriano JB, et al. **Thorax** 1995 Oct;50(10):1101–3

The International Study of Asthma and Allergies in Childhood (ISAAC): objectives and methods; results from German ISAAC centres concerning traffic density and wheezing and allergic rhinitis. Keil U, et al. **Toxicol Lett** 1996 Aug;86(2–3):99–103

The prevalence of asthma and other allergic diseases in a province of Turkey. Küçüködük S, et al. **Turk J Pediatr** 1996 Apr–Jun;38(2):149–53

[Asthma in primary school: survey in Saint–Nazaire and its region (letter)] Branger B, et al. **Arch Pediatr** 1996 Apr; 3(4):397–8 **(Fre)**

[Morbidity and mortality induced by asthma in 1996] Taytard A. **Rev Pneumol Clin** 1996;52(2):65–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[A statistical investigation of the influence of allergic factors on intractable asthma by multiple logistic regression] Terada M. **Arerugi** 1996 May;45(5):461–71 (Eng. Abstr.) **(Jpn)**

[Trends of air pollution versus those of consultation rate and mortality rate for bronchial asthma in individuals aged 40 years and above in the Yokkaichi region] Kitabatake M, et al. **Nippon Eiseigaku Zasshi** 1995 Aug;50(3):737–47 (Eng. Abstr.) **(Jpn)**

[Epidemiology of asthma (occurrence and death)] Sano Y. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):168–73 (5 ref.) **(Jpn)**

[Bronchial asthma and chronic respiratory symptoms in the population of children in the Katowice voivodship—prevalence and risk factors] Zejda JE, et al. **Pneumonol Alergol Pol** 1996;64(3–4):169–77 (Eng. Abstr.) **(Pol)**

[Respiratory symptoms in a pediatric population] Pereira Vega A, et al. **Arch Bronconeumol** 1995 Oct;31(8):383–8 (Eng. Abstr.) **(Spa)**

[Epidemiologic aspects of bronchial asthma in the Mexican Republic] Martínez–Cairo Cueto S, et al. **Gac Med Mex** 1995 May–Jun;131(3):277–82 (Eng. Abstr.) **(Spa)**

[European study on asthma. Prevalence of bronchial hyperreactivity and asthma in young adults from 5 Spanish areas. Spanish Group of the European Study on Asthma (see comments)] **Med Clin (Barc)** 1996 May 25; 106(20):761–7 (Eng. Abstr.). Comment in: Med Clin (Barc) 1996 May 25;106(20):780–1. **(Spa)**

[Unusual attendance at Hospital Emergency Services for asthma and chronic obstructive pulmonary disease and SO2 air pollution in Cartagena (Spain)] Guillén Pérez JJ, et al. **Rev Esp Salud Publica** 1995 May–Aug;69(3–4):305–14 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

The effect of lifestyle on wheeze, atopy, and bronchial hyperreactivity in Asian and white children. Carey OJ, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):537–40

Respiratory symptoms in urban Hispanic and non–Hispanic white women. David MM, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1285–91

Influence of ethnic group on asthma treatment in children in 1990–1: national cross sectional study. Duran–Tauleria E, et al. **BMJ** 1996 Jul 20;313(7050):148–52

Segregation analysis of physician–diagnosed asthma in Hispanic and non–Hispanic white families. Martinez FD, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:68–70; discussion 95–6

Exposure and sensitization to environmental allergen of predominantly Hispanic children with asthma in San Diego's inner city. Christiansen SC, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):288–94

Increased asthma hospitalizations among registered Indian children and adults in Saskatchewan, 1970–1989. Senthilselvan A, et al. **J Clin Epidemiol** 1995 Oct; 48(10):1277–83

Children with asthma in the emergency department: spectrum of disease, variation with ethnicity, and approach to treatment. Horowitz I, et al. **Pediatr Emerg Care** 1995 Aug; 11(4):240–2

Clinical characteristics of black asthmatic children. Luyt DK, et al. **S Afr Med J** 1995 Oct;85(10):999–1001

ETIOLOGY

The significance of transient mucosal IgA deficiency on the development of asthma and atopy in children. Gleeson M, et al. **Adv Exp Med Biol** 1995;371B:861–4

Can inhalation of garlic dust cause asthma? Armentia A. **Allergy** 1996 Feb;51(2):137–8

The role of the bone marrow in allergy and asthma. Denburg JA, et al. **Allergy** 1996 Mar;51(3):141–8 (109 ref.)

Occupational asthma and rhinoconjunctivitis caused by senna. Helin T, et al. **Allergy** 1996 Mar;51(3):181–4

Occupational asthma due to different spices. Sastre J, et al. **Allergy** 1996 Feb;51(2):117–20

Occupational asthma in horticulture caused by Lathyrus odoratus. Jansen A, et al. **Allergy Proc** 1995 May–Jun; 16(3):135–9

Pre– and perinatal risk factors for asthma in inner city African–American children. Oliveti JF, et al. **Am J Epidemiol** 1996 Mar 15;143(6):570–7

Pulmonary symptoms associated with gastroesophageal reflux: use of ambulatory pH monitoring to diagnose and to direct therapy [see comments] Schnatz PF, et al. **Am J Gastroenterol** 1996 Sep;91(9):1715–8. Comment in: Am J Gastroenterol 1996 Sep;91(9):1690–1.

Gastroesophageal reflux disease and pulmonary disease [editorial; comment] Schubert TT. **Am J Gastroenterol** 1996 Sep;91(9):1690–1. Comment on: Am J Gastroenterol 1996 Sep;91(9):1715–8.

Why does asthma become persistent? Barnes PJ, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S23–5 (49 ref.)

Mite and cat allergen levels in homes and severity of asthma. Chan–Yeung M, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1805–11

Environmental tobacco smoke, wheezing, and asthma in children in 24 communities. Cunningham J, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):218–24

Daily asthma severity in relation to personal ozone exposure and outdoor fungal spores. Delfino RJ, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):633–41

Risk factors for childhood asthma and wheezing. Importance of maternal and household smoking. Ehrlich RI, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):681–8

Is occupational asthma a relevant model? Fabbri LM. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S26 (21 ref.)

Exposure–sensitization relationship for alpha–amylase allergens in the baking industry. Houba R, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):130–6

High–affinity IgE receptor (FcepsilonRI)–bearing cells in bronchial biopsies from atopic and nonatopic asthma. Humbert M, et al. **Am J Respir Crit Care Med** 1996 Jun; 153(6 Pt 1):1931–7

The risk of asthma attributable to occupational exposures. A population–based study in Spain. Spanish Group of the European Asthma Study. Kogevinas M, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):137–43

House dust mite allergens. A major risk factor for childhood asthma in Australia. Peat JK, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):141–6

How does inflammation cause symptoms? Woolcock AJ. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S21–2 (28 ref.)

Noncompliance with immunotherapy secondary to adverse effects [letter; comment] [published erratum appears in Ann Allergy Asthma Immunol 1995 Dec;75(6 Pt 1):474] Craig TJ, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):290 . Comment on: Ann Allergy Asthma Immunol 1995 Mar;74(3):241–6.

Occupational asthma due to deer dander. Nahm DH, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):423–6

Asthma to carob bean flour [letter] Scoditti A, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):81

Indoor environmental risk factors in young asthmatics: a case–control study. Lindfors A, et al. **Arch Dis Child** 1995 Nov;73(5):408–12

Asthma associated with thunderstorms [editorial; comment] [see comments] Bauman A. **BMJ** 1996 Mar 9; 312(7031):590–1. Comment on: BMJ 1996 Mar 9;312(7031):601–4. Comment on: BMJ 1996 Mar 9;312(7031):604–7. Comment in: BMJ 1996 Jun 22;312(7046):1606.

Effect of air pollution on asthma is "small" [news] Carnall D. **BMJ** 1995 Oct 28;311(7013):1120

Thunderstorm associated asthma: a detailed analysis of environmental factors [see comments] Celenza A, et al. **BMJ** 1996 Mar 9;312(7031):604–7. Comment in: BMJ 1996 Mar 9;312(7031):590–1.

Sydney's asthma witch hunt [news] Chapman S. **BMJ** 1995 Nov 25;311(7017):1390

A major outbreak of asthma associated with a thunderstorm: experience of accident and emergency departments and patients' characteristics. Thames Regions Accident and Emergency Trainees Association [see comments] Davidson AC, et al. **BMJ** 1996 Mar 9;312(7031):601–4. Comment in: BMJ 1996 Mar 9;312(7031):590–1.

Moving house: a risk factor for the development of childhood asthma? [see comments] Hughes CH, et al. **BMJ** 1995 Oct 21;311(7012):1069–70. Comment in: BMJ 1996 Feb 3;312(7026):315.

ABC of work related disorders. Occupational asthma and other respiratory diseases. Madan I. **BMJ** 1996 Aug 3; 313(7052):291–4 (0 ref.)

Cockroaches linked with asthma [news] Roberts J. **BMJ** 1996 Jun 29;312(7047):1630

Home environment and severe asthma in adolescence: a population based case–control study. Strachan DP, et al. **BMJ** 1995 Oct 21;311(7012):1053–6

Moving house unlikely to pose substantial risk of childhood asthma [letter; comment] Strachan DP, et al. **BMJ** 1996 Feb 3;312(7026):315. Comment on: BMJ 1995 Oct 21;311(7012):1069–70.

Relation of indoor heating with asthma, allergic sensitisation, and bronchial responsiveness: survey of children in south Bavaria. von Mutius E, et al. **BMJ** 1996 Jun 8; 312(7044):1448–50

What exacerbates asthma? [letter] Abelsohn A, et al. **Can Fam Physician** 1996 Apr;42:620

Tachykinins, sensory nerves, and asthma—an overview. Lundberg JM. **Can J Physiol Pharmacol** 1995 Jul; 73(7):908–14 (99 ref.)

Role of mast cells and basophils in asthma. Redington AE, et al. **Chem Immunol** 1995;62:22–59 (293 ref.)

Gastroesophageal reflux disease and asthma. Reflux or reflex? [editorial; comment] Castell DO, et al. **Chest** 1995 Nov; 108(5):1186–7. Comment on: Chest 1995 Nov;108(5):1220–7.

Gastroesophageal reflux–induced bronchoconstriction. Is microaspiration a factor? [see comments] Harding SM, et al. **Chest** 1995 Nov;108(5):1220–7. Comment in: Chest 1995 Nov;108(5):1186–7. Comment in: Chest 1995 Nov;108(5):1187–8.

Cigarette smoking and incidence of chronic bronchitis and asthma in women. Troisi RJ, et al. **Chest** 1995 Dec; 108(6):1557–61

Gastroesophageal reflux–induced bronchial constriction [editorial; comment] Wright RA, et al. **Chest** 1995 Nov; 108(5):1187–8. Comment on: Chest 1995 Nov;108(5):1220–7.

Childhood asthma. Older children and adolescents. Gern JE,

et al. **Clin Chest Med** 1995 Dec;16(4):657–70 (99 ref.)
Gastroesophageal reflux and sinusitis in asthma. Hamilos DL. **Clin Chest Med** 1995 Dec;16(4):683–97 (61 ref.)
Asthmatic symptoms and indoor levels of micro–organisms and house dust mites. Björnsson E, et al. **Clin Exp Allergy** 1995 May;25(5):423–31
Food intolerance and asthma. Warner JO. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:29–30 (10 ref.)
Observations on asthma. Bates DV. **Environ Health Perspect** 1995 Sep;103 Suppl 6:243–7 (49 ref.)
Basic mechanisms of asthma. Boushey HA, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:229–33 (47 ref.)
Occupational asthma. Chan–Yeung M. **Environ Health Perspect** 1995 Sep;103 Suppl 6:249–52 (40 ref.)
Indoor air pollution and childhood asthma: effective environmental interventions. Etzel RA. **Environ Health Perspect** 1995 Sep;103 Suppl 6:55–8 (43 ref.)
Associations between criteria air pollutants and asthma. Koren HS. **Environ Health Perspect** 1995 Sep;103 Suppl 6:235–42 (106 ref.)
Evaluation of a possible association of urban air toxics and asthma. Leikauf GD, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:253–71 (179 ref.)
Environmental risk factors of childhood asthma in urban centers. Malveaux FJ, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:59–62 (30 ref.)
Fever and leucocytosis accompanying asthmatic reactions due to occupational agents: frequency and associated factors. Lemière C, et al. **Eur Respir J** 1996 Mar; 9(3):517–23
Occupational asthma in aluminium potroom workers related to pre–employment eosinophil count. Sorgdrager B, et al. **Eur Respir J** 1995 Sep;8(9):1520–4
Rubber latex in the air: an occupational and environmental cause of asthma? Hopkins J. **Food Chem Toxicol** 1995 Oct; 33(10):895–9 (23 ref.)
Cellular mechanisms in the pathogenesis of bronchial asthma [letter] Spinozzi F, et al. **Immunol Today** 1995 Aug; 16(8):407–8
The role of nitric oxide in the development of asthma. Curran AD. **Int Arch Allergy Immunol** 1996 Sep;111(1):1–4 (34 ref.)
A new risk of occupational disease: allergic asthma and rhinoconjunctivitis in persons working with beneficial arthropods. Cipolla C, et al. **Int Arch Occup Environ Health** 1996;68(2):133–5
Chronic and acute respiratory effects among grain mill workers. Gimenez C, et al. **Int Arch Occup Environ Health** 1995;67(5):311–5
Work–related late asthmatic response induced by latex allergy. Brugnami G, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):457–64
Inhaled beta 2–agonists and allergen–induced airway responses [letter; comment] Cockcroft DW, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):1013–4. Comment on: J Allergy Clin Immunol 1995 Mar;95(3):641–51.
Exposure to house dust mite allergens and the clinical activity of asthma. Custovic A, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):64–72
Occupational IgE–mediated sensitization and asthma caused by clam and shrimp. Desjardins A, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):608–17
Occupational asthma caused by imbuia wood dust [case report] Jeebhay MF, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):1025–7
Occupational asthma caused by roasted coffee: immunologic evidence that roasted coffee contains the same antigens as green coffee, but at a lower concentration. Lemière C, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):464–6
Royal jelly–induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Leung R, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):1004–7
Diagnosis of soybean–induced asthma. Morell F, et al. **J Allergy Clin Immunol** 1995 Sep;96(3):320–4
Allium cepa seeds: a new occupational allergen. Navarro JA, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):690–3
Influence of allergen avoidance on the eosinophil phase of airway inflammation in children with allergic asthma. Piacentini GL, et al. **J Allergy Clin Immunol** 1996 May; 97(5):1079–84
Investigation of the mechanism of alcohol–induced bronchial asthma. Shimoda T, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):74–84
Occupational asthma caused by grass juice. Subiza J, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):693–5
Occupational asthma induced by Chrysonilia sitophila in the logging industry. Tarlo SM, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1409–13
Asthma and oxidant stress: nutritional, environmental, and genetic risk factors. Greene LS. **J Am Coll Nutr** 1995 Aug; 14(4):317–24 (80 ref.)
Indoor air pollution and asthma in hospitalized children in a tropical environment. Azizi BH, et al. **J Asthma** 1995; 32(6):413–8
Risk factors for asthmatic patients requiring intubation. II. Observations in teenagers. LeSon S, et al. **J Asthma** 1995; 32(5):379–89
Neonatal characteristics as risk factors for preschool asthma. Schaubel D, et al. **J Asthma** 1996;33(4):255–64
Genetics reveals importance of platelet activating factor in asthma and possibly other inflammatory states [editorial; comment] Nadel JA. **J Clin Invest** 1996 Jun 15; 97(12):2689–90. Comment on: J Clin Invest 1996 Jun 15;97(12):2784–91.
Platelet–activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti–inflammatory phospholipase [see comments] Stafforini DM, et al. **J Clin Invest** 1996 Jun 15;97(12):2784–91. Comment in: J Clin Invest 1996 Jun 15;97(12):2689–90.
Sorting out the cytokines of asthma [comment] Drazen JM, et al. **J Exp Med** 1996 Jan 1;183(1):1–5. Comment on: J Exp Med 1995 Jan 1;183(1):109–17. Comment on: J Exp Med 1996 Jan 1;183(1):195–201.
Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model [see comments] Foster PS, et al. **J Exp Med** 1996 Jan 1; 183(1):195–201. Comment in: J Exp Med 1996 Jan 1;183(1):1–5.
Chronic infection and asthma [letter] Sherman B, et al. **J Fam Pract** 1996 May;42(5):529–30
Rhinovirus produces nonspecific activation of lymphocytes through a monocyte–dependent mechanism. Gern JE, et al. **J Immunol** 1996 Aug 15;157(4):1605–12
Lepidoglyphus destructor acarus in the urban house environment. Juliá JC, et al. **J Investig Allergol Clin Immunol** 1995 Nov–Dec; 5(6):318–21
Gastroesophageal reflux disease. Kahrilas PJ. **JAMA** 1996 Sep 25;276(12):983–8 (66 ref.)
Lack of association between pertussis vaccination and symptoms of asthma and allergy [letter] Nilsson L, et al. **JAMA** 1996 Mar 13;275(10):760
Singapore's haze and acute asthma in children [letter] Chew FT, et al. **Lancet** 1995 Nov 25;346(8987):1427
Salmon, ventilation, and mycotoxin inhalation [letter; comment] Leon FE. **Lancet** 1995 Dec 23–30; 346(8991–8992):1707. Comment on: Lancet 1995 Sep 16;346(8977):737–40.
Nonsensitizing causes of occupational asthma. Lemière C, et al. **Med Clin North Am** 1996 Jul;80(4):749–74 (67 ref.)
Are non–allergenic environmental factors important in asthma? Abramson MJ, et al. **Med J Aust** 1995 Nov 20; 163(10):542–5 (47 ref.)
Aetiology of asthma: how public health and molecular medicine work together. Chauhan AJ, et al. **Mol Med Today** 1996 May;2(5):192–7
Are cytokines responsible for the asthmatic state of the airways? Kips JC, et al. **Monaldi Arch Chest Dis** 1996 Jun; 51(3):223–7 (52 ref.)
Lego asthma [letter] Tseng R, et al. **N Engl J Med** 1996 Feb 8;334(6):406–7
Work–related asthma in a population exposed to grain, flour and other ingredient dusts. Smith TA, et al. **Occup Med (Oxf)** 1996 Feb;46(1):37–40
Food allergy and asthma. Businco L, et al. **Pediatr Pulmonol Suppl** 1995;11:59–60
Risk factors for airway hyperresponsiveness in childhood asthma. Sears MR. **Pediatr Pulmonol Suppl** 1995;11:42–3
The importance of inflammation in early asthma [editorial] Haahtela T. **Respir Med** 1995 Aug;89(7):461–2
New data help toxicologists home in on assessing risks [news] [see comments] Kaiser J. **Science** 1996 Apr 12;272(5259):200 . Comment in: Science 1996 May 24;272(5265):1083–4.
Asthma associated with small–cell lung cancer. Dionisi MS, et al. **Support Care Cancer** 1995 Sep;3(5):317–8
Usual dietary salt intake and asthma in children: a case–control study. Demissie K, et al. **Thorax** 1996 Jan; 51(1):59–63
Effect of dietary sodium on airways responsiveness and its importance in the epidemiology of asthma: an evaluation in three areas of northern England. Devereux G, et al. **Thorax** 1995 Sep;50(9):941–7
Microbial inciters of acute asthma in urban Nigerian children. Gbadero DA, et al. **Thorax** 1995 Jul;50(7):739–45
Progression of allergy and asthma through childhood to adolescence. von Mutius E. **Thorax** 1996 Jan;51 Suppl 1:S3–6 (58 ref.)
Occupational asthma. Brooks SM. **Toxicol Lett** 1995 Dec; 82–83:39–45 (32 ref.)
Asthma and the environment: do environmental factors affect the incidence and prognosis of asthma? Samet JM. **Toxicol Lett** 1995 Dec;82–83:33–8 (15 ref.)
Environmentally induced asthma. Utell MJ, et al. **Toxicol Lett** 1995 Dec;82–83:47–53 (21 ref.)
The evaluation of skin prick test in house dust mite allergy in Calcutta, India. Saha GK, et al. **Trop Geogr Med** 1995; 47(6):278–81
Asthma and air pollution. Balmes JR. **West J Med** 1995 Oct; 163(4):372–3
[The relationship between H2 receptor and the pathogenesis of bronchial asthma in guinea–pigs] Chen X, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Aug; 18(4):221–3, 255 (Eng. Abstr.) **(Chi)**
[The relationship between H2 receptor of airways and the pathogenesis of bronchial asthma] Ye Y, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Jun; 18(3):146–8, 189 (Eng. Abstr.) **(Chi)**
[Ski racing and asthma (editorial)] Laitinen L. **Duodecim** 1994;110(19):1754–6 (21 ref.) **(Fin)**
[The diagnosis of asthma caused by cow hair epithelium] Taivainen A, et al. **Duodecim** 1994;110(21):1999–2003 **(Fin)**
[In young children with severe asthma, suspect allergy to peanuts (letter)] Bidat E, et al. **Arch Pediatr** 1996 Jan; 3(1):91–2 **(Fre)**
[Occupational asthma in an agricultural setting] Bessot JC, et al. **Rev Mal Respir** 1996 Jul;13(3):205–15 (103 ref.) (Eng. Abstr.) **(Fre)**
[Asthma to green coffee of environmental origin] Mairesse M, et al. **Rev Mal Respir** 1996 Jul;13(3):308–9 (Eng. Abstr.) **(Fre)**
[Role of atmospheric pollutants in asthma] Charpin D, et al. **Rev Pneumol Clin** 1996;52(2):70–8 (54 ref.) (Eng. Abstr.) **(Fre)**
[New hypotheses in asthma: the mastocytes] Kassel O, et al. **Rev Pneumol Clin** 1996;52(2):59–63 (34 ref.) (Eng. Abstr.) **(Fre)**
[Therapy–resistant asthma: causes and therapy] Rothe TB, et al. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1118–24 (Eng. Abstr.) **(Ger)**
[Nasal patency patterns observed during working hours in a group of technicians habitually exposed to formaldehyde] Giordano C, et al. **Acta Otorhinolaryngol Ital** 1995 Oct; 15(5):335–44 (Eng. Abstr.) **(Ita)**
[Progress of allergology and cell reaction—recognition of adult onset intractable asthma] Kimura I. **Arerugi** 1995 Oct; 44(10):1193–8 (21 ref.) **(Jpn)**
[An adult case of rice–induced asthma with aspirin idiosyncrasy] Owan I, et al. **Arerugi** 1995 Jul;44(7):708–10 **(Jpn)**
[Occupational asthma] Shiro T. **Arerugi** 1995 Sep; 44(9):1105–10 (37 ref.) **(Jpn)**
[Occupational asthma] Fujimura N. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):234–9 (8 ref.) **(Jpn)**
[The role of viral respiratory tract infections on pathogenesis of bronchial asthma. I. Clinical and experimental investigations] Kroczyńska–Bednarek J, et al. **Pneumonol Alergol Pol** 1995;63(9–10):566–9 (35 ref.) **(Pol)**
[Progress in pathophysiology and therapy of bronchial asthma] Rutkowski R, et al. **Pneumonol Alergol Pol** 1995; 63 Suppl 2:93–9 (39 ref.) **(Pol)**
[Bronchial asthma—a chronic inflammatory disorder] Adamek–Guzik T, et al. **Przegl Lek** 1996;53(1):12–9 (25 ref.) (Eng. Abstr.) **(Pol)**
[Allergic bronchitis in bronchial asthma] Fal AM, et al. **Wiad Lek** 1994 Sep;47(17–18):688–93 (26 ref.) (Eng. Abstr.) **(Pol)**
[Arachnids as risk factors in occupational exposure] Dutkiewicz J. **Wiad Parazytol** 1995;41(3):253–66 (48 ref.) (Eng. Abstr.) **(Pol)**
[The etiopathogenesis of bronchial asthma] Petrui ID. **Pneumoftiziologia** 1995 Jan–Jun;44(1–2):53–61 (43 ref.) **(Rum)**
[Disorders in mineral metabolism at different stages of the development of bronchial asthma] Emel'ianov AV, et al. **Ter Arkh** 1995;67(8):45–7 (Eng. Abstr.) **(Rus)**
[The role of hypoxia in the development of bronchial asthma] Ialkut SI. **Ter Arkh** 1995;67(8):71–4 (40 ref.) **(Rus)**
[Effect of the home environment and maternal sensitizations on the bronchial asthma of their children] Sánchez Palacios A, et al. **Allergol Immunopathol (Madr)** 1996 May–Jun; 24(3):120–4 (Eng. Abstr.) **(Spa)**
[Early identification of respiratory viruses in asthmatic children] Morfin Maciel BM, et al. **Rev Alerg Mex** 1996 Mar–Apr;43(2):45–8 (22 ref.) (Eng. Abstr.) **(Spa)**
[The allergen–asthma relationship in the home microenvironment] Vázquez Nava F, et al. **Rev Alerg Mex** 1996 Mar–Apr;43(2):29–33 (Eng. Abstr.) **(Spa)**
[Unusual attendance at Hospital Emergency Services for asthma and chronic obstructive pulmonary disease and SO2 air pollution in Cartagena (Spain)] Guillén Pérez JJ, et al. **Rev Esp Salud Publica** 1995 May–Aug;69(3–4):305–14 (Eng. Abstr.) **(Spa)**

GENETICS

The genetics of asthma and atopy. Panhuysen CI, et al. **Allergy** 1995 Nov;50(11):863–9 (62 ref.)
Substance P (NK1)– and neurokinin A (NK2)–receptor gene expression in inflammatory airway diseases. Bai TR, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):L309–17
Increased interleukin–10 messenger RNA expression in atopic allergy and asthma. Robinson DS, et al. **Am J Respir Cell Mol Biol** 1996 Feb;14(2):113–7
Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyperresponsiveness. Doull IJ, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1280–4
Segregation analysis of physician–diagnosed asthma in Hispanic and non–Hispanic white families. A recessive component? Holberg CJ, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):144–50
Affected sib–pair and mutation analyses of the high affinity IgE receptor beta chain locus in Italian families with atopic asthmatic children. Martinati LC, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1682–5
The genetics of asthma. Sandford A, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1749–65 (188 ref.)

Familial aggregation of asthma in a South Bavarian population. von Mutius E, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1266–72

Asthma on Tristan da Cunha: looking for the genetic link. The University of Toronto Genetics of Asthma Research Group. Zamel N, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1902–6

Genetic factors in the presence, severity, and triggers of asthma. Sarafino EP, et al. **Arch Dis Child** 1995 Aug; 73(2):112–6

Recent Advances in the Genetics of Asthma and Allergy. Report of a symposium. Cannes, France, 28 September–1 October 1994. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:1–125

HLA class II haplotype in atopic asthmatic and non-atopic control subjects. Aron Y, et al. **Clin Exp Allergy** 1995 Nov; 25 Suppl 2:65–7; discussion 95–6

Transcription factors. Barnes PJ, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:46–9 (27 ref.)

Evidence for linkage of total serum IgE and bronchial hyperresponsiveness to chromosome 5q: a major regulatory locus important in asthma. Bleecker ER, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:84–8; discussion 95–6

Recent advances in the genetics of asthma. Bleecker ER, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:1–2

Collaborative studies on the genetics of asthma--National Heart, Lung and Blood Institute. Blumenthal MN, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:29–32

11q and high-affinity IgE receptor in asthma and allergy. Cookson WO. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:71–3; discussion 95–6 (23 ref.)

The genetics of allergy and asthma: concluding comments. Holgate ST. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:124–5

EGEA (Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy)--design issues. EGEA Co-operative Group. Kauffmann F, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:19–22

Asthma genetics studies in Western Australia. Le Souëf PN. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:26–8 (10 ref.)

Fine-structure mapping of genes providing susceptibility to asthma on chromosome 5q31–q33. Levitt RC, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:119–23

Genetics of beta 2-adrenergic receptor variants in asthma. Liggett SB. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:89–94; discussion 95–6

Genetic studies on atopy and asthma in Wessex. Morton NE. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:107–9; discussion 95–6

Dutch approach to the study of the genetics of asthma. Panhuysen CI, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:35–8

Genetic abnormalities of the human beta 2 adrenergic receptor. Potter PC. **Clin Exp Allergy** 1995 Jul;25(7):596–8 (18 ref.)

Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Rosenwasser LJ, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:74–8; discussion 95–6

Genetics of asthma: University of Toronto. The University of Toronto Genetics of Asthma Research Group. Slutsky AS, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:33–4

Collaborative study on the genetics of asthma in Germany. Wjst M, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:23–5

Association between toluene diisocyanate-induced asthma and DQB1 markers: a possible role for aspartic acid at position 57. Balboni A, et al. **Eur Respir J** 1996 Feb; 9(2):207–10

Lack of association between atopy and the Ile181Leu variant of the beta-subunit of the high-affinity immunoglobulin E receptor. Kofler H, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):44–7

Detection of allergen-induced genes in peripheral blood mononuclear cells of patients with allergic asthma using subtractive hybridization. Fukuda T, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1076–82

Who's to blame for asthma?[comment] Hayward A. **Lancet** 1995 Nov 11;346(8985):1243. Comment on: Lancet 1995 Nov 11;346(8985):1262–5.

Association between Fc epsilon RI beta and atopic disorder in a Japanese population [letter; comment] Shirakawa T, et al. **Lancet** 1996 Feb 10;347(8998):394–5. Comment on: Lancet 1995 Nov 11;346(8985):1262–5.

Linkage of high-affinity IgE receptor gene with bronchial hyperreactivity, even in absence of atopy [see comments] van Herwerden L, et al. **Lancet** 1995 Nov 11; 346(8985):1262–5. Comment in: Lancet 1995 Nov 11;346(8985):1243. Comment in: Lancet 1996 Feb 10;347(8998):394–5.

Quantitative locus analysis of airway hyperresponsiveness in A/J and C57BL/6J mice. De Sanctis GT, et al. **Nat Genet** 1995 Oct;11(2):150–4

The cystic fibrosis heterozygote advantage [letter; comment] Campbell H. **Nat Med** 1995 Nov;1(11):1100–2. Comment on: Nat Med 1995 Jul;1(7):703–5.

Heterozygotes for the delta F508 cystic fibrosis allele are not protected against bronchial asthma [letter] Mennie M, et al. **Nat Med** 1995 Oct;1(10):978–9

Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis [see comments] Schroeder SA, et al. **Nat Med** 1995 Jul; 1(7):703–5. Comment in: Nat Med 1995 Nov;1(11):1100–2.

A genome-wide search for quantitative trait loci underlying asthma. Daniels SE, et al. **Nature** 1996 Sep 19; 383(6597):247–50

Candidate gene loci in asthmatic and allergic inflammation [editorial] Wilkinson J, et al. **Thorax** 1996 Jan;51(1):3–8

Genetics of asthma and atopy. Rosenwasser LJ. **Toxicol Lett** 1996 Aug;86(2–3):73–7 (19 ref.)

HISTORY

Allemande l'Asthmatique by Marin Marais (1656–1728), French composer and virtuoso. Cohen SG. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):40–42

Antonio Vivaldi (1678–1741), Italian violin virtuoso, composer, and conductor. Cohen SG. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):50–1

John Arbuthnot (1667–1735), British physician and author. Cohen SG. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):43–6

Peter I/Peter the Great (1672–1725), Russian Czar. Cohen SG. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):47–9

Samuel Johnson (1709–1784), British poet, critic, essayist, and lexicographer. Cohen SG. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):52–5

John Calvin (1509–1564) French churchman and religious reformer. Cohen SG. **Allergy Proc** 1995 Sep–Oct; 16(5):276–8

John Hamilton (1511–1571) Scottish Archbishop. Cohen SG. **Allergy Proc** 1995 Sep–Oct;16(5):279–81

Jean Baptista van Helmont (1579–1644) Belgian physician and pioneer chemist. Cohen SG. **Allergy Proc** 1995 Sep–Oct;16(5):282–4

Jean Riolan (1580–1657) French physician and pioneer anatomist. Cohen SG. **Allergy Proc** 1995 Sep–Oct; 16(5):285–6

Henri de Mondeville (1260–1320) French pioneer surgeon. Cohen SG. **Allergy Proc** 1995 Jul–Aug;16(4):216–7

Lucius Annaeus Seneca (4 B.C.–79 A.D.) Roman orator, author, and statesman. Cohen SG. **Allergy Proc** 1995 Jul–Aug;16(4):210–1

Pliny the Elder (23–65 A.D.) Roman historian and encyclopedist. Cohen SG. **Allergy Proc** 1995 Jul–Aug; 16(4):212–3

Al-Afdal (1169–1225) Arab Sultan of Damascus and Egypt. Cohen SG. **Allergy Proc** 1995 Jul–Aug;16(4):214–5

Chu I-Hai, Prince of Lu (1618–1662) last regent of the Chinese Ming dynasty. Cohen SG. **Allergy Proc** 1995 Nov–Dec;16(6):320–1

John Locke (1632–1704) British physician and philosopher. Cohen SG. **Allergy Proc** 1995 Nov–Dec;16(6):322–5

Nicolas Boileaux-Despreaux (1636–1711) French poet, author, and literary critic. Cohen SG. **Allergy Proc** 1995 Nov–Dec;16(6):326–7

Sir John Floyer (1649–1734) British physician and pioneer clinical investigator. Cohen SG. **Allergy Proc** 1995 Nov–Dec;16(6):328–9

William III (1650–1702) Prince of Orange and King of England, Scotland, and Ireland. Cohen SG. **Allergy Proc** 1995 Nov–Dec;16(6):330–2

Biological miracles and misadventures: identification of sensitization and asthma in enzyme detergent workers [see comments] Flindt ML. **Am J Ind Med** 1996 Jan; 29(1):99–110. Comment in: Am J Ind Med 1996 Jan;29(1):1–2.

Comments on the Flindt enzyme history [editorial; comment] Greenberg M. **Am J Ind Med** 1996 Jan;29(1):1–2. Comment on: Am J Ind Med 1996 Jan;29(1):99–110.

Astute observers discover anti-asthma drugs. Persson CG. **Pharmacol Toxicol** 1995;77 Suppl 3:7–15

In vivo veritas: the continuing importance of discoveries in complex biosystems. Persson CG. **Thorax** 1996 Apr; 51(4):441–3

[Maimonides' treatise on asthma. Part I: Background] Garty BZ. **Harefuah** 1995 Dec 15;129(12):603–5 (Heb)

[Maimonides' treatise on asthma, Part II: Text] Garty BZ. **Harefuah** 1996 Jan 1;130(1):49–52 (Heb)

[Asthma and its treatment based on Polish source data from the end of the XVIII century] Kruszewski J, et al. **Pneumonol Alergol Pol** 1996;64(3–4):235–42 (Pol)

IMMUNOLOGY

Antibody-dependent cellular cytotoxicity, ingestion and digestion in Dermatophagoides pteronyssinus-sensitive asthmatic children. Barić I, et al. **Acta Med Croatica** 1995; 49(4–5):177–80

Interleukin-2 receptor positive T and B cells in children with acute severe asthmatic attack. Nabetani M, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):474–8

The immunological defects in allergic asthmatic children and the working mechanisms of immunotherapy (hyposensitization) [editorial] Hsieh KH. **Acta Paediatr Sin** 1995 Nov–Dec;36(6):399–400 (25 ref.)

Allergen-induced late airways reactions in the pig. Influence of endogenous and exogenous glucocorticoids. Fornhem C. **Acta Physiol Scand Suppl** 1995;631:1–48

Expression of the high affinity receptor for immunoglobulin E (IgE) by dendritic cells in normals and asthmatics. Semper AE, et al. **Adv Exp Med Biol** 1995;378:135–8

Local reaction to ocular disodium cromoglycate. Barranco P, et al. **Allergy** 1996 Feb;51(2):133–4

Platelet-derived growth factor in asthma. Chanez P, et al. **Allergy** 1995 Nov;50(11):878–83

Mast-cell-leukocyte cytokine cascades in allergic inflammation. Galli SJ, et al. **Allergy** 1995 Nov; 50(11):851–62 (129 ref.)

Survey of the allergic status of patients with bronchial asthma in Turkey: a multicenter study. Kalyoncu AF, et al. **Allergy** 1995 May;50(5):451–5

Effects of "systemic" budesonide concentrations on in vitro allergen-induced activation of blood mononuclear cells isolated from asthmatic patients. Oddera S, et al. **Allergy** 1995 May;50(5):397–404

Allergen challenge in asthma: association of eosinophils and lymphocytes with interleukin-5. Sur S, et al. **Allergy** 1995 Nov;50(11):891–8

Humoral and cellular immune responses in asthmatic isocyanate workers: report of two cases. Baur X, et al. **Am J Ind Med** 1996 May;29(5):467–73

Long-term antibody production in canine lung allografts: implications in pulmonary immunity and asthma. Bice DE, et al. **Am J Respir Cell Mol Biol** 1996 Apr;14(4):341–7

Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Cruikshank WW, et al. **Am J Respir Cell Mol Biol** 1995 Dec;13(6):738–47

The one-two of T helper cells: does interferon-gamma knock out the Th2 hypothesis for asthma? [comment] Holtzman MJ, et al. **Am J Respir Cell Mol Biol** 1996 Apr;14(4):316–8 (24 ref.). Comment on: Am J Respir Cell Mol Biol 1996 Apr;14(4):319–26.

T-cell cytokine profile evaluated at the single cell level in BAL and blood in allergic asthma [see comments] Krug N, et al. **Am J Respir Cell Mol Biol** 1996 Apr;14(4):319–26 . Comment in: Am J Respir Cell Mol Biol 1996 Apr;14(4):316–8.

Immunolocalization of interleukin-4 in eosinophils in the bronchial mucosa of atopic asthmatics. Möller GM, et al. **Am J Respir Cell Mol Biol** 1996 May;14(5):439–43

The relationship between parental and children's serum IgE and asthma. Burrows B, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1497–500

Development of bronchial hyperreactivity following transient absence of salivary IgA. Gleeson M, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1785–9

Inflammatory and T-cell profile of asthmatic airways 6 hours after local allergen provocation. Gratziou C, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):515–20

High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Humbert M, et al. **Am J Respir Crit Care Med** 1996 Jun; 153(6 Pt 1):1931–7

Cytokines in bronchoalveolar lavage fluid of patients with nocturnal asthma. Jarjour NN, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1474–7

Elevated B cells in sputum of asthmatics. Close correlation with eosinophils. Kidney JC, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):540–4

Exogenous stimuli and circadian peak expiratory flow variation in allergic asthmatic children. Meijer GG, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):237–42

Reactivity to IgE-dependent histamine-releasing activity in asthma or rhinitis. Pasmans SG, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):318–23

Pulmonary inflammation after segmental ragweed challenge in allergic asthmatic and nonasthmatic subjects. Shaver JR, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1189–97

Autoimmune phenomena in bronchial asthma with special reference to aspirin intolerance. Szczeklik A, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1753–6

Leukocyte recruitment after local endobronchial allergen challenge in asthma. Relationship to procedure and to airway interleukin-8 release. Teran LM, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):469–76

Major cat allergen (Fel d I) levels in the homes of patients with asthma and their relationship to sensitization to cat dander. Quirce S, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):325–30

Immunotherapy for childhood asthma: is there a rationale for its use? Sigman K, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):299–305; quiz 305–9 (39 ref.)

Sensitization to airborne allergens in children with respiratory symptoms. Silvestri M, et al. **Ann Allergy Asthma Immunol** 1996 Mar;76(3):239–44

Eosinophil activity reflects clinical status in patients with asthma before and during a prednisolone course. Skedinger M, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):250–5

Gamma delta T cells in asthma [editorial; comment] Rossman MD, et al. **Ann Intern Med** 1996 Jan 15;124(2):266–7. Comment on: Ann Intern Med 1996 Jan 15;124(2):223–7.

Increased allergen-specific, steroid-sensitive gamma delta T cells in bronchoalveolar lavage fluid from patients with asthma [see comments] Spinozzi F, et al. **Ann Intern Med** 1996 Jan 15;124(2):223–7. Comment in: Ann Intern Med 1996 Jan 15;124(2):266–7.

Immunoglobulin (Ig) and IgG subclasses in Asian children with bronchial asthma. Chan G, et al. **Ann Trop Paediatr** 1995 Dec;15(4):280–4

Modulation of mite antigen-induced immune responses by lecithin-bound iodine in peripheral blood lymphocytes from patients with bronchial asthma. Kawano Y, et al. **Br J Pharmacol** 1995 Aug;115(7):1141–8

A role for Th2 T-memory cells in early airway obstruction. Bell SJ, et al. **Cell Immunol** 1996 Jun 15;170(2):185–94

Immunologic responses to isocyanates in sensitized asthmatic

subjects. Redlich CA, et al. **Chest** 1996 Mar;109(3 Suppl):6S–8S

Effect of interferon–gamma on antigen–induced eosinophil infiltration into the mouse airway. Shi H, et al. **Chin Med J (Engl)** 1996 Mar;109(3):215–8

What the pulmonologist needs to know about allergy. Hoover GE, et al. **Clin Chest Med** 1995 Dec;16(4):603–20 (129 ref.)

Crossreactivity between Dermatophagoides siboney and other house dust mite allergens in sensitized asthmatic patients. Ferrándiz R, et al. **Clin Exp Allergy** 1995 Oct; 25(10):929–34

Effect of an asthmatic attack on CD23 and CD21 expression on lymphocytes from allergic children during the allergen season [see comments] Gagro A, et al. **Clin Exp Allergy** 1995 Aug;25(8):690–7. Comment in: Clin Exp Allergy 1995 Aug;25(8):678–9.

IL–5, IL–8 and GM–CSF immunostaining of sputum cells in bronchial asthma and chronic bronchitis. Hoshi H, et al. **Clin Exp Allergy** 1995 Aug;25(8):720–8

Eosinophil cationic protein (ECP) and eosinophil protein X (EPX) concentrations in serum and bronchial lavage fluid in asthma. Effect of prednisolone treatment. Robinson DS, et al. **Clin Exp Allergy** 1995 Nov;25(11):1118–27

Tumour necrosis factor alpha: a potential mediator of asthma. Shah A, et al. **Clin Exp Allergy** 1995 Nov;25(11):1038–44 (59 ref.)

Lymphocyte markers and disease activity in asthma [editorial; comment] Weller FR, et al. **Clin Exp Allergy** 1995 Aug; 25(8):678–9. Comment on: Clin Exp Allergy 1995 Aug;25(8):690–7.

Dual action of IL–4 on mite antigen–induced IgE synthesis in lymphocytes from individuals with bronchial asthma. Kawano Y, et al. **Clin Exp Immunol** 1995 Nov; 102(2):389–94

Analysis of the T cell receptor Vgamma region gene repertoire in bronchoalveolar lavage (BAL) and peripheral blood of atopic asthmatics and healthy subjects. Molfino NA, et al. **Clin Exp Immunol** 1996 Apr;104(1):144–53

Secretion of the eosinophil–active cytokines interleukin–5, granulocyte/macrophage colony–stimulating factor and interleukin–3 by bronchoalveolar lavage CD4+ and CD8+ T cell lines in atopic asthmatics, and atopic and non–atopic controls. Till S, et al. **Eur J Immunol** 1995 Oct; 25(10):2727–31

Role of the VLA–4 integrin in leucocyte recruitment and bronchial hyperresponsiveness in the guinea–pig. Milne AA, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):243–9

Distribution of Dermatophagoides mite (Acari: Pyroglyphidae) antigens in homes of allergic patients in Japan. Konishi E, et al. **Exp Appl Acarol** 1995 May; 19(5):275–86

Possible involvement of mononuclear cells stimulated with specific allergen from asthmatic patients in ICAM–1 expression on the eosinophilic cell line. Chihara J, et al. **Immunol Lett** 1995 Jun;46(3):241–4

Gene expression of interleukin–2 in purified human peripheral blood eosinophils. Bossé M, et al. **Immunology** 1996 Jan; 87(1):149–54

Identification of interleukin–2 in human peripheral blood eosinophils. Levi–Schaffer F, et al. **Immunology** 1996 Jan; 87(1):155–61

Interleukin 8 in bronchoalveolar lavage of asthmatic and chronic bronchitis patients. Chanez P, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):83–8

Lack of association between atopy and the Ile181Leu variant of the beta–subunit of the high–affinity immunoglobulin E receptor. Kofler H, et al. **Int Arch Allergy Immunol** 1996 Sep;111(1):44–7

IgE responsiveness to Dermatophagoides farinae in young asthmatic children: IgE binding study using recombinant allergens of Der f1, Der f2 and mutant proteins of Der f2. Noguchi E, et al. **Int Arch Allergy Immunol** 1996 Aug; 110(4):380–7

Surface antigens on eosinophils in bronchial asthma and eosinophilic pneumonia. Sakamoto S, et al. **Int Arch Allergy Immunol** 1995;108 Suppl 1:6–8

The modulatory effect of tetrandrine on the CD23, CD25 and HLA–DR expression and cytokine production in different groups of asthmatic patients. Tsai JJ, et al. **Int Arch Allergy Immunol** 1995 Oct;108(2):183–8

IgE antibodies reactive with silverfish, cockroach and chironomid are frequently found in mite–positive allergic patients. Witteman AM, et al. **Int Arch Allergy Immunol** 1995 Oct;108(2):165–9

Mite–specific induction of interleukin–2 receptor on T lymphocytes from children with mite–sensitive asthma: modified immune response with immunotherapy. Bonno M, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):680–8

Involvement of endothelin in mononuclear phagocyte inflammation in asthma. Chanez P, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):412–20

Exposure and sensitization to environmental allergen of predominantly Hispanic children with asthma in San Diego's inner city. Christiansen SC, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):288–94

CD4 T–lymphocyte activation is associated with peak expiratory flow variability in childhood asthma. Doi S, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):955–62

Hydrocortisone sodium succinate does not cross–react with aspirin in aspirin–sensitive patients with asthma. Feigenbaum BA, et al. **J Allergy Clin Immunol** 1995 Oct; 96(4):545–8

Cellular and mediator responses twenty–four hours after local endobronchial allergen challenge of asthmatic airways. Frew AJ, et al. **J Allergy Clin Immunol** 1996 Jul; 98(1):133–43

Quantitative assessment of exposure to dog (Can f 1) and cat (Fel d 1) allergens: relation to sensitization and asthma among children living in Los Alamos, New Mexico. Ingram JM, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):449–56

Bronchial asthma caused by onion [letter; comment] Kawane H. **J Allergy Clin Immunol** 1995 Oct;96(4):568. Comment on: J Allergy Clin Immunol 1994 Nov;94(5):928–30.

Occupational asthma caused by roasted coffee: immunologic evidence that roasted coffee contains the same antigens as green coffee, but at a lower concentration. Lemière C, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):464–6

Allergen–specific IgE levels and mite allergen exposure in children with acute asthma first seen in an emergency department and in nonasthmatic control subjects. Nelson RP Jr, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):258–63

Interleukin–4 and low–affinity receptor for IgE on B cells in peripheral blood of patients with atopic bronchial asthma. Park CS, et al. **J Allergy Clin Immunol** 1996 May; 97(5):1121–8

Is there a dose–response relationship between exposure to indoor allergens and symptoms of asthma? [editorial] Platts–Mills TA, et al. **J Allergy Clin Immunol** 1995 Oct; 96(4):435–40 (44 ref.)

Evaluation of household dust mite exposure and levels of specific IgE and IgG antibodies in asthmatic patients enrolled in a trial of immunotherapy. Rose G, et al. **J Allergy Clin Immunol** 1996 May;97(5):1071–8

Socioeconomic status and race as risk factors for cockroach allergen exposure and sensitization in children with asthma. Sarpong SB, et al. **J Allergy Clin Immunol** 1996 Jun; 97(6):1393–401

Prevalence of cross–sensitivity with acetaminophen in aspirin–sensitive asthmatic subjects. Settipane RA, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):480–5

The effects of prednisolone on the cutaneous tuberculin response in patients with corticosteroid–resistant bronchial asthma. Sousa AR, et al. **J Allergy Clin Immunol** 1996 Feb; 97(2):698–706

Eosinophil recruitment is associated with IL–5, but not with RANTES, twenty–four hours after allergen challenge. Sur S, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1272–8

Identification of IL–5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung. Venge J, et al. **J Allergy Clin Immunol** 1996 May;97(5):1110–5

The relationship between RAST and skin test results in patients with asthma or rhinitis: a quantitative study with purified major allergens. Witteman AM, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):16–25

Skin reactivity to sodium lauryl sulfate in patients with respiratory atopy. Seidenari S, et al. **J Am Acad Dermatol** 1996 Jul;35(1):47–52

Role of the adhesion molecule ICAM–1 in asthma. Ceyhan BB, et al. **J Asthma** 1995;32(6):419–27

Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non–anaphylactogenic anti–IgE antibody. Coyle AJ, et al. **J Exp Med** 1996 Apr 1; 183(4):1303–10

Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony–stimulating factor of intestinal mucosa in bronchial asthma. Wallaert B, et al. **J Exp Med** 1995 Dec 1;182(6):1897–904

Oligoclonality of lung T lymphocytes following exposure to allergen in asthma. Burastero SE, et al. **J Immunol** 1995 Dec 15;155(12):5836–46

Interleukin–4 and soluble CD23 serum levels in asthmatic atopic children. Daher S, et al. **J Investig Allergol Clin Immunol** 1995 Sep–Oct;5(5):251–4

Characteristics of mold allergy. Iversen M, et al. **J Investig Allergol Clin Immunol** 1995 Jul–Aug;5(4):205–8

Is mast cell activation during asthmatic reaction reflected in the circulation? Mędrala W, et al. **J Investig Allergol Clin Immunol** 1995 Nov–Dec;5(6):343–6

Bronchial provocation with cat allergen: long–term outcome of the late allergic reaction and the individual IgE CRIE pattern. Wasserfallen JB, et al. **J Investig Allergol Clin Immunol** 1995 May–Jun;5(3):134–41

Study of employees with anhydride–induced respiratory disease after removal from exposure. Grammer LC, et al. **J Occup Environ Med** 1995 Jul;37(7):820–5

Local expansion of allergen–specific CD30+Th2–type gamma delta T cells in bronchial asthma. Spinozzi F, et al. **Mol Med** 1995 Nov;1(7):821–6

Allergen levels causing sensitisation, bronchial hyperreactivity and asthma. Dreborg S. **Pediatr Allergy Immunol** 1995;6 Suppl 7:22–6 (44 ref.)

Severe varicella after low dose inhaled corticosteroids. Choong K, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):809–11

Update in allergy testing in childhood asthma: how do you know whether you are successfully controlling the patient's inflammation? Ahlstedt S, et al. **Pediatr Pulmonol Suppl** 1995;11:32–3

Early acquisition of sensitization in childhood asthma. Holt PG. **Pediatr Pulmonol Suppl** 1995;11:44–6

Role of eosinophils and cell adhesion molecules in the allergen–induced asthmatic response of rats. Uyama O, et al. **Res Commun Mol Pathol Pharmacol** 1995 Oct;90(1):3–15

HLA antigens and asthma in Greeks. Apostolakis J, et al. **Respir Med** 1996 Apr;90(4):201–4

Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Mueller R, et al. **Respir Med** 1996 Feb;90(2):79–85

Granulocyte–macrophage colony stimulating factor and bronchial asthma—a hypothesis for novel therapeutic options [letter] Tony JC. **Respir Med** 1995 Nov;89(10):713

Recurrent herpes zoster and high–dose inhaled steroids for asthma [letter] Bruning AH, et al. **S Afr Med J** 1994 Dec; 84(12):873

Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. Djukanović R, et al. **Thorax** 1996 Jun; 51(6):575–81

T cell receptor genetics, autoimmunity and asthma [editorial] Frew AJ, et al. **Thorax** 1995 Sep;50(9):919–22

[Human basophil degranulation test (HBDT) in fungal allergic asthmatic patients] Gu M, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Jun; 18(3):158–60, 190 (Eng. Abstr.) **(Chi)**

[The immunopathological basis of asthma] Zaks T, et al. **Harefuah** 1996 Jan 15;130(2):104–7 (42 ref.) **(Heb)**

[Atopy score in infancy and the severity of asthma at 7 years of age] Uhereczky G, et al. **Orv Hetil** 1996 Jan 28; 137(4):175–8 (46 ref.) (Eng. Abstr.) **(Hun)**

[Effect of specific immunotherapy on peripheral T–lymphocytes in atopic patients] Anania A, et al. **Minerva Med** 1996 Jun;87(6):263–7 (Eng. Abstr.) **(Ita)**

[Interleukin 1 production by peripheral blood mononuclear cells of children with bronchial asthma in remission] Ichikawa K, et al. **Arerugi** 1995 Sep;44(9):1132–9 (Eng. Abstr.) **(Jpn)**

[Endothelin–1 levels in sputum and plasma of asthmatic patient after allergen provocation] Kurokawa M, et al. **Arerugi** 1996 Apr;45(4):386–92 (Eng. Abstr.) **(Jpn)**

[Suppressive effect of roxithromycin on the induction of IL–2 responsiveness by DF–stimulated lymphocytes from patients with bronchial asthma] Nakajima T, et al. **Arerugi** 1996 Jun;45(6):554–61 (Eng. Abstr.) **(Jpn)**

[Inhibitory effect of Kanpo–medicines: saiboku–to, syouseryu–to, sairei–to on Dermatophagoides farinae antigen–induced IL2 responsiveness in lymphocytes from patients with bronchial asthma and their comparison] Noma T, et al. **Arerugi** 1996 May;45(5):494–502 (Eng. Abstr.) **(Jpn)**

[Study of cockroach allergy in asthmatic children. The positive rates and antigenicity of cockroach allergen] Onoue Y, et al. **Arerugi** 1995 Oct;44(10):1207–15 (Eng. Abstr.) **(Jpn)**

[Effect of IL–10 on the mite antigen–induced IFN–gamma production by peripheral blood lymphocytes from individuals with bronchial asthma] Kawano Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Oct;18(5):538–44 (Eng. Abstr.) **(Jpn)**

[Role of adhesion molecules (VLA–4) in the asthmatic response to allergens] Tanimukai T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1240–9 (Eng. Abstr.) **(Jpn)**

[Mechanism of airway inflammation in patients with asthma] Morita Y. **Nippon Naika Gakkai Zasshi** 1996 Feb 10; 85(2):174–7 (7 ref.) **(Jpn)**

[Comparison of study results for levels of specific antibodies using the RAST–IgE method and specific bronchial provocation in children with asthma] Mazurek H, et al. **Pediatr Pol** 1995 Aug;70(8):645–50 (Eng. Abstr.) **(Pol)**

[Activation of T lymphocytes and severity of atopic bronchial asthma in children] Bartkowiak M, et al. **Pneumonol Alergol Pol** 1995;63(9–10):490–7 (Eng. Abstr.) **(Pol)**

[Adhesion molecules in bronchial asthma] Fal AM, et al. **Pneumonol Alergol Pol** 1995;63(9–10):577–80 (23 ref.) **(Pol)**

[Role of viral respiratory tract infections on the pathogenesis of bronchial asthma. II. Effect on the immune system] Kroczyńska–Bednarek J, et al. **Pneumonol Alergol Pol** 1995; 63(9–10):570–6 (40 ref.) **(Pol)**

[Histamine releasing factors and chemotactic factors in evaluation of mucosal inflammation in bronchial asthma] Kuna P, et al. **Pneumonol Alergol Pol** 1995;63(5–6):322–7 (29 ref.) **(Pol)**

[Evaluation of allergic inflammation parameters in bronchoalveolar lavage in patients with asthma] Malolepszy J, et al. **Pneumonol Alergol Pol** 1995; 63(9–10):484–9 (Eng. Abstr.) **(Pol)**

[Selected cell–mediated immunologic parameters in patients with intrinsic asthma treated with long–term corticotherapy] Moniuszko T, et al. **Pneumonol Alergol Pol** 1995;63(9–10):521–6 (Eng. Abstr.) **(Pol)**

[Production of selected cytokines by monocytes (IL–1 beta, IL–6) and lymphocytes (IL–2, IL–4) in peripheral blood of patients with nonallergic bronchial asthma treated with Broncho–Vaxom] Moniuszko T, et al. **Pneumonol Alergol Pol** 1995;63 Suppl 2:66–70 (Eng. Abstr.) **(Pol)**

[Prognostication of the effect of therapeutic bronchoscopy in patients with bronchial asthma according to the state of local immunity] Smakov GM, et al. **Klin Med (Mosk)** 1995;73(5):76–7 **(Rus)**

[Immunotherapy, clinical and bronchial response] Martín Muñoz MF. **Allergol Immunopathol (Madr)** 1996;24 Suppl 1:68–79 **(Spa)**

[In vitro effect of disodium cromoglycate on phagocytic activity of polymorphonuclear cells of healthy asthmatic patients] Gómez Castillo CA, et al. **Rev Alerg Mex** 1995 Sep-Oct;42(5):89-95 (Eng. Abstr.) **(Spa)**

[Clinical value of receptors, mediators, and cells in asthma (editorial)] Pérez Martín J. **Rev Alerg Mex** 1995 Jul-Aug; 42(4):57-9 **(Spa)**

[Skin tests for different species of acari in asthmatic children from Mexico City] Prieto Ursúa L, et al. **Rev Alerg Mex** 1995 May-Jun;42(3):49-53 (Eng. Abstr.) **(Spa)**

METABOLISM

Volumetric bone mineral density--a potential role in paediatrics. Cowell CT, et al. **Acta Paediatr Suppl** 1995 Sep;411:12-6, discussion 17

Muscarinic and beta-adrenergic receptor expression in peripheral lung from normal and asthmatic patients. Haddad EB, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):L947-53

Eosinophils as a potential source of platelet-derived growth factor B-chain (PDGF-B) in nasal polyposis and bronchial asthma. Ohno I, et al. **Am J Respir Cell Mol Biol** 1995 Dec;13(6):639-47

Increased expression of heat shock protein 70 on airway cells in asthma and chronic bronchitis. Vignola AM, et al. **Am J Respir Cell Mol Biol** 1995 Dec;13(6):683-91

Glucocorticoid receptor localization in normal and asthmatic lung. Adcock IM, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):771-82

Increased MCP-1, RANTES, and MIP-1alpha in bronchoalveolar lavage fluid of allergic asthmatic patients. Alam R, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1398-404

Endothelin-1 receptor density, distribution, and function in human isolated asthmatic airways. Goldie RG, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1653-8

Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Keatings VM, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):530-4

Elevated nitric oxide concentrations in isolated lower airway gas of asthmatic subjects. Massaro AF, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1510-4

Nasal lavage cytokines in normal, allergic, and asthmatic school-age children. Noah TL, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1290-6

Interleukin-3 in bronchial biopsies from nonasthmatics and patients with mild and allergen-induced asthma. Woolley KL, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):350-5

Endogenous nitric oxide is decreased in asthmatic patients by an inhibitor of inducible nitric oxide synthase. Yates DH, et al. **Am J Respir Crit Care Med** 1996 Jul; 154(1):247-50

Persistent increase in plasma and urinary leukotrienes after acute asthma. Sampson AP, et al. **Arch Dis Child** 1995 Sep; 73(3):221-5

The house dust mite allergen Der p1 catalytically inactivates alpha 1-antitrypsin by specific reactive centre loop cleavage: a mechanism that promotes airway inflammation and asthma. Kalsheker NA, et al. **Biochem Biophys Res Commun** 1996 Apr 5;221(1):59-61

Bronchial epithelial cells of atopic patients with asthma lack the ability to inactivate allergens. Mori L, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):817-24

In vivo effect of prednisolone on release of leukotriene B4 from neutrophils from asthmatic patients. Shindo K, et al. **Biochem Biophys Res Commun** 1996 May 24;222(3):759-63

Plasma protein leakage and local secretion of proteins assessed in sputum in asthma and COPD. The effect of inhaled corticosteroids. Schoonbrood DF, et al. **Clin Chim Acta** 1995 Sep 15;240(2):163-78

Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthma. Koopmans RP, et al. **Clin Pharmacokinet** 1995 Oct;29(4):213-20 (47 ref.)

Skeletal muscle magnesium and potassium in asthmatics treated with oral beta 2-agonists. Gustafson T, et al. **Eur Respir J** 1996 Feb;9(2):237-40

Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Kharitonov SA, et al. **Eur Respir J** 1996 Feb;9(2):196-201

Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease. Nocker RE, et al. **Int Arch Allergy Immunol** 1996 Feb;109(2):183-91

Constitutive expression of endothelin in bronchial epithelial cells of patients with symptomatic and asymptomatic asthma and modulation by histamine and interleukin-1. Ackerman V, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):618-27

Interleukin-10 regulation in normal subjects and patients with asthma. Borish L, et al. **J Allergy Clin Immunol** 1996 Jun; 97(6):1288-96

Interleukin-5 messenger RNA expression in peripheral blood CD4+ cells in asthma. Lai CK, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1320-8

Inhaled beclomethasone and bone metabolism in young asthmatic children: a six month study. Le Bourgeois M, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):565-7

Eosinophilic inflammation is associated with elevation of interleukin-5 in the airways of patients with spontaneous symptomatic asthma. Sur S, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):661-8

5(S),15(S)-dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. Chavis C, et al. **J Exp Med** 1996 Apr 1;183(4):1633-43

Ultrastructural immunogold localization of interleukin 5 to the crystalloid core compartment of eosinophil secondary granules in patients with atopic asthma. Möller GM, et al. **J Histochem Cytochem** 1996 Jan;44(1):67-9

Evaluation of theophylline clearance in children with bronchial asthma. Yamazaki M, et al. **J Investig Allergol Clin Immunol** 1995 Jan-Feb;5(1):50-3

Activation and regulation of chemokines in allergic airway inflammation. Lukacs NW, et al. **J Leukoc Biol** 1996 Jan; 59(1):13-7 (34 ref.)

Cross-sectional study of bone density in asthmatic children. Hopp RJ, et al. **Pediatr Pulmonol** 1995 Sep;20(3):189-92

Cytokine expression in normal, atopic, and asthmatic subjects using the combination of sputum induction and the polymerase chain reaction. Gelder CM, et al. **Thorax** 1995 Oct;50(10):1033-7

Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients. Shindo K, et al. **Thorax** 1996 Feb;51(2):155-8

[Glucocorticoid receptor anomalies in asthma] Demoly P, et al. **Presse Med** 1996 May 4-11;25(16):769-74 (26 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary metabolism of beta-endorphin in asthmatic patients in asymptomatic periods and after bronchospasm induced by methacholine] Bottino G, et al. **Riv Eur Sci Med Farmacol** 1995 Mar-Jun;17(2-3):63-6 (Eng. Abstr.) **(Ita)**

[Clinical evaluation of eosinophil cationic protein in asthmatic children] Tanimoto K. **Arerugi** 1996 Jun; 45(6):546-53 (Eng. Abstr.) **(Jpn)**

[Evaluation of bradykinin levels and activation of Tame-esterase in Bronchial alveolar lavage fluid of patients with bronchial asthma] Gawlik R, et al. **Pneumonol Alergol Pol** 1995;63(5-6):268-72 (Eng. Abstr.) **(Pol)**

[Granulocyte-macrophage colony stimulating factor (GM-CSF) in material from broncho-alveolar lavage and serum of patients with bronchial asthma] Jahnz-Różyk K, et al. **Pneumonol Alergol Pol** 1996;64(3-4):165-8 (Eng. Abstr.) **(Pol)**

MICROBIOLOGY

Baker's asthma caused by Saccharomyces cerevisiae in dry powder form. Belchi-Hernandez J, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 1):131-4

Occupational asthma in a coal miner. Gamboa PM, et al. **Thorax** 1996 Aug;51(8):867-8

Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Sachs AP, et al. **Thorax** 1995 Jul; 50(7):758-63

MORTALITY

Asthma mortality in Israel 1971-1990. Livne M, et al. **Ann Allergy Asthma Immunol** 1996 Mar;76(3):261-5

A clinical study of mortality due to asthma. Matsuse H, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):267-72

Asthma deaths [letter] Randolph C. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):81-2

Asthma deaths in Washington State, 1980-1989: geographic and demographic distributions. Roberts C, et al. **Ann Allergy Asthma Immunol** 1996 Jan;76(1):20-6

Fatal asthma. FitzGerald JM, et al. **Annu Rev Med** 1996; 47:161-8 (32 ref.)

Physical illness in psychiatric patients may be managed poorly [comment] Davies T. **BMJ** 1996 Jan 13;312(7023):82 . Comment on: BMJ 1996 Jan 13;312(7023):79-82.

Increased mortality related to asthma among asthmatic patients using major tranquillisers. Underlying ill health is the main risk factor [letter] Jones A. **BMJ** 1996 Apr 13;312(7036):976

Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers [see comments] Joseph KS, et al. **BMJ** 1996 Jan 13; 312(7023):79-82. Comment in: BMJ 1996 Jan 13;312(7023):82. Comment in: BMJ 1996 Jan 13;312(7023):82-3.

Asthmatic patients with psychosis need special care [comment] Levy ML. **BMJ** 1996 Jan 13;312(7023):82-3. Comment on: BMJ 1996 Jan 13;312(7023):79-82.

US in the dark on doubling in asthma death rates [news] Roberts J. **BMJ** 1996 May 18;312(7041):1246

Increased mortality related to asthma among asthmatic patients using major tranquillisers. Smoking may increase mortality when patients stop using tranquillisers [letter] Rozewic L. **BMJ** 1996 Apr 13;312(7036):976-7

Asthma deaths confounded by substance abuse. An assessment of fatal asthma. Levenson T, et al. **Chest** 1996 Sep;110(3):604-10

Asthma mortality and beta-agonists [letter; comment] Skorodin MS. **Chest** 1995 Dec;108(6):1768. Comment on: Chest 1995 Apr;107(4):1116-24.

Patterns of asthma death and near-death in an inner-city tertiary care teaching hospital. Corn B, et al. **J Asthma** 1995;32(6):405-12

Sudden death from asthma in 108 children and young adults. Tough SC, et al. **J Asthma** 1996;33(3):179-88

Death from asthma: rare but real. Wobig EK, et al. **J Emerg Med** 1996 Mar-Apr;14(2):233-40 (90 ref.)

Asthma deaths in Mersey region 1989-1990. Somerville M, et al. **J Public Health Med** 1995 Dec;17(4):397-403

Asthma mortality and hospitalization among children and young adults--United States, 1980-1993. From the Centers for Disease Control and Prevention. **JAMA** 1996 May 22-29;275(20):1535-7

Mortality in adults with self-reported asthma. Copenhagen City Heart Study Group. Lange P, et al. **Lancet** 1996 May 11;347(9011):1285-9

Asthma mortality: where is it going? [editorial; comment] Wilson JW, et al. **Med J Aust** 1996 Apr 1;164(7):391-3. Comment on: Med J Aust 1996 Apr 1;164(7):403-6.

Asthma mortality and hospitalization among children and young adults--United States, 1980-1993. **MMWR Morb Mortal Wkly Rep** 1996 May 3;45(17):350-3

Rise in the number of asthma fatalities are poor patient education, lack of compliance, and underlying psychological disturbances [letter] Haida M. **Psychosom Med** 1995 Sep-Oct;57(5):506

Trends in mortality from bronchial asthma in Switzerland, 1969-1993. La Vecchia C, et al. **Rev Epidemiol Sante Publique** 1996 Apr;44(2):155-61

Asthma and the beta agonist debate. Crane J, et al. **Thorax** 1995 Sep;50 Suppl 1:S5-10 (37 ref.)

Asthma morbidity and mortality in New Zealand [letter; comment] Crane J, et al. **Thorax** 1995 Sep;50(9):1020-1. Comment on: Thorax 1995 Mar;50(3):303-11.

Death from airways obstruction: accuracy of certification in Northern Ireland. Smyth ET, et al. **Thorax** 1996 Mar; 51(3):293-7

Asthma morbidity and mortality in New Zealand [letter; comment] Taylor DR, et al. **Thorax** 1995 Sep;50(9):1021-2 . Comment on: Thorax 1995 Mar;50(3):303-11.

[Mortality and fatal risk factors in 1075 outpatients treated for asthma] Ulrik CS, et al. **Ugeskr Laeger** 1996 Jun 17; 158(25):3608-11 (Eng. Abstr.) **(Dan)**

[Trends in asthma-related death among adults in Japan, 1986-1991--analysis of responses to questionnaires sent to hospitals with at least 200 beds] Nakazawa T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):157-63 (Eng. Abstr.) **(Jpn)**

[Prevention of fatal asthma: how to identify the patient at risk? (editorial)] Plaza V. **Arch Bronconeumol** 1995 Nov; 31(9):433-6 **(Spa)**

NURSING

Gretchen's crisis. Ott MJ. **Am J Nurs** 1996 Jul;96(7):80

Proactive, nurse-run asthma care in general practice reduces asthma morbidity: scientific fact or medical assumption? Jones KP, et al. **Br J Gen Pract** 1995 Sep;45(398):497-9

Comments on the asthma protocol [letter; comment] Jones HD, et al. **J Am Coll Health** 1995 Mar;43(5):231. Comment on: J Am Coll Health 1994 Nov;43(3):133-5.

PATHOLOGY

Changes in nasal metachromatic cells during allergen immunotherapy in children. Cengizlier R, et al. **Allergol Immunopathol (Madr)** 1995 May-Jun;23(3):111-6

Lung inflammation and epithelial changes in a murine model of atopic asthma. Blyth DI, et al. **Am J Respir Cell Mol Biol** 1996 May;14(5):425-38

Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma. Fukuda T, et al. **Am J Respir Cell Mol Biol** 1996 Jan;14(1):84-94

Bronchial elastic fibers in normal subjects and asthmatic patients. Bousquet J, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1648-54

Morphologic aspects of airways of patients with pulmonary emphysema followed by bronchial asthma-like attack. Haraguchi M, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):638-43

Inflammatory events in the blood and airways of guinea pigs immunized to toluene diisocyanate. Mapp CE, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):201-8

Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Nasser SM, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):90-6

Extracellular matrix. Rennard SI. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S14-5 (24 ref.)

Intrasubject variability in airway inflammation in biopsies in mild to moderate stable asthma. Richmond I, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):899-903

Airway responsiveness to bradykinin is related to eosinophilic inflammation in asthma. Roisman GL, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):381-90

Greater ozone-induced inflammatory responses in subjects with asthma. Scannell C, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):24-9

Cellular infiltration of the airways in asthma of varying severity. Synek M, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):224-30

Airway muscle stereology: implications for increased shortening in asthma. Thomson RJ, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):749-57

Eosinophil apoptosis and the resolution of airway

inflammation in asthma. Woolley KL, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):237–43

Acute and chronic inflammatory mechanisms in asthma. Holgate ST. **Br J Clin Pract Symp Suppl** 1995 Sep;81:11–3 (0 ref.)

Cellular inflammation in asthma. Bousquet J, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:39–42 (23 ref.)

Eosinophils and asthma. What do measurements tell us? [editorial; comment] Robinson DS. **Clin Exp Allergy** 1995 Sep;25(9):795–8 (55 ref.). Comment on: Clin Exp Allergy 1995 Sep;25(9):820–7.

Intrasubject variability in airway inflammation sampled by bronchoalveolar lavage in stable asthmatics. Ward C, et al. **Eur Respir J** 1995 Nov;8(11):1866–71

Changes in mast cell reactivity in the course of allergic inflammation. Pearce FL, et al. **Inflamm Res** 1996 Mar;45 Suppl 1:S31–2

Differential modulation by betamethasone of allergen–induced cell influx and cell peroxidase in guinea–pig lungs. Yeadon M, et al. **Inflamm Res** 1995 Aug; 44 Suppl 2:S177–8

Cetirizine reduces ICAM–I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite–allergic asthma. Fasce L, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):272–6

Involvement of endothelin in mononuclear phagocyte inflammation in asthma. Chanez P, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):412–20

Influence of allergen avoidance on the eosinophil phase of airway inflammation in children with allergic asthma. Piacentini GL, et al. **J Allergy Clin Immunol** 1996 May; 97(5):1079–84

Airway basophil and mast cell density in patients with bronchial asthma: relationship to bronchial hyperresponsiveness. Koshino T, et al. **J Asthma** 1996; 33(2):89–95

Activation and regulation of chemokines in allergic airway inflammation. Lukacs NW, et al. **J Leukoc Biol** 1996 Jan; 59(1):13–7 (34 ref.)

Airway smooth muscle proliferation in asthma: the potential of vascular leakage to contribute to pathogenesis. Shiels IA, et al. **Med Hypotheses** 1995 Jul;45(1):37–40

Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin–sensitive asthmatic subjects. Nasser S, et al. **Thorax** 1996 Jan; 51(1):64–70

Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Sont JK, et al. **Thorax** 1996 May;51(5):496–502

Exacerbations of asthma without sputum eosinophilia. Turner MO, et al. **Thorax** 1995 Oct;50(10):1057–61

[Effects of a platelet–activating factor antagonist ONO–6240 on antigen induced eosinophil infiltration into the airways] Shi H, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Nov; 34(11):753–6 (Eng. Abstr.) **(Chi)**

[Histology of the respiratory system after exposure to bacterial infection and formalin vapors used to induce experimental bronchospasm] Sachs K, et al. **Pneumonol Alergol Pol** 1995;63(5–6):259–63 (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Airway responses in healthy and asthmatic subjects following exposure to low ambient air temperature. Zuškin E, et al. **Acta Med Croatica** 1996;50(2):97–101

Allergen–induced late airways reactions in the pig. Influence of endogenous and exogenous glucocorticoids. Fornhem C. **Acta Physiol Scand Suppl** 1995;631:1–48

Volume history response of airway resistance. Ahmad HR, et al. **Adv Exp Med Biol** 1995;393:111–5

Diagnostic value of the nasal provocation test with Dermatophagoides pteronyssinus in childhood asthma. Baki A, et al. **Allergy** 1995 Sep;50(9):751–4

Inhaled lysine acetylsalicylate (L–ASA) attenuates histamine–induced bronchoconstriction in asthma. Crimi N, et al. **Allergy** 1996 Mar;51(3):157–63

Airway eosinophilic inflammation, epithelial damage, and bronchial hyperresponsiveness in patients with mild–moderate, stable asthma. Oddera S, et al. **Allergy** 1996 Feb;51(2):100–7

Leukotrienes as therapeutic target in asthma. Pauwels RA, et al. **Allergy** 1995 Aug;50(8):615–22 (73 ref.)

Peak expiratory flow variation and bronchial hyperresponsiveness in asthmatic children during periods of antigen avoidance and reexposure. Valletta EA, et al. **Allergy** 1995 Apr;50(4):366–9

Neural receptors and asthma. Baraniuk JN. **Allergy Proc** 1995 Sep–Oct;16(5):227–33 (76 ref.)

The usefulness of questionnaire–derived information to predict the degree of nonspecific bronchial hyperresponsiveness. Hopp RJ, et al. **Allergy Proc** 1995 May–Jun;16(3):129–34

Drugs to be used with caution in patients with asthma. Craig TJ. **Am Fam Physician** 1996 Sep 1;54(3):947–53, 957–8 (24 ref.)

Lung inflammation and epithelial changes in a murine model of atopic asthma. Blyth DI, et al. **Am J Respir Cell Mol Biol** 1996 May;14(5):425–38

What is the role of nerves in chronic asthma and symptoms? Barnes PJ. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S5–8 (58 ref.)

Dissociation of bradykinin–induced plasma exudation and reactivity in the peripheral airways. Berman AR, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):418–23

Role of airway smooth muscle. Black JL. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S2–4 (39 ref.)

LFA–1, and not Mac–1, is crucial for the development of hyperreactivity in a murine model of nonallergic asthma. Bloemen PG, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):521–9

Relation of the course of bronchial responsiveness from age 9 to age 15 to allergy. Burrows B, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1302–8

Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma. Chetta A, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):910–7

Tryptase inhibitors block allergen–induced airway and inflammatory responses in allergic sheep. Clark JM, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2076–83

The inflammatory response. Denburg JA. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S11–3 (53 ref.)

Effect of chronic 5–lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Fischer AR, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1203–7

Detection of excessive bronchoconstriction in asthma. Gibbons WJ, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):582–9

Airway behavior and its regulation: how do structural changes affect airway behavior? Hogg JC. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S16–8 (31 ref.)

Effects of a PAF antagonist, Y–24180, on bronchial hyperresponsiveness in patients with asthma. Hozawa S, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1198–202

Airway reactivity changes in asthmatic patients undergoing blinded food challenges. James JM, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):597–603

The effect of inhaled FK224, a tachykinin NK–1 and NK–2 receptor antagonist, on neurokinin A–induced bronchoconstriction in asthmatics. Joos GF, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1781–4

The effect of ozone exposure on allergen responsiveness in subjects with asthma or rhinitis. Jörres R, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):56–64

Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals. Kaminsky DA, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1784–90

Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Kharitonov SA, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1773–80

Safety aspects of local endobronchial allergen challenge in asthmatic patients. Krug N, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1391–7

Outcome of specific bronchial responsiveness to occupational agents after removal from exposure. Lemière C, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):329–33

Can airway function be predicted? Macklem PT. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S19–20 (9 ref.)

Exogenous stimuli and circadian peak expiratory flow variation in allergic asthmatic children. Meijer GG, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):237–42

Inspiratory muscle strength and endurance in steroid–dependent asthma. Perez T, et al. **Am J Respir Crit Care Med** 1996 Feb;153(2):610–5

Epithelial cells: barrier functions and shedding–restitution mechanisms. Persson CG. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S9–10 (16 ref.)

The effect of inhaled nitric oxide in pediatric asthma. Pfeffer KD, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):747–51

Effects of air pollution on the respiratory health of asthmatic children living in Mexico City. Romieu I, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):300–7

Lung sounds during allergen–induced asthmatic responses in patients with asthma [see comments] Schreur HJ, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1474–80. Comment in: Am J Respir Crit Care Med 1996 May;153(5):1469–71.

Relationship of skin test reactivity to decrements in pulmonary function in children with asthma or frequent wheezing. Schwartz J, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2176–80

The relationship between wheezing and lung mechanics during methacholine–induced bronchoconstriction in asthmatic subjects. Spence DP, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):290–4

Concentrations of methacholine for bronchial responsiveness according to symptoms, smoking and immunoglobulin E in a population–based study in Spain. Spanish Group of the European Asthma Study. Sunyer J, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1273–9

Tidal breathing analysis as a measure of airway obstruction in children three years of age and older. van der Ent CK, et al. **Am J Respir Crit Care Med** 1996 Apr;153(4 Pt 1):1253–8

The effect of inspiratory maneuvers on expiratory flow rates in health and asthma: influence of lung elastic recoil. Wanger JS, et al. **Am J Respir Crit Care Med** 1996 Apr; 153(4 Pt 1):1302–8

Recurrent cough in childhood and its relation to asthma. Wright AL, et al. **Am J Respir Crit Care Med** 1996 Apr; 153(4 Pt 1):1259–65

Effect of acute and chronic inhaled furosemide on bronchial hyperresponsiveness in mild asthma. Yates DH, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):2173–5

Atracurium versus vecuronium in asthmatic patients. A blinded, randomized comparison of adverse events. Caldwell JE, et al. **Anesthesiology** 1995 Nov;83(5):986–91

A clinical study of mortality due to asthma. Matsuse H, et al. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):267–72

Patients' perceptions compared with objective ratings of asthma severity. Nguyen BP, et al. **Ann Allergy Asthma Immunol** 1996 Sep;77(3):209–15

Comparison between allergen–induced and exercise–induced asthma with respect to the late asthmatic response, airway responsiveness, and Creola bodies in sputum. Tateishi K, et al. **Ann Allergy Asthma Immunol** 1996 Sep;77(3):229–37

Is circadian variation in asthma severity relevant in the emergency department? Karras DJ, et al. **Ann Emerg Med** 1995 Nov;26(5):558–62

Nitric oxide and airway disease. Barnes PJ. **Ann Med** 1995 Jun;27(3):389–93 (56 ref.)

Pathophysiology of reactive airway disease and sinusitis. Marney SR Jr. **Ann Otol Rhinol Laryngol** 1996 Feb; 105(2):98–100

Effect of pulmonary function testing on the management of acute asthma. Emerman CL, et al. **Arch Intern Med** 1995 Nov 13;155(20):2225–8

The effect of the menstrual cycle on asthma presentations in the emergency department. Skobeloff EM, et al. **Arch Intern Med** 1996 Sep 9;156(16):1837–40

Continuous, noninvasive measurement of pulsus paradoxus in patients with acute asthma. Wright RO, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):914–8

Respiratory mucins: identification of core proteins and glycoforms. Thornton DJ, et al. **Biochem J** 1996 Jun 15; 316 (Pt 3):967–75

Neural mechanisms and axon reflexes in asthma. Where are we? Verleden GM. **Biochem Pharmacol** 1996 May 17; 51(10):1247–57 (176 ref.)

Interoception of respiratory resistance in asthmatic patients. Dahme B, et al. **Biol Psychol** 1996 Jan 5;42(1–2):215–29

Symptom reporting in asthma patients and insulin–dependent diabetics. Schandry R, et al. **Biol Psychol** 1996 Jan 5; 42(1–2):231–44

Evaluation of the suitability of weekly peak expiratory flow rate measurements in monitoring annual decline in lung function among patients with asthma and chronic bronchitis. Tirimanna PR, et al. **Br J Gen Pract** 1996 Jan; 46(402):15–8

BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics. Aizawa H, et al. **Chest** 1996 Feb;109(2):338–42

Ventilatory response to continuous incremental changes in respiratory resistance in patients with mild asthma. Fujimori K, et al. **Chest** 1996 Jun;109(6):1525–31

Tracheobronchial constriction in asthmatics induced by isocapnic hyperventilation with dry cold air. Julià–Serdà G, et al. **Chest** 1996 Aug;110(2):404–10

Effects of inhaled fluticasone propionate and oral prednisolone on lymphocyte beta 2–adrenoceptor function in asthmatic patients. Tan KS, et al. **Chest** 1996 Feb; 109(2):343–7

Evaluating the bronchodilator response in elderly who have asthma [letter; comment] Teramoto S. **Chest** 1996 Feb; 109(2):589–90. Comment on: Chest 1995 Aug;108(2):401–6.

Physiologic diagnosis and function in asthma. Cherniack RM. **Clin Chest Med** 1995 Dec;16(4):567–81 (17 ref.)

Inflammation and asthma. Horwitz RJ, et al. **Clin Chest Med** 1995 Dec;16(4):583–602 (161 ref.)

Allergy and the development of asthma and bronchial hyperresponsiveness. Burrows B. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:15–6; discussion 17–8

Leukotrienes as mediators of airway obstruction and inflammation in asthma. Dahlén B, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:50–4 (42 ref.)

Linkage homology for bronchial hyperresponsiveness between DNA markers on human chromosome 5q31–q33 and mouse chromosome 13. Levitt RC, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:61–3 (21 ref.)

Surfactant dysfunction develops when the immunized guinea–pig is challenged with ovalbumin aerosol. Liu M, et al. **Clin Exp Allergy** 1995 Nov;25(11):1053–60

The role of airway inflammation in the pathophysiology of nocturnal asthma. Oosterhoff Y, et al. **Clin Exp Allergy** 1995 Oct;25(10):915–21 (39 ref.)

Lung surfactants and asthma [editorial] Postle AD. **Clin Exp Allergy** 1995 Nov;25(11):1030–3 (31 ref.)

The place of airway hyperresponsiveness in the asthma phenotype. Sterk PJ. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:8–11; discussion 17–8 (30 ref.)

Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma [see comments] Ulrik CS. **Clin Exp Allergy** 1995 Sep;25(9):820–7. Comment in: Clin Exp Allergy 1995 Sep;25(9):795–8.

Spirometry and ventilation–perfusion inequality in patients with mild allergic asthma before and during the pollen season. Lagerstrand L, et al. **Clin Physiol** 1995 Jul; 15(4):355–64

Influence of treatment with beclomethasone, cromoglycate

and theophylline on perception of bronchoconstriction in patients with bronchial asthma. Higgs CM, et al. **Clin Sci (Colch)** 1996 Mar;90(3):227–34

Is there really a syndrome involving the co-occurrence of neurodevelopmental disorder talent, non-right handedness and immune disorder among children? Flannery KA, et al. **Cortex** 1995 Sep;31(3):503–15

Sulfuric acid aerosol followed by ozone exposure in healthy and asthmatic subjects. Frampton MW, et al. **Environ Res** 1995 Apr;69(1):1–14

High altitude exposure reduces bronchial responsiveness to hypo-osmolar aerosol in lowland asthmatics. Allegra L, et al. **Eur Respir J** 1995 Nov;8(11):1842–6

Pressure-volume analysis of the lung with an exponential and linear-exponential model in asthma and COPD. Dutch CNSLD Study Group. Bogaard JM, et al. **Eur Respir J** 1995 Sep;8(9):1525–31

Peak inspiratory flow through Turbuhaler in acute asthma. Brown PH, et al. **Eur Respir J** 1995 Nov;8(11):1940–1

Allergen-induced late-phase airways obstruction in the pig: mediator release and eosinophil recruitment. Fornhem C, et al. **Eur Respir J** 1995 Jul;8(7):1100–9

Facial cooling, but not nasal breathing of cold air, induces bronchoconstriction: a study in asthmatic and healthy subjects. Koskela H, et al. **Eur Respir J** 1995 Dec; 8(12):2088–93

Separation of airway and tissue properties by transfer respiratory impedance and thoracic gas volume in reversible airway obstruction. Marchal F, et al. **Eur Respir J** 1996 Feb;9(2):253–61

Absence of relationship between degree of nonspecific and specific bronchial responsiveness in occupational asthma due to platinum salts. Merget R, et al. **Eur Respir J** 1996 Feb;9(2):211–6

The effect of inhaled heparin on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma. Pavord I, et al. **Eur Respir J** 1996 Feb;9(2):217–9

Pulmonary function tests in normal Indian children and changes in respiratory disorders. Srivastava A, et al. **Indian Pediatr** 1995 Jun;32(6):629–34

Relationship between airway eosinophilia and airway hyperresponsiveness in a late asthmatic model of guinea pigs. Itoh K, et al. **Int Arch Allergy Immunol** 1996 Jan; 109(1):86–94

Protective effect of sodium cromoglycate on lipopolysaccharide-induced bronchial obstruction in asthmatics. Michel O, et al. **Int Arch Allergy Immunol** 1995 Nov;108(3):298–302

Effects of KW-4679, a new orally active antiallergic drug, on antigen-induced bronchial hyperresponsiveness, airway inflammation and immediate and late asthmatic responses in guinea pigs. Ohmori K, et al. **Int Arch Allergy Immunol** 1996 May;110(1):64–72

Two-year follow-up study of the effect of acid fog on adult asthma patients. Tanaka H, et al. **Intern Med** 1996 Feb; 35(2):100–4

Effect of psychological stress on airway impedance in individuals with asthma and panic disorder. Carr RE, et al. **J Abnorm Psychol** 1996 Feb;105(1):137–41

The effect of inhaled albuterol in moderate to severe asthma. Apter AJ, et al. **J Allergy Clin Immunol** 1996 Aug; 98(2):295–301

Increased intestinal permeability in bronchial asthma. Benard A, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1173–8

CD4 T-lymphocyte activation is associated with peak expiratory flow variability in childhood asthma. Doi S, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):955–62

Mite allergen (Der p 1) concentration in houses and its relation to the presence and severity of asthma in a population of Sydney schoolchildren. Marks GB, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):441–8

Late respiratory response and associated eosinophilic inflammation induced by repeated exposure to toluene diisocyanate in guinea pigs. Niimi A, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1308–19

Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. Verberne AA, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):938–46

An epidemiological investigation into nocturnal asthma. Chhabra SK. **J Asthma** 1995;32(2):147–50

An asthma self-management program for children, including instruction in peak flow monitoring by school nurses. Persaud DI, et al. **J Asthma** 1996;33(1):37–43

The capacity of children with and without asthma to detect external resistive loads on breathing. Rietveld S, et al. **J Asthma** 1996;33(4):221–30

Improving the treatment of nocturnal asthma: use of an office questionnaire to identify nocturnal asthma symptoms. Storms WW, et al. **J Asthma** 1996;33(3):165–8

Interleukin-11: stimulation in vivo and in vitro by respiratory viruses and induction of airways hyperresponsiveness. Einarsson O, et al. **J Clin Invest** 1996 Feb 15;97(4):915–24

Airway hyperresponsiveness in asthma: a problem of limited smooth muscle relaxation with inspiration. Skloot G, et al. **J Clin Invest** 1995 Nov;96(5):2393–403

Time of symptom onset of eight common medical emergencies. Wang H, et al. **J Emerg Med** 1995 Jul-Aug; 13(4):461–9

Antigen-induced generation of lyso-phospholipids in human airways. Chilton FH, et al. **J Exp Med** 1996 May 1; 183(5):2235–45

Time-activity patterns and diurnal variation of respiratory status in a panel of asthmatics: implications for short-term air pollution effects. Shamoo DA, et al. **J Expo Anal Environ Epidemiol** 1994 Apr-Jun;4(2):133–48

Self-management of asthma. Bramson R. **J Fam Pract** 1996 Jul;43(1):21–2

Increase of chemokine levels in sputum precedes exacerbation of acute asthma attacks. Kurashima K, et al. **J Leukoc Biol** 1996 Mar;59(3):313–6

Involvement of endothelins in immediate and late asthmatic responses of guinea pigs. Uchida Y, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1622–9

Exercise-induced bronchodilatation in asthmatic athletes. Todaro A. **J Sports Med Phys Fitness** 1996 Mar;36(1):60–6

Is bronchial asthma a pancreatic disease? Casacó A. **Med Hypotheses** 1995 Jun;44(6):516–8

A mechanism for masking receptors with particular application to asthma. Hills BA. **Med Hypotheses** 1996 Jan; 46(1):33–41

Airway smooth muscle proliferation in asthma: the potential of vascular leakage to contribute to pathogenesis. Shiels IA, et al. **Med Hypotheses** 1995 Jul;45(1):37–40

Asthma death [editorial; comment] Caramori G, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):256–7. Comment on: Monaldi Arch Chest Dis 1995 Aug;50(4):276–8.

Quantitative locus analysis of airway hyperresponsiveness in A/J and C57BL/6J mice. De Sanctis GT, et al. **Nat Genet** 1995 Oct;11(2):150–4

Comparison of disease-specific and a generic quality of life measure in patients with bronchial asthma. Thomas K, et al. **Natl Med J India** 1995 Nov-Dec;8(6):258–60

Effect of air pollution in asthma and respiratory allergy. Peden DB. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):242–7 (33 ref.)

Comparison of airway reactivity induced by cold air and metacholine challenges in asthmatic children. de Benedictis FM, et al. **Pediatr Pulmonol** 1995 Jun;19(6):326–9

Interrelationship between postocclusional oscillatory pressure transients and standard lung function in healthy and asthmatic children. Frey U, et al. **Pediatr Pulmonol** 1995 Jun;19(6):379–88

Spirometric patterns in childhood asthma: peak flow compared with other indices. Klein RB, et al. **Pediatr Pulmonol** 1995 Dec;20(6):372–9

Evaluation of the interrupter technique for measuring change in airway resistance in 5-year-old asthmatic children. Phagoo SB, et al. **Pediatr Pulmonol** 1995 Dec;20(6):387–95

Role of eosinophils in childhood asthma inflammation. Venge P. **Pediatr Pulmonol Suppl** 1995;11:34–5

Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Park CL, et al. **Pediatrics** 1996 Aug;98(2 Pt 1):196–200

Pulmonary mechanics in patients with asthma bronchiale in symptom-free interval. Duțu S, et al. **Pneumoftiziologia** 1995 Jan-Jun;44(1-2):49–52

Lung function measurement in general practice: a comparison of the Escort spirometer with the Micromed turbine spirometer and the mini-Wright peak flow meter. Jones KP, et al. **Respir Med** 1995 Nov;89(10):657–63

Perception of dyspnoea during acute changes in lung function in patients with either asthma or COPD. Noseda A, et al. **Respir Med** 1995 Aug;89(7):477–85

Extrinsic and intrinsic asthma from childhood to adult age: a 10-yr follow-up. Ulrik CS, et al. **Respir Med** 1995 Sep; 89(8):547–54

Breathlessness perception in asthmatic patients—clinical implications. Král B. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(4):185–8

Assessment of a new transtelephonic portable spirometer. Abboud S, et al. **Thorax** 1996 Apr;51(4):407–10

NO or no NO in asthma? Barnes PJ. **Thorax** 1996 Feb; 51(2):218–20 (12 ref.)

Impaired reflex responses to airway occlusion in the inspiratory muscles of asthmatic subjects. Butler JE, et al. **Thorax** 1996 May;51(5):490–5

Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide (SO)2-induced bronchoconstriction. Field PI, et al. **Thorax** 1996 Feb; 51(2):159–63

Asthma: is there an airway receptor barrier? [editorial] Hills BA. **Thorax** 1996 Aug;51(8):773–6

Significant differences in flow standardised breath sound spectra in patients with chronic obstructive pulmonary disease, stable asthma, and healthy lungs. Malmberg LP, et al. **Thorax** 1995 Dec;50(12):1285–91

Home assessment of peak inspiratory flow through the Turbohaler in asthmatic patients. Meijer RJ, et al. **Thorax** 1996 Apr;51(4):433–4

Effects of propranolol inhalation on the diurnal increase in FEV1 and on propranolol airways responsiveness in atopic subjects with asthma. Oosterhoff Y, et al. **Thorax** 1995 Sep; 50(9):937–40

Relationship between the acid-induced cough response and airway responsiveness and obstruction in children with asthma. Shimizu T, et al. **Thorax** 1996 Mar;51(3):284–7

Airway sensory nerves: a burning issue in asthma? Spina D. **Thorax** 1996 Mar;51(3):335–7

Use of tracheal auscultation for the assessment of bronchial responsiveness in asthmatic children. Sprikkelman AB, et al. **Thorax** 1996 Mar;51(3):317–9

Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma. van Velzen E, et al. **Thorax** 1996 Jun;51(6):582–4

Comparative short-term health responses to sulfur dioxide exposure and other common stresses in a panel of asthmatics. Gong H Jr, et al. **Toxicol Ind Health** 1995 Sep-Oct;11(5):467–87

Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Hay DW, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):304–9 (54 ref.)

[Peak expiratory flow rate (PEF) and serum eosinophil cationic protein (ECP) changes in nocturnal asthmatics] Sun B, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Jun; 18(3):143–5, 189 (Eng. Abstr.) **(Chi)**

[Perception of dyspnea in asthmatics—long-term study] Král B, et al. **Vnitr Lek** 1995 Dec;41(12):810–5 (Eng. Abstr.) **(Cze)**

[Oxygen radicals and asthma] Kinnula V. **Duodecim** 1994; 110(9):863–9 (29 ref.) **(Fin)**

[Indications for respiratory function tests (RFT). The role of RFT and blood gases in the monitoring of asthma and chronic obstructive bronchopnumopathies] **Rev Mal Respir** 1995;12 Suppl 3:R115–31 (57 ref.) **(Fre)**

[Chronic course of reactive bronchial dysfunction syndrome. Apropos of 6 further cases] Rivoire B, et al. **Rev Mal Respir** 1995;12(5):471–7 (Eng. Abstr.) **(Fre)**

[Right diaphragmatic kinetics measured by TM-mode ultrasonography with concomitant spirometry in normal subjects and asthmatic patients. Preliminary results] Targhetta R, et al. **Rev Med Interne** 1995;16(11):819–26 (Eng. Abstr.) **(Fre)**

[Clinical significance of bronchial hyperreactivity] Weber T. **Rev Med Liege** 1995 Sep;50(9):384–7 (32 ref.) **(Fre)**

[Occupational asthma: medical and social prognosis] Pauli G, et al. **Rev Pneumol Clin** 1996;52(2):104–9 (25 ref.) (Eng. Abstr.) **(Fre)**

[Patients with lung diseases and sports] Villiger B. **Schweiz Rundsch Med Prax** 1995 Sep 5;84(36):953–62 (38 ref.) (Eng. Abstr.) **(Ger)**

[Limits in the evaluation of bronchial reactivity in children with asthma] Mingoni S, et al. **Pediatr Med Chir** 1995 Sep-Oct;17(5):417–22 (49 ref.) (Eng. Abstr.) **(Ita)**

[Beta-2 agonists, exposure to allergens and bronchial hyperreactivity in children with allergic asthma] Piacentini GL, et al. **Pediatr Med Chir** 1995 Nov-Dec;17(6):515–7 (Eng. Abstr.) **(Ita)**

[Autoregressive analysis of variability in heart rate and blood pressure in asthmatic children—difference of severity] Korematsu S. **Arerugi** 1995 Sep;44(9):1140–9 (Eng. Abstr.) **(Jpn)**

[Respiratory function in students who had asthma in childhood] Tomita K, et al. **Arerugi** 1995 Sep;44(9):1125–31 (Eng. Abstr.) **(Jpn)**

[Symptoms, FEV1/FVC, and peak flow as indices of the control of asthma] Zang M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Mar;34(3):270–4 (Eng. Abstr.) **(Jpn)**

[Airway inflammation in asthma] Fukuda T. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):189–93 (7 ref.) **(Jpn)**

[Cough variant asthma] Hirata K, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):240–4 (5 ref.) **(Jpn)**

[Role of cytokines in pathophysiology of asthma] Ishioka S. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):184–8 (5 ref.) **(Jpn)**

[Management of asthma based on their peak expiratory flow rate monitoring] Tamura G. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):222–6 (11 ref.) **(Jpn)**

[Clinical state, bronchial reactivity and atopic symptoms in patients with occupational bronchial asthma 3-4 years after cessation of occupational exposure] Kołacińska B, et al. **Med Pr** 1996;47(4):347–52 (Eng. Abstr.) **(Pol)**

[Comparison of skin prick test and specific bronchial challenge results in asthmatic children] Mazurek H, et al. **Pediatr Pol** 1995 Apr;70(4):319–24 **(Pol)**

[Course of non-specific bronchial reactivity to histamine after bronchospasm induced by allergen challenge in patients with bronchial asthma] Grzelewska-Rzymowska I, et al. **Pneumonol Alergol Pol** 1995;63(5-6):273–80 (Eng. Abstr.) **(Pol)**

[The effect of bronchial allergen provocation on spontaneous production of histamine releasing factor (HRF) by mononuclear cells in patients with bronchial asthma] Grzelewska-Rzymowska I, et al. **Pneumonol Alergol Pol** 1996;64(3-4):204–11 (Eng. Abstr.) **(Pol)**

[Neurogenic mechanisms of asthmatic bronchitis (editorial)] Kowalski ML. **Pneumonol Alergol Pol** 1995;63(5-6):245–52 **(Pol)**

[Periodic breathing during sleep at high altitudes in patients with bronchial asthma] Koziej M, et al. **Pneumonol Alergol Pol** 1996;64(3-4):141–9 (Eng. Abstr.) **(Pol)**

[Ventilatory disturbances in school children with asthmatic symptoms in anamnesis] Niepsuj G, et al. **Pneumonol Alergol Pol** 1996;64(3-4):150–6 (Eng. Abstr.) **(Pol)**

[Behavior of various spirometry parameters during bronchial provocation tests with D. pteronyssinus in patients with asthma, sensitized to housedust mites] Siergiejko Z, et al.

Pneumonol Alergol Pol 1995;63 Suppl 2:60–5 (Eng. Abstr.) **(Pol)**

[Effect of indomethacin on bronchial reactivity to supernatant of mononuclear cell cultures from patients with bronchial asthma] Krasnowska M, et al. **Pneumonol Pol** 1990 Nov–Dec;58(11–12):604–9 (Eng. Abstr.) **(Pol)**

[Role of prostaglandins F and E in regulation of bronchial activity] Mastalerz L. **Pol Arch Med Wewn** 1995 Feb; 93(2):179–83 (35 ref.) (Eng. Abstr.) **(Pol)**

[Role of the autonomic nervous system (adrenergic, cholinergic and nonadrenergic, noncholinergic) in regulation of respiratory system function] Liebhart J, et al. **Postepy Hig Med Dosw** 1995;49(3):395–407 (45 ref.) (Eng. Abstr.) **(Pol)**

[Cerebral hemodynamics and bioelectric activity in patients with bronchial asthma] Karashurov SA. **Klin Med (Mosk)** 1996;74(1):34–6 (Eng. Abstr.) **(Rus)**

[Bronchial nonspecific reactivity in patients with bronchial asthma and in the preasthmatic state and its alteration under the influence of acupuncture] Aleksandrova RA, et al. **Ter Arkh** 1995;67(8):42–5 (Eng. Abstr.) **(Rus)**

[The hemodynamic status and right ventricular diastolic function of bronchial asthma patients] Eniseeva ES, et al. **Ter Arkh** 1995;67(8):39–42 (Eng. Abstr.) **(Rus)**

[Evaluation of the hormonal status of patients with bronchial asthma by using various drug doses] Kakhnovskiĭ IM, et al. **Vestn Ross Akad Med Nauk** 1995;(10):16–22 (Eng. Abstr.) **(Rus)**

[The effect of adaptation to hypoxia on the results of the health resort treatment of children with bronchial asthma] Legkikh MV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec;(6):42 **(Rus)**

[Bronchial asthma and bronchial hyperreactivity: friends for ever (editorial; comment)] Picado C. **Med Clin (Barc)** 1996 May 25;106(20):780–1. Comment on: Med Clin (Barc) 1996 May 25;106(20):761–7. **(Spa)**

PREVENTION & CONTROL

The non–drug treatment of asthma. Liang AY. **Acta Paediatr Sin** 1995 Nov–Dec;36(6):401–4 (12 ref.)

Preventing hospitalizations for asthma by improving ambulatory management [editorial; comment] Greenberger PA. **Am J Med** 1996 Apr;100(4):381–2. Comment on: Am J Med 1996 Apr;100(4):386–94.

Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Harding SM, et al. **Am J Med** 1996 Apr;100(4):395–405

An education program for parents of children with asthma: differences in attendance between smoking and nonsmoking parents. Fish L, et al. **Am J Public Health** 1996 Feb; 86(2):246–8

What are the prospects for immunization? Holt PG. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S27 (16 ref.)

Surfactant nebulization does not alter airflow obstruction and bronchial responsiveness to histamine in asthmatic children. Oetomo SB, et al. **Am J Respir Crit Care Med** 1996 Mar; 153(3):1148–52

Inhaled PGE2 prevents aspirin–induced bronchoconstriction and urinary LTE4 excretion in aspirin–sensitive asthma. Sestini P, et al. **Am J Respir Crit Care Med** 1996 Feb; 153(2):572–5

Longitudinal study of free running exercise challenge: reproducibility. Powell CV, et al. **Arch Dis Child** 1996 Feb; 74(2):108–14

Review of prescribed treatment for children with asthma. More recent data suggest guidelines are being adhered to [letter; comment] Martin R, et al. **BMJ** 1995 Dec 16; 311(7020):1645. Comment on: BMJ 1995 Sep 9;311(7006):663–6.

Review of prescribed treatment for children with asthma. Weaknesses in methods and analysis limit conclusions [letter; comment] Ross AM, et al. **BMJ** 1995 Dec 16; 311(7020):1644–5; discussion 1645. Comment on: BMJ 1995 Sep 9;311(7006):663–6.

A comparative study of the clinical efficacy of nedocromil sodium and placebo. How does cromolyn sodium compare as an active control treatment? Schwartz HJ, et al. **Chest** 1996 Apr;109(4):945–52

Asthma in pregnancy. Mabie WC. **Clin Obstet Gynecol** 1996 Mar;39(1):56–69 (44 ref.)

The excitation–adaptation model of pediatric chronic illness. Meijer AM, et al. **Fam Process** 1995 Dec;34(4):441–54

School absence—a valid morbidity marker for asthma? McCowan C, et al. **Health Bull (Edinb)** 1996 Jul; 54(4):307–13

An empowerment–centered, church–based asthma education program for African American adults. Ford ME, et al. **Health Soc Work** 1996 Feb;21(1):70–5

Effects of a thromboxane synthase inhibitor (CS–518) on the eosinophil–dependent late asthmatic response and airway hyperresponsiveness in guinea pigs. Itoh K, et al. **Int Arch Allergy Immunol** 1996 Jan;109(1):79–85

SOFT Issues in asthma management. McGovern SJ, et al. **Ir Med J** 1995 Nov–Dec;88(6):217–8

Reversion and antihistamines [letter] Gupta SK. **J Assoc Physicians India** 1996 Jan;44(1):72–3

Definition of 'controlled' asthma [letter] Gupta SK, et al. **J Assoc Physicians India** 1996 Jan;44(1):74

Zaditen SRO permits once–daily dosing with superior efficacy in the prophylaxis of asthma. Radielovic P, et al. **J Asthma** 1995;32(2):105–15

Physicians' prevention–related practice behaviors in treating adult patients with asthma: results of a national survey [corrected and republished in J Asthma 1995;32(4):309–18] Wolle JM, et al. **J Asthma** 1995;32(2):131–40

Inner–city asthma control campaign under way [news] Marwick C. **JAMA** 1995 Oct 4;274(13):1004

Asthma management in eastern Australia, 1990 and 1993 [see comments] Comino EJ, et al. **Med J Aust** 1996 Apr 1; 164(7):403–6. Comment in: Med J Aust 1996 Apr 1;164(7):391–3.

Consumption of oily fish and childhood asthma risk [see comments] Hodge L, et al. **Med J Aust** 1996 Feb 5; 164(3):137–40. Comment in: Med J Aust 1996 Feb 5;164(3):135–6.

Oily fish and asthma—a fishy story? Further studies are required before claims can be made of a beneficial effect of oily fish consumption on asthma [editorial; comment] Thien FC, et al. **Med J Aust** 1996 Feb 5;164(3):135–6. Comment on: Med J Aust 1996 Feb 5;164(3):137–40.

Aetiology of asthma: how public health and molecular medicine work together. Chauhan AJ, et al. **Mol Med Today** 1996 May;2(5):192–7

A community trial of a written self management plan for children with asthma. Asthma Foundation of NZ Children's Action. Gillies J, et al. **N Z Med J** 1996 Feb 9;109(1015):30–3

Naked DNA: new shots for allergy? [comment] Moffatt M, et al. **Nat Med** 1996 May;2(5):515–6. Comment on: Nat Med 1996 May;2(5):540–4.

Environmental control in childhood asthma. Naspitz CK, et al. **Pediatr Pulmonol Suppl** 1995;11:47–8

Does quality of care affect rates of hospitalization for childhood asthma? Homer CJ, et al. **Pediatrics** 1996 Jul; 98(1):18–23

Asthma. Specific preventive strategies. Morris RJ. **Postgrad Med** 1996 Aug;100(2):105–6, 109–12, 118 passim (21 ref.)

A non–compliant smoker with brittle asthma. Champ R, et al. **Practitioner** 1996 Jul;240(1564):413–6, 418–9

Meta–analysis of the effects of psychoeducational care in adults with asthma. Devine EC. **Res Nurs Health** 1996 Oct; 19(5):367–76

Decreasing asthma morbidity. Brandt HD, et al. **S Afr Med J** 1994 Dec;84(12):842–4

Issues in adolescent asthma: what are the needs? Price JF. **Thorax** 1996 Jan;51 Suppl 1:S13–7 (33 ref.)

Value of home peak flow monitoring for asthma control. Janson S. **West J Med** 1995 Oct;163(4):370–1

[Role of breast milk feeding in avoidance of asthma and other allergic disorders] Barr J, et al. **Harefuah** 1995 Oct; 129(7–8):274–8 (43 ref.) **(Heb)**

PSYCHOLOGY

Effect of allergy specialist care on the quality of life in patients with asthma. Storms B, et al. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):491–4

Asthma knowledge attitudes and quality of life in adolescents [letter; comment] Finn A, et al. **Arch Dis Child** 1996 Apr; 74(4):367. Comment on: Arch Dis Child 1995 Oct;73(4):321–6.

Measurement of psychological distress in asthma and asthma management programmes. Hyland ME, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):601–11

Social factors associated with behavioral problems in children with asthma. Butz AM, et al. **Clin Pediatr (Phila)** 1995 Nov; 34(11):581–90

The psychological factors associated with poor compliance with treatment in asthma. Bosley CM, et al. **Eur Respir J** 1995 Jun;8(6):899–904

The excitation–adaptation model of pediatric chronic illness. Meijer AM, et al. **Fam Process** 1995 Dec;34(4):441–54

Predictors of panic–fear in asthma. Carr RE, et al. **Health Psychol** 1995 Sep;14(5):421–6

Symptom perception in pediatric asthma: relationship to functional morbidity and psychological factors. Fritz GK, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug; 35(8):1033–41

Psychiatric family history in adolescents with severe asthma. Wamboldt MZ, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug;35(8):1042–9

Asthma, health behaviors, social adjustment, and psychosomatic symptoms in adolescence. Forero R, et al. **J Asthma** 1996;33(3):157–64

A preliminary study of factors that influence children's sense of competence to manage their asthma. Miles A, et al. **J Asthma** 1995;32(6):437–44

Psychosocial adjustment and the role of functional status for children with asthma. Padur JS, et al. **J Asthma** 1995; 32(5):345–53

Psychosocial characteristics of asthma. Wjst M, et al. **J Clin Epidemiol** 1996 Apr;49(4):461–6

Pediatric compliance and the roles of distinct treatment characteristics, treatment attitudes, and family stress: a preliminary report. Van Sciver MM, et al. **J Dev Behav Pediatr** 1995 Oct;16(5):350–8

A patient's view of asthma. Donaldson JM. **J R Soc Med** 1995 Oct;88(10):590P–593P

The effects of a cognitive behavioural intervention in asthmatic patients. Sommaruga M, et al. **Monaldi Arch Chest Dis** 1995 Oct;50(5):398–402

Perception, personality, and respiratory control in life–threatening asthma. Gibson GJ. **Thorax** 1995 Sep;50 Suppl 1:S2–4 (15 ref.)

Respiratory sensation during bronchial challenge testing with methacholine, sodium metabisulphite, and adenosine monophosphate. Marks GB, et al. **Thorax** 1996 Aug; 51(8):793–8

[The perception of improvement in asthma] Heredia JL, et al. **Med Clin (Barc)** 1995 Nov 11;105(16):612–4 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Fluoroscopic diagnosis of laryngeal asthma (paradoxical vocal cord motion). Shao W, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1229–31

Computed tomography of the lungs in asthma: influence of disease severity and etiology. Paganin F, et al. **Am J Respir Crit Care Med** 1996 Jan;153(1):110–4

Abnormalities of the airways and lung parenchyma in asthmatics: CT observations in 50 patients and inter– and intraobserver variability. Grenier P, et al. **Eur Radiol** 1996; 6(2):199–206

[Value of imaging in asthma] Paganin F, et al. **Rev Pneumol Clin** 1996;52(2):88–96 (36 ref.) (Eng. Abstr.) **(Fre)**

[Is the bronchial provocation test justified in occupational respiratory disease?] Pauli G, et al. **Rev Pneumol Clin** 1996; 52(2):97–102 (20 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

The change in the distribution of Tc–99m human serum albumin radioaerosols in asthma after a 1–week course of corticosteroid inhalation treatment. Changlai SP, et al. **Clin Nucl Med** 1995 Jul;20(7):626–9

Imaging allergen–invoked airway inflammation in atopic asthma with [18F]–fluorodeoxyglucose and positron emission tomography. Taylor IK, et al. **Lancet** 1996 Apr 6;347(9006):937–40

REHABILITATION

Decreasing hospital admissions for childhood asthma in Sweden [editorial] Foucard T. **Acta Paediatr** 1996 Feb; 85(2):131

Decreasing admissions for childhood asthma to a Swedish county hospital. Strömberg L. **Acta Paediatr** 1996 Feb; 85(2):173–6

High–intensity physical training in adults with asthma. A 10–week rehabilitation program. Emtner M, et al. **Chest** 1996 Feb;109(2):323–30

The consequences of asthma in terms of the ICIDH and the role of physical activities. Vermeer A. **Disabil Rehabil** 1995 Oct;17(7):386–90

An economic evaluation of short–term inpatient rehabilitation for children with severe asthma. Weinstein AG, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):264–73

Model for management of services to low income pediatric asthma patients. Horst ML. **Soc Work Health Care** 1995; 21(1):129–36

[The effect of adaptation to hypoxia on the results of the health resort treatment of children with bronchial asthma] Legkikh MV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec;(6):42 **(Rus)**

SURGERY

A comparison of intravenous and inhalational maintenance anaesthesia for endoscopic procedures in the aspirin intolerance syndrome. Novak–Jankovič V, et al. **Eur J Anaesthesiol** 1995 Jul;12(4):345–9

Successful surgical management of emphysematous giant bullae accompanied by severe bronchial asthma: report of a case. Ishikawa S, et al. **Surg Today** 1995;25(6):560–2

THERAPY

The immunological defects in allergic asthmatic children and the working mechanisms of immunotherapy (hyposensitization) [editorial] Hsieh KH. **Acta Paediatr Sin** 1995 Nov–Dec;36(6):399–400 (25 ref.)

A double–blind, placebo controlled study of Alpare mite D. pteronyssinus immunotherapy in asthmatic patients. Franco C, et al. **Allergol Immunopathol (Madr)** 1995 Mar–Apr; 23(2):58–66

Leukotrienes as therapeutic target in asthma. Pauwels RA, et al. **Allergy** 1995 Aug;50(8):615–22 (73 ref.)

Double–blind trial of house–dust mite immunotherapy in asthmatic children resident at high altitude. Peroni DG, et al. **Allergy** 1995 Nov;50(11):925–30

Commentary on the article "Management of the adult asthma patient" (Jan.–Feb., 1995) [comment] Catlett JB. **Allergy Proc** 1995 May–Jun;16(3):141. Comment on: Allergy Proc 1995 Jan–Feb;16(1):1–4.

The role of immunotherapy in allergic rhinitis/allergic asthma. Creticos PS. **Allergy Proc** 1995 Nov–Dec; 16(6):297–302 (78 ref.)

Asthma: diagnosis and management. Shuttari MF. **Am Fam Physician** 1995 Dec;52(8):2225–35

Educational and long–term therapeutic intervention in the ED: effect on outcomes in adult indigent minority asthmatics. Kelso TM, et al. **Am J Emerg Med** 1995 Nov; 13(6):632–7

Disease management program for asthma: baseline assessment

of resource use. MacKinnon NJ, et al. **Am J Health Syst Pharm** 1996 Mar 1;53(5):535–41

Protocol therapy for acute asthma: therapeutic benefits and cost savings. McFadden ER Jr, et al. **Am J Med** 1995 Dec; 99(6):651–61

Is allergen immunotherapy effective in asthma? A meta-analysis of randomized clinical trials [letter; comment] Bousquet J, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1737–8 . Comment on: Am J Respir Crit Care Med 1995 Apr;151(4):969–74.

National Asthma Education and Prevention Program working group report on the quality of asthma care. Headrick L, et al. **Am J Respir Crit Care Med** 1996 Sep; 154(3 Pt 2):S96–118

Muscle weakness in mechanically ventilated patients with severe asthma. Leatherman JW, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1686–90

National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. Sullivan S, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 2):S84–95

An intervention program to reduce the hospitalization cost of asthmatic patients requiring intubation. Doan T, et al. **Ann Allergy Asthma Immunol** 1996 Jun;76(6):513–8

Management of sinusitis in the asthmatic patient. Senior BA, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):6–15; quiz 15–9 (47 ref.)

Immunotherapy for childhood asthma: is there a rationale for its use? Sigman K, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):299–305; quiz 305–9 (39 ref.)

Managed care—the key to quality of management of asthma [editorial] Sly RM. **Ann Allergy Asthma Immunol** 1996 Sep; 77(3):161–3

Going beyond the National Asthma Education Program guidelines for the diagnosis and management of asthma: critical need for outcomes assessment [editorial] Stempel DA, et al. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):457–60

Asthma research: future directions for emergency medicine.The NHLBI Asthma Working Group. Nowak RM, et al. **Ann Emerg Med** 1996 Feb;27(2):244–9

Lidocaine and rapid sequence intubation [letter; comment] Walls RM. **Ann Emerg Med** 1996 Apr;27(4):528–9. Comment on: Ann Emerg Med 1995 Nov;26(5):660.

No support for intravenous lidocaine airway reflex suppression during rapid sequence intubation [letter] [see comments] Zemenick RB. **Ann Emerg Med** 1995 Nov; 26(5):660. Comment in: Ann Emerg Med 1996 Apr;27(4):528–9.

The asthma year in Swedish pharmacies: a nationwide information and pharmaceutical care program for patients with asthma. Lisper B, et al. **Ann Pharmacother** 1996 May; 30(5):455–60

Use of a pharmacy and medical claims database to document cost centers for 1993 annual asthma expenditures. Stempel DA, et al. **Arch Fam Med** 1996 Jan;5(1):36–40

Effect of pulmonary function testing on the management of acute asthma. Emerman CL, et al. **Arch Intern Med** 1995 Nov 13;155(20):2225–8

Readmissions to hospital: the contribution of morbidity data to the evaluation of asthma management. Rushworth RL, et al. **Aust J Public Health** 1995 Aug;19(4):363–7

North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management in adults. North of England Asthma Guideline Development Group. **BMJ** 1996 Mar 23;312(7033):762–6

North of England evidence based guidelines development project: methods of guideline development. Eccles M, et al. **BMJ** 1996 Mar 23;312(7033):760–2

Do clinical guidelines introduced with practice based education improve care of asthmatic and diabetic patients? A randomised controlled trial in general practices in east London. Feder G, et al. **BMJ** 1995 Dec 2;311(7018):1473–8

Evidence used to formulate guidelines on managing asthma did not include costs [letter] Fitzmaurice DA, et al. **BMJ** 1996 Jul 13;313(7049):113–4

Randomised comparison of guided self management and traditional treatment of asthma over one year. Lahdensuo A, et al. **BMJ** 1996 Mar 23;312(7033):748–52

Using information from asthma patients: a trial of information feedback in primary care. White P, et al. **BMJ** 1995 Oct 21;311(7012):1065–9

Do self-management plans reduce morbidity in patients with asthma? Hoskins G, et al. **Br J Gen Pract** 1996 Mar; 46(404):169–71

Management of asthma in the hospital emergency department. Beasley R, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):253–7 (18 ref.)

Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society. Beveridge RC, et al. **Can Med Assoc J** 1996 Jul 1;155(1):25–37 (167 ref.)

Does asthma education change behavior? To know is not to do [editorial; comment] Blessing-Moore J. **Chest** 1996 Jan;109(1):9–11. Comment on: Chest 1996 Jan;109(1):86–90.

Evaluation of heliox in children hospitalized with acute severe asthma. A randomized crossover trial. Carter ER, et al. **Chest** 1996 May;109(5):1256–61

Assessment of practical knowledge of self-management of acute asthma [see comments] Kolbe J, et al. **Chest** 1996 Jan;109(1):86–90. Comment in: Chest 1996 Jan;109(1):9–11.

Enhancing patient compliance in asthma management [letter] Marino JT. **Chest** 1996 Sep;110(3):862

Results of a program to improve the process of inpatient care of adult asthmatics. Mayo PH, et al. **Chest** 1996 Jul; 110(1):48–52

Asthma: current controversies and emerging therapies. Kavuru MS, et al. **Cleve Clin J Med** 1995 Sep–Oct; 62(5):293–304 (122 ref.)

How to implement an asthma education program. Kohler CL, et al. **Clin Chest Med** 1995 Dec;16(4):557–65 (18 ref.)

Speleotherapy in asthma and allergic diseases [letter; comment] Karakoca Y, et al. **Clin Exp Allergy** 1995 Jul; 25(7):666–7. Comment on: Clin Exp Allergy 1994 Sep;24(9):813–25.

Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Gelfand EW, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:61–6 (56 ref.)

Acute asthma. Kardon EM. **Emerg Med Clin North Am** 1996 Feb;14(1):93–114 (63 ref.)

Integrated care for asthma: matching care to the patient. Osman LM, et al. **Eur Respir J** 1996 Mar;9(3):444–8

Patient education and childhood asthma—fashion or progress? [editorial] Couriel J. **Ir Med J** 1993 May; 86(3):82–3

Effect of a preprinted form on the management of acute asthma in an accident and emergency department. Robinson SM, et al. **J Accid Emerg Med** 1996 Mar; 13(2):93–7

Practice parameters for the diagnosis and treatment of asthma. Joint Task Force on Practice Parameters, representing the American Academy of Allergy Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 2):707–870

Mite-specific induction of interleukin-2 receptor on T lymphocytes from children with mite-sensitive asthma: modified immune response with immunotherapy. Bonno M, et al. **J Allergy Clin Immunol** 1996 Feb;97(2):680–8

Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. Hedlin G, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):879–85

Evaluation of household dust mite exposure and levels of specific IgE and IgG antibodies in asthmatic patients enrolled in a trial of immunotherapy. Rose G, et al. **J Allergy Clin Immunol** 1996 May;97(5):1071–8

Asthma and managed care [editorial] Kaplan MS. **J Asthma** 1995;32(5):321–4

Patients' opinions on respiratory care: do doctors fulfill their needs? Koning CJ, et al. **J Asthma** 1995;32(5):355–63

Evaluation of individualized asthma self-management programs. Kotses H, et al. **J Asthma** 1996;33(2):113–8

Predicting the need for hospital admission in patients with acute bronchial asthma. Kunitoh H, et al. **J Asthma** 1996; 33(2):105–12

Risk factors for asthmatic patients requiring intubation. III. Observations in young adults. LeSon S, et al. **J Asthma** 1996;33(1):27–35

Risk factors for asthmatic patients requiring intubation. II. Observations in teenagers. LeSon S, et al. **J Asthma** 1995; 32(5):379–89

Risk factors for intubation of adult asthmatic patients. LeSon S, et al. **J Asthma** 1995;32(2):97–104

A preliminary study of factors that influence children's sense of competence to manage their asthma. Miles A, et al. **J Asthma** 1995;32(6):437–44

Managed care and the treatment of asthma. O'Brien KP. **J Asthma** 1995;32(5):325–34 (46 ref.)

Clinical features, management, and outcome of patients with severe asthma admitted to the intensive care unit. Pacht ER, et al. **J Asthma** 1995;32(5):373–7

An asthma self-management program for children, including instruction in peak flow monitoring by school nurses. Persaud DI, et al. **J Asthma** 1996;33(1):37–43

Care of asthmatics on discharge from hospital: a hospital audit. Schilling RJ, et al. **J Asthma** 1995;32(2):161–3

Education of parents of infants and very young children with asthma: a developmental evaluation of the Wee Wheezers program. Wilson SR, et al. **J Asthma** 1996;33(4):239–54

Physicians' prevention-related practice behaviors in treating adult patients with asthma: results of a national survey [corrected and republished in J Asthma 1995;32(4):309–18] Wolle JM, et al. **J Asthma** 1995;32(2):131–40

Immunotherapy in adult asthma. Squillace SP. **J Fam Pract** 1996 May;42(5):455

Treatment of asthma. Beck M. **J Fla Med Assoc** 1996 Jun–Jul; 83(6):384–8

A prototype computer decision support system for the management of asthma. Austin T, et al. **J Med Syst** 1996 Feb;20(1):45–55

Audit of asthma care in Army general practice. Bricknell MC, et al. **J R Army Med Corps** 1995 Jun;141(2):87–91

External approach to the treatment of pediatric asthma. Sun Y. **J Tradit Chin Med** 1995 Dec;15(4):290–1

Clinical experience of Dr. Shao Jingming in treatment of diseases by puncturing back-shu points. Wang M, et al. **J Tradit Chin Med** 1996 Mar;16(1):23–6

Effect of M-711 on experimental asthma in rats. Shichinohe K, et al. **J Vet Med Sci** 1996 Jan;58(1):55–9

Emergency hospital visits for asthma [letter] Johnson P, et al. **Lancet** 1996 Aug 24;348(9026):556

Peak-expiratory-flow meters and asthma self-management. Legge JS. **Lancet** 1996 Jun 22;347(9017):1709–10

Is it "urban" or is it "asthma"? Steigman DM. **Lancet** 1996 Jul 20;348(9021):143–4

Emergent management of acute asthma. Abou-Shala N, et al. **Med Clin North Am** 1996 Jul;80(4):677–99 (74 ref.)

Peak flow meter use in asthma management. Thoracic Society of Australia and New Zealand. **Med J Aust** 1996 Jun 17;164(12):727–30

Re-engineering care delivery to improve the health outcome of asthmatics in Campbelltown, New South Wales. Watson E, et al. **Medinfo** 1995;8 Pt 1:545

Near-fatal asthma and mechanical ventilation [editorial] Rossi A, et al. **Monaldi Arch Chest Dis** 1996 Apr; 51(2):99–101 (36 ref.)

Is immunotherapy for asthma worthwhile? [editorial; comment] [see comments] Barnes PJ. **N Engl J Med** 1996 Feb 22;334(8):531–2. Comment on: N Engl J Med 1996 Feb 22;334(8):501–6. Comment in: N Engl J Med 1996 Jul 18;335(3):203–4; discussion 205–6. Comment in: N Engl J Med 1996 Jul 18;335(3):204; discussion 205–6.

Ragweed immunotherapy in adult asthma [letter; comment] Chmelik F, et al. **N Engl J Med** 1996 Jul 18;335(3):205; discussion 205. Comment on: N Engl J Med 1996 Feb 22;334(8):501–6.

Ragweed immunotherapy in adult asthma [see comments] Creticos PS, et al. **N Engl J Med** 1996 Feb 22;334(8):501–6 . Comment in: N Engl J Med 1996 Feb 22;334(8):531–2. Comment in: N Engl J Med 1996 Jul 18;335(3):203; discussion 205. Comment in: N Engl J Med 1996 Jul 18;335(3):203–4; discussion 205–6. Comment in: N Engl J Med 1996 Jul 18;335(3):204; discussion 205–6. Comment in: N Engl J Med 1996 Jul 18;335(3):205; discussion 205.

Ragweed immunotherapy in adult asthma [letter; comment] Klein JS. **N Engl J Med** 1996 Jul 18;335(3):204; discussion 205–6. Comment on: N Engl J Med 1996 Feb 22;334(8):531–2.

Ragweed immunotherapy in adult asthma [letter; comment] Platts-Mills TA. **N Engl J Med** 1996 Jul 18;335(3):204; discussion 205–6. Comment on: N Engl J Med 1996 Feb 22;334(8):501–6.

Ragweed immunotherapy in adult asthma [letter; comment] Portnoy JM, et al. **N Engl J Med** 1996 Jul 18;335(3):203–4; discussion 205–6. Comment on: N Engl J Med 1996 Feb 22;334(8):501–6. Comment on: N Engl J Med 1996 Feb 22;334(8):531–2.

Ragweed immunotherapy in adult asthma [letter; comment] Weiner J, et al. **N Engl J Med** 1996 Jul 18;335(3):203; discussion 205. Comment on: N Engl J Med 1996 Feb 22;334(8):501–6.

After hours medical services [letter] Gray B. **N Z Med J** 1996 Aug 23;109(1028):325

Out-of-hours attendance and outcomes for asthmatic patients at two primary care services. Kljakovic M, et al. **N Z Med J** 1996 Jul 12;109(1025):254–7

The pattern of consultations for asthma in a general practice over 5 years. Kljakovic M, et al. **N Z Med J** 1996 Feb 23;109(1016):48–50

Asthma management at Christchurch Hospital: compliance with guidelines. McLeod SJ, et al. **N Z Med J** 1996 Apr 12;109(1019):115–8

Children with asthma: we can do better [editorial] Altemeier WA 3rd. **Pediatr Ann** 1996 Mar;25(3):120–1, 125

Prehospital management of pediatric asthma requiring hospitalization [see comments] Fisher JD, et al. **Pediatr Emerg Care** 1995 Aug;11(4):217–9. Comment in: Pediatr Emerg Care 1996 Feb;12(1):71–2.

Children with asthma in the emergency department: spectrum of disease, variation with ethnicity, and approach to treatment. Horowitz I, et al. **Pediatr Emerg Care** 1995 Aug; 11(4):240–2

C-reactive protein in acute pulmonary exacerbations of patients with cystic fibrosis. Friesen CA, et al. **Pediatr Pulmonol** 1995 Oct;20(4):215–9

Asthma. Calverley PM. **Postgrad Med J** 1996 Jan; 72(843):12–8 (34 ref.)

Do accident and emergency senior house officers know the British guidelines on the management of acute asthma? Ulahannan T, et al. **Postgrad Med J** 1996 Mar;72(845):162–3

Guidelines in asthma [editorial] Harrison BD. **Respir Med** 1996 Aug;90(7):375–8

Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors. Metzger WJ. **Springer Semin Immunopathol** 1995;16(4):467–78 (65 ref.)

Randomised trial of an asthma self-management programme for adults. Allen RM, et al. **Thorax** 1995 Jul;50(7):731–8

Peak flow based asthma self-management: a randomised controlled study in general practice. British Thoracic Society Research Committee. Jones KP, et al. **Thorax** 1995 Aug;50(8):851–7

Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation. Taylor IK. **Thorax** 1995 Sep;50(9):1005–10 (93 ref.)

Asthma advances and controversies. Kino R. **West J Med** 1996 Jan;164(1):65–6

Effectiveness of allergy immunotherapy for asthma. Sokol W. **West J Med** 1995 Oct;163(4):368

[Studies on regulatory effects of acupuncture on mucosal secretory IgA in patients with allergic asthma] Yang Y, et al. **Chen Tzu Yen Chiu** 1995;20(2):68–70 (Eng. Abstr.)

(Chi)
[Ion generators and bronchial asthma (letter)] Jonassen N. **Ugeskr Laeger** 1996 Jul 15;158(29):4203–4 (Dan)
[Problems in the use, cleaning and maintenance of nebulization equipment in the home situation] Struycken VH, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23; 140(12):654–8 (Eng. Abstr.) (Dut)
[Effectiveness of psychotherapy in asthma: meta-analysis] Khateeb Z. **Acta Psychiatr Belg** 1995 Jan–Feb;95(1):25–43 (Eng. Abstr.) (Fre)
[Do nasal and conjunctival provocation tests represent a trustworthy parameter for the follow-up of childhood IgE-dependent bronchial asthma?] Botey J, et al. **Allerg Immunol (Paris)** 1996 Feb;28(2):52–4 (Eng. Abstr.) (Fre)
[Inhalation therapy for asthma in children. Questions about effectiveness (editorial)] de Blic J. **Presse Med** 1995 Dec 2;24(37):1724–6 (Eng. Abstr.) (Fre)
[Management of severe acute asthma in adults] Teboul JL, et al. **Presse Med** 1995 Nov 11;24(34):1590–3 (27 ref.) (Fre)
[Asthma attacks in children over two years old in a pediatric hospital in Nice] Velin P, et al. **Rev Mal Respir** 1996; 13(2):169–74 (Eng. Abstr.) (Fre)
[Treatment of severe acute asthma] Roué C, et al. **Rev Pneumol Clin** 1996;52(2):129–34 (28 ref.) (Eng. Abstr.) (Fre)
[Severe life threatening asthma attack] Magnussen H, et al. **Internist (Berl)** 1995 Aug;36(8):779–84 (31 ref.) (Ger)
[Effectiveness of oral immunotherapy in bronchial asthma caused by Dermatophagoides pternyssinus] Pacor ML, et al. **Recenti Prog Med** 1995 Dec;86(12):489–91 (Eng. Abstr.) (Ita)
[Desensitization immunotherapy on patients with mite-positive bronchial asthma using purified mite feces antigen fractions] Asaoku Y, et al. **Arerugi** 1995 Jul; 44(7):692–700 (Eng. Abstr.) (Jpn)
[Adult onset of asthma and their therapy (discussion)] **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):245–62 (Jpn)
[Guidelines for the treatment of asthma] Akiyama K. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):199–204 (3 ref.) (Jpn)
[What is the benefit for patients and their parents in a stay at the Geilomo pediatric hospital?] Grangård EH. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):536 (Nor)
[An immunologic evaluation of Polish pollen extract Catalet "C" and Catalet "D" in patients with pollinosis] Chyrek-Borowska S, et al. **Pneumonol Alergol Pol** 1995; 63 Suppl 2:19–24 (Eng. Abstr.) (Pol)
[Efficacy and tolerance of allergenic extracts Allergovit and Novo-Helisen depot in immunotherapy of allergic diseases] Chyrek-Borowska S, et al. **Pneumonol Alergol Pol** 1995; 63 Suppl 2:32–41 (Eng. Abstr.) (Pol)
[Assessment of skin reactivity in patients with bronchial asthma undergoing non-specific immunotherapy] Faber M, et al. **Pneumonol Alergol Pol** 1995;63(9–10):516–20 (Pol)
[Progress in pathophysiology and therapy of bronchial asthma] Rutkowski R, et al. **Pneumonol Alergol Pol** 1995; 63 Suppl 2:93–9 (39 ref.) (Pol)
[Specific immunotherapy in patients with bronchial asthma hypersensitive to housedust mites] Złotnik I, et al. **Pneumonol Alergol Pol** 1995;63 Suppl 2:42–51 (Eng. Abstr.) (Pol)
[Leukotrienes and their antagonists in pathogenesis and treatment of bronchial asthma (editorial)] Rogala E. **Pol Arch Med Wewn** 1995 Sep;94(3):189–94 (Pol)
[Eosinophilic reactions in patients with bronchial asthma and possibilities of their neutralization during health resort treatment] Okopnaia LM, et al. **Klin Lab Diagn** 1995 May–Jun;(3):39–40 (Eng. Abstr.) (Rus)
[A complex of breathing exercises (hatha yoga) to arrest the developing attacks of dyspnea in bronchial asthma] Maevskiĭ AA. **Klin Med (Mosk)** 1995;73(4):87–8 (Rus)
[The correlational analysis assessment of exacerbation in bronchial asthma and treatment efficacy] Anaev EKh, et al. **Ter Arkh** 1996;68(3):55–8 (Eng. Abstr.) (Rus)
[The current treatment of asthma and chronic obstructive pulmonary diseases (an international consensus on diagnosis and treatment) (news)] Eliseev OM. **Ter Arkh** 1995; 67(8):81–3 (Rus)
[The correction of biological defects in bronchial asthma patients by the methods of Chinese medicine] Fedoseev GB, et al. **Ter Arkh** 1996;68(3):52–5 (Eng. Abstr.) (Rus)
[The factors determining the late outcome in bronchial asthma: the role of the quality of medical care and of patient education] Ovcharenko SI, et al. **Ter Arkh** 1996;68(3):41–4 (Eng. Abstr.) (Rus)
[A device for managing attacks of bronchial asthma] Potapov AV, et al. **Voen Med Zh** 1995 Sep;(9):54 (Rus)
[An analysis of the acupuncture treatment results in bronchial asthma patients] Aleksandrova RA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun; (3):10–2 (Eng. Abstr.) (Rus)
[Vitamin E: immunocorrecting effect in bronchial asthma patients] Pletsityĭ KD, et al. **Vopr Med Khim** 1995 Jul–Aug; 41(4):33–6 (Eng. Abstr.) (Rus)
[Immunotherapy, clinical and bronchial response] Martín Muñoz MF. **Allergol Immunopathol (Madr)** 1996;24 Suppl 1:68–79 (Spa)
[Oral immunotherapy versus parenteral immunotherapy] Romo A, et al. **Allergol Immunopathol (Madr)** 1996;24 Suppl 1:92–103 (Spa)
[Chronic eosinophilic pneumonia and difficult to control asthma] Rubi M, et al. **An Med Interna** 1996 Apr; 13(4):188–90 (Eng. Abstr.) (Spa)
[Recommendations for education of patients with asthma] López Viña A, et al. **Arch Bronconeumol** 1996 Apr;32 Suppl 1:10–4 (Spa)
[What is brought by asthma management consensus meetings? (editorial)] Perpiñá Tordera M. **Arch Bronconeumol** 1996 Apr;32(4):162–4 (Spa)
[Immunoglobulin in the treatment of asthma] Ortíz Aldana I, et al. **Rev Alerg Mex** 1995 May–Jun;42(3):54–6 (Eng. Abstr.) (Spa)
[Effect of a care program examined. Physicians interviewed on asthma therapy] Säfwenberg U, et al. **Lakartidningen** 1996 May 1;93(18):1755–7 (Swe)

URINE

Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. Asano K, et al. **J Allergy Clin Immunol** 1995 Nov;96(5 Pt 1):643–51
Urinary leukotriene E4 in the assessment of nocturnal asthma. Bellia V, et al. **J Allergy Clin Immunol** 1996 Mar; 97(3):735–41
Urinary eosinophil protein X in children with atopic asthma: a useful marker of antiinflammatory treatment. Kristjánsson S, et al. **J Allergy Clin Immunol** 1996 Jun;97(6):1179–87
[The excretion of free cortisol in the urine in healthy children and in asthmatics treated with long-term inhaled glucocorticoids] González Pérez-Yarza E, et al. **An Esp Pediatr** 1996 Jun;44(6):531–6 (Eng. Abstr.) (Spa)

VETERINARY

Feline asthma syndrome: a retrospective study of the clinical presentation in 29 cats. Corcoran BM, et al. **J Small Anim Pract** 1995 Nov;36(11):481–8
Feline asthma syndrome. Corcoran BM, et al. **Vet Q** 1995 Apr;17 Suppl 1:S15–6 (3 ref.)

VIROLOGY

The effects of rhinovirus infections on allergic airway responses. Gern JE, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S40–5 (40 ref.)
Natural and experimental rhinovirus infections of the lower respiratory tract. Johnston SL. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S46–52 (71 ref.)
The contribution of respiratory viruses to severe exacerbations of asthma in adults [letter; comment] Ahmed AH, et al. **Chest** 1996 Feb;109(2):588. Comment on: Chest 1995 Jun;107(6):1570–4.

ASTHMA, BRONCHIAL see **ASTHMA**

ASTHMA, CARDIAC see **DYSPNEA, PAROXYSMAL**

ASTHMA, EXERCISE-INDUCED

Exercise-induced bronchospasm in children: effects and therapies. Guill M. **Pediatr Ann** 1996 Mar;25(3):146–9, 153 (29 ref.)
Exercise-induced asthma and the asthmatic athlete. Enright T. **Wis Med J** 1996 Jun;95(6):375–8

DIAGNOSIS

Vocal cord dysfunction masquerading as exercise-induced asthma. a physiologic cause for "choking" during athletic activities. McFadden ER Jr, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):942–7
Exercise-induced asthma. What family physicians should do. D'Urzo A. **Can Fam Physician** 1995 Nov;41:1900–6 (50 ref.)
Exercise-induced airway narrowing in army recruits with a history of childhood asthma. Sinclair DG, et al. **Eur Respir J** 1995 Aug;8(8):1314–7
Maximal airway narrowing on the dose-response curve to methacholine is increased after exercise-induced bronchoconstriction. Koh YY, et al. **J Asthma** 1996; 33(1):55–65
Exercised-induced asthma in the athlete [letter; comment] Randolph C. **J Asthma** 1996;33(1):73. Comment on: J Asthma 1995;32(4):249–57.
Evaluation of bronchial responsiveness to exercise in children as an objective measure of asthma in epidemiological surveys. West JV, et al. **Thorax** 1996 Jun;51(6):590–5

DRUG THERAPY

A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Ichinose M, et al. **Am J Respir Crit Care Med** 1996 Mar; 153(3):936–41
The preventive effect and duration of action of two doses of inhaled furosemide on exercise-induced asthma in children. Novembre E, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):906–9
Action of nedocromil sodium in exercise-induced asthma in adolescents. Cavallo A, et al. **J Investig Allergol Clin Immunol** 1995 Sep–Oct;5(5):286–8

EPIDEMIOLOGY

The incidence of exercise-induced bronchospasm in competitive figure skaters. Provost-Craig MA, et al. **J Asthma** 1996;33(1):67–71

ETIOLOGY

Exercise-induced asthma. Is gastroesophageal reflux a factor? Wright RA, et al. **Dig Dis Sci** 1996 May;41(5):921–5

IMMUNOLOGY

Exercise-induced bronchospasm (EIB) in relation to seasonal and perennial specific IgE in young adults. Brutsche M, et al. **Allergy** 1995 Nov;50(11):905–9

PHYSIOPATHOLOGY

Exercise- and cold-induced asthma. Giesbrecht GG, et al. **Can J Appl Physiol** 1995 Sep;20(3):300–14 (100 ref.)
Asthma in athletes. Exercise-induced bronchoconstriction in figure skaters [editorial; comment] Corrao W. **Chest** 1996 Feb;109(2):298–9. Comment on: Chest 1996 Feb;109(2):312–5.
Exercise-induced asthma in figure skaters [see comments] Mannix ET, et al. **Chest** 1996 Feb;109(2):312–5. Comment in: Chest 1996 Feb;109(2):298.
Characteristics and diagnostic significance of wheezes during exercise-induced airway obstruction in children with asthma. Rietveld S, et al. **Chest** 1996 Sep;110(3):624–31
Exercise-induced airway obstruction. McFadden ER Jr. **Clin Chest Med** 1995 Dec;16(4):671–82 (103 ref.)
Bronchial hyperresponsiveness in children and adolescents. Backer V. **Dan Med Bull** 1995 Nov;42(5):397–409
Models and mechanisms of exercise-induced asthma. Freed AN. **Eur Respir J** 1995 Oct;8(10):1770–85 (183 ref.)
Regulation of ventilatory capacity during exercise in asthmatics. Johnson BD, et al. **J Appl Physiol** 1995 Sep; 79(3):892–901
Maximal airway narrowing on the dose-response curve to methacholine is increased after exercise-induced bronchoconstriction. Koh YY, et al. **J Asthma** 1996; 33(1):55–65
Prolonged recovery from exercise-induced asthma with increasing age in childhood. Hofstra WB, et al. **Pediatr Pulmonol** 1995 Sep;20(3):177–83
Hyperventilation during exercise: independence on exercise-induced bronchoconstriction in mild asthma. Kinnula VL, et al. **Respir Med** 1996 Mar;90(3):145–51
Exercise-induced asthma and cardiovascular fitness in asthmatic children. Thio BJ, et al. **Thorax** 1996 Feb; 51(2):207–9

PREVENTION & CONTROL

Time course of the protective effect of inhaled heparin on exercise-induced asthma. Garrigo J, et al. **Am J Respir Crit Care Med** 1996 May;153(5):1702–7
Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Meltzer SS, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):931–5
Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconstriction. Schaanning J, et al. **Ann Allergy Asthma Immunol** 1996 Jan;76(1):57–60
Screening adolescent athletes for exercise-induced asthma. Feinstein RA, et al. **Clin J Sport Med** 1996 Apr;6(2):119–23
Overnight protection by inhaled salmeterol on exercise-induced asthma in children. Carlsen KH, et al. **Eur Respir J** 1995 Nov;8(11):1852–5
Cromolyn versus nedocromil: duration of action in exercise-induced asthma in children. de Benedictis FM, et al. **J Allergy Clin Immunol** 1995 Oct;96(4):510–4
The preventive effect and duration of action of two doses of inhaled furosemide on exercise-induced asthma in children. Novembre E, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 1):906–9
The protective effect of inhaled terbutaline, sodium cromoglycate and budesonide on exercise-induced asthma in children. Pichaipat V, et al. **J Med Assoc Thai** 1995 Oct;78(10):505–8
Effectiveness of nedocromil sodium in preventing exercise-induced asthma in children. Verrotti A, et al. **Panminerva Med** 1995 Dec;37(4):210–3
Exercise-induced asthma. Milgrom E. **West J Med** 1996 May; 164(5):441

ASTHMATIC CRISIS see **STATUS ASTHMATICUS**

ASTHMATIC SHOCK see **STATUS ASTHMATICUS**

ASTIGMATISM

COMPLICATIONS

Excimer laser surgery for myopia and myopic astigmatism. Hadden OB, et al. **Aust N Z J Ophthalmol** 1995 Aug; 23(3):183–8

DIAGNOSIS

Measurement of astigmatism arising from the internal ocular surfaces. Dunne MC, et al. **Acta Ophthalmol Scand** 1996 Feb;74(1):14–20
Acquired corneal asigmatism [letter] Cannava PE.

Alaska Med 1996 Apr-Jun;38(2):81
Reproducibility of corneal astigmatism measurements with a hand held keratometer in preschool children. Harvey EM, et al. **Br J Ophthalmol** 1995 Nov;79(11):983–90
Intraoperative semiquantitative keratometry using the keratoscopic astigmatic ruler. Morlet N, et al.
J Cataract Refract Surg 1995 Nov;21(6):616–9
Evaluating surgically induced astigmatism by Fourier analysis of corneal topography data. Olsen T, et al.
J Cataract Refract Surg 1996 Apr;22(3):318–23
Corneal topography for intraocular lens power calculations. Alimisi S, et al. **J Refract Surg** 1996 Feb;12(2):S309–11
Comparison of three videokeratoscopes in measurement of toric test surfaces. Greivenkamp JE, et al.
J Refract Surg 1996 Feb;12(2):229–39
[A comparison analysis on methods of astigmatism examinations for children] Shi M, et al.
Chung Hua Yen Ko Tsa Chih 1995 May;31(3):209–11 (Eng. Abstr.) **(Chi)**
[Clinical experiences with the hand-held keratometer] Wassill KH, et al. **Klin Monatsbl Augenheilkd** 1995 Aug;207(2):81–6 (Eng. Abstr.) **(Ger)**
[Relation between preoperative and late postoperative keratometry] Pont uchová E, et al. **Cesk Slov Oftalmol** 1995 Apr;51(2):83–7 (Eng. Abstr.) **(Slo)**

EPIDEMIOLOGY

Distribution of astigmatism in the adult population. McKendrick AM, et al. **J Opt Soc Am A** 1996 Feb; 13(2):206–14 (42 ref.)

ETIOLOGY

Corneal astigmatism after phacoemulsification and lens implantation through unsutured scleral and corneal tunnel incisions. Gross RH, et al. **Am J Ophthalmol** 1996 Jan; 121(1):57–64
Disciform keratitis causing severe irregular astigmatism. Anastas CN, et al. **Aust N Z J Ophthalmol** 1996 Feb; 24(1):69–70
Astigmatism analysis after radial keratotomy. Li D, et al. **Chung Hua Yen Ko Tsa Chih** 1995 May;31(3):200–2
Astigmatism and visual recovery after phacoemulsification and conventional extracapsular cataract extraction. Naus NC, et al. **Doc Ophthalmol** 1995;90(1):53–9
Astigmatic decay following small incision, self-sealing cataract surgery: one-year follow-up. Feil SH, et al.
J Cataract Refract Surg 1995 Jul;21(4):433–6
Effect of age and astigmatism on the AMO Array multifocal intraocular lens. Jacobi PC, et al.
J Cataract Refract Surg 1995 Sep;21(5):556–61
Comparison of the induced astigmatism after temporal clear corneal tunnel incisions of different sizes. Kohnen T, et al. **J Cataract Refract Surg** 1995 Jul;21(4):417–24
Long-term course of induced astigmatism after clear corneal incision cataract surgery. Pfleger T, et al.
J Cataract Refract Surg 1996 Jan-Feb;22(1):72–7
Long-term astigmatic changes after phacoemulsification with single-stitch, horizontal suture closure. Storr-Paulsen A, et al. **J Cataract Refract Surg** 1995 Jul;21(4):429–32
Effects of wound architecture and suture technique on postoperative astigmatism. Gimbel HV, et al.
Ophthalmic Surg Lasers 1995 Nov-Dec;26(6):524–8
Corneal topographic changes and induced astigmatism resulting from superior and temporal scleral pocket incisions. Kohnen T, et al. **Ophthalmic Surg Lasers** 1996 Apr;27(4):263–9
Corneal curvature changes with corneal tunnel phacoemulsification [letter; comment] Leyland MD. **Ophthalmology** 1996 Jun;103(6):867–8. Comment on: Ophthalmology 1996 Feb;103(2):226–32.
A prospective evaluation of corneal curvature changes with 3.0- to 3.5-mm corneal tunnel phacoemulsification [see comments] Long DA, et al. **Ophthalmology** 1996 Feb; 103(2):226–32. Comment in: Ophthalmology 1996 Jun;103(6):867–8.
Does a tilted retina cause astigmatism? The ocular imagery and the retinoscopic reflex resulting from a tilted retina. Flüeler UR, et al. **Surv Ophthalmol** 1995 Jul-Aug; 40(1):45–50
[Induced astigmatism in extracapsular cataract extraction with tunnel incision and various wound closures] Häberle H, et al. **Klin Monatsbl Augenheilkd** 1995 Sep;207(3):176–9 (Eng. Abstr.) **(Ger)**
[Lens astigmatism in connection with implantation of a foldable one-piece silicone lens in a patient] Spiegel D, et al. **Klin Monatsbl Augenheilkd** 1995 Sep;207(3):197–9 (Eng. Abstr.) **(Ger)**
[Corneal astigmatism after refraction keratotomy] Alekseev IB. **Vestn Oftalmol** 1996 Jan-Mar;112(1):13–5 (Eng. Abstr.) **(Rus)**
[Principal factors affecting postoperative astigmatism after cataract extraction] Naim Dzheries Dzhadalla Kalkikh. **Vestn Oftalmol** 1995 Jul-Sep;111(3):34–6 (49 ref.) **(Rus)**

PATHOLOGY

Height measurement of astigmatic test surfaces by a keratoscope that uses plane geometry surface reconstruction. Tripoli NK, et al. **Am J Ophthalmol** 1996 Jun;121(6):668–76
The effect of trephination on corneal topography. Greenfield DS, et al. **Ophthalmic Surg Lasers** 1995 Nov-Dec; 26(6):560–7
Corneal topography and irregular astigmatism. Raasch TW. **Optom Vis Sci** 1995 Nov;72(11):809–15
[Early corneal topographic changes after intraocular lens implantation] Liu Y, et al.
Chung Hua Yen Ko Tsa Chih 1996 Jan;32(1):29–31 (Eng. Abstr.) **(Chi)**
[Changes in bulbus geometry after conventional detachment surgery. Study using video keratoscopy] Müller-Albach KA, et al. **Ophthalmologe** 1995 Oct;92(5):677–80 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Astigmatic and refractive stabilization after cataract surgery. Oshika T, et al. **Ophthalmic Surg** 1995 Jul-Aug; 26(4):309–15
Clinical and surgical factors influencing corneal graft survival, visual acuity, and astigmatism. Corneal Transplant Follow-up Study Collaborators. Vail A, et al.
Ophthalmology 1996 Jan;103(1):41–9
Does a tilted retina cause astigmatism? The ocular imagery and the retinoscopic reflex resulting from a tilted retina. Flüeler UR, et al. **Surv Ophthalmol** 1995 Jul-Aug; 40(1):45–50

PREVENTION & CONTROL

Modified scleral flap incision to reduce corneal astigmatism after intraocular lens implantation. Liu Y, et al.
Yen Ko Hsueh Pao 1995 Sep;11(3):136–9

REHABILITATION

Collaborative visual rehabilitation: high astigmatism, esotropia and elevator palsy. Arnold RW, et al.
Alaska Med 1995 Jul-Sep;37(3):88–90

SURGERY

Analysis of astigmatic keratotomy with a 5.0-mm optical clear zone [see comments] Chavez S, et al.
Am J Ophthalmol 1996 Jan;121(1):65–76. Comment in: Am J Ophthalmol 1996 Jun;121(6):731–2.
Analysis of astigmatic keratotomy with a 5.0-mm optical clear zone [letter; comment] Gills JP, et al.
Am J Ophthalmol 1996 Jun;121(6):731–2. Comment on: Am J Ophthalmol 1996 Jan;121(1):65–76.
Comparison of results of excimer laser correction of all degrees of myopia at 12 months postoperatively. The Melbourne Excimer Laser Group. McCarty CA, et al.
Am J Ophthalmol 1996 Apr;121(4):372–83
Astigmatic keratotomy combined with myopic keratomileusis in situ for compound myopic astigmatism. Manche EE, et al. **Am J Ophthalmol** 1996 Jul;122(1):18–28
Retreatment after excimer laser photorefractive keratectomy. The Melbourne Excimer Laser Group. Snibson GR, et al.
Am J Ophthalmol 1996 Mar;121(3):250–7
Bacterial ulcer 3 days after excimer laser phototherapeutic keratectomy. Fulton JC, et al. **Arch Ophthalmol** 1996 May; 114(5):626–7
Astigmatism Reduction Clinical Trial [letter; comment] Glasser DB. **Arch Ophthalmol** 1995 Oct;113(10):1226. Comment on: Arch Ophthalmol 1995 Mar;113(3):277–82.
Clinical analysis of steep central islands after excimer laser photorefractive keratectomy. Krueger RR, et al.
Arch Ophthalmol 1996 Apr;114(4):377–81
Overcorrection after excimer laser treatment of myopia and myopic astigmatism. Melbourne Excimer Laser Group [see comments] Vajpayee RB, et al. **Arch Ophthalmol** 1996 Mar; 114(3):252–6. Comment in: Arch Ophthalmol 1996 Mar;114(3):338–9.
Excimer laser surgery for myopia and myopic astigmatism. Hadden OB, et al. **Aust N Z J Ophthalmol** 1995 Aug; 23(3):183–8
Consultation section. A 73-year-old male with uncomplicated phacoemulsification in his right eye.
J Cataract Refract Surg 1995 Sep;21(5):489–92
Correcting simple myopic astigmatism with the excimer laser. Alió JL, et al. **J Cataract Refract Surg** 1995 Sep;21(5):512–5
Excimer laser correction of high astigmatism after keratoplasty. Amm M, et al. **J Cataract Refract Surg** 1996 Apr;22(3):313–7
Transverse keratotomy to correct high corneal astigmatism after cataract surgery. Güell JL, et al.
J Cataract Refract Surg 1996 Apr;22(3):331–6
Arcuate keratotomy for cataract surgery and astigmatism [letter; comment] Masket S. **J Cataract Refract Surg** 1995 Nov;21(6):597–8. Comment on: J Cataract Refract Surg 1995 May;21(3):274–7.
Excimer laser photorefractive keratectomy using an erodible mask to treat myopic astigmatism. Niles C, et al.
J Cataract Refract Surg 1996 May;22(4):436–40
Transverse incisions for mixed and myopic idiopathic astigmatism. Pulaski JP. **J Cataract Refract Surg** 1996 Apr; 22(3):307–12
Centration of excimer laser photorefractive keratectomy and changes in astigmatism. Aktunç R, et al. **J Refract Surg** 1996 Feb;12(2):S268–71
Combined wedge resection and relaxing incisions for astigmatism after penetrating keratoplasty. Belmont SC, et al. **J Refract Surg** 1995 Nov-Dec;11(6):472–6
Holmium: YAG laser to treat astigmatism associated with myopia or hyperopia. Cherry PM. **J Refract Surg** 1995 May-Jun;11(3 Suppl):S349–57
Cognitive styles and personality characteristics strongly influence the decision to have photorefractive keratectomy. Erickson DB, et al. **J Refract Surg** 1995 Jul-Aug; 11(4):267–74; discussion 274–81
Photorefractive keratectomy for myopic astigmatism using the emphasis erodible mask. Spanish User Group. Gomez de Liano MZ, et al. **J Refract Surg** 1995 May-Jun;11(3 Suppl):S343–8
Holmium:YAG laser thermokeratoplasty for correction of astigmatism. Hennekes R. **J Refract Surg** 1995 May-Jun; 11(3 Suppl):S358–60
Early results of photorefractive keratectomy for myopic astigmatism. Kaskaloglu M. **J Refract Surg** 1996 Feb; 12(2):S258–60
Corneal topography, arcuate keratotomy, and compression sutures for astigmatism after penetrating keratoplasty. Koffler BH, et al. **J Refract Surg** 1996 Feb;12(2):S306–9
The effect of spherical photorefractive keratectomy on myopic astigmatism. Loewenstein A, et al.
J Refract Surg 1995 May-Jun;11(3 Suppl):S263–4
Arcuate transverse keratotomy with a mechanical arcutome based on videokeratography. Pallikaris IG, et al.
J Refract Surg 1996 Feb;12(2):S296–9
Astigmatism and straight transverse corneal incisions [letter; comment] Sabates M, et al. **J Refract Surg** 1995 Jul-Aug; 11(4):305–6. Comment on: J Refract Corneal Surg 1994 May-Jun;10(3):327–32.
Treatment of astigmatism associated with myopia or hyperopia with the holmium laser: second year follow-up. Cherry PM. **Ophthalmic Surg Lasers** 1996 May;27(5 Suppl):S493–8
One year follow-up of photoastigmatic keratectomy (PARK) with the VISX 20/20 excimer laser. Hamberg-Nyström H, et al. **Ophthalmic Surg Lasers** 1996 May;27(5 Suppl):S499–502
One-year follow-up results of photorefractive keratectomy for low, moderate, and high primary astigmatism. Kremer I, et al. **Ophthalmology** 1996 May;103(5):741–8
Excimer laser keratectomy for astigmatism occurring after penetrating keratoplasty. Lazzaro DR, et al.
Ophthalmology 1996 Mar;103(3):458–64
[Evaluating vision after photorefractive keratectomy within the scope of legal police service requirement 300] Bodanowitz S, et al. **Klin Monatsbl Augenheilkd** 1995 Sep; 207(3):203–5 (Eng. Abstr.) **(Ger)**
[Curved lamellar keratotomy for correction of astigmatism. Experimental and initial clinical results] Anders N, et al. **Ophthalmologe** 1996 Jun;93(3):279–83 (Eng. Abstr.) **(Ger)**
[Long-term stability of astigmatism after suture correction in penetrating keratoplasty] Heider W, et al.
Ophthalmologe 1995 Aug;92(4):433–8 (Eng. Abstr.) **(Ger)**
[Excimer laser refractive surgery] Arosemena A, et al.
Rev Med Panama 1995 Sep;20(3):79–83 (Eng. Abstr.) **(Spa)**

THERAPY

Contact lens fitting after photorefractive keratectomy. Astin CL, et al. **Br J Ophthalmol** 1996 Jul;80(7):597–603
Thickness extrema at the edge of astigmatic lenses including those with straight, circular and elliptical edges. Harris WF. **Ophthalmic Physiol Opt** 1996 Mar;16(2):163–70
Predicting success with orthokeratology lens wear: a retrospective analysis of ocular characteristics. Carkeet NL, et al. **Optom Vis Sci** 1995 Dec;72(12):892–8

ASTRAGALUS see **TALUS**

ASTRINGENTS

PHARMACOLOGY

Tannin inhibition of protein kinase C in airway epithelium. Cloutier MM, et al. **Lung** 1995;173(5):307–19
Protection by baicalein against ascorbic acid-induced lipid peroxidation of rat liver microsomes. Gao D, et al.
Res Commun Mol Pathol Pharmacol 1995 Oct;90(1):103–14

THERAPEUTIC USE

[Frey's syndrome: physiopathology and medical therapy] Celoria G, et al. **Minerva Chir** 1995 Nov;50(11):1025–7 (Eng. Abstr.) **(Ita)**

ASTROBIOLOGY see **EXOBIOLOGY**

ASTROCYTES

see related
BLOOD-BRAIN BARRIER

CHEMISTRY

Localization of the Na(+)-Ca2+ exchanger in vascular smooth muscle, and in neurons and astrocytes. Juhaszova M, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:318–35 (31 ref.)
A novel P2-purinoceptor expressed by a subpopulation of astrocytes from the dorsal spinal cord of the rat. Ho C, et al. **Br J Pharmacol** 1995 Dec;116(7):2909–18
Corticotropin releasing factor binding protein (CRF-BP) is expressed in neuronal and astrocytic cells. Behan DP, et

al. **Brain Res** 1995 Nov 6;698(1-2):259-64
Colocalization of fructose-1,6-bisphosphatase and glial fibrillary acidic protein in rat brain. Schmoll D, et al. **Brain Res** 1995 Apr 24;677(2):341-4
Molecular environment of ZO-1 in epithelial and non-epithelial cells. Howarth AG, et al. **Cell Motil Cytoskeleton** 1995;31(4):323-32
Immunocytochemical characterization of a new marker of fibrous and reactive astrocytes. Ridet JL, et al. **Cell Tissue Res** 1996 Jan;283(1):39-49
Structural analysis of a human glial variant laminin. LeMosy EK, et al. **Exp Cell Res** 1996 Aug 25;227(1):80-8
Expression of synaptobrevin II, cellubrevin and syntaxin but not SNAP-25 in cultured astrocytes. Parpura V, et al. **FEBS Lett** 1995 Dec 27;377(3):489-92
Spatio-temporal pattern of proliferation of immunoglobulin G-containing astrocytes in the injured mouse cerebral hemisphere. Janeczko K. **Folia Histochem Cytobiol** 1995; 33(3):143-9
Chondroitin sulfate proteoglycan staining in astrocyte-Schwann cell co-cultures. Ghirnikar RS, et al. **Glia** 1995 Jun;14(2):145-52
Expression and function of membrane regulators of complement on rat astrocytes in culture. Rogers CA, et al. **Immunology** 1996 May;88(1):153-61
Platelet-derived growth factor receptors of mouse central nervous system cells in vitro. Hutchins JB. **J Comp Neurol** 1995 Sep 11;360(1):59-80
Identification and characterization of complement C3 receptors on human astrocytes. Gasque P, et al. **J Immunol** 1996 Mar 15;156(6):2247-55
Coupling of astroglial alpha 2-adrenoreceptors to second messenger pathways. Enkvist MO, et al. **J Neurochem** 1996 Jun;66(6):2394-401
Characterization of inhibitor-sensitive and -resistant adenosine transporters in cultured human fetal astrocytes. Gu JG, et al. **J Neurochem** 1996 Sep;67(3):972-7
Reactions of astrocytes and microglial cells around hematogenous metastases of the human brain. Expression of endothelin-like immunoreactivity in reactive astrocytes and activation of microglial cells. Zhang M, et al. **J Neurol Sci** 1995 Dec;134(1-2):26-32
A monoclonal antibody that specifically recognizes a novel mitochondrial protein of human astrocytes. Yokoo H, et al. **J Neuropathol Exp Neurol** 1996 Jun;55(6):716-21
S-100 immunoreactivity in rat brain glial cultures is associated with both astrocytes and oligodendrocytes. Richter-Landsberg C, et al. **J Neurosci Res** 1995 Dec; 42(5):657-65
Reactive astrocytes express substance-P immunoreactivity in the adult forebrain after injury. Lin RC. **Neuroreport** 1995 Dec 29;7(1):310-2
Immunoreactivity for apolipoprotein A-IV in tanycytes and astrocytes of rat brain. Fukagawa K, et al. **Neurosci Lett** 1995 Oct 13;199(1):17-20
A novel serpin-like protein, B-43, exists in both neurons and astrocytes: an immunohistochemical study in the parietal region of the bovine brain. Nishibori M, et al. **Neurosci Lett** 1995 Nov 17;200(2):125-8

CYTOLOGY

Growth and cytopathic effect of Japanese encephalitis virus in astrocyte-enriched cell cultures from neonatal mouse brains. Suri NK, et al. **Acta Virol** 1995 Jun;39(3):143-8
Regulation of astrocyte cell biology by the cAMP/protein kinase A signaling pathway. Huneycutt BS, et al. **Adv Neuroimmunol** 1995;5(3):261-9 (45 ref.)
Age-induced hypertrophy of astrocytes in rat supraoptic nucleus: a cytological, morphometric, and immunocytochemical study. Berciano MT, et al. **Anat Rec** 1995 Sep;243(1):129-44
Astrocytic volume fluctuates in the hippocampal CA1 region across the estrous cycle. Klintsova A, et al. **Brain Res** 1995 Sep 4;690(2):269-74
Gap junctions couple astrocytes but not neurons in dissociated cultures of rat suprachiasmatic nucleus. Welsh DK, et al. **Brain Res** 1996 Jan 8;706(1):30-6
Effects of leukemia inhibitory factor on the differentiation of astrocyte progenitor cells from embryonic mouse cerebral hemispheres. Nakagaito Y, et al. **Brain Res Dev Brain Res** 1995 Jul 14;87(2):220-3
Morphological differentiation of astroglial progenitor cells from EGF-responsive neurospheres in response to fetal calf serum, basic fibroblast growth factor, and retinol. Chiang YH, et al. **Cell Transplant** 1996 Mar-Apr; 5(2):179-89
Migration of oligodendrocyte precursors on astrocytes and meningeal cells. Fok-Seang J, et al. **Dev Biol** 1995 Sep; 171(1):1-15
Acetylcholine as a mitogen: muscarinic receptor-mediated proliferation of rat astrocytes and human astrocytoma cells. Guizzetti M, et al. **Eur J Pharmacol** 1996 Feb 22; 297(3):265-73
From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte-type-2 astrocyte lineage. Noble M, et al. **Glia** 1995 Nov;15(3):222-30 (63 ref.)
Astrocyte survival in the absence of exogenous substrate: comparison of immature and mature cells. Hertz L, et al. **Int J Dev Neurosci** 1995 Oct;13(6):523-7
Cocultures of meningeal and astrocytic cells--a model for the formation of the glial-limiting membrane. Struckhoff G. **Int J Dev Neurosci** 1995 Oct;13(6):595-606
Egr-1 activates basic fibroblast growth factor transcription. Mechanistic implications for astrocyte proliferation. Biesiada E, et al. **J Biol Chem** 1996 Aug 2;271(31):18576-81
Involvement of wound-associated factors in rat brain astrocyte migratory response to axonal injury: in vitro simulation. Faber-Elman A, et al. **J Clin Invest** 1996 Jan 1;97(1):162-71
Heterogeneity of astrocytes in human optic nerve head. Ye H, et al. **J Comp Neurol** 1995 Nov 27;362(4):441-52
Fatty acid composition of brain capillary endothelial cells: effect of the coculture with astrocytes. Bénistant C, et al. **J Lipid Res** 1995 Nov;36(11):2311-9
Membrane deformation of living glial cells using atomic force microscopy. Haydon PG, et al. **J Microsc** 1996 May;182 (Pt 2):114-20
Thrombin attenuates neuronal cell death and modulates astrocyte reactivity induced by beta-amyloid in vitro. Pike CJ, et al. **J Neurochem** 1996 Apr;66(4):1374-82
AMPA receptor activation is rapidly toxic to cortical astrocytes when desensitization is blocked. David JC, et al. **J Neurosci** 1996 Jan;16(1):200-9
Adaptation of C6 glioma cells to serum-free conditions leads to the expression of a mixed astrocyte-oligodendrocyte phenotype and increased production of neurite-promoting activity. Coyle DE. **J Neurosci Res** 1995 Jun 15; 41(3):374-85
Differentiation of serum-free mouse embryo cells into astrocytes is accompanied by induction of glutamine synthetase activity. Loo DT, et al. **J Neurosci Res** 1995 Oct 1;42(2):184-91
Preparation and use of cultured astrocytes for assay of gliotoxicity. Cookson MR, et al. **Methods Mol Biol** 1995; 43:17-23
Ultrastructural evidence for increased contact between astrocytes and synapses in rats reared in a complex environment. Jones TA, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):48-56
Glial fibrillary acidic protein (GFAP) immunohistochemistry in human cortex: a quantitative study using different antisera. Halliday GM, et al. **Neurosci Lett** 1996 May 3; 209(1):29-32
Lineage specification of neuronal precursors in the mouse spinal cord. Richards LJ, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24;92(22):10079-83
Immunohistochemical study of human optic nerve head astroglia. Triviño A, et al. **Vision Res** 1996 Jul; 36(14):2015-28

DRUG EFFECTS

Influence of chronic alcohol treatment on the GFAP-immunoreactivity in astrocytes of the hippocampus in rats. Franke H. **Acta Histochem** 1995 Jul;97(3):263-71
Trimethyltin-induced plastic neuronal changes in rat hippocampus are accompanied by astrocytic trophic activity. Koczyk D, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):237-41
Inhibition of vanadate-induced astrocytic stress fiber formation by C3 ADP-ribosyltransferase. Koyama Y, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):331-6
Effect of glucose deprivation on rat glutamine synthetase in cultured astrocytes. Rosier F, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):607-12
Differential induction of the mitogen-activated protein kinase pathway by bacterial lipopolysaccharide in cultured monocytes and astrocytes. Willis SA, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):519-24
Effects of aluminum(III) on catechol-stimulated nerve growth factor biosynthesis by cultured mouse brain astroglial cells. Kobayashi D, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):675-84
Rapid regulation of a cyclic AMP-specific phosphodiesterase (PDE IV) by forskolin and isoproterenol in LRM55 astroglial cells. Madelian V, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1739-47
Sustained activation of NF kappa B and transient I kappa B alpha degradation induced by tumour necrosis factor in 1321N1 human astrocytoma. O'Neill LA, et al. **Biochem Soc Trans** 1995 Nov;23(4):597S
Inhibitory effect of ginseng total saponins on glutamate-induced swelling of cultured astrocytes. Seong YH, et al. **Biol Pharm Bull** 1995 Dec;18(12):1776-8
Adenosine modulates methylmercuric chloride (MeHgCl)-induced D-aspartate release from neonatal rat primary astrocyte cultures. Aschner M, et al. **Brain Res** 1995 Aug 14;689(1):1-8
Monoamine oxidase B expression is selectively regulated by dexamethasone in cultured rat astrocytes. Carlo P, et al. **Brain Res** 1996 Mar 4;711(1-2):175-83
Inhibition of noradrenaline stimulated increase in [Ca2+]i in cultured astrocytes by chronic treatment with a therapeutically relevant lithium concentration. Chen Y, et al. **Brain Res** 1996 Mar 4;711(1-2):245-8
Cellular responses of cultured cerebellar astrocytes to ethacrynic acid-induced perturbation of subcellular glutathione homeostasis. Huang J, et al. **Brain Res** 1996 Mar 4;711(1-2):184-92
Oligodendroglial precursor cell susceptibility to hypoxia is related to poor ability to cope with reactive oxygen species. Husain J, et al. **Brain Res** 1995 Nov 6;698(1-2):86-94
CNTF regulation of astrogliosis and the activation of microglia in the developing rat central nervous system. Kahn MA, et al. **Brain Res** 1995 Jul 10;685(1-2):55-67
Astroglia proliferate in response to oxytocin and vasopressin. Lucas RL, et al. **Brain Res** 1995 May 29;681(1-2):218-22
Effect of progesterone, testosterone and their 5 alpha-reduced metabolites on GFAP gene expression in type 1 astrocytes. Melcangi RC, et al. **Brain Res** 1996 Mar 4;711(1-2):10-5
Differential regulation of phospholipases C and D by phorbol esters and the physiological activators carbachol and glutamate in astrocytes from chicken embryo cerebrum and cerebellum. Mangoura D, et al. **Brain Res Dev Brain Res** 1995 Jun 27;87(1):12-21
Differential effects of cysteamine on heat shock protein induction and cytoplasmic granulation in astrocytes and glioma cells. Chopra VS, et al. **Brain Res Mol Brain Res** 1995 Jul;31(1-2):173-84
Astrocytes and microglia as potential targets for calcitonin gene related peptide in the central nervous system. Reddington M, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):1047-9 (18 ref.)
Wild-type p53 renders mouse astrocytes resistant to 1,3-Bis(2-chloroethyl)-1-nitrosourea despite the absent of a p53-dependent cell cycle arrest. Nutt CL, et al. **Cancer Res** 1996 Jun 15;56(12):2748-51
The 21-aminosteroid U-74389F increases the number of glial fibrillary acidic protein-expressing astrocytes in the spinal cord of control and Wobbler mice. Gonzalez Deniselle MC, et al. **Cell Mol Neurobiol** 1996 Feb;16(1):61-72
Long-term induction of an aldose reductase protein by basic fibroblast growth factor in rat astrocytes in vitro. Laeng P, et al. **Electrophoresis** 1995 Jul;16(7):1240-50
The coat protein gp120 of HIV-1 inhibits astrocyte uptake of excitatory amino acids via macrophage arachidonic acid. Dreyer EB, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2502-7
IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage. Fattori E, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2441-9
Leukaemia inhibitory factor or related factors promote the differentiation of neuronal and astrocytic precursors within the developing murine spinal cord. Richards LJ, et al. **Eur J Neurosci** 1996 Feb;8(2):291-9
Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes. Sapena R, et al. **Eur J Pharmacol** 1996 Apr 4;300(1-2):159-62
Pentobarbitone induces Fos in astrocytes: increased expression following picrotoxin and seizures. Hiscock JJ, et al. **Exp Neurol** 1996 May;139(1):115-20
Vitronectin overrides a negative effect of TNF-alpha on astrocyte migration. Faber-Elman A, et al. **FASEB J** 1995 Dec;9(15):1605-13
Transduction signals induced in rat brain cortex astrocytes by the HIV-1 gp120 glycoprotein. Codazzi F, et al. **FEBS Lett** 1996 Apr 15;384(2):135-7
Redox perturbations in cysteamine-stressed astroglia: implications for inclusion formation and gliosis in the aging brain. Manganaro F, et al. **Free Radic Biol Med** 1995 Dec; 19(6):823-35
Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells derived from adult rat spinal cord: in vitro characteristics and response to PDGF, bFGF and NT-3. Engel U, et al. **Glia** 1996 Jan;16(1):16-26
Granulocyte macrophage colony stimulating factor stimulates in vitro proliferation of astrocytes derived from simian mature brains. Guillemin G, et al. **Glia** 1996 Jan; 16(1):71-80
Selective ablation of astrocytes by intracerebral injections of alpha-aminoadipate. Khurgel M, et al. **Glia** 1996 Apr; 16(4):351-8
Modulation of expression of genes involved in the inflammatory response by lipopolysaccharide and temperature in cultured human astroglial cells. Kimberlin DW, et al. **Immunol Invest** 1995 Aug;24(5):775-85
Histamine-sensitive 86Rb transport in cultured type-2 astrocytes of rat brain. Huszti Z, et al. **Inflamm Res** 1995 Apr;44 Suppl 1:S46-7
Effects of ATP analogues and basic fibroblast growth factor on astroglial cell differentiation in primary cultures of rat striatum. Abbracchio MP, et al. **Int J Dev Neurosci** 1995 Nov;13(7):685-93
S100 beta stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. Hu J, et al. **J Biol Chem** 1996 Feb 2;271(5):2543-7
Thrombin activates mitogen-activated protein kinase in primary astrocyte cultures. Bhat NR, et al. **J Cell Physiol** 1995 Nov;165(2):417-24
Protein synthesis-dependent induction of interleukin-1 beta by lipopolysaccharide is inhibited by dexamethasone via mRNA destabilization in human astroglial cells. Kimberlin DW, et al. **J Clin Immunol** 1995 Jul;15(4):199-204
Stat1 alpha expression is involved in IFN-gamma induction of the class II transactivator and class II MHC genes. Lee YJ, et al. **J Immunol** 1996 Aug 15;157(4):1559-68
Amyloid beta peptide (25-35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures. Harris ME, et al. **J Neurochem** 1996 Jul;67(1):277-86
Potassium-induced stimulation of glutamate uptake in mouse cerebral astrocytes: the role of intracellular pH. Judd MG, et al. **J Neurochem** 1996 Jan;66(1):169-76
Staurosporine induces astrocytic phenotypes and differential expression of specific PKC isoforms in C6 glial cells. Kronfeld I, et al. **J Neurochem** 1995 Oct;65(4):1505-14

Involvement of Na+,K(+)ATPase in the mitogenic effect of insulin-like growth factor-I on cultured rat astrocytes. Matsuda T, et al. **J Neurochem** 1996 Feb;66(2):511-6

Ethanol increases cytochrome P4502E1 and induces oxidative stress in astrocytes. Montoliu C, et al. **J Neurochem** 1995 Dec;65(6):2561-70

Metallothionein induction in neonatal rat primary astrocyte cultures protects against methylmercury cytotoxicity. Rising L, et al. **J Neurochem** 1995 Oct;65(4):1562-8

Interleukin-1 beta-mediated regulation of mu-opioid receptor mRNA in primary astrocyte-enriched cultures. Ruzicka BB, et al. **J Neurochem** 1996 Jan;66(1):425-8

Attenuation of astroglial reactivity by interleukin-10. Balasingam V, et al. **J Neurosci** 1996 May 1;16(9):2945-55

Vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, and noradrenaline induce the transcription factors CCAAT/enhancer binding protein (C/EBP)-beta and C/EBP delta in mouse cortical astrocytes: involvement in cAMP-regulated glycogen metabolism. Cardinaux JR, et al. **J Neurosci** 1996 Feb 1; 16(3):919-29

Changes in neurotrophic factor expression and receptor activation following exposure of hippocampal neuron/astrocyte cocultures to kainic acid. Rudge JS, et al. **J Neurosci** 1995 Oct;15(10):6856-67

Noradrenaline-induced stimulation of glutamine metabolism in primary cultures of astrocytes. Huang R, et al. **J Neurosci Res** 1995 Aug 1;41(5):677-83

Thyroid hormone and conditioned medium effects on astroglial cells from hypothyroid and normal rat brain: factor secretion, cell differentiation, and proliferation. Trentin AG, et al. **J Neurosci Res** 1995 Jun 15;41(3):409-17

Regulation of corticotropin-releasing factor-binding protein expression in cultured rat astrocytes. Maciejewski D, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):455-61

The mechanism of cytoprotective action of lazaroids I: Inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion. Taylor BM, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1224-31

Nordihydroguaiaretic acid and RHC 80267 potentiate astroglial injury during combined glucose-oxygen deprivation. Haun SE, et al. **Mol Chem Neuropathol** 1995 May;25(1):35-49

Inhibition by Cl- channel blockers of the volume-activated, diffusional mechanism of inositol transport in primary astrocytes in culture. González E, et al. **Neurochem Res** 1995 Aug;20(8):895-900

Effects of exogenous linoleic acid on fatty acid composition, receptor-mediated cAMP formation, and transport functions in rat astrocytes in primary culture. Murphy MG. **Neurochem Res** 1995 Nov;20(11):1365-75

Astrocyte differentiation is enhanced in chick embryos treated with ethanol during early neuroembryogenesis. Srivastava N, et al. **Neurochem Res** 1995 Sep;20(9):985-9

Expression of the neurofibromatosis 1 (NF1) gene in reactive astrocytes in vitro. Hewett SJ, et al. **Neuroreport** 1995 Jul 31;6(11):1565-8

Inhibition by dihydropyridines of regulatory volume decrease and osmolyte fluxes in cultured astrocytes is unrelated to extracellular calcium. Sánchez-Olea R, et al. **Neurosci Lett** 1995 Jul 7;193(3):165-8

Pharmacological characteristics of potassium-induced, glycogenolysis in astrocytes. Subbarao KV, et al. **Neurosci Lett** 1995 Aug 18;196(1-2):45-8

Differential activation of microglia and astrocytes following trimethyl tin-induced neurodegeneration. McCann MJ, et al. **Neuroscience** 1996 May;72(1):273-81

Prolonged lead exposure modifies astrocyte cytoskeletal proteins in the rat brain. Selvín-Testa A, et al. **Neurotoxicology** 1995 Fall;16(3):389-401

Stimulation of phospholipase A2 expression in rat cultured astrocytes by LPS, TNF alpha and IL-1 beta. Sun GY, et al. **Prog Brain Res** 1995;105:231-8 (27 ref.)

Effects of protein kinase C activation on prostaglandin production and cyclooxygenase mRNA levels in ovine astroglia. Nam MJ, et al. **Prostaglandins** 1996 Mar; 51(3):203-13

Re-evaluation of GABA transport in neuronal and glial cell cultures: correlation of pharmacology and mRNA localization. Borden LA, et al. **Receptors Channels** 1995; 3(2):129-46

The effects of diethyldithiocarbamate (DDC) on the astrocytic cytoskeleton. McManus MF, et al. **Scanning Microsc** 1995 Mar;9(1):257-69; discussion 269-70

Induction of metallothionein mRNA and protein in murine astrocyte cultures. Kramer KK, et al. **Toxicol Appl Pharmacol** 1996 Jan;136(1):94-100

An in vitro study of m-dinitrobenzene toxicity on the cellular components of the blood-brain barrier, astrocytes and endothelial cells. Romero IA, et al. **Toxicol Appl Pharmacol** 1996 Jul;139(1):94-101

ENZYMOLOGY

Effect of glucose deprivation on rat glutamine synthetase in cultured astrocytes. Rosier F, et al. **Biochem J** 1996 Apr 15;315 (Pt 2):607-12

Astrocytes synthesize and secrete prostaglandin D synthetase in vitro. Giacomelli S, et al. **Biochim Biophys Acta** 1996 Feb 29;1310(3):269-76

Involvement of tyrosine phosphorylation in the regulation of 5'-deiodinases in FRTL-5 rat thyroid cells and rat astrocytes. Mori K, et al. **Endocrinology** 1996 Apr; 137(4):1313-8

Evidence that type III iodothyronine deiodinase in rat astrocyte is a selenoprotein. Ramauge M, et al. **Endocrinology** 1996 Jul;137(7):3021-5

beta-Amyloid increases enzyme activity and protein levels of glutamine synthetase in cultured astrocytes. Pike CJ, et al. **Exp Neurol** 1996 May;139(1):167-71

Evidence for cyclooxygenase activation by nitric oxide in astrocytes. Molina-Holgado F, et al. **Glia** 1995 Oct; 15(2):167-72

Cytokine-induced expression of type II nitric oxide synthase in astrocytes is downregulated by ATP and glutamate. Murphy S, et al. **Glia** 1995 Sep;15(1):77-82

Degradation and recycling of the substrate-binding subunit of type II iodothyronine 5'-deiodinase in astrocytes. Farwell AP, et al. **J Biol Chem** 1996 Jul 5;271(27):16369-74

Heat shock protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by decreasing NFkappaB activation. Feinstein DL, et al. **J Biol Chem** 1996 Jul 26; 271(30):17724-32

Catalytic activity of type II iodothyronine 5'-deiodinase polypeptide is dependent upon a cyclic AMP activation factor. Safran M, et al. **J Biol Chem** 1996 Jul 5; 271(27):16363-8

Thrombin activates mitogen-activated protein kinase in primary astrocyte cultures. Bhat NR, et al. **J Cell Physiol** 1995 Nov;165(2):417-24

Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. Deb S, et al. **J Neurochem** 1996 Apr;66(4):1641-7

Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. O'Banion MK, et al. **J Neurochem** 1996 Jun;66(6):2532-40

CD14 mediate endotoxin induction of nitric oxide synthase in cultured brain glial cells. Galea E, et al. **J Neuroimmunol** 1996 Jan;64(1):19-28

Murine encephalitogenic lymphoid cells induce nitric oxide synthase in primary astrocytes. Hewett SJ, et al. **J Neuroimmunol** 1996 Feb;64(2):201-8

Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation. Baltuch GH, et al. **J Neurooncol** 1995;24(3):241-50

Ethanol enhances the in situ phosphorylation of MARCKS and protein kinase C activity in primary cultures of astrocytes. Smith TL, et al. **Life Sci** 1996;58(10):855-60

Astrocyte membrane Na+, K(+)-ATPase and Mg(2+)-ATPase as targets of organic solvent impact. Vaalavirta L, et al. **Life Sci** 1995;57(24):2223-30

Stimulation of group II phospholipase A2 mRNA expression and release in an immortalized astrocyte cell line (DITNC) by LPS, TNF alpha, and IL-1 beta. Interactive effects. Tong W, et al. **Mol Chem Neuropathol** 1995 May;25(1):1-17

Regulation of mitochondrial and cytosolic malic enzymes from cultured rat brain astrocytes. McKenna MC, et al. **Neurochem Res** 1995 Dec;20(12):1491-501

Regulation of fructose-1,6-bisphosphatase activity in primary cultured astrocytes. Vergé V, et al. **Neurochem Res** 1995 Sep;20(9):1049-56

Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Alkayed NJ, et al. **Stroke** 1996 May;27(5):971-9

IMMUNOLOGY

A monoclonal antibody that recognizes a carbohydrate epitope of human protoplasmic astrocytes. Yokoo H, et al. **Acta Neuropathol (Berl)** 1996;91(1):23-30

Antigen presentation by astrocytes primes rat T lymphocytes for apoptotic cell death. A model for T-cell apoptosis in vivo. Gold R, et al. **Brain** 1996 Apr;119 (Pt 2):651-9

T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture. Satoh J, et al. **Brain Res** 1995 Dec 15;704(1):92-6

Optimal preservation of the J1-31 antigen in astroglia examined by immunogold labelling. Bhatnagar R, et al. **Cytobios** 1995;82(331):239-49

Neuro-glial-immune interactions. An experimental, neural transplant and lesion study. Finsen B. **Dan Med Bull** 1995 Sep;42(4):323-41 (192 ref.)

Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. Glabinski AR, et al. **J Immunol** 1996 Jun 1;156(11):4363-8

Immunization-induced inflammatory infiltration of the central nervous system in transgenic mice expressing a microbial antigen in astrocytes. Borrow P, et al. **J Neuroimmunol** 1995 Sep;61(2):133-49

Proliferating cell nuclear antigen immunohistochemistry in astrocytes in experimental Creutzfeldt-Jakob disease and in human kuru, Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker syndrome. Biernat W, et al. **Neurodegeneration** 1995 Jun;4(2):195-201

Grumose or foamy spheroid bodies involving astrocytes in the human brain. Arai N. **Neuropathol Appl Neurobiol** 1995 Jun;21(3):238-45 (27 ref.)

METABOLISM

Astroglial localization of cholesteryl ester transfer protein in normal and Alzheimer's disease brain tissues. Yamada T, et al. **Acta Neuropathol (Berl)** 1995;90(6):633-6

Neurone-astrocyte interaction. Inhibitory influence of neurones on astrocytic oxytocin receptor expression. Di Scala-Guenot D, et al. **Adv Exp Med Biol** 1995;395:349-50

Protein kinase C modulates natriuretic peptide receptors in astroglial cultures from rat brain. Paulding WR, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C740-7

Neurotransmitter imaging in living cells based on native fluorescence detection. Tan W, et al. **Anal Chem** 1995 Aug 1;67(15):2575-9

Comparison of glutamine-enhanced glutamate release from slices and primary cultures of rat brain. Bowyer JF, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:72-85; discussion 98-9

NMDA-dependent prostaglandin E2 release by human cultured astroglial cells is driven by nitric oxide. Mollace V, et al. **Biochem Biophys Res Commun** 1995 Oct 24; 215(3):793-9

Synergistic induction of nitric oxide by beta-amyloid and cytokines in astrocytes. Rossi F, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):474-8

Binding of a protein to an AU-rich domain of tumour necrosis factor alpha mRNA as a 35 kDa complex and its regulation in primary rat astrocytes. Kim Y, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):455-60

Effects of aluminum(III) on catechol-stimulated nerve growth factor biosynthesis by cultured mouse brain astroglial cells. Kobayashi D, et al. **Biochem Mol Biol Int** 1996 Apr;38(4):675-84

Astroglia-released factor with negative allosteric modulatory properties at the GABA A receptor. Rigo JM, et al. **Biochem Pharmacol** 1996 Aug 9;52(3):465-73

Sustained activation of NF kappa B and transient I kappa B alpha degradation induced by tumour necrosis factor in 1321N1 human astrocytoma. O'Neill LA, et al. **Biochem Soc Trans** 1995 Nov;23(4):597S

Adenosine A1 receptor-mediated changes in basal and histamine-stimulated levels of intracellular calcium in primary rat astrocytes. Peakman MC, et al. **Br J Pharmacol** 1995 Jul;115(5):801-10

Occurrence of the opiate alkaloid-selective mu3 receptor in mammalian microglia, astrocytes and Kupffer cells. Dobrenis K, et al. **Brain Res** 1995 Jul 24;686(2):239-48

Monocular deprivation alters the morphology of glial fibrillary acidic protein-immunoreactive astrocytes in the rat visual cortex. Hawrylak N, et al. **Brain Res** 1995 Jun 19;683(2):187-99

Eicosanoids are produced by microglia, not by astrocytes, in rat glial cell cultures. Matsuo M, et al. **Brain Res** 1995 Jul 10;685(1-2):201-4

Hypoosmotic volume regulation and osmolyte transport in astrocytes is blocked by an anion transport inhibitor, L-644,711. Olson JE, et al. **Brain Res** 1995 Jun 5; 682(1-2):197-202

In situ transblot and immunocytochemical comparisons of astrocytic connexin-43 responses to NMDA and kainic acid in rat brain. Sawchuk MA, et al. **Brain Res** 1995 Jun 12; 683(1):153-7

Evidence for the involvement of 5-lipoxygenase products in the regulation of the expression of the proenkephalin gene in cultured astroglial cells. Mamot C, et al. **Brain Res Mol Brain Res** 1995 Oct;33(1):79-86

Primary astroglial cultures derived from several rat brain regions differentially express mu, delta and kappa opioid receptor mRNA. Ruzicka BB, et al. **Brain Res Mol Brain Res** 1995 Dec 28;34(2):209-20

A mathematical model of agonist-induced propagation of calcium waves in astrocytes. Roth BJ, et al. **Cell Calcium** 1995 Jan;17(1):53-64

Effect of external K+, Ca2+, and Ba2+ on membrane potential and ionic conductance in rat astrocytes. Anderson S, et al. **Cell Mol Neurobiol** 1995 Aug;15(4):439-50

Dexamethasone induces an increase in intracellular and membrane-associated lipocortin-1 (annexin-1) in rat astrocyte primary cultures. McLeod JD, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):193-205

Expression of mRNAs of multiple growth factors and receptors by astrocytes and glioma cells: detection with reverse transcription-polymerase chain reaction. Zaheer A, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):221-37

The triggering of astrocytic calcium waves by NMDA-induced neuronal activation. Dani JW, et al. **Ciba Found Symp** 1995;188:195-205; discussion 205-9

Increased immunoreactivities for the basic fibroblast growth factor and its receptor in astrocytes at the site of cerebral lesions and oedematous change in SHR. Kataoka H, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S262-4

Effect of antidepressants on ATP content, 3H-valine incorporation and cell morphometry of astrocytes cultured from rat brain. Trzeciak HI, et al. **Dev Neurosci** 1995; 17(5-6):292-9

Metabolic trafficking between neurons and astrocytes: the glutamate/glutamine cycle revisited. Westergaard N, et al. **Dev Neurosci** 1995;17(4):203-11 (97 ref.)

Relationship between the thyroid hormone transport system and the Na(+)-H+ exchanger in cultured rat brain astrocytes. Beslin A, et al. **Endocrinology** 1995 Dec; 136(12):5385-90

Thyroid hormone receptor isoform content in cultured type 1 and type 2 astrocytes. Carlson DJ, et al. **Endocrinology** 1996 Mar;137(3):911-7

Mathematical modelling of the citric acid cycle for the analysis of glutamine isotopomers from cerebellar astrocytes incubated with [1(-13)C]glucose. Merle M, et al. **Eur J Biochem** 1996 Aug 1;239(3):742-51

HIV-1 gp120 glycoprotein induces [Ca2+]i responses not only in type-2 but also type-1 astrocytes and oligodendrocytes of the rat cerebellum. Codazzi F, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1333-41

The coat protein gp120 of HIV-1 inhibits astrocyte uptake of excitatory amino acids via macrophage arachidonic acid. Dreyer EB, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2502-7

Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Lundberg C, et al. **Exp Neurol** 1996 May; 139(1):39-53

Inhibition of astrocyte gap junctional communication by ATP depletion is reversed by calcium sequestration. Vera B, et al. **FEBS Lett** 1996 Sep 2;392(3):225-8

Intracellular acidification and Ca2+ transients in cultured rat cerebellar astrocytes evoked by glutamate agonists and noradrenaline. Brune T, et al. **Glia** 1995 Jun;14(2):153-61

Sodium-dependent glutamate uptake as an activator of oxidative metabolism in primary astrocyte cultures from newborn rat. Eriksson G, et al. **Glia** 1995 Oct;15(2):152-6

Pneumococcal cell wall components induce nitric oxide synthase and TNF-alpha in astroglial-enriched cultures. Freyer D, et al. **Glia** 1996 Jan;16(1):1-6

Modulation of two functionally distinct Ca2+ stores in astrocytes: role of the plasmalemmal Na/Ca exchanger. Golovina VA, et al. **Glia** 1996 Apr;16(4):296-305

Endothelin-induced cytoskeletal actin re-organization in cultured astrocytes: inhibition by C3 ADP-ribosyltransferase. Koyama Y, et al. **Glia** 1996 Apr; 16(4):342-50

Long-term production of neurotrophic factors by astrocyte cultures from hemiparkinsonian rat brain. Langan TJ, et al. **Glia** 1995 Jul;14(3):174-84

Astrocytic gap junction removal, connexin43 redistribution, and epitope masking at excitatory amino acid lesion sites in rat brain. Ochalski PA, et al. **Glia** 1995 Aug;14(4):279-94

Octanol, a gap junction uncoupling agent, changes intracellular [H+] in rat astrocytes. Pappas CA, et al. **Glia** 1996 Jan;16(1):7-15

Differential regulation of astrocyte TNF-alpha expression by the cytokines TGF-beta, IL-6 and IL-10. Benveniste EN, et al. **Int J Dev Neurosci** 1995 Jun-Jul;13(3-4):341-9

Polysialylated neural cell adhesion molecule expression by neurons and astroglial processes in the rat dentate gyrus declines dramatically with increasing age. Fox GB, et al. **Int J Dev Neurosci** 1995 Nov;13(7):663-72

Autoradiographic studies on the uptake of 3H-noradrenaline and 3H-serotonin by neurones and astrocytes in explant and primary cultures of rat CNS: effects of antidepressants. Hösli E, et al. **Int J Dev Neurosci** 1995 Dec;13(8):897-908

Developmental changes in purine nucleotide metabolism in cultured rat astroglia. Zoref-Shani E, et al. **Int J Dev Neurosci** 1995 Dec;13(8):887-96

Egr-1 activates basic fibroblast growth factor transcription. Mechanistic implications for astrocyte proliferation. Biesiada E, et al. **J Biol Chem** 1996 Aug 2;271(31):18576-81

The major astrocytic phosphoprotein PEA-15 is encoded by two mRNAs conserved on their full length in mouse and human. Estellés A, et al. **J Biol Chem** 1996 Jun 21; 271(25):14800-6

Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. Fine SM, et al. **J Biol Chem** 1996 Jun 28;271(26):15303-6

Purification and characterization of a novel stress protein, the 150-kDa oxygen-regulated protein (ORP150), from cultured rat astrocytes and its expression in ischemic mouse brain. Kuwabara K, et al. **J Biol Chem** 1996 Mar 1; 271(9):5025-32

Pharmacological induction of heat shock protein 68 synthesis in cultured rat astrocytes. Nishimura RN, et al. **J Biol Chem** 1995 Dec 15;270(50):29967-70

Rapid, widespread, and longlasting induction of nestin contributes to the generation of glial scar tissue after CNS injury. Frisén J, et al. **J Cell Biol** 1995 Oct;131(2):453-64

Disrupted glial fibrillary acidic protein network in astrocytes from vimentin knockout mice. Galou M, et al. **J Cell Biol** 1996 May;133(4):853-63

Synergistic stimulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities by retinoic acid and astroglial factors in immortalized rat brain microvessel endothelial cells. el Hafny B, et al. **J Cell Physiol** 1996 Jun;167(3):451-60

Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. Gasque P, et al. **J Immunol** 1995 Nov 15;155(10):4882-9

Interferon regulatory factor element and interferon regulatory factor 1 in the induction of major histocompatibility complex class I genes in neural cells. Massa PT, et al. **J Interferon Cytokine Res** 1995 Sep; 15(9):799-810

Activation of a reporter gene responsive to NGFI-B in cultured neurons and astrocytes. Ciani E, et al. **J Mol Neurosci** 1995;6(2):131-9

Generation of ketone bodies from leucine by cultured astroglial cells. Bixel MG, et al. **J Neurochem** 1995 Dec; 65(6):2450-61

Astroglial cells express large amounts of GABAA receptor proteins in mature brain. Bureau M, et al. **J Neurochem** 1995 Nov;65(5):2006-15

Tyrosine kinase activity is essential for interleukin-1 beta--stimulated production of interleukin-6 in U373 human astrocytoma cells. Carlson RO, et al. **J Neurochem** 1995 Dec;65(6):2491-9

Components of the plasminogen activator system in astrocytes are modulated by tumor necrosis factor-alpha and interleukin-1 beta through similar signal transduction pathways. Faber-Elman A, et al. **J Neurochem** 1995 Oct; 65(4):1524-35

Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. Feindt J, et al. **J Neurochem** 1995 Nov;65(5):1997-2005

Apolipoprotein E and low-density lipoprotein binding and internalization in primary cultures of rat astrocytes: isoform-specific alterations. Guillaume D, et al. **J Neurochem** 1996 Jun;66(6):2410-8

Neuroligand-evoked calcium-dependent release of excitatory amino acids from cultured astrocytes. Jeftinija SD, et al. **J Neurochem** 1996 Feb;66(2):676-84

Coupling of ETB endothelin receptor to mitogen-activated protein kinase stimulation and DNA synthesis in primary cultures of rat astrocytes. Lazarini F, et al. **J Neurochem** 1996 Feb;66(2):459-65

Amyloid precursor protein metabolism in primary cell cultures of neurons, astrocytes, and microglia. LeBlanc AC, et al. **J Neurochem** 1996 Jun;66(6):2300-10

Exogenous glutamate concentration regulates the metabolic fate of glutamate in astrocytes. McKenna MC, et al. **J Neurochem** 1996 Jan;66(1):386-93

Ethanol increases cytochrome P4502E1 and induces oxidative stress in astrocytes. Montoliu C, et al. **J Neurochem** 1995 Dec;65(6):2561-70

Tumor necrosis factor-alpha and basic fibroblast growth factor decrease glial fibrillary acidic protein and its encoding mRNA in astrocyte cultures and glioblastoma cells. Murphy GM Jr, et al. **J Neurochem** 1995 Dec; 65(6):2716-24

Glutamine transport in mouse cerebral astrocytes. Nagaraja TN, et al. **J Neurochem** 1996 Apr;66(4):1665-74

Adenosine receptors modulate [Ca2+]i in hippocampal astrocytes in situ. Porter JT, et al. **J Neurochem** 1995 Oct; 65(4):1515-23

Metallothionein induction in neonatal rat primary astrocyte cultures protects against methylmercury cytotoxicity. Rising L, et al. **J Neurochem** 1995 Oct;65(4):1562-8

Lipopolysaccharide-enhanced expression of interleukin-6 in dibutyryl cyclic AMP-differentiated rat C6 glioma. Slegers H, et al. **J Neurochem** 1996 Feb;66(2):466-73

Angiotensin II regulation of intracellular calcium in astroglia cultured from rat hypothalamus and brainstem. Wang D, et al. **J Neurochem** 1996 Sep;67(3):996-1004

Astrocyte leucine metabolism: significance of branched-chain amino acid transamination. Yudkoff M, et al. **J Neurochem** 1996 Jan;66(1):378-85

Dynorphin 1-17 delays the vasopressin induced mobilization of intracellular calcium in cultured astrocytes from the rat neural lobe. Boersma CJ, et al. **J Neuroendocrinol** 1993 Oct;5(5):583-90

Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. Lacy M, et al. **J Neuroimmunol** 1995 Aug; 61(1):71-8

Expression of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL-6) mRNA in adult human astrocytes: comparison with adult microglia and fetal astrocytes. Lafortune L, et al. **J Neuropathol Exp Neurol** 1996 May; 55(5):515-21

Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. Mrak RE, et al. **J Neuropathol Exp Neurol** 1996 Mar;55(3):273-9

In vitro ischemia promotes calcium influx and intracellular calcium release in hippocampal astrocytes. Duffy S, et al. **J Neurosci** 1996 Jan;16(1):71-81

Whole-cell chloride currents in rat astrocytes accompany changes in cell morphology. Lascola CD, et al. **J Neurosci** 1996 Apr 15;16(8):2532-45

A distinct subset of tenascin/CS-6-PG-rich astrocytes restricts neuronal growth in vitro. Meiners S, et al. **J Neurosci** 1995 Dec;15(12):8096-108

GAT-1, a high-affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortex. Minelli A, et al. **J Neurosci** 1995 Nov; 15(11):7734-46

Changes in neurotrophic factor expression and receptor activation following exposure of hippocampal neuron/astrocyte cocultures to kainic acid. Rudge JS, et al. **J Neurosci** 1995 Oct;15(10):6856-67

Noradrenaline-induced stimulation of glutamine metabolism in primary cultures of astrocytes. Huang R, et al. **J Neurosci Res** 1995 Aug 1;41(5):677-83

Brain injury and tumor necrosis factors induce calbindin D-28k in astrocytes: evidence for a cytoprotective response. Mattson MP, et al. **J Neurosci Res** 1995 Oct 15; 42(3):357-70

Altered lipid metabolism in the presence and absence of extracellular Ca2+ during combined oxygen-glucose deprivation in primary astrocyte cultures. Murphy EJ, et al. **J Neurosci Res** 1995 Sep 1;42(1):109-16

Relationship of lead-induced proteins to stress response proteins in astroglial cells. Opanashuk LA, et al. **J Neurosci Res** 1995 Dec;42(5):623-32

Characterization of Na+/H+ exchange activity in cultured rat hippocampal astrocytes. Pizzonia JH, et al. **J Neurosci Res** 1996 Apr 15;44(2):191-8

Characterization of L-DOPA transport in cultured rat and mouse astrocytes. Tsai MJ, et al. **J Neurosci Res** 1996 Feb 15;43(4):490-5

Expression of bcl-2 in reactive and neoplastic astrocytes: lack of correlation with presence or degree of malignancy. Krishna M, et al. **J Neurosurg** 1995 Dec;83(6):1017-22

Albumin stimulates uptake of calcium into subcellular stores in rat cortical astrocytes. Nadal A, et al. **J Physiol (Lond)** 1996 May 1;492 (Pt 3):737-50

Expression of tissue factor is increased in astrocytes within the central nervous system during persistent infection with borna disease virus. Gonzalez-Dunia D, et al. **J Virol** 1996 Sep;70(9):5812-20

AUUUA-specific mRNA binding proteins in astrocytes. Jacobs DB, et al. **Life Sci** 1996;58(23):2083-9

Cyclic AMP-dependent regulation of fibroblast growth factor-2 messenger RNA levels in rat cortical astrocytes: comparison with fibroblast growth factor-1 and ciliary neurotrophic factor. Riva MA, et al. **Mol Pharmacol** 1996 Apr;49(4):699-706

Tumor necrosis factor-alpha and interleukin-1 alpha enhance glucose utilization by astrocytes: involvement of phospholipase A2. Yu N, et al. **Mol Pharmacol** 1995 Sep; 48(3):550-8

Effect of ammonia on endocytosis and cytokine production by immortalized human microglia and astroglia cells. Atanassov CL, et al. **Neurochem Int** 1995 Oct-Nov; 27(4-5):417-24

Endogenous excitatory amino acid release from brain slices and astrocyte cultures evoked by trimethyltin and other neurotoxic agents. Dawson R Jr, et al. **Neurochem Res** 1995 Jul;20(7):847-58

Energy metabolism in hypoxic astrocytes: protective mechanism of fructose-1,6-bisphosphate. Kelleher JA, et al. **Neurochem Res** 1995 Jul;20(7):785-92

A possible mechanism for the hypoxia-hypoglycemia-induced release of excitatory amino acids from cultured hippocampal astrocytes. Ogata T, et al. **Neurochem Res** 1995 Jun;20(6):737-43

Clearance and metabolism of arachidonic acid by C6 glioma cells and astrocytes. Staub F, et al. **Neurochem Res** 1995 Dec;20(12):1449-56

Deoxyglucose uptake by mouse astrocytes: effects of temperature and retrovirus infection. Vann JM, et al. **Neurochem Res** 1995 Sep;20(9):1013-20

Mechanism of heat shock protein 72 induction in primary cultured astrocytes after oxygen-glucose deprivation. Bergeron M, et al. **Neurol Res** 1996 Feb;18(1):64-72

Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Rothstein JD, et al. **Neuron** 1996 Mar; 16(3):675-86

Expression and distribution of GAP-43 in human astrocytes in culture. Moretto G, et al. **Neuropathol Appl Neurobiol** 1995 Aug;21(4):362-7

Lactate metabolism in mouse brain astrocytes studied by [13C]NMR spectroscopy. Alves PM, et al. **Neuroreport** 1995 Nov 13;6(16):2201-4

beta-Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for Alzheimer's disease. Harris ME, et al. **Neuroreport** 1995 Oct 2;6(14):1875-9

Glutamate regulation of GDNF gene expression in the striatum and primary striatal astrocytes. Ho A, et al. **Neuroreport** 1995 Jul 10;6(10):1454-8

Apolipoprotein E gene expression in astrocytes: developmental pattern and regulation. Mouchel Y, et al. **Neuroreport** 1995 Dec 29;7(1):205-8

Hyaluronectin binds to laminin and blocks laminin-dependent process formation by astrocytes. Namboodiri MS, et al. **Neuroreport** 1995 Oct 23;6(15):2037-40

Agmatine (decarboxylated arginine) is synthesized and stored in astrocytes. Regunathan S, et al. **Neuroreport** 1995 Oct 2;6(14):1897-900

Expression of interleukin-11 and its encoding mRNA by glioblastoma cells. Murphy GM Jr, et al. **Neurosci Lett** 1995 Aug 25;196(3):153-6

Expression of type I interleukin-1 receptor mRNA and its regulation in cultured astrocytes. Tomozawa Y, et al. **Neurosci Lett** 1995 Jul 28;195(1):57-60

Effect of ascorbic acid on hyperoxic rat astrocytes. Sharma P. **Neuroscience** 1996 May;72(2):391-7

Induction of heparin-binding growth-associated molecule expression in reactive astrocytes following hippocampal neuronal injury. Takeda A, et al. **Neuroscience** 1995 Sep; 68(1):57-64

Uptake and subcellular distribution of 51Cr in Gomori-positive astrocytes in primary culture. Brawer JR, et al. **Neurotoxicology** 1995 Summer;16(2):327-36

Astrocyte-derived growth factor (S100 beta) and motor function in rats following cardiac arrest. Jaw SP, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):667-70

An astrocytic binding site for neuronal Thy-1 and its effect on neurite outgrowth. Dreyer EB, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):11195-9

Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells. Gitter BD, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10738-41

A RT-PCR study of gene expression in a mechanical injury

model. Eng LF, et al. **Prog Brain Res** 1995;105:219–29 (29 ref.)
Gene expression in astrocytes during and after ischemia. Yu AC, et al. **Prog Brain Res** 1995;105:245–53 (50 ref.)
Protein kinases and prostaglandin production in ovine astroglia. Nam MJ, et al. **Prostaglandins** 1995 Jul; 50(1):33–45
Impaired pial arteriolar reactivity to hypercapnia during hyperammonemia depends on glutamine synthesis. Hirata T, et al. **Stroke** 1996 Apr;27(4):729–36
Activation of astrocytes in the spinal cord of mice chronically infected with a neurotropic coronavirus. Sun N, et al. **Virology** 1995 Nov 10;213(2):482–93

PATHOLOGY

Difluoromethylornithine counteracts lesion–induced astrogliosis in rat hippocampus: enhancement of inhibitory effect by combined treatment with GM1 ganglioside. Jegliński W, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(2):549–53
Exposure of neonatal rats to alcohol by vapor inhalation demonstrates specificity of microcephaly and Purkinje cell loss but not astrogliosis. Ryabinin AE, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):784–91
Trypanosoma brucei products activate components of the reactive response in astrocytes in vitro. Pentreath VW, et al. **Bull Soc Pathol Exot** 1994;87(5):323–9
Role for astrocytosis in HIV–1–associated dementia. Vitkovic L, et al. **Curr Top Microbiol Immunol** 1995;202:105–16 (49 ref.)
Rat glioma cell line as a model for astrogliosis. Malhotra SK, et al. **Cytobios** 1995;82(328):39–51
Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Stone J, et al. **Invest Ophthalmol Vis Sci** 1996 Feb; 37(2):290–9
Dysregulation of signal transduction pathways as a potential mechanism of nervous system alterations in HIV–1 gp120 transgenic mice and humans with HIV–1 encephalitis. Wyss–Coray T, et al. **J Clin Invest** 1996 Feb 1;97(3):789–98
A new model for rapid stretch–induced injury of cells in culture: characterization of the model using astrocytes. Ellis EF, et al. **J Neurotrauma** 1995 Jun;12(3):325–39
Atypical retinal astrocytic hamartoma diagnosed by fine–needle biopsy. Shields JA, et al. **Ophthalmology** 1996 Jun;103(6):949–52

PHYSIOLOGY

Astroglial cell–induced expression of Na–K–Cl cotransporter in brain microvascular endothelial cells. Sun D, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1506–12
Growth factors released from astroglial cells in primary culture participate in the cross talk between luteinizing hormone–releasing hormone (LHRH) neurons and astrocytes. Effects on LHRH neuronal proliferation and secretion. Gallo F, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:513–6
Somatostatin as a trophic factor. Analysis of transgenic mice overexpressing somatostatin in astrocytes. Schwartz JP, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:29–35
Hyperosmotic exposure alters total taurine quantity and cellular transport in rat astrocyte cultures. Beetsch JW, et al. **Biochim Biophys Acta** 1996 Jun 4;1290(2):141–8
Dual effects of thrombin and a 14–amino acid peptide agonist of the thrombin receptor on septal cholinergic neurons. Debeir T, et al. **Brain Res** 1996 Feb 5;708(1–2):159–66
An analysis of astrocytic cell lines with different abilities to promote axon growth. Fok–Seang J, et al. **Brain Res** 1995 Aug 21;689(2):207–23
Serum modulates cyclic AMP–dependent morphological changes in cultured neurohypophysial astrocytes. Ramsell KD, et al. **Brain Res Bull** 1996;39(2):109–14
Demonstration of hereditarily accelerated proliferation in astrocytes derived from spontaneously hypertensive rats. Yamagata K, et al. **Clin Exp Pharmacol Physiol** 1995 Sep; 22(9):605–9
Astroglial responses in photochemically induced focal ischemia of the rat cortex. Schroeter M, et al. **Exp Brain Res** 1995;106(1):1–6
Effects of axonal injury on astrocyte proliferation and morphology in vitro: implications for astrogliosis. Guenard V, et al. **Exp Neurol** 1996 Feb;137(2):175–90
Reactive astroglia support primary dendritic but not axonal outgrowth from mouse cortical neurons in vitro. Le Roux PD, et al. **Exp Neurol** 1996 Jan;137(1):49–65
Injury–induced proteoglycans inhibit the potential for laminin–mediated axon growth on astrocytic scars. McKeon RJ, et al. **Exp Neurol** 1995 Nov;136(1):32–43
Microglial ramification requires nondiffusible factors derived from astrocytes. Tanaka J, et al. **Exp Neurol** 1996 Feb; 137(2):367–75
Phenotypic diversity and kinetics of proliferating microglia and astrocytes following cortical stab wounds. Amat JA, et al. **Glia** 1996 Apr;16(4):368–82
Interleukin 1–beta– and tumor necrosis factor–alpha–mediated regulation of ICAM–1 gene expression in astrocytes requires protein kinase C activity. Ballestas ME, et al. **Glia** 1995 Aug;14(4):267–78
Relationship between astrocytic processes and "perineuronal nets" in rat neocortex. Blümcke I, et al. **Glia** 1995 Oct; 15(2):131–40
Hypoxia–induced vascular endothelial growth factor expression in normal rat astrocyte cultures. Ijichi A, et al. **Glia** 1995 Jun;14(2):87–93
Astrocytes modulate retinal vasculogenesis: effects on endothelial cell differentiation. Jiang B, et al. **Glia** 1995 Sep;15(1):1–10
Human epileptic astrocytes exhibit increased gap junction coupling. Lee SH, et al. **Glia** 1995 Oct;15(2):195–202
Redistribution and degeneration of retinal astrocytes in experimental murine cerebral malaria: relationship to disruption of the blood–retinal barrier. Medana IM, et al. **Glia** 1996 Jan;16(1):51–64
Dehydration–induced proliferation of identified pituicytes in fully adult rats. Murugaiyan P, et al. **Glia** 1995 Sep; 15(1):65–76
The role of intracellular calcium and protein kinase C in endothelin–stimulated proliferation of rat type I astrocytes. Stanimirovic DB, et al. **Glia** 1995 Oct;15(2):119–30
Cytokine regulation of astrocyte function: in–vitro studies using cells from the human brain. Aloisi F, et al. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):265–74
An ultrastructural study of the phagocytic activity of astrocytes in adult rat brain. al–Ali SY, et al. **J Anat** 1996 Apr;188 (Pt 2):257–62
Cloning of a novel RNA binding polypeptide (RA301) induced by hypoxia/reoxygenation. Matsuo N, et al. **J Biol Chem** 1995 Nov 24;270(47):28216–22
Surface complexity of human neocortical astrocytic cells: changes with development, aging, and dementia. Senitz D, et al. **J Hirnforsch** 1995;36(4):531–7
Transduction mechanisms involved in thrombin receptor–induced nerve growth factor secretion and cell division in primary cultures of astrocytes. Debeir T, et al. **J Neurochem** 1996 Jun;66(6):2320–8
Cytokine–regulated expression of platelet–derived growth factor gene and protein in cultured human astrocytes. Silberstein FC, et al. **J Neurochem** 1996 Apr;66(4):1409–17
Impairment of electrophysiological function of astrocytes by cerebrospinal fluid from a patient with Waldenström's macroglobulinemia. Köller H, et al. **J Neuroimmunol** 1995 Aug;61(1):35–9
Evolution of neuropathologic abnormalities associated with blood–brain barrier breakdown in transgenic mice expressing interleukin–6 in astrocytes. Brett FM, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):766–75
A clone of the MOCH–1 glial tumor in culture: multiple phenotypes expressed under different environmental conditions. Dyer CA, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):852–63
Astrocytes protect neurons from hydrogen peroxide toxicity. Desagher S, et al. **J Neurosci** 1996 Apr 15;16(8):2553–62
Upregulation of GABAA current by astrocytes in cultured embryonic rat hippocampal neurons. Liu QY, et al. **J Neurosci** 1996 May 1;16(9):2912–23
A distinct subset of tenascin/CS–6–PG–rich astrocytes restricts neuronal growth in vitro. Meiners S, et al. **J Neurosci** 1995 Dec;15(12):8096–108
Astrocyte–astrocytoma cell line interactions in culture. Lal PG, et al. **J Neurosci Res** 1996 May 1;44(3):216–22
Subcellular calcium oscillators and calcium influx support agonist–induced calcium waves in cultured astrocytes. Yagodin S, et al. **Mol Cell Biochem** 1995 Aug–Sep; 149–150:137–44
Ultrastructural evidence for increased contact between astrocytes and synapses in rats reared in a complex environment. Jones TA, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):48–56
Nitric oxide produced by activated astrocytes rapidly and reversibly inhibits cellular respiration. Brown GC, et al. **Neurosci Lett** 1995 Jul 7;193(3):201–4
Independent regulation of primary dendritic and axonal growth by maturing astrocytes in vitro. Le Roux PD, et al. **Neurosci Lett** 1995 Sep 22;198(1):5–8
Evidence for the role of protein kinase C in astrocyte–induced proliferation of rat cerebromicrovascular endothelial cells. Stanimirovic DB, et al. **Neurosci Lett** 1995 Sep 15;197(3):219–22
Promoter regions involved in density–dependent regulation of basic fibroblast growth factor gene expression in human astrocytic cells. Moffett J, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2470–5
Localization of vasopressin mRNA and immunoreactivity in pituicytes of pituitary stalk–transected rats after osmotic stimulation. Pu LP, et al. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10653–7
Studies on the cell tropism of Listeria monocytogenes in ovine fetal brain cell cultures. Peters M, et al. **Vet Microbiol** 1996 Apr;49(3–4):169–79

TRANSPLANTATION

Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Yoshimoto Y, et al. **Brain Res** 1995 Sep 11; 691(1–2):25–36
Expression of tyrosine hydroxylase in an immortalized human fetal astrocyte cell line; in vitro characterization and engraftment into the rodent striatum. Tornatore C, et al. **Cell Transplant** 1996 Mar–Apr;5(2):145–63
Migration of A7 immortalized astrocytic cells grafted into the adult rat striatum. Okoye GS, et al. **J Comp Neurol** 1995 Nov 27;362(4):524–34
Regeneration in the optic nerve of adult rats: influences of cultured astrocytes and optic nerve grafts of different ontogenetic stages. Sievers J, et al. **J Neurocytol** 1995 Oct; 24(10):783–93
Reconstruction of the glia limitans by sub–arachnoid transplantation of astrocyte–enriched cultures. Franklin RJ, et al. **Microsc Res Tech** 1995 Nov 1;32(4):295–301

ULTRASTRUCTURE

Thorn–shaped astrocytes: possibly secondarily induced tau–positive glial fibrillary tangles. Ikeda K, et al. **Acta Neuropathol (Berl)** 1995;90(6):620–5
Neurotransmitter imaging in living cells based on native fluorescence detection. Tan W, et al. **Anal Chem** 1995 Aug 1;67(15):2575–9
Morphological and quantitative analysis of the fascicular pattern of monkey optic nerve. Naito J. **Cell Tissue Res** 1996 Feb;283(2):255–61
Effect of antidepressants on ATP content, 3H–valine incorporation and cell morphometry of astrocytes cultured from rat brain. Trzeciak HI, et al. **Dev Neurosci** 1995; 17(5–6):292–9
Creutzfeldt–Jakob disease: ultrastructural study of brain biopsy: unusual interaction between astrocytes and oligo– and microglia. Liberski PP, et al. **Folia Neuropathol** 1995; 33(2):85–92
Isoform–specific expression of sodium channels in astrocytes in vitro: immunocytochemical observations. Black JA, et al. **Glia** 1995 Jun;14(2):133–44
Some unusual responses of astrocytes to ghost tangles in a long duration case of juvenile Alzheimer's disease: an electron microscopic study. Nakano I, et al. **J Neurol Sci** 1996 Mar;136(1–2):41–6
Structural alterations of human immortal astrocytes after inhibition of 3–hydroxy–3–methylglutaryl coenzyme A (HMG–CoA) reductase by lovastatin. Bobryshev YV, et al. **J Submicrosc Cytol Pathol** 1995 Oct;27(4):435–44
Experimental induction of corpora amylacea–like inclusions in rat astroglia. Cissé S, et al. **Neuropathol Appl Neurobiol** 1995 Oct;21(5):423–31
Astrocytes in the hypoglossal nuclei of sudden infant death syndrome (SIDS) infants: a quantitative study. Pamphlett R, et al. **Neuropathol Appl Neurobiol** 1996 Apr;22(2):136–43
Integrated evaluation of central nervous system lesions: stains for neurons, astrocytes, and microglia reveal the spatial and temporal features of MK–801–induced neuronal necrosis in the rat cerebral cortex. Fix AS, et al. **Toxicol Pathol** 1996 May–Jun;24(3):291–304

VIROLOGY

Spread of MHV–JHM from nasal cavity to white matter of spinal cord. Transneuronal movement and involvement of astrocytes. Perlman S, et al. **Adv Exp Med Biol** 1995; 380:73–8 (21 ref.)
Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. Ranki A, et al. **AIDS** 1995 Sep;9(9):1001–8
Polyomavirus–infected oligodendrocytes and macrophages within astrocytes in progressive multifocal leukoencephalopathy (PML). Mesquita R, et al. **APMIS** 1996 Feb;104(2):153–60
Astrocytes infected with replication–defective adenovirus containing a secreted form of CNTF or NT3 show enhanced support of neuronal populations in vitro. Smith GM, et al. **Exp Neurol** 1996 May;139(1):156–66
Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF–kappa B binding and protein kinase C activity in primary human astrocytes. Conant K, et al. **J Virol** 1996 Mar;70(3):1384–9
Infection of primary human fetal astrocytes by human herpesvirus 6. He J, et al. **J Virol** 1996 Feb;70(2):1296–300
Mechanisms of transcriptional transactivation and restriction of human immunodeficiency virus type I replication in an astrocytic glial cell. Niikura M, et al. **Oncogene** 1996 Jul 18;13(2):313–22

ASTROCYTOMA

Management of primary malignant brain tumours [editorial] Whittle IR. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):2–5 (50 ref.)

BLOOD SUPPLY

Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Leon SP, et al. **Cancer** 1996 Jan 15;77(2):362–72

CHEMISTRY

c–erbB–2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Haapasalo H, et al. **Br J Cancer** 1996 Mar;73(5):620–3
Expression of Fas/APO–1 during the progression of astrocytomas. Tachibana O, et al. **Cancer Res** 1995 Dec 1;55(23):5528–30
Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Zhu A, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1; 34(4):809–15
[Expression of glial fibrillary acidic protein and protein S–100 in cerebral astrocytic gliomas of varying degrees of

malignancy (immunohistochemical study)] Korshunov AG, et al. **Arkh Patol** 1995 Jul-Aug;57(4):30-8 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Gliofibroma: a distinct entity or a subtype of desmoplastic astrocytoma? Prayson RA. **Hum Pathol** 1996 Jun; 27(6):610-3

COMPLICATIONS

Papilledema following bowtie optic atrophy. Ing EB, et al. **Arch Ophthalmol** 1996 Mar;114(3):356-7

Malignant occipital astrocytoma in a patient with Lhermitte-Duclos disease (cerebellar dysplastic gangliocytoma). Domingo Z, et al. **Br J Neurosurg** 1996 Feb;10(1):99-102

A 4-month-old boy with severe emaciation, normal linear growth, and a happy affect. Greenes D, et al. **Curr Opin Pediatr** 1996 Feb;8(1):50-7

Tuberous sclerosis with a brain tumor. Chaudhary D, et al. **Indian Pediatr** 1995 Feb;32(2):235-8 (13 ref.)

Post-anesthesia uncal herniation secondary to a previously unsuspected temporal glioma. Vender JR, et al. **J Forensic Sci** 1995 Sep;40(5):900-2

Long-term memory deficits in patients with malignant gliomas. Salander P, et al. **J Neurooncol** 1995;25(3):227-38

"Pseudo-BECRS": intracranial focal lesions suggestive of a primary partial epilepsy syndrome. Shevell MI, et al. **Pediatr Neurol** 1996 Jan;14(1):31-5

[A case of astrocytoma of corpus callosum presented diagnostic dyspraxia] Koshimizu K, et al. **No To Shinkei** 1995 Aug;47(8):763-7 (Eng. Abstr.) **(Jpn)**

CONGENITAL

[A case of congenital brain tumor diagnosed during follow-up of neonatal intracranial hemorrhage] Nonaka M, et al. **No To Hattatsu** 1996 Jan;28(1):66-71 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

MR of malignant optic glioma of adulthood. Millar WS, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1673-6

Desmoplastic cerebral astrocytoma of infancy: report and review of the imaging characteristics. Serra A, et al. **AJR Am J Roentgenol** 1996 Jun;166(6):1459-61

Cerebellar astrocytoma manifesting as isolated, comitant esotropia in childhood. Simon JW, et al. **Am J Ophthalmol** 1996 May;121(5):584-6

Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions. Yaziji H, et al. **Am J Surg Pathol** 1996 Sep;20(9):1086-90

Magnetic resonance imaging changes after stereotactic radiation therapy for childhood low grade astrocytoma. Bakardjiev AI, et al. **Cancer** 1996 Aug 15;78(4):864-73

Central pathology review in clinical trials for patients with malignant glioma. A Report of Radiation Therapy Oncology Group 83-02. Scott CB, et al. **Cancer** 1995 Jul 15;76(2):307-13

Lid nystagmus as a sign of intrinsic midbrain disease. Brodsky MC, et al. **J Neuroophthalmol** 1995 Dec;15(4):236-40

Cerebral astroblastoma resembling an extra-axial neoplasm. Yunten N, et al. **J Neuroradiol** 1996 Jun;23(1):38-40

Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. Listernick R, et al. **J Pediatr** 1995 Nov; 127(5):718-22

Pilocytic astrocytoma presenting as an extra-axial tumor in the cerebellopontine angle: case report. Beutler AS, et al. **Neurosurgery** 1995 Jul;37(1):125-8

The role of frameless stereotactic techniques in the treatment of pediatric CNS lesions. Pollack IF, et al. **Pediatr Neurol** 1995 Oct;13(3):209-16

Low-grade astrocytomas: prognosis factors and elements of management. Loiseau H, et al. **Surg Neurol** 1995 Sep; 44(3):224-7 (44 ref.)

Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. Nicolato A, et al. **Surg Neurol** 1995 Sep; 44(3):208-21; discussion 221-3 (60 ref.)

[Magnetic resonance and computerized tomography of posterior cranial fossa tumors in childhood. Differential diagnosis and assessment of lesion extent] Colosimo C, et al. **Radiol Med (Torino)** 1995 Oct;90(4):386-95 (Eng. Abstr.) **(Ita)**

[A case of uncomplicated retinal astrocytoma] Ikeda T, et al. **Nippon Ganka Gakkai Zasshi** 1995 Sep;99(9):1052-5 (21 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study. Lunardi P, et al. **Acta Neurochir (Wien)** 1996; 138(2):215-20

Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Macdonald D, et al. **Ann Oncol** 1996 Feb;7(2):205-7

Chemotherapy for progressive pilocytic astrocytomas in the chiasmo-hypothalamic regions. Nishio S, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):300-6

Attempted dose intensified cyclophosphamide, etoposide, and granulocyte colony-stimulating factor for treatment of malignant astrocytoma. Newton HB, et al. **J Neurooncol** 1995;24(3):285-92

Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy. Shinoura N, et al. **J Neurosurg** 1996 May;84(5):839-45; discussion 846

Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide. McCowage G, et al. **Med Pediatr Oncol** 1996 Jul;27(1):32-9

Serial positron emission tomography imaging of changes in amino acid metabolism in low grade astrocytoma after radio- and chemotherapy-- Case report. Sato K, et al. **Neurol Med Chir (Tokyo)** 1995 Nov;35(11):808-12

Differential regulation of C3 gene expression in human astroglioma cells by interferon-gamma and interleukin-1 beta. Barnum SR, et al. **Neurosci Lett** 1995 Sep 8; 197(2):121-4

Effectiveness of early chemotherapy treatment in anaplastic astrocytoma patients. Silvani A, et al. **Tumori** 1995 Nov-Dec;81(6):424-8

ENZYMOLOGY

Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy. Lee SM, et al. **Carcinogenesis** 1996 Apr; 17(4):637-41

Expression of cathepsin D in human astrocytic neoplasias. Warich M, et al. **Gen Diagn Pathol** 1995 Oct;141(2):93-6

Molecular forms of acetyl- and butyrylcholinesterase in human glioma. Sáez-Valero J, et al. **Neurosci Lett** 1996 Mar 15;206(2-3):173-6

EPIDEMIOLOGY

Polyposis coli, craniofacial exostosis and astrocytoma: the concomitant occurrence of the Gardner's and Turcot syndromes. Koot RW, et al. **Surg Neurol** 1996 Mar; 45(3):213-8

GENETICS

Astrocytoma linked to familial ataxia-telangiectasia. Miyagi K, et al. **Acta Neurochir (Wien)** 1995;135(1-2):87-92

Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas. Platten M, et al. **Am J Pathol** 1996 Aug;149(2):621-7

Molecular analysis at the NF1 locus in astrocytic brain tumors. Jensen S, et al. **Cancer** 1995 Aug 15;76(4):674-7

Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Tsuzuki T, et al. **Cancer** 1996 Jul 15;78(2):287-93

Study on aneuploidy and p53 mutations in astrocytomas. Campomenosi P, et al. **Cancer Genet Cytogenet** 1996 Jun; 88(2):95-102

Low-grade astrocytoma with a complex four-breakpoint inversion of chromosome 8 as the sole cytogenetic aberration. Sawyer JR, et al. **Cancer Genet Cytogenet** 1995 Sep;83(2):168-71

Recurrent gain of chromosome arm 7q in low-grade astrocytic tumors studied by comparative genomic hybridization. Schröck E, et al. **Genes Chromosomes Cancer** 1996 Apr;15(4):199-205

Characterization of double minute chromosomes' DNA content in a human high grade astrocytoma cell line by using comparative genomic hybridization and fluorescence in situ hybridization. Giollant M, et al. **Hum Genet** 1996 Sep;98(3):265-70

p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. Patt S, et al. **Hum Pathol** 1996 Jun;27(6):586-9

c-myc oncogene expression and cell proliferation in mixed oligo-astrocytoma. Banerjee M, et al. **Int J Cancer** 1996 Mar 15;65(6):730-3

Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Tada M, et al. **Int J Cancer** 1996 Jul 29;67(3):447-50

Interleukin-1 beta uses common and distinct signaling pathways for induction of the interleukin-6 and tumor necrosis factor alpha genes in the human astrocytoma cell line U373. Lieb K, et al. **J Neurochem** 1996 Apr; 66(4):1496-503

Transfection of an invasive human astrocytoma cell line with a TIMP-1 cDNA: modulation of astrocytoma invasive potential. Matsuzawa K, et al. **J Neuropathol Exp Neurol** 1996 Jan;55(1):88-96

Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P 16ink4 homozygous deletions and CDK4 gene amplifications. Petronio J, et al. **J Neurosurg** 1996 Jun;84(6):1020-3

Instability of short tandem repeats (microsatellites) in human gliomas. van de Kelft E, et al. **J Neurosurg Sci** 1994 Dec; 38(4):203-8

The two types of mRNAs for neurofibromin isoforms produced by von Recklinghausen neurofibromatosis (NF1) gene: analysis in human astrocytic tumors. Tokuyama T, et al. **Neurosci Lett** 1995 Aug 25;196(3):189-92

Steroid hormone receptors in astrocytic neoplasms. Carroll RS, et al. **Neurosurgery** 1995 Sep;37(3):496-503; discussion 503-4

Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Danks RA, et al. **Neurosurgery** 1995 Aug;37(2):246-54

Differential display of messenger ribonucleic acid: a useful technique for analyzing differential gene expression in human brain tumors. Uchiyama CM, et al. **Neurosurgery** 1995 Sep;37(3):464-9; discussion 469-70

Microsatellite instability in human brain tumors [letter] van Meir E, et al. **Neurosurgery** 1995 Dec;37(6):1231-2

Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-ras. Gutmann DH, et al. **Oncogene** 1996 May 16;12(10):2121-7

Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas. Saxena A, et al. **Oncogene** 1996 Aug 1;13(3):661-4

Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Ohgaki H, et al. **Virchows Arch** 1995;427(2):113-8 (44 ref.)

[Expression of fibroblast growth factor receptors (FGFRs) mRNA in human astrocytomas] Yamada SM, et al. **No To Shinkei** 1996 Apr;48(4):363-70 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Tumor antigens in astrocytic gliomas. Kurpad SN, et al. **Glia** 1995 Nov;15(3):244-56 (105 ref.)

Adenosine A2b receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells. Fiebich BL, et al. **J Neurochem** 1996 Apr; 66(4):1426-31

[Immunohistochemical study of the expression of proliferating cell nuclear antigen in astrocytic gliomas of the cerebral hemispheres] Korshunov AG, et al. **Arkh Patol** 1996 Mar-Apr;58(2):32-7 (Eng. Abstr.) **(Rus)**

METABOLISM

Differentiation of glioblastoma multiforme from astrocytomas by in vitro 1H MRS analysis of human brain tumors. Carpinelli G, et al. **Anticancer Res** 1996 May-Jun; 16(3B):1559-63

Mobile lipid accumulation in necrotic tissue of high grade astrocytomas. Kuesel AC, et al. **Anticancer Res** 1996 May-Jun;16(3B):1485-9

Grading and therapy monitoring of astrocytomas with 1H-spectroscopy: preliminary study. Speck O, et al. **Anticancer Res** 1996 May-Jun;16(3B):1581-5

Human astrocytoma U138MG cells express predominantly type-A endothelin receptor. Wu-Wong JR, et al. **Biochim Biophys Acta** 1996 May 28;1311(3):155-63

Characteristics of the binding of [3H]-mepyramine to intact human U373 MG astrocytoma cells: evidence for histamine-induced H1-receptor internalisation. Hishinuma S, et al. **Br J Pharmacol** 1995 Nov;116(6):2715-23

Mastoparan-induced phosphatidylcholine hydrolysis by phospholipase D activation in human astrocytoma cells. Mizuno K, et al. **Br J Pharmacol** 1995 Oct;116(3):2090-6

Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Zagzag D, et al. **Cancer Res** 1996 Jan 1;56(1):182-9

Expression of the small heat shock protein (hsp) 27 in human astrocytomas correlates with histologic grades and tumor growth fractions. Khalid H, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):257-68

Influence of gastrin on human astrocytic tumor cell proliferation. Camby I, et al. **J Natl Cancer Inst** 1996 May 1;88(9):594-600

The mechanism of muscarinic receptor-stimulated phosphatidylinositol resynthesis in 1321N1 astrocytoma cells and its inhibition by Li+. Batty IH, et al. **J Neurochem** 1995 Nov;65(5):2279-89

Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. Ellison DW, et al. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):413-9

Degradation of collagen type IV by C6 astrocytoma cells. Del Maestro RF, et al. **J Neurooncol** 1995;24(1):75-81

Expression of variant CD44 epitopes in human astrocytic brain tumors. Eibl RH, et al. **J Neurooncol** 1995 Dec; 26(3):165-70

Granulocyte colony-stimulating factor (G-CSF) production by astrocytoma cells and its effect on tumor growth. Kikuchi T, et al. **J Neurooncol** 1996 Jan;27(1):31-8

p53 protein and epidermal growth factor receptor expression in human astrocytomas. Kordek R, et al. **J Neurooncol** 1995 Oct;26(1):11-6

Alpha6 beta4 and alpha6 beta1 integrins in astrocytomas and other CNS tumors. Previtali S, et al. **J Neuropathol Exp Neurol** 1996 Apr;55(4):456-65

Release of collagen type IV degrading activity from C6 astrocytoma cells and cell density. Tamaki M, et al. **J Neurosurg** 1996 Jun;84(6):1013-9

Immunohistochemical pattern of P53 protein in human astrocytic tumors. Howng SL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 May; 12(5):279-84

IL-1 beta and TNF alpha, but not IL-6, induce alpha 1-antichymotrypsin expression in the human astrocytoma cell line U373 MG. Machein U, et al. **Neuroreport** 1995

Nov 27;6(17):2283–6
p53 protein overexpression in astrocytic neoplasms. Cho MY, et al. **Yonsei Med J** 1995 Dec;36(6):521–6

MORTALITY

Survival of infants with malignant astrocytomas: a report from the Childrens Cancer Group [letter; comment] Kramer ED, et al. **Cancer** 1995 Nov 1;76(9):1685–6. Comment on: Cancer 1995 Feb 15;75(4):1045–50.
[Prognosis in primary tumors of the central nervous system. A patient material from the Norwegian Radium Hospital 1960–94] Lote K, et al. **Tidsskr Nor Laegeforen** 1996 Apr 30;116(11):1320–4 (Eng. Abstr.) **(Nor)**

PATHOLOGY

Cytology of tumors of the central nervous system [letter; comment] Piaton E. **Acta Cytol** 1996 Jul–Aug;40(4):846–8 . Comment on: Acta Cytol 1993 Nov–Dec;37(6):884–8. Comment on: Acta Cytol 1993 Nov–Dec;37(6):913–22.
Proliferation of gemistocytic cells and glial fibrillary acidic protein (GFAP)–positive oligodendroglial cells in gliomas: a MIB–1/GFAP double labeling study. Kros JM, et al. **Acta Neuropathol (Berl)** 1996;91(1):99–103
Sudden death due to undiagnosed medullary–pontine astrocytoma. Opeskin K, et al.
Am J Forensic Med Pathol 1995 Jun;16(2):168–71
Granular cell change in astrocytic tumors. Geddes JF, et al. **Am J Surg Pathol** 1996 Jan;20(1):55–63 (50 ref.)
Divergent differentiation in pleomorphic xanthoastrocytoma. Evidence for a neuronal element and possible relationship to ganglion cell tumors. Powell SZ, et al.
Am J Surg Pathol 1996 Jan;20(1):80–5
Stereotactic biopsies from astrocytic tumors. Diagnostic information contributed by the quantitative chromatin pattern description. Salmon I, et al.
Anal Quant Cytol Histol 1995 Oct;17(5):332–43
Malignant occipital astrocytoma in a patient with Lhermitte–Duclos disease (cerebellar dysplastic gangliocytoma). Domingo Z, et al. **Br J Neurosurg** 1996 Feb;10(1):99–102
Solitary astrocytoma of the retina in a child [letter] Lee JA, et al. **Br J Ophthalmol** 1996 Jul;80(7):674–5
Central pathology review in clinical trials for patients with malignant glioma. A Report of Radiation Therapy Oncology Group 83–02. Scott CB, et al. **Cancer** 1995 Jul 15;76(2):307–13
Prognostic significance of Ki–67 labeling indices obtained using MIB–1 monoclonal antibody in patients with supratentorial astrocytomas. Wakimoto H, et al. **Cancer** 1996 Jan 15;77(2):373–80
Expression of the small heat shock protein (hsp) 27 in human astrocytomas correlates with histologic grades and tumor growth fractions. Khalid H, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):257–68
Rapidly growing calcified cerebellar astrocytoma in infants. Shuto T, et al. **Childs Nerv Syst** 1996 Feb;12(2):107–9
Brain astrocytomas: biopsy, then irradiation. Lunsford LD, et al. **Clin Neurosurg** 1995;42:464–79 (43 ref.)
Acetylcholine as a mitogen: muscarinic receptor–mediated proliferation of rat astrocytes and human astrocytoma cells. Guizzetti M, et al. **Eur J Pharmacol** 1996 Feb 22; 297(3):265–73
DNA protein flow cytometry of dissociated cultures of human anaplastic gliomas. Pattern of proliferation and differentiation, and the effect of a new cytostatic drug cladribine (2–CdA). Grieb P, et al. **Folia Neuropathol** 1995; 33(3):145–52
Gliofibroma: a distinct entity or a subtype of desmoplastic astrocytoma? Prayson RA. **Hum Pathol** 1996 Jun; 27(6):610–3
c–myc oncogene expression and cell proliferation in mixed oligo–astrocytoma. Banerjee M, et al. **Int J Cancer** 1996 Mar 15;65(6):730–3
Dichotomy of astrocytoma migration and proliferation. Giese A, et al. **Int J Cancer** 1996 Jul 17;67(2):275–82
Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin–dependent kinase inhibitor p27KIP1. Chen J, et al. **J Clin Invest** 1996 Apr 15; 97(8):1983–8
CT and MRI of pleomorphic xanthoastrocytoma: unusual biologic behavior. Petropoulou K, et al.
J Comput Assist Tomogr 1995 Nov–Dec;19(6):860–5
Influence of gastrin on human astrocytic tumor cell proliferation. Camby I, et al. **J Natl Cancer Inst** 1996 May 1;88(9):594–600
Stimulation of the sphingomyelin pathway induces interleukin–6 gene expression in human astrocytoma cells. Fiebich BL, et al. **J Neuroimmunol** 1995 Dec 31; 63(2):207–11
Clinical, radiological, and therapeutic features of pleomorphic xanthoastrocytoma: report of three patients and review of the literature. van Roost D, et al.
J Neurol Neurosurg Psychiatry 1996 Jun;60(6):690–2 (12 ref.)
A grading study of gliomas using computer aided malignancy classification and histologic morphometry. Sharma S, et al. **J Neurooncol** 1996 Jan;27(1):75–85
Astrocyte–astrocytoma cell line interactions in culture. Lal PG, et al. **J Neurosci Res** 1996 May 1;44(3):216–22
Value of postoperative surveillance imaging in the management of children with some common brain tumors. Steinbok P, et al. **J Neurosurg** 1996 May;84(5):726–32
Postoperative surveillance imaging in children with cerebellar astrocytomas. Sutton LN, et al. **J Neurosurg** 1996 May;84(5):721–5
Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high–dose cyclophosphamide. McCowage G, et al.
Med Pediatr Oncol 1996 Jul;27(1):32–9
Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells. Chen J, et al. **Nat Med** 1995 Jul;1(7):638–43
Multiple neuroepithelial tumors of different cell types—case report. Akai T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec; 35(12):901–4 (9 ref.)
Production of tissue inhibitor of metalloproteinases–1 (TIMP–1) by human astrocytic tumors. Nakagawa T, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):728–31
Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl–2 and p53 proteins. Ellison DW, et al. **Neuropathol Appl Neurobiol** 1995 Aug;21(4):352–61
p53 allelic imbalance in astrocytoma detected using fluorescent PCR of microsatellite repeat polymorphisms. al–Sarraj S, et al. **Neuropathol Appl Neurobiol** 1995 Aug; 21(4):344–51
Presurgical integrated MRI/SPECT localization of the sensorimotor cortex in a patient with a low–grade astrocytoma in the rolandic area. Sabatini U, et al.
Neuroreport 1995 Dec 29;7(1):105–8
Substrates for astrocytoma invasion. Giese A, et al.
Neurosurgery 1995 Aug;37(2):294–301; discussion 301–2
Migration of human glioma cells on myelin. Giese A, et al.
Neurosurgery 1996 Apr;38(4):755–64
Age–related changes in diagnoses, histological features, and survival in children with brain tumors: 1930–1979. The Childhood Brain Tumor Consortium. Gilles FH, et al.
Neurosurgery 1995 Dec;37(6):1056–68
Minigemistocytic astrocytoma with frequent apoptoses: analysis of tumor growth. Higami Y, et al. **Pathol Int** 1995 Aug;45(8):610–5
Tuberous sclerosis associated with histologically confirmed ocular and cerebral tumors. Pascual–Castroviejo I, et al.
Pediatr Neurol 1995 Sep;13(2):172–4

PHYSIOPATHOLOGY

Effect of radiation on blood volume in low–grade astrocytomas and normal brain tissue: quantification with dynamic susceptibility contrast MR imaging. Wenz F, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):187–93
Prognostic value of flow cytometry and correlation to some conventional prognostic factors: a retrospective study of archival specimens of 134 astrocytomas. Vavruch L, et al.
J Neurosurg 1996 Jul;85(1):146–51
Human astrocytoma cells express a unique chloride current. Ullrich N, et al. **Neuroreport** 1995 Dec 29;7(1):343–7
Persistence of the typical spike–wave EEG pattern after surgical excision of a temporal lobe astrocytoma and apical lobectomy. Velasco M, et al.
Stereotact Funct Neurosurg 1995;64(1):4–15

PSYCHOLOGY

A survivor's tale [see comments] Cutler SB. **Pharos** 1996 Spring;59(2):37–40. Comment in: Pharos 1996 Spring;59(2):41.

RADIOGRAPHY

Pleomorphic xanthoastrocytoma presenting with massive intracranial hemorrhage. Levy RA, et al.
AJNR Am J Neuroradiol 1996 Jan;17(1):154–6
Radiology rounds. Cerebellar astrocytoma. McLennan MK, et al. **Can Fam Physician** 1995 Aug;41:1298, 1305–9
CT and MRI of pleomorphic xanthoastrocytoma: unusual biologic behavior. Petropoulou K, et al.
J Comput Assist Tomogr 1995 Nov–Dec;19(6):860–5

RADIONUCLIDE IMAGING

Proton magnetic resonance spectroscopic imaging of pediatric low–grade astrocytomas. Lazareff JA, et al.
Childs Nerv Syst 1996 Mar;12(3):130–5
Glucose consumption and methionine uptake in low–grade gliomas after iodine–125 brachytherapy. Würker M, et al.
Eur J Nucl Med 1996 May;23(5):583–6
Grade II astrocytoma visualized by technetium–99m–ECD SPECT. Hirano T, et al. **J Nucl Med** 1996 Feb;37(2):273–5
Thallium–201 in brain tumors: relationship between tumor cell activity in astrocytic tumor and proliferating cell nuclear antigen. Ishibashi M, et al. **J Nucl Med** 1995 Dec; 36(12):2201–6
Usefulness of thallium–201 single photon emission computed tomography to quantify the malignancy grade of brain tumors. Igase K, et al. **Neurol Med Chir (Tokyo)** 1996 Jul; 36(7):434–9

RADIOTHERAPY

Malignant transformation of benign gliomas during interstitial irradiation. Hellwig D, et al.
Acta Neurochir Suppl (Wien) 1995;63:101–8
Intralesional administration of I–131 labelled monoclonal antibodies in the treatment of malignant gliomas. Arista A, et al. **Acta Neurochir (Wien)** 1995;135(3–4):159–62
Radiation therapy with or without surgery in the management of low–grade brain astrocytomas. A retrospective study of 120 patients. Touboul E, et al.
Bull Cancer Radiother 1995;82(4):388–95
Magnetic resonance imaging changes after stereotactic radiation therapy for childhood low grade astrocytoma. Bakardjiev AI, et al. **Cancer** 1996 Aug 15;78(4):864–73
Radiotherapy in the treatment of low–grade astrocytomas. II. The physical and cognitive sequelae. Chadderton RD, et al. **Childs Nerv Syst** 1995 Aug;11(8):443–8
Radiotherapy in the treatment of low–grade astrocytomas. I. A survival analysis. West CG, et al.
Childs Nerv Syst 1995 Aug;11(8):438–42
Brain astrocytomas: biopsy, then irradiation. Lunsford LD, et al. **Clin Neurosurg** 1995;42:464–79 (43 ref.)
The low–grade glioma debate: evidence defending the position of early radiation therapy. Shaw EG.
Clin Neurosurg 1995;42:488–94 (10 ref.)
Neurological assessment of high grade astrocytomas following high dose radiotherapy as sole treatment [letter; comment] Grant P. **Clin Oncol (R Coll Radiol)** 1996; 8(1):64–5. Comment on: Clin Oncol (R Coll Radiol) 1995;7(2):110–2.
Neurological assessment of high grade astrocytomas following high dose radiotherapy as sole treatment [letter] Peat IM, et al. **Clin Oncol (R Coll Radiol)** 1995;7(4):273
Glucose consumption and methionine uptake in low–grade gliomas after iodine–125 brachytherapy. Würker M, et al.
Eur J Nucl Med 1996 May;23(5):583–6
Postoperative radiotherapy of patients with supratentorial astroglial tumours. Ianeva M. **Folia Med (Plovdiv)** 1995; 37(4A Suppl):48
Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine–125 in the adjuvant treatment of high–grade astrocytomas. Snelling L, et al. **Hybridoma** 1995 Apr;14(2):111–4
A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4–year results. Vigliani MC, et al.
Int J Radiat Oncol Biol Phys 1996 Jun 1;35(3):527–33
External beam radiotherapy: hard facts and painful realities. Vick NA, et al. **J Neurooncol** 1995;24(1):93–5 (15 ref.)
Intratumoral administration of 5–[123I]iodo–2'–deoxyuridine in a patient with a brain tumor. Kassis AI, et al.
J Nucl Med 1996 Apr;37(4 Suppl):19S–22S
Serial positron emission tomography imaging of changes in amino acid metabolism in low grade astrocytoma after radio– and chemotherapy— Case report. Sato K, et al.
Neurol Med Chir (Tokyo) 1995 Nov;35(11):808–12
MRI of spinal cord radiation necrosis simulating recurrent cervical cord astrocytoma and syringomyelia. Phuphanich S, et al. **Surg Neurol** 1996 Apr;45(4):362–5

SECONDARY

Ascending central nervous spreading of a spinal astrocytoma. Claus D, et al. **J Neurooncol** 1995;25(3):245–50

SECRETION

Secretion of transforming growth factor–beta 1 and –beta 2 by malignant glioma cells. Sasaki A, et al.
Neurol Med Chir (Tokyo) 1995 Jul;35(7):423–30

SURGERY

Management of low–grade gliomas: results of resections without electrocorticography. Fried I. **Clin Neurosurg** 1995;42:453–63 (41 ref.)
Surgical issues in the management of supratentorial low–grade gliomas. Kelly PJ. **Clin Neurosurg** 1995; 42:399–436 (39 ref.)
The possible role of linac–based stereotactic radiotherapy in the treatment of multifocally and heterochronously recurrent malignant astrocytomas. A case report. Nagane M, et al. **J Neurooncol** 1995 Oct;26(1):79–86
Intracranial meningioma and astrocytoma in the same patient. Case report and review of the literature. Dario A, et al.
J Neurosurg Sci 1995 Mar;39(1):27–35 (44 ref.)
Surgery of astrocytomas in the motor and premotor cortex under local anesthesia: report of 11 cases. Ebeling U, et al. **Minim Invasive Neurosurg** 1995 Jun;38(2):51–9
Fatal tumor hemorrhage after ventriculoperitoneal shunting. Case report. Schroeder HW, et al. **Neuropediatrics** 1995 Jun;26(3):177–9
Stereotactic radiosurgery for glial neoplasms of childhood. Grabb PA, et al. **Neurosurgery** 1996 Apr;38(4):696–701; discussion 701–2
Multicentric pleomorphic xanthoastrocytomas: case report. Haga S, et al. **Neurosurgery** 1996 Jun;38(6):1242–4; discussion 1244–5
Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis. Pahapill PA, et al.
Neurosurgery 1996 Apr;38(4):822–8; discussion 828–9 (32 ref.)
The role of frameless stereotactic techniques in the treatment of pediatric CNS lesions. Pollack IF, et al.
Pediatr Neurol 1995 Oct;13(3):209–16
Prognostic factors in low–grade supratentorial astrocytomas: a uni–multivariate statistical analysis in 76 surgically treated adult patients. Nicolato A, et al. **Surg Neurol** 1995 Sep; 44(3):208–21; discussion 221–3 (60 ref.)

ASTROCYTOMA

[Long-term results after conservative surgery of hypothalamic/ chiasmatic astrocytomas in childhood] Kortmann RD. **Strahlenther Onkol** 1996 May;172(5):280–1 **(Ger)**

[Recurrence of pleomorphic xanthoastrocytoma six years after total removal of mural nodule: a case report] Sakamoto T, et al. **No Shinkei Geka** 1995 Oct;23(10):941–5 (Eng. Abstr.) **(Jpn)**

[Mutism after posterior fossa tumor surgery. Report of 2 cases (see comments)] Wagner R, et al. **Arq Neuropsiquiatr** 1995 Mar;53(1):94–7 (Eng. Abstr.). Comment in: Arq Neuropsiquiatr 1995 Sep;53(3–A):533–4. **(Por)**

[Intraoprative identification and monitoring of motor structures of the brain stem] Shchekut'ev GA, et al. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):26–32 (Eng. Abstr.) **(Rus)**

THERAPY

Hospice at home. Woyka J. **BMJ** 1995 Dec 23–30; 311(7021):1687–8

Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme [see comments] Krishnasamy S, et al. **Cancer Invest** 1995;13(5):453–9. Comment in: Cancer Invest 1995;13(5):553–4.

Therapy of malignant astrocytoma [editorial; comment] Malkin MG. **Cancer Invest** 1995;13(5):553–4. Comment on: Cancer Invest 1995;13(5):453–9.

Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. Glantz MJ, et al. **J Clin Oncol** 1996 Feb;14(2):600–9

Low-grade pure and mixed cerebral astrocytomas treated in the CT scan era. Bahary JP, et al. **J Neurooncol** 1996 Feb;27(2):173–7

High-grade astrocytomas. Wen PY, et al. **Neurol Clin** 1995 Nov;13(4):875–900 (164 ref.)

The management of brainstem gliomas in patients with neurofibromatosis 1. Pollack IF, et al. **Neurology** 1996 Jun; 46(6):1652–60 (48 ref.)

Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Salazar AM, et al. **Neurosurgery** 1996 Jun;38(6):1096–103; discussion 1103–4

Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Glantz MJ, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):26–32

Low-grade astrocytomas: prognosis factors and elements of management. Loiseau H, et al. **Surg Neurol** 1995 Sep; 44(3):224–7 (44 ref.)

[Association of 5-FU, CDDP and hypofractionated radiotherapy in recurrences of subtentorial astrocytomas and malignant gliomas in adults] Bolla M, et al. **Bull Cancer Radiother** 1990;77(1):53–9 (Eng. Abstr.) **(Fre)**

[Treatment of hypothalamic-pituitary tumors—experiences at Hiroshima University School of Medicine] Uozumi T. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1019–36 (43 ref.) (Eng. Abstr.) **(Jpn)**

[Results of multimodal treatment of patients with glial tumors of cerebral hemispheres] Cheremisin VM, et al. **Vestn Rentgenol Radiol** 1995 Jul–Aug;(4):13–5 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Argyrophilic nucleolar organizer region (AgNOR) counting in astrocytic gliomas: prognostic value. Ferreres JC, et al. **Histol Histopathol** 1996 Jan;11(1):35–9

Products of cells from gliomas: IX. Evidence that two fundamentally different mechanisms change extracellular matrix expression by gliomas. McKeever PE, et al. **J Neurooncol** 1995;24(3):267–80

VETERINARY

Characterization of DBT cell clones derived from cells persistently infected with the JHM strain of mouse hepatitis virus. Maeda A, et al. **J Vet Med Sci** 1995 Oct;57(5):813–7

VIROLOGY

Adeno-associated virus (AAV) as a vector for gene transfer into glial cells of the human central nervous system. Tenenbaum L, et al. **Gene Ther** 1994;1 Suppl 1:S80

ASTROCYTOMA, SUBEPENDYMAL GIANT CELL see **GLIOMA**

ASTROGLIA see **ASTROCYTES**

ASTROLOGY

Variations in Vietnamese marriages, births and infant deaths by months of the Julian calendar and years of the Vietnamese and Chinese astrological calendars. Nguyen MT, et al. **J Biosoc Sci** 1996 Jul;28(3):367–77

ASTRONAUTS

Vestibular plasticity following orbital spaceflight: recovery from postflight postural instability. Black FO, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 2:450–4

Work capability during isolation. Gushin VI, et al. **Adv Space Biol Med** 1996;5:297–307

Erythropoietin after long-term spaceflight (30 d) [letter] Gunga HC, et al. **Aviat Space Environ Med** 1995 Sep; 66(9):913

Regional muscle loss after short duration spaceflight. LeBlanc A, et al. **Aviat Space Environ Med** 1995 Dec; 66(12):1151–4

A novel variable-gravity simulation method: potential for astronaut training. Sussingham JC, et al. **Aviat Space Environ Med** 1995 Nov;66(11):1094–6

Is there an effect of weightlessness on mental rotation of three-dimensional objects? Leone G, et al. **Brain Res Cogn Brain Res** 1995 Oct;2(4):255–67

McGill-trained MD, experiment give June 20 shuttle flight strong Canadian flavour. Thirsk R. **Can Med Assoc J** 1996 Jun 15;154(12):1884–8

Microdosimetric-based risk factors for radiation received in space activities during a trip to Mars. Zaider M. **Health Phys** 1996 Jun;70(6):845–51

Radiation protection in space. Blakely EA, et al. **Radiat Environ Biophys** 1995 Aug;34(3):129–31

Initiation-promotion model of tumor prevalence in mice from space radiation exposures. Cucinotta FA, et al. **Radiat Environ Biophys** 1995 Aug;34(3):145–9

Space and radiation protection: scientific requirements for space research. Schimmerling W. **Radiat Environ Biophys** 1995 Aug;34(3):133–7

[Study of the microgravity effect on the inertia of mental tracking of moving objects] Lipshits MI, et al. **Aviakosm Ekolog Med** 1995;29(5):20–3 (Eng. Abstr.) **(Rus)**

[Man in aviation and cosmonautics: past, present and future] Ushakov IB, et al. **Aviakosm Ekolog Med** 1995;29(4):58–64 **(Rus)**

[Blood serum constants in a healthy person: response to space flight] Natochin IuV, et al. **Fiziol Cheloveka** 1995 Sep–Oct; 21(5):121–30 **(Rus)**

PSYCHOLOGY

Group dynamics and crew interaction during isolation. Eskov KN, et al. **Adv Space Biol Med** 1996;5:233–44

Psychological evaluation and support during EXEMSI. Experimental Campaign for the European Manned Space Infrastructure. Gushin VI, et al. **Adv Space Biol Med** 1996; 5:283–95

Crew compatibility and interaction. Sandal GM, et al. **Adv Space Biol Med** 1996;5:213–31

Ethological analysis of crew member behavior: distances, orientations, and postures. Tafforin C. **Adv Space Biol Med** 1996;5:263–81

Interpersonal relations during simulated space missions. Sandal GM, et al. **Aviat Space Environ Med** 1995 Jul; 66(7):617–24

ASTRONOMY

The history of the galaxies. Fukugita M, et al. **Nature** 1996 Jun 6;381(6582):489–95 (94 ref.)

A water-vapour giga-maser in the active galaxy TXFS2226-184. Koekemoer AM, et al. **Nature** 1995 Dec 14;378(6558):697–9

A galactic chimney in the Perseus arm of the Milky Way [see comments] Normandeau M, et al. **Nature** 1996 Apr 25;380(6576):687–8. Comment in: Nature 1996 Apr 25;380(6576):668–9.

Detection of molecular gas in the quasar BR1202 - 0725 at redshift z = 4.69. Ohta K, et al. **Nature** 1996 Aug 1; 382(6590):426–8

Molecular gas and dust around a radio-quiet quasar at redshift 4.69. Omont A, et al. **Nature** 1996 Aug 1; 382(6590):428–31

How the galaxy keeps its halo [news; comment] Shull JM. **Nature** 1996 Apr 25;380(6576):668–9. Comment on: Nature 1996 Apr 25;380(6576):687–9.

Cosmological baryon density derived from the deuterium abundance at redshift z = 3.57. Tytler D, et al. **Nature** 1996 May 16;381(6579):207–9

New images wet researchers' appetites [news] Clery D. **Science** 1996 Feb 23;271(5252):1058

Astronomers probe creation by measuring isotopes [news] Glanz J. **Science** 1996 Jun 7;272(5267):1429–31

CO in the early universe clouds cosmologists' views [news] Glanz J. **Science** 1996 Aug 2;273(5275):581

Atmospheric, evolutionary, and spectral models of the brown dwarf Gliese 229 B. Marley MS, et al. **Science** 1996 Jun 28;272(5270):1919–21

Far-infrared hydrogen lasers in the peculiar star MWC 349A. Strelnitski V, et al. **Science** 1996 Jun 7;272(5267):1459–61

Shock-excited OH maser emission outlining the galactic center supernova remnant G359.1-0.05. Yusef-Zadeh F, et al. **Science** 1995 Dec 15;270(5243):1801–4

Stardust in the laboratory. Zinner E. **Science** 1996 Jan 5; 271(5245):41–2

HISTORY

Errors of judgement at Greenwich in 1796. Mollon JD, et al. **Nature** 1996 Mar 14;380(6570):101–2

ASTROVIRUSES

Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenström's macroglobulinemia. Björkholm M, et al. **Int J Hematol** 1995 Aug;62(2):117–20

GENETICS

Astrovirus ribosomal frameshifting in an infection-transfection transient expression system. Lewis TL, et al. **J Virol** 1996 May;70(5):2869–75

IMMUNOLOGY

Seroprevalence of astrovirus types 1 and 6 in London, determined using recombinant virus antigen. Kriston S, et al. **Epidemiol Infect** 1996 Aug;117(1):159–64

ISOLATION & PURIFICATION

Virologic features of an astrovirus diarrhea outbreak in a day care center revealed by reverse transcriptase-polymerase chain reaction. Mitchell DK, et al. **J Infect Dis** 1995 Dec;172(6):1437–44

Detection of astroviruses from stool samples in Japan using reverse transcription and polymerase chain reaction amplification. Saito K, et al. **Microbiol Immunol** 1995; 39(10):825–8

METABOLISM

Astrovirus ribosomal frameshifting in an infection-transfection transient expression system. Lewis TL, et al. **J Virol** 1996 May;70(5):2869–75

PATHOGENICITY

Astrovirus gastroenteritis. Blacklow NR, et al. **Trans Am Clin Climatol Assoc** 1994;106:58–66; discussion 66–8 (31 ref.)

ASYMMETRIC SEPTAL HYPERTROPHY see **CARDIOMYOPATHY, HYPERTROPHIC**

ASYSTOLE see **HEART ARREST**

ATARACTICS see **TRANQUILIZING AGENTS**

ATAXIA

CHEMICALLY INDUCED

Carbohydrate tolerance in patients with tropical ataxic neuropathy—A human model of chronic cyanide intoxication. Famuyiwa OO, et al. **Afr J Med Med Sci** 1995 Jun;24(2):151–7 (28 ref.)

Neurotoxicity related to the use of topical tretinoin (Retin-A). Bernstein AL, et al. **Ann Intern Med** 1996 Jan 15;124(2):227–8

Germanium intoxication with sensory ataxia. Asaka T, et al. **J Neurol Sci** 1995 Jun;130(2):220–3

Common genetic determinants of the ataxic and hypothermic effects of ethanol in BXD/Ty recombinant inbred mice: genetic correlations and quantitative trait loci. Crabbe JC, et al. **J Pharmacol Exp Ther** 1996 May;277(2):624–32

Identification of genetic markers for initial sensitivity and rapid tolerance to ethanol-induced ataxia using quantitative trait locus analysis in BXD recombinant inbred mice. Gallaher EJ, et al. **J Pharmacol Exp Ther** 1996 May; 277(2):604–12

Reversible myoclonus, tremor, and ataxia in a patient exposed to methyl ethyl ketone. Ortí-Pareja M, et al. **Neurology** 1996 Jan;46(1):272

Contingent drug tolerance: differential tolerance to the anticonvulsant, hypothermic, and ataxic effects of ethanol. Kim CK, et al. **Pharmacol Biochem Behav** 1995 Nov; 52(3):531–9

Tolerance to the anticonvulsant and ataxic effects of pentobarbital: effect of an ascending-dose regimen. Kim CK, et al. **Pharmacol Biochem Behav** 1995 Dec;52(4):825–9

Melaleuca oil poisoning in a 17-month-old. Del Beccaro MA. **Vet Hum Toxicol** 1995 Dec;37(6):557–8

CLASSIFICATION

Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. **Neurology** 1996 May;46(5):1470 (1 ref.)

COMPLICATIONS

Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Bhatia KP, et al. **Brain** 1995 Oct;118 (Pt 5):1087–93 (14 ref.)

Ataxic hemiparesis with bilateral leg ataxia from pontine infarct [letter] Withiam-Leitch S, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov;59(5):557–8

DIAGNOSIS

Mitochondrial cytopathy presenting as hereditary sensory neuropathy with progressive external ophthalmoplegia,

ataxia and fatal myoclonic epileptic status. van Domburg PH, et al. **Brain** 1996 Jun;119 (Pt 3):997-1010
Balint's syndrome [letter; comment] Uyama E, et al. **Neurology** 1995 Nov;45(11):2118-9. Comment on: Neurology 1994 Jul;44(7):1339-40.

DRUG THERAPY

Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. Valentine JL, et al. **J Pharmacol Exp Ther** 1996 Aug; 278(2):709-16

EPIDEMIOLOGY

Neurological signs, aging, and the neurodegenerative syndromes. Waite LM, et al. **Arch Neurol** 1996 Jun; 53(6):498-502
Seasonal ataxia in western Nigeria: evaluation of the impact of health education on hospital prevalence. Adamolekun B. **J Epidemiol Community Health** 1995 Oct;49(5):489-91

ETIOLOGY

Superficial siderosis of the central nervous system: an underdiagnosed cause of sensorineural hearing loss and ataxia. Pribitkin EA, et al. **Am J Otol** 1994 May;15(3):415-8
Vascular ataxic hemiparesis: a reevaluation [letter; comment] Lodder J. **J Neurol Neurosurg Psychiatry** 1995 Nov; 59(5):562-3. Comment on: J Neurol Neurosurg Psychiatry 1995 Apr;58(4):422-7.
[Sensory ataxic neuropathy associated with Sjögren's syndrome] Yasuda T, et al. **Nippon Rinsho** 1995 Oct; 53(10):2568-73 (23 ref.) (Eng. Abstr.) **(Jpn)**
[A case of diffuse idiopathic skeletal hyperostosis (DISH) with various neurological complications] Nishimura Y, et al. **Nippon Ronen Igakkai Zasshi** 1996 Mar;33(3):186-90 (Eng. Abstr.) **(Jpn)**
[Familial paroxysmal ataxia: a new case] Escribano JB, et al. **Rev Neurol** 1996 May;24(129):567-9 (Eng. Abstr.) **(Spa)**

GENETICS

Isolated case of mental retardation and ataxia due to a de novo mitochondrial T8993G mutation [letter] de Coo IF, et al. **Am J Hum Genet** 1996 Mar;58(3):636-8
Amelioration of the behavioral phenotype in genetically ataxic mice through bilateral intracerebellar grafting of fetal Purkinje cells. Triarhou LC, et al. **Cell Transplant** 1996 Mar-Apr;5(2):269-77
Identification of two new KCNA1 mutations in episodic ataxia/myokymia families. Browne DL, et al. **Hum Mol Genet** 1995 Sep;4(9):1671-2
Characterization of a nonsense mutation in the ceruloplasmin gene resulting in diabetes and neurodegenerative disease. Takahashi Y, et al. **Hum Mol Genet** 1996 Jan;5(1):81-84
Maternally inherited hearing loss, ataxia and myoclonus associated with a novel point mutation in mitochondrial tRNASer(UCN) gene. Tiranti V, et al. **Hum Mol Genet** 1995 Aug;4(8):1421-7
Allele distribution of a highly polymorphic repeat on chromosome 12 in patients with symptoms of chorea and ataxia [letter] Zühlke C, et al. **J Med Genet** 1995 Jul; 32(7):577-8
Selective failure of brain-derived neurotrophic factor mRNA expression in the cerebellum of stargazer, a mutant mouse with ataxia. Qiao X, et al. **J Neurosci** 1996 Jan 15; 16(2):640-8
Episodic ataxia results from voltage-dependent potassium channels with altered functions. Adelman JP, et al. **Neuron** 1995 Dec;15(6):1449-54
[Acute intermittent familial ataxia: report of a new family] Pérez-Rodríguez MJ, et al. **Rev Neurol** 1996 May; 24(129):570-1 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Autoimmune ataxic neuropathies (sensory ganglionopathies): are glycolipids the responsible autoantigens? [editorial] Dalakas MC, et al. **Ann Neurol** 1996 Apr;39(4):419-22
The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. Buckanovich RJ, et al. **J Neurosci** 1996 Feb 1;16(3):1114-22

METABOLISM

Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor. Matsumoto M, et al. **Nature** 1996 Jan 11;379(6561):168-71

PATHOLOGY

Non-progressive ataxia: origins, brain pathology and impairments in 78 swedish children. Esscher E, et al. **Dev Med Child Neurol** 1996 Apr;38(4):285-96
Progressive ataxia, focal seizures, and malabsorption syndrome in a 41 year old woman [clinical conference] Mumford CJ, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb;60(2):225-30

PHYSIOPATHOLOGY

Superficial siderosis of the central nervous system: an underdiagnosed cause of sensorineural hearing loss and ataxia. Pribitkin EA, et al. **Am J Otol** 1994 May;15(3):415-8
Motor evoked potentials by magnetic stimulation in hereditary and sporadic ataxia. Mondelli M, et al. **Electromyogr Clin Neurophysiol** 1995 Nov;35(7):415-24
Parietal kinetic ataxia without proprioceptive deficit. Ghika J, et al. **J Neurol Neurosurg Psychiatry** 1995 Nov; 59(5):531-3
Prion disease (PrP-A117V) presenting with ataxia instead of dementia. Mastrianni JA, et al. **Neurology** 1995 Nov; 45(11):2042-50
Frontal lobe ataxia. Terry JB, et al. **Surg Neurol** 1995 Dec; 44(6):583-8
[Regional cerebral glucose metabolism associated with ataxic gait--an FDG-PET activation study in patients with olivopontocerebellar atrophy] Mishina M, et al. **Rinsho Shinkeigaku** 1995 Nov;35(11):1199-204 (Eng. Abstr.) **(Jpn)**
[Tremor and ataxia] Dueñas DA. **Rev Neurol** 1995;23 Suppl 3:S349-54 (41 ref.) **(Spa)**

RADIOGRAPHY

[Hemiparesis-ataxia in an HIV-positive man] Días Silva JJ, et al. **Rev Clin Esp** 1995 Sep;195(9):663-4 **(Spa)**

THERAPY

Amelioration of the behavioral phenotype in genetically ataxic mice through bilateral intracerebellar grafting of fetal Purkinje cells. Triarhou LC, et al. **Cell Transplant** 1996 Mar-Apr;5(2):269-77

VETERINARY

What is your diagnosis? Blindness and ataxia in a foal caused by an abscess with gas-forming bacteria. Bullock P, et al. **J Am Vet Med Assoc** 1995 Oct 1;207(7):853-4
Ataxia associated with lymphosarcoma in a dog. Lefbom BK, et al. **J Am Vet Med Assoc** 1995 Oct 1;207(7):922-3
Diagnostic exercise: ataxia and incoordination in ferrets. Rozengurt N, et al. **Lab Anim Sci** 1995 Aug;45(4):432-4
Lithium toxicosis in a cow. Wallace MA, et al. **Vet Hum Toxicol** 1996 Apr;38(2):99-100
Progressive ataxia in a rottweiler dog. Boersma A, et al. **Vet Q** 1995 Sep;17(3):108-9

ATAXIA, CEREBELLAR see **CEREBELLAR ATAXIA**

ATAXIA TELANGIECTASIA

[Chromosome breakage syndrome and fragile X syndrome] Shiraishi Y. **Nippon Rinsho** 1995 Nov;53(11):2807-14 (16 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Ataxia telangiectasia heterozygotes and patients display increased fluidity and decrease in contents of sulfhydryl groups in red blood cell membranes. Rybczyńska M, et al. **Biochim Biophys Acta** 1996 Aug 16;1302(3):231-5

COMPLICATIONS

Leukemia and lymphoma in ataxia telangiectasia. Taylor AM, et al. **Blood** 1996 Jan 15;87(2):423-38 (110 ref.)

DIAGNOSIS

Ataxia-telangiectasia: somatosensory, brainstem auditory and motor evoked potentials in six patients. Scarpini C, et al. **Dev Med Child Neurol** 1996 Jan;38(1):65-73

DRUG THERAPY

Induction of p53 and increased sensitivity to cisplatin in ataxia-telangiectasia cells. Zhang N, et al. **Oncogene** 1996 Aug 1;13(3):655-9

ETIOLOGY

Insulin-resistant diabetes mellitus in a black woman with ataxia-telangiectasia. Blevins LS Jr, et al. **South Med J** 1996 Jun;89(6):619-21

GENETICS

Astrocytoma linked to familial ataxia-telangiectasia. Miyagi K, et al. **Acta Neurochir (Wien)** 1995;135(1-2):87-92
The gene for Nijmegen breakage syndrome (V2) is not located on chromosome 11 [letter] Komatsu K, et al. **Am J Hum Genet** 1996 Apr;58(4):885-8
Mutations associated with variant phenotypes in ataxia-telangiectasia. McConville CM, et al. **Am J Hum Genet** 1996 Aug;59(2):320-30
The ataxia-telangiectasia-variant genes 1 and 2 are distinct from the ataxia-telangiectasia gene on chromosome 11q23.1 [letter] Stumm M, et al. **Am J Hum Genet** 1995 Oct; 57(4):960-2
Ataxia-telangiectasia: mutations in ATM cDNA detected by protein-truncation screening. Telatar M, et al. **Am J Hum Genet** 1996 Jul;59(1):40-4
Ataxia-telangiectasia and cellular responses to DNA damage. Meyn MS. **Cancer Res** 1995 Dec 15;55(24):5991-6001 (148 ref.)
Genomic organization of the ATM locus involved in ataxia-telangiectasia. Rasio D, et al. **Cancer Res** 1995 Dec 15;55(24):6053-7
The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Vořechovský I, et al. **Cancer Res** 1996 Jun 15; 56(12):2726-32
ATM mutations in cancer families. Vořechovský I, et al. **Cancer Res** 1996 Sep 15;56(18):4130-3
VP16 hypersensitivity and increased faulty recombination in ataxia telangiectasia lymphocytes characterized by the tandem translocation t(14;14)(q11;q32). Petrinelli P, et al. **Carcinogenesis** 1996 Feb;17(2):203-7
Cancer predisposition. Ataxia-telangiectasia at the crossroads. Jackson SP. **Curr Biol** 1995 Nov 1;5(11):1210-2 (13 ref.)
Construction of YAC contigs at human chromosome 11q22.3-q23.1 region covering the Ataxia telangiectasia locus. Imai T, et al. **DNA Res** 1995 Jun 30;2(3):113-21
AT gene isolated [news] **Environ Health Perspect** 1995 Nov; 103(11):993
Ataxia-telangiectasia: closer to unraveling the mystery. Shiloh Y. **Eur J Hum Genet** 1995;3(2):116-38 (259 ref.)
Regulation of the cell cycle following DNA damage in normal and Ataxia telangiectasia cells. Lohrer HD. **Experientia** 1996 Apr 15;52(4):316-28 (186 ref.)
Comparative genome mapping of the ataxia-telangiectasia region in mouse, rat, and Syrian hamster. Matsuda Y, et al. **Genomics** 1996 Jun 15;34(3):347-52
Identification and chromosomal localization of Atm, the mouse homolog of the ataxia-telangiectasia gene. Pecker I, et al. **Genomics** 1996 Jul 1;35(1):39-45
New mutations in the ataxia telangiectasia gene. Baumer A, et al. **Hum Genet** 1996 Aug;98(2):246-9
Mutations revealed by sequencing the 5' half of the gene for ataxia telangiectasia. Byrd PJ, et al. **Hum Mol Genet** 1996 Jan;5(1):145-9
The ATM gene and the radiobiology of ataxia-telangiectasia. Jorgensen TJ, et al. **Int J Radiat Biol** 1996 May; 69(5):527-37 (104 ref.)
Micronucleus induction by 60Co gamma-rays and fast neutrons in ataxia telangiectasia lymphocytes. Vral A, et al. **Int J Radiat Biol** 1996 Aug;70(2):171-6
High frequency and error-prone DNA recombination in ataxia telangiectasia cell lines. Luo CM, et al. **J Biol Chem** 1996 Feb 23;271(8):4497-503
Breast cancer and radiotherapy in ataxia-telangiectasia heterozygote [letter] Ramsay J, et al. **Lancet** 1996 Jun 8; 347(9015):1627
Assignment of the mouse ataxia-telangiectasia gene (Atm) to mouse chromosome 9. Xia Y, et al. **Mamm Genome** 1996 Jul;7(7):554-5
Modulation of radiation-induced chromosomal damage by inhibitors of DNA repair and flow cytometric analysis in ataxia telangiectasia cells with 'intermediate radiosensitivity'. Antoccia A, et al. **Mutagenesis** 1995 Nov; 10(6):523-9
Complementation groups: one or more per gene? [news] Buchwald M. **Nat Genet** 1995 Nov;11(3):228-30
Accelerated telomere shortening in ataxia telangiectasia. Metcalfe JA, et al. **Nat Genet** 1996 Jul;13(3):350-3
The role of the Ataxia telangiectasia gene in the p53, WAF1/CIP1(p21)- and GADD45-mediated response to DNA damage produced by ionising radiation. Artuso M, et al. **Oncogene** 1995 Oct 19;11(8):1427-35
Expression of either the TCL1 oncogene, or transcripts from its homologue MTCP1/c6.1B, in leukaemic and non-leukaemic T cells from ataxia telangiectasia patients. Thick J, et al. **Oncogene** 1996 Jan 18;12(2):379-86
cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein. Cimprich KA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2850-5
Human cDNA clones that modify radiomimetic sensitivity of ataxia-telangiectasia (group A) cells. Ziv Y, et al. **Somat Cell Mol Genet** 1995 Mar;21(2):99-111
Relationship of the ataxia-telangiectasia protein ATM to phosphoinositide 3-kinase. Lavin MF, et al. **Trends Biochem Sci** 1995 Oct;20(10):382-3 (22 ref.)
The ataxia-telangiectasia gene: a link between checkpoint controls, neurodegeneration and cancer. Lehmann AR, et al. **Trends Genet** 1995 Oct;11(10):375-7 (23 ref.)
[Ataxia telangiectasia and genetic predisposition to cancer] Bay JO, et al. **Bull Cancer (Paris)** 1996 Mar;83(3):171-5 (31 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Simian virus 40 transformation alters the actin cytoskeleton, expression of matrix metalloproteinases and inhibitors of metalloproteinases, and invasive behavior of normal and ataxia-telangiectasia human skin fibroblasts. Hansell EJ, et al. **Biochem Cell Biol** 1995 Jul-Aug;73(7-8):373-89
Elevation of interferon beta-inducible proteins in ataxia telangiectasia cells. Siddoo-Atwal C, et al. **Cancer Res** 1996 Feb 1;56(3):443-7
Predominance of null mutations in ataxia-telangiectasia. Gilad S, et al. **Hum Mol Genet** 1996 Apr;5(4):433-9
The adaptive response of peripheral blood lymphocytes to low doses of mutagenic agents in patients with ataxia telangiectasia. Némethová G, et al. **Mutat Res** 1995 Nov; 348(3):101-4
Induction of p53 and increased sensitivity to cisplatin in ataxia-telangiectasia cells. Zhang N, et al. **Oncogene** 1996 Aug 1;13(3):655-9

ATAXIA TELANGIECTASIA

PATHOLOGY

Induction of p53 protein by gamma radiation in lymphocyte lines from breast cancer and ataxia telangiectasia patients. Birrell GW, et al. **Br J Cancer** 1995 Nov;72(5):1096–101

Glutathione determination by the Tietze enzymatic recycling assay and its relationship to cellular radiation response. Eady JJ, et al. **Br J Cancer** 1995 Nov;72(5):1089–95

Deregulated apoptosis in ataxia telangiectasia: association with clinical stigmata and radiosensitivity. Duchaud E, et al. **Cancer Res** 1996 Mar 15;56(6):1400–4

Regulation of the cell cycle following DNA damage in normal and Ataxia telangiectasia cells. Lohrer HD. **Experientia** 1996 Apr 15;52(4):316–28 (186 ref.)

Defect in multiple cell cycle checkpoints in ataxia–telangiectasia postirradiation. Beamish H, et al. **J Biol Chem** 1996 Aug 23;271(34):20486–93

Ionizing radiation–induced phosphorylation of RPA p34 is deficient in ataxia telangiectasia and reduced in aged normal fibroblasts. Cheng X, et al. **Radiother Oncol** 1996 Apr;39(1):43–52

PHYSIOPATHOLOGY

Atm–deficient mice: a paradigm of ataxia telangiectasia. Barlow C, et al. **Cell** 1996 Jul 12;86(1):159–71

Ataxia–teleangectasia: neurophysiological studies in 8 patients. Lelli S, et al. **Electromyogr Clin Neurophysiol** 1995 Aug–Sep;35(5):311–5

ATAXIAS, HEREDITARY see **SPINOCEREBELLAR DEGENERATION**

ATELECTASIS

CHEMICALLY INDUCED

Pulmonary collapse and pneumonia due to inhalation of a waterproofing aerosol in female CD–1 mice. Yamashita M, et al. **J Toxicol Clin Toxicol** 1995;33(6):631–7

CONGENITAL

Lobar emphysema and atelectasis syndrome, a nosological unity. Ring–Mrozik E, et al. **Eur J Pediatr Surg** 1995 Jun; 5(3):131–5 (27 ref.)

DIAGNOSIS

Evaluation of chronic atelectasis in children using chest comput..d tomography and bronchoscopy. Wong KS, et al. **Acta Paediatr Sin** 1996 May–Jun;37(3):193–6

ETIOLOGY

Atelectasis and chest wall shape during halothane anesthesia. Warner DO, et al. **Anesthesiology** 1996 Jul;85(1):49–59

Influence of inspired nitrogen concentration during anaesthesia for coronary artery bypass grafting on postoperative atelectasis. Joyce CJ, et al. **Br J Anaesth** 1995 Oct;75(4):422–7

Pulmonary atelectasis after reconstruction with a latissimus dorsi myocutaneous flap. Wax MK, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):268–72

Use of fiberoptic bronchoscopy in asthmatic children with lung collapse. Barbato A, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):253–5 (9 ref.)

Localized pneumothorax with lobar collapse and diffuse obstructive airway disease. Nimkin K, et al. **Pediatr Radiol** 1995;25(6):449–51

Localised pneumothorax with lobar collapse [letter] Petros A, et al. **Pediatr Radiol** 1996;26(3):238

[Complications of an asthma crisis] Delafosse C, et al. **Rev Mal Respir** 1996 Jul;13(3):313–5 **(Fre)**

[Hemilateral hydrothorax and atelectasis during laparoscopic Nissen fundoplication] Sudoh Y, et al. **Masui** 1996 Apr; 45(4):471–3 (Eng. Abstr.) **(Jpn)**

[Lung collapse. A common phenomenon during anesthesia] Hedenstierna G, et al. **Lakartidningen** 1996 Jun 12; 93(24):2323–5 **(Swe)**

METABOLISM

What is the role of absorption atelectasis in the genesis of perioperative pulmonary collapse? Joyce CJ, et al. **Anaesth Intensive Care** 1995 Dec;23(6):691–6 (57 ref.)

MICROBIOLOGY

Aspergillary bronchopneumonia: an unusual cause of atelectasis and asphyxia in a leukemic patient. Velloso ED, et al. **Rev Paul Med** 1994 Oct–Dec;112(4):639–41

PATHOLOGY

Rounded atelectasis associated with silicosis. Honma K, et al. **Wien Klin Wochenschr** 1995;107(19):585–9

PHYSIOPATHOLOGY

Effect of anemia on intrapulmonary shunt during atelectasis in rabbits. Deem S, et al. **J Appl Physiol** 1995 Dec; 79(6):1951–7

PREVENTION & CONTROL

Postoperative atelectasis and pneumonia: risk factors. Brooks–Brunn JA. **Am J Crit Care** 1995 Sep;4(5):340–9; quiz 350–1 (90 ref.)

Lung aeration. The effect of pre–oxygenation and hyperoxygenation during total intravenous anaesthesia. Reber A, et al. **Anaesthesia** 1996 Aug;51(8):733–7

The effect of physical therapy on respiratory complications following cardiac valve surgery. Johnson D, et al. **Chest** 1996 Mar;109(3):638–44

Prophylactic bronchial hygiene following cardiac surgery: what is necessary? [editorial; comment] Kacmarek RM. **Intensive Care Med** 1995 Jun;21(6):467–8. Comment on: Intensive Care Med 1995 Jun;21(6):469–74.

Mask physiotherapy in patients after heart surgery: a controlled study [see comments] Richter Larsen K, et al. **Intensive Care Med** 1995 Jun;21(6):469–74. Comment in: Intensive Care Med 1995 Jun;21(6):467–8.

RADIOGRAPHY

Computed tomography correlation in atypical (peripheral) right upper lobe collapse: the minor fissure as an explanation for the pleural–based density. Teel G, et al. **J Thorac Imaging** 1996 Winter;11(1):86–8

SURGERY

[Use of a laryngeal mask airway for anesthesia in a patient with bronchomalacia] Yamaguchi S, et al. **Masui** 1996 Mar; 45(3):348–51 (Eng. Abstr.) **(Jpn)**

THERAPY

Total liquid ventilation with perfluorocarbons increases pulmonary end–expiratory volume and compliance in the setting of lung atelectasis. Tooley R, et al. **Crit Care Med** 1996 Feb;24(2):268–73

Chest physical therapy for patients in the intensive care unit. Ciesla ND. **Phys Ther** 1996 Jun;76(6):609–25 (133 ref.)

["Treatment of total atelectasis of the left lung in severe ARDS with side–separated ventilation and surfactant administration" (see comments] Knoch M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):270–3 (Eng. Abstr.). Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 May;31(4):197–9. **(Ger)**

ULTRASONOGRAPHY

Ultrasound features of folded lung. Marchbank ND, et al. **Clin Radiol** 1996 Jun;51(6):433–7

[Color Doppler echography in the study of obstruction–related lung collapse] Ferrari FS, et al. **Radiol Med (Torino)** 1996 Mar;91(3):226–30 (Eng. Abstr.) **(Ita)**

ATELECTASIS, CONGESTIVE see **RESPIRATORY DISTRESS SYNDROME, ADULT**

ATELES see **CEBIDAE**

ATELINAE see **CEBIDAE**

ATELINE HERPESVIRUS 2 see **RHADINOVIRUS**

ATENOLOL

ADMINISTRATION & DOSAGE

A double–blind comparison of once–daily metoprolol controlled–release and atenolol in the treatment of Chinese patients with mild to moderate hypertension. Chen MF, et al. **Cardiovasc Drugs Ther** 1995 Jun;9(3):401–6

Miscompliance by proxy. Jamieson MJ, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):594

A cross–over study comparing the efficacy of a combination of atenolol and nifedipine at different doses in angina pectoris. Metcalfe MJ, et al. **Curr Med Res Opin** 1995; 13(5):251–6

ADVERSE EFFECTS

Persistent hypoglycemia and hyperinsulinemia: caution in using glucagon [letter] Thoma ME, et al. **Am J Emerg Med** 1996 Jan;14(1):99–101

Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non–diabetic hypertensive subjects. Satia MC, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):237–41

CHEMISTRY

Flux measurements across Caco–2 monolayers may predict transport in human large intestinal tissue. Rubas W, et al. **J Pharm Sci** 1996 Feb;85(2):165–9

CONTRAINDICATIONS

Don't get stung with the adrenergic blockers (beta or alpha)! Watson A. **Aust Fam Physician** 1995 Oct;24(10):1879

PHARMACOKINETICS

Effect of aging on atenolol pharmacokinetics and pharmacodynamics. Sowinski KM, et al. **J Clin Pharmacol** 1995 Aug;35(8):807–14

PHARMACOLOGY

The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomic function in mild to moderate hypertension. Panfilov V, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):563–9

Beta blockers in pregnancy and their effect on regional Doppler ultrasound and fetal weight. Crichton F. **Clin Exp Obstet Gynecol** 1996;23(1):15–7

Effect of combined atenolol and nifedipine administration on psychomotor performance in normal subjects. Gerrard L, et al. **Eur J Clin Pharmacol** 1995;48(3–4):229–33

Effects of angiotensin–converting enzyme inhibition versus beta–adrenergic blockade on aortic stiffness in essential hypertension. Savolainen A, et al. **J Cardiovasc Pharmacol** 1996 Jan;27(1):99–104

Sertraline does not alter the beta–adrenergic blocking activity of atenolol in healthy male volunteers. Ziegler MG, et al. **J Clin Psychiatry** 1996;57 Suppl 1:12–5

A comparison of the metabolic effects of captopril and atenolol on glucose, insulin and lipoproteins in patients with mild–to–moderate essential hypertension. Maritz FJ, et al. **S Afr Med J** 1995 Dec;85(12 Pt 2):1342–5

[Effects of long–term atenolol treatment on beta–adrenoceptor subtypes in rat heart] Wang LF, et al. **Sheng Li Hsueh Pao** 1995 Aug;47(4):381–6 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Randomized double–blind, placebo–controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. Mahanonda N, et al. **Am Heart J** 1995 Dec;130(6):1250–3

Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] Study). Pratt CM, et al. **Am J Cardiol** 1996 Jun 15;77(15):1302–9

Effect of sustained release diltiazem (Diltiazem–R) in patients with stable effort angina. Kaku T, et al. **Artery** 1994; 21(4):193–207

Different hemodynamic effects of celipropol and atenolol in patients with mild to moderate hypertension. Saner H, et al. **Arzneimittelforschung** 1995 Jul;45(7):790–5

Combination monoamine oxidase inhibitor and beta–blocker treatment of migraine, with anxiety and depression. Merikangas KR, et al. **Biol Psychiatry** 1995 Nov 1; 38(9):603–10

Reduction by beta–adrenoceptor blockade of hypoxia–induced right heart hypertrophy in the rat. Ostman–Smith I. **Br J Pharmacol** 1995 Nov; 116(6):2698–702

Diurnal variation of ischemic response to exercise in patients receiving a once–daily dose of beta–blockers. Implications for exercise testing and prescription of exercise and training heart rates. Franklin BA, et al. **Chest** 1996 Jan;109(1):253–7

Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients. Tuininga YS, et al. **Circulation** 1995 Dec 15;92(12):3415–23

Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Dargie HJ, et al. **Eur Heart J** 1996 Jan;17(1):104–12

The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Fox KM, et al. **Eur Heart J** 1996 Jan;17(1):96–103

Beta adrenergic blockade does not improve effort tolerance in patients with mitral stenosis in sinus rhythm. Patel JJ, et al. **Eur Heart J** 1995 Sep;16(9):1264–8

A diuretic is more effective than a beta–blocker in hypertensive patients not controlled on amlodipine and lisinopril. Antonios TF, et al. **Hypertension** 1996 Jun; 27(6):1325–8

Comparative effects of atenolol versus nifedipine on serum lipids and other biochemical parameters in diabetic and non–diabetic hypertensive subjects. Satia MC, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):237–41

Medium–term effects of beta–blockade on left ventricular mechanics: a double–blind, placebo–controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. Rousseau MF, et al. **J Card Fail** 1996 Mar;2(1):15–23

Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. Morel Y, et al. **J Cardiovasc Pharmacol** 1995 Aug;26(2):306–11

Comparative effects of rilmenidine and atenolol on tests of autonomic function and mental and dynamic exercise in patients with essential hypertension. Panfilov V, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S44–7

The effects of beta 1–adrenergic blockade on the growth response to growth hormone (GH)–releasing hormone therapy in GH–deficient children. Cassorla F, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2997–3001

Association between angiotensin–converting–enzyme gene polymorphism and failure of renoprotective therapy. van Essen GG, et al. **Lancet** 1996 Jan 13;347(8994):94–5

Effect of beta adrenergic receptor blockade on cardiac autonomic tone in patients with chronic stable angina.

Burger AJ, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):411–7

[Corotenol, its effectiveness and tolerance in light of new studies] Uhlíř O. **Vnitr Lek** 1996 Feb;42(2):82–5 (Eng. Abstr.) **(Cze)**

ATHERECTOMY

see related
ENDARTERECTOMY

Vascular repair mechanisms after directional atherectomy or percutaneous transluminal coronary angioplasty in atherosclerotic rabbit iliac arteries. Wilensky RL, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):13–22

Ultrastructural characteristics of human atherectomy tissue from coronary and lower extremity arterial stenoses. Bauriedel G, et al. **Am J Cardiol** 1996 Mar 1;77(7):468–74

Intravascular ultrasound imaging of peripheral arteries as an adjunct to balloon angioplasty and atherectomy. Korogi Y, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):1–9 (39 ref.)

Percutaneous transluminal rotational atherectomy for treatment of in-stent restenosis. Khanolkar UB. **Indian Heart J** 1996 May–Jun;48(3):281–2

Percutaneous rotational atherectomy in peripheral vascular disease for lesions unsuitable for balloon angioplasty. Tyagi S, et al. **Indian Heart J** 1996 Jan–Feb;48(1):45–8

Rotational atherectomy of calcified ostial saphenous vein graft lesion with long term follow-up: a case report. Abhyankar AD, et al. **Int J Cardiol** 1995 Nov 10;52(1):11–2

The ideal guidance imaging system for endovascular interventions. Verbin CS, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3 Suppl 1):5–9

Mid-term and long-term results with directional atherectomy of vein graft stenoses. Porter DH, et al. **J Vasc Surg** 1996 Apr;23(4):554–67

Outcome of percutaneous intervention in iliac artery stents. Sapoval MR, et al. **Radiology** 1996 Feb;198(2):481–6

[Intervention cardiology. Atherectomy or stenting?] Endresen K. **Tidsskr Nor Laegeforen** 1995 Nov 10; 115(27):3356–7 **(Nor)**

INSTRUMENTATION

Evaluation of the pullback atherectomy catheter in the treatment of lower limb vascular disease. Grubnic S, et al. **Cardiovasc Intervent Radiol** 1996 May–Jun;19(3):152–9

Current status of atherectomy for peripheral arterial occlusive disease. Ahn SS, et al. **World J Surg** 1996 Jul–Aug;20(6):635–43 (45 ref.)

[Percutaneous dynamic atherectomy with the aid of 12-F and 14-F transluminal atherectomy catheters (TEC): initial results] Rilinger N, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):233–7 (Eng. Abstr.) **(Ger)**

[Initial clinical results in the treatment of peripheral arterial occlusive diseases using new percutaneous atherectomy equipment (REDHA-CUT)] Redha F, et al. **Swiss Surg** 1996;(3):102–4 (Eng. Abstr.) **(Ger)**

[Ultrastructural characteristics of cellular reaction to experimental catheter-induced lesions of arterial blood vessels] Gonschior P, et al. **Vasa** 1995;24(4):325–32 (Eng. Abstr.) **(Ger)**

METHODS

Prospective study of extraction atherectomy in patients with acute myocardial infarction. Kaplan BM, et al. **Am J Cardiol** 1996 Aug 15;78(4):383–8

A randomized trial of transcutaneous extraction atherectomy in femoral arteries: intravascular ultrasound observations. Nakamura S, et al. **J Clin Ultrasound** 1995 Oct;23(8):461–71

[Atherectomy. A new catheterization method for coronary revascularization] Myreng Y, et al. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3358–60 (Eng. Abstr.) **(Nor)**

ATHERECTOMY, CORONARY

Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Abdelmeguid AE, et al. **Am Heart J** 1996 Jun; 131(6):1097–105

Directional coronary atherectomy and progressive coronary dilatation: a comparative analysis of acute outcome. Jackson BD, et al. **Am Heart J** 1995 Nov;130(5):966–70

Influence of plaque composition on luminal gain after balloon angioplasty, directional atherectomy, and coronary stenting. Marsico F, et al. **Am Heart J** 1995 Nov; 130(5):971–5

Variant angina after successful coronary atherectomy. Ruygrok PN, et al. **Am Heart J** 1995 Dec;130(6):1309–11

High-speed rotational atherectomy: six-month serial quantitative coronary angiographic follow-up. Stertzer SH, et al. **Am Heart J** 1996 Apr;131(4):639–48

Matching to guide the design and predict the outcome of randomized atherectomy trials [editorial] Umans VA, et al. **Am Heart J** 1995 Nov;130(5):1135–43 (48 ref.)

Increased extracellular matrix synthesis by smooth-muscle cells obtained from in vivo restenotic lesions by directional coronary atherectomy. Violaris AG, et al. **Am Heart J** 1996 Mar;131(3):613–5

Identification of coronary thrombus after myocardial infarction by intracoronary ultrasound compared with histology of tissues sampled by atherectomy. Chemarin-Alibelli MJ, et al. **Am J Cardiol** 1996 Feb 15; 77(5):344–9

Usefulness of adjunctive angioscopy and extraction atherectomy before stent implantation in high-risk aortocoronary saphenous vein grafts. Kaplan BM, et al. **Am J Cardiol** 1995 Oct 15;76(11):822–4

Outcome of narrowing related side branches after high-speed rotational atherectomy. Walton AS, et al. **Am J Cardiol** 1996 Feb 15;77(5):370–3

Influence of plaque morphology on the mechanism of luminal enlargement after directional coronary atherectomy and balloon angioplasty. Marsico F, et al. **Br Heart J** 1995 Aug; 74(2):134–9

Initial report of rotational ablation: the Toronto Hospital experience. Kimball BP, et al. **Can J Cardiol** 1996 Feb; 12(2):145–50

Coronary rotablation and reserve: can they occur together? [editorial; comment] Bowers TR, et al. **Cathet Cardiovasc Diagn** 1995 Nov;36(3):277. Comment on: Cathet Cardiovasc Diagn 1995 Nov;36(3):272–6.

Rotational atherectomy in restenotic lesions at the distal saphenous vein graft anastomosis. Cardenas JR, et al. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):53–7; discussion 58

Influence of adjunctive balloon angioplasty on coronary blood flow after rotational atherectomy [see comments] Khoury AF, et al. **Cathet Cardiovasc Diagn** 1995 Nov; 36(3):272–6. Comment in: Cathet Cardiovasc Diagn 1995 Nov;36(3):277.

Morphologic characteristics of restenotic lesions following coronary interventions: balloon angioplasty versus directional atherectomy: can we speculate about the mechanism of restenosis from morphologic analysis? Moreu J, et al. **Cathet Cardiovasc Diagn** 1995 Oct;36(2):103–9; discussion 110–1

Immunohistochemical characterization of immune cell composition and cytokine receptor expression in human coronary atherectomy tissue. Miller DD, et al. **Coron Artery Dis** 1995 Dec;6(12):965–72

Clinical, angiographic and histopathological predictors of restenosis after directional coronary atherectomy. Petkar S, et al. **Indian Heart J** 1995 May–Jun;47(3):227–31

Percutaneous revascularization of ostial saphenous vein graft stenoses. Abdel-Meguid AE, et al. **J Am Coll Cardiol** 1995 Oct;26(4):955–60

Effect of subintimal resection on initial outcome and restenosis for native coronary lesions and saphenous vein graft disease treated by directional coronary atherectomy. A report from the CAVEAT I and II investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial. Holmes DR Jr, et al. **J Am Coll Cardiol** 1996 Sep; 28(3):645–51

Influence of stenotic lesion morphology on immediate and long-term (6 months) angiographic outcome: comparative analysis of directional coronary atherectomy versus standard balloon angioplasty. Kimball BP, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):543–51

Do excimer laser angioplasty and rotational atherectomy facilitate balloon angioplasty? Implications for lesion-specific coronary intervention. Safian RD, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):552–9

Clinical and angiographic comparison of matched patients with successful directional coronary atherectomy or stent implantation for primary coronary artery lesions. Umans VA, et al. **J Am Coll Cardiol** 1996 Sep;28(3):637–44

Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. Zhou YF, et al. **N Engl J Med** 1996 Aug 29;335(9):624–30

Rotational ablation of discrete lesions in the coronary arteries is safe. A nonrandomized comparison with percutaneous transluminal coronary angioplasty. Cheirif J, et al. **Tex Heart Inst J** 1995;22(3):237–42

[Rotational atherectomy and PTCA in complex coronary lesions (B2 and C): the immediate and long-term results] Isabella G, et al. **G Ital Cardiol** 1995 Sep;25(9):1127–38 (Eng. Abstr.) **(Ita)**

[Late coronary artery aneurysm formation following directional coronary atherectomy] Nakamura H, et al. **J Cardiol** 1996 Jan;27(1):1–8 (Eng. Abstr.) **(Jpn)**

[Immunohistochemical analysis of adhesion molecules in directional coronary atherectomy specimens] Sakurai S, et al. **J Cardiol** 1995 Sep;26(3):139–47 (Eng. Abstr.) **(Jpn)**

[Directional coronary atherectomy in ostial lesions of the anterior descending coronary artery] Gallardo A, et al. **Rev Esp Cardiol** 1996 Apr;49(4):264–9 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Perforation of nontarget artery during directional coronary atherectomy. Cohen EA, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):240–3

Abrupt closure: the CAVEAT I experience. Coronary Angioplasty Versus Excisional Atherectomy Trial. Holmes DR Jr, et al. **J Am Coll Cardiol** 1995 Nov 15;26(6):1494–500

Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). Omoigui NA, et al. **J Am Coll Cardiol** 1995 Oct;26(4):922–30

Clinical and postmortem outcome of "no-reflow" phenomenon in a patient treated with rotational atherectomy. Bowles M, et al. **South Med J** 1996 Aug; 89(8):820–3

INSTRUMENTATION

Directional coronary atherectomy for lesions of the proximal left anterior descending artery: initial clinical results, complications and histopathological findings [see comments] Sankardas MA, et al. **Aust N Z J Med** 1995 Dec;25(6):676–80. Comment in: Aust N Z J Med 1995 Dec;25(6):661–2.

Directional coronary atherectomy in the era of stents [editorial; comment] Webster MW, et al. **Aust N Z J Med** 1995 Dec;25(6):661–2. Comment on: Aust N Z J Med 1995 Dec;25(6):676–806.

Dislocation of the rotating cutter during directional coronary atherectomy: a note of caution. Bauriedel G, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):244–9

Guidewire transection during rotational coronary atherectomy due to guide catheter dislodgement and wire kinking. Foster-Smith K, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):224–7

Retrieval of directional coronary atherectomy guiding catheter with angioplasty balloon catheter. el Ghamry Sabe AA, et al. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):237–9

Evaluation of a new 9F guiding catheter for directional coronary atherectomy. Guérin Y, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):99–104

Rotational atherectomy with a new device: initial clinical experience. Kjellgren O, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):459–66

Enhanced manipulation of directional coronary atherectomy and coronary angioplasty guide catheters. Ormiston JA, et al. **Cathet Cardiovasc Diagn** 1996 Apr;37(4):425–7

Separation of a flexible nose cone tip during directional atherectomy. Rashkow AM. **Cathet Cardiovasc Diagn** 1995 Jul;35(3):250–1

Emergency rotational ablation of a calcified left main coronary artery stenosis in a patient with ischemic induced cardiogenic shock. Rozenman Y, et al. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):63–6

Atherectomy (directional, rotational, extractional) and its role in percutaneous revascularization. Kaufmann UP, et al. **Curr Opin Cardiol** 1995 Jul;10(4):412–9 (53 ref.)

Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups [see comments] Foley DP, et al. **Eur Heart J** 1995 Oct; 16(10):1331–46. Comment in: Eur Heart J 1995 Oct;16(10):1307–8.

[Alternative methods in interventional therapy of coronary heart disease] Erbel R, et al. **Z Kardiol** 1995;84 Suppl 2:53–64 (72 ref.) (Eng. Abstr.) **(Ger)**

[Drug and instrumental therapeutic approaches for prevention of restenosis] Höfling B, et al. **Z Kardiol** 1995; 84 Suppl 4:151–8 (36 ref.) (Eng. Abstr.) **(Ger)**

[PTCA or alternative techniques? Balloon angioplasty remains dominant] Reifart N. **Z Kardiol** 1995;84 Suppl 2:43–52 (30 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Rotational atherectomy with adjunctive balloon angioplasty versus conventional percutaneous transluminal coronary angioplasty in type B2 lesions: results of a randomized study. Guérin Y, et al. **Am Heart J** 1996 May;131(5):879–83

Transluminal extraction catheter atherectomy in long saphenous vein grafts. Blankenship JC, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):368–72

Directional atherectomy for the dilatation of bifurcation stenoses in the coronary arteries. Gambhir DS, et al. **Indian Heart J** 1995 Mar–Apr;47(2):115–9

New devices in interventional cardiology: present and future. Beyar R. **Isr J Med Sci** 1996 Jul;32(7):515–25 (42 ref.)

Mechanisms and immediate and long-term results of adjunct directional coronary atherectomy after rotational atherectomy. Dussaillant GR, et al. **J Am Coll Cardiol** 1996 May;27(6):1390–7

Role of intraaortic balloon pump counterpulsation in high risk coronary rotational atherectomy. O'Murchu B, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1270–5

Percutaneous rotational coronary atherectomy: initial Green Lane and Mercy hospitals' experience. Porter GF, et al. **N Z Med J** 1996 Jun 14;109(1023):203–5

[Directional coronary atherectomy] de Cesare NB. **Cardiologia** 1996 Jan;41(1):71–4 **(Ita)**

ATHEROEMBOLISM see **EMBOLISM, CHOLESTEROL**

ATHEROMA see **ATHEROSCLEROSIS**

ATHEROSCLEROSIS

see related
ATHERECTOMY
EMBOLISM, CHOLESTEROL

Atherosclerosis: an update. Basha BJ, et al. **Am Heart J** 1996 Jun;131(6):1192–202 (107 ref.)

Satellite Symposia of the International Symposia on Atherosclerosis— brief history and selected aspects. Haust

MD. **Atherosclerosis** 1995 Oct;117(2):151–8
Fibrinolysis and atherosclerosis. Hamsten A, et al. **Baillieres Clin Haematol** 1995 Jun;8(2):345–63 (119 ref.)
Nutrition and Atherosclerosis. Proceedings of a satellite symposium of the Xth International Symposium on Atherosclerosis. Quebec City, Quebec, October 6–8, 1994. **Can J Cardiol** 1995 Oct;11 Suppl G:7G–137G
Peripheral arterial–vascular disease in women: prevalence, prognosis, and treatment. Gerhard M, et al. **Cardiology** 1995;86(4):349–55 (56 ref.)
Retinal artery occlusion in rabbit eyes using human atheroma. Ciulla TA, et al. **Curr Eye Res** 1995 Jul;14(7):573–8
Atherosclerosis: cell biology and lipoproteins. **Curr Opin Lipidol** 1995 Oct;6(5):B55–75
American Diabetes Association scientific sessions, 1995. Magnesium deficiency, atherosclerosis, and health care. Bloomgarden ZT. **Diabetes Care** 1995 Dec;18(12):1623–7
Frontiers of atherosclerosis and lipoprotein research. Special issue in memory of Professor Shlomo Eisenberg. **Isr J Med Sci** 1996 Jun;32(6):i, 345–508
Atherogenesis, families, and family practice: recognizing and treating an important syndrome [editorial] McBride PE. **J Am Board Fam Pract** 1996 Jan–Feb;9(1):64–6
Aneurysms of the infrapopliteal arteries. Marmorale A, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):324–6 (4 ref.)
Beyond oxidized LDL: the initiation and progression of atherosclerosis. Hirose N, et al. **Keio J Med** 1996 Jun; 45(2):90–4 (26 ref.)
Evaluation of hypercholesterolemia in childhood. Starc TJ, et al. **Pediatr Rev** 1996 Mar;17(3):94–7; quiz 98
The 64th congress of the European Atherosclerosis Society. Utrecht, The Netherlands, 10–13 June 1995. Dalby AJ. **S Afr Med J** 1996 Apr;86 Suppl 2:C100–2
Atherosclerosis of the inferior epigastric and internal mammary arteries. Teerenhovi O, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(2):59–61
Mouse models of atherosclerosis. Breslow JL. **Science** 1996 May 3;272(5262):685–8 (26 ref.)
[Atherosclerotic aneurysm of a branch of the deep femoral artery] Rampoldi V, et al. **Minerva Cardioangiol** 1996 Jan–Feb;44(1–2):29–32 (Eng. Abstr.) **(Ita)**

BLOOD

Lipoprotein Lp(a) and cerebrovascular disease in the elderly: correlations with the severity of extracranial carotid atherosclerosis assessed by ultrasonography. Denti L, et al. **Acta Biomed Ateneo Parmense** 1995;66(3–4):175–83
Re: "No association between serum ferritin and asymptomatic carotid atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study" [letter; comment] Sullivan JL. **Am J Epidemiol** 1996 Jun 1;143(11):1178–9. Comment on: Am J Epidemiol 1995 Apr 15;141(8):719–23.
A comparison of blood lipid and lipoprotein values in young adults who die suddenly and unexpectedly from atherosclerotic coronary artery disease with other noncardiac deaths. Hiserodt JC, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):101–6
Leukocyte flow properties, polymorphonuclear membrane fluidity, and cytosolic Ca2+ content in subjects with vascular atherosclerotic disease with and without noninsulin-dependent diabetes mellitus. Caimi G, et al. **Angiology** 1996 Aug;47(8):757–63
The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Wagenknecht LE, et al. **Ann Epidemiol** 1995 Nov;5(6):464–72
The role of lipoprotein(a) in atherogenesis and thrombosis. Hajjar KA, et al. **Annu Rev Med** 1996;47:423–42 (137 ref.)
Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Hirano K, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1849–56
In hypercholesterolemia, lower peripheral monocyte count is unique among the major predictors of atherosclerosis. Huang ZS, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb; 16(2):256–61
Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. Sharrett AR, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2122–9
Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. van den Berg M, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan; 16(1):165–71
Antithrombin and atherosclerosis in the Rotterdam Study. van der Bom JG, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):864–7
Serum levels of the TGF-beta receptor are increased in atherosclerosis. Blann AD, et al. **Atherosclerosis** 1996 Feb; 120(1–2):221–6
Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a population-based study. Jie KS, et al. **Atherosclerosis** 1995 Jul;116(1):117–23
Lipid peroxidation of circulating low density lipoproteins with age, smoking and in peripheral vascular disease. Sanderson KJ, et al. **Atherosclerosis** 1995 Nov;118(1):45–51
Lipoproteins and the progression/regression of atherosclerosis. Barth JD. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):849–66 (74 ref.)
Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated. Aviram M, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):501–13
The influence of age, gender and ABO blood group on soluble endothelial cell markers and adhesion molecules. Blann AD, et al. **Br J Haematol** 1996 Feb;92(2):498–500
Low-density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. Jialal I, et al. **Clin Chem** 1996 Apr;42(4):498–506 (92 ref.)
Cholesterol content of circulating immune complexes in patients with coronary stenosis and subjects without evidence of atherosclerosis. Lecomte E, et al. **Clin Chem** 1995 Oct;41(10):1526–31
Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias [editorial; comment] Sniderman AD, et al. **Clin Chem** 1996 Apr;42(4):489–91. Comment on: Clin Chem 1996 Apr;42(4):507–14. Comment on: Clin Chem 1996 Apr;42(4):515–23.
Laboratory assessment of mild hyperhomocysteinemia as an independent risk factor for occlusive vascular diseases [editorial; comment] Tsai MY. **Clin Chem** 1996 Apr; 42(4):492–3. Comment on: Clin Chem 1996 Apr;42(4):630–6.
Enhanced susceptibility of low-density lipoproteins to oxidation in coronary bypass patients with progression of atherosclerosis. De Rijke YB, et al. **Clin Chim Acta** 1995 Dec 29;243(2):137–49
The role of lipids in cardiovascular disease: lessons from rare mutations and special populations. Hegele RA. **Clin Invest Med** 1996 Jun;19(3):161–70 (42 ref.)
Antiatherogenic lipid profile in galactosaemic patients on soybean diets. Schulpis K, et al. **J Inherit Metab Dis** 1996; 19(1):91–2
Platelet activation mechanisms and markers in arterial thrombosis. Wu KK. **J Intern Med** 1996 Jan;239(1):17–34 (110 ref.)
Intraoperative autotransfusion in aortic surgery: comparison of whole blood autotransfusion versus cell separation. Bartels C, et al. **J Vasc Surg** 1996 Jul;24(1):102–8
Regarding "Lipoprotein (a) levels in peripheral atherosclerotic disease" [letter; comment] Simoni G, et al. **J Vasc Surg** 1995 Dec;22(6):813–5. Comment on: J Vasc Surg 1995 Mar;21(3):541–2.
Lipoprotein (a), homocysteine, and hypercoagulable states in young men with premature peripheral atherosclerosis: a prospective, controlled analysis. Valentine RJ, et al. **J Vasc Surg** 1996 Jan;23(1):53–61, discussion 61–3
Blood parameters associated with atherogenic and thrombogenic risk in smokers and nonsmokers with similar life-styles. McKarns SC, et al. **Mod Pathol** 1995 May; 8(4):434–40
Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Shimada M, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7242–6
Lp(a) levels and reduced risk of vascular atheromatosis in patients with alcoholic liver disease. Ricciardi R, et al. **Riv Eur Sci Med Farmacol** 1994 Sep–Dec;16(5–6):119–23
Dehydroepiandrosterone and insulinaemia. Svačina S, et al. **Sb Lek** 1995;96(4):303–6
von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Blann AD, et al. **Thromb Haemost** 1995 Aug;74(2):626–30
Hypercoagulable state indicates an additional risk factor for atherosclerosis in Werner's syndrome. Goto M, et al. **Thromb Haemost** 1995 Apr;73(4):576–8
Lipoprotein(a), plasmin modulation, and atherogenesis. Harpel PC, et al. **Thromb Haemost** 1995 Jul;74(1):382–6 (83 ref.)
Copper-induced low density lipoprotein oxidation is not a risk discriminator for intermittent claudication. Ziedén B, et al. **Vasa** 1996;25(2):121–6
[Decrease in plasma cholesterol and regression of atherosclerosis] Wang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Aug;34(8):561–4 (21 ref.) **(Chi)**
[Experimental study on anti-atherosclerotic effect of tongmai jiangzhi oral liquor] Lu CS, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):479–82 (Eng. Abstr.) **(Chi)**
[Regulation of HDL lipoprotein plasma levels in relation to atherogenesis] Ružek V. **Vnitr Lek** 1995 Aug;41(8):555–9 (56 ref.) (Eng. Abstr.) **(Cze)**
[The significance of ixidized low density lipoprotein in atherosclerosis] Hansen PR. **Ugeskr Laeger** 1996 May 6; 158(19):2706–10 (40 ref.) (Eng. Abstr.) **(Dan)**
[Phospholipid levels in exploration of cerebral atherosclerosis in African Senegalese population] Sall ND, et al. **Dakar Med** 1994;39(1):77–80 (Eng. Abstr.) **(Fre)**
[Atherogenicity of low-density lipoproteins (LDL). A problem of quantity or quality?] Dejager S, et al. **Presse Med** 1995 Dec 9;24(38):1772–6 (16 ref.) (Eng. Abstr.) **(Fre)**
[Fatty acids in the diet and their significance for serum lipids and atherosclerosis] **Internist (Berl)** 1993 Apr;34(4 Suppl):1–16 **(Ger)**
[Serum elastin peptide concentration and human leukocyte elastase/antiproteinase balance in peripheral obstructive atherosclerosis] Mohácsi A, et al. **Orv Hetil** 1996 Jan 7; 137(1):15–21 (49 ref.) (Eng. Abstr.) **(Hun)**
[Plasma, erythrocyte and platelet magnesium in essential hyperTension, diabetes mellitus without and with macrovascular complications and atherosclerotic vascular disease] Grifò G, et al. **Recenti Prog Med** 1995 Nov; 86(11):431–6 (Eng. Abstr.) **(Ita)**
[The influence of methionine and its metabolites on the progression of atherosclerosis in rabbits] Koyama J. **Nippon Eiseigaku Zasshi** 1995 Dec;62(6):596–604 (Eng. Abstr.) **(Jpn)**
[Calcium, magnesium, copper and zinc in blood serum in men with femoral atherosclerosis] Mielcarz G, et al. **Rocz Panstw Zakl Hig** 1995;46(1):59–65 (Eng. Abstr.) **(Pol)**
[Multiple modifications of low density lipoproteins in blood of patients with atherosclerosis] Orekhov AN, et al. **Biull Eksp Biol Med** 1995 Aug;120(8):118–21 (38 ref.) **(Rus)**
[The relationships between apoprotein levels and body mass and atherogenic indices and sports activity in Aragonese schoolchildren] León Puy JF, et al. **An Esp Pediatr** 1996 Jul;45(1):21–4 (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Cadmium and atherosclerosis in the rabbit: reduced atherogenesis by superseding of iron? Meijer GW, et al. **Food Chem Toxicol** 1996 Jul;34(7):611–21
Influence of components of oral contraceptive on lipid metabolism. Sissan MA, et al. **Indian J Exp Biol** 1996 Feb; 34(2):131–4
Does cyclosporin A have any effect on accelerated atherosclerosis in absence of graft rejection? Pathologic and morphometric evaluation in an experimental model. Bernucci P, et al. **J Heart Lung Transplant** 1995 Nov–Dec; 14(6 Pt 1):1187–96
Long-term effects of inhaled nicotine. Waldum HL, et al. **Life Sci** 1996;58(16):1339–46
[Evaluation of the toxic effects of cadmium on the body in light of research on the behavior of lipid compounds in aortic walls of animals] Grabowska-Maślanka H, et al. **Folia Med Cracov** 1994;35(1–4):39–44 (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Re: Atheromatous macroembolism after balloon angioplasty of the superficial femoral artery [letter; comment] Murphy TP. **AJR Am J Roentgenol** 1996 Jan;166(1):219. Comment on: AJR Am J Roentgenol 1995 Jun;164(6):1516–8.
Risk of catheter-related emboli in patients with atherosclerotic debris in the thoracic aorta. Karalis DG, et al. **Am Heart J** 1996 Jun;131(6):1149–55
Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case–control study. Guzick DS, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1224–9; discussion 1229–32
Objective tinnitus in patients with atherosclerotic carotid artery disease. Sismanis A, et al. **Am J Otol** 1994 May; 15(3):404–7
Experimental rabbit models of Chlamydia pneumoniae infection. Moazed TC, et al. **Am J Pathol** 1996 Feb; 148(2):667–76
Massive cerebral infarction: a potential fatal complication of plaque fissuring of lipid-rich atheromas of the carotid artery. Case reports. Chow LT, et al. **Angiology** 1996 Apr; 47(4):381–7
Secondary prevention of coronary heart disease in patients with extracoronary atherosclerosis: a need for accuracy of low density lipoprotein determination. Senti M, et al. **Angiology** 1996 Mar;47(3):241–6
Asymptomatic atherosclerosis in HIV-positive patients: A case–control ultrasound study. Constans J, et al. **Ann Med** 1995 Dec;27(6):683–5
Low diastolic blood pressure and atherosclerosis in elderly subjects. The Rotterdam study. Bots ML, et al. **Arch Intern Med** 1996 Apr 22;156(8):843–8
Correlates and consequences of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group. Wilt TJ, et al. **Arch Intern Med** 1996 Jun 10;156(11):1181–8
The proximal aorta: a source of stroke. Jones EF, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):207–20 (45 ref.)
Do glomerular atherosclerosis and lipid–mediated tubulo–interstitial disease cause progressive renal failure in man? Moorhead JF, et al. **Blood Purif** 1996;14(1):58–66 (69 ref.)
Atherosclerotic disease and stroke. Harris KA, et al. **Can J Surg** 1995 Oct;38(5):400
Vascular complications in hypertension: the VHAS study. Verapamil-Hypertension Atherosclerosis Study. Zanchetti A. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:529–31
Primary aortoesophageal fistula caused by an atherosclerotic thoracoabdominal aortic aneurysm: a case report and review of the literature. Hageman JH, et al. **Cardiovasc Surg** 1995 Oct;3(5):495–9 (17 ref.)
Intramural hematoma of the aorta caused by a penetrating atheromatous ulcer. Wann S, et al. **Clin Cardiol** 1996 May; 19(5):438–9
Association of below-knee atherosclerosis to medial arterial calcification in diabetes mellitus. Chantelau E, et al. **Diabetes Res Clin Pract** 1995 Sep;29(3):169–72
Two cases of infected atherosclerotic aneurysms and a comparison with infective endocarditis. Peacock SJ, et al. **Eur J Clin Microbiol Infect Dis** 1995 Nov;14(11):1004–8

Atherosclerosis in alcoholics. Thomsen JL.
Forensic Sci Int 1995 Oct 30;75(2–3):121–31

Association of carotid atherosclerosis with electrocardiographic myocardial ischemia and left ventricular hypertrophy. Okin PM, et al. **Hypertension** 1996 Jul;28(1):3–7

Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus. Belch JJ, et al. **Int Angiol** 1995 Dec;14(4):385–8

Aortic atherosclerotic plaques as a source of systemic embolism. Khatibzadeh M, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):664–9

Microembolization from atheroembolic disease or aneurysm. A case study. Caldwell BD, et al.
J Am Podiatr Med Assoc 1996 Jun;86(6):249–52

Aortic atheromatosis and risks of cerebral embolization. Barbut D, et al. **J Cardiothorac Vasc Anesth** 1996 Jan; 10(1):24–9; quiz 29–30 (72 ref.)

Study of etiologic relationship of arterial atherosclerosis to corporal veno–occlusive dysfunction in the rabbit. Azadzoi KM, et al. **J Urol** 1996 May;155(5):1795–800

Surgical management of ischemic penile gangrene in diabetics with end stage atherosclerosis. Weiner DM, et al.
J Urol 1996 Mar;155(3):926–9

Can low–back pain be due to lumbar–artery disease? Kauppila LI. **Lancet** 1995 Sep 30;346(8979):888–9

Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The French Study of Aortic Plaques in Stroke Group. **N Engl J Med** 1996 May 9; 334(19):1216–21

Embolic cilioretinal artery occlusion with atherosclerosis of the ipsilateral carotid artery. Horton JC. **Retina** 1995; 15(5):441–4

Studying low back pain (LBP) [letter] Kauppila LI. **Spine** 1996 Feb 15;21(4):527

Ischemic stroke events and carotid atherosclerosis. Results of the Osaka Follow–up Study for Ultrasonographic Assessment of Carotid Atherosclerosis (the OSACA Study). Handa N, et al. **Stroke** 1995 Oct;26(10):1781–6

Successful renal autotransplantation with Y–prosthetic aortic replacement in a patient with complete occlusion of abdominal aorta and renal artery. Yagisawa T, et al.
Urol Int 1995;55(1):46–50

[Atheromatous embolisms and cholesterol embolisms: medical treatment] Vayssairat M, et al. **J Mal Vasc** 1996; 21 Suppl A:97–9 (17 ref.) (Eng. Abstr.) **(Fre)**

[Cachexia, ascites and kidney failure (clinical conference)] Sieber C, et al. **Schweiz Rundsch Med Prax** 1996 Mar 26; 85(13):411–5 **(Ger)**

[A trial of antegrade perfusion to the lower half of the body with selective cerebral perfusion for repair of aortic arch aneurysm combined with atherosclerosis obliterance] Takagi H, et al. **Kyobu Geka** 1995 Sep;48(10):873–6 (Eng. Abstr.) **(Jpn)**

[Correction of hyperlipoproteinogenic microangiopathy and organ pathology at early stages of atherogenesis with thymalin and leu–enkephalin] Fozdniakov OM, et al.
Biull Eksp Biol Med 1996 Jan;121(1):108–11 **(Rus)**

CONGENITAL

A congenital syndrome of mental deficiency, gait disturbance, sensorineural deafness and pigmentary retinopathy associated with premature atherosclerosis. Kamphorst W, et al. **Clin Neuropathol** 1995 Jul–Aug; 14(4):211–5

DIAGNOSIS

Functional and anatomic evaluation of carotid atherothrombosis. A combined study of indium 111 platelet scintigraphy and B–mode ultrasonography. Moriwaki H, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec; 15(12):2234–40

T2–weighted contrast for NMR characterization of human atherosclerosis. Toussaint JF, et al.
Arterioscler Thromb Vasc Biol 1995 Oct;15(10):1533–42

Plasma cholesterol esterase level is a determinant for an atherogenic lipoprotein profile in normolipidemic human subjects. Brodt–Eppley J, et al. **Biochim Biophys Acta** 1995 Oct 17;1272(2):69–72

Relationship of cigarette smoking to the severity of coronary and thoracic aortic atherosclerosis. Inoue T, et al.
Cardiology 1995;86(5):374–9

Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Toussaint JF, et al. **Circulation** 1996 Sep 1;94(5):932–8

New diagnostic inroads in hypertension and atherosclerosis. Ayers CR. **Curr Opin Cardiol** 1995 Sep;10(5):480–4 (14 ref.)

A prospective evaluation of atherosclerotic risk factors and hypercoagulability in young adults with premature lower extremity atherosclerosis. Levy PJ, et al. **J Vasc Surg** 1996 Jan;23(1):36–43, discussion 43–5

Magnetic resonance imaging to study lesions of atherosclerosis in the hyperlipidemic rabbit aorta. Yuan C, et al. **Magn Reson Imaging** 1996;14(1):93–102

Lesion versus lumen [comment] Libby P. **Nat Med** 1995 Jan; 1(1):17–8. Comment on: Nat Med 1995 Jan;1(1):69–73.

Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo [see comments] [published erratum appears in Nat Med 1995 Mar;1(3):272] Skinner MP, et al. **Nat Med** 1995 Jan;1(1):69–73. Comment in: Nat Med 1995 Jan;1(1):17–8.

[The evaluation of 3DFT time–of–flight MR–angiography versus angiography in the study of carotid atheromatous lesions with a review of the literature] Auffray–Calvier E, et al. **J Neuroradiol** 1995 Dec;22(4):272–87 (30 ref.) (Eng. Abstr.) **(Fre)**

[Dracunculosis of the face erroneously judged as a suppurative atheroma] Pyshkin SA, et al. **Lik Sprava** 1995 Jul–Aug;(7–8):132–3 **(Rus)**

DIET THERAPY

Dietary nitroprusside alleviates atherosclerosis in hypercholesterolemic Japanese quail (Coturnix coturnix japonica). Hill CH, et al.
Comp Biochem Physiol A Physiol 1995 Sep;112(1):151–4

[Dietary treatment of hypercholesterolemia] Richter WO.
Wien Klin Wochenschr 1995;107(18):549–54 (83 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC–II). Byington RP, et al. **Am J Cardiol** 1995 Sep 28;76(9):54C–59C

Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. Probstfield JL, et al. **Am J Cardiol** 1995 Sep 28; 76(9):47C–53C

The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease [editorial] Roberts WC. **Am J Cardiol** 1996 Aug 1; 78(3):377–8

Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Hodis HN, et al. **Ann Intern Med** 1996 Mar 15; 124(6):548–56

Regression or progression. Dependency on vascular nitric oxide. Candipan RC, et al.
Arterioscler Thromb Vasc Biol 1996 Jan;16(1):44–50

Inhibition of hypercholesterolemia–induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. Chang MY, et al.
Arterioscler Thromb Vasc Biol 1995 Oct;15(10):1631–40

Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Shiomi M, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1938–44

Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol–lowering therapies in familial hypercholesterolemia. Tomochika Y, et al.
Arterioscler Thromb Vasc Biol 1996 Aug;16(8):955–62

Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol–fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. Matsuo M, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):254–60

Localized drug delivery in atherosclerotic arteries via a new balloon angioplasty catheter with intramural channels for simultaneous local drug delivery. Hong MK, et al.
Cathet Cardiovasc Diagn 1995 Mar;34(3):263–70; discussion 271

Elastase in the prevention of arterial aging and the treatment of atherosclerosis. Ooyama T, et al. **Ciba Found Symp** 1995; 192:307–17; discussion 318–20 (36 ref.)

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.
Byington RP, et al. **Circulation** 1995 Nov 1;92(9):2419–25

Chelation therapy for atherosclerosis: one man's view [editorial] Conti CR. **Clin Cardiol** 1995 Oct;18(10):545

New approaches to the prevention of atherosclerosis. Naito M, et al. **Drugs** 1995 Sep;50(3):440–53 (154 ref.)

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Feuerstein GZ, et al.
Eur Heart J 1995 Jul;16 Suppl F:38–42 (21 ref.)

Carotid plaque regression on oestrogen replacement: a pilot study. Akkad A, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):347–8

Pharmacologic approaches to the treatment of atherosclerotic arterial obstruction. Capron L. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S40–3 (15 ref.)

Effects of indapamide on atherosclerosis development in cholesterol–fed rabbits. Del Rio M, et al.
J Cardiovasc Pharmacol 1995 Jun;25(6):973–8

Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial [see comments] Borhani NO, et al. **JAMA** 1996 Sep 11;276(10):785–91. Comment in: JAMA 1996 Sep 11;276(10):829–30.

Calcium channel blockers. Lessons learned from MIDAS and other clinical trials [editorial; comment] Chobanian AV. **JAMA** 1996 Sep 11;276(10):829–30. Comment on: JAMA 1996 Sep 11;276(10):785–91.

Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Wilson T, et al. **Life Sci** 1996; 59(1):PL15–21

Targeting TGF–beta for treatment of disease [comment] Border WA, et al. **Nat Med** 1995 Oct;1(10):1000–1. Comment on: Nat Med 1995 Oct;1(10):1067–73.

Extractum Fagopyri reduces atherosclerosis in high–fat diet fed rabbits. Wójcicki J, et al. **Pharmazie** 1995 Aug; 50(8):560–2

Oxylanosterols as modifiers of cholesterol biosynthesis. Trzaskos JM. **Prog Lipid Res** 1995;34(2):99–116 (28 ref.)

Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n–3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease. Berrettini M, et al. **Thromb Haemost** 1996 Mar; 75(3):395–400

[Course of ischemic risk in treated atheromatous hypertensive patients. The PRIHAM study] Godeau P, et al.
Ann Med Interne (Paris) 1995;146(8):530–5 (Eng. Abstr.) **(Fre)**

[Platelet antiaggregants and atheromatous arteriopathy of the lower limbs] Lévesque H, et al. **Rev Med Interne** 1996; 17(2):163–8 (47 ref.) (Eng. Abstr.) **(Fre)**

[The preliminary clinical evidence from the ELSA study. The European Lacidipine Study on Atherosclerosis] Leonetti G. **Ann Ital Med Int** 1995 Oct;10 Suppl:74S–77S (Eng. Abstr.) **(Ita)**

[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action] Raiteri M, et al.
Ann Ital Med Int 1995 Oct;10 Suppl:35S–42S (74 ref.) (Eng. Abstr.) **(Ita)**

[Anti–atheromatous effects of fenofibrate, a hypolipidemic drug. I: Anti–atheromatous effects are independent of its hypolipidemic effect in cholesterol–fed rabbits] Saitoh K, et al. **Nippon Yakurigaku Zasshi** 1995 Jul;106(1):41–50 (Eng. Abstr.) **(Jpn)**

[Anti–atheromatous effects of fenofibrate, a hypolipidemic drug. II: Anti–atheromatous effects are independent of its hypolipidemic effect in hereditary hyperlipidemic rabbits] Saitoh K, et al. **Nippon Yakurigaku Zasshi** 1995 Jul; 106(1):51–60 (Eng. Abstr.) **(Jpn)**

[Anti–atherosclerotic action of ACE inhibitors. I. Inactivation of the renin–angiotensin system] Stajszczyk M, et al. **Postepy Hig Med Dosw** 1996;50(2):157–71 (80 ref.) (Eng. Abstr.) **(Pol)**

[Immunomodulating action of essentiale during prolonged intake of dietary cholesterol] Bart EV, et al.
Patol Fiziol Eksp Ter 1995 Oct–Dec;(4):15–8 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Secretory group II phospholipase A2 in human atherosclerotic plaques. Menschikowski M, et al.
Atherosclerosis 1995 Dec;118(2):173–81

Proteinases and restenosis in the human coronary artery: extracellular matrix production exceeds the expression of proteolytic activity. Tyagi SC, et al. **Atherosclerosis** 1995 Jul;116(1):43–57

Induction of 15–lipoxygenase mRNA and protein in early atherosclerotic lesions. Hiltunen T, et al. **Circulation** 1995 Dec 1;92(11):3297–303

Triglyceride lipases and atherosclerosis. Olivecrona G, et al.
Curr Opin Lipidol 1995 Oct;6(5):291–305 (122 ref.)

Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte–derived macrophages. Hultén LM, et al.
J Clin Invest 1996 Jan 15;97(2):461–8

Explanted vein grafts with an intact endothelium demonstrate reduced focal expression of endothelial nitric oxide synthase specific to atherosclerotic sites. Buttery LD, et al. **J Pathol** 1996 Jun;179(2):197–203

Matrilysin is expressed by lipid–laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Halpert I, et al.
Proc Natl Acad Sci U S A 1996 Sep 3;93(18):9748–53

[Modulation by some fatty acids of protein kinase C–dependent NADPH oxidase in human adherent monocyte: mechanism of action, possible implication in atherogenesis] Léger CL, et al.
C R Seances Soc Biol Fil 1995;189(5):765–79 (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Atherosclerosis: risk factors and the vascular endothelium. Glasser SP, et al. **Am Heart J** 1996 Feb;131(2):379–84 (56 ref.)

Increased prevalence of aortic calcification in chronic pancreatitis. Gullo L, et al. **Am J Gastroenterol** 1996 Apr; 91(4):759–61

Urine C–peptide and atherogenic risk factors in diabetes mellitus: relevance to "syndrome X". Kato H, et al.
Angiology 1995 Oct;46(10):915–21

Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dL: baseline results from the Cholesterol and Recurrent Events (CARE) Study. Wilt TJ, et al. **Angiology** 1996 Jun;47(6):533–41

Carotid artery atherosclerosis in a Mexico City population with high carbohydrate intake. González–Villalpando C, et al. **Arch Med Res** 1995 Winter;26(4):409–13

Dietary fat and age–related maculopathy [letter; comment] Friedman E. **Arch Ophthalmol** 1996 Feb;114(2):235–6. Comment on: Arch Ophthalmol 1995 Jun;113(6):743–8.

Atherosclerotic disease in the femoral artery in hypertensive patients at high cardiovascular risk. The value of ultrasonographic assessment of intima–media thickness and plaque occurrence. Risk Intervention Study (RIS) Group.

Suurküla M, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug; 16(8):971–7

SstI RFLP and hypertension as risk factors for extracoronary atherosclerosis in a male population of southern Italy. Pujia A, et al. **Artery** 1994;21(4):208–21

Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan—a unique experience. Pan WH, et al. **Atherosclerosis** 1995 Dec;118(2):285–95 (47 ref.)

Dietary antioxidants and carotid artery wall thickness. The ARIC Study. Atherosclerosis Risk in Communities Study. Kritchevsky SB, et al. **Circulation** 1995 Oct 15; 92(8):2142–50

Hyperlipidemia, hypertension and atherosclerosis in women. Reality and perspectives. Bugliosi R, et al. **Clin Ter** 1995 Aug–Sep;146(8–9):503–18 (66 ref.)

Relationship between dental caries and risk factors for atherosclerosis in Swedish adolescents? Larsson B, et al. **Community Dent Oral Epidemiol** 1995 Aug;23(4):205–10

Sensitivity to platelet aggregation appears related to the lipoprotein profile and atherosclerosis risk in humans and across species. Hayes KC, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Feb; 113(2):349–53

Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Haffner SM, et al. **Diabetes** 1996 Jun;45(6):742–8

A metabolic syndrome in whites and African-Americans. The Atherosclerosis Risk in Communities baseline study. Schmidt MI, et al. **Diabetes Care** 1996 May;19(5):414–8

Is oxidative stress the missing link between insulin resistance and atherosclerosis? [letter] Ceriello A, et al. **Diabetologia** 1995 Dec;38(12):1484–5

Reliability of body fat distribution measurements. The ARIC Study baseline cohort results. Atherosclerosis Risk in Communities Study. Ferrario M, et al. **Int J Obes Relat Metab Disord** 1995 Jul;19(7):449–57

Precursors of atherosclerosis in a random sample from a Hellenic population: the Athens Study. Adamopoulos PN, et al. **J Cardiovasc Risk** 1995 Dec;2(6):525–31

The hypothetical epidemic of coronary heart disease and atherosclerosis. Stehbens WE. **Med Hypotheses** 1995 Nov; 45(5):449–54 (55 ref.)

Lipoprotein(a) in chronic renal disease. Stenvinkel P, et al. **Miner Electrolyte Metab** 1996;22(1–3):16–21 (67 ref.)

A comparison of coronary arteries from Japanese and NZ subjects. Sims FH, et al. **Pathology** 1995 Jul;27(3):215–20

Carotid atherosclerosis in middle-aged men. Relation to conjugal circumstances and social support. Helminen A, et al. **Scand J Soc Med** 1995 Sep;23(3):167–72

Factors of carotid arterial enlargement in a population aged 59 to 71 years: the EVA study. Bonithon-Kopp C, et al. **Stroke** 1996 Apr;27(4):654–60

Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. O'Leary DH, et al. **Stroke** 1996 Feb; 27(2):224–31

Hyperinsulinism and cerebral microangiopathy. Zunker P, et al. **Stroke** 1996 Feb;27(2):219–23

[Arterial hypertension and atherosclerosis: their epidemiology and physiopathology] Lembo G, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:69S–72S (13 ref.) (Eng. Abstr.) **(Ita)**

[The prevalence of carotid and coronary diseases in asymptomatic patients at high risk for atherosclerosis] Pesavento R, et al. **Minerva Cardioangiol** 1996 Mar; 44(3):81–6 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Pathogenesis of atherosclerosis. Navab M, et al. **Am J Cardiol** 1995 Sep 28;76(9):18C–23C (34 ref.)

The early natural history of atherosclerosis and hypertension in the young: National Institutes of Health perspectives. Lenfant C, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S3–7 (16 ref.)

The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Wagenknecht LE, et al. **Ann Epidemiol** 1995 Nov;5(6):464–72

Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Bruno G, et al. **Ann Intern Med** 1996 Oct 15;125(8):653–7

Association of the auscultatory gap with vascular disease in hypertensive patients. Cavallini MC, et al. **Ann Intern Med** 1996 May 15;124(10):877–83

Internal mammary artery atherosclerosis fifteen years after correction of aortic coarctation [letter] De Salazar AO, et al. **Ann Thorac Surg** 1996 Aug;62(2):629

Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect. Carmena R, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):129–36

Role of intimal hyperplasia and arterial remodeling after balloon angioplasty: an experimental study in the atherosclerotic rabbit model. Guzman LA, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):479–87

Relation of a postmortem renal index of hypertension to atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. McGill HC Jr, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2222–8

The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Navab M, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):831–42 (108 ref.)

Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Schreiner PJ, et al. **Arterioscler Thromb Vasc Biol** 1996 Mar;16(3):471–8

Oxidized lipids in the diet accelerate the development of fatty streaks in cholesterol-fed rabbits. Staprāns I, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):533–8

Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Nomura S, et al. **Atherosclerosis** 1995 Aug;116(2):235–40

Study of causes underlying the low atherosclerotic response to dietary hypercholesterolemia in a selected strain of rabbits. Thiery J, et al. **Atherosclerosis** 1996 Mar; 121(1):63–73

Advances in atherosclerosis. Spence JD. **Baillieres Clin Neurol** 1995 Aug;4(2):191–205 (105 ref.)

Atherogenic and anti-atherogenic factors in the human diet. Addis PB, et al. **Biochem Soc Symp** 1995;61:259–71 (64 ref.)

Relative resistance of the hamster to aortic atherosclerosis in spite of prolonged vitamin E deficiency and dietary hypercholesterolemia. Putative effect of increased HDL? Stein O, et al. **Biochim Biophys Acta** 1996 Jan 19; 1299(2):216–22

A pivotal role for TGF-beta in atherogenesis? Grainger DJ, et al. **Biol Rev Camb Philos Soc** 1995 Nov;70(4):571–96 (108 ref.)

Flow in T-bifurcations: effect of the sharpness of the flow divider. He X, et al. **Biorheology** 1995 Jul–Aug;32(4):447–58

Junction complexes of endothelial cells in atherosclerosis-prone and atherosclerosis-resistant regions on flow dividers of brachiocephalic bifurcations in the rabbit aorta. Okano M, et al. **Biorheology** 1994 Mar–Apr; 31(2):155–61

Mechanisms of cardiovascular injury in renal disease. Rabelink TJ, et al. **Blood Purif** 1996;14(1):67–74 (64 ref.)

Atherosclerosis risk factors: variation in healthy hospital workers and members of local communities asymptomatic for vascular disease. Implications for normal controls. Blann AD, et al. **Br J Biomed Sci** 1995 Mar;52(1):31–4

Replacement of dietary saturated fat with monounsaturated fat: effect on atherogenesis in cholesterol-fed rabbits clamped at the same plasma cholesterol level. Nielsen LB, et al. **Br J Nutr** 1995 Oct;74(4):509–21

Sex-related alterations in antioxidant status and susceptibility to atherosclerosis in Japanese quail. Godin DV, et al. **Can J Cardiol** 1995 Nov;11(10):945–51

Role of mast cells in atherosclerosis. Kovanen PT. **Chem Immunol** 1995;62:132–70 (120 ref.)

Does atherosclerosis have an infectious etiology? [editorial; comment] Buja LM. **Circulation** 1996 Sep 1;94(5):872–3. Comment on: Circulation 1996 Sep 1;94(5):922–7.

Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators [see comments] Howard G, et al. **Circulation** 1996 May 15;93(10):1809–17 . Comment in: Circulation 1996 May 15;93(10):1777–9. Comment in: Circulation 1996 May 15;93(10):1780–3.

Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis [see comments] Nieto FJ, et al. **Circulation** 1996 Sep 1;94(5):922–7. Comment in: Circulation 1996 Sep 1;94(5):872–3.

Insulin resistance and atherosclerosis. Common roots for two common diseases? [editorial; comment] Taegtmeyer H. **Circulation** 1996 May 15;93(10):1777–9. Comment on: Circulation 1996 May 15;93(10):1809–17.

Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Weber C, et al. **Circulation** 1996 Apr 15;93(8):1488–92

Hyperinsulinemia and atherosclerosis. Standl E. **Clin Invest Med** 1995 Aug;18(4):261–6 (40 ref.)

Pediatric considerations in atherosclerosis [letter] Jones RE. **Clin Pediatr (Phila)** 1996 Apr;35(4):228

Dietary nitroprusside alleviates atherosclerosis in hypercholesterolemic Japanese quail (Coturnix coturnix japonica). Hill CH, et al. **Comp Biochem Physiol A Physiol** 1995 Sep;112(1):151–4

Oxidatively modified LDL and atherosclerosis: an evolving plausible scenario. Jialal I, et al. **Crit Rev Food Sci Nutr** 1996 Apr;36(4):341–55 (115 ref.)

Postprandial state and atherosclerosis. Ebenbichler CF, et al. **Curr Opin Lipidol** 1995 Oct;6(5):286–90 (37 ref.)

Smooth muscle cells and atherosclerosis. Stein O, et al. **Curr Opin Lipidol** 1995 Oct;6(5):269–74 (54 ref.)

Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Lopes-Virella MF, et al. **Diabetes** 1996 Jul;45 Suppl 3:S40–4 (49 ref.)

Atherogenic modified LDL in diabetes. Sobenin IA, et al. **Diabetes** 1996 Jul;45 Suppl 3:S35–9

Hyperinsulinemia and atherosclerosis. Stout RW. **Diabetes** 1996 Jul;45 Suppl 3:S45–6 (26 ref.)

Phagocytic activation induces formation of platelet-activating factor in human monocyte-derived macrophages and in macrophage-derived foam cells. Relevance to the inflammatory reaction in atherogenesis. Dentan C, et al. **Eur J Biochem** 1996 Feb 15;236(1):48–55

The role of oxidized lipoproteins in atherogenesis. Berliner JA, et al. **Free Radic Biol Med** 1996;20(5):707–27 (265 ref.)

Adherent leukocytes to the aortic wall promotes atherosclerosis in the Watanabe heritable hyperlipidemic rabbits. Hata H, et al. **Fukuoka Igaku Zasshi** 1995 Dec; 86(12):437–42

The association of mast cells and atherosclerosis: new insights into mast cells in atherogenesis [letter; comment] Chaldakov GN, et al. **Hum Pathol** 1995 Nov;26(11):1286 . Comment on: Hum Pathol 1994 Feb;25(2):154–9. Comment on: Hum Pathol 1995 Jan;26(1):127–8.

A macrophage-smooth muscle cell co-culture model: applications in the study of atherogenesis [letter] Fan YY, et al. **In Vitro Cell Dev Biol Anim** 1995 Jul–Aug;31(7):492–3

Vascular risk factors for atherosclerotic plaque progression in carotid artery. Delcker A, et al. **Int Angiol** 1995 Dec; 14(4):339–45

Ability of the Atherosclerosis Risk in Communities (ARIC)/Baecke Questionnaire to assess leisure-time physical activity. Richardson MT, et al. **Int J Epidemiol** 1995 Aug;24(4):685–93

Pressure-induced mechanical stress in the carotid artery bifurcation: a possible correlation to atherosclerosis. Salzar RS, et al. **J Biomech** 1995 Nov;28(11):1333–40

Gender differences in atherosclerosis: possible role of nitric oxide. Hayashi T, et al. **J Cardiovasc Pharmacol** 1995 Nov; 26(5):792–802

Increased atherosclerosis in streptozotocin-induced diabetic mice. Kunjathoor VV, et al. **J Clin Invest** 1996 Apr 1; 97(7):1767–73

Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. Shih DM, et al. **J Clin Invest** 1996 Apr 1;97(7):1630–9

On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. Bhakdi S, et al. **J Exp Med** 1995 Dec 1;182(6):1959–71

Increased prevalence of atherosclerotic wall changes in patients with hyperlipidaemia after renal transplantation. Jogestrand T, et al. **J Intern Med** 1996 Feb;239(2):177–80

Specificity of lecithin:cholesterol acyltransferase and atherogenic risk: comparative studies on the plasma composition and in vitro synthesis of cholesteryl esters in 14 vertebrate species. Liu M, et al. **J Lipid Res** 1995 Aug; 36(8):1813–24

Oxidized low density lipoprotein-mediated activation of phospholipase D in smooth muscle cells: a possible role in cell proliferation and atherogenesis. Natarajan V, et al. **J Lipid Res** 1995 Sep;36(9):2005–16

Obese pigs fed a high cholesterol diet from birth to 2 months are less susceptible than lean pigs to atherosclerosis. Hackman AM, et al. **J Nutr** 1996 Feb;126(2):564–73

The role of oxidized low density lipoprotein in atherogenesis. Jialal I, et al. **J Nutr** 1996 Apr;126(4 Suppl):1053S–7S (39 ref.)

Dietary fatty acids, low density lipoprotein composition and oxidation and primate atherosclerosis. Thomas MJ, et al. **J Nutr** 1996 Apr;126(4 Suppl):1058S–62S

Cigarette smoking and health of the heart. Leone A. **J R Soc Health** 1995 Dec;115(6):354–5 (13 ref.)

Enhanced scavenger receptor expression in monocyte-macrophages in dialysis patients. Ando M, et al. **Kidney Int** 1996 Mar;49(3):773–80

Mechanochemiemission and atherogenesis. Orel VE. **Med Hypotheses** 1995 Oct;45(4):343–4

Hyperglycemia-induced latent scurvy and atherosclerosis: the scorbutic-metaplasia hypothesis. Price KD, et al. **Med Hypotheses** 1996 Feb;46(2):119–29 (136 ref.)

Non-ischemic hypoxia of the arterial wall is a primary cause of atherosclerosis. Simanonok JP. **Med Hypotheses** 1996 Feb;46(2):155–61 (80 ref.)

Gender differences in the development of hyperlipemia and atherosclerosis in hybrid hamsters. Robins SJ, et al. **Metabolism** 1995 Oct;44(10):1326–31

Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. Benlian P, et al. **N Engl J Med** 1996 Sep 19; 335(12):848–54

Many roads lead to atheroma [comment] Hayden MR, et al. **Nat Med** 1995 Jan;1(1):22–3 (18 ref.). Comment on: Nat Med 1995 Jan;1(1):74–9.

Genetically modified mice as models of transplant atherosclerosis. Ross R. **Nat Med** 1996 May;2(5):527–8

Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients. Yang WS, et al. **Nephrol Dial Transplant** 1995;10(9):1668–71

Is atherosclerosis equivalent to cholesterol? [letter] Adeva Andany M. **Nephron** 1995;71(4):487–8

Homocysteine—an atherogenic and a thrombogenic factor? Ubbink JB. **Nutr Rev** 1995 Nov;53(11):323–5 (18 ref.)

Is atherosclerosis accelerated by CAPD? Kawaguchi Y, et al. **Perit Dial Int** 1996;16 Suppl 1:S223–30

Could atherosclerosis originate from defective smooth muscle cell death (apoptosis)? Rembold C. **Perspect Biol Med** 1996 Spring;39(3):405–8

Simple anthropometric measurements—relation to body fat mass, visceral adipose tissue and risk factors of atherogenesis. Kunešová M, et al. **Sb Lek** 1995;96(3):257–67

Pathogenesis of atherosclerosis. Massy ZA, et al. **Semin Nephrol** 1996 Jan;16(1):12–20 (65 ref.)

Plasma lipoprotein(a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients. Baldassarre D, et al. **Stroke** 1996 Jun;27(6):1044–9

Evaluation of the presence of premature atherosclerosis in adults with heterozygosity for cystathionine-beta-synthase deficiency [letter] de Valk HW, et al. **Stroke** 1996 Jun; 27(6):1134–6

Carotid intima-media thickness by ultrasound measurement in pancreas transplant candidates. Larsen JL, et al. **Transplant Proc** 1995 Dec;27(6):2996

[Smoking and peripheral vascular disorders] Stammler F, et al. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):459–66 (12 ref.) (Eng. Abstr.) **(Ger)**

[Hyperhomocysteinemia as a risk factor in atherosclerotic and thrombotic vascular processes] Sela B. **Harefuah** 1995 Nov 15;129(10):407–12 (35 ref.) **(Heb)**

[Oxidized lipoproteins and atherogenesis] Bellomo G, et al. **Cardiologia** 1996 May;41(5):417–25 (61 ref.) **(Ita)**

[Neutrophilic leukocytes, thrombotic risk factors in vascular diseases] Berti F. **Cardiologia** 1996 Feb;41(2):107–16 (95 ref.) **(Ita)**

[Fibrinogen as a cardiovascular risk factor] Giannasi G, et al. **Minerva Cardioangiol** 1995 May;43(5):169–75 (100 ref.) (Eng. Abstr.) **(Ita)**

[Obesity and vascular diseases] Oikawa S, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1246–50 (5 ref.) **(Jpn)**

[Phenotypic change of the smooth muscle cell and atherosclerosis] Mori S, et al. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):161–70 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Serum lipoprotein and atherogenicity--relationship with particle size and composition of low density lipoproteins, and their modifications by oxidation and glycation] Takeuchi N, et al. **Rinsho Byori** 1995 Aug;43(8):753–62 (47 ref.) (Eng. Abstr.) **(Jpn)**

[Modulation of the cell membrane function by cholesterol and its relation to disease] Mas Oliva J. **Gac Med Mex** 1994 Nov-Dec;130(6):438–44; discussion 444–5 **(Spa)**

[The pathogenesis of the evolution of the atheroma plaque] Ferreira Montero IJ, et al. **Rev Esp Cardiol** 1995;48 Suppl 5:13–22 (56 ref.) (Eng. Abstr.) **(Spa)**

[New discoveries on atherosclerosis. LDL oxidation plays a central role] Nilsson J. **Lakartidningen** 1995 Oct 4; 92(40):3684–6, 3691 (19 ref.) **(Swe)**

GENETICS

Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Groot PH, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):926–33

Genetic determination of cartilaginous metaplasia in mouse aorta. Qiao JH, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2265–72

Adenovirus-mediated gene transfer to normal and atherosclerotic arteries. A novel approach. Ríos CD, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2241–5

SstI RFLP and hypertension as risk factors for extracoronary atherosclerosis in a male population of southern Italy. Pujia A, et al. **Artery** 1994;21(4):208–21

Loss of heterozygosity and microsatellite instability in human atherosclerotic plaques. Hatzistamou J, et al. **Biochem Biophys Res Commun** 1996 Aug 5;225(1):186–90

Microsatellite instability in human atherosclerotic plaques. Spandidos DA, et al. **Biochem Biophys Res Commun** 1996 Mar 7;220(1):137–40

Insight into atherosclerosis: a review of c-myc and the vascular smooth muscle cell. Golja AM, et al. **Cell Mol Biol Res** 1995;41(6):487–99 (74 ref.)

The role of lipids in cardiovascular disease: lessons from rare mutations and special populations. Hegele RA. **Clin Invest Med** 1996 Jun;19(3):161–70 (42 ref.)

Bimonthly update in lipidology: Nutrition. Roberts DC. **Curr Opin Lipidol** 1995 Oct;6(5):U117–20

No association of apolipoprotein A-IV codon 347 and 360 variation with atherosclerosis and lipid transport in a sample of mixed hyperlipidemics. Carrejo MH, et al. **Genet Epidemiol** 1995;12(4):371–80

DNA polymorphisms in adhesion molecule genes--a new risk factor for early atherosclerosis. Wenzel K, et al. **Hum Genet** 1996 Jan;97(1):15–20

Can genes prevent atherosclerosis? Hoeg JM. **JAMA** 1996 Sep 25;276(12):989–92

New mutant rabbit strain with hypercholesterolemia and atherosclerotic lesions produced by serial inbreeding. Kurosawa T, et al. **Lab Anim Sci** 1995 Aug;45(4):385–92

Measurement by quantitative reverse transcription-polymerase chain reaction of the levels of tumor necrosis factor alpha mRNA in atherosclerotic arteries in Watanabe heritable hyperlipidemic rabbits. Lei X, et al. **Lab Invest** 1996 Jan;74(1):136–45

Environmental and genetic risk factors in early human atherogenesis: lessons from the PDAY study. Pathobiological Determinants of Atherosclerosis in Youth. Strong JP, et al. **Pathol Int** 1995 Jun;45(6):403–8 (30 ref.)

Mutant oocytic low density lipoprotein receptor gene family member causes atherosclerosis and female sterility. Bujo H, et al. **Proc Natl Acad Sci U S A** 1995 Oct 10; 92(21):9905–9

Detection of the apolipoprotein B-100 arg(3500) > gl mutation in familial defective apoB-100 by temperature-gradient gel electrophoresis. Koch M, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:16–8

Tissue specific expression of the human LCAT gene in transgenic mice and its effect on blood lipids. Mehlum A, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:139–42

Elevated levels of chylomicron- and VLDL-remnants leads to atherosclerosis in apoE transgenic mice. van Vlijmen BJ, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:113–5

[Molecular biology and biochemical study of hyperlipemia and atherosclerosis (editorial)] Chen B. **Chung Hua I Hsueh Tsa Chih** 1995 Oct;75(10):579–80 **(Chi)**

[Genetic variation in the apolipoprotein B gene] Vedie B, et al. **Ann Genet** 1995;38(4):187–201 (107 ref.) (Eng. Abstr.) **(Fre)**

[The metabolic syndrome and chronic vascular disease. Cellular mechanisms and potential candidate genes] Haller H, et al. **Internist (Berl)** 1996 Jul;37(7):687–97 (100 ref.) **(Ger)**

[Application of genetic principles to the causal assessment of atherosclerosis] Miserez AR, et al. **Ther Umsch** 1995 Dec;52(12):835–43 (48 ref.) (Eng. Abstr.) **(Ger)**

[Lipoprotein(a)--atherogenic waste product of evolution?] Kronenberg F, et al. **Wien Med Wochenschr** 1994; 144(12-13):324–30 (68 ref.) (Eng. Abstr.) **(Ger)**

[Atheroma plaque and Apo E alleles] Venarucci D, et al. **Minerva Cardioangiol** 1996 Jan-Feb;44(1-2):15–8 (Eng. Abstr.) **(Ita)**

[The relationship of apoB gene polymorphism to dyslipoproteinemia as the cause of atherosclerosis] Kravchenko NA. **Tsitol Genet** 1995 Jul-Aug;29(4):84–7 (33 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Emeson EE, et al. **Am J Pathol** 1996 Aug;149(2):675–85

Immunology of atherosclerosis: the promise of mouse models [comment] Lichtman AH, et al. **Am J Pathol** 1996 Aug; 149(2):351–7 (81 ref.). Comment on: Am J Pathol 1996 Aug;149(2):359–66.

Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice [see comments] Zhou X, et al. **Am J Pathol** 1996 Aug;149(2):359–66. Comment in: Am J Pathol 1996 Aug;149(2):351–7.

Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Palinski W, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1569–76

Lymphocyte populations in atherosclerotic lesions of apoE -/- and LDL receptor -/- mice. Decreasing density with disease progression. Roselaar SE, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1013–8

Cyclosporine treatment reduces early atherosclerosis in the cholesterol-fed rabbit. Drew AF, et al. **Atherosclerosis** 1995 Aug;116(2):181–9

Accessibility of human apolipoprotein B-100 epitopes in insulin-dependent diabetes: relation with the surface lipid environment of atherogenic particles. Ziegler O, et al. **Diabetes Metab** 1996 Jun;22(3):179–84

Atherosclerosis as an autoimmune condition. Kleindienst R, et al. **Isr J Med Sci** 1995 Oct;31(10):596–9 (26 ref.)

Atherosclerosis and expression of the neuro-immune-endocrine system [letter] Aller A, et al. **J Intern Med** 1996 Jul;240(1):50–1

Lipoproteins, anticardiolipin autoantibodies and artherosclerosis [letter] Cheng HM. **J Intern Med** 1996 Jul; 240(1):44–5

Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. Nityanand S, et al. **J Intern Med** 1995 Nov;238(5):437–43

[Atherosclerosis as an immune process (editorial)] George J, et al. **Harefuah** 1995 Oct;129(7-8):257–9 **(Heb)**

METABOLISM

Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. Jamieson DG, et al. **Am J Pathol** 1995 Dec;147(6):1567–74

Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Li Z, et al. **Am J Pathol** 1996 Jan;148(1):121–8

Expression of very low density lipoprotein receptor in the vascular wall. Analysis of human tissues by in situ hybridization and immunohistochemistry. Multhaupt HA, et al. **Am J Pathol** 1996 Jun;148(6):1985–97

Interleukin-8 production by macrophages from atheromatous plaques. Apostolopoulos J, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1007–12

A method for the assessment of hypoxia in the arterial wall, with potential application in vivo. Björnheden T, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):178–85

Expression of the macrophage scavenger receptor in atheroma. Relationship to immune activation and the T-cell cytokine interferon-gamma. Geng YJ, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1995–2002

Development of the lipid-rich core in human atherosclerosis. Guyton JR, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan; 16(1):4–11 (104 ref.)

Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Mancini FP, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1911–6

Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Mukhin DN, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1607–15

Osteopontin is not a marker for proliferating human vascular smooth muscle cells. Newman CM, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):2010–8

Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Robbie LA, et al. **Arterioscler Thromb Vasc Biol** 1996 Apr;16(4):539–45

Selective increase in cholesterol at atherosclerosis-susceptible aortic sites after short-term cholesterol feeding. Schwenke DC. **Arterioscler Thromb Vasc Biol** 1995 Nov;15(11):1928–37

Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. Suarna C, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1616–24

Effect of the antioxidant N,N'-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. Tangirala RK, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1625–30

Evidence of lipid oxidation in pulmonary artery atherosclerosis [letter] Carpenter KL, et al. **Atherosclerosis** 1995 Nov;118(1):169–72

Abnormal taurocholate ileal transepithelial transport in atherosclerotic mini-pigs and effects of ACE inhibitors. Rahmani-Jourdheuil D, et al. **Atherosclerosis** 1995 Oct; 117(2):285–93

Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. Sakata N, et al. **Atherosclerosis** 1995 Jul;116(1):63–75

Atherogenic change in the thoracic aorta of the senescence-accelerated mouse. Yagi K, et al. **Atherosclerosis** 1995 Dec;118(2):233–6

Do human atherosclerotic lesions contain nitrotyrosine? Evans P, et al. **Biochem Biophys Res Commun** 1996 Sep 13;226(2):346–51

The oxysterols cholest-5-ene-3 beta,4 alpha-diol, cholest-5-ene-3 beta,4 beta-diol and cholestane-3 beta,5 alpha,6 alpha-triol are formed during in vitro oxidation of low density lipoprotein, and are present in human atherosclerotic plaques. Breuer O, et al. **Biochim Biophys Acta** 1996 Jul 26;1302(2):145–52

Atherosclerosis alters the composition, structure and function of arterial smooth muscle cell plasma membranes. Chen M, et al. **Biochim Biophys Acta** 1995 Oct 17;1272(2):101–12

Neutrophils obtained from obliterative atherosclerotic patients exhibit enhanced resting respiratory burst and increased degranulation in response to various stimuli. Mohácsi A, et al. **Biochim Biophys Acta** 1996 Aug 23; 1316(3):210–6

Enhanced modifications of low-density lipoproteins (LDL) by endothelial cells from smokers: a possible mechanism of smoking-related atherosclerosis. Pech-Amsellem MA, et al. **Cardiovasc Res** 1996 Jun;31(6):975–83

A skeleton in the atherosclerosis closet [editorial; comment] Demer LL. **Circulation** 1995 Oct 15;92(8):2029–32. Comment on: Circulation 1995 Oct 15;92(8):2163–8.

Platelet-derived growth factor-A mRNA expression in fetal, normal adult, and atherosclerotic human aortas. Analysis by competitive polymerase chain reaction. Murry CE, et al. **Circulation** 1996 Mar 15;93(6):1095–106

Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. O'Brien KD, et al. **Circulation** 1996 Feb 15;93(4):672–82

Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Implications for antisense therapy of restenosis after angioplasty. Pickering JG, et al. **Circulation** 1996 Feb 15; 93(4):772–80

Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and balloon-injured rat carotid arteries. Riessen R, et al. **Circulation** 1996 Mar 15;93(6):1141–7

Stroke-prone SHR and arteriolipidosis-prone SHR as models for atherosclerosis: their mechanisms and application for nutritional and pharmacological studies. Yamori Y, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S244–5

Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Bruce C, et al. **Curr Opin Lipidol** 1995 Oct;6(5):306–11 (47 ref.)

Bimonthly update in lipidology. Atherosclerosis: cell biology and lipoproteins. Giddings J. **Curr Opin Lipidol** 1995 Oct; 6(5):U134–40

Structure of cholesterol-containing particles accumulating in atherosclerotic lesions and the mechanisms of their derivation. Hoff HF, et al. **Curr Opin Lipidol** 1995 Oct; 6(5):317–25 (91 ref.)

Apolipoprotein A-I-containing lipoproteins and atherosclerosis. Leroy A, et al. **Curr Opin Lipidol** 1995 Oct; 6(5):281–5 (36 ref.)

The stimulation of the cholesterol esterification pathway by atherogenic lipoproteins in macrophages. Tabas I. **Curr Opin Lipidol** 1995 Oct;6(5):260–8 (112 ref.)

The extracellular matrix and atherosclerosis. Wight TN. **Curr Opin Lipidol** 1995 Oct;6(5):326–34

Minimally oxidised LDL as estimated by a new method increase in plasma of type 2 diabetic patients with atherosclerosis or nephropathy. Picard S, et al. **Diabetes Metab** 1996 Feb;22(1):25–30

Localization of [125I]endothelin-1 in injured aorta of rabbits.

Kurata C, et al. **Eur J Pharmacol** 1995 Jul 1;293(2):109–14

Neutrophil elastase, von Willebrand factor, soluble thrombomodulin and percutaneous oxygen in peripheral atherosclerosis. Blann AD, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):218–22

Dietary effects of corn oil, oleic acid, perilla oil, and primrose oil on plasma and hepatic lipid level and atherosclerosis in Japanese quail. Sadi AM, et al. **Exp Anim** 1996 Jan; 45(1):55–62

Transition metal ions within human atherosclerotic lesions can catalyse the oxidation of low density lipoprotein by macrophages. Lamb DJ, et al. **FEBS Lett** 1995 Oct 23; 374(1):12–6

Depletion of alpha-tocopherol in human atherosclerotic lesions. Carpenter KL, et al. **Free Radic Res** 1995 Dec; 23(6):549–58

Glycation of lipoproteins and accelerated atherosclerosis in non-insulin-dependent diabetes mellitus. Yegin A, et al. **Int J Clin Lab Res** 1995;25(3):157–61

Small dense low density lipoprotein: formation and potential mechanisms for atherogenicity. Deckelbaum RJ, et al. **Isr J Med Sci** 1996 Jun;32(6):464–8

Apolipoprotein-AI-containing particles and atherosclerosis. Fruchart JC, et al. **Isr J Med Sci** 1996 Jun;32(6):498–502

Anti-atherogenicity of high density lipoprotein. Stein Y, et al. **Isr J Med Sci** 1996 Jun;32(6):503–8 (61 ref.)

Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. Wang N, et al. **J Biol Chem** 1996 Apr 12;271(15):8837–42

Atherogenic levels of low-density lipoprotein increase hydrogen peroxide generation in cultured human endothelial cells: possible mechanism of heightened endocytosis. Holland JA, et al. **J Cell Physiol** 1996 Jan; 166(1):144–51

Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. Bellosta S, et al. **J Clin Invest** 1995 Nov;96(5):2170–9

Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. Brand K, et al. **J Clin Invest** 1996 Apr 1;97(7):1715–22

H19, a marker of developmental transition, is reexpressed in human atherosclerotic plaques and is regulated by the insulin family of growth factors in cultured rabbit smooth muscle cells. Han DK, et al. **J Clin Invest** 1996 Mar 1; 97(5):1276–85

Presence of hypochlorite-modified proteins in human atherosclerotic lesions. Hazell LJ, et al. **J Clin Invest** 1996 Mar 15;97(6):1535–44

Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. McCaffrey TA, et al. **J Clin Invest** 1995 Dec; 96(6):2667–75

Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta. Nielsen LB, et al. **J Clin Invest** 1996 Jul 15;98(2):563–71

Increased ferritin gene expression in atherosclerotic lesions. Pang JH, et al. **J Clin Invest** 1996 May 15;97(10):2204–12

Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. Schett G, et al. **J Clin Invest** 1995 Dec;96(6):2569–77

Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. Uyemura K, et al. **J Clin Invest** 1996 May 1;97(9):2130–8

Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. Ylitalo R, et al. **J Lab Clin Med** 1996 Feb;127(2):200–6

Balloon angioplasty significantly increases collagen content but does not alter collagen subtype I/III ratios in the atherosclerotic rabbit iliac model. Coats WD Jr, et al. **J Mol Cell Cardiol** 1996 Feb;28(2):441–6

Endothelin-1-like immunoreactivity in human atherosclerotic coronary tissue: a detailed analysis of the cellular distribution of endothelin-1. Ihling C, et al. **J Pathol** 1996 Jul;179(3):303–8

Elevated levels of plasminogen-activator inhibitor type 1 in atherosclerotic aorta. Shireman PK, et al. **J Vasc Surg** 1996 May;23(5):810–7; discussion 817–8

Lipoprotein(a) concentration and risk of atherothrombotic disease [letter; comment] Craig WY, et al. **JAMA** 1995 Oct 18;274(15):1198–9. Comment on: JAMA 1995 Apr 26;273(16):1269–73.

Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Buttery LD, et al. **Lab Invest** 1996 Jul;75(1):77–85

Thymosin alpha 1 protects liver and aorta from oxidative damage in atherosclerotic rabbits. Gökkusu C, et al. **Life Sci** 1996;59(13):1059–67

Mature human atherosclerotic plaque contains peroxidized phosphatidylcholine as a major lipid peroxide. Piotrowski JJ, et al. **Life Sci** 1996;58(9):735–40

Lipids and atherosclerosis. Halpern MJ. **Mol Aspects Med** 1995;16(6):509–710 (1120 ref.)

Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Vlassara H, et al. **Mol Med** 1995 May; 1(4):447–56

Expression of PDGF in relation to cell division in atherosclerotic intima of human carotid arteries. Ito M, et al. **Neurol Res** 1995 Oct;17(5):345–8

Biodistribution and radioimmunopharmacokinetics of 131I-Ama monoclonal antibody in atherosclerotic rabbits. Chakrabarti M, et al. **Nucl Med Biol** 1995 Aug;22(6):693–7

Free radicals, ceruloplasmin, and copper concentration in serum and aortic tissue in experimental atherosclerosis. Vlad M, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):588–91

Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Hatanaka K, et al. **Pathol Int** 1995 Sep;45(9):635–41

Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Keaney JF Jr, et al. **Prog Cardiovasc Dis** 1995 Sep–Oct;38(2):129–54 (202 ref.)

[Role of lipid oxidation in the development of atherosclerosis] Ylä-Herttuala S, et al. **Duodecim** 1994;110(17):1643–52 (55 ref.) **(Fin)**

[Biology of the endothelial cell and atherogenesis] Demuth K, et al. **Ann Biol Clin (Paris)** 1995;53(4):171–91 (211 ref.) (Eng. Abstr.) **(Fre)**

[Non-hypertensive desoxycorticosterone treatment enhances the progression of atherosclerosis in WHHL rabbit] Villeneuve N, et al. **Arch Mal Coeur Vaiss** 1995 Aug; 88(8):1197–201 (Eng. Abstr.) **(Fre)**

[Elastolysis, aging and atherogenesis] Robert L, et al. **C R Seances Soc Biol Fil** 1995;189(5):853–9 (Eng. Abstr.) **(Fre)**

[Association of postoperative brain dysfunction and atherosclerosis, intraoperative rSO2 and CO2 reaction in open heart surgery] Konishi A, et al. **Masui** 1996 Mar; 45(3):287–92 (Eng. Abstr.) **(Jpn)**

[The liquid crystal state of the lipids and atherosclerosis (a cell-culture study)] Poliakov AE. **Fiziol Zh** 1995 May-Aug;41(3–4):90–6 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Significance of Chlamydia pneumoniae (TWAR) in atherosclerotic lesions [editorial; comment] Wissler RW. **Circulation** 1995 Dec 15;92(12):3376. Comment on: Circulation 1995 Dec 15;92(12):3397–400.

Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. Ong G, et al. **J Clin Pathol** 1996 Feb; 49(2):102–6

Chlamydia in coronary plaques--hidden culprit or harmless hobo? Capron L. **Nat Med** 1996 Aug;2(8):856–7 (9 ref.)

Chlamydia pneumoniae and atherosclerosis. Grayston JT. **Rev Med Interne** 1996;17 Suppl 1:45S–47S

Chlamydia linked to atherosclerosis [news] Mlot C. **Science** 1996 Jun 7;272(5267):1422

MORTALITY

Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Shahar E, et al. **Am Heart J** 1996 May;131(5):915–22 (37 ref.)

The influence of age on long-term survival pattern of patients operated on for lower limb ischaemia. Aune S, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):214–7

[Mortality among workers of the rubber industry. III. Results of further observation of the male cohort] Szeszenia-Dąbrowska N, et al. **Med Pr** 1995;46(4):317–25 (Eng. Abstr.) **(Pol)**

PATHOLOGY

In vitro atherosclerotic plaque and calcium quantitation by intravascular ultrasound and electron-beam computed tomography. Gutfinger DE, et al. **Am Heart J** 1996 May; 131(5):899–906

Vascular effects of diet-induced hypercalcemia after balloon artery injury in giant Flemish rabbits. Hong MK, et al. **Am Heart J** 1995 Oct;130(4):758–64

Comparison of thickness and distensibility in the carotid artery and descending thoracic aorta: in vivo ultrasound assessment. Pearson AC, et al. **Am Heart J** 1996 Apr; 131(4):655–62

A new method for studying plaque morphology. Thackray BD, et al. **Am J Card Imaging** 1995 Jul;9(3):149–56

Ultrastructural characteristics of human atherectomy tissue from coronary and lower extremity arterial stenoses. Bauriedel G, et al. **Am J Cardiol** 1996 Mar 1;77(7):468–74

Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia. Schmidt HH, et al. **Am J Cardiol** 1996 Mar 15;77(8):575–80

Risk factors and atherosclerosis in youth autopsy findings of the Bogalusa Heart Study. Tracy RE, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S37–41

An overview of the quantitative influence of several risk factors on progression of atherosclerosis in young people in the United States. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Wissler RW. **Am J Med Sci** 1995 Dec;310 Suppl 1:S29–36 (22 ref.)

Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Björkerud S, et al. **Am J Pathol** 1996 Aug; 149(2):367–80

Biotin- or digoxigenin-conjugated nucleotides bind to matrix vesicles in atherosclerotic plaques. Kockx MM, et al. **Am J Pathol** 1996 Jun;148(6):1771–7

Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Westermark P, et al. **Am J Pathol** 1995 Nov;147(5):1186–92

Granule-laden perivascular cells observed in rabbits with experimental cerebral atherosclerosis. Kato H, et al. **Angiology** 1996 Apr;47(4):343–7

Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of Vascular Dendritic Cells in athero-resistant and athero-prone areas of the normal aorta. Bobryshev YV, et al. **Arch Histol Cytol** 1995 Aug;58(3):307–22

T helper cell infiltration and foam cell proliferation are early events in the development of atherosclerosis in cholesterol-fed rabbits. Drew AF, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1563–8

Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis. A nonhuman primate model of restenosis. Geary RL, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):34–43

Development of the lipid-rich core in human atherosclerosis. Guyton JR, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan; 16(1):4–11 (104 ref.)

Relation of a postmortem renal index of hypertension to atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. McGill HC Jr, et al. **Arterioscler Thromb Vasc Biol** 1995 Dec;15(12):2222–8

Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Tonstad S, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):984–91

T2-weighted contrast for NMR characterization of human atherosclerosis. Toussaint JF, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1533–42

Deposition pattern of monocytes and fatty streak development in hypercholesterolemic rabbits. Back MR, et al. **Atherosclerosis** 1995 Jul;116(1):103–15

High-resolution mapping of the frequency of lipid deposits in thoracic aortae from cholesterol-fed and heritable hyperlipidaemic rabbits [letter; comment] Forster BA, et al. **Atherosclerosis** 1996 Feb;120(1–2):249–53. Comment on: Atherosclerosis 1995 May;115(1):73–84.

Correlation between the presence of an immature smooth muscle cell population in tunica media and the development of atherosclerotic lesion. A study on different-sized rabbit arteries from cholesterol-fed and Watanabe heritable hyperlipemic rabbits. Giuriato L, et al. **Atherosclerosis** 1995 Jul;116(1):77–92

Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol-fed rabbits. Kockx MM, et al. **Atherosclerosis** 1996 Feb;120(1–2):115–24

Evidence for more extensive deposits of epitopes of oxidized low density lipoprotein in aortas of young people with elevated serum thiocyanate levels. PDAY Research Group. Scanlon CE, et al. **Atherosclerosis** 1996 Mar;121(1):23–33

Histologic features of atherosclerosis and hypertension from autopsies of young individuals in a defined geographic population: the Bogalusa Heart Study. Tracy RE, et al. **Atherosclerosis** 1995 Aug;116(2):163–79

Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated. Aviram M, et al. **Biochem Biophys Res Commun** 1995 Nov 13;216(2):501–13

Probucol, but not MaxEPA fish oil, inhibits mononuclear cell adhesion to the aortic intima in the rat model of atherosclerosis. Barbeau ML, et al. **Biochem Cell Biol** 1995 May-Jun;73(5–6):283–8

The development of preatherosclerotic coronary artery lesions in perinatal piglets. Bolande RP, et al. **Biol Neonate** 1996;69(2):109–18

Induction of tissue inhibitor of metalloproteinase and its mitogenic response to endothelial cells in human atherosclerotic and restenotic lesions. Tyagi SC, et al. **Can J Cardiol** 1996 Apr;12(4):353–62 (42 ref.)

Pathophysiology and inflammatory aspects of plaque rupture. Schroeder AP, et al. **Cardiol Clin** 1996 May;14(2):211–20 (94 ref.)

Arterial grafts for coronary artery surgery. Wandschneider W, et al. **Cardiovasc Surg** 1995 Oct;3(5):525–7

Optical coherence tomography for optical biopsy. Properties and demonstration of vascular pathology. Brezinski ME, et al. **Circulation** 1996 Mar 15;93(6):1206–13

Different effects of estrogen and progesterone on experimental atherosclerosis in female versus male rabbits. Quantification of cellular proliferation by bromodeoxyuridine. Hanke H, et al. **Circulation** 1996 Jul 15;94(2):175–81

Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Jang Y, et al. **Circulation** 1995 Nov 15;92(10):3041–50

Apoptosis in human atherosclerosis and restenosis [letter; comment] Kockx M, et al. **Circulation** 1996 Jan 15; 93(2):394–5. Comment on: Circulation 1995 Jun 1;91(11):2703–11.

Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal

leukocyte content. O'Brien KD, et al. **Circulation** 1996 Feb 15;93(4):672–82

Effect of thrombin inhibition with desulfatohirudin on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits. Ragosta M, et al. **Circulation** 1996 Mar 15;93(6):1194–200

Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Wilensky RL, et al. **Circulation** 1995 Nov 15; 92(10):2995–3005

The pathogenesis of atherosclerosis. Hegele RA. **Clin Chim Acta** 1996 Mar 15;246(1–2):21–38 (19 ref.)

Diabetic macroangiopathy and atherosclerosis. Andresen JL, et al. **Diabetes** 1996 Jul;45 Suppl 3:S91–4 (39 ref.)

Numerical investigation and prediction of atherogenic sites in branching arteries. Lei M, et al. **J Biomech Eng** 1995 Aug;117(3):350–7

Sick vessel syndrome: vascular changes in hypertension and atherosclerosis. Heistad DD, et al. **J Hum Hypertens** 1995 Jun;9(6):449–53 (38 ref.)

Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor–deficient and apolipoprotein E–deficient mice. Tangirala RK, et al. **J Lipid Res** 1995 Nov; 36(11):2320–8

Phased-array magnetic resonance imaging of the carotid artery bifurcation: preliminary results in healthy volunteers and a patient with atherosclerotic disease. Yuan C, et al. **J Magn Reson Imaging** 1995 Sep–Oct;5(5):561–5

Atherosclerotic lesions of the gastroepiploic artery: one case requiring postoperative dilation and some interesting postmortem observations. Carrel T, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1768–70

Hypertension-enhanced monocyte adhesion in experimental atherosclerosis. Tropea BI, et al. **J Vasc Surg** 1996 Apr; 23(4):596–605

Mature human atherosclerotic plaque contains peroxidized phosphatidylcholine as a major lipid peroxide. Piotrowski JJ, et al. **Life Sci** 1996;58(9):735–40

Assessment of the reliability of the determination of carotid artery lumen sizes by quantitative image processing of magnetic resonance angiograms and images. Berr SS, et al. **Magn Reson Imaging** 1995;13(6):827–35

Morphological fate and sequelae of human atherosclerosis: evaluation of immune mechanisms in atherogenesis through immunohistological and ultrastructural analysis. Shimokama T, et al. **Pathol Int** 1995 Nov;45(11):801–14

Environmental and genetic risk factors in early human atherogenesis: lessons from the PDAY study. Pathobiological Determinants of Atherosclerosis in Youth. Strong JP, et al. **Pathol Int** 1995 Jun;45(6):403–8 (30 ref.)

Ultrastructure of the afferent arteries of experimental femoral arteriovenous fistulae in rabbits. Jones GT, et al. **Pathology** 1995 Oct;27(4):333–8

A comparison of coronary arteries from Japanese and NZ subjects. Sims FH, et al. **Pathology** 1995 Jul;27(3):215–20

Progressive ischemic gangrene in dialysis patients: a clinicopathological correlation. el-Reshaid K, et al. **Ren Fail** 1995 Jul;17(4):437–47

Molecular and cellular pathology of atheroma [letter] Joffe B, et al. **S Afr J Surg** 1995 Jun;33(2):88

Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. O'Leary DH, et al. **Stroke** 1996 Feb; 27(2):224–31

Age-related differences in the distribution of peripheral atherosclerosis: when is atherosclerosis truly premature? Hansen ME, et al. **Surgery** 1995 Nov;118(5):834–9

LDL-platelet interaction under oxidative stress induces macrophage foam cell formation. Aviram M. **Thromb Haemost** 1995 Jul;74(1):560–4 (41 ref.)

Assessment of factors important in atherosclerotic occlusion and restenosis. Schwartz SM, et al. **Thromb Haemost** 1995 Jul;74(1):541–51 (114 ref.)

Declining density of intimal smooth muscle cells and age as preconditions for atheronecrosis in the basilar artery. Tracy RE. **Virchows Arch** 1995;427(2):131–8

The clinical morphology of human atherosclerotic lesions. Lessons from the PDAY Study. Pathobiological Determinants of Atherosclerosis in Youth. Cornhill JF, et al. **Wien Klin Wochenschr** 1995;107(18):540–3

Atherosclerotic lesions in humans--plaque stabilization and regression. Kritz H, et al. **Wien Klin Wochenschr** 1995; 107(18):555–66 (60 ref.)

[Retrospect and prospect of cardiovascular pathology] Wang T, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):210–3 (25 ref.) **(Chi)**

[Biology of the endothelial cell and atherogenesis] Demuth K, et al. **Ann Biol Clin (Paris)** 1995;53(4):171–91 (211 ref.) (Eng. Abstr.) **(Fre)**

[Calcified proliferation of the descending thoracic aorta] Fadel E, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):1039–42 (10 ref.) (Eng. Abstr.) **(Fre)**

[Study of atherosclerosis regression in the elderly—central depression and its correlation to ulcerated plaques] Kakiuchi H, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jul; 32(7):503–10 (Eng. Abstr.) **(Jpn)**

[Subpopulations of lymphocytes and monocytes/macrophages at the early stages of human aorta atherosclerosis] Zhdanov VS, et al. **Arkh Patol** 1995 Jul–Aug;57(4):67–71 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Insulin resistance syndrome and atherosclerotic cardiovascular disease. Scheen AJ. **Acta Clin Belg** 1996; 51(2):65–9 (44 ref.)

Endothelial dysfunction in the early stage of atherosclerosis precedes appearance of intimal lesions assessable with intravascular ultrasound. Mano T, et al. **Am Heart J** 1996 Feb;131(2):231–8

Comparison of thickness and distensibility in the carotid artery and descending thoracic aorta: in vivo ultrasound assessment. Pearson AC, et al. **Am Heart J** 1996 Apr; 131(4):655–62

Objective tinnitus in patients with atherosclerotic carotid artery disease. Sismanis A, et al. **Am J Otol** 1994 May; 15(3):404–7

Endothelial constitutive nitric oxide synthase protein and mRNA increased in rabbit atherosclerotic aorta despite impaired endothelium-dependent vascular relaxation. Kanazawa K, et al. **Am J Pathol** 1996 Jun;148(6):1949–56

The vascular biology of nitric oxide and its role in atherogenesis. Lloyd-Jones DM, et al. **Annu Rev Med** 1996; 47:365–75 (52 ref.)

Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Uchida K, et al. **Arch Biochem Biophys** 1995 Dec 20;324(2):241–8

Blood velocity profiles in the human renal artery by Doppler ultrasound and their relationship to atherosclerosis. Yamamoto T, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):172–7

Lipoproteins and the progression/regression of atherosclerosis. Barth JD. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):849–66 (74 ref.)

beta-Adrenoceptors in endothelium of rabbit coronary artery and alteration in atherosclerosis. Lu Z, et al. **Biol Signals** 1995 May–Jun;4(3):150–9

Pathophysiology and inflammatory aspects of plaque rupture. Schroeder AP, et al. **Cardiol Clin** 1996 May;14(2):211–20 (94 ref.)

Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Duverger N, et al. **Circulation** 1996 Aug 15;94(4):713–7

Atherosclerotic arterial remodeling in the superficial femoral artery. Individual variation in local compensatory enlargement response. Pasterkamp G, et al. **Circulation** 1996 May 15;93(10):1818–25

Effects of ambulation on foot oxygen tension in limbs with peripheral atherosclerosis. Carter SA. **Clin Physiol** 1996 May;16(3):199–208

The atherogenic potential of endothelin. Hasdai D, et al. **Coron Artery Dis** 1995 Nov;6(11):901–4 (60 ref.)

Expression of monocyte chemoattractant protein-1 in vascular tissue. Seino Y, et al. **Cytokine** 1995 Aug; 7(6):575–9

Early atherogenesis in diabetes mellitus. Schaper NC. **Diabet Med** 1996;13 Suppl 1:S23–5 (30 ref.)

Insulin resistance and atherosclerosis. Garg A, et al. **Diabetes Care** 1996 Mar;19(3):274

Albuminuria is an independent predictor of carotid intima-media thickness and atherosclerosis in NIDDM patients [letter] Willey KA, et al. **Diabetes Care** 1995 Nov; 18(11):1502–3

Is oxidative stress the missing link between insulin resistance and atherosclerosis? [letter] Ceriello A, et al. **Diabetologia** 1995 Dec;38(12):1484–5

Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. Vittek J. **Experientia** 1995 Sep 29;51(9–10):927–35 (68 ref.)

Metal ion release from mechanically-disrupted human arterial wall. Implications for the development of atherosclerosis. Evans PJ, et al. **Free Radic Res** 1995 Nov; 23(5):465–9

Residual strain and local strain distributions in the rabbit atherosclerotic aorta. Matsumoto T, et al. **J Biomech** 1995 Oct;28(10):1207–17

Augmented responses to 5-HT2-receptor-mediated vasoconstrictions in atherosclerotic rabbit common carotid arteries. Fujiwara T, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):503–10

Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. Libby P, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S9–12 (23 ref.)

Endothelial nucleotide-mediated aorta relaxation in aged Watanabe heritable hyperlipidemic rabbits. Ragazzi E, et al. **J Cardiovasc Pharmacol** 1995 Jul;26(1):119–26

Sick vessel syndrome: vascular changes in hypertension and atherosclerosis. Heistad DD, et al. **J Hum Hypertens** 1995 Jun;9(6):449–53 (38 ref.)

Renal artery velocity mapping with MR imaging. Maier SE, et al. **J Magn Reson Imaging** 1995 Nov–Dec;5(6):669–76

Determination of wall shear stress in the aorta with the use of MR phase velocity mapping. Oshinski JN, et al. **J Magn Reson Imaging** 1995 Nov–Dec;5(6):640–7

The natural history of the external carotid artery after carotid endarterectomy: implications for management. Ascer E, et al. **J Vasc Surg** 1996 Apr;23(4):582–5; discussion 585–6

Endothelium, fibrinolysis, cardiac risk factors, and prostaglandins: a unified model of atherogenesis. Kadish J. **Med Hypotheses** 1995 Aug;45(2):205–13 (106 ref.)

Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion--the 'PKC syndrome'. McCarty MF. **Med Hypotheses** 1996 Mar; 46(3):191–221 (402 ref.)

Carbamylation of proteins and atherogenesis in renal failure. Roxborough HE, et al. **Med Hypotheses** 1995 Aug; 45(2):125–8 (28 ref.)

Effects of the anabolic steroid nandrolone decanoate on plasma lipids and coronary arteries of female cynomolgus macaques. Obasanjo IO, et al. **Metabolism** 1996 Apr; 45(4):463–8

Role of atherogenic lipoproteins in cytokine-mediated renovascular injury. Kirschenbaum MA, et al. **Miner Electrolyte Metab** 1996;22(1–3):47–50 (20 ref.)

Homocysteine and vascular disease. McCully KS. **Nat Med** 1996 Apr;2(4):386–9 (20 ref.)

Is the 'wait-and-see' approach justified in atherosclerotic renal artery stenosis? [editorial] Scoble JE. **Nephrol Dial Transplant** 1995;10(5):588–9

Eicosanoid precursors: potential factors for atherogenesis in diabetic CAPD patients? Holler C, et al. **Perit Dial Int** 1996;16 Suppl 1:S250–3

Impact of nutritional status on serum lipoprotein (a) concentration in patients undergoing continuous ambulatory peritoneal dialysis. Kang DH, et al. **Perit Dial Int** 1996;16 Suppl 1:S241–5

Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Cox DA, et al. **Pharmacol Rev** 1996 Mar;48(1):3–19 (182 ref.)

Elastic properties of human aortas in relation to age and atherosclerosis: a structural model. Wuyts FL, et al. **Phys Med Biol** 1995 Oct;40(10):1577–97

Cholesterol and atherosclerotic vascular disease: from science to public health policy. Fröhlich J. **Sb Lek** 1996;97(1):17–23

Homocysteine theory of atherosclerosis. Hladovec J. **Sb Lek** 1995;96(3):225–30

Influence of vascular risk factors for atherosclerotic carotid artery plaque progression. Delcker A, et al. **Stroke** 1995 Nov;26(11):2016–22

Effect of short-term regression of atherosclerosis on reactivity of carotid and retinal arteries. Sobey CG, et al. **Stroke** 1996 May;27(5):927–33

Quantification of blood flow patterns in human vessels by magnetic resonance imaging. Botnar R, et al. **Technol Health Care** 1996 Apr;4(1):97–112

The dynamics of pulsatile flow in distensible model arteries. Liepsch DW, et al. **Technol Health Care** 1995 Dec; 3(3):185–99

Mathematical modeling of arterial blood flow and correlation to atherosclerosis. Perktold K, et al. **Technol Health Care** 1995 Dec;3(3):139–51

Tissue factor induces migration of cultured aortic smooth muscle cells. Sato Y, et al. **Thromb Haemost** 1996 Mar; 75(3):389–92

Does atherosclerosis of the hypogastric artery in the recipient influence renal allograft function and blood pressure? Harada H, et al. **Transplant Proc** 1996 Jun;28(3):1621–2

Role of nitric oxide in progression and regression of atherosclerosis. Cooke JP. **West J Med** 1996 May; 164(5):419–24 (52 ref.)

[New findings on the pathogenesis of atherosclerosis] Fialová L. **Cesk Fysiol** 1995 Jun;44(2):92–101 (17 ref.) (Eng. Abstr.) **(Cze)**

[Protection of oxidation of LDL by nitric oxide: implication in atherogenesis] Maggi MF, et al. **C R Seances Soc Biol Fil** 1995;189(3):375–87 (Eng. Abstr.) **(Fre)**

[Spontaneous and recent thrombosis of tetrafluoroethylene vascular prostheses secondary to progression of atherosclerosis of the lower limbs. 2 cases (letter)] Desoutter P, et al. **Presse Med** 1996 Apr 6;25(12):600–1 **(Fre)**

[Atherosclerotic disease of the aorta: a source of thromboembolism] Gur H, et al. **Harefuah** 1996 Mar 1; 130(5):339–43 (34 ref.) **(Heb)**

[Non-inflammatory arteriopathies] Alvarez-Sabín J. **Rev Neurol** 1995;23 Suppl 1:S33–40 (52 ref.) **(Spa)**

PREVENTION & CONTROL

Atherosclerosis and cholesterol. The end of the controversy? [editorial] Heller FR. **Acta Clin Belg** 1996;51(1):1–7 (50 ref.)

The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Salonen R, et al. **Am J Cardiol** 1995 Sep 28;76(9):34C–39C

Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study. Espeland MA, et al. **Am J Epidemiol** 1995 Nov 15; 142(10):1011–9

Chronic alcohol feeding inhibits atherogenesis in C57BL/6 hyperlipidemic mice. Emeson EE, et al. **Am J Pathol** 1995 Dec;147(6):1749–58

Cannula length and arch flow erosion [letter; comment] Groom RC, et al. **Ann Thorac Surg** 1996 Feb;61(2):773–4 . Comment on: Ann Thorac Surg 1995 Mar;59(3):710–2.

Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Ameli S, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1074–9

Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral

endopeptidase 24.11 (EC 3.4.24.11). Kugiyama K, et al. **Arterioscler Thromb Vasc Biol** 1996 Aug;16(8):1080–7

Intravenous injection of rabbit apolipoprotein A–I inhibits the progression of atherosclerosis in cholesterol–fed rabbits. Miyazaki A, et al. **Arterioscler Thromb Vasc Biol** 1995 Nov; 15(11):1882–8

Prevention of preatheromatous lesions in sand rats by treatment with a nutritional supplement. Marquié G, et al. **Arzneimittelforschung** 1996 Jun;46(6):610–4

Lack of effect of oral N–acetylcysteine on the acute dialysis–related lowering of total plasma homocysteine in hemodialysis patients. Bostom AG, et al. **Atherosclerosis** 1996 Feb;120(1–2):241–4

Effect of vitamin E on atherogenesis in LDL receptor–deficient rabbits. Fruebis J, et al. **Atherosclerosis** 1995 Oct;117(2):217–24

Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Hanke H, et al. **Atherosclerosis** 1996 Mar;121(1):129–38

Is reverse cholesterol transport a misnomer for suggesting its role in the prevention of atheroma formation? Quintão EC. **Atherosclerosis** 1995 Jul;116(1):1–14 (162 ref.)

Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Zgliczynski S, et al. **Atherosclerosis** 1996 Mar;121(1):35–43

Beneficial effects of simvastatin may be due to non–lipid actions [letter; comment] Ravnskov U. **BMJ** 1995 Nov 25; 311(7017):1436–7. Comment on: BMJ 1995 May 20;310(6990):1280–1.

Hormone replacement therapy and cardiovascular disease: the rabbit model. Haarbo J. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:49–51; discussion 51–2

Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits. Soma MR, et al. **Br J Pharmacol** 1996 May;118(2):215–9

Inhibition of atherosclerosis development in cholesterol–fed human apolipoprotein A–I–transgenic rabbits. Duverger N, et al. **Circulation** 1996 Aug 15;94(4):713–7

Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials. Zanchetti A. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):489–99 (12 ref.)

Diet in the prevention and treatment of atherosclerosis. A perspective for the elderly. Srinath U, et al. **Clin Geriatr Med** 1995 Nov;11(4):591–611 (46 ref.)

Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: effects of fish oil and vitamin E administration. Panzetta O, et al. **Clin Nephrol** 1995 Nov;44(5):303–9

Early atherosclerosis is retarded by improved long–term blood glucose control in patients with IDDM. Jensen–Urstad KJ, et al. **Diabetes** 1996 Sep;45(9):1253–8

New approaches to the prevention of atherosclerosis. Naito M, et al. **Drugs** 1995 Sep;50(3):440–53 (154 ref.)

Hypocholesterolemic activity of nut shell extract of Semecarpus anacardium (Bhilawa) in cholesterol fed rabbits. Sharma A, et al. **Indian J Exp Biol** 1995 Jun; 33(6):444–8

Prevention of hypercholesterolemia and atherosclerosis in rabbits after supplementation of Myristica fragrans seed extract. Sharma A, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):407–10

Cardiovascular disease in women: implications of hormone replacement therapy. Sarrel PM. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):90–3 (20 ref.)

Recent studies regarding the role of childhood nutrition in the prevention of atherosclerosis [letter] Szamosi T. **J Am Coll Nutr** 1995 Aug;14(4):406

The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. Hilbrands LB, et al. **J Am Soc Nephrol** 1995 Jun; 5(12):2073–81

(–)–anipamil retards atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Hansen BF, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):485–9

Inhibition of restenosis by beraprost sodium (a prostaglandin I2 analogue) in the atherosclerotic rabbit artery after angioplasty. Isogaya M, et al. **J Cardiovasc Pharmacol** 1995 Jun;25(6):947–52

Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. Hayek T, et al. **J Clin Invest** 1995 Oct;96(4):2071–4

Beta–carotene inhibits atherosclerosis in hypercholesterolemic rabbits. Shaish A, et al. **J Clin Invest** 1995 Oct;96(4):2075–82

Progression of atherosclerosis in middle–aged men: effects of multifactorial intervention. Persson J, et al. **J Intern Med** 1996 May;239(5):425–33

Prevention of atherosclerosis with dietary antioxidants: fact or fiction? Duell PB. **J Nutr** 1996 Apr;126(4 Suppl):1067S–71S (38 ref.)

Antiatherogenic action of nitrendipine in hypercholesterolemic rabbits: changes in aortic macrophage accumulation and smooth muscle cell phenotype. Pauletto P, et al. **J Vasc Res** 1996 Jan–Feb; 33(1):5–12

Tamoxifen elevates transforming growth factor–beta and suppresses diet–induced formation of lipid lesions in mouse aorta [see comments] Grainger DJ, et al. **Nat Med** 1995 Oct;1(10):1067–73. Comment in: Nat Med 1995 Oct;1(10):1001–1.

Anticholesterol antibodies and plaque formation. Ordovas JM. **Nutr Rev** 1996 Apr;54(4 Pt 1):124–7 (28 ref.)

New targets for lipid lowering and atherosclerosis prevention. Sirtori CR. **Pharmacol Ther** 1995;67(3):433–47 (108 ref.)

Natural antioxidants for the prevention of atherosclerosis. Odeh RM, et al. **Pharmacotherapy** 1995 Sep–Oct; 15(5):648–59 (105 ref.)

Suppression of diet–induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Shimada M, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):7242–6

Low–dose aspirin does not attenuate platelet aggregation or atherosclerosis in miniature swine but decreases production of aortic wall prostacyclin. Smith MJ, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):331–40

Non–insulin–dependent diabetes mellitus: dietary monounsaturated fatty acids and low–density lipoprotein composition and function. Griffin ME, et al. **QJM** 1996 Mar;89(3):211–6

Protection against atherogenesis in mice mediated by human apolipoprotein A–IV. Duverger N, et al. **Science** 1996 Aug 16;273(5277):966–8

[Effects of coconut juice on the formation of hyperlipidemia and atherosclerosis] Zhao G, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul;29(4):216–8 (Eng. Abstr.) **(Chi)**

[1995 consensus guidelines for cholesterol. Society of Physicians in Vienna] Sinzinger H, et al. **Wien Klin Wochenschr** 1995;107(18):537–9 (5 ref.) **(Ger)**

[Nutrition–related prevention studies in children and adolescents on a population level—concepts, methods, outcome] Kersting M, et al. **Z Arztl Fortbild (Jena)** 1996 Feb;90(1):25–31 (34 ref.) (Eng. Abstr.) **(Ger)**

[Prevention of coronary disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension] Pyörälä K, et al. **Cardiologia** 1996 Feb;41(2):149–82 (192 ref.) **(Ita)**

[Relationship between lipid profile and blood viscosity in a sample of Calabrian population] Carallo C, et al. **Minerva Cardioangiol** 1996 Jan–Feb;44(1–2):53–7 (Eng. Abstr.) **(Ita)**

[Sex hormones, glycolipid metabolism, and atherogenesis] Sarubbi B, et al. **Minerva Med** 1995 Jun;86(6):265–73 (67 ref.) (Eng. Abstr.) **(Ita)**

[New developments in the prevention and treatment of atherosclerosis, ischemic heart disease, hyperlipidemia and other diseases] Samsonov MA, et al. **Vopr Pitan** 1995; (4):33–4 **(Rus)**

[The polymetabolic syndrome. The experiences of the DRECE study. Dieta y Riesgo de Enfermedades Cardiovasculares en España] Gutiérrez Fuentes JA. **Rev Esp Cardiol** 1995;48 Suppl 4:18–27 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Panoramic dental radiography: an aid in detecting individuals prone to stroke. Friedlander AH, et al. **Br Dent J** 1996 Jul 6;181(1):23–6

Variation in cardiovascular risk factors by angiographic site of lower limb atherosclerosis. Smith FB, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):340–6

Patterns of atherosclerotic occlusive disease of lower leg and pedal arteries in hypertensive patients undergoing infrainguinal bypass procedures. Karacagil S, et al. **Int Angiol** 1996 Mar;15(1):57–60

Atherosclerotic renal artery stenosis: ostial or truncal? Kaatee R, et al. **Radiology** 1996 Jun;199(3):637–40

RADIONUCLIDE IMAGING

Usefulness of dipyridamole–thallium imaging in 257 patients with atherosclerotic vascular disease. Toyama T, et al. **Nucl Med Commun** 1995 Oct;16(10):821–6

REHABILITATION

Exercise rehabilitation for patients with peripheral arterial disease. Regensteiner JG, et al. **Exerc Sport Sci Rev** 1995; 23:1–24 (95 ref.)

SURGERY

Vascular repair mechanisms after directional atherectomy or percutaneous transluminal coronary angioplasty in atherosclerotic rabbit iliac arteries. Wilensky RL, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):13–22

Ultrastructural characteristics of human atherectomy tissue from coronary and lower extremity arterial stenoses. Bauriedel G, et al. **Am J Cardiol** 1996 Mar 1;77(7):468–74

Surgical treatment of systemic atheroembolism from the thoracic aorta. Bojar RM, et al. **Ann Thorac Surg** 1996 May;61(5):1389–93

Recurrent cerebral vascular accidents are an indication for ascending aortic endarterectomy. Muehrcke DD, et al. **Ann Thorac Surg** 1996 May;61(5):1516–8

Anastomosis over a stent for heavily calcified arteries. Coggia M, et al. **Ann Vasc Surg** 1995;9 Suppl:S39–44

Isolated atherosclerotic aneurysms of the iliac arteries. Desiron Q, et al. **Ann Vasc Surg** 1995;9 Suppl:S62–6

Percutaneous transluminal angioplasty in adults less than 45 years of age with premature lower extremity atherosclerosis. Levy PJ, et al. **Ann Vasc Surg** 1995 Sep; 9(5):471–9

The relationship between arm–ankle pressure difference and peak systolic velocity in patients with stenotic lower extremity vein grafts. Papanicolaou G, et al. **Ann Vasc Surg** 1995 Nov;9(6):554–60

Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis. A nonhuman primate model of restenosis. Geary RL, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan;16(1):34–43

Evaluation of the pullback atherectomy catheter in the treatment of lower limb vascular disease. Grubnic S, et al. **Cardiovasc Intervent Radiol** 1996 May–Jun;19(3):152–9

The influence of age on long–term survival pattern of patients operated on for lower limb ischaemia. Aune S, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):214–7

Bilaterial renal artery atherosclerosis—the results of surgical treatment. Crinnion JN, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):353–8

Operative indication in asymptomatic carotid arterial disease. Robicsek F. **Eur J Vasc Endovasc Surg** 1995 Nov; 10(4):396–7

Patterns of atherosclerotic occlusive disease of lower leg and pedal arteries in hypertensive patients undergoing infrainguinal bypass procedures. Karacagil S, et al. **Int Angiol** 1996 Mar;15(1):57–60

Occlusion of vessels with posterior plaques. Barone GW, et al. **J Am Coll Surg** 1996 Jun;182(6):549–51

Surgical management of mobile aortic atheroma diagnosed by intraoperative transesophageal echocardiography [letter] Zenati M, et al. **J Card Surg** 1995 Sep;10(5):608–10

Influence of anatomic distribution of atherosclerosis on the outcome of revascularization with iliac stent placement. Laborde JC, et al. **J Vasc Interv Radiol** 1995 Jul–Aug; 6(4):513–21

Complementary distal arteriovenous fistula and deep vein interposition: a five–year experience with a new technique to improve infrapopliteal prosthetic bypass patency. Ascer E, et al. **J Vasc Surg** 1996 Jul;24(1):134–43

Intraoperative autotransfusion in aortic surgery: comparison of whole blood autotransfusion versus cell separation. Bartels C, et al. **J Vasc Surg** 1996 Jul;24(1):102–8

Renal artery reconstruction for the preservation of renal function. Cambria RP, et al. **J Vasc Surg** 1996 Sep; 24(3):371–80; discussion 380–2

Empirical reconstruction of the renal artery: long–term outcome. Chaikof EL, et al. **J Vasc Surg** 1996 Sep; 24(3):406–14

Is renal revascularization in diabetic patients worthwhile? Hansen KJ, et al. **J Vasc Surg** 1996 Sep;24(3):383–92; discussion 392–3

Long–term follow–up of patients with early atherosclerosis. Harris LM, et al. **J Vasc Surg** 1996 Apr;23(4):576–80; discussion 581

Management and outcome of chronic atherosclerotic infrarenal aortic occlusion. Ligush J Jr, et al. **J Vasc Surg** 1996 Sep;24(3):394–404; discussion 404–5

Progression of atherosclerosis in arteries distal to lower extremity revascularizations. McLafferty RB, et al. **J Vasc Surg** 1995 Oct;22(4):450–5; discussion 455–6

Surgical results: a justification of the surgeon selection process for the ACAS trial. The ACAS Investigators. Moore WS, et al. **J Vasc Surg** 1996 Feb;23(2):323–8

The treatment of focal aortic arch branch lesions with Palmaz stents. Queral LA, et al. **J Vasc Surg** 1996 Feb;23(2):368–75

Atherosclerosis of the lower extremity and free–tissue reconstruction for limb salvage. Serletti JM, et al. **Plast Reconstr Surg** 1995 Oct;96(5):1136–44

Late outcome of amputees with premature atherosclerosis. Valentine RJ, et al. **Surgery** 1996 May;119(5):487–93

Prediction of early cardiac morbidity and mortality following aorto–iliac reconstruction: comparison between clinical scoring systems, echocardiography and dipyridamole–thallium scanning. Carrel T, et al. **Vasa** 1995; 24(4):362–7

[Arterial vascularization of the foot. Its importance in operations of revascularization of the lower limb] Peret M, et al. **J Chir (Paris)** 1995 Dec;132(12):487–94 (Eng. Abstr.) **(Fre)**

[Preservation of renal function by revascularization in renovascular disease] Halimi JM, et al. **J Mal Vasc** 1995; 20(4):241–6 (55 ref.) (Eng. Abstr.) **(Fre)**

[Advances in surgery for carotid stenosis. 900 operations (1983–1994)] Becker F, et al. **Presse Med** 1996 Apr 6; 25(12):573–6 (Eng. Abstr.) **(Fre)**

[Isolated, true aneurysm of the tibiofibular trunk—a rarity among peripheral aneurysms] Nahrstedt U, et al. **Vasa** 1995; 24(4):373–6 (Eng. Abstr.) **(Ger)**

[Coronary artery bypass grafting in cases with the atherosclerotic ascending aorta] Bando M, et al. **Kyobu Geka** 1995 Oct;48(11):933–6 (Eng. Abstr.) **(Jpn)**

[A report of surgical treatment for atherosclerotic aneurysm in the aortic arch associated with type III acute aortic dissection] Hara Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):516–8 (Eng. Abstr.) **(Jpn)**

[A study of natural history in 208 patients with atherosclerosis of lower limb arteries and diabetes mellitus] Nazarewski S, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):19–22 (Eng. Abstr.) **(Pol)**

[Double transplantation of internal thoracic arteries in severe coronary artery disease and atherosclerosis of the ascending part and branches of the aorta] Olearchik AS. **Klin Khir** 1995;(7–8):41–3 **(Ukr)**

THERAPY

Spontaneous regression of postangioplasty restenosis in common iliac artery [letter] Hirai T, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):728–9

Microparticle deposition in periarterial microvasculature and intramural dissections after porous balloon delivery into atherosclerotic vessels: quantitation and localization by confocal scanning laser microscopy. Nasser TK, et al. **Am Heart J** 1996 May;131(5):892–8

Vascular repair mechanisms after directional atherectomy or percutaneous transluminal coronary angioplasty in atherosclerotic rabbit iliac arteries. Wilensky RL, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):13–22

The next generation extracorporeal method for the management of atherosclerosis [editorial] Matsuda Y, et al. **Artif Organs** 1995 Sep;19(9):877–9 (22 ref.)

An experimental study of intravascular stent in abdominal aorta of atherosclerotic miniature pigs. Huang J, et al. **Chin Med J (Engl)** 1995 Jul;108(7):497–500

Geometric remodeling [letter; comment] Currier JW, et al. **Circulation** 1995 Dec 15;92(12):3581–3. Comment on: Circulation 1994 Dec;90(6):3001–8.

Recommendations for the management of chronic critical lower limb ischaemia. The Audit Committee of the Vascular Surgical Society of Great Britain and Ireland. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):131–5

Percutaneous transluminal angioplasty of the infrarenal aorta: initial outcome and long-term clinical and angiographic results. Hedeman Joosten PP, et al. **Eur J Vasc Endovasc Surg** 1996 Aug;12(2):201–6

Efficacy of lipid apheresis: definitions and influencing factors. Bosch T, et al. **Int J Artif Organs** 1995 Apr;18(4):210–5

An unusually hard lesion in an aortocoronary saphenous vein graft refractory to standard balloon angioplasty. Kyriakidis M, et al. **Int J Cardiol** 1995 Nov 24;52(2):115–7

Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries. Simari RD, et al. **J Clin Invest** 1996 Jul 1;98(1):225–35

Percutaneous transluminal angioplasty of supra-aortic vessels. Motarjeme A. **J Endovasc Surg** 1996 May; 3(2):171–81

Percutaneous treatment of aortoiliac atherosclerosis: a case report. Maynar M, et al. **J La State Med Soc** 1996 Jan; 148(1):24–7

Vertebral artery stenting following percutaneous transluminal angioplasty. Technical note. Storey GS, et al. **J Neurosurg** 1996 May;84(5):883–7

Atherosclerotic lesions of the gastroepiploic artery: one case requiring postoperative dilation and some interesting postmortem observations. Carrel T, et al. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1768–70

Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Sarembock IJ, et al. **J Vasc Res** 1996 Jul–Aug;33(4):308–14

A personal view: the Asymptomatic Carotid Atherosclerosis Study results—read the label carefully. Hertzer NR. **J Vasc Surg** 1996 Jan;23(1):167–71

New ideas for restenosis research aired in Ohio [news] Huehns TY. **Lancet** 1996 Jun 29;347(9018):1824

Transluminal vascular stents for ostial atherosclerotic renal artery stenosis [letter; comment] MacLeod MJ, et al. **Lancet** 1995 Oct 21;346(8982):1109–10. Comment on: Lancet 1995 Sep 9;346(8976):672–4.

Transluminal vascular stents for ostial atherosclerotic renal artery stenosis [letter; comment] Plouin PF, et al. **Lancet** 1995 Oct 21;346(8982):1109. Comment on: Lancet 1995 Sep 9;346(8976):672–4.

Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Sluiter W, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):233–8 (44 ref.)

Selective gene therapy for proliferative disorders: sense and antisense [comment] Indolfi C, et al. **Nat Med** 1996 Jun; 2(6):634–5. Comment on: Nat Med 1996 Jun;2(6):668–75.

Balloon expandable intravascular stent in infrarenal aortic stenosis. Kang EH. **Nebr Med J** 1995 Nov;80(11):329–31

Atherosclerotic renal artery stenosis—when is intervention by PTA or surgery justified? [editorial] Zuccalà A, et al. **Nephrol Dial Transplant** 1995;10(5):585–7

Acute thrombolytic therapy and subsequent angioplasty for atherosclerotic stenosis of the basilar artery—case report. Nakano S, et al. **Neurol Med Chir (Tokyo)** 1995 Sep; 35(9):674–7

Molecular therapies for vascular diseases. Gibbons GH, et al. **Science** 1996 May 3;272(5262):689–93 (32 ref.)

Options for therapy of ischemic nephropathy: role of angioplasty and surgery. Novick AC. **Semin Nephrol** 1996 Jan;16(1):53–60 (61 ref.)

Association of antibodies to heat-shock protein-65 with percutaneous transluminal coronary angioplasty and subsequent restenosis. Mukherjee M, et al. **Thromb Haemost** 1996 Feb;75(2):258–60

Haemorrhage due to laceration of an aberrant inferior epigastric artery during femoropopliteal PTA in an obese patient; a rare complication of a high antegrade femoral puncture. Lampmann LE, et al. **Vasa** 1995;24(4):382–4

Gene therapy: prospects for treatment of liver disease. Sandig V, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:25–6 (32 ref.)

[The experimental observation on the procedure of atherosclerotic restenosis following PTCA] Sun B, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Aug;34(8):528–30 (Eng. Abstr.) **(Chi)**

[Angiology update] Ranke C, et al. **Med Klin** 1996 Apr 1; 91 Suppl 1:140–52 (129 ref.) **(Ger)**

[Feasibility of correction of blood aggregation properties in the course of extracorporeal hemosorption in atherosclerosis patients] Balonov KM, et al. **Gematol Transfuziol** 1995 Jul–Aug;40(4):23–5 (Eng. Abstr.) **(Rus)**

[Classification and strategy of treatment in diabetic angiopathies of the lower limbs] Ivashchenko VV, et al. **Klin Khir** 1995;(7–8):13–5 **(Rus)**

ULTRASONOGRAPHY

Endothelial dysfunction in the early stage of atherosclerosis precedes appearance of intimal lesions assessable with intravascular ultrasound. Mano T, et al. **Am Heart J** 1996 Feb;131(2):231–8

Three-dimensional transabdominal ultrasound identification of aortic plaque. Webber JD, et al. **Am J Card Imaging** 1995 Oct;9(4):245–9

Absence of atherosclerotic lesions in the thoracic aorta indicates absence of significant coronary artery disease. Parthenakis F, et al. **Am J Cardiol** 1996 May 15; 77(12):1118–21 SERIALS SUBS JAF

TEE and ascending aortic atherosclerosis [letter; comment] Allen G. **Anesth Analg** 1996 Jun;82(6):1301. Comment on: Anesth Analg 1995 Aug;81(2):225–8.

High reproducibility in the interpretation of intraoperative transesophageal echocardiographic evaluation of aortic atheromatous disease. Hartman GS, et al. **Anesth Analg** 1996 Mar;82(3):539–43

Duplex sonography of venous atheromatosis found in the venous part of hemodialysis fistula. Kröger K, et al. **Angiology** 1996 Jul;47(7):675–8

Asymptomatic atherosclerosis in HIV-positive patients: A case-control ultrasound study. Constans J, et al. **Ann Med** 1995 Dec;27(6):683–5

The original calibre of the lower limbs arteries as a possible risk factor for complications of atherosclerosis: a statistical investigation in 90 subjects by echocolor-doppler. Macchi C, et al. **Arch Ital Anat Embriol** 1994 Oct–Dec;99(4):219–28

Ultrasound morphology classification of the arterial wall and cardiovascular events in a 6-year follow-up study. Belcaro G, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):851–6

Relation of intima-media thickness to atherosclerotic plaques in carotid arteries. The Vascular Aging (EVA) Study. Bonithon-Kopp C, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):310–6

On quantifying plaque size and intima-media thickness in carotid and femoral arteries. Comments on results from a prospective ultrasound study in patients with familial hypercholesterolemia. Wendelhag I, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):843–50

Axial and lateral resolution of rotational intravascular ultrasound: in vitro observations and diagnostic implications. Engeler CE, et al. **Cardiovasc Intervent Radiol** 1995 Jul–Aug;18(4):239–42

Intravascular ultrasound imaging of peripheral arteries as an adjunct to balloon angioplasty and atherectomy. Korogi Y, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):1–9 (39 ref.)

Asymptomatic hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery. Yamasaki Y, et al. **Diabetologia** 1995 May;38(5):585–91

Unstable carotid plaques: preoperative identification and association with intraoperative embolisation detected by transcranial Doppler. Gaunt ME, et al. **Eur J Vasc Endovasc Surg** 1996 Jan;11(1):78–82

Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: correlation with high density lipoproteins. Hausmann D, et al. **J Am Coll Cardiol** 1996 Jun; 27(7):1562–70

Natural history of severe atheromatous disease of the thoracic aorta: a transesophageal echocardiographic study. Montgomery DH, et al. **J Am Coll Cardiol** 1996 Jan; 27(1):95–101

Surgical management of mobile aortic atheroma diagnosed by intraoperative transesophageal echocardiography [letter] Zenati M, et al. **J Card Surg** 1995 Sep;10(5):608–10

Progression of atherosclerosis in middle-aged men: effects of multifactorial intervention. Persson J, et al. **J Intern Med** 1996 May;239(5):425–33

Power Doppler ultrasound examination of the intracerebral and extracerebral vasculature. Griewing B, et al. **J Neuroimaging** 1996 Jan;6(1):32–5

High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kawagishi T, et al. **Kidney Int** 1995 Sep;48(3):820–6

Aortic atheromas and acute ischemic stroke: a transesophageal echocardiographic study in an ethnically mixed population. Di Tullio MR, et al. **Neurology** 1996 Jun;46(6):1560–6

Intravascular ultrasonography of supra-aortic arteries as an adjunct to percutaneous transluminal angioplasty. Hirai T, et al. **Neuroradiology** 1995 Jul;37(5):395–9

Role of Doppler US in screening for carotid atherosclerotic disease [see comments] Derdeyn CP, et al. **Radiology** 1995 Dec;197(3):635–43. Comment in: Radiology 1995 Dec;197(3):581–2.

Role of duplex US as a screening test for carotid atherosclerotic disease: benefit without cost? [editorial; comment] Polak JF. **Radiology** 1995 Dec;197(3):581–2. Comment on: Radiology 1995 Dec;197(3):635–43.

Risk factors and segment-specific carotid arterial enlargement in the Atherosclerosis Risk in Communities (ARIC) cohort. Crouse JR, et al. **Stroke** 1996 Jan; 27(1):69–75

Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Espeland MA, et al. **Stroke** 1996 Mar;27(3):480–5

Discrimination of intravascular lumen and dissections in single intravascular ultrasound images using subtraction, conventional averaging and saline flush. Pasterkamp G, et al. **Ultrasound Med Biol** 1995;21(2):149–56

[Should Doppler echography in the diagnosis of the extra-cardiac sites of atherosclerosis be routine in patients with coronary disease? Apropos of 248 cases] Charon P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Nov;44(9):477–85 (Eng. Abstr.) **(Fre)**

[The evaluation of atherosclerotic lesions of the extracranial carotid arteries in hypertensive subjects. A study by B-mode and pulsed Doppler echotomography] Guarini P, et al. **Cardiologia** 1992 Jul;37(7):489–95 (Eng. Abstr.) **(Ita)**

[Intravascular echography: a new approach to the pathophysiologic assessment of atherosclerotic lesions] Marsico F. **G Ital Cardiol** 1995 Dec;25(12):1649–51 (16 ref.) **(Ita)**

[Importance of ischemic heart disease in patients with carotid arteriosclerosis and lower extremity arteriopathy. Results of a prospective study] Racco F, et al. **Minerva Cardioangiol** 1995 Sep;43(9):345–54 (32 ref.) (Eng. Abstr.) **(Ita)**

[Ultrasonic evaluation of early atherosclerotic damage in patients with type 1 diabetes mellitus] Rossi M, et al. **Minerva Cardioangiol** 1995 Sep;43(9):355–60 (Eng. Abstr.) **(Ita)**

[Carotid atherosclerosis evaluated by two-dimensional ultrasonography in patients with primary hypercholesterolemia] Zambón D, et al. **Med Clin (Barc)** 1995 Dec 8;105(20):761–7 (Eng. Abstr.) **(Spa)**

URINE

Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. Deckert T, et al. **BMJ** 1996 Apr 6; 312(7035):871–4

VETERINARY

Atherosclerosis in Japanese Quail males selected for high or low plasma cholesterol. Siegel HS, et al. **Poult Sci** 1995 Oct;74(10):1712–6

VIROLOGY

Cytomegalovirus and atherosclerosis. Melnick JL, et al. **Bioessays** 1995 Oct;17(10):899–903 (28 ref.)

[Detection of human cytomegalovirus DNA in vascular plaques of atherosclerosis by in situ hybridization] Chen S, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Oct; 75(10):592–3, 638 (Eng. Abstr.) **(Chi)**

ATHEROSCLEROSIS, CORONARY see **CORONARY ARTERIOSCLEROSIS**

ATHETOSIS

CHEMICALLY INDUCED

Phenytoin-induced focal chorea [letter] Shulman LM, et al. **Mov Disord** 1996 Jan;11(1):111–4

Choreoathetotic movements: A possible side effect of gabapentin. Buetefisch CM, et al. **Neurology** 1996 Mar; 46(3):851–2

CLASSIFICATION

Paroxysmal choreoathetosis: an epileptic or non-epileptic disorder? Lombroso CT. **Ital J Neurol Sci** 1995 Jun; 16(5):271–7

COMPLICATIONS

Sport and the person with spasticity of cerebral origin. Richter KJ, et al. **Dev Med Child Neurol** 1996 Sep; 38(9):867–70

[Fahr syndrome and dysparathyroidism. 3 cases] el Maghraoui A, et al. **Presse Med** 1995 Sep 30;24(28):1301–4 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Chorea and athetosis in childhood] Fernández-Alvarez E. **Rev Neurol** 1995;23 Suppl 3:S330–3 (59 ref.) **(Spa)**

DRUG THERAPY

Anticholinergic treatment for choreoathetosis in a child after

induction with propofol [letter] Diltoer MW, et al. **Anesth Analg** 1996 Mar;82(3):670
Botulinum toxin for spasticity and athetosis in children with cerebral palsy. Gooch JL, et al. **Arch Phys Med Rehabil** 1996 May;77(5):508–11

ETIOLOGY

A case report of paroxysmal dystonic choreoathetosis due to hypoglycaemia induced by an insulinoma. Shaw C, et al. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):194–5
[Movement disorders and AIDS] Iranzo A, et al. **Neurologia** 1996 Feb;11(2):70–5 (Eng. Abstr.) **(Spa)**

GENETICS

Paroxysmal dystonic choreoathetosis: tight linkage to chromosome 2q. Fink JK, et al. **Am J Hum Genet** 1996 Jul;59(1):140–5
A gene for autosomal dominant paroxysmal choreoathetosis/spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome 1p, probably within 2 cM between D1S443 and D1S197. Auburger G, et al. **Genomics** 1996 Jan 1;31(1):90–4
Bilateral striatal necrosis with a novel point mutation in the mitochondrial ATPase 6 gene. De Meirleir L, et al. **Pediatr Neurol** 1995 Oct;13(3):242–6
[Choreoacanthocytosis. A neurologic–hematologic syndrome] Hiersemenzel LP, et al. **Nervenarzt** 1996 Jun; 67(6):490–5 (39 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Athetosis increases resting metabolic rate in adults with cerebral palsy. Johnson RK, et al. **J Am Diet Assoc** 1996 Feb;96(2):145–8

PATHOLOGY

Bilateral striatal necrosis with a novel point mutation in the mitochondrial ATPase 6 gene. De Meirleir L, et al. **Pediatr Neurol** 1995 Oct;13(3):242–6

PHYSIOPATHOLOGY

Athetosis–dystonia in intramedullary lesions of spinal cord. Madhusudanan M, et al. **Acta Neurol Scand** 1995 Oct; 92(4):308–12
Paroxysmal choreoathetosis. Marsden CD. **Adv Neurol** 1996; 70:467–70 (19 ref.)

RADIOGRAPHY

The cervical spine in athetoid cerebral palsy. A radiological study of 180 patients. Harada T, et al. **J Bone Joint Surg Br** 1996 Jul;78(4):613–9

REHABILITATION

A measurement system for the recognition of arm gestures using accelerometers. Harrington ME, et al. **Proc Inst Mech Eng [H]** 1995;209(2):129–34

ATHIORHODACEAE see **RHODOSPIRILLACEAE**

ATHLETE'S FOOT see **TINEA PEDIS**

ATHLETIC INJURIES

Sports injuries in young athletes. Bernhardt DT, et al. **Adv Pediatr** 1995;42:465–500 (77 ref.)
Gamekeeper's thumb: ulnar collateral ligament injury. Richard JR. **Am Fam Physician** 1996 Apr;53(5):1775–81 (12 ref.)
Simultaneous bilateral anterior cruciate ligament tears. Maywood RM, et al. **Am J Knee Surg** 1995 Fall;8(4):134–6
Peroneal nerve entrapment in athletes. Mitra A, et al. **Ann Plast Surg** 1995 Oct;35(4):366–8
Solitary kidney and sports participation. Anderson CR. **Arch Fam Med** 1995 Oct;4(10):885–8
Sports medicine training during pediatric residency [see comments] Stirling JM, et al. **Arch Pediatr Adolesc Med** 1996 Feb;150(2):211–5. Comment in: Arch Pediatr Adolesc Med 1996 Feb;150(2):133.
Hamstring injuries. Brukner P. **Aust Fam Physician** 1996 Jul; 25(7):1109–12
Periostitis of the upper extremity: a report of 2 cases and literature review. Meese MA, et al. **Clin Orthop** 1996 Mar; (324):222–6 (17 ref.)
Muscle–tendon injuries in young athletes. Best TM. **Clin Sports Med** 1995 Jul;14(3):669–86 (75 ref.)
Head and spine injuries in youth sports. Cantu RC. **Clin Sports Med** 1995 Jul;14(3):517–32 (31 ref.)
Back injuries in the young athlete. Gerbino PG 2nd, et al. **Clin Sports Med** 1995 Jul;14(3):571–90 (120 ref.)
Soft-tissue injuries of the wrist. Halikis MN, et al. **Clin Sports Med** 1996 Apr;15(2):235–59 (64 ref.)
Upper extremity injuries in young athletes. Ireland ML, et al. **Clin Sports Med** 1995 Jul;14(3):533–69 (101 ref.)
Shoulder instability in the overhand or throwing athlete. Kvitne RS, et al. **Clin Sports Med** 1995 Oct;14(4):917–35 (25 ref.)
Sports injuries in children and adolescents. Questions and controversies. Micheli LJ. **Clin Sports Med** 1995 Jul; 14(3):727–45 (43 ref.)
Injuries about the hip and pelvis in the young athlete. Paletta GA Jr, et al. **Clin Sports Med** 1995 Jul;14(3):591–628 (224 ref.)
Knee injuries in young athletes. Smith AD, et al. **Clin Sports Med** 1995 Jul;14(3):629–50 (76 ref.)
Lower leg, foot, and ankle injuries in young athletes. Stanish WD. **Clin Sports Med** 1995 Jul;14(3):651–68 (71 ref.)
Medical supervision of student athletes [letter] Fick D. **Iowa Med** 1995 Sep;85(9):362
The perils of bungee jumping. Shapiro MJ, et al. **J Emerg Med** 1995 Sep–Oct;13(5):629–31
Is sport good for us? A personal view on sporting injuries and how to manage them. McGregor JC. **J R Coll Surg Edinb** 1995 Dec;40(6):359–62 (20 ref.)
Lower leg overuse injuries in athletes. Järvinen M. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):126–30 (33 ref.)
Warning: games seriously damage health [editorial] **Lancet** 1996 Aug 3;348(9023):277
Paddler's palsy [letter] Rhodes CH, et al. **N Engl J Med** 1996 Jan 11;334(2):125
The best athletes are better [letter] Maffuli N. **Nature** 1996 Jul 25;382(6589):294
Science tracks down the training dangers [news] Surridge C. **Nature** 1996 Jul 4;382(6586):14–5
Common injuries in runners. Diagnosis, rehabilitation and prevention. Fredericson M. **Sports Med** 1996 Jan; 21(1):49–72 (137 ref.)
Aging, physical activity and sports injuries. An overview of common sports injuries in the elderly. Kallinen M, et al. **Sports Med** 1995 Jul;20(1):41–52 (76 ref.)
Former Packer physician lends perspective [editorial] Brusky E. **Wis Med J** 1996 Jun;95(6):332
Risk factors for anterior cruciate ligament injury. Goris JE, et al. **Wis Med J** 1996 Jun;95(6):367–9
Diagnosis and treatment of common knee injuries in athletes. Honari DB, et al. **Wis Med J** 1996 Jun;95(6):361–6 (20 ref.)
Pain medications and addiction [editorial] Miller M. **Wis Med J** 1996 Jun;95(6):332–3
Medical problems of adolescent female athletes. Timmerman MG. **Wis Med J** 1996 Jun;95(6):351–4
[Post-traumatic thrombosis of the portal vein] Beaufort P, et al. **Presse Med** 1996 Feb 17;25(6):247–8 (Eng. Abstr.) **(Fre)**
[Athletic injuries] König H. **Schweiz Rundsch Med Prax** 1995 Aug 29;84(35):928–32 (49 ref.) (Eng. Abstr.) **(Ger)**
[Limb injuries at the Aerodium hover sport facility in Eilat] Levy M, et al. **Harefuah** 1995 Dec 15;129(12):546–8, 616, 615 (Eng. Abstr.) **(Heb)**
[Injuries of the nasal bone in boxing] Lavorgna G, et al. **Minerva Chir** 1995 Oct;50(10):895–9 (Eng. Abstr.) **(Ita)**
[Acute myocardial infarction during sport] Fujiwara M, et al. **J Cardiol** 1995 Oct;26(4):213–7 (Eng. Abstr.) **(Jpn)**

BLOOD

The haematological, biochemical and immunological profile of athletes suffering from the overtraining syndrome. Rowbottom DG, et al. **Eur J Appl Physiol** 1995;70(6):502–9
Professional boxing, bleeding, and HIV testing [letter] Drotman DP. **JAMA** 1996 Jul 17;276(3):193

CLASSIFICATION

Injury patterns in recreational rock climbers. Rooks MD, et al. **Am J Sports Med** 1995 Nov–Dec;23(6):683–5

COMPLICATIONS

Traumatic rupture of hydatid cysts. Leviav S, et al. **Can J Surg** 1996 Aug;39(4):293–6
Pure hyperextension of the knee causing popliteal artery injury. Jones S, et al. **Injury** 1996 Jun;27(5):355–6
Left ventricular aneurysm as very slow complication of myocardial contusion in an athlete [letter] Ricci L, et al. **Int J Cardiol** 1995 Nov 10;52(1):89–91
Common hand warts in athletes: association with trauma to the hand. Roach MC, et al. **J Am Coll Health** 1995 Nov; 44(3):125–6
Axillary neuropathy in volleyball players: report of two cases and literature review. Paladini D, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):345–7 (14 ref.)
Water–ski douche injury in a premenarcheal female. Perlman SE, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):782–3
[Vaginal pressure trauma: a complication of jet–skis] Fauconnier A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):604–5 (Eng. Abstr.) **(Fre)**
[Progressive fragmentation of a bipartite patella: apropos of a case] Eberhard P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(1):78–80 (Eng. Abstr.) **(Fre)**
[False aneurysm of the posterior tibial artery complicating fracture of the tibia and fibula] Guiral J, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(6):546–8 (Eng. Abstr.) **(Fre)**
[Lesions of the growth plate caused by sports stress] Segesser B, et al. **Orthopade** 1995 Sep;24(5):446–56 (60 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

MR imaging of sports injuries in the adult elbow: a tailored approach. Sonin AH, et al. **AJR Am J Roentgenol** 1996 Aug;167(2):325–31
Vocal cord dysfunction masquerading as exercise–induced asthma. a physiologic cause for "choking" during athletic activities. McFadden ER Jr, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):942–7
Incomplete, intrasubstance strain injuries of the rectus femoris muscle. Hughes C 4th, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):500–6
The diagnosis of chronic groin pain in athletes: a review of 189 cases. Lovell G. **Aust J Sci Med Sport** 1995 Sep; 27(3):76–9
'Gilmore's groin'—or is it? Williams P, et al. **Br J Sports Med** 1995 Sep;29(3):206–8
Bilateral simultaneous rupture of the Achilles tendon. A rare traumatic injury. Habusta SF. **Clin Orthop** 1995 Nov; (320):231–4
Arthroscopy of the elbow. Baker CL, et al. **Clin Sports Med** 1996 Apr;15(2):261–81 (32 ref.)
The immature athlete. Common injuries and overuse syndromes of the elbow and wrist. Gill TJ 4th, et al. **Clin Sports Med** 1996 Apr;15(2):401–23 (49 ref.)
Bony injuries of the wrist, forearm, and elbow. Griggs SM, et al. **Clin Sports Med** 1996 Apr;15(2):373–400 (114 ref.)
Compressive neuropathies and tendinopathies in the athletic elbow and wrist. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):331–71 (142 ref.)
Medial and lateral epicondylitis in the athlete. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):283–305 (52 ref.)
The role of arthroscopy in athletic injuries of the wrist. Savoie FH 3rd, et al. **Clin Sports Med** 1996 Apr; 15(2):219–33 (12 ref.)
Unusual problems of the athlete's elbow, forearm, and wrist. Shaffer B, et al. **Clin Sports Med** 1996 Apr;15(2):425–38 (11 ref.)
The neuropsychiatric aspects of boxing. Mendez MF. **Int J Psychiatry Med** 1995;25(3):249–62 (74 ref.)
Differential diagnosis in physical therapy evaluation of thigh pain in an adolescent boy. Pellecchia GL, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):51–5
Sonographic findings in muscle strain injury: clinical and MR imaging correlation. Takebayashi S, et al. **J Ultrasound Med** 1995 Dec;14(12):899–905
The importance of arthroscopy in sports injuries in children and adolescents. Haus J, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(1):34–8
The difficult diagnosis of posterior tibialis tendon rupture in sports injuries. Marcus RE, et al. **Orthopedics** 1995 Aug; 18(8):715–21
Patellar tendinosis (jumper's knee): findings at histopathologic examination, US, and MR imaging. Victorian Institute of Sport Tendon Study Group. Khan KM, et al. **Radiology** 1996 Sep;200(3):821–7
The evaluation of pelvic injury in the female athlete. Short JW, et al. **Sports Med** 1995 Dec;20(6):422–8
[Shoulder problems in leisure athletes: physical examination, diagnosis and therapy. Sensible procedures in daily practice] Vaeckenstedt J, et al. **Schweiz Med Wochenschr** 1996 Mar 16;126(11):447–56 (21 ref.) (Eng. Abstr.) **(Ger)**
[Orthopedic examination of the foot: refresher course] Dvořák J, et al. **Sportverletz Sportschaden** 1995 Sep; 9(3):A19–29 **(Ger)**
[Stress fractures. Spondylolysis and spondylolisthesis of the lumbar vertebrae among young athletes with back pain] Halvorsen TM, et al. **Tidsskr Nor Laegeforen** 1996 Jun 30; 116(17):1999–2001 (Eng. Abstr.) **(Nor)**

DRUG THERAPY

[Treatment of muscular injuries with diclofenac–diethylammonium emulsion gel] Böhmer D, et al. **Sportverletz Sportschaden** 1995 Sep;9(3):94–5 **(Ger)**

EPIDEMIOLOGY

A case–control study of child bicycle injuries: relationship of risk to exposure. Carlin JB, et al. **Accid Anal Prev** 1995 Dec;27(6):839–44
Sports–related eye injuries. Ghosh F, et al. **Acta Ophthalmol Scand** 1995 Aug;73(4):353–4
A prospective study of ankle injury risk factors. Baumhauer JF, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):564–70
Sports injuries in the game of hurling. A one–year prospective study. Watson AW. **Am J Sports Med** 1996 May–Jun;24(3):323–8
Injuries and small–wheel skates. Orenstein JB. **Ann Emerg Med** 1996 Feb;27(2):204–9
Fair–play rules and injury reduction in ice hockey. Roberts WO, et al. **Arch Pediatr Adolesc Med** 1996 Feb;150(2):140–5
A comparison of the injuries sustained by female basketball and netball players. McKay GD, et al. **Aust J Sci Med Sport** 1996 Mar;28(1):12–7
An injury profile of elite ironman competitors. Pen LJ, et al. **Aust J Sci Med Sport** 1996 Mar;28(1):7–11
Acute injuries in soccer, ice hockey, volleyball, basketball, judo, and karate: analysis of national registry data [see comments] Kujala UM, et al. **BMJ** 1995 Dec 2; 311(7018):1465–8. Comment in: BMJ 1996 Mar 30;312(7034):844. Comment in: BMJ 1996 Mar 30;312(7034):844–5.
One hundred and ten sports related facial fractures. Carroll SM, et al. **Br J Sports Med** 1995 Sep;29(3):194–5

Value of wearing head protection gear while playing hurling. Crowley PJ, et al. **Br J Sports Med** 1995 Sep;29(3):191–3
Injuries on British climbing walls. Limb D. **Br J Sports Med** 1995 Sep;29(3):168–70
Volleyball injuries presenting in casualty: a prospective study. Solgård L, et al. **Br J Sports Med** 1995 Sep;29(3):200–4
Stress fractures: a review of 180 cases. Brukner P, et al. **Clin J Sport Med** 1996 Apr;6(2):85–9
Risk factors for ankle injury in college-aged athletes. Kumbhare DA. **Clin J Sport Med** 1996 Apr;6(2):136
Incidence and severity of injuries resulting from amateur boxing in Ireland. Porter M, et al. **Clin J Sport Med** 1996 Apr;6(2):97–101
The national jockey injury study: an analysis of injuries to professional horse-racing jockeys. Press JM, et al. **Clin J Sport Med** 1995 Oct;5(4):236–40
Athletic knee injuries. Similarities and differences between Asian and Western experience. Maffulli N, et al. **Clin Orthop** 1996 Feb;(323):98–105 (90 ref.)
Sport-related eye trauma: a survey of the presentation of eye injuries to a casualty clinic and the use of protective eye-wear. Pardhan S, et al. **Eye** 1995;9 (Pt 6 Su):50–3
Emergency medicine ... the most dangerous games -news- **Hosp Health Netw** 1996 Sep 5;70(17):10
Accidents with horses: what has changed in 20 years? Chitnavis JP, et al. **Injury** 1996 Mar;27(2):103–5
Severe snowboarding injuries. Prall JA, et al. **Injury** 1995 Oct;26(8):539–42
Maxillofacial fractures sustained during sports. Tanaka N, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):715–9; discussion 719–20
The incidence of musculoskeletal injuries in an amateur triathlete racing club. Wilk BR, et al. **J Orthop Sports Phys Ther** 1995 Sep;22(3):108–12
Tobogganing injuries in children. Kim PC, et al. **J Pediatr Surg** 1995 Aug;30(8):1135–7
Sports injuries in children and adolescents treated at a sports injury clinic. Watkins J, et al. **J Sports Med Phys Fitness** 1996 Mar;36(1):43–8
Do selected kinanthropometric and performance variables predict injuries in female netball players? Hopper DM, et al. **J Sports Sci** 1995 Jun;13(3):213–22
Spectrum of injuries from snowboarding. Chow TK, et al. **J Trauma** 1996 Aug;41(2):321–5
Horseback-riding-associated traumatic brain injuries—Oklahoma, 1992–1994. From the Centers for Disease Control and Prevention. **JAMA** 1996 Apr 10; 275(14):1072
Horseback-riding-associated traumatic brain injuries—Oklahoma, 1992–1994. **MMWR Morb Mortal Wkly Rep** 1996 Mar 15; 45(10):209–11
The seasonal incidence and nature of injuries in schoolboy cricketers. Stretch RA. **S Afr Med J** 1995 Nov; 85(11):1182–4
Former Packer doctor sees growing trend in injuries. Hoegemeier J. **Wis Med J** 1996 Jun;95(6):344–6
[Frequency and intensity of spinal syndromes in sailing. A comparative study at Bodensee and in the normal population] Buchhorn T, et al. **Sportverletz Sportschaden** 1996 Mar;10(1):22–4 **(Ger)**
[Are school sports too dangerous?] König DP, et al. **Sportverletz Sportschaden** 1995 Sep;9(3):92–3 **(Ger)**
[Snowboarding accidents 1991 to 1994—an analysis] Oberthaler G, et al. **Sportverletz Sportschaden** 1995 Dec; 9(4):118–22 (Eng. Abstr.) **(Ger)**
[Comparison of types of accidents in field and indoor soccer] Raschka C. **Sportverletz Sportschaden** 1995 Sep;9(3):101–2 **(Ger)**
[Injuries in horseback riding—incidence and causes] Rathfelder FJ, et al. **Sportverletz Sportschaden** 1995 Sep; 9(3):77–83 (Eng. Abstr.) **(Ger)**
[Stress fractures in childhood and adolescence] Schwendtner P, et al. **Sportverletz Sportschaden** 1996 Mar;10(1):19–21 (Eng. Abstr.) **(Ger)**
[Incidence of sports-related eye injuries] Pikkel J, et al. **Harefuah** 1995 Oct;129(7–8):249–50, 295, 294 (Eng. Abstr.) **(Heb)**

ETIOLOGY

Footwear: the hidden component in sporting injuries? A commentary. Tancred B. **Am J Phys Med Rehabil** 1996 Jan-Feb;75(1):66–7
Test-retest reliability of ankle injury risk factors. Baumhauer JF, et al. **Am J Sports Med** 1995 Sep-Oct;23(5):571–4
Pathogenesis of sports-related spondylolisthesis in adolescents. Radiographic and magnetic resonance imaging study. Ikata T, et al. **Am J Sports Med** 1996 Jan-Feb; 24(1):94–8
Rupture of the ischial origin of the hamstring muscles. Orava S, et al. **Am J Sports Med** 1995 Nov-Dec;23(6):702–5
Fair-play rules and injury reduction in ice hockey. Roberts WO, et al. **Arch Pediatr Adolesc Med** 1996 Feb;150(2):140–5.
The etiology of paddler's shoulder. Pelham TW, et al. **Aust J Sci Med Sport** 1995 Jun;27(2):43–7
Acute sports injuries. Way in which sports are played is important factor in injury [letter; comment] Nicholl J, et al. **BMJ** 1996 Mar 30;312(7034):844. Comment on: **BMJ** 1995 Dec 2;311(7018):1465–8.
Acute sports injuries. Data on leisure accidents and injuries should be collated centrally [letter; comment] O'Driscoll S, et al. **BMJ** 1996 Mar 30;312(7034):844–5. Comment on: **BMJ** 1995 Dec 2;311(7018):1465–8.
Traumatic carotid and vertebral artery dissection in a professional jockey: a cautionary tale. Fletcher J, et al. **Br J Sports Med** 1995 Jun;29(2):143–4
Causes of horse-related injuries in a rural western community. Thompson JM, et al. **Can Fam Physician** 1996 Jun;42:1103–9
Elbow injuries to the throwing athlete. Johnston J, et al. **Clin Sports Med** 1996 Apr;15(2):307–29 (33 ref.)
Sports-specific injuries. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):207–18 (16 ref.)
Bungee jumping causing a comminuted proximal femoral fracture. Omololu AB, et al. **Injury** 1995 Jul;26(6):413–4
Fracture through an osteochondroma. Prakash U, et al. **Injury** 1996 Jun;27(5):357–8
Facial fractures in Gaelic football and hurling. Carroll SM, et al. **Ir Med J** 1995 Sep-Oct;88(5):159–60
Eye injuries in women's lacrosse: strict rule enforcement and mandatory eyewear required. Livingston LA, et al. **J Trauma** 1996 Jan;40(1):144–5
Aortic transection secondary to rodeo injury. Tripp HF Jr, et al. **Mil Med** 1995 Aug;160(8):422–3
Injuries in windsurfing due to foot fixation. Witt J, et al. **Scand J Med Sci Sports** 1995 Oct;5(5):311–2
Injuries and bungee jumping. Vanderford L, et al. **Sports Med** 1995 Dec;20(6):369–74
[Traumatological risk in ambulatory cardiological rehabilitation] Unverdorben M, et al. **Med Klin** 1996 Mar 15;91(3):131–5 (Eng. Abstr.) **(Ger)**
[Risk of injuries, symptoms of excessive strain and preventive possibilities in cross-country skiing. A comparison between classical technique and skating technique] Frank BC. **Sportverletz Sportschaden** 1995 Dec;9(4):103–8 (Eng. Abstr.) **(Ger)**
[Muscular imbalances in high performance swimmers: damage to the locomotor system] Höltke V, et al. **Sportverletz Sportschaden** 1995 Sep;9(3):96–8 **(Ger)**
[Etiological accident types and recommendations for prevention in basketball] Raschka C, et al. **Sportverletz Sportschaden** 1995 Sep;9(3):84–91 (Eng. Abstr.) **(Ger)**
[Tennis shoulder] Schippinger G, et al. **Sportverletz Sportschaden** 1995 Dec;9(4):125–8 **(Ger)**
[Backward fall in Alpine skiing. Case study of the effect of the back spoiler of the ski shoe on muscle activity and kinematics] Senner V, et al. **Sportverletz Sportschaden** 1995 Dec;9(4):109–17 (Eng. Abstr.) **(Ger)**
[Shoulder injuries in sports (interview by Christiane Wesloh)] Thomas W. **Sportverletz Sportschaden** 1996 Mar; 10(1):V–VI **(Ger)**

IMMUNOLOGY

The haematological, biochemical and immunological profile of athletes suffering from the overtraining syndrome. Rowbottom DG, et al. **Eur J Appl Physiol** 1995;70(6):502–9

MORTALITY

Cyclist road deaths in London 1985–1992: drivers, vehicles, manoeuvres and injuries. McCarthy M, et al. **Accid Anal Prev** 1996 Mar;28(2):275–9
The epidemiology of leisure accidents in Scotland. Campbell H, et al. **Health Bull (Edinb)** 1995 Sep;53(5):280–93
Firearm fatalities and injuries from hunting accidents in Germany. Karger B, et al. **Int J Legal Med** 1996; 108(5):252–5

NURSING

The diagnosis and management of plantar fasciitis. Quaschnick MS. **Nurse Pract** 1996 Apr;21(4):50–4, 60–3, quiz 64–5 (33 ref.)

PATHOLOGY

An explanation for various rectus femoris strain injuries using previously undescribed muscle architecture. Hasselman CT, et al. **Am J Sports Med** 1995 Jul-Aug;23(4):493–9
Patellar tendinitis: MR imaging features, with suggested pathogenesis and proposed classification. McLoughlin RF, et al. **Radiology** 1995 Dec;197(3):843–8

PHYSIOPATHOLOGY

Upper limb nerve entrapments in elite wheelchair racers. Boninger ML, et al. **Am J Phys Med Rehabil** 1996 May-Jun;75(3):170–6
Characteristics of the leg extensors in male volleyball players with jumper's knee. Lian O, et al. **Am J Sports Med** 1996 May-Jun;24(3):380–5
Anterior knee pain. Brukner P. **Aust Fam Physician** 1996 Jun;25(6):908–11; 914
Overuse injuries in the young athlete. Outerbridge AR, et al. **Clin Sports Med** 1995 Jul;14(3):503–16 (38 ref.)
Sports medicine aspects of cervical spinal stenosis. Cantu RC. **Exerc Sport Sci Rev** 1995;23:399–409
Thrower's fracture: a comparison of two presentations of a rare fracture. Evans PA, et al. **J Accid Emerg Med** 1995 Sep;12(3):222–4
A new load application system for in vitro study of ligamentous injuries to the human knee joint. Bach JM, et al. **J Biomech Eng** 1995 Nov;117(4):373–82
[Stress fractures in athletes and military recruits. An overview] Orava S, et al. **Orthopade** 1995 Sep;24(5):457–66 (51 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Bicycle accidents and drivers' visual search at left and right turns. Summala H, et al. **Accid Anal Prev** 1996 Mar; 28(2):147–53
In-line skating: play it safe [editorial] Hensinger RN. **Am Fam Physician** 1996 Jun;53(8):2430
The role of limited echocardiography in screening athletes. Murry PM, et al. **Am J Cardiol** 1995 Oct 15;76(11):849–50
Sport stretching: effect on passive muscle stiffness of short hamstrings. Halbertsma JP, et al. **Arch Phys Med Rehabil** 1996 Jul;77(7):688–92
Mouthguard protection in sports injury. Author's reply [letter; comment] Dorney B. **Aust Dent J** 1996 Feb;41(1):63 . Comment on: Aust Dent J 1995 Dec;40(6):399.
Mouthguard protection in sports injuries [letter; comment] [see comments] Hook PC. **Aust Dent J** 1995 Dec;40(6):399 . Comment on: Aust Dent J 1994 Dec;39(6):372. Comment in: Aust Dent J 1996 Feb;41(1):63.
Leuko and Nessa Ankle braces: effectiveness before and after exercise. Tweedy R, et al. **Aust J Sci Med Sport** 1994 Sep-Dec;26(3-4):62–6
Preventing sports and leisure injuries [editorial] Campbell H, et al. **BMJ** 1996 Jul 27;313(7051):182–3
Evaluation of a thermoplastic splint to protect the proximal interphalangeal joints of volleyball players. Benaglia PG, et al. **J Hand Ther** 1996 Jan-Mar;9(1):52–6
Prophylactic ankle bracing vs. taping: effects on functional performance in female basketball players. MacKean LC, et al. **J Orthop Sports Phys Ther** 1995 Aug;22(2):77–81
Rollerblading injuries in young people. Heller DR, et al. **J Paediatr Child Health** 1996 Feb;32(1):35–8
Prevention of injuries in long-distance runners. Jakobsen BW, et al. **Knee Surg Sports Traumatol Arthrosc** 1994; 2(4):245–9
On the barbaric nature of boxing: thoughts following the panorama debate on banning boxing after yet another death. Moutoussis M. **Med Confl Surviv** 1996 Jan-Mar; 12(1):62–3
Preventing sports injury remains a challenge [editorial; comment] Larkins PA. **Med J Aust** 1995 Sep 4;163(5):230–1 . Comment on: Med J Aust 1995 Sep 4;163(5):242–4.
Marathon day. A view from the medical tent. Crouse BJ. **Minn Med** 1996 Jul;79(7):10–1
Safe hunting. Mills H. **Minn Med** 1995 Sep;78(9):25–8
Team spirit. Moriarity JM. **Minn Med** 1996 Jul;79(7):12–8
Sudden death during sports activities [letter; comment] Sinclair JB. **N Engl J Med** 1995 Dec 28;333(26):1785. Comment on: N Engl J Med 1995 Aug 10;333(6):380–1.
The first line of defense. Glassman M. **N Y State Dent J** 1995 Aug-Sep;61(7):48–50
Increasing bicycle helmet use among school-age children [letter] McEvoy M. **Nurse Pract** 1996 Apr;21(4):14–6, 150
Protective eye wear for young athletes. A joint statement of the American Academy of Pediatrics and the American Academy of Ophthalmology. **Ophthalmology** 1996 Aug; 103(8):1325–8
Protective eyewear for young athletes. American Academy of Pediatrics Committee on Sports Medicine and Fitness and American Academy of Ophthalmology Committee on Eye Safety and Sports Ophthalmology [see comments] **Pediatrics** 1996 Aug;98(2 Pt 1):311–3. Comment in: Pediatrics 1996 Aug;98(2 Pt 1):314.
The primary care physician as a sports medicine and exercise advocate and activist. Rouzier PA. **Prim Care** 1995 Dec; 22(4):785–804 (43 ref.)
Use of mouthguards and headgear in organized sports by school-aged children. Nowjack-Raymer RE, et al. **Public Health Rep** 1996 Jan-Feb;111(1):82–6
Inadequate pre-season preparation of schoolboy rugby players—a survey of players at 25 Cape Province high schools. Upton PA, et al. **S Afr Med J** 1996 May; 86(5):531–3
Use of knee braces in sport. Current recommendations [editorial] Albright JP, et al. **Sports Med** 1995 Nov; 20(5):281–301 (49 ref.)
[Proper adjustment of ski bindings] **Sportverletz Sportschaden** 1995 Dec;9(4):VI–VIII **(Ger)**
[Safety in skiing (interview by Dr. H.-P. Scharf)] Hauser W. **Sportverletz Sportschaden** 1995 Dec;9(4):V–VI **(Ger)**
[Craniocerebral trauma in fall from bicycles—what is the effect of a protective helmet?] Kelsch G, et al. **Unfallchirurg** 1996 Mar;99(3):202–6 (Eng. Abstr.) **(Ger)**
[Is there an "ideal" athletic shoe? (interview by Rita Engelhardt)] Segesser B. **Z Orthop Ihre Grenzgeb** 1996 Mar-Apr;134(2):Oa16–7 **(Ger)**
[Athletic shoes—wish and reality. Orthopedic considerations of athletic shoe construction and athletic shoe purchase] Segesser B. **Z Orthop Ihre Grenzgeb** 1996 Mar-Apr; 134(2):Oa7–14 **(Ger)**
[Sweating is important to endure the heat and air humidity] Nystrand A. **Lakartidningen** 1996 Jul 10;93(28–29):2577–82 **(Swe)**
[Snow-boarding injuries can be prevented] Björnstig J, et al. **Nord Med** 1996 Jan;111(1):7–9 (Eng. Abstr.) **(Swe)**

PSYCHOLOGY

Attributions for recovery and adherence to sport injury rehabilitation. Laubach WJ, et al. **Aust J Sci Med Sport** 1996 Mar;28(1):30–4

Situational correlates of emotional adjustment to athletic injury. Brewer BW, et al. **Clin J Sport Med** 1995 Oct; 5(4):241–5

Ability of middle-school soccer players to localize overuse leg pain correctly using a graphic self-report form. Gomez JE, et al. **Percept Mot Skills** 1996 Feb;82(1):335–8

Stress, coping, and injuries in male and female high school basketball players. Rider SP, et al. **Percept Mot Skills** 1995 Oct;81(2):499–503

[Lessons learned from the Råneälv accident. Role distribution important during crisis intervention] Johansson B. **Lakartidningen** 1995 Oct 25;92(43):3995–7 **(Swe)**

RADIOGRAPHY

Vertical fracture of the odontoid process: case report. Kokkino AJ, et al. **Neurosurgery** 1996 Jan;38(1):200–2; discussion 202–3

REHABILITATION

Effects of an accelerated rehabilitation program after anterior cruciate ligament reconstruction with combined semitendinosus–gracilis autograft and a ligament augmentation device. MacDonald PB, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):588–92

Achilles tendon ruptures. A new method of repair, early range of motion, and functional rehabilitation. Mandelbaum BR, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):392–5

Attributions for recovery and adherence to sport injury rehabilitation. Laubach WJ, et al. **Aust J Sci Med Sport** 1996 Mar;28(1):30–4

Early motion after repair of Achilles tendon ruptures. Troop RL, et al. **Foot Ankle Int** 1995 Nov;16(11):705–9

Silicone rubber splinting for athletic hand and wrist injuries. Canelón MF. **J Hand Ther** 1995 Oct–Dec;8(4):252–7 (43 ref.)

Video views [letter] Merrick C. **J Orthop Sports Phys Ther** 1995 Jul;22(1):39–40

Anterior cruciate ligament injuries in young athletes. Recommendations for treatment and rehabilitation. McCarroll JR, et al. **Sports Med** 1995 Aug;20(2):117–27 (32 ref.)

Rehabilitation following arthroscopic meniscectomy. St-Pierre DM. **Sports Med** 1995 Nov;20(5):338–47 (147 ref.)

Hometown sports medicine: teamwork in action. Kuester DJ. **Wis Med J** 1996 Jun;95(6):335–9

SURGERY

Achilles tendon ruptures. A new method of repair, early range of motion, and functional rehabilitation. Mandelbaum BR, et al. **Am J Sports Med** 1995 Jul–Aug;23(4):392–5

Results of arthroscopic debridement of glenoid labral tears. Martin DR, et al. **Am J Sports Med** 1995 Jul–Aug; 23(4):447–51

Treatment of thumb ulnar collateral ligament ruptures with the Mitek bone anchor. Kozin SH. **Ann Plast Surg** 1995 Jul;35(1):1–5

Surgical treatment of dislocations of the acromioclavicular joint in the athlete [letter] Combalia-Aleu A. **Br J Sports Med** 1995 Sep;29(3):210

Surgical repair of traumatic medial disruption of the elbow in competitive athletes. Inoue G, et al. **Br J Sports Med** 1995 Jun;29(2):139–42

Surgical treatment of ruptures of the Achilles tendon: a review of long-term results. Krueger-Franke M, et al. **Br J Sports Med** 1995 Jun;29(2):121–5

Early motion after repair of Achilles tendon ruptures. Troop RL, et al. **Foot Ankle Int** 1995 Nov;16(11):705–9

Surgical treatment of pubic pain refractory to conservative treatment. Moyen B, et al. **Ital J Orthop Traumatol** 1993; 19(1):43–9

Long-term survival of chondrocytes in an osteochondral articular cartilage allograft. A case report. Convery FR, et al. **J Bone Joint Surg Am** 1996 Jul;78(7):1082–8

Partial excision of the clavicle for nonunion in National Hunt Jockeys. Middleton SB, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):778–80

A severe acute Achilles rupture and repair. Kuwada GT. **J Foot Ankle Surg** 1995 May–Jun;34(3):262–5

Extrusion of fracture fragment into flexor sheath following proximal interphalangeal joint fracture-dislocation: a case report. Failla JM. **J Hand Surg [Am]** 1996 Mar;21(2):253–5

Complete disruption of the main pancreatic duct: a case successfully managed by percutaneous drainage. Ohno Y, et al. **J Pediatr Surg** 1995 Dec;30(12):1741–2

Avulsion of the anterior superior iliac spine in two adolescent sisters: operative versus conservative treatment. Cimerman M, et al. **Unfallchirurg** 1995 Oct;98(10):530–1

[Critical considerations in arthroscopic stabilization of the unstable shoulder joint] Jerosch J. **Sportverletz Sportschaden** 1996 Mar;10(1):1–12 (93 ref.) (Eng. Abstr.) **(Ger)**

[Tendon injuries/diseases of the shoulder joint] Resch H. **Sportverletz Sportschaden** 1996 Mar;10(1):A1–10 (0 ref.) **(Ger)**

[Differential indications for so-called "lateral release" in treatment of chondropathia patellae] Schultz W, et al. **Sportverletz Sportschaden** 1996 Mar;10(1):13–8 (Eng. Abstr.) **(Ger)**

[Acute isolated ventral dislocation of the head of the fibula] Kohler G, et al. **Unfallchirurg** 1996 Mar;99(3):221–2 (10 ref.) (Eng. Abstr.) **(Ger)**

[Injuries of the medial collateral ligament and anterior cruciate ligament of the knee joint and Lemaire surgical functional treatment. Long-term outcome] Schmid F. **Unfallchirurgie** 1996 Jun;22(3):124–9 (Eng. Abstr.) **(Ger)**

THERAPY

Treatment of osteitis pubis in athletes. Results of corticosteroid injections. Holt MA, et al. **Am J Sports Med** 1995 Sep–Oct;23(5):601–6

The conservative treatment of complete tears of the anterior cruciate ligament in skeletally immature patients [see comments] Mizuta H, et al. **J Bone Joint Surg Br** 1995 Nov;77(6):890–4. Comment in: J Bone Joint Surg Br 1996 Jul;78(4):680–1. Comment in: J Bone Joint Surg Br 1996 Jul;78(4):681.

Conservative treatment of isolated injuries to the posterior cruciate ligament in athletes. Shino K, et al. **J Bone Joint Surg Br** 1995 Nov;77(6):895–900

Material properties: a factor in the selection and application of splinting materials for athletic wrist and hand injuries. Canelón MF. **J Orthop Sports Phys Ther** 1995 Oct; 22(4):164–72

Bilateral inferior glenohumeral dislocations. Gelczer RK, et al. **J Trauma** 1996 May;40(5):825–6

Management of back pain in athletes. Dreisinger TE, et al. **Sports Med** 1996 Apr;21(4):313–20 (32 ref.)

Anterior cruciate ligament injuries in young athletes. Recommendations for treatment and rehabilitation. McCarroll JR, et al. **Sports Med** 1995 Aug;20(2):117–27 (32 ref.)

Going to bat for sports medicine in Wisconsin. Bialek F, et al. **Wis Med J** 1996 Jun;95(6):347–9

Establishing a high-school-based training room clinic. Niedfeldt MW, et al. **Wis Med J** 1996 Jun;95(6):356–60

ULTRASONOGRAPHY

Sonographic findings in muscle strain injury: clinical and MR imaging correlation. Takebayashi S, et al. **J Ultrasound Med** 1995 Dec;14(12):899–905

Ultrasound for diagnosis of apophyseal injuries. Lazović D, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;3(4):234–7

ATHLETICS see **SPORTS**

ATHYMIC MICE see **MICE, NUDE**

ATHYMIC RATS see **RATS, NUDE**

ATLANTO-AXIAL JOINT

Atlantoaxial rotatory instability secondary to odontoid hypoplasia as a cause of acute torticollis in children: report of one case. Lin CJ, et al. **Acta Paediatr Sin** 1995 Nov–Dec; 36(6):448–51

Atlanto-axial subluxation and cervical osteomyelitis: two unusual complications of adenoidectomy. Baker LL, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):295–9 (12 ref.)

A stiff collar for the treatment of rheumatoid atlantoaxial subluxation. Kauppi M, et al. **Br J Rheumatol** 1996 Aug; 35(8):771–4

Rapidly progressive seronegative spondylarthropathy with atlantodental subluxation in a patient with moderately advanced HIV infection. Schewe CK, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):83–5

Tuberculosis of the craniocervical junction: two case reports. Valaskatzis E, et al. **Eur Spine J** 1996;5(2):140–2

Atlanto-axial subluxation (Grisel's syndrome) following otolaryngological diseases and procedures. Samuel D, et al. **J Laryngol Otol** 1995 Oct;109(10):1005–9

Upper cervical instability: fact or fiction? Swinkels RA, et al. **J Manipulative Physiol Ther** 1996 Mar–Apr;19(3):185–94 (93 ref.)

Pathogenetic mechanism and prevalence of the stable atlantoaxial subluxation in rheumatoid arthritis. Kauppi M, et al. **J Rheumatol** 1996 May;23(5):831–4

[Progress in the study on occipitocervical biomechanics] Lu Y, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Mar; 33(3):158–60 (23 ref.) **(Chi)**

[Atlanto-axial osteoarthritis (letter)] Desbonnets A, et al. **Rev Med Interne** 1996;17(3):267–9 **(Fre)**

ABNORMALITIES

Craniovertebral junction anomalies in inherited disorders: part of the syndrome or caused by the disorder? Crockard HA, et al. **Eur J Pediatr** 1995 Jul;154(7):504–12 (48 ref.)

ANATOMY & HISTOLOGY

Difficult intubation: thyromental distance and the atlanto-occipital gap. Frerk CM, et al. **Anaesthesia** 1996 Aug;51(8):738–40

INJURIES

Atlanto-axial instability of a hypoplastic upper cervical spine. Case report. Kehler U, et al. **Acta Neurochir (Wien)** 1995; 136(1–2):106–8

Atlanto-axial rotatory fixation: improved demonstration using spiral CT. Cowan IA, et al. **Australas Radiol** 1996 May;40(2):119–24

Atlantoaxial instability in a 7-year-old boy associated with traumatic disrupture of the ossiculum terminale (apical odontoid epiphysis). Swoboda B, et al. **Eur Spine J** 1995; 4(4):248–51

Multifocal skeletal tuberculosis presenting as osteitis skull and atlantoaxial dislocation. Rajeshwari K, et al. **Indian Pediatr** 1995 Nov;32(11):1214–9

Open reduction of traumatic atlanto-axial rotatory dislocation with use of the extreme lateral approach. A report of two cases. Crockard HA, et al. **J Bone Joint Surg Am** 1996 Mar;78(3):431–6

A lethal case of atlantoaxial dislocation in a 56-year-old woman with Down's syndrome. Saad KF. **J Intellect Disabil Res** 1995 Oct;39 (Pt 5):447–9

Longitudinal atlantoaxial dislocation with type III odontoid fracture. Case report and review of the literature. Przybylski GJ, et al. **J Neurosurg** 1996 Apr;84(4):666–70

Patients with type IV Ehlers-Danlos syndrome may be predisposed to atlantoaxial subluxation. Halko GJ, et al. **J Rheumatol** 1995 Nov;22(11):2152–5

Frequency of atlantoaxial subluxation and neurologic involvement in patients with ankylosing spondylitis. Ramos-Remus C, et al. **J Rheumatol** 1995 Nov; 22(11):2120–5

C1–C2 fracture-dislocations in children and adolescents. Lui TN, et al. **J Trauma** 1996 Mar;40(3):408–11

Traumatic atlantoaxial rotatory subluxation and dislocation. Moore KR, et al. **Spine** 1995 Sep 1;20(17):1928–30 (10 ref.)

[Post-traumatic os odontoideum] Schwarz N, et al. **Unfallchirurg** 1995 Sep;98(9):483–6 (Eng. Abstr.) **(Ger)**

[Fixed atlanto-axial rotational dislocation—a rare cause of torticollis in the child] Schwarz N. **Unfallchirurg** 1995 Oct; 98(10):532–4 (Eng. Abstr.) **(Ger)**

[Wallenberg's syndrome following minor neck trauma: a case associated with atlanto-axial subluxation, an anomaly of the axis, and platelet activation] Arai M. **Rinsho Shinkeigaku** 1995 Jun;35(6):670–2 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Craniocervical junction as a focus for craniofacial growth studies. Huggare J. **Acta Odontol Scand** 1995 Jun; 53(3):186–91 (36 ref.)

Radiographic appearance of the odontoid lateral mass interspace in the occipitoatlantoaxial complex. Sutherland JP Jr, et al. **Spine** 1995 Oct 15;20(20):2221–5

PHYSIOPATHOLOGY

Imaging of childhood torticollis due to atlanto-axial rotatory fixation. Maheshwaran S, et al. **Childs Nerv Syst** 1995 Dec; 11(12):667–71

RADIOGRAPHY

Atlantoodontoid osteoarthritis: comparison of lateral cervical projection and CT. Zapletal J, et al. **Eur Spine J** 1995; 4(4):238–41

Association of transverse ligament calcification with anterior atlanto-odontoid osteoarthritis: CT findings. Zapletal J, et al. **Neuroradiology** 1995 Nov;37(8):667–9

Relationship between atlanto-odontoid osteoarthritis and idiopathic suboccipital neck pain. Zapletal J, et al. **Neuroradiology** 1996 Jan;38(1):62–5

Preoperative evaluation of the cervical spine in children with trisomy-21: results of a questionnaire study. Litman RS, et al. **Paediatr Anaesth** 1995;5(6):355–61

C1–2 arthrography. Chevrot A, et al. **Skeletal Radiol** 1995 Aug;24(6):425–9

SURGERY

Osteoarthrosis of the atlanto-axial joints. Long-term follow-up after treatment with arthrodesis. Ghanayem AJ, et al. **J Bone Joint Surg Am** 1996 Sep;78(9):1300–7

Occipito-atlanto-axial fusion in Morquio-Brailsford syndrome. A ten-year experience. Ransford AO, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):307–13

Posterior occipitoaxial fusion for atlantoaxial dislocation associated with occipitalized atlas. Jain VK, et al. **J Neurosurg** 1996 Apr;84(4):559–64

Occipitocervical fusion by Luque loop rod instrumentation in Down syndrome. Higo M, et al. **J Pediatr Orthop** 1995 Jul–Aug;15(4):539–42 (17 ref.)

Posterior spinal arthrodesis for atlantoaxial instability in Down syndrome. Rizzolo S, et al. **J Pediatr Orthop** 1995 Jul–Aug;15(4):543–8

Dorsal cross pinning of the atlantoaxial joint: new surgical technique for atlantoaxial subluxation. Jeffery ND. **J Small Anim Pract** 1996 Jan;37(1):26–9

Instrumentational posterior fusion for atlanto-axial subluxation in a young child with Down's syndrome—case report. Kohno M, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):753–8 (22 ref.)

Atlantoaxial arthrodesis using Halifax interlaminar clamps reinforced by halo vest immobilization: a long-term follow-up experience. Huang CI, et al. **Neurosurgery** 1996 Jun;38(6):1153–6; discussion 1156–7

C1–C2 fusion in children with atlantoaxial instability and spinal cord compression: technical note. Levy ML, et al. **Neurosurgery** 1996 Jan;38(1):211–5; discussion 215–6

Modification of technique and results of atlantoaxial transfacet stabilization. McGuire RA Jr, et al. **Orthopedics** 1995 Oct;18(10):1029–32

ATLANTO-OCCIPITAL JOINT

Atlanto-occipital subluxation in rheumatoid arthritis demonstrated by magnetic resonance imaging. Romanowski CA, et al. **Br J Rheumatol** 1995 Aug; 34(8):787-9

Pott's disease of the cervico-occipital junction in an AIDS patient. Ventura G, et al. **Tuber Lung Dis** 1996 Apr; 77(2):188-90

[Progress in the study on occipitocervical biomechanics] Lu Y, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Mar; 33(3):158-60 (23 ref.) **(Chi)**

[Disorders of the cranio-spinal junction] Zukiel R, et al. **Chir Narzadow Ruchu Ortop Pol** 1995;60(5):345-51 (Eng. Abstr.) **(Pol)**

ANATOMY & HISTOLOGY

Difficult intubation: thyromental distance and the atlanto-occipital gap. Frerk CM, et al. **Anaesthesia** 1996 Aug;51(8):738-40

Anatomic relation between the rectus capitis posterior minor muscle and the dura mater. Hack GD, et al. **Spine** 1995 Dec 1;20(23):2484-6

[Anatomical study of the ligaments in the occipito-atlantoaxial complex] Okazaki K. **Nippon Seikeigeka Gakkai Zasshi** 1995 Dec;69(12):1259-67 (Eng. Abstr.) **(Jpn)**

INJURIES

Traumatic atlanto-occipital dislocation: a potentially survivable injury. Ferrera PC, et al. **Am J Emerg Med** 1996 May;14(3):291-6

Traumatic atlantooccipital dislocation with survival: case report and review of the literature. Guigui P, et al. **Eur Spine J** 1995;4(4):242-7 (36 ref.)

Associated injuries and mechanism of atlanto-occipital dislocation caused by trauma. Imaizumi T, et al. **Neurol Med Chir (Tokyo)** 1995 Jun;35(6):385-91

[Traumatic atlanto-occipital dislocation: a case report with survival] Shirakawa K, et al. **No Shinkei Geka** 1996 May; 24(5):451-4 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Craniocervical junction as a focus for craniofacial growth studies. Huggare J. **Acta Odontol Scand** 1995 Jun; 53(3):186-91 (36 ref.)

Radiographic appearance of the odontoid lateral mass interspace in the occipitoatlantoaxial complex. Sutherland JP Jr, et al. **Spine** 1995 Oct 15;20(20):2221-5

PHYSIOPATHOLOGY

Traumatic atlanto-occipital dislocation with long-term survival. Yamaguchi N, et al. **Neurol Med Chir (Tokyo)** 1996 Jan;36(1):36-9

Atlanto-occipital hypermobility in subjects with Down's syndrome. Matsuda Y, et al. **Spine** 1995 Nov 1; 20(21):2283-6

SURGERY

Occipito-atlanto-axial fusion in Morquio-Brailsford syndrome. A ten-year experience. Ransford AO, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):307-13

Posterior occipitoaxial fusion for atlantoaxial dislocation associated with occipitalized atlas. Jain VK, et al. **J Neurosurg** 1996 Apr;84(4):559-64

The transcondylar approach to extradural nonneoplastic lesions of the craniovertebral junction. al-Mefty O, et al. **J Neurosurg** 1996 Jan;84(1):1-6

ATLAS

Publications. Health care atlas reveals inequities [news] **Hosp Health Netw** 1996 Mar 5;70(5):11

Health care's big picture. Davidson D. **Hosp Health Netw** 1996 Mar 20;70(6):23

ABNORMALITIES

Absence of foramen transversarium in the human atlas vertebra: a case report. Vasudeva N, et al. **Acta Anat (Basel)** 1995;152(3):230-3

Recurrent transient quadriparesis after minor cervical trauma associated with bilateral partial agenesis of the posterior arch of the atlas. Case report. Torreman M, et al. **J Neurosurg** 1996 Apr;84(4):663-5

[Operative treatment for cervical vertigo caused by foramen arcuale] Li S, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Mar;33(3):137-9 (Eng. Abstr.) **(Chi)**

ANATOMY & HISTOLOGY

Associations between atlantoaxial and craniomandibular anatomy. Huggare J, et al. **Growth Dev Aging** 1996 Spring; 60(1):21-30

INJURIES

C1-C2 posterior cervical fusion: long-term evaluation of results and efficacy. Coyne TJ, et al. **Neurosurgery** 1995 Oct;37(4):688-92; discussion 692-3

Injuries involving the transverse atlantal ligament: classification and treatment guidelines based upon experience with 39 injuries. Dickman CA, et al. **Neurosurgery** 1996 Jan;38(1):44-50

[Rare fracture of the atlas after hyperextension trauma] Theobald I, et al. **Radiologe** 1996 Mar;36(3):263-4 (Ger)

[Pseudarthrosis of the atlas after Jefferson's fracture] Wichmann HU, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):452-3 (11 ref.) **(Ger)**

PATHOLOGY

Cervical myelopathy caused by pseudoarthrosis between the atlas and axis associated with diffuse idiopathic skeletal hyperostosis. Goto S, et al. **Spine** 1995 Dec 1;20(23):2572-5

PHYSIOLOGY

Craniocervical junction as a focus for craniofacial growth studies. Huggare J. **Acta Odontol Scand** 1995 Jun; 53(3):186-91 (36 ref.)

RADIOGRAPHY

Calcification of the transverse ligament of the atlas in chondrocalcinosis: computed tomography study. Constantin A, et al. **Ann Rheum Dis** 1996 Feb;55(2):137-9

Association of transverse ligament calcification with anterior atlanto-odontoid osteoarthritis: CT findings. Zapletal J, et al. **Neuroradiology** 1995 Nov;37(8):667-9

[Pseudarthrosis of the atlas after Jefferson's fracture] Wichmann HU, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):452-3 (11 ref.) **(Ger)**

ATLASES

Mirror, mirror ... on the wall, who are the healthiest Americans of all? Hudson T. **Hosp Health Netw** 1996 Apr 5;70(7):24-6, 28, 30

ATLOIDO-OCCIPITAL JOINT see **ATLANTO-OCCIPITAL JOINT**

ATLV see **HTLV-I**

ATLV ANTIBODIES see **HTLV-I ANTIBODIES**

ATLV ANTIGENS see **HTLV-I ANTIGENS**

ATLV-ASSOCIATED LEUKEMIA-LYMPHOMA see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

ATMOSPHERE

Are chlorine-free compounds a solution for health problems caused by ozone-depleting substances? Valić F, et al. **Acta Med Croatica** 1996;50(2):61-3

Ozone depletion update. Coldiron BM. **Dermatol Surg** 1996 Mar;22(3):296-9 (11 ref.)

ENSO and disaster: droughts, floods and El Niño/Southern Oscillation warm events. Dilley M, et al. **Disasters** 1995 Sep;19(3):181-93

The association between El Niño/Southern Oscillation events and typhoons in the Marshall Islands. Spennemann DH, et al. **Disasters** 1995 Sep;19(3):194-7

Contraband in the stratosphere. Chase V. **Environ Health Perspect** 1995 Dec;103(12):1102-4

Significant correlations between certain spectra of atmospherics and daily periodic activities of Mongolian gerbils (Meriones unguiculatus L.). Lintzen T, et al. **Int J Biometeorol** 1995 Aug;39(1):13-6

Revised Galileo data leave Jupiter mysteriously dry [news; comment] Kerr RA. **Science** 1996 May 10;272(5263):814-5 . Comment on: Science 1996 May 10;272(5263):846-9.

The Galileo probe mass spectrometer: composition of Jupiter's atmosphere [see comments] Niemann HB, et al. **Science** 1996 May 10;272(5263):846-9. Comment in: Science 1996 May 10;272(5263):814-5.

Results of the Galileo probe nephelometer experiment. Ragent B, et al. **Science** 1996 May 10;272(5263):854-6

Solar and thermal radiation in Jupiter's atmosphere: initial results of the Galileo probe net flux radiometer. Sromovsky LA, et al. **Science** 1996 May 10;272(5263):851-4

The helium mass fraction in Jupiter's atmosphere. von Zahn U, et al. **Science** 1996 May 10;272(5263):849-51

Galileo probe: in situ observations of Jupiter's atmosphere. Young RE, et al. **Science** 1996 May 10;272(5263):837-8

[Decreased oxygen content in the atmosphere--an ecological disaster imperceptibly sneaking up?] Moiseeva NI. **Aviakosm Ekolog Med** 1995;29(3):52-5 (Eng. Abstr.) **(Rus)**

ATMOSPHERE EXPOSURE CHAMBERS

A laboratory method for generation of replicate filter samples of asbestos fibers in air. Skogstad A, et al. **Am Ind Hyg Assoc J** 1996 Aug;57(8):741-5

Vestibulo-ocular reflex gain as a measure of vestibular function in guinea pigs while in a recompression chamber: apparatus design and effects of nitrogen narcosis. Stevens DM, et al. **Am J Otol** 1995 May;16(3):360-4

A portable inhalation system for personal exposure to ozone. Asplund PT, et al. **Arch Environ Health** 1996 Mar-Apr; 51(2):138-45

Effect of accumulation of CO2 on the survival of immature pigs in a confined atmosphere. A: Gas exchange. Arieli R, et al. **J Basic Clin Physiol Pharmacol** 1995;6(1):1-18

Effect of accumulation of CO2 on the survival of immature pigs in a confined atmosphere. B: Blood gas exchange. Arieli R, et al. **J Basic Clin Physiol Pharmacol** 1995; 6(1):19-37

[The concentration of methane and trace organic admixtures in the air expired by submariners during a dive simulation in a hyperbaric chamber] Genin AM, et al. **Aviakosm Ekolog Med** 1995;29(2):21-4 (Eng. Abstr.) **(Rus)**

[Hypobaric hypoxia in the treatment of chronic anemia] Novikov VS, et al. **Voen Med Zh** 1995 Nov;(11):36-9, 80 (Eng. Abstr.) **(Rus)**

VETERINARY

Induction of anaesthesia with halothane and isoflurane in the rabbit: a comparison of the use of a face-mask or an anaesthetic chamber. Flecknell PA, et al. **Lab Anim** 1996 Jan;30(1):67-74

ATMOSPHERIC PRESSURE

see related
ALTITUDE
ANOXIA
BAROTRAUMA
DECOMPRESSION SICKNESS
HYPERBARIC OXYGENATION

Retinal haemorrhage during sustained hypobaric hypoxia in rats. Osada H, et al. **Acta Physiol Scand** 1995 Dec; 155(4):463-74

The effect of changes in atmospheric pressure on the occurrence of the spontaneous onset of labor in term pregnancies. Noller KL, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1192-7; discussion 1197-9

Is normobaric simulation of hypobaric hypoxia accurate in chronic airflow limitation? Naughton MT, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1956-60

Cardiovascular deconditioning occurs during a 7-day saturation dive at 31 ATA. Lin YC, et al. **Aviat Space Environ Med** 1995 Jul;66(7):656-60

Effects of gas density and ambient pressure on myocardial contractility in the rat. Risberg J, et al. **Aviat Space Environ Med** 1995 Dec;66(12):1159-68

Cerebrospinal fluid monoamine metabolites and atmospheric pressure. Heilig M, et al. **Biol Psychiatry** 1996 Feb 15; 39(4):299-301

Atmospheric pressure effects on glucose monitoring devices [letter] Piepmeier EH Jr, et al. **Diabetes Care** 1995 Mar; 18(3):423-4

Acute mountain sickness relates to sea-level partial pressure of oxygen. Savourey G, et al. **Eur J Appl Physiol** 1995; 70(6):469-76

Effects of diving and hyperbaria on responses to exercise. Shiraki K, et al. **Exerc Sport Sci Rev** 1995;23:459-85 (76 ref.)

High pressure represses expression of the malB operon in Escherichia coli. Sato T, et al. **FEMS Microbiol Lett** 1996 Jan 1;135(1):111-6

Dead Sea: natural oxygen enrichment at low altitude. Kramer MR, et al. **Isr J Med Sci** 1996 Jul;32 Suppl:S20-3

Brain glucose metabolism in hypobaric hypoxia. Harik SI, et al. **J Appl Physiol** 1995 Jul;79(1):136-40

Lung cytokinetics after exposure to hypobaria and/or hypoxia and undernutrition in growing rats. Sekhon HS, et al. **J Appl Physiol** 1995 Oct;79(4):1299-309

Application of a new atmospheric pressure ionization source for double focusing sector instruments. Dobbertein P, et al. **J Chromatogr A** 1995 Sep 29;712(1):3-15

Estimation of ranolazine and eleven phase I metabolites in human plasma by liquid chromatography-atmospheric pressure chemical ionisation mass spectrometry with selected-ion monitoring. Herron WJ, et al. **J Chromatogr A** 1995 Sep 29;712(1):55-60

Six patients whose perianal and ileocolic Crohn's disease improved in the Dead Sea environment. Fraser GM, et al. **J Clin Gastroenterol** 1995 Oct;21(3):217-9

Jet "leg", pulmonary embolism, and hypoxia [letter] James PB. **Lancet** 1996 Jun 15;347(9016):1697

Evidence for inert gas narcosis mechanisms in the occurrence of psychotic-like episodes at pressure environment. Abraini JH. **Neuroreport** 1995 Nov 27;6(17):2435-9

Study of ejection fraction of professional divers during simulated diving in hyperbarism and various respiratory mixture. Badiu G, et al. **Rom J Physiol** 1993 Jul-Dec; 30(3-4):173-8

Study of heart rate of professional divers in hyperbarism during simulated diving in saturation with different respiratory mixture. Ceamitru N, et al. **Rom J Physiol** 1993 Jul-Dec;30(3-4):179-82

Effect of 12 atmospheres helium-oxygen on the response of mice to convulsant drugs. Syapin PJ, et al. **Undersea Hyperb Med** 1996 Mar;23(1):35-41

[Angiotensin II receptors in a rat model of hypobaric hypoxic pulmonary hypertension] Mikami O, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):186-93 (Eng. Abstr.) **(Jpn)**

[The dynamics of the ion currents in the membrane of an

isolated mollusk neuron under the action of high pressure] Shushakov VV, et al. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):114–8 (Eng. Abstr.) **(Rus)**
[Grooming and motor activity of rats during hyperbaric exposure] Sledkov Alu. **Kosm Biol Aviakosm Med** 1991 Nov–Dec;25(6):30–3 (Eng. Abstr.) **(Rus)**

ATOMIC ENERGY see **NUCLEAR ENERGY**

ATOMIC FORCE MICROSCOPY see **MICROSCOPY, ATOMIC FORCE**

ATOMIC MEDICINE see **NUCLEAR MEDICINE**

ATOMIC WARFARE see **NUCLEAR WARFARE**

ATOMIZERS see **NEBULIZERS AND VAPORIZERS**

ATOPIC HYPERSENSITIVITY see **HYPERSENSITIVITY, IMMEDIATE**

ATP see **ADENOSINE TRIPHOSPHATE**

ATP-BINDING CASSETTE TRANSPORTERS see **ABC TRANSPORTERS**

ATP CHOLINE TRANSPHOSPHATASE see **CHOLINE KINASE**

ATP CITRATE LYASE

ANTAGONISTS & INHIBITORS

ATP–citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2–substituted butanedioic acids as novel, potent inhibitors of the enzyme. Gribble AD, et al. **J Med Chem** 1996 Aug 30;39(18):3569–84

GENETICS

Cloning and identification of exon–intron organization of the rat ATP–citrate lyase gene. Moon YA, et al. **Biochim Biophys Acta** 1996 Jul 17;1307(3):280–4
Insulin– and polyunsaturated fatty acid–responsive region(s) of rat ATP citrate lyase gene promoter. Fukuda H, et al. **FEBS Lett** 1996 Feb 12;380(1–2):204–7
Soybean protein suppresses hepatic lipogenic enzyme gene expression in Wistar fatty rats. Iritani N, et al. **J Nutr** 1996 Feb;126(2):380–8

METABOLISM

GTP, a nonsubstrate of ATP citrate lyase, is a phosphodonor for the enzyme histidine autophosphorylation. Tuháčková Z, et al. **Biochem Biophys Res Commun** 1996 Jan 5; 218(1):61–6
Effects of acute exercise on hepatic lipogenic enzymes in fasted and refed rats. Griffiths MA, et al. **J Appl Physiol** 1995 Sep;79(3):879–85

ATP-DIPHOSPHATASE see **APYRASE**

ATP RECEPTORS see **RECEPTORS, PURINERGIC P2**

ATP SULFURYLASE see **SULFATE ADENYLYLTRANSFERASE**

ATPASE see **ADENOSINETRIPHOSPHATASE**

ATPASE, ACTOMYOSIN see **MYOSIN ATPASE**

ATPASE, CALCIUM see **CA(2+)-TRANSPORTING ATPASE**

ATPASE, CALCIUM MAGNESIUM see **CA(2+) MG(2+)-ATPASE**

ATPASE, DYNEIN see **DYNEIN ATPASE**

ATPASE, F0 see **H(+)-TRANSPORTING ATP SYNTHASE**

ATPASE, F1 see **H(+)-TRANSPORTING ATP SYNTHASE**

ATPASE, HYDROGEN, POTASSIUM see **H(+)-K(+)-EXCHANGING ATPASE**

ATPASE, MAGNESIUM see **CA(2+) MG(2+)-ATPASE**

ATPASE, MYOSIN see **MYOSIN ATPASE**

ATPASE, SODIUM, POTASSIUM see **NA(+)-K(+)-EXCHANGING ATPASE**

ATRACTYLIC ACID see **ATRACTYLOSIDE**

ATRACTYLOSIDE

ANALOGS & DERIVATIVES

Fluorometric titration of the mitochondrial ADP/ATP carrier protein in muscle homogenate with atractyloside derivatives. Roux P, et al. **Anal Biochem** 1996 Feb 1; 234(1):31–7

PHARMACOLOGY

Bivascular liver perfusion in the anterograde and retrograde modes: zonation of the response to inhibitors of oxidative phosphorylation. Constantin J, et al. **Cell Biochem Funct** 1995 Sep;13(3):201–9

ATRACURIUM

Performance assessment of a fuzzy controller for atracurium–induced neuromuscular block. Mason DG, et al. **Br J Anaesth** 1996 Mar;76(3):396–400
Anaesthesia for the insertion of a catheter for peritoneal dialysis. Haslett RC, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):49–50
[Comparison of neuromuscular blockade by mivacurium and atracurium] Hofmockel R, et al. **Anaesthesiol Reanim** 1995; 20(1):4–11 (Eng. Abstr.) **(Ger)**
[Neuromuscular blockade after atracurium and alcuronium with propofol and thiopental] Ginz HF, et al. **Anaesthesist** 1996 Jan;45(1):47–51 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Reversal of atracurium–induced neuromuscular block in paediatric patients. Kirkegaard–Nielsen H, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):906–11
The duration of action of mivacurium is prolonged if preceded by atracurium or vecuronium. Rautoma P, et al. **Acta Anaesthesiol Scand** 1995 Oct;39(7):912–5
Administration of 51W89 by infusion—a comparison with atracurium—preliminary communication. Mellinghoff H, et al. **Acta Anaesthesiol Scand Suppl** 1995;106:95
Intubating conditions and onset of action after rocuronium, vecuronium, and atracurium in young children. Scheiber G, et al. **Anesth Analg** 1996 Aug;83(2):320–4
The effects of midazolam followed by administration of either vecuronium or atracurium on the QT interval in humans. Michaloudis DG, et al. **Eur J Anaesthesiol** 1995 Nov; 12(6):577–83
Atracurium resistance in a critically Ill patient. Tschida SJ, et al. **Pharmacotherapy** 1995 Jul–Aug;15(4):533–9
Inconsistency with train–of–four monitoring in a critically ill paralyzed patient. Tschida SJ, et al. **Pharmacotherapy** 1995 Jul–Aug;15(4):540–5
[Muscle relaxation with atracurium in myasthenia gravis] Walz R, et al. **Anaesthesiol Reanim** 1996;21(2):43–6 (Eng. Abstr.) **(Ger)**
[Intubation conditions following administration of atracurium and vecuronium. Bolus method versus priming technique] Bissinger U, et al. **Anaesthesist** 1996 Jun;45(6):512–7 (Eng. Abstr.) **(Ger)**
[Profile of the effect of succinylcholine after pre–curarization with atracurium, vecuronium or pancuronium] Ebeling BJ, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun;31(5):304–8 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Atracurium versus vecuronium in asthmatic patients. A blinded, randomized comparison of adverse events. Caldwell JE, et al. **Anesthesiology** 1995 Nov;83(5):986–91
Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids. Rubio ER, et al. **South Med J** 1996 Jun;89(6):624–6

ANTAGONISTS & INHIBITORS

Time to peak effect of neostigmine at antagonism of atracurium– or vecuronium–induced neuromuscular block. Kirkegaard–Nielsen H, et al. **J Clin Anesth** 1995 Dec; 7(8):635–9

BLOOD

In vitro plasma protein binding of neuromuscular blocking agents in different subpopulations of patients. Cameron M, et al. **Anesth Analg** 1995 Nov;81(5):1019–25
Pharmacokinetics of 1R–cis 1'R–cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. Eastwood NB, et al. **Br J Anaesth** 1995 Oct;75(4):431–5

PHARMACOKINETICS

Pharmacokinetics of 51W89: preliminary data. Hunter JM, et al. **Acta Anaesthesiol Scand Suppl** 1995;106:94
The effect of stabilization on the onset of neuromuscular block when assessed using accelerometry. Girling KJ, et al. **Anesth Analg** 1996 Jun;82(6):1257–60
Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Lien CA, et al. **Anesthesiology** 1996 Feb;84(2):300–8
Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. Ornstein E, et al. **Anesthesiology** 1996 Mar;84(3):520–5
Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. Sorooshian SS, et al. **Anesthesiology** 1996 May;84(5):1083–91
Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis–atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. Boyd AH, et al. **Br J Anaesth** 1996 Mar;76(3):382–8
Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end–stage liver disease undergoing liver transplantation. De Wolf AM, et al. **Br J Anaesth** 1996 May;76(5):624–8

PHARMACOLOGY

Resistance to atracurium in rats with experimental inflammation: role of protein binding. García E, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1019–23
Cost–effective treatment of atracurium resistance in critically ill patients [letter; comment] Tschida SJ, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1818–9. Comment on: Am J Health Syst Pharm 1995 Mar 15;52(6):635–9.
Cardiomyoplasty and muscle relaxants [letter] Ceriana P, et al. **Anaesthesia** 1995 Dec;50(12):1099
The effects of neuromuscular block on peak airway pressure and abdominal elastance during pneumoperitoneum. Chassard D, et al. **Anesth Analg** 1996 Mar;82(3):525–7
Recovery properties of cisatracurium and vecuronium in intensive care unit patients [letter; comment] Fuchs–Buder T, et al. **Anesth Analg** 1996 Apr;82(4):892–3. Comment on: Anesth Analg 1995 Jul;81(1):3–12.
A two–center comparison of the cardiovascular effects of cisatracurium (Nimbex) and vecuronium in patients with coronary artery disease. Konstadt SN, et al. **Anesth Analg** 1995 Nov;81(5):1010–4
Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats. Wastila WB, et al. **Anesthesiology** 1996 Jul;85(1):169–77
Interaction of gentamycin and atracurium in anaesthetised horses. Hildebrand SV, et al. **Equine Vet J** 1994 May; 26(3):209–11
Neuromuscular blocking drug pharmacodynamics after chronic exposure to H2– antagonists. Rana J, et al. **In Vivo** 1995 Mar–Apr;9(2):163–6
[Pharmacologic induction of fetal immobilization for prenatal diagnostic–therapeutic procedures] Greco P, et al. **Minerva Ginecol** 1995 May;47(5):207–10 (Eng. Abstr.) **(Ita)**
[Muscle relaxation in Emery–Dreifuss muscular dystrophy (letter)] Moncho JM, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):403 **(Spa)**

THERAPEUTIC USE

Rocuronium bromide in dental day case anaesthesia—a comparison with atracurium and vecuronium. Chetty MS, et al. **Anaesth Intensive Care** 1996 Feb;24(1):37–41

ATRACURIUM BESYLATE see **ATRACURIUM**

ATRACURIUM DIBESYLATE see **ATRACURIUM**

ATRAZINE

ANALOGS & DERIVATIVES

Effect of s–triazine compounds on testosterone metabolism in the rat prostate. Kniewald J, et al. **J Appl Toxicol** 1995 May–Jun;15(3):215–8

ANALYSIS

Antigen—antibody interactions in the reverse micellar system: quenching of the fluorescence of fluorescein–labeled atrazine by antibodies against atrazine. Matveeva EG, et al. **Anal Biochem** 1996 Feb 1;234(1):13–8
Development and evaluation of a dipstick immunoassay format for the determination of atrazine residues on–site. Wittmann C, et al. **Analyst** 1996 Jun;121(6):863–9
Seasonal atrazine contamination of drinking water in pig–breeding farm surroundings in agricultural and industrial areas of Croatia. Gojmerac T, et al. **Bull Environ Contam Toxicol** 1996 Feb;56(2):225–30
Dissipation of three s–triazine herbicides, atrazine, simazine, and ametryn, in subtropical soils. Wang YS, et al. **Bull Environ Contam Toxicol** 1995 Sep;55(3):351–8

IMMUNOLOGY

Antigen—antibody interactions in the reverse micellar system: quenching of the fluorescence of fluorescein–labeled atrazine by antibodies against atrazine. Matveeva EG, et al. **Anal Biochem** 1996 Feb 1;234(1):13–8

METABOLISM

Cloning, characterization, and expression of a gene region from Pseudomonas sp. strain ADP involved in the dechlorination of atrazine. de Souza ML, et al. **Appl Environ Microbiol** 1995 Sep;61(9):3373–8
Effect of corn plants and rhizosphere populations on pesticide degradation. Buyanovsky GA, et al. **Bull Environ Contam Toxicol** 1995 Nov;55(5):689–96
Cloning and expression of the s–triazine hydrolase gene (trzA) from Rhodococcus corallinus and development of Rhodococcus recombinant strains capable of dealkylating and dechlorinating the herbicide atrazine. Shao ZQ, et al. **J Bacteriol** 1995 Oct;177(20):5748–55
Atrazine retention and transport in soils. Ma L, et al. **Rev Environ Contam Toxicol** 1996;145:129–73 (209 ref.)

PHARMACOLOGY

Effects of atrazine on Ochrobactrum anthropi membrane fatty acids. Laura D, et al. **Appl Environ Microbiol** 1996 Jul;62(7):2644–6

Characterization of the Rhodococcus sp. NI86/21 gene encoding alcohol: N,N'-dimethyl-4-nitrosoaniline oxidoreductase inducible by atrazine and thiocarbamate herbicides. Nagy I, et al. **Arch Microbiol** 1995 Jun; 163(6):439–46

Growth responses of Typha latifolia and Scirpus acutus to atrazine contamination. Langan MM, et al. **Bull Environ Contam Toxicol** 1996 Aug;57(2):307–14

POISONING

Epidemiology of atrazine. Loosli R. **Rev Environ Contam Toxicol** 1995;143:47–57 (31 ref.)

TOXICITY

Histological studies of atrazine toxicity on the thyroid gland in rats. Kornilovskaya IN, et al. **Biomed Environ Sci** 1996 Mar;9(1):60–6

Segment specificity of the cytological response in rainbow trout (Oncorhynchus mykiss) renal tubules following prolonged exposure to sublethal concentrations of atrazine. Oulmi Y, et al. **Ecotoxicol Environ Saf** 1995 Oct;32(1):39–50

Atrazine treatment potentiates excretion of mutagenic urine in 2,6-dinitrotoluene-treated Fischer 344 rats. George SE, et al. **Environ Mol Mutagen** 1995;26(2):178–84

Serum biochemical and histopathological changes related to the hepatic function in pigs following atrazine treatment. Gojmerac T, et al. **J Appl Toxicol** 1995 May–Jun; 15(3):233–6

Effect of s-triazine compounds on testosterone metabolism in the rat prostate. Kniewald J, et al. **J Appl Toxicol** 1995 May–Jun;15(3):215–8

Teratogenic potential of atrazine and 2,4–D using FETAX. Morgan MK, et al. **J Toxicol Environ Health** 1996 Jun 7;48(2):151–68

Serum biochemical changes associated with cystic ovarian degeneration in pigs after atrazine treatment. Gojmerac T, et al. **Toxicol Lett** 1996 Apr;85(1):9–15

ATRESIA, BILIARY see **BILIARY ATRESIA**

ATRESIA, CHOANAL see **CHOANAL ATRESIA**

ATRESIA, ESOPHAGEAL see **ESOPHAGEAL ATRESIA**

ATRESIA, FOLLICULAR see **FOLLICULAR ATRESIA**

ATRESIA, INTESTINAL see **INTESTINAL ATRESIA**

ATRESIA, PULMONARY see **PULMONARY ATRESIA**

ATRESIA, TRICUSPID see **TRICUSPID ATRESIA**

ATRIAL ECTOPIC BEATS see **ATRIAL PREMATURE COMPLEXES**

ATRIAL ECTOPIC TACHYCARDIA see **TACHYCARDIA, ECTOPIC ATRIAL**

ATRIAL FIBRILLATION

Paroxysmal atrial fibrillation. A common but neglected entity. Aboaf AP, et al. **Arch Intern Med** 1996 Feb 26; 156(4):362–7 (55 ref.)

ABC of atrial fibrillation. History, epidemiology, and importance of atrial fibrillation [see comments] [published erratum appears in BMJ 1996 Jan 6;312(7022):49] Lip GY, et al. **BMJ** 1995 Nov 18;311(7016):1361–3 (0 ref.). Comment in: BMJ 1996 Mar 9;312(7031):641–2.

ABC of atrial fibrillation. Aetiology, pathophysiology, and clinical features. Lip GY, et al. **BMJ** 1995 Nov 25; 311(7017):1425–8 (0 ref.)

ABC of atrial fibrillation. Investigation and non-drug management of atrial fibrillation. Lip GY, et al. **BMJ** 1995 Dec 9;311(7019):1562–5 (0 ref.)

ABC of atrial fibrillation. Atrial fibrillation in general and hospital practice [see comments] Lip GY, et al. **BMJ** 1996 Jan 20;312(7024):175–8 (5 ref.). Comment in: BMJ 1996 Apr 27;312(7028):1101.

Atrial fibrillation and atrial flutter. Cuddy TE, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:9A–11A (20 ref.)

Introduction and the process of consensus. Kerr CR. **Can J Cardiol** 1996 Jan;12 Suppl A:7A–8A

[Nosology of atrial fibrillation. Attempt at clarification] Lévy S, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):1035–8 (Eng. Abstr.) **(Fre)**

[Canadian Society of Cardiology Consensus Conference on Atrial Fibrillation. 1994, 1995] **Can J Cardiol** 1996 Feb;12 Suppl A:1A–62A (0 ref.) **(Fre)**

[Idiopathic atrial fibrillation: clinical-instrumental characterization and thromboembolic risk] Boriani G, et al. **Cardiologia** 1995 Jan;40(1):23–30 (Eng. Abstr.) **(Ita)**

[Role of transesophageal echocardiography in the evaluation of the potential embolic risk in left atrial thrombosis. Report of a clinical case] Iannoni E, et al. **Minerva Cardioangiol** 1995 Jul–Aug;43(7–8):329–34 (Eng. Abstr.) **(Ita)**

BLOOD

Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Lip GY, et al. **Am Heart J** 1996 Apr;131(4):724–30

Effects of aspirin on status of thrombin generation in atrial fibrillation. Yamamoto K, et al. **Am J Cardiol** 1996 Mar 1;77(7):528–30

Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Lip GY, et al. **Int J Cardiol** 1995 Oct;51(3):245–51

Plasma concentrations of atrial natriuretic peptide in cardioembolic stroke with atrial fibrillation. Sato Y, et al. **Kurume Med J** 1995;42(2):71–7

Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Mitusch R, et al. **Thromb Haemost** 1996 Feb;75(2):219–23

Clinical significance of serum TSH in euthyroid patients with paroxysmal atrial fibrillation. Kwon HM, et al. **Yonsei Med J** 1995 Nov;36(5):448–56

CHEMICALLY INDUCED

Adenosine-induced atrial fibrillation. Silverman AJ, et al. **Am J Emerg Med** 1996 May;14(3):300–1

CLASSIFICATION

[Auricular fibrillation: future orientation] Kerr CR, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:59A–62A (32 ref.) **(Fre)**

COMPLICATIONS

Correlation of paroxysmal supraventricular tachycardia, atrial fibrillation, and sinus rhythm with incidences of new thromboembolic stroke in 1476 old-old patients. Aronow WS, et al. **Aging (Milano)** 1996 Feb;8(1):32–4

Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. Boriani G, et al. **Am Heart J** 1996 Jun;131(6):1214–6

Multiple coronary thromboemboli complicating valvular heart disease and atrial fibrillation. Takenaka T, et al. **Am Heart J** 1996 Jan;131(1):194–6

Effect of atrial fibrillation on exercise capacity in mitral stenosis [letter; comment] Cohen-Solal A. **Am J Cardiol** 1996 Feb 1;77(4):328–9. Comment on: Am J Cardiol 1995 Aug 1;76(4):282–6.

Atrial fibrillation with left atrial spontaneous contrast detected by transesophageal echocardiography is a potent risk factor for stroke. Jones EF, et al. **Am J Cardiol** 1996 Aug 15;78(4):425–9

Atrial fibrillation, anticoagulation, and stroke. Morley J, et al. **Am J Cardiol** 1996 Jan 25;77(3):38A–44A (29 ref.)

The results of atrial flutter ablation in patients with and without a history of atrial fibrillation. Movsowitz C, et al. **Am J Cardiol** 1996 Jul 1;78(1):93–6

Interatrial block and atrial arrhythmias [letter; comment] Spodick DH. **Am J Cardiol** 1996 Feb 1;77(4):326. Comment on: Am J Cardiol 1995 Jul 1;76(1):47–50.

Left atrial size changes in patients with paroxysmal lone atrial fibrillation. An echocardiographic follow-up. Rostagno C, et al. **Angiology** 1996 Aug;47(8):797–801

New knowledge, old patients [editorial; comment] Brechtelsbauer DA. **Arch Fam Med** 1995 Dec;4(12):1014–6 . Comment on: Arch Fam Med 1995 Dec;4(12):1017–26.

Use of warfarin for nonvalvular atrial fibrillation in nursing home patients [see comments] Lackner TE, et al. **Arch Fam Med** 1995 Dec;4(12):1017–26. Comment in: Arch Fam Med 1995 Dec;4(12):1014–6.

Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. **Arch Intern Med** 1996 Feb 26;156(4):409–16

Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapy. Blackshear JL, et al. **Arch Intern Med** 1996 Mar 25;156(6):658–60

Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Manning WJ, et al. **Arch Intern Med** 1995 Nov 13;155(20):2193–8

Does activated protein C resistance increase the risk of systematic embolism in non rheumatic atrial fibrillation? [letter] Eikelboom J, et al. **Aust N Z J Med** 1996 Apr; 26(2):243–4

Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. Lip GY, et al. **Br J Clin Pharmacol** 1996 May; 41(5):369–79 (83 ref.)

Calcium channel blockers for heart rate control in atrial fibrillation complicated by congestive heart failure. Heywood JT. **Can J Cardiol** 1995 Oct;11(9):823–6

Prognosis of individuals with atrial fibrillation. Laupacis A, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:14A–16A (22 ref.)

Canadian atrial fibrillation anticoagulation study: were the patients subsequently treated with warfarin? Canadian Atrial Fibrillation Anticoagulation Study Group. Laupacis A, et al. **Can Med Assoc J** 1996 Jun 1;154(11):1669–74

Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Ezekowitz MD, et al. **Circulation** 1995 Oct 15;92(8):2178–82

Silent cortical strokes associated with atrial fibrillation. Hara M, et al. **Clin Cardiol** 1995 Oct;18(10):573–4

Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. Aronow WS, et al. **J Am Geriatr Soc** 1996 May;44(5):521–3

Does atrial fibrillation confer a hypercoagulable state? Lip GY. **Lancet** 1995 Nov 18;346(8986):1313–4 (16 ref.)

Primary prevention of stroke [letter; comment] Martinez-Riera A, et al. **N Engl J Med** 1996 Apr 25; 334(17):1138; discussion 1139. Comment on: N Engl J Med 1995 Nov 23;333(21):1392–400.

Optimal oral anticoagulation for patients with nonrheumatic atrial fibrillation and recent cerebral ischemia [letter; comment] Singer DE, et al. **N Engl J Med** 1995 Nov 30; 333(22):1504. Comment on: N Engl J Med 1995 Jul 6;333(1):5–10. Comment on: N Engl J Med 1995 Jul 6;333(1):11–7.

Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Miller VT, et al. **Neurology** 1996 Jan;46(1):238–40

Control of rapid heart rate in patients with atrial fibrillation: drugs or ablation? Brignole M, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):348–56 (63 ref.)

Stratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography and transesophageal echocardiography: the relative role of left atrial appendage function, mitral valve disease, and spontaneous echocardiographic contrast. Fatkin D, et al. **Prog Cardiovasc Dis** 1996 Jul–Aug;39(1):57–68

Risk of thromboembolism in new onset or transient atrial fibrillation. Stoddard MF. **Prog Cardiovasc Dis** 1996 Jul–Aug;39(1):69–80 (67 ref.)

Cardiovascular risk factors, ECG abnormalities and quality of life in subjects with atrial fibrillation. Gehring J, et al. **Soz Praventivmed** 1996;41(3):185–93

Pulsus irregularis perpetus--100 years of progress, but many issues still unresolved [editorial] Morady F. **West J Med** 1996 May;164(5):451

Warfarin sodium or aspirin therapy to prevent stroke in nonrheumatic atrial fibrillation. Answered and unanswered questions [editorial; comment] Stratton JR. **West J Med** 1995 Aug;163(2):177–9. Comment on: West J Med 1995 Aug;163(2):145–57.

Anticoagulation and atrial fibrillation. Putting the results of clinical trials into practice [clinical conference] [see comments] Wipf JE. **West J Med** 1995 Aug;163(2):145–52 . Comment in: West J Med 1995 Aug;163(2):177–9.

[Atrial fibrillation and apoplexy--risks and prevention] Koefoed BG, et al. **Nord Med** 1996 Jun;111(6):171–5 (Eng. Abstr.) **(Dan)**

[Syncopal ventricular tachycardia complicating paroxysmal atrial fibrillation in severe myocardial ischemia] Haïat R, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1905–10 (Eng. Abstr.) **(Fre)**

[Complete arrhythmia, caused by atrial fibrillation, causing ischemic cerebral vascular accident following acute alcoholic intoxication in a young subject (letter)] Rosolacci T, et al. **Presse Med** 1995 Dec 16–23;24(39):1911 **(Fre)**

[Diagnosis and treatment of cerebrovascular accidents of cardioembolic origin] Ricou FJ, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):155–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Anticoagulation in patients with atrial fibrillation] Mügge A. **Herz** 1996 Feb;21(1):28–36 (60 ref.) (Eng. Abstr.) **(Ger)**

[Embolic complications in atrial fibrillation. Data of the Studio Italiano Fibrillation Atriale (SIFA)] **G Chir** 1995 Mar;16(3):137–9 **(Ita)**

[Secondary prevention of stroke in non-valvular atrial fibrillation, study SIFA] Matteoli S, et al. **G Chir** 1995 Jun–Jul;16(6–7):323–5 **(Ita)**

[Stratification of the thromboembolic risk in patients with non-rheumatic atrial fibrillation: assessment of left atrial dysfunction] Scardi S, et al. **G Ital Cardiol** 1996 Mar; 26(3):273–85 (Eng. Abstr.) **(Ita)**

[Ischemic cerebrovascular disease in patients with atrial fibrillation] Nakajima K, et al. **Nippon Ronen Igakkai Zasshi** 1995 Jul;32(7):497–502 (Eng. Abstr.) **(Jpn)**

[Ischemic stroke in elderly patients with paroxysmal atrial fibrillation] Nakajima K, et al. **Nippon Ronen Igakkai Zasshi** 1996 Apr;33(4):273–7 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Signal-averaged P-wave duration and risk of paroxysmal atrial fibrillation in hyperthyroidism. Montereggi A, et al. **Am J Cardiol** 1996 Feb 1;77(4):266–9

ABC of atrial fibrillation. Differential diagnosis of atrial fibrillation. Lip GY, et al. **BMJ** 1995 Dec 2; 311(7018):1495–8 (0 ref.)

Investigation of the patient with atrial fibrillation. Gillis AM, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:12A–13A (27 ref.)

Palpitations and lightheadedness in a 42-year-old man. Larry JA, et al. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):24O, 24S

An irregularly irregular rhythm. Barillà F, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):861–2

Regular atrial fibrillation spells trouble. Drew BJ, et al. **Prog Cardiovasc Nurs** 1995 Summer;10(3):44–5

[Study of auricular fibrillation] Gillis AM, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:9A–11A (27 ref.) **(Fre)**

[Ischemic hepatitis] Gepstein L, et al. **Harefuah** 1995 Dec 1;129(11):468–70, 535 (Eng. Abstr.) **(Heb)**

[Atrial fibrillation as the onset of cancer of the left lung] Andrushenko EV, et al. **Lik Sprava** 1995 Jul–Aug; (7–8):128–30 **(Rus)**

DRUG THERAPY

Xamoterol improves the control of chronic atrial fibrillation in elderly patients. Lawson-Matthew PJ, et al. **Age Ageing** 1995 Jul;24(4):321–5

Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan. Massie BM, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):130–6

A symposium: Supraventricular Arrhythmias: Update 1995. Boston, Massachusetts, May 6, 1995. **Am J Cardiol** 1996 Jan 25;77(3):1A–95A

Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Aliot E, et al. **Am J Cardiol** 1996 Jan 25;77(3):66A–71A

Maintaining sinus rhythm with antifibrillatory drugs in atrial fibrillation. Antman EM. **Am J Cardiol** 1996 Aug 29; 78(4A):67–72 (23 ref.)

Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. Chimienti M, et al. **Am J Cardiol** 1996 Jan 25;77(3):60A–75A

Drug therapy for prevention of atrial fibrillation. Coumel P, et al. **Am J Cardiol** 1996 Jan 25;77(3):3A–9A (27 ref.)

Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Naccarelli GV, et al. **Am J Cardiol** 1996 Jan 25; 77(3):53A–59A

Effects of aspirin on status of thrombin generation in atrial fibrillation. Yamamoto K, et al. **Am J Cardiol** 1996 Mar 1;77(7):528–30

Pharmacists and stroke prevention [editorial] Wittkowsky AK. **Am J Health Syst Pharm** 1996 May 1;53(9):1009

Anticoagulation for cardioversion of atrial fibrillation [letter] Carlsson J, et al. **Arch Intern Med** 1996 Sep 9;156(16):1889, 1894–5

The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. Kerin NZ, et al. **Arch Intern Med** 1996 Jan 8;156(1):49–53

Anticoagulation for atrial fibrillation [letter] Liron M. **Arch Intern Med** 1996 Sep 9;156(16):1895, 1899

Warfarin for atrial fibrillation. The patient's perspective. Man-Son-Hing M, et al. **Arch Intern Med** 1996 Sep 9; 156(16):1841–8

Intravenous amiodarone for the conversion of atrial fibrillation [letter] Storch HD. **Arch Intern Med** 1996 Sep 9;156(16):1889

Effects of a sinus node inhibitor on the normal and failing rabbit heart. Ryu KH, et al. **Basic Res Cardiol** 1996 Mar-Apr;91(2):131–9

Magnesium is underused in acute atrial fibrillation [letter; comment] Dietch D, et al. **BMJ** 1996 Apr 27; 312(7038):1101. Comment on: BMJ 1996 Jan 20;312(7024):175–8.

Quality of service provision for anticoagulation in atrial fibrillation. Bridges from evidence to practice are fragile [letter; comment] Edwards A, et al. **BMJ** 1996 Jan 6; 312(7022):51. Comment on: BMJ 1995 Aug 26;311(7004):558–60.

Quality of service provision for anticoagulation in atrial fibrillation. In Finland anticoagulant treatment is monitored by general practitioners [letter; comment] Eskola K, et al. **BMJ** 1996 Jan 6;312(7022):52–3. Comment on: BMJ 1995 Aug 26;311(7004):558–60.

Drugs for atrial fibrillation. Digoxin comes from Digitalis lanata [letter; comment] Hollman A. **BMJ** 1996 Apr 6; 312(7035):912. Comment on: BMJ 1995 Dec 16;311(7020):1631–4.

ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. Lip GY, et al. **BMJ** 1996 Jan 6;312(7022):45–9 (0 ref.)

Quality of service provision for anticoagulation in atrial fibrillation. Many patients are ineligible [letter; comment] Lip GY. **BMJ** 1996 Jan 6;312(7022):51. Comment on: BMJ 1995 Aug 26;311(7004):558–60.

ABC of atrial fibrillation. Drugs for atrial fibrillation [see comments] Lip GY, et al. **BMJ** 1995 Dec 16; 311(7020):1631–4 (4 ref.). Comment in: BMJ 1996 Apr 6;312(7035):911–2. Comment in: BMJ 1996 Apr 6;312(7035):912.

Quality of service provision for anticoagulation in atrial fibrillation. Difficulties of routine treatment are exaggerated [letter; comment] Marshall T. **BMJ** 1996 Jan 6;312(7022):52 . Comment on: BMJ 1995 Aug 26;311(7004):558–60.

Quality of service provision for anticoagulation in atrial fibrillation. Patients and doctors play it safe [letter; comment] Scott ME, et al. **BMJ** 1996 Jan 6;312(7022):51–2 . Comment on: BMJ 1995 Aug 26;311(7004):558–60.

Drugs for atrial fibrillation. Measurement of the pulse deficit is unnecessary [letter; comment] Snow T. **BMJ** 1996 Apr 6;312(7035):911–2. Comment on: BMJ 1995 Dec 16;311(7020):1631–4.

Effect of low dose sotalol on the signal averaged P wave in patients with paroxysmal atrial fibrillation. Stafford PJ, et al. **Br Heart J** 1995 Dec;74(6):636–40

Warfarin for elderly patients [letter] Frame AC. **Br J Gen Pract** 1996 Jan;46(402):49–50

Antithrombotic therapy in atrial fibrillation. Turpie AG, et al. **Can Fam Physician** 1996 Jul;42:1341–5 (16 ref.)

Antithrombotic therapy in atrial fibrillation. Connolly SJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:17A–20A (13 ref.)

Heart rate control in patients with atrial fibrillation. Gardner MJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:21A–23A (26 ref.)

Chronic drug therapy to prevent recurrence of atrial fibrillation. Newman D, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:24A–28A (43 ref.)

Antithrombotic therapy in atrial fibrillation. Laupacis A, et al. **Chest** 1995 Oct;108(4 Suppl):352S–359S (52 ref.)

Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study. Bellandi F, et al. **Clin Cardiol** 1995 Nov;18(11):631–4

Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. Fresco C, et al. **Clin Cardiol** 1996 May;19(5):409–12

The antiarrhythmic treatment of atrial fibrillation. **Drug Ther Bull** 1996 Jun;34(6):41–5 (34 ref.)

Atrial fibrillation: steering a management course between thromboembolism and proarrhythmic risk. Campbell RW. **Eur Heart J** 1995 Aug;16 Suppl G:28–31 (56 ref.)

Studies on conversion of recent onset AF to sinus rhythm have to be controlled [letter; comment] Capucci A, et al. **Eur Heart J** 1995 May;16(5):719–20. Comment on: Eur Heart J 1994 Oct;15(10):1396–402.

Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Chimienti M, et al. **Eur Heart J** 1995 Dec;16(12):1943–51

Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. Di Biasi P, et al. **Eur J Cardiothorac Surg** 1995;9(10):587–91

Anticoagulation: risks and benefits in atrial fibrillation. Fiore LD. **Geriatrics** 1996 Jun;51(6):22–4, 27–8, 31 (37 ref.)

Is aspirin safe for patients with heart failure? [letter] Jolobe OM. **Heart** 1996 Feb;75(2):214

Physician variation in the management of patients with atrial fibrillation. Lip GY, et al. **Heart** 1996 Feb;75(2):200–5

Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. Koh KK, et al. **Int J Cardiol** 1995 Nov 24;52(2):167–74

Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. Ellenbogen KA, et al. **J Am Coll Cardiol** 1996 Jul; 28(1):130–6

Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. Galve E, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1079–82

Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Hohnloser SH, et al. **J Am Coll Cardiol** 1995 Oct;26(4):852–8

The utilization of antithrombotic prophylaxis for atrial fibrillation in a geriatric rehabilitation hospital. Lawson F, et al. **J Am Geriatr Soc** 1996 Jun;44(6):708–11

Efficacy of oral diltiazem and digoxin alone and in combination in chronic atrial fibrillation. Gupta RP, et al. **J Assoc Physicians India** 1995 Nov;43(11):781

Clinical effects and pharmacokinetics of a single oral dose of pirmenol hydrochloride. Atarashi H, et al. **J Cardiovasc Pharmacol** 1996 Apr;27(4):556–62

Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation [see comments] Gage BF, et al. **JAMA** 1995 Dec 20; 274(23):1839–45. Comment in: JAMA 1996 Mar 27;275(12):909; discussion 910.

Cost-effectiveness of stroke prophylaxis for nonvalvular atrial fibrillation [letter; comment] Kan BD, et al. **JAMA** 1996 Mar 27;275(12):909; discussion 910. Comment on: JAMA 1995 Dec 20;274(23):1839–45.

Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction. Abe H, et al. **Jpn Heart J** 1995 Jul;36(4):483–7

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. **Lancet** 1996 Sep 7; 348(9028):633–8

The risks and benefits of antithrombotic therapy in chronic atrial fibrillation. Hankey GJ, et al. **Med J Aust** 1996 May 20;164(10):624–6 (16 ref.)

An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation [see comments] Hylek EM, et al. **N Engl J Med** 1996 Aug 22;335(8):540–6. Comment in: N Engl J Med 1996 Aug 22;335(8):587–9.

The Scylla and Charybdis of oral anticoagulant treatment [editorial; comment] Rosendaal FR. **N Engl J Med** 1996 Aug 22;335(8):587–9. Comment on: N Engl J Med 1996 Aug 22;335(8):540–6.

KePRO project sheds light on anticoagulation in atrial fibrillation. Whittle J. **Pa Med** 1995 Dec;98(12):30–1

Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent. Isomoto S, et al. **Pacing Clin Electrophysiol** 1995 Nov;18(11):2022–7

Current recommendations for the anticoagulation of patients with atrial fibrillation. Orsinelli DA. **Prog Cardiovasc Dis** 1996 Jul–Aug;39(1):1–20 (52 ref.)

Antithrombotic therapy in atrial fibrillation: a review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) Trial. Shivkumar K, et al. **Prog Cardiovasc Dis** 1996 Jan–Feb; 38(4):337–42 (25 ref.)

Antithrombotic therapy prescribed for patients with non-rheumatic atrial fibrillation. Hendry A, et al. **Scott Med J** 1994 Aug;39(4):110–1

Anti-thrombotic therapy prescribed for patients with non-rheumatic atrial fibrillation (Scot Med J 1994: 39; 110–111) [letter] Jolobe OM. **Scott Med J** 1994 Oct; 39(5):139–40

Anti-thrombotic therapy prescribed for patients with non-rheumatic atrial fibrillation (Scot Med J 1994:39;110–111) [letter] Oldroyd KG. **Scott Med J** 1994 Oct;39(5):140

Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. Kumar A. **South Med J** 1996 Aug; 89(8):779–85

The role of coumadin and aspirin in atrial fibrillation. Hutter AM Jr. **Trans Am Clin Climatol Assoc** 1995;107:79–85; discussion 85–6 (17 ref.)

New treatment of atrial fibrillation. Herbert ME, et al. **West J Med** 1996 Jan;164(1):63

Atrial fibrillation pearls and perils of management. Kudenchuk PJ. **West J Med** 1996 May;164(5):425–34 (109 ref.)

Warfarin encouraged for stroke prevention in atrial fibrillation. Gold JA. **Wis Med J** 1996 Jan;95(1):42–3

[Programmed esophageal stimulation of the atrium and the long-term effects of anti-arrhythmia therapy of atrial fibrillation and flutter] Novotný E, et al. **Vnitr Lek** 1995 Sep;41(9):586–9 (Eng. Abstr.) **(Cze)**

[The treatment of atrial fibrillation] Halinen MO. **Duodecim** 1995;111(8):705–13 (29 ref.) **(Fin)**

[Antiarrhythmic drugs in paroxysmal atrial fibrillation. When and how?] Lévy S, et al. **Arch Mal Coeur Vaiss** 1996 Feb; 89 Spec No 1:19–24 (Eng. Abstr.) **(Fre)**

[Antithrombotic treatment of atrial fibrillation] Connelly SJ, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:14A–18A (13 ref.) **(Fre)**

[Long term drug therapy for the prevention of recurrence in atrial fibrillation] Newman D, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:21A–26A (43 ref.) **(Fre)**

[Restoration of the sinus rhythm in atrial fibrillation] Talajic M, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:27A–34A (83 ref.) **(Fre)**

[Pharma-clinics. How I treat... a patient with atrial fibrillation. 2] Soyeur D. **Rev Med Liege** 1995 Aug; 50(8):313–4 **(Fre)**

[A comparison between propafenone and hydroquinidine perorally in the treatment of recent-onset atrial fibrillation] Satullo G, et al. **Minerva Cardioangiol** 1996 Mar;44(3):141–4 (Eng. Abstr.) **(Ita)**

[Digitalis in atrial fibrillation. Still relevant treatment or an old-fashioned therapy?] Gjesdal K. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):973–5 (39 ref.) (Eng. Abstr.) **(Nor)**

[Auricular fibrillation. Antiarrhythmic treatment revisited] Elvas L, et al. **Acta Med Port** 1995 Mar;8(3):173–9 (55 ref.) (Eng. Abstr.) **(Por)**

[Atrial fibrillation due to non-valvular causes: indications for antithrombotic therapy] Codinach Huix P. **Med Clin (Barc)** 1996 Apr 20;106(15):586–9 (25 ref.) **(Spa)**

[Anticoagulation in auricular fibrillation (letter; comment)] Rojo Sebastián A, et al. **Med Clin (Barc)** 1995 Nov 11; 105(16):638. Comment on: Med Clin (Barc) 1994 Sep 10;103(7):267–70. **(Spa)**

[Non-rheumatic atrial fibrillation and antithrombotic treatment: current status] Gayán Laviña R, et al. **Rev Clin Esp** 1995 Aug;195(8):559–64 (28 ref.) **(Spa)**

EPIDEMIOLOGY

Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Wolf PA, et al. **Am Heart J** 1996 Apr; 131(4):790–5

Atrial fibrillation in acute myocardial infarction: a prospective study based on data from a consecutive series of patients admitted to the coronary care unit. Madias JE, et al. **Clin Cardiol** 1996 Mar;19(3):180–6

Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. Aronow WS, et al. **J Am Geriatr Soc** 1996 May;44(5):521–3

[Ischemic stroke associated with atrial fibrillation: the demographic and clinical characteristics and 30-day mortality in a hospital stroke registry. The European Community Stroke Project, Florence Unit]

Ann Ital Med Int 1996 Jan-Mar;11(1):20-6 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Hemodynamic predictors of atrial fibrillation or flutter after coronary artery bypass grafting. Frost L, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):690-7

Persistent atrial mechanical dysfunction after spontaneous conversion of chronic atrial fibrillation to sinus rhythm. Kahn ZU, et al. **Am Heart J** 1996 Mar;131(3):606-8 (14 ref.)

Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. Diker E, et al. **Am J Cardiol** 1996 Jan 1;77(1):96-8

Postoperative atrial fibrillation due to full bladder [letter] Griffin M, et al. **Anaesth Intensive Care** 1995 Dec; 23(6):752-3

Acute exacerbation of masked hyperthyroidism after iodine restriction followed by thyrotoxic atrial fibrillation and cerebral embolism. A case report. Kuroda T, et al. **Angiology** 1996 Jul;47(7):709-12

Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Kalman JM, et al. **Ann Thorac Surg** 1995 Dec;60(6):1709-15

Coronary heart disease and atrial fibrillation. Studies have not shown a causal relation [letter; comment] Wheeldon N. **BMJ** 1996 Mar 9;312(7031):641-2. Comment on: BMJ 1995 Nov 18;311(7016):1361-3.

Atrial fibrillation and flutter in children and in young adults with congenital heart disease. Gow RM. **Can J Cardiol** 1996 Jan;12 Suppl A:45A-48A (40 ref.)

Atrial fibrillation following cardiac surgery. Pagé PL, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:40A-44A (45 ref.)

An intracardiac mass presenting as atrial fibrillation in a patient with testicular carcinoma. Yu E, et al. **Can J Cardiol** 1996 Mar;12(3):303-5

Mechanoelectric feedback and atrial arrhythmias. Nazir SA, et al. **Cardiovasc Res** 1996 Jul;32(1):52-61 (92 ref.)

Low vagal tone and supraventricular ectopic activity predict atrial fibrillation and flutter after coronary artery bypass grafting. Frost L, et al. **Eur Heart J** 1995 Jun;16(6):825-31

Atrial fibrillation during flexible sigmoidoscopy in a 36-year-old man. Bruehlman RD. **J Am Board Fam Pract** 1995 Sep-Oct;8(5):403-4

Atrial fibrillation during flexible sigmoidoscopy [letter] Varma JR. **J Am Board Fam Pract** 1996 Jan-Feb;9(1):73

Premature atrial beat eliciting atrial fibrillation after coronary artery bypass grafting. Frost L, et al. **J Electrocardiol** 1995 Oct;28(4):297-305

Atrial compartment surgery for chronic atrial fibrillation associated with congenital heart defects. Lin FY, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):231-7

Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. Mathew JP, et al. **JAMA** 1996 Jul 24-31; 276(4):300-6

Augmented sympathoadrenal activity during treadmill exercise in patients with Wolff-Parkinson-White syndrome and atrial fibrillation. Honda T, et al. **Jpn Circ J** 1996 Jan; 60(1):43-9

Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction. Abe H, et al. **Jpn Heart J** 1995 Jul;36(4):483-7

A 72-year-old man with shortness of breath [clinical conference] Bennett SK, et al. **Md Med J** 1996 Jul; 45(7):547-52

Clinical problem solving. The invisible patient [see comments] Sirmon M, et al. **N Engl J Med** 1996 Apr 4; 334(14):908-11. Comment in: N Engl J Med 1996 Aug 22;335(8):594; discussion 596. Comment in: N Engl J Med 1996 Aug 22;335(8):594-5; discussion 596. Comment in: N Engl J Med 1996 Aug 22;335(8):595; discussion 596. Comment in: N Engl J Med 1996 Aug 22;335(8):595-6; discussion 596.

Transient disappearance of hyperthyroidism with atrial fibrillation during the course of acute renal failure caused by haemorrhagic fever with renal syndrome. Park CW, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):702-3

Atrial pressure and experimental atrial fibrillation. Sideris DA, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1679-85

Atrial fibrillation and flutter after coronary artery bypass surgery: impact on recovery. Shinn JA. **Prog Cardiovasc Nurs** 1995 Summer;10(3):46-7

Atrial fibrillation after blood and crystalloid cardioplegia in CABG patients. Pehkonen EJ, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):200-3

[Atrial fibrillation after coronary artery bypass surgery. The significance of preoperative vagus modulation and ectopic atrial activity] Frost L, et al. **Ugeskr Laeger** 1996 Jul 1; 158(27):3919-23 (Eng. Abstr.) **(Dan)**

[Auricular fibrillation and flutter] Cuddy TE, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:6A-9A **(Fre)**

[Atrial fibrillation and flutter in children and young adults with congenital cardiopathies] Gow RM. **Can J Cardiol** 1996 Feb;12 Suppl A:43A-48A (40 ref.) **(Fre)**

[Post-heart surgery auricular fibrillation] Pagé PL, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:38A-43A (45 ref.) **(Fre)**

[Myopericarditis and atrial fibrillation disclosing leptospirosis septicemia (letter)] Constans J, et al. **Presse Med** 1996 Mar 30;25(11):555 **(Fre)**

[DDD versus DDDR pacemaker stimulation: comparison of cardiopulmonary performance, incidence of atrial arrhythmias and quality of life] Epperlein S, et al. **Z Kardiol** 1996 Apr;85(4):226-36 (Eng. Abstr.) **(Ger)**

[Atrial fibrillation in lacunar-type cerebral infarction (letter)] Arboix A, et al. **Med Clin (Barc)** 1995 Nov 25;105(18):716 **(Spa)**

[Atrial fibrillation due to non-valvular causes: indications for antithrombotic therapy] Codinach Huix P. **Med Clin (Barc)** 1996 Apr 20;106(15):586-9 (25 ref.) **(Spa)**

MORTALITY

[Prognosis of auricular fibrillation] Laupacis A, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:11A-13A (22 ref.) **(Fre)**

PHYSIOPATHOLOGY

Characterization of left atrial appendage Doppler flow in atrial fibrillation and flutter by Fourier analysis. Grimm RA, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):286-96

Electrophysiologic characteristics of human atrial muscle in paroxysmal atrial fibrillation. Hashiba K, et al. **Am Heart J** 1996 Apr;131(4):778-89 (77 ref.)

Changes in transmitral and pulmonary venous flow velocity patterns after cardioversion of atrial fibrillation. Iuchi A, et al. **Am Heart J** 1996 Feb;131(2):270-5

Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Allessie MA, et al. **Am J Cardiol** 1996 Jan 25; 77(3):10A-23A (56 ref.)

Effects of atrial fibrillation and atrial flutter on the signal-averaged electrocardiogram. Fitzgerald DM, et al. **Am J Cardiol** 1996 Jan 15;77(2):205-9

Ambulatory blood pressure monitoring in atrial fibrillation. Lip GY, et al. **Am J Cardiol** 1996 Aug 1;78(3):350-3

Clinical course of lone atrial fibrillation since first symptomatic arrhythmic episode. Rostagno C, et al. **Am J Cardiol** 1995 Oct 15;76(11):837-9

Regional and functional factors determining induction and maintenance of atrial fibrillation in dogs. Wang J, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H148-58

Optimizing external cardiac-assist compressions in patients with atrial fibrillation by anticipating the next beat. Dillon RS. **Angiology** 1996 Feb;47(2):123-9

Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Golzari H, et al. **Ann Intern Med** 1996 Aug 15;125(4):311-23 (205 ref.)

Atrial activation during chronic atrial fibrillation in patients with isolated mitral valve disease. Harada A, et al. **Ann Thorac Surg** 1996 Jan;61(1):104-11; discussion 111-2

Optimal analysis of the signal averaged P wave in patients with paroxysmal atrial fibrillation. Stafford PJ, et al. **Br Heart J** 1995 Oct;74(4):413-8

Restoration of atrial function after atrial fibrillation of different etiological origins. Mattioli AV, et al. **Cardiology** 1996 May-Jun;87(3):205-11

Chaos in the Hall of Mirrors. Weber KT, et al. **Cardiovasc Res** 1995 Sep;30(3):336-44

Quantitative assessment of the spatial organization of atrial fibrillation in the intact human heart. Botteron GW, et al. **Circulation** 1996 Feb 1;93(3):513-8

RR interval variability in irregular monomorphic ventricular tachycardia and atrial fibrillation. García-Alberola A, et al. **Circulation** 1996 Jan 15;93(2):295-300

Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. Leistad E, et al. **Circulation** 1996 May 1; 93(9):1747-54

Ventricular rate during atrial fibrillation before and after slow-pathway ablation. Effects of autonomic blockade and beta-adrenergic stimulation. Strickberger SA, et al. **Circulation** 1996 Sep 1;94(5):1023-6

F-amplitude, left atrial appendage velocity, and thromboembolic risk in nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Blackshear JL, et al. **Clin Cardiol** 1996 Apr;19(4):309-13

Effects of heart rate on flow velocity of the left atrial appendage in patients with nonvalvular atrial fibrillation. Noda T, et al. **Clin Cardiol** 1996 Apr;19(4):295-300

Local latency of conduction time during premature stimulation: a real or apparent phenomenon? [editorial; comment] Chimienti M, et al. **Eur Heart J** 1995 Dec; 16(12):1749-51. Comment on: Eur Heart J 1995 Dec;16(12):1920-4.

Clinical, adrenergic and heart endocrine measures in chronic atrial fibrillation as predictors of conversion and maintenance of sinus rhythm after direct current cardioversion. Theodorakis GN, et al. **Eur Heart J** 1996 Apr;17(4):550-6

Analysis of heart rate variability in a patient with paroxysmal atrial fibrillation [letter] van den Berg MP, et al. **Eur Heart J** 1995 Dec;16(12):2011-2

Analysis of randomness of atrial and ventricular rhythm in atrial fibrillation. van den Berg MP, et al. **Eur Heart J** 1995 Jul;16(7):971-6

Familial idiopathic atrial fibrillation with bradyarrhythmia. Bertram H, et al. **Eur J Pediatr** 1996 Jan;155(1):7-10

The physics of left ventricular filling: exploring the seemingly obvious [editorial] Flachskampf FA, et al. **Heart** 1996 Feb; 75(2):116-7

A new method for analysis of atrial activation during chronic atrial fibrillation in man. Holm M, et al. **IEEE Trans Biomed Eng** 1996 Feb;43(2):198-210

Atrial ectopic activity and atrial fibrillation/flutter after coronary artery bypass surgery. A case-base study controlling for confounding from age, beta-blocker treatment, and time distance from operation. Frost L, et al. **Int J Cardiol** 1995 Jun 30;50(2):153-62

Effects of disopyramide on the atrial fibrillation threshold in the human atrium. Ishibashi K, et al. **Int J Cardiol** 1995 Nov 24;52(2):177-84

Left ventricular beat-to-beat performance in atrial fibrillation: contribution of Frank-Starling mechanism after short rather than long RR intervals. Gosselink AT, et al. **J Am Coll Cardiol** 1995 Nov 15;26(6):1516-21

Distribution of atrial electrogram types during atrial fibrillation: effect of rapid atrial pacing and intercaval junction ablation. Li H, et al. **J Am Coll Cardiol** 1996 Jun; 27(7):1713-21

Regional left atrial stasis during atrial fibrillation and flutter: determinants and relation to stroke. Shively BK, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1722-9

Induced termination of fibrillation. Abildskov JA. **J Cardiovasc Electrophysiol** 1996 Jan;7(1):71-81

Electrophysiologic determinants of ventricular rate in human atrial fibrillation. Asano Y, et al. **J Cardiovasc Electrophysiol** 1995 May;6(5):343-9

Facilitation of sustained bundle branch reentry by atrial fibrillation. Blanck Z, et al. **J Cardiovasc Electrophysiol** 1996 Apr;7(4):348-52

Regular wide QRS complex tachycardia during atrial fibrillation in a patient with preexcitation syndrome: a case report. Gatzoulis K, et al. **J Cardiovasc Electrophysiol** 1995 Jun;6(6):493-7

Stability: an ICD detection criterion for discriminating atrial fibrillation from ventricular tachycardia. Higgins SL, et al. **J Cardiovasc Electrophysiol** 1995 Dec;6(12):1081-8

Nonlinear analysis of epicardial atrial electrograms of electrically induced atrial fibrillation in man [see comments] Hoekstra BP, et al. **J Cardiovasc Electrophysiol** 1995 Jun; 6(6):419-40. Comment in: J Cardiovasc Electrophysiol 1995 Jun;6(6):441-2.

Slowing of the ventricular rate during atrial fibrillation by ablation of the slow pathway of AV nodal reentrant tachycardia. Tebbenjohanns J, et al. **J Cardiovasc Electrophysiol** 1995 Sep;6(9):711-5

The relation between atrial fibrillation wavefront characteristics and accessory pathway conduction. Ong JJ, et al. **J Clin Invest** 1995 Nov;96(5):2284-96

Atrial fibrillation--new aspects on mechanism and treatment. Olsson SB. **J Intern Med** 1996 Jan;239(1):3-15 (43 ref.)

Silent brain infarction in nonrheumatic atrial fibrillation. EAFT Study Group. European Atrial Fibrillation Trial. **Neurology** 1996 Jan;46(1):159-65

Changes of QT intervals associated with postural change in patients with chronic atrial fibrillation. Malik M, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):490-5

Influence of age, lead axis, frequency of arrhythmic episodes, and atrial dimensions on P wave triggered SAECG in patients with lone paroxysmal atrial fibrillation. Michelucci A, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):758-67

A shorter R-R interval causes a larger endocardial R wave amplitude in cases with atrial fibrillation. Yokoyama M, et al. **Pacing Clin Electrophysiol** 1995 Dec;18(12 Pt 1):2180-2

[Atrial electrophysiological study of unexplained ischemic cerebrovascular disorders] Reeb T, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1855-61 (Eng. Abstr.) **(Fre)**

[Control of heart rate and atrial fibrillation] Gardner MJ, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:18A-21A (26 ref.) **(Fre)**

[Mechanisms of atrial fibrillation. Recent progress and therapeutic implications] Le Heuzey JY, et al. **Presse Med** 1996 Apr 6;25(12):590-4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Intermittent atrial fibrillation/flutter: contraindication for implantation of a dual chamber pacemaker?] Schuchert A, et al. **Z Kardiol** 1996 Apr;85(4):248-54 (Eng. Abstr.) **(Ger)**

[The influence of organic myocardial damage on parameters of signal-averaged electrocardiogram in patients with electrically-induced atrial fibrillation] Banasiak W, et al. **Pol Arch Med Wewn** 1996 May;95(5):402-13 (Eng. Abstr.) **(Pol)**

[Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation] Telichowski A, et al. **Pol Arch Med Wewn** 1995 Aug;94(2):132-43 (Eng. Abstr.) **(Pol)**

[Atrial fibrillation and Wolff-Parkinson-White syndrome. The hidden danger of manifested pathways (editorial)] Cruz Filho FE. **Arq Bras Cardiol** 1995 Feb;64(2):97-100 **(Por)**

[High-resolution P-wave electrocardiogram in patients with a history of paroxysmal atrial fibrillation] Maia IG, et al. **Arq Bras Cardiol** 1995 Apr;64(4):311-3 (Eng. Abstr.) **(Por)**

[Non-valvular atrial fibrillation and cerebral infarction] Martin R. **Rev Neurol** 1995 Mar-Apr;23(120):370-6 (81 ref.) (Eng. Abstr.) **(Spa)**

ATRIAL FIBRILLATION

PREVENTION & CONTROL

Drug therapy for prevention of atrial fibrillation. Coumel P, et al. **Am J Cardiol** 1996 Jan 25;77(3):3A–9A (27 ref.)

Amiodarone for prevention of atrial fibrillation [letter; comment] van 't Hof AW, et al. **Am J Cardiol** 1996 Feb 1;77(4):327. Comment on: Am J Cardiol 1995 Jul 1;76(1):47–50.

Sotalol prophylaxis and treatment of atrial fibrillation. Pill MW, et al. **Ann Pharmacother** 1996 Apr;30(4):399–401

Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. Klemperer JD, et al. **Ann Thorac Surg** 1996 May;61(5):1323–7; discussion 1328–9

Verapamil as prophylactic treatment for atrial fibrillation after lung operations. Van Mieghem W, et al. **Ann Thorac Surg** 1996 Apr;61(4):1083–5; discussion 1086

Changing incidence of atrial fibrillation following coronary artery bypass grafting: a retrospective analysis. Gaylard E. **Br J Clin Pract** 1996 Apr–May;50(3):164–5

A randomized, placebo–controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. **Circulation** 1995 Nov 1;92(9):2550–7

[Comparative effects of cibenzoline and hydroquinidine in the prevention of auricular fibrillation. A randomized double–blind study] Touboul P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Nov;44(9):525–31 (Eng. Abstr.) **(Fre)**

[Propafenone and sotalol: long–term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo–controlled double–blind study] Bellandi F, et al. **G Ital Cardiol** 1996 Apr;26(4):379–90 (Eng. Abstr.) **(Ita)**

RADIOTHERAPY

[Long–term results following 131I treatment of thyrotoxic heart disease: a report of 68 cases] Xing J, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):591–4 (Eng. Abstr.) **(Chi)**

REHABILITATION

Exercise training for patients with chronic atrial fibrillation. Mertens DJ, et al. **J Cardpulm Rehabil** 1996 May–Jun; 16(3):193–6

SURGERY

Selective radiofrequency ablation of the "slow" atrioventricular nodal pathway for control of the ventricular response to atrial fibrillation. Canby RC, et al. **Am J Cardiol** 1996 Jun 15;77(15):1358–61

Ablation therapy of type I atrial flutter may eradicate paroxysmal atrial fibrillation. Katritsis D, et al. **Am J Cardiol** 1996 Aug 1;78(3):345–7

Concomitant mitral valve or atrial septal defect surgery and the modified Cox–maze procedure. Sandoval N, et al. **Am J Cardiol** 1996 Mar 15;77(8):591–6

Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation [see comments] Blackshear JL, et al. **Ann Thorac Surg** 1996 Feb;61(2):755–9 (59 ref.) . Comment in: Ann Thorac Surg 1996 Feb;61(2):515.

Heart transplantation with bicaval anastomoses after a maze operation. Vogt PR, et al. **Ann Thorac Surg** 1996 Jan; 61(1):224–5

Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Edner M, et al. **Br Heart J** 1995 Sep;74(3):261–7

Electrophysiological mechanisms in successful radiofrequency catheter modification of atrioventricular junction for patients with medically refractory paroxysmal atrial fibrillation. Chen SA, et al. **Circulation** 1996 May 1;93(9):1690–701

Modified maze procedure for patients with atrial fibrillation undergoing simultaneous open heart surgery. Kosakai Y, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II359–64

Effect of slow pathway ablation on ventricular rate during atrial fibrillation. Dependence on electrophysiological properties of the fast pathway. Kreiner G, et al. **Circulation** 1996 Jan 15;93(2):277–83

Successful radiofrequency catheter ablation of right sided accessory pathways during sustained atrial fibrillation [see comments] Hindricks G, et al. **Eur Heart J** 1995 Jul; 16(7):967–70. Comment in: Eur Heart J 1995 Jul;16(7):876–7.

Ablation of accessory pathways during atrial fibrillation—adapting to change [editorial; comment] Rankin AC, et al. **Eur Heart J** 1995 Jul;16(7):876–7. Comment on: Eur Heart J 1995 Jul;16(7):967–70.

Effect of sequential radiofrequency ablation lesions at fast and slow atrioventricular nodal pathway positions in patients with paroxysmal atrial fibrillation. Garratt CJ, et al. **Heart** 1996 May;75(5):502–8

Successful atrial defibrillation with very–low–energy shocks by means of temporary epicardial wire electrodes. Cmolik BL, et al. **J Thorac Cardiovasc Surg** 1996 Feb;111(2):392–7; discussion 397–8

Atrial compartment surgery for chronic atrial fibrillation associated with congenital heart defects. Lin FY, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):231–7

Myocardial infarction after a maze procedure for idiopathic atrial fibrillation. Sueda T, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):549–50

Atrial septal defect [letter; comment] Cox JL, et al. **N Engl J Med** 1996 Jan 4;334(1):57. Comment on: N Engl J Med 1995 Aug 24;333(8):469–73.

The surgical cure of atrial flutter or fibrillation [letter] von Oppell UO, et al. **S Afr Med J** 1996 Mar;86(3):276–7

[Current status of heart surgery and surgical–therapy of atrial fibrillation in China (editorial)] Chen BT. **Chung Hua I Hsueh Tsa Chih** 1996 Mar;76(3):177–8 **(Chi)**

[Non–chemical treatment of atrial fibrillation] Klein GJ, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:49A–50A **(Fre)**

[Junctional arrhythmias in radiofrequency modification of the atrioventricular node] Schumacher B, et al. **Z Kardiol** 1995 Dec;84(12):977–85 (Eng. Abstr.) **(Ger)**

[Efficacy of left atrial only procedure for the treatment of chronic atrial fibrillation associated with mitral valve disease] Sueda T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):785–9 (Eng. Abstr.) **(Jpn)**

THERAPY

Quality of life and outcomes after radiofrequency His–bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Fitzpatrick AP, et al. **Am Heart J** 1996 Mar; 131(3):499–507

Effect of parenteral d–sotalol on transvenous atrial defibrillation threshold in a canine model of atrial fibrillation. Iskos D, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):116–9

Changes in transmitral and pulmonary venous flow velocity patterns after cardioversion of atrial fibrillation. Iuchi A, et al. **Am Heart J** 1996 Feb;131(2):270–5

Newer developments in the management of atrial fibrillation. Nattel S. **Am Heart J** 1995 Nov;130(5):1094–106 (169 ref.)

Recurrent atrial fibrillation [letter; comment] Sgarbossa EB. **Am Heart J** 1996 Jun;131(6):1233–4. Comment on: Am Heart J 1995 Jun;129(6):1127–32.

Nonpharmacologic strategies for treating atrial fibrillation. Lüderitz B, et al. **Am J Cardiol** 1996 Jan 25;77(3):45A–52A (53 ref.)

Clinical efficacy and safety of atrial defibrillation using biphasic shocks and current nonthoracotomy endocardial lead configurations [published erratum appears in Am J Cardiol 1995 Dec 15;76(17):1323] Saksena S, et al. **Am J Cardiol** 1995 Nov 1;76(12):913–21

Atrial fibrillation: maintenance of sinus rhythm versus rate control. Sopher SM, et al. **Am J Cardiol** 1996 Jan 25; 77(3):24A–37A (128 ref.)

Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Golzari H, et al. **Ann Intern Med** 1996 Aug 15;125(4):311–23 (205 ref.)

Physician practices regarding anticoagulation and cardioversion of atrial fibrillation. Schlicht JR, et al. **Arch Intern Med** 1996 Feb 12;156(3):290–4

Quality of service provision for anticoagulation in atrial fibrillation. Cardioversion should be attempted [letter; comment] Davis RC. **BMJ** 1996 Jan 6;312(7022):52. Comment on: BMJ 1995 Aug 26;311(7004):558–60.

ABC of atrial fibrillation. Cardioversion of atrial fibrillation [see comments] Lip GY, et al. **BMJ** 1996 Jan 13; 312(7023):112–5 (0 ref.). Comment in: BMJ 1996 May 18;312(7041):1300.

Correct technique is important in cardioversion of atrial fibrillation [letter; comment] Slade AK, et al. **BMJ** 1996 May 18;312(7041):1300. Comment on: BMJ 1996 Jan 13;312(7023):112–5.

Atrial fibrillation: the last challenge in interventional electrophysiology [editorial] Murgatroyd FD, et al. **Br Heart J** 1995 Sep;74(3):209–11

Atrial and ventricular function after cardioversion of atrial fibrillation. Xiong C, et al. **Br Heart J** 1995 Sep; 74(3):254–60

The implantable cardiac defibrillator. Kamalvand K, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):37–41 (16 ref.)

Atrial fibrillation and flutter in children and in young adults with congenital heart disease. Gow RM. **Can J Cardiol** 1996 Jan;12 Suppl A:45A–48A (40 ref.)

Pacing and atrial fibrillation. Kerr CR, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:36A–39A (31 ref.)

Atrial fibrillation—future directions. Kerr CR, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:58A–61A (30 ref.)

Nonpharmacological therapy of atrial fibrillation. Klein GJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:49A–50A (18 ref.)

Restoration of sinus rhythm in patients with atrial fibrillation. Talajic M, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:29A–35A (83 ref.)

Factors predicting maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation and flutter: a reanalysis with recently acquired data. Arnar DO, et al. **Cardiology** 1996 May–Jun;87(3):181–8

Restoration of mechanical atrial function after electrical cardioversion of chronic atrial fibrillation in patients after surgical treatment of mitral valve disease—hemodynamic effects and prognostic value of maintenance of sinus rhythm. Szyszka A, et al. **Cardiology** 1996 Mar–Apr; 87(2):98–103

Antithrombotic therapy in atrial fibrillation [letter] Manning WJ, et al. **Chest** 1996 Jun;109(6):1663–4

Pulmonary edema following electrical cardioversion of atrial fibrillation. Mayosi BM, et al. **Chest** 1996 Jan;109(1):278–80

Response of type I atrial fibrillation to atrial pacing in humans. Daoud EG, et al. **Circulation** 1996 Sep 1; 94(5):1036–40

Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Prystowsky EN, et al. **Circulation** 1996 Mar 15;93(6):1262–77 (155 ref.)

Alternations in atrial natriuretic peptide release after DC cardioversion of non–valvular chronic atrial fibrillation. Arakawa M, et al. **Eur Heart J** 1995 Jul;16(7):977–85

Future prospects of antiarrhythmic treatment based on experimental studies. Janse MJ. **Eur Heart J** 1995 Aug;16 Suppl G:2–6 (44 ref.)

Clinical, adrenergic and heart endocrine measures in chronic atrial fibrillation as predictors of conversion and maintenance of sinus rhythm after direct current cardioversion. Theodorakis GN, et al. **Eur Heart J** 1996 Apr;17(4):550–6

Low energy internal cardioversion of atrial fibrillation resistant to transthoracic shocks. Sopher SM, et al. **Heart** 1996 Jun;75(6):635–8

Plasma fibrinogen and fibrin D–dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Lip GY, et al. **Int J Cardiol** 1995 Oct;51(3):245–51

Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo–controlled study. Bianconi L, et al. **J Am Coll Cardiol** 1996 Sep;28(3):700–6

Transesophageal echocardiography versus oral anticoagulation before electrical cardioversion of atrial fibrillation: what about atrial clot size? [letter; comment] Letac B. **J Am Coll Cardiol** 1996 Jan;27(1):251–2. Comment on: J Am Coll Cardiol 1995 May;25(6):1354–61.

Atrial defibrillation using temporary epicardial defibrillation stainless steel wire electrodes: studies in the canine sterile pericarditis model. Ortiz J, et al. **J Am Coll Cardiol** 1995 Nov 1;26(5):1356–64

Prevention of recurrent atrial fibrillation with chronic dual–site right atrial pacing. Saksena S, et al. **J Am Coll Cardiol** 1996 Sep;28(3):687–94

Testing different biphasic waveforms and capacitances: effect on atrial defibrillation threshold and pain perception. Tomassoni G, et al. **J Am Coll Cardiol** 1996 Sep;28(3):695–9

Atrial fibrillation and flutter: maintaining stability of sinus rhythm versus ventricular rate control. Antman EM. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):962–71 (75 ref.)

Nonpharmacologic approaches to the treatment of atrial fibrillation and atrial flutter. Baker BM, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):972–8 (66 ref.)

Implantable atrial defibrillators [see comments] Hillsley RE, et al. **J Cardiovasc Electrophysiol** 1995 Aug;6(8):634–48 (107 ref.). Comment in: J Cardiovasc Electrophysiol 1995 Aug;6(8):649–51.

The automatic implantable defibrillator: it can be done, but should it? [comment] Ruffy R. **J Cardiovasc Electrophysiol** 1995 Aug;6(8):649–51. Comment on: J Cardiovasc Electrophysiol 1995 Aug;6(8):634–48.

The causes and management of atrial fibrillation. Rudd JH, et al. **J Clin Pharm Ther** 1996 Feb;21(1):37–43 (34 ref.)

Atrial fibrillation—new aspects on mechanism and treatment. Olsson SB. **J Intern Med** 1996 Jan;239(1):3–15 (43 ref.)

Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment. Blackshear JL, et al. **Mayo Clin Proc** 1996 Feb;71(2):150–60 (65 ref.)

Internal cardioversion in two patients with atrial fibrillation refractory to external cardioversion. Cooper RA, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):872–5

Low energy endocardial cardioversion of atrial arrhythmias in humans. Kalman JM, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1869–75

Cardioversion of atrial fibrillation. Lip GY. **Postgrad Med J** 1995 Aug;71(838):457–65 (68 ref.)

Options for managing atrial fibrillation. Schofield P. **Practitioner** 1995 Nov;239(1556):682–5

Transesophageal echocardiography–guided approach to cardioversion of atrial fibrillation. Leung DY, et al. **Prog Cardiovasc Dis** 1996 Jul–Aug;39(1):21–32 (67 ref.)

Atrial anatomy and function postcardioversion: insights from transthoracic and transesophageal echocardiography. Manning WJ, et al. **Prog Cardiovasc Dis** 1996 Jul–Aug; 39(1):33–46 (60 ref.)

Cardioversion of atrial fibrillation: how important is a long arrhythmia duration? Lip GY, et al. **Scott Med J** 1994 Jun; 39(3):78–9

[The treatment of chronic atrial fibrillation] Gosselink AT. **Tijdschr Gerontol Geriatr** 1995 Dec;26(6):259–63 (20 ref.) (Eng. Abstr.) **(Dut)**

[Protection systems of dual–chamber pacemakers against atrial arrhythmia] Deharo JC, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):465–70 (Eng. Abstr.) **(Fre)**

[Non–pharmacological treatment of atrial fibrillation] Kirkorian G. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:49–54 (22 ref.) (Eng. Abstr.) **(Fre)**

[Cardiac stimulation and atrial fibrillation] Kerr CR, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:34A–37A (31 ref.) **(Fre)**

[Reduction of atrial fibrillation. New concepts, new strategies] Lardoux H, et al. **Presse Med** 1995 Dec 9; 24(38):1820–3 (33 ref.) (Eng. Abstr.) **(Fre)**

[Urban & Vogel Workshop. Atrial fibrillation—decision aids for ambulatory therapy] **Herz** 1995 Dec;20 Suppl 3:1–16 **(Ger)**

[Cardioversion in atrial fibrillation. Results and complications in 1,152 prospective patients. Study Group of the Working Society of Leading Cardiologic Hospital Physicians] Tebbe U, et al. **Med Klin** 1995 Dec 15;90(12):681–7 (Eng. Abstr.) **(Ger)**

[Atrial fibrillation] Kappenberger L, et al. **Schweiz Rundsch Med Prax** 1996 Apr 30;85(18):600–3 (Eng. Abstr.) **(Ger)**

[The use of transesophageal echocardiography in cardioversion for atrial fibrillation (letter)] Galzerano D, et al. **G Ital Cardiol** 1995 Dec;25(12):1681–2 **(Ita)**

[Elective electric cardioversion of atrial fibrillation in adults with underlying heart disease: a proposal of optimizing the procedure] Sermasi S, et al. **G Ital Cardiol** 1995 Nov; 25(11):1399–406 (Eng. Abstr.) **(Ita)**

[The late results of electrical cardioversion in patients with a chronic form of atrial fibrillation] Vatutin NT, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):114–6 (Eng. Abstr.) **(Rus)**

[When, why, and how to treat atrial fibrillation] Thumala A. **Rev Med Chil** 1995 Jan;123(1):90–7 (44 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Echocardiographic findings associated with atrial fibrillation in 1,699 patients aged > 60 years. Aronow WS, et al. **Am J Cardiol** 1995 Dec 1;76(16):1191–2

Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Falcone RA, et al. **Am J Cardiol** 1996 Aug 15;78(4):435–9

Evaluation of left atrial appendage stasis in patients with atrial fibrillation using transesophageal echocardiography with an intravenous albumin–contrast agent. Kato H, et al. **Am J Cardiol** 1996 Aug 1;78(3):365–9

Shadows on the cave wall: the role of transesophageal echocardiography in atrial fibrillation [editorial; comment] Gersh BJ, et al. **Ann Intern Med** 1995 Dec 1;123(11):882–4 . Comment on: Ann Intern Med 1995 Dec 1;123(11):817–22.

ELAT study (embolism in left atrial thrombi): baseline clinical and echocardiographic data. **Cardiology** 1995; 86(6):457–63

F-amplitude, left atrial appendage velocity, and thromboembolic risk in nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Blackshear JL, et al. **Clin Cardiol** 1996 Apr;19(4):309–13

Assessment of posterior aortic wall motion using echocardiogram in patients with atrial fibrillation. Nobuoka S, et al. **Clin Cardiol** 1996 Mar;19(3):221–4

Stratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography and transesophageal echocardiography: the relative role of left atrial appendage function, mitral valve disease, and spontaneous echocardiographic contrast. Fatkin D, et al. **Prog Cardiovasc Dis** 1996 Jul–Aug;39(1):57–68

[The probability of an embolism in the conversion of atrial fibrillation] Mathey D. **Dtsch Med Wochenschr** 1995 Nov 10;120(45):1568 **(Ger)**

[Alcoholic cardiomyopathy in the initial phase: the earliness of an arrhythmic substrate in relation to Doppler echocardiographic changes] Doni F, et al. **Cardiologia** 1996 Jan;41(1):69–70 **(Ita)**

[The use of transesophageal echocardiography in cardioversion for atrial fibrillation (letter)] Galzerano D, et al. **G Ital Cardiol** 1995 Dec;25(12):1681–2 **(Ita)**

[The dynamic echocardiographic indices after restoration of the sinus rhythm in patients with the compensated type of atrial fibrillation] Denisiuk VI, et al. **Ter Arkh** 1995; 67(9):70–2 (Eng. Abstr.) **(Rus)**

VETERINARY

An echocardiographic study of atrial fibrillation in horses: before and after conversion to sinus rhythm. Marr CM, et al. **J Vet Intern Med** 1995 Sep–Oct;9(5):336–40

ATRIAL FLUTTER

Atrial fibrillation and atrial flutter. Cuddy TE, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:9A–11A (20 ref.)

COMPLICATIONS

The results of atrial flutter ablation in patients with and without a history of atrial fibrillation. Movsowitz C, et al. **Am J Cardiol** 1996 Jul 1;78(1):93–6

Interatrial block and atrial arrhythmias [letter; comment] Spodick DH. **Am J Cardiol** 1996 Feb 1;77(4):326. Comment on: Am J Cardiol 1995 Jul 1;76(1):47–50.

DIAGNOSIS

Atrial flutter in a man with mediastinal cancer. Hancock EW. **Hosp Pract (Off Ed)** 1996 Jan 15;31(1):15–6, 20

DRUG THERAPY

Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Aliot E, et al. **Am J Cardiol** 1996 Jan 25;77(3):66A–71A

Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Naccarelli GV, et al. **Am J Cardiol** 1996 Jan 25; 77(3):53A–59A

Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. Di Biasi P, et al. **Eur J Cardiothorac Surg** 1995;9(10):587–91

Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. Ellenbogen KA, et al. **J Am Coll Cardiol** 1996 Jul; 28(1):130–6

Use of intravenous dofetilide in atrial flutter with hemodynamic instability. Kuruma A, et al. **Jpn Circ J** 1996 Jan;60(1):67–9

Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. Kumar A. **South Med J** 1996 Aug; 89(8):779–85

[Programmed esophageal stimulation of the atrium and the long-term effects of anti-arrhythmia therapy of atrial fibrillation and flutter] Novotný E, et al. **Vnitr Lek** 1995 Sep;41(9):586–9 (Eng. Abstr.) **(Cze)**

ETIOLOGY

Hemodynamic predictors of atrial fibrillation or flutter after coronary artery bypass grafting. Frost L, et al. **Acta Anaesthesiol Scand** 1995 Jul;39(5):690–7

Atrial fibrillation and flutter in children and in young adults with congenital heart disease. Gow RM. **Can J Cardiol** 1996 Jan;12 Suppl A:45A–48A (40 ref.)

Improvement of ventricular function after atrioventricular junction ablation in a patient with atrial flutter after Mustard's operation. Tang AS, et al. **Can J Cardiol** 1996 May;12(5):523–5

Low vagal tone and supraventricular ectopic activity predict atrial fibrillation and flutter after coronary artery bypass grafting. Frost L, et al. **Eur Heart J** 1995 Jun;16(6):825–31

Atrial flutter after lateral tunnel construction in the modified Fontan operation: a canine model. Rodefeld MD, et al. **J Thorac Cardiovasc Surg** 1996 Mar;111(3):514–26

Atrial fibrillation and flutter after coronary artery bypass surgery: impact on recovery. Shinn JA. **Prog Cardiovasc Nurs** 1995 Summer;10(3):46–7

[Late supraventricular arrhythmia complicating Fontan or cavopulmonary type procedures. Apropos of 7 cases] Maragnès P, et al. **Arch Mal Coeur Vaiss** 1996 May; 89(5):605–9 (Eng. Abstr.) **(Fre)**

[Auricular fibrillation and flutter] Cuddy TE, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:6A–9A **(Fre)**

[Atrial fibrillation and flutter in children and young adults with congenital cardiopathies] Gow RM. **Can J Cardiol** 1996 Feb;12 Suppl A:43A–48A (40 ref.) **(Fre)**

PHYSIOPATHOLOGY

Characterization of left atrial appendage Doppler flow in atrial fibrillation and flutter by Fourier analysis. Grimm RA, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):286–96

Effects of atrial fibrillation and atrial flutter on the signal-averaged electrocardiogram. Fitzgerald DM, et al. **Am J Cardiol** 1996 Jan 15;77(2):205–9

Regional differences in transient outward current density and inhomogeneities of repolarization in rabbit right atrium. Yamashita T, et al. **Circulation** 1995 Nov 15;92(10):3061–9

Atrial ectopic activity and atrial fibrillation/flutter after coronary artery bypass surgery. A case-base study controlling for confounding from age, beta-blocker treatment, and time distance from operation. Frost L, et al. **Int J Cardiol** 1995 Jun 30;50(2):153–62

Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. Guo GB, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1083–9

Regional left atrial stasis during atrial fibrillation and flutter: determinants and relation to stroke. Shively BK, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1722–9

Pharmacologic alterations in human type I atrial flutter cycle length and monophasic action potential duration. Evidence of a fully excitable gap in the reentrant circuit. Stambler BS, et al. **J Am Coll Cardiol** 1996 Feb;27(2):453–61

Spontaneous onset of type I atrial flutter in patients. Waldo AI, et al. **J Am Coll Cardiol** 1996 Sep;28(3):707–12

Surgical technique and atrial arrhythmias after total cavopulmonary connection [letter; comment] Gandhi SK, et al. **J Thorac Cardiovasc Surg** 1996 Jun;111(6):1291–2. Comment on: J Thorac Cardiovasc Surg 1995 Sep;110(3):625–32.

Atrial flutter mapping and ablation. I. Studying atrial flutter mechanisms by mapping and entrainment. Cosio FG, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):841–53 (39 ref.)

[Atrial electrophysiological study of unexplained ischemic cerebrovascular disorders] Reeb T, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1855–61 (Eng. Abstr.) **(Fre)**

[Intermittent atrial fibrillation/flutter: contraindication for implantation of a dual chamber pacemaker?] Schuchert A, et al. **Z Kardiol** 1996 Apr;85(4):248–54 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Amiodarone for prevention of atrial fibrillation [letter; comment] van 't Hof AW, et al. **Am J Cardiol** 1996 Feb 1;77(4):327. Comment on: Am J Cardiol 1995 Jul 1;76(1):47–50.

Lateral tunnel suture line variation reduces atrial flutter after the modified Fontan operation. Gandhi SK, et al. **Ann Thorac Surg** 1996 May;61(5):1299–309

SURGERY

Ablation therapy of type I atrial flutter may eradicate paroxysmal atrial fibrillation. Katritsis D, et al. **Am J Cardiol** 1996 Aug 1;78(3):345–7

The results of atrial flutter ablation in patients with and without a history of atrial fibrillation. Movsowitz C, et al. **Am J Cardiol** 1996 Jul 1;78(1):93–6

Results of radiofrequency catheter ablation for atrial flutter. Saxon LA, et al. **Am J Cardiol** 1996 May 1;77(11):1014–6 (18 ref.)

Radiofrequency ablation of the His bundle for malignant atrial flutter after Mustard procedure for transposition of the great arteries. Vaksmann G, et al. **Am J Cardiol** 1996 Mar 15;77(8):669–70

Characterization and surgical ablation of atrial flutter after the classic Fontan repair. Gandhi SK, et al. **Ann Thorac Surg** 1996 Jun;61(6):1666–78; discussion 1678–9

Radiofrequency catheter ablation of atrial flutter circuits. Cosio FG, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:75–81

Electrophysiological effects of catheter ablation of inferior vena cava-tricuspid annulus isthmus in common atrial flutter. Cauchemez B, et al. **Circulation** 1996 Jan 15; 93(2):284–94

Radiofrequency catheter ablation of common atrial flutter: comparison of electrophysiologically guided focal ablation technique and linear ablation technique. Chen SA, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):860–8

Radiofrequency ablation of atrial flutter. Cosio FG, et al. **J Cardiovasc Electrophysiol** 1996 Jan;7(1):60–70

The surgical cure of atrial flutter or fibrillation [letter] von Oppell UO, et al. **S Afr Med J** 1996 Mar;86(3):276–7

[Practical experience of specific catheter ablation of atrial flutter in 110 patients] Fischer B, et al. **Arch Mal Coeur Vaiss** 1995 Feb;88(2):205–12 (Eng. Abstr.) **(Fre)**

[Ablation therapy of type I atrial flutter with radiofrequency] Cruz Filho FE, et al. **Arq Bras Cardiol** 1995 Apr; 64(4):323–30 (Eng. Abstr.) **(Por)**

[Auricular flutter associated with an interatrial septal aneurysm submitted to radiofrequency ablation] Araya Gómez V, et al. **Arch Inst Cardiol Mex** 1995 May–Jun; 65(3):245–54 (17 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Direct-current cardioversion for the conversion of atrial flutter. Chalasani P, et al. **Am J Cardiol** 1996 Mar 15; 77(8):658–60

Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. Doni F, et al. **Am J Cardiol** 1995 Dec 15;76(17):1243–6

Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Stambler BS, et al. **Am J Cardiol** 1996 May 1;77(11):960–6

Atrial fibrillation and flutter in children and in young adults with congenital heart disease. Gow RM. **Can J Cardiol** 1996 Jan;12 Suppl A:45A–48A (40 ref.)

Factors predicting maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation and flutter: a reanalysis with recently acquired data. Arnar DO, et al. **Cardiology** 1996 May–Jun;87(3):181–8

Atrial fibrillation and flutter: maintaining stability of sinus rhythm versus ventricular rate control. Antman EM. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):962–71 (75 ref.)

Nonpharmacologic approaches to the treatment of atrial fibrillation and atrial flutter. Baker BM, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):972–8 (66 ref.)

New approaches to treatment of atrial flutter and tachycardia. Lesh MD, et al. **J Cardiovasc Electrophysiol** 1996 Apr;7(4):368–81 (72 ref.)

Induced cardioversion of fetal flutter by artificial rupture of membranes at term. Hourvitz A, et al. **J Perinat Med** 1995;23(5):403–7

Inconsistent response to rapid atrial rhythms in a DDD pacemaker with the fallback feature. Johnson NJ. **Pacing Clin Electrophysiol** 1995 Jul;18(7):1458–62

Low energy endocardial cardioversion of atrial arrhythmias in humans. Kalman JM, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1869–75

[Protection systems of dual-chamber pacemakers against atrial arrhythmia] Deharo JC, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):465–70 (Eng. Abstr.) **(Fre)**

[Facilitating effect of propafenone pretreatment in the interruption of atrial flutter by transesophageal pacing]

Doni F, et al. **Cardiologia** 1996 Feb;41(2):135–40 (Eng. Abstr.) **(Ita)**

ATRIAL FUNCTION

Effects of atrial pacing site on rate-dependent AV nodal function in rabbit hearts. Amellal F, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H934–42

Regional vascular reserve in canine atria and ventricles during rest and exercise. Bauman RP, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1578–82

Spatiotemporal changes of Ca2+ during electrically evoked contractions in atrial and ventricular cells. Berlin JR. **Am J Physiol** 1995 Sep;269(3 Pt 2):H1165–70

Maximum speed of shortening and ATPase activity in atrial and ventricular myocardia of hyperthyroid rats. Bottinelli R, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C785–90

Effect of pregnancy on activation of central pathways following atrial distension. Deng Y, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):R552–6

Relationship of simultaneous atrial and ventricular pressures in stage 16–27 chick embryos. Hu N, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1359–62

Coronary flow stimulates auricular–ventricular transmission in the isolated perfused guinea pig heart. Rubio R, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1177–85

Endothelin acts as a paracrine regulator of stretch-induced atrial natriuretic peptide release. Skvorak JP, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1093–8

Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods. Yue L, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2157–68

Restoration of atrial function after atrial fibrillation of different etiological origins. Mattioli AV, et al. **Cardiology** 1996 May–Jun;87(3):205–11

Adrenergic modulation of ultrarapid delayed rectifier K+ current in human atrial myocytes. Li GR, et al. **Circ Res** 1996 May;78(5):903–15

Nonlinear analysis of epicardial atrial electrograms of electrically induced atrial fibrillation in man [see comments] Hoekstra BP, et al. **J Cardiovasc Electrophysiol** 1995 Jun; 6(6):419–40. Comment in: J Cardiovasc Electrophysiol 1995 Jun;6(6):441–2.

Computer simulation of the electrotonic modulation of pacemaker activity in the sinoatrial node by atrial muscle. Toyama J, et al. **J Electrocardiol** 1995;28 Suppl:212–5

Age-related characterization of atrial adenosine A1 receptor activation: direct effects on chronotropic and inotropic function in the Fischer 344 rat. Montamat SC, et al. **J Gerontol A Biol Sci Med Sci** 1996 Jul;51(4):B239–46

Thromboembolism associated with junctional escape rhythm and atrial standstill after orthotopic heart transplantation. Koller-Strametz J, et al. **J Heart Lung Transplant** 1995 Sep–Oct;14(5):999–1002

Missing atrial stimulus during DDD pacing. Barold SS. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1711–2

Atrial pressure and experimental atrial fibrillation. Sideris DA, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1679–85

DRUG EFFECTS

Effects of intravenous anesthetics on atrial wavelength and atrioventricular nodal conduction in guinea pig heart. Potential antidysrhythmic properties and clinical implications. Napolitano CA, et al. **Anesthesiology** 1996 Aug;85(2):393–402

Alpha 1-adrenergic stimulation of isolated rat atria results in discoordinate increases in natriuretic peptide secretion and gene expression and enhances Egr-1 and c-Myc expression. Bruneau BG, et al. **Endocrinology** 1996 Jan; 137(1):137–43

Effects of disopyramide on the atrial fibrillation threshold in the human atrium. Ishibashi K, et al. **Int J Cardiol** 1995 Nov 24;52(2):177–84

Erythropoietin stimulates atrial natriuretic peptide secretion from adult rat cardiac atrium. Porat O, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1162–8

PHYSIOLOGY

Modulation of pacemaker activity of sinoatrial node cells by electrical load imposed by an atrial cell model. Watanabe EI, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1735–42

Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Dubrey S, et al. **Br Heart J** 1995 Nov; 74(5):541–4

Left atrial appendage blood flow determined by transesophageal echocardiography in patients with complete atrioventricular block. Lin JM, et al. **Cardiology** 1996 Jan–Feb;87(1):71–5

F-amplitude, left atrial appendage velocity, and thromboembolic risk in nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Blackshear JL, et al. **Clin Cardiol** 1996 Apr;19(4):309–13

Effects of heart rate on flow velocity of the left atrial appendage in patients with nonvalvular atrial fibrillation. Noda T, et al. **Clin Cardiol** 1996 Apr;19(4):295–300

A new method for analysis of atrial activation during chronic atrial fibrillation in man. Holm M, et al. **IEEE Trans Biomed Eng** 1996 Feb;43(2):198–210

Exaggerated atrial repolarization waves as a predictor of false positive exercise tests in an unselected population. Sapin PM, et al. **J Electrocardiol** 1995 Oct;28(4):313–21

Assessment of right and left atrial function in patients with transplanted hearts with the use of magnetic resonance imaging. Lauerma K, et al. **J Heart Lung Transplant** 1996 Apr;15(4):360–7

Recipient-donor atrial synchronization benefits acute hemodynamics after orthotopic heart transplantation. McClurken JB, et al. **J Heart Lung Transplant** 1996 Apr; 15(4):368–70

Right and left atrial phasic volumetric function in mildly symptomatic dilated and hypertrophic cardiomyopathy: cine MR imaging assessment. Järvinen VM, et al. **Radiology** 1996 Feb;198(2):487–95

[Comparison of the infusion of acetylcholine into the artery of the sinoatrial node with the electric stimulation of cardiac parasympathetic nerves] Pagé PL, et al. **Ann Chir** 1995;49(8):719–27 (Eng. Abstr.) **(Fre)**

ATRIAL FUNCTION, LEFT

Characterization of left atrial appendage Doppler flow in atrial fibrillation and flutter by Fourier analysis. Grimm RA, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):286–96

Influence of left atrial function on Doppler transmitral and pulmonary venous flow patterns in dilated and hypertrophic cardiomyopathy: evaluation of left atrial appendage function by transesophageal echocardiography. Ito T, et al. **Am Heart J** 1996 Jan;131(1):122–30

Left atrial appendage function in patients with single-chamber ventricular pacing. Asanuma T, et al. **Am J Cardiol** 1995 Oct 15;76(11):840–2

Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Falcone RA, et al. **Am J Cardiol** 1996 Aug 15;78(4):435–9

Evaluation of left atrial appendage stasis in patients with atrial fibrillation using transesophageal echocardiography with an intravenous albumin–contrast agent. Kato H, et al. **Am J Cardiol** 1996 Aug 1;78(3):365–9

Left atrial mechanical function after cardioversion [letter; comment] Macieira-Coelho E. **Am J Cardiol** 1996 Feb 1; 77(4):326. Comment on: Am J Cardiol 1995 Mar 15;75(8):624–6.

Assessment of mean left atrial pressure from the left ventricular pressure tracing in patients with cardiomyopathies. Yamamoto K, et al. **Am J Cardiol** 1996 Jul 1;78(1):107–10

Left atrial size and function: assessment using echocardiographic automatic boundary detection. Clarkson PB, et al. **Br Heart J** 1995 Dec;74(6):664–70

Standard orthotopic heart transplantation versus total orthotopic heart transplantation. A transesophageal echocardiography study of the incidence of left atrial thrombosis. Derumeaux G, et al. **Circulation** 1995 Nov 1; 92(9 Suppl):II196–201

Left atrial size—a risk factor for left atrial thrombi in mitral stenosis. Conradie C, et al. **Clin Cardiol** 1995 Sep; 18(9):518–20

Comparison of leads V4R and V1 in the electrocardiographic diagnosis of left atrial enlargement and right ventricular hypertrophy in mitral stenosis [letter] Mittal B, et al. **Indian Heart J** 1995 Jul–Aug;47(4):412

Left atrial mechanical function in the healthy elderly: new insights from a combined assessment of changes in atrial volume and transmitral flow velocity. Triposkiadis F, et al. **J Am Soc Echocardiogr** 1995 Nov–Dec;8(6):801–9

Continuous direct left atrial pressure monitoring during closed mitral commissurotomy [see comments] Neema PK, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):786–7. Comment in: J Cardiothorac Vasc Anesth 1995 Dec;9(6):772–4.

Left atrial performance indices in chronic mitral valve disease. Boudoulas H, et al. **J Heart Valve Dis** 1995 Oct; 4 Suppl 2:S242–7; discussion S248

Assessment of left atrial pressure and volume changes during atrial systole with transesophageal pulsed Doppler echocardiography of transmitral and pulmonary venous flow velocities. Oki T, et al. **Jpn Heart J** 1996 May; 37(3):333–42

A simplified method for the determination of left atrial size and function using cine magnetic resonance imaging. Järvinen VM, et al. **Magn Reson Imaging** 1996;14(3):215–26

An irregularly irregular rhythm. Barillà F, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):861–2

Stratification of thromboembolic risk of atrial fibrillation by transthoracic echocardiography and transesophageal echocardiography: the relative role of left atrial appendage function, mitral valve disease, and spontaneous echocardiographic contrast. Fatkin D, et al. **Prog Cardiovasc Dis** 1996 Jul–Aug;39(1):57–68

[Echocardiographic evaluation of left atrial emptying index in hypertension] Qirko S. **Arch Mal Coeur Vaiss** 1995 Aug; 88(8):1105–9 (Eng. Abstr.) **(Fre)**

[Recent morphofunctional findings on the left atrium: their relations to thromboembolic risk] Zeppellini R, et al. **G Ital Cardiol** 1995 Aug;25(8):1055–65 (57 ref.) (Eng. Abstr.) **(Ita)**

[Effects of erythrocytopheresis on the state of the left heart in patients with polycythemia vera: echocardiographic findings] Bessmel'tsev SS, et al. **Klin Med (Mosk)** 1995; 73(4):80–2 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Contribution of atrial reservoir function to ventricular filling in hypertensive patients. Effects of nifedipine administration. Nagano R, et al. **Hypertension** 1995 Nov; 26(5):815–9

S-(–)-ET 126: a potent and selective M1 antagonist in vitro and in vivo. Ghelardini C, et al. **Life Sci** 1996; 58(12):991–1000

PHYSIOLOGY

Changes in transmitral and pulmonary venous flow velocity patterns after cardioversion of atrial fibrillation. Iuchi A, et al. **Am Heart J** 1996 Feb;131(2):270–5

Response of left atrial systolic function to handgrip in normal subjects. Trikas A, et al. **Am Heart J** 1995 Dec; 130(6):1303–5

Non-invasive detection of left atrial mechanical failure in patients with left ventricular disease. Wang K, et al. **Br Heart J** 1995 Nov;74(5):536–40

Left atrial paralysis after mitral valve replacement [letter] Tomcsányi J, et al. **Eur Heart J** 1995 Dec;16(12):2008–9

Impaired left atrial function after heart transplantation: disparate contribution of donor and recipient atrial components studied on-line with quantitative echocardiography. Cresci S, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):647–53

Left atrial dysfunction after orthotopic heart transplantation [letter] Starling RC, et al. **J Heart Lung Transplant** 1996 Apr;15(4):431–2

Quantification of the voltage-response relationship between punctate and field electrical stimulation and the function of isolated rat left atria and papillary muscles. Olson RD, et al. **J Pharmacol Toxicol Methods** 1995 Dec;34(4):225–30

Noninvasive measurement of left atrial functions using transesophageal echocardiography. Nakao T, et al. **Jpn Heart J** 1996 Mar;37(2):227–38

Effect of blood pH on pulmonary artery pressure, left atrial pressure and fluid filtration rate in isolated rabbit lung. Pinto-Plata VM, et al. **Rev Esp Fisiol** 1995 Sep; 51(3):117–23

[Stratification of the thromboembolic risk in patients with non-rheumatic atrial fibrillation: assessment of left atrial dysfunction] Scardi S, et al. **G Ital Cardiol** 1996 Mar; 26(3):273–85 (Eng. Abstr.) **(Ita)**

ATRIAL FUNCTION, RIGHT

Relation of mean right atrial pressure to echocardiographic and Doppler parameters of right atrial and right ventricular function. Nagueh SF, et al. **Circulation** 1996 Mar 15; 93(6):1160–9

Effects of atrioventricular intervals on right atrial monophasic action potential duration during pacing or reciprocating tachycardia. Kanda A, et al. **Jpn Heart J** 1995 Jul;36(4):439–50

An irregularly irregular rhythm. Barillà F, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):861–2

[Hemodynamics of right circulation in ewes: normal values] Martinot S, et al. **Vet Res** 1996;27(1):63–9 (Eng. Abstr.) **(Fre)**

[Thromboendarterectomy in chronic thromboembolic pulmonary hypertension. Hemodynamics and right-heart function over the long term] Mayer E, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):9–15 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Effects of morphine on atrial preparations obtained from nonfailing and failing human hearts. Llobel F, et al. **Br J Anaesth** 1996 Jan;76(1):106–10

Labelling with [125I]-SB 207710 of a small 5-HT4 receptor population in piglet right atrium: functional relevance. Kaumann AJ, et al. **Br J Pharmacol** 1995 Jul;115(6):933–6

Reactivity of isolated human right atria to norepinephrine in various disease states. Golba KS, et al. **J Physiol Pharmacol** 1995 Sep;46(3):323–8

PHYSIOLOGY

Further evidence from functional studies for somatostatin receptor heterogeneity in guinea-pig isolated ileum, vas deferens and right atrium. Feniuk W, et al. **Br J Pharmacol** 1995 Jul;115(6):975–80

Influence of negative intrathoracic pressure on right atrial and systemic venous dynamics. Virolainen J, et al. **Eur Heart J** 1995 Sep;16(9):1293–9

ATRIAL NATRIURETIC FACTOR

see related
RECEPTORS, ATRIAL NATRIURETIC FACTOR

[Histocytochemical and functional aspects on the "brain-vascular peptides"] Yamada H, et al. **Kaibogaku Zasshi** 1995 Oct;70(5):422–35 (108 ref.) (Eng. Abstr.) **(Jpn)**

[Atrial natriuretic factor] Tarverdieva GA. **Klin Med (Mosk)** 1996;74(1):12–4 (32 ref.) **(Rus)**

ADMINISTRATION & DOSAGE

Mechanisms of action of atrial natriuretic factor and C-type natriuretic peptide. Amin J, et al. **Hypertension** 1996 Mar; 27(3 Pt 2):684-7

Atrial natriuretic peptide increases creatinine clearance and reduces need for dialysis in patients with established acute renal failure. Conger JD, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):71-5

Effects of high dose atrial natriuretic peptide on renal haemodynamics, sodium handling and hormones in cirrhotic patients with and without ascites. Jespersen B, et al. **Scand J Clin Lab Invest** 1995 Jul;55(4):273-87

[A study on combined treatment with ANP and dopamine in acute renal failure in rats] Chen X, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):609-11 (Eng. Abstr.) **(Chi)**

ANALYSIS

The volume protective natriuretic peptide system in the inner ear. Comparison between vestibular and cochlear compartments. Meyer zum Gottesberge A, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:170-3

Detection of immunoreactive atrial and brain natriuretic peptides in the equine atrium. Mifune H, et al. **Anat Embryol (Berl)** 1995 Aug;192(2):117-21

Molecular forms of atrial natriuretic peptide in atria and plasma from fetal and adult female rats. Deloof S, et al. **Biol Neonate** 1995;68(4):292-300

Endothelin-1 and angiotensin II receptors in cells from rat hypertrophied heart. Receptor regulation and intracellular Ca2+ modulation. Fareh J, et al. **Circ Res** 1996 Feb; 78(2):302-11

Changes in myocardial and circulating atrial natriuretic peptide following thorax irradiation in rat. Persons CC, et al. **Int J Radiat Biol** 1996 Jul;70(1):61-8

Immunoreactive endothelin in the human kidney: comparison with natriuretic peptides. Takahashi K, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S510-2

ANTAGONISTS & INHIBITORS

Renal effects of high-dose natriuretic peptide receptor blockade in rats with congestive heart failure. Zhang PL, et al. **Circ Res** 1995 Dec;77(6):1240-5

Inhibition of atrial natriuretic peptide excretory action by bradykinin. Boric MP, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1167-72

A fragment of human kininogen containing bradykinin blunts the diuretic effect of atrial natriuretic peptide. Croxatto HR, et al. **Proc Soc Exp Biol Med** 1996 Jun;212(2):128-34

BIOSYNTHESIS

Linear correlation between bacterial overexpression of recombinant peptides and cell light scatter. Lavergne-Mazeau F, et al. **Appl Environ Microbiol** 1996 Aug;62(8):3042-6

Expression of atrial natriuretic peptide in cultured adult cardiac ventricular muscle cells as studied by immunofluorescence microscopy. Nag AC, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Sep;41(6):813-25

Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Ogawa T, et al. **Circulation** 1996 Jun 1;93(11):2059-67

The sites of gene expression of atrial, brain, and C-type natriuretic peptides in mouse fetal development: temporal changes in embryos and placenta. Cameron VA, et al. **Endocrinology** 1996 Mar;137(3):817-24

Selective regulation of the atrial natriuretic peptide gene by individual components of the activator protein-1 complex. Kovacic-Milivojevic B, et al. **Endocrinology** 1996 Mar; 137(3):1108-17

Messenger RNAs encoding the natriuretic peptides and their receptors are expressed in the eye. Fernandez-Durango R, et al. **Exp Eye Res** 1995 Dec;61(6):723-9

Immunohistochemical research on the atrial natriuretic factor (ANF) in rat atrioventricular valves. Valentino B, et al. **Ital J Anat Embryol** 1995 Apr-Jun;100(2):65-73

Atrial natriuretic factor production by the human placenta. Lim AT, et al. **J Clin Endocrinol Metab** 1995 Oct; 80(10):3091-3

Influence of fibroblast growth factor (bFGF) and insulin-like growth factor (IGF-I) on cytoskeletal and contractile structures and on atrial natriuretic factor (ANF) expression in adult rat ventricular cardiomyocytes in culture. Harder BA, et al. **J Mol Cell Cardiol** 1996 Jan;28(1):19-31

BLOOD

Plasma cyclic GMP concentrations and their relationship with changes of blood pressure levels in pre-eclampsia. Schneider F, et al. **Acta Obstet Gynecol Scand** 1996 Jan; 75(1):40-4

Plasma atrial natriuretic peptide in standardbred and Finnhorse trotters during and after exercise. Kokkonen UM, et al. **Acta Physiol Scand** 1995 May;154(1):51-8

Effects of different types of anti-aging dietary restrictions on age-related atrial natriuretic factor changes: an immunochemical and ultrastructural study. Cavallini G, et al. **Aging (Milano)** 1995 Apr;7(2):117-22

Acute changes in atrial natriuretic peptide, insulin-like growth factor-1, and lactate levels during left anterior descending coronary artery angioplasty. Gill JS, et al. **Am Heart J** 1995 Oct;130(4):717-22

Atrial natriuretic peptide release during myocardial ischemia induced by percutaneous transluminal coronary angioplasty. Nigri A, et al. **Am Heart J** 1996 Sep; 132(3):698-9

Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure. Yoshikawa T, et al. **Am Heart J** 1996 Feb;131(2):329-36

Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Darbar D, et al. **Am J Cardiol** 1996 Aug 1;78(3):284-7

Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Davidson NC, et al. **Am J Cardiol** 1996 Apr 15;77(10):828-31

Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. Dickstein K, et al. **Am J Cardiol** 1995 Oct 1;76(10):679-83

Atrial natriuretic peptide and nitric oxide in children with pulmonary hypertension after surgical repair of congenital heart disease. Ivy DD, et al. **Am J Cardiol** 1996 Jan 1; 77(1):102-5

Congestive heart failure and atrial natriuretic factor: a room for endothelins? [letter] Tuzcu V, et al. **Am J Cardiol** 1996 Jul 1;78(1):128-9

Influence of humoral and neurohormonal factors on cardiovascular hypertrophy in untreated essential hypertensives. Schroeder AP, et al. **Am J Hypertens** 1996 Mar;9(3):207-15

Catecholamines, renin-angiotensin-aldosterone system, and atrial natriuretic peptide at rest and during submaximal exercise in patients with congestive heart failure. Kinugawa T, et al. **Am J Med Sci** 1996 Sep;312(3):110-7

Hemodynamic and hormonal responses to atrial distension in the ovine fetus. Jaekle RK, et al. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 1):694-701

Hemodynamic control of atrial natriuretic peptide plasma levels in neonatal respiratory distress syndrome. Kääpä P, et al. **Am J Perinatol** 1995 Jul;12(4):235-9

Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men. Hunt PJ, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1397-403

Forearm vasodilator mechanisms during mental stress: possible roles for epinephrine and ANP. Lindqvist M, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):E393-9

Effect of intravenous fluid preload on vasoactive peptide secretion during Caesarean section under spinal anaesthesia [see comments] Pouta AM, et al. **Anaesthesia** 1996 Feb; 51(2):128-32. Comment in: Anaesthesia 1996 Jun;51(6):609.

Perioperative plasma concentrations of endothelin and natriuretic peptides in children undergoing living-related liver transplantation. Shirakami G, et al. **Anesth Analg** 1996 Feb;82(2):235-40

Molecular forms of atrial natriuretic peptide in atria and plasma from fetal and adult female rats. Deloof S, et al. **Biol Neonate** 1995;68(4):292-300

Increased plasma atrial natriuretic peptide and endothelin concentrations after surgery in patients with esophageal and gastric cancer. Itoh K, et al. **Bull Tokyo Med Dent Univ** 1996 Jun;43(2):45-51

Brain and atrial natriuretic peptides in patients with ischemic heart disease with and without heart failure. Arad M, et al. **Cardiology** 1996 Jan-Feb;87(1):12-7

Plasma concentrations of atrial, brain, and C-type natriuretic peptides and endothelin-1 in patients with chronic respiratory diseases. Ando T, et al. **Chest** 1996 Aug; 110(2):462-8

Right ventricular function and plasma atrial natriuretic peptide levels during fiberbronchoscopic alveolar lavage in critically ill, mechanically ventilated patients. Bein T, et al. **Chest** 1995 Oct;108(4):1030-5

Volemic status influences the response of plasma atrial natriuretic factor to positive airway pressure. Beuret P, et al. **Chest** 1996 May;109(5):1313-9

Changes of plasma endothelin and atrial natriuretic peptide during the onset and after termination of paroxysmal supraventricular tachycardia. Li C, et al. **Chin Med Sci J** 1995 Sep;10(3):161-4

Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure. Sothern RB, et al. **Chronobiol Int** 1995 Apr;12(2):106-20

Functional explanation for increased atrial natriuretic peptide in systemic sclerosis. Kazzam E, et al. **Clin Cardiol** 1995 Nov;18(11):647-52

The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in normotensive and hypertensive rats. Nomura N, et al. **Clin Exp Hypertens** 1995 Nov;17(8):1219-31

The mechanisms of the renal effects of neutral endopeptidase inhibitor in rats. Ura N, et al. **Clin Exp Hypertens** 1995 Nov;17(8):1183-96

Do different opioid analgetics affect the plasma concentration of atrial natriuretic factor differently in man? [letter] Pedersen CB, et al. **Clin Nephrol** 1996 Feb;45(2):134-5

Fluid, ionic and hormonal changes induced by high salt intake in salt-sensitive and salt-resistant hypertensive patients. de la Sierra A, et al. **Clin Sci (Colch)** 1996 Aug; 91(2):155-61

Epoprostenol increases plasma level of atrial natriuretic peptide in humans. Nielsen CB, et al. **Clin Sci (Colch)** 1996 Feb;90(2):87-9

Nitric oxide synthase inhibition during experimental sepsis improves renal excretory function in the presence of chronically increased atrial natriuretic peptide. Hinder F, et al. **Crit Care Med** 1996 Jan;24(1):131-6

Recurrent seizures alter renal function and plasma atrial natriuretic peptide levels in rats. Perrone BL, et al. **Epilepsia** 1995 Jul;36(7):649-57

Alternations in atrial natriuretic peptide release after DC cardioversion of non-valvular chronic atrial fibrillation. Arakawa M, et al. **Eur Heart J** 1995 Jul;16(7):977-85

Influence of alcohol on the hydromineral hormone responses to exercise in a warm environment. Saini J, et al. **Eur J Appl Physiol** 1995;72(1-2):32-6

The dihydropyridine calcium channel blocker BAY t 7207 attenuates the exercise induced increase in plasma ANF and cyclic GMP in patients with mildly impaired left ventricular function. Kentsch M, et al. **Eur J Clin Pharmacol** 1995;49(3):177-82

The concentration of plasma atrial natriuretic peptide in normotensive and preeclamptic pregnancies. Senöz S, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):173-7

Atrial natriuretic peptide (ANP) in preeclampsia-like syndrome in a rat model. Casper FW, et al. **Exp Clin Endocrinol Diabetes** 1995;103(5):292-6

Disturbance of peripheral microvascular fluid permeability by the onset of atrioventricular asynchrony in patients with programmable pacemakers. Mahy IR, et al. **Heart** 1996 May;75(5):509-12

Twenty four hour variation in plasma atrial natriuretic factor during VVI and DDD pacing. Vardas PE, et al. **Heart** 1996 Jun;75(6):620-2

Atrial natriuretic peptide, oestradiol and progesterone in women undergoing spontaneous and gonadotrophin-stimulated ovulatory cycles. Yeko TR, et al. **Hum Reprod** 1995 Nov;10(11):2872-4

Angiotensin II-induced hypertension: effects on central and peripheral atrial natriuretic peptide. Bahner U, et al. **Hypertens Res** 1995 Dec;18(4):279-84

Reduced natriuretic response to increased renal interstitial hydrostatic pressure in Dahl salt-sensitive rats during volume expansion. Nakamura T, et al. **Hypertens Res** 1995 Dec;18(4):313-7

Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Nishikimi T, et al. **Hypertension** 1996 Jul;28(1):22-30

Renal extraction of atrial natriuretic peptide in hypertensive patients with or without renal artery stenosis. Schreij G, et al. **Hypertension** 1996 Jun;27(6):1254-8

Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt. Willenbrock R, et al. **Hypertension** 1996 Jun;27(6):1259-66

beta-blockade, atrial natriuretic peptide and exercise. Kantola I, et al. **Int J Clin Pharmacol Ther** 1996 Jan;34(1):12-6

Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators. Hall C, et al. **J Am Coll Cardiol** 1995 Nov 15;26(6):1452-6

Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. Pacher R, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):633-41

Hormonal changes in normal and polycythemic high-altitude natives. Antezana AM, et al. **J Appl Physiol** 1995 Sep; 79(3):795-800

Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease. Cohen N, et al. **J Clin Endocrinol Metab** 1996 Apr; 81(4):1411-5

Atrial natriuretic factor and digoxin-like immunoreactive factor in diabetic patients: their interrelation and the influence of the autonomic nervous system. Straub RH, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3385-9

Orthostatic hypotension and vasodilatory peptides in bronchial carcinoma. Gosney MA, et al. **J Clin Pathol** 1995 Dec;48(12):1102-5

Plasma levels and molecular forms of proatrial natriuretic peptides in healthy subjects and in patients with congestive heart failure. Azizi C, et al. **J Endocrinol** 1996 Jan; 148(1):51-7

Effects of octreotide on cardiovascular hormones and haemodynamics in conscious dogs. Donckier J, et al. **J Endocrinol Invest** 1996 Feb;19(2):106-13

Atrial natriuretic peptide levels in the elderly: differentiating normal aging changes from disease. Davis KM, et al. **J Gerontol A Biol Sci Med Sci** 1996 May;51(3):M95-101

Second and early third trimester atrial natriuretic peptide (ANP) levels in pregnancies subsequently complicated by hypertension. Chung TK, et al. **J Obstet Gynaecol** 1995 Oct;21(5):515-20

Elevated arginine vasopressin and lowered atrial natriuretic factor associated with hypertension in coarctation of the aorta. Stewart JM, et al. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 1):900-8

Changes in the E/A ratio induced by handgrip-exercise are related to changes in the plasma atrial natriuretic peptide level, but not to changes in brain natriuretic peptide in mild essential hypertension. Tomiyama H, et al. **Jpn Circ J** 1995 Sep;59(9):617-23

Plasma atrial natriuretic peptide levels in rabbits with alloxan monohydrate-induced diabetes mellitus. Yeğen E, et al. **Jpn Heart J** 1995 Nov;36(6):789-95

Plasma concentrations of atrial natriuretic peptide in cardioembolic stroke with atrial fibrillation. Sato Y, et al. **Kurume Med J** 1995;42(2):71–7

Role of atrial natriuretic peptide in disturbed water and electrolyte metabolism of guinea pigs infected with Pichinde virus. Guo ZM, et al. **Lab Anim Sci** 1995 Oct; 45(5):484–92

Atrial natriuretic peptide and blood pressure [letter; comment] Flickinger AL, et al. **Mayo Clin Proc** 1996 Apr; 71(4):424. Comment on: Mayo Clin Proc 1995 Oct;70(10):1015–7.

Atrial natriuretic peptide and blood pressure in a population-based sample [see comments] Flickinger AL, et al. **Mayo Clin Proc** 1995 Oct;70(10):932–8. Comment in: Mayo Clin Proc 1995 Oct;70(10):1015–7.

The elusive role of atrial natriuretic peptide in hypertension [editorial; comment] [see comments] Oparil S. **Mayo Clin Proc** 1995 Oct;70(10):1015–7. Comment on: Mayo Clin Proc 1995 Oct;70(10):932–8. Comment in: Mayo Clin Proc 1996 Apr;71(4):424.

Atrial natriuretic peptide in childhood nephrotic syndrome [letter] Saatçi U, et al. **Nephrol Dial Transplant** 1996 May; 11(5):905

Acute and chronic changes in atrial natriuretic factor induced by ventricular pacing: a self controlled clinical trial. Cabello JB, et al. **Pacing Clin Electrophysiol** 1996 May; 19(5):815–21

Plasma atrial natriuretic factor levels, impaired myocardial contractility and pain intensity in uncomplicated acute myocardial infarction. Fontana F, et al. **Pain** 1995 Aug; 62(2):213–8

Plasma atrial natriuretic peptide during spontaneous bronchoconstriction in asthmatics. Robichaud A, et al. **Peptides** 1995;16(4):653–6

Changes of plasma atrial and brain natriuretic peptide levels during hemodialysis. Ishikura F, et al. **Ren Fail** 1996 Mar; 18(2):261–70

Plasma concentrations of natriuretic peptides in patients on hemodialysis. Takahashi M, et al. **Res Commun Mol Pathol Pharmacol** 1996 Apr;92(1):19–30

Proatrial natriuretic polypeptide (31–67) in healthy individuals: day-to-day variation and influence of sex and age. Hansen JB, et al. **Scand J Clin Lab Invest** 1995 Aug; 55(5):447–52

Ambulatory 24-hour blood pressure and peptide balance in hemodialysis patients. Viidas U, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):259–63

[Are atrial natriuretic factor, renin, aldosterone and catecholamines modified during general anesthesia for total hip arthroplasty?] Hachimi A, et al. **Cah Anesthesiol** 1995; 43(5):449–53 **(Fre)**

[Atrial natriuretic factor and brain natriuretic peptide. Variations in elderly subjects with heart failure] Tissandier O, et al. **Presse Med** 1995 Dec 9;24(38):1837–41 (27 ref.) (Eng. Abstr.) **(Fre)**

[Atrial natriuretic peptide in normotensive pregnancy: concentrations in physical stress, pre- and postpartal and in the umbilical cord] Günter HH, et al. **Zentralbl Gynakol** 1995;117(11):592–7 (Eng. Abstr.) **(Ger)**

[Atrial natriuretic factor (ANF) and chronic obstructive bronchopneumonia (COBP): the effects of theophylline treatment] Bartolucci L, et al. **Clin Ter** 1996 Apr; 147(4):173–9 (Eng. Abstr.) **(Ita)**

[Calcitonin gene-related peptide and human atrial natriuretic hormone levels in response to cardiac operation under high dose fentanyl anesthesia] Terazawa E, et al. **Masui** 1995 Sep;44(9):1202–7 (Eng. Abstr.) **(Jpn)**

[Participation of atrial natriuretic peptide (hANP) levels and arginine vasopressin (AVP) in aged persons with nocturia] Kikuchi Y. **Nippon Hinyokika Gakkai Zasshi** 1995 Nov; 86(11):1651–9 (Eng. Abstr.) **(Jpn)**

[Relationship between vasoactive substances and changes in blood pressure during hemodialysis] Takahashi M. **Nippon Jinzo Gakkai Shi** 1995 Oct;37(10):549–57 (Eng. Abstr.) **(Jpn)**

[Human atrial natriuretic peptide (hANP), human brain natriuretic peptide (hBNP)] Tsujino M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:737–40 (8 ref.) **(Jpn)**

[The effects of upper gastrointestinal endoscopy on the circulatory system of elderly patients as evaluated by measuring hANP and hBNP] Shimamoto C, et al. **Nippon Ronen Igakkai Zasshi** 1995 Aug–Sep;32(8–9):581–6 (Eng. Abstr.) **(Jpn)**

[Pro-atrial natriuretic factor is predictive for the clinical status of patients with heart failure] Dickstein K, et al. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1562–6 (Eng. Abstr.) **(Nor)**

[Can heart failure be diagnosed by hormone tests?] Smiseth OA. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1560–1 **(Nor)**

[Secretion of atrial natriuretic peptide and vasopressin during hemodialysis in patients with chronic renal failure] Grzeszczak W, et al. **Pol Arch Med Wewn** 1995 Sep; 94(3):195–207 (Eng. Abstr.) **(Pol)**

[Level of atrial natriuretic peptide (ANP) in plasma of patients with chronic renal failure during hemodialysis] Grzeszczak W, et al. **Pol Arch Med Wewn** 1995 Feb; 93(2):107–13 (Eng. Abstr.) **(Pol)**

[Effects of changes in central hemodynamics and hormonal systems of its regulation on the etiology of portal hypertension complications in patients with liver cirrhosis] Tsykin DB, et al. **Klin Med (Mosk)** 1995;73(4):99 **(Rus)**

CHEMICAL SYNTHESIS

Synthesis of human C-type natriuretic peptide 22 using chlorotrityl resin and tetrafluoroboric acid deprotection. Fujiwara Y, et al. **Chem Pharm Bull (Tokyo)** 1996 Jul; 44(7):1326–31

CHEMISTRY

Stability of plasma concentrations of N and C terminal atrial natriuretic peptides at room temperature. Cleland JG, et al. **Heart** 1996 Apr;75(4):410–3

Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats. Jin H, et al. **J Clin Invest** 1996 Aug 15;98(4):969–76

Minimization of a polypeptide hormone. Li B, et al. **Science** 1995 Dec 8;270(5242):1657–60

DEFICIENCY

Blood pressure and fluid-electrolyte balance in mice with reduced or absent ANP. John SW, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R109–14

DRUG EFFECTS

Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Sanderson JE, et al. **Br Heart J** 1995 Nov;74(5):502–7

Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure. Kimmelstiel CD, et al. **Cardiology** 1996 Jan–Feb; 87(1):46–53

GENETICS

Gene expression of A- and B-type natriuretic peptides in response to acute ethanol ingestion. Wigle DA, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1317–20

Functional characterization of a 1,25-dihydroxyvitamin D3 receptor binding site found in the rat atrial natriuretic factor promoter. Kahlen JP, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):882–6

Long-PCR of the ANP gene and PCR-SSCP analysis of the proximal promoter region of the ANP gene in patients with aldosterone producing adenoma. Tunny TJ, et al. **Biochem Biophys Res Commun** 1995 Oct 4;215(1):172–8

The atrial natriuretic peptide gene in patients with familial primary open-angle glaucoma. Tunny TJ, et al. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):221–5

Stimulation of atrial natriuretic factor promoter activity by Src and Ras in cultured neonatal rat ventricular myocytes. Gillespie-Brown J, et al. **Biochem Soc Trans** 1995 Aug; 23(3):445S

Involvement of multiple cis elements in basal- and alpha-adrenergic agonist-inducible atrial natriuretic factor transcription. Roles for serum response elements and an SP-1-like element. Sprenkle AB, et al. **Circ Res** 1995 Dec; 77(6):1060–9

Alteration of atrial natriuretic peptide and brain natriuretic peptide gene expression associated with progression and regression of cardiac hypertrophy in renovascular hypertensive rats. Kawakami H, et al. **Clin Sci (Colch)** 1996 Mar;90(3):197–204

Alpha 1-adrenergic stimulation of isolated rat atria results in discoordinate increases in natriuretic peptide secretion and gene expression and enhances Egr-1 and c-Myc expression. Bruneau BG, et al. **Endocrinology** 1996 Jan; 137(1):137–43

Glucocorticoid stimulation of pro-ANF mRNA expression of adult rat hypothalamic neurons in culture: a cAMP-dependent effect. Wang G, et al. **Endocrinology** 1996 Jan;137(1):379–82

Alterations in atrial natriuretic peptide gene expression during endurance training in rats. Azizi C, et al. **Eur J Endocrinol** 1995 Sep;133(3):361–5

Atrial natriuretic peptide gene expression within invertebrate hearts. Poulos JE, et al. **Gen Comp Endocrinol** 1995 Oct; 100(1):61–8

An E-box motif conveys inhibitory activity on the atrial natriuretic peptide gene. Garami M, et al. **Hypertension** 1996 Aug;28(2):315–9

Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Lin KF, et al. **Hypertension** 1995 Dec;26(6 Pt 1):847–53

Renal artery stenosis rapidly enhances atrial natriuretic peptide gene expression. Wolf K, et al. **Hypertension** 1995 Dec;26(6 Pt 1):1011–7

Opposite actions of transforming growth factor-beta 1 on the gene expression of atrial natriuretic peptide biological and clearance receptors in a murine thymic stromal cell line. Agui T, et al. **J Biochem (Tokyo)** 1995 Sep; 118(3):500–7

Polymorphisms within the atrial natriuretic peptide gene in essential hypertension. Rutledge DR, et al. **J Hypertens** 1995 Sep;13(9):953–5

The atrial natriuretic factor promoter is a downstream target for Nkx-2.5 in the myocardium. Durocher D, et al. **Mol Cell Biol** 1996 Sep;16(9):4648–55

Cardiac gene expression of atrial natriuretic peptide and brain natriuretic peptide in trisomic fetuses. Hyett JA, et al. **Obstet Gynecol** 1996 Apr;87(4):506–10

IMMUNOLOGY

Presence and release of immunoreactive atrial natriuretic peptide (ANP) in Bufo arenarum spermatozoa after HCG treatment. Paz DA, et al. **Biocell** 1996 Apr;20(1):47–54

Atrial natriuretic peptide stimulates the expression of transforming growth factor-beta in cultured murine mesangial cells: relationship to suppression of proliferation. Wolf G, et al. **J Am Soc Nephrol** 1995 Aug;6(2):224–33

Cardiac accumulation of 125I-labeled monoclonal antibody to atrial natriuretic peptide in a rat model of myocardial infarction. Kanda T, et al. **J Med** 1995;26(1–2):53–64

METABOLISM

Atrial natriuretic peptide and its mRNA in heart and brain of vasopressin-deficient Brattleboro rats. Arjamaa O, et al. **Acta Physiol Scand** 1995 May;154(1):35–42

Pharmacokinetics and renal metabolism of atrial natriuretic factor during rat pregnancy. Omer S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F194–7

Mechanism of anoxia-induced atrial natriuretic peptide release in the isolated rat atria. Skvorak JP, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):R237–43

Endothelin acts as a paracrine regulator of stretch-induced atrial natriuretic peptide release. Skvorak JP, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R1093–8

Atrial natriuretic factor (ANF) prohormone accumulates in the IgG fraction of anti-ANF hybridoma-bearing mice. Milne RW, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):665–9

Atrial-natriuretic-peptide receptors in glomerular cryosections of renal malignant and spontaneously hypertensive rats. Marin-Grez M, et al. **Biol Chem Hoppe Seyler** 1995 Sep;376(9):539–44

Effects of angiotensin II on plasma atrial natriuretic factor in nonpregnant and pregnant ewes. Fan L, et al. **Can J Physiol Pharmacol** 1995 May;73(5):644–50

'Til death do us part: a case of failed affection. Weber KT, et al. **Cardiovasc Res** 1995 Jul;30(1):26–30 (32 ref.)

Preparation of mono-radioiodinated tracers for study of the in vivo metabolism of atrial natriuretic peptide in humans. Clerico A, et al. **Eur J Nucl Med** 1995 Sep;22(9):997–1004

Atrial natriuretic peptide (ANP)-granules of auricular cardiocytes in dehydrated and rehydrated mice. Toyoshima Y, et al. **Exp Anim** 1996 Apr;45(2):135–40

Anterior hypothalamic norepinephrine, atrial natriuretic peptide, and hypertension. Oparil S, et al. **Front Neuroendocrinol** 1996 Apr;17(2):212–46 (122 ref.)

Atrial natriuretic peptide gene expression within invertebrate hearts. Poulos JE, et al. **Gen Comp Endocrinol** 1995 Oct; 100(1):61–8

The nocturnal polyuria syndrome (NPS). Asplund R. **Gen Pharmacol** 1995 Oct;26(6):1203–9 (29 ref.)

Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension. Pidgeon GB, et al. **Hypertension** 1996 Apr;27(4):906–13

Reduced renal extraction of atrial natriuretic peptide in primary aldosteronism. Tunny TJ, et al. **Hypertension** 1995 Oct;26(4):624–7

Plasma and cardiac tissue atrial and brain natriuretic peptides in experimental heart failure. Moe GW, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):720–7

Distribution of atrial natriuretic peptides in the sand rat (Psammomys obesus) in comparison to that in the rat. Bachar H, et al. **J Basic Clin Physiol Pharmacol** 1993 Apr–Jun;4(1–2):47–56

Molecular determinants of the clearance function of type C receptors of natriuretic peptides. Cohen D, et al. **J Biol Chem** 1996 Apr 19;271(16):9863–9

Increased natriuretic peptides in fetal hearts of diabetic rats. Mulay S, et al. **J Endocrinol** 1995 Aug;146(2):255–9

Clearance receptors for atrial natriuretic petide in Milan hypertensive and normotensive rats. Aptel HB, et al. **J Hypertens** 1996 Apr;14(4):461–8

Regulation of secretion and clearance of C-type natriuretic peptide in the interaction of vascular endothelial cells and smooth muscle cells. Komatsu Y, et al. **J Hypertens** 1996 May;14(5):585–92

Expression of C-type natriuretic peptide in the bovine pineal gland. Middendorff R, et al. **J Neurochem** 1996 Aug; 67(2):517–24

Atrial natriuretic factor release during pregnancy in rats. Zhang Y, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):509–14

Preparations of psi-peptide bond and peptide-aldehyde inhibitors of atrial granule serine proteinase, a candidate processing enzyme of pro-atrial natriuretic factor. Damodaran A, et al. **J Protein Chem** 1995 Aug;14(6):431–40

Atrial natriuretic peptide release at rest and with exercise after cardiac transplantation with bicaval anastomoses. Jahnke AW, et al. **J Thorac Cardiovasc Surg** 1995 Dec; 110(6):1600–5

Cellular mechanism of angiotensin II-induced atrial natriuretic peptide release in rat right atrial tissue. Soualmia H, et al. **Life Sci** 1996;58(19):1621–9

Alterations with age of the T3-stimulated release of atrial natriuretic peptide and its effect on water and sodium metabolism in rats. Hwu CM, et al. **Mech Ageing Dev** 1995

Nov 24;85(2-3):161-70

Preoptic neuronal circuit: atrial natriuretic peptide-containing neurons are sensitive to acute and chronic alterations in body fluid volume. Palkovits M, et al. **Miner Electrolyte Metab** 1995;21(6):423-7

Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Lopez MJ, et al. **Nature** 1995 Nov 2;378(6552):65-8

High concentrations of atrial natriuretic peptide and brain natriuretic peptide in rat pericardial fluid and their reduction by reserpine in vivo. Klemola R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Sep; 352(3):331-6

Release of urodilatin from perfused rat kidney and from cultured neonatal rat kidney cells. Kirchhoff K, et al. **Pflugers Arch** 1995 Sep;430(5):739-44

Secretory granule targeting of atrial natriuretic peptide correlates with its calcium-mediated aggregation. Canaff L, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9483-7

Time-dependent decreases of atrial natriuretic peptide release from the isolated rat atrium: evidence for a readily releasable pool. Dowsley TF, et al. **Regul Pept** 1995 Dec 7;60(1):9-18

Natriuretic peptide system in the rat submaxillary gland. Jankowski M, et al. **Regul Pept** 1996 Apr 9;62(1):53-61

Atrial natriuretic factor and sympathetic activation in human heart failure. Liguori A, et al. **Riv Eur Sci Med Farmacol** 1994 May-Aug;16(3-4):61-7

[Relative changes between calcium content and number of atrial specific granules induced by water and salt loading] Yu Z, et al. **Sheng Li Hsueh Pao** 1995 Oct;47(5):463-70 (Eng. Abstr.) **(Chi)**

PHARMACOKINETICS

Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance. Lang CC, et al. **Eur J Clin Pharmacol** 1995;48(6):429-34

PHARMACOLOGY

Atrial natriuretic peptides and cyclic guanosine monophosphate metabolism. Vesely DL, et al. **Am J Med Sci** 1995 Oct;310(4):143-9

Effects of urodilatin and diltiazem on renal function in ischemic acute renal failure in the rat. Schramm L, et al. **Am J Nephrol** 1995;15(5):418-26

The effects of atrial natriuretic factor and angiotensin II on fetal-placental perfusion pressure in the ex vivo cotyledon model. Markenson GR, et al. **Am J Obstet Gynecol** 1995 Oct;173(4):1143-7

Effect of proANF-(31--67) on sodium excretion in conscious monkeys. Benjamin BA, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1351-5

Effect of atrial natriuretic peptide on renal hemodynamics and sodium excretion during human pregnancy. Irons DW, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F239-42

Protein kinase C modulates natriuretic peptide receptors in astroglial cultures from rat brain. Paulding WR, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C740-7

Role of large Ca(2+)-activated K+ channels in regulation of mesangial contraction by nitroprusside and ANP. Stockand JD, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1773-9

Dose-response analysis of acute hypotensive and renal effects of atrial natriuretic peptide in the rat. Caron N, et al. **Arch Int Pharmacodyn Ther** 1995 May-Jun;329(3):379-96

Effects of atrial natriuretic factor on norepinephrine release evoked by angiotensins II and III in the rat adrenal medulla. Papouchado ML, et al. **Arch Physiol Biochem** 1995 Apr; 103(1):55-8

Stimulation by C-type natriuretic peptide of the differentiation of clonal osteoblastic MC3T3-E1 cells. Inoue A, et al. **Biochem Biophys Res Commun** 1996 Apr 25;221(3):703-7

Intestinal secretory response to atrial natriuretic peptide during postnatal development in the rabbit. Brockway PD, et al. **Biol Neonate** 1996;69(1):60-6

Effects of atrial natriuretic peptide on angiotensin II-induced antinatriuresis in anesthetized dogs. Tomura Y, et al. **Biol Pharm Bull** 1995 Sep;18(9):1211-4

Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans. Cargill RI, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):585-90

Effects of intradermal injection of atrial natriuretic peptide. Sharara AM, et al. **Br J Clin Pharmacol** 1995 Sep; 40(3):283-5

Effect of endopeptidase-24.11 inhibitors and C-ANP receptor ligand on responses evoked in arterioles of rat cremaster muscle by atrial natriuretic peptide. Peyroux J, et al. **Br J Pharmacol** 1995 Dec;116(8):3117-24

The mechanism of relaxation induced by atrial natriuretic peptide in the porcine renal artery. Seguchi H, et al. **Br J Pharmacol** 1996 May;118(2):343-51

Detection of membrane-bound guanylate cyclase activity in rat C6 glioma cells at different growth states following activation by natriuretic peptides. Sorci G, et al. **Brain Res** 1995 Jun 12;683(1):51-8

Atrial natriuretic peptide modulates the effect of angiotensin II on the concentration of free calcium in the cytosol of Mandin-Darby canine kidney cells. Nascimento-Gomes G, et al. **Braz J Med Biol Res** 1995 May;28(5):609-13

cGMP and atrial natriuretic factor regulate cell volume of rabbit atrial myocytes. Clemo HF, et al. **Circ Res** 1995 Oct;77(4):741-9

Atrial natriuretic factor and angiotensin II stimulate nitric oxide release from human proximal tubular cells. McLay JS, et al. **Clin Sci (Colch)** 1995 Nov;89(5):527-31

Natriuretic peptide receptors on rat thymocytes: inhibition of proliferation by atrial natriuretic peptide. Vollmar AM, et al. **Endocrinology** 1996 May;137(5):1706-13

Effects of intracerebroventricular administration of atrial natriuretic peptide on subcortical EEG activity in conscious rabbits. Angelopoulos N, et al. **Exp Brain Res** 1996 Mar;108(3):427-32

Atrial natriuretic peptide stimulates aldosterone production by turkey (Meleagris gallopavo) adrenal steroidogenic cells. Kocsis JF, et al. **Gen Comp Endocrinol** 1995 Sep; 99(3):364-72

Platelet aggregation and atrial natriuretic peptide. Ulker S, et al. **Gen Pharmacol** 1995 Oct;26(6):1409-12

Effects of atrial natriuretic peptide and cyclic guanosine monophosphate on isolated human myometrial arteries preconstricted by endothelin-1. Kublickiene KR, et al. **Gynecol Obstet Invest** 1995;40(3):190-4

Pharmacodynamics of atrial natriuretic peptide in isolated perfused Dahl rat kidneys. Brier ME, et al. **Hypertens Res** 1995 Sep;18(3):219-25

Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Ando S, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1160-6

Natriuretic peptide receptors in human artery and vein and rabbit vein graft. Ikeda T, et al. **Hypertension** 1996 Mar; 27(3 Pt 2):833-7

Atrial natriuretic peptide in chronically hypertensive dogs. Seymour AA, et al. **Hypertension** 1995 Oct;26(4):634-41

Atrial natriuretic peptide blunts arterial baroreflex in spontaneously hypertensive rats. Zhu ST, et al. **Hypertension** 1996 Feb;27(2):297-302

Presence of functional type B natriuretic peptide receptor in human ocular cells. Pang IH, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1724-31

Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus. Zietse R, et al. **J Am Soc Nephrol** 1995 Jun;5(12):2057-66

Atrial natriuretic peptide suppresses the transcription of its guanylyl cyclase-linked receptor. Cao L, et al. **J Biol Chem** 1995 Oct 20;270(42):24891-7

Atrial natriuretic peptide inhibits mitogen-activated protein kinase through the clearance receptor. Potential role in the inhibition of astrocyte proliferation. Prins BA, et al. **J Biol Chem** 1996 Jun 14;271(24):14156-62

Atrial natriuretic peptide induces the expression of MKP-1, a mitogen-activated protein kinase phosphatase, in glomerular mesangial cells. Sugimoto T, et al. **J Biol Chem** 1996 Jan 5;271(1):544-7

The guanylyl cyclase-A receptor transduces an atrial natriuretic peptide/ATP activation signal in the absence of other proteins. Wong SK, et al. **J Biol Chem** 1995 Dec 22;270(51):30818-22

Pharmacologic atrial natriuretic peptide reduces human leg capillary filtration. Watenpaugh DE, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):414-9

Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophils-induced endothelial cytotoxity. Matsumura T, et al. **J Clin Invest** 1996 May 15;97(10):2192-203

Atrial natriuretic peptide inhibits mineralocorticoid receptor function in rat colonic surface cells. Schulman G, et al. **J Clin Invest** 1996 Jul 1;98(1):157-66

Cyclic nucleotides attenuate endothelin-1-induced activation of mitogen-activated protein kinase in cultured rat mesangial cells. Sugimoto T, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):249-51

Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion. Vesely DL, et al. **J Endocrinol** 1995 Sep;146(3):373-80

Inhibitory effects of natriuretic peptides on vasopressin neurons mediated through cGMP and cGMP-dependent protein kinase in vitro. Akamatsu N, et al. **J Neuroendocrinol** 1993 Oct;5(5):517-22

Opposing neuroendocrine actions of the natriuretic peptides: C-type and A-type natriuretic peptides do not interact with the same hypothalamic cells controlling prolactin secretion. Samson WK, et al. **J Neuroendocrinol** 1995 Oct; 7(10):759-63

Interactions of nitrovasodilators, atrial natriuretic peptide and endothelium-derived nitric oxide. Murohara T, et al. **J Vasc Res** 1996 Jan-Feb;33(1):78-85

Renal responses to atrial natriuretic peptide (ANP) in rats with non-oliguric acute renal failure induced by cisplatin. Nagano N, et al. **J Vet Med Sci** 1995 Dec;57(6):997-1002

A novel natriuretic, hypotensive factor derived from the spleen. Deng Y, et al. **Life Sci** 1995;57(18):1647-53

Effect of glycosylation on cloned ANF-sensitive guanylyl cyclase. Heim JM, et al. **Life Sci** 1996;59(4):PL61-8

Specific potentiation by cyclic AMP of natriuretic peptide-mediated cyclic GMP production in adipose tissue. Thibault G, et al. **Life Sci** 1996;58(25):2345-53

Atrial natriuretic peptide increases adrenomedullin in the circulation of healthy humans. Vesely DL, et al. **Life Sci** 1996;59(3):243-54

Atrial natriuretic peptides negatively and positively modulate circulating endothelin in humans. Vesely DL, et al. **Metabolism** 1996 Mar;45(3):315-9

Effect of cyclic GMP-increasing agents nitric oxide and C-type natriuretic peptide on bovine chromaffin cell function: inhibitory role mediated by cyclic GMP-dependent protein kinase. Rodriguez-Pascual F, et al. **Mol Pharmacol** 1996 Jun;49(6):1058-70

Effect of atrial natriuretic factor on vasopressin-stimulated cyclic AMP accumulation in papillary collecting tubule [letter] Appel RG, et al. **Nephron** 1995;71(3):369-70

Role of cadmium-induced lipid peroxidation in the kidney response to atrial natriuretic hormone. Oner G, et al. **Nephron** 1996;72(2):257-62

C-type natriuretic peptide can modify the acute and chronic effects of morphine. Babarczy E, et al. **Neuropeptides** 1995 Sep;29(3):145-9

Involvement of neurotransmitters in the 'anxiolytic-like' action of atrial natriuretic peptide in rats. Bíró É, et al. **Neuropeptides** 1995 Oct;29(4):215-20

Effects of angiotensin, vasopressin and atrial natriuretic peptide on intraocular pressure in anesthetized rats. Palm DE, et al. **Neuropeptides** 1995 Oct;29(4):193-203

Atrial natriuretic factor enhances norepinephrine uptake in circumventricular organs, locus coeruleus and nucleus tractus solitarii of the rat. Vatta M, et al. **Neurosci Lett** 1995 Sep 1;197(1):29-32

Cardiovascular-related peptides influence hypothalamic neurons involved in control of body water homeostasis. Yamamoto S, et al. **Obes Res** 1995 Dec;3 Suppl 5:789S-794S

Atrial natriuretic peptide attenuates flow in an isolated lymph duct preparation. Atchison DJ, et al. **Pflugers Arch** 1996 Feb;431(4):618-24

Natriuretic peptides increase a K+ conductance in rat mesangial cells. Cermak R, et al. **Pflugers Arch** 1996 Feb; 431(4):571-7

Bronchodilating effects of natriuretic and vasorelaxant peptides compared to salbutamol in asthmatics. Flüge T, et al. **Regul Pept** 1995 Nov 10;59(3):357-70

Histamine release induced by human natriuretic peptide from rat peritoneal mast cells. Yoshida H, et al. **Regul Pept** 1996 Jan 16;61(1):45-9

Atrial natriuretic peptide inhibits mesangial cell proliferation induced by early postnephrectomy serum. Averbukh Z, et al. **Ren Fail** 1995 Nov;17(6):659-64

PMA and ionomycin differently affect atrial natriuretic peptide stimulated cyclic GMP production in rat mesangial cells. Akai Y, et al. **Tohoku J Exp Med** 1996 Feb; 178(2):137-49

Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide. Deegan PM, et al. **Toxicology** 1996 Jan 8;106(1-3):159-66

PHYSIOLOGY

Cerebral salt wasting in children: the role of atrial natriuretic hormone. Kappy MS, et al. **Adv Pediatr** 1996;43:271-308 (104 ref.)

Comparative bioactivity of atrial, brain, and C-type natriuretic peptides in conscious sheep. Charles CJ, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1324-31

Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men. Hunt PJ, et al. **Am J Physiol** 1995 Dec;269(6 Pt 2):R1397-403

Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Lee EY, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F3-6 (27 ref.)

Reduced plasma cyclic GMP but normal renal responses to atrial natriuretic factor in pre-hypertension. Ferrari P, et al. **Blood Press** 1996 Jan;5(1):16-26

Possible involvement of atrial natriuretic peptides in olfaction. Bachar C, et al. **Brain Res** 1995 Jun 5; 682(1-2):231-4

Atrial natriuretic peptide and body fluid homeostasis: leading actor or bit-part player? Richards AM, et al. **Cardiologia** 1995 Sep;40(9):643-50 (71 ref.)

Renal effects of high-dose natriuretic peptide receptor blockade in rats with congestive heart failure. Zhang PL, et al. **Circ Res** 1995 Dec;77(6):1240-5

New insights into the cardiac natriuretic peptides [editorial; comment] Bonow RO. **Circulation** 1996 Jun 1; 93(11):1946-50. Comment on: Circulation 1996 Jun 1;93(11):1963-9. Comment on: Circulation 1996 Jun 1;93(11):2037-42.

Role for the endogenous natriuretic peptide system in the control of basal coronary vascular tone in dogs. Supaporn T, et al. **Clin Sci (Colch)** 1996 May;90(5):357-62

Circulating concentrations and physiologic role of atrial natriuretic peptide during endotoxic shock in the rat. Aiura K, et al. **Crit Care Med** 1995 Nov;23(11):1898-906

Response of human artery, vein, and cultured smooth muscle cells to atrial and C-type natriuretic peptides. Zhang LM, et al. **Crit Care Med** 1996 Feb;24(2):306-10

The natriuretic peptides in hypertension. Januszewicz A. **Curr Opin Cardiol** 1995 Sep;10(5):495-500 (32 ref.)

Natriuretic peptides and hypertension. Prins BA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):170-3 (29 ref.)

Similarities in cellular expression and functions of melanin-concentrating hormone and atrial natriuretic factor in the rat digestive tract. Hervieu G, et al. **Endocrinology** 1996 Feb;137(2):561-71

Interaction between atrial natriuretic peptide and vasoactive intestinal peptide in guinea pig cecal smooth muscle. Akiho

H, et al. **Gastroenterology** 1995 Oct;109(4):1105–12

Vasoactive peptides and uterine vessels. Stjernquist M, et al. **Gynecol Endocrinol** 1995 Jun;9(2):165–76 (77 ref.)

Atrial natriuretic peptide participates in the regulation of vestibular blood flow. Rachel JD, et al. **Hear Res** 1995 Sep;89(1–2):181–6

Brain natriuretic peptide in hypertension. Takeda T, et al. **Hypertens Res** 1995 Dec;18(4):259–66 (52 ref.)

Evaluation of the endocrine function of the heart in humans: proposal for an integrated approach for the assessment of production, secretion, distribution and degradation of atrial natriuretic factor and related peptides. Clerico A, et al. **Int J Clin Pharmacol Res** 1995;15(2):65–86 (73 ref.)

Characterization of the atrial natriuretic factor system in lungs of the toad Bufo paracnemis. Glass ML, et al. **J Exp Biol** 1996 Jul;199 (Pt 7):1493–9

Atrial natriuretic factor modulates nitric oxide production: an ANF–C receptor–mediated effect. McLay JS, et al. **J Hypertens** 1995 Jun;13(6):625–30

Defective ANF–R2/ANP–C receptor–mediated signalling in hypertension. Marcil J, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:223–31 (92 ref.)

Natriuretic peptides and acute renal failure. Weinmann M. **New Horiz** 1995 Nov;3(4):624–33 (110 ref.)

Role of endogenous atrial natriuretic peptide in chronic anemia in the ovine fetus: effects of a non–peptide antagonist for atrial natriuretic peptide receptor. Silberbach M, et al. **Pediatr Res** 1995 Nov;38(5):722–8

Hormonal control of sodium and water excretion in obstructive sleep apnoea. Krieger J. **Scand J Urol Nephrol Suppl** 1995;173:65–8; discussion 68–9

Role of atrial natriuretic peptide in interleukin 1 beta–induced natriuresis in conscious rats. Funyu T, et al. **Tohoku J Exp Med** 1995 Sep;177(1):73–87

[Natriuresis and atrial natriuretic factors during extracorporeal circulation for cardiac surgery] Pipien I, et al. **Cah Anesthesiol** 1995;43(4):343–50 (Eng. Abstr.) **(Fre)**

[Cardiac natriuretic peptide] Ecker–Schlipf BB. **Med Monatsschr Pharm** 1995 Sep;18(9):252–4 **(Ger)**

[Etiological significance of humoral nerve factors in congestive heart failure] Kinoshita M, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1454–8 (14 ref.) **(Jpn)**

[The clinical significance of natriuretic hormones] Lazúrová I, et al. **Bratisl Lek Listy** 1995 Nov;96(11):597–9 (Eng. Abstr.) **(Slo)**

[Natriuretic peptides and the homeostasis of renal circulation in cirrhosis (editorial)] Jiménez W. **Gastroenterol Hepatol** 1995 Nov;18(9):477–9 (20 ref.) **(Spa)**

SECRETION

Standard error of the mean or standard deviation—does it matter? [letter; comment] Malagon I. **Anaesthesia** 1996 Jun; 51(6):609. Comment on: Anaesthesia 1996 Feb;51(2):128–32.

Stimulation by corticotropin–releasing factor of atrial natriuretic peptide and brain natriuretic peptide secretions from cultured neonatal rat cardiomyocytes. Tojo K, et al. **Biochem Biophys Res Commun** 1996 Aug 14;225(2):340–6

In rats, atrial natriuretic peptide secretion is regulated differently in the right and left atria. Miller H 3rd, et al. **Endocr Res** 1996 Feb;22(1):43–57

Alpha 1–adrenergic stimulation of isolated rat atria results in discoordinate increases in natriuretic peptide secretion and gene expression and enhances Egr–1 and c–Myc expression. Bruneau BG, et al. **Endocrinology** 1996 Jan; 137(1):137–43

Glucocorticoids inhibit D1B, but not D2, receptor–mediated effects on hypothalamic atrial natriuretic factor neurons. Lee D, et al. **Endocrinology** 1995 Dec;136(12):5570–6

Pituitary adenylate cyclase–activating polypeptide stimulates cardiodilatin/atrial natriuretic peptide (CDD/ANP–(99–126) secretion from cultured neonatal rat myocardiocytes. Bäsler I, et al. **Eur J Pharmacol** 1995 Nov 30;291(3):335–42

Effect of neuromimetics upon the release of atrial natriuretic peptide granules: are multiple pathways involved in secretion? Newman TM, et al. **J Cell Physiol** 1996 Jul; 168(1):134–40

Osmotic and volaemic regulation of atrial and ventricular natriuretic peptide secretion in conscious eels. Kaiya H, et al. **J Endocrinol** 1996 Jun;149(3):441–7

Mechanism of atrial natriuretic peptide release with increased inspiratory resistance. Yalkut D, et al. **J Lab Clin Med** 1996 Sep;128(3):322–8

Vasopressin, atrial natriuretic factor and renal water homeostasis in premature newborn infants with respiratory distress syndrome. Ronconi M, et al. **J Perinat Med** 1995; 23(4):307–14

Thrombin stimulates atrial natriuretic peptide secretion from rat cardiac atrium. Klapper L, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):476–81

Erythropoietin stimulates atrial natriuretic peptide secretion from adult rat cardiac atrium. Porat O, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1162–8

Augmented secretion of atrial and brain natriuretic peptides during dynamic exercise in patients with old myocardial infarction. Marumoto K, et al. **Jpn Circ J** 1995 Nov; 59(11):715–24

Requirement for prostaglandin synthesis in secretion of atrial natriuretic factor from isolated rat heart. Melo LG, et al. **Regul Pept** 1995 Dec 7;60(1):79–87

[Secretion of atrial natriuretic peptide in patients with active renal stone disease] Klimek D, et al. **Pol Arch Med Wewn** 1996 Jan;95(1):3–10 (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Treatment of acute renal failure with urodilatin after unrelated bone marrow transplantation in an 18–month–old boy. Laws HJ, et al. **Bone Marrow Transplant** 1995 Aug; 16(2):307–10

Effect of 1–28 alpha–h atrial natriuretic peptide on acute renal failure in cadaveric renal transplantation. Gianello P, et al. **Clin Transplant** 1995 Dec;9(6):481–9

Urodilatin (ularitide, INN): a potent bronchodilator in asthmatic subjects. Flüge T, et al. **Eur J Clin Invest** 1995 Oct;25(10):728–36

Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after cardiac surgery. Valsson F, et al. **Intensive Care Med** 1996 Mar;22(3):230–6

Reduced natriuretic effect of atrial natriuretic peptide in nephrotic syndrome: a possible role of decreased cyclic guanosine monophosphate. Jespersen B, et al. **Nephron** 1995;71(1):44–53

Natriuretic peptides and acute renal failure. Weinmann M. **New Horiz** 1995 Nov;3(4):624–33 (110 ref.)

Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide (ANP). Angus RM, et al. **Thorax** 1996 Jan; 51(1):71–4

[Urodilatin (INN: ularitide). A new peptide in the treatment of acute kidney failure following liver transplantation] Kuse ER, et al. **Anaesthesist** 1996 Apr;45(4):351–8 (Eng. Abstr.) **(Ger)**

URINE

Urinary clearance of atrial natriuretic peptide in Pekin ducks. Gray DA. **J Endocrinol** 1995 Nov;147(2):211–5

[Involvement of urodilatin in the hydro–electrolytic modifications induced in man by a 6 degree head–down tilt] Gauquelin G, et al. **Arch Physiol Biochem** 1995 Aug; 103(4):450–5 (Eng. Abstr.) **(Fre)**

ATRIAL NATRIURETIC FACTOR RECEPTORS see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

ATRIAL NATRIURETIC PEPTIDES see **ATRIAL NATRIURETIC FACTOR**

ATRIAL NATRIURETIC PEPTIDES RECEPTORS see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

ATRIAL PREMATURE COMPLEXES

COMPLICATIONS

Premature atrial beat eliciting atrial fibrillation after coronary artery bypass grafting. Frost L, et al. **J Electrocardiol** 1995 Oct;28(4):297–305

DIAGNOSIS

A man who coughed for 15 years before a doctor took his pulse. Odeh M, et al. **Lancet** 1996 Aug 10;348(9024):378

[Problems in the diagnosis and clinical assessment of atrial dissociation (a report on 2 cases and review of the literature)] Snezhitskiĭ VA, et al. **Ter Arkh** 1995;67(9):73–5 (11 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

[Late supraventricular arrhythmia complicating Fontan or cavopulmonary type procedures. Apropos of 7 cases] Maragnès P, et al. **Arch Mal Coeur Vaiss** 1996 May; 89(5):605–9 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Local latency of conduction time during premature stimulation: a real or apparent phenomenon? [editorial; comment] Chimienti M, et al. **Eur Heart J** 1995 Dec; 16(12):1749–51. Comment on: Eur Heart J 1995 Dec;16(12):1920–4.

Low vagal tone and supraventricular ectopic activity predict atrial fibrillation and flutter after coronary artery bypass grafting. Frost L, et al. **Eur Heart J** 1995 Jun;16(6):825–31

Prolongation of conduction time during premature stimulation in the human atrium is primarily caused by local stimulus response latency [see comments] Koller BS, et al. **Eur Heart J** 1995 Dec;16(12):1920–4. Comment in: Eur Heart J 1995 Dec;16(12):1749–51.

ULTRASONOGRAPHY

[Prenatal echocardiographic study of septum primum redundancy and its relationship to the genesis of atrial extrasystole in the fetus] Zielinsky P, et al. **Arq Bras Cardiol** 1995 Aug;65(2):153–7 (Eng. Abstr.) **(Por)**

ATRIAL SEPTAL DEFECTS see **HEART SEPTAL DEFECTS, ATRIAL**

ATRIOPEPTIN RECEPTORS see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

ATRIOPEPTINS see **ATRIAL NATRIURETIC FACTOR**

ATRIOVENTRICULAR BLOCK see **HEART BLOCK**

ATRIOVENTRICULAR BUNDLE see **BUNDLE OF HIS**

ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA see **TACHYCARDIA, ATRIOVENTRICULAR NODAL REENTRY**

ATRIOVENTRICULAR NODE

Atrioventricular septal defect with pulmonary atresia in DiGeorge anomaly: expansion of the cardiac phenotype [letter] Kumar A, et al. **Am J Med Genet** 1996 Jan 2; 61(1):89–91

Intermittent preexcitation and mesothelioma of the atrioventricular node: a hitherto undescribed entity. Bharati S, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 1):823–31

Atrio–ventricular nodal tumor associated with polyendocrine anomalies. Declich P, et al. **Pathol Res Pract** 1996 Jan; 192(1):54–9; discussion 60–1

ABNORMALITIES

Left atrioventricular valve incompetence after repair of common atrioventricular canal defects. Michielon G, et al. **Ann Thorac Surg** 1995 Dec;60(6 Suppl):S604–9

Electrophysiological properties of dual atrioventricular nodes in patients with right atrial isomerism. Wu MH, et al. **Br Heart J** 1995 Nov;74(5):553–5

[The radiofrequency catheter ablation of occult accessory atrioventricular pathways] Parreira L, et al. **Rev Port Cardiol** 1996 Feb;15(2):111–7, 99 (Eng. Abstr.) **(Por)**

ANATOMY & HISTOLOGY

Anatomy of the sinus node, AV node, and His bundle of the heart of the sperm whale (Physeter macrocephalus), with a note on the absence of an os cordis. James TN, et al. **Anat Rec** 1995 Jul;242(3):355–73

[Arterial vascularization of the sinoatrial and atrioventricular node (preliminary study apropos of 15 anatomic parts] Ndiaye M, et al. **Dakar Med** 1994;39(1):1–4 (Eng. Abstr.) **(Fre)**

[Individual and age–related variability of the arteries to the atrioventricular node in the human heart] Spirina GA. **Morfologiia** 1994 Apr–Jun;106(4–6):129–39 (Eng. Abstr.) **(Rus)**

CYTOLOGY

Electrophysiological properties of two distinct populations of myocytes isolated from the rabbit atrioventricular node. Munk AA. **J Electrocardiol** 1995 Oct;28(4):352–3

Nitric oxide mediates the anti–adrenergic effect of adenosine on calcium current in isolated rabbit atrioventricular nodal cells. Martynyuk AE, et al. **Pflugers Arch** 1996 Jan; 431(3):452–7

DRUG EFFECTS

The effects of dobutamine and phenylephrine on atrioventricular conduction during combined use of halothane and thoracic epidural lidocaine. Nishikawa K, et al. **Anesth Analg** 1996 Mar;82(3):551–7

Effects of intravenous anesthetics on atrial wavelength and atrioventricular nodal conduction in guinea pig heart. Potential antidysrhythmic properties and clinical implications. Napolitano CA, et al. **Anesthesiology** 1996 Aug;85(2):393–402

Cellular basis for the negative dromotropic effect of adenosine on rabbit single atrioventricular nodal cells. Wang D, et al. **Circ Res** 1996 Apr;78(4):697–706

Negative chronotropic and dromotropic effects of E–4031, an IKr blocker, on the atrioventricular node in anesthetized dog hearts. Yamazaki K, et al. **Eur J Pharmacol** 1996 Feb 22;297(3):233–9

The actions of nickel on membrane currents activated by hyperpolarisation in single cells from the rabbit atrioventricular node. Hancox JC, et al. **Gen Pharmacol** 1995 Dec;26(8):1727–34

Responses to calcium and binding of 3H–nimodipine in the atrioventricular node, atria, and ventricles of mature and old male Fischer 344 rats. Kusumoto FM, et al. **J Cardiovasc Pharmacol** 1995 Sep;26(3):348–53

Inhibition of the subsidiary pacemaker activity by zatebradine, an If inhibitor, in the anesthetized dog heart. Yamazaki K, et al. **J Cardiovasc Pharmacol** 1995 Dec; 26(6):957–64

Haemodynamic and electrophysiological acute toxic effects of mercury in anaesthetized rats and in langendorff perfused rat hearts. Massaroni L, et al. **Pharmacol Res** 1995 Jul–Aug; 32(1–2):27–36

Sino–atrial and atrio–ventricular node dysfunction in a case of tizanidine overdose. Luciani A, et al. **Vet Hum Toxicol** 1995 Dec;37(6):556–7

EMBRYOLOGY

Antibodies to the Type II TGFbeta receptor block cell activation and migration during atrioventricular cushion transformation in the heart. Brown CB, et al. **Dev Biol** 1996 Mar 15;174(2):248–57

INNERVATION

Independent autonomic modulation of the human sinus and AV nodes: evidence from beat–to–beat measurements of PR and PP intervals during sleep. Kowallik P, et al. **J Cardiovasc Electrophysiol** 1995 Nov;6(11):993–1003

METABOLISM

Adenosine increases potassium conductance in isolated rabbit atrioventricular nodal myocytes. Martynyuk AE, et al. **Cardiovasc Res** 1995 Nov;30(5):668–75

Nitric oxide synthase (NOS3)–mediated cholinergic modulation of Ca2+ current in adult rabbit atrioventricular nodal cells. Han X, et al. **Circ Res** 1996 Jun;78(6):998–1008

Enrichment of G protein alpha–subunit mRNAS in the AV–conducting system of the mammalian heart. Eschenhagen T, et al. **J Mol Cell Cardiol** 1995 Oct; 27(10):2249–63

PATHOLOGY

Mahaim, Kent and abnormal atrioventricular conduction. Anderson RH, et al. **Cardiovasc Res** 1996 Apr;31(4):480–91 (44 ref.)

Apoptosis as a possible cause of gradual development of complete heart block and fatal arrhythmias associated with absence of the AV node, sinus node, and internodal pathways. James TN, et al. **Circulation** 1996 Apr 1; 93(7):1424–38

PHYSIOLOGY

Effects of atrial pacing site on rate–dependent AV nodal function in rabbit hearts. Amellal F, et al. **Am J Physiol** 1995 Sep;269(3 Pt 2):H934–42

Mechanisms of conduction time hysteresis in rabbit atrioventricular node. Billette J, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1258–67

Characteristics and mechanisms of the effects of heart rate history on transient AV nodal responses. Zhao J, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2070–80

Transcatheter modification of the atrioventricular node in dogs, using radiofrequency energy. Wright KN, et al. **Am J Vet Res** 1996 Feb;57(2):229–35

Selective functional properties of dual atrioventricular nodal inputs. Role in nodal conduction, refractoriness, summation, and rate–dependent function in rabbit heart. Amellal F, et al. **Circulation** 1996 Aug 15;94(4):824–32

Characteristics of atrial re–entry and meander computed from a model of a rabbit single atrial cell. Holden AV, et al. **J Theor Biol** 1995 Aug 21;175(4):545–51

Recovery curve and concealed conduction in the His–Purkinje system of the rabbit heart: effects of radiofrequency modification of the low AV junction. Sanchis J, et al. **Pacing Clin Electrophysiol** 1996 Jan; 19(1):31–41

PHYSIOPATHOLOGY

Electrophysiologic significance of discrete slow potentials in dual atrioventricular node physiology: implications for selective radiofrequency ablation of slow pathway conduction. Kuo C–T, et al. **Am Heart J** 1996 Mar; 131(3):490–8

Atrioventricular node properties in patients with accessory pathways. Niebauer MJ, et al. **Am Heart J** 1996 Apr; 131(4):716–9

Transient complete atrioventricular block during radiofrequency ablation of slow pathway for atrioventricular nodal reentrant tachycardia. Chen SA, et al. **Am J Cardiol** 1996 Jun 15;77(15):1367–70

Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. Grimm W, et al. **Am J Cardiol** 1996 Jun 15;77(15):1310–4

Effect of continuous vagal enhancement on concealed conduction and refractoriness within the atrioventricular node. Page RL, et al. **Am J Cardiol** 1996 Feb 1;77(4):260–5

Triple atrioventricular nodal pathways can be masked. Yamashita T, et al. **Am J Cardiol** 1996 Jun 15;77(15):1365–7

An algorithm for complete enumeration of the mechanisms of supraventricular tachycardias that use multiple atrioventricular, AV nodal, and/or Mahaim pathways. Widman LE, et al. **Artif Intell Med** 1995 Aug;7(4):361–86

Longitudinal clinical and electrophysiological assessment of patients with symptomatic Wolff–Parkinson–White syndrome and atrioventricular node reentrant tachycardia. Chen SA, et al. **Circulation** 1996 Jun 1;93(11):2023–32

Para–Hisian pacing. A new method for differentiating retrograde conduction over an accessory AV pathway from conduction over the AV node. Hirao K, et al. **Circulation** 1996 Sep 1;94(5):1027–35

Atrioventricular nodal conduction gap and dual pathway electrophysiology. Mazgalev T, et al. **Circulation** 1995 Nov 1;92(9):2705–14

Atrioventricular node reentry with 'smooth' AV node function curves: a different arrhythmia substrate? Sheahan RG, et al. **Circulation** 1996 Mar 1;93(5):969–72

Different vagal modulation of the sinoatrial node and AV node in patients with congestive heart failure. Kowallik P, et al. **Clin Sci (Colch)** 1996;91 Suppl:58–61

Effect of sequential radiofrequency ablation lesions at fast and slow atrioventricular nodal pathway positions in patients with paroxysmal atrial fibrillation. Garratt CJ, et al. **Heart** 1996 May;75(5):502–8

Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. Xiao HB, et al. **Int J Cardiol** 1996 Feb;53(2):163–70

Multiple anterograde atrioventricular node pathways in patients with atrioventricular node reentrant tachycardia. Tai CT, et al. **J Am Coll Cardiol** 1996 Sep;28(3):725–31

PR/RR interval ratio during rapid atrial pacing: a simple method for confirming the presence of slow AV nodal pathway conduction. Baker JH 2nd, et al. **J Cardiovasc Electrophysiol** 1996 Apr;7(4):287–94

Nonreentrant supraventricular tachycardia due to double ventricular response via dual atrioventricular nodal pathways. Ajiki K, et al. **J Electrocardiol** 1996 Apr; 29(2):155–60

Effects of atrioventricular intervals on right atrial monophasic action potential duration during pacing or reciprocating tachycardia. Kanda A, et al. **Jpn Heart J** 1995 Jul;36(4):439–50

The relationship between refractory period and conduction time of the AV node under various cycle lengths in the canine heart. The significance of wavelength and excitable gap in reentrant tachycardia. Segawa K. **Jpn Heart J** 1996 May;37(3):373–82

An unusual cause of tachycardia–induced myopathy. Anselme F, et al. **Pacing Clin Electrophysiol** 1996 Jan; 19(1):115–9

Complex arrhythmia substrate in supraventricular tachycardia: implications for radiofrequency ablation. Csanádi Z. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):496–7

Reproducibility of electrophysiological measurements in cardiac transplant recipients. Scott CD, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):282–7

[Variant gap phenomenon in A–V conduction] Guo J, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Aug;75(8):494–7, 512 (Eng. Abstr.) **(Chi)**

[Unusual manifestations of dual atrioventricular nodal conduction] Mádle A. **Vnitr Lek** 1995 Nov;41(11):783–6 (Eng. Abstr.) **(Cze)**

[Importance of atrioventricular synchrony in hypertrophic obstructive cardiomyopathy treated by cardiac pacing] Gras D, et al. **Arch Mal Coeur Vaiss** 1995 Feb;88(2):215–23 (Eng. Abstr.) **(Fre)**

[Double responses] Motté G, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:11–8 (Eng. Abstr.) **(Fre)**

[Shortening of atrioventricular interval improves ventricular filling and clinical outcome in patients with DDD pacemaker and left ventricular hypertrophy] Rossi R, et al. **Cardiologia** 1996 May;41(5):441–7 (Eng. Abstr.) **(Ita)**

[Mechanisms and dynamics of episodes of progression of of 2:1 atrioventricular to high degree atrioventricular block] Fagundes ML, et al. **Arq Bras Cardiol** 1995 May; 64(5):447–53 (Eng. Abstr.) **(Por)**

[Analysis of the junctional rhythm characteristics in patients with nodal reentry tachycardia treated with slow pathway radiofrequency ablation] Mendonça A, et al. **Arq Bras Cardiol** 1995 Jul;65(1):23–6 (Eng. Abstr.) **(Por)**

SURGERY

Selective radiofrequency ablation of the "slow" atrioventricular nodal pathway for control of the ventricular response to atrial fibrillation. Canby RC, et al. **Am J Cardiol** 1996 Jun 15;77(15):1358–61

Transcatheter modification of the atrioventricular node in dogs, using radiofrequency energy. Wright KN, et al. **Am J Vet Res** 1996 Feb;57(2):229–35

Cryosurgical ablation of fetal atrioventricular node: new model to treat fetal malignant tachyarrhythmias. Assad RS, et al. **Ann Thorac Surg** 1995 Dec;60(6 Suppl):S629–32

Left atrioventricular valve incompetence after repair of common atrioventricular canal defects. Michielon G, et al. **Ann Thorac Surg** 1995 Dec;60(6 Suppl):S604–9

Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Edner M, et al. **Br Heart J** 1995 Sep;74(3):261–7

Prediction of atrioventricular block during radiofrequency ablation of the slow pathway of the atrioventricular node. Hintringer F, et al. **Circulation** 1995 Dec 15;92(12):3490–6

Incidence of complete atrioventricular block following attempted radiofrequency catheter modification of the atrioventricular node in 880 patients. Results of the Multicenter European Radiofrequency Survey (MERFS) The Working Group on Arrhythmias of the European Society of Cardiology. Hindricks G. **Eur Heart J** 1996 Jan; 17(1):82–8

Emergent radiofrequency ablation of the AV node in a neonate with unstable, refractory supraventricular tachycardia. Erickson CC, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1959–62

Feasibility of radiofrequency powered, thermal balloon ablation of atrioventricular bypass tracts via the coronary sinus: in vivo canine studies. Fram DB, et al. **Pacing Clin Electrophysiol** 1995 Aug;18(8):1518–30

Long–term follow–up of patients treated by radiofrequency ablation of the atrioventricular junction. Jensen SM, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1609–14

Transcatheter radiofrequency ablation of atrioventricular by–pass tracts—a definitive cure of Wolff–Parkinson White syndrome. Dan GA, et al. **Rom J Intern Med** 1995 Jul–Dec; 33(3–4):169–88

[Mid–term outcome of escape rhythm after radiofrequency ablation of the atrioventricular junction] Deharo JC, et al. **Arch Mal Coeur Vaiss** 1996 Mar;89(3):319–24 (Eng. Abstr.) **(Fre)**

[Management of nodal reentrant tachycardia with radiofrequency: predictive criteria of success] Jaïs P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1849–54 (Eng. Abstr.) **(Fre)**

[Radiofrequency ablation of intranodal tachycardia] Moncada E, et al. **Arch Mal Coeur Vaiss** 1995 Feb; 88(2):235–40 (Eng. Abstr.) **(Fre)**

[Catheter ablation and modulation of the atrioventricular junction; current aspects] Robert F, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:65–73 (50 ref.) (Eng. Abstr.) **(Fre)**

[Junctional arrhythmias in radiofrequency modification of the atrioventricular node] Schumacher B, et al. **Z Kardiol** 1995 Dec;84(12):977–85 (Eng. Abstr.) **(Ger)**

[The radiofrequency catheter ablation of occult accessory atrioventricular pathways] Parreira L, et al. **Rev Port Cardiol** 1996 Feb;15(2):111–7, 99 (Eng. Abstr.) **(Por)**

[Ablation of the atrioventricular node using radiofrequency in a cirrhosis patient] Oropeza ES, et al. **Rev Invest Clin** 1995 Jul–Aug;47(4):297–302 (Eng. Abstr.) **(Spa)**

ATROCITIES see VIOLENCE

ATROPA BELLADONNA see BELLADONNA

ATROPHY

DIAGNOSIS

Electro–oculogram in multiple system and late onset cerebellar atrophies. Arpa J, et al. **Rev Neurol** 1995 Sep–Oct;23(123):969–74

[Norman's cerebellar atrophy. A case diagnosed by clinical signs and neuroimaging] Pascual–Castroviejo I, et al. **Neurologia** 1995 Jun–Jul;10(6):249–51 (Eng. Abstr.) **(Spa)**

GENETICS

A sporadic case of dentatorubral pallidoluysian atrophy (DRPLA) with CAG repeat expansion but no clinical abnormalities in the father [letter] Shimizu N, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):113–4

Hereditary motor and sensory neuropathy associated with cerebellar atrophy (HMSNCA): a new disease. Fukuhara N, et al. **J Neurol Sci** 1995 Nov;133(1–2):140–51

[Striato–pallido–dentate calcifications and acquired facial atrophy] Derex L, et al. **Rev Neurol (Paris)** 1995 Oct; 151(10):559–62 (13 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Alterations in skeletal muscle related to short–term impaired physical mobility. Kasper CE, et al. **Res Nurs Health** 1996 Apr;19(2):133–42

PHYSIOPATHOLOGY

Reactive and degenerative changes of tissues surrounding a brain tumor. Majchrowska A, et al. **Folia Neuropathol** 1995;33(2):105–10

Brain atrophy in frontotemporal dementia. Frisoni GB, et al. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):157–65

A sporadic case of dentatorubral pallidoluysian atrophy (DRPLA) with CAG repeat expansion but no clinical abnormalities in the father [letter] Shimizu N, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):113–4

Electro–oculogram in multiple system and late onset cerebellar atrophies. Arpa J, et al. **Rev Neurol** 1995 Sep–Oct;23(123):969–74

[Norman's cerebellar atrophy. A case diagnosed by clinical signs and neuroimaging] Pascual–Castroviejo I, et al. **Neurologia** 1995 Jun–Jul;10(6):249–51 (Eng. Abstr.) **(Spa)**

ATROPINE

ADMINISTRATION & DOSAGE

Standard and higher doses of atropine in a canine model of pulseless electrical activity [see comments] DeBehnke DJ, et al. **Acad Emerg Med** 1995 Dec;2(12):1034–41. Comment in: Acad Emerg Med 1995 Dec;2(12):1023–4.

Duration of action of intranasal atropine on methacholine–induced nasal secretions. Baroody FM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar; 122(3):321–3

Should the routine use of atropine before succinylcholine in children be reconsidered? McAuliffe G, et al. **Can J Anaesth** 1995 Aug;42(8):724–9

Comparison of the effects of atropine in vivo and ex vivo (radioreceptor assay) after oral and intramuscular administration to man. Volz–Zang C, et al.

Eur J Clin Pharmacol 1995;49(1-2):45-49
A placebo-controlled trial using intravenous atropine as an adjunct to conscious sedation in pediatric esophagogastroduodenoscopy. Hofley MA, et al. **Gastrointest Endosc** 1995 Nov;42(5):457-60
[Comparison of the effect of selected cholinesterase reactivators combined with atropine on the toxicity of soman and foadrin in mice] Kassa J. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(1 Suppl):63-6 (Eng. Abstr.) **(Cze)**

ADVERSE EFFECTS

Accidental prolonged mydriasis in anesthesiologists [letter] Tabboush ZS. **Anesth Analg** 1995 Dec;81(6):1312-3
Neostigmine, atropine, and glycopyrrolate: does neostigmine cross the placenta? Clark RB, et al. **Anesthesiology** 1996 Feb;84(2):450-2

ANALOGS & DERIVATIVES see ATROPINE DERIVATIVES

BLOOD

Plasma and urine concentrations of atropine after the ingestion of cooked deadly nightshade berries. Schneider F, et al. **J Toxicol Clin Toxicol** 1996;34(1):113-7

DIAGNOSTIC USE

Prognostic significance of normal dobutamine-atropine stress sestamibi scintigraphy in women with chest pain. Geleijnse ML, et al. **Am J Cardiol** 1996 May 15;77(12):1057-61
Dobutamine-atropine stress echocardiography in asymptomatic healthy individuals. The relativity of stress-induced hyperkinesia. Carstensen S, et al. **Circulation** 1995 Dec 15;92(12):3453-63
Results of dipyridamole plus atropine echo stress test for the diagnosis of coronary artery disease. Lanzarini L, et al. **Int J Card Imaging** 1995 Dec;11(4):233-40
Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. Geleijnse ML, et al. **J Am Coll Cardiol** 1996 Aug;28(2):447-54
Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. Ling LH, et al. **J Am Coll Cardiol** 1996 Sep;28(3):551-7
Safety and feasibility of dobutamine-atropine stress echocardiography in patients with ischemic left ventricular dysfunction. Cornel JH, et al. **J Am Soc Echocardiogr** 1996 Jan-Feb;9(1):27-32
[Use of high doses of atropine during dipyridamole echocardiography: safety and efficacy of the combined test] Coletta C, et al. **G Ital Cardiol** 1995 Nov;25(11):1389-98 (Eng. Abstr.) **(Ita)**
[Results and prognostic significance of echocardiography-dobutamine + atropine test in recent non-Q wave myocardial infarction] Lanzarini L, et al. **G Ital Cardiol** 1996 Mar;26(3):261-72 (Eng. Abstr.) **(Ita)**
[Postischemic dysfunction and persistent ischemia in the early postinfarction period. Evaluation by echo-dobutamine-atropine test] Rosselli P, et al. **G Ital Cardiol** 1996 Feb;26(2):177-86 (Eng. Abstr.) **(Ita)**
[Stress echocardiography with dipyridamole/atropine in the detection of myocardial ischemia: a comparison with thallium-201 scintigraphy and an angiographic correlation] Trabulo M, et al. **Rev Port Cardiol** 1995 Nov;14(11):959-62 **(Por)**
[Diagnosis of myocardial ischemia by dynamic digital echocardiography with dobutamine and atropine] Guadalajara Boo JF, et al. **Arch Inst Cardiol Mex** 1995 Jul-Aug;65(4):330-41 (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine. Clement JG, et al. **Biopharm Drug Dispos** 1995 Jul;16(5):415-25
Pharmacokinetics of HI-6 and atropine in anaesthetized pigs after administration by a new autoinjector. Nyberg AG, et al. **Biopharm Drug Dispos** 1995 Nov;16(8):635-51

PHARMACOLOGY

The effect of cholinergic stimulation on cultured smooth muscle cells. Malkowicz SB, et al. **Adv Exp Med Biol** 1995; 385:257-60
Effects of furosemide, exercise, and atropine on tracheal mucus transport rate in horses. Maxson AD, et al. **Am J Vet Res** 1995 Jul;56(7):908-12
Characterization of chronotropic and dysrhythmogenic effects of atropine in dogs with bradycardia. Rishniw M, et al. **Am J Vet Res** 1996 Mar;57(3):337-41
Microwave influence on the isolated heart function: II. Combined effect of radiation and some drugs. Pakhomov AG, et al. **Bioelectromagnetics** 1995;16(4):250-4
Effect of selective and non-selective muscarinic blockade on baclofen inhibition of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Tatsuta M, et al. **Carcinogenesis** 1996 Feb;17(2):293-6
Muscarinic cholinergic antagonism does not enhance recovery from hypoglycemia in IDDM. Hvidberg A, et al. **Diabetes Care** 1995 Mar;18(3):404-7
Atropine inhibits the increase in gastric emptying during hypoglycemia in humans. Schvarcz E, et al. **Diabetes Care** 1995 Nov;18(11):1463-7
Effects of atropine and soman on the pharmacokinetics of the oxime HLö 7 dimethanesulfonate in anesthetized guinea-pigs. Worek F, et al. **Drug Chem Toxicol** 1995 May-Aug;18(2-3):137-49
Comparison of the effects of atropine in vivo and ex vivo (radioreceptor assay) after oral and intramuscular administration to man. Volz-Zang C, et al. **Eur J Clin Pharmacol** 1995;49(1-2):45-49
Is alpha-adrenoceptor blockade responsible for atropine flush? Chang KC, et al. **Eur J Pharmacol** 1995 Sep 25; 284(3):331-4
Effect of atropine on the frequency of reflux and transient lower esophageal sphincter relaxation in normal subjects. Mittal RK, et al. **Gastroenterology** 1995 Nov;109(5):1547-54
The atropine factor in pharmacologic stress echocardiography. Echo Persantine (EPIC) and Echo Dobutamine International Cooperative (EDIC) Study Groups. Pingitore A, et al. **J Am Coll Cardiol** 1996 Apr; 27(5):1164-70
Interactions of the cardiac chronotropic effects of rilmenidine with the autonomic nervous system in conscious dogs: comparison with clonidine. Boucher M, et al. **J Auton Pharmacol** 1996 Feb;16(1):13-20
Induction of insulin resistance by cholinergic blockade with atropine in the cat. Xie H, et al. **J Auton Pharmacol** 1995 Oct;15(5):361-9
Effect of sodium naproxen on inflammatory response induced by anterior chamber paracentesis in the rabbit. Bucolo C, et al. **J Pharm Pharmacol** 1995 Sep;47(9):708-12
Effects of benztropine on behavioral and toxic effects of cocaine: comparison with atropine and the selective dopamine uptake inhibitor 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-propyl)-piperazine. Acri JB, et al. **J Pharmacol Exp Ther** 1996 Apr; 277(1):198-206
Amygdala beta-noradrenergic influences on memory storage involve cholinergic activation. Introini-Collison IB, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):57-64
Effects of posttraining administration of glucose on retention of a habituation response in mice: participation of a central cholinergic mechanism. Kopf SR, et al. **Neurobiol Learn Mem** 1996 May;65(3):253-60
Betel chewing increases the skin temperature: effects of atropine and propranolol. Chu NS. **Neurosci Lett** 1995 Jul 14;194(1-2):130-2
Modulation of the relationship between amylase and chymotrypsinogen secretion in atropine- and MK329-infused rats. Maouyo D, et al. **Pancreas** 1995 Nov; 11(4):330-40
Effects of TRH and atropine on induction and duration of anesthesia with propofol in rats. Larsson JE, et al. **Peptides** 1996;17(2):293-7
Atropine increases pilocarpine-induced yawning behavior in paradoxical sleep deprived rats. Lobo LL, et al. **Pharmacol Biochem Behav** 1995 Nov;52(3):485-8
Effect of atropine on cyanide-induced acute lethality in mice. Yamamoto H. **Toxicol Lett** 1995 Oct;80(1-3):29-33
The effects of atropine and glycopyrrolate on heart rates in conscious mature goats. Pablo LS, et al. **Vet Surg** 1995 Nov-Dec;24(6):531-4
[Study on CCK-induced gallbladder emptying with real-time ultrasonography] Wang Z, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jun;34(6):385-7 (Eng. Abstr.) **(Chi)**
[Protective effect of M- and N-cholinergic receptor blockaders during acute ammonia poisoning] Kosenko EA, et al. **Biull Eksp Biol Med** 1995 Nov;120(11):489-92 **(Rus)**
[Atropine suppresses associative potentiation in the hippocampus] Sokolov MV, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):34-8 (Eng. Abstr.) **(Rus)**

POISONING

Poisoning by antidiarrhoeals [letter] Kulkarni ML, et al. **Natl Med J India** 1995 Sep-Oct;8(5):244
[Accidental atropine poisoning. Anticholinergic syndrome in a child after intranasal overdose] Jelstad A, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3030-1 (Eng. Abstr.) **(Nor)**

THERAPEUTIC USE

The principles and the PEA [editorial; comment] Christenson JM. **Acad Emerg Med** 1995 Dec;2(12):1023-4. Comment on: Acad Emerg Med 1995 Dec;2(12):1034-41.
Small-bowel obstruction and the effects of lidocaine, atropine and hexamethonium on inflammation and fluid losses [see comments] Nellgård P, et al. **Acta Anaesthesiol Scand** 1996 Mar;40(3):287-92. Comment in: Acta Anaesthesiol Scand 1996 Mar;40(3):285-6.
GI cocktail [letter; comment] Rosenberg CA. **Ann Emerg Med** 1996 Jul;28(1):104-5. Comment on: Ann Emerg Med 1995 Dec;26(6):687-90.
Arrhythmias in organophosphate poisoning: effect of atropine and bispyridinium oximes. Worek F, et al. **Arch Int Pharmacodyn Ther** 1995 May-Jun;329(3):418-35
Antihistaminics in idiopathic dystonia [letter; comment] Lang AE. **Arch Neurol** 1996 May;53(5):405. Comment on: Arch Neurol 1995 Apr;52(4):405-7.
Treatment of organophosphate poisoning in pigs: antidote administration by a new binary autoinjector. Göransson-Nyberg A, et al. **Arch Toxicol** 1995;70(1):20-7
Dose-response effects of atropine and HI-6 treatment of organophosphorus poisoning in guinea pigs. Koplovitz I, et al. **Drug Chem Toxicol** 1995 May-Aug;18(2-3):119-36
Reversal of atropine-resistant atrioventricular block with intravenous aminophylline in the early phase of inferior wall acute myocardial infarction following treatment with streptokinase. Goodfellow J, et al. **Eur Heart J** 1995 Jun; 16(6):862-5
Is atropine alone sufficient in acute severe organophosphorus poisoning?: experience of a North West Indian Hospital. Singh S, et al. **Int J Clin Pharmacol Ther** 1995 Nov; 33(11):628-30
Antidotal action of atropine sulfate against insecticide benfuracarb poisoning in rats. Ichikawa S, et al. **J Toxicol Sci** 1995 May;20(2):143-8
Anticholinergic prophylaxis does not prevent emesis following strabismus surgery in children. Chisakuta AM, et al. **Paediatr Anaesth** 1995;5(2):97-100
Atropine reverses antinociception induced by 2,5-hexanedione in rats. Pereira ME, et al. **Pharmacol Toxicol** 1995 Aug;77(2):91-4

URINE

Plasma and urine concentrations of atropine after the ingestion of cooked deadly nightshade berries. Schneider F, et al. **J Toxicol Clin Toxicol** 1996;34(1):113-7

ATROPINE DERIVATIVES

PHARMACOLOGY

Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse. Ahrén B, et al. **Diabetologia** 1996 Apr;39(4):383-90

ATT SITES see ATTACHMENT SITES (MICROBIOLOGY)

ATTACHMENT LOSS, PERIODONTAL see PERIODONTAL ATTACHMENT LOSS

ATTACHMENT SITES (MICROBIOLOGY)

Mutational analysis of the att DNA-binding domain of phage Mu transposase. Kim K, et al. **Nucleic Acids Res** 1995 Oct 11;23(19):3937-43

GENETICS

Spontaneous deletion mutants of the Lactococcus lactis temperate bacteriophage BK5-T and localization of the BK5-T attP site. Boyce JD, et al. **Appl Environ Microbiol** 1995 Nov;61(11):4105-9

ATTENDING PHYSICIANS, HOSPITAL see MEDICAL STAFF, HOSPITAL

ATTENTION

The effects of a mobile telephone task on driver behaviour in a car following situation. Alm H, et al. **Accid Anal Prev** 1995 Oct;27(5):707-15
Young drivers' overestimation of their own skill--an experiment on the relation between training strategy and skill. Gregersen NP. **Accid Anal Prev** 1996 Mar; 28(2):243-50
Bicycle accidents and drivers' visual search at left and right turns. Summala H, et al. **Accid Anal Prev** 1996 Mar; 28(2):147-53
Sustained attention problems in children with early treated congenital hypothyroidism. Kooistra L, et al. **Acta Paediatr** 1996 Apr;85(4):425-9
The effects of variation of an irrelevant dimension on same-different visual judgments. Ballesteros S, et al. **Acta Psychol (Amst)** 1996 Jun;92(1):1-16
Where did you go wrong? Errors, partial errors, and the nature of human information processing. Coles MG, et al. **Acta Psychol (Amst)** 1995 Nov;90(1-3):129-44
Perception-action coupling and S-R compatibility. de Jong R. **Acta Psychol (Amst)** 1995 Nov;90(1-3):287-99
Cross-task cross talk in memory and perception. Dutta A, et al. **Acta Psychol (Amst)** 1995 Nov;90(1-3):49-62
Speed-accuracy decomposition yields a sudden insight into all-or-none information processing. Kounios J, et al. **Acta Psychol (Amst)** 1995 Nov;90(1-3):229-41
Does perceptual analysis continue during selection and production of a speeded response? Levy J, et al. **Acta Psychol (Amst)** 1995 Nov;90(1-3):245-60
Continuous versus discrete information processing in pattern recognition. Massaro DW, et al. **Acta Psychol (Amst)** 1995 Nov;90(1-3):193-209
Overlapping stage models and reaction time additivity: effects of the activation equation. Miller J, et al. **Acta Psychol (Amst)** 1995 Nov;90(1-3):11-28
Inattention and the perception of visual feature conjunctions. Modigliani V, et al. **Acta Psychol (Amst)** 1996 Mar; 91(2):121-9

Discrete vs. continuous processing: the fate of an incompletely processed perceptual dimension. Sanders AF. **Acta Psychol (Amst)** 1995 Nov;90(1-3):211-27

The availability versus the use of partial information: multiple levels of selective processing between perception and action. Smid HG, et al. **Acta Psychol (Amst)** 1995 Nov; 90(1-3):145-62

On-line visual control of aiming movements? Spijkers W, et al. **Acta Psychol (Amst)** 1995 Nov;90(1-3):333-48

Information integration in cross-modal pattern recognition: an argument for acquired modularity. Thompson LA, et al. **Acta Psychol (Amst)** 1996 Jun;92(1):79-104

Viability of resource theories in explaining time-sharing performance. Tsang PS, et al. **Acta Psychol (Amst)** 1996 Mar;91(2):175-206

The role of vision in repetitive circle drawing. Zelaznik HN, et al. **Acta Psychol (Amst)** 1996 Jun;92(1):105-18

Attention and mental performance in confinement: evidence from cognitive psychophysiology. Mecklinger A, et al. **Adv Space Biol Med** 1996;5:183-200

Specific impairments in self-regulation in children exposed to alcohol prenatally. Kodituwakku PW, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1558-64

Effects of disease-related cues in alcoholic inpatients: results of a controlled "Alcohol Stroop" study. Stetter F, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):593-9

Alzheimer disease, attention, and the cholinergic system. Lawrence AD, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:43-9

Replication and extended analysis of behavior state, environmental events, and related variables among individuals with profound disabilities. Guess D, et al. **Am J Ment Retard** 1995 Jul;100(1):36-51

Attention regulation by children with Down syndrome: coordinated joint attention and social referencing looks. Kasari C, et al. **Am J Ment Retard** 1995 Sep;100(2):128-36

Electrodermal orienting activity in children with Down syndrome. Martinez-Selva JM, et al. **Am J Ment Retard** 1995 Jul;100(1):51-8

Gross motor activity and attention in three adults with brain injury. Shimelman A, et al. **Am J Occup Ther** 1995 Nov-Dec;49(10):973-9

Attentional selection and word processing in Stroop and word search tasks: the role of selection for action. Brown TL. **Am J Psychol** 1996 Summer;109(2):265-86

Attention in direct and indirect memory tasks with short- and long-term probes. Kellogg RT, et al. **Am J Psychol** 1996 Summer;109(2):205-17

Effects of memory demand and motivation on sustained attention in young and older adults. Tomporowski PD, et al. **Am J Psychol** 1996 Summer;109(2):187-204

Auditory psychophysics and perception. Hirsh IJ, et al. **Annu Rev Psychol** 1996;47:461-84 (110 ref.)

Activity measurements support dimensional assessment. Pinto LP, et al. **Behav Modif** 1996 Jul;20(3):243-58

Overt orienting in the rat: parametric studies of cued detection of visual targets. Bushnell PJ. **Behav Neurosci** 1995 Dec;109(6):1095-105

The assessment of unwanted intrusive thoughts: a review and critique of the literature. Clark DA, et al. **Behav Res Ther** 1995 Nov;33(8):967-76 (60 ref.)

A follow-up study of cognitive bias in generalized anxiety disorder. Mogg K, et al. **Behav Res Ther** 1995 Nov; 33(8):927-35

Attentional bias in obsessional compulsive disorder. Tata PR, et al. **Behav Res Ther** 1996 Jan;34(1):53-60

Do semantic priming effects correlate with sensory gating in schizophrenia? Vinogradov S, et al. **Biol Psychiatry** 1996 May 1;39(9):821-4

Visual attention in patients with chronic obstructive pulmonary disease. Vos PJ, et al. **Biol Psychol** 1995 Nov 16;41(3):295-305

Hunger, caloric preloading and the selective processing of food and body shape words. Green MW, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):143-51

Applying the health belief model to the prediction of attendance at health checks in general practice. Norman P. **Br J Clin Psychol** 1995 Sep;34 (Pt 3):461-70

Reality discrimination, reality monitoring and disposition towards hallucination. Rankin PM, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):517-28

The effects of varying information content and speaking aloud on auditory hallucinations. Gallagher AG, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):143-55

Are visual search procedures adapted to the nature of the script? Green DW, et al. **Br J Psychol** 1996 May;87 (Pt 2):311-26

Screening cervical smears. Laming D. **Br J Psychol** 1995 Nov;86 (Pt 4):507-16

Emotional expression in upside-down faces: evidence for configurational and componential processing. McKelvie SJ. **Br J Soc Psychol** 1995 Sep;34 (Pt 3):325-34

Mindless processing of requests? Don't ask twice. Slugoski BR. **Br J Soc Psychol** 1995 Sep;34 (Pt 3):335-50

Directional bias of initial visual exploration. A symptom of neglect in Parkinson's disease. Ebersbach G, et al. **Brain** 1996 Feb;119 (Pt 1):79-87

Non-spatial attention disorders in patients with frontal or posterior brain damage. Godefroy O, et al. **Brain** 1996 Feb; 119 (Pt 1):191-202

Asymmetries in the covert orienting of visual spatial attention to spatial and non-spatial cues in Alzheimer's disease. Maruff P, et al. **Brain** 1995 Dec;118 (Pt 6):1421-35

Reading direction and attention: effects on lateralized ignoring. Eviatar Z. **Brain Cogn** 1995 Nov;29(2):137-50

On functional brain asymmetries in perceptual priming. Koivisto M. **Brain Cogn** 1995 Oct;29(1):36-53

Attention deficits and dual task demands after mild traumatic brain injury. Cicerone KD. **Brain Inj** 1996 Feb;10(2):79-89

Recognition potential latency and word image degradation. Rudell AP, et al. **Brain Lang** 1995 Nov;51(2):229-41

Conceptual automaticity in recognition memory: levels-of-processing effects on familiarity. Toth JP. **Can J Exp Psychol** 1996 Mar;50(1):123-38

Integration of orthographic, conceptual, and episodic information on implicit and explicit tests. Weldon MS, et al. **Can J Exp Psychol** 1996 Mar;50(1):72-86

Information-processing correlates of reported sexual abuse in eating-disordered and comparison women. Waller G, et al. **Child Abuse Negl** 1995 Jun;19(6):745-59

A developmental investigation of inattentiveness and hyperactivity. Carlson EA, et al. **Child Dev** 1995 Feb; 66(1):37-54

Individual differences in infant visual attention: recognition of degraded visual forms by four-month-olds. Frick JE, et al. **Child Dev** 1996 Feb;67(1):188-204

What can be learned from something's not being named. Merriman WE, et al. **Child Dev** 1995 Dec;66(6):1890-908

Anxiety and the processing of emotionally threatening stimuli: distinctive patterns of selective attention among high- and low-test-anxious children. Vasey MW, et al. **Child Dev** 1996 Jun;67(3):1173-85

Aggressive boys' hostile perceptual and response biases: the role of attention and impulsivity. Waldman ID. **Child Dev** 1996 Jun;67(3):1015-33

A laboratory method for investigating influences on switching attention to task-unrelated imagery and thought. Giambra LM. **Conscious Cogn** 1995 Mar;4(1):1-21

Using self-view television to distinguish between self-examination and social behavior in the bottlenose dolphin (Tursiops truncatus). Marten K, et al. **Conscious Cogn** 1995 Jun;4(2):205-24

Unilateral neglect can be affected by stimuli in the neglected field. Berti A, et al. **Cortex** 1995 Jun;31(2):331-43

Development of an aspect of executive control: development of the abilities to remember what I said and to "do as I say, not as I do". Diamond A, et al. **Dev Psychobiol** 1996 May;29(4):315-34

Contributions of experience to the development of musical processing in infancy. Lynch MP, et al. **Dev Psychobiol** 1995 Nov;28(7):377-98

Asymmetry of rapid eye movements in chronic unilateral neglect does not change with behavioral improvement induced by rehabilitation treatment. Doricchi F, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jan;98(1):51-8

Visual search performance with complete and incomplete visual lobe areas. Courtney AJ, et al. **Ergonomics** 1996 May; 39(5):749-56

Evidence of strategic effects in the modulation of orienting of attention. Nougier V, et al. **Ergonomics** 1996 Sep; 39(9):1119-33

Human errors in fatal and serious occupational accidents in Finland. Salminen S, et al. **Ergonomics** 1996 Jul;39(7):980-8

Fluctuations in visual neglect after stroke? Levy D, et al. **Eur Neurol** 1995;35(6):341-3

The development of visual preferences in art-trained and non-art-trained schoolchildren. Bezruczko N, et al. **Genet Soc Gen Psychol Monogr** 1996 May;122(2):179-96

Aging and encoding in memory: false alarms and decision criteria in a word-pair recognition task. Isingrini M, et al. **Int J Aging Hum Dev** 1995;41(1):79-88

Stroop interference and food intake. Overduin J, et al. **Int J Eat Disord** 1995 Nov;18(3):277-85

Increase of REM duration and decrease of REM latency after a prolonged test of visual attention. De Gennaro L, et al. **Int J Neurosci** 1995 Jun;82(3-4):163-8

The attentional system in brain injury survivors. León-Carrión J, et al. **Int J Neurosci** 1996 Apr; 85(3-4):231-6

A particular perspective on impasses in the clinical situation: further reflections on psychoanalytic listening. Schwaber EA. **Int J Psychoanal** 1995 Aug;76 (Pt 4):711-22

The Pavlovian "principle of strength". Windholz G. **Integr Physiol Behav Sci** 1995 Jul-Sep;30(3):228-36

Working memory, attention, and communication disturbances in schizophrenia. Docherty NM, et al. **J Abnorm Psychol** 1996 May;105(2):212-9

Display visual angle and attentional scanpaths on the span of apprehension task in schizophrenia. Granholm E, et al. **J Abnorm Psychol** 1996 Feb;105(1):17-24

Effects of modality shift and motor response shift on simple reaction time in schizophrenia patients. Hanewinkel R, et al. **J Abnorm Psychol** 1996 Aug;105(3):459-63

Psychopathy and dual-task performance under focusing conditions. Kosson DS. **J Abnorm Psychol** 1996 Aug; 105(3):391-400

Dot Enumeration Perceptual Organization Task (DEPOT): evidence for a short-term visual memory deficit in schizophrenia. Rabinowicz EF, et al. **J Abnorm Psychol** 1996 Aug;105(3):336-48

Anxiety and the use of strategies in the performance of a sentence-picture verification task. Richards A, et al. **J Abnorm Psychol** 1996 Feb;105(1):132-6

Stimulus configuration and context effects in perceptual organization in schizophrenia. Silverstein SM, et al. **J Abnorm Psychol** 1996 Aug;105(3):410-20

Unconscious mood-congruent memory bias in depression. Watkins PC, et al. **J Abnorm Psychol** 1996 Feb;105(1):34-41

Effects of focus of attention on anxiety levels and social performance of individuals with social phobia. Woody SR. **J Abnorm Psychol** 1996 Feb;105(1):61-9

Auditory attentional bandwidth: effect of level and frequency range. Botte MC. **J Acoust Soc Am** 1995 Nov;98(5 Pt 1):2475-85

Retardation of mentation in depressives: Posner's covert orientation of visual attention test. Smith MJ, et al. **J Affect Disord** 1995 Dec 13;35(3):107-15

On focused association and the analytic surface: clinical opportunities in resolving analytic stalemate. Kern JW. **J Am Psychoanal Assoc** 1995;43(2):393-422

On the reinforcing effects of the content of verbal attention. Fisher WW, et al. **J Appl Behav Anal** 1996 Summer; 29(2):235-8

Psychophysiological detection through the guilty knowledge technique: effects of mental countermeasures. Ben-Shakhar G, et al. **J Appl Psychol** 1996 Jun;81(3):273-81

Disorders of regulation of cognitive activity in autistic children. Adrien JL, et al. **J Autism Dev Disord** 1995 Jun; 25(3):249-63

Impact of time delay, observational learning, and attentional cuing upon word recognition during integrated small-group instruction. Schoen SF, et al. **J Autism Dev Disord** 1995 Oct;25(5):503-19

Visuo-spatial working memory limitations in low visuo-spatial high verbal intelligence children. Cornoldi C, et al. **J Child Psychol Psychiatry** 1995 Sep;36(6):1053-64

Construct validity in the Trail Making Test: what makes Part B harder? Gaudino EA, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):529-35

Construct validity of various verbal and visual memory tests. Larrabee GJ, et al. **J Clin Exp Neuropsychol** 1995 Aug; 17(4):536-47

Perils and pitfalls on the path to normal potential: the role of impaired attention. Homage to Herbert G. Birch. Mirsky AF. **J Clin Exp Neuropsychol** 1995 Aug;17(4):481-98 (36 ref.)

Continuous performance tests: a comparison of modalities. Baker DB, et al. **J Clin Psychol** 1995 Jul;51(4):548-51

Rey 15-item memorization and Dot counting scores in a "stress" claim worker's compensation population: relationship to personality (MCMI) scores. Boone KB, et al. **J Clin Psychol** 1995 May;51(3):457-63

Orientation invariant pattern recognition by pigeons (Columba livia) and humans (Homo sapiens). Delius JD, et al. **J Comp Psychol** 1995 Sep;109(3):278-90

Hand preferences for a coordinated bimanual task in 110 chimpanzees (Pan troglodytes): cross-sectional analysis. Hopkins WD. **J Comp Psychol** 1995 Sep;109(3):291-7

Diet preference in rats (Rattus norvegicus) as a function of odor exposure, odor concentration, and conspecific presence. Stetter KR, et al. **J Comp Psychol** 1995 Dec; 109(4):384-9

Scent counter-marks: specialized mechanisms of perception and response to individual odors in golden hamsters (Mesocricetus auratus). Wilcox RM, et al. **J Comp Psychol** 1995 Dec;109(4):349-56

Concurrent-schedule performance in dairy cows: persistent undermatching. Foster TM, et al. **J Exp Anal Behav** 1996 Jan;65(1):57-80

A computer touch-screen apparatus for training visual discriminations in rats. Markham MR, et al. **J Exp Anal Behav** 1996 Jan;65(1):173-82

The development of phonological rules and visual strategies in average and poor spellers. Lennox C, et al. **J Exp Child Psychol** 1996 Jun;62(1):60-83

Valuing of identity, distribution of attention, and perceptual salience in free and rule-governed classifications. Odom RD, et al. **J Exp Child Psychol** 1996 Mar;61(2):173-89

Children's metamemory about the influence of conceptual relations on recall. O'Sullivan JT. **J Exp Child Psychol** 1996 Jun;62(1):1-29

Children's performance on "animal tests" of oddity: implications for cognitive processes required for tests of oddity and delayed nonmatch to sample. Overman W, et al. **J Exp Child Psychol** 1996 Jul;62(2):223-42

Performance demands in the selection of objects for counting. Towse JN, et al. **J Exp Child Psychol** 1996 Feb;61(1):67-79

Conditions affecting beliefs about visual perception among children and adults. Winer GA, et al. **J Exp Child Psychol** 1996 Mar;61(2):93-115

Effect of relative stimulus validity: learning or performance deficit? Cole RP, et al. **J Exp Psychol Anim Behav Process** 1995 Oct;21(4):293-303

Conditioned antisickness: heat as an internal stimulus in conditioning taste aversion and aversion failure in rats. Davey VA, et al. **J Exp Psychol Anim Behav Process** 1996 Jul;22(3):235-43

Serial position effects and duration of memory for nonspatial stimuli in rats. Deacon RM, et al. **J Exp Psychol Anim Behav Process** 1995 Oct;21(4):285-92

Role of stimulus ambiguity in conditional learning. de Brugada I, et al. **J Exp Psychol Anim Behav Process** 1995 Oct;21(4):275-84

Judging relative duration: the role of rule and instructional variables. Fetterman JG, et al. **J Exp Psychol Anim Behav Process** 1996 Jul;22(3):350-61

Effect of US signal value on blocking of a CS–US association. Goddard MJ. **J Exp Psychol Anim Behav Process** 1996 Jul;22(3):258–64

Discrimination of relative numerosity and stimulus mixture by pigeons with comparable tasks. Honig WK, et al. **J Exp Psychol Anim Behav Process** 1995 Oct;21(4):348–62

Impact of shock on pain reactivity: I. Whether hypo- or hyperalgesia is observed depends on how pain reactivity is tested. Illich PA, et al. **J Exp Psychol Anim Behav Process** 1995 Oct;21(4):331–47

Speeding up an internal clock in humans? Effects of click trains on subjective duration. Penton-Voak IS, et al. **J Exp Psychol Anim Behav Process** 1996 Jul;22(3):307–20

Categorical scaling of stimulus duration by humans [comment] Wearden JH. **J Exp Psychol Anim Behav Process** 1995 Oct;21(4):318–30 . Comment on: J Exp Psychol Anim Behav Process 1995 Jan;21(1):43–63.

The effects of divided attention on encoding and retrieval processes in human memory. Craik FI, et al. **J Exp Psychol Gen** 1996 Jun;125(2):159–80

Vertical orienting control: evidence for attentional bias and "neglect" in the intact brain. Drain M, et al. **J Exp Psychol Gen** 1996 Jun;125(2):139–58

Attentional persistence for features of hierarchical patterns. Robertson LC. **J Exp Psychol Gen** 1996 Sep;125(3):227–49

Repetition deficit in rapid-serial-visual-presentation displays: encoding failure or retrieval failure? Armstrong IT, et al. **J Exp Psychol Hum Percept Perform** 1995 Oct; 21(5):1044–52

Grasping a fruit: selection for action. Castiello U. **J Exp Psychol Hum Percept Perform** 1996 Jun; 22(3):582–603

Morphological and orthographic similarity in visual word recognition. Drews E, et al. **J Exp Psychol Hum Percept Perform** 1995 Oct; 21(5):1098–116

Texture segmentation along the horizontal meridian: nonmonotonic changes in performance with eccentricity. Gurnsey R, et al. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):738–57

Spatial precues affect target discrimination in the absence of visual noise. Henderson JM. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):780–7

Effects of lighting on the perception of facial surfaces. Hill H, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):986–1004

Mechanisms of visual-spatial attention: resource allocation or uncertainty reduction? Luck SJ, et al. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):725–37

Visual stability across saccades while viewing complex pictures. McConkie GW, et al. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):563–81

Perceptual separability, decisional separability, and the identification-speeded classification relationship. Maddox WT, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):795–817

Perception of local three-dimensional shape. Phillips F, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):930–44

Lexical control of within-word eye movements. Pynte J. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):958–69

Spectral regularity as a factor distinct from harmonic relations in auditory grouping. Roberts B, et al. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):604–14

Inversion and processing of component and spatial-relational information in faces. Searcy JH, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):904–15

Is there feature-based attentional selection in visual search? Shih SI, et al. **J Exp Psychol Hum Percept Perform** 1996 Jun;22(3):758–79

Audiovisual links in endogenous covert spatial attention. Spence C, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug;22(4):1005–30

Wayfinding, displacements, and mental maps: velocity fields are not typically used to determine one's aimpoint. Vishton PM, et al. **J Exp Psychol Hum Percept Perform** 1995 Oct; 21(5):978–95

Visual control of posture during walking: functional specificity. Warren WH, et al. **J Exp Psychol Hum Percept Perform** 1996 Aug; 22(4):818–38

Reliability of prosodic cues for resolving syntactic ambiguity. Allbritton DW, et al. **J Exp Psychol Learn Mem Cogn** 1996 May;22(3):714–35

Summation of activation: evidence from multiple primes that converge and diverge within semantic memory. Balota DA, et al. **J Exp Psychol Learn Mem Cogn** 1996 Jul;22(4):827–45

Eye movements and lexical ambiguity resolution: effects of prior encounter and discourse topic. Binder KS, et al. **J Exp Psychol Learn Mem Cogn** 1995 Sep;21(5):1186–96

Attentional limits in memory retrieval. Carrier LM, et al. **J Exp Psychol Learn Mem Cogn** 1995 Sep;21(5):1339–48

Effects of color and pattern on implicit and explicit picture memory. Cave CB, et al. **J Exp Psychol Learn Mem Cogn** 1996 May;22(3):639–53

A syntactic complexity effect with visual patterns: evidence for the syntactic nature of the memory representation. Chechile RA, et al. **J Exp Psychol Learn Mem Cogn** 1996 May;22(3):654–69

Visual memory for novel shapes: implicit coding without attention. DeSchepper B, et al. **J Exp Psychol Learn Mem Cogn** 1996 Jan;22(1):27–47

Interactions of stimulus attributes, base rates, and feedback in recognition. Estes WK, et al. **J Exp Psychol Learn Mem Cogn** 1995 Sep;21(5):1075–95

No enemies in the neighborhood: absence of inhibitory neighborhood effects in lexical decision and semantic categorization. Forster KI, et al. **J Exp Psychol Learn Mem Cogn** 1996 May;22(3):696–713

Alignment-based nonmonotonicities in similarity. Goldstone RL. **J Exp Psychol Learn Mem Cogn** 1996 Jul; 22(4):988–1001

Repetition priming effects for newly formed associations are perceptually based: evidence from shallow encoding and format specificity. Goshen-Gottstein Y, et al. **J Exp Psychol Learn Mem Cogn** 1995 Sep;21(5):1249–62

Level-of-processing effects in word-completion priming: a neuropsychological study. Hamann SB, et al. **J Exp Psychol Learn Mem Cogn** 1996 Jul;22(4):933–47

Processing across the language boundary: a cross-modal priming study of Spanish-English bilinguals. Hernandez AE, et al. **J Exp Psychol Learn Mem Cogn** 1996 Jul; 22(4):846–64

An eye movement analysis of topic-shift effect during repeated reading. Hyönä J. **J Exp Psychol Learn Mem Cogn** 1995 Sep;21(5):1365–73

Intralist interference in recognition memory. Kim K, et al. **J Exp Psychol Learn Mem Cogn** 1995 Sep;21(5):1096–107

Structural alignment in induction and similarity. Lassaline ME. **J Exp Psychol Learn Mem Cogn** 1996 May; 22(3):754–70

Judgments of learning are affected by the kind of encoding in ways that cannot be attributed to the level of recall. Mazzoni G, et al. **J Exp Psychol Learn Mem Cogn** 1995 Sep;21(5):1263–74

Competition and segmentation in spoken-word recognition. Norris D, et al. **J Exp Psychol Learn Mem Cogn** 1995 Sep; 21(5):1209–28

Sequential effects in lexical decision: tests of compound-cue retrieval theory. Ratcliff R, et al. **J Exp Psychol Learn Mem Cogn** 1995 Sep;21(5):1380–8

Attribute conjunctions and the part configuration advantage in object category learning. Saiki J, et al. **J Exp Psychol Learn Mem Cogn** 1996 Jul;22(4):1002–19

Belief revision in children: serial judgment in social cognition and decision-making domains. Schlottmann A, et al. **J Exp Psychol Learn Mem Cogn** 1995 Sep;21(5):1349–64

Cognitive sequence knowledge: what is learned? Wenger JL, et al. **J Exp Psychol Learn Mem Cogn** 1996 May; 22(3):599–619

The effects of category distinctiveness and stimulus relations on young children's use of retrieval clustering strategies. Nida RE, et al. **J Gen Psychol** 1995 Oct;122(4):345–53

Separating the effects of alertness from the effects of encoding in a pitch-imagery task. Sullivan C, et al. **J Gen Psychol** 1996 Apr;123(2):105–14

Rorschach inkblots in the peripheral visual fields: enhanced associative quality to the left of fixation. Brugger P, et al. **J Genet Psychol** 1995 Sep;156(3):385–7

Delay of gratification: mothers' predictions about four attentional techniques. Hom HL Jr, et al. **J Genet Psychol** 1996 Jun;157(2):180–90

Predicting age-related differences in visual information processing using a two-stage queuing model. Ellis RD, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 May; 51(3):P155–65

Age changes in the distribution of visual attention. McCalley LT, et al. **J Gerontol B Psychol Sci Soc Sci** 1995 Nov; 50(6):P316–31

Eye scanning behavior as a discriminator of instrument- and scenery-centered flight task. Katoh Z, et al. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):80–4

Cognitive performance in seasonal affective disorder: pattern recognition and the Stroop task. Drake CL, et al. **J Nerv Ment Dis** 1996 Jan;184(1):56–9

Formal thought disorder in schizophrenia. Linguistic, attentional, and intellectual correlates. Landre NA, et al. **J Nerv Ment Dis** 1995 Nov;183(11):673–80

Attention disturbance in clinical depression. Deficient distractor inhibition or processing resource deficit? Lemelin S, et al. **J Nerv Ment Dis** 1996 Feb;184(2):114–21

Effects of cueing on visuospatial processing in unilateral spatial neglect. Ishiai S, et al. **J Neurol** 1995 Jun; 242(6):367–73

Semantic neglect? [letter] Anderson B. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):349–50

Attentional functions in multiple system atrophy and Parkinson's disease. Meco G, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):393–8

Right sided hemispatial neglect and bilateral cerebral lesions. Weintraub S, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):342–4

The dissection of selection in person perception: inhibitory processes in social stereotyping. Macrae CN, et al. **J Pers Soc Psychol** 1995 Sep;69(3):397–407

Additivity of nonconscious affect: combined effects of priming and exposure. Murphy ST, et al. **J Pers Soc Psychol** 1995 Oct;69(4):589–602

The use of node-link mapping in drug abuse counseling: the role of attentional factors. Czuchry M, et al. **J Psychoactive Drugs** 1995 Apr-Jun;27(2):161–6

Visual laterality patterns for the perception of emotional words in alcoholic and aging individuals. Hutner N, et al. **J Stud Alcohol** 1996 Mar;57(2):144–54

Recognition failure of categorised words: further evidence of exceptions. Gardiner JM, et al. **Memory** 1995 Mar; 3(1):57–66

Does inhibition spread in a manner analogous to spreading activation? Neumann E, et al. **Memory** 1993 Jun;1(2):81–105

Hindsight bias and the misinformation effect: separating blended recollections from other recollection types. Pohl RF, et al. **Memory** 1995 Mar;3(1):21–55

Contextual dependencies: influence on response latency. Shea CH, et al. **Memory** 1995 Mar;3(1):81–95

Flashbulb memories: conceptual and methodological issues. Wright DB, et al. **Memory** 1995 Mar;3(1):67–80 (55 ref.)

Anosognosia for hemiplegia: test of the personal neglect hypothesis. Adair JC, et al. **Neurology** 1995 Dec; 45(12):2195–9

Electrophysiological signs of sustained and transient attention to spatial locations. Heinze HJ, et al. **Neuropsychologia** 1995 Jul;33(7):889–908

Stroop interference and disorders of selective attention. Kingma A, et al. **Neuropsychologia** 1996 Apr;34(4):273–81

Asymmetries in the covert orienting of visual spatial attention in schizophrenia. Maruff P, et al. **Neuropsychologia** 1995 Oct;33(10):1205–23

Sustained arousal and attention after traumatic brain injury. Whyte J, et al. **Neuropsychologia** 1995 Jul;33(7):797–813

Evidence for a global scanpath strategy in viewing abstract compared with realistic images. Zangemeister WH, et al. **Neuropsychologia** 1995 Aug;33(8):1009–25

The intention to act improves unilateral left neglect: two demonstrations. Robertson IH, et al. **Neuroreport** 1995 Dec 29;7(1):246–8

The attentional control of pain: methodological and theoretical concerns. Eccleston C. **Pain** 1995 Oct; 63(1):3–10 (45 ref.)

Short-term memory for color names using Stroop material. Allen CK. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1355–62

Interference with olfactory memory by visual and verbal tasks. Annett JM, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1307–17

Primacy and recency in recognition of odours and recall of odour names. Annett JM, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):787–94

Human memory for odour following monorhinal presentation with and without verbal elaboration. Annett JM, et al. **Percept Mot Skills** 1996 Apr;82(2):378

Measuring the typicality of objects included in environmental scenes: a logistic model for atypicality. Beltran FS, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1343–52

Pop-out in visual search requires practice. Boersema T, et al. **Percept Mot Skills** 1996 Apr;82(2):355–65

Sensory interaction and descriptions of fabric hand. Burns LD, et al. **Percept Mot Skills** 1995 Aug;81(1):120–2

Color-specificity to enhance identification of rear lights. Cameron DL. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):755–69

On the psychophysics of arm-positioning movements. Choi SO, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1163–9

Effects of instruction on a divided visual-field task of face processing. Cormier P, et al. **Percept Mot Skills** 1995 Jun; 80(3 Pt 1):923–30

Observation of response strategies in cycling time trials. DeFrancesco C, et al. **Percept Mot Skills** 1995 Aug; 81(1):299–304

Effect of complexity of a physical task on estimation of time to complete. Druyan S, et al. **Percept Mot Skills** 1995 Dec; 81(3 Pt 1):707–22

Influence of concurrent tasks on gait: a dual-task approach. Ebersbach G, et al. **Percept Mot Skills** 1995 Aug; 81(1):107–13

A cross-modal aftereffect: auditory displacement following adaptation to visual motion. Ehrenstein WH, et al. **Percept Mot Skills** 1996 Feb;82(1):23–6

Intermittent vision and discrete manual aiming. Elliott D, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1203–13

Effect of velocity on judgments of relative mass. Flynn SB. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):979–87

Re-examination of evidence questions Christman's (1989) report of moderate experimental support for the visual spatial frequency hypothesis. Fudin R. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):955–62

Task-specific conjugate lateral eye movements. Galluscio EH, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):755–62

Visual inspection alone produces a decrement in the horizontal-vertical illusion. Glaser ML, et al. **Percept Mot Skills** 1995 Aug;81(1):323–30

Use of the long vs short form of the speech sounds perception test in a school-age population. Gray RM, et al. **Percept Mot Skills** 1996 Apr;82(2):475–80

Alphanumeric sequencing and cognitive impairment among elderly persons. Grigsby J, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):732–4

Effects of stimulus duration, temporal delay, and complexity on the judgments of dot location. Hanari T. **Percept Mot Skills** 1996 Apr;82(2):459–66

Stimulus-driven or autonomous shift or attention? Hsieh S. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1187–99

Effects of color on children's naming of pictures. Johnson CJ. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1091–101

Temporal factors in visual perception: a differential approach.

Jones MB, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):859–67

Reexamining the Snodgrass and Corwin 1988 picture identification norms. Koch C, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):763–9

Acceptable levels of tonal and broad-band repetitive and continuous sounds during the performance of nonauditory tasks. Landström U, et al. **Percept Mot Skills** 1995 Dec; 81(3 Pt 1):803–16

Effects of auditory radio interference on a fine, continuous, open motor skill. Lazar JM, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):739–45

Occlusion rate of ball texture as a source of velocity information. Li FX, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):871–80

Pattern of efficacy of a musical mnemonic on recall of familiar words over several presentations. McElhinney M, et al. **Percept Mot Skills** 1996 Apr;82(2):395–400

Factors affecting accuracy of producing time intervals. Marmaras N, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):1043–56

Temporal coupling between external auditory information and the phases of walking. Mauerberg E, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):851–61

Effects of background stimulation upon eye-movement information. Nakamura S. **Percept Mot Skills** 1996 Apr; 82(2):627–35

Effect of tone on directional orientation during stepping in place with eyes closed. Okuzumi H, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):719–22

Relations among heart rate, immediate memory, and time estimation under two different instructions. Osato E, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):831–42

In similarity judgments hunter-gatherers prefer shapes over spatial relations in contrast to literate groups. Pontius AA. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):1027–41

Prospective and retrospective time estimates as a function of clock duration. Predebon J. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):941–2

Differential gazing and vocal response to mother and stranger of full-term and preterm infants across age. Roe KV. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):929–30

Zero effect of crowding on arousal and performance: on 'proving' the null hypothesis. Rousseau F, et al. **Percept Mot Skills** 1995 Aug;81(1):72–4

Effect of task demand and stimulus relevance on preattentive processing. Schweizer K. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1123–8

Effects of report order, identification method, and stimulus characteristics on multidimensional stimulus identification. Shieh KK, et al. **Percept Mot Skills** 1996 Feb;82(1):99–111

Differential categorization of words by learning disabled, gifted, and nonexceptional students. Siegel J, et al. **Percept Mot Skills** 1995 Aug;81(1):243–50

Explanation of illusory contours in terms of strength of pattern and its spread effect. Sohmiya T, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):1003–20

Redundant leading and following zeros in comparative numerical judgment. Takayanagi S, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):819–29

When proper names are not forgotten: recall of eponymous medical disorders. Terry WS. **Percept Mot Skills** 1995 Dec; 81(3 Pt 1):928–8

Figure-ground organization in different phases of the perceptual alternation phenomenon. Tuccio MT. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):1043–58

Performance differences as a function of stimulus-response compatibility with rapid serial visual presentation and spatially distributed presentation styles. Utesch BS, et al. **Percept Mot Skills** 1996 Apr;82(2):643–7

Effects of presentation rate of stimuli on response inhibition in ADHD children with and without tics [comment] van der Meere J, et al. **Percept Mot Skills** 1995 Aug; 81(1):259–62. Comment on: Percept Mot Skills 1994 Dec;79(3 Pt 2):1479–90.

Respective contribution of orientation contrast and illusion of self-tilt to the rod-and-frame effect. Cian C, et al. **Perception** 1995;24(6):623–30

The haptic 'oblique effect' in children's and adults' perception of orientation. Gentaz E, et al. **Perception** 1995;24(6):631–46

Temporal-discontinuity detection with contrast-modulated gratings. Ichihara S, et al. **Perception** 1995;24(11):1257–64

The contribution of stimulus attributes of three-dimensional solid forms and level of discrimination to the visual and haptic percept of balance. Locher P, et al. **Perception** 1995; 24(6):647–63

Local-level and global-level form characteristics in apparent-motion correspondence. Palmer T, et al. **Perception** 1995;24(11):1233–45

The microgenesis of illusory figures: evidence for visual hypothesis testing. Parks TE. **Perception** 1995;24(6):681–4

Phenomena of illusory form: can we bridge the gap between levels of explanation? Spillmann L, et al. **Perception** 1995; 24(11):1333–64

The detection of gaze direction: a stare-in-the-crowd effect. von Grünau M, et al. **Perception** 1995;24(11):1297–313

Presaccadic processes in the generation of pro and anti saccades in human subjects--a reaction-time study. Weber H. **Perception** 1995;24(11):1265–80

The discrimination of dynamic orientation changes in gratings. Wright MJ, et al. **Perception** 1995;24(6):665–79

Feature, phoneme, syllable or word: how is speech mentally represented? Sendlmeier WF. **Phonetica** 1995;52(3):131–43 (30 ref.)

Light-dark and food restriction cycles in sea bass: effect of conflicting zeitgebers on demand-feeding rhythms. Sánchez-Vázquez FJ, et al. **Physiol Behav** 1995 Oct; 58(4):705–14

Distractibility in schizophrenia. Bergman A, et al. **Psychiatry Res** 1995 Jul 28;57(2):131–40

Tone discrimination performance in schizophrenic patients and normal volunteers: impact of stimulus presentation levels and frequency differences. Holcomb HH, et al. **Psychiatry Res** 1995 Jun 29;57(1):75–82

Auditory sustained attention in schizophrenia: a comparison of the Continuous Performance Test and the Pigache Attention Task. Pigache RM. **Psychiatry Res** 1996 Mar 29;60(2–3):155–65

A simple clinical assessment of attention in schizophrenia. Weiss KM. **Psychiatry Res** 1996 Mar 29;60(2–3):147–54

Age-related differences in the detection of three-dimensional surfaces from optic flow. Andersen GJ, et al. **Psychol Aging** 1995 Dec;10(4):650–8

Long-term cued recall of tasks in senile dementia. Bird M, et al. **Psychol Aging** 1996 Mar;11(1):45–56

Aging, distraction, and the benefits of predictable location. Carlson MC, et al. **Psychol Aging** 1995 Sep;10(3):427–36

Age differences in retrieval: further support for the resource-reduction hypothesis. Fastenau PS, et al. **Psychol Aging** 1996 Mar;11(1):140–6

Attentional flexibility and aging: you don't need to be 20 years of age to split the beam. Hahn S, et al. **Psychol Aging** 1995 Dec;10(4):597–609

Adult age differences in the inhibition of return of visual attention. Hartley AA, et al. **Psychol Aging** 1995 Dec; 10(4):670–83

Aging and interference: evidence from indirect memory tests. Hartman M. **Psychol Aging** 1995 Dec;10(4):659–69

Aging and single versus multiple cues in source monitoring. Johnson MK, et al. **Psychol Aging** 1995 Dec;10(4):507–17

Age-related impairment in an event-based prospective-memory task. Maylor EA. **Psychol Aging** 1996 Mar;11(1):74–8

Contextual constraint facilitates semantic decisions about object pictures by Alzheimer patients. Nebes RD, et al. **Psychol Aging** 1995 Dec;10(4):590–6

Inverse-intensity effect in duration of visible persistence. Di Lollo V, et al. **Psychol Bull** 1995 Sep;118(2):223–37 (100 ref.)

Alcohol and aggression: a meta-analysis on the moderating effects of inhibitory cues, triggering events, and self-focused attention. Ito TA, et al. **Psychol Bull** 1996 Jul; 120(1):60–82

Cognitive components of picture naming. Johnson CJ, et al. **Psychol Bull** 1996 Jul;120(1):113–39 (310 ref.)

The emotional Stroop task and psychopathology. Williams JM, et al. **Psychol Bull** 1996 Jul;120(1):3–24 (95 ref.)

Laterality of visuo-spatial attention in acute and chronic schizophrenia, major depression and in healthy controls. O'Carroll RE, et al. **Psychol Med** 1995 Sep;25(5):1091–5

Precued shifting of attention between cognitive sets in Parkinson patients. Hsieh S, et al. **Psychol Rep** 1996 Jun; 78(3 Pt 1):815–23

Delayed matching to complex samples and the formation of stimulus classes in children. Maguire RW, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1059–76

A dotted line assimilates in visibility to a solid line. King DL, et al. **Psychol Res** 1996;59(1):4–15

Action planning during the presentation of stimulus sequences: effects of compatible and incompatible stimuli. Müsseler J, et al. **Psychol Res** 1996;59(1):48–63

The effect of enactment on memory for order. Olofsson U. **Psychol Res** 1996;59(1):75–9

A formal theory of feature binding in object perception. Ashby FG, et al. **Psychol Rev** 1996 Jan;103(1):165–92

Reconciling simplicity and likelihood principles in perceptual organization. Chater N. **Psychol Rev** 1996 Jul;103(3):566–81 (80 ref.)

Orthographic processing in visual word recognition: a multiple read-out model. Grainger J, et al. **Psychol Rev** 1996 Jul;103(3):518–65

On the reality of cognitive illusions. Kahneman D, et al. **Psychol Rev** 1996 Jul;103(3):582–91; discusion 592–6

Monitoring and control processes in the strategic regulation of memory accuracy. Koriat A, et al. **Psychol Rev** 1996 Jul;103(3):490–517 (140 ref.)

Goodness of visual regularities: a nontransformational approach. van der Helm PA, et al. **Psychol Rev** 1996 Jul; 103(3):429–56 (95 ref.)

Effects of irrelevant sounds on phonological coding in reading comprehension and short-term memory. Boyle R, et al. **Q J Exp Psychol A** 1996 May;49(2):398–416

Bias in conditional inference: implications for mental models and mental logic. Evans JS, et al. **Q J Exp Psychol A** 1995 Aug;48(3):644–70

Implicit learning and concept learning. Frick RW, et al. **Q J Exp Psychol A** 1995 Aug;48(3):762–82

Response biases in oral reading: an account of the co-occurrence of surface dyslexia and semantic dementia. Funnell E. **Q J Exp Psychol A** 1996 May;49(2):417–46

To forget or not to forget: the effect of probability of test on directed forgetting. Golding JM, et al. **Q J Exp Psychol A** 1996 May;49(2):326–40

Pupil dilation as a measure of processing load in simultaneous interpretation and other language tasks. Hyönä J, et al. **Q J Exp Psychol A** 1995 Aug;48(3):598–612

Testing the mental model theory of propositional reasoning. Klauer KC, et al. **Q J Exp Psychol A** 1995 Aug; 48(3):671–87

Spatial orienting controlled without awareness: a semantically based implicit learning effect. Lambert AJ, et al. **Q J Exp Psychol A** 1996 May;49(2):490–518

An analysis of errors in the learning, overlearning, and forgetting of sequences. Lansdale M, et al. **Q J Exp Psychol A** 1996 May;49(2):341–56

Contrasting effects of letter-spacing in alexia: further evidence that different strategies generate word length effects in reading. Price CJ, et al. **Q J Exp Psychol A** 1995 Aug;48(3):573–97

Priming the identification of environmental sounds. Stuart GP, et al. **Q J Exp Psychol A** 1995 Aug;48(3):741–61

The perceptual centre of a stimulus as the cue for synchronization to a metronome: evidence from asynchronies. Vos PG, et al. **Q J Exp Psychol A** 1995 Nov; 48(4):1024–40

Rats' memory for serially presented novel flavours: evidence for non-spatial primacy effects. Reed P, et al. **Q J Exp Psychol B** 1996 May;49(2):174–87

Perceptual unit formation in simple motion patterns. Ahlström U. **Scand J Psychol** 1995 Dec;36(4):343–54

Preferential looking: a sudden shift in visual fixation pattern at 32 months of age. Jacobsen K, et al. **Scand J Psychol** 1995 Sep;36(3):323–6

Situational familiarity and feature recognition in schizophrenia. Corrigan PW, et al. **Schizophr Bull** 1996; 22(1):153–61

Cognitive inhibition and schizophrenic symptom subgroups. Williams LM. **Schizophr Bull** 1996;22(1):139–51

Investigating thought disorder in schizophrenia with the lexical decision task. Blum NA, et al. **Schizophr Res** 1995 Aug 15;16(3):217–24

The effects of cognitive complexity on a social sequencing task in schizophrenia. Corrigan PW, et al. **Schizophr Res** 1995 Aug 1;16(2):137–44

Memory and vigilance training to improve social perception in schizophrenia. Corrigan PW, et al. **Schizophr Res** 1995 Nov;17(3):257–65

Durable improvements in Wisconsin Card Sorting Test performance in schizophrenic patients. Vollema MG, et al. **Schizophr Res** 1995 Aug 15;16(3):209–15

Scaffolded instruction and the remediation of Wisconsin Card Sorting Test deficits in chronic schizophrenia. Young DA, et al. **Schizophr Res** 1995 Aug 15;16(3):199–207

Superior parietal cortex activation during spatial attention shifts and visual feature conjunction. Corbetta M, et al. **Science** 1995 Nov 3;270(5237):802–5

Symptom management: loss of concentration. Cimprich B. **Semin Oncol Nurs** 1995 Nov;11(4):279–88 (80 ref.)

Effects of cross-modal manipulations of attention on the ability of human subjects to discriminate changes in texture. Zompa IC, et al. **Somatosens Mot Res** 1995;12(2):87–102

Time-dependent changes in dopamine agonist-induced striatal Fos immunoreactivity are related to sensory neglect and its recovery after unilateral prefrontal cortex injury. Vargo JM, et al. **Synapse** 1995 Aug;20(4):305–15

Saccade target selection and object recognition: evidence for a common attentional mechanism. Deubel H, et al. **Vision Res** 1996 Jun;36(12):1827–37

Attentional frames, frame curves and figural boundaries: the inside/outside dilemma. Subirana-Vilanova JB, et al. **Vision Res** 1996 May;36(10):1493–501

[Evenly floating attention, models and theories of the cognitive process of the psychoanalyst] König H. **Psyche (Stuttg)** 1996 Apr;50(4):337–75 (Eng. Abstr.) **(Ger)**

[Neuropsychological analysis of schizophrenia-induced attention deficits--attempt at an overview] Gebauer W, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):128–38 (85 ref.) (Eng. Abstr.) **(Ger)**

[Interaction effects in the lateral visual field: an extension of Bouma's (1970) approach] Heller D, et al. **Z Exp Psychol** 1995;42(3):386–418 (Eng. Abstr.) **(Ger)**

[Modification of performance by activation in the elderly] Hüppe M, et al. **Z Exp Psychol** 1996;43(1):69–84 (Eng. Abstr.) **(Ger)**

[Cognitive load and listener orientation in monologue instruction] Rossnagel C. **Z Exp Psychol** 1995;42(1):94–110 (Eng. Abstr.) **(Ger)**

[Effects of presentation mode on visual-spatial working memory performance in children and adults] Schumann-Hengsteler R, et al. **Z Exp Psychol** 1995; 42(4):594–616 (Eng. Abstr.) **(Ger)**

[Priming effects in picture problems: preliminary solutions] Wippich W, et al. **Z Exp Psychol** 1995;42(2):324–52 (Eng. Abstr.) **(Ger)**

[Integration of prior knowledge in speech comprehension in relation to age] Beyer R, et al. **Z Psychol Z Angew Psychol** 1995;203(4):361–78 (Eng. Abstr.) **(Ger)**

[Recall of personal performance in the elderly] Knopf M. **Z Psychol Z Angew Psychol** 1995;203(4):335–49 (Eng. Abstr.) **(Ger)**

[A case of hemichorea presenting with inattention and denial of involuntary movement] Ichikawa H, et al. **Rinsho Shinkeigaku** 1995 Nov;35(11):1230–4 (15 ref.) (Eng. Abstr.) **(Jpn)**

[A study on the mechanism of anxiety reduction through training: a comparison and examination of the stress-model and the distraction-model] Ikezuki M, et al. **Shinrigaku Kenkyu** 1996 Apr;67(1):9-17 (Eng. Abstr.) **(Jpn)**

[The effect of stimulus-driven factor on attentional capture: evidence from visual search paradigm containing static and dynamic stimuli] Kawahara J. **Shinrigaku Kenkyu** 1996 Apr; 67(1):25-32 (Eng. Abstr.) **(Jpn)**

[Continuous attention in schizophrenic patients] Kasperksa E, et al. **Psychiatr Pol** 1996 May-Jun;30(3):459-69 (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

Short-term withdrawal of antiepileptic medication: effects on attention and memory. Tuunainen A, et al. **Acta Neurol Scand** 1995 Sep;92(3):198-205

Task persistence after alcohol consumption among children of alcoholics. Baer JS, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):955-60

Low dose of ethanol suppresses mismatch negativity of auditory event-related potentials. Jääskeläinen IP, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):607-10

Methylphenidate effect on attention deficit in the acutely brain-injured adult. Kaelin DL, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):6-9

Specific effects of idazoxan in a distraction task: evidence that endogenous norepinephrine plays a role in selective attention in rats. Bunsey MD, et al. **Behav Neurosci** 1995 Oct;109(5):903-11

Detailed behavioral analysis of water maze acquisition under systemic NMDA or muscarinic antagonism: nonspatial pretraining eliminates spatial learning deficits. Saucier D, et al. **Behav Neurosci** 1996 Feb;110(1):103-16

Influences of dietary and intraduodenal lipid on alertness, mood, and sustained concentration. Wells AS, et al. **Br J Nutr** 1995 Jul;74(1):115-23

Pharmacologically induced changes in arousal: effects on behavioral and electrophysiologic measures of alertness and attention. Oken BS, et al. **Electroencephalogr Clin Neurophysiol** 1995 Nov; 95(5):359-71

Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. Rush CR, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):146-57

Working memory in medicated patients with Parkinson's disease: the central executive seems to work. Fournet N, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):313-7

Effects of chronic haloperidol on reaction time and errors in a sustained attention task: partial reversal by anticholinergics and by amphetamine. Brockel BJ, et al. **J Pharmacol Exp Ther** 1995 Dec;275(3):1090-8

An effect of alcohol on the distribution of spatial attention. Post RB, et al. **J Stud Alcohol** 1996 May;57(3):260-6

Behavioural effects of different intensities of formalin pain in rats. Aloisi AM, et al. **Physiol Behav** 1995 Sep; 58(3):603-10

Clonidine and diazepam have differential effects on tests of attention and learning. Coull JT, et al. **Psychopharmacology (Berl)** 1995 Aug;120(3):322-32

Differential effects of clonidine, haloperidol, diazepam and tryptophan depletion on focused attention and attentional search. Coull JT, et al. **Psychopharmacology (Berl)** 1995 Sep;121(2):222-30

Encoding, remembering and awareness in lorazepam-induced amnesia. Curran HV, et al. **Psychopharmacology (Berl)** 1995 Nov;122(2):187-93

An effect of triazolam on visual attention and information processing. Johnson DN, et al. **Psychopharmacology (Berl)** 1995 Sep;121(2):145-9

Effect of scopolamine on visual attention in rats. Jones DN, et al. **Psychopharmacology (Berl)** 1995 Jul;120(2):142-9

Acute effects of caffeine on selective attention and visual search processes. Lorist MM, et al. **Psychophysiology** 1996 Jul;33(4):354-61

[Test performance with minimal alcoholic intoxication] Bartl G, et al. **Blutalkohol** 1996 Jan;33(1):1-16 (Eng. Abstr.) **(Ger)**

[Effects of piracetam on occupationally significant functions of patients with arterial hypertension working under conditions of psychoemotional stress] Dasaeva LA. **Med Tr Prom Ekol** 1995;(10):26-8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Unilateral spatial neglect in Alzheimer's disease. A line bisection study. Ishiai S, et al. **Acta Neurol Scand** 1996 Feb-Mar;93(2-3):219-24

The role of neuroimaging in the discovery of processing stages. A review. Mulder G, et al. **Acta Psychol (Amst)** 1995 Nov;90(1-3):63-79 (66 ref.)

The temporal selectivity of additive factor effects on the reaction process revealed in ERP component latencies. Smulders FT, et al. **Acta Psychol (Amst)** 1995 Nov; 90(1-3):97-109

Auditory event-related potentials in fetal alcohol syndrome and Down's syndrome children. Kaneko WM, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):35-42

A simple auditory oddball task in young adult males at high risk for alcoholism. Ramachandran G, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):9-15

Event-related potentials and information processing in infants with and without Down syndrome. Karrer R, et al. **Am J Ment Retard** 1995 Sep;100(2):146-59

Does so-called interhemispheric transfer time depend on attention? Braun CM, et al. **Am J Psychol** 1995 Winter; 108(4):527-46

A multidisciplinary approach to anterior attentional functions. Stuss DT, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:191-211 (87 ref.)

Auditory attentional deficits in patients with schizophrenia. A positron emission tomography study. O'Leary DS, et al. **Arch Gen Psychiatry** 1996 Jul;53(7):633-41

Oculomotor activity and visual spatial attention. Chelazzi L, et al. **Behav Brain Res** 1995 Nov;71(1-2):81-8

Object segmentation and visual neglect. Driver J. **Behav Brain Res** 1995 Nov;71(1-2):135-46 (74 ref.)

Multiple mechanisms of visual-spatial attention: recent evidence from human electrophysiology. Luck SJ. **Behav Brain Res** 1995 Nov;71(1-2):113-23 (52 ref.)

Processing of visual motion direction in the fronto-parallel plane in the stationary or moving observer. Probst T, et al. **Behav Brain Res** 1995 Oct;70(2):133-44

Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention? Voytko ML. **Behav Brain Res** 1996 Feb;75(1-2):13-25 (123 ref.)

Sex differences in learning and memory in mice: effects of sequence of testing and cholinergic blockade. Berger-Sweeney J, et al. **Behav Neurosci** 1995 Oct; 109(5):859-73

Conditioned diminution of the unconditioned response in rabbit eyeblink conditioning: identifying neural substrates in the cerebellum and brainstem. Canli T, et al. **Behav Neurosci** 1995 Oct;109(5):874-92

Prepulse inhibition in the rat is regulated by ventral and caudodorsal striato-pallidal circuitry. Kodsi MH, et al. **Behav Neurosci** 1995 Oct;109(5):912-28

Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. McGaughy J, et al. **Behav Neurosci** 1996 Apr; 110(2):247-65

Stimulus-elicited behavior in rapid eye movement sleep without atonia. Morrison AR, et al. **Behav Neurosci** 1995 Oct;109(5):972-9

Intraocular transfer and simultaneous processing of stimuli presented in different visual fields of the pigeon. Roberts WA, et al. **Behav Neurosci** 1996 Apr;110(2):290-9

Effects of lesions of the associative parietal cortex on the acquisition and use of spatial memory in egocentric and allocentric navigation tasks in the rat. Save E, et al. **Behav Neurosci** 1996 Feb;110(1):74-85

The role of attention in learning about odorants. Smith BH. **Biol Bull** 1996 Aug;191(1):76-83 (54 ref.)

Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Castellanos FX, et al. **Biol Psychiatry** 1996 Jan 1;39(1):33-41

Gender differences in gating of the auditory evoked potential in normal subjects. Hetrick WP, et al. **Biol Psychiatry** 1996 Jan 1;39(1):51-8

Psychophysiological responses to changes in workload during simulated air traffic control. Brookings JB, et al. **Biol Psychol** 1996 Feb 5;42(3):361-77

How good are patients with panic disorder at perceiving their heartbeats? Ehlers A, et al. **Biol Psychol** 1996 Jan 5;42(1-2):165-82 (55 ref.)

Event-related potential correlates of transient attention shifts to color and location. Eimer M. **Biol Psychol** 1995 Oct; 41(2):167-82

'Interoception' of heart rate, blood pressure, and myocardial metabolism during ergometric work load in healthy young subjects. Kollenbaum VE, et al. **Biol Psychol** 1996 Jan 5; 42(1-2):183-97

Psychophysiological assessment of human reliability in a simulated complex system. Rau R. **Biol Psychol** 1996 Feb 5;42(3):287-300

When global information and local information collide: a brain potential analysis of the locus of interference effects. Ridderinkhof KR, et al. **Biol Psychol** 1995 Aug;41(1):29-53

Event related potentials during covert orientation of visual attention: effects of cue validity and directionality. Wright MJ, et al. **Biol Psychol** 1995 Oct;41(2):183-202

Classification of veterans with post-traumatic stress disorder using visual brain evoked P3s to traumatic stimuli. Attias J, et al. **Br J Psychiatry** 1996 Jan;168(1):110-5

A mathematical model of line bisection behaviour in neglect. Anderson B. **Brain** 1996 Jun;119 (Pt 3):841-50

The Simon effect and attention deficits in Gilles de la Tourette's syndrome and Huntington's disease. Georgiou N, et al. **Brain** 1995 Oct;118 (Pt 5):1305-18

Personal name recognition and associative priming in patients with unilateral brain damage. Schweinberger SR. **Brain Cogn** 1995 Oct;29(1):23-35

Luminance and spatial attention effects on early visual processing. Johannes S, et al. **Brain Res Cogn Brain Res** 1995 Jul;2(3):189-205

Selective impairment of auditory attention following closed head injuries or right cerebrovascular accidents. Keller I, et al. **Brain Res Cogn Brain Res** 1995 Dec;3(1):9-15

Learning to ignore: psychophysics and computational modeling of fast learning of direction in noisy motion stimuli. Vaina LM, et al. **Brain Res Cogn Brain Res** 1995 Jul;2(3):155-63

Electrophysiologic correlates of age effects on visuospatial attention shift. Yamaguchi S, et al. **Brain Res Cogn Brain Res** 1995 Dec;3(1):41-9

Generators of electrical and magnetic mismatch responses in humans. Näätänen R, et al. **Brain Topogr** 1995 Summer; 7(4):315-20 (63 ref.)

Dissociation of ophthalmokinetic and melokinetic attention in unilateral neglect. Bisiach E, et al. **Cereb Cortex** 1995 Sep-Oct;5(5):439-47

The cerebral cortex of the rat and visual attentional function: dissociable effects of mediofrontal, cingulate, anterior dorsolateral, and parietal cortex lesions on a five-choice serial reaction time task. Muir JL, et al. **Cereb Cortex** 1996 May-Jun;6(3):470-81

Neurophysiological evidence for a role of posterior parietal cortex in redirecting visual attention. Steinmetz MA, et al. **Cereb Cortex** 1995 Sep-Oct;5(5):448-56

The intralaminar thalamic nuclei: subjectivity pumps or attention-action coordinators? [comment] Kinsbourne M. **Conscious Cogn** 1995 Jun;4(2):167-71. Comment on: Conscious Cogn 1995 Jun;4(2):137-58.

Anosognosia in parietal lobe syndrome. Ramachandran VS. **Conscious Cogn** 1995 Mar;4(1):22-51

Temporal and spatial processing in reading disabled and normal children. Eden GF, et al. **Cortex** 1995 Sep; 31(3):451-68

Selective impairment of the retrieval of people's names: a case of category specificity. Harris DM, et al. **Cortex** 1995 Sep;31(3):575-82

The role of visual discrimination disorders and neglect in perceptual categorization deficits in right and left hemisphere damaged patients. Mulder JL, et al. **Cortex** 1995 Sep;31(3):487-501

Covert face recognition in prosopagnosia: a dissociable function? Schweinberger SR, et al. **Cortex** 1995 Sep; 31(3):517-29

Peripheral aspects of writing can be differentially affected by sensorial and attentional defect: evidence from a patient with afferent dysgraphia and case dissociation. Silveri MC. **Cortex** 1996 Mar;32(1):155-72

Vestibular stimulation, spatial hemineglect and dysphasia, selective effects. Vallar G, et al. **Cortex** 1995 Sep; 31(3):589-93

Augmented prenatal visual stimulation alters postnatal auditory and visual responsiveness in bobwhite quail chicks. Sleigh MJ, et al. **Dev Psychobiol** 1995 Nov;28(7):353-66

Frontal processing negativity in a visual selective attention task. Karayanidis F, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jul;99(1):38-56

Is the somatosensory N250 related to deviance discrimination or conscious target detection? Kekoni J, et al. **Electroencephalogr Clin Neurophysiol** 1996 Mar; 100(2):115-25

ERP signs of early selective attention effects to check size. Zani A, et al. **Electroencephalogr Clin Neurophysiol** 1995 Oct;95(4):277-92

Fast Fourier transform analysis of the masseter muscle EMG during reaction to a warning signal. Nakajima I. **Electromyogr Clin Neurophysiol** 1995 Aug-Sep;35(5):281-4

Remote cortical dysfunction as a possible cause of subcortical neglect? A regional cerebral blood flow study. Hublet C, et al. **Eur Neurol** 1995;35(5):254-8

Abnormalities in midline attentional circuitry in schizophrenia: evidence from magnetic resonance and positron emission tomography. Andreasen NC, et al. **Eur Neuropsychopharmacol** 1995;5 Suppl:37-41

Inter- and intra-individual differences in semantic priming among young and older adults. Lyons KE, et al. **Exp Aging Res** 1995 Jul-Sep;21(3):221-37

Spatial attention and eye movements. Sheliga BM, et al. **Exp Brain Res** 1995;105(2):261-75

Slowed reaction time performance on a divided attention task in elderly with environmental chemical odor intolerance. Bell IR, et al. **Int J Neurosci** 1996 Feb; 84(1-4):127-34

Auditory event-related potentials while ignoring tone stimuli: attentional differences reflected in stimulus intensity and latency responses in low and highly hypnotizable persons. Crawford HJ, et al. **Int J Neurosci** 1996 Mar;85(1-2):57-69

Visual field asymmetry in facial affect perception: moderating effects of hypnosis, hypnotic susceptibility level, absorption, and sustained attentional abilities. Crawford HJ, et al. **Int J Neurosci** 1995 May;82(1-2):11-23

The endogenous eyeblink and hypnotic susceptibility in a real-simulator design. Field BJ, et al. **Int J Neurosci** 1996 Mar;85(1-2):71-7

Brainstem frequency-following and behavioral responses during selective attention to pure tone and missing fundamental stimuli. Galbraith GC, et al. **Int J Psychophysiol** 1995 Apr;19(3):203-14

Assessing adult receptive vocabulary with event-related potentials: an investigation of cross-modal and cross-form priming. Connolly JF, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):548-65

Visual attention and perception in patients with Huntington's disease: comparisons with other subcortical and cortical dementias. Filoteo JV, et al. **J Clin Exp Neuropsychol** 1995 Oct;17(5):654-67

Magnetic coil suppression of extrafoveal visual perception using disappearance targets. Epstein CM, et al. **J Clin Neurophysiol** 1996 May;13(3):242-6

Magnetic coil suppression of visual perception at an extracalcarine site. Epstein CM, et al.

J Clin Neurophysiol 1996 May;13(3):247–52

Dynamic neuroimaging of brain function. Simpson GV, et al. **J Clin Neurophysiol** 1995 Sep;12(5):432–49 (65 ref.)

Endogenous event-related potentials in term and preterm infants. Tokioka AB, et al. **J Clin Neurophysiol** 1995 Sep; 12(5):468–75

Event-related potentials during the Continuous Visual Memory Test. Retzlaff PD, et al. **J Clin Psychol** 1996 Jan; 52(1):43–7

Visual search for natural grains in pigeons (Columba livia): search images and selective attention. Langley CM, et al. **J Exp Psychol Anim Behav Process** 1996 Apr;22(2):139–51

Search images: selective attention to specific visual features of prey. Langley CM.
J Exp Psychol Anim Behav Process 1996 Apr;22(2):152–63

Partial advance information and response preparation: inferences from the lateralized readiness potential. Leuthold H, et al. **J Exp Psychol Gen** 1996 Sep;125(3):307–23

Allocating visual attention: tests of a two-process model. Johnson DN, et al.
J Exp Psychol Hum Percept Perform 1995 Dec; 21(6):1376–90

Inhibition of return to successively cued spatial locations. Pratt J, et al. **J Exp Psychol Hum Percept Perform** 1995 Dec;21(6):1343–53

Loosening the constraints on illusory conjunctions: assessing the roles of exposure duration and attention. Prinzmetal W, et al. **J Exp Psychol Hum Percept Perform** 1995 Dec; 21(6):1362–75

Automaticity and word perception: evidence from Stroop and Stroop dilution effects. Brown TL, et al.
J Exp Psychol Learn Mem Cogn 1995 Nov;21(6):1395–411

Explicit and implicit learning of event sequences: evidence from event-related brain potentials. Eimer M, et al.
J Exp Psychol Learn Mem Cogn 1996 Jul;22(4):970–87

Stepping over obstacles: dividing attention impairs performance of old more than young adults. Chen HC, et al. **J Gerontol A Biol Sci Med Sci** 1996 May; 51(3):M116–22

Fast spin-echo characteristics of visual stimulation-induced signal changes in the human brain. Gao JH, et al.
J Magn Reson Imaging 1995 Nov–Dec;5(6):709–14

Reduced attention-related negative potentials in methamphetamine psychosis. Iwanami A, et al.
J Nerv Ment Dis 1995 Nov;183(11):693–7

Memory, attention, and executive function in chronic fatigue syndrome. Joyce E, et al.
J Neurol Neurosurg Psychiatry 1996 May;60(5):495–503

Lateralization of prefrontal activation during internal mental calculation: a functional magnetic resonance imaging study. Burbaud P, et al. **J Neurophysiol** 1995 Nov;74(5):2194–200

Covert orienting of attention in macaques. II. Contributions of parietal cortex. Robinson DL, et al. **J Neurophysiol** 1995 Aug;74(2):698–712

Covert orienting of attention in macaques. III. Contributions of the superior colliculus. Robinson DL, et al.
J Neurophysiol 1995 Aug;74(2):713–21

Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis. Karper LP, et al.
J Neuropsychiatry Clin Neurosci 1996 Winter;8(1):60–6

Abnormalities of visual spatial attention in HIV infection and the HIV-associated dementia complex. Maruff P, et al.
J Neuropsychiatry Clin Neurosci 1995 Summer;7(3):325–33

The Cognitive Bias Task and lateralized frontal lobe functions in males. Podell K, et al.
J Neuropsychiatry Clin Neurosci 1995 Fall;7(4):491–501

Attention and target selection for smooth pursuit eye movements. Ferrera VP, et al. **J Neurosci** 1995 Nov; 15(11):7472–84

Age-associated impairments in a test of attention: evidence for involvement of cholinergic systems. Jones DN, et al.
J Neurosci 1995 Nov;15(11):7282–92

Covert orienting of attention in the rat and the role of striatal dopamine. Ward NM, et al. **J Neurosci** 1996 May 1; 16(9):3082–8

Effects of auditory stimuli on intracranial pressure and cerebral perfusion pressure in traumatic brain injury. Schinner KM, et al. **J Neurosci Nurs** 1995 Dec;27(6):348–54

Auditory P3 event related potentials (ERP) and brainstem auditory evoked responses (BAER) after spinal cord injury in humans. Ament PA, et al. **J Spinal Cord Med** 1995 Jul; 18(3):208–15

Influence of arousal and attention on the control of postural sway. Maki BE, et al. **J Vestib Res** 1996 Jan–Feb;6(1):53–9

Visual attention orienting in liver cirrhosis without overt hepatic encephalopathy. Amodio P, et al.
Metab Brain Dis 1995 Dec;10(4):335–45

Cortical neurophysiology. Attention is everywhere [news] Britten KH. **Nature** 1996 Aug 8;382(6591):497–8

Dissociation in prefrontal cortex of affective and attentional shifts. Dias R, et al. **Nature** 1996 Mar 7;380(6569):69–72

Enhancement of selective listening by illusory mislocation of speech sounds due to lip-reading. Driver J. **Nature** 1996 May 2;381(6577):66–8

Where in the brain does visual attention select the forest and the trees? Fink GR, et al. **Nature** 1996 Aug 15; 382(6592):626–8

Attentional resolution and the locus of visual awareness [see comments] He S, et al. **Nature** 1996 Sep 26;383(6598):334–7 . Comment in: Nature 1996 Sep 26;383(6598):301, 303.

Visual psychophysics: stimulating brain but not mind [news; comment] Koch C, et al. **Nature** 1996 Sep 26;383(6598):301, 303. Comment on: **Nature** 1996 Sep 26;383(6598):334–7.

Noradrenaline and attention lapses [letter] Smith A, et al. **Nature** 1996 Mar 28;380(6572):291

Attentional modulation of visual motion processing in cortical areas MT and MST. Treue S, et al. **Nature** 1996 Aug 8;382(6591):539–41

Ictal radial and horizontal neglect. Boyle CA, et al.
Neurology 1996 Jul;47(1):299–300

Corpus callosum and simple visuomotor integration. Berlucchi G, et al. **Neuropsychologia** 1995 Aug; 33(8):923–36 (74 ref.)

Physiological activation of a cortical network during performance of the Wisconsin Card Sorting Test: a positron emission tomography study. Berman KF, et al.
Neuropsychologia 1995 Aug;33(8):1027–46

Visual integration in the split brain. Corballis MC.
Neuropsychologia 1995 Aug;33(8):937–59 (78 ref.)

Extent and limits of callosal plasticity: presence of disconnection symptoms in callosal agenesis. Lassonde M, et al. **Neuropsychologia** 1995 Aug;33(8):989–1007

Affective and attentive neural networks in humans: a PET study of Pavlovian conditioning. Fredrikson M, et al.
Neuroreport 1995 Dec 29;7(1):97–101

Prefrontal neurones sensitive to increased visual attention in the monkey. Lecas JC. **Neuroreport** 1995 Dec 29;7(1):305–9

Selective impairment of spatial attention during visual search in Alzheimer's disease. Parasuraman R, et al.
Neuroreport 1995 Oct 2;6(14):1861–4

Gravity and hemineglect. Pizzamiglio L, et al.
Neuroreport 1995 Dec 29;7(1):370–1

Topography of afferent and efferent flows in the mechanisms of auditory selective attention. Shostak VI, et al.
Neurosci Behav Physiol 1995 Sep–Oct;25(5):378–85

Developmental changes in P300 wave elicited during two different experimental conditions. Fuchigami T, et al.
Pediatr Neurol 1995 Jul;13(1):25–8

Relations between attentional and intentional neural systems. Basso G, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):947–51

Repeated verbal interruptions during exposure to complex transcerebral magnetic fields elicit irritability: implications for opiate effects. Freeman J, et al. **Percept Mot Skills** 1996 Apr;82(2):639–42

Functional brain organization in bipolar affective patients during manic phase and after recovery: a digit dichotic listening study. Kaprinis G, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1275–82

Brain-emitted event-related potentials recorded during rapid decision-making may be useful in monitoring the neuropathogenesis of the human immunodeficiency virus (HIV). Linnville SE. **Percept Mot Skills** 1995 Aug; 81(1):209–10

Cutaneous thresholds and anxiety: influence of eye orientation and lateral asymmetry. Naveteur J, et al.
Percept Mot Skills 1995 Jun;80(3 Pt 1):707–16

Human EEG responses to classical music and simulated white noise: effects of a musical loudness component on consciousness. Ogata S. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):779–90

Baroreceptor activity and the induction of sleep. Velden M, et al. **Percept Mot Skills** 1996 Feb;82(1):178

Edge computation in human vision: anisotropy in the combining of oriented filters. Meese TS, et al.
Perception 1995;24(6):603–22

Attention and evoked otoacoustic emissions: attempts at characterization of intersubject variation. Meric C, et al.
Physiol Behav 1996 Jan;59(1):1–9

Effects of novelty and conditioned fear on small intestinal and colonic motility and behaviour in the rat. Stam R, et al. **Physiol Behav** 1995 Oct;58(4):803–9

Visual attention to surfaces in three-dimensional space. He ZJ, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21; 92(24):11155–9

The resource consumption principle: attention and memory in volumes of neural tissue. Montague PR.
Proc Natl Acad Sci U S A 1996 Apr 16;93(8):3619–23

Selective attention to stimulus location modulates the steady-state visual evoked potential. Morgan ST, et al.
Proc Natl Acad Sci U S A 1996 May 14;93(10):4770–4

Single-word auditory stimulation and regional cerebral blood flow as studied by SPECT. Beversdorf D, et al.
Psychiatry Res 1995 Sep 29;61(3):181–9

The P50 evoked potential component and mismatch detection in normal volunteers: implications for the study of sensory gating. Boutros NN, et al. **Psychiatry Res** 1995 Jun 29; 57(1):83–8

A controlled positron emission tomography study of obsessive and neutral auditory stimulation in obsessive-compulsive disorder with checking rituals. Cottraux J, et al. **Psychiatry Res** 1996 Mar 29; 60(2–3):101–12

Numbers of preceding nontargets differentially affect responses to targets in normal volunteers and patients with schizophrenia: a study of event-related potentials. Gonsalvez CJ, et al. **Psychiatry Res** 1995 Sep 8;58(1):69–75

Abnormal saccadic distractibility in patients with schizophrenia: a 99mTc-HMPAO SPET study. Crawford TJ, et al. **Psychol Med** 1996 Mar;26(2):265–77

Aberrant interhemispheric alpha coherence on electroencephalography in schizophrenic patients during activation tasks. Morrison-Stewart SL, et al.
Psychol Med 1996 May;26(3):605–12

Loss of vision during the retinal stabilization of letters. Topolski R, et al. **Psychol Res** 1995;58(3):155–62

Neurofunctional mechanisms in autism. Waterhouse L, et al.
Psychol Rev 1996 Jul;103(3):457–89 (280 ref.)

Predicting sleep latency from the three-process model of alertness regulation. Akerstedt T, et al.
Psychophysiology 1996 Jul;33(4):385–9

ERP modulations indicate the selective processing of visual stimuli as a result of transient and sustained spatial attention. Eimer M. **Psychophysiology** 1996 Jan;33(1):13–21

Somatosensory responses during selective spatial attention: The N120-to-N140 transition. García-Larrea L, et al.
Psychophysiology 1995 Nov;32(6):526–37

Spatial orienting and focused attention in attention deficit hyperactivity disorder. Novak GP, et al.
Psychophysiology 1995 Nov;32(6):546–59

Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Gray NS, et al. **Schizophr Res** 1995 Sep;17(1):95–107

Information processing during eye tracking as revealed by event-related potentials in schizophrenics, alcoholics, and healthy controls. Kathmann N, et al. **Schizophr Res** 1995 Aug 1;16(2):145–56

Olfactory deficits in schizophrenia are not a function of task complexity. Kopala L, et al. **Schizophr Res** 1995 Oct; 17(2):195–9

Glucose metabolic correlates of continuous performance test performance in adults with a history of infantile autism, schizophrenics, and controls. Siegel BV Jr, et al.
Schizophr Res 1995 Sep;17(1):85–94

A K+ channel worthy of attention [comment] Hille B. **Science** 1996 Sep 20;273(5282):1677. Comment on: Science 1996 Sep 20;273(5282):1709–14.

Activation by attention of the human reticular formation and thalamic intralaminar nuclei. Kinomura S, et al. **Science** 1996 Jan 26;271(5248):512–5

Motion capture and visual attention: comments on Culham and Cavanagh (1994) [letter] Ramachandran VS.
Vision Res 1996 Jan;36(1):77–80

[Parallel visual processing characteristics in healthy alexithymic subjects. Administration of the Toronto Alexithymia Scale and the parallel visual information test (see comments)] Montreuil M, et al. **Encephale** 1995 Sep–Oct;21(5):589–95 (Eng. Abstr.). Comment in: Encephale 1996 Jan–Feb;22(1):69–70. **(Fre)**

[Interindividual variability of exogenous and endogenous auditory evoked potentials in a condition of voluntary attention] Lembreghts M, et al. **Neurophysiol Clin** 1995; 25(4):203–23 (Eng. Abstr.) **(Fre)**

[Intracranial blood flow parameters in cerebral functional changes and cognitive cerebral performance] Klingelhöfer J, et al. **Nervenarzt** 1996 Apr;67(4):283–93 (Eng. Abstr.) **(Ger)**

[Effect of task difficulty on hemispheric differences in visual image processing] Hildebrandt H, et al. **Z Exp Psychol** 1995;42(2):256–79 (Eng. Abstr.) **(Ger)**

[The effect of geomagnetic disturbances on the functions of attention and memory] Tambiev AE, et al.
Aviakosm Ekolog Med 1995;29(3):43–5 (Eng. Abstr.) **(Rus)**

[Correlations of brain potentials during various degrees of concentration of attention] Tambiev AE, et al.
Fiziol Cheloveka 1995 Jul–Aug;21(4):30–5 **(Rus)**

RADIATION EFFECTS

Motor and psychological functions of school children living in the area of the Skrunda Radio Location Station in Latvia. Kolodynski AA, et al. **Sci Total Environ** 1996 Feb 2; 180(1):87–93

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY

Attention-deficit hyperactivity disorder: the pharmacist's role. Levin GM. **Am Pharm** 1995 Nov;NS35(11):10–20 (34 ref.)

Attention-deficit hyperactivity disorder in children. Baxter PS. **Curr Opin Pediatr** 1995 Aug;7(4):381–6 (50 ref.)

Childhood mania revisited. Biederman J, et al.
Isr J Med Sci 1995 Nov;31(11):647–51 (71 ref.)

Attention deficit disorder: a review of the past 10 years. Cantwell DP. **J Am Acad Child Adolesc Psychiatry** 1996 Aug;35(8):978–87 (60 ref.)

Assisting medical students with undiagnosed ADHD [letter] Uva JL. **JAMA** 1996 Feb 7;275(5):417

Attention-deficit hyperactivity disorder in adults. Feifel D. **Postgrad Med** 1996 Sep;100(3):207–11, 215–8 (15 ref.)

BLOOD

Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. Bekaroğlu M, et al. **J Child Psychol Psychiatry** 1996 Feb; 37(2):225–7

Blunted catecholamine responses after glucose ingestion in children with attention deficit disorder. Girardi NL, et al.
Pediatr Res 1995 Oct;38(4):539–42

Attention deficit hyperactivity disorder and whole-blood serotonin levels: effects of comorbidity. Cook EH Jr, et al. **Psychiatry Res** 1995 Jun 29;57(1):13–20

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY

CHEMICALLY INDUCED

Lead screening in children with attention deficit hyperactivity disorder and developmental delay. Kahn CA, et al. **Clin Pediatr (Phila)** 1995 Sep;34(9):498–501

COMPLICATIONS

Affective comorbidity in children and adolescents with attention deficit hyperactivity disorder. Butler SF, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):51–5

Attention–deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? Biederman J, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug; 35(8):997–1008

Relationship between ADHD and anxiety in boys: results from a family study. Perrin S, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug;35(8):988–96

Case 6: a free solution. Shader RI, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):297

A 35–year–old man with epigastric pain, 1 year later [comment] Delbanco TL, et al. **JAMA** 1996 Mar 6; 275(9):722. Comment on: JAMA 1995 Aug 9;274(6):495–500.

ADHD and co–morbidities in infants, toddlers, and preschoolers at risk. Billeaud FP. **Semin Speech Lang** 1995 Nov;16(4):289–302 (50 ref.)

DIAGNOSIS

Compared to attention deficit hyperactivity disorder... [editorial] Carlson GA. **Am J Psychiatry** 1996 Sep; 153(9):1128–30

Age–dependent decline of attention deficit hyperactivity disorder. Hill JC, et al. **Am J Psychiatry** 1996 Sep; 153(9):1143–6

Backward–masking deficit in adolescents with schizophrenic disorders or attention deficit hyperactivity disorder. Rund BR, et al. **Am J Psychiatry** 1996 Sep;153(9):1154–7

Diagnosing children with attention deficit disorders through a health department–public school partnership. Shea KM, et al. **Am J Public Health** 1996 Aug;86(8 Pt 1):1168–9

Impulse control disorders and attention deficit disorder in pathological gamblers. Specker SM, et al. **Ann Clin Psychiatry** 1995 Dec;7(4):175–9

A prospective 4–year follow–up study of attention–deficit hyperactivity and related disorders. Biederman J, et al. **Arch Gen Psychiatry** 1996 May;53(5):437–46

Quantitative brain magnetic resonance imaging in attention–deficit hyperactivity disorder. Castellanos FX, et al. **Arch Gen Psychiatry** 1996 Jul;53(7):607–16

School problems in Tourette's syndrome. Abwender DA, et al. **Arch Neurol** 1996 Jun;53(6):509–11

Pediatricians' knowledge and attitudes concerning diagnosis and treatment of attention deficit and hyperactivity disorders. A national survey approach. Kwasman A, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1211–6

Activity measurements support dimensional assessment. Pinto LP, et al. **Behav Modif** 1996 Jul;20(3):243–58

Behavioural disorders are overdiagnosed in US [news] Roberts J. **BMJ** 1996 Mar 16;312(7032):657

The diagnosis and prevalence of hyperactivity in Chinese schoolboys. Leung PW, et al. **Br J Psychiatry** 1996 Apr; 168(4):486–96

A developmental investigation of inattentiveness and hyperactivity. Carlson EA, et al. **Child Dev** 1995 Feb; 66(1):37–54

No confirmation of Geschwind's hypothesis of associations between reading disability, immune disorders, and motor preference in ADHD. Biederman J, et al. **J Abnorm Child Psychol** 1995 Oct;23(5):545–52

A behavioral assessment scale for attention deficit disorder in Brazilian children based on DSM–IIIR criteria. Brito GN, et al. **J Abnorm Child Psychol** 1995 Aug;23(4):509–20

Developmental change in attention–deficit hyperactivity disorder in boys: a four–year longitudinal study. Hart EL, et al. **J Abnorm Child Psychol** 1995 Dec;23(6):729–49

External validation of oppositional disorder and attention deficit disorder with hyperactivity. Paternite CE, et al. **J Abnorm Child Psychol** 1995 Aug;23(4):453–71

Deficient inhibitory control in attention deficit hyperactivity disorder. Schachar R, et al. **J Abnorm Child Psychol** 1995 Aug;23(4):411–37

Attention–deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? Biederman J, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug; 35(8):997–1008

ADD and soft signs [letter] Foodman A, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):841–2

Distractibility as a symptom of ADHD [letter] Kalm MA. **J Am Acad Child Adolesc Psychiatry** 1995 Sep;34(9):1119

Quantitative EEG differences in a nonclinical sample of children with ADHD and undifferentiated ADD. Kuperman S, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug; 35(8):1009–17

Distractibility in hyperactive and conduct–disordered children. Leung PW, et al. **J Child Psychol Psychiatry** 1996 Mar;37(3):305–12

Developmental dyscalculia behavioral and attentional aspects: a research note. Shalev RS, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1261–8

ADHD and thyroid abnormalities: a research note. Spencer T, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):879–85

School underachievement in the fifth grade. Stein MT, et al. **J Dev Behav Pediatr** 1996 Apr;17(2):109–13

Attention–deficit hyperactivity disorders in adolescence. Wender EH. **J Dev Behav Pediatr** 1995 Jun;16(3):192–5 (10 ref.)

Primary–care approach to the diagnosis and management of attention–deficit hyperactivity disorder. Barbaresi WJ. **Mayo Clin Proc** 1996 May;71(5):463–71

Three cases of adult attention–deficit hyperactivity disorder. Bourgeois JA. **Mil Med** 1995 Sep;160(9):473–6

Teaching deficit disorder [letter] Van Dervoort RL Jr, et al. **Pediatrics** 1996 Jul;98(1):167–8

Attention–deficit hyperactivity disorder: a longitudinal case study of handwriting characteristics. Peeples EE, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1243–52

Attention–deficit hyperactivity disorder and comorbid substance use disorders in adults. Wilens TE, et al. **Psychiatr Serv** 1995 Aug;46(8):761–3, 765

Validity of the Amsterdam Child Behavior Checklist: a short rating scale for children. de Jong PF. **Psychol Rep** 1995 Dec;77(3 Pt 2):1139–44

Retrospective self–reported symptoms of attention–deficit hyperactivity disorder: reliability of the Wender Utah Rating Scale. Rossini ED, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):751–4

Methylphenidate effects on a laboratory aggression measure in children with ADHD. Casat CD, et al. **Psychopharmacol Bull** 1995;31(2):353–6

Psychometric characteristics of the Wender Utah Rating Scale (WURS): reliability and factor structure for men and women. Stein MA, et al. **Psychopharmacol Bull** 1995; 31(2):425–33

The comorbidity of attention–deficit hyperactivity disorder in adolescent mania: potential diagnostic and treatment implications. West SA, et al. **Psychopharmacol Bull** 1995; 31(2):347–51

Paying attention. The controversy over ADHD and the drug Ritalin is obscuring a real look at the disorder and its underpinnings. Leutwyler K. **Sci Am** 1996 Aug;275(2):12; 14

Attention deficit hyperactivity disorder: the scope of the problem. Augustine LE, et al. **Semin Speech Lang** 1995 Nov;16(4):243–57; quiz 257–8 (72 ref.)

Social considerations in the labeling of students as attention deficit hyperactivity disordered. Damico JS, et al. **Semin Speech Lang** 1995 Nov;16(4):259–73; quiz 274

The metaphysics of ADHD a unifying case scenario. Smith MD, et al. **Semin Speech Lang** 1995 Nov;16(4):303–12; quiz 312–3 (29 ref.)

[Attention deficit hyperactivity disorder in an adult] Sáiz Ruiz J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May–Jun;24(3):135–40 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Six–week, double–blind, placebo–controlled study of desipramine for adult attention deficit hyperactivity disorder. Wilens TE, et al. **Am J Psychiatry** 1996 Sep; 153(9):1147–53

The use of methylphenidate in Michigan [letter; comment] Kaufman G, et al. **Arch Pediatr Adolesc Med** 1996 May; 150(5):558–9. Comment on: Arch Pediatr Adolesc Med 1995 Jun;149(6):675–9.

Tricyclic medication in children and the QT interval: case report and discussion. Alderton HR. **Can J Psychiatry** 1995 Aug;40(6):325–9 (30 ref.)

ECG changes in pediatric patients on tricyclic antidepressants, desipramine, and imipramine. Johnson A, et al. **Can J Psychiatry** 1996 Mar;41(2):102–6

The run on Ritalin. Attention deficit disorder and stimulant treatment in the 1990s. Diller LH. **Hastings Cent Rep** 1996 Mar–Apr;26(2):12–8 (45 ref.)

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1124–32 (132 ref.)

Fluoxetine for ADHD in a young child [letter] Campbell NB, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1259–60

Guanfacine treatment of comorbid attention–deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. Chappell PB, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep;34(9):1140–6

Buspirone in ADHD with ODD [letter] Gross MD. **J Am Acad Child Adolesc Psychiatry** 1995 Oct;34(10):1260

Untoward effects of lithium treatment in children aged four through six years. Hagino OR, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1584–90

Clinical perspectives: combined pharmacotherapy [letter; comment] O'Malley KD. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1558–9. Comment on: J Am Acad Child Adolesc Psychiatry 1993 Mar;32(2):333–42. Comment on: J Am Acad Child Adolesc Psychiatry 1995 Jan;34(1):110–2.

Pemoline effects on children with ADHD: a time–response by dose–response analysis on classroom measures. Pelham WE Jr, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov;34(11):1504–13

An open trial of pemoline in drug–dependent delinquents with attention–deficit hyperactivity disorder. Riggs PD, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug; 35(8):1018–24

Enuresis with combined risperidone and SSRI use [letter] Took KJ, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):840–1

Resolved: cardiac arrhythmias make desipramine an unacceptable choice in children. Werry JS, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1239–45; discussion 1245–8

Medication for attention deficit hyperactivity disorder: commentary and response [see comments] Faigel HC, et al. **J Am Coll Health** 1996 Jul;45(1):40–1; discussion 41–2 . Comment in: J Am Coll Health 1996 Jul;45(1):35–9.

Pemoline therapy in college students with attention deficit hyperactivity disorder: a retrospective study [comment] Heiligenstein E, et al. **J Am Coll Health** 1996 Jul;45(1):35–9 . Comment on: J Am Coll Health 1996 Jul;45(1):40–1; discussion 41–2.

Venlafaxine in adults with attention–deficit/hyperactivity disorder: an open clinical trial. Findling RL, et al. **J Clin Psychiatry** 1996 May;57(5):184–9

Treatment of a 4–year–old boy with ADHD with the dopamine releaser phentermine [letter] Rothman RB. **J Clin Psychiatry** 1996 Jul;57(7):308–9

Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. Wilens TE, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):270–9 (81 ref.)

School observations of children with attention–deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Gadow KD, et al. **J Dev Behav Pediatr** 1995 Jun;16(3):167–76

The acceptability of interventions for attention–deficit hyperactivity disorder among elementary and middle school teachers. Power TJ, et al. **J Dev Behav Pediatr** 1995 Aug;16(4):238–43

Neuroendocrine responses to methylphenidate and d–amphetamine: applications to attention–deficit disorder. Lurie S, et al. **J Neuropsychiatry Clin Neurosci** 1991 Winter; 3(1):41–50 (70 ref.)

Attention–deficit disorder with hyperactivity [letter] Ryan MG. **Med J Aust** 1996 Aug 5;165(3):173–4

Medication for children with attentional disorders. American Academy of Pediatrics Committee on Children With Disabilities and Committee on Drugs. **Pediatrics** 1996 Aug; 98(2 Pt 1):301–4

Need for bedtime dose of ritalin [letter; comment] Rogers WB. **Pediatrics** 1996 Aug;98(2 Pt 1):314. Comment on: Pediatrics 1995 Aug;96(2 Pt 1):320–5.

Methylphenidate effects on a laboratory aggression measure in children with ADHD. Casat CD, et al. **Psychopharmacol Bull** 1995;31(2):353–6

Paying attention. The controversy over ADHD and the drug Ritalin is obscuring a real look at the disorder and its underpinnings. Leutwyler K. **Sci Am** 1996 Aug;275(2):12; 14

Medication for attention–deficit hyperactivity disorder: balancing art and science [editorial] Block RW. **South Med J** 1996 Jan;89(1):95–6

Drug therapy in attention–deficit hyperactivity disorder. Kessler S. **South Med J** 1996 Jan;89(1):33–8

[Clinical and experimental studies on tiaoshen liquor for infantile hyperkinetic syndrome] Wang LH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun; 15(6):337–40 (Eng. Abstr.) **(Chi)**

[Treatment of hyperactivity and attention deficit with amphetamine. Experience with five adult prisoners] Stovner AM, et al. **Tidsskr Nor Laegeforen** 1996 Jun 30; 116(17):2002–5 (Eng. Abstr.) **(Nor)**

EPIDEMIOLOGY

Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Biederman J, et al. **Am J Psychiatry** 1995 Nov;152(11):1652–8

Attention deficit hyperactivity disorder and comorbid disorders: issues of overlapping symptoms. Milberger S, et al. **Am J Psychiatry** 1995 Dec;152(12):1793–9

Hair lead levels related to children's classroom attention–deficit behavior. Tuthill RW. **Arch Environ Health** 1996 May–Jun;51(3):214–20

The use of methylphenidate in Michigan [letter; comment] Kaufman G, et al. **Arch Pediatr Adolesc Med** 1996 May; 150(5):558–9. Comment on: Arch Pediatr Adolesc Med 1995 Jun;149(6):675–9.

Child Behavior Checklist findings further support comorbidity between ADHD and major depression in a referred sample. Biederman J, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):734–42

Presentation of unrecognized attention deficit hyperactivity disorder in college students. Heiligenstein E, et al. **J Am Coll Health** 1995 Mar;43(5):226–8

Adult attention deficit disorder in the United Kingdom [letter] Riddall MW. **J Nerv Ment Dis** 1996 Apr; 184(4):257–8

Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. Pomerleau OF, et al. **J Subst Abuse** 1995;7(3):373–8

Is childhood hyperactivity the product of western culture? Anderson JC. **Lancet** 1996 Jul 13;348(9020):73–4

Situational versus pervasive hyperactivity in a community sample. Ho TP, et al. **Psychol Med** 1996 Mar;26(2):309–21

[Hyperkinetic syndrome and behavioral disorders in street traffic: a case control pilot study] Beck N, et al.

Z Kinder Jugenpsychiatr 1996 Jun;24(2):82–91 (Eng. Abstr.) **(Ger)**
[Study of the prevalence of the attention deficit hyperactivity disorder in ten–year–old children living in the Valencia metropolitan area] Andrés Carrasco MA, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1995 Jul–Aug;23(4):184–8 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children? Milberger S, et al. **Am J Psychiatry** 1996 Sep; 153(9):1138–42
Attention deficit disorder: a review of the past 10 years. Cantwell DP. **J Am Acad Child Adolesc Psychiatry** 1996 Aug;35(8):978–87 (60 ref.)

GENETICS

Role of genetic factors in depression based on studies of Tourette syndrome and ADHD probands and their relatives. Comings DE. **Am J Med Genet** 1995 Apr 24; 60(2):111–21
Etiology of ADHD: nature or nurture? [letter] Diller LH, et al. **Am J Psychiatry** 1996 Mar;153(3):451–2
Psychiatric and developmental disorders in families of children with attention–deficit hyperactivity disorder. Roizen NJ, et al. **Arch Pediatr Adolesc Med** 1996 Feb; 150(2):203–8
Childhood hyperactivity scores are highly heritable and show sibling competition effects: twin study evidence. Thapar A, et al. **Behav Genet** 1995 Nov;25(6):537–44
Fragile X syndrome—a review. Keenan E, et al.
Ir Med J 1993 May;86(3):92, 95–6 (28 ref.)
Impact of adversity on functioning and comorbidity in children with attention–deficit hyperactivity disorder. Biederman J, et al.
J Am Acad Child Adolesc Psychiatry 1995 Nov; 34(11):1495–503
Relationship between ADHD and anxiety in boys: results from a family study. Perrin S, et al.
J Am Acad Child Adolesc Psychiatry 1996 Aug;35(8):988–96
A pilot family study of childhood–onset mania. Wozniak J, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1577–83
The role of genetic factors in conduct disorder based on studies of Tourette syndrome and attention–deficit hyperactivity disorder probands and their relatives. Comings DE. **J Dev Behav Pediatr** 1995 Jun;16(3):142–57
Neurocognitive characteristics of individuals with resistance to thyroid hormone: comparisons with individuals with attention–deficit hyperactivity disorder. Stein MA, et al.
J Dev Behav Pediatr 1995 Dec;16(6):406–11

METABOLISM

Essential fatty acid metabolism in boys with attention–deficit hyperactivity disorder. Stevens LJ, et al.
Am J Clin Nutr 1995 Oct;62(4):761–8
The comorbidity of attention–deficit hyperactivity disorder in adolescent mania: potential diagnostic and treatment implications. West SA, et al. **Psychopharmacol Bull** 1995; 31(2):347–51

PHYSIOPATHOLOGY

The contribution of alpha 2–noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention–deficit hyperactivity disorder. Arnsten AF, et al. **Arch Gen Psychiatry** 1996 May;53(5):448–55 (130 ref.)
Binaural function in children with attention–deficit hyperactivity disorder. Pillsbury HC, et al.
Arch Otolaryngol Head Neck Surg 1995 Dec; 121(12):1345–50
Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Castellanos FX, et al.
Biol Psychiatry 1996 Jan 1;39(1):33–41
Sensitivity and specificity of QEEG in children with attention deficit or specific developmental learning disorders. Chabot RJ, et al. **Clin Electroencephalogr** 1996 Jan;27(1):26–34
Abnormal auditory P300 topography in attention deficit disorder predicts poor response to pemoline. Sangal JM, et al. **Clin Electroencephalogr** 1995 Oct;26(4):204–13
Biological correlates of learning and attention: what is relevant to learning disability and attention–deficit hyperactivity disorder? Denckla MB.
J Dev Behav Pediatr 1996 Apr;17(2):114–9 (37 ref.)
Neurometrics, dynamic brain imaging and attention deficit hyperactivity disorder. Levy F, et al.
J Paediatr Child Health 1995 Aug;31(4):279–83 (49 ref.)
[Effect of functional bio–regulation on the non–specific brain systems in children suffering from neurotic hyperkinesia] Allakhverdiev AR, et al. **Fiziol Cheloveka** 1995 Jul–Aug; 21(4):45–9 **(Rus)**

PSYCHOLOGY

Parents of children with attention–deficit/hyperactivity disorder: psychological and attentional impairment. Murphy KR, et al. **Am J Orthopsychiatry** 1996 Jan; 66(1):93–102
The Mania Rating Scale (MRS): further reliability and validity studies with children. Fristad MA, et al.
Ann Clin Psychiatry 1995 Sep;7(3):127–32
Psychiatric and developmental disorders in families of children with attention–deficit hyperactivity disorder. Roizen NJ, et al. **Arch Pediatr Adolesc Med** 1996 Feb; 150(2):203–8
Re: Support groups and psychiatry [letter] Smith DH.
Can J Psychiatry 1996 Mar;41(2):128; discussion 129
Injury risk factors in children with attention deficit hyperactivity disorder. Farmer JE, et al.
Health Psychol 1995 Jul;14(4):325–32
Clinical correlates of enuresis in ADHD and non–ADHD children. Biederman J, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):865–77
Executive functions and developmental psychopathology. Pennington BF, et al. **J Child Psychol Psychiatry** 1996 Jan; 37(1):51–87 (225 ref.)
Personality attributes of attention deficit hyperactivity disorder (ADHD) using the Rorschach Inkblot Test. Cotugno AJ. **J Clin Psychol** 1995 Jul;51(4):554–62
Behavioral variability in SHR and WKY rats as a function of rearing environment and reinforcement contingency. Hunziker MH, et al. **J Exp Anal Behav** 1996 Jan; 65(1):129–44
Teaching deficit disorder [letter] Van Dervoort RL Jr, et al. **Pediatrics** 1996 Jul;98(1):167–8
Effects of presentation rate of stimuli on response inhibition in ADHD children with and without tics [comment] van der Meere J, et al. **Percept Mot Skills** 1995 Aug; 81(1):259–62. Comment on: Percept Mot Skills 1994 Dec;79(3 Pt 2):1479–90.
Spatial orienting and focused attention in attention deficit hyperactivity disorder. Novak GP, et al.
Psychophysiology 1995 Nov;32(6):546–59

THERAPY

Multimodal treatment for attention deficit hyperactivity disorder? [letter; comment] Chabrol H, et al.
Am J Psychiatry 1996 Jul;153(7):967. Comment on: Am J Psychiatry 1995 Jun;152(6):895–900.
The management of hyperactive children. **Drug Ther Bull** 1995 Aug;33(8):57–60 (22 ref.)
Pets play role in child development [news] Meehan SK.
J Am Vet Med Assoc 1995 Oct 15;207(8):1010–1
The acceptability of interventions for attention–deficit hyperactivity disorder among elementary and middle school teachers. Power TJ, et al. **J Dev Behav Pediatr** 1995 Aug;16(4):238–43
Identifying substance abusers at preschool age [news] Cole TB. **JAMA** 1996 May 8;275(18):1391–2
Primary–care approach to the diagnosis and management of attention–deficit hyperactivity disorder. Barbaresi WJ.
Mayo Clin Proc 1996 May;71(5):463–71
Brief behavioral treatment for attention–deficit hyperactivity disorder. Cocciarella A, et al. **Percept Mot Skills** 1995 Aug; 81(1):225–6
The responsibilities of speech–language pathologists toward children with ADHD. Heyer JL. **Semin Speech Lang** 1995 Nov;16(4):275–88

ATTENTION DEFICIT HYPERACTIVITY DISORDER
see **ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY**

ATTITUDE

see related
PUBLIC OPINION
SET (PSYCHOLOGY)

Students' attitudes toward alternative health care [letter] Gracely EJ, et al. **Acad Med** 1996 Feb;71(2):109–10
Influence of tutors on students' perceptions of small–group, case–based courses. Schwartz PL, et al. **Acad Med** 1995 Dec;70(12):1146–7
Using faculty and student perceptions of group dynamics to develop recommendations for PBL training. Tipping J, et al. **Acad Med** 1995 Nov;70(11):1050–2
Patient attitudes to myelography, computed tomography and magnetic resonance imaging when examined for suspected lumbar disc herniation. Albeck MJ, et al.
Acta Neurochir (Wien) 1995;133(1–2):3–6
Coercive measures in psychiatric care. Reports and reactions of patients and other people involved. Eriksson KI, et al.
Acta Psychiatr Scand 1995 Sep;92(3):225–30
Adolescents' perceived risk and personal experience with natural disasters: an evaluation of cognitive heuristics. Greening L, et al. **Acta Psychol (Amst)** 1996 Feb; 91(1):27–38
Factors affecting students' participation in the Cincinnati public schools lunch program. Marples CA, et al.
Adolescence 1995 Fall;30(119):745–54
Perceptions of pregnant/parenting teens: reframing issues for an integrated approach to pregnancy problems. Rodriquez C Jr, et al. **Adolescence** 1995 Fall;30(119):685–706
There is some Luddite in all of us. Conner SL. **Ala Med** 1995 Jul;65(1):2–3
The effects of imagery on attitudes and moods in multiple sclerosis patients. Maguire BL. **Altern Ther Health Med** 1996 Sep;2(5):75–9
Believability and importance as determinants of rumor among deaf college students. Anthony S, et al. **Am Ann Deaf** 1995 Jul;140(3):271–8
Stage hypnosis and public lecture effects on attitudes and beliefs regarding hypnosis. Echterling LG, et al.
Am J Clin Hypn 1995 Jul;38(1):13–21
The role of work experience and individual beliefs in police officers' perceptions of date rape: an integration of quantitative and qualitative methods. Campbell R.
Am J Community Psychol 1995 Apr;23(2):249–77
Evaluation of a medical ethics consultation service: opinions of patients and health care providers. McClung JA, et al.
Am J Med 1996 Apr;100(4):456–60
Disclosure of donor insemination: parental attitudes. Cook R, et al. **Am J Orthopsychiatry** 1995 Oct;65(4):549–59
Patients' attitudes to rectal drug administration [see comments] Vyvyan HA, et al. **Anaesthesia** 1995 Nov; 50(11):983–4. Comment in: Anaesthesia 1996 Apr;51(4):401–2. Comment in: Anaesthesia 1996 Apr;51(4):402.
Surgical patients' attitudes regarding participation in clinical anesthesia research [see comments] Mingus ML, et al.
Anesth Analg 1996 Feb;82(2):332–7. Comment in: Anesth Analg 1996 Aug;83(2):438.
How sexually permissive are Singaporeans? Kok LP, et al.
Ann Acad Med Singapore 1995 Sep;24(5):679–84
A survey in Puglia: the attitudes and opinions of specialists, general physicians and patients on follow–up practice. G.S.Bio.Ca.M. Paradiso A, et al. **Ann Oncol** 1995;6 Suppl 2:53–6
Psychosocial determinants of fruit and vegetable consumption. Brug J, et al. **Appetite** 1995 Dec;25(3):285–96
Perceived behavioural control, unrealistic optimism and dietary change: an exploratory study. Sparks P, et al.
Appetite 1995 Jun;24(3):243–55
Content analysis of prime–time television medical news. A pediatric perspective. Prabhu NP, et al.
Arch Pediatr Adolesc Med 1996 Jan;150(1):46–9
Elders' perceptions of the role of group psychotherapy in fostering self–transcendence. Young CA, et al.
Arch Psychiatr Nurs 1995 Dec;9(6):338–47
Eating attitudes and body shape perceptions among elite rowers: effects of age, gender and weight category. Terry PC, et al. **Aust J Sci Med Sport** 1996 Mar;28(1):3–6
Tail docking in dogs: a sample of attitudes of veterinarians and dog breeders in Queensland. Noonan GJ, et al.
Aust Vet J 1996 Mar;73(3):86–8
Social contact, social attitudes, and twin similarity. Posner SF, et al. **Behav Genet** 1996 Mar;26(2):123–33
Correcting faulty appraisals of obsessional thoughts. Freeston MH, et al. **Behav Res Ther** 1996 May–Jun;34(5–6):433–46 (52 ref.)
Children and sport. Not all schoolchildren prefer team sports [letter; comment] Coffey R. **BMJ** 1996 May 11; 312(7040):1229. Comment on: BMJ 1996 Jan 27;312(7025):199–200.
People's cultural beliefs should be respected [letter] Shaw PQ. **BMJ** 1996 Jan 13;312(7023):125
Credibility and outcome of cognitive–behavioural and psychodynamic–interpersonal psychotherapy. Hardy GE, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):555–69
Confidentiality of medical records: the patient's perspective. Carman D, et al. **Br J Gen Pract** 1995 Sep;45(398):485–8
Perceptions of the significant other of the effects of psychodynamic psychotherapy. Implications for thinking about psychodynamic and systemic approaches. Roberts J. **Br J Psychiatry** 1996 Jan;168(1):87–93
Manners of expressing negative and sympathetic attitudes towards the unemployed. McFadyen RG, et al.
Br J Soc Psychol 1995 Sep;34 (Pt 3):303–23
Seeking influence through characterizing self–categories: an analysis of anti–abortionist rhetoric. Reicher S, et al.
Br J Soc Psychol 1996 Jun;35 (Pt 2):297–311
Chemotherapy for advanced disease. How to raise enthusiasm. McVie JG. **Chest** 1996 May;109(5 Suppl):80S–82S
Validity of a scale measuring beliefs regarding the "positive" effects of punishing children: a study of Mexican mothers. Corral–Verdugo V, et al. **Child Abuse Negl** 1995 Jun; 19(6):669–79
The impact of child sexual abuse on attitudes toward God and the Catholic Church. Rossetti SJ. **Child Abuse Negl** 1995 Dec;19(12):1469–81
Parental attitude and practice regarding physical punishment of school children in Santiago de Chile. Vargas NA, et al. **Child Abuse Negl** 1995 Sep;19(9):1077–82
Maternal attitudes and knowledge of child–rearing: associations with family and child outcomes. Benasich AA, et al. **Child Dev** 1996 Jun;67(3):1186–205
Perceptions and attitudes of black students toward school, achievement, and other educational variables. Ford DY, et al. **Child Dev** 1996 Jun;67(3):1141–52
Adolescents' and young adults' conceptions of civil liberties: freedom of speech and religion. Helwig CC. **Child Dev** 1995 Feb;66(1):152–66
Attributions and responses to the Arab–Israeli conflict: a developmental analysis. Hoffman MA, et al. **Child Dev** 1996 Feb;67(1):117–28
Parents' attributions for their children's behavior. Miller SA. **Child Dev** 1995 Dec;66(6):1557–84 (110 ref.)
Adolescents' conceptions of teachers' authority and their relations to rule violations in school. Smetana JG, et al. **Child Dev** 1996 Jun;67(3):1153–72
Surveying donor families: a comparison of two organ procurement organizations. Gordon AK, et al.
Clin Transplant 1995 Jun;9(3 Pt 1):141–5

The influence of parents' martial dissolutions on children's attitudes toward family formation. Axinn WG, et al. **Demography** 1996 Feb;33(1):66–81

Appreciation of community–based rehabilitation by caregivers of children with a disability. Finkenflügel HJ, et al. **Disabil Rehabil** 1996 May;18(5):255–60

The climacteric in The Netherlands: a review of Dutch studies on epidemiology, attitudes and use of hormone replacement therapy. Barentsen R. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;64 Suppl:S7–11 (22 ref.)

What women want from hormone replacement therapy: results of an international survey. Limouzin–Lamothe MA. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;64 Suppl:S21–4

Women's postpartum maternity benefits and work experience. Gjerdingen DK, et al. **Fam Med** 1995 Oct;27(9):592–8

Medical students' and private family physicians' perceptions of family practice. Miller KE, et al. **Fam Med** 1996 Jan; 28(1):33–8

Opening Pandora's box: patients' attitudes towards trainees. Dublin General Practice Vocational Training Scheme Third Year Group 1991–1992. Murphy AW. **Fam Pract** 1995 Sep;12(3):318–23

Preliminary study into the opinions of patients about the presence of medical students in the general practice consultation. Morrison JM, et al. **Health Bull (Edinb)** 1995 Nov;53(6):343–4

Multiple perceptions of discharge planning in one urban hospital. Clemens EL. **Health Soc Work** 1995 Nov; 20(4):254–61

Current attitudes towards egg donation among men and women. Kazem R, et al. **Hum Reprod** 1995 Jun;10(6):1543–8

Perceptions of senior residents about a community–based nursing center. Scott CB, et al. **Image J Nurs Sch** 1995 Fall;27(3):181–6

Age and responses to the Love Attitudes Scale: consistency in structure, differences in scores. Butler R, et al. **Int J Aging Hum Dev** 1995;40(4):281–96

Sociocultural influences on eating attitudes and behaviors, body image, and psychological functioning: a comparison of African–American, Asian–American, and Caucasian college women. Akan GE, et al. **Int J Eat Disord** 1995 Sep;18(2):181–7

The eating attitudes test and the eating disorders inventory in four Bulgarian clinical and nonclinical samples. Boyadjieva S, et al. **Int J Eat Disord** 1996 Jan;19(1):93–8

Cross–cultural differences in maternal evaluation of children's body shapes. Hodes M, et al. **Int J Eat Disord** 1996 Apr;19(3):257–63

Attitudes about overweight and dating among secondary school students. Sobal J, et al. **Int J Obes Relat Metab Disord** 1995 Jun;19(6):376–81

Negative work behaviours: their impact on disabled people seeking work. Mitchell JA. **Int J Rehabil Res** 1995 Sep; 18(3):215–23

Insight and general public attitude on psychotic experiences in Hong Kong. Lam LC, et al. **Int J Soc Psychiatry** 1996 Spring;42(1):10–7

The pastoral myth of the mental hospital: a personal account. Stevenson V, et al. **Int J Soc Psychiatry** 1995 Summer; 41(2):147–51

Patients' attitudes about gifts to physicians from pharmaceutical companies. Blake RL Jr, et al. **J Am Board Fam Pract** 1995 Nov–Dec;8(6):457–64

Attitudes about condoms and condom use among college students. Beckman LJ, et al. **J Am Coll Health** 1996 May; 44(6):243–9

Change in eating attitudes: an outcome measure of patients with eating disorders. Eiger MR, et al. **J Am Diet Assoc** 1996 Jan;96(1):62–4

Nutrition and food industry professionals' opinions about the nutrition label and its components. Osborn L, et al. **J Am Diet Assoc** 1996 Jun;96(6):607–9

Impact of preceptors on student attitudes toward supervised practice. Wolf KN, et al. **J Am Diet Assoc** 1996 Aug; 96(8):800–2

Guilt appeals in advertising: what are their effects? Coulter RH, et al. **J Appl Psychol** 1995 Dec;80(6):697–705

American society and hostility to the goals, methods and ideas which have created our economy and its world–leading medical device industry [letter] Lee SJ. **J Biomater Appl** 1995 Oct;10(2):116–20

Spinal phobia: survey results of patient attitudes and preferences regarding anesthesia. Sosis MB, et al. **J Clin Anesth** 1995 Aug;7(5):389–94

Attitudes of 47 mothers of pediatric oncology patients toward genetic testing for cancer predisposition. Patenaude AF, et al. **J Clin Oncol** 1996 Feb;14(2):415–21

Funeral directors, mortuaries and necropsies: implications for necropsy consent rates and the prevention of infection. Start RD, et al. **J Clin Pathol** 1996 Mar;49(3):217–22

Attributions and behavior in functional and dysfunctional marriages. Bradbury TN, et al. **J Consult Clin Psychol** 1996 Jun;64(3):569–76

Perceived benefit from child sexual abuse. McMillen C, et al. **J Consult Clin Psychol** 1995 Dec;63(6):1037–43

Program directors' opinions on the competency of postdoctoral general dentistry program graduates. Glassman P, et al. **J Dent Educ** 1996 Sep;60(9):747–54

Childrearing attitudes among parents of very low birth weight and normal birth weight children. Zelkowitz P, et al. **J Dev Behav Pediatr** 1996 Apr;17(2):84–9

Family involvement in routine health care: a survey of patients' behaviors and preferences. Botelho RJ, et al. **J Fam Pract** 1996 Jun;42(6):572–6

Maternal factors related to parenting practices, developmental expectations, and perceptions of child behavior problems. Fox RA, et al. **J Genet Psychol** 1995 Dec;156(4):431–41

Science and belief: psychobiological research on sexual orientation. Byne W. **J Homosex** 1995;28(3–4):303–44 (140 ref.)

The attitudes of undergraduate college students toward gay parenting. Crawford I, et al. **J Homosex** 1996;30(4):63–77

Testing the reliability and validity of the Index of Attitudes Toward Homosexuals (IAH) in Australia. Pain MD, et al. **J Homosex** 1995;30(2):99–110

Some correlates of individuals' attitudes toward lesbians. Simon A. **J Homosex** 1995;29(1):89–103

Does a clerkship affect students' views of psychiatric patients? Fabrega H Jr. **J Nerv Ment Dis** 1995 Dec; 183(12):736–42

Improving examination performance using Exam Analysis. Condon VM, et al. **J Nurs Educ** 1995 Sep;34(6):254–61

Nursing students' opinions on interpersonal violence. Kiner HP. **J Nurs Educ** 1995 Oct;34(7):325–31

Exclusive breast–feeding duration is associated with attitudinal, socioeconomic and biocultural determinants in three Latin American countries. Pérez–Escamilla R, et al. **J Nutr** 1995 Dec;125(12):2972–84

Fathers' parenting attitudes during a child's first year. Tiller CM. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug; 24(6):508–14

Environmental health in medical school curricula: views of academic deans [see comments] Graber DR, et al. **J Occup Environ Med** 1995 Jul;37(7):807–11. Comment in: J Occup Environ Med 1996 Feb;38(2):123.

Prevalence of abnormal eating attitudes and behaviors in hospital–based primary and tertiary care clinics: a window of opportunity? Rome ES, et al. **J Pediatr Adolesc Gynecol** 1996 Aug;9(3):133–8

Variability in automatic activation as an unobtrusive measure of racial attitudes: a bona fide pipeline? Fazio RH, et al. **J Pers Soc Psychol** 1995 Dec;69(6):1013–27

Identified and introjected forms of political internalization: extending self–determination theory. Koestner R, et al. **J Pers Soc Psychol** 1996 May;70(5):1025–36

Attitude strength and resistance processes. Pomerantz EM, et al. **J Pers Soc Psychol** 1995 Sep;69(3):408–19

Adult attachment security and symptoms of depression: the mediating roles of dysfunctional attitudes and low self–esteem. Roberts JE, et al. **J Pers Soc Psychol** 1996 Feb;70(2):310–20

Gender differences in perceptions of household labor. Kiger G, et al. **J Psychol** 1996 Jul;130(4):357–70

Time–management training: effects on time behaviors, attitudes, and job performance. Macan TH. **J Psychol** 1996 May;130(3):229–36

Motives for having or not having children: a comparison between questionnaire and interview methods. Wikman M, et al. **J Psychosom Obstet Gynaecol** 1995 Dec;16(4):171–80

Dating relationships and infidelity: attitudes and behaviors. Sheppard VJ, et al. **J Sex Marital Ther** 1995 Fall; 21(3):202–12

Preemployment predictors of children's union attitudes: the moderating role of identification with parents. Kelloway EK, et al. **J Soc Psychol** 1996 Jun;136(3):413–5

Effects of sexual orientation of interviewer on expressed attitudes toward male homosexuality. Kemph BT, et al. **J Soc Psychol** 1996 Jun;136(3):401–3

An attributional analysis of suicide. Lester D. **J Soc Psychol** 1996 Jun;136(3):399–400

Rape myth acceptance among Scottish and American students. Muir G, et al. **J Soc Psychol** 1996 Apr; 136(2):261–2

A retrospective study of the concept of spirituality as understood by recovering individuals. Mathew RJ, et al. **J Subst Abuse Treat** 1996 Jan–Feb;13(1):67–73

A piece of my mind. Frozen in time. Burns R. **JAMA** 1996 Jun 12;275(22):1775

Medical student attitudes to psychiatry: lack of effect of psychiatric hospital experience. Galletly CA, et al. **Med Educ** 1995 Nov;29(6):449–51

The value of medical student research: the experience at Stanford University School of Medicine. Jacobs CD, et al. **Med Educ** 1995 Sep;29(5):342–6

Attitudes of patients to medical student participation: general practice consultations on the Cambridge Community–Based Clinical Course. Jones S, et al. **Med Educ** 1996 Jan;30(1):14–7

Comparison of medical and non–medical student attitudes to social issues in medicine. Nnodim JO, et al. **Med Educ** 1995 Jul;29(4):273–7

The Community Living Attitudes Scale, Mental Retardation Form: development and psychometric properties. Henry D, et al. **Ment Retard** 1996 Jun;34(3):149–58

The enemy of science is within [letter] Fox CH. **Nature** 1996 Jan 25;379(6563):292

The enemy of science is within [letter] Grünewald H. **Nature** 1996 Jan 25;379(6563):292

The enemy of science is within [letter] Halestrap AP. **Nature** 1996 Jan 25;379(6563):292

The enemy of science is within [letter] Keast S. **Nature** 1996 Jan 25;379(6563):292

The prevalent distrust of science. Maddox J. **Nature** 1995 Nov 30;378(6556):435–7

American attitudes toward body fatness [letter] Segal–Isaacson CJ. **Nurse Pract** 1996 Mar;21(3):9–10, 12–3

Weight–related attitudes and behaviors of women who diet to lose weight: a comparison of black dieters and white dieters. Striegel–Moore RH, et al. **Obes Res** 1996 Mar; 4(2):109–16

Student doctors and women in labor: attitudes and expectations. Magrane D, et al. **Obstet Gynecol** 1996 Aug; 88(2):298–302

Do attitudes and beliefs influence work loss due to low back trouble? Symonds TL, et al. **Occup Med (Oxf)** 1996 Feb; 46(1):25–32

Scholarship player or walk–on [editorial] Peterson LJ. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):131

Parents' attitudes toward firearm injury prevention counseling in urban pediatric clinics. Haught K, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):649–53

Advance care planning for children with special health care needs: a survey of parental attitudes. Wharton RH, et al. **Pediatrics** 1996 May;97(5):682–7

Relationships between leisure time physical activity and perceived stress. Aldana SG, et al. **Percept Mot Skills** 1996 Feb;82(1):315–21

Preschool children's comprehension of the world "handicapped". Cohen TL, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):747–50

Male nurturing: older men don't want to share their views; young women do. Draper TW. **Percept Mot Skills** 1996 Feb;82(1):313–4

A new method for prescribing exercise: three–point ratings of perceived exertion. Dunbar CC, et al. **Percept Mot Skills** 1996 Feb;82(1):139–46

College students' perceptions of the purposes of sports. Finkenberg ME, et al. **Percept Mot Skills** 1996 Feb; 82(1):19–22

Validity and reliability of a Mainstreaming Attitude Inventory for child–care providers. Folsom–Meek SL. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1113–4

Annoyance and discomfort during exposure to high–frequency noise from an ultrasonic washer. Holmberg K, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):819–27

Effects of positive attitude toward giving a speech on cardiovascular and subjective fear responses during speech in anxious subjects. Hu S, et al. **Percept Mot Skills** 1995 Oct;81(2):609–10

The moral acceptability of suicide. Lester D. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1106

Characteristics of elementary school principals and their support for the physical education program. Lock RS, et al. **Percept Mot Skills** 1995 Aug;81(1):307–15

Estimates of reliabilities for the Teacher Integration Attitude Questionnaire. Sideridis GD, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1214

Health promotion and osteoporosis prevention among postmenopausal women. Ali NS, et al. **Prev Med** 1995 Sep; 24(5):528–34

Consumer case management and attitudes concerning family relations among persons with mental illness. Solomon P, et al. **Psychiatr Q** 1995 Fall;66(3):249–61

Forgetting in the workplace: attributions and recommendations for young and older employees. Erber JT, et al. **Psychol Aging** 1995 Dec;10(4):565–9

Aging mothers' and their adult daughters' perceptions of conflict behaviors. Fingerman KL. **Psychol Aging** 1995 Dec;10(4):639–49

Stability and accuracy of metamemory in adulthood and aging: a longitudinal analysis. McDonald–Miszczak L, et al. **Psychol Aging** 1995 Dec;10(4):553–64

Perceptions of baby talk, frequency of receiving baby talk, and self–esteem among community and nursing home residents. O'Connor BP, et al. **Psychol Aging** 1996 Mar; 11(1):147–54

Insight and psychosis: a social perspective. Johnson S, et al. **Psychol Med** 1995 May;25(3):515–20 (24 ref.)

Abnormal eating attitudes and behaviours in two ethnic groups from a female British urban population. Reiss D. **Psychol Med** 1996 Mar;26(2):289–99

Importance of central issues and students positive evaluation of life events. Bernstein BL, et al. **Psychol Rep** 1995 Dec; 77(3 Pt 1):848–50

Self–interest and attitudes about legislation controlling alcohol. Crowe JW, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):995–1003

Dubious value of the "reasonable woman" standard in understanding sexual harassment [comment] Eisenman R. **Psychol Rep** 1995 Dec;77(3 Pt 2):1145–6. Comment on: Psychol Rep 1995 Aug;77(1):79–82.

Nonsmoking college students' attitudes toward smokers and smoking. Hines D. **Psychol Rep** 1996 Jun;78(3 Pt 1):860–2

Questionnaire format bias: when are juxtaposed scales appropriate: a call for further research. Hunt DM, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):931–41

Judgments of substance use and creativity in 'ordinary' people's everyday lifestyles. Lowe G. **Psychol Rep** 1995 Jun;76(3 Pt 2):1147–54

Relationship between personal prayer and school–related attitudes among 11–16–year–old girls. Montgomery A, et al. **Psychol Rep** 1996 Jun;78(3 Pt 1):787–93

Negative evaluations of men's nurturant touching of young

children. Rane TR, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):811–8

Development of the Relationship Beliefs Questionnaire. Romans JS, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1248–50

Perceptions of childhood obesity of undergraduate students in physical education. Savage MP. **Psychol Rep** 1995 Jun; 76(3 Pt 2):1251–9

Comparison of attitudes of teachers of physical and musical education toward inclusion of children with disabilities. Sideridis GD, et al. **Psychol Rep** 1996 Jun;78(3 Pt 1):768–70

Men's preferences in romantic partners: obesity vs addiction. Sitton S, et al. **Psychol Rep** 1995 Dec;77(3 Pt 2):1185–6

Consistency between maternal employment attitudes and employment status. Youngblut JM. **Res Nurs Health** 1995 Dec;18(6):501–13

Fair Play for Kids: effects on the moral development of children in physical education. Gibbons SL, et al. **Res Q Exerc Sport** 1995 Sep;66(3):247–55

Gender differences in risk perception: effects differ in stressed vs. non-stressed environments. Greenberg MR, et al. **Risk Anal** 1995 Aug;15(4):503–11 (29 ref.)

Perception of nuclear energy and coal in France and The Netherlands. Wiegman O, et al. **Risk Anal** 1995 Aug; 15(4):513–21

Predicting 13-year-olds' drinking using parents' self-reported alcohol use and restrictiveness compared with offspring's perception. Aas H, et al. **Scand J Psychol** 1996 Jun;37(2):113–20

Parental perceptions and attitudes about informed consent in clinical research involving children. Harth SC, et al. **Soc Sci Med** 1995 Dec;41(12):1647–51

Blue roads and homework [editorial] Moser RH. **South Med J** 1996 Jan;89(1):93–4

Clinicians' attitudes toward no-suicide agreements. Davidson MW, et al. **Suicide Life Threat Behav** 1995 Fall;25(3):410–4

Cross-validation of the five-factor interpretive model of the Suicide Opinion Questionnaire. Rogers JR, et al. **Suicide Life Threat Behav** 1995 Summer;25(2):305–9

Language, poetry and attitude to sound. Ordinary meeting; Monday, 28th February, 1994. Douek E. **Trans Med Soc Lond** 1993–94;110:54–8

Attitudes to companion animals [letter] Houghton L. **Vet Rec** 1996 Jan 27;138(4):95

Alcohol expectancies and the personal and parental drinking patterns of women. Bogart CJ, et al. **Women Health** 1995; 22(4):51–66

Barriers to condom use among women attending planned parenthood clinics. Detzer MJ, et al. **Women Health** 1995; 23(1):91–102

[Attitude and considerations of sperm donors in relation to insemination] Pedersen B, et al. **Ugeskr Laeger** 1995 Aug 7;157(32):4462–5 (Eng. Abstr.) **(Dan)**

[Child sex abuse: pretext to a return of sexual repression] Marneffe C. **Acta Psychiatr Belg** 1995;95(6):358–68 (Eng. Abstr.) **(Fre)**

[Attitude and behavior of the youth of Senegal toward drugs] Seck B, et al. **Dakar Med** 1994;39(1):17–22 (Eng. Abstr.) **(Fre)**

[Fate of supernumerary embryos and risk of multiple pregnancy in in-vitro fertilization: attitude of involved couples] Laruelle C, et al. **Rev Med Brux** 1996 Jun; 17(3):115–9 (Eng. Abstr.) **(Fre)**

[Change in automobile driving capacity assessment—a contribution to the correlation between diagnosis and therapy] Pund B, et al. **Blutalkohol** 1996 Jan;33(1):31–43 (Eng. Abstr.) **(Ger)**

[How can acceptance by psychiatric patients of group psychotherapy be improved? An empirical study of the effect of combined individual and group psychotherapy on attitude to group psychotherapy] Teusch L, et al. **Z Klin Psychol Psychopathol Psychother** 1995;43(4):355–63 (Eng. Abstr.) **(Ger)**

[Persistence of polarization in self-generated attitude change] Isozaki M. **Shinrigaku Kenkyu** 1995 Aug;66(3):161–8 (Eng. Abstr.) **(Jpn)**

[Tools for a clinical assessment of patients' attitudes toward schizophrenic illness: 2. "My experience of illness" scale (MEIS)] Wciórka J. **Psychiatr Pol** 1996 May–Jun; 30(3):397–413 (Eng. Abstr.) **(Pol)**

[Tools for a clinical assessment of patients' attitudes toward their schizophrenic illness: 1. "Experience of illness" scale (EIS)] Wciórka J, et al. **Psychiatr Pol** 1996 May–Jun; 30(3):381–96 (Eng. Abstr.) **(Pol)**

[Sibenik schoolchildren and the war (7 months later)] Cala D. **Lijec Vjesn** 1995 Jul–Aug;117(7–8):197–201 (Eng. Abstr.) **(Scr)**

[Sexual myths in an adult population] van-der Hofstadt CJ, et al. **Med Clin (Barc)** 1995 Nov 25;105(18):691–5 (Eng. Abstr.) **(Spa)**

[Autonomous National University of Mexico (UNAM) medical students' attitudes to research and learning: 1984–1994] Nobigrot-Kleinman D, et al. **Salud Publica Mex** 1995 Jul–Aug;37(4):316–22 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Voices of Korean-American students. Park EJ. **Adolescence** 1995 Winter;30(120):945–53

Cultural response to mental illness in Senegal: Reflections through patient companions—Part I. Methods and descriptive data. Franklin RR, et al. **Soc Sci Med** 1996 Feb; 42(3):325–38

Cultural response to mental illness in Senegal: reflections through patient companions—Part II. Statistical correlates. Franklin RR, et al. **Soc Sci Med** 1996 Feb;42(3):339–52

ATTITUDE OF HEALTH PERSONNEL

Psychiatrists' attitudes toward psychiatry [letter] Berman I, et al. **Acad Med** 1996 Feb;71(2):110–1

Professional competencies in the changing health care system: physicians' views on the importance and adequacy of formal training in medical school. Finocchio LJ, et al. **Acad Med** 1995 Nov;70(11):1023–8

Should half of all medical school graduates enter primary care? Perceptions of faculty members at Jefferson Medical College. Gottlieb J, et al. **Acad Med** 1995 Dec; 70(12):1125–33

Using attribution theory models to predict senior medical students' perceptions of patients and career choice. Merrill JM, et al. **Acad Med** 1996 Jan;71(1 Suppl):S67–9

Knowledge, confidence, and attitudes regarding medical ethics: how do faculty and housestaff compare? Sulmasy DP, et al. **Acad Med** 1995 Nov;70(11):1038–40

Housestaff attitudes about work rounds [letter] Ways M, et al. **Acad Med** 1996 Feb;71(2):108–9

Examining what residents look for in their role models. Wright S. **Acad Med** 1996 Mar;71(3):290–2

Mentality and behaviour of a Mediterranean neurosurgeon. Foroglou G. **Acta Neurochir (Wien)** 1995;132(4):202–5

Mentality and behaviour of neurosurgeons and patients in China. Wang CC. **Acta Neurochir (Wien)** 1995;132(4):196–8

Parental and primary care physicians' views on the management of chronic diseases: a study in Italy. The Italian Collaborative Group on Paediatric Chronic Diseases. Marchetti F, et al. **Acta Paediatr** 1995 Oct; 84(10):1165–72

Psychological climate and countertransference in psychiatric treatment homes. Holmqvist R, et al. **Acta Psychiatr Scand** 1996 Apr;93(4):288–95

Management and treatment efficacy of drug and alcohol problems: what do doctors believe? Roche AM, et al. **Addiction** 1995 Oct;90(10):1357–66

Menstruation, menarche, and sexuality in the public school curriculum: school nurses' perceptions. Swenson IE, et al. **Adolescence** 1995 Fall;30(119):677–83

The implications of HIV/AIDS for a range of workers in the Scottish context. Barbour RS. **AIDS Care** 1995; 7(4):521–35

Promoting safer sexual practices among young adults: a survey of health workers in Moshi Rural District, Tanzania. Ngomuo ET, et al. **AIDS Care** 1995;7(4):501–7

The Nurses' Attitudes About AIDS Scale (NAAS): development and psychometric analysis. Preston DB, et al. **AIDS Educ Prev** 1995 Oct;7(5):443–54

Physicians' opinions on the delivery of mammographic screening services: immediate interpretation versus double reading. Slanetz PJ, et al. **AJR Am J Roentgenol** 1996 Aug; 167(2):377–9

Point-of-care testing in the intensive care unit. The intensive care physician's perspective. Castro HJ, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S95–9 (22 ref.)

Current nursing practice of point-of-care laboratory diagnostic testing in critical care units. Lamb LS Jr, et al. **Am J Crit Care** 1995 Nov;4(6):429–34

Thinking about homeopathy [editorial] Hasegawa GR. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2411

Predictors of organizational and career commitment among Illinois pharmacists. Kong SX. **Am J Health Syst Pharm** 1995 Sep 15;52(18):2005–11

Evaluation of a medical ethics consultation service: opinions of patients and health care providers. McClung JA, et al. **Am J Med** 1996 Apr;100(4):456–60

Patterns of hospital care and physician perspectives from an Italian, Japanese, and USA hospital. Louis CZ, et al. **Am J Med Qual** 1996 Fall;11(3):123–34

When a loved one is dying: families talk about nursing care. Czerwiec M. **Am J Nurs** 1996 May;96(5):32–6

Tools of the heart. Fisher R. **Am J Nurs** 1996 Jul;96(7):56–7

Physician attitudes toward human immunodeficiency virus testing in pregnancy. Segal AI. **Am J Obstet Gynecol** 1996 Jun;174(6):1750–5; discussion 1755–6

Factors influencing entry-level occupational therapists' attitudes toward persons with disabilities. Eberhardt K, et al. **Am J Occup Ther** 1995 Jul–Aug;49(7):629–36

Indications for cranial nerve monitoring during otologic and neurotologic surgery. Jackler RK, et al. **Am J Otol** 1994 Sep;15(5):611–3

Barriers to learning preventive medicine: student experiences in undergraduate medical education [letter] Jung P, et al. **Am J Prev Med** 1996 May–Jun;12(3):141–2

The treatment of non-HIV-related conditions in newborns at risk for HIV: a survey of neonatologists [see comments] Levin BW, et al. **Am J Public Health** 1995 Nov; 85(11):1507–13. Comment in: Am J Public Health 1995 Nov;85(11):1484–5.

Abortions in rural Idaho: physicians' attitudes and practices. Rosenblatt RA, et al. **Am J Public Health** 1995 Oct; 85(10):1423–5

Prescribing authority: an examination of Ohio pharmacists' opinions. Desikan R, et al. **Am Pharm** 1995 Oct; NS35(10):19–23

Acute pain management in Australia and New Zealand. Goucke CR, et al. **Anaesth Intensive Care** 1995 Dec; 23(6):715–7

Emergency medicine residents' perspectives on injury prevention. Anglin D, et al. **Ann Emerg Med** 1996 Jul; 28(1):31–3

Clinical incoherence about persons: the problem of the persistent vegetative state [editorial; comment] Cassell EJ. **Ann Intern Med** 1996 Jul 15;125(2):146–7. Comment on: Ann Intern Med 1996 Jul 15;125(2):104–10.

Important elements of outpatient care: a comparison of patients' and physicians' opinions. Laine C, et al. **Ann Intern Med** 1996 Oct 15;125(8):640–5

Physicians' attitudes about the care of patients in the persistent vegetative state: a national survey [see comments] Payne K, et al. **Ann Intern Med** 1996 Jul 15;125(2):104–10 . Comment in: Ann Intern Med 1996 Jul 15;125(2):146–7.

Freudian suspicion versus suspicion of Freud. Crews F. **Ann N Y Acad Sci** 1996 Jun 24;775:470–82 (58 ref.)

A survey in Puglia: the attitudes and opinions of specialists, general physicians and patients on follow-up practice. G.S.Bio.Ca.M. Paradiso A, et al. **Ann Oncol** 1995;6 Suppl 2:53–6

Comparison of activities and attitudes of baccalaureate level and entry-level doctor of pharmacy graduates of the University of Illinois at Chicago. Fjortoft NF, et al. **Ann Pharmacother** 1995 Oct;29(10):977–82

Maxillofacial senior house officer posts: the trainee's perspective. Lyons AJ, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5 Suppl):242–5

Subjective effects of double gloves on surgical performance. Wilson SJ, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):20–2

Attitudes and opinions toward surgical research. A survey of surgical residents and their chairpersons. Souba WW, et al. **Ann Surg** 1996 Apr;223(4):377–83

Educational research [letter; comment] Brazen L. **AORN J** 1995 Jul;62(1):17. Comment on: AORN J 1995 May;61(5):852–7.

Does perioperative nursing include caring? Burchiel RN. **AORN J** 1995 Aug;62(2):257–9

Let us respect and value each other as we celebrate the nature of caring. Murphy EK. **AORN J** 1995 Nov;62(5):697, 700

A surgical services learning needs assessment. Piatkowski CA. **AORN J** 1995 Aug;62(2):251–4

Nurses' educational preparation and attitudes toward cost containment. Robinson BJ, et al. **AORN J** 1995 Sep; 62(3):404–7, 409–10

Genetic testing of children. Fryer A. **Arch Dis Child** 1995 Aug;73(2):97–9 (9 ref.)

Attitudes of Dutch general practitioners and nursing home physicians to active voluntary euthanasia and physician-assisted suicide. Onwuteaka-Philipsen BD, et al. **Arch Fam Med** 1995 Nov;4(11):951–5

The relativity of alternative medicine [editorial; comment] Alpert JS. **Arch Intern Med** 1995 Dec 11–25;155(22):2385 . Comment on: Arch Intern Med 1995 Dec 11–25;155(22):2405–8.

New York State primary care physicians' attitudes to community pharmacists' clinical services. Bailie GR, et al. **Arch Intern Med** 1996 Jul 8;156(13):1437–41

Complementary medicine. What physicians think of it: a meta-analysis [see comment] Ernst E, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2405–8. Comment in: Arch Intern Med 1995 Dec 11–25;155(22):2385.

Who decides? Physicians' willingness to use life-sustaining treatment. Hanson LC, et al. **Arch Intern Med** 1996 Apr 8;156(7):785–9

Detours on the road to autonomy. A critique of the New York State do-not-resuscitate law. Pollack S. **Arch Intern Med** 1996 Jul 8;156(13):1369–71

Reverse gullibility and scientific evidence. Riffenburgh RH. **Arch Otolaryngol Head Neck Surg** 1996 Jun;122(6):600–1

Desirable performance standards for imprecision and bias in alternate sites. The views of laboratory professionals. Fraser CG, et al. **Arch Pathol Lab Med** 1995 Oct; 119(10):909–13

Use of checklists in pediatric practice [letter; comment] Cheng TL, et al. **Arch Pediatr Adolesc Med** 1996 Jul; 150(7):768–9. Comment on: Arch Pediatr Adolesc Med 1995 Jul;149(7):740–6.

Tuberculosis testing. Physician attitudes and practice. Cheng TL, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):682–5

Psychiatric nurses' attitudes toward sexuality, sexual assault/rape, and incest. Boutcher F, et al. **Arch Psychiatr Nurs** 1996 Jun;10(3):184–91

Bias towards gay patients by psychoanalytic clinicians: an empirical investigation. Lilling AH, et al. **Arch Sex Behav** 1995 Oct;24(5):563–70

Removable prosthodontics: a survey of practices and attitudes among South Australian dentists. Coates AJ, et al. **Aust Dent J** 1996 Jun;41(3):151–8

Infection control and human immunodeficiency virus: perceptions of risk among nurses and hospital domestic workers. Parsons CD, et al. **Aust J Public Health** 1995 Oct;19(5):492–500

Brisbane GPs' perceptions of screening for primary open-angle glaucoma. Jackson C, et al. **Aust N Z J Ophthalmol** 1995 Aug;23(3):179–81

Adults' responses to self-injurious behavior. An experimental analysis using a computer-simulation paradigm. Hastings RP, et al. **Behav Modif** 1995 Oct;19(4):425–50

Survey of general practitioners' views of consultants' non-urgent referral of outpatients to other consultants [see comments] Bridger S, et al. **BMJ** 1996 Mar 30;

312(7034):821–2. Comment in: BMJ 1996 Jul 13;313(7049):111–2. Comment in: BMJ 1996 Jul 13;313(7049):112.

Training of overseas qualified doctors in Britain. View of overseas doctors training in obstetrics and gynaecology [letter; comment] Carty MJ. **BMJ** 1996 Feb 3;312(7026):311 . Comment on: BMJ 1995 Sep 9;311(7006):642–3.

Responding to out of hours requests for visits: a survey of general practitioner opinion. Court BV, et al. **BMJ** 1996 Jun 1;312(7043):1401–2

Local research ethics committees. Attitude of their members is the critical factor [letter; comment] Dudley H. **BMJ** 1995 Dec 9;311(7019):1571. Comment on: BMJ 1995 Sep 9;311(7006):639–40.

General practitioners' views on over the counter sales by community pharmacists [see comments] Erwin J, et al. **BMJ** 1996 Mar 9;312(7031):617–8. Comment in: BMJ 1996 Mar 9;312(7031):593–4. Comment in: BMJ 1996 Jul 13;313(7049):116.

Attitudes of consultant physicians to Calman proposals. Royal College of Physicians gave qualified support to proposals [letter] [see comments] London D. **BMJ** 1995 Dec 9;311(7019):1573. Comment in: BMJ 1996 Feb 17;312(7028):443.

Attitudes of consultant physicians to the Calman proposals: a questionnaire survey. North West Thames Diabetes and Endocrinology Specialist Group [see comments] Mather HM, et al. **BMJ** 1995 Oct 21;311(7012):1060–2. Comment in: BMJ 1995 Nov 11;311(7015):1298. Comment in: BMJ 1996 Feb 17;312(7028):443–4.

Attitude of consultant physicians to Calman proposals. Anxieties are widespread [letter; comment] Mather HM, et al. **BMJ** 1996 Feb 17;312(7028):443. Comment on: BMJ 1995 Nov 11;311(7015):1298. Comment on: BMJ 1995 Dec 9;311(7019):1573.

GPs in Glasgow are in favour of primary care emergency centres [letter; comment] [see comments] O'Neil J. **BMJ** 1996 Jun 22;312(7046):1610. Comment on: BMJ 1996 Feb 10;312(7027):352–6. Comment in: BMJ 1996 Jun 22;312(7046):1553–4.

Treating anorexia nervosa. Psychiatrists have mixed views on use of terminal care for anorexia nervosa [letter; comment] Ramsay R, et al. **BMJ** 1996 Jan 20;312(7024):182 . Comment on: BMJ 1995 Sep 2;311(7005):584.

Attitude of consultant physicians to Calman proposals. Who is responsible for quality of acute medical care? [letter; comment] Taylor BL, et al. **BMJ** 1996 Feb 17; 312(7028):443–4. Comment on: BMJ 1995 Oct 21;311(7012):1060–2.

Routine surgical follow up: do surgeons agree? [see comments] Waghorn A, et al. **BMJ** 1995 Nov 18; 311(7016):1344–5. Comment in: BMJ 1995 Nov 18;311(7016):1315–6.

Scare over oral contraceptives. Doctors should take warning seriously [letter] Watson C. **BMJ** 1995 Dec 16; 311(7020):1638

Professional attitudes to specialisation and minor oral surgery in general dental practice. Clark S. **Br Dent J** 1995 Sep 23;179(6):209–13

Dentists practising in Lothian treat HIV seropositive patients: is this a resolution of conflict or a case of Hobson's choice? [see comments] Gibson BJ, et al. **Br Dent J** 1996 Jan 20; 180(2):53–6. Comment in: Br Dent J 1996 May 11;180(9):326.

Attitudes of dental health care workers to HIV infected persons [letter; comment] Porter S, et al. **Br Dent J** 1996 May 11;180(9):326. Comment on: Br Dent J 1996 Jan 20;180(2):53–6.

Attitudes to adverse drug reaction reporting [letter] Inman WH. **Br J Clin Pharmacol** 1996 May;41(5):434–5

What do general practitioners want from a dermatology department? Harlow ED, et al. **Br J Dermatol** 1996 Feb; 134(2):313–8

The views of general practitioners on community carrier screening for cystic fibrosis. Boulton M, et al. **Br J Gen Pract** 1996 May;46(406):299–301

General practitioners and occupational health services. Parker G. **Br J Gen Pract** 1996 May;46(406):303–5

Epilepsy monitoring and advice recorded: general practitioners' views, current practice and patients' preferences. Ridsdale L, et al. **Br J Gen Pract** 1996 Jan; 46(402):11–4

General practitioner registrars' views about a career in general practice. Rowsell R, et al. **Br J Gen Pract** 1995 Nov;45(400):601–4

Clinical guidelines in primary care: a survey of general practitioners' attitudes and behaviour. Siriwardena AN. **Br J Gen Pract** 1995 Dec;45(401):643–7

What do deans of medical schools and heads of departments of general practice think of preregistration rotations in general practice? Wilton J. **Br J Gen Pract** 1996 Jan; 46(402):33–4

Why do psychiatrists neglect religion? Neeleman J, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):169–78 (83 ref.)

Bias towards chronicity in schizophrenia? [letter] Murthy RS. **Br J Psychiatry** 1996 May;168(5):656–7

Change in care staff's attitudes towards people with learning disabilities following intervention at the Leros PIKPA asylum. Kordoutis P, et al. **Br J Psychiatry Suppl** 1995 Jul;(28):56–69

Circumcision: how do urologists do it? O'Sullivan DC, et al. **Br J Urol** 1996 Aug;78(2):265–70

Cutting the cost of catheterization for acute retention—a hospital or domiciliary procedure? Webb VJ, et al. **Br J Urol** 1995 Oct;76(4):443–5

A clinician with a family member with schizophrenia: a case report. Hough G. **Bull Menninger Clin** 1995 Summer; 59(3):345–56

Attitudes of Bolivian pharmacists in dealing with diarrhea cases. Zamora Gutiérrez AD, et al. **Bull Pan Am Health Organ** 1995 Dec;29(4):322–7

Clinical practice guidelines. New-to-practice family physicians' attitudes. Ferrier BM, et al. **Can Fam Physician** 1996 Mar;42:463–8

Normal people with special needs [editorial] Gibson GA. **Can Fam Physician** 1996 May;42:831–3; 839–42 **(Eng, Fre)**

Debating benzodiazepine use [letter; comment] [see comments] Lexchin J. **Can Fam Physician** 1995 Aug; 41:1293, 1295. Comment on: Can Fam Physician 1995 May;41:760, 763–5, 772–6. Comment in: Can Fam Physician 1995 Nov;41:1848.

Needs for CME in geriatrics. Part 2: Physician priorities and perceptions of community representatives. Pereles I, et al. **Can Fam Physician** 1996 Apr;42:632–40

What breast cancer self-help groups want you to know [editorial] Phillips C, et al. **Can Fam Physician** 1996 Aug; 42:1447–9, 1455–7 **(Eng, Fre)**

Cancer in remission. Challenge in collaboration for family physicians and oncologists. Wood ML, et al. **Can Fam Physician** 1996 May;42:899–904; 907–10

Current health policy initiatives and options. New-to-practice family physicians' attitudes. Woodward CA, et al. **Can Fam Physician** 1995 Dec;41:2104–11

Re: Psychiatrists' attitudes to multiple personality disorder [letter; comment] Baldock J, et al. **Can J Psychiatry** 1995 Oct;40(8):495–6. Comment on: Can J Psychiatry 1995 Apr;40(3):164–7.

The euthanasia debate: attitudes, practices and psychiatric considerations. Chochinov HM, et al. **Can J Psychiatry** 1995 Dec;40(10):593–602 (69 ref.)

Health professionals' perceptions of partnership with self-help groups. Stewart MJ, et al. **Can J Public Health** 1995 Sep-Oct;86(5):340–4

Politician, MDs offer educators opinions on managing unprecedented health care change. Cairney R. **Can Med Assoc J** 1996 Jul 1;155(1):106–7

Twelve weeks of coronary artery disease. Fedak PW. **Can Med Assoc J** 1996 May 15;154(10):1545–6

Do Canadian female surgeons feel discriminated against as women? Ferris LE, et al. **Can Med Assoc J** 1996 Jan 1; 154(1):21–7

Mixed reaction to suicide of terminally ill woman [letter] Harding SR. **Can Med Assoc J** 1995 Nov 1;153(9):1226

Habit, prejudice, power and politics: issues in the conversion of H2-receptor antagonists to over-the-counter use [editorial] Hunt RH. **Can Med Assoc J** 1996 Jan 1; 154(1):49–53

Physicians say government-approved love affair with gambling sure bet to cause problems. Kezwer G. **Can Med Assoc J** 1996 Jan 1;154(1):84–8

Complementary medicine and the scientific method [letter; comment] McGoey JS. **Can Med Assoc J** 1996 Jan 1; 154(1):14–5; discussion 15–6. Comment on: Can Med Assoc J 1995 Jul 1;153(1):45–9.

The politics of despair: AIDS and the failure of treatment [see comments] Mackie ID. **Can Med Assoc J** 1995 Oct 1;153(7):967–8. Comment in: Can Med Assoc J 1996 Jan 15;154(2):139; discussion 140. Comment in: Can Med Assoc J 1996 Jan 15;154(2):139–40. Comment in: Can Med Assoc J 1996 Jan 15;154(2):140.

Triviality and frequency of night calls irk British GPs. Richmond C. **Can Med Assoc J** 1996 Jan 1;154(1):82–3

Frustrated residents worry as they look toward an uncertain future. Robb N. **Can Med Assoc J** 1996 Apr 15; 154(8):1233–6

Gun control [letter; comment] Sobrian J. **Can Med Assoc J** 1996 Jan 1;154(1):11; discussion 12–3. Comment on: Can Med Assoc J 1995 Oct 1;153(7):879. Comment on: Can Med Assoc J 1995 Oct 1;153(7):879–80. Comment on: Can Med Assoc J 1995 Oct 1;153(7):880.

Teaching cancer pain management: durability of educational effects of a role model program. Janjan NA, et al. **Cancer** 1996 Mar 1;77(5):996–100i

Oncologists and primary care physicians' attitudes toward pain control and morphine prescribing in France [see comments] Larue F, et al. **Cancer** 1995 Dec 1; 76(11):2375–82. Comment in: Cancer 1995 Dec 1;76(11):2181–5.

Impact of patient history on residents' evaluation on child sexual abuse. Ashworth CS, et al. **Child Abuse Negl** 1995 Aug;19(8):943–51

A study of the variability of training and beliefs among professionals who interview children to investigate suspected sexual abuse. Davey RI, et al. **Child Abuse Negl** 1995 Aug;19(8):933–42

Child abuse treatment: a fallow land. Marneffe C. **Child Abuse Negl** 1996 May;20(5):379–84

The approach of Israeli health and mental health students toward child maltreatment. Shor R, et al. **Child Abuse Negl** 1996 May;20(5):425–35

Childhood sexually transmitted diseases and child sexual abuse: results of a Canadian survey of three professional groups. Thomas BH, et al. **Child Abuse Negl** 1995 Sep; 19(9):1019–29

Assisted suicide: opinions of Alberta physicians. Kinsella TD, et al. **Clin Invest Med** 1995 Oct;18(5):406–12

A physician survey of therapy for exercise-associated amenorrhea: a brief report. Haberland CA, et al. **Clin J Sport Med** 1995 Oct;5(4):246–50

Ultrasound training for non-radiologists [editorial] Martin DF. **Clin Radiol** 1995 Sep;50(9):589–92

Tobacco habits, attitudes and participating behavior in tobacco prevention among dental personnel in Sweden. Halling A, et al. **Community Dent Oral Epidemiol** 1995 Aug; 23(4):254–5

Ideologies of care in community residential services: what do caregivers believe? Heaney CA, et al. **Community Ment Health J** 1995 Oct;31(5):449–62

Changing MSW students' attitudes towards the severely mentally ill. Shera W, et al. **Community Ment Health J** 1996 Apr;32(2):159–69

End-user satisfaction of a patient education tool manual versus computer-generated tool. Tronni C, et al. **Comput Nurs** 1996 Jul-Aug;14(4):235–8

Caring for HIV-infected drug users: a provider's perspective [editorial] Selwyn PA. **Cutis** 1995 Nov;56(5):250–2

Canadian attitudes toward use of primary repair in management of colon trauma. A survey of 317 members of the Canadian Association of General Surgeons. Pezim ME, et al. **Dis Colon Rectum** 1996 Jan;39(1):40–4

Post-operative analgesia for craniotomy patients: current attitudes among neuroanaesthetists. Stoneham MD, et al. **Eur J Anaesthesiol** 1995 Nov;12(6):571–5

Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy [see comments] Bremnes RM, et al. **Eur J Cancer** 1995 Nov;31A(12):1955–9 . Comment in: Eur J Cancer 1995 Nov;31A(12):1917–8.

Clinical trials and quality of life assessment: the nurses' viewpoint. Molin C, et al. **Eur J Cancer** 1995;31A Suppl 6:S8–10 (25 ref.)

Family practice educators' perceptions of computer-based patient records. Musham C, et al. **Fam Med** 1995 Oct; 27(9):571–5

Reactions of family medicine community preceptors to teaching medical students. Usatine RP, et al. **Fam Med** 1995 Oct;27(9):566–70

Short-term acceptability of the female condom among staff and patients at a New York City Hospital. Gollub EL, et al. **Fam Plann Perspect** 1995 Jul-Aug;27(4):155–8

Undergraduate medical students' rating of clerkship in general practice. Foldevi M. **Fam Pract** 1995 Jun; 12(2):207–13

Constipation: a different entity for patients and doctors. Herz MJ, et al. **Fam Pract** 1996 Apr;13(2):156–9

"I know what to do, but it's not possible to do it"—general practitioners' perceptions of their ability to detect psychological distress. Howe A. **Fam Pract** 1996 Apr; 13(2):127–32

Not another questionnaire!: eliciting the views of general practitioners. MacPherson I, et al. **Fam Pract** 1995 Sep; 12(3):335–8

The value of curiosity and naiveté for the cross-cultural psychotherapist. Dyche L, et al. **Fam Process** 1995 Dec; 34(4):389–99 (33 ref.)

Training to think culturally: a multidimensional comparative framework. Falicov CJ. **Fam Process** 1995 Dec; 34(4):373–88 (56 ref.)

Nursing home reviews can be frustrating to dedicated staff [letter; comment] Matthies RW. **Geriatrics** 1996 Jul;51(7):16 . Comment on: Geriatrics 1995 Dec;50(12):11. Comment on: Geriatrics 1996 Feb;51(2):9, 13.

Percutaneous endoscopic gastrostomy in geriatric patients: attitudes of health care professionals. Hasan M, et al. **Gerontology** 1995;41(6):326–31

Successful strategies for surviving managed care [letter] Harris B. **Hawaii Med J** 1996 Jul;55(7):112

Survey of Hawaii physicians' attitudes on health care reform. Sunderland P. **Hawaii Med J** 1995 Oct;54(10):740–5

Medical audit activity in primary and secondary care in the west of Scotland. Kinn SR, et al. **Health Bull (Edinb)** 1996 May;54(3):252–7

A controlled trial of general practitioners' attitudes to patients with schizophrenia. Lawrie SM, et al. **Health Bull (Edinb)** 1996 May;54(3):201–3

Scottish neonatal intensive care units; a study of staff and parental attitudes. Reid M, et al. **Health Bull (Edinb)** 1995 Sep;53(5):314–25

The educational needs of staff grade doctors and dentists in Scotland. Rippin H, et al. **Health Bull (Edinb)** 1996 Jul; 54(4):318–31

Physician attitudes toward pharmaceutical sales representatives. Andaleeb SS, et al. **Health Care Manage Rev** 1995 Summer;20(3):68–76

Reactions of salaried physicians to hospital decline. Lachman R, et al. **Health Serv Res** 1996 Jun;31(2):171–90

Effects of ageism on individual and health care providers' responses to healthy aging. Grant LD. **Health Soc Work** 1996 Feb;21(1):9–15 (46 ref.)

Gender bias in the diagnosis and treatment of coronary artery disease. Beery TA. **Heart Lung** 1995 Nov-Dec;24(6):427–35 (64 ref.)

Critical care nurses' perceptions of appropriate care of the patient with orders not to resuscitate. Sherman DA, et al. **Heart Lung** 1995 Jul-Aug;24(4):321–9

The haunting memory of a trauma patient [clinical

conference] Elder J, et al. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):147–50, 153–6

Missed opportunities for immunization in children under 2 years attending an urban teaching hospital. Deivanayagam N, et al. **Indian Pediatr** 1995 Jan;32(1):51–7

Effecting attitudinal change towards rational drug use. Singh T, et al. **Indian Pediatr** 1995 Jan;32(1):43–6

How solo physicians view their practices. Carlson B. **Indiana Med** 1996 May–Jun;89(3):250–4

Blood and body fluid exposures among surgeons: a survey of attitudes and perceptions five years following Universal Precautions. Manian FA. **Infect Control Hosp Epidemiol** 1996 Mar;17(3):172–4

Criteria of good dental practice generated by general dental practitioners and patients. Burke L, et al. **Int Dent J** 1996 Feb;46(1):3–9

Physicians' approach to the management of hypertension in a developing community. Olubodun JO. **Int J Cardiol** 1995 Sep;51(2):193–7

Clinicians' opinions on alarm limits and urgency of therapeutic responses. Koski EM, et al. **Int J Clin Monit Comput** 1995 May;12(2):85–8

Development, refinement and future usage of the scale: "attitudes toward learning in pregnancy". Jackson MS, et al. **Int J Nurs Stud** 1996 Feb;33(1):37–46

Conflicting attitudes to corneal and organ donation: a study of nurses' attitudes to organ donation. Kent B, et al. **Int J Nurs Stud** 1995 Oct;32(5):484–92

The pattern and effect of on call work in transplant coordinators in the United Kingdom. Smithers F. **Int J Nurs Stud** 1995 Oct;32(5):469–83

Divergent views—patient, career and staff perceptions of diagnosis and reasons for psychiatric admission to a district general hospital. Round A, et al. **Int J Soc Psychiatry** 1995 Autumn;41(3):210–6

Preoperative HIV antibody testing: the views of surgeons and patients. Meadows J, et al. **Int J STD AIDS** 1995 Nov–Dec;6(6):426–30

Cyberdoc. Weaver KM. **Internist (Berl)** 1996 Feb;37(2):6–8

Chest computed tomography display preferences. Survey of thoracic radiologists. Stern EJ, et al. **Invest Radiol** 1995 Sep;30(9):517–21

Student abuse in medical school: a comparison of students' and faculty's perceptions. Lebenthal A, et al. **Isr J Med Sci** 1996 Mar–Apr;32(3–4):229–38

A survey of current Israeli practices and approach to partially treated meningitis in children [see comments] Meshulach–Netzer I, et al. **Isr J Med Sci** 1995 Oct; 31(10):611–5. Comment in: Isr J Med Sci 1995 Oct;31(10):638–9.

The reactions of patients and doctors in the united arab emirates towards smoking. Harrison A, et al. **J Addict Dis** 1996;15(1):75–92

Participation in continuing professional education in nursing: findings of an interview study. Barriball KL, et al. **J Adv Nurs** 1996 May;23(5):999–1007

Nursing students' experiences caring for cognitively impaired elderly people. Beck CT. **J Adv Nurs** 1996 May;23(5):992–8

A study of the attitudes of nurses to parental involvement in the initial child–protection conference, and their preparation for it. Bell M. **J Adv Nurs** 1995 Aug;22(2):250–7

Neglected conflicts in the discipline of nursing: perceptions of the importance and value of practical skill. Bjørk IT. **J Adv Nurs** 1995 Jul;22(1):6–12 (44 ref.)

Identifying the characteristics of optimum practice: findings from a survey of practice experts in nursing, midwifery and health visiting. Butterworth T, et al. **J Adv Nurs** 1995 Jul;22(1):24–32

Psychiatric nursing and Project 2000 [letter] Clarke L. **J Adv Nurs** 1996 Feb;23(2):420–1

Challenging old notions of professionalism: how can nurses work with paraprofessional ethnic health workers? Fuller J. **J Adv Nurs** 1995 Sep;22(3):465–72 (44 ref.)

Nursing leaders' and nurses' view of health. Herberts S, et al. **J Adv Nurs** 1995 Nov;22(5):868–78

A study of nurses' attitudes towards research: a factor analytic approach. Hicks C. **J Adv Nurs** 1996 Feb; 23(2):373–9

Situating theory in practice: student views of theory–practice in Project 2000 nursing programmes. Hislop S, et al. **J Adv Nurs** 1996 Jan;23(1):171–7

Nurses' perceptions of the impact of continuing professional education on the quality of nursing care. Hogston R. **J Adv Nurs** 1995 Sep;22(3):586–93

British National Health Service trust chief executives on nurse education: corporate instrumentalism and doubts on quasi–market structure. Humphreys J. **J Adv Nurs** 1996 Jan;23(1):160–70

Attributions for illness and treatment interventions by community nurses. Ogden J, et al. **J Adv Nurs** 1995 Aug; 22(2):290–3

Attitudes and stereotypes: nurses' work with older people. Pursey A, et al. **J Adv Nurs** 1995 Sep;22(3):547–55

Registered nurses' perceptions of gerontological continuing education needs in the United Kingdom and in the USA. Timms J, et al. **J Adv Nurs** 1995 Aug;22(2):300–7

Exploring the value of clinical nursing practice: the practitioner's perspective. Waterworth S. **J Adv Nurs** 1995 Jul;22(1):13–7

Physicians' attitudes toward complementary or alternative medicine: a regional survey. Berman BM, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):361–6

The financing and delivery of dental care: a nationwide survey of dentists. Bauman GH. **J Am Dent Assoc** 1996 Jul;127(7):1108–13

Dentists' personal values: an exploratory investigation. Becker BW, et al. **J Am Dent Assoc** 1996 Apr;127(4):503–9

A method to communicate patient preferences about medically indicated life–sustaining treatment in the out–of–hospital setting. Dunn PM, et al. **J Am Geriatr Soc** 1996 Jul;44(7):785–91

Attitudes of beginning medical students toward older persons: a five–campus study. The University of California Academic Geriatric Resource Program Student Survey Research Group. Reuben DB, et al. **J Am Geriatr Soc** 1995 Dec;43(12):1430–6

Chain pharmacists' attitudes on and awareness of domestic abuse. Ford J, et al. **J Am Pharm Assoc (Wash)** 1996 May; NS36(5):323–8

Rewards of entering podiatric medicine and attitudes toward older adults. Chumbler NR, et al. **J Am Podiatr Med Assoc** 1996 Jun;86(6):288–94

Physicians' attitudes regarding Down syndrome. Hermann R, et al. **J Child Neurol** 1996 Jan;11(1):66–70

The ghost walks again: unpacking the assumptions of circular questioning [comment] Bernal EW, et al. **J Clin Ethics** 1995 Summer;6(2):171–5. Comment on: J Clin Ethics 1995 Summer;6(2):163–5.

Of circles and lines, metaphors and narratives: toward a systems theory of ethics consultation [comment] Marta J. **J Clin Ethics** 1995 Summer;6(2):166–70. Comment on: J Clin Ethics 1994 Spring;5(1):19–22. Comment on: J Clin Ethics 1994 Spring;5(1):47–9. Comment on: J Clin Ethics 1994 Spring;5(1):49–54. Comment on: J Clin Ethics 1994 Summer;5(2):173–4. Comment on: J Clin Ethics 1994 Summer;5(2):174.

Circular questioning by ethics committees: who's asking the doctors? [comment] [see comments] Tiemstra JD. **J Clin Ethics** 1995 Summer;6(2):163–5. Comment on: J Clin Ethics 1994 Spring;5(1):19–22. Comment in: J Clin Ethics 1995 Summer;6(2):171–5.

Use of oral pathology services by general histopathologists and their attitudes to training of oral pathologists. Barret AW, et al. **J Clin Pathol** 1996 Jul;49(7):565–9

Clinical interventions by psychologists with lesbians and gay men. Jordan KM, et al. **J Clin Psychol** 1995 May; 51(3):448–56

Effects of preinterview suggestion on counselor memory, clinical impression, and confidence in judgments. Lee DY, et al. **J Clin Psychol** 1995 Sep;51(5):666–75

Therapists' attitudes about addressing the role of exercise in psychotherapy. McEntee DJ, et al. **J Clin Psychol** 1996 Jan;52(1):48–60

Researcher allegiance and meta–analysis: the case of cognitive therapy for depression. Gaffan EA, et al. **J Consult Clin Psychol** 1995 Dec;63(6):966–80

Dental hygienists' perceptions of preparation and importance of curriculum topics. Perry DA, et al. **J Dent Educ** 1995 Aug;59(8):830–5

Survey of ethical issues in dental research. Bebeau MJ, et al. **J Dent Res** 1996 Feb;75(2):845–55

What ethical issues are Japanese epidemiologists facing? Results of a questionnaire study for members of the Monbusho Research Committee on evaluation of risk factors for cancer by large–scale cohort study. Subcommittee of Ethical Issues. **J Epidemiol** 1996 Aug;6(3 Suppl):S141–6

Studying episiotomy: when beliefs conflict with science. Klein MC. **J Fam Pract** 1995 Nov;41(5):483–8

Attitudes of Florida Academic Physicians toward the Florida Medical Association. Herold AE. **J Fla Med Assoc** 1996 May;83(5):321–6

Who are we? We are against violence [editorial] Shea JD. **J Fla Med Assoc** 1995 Oct;82(10):661–2

The night float system of resident on call: what do the nurses think? Buff DD, et al. **J Gen Intern Med** 1995 Jul; 10(7):400–2

Measuring attending physician performance in a general medicine outpatient clinic. Hayward RA, et al. **J Gen Intern Med** 1995 Sep;10(9):504–10

Physicians' psychosocial beliefs correlate with their patient communication skills [see comments] Levinson W, et al. **J Gen Intern Med** 1995 Jul;10(7):375–9. Comment in: J Gen Intern Med 1995 Jul;10(7):411.

Physician visit frequency in Alzheimer's disease [letter; comment] Murden RA. **J Gen Intern Med** 1995 Sep; 10(9):533. Comment on: J Gen Intern Med 1995 Apr;10(4):187–93.

Improving patient quality of life with feedback to physicians about functional status. Rubenstein LV, et al. **J Gen Intern Med** 1995 Nov;10(11):607–14

Policies, practices, and attitudes of North American medical journal editors [see comments] Wilkes MS, et al. **J Gen Intern Med** 1995 Aug;10(8):443–50. Comment in: J Gen Intern Med 1995 Aug;10(8):474–5.

Learners as teachers: the conflicting roles of medical residents. Yedidia MJ, et al. **J Gen Intern Med** 1995 Nov; 10(11):615–23

Presidential address: sleeping with the enemy. Taleisnik J. **J Hand Surg [Am]** 1995 Jul;20(4):527–33

Physicians' discourses on malpractice and the meaning of medical malpractice. Marjoribanks T, et al. **J Health Soc Behav** 1996 Jun;37(2):163–78

Changes in physicians' attitudes toward AIDS during residency training: a longitudinal study of medical school graduates. Yedidia MJ, et al. **J Health Soc Behav** 1996 Jun; 37(2):179–91

A survey of glove preferences of general and orthopaedic surgeons in North West Thames Regional Health Authority. Keeling NJ, et al. **J Hosp Infect** 1995 Aug; 30(4):305–8

Influence of mental retardation severity and respondent characteristics on self–reported attitudes toward mental retardation and eugenics. Antonak RF, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):316–25

Measurement of attitudes of trainee professionals to people with disabilities. Beckwith JB, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):255–62

Beliefs and emotional reactions of care staff working with people with challenging behaviour. Bromley J, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):341–52

Experienced and inexperienced health care workers' beliefs about challenging behaviours. Hastings RP, et al. **J Intellect Disabil Res** 1995 Dec;39 (Pt 6):474–83

Offending by adults with learning disabilities and the attitudes of staff to offending behaviour: implications for service development. Lyall I, et al. **J Intellect Disabil Res** 1995 Dec;39 (Pt 6):501–8

Attitudes on immunization: a survey of American chiropractors [letter; comment] Cashley MA. **J Manipulative Physiol Ther** 1995 Jul–Aug;18(6):420–1. Comment on: J Manipulative Physiol Ther 1994 Nov–Dec;17(9):584–90.

Chiropractic referral: the views of a group of conventional medical practitioners with an interest in unconventional therapies. Jamison JR. **J Manipulative Physiol Ther** 1995 Oct;18(8):512–8

Why bioethicists have nothing useful to say about health care rationing. Seedhouse D. **J Med Ethics** 1995 Oct; 21(5):288–91

What do they really think about us? [editorial] Lockey M. **J Miss State Med Assoc** 1996 Jul;37(7):663

Healthy People 2000 Goal 1.12: primary care physicians and exercise counseling. Royals G, et al. **J Miss State Med Assoc** 1996 Jun;37(6):605–8

Attitudes of Colorado health professionals toward breast and cervical cancer screening in Hispanic women. Bakemeier RF, et al. **J Natl Cancer Inst Monogr** 1995;(18):95–100

Bilateral prophylactic mastectomy: issues and concerns. Stefanek ME. **J Natl Cancer Inst Monogr** 1995;(17):37–42 (31 ref.)

The perceptions of African–American physicians concerning their treatment by managed care organizations [editorial] Lavizzo–Mourey R, et al. **J Natl Med Assoc** 1996 Apr; 88(4):210–4

Ethnically sensitive messengers: an exploration of racial attitudes of health–care workers and organ procurement officers. Mitchell AA, et al. **J Natl Med Assoc** 1996 Jun; 88(6):349–52

Attitudes of referring physicians regarding total joint replacement: a preliminary report. Rankin EA, et al. **J Natl Med Assoc** 1996 Aug;88(8):506–8

The effect of a professional practice model on staff nurse perception of work groups and nurse leaders. Ingersoll GL, et al. **J Nurs Adm** 1996 May;26(5):52–60

Keeping the care in nursing care: our biggest challenge. Miller KL. **J Nurs Adm** 1995 Nov;25(11):29–32

What do nurses want in a mentor? Thorne T. **J Nurs Adm** 1996 Apr;26(4):6–7

The search for the sacred. How to find new meanings in your career [editorial] Veninga RL. **J Nurs Adm** 1996 Jan; 26(1):3–6

Valuing authority/responsibility relationships. The essence of professional practice. Webb SS, et al. **J Nurs Adm** 1996 Feb;26(2):28–33

How wide is the gap in defining quality care? Comparison of patient and nurse perceptions of important aspects of patient care. Young WB, et al. **J Nurs Adm** 1996 May; 26(5):15–20

Inquiry based learning, nursing student attitudes and the HIV patient. Cerny JE, et al. **J Nurs Educ** 1996 May; 35(5):219–22 (24 ref.)

The experience of being a male student nurse. Kelly NR, et al. **J Nurs Educ** 1996 Apr;35(4):170–4

Stigma: baccalaureate nursing students' attitudes toward persons living with AIDS. Leasure R, et al. **J Nurs Educ** 1996 May;35(5):234–6

Connecting the research and nursing processes: making a difference in baccalaureate students' attitudes and abilities. Morse W, et al. **J Nurs Educ** 1996 Apr;35(4):148–51

Attitudes of nursing students toward research: a participatory exercise. Pond EF, et al. **J Nurs Educ** 1996 Apr;35(4):182–5

Attitudes and perceptions of nursing students toward chemically impaired nurses: implications for nursing education. Wennerstrom PA, et al. **J Nurs Educ** 1996 May; 35(5):237–9

Primary care for women. Cultural competence in primary care services. Rorie JA, et al. **J Nurse Midwifery** 1996 Mar–Apr;41(2):92–100

The experience of psychiatric residents with disaster support: a descriptive report. Sansone RA, et al. **J Okla State Med Assoc** 1996 Jul;89(7):238–41

Women in oral and maxillofacial surgery: factors affecting career choices, attitudes, and practice characteristics. Risser MJ, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):753–7

Survey on developmental–behavioural training experiences

of Australian paediatric advanced trainees [letter; comment] Roy LP. **J Paediatr Child Health** 1995 Aug; 31(4):362–4. Comment on: J Paediatr Child Health 1994 Dec;30(6):478–82.

What do nurses know and believe about patients with pain? Results of a hospital survey. Brunier G, et al. **J Pain Symptom Manage** 1995 Aug;10(6):436–45

A survey of physician knowledge of drug costs. Hoffman J, et al. **J Pain Symptom Manage** 1995 Aug;10(6):432–5

A questionnaire to medical students on palliative care and euthanasia. Dionne L, et al. **J Palliat Care** 1996 Summer; 12(2):39–43

What do palliative staff think about audit? Higginson I, et al. **J Palliat Care** 1995 Autumn;11(3):17–9

Directions for palliative care nursing in Canada: report of a national survey. Kristjanson LJ, et al. **J Palliat Care** 1995 Autumn;11(3):5–8

Use of minors as bone marrow donors: current attitude and management. A survey of 56 pediatric transplantation centers. Chan KW, et al. **J Pediatr** 1996 May;128(5 Pt 1):644–8

When cancer strikes home. Neville K. **J Pediatr Oncol Nurs** 1996 Jul;13(3):153–4

Nurses' attitudes toward caring for patients with acquired immunodeficiency syndrome. Baylor RA, et al. **J Prof Nurs** 1996 Mar–Apr;12(2):99–105

Nurses' attitudes about acquired immunodeficiency syndrome care: what research tells us. Bennett JA. **J Prof Nurs** 1995 Nov–Dec;11(6):339–50 (67 ref.)

The beliefs of members of the American Psychiatric Association on the etiology of male homosexuality: a national survey. Vreeland CN, et al. **J Psychol** 1995 Sep; 129(5):507–17

Health visitors' knowledge, attitudes and practices in childhood accident prevention. Marsh P, et al. **J Public Health Med** 1995 Jun;17(2):193–9

Medical investigators' views about ethics and fraud in medical research. Jacobsen G, et al. **J R Coll Physicians Lond** 1995 Sep–Oct;29(5):405–9

Content of a discharge summary from a medical ward: views of general practitioners and hospital doctors. Solomon JK, et al. **J R Coll Physicians Lond** 1995 Jul–Aug;29(4):307–10

Eusol: the plastic surgeon's choice? Humzah MD, et al. **J R Coll Surg Edinb** 1996 Aug;41(4):269–70

Doctors at risk of hepatitis B and HIV infection from patients in Nigeria. Olubuyide IO. **J R Soc Health** 1996 Jun; 116(3):157–60

Can a lecture influence attitudes to suicide prevention? Morgan HG, et al. **J R Soc Med** 1996 Feb;89(2):87–90

Parental presence during procedures: a survey of attitudes amongst paediatricians. Pejaver RK, et al. **J R Soc Med** 1995 Sep;88(9):508–10

Characteristics of referrals to an inpatient hospice and a survey of general practitioner perceptions of palliative care. Seamark DA, et al. **J R Soc Med** 1996 Feb;89(2):79–84

'Get some research under your belt!'—good advice? A personal view [editorial] [see comments] Treasure T. **J R Soc Med** 1995 Aug;88(8):425–6. Comment in: J R Soc Med 1996 Feb;89(2):119–20. Comment in: J R Soc Med 1996 Mar;89(3):178–9.

Recovering substance abuse staff members' beliefs about addiction. Humphreys K, et al. **J Subst Abuse Treat** 1996 Jan–Feb;13(1):75–8

Attitudes toward nicotine dependence among chemical dependence unit staff—before and after a smoking cessation trial. Hurt RD, et al. **J Subst Abuse Treat** 1995 Jul–Aug; 12(4):247–52

Trauma surgeons on violence prevention: ready, willing, and able? [editorial; comment] Schwab CW, et al. **J Trauma** 1996 Apr;40(4):671–2. Comment on: J Trauma 1996 Apr;40(4):602–6.

Health care professional attitudes toward donation: effect on practice and procurement. Siminoff LA, et al. **J Trauma** 1995 Sep;39(3):553–9

Violence prevention involvement among trauma surgeons: description and preliminary evaluation [see comments] Tellez ML, et al. **J Trauma** 1996 Apr;40(4):602–6. Comment in: J Trauma 1996 Apr;40(4):671–2.

Academia's chilly climate for primary care. Block SD, et al. **JAMA** 1996 Sep 4;276(9):677–82

Obstetricians' views on caesarean section versus vaginal birth [letter; comment] Bewley S. **Lancet** 1996 Apr 27; 347(9009):1189. Comment on: Lancet 1996 Feb 24;347(9000):544.

The effect of weapons on health [see comments] Coupland RM. **Lancet** 1996 Feb 17;347(8999):450–1. Comment in: Lancet 1996 Mar 30;347(9005):906.

Tonsillectomy: a family-transmissible surgical procedure [letter] Domenighetti G, et al. **Lancet** 1995 Nov 18; 346(8986):1376

Euthanasia and physician-assisted suicide: attitudes and experiences of oncology patients, oncologists, and the public. Emanuel EJ, et al. **Lancet** 1996 Jun 29; 347(9018):1805–10

Attitudes of Japanese physicians towards life-sustaining treatment [letter; comment] Fair D. **Lancet** 1995 Oct 7; 346(8980):971. Comment on: Lancet 1995 Aug 5;346(8971):356–9.

I believe therefore I practise. Graham I. **Lancet** 1996 Jan 6;347(8993):4–5

Survey of British clinicians' views on management of patients in persistent vegetative state. Grubb A, et al. **Lancet** 1996 Jul 6;348(9019):35–40

Betrayal by the surgeons [letter; comment] Kaufman L. **Lancet** 1996 May 18;347(9012):1405. Comment on: Lancet 1996 Mar 23;347(9004):812–3.

Midwifery in obstetrics [letter; comment] Mullens JE. **Lancet** 1995 Dec 2;346(8988):1493. Comment on: Lancet 1995 Oct 14;346(8981):1020–2.

Euthanasia, physician-assisted suicide, and persistent vegetative state [letter] Papapetropoulos T, et al. **Lancet** 1996 Aug 24;348(9026):548

Attitudes about clinical research [letter] Reidenberg MM. **Lancet** 1996 Apr 27;347(9009):1188

Midwifery in obstetrics [letter; comment] Sloan DS. **Lancet** 1995 Dec 2;346(8988):1493. Comment on: Lancet 1995 Oct 14;346(8981):1020–2.

Attitudes of Japanese physicians towards life-sustaining treatment [letter; comment] Tanida N. **Lancet** 1995 Oct 7;346(8980):970–1. Comment on: Lancet 1995 Aug 5;346(8971):327–8. Comment on: Lancet 1995 Aug 5;346(8971):356–9.

Euthanasia, physician assisted suicide, and persistent vegetative state [letter] Treloar A. **Lancet** 1996 Aug 24; 348(9026):549

The Mini-Mental State Examination in general medical practice: clinical utility and acceptance. Tangalos EG, et al. **Mayo Clin Proc** 1996 Sep;71(9):829–37

Why do physicians prefer to withdraw some forms of life support over others? Intrinsic attributes of life-sustaining treatments are associated with physicians' preferences. Asch DA, et al. **Med Care** 1996 Feb;34(2):103–11

Attitudes of medical students and primary care physicians regarding input of older and younger patients in medical decisions. Beisecker AE, et al. **Med Care** 1996 Feb; 34(2):126–37

Predictors of hepatitis B vaccine acceptance in health care workers. Doebbeling BN, et al. **Med Care** 1996 Jan; 34(1):58–72

Are differences in practitioners' acceptance of a quality assurance intervention related to their performance? Hargraves JL, et al. **Med Care** 1996 Sep;34(9 Suppl):SS77–86

Physician satisfaction with human immunodeficiency virus type I and hepatitis B virus testing in San Diego County. Rau J, et al. **Med Care** 1996 Jan;34(1):1–10

A comparison of US and Canadian family physician attitudes toward their respective health-care systems. Scanlan A, et al. **Med Care** 1996 Aug;34(8):837–44

Disease prevention and health promotion: a study of medical students and teachers. Meakin RP, et al. **Med Educ** 1996 Mar;30(2):97–104

General practitioner attitudes to recall systems for cervical screening [see comments] Beilby JJ, et al. **Med J Aust** 1995 Sep 4;163(5):245–8. Comment in: Med J Aust 1996 Jan 1;164(1):55.

"The Elsewhere bias". Dickinson JA. **Med J Aust** 1996 Apr 1;164(7):438–40

Doctors and handwashing: instilling Semmelweis' message [editorial; comment] Pritchard RC, et al. **Med J Aust** 1996 Apr 1;164(7):389–90. Comment on: Med J Aust 1996 Apr 1;164(7):395–8.

Managing HIV. Part 7: Professional issues. 7.3 What do people with HIV, their carers and families want of their medical carers? Scott M, et al. **Med J Aust** 1996 Jul 15; 165(2):92–3

Barriers to effective primary health care for adolescents. Veit FC, et al. **Med J Aust** 1996 Aug 5;165(3):131–3

Teaching hospital medical staff to handwash [letter] Whitby MR, et al. **Med J Aust** 1996 Aug 5;165(3):172–3

Exploration of a self-protective strategy in pediatric oncology staff. Grootenhuis MA, et al. **Med Pediatr Oncol** 1996 Jul;27(1):40–7

Serious business [see comments] Allen T. **Minn Med** 1995 Oct;78(10):6–7, 56. Comment in: Minn Med 1995 Oct;78(10):5.

Going the distance. Clement D. **Minn Med** 1996 Jul;79(7):6–8

Psychiatry and managed care: under analysis. Miller JP. **Minn Med** 1996 Jan;79(1):10–13, 58–9

MMA speaks out on national and state issues. Murray MJ. **Minn Med** 1996 Jan;79(1):34

Physicians stand firm against assisted suicide. Murray MJ. **Minn Med** 1996 Jul;79(7):34

Cultural barriers to health care for refugees and immigrants. Providers' perceptions. Ohmans P, et al. **Minn Med** 1996 May;79(5):26–30

Some good sources on cross-cultural medicine [letter] Richards HN. **Minn Med** 1996 Jul;79(7):2

Snapshot of an illness. Reinhart CL. **N C Med J** 1995 Oct; 56(10):520–2

Attitudes of Michigan physicians and the public toward legalizing physician-assisted suicide and voluntary euthanasia [see comments] Bachman JG, et al. **N Engl J Med** 1996 Feb 1;334(5):303–9. Comment in: N Engl J Med 1996 Aug 15;335(7):518; discussion 519–20. Comment in: N Engl J Med 1996 Aug 15;335(7):518–9; discussion 519–20.

Physician-assisted suicide [letter; comment] Kavanaugh A. **N Engl J Med** 1996 Aug 15;335(7):518; discussion 519–20 . Comment on: N Engl J Med 1996 Feb 1;334(5):303–9. Comment on: N Engl J Med 1996 Feb 1;334(5):310–5.

Assessment of patients' pain [letter] Krivo S, et al. **N Engl J Med** 1996 Jan 4;334(1):59

Legalizing assisted suicide—views of physicians in Oregon [see comments] Lee MA, et al. **N Engl J Med** 1996 Feb 1;334(5):310–5. Comment in: N Engl J Med 1996 Aug 15;335(7):518; discussion 519–20. Comment in: N Engl J Med 1996 Aug 15;335(7):518–9; discussion 519–20. Comment in: N Engl J Med 1996 Aug 15;335(7):519; discussion 519–20.

The physician's role in health promotion revisited—a survey of primary care practitioners [see comments] Wechsler H, et al. **N Engl J Med** 1996 Apr 11;334(15):996–8. Comment in: N Engl J Med 1996 Aug 22;335(8):599; discussion 600. Comment in: N Engl J Med 1996 Aug 22;335(8):599–600; discussion 600.

Physician-assisted suicide [letter; comment] Wilson KG, et al. **N Engl J Med** 1996 Aug 15;335(7):518–9; discussion 519–20. Comment on: N Engl J Med 1994 Jul 14;331(2):89–94. Comment on: N Engl J Med 1996 Feb 1;334(5):303–9. Comment on: N Engl J Med 1996 Feb 1;334(5):310–5.

Attitudes of physicians regarding physician-assisted suicide. Reisner M, et al. **N J Med** 1995 Oct;92(10):663–6

Dentistry, self-esteem and criticism. Davidove DM. **N Y State Dent J** 1996 Apr;62(4):43–5

Judgment lacking in evidence [letter] Dodes JE. **N Y State Dent J** 1996 Jun–Jul;62(6):14–5

Medical discipline and sexual activity between doctors and patients [see comments] Cullen RM, et al. **N Z Med J** 1995 Nov 24;108(1012):481–3. Comment in: N Z Med J 1996 Jan 26;109(1014):17. Comment in: N Z Med J 1996 Apr 12;109(1019):127–8.

Alcohol and pregnancy: doctors' attitudes, knowledge and clinical practice. Leversha AM, et al. **N Z Med J** 1995 Oct 27;108(1010):428–30

One doctor against managed care. Duvall CP. **Nat Med** 1996 Jul;2(7):735–6

AIDS—reply to J. Nandi [letter; comment] Priya R. **Natl Med J India** 1995 Nov–Dec;8(6):296. Comment on: Natl Med J India 1995 Mar–Apr;8(2):95.

Aversion to xenotransplantation [letter; comment] [see comments] Mohacsi PJ, et al. **Nature** 1995 Nov 30; 378(6556):434. Comment on: Nature 1995 Jul 6;376(6535):8. Comment in: Nature 1996 Feb 15;379(6566):578.

Survey of patient selection for cadaveric renal transplantation in the United Kingdom. McMillan MA, et al. **Nephrol Dial Transplant** 1995;10(6):855–8

US neurologists: attitudes on the US health care system. Ringel SP, et al. **Neurology** 1996 Jul;47(1):279–87

Nurses' attitudes toward active euthanasia. Davis AJ, et al. **Nurs Outlook** 1995 Jul–Aug;43(4):174–9

Nursing in Lithuania as perceived by Lithuanian nurses. Karosas LM. **Nurs Outlook** 1995 Jul–Aug;43(4):153–7

Opinions of obesity experts on the causes and treatment of obesity—a new survey. Bray GA, et al. **Obes Res** 1995 Nov;3 Suppl 4:419S–423S

Changes in dentists' infection control practices, knowledge, and attitudes about HIV over a 2-year period. McCarthy GM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Mar;81(3):297–302

A pediatrician's view: anyone for a game of bridge? [letter] Austin G. **Pediatr Ann** 1995 Oct;24(10):503, 518, 530

Survey of pediatric dentists concerning dental sealants. Halterman CW, et al. **Pediatr Dent** 1995 Nov–Dec; 17(7):455–6

Pediatric dentists' attitudes regarding parental presence during dental procedures. Marcum BK, et al. **Pediatr Dent** 1995 Nov–Dec;17(7):432–6

Beliefs and practices regarding childhood vaccination among urban pediatric providers in New Jersey. Askew GL, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):889–92

Self-efficacy in pediatric resuscitation: implications for education and performance. Maibach EW, et al. **Pediatrics** 1996 Jan;97(1):94–9 (33 ref.)

On priorities [editorial; comment] Barondess JA. **Pharos** 1996 Spring;59(2):41. Comment on: Pharos 1996 Spring;59(2):20–1. Comment on: Pharos 1996 Spring;59(2):30–3. Comment on: Pharos 1996 Spring;59(2):37–40.

The metaphysics of holism: laughter in carnival with alternative medicine. Elgee NJ. **Pharos** 1995 Fall; 58(4):18–20

Early family experiences and helping behaviors of physical therapists. Curtis KA, et al. **Phys Ther** 1995 Dec; 75(12):1089–100

Physical therapist assistants' perceptions of the documented roles of the physical therapist assistant. Robinson AJ, et al. **Phys Ther** 1995 Dec;75(12):1054–64; discussion 1064–6

Notes on the history of the adoption of liposuction [letter; comment] Burnham BE. **Plast Reconstr Surg** 1996 Jan; 97(1):258–9. Comment on: Plast Reconstr Surg 1995 May;95(6):1135.

Glad to be alive. Pollack B. **Postgrad Med** 1995 Nov;98(5):36, 38

Successful implementation of an integrated physician order entry application: a systems perspective. Weir C, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:790–4

Psychiatry clerkship directors: who they are, what they do, and what they think. Sierles FS, et al. **Psychiatr Q** 1996 Summer;67(2):153–62

Washington psychiatrists protest calls to close historic D.C. hospital, citing lack of other settings [news] **Psychiatr Serv** 1996 Apr;47(4):442

Factors contributing to nurses' difficulty in treating patients

in short-stay psychiatric settings. Lancee WJ, et al. **Psychiatr Serv** 1995 Jul;46(7):724–6

A survey of psychiatrists with APA certification in administrative psychiatry. Rodenhauser P, et al. **Psychiatr Serv** 1995 Dec;46(12):1278–83

A survey of Japanese physicians' attitudes and practice in caring for terminally ill cancer patients. Uchitomi Y, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):53–7

Age and health bias in practicing clinical psychologists. James JW, et al. **Psychol Aging** 1995 Dec;10(4):610–6

Differences in attitudes among medical students towards psychiatry in one English university. Chung MC, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):843–7

Attitudes of Hong Kong medical students toward different modalities of treatment for cancer. Ho SM, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1291–6

Measuring social desirability among senior medical students. Merrill JM, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):859–64

Perceived consequences to the predictor: a variable in the release of psychiatric patients. Stevens HB, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1371–8

A corporate needs assessment for the purchase of district nursing: a qualitative approach. Conway M, et al. **Public Health** 1995 Sep;109(5):337–45

Perceived usefulness of the Director of Public Health Annual Report: a consumer survey. Gordon DS, et al. **Public Health** 1996 Jan;110(1):25–9

Factors associated with influenza vaccination coverage among the elderly: role of health care personnel. Honkanen PO, et al. **Public Health** 1996 May;110(3):163–8

Capital punishment and the physician: the views of six Rhode Island physicians [see comments] Crowley JP, et al. **R I Med** 1995 Aug;78(8):215–21. Comment in: R I Med 1995 Oct;78(10):277.

HIV risk: no impact on medical student specialty choice. Gady J, et al. **R I Med** 1995 Oct;78(10):293–4

Physician-assisted suicide, a symposium. Death made too easy or an act of profound compassion? Martin E, et al. **R I Med** 1995 Aug;78(8):222–30

Opinions of Medical Officers of Health on the establishment of health districts [letter] Blecher MS, et al. **S Afr Med J** 1995 Nov;85(11):1197–8

Acceptability to general practitioners of national health insurance and capitation as a reimbursement mechanism. Blecher MS, et al. **S Afr Med J** 1995 Sep;85(9):847–51

Attitudes towards parental presence at induction of anaesthesia. Bösenberg AT, et al. **S Afr Med J** 1996 Jun; 86(6):664–7

South African geneticists' attitudes to the present Abortion and Sterilisation Act of 1975. Christianson MA, et al. **S Afr Med J** 1996 May;86(5):534–6

Alternative medicine—a doctor's perspective [letter] Levin S. **S Afr Med J** 1996 Feb;86(2):183–4

Alternative medicine—a doctor's perspective [letter] Pantanowitz D. **S Afr Med J** 1996 Feb;86(2):184

Is registrarship a different experience for women? Saloojee H, et al. **S Afr Med J** 1996 Mar;86(3):253–7

Do general practitioners need guidelines? [editorial] Mäkelä M. **Scand J Prim Health Care** 1996 Mar;14(1):2–3

People: the keys to profitability. Russell RL. **Semin Vet Med Surg (Small Anim)** 1996 Feb;11(1):23–9

Rationing health care: views from general practice. Ayres PJ. **Soc Sci Med** 1996 Apr;42(7):1021–5

Attitudes of pediatric nurses facing HIV risk. Berkowitz NF, et al. **Soc Sci Med** 1996 Feb;42(3):463–9

Decisional conflict in general practice: strategies of patient management. Di Caccavo A, et al. **Soc Sci Med** 1995 Aug; 41(3):347–53

Physician participation in Medicaid managed care. Silverstein G, et al. **Soc Sci Med** 1995 Aug;41(3):355–63

Pipedreams [letter] Uzych L. **Soc Sci Med** 1996 Apr; 42(7):1113–5

Quality of care: a comparison of preferences between medical specialists and patients with chronic diseases. van der Waal MA, et al. **Soc Sci Med** 1996 Mar;42(5):643–9

How do health service managers respond to qualitative research? Van der Walt H, et al. **Soc Sci Med** 1995 Dec; 41(12):1725–9

General practitioners' assessment of and interest in alternative medicine in Canada. Verhoef MJ, et al. **Soc Sci Med** 1995 Aug;41(4):511–5

Malpractice litigation fear and risk management beliefs among teaching hospital physicians. Schumacher JE, et al. **South Med J** 1995 Dec;88(12):1204–11

Skepticism toward carotid ultrasonography. A virtue, an attitude, or fanaticism? [editorial; comment] Ringelstein EB. **Stroke** 1995 Oct;26(10):1743–6. Comment on: Stroke 1995 Oct;26(10):1747–52.

Physicians' attitudes and retention of patients in their methadone maintenance programs. Caplehorn JR, et al. **Subst Use Misuse** 1996 May;31(6):663–77

Empirically based criteria for rational suicide: a survey of psychotherapists. Werth JL Jr, et al. **Suicide Life Threat Behav** 1995 Summer;25(2):231–40

A matter of concern. BeSaw L. **Tex Med** 1996 Jul;92(7):22–7

Who will manage change? Ortolon K. **Tex Med** 1996 Aug; 92(8):22–4; 27

Tuberculosis in the community: 2. The perceptions of members of a tuberculosis health team towards a voluntary health worker programme. Dick J, et al. **Tuber Lung Dis** 1996 Aug;77(4):380–3

Staff and patient attitudes to tuberculosis and compliance with treatment: an exploratory study in a district in Vietnam. Johansson E, et al. **Tuber Lung Dis** 1996 Apr; 77(2):178–83

Doctors join protest [editorial] Ward SD. **W V Med J** 1996 Jan–Feb;92(1):33

The physician-assisted suicide debate [letter; comment] Gibes JP. **Wis Med J** 1996 Jan;95(1):10. Comment on: Wis Med J 1995;94(9):509–14.

[The attitude of students regarding human dignity] Munzarová M. **Cas Lek Cesk** 1995 Aug 2;134(15):488–90 (Eng. Abstr.) (Cze)

[How physicians evaluate the activity of Czech health insurance companies (editorial)] Hájek M. **Rozhl Chir** 1996 Jan;75(1):3–4 (Cze)

[2 years further on: a poignant WAO (Law for Work Disability Insurance) (letter; comment)] de Jong GD. **Ned Tijdschr Geneeskd** 1996 Feb 17;140(7):387–8. Comment on: Ned Tijdschr Geneeskd 1995 Dec 9;139(49):2576–9. (Dut)

[Active euthanasia in newborn infants with spina bifida? (letter)] Molenaar JC. **Ned Tijdschr Geneeskd** 1996 Apr 6;140(14):801–2 (Dut)

[Study on the prevention of HIV transmission between patients in the psychiatric hospital milieu] Charmasson C, et al. **Ann Med Psychol (Paris)** 1995 Oct;153(8):512–6; discussion 516–7 (Eng. Abstr.) (Fre)

[Attitude of the pediatrician facing a therapeutic accident] Olive G, et al. **Arch Pediatr** 1996;3 Suppl 1:242s–244s (Fre)

[Pregnancy after breast cancer] Mignot L, et al. **Contracept Fertil Sex** 1996 Apr;24(4):319–21 (16 ref.) (Eng. Abstr.) (Fre)

[Opinion and attitude of physicians regarding organization and participation on a multidisciplinary alcoholism unit] Boitel S, et al. **Schweiz Arch Neurol Psychiatr** 1996; 147(1):19–24 (Eng. Abstr.) (Fre)

[The Ulm Emergency Training Course. 2: Realization and acceptance of the emergency medicine practicum] Dirks B, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):222–7 (Eng. Abstr.) (Ger)

[Abortion as experienced by the physician in charge—attitudes in the conflict area of abortion] Poettgen H. **Arch Gynecol Obstet** 1995;257(1–4):499–510 (Ger)

[Rheumatism: a too long pathway to adequate therapy. Experiences of a physician as rheumatism patient] Genth-Stolzenburg S. **Fortschr Med** 1996 Jan 20; 114(1–2):19 (Ger)

[Benefits and risks of intramuscular injection. Are expectations of physicians and patients irrational?] Sohn W. **Fortschr Med** 1996 Jun 20;114(17):217–20 (28 ref.) (Eng. Abstr.) (Ger)

[Endometriosis—diagnosis and therapy. Results of a current survey of 6,700 gynecologists] Christensen B, et al. **Geburtshilfe Frauenheilkd** 1995 Dec;55(12):674–9 (Eng. Abstr.) (Ger)

[Academic recommendations on the need for treating carious deciduous molars and canine teeth in elementary school children—results of a survey of university dental clinics] Steinmeyer R. **Gesundheitswesen** 1995 Dec;57(12):778–81 (Eng. Abstr.) (Ger)

[Attitude of established physicians to treating HIV-infected patients and to "acquired immunodeficiency syndrome". An empirical study] Loew TH, et al. **Med Klin** 1996 May 15; 91(5):272–6 (Eng. Abstr.) (Ger)

[Assessment of curriculum by medical students: comparison of participants and non-participants in voluntary anamnesis groups. An empirical study] Loew TH, et al. **Nervenarzt** 1995 Nov;66(11):845–50 (Eng. Abstr.) (Ger)

[Psychiatrist—psychiatric critic—"Pazjent". The anti-psychiatry concept of Oskar Panizza (1853–1921)] Müller J. **Nervenarzt** 1995 Nov;66(11):851–7 (Eng. Abstr.) (Ger)

[Follow-up and typologic description of requirements in an intensive care unit] Laubach W, et al. **Psychother Psychosom Med Psychol** 1995 Nov;45(11):381–8 (Eng. Abstr.) (Ger)

[Quality of the therapeutic relationship: do common factors in psychotherapy correspond with common characteristics of psychotherapists? SPR Collaborative Research Network] Orlinsky DE, et al. **Psychother Psychosom Med Psychol** 1996 Mar–Apr; 46(3–4):102–10 (Eng. Abstr.) (Ger)

[Attitude of physicians to rehabilitation—an empirical study of rheumatologists] Riehemann W, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):154–60 (Eng. Abstr.) (Ger)

[Mental image of the human being and of the physician in future-oriented medicine] Nager F. **Schweiz Rundsch Med Prax** 1996 Jul 2;85(27–28):883–9 (Eng. Abstr.) (Ger)

[Medical malpractice from the physician's viewpoint] Carstensen G. **Z Arztl Fortbild (Jena)** 1995 Nov;89(6):570–5 (Eng. Abstr.) (Ger)

[Legal liability in failed sterilization from the physician's viewpoint] Hammerstein J. **Z Arztl Fortbild (Jena)** 1995 Nov;89(6):678–81; discussion 681–3 (Eng. Abstr.) (Ger)

[Liability in consultation of physicians from different specialties from the physician's viewpoint] Hempel K. **Z Arztl Fortbild (Jena)** 1995 Nov;89(6):632–4; discussion 635–7 (Eng. Abstr.) (Ger)

[Legal liability in clinical trials from the viewpoint of the clinician] Luft FC. **Z Arztl Fortbild (Jena)** 1995 Nov; 89(6):646–8; discussion 649–52 (Eng. Abstr.) (Ger)

[Liability in the hospital from the physician's viewpoint] Specht G. **Z Arztl Fortbild (Jena)** 1995 Nov;89(6):620–2; discussion 623–5 (Eng. Abstr.) (Ger)

[Breech presentation—information, anxiety and pattern of expectations of established obstetricians and pregnant patients. 2: Results of a survey of women with breech presentation] Fischer T, et al. **Z Geburtshilfe Neonatol** 1996 Mar–Apr;200(2):61–5 (Eng. Abstr.) (Ger)

[A change in attitude to the problem of obesity is necessary] Feifel G. **Zentralbl Chir** 1996;121(6):493–5 (Ger)

[Can we determine attitudes towards "right to die" among Israeli doctors?] Ishay R. **Harefuah** 1996 Feb 15; 130(4):288–91 (Heb)

[Children feel pain too! (editorial)] Halvorsen S. **Nord Med** 1995;110(11):270 (Nor)

[Physicians and the mass media. Opinion of physicians on the coverage of medicine, health policy and the medical profession by the mass media] Hofoss D, et al. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):270–4 (Eng. Abstr.) (Nor)

[Attitude of Norwegian physicians to homeopathy] Nessa J. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2149–50 (Nor)

[Attitudes of Norwegian physicians to homeopathy. A questionnaire among 2 019 physicians on their cooperation with homeopathy specialists] Pedersen EJ, et al. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2186–9 (Eng. Abstr.) (Nor)

[Physicians' view on drug therapy for hypertension. A questionnaire in the county of Hordaland] Smiseth OA, et al. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1588–90 (Eng. Abstr.) (Nor)

[Changes in relevant attitudes of nurses after one year of working with Balint groups] Kraljević R, et al. **Lijec Vjesn** 1995 Jul–Aug;117(7–8):164–6 (Eng. Abstr.) (Scr)

[Computerization: equipment, attitudes and aptitudes at health centers of the Autonomous Basque Community] Alonso López FA, et al. **Aten Primaria** 1995 Sep 30; 16(5):285–7 (Eng. Abstr.) (Spa)

[The development of a test for evaluating the knowledge of and attitudes on human immunodeficiency virus infection in primary health care professionals] Llobera Serentill A, et al. **Aten Primaria** 1996 May 31;17(9):564–9 (Eng. Abstr.) (Spa)

[The opinions of family medicine residents in Andalucía on some aspects related to their specialty (letter)] Ruiz Moral R, et al. **Aten Primaria** 1996 May 31;17(9):595–6 (Spa)

[Discordance between knowledge and attitudes among health professionals concerning organ donation] Malavé M, et al. **Bol Asoc Med P R** 1995 May–Jun;87(5–6):87–9 (Spa)

[Evolution in consumption of and attitude towards tobacco towards physicians at the regional hospital "Reina Sofía," Córdoba] Mengual Luque P, et al. **Gac Sanit** 1996 Jan–Feb; 10(52):18–24 (32 ref.) (Eng. Abstr.) (Spa)

[Anesthesia preferences among the medical population (letter)] Isla-Baranda A, et al. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):117 (Spa)

[Disagreement among physicians about active euthanasia. 245 answers from a Swedish questionnaire reflect uncertainty] Nilstun T, et al. **Lakartidningen** 1996 Apr 3;93(14):1350–1 (Swe)

[More aggressive leadership by physicians is needed in future health care (interview by Eva Oldinger)] Berg O. **Nord Med** 1996 Mar;111(3):71–3 (Swe)

ATTITUDE TO COMPUTERS

Human interaction with technology: the accidental user. Marsden P, et al. **Acta Psychol (Amst)** 1996 Apr; 91(3):345–58

There is some Luddite in all of us. Conner SL. **Ala Med** 1995 Jul;65(1):2–3

Improving organizational processes for gains during implementation. FitzHenry F, et al. **Comput Nurs** 1996 May–Jun;14(3):171–80; quiz 181–2

User expectations and perceptions of a patient management information system. Henderson RD, et al. **Comput Nurs** 1996 May–Jun;14(3):188–93

Attitudes toward computers. A test of construct validity. McBride SH, et al. **Comput Nurs** 1996 May–Jun; 14(3):164–70

Family practice educators' perceptions of computer-based patient records. Musham C, et al. **Fam Med** 1995 Oct; 27(9):571–5

Cyberdoc. Weaver KM. **Internist (Berl)** 1996 Feb;37(2):6–8

Informationally challenged. Caplan R. **Iowa Med** 1996 Jan; 86(1):35

Trends in students' knowledge, opinions, and experience regarding dental informatics and computer applications. Lang WP. **J Am Med Inform Assoc** 1995 Nov–Dec; 2(6):374–82

Readiness of nurses for electronic networking for quality assessment and improvement. Crosby F, et al. **J Nurs Care Qual** 1995 Oct;10(1):40–5

Neural networks [letter; comment] Dodds SR. **Lancet** 1995 Dec 2;346(8988):1500–1. Comment on: Lancet 1995 Oct 21;346(8982):1075–9.

The impact of computer implementation on nursing work patterns: study design and preliminary results. Burkle T,

et al. **Medinfo** 1995;8 Pt 2:1321–5

Assessment of the level of the actual and desirable levels of computer literacy, usage and expected knowledge of undergraduate students of nursing. Hardy JL. **Medinfo** 1995;8 Pt 2:1326–30

Front-line hospital staff from six hospitals rate benefits of hospital information systems. Nauright LP, et al. **Medinfo** 1995;8 Pt 1:594–7

Predictors of nurse adoption of a computerized information system as an innovation. Romano CA. **Medinfo** 1995;8 Pt 2:1335–9

Assessing functional status of elderly adults via microcomputer. Yarnold PR, et al. **Percept Mot Skills** 1996 Apr;82(2):689–90

Computers in the examining room: the patient's perspective. Aydin CE, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:824–8

Acceptance and performance by clinicians using an ambulatory electronic medical record in an HMO. Krall MA. **Proc Annu Symp Comput Appl Med Care** 1995;:708–11

Successful implementation of an integrated physician order entry application: a systems perspective. Weir C, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:790–4

Psychology of computer use: XXXVII. Computer-related stress and amount of computer experience. Ballance CT, et al. **Psychol Rep** 1996 Jun;78(3 Pt 1):968–70

Psychology of computer use: XXXIX. Prevalence of computer anxiety in British managers and professionals. Bozionelos N. **Psychol Rep** 1996 Jun;78(3 Pt 1):995–1002

Psychology of computer use: XXXV. Differences in computer users' stress and self-concept in college personnel and students. Hudiburg RA, et al. **Psychol Rep** 1996 Jun; 78(3 Pt 1):931–7

Psychology of computer use: XXXIV. The Computer Hassles Scale: subscales, norms, and reliability. Hudiburg RA. **Psychol Rep** 1995 Dec;77(3 Pt 1):779–82

[Computer systems in medical practice. I. The aims, difficulties and implementation of computerization in health care organizations] Michalak J. **Med Pr** 1995;46(5):509–16 (12 ref.) (Eng. Abstr.) **(Pol)**

ATTITUDE TO DEATH

Family response to out-of-hospital death. Schmidt TA, et al. **Acad Emerg Med** 1995 Jun;2(6):513–8

Factors associated with the wish to die in elderly people. Jorm AF, et al. **Age Ageing** 1995 Sep;24(5):389–92

Tools of the heart. Fisher R. **Am J Nurs** 1996 Jul;96(7):56–7

When your patient is in denial. Goetzke E. **Am J Nurs** 1995 Sep;95(9):18–21

Grandmom's blessing. O'Kinsky A. **Am J Nurs** 1996 Jan; 96(1):54–7

Field termination of unsuccessful out-of-hospital cardiac arrest resuscitation: acceptance by family members. Delbridge TR, et al. **Ann Emerg Med** 1996 May; 27(5):649–54

Clinical incoherence about persons: the problem of the persistent vegetative state [editorial; comment] Cassell EJ. **Ann Intern Med** 1996 Jul 15;125(2):146–7. Comment on: Ann Intern Med 1996 Jul 15;125(2):104–10.

Whose death is it, anyway? [comment] Gilligan T, et al. **Ann Intern Med** 1996 Jul 15;125(2):137–41. Comment on: Ann Intern Med 1996 Jul 15;125(2):149–51.

Doctor's orders. Rodowski MF. **Ann Intern Med** 1996 Sep 15;125(6):512

A study of bereavement care after a sudden and unexpected death. Dent A, et al. **Arch Dis Child** 1996 Jun;74(6):522–6

End of life issues in ESRD. A study of three decision variables that affect patient attitudes. Rutecki GW, et al. **ASAIO J** 1994 Jul-Sep;40(3):M798–802

Cancer patients' place of death [letter; comment] Gannon C. **Br J Gen Pract** 1995 Nov;45(400):630–1. Comment on: Br J Gen Pract 1995 Jul;45(396):359–63.

Redefining death in America, 1968. Stevens ML. **Caduceus** 1995 Winter;11(3):207–19 (41 ref.)

Treating AIDS: hope and despair [letter; comment] Brown MG. **Can Med Assoc J** 1996 Jan 15;154(2):139–40. Comment on: Can Med Assoc J 1995 Oct 1;153(7):967–8.

Treating AIDS: hope and despair [letter; comment] Brown RH. **Can Med Assoc J** 1996 Jan 15;154(2):139; discussion 140. Comment on: Can Med Assoc J 1995 Oct 1;153(7):967–8.

Mixed reaction to suicide of terminally ill woman [letter] Gugliotta D. **Can Med Assoc J** 1995 Nov 1;153(9):1225–6

Mixed reaction to suicide of terminally ill woman [letter] Harding SR. **Can Med Assoc J** 1995 Nov 1;153(9):1226

Treating AIDS: hope and despair [letter; comment] Sauls R. **Can Med Assoc J** 1996 Jan 15;154(2):140. Comment on: Can Med Assoc J 1995 Oct 1;153(7):967–8.

Counselling patients before death: support for their decisions [letter; comment] Waugh D. **Can Med Assoc J** 1995 Nov 15;153(10):1417. Comment on: Can Med Assoc J 1995 Nov 1;153(9):1340–2.

Fatalism among elderly African Americans. Effects on colorectal cancer screening. Powe BD. **Cancer Nurs** 1995 Oct;18(5):385–92

CPR or DNR: lessons from Buddha [editorial] Karetzky PE, et al. **Chest** 1996 Jun;109(6):1415–6

Preclinical student reactions to dissection, death, and dying. Nnodim JO. **Clin Anat** 1996;9(3):175–82

Death and dying and recognizing approaching death. Long MC. **Clin Geriatr Med** 1996 May;12(2):359–68 (25 ref.)

The SUPPORT Study. Who's talking? Marshall PA. **Hastings Cent Rep** 1995 Nov-Dec;25(6):S9–11

Is capital punishment ever ethical? [news] Nicholson RH. **Hastings Cent Rep** 1995 Jul-Aug;25(4):5

Does apologizing help? The role of self-blame and making amends in recovery from bereavement. Weinberg N. **Health Soc Work** 1995 Nov;20(4):294–9

The face of death—grim reaper or rite of passage? [editorial] Parmley WW. **J Am Coll Cardiol** 1996 Jan;27(1):234–5

College students' views on suicide. King SR, et al. **J Am Coll Health** 1996 May;44(6):283–7

The defeat of aging versus the importance of death. Kane RS. **J Am Geriatr Soc** 1996 Mar;44(3):321–5

Aging as death rehearsal: the oppressiveness of reason. Gadow S. **J Clin Ethics** 1996 Spring;7(1):35–40

Pseudonecrophilia following spousal homicide. Meloy JR. **J Forensic Sci** 1996 Jul;41(4):706–8

Rehearsing one's death. Sirois F. **J Palliat Care** 1995 Autumn; 11(3):50–2

The relationship of death anxiety with age and psychosocial maturity. Rasmussen CA, et al. **J Psychol** 1996 Mar; 130(2):141–4

Good care of the dying patient. Council on Scientific Affairs, American Medical Association. **JAMA** 1996 Feb 14; 275(6):474–8 (96 ref.)

A piece of my mind. Respect for the dead. Smith DG. **JAMA** 1995 Nov 1;274(17):1408

Euthanasia and physician-assisted suicide: attitudes and experiences of oncology patients, oncologists, and the public. Emanuel EJ, et al. **Lancet** 1996 Jun 29; 347(9018):1805–10

Transcending mortality: organ transplants and the practice of contradictions. Lock M. **Med Anthropol Q** 1995 Sep; 9(3):390–3; discussion 398–9

Medicine and the community—the euthanasia debate [letter; comment] Jansz AW. **Med J Aust** 1996 Jul 15;165(2):118 . Comment on: Med J Aust 1995 Jun 5;162(11):566. Comment on: Med J Aust 1995 Aug 21;163(4):219–20. Comment on: Med J Aust 1995 Aug 21;163(4):220; discussion 219–20.

Improving end-of-life care for New Jerseyans. Armstrong PW. **N J Med** 1996 Jul;93(7):23–5

Attitudes of physicians regarding physician-assisted suicide. Reisner M, et al. **N J Med** 1995 Oct;92(10):663–6

Do not go gentle into that good night [editorial] Slobodien HD. **N J Med** 1996 Jul;93(7):15–6

Euthanasia [letter; comment] Curtis D. **Nat Med** 1995 Sep; 1(9):849–51. Comment on: Nat Med 1995 Jul;1(7):618–20.

Balancing our lives: a study of the married couple's experience with breast cancer recurrence. Lewis FM, et al. **Oncol Nurs Forum** 1995 Jul;22(6):943–53

A tolerable death. Shulman B. **Palliat Med** 1995 Oct; 9(4):339–40

Psychological changes in parents eight months after the loss of an infant from stillbirth, neonatal death, or sudden infant death syndrome—a longitudinal study. Vance JC, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):933–8

A reason to choose medicine [letter; comment] McKinley RA. **Pharos** 1995 Fall;58(4):36. Comment on: Pharos 1995 Summer;58(3):38–42.

Ulysses and I: a brief memoir of a long analysis. Adams B. **Psychoanal Rev** 1995 Oct;82(5):727–40

Doubling back on Dennis Potter's doubles: the invisible man and the invisible woman. Harrison IB. **Psychoanal Rev** 1996 Feb;83(1):67–96

In the shadow of death. Meissner WW. **Psychoanal Rev** 1995 Aug;82(4):535–57

Survivors' trauma and departmental response following deaths of police officers. Violanti JM. **Psychol Rep** 1995 Oct;77(2):611–5

Death anxiety, locus of control, and purpose in life of physicians. Their relationship to patient death notification. Viswanathan R. **Psychosomatics** 1996 Jul-Aug;37(4):339–45

Origins of cardiopulmonary resuscitation. Death, life and resuscitation in ancient Greek religion. Papageorgiou E. **Resuscitation** 1995 Oct;30(2):177–8

Support for donor families: the need for a structure and psychiatric help. Corbin D, et al. **Transplant Proc** 1996 Feb;28(1):386

On accepting death: languages of access to organ sharing. Fontana R, et al. **Transplant Proc** 1996 Feb;28(1):392

Analysis of organ donation refusal. Jouan MC, et al. **Transplant Proc** 1996 Feb;28(1):388–9

Frustrated mastery. The cultural context of death in America. Callahan D. **West J Med** 1995 Sep;163(3):226–30

Patients' perspectives on dying and on the care of dying patients. McCormick TR, et al. **West J Med** 1995 Sep; 163(3):236–43

[The new patient] Imbert C. **Bull Acad Natl Med** 1996 Jan; 180(1):33–40 **(Fre)**

["I non-exist". Paradoxes of death in adolescence] Chabert C. **Psychiatr Enfant** 1995;38(2):555–71 (Eng. Abstr.) **(Fre)**

[Reaction of a young boy in early latency to the sudden death of his newborn brother] Davids J. **Psychiatr Enfant** 1995; 38(1):47–68 (Eng. Abstr.) **(Fre)**

[The meaning of life and life after death? (editorial)] Werning C. **Med Monatsschr Pharm** 1996 Jan;19(1):1 **(Ger)**

[The hospice idea—a new ars moriendi?] Ballnus W. **Z Gerontol Geriatr** 1995 Jul-Aug;28(4):242–6 (Eng. Abstr.) **(Ger)**

[Experiences from terminal care. Anthropological principles in human practice] Helle-Feldmann A. **Z Gerontol Geriatr** 1995 Jul-Aug;28(4):260–3 (Eng. Abstr.) **(Ger)**

[Support in dying: orientation of expectations and needs of dying patients] Howe J. **Z Gerontol Geriatr** 1995 Jul-Aug; 28(4):252–9 (Eng. Abstr.) **(Ger)**

[Patients in the terminal phase and their caregivers as a "dyad": how do they perceive the finite stage of life, how do they cope with it?—Results of a longitudinal study] Kruse A. **Z Gerontol Geriatr** 1995 Jul-Aug;28(4):264–72 (Eng. Abstr.) **(Ger)**

[Terminal care—a burden for professional and familial caregivers?] Schmitz-Scherzer R. **Z Gerontol Geriatr** 1995 Jul-Aug;28(4):247–51 (Eng. Abstr.) **(Ger)**

[Assisted dying and death on demand (editorial)] Schütz RM. **Z Gerontol Geriatr** 1995 Jul-Aug;28(4):233–5 **(Ger)**

[Four important subjects of successful care at home for patients of terminally ill] Ashino Y, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:358–64 (Eng. Abstr.) **(Jpn)**

[A consideration in regard to 16 patients died at home] Hashimoto Y, et al. **Gan To Kagaku Ryoho** 1995 Dec;22 Suppl 4:341–4 (Eng. Abstr.) **(Jpn)**

[Thanatotherapeutics] Lolas Stepke F. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):282–92 (Eng. Abstr.) **(Spa)**

[Attitude to incurable disease] Fernández Díaz R, et al. **Aten Primaria** 1996 Apr 15;17(6):389–93 (Eng. Abstr.) **(Spa)**

[Facing death requires maturity and courage (letter)] Bring G. **Lakartidningen** 1996 Jan 31;93(5):339 **(Swe)**

[Conditions of the good death—an important debate in our time] Dahlström G. **Lakartidningen** 1996 Jan 31;93(5):386–9 **(Swe)**

[Quality of death—is it time for an open debate?] Fallberg LH, et al. **Lakartidningen** 1995 Oct 25;92(43):3971–4 **(Swe)**

ETHNOLOGY

Cultural considerations of death and dying in the United States. Hallenbeck J, et al. **Clin Geriatr Med** 1996 May; 12(2):393–406

Cancer fatalism among elderly Caucasians and African Americans. Powe BD. **Oncol Nurs Forum** 1995 Oct; 22(9):1355–9

ATTITUDE TO HEALTH

see related
PATIENT DROPOUTS
SICK ROLE

Helmets, injuries and cultural definitions: motorcycle injury in urban Indonesia. Conrad P, et al. **Accid Anal Prev** 1996 Mar;28(2):193–200

Attitudes towards financing of dental care in a Swedish population. Arnbjerg D, et al. **Acta Odontol Scand** 1996 Apr;54(2):81–6

Anxiety, depression and worry in gastrointestinal cancer patients attending medical follow-up control visits. Nordin K, et al. **Acta Oncol** 1996;35(4):411–6

Use of non-proven therapies. Differences in attitudes between Norwegian patients with non-malignant disease and patients suffering from cancer. Risberg T, et al. **Acta Oncol** 1995;34(7):893–8

Parental and primary care physicians' views on the management of chronic diseases: a study in Italy. The Italian Collaborative Group on Paediatric Chronic Diseases. Marchetti F, et al. **Acta Paediatr** 1995 Oct; 84(10):1165–72

Bias in reported body weight as a function of education, occupation, health and weight concern. Jeffery RW. **Addict Behav** 1996 Mar-Apr;21(2):217–22

Factors associated with premature termination of psychotherapy by children. Chung WS, et al. **Adolescence** 1995 Fall;30(119):717–21

Stress, coping, and attitudes toward HIV treatment in injecting drug users: a qualitative study. Demas P, et al. **AIDS Educ Prev** 1995 Oct;7(5):429–42

The perceived social context of AIDS: study of inner-city sexually transmitted disease clinic patients. Kalichman SC, et al. **AIDS Educ Prev** 1995 Aug;7(4):298–307

A history of attitudes toward opiate addiction. Tucker WH. **Ala Med** 1995 Nov-1996 Jan;65(5-7):18–25

Group similarities in beliefs concerning the causes of alcohol problems and the effectiveness of means of overcoming problem alcohol use. Peralta CD, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):964–8

Alcohol schema acquisition in preschoolers: differences between children of alcoholics and children of nonalcoholics. Zucker RA, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):1011–7

Author of optimal wellness defends against reviewer's assessment [letter] Golan RT. **Altern Ther Health Med** 1996 Sep;2(5):18, 101

Denies 'naturalness' of menopause [letter] Kincheloe L. **Altern Ther Health Med** 1996 Sep;2(5):14

Artistic expressions of illness. Soffa VM. **Altern Ther Health Med** 1996 May;2(3):63–6

Alcohol intake and subjective health. Poikolainen K, et al. **Am J Epidemiol** 1996 Aug 15;144(4):346–50

Thinking about homeopathy [editorial] Hasegawa GR. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2411

Save a seat on the bus for me. Cristo MG. **Am J Nurs** 1995 Sep;95(9):72

Orthodontic concern among 11-year-old children and their parents compared with orthodontic treatment need assessed by index of orthodontic treatment need. Birkeland K, et al. **Am J Orthod Dentofacial Orthop** 1996 Aug; 110(2):197-205

Anosognosia for depressive signs [letter; comment] Black KJ. **Am J Psychiatry** 1996 Feb;153(2):298. Comment on: Am J Psychiatry 1995 Jan;152(1):37-44.

Interest in physician-assisted suicide among ambulatory HIV-infected patients. Breitbart W, et al. **Am J Psychiatry** 1996 Feb;153(2):238-42

Life-sustaining treatment preferences of the elderly depressed [letter; comment] Gilbert CP 2nd, et al. **Am J Psychiatry** 1995 Dec;152(12):1836-7. Comment on: Am J Psychiatry 1994 Nov;151(11):1631-6.

Patients' preferences for sex of therapist [letter] Kaplan M. **Am J Psychiatry** 1996 Jan;153(1):136-7

Gender, type of treatment, dysfunctional attitudes, social support, life events, and depressive symptoms over naturalistic follow-up. Zlotnick C, et al. **Am J Psychiatry** 1996 Aug;153(8):1021-7

Needle exchange programs and the law--time for a change [comment] Glantz LH, et al. **Am J Public Health** 1996 Aug; 86(8 Pt 1):1077-8. Comment on: Am J Public Health 1996 Aug;86(8 Pt 1):1161-6.

AIDS phobia, public health warnings, and lawsuits: deterring harm or rewarding ignorance? Mariner WK. **Am J Public Health** 1995 Nov;85(11):1562-8 (42 ref.)

From alcohol and breast cancer to beef and BSE--improving our communication of risk [editorial] Marmot M. **Am J Public Health** 1996 Jul;86(7):921-3

Attitudes toward genetic testing for colon cancer risk. Smith KR, et al. **Am J Public Health** 1995 Oct;85(10):1435-8

Attitudes to pain and pain relief in adult surgical patients. Brydon CW, et al. **Anaesthesia** 1996 Mar;51(3):279-81

Recognition of the anaesthetists: a Spanish view [letter; comment] Garcia MA, et al. **Anaesthesia** 1995 Oct; 50(10):923. Comment on: Anaesthesia 1995 May;50(5):381-2.

Attitudes and preferences of patients to routes of analgesic administration [letter] Skinner TA, et al. **Anaesthesia** 1996 Mar;51(3):290-1

Patients' experiences of patient-controlled analgesia. Taylor NM, et al. **Anaesthesia** 1996 Jun;51(6):525-8

The Amsterdam Preoperative Anxiety and Information Scale (APAIS) [see comments] Moerman N, et al. **Anesth Analg** 1996 Mar;82(3):445-51. Comment in: Anesth Analg 1996 Mar;82(3):443-4.

How much do they really want to know? Preoperative patient interviews and the anesthesiologist [editorial; comment] Roizen MF, et al. **Anesth Analg** 1996 Mar; 82(3):443-4. Comment on: Anesth Analg 1996 Mar;82(3):445-51.

The influence of video imaging on patients' perceptions and expectations [see comments] Phillips C, et al. **Angle Orthod** 1995;65(4):263-70. Comment in: Angle Orthod 1995;65(4):243.

Health values of the seriously ill [letter; comment] Letvak R. **Ann Intern Med** 1996 Jan 15;124(2):279. Comment on: Ann Intern Med 1995 Apr 1;122(7):514-20.

Psychosocial and ethical implications of defining genetic risk for cancers. Kash KM. **Ann N Y Acad Sci** 1995 Sep 30; 768:41-52 (26 ref.)

Breast cancer in African-American families. Risk perception, cancer worry, and screening practices of first-degree relatives. Royak-Schaler R, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:281-5

Behavioral and social factors that predict participation in the Breast Cancer Prevention Trial. Vernon SW, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:300

Harnessing the power of the placebo effect and renaming it "remembered wellness". Benson H, et al. **Annu Rev Med** 1996;47:193-9 (18 ref.)

Functional performance in people with chronic obstructive pulmonary disease: a qualitative analysis. Leidy NK, et al. **ANS Adv Nurs Sci** 1996 Mar;18(3):77-89

Creating health with chronic illness. McWilliam CL, et al. **ANS Adv Nurs Sci** 1996 Mar;18(3):1-15

Struggling to gain meaning: living with the uncertainty of breast cancer. Nelson JP. **ANS Adv Nurs Sci** 1996 Mar; 18(3):59-76

Older women and their images of health: a replication study. Perry J, et al. **ANS Adv Nurs Sci** 1995 Sep;18(1):51-61

Harrison's. Lemkau JP. **Arch Fam Med** 1995 Nov;4(11):920-1

What role do patients wish to play in treatment decision making? Deber RB, et al. **Arch Intern Med** 1996 Jul 8; 156(13):1414-20

Anosognosia in Alzheimer's disease [letter; comment] Auchus AP, et al. **Arch Neurol** 1996 Jan;53(1):10. Comment on: Arch Neurol 1995 Apr;52(4):415-20.

The undoing of a diagnosis. The effect of a misdiagnosis of a disease. Barbero GJ. **Arch Pediatr Adolesc Med** 1995 Dec; 149(12):1341-4

The public and the welfare reform debate [see comments] Blendon RJ, et al. **Arch Pediatr Adolesc Med** 1995 Oct; 149(10):1065-9. Comment in: Arch Pediatr Adolesc Med 1995 Oct;149(10):1059-60.

The Adolescents Training and Learning to Avoid Steroids (ATLAS) prevention program. Background and results of a model intervention. Goldberg L, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):713-21

Trends and predictors of human immunodeficiency virus antibody testing by homosexual and bisexual adolescent males, 1989-1994. Povinelli M, et al. **Arch Pediatr Adolesc Med** 1996 Jan;150(1):33-8

The three faces of welfare. Public opinion and the debate over reform [editorial; comment] Stern MJ. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1059-60. Comment on: Arch Pediatr Adolesc Med 1995 Oct;149(10):1065-9.

Patient perceptions of self-induced water intoxication. May DL. **Arch Psychiatr Nurs** 1995 Oct;9(5):295-304

Patients' perceptions of psychiatric home care. Morris M. **Arch Psychiatr Nurs** 1996 Jun;10(3):176-83

Increasing attendance at immunisation clinics: lessons from a trial program that failed. Bazeley P, et al. **Aust J Public Health** 1995 Oct;19(5):459-64

Medical and health stories on the Syndey Morning Herald's front page. Lupton D. **Aust J Public Health** 1995 Oct; 19(5):501-8

Community attitudes to bans on smoking in licensed premises. Schofield MJ, et al. **Aust J Public Health** 1995 Aug; 19(4):399-402

The impact of exercise deprivation on well-being of habitual exercises. Szabo A. **Aust J Sci Med Sport** 1995 Sep; 27(3):68-75

Quality of life assessment in gynaecological cancer patients. Carter J, et al. **Aust N Z J Obstet Gynaecol** 1995 Aug; 35(3):293-7

Scare over oral contraceptives. Effect on behaviour of women attending a family planning clinic [letter] Armstrong JL, et al. **BMJ** 1995 Dec 16;311(7020):1637

Continuing transmission of sexually transmitted diseases among patients infected with HIV. HIV infection must be destigmatised [letter; comment] Danziger R. **BMJ** 1996 Jun 15;312(7045):1541. Comment on: BMJ 1996 Mar 2;312(7030):539-42.

Patients' views of priority setting in health care: an interview survey in one practice [see comments] Dicker A, et al. **BMJ** 1995 Oct 28;311(7013):1137-9. Comment in: BMJ 1996 Feb 17;312(7028):447.

Media coverage of the Child B case [see comments] Entwistle VA, et al. **BMJ** 1996 Jun 22;312(7046):1587-91. Comment in: BMJ 1996 Jun 22;312(7046):1553-4.

Italy's fertility rate falls as women reject childbearing [news] Evans L. **BMJ** 1996 Mar 2;312(7030):530

Teenage smokers fail to recognise health risks [news] Goldbeck-Wood S. **BMJ** 1996 Jun 15;312(7045):1501

Centres that work with cochlear implants listen to views of deaf community [letter; comment] Graham J, et al. **BMJ** 1996 Jul 13;313(7049):113. Comment on: BMJ 1996 Mar 30;312(7034):850.

Patients want ban on operations by doctors with hepatitis B [news] Halle M. **BMJ** 1996 Sep 7;313(7057):576

Cognitive behaviour therapy for the chronic fatigue syndrome. Patients' beliefs about their illness were probably not a major factor [letter; comment] Ho-Yen DO. **BMJ** 1996 Apr 27;312(7038):1097-8. Comment on: BMJ 1996 Jan 6;312(7022):22-6.

Blood money: blood donors' attitudes to changes in the New Zealand blood transfusion service [see comments] Howden-Chapman P, et al. **BMJ** 1996 May 4; 312(7039):1131-2. Comment in: BMJ 1996 May 4;312(7039):1114.

Family members' attitudes toward telling the patient with Alzheimer's disease their diagnosis. Maguire CP, et al. **BMJ** 1996 Aug 31;313(7056):529-30

Concerns about AIDS in general practice. Moons MA, et al. **BMJ** 1996 Feb 3;312(7026):285-6

Teenage sex. Image of various providers of sexual health care varies [letter; comment] Pallecaros A, et al. **BMJ** 1996 Jun 1;312(7043):1419-20. Comment on: BMJ 1996 Feb 17;312(7028):390-1.

Patient's views of priority setting. Details of qualitative studies are needed [letter; comment] Perry S. **BMJ** 1996 Feb 17;312(7028):447. Comment on: BMJ 1995 Oct 28;311(7013):1137-9.

Role of patients' view of their illness in predicting return to work and functioning after myocardial infarction: longitudinal study. Petrie KJ, et al. **BMJ** 1996 May 11; 312(7040):1191-4

Scare over oral contraceptives. Effect on women in a general practice in Devon... [letter] Seamark CJ. **BMJ** 1995 Dec 16;311(7020):1637

Survey of HIV patients' views on confidentiality and non-discrimination policies in general practice. Shaw M, et al. **BMJ** 1996 Jun 8;312(7044):1463-4

Children and sport [editorial] [see comments] Trippe H. **BMJ** 1996 Jan 27;312(7025):199-200. Comment in: BMJ 1996 May 11;312(7040):1229. Comment in: BMJ 1996 May 18;312(7041):1300.

Attitudes of dental health care workers to HIV infected persons [letter; comment] Porter S, et al. **Br Dent J** 1996 May 11;180(9):326. Comment on: Br Dent J 1996 Jan 20;180(2):53-6.

Ethnicity and health beliefs with respect to cancer: a critical review of methodology. Pfeffer N, et al. **Br J Cancer** 1996 Sep;74 Suppl 29:S66-72 (112 ref.)

Eliciting lay beliefs across cultures: principles and methodology. Sensky T. **Br J Cancer** 1996 Sep;74 Suppl 29:S63-5

Anxiety in women "at risk' of developing breast cancer. Thirlaway K, et al. **Br J Cancer** 1996 Jun;73(11):1422-4

Ethnicity and health beliefs with respect to cancer: a critical review of methodology. Pfeffer N, et al. **Br J Cancer Suppl** 1996 Sep;29:S66-72 (112 ref.)

Eliciting lay beliefs across cultures: principles and methodology. Sensky T. **Br J Cancer Suppl** 1996 Sep; 29:S63-5

The psychological effects of breast screening in terms of patients' perceived health anxieties. Swanson V, et al. **Br J Clin Pract** 1996 Apr-May;50(3):129-35

The health beliefs and behaviours of orthodox and complementary medicine clients. Furnham A, et al. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):49-61

Parental satisfaction with intervention: differences between respondents and non-respondents to a postal questionnaire. Stallard P. **Br J Clin Psychol** 1995 Sep;34 (Pt 3):397-405

Who should give lifestyle advice in general practice and what factors influence attendance at health promotion clinics? Survey of patients' views. Eggleston J, et al. **Br J Gen Pract** 1995 Dec;45(401):669-71

Epilepsy monitoring and advice recorded: general practitioners' views, current practice and patients' preferences. Ridsdale L, et al. **Br J Gen Pract** 1996 Jan; 46(402):11-4

Do patients prefer women doctors? Cockburn J, et al. **Br J Obstet Gynaecol** 1996 Jan;103(1):2-3

Clients' view of neuropsychological rehabilitation. Pössl J, et al. **Brain Inj** 1996 Feb;10(2):125-32

Perceived risks and benefits of alcohol, cigarette, and drug use among urban low-income African-American early adolescents. Feigelman S, et al. **Bull N Y Acad Med** 1995 Summer;72(1):57-75

Prospective care of elderly patients in family practice. Part 3: Prevalence of unrecognized treatable health concerns. Hay WI, et al. **Can Fam Physician** 1995 Oct;41:1695-704, 1707-10

Needs for CME in geriatrics. Part 2: Physician priorities and perceptions of community representatives. Pereles I, et al. **Can Fam Physician** 1996 Apr;42:632-40

Cigarette smoking during pregnancy. Stewart DE, et al. **Can J Psychiatry** 1995 Dec;40(10):603-7

Public support for a 100% smoke-free by-law in Scarborough. Fleiszer PM, et al. **Can J Public Health** 1996 May-Jun;87(3):170-1

Plans to run private facility in public hospital draw some strong opposition in Alberta. Cairney R. **Can Med Assoc J** 1996 May 15;154(10):1543-4

Complementary medicine and the scientific method [letter; comment] McGoey JS. **Can Med Assoc J** 1996 Jan 1; 154(1):14-5; discussion 15-6. Comment on: Can Med Assoc J 1995 Jul 1;153(1):45-9.

Breast-feeding still faces many roadblocks, national survey finds. Sullivan P. **Can Med Assoc J** 1996 May 15; 154(10):1569-70

Estrogen replacement therapy after treatment for localized breast carcinoma. Patient responses and opinions. Vassilopoulou-Sellin R, et al. **Cancer** 1996 Sep 1; 78(5):1043-8

Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Yeomans-Kinney A, et al. **Cancer** 1995 Jul 1;76(1):46-56

Psychosocial aspects of participation in early anticancer drug trials. Report of a pilot study. Cox K, et al. **Cancer Nurs** 1996 Jun;19(3):177-86

Hope and quality of life, two central issues for cancer patients: a theoretical analysis. Rustøen T. **Cancer Nurs** 1995 Oct;18(5):355-61 (60 ref.)

The effects of a health newsletter for foster parents on their perceptions of the behavior and development of foster children. Rich H. **Child Abuse Negl** 1996 May;20(5):437-45

Using spoken attributions to classify abusive families. Silvester J, et al. **Child Abuse Negl** 1995 Oct;19(10):1221-32

Children's anticipation of and response to colposcopic examination. Steward MS, et al. **Child Abuse Negl** 1995 Aug;19(8):997-1005

Moral reasoning about sexually transmitted diseases. Jadack RA, et al. **Child Dev** 1995 Feb;66(1):167-77

Do changes in patient beliefs and coping strategies predict temporomandibular disorder treatment outcomes? Turner JA, et al. **Clin J Pain** 1995 Sep;11(3):177-88

Attitudes of commercial renal transplant recipients toward renal transplantation in India. Qunibi W, et al. **Clin Transplant** 1995 Aug;9(4):317-21

Developmental defects of enamel in regularly attending adolescent dental patients in Scotland; prevalence and patient awareness. Fyffe HE, et al. **Community Dent Health** 1996 Jun;13(2):76-80

A comparison of the perceived and normative needs for dental care in 12-year-old children in the northwest of England. Hancock PA, et al. **Community Dent Health** 1996 Jun;13(2):81-5

Negative dental experiences and their relationship to dental anxiety. Locker D, et al. **Community Dent Health** 1996 Jun; 13(2):86-92

Perception of dental and other individual problems: adolescents versus young adults. Assink MH, et al. **Community Dent Oral Epidemiol** 1995 Dec;23(6):369-73

Tobacco habits, attitudes and participating behavior in tobacco prevention among dental personnel in Sweden. Halling A, et al. **Community Dent Oral Epidemiol** 1995 Aug; 23(4):254-5

Initial development of a scale to measure dental indifference. Nuttall NM. **Community Dent Oral Epidemiol** 1996 Apr; 24(2):112–6

Subjective and objective orthodontic treatment need among orthodontically treated and untreated Finnish adolescents. Tuominen ML, et al. **Community Dent Oral Epidemiol** 1995 Oct;23(5):286–90

Self–interest and altruism in intergenerational relations. Logan JR, et al. **Demography** 1995 Aug;32(3):353–64

Eating attitude and behavior in IDDM patients [letter] Mannucci E, et al. **Diabetes Care** 1995 Nov;18(11):1503–4

Symptoms and well–being in relation to glycemic control in type II diabetes. Van der Does FE, et al. **Diabetes Care** 1996 Mar;19(3):204–10

Patient attitudes to prenatal screening and termination of pregnancy at Groote Schuur Hospital: a two year prospective study. Viljoen D, et al. **East Afr Med J** 1996 May;73(5):327–9

Kentuckians' attitudes toward children with epilepsy. Baumann RJ, et al. **Epilepsia** 1995 Oct;36(10):1003–8

Parental assessment of functional outcome after corpus callosotomy. Gilliam F, et al. **Epilepsia** 1996 Aug; 37(8):753–7

Public perceptions about epilepsy [editorial] McLin WM, et al. **Epilepsia** 1995 Oct;36(10):957–9

Recommendation of early surgery from the viewpoint of daily quality of life. Mihara T, et al. **Epilepsia** 1996;37 Suppl 3:33–6

Quality of life and life satisfaction in families after a child has undergone corpus callostomy. Yang TF, et al. **Epilepsia** 1996 Jan;37(1):76–80

The impact of cancer on key relatives: a comparison of relative and patient concerns [see comments] Harrison J, et al. **Eur J Cancer** 1995 Oct;31A(11):1736–40. Comment in: Eur J Cancer 1995 Oct;31A(11):1731–2.

Spiritual healing among Norwegian hospitalised cancer patients and patients' religious needs and preferences of pastoral services. Risberg T, et al. **Eur J Cancer** 1996 Feb; 32A(2):274–81

Patient self–reported and clinician–rated quality of life in head and neck cancer patients: a cross–sectional study. Bjordal K, et al. **Eur J Cancer B Oral Oncol** 1995 Jul; 31B(4):235–41

Well–being and coping in oral and pharyngeal cancer patients. Langius A, et al. **Eur J Cancer B Oral Oncol** 1995 Jul;31B(4):242–9

Singers' and non–singers' vocal health, vocal behaviours, and attitudes towards voice and singing: indirect findings from a questionnaire. Sapir S, et al. **Eur J Disord Commun** 1996; 31(2):193–209

Disease–related worries and concerns: a study on out–patients with inflammatory bowel disease. Moser G, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):853–8

Adolescents' attitude towards carrier testing for cystic fibrosis and its relative stability over time. Welkenhuysen M, et al. **Eur J Hum Genet** 1996;4(1):52–62

Interruptions during general practice consultations—the patients' view. Dearden A, et al. **Fam Pract** 1996 Apr; 13(2):166–9

Constipation: a different entity for patients and doctors. Herz MJ, et al. **Fam Pract** 1996 Apr;13(2):156–9

No symptoms, no problem? Patients' understandings of non–insulin dependent diabetes. Murphy E, et al. **Fam Pract** 1995 Jun;12(2):184–92

An interview based approach to seeking user views in genitourinary medicine. Evans D, et al. **Genitourin Med** 1996 Jun;72(3):223–6

HIV/AIDS knowledge and high risk sexual practices among southern California Vietnamese. Gellert GA, et al. **Genitourin Med** 1995 Aug;71(4):216–23

Judging the past. The case of the human radiation experiments. Buchanan A. **Hastings Cent Rep** 1996 May–Jun;26(3):25–30

Patients' desire for information about anaesthesia: change in Scottish attitudes over five years. Kennedy S, et al. **Health Bull (Edinb)** 1996 Mar;54(2):118–21

Willingness to pay for antenatal carrier screening for cystic fibrosis. Donaldson C, et al. **Health Econ** 1995 Nov–Dec; 4(6):439–52

A healthy outlook. Hood SC, et al. **Health Rep** 1996 Spring; 7(4):25–32, 27–35 **(Eng, Fre)**

Older people's responses to education about advance directives. Bailly DJ, et al. **Health Soc Work** 1995 Aug; 20(3):223–8

Hispanic Americans. Who are they, where are they, and how do we talk to them? [see comments] Ross J. **Hosp Health Netw** 1995 Oct 5;69(19):65–6, 68. Comment in: Hosp Health Netw 1995 Dec 20;69(24):10.

Scientific literacy. Morowitz HJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):17–8

The relevance of health state utilities to lower third molar surgery. Brickley M, et al. **Int Dent J** 1995 Apr;45(2):124–8

Criteria of good dental practice generated by general dental practitioners and patients. Burke L, et al. **Int Dent J** 1996 Feb;46(1):3–9

Older adults' expectations about mental health counseling: a multivariate and discriminant analysis. Lagana L. **Int J Aging Hum Dev** 1995;40(4):297–316

Concerns about aging and a drive for thinness: a factor in the biopsychosocial model of eating disorders? Gupta MA. **Int J Eat Disord** 1995 Dec;18(4):351–7

Perfectionism traits and perfectionistic self–presentation in eating disorder attitudes, characteristics, and symptoms. Hewitt PL, et al. **Int J Eat Disord** 1995 Dec;18(4):317–26

Social variation in attitudes to obesity in children. Wardle J, et al. **Int J Obes Relat Metab Disord** 1995 Aug; 19(8):562–9

Judging a book by its cover: gay men's use of perceptible characteristics to infer antibody status. Gold RS, et al. **Int J STD AIDS** 1996 Jan–Feb;7(1):39–43

Preoperative HIV antibody testing: the views of surgeons and patients. Meadows J, et al. **Int J STD AIDS** 1995 Nov–Dec;6(6):426–30

Stigma and psychiatric disorder in Israeli society [letter] **Isr J Psychiatry Relat Sci** 1996;33(1):68–71

Stigma and psychiatric disorder—a commentary [letter] Katzenelson–Bank D. **Isr J Psychiatry Relat Sci** 1996; 33(2):137–8

Knesset members' attitudes towards combat stress reaction casualties. Solomon Z, et al. **Isr J Psychiatry Relat Sci** 1996;33(2):110–20

The Diagnostic Interview Schedule for Children (PC–DISC v.3.0): parents and adolescents suggest reasons for expecting discrepant answers. Bidaut–Russell M, et al. **J Abnorm Child Psychol** 1995 Oct;23(5):641–59

Acceptability of interventions to reduce mother–to–child transmission of HIV–1 in west Africa. Cartoux M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jul; 12(3):290–2

The reactions of patients and doctors in the united arab emirates towards smoking. Harrison A, et al. **J Addict Dis** 1996;15(1):75–92

Neglected conflicts in the discipline of nursing: perceptions of the importance and value of practical skill. Bjørk IT. **J Adv Nurs** 1995 Jul;22(1):6–12 (44 ref.)

Hysterectomy: British National Health Service and private patients have very different experiences. Chapple A. **J Adv Nurs** 1995 Nov;22(5):900–6

Nursing leaders' and nurses' view of health. Herberts S, et al. **J Adv Nurs** 1995 Nov;22(5):868–78

The biomedical construction of ageing: implications for nursing care of older people. Koch T, et al. **J Adv Nurs** 1996 May;23(5):954–9

Diabetes: an adolescent's perspective. Kyngäs H, et al. **J Adv Nurs** 1995 Nov;22(5):941–7

Promoting participation of informal caregivers in the hospital care of the elderly patient: informal caregivers' perceptions. Laitinen P, et al. **J Adv Nurs** 1996 May;23(5):942–7

Adjustment and social behaviour in older adults with chronic obstructive pulmonary disease: the family's perspective. Leidy NK, et al. **J Adv Nurs** 1996 Feb;23(2):252–9

Making sense of it: a neuro–interactional model of meaning emergence in critically ill ventilated patients. Lusardi PT, et al. **J Adv Nurs** 1996 May;23(5):896–903

Client views on periodic health examinations: opinions and personal experience. Nupponen R. **J Adv Nurs** 1996 Mar; 23(3):521–7

The subculture of adolescence: beliefs about care, health and individuation within Leininger's theory. Rosenbaum JN, et al. **J Adv Nurs** 1996 Apr;23(4):741–6

The health belief model and use of accident and emergency services by the general public. Walsh M. **J Adv Nurs** 1995 Oct;22(4):694–9

A hermeneutic study of the experiences of relatives of critically ill patients. Walters AJ. **J Adv Nurs** 1995 Nov; 22(5):998–1005

Symptom perception in pediatric asthma: relationship to functional morbidity and psychological factors. Fritz GK, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug; 35(8):1033–41

Trends in photoprotection in American fashion magazines, 1983–1993. will fashion make you look old and ugly? George PM, et al. **J Am Acad Dermatol** 1996 Mar; 34(3):424–8

Propensity for seeking counseling services: a comparison of Asian and American undergraduates. Lippincott JA, et al. **J Am Coll Health** 1995 Mar;43(5):201–4

Spouse caregivers' attitudes toward obtaining a diagnosis of a dementing illness. Connell CM, et al. **J Am Geriatr Soc** 1996 Aug;44(8):1003–9

Attitudes of older adults' on being told the diagnosis of Alzheimer's disease. Holroyd S, et al. **J Am Geriatr Soc** 1996 Apr;44(4):400–3

Patients' willingness to accept life–sustaining treatment when the expected outcome is a diminished mental health state: an exploratory study. Mazur DJ, et al. **J Am Geriatr Soc** 1996 May;44(5):565–8

Alzheimer's disease as a metaphor for contemporary fears of aging [letter] O'Rourke N. **J Am Geriatr Soc** 1996 Feb; 44(2):220–1

Seasickness as a self–fulfilling prophecy: raising self–efficacy to boost performance at sea. Eden D, et al. **J Appl Psychol** 1995 Oct;80(5):628–35

The credibility of the profession [editorial] Gleicher N. **J Assist Reprod Genet** 1995 Nov;12(10):661–2

Effect of interventions on stage of mammography adoption. Champion V, et al. **J Behav Med** 1995 Apr;18(2):169–87

Questionnaire on the perceptions of patients about shoulder surgery. Dawson J, et al. **J Bone Joint Surg Br** 1996 Jul; 78(4):593–600

Attitudes and behavior of HIV–infected patients concerning dental care. McCarthy GM, et al. **J Can Dent Assoc** 1996 Jan;62(1):63–9

Women's views of cardiac rehabilitation programs. Moore SM. **J Cardpulm Rehabil** 1996 Mar–Apr;16(2):123–9

The effect of experience of illness on health state valuations. Dolan P. **J Clin Epidemiol** 1996 May;49(5):551–64

Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. Couzi RJ, et al. **J Clin Oncol** 1995 Nov;13(11):2737–44

Exploring the attitudes of adults who stutter. Watson JB. **J Commun Disord** 1995 Jun;28(2):143–64 (55 ref.)

Perceptions of cervical cancer and Pap smear screening behavior by women's sexual orientation. Price JH, et al. **J Community Health** 1996 Apr;21(2):89–105

Attitude of African–Americans regarding prostate cancer clinical trials. Robinson SB, et al. **J Community Health** 1996 Apr;21(2):77–87

Impact of fear of infectious diseases on choice of a health career. Grace EG, et al. **J Dent Educ** 1996 Sep;60(9):770–4

Perception of the impact of a child's chronic illness: does it predict maternal mental health? Ireys HT, et al. **J Dev Behav Pediatr** 1996 Apr;17(2):77–83

Pediatric compliance and the roles of distinct treatment characteristics, treatment attitudes, and family stress: a preliminary report. Van Sciver MM, et al. **J Dev Behav Pediatr** 1995 Oct;16(5):350–8

Patient desire for information and decision making in health care decisions: the Autonomy Preference Index and the Health Opinion Survey [see comments] Nease RF Jr, et al. **J Gen Intern Med** 1995 Nov;10(11):593–600. Comment in: J Gen Intern Med 1995 Nov;10(11):643–4.

The meaning of older adults' health appraisals: congruence with health status and determinant of mortality. Borawski EA, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 May; 51(3):S157–70

Self–efficacy and pain in disability with osteoarthritis of the knee. Rejeski WJ, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):P24–9

Voluntary public health insurance for low–income families: the decision to enroll. Madden CW, et al. **J Health Polit Policy Law** 1995 Winter;20(4):955–72

Public attitudes towards the selection of desirable characteristics in children. Marteau T, et al. **J Med Genet** 1995 Oct;32(10):796–8

Psychological consequences of screening mammography. Cockburn J, et al. **J Med Screen** 1994 Jan;1(1):7–12

Is psychological wellbeing impaired in long–term survivors of breast cancer? Ellman R, et al. **J Med Screen** 1995; 2(1):5–9

Bilateral prophylactic mastectomy: issues and concerns. Stefanek ME. **J Natl Cancer Inst Monogr** 1995;(17):37–42 (31 ref.)

Psychosocial/cultural issues in medicine and psychiatry: treating African Americans. Carter JH. **J Natl Med Assoc** 1995 Dec;87(12):857–60 (18 ref.)

The stress of caring for disabling mental disorders in a home–based rehabilitation service. Falloon IR, et al. **J Nerv Ment Dis** 1996 Jun;184(6):381–4

Insight in clinical psychiatry. A new model. Marková IS, et al. **J Nerv Ment Dis** 1995 Dec;183(12):743–51 (44 ref.)

The impact of individualized consultation and group workshop family education interventions in ill relative outcomes. Solomon P, et al. **J Nerv Ment Dis** 1996 Apr; 184(4):252–5

The essence of nurse–midwifery care. The woman's story. Kennedy HP. **J Nurse Midwifery** 1995 Sep–Oct;40(5):410–7

The underuse of women's health care services in hungary. A preliminary study. Scanlan KA, et al. **J Nurse Midwifery** 1996 May–Jun;41(3):251–8

Health risk appraisal in an occupational setting and its impact on exercise behavior. Boudreau F, et al. **J Occup Environ Med** 1995 Sep;37(9):1145–50

ETS exposure in the workplace. Perceptions and reactions by employees in 114 work sites. Thompson B, et al. **J Occup Environ Med** 1995 Sep;37(9):1086–92

Oral conditions and aptitude to receive implants in patients with removable partial denture: a cross–sectional study. Part II Aptitude. Bassi F, et al. **J Oral Rehabil** 1996 Mar; 23(3):175–8

Dental impacts on daily life and satisfaction with teeth in relation to dental status in adults. Rosenoer LM, et al. **J Oral Rehabil** 1995 Jul;22(7):469–80

Long–term follow–up of cross–arch fixed partial dentures in patients with advanced periodontal destruction: evaluation of occlusion and subjective function. Yi SW, et al. **J Oral Rehabil** 1996 Mar;23(3):186–96

Children in Jordan: what is their health status and how do they perceive nurses? al–Ma'aitah R. **J Pediatr Nurs** 1995 Oct;10(5):335–9

A pilot study to evaluate in–hospital care by mothers. Evans M. **J Pediatr Oncol Nurs** 1996 Jul;13(3):138–45

Misconceptions about AIDS among children who can identify the major routes of HIV transmission. Wells EA, et al. **J Pediatr Psychol** 1995 Oct;20(5):671–86

The perception of risk over time as a factor influencing attitudes toward children with physical disabilities. Weiserbs B, et al. **J Psychol** 1995 Nov;129(6):689–99

A controlled study of anxiety and morbid cognitions at initial screening for human immunodeficiency virus (HIV) in a cohort of people with haemophilia. Jones QJ, et al. **J Psychosom Res** 1995 Jul;39(5):597–608

A validation study of the Whitely Index, the Illness Attitude Scales, and the Somatosensory Amplification Scale in general medical and general practice patients. Speckens

AE, et al **J Psychosom Res** 1996 Jan;40(1):95–104
Dental care satisfaction: the reliability and validity of the DSQ in a low-income population. Golletz D, et al. **J Public Health Dent** 1995 Fall;55(4):210–7
Attitudes of college football coaches regarding NCAA mouthguard regulations and player compliance. Ranalli DN, et al. **J Public Health Dent** 1995 Summer;55(3):139–42
Determinants of breastfeeding in Salisbury and Durham [letter; comment] Fitzpatrick P, et al. **J Public Health Med** 1995 Jun;17(2):238. Comment on: J Public Health Med 1994 Sep;16(3):291–5.
Improving the coverage and quality of cervical screening: women's views. Summers A, et al. **J Public Health Med** 1995 Sep;17(3):277–81
A patient's view of asthma. Donaldson JM. **J R Soc Med** 1995 Oct;88(10):590P–593P
What do patients want from medical research? [editorial] Fox R. **J R Soc Med** 1996 Jun;89(6):301–2
Gender and developmental differences in exercise beliefs among youth and prediction of their exercise behavior. Garcia AW, et al. **J Sch Health** 1995 Aug;65(6):213–9
Feasibility of school-based smoking cessation programs. Gillespie A, et al. **J Sch Health** 1995 Dec;65(10):432–7
Cues to parent involvement in drug prevention and school activities. Hahn EJ, et al. **J Sch Health** 1996 May; 66(5):165–70
The Claxton Elementary School Health Program: merging perceptions and behaviors to identify problems. Landis SE, et al. **J Sch Health** 1995 Sep;65(7):250–4
Attitude toward recovery and completion of a substance abuse treatment program. Britt GC, et al. **J Subst Abuse Treat** 1995 Sep–Oct;12(5):349–53
Patients' perspective on the process of change in substance abuse treatment. Lovejoy M, et al. **J Subst Abuse Treat** 1995 Jul–Aug;12(4):269–82
Addiction among high school pupils in Holon (Israel) and their attitudes towards drugs: a pilot study (1993–1994). Brook U. **J Trop Pediatr** 1996 Jun;42(3):175–7
The public's view of the future of Medicare. Blendon RJ, et al. **JAMA** 1995 Nov 22–29;274(20):1645–8
An 82-year-old woman with cataracts. Obstbaum SA. **JAMA** 1996 Jun 5;275(21):1675–80
Nocebos contribute to host of ills [news] Voelker R. **JAMA** 1996 Feb 7;275(5):345, 347
Folate prophylaxis in pregnancy [letter] De Jong-Van den Berg LT, et al. **Lancet** 1995 Nov 4;346(8984):1227–8
Returning home: reflections on the USA's response to the HIV/AIDS epidemic. Merson MH. **Lancet** 1996 Jun 15; 347(9016):1673–6
Influence and power of the media. Radford T. **Lancet** 1996 Jun 1;347(9014):1533–5
Screening for familial hypercholesterolaemia in relatives [letter] Tonstad S, et al. **Lancet** 1995 Nov 25;346(8987):1438
Little arrows [see comments] Waldron HA. **Lancet** 1995 Dec 2;346(8988):1475. Comment in: Lancet 1996 Jan 27;347(8996):267–8.
A community-based study of menopause symptoms and estrogen replacement in older women. von Mühlen DG, et al. **Maturitas** 1995 Sep;22(2):71–8
Women's responses to Depo-Provera. Comerford Freda M, et al. **MCN Am J Matern Child Nurs** 1996 Jul–Aug; 21(4):183–6
Intracultural diversity and the sociocultural correlates of blood pressure: a Jamaican example. Dressler WW, et al. **Med Anthropol Q** 1995 Sep;9(3):291–313
Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. Tsevat J, et al. **Med Care** 1996 Jan; 34(1):44–57
Angina patients' ratings of current health and health without angina: associations with severity of angina and comorbidity [see comments] Chen AY, et al. **Med Decis Making** 1996 Apr–Jun;16(2):169–77. Comment in: Med Decis Making 1996 Apr–Jun;16(2):195–6.
Disease spectrum and health-status perceptions [editorial; comment] Dawson NV. **Med Decis Making** 1996 Apr–Jun; 16(2):195–6. Comment on: Med Decis Making 1996 Apr–Jun;16(2):169–77.
The relationship between cardiac functional capacity and patients' symptom-specific utilities for angina: some findings and methodologic lessons. Nichol G, et al. **Med Decis Making** 1996 Jan–Mar;16(1):78–85
Assessing preferences about the DNR order: does it depend on how you ask? Percy ME, et al. **Med Decis Making** 1995 Jul–Sep;15(3):209–16
Protecting Australian overseas travellers [letter] Jackson MS, et al. **Med J Aust** 1996 Jul 15;165(2):119–20
Managing HIV. Part 7: Professional issues. 7.3 What do people with HIV, their carers and families want of their medical carers? Scott M, et al. **Med J Aust** 1996 Jul 15; 165(2):92–3
How parents in a rural area of Pekan district, Pahang perceive immunisation [letter] Amal MN. **Med J Malaysia** 1995 Jun;50(2):198–200
Physical activity and the initiation of high-risk health behaviors in adolescents. Aaron DJ, et al. **Med Sci Sports Exerc** 1995 Dec;27(12):1639–45
Entitlements and the federal budget: facts, folklore, and future. Gist JR. **Milbank Q** 1996;74(3):327–59 (42 ref.)
Patients' interest in educational programmes on asthma. Moscato G, et al. **Monaldi Arch Chest Dis** 1995 Aug; 50(4):319–22
Snapshot of an illness. Reinhart CL. **N C Med J** 1995 Oct; 56(10):520–2
Lip service. Ranalli DN, et al. **N Y State Dent J** 1995 Aug–Sep;61(7):34–8
A community's attitudes towards the mentally ill. Ng SL, et al. **N Z Med J** 1995 Dec 8;108(1013):505–8
AIDS survey traces shifting attitudes [news] Tastemain C. **Nature** 1995 Dec 7;378(6557):530
Multiple meanings of pain and complexities of pain management. Benoliel JQ. **Nurs Clin North Am** 1995 Dec; 30(4):583–96 (91 ref.)
Family members' perceptions of cancer pain. Comparisons with patient sensory report and by patient psychologic status. Madison JL, et al. **Nurs Clin North Am** 1995 Dec; 30(4):625–45
HIV infection. What nurses need to know. The consumer perspective. Schietinger H, et al. **Nurs Clin North Am** 1996 Mar;31(1):137–52 (21 ref.)
Impact of surgery on head and neck cancer patients and their caregivers. Watt-Watson J, et al. **Nurs Clin North Am** 1995 Dec;30(4):659–71
Epilepsy self-management: a test of a theoretical model. DiIorio C, et al. **Nurs Res** 1996 Jul–Aug;45(4):211–7
The factor structure of the perception of birth scale. Fawcett J, et al. **Nurs Res** 1996 Mar–Apr;45(2):83–6
Parents' opinions concerning possible causes of cerebral palsy. Radeka N, et al. **Nurse Pract** 1996 Apr;21(4):116–8, 128
Learning from the community about barriers to health care [see comments] Leppert PC, et al. **Obstet Gynecol** 1996 Jan;87(1):140–1. Comment in: Obstet Gynecol 1996 May;87(5 Pt 1):797–8.
How have Zambian businesses reacted to the HIV epidemic? Baggaley R, et al. **Occup Environ Med** 1995 Sep;52(9):565–9
Postoperative pain in children: a survey of parents' expectations and perceptions of their children's experiences. Rømsing J, et al. **Paediatr Anaesth** 1996; 6(3):215–8
The Pain Beliefs and Perceptions Inventory: a British replication. Morley S, et al. **Pain** 1995 Jun;61(3):427–33
Parents' attitudes toward school-based hepatitis B vaccination of their children. Woodruff BA, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):410–3
Effect of instruction on perceived physical ability and exercise adherence. Cain RE. **Percept Mot Skills** 1996 Apr; 82(2):494
Mental activity, health, and life-satisfaction. Delin CR, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):944–6
Effect of carbohydrate substrate availability on ratings of perceived exertion during prolonged exercise of moderate intensity. Kang J, et al. **Percept Mot Skills** 1996 Apr; 82(2):495–506
Perceived exertion during physical exercise among individuals high and low in fitness. Travlos AK, et al. **Percept Mot Skills** 1996 Apr;82(2):419–24
The metaphysics of holism: laughter in carnival with alternative medicine. Elgee NJ. **Pharos** 1995 Fall; 58(4):18–20
Read Don Quixote. King CR. **Pharos** 1995 Summer; 58(3):24–8
On breast reduction [letter] Wall K. **Plast Reconstr Surg** 1996 Jan;97(1):255–6
Glad to be alive. Pollack B. **Postgrad Med** 1995 Nov;98(5):36, 38
On the belief that arthritis pain is related to the weather. Redelmeier DA, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2895–6
Age and health bias in practicing clinical psychologists. James JW, et al. **Psychol Aging** 1995 Dec;10(4):610–6
Doctor-dependent changes in complaint-related cognitions and anxiety during medical consultations in functional abdominal complaints. Van Dulmen AM, et al. **Psychol Med** 1995 Sep;25(5):1011–8
Reconstruction and augmentation patients' reaction to the media coverage of silicone gel-filled implants: anxiety evaluated. Anderson RC, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1323–30
Is health locus of control related to health education activity. Carey P, et al. **Psychol Rep** 1995 Jun;76(3 Pt 2):1389–90
Perceptions of disability by students, the formerly obese, and the general community. Delin CR. **Psychol Rep** 1995 Jun; 76(3 Pt 2):1219–25
Optimistic bias in cancer risk perception: a cross-national study. Fontaine KR, et al. **Psychol Rep** 1995 Aug; 77(1):143–6
Psychosocial effects of skin treatment with Imedeen. Stronks DL, et al. **Psychol Rep** 1995 Dec;77(3 Pt 1):811–6
Some interpersonal and attitudinal factors characterizing patients satisfied with medical care. Twemlow SW, et al. **Psychol Rep** 1995 Aug;77(1):51–9
Development and psychometric validation of the Mental, Physical, and Spiritual Well-Being Scale. Vella-Brodrick DA, et al. **Psychol Rep** 1995 Oct;77(2):659–74
To control or to be controlled? From health locus of control to morphine control during patient-controlled analgesia. Reynaert C, et al. **Psychother Psychosom** 1995;64(2):74–81
Alexithymia: a further exploration of its nomological network. Vingerhoets AJ, et al. **Psychother Psychosom** 1995;64(1):32–42
The school health service in Fife: a survey of the views of school head and guidance teachers. Campbell H, et al. **Public Health** 1995 Sep;109(5):319–26
Consulting the public—token gestures or democratic right? [editorial; comment] Slack RC. **Public Health** 1996 May; 110(3):137. Comment on: Public Health 1996 May;110(3):145–50.
Yet another treatise on managed care [editorial] Shamansky SL. **Public Health Nurs** 1996 Jun;13(3):161–2
Youth beliefs and knowledge about the risks of drinking while pregnant. MacKinnon DP, et al. **Public Health Rep** 1995 Nov–Dec;110(6):754–63
Coping with radiation therapy: optimism and the effect of preparatory interventions. Johnson JE. **Res Nurs Health** 1996 Feb;19(1):3–12
Development and psychometric testing of the Leddy Healthiness Scale. Leddy SK. **Res Nurs Health** 1996 Oct; 19(5):431–40
HIV/AIDS testing remains prickly affair [news] van der Linde I. **S Afr Med J** 1995 Aug;85(8):725–6
On metaphor [editorial] Freeman JW. **S D J Med** 1996 Jun; 49(6):183–4
Assessment of sickness certification and concepts of musculoskeletal disease and illness in the general population. Brage S, et al. **Scand J Prim Health Care** 1995 Sep;13(3):188–96
Psychological reactions to information about risk of ischaemic heart disease in general practice. Christensen B. **Scand J Prim Health Care** 1995 Sep;13(3):164–7
Evaluation of a Swedish version of the arthritis self-efficacy scale in people with fibromyalgia. Lomi C, et al. **Scand J Rheumatol** 1995;24(5):282–7
Parents' perceptions of their children's recovery 5 to 10 years following day-care abuse. Burgess AW, et al. **Sch Inq Nurs Pract** 1996 Spring;10(1):75–92; discussion 93–6
Science, advocacy, human and environmental health. Rolston H 3rd. **Sci Total Environ** 1996 May 17;184(1–2):51–6
Environmental integrity, racism, health. Westra L. **Sci Total Environ** 1996 May 17;184(1–2):57–66
Epilepsy and employment—employers' attitudes. Cooper M. **Seizure** 1995 Sep;4(3):193–9
Women's psychological reactions to breast cancer. Payne DK, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):89–97 (27 ref.)
A change in expectations [editorial] Miller WT. **Semin Roentgenol** 1995 Oct;30(4):307
Self-rated health and mortality in a Lithuanian and a Dutch population. Appels A, et al. **Soc Sci Med** 1996 Mar; 42(5):681–9
The menstrual cycle and the well being of women. Bancroft J. **Soc Sci Med** 1995 Sep;41(6):785–91 (29 ref.)
Notions and treatment of guinea worm in northern Ghana. Bierlich B. **Soc Sci Med** 1995 Aug;41(4):501–9
What things are important in people's lives? A survey of the public's judgements to inform scales of health related quality of life. Bowling A. **Soc Sci Med** 1995 Nov; 41(10):1447–62
The subjective experience of health and illness in Ocuituco: a case study. Castro R. **Soc Sci Med** 1995 Oct;41(7):1005–21
Socio-economic differences in smoking: Dutch adolescents' beliefs and behaviour. de Vries H. **Soc Sci Med** 1995 Aug; 41(3):419–24
Health care utilization as a function of subjective health status, job satisfaction and gender among health care workers in Guangzhou, southern China. Fielding R, et al. **Soc Sci Med** 1995 Oct;41(8):1103–10
Attitudes towards people with HIV: are they as stigmatizing as people with HIV perceive them to be? Green G. **Soc Sci Med** 1995 Aug;41(4):557–68
Maximizing health benefits vs egalitarianism: an Australian survey of health issues. Nord E, et al. **Soc Sci Med** 1995 Nov;41(10):1429–37
The pregnancy that doesn't stay: the practice and perception of abortion by Ekiti Yoruba women. Renne EP. **Soc Sci Med** 1996 Feb;42(4):483–94
Pre-marital genetic counselling to consanguineous couples: attitudes, beliefs and decisions among counselled, noncounselled and unrelated couples in Israel. Shiloh S, et al. **Soc Sci Med** 1995 Nov;41(9):1301–10
Which resources pay for treatment? A model for estimating the informal economy of health. Wallman S, et al. **Soc Sci Med** 1996 Mar;42(5):671–9
Fear of AIDS and homophobia: implications for direct practice and advocacy. O'Hare T, et al. **Soc Work** 1996 Jan;41(1):51–8 (22 ref.)
Fewer black kidney donors: what's the problem? Griffin LW, et al. **Soc Work Health Care** 1995;22(2):19–42
Patients' beliefs about cancer management [see comments] Buchanan J, et al. **Support Care Cancer** 1996 Mar;4(2):110–7 . Comment in: Support Care Cancer 1996 Mar;4(2):73–4.
Concerns, coping and quality of life in head and neck cancer patients. Chaturvedi SK, et al. **Support Care Cancer** 1996 May;4(3):186–90
Quality of final care for terminal cancer patients in a comprehensive cancer centre from the point of view of patients' families [see comments] Merrouche Y, et al. **Support Care Cancer** 1996 May;4(3):163–8. Comment in: Support Care Cancer 1996 May;4(3):157.
Perceptions by Hispanics of channels and sources of health messages regarding cigarette smoking. Marin G. **Tob Control** 1996 Spring;5(1):30–6
The ruin of the constitution: the early interpretation of gout. Ordinary meeting Monday, 25th April 1994. Porter R. **Trans Med Soc Lond** 1993–94;110:90–103

Effect of socio-cultural beliefs on patients' perception of leprosy. The gender factor. Awofeso N.
Trop Geogr Med 1995;47(4):175–8

Staff and patient attitudes to tuberculosis and compliance with treatment: an exploratory study in a district in Vietnam. Johansson E, et al. **Tuber Lung Dis** 1996 Apr; 77(2):178–83

Patients' perception of day case surgery. Kelly MC.
Ulster Med J 1994 Apr;63(1):27–31

Relative risk [letter] Michell B. **Vet Rec** 1996 Mar 30; 138(13):311

Age differences in attitudes toward menopause and estrogen replacement therapy. Wagner PJ, et al. **Women Health** 1995;23(4):1–16

Medical negligence. Riis P. **World Health Forum** 1996; 17(3):215–8; discussion 219–39

Mexico: maternal deaths, fertility patterns, and social cost—an anthropological study. Elu MC.
World Health Stat Q 1995;48(1):47–9

[Prioritization of health care: is there room for selection or risk?] Niiniluoto I. **Duodecim** 1995;111(1):45–50 **(Fin)**

[Mental representation of drugs: construction of two questionnaires to study patients treated with psychotropic or oral hypoglycemic drugs] Sabran V, et al.
Ann Med Psychol (Paris) 1995 Oct;153(8):536–41; discussion 541–2 (Eng. Abstr.) **(Fre)**

[Tuberculosis and patient compliance: proposition for a study methodology of patient dropouts] Comolet T, et al.
Arch Inst Pasteur Madagascar 1995;62(1):68–71 (Eng. Abstr.) **(Fre)**

[The new patient] Imbert C. **Bull Acad Natl Med** 1996 Jan; 180(1):33–40 **(Fre)**

[Transcultural symptomatology. Its expression in family practice] Ferron M. **Can Fam Physician** 1995 Oct; 41:1718–25 (20 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of a new AIDS communication and prevention model. Analysis of reactions to the program "3000 scenarios against a virus"] Bajos N, et al.
Rev Epidemiol Sante Publique 1996 Jun;44(3):237–47 (Eng. Abstr.) **(Fre)**

[Benefits and risks of intramuscular injection. Are expectations of physicians and patients irrational?] Sohn W. **Fortschr Med** 1996 Jun 20;114(17):217–20 (28 ref.) (Eng. Abstr.) **(Ger)**

[Disease models and change in attitude of involuntarily admitted schizophrenic patients] Ullrich J, et al.
Fortschr Neurol Psychiatr 1995 Dec;63(12):480–6 (Eng. Abstr.) **(Ger)**

[Public health fairs on "environment and human health"—participants, topics, attitudes] Seidel HJ, et al.
Gesundheitswesen 1996 Apr;58(4):243–8 (Eng. Abstr.) **(Ger)**

[What is the attitude of parents to dental preventive examinations in schools and kindergarten? Results of a parent survey] Van Steenkiste M, et al.
Gesundheitswesen 1996 Apr;58(4):237–42 (Eng. Abstr.) **(Ger)**

[Self assessment and actual intelligibility of speech audiometry test material] Klotz B, et al.
Laryngorhinootologie 1995 Oct;74(10):591–3 (Eng. Abstr.) **(Ger)**

[Perception of patients in magnetic resonance tomography] Heuck A, et al. **Rontgenpraxis** 1995 Dec;48(12):349–52 **(Ger)**

[Critical and heretical thoughts on the development of cardiology. Limits of mental and social compliance attitude of the population] Diewitz M. **Versicherungsmedizin** 1996 Apr 1;48(2):43–5 (Eng. Abstr.) **(Ger)**

[Irrationality and risk—a problem analysis] Bergler R.
Zentralbl Hyg Umweltmed 1995 Apr;197(1–3):260–75 (Eng. Abstr.) **(Ger)**

[Use of medication for hypertension and coronary heart disease by Russian immigrants] Ben-Noun L. **Harefuah** 1995 Nov 15;129(10):392–4, 446 (Eng. Abstr.) **(Heb)**

[Was Illich right? Is ill health created by focusing on risks?] Førde R. **Nord Med** 1996 Apr;111(4):113–5 **(Nor)**

[Dangerous health] Fugelli P. **Nord Med** 1996 Jun;111(6):189 **(Nor)**

[Cultural variations of view on differences between the psyche and the soma] Ingstad B.
Tidsskr Nor Laegeforen 1995 Nov 10;115(27):3404–7 **(Nor)**

[Do tough men and women tolerate the sight of blood? (letter)] Malt UF. **Tidsskr Nor Laegeforen** 1996 May 20; 116(13):1617 **(Nor)**

[Health care seeking behavior of patients with AIDS] Talle A, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3284–5 (Eng. Abstr.) **(Nor)**

[Patients' attitudes toward their schizophrenic illness after their hospitalization] Wciórka J. **Psychiatr Pol** 1996 Jan–Feb;30(1):5–16 (Eng. Abstr.) **(Pol)**

[Patients' attitudes toward their psychosis after its long-term duration] Wciórka J, et al. **Psychiatr Pol** 1996 Jan–Feb; 30(1):17–29 (Eng. Abstr.) **(Pol)**

[Patient opinion about the quality of psychiatric care] Sosnovskii AIu.
Zh Nevropatol Psikhiatr Im S S Korsakova 1995;95(2):69–70 (Eng. Abstr.) **(Rus)**

[Patterns of use, popular beliefs and proneness to accidents of a baby walker (go-cart). Bases for a health information campaign] Santos Serrano L, et al. **An Esp Pediatr** 1996 Apr;44(4):337–40 (Eng. Abstr.) **(Spa)**

[What do adolescents think about their physician: a comparison between pediatricians and physicians for adults] Suris i Granell JC, et al. **An Esp Pediatr** 1996 Apr; 44(4):326–8 (Eng. Abstr.) **(Spa)**

[Who is not sick? One of health care's major problems] Malmquist J. **Nord Med** 1996 Apr;111(4):116 **(Swe)**

ETHNOLOGY

Rationing health care and the need for credible scarcity: why Americans can't say no. Mariner WK.
Am J Public Health 1995 Oct;85(10):1439–45 (50 ref.)

Study of new mothers looks at language and cultural barriers facing immigrant women. Williams LS.
Can Med Assoc J 1996 May 15;154(10):1563–4

Kufungisisa (thinking too much): a Shona idiom for non-psychotic mental illness. Patel V, et al.
Cent Afr J Med 1995 Jul;41(7):209–15

Child maltreatment as perceived by Arab students of social science in the West Bank. Haj-Yahia MM, et al.
Child Abuse Negl 1995 Oct;19(10):1209–19

A pill for every ill? Lam CL, et al. **Fam Pract** 1995 Jun; 12(2):171–5

Measuring quality of life in Thai and US communities. Watanakij P, et al. **Int Nurs Rev** 1995 Jul–Aug;42(4):121–3

The relationship between ethnicity and advance directives in a frail older population. Eleazer GP, et al.
J Am Geriatr Soc 1996 Aug;44(8):938–43

Attitudes toward use of nursing homes and home care in older Japanese-Americans. McCormick WC, et al.
J Am Geriatr Soc 1996 Jul;44(7):769–77

The Quinlan case revisited: a history of the cultural politics of medicine and the law. Stevens ML.
J Health Polit Policy Law 1996 Summer;21(2):347–66; discussion 367–72

Attitudes of African Americans regarding screening for prostate cancer. Robinson SB, et al. **J Natl Med Assoc** 1996 Apr;88(4):241–6

Access, expectations and communication: Japanese mothers' interaction with GPs in a pilot study in North London. Arai Y, et al. **Public Health** 1995 Sep;109(5):353–61

Differing beliefs about breast cancer among Latinas and Anglo women. Hubbell FA, et al. **West J Med** 1996 May; 164(5):405–9

Health concept of older Hispanic immigrants. Ailinger RL, et al. **West J Nurs Res** 1995 Dec;17(6):605–13

Cultural differences in attitudes, values, and beliefs about osteoporosis in first and second generation Japanese-American women. Matsumoto D, et al.
Women Health 1995;23(4):39–56

[Study of a custom in Somalia: the circumcision of girls] Bayoudh F, et al. **Med Trop (Mars)** 1995;55(3):238–42 (15 ref.) (Eng. Abstr.) **(Fre)**

[Myth reconstruction and health representations in a Southern Congolese therapeutic sect]
Hagenbucher-Sacripanti F. **Sante** 1996 Jan–Feb;6(1):43–52 (6 ref.) **(Fre)**

ATYPICAL ANTIDEPRESSANTS see **ANTIDEPRESSIVE AGENTS, SECOND-GENERATION**

ATYPICAL BACTERIAL FORMS

'Atypical' bacteria—a common cause of community-acquired pneumonia in hospitalised adults? [letter; comment] Potgieter P. **S Afr Med J** 1995 Oct;85(10):1031–2, 1034. Comment on: S Afr Med J 1994 Oct;84(10):678–82.

ISOLATION & PURIFICATION

Appropriateness of laboratory tests: requests for atypical pneumonia serology in a teaching hospital. Jackson LM, et al. **Ir J Med Sci** 1996 Apr–Jun;165(2):93–4

AUDIOLOGY

Possibilities of mission impossible: market to survive. Smith TM. **ASHA** 1996 Summer;38(3):33–7

Scope of practice in audiology. Ad Hoc Committee on scope of Practice in Audiology. **ASHA Suppl** 1996 Spring;38(2 Suppl 16):12–5

Reference list. Position statements, guidelines, and other relevant papers. **ASHA Suppl** 1996 Spring;38(2 Suppl 16):64–6

The role of speech-language pathologists and audiologists in medicine. Yates J. **Hawaii Med J** 1996 Jan;55(1):6–7

Should the audiometric database analysis method (draft ANSI S12.13–1991) for evaluating the effectiveness of hearing conservation programs be accepted as a US national standard?. Adera T, et al. **J Am Acad Audiol** 1995 Jul;6(4):302–10

Proceedings of the 1994 Bari Ear Care Workshop. Bari, Italy. **Scand Audiol Suppl** 1996;42:1–56

The Bari Center: an audiology and otology pilot center for Mediterranean countries. Quaranta A.
Scand Audiol Suppl 1996;42:5–7

[Audiologic care (letter)] Jørgensen IL. **Ugeskr Laeger** 1996 Mar 18;158(12):1689–90 **(Dan)**

EDUCATION

Audiology and the ethics of leadership. Gladstone VS.
ASHA 1995 Nov–Dec;37(11–12):43–4

What are the best educational models for the professional preparation of audiologists? Margolis RH, et al. **ASHA** 1996 Summer;38(3):20–1

Community based education in speech pathology and audiology at the University of Durban-Westville in an under served community. Jager GW.
S Afr J Commun Disord 1994;41:93–102

Strategy for D-Country Ear Care. Lundborg T.
Scand Audiol Suppl 1996;42:53–6

Proposal for the development of an audiological assistant training program. Muller A. **Scand Audiol Suppl** 1996; 42:47–8

HISTORY

[History of hearing perception. Different shapes of hearing aids: from the "cupped hand" to cochlear implants] Hansson H, et al. **Lakartidningen** 1995 Dec 20;92(51–52):4891–6 **(Swe)**

LEGISLATION & JURISPRUDENCE

Medical-legal evaluation of hearing loss: are methods of allocation testable? [letter] Dobie RA. **Ear Hear** 1995 Aug; 16(4):436

MANPOWER

Speechreading and speechreading tests: a survey of rehabilitative audiologists. White S, et al. **Am Ann Deaf** 1996 Jul;141(3):236–9

Clinical practice by certificate holders in the profession in which they are not certified. Ethical Practice Board.
ASHA Suppl 1996 Spring;38(2 Suppl 16):62–3

Guidelines on the audiologist's role in occupational and environmental hearing conservation. Ad Hoc Committee on Occupational and Environmental Hearing Conservation.
ASHA Suppl 1996 Spring;38(2 Suppl 16):45–52

Proposal for the development of an audiological assistant training program. Muller A. **Scand Audiol Suppl** 1996; 42:47–8

METHODS

Patient comfort in audiological testing. Beynon GJ, et al.
Br J Audiol 1995 Feb;29(1):1–5

Computerized digital photography in auditory research: a comparison of publication-quality digital printers with traditional darkroom methods. Trune DR, et al.
Hear Res 1995 Jun;86(1–2):163–70

ORGANIZATION & ADMINISTRATION

Strategy for D-Country Ear Care. Lundborg T.
Scand Audiol Suppl 1996;42:53–6

[Hearing problems—what do general practitioners do?] Parving A. **Ugeskr Laeger** 1996 Sep 9;158(37):5145–7 (Eng. Abstr.) **(Dan)**

STANDARDS

Managed care 101. Introducing managed care into the curriculum. Vekovius GT. **ASHA** 1995 Sep;37(9):44–7

Guidelines on the audiologist's role in occupational and environmental hearing conservation. Ad Hoc Committee on Occupational and Environmental Hearing Conservation.
ASHA Suppl 1996 Spring;38(2 Suppl 16):45–52

Technical report of the Ad Hoc Committee on Multiskilling.
ASHA Suppl 1996 Spring;38(2 Suppl 16):53–60

Clinical practice by certificate holders in the profession in which they are not certified. Ethical Practice Board.
ASHA Suppl 1996 Spring;38(2 Suppl 16):62–3

[Audiological service—reorganization with quality improvement (editorial)] Parving A. **Ugeskr Laeger** 1995 Dec 11;157(50):6991 **(Dan)**

[Audiologic care (letter)] Uldall-Hansen A.
Ugeskr Laeger 1996 Feb 12;158(7):929–30 **(Dan)**

TRENDS

Applied audiology [editorial] Oyer HJ.
Folia Phoniatr Logop 1996;48(3):109–10

AUDIOMETRY

see related
ACOUSTIC IMPEDANCE TESTS

Utility of auditory brainstem response audiometry in diagnosis of acoustic neuromas. Chandrasekhar SS, et al.
Am J Otol 1995 Jan;16(1):63–7

Early audiological findings of NF2 with an acoustic neuroma [letter] Sirimanna KS. **Ceylon Med J** 1995 Dec;40(4):163–4

Criteria for managing audiometric data in occupational hearing conservation. Delaney CM.
S Afr J Commun Disord 1994;41:33–6

[Audiometric results of 81 ossiculoplasties after tympanoplasty with closed technique in chronic cholesteatomatous otitis] Caprio D, et al.
Ann Otolaryngol Chir Cervicofac 1995;112(3):107–17 (16 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Audiometer calibration: applying the earphone to the coupler. Haughton PM. **Br J Audiol** 1995 Jun;29(3):188–91

METHODS

VISAUDIO: a Windows software application for Bekesy audiogram analysis and hearing research. Job A, et al. **Comput Methods Programs Biomed** 1996 Jan;49(1):95–103

Intraoperative audiometry. Lippy WH, et al. **Laryngoscope** 1995 Feb;105(2):214–6

STANDARDS

Exaggerated hearing loss in noise-induced hearing loss compensation claims in Victoria [letter; comment] Williams BJ. **Med J Aust** 1996 Feb 19;164(4):251–2. Comment on: Med J Aust 1995 Oct 2;163(7):360–3.

The precision level of the objective hearing tests. Podoshin L, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(5):373–5

[Hearing of small children. Satisfactory testing at health centers?] Lagerløv P. **Tidsskr Nor Laegeforen** 1995 Nov 20;115(28):3485–6 (Eng. Abstr.) **(Nor)**

AUDIOMETRY, BEKESY see **AUDIOMETRY, PURE-TONE**

AUDIOMETRY, ELECTROENCEPHALIC RESPONSE see **AUDIOMETRY, EVOKED RESPONSE**

AUDIOMETRY, EVOKED RESPONSE

Diagnostic significance of electrocochleogram and auditory evoked brainstem response in totally or subtotally deaf patients. Ohashi T, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:11–6

Abnormal electrocochleography after excision of acoustic neuroma. Ohashi T, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;522:17–21

A preliminary report on the correlation of vestibular Menière's disease with electrocochleography and glycerol test. Yen PT, et al. **Acta Otolaryngol Suppl (Stockh)** 1995; 520 Pt 2:241–6

Electrocochleography in profoundly deaf children: comparison of promontory and round window techniques. Aso S, et al. **Am J Otol** 1994 May;15(3):376–9

Loss of perilymph affects electrocochleographic potentials in the guinea pig. Badr-el-Dine M, et al. **Am J Otol** 1994 Nov;15(6):717–22

Perilymphatic fistula with no visible leak of fluid into the middle ear: a new method of intraoperative diagnosis using electrocochleography [letter; comment] Morris MS. **Am J Otol** 1994 Sep;15(5):695. Comment on: Am J Otol 1994 Jan;15(1):96–100.

Comparison of the effects of enflurane/N2O on the 40-Hz auditory steady-state response versus the auditory middle-latency response. Plourde G, et al. **Anesth Analg** 1996 Jan;82(1):75–83

Physiological identification of the auditory nerve during surgery for acoustic neuroma. Butler S, et al. **Clin Otolaryngol** 1995 Aug;20(4):312–7

Hearing loss in multiple sclerosis: localization of the auditory pathway lesion according to electrocochleographic findings. Marangos N. **J Laryngol Otol** 1996 Mar; 110(3):252–7

Ketamine anaesthesia for electrocochleography in children. Are psychic side effects really rare? Valentin N, et al. **Scand Audiol** 1996;25(1):39–43

[A preliminary observation of EcochG and cochlear morphology after cervical sympathectomy in guinea pigs] Shi X, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Jun; 17(3):230–3 (Eng. Abstr.) **(Chi)**

[Effect of variations in middle ear pressure on ruptures of the round window membrane of the inner ear of the guinea pig (Cavia porcellus)] Mertens J. **HNO** 1995 Oct; 43(10):611–8 (Eng. Abstr.) **(Ger)**

[Diagnostic intra-meatal acoustic neurinoma--the role of acoustically evoked brain stem potentials and other otoneurologic studies] Gosepath K, et al. **Laryngorhinootologie** 1995 Dec;74(12):728–32 (Eng. Abstr.) **(Ger)**

[Reliability of brain stem audiometry in specific learning disorders (disorders of sensory integration)] von Deuster C, et al. **Laryngorhinootologie** 1995 Sep;74(9):539–42 (Eng. Abstr.) **(Ger)**

[Changes with aging in ECochG] Ota Y. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jun;99(6):944–53 (Eng. Abstr.) **(Jpn)**

[A study on the reliability of evoked response audiometry in infants below one year of age; a long-term follow-up] Takamatsu I, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Sep;98(9):1373–80 (Eng. Abstr.) **(Jpn)**

[Electrocochleographic analysis of the suppression of tinnitus by electrical promontory stimulation and changes in compound action potentials] Watanabe K, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Aug;98(8):1310–7 (Eng. Abstr.) **(Jpn)**

METHODS

Simultaneous comparison between transtympanic and extratympanic electrocochleography. Roland PS, et al. **Am J Otol** 1995 Jul;16(4):444–50

Early hearing testing of still critically ill neonates. Eavey RD, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar; 122(3):289–93

Effect of sampling frequencies and averaging resolution on medical parameters of auditory brainstem responses. Grönfors T, et al. **Comput Biol Med** 1995 Sep;25(5):447–54

Universal newborn hearing screening: feasibility in a community hospital. Huynh MT, et al. **J Fam Pract** 1996 May;42(5):487–90

Dilemmas in auditory assessment of developmentally retarded children using behavioural observation audiometry and brain stem evoked response audiometry. Rupa V. **J Laryngol Otol** 1995 Jul;109(7):605–9

[Use of electrophysiologic hearing tests in clinical practice] Kochanek K. **Pol Tyg Lek** 1995 Oct;50(40–44):64–5 **(Pol)**

STANDARDS

Difficulties experienced in implementing the ABR travelling wave velocity (Delta V) technique with two commercially available systems. Munro KJ, et al. **Br J Audiol** 1995 Feb; 29(1):23–9

STATISTICS & NUMERICAL DATA

Composite probability modelling of increasing resolution where diagnostic covariates are unmeasurable for some subjects. Szalai JP, et al. **Psychol Rep** 1995 Aug;77(1):67–78

AUDIOMETRY, IMPEDANCE see **ACOUSTIC IMPEDANCE TESTS**

AUDIOMETRY, PURE-TONE

Air-bone gap in patients with X-linked stapes gusher syndrome. Snik AF, et al. **Am J Otol** 1995 Mar;16(2):241–6

Pure-tone audiometry and auditory brainstem responses in noise-induced deafness. Noorhassim I, et al. **Am J Otolaryngol** 1996 Jan-Feb;17(1):31–5

Audiometric findings in children with chronic suppurative otitis media without cholesteatoma. Kaplan DM, et al. **Int J Pediatr Otorhinolaryngol** 1996 Apr;35(2):89–96

Growth of low-pass masking of pure tones and speech for hearing-impaired and normal-hearing listeners. Dubno JR, et al. **J Acoust Soc Am** 1995 Dec;98(6):3113–24

Evaluation of a maximum likelihood procedure for measuring pure-tone thresholds under computer control. Formby C, et al. **J Am Acad Audiol** 1996 Apr;7(2):125–9

[Human's magnetoencephalography and normal value of auditory evoked magnetic field evoked by tone burst] Li K, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Sep; 75(9):548–51, 575 (Eng. Abstr.) **(Chi)**

[The value of clinical examination methods in diagnosis of acoustic neuroma] Scherler M, et al. **HNO** 1995 Aug; 43(8):487–91 (Eng. Abstr.) **(Ger)**

[Reaction times at auditory threshold: a comparison of normal hearing probands and patients with hearing damage] Hustert B, et al. **Laryngorhinootologie** 1996 Mar; 75(3):135–40 (Eng. Abstr.) **(Ger)**

[The audiometric evaluation of Buenos Aires schoolchildren] Agüero AL, et al. **Bol Oficina Sanit Panam** 1995 Oct; 119(4):292–8 (Eng. Abstr.) **(Spa)**

HISTORY

Bluestone et al.: Audiometry and tympanometry in relation to middle ear effusions in children. (Laryngoscope. 1973;83;594–604). Meyerhoff WL. **Laryngoscope** 1996 Jun; 106(6):684–7

[The monochord, its path from Pythagorean musicology to testing the upper auditory tone limit. Pictures from the history of otorhinolaryngology, represented by instruments of the Ingolstadt German Medical History Museum] Feldmann H. **Laryngorhinootologie** 1995 Aug;74(8):519–23 (Eng. Abstr.) **(Ger)**

METHODS

Distortion product otoacoustic emissions in the elderly. Karzon RK, et al. **Am J Otol** 1994 Sep;15(5):596–605

AUDIOMETRY, SPEECH

Improving the efficiency of speech audiometry: computer-based approach. Stach BA, et al. **J Am Acad Audiol** 1995 Jul;6(4):330–3

[Self assessment and actual intelligibility of speech audiometry test material] Klotz B, et al. **Laryngorhinootologie** 1995 Oct;74(10):591–3 (Eng. Abstr.) **(Ger)**

METHODS

Speech pattern audiometry for clinical use. Hazan V, et al. **Eur J Disord Commun** 1995;30(2):116–23 (15 ref.)

AUDIOVISUAL AIDS

Visual aids for communicating information to patients: an excellent second step [editorial; comment] Klamen D, et al. **Acad Emerg Med** 1996 Mar;3(3):200–1. Comment on: Acad Emerg Med 1996 Mar;3(3):264–70.

Still-frame simulations of cardiac motion studies: validity evidence from the cardiovascular disease certification examination. Downing SM, et al. **Acad Med** 1996 Jan;71(1 Suppl):S43–5

Graphic format for teaching long-term control of systemic arterial pressure. Faber JJ. **Am J Physiol** 1996 Jun;270(6 Pt 3):S40–9 (22 ref.)

Graphic analysis for the study of metabolic states. Summers RL, et al. **Am J Physiol** 1996 Jun;270(6 Pt 3):S81–7

Home-made videoscopic trainer for operative laparoscopic surgery. Gue S. **Aust N Z J Surg** 1995 Nov;65(11):820–1

Accuracy of injection site identification among children with insulin dependent diabetes mellitus: a comparison of traditional and new visual aids. Monaco L, et al. **Clin Pediatr (Phila)** 1996 Apr;35(4):191–7

The influence of audiotapes on patient participation in the cancer consultation. Ford S, et al. **Eur J Cancer** 1995 Dec; 31A(13-14):2264–9

'Video, health education and the General Practitioner Contract'. Barber JH, et al. **Health Bull (Edinb)** 1995 Sep; 53(5):326–33

Musical versus visual graphs: cross-modal equivalence in perception of time series data. Flowers JH, et al. **Hum Factors** 1995 Sep;37(3):553–69

Poster presentation: an effective means of scientific communication. Harikrishnan KM, et al. **J Assoc Physicians India** 1995 Aug;43(8):546–7 (4 ref.)

From strategic planning to TQM: a complete management approach. Bader SA, et al. **J Audiov Media Med** 1995 Sep; 18(3):101–3

Design standards for computer-generated teaching slides. Bellamy K. **J Audiov Media Med** 1995 Sep;18(3):115–20

A method for duplicating bones as anatomical models. Gungec KA, et al. **J Audiov Media Med** 1995 Mar; 18(1):27–30

An introduction to scriptwriting for video and multimedia. Guth J. **J Audiov Media Med** 1995 Jun;18(2):65–8

Design for slides. Johns M. **J Audiov Media Med** 1995 Sep; 18(3):121–8

Clinical photographs as teaching aids: how reliable are they? McCombe A, et al. **J Laryngol Otol** 1995 Aug;109(8):741–3

An optical intervention for visual hallucinations associated with visual impairment and dementia in elderly patients. Pankow L, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):88–92

Relaxation effect of an audiovisual system on dental patients. Part 2. Palus-amplitude. Satoh Y, et al. **J Nihon Univ Sch Dent** 1995 Sep;37(3):138–45

Current status of interactive multimedia education in medicine. Stocking JE, et al. **MD Comput** 1995 Sep-Oct; 12(5):373–81, 413

FDDI information management system for centralizing interactive, computerized multimedia clinical experiences in pediatric rheumatology/Immunology. Rouhani R, et al. **Medinfo** 1995;8 Pt 2:1204–8

The AMUSE-environment: a didactical environment where active multimedia use stimulates expertise. Veldeman F, et al. **Medinfo** 1995;8 Pt 2:1226–8

Selected list of video programs on mental illness and treatment for patients and their families. Reavis PA, et al. **Psychiatr Serv** 1995 Dec;46(12):1238–40

Training traditional birth attendants in Nigeria--the pictorial method. Matthews MK, et al. **World Health Forum** 1995; 16(4):409–13

[My use of the Association Française d'Études des Ambroisies pollen calendar for Lyon-Bron (P. Cour collector)] Bouteloup F. **Allerg Immunol (Paris)** 1995 Nov; 27(9):326–31 (Eng. Abstr.) **(Fre)**

[Computerized slides and scientific communication: art and method] Dupont JY. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(1):49–58 **(Fre)**

[Making a backlight display panel using a personal computer and a laser imager: a less expensive and less time-consuming method] Aihara T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Nov;55(14):998 (Eng. Abstr.) **(Jpn)**

AUDITORY BRAIN STEM EVOKED RESPONSES see **EVOKED POTENTIALS, AUDITORY, BRAIN STEM**

AUDITORY CANAL, EXTERNAL see **EAR CANAL**

AUDITORY CORTEX

see related
AUDITORY DISEASES, CENTRAL

Central auditory processing: a view from auditory neuroscience. Phillips DP. **Am J Otol** 1995 May; 16(3):338–52 (88 ref.)

ANATOMY & HISTOLOGY

Patchy and laminar terminations of medial geniculate axons in monkey auditory cortex. Hashikawa T, et al. **J Comp Neurol** 1995 Nov 13;362(2):195–208

Auditory thalamocortical pathways defined in monkeys by calcium-binding protein immunoreactivity. Molinari M, et al. **J Comp Neurol** 1995 Nov 13;362(2):171–94

Anatomy of the auditory cortex. Pandya DN. **Rev Neurol (Paris)** 1995 Aug-Sep;151(8-9):486–94 (60 ref.)

CHEMISTRY

Amino acid concentrations and selected enzyme activities in rat auditory, olfactory, and visual systems. Ross CD, et al. **Neurochem Res** 1995 Dec;20(12):1483–90

AUDITORY CORTEX

CYTOLOGY

Neural connections of auditory association cortex with the posterior cingulate cortex in the monkey. Yukie M. **Neurosci Res** 1995 May;22(2):179–87

DRUG EFFECTS

The alpha 2–adrenergic antagonist idazoxan enhances the frequency selectivity and increases the threshold of auditory cortex neurons. Edeline JM. **Exp Brain Res** 1995; 107(2):221–40

Onset of ototoxicity in the cat is related to onset of auditory function. Shepherd RK, et al. **Hear Res** 1995 Dec; 92(1–2):131–42

METABOLISM

Comparison of frequency–specific c–Fos expression and fluoro–2–deoxyglucose uptake in auditory cortex of gerbils (Meriones unguiculatus). Zuschratter W, et al. **Eur J Neurosci** 1995 Jul 1;7(7):1614–26

Retrograde axonal transport of different fluorescent tracers from the neocortex to the suprageniculate nucleus in the rat. Kurokawa T, et al. **Hear Res** 1995 May;85(1–2):103–8

Subdivisions of macaque monkey auditory cortex revealed by calcium–binding protein immunoreactivity. Jones EG, et al. **J Comp Neurol** 1995 Nov 13;362(2):153–70

PATHOLOGY

Effect of profound hearing loss on a central auditory nucleus. Moore JK, et al. **Am J Otol** 1994 Sep;15(5):588–95

PHYSIOLOGY

Pyramidal cells in primary auditory cortex project to cochlear nucleus in rat. Weedman DL, et al. **Brain Res** 1996 Jan 8;706(1):97–102

Generators of electrical and magnetic mismatch responses in humans. Näätänen R, et al. **Brain Topogr** 1995 Summer; 7(4):315–20 (63 ref.)

Hearing. Asking the auditory cortex the right question. King AJ. **Curr Biol** 1995 Oct 1;5(10):1110–3 (23 ref.)

Order and disorder in auditory cortical maps. Schreiner CE. **Curr Opin Neurobiol** 1995 Aug;5(4):489–96 (60 ref.)

Development of electrical membrane properties and discharge characteristics of superior olivary complex neurons in fetal and postnatal rats. Kandler K, et al. **Eur J Neurosci** 1995 Aug 1;7(8):1773–90

Auditory responsive cortex in the squirrel monkey: neural responses to amplitude–modulated sounds. Bieser A, et al. **Exp Brain Res** 1996 Mar;108(2):273–84

The auditory pathway in cat corpus callosum. Clarke S, et al. **Exp Brain Res** 1995;104(3):534–40

Synaptic interactions involving acetylcholine, glutamate, and GABA in rat auditory cortex. Metherate R, et al. **Exp Brain Res** 1995;107(1):59–72

A two–filter model for frequency discrimination. Dai H, et al. **Hear Res** 1995 May;85(1–2):109–14

Acoustic features and acoustic changes are represented by different central pathways. King C, et al. **Hear Res** 1995 May;85(1–2):45–52

Comodulation masking release in a songbird. Klump GM, et al. **Hear Res** 1995 Jul;87(1–2):157–64

Cortical sources of middle latency responses of auditory evoked magnetic field. Kuriki S, et al. **Hear Res** 1995 Dec; 92(1–2):47–51

On the heritability of spontaneous otoacoustic emissions: A twins study. McFadden D, et al. **Hear Res** 1995 May; 85(1–2):181–98

Middle latency responses to acoustical and electrical stimulation of the cochlea in cats. Popelář J, et al. **Hear Res** 1995 Dec;92(1–2):63–77

Envelope–following response and modulation transfer function in the dolphin's auditory system. Supin AY, et al. **Hear Res** 1995 Dec;92(1–2):38–46

Auditory cortex activity changes in long–term sensorineural deprivation during crude cochlear electrical stimulation: evaluation by positron emission tomography. Truy E, et al. **Hear Res** 1995 Jun;86(1–2):34–42

Effect of stimulation on burst firing in cat primary auditory cortex. Bowman DM, et al. **J Neurophysiol** 1995 Nov; 74(5):1841–55

Comparison of noise and tone azimuth tuning of neurons in cat primary auditory cortex and medical geniculate body. Clarey JC, et al. **J Neurophysiol** 1995 Sep;74(3):961–80

Comparison of evoked potentials and high–frequency (gamma–band) oscillating potentials in rat auditory cortex. Franowicz MN, et al. **J Neurophysiol** 1995 Jul;74(1):96–112

Representation of a species–specific vocalization in the primary auditory cortex of the common marmoset: temporal and spectral characteristics. Wang X, et al. **J Neurophysiol** 1995 Dec;74(6):2685–706

The structure of spatial receptive fields of neurons in primary auditory cortex of the cat. Brugge JF, et al. **J Neurosci** 1996 Jul 15;16(14):4420–37

The effects of superior temporal cortex lesions on the processing and retention of auditory information in monkeys (Cebus apella). Colombo M, et al. **J Neurosci** 1996 Jul 15;16(14):4501–17

Receptive–field plasticity in the adult auditory cortex induced by Hebbian covariance. Cruikshank SJ, et al. **J Neurosci** 1996 Jan 15;16(2):861–75

Multi–electrode array for measuring evoked potentials from surface of ferret primary auditory cortex. Owens AL, et al. **J Neurosci Methods** 1995 May;58(1–2):209–20

The effects of low–pass filtering on the primary cortical auditory potential of the rat. Shaw NA. **J Neurosci Methods** 1995 Jul;59(2):209–16

Thalamic modulation of high–frequency oscillating potentials in auditory cortex [see comments] Barth DS, et al. **Nature** 1996 Sep 5;383(6595):78–81. Comment in: Nature 1996 Sep 5;383(6595):24–5.

Primary cortical representation of sounds by the coordination of action–potential timing. deCharms RC, et al. **Nature** 1996 Jun 13;381(6583):610–3

Alteration of auditory cortex activity with a visual stimulus through conditioning: a 2–deoxyglucose analysis. Cahill L, et al. **Neurobiol Learn Mem** 1996 May;65(3):213–22

Separating local from global effects in neural pair correlograms. Eggermont JJ, et al. **Neuroreport** 1995 Nov 13;6(16):2121–4

Rate covariance dominates spontaneous cortical unit–pair correlograms. Eggermont JJ, et al. **Neuroreport** 1995 Nov 13;6(16):2125–8

Neural correlates of gap detection and auditory fusion in cat auditory cortex. Eggermont JJ. **Neuroreport** 1995 Aug 21;6(12):1645–8

Age–related functional differences between auditory cortices: a whole–head MEG study. Pekkonen E, et al. **Neuroreport** 1995 Sep 11;6(13):1803–6

From objective to subjective: pitch representation in the human auditory cortex. Winkler I, et al. **Neuroreport** 1995 Nov 27;6(17):2317–20

Inhibitory interactions in neuronal networks including cells of the auditory cortex and the medial geniculate body. Sil'kis IG. **Neurosci Behav Physiol** 1996 Jan–Feb; 26(1):62–72

Plastic reorganizations of the receptive fields of neurons of the auditory cortex and the medial geniculate body induced by microstimulation of the auditory cortex. Sil'kis IG, et al. **Neurosci Behav Physiol** 1995 Jul–Aug;25(4):322–39

Excitatory interactions in neuronal networks which include cells of the auditory cortex and the medial geniculate body. Sil'kis IG. **Neurosci Behav Physiol** 1995 Nov–Dec; 25(6):462–73

Functional brain block preparation of the rat auditory cortex. Fujisaki T, et al. **Neurosci Res** 1995 Oct;23(3):321–6

Processing of complex sounds in the human auditory cortex as revealed by magnetic brain responses. Alho K, et al. **Psychophysiology** 1996 Jul;33(4):369–75

Corticofugal modulation of time–domain processing of biosonar information in bats. Yan J, et al. **Science** 1996 Aug 23;273(5278):1100–3

[Cortical mechanisms of auditive perception in man: contribution of cerebral potentials and evoked magnetic fields by auditive stimulations] Liégeois–Chauvel C, et al. **Rev Neurol (Paris)** 1995 Aug–Sep;151(8–9):495–504 (Eng. Abstr.) **(Fre)**

[Specificity of the effect of a super high frequency pulse–modulated electromagnetic field on evoked potentials of the cat visual, auditory,and sensomotor cortex upon stimulation with light and sound] Khlunovskaia EA, et al. **Biofizika** 1995 Mar–Apr;40(2):412–6 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Auditory sensory ("echoic") memory dysfunction in schizophrenia. Strous RD, et al. **Am J Psychiatry** 1995 Oct; 152(10):1517–9

RADIATION EFFECTS

[A comparative histochemical study of cytochrome oxidase activity in the somatosensory and auditory brain centers in the normal rat and after exposure to superhigh–frequency electromagnetic fields] Krasnoshchekova EI, et al. **Zh Evol Biokhim Fiziol** 1995 Sep–Dec;31(5–6):573–83 (Eng. Abstr.) **(Rus)**

AUDITORY DISEASES, CENTRAL

COMPLICATIONS

Learning disabilities and central auditory dysfunction. Welsh LW, et al. **Ann Otol Rhinol Laryngol** 1996 Feb; 105(2):117–22

ETIOLOGY

Cortical auditory disorder caused by bilateral temporal infarctions. Ishii K, et al. **Intern Med** 1995 Aug;34(8):801–5

AUDITORY EVOKED POTENTIALS see **EVOKED POTENTIALS, AUDITORY**

AUDITORY EVOKED RESPONSE see **EVOKED POTENTIALS, AUDITORY**

AUDITORY FATIGUE

Evaluation of exposure to noise in seafarers on several types of vessels in Polish Merchant Navy. Szczepański C, et al. **Bull Inst Marit Trop Med Gdynia** 1995;46(1–4):13–7

Hearing loss and motorcyclists. McCombe AW, et al. **J Laryngol Otol** 1995 Jul;109(7):599–604

PHYSIOLOGY

Reduction in excitability of the auditory nerve following electrical stimulation at high stimulus rates. Tykocinski M, et al. **Hear Res** 1995 Aug;88(1–2):124–42

Additivity of loud–sound––induced threshold losses in the cat under conditions of active or inactive cochlear efferent–mediated protection. Rajan R. **J Neurophysiol** 1996 Apr;75(4):1601–18

[Detection of hearing loss in patrons of a discoteque using TEOAE and DPOAE] Liebel J, et al. **Laryngorhinootologie** 1996 May;75(5):259–64 (Eng. Abstr.) **(Ger)**

[Amplitude changes in distortion products of otoacoustic emissions after acute noise exposure] Oeken J, et al. **Laryngorhinootologie** 1996 May;75(5):265–9 (Eng. Abstr.) **(Ger)**

AUDITORY LOCALIZATION see **SOUND LOCALIZATION**

AUDITORY NERVE see **ACOUSTIC NERVE**

AUDITORY OSSICLES see **EAR OSSICLES**

AUDITORY PATHWAYS

see related
AUDITORY DISEASES, CENTRAL

Biologic bases of noise–induced hearing loss. Henderson D, et al. **Occup Med** 1995 Jul–Aug;10(3):513–34 (27 ref.)

ANATOMY & HISTOLOGY

Visual movement and pattern are important for the development of a map of auditory space in the guinea pig superior colliculus. Thornton SK, et al. **Exp Brain Res** 1995;106(2):257–64

Seeing how we hear. Momose A, et al. **Nat Med** 1996 Aug; 2(8):852–3

Applying very high resolution microfocus X–ray CT and 3–D reconstruction to the human auditory apparatus [see comments] Shibata T, et al. **Nat Med** 1996 Aug;2(8):933–5 . Comment in: Nat Med 1996 Aug;2(8):860–2.

Origin of auditory fractal random signals in guinea pigs. Ehrenberger K, et al. **Neuroreport** 1995 Nov 13; 6(16):2117–20

DRUG EFFECTS

Muscarine induces an anomalous inhibition of synaptic transmission in rat auditory thalamic neurons in vitro. Mooney DM, et al. **J Pharmacol Exp Ther** 1995 Nov; 275(2):838–44

EMBRYOLOGY

Development of second–order vestibular projections in the chicken embryo. Glover JC. **Ann N Y Acad Sci** 1996 Jun 19;781:13–20 (12 ref.)

Afferent calyces and type I hair cells during development. A new morphofunctional hypothesis. Sans A, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:1–12

GROWTH & DEVELOPMENT

Ontogeny of eyeblink conditioning in the rat: auditory frequency and discrimination learning effects. Andrews SJ, et al. **Dev Psychobiol** 1995 Sep;28(6):307–20

METABOLISM

Cobalt–permeable non–NMDA receptors in developing chick brainstem auditory nuclei. Zhou N, et al. **Neuroreport** 1995 Nov 27;6(17):2273–76

PATHOLOGY

Temporal bone findings in Alzheimer's disease. Sinha UK, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):1–5

PHYSIOLOGY

Functional network interactions between parallel auditory pathways during Pavlovian conditioned inhibition. McIntosh AR, et al. **Brain Res** 1995 Jun 19;683(2):228–41

Electrically induced fos–like immunoreactivity in the auditory pathway of the rat: effects of survival time, duration, and intensity of stimulation. Zhang JS, et al. **Brain Res Bull** 1996;39(2):75–82

The auditory pathway in cat corpus callosum. Clarke S, et al. **Exp Brain Res** 1995;104(3):534–40

Neural responses to free–field auditory stimulation in the superior colliculus of the wallaby (Macropus eugenii). Withington DJ, et al. **Exp Brain Res** 1995;105(2):233–40

Transient effects during the chopping response of LSO neurons. Zacksenhouse M, et al. **J Acoust Soc Am** 1995 Sep;98(3):1410–22

Convergence of somatosensory and auditory projections in the avian torus semicircularis, including the central auditory nucleus. Wild JM. **J Comp Neurol** 1995 Aug 7; 358(4):465–86

Two voltage–dependent K+ conductances with complementary functions in postsynaptic integration at a central auditory synapse. Brew HM, et al. **J Neurosci** 1995 Dec;15(12):8011–22

Whole–cell patch–clamp recording reveals subthreshold

sound-evoked postsynaptic currents in the inferior colliculus of awake bats. Covey E, et al. **J Neurosci** 1996 May 1;16(9):3009-18

Development of glycinergic and glutamatergic synaptic transmission in the auditory brainstem of perinatal rats. Kandler K, et al. **J Neurosci** 1995 Oct;15(10):6890-904

Changes of synaptic efficacy in the medial geniculate nucleus as a result of auditory classical conditioning. McEchron MD, et al. **J Neurosci** 1996 Feb 1;16(3):1273-83

In vitro analysis of optimal stimuli for phase-locking and time-delayed modulation of firing in avian nucleus laminaris neurons. Reyes AD, et al. **J Neurosci** 1996 Feb 1;16(3):993-1007

Pharmacological characterization of presynaptic calcium currents underlying glutamatergic transmission in the avian auditory brainstem. Sivaramakrishnan S, et al. **J Neurosci** 1995 Oct;15(10):6576-85

A rapid correlation method for the analysis of spectro-temporal receptive fields of auditory neurons. Richard JP, et al. **J Neurosci Methods** 1995 Sep-Oct; 61(1-2):99-103

Functional magnetic resonance imaging of the central auditory pathway following speech and pure-tone stimuli. Millen SJ, et al. **Laryngoscope** 1995 Dec;105(12 Pt 1):1305-10

Resonant tectorial membrane motion in the inner ear: its crucial role in frequency tuning. Gummer AW, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8727-32

PHYSIOPATHOLOGY

Auditory neurophysiologic responses and discrimination deficits in children with learning problems [see comments] Kraus N, et al. **Science** 1996 Aug 16;273(5277):971-3. Comment in: Science 1996 Aug 16;273(5277):867.

ULTRASTRUCTURE

Distribution of synapses on two local auditory interneurones, ON1 and ON2, in the prothoracic ganglion of the cricket: relationships with GABA-immunoreactive neurones. Watson AH, et al. **Cell Tissue Res** 1996 Feb;283(2):231-46

AUDITORY PERCEPTION

The management of drug-resistant, persistent and unpleasant auditory hallucinations. Lecompte D. **Acta Psychiatr Belg** 1996 Jan-Feb;96(1):21-9 (21 ref.)

Clinical characteristics of auditory hallucinations. Oulis PG, et al. **Acta Psychiatr Scand** 1995 Aug;92(2):97-102

New-onset auditory hallucinations after right temporal lobectomy [letter] Bremer J. **Am J Psychiatry** 1996 Mar; 153(3):442-3

Auditory psychophysics and perception. Hirsh IJ, et al. **Annu Rev Psychol** 1996;47:461-84 (110 ref.)

Re: Cobb FE: Age-associated degeneration of backward masking task performance: evidence of declining temporal resolution abilities in normal listeners [letter] Cobb FE. **Audiology** 1995 May-Jun;34(3):160

On mechanical preprocessing in the cochlea: the three great hearing theories combined. Fritze W. **Biochem Biophys Res Commun** 1996 Jun 14;223(2):211-5

A pilot study of exposure control of chronic auditory hallucinations in schizophrenia. Persaud R, et al. **Br J Psychiatry** 1995 Jul;167(1):45-50

The functional anatomy of recovery from auditory agnosia. A PET study of sound categorization in a neurological patient and normal controls. Engelien A, et al. **Brain** 1995 Dec;118 (Pt 6):1395-409

Preoperative and postoperative analysis of visual and auditory memory in children with cerebellar tumors. Lazareff JA, et al. **Childs Nerv Syst** 1996 Feb;12(2):81-6

Asymmetric headturning to speech and nonspeech in human newborns. Ecklund-Flores L, et al. **Dev Psychobiol** 1996 Apr;29(3):205-17

Contributions of experience to the development of musical processing in infancy. Lynch MP, et al. **Dev Psychobiol** 1995 Nov;28(7):377-98

Effects of reference interaural time and intensity differences on binaural performance in listeners with normal and impaired hearing. Koehnke J, et al. **Ear Hear** 1995 Aug; 16(4):331-53

Cortical stimulation elicits regional distinctions in auditory and visual naming. Malow BA, et al. **Epilepsia** 1996 Mar; 37(3):245-52

Application of a three-dimensional auditory display in a flight task. Bronkhorst AW, et al. **Hum Factors** 1996 Mar; 38(1):23-33

Musical versus visual graphs: cross-modal equivalence in perception of time series data. Flowers JH, et al. **Hum Factors** 1995 Sep;37(3):553-69

Abnormalities of ABR and auditory perception test findings in acquired palatal myoclonus. Kurauchi T, et al. **Int J Neurosci** 1996 Apr;85(3-4):273-83

Effects of modality shift and motor response shift on simple reaction time in schizophrenia patients. Hanewinkel R, et al. **J Abnorm Psychol** 1996 Aug;105(3):459-63

Template-based automatic recognition of birdsong syllables from continuous recordings. Anderson SE, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1209-19

Comments on "Manipulations of the duration and relative onsets of two-tone forward maskers" [J. Acoust. Soc. Am. 94, 1269-1274 (1993)] [letter] Bacon SP. **J Acoust Soc Am** 1996 May;99(5):3246-8

Auditory attentional bandwidth: effect of level and frequency range. Botte MC. **J Acoust Soc Am** 1995 Nov;98(5 Pt 1):2475-85

Masker asynchrony impairs the fundamental-frequency discrimination of unresolved harmonics. Carlyon RP. **J Acoust Soc Am** 1996 Jan;99(1):525-33

On measuring psychometric functions: a comparison of the constant-stimulus and adaptive up-down methods. Dai H. **J Acoust Soc Am** 1995 Dec;98(6):3135-9

The perception of frequency peaks and troughs in wide frequency modulations. III. Complex carriers. Demany L, et al. **J Acoust Soc Am** 1995 Nov;98(5 Pt 1):2515-23

Spectral weights for overall level discrimination in listeners with sensorineural hearing loss. Doherty KA, et al. **J Acoust Soc Am** 1996 Feb;99(2):1053-8

The effect of distractor frequency on judgments of target laterality based on interaural delays. Dye RH Jr, et al. **J Acoust Soc Am** 1996 Feb;99(2):1096-107

Age effects on duration discrimination with simple and complex stimuli. Fitzgibbons PJ, et al. **J Acoust Soc Am** 1995 Dec;98(6):3140-5

The use of cumulative distributions to determine critical values and levels of confidence for clinical distortion product otoacoustic emission measurements. Gorga MP, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):968-77

Across-frequency processing of multiple modulation patterns. Grose JH, et al. **J Acoust Soc Am** 1996 Jan; 99(1):534-41

The perceptual magnet effect as an emergent property of neural map formation. Guenther FH, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1111-21

Gap detection for pairs of noise bands: effects of stimulus level and frequency separation. Hall JW 3rd, et al. **J Acoust Soc Am** 1996 Feb;99(2):1091-5

Extents of laterality and binaural interference effects. Heller LM, et al. **J Acoust Soc Am** 1996 Jun;99(6):3632-7

Some factors influencing comodulation masking release and across-channel masking. Hicks ML, et al. **J Acoust Soc Am** 1995 Nov;98(5 Pt 1):2504-14

Sound orientation behavior in cats. II. Mid-frequency spectral cues for sound localization. Huang AY, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1070-80

Binaural advantage for sound pattern identification. Kidd G Jr, et al. **J Acoust Soc Am** 1995 Oct;98(4):1977-86

Detection of frequency changes in transposed sequences of tones. Kidd GR, et al. **J Acoust Soc Am** 1996 Jan; 99(1):553-66

Placement of observations for the efficient estimation of a psychometric function. Lam CF, et al. **J Acoust Soc Am** 1996 Jun;99(6):3689-93

Perceptual constancy of a global spectral property: spectral slope discrimination. Li X, et al. **J Acoust Soc Am** 1995 Oct;98(4):1956-68

The perceptual dimensions of single-electrode and nonsimultaneous dual-electrode stimuli in cochlear implantees. McKay CM, et al. **J Acoust Soc Am** 1996 Feb; 99(2):1079-90

Sound orientation behavior in cats. I. Localization of broadband noise. May BJ, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1059-69

The probe-signal method and auditory-filter shape: results from normal- and hearing-impaired subjects. Moore BC, et al. **J Acoust Soc Am** 1996 Jan;99(1):542-52

Detection of decrements and increments in sinusoids at high overall levels. Moore BC, et al. **J Acoust Soc Am** 1996 Jun;99(6):3669-77

The effect of level and relative frequency region on the recovery of overshoot. Overson GJ, et al. **J Acoust Soc Am** 1996 Feb;99(2):1059-65

Time-domain modeling of peripheral auditory processing: a modular architecture and a software platform. Patterson RD, et al. **J Acoust Soc Am** 1995 Oct;98(4):1890-4

Temporal factors in referential intensity coding. Plack CJ. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1031-42

Some considerations on the use of adaptive methods for estimating interaural-delay thresholds [letter] Saberi K. **J Acoust Soc Am** 1995 Sep;98(3):1803-6

Observer weighting of concurrent binaural information. Stellmack MA, et al. **J Acoust Soc Am** 1996 Jan; 99(1):579-87

Toward optimizing the clinical utility of distortion product otoacoustic emission measurements. Stover L, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):956-67

Cues for discrimination of envelopes. Strickland EA, et al. **J Acoust Soc Am** 1996 Jun;99(6):3638-46

Gap detection in infants, children, and adults. Trehub SE, et al. **J Acoust Soc Am** 1995 Nov;98(5 Pt 1):2532-41

Detectability of simultaneously masked signals as a function of signal bandwidth for different signal delays. Wright BA. **J Acoust Soc Am** 1995 Nov;98(5 Pt 1):2493-503

Auditory filter shapes at high frequencies. Zhou B. **J Acoust Soc Am** 1995 Oct;98(4):1935-42

Evaluation of a maximum likelihood procedure for measuring pure-tone thresholds under computer control. Formby C, et al. **J Am Acad Audiol** 1996 Apr;7(2):125-9

Effects of age, signal level, and signal rate on the auditory middle latency response. Tucker DA, et al. **J Am Acad Audiol** 1996 Apr;7(2):83-91

Identification performance by right- and left-handed listeners on dichotic CV materials. Wilson RH, et al. **J Am Acad Audiol** 1996 Jan;7(1):1-6

Prenatal auditory experience directs species-typical perceptual responsiveness in bobwhite quail chicks (Colinus virginianus). McBride T, et al. **J Comp Psychol** 1995 Sep; 109(3):321-9

Early auditory experience and the ontogeny of alarm-call discrimination in Belding's ground squirrels (Spermophilus beldingi). Mateo JM. **J Comp Psychol** 1996 Jun; 110(2):115-24

Ultrasound acoustic startle response in scarab beetles. Forrest TG, et al. **J Exp Biol** 1995 Dec;198 (Pt 12):2593-8

Speeding up an internal clock in humans? Effects of click trains on subjective duration. Penton-Voak IS, et al. **J Exp Psychol Anim Behav Process** 1996 Jul;22(3):307-20

Asymmetrical perception of changing intensity in short tonal stimuli: duration of stimulus. Reinhardt-Rutland AH. **J Gen Psychol** 1996 Apr;123(2):115-22

Visual and auditory information as determinants of primacy effects. Sharps MJ, et al. **J Gen Psychol** 1996 Apr; 123(2):123-36

Patients' strategies for coping with auditory hallucinations. Carter DM, et al. **J Nerv Ment Dis** 1996 Mar;184(3):159-64

Perceptual and conceptual cueing in implicit and explicit retrieval. Challis BH, et al. **Memory** 1993 Jun;1(2):127-51

Similarity as an organising principle in short-term memory. LeCompte DC, et al. **Memory** 1993 Mar;1(1):3-22

Auditory sensitization during the perception of acoustical negative afterimages: analogies to visual processing? Wiegrebe L, et al. **Naturwissenschaften** 1995 Aug; 82(8):387-9

Habituation and sensitization of the acoustic startle response in rats: amplitude, threshold, and latency measures. Pilz PKD, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):67-79

Comments to dr. LeBlanc's report. Iwanaga M. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1293-4

Differing results in research on preference for music tempo. LeBlanc A. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1253-4

Temporal coupling between external auditory information and the phases of walking. Mauerberg E, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):851-61

An experimental test of "the mozart effect": does listening to his music improve spatial ability? Newman J, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1379-87

Auditory isochrony: time shrinking and temporal patterns. ten Hoopen G, et al. **Perception** 1995;24(5):577-93

Aging and experience in the recognition of musical transpositions. Halpern AR, et al. **Psychol Aging** 1995 Sep; 10(3):325-42

Perceptual scaling of synthesized musical timbres: common dimensions, specificities, and latent subject classes. McAdams S, et al. **Psychol Res** 1995;58(3):177-92

An auditory illusion predicted from a weighted cross-correlation model of binaural interaction. Saberi K. **Psychol Rev** 1996 Jan;103(1):137-42

Priming the identification of environmental sounds. Stuart GP, et al. **Q J Exp Psychol A** 1995 Aug;48(3):741-61

The perceptual centre of a stimulus as the cue for synchronization to a metronome: evidence from asynchronies. Vos PG, et al. **Q J Exp Psychol A** 1995 Nov; 48(4):1024-40

Calibration of ipsilateral stimulus transducer for acoustic reflex measurements. Olsen S, et al. **Scand Audiol** 1995; 24(3):161-4

Ipsilateral acoustic reflex thresholds at varying click rates in humans. Rawool VW. **Scand Audiol** 1995;24(3):199-205

Effect of contralateral white noise masking on the mismatch negativity. Salo SK, et al. **Scand Audiol** 1995;24(3):165-73

Categorical perception of sound frequency by crickets. Wyttenbach RA, et al. **Science** 1996 Sep 13; 273(5281):1542-4

[The assessment of the noise factor and the state of the auditory analyzer in workers in metal rolling production] Ivanovich E, et al. **Probl Khig** 1995;20:100-9 (Eng. Abstr.) **(Bul)**

[Differential aspects of subjective burden of tinnitus aurium] Perrig-Chiello P, et al. **Psychother Psychosom Med Psychol** 1996 Mar-Apr; 46(3-4):139-46 (Eng. Abstr.) **(Ger)**

[An analytical study on recognition confusion of vowels in patients with 22 channel cochlear implant] Momoi T. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Aug;98(8):1318-22 (Eng. Abstr.) **(Jpn)**

[Model for isolating spectral maxima of an acoustic signal at the first levels of the hearing system] Arkhipenko SA, et al. **Biofizika** 1996 Mar-Apr;41(2):463-70 (Eng. Abstr.) **(Rus)**

[Effect of microphone potential feedback on formation of adjusted curves of the hearing periphery] Babkina LN, et al. **Biofizika** 1996 Mar-Apr;41(2):471-8 (Eng. Abstr.) **(Rus)**

[History of hearing perception. Different shapes of hearing aids: from the "cupped hand" to cochlear implants] Hansson H, et al. **Lakartidningen** 1995 Dec 20;92(51-52):4891-6 **(Swe)**

DRUG EFFECTS

Differential effects of glucocorticoids on human auditory perception. Fehm-Wolfsdorf G, et al. **Biol Psychol** 1996 Jan 5;42(1-2):117-30

Auditory cerebral lateralization following cross-gender hormone therapy. Cohen H, et al. **Cortex** 1995 Sep; 31(3):565-73

Scopolamine administered before and after training impairs

both contextual and auditory-cue fear conditioning. Rudy JW. **Neurobiol Learn Mem** 1996 Jan;65(1):73–81

[A model for the study of the ototoxic effects of drugs in an experiment] Fisenko VP, et al. **Vestn Otorinolaringol** 1996 Jan–Feb;(1):25–8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Effect of driving speed on reaction time during motorway driving. Törnros J. **Accid Anal Prev** 1995 Aug;27(4):435–42

Short latency vestibular evoked responses to linear acceleration stimuli in small mammals: masking effects and experimental applications. Böhmer A. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:120–3

Central auditory processing: a view from auditory neuroscience. Phillips DP. **Am J Otol** 1995 May; 16(3):338–52 (88 ref.)

Auditory attentional deficits in patients with schizophrenia. A positron emission tomography study. O'Leary DS, et al. **Arch Gen Psychiatry** 1996 Jul;53(7):633–41

Disruptive effects of posttraining perirhinal cortex lesions on conditioned fear: contributions of contextual cues. Corodimas KP, et al. **Behav Neurosci** 1995 Aug; 109(4):613–9

Amygdala central nucleus lesions attenuate acoustic startle stimulus-evoked heart rate changes in rats. Young BJ, et al. **Behav Neurosci** 1996 Apr;110(2):228–37

P300 from auditory stimuli: intensity and frequency effects. Sugg MJ, et al. **Biol Psychol** 1995 Nov 16;41(3):255–69

Functional neuroanatomy of verbal self-monitoring. McGuire PK, et al. **Brain** 1996 Jun;119 (Pt 3):907–17

Hearing and saying. The functional neuro-anatomy of auditory word processing. Price CJ, et al. **Brain** 1996 Jun; 119 (Pt 3):919–31

Selective impairment of auditory attention following closed head injuries or right cerebrovascular accidents. Keller I, et al. **Brain Res Cogn Brain Res** 1995 Dec;3(1):9–15

Hearing. Asking the auditory cortex the right question. King AJ. **Curr Biol** 1995 Oct 1;5(10):1110–3 (23 ref.)

Augmented prenatal visual stimulation alters postnatal auditory and visual responsiveness in bobwhite quail chicks. Sleigh MJ, et al. **Dev Psychobiol** 1995 Nov;28(7):353–66

Synaesthesia: reconciling the subjective with the objective. Harrison J, et al. **Endeavour** 1995;19(4):157–60 (20 ref.)

The effect of eye position on auditory lateralization. Lewald J, et al. **Exp Brain Res** 1996 Mar;108(3):473–85

Perception of spectrally and temporally complex sounds by the goldfish (Carassius auratus). Fay RR. **Hear Res** 1995 Sep;89(1–2):146–54

Development of auditory information integration abilities. Allen P, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1043–51

On the relation between comodulation masking release and temporal modulation transfer functions. Berg BG. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1013–23

A quantitative model of the "effective" signal processing in the auditory system. I. Model structure. Dau T, et al. **J Acoust Soc Am** 1996 Jun;99(6):3615–22

A quantitative model of the "effective" signal processing in the auditory system. II. Simulations and measurements. Dau T, et al. **J Acoust Soc Am** 1996 Jun;99(6):3623–31

Preservation of amplitude modulation coding in the presence of background noise by chinchilla auditory-nerve fibers. Frisina RD, et al. **J Acoust Soc Am** 1996 Jan;99(1):475–90

Sound transmission to and within the human ear canal. Hammershøi D, et al. **J Acoust Soc Am** 1996 Jul; 100(1):408–27

Functional development of auditory sensitivity in the fetus and neonate. Sohmer H, et al. **J Basic Clin Physiol Pharmacol** 1995;6(2):95–108 (74 ref.)

Postmetamorphic changes in auditory sensitivity of the bullfrog midbrain. Boatright-Horowitz SS, et al. **J Comp Physiol [A]** 1995 Nov;177(5):577–90

Responses to simulated echoes by neurons in the barn owl's auditory space map. Keller CH, et al. **J Comp Physiol [A]** 1996 Apr;178(4):499–512

Effects of auditory stimuli on intracranial pressure and cerebral perfusion pressure in traumatic brain injury. Schinner KM, et al. **J Neurosci Nurs** 1995 Dec;27(6):348–54

Short note: on the unpleasantness of certain harsh sounds. Ramachandran VS. **Med Hypotheses** 1996 May;46(5):487

The audiogenic startle response in Tourette's syndrome. Stell R, et al. **Mov Disord** 1995 Nov;10(6):723–30

Enhancement of selective listening by illusory mislocation of speech sounds due to lip-reading. Driver J. **Nature** 1996 May 2;381(6577):66–8

A neuronal learning rule for sub-millisecond temporal coding. Gerstner W, et al. **Nature** 1996 Sep 5; 383(6595):76–81

Functional anatomy of a common semantic system for words and pictures. Vandenberghe R, et al. **Nature** 1996 Sep 19; 383(6597):254–6

Perception of music by infants [letter] Zentner MR, et al. **Nature** 1996 Sep 5;383(6595):29

Time can be traded for intensity in the lower auditory system. Grothe B, et al. **Naturwissenschaften** 1995 Nov;82(11):521–3

Neural correlates of gap detection and auditory fusion in cat auditory cortex. Eggermont JJ. **Neuroreport** 1995 Aug 21;6(12):1645–8

Intelligible speech encoded in the human brain stem frequency-following response. Galbraith GC, et al. **Neuroreport** 1995 Nov 27;6(17):2363–7

Changes in alertness are a principal component of variance in the EEG spectrum. Makeig S, et al. **Neuroreport** 1995 Dec 29;7(1):213–6

Spectral responses in the gamma-band: physiological signs of higher cognitive processes? Pulvermüller F, et al. **Neuroreport** 1995 Oct 23;6(15):2059–64

From objective to subjective: pitch representation in the human auditory cortex. Winkler I, et al. **Neuroreport** 1995 Nov 27;6(17):2317–20

Role of the activation of the intralaminar nuclei of the thalamus in regulating the participation of the neostriatal cholinergic system in the differentiation of acoustic signals in dogs. Shapalova KB, et al. **Neurosci Behav Physiol** 1995 Nov–Dec;25(6):504–7

An auditory event related potential evaluation of sonar task experience and age. Merrill LL, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1363–76

Calmodulin controls adaptation of mechanoelectrical transduction by hair cells of the bullfrog's sacculus. Walker RG, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5; 93(5):2203–7

Schizophrenic auditory hallucinations are associated with increased regional cerebral blood flow during verbal memory activation in a study using single photon emission computed tomography. Busatto GF, et al. **Psychiatry Res** 1995 Nov 10;61(4):255–64

A controlled positron emission tomography study of obsessive and neutral auditory stimulation in obsessive-compulsive disorder with checking rituals. Cottraux J, et al. **Psychiatry Res** 1996 Mar 29; 60(2–3):101–12

Processing of complex sounds in the human auditory cortex as revealed by magnetic brain responses. Alho K, et al. **Psychophysiology** 1996 Jul;33(4):369–75

Naming norms for brief environmental sounds: effects of age and dementia. Fabiani M, et al. **Psychophysiology** 1996 Jul; 33(4):462–75

Newly learned auditory responses mediated by NMDA receptors in the owl inferior colliculus. Feldman DE, et al. **Science** 1996 Jan 26;271(5248):525–8

[Cortical mechanisms of auditive perception in man: contribution of cerebral potentials and evoked magnetic fields by auditive stimulations] Liégeois-Chauvel C, et al. **Rev Neurol (Paris)** 1995 Aug–Sep;151(8–9):495–504 (Eng. Abstr.) **(Fre)**

[Prenatal auditory perception—on the relevance of new concepts of perception] Schmidt HU, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):M125–8 (13 ref.) **(Ger)**

[Auditory comprehension in transcortical motor aphasia due to a medial lesions of the left frontal lobe] Otsuki M, et al. **No To Shinkei** 1995 Nov;47(11):1081–5 (Eng. Abstr.) **(Jpn)**

[Disorders of perception of stimulus intensity in peripheral involvement of the sound-perceiving apparatus] Petrov SM. **Fiziol Cheloveka** 1995 Jul–Aug;21(4):167–70 **(Rus)**

[The auditory perception of frequency-localized acoustic on-events] Liublinskaia VV, et al. **Fiziol Zh Im I M Sechenova** 1995 Jul;81(7):120–30 (Eng. Abstr.) **(Rus)**

[The discrimination by the long-tailed Arctic suslik Citellus parryi of short frequency-modulated sounds] Movchan VN. **Zh Evol Biokhim Fiziol** 1994 Sep–Oct;30(5):712–4 (Eng. Abstr.) **(Rus)**

AUDITORY PERCEPTUAL DISORDERS

COMPLICATIONS

Auditory hallucinations and perception of external speech [letter; comment] Colover J. **Lancet** 1995 Oct 14; 346(8981):1036. Comment on: Lancet 1995 Sep 2;346(8975):596–600.

Auditory hallucinations and perception of external speech [letter; comment] Lawrie SM, et al. **Lancet** 1995 Oct 14; 346(8981):1036. Comment on: Lancet 1995 Sep 2;346(8975):596–600.

DIAGNOSIS

The development and reliability of the Mental Health Research Institute Unusual Perceptions Schedule (MUPS): an instrument to record auditory hallucinatory experience. Carter DM, et al. **Schizophr Res** 1995 Aug 1;16(2):157–65

ETIOLOGY

Is central hyperacusis a symptom of 5-hydroxytryptamine (5-HT) dysfunction? Marriage J, et al. **J Laryngol Otol** 1995 Oct;109(10):915–21 (73 ref.)

PHYSIOPATHOLOGY

Absence of ear advantage on the consonant-vowel dichotic listening test in adolescent and adult dyslexics: specific auditory-phonetic dysfunction. Hugdahl K, et al. **J Clin Exp Neuropsychol** 1995 Dec;17(6):833–40

Learning defect identified in brain [news; comment] Barinaga M. **Science** 1996 Aug 16;273(5277):867–8. Comment on: Science 1996 Aug 16;273(5277):971–3.

Auditory neurophysiologic responses and discrimination deficits in children with learning problems [see comments] Kraus N, et al. **Science** 1996 Aug 16;273(5277):971–3. Comment in: Science 1996 Aug 16;273(5277):867.

[Reliability of brain stem audiometry in specific learning disorders (disorders of sensory integration)] von Deuster C, et al. **Laryngorhinootologie** 1995 Sep;74(9):539–42 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

[Acoustic and optical perceptual disorders in depressive diseases--an overview of results from experimental studies] Kallert TW. **Schweiz Arch Neurol Psychiatr** 1996; 147(1):4–11 (61 ref.) (Eng. Abstr.) **(Ger)**

AUDITORY PROSTHESIS see **COCHLEAR IMPLANT**

AUDITORY STIMULATION see **ACOUSTIC STIMULATION**

AUDITORY THRESHOLD

see related

AUDIOMETRY

Comparison of tympanic membrane-recorded electrocochleography and the auditory brainstem response in threshold determination. Laureano AN, et al. **Am J Otol** 1995 Mar;16(2):209–15

The automated prediction of hearing thresholds in sleeping subjects using auditory steady-state evoked potentials. Rance G, et al. **Ear Hear** 1995 Oct;16(5):499–507

Thresholds for auditory brain stem responses to tones in notched noise from infants and young children with normal hearing or sensorineural hearing loss. Stapells DR, et al. **Ear Hear** 1995 Aug;16(4):361–71

Audiogram construction using frequency-specific auditory brainstem response (ABR) thresholds. Frattali MA, et al. **Ear Nose Throat J** 1995 Oct;74(10):691–4, 696, 698, passim

Evaluation of noise-induced hearing loss by reference to the upper limit of hearing. Morioka I, et al. **Int Arch Occup Environ Health** 1995;67(5):301–4

Identification of childhood hearing impairment in Uusimaa County, Finland. Marttila TI, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):45–51

Stimulus features affecting psychophysical detection thresholds for electrical stimulation of the cochlea. III. Pulse polarity. Coste RL, et al. **J Acoust Soc Am** 1996 May;99(5):3099–108

Vowel discrimination in cats: thresholds for the detection of second formant changes in the vowel /epsilon/. Hienz RD, et al. **J Acoust Soc Am** 1996 Aug;100(2 Pt 1):1052–8

Slopes of distortion-product otoacoustic emission growth curves corrected for noise-floor levels. Nelson DA, et al. **J Acoust Soc Am** 1996 Jan;99(1):468–74

Misdiagnosis of hearing loss due to ear canal collapse: a report of two cases. Mahoney CF, et al. **J Laryngol Otol** 1996 Jun;110(6):561–6

Temporary and permanent threshold shift caused by hearing aid use. Macrae JH. **J Speech Hear Res** 1995 Aug; 38(4):949–59

Evaluating hearing threshold differences between ears as a screen for acoustic neuroma. Schlauch RS, et al. **J Speech Hear Res** 1995 Oct;38(5):1168–75

Age-related alterations in the auditory brainstem responses and the compound action potentials in guinea pigs. Nozawa I, et al. **Laryngoscope** 1996 Aug;106(8):1034–9

A threshold model analysis of deafness in Dalmatians. Famula TR, et al. **Mamm Genome** 1996 Sep;7(9):650–3

The precision level of the objective hearing tests. Podoshin L, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(5):373–5

Preferred test conditions for determining hearing thresholds for standardization. ISO/TC 43/WG 1 Threshold of hearing. International Organization for Standardization Technical Committee 43. **Scand Audiol** 1996;25(1):45–52

Ipsilateral acoustic reflex thresholds at varying click rates in humans. Rawool VW. **Scand Audiol** 1995;24(3):199–205

[Referential value of auditory threshold depending on age] Giordano G. **Acta Otorhinolaryngol Ital** 1995 Jun; 15(3):198–204 (Eng. Abstr.) **(Ita)**

DRUG EFFECTS

Effect of intratympanically administered gentamicin on hearing and tinnitus in Menière's disease. Kaasinen S, et al. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:184–5

Effects of prenatal alcohol exposure and aging on auditory function in the rat: preliminary results. Church MW, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):172–9

Salicylate-induced changes in auditory thresholds of adolescent and adult rats. Brennan JF, et al. **Dev Psychobiol** 1996 Jan;29(1):69–86

Auditory brainstem responses of CBA/J mice with neonatal conductive hearing losses and treatment with GM1 ganglioside. Money MK, et al. **Hear Res** 1995 Jul; 87(1–2):104–13

Combined effects of noise and chemicals. Fechter LD. **Occup Med** 1995 Jul–Aug;10(3):609–21 (51 ref.)

[Reduced nutritional status enhances ototoxicity] Lautermann J, et al. **Laryngorhinootologie** 1995 Dec;74(12):724–7 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Age-related changes in auditory evoked potentials of gerbils. III. Low-frequency responses and repetition rate effects. Boettcher FA, et al. **Hear Res** 1995 Jul;87(1–2):208–19

A two-filter model for frequency discrimination. Dai H, et al. **Hear Res** 1995 May;85(1-2):109-14

The relationship between sound transfer functions and hearing levels. Hellström PA. **Hear Res** 1995 Aug; 88(1-2):54-60

Development of the VIIIth nerve compound action potential evoked by low-intensity tone pips in the Mongolian gerbil. Huang JM, et al. **Hear Res** 1995 Aug;88(1-2):14-8

Responses of neurons in the inferior colliculus of the rat to interaural time and intensity differences in transient stimuli: Implications for the latency hypotheses. Irvine DR, et al. **Hear Res** 1995 May;85(1-2):127-41

Comodulation masking release in a songbird. Klump GM, et al. **Hear Res** 1995 Jul;87(1-2):157-64

Masking and pitch shift of tone bursts and clicks by low-frequency tones. Mrowinski D, et al. **Hear Res** 1995 May;85(1-2):95-102

Estimating the contribution of non-sensory factors to infant-adult differences in behavioral thresholds. Nozza RJ. **Hear Res** 1995 Nov;91(1-2):72-8

Effects of electrode configuration on threshold functions for electrical stimulation of the cochlea. Pfingst BE, et al. **Hear Res** 1995 May;85(1-2):76-84

Middle latency responses to acoustical and electrical stimulation of the cochlea in cats. Popelář J, et al. **Hear Res** 1995 Dec;92(1-2):63-77

Ontogeny of hearing in the marsupial, Monodelphis domestica, as revealed by brainstem auditory evoked potentials. Reimer K. **Hear Res** 1995 Dec;92(1-2):143-50

Envelope-following response and modulation transfer function in the dolphin's auditory system. Supin AY, et al. **Hear Res** 1995 Dec;92(1-2):38-46

Sensorineural hearing loss alters recovery from short-term adaptation in the C57BL/6 mouse. Walton JP, et al. **Hear Res** 1995 Aug;88(1-2):19-26

Genetics of age-related hearing loss in mice. II. Strain differences and effects of caloric restriction on cochlear pathology and evoked response thresholds. Willott JF, et al. **Hear Res** 1995 Aug;88(1-2):143-55

Responses of pontine neurons of the big brown bat, Eptesicus fuscus, to temporally patterned sound pulses. Wu MI, et al. **Hear Res** 1995 May;85(1-2):155-68

Lateralization and discrimination of dichotic clicks: evidence from patients with brainstem lesions and normal cohorts. Furst M, et al. **J Basic Clin Physiol Pharmacol** 1995; 6(2):149-71

ABR interpeak latencies in rats are shorter at low click intensities. Levi H, et al. **J Basic Clin Physiol Pharmacol** 1995;6(2):129-38

Neural correlates of gap detection and auditory fusion in cat auditory cortex. Eggermont JJ. **Neuroreport** 1995 Aug 21;6(12):1645-8

[Reaction times at auditory threshold: a comparison of normal hearing probands and patients with hearing damage] Hustert B, et al. **Laryngorhinootologie** 1996 Mar; 75(3):135-40 (Eng. Abstr.) **(Ger)**

[Detection of hearing loss in patrons of a discoteque using TEOAE and DPOAE] Liebel J, et al. **Laryngorhinootologie** 1996 May;75(5):259-64 (Eng. Abstr.) **(Ger)**

[Changes in the auditory threshold for air and bone conduction in relation to middle ear pressure in probands with normal hearing] Maier W, et al. **Laryngorhinootologie** 1995 Sep;74(9):525-30 (Eng. Abstr.) **(Ger)**

[Specificity and sensitivity of transient click-evoked otoacoustic emissions (TEOAE)] Pröschel U, et al. **Laryngorhinootologie** 1995 Aug;74(8):481-8 (Eng. Abstr.) **(Ger)**

[Diagnosis of auditory threshold with frequency-specific recording of auditory evoked potentials: personal results and methodological aspects] Schönweiler R, et al. **Laryngorhinootologie** 1995 Sep;74(9):531-8 (Eng. Abstr.) **(Ger)**

[A longitudinal study of hearing level aggravation due to aging] Ono Y. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Apr; 99(4):558-66 (Eng. Abstr.) **(Jpn)**

[A delay in the development of auditory sensitivity in nestlings and the reorganization of their feeding behavior] Aleksandrov LI. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Sep-Oct;45(5):1047-50 **(Rus)**

AUDITORY TUBE see **EUSTACHIAN TUBE**

AUERBACH'S PLEXUS see **MYENTERIC PLEXUS**

AUJESZKY'S DISEASE see **PSEUDORABIES**

AUJESZKY'S DISEASE VIRUS see **HERPESVIRUS 1, SUID**

AURANOFIN

PHARMACOLOGY

Auranofin inhibits the induction of interleukin 1 beta and tumor necrosis factor alpha mRNA in macrophages. Bondeson J, et al. **Biochem Pharmacol** 1995 Nov 27; 50(11):1753-9

Auranofin inhibits calcium uptake into opsonized-zymosan-stimulated neutrophils obtained from rats. Ishitani K, et al. **Inflamm Res** 1995 Nov;44(11):482-5

THERAPEUTIC USE

The effect of auranofin and sulphasalazine therapy on circulating levels of interleukin 6 in rheumatoid arthritis patients. Crilly A, et al. **Clin Rheumatol** 1995 Sep; 14(5):561-5

A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. Bernstein IL, et al. **J Allergy Clin Immunol** 1996 Aug;98(2):317-24

Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis--a double blind study. Rao UR, et al. **J Rheumatol** 1995 Jul;22(7):1235-40

AUREOLIC ACID see **PLICAMYCIN**

AURICULAR FIBRILLATION see **ATRIAL FIBRILLATION**

AURICULAR FLUTTER see **ATRIAL FLUTTER**

AURICULIN see **ATRIAL NATRIURETIC FACTOR**

AURICULO-VENTRICULAR DISSOCIATION see **HEART BLOCK**

AURICULOTEMPORAL SYNDROME see **SWEATING, GUSTATORY**

AURINTRICARBOXYLATE see **AURINTRICARBOXYLIC ACID**

AURINTRICARBOXYLIC ACID

ANALOGS & DERIVATIVES

Correlation of anti-HIV potency with lipophilicity in a series of cosalane analogs having normal alkenyl and phosphodiester chains as cholestane replacements. Keyes RF, et al. **J Med Chem** 1996 Jan 19;39(2):508-14

PHARMACOLOGY

Studies on the effect of aurintricarboxylic acid (ATA) on cell proliferation of renewable epithelial tissues in the mouse. Bassukas ID, et al. **In Vivo** 1995 May-Jun; 9(3):219-23

The effect of aurintricarboxylic acid, an endonuclease inhibitor, on ischemia/reperfusion damage in rat retina. Lam TT, et al. **J Ocul Pharmacol Ther** 1995 Fall; 11(3):253-9

Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions. Golino P, et al. **Thromb Haemost** 1995 Sep;74(3):974-9

Inhibition of NAD(H)/NADP(H)--requiring enzymes by aurintricarboxylic acid. Thompson DC, et al. **Toxicol Lett** 1995 Nov 15;81(2-3):141-9

AUROTHIOGLUCOSE

Insulin response to a spontaneously ingested standard meal during the development of obesity in GTG-injected mice. Blair SC, et al. **Int J Obes Relat Metab Disord** 1996 Apr; 20(4):319-23

PHARMACOLOGY

Effects of gold thioglucose on neuropeptide Y messenger RNA levels in the mouse hypothalamus. Marks JL, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):R1208-14

Insulin stimulation of mitogen-activated protein kinase, p90rsk, and p70 S6 kinase in skeletal muscle of normal and insulin-resistant mice. Implications for the regulation of glycogen synthase. Chang PY, et al. **J Biol Chem** 1995 Dec 15;270(50):29928-35

AUROTHIOMALATE see **GOLD SODIUM THIOMALATE**

AUROVERTINS

CHEMISTRY

The structure of bovine F1-ATPase complexed with the antibiotic inhibitor aurovertin B. van Raaij MJ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6913-7

METABOLISM

The structure of bovine F1-ATPase complexed with the antibiotic inhibitor aurovertin B. van Raaij MJ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6913-7

AUSCULTATION

see related
HEART AUSCULTATION
STETHOSCOPES

Assessment of lung auscultation by paramedics. Wigder HN, et al. **Ann Emerg Med** 1996 Sep;28(3):309-12

The role of occlusal auscultation in assessing dental occlusions. Tyson KW. **Br Dent J** 1996 Apr 20; 180(8):307-10

Acoustic properties of the normal chest. Dalmay F, et al. **Eur Respir J** 1995 Oct;8(10):1761-9 (68 ref.)

Chest percussion. Yernault JC, et al. **Eur Respir J** 1995 Oct; 8(10):1756-60 (33 ref.)

Is listening for abdominal bruits useful in the evaluation of hypertension? Turnbull JM. **JAMA** 1995 Oct 25; 274(16):1299-301 (26 ref.)

Ambient noise interferes with auscultatory blood pressure measurement during exercise. Lightfoot JT, et al. **Med Sci Sports Exerc** 1996 Apr;28(4):502-8

Incidence of intracranial bruits in neonates. Friederich RL, et al. **Pediatr Neurol** 1996 Feb;14(2):129-30

Use of tracheal auscultation for the assessment of bronchial responsiveness in asthmatic children. Sprikkelman AB, et al. **Thorax** 1996 Mar;51(3):317-9

[Stethoscopy of carotid artery--for what purpose? (letter)] Sillesen HH, et al. **Ugeskr Laeger** 1995 Nov 20;157(47):6595 **(Dan)**

[Do we know enough about pulmonary sounds? (letter)] Johnson B. **Tidsskr Nor Laegeforen** 1996 Feb 20;116(5):656 **(Nor)**

HISTORY

90th Anniversary of the development by Nikolai S. Korotkoff of the auscultatory method of measuring blood pressure [news] Shevchenko YL, et al. **Circulation** 1996 Jul 15; 94(2):116-8

Henry Ingersoll Bowditch. Fye WB. **Clin Cardiol** 1995 Nov; 18(11):685-6

INSTRUMENTATION

Contaminated stethoscopes revisited. Smith MA, et al. **Arch Intern Med** 1996 Jan 8;156(1):82-4

METHODS

Bio-acoustic signals from stenotic tube flow: state of the art and perspectives for future methodological development. Ask P, et al. **Med Biol Eng Comput** 1995 Sep;33(5):669-75 (29 ref.)

Localization of knee joint cartilage pathology by multichannel vibroarthrography. Shen Y, et al. **Med Eng Phys** 1995 Dec;17(8):583-94

Interrater reliability of auscultation of breath sounds among physical therapists. Brooks D, et al. **Phys Ther** 1995 Dec; 75(12):1082-8

AUSTRALIA ANTIGEN see **HEPATITIS B SURFACE ANTIGENS**

AUSTRALOID RACE

An investigation into the disparity between Australian aboriginal and Caucasian perinatal mortality rates. Coory M. **Ann Epidemiol** 1995 Sep;5(5):393-9

Risk factors for ill-health in a remote desert-dwelling aboriginal community in Western Australia. Gracey M, et al. **Aust N Z J Med** 1996 Apr;26(2):171-9

Discoid erythematosus in Australian aborigines [letter; comment] Green A. **Australas J Dermatol** 1995 Aug; 36(3):175-7. Comment on: Australas J Dermatol 1995 Feb;36(1):3-10; quiz 11-2.

New World syndrome in Western Australian aborigines. Gracey M. **Clin Exp Pharmacol Physiol** 1995 Mar; 22(3):220-5 (38 ref.)

Risk factors for diabetes and cardiovascular disease in young Australian aborigines. A 5-year follow-up study. Braun B, et al. **Diabetes Care** 1996 May;19(5):472-9

Does rheumatoid arthritis exist in the indigenous Australian Aboriginal population? [letter] Douglas WA. **Med J Aust** 1996 Feb 5;164(3):191-2

High and low roads to aboriginal health [letter; comment] Griffiths SE. **Med J Aust** 1995 Oct 2;163(7):392. Comment on: Med J Aust 1995 Jul 17;163(2):97-9.

Renal disease in Australian aboriginals [editorial] Hoy WE. **Med J Aust** 1996 Aug 5;165(3):126-7

Does rheumatoid arthritis exist in the indigenous Australian aboriginal population? [letter] Roberts-Thomson PJ. **Med J Aust** 1995 Oct 16;163(8):444-5

High and low roads to aboriginal health [letter] Scrimgeour DJ, et al. **Med J Aust** 1995 Nov 20;163(10):557-8

Asthma and atopy in four rural Australian aboriginal communities. Veale AJ, et al. **Med J Aust** 1996 Aug 19; 165(4):192-6

Glomerular disease in whites versus Australian aboriginals: 'last of a race in ruin' (G.K. Chesterton) [editorial] Seymour AE. **Nephrol Dial Transplant** 1995;10(6):769-70

GENETICS

Multiple independent origins of the COII/tRNA(Lys) intergenic 9-bp mtDNA deletion in aboriginal Australians [letter] Betty DJ, et al. **Am J Hum Genet** 1996 Feb; 58(2):428-33

An ancient common origin of aboriginal Australians and New Guinea highlanders is supported by alpha-globin haplotype analysis. Roberts-Thomson JM, et al. **Am J Hum Genet** 1996 May;58(5):1017-24

Systemic lupus erythematosus (SLE): different prevalences in different populations of Australian aborigines [letter] Anstey NM, et al. **Aust N Z J Med** 1995 Dec;25(6):736

Distribution of HLA DQA.1 alleles in New Zealand Caucasian, Maori and Pacific Islander populations.

AUSTRALOID RACE

Comparison with other population studies. Stringer P, et al. **Int J Legal Med** 1995;108(1):2–7

Marfan syndrome in aboriginals [letter] Adès LC. **Med J Aust** 1996 Jan 1;164(1):54–5

AUSTRALORBIS see **BIOMPHALARIA**

AUTACOIDS

see related
NEUROTRANSMITTERS

Three autacoids—endogenous digitalis-like factor, clonidine-displacing substance, and quinidine-like immunoreactivity. Kölbel F, et al. **Sb Lek** 1995; 96(4):405–15 (65 ref.)

ANTAGONISTS & INHIBITORS

KW-4679, an antiallergic drug, inhibits the production of inflammatory lipids in human polymorphonuclear leukocytes and guinea pig eosinophils. Ikemura T, et al. **Int Arch Allergy Immunol** 1996 May;110(1):57–63

BIOSYNTHESIS

KW-4679, an antiallergic drug, inhibits the production of inflammatory lipids in human polymorphonuclear leukocytes and guinea pig eosinophils. Ikemura T, et al. **Int Arch Allergy Immunol** 1996 May;110(1):57–63

PHARMACOLOGY

Effects of variation in oxygen tension on responses of the human fetoplacental vasculature to vasoactive agents in vitro. Read MA, et al. **Placenta** 1995 Dec;16(8):667–78

AUTHORITARIANISM

Adolescents' conceptions of teachers' authority and their relations to rule violations in school. Smetana JG, et al. **Child Dev** 1996 Jun;67(3):1153–72

Self-reported narcissism and perceived parental permissiveness and authoritarianism. Ramsey A, et al. **J Genet Psychol** 1996 Jun;157(2):227–38

Conservative orientation as a determinant of hopelessness. Cheung CK, et al. **J Soc Psychol** 1996 Jun;136(3):333–47

The production of authoritative knowledge in American prenatal care. Browner CH, et al. **Med Anthropol Q** 1996 Jun;10(2):141–56

Intuition as authoritative knowledge in midwifery and homebirth. Davis-Floyd R, et al. **Med Anthropol Q** 1996 Jun;10(2):237–69

The social production of authoritative knowledge in pregnancy and childbirth. Davis-Floyd R, et al. **Med Anthropol Q** 1996 Jun;10(2):111–20

Authoritative knowledge and birth territories in contemporary Japan. Fiedler DC. **Med Anthropol Q** 1996 Jun;10(2):195–212

Intuition and the emergence of midwifery as authoritative knowledge. Gaskin IM. **Med Anthropol Q** 1996 Jun; 10(2):295–8

Fetal ultrasound imaging and the production of authoritative knowledge in Greece. Georges E. **Med Anthropol Q** 1996 Jun;10(2):157–75

Authority and authoritative knowledge in American birth. Hays BM. **Med Anthropol Q** 1996 Jun;10(2):291–4

Maternal health, war, and religious tradition: authoritative knowledge in Pujehun District, Sierra Leone. Jambai A, et al. **Med Anthropol Q** 1996 Jun;10(2):270–86

Changes in clinical practice in response to reductions in reimbursement: physician autonomy and resistance to bureaucratization. Posner KL, et al. **Med Anthropol Q** 1995 Dec;9(4):476–92

Ways of knowing about birth in three cultures. Sargent C, et al. **Med Anthropol Q** 1996 Jun;10(2):213–36

"Women come here on their own when they need to": prenatal care, authoritative knowledge, and maternal health in Oaxaca. Sesia PM. **Med Anthropol Q** 1996 Jun; 10(2):121–40

The evolution of bipedalism and assisted birth. Trevathan WR. **Med Anthropol Q** 1996 Jun;10(2):287–90

Authoritarianism and projection. Lewis CA, et al. **Psychol Rep** 1995 Oct;77(2):362

["New" authoritarianism and right extremism. A time-related diagnostic conjecture] Brede K. **Psyche (Stuttg)** 1995 Nov; 49(11):1019–42 (Eng. Abstr.) **(Ger)**

AUTHORSHIP

Ethics and journal publishing: taking the debate forward. Why it is helpful to know the funding source [letter] Caswell S. **Addiction** 1995 Oct;90(10):1317–8

Ethics and journal publishing: taking the debate forward. Ethics as everyone's business [letter] Chowdhury AN. **Addiction** 1995 Oct;90(10):1318–20

Ethics and journal publishing: taking the debate forward. Ethics of refereeing re-examined [letter] Heok KE. **Addiction** 1995 Oct;90(10):1311–2

Ethics and journal publishing: taking the debate forward. Ethics and the incentive structure [letter] Maynard A. **Addiction** 1995 Oct;90(10):1320–1

Ethics and journal publishing: taking the debate forward. Evolving standards for authorship [letter] Room R. **Addiction** 1995 Oct;90(10):1321–2

Ethics and journal publishing: taking the debate forward. The sensible way forward [letter] Saxena S. **Addiction** 1995 Oct;90(10):1312–3

Ethics and journal publishing: taking the debate forward. A first kick [letter] Seijas D. **Addiction** 1995 Oct; 90(10):1315–6

Ethics and journal publishing: taking the debate forward. The ordeals of editors [letter] [see comments] Yankauer A. **Addiction** 1995 Oct;90(10):1309–11. Comment in: Addiction 1996 Jul;91(7):1063–4.

Coauthors' contributions to major papers published in the AJR: frequency of undeserved coauthorship. Slone RM. **AJR Am J Roentgenol** 1996 Sep;167(3):571–9

Some thoughts and reflections on authorship. Jones AW. **Alcohol Alcohol** 1996 Jan;31(1):11–5

How many are too many? [letter; comment] Kumar A. **Am J Gastroenterol** 1995 Oct;90(10):1899–900. Comment on: Am J Gastroenterol 1995 Apr;90(4):677–8.

Clarification of source [letter] Brucker MC. **Am J Obstet Gynecol** 1995 Dec;173(6):1899–900

Authors interactive: AJO on the Internet [editorial] Straatsma BR. **Am J Ophthalmol** 1995 Oct;120(4):523–4

Misrepresentation of research publications among emergency medicine residency applicants [see comments] Gurudevan SV, et al. **Ann Emerg Med** 1996 Mar;27(3):327–30. Comment in: Ann Emerg Med 1996 Mar;27(3):366–7.

Misrepresentation of resident credentials [editorial; comment] Knopp RK. **Ann Emerg Med** 1996 Mar;27(3):366–7. Comment on: Ann Emerg Med 1995 Mar;27(3):327–30.

Authorship. A matter of concern [editorial] Bribiesca LB. **Arch Med Res** 1996 Summer;27(2):105–6

Prior authorship [letter; comment] Komisar A. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):207. Comment on: Arch Otolaryngol Head Neck Surg 1994 Jun;120(6):676.

Redefining authorship. Relative contribution should be given after each author's name [letter; comment] Foulkes W, et al. **BMJ** 1996 Jun 1;312(7043):1423. Comment on: BMJ 1996 Mar 23;312(7033):723.

Definition of authorship may be changed [news] Godlee F. **BMJ** 1996 Jun 15;312(7045):1501–2

Time to redefine authorship [editorial] [see comments] Horton R, et al. **BMJ** 1996 Mar 23;312(7033):723. Comment in: BMJ 1996 Jun 1;312(7043):1423.

Redefining authorship. Drug industry is increasingly allowing employees to be named as authors [letter; comment] Wager E. **BMJ** 1996 Jun 1;312(7043):1423. Comment on: BMJ 1996 Mar 23;312(7033):723.

Case reports and confidentiality [letter] Bronks IG. **Br J Psychiatry** 1995 Oct;167(4):552–4

Verbal creativity, depression and alcoholism. An investigation of one hundred American and British writers. Post F. **Br J Psychiatry** 1996 May;168(5):545–55

Systematization of academic and scientific affiliation, or how to prevent data on your publications from being lost in the national and international data base. Meneghini R. **Braz J Med Biol Res** 1995 Jun;28(6):617–9

Authorship in anaesthesia journals [letter] Gajraj NM, et al. **Can J Anaesth** 1995 Aug;42(8):749–50

Ethical responsibilities in scientific publication [editorial] Rosner F. **Cancer Invest** 1996;14(5):503–5

The use of interferon for the treatment of viral hepatitis in pediatric liver transplant recipients [letter] Nour B, et al. **J Okla State Med Assoc** 1995 Sep;88(9):406–7

Promoting scientific integrity in nursing research, Part II: Strategies. Ketefian S, et al. **J Prof Nurs** 1995 Sep–Oct; 11(5):263–9

Great researcher ... good teacher? Melland HI. **J Prof Nurs** 1996 Jan–Feb;12(1):31–8

Multiple authorship: trends over 50 years in the Journal of Studies on Alcohol [letter] Howard MO, et al. **J Stud Alcohol** 1996 Jan;57(1):105–6

What does authorship mean in a peer-reviewed medical journal? [editorial] Lundberg GD, et al. **JAMA** 1996 Jul 3;276(1):75

Signing up for authorship. Horton R, et al. **Lancet** 1996 Mar 23;347(9004):780

Polyauthoritis giftosa [letter] Kapoor VK. **Lancet** 1995 Oct 14;346(8981):1039

Signing up for authorship [letter] Simon D, et al. **Lancet** 1996 May 18;347(9012):1412

International collaboration [letter] Katz JS, et al. **Nature** 1996 May 2;381(6577):16

ISI miscount? [letter; comment] [see comments] Persson O. **Nature** 1996 Mar 14;380(6570):100. Comment on: Nature 1996 Jan 25;379(6563):287. Comment in: Nature 1996 May 2;381(6577):15.

Author—what does it mean to be one? [editorial] Anderson CA. **Nurs Outlook** 1995 Sep–Oct;43(5):199–200

Who qualifies as a coauthor? [editorial] Walton RE. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Oct;80(4):377

Dissemination of the work of public health medicine trainees in peer-reviewed publications: an unfulfilled potential. Donaldson IJ, et al. **Public Health** 1996 Jan;110(1):61–3

Anonymity in peer review—time for a change? Clayson DB. **Regul Toxicol Pharmacol** 1995 Aug;22(1):101

Editor and authors: common way. Battistella LR. **Rev Paul Med** 1995 Jan–Feb;113(1):675–7

Lights, camera ... and action! [letter; comment] Chen C. **Science** 1995 Oct 6;270(5233):14. Comment on: Science 1995 Jun 23;268(5218):1679.

Authorship disputes [letter; comment] McCutchen CW. **Science** 1995 Dec 8;270(5242):1557. Comment on: Science 1995 Sep 29;269(5232):1811.

Urgently needed: policies on access to data by erstwhile collaborators [see comments] Mishkin B. **Science** 1995 Nov 10;270(5238):927–8. Comment in: Science 1995 Dec 15;270(5243):1741. Comment in: Science 1996 Jan 12;271(5246):129–30.

[Number of authors in Actas Urológicas Españolas] Fariña LA. **Actas Urol Esp** 1996 Feb;20(2):194–8 (Eng. Abstr.) **(Spa)**

[Collective authorship (letter)] Ramalle-Gómara E. **Med Clin (Barc)** 1996 May 18;106(19):756 **(Spa)**

AUTISM

Diagnosis, treatment, and neurobiology of autism in children. Lainhart JE, et al. **Curr Opin Pediatr** 1995 Aug; 7(4):392–400 (89 ref.)

Autism: talking in a world without language. Fagan LL. **JAMA** 1996 Feb 7;275(5):417

CEREBROSPINAL FLUID

Gangliosides in children with autism. Lekman A, et al. **Acta Paediatr** 1995 Jul;84(7):787–90

COMPLICATIONS

EEG features and epilepsy in patients with autism [see comments] Rossi PG, et al. **Brain Dev** 1995 May–Jun; 17(3):169–74. Comment in: Brain Dev 1995 Sep–Oct;17(5):362.

Autism and multiple pituitary deficiency. Gingell K, et al. **Dev Med Child Neurol** 1996 Jun;38(6):545–9

Preventing factitious gingival injury in an autistic patient. Johnson CD, et al. **J Am Dent Assoc** 1996 Feb;127(2):244–7

Repeated pseudo-obstruction, mental subnormality—and serious snags. Guy RJ, et al. **J R Nav Med Serv** 1995 Summer;81(2):117–9

DIAGNOSIS

Autism: time for a national approach to early assessment and management [editorial] Tonge BJ. **Med J Aust** 1996 Sep 2;165(5):244–5

DRUG THERAPY

The effective treatment of severe repetitive behaviour with fluvoxamine in a 20 year old autistic female. Harvey RJ, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):201–3

[Effects of naltrexone on automutilation behavior in autistic psychosis (letter)] Decocq G, et al. **Presse Med** 1996 Feb 24;25(7):305 **(Fre)**

EPIDEMIOLOGY

Hypoplasia of the cerebellar vermis in neurogenetic syndromes. Schaefer GB, et al. **Ann Neurol** 1996 Mar; 39(3):382–5

Autism spectrum disorders in children with physical or mental disability or both. II: Screening aspects. Nordin V, et al. **Dev Med Child Neurol** 1996 Apr;38(4):314–24

Autism spectrum disorders in children with physical or mental disability or both. I: Clinical and epidemiological aspects. Nordin V, et al. **Dev Med Child Neurol** 1996 Apr; 38(4):297–313

Circannual pattern of autistic births: reanalysis in three ethnic groups. Ticher A, et al. **Hum Biol** 1996 Aug;68(4):585–92

Autism in Angelman syndrome: a population-based study. Steffenburg S, et al. **Pediatr Neurol** 1996 Feb;14(2):131–6

ETIOLOGY

An enzyme/brain-barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism, schizophrenia and postpartum psychosis. Seim AR, et al. **Med Hypotheses** 1995 Nov;45(5):498–502 (36 ref.)

Increased frequency of the extended or ancestral haplotype B44-SC30-DR4 in autism. Daniels WW, et al. **Neuropsychobiology** 1995;32(3):120–3

Autism, mental retardation, multiple exostoses and short stature in a female with 46,X,t(X;8)(p22.13;q22.1). Bolton P, et al. **Psychiatr Genet** 1995 Summer;5(2):51–5

GENETICS

Cytogenetic and molecular analysis of inv dup(15) chromosomes observed in two patients with autistic disorder and mental retardation. Flejter WL, et al. **Am J Med Genet** 1996 Jan 11;61(2):182–7

Male-to-male transmission in extended pedigrees with multiple cases of autism. Hallmayer J, et al. **Am J Med Genet** 1996 Feb 16;67(1):13–8

Autism and genetics: clinical approach and association study with two markers of HRAS gene. Hérault J, et al. **Am J Med Genet** 1995 Aug 14;60(4):276–81

Autism, affective disorders, and social phobia. Smalley SL, et al. **Am J Med Genet** 1995 Feb 27;60(1):19–26

Verbal skills in relatives of autistic females. Plumet MH, et al. **Cortex** 1995 Dec;31(4):723–33

Strong association of the third hypervariable region of HLA-DR beta 1 with autism. Warren RP, et al. **J Neuroimmunol** 1996 Jul;67(2):97–102

Increased frequency of the extended or ancestral haplotype

B44-SC30-DR4 in autism. Daniels WW, et al. **Neuropsychobiology** 1995;32(3):120-3

IMMUNOLOGY

Strong association of the third hypervariable region of HLA-DR beta 1 with autism. Warren RP, et al. **J Neuroimmunol** 1996 Jul;67(2):97-102

PATHOLOGY

Hippocampus in autism: a Golgi analysis. Raymond GV, et al. **Acta Neuropathol (Berl)** 1996;91(1):117-9

Autism, macrocrania and epilepsy: a syndrome? [letter; comment] Andermann F. **Brain Dev** 1995 Sep-Oct; 17(5):362. Comment on: Brain Dev 1995 May-Jun;17(3):169-74.

PHYSIOPATHOLOGY

Autism spectrum disorders in children with physical or mental disability or both. I: Clinical and epidemiological aspects. Nordin V, et al. **Dev Med Child Neurol** 1996 Apr; 38(4):297-313

Hemispheric function in developmental language disorders and high-level autism. Shields J, et al. **Dev Med Child Neurol** 1996 Jun;38(6):473-86

PSYCHOLOGY

Verbal skills in relatives of autistic females. Plumet MH, et al. **Cortex** 1995 Dec;31(4):723-33

Autism spectrum disorders in children with physical or mental disability or both. II: Screening aspects. Nordin V, et al. **Dev Med Child Neurol** 1996 Apr;38(4):314-24

Social cognition in developmental language disorders and high-level autism. Shields J, et al. **Dev Med Child Neurol** 1996 Jun;38(6):487-95

THERAPY

On the reinforcing effects of the content of verbal attention. Fisher WW, et al. **J Appl Behav Anal** 1996 Summer; 29(2):235-8

URINE

Analysis of urinary pterins in autism. Harrison KL, et al. **Biochem Soc Trans** 1995 Nov;23(4):603S

AUTISM, INFANTILE

Autistic spectrum disorders [editorial] Wing L. **BMJ** 1996 Feb 10;312(7027):327-8

The State of the Science in Autism. Conference proceedings. Bethesda, Maryland, April 1995. **J Autism Dev Disord** 1996 Apr;26(2):115-280 (0 ref.)

State of the science in autism: report to the National Institutes Health. Bristol MM, et al. **J Autism Dev Disord** 1996 Apr; 26(2):121-54 (0 ref.)

Control of action and thought: normal development and dysfunction in autism: a research note. Hughes C. **J Child Psychol Psychiatry** 1996 Feb;37(2):229-36

Can children with autism be taught to understand false belief using computers? Swettenham J. **J Child Psychol Psychiatry** 1996 Feb;37(2):157-65

[Infantile autism in France in 1994] Golse B. **Psychiatr Enfant** 1995;38(2):463-76 (23 ref.) (Eng. Abstr.) **(Fre)**

[One child out of a thousand is affected by autism. Sweden has leading position in pediatric neurology/psychiatry] Gillberg C. **Lakartidningen** 1996 Mar 13;93(11):1033-4 **(Swe)**

BLOOD

Low serum tryptophan to large neutral amino acids ratio in idiopathic infantile autism. D'Eufemia P, et al. **Biomed Pharmacother** 1995;49(6):288-92

Plasma androgens in autism. Tordjman S, et al. **J Autism Dev Disord** 1995 Jun;25(3):295-304

CLASSIFICATION

Subgroups of autistic children based on social behavior display distinct patterns of brain activity. Dawson G, et al. **J Abnorm Child Psychol** 1995 Oct;23(5):569-83

COMPLICATIONS

Levels of autistic behaviour among the mentally handicapped children in Zimbabwe. Khan N, et al. **Cent Afr J Med** 1996 Feb;42(2):36-9

A group therapy program for individuals identified as autistic who are without speech and use facilitated communication. Eliasoph E, et al. **Int J Group Psychother** 1995 Oct; 45(4):549-60

From categorization to classification: a comparison among individuals with autism, mental retardation, and normal development. Shulman C, et al. **J Abnorm Psychol** 1995 Nov;104(4):601-9

[Clinical-radiological evaluation of infantile autism and epileptic syndromes associated with autism] Carod FJ, et al. **Rev Neurol** 1995 Nov-Dec;23(124):1203-7 (Eng. Abstr.) **(Spa)**

[Autistic syndrome associated with refractory temporal epilepsy] Carracedo A, et al. **Rev Neurol** 1995 Nov-Dec; 23(124):1239-41 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Autistic behaviors in offspring of mothers abusing alcohol and other drugs: a series of case reports. Harris SR, et al. **Alcohol Clin Exp Res** 1995 Jun;19(3):660-5

Current research findings on childhood autism. Sigman M, et al. **Can J Psychiatry** 1995 Aug;40(6):289-94 (48 ref.)

Neuropathological study of a case of autistic syndrome with severe mental retardation. Guerin P, et al. **Dev Med Child Neurol** 1996 Mar;38(3):203-11

The sleep/wake rhythm in children with autism. Richdale AL, et al. **Eur Child Adolesc Psychiatry** 1995 Jul; 4(3):175-86

Identification of behaviour profiles with a population of autistic children using multivariate statistical methods. Roux S, et al. **Eur Child Adolesc Psychiatry** 1995 Oct; 4(4):249-58

Case study: anorexia nervosa and autistic disorder in an adolescent girl. Fisman S, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):937-40

Asperger's syndrome and autism: differences in behavior, cognition, and adaptive functioning. Szatmari P, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1662-71

Asperger's syndrome [clinical conference] Volkmar FR, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan; 35(1):118-23

Consultation with young autistic children and their families. Wakschlag LS, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):963-5

Disorders of regulation of cognitive activity in autistic children. Adrien JL, et al. **J Autism Dev Disord** 1995 Jun; 25(3):249-63

Brief report: the impact of regression on language development in autism. Brown J, et al. **J Autism Dev Disord** 1995 Jun;25(3):305-9

Brief report: neuropsychology of autism: a report on the state of the science. Dawson G. **J Autism Dev Disord** 1996 Apr; 26(2):179-84 (38 ref.)

The pre-linguistic autism diagnostic observation schedule. DiLavore PC, et al. **J Autism Dev Disord** 1995 Aug; 25(4):355-79

Brief report: neuroimaging in autism: the state of the science 1995. Filipek PA. **J Autism Dev Disord** 1996 Apr; 26(2):211-5 (21 ref.)

Brief report: response to National Institutes of Health report. Grandin T. **J Autism Dev Disord** 1996 Apr;26(2):185-7

An examination of the phenomenology and the reliability of ratings of compulsive behavior in autism. McBride JA, et al. **J Autism Dev Disord** 1995 Aug;25(4):381-96

Brief report: communication, language, social, and emotional development. Prizant BM. **J Autism Dev Disord** 1996 Apr; 26(2):173-8

Brief report: a life-span perspective on the development of individuals with autism. Schroeder SR, et al. **J Autism Dev Disord** 1996 Apr;26(2):251-5

Brief report: current theory and research on language and communication in autism. Tager-Flusberg H. **J Autism Dev Disord** 1996 Apr;26(2):169-72

Brief report: diagnostic issues in autism: results of the DSM-IV field trial. Volkmar FR. **J Autism Dev Disord** 1996 Apr;26(2):155-7

Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives. Bailey A, et al. **J Child Psychol Psychiatry** 1996 Jan; 37(1):89-126 (280 ref.)

Validity and neuropsychological characterization of Asperger syndrome: convergence with nonverbal learning disabilities syndrome. Klin A, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1127-40

Schizoid personality in girls: a follow-up study--what are the links with Asperger's syndrome? Wolff S, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):793-817

Obstetric factors in Asperger syndrome: comparison with high-functioning autism. Ghaziuddin M, et al. **J Intellect Disabil Res** 1995 Dec;39 (Pt 6):538-43

Differential diagnostics and treatment of an inpatient adolescent showing pervasive developmental disorder and mania. Atlas JA, et al. **Psychol Rep** 1995 Aug;77(1):207-10

Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children. Armenteros JL, et al. **Psychopharmacol Bull** 1995;31(2):363-9

Characteristics of autism as assessed by the Diagnostic Assessment for the Severely Handicapped-II (DASH-II). Matson JL, et al. **Res Dev Disabil** 1996 Mar-Apr; 17(2):135-43

Asperger's syndrome: a report of two cases from Malaysia. Kasmini K, et al. **Singapore Med J** 1995 Dec;36(6):641-3

[Prevalence of autistic states in a cohort of very young children followed up in home care] Drossart F, et al. **Acta Psychiatr Belg** 1995 May-Jun;95(3):122-38 (64 ref.) (Eng. Abstr.) **(Fre)**

[Clinical-radiological evaluation of infantile autism and epileptic syndromes associated with autism] Carod FJ, et al. **Rev Neurol** 1995 Nov-Dec;23(124):1203-7 (Eng. Abstr.) **(Spa)**

[It is unfortunate to make a diagnosis based on news advertisement (letter)] Lidberg L, et al. **Lakartidningen** 1995 Sep 27;92(39):3550 **(Swe)**

DRUG THERAPY

Clinical effects of clozapine on autistic disorder [letter] Zuddas A, et al. **Am J Psychiatry** 1996 May;153(5):738

Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. Aman MG, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1672-81

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1124-32 (132 ref.)

Enuresis with combined risperidone and SSRI use [letter] Took KJ, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):840-1

Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism. Komori H, et al. **J Autism Dev Disord** 1995 Apr;25(2):183-93

Brief report: variables related to parental choice to medicate their autistic children. Konstantareas M, et al. **J Autism Dev Disord** 1995 Aug;25(4):443-52

Brief report: psychopharmacology of autism spectrum disorders. Lewis MH. **J Autism Dev Disord** 1996 Apr; 26(2):231-5 (11 ref.)

Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes. Pfeiffer SI, et al. **J Autism Dev Disord** 1995 Oct; 25(5):481-93 (36 ref.)

Use of methylphenidate in the treatment of children with autistic disorder. Quintana H, et al. **J Autism Dev Disord** 1995 Jun;25(3):283-94

Sertraline response in adults with mental retardation and autistic disorder. Hellings JA, et al. **J Clin Psychiatry** 1996 Aug;57(8):333-6

Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Bouvard MP, et al. **Psychiatry Res** 1995 Oct 16;58(3):191-201

Placebo-controlled acute dosage naltrexone study in young autistic children. Willemsen-Swinkels SH, et al. **Psychiatry Res** 1995 Oct 16;58(3):203-15

A comparison of live and videotape ratings: clomipramine and haloperidol in autism. Sanchez LE, et al. **Psychopharmacol Bull** 1995;31(2):371-8

[Psychopharmacology of autism] Chabrol H, et al. **Encephale** 1996 May-Jun;22(3):197-203 (40 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Crystallization and preliminary structural analysis of Bacillus subtilis adenylosuccinate lyase, an enzyme implicated in infantile autism. Redinbo MR, et al. **Protein Sci** 1996 Apr; 5(4):786-8

EPIDEMIOLOGY

No association between prenatal exposure to influenza and autism. Dassa D, et al. **Acta Psychiatr Scand** 1995 Aug; 92(2):145-9

Hypoplasia of the cerebellar vermis in neurogenetic syndromes. Schaefer GB, et al. **Ann Neurol** 1996 Mar; 39(3):382-5

Brief report: epidemiology of autism. Bryson SE. **J Autism Dev Disord** 1996 Apr;26(2):165-7

Questionnaire screening for comorbid pervasive developmental disorders in congenitally blind children: a pilot study. Goodman R, et al. **J Autism Dev Disord** 1995 Apr;25(2):195-203

Brief report: comorbid psychiatric disorders of autistic disorder. Tsai LY. **J Autism Dev Disord** 1996 Apr; 26(2):159-63

ETIOLOGY

Autism and medical disorders: a review of the literature. Gillberg C, et al. **Dev Med Child Neurol** 1996 Mar; 38(3):191-202 (75 ref.)

Autism research: prospects and priorities. Rutter M. **J Autism Dev Disord** 1996 Apr;26(2):257-75 (50 ref.)

Brief report: genetic, prenatal, and immunologic factors. Smalley SL, et al. **J Autism Dev Disord** 1996 Apr; 26(2):195-8 (16 ref.)

[Theoretical perspectives on autism] Klin A, et al. **Psychiatr Enfant** 1995;38(2):477-94 (14 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Brief report: atypical autism and tuberous sclerosis in a sibling pair. Williamson DA, et al. **J Autism Dev Disord** 1995 Aug; 25(4):435-42

The abilities of a musical savant and his family. Young RL, et al. **J Autism Dev Disord** 1995 Jun;25(3):231-48

HISTORY

Itard's 1828 mémoire on "Mutism caused by a lesion of the intellectual functions": a historical analysis. Carrey NJ. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1655-61

[Follow-up study of eleven autistic children originally reported in 1943. 1971 (classical article) (see comments)] Kanner L. **Psychiatr Enfant** 1995;38(2):421-61 (Eng. Abstr.). Comment in: Psychiatr Enfant 1995;38(2):413-9.

(Fre)
[Introductory comment on the translation of Leo Kanner's article: "Follow-up study of eleven autistic children originally reported in 1943. Journal of Autism and Childhood Schizophrenia, 1971, 1-2, 119-145 (comment)] Sanchez-Cardenas M, et al. **Psychiatr Enfant** 1995; 38(2):413-9. Comment on: Psychiatr Enfant 1995;38(2):421-61. (Fre)

IMMUNOLOGY

Brief report: allergological evaluation of children with autism. Renzoni E, et al. **J Autism Dev Disord** 1995 Jun; 25(3):327-33

PATHOLOGY

Brief report: neuroanatomic observations of the brain in pervasive developmental disorders. Bauman ML. **J Autism Dev Disord** 1996 Apr;26(2):199-203 (18 ref.)

Brief report: the role of National Brain and Tissue Banks in research on autism and developmental disorders. Zielke HR, et al. **J Autism Dev Disord** 1996 Apr;26(2):227-30

PHYSIOPATHOLOGY

Clinical and neurophysiological aspects of epilepsy in subjects with autism and mental retardation. Elia M, et al. **Am J Ment Retard** 1995 Jul;100(1):6-16

Auditory event-related brain potentials in autistic children and three different control groups. Kemner C, et al. **Biol Psychiatry** 1995 Aug 1;38(3):150-65

Plasma beta-endorphin concentrations in people with learning disability and self-injurious and/or autistic behaviour. Willemsen-Swinkels SH, et al. **Br J Psychiatry** 1996 Jan;168(1):105-9

An exploration of right-hemisphere contributions to the pragmatic impairments of autism. Ozonoff S, et al. **Brain Lang** 1996 Mar;52(3):411-34

Brief report: medial temporal lobe and autism: a putative animal model in primates. Bachevalier J. **J Autism Dev Disord** 1996 Apr;26(2):217-20 (5 ref.)

Brief report: pathophysiology of autism: neurochemistry. Cook EH Jr. **J Autism Dev Disord** 1996 Apr;26(2):221-5 (11 ref.)

Sensory modulation of auditory stimuli in children with autism and receptive developmental language disorder: event-related brain potential evidence. Lincoln AJ, et al. **J Autism Dev Disord** 1995 Oct;25(5):521-39

Brief report: brain mechanisms in autism: functional and structural abnormalities. Minshew NJ. **J Autism Dev Disord** 1996 Apr;26(2):205-9 (6 ref.)

Brief report: developmental neurobiological aspects of autism. Voeller KK. **J Autism Dev Disord** 1996 Apr; 26(2):189-93 (9 ref.)

Right-hemisphere dysfunction in Asperger's syndrome. McKelvey JR, et al. **J Child Neurol** 1995 Jul;10(4):310-4

Psychophysiological aspects of autistic disorders: overview. Murray JB. **J Psychol** 1996 Mar;130(2):145-58 (95 ref.)

Neurofunctional mechanisms in autism. Waterhouse L, et al. **Psychol Rev** 1996 Jul;103(3):457-89 (280 ref.)

PSYCHOLOGY

Functional communication training for the treatment of multiply determined challenging behavior in two boys with autism. Sigafoos J, et al. **Behav Modif** 1996 Jan;20(1):60-84

Autistic defenses and the impairment of cognitive development. Kilchenstein MW, et al. **Bull Menninger Clin** 1995 Fall;59(4):443-59

Siblings of a child with autism, with mental retardation and with a normal development. Roeyers H, et al. **Child Care Health Dev** 1995 Sep;21(5):305-19

Brief report: thought disorder in Asperger syndrome: comparison with high-functioning autism. Ghaziuddin M, et al. **J Autism Dev Disord** 1995 Jun;25(3):311-7

Is it possible to assess the impact of abuse on children with pervasive developmental disorders? Howlin P, et al. **J Autism Dev Disord** 1995 Aug;25(4):337-54

Generativity in the play of young people with autism. Lewis V, et al. **J Autism Dev Disord** 1995 Apr;25(2):105-21

Brief report: assessing allegations of sexual molestation made through facilitated communication. Siegel B. **J Autism Dev Disord** 1995 Jun;25(3):319-26

Obstetrical suboptimality in children with autism: an Italian sample [letter] Zambrino CA, et al. **J Autism Dev Disord** 1995 Oct;25(5):553-5

The development of emotional concepts in autism. Bormann-Kischkel C, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1243-59

Proximity and sociable behaviours in autism: evidence for attachment. Dissanayake C, et al. **J Child Psychol Psychiatry** 1996 Feb;37(2):149-56

Sibling interaction of children with learning disabilities: a comparison of autism and Down's syndrome. Knott F, et al. **J Child Psychol Psychiatry** 1995 Sep;36(6):965-76

Executive functions and developmental psychopathology. Pennington BF, et al. **J Child Psychol Psychiatry** 1996 Jan; 37(1):51-87 (225 ref.)

Savants, segments, art and autism. Pring L, et al. **J Child Psychol Psychiatry** 1995 Sep;36(6):1065-76

Simple reaction times and timing of serial reactions of adolescents with mental retardation, autism, and Down syndrome. Inui N, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 1):739-45

Perspective production in a savant autistic draughtsman. Mottron L, et al. **Psychol Med** 1995 May;25(3):639-48

[Clinical guide scale for the developmental stages of treated autism] Haag G, et al. **Psychiatr Enfant** 1995;38(2):495-527 (Eng. Abstr.) (Fre)

[Theoretical perspectives on autism] Klin A, et al. **Psychiatr Enfant** 1995;38(2):477-94 (14 ref.) (Eng. Abstr.) (Fre)

RADIONUCLIDE IMAGING

SPECT of the brain in childhood autism: evidence for a lack of normal hemispheric asymmetry. Chiron C, et al. **Dev Med Child Neurol** 1995 Oct;37(10):849-60

Glucose metabolic correlates of continuous performance test performance in adults with a history of infantile autism, schizophrenics, and controls. Siegel BV Jr, et al. **Schizophr Res** 1995 Sep;17(1):85-94

REHABILITATION

Teaching theory of mind: a new approach to social skills training for individuals with autism. Ozonoff S, et al. **J Autism Dev Disord** 1995 Aug;25(4):415-33

Participation of children with autism and nondisabled peers in a cooperatively structured community art program. Schleien SJ, et al. **J Autism Dev Disord** 1995 Aug; 25(4):397-413

Collaboration between research professional and consumer. Schopler E. **J Autism Dev Disord** 1996 Apr;26(2):277-80

Teaching symbolic play skills to children with autism using pivotal response training. Stahmer AC. **J Autism Dev Disord** 1995 Apr;25(2):123-41

THERAPY

Maintaining instructional behavior after on-the-job training with process-based performance feedback. Arco L, et al. **Behav Modif** 1996 Jul;20(3):300-20

Applied behavioral analysis: astonishing results? [letter; comment] Shapiro T, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1255-6. Comment on: J Am Acad Child Adolesc Psychiatry 1995 Feb;34(2):232-7.

Pyramidal parent training by peers. Neef NA. **J Appl Behav Anal** 1995 Fall;28(3):333-7

Increasing complex social behaviors in children with autism: effects of peer-implemented pivotal response training. Pierce K, et al. **J Appl Behav Anal** 1995 Fall;28(3):285-95

Analysis of free-time contingencies as positive versus negative reinforcement. Zarcone JR, et al. **J Appl Behav Anal** 1996 Summer;29(2):247-50

Increasing reading and communication skills in children with autism through an interactive multimedia computer program. Heimann M, et al. **J Autism Dev Disord** 1995 Oct;25(5):459-80

Exercise prescription for autistic populations [letter] Lochbaum MR, et al. **J Autism Dev Disord** 1995 Jun; 25(3):335-6

Brief report: alternative approaches to the development of effective treatments for autism. Rimland B, et al. **J Autism Dev Disord** 1996 Apr;26(2):237-41 (7 ref.)

Brief report: early intervention in autism. Rogers SJ. **J Autism Dev Disord** 1996 Apr;26(2):243-6 (10 ref.)

Brief report: the case for social and behavioral intervention research. Schreibman L. **J Autism Dev Disord** 1996 Apr; 26(2):247-50 (8 ref.)

Effects of sociodramatic play training on children with autism. Thorp DM, et al. **J Autism Dev Disord** 1995 Jun; 25(3):265-82

Brief report: musical interaction therapy for children with autism: an evaluative case study with two-year follow-up. Wimpory D, et al. **J Autism Dev Disord** 1995 Oct; 25(5):541-52

VIROLOGY

Stealth virus isolated from an autistic child [letter] Martin WJ. **J Autism Dev Disord** 1995 Apr;25(2):223-4

AUTO-PEEP see **POSITIVE-PRESSURE RESPIRATION, INTRINSIC**

AUTOANALYSIS

Automated DNA purification and amplification from blood-stained cards using a robotic workstation. Belgrader P, et al. **Biotechniques** 1995 Sep;19(3):426-32

Automated fluorescent dye-terminator sequencing of G+C-rich tracts with the aid of dimethyl sulfoxide. Scheidl TM, et al. **Biotechniques** 1995 Nov;19(5):691-4

Simple gold overstaining enhances sensitivity of automated electrophoresis of unconcentrated urine. Cesati R. **Clin Chem** 1996 Aug;42(8 Pt 1):1293-4

Automated rescreening of Papanicolaou smears: what are the implications? [editorial] Birdsong GG. **Diagn Cytopathol** 1995 Nov;13(4):283-6

Fluorescence-based classification of microsatellites using a single-wavelength semiautomatic sequencer: genotype assignment and identity tests by analysis of comigrating peak profiles. Moscetti A, et al. **Electrophoresis** 1995 Oct; 16(10):1875-80

Automated solid-phase extraction coupled to gas chromatography with electron-capture detection: a combination of extraction and clean-up of pyrethroids in the analysis of surface water. van der Hoff GR, et al. **J Chromatogr A** 1996 Jan 5;719(1):59-67

Automated determination of polyamines by high-performance liquid chromatography with simple sample preparation. van Eijk HM, et al. **J Chromatogr A** 1996 Apr 12;730(1-2):115-20

Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography. Sumi S, et al. **J Chromatogr B Biomed Appl** 1995 Oct 20;672(2):233-9

Anti-D quantification by flow cytometry: an alternative to the AutoAnalyser? Austin EB, et al. **Transfus Med** 1995 Sep;5(3):203-8

INSTRUMENTATION

Adaptation of a functional assay for protein S to a Cobas Fara II centrifugal analyzer. Solomon HM, et al. **Am J Clin Pathol** 1995 Dec;104(6):655-9

Utilization of glass HPLC autosampler vials as cuvettes in an iodometric assay of hydroperoxides. Caldwell CR. **Anal Biochem** 1996 Feb 15;234(2):234-6

"Doublex" fluorescent DNA sequencing: two independent sequences obtained simultaneously in one reaction with internal labeling and unlabeled primers. Wiemann S, et al. **Anal Biochem** 1996 Feb 15;234(2):166-74

A computer program for predicting recovery of SDS-protein in the automated HPGE-1000 apparatus. Aldroubi A, et al. **Appl Theor Electrophor** 1995;5(1):31-4

Recovery of SDS-protein and DNA using commercial automated gel electrophoresis apparatus. Zakharov SF, et al. **Appl Theor Electrophor** 1995;5(1):25-9

Optimization of Applied Biosystems 373 sequencer stretch modification. McDonald LA, et al. **Biotechniques** 1995 Sep; 19(3):464-71

Four automated random-access immunoassay analyzers evaluated for thyroid function testing. Abubaker MA, et al. **Clin Chem** 1995 Oct;41(10):1538-40

Technical performance evaluation of BM/Hitachi 747-200 serum fructosamine assay. Lin MJ, et al. **Clin Chem** 1996 Feb;42(2):244-8

Further comparative experience with the Roche Cobas Argos Analyser [letter] Wilson S, et al. **Clin Lab Haematol** 1995 Sep;17(3):253-4

Lymphocyte subset determination using a hematology analyzer. Hudson JC, et al. **Cytometry** 1995 Jun 15; 22(2):150-3

[Automated blood cell measurements: a comparison between the Bayer H2 and the Abbott Cell-Dyn 3500] Devoto GL, et al. **Minerva Med** 1996 Jan-Feb;87(1-2):57-64 (Eng. Abstr.) (Ita)

METHODS

Semiautomated method for the quantitation of plasma or sera androstenedione, testosterone, and dihydrotestosterone in population studies. Walker VR, et al. **Anal Biochem** 1996 Feb 15;234(2):194-203

Efficient automated large-scale sequencing of unpurified PCR product. Tsui SK, et al. **Biotechniques** 1995 Oct; 19(4):577-8

Four automated methods for plasma lactate assessed by comparison with capillary gas chromatography. Brooks KE, et al. **Clin Chem** 1996 Jul;42(7):1111-3

Automation of a kinetic method for determining angiotensin-converting enzyme in serum. Groff JL, et al. **Clin Chem** 1995 Nov;41(11):1662-3

Automated assay of plasma bromide after a single deproteinization step. Jennings G, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1210-3

Completely automated extraction of DNA from whole blood. Merel P, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1285-6

Water-soluble conductive polymer homogeneous immunoassay (SOPHIA). A novel immunoassay capable of automation. Englebienne P, et al. **J Immunol Methods** 1996 May 27;191(2):159-70

Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. Kulkarni KR, et al. **J Lipid Res** 1995 Nov; 36(11):2291-302

STATISTICS & NUMERICAL DATA

Accuracy of automated DNA sequencing: a multi-laboratory comparison of sequencing results. Naeve CW, et al. **Biotechniques** 1995 Sep;19(3):448-53

Use of precision profiles to evaluate precision of the automated leukocyte differential. Hübl W, et al. **Clin Chem** 1996 Jul;42(7):1068-73

Interlaboratory variability of bilirubin measurements [see comments] Vreman HJ, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):869-73. Comment in: Clin Chem 1996 Jun;42(6 Pt 1):845-8.

AUTOANTIBODIES

see related
AUTOIMMUNE DISEASES
AUTOIMMUNITY

Amyotrophic lateral sclerosis with paraproteins and autoantibodies. Rowland LP. **Adv Neurol** 1995;68:93-105; discussion 107-11 (136 ref.)

Anti-calcium channel autoantibodies in amyotrophic lateral sclerosis. A review of the evidence. Seagar MJ, et al. **Adv Neurol** 1995;68:67-72 (30 ref.)

Human cytokine autoantibodies. Characteristics, test procedures and possible physiological and clinical significance. Hansen MB. **APMIS Suppl** 1996;59:1-33 (258 ref.)

Cell-type specificity of anti-CD45 autoantibodies in systemic lupus erythematosus. Czyzyk J, et al. **Arthritis Rheum** 1996 Apr;39(4):592-9

Human anti-mitochondria autoantibodies appearing in iproniazid-induced immunoallergic hepatitis recognize human liver monoamine oxidase B. Pons C, et al. **Biochem Biophys Res Commun** 1996 Jan 5;218(1):118-24

Do heat-shock proteins (Hsps)65-reactive lymphocytes in rheumatoid arthritis, Hashimoto's thyroiditis & systemic lupus erythematosus implicate Hsp65 in autoimmunity? Bell CG. **Biochem Soc Trans** 1996 Feb;24(1):85S

Anti-endothelial cell antibodies: only for scientists or for clinicians too? Meroni PL, et al. **Clin Exp Immunol** 1996 May;104(2):199-202 (29 ref.)

DNA methylation: a potential pathway to abnormal autoreactive lupus B cells. Huck S, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):1-8 (85 ref.)

The prevalence of IgG1 and IgG4 autoantibodies to IgE in patients with allergic and non-allergic rhinitis. Smith SJ, et al. **Clin Otolaryngol** 1995 Dec;20(6):540-3

Shared amino acid sequences between glutamic acid decarboxylase 65 and 67 and alpha-2-macroglobulin. A focus for cross-reactive autoantibodies? [letter] [see comments] Norazmi MN, et al. **Diabetologia** 1995 Jul; 38(7):874-5. Comment in: Diabetologia 1996 Feb;39(2):246-7.

The quest for the autoantibody immunodominant region on thyroid peroxidase: guided mutagenesis based on a hypothetical three-dimensional model. Nishikawa T, et al. **Endocrinology** 1996 Mar;137(3):1000-6

An autoantibody to C1-inhibitor recognizes the reactive center of the inhibitor. Donaldson VH, et al. **J Lab Clin Med** 1996 Feb;127(2):229-32

Autoimmune hepatitis versus viral hepatitis C. Strassburg CP, et al. **Liver** 1995 Oct;15(5):225-32 (72 ref.)

Natural autoantibodies: the other side of the immune system. Avrameas S, et al. **Res Immunol** 1995 May-Jun; 146(4-5):235-48 (116 ref.)

Antibody removal and subsequent transplantation of a highly sensitised paediatric renal patient. Bevan DJ, et al. **Transpl Int** 1996;9(2):155-60

[Anti-endothelial cell antibodies] Mayet WJ, et al. **Dtsch Med Wochenschr** 1996 May 24;121(21):702-9 (68 ref.) **(Ger)**

[Primary biliary cirrhosis--antimitochondrial antibody and the reactive antigens] Ishibashi H. **Fukuoka Igaku Zasshi** 1995 Oct;86(10):385-8 (4 ref.) **(Jpn)**

[Studies on functions of neutrophils in MPO-ANCA related glomerulonephiritis and plasma effect on MPO release from neutrophils] Minoshima S. **Nippon Jinzo Gakkai Shi** 1995 Sep;37(9):481-90 (Eng. Abstr.) **(Jpn)**

[Neuropathy and anti-ganglioside antibodies] Kusunoki S. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):629-34 (13 ref.) **(Jpn)**

[Autoantibodies to coagulation factors] Suehisa E, et al. **Rinsho Byori** 1995 Dec;43(12):1189-94 (13 ref.) **(Jpn)**

ADVERSE EFFECTS

Sperm immobilizing antibodies interfere with sperm migration from the uterine cavity through the fallopian tubes. Shibahara H, et al. **Am J Reprod Immunol** 1995 Aug; 34(2):120-4

ANALYSIS

A quantitative ELISA for measuring red cell-bound immunoglobulins. Hazlehurst DD, et al. **Acta Haematol** 1996;95(2):112-6

Analysis of 15 cases with platelet EDTA-dependent antibodies. Zupańska B, et al. **Acta Haematol Pol** 1995; 26(4):361-5

Immunocytes and cell-mediated immunity in the pathology of reproduction. Nouza K, et al. **Adv Exp Med Biol** 1995; 371A:373-7

Prevalence of autoantibodies in the very elderly: association with symptoms of ischemic heart disease. Potocka-Plazak K, et al. **Aging (Milano)** 1995 Aug;7(4):218-20

Acute exacerbation of antiliver cytosol antibody-positive autoimmune chronic hepatitis by alpha-interferon. Gschwantler M, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2239-40

ANCA in IBD: nice, but necessary? Heiman DR, et al. **Am J Gastroenterol** 1995 Nov;90(11):2066-7

Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis complicating the course of Graves' disease: report of three adult cases. Tanemoto M, et al. **Am J Kidney Dis** 1995 Nov;26(5):774-80

Acute interstitial nephritis and uveitis with bone marrow granulomas and anti-neutrophil cytoplasmic antibodies. Okada K, et al. **Am J Nephrol** 1995;15(4):337-42

Profile of anti-stratum corneum autoantibodies in patients with aural cholesteatoma. Bujía J, et al. **Am J Otol** 1994 Jul;15(4):532-5

Pregnancy and warm autoantibodies: a case report. Gerson A, et al. **Am J Perinatol** 1996 Jan;13(1):19-20

Detection of antibodies toward epididymal sperm antigens--an obligatory step in evaluation of human immunologic infertility? Fichorova RN, et al. **Am J Reprod Immunol** 1995 May;33(5):341-9

Antineutrophil cytoplasmic antibodies (ANCA) and abnormal angiograms in polyarteritis nodosa and Churg-Strauss syndrome: indications for the diagnosis of microscopic polyangiitis. Guillevin L, et al. **Ann Med Interne (Paris)** 1995;146(8):548-50

Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Rees JH, et al. **Ann Neurol** 1995 Nov; 38(5):809-16

Circulating auto-antibodies in Ménière's disease. Perez Garrigues H, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(5):225-8

The clinical utility of ANCA positivity [editorial] Edgar JD. **Ann Rheum Dis** 1996 Aug;55(8):494-6 (37 ref.)

Rheumatic fever: autoantibodies against a variety of cardiac, nuclear, and streptococcal antigens. Eichbaum QG, et al. **Ann Rheum Dis** 1995 Sep;54(9):740-3

Clinical significance of antibodies against oxidised low density lipoprotein in early RA [letter] Paimela L, et al. **Ann Rheum Dis** 1996 Aug;55(8):558-9

Quinine induced lupus-like syndrome and cardiolipin antibodies [letter] Rosa-Re D, et al. **Ann Rheum Dis** 1996 Aug;55(8):559-60

Is immunogenetic susceptibility to neuropsychiatric systemic lupus erythematosus (SLE) different from non-neuropsychiatric SLE? Silva LM, et al. **Ann Rheum Dis** 1996 Aug;55(8):544-7

Antibodies to ribosomal P proteins and hepatic damage in undifferentiated CTD [letter] Torre JC, et al. **Ann Rheum Dis** 1996 Aug;55(8):562-3

Antineutrophil cytoplasmic antibodies in the classification of vasculitis. Niles JL. **Annu Rev Med** 1996;47:303-13 (32 ref.)

Enhanced levels of colony stimulating factor-1 (CSF-1) in sera and seminal plasma of antisperm antibody-positive infertile men. Naz RK, et al. **Arch Androl** 1995 Jul-Aug; 35(1):5-11

Autoantigenicity of human sperm: molecular identities of sperm antigens recognized by sera of immunoinfertile men in the immunoprecipitation procedure. Naz RK, et al. **Arch Androl** 1995 Nov-Dec;35(3):225-31

Linear IgA bullous dermatosis. Characterization of a subset of patients with concurrent IgA and IgG anti-basement membrane autoantibodies. Chan LS, et al. **Arch Dermatol** 1995 Dec;131(12):1432-7

Detection of antineutrophil cytoplasmic antibodies in patients with hepatitis C virus-induced cutaneous vasculitis with mixed cryoglobulinemia [letter] Romaní J, et al. **Arch Dermatol** 1996 Aug;132(8):974-5

Autoantibodies to the heat-shock protein hsp73 in localized scleroderma. Fujimoto M, et al. **Arch Dermatol Res** 1995; 287(6):581-5

False-positive antineutrophil cytoplasmic antibody in aspergillosis with oxalosis [letter; comment] Nakajima M, et al. **Arch Pathol Lab Med** 1996 May;120(5):425-6. Comment on: Arch Pathol Lab Med 1995 Jun;119(6):558-61.

Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. Del Papa N, et al. **Arthritis Rheum** 1996 May;39(5):758-66

Detection of autoantibodies to nucleolar transcription factor NOR 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. Fujii T, et al. **Arthritis Rheum** 1996 Aug;39(8):1313-8

Novel autoantibodies directed against the common tertiary configuration of transfer RNA in a patient with interstitial lung disease. Matsumura M, et al. **Arthritis Rheum** 1996 Aug;39(8):1308-12

Chronic intestinal pseudoobstruction associated with autoantibodies against proliferating cell nuclear antigen. Nojima Y, et al. **Arthritis Rheum** 1996 May;39(5):877-9

Detection of anticentromere antibodies using recombinant human CENP-A protein. Sun D, et al. **Arthritis Rheum** 1996 May;39(5):863-7

Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis. Akimoto S, et al. **Br J Dermatol** 1996 Mar;134(3):407-10

Coexistence of psoriasis and an unusual IgG-mediated subepidermal bullous dermatosis: identification of a novel 200-kDa lower lamina lucida target antigen. Chen KR, et al. **Br J Dermatol** 1996 Feb;134(2):340-6

A case of Sjögren's syndrome, sarcoidosis, previous ulcerative colitis and gastric autoantibodies. Cox NH, et al. **Br J Dermatol** 1996 Jun;134(6):1138-40

Pemphigoid gestationis with autoantibodies exclusively directed to the 230-kDa bullous pemphigoid antigen (BP230Ag) [letter] Ghohestani R, et al. **Br J Dermatol** 1996 Mar;134(3):603-4

A case of linear IgA bullous dermatosis with IgA anti-type VII collagen autoantibodies. Hashimoto T, et al. **Br J Dermatol** 1996 Feb;134(2):336-9

Dermatological presentation of disease associated with antineutrophil cytoplasmic antibodies: a report of two contrasting cases and a review of the literature. Irvine AD, et al. **Br J Dermatol** 1996 May;134(5):924-8 (30 ref.)

Association of autoantibodies against platelet glycoproteins Ib/IX and IIb/IIIa, and platelet-reactive anti-HIV antibodies in thrombocytopenic narcotic addicts. Gonzalez-Conejero R, et al. **Br J Haematol** 1996 May; 93(2):464-71

Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy. Hebbar M, et al. **Br J Haematol** 1996 Jul; 94(1):112-5

Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. D'Cruz D, et al. **Br J Rheumatol** 1995 Nov; 34(11):1090-1

Antineutrophil cytoplasmic antibodies in inflammatory arthritis--potential for misdiagnosis? Helsloot J, et al. **Br J Rheumatol** 1995 Sep;34(9):820-4

Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies are not increased in Kawasaki disease. Nash MC, et al. **Br J Rheumatol** 1995 Sep;34(9):882-7

Prevalence and clinical significance of antibodies to ribonucleoproteins in systemic lupus erythematosus in Malaysia. Wang CL, et al. **Br J Rheumatol** 1996 Feb; 35(2):129-32

Immunological infertility among Nigerian men: incidence of circulating antisperm auto-antibodies and some clinical observations: a preliminary report. Ekwere PD. **Br J Urol** 1995 Sep;76(3):366-70

Serum autoantibodies in recurrent parotitis in children. Babál P, et al. **Bratisl Lek Listy** 1995 Jul;96(7):384-8

Antineutrophil cytoplasmic autoantibodies (ANCA) associated vasculitides--immunologic and clinical aspects. Schulz JI. **Bratisl Lek Listy** 1995 Oct;96(10):520-2 (20 ref.)

Localization of anti-CENP antibodies and alphoid sequences in acentric heterochromatin in a breast cancer cell line. Vig BK, et al. **Cancer Genet Cytogenet** 1996 Jun; 88(2):118-25

Autoantibodies against p53 are not increased in human ascites and pleural effusions. Munker R, et al. **Cancer Immunol Immunother** 1996 Mar;42(3):200-1

Respiratory failure in ANCA-associated vasculitis. ter Maaten JC, et al. **Chest** 1996 Aug;110(2):357-62

Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor. Feldt-Rasmussen U. **Clin Chem** 1996 Jan;42(1):160-3 (20 ref.)

Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Boullier A, et al. **Clin Chim Acta** 1995 Jun 30;238(1):1-10

TSH receptor antibodies and ultrasonography in Graves' disease [letter; comment] Zingrillo M, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):387-9. Comment on: Clin Endocrinol (Oxf) 1994 Nov;41(5):667-71.

D-penicillamine-induced autoantibodies in a mouse model. Brik R, et al. **Clin Exp Rheumatol** 1995 Jul-Aug;13(4):483-8

Primary Sjögren's syndrome and primary biliary cirrhosis: differences and similarities in the autoantibody profile. Tishler M, et al. **Clin Exp Rheumatol** 1995 Jul-Aug; 13(4):497-500

Detection of anti-neutrophil cytoplasmic antibodies by immunoprecipitation. Lucena-Fernandes F, et al. **Clin Invest Med** 1995 Jun;18(3):153-62

Antihistone antibodies in scleroderma. Parodi A, et al. **Dermatology** 1995;191(1):16-8

A case of herpetiform pemphigus associated with autoimmune hemolytic anemia: detection of autoantibodies against multiple epidermal antigens. Shimizu K, et al. **Dermatology** 1996;192(2):179-82

Concordance between twins for beta-cell autoimmunity [letter] David R, et al. **Diabetes** 1996 Sep;45(9):1284

Islet cell and thyroid autoimmunity in Chinese patients with IDDM [letter] Thai AC, et al. **Diabetes Care** 1995 Apr; 18(4):586-7

Assignment of islet cell antibody titres and selection of subjects for IDDM prevention trials [letter] Morales J, et al. **Diabetologia** 1995 May;38(5):633-4

Sexual dimorphism in transmission of expression of islet autoantibodies to offspring. Yu L, et al. **Diabetologia** 1995 Nov;38(11):1353-7

Inadequate response to H2-receptor antagonists. Absence of parietal cell cAMP-stimulating autoantibodies. Bergmann C, et al. **Dig Dis Sci** 1995 Dec;40(12):2678-83

A zebra is not always a zebra and a zero is not always a zero [letter] Krantz I, et al. **Dig Dis Sci** 1996 Aug; 41(8):1655-7

Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Raedle J, et al. **Dig Dis Sci** 1995 Dec; 40(12):2587-94

Is small bowel biopsy necessary in adults with suspected celiac disease and IgA anti-endomysium antibodies? 100% positive predictive value for celiac disease in adults. Valdimarsson T, et al. **Dig Dis Sci** 1996 Jan;41(1):83-7

Multivariate statistical comparison of autoantibody-repertoires (western blots) by discriminant analysis. Zimmermann CW, et al. **Electrophoresis** 1995 Jun; 16(6):941-7

Cryptogenic partial epilepsies with anti-GM1 antibodies: a new form of immune-mediated epilepsy? Bartolomei F, et al. **Epilepsia** 1996 Oct;37(10):922-6

Rheumatoid factor, anti-heat shock protein (65 kDa)

antibodies and anti-nuclear antibodies in equine joint diseases. Carter SD, et al. **Equine Vet J** 1995 Jul; 27(4):288–95

Absence of antineutrophil cytoplasmic antibodies in relatives of UK patients with primary sclerosing cholangitis and ulcerative colitis. Bansi DS, et al.
Eur J Gastroenterol Hepatol 1996 Feb;8(2):111–6

Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: do they recognize different subsets of a heterogeneous disease? Castellino F, et al.
Eur J Gastroenterol Hepatol 1995 Sep;7(9):859–64

Autoimmune mechanisms in chronic hepatitis B and delta virus infections. McFarlane BM, et al.
Eur J Gastroenterol Hepatol 1995 Jul;7(7):615–21

Determination of anti GAD65 autoantibodies with an ELISA before and after standardization with the new international reference serum. Pfützner A, et al.
Exp Clin Endocrinol Diabetes 1995;103(2):123–5

Orbital myositis [letter; comment] Simcock PR, et al. **Eye** 1995;9 (Pt 5):666–8. Comment on: Eye 1995;9 (Pt 1):96–101.

Antibodies to oxidized low-density lipoprotein and to cardiolipin in nonpregnant and pregnant women with habitual abortion. Tulppala M, et al. **Fertil Steril** 1995 Nov; 64(5):947–50

Indirect immunofluorescence study of the cornea and the conjunctiva in a xenogeneic system: analysis of humoral reactivity in patients with Wegener's granulomatosis. Przyklang U, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Feb;234(2):79–86

Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Bansi DS, et al.
Gut 1996 Mar;38(3):384–9

Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Todros L, et al. **Hepatology** 1995 Nov;22(5):1374–8

Ovarian autoimmunity and corticotherapy in an in-vitro fertilization attempt. Barbarino-Monnier P, et al.
Hum Reprod 1995 Aug;10(8):2006–7

Anti-endometrial antibodies in women measured by an enzyme-linked immunosorbent assay. Fernandéz-Shaw S, et al. **Hum Reprod** 1996 Jun;11(6):1180–4

Autoantibodies and antisperm antibodies in sera and follicular fluids of infertile patients; relation to reproductive outcome after in-vitro fertilization. Nip MM, et al. **Hum Reprod** 1995 Oct;10(10):2564–9

Comparison of different methods for the detection of autoantibodies in autoimmune diseases. Grigolo B, et al. **Int J Clin Lab Res** 1995;25(4):205–10

Antismooth muscle and antiparietal cell antibodies in Indians with alopecia areata. Kumar B, et al. **Int J Dermatol** 1995 Aug;34(8):542–5

Phospholipid-dependent anti-beta 2-glycoprotein I (beta 2-GPI) antibodies and antiphospholipid syndrome. Kaburaki J, et al. **Intern Med** 1996 Feb;35(2):105–10

Antidopaminergic antibodies in a patient with a complex autoimmune disorder and rapidly progressing Parkinson's disease. Kunas RC, et al. **J Allergy Clin Immunol** 1995 Nov; 96(5 Pt 1):688–90

Absence of antiphospholipid and anti-endothelial cell antibodies in malignant atrophic papulosis: a study of 15 cases. Assier H, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):831–3

Pemphigus herpetiformis is a rare clinical expression of nonendemic pemphigus foliaceus, fogo selvagem, and pemphigus vulgaris. Cooperative Group on Fogo Selvagem Research. Santi CG, et al. **J Am Acad Dermatol** 1996 Jan; 34(1):40–6

High prevalence of antibodies against beta 1- and beta 2-adrenoceptors in patients with primary electrical cardiac abnormalities. Chiale PA, et al. **J Am Coll Cardiol** 1995 Oct;26(4):864–9

Anticardiolipin and antihiston levels during the treatment of IVF patients with endometriosis by Goserelin. Crha I, et al. **J Assist Reprod Genet** 1996 Apr;13(4):366–8

Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. Vidrich A, et al. **J Clin Immunol** 1995 Nov;15(6):293–9

Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes. Aanstoot HJ, et al. **J Clin Invest** 1996 Jun 15;97(12):2772–83

Non-specific autoantibodies in cardiomyopathies and myocardial infarction. Syrigou EI, et al.
J Clin Lab Immunol 1995;46(4):155–62

Detection of autoantibodies to neutrophil cytoplasmic antigens [letter; comment] Savige J. **J Clin Pathol** 1995 Aug;48(8):785–6. Comment on: J Clin Pathol 1994 Jan;47(1):4–8.

Anti-ribosomal P protein antibodies in a Japanese patient with systemic sclerosis. Fujimoto M, et al. **J Dermatol** 1996 Jan;23(1):33–6

Paraneoplastic pemphigus: report of a case. Izaki S, et al. **J Dermatol** 1996 Jun;23(6):397–404 (24 ref.)

A case of bullous pemphigoid with antibodies against intercellular 130 kd antigen. Takahashi H, et al.
J Dermatol 1995 Aug;22(8):576–81

IgA autoantibodies against human eye muscle antigen detected by western blotting and immunohistochemical methods in Graves' disease. Molnár I, et al.
J Endocrinol Invest 1995 Jun;18(6):408–14

Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. Falorni A, et al.
J Immunol Methods 1995 Oct 12;186(1):89–99

Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques. Muratori L, et al. **J Immunol Methods** 1995 Dec 1; 187(2):259–64

Patterns of immune responses to the host-encoded GOR and hepatitis C virus core-derived epitopes with relation to hepatitis C viremia, genotypes, and liver disease severity. Quiroga JA, et al. **J Infect Dis** 1996 Feb;173(2):300–5

Lipoproteins, anticardiolipin autoantibodies and artherosclerosis [letter] Cheng HM. **J Intern Med** 1996 Jul; 240(1):44–5

Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. Nityanand S, et al. **J Intern Med** 1995 Nov;238(5):437–43

In situ-bound antibodies eluted from the skin of patients with bullous pemphigoid are preferentially directed against the 230-kD bullous pemphigoid antigen. Korman NJ.
J Invest Dermatol 1995 Dec;105(6):824–30

Stiff-person syndrome with anti-glutamic acid decarboxylase autoantibodies: complete remission of symptoms after intrathecal baclofen administration. Seitz RJ, et al.
J Neurol 1995 Oct;242(10):618–22 (32 ref.)

Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. Honnorat J, et al.
J Neurol Neurosurg Psychiatry 1996 Sep;61(3):270–8

Antibodies to human optic nerve in Leber's hereditary optic neuropathy. Smith PR, et al. **J Neurol Sci** 1995 Jun; 130(2):134–8

Acetylcholine receptor antibodies in patients with Graves' ophthalmopathy. Jacobson DM. **J Neuroophthalmol** 1995 Sep;15(3):166–70

Steroid-resistant chronic urticaria associated with anti-thyroid microsomal antibodies in a nine-year-old boy. Dreyfus DH, et al. **J Pediatr** 1996 Apr;128(4):576–8

Circulating ovarian autoantibodies and FSH and LH levels in adolescent girls with primary menstrual cycle disorders. Hořejší J, et al. **J Pediatr Adolesc Gynecol** 1996 Apr; 9(2):74–8

Autoantibodies, neurotoxins and the nervous system. Vincent A, et al. **J Physiol Paris** 1995;89(3):129–36 (75 ref.)

ANCA associated with Behçet's disease. Burrows NP, et al.
J R Soc Med 1996 Jan;89(1):47P–8P

Occurrence of antineutrophil cytoplasmic and antineutrophil (peri)nuclear antibodies in rheumatoid arthritis. Bosch X, et al. **J Rheumatol** 1995 Nov;22(11):2038–45

The immunological features of Peyronie's disease. Ralph DJ, et al. **J Urol** 1996 Jan;155(1):159–62

Anti-liver membrane protein antibodies in dogs with chronic hepatitis. Weiss DJ, et al. **J Vet Intern Med** 1995 Jul-Aug; 9(4):267–71

Lack of association between early exposure to cow's milk protein and beta-cell autoimmunity. Diabetes Autoimmunity Study in the Young (DAISY) [see comments] Norris JM, et al. **JAMA** 1996 Aug 28; 276(8):609–14. Comment in: JAMA 1996 Aug 28;276(8):647–8.

The PiZ gene of alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Segelmark M, et al. **Kidney Int** 1995 Sep;48(3):844–50

Definition of cut-off points for autoantibody assays in cohorts of healthy individuals. The Sardinian School Children-IDDM (SSI) & Newborn-IDDM (SNI) Study Groups [letter] Sepe V, et al. **Lancet** 1996 Mar 9; 347(9002):693

pANCA and classification resistance in ulcerative colitis [editorial; comment] Hanauer SB. **Mayo Clin Proc** 1996 May;71(5):517–8. Comment on: Mayo Clin Proc 1996 May;71(6):431–6.

Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study [see comments] Sandborn WJ, et al. **Mayo Clin Proc** 1996 May;71(5):431–6. Comment in: Mayo Clin Proc 1996 May;71(5):517–8.

Autoantibodies to triiodothyronine and thyroxine in primary hypothyreosis. Biuković M, et al. **Med Pregl** 1993;46 Suppl 1:80–1

Neuromuscular transmission and acetylcholine receptor antibodies in penicillamine-treated Wilson's disease patients [letter] Anlar B, et al. **Muscle Nerve** 1996 May;19(5):676–7

Anti-MAG and anti-SGPG antibodies in neuropathy. Van den Berg L, et al. **Muscle Nerve** 1996 May;19(5):637–43

Autoantibodies against erythropoietin in a patient with pure red-cell aplasia [see comments] Casadevall N, et al.
N Engl J Med 1996 Mar 7;334(10):630–3. Comment in: N Engl J Med 1996 Mar 7;334(10):660–2. Comment in: N Engl J Med 1996 Aug 15;335(7):523–4.

Activation of chronic hepatitis C virus infection by cyclophosphamide in a patient with cANCA-positive vasculitis. Arend SM, et al. **Nephrol Dial Transplant** 1995; 10(6):884–7

Renal vasculitis in antiglomerular basement antibody-positive Goodpasture disease. Banks RA, et al.
Nephrol Dial Transplant 1996 Feb;11(2):360–2

The crucial role of renal biopsy in the management of ANCA-associated renal vasculitis. Ferrario F, et al.
Nephrol Dial Transplant 1996 Apr;11(4):726–8

ANCA-positive crescentic glomerulonephritis in chronic bronchiectasis. McKane WS, et al.
Nephrol Dial Transplant 1995;10(8):1447–50

Phenytoin-associated vasculitis and ANCA positivity: a case report. Parry RG, et al. **Nephrol Dial Transplant** 1996 Feb; 11(2):357–9

Hydralazine-induced constrictive pericarditis. Franssen CF, et al. **Neth J Med** 1996 May;48(5):193–7 (21 ref.)

Anti-Jo-1 syndrome presenting as cryptogenic organizing pneumonia. Chan WM, et al. **Respir Med** 1995 Oct; 89(9):639–41

Antineutrophil cytoplasmic autoantibody testing in vasculitides. Gross WL. **Rheum Dis Clin North Am** 1995 Nov;21(4):987–1011 (182 ref.)

Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study. Röther E, et al.
Rheumatol Int 1996;15(6):231–7

Study of lung antibodies in patients with silicosis. Cojocaru M, et al. **Rom J Intern Med** 1995 Jul-Dec;33(3–4):243–7

Anti-neutrophil cytoplasmic antibodies in chronic inflammatory bowel disease. Prevalence and diagnostic role. Hertervig E, et al. **Scand J Gastroenterol** 1995 Jul; 30(7):693–8

Serum antibodies from patients with primary Sjögren's syndrome and systemic lupus erythematosus recognize multiple epitopes on the La(SS-B) autoantigen resembling viral protein sequences. Haaheim LR, et al.
Scand J Immunol 1996 Jan;43(1):115–21

Detection of antibodies to HIV-1 gp41- and HLA class II antigen-derived peptides in SLE patients. Koshino K, et al. **Scand J Rheumatol** 1995;24(5):288–92

[Antikeratin antibodies: another specific antibodies in rheumatoid arthritis patients] Zhou Z, et al.
Chung Hua Nei Ko Tsa Chih 1995 May;34(5):330–2 (Eng. Abstr.) **(Chi)**

[Diagnostic and pathogenic significance of antineutrophil cytoplasmic antibodies in vasculitides] Bartuňková J, et al.
Bratisl Lek Listy 1995 Oct;96(10):528–33 (Eng. Abstr.) **(Cze)**

[Renal vasculitis and glomerulonephritis with anti-neutrophil cytoplasmic antibody positivity] Tesař V, et al.
Cas Lek Cesk 1996 Jan 31;135(3):79–83 (Eng. Abstr.) **(Cze)**

[Autoimmunity and glutamate decarboxylase antibodies in the pathogenesis of type I diabetes mellitus in experimental and clinical practice] Kučera P, et al. **Vnitr Lek** 1996 May; 42(5):359–67 (65 ref.) (Eng. Abstr.) **(Cze)**

[When and why assay neutrophil cytoplasmic antibodies in dermatology?] Delaporte E. **Ann Dermatol Venereol** 1995; 122(8):558–62 **(Fre)**

[Linear IgA bullous dermatosis in children with autoantibodies against 180 kDa pemphigoid antigen] Bérard F, et al. **Arch Pediatr** 1996 Apr;3(4):345–7 (Eng. Abstr.) **(Fre)**

[Acquired factor VIII inhibitor and chronic lymphoid leukemia: apropos of a case] Ceballos P, et al.
Rev Med Interne 1996;17(2):150–3 (15 ref.) (Eng. Abstr.) **(Fre)**

[Pure cerebellar syndrome associated with anti-Hu antibodies] Pradat PF, et al. **Rev Neurol (Paris)** 1995 May; 151(5):341–3 (12 ref.) (Eng. Abstr.) **(Fre)**

[Recurrent Miller Fisher syndrome. Significance of anti-GQ1B antibodies] Dewarrat A, et al.
Schweiz Arch Neurol Psychiatr 1995;146(4):180–4 (Eng. Abstr.) **(Fre)**

[Cytoplasmic islet cell antibodies and GAD antibodies in diagnosis of diabetes] Bieg S, et al. **Med Klin** 1995 Oct 15;90(10):594–8 (48 ref.) **(Ger)**

[Follow-up and immunologic findings in drug-induced myasthenia] Brüggemann W, et al. **Med Klin** 1996 May 15;91(5):268–71 (Eng. Abstr.) **(Ger)**

[Significance of antineutrophil cytoplasmic antibodies (ANCA) in diagnosis and immunopathogenesis of chronic inflammatory liver diseases] Mayet WJ, et al. **Med Klin** 1996 Jun 15;91(6):384–8 (33 ref.) **(Ger)**

[Sensitivity and specificity for detection of islet cell cytoplasmic antibodies using rat pancreatic sections] Takahashi K, et al.
Nihon Rinsho Meneki Gakkai Kaishi 1995 Apr;18(2):188–96 (Eng. Abstr.) **(Jpn)**

[The first case of Sjögren's syndrome with anti-Wa antibody] Ueda A, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr;18(2):215–20 (Eng. Abstr.) **(Jpn)**

[Clinical analysis of 14 patients with anti-myeloperoxidase antibody positive rapid progressive glomerulonephritic syndrome] Hiromura K, et al. **Nippon Jinzo Gakkai Shi** 1995 Oct;37(10):573–9 (Eng. Abstr.) **(Jpn)**

[Three thyroid patients showing fluctuation of thyroid hormone autoantibody titers during long-term treatment] Ikekubo K, et al. **Nippon Naibunpi Gakkai Zasshi** 1995 Jul 20;71(5):695–708 (Eng. Abstr.) **(Jpn)**

[A case of Churg-Strauss syndrome presenting positive anti-neutrophil cytoplasmic autoantibodies] Hisayama F, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10; 84(8):1327–8 **(Jpn)**

[Anti-GOR antibodies] Kato M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:241–6 (23 ref.) **(Jpn)**

[Autoantibodies in patients with Sjögren's syndrome and their clinical significance] Miyawaki S. **Nippon Rinsho** 1995 Oct;53(10):2422–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Enzyme-immunoassay for autoantibodies using recombinant antigens] Yamanaka K, et al. **Nippon Rinsho** 1995 Sep; 53(9):2283–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical subsets and phospholipid-dependent anti-beta 2-glycoprotein I antibodies in antiphospholipid syndrome] Kaburaki J, et al. **Rinsho Ketsueki** 1995 Oct;36(10):1170–4 (Eng. Abstr.) **(Jpn)**

[Mixed warm and cold antibody type autoimmune hemolytic anemia associated with systemic lupus erythematosus] Watanabe A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):77–81 (Eng. Abstr.) **(Jpn)**

[Marked clinical improvement by plasmapheresis in a patient with stiff-man syndrome: a case with a negative anti-GAD antibody] Nakamagoe K, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):897–900 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Paraneoplastic cerebellar degeneration—characterization of anti-Yo antibody and underlying cancer] Tanaka K, et al. **Rinsho Shinkeigaku** 1995 Jul;35(7):770–4 (Eng. Abstr.) **(Jpn)**

[A case of p-ANCA positive necrotizing vasculitis associated with Graves' disease] Aoki A, et al. **Ryumachi** 1995 Aug; 35(4):683–7 (Eng. Abstr.) **(Jpn)**

[Autoantibodies against neutrophil cytoplasm and their significance in the classification of systemic vasculitis] Fijałkowska-Morawska J, et al. **Przegl Lek** 1995; 52(6):318–22 (20 ref.) (Eng. Abstr.) **(Pol)**

[Clinical significance of antibodies to vascular endothelium (editorial)] Youinou P, et al. **Klin Med (Mosk)** 1995; 73(5):5–7 **(Rus)**

[Occurrence of TSH receptor antibodies and thyroid microsomal antibodies in Graves-Basedow disease] Paunković N, et al. **Med Pregl** 1995;48(1–2):10–4 (Eng. Abstr.) **(Scr)**

[Retroperitoneal and mediastinal fibrosis with serum p-ANCA increase. A new evidence of immunological etiology? (letter)] Fernandez Guerra J, et al. **An Med Interna** 1995 Dec;12(12):622–3 **(Spa)**

BIOSYNTHESIS

In vitro suppression of anti-TSH receptor antibody by autologous anti-idiotypic antibody in patients with Graves' disease. Balázs C, et al. **Acta Microbiol Immunol Hung** 1995; 42(2):163–9

A role for antigen in the evolution of gastrointestinal MALT-type B cell lymphoma. Hussell T, et al. **Adv Exp Med Biol** 1995;371A:145–7

Amelioration of autoimmune reactions by antigen-induced apoptosis of T cells. McFarland HI, et al. **Adv Exp Med Biol** 1995;383:157–66

Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-1 alpha expression in 15 cases of antineutrophil cytoplasmic autoantibody-associated renal vasculitis. Rastaldi MP, et al. **Am J Kidney Dis** 1996 Jan;27(1):48–57

neu/HER-2 cDNA vaccination and pregnancy loss. Venanzi FM, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:274–7

Increased serum and synovial fluid antibodies to immunoselected peptides in patients with rheumatoid arthritis. Dybwad A, et al. **Ann Rheum Dis** 1996 Jul; 55(7):437–41

Autoimmune mechanisms of depletion of CD4 cells in HIV infection. Dalgleish AG. **Br J Haematol** 1995 Nov; 91(3):525–34 (106 ref.)

Autoimmune hemolytic anemia in chronic mucocutaneous candidiasis. Oyefara BI, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):38–43

Autoantibodies to human heat shock protein (hsp)60 may be induced by Escherichia coli groEL. Handley HH, et al. **Clin Exp Immunol** 1996 Mar;103(3):429–35

Detection on immunoblot of new proteins from the soluble fraction of the cell recognized either by anti-liver-kidney microsome antibodies type 1 or by anti-liver cytosol antibodies type 1—relationship with hepatitis C virus infection. Ballot E, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):245–54

A prospective study on anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Chan TM, et al. **Clin Immunol Immunopathol** 1996 Jan;78(1):41–6

Intrathymic injection of polynucleosomes delays autoantibody production in BXSB mice. Duncan SR, et al. **Clin Immunol Immunopathol** 1996 May;79(2):171–81

Distinct production of autoantibodies to nuclear components in ulcerative colitis and in Crohn's disease. Reumaux D, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):349–57

The mechanism of autoantibody formation to cartilage in rheumatoid arthritis: possible cross-reaction of antibodies to dietary collagens with autologous type II collagen. Terato K, et al. **Clin Immunol Immunopathol** 1996 May; 79(2):142–54

Induction of thyroid autoantibodies in naive mice by idiotypic manipulation. Tomer Y, et al. **Clin Immunol Immunopathol** 1996 Feb;78(2):180–7

Perinatal autoimmunity in offspring of diabetic parents. The German Multicenter BABY-DIAB study: detection of humoral immune responses to islet antigens in early childhood. Roll U, et al. **Diabetes** 1996 Jul;45(7):967–73

Insulitis and islet-cell antibody formation in rats with experimentally reduced beta-cell mass. Lampeter EF, et al. **Diabetologia** 1995 Dec;38(12):1397–404

Identification of 2 stallion sperm-specific proteins and their autoantibody response. Teuscher C, et al. **Equine Vet J** 1994 Mar;26(2):148–51

Mercury induces polyclonal B cell activation, autoantibody production and renal immune complex deposits in young (NZB x NZW)F1 hybrids. al-Balaghi S, et al. **Eur J Immunol** 1996 Jul;26(7):1519–26

The Yaa gene-mediated acceleration of murine lupus: Yaa- T cells from non-autoimmune mice collaborate with Yaa+ B cells to produce lupus autoantibodies in vivo. Fossati L, et al. **Eur J Immunol** 1995 Dec;25(12):3412–7

Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Nakajima A, et al. **Eur J Immunol** 1995 Nov;25(11):3060–9

Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics. Clot P, et al. **Gastroenterology** 1996 Jul;111(1):206–16

Induction of Goodpasture antibodies to noncollagenous domain (NC1) of type IV collagen in mice by idiotypic manipulation. Shoenfeld Y, et al. **Hum Antibodies Hybridomas** 1995;6(4):122–8

Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Nishizumi H, et al. **Immunity** 1995 Nov;3(5):549–60

Proliferation and autoantibody production by mouse thyroglobulin (MTg)-specific B cells activated in vitro by MTg and MTg-specific T cells. Cong Y, et al. **Immunol Lett** 1995 Mar;45(3):189–93

Mechanisms of the pathogenic autoimmune response in lupus: prospects for specific immunotherapy. Datta SK, et al. **Immunol Res** 1995;14(2):132–47 (156 ref.)

Involvement of B-1 cells in mucosal immunity and autoimmunity. Murakami M, et al. **Immunol Today** 1995 Nov;16(11):534–9 (38 ref.)

Prolactin-induced immunoglobulin and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals. Gutiérrez MA, et al. **Int Arch Allergy Immunol** 1996 Mar; 109(3):229–35

Dysregulation of the humoral immune response in old mice. Zhao KS, et al. **Int Immunol** 1995 Jun;7(6):929–34

HLA-associated heterogeneity of the humoral response to islet antigens in insulin-dependent diabetes. Delamaire M, et al. **J Autoimmun** 1995 Oct;8(5):645–57

Significantly increased maternal and fetal IgG autoantibody levels to 52 kD Ro (SS-A) and La(SS-B) in complete congenital heart block. Dörner T, et al. **J Autoimmun** 1995 Oct;8(5):675–84

Human immunoglobulin G autoantibodies to the thyrotropin receptor from Epstein-Barr virus-transformed B lymphocytes: characterization by immunoprecipitation with recombinant antigen and biological activity. Morgenthaler NG, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3155–61

Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. Desai-Mehta A, et al. **J Clin Invest** 1996 May 1; 97(9):2063–73

Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease. Mizoguchi A, et al. **J Exp Med** 1996 Mar 1; 183(3):847–56

Germinal center formation, immunoglobulin class switching, and autoantibody production driven by "non alpha/beta" T cells. Wen L, et al. **J Exp Med** 1996 May 1; 183(5):2271–82

Rapid induction of autoantibodies by endogenous ovarian antigens and activated T cells: implication in autoimmune disease pathogenesis and B cell tolerance. Lou YH, et al. **J Immunol** 1996 May 1;156(9):3535–40

Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses. Ma J, et al. **J Immunol** 1996 Jul 1;157(1):417–26

Both Sm and DNA are selecting antigens in the anti-Sm B cell response in autoimmune MRL/lpr mice. Retter MW, et al. **J Immunol** 1996 Feb 1;156(3):1296–306

In vitro production of human anti-sperm antibodies: effect of an oligoclonal antibody (F6) on sperm-egg interaction. Fusi FM, et al. **J Reprod Immunol** 1995 Jul;29(2):135–47

In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. Barcellini W, et al. **Lupus** 1996 Apr; 5(2):139–45

Single-chain anti-DNA FV. Polymenis M, et al. **Methods Mol Biol** 1995;51:265–79

Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor. Garrone P, et al. **Mol Immunol** 1996 May-Jun;33(7–8):649–58

Lack of autoantibody expression in children born to mothers with silicone breast implants. Levine JJ, et al. **Pediatrics** 1996 Feb;97(2):243–5

In vivo expression of a single viral DNA-binding protein generates systemic lupus erythematosus-related autoimmunity to double-stranded DNA and histones. Moens U, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19; 92(26):12393–7

Immune functional impairment in patients with clinical abnormalities and silicone breast implants. Vojdani A, et al. **Toxicol Ind Health** 1992 Nov-Dec;8(6):415–29

Immune-mediated side-effects of cytokines in humans. Vial T, et al. **Toxicology** 1995 Dec 20;105(1):31–57 (239 ref.)

In vitro cytokine treatment of B cell defects in HIV-infected hemophilia patients. Weimer R, et al. **Vox Sang** 1995; 69(1):27–37

[The dynamics of the formation of spontaneous autoantibodies to the synaptonemal complex in male mice] Dadashev SIa, et al. **Ontogenez** 1995 Sep-Oct;26(5):384–9 (Eng. Abstr.) **(Rus)**

[Successful treatment of acquired F:VIII C inhibitor after delivery using plasmapheresis and high doses of immunoglobulins] Belić A, et al. **Med Pregl** 1994; 47(9–10):359–61 (Eng. Abstr.) **(Scr)**

BLOOD

Autoantibodies against constituents of nuclear pore complexes in patients with primary biliary cirrhosis and autoimmune hepatitis. Wesierska-Gądek J, et al. **Acta Biochim Pol** 1995;42(2):197–200

Serum cytokine and anti-Fc gamma R autoantibody measurements in patients with systemic sclerosis. Szegedi A, et al. **Acta Derm Venereol** 1996 Jan;76(1):21–3

Development of factor VIII:C inhibitors following vaccination. Ferri GM, et al. **Acta Haematol** 1996; 96(2):110–1

Characterization of antineutrophil antibodies in patients with neutropenia associated with nutritional copper deficiency. Higuchi S, et al. **Acta Haematol** 1995;94(4):192–5

Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies. Vitti P, et al. **Acta Med Austriaca** 1996;23(1–2):52–6

Platelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers. Hirashima Y, et al. **Acta Neurochir (Wien)** 1995;137(1–2):15–8

Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acarín N, et al. **Acta Neurol Scand** 1996 Feb-Mar; 93(2–3):99–103

Neuronal targets of serum and cerebrospinal fluid autoantibodies in amyotrophic lateral sclerosis. Greiner A, et al. **Acta Neuropathol (Berl)** 1996;91(1):67–71

Acute anterior uveitis in a child with HLA-B60 after Salmonella enteritis associated with the transient appearance of auto-antibody. Aihara Y, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):286–7

Obstetric complications and autoantibodies in schizophrenia. Chengappa KN, et al. **Acta Psychiatr Scand** 1995 Oct; 92(4):270–3

Anti-parietal cell antibody in autoimmune liver diseases is associated with gastric mucosal atrophy and intestinal metaplasia. Oya H, et al. **Adv Exp Med Biol** 1995; 371B:1087–9

Autoregulation of Tcr V region epitopes in autoimmune disease. Schluter SF, et al. **Adv Exp Med Biol** 1995; 383:231–6

Chronic motor neuropathies. Kornberg AJ, et al. **Adv Neurol** 1995;68:113–9 (52 ref.)

Lipocortin-1 autoantibody concentration in children with inflammatory bowel disease. Beattie RM, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):541–5

Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Bui MN, et al. **Am Heart J** 1996 Apr;131(4):663–7

Comparative study of ELISA and indirect immunofluorescence for the detection of anti-neutrophil cytoplasmic antibodies. Evaluation of the SCIMEDX/EURO Diagnostica ELISA assay in a clinical setting. Godbole MS, et al. **Am J Clin Pathol** 1995 Dec; 104(6):667–72

The value of p-ANCA as a serological marker in diagnosing the coexistence of chronic active invasive amebic colitis and ulcerative colitis [letter] Arslan S, et al. **Am J Gastroenterol** 1995 Dec;90(12):2265–6

Role of antineutrophil cytoplasmic antibodies in an ethnically distinct population: Korean patients with ulcerative colitis. Kim WH, et al. **Am J Gastroenterol** 1995 Nov;90(11):1953–8

Antineutrophil cytoplasmic antibodies in relatives of patients with inflammatory bowel disease. Papo M, et al. **Am J Gastroenterol** 1996 Aug;91(8):1512–5

Simultaneous occurrence of lupus anticoagulant, factor VIII inhibitor and localized pemphigoid [letter] Biron C, et al. **Am J Hematol** 1996 Mar;51(3):250–1

EDTA-dependent pseudothrombocytopenia: a clinical and epidemiological study of 112 cases, with 10-year follow-up. Bizzaro N. **Am J Hematol** 1995 Oct;50(2):103–9

Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma [letter] Shurafa M, et al. **Am J Hematol** 1995 Oct;50(2):149–50

Antibodies to neutrophil elastase: a study in patients with vasculitis. Apenberg S, et al. **Am J Kidney Dis** 1996 Aug; 28(2):178–85

Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Coremans IE, et al. **Am J Kidney Dis** 1995 Oct;26(4):595–601

Disease activity and autoantibodies to endothelial cells in patients with Wegener's granulomatosis. Göbel U, et al. **Am J Kidney Dis** 1996 Aug;28(2):186–94

Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P. Arnett FC, et al. **Am J Med** 1995 Nov;99(5):465–72

Long-term outcome of mothers of children with complete congenital heart block. Press J, et al. **Am J Med** 1996 Mar; 100(3):328–32

Correlates of insulin autoantibodies with beta cell function

at the time of diagnosis of diabetes mellitus. al-Attas OS. **Am J Med Sci** 1995 Oct;310(4):138–42

Prevalence of antibodies to glutamic acid decarboxylase in women who have had gestational diabetes. Beischer NA, et al. **Am J Obstet Gynecol** 1995 Nov;173(5):1563–9

Antiplatelet antibody testing in thrombocytopenic pregnant women. Lescale KB, et al. **Am J Obstet Gynecol** 1996 Mar; 174(3):1014–8

Serum antibodies against heat shock protein 70 in Menière's disease. Rauch SD, et al. **Am J Otol** 1995 Sep;16(5):648–52

Autoimmunity in chronic active Helicobacter hepatitis of mice. Serum antibodies and expression of heat shock protein 70 in liver. Ward JM, et al. **Am J Pathol** 1996 Feb; 148(2):509–17

Study of antisperm antibodies bound to the sperm cell surface and their relationship to circulating ASA. Gandini L, et al. **Am J Reprod Immunol** 1995 Dec;34(6):375–80

Detection of antiendometrial antibodies in sera of patients with endometriosis by dual-colored, double-labeling immunohistochemical method and western blot. Kim JG, et al. **Am J Reprod Immunol** 1995 Aug;34(2):80–7

Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Batlle J, et al. **Ann Hematol** 1996 May;72(5):321–6

Testing with antineutrophil cytoplasmic antibody to diagnose Wegener granulomatosis [letter] Hoffman GS. **Ann Intern Med** 1996 Oct 1;125(7):622; discussion 622–3

Anti-alpha1(IV) collagen autoantibodies associated with lung adenocarcinoma presenting as the Goodpasture syndrome. Kalluri R, et al. **Ann Intern Med** 1996 Apr 1;124(7):651–3

Testing with antineutrophil cytoplasmic antibody to diagnose Wegener granulomatosis [letter] Malnick SD. **Ann Intern Med** 1996 Oct 1;125(7):622; discussion 622–3

The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Rao JK, et al. **Ann Intern Med** 1995 Dec 15;123(12):925–32

Antiubiquitin antibody in localised and systemic scleroderma. Fujimoto M, et al. **Ann Rheum Dis** 1996 Jun;55(6):399–402

Antimyeloperoxidase antibodies in individuals with occupational exposure to silica. Wichmann I, et al. **Ann Rheum Dis** 1996 Mar;55(3):205–7

The significance of p53 autoantibodies in the serum of patients with breast cancer. Willsher PC, et al. **Anticancer Res** 1996 Mar-Apr;16(2):927–30

[125I]IgM (KAU) human monoclonal cold agglutinin: labelling and studies on its biological activity. Vigorito E, et al. **Appl Radiat Isot** 1995 Oct;46(10):975–9

A child with antibodies targeting both linear IgA bullous dermatosis and bullous pemphigoid antigens. Darling TN, et al. **Arch Dermatol** 1995 Dec;131(12):1438–42

Similar Ro/SS-A autoantibody epitope and titer responses in annular erythema of Sjögren's syndrome and subacute cutaneous lupus erythematosus. McCauliffe DP, et al. **Arch Dermatol** 1996 May;132(5):528–31

Absorption with K562 erythroblastoma cells as a means for discrimination between auto- and alloantibodies in sera of hypersensitized renal patients. Baldy-Chudzik K, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(3):223–6

The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Niles JL, et al. **Arch Intern Med** 1996 Feb 26;156(4):440–5

Serum antibodies to heat shock protein 70 in sensorineural hearing loss. Bloch DB, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct; 121(10):1167–71

Prediabetic markers in children with stress hyperglycemia. Bhisitkul DM, et al. **Arch Pediatr Adolesc Med** 1996 Sep; 150(9):936–41

Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Palinski W, et al. **Arterioscler Thromb Vasc Biol** 1995 Oct;15(10):1569–76

Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arnett FC, et al. **Arthritis Rheum** 1996 Jul; 39(7):1151–60

Autoantibodies to glycyl-transfer RNA synthetase in myositis. Association with dermatomyositis and immunologic heterogeneity. Hirakata M, et al. **Arthritis Rheum** 1996 Jan;39(1):146–51

Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases. Kuwana M, et al. **Arthritis Rheum** 1996 Apr;39(4):686–91

Monoclonal anticardiolipin autoantibodies established from the (New Zealand white x BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Mizutani H, et al. **Arthritis Rheum** 1995 Oct;38(10):1382–8

Anti-lamin autoantibodies and the clinical utility of autoimmune serology [editorial; comment] Sturgess AD. **Aust N Z J Med** 1996 Apr;26(2):145–6. Comment on: Aust N Z J Med 1996 Apr;26(2):162–6.

Anti-neutrophil cytoplasm antibodies in patients with ACR criteria for polyarteritis nodosa: help for systemic vasculitis classification? Baranger TA, et al. **Autoimmunity** 1995; 20(1):33–7

Increased natural autoantibody activity to cytoskeleton proteins in sera from patients with necrobiosis lipoidica, with or without insulin-dependent diabetes mellitus. Haralambous S, et al. **Autoimmunity** 1995;20(4):267–75

Study of self reactive antibodies in kappa-light chain deficient mice. Hatakeyama A, et al. **Autoimmunity** 1995; 20(2):113–20

The relationship of anti-endothelial cell antibodies to anti-phospholipid antibodies in patients with giant cell arteritis and/or polymyalgia rheumatica. Le Tonquèze M, et al. **Autoimmunity** 1995;20(1):59–66

Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Skeie GO, et al. **Autoimmunity** 1995; 20(2):99–104

The humoral immune system in coeliac disease. Mäki M. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):231–49 (115 ref.)

Autoantibody against Na+/I- symporter in the sera of patients with autoimmune thyroid disease. Endo T, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):92–5

Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Amiral J, et al. **Blood** 1996 Jul 15;88(2):410–6

Visualization of IgG-binding loci on the surface of sickle erythrocytes [letter] Green GA. **Blood** 1996 Mar 15; 87(6):2609

Presentation of an acquired factor VIII inhibitor with a muscular haematoma mimicking a deep venous thrombosis in a patient with breast cancer. López R, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):680–2

Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor. Mohri H, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):561–6

Autoantibodies against 70-kDa heat shock proteins (HSP70) in allogeneic bone marrow transplant recipients. Lee M, et al. **Bone Marrow Transplant** 1995 Oct;16(4):583–8

Autoimmunity to alpha myosin in a subset of patients with idiopathic dilated cardiomyopathy. Goldman JH, et al. **Br Heart J** 1995 Dec;74(6):598–603

Detection of autoantibodies directed against human hepatic endoplasmic reticulum in sera from patients with halothane-associated hepatitis. Kitteringham NR, et al. **Br J Clin Pharmacol** 1995 Oct;40(4):379–86

Comparative sensitivity of indirect immunofluorescence to immunoblot assay for the detection of circulating antibodies to bullous pemphigoid antigens 1 and 2. Ghohestani R, et al. **Br J Dermatol** 1996 Jul;135(1):74–9

The DEBR rat, alopecia areata and autoantibodies to the hair follicle. McElwee KJ, et al. **Br J Dermatol** 1996 Jan; 134(1):55–63

Diffuse plane xanthomatosis associated with a monoclonal band displaying anti-smooth muscle antibody activity. Sharpe PC, et al. **Br J Dermatol** 1995 Dec;133(6):961–6

Antineutrophil cytoplasmic antibodies in rheumatoid arthritis patients. de Bandt M, et al. **Br J Rheumatol** 1996 Jan; 35(1):38–43

Increased levels of beta 2 glycoprotein-I antigen and beta 2 glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. McNally T, et al. **Br J Rheumatol** 1995 Nov;34(11):1031–6

Phosphatidyl serine-dependent antiprothrombin antibody is exclusive to patients with lupus anticoagulant. Matsuda J, et al. **Br J Rheumatol** 1996 Jun;35(6):589–91

Changing autoantibody profiles with variable clinical manifestations in a patient with relapsing systemic lupus erythematosus and polymyositis. Satoh M, et al. **Br J Rheumatol** 1995 Oct;34(10):915–9

Atypical Cogan's syndrome associated with antineutrophil cytoplasmic autoantibodies [letter] Yamanishi Y, et al. **Br J Rheumatol** 1996 Jun;35(6):601–3

Selective loss of myelin-associated glycoprotein from myelin correlates with anti-MAG antibody titre in demyelinating paraproteinaemic polyneuropathy. Gabriel JM, et al. **Brain** 1996 Jun;119 (Pt 3):775–87

Circulating immune complexes in patients with advanced tuberculosis and their association with autoantibodies and reduced CD4+ lymphocytes. Dlugovitzky D, et al. **Braz J Med Biol Res** 1995 Mar;28(3):331–5

Antimitochondrial antibodies after acute myocardial infarction. Schifter T, et al. **Cardiology** 1996 Jan-Feb; 87(1):67–70

Correlation between the concentration of serum anti-topoisomerase I autoantibodies and histological and biochemical alterations in the skin of tight skin mice. Hatakeyama A, et al. **Cell Immunol** 1996 Jan 10; 167(1):135–40

Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Filep JG, et al. **Circulation** 1995 Nov 15;92(10):2969–74

Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Heitzer T, et al. **Circulation** 1996 Apr 1;93(7):1346–53

ELISA for thyroglobulin in serum: recovery studies to evaluate autoantibody interference and reliability of thyroglobulin values. Erali M, et al. **Clin Chem** 1996 May; 42(5):766–70

Reference calibrators for IgG antibodies to beta2-glycoprotein I: preparation, properties and availability to investigators. Erickson EN Jr, et al. **Clin Chem** 1996 Jul;42(7):1116–7

Markers of neurotoxicity: from behavior to autoantibodies against brain proteins. Evans HL. **Clin Chem** 1995 Dec; 41(12 Pt 2):1874–81 (116 ref.)

Detection of glutamic acid decarboxylase autoantibodies with the varelisa ELISA. Gronowski AM, et al. **Clin Chem** 1995 Oct;41(10):1532–4

Highly sensitive immunoradiometric assay for serum thyroglobulin with minimal interference from autoantibodies. Marquet PY, et al. **Clin Chem** 1996 Feb; 42(2):258–62

DELISA: sensitive nonisotopic assay for GAD65 autoantibodies, a key risk-assessment marker for insulin-dependent diabetes mellitus. Mehta HB, et al. **Clin Chem** 1996 Feb;42(2):263–9

Anti-solid phase antibodies interfering in labeled-antibody assays of free thyroid hormones [letter] Sapin R, et al. **Clin Chem** 1995 Dec;41(12 Pt 1):1790–2

Calpastatin autoantibodies: detection, epitope mapping, and development of a specific peptide ELISA. Schlosser U, et al. **Clin Chem** 1996 Aug;42(8 Pt 1):1250–6

Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies [editorial] Spencer CA. **Clin Chem** 1996 May;42(5):661–3

Multireactive pattern of serum autoantibodies in asymptomatic individuals with immunoglobulin A deficiency. Barka N, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):469–72

A confocal microscopy study of anticytoskeletal antibody activity in patients with connective tissue disease. French PW, et al. **Clin Diagn Lab Immunol** 1994 Jan;1(1):71–7

Anti-human immunodeficiency virus type 1 antibodies of noninfected subjects are not related to autoantibodies occurring in systemic diseases. Kämmerer R, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):458–61

Frequency of biochemical hypothyroidism in sera referred for autoantibody testing. Reyes H, et al. **Clin Diagn Lab Immunol** 1994 May;1(3):351–2

Detection of anti-neutrophil cytoplasmic antibodies after acute Plasmodium falciparum malaria. Wenisch C, et al. **Clin Diagn Lab Immunol** 1996 Jan;3(1):132–4

Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Marazuela M, et al. **Clin Endocrinol (Oxf)** 1996 Jun; 44(6):635–42

Reduction in serum levels of antimitochondrial (M2) antibodies following immunoglobulin therapy in severe combined immunodeficient (SCID) mice reconstituted with lymphocytes from patients with primary biliary cirrhosis (PBC). Abedi MR, et al. **Clin Exp Immunol** 1996 Aug; 105(2):266–73

Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura. Bettaieb A, et al. **Clin Exp Immunol** 1996 Jan; 103(1):19–23

Anti-M4 antibodies measured by a sulphite oxidase ELISA in patients with both anti-centromere and anti-M2 antibodies. Bunn CC, et al. **Clin Exp Immunol** 1995 Oct; 102(1):131–6

Autoantibodies to thyroid hormones: the role of thyroglobulin. Erregragui K, et al. **Clin Exp Immunol** 1996 Jul;105(1):140–7

Autoantibodies to mitochondrial 2-oxo-acid dehydrogenase complexes in localized scleroderma. Fujimoto M, et al. **Clin Exp Immunol** 1996 Aug;105(2):297–301

Presence of antibodies to replication protein A in some patients with systemic lupus erythematosus (SLE). Garcia-Lozano R, et al. **Clin Exp Immunol** 1996 Jan; 103(1):74–6

Clinical features of anti-chromo antibodies associated with anti-centromere antibodies. Iwai T, et al. **Clin Exp Immunol** 1996 Aug;105(2):285–90

Neutrophil and recombinant myeloperoxidase as antigens in ANCA positive systemic vasculitis. Short AK, et al. **Clin Exp Immunol** 1995 Oct;102(1):106–11

Significance of anti-nuclear and anti-extracellular matrix autoantibodies for albuminuria in murine lupus nephritis; a longitudinal study on plasma and glomerular eluates in MRL/l mice. van Bruggen MC, et al. **Clin Exp Immunol** 1996 Jul;105(1):132–9

Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Wu R, et al. **Clin Exp Immunol** 1995 Oct;102(1):174–80

Frequency of anti-bactericidal/permeability-increasing protein (BPI) and anti-azurocidin in patients with renal disease. Yang JJ, et al. **Clin Exp Immunol** 1996 Jul; 105(1):125–31

Azurocidin is a novel antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis. Zhao MH, et al. **Clin Exp Immunol** 1996 Mar;103(3):397–402

Incidence of anti Hsp 90 and 70 antibodies in children with SLE, juvenile dermatomyositis and juvenile chronic arthritis. Conroy SE, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):99–104

Gliadin immune reactivity in patients with rheumatoid arthritis. Paimela L, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):603–7

The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Adamus G, et al. **Clin Immunol Immunopathol** 1996 Feb;78(2):120–9

Detection on immunoblot of new proteins from the soluble fraction of the cell recognized either by anti-liver-kidney microsome antibodies type 1 or by anti-liver cytosol antibodies type 1—relationship with hepatitis C virus infection. Ballot E, et al. **Clin Immunol Immunopathol** 1996

Sep;80(3 Pt 1):245-54

Detection on immunoblot of new proteins from the microsomal fraction recognized by anti-liver-kidney microsome antibodies type 1. Ballot E, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):255-65

A patient with autoimmune thrombocytopenic purpura demonstrating serum antibodies reactive with mouse cross-reactive idiotypes. Clofent-Sanchez G, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):271-81

Normal levels of allo- but increased levels of potentially autoreactive antibodies against ABO histo-blood group antigens in AIDS patients. Friedli F, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):96-100

Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Krams SM, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):311-20

Neutrophil attractant protein-1 interleukin 8 and its autoantibodies in IgA nephropathy. Lai KN, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):47-54

IgG autoantibody response in HTLV-I-infected patients. Muller S, et al. **Clin Immunol Immunopathol** 1995 Dec; 77(3):282-90

Anti-GOR and anti-thyroid autoantibodies in patients with chronic hepatitis C. Tran A, et al. **Clin Immunol Immunopathol** 1995 Nov;77(2):127-30

The value of gel test and ELAT in autoimmune haemolytic anaemia. Fabijanska-Mitek J, et al. **Clin Lab Haematol** 1995 Dec;17(4):311-6

Enzyme-linked antiglobulin test for the evaluation of the amount of IgG autoantibodies on red blood cells. Namirska-Krzton H, et al. **Clin Lab Haematol** 1995 Sep; 17(3):221-4

Anti-mesangial and anti-endothelial cell antibodies in IgA mesangial nephropathy. Fornasieri A, et al. **Clin Nephrol** 1995 Aug;44(2):71-9

Detection of antibodies to 65 KD heat shock protein and to human superoxide dismutase in autoimmune hepatitis-molecular mimicry between 65 KD heat shock protein and superoxide dismutase. Miyata M, et al. **Clin Rheumatol** 1995 Nov;14(6):673-7

Anti-neutrophil cytoplasmic antibodies in familial Mediterranean fever [letter] Simsek H, et al. **Clin Rheumatol** 1996 Mar;15(2):216-8

Novel anti-silicone surface-associated antigen antibodies (anti-SSAA(x)) may help differentiate symptomatic patients with silicone breast implants from patients with classical rheumatological disease. Kossovsky N, et al. **Curr Top Microbiol Immunol** 1996;210:327-36

Comparative epitope mapping of antibodies to collagen in women with silicone breast implants, systemic lupus erythematosus and rheumatoid arthritis. Rowley MJ, et al. **Curr Top Microbiol Immunol** 1996;210:307-16

In new-onset insulin-dependent diabetic patients the presence of anti-thyroid peroxidase antibodies is associated with islet cell autoimmunity and the high risk haplotype HLA DQA1*0301-DQB1*0302. Belgian Diabetes Registry. Abrams P, et al. **Diabet Med** 1996 May; 13(5):415-9

Heat shock protein studies in type 1 and type 2 diabetes and human islet cell culture. Child DF, et al. **Diabet Med** 1995 Jul;12(7):595-9

Islet cell antibodies and beta-cell function in gestational diabetic women: comparison to first-degree relatives of type 1 (insulin-dependent) diabetic subjects. Mauricio D, et al. **Diabet Med** 1995 Nov;12(11):1009-14

HLA and glutamic acid decarboxylase in human insulin-dependent diabetes mellitus. Sanjeevi CB, et al. **Diabet Med** 1996 Mar;13(3):209-17 (68 ref.)

Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM. Chang YH, et al. **Diabetes** 1996 Apr;45(4):408-14

Autoimmunity to the GM2-1 islet ganglioside before and at the onset of type I diabetes. Dotta F, et al. **Diabetes** 1996 Sep;45(9):1193-6

Anti-endothelial cell autoantibodies in BB rats with spontaneous and induced IDDM. Doukas J, et al. **Diabetes** 1996 Sep;45(9):1209-16

Cellular immune response to diverse islet cell antigens in IDDM. Durinovic-Bellò I, et al. **Diabetes** 1996 Jun; 45(6):795-800

ICA512 autoantibody radioassay. Gianani R, et al. **Diabetes** 1995 Nov;44(11):1340-4

Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2. Hawkes CJ, et al. **Diabetes** 1996 Sep;45(9):1187-92

Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Kobayashi T, et al. **Diabetes** 1996 May; 45(5):622-6

Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Myers MA, et al. **Diabetes** 1995 Nov;44(11):1290-5

Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Verge CF, et al. **Diabetes** 1996 Jul; 45(7):926-33

Late progression to diabetes and evidence for chronic beta-cell autoimmunity in identical twins of patients with type I diabetes. Verge CF, et al. **Diabetes** 1995 Oct; 44(10):1176-9

Psychological impact of islet cell antibody screening for IDDM on children, adults, and their family members. Bennett Johnson S, et al. **Diabetes Care** 1995 Oct; 18(10):1370-2

Is the oral glucose tolerance test obsolete? [editorial] Drash AL. **Diabetes Care** 1995 Jul;18(7):1072-3

Immunogenetic, clinical, and demographic characterization of childhood type I diabetes in New Zealand. Forbes LV, et al. **Diabetes Care** 1995 Nov;18(11):1428-33

Islet cell antibodies at diagnosis, but not leanness, relate to a better cardiovascular risk factor profile 5 years after diagnosis of NIDDM. Gottsäter A, et al. **Diabetes Care** 1996 Jan;19(1):60-3

Five cases of hyperthyroidism in type I diabetic patients treated with intraperitoneal insulin infusion [letter] Jeandidier N, et al. **Diabetes Care** 1995 Jun;18(6):888-9

Antibodies against bovine albumin and other diabetes markers in French children. Lévy-Marchal C, et al. **Diabetes Care** 1995 Aug;18(8):1089-94

GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Niskanen LK, et al. **Diabetes Care** 1995 Dec; 18(12):1557-65

The low prevalence of immunogenetic markers in Korean adult-onset IDDM patients. Park Y, et al. **Diabetes Care** 1996 Mar;19(3):241-5

Proinsulin immunoreactivity in recent-onset IDDM: the significance of insulin antibodies and insulin autoantibodies. Snorgaard O, et al. **Diabetes Care** 1996 Feb;19(2):146-50

Serial changes in the prevalence of islet cell antibodies and islet cell antibody titer in children with IDDM of abrupt or slow onset. Urakami T, et al. **Diabetes Care** 1995 Aug; 18(8):1095-9

Phospholipid and glutamic acid decarboxylase autoantibodies in diabetic neuropathy. Vinik AI, et al. **Diabetes Care** 1995 Sep;18(9):1225-32

Relationship between GAD antibody and residual beta-cell function in children after overt onset of IDDM. Yokota I, et al. **Diabetes Care** 1996 Jan;19(1):74-5

The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Zimmet PZ. **Diabetes Care** 1995 Jul;18(7):1050-64 (142 ref.)

Occurrence of islet cell reactive autoantibodies in diabetes-prone BB/OK rats is not associated with the onset of diabetes: a cross-sectional study of BB rats and their diabetes-resistant congenic strains. Schlosser M, et al. **Diabetes Res** 1994;26(2):67-77

Anti platelet property of anti-single-stranded DNA antibodies in type 1 (insulin-dependent) diabetes mellitus. Triolo G, et al. **Diabetes Res** 1994;26(2):79-87

Antibodies to GAD in Japanese diabetic patients: a multicenter study. Tsuruoka A, et al. **Diabetes Res Clin Pract** 1995 Jun;28(3):191-9

Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Bonifacio E, et al. **Diabetologia** 1995 Jul;38(7):816-22

Epstein-Barr virus infection is not associated with islet cell and insulin auto-antibody seroconversion [letter] Elliott RB, et al. **Diabetologia** 1995 Sep;38(9):1130

Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis [letter] Imagawa A, et al. **Diabetologia** 1996 Jan;39(1):126

Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis. A case-control study. Aisenberg J, et al. **Dig Dis Sci** 1995 Sep;40(9):1866-72

Anti 70 kDa heat shock protein antibodies in sera of patients affected by autoimmune and non-autoimmune thyroid diseases. Paggi A, et al. **Endocr Res** 1995 Aug;21(3):555-67

Organ-specific cardiac autoantibodies in dilated cardiomyopathy. Frequency and clinical correlates in Polish patients. Bilińska ZT, et al. **Eur Heart J** 1995 Dec; 16(12):1907-11

Anti-peptide antibodies against an autoimmune epitope on human muscarinic receptor mimic functional autoantibodies against the same epitope in patients with idiopathic dilated cardiomyopathy. Fu ML. **Eur Heart J** 1995 Dec;16 Suppl O:89-91

The beta 1-adrenoceptor as antigen: functional aspects. Wallukat G, et al. **Eur Heart J** 1995 Dec;16 Suppl O:85-8

Rapid and easy procedure for the determination of immunoglobulin class and light chain type of anti-lactate dehydrogenase antibodies in macro-lactate dehydrogenase. Kleinveld HA, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul;33(7):441-2

Discordant results in the assay of cytoplasmic islet cell autoantibodies with ELISA and immunohistochemical techniques. Kohnert KD, et al. **Eur J Clin Chem Clin Biochem** 1995 Jul;33(7):447-9

Autoimmune hypothyroidism and hyperthyroidism in patients with Turner's syndrome. Chiovato L, et al. **Eur J Endocrinol** 1996 May;134(5):568-75

Recurrent miscarriage is associated with increased numbers of CD5/20 positive lymphocytes and an increased incidence of thyroid antibodies. Roberts J, et al. **Eur J Endocrinol** 1996 Jan;134(1):84-6

Low prevalence of anti-neutrophil cytoplasmic antibodies in ulcerative colitis patients with long-term remission. Lindgren S, et al. **Eur J Gastroenterol Hepatol** 1995 Jun; 7(6):563-8

Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist? Regidor PA, et al. **Eur J Gynaecol Oncol** 1996;17(3):192-9

Different immunophenotype and autoantibody production by peripheral blood and thyroid-derived lymphocytes in patients with Graves' disease. Aust G, et al. **Exp Clin Endocrinol Diabetes** 1996;104(1):50-8

Specific detection of anti-cell surface antibodies in herpes gestationis sera. Hashimoto T, et al. **Exp Dermatol** 1996 Apr;5(2):96-101

Bullous pemphigoid: serum antibody titre and antigen specificity. Pas HH, et al. **Exp Dermatol** 1995 Dec; 4(6):372-6

Antibodies to carbonic anhydrase in endometriosis: prevalence, specificity, and relationship to clinical and laboratory parameters. D'Cruz OJ, et al. **Fertil Steril** 1996 Oct;66(4):547-56

Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren's syndrome. Kino-Ohsaki J, et al. **Gastroenterology** 1996 May;110(5):1579-86

Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Węsierska-Gądek J, et al. **Gastroenterology** 1996 Mar;110(3):840-7

The anti-oligosaccharide antibodies present in sera from patients with motor neuron disease and neuropathy recognize the N-glycolylneuraminic acid containing gangliotetrahexosyl oligosaccharide. Carpo M, et al. **Glycoconj J** 1995 Oct;12(5):729-31

Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Bandin O, et al. **Hepatology** 1996 May; 23(5):1020-4

Heat serum inactivation as a mandatory procedure for antiactin antibody detection in cell culture. Cançado EL, et al. **Hepatology** 1996 May;23(5):1098-104

Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. Moteki S, et al. **Hepatology** 1996 Jul;24(1):97-103

Thyroid autoantibodies in euthyroid non-pregnant women with recurrent spontaneous abortions. Bussen S, et al. **Hum Reprod** 1995 Nov;10(11):2938-40

Autoimmune disorders: another possible cause for in-vitro fertilization and embryo transfer failure. Geva E, et al. **Hum Reprod** 1995 Oct;10(10):2560-3

Identification and characterization of antimitochondrial autoantibodies in sera of patients with monoclonal gammopathies. Gilbrud B, et al. **Immunol Lett** 1995 Mar; 45(3):163-6

Anti-actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA. Leibovitch L, et al. **Immunol Lett** 1995 Dec;48(2):129-32

A need for standardization of the anti-endothelial-cell antibody test. Youinou P, et al. **Immunol Today** 1995 Aug; 16(8):363-4

Hexachlorobenzene treatment increases the number of splenic B-1-like cells and serum autoantibody levels in the rat. Schielen P, et al. **Immunology** 1995 Dec;86(4):568-74

Antibodies to serum IgA detected by ELISA in duodenal ulcer and their relationship to chronicity of the disease. Begum S, et al. **Indian J Exp Biol** 1996 Feb;34(2):180-1

Disproportional distribution of isotype and non-isotype-specific IgG subclass anti-IgE autoantibodies in human cord serum. Magnusson CG, et al. **Int Arch Allergy Immunol** 1996 May;110(1):31-40

Autoantibodies against insulin and beta-islet cells in pancreatic adenocarcinoma: a possible explanation for diabetes mellitus. Syrigos KN, et al. **Int J Cancer** 1996 May 29;66(5):624-6

Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Yamamoto A, et al. **Int J Cancer** 1996 Aug 22;69(4):283-9

Immunological study of anti-M2 in antimitochondrial antibody-negative primary biliary cirrhosis. Kitami N, et al. **Intern Med** 1995 Jun;34(6):496-501

Acquired factor VIII-specific antibody disorder accompanied by a life-threatening retroperitoneal hematoma. Kondo E, et al. **Intern Med** 1995 Sep; 34(9):901-3

Renal vasculitis and antineutrophil cytoplasmic antibody [editorial; comment] Nagasawa T. **Intern Med** 1995 Oct; 34(10):936-7. Comment on: Intern Med 1995 Oct;34(10):1000-4.

Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma). Shoenfeld Y, et al. **Isr J Med Sci** 1996 Jul;32(7):537-42 (32 ref.)

Reactivity of autoantibodies from patients with defined subepidermal bullous diseases against 1 mol/L salt-split skin. Specificity, sensitivity, and practical considerations. Lazarova Z, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):398-403

Detection of anti-Fc gamma R antibodies and different cytokines in sera from patients with systemic sclerosis [letter; comment] Szegedi A, et al. **J Am Acad Dermatol** 1996 Jul;35(1):134. Comment on: J Am Acad Dermatol 1995 Oct;33(4):612-6.

Autoantibodies to triiodothyronine and thyroxine in a golden retriever. Kemppainen RJ, et al. **J Am Anim Hosp Assoc** 1996 May-Jun;32(3):195-8

Autoantibody profile in the sera of women with hyperprolactinemia. Buskila D, et al. **J Autoimmun** 1995

Jun;8(3):415–24

Antibody to the M(r) 65,000 isoform of glutamic acid decarboxylase are detected in non–insulin–dependent diabetes in Japanese. **Kasuga A, et al. J Autoimmun** 1996 Feb;9(1):105–11

Autoantibodies to glutamic acid decarboxylase in patients with autoimmune thyroid disease: relation to competitive insulin autoantibodies. **Kawasaki E, et al. J Autoimmun** 1995 Oct;8(5):633–43

Unique autoantibody epitopes in an immunodominant region of thyroid peroxidase. **Arscott PL, et al. J Biol Chem** 1996 Mar 1;271(9):4966–73

Prolonged treatment with recombinant insulin–like growth factor–I in children with growth hormone insensitivity syndrome—a clinical research center study. GHIS Collaborative Group. **Backeljauw PF, et al. J Clin Endocrinol Metab** 1996 Sep;81(9):3312–7

Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. **Chen S, et al. J Clin Endocrinol Metab** 1996 May;81(5):1871–6

Monoclonal, human autoantibodies to the TSH receptor—the Holy Grail and why are we looking for it? [editorial] **McLachlan SM, et al. J Clin Endocrinol Metab** 1996 Sep; 81(9):3152–4 (29 ref.)

Binding of antithyrotropin receptor autoantibodies in Graves' disease serum to nascent, in vitro translated thyrotropin receptor: ability to map epitopes recognized by antibodies. **Morgenthaler NG, et al. J Clin Endocrinol Metab** 1996 Feb;81(2):700–6

Relationship of antibodies to thyrotropin receptors and to thyroid ultrasonographic volume in euthyroid and hypothyroid patients with autoimmune thyroiditis. **Rieu M, et al. J Clin Endocrinol Metab** 1996 Feb;81(2):641–5

Effect of methimazole with or without exogenous L–thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease. **Rittmaster RS, et al. J Clin Endocrinol Metab** 1996 Sep; 81(9):3283–8

Antibody–dependent cell–mediated cytotoxicity in autoimmune thyroid disease: relationship to antithyroperoxidase antibodies. **Rodien P, et al. J Clin Endocrinol Metab** 1996 Jul;81(7):2595–600

Glutamic acid decarboxylase antibodies in relation to other autoantibodies and genetic risk markers in children with newly diagnosed insulin–dependent diabetes. Childhood Diabetes in Finland Study Group. **Sabbah E, et al. J Clin Endocrinol Metab** 1996 Jul;81(7):2455–9

Antibodies to glutamic acid decarboxylase and insulin–dependent diabetes in patients with autoimmune polyendocrine syndrome type I. **Tuomi T, et al. J Clin Endocrinol Metab** 1996 Apr;81(4):1488–94

Evidence for IgG autoantibodies to galectin–3, a beta–galactoside–binding lectin (Mac–2, epsilon binding protein, or carbohydrate binding protein 35) in human serum. **Mathews KP, et al. J Clin Immunol** 1995 Nov; 15(6):329–37

Natural autoantibodies in sera of patients with Gaucher's disease. **Shoenfeld Y, et al. J Clin Immunol** 1995 Nov; 15(6):363–72

Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? **Fiebiger E, et al. J Clin Invest** 1995 Dec;96(6):2606–12

Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein. **Satoh M, et al. J Clin Invest** 1996 Jun 1; 97(11):2619–26

Antigen association of total HEp–2 cell extract in the screening of autoimmune diseases by western blot. **Capin N, et al. J Clin Lab Anal** 1996;10(3):140–3

Clinical evaluation of antineutrophil cytoplasmic autoantibodies in ANCA–associated diseases. **Cristea A, et al. J Clin Lab Immunol** 1995;46(2):85–94

Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. **Aitola P, et al. J Clin Pathol** 1995 Jul;48(7):645–7

Anti–GM1 antibodies in polyneuropathies of unknown origin. **Finsterer J, et al. J Clin Pathol** 1996 May;49(5):422–5

Simple radioimmunological assay of anti–alpha–galactosyl antibody (anti–Gal): application to autoimmune thyroid diseases and thyroid–associated ophthalmopathy. **Winand RJ, et al. J Endocrinol Invest** 1995 Nov;18(10):749–53

Autoantibodies from patients with primary biliary cirrhosis preferentially react with the amino–terminal domain of nuclear pore complex glycoprotein gp210. **Wesierska–Gadek J, et al. J Exp Med** 1995 Oct 1; 182(4):1159–62

High prevalence of antibodies to recombinant CENP–B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. **Parveen S, et al. J Gastroenterol Hepatol** 1995 Jul–Aug;10(4):438–45

Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. **Boadas J, et al. J Hepatol** 1995 Jun;22(6):611–5

Kinetics of anti–M2 antibodies after liver transplantation for primary biliary cirrhosis. **Dubel L, et al. J Hepatol** 1995 Dec;23(6):674–80

The Hôpital Saint Antoine and Hôpital Paul Brousse experience of anti–M4 and anti–M9 antibodies as markers of severity of primary biliary cirrhosis [letter] **Dubel L, et al. J Hepatol** 1995 Nov;23(5):627–8

Recurrent episodes of acute hepatitis associated with LKM–1 (cytochrome P450 2D6) antibodies in identical twin brothers. **Nolte W, et al. J Hepatol** 1995 Dec;23(6):734–9

Autoantibody against 70 kD heat shock protein in patients with autoimmune liver diseases. **Shingai R, et al. J Hepatol** 1995 Oct;23(4):382–90

The sera of spontaneously hypertensive rats contain agonistic auto–antibodies against the beta 1–adrenoceptor. **Wallukat G, et al. J Hypertens** 1995 Sep;13(9):1031–6

Epitope mapping of C1 inhibitor autoantibodies from patients with acquired C1 inhibitor deficiency. **He S, et al. J Immunol** 1996 Mar 1;156(5):2009–13

Thyroid antibodies in northern Norway: prevalence, persistence and relevance. **Bryhni B, et al. J Intern Med** 1996 Jun;239(6):517–23

Urolithiasis and distal renal tubular acidosis preceding primary Sjögren's syndrome: a retrospective study 5–53 years after the presentation of urolithiasis. **Eriksson P, et al. J Intern Med** 1996 Jun;239(6):483–8

Islet cell and glutamic acid decarboxylase antibodies in hyperthyroid patients: at diagnosis and following treatment. **Hallengren B, et al. J Intern Med** 1996 Jan;239(1):63–8

Autoantibodies against adrenal medulla in type 1 and type 2 diabetes mellitus: no evidence for an association with autonomic neuropathy. **Husebye ES, et al. J Intern Med** 1996 Feb;239(2):139–46

Euthyroid Graves' disease showing no thyroid abnormalities except positive thyroid–stimulating antibody (TSAb): two case reports. **Watanabe M, et al. J Intern Med** 1995 Oct; 238(4):379–84

Autoantibodies against desmoplakin I and II define a subset of patients with erythema multiforme major. **Foedinger D, et al. J Invest Dermatol** 1996 May;106(5):1012–6

Recombinant ribosomal P2 protein can unmask anti–ribosomal P autoantibodies from healthy adults. **Pan ZJ, et al. J Lab Clin Med** 1996 Apr;127(4):333–9

Circulating antibodies directed against conjugated fatty acids in sera of patients with multiple sclerosis. **Boullerne A, et al. J Neuroimmunol** 1996 Mar;65(1):75–81

Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. **Uchuya M, et al. J Neurol Neurosurg Psychiatry** 1996 Apr; 60(4):388–92

Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert–Eaton myasthenic syndrome. **Takamori M, et al. J Neurol Sci** 1995 Nov;133(1–2):95–101

Anti–neutrophil cytoplasmic antibodies in Japanese children with ulcerative colitis. **Kaneko K, et al. J Paediatr Child Health** 1995 Aug;31(4):336–8

Serological diagnosis of celiac disease. **Rittmeyer C. J Pediatr Gastroenterol Nutr** 1995 Aug;21(2):238–9

Acute transient hemolytic anemia with a positive Donath–Landsteiner test following parvovirus B19 infection. **Chambers LA, et al. J Pediatr Hematol Oncol** 1996 May;18(2):178–81

IgM class autoantibodies in human cord serum. **Ailus K, et al. J Reprod Immunol** 1995 May;29(1):61–7

Anti–CENP–B response in sera of uranium miners exposed to quartz dust and patients with possible development of systemic sclerosis (scleroderma). **Conrad K, et al. J Rheumatol** 1995 Jul;22(7):1286–94

Autoantibodies in systemic lupus erythematosus and urticarial vasculitis. **D'Cruz DP, et al. J Rheumatol** 1995 Sep; 22(9):1669–73

High levels of antibodies to annexins V and VI in patients with rheumatoid arthritis. **Dubois T, et al. J Rheumatol** 1995 Jul;22(7):1230–4

Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. **Fritzler MJ, et al. J Rheumatol** 1995 Sep;22(9):1688–93

Clinical and serological identification of 2 forms of complete heart block in children. **Hubscher O, et al. J Rheumatol** 1995 Jul;22(7):1352–5

Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti–U3RNP antibody. **Sacks DG, et al. J Rheumatol** 1996 Apr;23(4):639–42

A canine case of discoid lupus erythematosus with circulating autoantibody. **Iwasaki T, et al. J Vet Med Sci** 1995 Dec; 57(6):1097–9

Absence of anti–LKM–1 antibody in hepatitis C viral infection in the United States of America. **Reddy KR, et al. J Viral Hepat** 1995;2(4):175–9

Autoantigens interact with cis–acting elements of rubella virus RNA. **Pogue GP, et al. J Virol** 1996 Sep; 70(9):6269–77

The cell proliferation–associated protein Ki–67 is a target of autoantibodies in the serum of MRL mice. **Bloch DB, et al. Lab Invest** 1995 Sep;73(3):366–71

c–ANCA as a marker of Wegener's disease [letter; comment] **Bosch X, et al. Lancet** 1996 Jan 13;347(8994):117; discussion 118. Comment on: Lancet 1995 Oct 7;346(8980):926–31.

c–ANCA as a marker of Wegener's disease [letter; comment] **Clark HE. Lancet** 1996 Jan 13;347(8994):117; discussion 118. Comment on: Lancet 1995 Oct 7;346(8980):926–31.

c–ANCA as a marker of Wegener's disease [letter; comment] **Franssen CF, et al. Lancet** 1996 Jan 13;347(8994):116; discussion 118. Comment on: Lancet 1995 Oct 7;346(8980):926–31.

c–ANCA as a marker of Wegener's disease [letter; comment] **Malnick SD, et al. Lancet** 1996 Jan 13;347(8994):117–8. Comment on: Lancet 1995 Oct 7;346(8980):926–31.

c–ANCA as a marker of Wegener's disease [letter; comment] **Niles JL, et al. Lancet** 1996 Jan 13;347(8994):116–7; discussion 118. Comment on: Lancet 1995 Oct 7;346(8980):926–31.

A prospective study of antineutrophil cytoplasmic antibody (c–ANCA) and clinical criteria in diagnosing Wegener's granulomatosis [see comments] **Rao JK, et al. Lancet** 1995 Oct 7;346(8980):926–31. Comment in: Lancet 1996 Jan 13;347(8994):115–6; discussion 118. Comment in: Lancet 1996 Jan 13;347(8994):116; discussion 118. Comment in: Lancet 1996 Jan 13;347(8994):116–7; discussion 118. Comment in: Lancet 1996 Jan 13;347(8994):117; discussion 118. Comment in: Lancet 1996 Jan 13;347(8994):117–8.

c–ANCA as a marker of Wegener's disease [letter; comment] **Unsworth DJ, et al. Lancet** 1996 Jan 13;347(8994):115–6; discussion 118. Comment on: Lancet 1995 Oct 7;346(8980):926–31.

Posttranslational changes in band 3 in adult and aging brain following treatment with ergoloid mesylates, comparison to changes observed in Alzheimer's disease. **Cover CC, et al. Life Sci** 1996;58(8):655–64

Circulating autoantibodies to a 240 kD fetal brain protein. **Peltola JT, et al. Life Sci** 1996;58(6):519–23

Antibodies reactive with HIV–1 antigens in systemic lupus erythematosus. **Gül A, et al. Lupus** 1996 Apr;5(2):120–2

Thyroid peroxidase autoantibodies and their effects on enzyme activity in patients with systemic lupus erythematosus. **Tsai RT, et al. Lupus** 1995 Aug;4(4):280–5

Use and interpretation of rheumatologic tests: a guide for clinicians. **Moder KG. Mayo Clin Proc** 1996 Apr; 71(4):391–6 (17 ref.)

DNA hydrolysis by antibodies. **Gabibov AG, et al. Methods Mol Biol** 1995;51:223–35

Epitope and idiotope mapping using monoclonal antibodies. **Kaveri S. Methods Mol Biol** 1995;51:171–81

Detection of inner ear disease autoantibodies by immunoblotting. **Cao MY, et al. Mol Cell Biochem** 1995 May 24;146(2):157–63

Autoantibodies to neuronal glutamate receptors in patients with paraneoplastic neurodegenerative syndrome enhance receptor activation. **Gahring LC, et al. Mol Med** 1995 Mar; 1(3):245–53

Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin–dependent diabetes. **Rudy G, et al. Mol Med** 1995 Sep;1(6):625–33

Discordant manifestations of hepatitis C in monozygotic twins [letter] **Vento S, et al. N Engl J Med** 1995 Nov 2; 333(18):1224–5

Serum p53 antibodies as early markers of lung cancer. **Lubin R, et al. Nat Med** 1995 Jul;1(7):701–2

High titres of circulating 29–kDa ANCAs in two patients with Wegener's granulomatosis in long–term clinical remission [letter] **Zoumbaridis N, et al. Nephrol Dial Transplant** 1996 May;11(5):906

Abnormal circulating pancreatic enzyme activities in more than twenty–five percent of recent–onset insulin–dependent diabetic patients: association of hyperlipasemia with high–titer islet cell antibodies. Belgian Diabetes Registry. **Semakula C, et al. Pancreas** 1996 May;12(4):321–33

Autoantibody profile of primary sclerosing cholangitis. **Gur H, et al. Pathobiology** 1995;63(2):76–82

Autoimmune aspects of primary pulmonary hypertension. **Yanai–Landau H, et al. Pathobiology** 1995;63(2):71–5

Cold agglutinins: preoperative diagnosis leads to an uneventful perfusion. **Innet LM, et al. Perfusion** 1995 Sep; 10(5):343–5

The 37/40–kilodalton autoantigen in insulin–dependent diabetes mellitus is the putative tyrosine phosphatase IA–2. **Passini N, et al. Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9412–6

Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. **Short AK, et al. QJM** 1995 Nov; 88(11):775–83

Autoantibodies against bactericidal/permeability–increasing protein in patients with cystic fibrosis. **Zhao MH, et al. QJM** 1996 Apr;89(4):259–65

Autoantibodies to cytokines in inflammatory joint disorders [editorial] **Jouvenne P, et al. Rev Rhum Engl Ed** 1995 Oct; 62(9):541–5 (20 ref.)

Antineutrophil cytoplasmic autoantibodies (ANCA)—markers in diagnosis and monitoring systemic vasculitides. **Cristea A, et al. Rom J Intern Med** 1995 Jan–Jun;33(1–2):37–46

Immunogenicity of oxidised low–density lipoprotein and atherosclerosis [letter] **Cheng HM. S Afr Med J** 1996 Jun; 86(6):698–9

Measurement of anti–acetylcholine receptor auto–antibodies in myasthenia gravis. **Steenkamp KJ, et al. S Afr Med J** 1995 Dec;85(12):1293–4

Thyroid antibodies in association with thyroid malignancy II: Qualitative properties of thyroglobulin antibodies. **Haapala AM, et al. Scand J Clin Lab Invest** 1995 Jul; 55(4):317–22

Characterization of autoantibodies to natural killer cells in HIV–infected patients. **Müller C, et al. Scand J Immunol** 1996 May;43(5):583–92

Autoantibodies to IL–1 alpha in sera from umbilical cords, children, and adults, and from patients with juvenile chronic arthritis. **Müller K, et al. Scand J Rheumatol** 1996; 25(3):164–7

Cutaneous polyarteritis nodosa in a child with positive

antiphospholipid and P-ANCA. Pereira BA, et al. **Scand J Rheumatol** 1995;24(6):386–8 (14 ref.)

Anti–neutrophil cytoplasmic antibodies in primary small vessel vasculitides. Wiik AS. **Scand J Rheumatol** 1996; 25(2):65–9 (35 ref.)

Auto–antibodies in the hospitalised Oriental elderly. Teo SK, et al. **Singapore Med J** 1995 Dec;36(6):609–11

Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Arvieux J, et al. **Thromb Haemost** 1995 Oct;74(4):1120–5

Diagnostic methodologies for circulating anticoagulants. Exner T. **Thromb Haemost** 1995 Jul;74(1):338–44 (59 ref.)

The serological investigation of patients with autoimmune thrombocytopenia. Kelton JG. **Thromb Haemost** 1995 Jul; 74(1):228–33

Novel thyrotropin (TSH)–TSH antibody complex in a healthy woman and her neonates. Tamaki H, et al. **Thyroid** 1995 Aug;5(4):299–303

Characterization of antibodies directed against platelet cryptantigens detected during the immunological study of 356 consecutive patients with presumed autoimmune thrombocytopenia (AITP). Muñiz–Diaz E, et al. **Transfus Med** 1995 Sep;5(3):185–91

Studies of antibodies in the sera of patients who have made red cell autoantibodies. Issitt PD, et al. **Transfusion** 1996 Jun;36(6):481–6

An unusual case of autoimmune hemolytic anemia with reticulocytopenia, erythroid dysplasia, and an IgG2 autoanti–U. Roush GR, et al. **Transfusion** 1996 Jun; 36(6):575–80

Plasma membrane DNA in autoimmune diseases. Keyhani J, et al. **Transplant Proc** 1995 Oct;27(5):2756–8

Preexisting antibodies: the clinical relevance of auto–B–lymphocyte antibody and positive B–cell crossmatch. Mongkolsuk T, et al. **Transplant Proc** 1996 Jun;28(3):1215–6

Pretransplant IgA–anti–hinge and IgA–anti–Fab autoantibody activity is associated with good kidney graft survival. Süsal C, et al. **Transplant Proc** 1995 Oct; 27(5):2663–5

Antineutrophil cytoplasmic antibodies in myelodysplasia. Hull DR, et al. **Ulster Med J** 1996 May;65(1):55–7

Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response. Fitchen J, et al. **Vaccine** 1995 Aug;13(12):1051–7

Demonstration of serum antiplatelet antibodies in experimental acute canine ehrlichiosis. Waner T, et al. **Vet Immunol Immunopathol** 1995 Sep;48(1–2):177–82

Effect of substrate on indirect immunofluorescence test for canine pemphigus foliaceus. Iwasaki T, et al. **Vet Pathol** 1996 May;33(3):332–6

Canine bullous pemphigoid (BP): identification of the 180–kd canine BP antigen by circulating autoantibodies. Iwasaki T, et al. **Vet Pathol** 1995 Jul;32(4):387–93

CD8+ lymphocyte decrease in HIV disease: association with anti–CD4+ but not with anti–CD8+ lymphocyte autoantibodies. Daniel V, et al. **Vox Sang** 1996;70(2):86–91

Flow cytometric analyses of the subclasses of red cell IgG antibodies. Lynen R, et al. **Vox Sang** 1995;69(2):126–30

[Western blot analysis of serum autoantibodies against inner ear antigens in patients with systemic lupus erythematosus] Xiao H, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995;30(4):236–8 (Eng. Abstr.) **(Chi)**

[Simplified enzyme–linked immunoadsorbent assays for myelin basic protein and antibodies to myelin basic protein] Chen J, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Jun;26(2):125–30 (Eng. Abstr.) **(Chi)**

[Enzyme–linked immunoadsorbent assays for myelin basic protein and antibodies to myelin basic protein in serum and CSF of patients with diseases of the nervous system] Wang R, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Jun;26(2):131–4 (Eng. Abstr.) **(Chi)**

[Analysis of dot–blot technique for the detection of three autoantibodies (anti–Jo–1, anti–M2, anti–ribosome). Comparison with reference techniques] Roussel B, et al. **Ann Biol Clin (Paris)** 1995;53(9):487–90 (Eng. Abstr.) **(Fre)**

[The detection of anti–galactocerebroside autoantibodies in human African trypanosomiasis] Jauberteau PM, et al. **Bull Soc Pathol Exot** 1994;87(5):333–6 (Eng. Abstr.) **(Fre)**

[Anticytoplasmic antibodies (cANCA) in syphilitic nodules of the lung] Wöckel W, et al. **Dtsch Med Wochenschr** 1996 May 10;121(19):617–21 (Eng. Abstr.) **(Ger)**

[Prediction of type I diabetes by antibody screening] Roll U, et al. **Fortschr Med** 1995 Sep 20;113(26):365–7 (Eng. Abstr.) **(Ger)**

[Flow cytometry detection of erythrocyte antigens and antibodies. Technical aspects and new clinical applications] Fischer K, et al. **Infusionsther Transfusionsmed** 1995 Dec; 22(6):344–9 (Eng. Abstr.) **(Ger)**

[Primary sclerosing cholangitis (PSC)—humoral immune phenomena, pathogenetic aspects and therapeutic possibilities] Hopf U, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:106–10 (31 ref.) (Eng. Abstr.) **(Ger)**

[ANCA–associated vasculitis (Wegener's granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis). 2. Diagnostic procedure (see comments)] de Groot K, et al. **Z Rheumatol** 1995 Sep–Oct;54(5):291–302 (59 ref.) (Eng. Abstr.). Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**

[ANCA–associated vasculitis (Wegener's granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis). 1. Systemic aspects, pathogenesis and clinical aspects (see comments)] Gross WL, et al. **Z Rheumatol** 1995 Sep–Oct; 54(5):279–90 (22 ref.) (Eng. Abstr.). Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**

[ANCA: vasculitis research on the upswing (editorial; comment)] Michel BA. **Z Rheumatol** 1995 Sep–Oct; 54(5):277–8. Comment on: Z Rheumatol 1995 Sep–Oct;54(5):279–90. Comment on: Z Rheumatol 1995 Sep–Oct;54(5):291–302. Comment on: Z Rheumatol 1995 Sep–Oct;54(5):303–9. **(Ger)**

[ANCA–associated vasculitis (Wegener's granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis). 3. Therapeutic procedure (see comments)] Reinhold–Keller E, et al. **Z Rheumatol** 1995 Sep–Oct;54(5):303–9 (30 ref.) (Eng. Abstr.). Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**

[The detection of anti–cerebellar antibody western blot analysis in serum from a patient with Miller Fisher syndrome] Iwahashi T, et al. **Arerugi** 1995 Sep; 44(9):1176–80 (Eng. Abstr.) **(Jpn)**

[A case of Sjögren's syndrome with rheumatoid arthritis manifesting transverse myelitis with antineuronal antibody] Fujimoto Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):76–82 (Eng. Abstr.) **(Jpn)**

[Anti–platelet antibodies in sera from patients with systemic lupus erythematosus by immunoblot analysis] Ishikawa A, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb; 18(1):20–8 (Eng. Abstr.) **(Jpn)**

[A case of acquired factor VIII inhibitor] Murakami R, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1739–41 **(Jpn)**

[Thyroglobulin antibodies] Kobayashi I. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:410–3 (10 ref.) **(Jpn)**

[Microsomal antibodies] Kobayashi I. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:414–7 (10 ref.) **(Jpn)**

[TSH receptor antibody] Shishiba Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:407–9 (11 ref.) **(Jpn)**

[Transitions of each inhibitor in a patient with lupus anticoagulant and anti–prothrombin antibody] Murakami F, et al. **Rinsho Byori** 1996 Jul;44(7):692–6 (Eng. Abstr.) **(Jpn)**

[Estimation of anti–thyroid peroxidase autoantibody (TPOAb) and anti–thyroglobulin autoantibody (TgAb) in patients with various thyroid disease—comparison between histopathological findings and serological results in patients with Hashimoto's thyroiditis] Senda Y, et al. **Rinsho Byori** 1995 Dec;43(12):1243–50 (Eng. Abstr.) **(Jpn)**

[Analysis of factors which affect the measurement of factor VIII inhibitor by Bethesda method] Takahashi Y, et al. **Rinsho Byori** 1996 May;44(5):449–55 (Eng. Abstr.) **(Jpn)**

[Serum antigliadin antibodies in the diagnosis and follow–up of celiac disease] Medeiros EH, et al. **Arq Gastroenterol** 1994 Oct–Dec;31(4):154–8 (Eng. Abstr.) **(Por)**

[Comparison between immunofluorescence techniques and ELISA, using whole neutrophil extract and primary granules, for the detection of antineutrophil cytoplasma antibodies (ANCA)] Bueno C, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Mar–Apr; 50(2):101–6 (Eng. Abstr.) **(Por)**

[An autoantibody to human chorionic gonadotropin in habitual abortion] Ponomareva IV, et al. **Biull Eksp Biol Med** 1996 Apr;121(4):450–2 **(Rus)**

[The clinical significance of detecting antibodies to neutrophil cytoplasmic antigens in Wegener granulomatosis] Beketova TV, et al. **Ter Arkh** 1995;67(10):24–7 **(Rus)**

[Endothelial antibodies in Sneddon's syndrome] Kalashnikova LA, et al. **Ter Arkh** 1996;68(1):54–6 (Eng. Abstr.) **(Rus)**

[Antineutrophil cytoplasmic autoantibodies (ANCA)—in patients with connective tissue diseases] Prus V, et al. **Reumatizam** 1994;41(2):9–11 (Eng. Abstr.) **(Ser)**

[Chronic hepatitis C virus infection associated with anti–LKM 1] Macenlle R, et al. **Gastroenterol Hepatol** 1996 Apr;19(4):203–5 (Eng. Abstr.) **(Spa)**

[Prevalence and clinical significance of autoantibodies in chronic hepatitis C treated with interferon alfa] Olaso V, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):577–81 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Neuronal targets of serum and cerebrospinal fluid autoantibodies in amyotrophic lateral sclerosis. Greiner A, et al. **Acta Neuropathol (Berl)** 1996;91(1):67–71

Antibodies against microglia/brain macrophages in the cerebrospinal fluid of a patient with acute amyotrophic lateral sclerosis and presenile dementia. Banati RB, et al. **Clin Neuropathol** 1995 Jul–Aug;14(4):197–200

CHEMISTRY

Can the immunobead assay for detecting sperm antibodies in fresh samples be reproduced in cryopreserved/thawed human spermatozoa? Melo–Abreu S, et al. **Am J Reprod Immunol** 1995 Aug;34(2):116–9

Identification and characterization of a 230–kDa Golgi–associated protein recognized by autoantibodies from a patient with HBV hepatitis. Funaki T, et al. **Cell Struct Funct** 1996 Feb;21(1):63–72

Cholesterol sulphate–reactive autoantibodies are specifically increased in chronic chagasic human patients. Avila JL, et al. **Clin Exp Immunol** 1996 Jan;103(1):40–6

Autoantibodies to the collagenous region of C1q occur in three strains of lupus–prone mice. Hogarth MB, et al. **Clin Exp Immunol** 1996 May;104(2):241–6

Structural differences between the human and mouse 52–kD Ro autoantigens associated with poorly conserved autoantibody activity across species. Keech CL, et al. **Clin Exp Immunol** 1996 May;104(2):255–63

Anti–neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti–cathepsin G and a novel antibody correlate with a refractory type. Sobajima J, et al. **Clin Exp Immunol** 1996 Jul;105(1):120–4

The mechanism of autoantibody formation to cartilage in rheumatoid arthritis: possible cross–reaction of antibodies to dietary collagens with autologous type II collagen. Terato K, et al. **Clin Immunol Immunopathol** 1996 May; 79(2):142–54

Expression of monovalent fragments derived from a human IgM autoantibody in E. coli. The input of the somatically mutated CDR1/CDR2 and of the CDR3 into antigen binding specificity. Jahn S, et al. **Immunobiology** 1995 Aug; 193(5):400–19

IgG isotype–specific auto–antibodies bind preferentially to cross–linked membrane Ig. Fazekas G, et al. **Int Immunol** 1995 Jul;7(7):1125–34

Pancreatic expression of antigens for islet cell antibodies in non–obese diabetic mice. Martignat L, et al. **J Autoimmun** 1995 Aug;8(4):465–82

Variable region–connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. Vassilev TL, et al. **J Autoimmun** 1995 Jun;8(3):405–13

Structural studies of human autoantibodies. Crystal structure of a thyroid peroxidase autoantibody Fab. Chacko S, et al. **J Biol Chem** 1996 May 24;271(21):12191–8

Human autoantibodies against Clq: lack of cross reactivity with the collectins mannan–binding protein, lung surfactant protein A and bovine conglutinin. Mårtensson U, et al. **Scand J Immunol** 1996 Mar;43(3):314–20

Antigastric autoantibodies in Helicobacter pylori gastritis: prevalence, in–situ binding sites and clues for clinical relevance. Faller G, et al. **Virchows Arch** 1996 Feb; 427(5):483–6

[Equilibrium and kinetic parameters of the interaction of strophanthin K and its peroxidase conjugates with soluble and immobilized specific antibodies] Tarun EI, et al. **Biokhimiia** 1995 Jul;60(7):1062–72 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Disproportional distribution of isotype and non–isotype–specific IgG subclass anti–IgE autoantibodies in human cord serum. Magnusson CG, et al. **Int Arch Allergy Immunol** 1996 May;110(1):31–40

Paraneoplastic antibodies [letter; comment] Drlicek M, et al. **Neurology** 1995 Nov;45(11):2120–2. Comment on: Neurology 1994 Dec;44(12):2236–40. Comment on: Neurology 1994 Dec;44(12):2241–6.

Anticardiolipin and anti–beta 2–GPI are two distinct populations of autoantibodies. Sorice M, et al. **Thromb Haemost** 1996 Feb;75(2):303–8

[Immunoglobulin G subclass distribution of anti–intercellular substance antibodies in pemphigus] Trémeau–Martinage C, et al. **Ann Dermatol Venereol** 1995;122(6–7):409–11 (Eng. Abstr.) **(Fre)**

DIAGNOSTIC USE

Non–invasive detection of myocyte necrosis in myocarditis and dilated cardiomyopathy with radiolabelled antimyosin. Khaw BA, et al. **Eur Heart J** 1995 Dec;16 Suppl O:119–23 (16 ref.)

Autoimmune enteropathy with anti–goblet cell antibodies. Moore L, et al. **Hum Pathol** 1995 Oct;26(10):1162–8

DRUG EFFECTS

Immunomodulating effects of the new anti–rheumatic drug tenidap on collagen–induced arthritis. Matsushita I, et al. **Int J Immunopharmacol** 1995 Mar;17(3):213–9

GENETICS

Analysis of immunoglobulin gamma heavy chains from rheumatoid arthritis synovium. Evidence of antigen–driven selection. Bridges SL Jr, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:450–2

Immunoglobulin gene usage in diabetes–associated human monoclonal antibodies recognizing glutamate decarboxylase. Richter W, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:457–60

In situ hybridization analysis of immunoglobulin VH gene family expression in rheumatoid arthritis. Rundle CH, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:453–6

Expression and regulation of clonally ignorant B cells. Thomas JW, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:461–2

Genetic and functional characterization of human autoantibodies using combinatorial phage display libraries. Zeidel M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:559–64

HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma). Kuwana M, et al. **Ann Rheum Dis** 1995 Dec;54(12):983–7

Selection of a gene for apolipoprotein A1 using

autoantibodies from a patient with systemic lupus erythematosus. Merrill JT, et al. **Arthritis Rheum** 1995 Nov; 38(11):1655–9

Analysis of the V kappa I family: germline genes from an SLE patient and expressed autoantibodies. Manheimer-Lory A, et al. **Autoimmunity** 1995;20(4):259–65

A genetic view on the etiology of the inhibitor complication [letter] Giannelli F, et al. **Blood** 1996 Mar 15;87(6):2612

Molecular characteristics of anti-self antibody fragments against neutrophil cytoplasmic antigens from human V gene phage display libraries. Finnern R, et al. **Clin Exp Immunol** 1995 Dec;102(3):566–74

Variable-region gene family usage for type II collagen autoantibodies in arthritis-susceptible DBA/1 mice. Ye XJ, et al. **Clin Immunol Immunopathol** 1996 Mar;78(3):263–75

A new germline VH gene encoding a mouse nephritogenic autoantibody. Ono M, et al. **Immunogenetics** 1995; 42(5):426–7

Analysis of immunoglobulin variable region genes of a human IgM anti-myeloperoxidase antibody derived from a patient with vasculitis. Longhurst C, et al. **Immunology** 1996 Feb; 87(2):334–8

Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. Palinski W, et al. **J Clin Invest** 1996 Aug 1;98(3):800–14

A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1–18 [see comments] Willison HJ, et al. **J Clin Invest** 1996 Mar 1; 97(5):1155–64. Comment in: J Clin Invest 1996 Mar 1;97(5):1136–7.

Analysis of central B cell tolerance in autoimmune-prone MRL/lpr mice bearing autoantibody transgenes. Rubio CF, et al. **J Immunol** 1996 Jul 1;157(1):65–71

Molecular cloning and characterization of human thyroid peroxidase autoantibodies of lambda light chain type. Portolano S, et al. **Mol Immunol** 1995 Oct; 32(14–15):1157–69

The INS B allele (1,428 Fok I) is associated with reduced IDDM incidence in autoantibody-positive first degree relatives despite the presence of autoantibodies and high-risk HLA alleles. Pugliese A, et al. **Transplant Proc** 1995 Dec;27(6):3392

[Neonatal hyperthyroidism caused by TSH receptor antibodies in maternal autoimmune hyperthyroidism] Resch B, et al. **Z Geburtshilfe Neonatol** 1995 Nov–Dec; 199(6):248–52 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Kinetic characterization of thyroid peroxidase enzyme and its inhibition by autoantibodies. Kaczur V, et al. **Acta Microbiol Immunol Hung** 1995;42(4):345–50

Obstetric complications and autoantibodies in schizophrenia. Chengappa KN, et al. **Acta Psychiatr Scand** 1995 Oct; 92(4):270–3

Antinuclear autoantibodies in chronic schizophrenia. Spivak B, et al. **Acta Psychiatr Scand** 1995 Oct;92(4):266–9

Autoimmune recognition of acetylcholine receptor and manipulation of the autoimmune responses by synthetic peptides. Atassi MZ, et al. **Adv Exp Med Biol** 1995; 383:141–56 (71 ref.)

Characterization of autoantibodies directed against T cell receptors. Lake DF, et al. **Adv Exp Med Biol** 1995; 383:223–9

Autoantibodies against peptide-defined epitopes of T-cell receptors in retrovirally infected humans and mice. Marchalonis JJ, et al. **Adv Exp Med Biol** 1995;383:211–22

Antiplatelet antibodies during the course of HIV-preventive vaccine trial [letter] Kaplan C, et al. **AIDS** 1996 Apr; 10(4):447–9

Acquired free protein S deficiency associated with multiple myeloma: a case report. Deitcher SR, et al. **Am J Hematol** 1996 Apr;51(4):319–23

Multimodality therapy of an acquired factor V inhibitor. Fu YX, et al. **Am J Hematol** 1996 Apr;51(4):315–8

Negligible synergistic effect of beta2-glycoprotein I on the reactivity of antioxidized low-density lipoprotein antibody to oxidized low-density lipoprotein. Matsuda J, et al. **Am J Hematol** 1996 Jun;52(2):114–6

Inhibitors to factor VIII:C in nonhemophiliacs [letter] Milica CD, et al. **Am J Hematol** 1996 May;52(1):61

Antiplatelet antibodies in childhood idiopathic thrombocytopenic purpura [letter] Ozsoylu S. **Am J Hematol** 1996 Apr;51(4):328

Platelet autoantibodies in patients with chronic liver disease. Pereira J, et al. **Am J Hematol** 1995 Nov;50(3):173–8

Acute tubulointerstitial nephritis and uveitis with antineutrophil cytoplasmic antibody. Simon AH, et al. **Am J Kidney Dis** 1996 Jul;28(1):124–7

Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Billing P, et al. **Am J Pathol** 1995 Oct; 147(4):979–87

The effect of the antisperm auto-antibody-bound sperm on in vitro fertilization outcome. Sukcharoen N, et al. **Andrologia** 1995 Sep–Oct;27(5):281–9

Autoantibodies to specific enzymes: a review. Kiechle FL, et al. **Ann Clin Lab Sci** 1996 May–Jun;26(3):195–207 (70 ref.)

Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Kiefel V, et al. **Ann Hematol** 1996 Apr;72(4):280–5

Light chain-restricted autoantibodies in chronic idiopathic thrombocytopenic purpura, but no evidence for circulating clone B-lymphocytes. Stockelberg D, et al. **Ann Hematol** 1996 Jan;72(1):29–34

Analysis of the structural correlates for self-antigen binding by natural and disease-related autoantibodies. In vitro expression of recombinant and/or mutagenized human IgG. Ichiyoshi Y, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:328–41 (35 ref.)

B-1 cells and autoimmunity. Murakami M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:402–9 (34 ref.)

Isolation and characterization of human antioxidized LDL autoantibodies. Mironova M, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):222–9

Finding a valid model for human Wegener's granulomatosis: comment on the article by Tomer et al [letter; comment] Langford CA, et al. **Arthritis Rheum** 1996 Jul;39(7):1262–3 . Comment on: Arthritis Rheum 1995 Oct;38(10):1375–81.

Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Mierau R, et al. **Arthritis Rheum** 1996 May;39(5):868–76

An epitope on Ki antigen recognized by autoantibodies from lupus patients shows homology with the SV40 large T antigen nuclear localization signal. Takasaki Y, et al. **Arthritis Rheum** 1996 May;39(5):855–62

Some autoantibodies to Ro/SS-A and La/SS-B are antiidiotypes to anti-double-stranded DNA. Zhang W, et al. **Arthritis Rheum** 1996 Mar;39(3):522–31

Glycolipids as the major autoantigens of cytoplasmatic islet cell antibodies. Cabrera-Rode E, et al. **Autoimmunity** 1995; 20(3):145–51

Dilated cardiomyopathy defines serum autoantibodies against G-protein-coupled cardiovascular receptors. Matsui S, et al. **Autoimmunity** 1995;21(2):85–8

Autoantibody associations with MHC class II antigens in scleroderma and autoimmune vasculitis. Thomson JB, et al. **Autoimmunity** 1994;19(4):265–9

Autoantibodies in hepatitis delta. Philipp T, et al. **Biomed Pharmacother** 1995;49(7–8):344–9

Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Brighton TA, et al. **Blood** 1996 Jul 1; 88(1):194–201

Restricted immunoglobulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. Efremov DG, et al. **Blood** 1996 May 1; 87(9):3869–76

Extracellular epitopes of platelet glycoprotein Ib alpha reactive with serum antibodies from patients with chronic idiopathic thrombocytopenic purpura. He R, et al. **Blood** 1995 Nov 15;86(10):3789–96

Heterogeneity of neutrophil antibodies in patients with primary Sjögren's syndrome. Lamour A, et al. **Blood** 1995 Nov 1;86(9):3553–9

Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Reumaux D, et al. **Blood** 1995 Oct 15;86(8):3189–95

Reactivity of autoantibodies from chronic ITP patients with recombinant glycoprotein IIIa peptides. Bowditch RD, et al. **Br J Haematol** 1995 Sep;91(1):178–84

Glycoprotein IIb/IIIa autoantigenic repertoire in chronic idiopathic thrombocytopenic purpura. Hou M, et al. **Br J Haematol** 1995 Dec;91(4):971–5

Autoantibody against a 58 kD molecule in a patient with neutropenia and NK cell deficiency. Witte T, et al. **Br J Haematol** 1996 Mar;92(3):565–70

Antibodies to endothelial cells and to beta 2-glycoprotein I in the antiphospholipid syndrome: prevalence and isotype distribution. Navarro M, et al. **Br J Rheumatol** 1996 Jun; 35(6):523–8

Characterization of murine brain-reactive monoclonal IgG autoantibodies. Crimando J, et al. **Brain Behav Immun** 1995 Sep;9(3):165–81

Oligodendrocyte-reactive O1, O4, and HNK-1 monoclonal antibodies are encoded by germline immunoglobulin genes. Asakura K, et al. **Brain Res Mol Brain Res** 1995 Dec 28; 34(2):283–93

High prevalence and little change in TSH receptor blocking antibody titres with thyroxine and antithyroid drug therapy in patients with non-goitrous autoimmune thyroiditis. Cho BY, et al. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):465–71

A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs. Kawai K, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):551–6

Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration. Blank M, et al. **Clin Exp Immunol** 1995 Oct;102(1):120–30

Transforming growth factor-beta (TGF-beta) expression and interaction with proteinase 3 (PR3) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Csernok E, et al. **Clin Exp Immunol** 1996 Jul;105(1):104–11

Association of T cell dysfunction with the presence of IgG autoantibodies on CD4+ lymphocytes in haemophilia patients; results of a 10-year study. Daniel V, et al. **Clin Exp Immunol** 1996 Apr;104(1):4–10

Diverse antigen specificity of erythrocyte-reactive monoclonal autoantibodies from NZB mice. de Sá Oliveira GG, et al. **Clin Exp Immunol** 1996 Aug;105(2):313–20

T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Griffith ME, et al. **Clin Exp Immunol** 1996 Feb;103(2):253–8

Identification of human IgG autoantibodies specific for IL-10. Menetrier-Caux C, et al. **Clin Exp Immunol** 1996 Apr;104(1):173–9

Induction of autoimmune hepatitis and autoantibodies to liver antigens by neonatal thymectomy in mice. Myozaki M, et al. **Clin Exp Immunol** 1996 Apr;104(1):133–43

Leucocyte activation by anti-lactoferrin antibodies bound to vascular endothelium. Peen E, et al. **Clin Exp Immunol** 1996 Mar;103(3):403–7

Anti-collagen antibodies in systemic sclerosis and in primary Raynaud's phenomenon. Riente L, et al. **Clin Exp Immunol** 1995 Nov;102(2):354–9

Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type. Sobajima J, et al. **Clin Exp Immunol** 1996 Jul;105(1):120–4

Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Stoffel MP, et al. **Clin Exp Immunol** 1996 Apr;104(1):54–9

Azurocidin is a novel antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis. Zhao MH, et al. **Clin Exp Immunol** 1996 Mar;103(3):397–402

Increased serum levels of IgA antibodies to hsp70 protein in patients with diabetes mellitus: their relationship with vascular complications. Figueredo A, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):252–5

Absence of anti-idiotypic antibodies in IVIG preparations to autoantibodies of rare autoimmune diseases. Krause I, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):229–35

Characterization of anti-endothelial cell antibodies in the patients with systemic lupus erythematosus: a potential marker for disease activity. Li JS, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):211–6

Rabbit anti-chromatin antibodies recognize similar epitopes on a histone H1 molecule as lupus autoantibodies. Morino N, et al. **Clin Immunol Immunopathol** 1995 Oct;77(1):52–8

IgG autoantibody response in HTLV-I-infected patients. Muller S, et al. **Clin Immunol Immunopathol** 1995 Dec; 77(3):282–90

Complement-fixing islet cell antibodies in type-1 diabetes can trigger the assembly of the terminal complement complex on human islet cells and are potentially cytotoxic. Radillo O, et al. **Clin Immunol Immunopathol** 1996 Jun; 79(3):217–23

Cell injury mediated by autoantibodies to intracellular antigens. Reichlin M. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):215–9 (31 ref.)

In vitro RNA selection of an autoimmune epitope on stem-loop II of U1 RNA. St Clair EW, et al. **Clin Immunol Immunopathol** 1996 Apr;79(1):60–70

Anti-cardiolipin antibodies are associated with anti-endothelial cell antibodies but not with anti-beta 2 glycoprotein I antibodies in HIV infection. Weiss L, et al. **Clin Immunol Immunopathol** 1995 Oct;77(1):69–74

Identification of antigenic epitopes of 1D antigen recognized by antibodies in the serum of patients with thyroid-associated ophthalmopathy. Zhang ZG, et al. **Clin Immunol Immunopathol** 1995 Nov;77(2):193–200

A case report of mixed P- and C-ANCA positive patients with pauci-immune crescentic glomerulonephritis. Shimizu E, et al. **Clin Nephrol** 1995 Oct;44(4):266–70

Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations. Tikly M, et al. **Clin Rheumatol** 1996 Mar;15(2):143–7

Natural autoantibodies. Coutinho A, et al. **Curr Opin Immunol** 1995 Dec;7(6):812–8 (90 ref.)

Bullous skin diseases. Nousari HC, et al. **Curr Opin Immunol** 1995 Dec;7(6):844–52 (76 ref.)

Autoantibodies in systemic lupus erythematosus. Elkon K. **Curr Opin Rheumatol** 1995 Sep;7(5):384–8 (40 ref.)

Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Verge CF, et al. **Diabetes** 1996 Jul; 45(7):926–33

Organ-specific cardiac autoantibodies in dilated cardiomyopathy—an update. Caforio AL, et al. **Eur Heart J** 1995 Dec;16 Suppl O:68–70

Correlations of antimyosin accumulation and histological manifestation of myocyte necrosis at different stages of idiopathic cardiomyopathy. Nakata T, et al. **Eur Heart J** 1995 Aug;16(8):1108–14

Anti-prolactin autoantibodies and hyperprolactinaemia [letter; comment] Olukoga AO, et al. **Eur J Endocrinol** 1995 Oct;133(4):463–4. Comment on: Eur J Endocrinol 1994 May;130(5):434–7. Comment on: Eur J Endocrinol 1994 May;130(5):438–45.

Antigen specificity of circulating anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease. Kossa K, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):783–9

Antibodies against platelet GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Hou M, et al. **Eur J Haematol** 1995 Nov; 55(5):307–14

Is immune thrombocytopenic purpura (ITP) due to natural antibodies specific to platelets? [letter] Souberbielle BE. **Eur J Haematol** 1996 Mar;56(3):178–80

Detection of platelet antibodies in chronic idiopathic thrombocytopenic purpura (ITP). A comparative study using flow cytometry, a whole platelet ELISA, and an antigen capture ELISA. Stockelberg D, et al. **Eur J Haematol** 1996 Jan–Feb;56(1–2):72–7

HLA-associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent-onset insulin-dependent diabetes mellitus. Roep BO, et al. **Eur J Immunol** 1996 Jun;26(6):1285–9

Technetium-99m scintigraphy: more accurate assessment of ulcerative colitis with exametazime-labelled leucocytes than with antigranulocyte antibodies. Almers S, et al. **Eur J Nucl Med** 1996 Mar;23(3):247–55

The functional affinity and specificity of autoantibodies in animal models of anti-glomerular basement membrane disease. Marriott JB, et al. **Exp Nephrol** 1995 Jul–Aug; 3(4):257–64

Characterization of monoclonal antibodies to proteinase-3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies. Sommarin Y, et al. **Exp Nephrol** 1995 Jul–Aug;3(4):249–56

Down-regulation of non-L-, non-N-type (Q-like) Ca2+ channels by Lambert-Eaton myasthenic syndrome (LEMS) antibodies in rat insulinoma RINm5F cells. Magnelli V, et al. **FEBS Lett** 1996 May 27;387(1):47–52

Recombinant human proteinase 3, the Wegener's autoantigen, expressed in HMC-1 cells is enzymatically active and recognized by c-ANCA. Specks U, et al. **FEBS Lett** 1996 Jul 29;390(3):265–70

Characterization of a recombinant proteinase 3, the autoantigen in Wegener's granulomatosis and its reactivity with anti-neutrophil cytoplasmic autoantibodies. Witko-Sarsat V, et al. **FEBS Lett** 1996 Mar 11; 382(1–2):130–6

Autoantibodies and embryo implantation rates [letter] Cahill DJ, et al. **Fertil Steril** 1996 Jan;65(1):208–9; discussion 209–10

Autoantibodies and embryo implantation rates [letter] Shulman S. **Fertil Steril** 1996 Jan;65(1):207–8; discussion 209–10

External ophthalmoplegia with ragged-red fibres and acetylcholine receptor antibodies. Mitsikostas D, et al. **Funct Neurol** 1995 Jul–Oct;10(4–5):209–15

Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Muratori L, et al. **Gut** 1995 Sep;37(3):406–12

Autoantibodies from patients with primary biliary cirrhosis recognize a region within the nucleoplasmic domain of inner nuclear membrane protein LBR. Lin F, et al. **Hepatology** 1996 Jan;23(1):57–61

Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Moteki S, et al. **Hepatology** 1996 Mar;23(3):436–44

Comparison of anti-TNF alpha autoantibodies in plasma and from EBV transformed lymphocytes of autoimmune and normal individuals. Tsuchiyama L, et al. **Hum Antibodies Hybridomas** 1995;6(2):73–6

Anatomy of autoantibody production: dominant localization of antibody-producing cells to T cell zones in Fas-deficient mice. Jacobson BA, et al. **Immunity** 1995 Oct;3(4):509–19

The collagen-like component of the complement system, C1q, is recognized by 7 S autoantibodies and is functionally impaired in synovial fluids of patients with rheumatoid arthritis. Trinder PK, et al. **Immunology** 1996 Mar; 87(3):355–61

Role of antineural antibodies in perpetuation of a pre-existing peripheral nerve damage in leprosy. Desikan P, et al. **Indian J Lepr** 1995 Jul–Sep;67(3):293–300

Anti-neutrophil cytoplasmic antibodies in generalized autoimmune diseases. Schnabel A, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):201–6 (32 ref.)

Immunomodulating effects of the new anti-rheumatic drug tenidap on collagen-induced arthritis. Matsushita I, et al. **Int J Immunopharmacol** 1995 Mar;17(3):213–9

Auto-anti-idiotypy, autoimmunity and some thoughts on the structure of internal images. Erlanger BF. **Int Rev Immunol** 1989;5(2):131–7 (29 ref.)

Anti-idiotypes against autoantibodies to procoagulant factor VIII (VIII:C) in intravenous immunoglobulins. Kazatchkine MD, et al. **Int Rev Immunol** 1989;5(2):157–63

Properties of a system of public idiotypes of lupus autoantibodies. Schwartz RS. **Int Rev Immunol** 1989; 5(2):153–5 (13 ref.)

Pathogenicity of anti-basement membrane (NC1) antibodies: an experimental Goodpasture's syndrome. Shoenfeld Y. **Isr J Med Sci** 1996 Jan;32(1):29–31

Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. Verge CF, et al. **J Autoimmun** 1996 Jun;9(3):379–83

Binding of anti-band 3 autoantibody to sialylated poly-N-acetyllactosaminyl sugar chains of band 3 glycoprotein on polyvinylidene difluoride membrane and sepharose gel: further evidence for anti-band 3 autoantibody binding to the sugar chains of oxidized and senescent erythrocytes. Ando K, et al. **J Biochem (Tokyo)** 1996 Apr;119(4):639–47

Critical relationship between autoantibody recognition and thyrotropin receptor maturation as reflected in the acquisition of complex carbohydrate. Rapoport B, et al. **J Clin Endocrinol Metab** 1996 Jul;81(7):2525–33

Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. Jordan SC. **J Clin Immunol** 1995 Nov;15(6 Suppl):76S–85S (40 ref.)

Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism [see comments] Li Y, et al. **J Clin Invest** 1996 Feb 15;97(4):910–4. Comment in: J Clin Invest 1996 Feb 15;97(4):899–90.

Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. Sgonc R, et al. **J Clin Invest** 1996 Aug 1;98(3):785–92

Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. Singh RR, et al. **J Clin Invest** 1995 Dec;96(6):2990–6

Autoantibodies to DNA-dependent protein kinase. Probes for the catalytic subunit. Suwa A, et al. **J Clin Invest** 1996 Mar 15;97(6):1417–21

Characterization of insulin autoantibodies in a patient with autoimmune hypoglycemia. Di Cerbo A, et al. **J Endocrinol Invest** 1995 Apr;18(4):299–304

Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. Lee SW, et al. **J Exp Med** 1996 Aug 1; 184(2):315–24

Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. Calleja JL, et al. **J Hepatol** 1996 Mar;24(3):308–12

Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. Bonifacio E, et al. **J Immunol** 1995 Dec 1;155(11):5419–26

Pathogenic role of anti-endothelial cell antibodies in vasculitis. An idiotypic experimental model. Damianovich M, et al. **J Immunol** 1996 Jun 15;156(12):4946–51

Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. Daw K, et al. **J Immunol** 1996 Jan 15;156(2):818–25

Phage display cloning and characterization of an immunogenetic marker (perinuclear anti-neutrophil cytoplasmic antibody) in ulcerative colitis. Eggena M, et al. **J Immunol** 1996 May 15;156(10):4005–11

Frequency of molecular mimicry among T cell peptides as the basis for autoimmune disease and autoantibody induction. Garza KM, et al. **J Immunol** 1995 Dec 1; 155(11):5444–8

Clinical correlates and substrate specificities of antibodies exhibiting neutrophil nuclear reactivity--a methodological study. Bang la Cour B, et al. **J Immunol Methods** 1995 Dec 1;187(2):287–95

Detection of brain-reactive autoantibodies in the sera of patients with systemic lupus erythematosus and cerebral involvement. Ochola J, et al. **J Immunol Methods** 1995 Sep 25;185(2):259–61

Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. Balding SD, et al. **J Invest Dermatol** 1996 Jan;106(1):141–6

Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5. Kirtschig G, et al. **J Invest Dermatol** 1995 Oct;105(4):543–8

Autoepitopes in lupus. Harley JB, et al. **J Lab Clin Med** 1995 Dec;126(6):509–16 (75 ref.)

A monoclonal autoantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens. Asakura K, et al. **J Neuroimmunol** 1996 Mar;65(1):11–9

HLA and anti-GQ1b IgG antibody in Miller Fisher syndrome and Guillain-Barré syndrome. Chiba A, et al. **J Neuroimmunol** 1995 Aug;61(1):85–8

The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. Buckanovich RJ, et al. **J Neurosci** 1996 Feb 1;16(3):1114–22

Incidence, target antigens, and clinical implications of antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Braun MG, et al. **J Rheumatol** 1996 May; 23(5):826–30

Retroperitoneal fibrosis with antineutrophil cytoplasmic antibodies. Kaipiainen-Seppänen O, et al. **J Rheumatol** 1996 Apr;23(4):779–81

The herpes simplex virus type 1 regulatory protein ICP27 coimmunoprecipitates with anti-Sm antiserum, and the C terminus appears to be required for this interaction. Sandri-Goldin RM, et al. **J Virol** 1996 Jan;70(1):108–18

The cell proliferation-associated protein Ki-67 is a target of autoantibodies in the serum of MRL mice. Bloch DB, et al. **Lab Invest** 1995 Sep;73(3):366–71

Ruptured spleen and autoantibodies to superoxide dismutase in infectious mononucleosis [letter] Semrau F, et al. **Lancet** 1996 Apr 20;347(9008):1124–5

Analysis of three new idiotypes on human monoclonal autoantibodies. Kalsi JK, et al. **Lupus** 1995 Oct;4(5):375–89

Fluctuations of antibody to ribosomal P proteins correlate with appearance and remission of nephritis in SLE. Martin AL, et al. **Lupus** 1996 Feb;5(1):22–9

Human T cell responses to autoantibody variable region peptides. Williams WM, et al. **Lupus** 1995 Dec;4(6):464–71

Evidence for an antigen-driven selection process in human autoantibodies against acetylcholine receptor. Cardona A, et al. **Mol Immunol** 1995 Nov;32(16):1215–23

Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Lecoeur S, et al. **Mol Pharmacol** 1996 Aug; 50(2):326–33

The molecular recognition theory applied to bispecific antibodies... [letter; comment] Ruf J, et al. **Nat Med** 1995 Dec;1(12):1222. Comment on: Nat Med 1995 Sep;1(9):876–8. Comment on: Nat Med 1995 Sep;1(9):894–901.

Goodpasture-like syndrome associated with anti-myeloperoxidase antibodies following penicillamine treatment. Gaskin G, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1925–8

C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Griffith ME, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):438–43

Antiglomerular basement membrane disease with cANCA positivity without pulmonary involvement. Neary P, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):693–5

The kinetics of the pathogenic pronase-digested renal proximal tubular antigen and antibody in rat active Heymann nephritis. Maezawa A, et al. **Nephron** 1995; 71(4):448–53

Chronic steroid-responsive encephalitis without autoantibodies to glutamate receptor GluR3. Krauss GL, et al. **Neurology** 1996 Jan;46(1):247–9

Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies: report from the Workshop to the Fourth Meeting of the International Society of Neuro-Immunology on paraneoplastic neurological disease, held October 22–23, 1994, in Rotterdam, The Netherlands. Moll JW, et al. **Neurology** 1995 Oct;45(10):1937–41

Pitfalls in the diagnosis of autoantibodies associated with paraneoplastic neurologic disease. Sillevis-Smitt P, et al. **Neurology** 1996 Jun;46(6):1739–41

A patient with Down's syndrome and anti-neutrophilic cytoplasmic antibody-positive vasculitis [letter] Schwab M, et al. **Pediatr Nephrol** 1996 Apr;10(2):249–50

Specificity of circulating and tissue-bound autoantibodies in Goodpasture syndrome. Kalluri R, et al. **Proc Assoc Am Physicians** 1996 Mar;108(2):134–9

Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Ray SK, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2019–24

Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Kane GC, et al. **Respir Med** 1996 Apr;90(4):223–30

Membranoproliferative glomerulonephritis, p-antineutrophil cytoplasmic antibodies, and rheumatoid arthritis. Report of a case. Constantin A, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):141–4

Autoreactivity to mouse C1q in a murine model of SLE. Trinder PK, et al. **Rheumatol Int** 1995;15(3):117–20

The self-reactive antibody repertoire of normal human serum IgM is acquired in early childhood and remains conserved throughout life. Mouthon L, et al. **Scand J Immunol** 1996 Sep;44(3):243–51

Distributions of HLA class II alleles in autoantibody subsets among Norwegian patients with systemic lupus erythematosus. Skarsvåg S, et al. **Scand J Immunol** 1995 Nov;42(5):564–71

Cytokine autoantibodies in rheumatoid arthritis. Hansen MB, et al. **Scand J Rheumatol** 1995;24(4):197–203

Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations. Schultz DR, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):143–59 (120 ref.)

Which patients undergoing cardiopulmonary bypass should be assessed for development of heparin-induced thrombocytopenia? [letter] Cummins D, et al. **Thromb Haemost** 1995 May;73(5):890

Platelet-associated anti-glycoprotein (GP) IIb-IIIa autoantibodies in chronic immune thrombocytopenic purpura mainly recognize cation-dependent conformations: comparison with the epitopes of serum autoantibodies. Kosugi S, et al. **Thromb Haemost** 1996 Feb;75(2):339–45

Inhibition of platelet aggregation by an SLE-derived human hybridoma autoantibody against an activation-dependent antigen. Xu H, et al. **Thromb Haemost** 1995 Oct; 74(4):1152–62

Effects of H1 histones and a monoclonal autoantibody to H1 histones on clot formation in vitro: possible implications in the antiphospholipid syndrome. Kheiri SA, et al. **Thromb Res** 1996 Apr 1;82(1):43–50

Infertility due to antisperm antibodies. Ohl DA, et al. **Urology** 1995 Oct;46(4):591–602 (170 ref.)

Reactivity of anti-erythrocyte antibody induced by Babesia gibsoni infection against aged erythrocytes. Morita T, et al. **Vet Parasitol** 1995 Jul;58(4):291–9

[Proliferation of PBMC in patients with Sjögren's syndrome via CD2 pathway] Wang X, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Oct; 17(5):395–9 (Eng. Abstr.) **(Chi)**

["Autoantibodies" and cell aging. Does malonic dialdehyde

constitute an immunological marker of cell aging?] Chancerelle Y. **Ann Pharm Fr** 1996;54(2):60–3 (Eng. Abstr.) **(Fre)**

[The role of Fc gamma R specific autoantibodies in autoimmune diseases. Review of the literature and authors' own research] Szegedi A, et al. **Orv Hetil** 1996 Mar 17; 137(11):581–4 (34 ref.) (Eng. Abstr.) **(Hun)**

[Recent findings on antigens reactive to antiphospholipid antibodies] Matsuda S. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):27–38 (66 ref.) **(Jpn)**

[Epitopes of the target proteins of anti-SS-A/Ro and anti-SS-B/La autoantibodies] Kato T. **Nippon Rinsho** 1995 Oct;53(10):2434–9 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular mimicry between LKM 1-autoantigen and HCV-polyproteins] Miyakawa H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:885–91 (20 ref.) **(Jpn)**

[Antimitochondrial antibody negative primary biliary cirrhosis] Aizawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):527–30 (12 ref.) **(Jpn)**

[Anti-MI-2 antibody as a specific marker of dermatomyositis] Kowalska-Olędzka E, et al. **Neurol Neurochir Pol** 1995 Sep-Oct;29(5):703–11; discussion 712 (Eng. Abstr.) **(Pol)**

[Immunologic reactions in the male and female reproductive system] Kasprzak M, et al. **Postepy Hig Med Dosw** 1995; 49(6):693–717 (47 ref.) (Eng. Abstr.) **(Pol)**

[The effect of antibodies to erythrocyte superoxide dismutase on its activity in the blood of rheumatoid arthritis patients] Gontar' IP, et al. **Biull Eksp Biol Med** 1995 Oct; 120(10):391–3 **(Rus)**

[Occurrence of TSH receptor antibodies and thyroid microsomal antibodies in Graves-Basedow disease] Paunković N, et al. **Med Pregl** 1995;48(1–2):10–4 (Eng. Abstr.) **(Scr)**

[Autoantibodies in liver diseases: interpretation and pathogenic importance] Pons Romero F, et al. **Gastroenterol Hepatol** 1996 Jun-Jul;19(6):326–33 (70 ref.) **(Spa)**

ISOLATION & PURIFICATION

Isolation of human anti-red blood cell antibodies by repertoire cloning. Siegel DL. **Ann N Y Acad Sci** 1995 Sep 29;764:547–58

Isolation and characterization of human antioxidized LDL autoantibodies. Mironova M, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):222–9

Detection of human IgG antibodies against free N-acetyl-L-cysteine. Maes RF. **Immunol Lett** 1995 Nov; 48(1):49–52

c-ANCA as a marker of Wegener's disease [letter; comment] Bosch X, et al. **Lancet** 1996 Jan 13;347(8994):117; discussion 118. Comment on: Lancet 1995 Oct 7;346(8980):926–31.

DNA hydrolysis by antibodies. Gabibov AG, et al. **Methods Mol Biol** 1995;51:223–35

Tryptophan-immobilized column adsorbs immunoglobulin G anti-GQ1b antibody from Fisher's syndrome: A new approach to treatment. Yuki N. **Neurology** 1996 Jun; 46(6):1644–51

The isolation of U1 RNA-binding antibody fragments from autoimmune human-derived bacteriophage display libraries. Powers JE, et al. **Nucleic Acids Symp Ser** 1995; (33):240–3

[Does a clinician need autoimmune assays of the thyroid gland?] Välimäki MJ. **Duodecim** 1994;110(10):969–73 (14 ref.) **(Fin)**

[Cryofibrinogenemia caused by monoclonal anti-fibrinogen antibodies] Zeuner RA, et al. **Dtsch Med Wochenschr** 1996 Sep 6;121(36):1084–9 (Eng. Abstr.) **(Ger)**

[Immunoadsorption therapy on Fisher's syndrome--removal ability of anti-ganglioside antibodies by tryptophan-linked immunoadsorbent] Deguchi K, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):884–8 (Eng. Abstr.) **(Jpn)**

[Identification of anti-neuronal antibody (letter)] Ito H, et al. **Rinsho Shinkeigaku** 1995 Nov;35(11):1259 **(Jpn)**

METABOLISM

P-ANCA as a differential diagnostic marker in inflammatory bowel disease. Oberstadt K, et al. **Adv Exp Med Biol** 1995; 371B:1313–6

Study of antisperm antibodies bound to the sperm cell surface and their relationship to circulating ASA. Gandini L, et al. **Am J Reprod Immunol** 1995 Dec;34(6):375–80

Catalytic activity of anti-thyroglobulin antibodies. Li L, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:570–2

Analysis of anti-U1 RNA antibodies in patients with connective tissue disease. Association with HLA and clinical manifestations of disease. Hoffman RW, et al. **Arthritis Rheum** 1995 Dec;38(12):1837–44

Segregation of autoantibodies with disease in monozygotic twin pairs discordant for systemic sclerosis. Three further cases. McHugh NJ, et al. **Arthritis Rheum** 1995 Dec; 38(12):1845–50

A patient with antineutrophil cytoplasmic antibody-negative pulmonary capillaritis and circulating primed neutrophils. Nierman DM, et al. **Arthritis Rheum** 1995 Dec; 38(12):1855–8

Efficient vasoactive intestinal polypeptide hydrolyzing autoantibody light chains selected by phage display. Tyutyulkova S, et al. **Biochim Biophys Acta** 1996 Aug 23; 1316(3):217–23

Binding of beta 2 glycoprotein I to activated polystyrene and its recognition by human IgG autoantibodies. Keil LB, et al. **Biotechnol Appl Biochem** 1995 Dec;22 (Pt 3):305–13

Fab-mediated binding of glycoprotein Ib/IX and IIb/IIIa specific antibodies in chronic idiopathic thrombocytopenic purpura. Hou M, et al. **Br J Haematol** 1995 Dec; 91(4):944–50

Effective treatment of anti Jo-1 antibody-positive polymyositis with cyclosporine [letter] Tellus MM, et al. **Br J Rheumatol** 1995 Dec;34(12):1187–8

The effect of intermittent steroid therapy on anti-sperm antibody levels. Keane D, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):75–9

Antineutrophil cytoplasmic antibodies in autoimmune hepatitis [letter; comment] Bansi DS, et al. **Gastroenterology** 1995 Dec;109(6):2049–50. Comment on: Gastroenterology 1995 Apr;108(4):1159–66.

Relationship between an asymptomatic male genital tract exposure to Chlamydia trachomatis and an autoimmune response to spermatozoa. Witkin SS, et al. **Hum Reprod** 1995 Nov;10(11):2952–5

Studies of patients with anti-epiligrin cicatricial pemphigoid. Yancey KB, et al. **J Dermatol** 1995 Nov;22(11):829–35 (25 ref.)

Characterization of insulin autoantibodies in a patient with autoimmune hypoglycemia. Di Cerbo A, et al. **J Endocrinol Invest** 1995 Apr;18(4):299–304

Primate erythrocyte (E) complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulation. Taylor RP, et al. **J Hematother** 1995 Oct;4(5):357–62

Human lupus anti-spliceosome A protein autoantibodies bind contiguous surface structures and segregate into two sequential epitope binding patterns. James JA, et al. **J Immunol** 1996 May 15;156(10):4018–26

A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. Zillikens D, et al. **J Invest Dermatol** 1996 Mar; 106(3):465–70

The I binding specificity of human VH 4-34 (VH 4-21) encoded antibodies is determined by both VH framework region 1 and complementarity determining region 3. Li Y, et al. **J Mol Biol** 1996 Mar 1;256(3):577–89

Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. D'Andrea DM, et al. **Kidney Int** 1996 May;49(5):1214–21

Methods of measuring thyroglobulin and peptide-methylcoumarinamide hydrolysis by autoantibodies. Li L, et al. **Methods Mol Biol** 1995; 51:417–21

Carbohydrate-binding proteins (plant/human lectins and autoantibodies from human serum) as mediators of release of lysozyme, elastase, and myeloperoxidase from human neutrophils. Timoshenko AV, et al. **Res Exp Med (Berl)** 1995;195(3):153–62

Pre-transplant anti-epithelial cell antibodies and graft failure after single lung transplantation. Smith JD, et al. **Transpl Immunol** 1995 Mar;3(1):68–73

Spectrotype analysis of human ABO antibodies: evidence for different clonal heterogeneity of IgM, IgG, and IgA antibody populations. Rieben R, et al. **Vox Sang** 1996; 70(2):104–11

[Anti-platelet antibody and severe thrombocytopenia during interferon-alpha therapy for chronic active hepatitis C] Tanaka Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr;19(2):150–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Diffuse panbronchiolitis with P-ANCA-positive arteritis and necrotizing glomerulitis] Saku N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Apr;34(4):434–8 (Eng. Abstr.) **(Jpn)**

[A case of acute progressive glomerulonephritis with positive P-ANCA and C-ANCA] Toba T, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):620–1 **(Jpn)**

PHARMACOLOGY

Autoantibodies inhibit interleukin-7-mediated proliferation and are associated with the age-dependent loss of pre-B cells in autoimmune New Zealand Black Mice. Merchant MS, et al. **Blood** 1996 Apr 15;87(8):3289–96

Human auto-anti-idiotypic antibodies to mite-specific IgE can degranulate human basophils in vitro. Weyer A, et al. **Clin Exp Allergy** 1995 Oct;25(10):935–41

Leucocyte activation by anti-lactoferrin antibodies bound to vascular endothelium. Peen E, et al. **Clin Exp Immunol** 1996 Mar;103(3):403–7

Loss of autoantibody activity by alteration in autoantigen. Spitzer RE, et al. **Clin Immunol Immunopathol** 1996 Aug; 80(2):211–3

Effect on sperm-immobilizing antibodies on the spontaneous and calcium-ionophore (A23187)-induced acrosome reaction. Tasdemir I, et al. **Int J Fertil Menopausal Stud** 1995 Jul-Aug;40(4):192–5

IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. Carvalho D, et al. **J Clin Invest** 1996 Jan 1; 97(1):111–9

Antibodies to an autostimulatory growth factor (IL-2) or its receptor induce death of leukemogenic cells. Orban PC, et al. **J Immunol** 1996 May 1;156(9):3334–41

Antibodies to neutrophil cytoplasmic antigens induce monocyte chemoattractant protein-1 secretion from human monocytes. Casselman BL, et al. **J Lab Clin Med** 1995 Nov; 126(5):495–502

In vitro production of human anti-sperm antibodies: effect of an oligoclonal antibody (F6) on sperm-egg interaction. Fusi FM, et al. **J Reprod Immunol** 1995 Jul;29(2):135–47

Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor. Garrone P, et al. **Mol Immunol** 1996 May-Jun;33(7–8):649–58

Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by beta 2-glycoprotein I and anti-beta 2-glycoprotein I. Schousboe I, et al. **Thromb Haemost** 1995 May;73(5):798–804

PHYSIOLOGY

Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves [see comments] Shillito P, et al. **Ann Neurol** 1995 Nov; 38(5):714–22. Comment in: Ann Neurol 1995 Nov;38(5):701–2.

Cardiac surgery and cold-reactive proteins. Agarwal SK, et al. **Ann Thorac Surg** 1995 Oct;60(4):1143–50 (47 ref.)

Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Lefkowith JB, et al. **Arthritis Rheum** 1996 Jun;39(6):894–903 (100 ref.)

Characterization of biologically active antineutrophil cytoplasmic antibodies induced in mice. Pathogenetic role in experimental vasculitis [see comments] Tomer Y, et al. **Arthritis Rheum** 1995 Oct;38(10):1375–81. Comment in: Arthritis Rheum 1996 Jul;39(7):1262–3.

The glycosylation of red cell autoantibodies affects their functional activity in vitro. Hadley AG, et al. **Br J Haematol** 1995 Nov;91(3):587–94

Cardiac cytotoxic mechanism mediated by antibodies against myocardial mitochondrial ADP/ATP carrier in patients with dilated cardiomyopathy. Liao Y, et al. **Chin Med J (Engl)** 1996 Mar;109(3):193–6

Emerging concepts regarding B cells and autoantibodies in murine lupus nephritis. B cells have multiple roles; all autoantibodies are not equal [editorial] Madaio MP, et al. **J Am Soc Nephrol** 1996 Mar;7(3):387–96 (104 ref.)

Antiovarian antibodies and their effect on the outcome of assisted reproduction. Narayanan M, et al. **J Assist Reprod Genet** 1995 Oct;12(9):599–605

Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. Schett G, et al. **J Clin Invest** 1995 Dec;96(6):2569–77

Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. Niimi N, et al. **J Invest Dermatol** 1996 May;106(5):1001–6

Acquired factor VIII inhibitor at the onset of prolymphocytic leukemia [letter] Longo G, et al. **Leukemia** 1996 Sep; 10(9):1557–8

Assessment of the influence of thyroglobulin (Tg) autoantibodies and other interfering factors on the use of serum Tg as tumor marker in differentiated thyroid carcinoma. Schaadt B, et al. **Thyroid** 1995 Jun;5(3):165–70

[Multiple hematomas caused by acquired factor VIII inhibitor (letter)] Collet C, et al. **Rev Med Interne** 1996;17(2):171–2 **(Fre)**

[Role of autoantibody in preeclampsia] Yamamoto T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr;18(2):146–51 (Eng. Abstr.) **(Jpn)**

AUTOANTIGENS

The lipoic acid containing components of the 2-oxoacid dehydrogenase complexes mimic trifluoroacetylated proteins and are autoantigens associated with halothane hepatitis. Frey N, et al. **Chem Res Toxicol** 1995 Jul-Aug; 8(5):736–46

Tyrosinase as an autoantigen in patients with vitiligo. Baharav E, et al. **Clin Exp Immunol** 1996 Jul;105(1):84–8

Megalin (gp330) possesses an antigenic epitope capable of inducing passive Heymann nephritis independent of the nephritogenic epitope in receptor-associated protein. Orlando RA, et al. **J Am Soc Nephrol** 1995 Jul;6(1):61–7

Human self-reactive T cell clones expressing identical T cell receptor beta chains differ in their ability to recognize a cryptic self-epitope. Quaratino S, et al. **J Exp Med** 1996 Feb 1;183(2):349–58

A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. Zillikens D, et al. **J Invest Dermatol** 1996 Mar; 106(3):465–70

Recent progress in studies on autoantigens for various autoimmune blistering skin diseases. Hashimoto T. **Keio J Med** 1995 Dec;44(4):115–23 (84 ref.)

Antigen-specific therapies for the treatment of autoimmune diseases. Hafler DA, et al. **Springer Semin Immunopathol** 1995;17(1):61–76 (78 ref.)

[Primary biliary cirrhosis--antimitochondrial antibody and the reactive antigens] Ishibashi H. **Fukuoka Igaku Zasshi** 1995 Oct;86(10):385–8 (4 ref.) **(Jpn)**

[Recent findings on antigens reactive to antiphospholipid antibodies] Matsuda S. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):27–38 (66 ref.) **(Jpn)**

[Autoantigenic regulation in type 1 diabetes] Björk E. **Lakartidningen** 1996 Jul 24;93(30-31):2676-7 **(Swe)**

ADMINISTRATION & DOSAGE

Treatment of autoimmune diseases by oral tolerance to autoantigens. Weiner HL, et al. **Adv Exp Med Biol** 1995; 371B:1217-23 (30 ref.)

Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. Trentham DE. **Ann N Y Acad Sci** 1996 Feb 13; 778:306-14 (15 ref.)

Food for thought--is induction of oral tolerance feasible and practical in human thyroid autoimmunity? [editorial; comment] Rapoport B, et al. **Endocrinology** 1996 Jun; 137(6):2197-8. Comment on: Endocrinology 1996 Jun;137(6):2199-207.

Experimental autoimmune dacryoadenitis. I. Lacrimal gland disease in the rat. Liu SH, et al. **Invest Ophthalmol Vis Sci** 1987 Feb;28(2):270-5

Experimental autoimmune dacryoadenitis. II. Harderian gland disease in the rat. Liu SH, et al. **Invest Ophthalmol Vis Sci** 1987 Feb;28(2):276-80

ANALYSIS

Molecular analysis of the pathological autoimmune antigens of Heymann nephritis [comment] Farquhar MG. **Am J Pathol** 1996 May;148(5):1331-7 (46 ref.). Comment on: Am J Pathol 1996 May;148(5):1613-24.

Enhanced membrane expression of the 52 kDa Ro(SS-A) and La(SS-B) antigens by human keratinocytes induced by TNF alpha. Dörner T, et al. **Ann Rheum Dis** 1995 Nov; 54(11):904-9

Glomerular antigens in severe hereditary nephrosis. Holthöfer H, et al. **APMIS** 1995 Nov;103(11):823-31

Autoantigenicity of human sperm: molecular identities of sperm antigens recognized by sera of immunoinfertile men in the immunoprecipitation procedure. Naz RK, et al. **Arch Androl** 1995 Nov-Dec;35(3):225-31

Ultrastructural localization of binding sites of sera from patients with linear IgA bullous dermatosis. Kowalewski C, et al. **Arch Dermatol Res** 1995;287(7):636-40

Heterogeneity in the expression of Ro and La antigens in human skin. Niimi Y, et al. **Arthritis Rheum** 1995 Sep; 38(9):1271-6

Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Sánchez-Guerrero J, et al. **Arthritis Rheum** 1996 Jun;39(6):1055-61

Target antigen(s) in endometrial autoimmunity of endometriosis. Mathur S, et al. **Autoimmunity** 1995; 20(4):211-22

Expression pattern of the bullous pemphigoid-180 antigen in normal and neoplastic epithelia. Fairley JA, et al. **Br J Dermatol** 1995 Sep;133(3):385-91

Differences in the expression of pemphigus antigens during epidermal differentiation. Iwatsuki K, et al. **Br J Dermatol** 1995 Aug;133(2):209-16

Characterisation of a sperm coating auto-antigen reacting with antisperm antibodies of infertile males using monoclonal antibodies. Poulton TA, et al. **Br J Obstet Gynaecol** 1996 May;103(5):463-7

A clinicopathologic study of 233 cases with special reference to evaluation with the MIB-1 index. Nakamura S, et al. **Cancer** 1995 Oct 15;76(8):1313-24

Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3. King WJ, et al. **Clin Exp Immunol** 1995 Oct;102(1):98-105

The association of hepatitis C virus infection with monoclonal rheumatoid factors bearing the WA cross-idiotype: implications for the etiopathogenesis and therapy of mixed cryoglobulinemia. Agnello V, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S101-4

Peptide autoantigenicity of the small nuclear ribonucleoprotein C. James JA, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):299-305

Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM. Chang YH, et al. **Diabetes** 1996 Apr;45(4):408-14

Islet cell and thyroid autoimmunity in Chinese patients with IDDM [letter] Thai AC, et al. **Diabetes Care** 1995 Apr; 18(4):586-7

Sequestration of PML and Sp100 proteins in an intranuclear viral structure during herpes simplex virus type 1 infection. Puvion-Dutilleul F, et al. **Exp Cell Res** 1995 Dec; 221(2):448-61

Functional CD4+ T cell subsets defined by expression of CD45RC and NTA260 antigens and age-associated polarization in murine lupus. Nishimura H, et al. **Int Immunol** 1995 Jul;7(7):1115-23

PC-10 as a predictor of prognosis after antigen retrieval in posterior uveal melanoma. Seregard S, et al. **Invest Ophthalmol Vis Sci** 1996 Jun;37(7):1451-8

MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. Böni R, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):416-8

Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes. Aanstoot HJ, et al. **J Clin Invest** 1996 Jun 15;97(12):2772-83

A case of bullous pemphigoid with antibodies against intercellular 130 kd antigen. Takahashi H, et al. **J Dermatol** 1995 Aug;22(8):576-81

Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. Bonifacio E, et al. **J Immunol** 1995 Dec 1;155(11):5419-26

Both Sm and DNA are selecting antigens in the anti-Sm B cell response in autoimmune MRL/lpr mice. Retter MW, et al. **J Immunol** 1996 Feb 1;156(3):1296-306

Identification of a 450-kDa human epidermal autoantigen as a new member of the plectin family. Fujiwara S, et al. **J Invest Dermatol** 1996 May;106(5):1125-30

97-kDa linear IgA bullous dermatosis (LAD) antigen localizes to the lamina lucida of the epidermal basement membrane. Ishiko A, et al. **J Invest Dermatol** 1996 Apr; 106(4):739-43

LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. Marinkovich MP, et al. **J Invest Dermatol** 1996 Apr;106(4):734-8

Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: predictive value of anti-Ro(SSA) and anti-La(SSB) antibodies and treatment with indomethacin and hydroxychloroquine. Senécal JL, et al. **J Rheumatol** 1995 May;22(5):868-75

Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of unknown origin. Krakauer J, et al. **Neurology** 1996 May;46(5):1486-7

Caenorhabditis elegans embryos contain only one major species of Ro RNP. Van Horn DJ, et al. **RNA** 1995 May; 1(3):293-303

Nuclear Sm antigens in the sperm of different organisms. Delgado F, et al. **Zygote** 1994 Aug;2(3):227-35

BIOSYNTHESIS

Expression of the human autoantigen of Wegener's granulomatosis (PR3) in a baculovirus expression system. Szymkowiak CH, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):283-9

Ultraviolet B irradiation and cytomegalovirus infection synergize to induce the cell surface expression of 52-kD/Ro antigen. Zhu J. **Clin Exp Immunol** 1996 Jan; 103(1):47-53

Gene expression of islet cell antigen p69 in human, mouse, and rat. Karges W, et al. **Diabetes** 1996 Apr;45(4):513-21

ICA69 is expressed equally in the human endocrine and exocrine pancreas. Mally MI, et al. **Diabetologia** 1996 Apr; 39(4):474-80

Expression of a gastric autoantigen in pancreatic islets results in non-destructive insulitis after neonatal thymectomy. Barrett SP, et al. **Eur J Immunol** 1995 Sep;25(9):2686-94

Cyclosporin depresses pancreatic islet expression of antigens for islet cell autoantibodies in non obese diabetic mice. el Mansour A, et al. **J Autoimmun** 1996 Feb;9(1):29-39

Cytomegalovirus infection induces expression of 60 KD/Ro antigen on human keratinocytes. Zhu J. **Lupus** 1995 Oct; 4(5):396-406

Expression of messenger RNA encoding a paraneoplastic cerebellar degeneration-associated antigen in the rat hippocampus. Sakai K, et al. **Neurosci Lett** 1995 Sep 1; 197(1):33-6

BLOOD

A child with antibodies targeting both linear IgA bullous dermatosis and bullous pemphigoid antigens. Darling TN, et al. **Arch Dermatol** 1995 Dec;131(12):1438-42

Visualization of IgG-binding loci on the surface of sickle erythrocytes [letter] Green GA. **Blood** 1996 Mar 15; 87(6):2609

Increased levels of beta 2 glycoprotein-I antigen and beta 2 glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. McNally T, et al. **Br J Rheumatol** 1995 Nov;34(11):1031-6

Bullous pemphigoid: serum antibody titre and antigen specificity. Pas HH, et al. **Exp Dermatol** 1995 Dec; 4(6):372-6

Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism [see comments] Li Y, et al. **J Clin Invest** 1996 Feb 15;97(4):910-4. Comment in: J Clin Invest 1996 Feb 15;97(4):899-90.

P1 blood group antigen expression and epidemic hemolytic uremic syndrome. Orr PH, et al. **Pediatr Nephrol** 1995 Oct; 9(5):612-3

The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2. Passini N, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9412-6

Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. Short AK, et al. **QJM** 1995 Nov; 88(11):775-83

Canine bullous pemphigoid (BP): identification of the 180-kd canine BP antigen by circulating autoantibodies. Iwasaki T, et al. **Vet Pathol** 1995 Jul;32(4):387-93

CHEMISTRY

The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Seelig HP, et al. **Arthritis Rheum** 1995 Oct;38(10):1389-99

The protein conformation and a zinc-binding domain of an autoantigen from mouse seminal vesicle. Huang YH, et al. **Biophys J** 1995 Nov;69(5):2084-9

Identification and characterization of a 230-kDa Golgi-associated protein recognized by autoantibodies from a patient with HBV hepatitis. Funaki T, et al. **Cell Struct Funct** 1996 Feb;21(1):63-72

Structural differences between the human and mouse 52-kD Ro autoantigens associated with poorly conserved autoantibody activity across species. Keech CL, et al. **Clin Exp Immunol** 1996 May;104(2):255-63

A charged segment mainly composed of basic amino acids forms an autoepitope of CENP-A. Muro Y, et al. **Clin Immunol Immunopathol** 1996 Jan;78(1):86-9

Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105-14 (65 ref.)

Anti-La monoclonal antibodies recognizing epitopes within the RNA-binding domain of the La protein show differential capacities to immunoprecipitate RNA-associated La protein. Pruijn GJ, et al. **Eur J Biochem** 1995 Sep 1;232(2):611-9

Sequence similarity between beta-cell autoantigens [letter] Rudy G, et al. **Immunol Today** 1995 Aug;16(8):406-7

Pancreatic expression of antigens for islet cell antibodies in non-obese diabetic mice. Martignat L, et al. **J Autoimmun** 1995 Aug;8(4):465-82

Demonstration of the molecular shape of BP180, a 180-kDa bullous pemphigoid antigen and its potential for trimer formation. Hirako Y, et al. **J Biol Chem** 1996 Jun 7; 271(23):13739-45

The Goodpasture autoantigen. Structural delineation of two immunologically privileged epitopes on alpha3(IV) chain of type IV collagen. Kalluri R, et al. **J Biol Chem** 1996 Apr 12;271(15):9062-8

Structural analysis of the predicted coiled-coil rod domain of the cytoplasmic bullous pemphigoid antigen (BPAG1). Empirical localization of the N-terminal globular domain-rod boundary. Tang HY, et al. **J Biol Chem** 1996 Apr 19;271(16):9716-22

Mass spectrometric identification of leucine zipper-like homodimer complexes of the autoantigen L7. Witte S, et al. **J Biol Chem** 1996 Jul 26;271(30):18171-5

The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies. Fujinaga M, et al. **J Mol Biol** 1996 Aug 16;261(2):267-78

Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Rudy G, et al. **Mol Med** 1995 Sep;1(6):625-33

Mapping rat megalin: the second cluster of ligand binding repeats contains a 46-amino acid pathogenic epitope involved in the formation of immune deposits in Heymann nephritis. Saito A, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8601-5

GENETICS

Gene structure, DNA methylation, and imprinted expression of the human SNRPN gene. Glenn CC, et al. **Am J Hum Genet** 1996 Feb;58(2):335-46

Deletion of small nuclear ribonucleoprotein polypeptide N (SNRPN) in Prader-Willi syndrome detected by fluorescence in situ hybridization: two sibs with the typical phenotype without a cytogenetic deletion in chromosome 15q. Ishikawa T, et al. **Am J Med Genet** 1996 Apr 24; 62(4):350-2

The autoantigen La/SS-B: analysis of the expression of alternatively spliced La mRNA isoforms. Hilker M, et al. **Cell Tissue Res** 1996 Jun;284(3):383-9

Isolation of cDNAs encoding immunogenic regions of gp330, the autoantigen involved in Heymann nephritis. Luca ME, et al. **Clin Exp Immunol** 1996 May;104(2):312-7

Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML). Grötzinger T, et al. **Eur J Biochem** 1996 Jun 1;238(2):554-60

The Caenorhabditis elegans rop-1 gene encodes the homologue of the human 60-kDa Ro autoantigen. Labbé JC, et al. **Gene** 1995 Dec 29;167(1-2):227-31

Cloning and characterization of the neural isoforms of human dystonin. Brown A, et al. **Genomics** 1995 Oct 10; 29(3):777-80

A member of the mouse LRR transcript family with homology to the human Sp100 gene. Plass C, et al. **Hereditas** 1995;122(3):245-56

Breakage in the SNRPN locus in a balanced 46,XY,t(15;19) Prader-Willi syndrome patient. Sun Y, et al. **Hum Mol Genet** 1996 Apr;5(4):517-24

Presentation of endogenous acetylcholine receptor antigen to a specific CD4+ T-cell line by a transfected B-cell line. Mulcahy AF, et al. **Immunology** 1995 Sep;86(1):116-21

Molecular characterization of trans-Golgi p230. A human peripheral membrane protein encoded by a gene on chromosome 6p12-22 contains extensive coiled-coil alpha-helical domains and a granin motif. Erlich R, et al. **J Biol Chem** 1996 Apr 5;271(14):8328-37

Molecular characterization of Golgin-245, a novel Golgi complex protein containing a granin signature. Fritzler MJ, et al. **J Biol Chem** 1995 Dec 29;270(52):31262-8

Mutational analysis of p80 coilin indicates a functional

interaction between coiled bodies and the nucleolus. Bohmann K, et al. **J Cell Biol** 1995 Nov;131(4):817–31

Imogen 38: a novel 38–kD islet mitochondrial autoantigen recognized by T cells from a newly diagnosed type 1 diabetic patient. Arden SD, et al. **J Clin Invest** 1996 Jan 15;97(2):551–61

Molecular analysis of a major antigenic region of the 240–kD protein of Mi–2 autoantigen. Ge Q, et al. **J Clin Invest** 1995 Oct;96(4):1730–7

52–kD SS–A/Ro: genomic structure and identification of an alternatively spliced transcript encoding a novel leucine zipper–minus autoantigen expressed in fetal and adult heart. Chan EK, et al. **J Exp Med** 1995 Oct 1;182(4):983–92

A homozygous deletion mutation in the gene encoding the 180–kDa bullous pemphigoid antigen (BPAG2) in a family with generalized atrophic benign epidermolysis bullosa. McGrath JA, et al. **J Invest Dermatol** 1996 Apr; 106(4):771–4

Ku86 defines the genetic defect and restores X–ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants. Errami A, et al. **Mol Cell Biol** 1996 Apr;16(4):1519–26

A highly amplified mouse gene is homologous to the human interferon–responsive Sp100 gene encoding an autoantigen associated with nuclear dots. Grötzinger T, et al. **Mol Cell Biol** 1996 Mar;16(3):1150–6

Calreticulin is transcriptionally upregulated by heat shock, calcium and heavy metals. Nguyen TO, et al. **Mol Immunol** 1996 Mar–Apr;33(4–5):379–86

Exclusion of SNRPN as a major determinant of Prader–Willi syndrome by a translocation breakpoint. Schulze A, et al. **Nat Genet** 1996 Apr;12(4):452–4

A nucleolar RNA helicase recognized by autoimmune antibodies from a patient with watermelon stomach disease. Valdez BC, et al. **Nucleic Acids Res** 1996 Apr 1; 24(7):1220–4

Definition of the HLA–A29 peptide ligand motif allows prediction of potential T–cell epitopes from the retinal soluble antigen, a candidate autoantigen in birdshot retinopathy. Boisgerault F, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3466–70

IA–2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin–dependent diabetes mellitus. Lan MS, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6367–70

T–cell epitope analysis using subtracted expression libraries (TEASEL): application to a 38–kDA autoantigen recognized by T cells from an insulin–dependent diabetic patient. Neophytou PI, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2014–8

[Rhesus blood group (see comments)] Leeksma OC. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2574–6. Comment in: Ned Tijdschr Geneeskd 1996 Jan 27;140(4):221. **(Dut)**

IMMUNOLOGY

A role for antigen in the evolution of gastrointestinal MALT–type B cell lymphoma. Hussell T, et al. **Adv Exp Med Biol** 1995;371A:145–7

Analysis of immunoglobulin gamma heavy chains from rheumatoid arthritis synovium. Evidence of antigen–driven selection. Bridges SL Jr, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:450–2

Oral tolerance in myasthenia gravis. Drachman DB, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:258–72 (58 ref.)

Effects of cyclosporin A on the induction of oral tolerance. Fukushima A, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:376–8

Analysis of the structural correlates for self–antigen binding by natural and disease–related autoantibodies. In vitro expression of recombinant and/or mutagenized human IgG. Ichiyoshi Y, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:328–41 (35 ref.)

Origins of anti–DNA antibodies and their implications for B–cell tolerance. Radic MZ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:384–96 (13 ref.)

Immunoglobulin gene usage in diabetes–associated human monoclonal antibodies recognizing glutamate decarboxylase. Richter W, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:457–60

Unconventional B–cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342–55 (42 ref.)

Genetic and functional characterization of human autoantibodies using combinatorial phage display libraries. Zeidel M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:559–64

Autoimmune ataxic neuropathies (sensory ganglionopathies): are glycolipids the responsible autoantigens? [editorial] Dalakas MC, et al. **Ann Neurol** 1996 Apr;39(4):419–22

Cellular immunity to cartilage aggrecan core protein in patients with rheumatoid arthritis and non–arthritic controls. Goodstone NJ, et al. **Ann Rheum Dis** 1996 Jan; 55(1):40–6

T–cell recognition of beta–cell autoantigens in insulin–dependent diabetes mellitus. Kallan AA, et al. **APMIS** 1996 Jan;104(1):3–11 (84 ref.)

Autoantigenicity of human sperm: molecular identities of sperm antigens recognized by sera of immunoinfertile men in the immunoprecipitation procedure. Naz RK, et al. **Arch Androl** 1995 Nov–Dec;35(3):225–31

Generalized atrophic benign epidermolysis bullosa. Either 180–kd bullous pemphigoid antigen or laminin–5 deficiency. Jonkman MF, et al. **Arch Dermatol** 1996 Feb; 132(2):145–50

Significance of anti–nuclear matrix antibodies in patients with in vivo speckled antinuclear antibody staining. Deng JS, et al. **Arthritis Rheum** 1996 Aug;39(8):1300–7

Strong association of dermatomyositis–specific Mi–2 autoantibodies with a tryptophan at position 9 of the HLA–DR beta chain. Mierau R, et al. **Arthritis Rheum** 1996 May;39(5):868–76

Maternal–fetal immunology and autoimmune disease: is some autoimmune disease auto–alloimmune or allo–autoimmune? Nelson JL. **Arthritis Rheum** 1996 Feb;39(2):191–4

Immune surveillance and autoantigen recognition in the central nervous system. Sedgwick JD. **Aust N Z J Med** 1995 Dec;25(6):784–92 (46 ref.)

Glycolipids as the major autoantigens of cytoplasmatic islet cell antibodies. Cabrera–Rode E, et al. **Autoimmunity** 1995; 20(3):145–51

Are sulfatides ICA–specific antigens? [letter] Diaz–Horta O, et al. **Autoimmunity** 1995;21(2):149

Prospective evaluation of the clinical usefulness of an antigen–specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Brighton TA, et al. **Blood** 1996 Jul 1; 88(1):194–201

Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow–derived cells. Filion MC, et al. **Blood** 1996 Sep 15;88(6):2144–50

Heterogeneity of neutrophil antibodies in patients with primary Sjögren's syndrome. Lamour A, et al. **Blood** 1995 Nov 1;86(9):3553–9

Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self–antigen: implications for lymphomagenesis in acquired immunodeficiency syndrome. Roncella S, et al. **Blood** 1996 Jul 15; 88(2):599–608

Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen–PE complex. Sugi T, et al. **Blood** 1995 Oct 15;86(8):3083–9

Pemphigoid gestationis with autoantibodies exclusively directed to the 230–kDa bullous pemphigoid antigen (BP230Ag) [letter] Ghohestani R, et al. **Br J Dermatol** 1996 Mar;134(3):603–4

Comparative sensitivity of indirect immunofluorescence to immunoblot assay for the detection of circulating antibodies to bullous pemphigoid antigens 1 and 2. Ghohestani R, et al. **Br J Dermatol** 1996 Jul;135(1):74–9

Effective treatment of anti Jo–1 antibody–positive polymyositis with cyclosporine [letter] Tellus MM, et al. **Br J Rheumatol** 1995 Dec;34(12):1187–8

Prevalence and clinical significance of antibodies to ribonucleoproteins in systemic lupus erythematosus in Malaysia. Wang CL, et al. **Br J Rheumatol** 1996 Feb; 35(2):129–32

Macrophage presentation of endogenous self–protein: the MHC class II presentation pathway is not accessible to intracellular C5 or alpha 1–antitrypsin. Grant CF, et al. **Cell Immunol** 1996 Feb 1;167(2):230–40

Unique T cell antagonist properties of the exact self–correlate of a peptide antigen revealed by self–substitution of non–self–positions in the peptide sequence. Schountz T, et al. **Cell Immunol** 1996 Mar 15;168(2):193–200

Development of ulcerative colitis–associated anti–idiotype antibody using a novel monoclonal antibody against a colonic autoantigen. Shah U, et al. **Cell Immunol** 1995 Nov; 166(1):154–7

Epitope mapping of anti–proteinase 3 and anti–myeloperoxidase antibodies. Chang L, et al. **Clin Exp Immunol** 1995 Oct;102(1):112–9

Significance of extractable nuclear antigens in childhood autoimmune liver disease. Gregorio GV, et al. **Clin Exp Immunol** 1995 Nov;102(2):308–13

Characterization and specificity of anti–endothelial cell membrane antibodies and their relationship to thrombosis in primary antiphospholipid syndrome (APS). Hill MB, et al. **Clin Exp Immunol** 1995 Nov;102(2):368–72

HLA–DR–restricted T cell lines from newly diagnosed type 1 diabetic patients specific for insulinoma and normal islet beta cell proteins: lack of reactivity to glutamic acid decarboxylase. Huang GC, et al. **Clin Exp Immunol** 1995 Oct;102(1):152–8

Structural differences between the human and mouse 52–kD Ro autoantigens associated with poorly conserved autoantibody activity across species. Keech CL, et al. **Clin Exp Immunol** 1996 May;104(2):255–63

Monoclonal gammopathies antigen driven in autoimmune diseases. Osterland CK. **Clin Exp Rheumatol** 1996 Jan–Feb; 14 Suppl 14:S37–44 (34 ref.)

Nonprecipitating anti–La(SS–B) autoantibodies in primary Sjögren's syndrome. Beer RG, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):314–8

Cytotoxicity to endothelial cells by sera from aged MRL/lpr/lpr mice is associated with autoimmunity to cell surface heparan sulfate. Dimitriu–Bona A, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):234–40

Definition of a discontinuous immunodominant epitope of intestinal alkaline phosphatase, an autoantigen in acute bacterial infections. Kolbus N, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):298–306

Rabbit anti–chromatin antibodies recognize similar epitopes on a histone H1 molecule as lupus autoantibodies. Morino N, et al. **Clin Immunol Immunopathol** 1995 Oct;77(1):52–8

IgG autoantibody response in HTLV–I–infected patients. Muller S, et al. **Clin Immunol Immunopathol** 1995 Dec; 77(3):282–90

Cell injury mediated by autoantibodies to intracellular antigens. Reichlin M. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):215–9 (31 ref.)

In vitro RNA selection of an autoimmune epitope on stem–loop II of U1 RNA. St Clair EW, et al. **Clin Immunol Immunopathol** 1996 Apr;79(1):60–70

Loss of autoantibody activity by alteration in autoantigen. Spitzer RE, et al. **Clin Immunol Immunopathol** 1996 Aug; 80(2):211–3

Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations. Tikly M, et al. **Clin Rheumatol** 1996 Mar;15(2):143–7

Glutamic acid decarboxylase and other autoantigens in IDDM. Nepom GT. **Curr Opin Immunol** 1995 Dec; 7(6):825–30 (63 ref.)

Ribonucleoprotein complexes as autoantigens. van Venrooij WJ, et al. **Curr Opin Immunol** 1995 Dec;7(6):819–24 (48 ref.)

Autoimmunity to the GM2–1 islet ganglioside before and at the onset of type I diabetes. Dotta F, et al. **Diabetes** 1996 Sep;45(9):1193–6

Cellular immune response to diverse islet cell antigens in IDDM. Durinovic–Bellò I, et al. **Diabetes** 1996 Jun; 45(6):795–800

Identification of the 37–kDa antigen in IDDM as a tyrosine phosphatase–like protein (phogrin) related to IA–2. Hawkes CJ, et al. **Diabetes** 1996 Sep;45(9):1187–92

T–cell responses to autoantigens in IDDM. The search for the Holy Grail. Roep BO. **Diabetes** 1996 Sep;45(9):1147–56 (123 ref.)

SR–Ca2+ ATPase as an autoimmunogen in experimental myocarditis. Khaw BA, et al. **Eur Heart J** 1995 Dec;16 Suppl O:92–6

Is immune thrombocytopenic purpura (ITP) due to natural antibodies specific to platelets? [letter] Souberbielle BE. **Eur J Haematol** 1996 Mar;56(3):178–80

Processing and presentation of type II collagen, a fibrillar autoantigen, by H–2q antigen–presenting cells. Manoury–Schwartz B, et al. **Eur J Immunol** 1995 Dec; 25(12):3235–42

Recognition of altered self major histocompatibility complex molecules modulated by specific peptide interactions. Nepom GT, et al. **Eur J Immunol** 1996 Apr;26(4):949–52

Autoreactive T cell specificity in autoimmune hemolytic anemia of the NZB mouse. Perry FE, et al. **Eur J Immunol** 1996 Jan;26(1):136–41

HLA–associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent–onset insulin–dependent diabetes mellitus. Roep BO, et al. **Eur J Immunol** 1996 Jun;26(6):1285–9

Characterization of a recombinant proteinase 3, the autoantigen in Wegener's granulomatosis and its reactivity with anti–neutrophil cytoplasmic autoantibodies. Witko–Sarsat V, et al. **FEBS Lett** 1996 Mar 11; 382(1–2):130–6

Antigenic cross–reactivity of human tracheal mucin with human sperm and trophoblasts correlates with the expression of mucin 8 gene messenger ribonucleic acid in reproductive tract tissues. D'Cruz OJ, et al. **Fertil Steril** 1996 Aug;66(2):316–26

Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics. Clot P, et al. **Gastroenterology** 1996 Jul;111(1):206–16

Proliferation index determined by MIB–1 and recurrence in endometrial cancer. Geisler JP, et al. **Gynecol Oncol** 1996 Jun;61(3):373–7

Autoantibodies from patients with primary biliary cirrhosis recognize a region within the nucleoplasmic domain of inner nuclear membrane protein LBR. Lin F, et al. **Hepatology** 1996 Jan;23(1):57–61

Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. Moteki S, et al. **Hepatology** 1996 Jul;24(1):97–103

Epitope mapping and reactivity of autoantibodies to the E2 component of 2–oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2–oxoglutarate dehydrogenase complex. Moteki S, et al. **Hepatology** 1996 Mar;23(3):436–44

T cell–independent B cell response to self–monosialogangliosides: primary response monoclonal antibodies. Alfonso M, et al. **Hybridoma** 1995 Jun; 14(3):209–16

Antigen–induced exclusion from follicles and anergy are separate and complementary processes that influence peripheral B cell fate. Cyster JG, et al. **Immunity** 1995 Dec; 3(6):691–701

Low avidity recognition of self–antigen by T cells permits escape from central tolerance. Liu GY, et al. **Immunity** 1995 Oct;3(4):407–15

Idiotypic restriction of murine monoclonal antibodies to a defined antigenic region of human thyroglobulin. Del Rio M, et al. **Immunol Invest** 1995 Aug;24(5):655–67

Autoreactive T–cell line derived from PBMC of a rhesus macaque immunized with inactivated SIV vaccine. Teng XC, et al. **Immunol Lett** 1995 Jul–Aug;47(1–2):145–6

Cellular immune responses of patients with juvenile chronic arthritis to retinal antigens and their synthetic peptides.

Gupta D, et al. **Immunol Res** 1996;15(1):74–83

Lupus autoimmunity: from peptides to particles. Mamula MJ. **Immunol Rev** 1995 Apr;144:301–14 (58 ref.)

Restricted diversity in the T-cell repertoire [letter] Petrovsky N. **Immunol Today** 1995 Aug;16(8):408–9

A need for standardization of the anti-endothelial-cell antibody test. Youinou P, et al. **Immunol Today** 1995 Aug; 16(8):363–4

Analysis of variable region genes encoding anti-Sm and anti-cardiolipin antibodies from a systemic lupus erythematosus patient. Demaison C, et al. **Immunology** 1995 Nov;86(3):487–94

The induction of renal autoantigen-specific T cells by a local Listeria monocytogenes infection. Sonoda K, et al. **Immunology** 1995 Oct;86(2):190–8

Murine systemic autoimmune disease induced by mercuric chloride: T helper cells reacting to self proteins. Kubicka-Muranyi M, et al. **Int Arch Allergy Immunol** 1996 Jan;109(1):11–20

Induction of antigen-specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions. Wraith DC. **Int Arch Allergy Immunol** 1995 Dec;108(4):355–9 (29 ref.)

Low avidity recognition of a class II-restricted neo-self peptide by virus-specific T cells. Cerasoli DM, et al. **Int Immunol** 1995 Jun;7(6):935–45

Characterization of development-specific, cell type-specific mouse testicular antigens using testis-specific polyclonal antibodies. Tsuchida J, et al. **Int J Androl** 1995 Aug; 18(4):208–12

Regulation of CD4 T cell reactivity to self and non-self. Lo D, et al. **Int Rev Immunol** 1995;13(2):147–60 (38 ref.)

Absence of cellular responses to a putative autoantigen in onchocercal chorioretinopathy: cellular autoimmunity in onchocercal chorioretinopathy [letter] Braun G, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1717–9

Absence of cellular responses to a putative autoantigen in onchocercal chorioretinopathy. Cellular autoimmunity in onchocercal chorioretinopathy. Cooper PJ, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):405–12

Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. Kalluri R, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1178–85 (64 ref.)

Insulin-dependent diabetes mellitus as a beta-cell targeted disease of immunoregulation. Bach JF. **J Autoimmun** 1995 Aug;8(4):439–63 (172 ref.)

HLA-associated heterogeneity of the humoral response to islet antigens in insulin-dependent diabetes. Delamaire M, et al. **J Autoimmun** 1995 Oct;8(5):645–57

Significantly increased maternal and fetal IgG autoantibody levels to 52 kD Ro (SS-A) and La(SS-B) in complete congenital heart block. Dörner T, et al. **J Autoimmun** 1995 Oct;8(5):675–84

Relation between cellular and humoral immunity to islet cell antigens in type 1 diabetes. Hummel M, et al. **J Autoimmun** 1996 Jun;9(3):427–30

Transgenic mice that express different forms of the influenza virus hemagglutinin as a neo-self-antigen. Caton AJ, et al. **J Clin Immunol** 1995 Nov;15(6 Suppl):106S–112S

Activation and negative selection of functionally distinct subsets of antibody-secreting cells by influenza hemagglutinin as a viral and a neo-self antigen. Caton AJ, et al. **J Exp Med** 1996 Jan 1;183(1):13–26

Genetic basis for T cell recognition of a major histocompatibility complex class II-restricted neo-self peptide. Cerasoli DM, et al. **J Exp Med** 1995 Nov 1; 182(5):1327–36

Myocarditis-inducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart. Donermeyer DL, et al. **J Exp Med** 1995 Nov 1; 182(5):1291–300

Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus. Fedoseyeva EV, et al. **J Exp Med** 1995 Nov 1;182(5):1481–91

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. Hara I, et al. **J Exp Med** 1995 Nov 1; 182(5):1609–14

High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. Parveen S, et al. **J Gastroenterol Hepatol** 1995 Jul–Aug;10(4):438–45

The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. Carrasco-Marin E, et al. **J Immunol** 1996 Jan 15;156(2):450–8

CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. Chen W, et al. **J Immunol** 1996 Aug 1;157(3):1000–5

Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice. Th2-mediated suppression of autoimmune disease. Cua DJ, et al. **J Immunol** 1995 Oct 15;155(8):4052–9

Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. Daw K, et al. **J Immunol** 1996 Jan 15;156(2):818–25

Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. Liu Z, et al. **J Immunol** 1995 Dec 1;155(11):5449–54

Immunization with short peptides from the sequence of the systemic lupus erythematosus-associated 60-kDa Ro autoantigen results in anti-Ro ribonucleoprotein autoimmunity. Scofield RH, et al. **J Immunol** 1996 May 15;156(10):4059–66

Thymus-leukemia antigen interacts with T cells and self-peptides. Sharma P, et al. **J Immunol** 1996 Feb 1; 156(3):987–96

Pathogenesis of post-thymectomy autoimmune gastritis. Identification of anti-H/K adenosine triphosphatase-reactive T cells. Suri-Payer E, et al. **J Immunol** 1996 Aug 15;157(4):1799–805

Lupus autoantibodies to double-stranded DNA cross-react with ribosomal protein S1. Tsuzaka K, et al. **J Immunol** 1996 Feb 15;156(4):1668–75

Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques. Muratori L, et al. **J Immunol Methods** 1995 Dec 1; 187(2):259–64

Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. Balding SD, et al. **J Invest Dermatol** 1996 Jan;106(1):141–6

In situ-bound antibodies eluted from the skin of patients with bullous pemphigoid are preferentially directed against the 230-kD bullous pemphigoid antigen. Korman NJ. **J Invest Dermatol** 1995 Dec;105(6):824–30

Cryptocrine signaling in the thymus network and T cell education to neuroendocrine self-antigens. Geenen V, et al. **J Mol Med** 1995 Sep;73(9):449–55 (49 ref.)

HLA and anti-GQ1b IgG antibody in Miller Fisher syndrome and Guillain-Barré syndrome. Chiba A, et al. **J Neuroimmunol** 1995 Aug;61(1):85–8

Anti-CENP-B response in sera of uranium miners exposed to quartz dust and patients with possible development of systemic sclerosis (scleroderma). Conrad K, et al. **J Rheumatol** 1995 Jul;22(7):1286–94

Clinical and serological identification of 2 forms of complete heart block in children. Hubscher O, et al. **J Rheumatol** 1995 Jul;22(7):1352–5

Identification of Ro(SSA) 52 kDa reactive T cells in labial salivary glands from patients with Sjögren's syndrome. Namekawa T, et al. **J Rheumatol** 1995 Nov;22(11):2092–9

Sequences within a small yeast RNA required for inhibition of internal initiation of translation: interaction with La and other cellular proteins influences its inhibitory activity. Das S, et al. **J Virol** 1996 Mar;70(3):1624–32

Autoantigens interact with cis-acting elements of rubella virus RNA. Pogue GP, et al. **J Virol** 1996 Sep; 70(9):6269–77

The herpes simplex virus type 1 regulatory protein ICP27 coimmunoprecipitates with anti-Sm antiserum, and the C terminus appears to be required for this interaction. Sandri-Goldin RM, et al. **J Virol** 1996 Jan;70(1):108–18

A single-chain Fv reactive with the Goodpasture antigen. Ross CN, et al. **Lab Invest** 1996 Jun;74(6):1051–9

Aetiopathogenesis of Takayasu's arteritis and BCG vaccination: the missing link? Kothari SS. **Med Hypotheses** 1995 Sep;45(3):227–30

Studies on the expression and immunogenicity of the B50 melanoma antigen and its relationship with calreticulin. Bijwaard K, et al. **Melanoma Res** 1995 Oct;5(5):327–36

Immune responses to self peptides naturally presented by murine ciass II major histocompatibility complex molecules. Rider BJ, et al. **Mol Immunol** 1996 May–Jun; 33(7–8):625–33

Coxsackieviruses and diabetes [see comments] [published erratum appears in Nat Med 1995 Mar;1(3):272] Solimena M, et al. **Nat Med** 1995 Jan;1(1):25–6. Comment in: Nat Med 1995 May;1(5):388.

The kinetics of the pathogenic pronase-digested renal proximal tubular antigen and antibody in rat active Heymann nephritis. Maezawa A, et al. **Nephron** 1995; 71(4):448–53

Pitfalls in the diagnosis of autoantibodies associated with paraneoplastic neurologic disease. Sillevis-Smitt P, et al. **Neurology** 1996 Jun;46(6):1739–41

An animal model of bullous pemphigoid: what can it teach us? Giudice GJ, et al. **Proc Assoc Am Physicians** 1995 Jul; 107(2):237–41 (33 ref.)

Viruses, cytokines, antigens, and autoimmunity. Gianani R, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2257–9 (43 ref.)

Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Lu J, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2307–11

The BALB/c mouse B-cell response to pigeon cytochrome c initiates as a heteroclitic response specific for the self antigen mouse cytochrome c. Minnerath JM, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):12379–83

Aromatic-L-amino-acid decarboxylase, a pyridoxal phosphate-dependent enzyme, is a beta-cell autoantigen. Rorsman F, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8626–9

A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Steinman L. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2253–6 (26 ref.)

Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Wucherpfennig KW, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11935–9

HLA-B27-restricted cytotoxic T lymphocyte responses to arthritogenic enterobacteria or self-antigens are dominated by closely related TCRBV gene segments. A study in patients with reactive arthritis. Duchmann R, et al. **Scand J Immunol** 1996 Jan;43(1):101–8

Serum antibodies from patients with primary Sjögren's syndrome and systemic lupus erythematosus recognize multiple epitopes on the La(SS-B) autoantigen resembling viral protein sequences. Haaheim LR, et al. **Scand J Immunol** 1996 Jan;43(1):115–21

Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations. Schultz DR, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):143–59 (120 ref.)

Induction of T cell responses to a self-antigen following allotransplantation. Fedoseyeva EV, et al. **Transplantation** 1996 Mar 15;61(5):679–83

Role of viruses in the loss of tolerance to self-antigens and in autoimmune diseases. von Herrath MG, et al. **Trends Microbiol** 1995 Nov;3(11):424–30 (61 ref.)

Red blood cell glycophorins as B and T-cell antigens in canine autoimmune haemolytic anaemia. Barker RN, et al. **Vet Immunol Immunopathol** 1995 Aug;47(3–4):225–38

[Autoimmune diseases and autoantigens] Miettinen A. **Duodecim** 1994;110(2):207–14 (38 ref.) **(Fin)**

[Study of epitopic sites of the major bullous pemphigoid antigen (BPAg1)] Peyron E, et al. **Ann Biol Clin (Paris)** 1995;53(4):193–7 (Eng. Abstr.) **(Fre)**

[Therapeutic immunomodulation in neurology: from hope to reality. Exemplified by multiple sclerosis] Schluep M, et al. **Schweiz Rundsch Med Prax** 1995 Sep 19;84(38):1021–4 (Eng. Abstr.) **(Fre)**

[Infiltrating T-cells in primary biliary cirrhosis recognize mitochondrial epitopes] Löhr H, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:99–103 (Eng. Abstr.) **(Ger)**

[Molecular mimicry between LKM 1-autoantigen and HCV-polyproteins] Miyakawa H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:885–91 (20 ref.) **(Jpn)**

[Paraneoplastic cerebellar degeneration--characterization of anti-Yo antibody and underlying cancer] **Tanaka K**, et al. **Rinsho Shinkeigaku** 1995 Jul;35(7):770–4 (Eng. Abstr.) **(Jpn)**

[Immunopathogenic mechanisms in autoimmune processes: autoantigens] Buc M. **Bratisl Lek Listy** 1996 Apr; 97(4):187–95 (Eng. Abstr.) **(Slo)**

ISOLATION & PURIFICATION

A basement membrane molecule preferentially associated with mucosal post-capillary venules. Hussell T, et al. **Adv Exp Med Biol** 1995;371A:111–5

Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins. Harris PE, et al. **Blood** 1996 Jun 15; 87(12):5104–12

Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles. Tanaka M, et al. **Clin Exp Dermatol** 1996 Jan;21(1):23–7

The Heymann nephritis antigenic complex: megalin (gp330) and RAP [editorial] Farquhar MG, et al. **J Am Soc Nephrol** 1995 Jul;6(1):35–47 (70 ref.)

[Intra-epidermal pustulosis in a child. Demonstration of a target antigen similar to foliaceus pemphigus antigen] Cordoliani F, et al. **Ann Dermatol Venereol** 1995; 122(10):671–4 (Eng. Abstr.) **(Fre)**

METABOLISM

Epithelial deposits of immunoglobulin G1 and activated complement co-localize with the "M(r) 40kD" putative auto-antigen in ulcerative colitis. Halstensen TS, et al. **Adv Exp Med Biol** 1995;371B:1273–6

Evaluation of anastomotic hyperplasia progression using the cyclin specific antibody MIB-1. Hamdan AD, et al. **Am J Surg** 1996 Aug;172(2):168–70; discussion 170–1

Aberrant expression pattern of the SS-B/La antigen in the labial salivary glands of patients with Sjögren's syndrome. de Wilde PC, et al. **Arthritis Rheum** 1996 May;39(5):783–91

The two isoforms of the 90-kDalton nucleolus organizer region autoantigen (upstream binding factor) bind with different avidity to DNA modified by the antitumor drug cisplatin. Codony-Servat J, et al. **Biochem Pharmacol** 1996 May 3;51(9):1131–6

Sequence and localization of the mouse sperm autoantigenic protein, Sp17. Kong M, et al. **Biol Reprod** 1995 Sep; 53(3):579–90

Expression of proliferation-associated nuclear autoantigens, p330d/CENP-F and PCNA, in differentiation and in drug-induced growth inhibition using two-parameter flow cytometry. Báez A, et al. **Cell Prolif** 1996 Apr;29(4):183–96

Loss of autoantibody activity by alteration in autoantigen. Spitzer RE, et al. **Clin Immunol Immunopathol** 1996 Aug; 80(2):211–3

ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. Solimena M, et al. **EMBO J** 1996 May 1;15(9):2102–14

AUTOANTIGENS

A hemidesmosomal transmembrane collagenous molecule, the 180-kDa bullous pemphigoid antigen (BPA II), is phosphorylated with 12-O-tetradecanoylphorbol-13-acetate in a human squamous cell carcinoma cell line (DJM-1). Kitajima Y, et al. **Epithelial Cell Biol** 1995;4(2):70-5

Interaction of the La (SS-B) autoantigen with small ribosomal subunits. Peek R, et al. **Eur J Biochem** 1996 Mar 1;236(2):649-55

Characterization of cis-acting signals for nuclear import and retention of the La (SS-B) autoantigen. Simons FH, et al. **Exp Cell Res** 1996 May 1;224(2):224-36

Behavior of nuclear matrix proteins during camptothecin-induced apoptosis in HL-60 human leukemia cells. Zweyer M, et al. **Exp Cell Res** 1995 Nov;221(1):27-40

Diminished expression of the extracellular domain of bullous pemphigoid antigen 2 (BPAG2) in the epidermal basement membrane of patients with generalized atrophic benign epidermolysis bullosa. Pohla-Gubo G, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 1):199-206

Cytoplasmic accumulation of the 52 kDa Ro/SS-A nuclear autoantigen in transfected cell lines. Keech CL, et al. **J Autoimmun** 1995 Oct;8(5):699-712

Ku80-deficient cells exhibit excess degradation of extrachromosomal DNA. Liang F, et al. **J Biol Chem** 1996 Jun 14;271(24):14405-11

Direct identification of naturally processed autoantigen-derived peptides bound to HLA-DR15. Phelps RG, et al. **J Biol Chem** 1996 Aug 2;271(31):18549-53

Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase. Turchi JJ, et al. **J Biol Chem** 1996 Jun 7;271(23):13861-7

DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. Casciola-Rosen LA, et al. **J Exp Med** 1995 Dec 1; 182(6):1625-34

Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. Casiano CA, et al. **J Exp Med** 1996 Aug 1;184(2):765-70

Calreticulin binds hYRNA and the 52-kDa polypeptide component of the Ro/SS-A ribonucleoprotein autoantigen. Cheng ST, et al. **J Immunol** 1996 Jun 1;156(11):4484-91

A Xenopus laevis homologue of the La autoantigen binds the pyrimidine tract of the 5' UTR of ribosomal protein mRNAs in vitro: implication of a protein factor in complex formation. Pellizzoni L, et al. **J Mol Biol** 1996 Jun 28; 259(5):904-15

Mosquito homolog of the La autoantigen binds to Sindbis virus RNA. Pardigon N, et al. **J Virol** 1996 Feb; 70(2):1173-81

Modulation of thermal induction of hsp70 expression by Ku autoantigen or its individual subunits. Yang SH, et al. **Mol Cell Biol** 1996 Jul;16(7):3799-806

Sequence-specific DNA binding by Ku autoantigen and its effects on transcription. Giffin W, et al. **Nature** 1996 Mar 21;380(6571):265-8

Transcription termination factor La is also an initiation factor for RNA polymerase III. Maraia RJ. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3383-7

A misfolded form of 5S rRNA is complexed with the Ro and La autoantigens. Shi H, et al. **RNA** 1996 Aug; 2(8):769-84

The Sm binding site targets U7 snRNA to coiled bodies (spheres) of amphibian oocytes. Wu CH, et al. **RNA** 1996 Aug;2(8):811-23

Phosphorylation profiles of 60 kD Ro antigen in synchronized HEp-2 cells. López-Luna A, et al. **Scand J Rheumatol** 1995;24(5):293-9

PHARMACOLOGY

Treatment of autoimmune disease by oral tolerance to autoantigens. Whitacre CC, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S31-9 (75 ref.)

Autoantigen-induced deletion of peripheral self-reactive T cells. Miller JF. **Int Rev Immunol** 1995;13(2):107-14 (47 ref.)

Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. Fukaura H, et al. **J Clin Invest** 1996 Jul 1;98(1):70-7

Rapid induction of autoantibodies by endogenous ovarian antigens and activated T cells: implication in autoimmune disease pathogenesis and B cell tolerance. Lou YH, et al. **J Immunol** 1996 May 1;156(9):3535-40

PHYSIOLOGY

An essential cytoskeletal linker protein connecting actin microfilaments to intermediate filaments. Yang Y, et al. **Cell** 1996 Aug 23;86(4):655-65

Ro/SS-A and La/SS-B: autoantigens in Sjögren's syndrome? Smeenk RJ. **Clin Rheumatol** 1995 Jul;14 Suppl 1:11-6 (53 ref.)

The role of the La autoantigen in internal initiation. Belsham GJ, et al. **Curr Top Microbiol Immunol** 1995;203:85-98 (57 ref.)

The interactions with Ro60 and La differentially affect nuclear export of hY1 RNA. Simons FH, et al. **RNA** 1996 Mar;2(3):264-73

RADIATION EFFECTS

Ultraviolet B irradiation and cytomegalovirus infection synergize to induce the cell surface expression of 52-kD/Ro antigen. Zhu J. **Clin Exp Immunol** 1996 Jan; 103(1):47-53

THERAPEUTIC USE

Primate erythrocyte (E) complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulation. Taylor RP, et al. **J Hematother** 1995 Oct;4(5):357-62

AUTOBIOGRAPHIES see **AUTOBIOGRAPHY**

AUTOBIOGRAPHY

Treating alcoholism through a narrative approach. Case study and rationale. Kaminsky D, et al. **Can Fam Physician** 1996 Apr;42:673-6

Autobiographical memory across personalities in dissociative identity disorder: a case report. Bryant RA. **J Abnorm Psychol** 1995 Nov;104(4):625-31

Autobiographical memory functioning in depression and reports of early abuse. Kuyken W, et al. **J Abnorm Psychol** 1995 Nov;104(4):585-91

AUTOCRINE MOTILITY FACTOR

ANALYSIS

Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Watanabe H, et al. **Cancer Res** 1996 Jul 1;56(13):2960-3

ANTAGONISTS & INHIBITORS

IL-10 blocks collagen IV invasion by "invasion stimulating factor" activated PC-3 ML cells: upregulation of TIMP-1 expression. Stearns ME, et al. **Oncol Res** 1995;7(3-4):157-63

DRUG EFFECTS

Antiproliferative effect of multiple autocrine loop blockade in human malignant glioma cell lines. Kurimoto M, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):723-7

GENETICS

Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Lee HY, et al. **Biochem Biophys Res Commun** 1996 Jan 26;218(3):714-9

METABOLISM

Autotaxin is an N-linked glycoprotein but the sugar moieties are not needed for its stimulation of cellular motility. Stracke ML, et al. **Melanoma Res** 1995 Aug;5(4):203-9

PHARMACOLOGY

Autocrine motility factor signals integrin-mediated metastatic melanoma cell adhesion and invasion. Timar J, et al. **Cancer Res** 1996 Apr 15;56(8):1902-8

Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. Silletti S, et al. **Int J Cancer** 1995 Sep 27;63(1):100-5

Autotaxin is an N-linked glycoprotein but the sugar moieties are not needed for its stimulation of cellular motility. Stracke ML, et al. **Melanoma Res** 1995 Aug;5(4):203-9

PHYSIOLOGY

Tumor autocrine motility factor responses are mediated through cell contact and focal adhesion rearrangement in the absence of new tyrosine phosphorylation in metastatic cells. Silletti S, et al. **Am J Pathol** 1996 May;148(5):1649-60

Stimulation and regulation of tumor cell motility in invasion and metastasis. Levine MD, et al. **EXS** 1995;74:157-79 (135 ref.)

AUTOGENIC TRAINING

The treatment of persistent night terrors with autogenic training: a case study. Sadigh MR, et al. **Biofeedback Self Regul** 1995 Sep;20(3):205-9

A clinical study of autogenic training-based behavioral treatment for panic disorder. Sakai M. **Fukuoka Igaku Zasshi** 1996 Mar;87(3):77-84

Responders and nonresponders to autogenic training and cognitive self-hypnosis: prediction of short- and long-term success in tension-type headache patients. ter Kuile MM, et al. **Headache** 1995 Nov-Dec;35(10):630-6

[Effects of relaxation therapy as group and individual treatment of chronic tinnitus] Winter B, et al. **Psychother Psychosom Med Psychol** 1996 Mar-Apr; 46(3-4):147-52 (Eng. Abstr.) **(Ger)**

[Autogenic training versus Erickson's analogical technique in treatment of fibromyalgia syndrome] Rucco V, et al. **Riv Eur Sci Med Farmacol** 1995 Jan-Feb;17(1):41-50 (Eng. Abstr.) **(Ita)**

METHODS

[Adaptive biocontrol in the system of treating epilepsy patients] Akimenko MA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):45-8 (Eng. Abstr.) **(Rus)**

AUTOGRAFT see **TRANSPLANTATION, AUTOLOGOUS**

AUTOIMMUNE DISEASES

Autoimmune-associated hemophagocytosis [letter] Kumakura S, et al. **Am J Hematol** 1995 Oct;50(2):148-9

Further insights into autoimmune thrombocytopenia in pregnancy [letter; comment] Skupski DW, et al. **Am J Obstet Gynecol** 1996 Jun;174(6):1944-6. Comment on: Am J Obstet Gynecol 1995 Aug;173(2):479-82.

Transforming growth factor-beta 1 in experimental autoimmune neuritis. Cellular localization and time course. Kiefer R, et al. **Am J Pathol** 1996 Jan;148(1):211-23

The variant forms of autoimmune hepatitis. Czaja AJ. **Ann Intern Med** 1996 Oct 1;125(7):588-98 (85 ref.)

Viral myocarditis: are we dealing with an autoimmune phenomenon? Finkelstein Y, et al. **Ann Med Interne (Paris)** 1995;146(5):322-4 (28 ref.)

Neuromyotonia: a new autoimmune disease [editorial; comment] Layzer RB. **Ann Neurol** 1995 Nov;38(5):701-2 . Comment on: Ann Neurol 1995 Nov;38(5):714-22.

The paradoxical association between immunodeficiency and autoimmunity: comment on the article by Atkinson [letter; comment] Petrovsky N. **Arthritis Rheum** 1996 Jan; 39(1):179-80. Comment on: Arthritis Rheum 1995 Mar;38(3):301-5.

A novel concept of type VII hypersensitivity introduced by insulin autoimmune syndrome (Hirata's disease) [letter] Uchigata Y, et al. **Autoimmunity** 1995;20(3):207-8

Progression of disease in ocular cicatricial pemphigoid. Elder MJ, et al. **Br J Ophthalmol** 1996 Apr;80(4):292-6

The effects of pregnancy on autoimmune diseases. Buyon JP, et al. **Clin Immunol Immunopathol** 1996 Feb; 78(2):99-104 (57 ref.)

Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105-14 (65 ref.)

Impact of international autoimmune hepatitis group scoring system in definition of autoimmune hepatitis. An Italian experience. Bianchi FB, et al. **Dig Dis Sci** 1996 Jan; 41(1):166-71

Autoimmune disorders and reproductive failure [letter] Royburt M, et al. **Hum Reprod** 1996 May;11(5):1138-9

Cicatricial pemphigoid: diagnosis and treatment. Nguyen QD, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):41-60 (52 ref.)

Celiac disease and autoimmunity. Lerner A, et al. **Isr J Med Sci** 1996 Jan;32(1):33-6

Increased risk of autoimmune hypothyroidism in patients affected by retinitis pigmentosa. Scanelli G, et al. **J Endocrinol Invest** 1996 Mar;19(3):170-4

Inclusion body myositis [editorial] Garlepp MJ, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):251-5 (73 ref.)

Hypercalcaemia with lymphoedema. Katchan B, et al. **Lancet** 1996 Jan 20;347(8995):161

Autoimmune hepatitis. Krawitt EL. **N Engl J Med** 1996 Apr 4;334(14):897-903 (79 ref.)

Histiocytic necrotizing lymphadenitis with autoimmune phenomena and meningitis in a 14-year-old girl. Debley JS, et al. **Pediatrics** 1996 Jul;98(1):130-3

Protean clinical presentation of antiphospholipid-protein antibodies (APA). Triplett DA. **Thromb Haemost** 1995 Jul; 74(1):329-37 (138 ref.)

[Autoimmune enteropathy] Lachaux A. **Arch Pediatr** 1996 Mar;3(3):261-6 (32 ref.) (Eng. Abstr.) **(Fre)**

[Autoimmune asthenospermia induced by an epididymal protein, ovine prealbumin (oPES)] Fournier-Delpech S, et al. **Reprod Nutr Dev** 1995;35(4):427-36 (Eng. Abstr.) **(Fre)**

[Acquired hemophilia caused by anti-factor VIII autoantibodies: a model of autoimmunity (editorial)] Cabane J, et al. **Rev Med Interne** 1996;17(2):115-6 **(Fre)**

[Autoimmune hepatitis and hepatitis C] Cacoub P, et al. **Rev Med Interne** 1996;17(2):131-4 (23 ref.) (Eng. Abstr.) **(Fre)**

[Autoimmune neutropenia] Bux J. **Dtsch Med Wochenschr** 1996 Mar 1;121(9):287 **(Ger)**

[Multicentric gastric carcinoid in autoimmune gastritis] Glasbrenner B, et al. **Dtsch Med Wochenschr** 1996 Feb 23; 121(8):231-6 (Eng. Abstr.) **(Ger)**

[Autoimmune hepatitis: pediatric aspects] Balli F, et al. **Pediatr Med Chir** 1996 Mar-Apr;18(2):123-9 (Eng. Abstr.) **(Ita)**

[Human leukocyte antigen (HLA) and the related diseases] Mizuki N, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2091-103 (12 ref.) **(Jpn)**

[Autoimmune liver cirrhosis] Yamada G, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):175-80 (13 ref.) **(Jpn)**

[Retrovirus and autoimmune diseases] Shibata M, et al. **Ryumachi** 1995 Aug;35(4):705-11 (33 ref.) **(Jpn)**

[Chronic urticaria from the aspect of autoimmune diseases] Jovanović M, et al. **Med Pregl** 1995;48(5-6):183-6 (Eng. Abstr.) **(Scr)**

[Autoimmune diseases of the liver, III. Primary sclerosing cholangitis] Garassini Serra MA, et al. **G E N** 1995

Apr-Jun;49(2):170-8 (59 ref.) (Eng. Abstr.) **(Spa)**
[Liver autoimmune diseases. II. Primary biliary cirrhosis] Garassini Serra MA, et al. **G E N** 1995 Jan-Mar;49(1):82-9 (55 ref.) **(Spa)**
[Chronic hepatitis C virus infection associated with anti-LKM 1] Macenlle R, et al. **Gastroenterol Hepatol** 1996 Apr;19(4):203-5 (Eng. Abstr.) **(Spa)**
[Autoimmune cholangiopathy (editorial)] Solís Herruzo JA. **Gastroenterol Hepatol** 1996 Apr;19(4):213-6 **(Spa)**
[Chronic autoimmune hepatitis following cholestatic hepatitis caused by droxicam] Pérez-Aguilar F, et al. **Med Clin (Barc)** 1996 Mar 30;106(12):460-2 (Eng. Abstr.) **(Spa)**
[Autoimmunity may be initiated by non-genetic risk factors] Dahlquist G. **Lakartidningen** 1996 Jul 24;93(30-31):2673-4 **(Swe)**

BLOOD

Long-term outcome of mothers of children with complete congenital heart block. Press J, et al. **Am J Med** 1996 Mar; 100(3):328-32
Longitudinal changes of serum insulin concentration and insulin antibody features in persistent insulin autoimmune syndrome (Hirata's disease). Eguchi Y, et al. **Autoimmunity** 1994;19(4):279-84
Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Semple JW, et al. **Blood** 1996 May 15;87(10):4245-54
Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Krams SM, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):311-20
Polyethylene glycol precipitates of serum contain a large proportion of uncomplexed immunoglobulins and C3. Crowley-Nowick PA, et al. **Immunol Invest** 1996 Jan-Mar; 25(1-2):91-101
Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein. Satoh M, et al. **J Clin Invest** 1996 Jun 1; 97(11):2619-26
Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Casciola-Rosen L, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1624-9
Antiphospholipid antibodies, haemostatic variables and thrombosis--a survey of 144 patients. Ames PR, et al. **Thromb Haemost** 1995 May;73(5):768-73
High level of plasmatic von Willebrand factor limits the bleeding time in thrombopenic HIV-infected patients [letter] Guérin V, et al. **Thromb Haemost** 1995 Aug; 74(2):803-4
[The characteristics of T-lymphocyte differentiation in type-1 diabetes mellitus] Zhuk EA, et al. **Ter Arkh** 1995; 67(10):12-5 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Silicone gels as adjuvants. Effects on humoral and cell-mediated immune responses. Naim JO, et al. **Adv Exp Med Biol** 1995;383:1-6
Nitric oxide contributes to tissue injury in mercuric chloride-induced autoimmunity. Woolfson RG, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):515-21
Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Amiral J, et al. **Blood** 1996 Jul 15;88(2):410-6
Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome [see comments] Gough A, et al. **BMJ** 1996 Jan 20;312(7024):169-72. Comment in: BMJ 1996 Jan 20;312(7024):138. Comment in: BMJ 1996 Apr 27;312(7038):1101.
Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease [letter] Borg AA. **Br J Rheumatol** 1995 Nov;34(11):1097-8
Mercury: god of Th2 cells? [editorial; comment] Mathieson PW. **Clin Exp Immunol** 1995 Nov;102(2):229-30 (26 ref.) . Comment on: Clin Exp Immunol 1995 Nov;102(2):297-307.
Cutaneous immunopathology of cyclosporin-A-induced autoimmunity in the rat. Damoiseaux JG, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):315-23
Metal ion induced autoimmunity. Griem P, et al. **Curr Opin Immunol** 1995 Dec;7(6):831-8 (57 ref.)
Strong increase in the percentage of the CD8bright+ CD28- T-cells and delayed engraftment associated with cyclosporine-induced autologous GVHD. Garin L, et al. **Eur J Haematol** 1996 Mar;56(3):119-23
Self-reported allergy, infection, and autoimmune diseases among men and women exposed in utero to diethylstilbestrol. Baird DD, et al. **J Clin Epidemiol** 1996 Feb;49(2):263-6
Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. Herold KC, et al. **J Immunol** 1996 May 1;156(9):3521-7
Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment [letter] Piccolo G, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):348
Hydralazine-induced constrictive pericarditis. Franssen CF, et al. **Neth J Med** 1996 May;48(5):193-7 (21 ref.)
Which patients undergoing cardiopulmonary bypass should be assessed for development of heparin-induced thrombocytopenia? [letter] Cummins D, et al. **Thromb Haemost** 1995 May;73(5):890
Cytokine knockout mice: possible application in toxicological research. Ryffel B. **Toxicology** 1995 Dec 20;105(1):69-80 (55 ref.)

COMPLICATIONS

Hepatitis C and inclusion body myositis. Alexander JA, et al. **Am J Gastroenterol** 1996 Sep;91(9):1845-7
Autoimmune hepatitis in a patient with sickle cell disease. el Younis CM, et al. **Am J Gastroenterol** 1996 May; 91(5):1016-8 (26 ref.)
Cerebral and vein thrombosis, transient protein S deficiency, and anticardiolipin antibodies [letter] Ricchieri GL, et al. **Am J Hematol** 1996 May;52(1):69-70
Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an HIV-positive patient: case report and review of the literature. Yospur LS, et al. **Am J Hematol** 1996 Jan;51(1):73-8 (29 ref.)
Autoimmune thyroid disease in primary Sjögren's syndrome. Pérez B, et al. **Am J Med** 1995 Nov;99(5):480-4
Rheumatological manifestations of haematological diseases. Menon S, et al. **Ann Rheum Dis** 1995 Oct;54(10):787-95 (126 ref.)
Antiphospholipid antibodies and venous thromboembolism. Ginsberg JS, et al. **Blood** 1995 Nov 15;86(10):3685-91
Coexistence of psoriasis and an unusual IgG-mediated subepidermal bullous dermatosis: identification of a novel 200-kDa lower lamina lucida target antigen. Chen KR, et al. **Br J Dermatol** 1996 Feb;134(2):340-6
Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Enright H, et al. **Br J Haematol** 1995 Oct;91(2):403-8
Autoimmune hepatitis in an area endemic for hepatitis B virus infection: a report of three cases. Huo TL, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 May;57(5):360-4
Autoimmune hypothyroidism and hyperthyroidism in patients with Turner's syndrome. Chiovato L, et al. **Eur J Endocrinol** 1996 May;134(5):568-75
Aortic aneurysms in patients with autoimmune disorders treated with corticosteroids. Sato O, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):366-9 (17 ref.)
Insulin autoimmune syndrome as a cause of spontaneous hypoglycemia in alcoholic cirrhosis. Shah P, et al. **Gastroenterology** 1995 Nov;109(5):1673-6
Fever in rheumatic and autoimmune disease. Carsons SE. **Infect Dis Clin North Am** 1996 Mar;10(1):67-84 (49 ref.)
Severe hypotension and coma secondary to unrecognized chronic anterior hypophysitis. Kaufmann P, et al. **Intensive Care Med** 1995 Oct;21(10):847-9
Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. Ben Ari Z, et al. **J Hepatol** 1995 Sep;23(3):351-4
Autoimmune premature ovarian failure. Kim JG, et al. **J Obstet Gynaecol** 1995 Feb;21(1):59-66 (53 ref.)
Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: predictive value of anti-Ro(SSA) and anti-La(SSB) antibodies and treatment with indomethacin and hydroxychloroquine. Senécal JL, et al. **J Rheumatol** 1995 May;22(5):868-75
Successful trial of steroids in two haemodialysis patients with inflammatory disease and anaemia unresponsive to recombinant erythropoietin [letter] Tzanakis I, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):400-1
Linear IgA dermatosis: a new cause of fever of unknown origin. Blockmans D, et al. **Neth J Med** 1995 Nov; 47(5):214-8
Recurrent hypoglycaemia caused by the insulin autoimmune syndrome: the first Dutch case [see comments] Schlemper RJ, et al. **Neth J Med** 1996 May;48(5):188-92 (27 ref.). Comment in: Neth J Med 1996 May;48(5):167-8.
Reversible dementia and chorea in a young woman with the lupus anticoagulant. Van Horn G, et al. **Neurology** 1996 Jun;46(6):1599-603
Allergic and immunologic aspects of Meniere's disease. Derebery MJ. **Otolaryngol Head Neck Surg** 1996 Mar; 114(3):360-5
Two cases of multiple autoimmune disorders in patients with selective IgA deficiency [letter] Caramaschi P, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):151-2
Selective IgA deficiency, hypothyroidism and congenital lymphoedema. Jones AL, et al. **Scott Med J** 1996 Feb; 41(1):22-3
Lipoprotein (a) and anticardiolipin antibodies as risk factors for vascular disease in rheumatoid arthritis [letter; comment] Seriolo B, et al. **Thromb Haemost** 1995 Aug; 74(2):799-800. Comment on: Thromb Haemost 1994 Apr;71(4):424-7. Comment on: Thromb Haemost 1994 Oct;72(4):563-6.
[Inclusion body myositis] Serratrice G. **Presse Med** 1996 Jun 15;25(21):985-8 (23 ref.) (Eng. Abstr.) **(Fre)**
[Undifferentiated connective tissue syndromes (UCTS) accompanied by laryngeal involvement and autoimmune hepatitis] Nishinarita M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Oct;18(5):559-65 (Eng. Abstr.) **(Jpn)**
[Malignancy in autoimmune diseases] Sugai S. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):1-14 (38 ref.) (Eng. Abstr.) **(Jpn)**
[HCV infection in autoimmune hepatitis] Komeda T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:871-6 (23 ref.) **(Jpn)**
[A case report of autoimmune hepatitis with Felty's syndrome] Inaba H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1876-81 **(Jpn)**
[Migraine with pleocytosis: another autoimmune disease?] Pascual J. **Rev Neurol** 1995 Jul-Aug;23(122):792-3 **(Spa)**
[Association of splenic villous-lymphocyte lymphoma and primary biliary cirrhosis (letter)] de Figuereido M, et al. **Sangre (Barc)** 1996 Feb;41(1):71 **(Spa)**

DIAGNOSIS

A quantitative ELISA for measuring red cell-bound immunoglobulins. Hazlehurst DD, et al. **Acta Haematol** 1996;95(2):112-6
Anti-lamin autoantibodies and the clinical utility of autoimmune serology [editorial; comment] Sturgess AD. **Aust N Z J Med** 1996 Apr;26(2):145-6. Comment on: Aust N Z J Med 1996 Apr;26(2):162-6.
Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Brighton TA, et al. **Blood** 1996 Jul 1; 88(1):194-201
Addison's disease. Brosnan CM, et al. **BMJ** 1996 Apr 27; 312(7038):1085-7
Primary sclerosing cholangitis and multiple autoimmune disorders in a patient with Down syndrome. Mehta DI, et al. **Clin Pediatr (Phila)** 1995 Sep;34(9):502-5
CD4 Lymphocyte enumeration: comparison between flow cytometry and enzyme immunoassay. Cordiali Fei P, et al. **Cytometry** 1995 Mar 15;22(1):70-4
Recurrent perimyocarditis following a non penetrating chest trauma. A case report. De Santis A, et al. **G Ital Cardiol** 1996 Jan;26(1):57-60
Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Boberg KM, et al. **Hepatology** 1996 Jun;23(6):1369-76
How to diagnose autoimmune hepatitis in systemic lupus erythematosus? [letter] Kooy A, et al. **Hepatology** 1996 Apr;23(4):936-8
Autoimmune hepatitis and/or hepatitis C: how to decide. Schapiro GD, et al. **Hepatology** 1996 Mar;23(3):647-9
Anti-neutrophil cytoplasmic antibodies in generalized autoimmune diseases. Schnabel A, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):201-6 (32 ref.)
Case study: acute basal ganglia enlargement and obsessive-compulsive symptoms in an adolescent boy. Giedd JN, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):913-5
Antigen association of total HEp-2 cell extract in the screening of autoimmune diseases by western blot. Capin N, et al. **J Clin Lab Anal** 1996;10(3):140-3
A young woman with hepatitis after a sore throat. Aceti A, et al. **Lancet** 1995 Dec 16;346(8990):1603
Clinical, immunological, and pathological consequences of Fas-deficient conditions. Le Deist F, et al. **Lancet** 1996 Sep 14;348(9029):719-23
Diagnosis and therapy of autoimmune liver disease. Czaja AJ. **Med Clin North Am** 1996 Sep;80(5):973-94 (100 ref.)
Autoimmune hepatitis [letter] Rich JD. **N Engl J Med** 1996 Sep 5;335(10):753
Auto-antibodies in the hospitalised Oriental elderly. Teo SK, et al. **Singapore Med J** 1995 Dec;36(6):609-11
Human adjuvant disease: presentation as a multiple sclerosis-like syndrome [see comments] Shoaib BO, et al. **South Med J** 1996 Feb;89(2):179-88. Comment in: South Med J 1996 Feb;89(2):251-2.
[Diagnostic and pathogenic significance of antineutrophil cytoplasmic antibodies in vasculitides] Bartuňková J, et al. **Bratisl Lek Listy** 1995 Oct;96(10):528-33 (Eng. Abstr.) **(Cze)**
[An alternative to immunofluorescence on frozen tissue for the diagnosis of sub-epidermal auto-immune bullous dermatosis] Heller M, et al. **Bull Assoc Anat (Nancy)** 1995 Jun;79(245):21-7 (Eng. Abstr.) **(Fre)**
[The diagnosis and therapy of acquired factor-VIII inhibitors in combination with lupus anticoagulants] Grossmann R, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28-29):906-10 (14 ref.) (Eng. Abstr.) **(Ger)**
[The desire for children in Werlhof's disease] Kiefel V. **Dtsch Med Wochenschr** 1996 Aug 2;121(31-32):999 **(Ger)**
[Paraneoplastic cerebellar degeneration: case report of a patient with breast carcinoma] Huober J, et al. **Geburtshilfe Frauenheilkd** 1996 Apr;56(4):214-6 (Eng. Abstr.) **(Ger)**
[Flow cytometry detection of erythrocyte antigens and antibodies. Technical aspects and new clinical applications] Fischer K, et al. **Infusionsther Transfusionsmed** 1995 Dec; 22(6):344-9 (Eng. Abstr.) **(Ger)**
[Cogan I syndrome: too often detected too late? A contribution to early diagnosis of Cogan I syndrome] Pleyer U, et al. **Klin Monatsbl Augenheilkd** 1995 Jul; 207(1):3-10 (Eng. Abstr.) **(Ger)**
[Methodical evaluation of immunoluminometric determination of thyroid peroxidase in serum] Herbig J,

et al. **Nuklearmedizin** 1996 Jun;35(3):94–8 (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of autoimmune hepatitis] Heintges T, et al. **Z Gastroenterol** 1995 Aug;33(8):462–7 (52 ref.) (Eng. Abstr.) **(Ger)**

[Postgravid health care and laboratory tests] Hidaka Y, et al. **Rinsho Byori** 1995 Nov;43(11):1101–7 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Autoimmune hepatitis] Zeniya M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):526–33 (25 ref.) **(Jpn)**

[Endocrine exophthalmos] Apostol S, et al. **Oftalmologia** 1996 Jan–Mar;40(1):4–10 (5 ref.) (Eng. Abstr.) **(Rum)**

[Clinical significance of antibodies to vascular endothelium (editorial)] Youinou P, et al. **Klin Med (Mosk)** 1995; 73(5):5–7 **(Rus)**

DRUG THERAPY

Influence of androgen therapy on lacrimal autoimmune disease in a mouse model of Sjögren's syndrome. Sullivan DA, et al. **Adv Exp Med Biol** 1995;371B:1199–202

Steroid therapy of chronic hepatitis: characteristics associated with response in anti-hepatitis C virus-positive and -negative patients. Thiele DL, et al. **Am J Gastroenterol** 1996 Feb;91(2):300–8

High-dose dexamethasone therapy for resistant autoimmune thrombocytopenic purpura [letter] Godeau B, et al. **Am J Hematol** 1996 Apr;51(4):334

The Myocarditis Treatment Trial: design, methods and patients enrollment. Hahn EA, et al. **Eur Heart J** 1995 Dec;16 Suppl O:162–7

Treatment of chronic myocarditis with corticosteroids. Kühl U, et al. **Eur Heart J** 1995 Dec;16 Suppl O:168–72

Immunosuppressive treatment for myocarditis and dilated cardiomyopathy. Maisch B, et al. **Eur Heart J** 1995 Dec; 16 Suppl O:153–61 (81 ref.)

Corticosteroid treatment does not improve the results of intrauterine insemination in male subfertility caused by antisperm antibodies. Grigoriou O, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65(2):227–30

Uniocular fields of fixation in thyroid eye disease. Steel DH, et al. **Eye** 1995;9 (Pt 3):348–51

Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Bousvaros A, et al. **Gastroenterology** 1996 Jul;111(1):237–43

The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Pratt DS, et al. **Gastroenterology** 1996 Jan;110(1):271–4

Influence of treatment on the clinical course of pemphigus vulgaris. Carson PJ, et al. **J Am Acad Dermatol** 1996 Apr; 34(4):645–52

Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy. Conti A, et al. **J Endocrinol Invest** 1996 Feb;19(2):127–30

Isradipine, a calcium-channel antagonist, has immunosuppressor activity on T lymphocytes from peripheral blood and synovial fluid from patients with autoimmune arthritis. Guillen C, et al. **J Immunother Emphasis Tumor Immunol** 1995 Jul; 18(1):66–74

Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. Rieckmann P, et al. **J Neuroimmunol** 1996 Feb;64(2):193–200

ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Ruiz-Ortega M, et al. **Kidney Int** 1995 Dec;48(6):1778–91

Pharmacological intervention in antibody mediated disease. Coutts SM, et al. **Lupus** 1996 Apr;5(2):158–9 (13 ref.)

Diagnosis and therapy of autoimmune liver disease. Czaja AJ. **Med Clin North Am** 1996 Sep;80(5):973–94 (100 ref.)

Management of acquired bullous skin diseases [see comments] Fine JD. **N Engl J Med** 1995 Nov 30;333(22):1475–84 (112 ref.). Comment in: N Engl J Med 1996 Mar 28;334(13):864–5. Comment in: N Engl J Med 1996 Mar 28;334(13):865.

Autoimmune hepatitis [letter; comment] Yarze JC. **N Engl J Med** 1996 Apr 4;334(14):923–4. Comment on: N Engl J Med 1995 Oct 12;333(15):1004–5.

Effects of vitamin D3 and cyclosporin A on HgCl2-induced autoimmunity in brown Norway rats. Vendeville B, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2020–6

Deoxyspergualin: a new immunosuppressive drug for the treatment of auto-immune disease [editorial] Nikolic-Paterson DJ, et al. **Nephron** 1995;70(4):391–6 (63 ref.)

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Confavreux C, et al. **Neurology** 1996 Jun;46(6):1607–12

Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Tamesis RR, et al. **Ophthalmology** 1996 May;103(5):768–75

[Systemic enzyme therapy in diseases of the vascular system] Nouza K. **Bratisl Lek Listy** 1995 Oct;96(10):566–9 (Eng. Abstr.) **(Cze)**

[Treatment of inflammation with anti-inflammatory cytokines: example in models of auto-immune diseases] Bessis N, et al. **C R Seances Soc Biol Fil** 1995;189(4):579–90 (33 ref.) (Eng. Abstr.) **(Fre)**

[Azathioprine maintains remission in autoimmune hepatitis (letter)] Pariente E-A. **Gastroenterol Clin Biol** 1996; 20(3):328–30 **(Fre)**

[Pemphigus vulgaris. Clinical aspects, pathophysiology and therapy of a bullous autoimmune dermatosis] Sunderkötter CH, et al. **Med Monatsschr Pharm** 1995 Sep;18(9):255–63 (39 ref.) **(Ger)**

[Anti-Jo-1-positive polymyositis with interstitial alveolitis and pericardial effusion. Overview of 3 years treatment] Krajnc I. **Wien Klin Wochenschr** 1995;107(19):590–2 (Eng. Abstr.) **(Ger)**

[Pulse-dose cyclophosphamide therapy for steroid-refractory autoimmune neurological diseases] Watanabe T, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):611–6 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Current approaches to the treatment of diffuse toxic goiter] Balabolkin MI. **Ter Arkh** 1995;67(10):15–8 **(Rus)**

ENZYMOLOGY

Regulation of ornithine decarboxylase in the kidney of autoimmune mice with the lpr gene. Hsu HC, et al. **Autoimmunity** 1994;19(4):253–64

Modulation of antioxidant enzymes and programmed cell death by n-3 fatty acids. Fernandes G, et al. **Lipids** 1996 Mar;31 Suppl:S91–6

Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Rosenberg GA, et al. **Neurology** 1996 Jun;46(6):1626–32

EPIDEMIOLOGY

Pemphigus in Mali: a study of 30 cases. Mahé A, et al. **Br J Dermatol** 1996 Jan;134(1):114–9

Combined autoimmune cytopenias. Martino R, et al. **Haematologica** 1995 Jul–Aug;80(4):305–10 (25 ref.)

Exposure to superantigens as an immunogenetic explanation of type I diabetes mini-epidemics. Trucco M, et al. **J Pediatr Endocrinol Metab** 1995 Jan–Mar;8(1):3–10 (41 ref.)

Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Weinshenker BG, et al. **Neurology** 1996 Jun;46(6):1613–9

ETHNOLOGY

HLA-DQ3 is associated with Graves' disease in African-Americans. Ofosu MH, et al. **Immunol Invest** 1996 Jan–Mar;25(1–2):103–10

ETIOLOGY

Autoimmune reactions induced by gliadin. Tlaskalová-Hogenová H, et al. **Adv Exp Med Biol** 1995; 371B:1191–8

Ovarian dermoid cyst-associated autoimmune hemolytic anemia: a case report with emphasis on pathogenic mechanisms. Cobo F, et al. **Am J Clin Pathol** 1996 May; 105(5):567–71

Acquired free protein S deficiency associated with multiple myeloma: a case report. Deitcher SR, et al. **Am J Hematol** 1996 Apr;51(4):319–23

Silica exposure and autoimmune diseases. Steenland K, et al. **Am J Ind Med** 1995 Nov;28(5):603–8 (24 ref.)

Type II collagen-induced autoimmune ear disease in mice: a preliminary report on an epitope of the type II collagen molecule that induced inner ear lesions. Takeda T, et al. **Am J Otol** 1996 Jan;17(1):69–75

Murine experimental autoimmune oophoritis develops independently of gonadotropin stimulation and is primarily localized in the stroma and theca. Nair S, et al. **Am J Reprod Immunol** 1995 Aug;34(2):132–9

The postmyocardial infarction syndrome--vanished or vanquished? A twenty-five-year follow-up. A case report. Kossowsky WA, et al. **Angiology** 1996 Jan;47(1):83–5

Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Siciliano R, et al. **Ann Ital Med Int** 1995 Jul–Sep; 10(3):193–4 (10 ref.)

Arthritis in mice induced by a single immunisation with collagen. Kato F, et al. **Ann Rheum Dis** 1996 Aug; 55(8):535–9

Autoimmune hepatitis. Mieli-Vergani G, et al. **Arch Dis Child** 1996 Jan;74(1):2–5 (35 ref.)

Recipient-derived T cells participate in autoimmune-like hepatic lesions induced by graft-versus-host reaction. Ikarashi Y, et al. **Autoimmunity** 1995;20(2):121–7

Mechanism of the development of autoimmune dacryoadenitis in the mouse model for primary Sjögren's syndrome. Takahashi M, et al. **Cell Immunol** 1996 May 25;170(1):54–62

TSH receptor and disease. Tonacchera M, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):621–33 (106 ref.)

The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Mountz JD, et al. **Clin Immunol Immunopathol** 1996 Sep; 80(3 Pt 2):S2–14 (103 ref.)

The pathogenesis of postinfectious myocarditis. Rose NR, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S92–9 (51 ref.)

Epidemiology of autoimmune and immunological diseases in association with silicone implants: is there an excess of clinical disease or antibody response in population-based or other "controlled" studies? Kurland LT, et al. **Curr Top Microbiol Immunol** 1996;210:427–30

Re-evaluation of autoantibodies and clinical overview of silicone-related disorders. Tan EM, et al. **Curr Top Microbiol Immunol** 1996;210:291–8

Transmission of thyrotoxicosis of autoimmune type by sibling allogeneic bone marrow transplant. Thomson JA, et al. **Eur J Endocrinol** 1995 Nov;133(5):564–6

Interferon-gamma is required during the initiation of an organ-specific autoimmune disease. Barrett SP, et al. **Eur J Immunol** 1996 Jul;26(7):1652–5

Non-tolerant B cells cause autoimmunity in anti-CD8 IgG2a-transgenic mice. Battegay M, et al. **Eur J Immunol** 1996 Jan;26(1):250–8

Induction of diabetes in standard mice by immunization with the p277 peptide of a 60-kDa heat shock protein. Elias D, et al. **Eur J Immunol** 1995 Oct;25(10):2851–7

Administration of anti-interleukin-2 receptor alpha antibody in vivo induces localized autoimmune disease. Taguchi O, et al. **Eur J Immunol** 1996 Jul;26(7):1608–12

A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Taylor GA, et al. **Immunity** 1996 May;4(5):445–54

T cell receptor usage in autoimmune disease. Olive C. **Immunol Cell Biol** 1995 Aug;73(4):297–307 (174 ref.)

Heterogeneity of organ-specific autoimmune diseases [letter; comment] McLachlan SM, et al. **Immunol Today** 1995 Sep; 16(9):457–8. Comment on: Immunol Today 1995 Jan;16(1):34–8.

Guillain-Barré as an autoimmune disease. Shoenfeld Y, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):318–26

Cryoglobulinemia: recent findings in cutaneous and extracutaneous manifestations. Davis MD, et al. **Int J Dermatol** 1996 Apr;35(4):240–8 (50 ref.)

Experimental autoimmune dacryoadenitis. II. Harderian gland disease in the rat. Liu SH, et al. **Invest Ophthalmol Vis Sci** 1987 Feb;28(2):276–80

Experimental autoimmune dacryoadenitis. I. Lacrimal gland disease in the rat. Liu SH, et al. **Invest Ophthalmol Vis Sci** 1987 Feb;28(2):270–5

Antigen presentation in the pathogenesis of autoimmune endocrine disease. Weetman AP. **J Autoimmun** 1995 Jun; 8(3):305–12 (38 ref.)

Dual T cell receptor alpha chain T cells in autoimmunity. Elliott JI, et al. **J Exp Med** 1995 Oct 1;182(4):953–9

Autoimmune hepatitis following hepatitis A virus infection. Huppertz HI, et al. **J Hepatol** 1995 Aug;23(2):204–8

Induction of autoimmunity in the absence of CD28 costimulation. Bachmaier K, et al. **J Immunol** 1996 Aug 15;157(4):1752–7

Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. Mieza MA, et al. **J Immunol** 1996 May 15;156(10):4035–40

Prevention of lpr-graft-versus-host disease and transfer of autoimmune diseases in normal C57BL/6 mice by transplantation of bone marrow cells plus bones (stromal cells) from MRL/lpr mice. Miyashima S, et al. **J Immunol** 1996 Jan 1;156(1):79–84

Immunization with short peptides from the sequence of the systemic lupus erythematosus-associated 60-kDa Ro autoantigen results in anti-Ro ribonucleoprotein autoimmunity. Scofield RH, et al. **J Immunol** 1996 May 15;156(10):4059–66

Pathogenesis of post-thymectomy autoimmune gastritis. Identification of anti-H/K adenosine triphosphatase-reactive T cells. Suri-Payer E, et al. **J Immunol** 1996 Aug 15;157(4):1799–805

Collagen-induced arthritis in CD4- or CD8-deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis. Tada Y, et al. **J Immunol** 1996 Jun 1;156(11):4520–6

Autoimmune arthritis caused by Candida septic arthritis. Rovinsky D, et al. **J Shoulder Elbow Surg** 1995 Nov-Dec; 4(6):472–6

Analysis of immunological alterations associated with testicular prostheses. Henderson J, et al. **J Urol** 1995 Nov; 154(5):1748–51

Autoimmune phenomena in non-Hodgkin's lymphoma. Grønbaek K, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):311–6

Multiple autoimmune manifestations in monoclonal gammopathy of undetermined significance and chronic lymphocytic leukemia. Jønsson V, et al. **Leukemia** 1996 Feb;10(2):327–32

Aetiopathogenesis of Takayasu's arteritis and BCG vaccination: the missing link? Kothari SS. **Med Hypotheses** 1995 Sep;45(3):227–30

Evaluating the health risks of breast implants [letter] Goldberg EP. **N Engl J Med** 1996 Oct 10;335(15):1154; discussion 1156

A picornaviral protein synthesized out of frame with the polyprotein plays a key role in a virus-induced immune-mediated demyelinating disease. Chen HH, et al. **Nat Med** 1995 Sep;1(9):927–31

Autoimmune inner ear disease [letter] Luetje CM. **Otolaryngol Head Neck Surg** 1996 Mar;114(3):507–8

The real cause of silicone autoimmune disease [letter] Roven AN. **Plast Reconstr Surg** 1996 May;97(6):1307

Autoimmune disease of the kidney: an update. Biancone L, et al. **Proc Soc Exp Biol Med** 1996 Jul;212(3):225–38 (175 ref.)

Is silicone safe? Let science decide [editorial; comment] Shack RB. **South Med J** 1996 Feb;89(2):251–2. Comment on: South Med J 1996 Feb;89(2):179–88.

Interferon alfa and autoimmunity [letter; comment] Stricker RB. **South Med J** 1996 Jun;89(6):645. Comment on: South Med J 1996 Jan;89(1):81–3.

Immune-mediated side-effects of cytokines in humans. Vial T, et al. **Toxicology** 1995 Dec 20;105(1):31-57 (239 ref.)
[Murine "sympathetic orchitis" induced by unilateral testicular injury and autoimmune response] Sakamoto Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec; 86(12):1751-6 (Eng. Abstr.) **(Jpn)**
[Autoimmune liver disease complicating Sjögren's syndrome] Masaki N, et al. **Nippon Rinsho** 1995 Oct;53(10):2530-5 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Campylobacter jejuni and autoimmune-mediated neurologic diseases: pathogenesis of Guillain-Barré syndrome and Fisher's syndrome] Yuki N. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):991-1003 (41 ref.) **(Jpn)**
[A case of autoimmune cholangiopathy which developed 11 years after occurrence of SLE] Hoshino T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):212-5 **(Jpn)**
[A case of primary biliary cirrhosis complicated with autoimmune hepatitis] Nakao M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):49-53 (23 ref.) **(Jpn)**
[Autoimmune hypoglycemia] Wiszniewski P, et al. **Pol Arch Med Wewn** 1995 Mar;93(3):250-2 (18 ref.) **(Pol)**
[The current concepts of the etiology and pathogenesis of autoimmune endocrinopathies (editorial)] Luk'ianchikov VS, et al. **Ter Arkh** 1995;67(10):3-6 (22 ref.) **(Rus)**

GENETICS

Gene hypothesis of autoimmunity, and autoimmune disease. Storch WB. **Adv Exp Med Biol** 1995;371B:1213-5 (22 ref.)
A family study of anticardiolipin antibodies and associated clinical conditions. Goldberg SN, et al. **Am J Med** 1995 Nov;99(5):473-9
Genetic and functional characterization of human autoantibodies using combinatorial phage display libraries. Zeidel M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:559-64
Interactions of B6 wild and B6 gld cells engrafted within athymic nude beige recipients. Rosenblatt N, et al. **Autoimmunity** 1995;20(1):9-18
Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Yaswen L, et al. **Blood** 1996 Feb 15;87(4):1439-45
Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Hibbs ML, et al. **Cell** 1995 Oct 20;83(2):301-11
Genetic analysis of autoimmune disease. Vyse TJ, et al. **Cell** 1996 May 3;85(3):311-8 (73 ref.)
Genetics of autoimmune disease. Merriman TR, et al. **Curr Opin Immunol** 1995 Dec;7(6):786-92 (69 ref.)
Transgenic/knockout mice--tools to study autoimmunity. Mueller R, et al. **Curr Opin Immunol** 1995 Dec;7(6):799-803 (53 ref.)
Differential immunogenetic determinants of polyclonal insulin autoimmune syndrome (Hirata's disease) and monoclonal insulin autoimmune syndrome. Uchigata Y, et al. **Diabetes** 1995 Oct;44(10):1227-32
Twin studies in insulin dependent diabetes and other autoimmune diseases. Rowe RE, et al. **Diabetes Metab Rev** 1995 Jul;11(2):121-35 (85 ref.)
Immunoprinting reveals different genetic bases for (auto)immuno diseases. Epplen C, et al. **Electrophoresis** 1995 Sep;16(9):1693-7 (32 ref.)
Transmission of thyrotoxicosis of autoimmune type by sibling allogeneic bone marrow transplant. Thomson JA, et al. **Eur J Endocrinol** 1995 Nov;133(5):564-6
Immunoprinting excludes many potential susceptibility genes as predisposing to early onset pauciarticular juvenile chronic arthritis except HLA class II and TNF. Epplen C, et al. **Eur J Immunogenet** 1995 Aug;22(4):311-22
TCR gene polymorphisms and autoimmune disease. Kay RA. **Eur J Immunogenet** 1996 Apr;23(2):161-77 (129 ref.)
PVU II polymorphism of LST-1 (leucocyte specific transcript-1) in type I diabetes mellitus, Graves' disease and healthy controls. Rau H, et al. **Eur J Immunogenet** 1995 Jun;22(3):277-82
HLA-DRB1*0401 is associated with susceptibility to insulin-dependent diabetes mellitus independently of the DQB1 locus. Tait BD, et al. **Eur J Immunogenet** 1995 Aug; 22(4):289-97
Non-tolerant B cells cause autoimmunity in anti-CD8 IgG2a-transgenic mice. Battegay M, et al. **Eur J Immunol** 1996 Jan;26(1):250-8
Non-obese diabetic mice hemizygous at the T cell receptor alpha locus are susceptible to diabetes and sialitis. Elliott JI, et al. **Eur J Immunol** 1996 Apr;26(4):953-6
Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy [letter; comment] Kobayashi I, et al. **Eur J Pediatr** 1995 Jul; 154(7):594-5. Comment on: Eur J Pediatr 1993 Apr;152(4):313-5.
Genetics of autoimmune diseases. Miller FW. **Exp Clin Immunogenet** 1995;12(3):182-90 (52 ref.)
Autoimmune diabetes-prone NOD mice express the Lyt2 alpha (Lyt2.1) and Lyt3 alpha (Lyt3.1) alleles of CD8. Johnson-Tardieu JM, et al. **Immunogenetics** 1996; 43(1-2):6-12
MHC class I polymorphism in lupus-prone MRL/Mp mice. Peng SL, et al. **Immunogenetics** 1996;44(5):407-8
Induction and natural occurrence of serum nucleosomal DNA in autoimmune MRL/lpr/lpr mice: its relation to apoptosis in the thymus. Kanai Y, et al. **Immunol Lett** 1995 May;46(1-2):207-14
Characterization of the non-functional Fas ligand of gld mice. Hahne M, et al. **Int Immunol** 1995 Sep;7(9):1381-6
Identification of an Mhc-DPB1 allele involved in susceptibility to experimental autoimmune encephalomyelitis in rhesus macaques. Slierendregt BL, et al. **Int Immunol** 1995 Oct;7(10):1671-9
HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. Ito K, et al. **J Exp Med** 1996 Jun 1; 183(6):2635-44
Aod2, the locus controlling development of atrophy in neonatal thymectomy-induced autoimmune ovarian dysgenesis, co-localizes with Il2, Fgfb, and Idd3. Teuscher C, et al. **J Exp Med** 1996 Feb 1;183(2):631-7
B and T cells are not required for the viable motheaten phenotype. Yu CC, et al. **J Exp Med** 1996 Feb 1; 183(2):371-80
Analysis of central B cell tolerance in autoimmune-prone MRL/lpr mice bearing autoantibody transgenes. Rubio CF, et al. **J Immunol** 1996 Jul 1;157(1):65-71
Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. Zhou T, et al. **J Immunol** 1996 Apr 15;156(8):2661-5
Comparative expression of TNF-alpha alleles from normal and autoimmune-prone MHC haplotypes. Bazzoni F, et al. **J Inflamm** 1995;45(2):106-14
Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. Wilson AG, et al. **J Inflamm** 1995;45(1):1-12 (114 ref.)
Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. Nielsen EW, et al. **J Intern Med** 1996 Feb; 239(2):119-30
A thyroid hormone receptor beta gene polymorphism associated with Graves' disease. Tassi V, et al. **J Mol Endocrinol** 1995 Dec;15(3):267-72
Genetic background and environment contribute synergistically to the onset of autoimmune diseases. Luppi P, et al. **J Mol Med** 1995 Aug;73(8):381-93 (190 ref.)
Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Morel L, et al. **Mamm Genome** 1996 May;7(5):335-9

IMMUNOLOGY

Autoantibodies against constituents of nuclear pore complexes in patients with primary biliary cirrhosis and autoimmune hepatitis. Wesierska-Gądek J, et al. **Acta Biochim Pol** 1995;42(2):197-200
The anti-Hu syndrome: a clinical and immunological study of 7 cases. Pieret F, et al. **Acta Neurol Belg** 1996 Jun; 96(2):108-16
Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acarin N, et al. **Acta Neurol Scand** 1996 Feb-Mar; 93(2-3):99-103
Celiac disease and insulin-dependent diabetes mellitus--no proof for a causal association [comment] Dahlqvist G. **Acta Paediatr** 1995 Dec;84(12):1337-8. Comment on: Acta Paediatr 1995 Dec;84(12):1432-3.
Coeliac disease and insulin-dependent diabetes mellitus: a causal association? [see comments] Pocecco M, et al. **Acta Paediatr** 1995 Dec;84(12):1432-3. Comment in: Acta Paediatr 1995 Dec;84(12):1337-8.
Anti-parietal cell antibody in autoimmune liver diseases is associated with gastric mucosal atrophy and intestinal metaplasia. Oya H, et al. **Adv Exp Med Biol** 1995; 371B:1087-9
Immune-mediated cell death in neurodegenerative disease. Appel SH, et al. **Adv Neurol** 1996;69:153-9 (55 ref.)
Acquired factor V inhibitor in a patient with acquired human immunodeficiency syndrome [letter] Brickner LA, et al. **Am J Hematol** 1996 Aug;52(4):332-3
Multimodality therapy of an acquired factor V inhibitor. Fu YX, et al. **Am J Hematol** 1996 Apr;51(4):315-8
Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1 1/2-year-old girl: report of a case and review of the literature. Lee MT, et al. **Am J Hematol** 1996 Apr; 51(4):307-14 (46 ref.)
Antiplatelet antibodies in childhood idiopathic thrombocytopenic purpura [letter] Ozsoylu S. **Am J Hematol** 1996 Apr;51(4):328
Antibodies to neutrophil elastase: a study in patients with vasculitis. Apenberg S, et al. **Am J Kidney Dis** 1996 Aug; 28(2):178-85
A family study of anticardiolipin antibodies and associated clinical conditions. Goldberg SN, et al. **Am J Med** 1995 Nov;99(5):473-9
Pregnancy and warm autoantibodies: a case report. Gerson A, et al. **Am J Perinatol** 1996 Jan;13(1):19-20
Analysis of immunoglobulin gamma heavy chains from rheumatoid arthritis synovium. Evidence of antigen-driven selection. Bridges SL Jr, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:450-2
Cytokine-dependent modulation of oral tolerance in a murine model of autoimmune uveitis. Caspi RR, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:315-24
Effects of cyclosporin A on the induction of oral tolerance. Fukushima A, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:376-8
B-1 cellular origin and VH segment structure of IgG, IgA, and IgM anti-DNA autoantibodies in patients with systemic lupus erythematosus. Kasaian MT, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:410-23 (52 ref.)
Analysis of V kappa I and V lambda II light chain genes in the expressed B-cell repertoire. Manheimer-Lory A, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:301-11
Immunoglobulin gene usage in diabetes-associated human monoclonal antibodies recognizing glutamate decarboxylase. Richter W, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:457-60
In situ hybridization analysis of immunoglobulin VH gene family expression in rheumatoid arthritis. Rundle CH, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:453-6
Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene. A possible link between infection and lupus. Spellerberg M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:427-32
V-gene repertoire and hypermutation of rheumatoid factors produced in rheumatoid synovial inflammation and immunized healthy donors. Thompson KM, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:440-9
Human pathogenic autoantibodies and their escape from deletion. Zouali M. **Ann N Y Acad Sci** 1995 Sep 29; 764:436-9
Autoimmune ataxic neuropathies (sensory ganglionopathies): are glycolipids the responsible autoantigens? [editorial] Dalakas MC, et al. **Ann Neurol** 1996 Apr;39(4):419-22
Tumor necrosis factor: immunogenetics and disease [editorial; comment] Hauser SL. **Ann Neurol** 1995 Nov;38(5):702-4. Comment on: Ann Neurol 1995 Nov;38(5):723-30.
Increased serum and synovial fluid antibodies to immunoselected peptides in patients with rheumatoid arthritis. Dybwad A, et al. **Ann Rheum Dis** 1996 Jul; 55(7):437-41
Cellular immunity to cartilage aggrecan core protein in patients with rheumatoid arthritis and non-arthritic controls. Goodstone NJ, et al. **Ann Rheum Dis** 1996 Jan; 55(1):40-6
Human cytokine autoantibodies. Characteristics, test procedures and possible physiological and clinical significance. Hansen MB. **APMIS Suppl** 1996;59:1-33 (258 ref.)
Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Goel N, et al. **Arthritis Rheum** 1995 Dec;38(12):1738-43
Maternal-fetal immunology and autoimmune disease: is some autoimmune disease auto-alloimmune or allo-autoimmune? Nelson JL. **Arthritis Rheum** 1996 Feb;39(2):191-4
Antibody reactivity to the HRES-1 endogenous retroviral element identifies a subset of patients with systemic lupus erythematosus and overlap syndromes. Correlation with antinuclear antibodies and HLA class II alleles. Perl A, et al. **Arthritis Rheum** 1995 Nov;38(11):1660-71
Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. Vázquez-Abad D, et al. **Arthritis Rheum** 1996 Feb;39(2):292-6
Clinical associations of anti-lamin autoantibodies [see comments] Hill C, et al. **Aust N Z J Med** 1996 Apr; 26(2):162-6. Comment in: Aust N Z J Med 1996 Apr;26(2):145-6.
Characterization of a novel human IgG antibody reactive with a Ca(2+)-sensitive cell-cell adhesion epitope of PtK2 epithelial cells. Girard D, et al. **Autoimmunity** 1995; 20(4):237-45
Extracellular epitopes of platelet glycoprotein Ib alpha reactive with serum antibodies from patients with chronic idiopathic thrombocytopenic purpura. He R, et al. **Blood** 1995 Nov 15;86(10):3789-96
Heterogeneity of neutrophil antibodies in patients with primary Sjögren's syndrome. Lamour A, et al. **Blood** 1995 Nov 1;86(9):3553-9
Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Reumaux D, et al. **Blood** 1995 Oct 15;86(8):3189-95
Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Sugi T, et al. **Blood** 1995 Oct 15;86(8):3083-9
A case of linear IgA bullous dermatosis with IgA anti-type VII collagen autoantibodies. Hashimoto T, et al. **Br J Dermatol** 1996 Feb;134(2):336-9
An acquired bullous dermatosis due to an autoimmune reaction against uncein. Horiguchi Y, et al. **Br J Dermatol** 1996 May;134(5):934-8
Dermatological presentation of disease associated with antineutrophil cytoplasmic antibodies: a report of two contrasting cases and a review of the literature. Irvine AD, et al. **Br J Dermatol** 1996 May;134(5):924-8 (30 ref.)
Hypergammaglobulinaemic purpura of Waldenström and Ro/SSA autoantibodies. Miyagawa S, et al. **Br J Dermatol** 1996 May;134(5):919-23
Progesterone-induced urticaria--need it be autoimmune? Wilkinson SM, et al. **Br J Dermatol** 1995 Nov;133(5):792-4
Reactivity of autoantibodies from chronic ITP patients with recombinant glycoprotein IIIa peptides. Bowditch RD, et al. **Br J Haematol** 1995 Sep;91(1):178-84
The contribution of animal models to the understanding of the pathogenesis of type 1 diabetes. Carnaud C. **Braz J Med Biol Res** 1995 Aug;28(8):925-9 (35 ref.)
V beta 8.2 transgene expression interferes with development

of experimental autoimmune thyroiditis in CBA k/q but not k/k mice. Lomo LC, et al. **Cell Immunol** 1996 Mar 15;168(2):297–301

Nitric oxide in infectious and autoimmune diseases. Liew FY. **Ciba Found Symp** 1995;195:234–9; discussion 239–44 (26 ref.)

T cell subsets in infectious and autoimmune diseases. Introduction. Mitchison NA. **Ciba Found Symp** 1995; 195:1–5; discussion 5–6 (9 ref.)

Analysis of heart-infiltrating T-cell clonotypes in experimental autoimmune myocarditis in rats. Hanawa H, et al. **Circ Res** 1996 Jan;78(1):118–25

Anti-human immunodeficiency virus type 1 antibodies of noninfected subjects are not related to autoantibodies occurring in systemic diseases. Kämmerer R, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):458–61

The metabolism of C9 in normal subjects and in patients with autoimmune disease. Greenstein JD, et al. **Clin Exp Immunol** 1996 Apr;104(1):160–6

Significance of extractable nuclear antigens in childhood autoimmune liver disease. Gregorio GV, et al. **Clin Exp Immunol** 1995 Nov;102(2):308–13

Beneficial effect of Salmonella typhimurium infection and of immunoglobulins from S. typhimurium–infected mice on the autoimmune disease of (NZB x NZW) F1 mice. Matsiota-Bernard P, et al. **Clin Exp Immunol** 1996 May; 104(2):228–35

Identification of human IgG autoantibodies specific for IL-10. Menetrier-Caux C, et al. **Clin Exp Immunol** 1996 Apr;104(1):173–9

Anti-endothelial cell antibodies: only for scientists or for clinicians too? Meroni PL, et al. **Clin Exp Immunol** 1996 May;104(2):199–202 (29 ref.)

Anti-collagen antibodies in systemic sclerosis and in primary Raynaud's phenomenon. Riente L, et al. **Clin Exp Immunol** 1995 Nov;102(2):354–9

Autoimmune diseases and monoclonal gammopathies. Youinou P, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S55–8 (27 ref.)

Absence of anti-idiotypic antibodies in IVIG preparations to autoantibodies of rare autoimmune diseases. Krause I, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):229–35

Animal models of human disease. Transgenic and knockout models of autoimmunity: Building a better disease? [see comments] Lo D. **Clin Immunol Immunopathol** 1996 May; 79(2):96–104 (60 ref.). Comment in: Clin Immunol Immunopathol 1996 May;79(2):93–4.

Abnormal complement-mediated immune clearance in MRL-lpr/+ heterozygote mice: dose-dependent effect of the Fas antigen mutation. Meryhew NL, et al. **Clin Immunol Immunopathol** 1996 Mar;78(3):236–44

Treatment of autoimmune disease by oral tolerance to autoantigens. Whitacre CC, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S31–9 (75 ref.)

Bacterial pyrogenic exotoxins as superantigens. Kotb M. **Clin Microbiol Rev** 1995 Jul;8(3):411–26 (292 ref.)

Antibodies to human immunodeficiency virus (HIV–1) in autoimmune diseases: primary Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis and autoimmune thyroid diseases. Coll J, et al. **Clin Rheumatol** 1995 Jul;14(4):451–7

Detection of antibodies to 65 KD heat shock protein and to human superoxide dismutase in autoimmune hepatitis–molecular mimicry between 65 KD heat shock protein and superoxide dismutase. Miyata M, et al. **Clin Rheumatol** 1995 Nov;14(6):673–7

Immune rainbow trout serum has an anti-proliferation effect on isolated mouse T-cells: possible autoimmune downregulatory implications. Freedman SJ. **Comp Biochem Physiol A Physiol** 1996 Feb;113(2):181–4

Immunohistochemical studies on melanin associated antigen (MAA) induced experimental autoimmune anterior uveitis (EAAU). Kim MC, et al. **Curr Eye Res** 1995 Aug; 14(8):703–10

Apoptosis in brain-specific autoimmune disease. Bauer J, et al. **Curr Opin Immunol** 1995 Dec;7(6):839–43 (48 ref.)

Transgenic/knockout mice--tools to study autoimmunity. Mueller R, et al. **Curr Opin Immunol** 1995 Dec;7(6):799–803 (53 ref.)

Emv30null NOD–scid mice. An improved host for adoptive transfer of autoimmune diabetes and growth of human lymphohematopoietic cells. Serreze DV, et al. **Diabetes** 1995 Dec;44(12):1392–8

Differential immunogenetic determinants of polyclonal insulin autoimmune syndrome (Hirata's disease) and monoclonal insulin autoimmune syndrome. Uchigata Y, et al. **Diabetes** 1995 Oct;44(10):1227–32

Validation of scoring system for diagnosis of autoimmune hepatitis. Czaja A, et al. **Dig Dis Sci** 1996 Feb;41(2):305–14

Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Czaja AJ, et al. **Dig Dis Sci** 1996 Sep;41(9):1733–40

Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. Czaja AJ, et al. **Dig Dis Sci** 1995 Oct;40(10):2098–106

Anti 70 kDa heat shock protein antibodies in sera of patients affected by autoimmune and non-autoimmune thyroid diseases. Paggi A, et al. **Endocr Res** 1995 Aug;21(3):555–67

Organ-specific cardiac autoantibodies in dilated cardiomyopathy. Frequency and clinical correlates in Polish patients. Bilińska ZT, et al. **Eur Heart J** 1995 Dec; 16(12):1907–11

Anti-peptide antibodies against an autoimmune epitope on human muscarinic receptor mimic functional autoantibodies against the same epitope in patients with idiopathic dilated cardiomyopathy. Fu ML. **Eur Heart J** 1995 Dec;16 Suppl O:89–91

Coxsackievirus-induced chronic myocarditis in murine models. Gauntt CJ, et al. **Eur Heart J** 1995 Dec;16 Suppl O:56–8

SR-Ca2+ ATPase as an autoimmunogen in experimental myocarditis. Khaw BA, et al. **Eur Heart J** 1995 Dec;16 Suppl O:92–6

Characterization of relevant membrane antigens by two-dimensional immunoblot and n-terminal sequence analysis in patients with myocarditis. Pankuweit S, et al. **Eur Heart J** 1995 Dec;16 Suppl O:81–4

Cellular immune mechanisms in myosin-induced myocarditis. Pummerer C, et al. **Eur Heart J** 1995 Dec;16 Suppl O:71–4

The role of the ADP/ATP carrier in the pathogenesis of viral heart disease. Schulze K, et al. **Eur Heart J** 1995 Dec; 16 Suppl O:64–7

Impairment of left ventricular function in combined immune deficiency mice after transfer of peripheral blood leukocytes from patients with myocarditis. Schwimmbeck PL, et al. **Eur Heart J** 1995 Dec;16 Suppl O:59–63

Leucocyte migration into autoimmune diseased endocrine tissues [comment] Delemarre FG, et al. **Eur J Endocrinol** 1996 Jan;134(1):9–11 (35 ref.). Comment on: Eur J Endocrinol 1996 Jan;134(1):51–60.

Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes. Arfors L, et al. **Eur J Haematol** 1996 Apr;56(4):230–4

Is immune thrombocytopenic purpura (ITP) due to natural antibodies specific to platelets? [letter] Souberbielle BE. **Eur J Haematol** 1996 Mar;56(3):178–80

TCR gene polymorphisms and autoimmune disease. Kay RA. **Eur J Immunogenet** 1996 Apr;23(2):161–77 (129 ref.)

Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Sadlack B, et al. **Eur J Immunol** 1995 Nov;25(11):3053–9

Potential of endogenous peptides to induce immunological reactions as observed in type I diabetes, a study in mice. Petersen KG, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(3):162–7

Antineutrophil cytoplasmic antibodies in autoimmune hepatitis [letter; comment] Bansi DS, et al. **Gastroenterology** 1995 Dec;109(6):2049–50. Comment on: Gastroenterology 1995 Apr;108(4):1159–66.

Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Muratori L, et al. **Gut** 1995 Sep;37(3):406–12

Interferon alpha treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation. Van Thiel DH, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):900–6

Hepatic sinusoidal endothelial cells can store and metabolize serum immunoglobulin. Iwamura S, et al. **Hepatology** 1995 Nov;22(5):1456–61

Elevation of gamma delta T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune liver diseases. Martins EB, et al. **Hepatology** 1996 May;23(5):988–93

Oral tolerance: mobilizing the gut. Weiner HL. **Hosp Pract (Off Ed)** 1995 Sep 15;30(9):53–8 (6 ref.)

Analysis of health insurance cover for reproductive immunology. Engemann KJ, et al. **Hum Reprod** 1996 Jan; 11(1):72–6

Autoimmune disorders: another possible cause for in-vitro fertilization and embryo transfer failure. Geva E, et al. **Hum Reprod** 1995 Oct;10(10):2560–3

Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Nishizumi H, et al. **Immunity** 1995 Nov;3(5):549–60

H2-A polymorphism contributes to H2-Ebeta-mediated protection in collagen-induced arthritis. Gonzalez-Gay MA, et al. **Immunogenetics** 1996;44(5):377–84

IL-3-LA production by mononuclear cells of patients with multiple sclerosis: effect of treatment with intravenous immunoglobulins. Djaldetti R, et al. **Immunol Invest** 1995 Aug;24(5):765–73

Anti-actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA. Leibovitch L, et al. **Immunol Lett** 1995 Dec;48(2):129–32

Primary biliary cirrhosis: the molecule and the mimic. Coppel RL, et al. **Immunol Rev** 1995 Apr;144:17–49 (140 ref.)

Chronicity of tissue-specific experimental autoimmune disease: a role for B cells? Holmdahl R, et al. **Immunol Rev** 1995 Apr;144:109–35 (164 ref.)

Organ-specific autoimmunity. Bach JF. **Immunol Today** 1995 Jul;16(7):353–5 (15 ref.)

Involvement of B-1 cells in mucosal immunity and autoimmunity. Murakami M, et al. **Immunol Today** 1995 Nov;16(11):534–9 (38 ref.)

Sequence similarity between beta-cell autoantigens [letter] Rudy G, et al. **Immunol Today** 1995 Aug;16(8):406–7

The role of IL-12 in the induction of organ-specific autoimmune diseases. Trembleau S, et al. **Immunol Today** 1995 Aug;16(8):383–6 (51 ref.)

A need for standardization of the anti-endothelial-cell antibody test. Youinou P, et al. **Immunol Today** 1995 Aug; 16(8):363–4

A protective role of gamma delta T cells in primary infection with Listeria monocytogenes in autoimmune non-obese diabetic mice. Usami J, et al. **Immunology** 1995 Oct; 86(2):199–205

Leprous neuropathy as an autoimmune phenomenon. Desikan P. **Indian J Lepr** 1996 Jan-Mar;68(1):15–21 (34 ref.)

Effect of cyclophosphamide on lymphokine production in MRL/lpr.Yaa mice. Kamada H, et al. **Inflamm Res** 1995 Nov;44(11):491–8

Murine systemic autoimmune disease induced by mercuric chloride: T helper cells reacting to self proteins. Kubicka-Muranyi M, et al. **Int Arch Allergy Immunol** 1996 Jan;109(1):11–20

Comparison of different methods for the detection of autoantibodies in autoimmune diseases. Grigolo B, et al. **Int J Clin Lab Res** 1995;25(4):205–10

Are autoimmune mechanisms involved in critical illness polyneuropathy? [letter] Terasako K, et al. **Intensive Care Med** 1995 Jan;21(1):96–7

Immune network and autoimmunity. George J, et al. **Intern Med** 1996 Jan;35(1):3–9 (49 ref.)

Prolactin, bromocriptine and autoimmune diseases. Buskila D, et al. **Isr J Med Sci** 1996 Jan;32(1):23–7

Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. Kalluri R, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1178–85 (64 ref.)

Mode of inflammatory cell infiltration in testes of mice injected with syngeneic testicular germ cells without adjuvant. Itoh M, et al. **J Anat** 1995 Dec;187 (Pt 3):671–9

Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. Casiano CA, et al. **J Autoimmun** 1995 Aug; 8(4):575–86

Expression of the human heat shock protein 60 in thyroid, pancreatic, hepatic and adrenal autoimmunity. Mallard K, et al. **J Autoimmun** 1996 Feb;9(1):89–96

On the issue of inappropriate HLA class II expression on endocrine cells: an answer to a sceptic. Todd I, et al. **J Autoimmun** 1995 Jun;8(3):313–22 (48 ref.)

Although DR3-DQB1*0201 may be associated with multiple component diseases of the autoimmune polyglandular syndromes, the human leukocyte antigen DR4-DQB1*0302 haplotype is implicated only in beta-cell autoimmunity. Huang W, et al. **J Clin Endocrinol Metab** 1996 Jul; 81(7):2559–63

Human pancreatic islet beta-cell destruction by cytokines involves oxygen free radicals and aldehyde production. Rabinovitch A, et al. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3197–202

Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. Vidrich A, et al. **J Clin Immunol** 1995 Nov;15(6):293–9

Identification of cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice. Pummerer CL, et al. **J Clin Invest** 1996 May 1;97(9):2057–62

Is idiopathic hypoparathyroidism an autoimmune disease? [editorial; comment] Rose NR. **J Clin Invest** 1996 Feb 15; 97(4):899–900. Comment on: J Clin Invest 1996 Feb 15;97(4):910–4.

Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein. Satoh M, et al. **J Clin Invest** 1996 Jun 1; 97(11):2619–26

Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. Takahashi S, et al. **J Clin Invest** 1996 Apr 1; 97(7):1597–604

Characterization of insulin autoantibodies in a patient with autoimmune hypoglycemia. Di Cerbo A, et al. **J Endocrinol Invest** 1995 Apr;18(4):299–304

Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. Asano M, et al. **J Exp Med** 1996 Aug 1;184(2):387–96

Distinct regulatory roles of lymphocyte costimulatory pathways on T helper type-2 mediated autoimmune disease. Biancone L, et al. **J Exp Med** 1996 Apr 1; 183(4):1473–81

Myocarditis-inducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart. Donermeyer DL, et al. **J Exp Med** 1995 Nov 1; 182(5):1291–300

T cells, but not B cells, are required for bowel inflammation in interleukin 2-deficient mice. Ma A, et al. **J Exp Med** 1995 Nov 1;182(5):1567–72

Selective reduction of T cells bearing invariant V alpha 24J alpha Q antigen receptor in patients with systemic sclerosis. Sumida T, et al. **J Exp Med** 1995 Oct 1;182(4):1163–8

Refractory immune thrombocytopenia after heart transplantation: a case report. Dhar SC, et al. **J Heart Lung Transplant** 1995 Jul–Aug;14(4):785–7

Frequency and significance of antibodies to histones in autoimmune hepatitis. Czaja AJ, et al. **J Hepatol** 1995 Jul; 23(1):32–8

Autoantibody against 70 kD heat shock protein in patients with autoimmune liver diseases. Shingai R, et al. **J Hepatol** 1995 Oct;23(4):382–90

T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. Breban M, et al. **J Immunol** 1996 Jan 15;156(2):794–803

The class II MHC I-Ag7 molecules from non-obese diabetic

mice are poor peptide binders. Carrasco-Marin E, et al. **J Immunol** 1996 Jan 15;156(2):450-8

Self-reactive cytotoxic gamma delta T lymphocytes in Graves' disease specifically recognize thyroid epithelial cells. Catálfamo M, et al. **J Immunol** 1996 Jan 15; 156(2):804-11

beta2-microglobulin dependence of the lupus-like autoimmune syndrome of MRL-lpr mice. Christianson GJ, et al. **J Immunol** 1996 Jun 15;156(12):4932-9

Intervention of CD4+ cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig. Chu EB, et al. **J Immunol** 1996 Feb 1;156(3):1262-8

MHC genes modify systemic autoimmune disease. The role of the I-E locus. Creech EA, et al. **J Immunol** 1996 Jan 15;156(2):812-7

Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. Daw K, et al. **J Immunol** 1996 Jan 15;156(2):818-25

Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. Edwards CK 3rd, et al. **J Immunol** 1996 Aug 15;157(4):1758-72

Frequency of molecular mimicry among T cell peptides as the basis for autoimmune disease and autoantibody induction. Garza KM, et al. **J Immunol** 1995 Dec 1; 155(11):5444-8

Biochemical characterization and microsequencing of a 205-kDa synovial protein stimulatory for T cells and reactive with rheumatoid factor containing sera. Hain NA, et al. **J Immunol** 1996 Aug 15;157(4):1773-80

T-T cellular interaction between CD4-CD8- regulatory T cells and T cell clones presenting TCR peptide. Its implication for TCR vaccination against experimental autoimmune encephalomyelitis. Kozovska MF, et al. **J Immunol** 1996 Aug 15;157(4):1781-90

Rapid induction of autoantibodies by endogenous ovarian antigens and activated T cells: implication in autoimmune disease pathogenesis and B cell tolerance. Lou YH, et al. **J Immunol** 1996 May 1;156(9):3535-40

Altered target organ. A mechanism of postrecovery resistance to murine autoimmune oophoritis. Lou YH, et al. **J Immunol** 1995 Oct 1;155(7):3667-73

Monoclonal antibodies from NZW x BXSB F1 mice to beta2 glycoprotein I and cardiolipin. Species specificity and charge-dependent binding. Monestier M, et al. **J Immunol** 1996 Apr 1;156(7):2631-41

Restriction of the TCR repertoire inhibits the development of memory T cells and prevents autoimmunity in lpr mice. Perkins DL, et al. **J Immunol** 1996 Jun 15;156(12):4961-8

CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. Perrin PJ, et al. **J Immunol** 1996 Aug 15;157(4):1333-6

Both Sm and DNA are selecting antigens in the anti-Sm B cell response in autoimmune MRL/lpr mice. Retter MW, et al. **J Immunol** 1996 Feb 1;156(3):1296-306

Analysis of central B cell tolerance in autoimmune-prone MRL/lpr mice bearing autoantibody transgenes. Rubio CF, et al. **J Immunol** 1996 Jul 1;157(1):65-71

Collagen-induced arthritis in CD4- or CD8-deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis. Tada Y, et al. **J Immunol** 1996 Jun 1;156(11):4520-6

Clinical correlates and substrate specificities of antibodies exhibiting neutrophil nuclear reactivity--a methodological study. Bang la Cour B, et al. **J Immunol Methods** 1995 Dec 1;187(2):287-95

Autoantibodies against adrenal medulla in type 1 and type 2 diabetes mellitus: no evidence for an association with autonomic neuropathy. Husebye ES, et al. **J Intern Med** 1996 Feb;239(2):139-46

Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. Nielsen EW, et al. **J Intern Med** 1996 Feb; 239(2):119-30

Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5. Kirtschig G, et al. **J Invest Dermatol** 1995 Oct;105(4):543-8

A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. Zillikens D, et al. **J Invest Dermatol** 1996 Mar; 106(3):465-70

HLA and anti-GQ1b IgG antibody in Miller Fisher syndrome and Guillain-Barré syndrome. Chiba A, et al. **J Neuroimmunol** 1995 Aug;61(1):85-8

Major histocompatibility complex class II molecule expression on muscle cells is regulated by differentiation: implications for the immunopathogenesis of muscle autoimmune diseases. Mantegazza R, et al. **J Neuroimmunol** 1996 Aug;68(1-2):53-60

Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. Rieckmann P, et al. **J Neuroimmunol** 1996 Feb;64(2):193-200

Lupus in the Fas lane? Singh AK. **J R Coll Physicians Lond** 1995 Nov-Dec;29(6):475-8 (40 ref.)

ANCA associated with Behçet's disease. Burrows NP, et al. **J R Soc Med** 1996 Jan;89(1):47P-8P

Psoriasis, T cells and autoimmunity. Griffiths CE, et al. **J R Soc Med** 1996 Jun;89(6):315-9 (60 ref.)

The Hughlings Jackson Lecture: autoimmunity and the nervous system. Newsom-Davis J. **J R Soc Med** 1995 Nov; 88(11):639P-643P (20 ref.)

Anetoderma of Jadassohn-Pellizzari. Roberts NM, et al. **J R Soc Med** 1995 Oct;88(10):599P-600P

Subclass distribution of maternal and neonatal anti-Ro(SSA) and La(SSB) antibodies in congenital heart block. Tseng CE, et al. **J Rheumatol** 1996 May;23(5):925-32

Molecular weights and isoelectric points of sperm antigens relevant to autoimmune infertility in men. Pillai S, et al. **J Urol** 1996 Jun;155(6):1928-33

The immunological features of Peyronie's disease. Ralph DJ, et al. **J Urol** 1996 Jan;155(1):159-62

Raised levels of antibodies to human viruses at the clinical onset of autoimmune chronic active hepatitis. Kalvenes MB, et al. **J Viral Hepat** 1995;2(2):159-64

Autoantigens interact with cis-acting elements of rubella virus RNA. Pogue GP, et al. **J Virol** 1996 Sep; 70(9):6269-77

Recent progress in studies on autoantigens for various autoimmune blistering skin diseases. Hashimoto T. **Keio J Med** 1995 Dec;44(4):115-23 (84 ref.)

Cardiac myosin-induced myocarditis: target recognition by autoreactive T cells requires prior activation of cardiac interstitial cells. Pummerer CL, et al. **Lab Invest** 1996 May; 74(5):845-52

Guinea pig inner ear antigens: extraction and application to the study of human autoimmune inner ear disease. Cao MY, et al. **Laryngoscope** 1996 Feb;106(2 Pt 1):207-12

Autoimmune hepatitis versus viral hepatitis C. Strassburg CP, et al. **Liver** 1995 Oct;15(5):225-32 (72 ref.)

Role of beta 2-glycoprotein I in the anticardiolipin antibody affinity for phospholipid in autoimmune disease. Dueymes M, et al. **Lupus** 1995 Dec;4(6):477-81

Specific antiphospholipid antibodies (aPL) eluted from placentae of pregnant women with aPL-positive sera. Katano K, et al. **Lupus** 1995 Aug;4(4):304-8

HLA-DQ associations in type 1 autoimmune hepatitis. Czaja AJ, et al. **Mayo Clin Proc** 1995 Dec;70(12):1154-60

Managing HIV. Part 3. Mechanisms of disease. 3.4 How HIV leads to autoimmune disorders. Gala S, et al. **Med J Aust** 1996 Feb 19;164(4):224-6 (15 ref.)

Interference between Neisseria meningitidis and PC-KLH induced anti-phosphorylcholine PFC responses in NZB/W autoimmune mice. Seoane R, et al. **Microbiol Immunol** 1995;39(7):491-7

Oligoclonality in the human CD8+ T cell repertoire in normal subjects and monozygotic twins: implications for studies of infectious and autoimmune diseases. Monteiro J, et al. **Mol Med** 1995 Sep;1(6):614-24

Structure and function of the natural-resistance-associated macrophage protein (Nramp1), a candidate protein for infectious and autoimmune disease susceptibility. Blackwell JM. **Mol Med Today** 1996 May;2(5):205-11 (38 ref.)

Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Lecoeur S, et al. **Mol Pharmacol** 1996 Aug; 50(2):326-33

Pitfalls in the diagnosis of autoantibodies associated with paraneoplastic neurologic disease. Sillevis-Smitt P, et al. **Neurology** 1996 Jun;46(6):1739-41

A nucleolar RNA helicase recognized by autoimmune antibodies from a patient with watermelon stomach disease. Valdez BC, et al. **Nucleic Acids Res** 1996 Apr 1; 24(7):1220-4

Autoantibody profile of primary sclerosing cholangitis. Gur H, et al. **Pathobiology** 1995;63(2):76-82

Autoimmune aspects of primary pulmonary hypertension. Yanai-Landau H, et al. **Pathobiology** 1995;63(2):71-5

Checkpoints in the progression of autoimmune disease: lessons from diabetes models. André I, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2260-3 (67 ref.)

Definition of the HLA-A29 peptide ligand motif allows prediction of potential T-cell epitopes from the retinal soluble antigen, a candidate autoantigen in birdshot retinopathy. Boisgerault F, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3466-70

Insulin-secreting non-islet cells are resistant to autoimmune destruction. Lipes MA, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8595-600

Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Ray SK, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2019-24

Superantigens: structure and relevance to human disease. Johnson HM, et al. **Proc Soc Exp Biol Med** 1996 Jun; 212(2):99-109 (88 ref.)

Superantigens in autoimmune disease. Youinou P, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):591-7 (35 ref.)

The role of immune processes in amyotrophic lateral sclerosis pathogenesis. Alexianu ME. **Rom J Neurol Psychiatry** 1995 Jul-Dec;33(3-4):215-27

Interleukin-2-knockout mice: a new model to study autoimmunity and self-tolerance. Horák I. **Sb Lek** 1996; 97(1):25-8

T cell receptor genetics, autoimmunity and asthma [editorial] Frew AJ, et al. **Thorax** 1995 Sep;50(9):919-22

The serological investigation of patients with autoimmune thrombocytopenia. Kelton JG. **Thromb Haemost** 1995 Jul; 74(1):228-33

Platelet-associated anti-glycoprotein (GP) IIb-IIIa autoantibodies in chronic immune thrombocytopenic purpura mainly recognize cation-dependent conformations: comparison with the epitopes of serum autoantibodies. Kosugi S, et al. **Thromb Haemost** 1996 Feb;75(2):339-45

Anticardiolipin and anti-beta 2-GPI are two distinct populations of autoantibodies. Sorice M, et al. **Thromb Haemost** 1996 Feb;75(2):303-8

Characterization of antibodies directed against platelet cryptantigens detected during the immunological study of 356 consecutive patients with presumed autoimmune thrombocytopenia (AITP). Muñiz-Diaz E, et al. **Transfus Med** 1995 Sep;5(3):185-91

Abnormal cellular immune mechanisms associated with autoimmune thrombocytopenia. Semple JW, et al. **Transfus Med Rev** 1995 Oct;9(4):327-38 (102 ref.)

Plasma membrane DNA in autoimmune diseases. Keyhani J, et al. **Transplant Proc** 1995 Oct;27(5):2756-8

Nephritogenicity and alpha-chain composition of NC1 fractions of type IV collagen from bovine renal basement membrane. Rauf S, et al. **Virchows Arch** 1996 Jul; 428(4-5):281-8

Relation between autoimmune liver diseases and viral hepatitis: clinical and serological characteristics in 859 patients. Lohse AW, et al. **Z Gastroenterol** 1995 Sep; 33(9):527-33

[Laboratory diagnosis of autoimmune sensorineural hearing loss with modified western blotting method] Zou J, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995;30(3):154-6 (Eng. Abstr.) **(Chi)**

[Autoimmune oophoritis] Jokimaa V, et al. **Duodecim** 1995; 111(2):168-72 **(Fin)**

[Autoimmune diseases and autoantigens] Miettinen A. **Duodecim** 1994;110(2):207-14 (38 ref.) **(Fin)**

[Superantigens and their implication in autoimmune diseases] Meyer O. **Presse Med** 1995 Sep 2-9;24(25):1171-7 (28 ref.) (Eng. Abstr.) **(Fre)**

[Psoriasis--an immunologic disorder? Symposium, 14 July 1993, Düsseldorf] **Hautarzt** 1993 Sep;44(9 Suppl):1-4 **(Ger)**

[Autoimmune diseases of the peripheral cornea. Immunopathology, clinical aspects and therapy] Pleyer U, et al. **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):73-81 (45 ref.) (Eng. Abstr.) **(Ger)**

[ANCA: vasculitis research on the upswing (editorial; comment)] Michel BA. **Z Rheumatol** 1995 Sep-Oct; 54(5):277-8. Comment on: Z Rheumatol 1995 Sep-Oct;54(5):279-90. Comment on: Z Rheumatol 1995 Sep-Oct;54(5):291-302. Comment on: Z Rheumatol 1995 Sep-Oct;54(5):303-9. **(Ger)**

[The role of Fc gamma R specific autoantibodies in autoimmune diseases. Review of the literature and authors' own research] Szegedi A, et al. **Orv Hetil** 1996 Mar 17; 137(11):581-4 (34 ref.) (Eng. Abstr.) **(Hun)**

[Autoimmune Addison's disease. Current knowledge and prospects] De Bellis A, et al. **Minerva Endocrinol** 1996 Mar; 21(1):1-6 (35 ref.) (Eng. Abstr.) **(Ita)**

[Recent findings on antigens reactive to antiphospholipid antibodies] Matsuda S. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):27-38 (66 ref.) **(Jpn)**

[Heat shock protein and immunity] Nomaguchi H. **Nippon Rai Gakkai Zasshi** 1995 Nov;64(3):188-99 (66 ref.) **(Jpn)**

[Clinical manifestation and immunogenetic background of HCV-marker-positive autoimmune hepatitis] Zeniya M. **Nippon Rinsho** 1995 Sep;53 Suppl:877-84 (11 ref.) **(Jpn)**

[Immune cytopenias and some associated problems of immunohematology] Zotikov EA. **Biull Eksp Biol Med** 1996 Apr;121(4):364-9 (41 ref.) **(Rus)**

[The role of immunological changes in diseases in regions contaminated by radionuclides after the accident at the Chernobyl Atomic Electric Power Station] Shubik VM, et al. **Radiats Biol Radioecol** 1996 May-Jun;36(3):332-7 (Eng. Abstr.) **(Rus)**

[Antibodies to organ-nonspecific and organ-specific antigens in the blood sera of persons with bronchopulmonary diseases] Iastrebova NE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):67-8 **(Rus)**

[Immunopathogenic mechanisms in autoimmune processes: autoantigens] Buc M. **Bratisl Lek Listy** 1996 Apr; 97(4):187-95 (Eng. Abstr.) **(Slo)**

[Autoimmune diseases of the liver. Autoimmune hepatitis] Garassini Serra MA, et al. **G E N** 1994 Oct-Dec; 48(4):256-63 (51 ref.) **(Spa)**

[Structure and function of the T-lymphocyte antigen receptor and its role in infectious diseases] Peralta Zaragoza O, et al. **Rev Invest Clin** 1996 Jan-Feb;48(1):69-79 (84 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Downregulation of microglial keratan sulfate proteoglycans coincident with lymphomonocytic infiltration of the rat central nervous system. Jander S, et al. **Am J Pathol** 1996 Jan;148(1):71-8

Embryonic fibronectin isoforms are synthesized in crescents in experimental autoimmune glomerulonephritis. Nickeleit V, et al. **Am J Pathol** 1995 Oct;147(4):965-78

Increases in cyclic AMP levels couple to H1 receptors in atria from autoimmune myocarditis mice. Goren N, et al. **Cell Signal** 1995 Nov;7(8):759-64

Production of reactive nitrogen intermediates (RNI) by

peritoneal macrophages from rats with experimental autoimmune prostatitis (EAP). Orsilles MA, et al. **Inflammation** 1995 Aug;19(4):415–22

Expression of the human heat shock protein 60 in thyroid, pancreatic, hepatic and adrenal autoimmunity. Mallard K, et al. **J Autoimmun** 1996 Feb;9(1):89–96

Expression of intercellular adhesion molecule-1 on human thyroid cells from patients with autoimmune thyroid disease: study of thyroid xenografts in nude and severe combined immunodeficient mice and treatment with FK-506. Arreaza G, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3724–31

Biliary expression of heat shock protein: a non-specific feature of chronic cholestatic liver diseases. Martins EB, et al. **J Clin Pathol** 1996 Jan;49(1):53–6

HLA association with autoimmune disease: restricted binding or T-cell selection? [letter] Baum H, et al. **Lancet** 1995 Oct 14;346(8981):1042–3

High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease [letter] van Genderen PJ, et al. **Thromb Haemost** 1995 May; 73(5):891–2

PATHOLOGY

Immune-mediated cell death in neurodegenerative disease. Appel SH, et al. **Adv Neurol** 1996;69:153–9 (55 ref.)

Histologic spectrum of cryptogenic chronic liver disease and comparison with chronic autoimmune and chronic type C hepatitis. Goldstein NS, et al. **Am J Clin Pathol** 1995 Nov;104(5):567–73

A case of autoimmune bullous dermatosis with features of pemphigus vulgaris and bullous pemphigoid. Kore-eda S, et al. **Am J Dermatopathol** 1995 Oct;17(5):511–6

Anamnestic development of lymphocytic infiltration in murine experimental autoimmune oophoritis is primarily localized in the stroma and theca. Raj S, et al. **Am J Reprod Immunol** 1995 Aug;34(2):125–31

Sympathetic auto-immune orchitis. Suominen JJ. **Andrologia** 1995 Jul-Aug;27(4):213–6

Pemphigus vulgaris: gingival involvement. A case report. Weinberg MA, et al. **Ann Dent** 1995 Summer-Fall; 54(1-2):8–13

The pathology of the endocrine pancreas in type 1 (insulin-dependent) diabetes mellitus. Foulis AK. **APMIS** 1996 Mar;104(3):161–7 (32 ref.)

Histopathology of the seminiferous tubules in mice injected with syngeneic testicular germ cells alone. Itoh M, et al. **Arch A drol** 1995 Sep-Oct;35(2):93–103

Multinucleated giant cells undergoing apoptosis in experimental autoimmune myocarditis. Suzuki K, et al. **Arch Histol Cytol** 1995 Jun;58(2):231–41

Autoantibodies inhibit interleukin-7-mediated proliferation and are associated with the age-dependent loss of pre-B cells in autoimmune New Zealand Black Mice. Merchant MS, et al. **Blood** 1996 Apr 15;87(8):3289–96

Sjögren's syndrome revisited: autoimmune epithelitis [editorial] Moutsopoulos HM, et al. **Br J Rheumatol** 1996 Mar;35(3):204–6

Pandysautonomia: clinicopathological. Report of 5 cases. Li S, et al. **Chin Med J (Engl)** 1995 Nov;108(11):829–34

The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Mountz JD, et al. **Clin Immunol Immunopathol** 1996 Sep; 80(3 Pt 2):S2–14 (103 ref.)

An ultrastructural study on experimental autoimmune myocarditis with special reference to effector cells. Izumi T, et al. **Eur Heart J** 1995 Dec;16 Suppl O:75–7

Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Dick AD, et al. **Eur J Immunol** 1996 May; 26(5):1018–25

Tissue repair in the iris in experimental autoimmune uveoretinitis. Wang J, et al. **Exp Mol Pathol** 1995 Aug; 63(1):41–51

Autoimmune alterations in choroid plexus basement membrane of some patients with Alzheimer's disease [letter; comment] Cserni G. **Hum Pathol** 1995 Oct;26(10):1168–9 . Comment on: Hum Pathol 1994 Nov;25(11):1185–90.

Autoimmune enteropathy with anti-goblet cell antibodies. Moore L, et al. **Hum Pathol** 1995 Oct;26(10):1162–8

Free radical tissue damages in the anterior segment of the eye in experimental autoimmune uveitis. Ishimoto S, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):630–6

Dermatitis herpetiformis associated with lichen planopilaris. Isaac M, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1050–1 (3 ref.)

Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. Zhou T, et al. **J Immunol** 1996 Apr 15;156(8):2661–5

A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. Zillikens D, et al. **J Invest Dermatol** 1996 Mar; 106(3):465–70

Experimental neonatal autoimmune myasthenia gravis: an immunohistochemical, ultrastructural and electrophysiological study of the motor end-plate. Tetsuo N, et al. **J Neurol Sci** 1995 Oct;132(2):97–104

Histologic examination of the NOD-mouse lacrimal glands, a potential model for idiopathic autoimmune dacryoadenitis in Sjogren's syndrome. Moore PA, et al. **Lab Anim Sci** 1996 Feb;46(1):125–8

Effect of chronic autoimmune nerve growth factor deprivation on sympathetic neuroaxonal dystrophy in rats. Schroer JA, et al. **Synapse** 1995 Jul;20(3):249–56

[Pathology of autoimmune diseases. On the 80th Congress of the German Society of Pathology in Dresden 27 May – 1 June 1996] Müller-Hermelink HK. **Pathologe** 1996 Mar; 17(2):107–9 **(Ger)**

[Autoimmune hepatitis] Dienes HP. **Verh Dtsch Ges Pathol** 1995;79:177–85 (18 ref.) (Eng. Abstr.) **(Ger)**

[A case of autoimmune hepatitis with multinucleated giant hepatocytes] Nakasho K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):266–71 **(Jpn)**

[Apoptosis in autoimmune diseases] Kobayashi S, et al. **Ryumachi** 1995 Aug;35(4):712–25 (64 ref.) **(Jpn)**

[Apoptosis and autoimmune diseases (editorial)] Font J, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):619–21 (37 ref.) **(Spa)**

PHYSIOPATHOLOGY

Acute exacerbation of antiliver cytosol antibody-positive autoimmune chronic hepatitis by alpha-interferon. Gschwantler M, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2239–40

Defective signal-transduction pathways in T-cells from autoimmune MRL-lpr/lpr mice are associated with increased polyamine concentrations. Thomas TJ, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):175–82

Talents and disorders: relationships among handedness, sex, and college major. Martino G, et al. **Brain Cogn** 1995 Oct; 29(1):66–84

Experimental rat model representing both acute and chronic heart failure related to autoimmune myocarditis. Koyama S, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):701–7

In vivo role of IL-10 and IL-12 during development of Sjögren's syndrome in MRL/lpr mice. Yanagi K, et al. **Cell Immunol** 1996 Mar 15;168(2):243–50

Sex steroids and the immune system. Fox HS. **Ciba Found Symp** 1995;191:203–11; discussion 211–7 (31 ref.)

Pathogenic and protective roles of CD45RB(low) CD4+ cells correlate with cytokine profiles in the spontaneously autoimmune diabetic mouse. Shimada A, et al. **Diabetes** 1996 Jan;45(1):71–8

Cytokines and the endocrine system. II. Roles in substrate metabolism, modulation of thyroidal and pancreatic endocrine cell functions and autoimmune endocrine diseases. Mandrup-Poulsen T, et al. **Eur J Endocrinol** 1996 Jan;134(1):21–30 (174 ref.)

Unique role of thyroxine in T cell recognition of a pathogenic peptide in experimental autoimmune thyroiditis. Dawe KI, et al. **Eur J Immunol** 1996 Apr;26(4):768–72

A 28-year-old woman with a combined hepatitic/cholestatic syndrome [clinical conference] Wurbs D, et al. **Hepatology** 1995 Nov;22(5):1598–605

Experimental neonatal autoimmune myasthenia gravis: an immunohistochemical, ultrastructural and electrophysiological study of the motor end-plate. Tetsuo N, et al. **J Neurol Sci** 1995 Oct;132(2):97–104

Pre-eclampsia, autoimmune diseases and breast cancer etiology. Polednak AP. **Med Hypotheses** 1995 May; 44(5):414–8 (46 ref.)

"Spontaneous" hypoglycaemia: facing a hydra [editorial; comment] Holleman F, et al. **Neth J Med** 1996 May; 48(5):167–8. Comment on: Neth J Med 1996 May;48(5):180–4. Comment on: Neth J Med 1996 May;48(5):185–7. Comment on: Neth J Med 1996 May;48(5):188–92.

kappa-Opioid receptor functions: possible relevance to experimental allergic encephalomyelitis. Radulović J, et al. **Neuroimmunomodulation** 1994 Jul-Aug;1(4):236–41

Rapid progress in the field of infectious and autoimmune disorders of the nervous system. Deckert-Schlüter M, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):548–51

[Demonstration of the role of the idiotypic system in the physiopathology of autoimmune manifestations in Mycoplasma pneumoniae infections] Ben Aïssa-Fennira F, et al. **Arch Inst Pasteur Tunis** 1994 Jul-Oct;71(3-4):517–23 **(Fre)**

[Fungi and autoimmune conditions] George J, et al. **Harefuah** 1996 Mar 15;130(6):388–90 (24 ref.) **(Heb)**

PREVENTION & CONTROL

The development and use of T cell receptor peptide vaccines. Brostoff S. **Adv Exp Med Biol** 1995;383:249–54 (18 ref.)

Failure of immunoglobulins to prevent neonatal thrombocytopenia in mothers with immunothrombocytopenic purpura. Zuppa AA, et al. **Biol Neonate** 1995;67(6):450–2

Native, but not genetically inactivated, pertussis toxin protects mice against experimental allergic encephalomyelitis. Robbinson D, et al. **Cell Immunol** 1996 Mar 15;168(2):165–73

Immunotolerance and prevention of ocular autoimmune disease. Rizzo LV, et al. **Curr Eye Res** 1995 Sep; 14(9):857–64 (99 ref.)

Suramin treatment suppresses induction of experimental autoimmune uveoretinitis (EAU) in rodents. Sartani G, et al. **Curr Eye Res** 1995 Oct;14(10):887–96

Oxpentifylline inhibits tumor necrosis factor-alpha mRNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats. Kiely PD, et al. **Eur J Immunol** 1995 Oct;25(10):2899–906

Orally induced, peptide-specific gamma/delta TCR+ cells suppress experimental autoimmune uveitis. Wildner G, et al. **Eur J Immunol** 1996 Sep;26(9):2140–8

Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Chanaud NP 3rd, et al. **Exp Eye Res** 1995 Oct;61(4):429–34

Vitamin C and the genesis of autoimmune disease and allergy (review). Kodama M, et al. **In Vivo** 1995 May-Jun; 9(3):231–8 (38 ref.)

Vaccines to prevent and treat autoimmune diseases. Mor F, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):345–9 (42 ref.)

Prevention of autoimmune symptoms in autoimmune-prone mice by elimination of B-1 cells. Murakami M, et al. **Int Immunol** 1995 May;7(5):877–82

Cyclosporine therapy suppresses ocular and lacrimal gland disease in MRL/Mp-lpr/lpr mice. Jabs DA, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):377–83

Dietary omega-3 lipids delay the onset and progression of autoimmune lupus nephritis by inhibiting transforming growth factor beta mRNA and protein expression. Chandrasekar B, et al. **J Autoimmun** 1995 Jun;8(3):381–93

Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. Delaney CP, et al. **J Clin Invest** 1996 Jan 1;97(1):217–25

Long-term treatment with dimethylthiourea inhibits the development of autoimmune disease in NZB x NZWF1 mice. Hayashi T, et al. **J Comp Pathol** 1995 May; 112(4):423–8

Prevention of autoimmune disease by retroviral-mediated gene therapy. Ally BA, et al. **J Immunol** 1995 Dec 1; 155(11):5404–8

Virus encoding an encephalitogenic peptide protects mice from experimental allergic encephalomyelitis. Brnett LA, et al. **J Neuroimmunol** 1996 Feb;64(2):163–73

Glimepiride-induced prevention of diabetes and autoimmune events in the BB rat: revised. Cheta DM, et al. **Life Sci** 1995;57(24):2281–90

[Immune modulation by vitamin D analogs in the prevention of autoimmune diseases] Bouillon R, et al. **Verh K Acad Geneeskd Belg** 1995;57(5):371–85; discussion 385–7 (Eng. Abstr.) **(Dut)**

[Prediction of type I diabetes by antibody screening] Roll U, et al. **Fortschr Med** 1995 Sep 20;113(26):365–7 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Inflammatory myopathies: radiologic evaluation. Fleckenstein JL, et al. **Radiol Clin North Am** 1996 Mar; 34(2):427–39, xii (92 ref.)

RADIONUCLIDE IMAGING

Splenosis in a patient with autoimmune thrombocytopenia. Macfarlane DJ, et al. **Clin Nucl Med** 1996 Jan;21(1):61–2

RADIOTHERAPY

Splenic irradiation for chronic autoimmune thrombocytopenic purpura in patients with contra-indications to splenectomy. Caulier MT, et al. **Br J Haematol** 1995 Sep;91(1):208–11

SURGERY

Islet and pancreatic transplantation--autoimmunity and alloimmunity [editorial; comment] Eisenbarth GS, et al. **N Engl J Med** 1996 Sep 19;335(12):888–90. Comment on: N Engl J Med 1996 Sep 19;335(12):860–3.

Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts [see comments] Tydén G, et al. **N Engl J Med** 1996 Sep 19;335(12):860–3. Comment in: N Engl J Med 1996 Sep 19;335(12):888–90.

Thymus transplantation, a critical factor for correction of autoimmune disease in aging MRL/+mice. Hosaka N, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8558–62

THERAPY

Treatment of autoimmune diseases by oral tolerance to autoantigens. Weiner HL, et al. **Adv Exp Med Biol** 1995; 371B:1217–23 (30 ref.)

Oral tolerance: mechanisms and applications. Introduction. Weiner HL, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:xiii–xviii

Haemopoietic stem and progenitor cells in the treatment of severe autoimmune diseases. Tyndall A, et al. **Ann Rheum Dis** 1996 Mar;55(3):149–51

Bone marrow transplantation in auto-immune disease. Hamilton JA, et al. **Baillieres Clin Rheumatol** 1995 Nov; 9(4):673–87 (58 ref.)

Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments] George JN, et al. **Blood** 1996 Jul 1;88(1):3–40 (295 ref.). Comment in: Blood 1996 Jul 1;88(1):1–2.

Stem cell transplantation for severe autoimmune diseases: new proposals but still unanswered questions. Marmont AM, et al. **Bone Marrow Transplant** 1995 Oct;16(4):497–8

The use of oral tolerance as a therapy for ocular

autoimmunity. Rizzo LV. **Braz J Med Biol Res** 1995 Aug; 28(8):931–6 (23 ref.)
Modulation of complement-mediated immune damage by intravenous immune globulin. Basta M. **Clin Exp Immunol** 1996 May;104 Suppl 1:21–5
Beneficial effect of Salmonella typhimurium infection and of immunoglobulins from S. typhimurium-infected mice on the autoimmune disease of (NZB x NZW) F1 mice. Matsiota-Bernard P, et al. **Clin Exp Immunol** 1996 May; 104(2):228–35
Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Mouthon L, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:3–9 (63 ref.)
Antigen-specific immunotherapy of autoimmune disease: a commentary [editorial] Wraith DC. **Clin Exp Immunol** 1996 Mar;103(3):349–52 (38 ref.)
Autoimmunity and clonal B-cell expansion. Biological basis for therapeutic interventions. Udine, Italy, 15–16 March 1996. Conference proceedings. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S1–80
Adhesion molecules as targets for the treatment of autoimmune diseases. Oppenheimer-Marks N, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):203–10 (58 ref.)
Treatment of autoimmune disease by oral tolerance to autoantigens. Whitacre CC, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S31–9 (75 ref.)
The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Maisch B, et al. **Eur Heart J** 1995 Dec;16 Suppl O:173–5
Prospects for treating autoimmune and inflammatory diseases by gene therapy [editorial] Robbins PD, et al. **Gene Ther** 1996 Mar;3(3):187–9
Vaccines to prevent and treat autoimmune diseases. Mor F, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):345–9 (42 ref.)
Induction of antigen-specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions. Wraith DC. **Int Arch Allergy Immunol** 1995 Dec;108(4):355–9 (29 ref.)
Idiopathic thrombocytopenic purpura (ITP): immunomodulation by intravenous immunoglobulin (IVIg). Imbach P, et al. **Int Rev Immunol** 1989;5(2):181–8 (34 ref.)
Paradoxic effect of anti-CD4 therapy on lacrimal gland disease in MRL/Mp-lpr/lpr mice. Jabs DA, et al. **Invest Ophthalmol Vis Sci** 1996 Jan;37(1):246–50
Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. Jordan SC. **J Clin Immunol** 1995 Nov;15(6 Suppl):76S–85S (40 ref.)
T cell receptor peptides in treatment of autoimmune disease: rationale and potential. Vandenbark AA, et al. **J Neurosci Res** 1996 Feb 15;43(4):391–402 (80 ref.)
Biologic agents in autoimmune diseases. Keystone EC, et al. **J Rheumatol** 1996 Apr;23(4):743–6
Resolution of autoimmune hepatitis after bone-marrow transplantation [letter] Vento S, et al. **Lancet** 1996 Aug 24;348(9026):544–5
Complications of intravenous gammaglobulin in neuromuscular and other diseases. Bertorini TE, et al. **Muscle Nerve** 1996 Mar;19(3):388–91
Clues to B-cell memory. Fuchs E **Nat Med** 1996 Jul; 2(7):743–4
Five years' experience at one centre with protein A immunoadsorption in patients with deleterious allo/autoantibodies (anti-HLA antibodies, autoimmune bleeding disorders) and post-transplant patients relapsing with focal glomerular sclerosis. Kriaa F, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:108–10
Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Brod SA, et al. **Neurology** 1996 Jun; 46(6):1633–8
Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. Sørensen PS, et al. **Neurology** 1996 Jun; 46(6):1620–5
Tryptophan-immobilized column adsorbs immunoglobulin G anti-GQ1b antibody from Fisher's syndrome: A new approach to treatment. Yuki N. **Neurology** 1996 Jun; 46(6):1644–51
Antigen-specific therapies for the treatment of autoimmune diseases. Hafler DA, et al. **Springer Semin Immunopathol** 1995;17(1):61–76 (78 ref.)
Immunospecific drug design—prospects for treatment of autoimmune diseases. Arnon R, et al. **Ther Immunol** 1994 Jan;1(1):65–70 (59 ref.)
Mucosal tolerance and the immunotherapy of autoimmune disease: a commentary. Wraith DC, et al. **Ther Immunol** 1995 Feb;2(1):53–8 (49 ref.)
[Mooren's ulcer] Hoang-Xuan T, et al. **J Fr Ophtalmol** 1996; 19(4):315–6 **(Fre)**
[Immunosuppressive therapy in an asymptomatic female patient with an autoimmune disease?] Helbling A. **Dtsch Med Wochenschr** 1996 Feb 9;121(6):186 **(Ger)**
[Plasma- and lymphapheresis in autoimmune diseases] Schneider M. **Z Rheumatol** 1996 Mar-Apr;55(2):90–104 (165 ref.) (Eng. Abstr.) **(Ger)**
[Indication for use and mechanisms of action of intravenous immune globulin in autoimmune diseases] Cohen AD, et al. **Harefuah** 1995 Aug;129(3–4):123–7 (50 ref.) **(Heb)**
[Selection of therapy for chronic hepatitis C with feature of autoimmune hepatitis] Kakumu S. **Nippon Rinsho** 1995 Sep;53 Suppl:892–6 (16 ref.) **(Jpn)**
[The use of interferon alfa-2r in the treatment of autoimmune uveitis (primary or associated with Behçet's disease)] Sánchez Román J, et al. **Rev Clin Esp** 1996 May; 196(5):293–8 (Eng. Abstr.) **(Spa)**
[Efficacy of various treatments in the management of idiopathic thrombocytopenic purpura in the adult] Llamas P, et al. **Sangre (Barc)** 1995 Jun;40(3):181–5 (Eng. Abstr.) **(Spa)**

VETERINARY

Canine immune-mediated diabetes mellitus: a case report. Elie M, et al. **J Am Anim Hosp Assoc** 1995 Jul-Aug; 31(4):295–9
Megaoesophagus secondary to acquired myasthenia gravis. Yam PS, et al. **J Small Anim Pract** 1996 Apr;37(4):179–83
Skin allograft survival in chicken strains with spontaneous autoimmune diseases. Dietrich HM, et al. **Poult Sci** 1996 Mar;75(3):285–93
Alterations in blood leukocyte populations in Smyth line chickens with autoimmune vitiligo. Erf GF, et al. **Poult Sci** 1996 Mar;75(3):351–6

VIROLOGY

Polymerase chain reaction detection of the hemagglutinin gene from an attenuated measles vaccine strain in the peripheral mononuclear cells of children with autoimmune hepatitis. Kawashima H, et al. **Arch Virol** 1996; 141(5):877–84
Human T lymphotropic virus type I in arthropathy and autoimmune disorders. Nishioka K, et al. **Arthritis Rheum** 1996 Aug;39(8):1410–8 (55 ref.)
The pathogenesis of postinfectious myocarditis. Rose NR, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S92–9 (51 ref.)
Epstein-Barr virus and autoimmune hepatitis [letter; comment] Mahalingam M. **Lancet** 1995 Sep 30; 346(8979):913. Comment on: Lancet 1995 Sep 2;346(8975):608–9.
Managing HIV. Part 3. Mechanisms of disease. 3.4 How HIV leads to autoimmune disorders. Gala S, et al. **Med J Aust** 1996 Feb 19;164(4):224–6 (15 ref.)
Glomerulonephritis, thrombocytopenia, and autoimmune neutropenia probably induced by a virus-like illness: case report and review of the literature. Mackey JR, et al. **Nephron** 1995;71(4):454–8 (33 ref.)
The Epstein-Barr virus in autoimmunity. Vaughan JH. **Springer Semin Immunopathol** 1995;17(2–3):203–30 (162 ref.)
Role of viruses in the loss of tolerance to self-antigens and in autoimmune diseases. von Herrath MG, et al. **Trends Microbiol** 1995 Nov;3(11):424–30 (61 ref.)
The viral-autoimmunity relationship. Cohen AD, et al. **Viral Immunol** 1995;8(1):1–9 (83 ref.)

AUTOIMMUNE POLYENDOCRINOPATHY-CANDIDIASIS-ECTODERMAL-DYSTROPHY see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

AUTOIMMUNE RESPONSE see **AUTOIMMUNITY**

AUTOIMMUNE SYNDROME TYPE I, POLYGLANDULAR see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

AUTOIMMUNE SYNDROME TYPE II, POLYGLANDULAR see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

AUTOIMMUNE THROMBOCYTOPENIC PURPURA see **PURPURA, THROMBOCYTOPENIC, IDIOPATHIC**

AUTOIMMUNE THYROIDITIS see **THYROIDITIS, AUTOIMMUNE**

AUTOIMMUNITY

see related
AUTOANTIBODIES
AUTOIMMUNE DISEASES

Antinuclear autoantibodies in chronic schizophrenia. Spivak B, et al. **Acta Psychiatr Scand** 1995 Oct;92(4):266–9
Autoimmunity, apoptosis defects and retroviruses. Mountz JD, et al. **Adv Exp Med Biol** 1995;374:183–201 (84 ref.)
Autoimmunity as an etiological factor in sporadic amyotrophic lateral sclerosis. Appel SH, et al. **Adv Neurol** 1995;68:47–57 (88 ref.)
Amyotrophic lateral sclerosis. An autoimmune disease? Drachman DB, et al. **Adv Neurol** 1995;68:59–65 (54 ref.)
The possible role of a secondary pathogenetic factor in amyotrophic lateral sclerosis. Pinelli P, et al. **Adv Neurol** 1995;68:29–40 (25 ref.)
Role of autoimmunity in contralateral delayed endolymphatic hydrops. Harris JP, et al. **Am J Otol** 1994 Nov;15(6):710–6
Lessons learned from the non-obese diabetic mouse II: Amelioration of pancreatic autoimmune isograft rejection during pregnancy. Chen HM, et al. **Am J Perinatol** 1996 May;13(4):249–54
Autoimmune phenomena in bronchial asthma with special reference to aspirin intolerance. Szczeklik A, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 1):1753–6
B-1 cells and autoimmunity. Murakami M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:402–9 (34 ref.)
Gender differences in autoimmune demyelination in the mouse: implications for multiple sclerosis. Voskuhl RR, et al. **Ann Neurol** 1996 Jun;39(6):724–33
Features of autoimmunity in the abdominal aortic aneurysm. Gregory AK, et al. **Arch Surg** 1996 Jan;131(1):85–8
Prevention of autoimmunity in nonobese diabetic (NOD) mice by neonatal transfer of allogeneic thymic macrophages. Georgiou HM, et al. **Autoimmunity** 1995; 21(2):89–97
Aberrant hormone balance in fetal autoimmune NZB/W mice following prenatal exposure to testosterone excess or the androgen blocker flutamide. Keisler LW, et al. **Biol Reprod** 1995 Nov;53(5):1190–7
B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Caligaris-Cappio F. **Blood** 1996 Apr 1; 87(7):2615–20
Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells. Filion MC, et al. **Blood** 1996 Sep 15;88(6):2144–50
Autoimmunity to collagen in human lung cancer. Fernandez-Madrid F, et al. **Cancer Res** 1996 Jan 1; 56(1):121–6
Superantigen-mediated proliferation and cytotoxicity of T cells isolated from the inflammatory tissues and peripheral blood of arthritis patients. Li S, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):278–87
Apoptosis and its association with autoimmunity [editorial] George J, et al. **Clin Rheumatol** 1995 Sep;14(5):505–9 (29 ref.)
Autoimmunity. **Curr Opin Immunol** 1995 Dec;7(6):860–76
The Th1/Th2 balance in autoimmunity. Charlton B, et al. **Curr Opin Immunol** 1995 Dec;7(6):793–8 (51 ref.)
The regulation of self-reactive B cells. Cornall RJ, et al. **Curr Opin Immunol** 1995 Dec;7(6):804–11 (52 ref.)
Metal ion induced autoimmunity. Griem P, et al. **Curr Opin Immunol** 1995 Dec;7(6):831–8 (57 ref.)
Autoimmunity [editorial] Wicker L, et al. **Curr Opin Immunol** 1995 Dec;7(6):783–5
Autoimmunity to the GM2-1 islet ganglioside before and at the onset of type I diabetes. Dotta F, et al. **Diabetes** 1996 Sep;45(9):1193–6
Perinatal autoimmunity in offspring of diabetic parents. The German Multicenter BABY-DIAB study: detection of humoral immune responses to islet antigens in early childhood. Roll U, et al. **Diabetes** 1996 Jul;45(7):967–73
Late progression to diabetes and evidence for chronic beta-cell autoimmunity in identical twins of patients with type I diabetes. Verge CF, et al. **Diabetes** 1995 Oct; 44(10):1176–9
Food for thought—is induction of oral tolerance feasible and practical in human thyroid autoimmunity? [editorial; comment] Rapoport B, et al. **Endocrinology** 1996 Jun; 137(6):2197–8. Comment on: Endocrinology 1996 Jun;137(6):2199–207.
High frequency of endocrine autoimmunity in patients with sarcoidosis. Papadopoulos KI, et al. **Eur J Endocrinol** 1996 Mar;134(3):331–6
Marked depletion at the late pro-B cell stage in the bone marrow of lpr mice correlates with the development of lymphadenopathy but not autoimmunity. Dautigny N, et al. **Eur J Immunol** 1996 Sep;26(9):2087–92
Carrier-reactive hapten-specific cytotoxic T lymphocyte clones originate from a highly preselected T cell repertoire: implications for chemical-induced self-reactivity. Martin S, et al. **Eur J Immunol** 1995 Oct;25(10):2788–96
Immunthrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity. Imbach P, et al. **Eur J Pediatr** 1995;154(9 Suppl 4):S60–4 (37 ref.)
Induction of IgA B cell differentiation of bone marrow-derived B cells by Peyer's patch autoreactive helper T cells. Kihira T, et al. **Immunol Invest** 1995 Aug; 24(5):701–11
Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Appelmelk BJ, et al. **Infect Immun** 1996 Jun;64(6):2031–40
Chronic experimental Chagas' disease: functional syngeneic T-B-cell cooperation in vitro in the absence of an exogenous stimulus. Freire-de-Lima C, et al. **Infect Immun** 1996 Jul;64(7):2861–6
Evaluation of presence and functional activity of potentially self-reactive T cells in aged mice. Crisi GM, et al. **Int Immunol** 1996 Mar;8(3):387–95
Costimulation in tolerance and autoimmunity. Guerder S, et al. **Int Rev Immunol** 1995;13(2):135–46 (49 ref.)
Atherosclerosis as an autoimmune condition. Kleindienst R, et al. **Isr J Med Sci** 1995 Oct;31(10):596–9 (26 ref.)
Antibodies against malondialdehyde (MDA) in MRL/lpr/lpr mice: evidence for an autoimmune mechanism involving lipid peroxidation. Yahya MD, et al. **J Autoimmun** 1996 Feb;9(1):3–9
Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. Singh RR, et al. **J Clin Invest** 1995 Dec;96(6):2990–6
Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: implications for antibody vs. T cell-mediated autoimmunity

[see comments] Singh RR, et al. **J Exp Med** 1996 Apr 1; 183(4):1613–21. Comment in: J Exp Med 1996 Apr 1;183(4):1297–301.

Autoimmune Sjögren's-like lesions in salivary glands of TGF-beta1-deficient mice are inhibited by adhesion-blocking peptides. McCartney-Francis NL, et al. **J Immunol** 1996 Aug 1;157(3):1306–12

The Hughlings Jackson Lecture: autoimmunity and the nervous system. Newsom-Davis J. **J R Soc Med** 1995 Nov; 88(11):639P–643P (20 ref.)

Lack of association between early exposure to cow's milk protein and beta-cell autoimmunity. Diabetes Autoimmunity Study in the Young (DAISY) [see comments] Norris JM, et al. **JAMA** 1996 Aug 28; 276(8):609–14. Comment in: JAMA 1996 Aug 28;276(8):647–8.

Cow's milk and insulin-dependent diabetes mellitus. Innocent until proven guilty [editorial; comment] Schatz DA, et al. **JAMA** 1996 Aug 28;276(8):647–8. Comment on: JAMA 1996 Aug 28;276(8):609–14.

Autoimmunity and onchocerciasis [letter; comment] Cooper PJ. **Lancet** 1996 Feb 10;347(8998):404. Comment on: Lancet 1995 Nov 18;346(8986):1311–2.

What can a worm teach us about autoimmunity? [see comments] Good MF. **Lancet** 1995 Nov 18; 346(8986):1311–2. Comment in: Lancet 1996 Feb 10;347(8998):404.

Polyamine involvement in the cell cycle, apoptosis, and autoimmunity. Brooks WH. **Med Hypotheses** 1995 May; 44(5):331–8

Reflections on an interface. Kennedy JR. **Med Hypotheses** 1995 Jul;45(1):45–7

The clinical significance of an autoimmune response against glutamic acid decarboxylase. Ellis TM, et al. **Nat Med** 1996 Feb;2(2):148–53 (30 ref.)

Recognition of mycobacterial HSP65 in association with HLA-DR4 is not sufficient for autoreactivity. Mustafa AS. **Nutrition** 1995 Sep-Oct;11(5 Suppl):661–4

Viruses, cytokines, antigens, and autoimmunity. Gianani R, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2257–9 (43 ref.)

Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Goodnow CC. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2264–71 (256 ref.)

A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Steinman L. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2253–6 (26 ref.)

Autoimmunity in Chagas' heart disease. Cunha-Neto E, et al. **Rev Paul Med** 1995 Mar-Apr;113(2):757–66 (39 ref.)

Interferon alfa and autoimmunity [letter; comment] Stricker RB. **South Med J** 1996 Jun;89(6):645. Comment on: South Med J 1996 Jan;89(1):81–3.

Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. Uchikoshi F, et al. **Transplantation** 1996 Jun 15;61(11):1629–36

[Autoimmunity and glutamate decarboxylase antibodies in the pathogenesis of type I diabetes mellitus in experimental and clinical practice] Kučera P, et al. **Vnitr Lek** 1996 May; 42(5):359–67 (65 ref.) (Eng. Abstr.) **(Cze)**

[Clinical assessment of autoimmune and immunocomplex reactions in patients with leptospirosis] Frolov VM, et al. **Klin Med (Mosk)** 1996;74(1):68 **(Rus)**

[Inner ear diseases of probable autoimmune origin and its response to steroid treatment] García Berrocal JR, et al. **Acta Otorrinolaringol Esp** 1995 Nov-Dec;46(6):416–20 (Eng. Abstr.) **(Spa)**

[Lichen sclerosus and atrophicus and autoimmunity (letter)] García-Porrúa C, et al. **Rev Clin Esp** 1995 Aug; 195(8):592–3 **(Spa)**

DRUG EFFECTS

Genetic susceptibility to silver-induced anti-fibrillarin autoantibodies in mice. Hultman P, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):291–7

Tumor necrosis factor mediates the protective effect of Freund's adjuvant against autoimmune diabetes in BB rats. Rabinovitch A, et al. **J Autoimmun** 1995 Jun;8(3):357–66

Effects of vitamin D3 and cyclosporin A on HgCl2-induced autoimmunity in brown Norway rats. Vendeville B, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2020–6

Enhanced T lymphocyte expression of LFA-1, ICAM-1, and the TNF receptor family member OX40 in HgCl2-induced systemic autoimmunity. Roos A, et al. **Scand J Immunol** 1996 May;43(5):507–18

No evidence for emergence of autoreactive V beta 6+ T cells in Mls-1a mice following exposure to a thymotoxic dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin. de Heer C, et al. **Toxicology** 1995 Dec 10;103(3):195–203

GENETICS

Gene hypothesis of autoimmunity, and autoimmune disease. Storch WB. **Adv Exp Med Biol** 1995;371B:1213–5 (22 ref.)

Genetic susceptibility to silver-induced anti-fibrillarin autoantibodies in mice. Hultman P, et al. **Clin Immunol Immunopathol** 1995 Dec;77(3):291–7

Stress modulates acute inflammation triggered by mycobacteria in autoimmunity-prone and normal mice. Martins TC, et al. **Inflamm Res** 1995 Sep;44(9):393–9

Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice—implications for autoimmunity. Liu GY, et al. **Int Immunol** 1995 Aug;7(8):1255–63

Dual T cell receptor alpha chain T cells in autoimmunity. Elliott JI, et al. **J Exp Med** 1995 Oct 1;182(4):953–9

Di- and trinucleotide target preferences of somatic mutagenesis in normal and autoreactive B cells. Smith DS, et al. **J Immunol** 1996 Apr 1;156(7):2642–52

IMMUNOLOGY

Cells involved in the regulation of the autoimmune response to rat male accessory glands. Rivero VE, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2579–89

The role of subsets of CD4+ T cells in autoimmunity. Fowell D, et al. **Ciba Found Symp** 1995;195:173–82; discussion 182–8 (42 ref.)

Autoimmunity and clonal B-cell expansion. Biological basis for therapeutic interventions. Udine, Italy, 15–16 March 1996. Conference proceedings. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S1–80

Identification of antigenic epitopes of 1D antigen recognized by antibodies in the serum of patients with thyroid-associated ophthalmopathy. Zhang ZG, et al. **Clin Immunol Immunopathol** 1995 Nov;77(2):193–200

Autoimmunity. The Fas track. Rathmell JC, et al. **Curr Biol** 1995 Nov 1;5(11):1218–21 (31 ref.)

Autoimmune mechanisms in chronic hepatitis B and delta virus infections. McFarlane BM, et al. **Eur J Gastroenterol Hepatol** 1995 Jul;7(7):615–21

Immune network and autoimmunity. George J, et al. **Intern Med** 1996 Jan;35(1):3–9 (49 ref.)

Absence of cellular responses to a putative autoantigen in onchocercal chorioretinopathy. Cellular autoimmunity in onchocercal chorioretinopathy. Cooper PJ, et al. **Invest Ophthalmol Vis Sci** 1996 Feb;37(2):405–12

Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. Delaney CP, et al. **J Clin Invest** 1996 Jan 1;97(1):217–25

Humoral and cell-mediated autoimmunity in allergy to Aspergillus fumigatus. Crameri R, et al. **J Exp Med** 1996 Jul 1;184(1):265–70

Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Albani S, et al. **Nat Med** 1995 May;1(5):448–52

Infection, evolution and autoimmunity: a hypothesis. Jones DE, et al. **QJM** 1995 Dec;88(12):919–25 (56 ref.)

Autoimmunity. Insights provided by the SCID mouse model. Jorgensen C, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep; 62(7–8):519–24 (38 ref.)

The two-signal model and 'self'-reactivity: are they really compatible? A reply to Faro & Carneiro. Cohn M. **Scand J Immunol** 1996 Jan;43(1):1–5; discussion 6–8 (8 ref.)

Dysregulation of T helper cell cytokines in autoimmune prone NZB x NZW F1 mice. Lin LC, et al. **Scand J Immunol** 1995 Oct;42(4):466–72

T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Weltzien HU, et al. **Toxicology** 1996 Feb 22;107(2):141–51 (54 ref.)

CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients. Soderberg C, et al. **Transplantation** 1996 Feb 27;61(4):594–600

[B-cell function and autoimmunity in humans] Zouali M. **Arch Inst Pasteur Tunis** 1994 Jul-Oct;71(3–4):511–6 (27 ref.) **(Fre)**

[Apoptosis (programmed cell death) in autoimmunity—autoimmunological aspect] George J, et al. **Harefuah** 1995 Nov 1;129(9):339–41 (27 ref.) **(Heb)**

[The characteristics of the autoimmune reactions in donors immunized with influenza vaccine and staphylococcal anatoxin] Krutitskaia LI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):44–7 (Eng. Abstr.) **(Rus)**

[Autoimmune reactions in rabbits induced by immunization and hyperimmunization] Krutitskaia LI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):50–1 **(Rus)**

PHYSIOLOGY

Autoimmunity in the peripheral nervous system. Hartung HP, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):1–45 (310 ref.)

Dietary fat influences Ia antigen expression, cytokines and prostaglandin E2 production of immune cells in autoimmune-prone NZB x NZW F1 mice. Lin BF, et al. **Br J Nutr** 1996 May;75(5):711–22

AUTOLOGOUS FIBRIN TISSUE ADHESIVE see **FIBRIN TISSUE ADHESIVE**

AUTOLYSIS

Behaviour of the yeast Kluyveromyces marxianus var. marxianus during its autolysis. Amrane A, et al. **Antonie Van Leeuwenhoek** 1996 Apr;69(3):267–72

[The effect of autolysis on characteristics of amino acid mixtures, obtained using ethanol-assimilating yeasts] Belousova NI, et al. **Prikl Biokhim Mikrobiol** 1995 Jul-Aug;31(4):458–62 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Some properties of the ecdysteroid receptor in the salivary gland of the ixodid tick, Amblyomma hebraeum. Mao H, et al. **Gen Comp Endocrinol** 1995 Sep;99(3):340–8

VETERINARY

Hepatocyte vacuolation and autolytic changes in the liver of pilot whales, Globicephala melas, stranded on Cape Cod, MA, USA. Moore MJ, et al. **Sci Total Environ** 1996 Jul 16;186(1–2):105–8

AUTOMATED MEDICAL RECORDS SYSTEMS see **MEDICAL RECORDS SYSTEMS, COMPUTERIZED**

AUTOMATED MULTIPHASIC HEALTH TESTING see **MULTIPHASIC SCREENING**

AUTOMATIC DATA PROCESSING

Development of computer-assisted patient control for use in the hospital setting during mass casualty incidents. Noordergraaf GJ, et al. **Am J Emerg Med** 1996 May; 14(3):257–61

Using bar-code technology to capture clinical intervention data in a hospital with a stand-alone pharmacy computer system. Scott MG, et al. **Am J Health Syst Pharm** 1996 Mar 15;53(6):651–4

Amino acid data processing [letter] Briddon A. **Ann Clin Biochem** 1995 Nov;32 (Pt 6):595

'Soundex' codes of surnames provide confidentiality and accuracy in a national HIV database. Mortimer JY, et al. **Commun Dis Rep CDR Rev** 1995 Nov 10;5(12):R183–6

Improving clinician's coded data entry through the use of an electronic patient record system: 3.5 years experience with a semiautomatic browsing and encoding tool in clinical routine. Hohnloser JH, et al. **Comput Biomed Res** 1996 Feb;29(1):41–7

Automated smear counting and data processing using a notebook computer in a biomedical research facility. Ogata Y, et al. **Health Phys** 1995 Oct;69(4):566–9

Electronic claims [letter; comment] Shulman I. **J Am Dent Assoc** 1996 Apr;127(4):424. Comment on: J Am Dent Assoc 1995 Dec;126(12):1670–3.

Intraoperative data acquisition for the study of cerebral dysfunction following cardiopulmonary bypass. Heyer EJ, et al. **J Clin Monit** 1995 Sep;11(5):305–10

Memorial Sloan-Kettering goes electronic to manage patient care [news] McIntosh H. **J Natl Cancer Inst** 1996 Aug 7;88(15):1024–6

Two miniature monitors for long-term ambulatory studies. Perkins MA, et al. **Med Eng Phys** 1995 Sep;17(6):410–5

Dimensional modeling: beyond data processing constraints. Bunardzic A. **Medinfo** 1995;8 Pt 1:520

Automated coding of patient discharge summaries using conceptual graphs. Delamarre D, et al. **Methods Inf Med** 1995 Sep;34(4):345–51

PDA response: electronic records; electronic signatures. Parenteral Drug Association. **PDA J Pharm Sci Technol** 1995 Sep-Oct;49(5):207–11

Data processing techniques for serial EIT spectroscopy images: a review of some preliminary results. Smallwood RH, et al. **Physiol Meas** 1995 Aug;16(3 Suppl A):A129–42 (37 ref.)

Teleform scannable data entry: an efficient method to update a community-based medical record? Community care coordination network Database Group. Guerette P, et al. **Proc Annu Symp Comput Appl Med Care** 1995;:86–90

Using data preprocessing and single layer perceptron to analyze laboratory data. Forsström JJ, et al. **Scand J Clin Lab Invest Suppl** 1995;222:75–81

Computer classification of sleep in preterm and full-term neonates at similar postconceptional term ages. Scher MS, et al. **Sleep** 1996 Jan;19(1):18–25

[Electronic identification companion animals. 'Be sensible and wait!'] Deleu S. **Tijdschr Diergeneeskd** 1995 Dec 15; 120(24):734 **(Dut)**

[Computer program for improved diagnostic coding in ophthalmology based on the expanded ICD 10] Kuchenbecker J, et al. **Klin Monatsbl Augenheilkd** 1995 Jul;207(1):46–50 (Eng. Abstr.) **(Ger)**

[Computer-assisted classification of ICD-9/10 and IKPM in compliance with the new federal health care regulation—practice-oriented solution for trauma surgery and orthopedics] Deimel D, et al. **Unfallchirurg** 1995 Oct; 98(10):545–50 (Eng. Abstr.) **(Ger)**

[An attempt of applying the image processing for the automatic estimation of sampled airborne pollen] Kawashima S, et al. **Arerugi** 1995 Sep;44(9):1150–8 (Eng. Abstr.) **(Jpn)**

[From informatics as an obstacle to informatics as an excuse: looking towards the future (editorial)] Alonso López FA, et al. **Aten Primaria** 1995 Dec;16(10):579–80, 582 **(Spa)**

INSTRUMENTATION

[An automated system for public opinion polling on life style, health status and health behavior] Kochin IV, et al. **Vrach Delo** 1995 Jan-Feb;(1–2):151–3 (Eng. Abstr.) **(Ukr)**

METHODS

Rapid accurate entry of microbiology results. Aller RD, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):57–61

A technique for the computerized identification of orthodontic instruments. Jones ML, et al. **Br J Orthod** 1995 Aug;22(3):269–71

A simplified procedure for entry of raw genotypic data. Rohrer GA, et al. **J Comput Biol** 1994 Summer;1(2):111–9

[The use of computer technology for the processing of coagulograms in clinical studies] Kotov IuB. **Klin Lab Diagn** 1995 Nov–Dec;(6):86–7 **(Rus)**

STANDARDS

Danger in the interpretation of polyester–bag method parameters fitted by computer software [letter] [see comments] Sandoval–Castro CA. **Br J Nutr** 1996 Jan; 75(1):140–2. Comment in: Br J Nutr 1996 Jan;75(1):142–8.

STATISTICS & NUMERICAL DATA

[Electronic data processing in the physician's practice] Lamers WM. **Arch Gynecol Obstet** 1995;257(1–4):658–66 **(Ger)**

AUTOMATION

Developing policies for automated speed enforcement: a survey of Michigan opinions. Streff FM, et al. **Accid Anal Prev** 1995 Aug;27(4):611–6

Work activities before and after implementation of an automated dispensing system. Guerrero RM, et al. **Am J Health Syst Pharm** 1996 Mar 1;53(5):548–54

Improving organizational processes for gains during implementation. FitzHenry F, et al. **Comput Nurs** 1996 May–Jun;14(3):171–80; quiz 181–2

A survey of automatic teller machine usage across the adult life span. Rogers WA, et al. **Hum Factors** 1996 Mar; 38(1):156–66

Endoscope decontamination: automated vs. manual. Bradley CR, et al. **J Hosp Infect** 1995 Jun;30 Suppl:537–42

An automated method for dynamic ligand design. Miranker A, et al. **Proteins** 1995 Dec;23(4):472–90

INSTRUMENTATION

Psychophysiology and adaptive automation. Byrne EA, et al. **Biol Psychol** 1996 Feb 5;42(3):249–68 (75 ref.)

AUTOMATION, OFFICE see **OFFICE AUTOMATION**

AUTOMATISM

Automaticity of social behavior: direct effects of trait construct and stereotype–activation on action. Bargh JA, et al. **J Pers Soc Psychol** 1996 Aug;71(2):230–44

Automatism re–visited: post–traumatic automatism as a defence to a serious criminal charge. Wright N, et al. **Med Sci Law** 1995 Oct;35(4):327–32

[Uncommon reflex automatisms after brain death] Awada A. **Rev Neurol (Paris)** 1995 Oct;151(10):586–8 (11 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Structure of mental disorders and diagnostic criteria. On Clerambault syndrome] Marchais P. **Ann Med Psychol (Paris)** 1996 May;154(2):126–30; discussion 130–1 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Paroxysmal staring and masticatory automatisms during postural hypotension in a patient with multiple system atrophy. Iani C, et al. **Epilepsia** 1996 Jul;37(7):690–3

HISTORY

The evolution and definition of the concept of 'automatism' in Canadian case law. Jang D, et al. **Med Law** 1995; 14(3–4):221–38 (22 ref.)

AUTOMOBILE DRIVER EXAMINATION

Some implications of driver training for road accidents in Gaborone. Oladiran MT, et al. **Accid Anal Prev** 1995 Aug; 27(4):583–90

Neuropsychological driving fitness tests for brain–damaged subjects. Korteling JE, et al. **Arch Phys Med Rehabil** 1996 Feb;77(2):138–46

How much blame can be placed on laser photocoagulation for failure to attain driving standards [letter] Buckley SA, et al. **Eye** 1996;10 (Pt 3):404–5

How much blame can be placed on laser photocoagulation for failure to attain driving standards? Mackie SW, et al. **Eye** 1995;9 (Pt 4):517–25

Two new stereotests for long distance: examination of stereopsis with regard to the permission of driving. Fleck R, et al. **Ger J Ophthalmol** 1996 Jan;5(1):53–9

Medical screening of older drivers as a traffic safety measure—a comparative Finnish–Swedish evaluation study. Hakamies–Blomqvist L, et al. **J Am Geriatr Soc** 1996 Jun;44(6):650–3

Occupational and nonoccupational correlates of alcohol consumption in urban transit operators. Ragland DR, et al. **Prev Med** 1995 Nov;24(6):634–45

LEGISLATION & JURISPRUDENCE

An evaluation of the New Zealand graduated driver licensing system. Langley JD, et al. **Accid Anal Prev** 1996 Mar; 28(2):139–46

[Congenital nystagmus in the ophthalmologic automobile driving fitness verdict] Piper HF, et al. **Klin Monatsbl Augenheilkd** 1995 Aug;207(2):123–9 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Young novice drivers: towards a model of their accident involvement. Gregersen NP, et al. **Accid Anal Prev** 1996 Mar;28(2):229–41

The relationship of age and state license renewal policies to driving licensure rates. Levy DT. **Accid Anal Prev** 1995 Aug;27(4):461–7

AUTOMOBILE DRIVING

see related
ACCIDENTS, TRAFFIC
MOTOR VEHICLES

How drivers sit in cars. Parkin S, et al. **Accid Anal Prev** 1995 Dec;27(6):777–83

Rejoinder to Hemenway [letter; comment] Peck RC. **Accid Anal Prev** 1995 Aug;27(4):617. Comment on: Accid Anal Prev 1994 Feb;26(1):127–9.

Trends in highway safety: effects of an aging population on accident propensity. Stamatiadis N, et al. **Accid Anal Prev** 1995 Aug;27(4):443–59

The geography of availability and driving after drinking. Gruenewald PJ, et al. **Addiction** 1996 Jul;91(7):967–83

The diagnostic value of BAC for identifying alcohol–related problems among DWI offenders: another look. Lucker GW, et al. **Am J Drug Alcohol Abuse** 1995 Nov; 21(4):573–80

Simulated driving performance in patients with obstructive sleep apnea. George CF, et al. . **Am J Respir Crit Care Med** 1996 Jul;154(1):175–81

Crasnes and violations among drivers with Alzheimer disease. Trobe JD, et al. **Arch Neurol** 1996 May;53(5):411–6

Who develops PTSD from motor vehicle accidents? Blanchard EB, et al. **Behav Res Ther** 1996 Jan;34(1):1–10

Medical aspects of fitness to drive. Assessments should be independent [letter] Finlay F, et al. **BMJ** 1995 Oct 28; 311(7013):1163

Pregnant women should wear seat belts [letter] Griffiths M. **BMJ** 1995 Dec 2;311(7018):1501

Medical aspects of fitness to drive. Rigid rules for hypomanic patients are unfair [letter] Halloran E. **BMJ** 1995 Oct 28; 311(7013):1163

Air pollution related to transport. Diesel is the main problem [letter] Jones RR. **BMJ** 1996 Jun 22;312(7046):1605–6

Medical aspects of fitness to drive. Unfit patients are a common and difficult problem [letter] Morris DE. **BMJ** 1995 Oct 28;311(7013):1162

Medical aspects of fitness to drive. Enabling patients to drive is also important [letter] O'Neill D. **BMJ** 1995 Oct 28; 311(7013):1162–3

Patients taking stable doses of morphine may drive [letter] Smith AM. **BMJ** 1996 Jan 6;312(7022):56–7

Road traffic noise and psychiatric disorder: prospective findings from the Caerphilly Study. Stansfeld S, et al. **BMJ** 1996 Aug 3;313(7052):266–7

Advice to car drivers with rheumatoid arthritis [letter] Dawson JK, et al. **Br J Rheumatol** 1995 Aug;34(8):796–7

Environmental air pollution and DNA adducts in Copenhagen bus drivers—effect of GSTM1 and NAT2 genotypes on adduct levels. Nielsen PS, et al. **Carcinogenesis** 1996 May;17(5):1021–7

Epidemiology of HIV infection among long distance truck drivers in Kenya. Mbugua GG, et al. **East Afr Med J** 1995 Aug;72(8):515–8

Speeding in relation to perceptions of risk, utility and driving style by British company car drivers. Adams–Guppy JR, et al. **Ergonomics** 1995 Dec;38(12):2525–35

Drugs usage of drivers suspected of driving under the influence of alcohol and/or drugs. A study of one week's samples in 1979 and 1993 in Finland. Lillsunde P, et al. **Forensic Sci Int** 1996 Jan 12;77(1–2):119–29

Female drivers suspected for drunken or drugged driving. Skurtveit S, et al. **Forensic Sci Int** 1995 Oct 30; 75(2–3):139–48

The older driver: a handy tool to assess competence behind the wheel. Wiseman EJ, et al. **Geriatrics** 1996 Jul; 51(7):36–8, 41–2, 45

Injuries related to car crime: the joy–riding epidemic. Marshall C, et al. **Injury** 1996 Mar;27(2):79–80

The exposure of cyclists, car drivers and pedestrians to traffic–related air pollutants. van Wijnen JH, et al. **Int Arch Occup Environ Health** 1995;67(3):187–93

The "co–pilot" driver syndrome [see comments] Shua–Haim JR, et al. **J Am Geriatr Soc** 1996 Jul;44(7):815–7. Comment in: J Am Geriatr Soc 1996 Jul;44(7):876–7.

Acute bilateral adrenal hemorrhage secondary to rough truck ride. Ikekpeazzu N, et al. **J Emerg Med** 1996 Jan–Feb; 14(1):15–8

Methamphetamine and driving impairment. Logan BK. **J Forensic Sci** 1996 May;41(3):457–64 (37 ref.)

Screening for urinary amphetamine in truck drivers and drug addicts. Pidetcha P, et al. **J Med Assoc Thai** 1995 Oct; 78(10):554–8

Risk of accidents in drivers with epilepsy. Taylor J, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):621–7

Sleepiness and performance of professional drivers in a truck simulator—comparisons between day and night driving. Gillberg M, et al. **J Sleep Res** 1996 Mar;5(1):12–5

Sleepiness, snoring and driving habits. Hanning CD, et al. **J Sleep Res** 1996 Mar;5(1):51–4

Urine toxicology screens in drivers suspected of driving while impaired from drugs. Tomaszewski C, et al. **J Toxicol Clin Toxicol** 1996;34(1):37–44

Traffic safety experts prescribe treatment, sanctions to improve driving [news] Cole TB. **JAMA** 1995 Nov 22–29; 274(20):1571–3

Older drivers and physicians [editorial; comment] Martinez R. **JAMA** 1995 Oct 4;274(13):1060. Comment on: JAMA 1995 Oct 4;274(13):1026–30.

Driving and Alzheimer disease [letter; comment] Mattes JA. **JAMA** 1996 Jan 17;275(3):182; discussion 182–3. Comment on: JAMA 1995 May 3;273(17):1360–5.

Driving and Alzheimer disease [letter; comment] Weintraub MI. **JAMA** 1996 Jan 17;275(3):182; discussion 182–3. Comment on: JAMA 1995 May 3;273(17):1360–5.

Alcohol and driving. Alvarez FJ, et al. **Lancet** 1996 Apr 13;347(9007):985–6

Driving and the implantable cardioverter defibrillator. Study Group on ICD and Driving [letter] Jung W, et al. **Lancet** 1996 Sep 7;348(9028):687–8

Breast cancer: a significant causal relationship. Robinson AA. **Med Hypotheses** 1996 May;46(5):483–5

Are cycling, physical exercise and traffic fumes compatible? [letter] Gapella JP. **Med J Aust** 1996 Feb 5;164(3):192

Roadside driver alcohol survey and hospital alcohol survey in Port Moresby, Papua New Guinea. Attah Johnson FY, et al. **Med Law** 1995;14(3–4):157–61

Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability. Watanabe A, et al. **Metab Brain Dis** 1995 Sep;10(3):239–48

Which parts of the road guide steering? Land M, et al. **Nature** 1995 Sep 28;377(6547):339–40

Myocardial infarction among male bus, taxi, and lorry drivers in middle Sweden. Gustaysson P, et al. **Occup Environ Med** 1996 Apr;53(4):235–40

Q.E.D. saliva testing isn't flawed [letter] Hinchey WM. **Occup Health Saf** 1996 May;65(5):10

Night driving: effects of glare from vehicle headlights on motion perception. Anderson SJ, et al. **Ophthalmic Physiol Opt** 1995 Nov;15(6):545–51

Deterioration of the high–mounted brake light. Cameron DL. **Percept Mot Skills** 1995 Oct;81(2):418

Factors related to driving in persons with an implantable cardioverter defibrillator. Craney JM, et al. **Prog Cardiovasc Nurs** 1995 Summer;10(3):12–7

Driving appliances for upper limb amputees. Verrall T, et al. **Prosthet Orthot Int** 1995 Aug;19(2):124–7

Review of regulations and guidelines for commercial and noncommercial drivers with sleep apnea and narcolepsy. Pakola SJ, et al. **Sleep** 1995 Nov;18(9):787–96

A polysomnographically documented case of adult somnambulism with long–distance automobile driving and frequent nocturnal violence: parasomnia with continuing danger as a noninsane automatism? Schenck CH, et al. **Sleep** 1995 Nov;18(9):765–72

Physicians need to know disabled parking guidelines. Pietrobono J. **Tex Med** 1995 Dec;91(12):39–40

[Is there a relationship between alcoholism and the chance of traffic accidents? (letter; comment)] van Pelt J. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2758. Comment on: Ned Tijdschr Geneeskd 1995 Oct 7;139(40):2020–3. **(Dut)**

[Drunkenness in traffic in Geneva: occasional abuse or alcoholism?] Michiels W, et al. **Soz Praventivmed** 1996; 41(1):28–35 (Eng. Abstr.) **(Fre)**

[Drunkenness in traffic in Geneva: distribution and detection] Michiels W, et al. **Soz Praventivmed** 1996;41(1):19–27 (Eng. Abstr.) **(Fre)**

[Test performance with minimal alcoholic intoxication] Bartl G, et al. **Blutalkohol** 1996 Jan;33(1):1–16 (Eng. Abstr.) **(Ger)**

[Driving of a motor vehicle after implantation of a cardioverter–defibrillator in malignant heart rhythm disorders. Criteria for the medical assessment of driving fitness in Europe] Lüderitz B, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):119–23 (Eng. Abstr.) **(Ger)**

[Iatrogenic driving incapacity] Beer JH, et al. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):584–93 (46 ref.) (Eng. Abstr.) **(Ger)**

[Symposium on drowsy driver—a round–table discussion. Sheba Medical Center, Tel–Hashomer, June 6, 1995] Askenasy JM. **Harefuah** 1996 Jan 1;130(1):58–62 **(Heb)**

[Cardiovascular diseases in motor vehicle drivers and traffic safety] El'garov AA, et al. **Med Tr Prom Ekol** 1995;(6):10–3 (Eng. Abstr.) **(Rus)**

[The work capacity expertise of motor vehicle drivers suffering from IHD with rhythm disorders and the possibilities for their social and vocational rehabilitation] Petrov MN, et al. **Ter Arkh** 1995;67(9):21–3 (Eng. Abstr.) **(Rus)**

[Automobile driving by the aged] Cortés Blanco M. **Rev Esp Salud Publica** 1995 Mar–Apr;69(2):189–93 (Eng. Abstr.) **(Spa)**

[The presence of pathological processes among spanish drivers: its relevance to road safety] Prada Pérez R, et al. **Rev Esp Salud Publica** 1995 Nov–Dec;69(6):499–508 (Eng. Abstr.) **(Spa)**

[Neurological diseases and driving] Mola S. **Rev Neurol** 1995 Mar–Apr;23(120):334–50 (139 ref.) (Eng. Abstr.) **(Spa)**

EDUCATION

Young drivers' overestimation of their own skill—an experiment on the relation between training strategy and skill. Gregersen NP. **Accid Anal Prev** 1996 Mar; 28(2):243–50

Some implications of driver training for road accidents in Gaborone. Oladiran MT, et al. **Accid Anal Prev** 1995 Aug; 27(4):583–90

LEGISLATION & JURISPRUDENCE

Differences in young driver crash involvement in states with varying licensure practices. Ferguson SA, et al. **Accid Anal Prev** 1996 Mar;28(2):171–80

Developing policies for automated speed enforcement: a survey of Michigan opinions. Streff FM, et al. **Accid Anal Prev** 1995 Aug;27(4):611–6

Lowering state legal blood alcohol limits to 0.08%: the effect on fatal motor vehicle crashes. Hingson R, et al. **Am J Public Health** 1996 Sep;86(9):1297–9

Enforcement of drunken driving laws in cases involving injured intoxicated drivers. Runge JW, et al. **Ann Emerg Med** 1996 Jan;27(1):66–72

Air pollution related to transport. Doctors should support parliamentary bill [letter] Hill S. **BMJ** 1996 Jun 22; 312(7046):1606

Alcohol purchase age laws and the serial beginning drinker in New York. Yu J. **Int J Addict** 1995 Aug;30(10):1289–301

Should Alzheimer's disease patients be allowed to drive? A medical, legal, and ethical dilemma [editorial; comment] Freedman ML, et al. **J Am Geriatr Soc** 1996 Jul;44(7):876–7 . Comment on: J Am Geriatr Soc 1996 Jul;44(7):815–7.

Driving vision [letter; comment] Rosenwasser HM. **J Am Optom Assoc** 1995 Oct;66(10):602. Comment on: J Am Optom Assoc 1995 Jun;66(6):343–51.

MADD's position on alcohol advertising: a response to Marshall and Oleson [comment] DeJong W, et al. **J Public Health Policy** 1995;16(2):231–8. Comment on: J Public Health Policy 1994 Spring;15(1):54–70.

Characteristics of fatal crashes of 16-year-old drivers: implications for licensure policies. Williams AF, et al. **J Public Health Policy** 1995;16(3):347–60

Relationship between driver's license renewal policies and fatal crashes involving drivers 70 years or older [see comments] Levy DT, et al. **JAMA** 1995 Oct 4; 274(13):1026–30. Comment in: JAMA 1995 Oct 4;274(13):1060.

Epidemiological perspectives on alcohol and the law [letter] Girard M. **Lancet** 1996 Jun 22;347(9017):1772

Driving and the implantable cardioverter defibrillator [letter] Petch MC. **Lancet** 1996 Aug 3;348(9023):339

Drink driving legislation: medicine and the law. Marks P. **Med Leg J** 1995;63 (Pt 3):119–27 (17 ref.)

Visual field defects due to spectacle frames: their prediction and relationship to UK driving standards. Steel SE, et al. **Ophthalmic Physiol Opt** 1996 Mar;16(2):95–100

The older driver—a review. Morgan R, et al. **Postgrad Med J** 1995 Sep;71(839):525–8 (30 ref.)

[Joy riding: multiple criminal car rides in an intoxicated state in relation to dyssocial personality with addictive tendencies] Knecht T. **Arch Kriminol** 1995 Jul–Aug; 196(1–2):1–5 (Eng. Abstr.) **(Ger)**

[Lowering the promille limit?] Bialas B. **Blutalkohol** 1996 May;33(3):142–51 (Eng. Abstr.) **(Ger)**

[Revoked driving right—a blunt weapon? (comment) (see comments)] Bode HJ. **Blutalkohol** 1995 Nov;32(6):314–6 (Eng. Abstr.). Comment on: Blutalkohol 1995 Sep;32(5):254–67. Comment in: Blutalkohol 1996 Jan;33(1):44–6. **(Ger)**

[Change in automobile driving capacity assessment—a contribution to the correlation between diagnosis and therapy] Pund B, et al. **Blutalkohol** 1996 Jan;33(1):31–43 (Eng. Abstr.) **(Ger)**

[Determining the duration of suspended license for alcohol intoxicated drivers] Winkler W. **Blutalkohol** 1995 Nov; 32(6):305–13 (Eng. Abstr.) **(Ger)**

[Alcohol and aggression—violence prone drivers preventing passing maneuvers] Zabel GE. **Blutalkohol** 1996 Mar; 33(2):84–93 (Eng. Abstr.) **(Ger)**

[Revoking the right to drive—a blunt weapon against alcohol intoxicated drivers, hit-and-run drivers and speed limit and red light offenders? (see comments)] Zabel GE. **Blutalkohol** 1995 Sep;32(5):254–67 (56 ref.) (Eng. Abstr.). Comment in: Blutalkohol 1995 Nov;32(6):314–6. **(Ger)**

[Driving ban—a blunt weapon? Response to the comment by Bode (letter; comment)] Zabel RG. **Blutalkohol** 1996 Jan;33(1):44–6. Comment on: Blutalkohol 1995 Nov;32(6):314–6. **(Ger)**

[Basic principles of medical confidentiality within the scope of traffic safety] Schlund GH. **Chirurg** 1995 Sep;66(9):suppl 212–7 **(Ger)**

PSYCHOLOGY

The effects of a mobile telephone task on driver behaviour in a car following situation. Alm H, et al. **Accid Anal Prev** 1995 Oct;27(5):707–15

Enhanced tiredness among young impaired male nighttime drivers. Corfitsen MT. **Accid Anal Prev** 1996 Mar; 28(2):155–62

Behavioural characteristics and involvement in different types of traffic accident. Parker D, et al. **Accid Anal Prev** 1995 Aug;27(4):571–81

Bicycle accidents and drivers' visual search at left and right turns. Summala H, et al. **Accid Anal Prev** 1996 Mar; 28(2):147–53

Effect of driving speed on reaction time during motorway driving. Törnros J. **Accid Anal Prev** 1995 Aug;27(4):435–42

The dominant role of driver behavior in traffic safety [comment] Evans L. **Am J Public Health** 1996 Jun; 86(6):784–6. Comment on: Am J Public Health 1996 Jun;86(6):791–7.

Spatial reference frames and driver performance. Rogé J. **Ergonomics** 1996 Sep;39(9):1134–45

Road traffic offending, stress, age, and accident history among male and female drivers. Simon F, et al. **Ergonomics** 1996 May;39(5):757–80

Rural elders and the decision to stop driving. Johnson JE. **J Community Health Nurs** 1995;12(3):131–8

Visual control of braking: a test of the tau hypothesis. Yilmaz EH, et al. **J Exp Psychol Hum Percept Perform** 1995 Oct; 21(5):996–1014

The Driving Expectancy Questionnaire: development, psychometric assessment and predictive utility among young drink-drivers. Deery HA, et al. **J Stud Alcohol** 1996 Mar;57(2):193–202

College students' decisions to intervene in alcohol-related situations. Thomas RW, et al. **J Stud Alcohol** 1995 Sep; 56(5):580–8

Automobile driving in Huntington's disease. Rebok GW, et al. **Mov Disord** 1995 Nov;10(6):778–87

Color-specificity to enhance identification of rear lights. Cameron DL. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):755–69

Memory for parking location in large lots. Means LW, et al. **Psychol Rep** 1995 Jun;76(3 Pt 1):775–9

[Self-assessment of blood alcohol content in acute alcoholic intoxication] Seidl S, et al. **Blutalkohol** 1996 Jan;33(1):23–30 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Rejoinder to Mannering [letter; comment] Peck RC. **Accid Anal Prev** 1995 Aug;27(4):618–21. Comment on: Accid Anal Prev 1994 Feb;26(1):130–3.

Rollovers on sideslopes and ditches. Viner JG. **Accid Anal Prev** 1995 Aug;27(4):483–91

Drinking and driving among Ontario high school students, 1977–1995. Stoduto G, et al. **Can J Public Health** 1996 May–Jun;87(3):187–8

Drinking by police officers, general drivers and late-night drivers. Meyers AR, et al. **J Stud Alcohol** 1996 Mar; 57(2):187–92

The prevalence of drivers in acute geriatric wards. Morgan R, et al. **Postgrad Med J** 1995 Oct;71(840):590–2

[Automobile driving with alcohol impaired abilities in young people from rural areas in Quebec: a comparison of the years 1983 and 1992] Audet T, et al. **Can J Public Health** 1995 Sep–Oct;86(5):333–4 **(Fre)**

AUTOMOBILE EXHAUST see **VEHICLE EMISSIONS**

AUTOMOBILES

see related
AIR BAGS
SEAT BELTS

Effectiveness estimates for center high mounted stop lamps: a six-year study. Farmer CM. **Accid Anal Prev** 1996 Mar; 28(2):201–8

Compatibility considerations for low-mass rigid-belt vehicles. Niederer PF, et al. **Accid Anal Prev** 1995 Aug; 27(4):551–60

How drivers sit in cars. Parkin S, et al. **Accid Anal Prev** 1995 Dec;27(6):777–83

The influence of seat-back and head-restraint properties on the head-neck motion during rear-impact. Svensson MY, et al. **Accid Anal Prev** 1996 Mar;28(2):221–7

Daytime running lights as a vehicle collision countermeasure: the Swedish evidence reconsidered. Theeuwes J, et al. **Accid Anal Prev** 1995 Oct;27(5):633–42

Selenium levels in the serum of workers at a rubber tire repair shop. Sánchez-Ocampo A, et al. **Am Ind Hyg Assoc J** 1996 Jan;57(1):72–5

Race, gender, and the response to stress: autoworkers' vulnerability to long-term unemployment. Broman CL, et al. **Am J Community Psychol** 1995 Dec;23(6):813–42

Hanging in an automobile: a report on a unique case history. Durso S, et al. **Am J Forensic Med Pathol** 1995 Dec; 16(4):352–4

Characteristics of forearm-hand exposure in relation to symptoms among automobile assembly line workers. Fransson-Hall C, et al. **Am J Ind Med** 1996 Jan;29(1):15–22

Responsiveness of auto makers to a simple public health initiative [letter] Elliott SJ. **Am J Prev Med** 1995 Jul–Aug; 11(4):213

Thermal aspects of vehicle comfort. Holmér I, et al. **Appl Human Sci** 1995 Jul;14(4):159–65 (19 ref.)

Surface electromyography as a tool to study the head rest comfort in cars. Lamotte T, et al. **Ergonomics** 1996 May; 39(5):781–96

Predictors of hearing protection use among workers: implications for training programs. Lusk SL, et al. **Hum Factors** 1995 Sep;37(3):635–40

Prediction of traffic noise: a screening technique. Barboza MJ, et al. **J Air Waste Manag Assoc** 1995 Sep;45(9):703–8

Heat exposure in an enclosed automobile. Gibbs LI, et al. **J La State Med Soc** 1995 Dec;147(12):545–6

Self-reported physical exposure and musculoskeletal symptoms of the forearm-hand among automobile assembly-line workers. Fransson-Hall C, et al. **J Occup Environ Med** 1995 Sep;37(9):1136–44

From the Centers for Disease Control and Prevention. Carbon monoxide poisonings associated with snow-obstructed vehicle exhaust systems—Philadelphia and New York City, January 1996. **JAMA** 1996 Feb 14; 275(6):426–7

From the Centers for Disease Control and Prevention. Air-bag-associated fatal injuries to infants and children riding in front passenger seats—United States. **JAMA** 1995 Dec 13;274(22):1752–3

Breast cancer: a significant causal relationship. Robinson AA. **Med Hypotheses** 1996 May;46(5):483–5

Biopsy-confirmed hypersensitivity pneumonitis in automobile production workers exposed to metalworking fluids—Michigan, 1994–1995. **MMWR Morb Mortal Wkly Rep** 1996 Jul 19;45(28):606–10

Air-bag-associated fatal injuries to infants and children riding in front passenger seats—United States. **MMWR Morb Mortal Wkly Rep** 1995 Nov 17;44(45):845–7

Carbon monoxide poisonings associated with snow-obstructed vehicle exhaust systems—Philadelphia and New York City, January 1996. **MMWR Morb Mortal Wkly Rep** 1996 Jan 12;45(1):1–3

Exposure to glycols and their renal effects in motor servicing workers. Laitinen J, et al. **Occup Med (Oxf)** 1995 Oct; 45(5):259–62

A descriptive study of health problems on car mechanics' hands. Moen BE, et al. **Occup Med (Oxf)** 1995 Dec; 45(6):318–22

Safe transportation of premature and low birth weight infants. American Academy of Pediatrics. Committee on Injury and Poison Prevention and Committee on Fetus and Newborn. **Pediatrics** 1996 May;97(5):758–60

Selecting and using the most appropriate car safety seats for growing children: guidelines for counseling parents. American Academy of Pediatrics. Committee on Injury and Poison Prevention. **Pediatrics** 1996 May;97(5):761–3

Instantaneous change in sleep stage with noise of a passing truck. Kawada T, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):1031–40

[The toxic hygiene problems of workers in the Dinamik automobile tire plant in Sofia] Ivanova-Chemishanska L, et al. **Probl Khig** 1995;20:138–45 (Eng. Abstr.) **(Bul)**

[The cytogenetic effects (the frequency of micronuclei) in lymphocyte cultures from the peripheral blood of workers in automobile tire manufacture] Mirkova E, et al. **Probl Khig** 1995;20:146–62 (Eng. Abstr.) **(Bul)**

[Reconstruction of the explosion site of a hand granade on an automobile seat] Biermann TW, et al. **Arch Kriminol** 1995 Sep-Oct;196(3–4):105–13 (Eng. Abstr.) **(Ger)**

[Application of neurobehavioral tests in a manufacturing automotive parts factory] Ohnishi A, et al. **Sangyo Ika Daigaku Zasshi** 1995 Sep 1;17(3):165–72 (Eng. Abstr.) **(Jpn)**

[A physician in Gothenburg wanted to test something new. A private emergency call car improved quality of life] Orn P. **Lakartidningen** 1995 Nov 15;92(46):4292–3 **(Swe)**

CLASSIFICATION

Can emergency physicians correlate between vehicle damage and velocity change? Ros SP, et al. **Pediatr Emerg Care** 1995 Oct;11(5):277–9

HISTORY

The physician automobilist. Dumesic DA. **J Hist Med Allied Sci** 1996 Apr;51(2):208–22

LEGISLATION & JURISPRUDENCE

Protecting children in cars from tobacco smoke [letter] Bauman A, et al. **BMJ** 1995 Oct 28;311(7013):1164

Australia aims for smoke free cars and Olympics [news] Zinn C. **BMJ** 1995 Dec 2;311(7018):1455

STANDARDS

Alcohol interventions in trauma centers [letter; comment] Gitlitz GF. **JAMA** 1996 Feb 7;275(5):358. Comment on: JAMA 1995 Oct 4;274(13):1043–8.

STATISTICS & NUMERICAL DATA

Rejoinder to Field and Clarke [letter; comment] Hazelbaker KL. **Accid Anal Prev** 1995 Aug;27(4):622. Comment on: Accid Anal Prev 1993 Jun;25(3):297–306.

Differences in mortality by housing tenure and by car access from the OPCS Longitudinal Study. Filakti H, et al.

Popul Trends 1995 Autumn;(81):27-30

AUTONOMIC AGENTS

THERAPEUTIC USE

Cisapride for children with intractable constipation: an interim verdict! [editorial; comment] Loening-Baucke V. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):3-5. Comment on: J Pediatr Gastroenterol Nutr 1996 Jan;22(1):38-44.

AUTONOMIC DENERVATION

Transcutaneous neuromuscular electrical stimulation effect on the degree of microvascular perfusion in autonomically denervated rat skeletal muscle. Clemente FR, et al. **Arch Phys Med Rehabil** 1996 Feb;77(2):155-60

Denervation, but not decentralization, reduces nerve growth factor content of the mesenteric artery. Liu DT, et al. **J Neurochem** 1996 Jun;66(6):2295-9

AUTONOMIC FIBERS, POSTGANGLIONIC

ENZYMOLOGY

Nitric oxide synthase and chemical coding in cat sympathetic postganglionic neurons. Anderson CR, et al. **Neuroscience** 1995 Sep;68(1):255-64

PHYSIOLOGY

The ratio of pre- to postganglionic neurons and related issues in the autonomic nervous system. Wang FB, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):93-115 (260 ref.)

AUTONOMIC FIBERS, PREGANGLIONIC

ANATOMY & HISTOLOGY

The spinal sympathetic preganglionic cell column in the puffer fish, Takifugu niphobles. Funakoshi K, et al. **Cell Tissue Res** 1996 Apr;284(1):111-6

CHEMISTRY

Oxytocinergic innervation to the upper thoracic sympathetic preganglionic neurons in the rat. A light and electron microscopical study using a combined retrograde transport and immunocytochemical technique. Hosoya Y, et al. **Exp Brain Res** 1995;107(1):9-16

CYTOLOGY

Synaptic contact of neuropeptide-and amine-containing axons on parasympathetic preganglionic neurons in the superior salivatory nucleus of the rat. Nemoto T, et al. **Brain Res** 1995 Jul 10;685(1-2):33-45

Kinetics of A-currents in sympathetic preganglionic neurones and glial cells. Bordey A, et al. **Neuroreport** 1995 Dec 29;7(1):37-40

Vagal preganglionic neurons innervating the different gastric regions in the Japanese quail (Coturnix japonica). Iizuka Y, et al. **Okajimas Folia Anat Jpn** 1995 Aug;72(2-3):149-62

DRUG EFFECTS

Effects of 5-HT and 5-HT1A receptor agonists and antagonists on dorsal vagal preganglionic neurones in anaesthetized rats: an ionophoretic study. Wang Y, et al. **Br J Pharmacol** 1995 Oct;116(4):2291-7

Calcium-activated release of nitric oxide potentiates excitatory synaptic potentials in immature rat sympathetic preganglionic neurons. Wu SY, et al. **J Neurophysiol** 1995 Dec;74(6):2600-3

Sub-nanomolar concentrations of ciguatoxin-1 excite preganglionic terminals in guinea pig sympathetic ganglia. Hamblin PA, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Aug; 352(2):236-46

[A pharmacological analysis of the central control of the preganglionic sympathetic neurons during stimulation of the afferent nerve fibers of the digestive tract] Itina LV, et al. **Fiziol Zh Im I M Sechenova** 1995 Dec;81(12):164-74 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

A comparative study of NADPH-diaphorase in the sympathetic preganglionic neurons of the upper thoracic cord between spontaneously hypertensive rats and Wistar-Kyoto rats. Tang FR, et al. **Brain Res** 1995 Sep 11;691(1-2):153-9

PHYSIOLOGY

Pre-sympathetic neurones in the rostral ventrolateral medulla of the rat: electrophysiology, morphology and relationship to adjacent neuronal groups. Lipski J, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):373-84 (44 ref.)

Angiotensin II decreases a resting K+ conductance in rat bulbospinal neurons of the C1 area. Li YW, et al. **Circ Res** 1996 Feb;78(2):274-82

Monosynaptic projections from the medullary gigantocellular reticular formation to sympathetic preganglionic neurons in the thoracic spinal cord. Aicher SA, et al. **J Comp Neurol** 1995 Dec 25;363(4):563-580

Medullary-evoked EPSPs in neonatal rat sympathetic preganglionic neurones in vitro. Deuchars SA, et al. **J Physiol (Lond)** 1995 Sep 1;487 (Pt 2):453-63

In vivo activity of B- and C-neurones in the paravertebral sympathetic ganglia of the bullfrog. Ivanoff AY, et al. **J Physiol (Lond)** 1995 Jun 15;485 (Pt 3):797-815

Excitation of sympathetic preganglionic neurons via metabotropic excitatory amino acid receptors. Spanswick D, et al. **Neuroscience** 1995 Oct;68(4):1247-61

ULTRASTRUCTURE

Preganglionic fibres of the adrenal medulla and cervical sympathetic ganglia: differential involvement during experimental American trypanosomiasis in rats. Camargos ER, et al. **Int J Exp Pathol** 1996 Jun;77(3):115-24

AUTONOMIC GANGLIA see **GANGLIA, AUTONOMIC**

AUTONOMIC NERVE BLOCK

Plasma concentrations of bupivacaine following single needle lumbar sympathectomy using two volumes of 0.25% bupivacaine plain solution. Dick AM, et al. **Anaesthesia** 1996 Aug;51(8):750-1

The effect of a combination of rectal diclofenac and caudal bupivacaine on postoperative analgesia in children. Gadiyar V, et al. **Anaesthesia** 1995 Sep;50(9):820-2

Retrieval of catheter using guide wire [letter] Elias MA, et al. **Anesth Analg** 1996 Jul;83(1):196-7

Stellate ganglion block is associated with increased tibial nerve muscle sympathetic activity in humans. Ikeda T, et al. **Anesthesiology** 1996 Apr;84(4):843-50

Effect of autonomic blockade on heart rate and blood pressure in sleep apnea syndrome [see comments] Januel B, et al. **Blood Press** 1995 Jul;4(4):226-31. Comment in: Blood Press 1995 Jul;4(4):197-8.

The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation. Brizel DM, et al. **Br J Cancer** 1995 Nov;72(5):1120-4

Phenol lumbar sympathetic block in diabetic lower limb ischemia. Mashiah A, et al. **J Cardiovasc Risk** 1995 Oct; 2(5):467-9

Computerized axial tomography to define the distribution of solution after stellate ganglion nerve block. Christie JM, et al. **J Clin Anesth** 1995 Jun;7(4):306-11

The use of topical 4% lidocaine in spheno-palatine ganglion blocks for the treatment of chronic muscle pain syndromes: a randomized, controlled trial. Scudds RA, et al. **Pain** 1995 Jul;62(1):69-77

Does sympathetic ganglionic block prevent postherpetic neuralgia? Literature review. Ali NM. **Reg Anesth** 1995 May-Jun;20(3):227-33 (44 ref.)

Ultrasound imaging for stellate ganglion block: direct visualization of puncture site and local anesthetic spread. A pilot study. Kapral S, et al. **Reg Anesth** 1995 Jul-Aug; 20(4):323-8

Continuous celiac plexus block in acute pancreatitis. Rykowski JJ, et al. **Reg Anesth** 1995 Nov-Dec;20(6):528-32

Plasma concentrations of bupivacaine in celiac plexus block. Wulf H, et al. **Reg Anesth** 1995 May-Jun;20(3):222-6

The effects of medetomidine on cardiac contractility in autonomically blocked dogs. de Morais HS, et al. **Vet Surg** 1995 Jul-Aug;24(4):356-64

[A case of RSD with complete disappearance of symptoms following intravenous ketamine infusion combined with stellate ganglion block and continuous epidural block] Kishimoto N, et al. **Masui** 1995 Dec;44(12):1680-4 (Eng. Abstr.) **(Jpn)**

[A case of atopic dermatitis treated with stellate ganglion block--the change of serum IgE and blood eosinophil levels] Wajima Z, et al. **Masui** 1995 Aug;44(8):1135-8 (Eng. Abstr.) **(Jpn)**

[Effect of pharmacologic blockade of the autonomic system on time domain parameters of atrial and ventricular signal-averaged ECG in subjects with mitral valve prolapse] Banasiak W, et al. **Pol Arch Med Wewn** 1995 Jan;93(1):9-18 (Eng. Abstr.) **(Pol)**

[Carotid endarterectomy using cervical plexus block] Aguilar C, et al. **Rev Esp Anestesiol Reanim** 1995 Dec;42(10):428-31 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Paravertebral blockade. Failure rate and complications. Lönnqvist PA, et al. **Anaesthesia** 1995 Sep;50(9):813-5

Chronic diarrhea: an uncommon side effect of celiac plexus block. Chan VW. **Anesth Analg** 1996 Jan;82(1):205-7

Anterior spinal artery syndrome after left celiac plexus block. Takeda J, et al. **Anesth Analg** 1996 Jul;83(1):178-9

Neurolytic celiac plexus block should include contrast media [letter] Hong YY. **Anesthesiology** 1996 Mar;84(3):748-9

Neurolytic celiac plexus block: can paraplegia and death after neurolytic celiac plexus block be eliminated? [letter; comment] Moore DC. **Anesthesiology** 1996 Jun; 84(6):1522-3. Comment on: Anesthesiology 1995 Sep;83(3):632-5.

METHODS

Microlaryngeal surgery without a tracheal tube [letter] MacGillivray RG, et al. **Anaesthesia** 1995 Sep;50(9):832-3

Thoracic paravertebral space location. A new method using pressure measurement. Richardson J, et al. **Anaesthesia** 1996 Feb;51(2):137-9

A double-blind randomized comparison of lidocaine and saline for cervical anesthesia. Miller L, et al. **Obstet Gynecol** 1996 Apr;87(4):600-4

AUTONOMIC NERVES see **AUTONOMIC PATHWAYS**

AUTONOMIC NERVOUS SYSTEM

see related
AUTONOMIC DENERVATION
VISCERAL AFFERENTS

Anatomical basis of autonomic nerve-preserving total mesorectal excision for rectal cancer. Havenga K, et al. **Br J Surg** 1996 Mar;83(3):384-8

Conjoint meeting of the VI International Symposium of the Autonomic Nervous System and XXII International Congress of Neurovegetative Research. Phoenix, Arizona, 17-19 November 1995. Abstracts. **Clin Auton Res** 1995 Dec;5(6):311-49

ANATOMY & HISTOLOGY

Connectivity between brainstem autonomic structures and expression of c-fos following electrical stimulation of the central nucleus of the amygdala in rat. Petrov T, et al. **Cell Tissue Res** 1996 Mar;283(3):367-74

The innervation of the human myocardium at birth. Chow LT, et al. **J Anat** 1995 Aug;187 (Pt 1):107-14

[The 90th anniversary of the creation by J. Newport Langley of the theory of autonomic nervous system structure (historical essay)] Nozdrachev AD. **Fiziol Zh Im I M Sechenova** 1995 Dec;81(12):175-84 **(Rus)**

CHEMISTRY

Calcitonin gene-related peptide innervation of A2-catecholamine cells in the nucleus of the solitary tract of the rat. Fodor M, et al. **Brain Res** 1995 Aug 28; 690(1):141-4

Peptides as neurotransmitters in vascular autonomic neurons. Morris JL. **Clin Exp Pharmacol Physiol** 1995 Nov; 22(11):792-802 (119 ref.)

CYTOLOGY

Immunohistochemical properties and spinal connections of pelvic autonomic neurons that innervate the rat prostate gland. Kepper M, et al. **Cell Tissue Res** 1995 Sep; 281(3):533-42

Vestibular nucleus projections to the parabrachial nucleus in rabbits: implications for vestibular influences on the autonomic nervous system. Balaban CD. **Exp Brain Res** 1996 Mar;108(3):367-81

DRUG EFFECTS

Cardiovascular and autonomic effects of sevoflurane. Ebert TJ. **Acta Anaesthesiol Belg** 1996;47(1):15-21 (22 ref.)

Autonomic and central nervous system effects of lead in female glass workers in China. Murata K, et al. **Am J Ind Med** 1995 Aug;28(2):233-44

Gender differences in heart rate before and after autonomic blockade: evidence against an intrinsic gender effect. Burke JH, et al. **Am J Med** 1996 May;100(5):537-43

Perioperative changes in cardiac autonomic control in patients receiving either general or local anesthesia for ophthalmic surgery. Keyl C, et al. **Anesth Analg** 1996 Jan; 82(1):113-8

Paradoxical autonomic response to procyclidine in the neuroleptic malignant syndrome. Balzan MV. **Can J Neurol Sci** 1995 Aug;22(3):244-6

Chaos-related deterministic regulation of heart rate variability in time- and frequency domains: effects of autonomic blockade and exercise. Hagerman I, et al. **Cardiovasc Res** 1996 Mar;31(3):410-8

Selective and unselective blockade of sympathicus and parasympathicus and vagal enhancement by pirenzepine: effects on heart rate and heart rate variability in healthy subjects. Wilhelmy R, et al. **Clin Sci (Colch)** 1996;91 Suppl:124

Comparative effects of rilmenidine and atenolol on tests of autonomic function and mental and dynamic exercise in patients with essential hypertension. Panfilov V, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S44-7

Botulinum toxin: influence on respiratory heart rate variation. Claus D, et al. **Mov Disord** 1995 Sep;10(5):574-9

Effects of arginine-lysine mixture, glucose and ATP on the autonomic outflows to the thymus and spleen. Niijima A, et al. **Neurobiology (Bp)** 1995;3(3-4):299-307

Tumor necrosis factor-alpha in the dorsal vagal complex suppresses gastric motility. Hermann G, et al. **Neuroimmunomodulation** 1995 Mar-Apr;2(2):74-81

Comparisons of the acute effects of cholinesterase inhibitors using a neurobehavioral screening battery in rats. Moser VC. **Neurotoxicol Teratol** 1995 Nov-Dec;17(6):617-25

Effect of beta adrenergic receptor blockade on cardiac autonomic tone in patients with chronic stable angina. Burger AJ, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):411-7

Electrophysiological, rate dependent, and autonomic effects of the class III antiarrhythmic almokalant after myocardial infarction in the pig. Tuininga YS, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):802–10

Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Lundberg JM. **Pharmacol Rev** 1996 Mar;48(1):113–78 (975 ref.)

Effect of alpha-chymotrypsin on the nonadrenergic, noncholinergic contraction of the rat urinary bladder in vitro. Tong YC, et al. **Pharmacology** 1995 Nov;51(5):281–7

Autonomic and behavioral thermoregulation in golden hamsters exposed perinatally to dioxin. Gordon CJ, et al. **Toxicol Appl Pharmacol** 1996 Mar;137(1):120–5

EMBRYOLOGY

Autonomic and sensory neuron cultures. Nishi R. **Methods Cell Biol** 1996;51:249–63 (11 ref.)

The cellular function of MASH1 in autonomic neurogenesis. Sommer L, et al. **Neuron** 1995 Dec;15(6):1245–58

ENZYMOLOGY

Nitric oxide synthase in autonomic innervation of the cat carotid body. Grimes PA, et al. **J Auton Nerv Syst** 1995 Jul 14;54(1):80–6

Axonal transport of nitric oxide synthase in autonomic nerves. Lumme A, et al. **J Auton Nerv Syst** 1996 Jan 5; 56(3):207–14

GROWTH & DEVELOPMENT

Postnatal development of the putative neuropeptide-Y-mediated sympathetic--parasympathetic autonomic interaction. Rios R, et al. **Cardiovasc Res** 1996 Feb;31 Spec No:E96–103

IMMUNOLOGY

Autoantibodies against adrenal medulla in type 1 and type 2 diabetes mellitus: no evidence for an association with autonomic neuropathy. Husebye ES, et al. **J Intern Med** 1996 Feb;239(2):139–46

Local regulation of the immune response by the autonomic nervous system. Esquifino AI, et al. **Neuroimmunomodulation** 1994 Sep–Oct;1(5):265–73 (61 ref.)

METABOLISM

Biological adaptation of the myocardium to chronic mechanical overload. Molecular determinants of the autonomic nervous system. Mondry A, et al. **Eur Heart J** 1995 Aug;16 Suppl I:64–73 (96 ref.)

Co-existence of NADPH-diaphorase, fibroblast growth factor-2 and fibroblast growth factor receptor in spinal autonomic system suggests target-specific actions. Stapf C, et al. **Neuroscience** 1995 Dec;69(4):1253–62

PATHOLOGY

[Acute Chagas cardiopathy. A systematic study of the intracardiac excitatory-conduction and autonomic nervous systems in an autochthonous case in Acre] Rocha A, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):367–71 (12 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

The sinus node and the autonomic nervous system in normals and in sick sinus patients. de Marneffe M, et al. **Acta Cardiol** 1995;50(4):291–308

Electrophysiological study of blink reflex in humans: differences in mental and supraorbital nerves. Jääskeläinen SK. **Acta Physiol Scand** 1995 Jun;154(2):143–50

The effect of change in sympatho-vagal balance on heart rate and blood pressure variability in the foetal lamb. Metsälä T, et al. **Acta Physiol Scand** 1995 Jun;154(2):85–92

Influence of cerebrovascular sympathetic, parasympathetic, and sensory nerves on autoregulation and spontaneous vasomotion. Morita Y, et al. **Acta Physiol Scand** 1995 Jun; 154(2):121–30

The role of autonomic arousal in problem gambling. Sharpe L, et al. **Addiction** 1995 Nov;90(11):1529–40

Pupillometric evaluation and analysis of light reflex in healthy subjects as a tool to study autonomic nervous system changes with aging. Pozzessere G, et al. **Aging (Milano)** 1996 Feb;8(1):55–60

Age, race, and sex differences in autonomic cardiac function measured by spectral analysis of heart rate variability--the ARIC study. Atherosclerosis Risk in Communities. Liao D, et al. **Am J Cardiol** 1995 Nov 1;76(12):906–12

Gender differences in heart rate before and after autonomic blockade: evidence against an intrinsic gender effect. Burke JH, et al. **Am J Med** 1996 May;100(5):537–43

Effects of constant cardiac autonomic nerve stimulation on heart rate variability. Bailey JR, et al. **Am J Physiol** 1996 Jun;270(6 Pt 2):H2081–7

Explorations into development of a neurally regulated cardiac pacemaker. Ikeda Y, et al. **Am J Physiol** 1995 Dec; 269(6 Pt 2):H2141–6

Bidirectional augmentation of heart rate regulation by autonomic nervous system in rabbits. Kawada T, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):H288–95

Autonomic and ventilatory components of heart rate and blood pressure variability in freely behaving rats. Perlini S, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):H1729–34

Muscle metaboreceptors in hemodynamic, autonomic, and ventilatory responses to exercise in men. Piepoli M, et al. **Am J Physiol** 1995 Oct;269(4 Pt 2):H1428–36

Alterations in spectral characteristics of heart rate variability as a correlate of cardiac autonomic dysfunction after esophagectomy or pulmonary resection. Kimura T, et al. **Anesthesiology** 1996 May;84(5):1068–76

Estimation of autonomic nervous activity using the inverse dynamic model of the pupil muscle plant. Usui S, et al. **Ann Biomed Eng** 1995 Jul–Aug;23(4):375–87

Interactions and coexistence of neuropeptides and serotonin in spinal autonomic systems. Helke CJ, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:185–92 (49 ref.)

Vestibular influences on the autonomic nervous system. Yates BJ. **Ann N Y Acad Sci** 1996 Jun 19;781:458–73

Effect of HeartMate left ventricular assist device on cardiac autonomic nervous activity. Kim SY, et al. **Ann Thorac Surg** 1996 Feb;61(2):591–3

Effect of state of alertness on the heart rate response to ocular compression in human infants. Ramet J, et al. **Biol Neonate** 1995;68(4):270–5

Number, size and distribution of ganglion neurons in urinary bladder of rodents. Liberti E, et al. **Biol Res** 1994; 27(2):123–8

The role of the autonomic nerves in the control of nasal circulation. Lung MA. **Biol Signals** 1995 May–Jun; 4(3):179–85 (33 ref.)

Heart rate and respiratory rhythm dynamics on ascent to high altitude. Lipsitz LA, et al. **Br Heart J** 1995 Oct; 74(4):390–6

Regulation by phosphodiesterase isoenzymes of non-adrenergic non-cholinergic contraction in guinea-pig isolated main bronchus. Spina D, et al. **Br J Pharmacol** 1995 Oct;116(4):2334–40

Characteristics of the NANC post-stimulus ('rebound') contraction of the urinary bladder neck muscle in sheep. Thornbury KD, et al. **Br J Pharmacol** 1995 Nov; 116(5):2451–6

Vestibular inputs to the lateral tegmental field of the cat: potential role in autonomic control. Yates BJ, et al. **Brain Res** 1995 Aug 21;689(2):197–206

The ratio of pre- to postganglionic neurons and related issues in the autonomic nervous system. Wang FB, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):93–115 (260 ref.)

Angiotensin II as a modulator of cardiovascular autonomic control. Townend JN. **Cardiologia** 1996 Mar;41(3):217–25 (83 ref.)

Power spectral analysis of heart rate variability during upright tilt test: a comparison of patients with syncope and normal subjects. Boulos M, et al. **Cardiology** 1996 Jan–Feb; 87(1):28–32 (20 ref.)

Cardiovascular protection by oestrogen is partly mediated through modulation of autonomic nervous function. Du XJ, et al. **Cardiovasc Res** 1995 Aug;30(2):161–5 (57 ref.)

Autonomic receptor--effector coupling during post-natal development. Robinson RB. **Cardiovasc Res** 1996 Feb;31 Spec No:E68–76 (68 ref.)

Capsaicin-sensitive sensory-motor neurotransmission in the peripheral control of cardiovascular function. Rubino A, et al. **Cardiovasc Res** 1996 Apr;31(4):467–79 (160 ref.)

Neurogenic control of the cerebral circulation. Branston NM. **Cerebrovasc Brain Metab Rev** 1995 Winter;7(4):338–49 (61 ref.)

Electrocortical and autonomic alteration by administration of a pleasant and an unpleasant odor. Brauchli P, et al. **Chem Senses** 1995 Oct;20(5):505–15

Sex-related differences in autonomic modulation of heart rate in middle-aged subjects. Huikuri HV, et al. **Circulation** 1996 Jul 15;94(2):122–5

Effect of neurovestibular stimulation on autonomic regulation. Costa F, et al. **Clin Auton Res** 1995 Oct; 5(5):289–93

Interrelationships among measures of autonomic activity and cardiovascular risk factors during orthostasis and the oral glucose tolerance test. Peles E, et al. **Clin Auton Res** 1995 Oct;5(5):271–8

Changes in the sweatspot test with ageing and relation to cardiovascular autonomic function. Robinson T, et al. **Clin Auton Res** 1995 Jun;5(3):135–8

Chronotropic incompetence--Part I: Normal regulation of the heart rate. Camm AJ, et al. **Clin Cardiol** 1996 May; 19(5):424–8 (45 ref.)

The power spectral analysis of heart rate variability in athletes during dynamic exercise--Part II. Shin K, et al. **Clin Cardiol** 1995 Nov;18(11):664–8

Autonomic responses to the Valsalva manoeuvre in healthy subjects. Piha SJ. **Clin Physiol** 1995 Jul;15(4):339–47

Electrodermal activity reveals respiratory and slower rhythms of the autonomic nervous system. Rittweger J, et al. **Clin Physiol** 1996 May;16(3):323–6

Autonomic control of skin microvessels: assessment by power spectrum of photoplethysmographic waves. Bernardi L, et al. **Clin Sci (Colch)** 1996 May;90(5):345–55

On the quantification of heart rate changes in autonomic function tests: relations between measures in beats per minute, seconds and dimensionless ratios. Faes TJ, et al. **Clin Sci (Colch)** 1995 Dec;89(6):557–64

New techniques to assess autonomic cardiovascular regulation. Macerata A, et al. **Clin Sci (Colch)** 1996;91 Suppl:65–6

Methodological aspects of noninvasive analysis of autonomic regulation of cardiovascular variability. Malliani A, et al. **Clin Sci (Colch)** 1996;91 Suppl:68–71

Autonomic regulation of heart rate and peripheral circulation: comparison of high altitude and sea level residents. Passino C, et al. **Clin Sci (Colch)** 1996;91 Suppl:81–3

Transfer function analysis of cardiorespiratory variability to assess autonomic regulation. Saul JP. **Clin Sci (Colch)** 1996; 91 Suppl:101

Psychophysiological correlates of infant temperament: stability of behavior and autonomic patterning from 5 to 18 months. Stifter CA, et al. **Dev Psychobiol** 1996 May; 29(4):379–91

Changes in autonomic nervous system activity and consecutive hyperinsulinaemia: respective roles in the development of obesity in rodents. Pénicaud L, et al. **Diabetes Metab** 1996 Feb;22(1):15–24 (67 ref.)

Insulin, corticosterone and the autonomic nervous system in animal obesities: a viewpoint. Jeanrenaud B. **Diabetologia** 1995 Aug;38(8):998–1002 (61 ref.)

Evidence for fibroblast growth factor mediation of compensatory adrenocortical proliferation. Holzwarth MA. **Endocr Res** 1995 Feb–May;21(1–2):115–9

Inhibition of non-adrenergic non-cholinergic relaxations by nitric oxide donors. De Man JG, et al. **Eur J Pharmacol** 1995 Oct 24;285(3):269–74

Regulation of airway cholinergic neurotransmission by Ca(2+)-activated K+ channel and Na(+)-K+ adenosinetriphosphatase. Tagaya E, et al. **Exp Lung Res** 1995 Sep–Oct;21(5):683–94

Assessment of autonomic function using complex demodulation and posture entrainment techniques: an application to normal subjects and diabetic patients. Kamal A. **Front Med Biol Eng** 1996;7(1):1–10

How do we study autonomic function in humans? Macdonald IA. **Fundam Clin Pharmacol** 1995;9(5):443–9 (25 ref.)

Dispersion of the QT interval and autonomic modulation of heart rate in hypertensive men with and without left ventricular hypertrophy. Perkiömäki JS, et al. **Hypertension** 1996 Jul;28(1):16–21

Effects of a single cognitive task on power spectra of R-R interval and arterial blood pressure. Takahashi M, et al. **Ind Health** 1996;34(3):287–92

Autonomic changes during "OM" meditation. Telles S, et al. **Indian J Physiol Pharmacol** 1995 Oct;39(4):418–20

Autonomic nervous function and blood volume monitoring during hemodialysis. Enzmann G, et al. **Int J Artif Organs** 1995 Sep;18(9):504–8

Blocking and unconditioned response diminution in human classical autonomic conditioning. Kimmel HD, et al. **Integr Physiol Behav Sci** 1996 Jan–Mar;31(1):18–43

Age-dependent influence on heart rate variability in salt-sensitive hypertensive subjects. Piccirillo G, et al. **J Am Geriatr Soc** 1996 May;44(5):530–8

Extreme blood pressure fluctuations in a patient with intact autonomic reflexes and intact sodium conservation. Barri YM, et al. **J Am Soc Nephrol** 1995 Nov;6(5):1347–53

Human pupillary light reflex during and after two-fold Valsalva maneuver. Gavriysky VS. **J Auton Nerv Syst** 1995 Sep 5;54(3):247–52

Autonomic mediation of short-term cardiovascular oscillations after acute hemorrhage in conscious rats. Gonzalez Gonzalez J, et al. **J Auton Nerv Syst** 1995 Oct 5;55(1-2):123–30

Reaction of pituitary-adrenal and autonomic nervous systems to stress in trained and untrained elderly people. Korkushko OV, et al. **J Auton Nerv Syst** 1995 Jul 14;54(1):27–32

The norepinephrine tissue concentration and neuropeptide Y immunoreactivity in genitourinary organs of the spontaneously hypertensive rat. Tong YC, et al. **J Auton Nerv Syst** 1996 Jan 5;56(3):215–8

Independent autonomic modulation of the human sinus and AV nodes: evidence from beat-to-beat measurements of PR and PP intervals during sleep. Kowallik P, et al. **J Cardiovasc Electrophysiol** 1995 Nov;6(11):993–1003

Autonomic nervous control of heart rate in muskrats during exercise in air and under water. Signore PE, et al. **J Exp Biol** 1996 Jul;199 (Pt 7):1563–8

Neurogenic vasodilation in canine uterine and iliac arteries. Okamura T, et al. **J Hypertens** 1995 Oct;13(10):1163–8

Autonomic control of penile erection: modulation by testosterone in the rat. Giuliano F, et al. **J Neuroendocrinol** 1993 Dec;5(6):677–83

Convergent influence of the central nucleus of the amygdala and the paraventricular hypothalamic nucleus upon brainstem autonomic neurons as revealed by c-fos expression and anatomical tracing. Petrov T, et al. **J Neurosci Res** 1995 Dec 15;42(6):835–45

Assessment of training-induced autonomic adaptations in athletes with spectral analysis of cardiovascular variability signals. Shin K, et al. **Jpn J Physiol** 1995;45(6):1053–69

Autonomic nervous system control of the heart: endurance exercise training. Shi X, et al. **Med Sci Sports Exerc** 1995 Oct;27(10):1406–13

Botulinum toxin: influence on respiratory heart rate variation. Claus D, et al. **Mov Disord** 1995 Sep;10(5):574–9

Comparison of standard autonomic tests and power spectral analysis in normal adults. Linden D, et al. **Muscle Nerve** 1996 May;19(5):556–62

Influence of pudendal nerve blockade on stress relaxation in the female urethra. Thind P, et al. **Neurourol Urodyn**

1996;15(1):31–6

[Correlation between the nervous system and immune system] Katafuchi T. **Fukuoka Igaku Zasshi** 1996 Jun;87(6):127–32 (3 ref.) **(Jpn)**

[The control of smooth muscle tissues by nonadrenergic noncholinergic (NANC) nerve fibres in the autonomic nervous system] Itoh H, et al. **J Smooth Muscle Res** 1995 Jun;31(3):67–78 (41 ref.) (Eng. Abstr.) **(Jpn)**

[A research tool for autonomic nervous function: methodology and application of microneurography] Mano T. **Masui** 1995;44 Suppl:S17–25 (41 ref.) **(Jpn)**

[Nervous regulation of metabolism] Niijima A. **Nippon Rinsho** 1995 Jun;53 Suppl:3–10 (10 ref.) **(Jpn)**

[Role of the autonomic nervous system (adrenergic, cholinergic and nonadrenergic, noncholinergic) in regulation of respiratory system function] Liebhart J, et al. **Postepy Hig Med Dosw** 1995;49(3):395–407 (45 ref.) (Eng. Abstr.) **(Pol)**

[Characteristics of adaptive reactions of pregnant women with chronic inflammatory gynecologic diseases and in their newborn in the early neonatal period] Krylov VI, et al. **Akush Ginekol (Mosk)** 1995;(4):24–6 (Eng. Abstr.) **(Rus)**

[Psychophysiologic and autonomic parameters in sluggish and active youngsters (longitudinal studies)] Antropova MV, et al. **Fiziol Cheloveka** 1995 Sep–Oct;21(5):68–74 **(Rus)**

[Autonomic correlates of the activity of a human computer operator in various levels of performance] Fudin NA, et al. **Fiziol Cheloveka** 1995 Jul–Aug;21(4):73–8 **(Rus)**

[Energy metabolism and autonomic function in students under study and examination stress] Umiriukhin EA, et al. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):108–11 **(Rus)**

[The current status of the study of the physiology of the autonomic nervous system in Russia] Nozdrachev AD. **Fiziol Zh Im I M Sechenova** 1995 Jan;81(1):3–18 (55 ref.) **(Rus)**

[The neural mechanisms of the autonomic responses evoked by somatic sensory stimulation] Sato A. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):56–69 (27 ref.) **(Rus)**

[Characteristics of the state of the autonomic nervous system in miners with heat injuries] Tkachenko LN, et al. **Med Tr Prom Ekol** 1995;(10):42–4 **(Rus)**

[The chemical structure of the peripheral autonomic (visceral) reflex] Nozdrachev AD. **Usp Fiziol Nauk** 1996 Apr–Jun;27(2):28–60 (74 ref.) (Eng. Abstr.) **(Rus)**

[Multimeasurement analysis of the autonomic status in the development of stress in man] Dmitrieva NV. **Vestn Ross Akad Med Nauk** 1995;(11):16–21 (Eng. Abstr.) **(Rus)**

[Physiological evaluation of the resultant activity of school children working with computers] Umriukhin EA, et al. **Vestn Ross Akad Med Nauk** 1995;(11):47–52 (Eng. Abstr.) **(Rus)**

[Conscious perception of a stimulus as a somatopsychic process] Uryvaev IuV. **Vestn Ross Akad Med Nauk** 1995; (11):26–9 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Participation of autonomic nervous system in the pathogenesis of Chagas disease. Sterin-Borda LJ, et al. **Acta Physiol Pharmacol Ther Latinoam** 1994;44(4):109–23 (89 ref.)

Biochemical and pharmacologic assessment of autonomic function. Polinsky RJ. **Adv Neurol** 1996;69:373–6 (17 ref.)

Cue-exposure to alcohol-associated stimuli reduces autonomic reactivity, but not craving and anxiety, in dependent drinkers. McCusker CG, et al. **Alcohol Alcohol** 1995 May;30(3):319–27

Can serial tilt testing be used to evaluate therapy in neurally mediated syncope? Morillo CA, et al. **Am J Cardiol** 1996 Mar 1;77(7):521–3 (34 ref.)

Transient autonomic dysfunction precedes ST-segment depression in patients with syndrome X. Ponikowski P, et al. **Am J Cardiol** 1996 May 1;77(11):942–7

Circadian rhythm and variability of heart rate in Duchenne-type progressive muscular dystrophy. Yotsukura M, et al. **Am J Cardiol** 1995 Nov 1;76(12):947–51

Autonomic function in type I diabetes mellitus complicated by nephropathy. A cross-sectional analysis in the presymptomatic phase. Weinrauch LA, et al. **Am J Hypertens** 1995 Aug;8(8):782–9

Face immersion reflex for diagnosis of diabetic cardiovascular autonomic neuropathy. Raúl Ariza C, et al. **Arch Med Res** 1995 Autumn;26(3):227–31

Extent of autonomic activation following cerebral ischemia is different in hypertensive and normotensive humans. Sander D, et al. **Arch Neurol** 1996 Sep;53(9):890–4

Effect of autonomic blockade on heart rate and blood pressure in sleep apnea syndrome [see comments] Januel B, et al. **Blood Press** 1995 Jul;4(4):226–31. Comment in: Blood Press 1995 Jul;4(4):197–8.

Transcranial Doppler and cardiovascular responses during cardiovascular autonomic tests in migraineurs during and outside attacks. Thomsen LL, et al. **Brain** 1995 Oct;118 (Pt 5):1319–27

The hibernator heart--nature's model of resistance to ventricular fibrillation. Johansson BW. **Cardiovasc Res** 1996 May;31(5):826–32 (39 ref.)

A controlled study of the autonomic changes produced by habitual cigarette smoking in healthy subjects. Lucini D, et al. **Cardiovasc Res** 1996 Apr;31(4):633–9

Relation between depressed cardiac response to exercise and autonomic nervous activity in mildly symptomatic patients with idiopathic dilated cardiomyopathy. Nagaoka H, et al. **Chest** 1996 Apr;109(4):925–32

Autonomic imbalance and congestive heart failure [letter] Friedman EH. **Circulation** 1996 Sep 1;94(5):1138

Insulin resistance and autonomic function in traumatic lower limb amputees. Peles E, et al. **Clin Auton Res** 1995 Oct; 5(5):279–88

Comparison of autonomic function using Valsalva ratio and 30:15 postural ratio prior to and after haemodialysis treatment. Rosansky SJ, et al. **Clin Auton Res** 1995 Jun; 5(3):151–4

The autonomic nervous system and the regulation of arterial tone in migraine. Thomsen LL, et al. **Clin Auton Res** 1995 Oct;5(5):243–50 (111 ref.)

Cardiovascular autonomic control is disturbed in nocturnal teethgrinders. Sjöholm TT, et al. **Clin Physiol** 1995 Jul; 15(4):349–54

Autonomic regulations in non-transplant cardiac surgery. Baumert JH, et al. **Clin Sci (Colch)** 1996;91 Suppl:16–8

Effect of different interventions on heart rate variability after heart transplantation: non-autonomic vs autonomic factors. Bernardi L, et al. **Clin Sci (Colch)** 1996;91 Suppl:22–4 (24 ref.)

Cardiovascular reflex changes preceding episodes of vasovagal syncope in paediatric subjects. Bernardi L, et al. **Clin Sci (Colch)** 1996;91 Suppl:25–7

Heart rate variability and myocardial infarction: acute and subacute phase. CNR-PF FATMA Multicenter Study on psycho-neurological risk factors in acute myocardial infarction. Carpeggiani C, et al. **Clin Sci (Colch)** 1996;91 Suppl:28–9

Autonomic modulation in postinfarction patients with sustained ventricular tachyarrhythmias. Klingenheben T, et al. **Clin Sci (Colch)** 1996;91 Suppl:141–5

Different vagal modulation of the sinoatrial node and AV node in patients with congestive heart failure. Kowallik P, et al. **Clin Sci (Colch)** 1996;91 Suppl:58–61

Autonomic markers of prognosis after myocardial infarction. La Rovere MT. **Clin Sci (Colch)** 1996;91 Suppl:133–5 (30 ref.)

Heart rate and blood pressure variability in orthostatic syncope. Lagi A, et al. **Clin Sci (Colch)** 1996;91 Suppl:62–4

Analysis of heart rate and blood pressure variability in the assessment of autonomic regulation in arterial hypertension. Parati G, et al. **Clin Sci (Colch)** 1996;91 Suppl:129–32 (39 ref.)

Autonomic abnormality in chronic heart failure evaluated by heart rate variability. Piepoli M, et al. **Clin Sci (Colch)** 1996;91 Suppl:84–6

Physical training enhances sympathetic and parasympathetic control of heart rate and peripheral vessels in chronic heart failure. Radaelli A, et al. **Clin Sci (Colch)** 1996;91 Suppl:92–4

Dysregulation in blood pressure homeostasis during spinal anaesthesia in elderly patients. Röhrle G, et al. **Clin Sci (Colch)** 1996;91 Suppl:95–6

Influence of exercise training and restriction of activity on autonomic balance in patients with severe congestive heart failure. Toepfer M, et al. **Clin Sci (Colch)** 1996;91 Suppl:116

Heart rate variability and autonomic balance in patients with different stages of severe congestive heart failure. Toepfer M, et al. **Clin Sci (Colch)** 1996;91 Suppl:117

Abnormal baroreceptor-cardiac reflex sensitivity is not detected by conventional tests of autonomic function in patients with insulin-dependent diabetes mellitus. Weston PJ, et al. **Clin Sci (Colch)** 1996 Jul;91(1):59–64

Autonomic control of heart rate after brain injury in children. Goldstein B, et al. **Crit Care Med** 1996 Feb;24(2):234–40

Prospective assessment of autonomic and peripheral nerve function in adolescents with diabetes. Donaghue KC, et al. **Diabet Med** 1996 Jan;13(1):65–71

The prospective assessment of autonomic nerve function by pupillometry in adolescents with type 1 diabetes mellitus. Pena MM, et al. **Diabet Med** 1995 Oct;12(10):868–73

Insulin, corticosterone and the autonomic nervous system in animal obesities: a viewpoint. Jeanrenaud B. **Diabetologia** 1995 Aug;38(8):998–1002 (61 ref.)

Renin-angiotensin-aldosterone system, RR-interval and blood pressure variability during postural changes after myocardial infarction. Duprez D, et al. **Eur Heart J** 1995 Aug;16(8):1050–6

Autonomic balance in patients with angina and a normal coronary angiogram. Frøbert O, et al. **Eur Heart J** 1995 Oct;16(10):1356–60

Sympathetic predominance followed by functional denervation in the progression of chronic heart failure. Guzzetti S, et al. **Eur Heart J** 1995 Aug;16(8):1100–7

Short and long term effects of exercise training on the tonic autonomic modulation of heart rate variability after myocardial infarction. Malfatto G, et al. **Eur Heart J** 1996 Apr;17(4):532–8

Spectral analysis of RR variability during transient myocardial ischaemia: have we moved from the computer console to the bedside? [editorial; comment] Pagani M. **Eur Heart J** 1996 Mar;17(3):331–3. Comment on: Eur Heart J 1996 Mar;17(3):388–93.

Exercise training and the autonomic nervous system in chronic heart failure [editorial; comment] Tavazzi L, et al. **Eur Heart J** 1995 Oct;16(10):1308–10. Comment on: Eur Heart J 1995 Oct;16(10):1380–6.

Spectral analysis of heart rate variability before and during episodes of nocturnal ischaemia in patients with extensive coronary artery disease [see comments] Vardas PE, et al. **Eur Heart J** 1996 Mar;17(3):388–93. Comment in: Eur Heart J 1996 Mar;17(3):331–3.

Assessment of cardiac autonomic control by heart period variability in patients with early-onset familial obesity. Petretta M, et al. **Eur J Clin Invest** 1995 Nov;25(11):826–32

Hyperventilation, central autonomic control, and colonic tone in humans. Ford MJ, et al. **Gut** 1995 Oct;37(4):499–504

The role of the autonomic nervous system in hypertension. Amerena J, et al. **Hypertens Res** 1995 Jun;18(2):99–110 (119 ref.)

Acute exercise attenuates cardiac autonomic regulation in hypertensive rats. Chen Y, et al. **Hypertension** 1995 Oct; 26(4):676–83

Autonomic nervous function in non-dipper essential hypertensive subjects. Evaluation by power spectral analysis of heart rate variability. Kohara K, et al. **Hypertension** 1995 Nov;26(5):808–14

Autonomic dysfunction in short-term experimental diabetes. Maeda CY, et al. **Hypertension** 1995 Dec;26(6 Pt 2):1100–4

Changes of autonomic nerve function in the first two weeks of acute neuritis in a patient with borderline leprosy [letter] Wilder-Smith E, et al. **Int J Lepr Other Mycobact Dis** 1996 Jun;64(2):169–71

Autonomic nervous system and sudden cardiac death. Barron HV, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1053–60 (42 ref.)

Assessment of autonomic function in traumatic quadriplegic and paraplegic patients by spectral analysis of heart rate variability. Inoue K, et al. **J Auton Nerv Syst** 1995 Sep 5;54(3):225–34

Assessment of autonomic function in myotonic dystrophy by spectral analysis of heart-rate variability. Inoue K, et al. **J Auton Nerv Syst** 1995 Oct 5;55(1–2):131–4

Reperfusion arrhythmias: role of early afterdepolarizations studied by monophasic action potential recordings in the intact canine heart during autonomically denervated and stimulated states. Vera Z, et al. **J Cardiovasc Electrophysiol** 1995 Jul;6(7):532–43

Atrial natriuretic factor and digoxin-like immunoreactive factor in diabetic patients: their interrelation and the influence of the autonomic nervous system. Straub RH, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3385–9

Baroreflex control of heart rate in Dahl hypertensive (SS/Jr) and normotensive (SR/Jr) rats. Murphy CA, et al. **J Hypertens** 1995 Oct;13(10):1145–51

Effects of vitamin E deficiency on autonomic neuroeffector mechanisms in the rat caecum, vas deferens and urinary bladder. Hoyle CH, et al. **J Physiol (Lond)** 1995 Sep 15; 487 (Pt 3):773–86

Cardiac autonomic function during sleep of never-depressed borderline subjects: a pilot study. Battaglia M, et al. **J Psychiatr Res** 1995 Sep–Oct;29(5):397–405

Changes in autonomic response of the cerebral circulation after normothermic extracorporeal circulation. Sellke FW, et al. **J Thorac Cardiovasc Surg** 1996 Aug;112(2):450–61

Silent autonomic dysreflexia during voiding in men with spinal cord injuries. Linsenmeyer TA, et al. **J Urol** 1996 Feb;155(2):519–22

Heart rate variability and cardiac autonomic function in systemic lupus erythematosus. Laganá B, et al. **Lupus** 1996 Feb;5(1):49–55

Heart rate variability in patients with systemic lupus erythematosus. Stein KS, et al. **Lupus** 1996 Feb;5(1):44–8

Value of autonomic testing in reflex sympathetic dystrophy [see comments] Chelimsky TC, et al. **Mayo Clin Proc** 1995 Nov;70(11):1029–40. Comment in: Mayo Clin Proc 1995 Nov;70(11):1124–6.

Insulin resistance syndrome and autonomically mediated physiological responses to experimentally induced mental stress in adolescent boys. Keltikangas-Jarvinen L, et al. **Metabolism** 1996 May;45(5):614–21

Hypothalamic-pituitary-adrenal axis activity and its relationship to the autonomic nervous system in women with visceral and subcutaneous obesity: effects of the corticotropin-releasing factor/arginine-vasopressin test and of stress. Pasquali R, et al. **Metabolism** 1996 Mar; 45(3):351–6

Somatic and autonomic nerve studies in Chagas' disease [letter] Idiaquez J. **Muscle Nerve** 1996 May;19(5):678–9

Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. **Neurology** 1996 Mar;46(3):873–80 (101 ref.)

Autonomic activity assessed by heart rate spectral analysis varies with fat distribution in obese women. Gao YY, et al. **Obes Res** 1996 Jan;4(1):55–63

Energy homeostasis, autonomic activity and obesity. Scheurink AJ, et al. **Obes Res** 1995 Dec;3 Suppl 5:721S–727S (54 ref.)

Decreased heart rate variability in patients with congestive heart failure and chronotropic incompetence. Fei L, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):477–83

Electro-oculogram in multiple system and late onset cerebellar atrophies. Arpa J, et al. **Rev Neurol** 1995 Sep–Oct;23(123):969–74

Functional alterations of the autonomic nervous system in Chagas' heart disease. Amorim DD, et al. **Rev Paul Med** 1995 Mar–Apr;113(2):772–84 (75 ref.)

AUTONOMIC NERVOUS SYSTEM

[Autonomic nervous activity at episodes of myocardial ischemia in patients with coronary artery disease by heart rate power spectral analysis] Wu B, et al. **Chung Hua Nei Ko Tsa Chih** 1995 May;34(5):295–7 (Eng. Abstr.) **(Chi)**

[Studies on function of vegetative nervous system in cardiopathic patients with heart–qi deficiency syndromes and heart–yin deficiency syndromes] Zhang DL, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):586–8 (Eng. Abstr.) **(Chi)**

[Autonomous hyperreflexia and labor] Nielsen PH, et al. **Ugeskr Laeger** 1996 May 13;158(20):2859–60 (Eng. Abstr.) **(Dan)**

[Autonomic nervous systems and cardiovascular diseases] Inoue H. **Nippon Naika Gakkai Zasshi** 1996 Mar 10; 85(3):428–31 (8 ref.) **(Jpn)**

[Laboratory evaluation of autonomic function] Koike Y. **Rinsho Byori** 1995 Sep;43(9):871–6 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Automatic regulation of sinus rhythm in patients with migraine] Rozentryt P, et al. **Neurol Neurochir Pol** 1995 Nov–Dec;29(6):889–900 (Eng. Abstr.) **(Pol)**

[Function of the autonomic nervous system in uremia] Rozentryt P, et al. **Postepy Hig Med Dosw** 1995; 49(4):551–61 (100 ref.) (Eng. Abstr.) **(Pol)**

[The connection between multiday rhythms of certain indicators of systemic and cerebral hemodynamics and autonomic function with cosmophysical rhythms in patients with essential hypertension] Agulova LP, et al. **Biofizika** 1995 Jul–Aug;40(4):848–55 (Eng. Abstr.) **(Rus)**

[Role of external respiration in the formation of the autonomic component in motion sickness] Baranov VM, et al. **Kosm Biol Aviakosm Med** 1991 Sep–Oct;25(5):20–4 (Eng. Abstr.) **(Rus)**

[The indices of central and peripheral hemodynamics and of autonomic nervous system function in subjects with arterial hypertension working under different manufacturing conditions] Shelygin SI, et al. **Lik Sprava** 1995 May–Jun;(5–6):80–3 (Eng. Abstr.) **(Rus)**

[Autonomic nervous system and resistance of cardiovascular functions in experimental acute emotional stress] Gorbunova AV. **Vestn Ross Akad Med Nauk** 1995;(11):3–9 (Eng. Abstr.) **(Rus)**

[The characteristics of the autonomic regulation of the heart rhythm in patients with the obstructive sleep apnea syndrome] Eligulashvili TS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):28–31 (Eng. Abstr.) **(Rus)**

[Peripheral autonomic nervous system function in patients with hypothalamic insufficiency] Filatova EG, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):14–20 (Eng. Abstr.) **(Rus)**

[Autonomic regulation of the cardiovascular system in patients with schizoaffective psychosis] Mel'nikova TS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(6):81–3 (Eng. Abstr.) **(Rus)**

[Neurohormonal factors in heart failure. I] Cosín Aguilar J, et al. **Rev Esp Cardiol** 1996 Apr;49(4):239–52 (112 ref.) (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

[Adaptive changes in autonomic functions in liquidators of the accident at the Chernobyl nuclear power plant in the process of conducting rehabilitation measures] Fudin NA, et al. **Fiziol Cheloveka** 1995 Nov–Dec;21(6):137–45 **(Rus)**

[The autonomic regulation of the cardiovascular system in subjects with the autonomic dystonia syndrome subjected to ionizing radiation exposure as a result of the accident at the Chernobyl Atomic Electric Power Station] Niagu AI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(4):32–5 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Light and electron microscopic studies of the distribution of NADPH-diaphorase in the rat upper thoracic spinal cord with special reference to the spinal autonomic region. Tang FR, et al. **Arch Histol Cytol** 1995 Dec;58(5):493–505

An ultrastructural study of cholinergic and non-cholinergic neurons in the laterodorsal and pedunculopontine tegmental nuclei in the rat. Honda T, et al. **Neuroscience** 1995 Oct;68(3):837–53

VIROLOGY

Generation of recombinant herpes simplex virus type 1 to be used for automatic tract tracing. LeVatte MA, et al. **Gene Ther** 1994;1 Suppl 1:S77

AUTONOMIC NERVOUS SYSTEM DISEASES

The definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. **J Auton Nerv Syst** 1996 Apr 20;58(1–2):123–4 (1 ref.)

[Dysautonomia. An introduction] Soares JL. **Acta Med Port** 1995 Jul–Aug;8(7–8):425–32 (40 ref.) (Eng. Abstr.) **(Por)**

[Occupational vegetative dystonia or psychogenic disorder?] Reshetova TV. **Med Tr Prom Ekol** 1995;(7):28–9 **(Rus)**

BLOOD

Circulating alpha-actin in non-insulin-dependent diabetics with autonomic dysfunction. Prados J, et al. **Int J Cardiol** 1995 Sep;51(2):127–30

CHEMICALLY INDUCED

Cardiovascular and autonomic function in Down syndrome—prescribing implications [letter] Carpenter PK. **Br J Psychiatry** 1995 Jul;167(1):118–9

192IGG-saporin-induced selective lesion of cholinergic basal forebrain system: neurochemical effects on cholinergic neurotransmission in rat cerebral cortex and hippocampus. Rossner S, et al. **Brain Res Bull** 1995;38(4):371–81

Cisplatin-induced autonomic neuropathy: does it really exist? Vandertop WP, et al. **J Neurooncol** 1996 Jan;27(1):53–60

Acute severe autonomic insufficiency during pentamidine therapy [letter] Siddiqui MA, et al. **South Med J** 1995 Oct; 88(10):1087–8

CLASSIFICATION

The classification and nomenclature of autonomic disorders—ending chaos, resolving conflict and hopefully achieving clarity [editorial] Mathias CJ. **Clin Auton Res** 1995 Dec;5(6):307–10

Failure of the autonomic nervous system. Mitsky V, et al. **Compr Ther** 1995 Sep;21(9):529–34 (8 ref.)

Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. **Neurology** 1996 May;46(5):1470 (1 ref.)

COMPLICATIONS

Tests of autonomic dysfunction in patients with multiple sclerosis. Drory VE, et al. **Acta Neurol Scand** 1995 Nov; 92(5):356–60

Disorders affecting autonomic function in parkinsonian patients. Mathias CJ. **Adv Neurol** 1996;69:383–91 (20 ref.)

Autonomic neuropathy in adult celiac disease [letter] Usai P, et al. **Am J Gastroenterol** 1996 Aug;91(8):1676–7

Energy expenditure and anaemia of autonomic failure [letter] Ducla-Soares JL, et al. **Clin Auton Res** 1995 Jun;5(3):179

Sympathetic skin response in patients with amyotrophic lateral sclerosis. Masur H, et al. **Funct Neurol** 1995 May–Jun;10(3):131–5

Transient sympathovagal imbalance triggers "ischemic" sudden death in patients undergoing electrocardiographic Holter monitoring. Pozzati A, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):847–52

Effects of smoking on blood pressure and proteinuria in patients with diabetic nephropathy. Sawicki PT, et al. **J Intern Med** 1996 Apr;239(4):345–52

Pure autonomic failure with motor neuron disease: report of a clinical study and postmortem examination of a patient [letter] Noda K, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):351–2

Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Low PA, et al. **Pain** 1995 Aug;62(2):163–8

Octreotide reduces alcohol-induced hypotension and orthostatic symptoms in primary autonomic failure. Chaudhuri KR, et al. **QJM** 1995 Oct;88(10):719–25

Disorders of the central and autonomic nervous systems as a cause for emesis in infants. Johns DW. **Semin Pediatr Surg** 1995 Aug;4(3):152–6 (37 ref.)

Autonomic neuropathy predicts the development of stroke in patients with non-insulin-dependent diabetes mellitus. Töyry JP, et al. **Stroke** 1996 Aug;27(8):1316–8

[Autonomic dysreflexia: a life-threatening complication in patients with a high-level spinal cord injury] Snoek GJ. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1729–32 (Eng. Abstr.) **(Dut)**

[Autonomic nervous system disease—sweat disorders] Kihara M, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10; 84(9):1435–7 (12 ref.) **(Jpn)**

[Intradialysis arterial hypotension in chronic hemodialysis and its relation to autonomic dysfunction] Amado J, et al. **Rev Port Cardiol** 1995 Oct;14(10):717–9 **(Por)**

[Dynamic scintigraphy of gastric emptying in non-insulin dependent diabetics with autonomic neuropathy] Kostić N, et al. **Med Pregl** 1995;48(3–4):80–3 (Eng. Abstr.) **(Scr)**

DIAGNOSIS

Tests of autonomic dysfunction in patients with multiple sclerosis. Drory VE, et al. **Acta Neurol Scand** 1995 Nov; 92(5):356–60

Characteristics of the dysarthria of multiple system atrophy. Kluin KJ, et al. **Arch Neurol** 1996 Jun;53(6):545–8

Depression in multiple system atrophy and in idiopathic Parkinson's disease: a pilot comparative study. Pilo L, et al. **Biol Psychiatry** 1996 May 1;39(9):803–7

Failure of the autonomic nervous system. Mitsky V, et al. **Compr Ther** 1995 Sep;21(9):529–34 (8 ref.)

Sympathetic skin response: correlation with autonomic and somatic involvement in multiple sclerosis. Caminero AB, et al. **Electromyogr Clin Neurophysiol** 1995 Dec; 35(8):457–62

Association between QT dispersion and autonomic dysfunction in patients with diabetes mellitus. Wei K, et al. **J Am Coll Cardiol** 1995 Oct;26(4):859–63

Autonomic dysfunction in newly diagnosed insulin-dependent diabetes mellitus children. Verrotti A, et al. **Pediatr Neurol** 1996 Jan;14(1):49–52

[Diabetic cardiovascular neuropathy] Luft D. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):139–43 (38 ref.) (Eng. Abstr.) **(Ger)**

[Uremic autonomic neuropathy—pathogenesis, diagnostic methods] Rozentryt P, et al. **Postepy Hig Med Dosw** 1995; 49(5):671–89 (101 ref.) (Eng. Abstr.) **(Pol)**

[Response of pancreatic polypeptide to a protein test meal in the evaluation of diabetic autonomic neuropathy] Kostić N, et al. **Med Pregl** 1996;49(5–6):177–9 (Eng. Abstr.) **(Scr)**

[Diagnosis and treatment of the neurovegetative disorders: autonomic neuropathies] Suárez GA. **Rev Neurol** 1996 Jun; 24(130):671–5 (3 ref.) **(Spa)**

[Estimated stress verifies autonomic dysfunction] Nyström C, et al. **Lakartidningen** 1996 Jul 10;93(28–29):2583–4 **(Swe)**

DRUG THERAPY

Management of autonomic dysfunction in severe tetanus: the use of fentanyl [letter] Moughabghab AV, et al. **Can J Anaesth** 1995 Oct;42(10):955

Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Perera R, et al. **Clin Auton Res** 1995 Sep;5(4):211–3

New potential uses for transdermal scopolamine (hyoscine). La Rovere MT, et al. **Drugs** 1995 Nov;50(5):769–76 (49 ref.)

Acute pandysautonomia: mass spectrometric and histopathological studies of the sympathetic nervous system during long term L-threo-3,4-dihydroxyphenylserine treatment. Ushiyama M, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):99–102

EPIDEMIOLOGY

Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. Töyry JP, et al. **Diabetes** 1996 Mar; 45(3):308–15

ETIOLOGY

Autonomic neuropathy with gastropathy and elevated urinary 5-hydroxy indole acetic acid in insulin-dependent diabetes mellitus [letter] Nolan B, et al. **Am J Gastroenterol** 1996 Jun;91(6):1286

Relationship between the degree of cardiovascular autonomic dysfunction and symptoms of neuropathy and other complications of diabetes mellitus. Neumann C, et al. **Braz J Med Biol Res** 1995 Jul;28(7):751–7

Autonomic dysreflexia in tetraplegic patients: evidence for alpha-adrenoceptor hyper-responsiveness. Arnold JM, et al. **Clin Auton Res** 1995 Oct;5(5):267–70

Predicting cardiac autonomic neuropathy in type I (insulin-dependent) diabetes mellitus. Jaffe RS, et al. **Clin Auton Res** 1995 Jun;5(3):155–8

Measurement of heart rate variations: influencing factors, normal values and diagnostic impact on diabetic autonomic neuropathy. Braune HJ, et al. **Diabetes Res Clin Pract** 1995 Sep;29(3):179–87

Proliferative diabetic retinopathy is related to cardiovascular autonomic neuropathy in non-insulin-dependent diabetes mellitus. Schmid H, et al. **Diabetes Res Clin Pract** 1995 Sep;29(3):163–8

Presence of autonomic neuropathy is a poor prognostic indicator in patients with advanced liver disease. Fleckenstein JF, et al. **Hepatology** 1996 Mar;23(3):471–5

Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Mohamed R, et al. **Hepatology** 1996 May;23(5):1128–34

Autonomic nervous disorder in motor neuron disease: a study of advanced stage patients. Sato K, et al. **Intern Med** 1995 Oct;34(10):972–5

Diabetic esophageal neuropathy and esophageal changes. Prikazska M, et al. **Isr J Med Sci** 1995 Nov;31(11):681–4

A study of autonomic neuropathy in diabetes mellitus in relation to its metabolic control. Gupta RC, et al. **J Assoc Physicians India** 1995 Jul;43(7):464–6

Role of cortisol in the pathogenesis of deficient counterregulation after antecedent hypoglycemia in normal humans. Davis SN, et al. **J Clin Invest** 1996 Aug 1; 98(3):680–91

Relationship between cardiac autonomic neuropathy and diabetic microangiopathies and macroangiopathy in patients with non-insulin-dependent diabetes mellitus. Okada S, et al. **J Int Med Res** 1996 Jan–Feb;24(1):92–8

Relationship between cardiosympathetic neuropathy and diabetic somatic neuropathy in patients with non-insulin-dependent diabetes mellitus. Okada S, et al. **J Int Med Res** 1995 Jul–Aug;23(4):228–33

Autonomic disorders in Parkinson's disease. Martignoni E, et al. **J Neural Transm Suppl** 1995;45:11–9 (51 ref.)

Sacral insufficiency stress fracture as etiology of positional autonomic dysreflexia: case report. Beard JP, et al. **Paraplegia** 1996 Mar;34(3):173–5

Severe sensory-autonomic neuropathy and endocrinopathy in insulin-dependent diabetes. Watkins PJ, et al. **QJM** 1995 Nov;88(11):795–804

Autonomic cardiovascular neuropathy in primary Sjögren's

syndrome. Andonopoulos AP, et al. **Rheumatol Int** 1995; 15(3):127–9

Autonomic nervous system disorders and reflex sympathetic dystrophy in lightning and electrical injuries. Cohen JA. **Semin Neurol** 1995 Dec;15(4):387–90 (23 ref.)

[Paraplegia after aorto–bifemoral prosthesis: systematized dysautonomic symptoms should evoke spinal cord damage] Loeb T, et al. **Ann Fr Anesth Reanim** 1995;14(3):300–2 (Eng. Abstr.) **(Fre)**

[Acute hepatic porphyria and its neurological syndrome] Bont A, et al. **Schweiz Med Wochenschr** 1996 Jan 9; 126(1–2):6–14 (45 ref.) (Eng. Abstr.) **(Ger)**

[Obesity associated with distorted function of autonomic nervous system] Ookuma K, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:371–6 (13 ref.) **(Jpn)**

[Sensory ataxic neuropathy associated with Sjögren's syndrome] Yasuda T, et al. **Nippon Rinsho** 1995 Oct; 53(10):2568–73 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Prolonged QTc intervals in Parkinson's disease—relation to sudden death and autonomic dysfunction] Ishizaki F, et al. **No To Shinkei** 1996 May;48(5):443–8 (Eng. Abstr.) **(Jpn)**

[Uremic autonomic neuropathy—pathogenesis, diagnostic methods] Rozentryt P, et al. **Postepy Hig Med Dosw** 1995; 49(5):671–89 (101 ref.) (Eng. Abstr.) **(Pol)**

[Psychoautonomic disorders in bronchial asthma patients] Ubaĭdullaev AM, et al. **Ter Arkh** 1996;68(3):44–7 (Eng. Abstr.) **(Rus)**

[The characteristics of a psycho–autonomic syndrome in the sequelae of closed craniocerebral trauma] Osetrov AS. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):7–9 (Eng. Abstr.) **(Rus)**

METABOLISM

Energy expenditure and anaemia of autonomic failure [letter] Ducla-Soares JL, et al. **Clin Auton Res** 1995 Jun;5(3):179

Memory deficits and cholinergic impairments in apolipoprotein E–deficient mice. Gordon I, et al. **Neurosci Lett** 1995 Oct 13;199(1):1–4

Hormonal, renal, and autonomic nerve factors involved in the excretion of sodium and water during dynamic salt and water loading in hypoxaemic chronic obstructive pulmonary disease. Stewart AG, et al. **Thorax** 1995 Aug; 50(8):838–45

NURSING

Protocols constructed around the nursing process. 3: Autonomic dysreflexia. Pinder PM. **J Am Coll Health** 1995 Mar;43(5):229–30

PATHOLOGY

Pandysautonomia: clinicopathological. Report of 5 cases. Li S, et al. **Chin Med J (Engl)** 1995 Nov;108(11):829–34

Pure autonomic failure with motor neuron disease: report of a clinical study and postmortem examination of a patient [letter] Noda K, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):351–2

PHYSIOPATHOLOGY

Association of relative nocturnal hypertension and autonomic neuropathy in insulin-dependent diabetic children. Madácsy L, et al. **Acta Biomed Ateneo Parmense** 1995; 66(3–4):111–8

Transcranial magnetic stimulation in multiple system and late onset cerebellar atrophies. Cruz Martínez A, et al. **Acta Neurol Scand** 1995 Sep;92(3):218–24

Autonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences. Montastruc JL, et al. **Adv Neurol** 1996;69:377–81 (36 ref.)

Cardiovascular autonomic dysfunction in diabetes mellitus. Barkai L, et al. **Arch Dis Child** 1995 Dec;73(6):515–8

Evaluation of the autonomic cardiovascular response in Arnold–Chiari deformities and cough syncope syndrome. Ireland PD, et al. **Arch Neurol** 1996 Jun;53(6):526–31

The WAGxDA rat: an animal model of cholinergic supersensitivity. Orpen G, et al. **Biol Psychiatry** 1995 Jun 15;37(12):874–83

Abnormalities in gallbladder dynamics of type 1 (insulin-dependent) diabetic patients with autonomic neuropathy. Ludwig EB, et al. **Braz J Med Biol Res** 1995 May;28(5):531–6

Sympathetic skin response in Guillain–Barré syndrome. Taly AB, et al. **Clin Auton Res** 1995 Sep;5(4):215–9

Effect of the somatostatin analogue, octreotide, on exercise-induced hypotension in human subjects with chronic sympathetic failure. Smith GD, et al. **Clin Sci (Colch)** 1995 Oct;89(4):367–73

Twenty-four-hour pattern of blood pressure and spectral analysis of heart rate variability in diabetic patients with various degrees of autonomic neuropathy. Comparison to standard cardiovascular tests. Spallone V, et al. **Clin Sci (Colch)** 1996;91 Suppl:105–7

Excessive gravitational blood pooling caused by impaired venous tone is the predominant non-cardiac mechanism of orthostatic intolerance. Streeten DH, et al. **Clin Sci (Colch)** 1996 Apr;90(4):277–85

Diabetic autonomic neuropathy. Spallone V, et al. **Diabetes Metab Rev** 1995 Oct;11(3):227–57 (322 ref.)

Involvement of the autonomic nervous system in patients with syringomyelia—a study with the sympathetic skin response. Masur H, et al. **Electromyogr Clin Neurophysiol** 1996 Jan–Feb;36(1):43–7

Autonomic neuropathy in chronic alcoholism: evaluation of cardiovascular, pupillary and sympathetic skin responses. Miralles R, et al. **Eur Neurol** 1995;35(5):287–92

QT interval and dispersion in primary autonomic failure. Lo SS, et al. **Heart** 1996 May;75(5):498–501

Diseases affecting sudomotor function. Kihara M, et al. **Intern Med** 1996 Jan;35(1):50–2

Relationship between cardiac autonomic neuropathy and diabetic microangiopathies and macroangiopathy in patients with non-insulin-dependent diabetes mellitus. Okada S, et al. **J Int Med Res** 1996 Jan–Feb;24(1):92–8

Cardiac autonomic function during sleep and wakefulness in multiple sclerosis. Ferini-Strambi L, et al. **J Neurol** 1995 Oct;242(10):639–43

Subclinical autonomic disturbances in multiple sclerosis. Linden D, et al. **J Neurol** 1995 Jun;242(6):374–8

Clinico–pathophysiological features of acute autonomic and sensory neuropathy: a long-term follow-up study. Yasuda T, et al. **J Neurol** 1995 Oct;242(10):623–8

Acute pandysautonomia: mass spectrometric and histopathological studies of the sympathetic nervous system during long term L-threo-3,4-dihydroxyphenylserine treatment. Ushiyama M, et al. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):99–102

Transient autonomic neuropathy in an adolescent with insulin dependent diabetes mellitus. Oduwole A, et al. **J Pediatr Endocrinol Metab** 1995 Jul–Sep;8(3):195–7

Electrophysiological tests of autonomic function in patients with idiopathic autonomic failure syndromes. Ravits J, et al. **Muscle Nerve** 1996 Jun;19(6):758–63

Effect of autonomic neuropathy on ventilatory response to progressive hypercapnia in dialysis patients. Auinger M, et al. **Nephrol Dial Transplant** 1995;10(6):825–30

Identifying delirious states and autonomic cardiovascular dysfunction associated with amitriptyline treatment by standardized analysis of heart rate. Rechlin T, et al. **Psychiatry Res** 1995 Apr 28;56(3):279–87

Cough reflex threshold in diabetes mellitus with and without autonomic neuropathy. Behera D, et al. **Respiration** 1995; 62(5):263–8

Autonomic epilepsy. Freeman R, et al. **Semin Neurol** 1995 Jun;15(2):158–66 (134 ref.)

Prolongation of the QTc-interval reflects the severity of autonomic neuropathy in primary biliary cirrhosis and in other non-alcoholic liver diseases. Kempler P, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:96–8

[The autonomic regulation of the cardiovascular system in subjects with the autonomic dystonia syndrome subjected to ionizing radiation exposure as a result of the accident at the Chernobyl Atomic Electric Power Station] Niagu AI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(4):32–5 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Uremic autonomic neuropathy: recovery following bicarbonate hemodialysis. Vita G, et al. **Clin Nephrol** 1996 Jan;45(1):56–60

RADIONUCLIDE IMAGING

Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy. Schnell O, et al. **Diabetologia** 1995 Nov;38(11):1345–52

Evaluation of cardiac sympathetic neuronal integrity in diabetic patients using iodine-123 metaiodobenzylguanidine. Kim SJ, et al. **Eur J Nucl Med** 1996 Apr;23(4):401–6

A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. Hirayama M, et al. **J Auton Nerv Syst** 1995 Jun 25;53(2–3):230–4

Clinical usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy in diabetic patients with cardiac sympathetic nerve dysfunction. Miyanaga H, et al. **Jpn Circ J** 1995 Sep;59(9):599–607

[Localized cardiac uptake defect with 123I-MIBG SPECT in a case with pure progressive autonomic failure] Yoshida M, et al. **Rinsho Shinkeigaku** 1996 Jan;36(1):25–9 (Eng. Abstr.) **(Jpn)**

SURGERY

Sporadic visceral neuropathy. Niwamoto H, et al. **Surg Today** 1995;25(9):763–70

[Tumor of the gastrointestinal autonomic nervous system (GAN-tumor or plexus sarcoma)] Flückiger R, et al. **Chirurg** 1996 Apr;67(4):371–9 (20 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Cardiac coherence: a new, noninvasive measure of autonomic nervous system order. Tiller WA, et al. **Altern Ther Health Med** 1996 Jan;2(1):52–65 (65 ref.)

Autonomic hyperreflexia during labour. Kobayashi A, et al. **Can J Anaesth** 1995 Dec;42(12):1134–6

Failure of the autonomic nervous system. Mitsky V, et al. **Compr Ther** 1995 Sep;21(9):529–34 (8 ref.)

Idiopathic dysautonomia treated with intravenous gammaglobulin. Heafield MT, et al. **Lancet** 1996 Jan 6; 347(8993):28–9

[Prevention and treatment of uremic autonomic neuropathy] Rozentryt P, et al. **Postepy Hig Med Dosw** 1995; 49(6):767–82 (97 ref.) (Eng. Abstr.) **(Pol)**

[Psychoautonomic and neurovascular disorders in patients with autonomic vascular dystonia and the hyperventilation syndrome and methods for their correction] Poliakov VA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(4):25–7 (Eng. Abstr.) **(Rus)**

VETERINARY

Dysautonomia in dogs: a retrospective study. Longshore RC, et al. **J Vet Intern Med** 1996 May–Jun;10(3):103–9

Patterns of feeding and behaviour in horses recovering from dysautonomia (grass sickness). Doxey DL, et al. **Vet Rec** 1995 Aug 19;137(8):181–3

Recovery of horses from dysautonomia (grass sickness). Doxey DL, et al. **Vet Rec** 1995 Dec 2;137(23):585–8

Small intestine and small colon neuropathy in equine dysautonomia (grass sickness). Doxey DL, et al. **Vet Res Commun** 1995;19(6):529–43

[What is your diagnosis? Key-Gaskell syndrome or feline dysautonomia] Monnin E, et al. **Schweiz Arch Tierheilkd** 1995;137(11):515–6 **(Fre)**

AUTONOMIC PATHWAYS

[Gastric plexosarcoma (letter)] Villeta Plaza R, et al. **Rev Esp Enferm Dig** 1996 Jun;88(6):451–2 **(Spa)**

DRUG EFFECTS

Evidence for activation of both adrenergic and cholinergic nervous pathways by yohimbine, an alpha 2-adrenoceptor antagonist. Bagheri H, et al. **Fundam Clin Pharmacol** 1995; 9(3):248–54

Acrylamide-induced neuropathic changes in rat enteric nerves: similarities with effects of streptozotocin–diabetes. Belai A, et al. **J Auton Nerv Syst** 1996 Apr 20;58(1–2):56–62

ENZYMOLOGY

Localization of nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d) activity in the gastrointestinal sphincters in the guinea pig. Wang XY, et al. **J Auton Nerv Syst** 1996 Apr 20;58(1–2):51–5

METABOLISM

Pseudorabies virus mutants as transneuronal markers. Sams JM, et al. **Brain Res** 1995 Jul 31;687(1–2):182–90

PHYSIOLOGY

Role of peripheral autonomic neurones in maintaining adequate cardiac function. Horackova M, et al. **Cardiovasc Res** 1995 Sep;30(3):326–35 (88 ref.)

Can the neurotrophic hypothesis explain degeneration and loss of plasticity in mature and ageing autonomic nerves? Gavazzi I, et al. **J Auton Nerv Syst** 1996 Apr 20; 58(1–2):1–10 (79 ref.)

Power spectral analysis of heart-rate variability reflects the level of cardiac autonomic activity in rabbits. Moguilevski VA, et al. **J Auton Nerv Syst** 1996 Apr 20;58(1–2):18–24

PHYSIOPATHOLOGY

Prospective study of autonomic nerve function in type 1 and type 2 diabetic patients: 24 hour heart rate variation and plasma motilin levels disturbed in parasympathetic neuropathy. Nilsson H, et al. **Diabet Med** 1995 Nov; 12(11):1015–21

Autonomic nerve affection in leprosy. Katoch K. **Indian J Lepr** 1996 Jan–Mar;68(1):49–54 (33 ref.)

AUTONOMOUS REPLICATION see **DNA REPLICATION**

AUTOPHAGOCYTOSIS

Active cell death induced by the anti–estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Bursch W, et al. **Carcinogenesis** 1996 Aug;17(8):1595–607

The role of the intralysosomal pH in the control of autophagic proteolytic flux in rat hepatocytes. Luiken JJ, et al. **Eur J Biochem** 1996 Feb 1;235(3):564–73

Ultrastructural and immunocytochemical characterization of autophagic vacuoles in isolated hepatocytes: effects of vinblastine and asparagine on vacuole distributions. Fengsrud M, et al. **Exp Cell Res** 1995 Dec;221(2):504–19

GENETICS

Genetic and phenotypic overlap between autophagy and the cytoplasm to vacuole protein targeting pathway. Harding TM, et al. **J Biol Chem** 1996 Jul 26;271(30):17621–4

PHYSIOLOGY

The metabolism of sphingo(glyco)lipids is correlated with the differentiation-dependent autophagic pathway in HT-29 cells. Ghidoni R, et al. **Eur J Biochem** 1996 Apr 15;237(2):454–9

Role of cAMP in the regulation of hepatocytic autophagy.

Holen I, et al. **Eur J Biochem** 1996 Feb 15;236(1):163–70
Autophagic death after cell cycle arrest at the restrictive temperature in temperature-sensitive cell division cycle and secretory mutants of the yeast Saccharomyces cerevisiae. Motizuki M, et al. **Eur J Cell Biol** 1995 Nov;68(3):275–87
Ultrastructural and biochemical characterization of autophagy in higher plant cells subjected to carbon deprivation: control by the supply of mitochondria with respiratory substrates. Aubert S, et al. **J Cell Biol** 1996 Jun;133(6):1251–63
Test-tube simulated lipofuscinogenesis. Effect of oxidative stress on autophagocytotic degradation. Yin D, et al. **Mech Ageing Dev** 1995 Jun 30;81(1):37–50

AUTOPROTHROMBIN C see **FACTOR XA**

AUTOPROTHROMBIN II see **FACTOR IX**

AUTOPROTHROMBIN III see **FACTOR X**

AUTOPSY

Autopsy practices at CERAD and Alzheimer disease center sites: a survey of neuropathologists. Cochran EJ, et al. **Alzheimer Dis Assoc Disord** 1995 Winter;9(4):203–7
Results of autopsy survey [letter; comment] Marley EF. **Am J Clin Pathol** 1996 Jul;106(1):155–6. Comment on: Am J Clin Pathol 1996 Feb;105(2):144–8.
American Society of Clinical Pathologists—Resident Physician Section. Results of autopsy survey (Winter 1994–1995) [see comments] Nayar R, et al. **Am J Clin Pathol** 1996 Feb;105(2):144–8. Comment in: Am J Clin Pathol 1996 Jul;106(1):155–6.
Protective gloves for high-risk autopsies [letter] Zugibe FT, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):182
Viability of the autopsy outside the institutions [letter; comment] Bryant J. **Arch Pathol Lab Med** 1996 Jan; 120(1):9–10. Comment on: Arch Pathol Lab Med 1995 Mar;119(3):289–91.
Organ-limited autopsies: obtaining permission for postmortem examination of the urinary tract [letter; comment] [see comments] Davis GJ. **Arch Pathol Lab Med** 1995 Dec;119(12):1092. Comment on: Arch Pathol Lab Med 1995 May;119(5):440–3. Comment in: Arch Pathol Lab Med 1996 May;120(5):428.
Obtaining permission for postmortem examination [letter; comment] Hanzlick R. **Arch Pathol Lab Med** 1996 May; 120(5):428. Comment on: Arch Pathol Lab Med 1995 Dec;119(12):1092.
The autopsy and the public need [letter; comment] Haque AK. **Arch Pathol Lab Med** 1995 Dec;119(12):1092–4. Comment on: Arch Pathol Lab Med 1994 Sep;118(9):870–2. Comment on: Arch Pathol Lab Med 1995 May;119(5):393; discussion 395. Comment on: Arch Pathol Lab Med 1995 May;119(5):393, 395.
Autopsy. A crucial component of human clinical investigation. Kaufman SR. **Arch Pathol Lab Med** 1996 Aug;120(8):767–70 (43 ref.)
A prototype Internet autopsy database. 1625 consecutive fetal and neonatal autopsy facesheets spanning 20 years. Moore GW, et al. **Arch Pathol Lab Med** 1996 Aug;120(8):782–5
The autopsy. Some ethical reflections on the obligations of pathologists, hospitals, families, and society. Pellegrino ED. **Arch Pathol Lab Med** 1996 Aug;120(8):739–42 (0 ref.)
GP autopsies [letter; comment] Colebatch T. **Aust Fam Physician** 1995 Nov;24(11):2146. Comment on: Aust Fam Physician 1995 Sep;24(9):1765.
Should perinatal postmortems be carried out by specialist pathologists [letter; comment] Hickey K, et al. **Br J Obstet Gynaecol** 1995 Sep;102(9):757–8. Comment on: Br J Obstet Gynaecol 1991 Jul;98(7):624–7.
Association of pre mortem diagnosis and autopsy findings in pediatric intensive care unit versus emergency department versus ward patients. Goldstein B, et al. **Crit Care Med** 1996 Apr;24(4):683–6
Accuracy of admission and clinical diagnosis of tumours as revealed by 2000 autopsies. Szende B, et al. **Eur J Cancer** 1996 Jun;32A(7):1102–8
Study on electrocution death by low-voltage. Zhang P, et al. **Forensic Sci Int** 1995 Dec 18;76(2):115–9 (4 ref.)
Value and impact of necropsy in paediatric cardiology. Gatzoulis MA, et al. **Heart** 1996 Jun;75(6):626–31
Clinical detachment [letter] Taxy JB. **Hum Pathol** 1996 Mar; 27(3):313–5
Use of the National Register of medico-legal autopsies in epidemiological suicide research. Lindeman SM, et al. **Int J Legal Med** 1995;107(6):306–9
Confidentiality, death and the doctor. James DS, et al. **J Clin Pathol** 1996 Jan;49(1):1–4
Funeral directors, mortuaries and necropsies: implications for necropsy consent rates and the prevention of infection. Start RD, et al. **J Clin Pathol** 1996 Mar;49(3):217–22
Where have all the autopsies gone? A proposal for a centralized autopsy service. Mitchell EK, et al. **J Community Health** 1995 Oct;20(5):441–6
The value of neonatal autopsies. D'Costa G, et al. **J Trop Pediatr** 1995 Oct;41(5):311–3
A piece of my mind. Respect for the dead. Smith DG. **JAMA** 1995 Nov 1;274(17):1408
Hazard to pathologists and anatomists from vena-caval (Greenfield) filters [letter] Abraham JL, et al. **Lancet** 1995 Oct 21;346(8982):1100
Antimony detected in necropsy tissues may derive from contaminated formalin [letter] Byard RW, et al. **Lancet** 1995 Dec 16;346(8990):1633–4
Gas gangrene: necropsy is imperative [letter] [see comments] Hengster P, et al. **Lancet** 1996 Feb 24;347(9000):553. Comment in: Lancet 1996 Apr 20;347(9008):1116. Comment in: Lancet 1996 Apr 20;347(9008):1116–7.
Necropsy as a research method in the age of molecular pathology. Kleiner DE, et al. **Lancet** 1995 Oct 7; 346(8980):945–8 (31 ref.)
Molecular and epidemiological necropsy: two or a pair? Offerhaus GJ. **Lancet** 1996 Feb 10;347(8998):346
Managing HIV. Part 5: Treating secondary outcomes. 5.20 HIV and autopsies. Duflou J, et al. **Med J Aust** 1996 May 20;164(10):616–7
The decline in hospital autopsy rates [letter] Hilton JM. **Med J Aust** 1996 Jul 1;165(1):62–3
The autopsy. An antidote to misdiagnosis. McPhee SJ. **Medicine (Baltimore)** 1996 Jan;75(1):41–3
Becoming a Third World country: the verbal autopsy [editorial] Wagner BM. **Mod Pathol** 1995 May;8(4):348
Case records of the Massachusetts General Hospital: a home-court advantage? [letter; comment] Gill JR. **N Engl J Med** 1996 Jan 18;334(3):197. Comment on: N Engl J Med 1995 Sep 28;333(13):883–4.
Lessons learned from autopsies at a pediatric teaching hospital. Stolman CJ, et al. **N J Med** 1995 Dec;92(12):794–7
The consortium to establish a registry for Alzheimer's Disease (CERAD). Part XIII. Obtaining autopsy in Alzheimer's disease. Fillenbaum GG, et al. **Neurology** 1996 Jan;46(1):142–5
An autopsy case of abandoned infant body with severe destruction. Funayama M, et al. **Nippon Hoigaku Zasshi** 1996 Apr;50(2):92–7
Occupational tuberculosis and a failed postgraduate medical examination. Stenton SC, et al. **Occup Med (Oxf)** 1996 Feb; 46(1):87–8
The postmortem examination. Valdes-Dapena M. **Pediatr Ann** 1995 Jul;24(7):365–72
Clinician beliefs underlying autopsy requests. Birdi KS, et al. **Postgrad Med J** 1996 Apr;72(846):224–8
Muslim customs regarding autopsies [letter] Patel H. **S Afr Med J** 1995 Nov;85(11):1198
Muslim customs regarding autopsies [letter] Seedat OH. **S Afr Med J** 1995 Aug;85(8):789–90
Muslim customs regarding autopsies [letter] Wadee SA. **S Afr Med J** 1995 Nov;85(11):1198–9
Asymptomatic large pituitary adenomas discovered at autopsy. Auer RN, et al. **Surg Neurol** 1996 Jul;46(1):28–31
Tuberculosis in the autopsy material: analysis of 1500 autopsies performed between 1972 and 1991 in the Institute of Tuberculosis and Chest Diseases, Warsaw, Poland [see comments] Rowińska-Zakrzewska E, et al. **Tuber Lung Dis** 1995 Aug;76(4):349–54. Comment in: Tuber Lung Dis 1995 Aug;76(4):279–80.
[The establishment of ADBS data bank system for autopsy records] Li G, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1995 Dec;26(4):416–9 (Eng. Abstr.) **(Chi)**
[Epidemiologic value of autopsy records (base on a number of actual cases] Károlyi G, et al. **Orv Hetil** 1996 May 19; 137(20):1083–4 **(Hun)**
[Clinical autopsy in primary care?] Monzón Muñoz FJ, et al. **Aten Primaria** 1996 Jun 15;18(1):40–3 **(Spa)**
[Who is responsible for autopsy? (letter)] Olofsson G. **Lakartidningen** 1996 Jun 26;93(26–27):2488 **(Swe)**

ECONOMICS

The role of managed health care organizations in autopsy reimbursement. Chernof D. **Arch Pathol Lab Med** 1996 Aug;120(8):771–2 (0 ref.)
College of American Pathologists Conference XXIX on restructuring autopsy practice for health care reform. Let's make this autopsy conference matter. Lundberg GD. **Arch Pathol Lab Med** 1996 Aug;120(8):736–8 (11 ref.)
The role for regional autopsy centers in the evaluation of covered deaths. Survey of opinions of US and Canadian chairs of pathology and major health insurers in the United States. Trelstad RL, et al. **Arch Pathol Lab Med** 1996 Aug; 120(8):753–8 (48 ref.)
Funding the clinical autopsy [editorial] Start RD, et al. **J Pathol** 1995 Sep;177(1):5–9 (17 ref.)

HISTORY

The recent history of the autopsy. Hill RB, et al. **Arch Pathol Lab Med** 1996 Aug;120(8):702–12

INSTRUMENTATION

Three years of experience with a dissection table ventilation system. Martin WD, et al. **Clin Anat** 1995;8(4):297–302

LEGISLATION & JURISPRUDENCE

A potpourri of legal issues relating to the autopsy. Bierig JR. **Arch Pathol Lab Med** 1996 Aug;120(8):759–62 (26 ref.)
Confession of ignorance of causation in coroners' necropsies—a common problem? Davison AM, et al. **J Clin Pathol** 1996 Jun;49(6):439–43
Ethical considerations of the perinatal necropsy. Khong TY. **J Med Ethics** 1996 Apr;22(2):111–4

METHODS

Endoscopic autopsy. Avrahami R, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):147–50
Epidemiologic and clinical challenges in reviving the necropsy. Feinstein AR. **Arch Pathol Lab Med** 1996 Aug; 120(8):749–52 (11 ref.)
Human tissue retrieval at post-mortem for musculoskeletal research. McCaskie AW, et al. **Br J Biomed Sci** 1995 Sep; 52(3):222–4
Algorithms for verbal autopsies: a validation study in Kenyan children. Quigley MA, et al. **Bull World Health Organ** 1996; 74(2):147–54
The analysis of methomyl, a carbamate pesticide, in post-mortem samples. Tsatsakis AM, et al. **Sci Justice** 1996 Jan-Mar;36(1):41–5
[Apropos of laparoscopic autopsy (letter)] Clotteau JE, et al. **Presse Med** 1996 Jan 20;25(2):85 **(Fre)**
[Personal-likeness identification based on the corpse and intravital photography. Methodological recommendations No. 94/266. Approved by the Ministry of Health and the Medical Industry of Russia 3 July 95] Zviagin VN, et al. **Sud Med Ekspert** 1996 Jan-Mar;39(1):39–42 **(Rus)**

STANDARDS

Enhancing autopsy performance and reporting. A system for a 5-day completion time. Adickes ED, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):249–53
On the need for more expertise in death investigation (and a National Office of Death Investigation Affairs?) [editorial] Hanzlick R. **Arch Pathol Lab Med** 1996 Apr; 120(4):329–32 (26 ref.)
Relating autopsy requirements to the contemporary accreditation process. O'Leary DS. **Arch Pathol Lab Med** 1996 Aug;120(8):763–6 (5 ref.)
The need for a national autopsy policy. Setlow VP. **Arch Pathol Lab Med** 1996 Aug;120(8):773–7 (6 ref.)
Quality assurance of autopsy permit form information, timeliness of performance, and issuance of preliminary report. A College of American Pathologists Q-Probes study of 5434 autopsies from 452 institutions. Zarbo RJ, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):346–52
Audit study of next of kin's satisfaction with clinical necropsy service. Start RD, et al. **BMJ** 1996 Jun 15;312(7045):1516
Perinatal and infant postmortem examinations: how well are we doing? Vujanić GM, et al. **J Clin Pathol** 1995 Nov; 48(11):998–1001

STATISTICS & NUMERICAL DATA

Unanticipated diagnoses found at autopsy in an urban public teaching hospital. Bernicker EH, et al. **Am J Med Sci** 1996 May;311(5):215–20
High autopsy rates at a university medical center. What has gone right? Haque AK, et al. **Arch Pathol Lab Med** 1996 Aug;120(8):727–32 (19 ref.)
Maximizing the benefits of autopsy for clinicians and families. What needs to be done. McPhee SJ. **Arch Pathol Lab Med** 1996 Aug;120(8):743–8 (53 ref.)
Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Stein PD, et al. **Chest** 1995 Oct;108(4):978–81
Post-mortem rates and junior doctors in Tayside—three years after the Joint Working Party report. Inglis FG, et al. **Health Bull (Edinb)** 1995 Nov;53(6):379–85
Analysis of necropsy request behaviour of clinicians. Start RD, et al. **J Clin Pathol** 1996 Jan;49(1):29–33
Influence of necropsy on clinical practice [letter] Kovachev LS, et al. **Lancet** 1996 Jan 27;347(8996):267
The decline in hospital autopsy rates [letter] Crowley PF, et al. **Med J Aust** 1996 Feb 5;164(3):188–9
Prevalence of the neonatal autopsy: a report of the Study Group for Complications of Perinatal Care. Landers S, et al. **Pediatr Pathol Lab Med** 1995 Jul-Aug;15(4):539–45
The death of the postmortem. Inglis FG, et al. **Scott Med J** 1995 Oct;40(5):131–2

VETERINARY

Postmortem migration of Hymenolepis diminuta (Cestoidea: Cyclophyllidea) in the laboratory rat. Platt TR, et al. **J Parasitol** 1995 Dec;81(6):1024–7

AUTORADIOGRAPHY

Autoradiographic evidence of steroid affinity sites in nasal tissue. Kai S, et al. **Acta Otolaryngol Suppl (Stockh)** 1996; 522:57–62
Quantitative measurement of neuronal calbindin-D28k by radioimmunocytochemistry. Ng MC, et al. **Brain Res Mol Brain Res** 1995 Aug;32(1):82–6
Relevance of tissue distribution studies and cytopharmacology: utility of radioassay combined with autoradiography [letter] Stumpf WE. **Drug Metab Dispos** 1995 Sep;23(9):885–6
Autoradiographic localization and characterization of bradykinin receptors in human skin. Schremmer-Danninger E, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):207–16
Autoradiographic visualisation of [3H]5-carboxamidotryptamine binding sites in the guinea pig and rat brain. Waeber C, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):31–46

Comparison of conventional autoradiography with a new DNA enzyme immunoassay for the detection of hepatitis C virus–polymerase chain reaction amplification products. Feucht HH, et al. **J Virol Methods** 1995 Sep;55(1):105–10

Autoradiographical study of types 1 and 2 of benzodiazepine receptors in rat brain after chronic ethanol treatment and its withdrawal. Negro M, et al. **Neuropharmacology** 1995 Sep;34(9):1177–82

Autoradiographic localization of NK1 and NK3 tachykinin receptors in rat kidney. Chen Y, et al. **Peptides** 1995; 16(4):673–81

Autoradiographic localization of calcitonin gene–related peptide receptors in guinea pig respiratory tract: effect of capsaicin pretreatment. Watkins DJ, et al. **Peptides** 1995; 16(4):683–92

METHODS

Error analysis of autoradiography method for measurement of cerebral blood flow by 123I–IMP brain SPECT: a comparison study with table look–up method and microsphere model method. Ito H, et al. **Ann Nucl Med** 1995 Nov;9(4):185–190

Study of the de novo synthesis of cholesterol in the rat liver: a newly developed radiotracer technique, "TLC–autoradioluminography". Okuyama M, et al. **Biol Pharm Bull** 1995 Nov;18(11):1467–71

ImageCalc: a Microsoft Windows application for quantitative image analysis and comparison. van de Lest CH, et al. **Biotechniques** 1995 Jun;18(6):1050–5

Radioluminography for quantitative autoradiography of 14C. Motoji N, et al. **Eur J Drug Metab Pharmacokinet** 1995 Apr–Jun;20(2):89–105

Local cerebral glucose utilization in fetal guinea pigs at 0.75 gestation. Berger R, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):175–8

Autoradiography–based cytochemical detection of ecto–ATPase, ecto–ADPase, 5'–nucleotidase, and extracellular adenosine production, employing 141Ce3+ as a capturing agent. Culic O, et al. **Histochem J** 1995 Jul; 27(7):555–64

A method of quantitative autoradiography for the spatial localization of proteoglycan synthesis rates in cartilage. Buschmann MD, et al. **J Histochem Cytochem** 1996 May; 44(5):423–31

Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double–tracer autoradiography in rats. Sugimoto S, et al. **J Neurooncol** 1995;24(3):229–40

A novel quantitative receptor autoradiography and in situ hybridization histochemistry technique using storage phosphor screen imaging. Ito T, et al. **J Neurosci Methods** 1995 Jul;59(2):265–71

An improved autoradiographic coating technique for neurohistopathological stains and electron microscopy. Kornhauser GV, et al. **J Neurosci Methods** 1995 Aug; 60(1–2):43–7

Zone–specific cell biosynthetic activity in mature bovine articular cartilage: a new method using confocal microscopic stereology and quantitative autoradiography. Wong M, et al. **J Orthop Res** 1996 May;14(3):424–32

Photoelectrons facilitate autoradiography for 192Ir remote afterloaders. Anderson LL, et al. **Med Phys** 1995 Nov;22(11 Pt 1):1759–61

Quantitative verification of 192Ir PDR and HDR source structure by pin–hole autoradiography. Kirov AS, et al. **Med Phys** 1995 Nov;22(11 Pt 1):1753–7

Dual–tracer autoradiography using 125I–iomazenil and 99Tcm–HMPAO in experimental brain ischaemia. Matsuda H, et al. **Nucl Med Commun** 1995 Jul;16(7):581–90

In vitro labeling of gonadal steroid hormone receptors in brain tissue sections. Brown TJ, et al. **Steroids** 1995 Nov; 60(11):726–37

UTILIZATION

Progressive application of autoradiography in pharmacokinetic and metabolic studies for the development of new drugs. Shigematsu A, et al. **Regul Toxicol Pharmacol** 1995 Oct;22(2):122–42 (20 ref.)

AUTORECEPTORS

CLASSIFICATION

Subclassification of presynaptic 5–HT autoreceptors in the human cerebral cortex as 5–HT1D receptors. Fink K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Oct; 352(4):451–4

Subclassification of presynaptic alpha 2–adrenoceptors: alpha 2A–autoreceptors in rabbit atria and kidney. Limberger N, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):31–42

Subclassification of presynaptic alpha 2–adrenoceptors: alpha 2D–autoreceptors in mouse brain. Limberger N, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):43–8

Subclassification of presynaptic alpha 2–adrenoceptors: alpha 2D–autoreceptors in guinea–pig atria and brain. Trendelenburg AU, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):49–57

DRUG EFFECTS

Dopamine autoreceptor sensitivity is unchanged in rat nucleus accumbens after chronic haloperidol treatment: an in vivo and in vitro voltammetric study. Chesi AJ, et al. **Eur J Neurosci** 1995 Dec 1;7(12):2450–7

The presynaptic alpha–2 autoreceptors in pig brain cortex are alpha–2A. Trendelenburg AU, et al. **J Pharmacol Exp Ther** 1996 Aug;278(2):462–7

Pancuronium masks the prejunctional muscarinic autoreceptor in guinea pig tracheal smooth muscle. Nagtegaal JE, et al. **Life Sci** 1995;57(25):2325–33

[Chronic treatment with nicotine enhances the sensitivity of dopamine autoreceptors that modulate dopamine release from the rat striatum] Takaki T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Aug; 15(4):335–44 (Eng. Abstr.) (Jpn)

METABOLISM

Evidence for presynaptic location of inhibitory 5–HT1D beta–like autoreceptors in the guinea–pig brain cortex. Bühlen M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Feb;353(3):281–9

PHYSIOLOGY

Somatodendritic autoreceptors on oxytocin neurones. Freund–Mercier MJ, et al. **Adv Exp Med Biol** 1995; 395:185–94 (31 ref.)

Muscarinic inhibitory autoreceptors in different generations of human airways. ten Berge RE, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):43–9

Aminotetralin drugs and D3 receptor functions. What may partially selective D3 receptor ligands tell us about dopamine D3 receptor functions? Lévesque D. **Biochem Pharmacol** 1996 Aug 23;52(4):511–8 (102 ref.)

Presynaptic 5–HT autoreceptors modulate N–methyl–D–aspartate–evoked 5–hydroxytryptamine release in the guinea–pig brain cortex. Fink K, et al. **Eur J Pharmacol** 1996 Apr 4;300(1–2):79–82

Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. O'Hara CM, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):186–92

Subclassification of presynaptic alpha 2–adrenoceptors: alpha 2D–autoreceptors and alpha 2D–adrenoceptors modulating release of acetylcholine in guinea–pig ileum. Funk L, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):58–66

AUTOREGULATION see **HOMEOSTASIS**

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY see **KIDNEY, POLYCYSTIC, AUTOSOMAL DOMINANT**

AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY see **KIDNEY, POLYCYSTIC, AUTOSOMAL RECESSIVE**

AUTOSOME ABNORMALITIES see **CHROMOSOME ABNORMALITIES**

AUTOTRANSFUSION see **BLOOD TRANSFUSION, AUTOLOGOUS**

AUTOTRANSPLANT see **TRANSPLANTATION, AUTOLOGOUS**

AUXINS

see related
GRAVITROPISM

Stable expression of maize auxin–binding protein in insect cell lines. Henderson J, et al. **FEBS Lett** 1995 Sep 11; 371(3):293–6

BIOSYNTHESIS

Superroot, a recessive mutation in Arabidopsis, confers auxin overproduction. Boerjan W, et al. **Plant Cell** 1995 Sep; 7(9):1405–19

GENETICS

The diageotropica mutation and synthetic auxins differentially affect the expression of auxin–regulated genes in tomato. Mito N, et al. **Plant Physiol** 1995 Sep; 109(1):293–7

METABOLISM

Effect of chlorpromazine and benzo[a]phenothiazines on heterotrophic auxin requiring and autotrophic auxin non–requiring tobacco tissue cultures. Szabó M, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2113–6

LOP1: a gene involved in auxin transport and vascular patterning in Arabidopsis. Carland FM, et al. **Development** 1996 Jun;122(6):1811–9

A mutation in protein phosphatase 2A regulatory subunit A affects auxin transport in Arabidopsis. Garbers C, et al. **EMBO J** 1996 May 1;15(9):2115–24

Auxin–binding protein 1 does not bind auxin within the endoplasmic reticulum despite this being the predominant subcellular location for this hormone receptor. Tian H, et al. **J Biol Chem** 1995 Nov 10;270(45):26962–9

The mode of expression and promoter analysis of the arcA gene, an auxin–regulated gene in tobacco BY–2 cells. Ishida S, et al. **Plant Cell Physiol** 1996 Jun;37(4):439–48

Molecular cloning and analysis of the cDNA for an auxin–regulated calmodulin gene. Okamoto H, et al. **Plant Cell Physiol** 1995 Dec;36(8):1531–9

PHARMACOLOGY

Auxin–induced differential sensitivity of the H+–ATPase in plasma membrane subfractions from tobacco cells. Peltier JB, et al. **Biochem Biophys Res Commun** 1996 Feb 15; 219(2):492–6

DNA elements responsive to auxin. Abel S, et al. **Bioessays** 1996 Aug;18(8):647–54 (62 ref.)

Organ–specific and auxin–inducible expression of two tobacco par A–related genes in transgenic plants. Niwa Y, et al. **DNA Res** 1994;1(5):213–21

Composite structure of auxin response elements. Ulmasov T, et al. **Plant Cell** 1995 Oct;7(10):1611–23

5'–regulatory region of Agrobacterium tumefaciens T–DNA gene 6b directs organ–specific, wound–inducible and auxin–inducible expression in transgenic tobacco. Bagyan IL, et al. **Plant Mol Biol** 1995 Dec;29(6):1299–304

The diageotropica mutation and synthetic auxins differentially affect the expression of auxin–regulated genes in tomato. Mito N, et al. **Plant Physiol** 1995 Sep; 109(1):293–7

Auxin–sensitive elements from promoters of tobacco GST genes and a consensus as–1–like element differ only in relative strength. van der Zaal BJ, et al. **Plant Physiol** 1996 Jan;110(1):79–88

Characterization of an endo–beta–1,4–glucanase gene induced by auxin in elongating pea epicotyls. Wu SC, et al. **Plant Physiol** 1996 Jan;110(1):163–70

Modification of phytohormone response by a peptide encoded by ENOD40 of legumes and a nonlegume. van de Sande K, et al. **Science** 1996 Jul 19;273(5273):370–3

Expression of the isopentenyl transferase gene is regulated by auxin in transgenic tobacco tissues. Zhang XD, et al. **Transgenic Res** 1996 Jan;5(1):57–65

PHYSIOLOGY

Differential activation of the primary auxin response genes, PS–IAA4/5 and PS–IAA6, during early plant development. Wong LM, et al. **Plant J** 1996 May; 9(5):587–99

Promoter analysis of the auxin–regulated tobacco glutathione S–transferase genes Nt103–1 and Nt103–35. Droog F, et al. **Plant Mol Biol** 1995 Nov;29(3):413–29

Characterization of a strawberry gene for auxin–binding protein, and its expression in insect cells. Lazarus CM, et al. **Plant Mol Biol** 1996 May;31(2):267–77

Early genes and auxin action. Abel S, et al. **Plant Physiol** 1996 May;111(1):9–17

AV NODE see **ATRIOVENTRICULAR NODE**

AVAILABILITY EQUIVALENCY see **BIOLOGICAL AVAILABILITY**

AVAILABILITY OF HEALTH SERVICES see **HEALTH SERVICES ACCESSIBILITY**

AVENA SATIVA see **OATS**

AVERSIVE THERAPY

INSTRUMENTATION

Therapeutic shock device (TSD): clinical evaluation with self–injurious behaviors. Mudford OC, et al. **Res Dev Disabil** 1995 Jul–Aug;16(4):253–67

AVIADENOVIRUS

Gross and histologic lesions of adenovirus group I in guinea fowl. Charlton BR, et al. **J Vet Diagn Invest** 1995 Oct; 7(4):552–4

CHEMISTRY

The avian adenovirus penton: two fibres and one base. Hess M, et al. **J Mol Biol** 1995 Sep 29;252(4):379–85

GENETICS

Genes for fowl adenovirus CELO penton base and core polypeptides. Akopian TA, et al. **Arch Virol** 1996; 141(2):357–65

Characterization of the haemorrhagic enteritis virus genome and the sequence of the putative penton base and core protein genes. Jucker MT, et al. **J Gen Virol** 1996 Mar; 77 (Pt 3):469–79

Genomic mapping and sequence analysis of the fowl adenovirus serotype 10 hexon gene. Sheppard M, et al. **J Gen Virol** 1995 Oct;76 (Pt 10):2595–600

The complete DNA sequence and genomic organization of the avian adenovirus CELO. Chiocca S, et al. **J Virol** 1996 May;70(5):2939–49

Comparison by restriction enzyme analysis of three fowl adenoviruses of varying pathogenicity. Pallister JA, et al. **Vet Microbiol** 1996 Jan;48(1–2):155–63

AVIADENOVIRUS

IMMUNOLOGY

Immunosuppressive potential and pathogenicity of an avian adenovirus isolate involved in hydropericardium syndrome in broilers. Naeem K, et al. **Avian Dis** 1995 Oct-Dec; 39(4):723-8

Comparison of agar-gel precipitin responses among strains of fowl adenovirus using antigens prepared from chorioallantoic membranes and chicken kidney cell cultures. Takase K, et al. **J Vet Med Sci** 1995 Apr; 57(2):327-30

Approaches to food-based vaccines for domestic chickens. Bensink Z, et al. **Vet Microbiol** 1995 Sep;46(1-3):29-35

PATHOGENICITY

Pathogenesis of type II avian adenovirus infection in turkeys: in vivo immune cell tropism and tissue distribution of the virus. Suresh M, et al. **J Virol** 1996 Jan;70(1):30-6

Pathogenicity of quail's inclusion body hepatitis virus (avian adenovirus-1) for Japanese quails and broiler chicks. Singh A, et al. **Vet Res Commun** 1995;19(6):545-51

AVIAN ADENOVIRUSES see **AVIADENOVIRUS**

AVIAN ARTHRITIS VIRUS see **ORTHOREOVIRUS**

AVIAN ENCEPHALOMYELITIS VIRUS see **ENCEPHALOMYELITIS VIRUS, AVIAN**

AVIAN ERYTHROBLASTOSIS VIRUS see **ERYTHROBLASTOSIS VIRUS, AVIAN**

AVIAN HYPERSENSITIVITY PNEUMONITIS see **BIRD FANCIER'S LUNG**

AVIAN INFECTIOUS BRONCHITIS VIRUS see **INFECTIOUS BRONCHITIS VIRUS, AVIAN**

AVIAN INFECTIOUS LARYNGOTRACHEITIS VIRUS see **HERPESVIRUS 1, GALLID**

AVIAN LEUKOSIS

GENETICS

Gene regulation by NF-M and Myb during differentiation and leukemic transformation. Kowenz-Leutz E, et al. **Immunobiology** 1995 Jul;193(2-4):356-62 (15 ref.)

IMMUNOLOGY

Effect of serotype 2 and 3 Marek's disease vaccines on the development of avian leukosis virus-induced pre-neoplastic bursal follicles. Marsh JD, et al. **Avian Dis** 1995 Oct-Dec;39(4):743-51

PATHOLOGY

Lymphoid leukosis viruses, their recognition as 'persistent' viruses and comparisons with certain other retroviruses of veterinary importance. Darcel C. **Vet Res Commun** 1996; 20(1):83-108 (112 ref.)

VIROLOGY

The noncoding and surface envelope coding sequences of myeloblastosis-associated virus are respectively responsible for nephroblastoma development and renal hyperplasia. Joliot V, et al. **J Virol** 1996 Apr;70(4):2576-80

AVIAN LEUKOSIS-SARCOMA VIRUSES see **RETROVIRUSES, ALV-RELATED**

AVIAN MYELOBLASTOSIS VIRUS see **MYELOBLASTOSIS VIRUS, AVIAN**

AVIAN NEPHROSIS VIRUS see **INFECTIOUS BURSAL DISEASE VIRUS**

AVIAN ORTHOMYXOVIRUS TYPE A see **ORTHOMYXOVIRUS TYPE A, AVIAN**

AVIAN PARAMYXOVIRUS TYPE 1 see **NEWCASTLE DISEASE VIRUS**

AVIAN PARAMYXOVIRUSES see **PARAMYXOVIRUSES, AVIAN**

AVIAN RETICULOENDOTHELIOSIS VIRUS see **RETICULOENDOTHELIOSIS VIRUS, AVIAN**

AVIAN SARCOMA see **SARCOMA, AVIAN**

AVIAN SARCOMA VIRUS B77 see **SARCOMA VIRUSES, AVIAN**

AVIAN SARCOMA VIRUSES see **SARCOMA VIRUSES, AVIAN**

AVIATION

see related
AIRCRAFT

Diurnal rhythmicity of human cholesterol synthesis: normal pattern and adaptation to simulated "jet lag". Cella LK, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E489-98

NASA/FAA partnership improves airspace efficiency [news] **Aviat Space Environ Med** 1995 Nov;66(11):1122

Crash and violation experience of pilots involved in prior commuter and air taxi crashes: a historical cohort study. Li G, et al. **Aviat Space Environ Med** 1995 Dec; 66(12):1131-5

Flying therapy for flying phobia. McCarthy GW, et al. **Aviat Space Environ Med** 1995 Dec;66(12):1179-84

Diabetes mellitus: rates and outcomes among U.S. Army aviators. Mason KT, et al. **Aviat Space Environ Med** 1995 Dec;66(12):1175-8

A comparison between phosphors for aviator's night vision imaging system. Rabin J, et al. **Aviat Space Environ Med** 1996 May;67(5):429-33

Convulsive syncope in the aviation environment. Voge VM, et al. **Aviat Space Environ Med** 1995 Dec;66(12):1198-204 (45 ref.)

Visual performance effects and user acceptance of the M43A1 aviation protective mask frontserts. Wildzunas RM. **Aviat Space Environ Med** 1995 Dec;66(12):1136-43

Health physics and aviation: 1990-1994. Barish RJ. **Health Phys** 1995 Oct;69(4):538-42

Non-fatal strangulation: an uncommon parachute-related accident. Lwin M, et al. **Med J Malaysia** 1995 Dec; 50(4):419-20

Exposure to cosmic radiation of British Airways flying crew on ultralonghaul routes. Bagshaw M, et al. **Occup Environ Med** 1996 Jul;53(7):495-8

A survey of hearing loss in Army aircrew. Owen MJ. **Occup Med (Oxf)** 1996 Feb;46(1):53-8

Activation in novice and expert parachutists while jumping. Roth WT, et al. **Psychophysiology** 1996 Jan;33(1):63-72

[Man in aviation and cosmonautics: past, present and future] Ushakov IB, et al. **Aviakosm Ekolog Med** 1995;29(4):58-64 **(Rus)**

[Influence of pilot's mental state on the quality of his professional activities] Shalimov PM, et al. **Med Tr Prom Ekol** 1995;(9):4-8 (Eng. Abstr.) **(Rus)**

EDUCATION

Attitudes toward urinalysis drug testing within a civilian pilot training program. Lindseth PD, et al. **Aviat Space Environ Med** 1995 Sep;66(9):837-40

[The effect of training flights on the level of statokinetic resistance in the aviation cadets of foreign armies] Novikov VS, et al. **Voen Med Zh** 1995 Mar;(3):64-5, 80 (Eng. Abstr.) **(Rus)**

[The psychophysiological support of the professional training of flight personnel today] Vorona AA, et al. **Voen Med Zh** 1996 May;317(5):44-7 **(Rus)**

[The dependence of the flight training of students on their individual psychophysiological traits] Makarenko MV. **Fiziol Zh** 1995 Jan-Apr;41(1-2):54-60 (Eng. Abstr.) **(Ukr)**

HISTORY

Some problems of high altitude in the 1930's: a world record attempt. Hawkins MF. **Aviat Space Environ Med** 1995 Dec; 66(12):1212-4

BLB oxygen mask and aviation [letter] Miller JM. **Mayo Clin Proc** 1995 Oct;70(10):1020

[Xth Moscow International Symposium on History of Aviation and Cosmonautics] Gazenko OG, et al. **Aviakosm Ekolog Med** 1995;29(5):59-61 **(Rus)**

AVIATION MEDICINE see **AEROSPACE MEDICINE**

AVIDIN

Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method. Garkavij M, et al. **Acta Oncol** 1996;35(3):309-12

Target-sensitive immunoerythrocytes: interaction of biotinylated red blood cells with immobilized avidin induces their lysis by complement. Muzykantov VR, et al. **Biochim Biophys Acta** 1996 Mar 13;1279(2):137-43

An enzymeimmunoassay for total thyroxine using avidin-biotin separation system and thyroxine-peroxidase conjugate. Akman S, et al. **J Immunoassay** 1995 Aug; 16(3):325-41

Enzyme-labelled antibody-avidin conjugates: new flexible and sensitive immunochemical reagents. van Gijlswijk RP, et al. **J Immunol Methods** 1996 Jan 16;189(1):117-27

ANALOGS & DERIVATIVES

Pharmacokinetics of [3H]biotin bound to different avidin analogues. Kang YS, et al. **J Drug Target** 1995;3(2):159-65

CHEMISTRY

Homogeneous assays for riboflavin mediated by the interaction between enzyme-biotin and avidin-riboflavin conjugates. Kim MJ, et al. **Anal Biochem** 1995 Nov 1; 231(2):400-6

Reversibility of biotin-binding by selective modification of tyrosine in avidin. Morag E, et al. **Biochem J** 1996 May 15;316 (Pt 1):193-9

Avidin-biotin interactions at vesicle surfaces: adsorption and binding, cross-bridge formation, and lateral interactions. Noppl-Simson DA, et al. **Biophys J** 1996 Mar; 70(3):1391-401

Rapid purification of recombinant proteins fused to chicken avidin. Airenne KJ, et al. **Gene** 1995 Dec 29;167(1-2):63-8

DIAGNOSTIC USE

Avidin and 111In-labelled biotin scan: a new radioisotopic method for localising vascular graft infection. Chiesa R, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):405-14

Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis. Rosebrough SF, et al. **J Nucl Med** 1996 Aug;37(8):1380-4

Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. Samuel A, et al. **J Nucl Med** 1996 Jan;37(1):55-61

IMMUNOLOGY

Induction of systemic and mucosal immune responses following immunization with somatostatin-avidin complexes incorporated into ISCOMS. Estrada A, et al. **Immunol Invest** 1995 Aug;24(5):819-28

Intestinal immunization of mice with antigen conjugated to anti-MHC class II antibodies. Estrada A, et al. **Vaccine** 1995 Jul;13(10):901-7

Humoral and cellular responses induced by intradermally administered cytokine and conventional adjuvants. Lofthouse SA, et al. **Vaccine** 1995 Aug;13(12):1131-7

METABOLISM

Reversibility of biotin-binding by selective modification of tyrosine in avidin. Morag E, et al. **Biochem J** 1996 May 15;316 (Pt 1):193-9

Repeating the avidin "chase" markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity. Kobayashi H, et al. **Eur J Cancer** 1995 Sep; 31A(10):1689-96

Avidin fusion protein as a tool to generate a stable translocation intermediate spanning the mitochondrial membranes. Endo T, et al. **J Biochem (Tokyo)** 1995 Oct; 118(4):753-9

Polyethylene glycol-modified avidin: a novel agent for the selective extraction of biotinylated immune-complex in an aqueous two-phase system. Nishimura H, et al. **J Biomater Sci Polym Ed** 1995;7(3):289-96

PHARMACOKINETICS

Pharmacokinetics of [3H]biotin bound to different avidin analogues. Kang YS, et al. **J Drug Target** 1995;3(2):159-65

PHARMACOLOGY

Distribution of neocarzinostatin conjugated to biotinylated chimeric monoclonal antibody Fab fragments after administration of avidin. Otsuji E, et al. **Br J Cancer** 1996 Aug;74(4):597-602

Antibody-dependent signal amplification in tumor xenografts after pretreatment with biotinylated monoclonal antibody and avidin or streptavidin. Kassis AI, et al. **J Nucl Med** 1996 Feb;37(2):343-52

AVIDITY, ANTIBODY see **ANTIBODY AFFINITY**

AVIPOXVIRUS

Canary-pox (ALVAC) virus-mediated cytokine gene therapy induces tumor specific and non-specific immunity against mouse prostate tumor. Ratliff TL, et al. **Acta Urol Belg** 1996 May;64(2):85

Pox in ostrich chicks. Raidal SR, et al. **Aust Vet J** 1996 Jan; 73(1):32-3

Canarypox as a vector for HIV vaccine [news] Fricker J. **Mol Med Today** 1996 Jun;2(6):225

GENETICS

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Fries LF, et al. **Vaccine** 1996 Apr; 14(5):428-34

IMMUNOLOGY

Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Taylor J, et al. **Vaccine** 1995 Apr;13(6):539-49

AVITAMINOSIS

[Malnutrition] Hosoda S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):297-300 (9 ref.) **(Jpn)**

BLOOD

Hyperhomocysteinemia as a risk factor for deep-vein thrombosis [letter] Jacobson MW. **N Engl J Med** 1996 Sep 26;335(13):975; discussion 975-6

COMPLICATIONS

Interaction of vitamins with mental performance. Heseker H, et al. **Bibl Nutr Dieta** 1995;(52):43-55

DIAGNOSIS

Vitamin status of eating disorder patients: relationship to clinical indices and effect of treatment. Rock CL, et al. **Int J Eat Disord** 1995 Nov;18(3):257–62

[Markers of vitamin deficiencies (editorial)] Poulsen HE. **Ugeskr Laeger** 1996 Jul 1;158(27):3906 **(Dan)**

EPIDEMIOLOGY

[Vitamin and mineral deficiency in Mexico. A critical review of the state of the art. II. Vitamin deficiency] Rosado JL, et al. **Salud Publica Mex** 1995 Sep–Oct;37(5):452–61 (59 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Deficiency of water–soluble vitamins in Crohn's disease [letter] Lavy A, et al. **Dig Dis Sci** 1995 Dec;40(12):2549

[Vitamin disturbances in chronic renal insufficiency. II. Fat soluble vitamins] Pietrzak I. **Przegl Lek** 1996;53(1):29–32 (22 ref.) (Eng. Abstr.) **(Pol)**

AVOIDANCE LEARNING

see related

ESCAPE REACTION

Effects of a model on food neophobia in humans. Hobden K, et al. **Appetite** 1995 Oct;25(2):101–13

The CS–US interval and taste aversion learning: a brief look. Schafe GE, et al. **Behav Neurosci** 1995 Aug;109(4):799–802

Enhanced retrieval of unpleasant memories influenced by shock controllability, shock sequence, and rat strain. Paré WP. **Biol Psychiatry** 1996 May 1;39(9):808–13

Electrophysiological correlates of prior training: an in vitro study of an area of the avian brain which is essential for early learning. Bradley PM, et al. **Brain Res** 1996 Feb 5; 708(1–2):100–7

Conditioned antisickness: heat as an internal stimulus in conditioning taste aversion and aversion failure in rats. Davey VA, et al. **J Exp Psychol Anim Behav Process** 1996 Jul;22(3):235–43

Changes in rat brain muscarinic receptors after inhibitory avoidance learning. Ortega A, et al. **Life Sci** 1996; 58(9):799–809

Latent inhibition in conditioned taste aversion: the roles of stimulus frequency and duration and the amount of fluid ingested during preexposure. De la Casa G, et al. **Neurobiol Learn Mem** 1995 Sep;64(2):125–32

Micro– and macrostructure of learning in active avoidance: a quantitative approach. Giuliani A, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):82–90

Prior exposure to cocaine diminishes behavioral and biochemical responses to aversive conditioning: reversal by glycine/N–methyl–D–aspartate antagonist co–treatment. Morrow BA, et al. **Neuroscience** 1995 Nov; 69(1):233–40

Permanent occlusion of bilateral internal carotid arteries produces cognitive deficits in two learning behavior tasks. Watanabe H, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Feb; 16(1):19–24

Conditioned taste aversions and latent inhibition in Egyptian spiny mice and Long–Evans rats. Brosvic GM, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):995–8

Retention of rotationally induced taste aversions. Batsell WR Jr, et al. **Physiol Behav** 1995 Oct;58(4):815–8

DRUG EFFECTS

Ginseng root prevents learning disability and neuronal loss in gerbils with 5–minute forebrain ischemia. Wen TC, et al. **Acta Neuropathol (Berl)** 1996;91(1):15–22

Conditioned taste aversion in rats following intrathecal administration of contrast media. La Noce A, et al. **Acta Radiol** 1996 Jan;37(1):116–20

Genetic differences in ethanol–induced conditioned taste aversion after ethanol preexposure. Risinger FO, et al. **Alcohol** 1995 Nov–Dec;12(6):535–9

Conditioned taste aversions induced by alcohol and lithium in rats selectively bred for ethanol neurosensitivity. Kulkosky PJ, et al. **Alcohol Clin Exp Res** 1995 Aug; 19(4):945–50

Area postrema mediates the formation of rapid, conditioned palatability shifts in lithium–treated rats. Eckel LA, et al. **Behav Neurosci** 1996 Feb;110(1):202–12

Limited impairment of learning performances in mice treated with cysteamine. Nakata A, et al. **Biol Pharm Bull** 1995 Dec;18(12):1773–5

Behavioural interactions between 5–hydroxytryptophan, neuroleptic agents and 5–HT receptor antagonists in modifying rodent responding to aversive situations. Costall B, et al. **Br J Pharmacol** 1995 Dec;116(7):2989–99

The area postrema is involved in paraquat–induced conditioned aversion behavior and neuroendocrine activation of the hypothalamic–pituitary–adrenal axis. Edmonds BK, et al. **Brain Res** 1996 Mar 11;712(1):127–33

The effects of pregnenolone sulfate and ethylestrenol on retention of a passive avoidance task. Isaacson RL, et al. **Brain Res** 1995 Aug 14;689(1):79–84

Nerve growth factor facilitates conditioned taste aversion learning in normal rats. Lipinski WJ, et al. **Brain Res** 1995 Sep 18;692(1–2):143–53

Involvement of benzodiazepine/GABA–A receptor complex in ethanol–induced state–dependent learning in rats. Nakagawa Y, et al. **Brain Res** 1995 Jul 17;686(1):70–6

The opposing effects of interleukin –1 beta microinjected into the preoptic hypothalamus and the ventromedial hypothalamus on nociceptive behavior in rats. Oka T, et al. **Brain Res** 1995 Nov 27;700(1–2):271–8

Effects of scopolamine infusions into the anterior and posterior cingulate on passive avoidance and water maze navigation. Riekkinen P Jr, et al. **Brain Res** 1995 Jul 10; 685(1–2):46–54

Effect of capsaicin on learning, retention and extinction of spatial and active avoidance tasks in adult rats neonatally treated. Carobi C, et al. **Brain Res Cogn Brain Res** 1995 Oct;2(4):221–7

Glycogenolytic response of primary chick and mouse cultures of astrocytes to noradrenaline across development. O'Dowd BS, et al. **Brain Res Dev Brain Res** 1995 Sep 29; 88(2):220–3

Amiloride is an ineffective conditioned stimulus in taste aversion learning. Markison S, et al. **Chem Senses** 1995 Oct; 20(5):559–63

Inhibitors of cyclooxygenases produce amnesia for a passive avoidance task in the chick. Hölscher C. **Eur J Neurosci** 1995 Jun 1;7(6):1360–5

Effects of dynorphin A–(1–13) on carbon monoxide–induced delayed amnesia in mice studied in a step–down type passive avoidance task. Hiramatsu M, et al. **Eur J Pharmacol** 1995 Aug 25;282(1–3):185–91

The pentadecapeptide [Ser1]histogranin impairs passive avoidance learning in mice. Maurice T, et al. **Eur J Pharmacol** 1995 Sep 5;283(1–3):251–4

Corrigendum to 'the pentadecapeptide [Ser1]histogranin impairs passive avoidance learning in mice' [Eur. J. Pharmacol. 283 (1995) 251–254]. Maurice T, et al. **Eur J Pharmacol** 1995 Dec 12;287(2):219

Effects of combined block of alpha 1–adrenoceptors and NMDA receptors on spatial and passive avoidance behavior in rats. Riekkinen M, et al. **Eur J Pharmacol** 1996 Apr 4;300(1–2):9–16

Differential effect of buspirone and diazepam on negative contrast in one–way avoidance learning. Torres C, et al. **Eur J Pharmacol** 1995 Jul 14;280(3):277–84

Effect of a composite Indian herbal preparation, CIHP(III) on avoidance learning during endurance performance of rats. Bhardwaj SK, et al. **Indian J Exp Biol** 1995 Aug; 33(8):580–4

Effect of prenatal undernutrition and phenobarbitone administration on discrimination learning and passive avoidance behaviour in rats. Jaiswal AK, et al. **Indian J Exp Biol** 1996 Feb;34(2):118–23

Infusion of glial maturation factor–beta reduces behavioral deficits after caudate nucleus injury in rats. Palatucci CM, et al. **Int J Neurosci** 1996 Feb;84(1–4):135–47

Effects of Celastrus paniculatus on passive avoidance performance and biogenic amine turnover in albino rats. Nalini K, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):101–8

Effects of localized histamine microinjections into the hippocampal formation on the retrieval of a one–way active avoidance response in rats. Alvarez EO, et al. **J Neural Transm Gen Sect** 1995;101(1–3):201–11

Effects of ACTH and ACTH 4–10 on aversive memory retrieval in rats. Kumar KB, et al. **J Neural Transm Gen Sect** 1995;101(1–3):223–9

Prevention of nimodipine–induced impairment of learning by the selective sigma ligand PRE–084. Maurice T, et al. **J Neural Transm Gen Sect** 1995;102(1):1–18

Effects of (–)–S–2,8–dimethyl–3–methylene–1–oxa–8–azaspiro[4,5]decane L–tartrate monohydrate (YM796), a novel muscarinic agonist, on disturbance of passive avoidance learning behavior in drug–treated and senescence–accelerated mice. Suzuki M, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):728–36

High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers. Knoll J, et al. **Life Sci** 1996;58(11):945–52

Genetic differences in nicotine–induced conditioned taste aversion. Risinger FO, et al. **Life Sci** 1996;58(12):223–9

omega–Conotoxin GVIA disrupts memory formation in the day–old chick. Clements MP, et al. **Neurobiol Learn Mem** 1995 Nov;64(3):276–84

High level of footshock during inhibitory avoidance training prevents amnesia induced by intranigral injection of GABA antagonists. Cobos–Zapiain GG, et al. **Neurobiol Learn Mem** 1996 May;65(3):202–6

Amnesic effects of preacquisition, postacquisition, or preretrieval tetrodotoxin administration into the medial septal area on rat's passive avoidance memorization. Lorenzini CA, et al. **Neurobiol Learn Mem** 1996 Jul; 66(1):80–4

Amygdaloid nuclei lesions differentially affect glucocorticoid–induced memory enhancement in an inhibitory avoidance task. Roozendaal B, et al. **Neurobiol Learn Mem** 1996 Jan;65(1):1–8

Inhibitors of cAMP–dependent protein kinase impair long–term memory formation in day–old chicks. Zhao WQ, et al. **Neurobiol Learn Mem** 1995 Sep;64(2):106–18

Repeated inescapable stress produces a neuroleptic–like effect on the conditioned avoidance response. Friedhoff AJ, et al. **Neuropsychopharmacology** 1995 Oct;13(2):129–38

Effects of training, early handling, and perinatal flumazenil on shuttle box acquisition in Roman low–avoidance rats: toward overcoming a genetic deficit. Escorihuela RM, et al. **Neurosci Biobehav Rev** 1995 Fall;19(3):353–67

Corticosterone facilitates long–term memory formation via enhanced glycoprotein synthesis. Sandi C, et al. **Neuroscience** 1995 Dec;69(4):1087–93

The involvement of dopamine in the striatum in passive avoidance training in the chick. Stewart MG, et al. **Neuroscience** 1996 Jan;70(1):7–14

Prenatal ethanol exposure in rats: long–lasting effects on learning. Clausing P, et al. **Neurotoxicol Teratol** 1995 Sep–Oct;17(5):545–52

Blockade of lithium chloride–induced conditioned place aversion as a test for antiemetic agents: comparison of metoclopramide with combined extracts of Zingiber officinale and Ginkgo biloba. Frisch C, et al. **Pharmacol Biochem Behav** 1995 Oct;52(2):321–7

Role of 5–HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Nogueira RL, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):1–6

Effects of CGRP on active avoidance behavior in rats. Kovács A, et al. **Physiol Behav** 1995 Sep;58(3):429–35

Minaprine, but not oxiracetam, prevents desipramine–induced impairment of avoidance learning in mice. Sansone M, et al. **Pol J Pharmacol** 1995 Jan–Feb;47(1):69–73

Irreversible impairment of active avoidance behavior in rats prenatally exposed to mild concentrations of carbon monoxide. De Salvia MA, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):66–71

Effects of prenatal diazepam on two–way avoidance behavior, swimming navigation and brain levels of benzodiazepine–like molecules in male Roman high– and low–avoidance rats. Driscoll P, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):51–7

The effects of repeated treatment with 8–hydroxy–2–(di–n–propylamino) tetralin (8–OH–DPAT) on the lever press responding of the rat under FI and DRL schedules of food reinforcement. Evenden J, et al. **Psychopharmacology (Berl)** 1995 Jul;120(1):81–92

Chronic treatment with MK–801 affects the behavioral response to both D1 and D2 dopamine agonist in the one–trial inhibitory avoidance. Mele A, et al. **Psychopharmacology (Berl)** 1995 Oct;121(3):401–5

Instrumental outcome devaluation is attenuated by the anti–emetic ondansetron. Balleine B, et al. **Q J Exp Psychol B** 1995 Aug;48(3):235–51

[Effects of Chinese ginseng root and stem–leaf saponins on learning, memory and biogenic monoamines of brain in rats] Wang A, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Aug; 20(8):493–5, inside backcover (Eng. Abstr.) **(Chi)**

[Effects of systemic lidocaine, mepivacaine and bupivacaine on passive avoidance learning in mice] Nakai T, et al. **Masui** 1995 Oct;44(10):1356–61 (Eng. Abstr.) **(Jpn)**

[Reverse–tolerance phenomenon in methamphetamine–induced behavioral stereotypy and impairment of cliff avoidance reaction after subchronic methamphetamine administration in rats] Yoshida S, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Oct; 15(5):397–403 (Eng. Abstr.) **(Jpn)**

[The effect of thymoptin on development of a conditioned passive avoidance reaction in 18–month old and castrated rats] Burov IuV, et al. **Biull Eksp Biol Med** 1995 Aug; 120(8):167–8 **(Rus)**

[The effect of the polysaccharide fraction of Korean ginseng on learning and memory in rats (exemplified by active avoidance reactions)] Liubimov II, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):169–73 **(Rus)**

PHYSIOLOGY

Transplantation of basal forebrain cells of foetal rats into the subarachnoid space: improvement of disturbance of passive avoidance memory due to injury of nucleus basalis magnocellularis. Kyoshima K, et al. **Acta Neurochir (Wien)** 1995;133(1–2):68–72

Effects of pretraining paradoxical sleep deprivation upon two–way active avoidance. Gruart–Masso A, et al. **Behav Brain Res** 1995 Dec 14;72(1–2):181–3

Effects of postnatal stimulation on the passive avoidance behaviour of young rats. Gschanes A, et al. **Behav Brain Res** 1995 Oct;70(2):191–6

The effect of archistriatal lesions on 'open field' and fear/avoidance behaviour in the domestic chick. Lowndes M, et al. **Behav Brain Res** 1995 Dec 14;72(1–2):25–32

Double dissociation of passive avoidance and milk maze performance deficits with discrete lesions of substantia innominata or globus pallidus of rats. Meyer RC, et al. **Behav Brain Res** 1995 Dec 14;72(1–2):157–80

Reversible inactivation of the medial septal area impairs consolidation but not retrieval of passive avoidance learning in rats. Rashidy–Pour A, et al. **Behav Brain Res** 1995 Dec 14;72(1–2):185–8

Genetic analysis of the relationships between behavioral and neuroendocrine traits in Roman High and Low Avoidance rat lines. Castanon N, et al. **Behav Genet** 1995 Jul; 25(4):371–84

Shuttle–box memory facilitation by posttraining intracranial self–stimulation: differential effects in rats with high and low basic conditioning levels. Aldavert–Vera L, et al. **Behav Neurosci** 1996 Apr;110(2):346–52

Differential effects of pretraining inactivation of the right or left amygdala on retention of inhibitory avoidance training. Coleman–Mesches K, et al. **Behav Neurosci** 1995

Aug;109(4):642–7
Spared retention of inhibitory avoidance learning after posttraining amygdala lesions. Parent MB, et al. **Behav Neurosci** 1995 Aug;109(4):803–7
Excitotoxic lesions of the parabrachial nuclei prevent conditioned taste aversions and sodium appetite in rats. Scalera G, et al. **Behav Neurosci** 1995 Oct;109(5):997–1008
Gustatory detection thresholds after parabrachial nuclei lesions in rats. Spector AC, et al. **Behav Neurosci** 1995 Oct; 109(5):939–54
Comparative analysis of the jamming avoidance response in African and South American wave-type electric fishes. Kawasaki M. **Biol Bull** 1996 Aug;191(1):103–8
Studies on the optic chiasm of the leopard frog. I. Selective loss of visually elicited avoidance behavior after optic chiasm hemisection. Waldeck RF, et al. **Brain Behav Evol** 1995;46(2):84–94
The bidirectional interaction between ventral tegmental rewarding and hindbrain aversive stimulation effects in the rat. Anderson R, et al. **Brain Res** 1995 Aug 7; 688(1–2):15–20
Learning-specific, time-dependent increase in [3H]phorbol dibutyrate binding to protein kinase C in selected regions of the rat brain. Bernabeu R, et al. **Brain Res** 1995 Jul 10;685(1–2):163–8
Extracellular acetylcholine is increased in the nucleus accumbens following the presentation of an aversively conditioned taste stimulus. Mark GP, et al. **Brain Res** 1995 Aug 7;688(1–2):184–8
Acquisition of conditioned inhibition in rats is impaired by ablation of serotoninergic pathways. Lister S, et al. **Eur J Neurosci** 1996 Feb;8(2):415–23
Involvement of AMPA receptors in maintenance of memory for a passive avoidance task in day-old domestic chicks (Gallus domesticus). Steele RJ, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1297–304
Sound localization in chinchillas. II. Front/back and vertical localization. Heffner RS, et al. **Hear Res** 1995 Aug; 88(1–2):190–8
Impaired avoidance learning after closed-head injury: dissociation between two tasks due to classical conditioning. Kosmidis MH, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):622–33
Time-dependent increase in release of arachidonic acid following passive avoidance training in the day-old chick. Clements MP, et al. **J Neurochem** 1996 Sep;67(3):1317–23
Inhibition of memory consolidation after active avoidance conditioning by antisense intervention with ependymin gene expression. Schmidt R, et al. **J Neurochem** 1995 Oct; 65(4):1465–71
Context-specific multi-site cingulate cortical, limbic thalamic, and hippocampal neuronal activity during concurrent discriminative approach and avoidance training in rabbits. Freeman JH Jr, et al. **J Neurosci** 1996 Feb 15; 16(4):1538–49
Forebrain contribution to the induction of a cellular correlate of conditioned taste aversion in the nucleus of the solitary tract. Schafe GE, et al. **J Neurosci** 1995 Oct;15(10):6789–96
The effects of tropicamide on mydriasis in young rats exhibiting a natural deficit in passive-avoidance responding. Smith RD, et al. **Life Sci** 1996;59(9):753–60
Preferential activation of midbrain dopamine neurons by appetitive rather than aversive stimuli. Mirenowicz J, et al. **Nature** 1996 Feb 1;379(6564):449–51
Reversible changes in hippocampal 3H-AMPA binding following inhibitory avoidance training in the rat. Cammarota M, et al. **Neurobiol Learn Mem** 1996 Jul; 66(1):85–8
Inhibitory avoidance training induces rapid and selective changes in 3[H]AMPA receptor binding in the rat hippocampal formation. Cammarota M, et al. **Neurobiol Learn Mem** 1995 Nov;64(3):257–64
Neuroanatomical and functional specificity of the basolateral amygdaloid nucleus in taste-potentiated odor aversion. Ferry B, et al. **Neurobiol Learn Mem** 1995 Sep;64(2):169–80
Effects of parafascicular electrical stimulation and lesion upon two-way active avoidance in rats. Guillazo-Blanch G, et al. **Neurobiol Learn Mem** 1995 Nov;64(3):215–25
Age-related changes in plasma catecholamine and glucose responses of F-344 rats to a single footshock as used in inhibitory avoidance training. Mabry TR, et al. **Neurobiol Learn Mem** 1995 Sep;64(2):146–55
Differential effects of anterior and posterior insular cortex lesions on the acquisition of conditioned taste aversion and spatial learning. Nerad L, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):44–50
Effects of feeding on conditioned avoidance responses in rats. Ninomiya Y, et al. **Neurobiol Learn Mem** 1996 May; 65(3):287–90
The involvement of Ca2+/calmodulin-dependent protein kinase in memory formation in day-old chicks. Zhao WQ, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):24–35
Role of hippocampal NO in the acquisition and consolidation of inhibitory avoidance learning. Bernabeu R, et al. **Neuroreport** 1995 Jul 31;6(11):1498–1500
Differential modulation of brain immediate early genes by intraperitoneal LiCl. Lamprecht R, et al. **Neuroreport** 1995 Dec 29;7(1):289–93
Single unit responses of the amygdala after conditioned taste aversion in conscious rats. Yasoshima Y, et al. **Neuroreport** 1995 Nov 27;6(17):2424–8
Varied influence of damage to the motor cortex on precision avoidance and escape reactions in dogs. Frolov AG, et al. **Neurosci Behav Physiol** 1995 Sep–Oct;25(5):393–402
Population trends in the fine spatial re-organization of synaptic elements in forebrain regions of chicks 0.5 and 24 hours after passive avoidance training. Ruskov DA, et al. **Neuroscience** 1995 May;66(2):291–307
Decreased predator avoidance in parasitized mice: neuromodulatory correlates. Kavaliers M, et al. **Parasitology** 1995 Sep;111 (Pt 3):257–63
Preavoidance hypercapnia and decreased hematocrit in micropigs. Anderson DE, et al. **Physiol Behav** 1996 Apr–May;59(4–5):857–61
Locomotor and passive avoidance deficits following occlusion of the middle cerebral artery. Borlongan CV, et al. **Physiol Behav** 1995 Nov;58(5):909–17
Effect of ovarian steroids on footshock avoidance learning and retention in female mice. Farr SA, et al. **Physiol Behav** 1995 Oct;58(4):715–23
Behavior of the Roman/Verh high- and low-avoidance rat lines in anxiety tests: relationship with defecation and self-grooming. Ferré P, et al. **Physiol Behav** 1995 Dec; 58(6):1209–13
Age-related changes in learning, memory, and lipofuscin as a function of the percentage of SAMP8 genes. Flood JF, et al. **Physiol Behav** 1995 Oct;58(4):819–22
Wheel running induces conditioned taste aversion in rats trained while hungry and thirsty. Lett BT, et al. **Physiol Behav** 1996 Apr–May;59(4–5):699–702
Spontaneous avoidance behavior in Drosophila null for calmodulin expression. Heiman RG, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2420–5
Adrenocortical suppression blocks the memory-enhancing effects of amphetamine and epinephrine. Roozendaal B, et al. **Proc Natl Acad Sci U S A** 1996 Feb 20;93(4):1429–33
[The characteristics of the effect of the rat neostriatal cholinergic system on normal active avoidance learning and in destruction of the intralaminar thalamic nuclei] Shapovalova KB, et al. **Fiziol Zh Im I M Sechenova** 1996 Feb;82(2):1–12 (Eng. Abstr.) **(Rus)**
[Food-acquisition and avoidance behaviors: the role of immunomodulators in their systemic organization] Zhuravlev BV, et al. **Usp Fiziol Nauk** 1996 Apr–Jun; 27(2):90–106 (107 ref.) (Eng. Abstr.) **(Rus)**
[The vasopressin- and oxytocinergic systems of rat strains selected for their capacity to acquire active avoidance] Chernigovskaia EV, et al. **Zh Evol Biokhim Fiziol** 1995 Sep–Dec;31(5–6):597–604 (Eng. Abstr.) **(Rus)**
[Delayed reactions of active avoidance in white rats under conditions of an alternative choice] Ioseliani TK, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul–Aug; 45(4):686–92 (Eng. Abstr.) **(Rus)**
[Sex dimorphism in the patterns of conditioned-reflex taste aversion and orienting-exploratory and passive-defensive behaviors] Kassil' VG, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):63–72 (Eng. Abstr.) **(Rus)**
[The role of the neurochemical mechanisms of the basolateral amygdaloid nucleus in anxiety states of different aversive origins] Talalaenko AN, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):184–7 **(Rus)**

RADIATION EFFECTS

Failure to produce taste-aversion learning in rats exposed to static electric fields and air ions. Creim JA, et al. **Bioelectromagnetics** 1995;16(5):301–6

AWARDS AND PRIZES

Abraham Flexner Award for Distinguished Service to Medical Education. **Acad Med** 1996 Feb;71(2):152–3
David E. Rogers Award. **Acad Med** 1996 Feb;71(2):153
Baxter Award for Distinguished Research in the Biomedical Sciences. **Acad Med** 1996 Feb;71(2):153–4
AOA Distinguished Teacher Award for Senior Faculty in the Basic Sciences. **Acad Med** 1996 Feb;71(2):154–5
AOA Distinguished Teacher Award for Senior Faulty in the Clinical Sciences. **Acad Med** 1996 Feb;71(2):156–7
Acta Ophthalmologica Award 1995. **Bek T.** **Acta Ophthalmol Scand** 1995 Aug;73(4):289–90
Rosén von Rosenstein. His textbook and the award [editorial] Zetterström R. **Acta Paediatr** 1995 Sep;84(9):965–70
Gloria Niemeyer Francke is fourth recipient of Donald E. Francke Medal [news] **Am J Health Syst Pharm** 1995 Aug 15;52(16):1743
An iconoclastic perspective on progress in pharmacy practice. Pierpaoli PG. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1763–70
1995 William Allan Award address. Human genetics: a discipline at risk for fragmentation. Hirschhorn K. **Am J Hum Genet** 1996 Jan;58(1):1–6
Presentation of the Southern Society for Clinical Investigation Founders Medal to Dr. Neil Kurtzman. Martinez-Maldonado M. **Am J Med Sci** 1996 Jun; 311(6):254–8
Ten nurses define heroism: Valor above and beyond the call of duty' [news] **Am J Nurs** 1996 Jul;96(7):70, 72
E. Eugene Coben recipient of the 1996 Jarabak Award [news] **Am J Orthod Dentofacial Orthop** 1996 Sep;110(3):18A
Anthony Gianelly receives first Spencer N. Frankl Award for Excellence in Teaching [news] **Am J Orthod Dentofacial Orthop** 1996 Sep;110(3):19A
Joseph A. Gryson and Grady L.Price receive the 1996 James E. Brophy AAO Distinguished Service Award [news] **Am J Orthod Dentofacial Orthop** 1996 Sep;110(3):14A–17A
J. Daniel Subtelny and Samuel Pruzansky receive the 1996 Albert H. Ketcham Memorial Award [news] **Am J Orthod Dentofacial Orthop** 1996 Sep;110(3):16A–18A
Albert H. Ketcham Award recipients for 1996 announced by the ABO [news] **Am J Orthod Dentofacial Orthop** 1995 Nov;108(5):11A–12A
1995 Edward H. Angle research prize. **Angle Orthod** 1995; 65(6):386
Wylie W. Vale. Recipient of the 1994 Hans Selye Award. **Ann N Y Acad Sci** 1995 Dec 29;771:xii–xiv
The AK Sutherland oration [see comments] Hughes KL. **Aust Vet J** 1995 Oct;72(10):361–3. Comment in: Aust Vet J 1996 Mar;73(3):118.
1995 award winners of the Aerospace Medical Association [news] **Aviat Space Environ Med** 1995 Jul;66(7):708–15
John Paul Stapp Award—1995 presented to James W. Brinkley [news] **Aviat Space Environ Med** 1995 Jul; 66(7):709
Avery-Landsteiner Prize awarded to Tim R. Mosmann, professor and chairman of the Department of Immunology of the University of Alberta in Edmonton/Alberta, Canada. Melchers F. **Behring Inst Mitt** 1995 Jun;(96):3 p preceding table of contents **(Eng, Ger)**
d'Arsonval Medal: introduction. Om P. Gandhi: 1995 recipient of the d'Arsonval Medal. Lin JC. **Bioelectromagnetics** 1996;17(1):1–2
1995 Carl G. Hartman Award. Andrzej Bartke. **Biol Reprod** 1996 Feb;54(2):312–3
SSR Research Award. David Garbers. **Biol Reprod** 1996 Feb; 54(2):313
Distinguished Service Award. Rupert P. Amann. **Biol Reprod** 1996 Feb;54(2):313–5
Citation for the presentation of the 1995 De Puy Surgical Prize to Mr Leo Stassen. McManners J. **Br J Oral Maxillofac Surg** 1995 Oct;33(5):325
Canadian Anaesthetists' Society Gold Medal. Sandinson JW, et al. **Can J Anaesth** 1995 Nov;42(11):1060–2 **(Eng, Fre)**
The 4th American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention. Phenotypes, Genotypes, and Interventions for Hereditary Cancers. Li FP. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):579–82
20th Muntendam Award. **Cancer Nurs** 1995 Oct;18(5):335–6
Leslie G. Ungerleider: Cortical Discoverer Award. Gerson M. **Cereb Cortex** 1995 Jul–Aug;5(4):374–5
Dr. Attila Gulyás: Cortical Explorer Award. Gerson M. **Cereb Cortex** 1995 Jul–Aug;5(4):375
Stephen Mark Williams: Cortical Scholar Award. Gerson M. **Cereb Cortex** 1995 Jul–Aug;5(4):375–6
Dr Barney Clark Award [news] **Circulation** 1996 Aug 15; 94(4):591
Awards and named lectures at the 68th scientific sessions [news] Schneider MD. **Circulation** 1996 Apr 15; 93(8):1479–80
Citation for the 1995 Fred Conrad Koch Award of the Endocrine Society to Jack Gorski. **Endocr Rev** 1995 Aug; 16(4):549–50
Citation for the 1995 Edwin B. Astwood Lecture Award to Kenneth S. Korach. **Endocr Rev** 1995 Aug;16(4):550–1
Citation for the 1995 Rhône-Poulenc-Rorer Clinical Investigator Award to Maria I. New. **Endocr Rev** 1995 Aug;16(4):551–2
Citation for the 1995 Sidney H. Ingbar Distinguished Service Award of the Endocrine Society to Jacob Robbins and Joseph Edward Rall. **Endocr Rev** 1995 Aug;16(4):552–3
Citation of the 1995 Gerald D. Aurbach Lecture Award to Robert Joseph Lefkowitz. **Endocr Rev** 1995 Aug; 16(4):553–4
Citation for the 1995 Robert H. Williams Distinguished Leadership Award of the Endocrine Society to David N. Orth. **Endocr Rev** 1995 Aug;16(4):554–6
Citation for the 1995 Ernst Oppenheimer Memorial Award of the Endocrine Society to Deborah L. Segaloff. **Endocr Rev** 1995 Aug;16(4):556–7
Citation for the 1995 Richard E. Weitzman Memorial Award of the Endocrine Society to Mitchell Avery Lazar. **Endocr Rev** 1995 Aug;16(4):557–8
Sir Frederick Hobday Memorial Lecture. Some observations on condylar fractures of the third metacarpus and third metatarsus in young thoroughbreds. Ellis DR. **Equine Vet J** 1994 May;26(3):178–83
Laudatio to Sohan Singh Hayreh recipient of the Von Sallmann Prize. New Delhi, India, November 1994. Gouras P. **Exp Eye Res** 1995 Sep;61(3):257–8
Presentation of the Julius M. Friedenwald Medal to John T. Farrar, M.D. Vlahcevic ZR, et al. **Gastroenterology** 1995 Dec;109(6):1732–5
The 1995 Thomas Hunt Morgan Medal. Matthew Meselson. Drake JW. **Genetics** 1996 Jan;142(1):1–2
The 1995 Genetics Society of America Medal. Eric Wieschaus. Meyer BJ. **Genetics** 1996 Jan;142(1):3
At the juncture of theory and practice. Remarks on receiving the Henry Knowles Beecher Award. Bok S. **Hastings Cent Rep** 1996 May–Jun;26(3):5–8
1995 William McAdams Outstanding Service Award. Presented to William R. Casey. Buhl T. **Health Phys** 1995 Dec;69(6):879–80
1995 Distinguished Scientific Achievement Award. Presented to Keith Eckerman. Cember H. **Health Phys**

1995 Dec;69(6):869–70
1995 Elda E. Anderson Award. Presented to Kathryn A. Higley. Hickey EE. **Health Phys** 1995 Dec;69(6):875–6
1995 National Registry of Radiation Protection Technologists Arthur F. Humm, Jr., Memorial Award. Presented to Francis J. Haughey. Molner J. **Health Phys** 1995 Dec;69(6):883
1995 Distinguished Scientific Achievement Award Memorialization. Presented in memory of Ralph G. Fairchild. Musolino SV. **Health Phys** 1995 Dec;69(6):873–4
1995 Distinguished Scientific Achievement Award. Presented to Robert G. Thomas. Stannard N. **Health Phys** 1995 Dec;69(6):871–2
1995 National Registry of Radiation Protection Technologists Arthur F. Humm, Jr., Memorial Award. Presented to Don W. Marshall. Sunderland NR. **Health Phys** 1995 Dec;69(6):881–2
Leadership ... Terry Berry Brazelton was recently given the 1995 C. Everett Koop Health Advocate Award [news] **Hosp Health Netw** 1995 Nov 5;69(21):19
Foster McGaw. Their turf, their terms. Larson L, et al. **Hosp Health Netw** 1996 Sep 5;70(17):48–9
1996 NOVA Award. Breaking down barriers, building up hopes. Lumsdon K. **Hosp Health Netw** 1996 Jan 20; 70(2):33–8
Great comebacks: sweet inspiration. Meyer H. **Hosp Health Netw** 1996 Aug 5;70(15):21–33
Role models. Painting physicians in a positive light. Morrall K. **Hosp Health Netw** 1996 Jan 5;70(1):44
11th Annual Hoechst Marion Roussel Hypertension Research Clinical Fellowship Award 1995. **Hypertension** 1996 Mar; 27(3 Pt 2):838–9
Council for High Blood Pressure Research Lifetime Achievement Award 1995. **Hypertension** 1996 Mar;27(3 Pt 2):840
CIBA Award for Hypertension Research 1995. **Hypertension** 1996 Mar;27(3 Pt 2):841
CIBA Award for Hypertension Research 1995. **Hypertension** 1996 Mar;27(3 Pt 2):842–3
Harry Goldblatt Award 1995. **Hypertension** 1996 Mar;27(3 Pt 2):844
F. Merlin Bumpus Award 1995. **Hypertension** 1996 Mar;27(3 Pt 2):845
1995 Damien–Dutton Award Recipient. **Int J Lepr Other Mycobact Dis** 1996 Mar;64(1):87–9
Introduction of William L. Pak 1995 recipient of the Friedenwald Award. Ostroy SE. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2337–9
Geneticist/oral pathologist earns 1995 Ross Award [news] **J Am Dent Assoc** 1995 Oct;126(10):1344, 1346
Jack J. Bellick, MA, RD, receives 1995 Copher Memorial Award. **J Am Diet Assoc** 1995 Nov;95(11):1323
Homer Smith Award recipient—Peter Aronson. Giebisch G. **J Am Soc Nephrol** 1995 Jun;5(12):2000
The 1995 Lindberg Award. Nonthermally mediated muscle injury and necrosis in electrical trauma. Block TA, et al. **J Burn Care Rehabil** 1995 Nov–Dec;16(6):581–8
The 1995 Moyer Award. The effect of burn injury on allograft rejection, alloantigen processing, and cytotoxic T-lymphocyte sensitization. Hultman CS, et al. **J Burn Care Rehabil** 1995 Nov–Dec;16(6):573–80
The 1995 Clinical Research Award. Younger pediatric patients with burns are at risk for continuing postdischarge weight loss. Mittendorfer B, et al. **J Burn Care Rehabil** 1995 Nov–Dec;16(6):589–95
Jacob Markowitz Award [editorial] **J Invest Surg** 1995 Sep–Oct;8(5):iii–iv
Aebersold Award winner recognized for development of novel radiopharmaceuticals [news] **J Nucl Med** 1996 Sep; 37(9):22N–23N
"Father of emission tomography" receives 1996 Cassen Prize [news] Silver S. **J Nucl Med** 1996 Aug;37(8):23N–24N
Improving healthcare quality. Application of the Baldrige process. Jensen LA. **J Nurs Adm** 1996 Jul–Aug; 26(7–8):51–4
Presentation of the President's Special Award for Distinguished Service. Desser SS. **J Parasitol** 1995 Dec; 81(6):851
Introduction of Richard W. Komuniecki as the Henry Baldwin Ward Medalist for 1995. Fayer R. **J Parasitol** 1995 Dec;81(6):847
The Shwachman Award of the North American Society for Pediatric Gastroenterology and Nutrition. Presentation: Shwachman Award. Kleinman R. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):233–5
The Journal of Thoracic and Cardiovascular Surgery Scientific Achievement Award. Recipient of 1995 Achievement Award. Wallace RB. **J Thorac Cardiovasc Surg** 1995 Dec;110(6):1581–2
The Dr Albert Dubois Prize of tropical pathology. **J Trop Pediatr** 1996 Jun;42(3):188
Pediatric Urology Medal. Victor A. Politano. Gosalbez R. **J Urol** 1996 Aug;156(2 Pt 2):811
The Lasker Awards at fifty [editorial] DeBakey ME, et al. **JAMA** 1995 Oct 4;274(13):1061
Presentation of the 1995 Jean Hamburger Award to Donald W. Seldin. Alpern RJ. **Kidney Int** 1995 Dec;48(6):2036–9
Presentation of the 1995 A.N. Richards Award to Maurice Burg. Ullrich KJ. **Kidney Int** 1995 Dec;48(6):2032–5
Presentation of the 1995 A.N. Richards Award to François Morel. Ullrich KJ. **Kidney Int** 1995 Dec;48(6):2029–31
Theo van Rens Prize. Arthroscopic assessment of the unstable shoulder. Hintermann B, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(2):64–9
Citation for the 1995 Fred Conrad Koch Award of the Endocrine Society to Jack Gorski. **Mol Endocrinol** 1995 Aug;9(8):1101–2
Citation for the 1995 Edwin B. Astwood Lecture Award to Kenneth S. Korach. **Mol Endocrinol** 1995 Aug; 9(8):1102–3
Citation for the 1995 Rhône–Poulenc–Rorer Clinical Investigator Award to Maria I. New. **Mol Endocrinol** 1995 Aug;9(8):1103–4
Citation for the 1995 Sidney H. Ingbar Distinguished Service Award of the Endocrine Society to Jacob Robbins and Joseph Edward Rall. **Mol Endocrinol** 1995 Aug;9(8):1104–6
Citation for the 1995 Gerald D. Aurbach Lecture Award to Robert Joseph Lefkowitz. **Mol Endocrinol** 1995 Aug; 9(8):1106–7
Citation for the 1995 Robert H. Williams Distinguished Leadership Award of the Endocrine Society to David N. Orth. **Mol Endocrinol** 1995 Aug;9(8):1107–9
Citation for the 1995 Ernst Oppenheimer Memorial Award of the Endocrine Society to Deborah L. Segaloff. **Mol Endocrinol** 1995 Aug;9(8):1109–10
Citation for the 1995 Richard E. Weitzman Memorial Award of the Endocrine Society to Mitchell Avery Lazar. **Mol Endocrinol** 1995 Aug;9(8):1110–1
The first EEMS Frits Sobels Award to prof. H.J. Evans [editorial] Sankaranarayanan K, et al. **Mutat Res** 1996 Apr 13;351(2):87–8
August Heidland (Würzburg)—recipient of the Franz Volhard Medal. **Nephrol Dial Transplant** 1996 Mar; 11(3):554
The Alfred Meyer Memorial Award. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):469
The Theiler Memorial Trust Award. Dr Walter Plowright. **Onderstepoort J Vet Res** 1994 Dec;61(4):2 p.
Human papillomavirus types important in progression of inverted papilloma. Beck JC, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):558–63
Academy Foundation Distinguished Award for Contributions in Clinical Otology. Forty years of ear after ear, year after year. House WF. **Otolaryngol Head Neck Surg** 1996 Jun;114(6):717–9
Mitochondrial role in hair cell survival after injury. Hyde GE, et al. **Otolaryngol Head Neck Surg** 1995 Nov; 113(5):530–40
Transverse cervical artery fasciocutaneous free flap for head and neck reconstruction: initial anatomic and dye studies. Mizerny BR, et al. **Otolaryngol Head Neck Surg** 1995 Nov; 113(5):564–8
Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Rosbe KW, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):541–9
Signal transduction mechanisms in substance P-mediated ciliostimulation. Schlosser RJ, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):582–8
A mechanism for sympathectomy-induced bone resorption in the middle ear. Sherman BE, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):569–81
Signal averaging and waveform analysis of laser Doppler flowmetry monitoring of porcine myocutaneous flaps: I. Acute assessment of flap viability. Stack BC Jr, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):550–7
Reinnervation of the allograft larynx in the rat laryngeal transplant model. Weed DT, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):517–29
1995 John Howland Award presentation to Floyd W. Denny, Jr. van Wyk JJ. **Pediatr Res** 1995 Dec;38(6):1032–8
Presentation of the George M. Kober Medal to David M. Kipnis. Peck WA. **Proc Assoc Am Physicians** 1995 Apr; 107(1):166–71
Graham named recipient of the Gold Medal Award for Life Achievement in Psychological Science by the American Psychological Association. **Psychophysiology** 1995 Nov; 32(6):598
1994 Gaston Labat Lecturer. Rudolph H. de Jong. Winnie AP. **Reg Anesth** 1995 Nov–Dec;20(6):471–3
Pharmacia Biotech & Science prize. Grand prize winner. Life and death decisions: ced-9 and programmed cell death in Caenorhabditis elegans. Hengartner MO. **Science** 1995 Nov 10;270(5238):930–1
The Gerald Marks Lecture. SAGES and surgery. Barbers, endoscopists, minimal access surgeons, interventionists. Forde KA. **Surg Endosc** 1995 Jun;9(6):669–73
Jim Bob Brame, MD, receives Distinguished Service Award. **Tex Med** 1996 Jul;92(7):13
[Rewarded articles in 1994 from hepatitis in hemophiliacs to infertility] Sariola H. **Duodecim** 1994;110(23–24):2191–2 **(Fin)**
[The GCB–Glaxo prize for the DEA continues its support of research (editorial)] Rigaud D, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):597 **(Fre)**
[German Cancer Award 1996 (news)] **Dtsch Med Wochenschr** 1996 Mar 29;121(13):A8 **(Ger)**
[The Aids Research Prize 1996 (news)] **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):A37 **(Ger)**
[Academic degrees and changing ceremonies] Nordhagen R. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3753–6 (Eng. Abstr.) **(Nor)**
[Professor Igor S. Glasunov awarded the honorary medal of the Polish Society of Internal Medicine] Kucharz EJ. **Pol Arch Med Wewn** 1996 Jan;95(1):87–8 **(Pol)**

AWARENESS

Young drivers' overestimation of their own skill—an experiment on the relation between training strategy and skill. Gregersen NP. **Accid Anal Prev** 1996 Mar; 28(2):243–50
Children's and adolescents' awareness of the physical and mental health risks associated with tattooing: a focus group study. Houghton S, et al. **Adolescence** 1995 Winter; 30(120):971–88
Journal broadens awareness, reinforces nurse's beliefs [letter] Meehan MW. **Altern Ther Health Med** 1996 Sep;2(5):14, 15
Suicidal behavior in schizophrenia and its relationship to awareness of illness. Amador XF, et al. **Am J Psychiatry** 1996 Sep;153(9):1185–8
A case of intra-operative awareness during balanced anaesthesia with sufentanil [letter] Maeckelmann S, et al. **Anaesthesia** 1996 Aug;51(8):802
Importance of increasing public awareness regarding glaucoma [letter] Yen MT, et al. **Arch Ophthalmol** 1996 May;114(5):635
In defense of traditional views of spatial disorientation and loss of situation awareness: a reply to Navathe and Singh's "An operational definition of spatial disorientation" [comment] Previc FH, et al. **Aviat Space Environ Med** 1995 Nov;66(11):1103–6. Comment on: Aviat Space Environ Med 1994 Dec;65(12):1153–5.
"If I feel anxious, there must be danger": ex-consequentia reasoning in inferring danger in anxiety disorders. Arntz A, et al. **Behav Res Ther** 1995 Nov;33(8):917–25
Patients' awareness of adverse relation between Crohn's disease and their smoking: questionnaire survey. Shields PL, et al. **BMJ** 1996 Aug 3;313(7052):265–6
Post traumatic stress disorders [letter] Cundy JM. **Br J Anaesth** 1995 Oct;75(4):501–2
Removal of the laryngeal mask airway in children: anaesthetized compared with awake. Kitching AJ, et al. **Br J Anaesth** 1996 Jun;76(6):874–6
Isolated forearm technique [letter; comment] Russell IF, et al. **Br J Anaesth** 1996 Jun;76(6):884–6. Comment on: Br J Anaesth 1995 Dec;75(6):819–21.
Intraoperative awareness and the isolated forearm technique [letter] [see comments] Russell IF. **Br J Anaesth** 1995 Dec; 75(6):819–21. Comment in: Br J Anaesth 1996 Jun;76(6):884–6.
Insight and adherence to treatment in psychotic disorders. Kemp RA, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):222–7 (46 ref.)
Insight and psychotic illness. Cross-sectional and longitudinal associations. David A, et al. **Br J Psychiatry** 1995 Nov; 167(5):621–8
Self-awareness of deficits in adults with traumatic brain injury: how best to measure? Fleming JM, et al. **Brain Inj** 1996 Jan;10(1):1–15
Malignant melanoma: perspectives on incidence and its effects on awareness, diagnosis, and treatment [editorial] Rigel DS. **CA Cancer J Clin** 1996 Jul–Aug;46(4):195–8 (21 ref.)
Awareness during anaesthesia: when is an anaesthetic not an anaesthetic? [editorial] Aitkenhead AR. **Can J Anaesth** 1996 Mar;43(3):206–11 **(Eng, Fre)**
Unintentional intraoperative awareness during sufentanil anaesthesia for cardiac surgery. Gilron I, et al. **Can J Anaesth** 1996 Mar;43(3):295–8
Awareness of heightened breast cancer risk among first-degree relatives of recently diagnosed breast cancer patients. The High Risk Breast Cancer Consortium. Audrain J, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul–Aug;4(5):561–5
The media and public awareness of child abuse and neglect: it's time for a change [editorial; comment] Krugman RD. **Child Abuse Negl** 1996 Apr;20(4):259–60. Comment on: Child Abuse Negl 1996 Apr;20(4):261–74.
The impact of news media on child abuse reporting [see comments] McDevitt S. **Child Abuse Negl** 1996 Apr; 20(4):261–74. Comment in: Child Abuse Negl 1996 Apr;20(4):259–60.
Insight in clinical psychiatry revisited. Marková IS, et al. **Compr Psychiatry** 1995 Sep–Oct;36(5):367–76 (37 ref.)
Self-recognition in dolphins: credible cetaceans; compromised criteria, controls, and conclusions. Anderson JR. **Conscious Cogn** 1995 Jun;4(2):239–43
Steps toward healing: false memories and traumagenic amnesia may coexist in vulnerable populations. Baars BJ, et al. **Conscious Cogn** 1995 Mar;4(1):68–74
Reflections from reading the first sentence. Candland DK. **Conscious Cogn** 1995 Jun;4(2):248–50
Mirrors, minds, and cetaceans. Gallup GG Jr. **Conscious Cogn** 1995 Jun;4(2):226–8
Windows on animal minds. Griffin DR. **Conscious Cogn** 1995 Jun;4(2):194–204
Belief in pain. Gustafson D. **Conscious Cogn** 1995 Sep; 4(3):323–45
The experience of self in the bottlenose dolphin. Hart D, et al. **Conscious Cogn** 1995 Jun;4(2):244–7
Self-recognition in the bottlenose dolphin: ecological considerations. Loveland KA. **Conscious Cogn** 1995 Jun; 4(2):254–7

Evidence of dolphin self-recognition and the difficulties of interpretation. Mitchell RW. **Conscious Cogn** 1995 Jun; 4(2):229–34

Metamemory and memory construction. O'Sullivan JT, et al. **Conscious Cogn** 1995 Mar;4(1):104–10

Self-view television as a test of self-awareness: only in the eye of the beholder? Reiss D, et al. **Conscious Cogn** 1995 Jun;4(2):235–8

"Is it live or is it Memorex?" Sevcik RA. **Conscious Cogn** 1995 Jun;4(2):251–3

Hypoglycaemic threshold after pancreatic transplantation [letter] Sachon C, et al. **Diabet Med** 1995 Jul;12(7):637–8

Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Clarke WL, et al. **Diabetes Care** 1995 Apr;18(4):517–22

A multicenter evaluation of blood glucose awareness training–II. Cox D, et al. **Diabetes Care** 1995 Apr; 18(4):523–8

It is not harmful for patients with epilepsy to view their own seizures. Sanders PT, et al. **Epilepsia** 1995 Nov; 36(11):1138–41

An assessment of AIDS awareness program—for I.C.D.S. functionaries. Ray SK, et al. **Indian J Public Health** 1995 Jul–Sep;39(3):100–4

Making hypnosis happen: the involuntariness of the hypnotic experience. Zamansky HS, et al. **Int J Clin Exp Hypn** 1995 Oct;43(4):386–98

Processing of threat-related information by women with bulimic eating attitudes. Waller G, et al. **Int J Eat Disord** 1995 Sep;18(2):189–93

Resistance to awareness of the supervisor's transferences with special reference to the parallel process. Stimmel B. **Int J Psychoanal** 1995 Jun;76 (Pt 3):609–18

The nightmare of returning home: a case of acute onset nightmare disorder treated by lucid dreaming. Abramovitch H. **Isr J Psychiatry Relat Sci** 1995; 32(2):140–5

Psychological-mindedness as a defense. Fogel GI. **J Am Psychoanal Assoc** 1995;43(3):793–822

Cancer awareness and self-examination practices in young men and women. Katz RC, et al. **J Behav Med** 1995 Aug; 18(4):377–84

Cholesterol awareness and treatment in patients with coronary artery disease participating in cardiac rehabilitation. Bairey Merz CN, et al. **J Cardpulm Rehabil** 1996 Mar–Apr;16(2):117–22

Introspective capacities in patients with cognitive deficits after subarachnoid hemorrhage. Hütter BO, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):499–517

Change processes in a creation of meaning event. Clarke KM. **J Consult Clin Psychol** 1996 Jun;64(3):465–70

Self-knowledge of an amnesic patient: toward a neuropsychology of personality and social psychology. Klein SB, et al. **J Exp Psychol Gen** 1996 Sep;125(3):250–60

Insight in clinical psychiatry. A new model. Marková IS, et al. **J Nerv Ment Dis** 1995 Dec;183(12):743–51 (44 ref.)

Insight in schizophrenia and mania. Swanson CL Jr, et al. **J Nerv Ment Dis** 1995 Dec;183(12):752–5

Expert role assignment and information sampling during collective recall and decision making. Stewart DD, et al. **J Pers Soc Psychol** 1995 Oct;69(4):619–28

Further contrasts between self-reflectiveness and internal state awareness factors of private self-consciousness. Watson PJ, et al. **J Psychol** 1996 Mar;130(2):183–92

Accurate awareness of heartbeat in hypochondriacal and non-hypochondriacal patients. Barsky AJ, et al. **J Psychosom Res** 1995 May;39(4):489–97

Effect of caffeine on recognition of and physiological responses to hypoglycaemia in insulin-dependent diabetes. Debrah K, et al. **Lancet** 1996 Jan 6;347(8993):19–24

Experimentally induced hypoglycaemia [letter; comment] Frier BM, et al. **Lancet** 1996 Jul 6;348(9019):61. Comment on: Lancet 1996 May 11;347(9011):1343–4.

Experimentally induced hypoglycaemia [letter] Hirst J, et al. **Lancet** 1996 Aug 10;348(9024):406

Experimentally induced hypoglycaemia [letter] Kiln M. **Lancet** 1996 Aug 10;348(9024):406–7

Consciousness and the natural method. Flanagan O. **Neuropsychologia** 1995 Sep;33(9):1103–15 (26 ref.)

Solution of an insight problem at different age levels. Antonietti A, et al. **Percept Mot Skills** 1995 Jun;80(3 Pt 2):1215–8

Gender affects the detection of resistive loads. Harver A, et al. **Percept Mot Skills** 1996 Feb;82(1):301–2

Alexithymia, affect recognition, and five factors of personality in substance abusers. Mann LS, et al. **Percept Mot Skills** 1995 Aug;81(1):35–40

CMHS launches national campaign to increase awareness of children's mental health problems [news] **Psychiatr Serv** 1996 Apr;47(4):441

Effects of age on state of awareness following implicit and explicit word-association tasks. Java RI. **Psychol Aging** 1996 Mar;11(1):108–11

Insight and psychosis: a social perspective. Johnson S, et al. **Psychol Med** 1995 May;25(3):515–20 (24 ref.)

Awareness of time in dementia of the Alzheimer type. Grewal RP. **Psychol Rep** 1995 Jun;76(3 Pt 1):717–8

Spatial orienting controlled without awareness: a semantically based implicit learning effect. Lambert AJ, et al. **Q J Exp Psychol A** 1996 May;49(2):490–518

Schizophrenia, symptomatology and social inference: investigating "theory of mind" in people with schizophrenia. Corcoran R, et al. **Schizophr Res** 1995 Sep;17(1):5–13

AIDS awareness in blood donors in north India. Choudhury N, et al. **Transfus Med** 1995 Dec;5(4):267–71

[Awareness during general anesthesia (editorial)] Ranta S, et al. **Duodecim** 1994;110(21):1967–9 (15 ref.) **(Fin)**

[Self-assessment of blood alcohol content in acute alcoholic intoxication] Seidl S, et al. **Blutalkohol** 1996 Jan;33(1):23–30 (Eng. Abstr.) **(Ger)**

[Becoming aware of unaware body sensations. Psychotherapy series, 12: Functional relaxation] von Weizsäcker V. **Fortschr Med** 1995 Dec 10;113(34):14, 16 **(Ger)**

[The subjective experience in catatonia: systematic study of 24 catatonic patients] Northoff G, et al. **Psychiatr Prax** 1996 Mar;23(2):69–73 (Eng. Abstr.) **(Ger)**

[Questionnaire survey of AIDS examination recipients at government-run public health center regarding AIDS awareness promotion and HIV examinations] Hasegawa S, et al. **Nippon Koshu Eisei Zasshi** 1996 Apr;43(4):276–85 (Eng. Abstr.) **(Jpn)**

[The phenomenon of hypoglycemia unawareness—definition, frequency, pathogenesis and clinical forms] Mokáň M. **Bratisl Lek Listy** 1995 Aug;96(8):413–9 (39 ref.) (Eng. Abstr.) **(Slo)**

DRUG EFFECTS

Therapeutic suggestion has not effect on postoperative morphine requirements. van der Laan WH, et al. **Anesth Analg** 1996 Jan;82(1):148–52

Omitting nitrous oxide in general anaesthesia: meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials. Tramèr M, et al. **Br J Anaesth** 1996 Feb;76(2):186–93

Learning during anaesthesia: a review. Andrade J. **Br J Psychol** 1995 Nov;86 (Pt 4):479–506 (110 ref.)

An information processing theory of anaesthesia. Flohr H. **Neuropsychologia** 1995 Sep;33(9):1169–80 (74 ref.)

Effects of oxazepam on event-related brain potentials, EEG frequency bands, and vigilance performance. van Leeuwen TH, et al. **Psychopharmacology (Berl)** 1995 Dec; 122(3):244–62

[Intraoperative awareness and auditory evoked potentials] Schwender D, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S46–51 (30 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Special issue: Interoception and behavior. **Biol Psychol** 1996 Jan 5;42(1–2):1–244

Interoception of respiratory resistance in asthmatic patients. Dahme B, et al. **Biol Psychol** 1996 Jan 5;42(1–2):215–29

How good are patients with panic disorder at perceiving their heartbeats? Ehlers A, et al. **Biol Psychol** 1996 Jan 5;42(1–2):165–82 (55 ref.)

Visceral perception, anhedonia, and emotion. Ferguson ML, et al. **Biol Psychol** 1996 Jan 5;42(1–2):131–45

Detection, discrimination and sensation of visceral stimuli. Hölzl R, et al. **Biol Psychol** 1996 Jan 5;42(1–2):199–214

Neurobiology of visceral afferent neurons: neuroanatomy, functions, organ regulations and sensations. Jänig W. **Biol Psychol** 1996 Jan 5;42(1–2):29–51 (105 ref.)

'Interoception' of heart rate, blood pressure, and myocardial metabolism during ergometric work load in healthy young subjects. Kollenbaum VE, et al. **Biol Psychol** 1996 Jan 5; 42(1–2):183–97

Perception of emotions in everyday life: studies with patients and normals. Myrtek M, et al. **Biol Psychol** 1996 Jan 5; 42(1–2):147–64

Event-related brain potentials and the processing of cardiac activity. Schandry R, et al. **Biol Psychol** 1996 Jan 5; 42(1–2):75–85

Symptom reporting in asthma patients and insulin-dependent diabetics. Schandry R, et al. **Biol Psychol** 1996 Jan 5; 42(1–2):231–44

Interoception. Vaitl D. **Biol Psychol** 1996 Jan 5;42(1–2):1–27 (100 ref.)

Tutorial commentary: surprisingly small subcortical structures are needed for the state of waking consciousness, while cortical projection areas seem to provide perceptual contents of consciousness [comment] Baars BJ. **Conscious Cogn** 1995 Jun;4(2):159–62. Comment on: Conscious Cogn 1995 Jun;4(2):137–58.

Evidence for consciousness. Banks WP. **Conscious Cogn** 1995 Jun;4(2):270–2

On the neurophysiology of consciousness: Part II. Constraining the semantic problem [see comments] Bogen JE. **Conscious Cogn** 1995 Jun;4(2):137–58 (100 ref.). Comment in: Conscious Cogn 1995 Jun;4(2):159–62. Comment in: Conscious Cogn 1995 Jun;4(2):163–6. Comment in: Conscious Cogn 1995 Jun;4(2):167–71. Comment in: Conscious Cogn 1995 Jun;4(2):172–93.

On the neurophysiology of consciousness: I. An overview. Bogen JE. **Conscious Cogn** 1995 Mar;4(1):52–62 (70 ref.)

The intralaminar thalamic nuclei: subjectivity pumps or attention-action coordinators? [comment] Kinsbourne M. **Conscious Cogn** 1995 Jun;4(2):167–71. Comment on: Conscious Cogn 1995 Jun;4(2):137–58.

Visual awareness and the thalamic intralaminar nuclei [comment] Koch C. **Conscious Cogn** 1995 Jun;4(2):163–6. Comment on: Conscious Cogn 1995 Jun;4(2):137–58.

Thalamic contributions to attention and consciousness [comment] Newman J. **Conscious Cogn** 1995 Jun; 4(2):172–93 (65 ref.). Comment on: Conscious Cogn 1995 Jun;4(2):137–58.

Anosognosia in parietal lobe syndrome. Ramachandran VS. **Conscious Cogn** 1995 Mar;4(1):22–51

Physical motion in dreams: one measure of three theories. Porte HS, et al. **J Abnorm Psychol** 1996 Aug;105(3):329–35 (45 ref.)

Attentional resolution and the locus of visual awareness [see comments] He S, et al. **Nature** 1996 Sep 26;383(6598):334–7 . Comment in: Nature 1996 Sep 26;383(6598):301, 303.

Visual psychophysics: stimulating brain but not mind [news; comment] Koch C, et al. **Nature** 1996 Sep 26;383(6598):301, 303. Comment on: Nature 1996 Sep 26;383(6598):334–7.

Patient awareness of seizures. Blum DE, et al. **Neurology** 1996 Jul;47(1):260–4

Consciousness: perspectives from symbolic and connectionist AI. Bechtel W. **Neuropsychologia** 1995 Sep;33(9):1075–86 (37 ref.)

An introduction to the biology of consciousness. Delacour J. **Neuropsychologia** 1995 Sep;33(9):1061–74 (55 ref.)

Cerebral correlates of visual awareness. Milner AD. **Neuropsychologia** 1995 Sep;33(9):1117–30 (84 ref.)

Conscious and pre-conscious processes as seen from the standpoint of sleep-waking cycle neurophysiology. Paré D, et al. **Neuropsychologia** 1995 Sep;33(9):1155–68 (98 ref.)

Bodily perception in the organization of postural attitude and movement. Ruggieri V, et al. **Percept Mot Skills** 1996 Feb; 82(1):307–12

Hypoglycemia-induced cognitive dysfunction in diabetes mellitus: effect of hypoglycemia unawareness. Gold AE, et al. **Physiol Behav** 1995 Sep;58(3):501–11

AXENIC ANIMALS see **GERM-FREE LIFE**

AXEROPHTHAL see **RETINALDEHYDE**

AXILLA

Ultrastructural quantitative analysis of the innervation of axillary lymph nodes of the rat after antigenic stimulation. Novotny GE, et al. **Anat Rec** 1995 Oct;243(2):208–22

Ultrastructural quantitative analysis of the innervation of axillary lymph nodes in juvenile and old rats. Novotny GE, et al. **Anat Rec** 1995 Oct;243(2):223–33

Axillary breast tissue: clinical presentation and surgical treatment. Lesavoy MA, et al. **Ann Plast Surg** 1995 Oct; 35(4):356–60

Comparison of rectal, axillary, and forehead temperatures. Shann F, et al. **Arch Pediatr Adolesc Med** 1996 Jan; 150(1):74–8

High grade soft tissue sarcoma of the flexor fossae. Size rather than compartmental status determine prognosis. Yang RS, et al. **Cancer** 1995 Oct 15;76(8):1398–405

Axillary breast tissue in an adolescent girl. Karnak I, et al. **J Pediatr Surg** 1995 Sep;30(9):1369

Early prenatal diagnosis of axillary cystic hygroma. Reichler A, et al. **J Ultrasound Med** 1995 Aug;14(8):581–4

Ganglion cyst presenting as a mass in the axilla. Babloyan GV, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1442–3

A human axillary odorant is carried by apolipoprotein D. Zeng C, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25; 93(13):6626–30

Myofibroblastoma of the axilla. Mackay B, et al. **Ultrastruct Pathol** 1995 Jul–Aug;19(4):265–8

BLOOD SUPPLY

Crutch-induced axillary artery injury. Feldman DR, et al. **Cardiovasc Intervent Radiol** 1995 Sep–Oct;18(5):296–9

INJURIES

Case of torticollis occurring following electrical injury [letter] Boonkongchuen P, et al. **Mov Disord** 1996 Jan; 11(1):109–10

INNERVATION

Axillary nerve injury after anterior glenohumeral dislocation: MR findings in three patients. Tuckman GA, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):695–7

Axillary artery pseudoaneurysm and axillary nerve palsy: delayed sequelae of anterior shoulder dislocation [letter] Emadian SM, et al. **Am J Emerg Med** 1996 Jan;14(1):108–9

Axillary neuropathy in volleyball players: report of two cases and literature review. Paladini D, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):345–7 (14 ref.)

Wrap-around neurorrhaphy: an improved method of repair for disparate nerve stumps. Nishijima N, et al. **Nippon Geka Hokan** 1995 Mar 1;64(2):74–82

PATHOLOGY

Solid glomus tumor presenting as an axillary mass: report of a case with morphologic study, including cytologic characteristics. Holck S, et al. **Acta Cytol** 1996 May–Jun; 40(3):555–62

Monitoring the axilla in patients with silicone gel implants. Kulber DA, et al. **Ann Plast Surg** 1995 Dec;35(6):580–4

Recurrent fibromatosis in a patient with breast carcinoma. Computed tomography findings with magnetic resonance imaging and pathologic correlation. Pretorius ES, et al. **Invest Radiol** 1995 Jun;30(6):381–3

Half-Fourier, three-dimensional technique for dynamic contrast-enhanced MR imaging of both breasts and axillae: initial characterization of breast lesions. Perman WH, et al. **Radiology** 1996 Jul;200(1):263-9

RADIONUCLIDE IMAGING

Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Avril N, et al. **J Natl Cancer Inst** 1996 Sep 4;88(17):1204-9

SURGERY

Access to the axilla using Chinese finger traps [letter] Khan K, et al. **Br J Plast Surg** 1996 Jun;49(4):257

Transient axillary-upper inner arm subcutaneous fibrous banding following transaxillary subpectoral endoscopic breast augmentation [letter] Maximovich SP. **Plast Reconstr Surg** 1996 May;97(6):1304-5

Surgical management of axillary bromidrosis--a modified skoog procedure by an axillary bipedicle flap approach. Wang HJ, et al. **Plast Reconstr Surg** 1996 Sep;98(3):524-9

[Expectant management concerning the breast in 5 patients with occult breast carcinoma (see comments)] van de Weijer GH, et al. **Ned Tijdschr Geneeskd** 1995 Aug 12; 139(32):1648-50 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1995 Dec 2;139(48):2514. **(Dut)**

[Axillary accessory breast tissue] Hrabovszky T, et al. **Hautarzt** 1995 Aug;46(8):576-8 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Role of ultrasonography to detect axillary node involvement in operable breast cancer. Vaidya JS, et al. **Eur J Surg Oncol** 1996 Apr;22(2):140-3

AXILLARY ARTERY

Percutaneous axillary artery insertion of an intra-aortic balloon pump [letter] Blythe D. **Anaesth Intensive Care** 1995 Jun;23(3):406-7

Axillary artery for extracorporeal circulation [letter; comment] Borst HG. **J Thorac Cardiovasc Surg** 1995 Dec; 110(6):1775. Comment on: J Thorac Cardiovasc Surg 1995 May;109(5):885-90; discussion 890-1.

Ruptured axillary pseudoaneurysm from chronic shoulder dislocation [letter] Orecchia PM, et al. **J Vasc Surg** 1996 Sep;24(3):499-500

Brachial plexopathy secondary to mycotic subclavian-axillary artery aneurysm. Veilleux M, et al. **Muscle Nerve** 1996 Jan;19(1):92-3

[Revascularization of supra-aortic trunks from the femoral artery] Etienne G, et al. **Presse Med** 1995 Jul 1-8; 24(24):1124-6 (Eng. Abstr.) **(Fre)**

[A technique for removal of entrapped intra-aortic balloon catheter through the left axillary artery] Fukushima Y, et al. **Kyobu Geka** 1995 Sep;48(10):880-2 (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

The superficial ulnar artery originating from the axillary artery. Nakatani T, et al. **Anat Anz** 1996 Jun;178(3):277-9

[Examination on the courses of the arteries in the axillary region I. The course of the subscapular artery system, especially the relationships between the arteries and the posterior cord of the brachial plexus] Aizawa Y, et al. **Kaibogaku Zasshi** 1995 Dec;70(6):554-68 (Eng. Abstr.) **(Jpn)**

INJURIES

Axillary artery pseudoaneurysm and axillary nerve palsy: delayed sequelae of anterior shoulder dislocation [letter] Emadian SM, et al. **Am J Emerg Med** 1996 Jan;14(1):108-9

Vascular trauma of the upper limb and associated nerve injuries. Shaw AD, et al. **Injury** 1995 Oct;26(8):515-8

Late lateral displacement of the humeral head after closed reduction of glenohumeral dislocation: a sign of vascular injury. Report of a case. Waxman DL, et al. **J Bone Joint Surg Am** 1996 Jun;78(6):907-10

Axillary artery injuries secondary to anterior dislocation of the shoulder. Gates JD, et al. **J Trauma** 1995 Sep; 39(3):581-3 (17 ref.)

PATHOLOGY

Large vessel vasculitis without temporal artery involvement: isolated form of giant cell arteritis? Lambert M, et al. **Clin Rheumatol** 1996 Mar;15(2):174-80

RADIATION EFFECTS

Regarding "percutaneous transluminal angioplasty for emboligenic arterial lesions after radiotherapy of axillary arteries" [letter] Lorenzi G, et al. **J Vasc Surg** 1996 Aug; 24(2):297-8

SURGERY

Upper extremity thromboembolism after axillary-axillary bypass grafting. McLafferty RB, et al. **Cardiovasc Surg** 1996 Feb;4(1):111-3

Augmentation of pulmonary blood flow with an axillary arteriovenous fistula after a cavopulmonary shunt. Magee A, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):176-80

Carotid-axillary artery bypass: a ten-year experience. Criado FJ, et al. **J Vasc Surg** 1995 Dec;22(6):717-22; discussion 722-3

Axillary grafts for difficult hemodialysis access. McCann RL. **J Vasc Surg** 1996 Sep;24(3):457-61; discussion 461-2

Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive disease. Passman MA, et al. **J Vasc Surg** 1996 Feb;23(2):263-9; discussion 269-71

[Axillo-iliac bypass grafting for reoperation of graft stenosis after aortic arch reconstruction of type B interruption of the aortic arch: two cases report] Tsukuda K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):212-5 (Eng. Abstr.) **(Jpn)**

AXILLARY VEIN

Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study. Balestreri L, et al. **Eur J Radiol** 1995 Jul;20(2):108-11

Rare cause of axillary vein thrombosis [letter] Danzl DF, et al. **J Emerg Med** 1995 Nov-Dec;13(6):821

Thrombolytic therapy and surgery for primary axillosubclavian vein thrombosis: current approach. Machleder HI. **Semin Vasc Surg** 1996 Mar;9(1):46-9

SURGERY

Decompression of the occluded subclavian vein in the patient with ipsilateral threatened access by transposition of the internal jugular vein. Gertler JP. **ASAIO J** 1995 Oct-Dec; 41(4):896-8

Surgical management of brachioaxillary-subclavian vein occlusion. Sottiurai VS, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):225-9

Augmentation of pulmonary blood flow with an axillary arteriovenous fistula after a cavopulmonary shunt. Magee A, et al. **J Thorac Cardiovasc Surg** 1996 Jan;111(1):176-80

[Superficial axillary vein cut-down as alternative at insertion of epicutaneocava venous catheters in newborn infants (letter)] Narcy P, et al. **Arch Pediatr** 1996 Mar;3(3):292-3 **(Fre)**

ULTRASONOGRAPHY

The diagnostic value of colour Doppler ultrasound in central venous catheter related thrombosis. Köksoy C, et al. **Clin Radiol** 1995 Oct;50(10):687-9

AXIOGRAPHY see **JAW RELATION RECORD**

AXIS

ABNORMALITIES

[Symptomatic os odontoideum in a patient with Down's syndrome. A case report and review of the literature] Barbuti D, et al. **Radiol Med (Torino)** 1995 Oct;90(4):486-8 **(Ita)**

[Wallenberg's syndrome following minor neck trauma: a case associated with atlanto-axial subluxation, an anomaly of the axis, and platelet activation] Arai M. **Rinsho Shinkeigaku** 1995 Jun;35(6):670-2 (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

Associations between atlantoaxial and craniomandibular anatomy. Huggare J, et al. **Growth Dev Aging** 1996 Spring; 60(1):21-30

INJURIES

What is your diagnosis? Spinal fractures. Ferguson JF. **J Small Anim Pract** 1995 Sep;36(9):381, 406

[Fracture of the dens--conservative or surgical treatment?] Paściak M, et al. **Chir Narzadow Ruchu Ortop Pol** 1994; 59(2):115-8 (Eng. Abstr.) **(Pol)**

[Treatment of traumatic spondylolisthesis of the axis] Paściak M, et al. **Chir Narzadow Ruchu Ortop Pol** 1994;59(1):5-8 (Eng. Abstr.) **(Pol)**

PATHOLOGY

Cervical myelopathy caused by pseudoarthrosis between the atlas and axis associated with diffuse idiopathic skeletal hyperostosis. Goto S, et al. **Spine** 1995 Dec 1;20(23):2572-5

SURGERY

Management strategies for tumors of the axis vertebra. Piper JG, et al. **J Neurosurg** 1996 Apr;84(4):543-51

AXOLOTL see **AMBYSTOMA**

AXOLOTL, MEXICAN see **AMBYSTOMA MEXICANUM**

AXON-ASSOCIATED ADHESION MOLECULES see **CELL ADHESION MOLECULES, NEURONAL**

AXON REACTION see **RETROGRADE DEGENERATION**

AXON TERMINALS see **PRESYNAPTIC TERMINALS**

AXONAL TRANSPORT

Horseradish peroxidase in axons of the dorsal funiculi of the cat: distribution after an injection of the enzyme into the dorsal column nuclei. Fabricius C, et al. **Cell Tissue Res** 1996 Jan;283(1):67-73

Neurospecific binding, internalization, and retrograde axonal transport. Halpern JL, et al. **Curr Top Microbiol Immunol** 1995;195:221-41 (147 ref.)

Rab3a, a small GTP-binding protein, undergoes fast anterograde transport but not retrograde transport in neurons. Li JY, et al. **Eur J Cell Biol** 1995 Aug; 67(4):297-307

Active transport of photoactivated tubulin molecules in growing axons revealed by a new electron microscopic analysis. Funakoshi T, et al. **J Cell Biol** 1996 Jun; 133(6):1347-53

Tubulin transport in neurons. Miller KE, et al. **J Cell Biol** 1996 Jun;133(6):1355-66

The progression of deafferentation as a retrograde reaction to hypoglossal nerve injury. Borke RC, et al. **J Neurocytol** 1995 Oct;24(10):763-74

Three distinct axonal transport rates for tau, tubulin, and other microtubule-associated proteins: evidence for dynamic interactions of tau with microtubules in vivo. Mercken M, et al. **J Neurosci** 1995 Dec;15(12):8259-67

Axonal transport of fluorescent carbocyanine dyes allows mapping of peripheral nerve territories in gingiva. Sugaya A, et al. **J Periodontol** 1995 Sep;66(9):817-21

Effects of nerve growth factor on axonal retrograde transport after axonal injury of motoneurons. Fang H, et al. **J Tongji Med Univ** 1996;16(1):27-31

Cytoplasmic dynein is associated with slow axonal transport. Dillman JF 3rd, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):141-4

Visualization of slow axonal transport in vivo. Terada S, et al. **Science** 1996 Aug 9;273(5276):784-8

DRUG EFFECTS

Effects of acetylcholine and adrenaline on axoplasmic transport at different regions of mouse superior cervical ganglion cells in culture. Kawakami T, et al. **Brain Res** 1995 Jun 12;683(1):88-92

Actin-based motility of isolated axoplasmic organelles. Bearer EL, et al. **Cell Motil Cytoskeleton** 1996;33(2):106-14

Polylysine cross-links axoplasmic neurofilaments into tight bundles. Brown A, et al. **Cell Motil Cytoskeleton** 1995; 31(1):9-21

Interleukin-1 beta induces long-term increase of axonally transported opiate receptors and substance P. Jeanjean AP, et al. **Neuroscience** 1995 Sep;68(1):151-7

GENETICS

Mutation of the axonal transport motor kinesin enhances paralytic and suppresses Shaker in Drosophila. Hurd DD, et al. **Genetics** 1996 Jan;142(1):195-204

Axonal transport of protein products of the bacterial reporter gene in the brain of transgenic mice. Arai R, et al. **Kaibogaku Zasshi** 1995 Dec;70(6):581-6

PHYSIOLOGY

Alpha calcium/calmodulin-dependent protein kinase II immunoreactivity in corticospinal neurons: combination of axonal transport method and immunofluorescence. Terashima T, et al. **Anat Embryol (Berl)** 1995 Aug; 192(2):123-36

Tubulin expression and axonal transport in injured and regenerating neurons in the adult mammalian central nervous system. Fournier AE, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):659-64 (39 ref.)

Retrograde axonal transport of the alpha subunit of the GTP-binding protein Gz to the nucleus of sensory neurons. Hendry IA, et al. **Brain Res** 1995 Nov 27;700(1-2):157-63

Retrograde axonal transport of signal transduction proteins in rat sciatic nerve. Johanson SO, et al. **Brain Res** 1995 Aug 28;690(1):55-63

Axonal transport and targeting of the t-SNAREs SNAP-25 and syntaxin 1 in the peripheral nervous system. Li JY, et al. **Eur J Cell Biol** 1996 May;70(1):12-22

Changes in fast axonal transport in sensory neurons during tadpole metamorphosis. Tang HZ, et al. **Int J Dev Neurosci** 1995 Aug;13(5):473-81

Axonal transport of nitric oxide synthase in autonomic nerves. Lumme A, et al. **J Auton Nerv Syst** 1996 Jan 5; 56(3):207-14

Acute stretching of peripheral nerves inhibits retrograde axonal transport. Tanoue M, et al. **J Hand Surg [Br]** 1996 Jun;21(3):358-63

Slow axonal transport of soluble actin with actin depolymerizing factor, cofilin, and profilin suggests actin moves in an unassembled form. Mills RG, et al. **J Neurochem** 1996 Sep;67(3):1225-34

Axonal transport and distribution of synaptobrevin I and II in the rat peripheral nervous system. Li JY, et al. **J Neurosci** 1996 Jan;16(1):137-47

Improved retrograde axonal transport and subsequent visualization of tetramethylrhodamine (TMR) -dextran amine by means of an acidic injection vehicle and antibodies against TMR. Kaneko T, et al. **J Neurosci Methods** 1996 Apr;65(2):157-65

Assembly of microfilaments and microtubules from axonally transported actin and tubulin after axotomy. Jacob JM, et al. **J Neurosci Res** 1996 Feb 15;43(4):412-9

Acute treatment with pulsed electromagnetic fields and its

effect on fast axonal transport in normal and regenerating nerve. Sisken BF, et al. **J Neurosci Res** 1995 Dec; 42(5):692–9

Direct measurement of fast axonal transport rates in corticospinal axons of the adult rat. Jacob JM, et al. **Neurosci Lett** 1995 Sep 1;197(1):17–20

Axonal and dendritic transport of internalized neurotensin in rat mesostriatal dopaminergic neurons. Faure MP, et al. **Neuroscience** 1995 Sep;68(2):519–29

Transport of cytoskeletal elements in the squid giant axon. Terasaki M, et al. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11500–3

Functional consequences of retrograde axonal transport of receptor–bound neurotensin. Laduron PM. **Trends Pharmacol Sci** 1995 Oct;16(10):338–43 (55 ref.)

RADIATION EFFECTS

Differential suppression of axoplasmic transport: effects of light irradiation to the growth cone of cultured dorsal root ganglion neurons. Kano M, et al. **Cell Mol Neurobiol** 1995 Jun;15(3):297–306

AXONS

Fluorescent labeling of the glial sheath of giant nerve fibers. Eddleman CS, et al. **Biol Bull** 1995 Oct–Nov;189(2):218–9

Distinct projections of two populations of olfactory receptor axons in the antennal lobe of the sphinx moth Manduca sexta. Christensen TA, et al. **Chem Senses** 1995 Jun; 20(3):313–23

The death domain motif found in Fas (Apo–1) and TNF receptor is present in proteins involved in apoptosis and axonal guidance. Hofmann K, et al. **FEBS Lett** 1995 Sep 11;371(3):321–3

Identification of axons in the peri–implant region by immunohistochemistry. Weiner S, et al. **Int J Oral Maxillofac Implants** 1995 Nov–Dec;10(6):689–95

Organization of primary afferent axons in the trigeminal sensory root and tract of the rat. Crissman RS, et al. **J Comp Neurol** 1996 Jan 1;364(1):169–83

The F wave disappears due to impaired excitability of motor neurons or proximal axons in inflammatory demyelinating neuropathies. Yokota T, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):650–4

[The method of axonal stimulation (AS) for jitter evaluation in the diagnosis of neuromuscular transmission disorders] Michalska T, et al. **Neurol Neurochir Pol** 1995 May–Jun; 29(3):333–42 (Eng. Abstr.) **(Pol)**

[Ultrastructure of the motor ends of the beta–axon on intra– and extrafusal muscle fibers in rat quadriceps muscle] Umnova MM, et al. **Dokl Akad Nauk** 1995 Dec; 345(6):837–42 **(Rus)**

[Ischemic neuropathy with conduction blocks] Traba A, et al. **Neurologia** 1995 Aug–Sep;10(7):302–6 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Amyloid beta protein and its 3–kDa fragment are present in the axoplasm fraction of the white matter in human brain. Tokuda T, et al. **Biochem Biophys Res Commun** 1996 Jun 5;223(1):165–9

Synaptic contact of neuropeptide–and amine–containing axons on parasympathetic preganglionic neurons in the superior salivatory nucleus of the rat. Nemoto T, et al. **Brain Res** 1995 Jul 10;685(1–2):33–45

Nuk controls pathfinding of commissural axons in the mammalian central nervous system. Henkemeyer M, et al. **Cell** 1996 Jul 12;86(1):35–46

An analysis of an axonal gradient of phosphorylated MAP 1B in cultured rat sensory neurons. Bush MS, et al. **Eur J Neurosci** 1996 Feb;8(2):235–48

A neuron–specific isoform of brain ankyrin, 440–kD ankyrinB, is targeted to the axons of rat cerebellar neurons. Kunimoto M. **J Cell Biol** 1995 Dec;131(6 Pt 2):1821–9

Kinesin–II, a membrane traffic motor in axons, axonemes, and spindles. Scholey JM. **J Cell Biol** 1996 Apr;133(1):1–4 (29 ref.)

Subunit composition of neurofilaments specifies axonal diameter. Xu Z, et al. **J Cell Biol** 1996 Jun;133(5):1061–9

A population of wide–field bipolar cells in the rabbit's retina. Jeon CJ, et al. **J Comp Neurol** 1995 Sep 25;360(3):403–12

Axon terminals immunolabeled for dopamine or tyrosine hydroxylase synapse on GABA–immunoreactive dendrites in rat and monkey cortex. Sesack SR, et al. **J Comp Neurol** 1995 Dec 11;363(2):264–80

Serotonergic axons in monkey prefrontal cerebral cortex synapse predominantly on interneurons as demonstrated by serial section electron microscopy. Smiley JF, et al. **J Comp Neurol** 1996 Apr 8;367(3):431–43

Projection of individual axons from the pretectum to the dorsal lateral geniculate complex in the cat. Uhlrich DJ, et al. **J Comp Neurol** 1995 Dec 4;363(1):147–59

Overlapping and differential expression of BIG–2, BIG–1, TAG–1, and F3: four members of an axon–associated cell adhesion molecule subgroup of the immunoglobulin superfamily. Yoshihara Y, et al. **J Neurobiol** 1995 Sep; 28(1):51–69

Tau is enriched on dynamic microtubules in the distal region of growing axons. Black MM, et al. **J Neurosci** 1996 Jun 1;16(11):3601–19

Distribution of high–conductance Ca(2+)–activated K+ channels in rat brain: targeting to axons and nerve terminals. Knaus HG, et al. **J Neurosci** 1996 Feb 1; 16(3):955–63

Cortical plaque–like structures identify ribosome–containing domains in the Mauthner cell axon. Koenig E, et al. **J Neurosci** 1996 Feb 15;16(4):1400–11

Characterization of alpha 2 adrenoceptors and other adrenoceptors in membranes isolated from dog mesenteric nerve axons. Daniel EE, et al. **J Pharmacol Exp Ther** 1995 Nov;275(2):978–86

Distribution and peptide content of sympathetic axons innervating different regions of the cutaneous venous bed in the pinna of the guinea pig ear. Morris JL. **J Vasc Res** 1995 Nov–Dec;32(6):378–86

Identification of the Ulex europaeus agglutinin–I–binding protein as a unique glycoform of the neural cell adhesion molecule in the olfactory sensory axons of adults rats. Pestean A, et al. **Neurosci Lett** 1995 Aug 4;195(2):117–20

Ubiquitin expression in degenerating axons of equine cervical compressive myelopathy. Jortner BS, et al. **Vet Pathol** 1996 May;33(3):356–9

Ultrastructure and immunoreactivity of dystrophic axons indicate a different pathogenesis of Hallervorden–Spatz disease and infantile neuroaxonal dystrophy. Malandrini A, et al. **Virchows Arch** 1995;427(4):415–21

DRUG EFFECTS

Differential nerve block. Direct measurements on individual myelinated and unmyelinated dorsal root axons. Jaffe RA, et al. **Anesthesiology** 1996 Jun;84(6):1455–64

Ciliary neurotrophic factors enhances peripheral nerve regeneration. Newman JP, et al. **Arch Otolaryngol Head Neck Surg** 1996 Apr;122(4):399–403

Polylysine cross–links axoplasmic neurofilaments into tight bundles. Brown A, et al. **Cell Motil Cytoskeleton** 1995; 31(1):9–21

Neurotrophin–4/5 maintains the cholinergic phenotype of axotomized septal neurons. Alderson RF, et al. **Eur J Neurosci** 1996 Feb;8(2):282–90

Methylprednisolone administration improves axonal regeneration into Schwann cell grafts in transected adult rat thoracic spinal cord. Chen A, et al. **Exp Neurol** 1996 Apr;138(2):261–76

Nerve growth factor promotes regeneration of sensory axons into adult rat spinal cord. Oudega M, et al. **Exp Neurol** 1996 Aug;140(2):218–29

A combination of BDNF and NT–3 promotes supraspinal axonal regeneration into Schwann cell grafts in adult rat thoracic spinal cord. Xu XM, et al. **Exp Neurol** 1995 Aug; 134(2):261–72

Rapid induction by kainic acid of both axonal growth and F1/GAP–43 protein in the adult rat hippocampal granule cells. Cantallops I, et al. **J Comp Neurol** 1996 Mar 4; 366(2):303–19

Nimodipine accelerates axonal sprouting after surgical repair of rat facial nerve. Angelov DN, et al. **J Neurosci** 1996 Feb 1;16(3):1041–8

The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. Gold BG, et al. **J Neurosci** 1995 Nov;15(11):7509–16

Increased cyclic AMP in in vitro regenerating frog sciatic nerves inhibits Schwann cell proliferation but has no effect on axonal outgrowth. Ekström PA. **J Neurosci Res** 1995 Sep 1;42(1):54–62

Immunohistochemical evidence of neuroprotection by R(–)–deprenyl and N–(2–hexyl)–N–methylpropargylamine on DSP–4–induced degeneration of rat brain noradrenergic axons and terminals. Zhang X, et al. **J Neurosci Res** 1996 Feb 15;43(4):482–9

Effects of nicotine on dopaminergic nigrostriatal axons requires stimulation of presynaptic glutamatergic receptors. Garcia–Munoz M, et al. **J Pharmacol Exp Ther** 1996 Jun; 277(3):1685–93

Increased Cu/Zn superoxide dismutase–like immunoreactivity in the swollen axons of rats intoxicated chronically with beta,beta'–iminodipropionitrile. Nishiyama K, et al. **Neurosci Lett** 1995 Jul 21;194(3):205–8

Insulin–like growth factor–I influences the initiation of myelination: studies of the anterior commissure of transgenic mice. Ye P, et al. **Neurosci Lett** 1995 Dec 15; 201(3):235–8

Capsaicin–induced flare and vasodilatation in patients with post–herpetic neuralgia. Morris GC, et al. **Pain** 1995 Oct; 63(1):93–101

Modulation of delayed rectifier K+ channel activity by external K+ ions in Xenopus axon. Safronov BV, et al. **Pflugers Arch** 1995 Oct;430(6):879–86

Evaluation of tissue adhesive to contain axonal regeneration in horses. Turner AS, et al. **Vet Surg** 1995 Jul–Aug; 24(4):308–14

ENZYMOLOGY

Receptor tyrosine phosphatases are required for motor axon guidance in the Drosophila embryo. Desai CJ, et al. **Cell** 1996 Feb 23;84(4):599–609

The transmembrane tyrosine phosphatase DLAR controls motor axon guidance in Drosophila. Krueger NX, et al. **Cell** 1996 Feb 23;84(4):611–22

Acetylcholinesterase–positive afferent axons in mucosa of urinary bladder of adult cats: retrograde tracing and degeneration studies. Wakabayashi Y, et al. **Histol Histopathol** 1995 Jul;10(3):523–30

Axonal transport of nitric oxide synthase in autonomic nerves. Lumme A, et al. **J Auton Nerv Syst** 1996 Jan 5; 56(3):207–14

Expression of the beta–galactoside alpha 1,2–fucosyltransferase gene suppresses axonal outgrowth of neuro2a neuroblastoma cells. Hitoshi S, et al. **J Neurochem** 1996 Apr;66(4):1633–40

Inhibition of protein tyrosine kinases impairs axon extension in the embryonic optic tract. Worley T, et al. **J Neurosci** 1996 Apr 1;16(7):2294–306

Reduced sympathetic innervation after alteration of target cell neurotransmitter phenotype in transgenic mice. Cho S, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):2862–6

IMMUNOLOGY

Pathology of the motor–sensory axonal Guillain–Barré syndrome [see comments] Griffin JW, et al. **Ann Neurol** 1996 Jan;39(1):17–28. Comment in: Ann Neurol 1996 Jan;39(1):4–5.

The axon in Guillain–Barré syndrome: immune target or innocent bystander? [editorial; comment] Powell HC, et al. **Ann Neurol** 1996 Jan;39(1):4–5. Comment on: Ann Neurol 1996 Jan;39(1):17–28.

METABOLISM

Axonal accumulation of p75NTR and TrkA in the septum following lesion of septo–hippocampal pathways. Skup M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):515–25

Effect of K+ accumulation removal and high extracellular osmolarity on K+ current in insect axonal membrane. Stankiewicz M, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):95–102

Calcitonin gene–related peptide– and substance P–immunoreactive axons in the nucleus gracilis of the rat with special reference to axonal dystrophy: light and electron microscopic observations. Fujiwara K, et al. **Acta Neuropathol (Berl)** 1995;90(4):347–55

Expression of ubiquitin–like immunoreactivity in axons after compression trauma to rat spinal cord. Li GL, et al. **Acta Neuropathol (Berl)** 1996;91(2):155–60

In squid axons phosphoarginine plays a key role in modulating Na–Ca exchange fluxes at micromolar [Ca2+]i. DiPolo R, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:199–207

Na(+)–Ca2+ exchange in anoxic/ischemic injury of CNS myelinated axons. Stys PK, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:366–78 (41 ref.)

Strongly anionic sites in peripheral axons of the rat sciatic nerve: light and electron microscopic detection using cationic colloidal iron. Toda K, et al. **Arch Histol Cytol** 1995 Oct;58(4):485–92

Retardation of the spread of extracellular Ca2+ into transected, unsealed squid giant axons. Fishman HM, et al. **Biol Bull** 1995 Oct–Nov;189(2):208–9

Incorporation of amino acids into the axoplasm is enhanced by electrical stimulation of the fiber. Eugenín J, et al. **Brain Res** 1995 Apr 24;677(2):319–25

A newly–synthesized GPI–anchored protein, TAG–1/axonin–1, is inserted into axonal membranes along the entire length of the axon and not exclusively at the growth cone. Harel R, et al. **Brain Res** 1996 Mar 18; 712(2):345–8

Substance P– and GABA–like immunoreactivities are co–localized in axonal varicosities in the superficial laminae of cat but not rat spinal cord. Ma W, et al. **Brain Res** 1995 Sep 18;692(1–2):99–110

Hedgehog, transmitted along retinal axons, triggers neurogenesis in the developing visual centers of the Drosophila brain. Huang Z, et al. **Cell** 1996 Aug 9; 86(3):411–22

Calcium diffusion coefficient in Myxicola axoplasm. al–Baldawi NF, et al. **Cell Calcium** 1995 Jun;17(6):422–30

c–fos mRNA is present in axons of the hypothalamo–neurohypophysial system of the rat. Skutella T, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Sep; 41(6):793–8

NADPH diaphorase expression in the rat retina after axotomy—a supportive role for nitric oxide. Huxlin KR, et al. **Eur J Neurosci** 1995 Nov 1;7(11):2226–39

Effect of hypoosmolality on the abundance, poly(A) tail length and axonal targeting of arginine vasopressin and oxytocin mRNAs in rat hypothalamic magnocellular neurons. Svane PC, et al. **FEBS Lett** 1995 Oct 2;373(1):35–8

Characterization of a voltage–dependent potassium channel in squid Schwann cells reconstituted in planar lipid bilayers. Noceti F, et al. **Glia** 1995 Sep;15(1):33–42

Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae–like properties. Bouillot C, et al. **J Biol Chem** 1996 Mar 29; 271(13):7640–4

Purification, cloning, and sequence analysis of a Mr = 30,000 protein from sea urchin axonemes that is important for sperm motility. Relationship of the protein to a dynein light chain. Gingras D, et al. **J Biol Chem** 1996 May 31; 271(22):12807–13

Tubulin transport in neurons. Miller KE, et al. **J Cell Biol** 1996 Jun;133(6):1355–66

Axonal transport of mitochondria along microtubules and F–actin in living vertebrate neurons. Morris RL, et al. **J Cell Biol** 1995 Dec;131(5):1315–26

Adenosine A1 receptors are located predominantly on axons

in the rat hippocampal formation. Swanson TH, et al. **J Comp Neurol** 1995 Dec 25;363(4):517–531

K(+)- and HCO3(-)-dependent acid-base transport in squid giant axons. I. Base efflux. Hogan EM, et al. **J Gen Physiol** 1995 Nov;106(5):821–44

K(+)- and HCO3(-)-dependent acid-base transport in squid giant axons II. Base influx. Hogan EM, et al. **J Gen Physiol** 1995 Nov;106(5):845–62

Mechanisms of injury-induced calcium entry into peripheral nerve myelinated axons: role of reverse sodium–calcium exchange. Lehning EJ, et al. **J Neurochem** 1996 Feb; 66(2):493–500

Elemental composition and water content of rat optic nerve myelinated axons and glial cells: effects of in vitro anoxia and reoxygenation. LoPachin RM Jr, et al. **J Neurosci** 1995 Oct;15(10):6735–46

Localization and active transport of mRNA in axons of sympathetic neurons in culture. Olink-Coux M, et al. **J Neurosci** 1996 Feb 15;16(4):1346–58

A retrograde double-labeling technique for light microscopy. A combination of axonal transport of cholera toxin B-subunit and a gold–lectin conjugate. Ruigrok TJ, et al. **J Neurosci Methods** 1995 Sep–Oct;61(1–2):127–38

Phosphoarginine stimulation of Na(+)–Ca2+ exchange in squid axons—a new pathway for metabolic regulation? DiPolo R, et al. **J Physiol (Lond)** 1995 Aug 15;487 (Pt 1):57–66

A simple model of K+ channel activation in nerve membrane. Clay JR. **J Theor Biol** 1995 Jul 12;175(2):257–62

Differential effects of the Rac GTPase on Purkinje cell axons and dendritic trunks and spines. Luo L, et al. **Nature** 1996 Feb 29;379(6568):837–40

Anterograde transport of neurotrophins and axodendritic transfer in the developing visual system. von Bartheld CS, et al. **Nature** 1996 Feb 29;379(6568):830–3

No diffusion barrier at axon hillock [letter] Winckler B, et al. **Nature** 1996 Jan 18;379(6562):213

Characterization of squid enolase mRNA: sequence analysis, tissue distribution, and axonal localization. Chun JT, et al. **Neurochem Res** 1995 Aug;20(8):923–30

Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin. Carlton SM, et al. **Neurosci Lett** 1995 Sep 1;197(1):25–8

Evidence for a sodium-dependent potassium conductance in frog myelinated axon. Poulter MO, et al. **Neuroscience** 1995 Sep;68(2):487–95

An axoplasmic myosin with a calmodulin-like light chain. Bearer EL, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11; 93(12):6064–8

Visualization of slow axonal transport in vivo. Terada S, et al. **Science** 1996 Aug 9;273(5276):784–8

PATHOLOGY

Axonal swellings in cerebellar white matter of groggy mutant rat. Takeuchi IK, et al. **Acta Neuropathol (Berl)** 1995; 90(5):486–92

Homicidal blunt head trauma, diffuse axonal injury, alcoholic intoxication, and cardiorespiratory arrest: a case report of a forensic syndrome of acute brainstem dysfunction. Ramsay DA, et al. **Am J Forensic Med Pathol** 1995 Jun; 16(2):107–14

Pathology of the motor-sensory axonal Guillain–Barré syndrome [see comments] Griffin JW, et al. **Ann Neurol** 1996 Jan;39(1):17–28. Comment in: Ann Neurol 1996 Jan;39(1):4–5.

Chronic idiopathic axonal polyneuropathy. Comparison of patients with and without monoclonal gammopathy. Notermans NC, et al. **Brain** 1996 Apr;119 (Pt 2):421–7

Aggregation of a subpopulation of vimentin filaments in cultured human skin fibroblasts derived from patients with giant axonal neuropathy. Bousquet O, et al. **Cell Motil Cytoskeleton** 1996;33(2):115–29

Trauma, axonal injury, and amyotrophic lateral sclerosis: a clinical correlate of a neuropharmacologic model. Riggs JE. **Clin Neuropharmacol** 1995 Jun;18(3):273–6

The axonal carpal tunnel syndrome. Seror P. **Electroencephalogr Clin Neurophysiol** 1996 Jun; 101(3):197–200

Magnetization transfer imaging of diffuse axonal injury following experimental brain injury in the pig: characterization by magnetization transfer ratio with histopathologic correlation. Kimura H, et al. **J Comput Assist Tomogr** 1996 Jul–Aug;20(4):540–6

Axonal atrophy in aging is associated with a decline in neurofilament gene expression. Parhad IM, et al. **J Neurosci Res** 1995 Jun 15;41(3):355–66

Neuroaxonal dystrophy in a litter of papillon pups. Franklin RJ, et al. **J Small Anim Pract** 1995 Oct;36(10):441–4

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Blennow K, et al. **Mol Chem Neuropathol** 1995 Dec;26(3):231–45

Axonal CIDP: a premature concept? Feasby TE. **Muscle Nerve** 1996 Mar;19(3):372–4 (16 ref.)

Another case of chronic relapsing axonal neuropathy [letter; comment] Morino S, et al. **Muscle Nerve** 1996 Apr; 19(4):533; discussion 532–3. Comment on: Muscle Nerve 1995 Jan;37(1):112–5.

Chronic progressive steroid responsive axonal polyneuropathy: a CIDP vaariant or a primary axonal disorder? Uncini A, et al. **Muscle Nerve** 1996 Mar; 19(3):365–71

Detection of heparan sulfate in spinal spheroids of beta, beta'-iminodipropionitrile (IDPN)-treated rats. Wada M, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):137–40

Expression of beta-amyloid precursor protein in axons of periventricular leukomalacia brains. Arai Y, et al. **Pediatr Neurol** 1995 Sep;13(2):161–3

Axonal atrophy is a specific component of 2,5-hexanedione peripheral neuropathy. Lehning EJ, et al. **Toxicol Appl Pharmacol** 1995 Nov;135(1):58–66

Fine structural changes of muscle spindles in the gracile axonal dystrophy mutant mouse. Takagi A, et al. **Virchows Arch** 1996 Jul;428(4–5):289–96

[Giant axonal neuropathy. A case report] Yuan Y, et al. **Pathologe** 1996 May;17(3):213–8 (Eng. Abstr.) (Ger)

PHYSIOLOGY

Differential expression of triiodothyronine receptors in schwannoma and neurofibroma: role of Schwann cell–axon interaction. Walter IB, et al. **Acta Neuropathol (Berl)** 1995; 90(2):142–9

Human motor units studied by intramuscular microstimulation. Elek JM, et al. **Adv Exp Med Biol** 1995; 384:161–71

Human motor units studied by spike-triggered averaging and intraneural motor axon stimulation. Thomas CK. **Adv Exp Med Biol** 1995;384:147–60 (75 ref.)

Effect of inferior alveolar nerve axotomy on immune cells and nerve fibres in young rat molars. Fristad I, et al. **Arch Oral Biol** 1995 Nov;40(11):1053–62

Ciliary neurotrophic factors enhances peripheral nerve regeneration. Newman JP, et al. **Arch Otolaryngol Head Neck Surg** 1996 Apr;122(4):399–403

Changes in retinal ganglion cell axons after optic nerve crush: neurofilament expression is not the sole determinant of calibre. Minzenberg M, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):599–604

Alkylphosphocholines inhibit choline uptake and phosphatidylcholine biosynthesis in rat sympathetic neurons and impair axonal extension. Posse de Chaves E, et al. **Biochem J** 1995 Dec 1;312 (Pt 2):411–7

Neural mechanisms and axon reflexes in asthma. Where are we? Verleden GM. **Biochem Pharmacol** 1996 May 17; 51(10):1247–57 (176 ref.)

Axonal growth mediated by cell adhesion molecules requires activation of fibroblast growth factor receptors. Saffell JL, et al. **Biochem Soc Trans** 1995 Aug;23(3):469–70 (12 ref.)

The neurofilamentous network-smooth endoplasmic reticulum complex in transected squid giant axon. Metuzals J, et al. **Biol Bull** 1995 Oct–Nov;189(2):216–8

Axonal regeneration. Brecknell JE, et al. **Biol Rev Camb Philos Soc** 1996 May;71(2):227–55 (260 ref.)

Asymmetric modulation and blockade of the delayed rectifier in squid giant axons by divalent cations. Clay JR. **Biophys J** 1995 Nov;69(5):1773–9

A mechanism for ectopic firing in central demyelinated axons. Felts PA, et al. **Brain** 1995 Oct;118 (Pt 5):1225–31

Activity-dependent changes in impulse conduction in normal human cutaneous axons. Miller TA, et al. **Brain** 1995 Oct; 118 (Pt 5):1217–24

Moderate elevation of extracellular potassium transiently inhibits regeneration of sensory axons in cultured adult sciatic nerves. Edström A, et al. **Brain Res** 1995 Sep 25; 693(1–2):148–54

Assessment of axonal dysfunction in an in vitro model of acute compressive injury to adult rat spinal cord axons. Fehlings MG, et al. **Brain Res** 1995 Apr 24;677(2):291–9

An analysis of astrocytic cell lines with different abilities to promote axon growth. Fok-Seang J, et al. **Brain Res** 1995 Aug 21;689(2):207–23

The axonal transport of beta III-tubulin is altered in both branches of sensory axons after injury of the rat sciatic nerve. Hoffman PN, et al. **Brain Res** 1996 Feb 5; 708(1–2):182–4

Prolonged and extensive IgG immunoreactivity after severe fluid–percussion injury in rat brain. Hoshino S, et al. **Brain Res** 1996 Mar 4;711(1–2):73–83

Axonal degeneration promotes abnormal accumulation of amyloid beta-protein in ascending gracile tract of gracile axonal dystrophy (GAD) mouse. Ichihara N, et al. **Brain Res** 1995 Oct 16;695(2):173–8

Enkephalin–immunoreactive fastigial neurons in the rat cerebellum project to upper cervical cord segments. Ikeda M, et al. **Brain Res** 1995 Sep 4;690(2):225–30

Fast axonal transport rates are unchanged in 6- and 24-month F344 rats. Jacob JM. **Brain Res** 1995 Nov 13;699(1):154–6

Synaptic relationships between axon terminals from the mediodorsal thalamic nucleus and layer III pyramidal cells in the prelimbic cortex of the rat. Kuroda M, et al. **Brain Res** 1996 Feb 5;708(1–2):185–90

LIF-and IL-1 beta-mediated increases in substance P receptor mRNA in axotomized, explanted or dissociated sympathetic ganglia. Ludlam WH, et al. **Brain Res** 1995 Jul 10;685(1–2):12–20

Functional properties of regenerated optic axons terminating in the primary olfactory cortex. Scalia F, et al. **Brain Res** 1995 Jul 10;685(1–2):187–97

Backpropagation of action potentials generated at ectopic axonal loci: hypothesis that axon terminals integrate local environmental signals. Pinault D. **Brain Res Brain Res Rev** 1995 Jul;21(1):42–92 (484 ref.)

Branching pattern of corticothalamic projections from the somatosensory cortex during postnatal development in the rat. Frassoni C, et al. **Brain Res Dev Brain Res** 1995 Dec 21;90(1–2):111–21

Characterization of microtubule-associated protein phosphoisoforms present in isolated growth cones. García Rocha M, et al. **Brain Res Dev Brain Res** 1995 Oct 27; 89(1):47–55

Control of myelination, axonal growth, and synapse formation in spinal cord explants by ion channels and electrical activity. Shrager P, et al. **Brain Res Dev Brain Res** 1995 Aug 28;88(1):68–78

Differential expression of alpha-CGRP and beta-CGRP genes within hypoglossal motoneurons in response to axotomy. Sarasa M, et al. **Brain Res Mol Brain Res** 1996 Jan;35(1–2):269–77

Neuronal growth and death: order and disor ler in the axoplasm. Cleveland DW. **Cell** 1996 Mar 8;84(5):663–6 (17 ref.)

Axon membrane flows from the growth cone to the cell body. Dai J, et al. **Cell** 1995 Dec 1;83(5):693–701

Axon guidance molecules. Keynes R, et al. **Cell** 1995 Oct 20;83(2):161–9 (60 ref.)

Topographically specific effects of ELF-1 on retinal axon guidance in vitro and retinal axon mapping in vivo. Nakamoto M, et al. **Cell** 1996 Sep 6;86(5):755–66

Cortical target depletion and ingrowth of geniculocortical axons: implications for cortical specification. Woo TU, et al. **Cereb Cortex** 1996 May–Jun;6(3):457–69

Schwann cells and the regrowth of axons in the mammalian CNS: a review of transplantation studies in the rat visual system. Harvey AR, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):569–79 (77 ref.)

The Nicolas Andry Award. The pathomechanics and pathophysiology of cervical spinal cord injury. Torg JS, et al. **Clin Orthop** 1995 Dec;(321):259–69

Axon guidance: following the Eph plan. Orike N, et al. **Curr Biol** 1996 Feb 1;6(2):108–10 (15 ref.)

Regeneration in the adult mammalian CNS: guided by development. Aubert I, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):625–35 (118 ref.)

The GAL4 system as a tool for unravelling the mysteries of the Drosophila nervous system. Brand AH, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):572–8 (60 ref.)

Myelin-associated glycoprotein: a role in myelination and in the inhibition of axonal regeneration? Filbin MT. **Curr Opin Neurobiol** 1995 Oct;5(5):588–95 (58 ref.)

Intraretinal grafting reveals growth requirements and guidance cues for optic axons in the developing avian retina. Halfter W. **Dev Biol** 1996 Jul 10;177(1):160–77

Clustering and functional cooperation of Ng-CAM and axonin-1 in the substratum-contact area of growth cones. Stoeckli ET, et al. **Dev Biol** 1996 Jul 10;177(1):15–29

Targeted ablation of glia disrupts axon tract formation in the Drosophila CNS. Hidalgo A, et al. **Development** 1995 Nov;121(11):3703–12

Periaxin expression in myelinating Schwann cells: modulation by axon–glial interactions and polarized localization during development. Scherer SS, et al. **Development** 1995 Dec; 121(12):4265–73

The C. elegans gene vab-8 guides posteriorly directed axon outgrowth and cell migration. Wightman B, et al. **Development** 1996 Feb;122(2):671–82

Guidance of thalamocortical axons by growth-promoting molecules in developing rat cerebral cortex. Hübener M, et al. **Eur J Neurosci** 1995 Sep 1;7(9):1963–72

Prominent expression of bFGF in dorsal root ganglia after axotomy. Ji RR, et al. **Eur J Neurosci** 1995 Dec 1; 7(12):2458–68

Lines of murine oligodendroglial precursor cells immortalized by an activated neu tyrosine kinase show distinct degrees of interaction with axons in vitro and in vivo. Jung M, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1245–65

Failure of axon regeneration in postnatal rat entorhinohippocampal slice coculture is due to maturation of the axon, not that of the pathway or target. Li D, et al. **Eur J Neurosci** 1995 Jun 1;7(6):1164–71

A critical period for axon regrowth through a lesion in the developing mammalian retina. MacLaren RE, et al. **Eur J Neurosci** 1995 Oct 1;7(10):2111–8

Expression of NMDA receptor mRNAs in rat motoneurons is down-regulated after axotomy. Piehl F, et al. **Eur J Neurosci** 1995 Oct 1;7(10):2101–10

Persistence of neuromuscular junctions after axotomy in mice with slow Wallerian degeneration (C57BL/WldS). Ribchester RR, et al. **Eur J Neurosci** 1995 Jul 1; 7(7):1641–50

The expression of different cytochemical markers in normal and axotomised dorsal root ganglion cells projecting to the nucleus gracilis in the adult rat. Persson JK, et al. **Exp Brain Res** 1995;105(3):331–44

Differential macrophage responses in the peripheral and central nervous system during wallerian degeneration of axons. Avellino AM, et al. **Exp Neurol** 1995 Dec; 136(2):183–98

Tubulization increases axonal outgrowth of rat sciatic nerve after crush injury. Danielsson P, et al. **Exp Neurol** 1996 Jun;139(2):238–43

Effects of axonal injury on astrocyte proliferation and morphology in vitro: implications for astrogliosis. Guenard V, et al. **Exp Neurol** 1996 Feb;137(2):175–90

Schwann cells and fetal tectal tissue cografted to the midbrain of newborn rats: fate of Schwann cells and their influence on host retinal innervation of grafts. Harvey AR, et al. **Exp Neurol** 1995 Aug;134(2):179–91

Synaptic evoked potentials from regenerating dorsal root axons within fetal spinal cord tissue transplants. Houle JD, et al. **Exp Neurol** 1996 Jun;139(2):278–90

Reactive astroglia support primary dendritic but not axonal outgrowth from mouse cortical neurons in vitro. Le Roux PD, et al. **Exp Neurol** 1996 Jan;137(1):49–65

Injury–induced proteoglycans inhibit the potential for laminin–mediated axon growth on astrocytic scars. McKeon RJ, et al. **Exp Neurol** 1995 Nov;136(1):32–43

Axonal growth into tubes implanted within lesions in the spinal cords of adult rats. Montgomery CT, et al. **Exp Neurol** 1996 Feb;137(2):277–90

Reductions in motoneuronal neurofilament synthesis by successive axotomies: a possible explanation for the conditioning lesion effect on axon regeneration. Tetzlaff W, et al. **Exp Neurol** 1996 May;139(1):95–106

Regeneration of entorhino–dentate projections in organotypic slice cultures: mode of axonal regrowth and effects of growth factors. Woodhams PL, et al. **Exp Neurol** 1996 Jul;140(1):68–78

The extracellular matrix molecule, tenascin is associated with adult rat CNS axons regenerating into peripheral nerve grafts. Zhang Y, et al. **Gene Ther** 1994;1 Suppl 1:S67

Genetic interactions between the Drosophila Abelson (Abl) tyrosine kinase and failed axon connections (fax), a novel protein in axon bundles. Hill KK, et al. **Genetics** 1995 Oct; 141(2):595–606

Olfactory bulb ensheathing glia: a unique cell type with axonal growth–promoting properties. Ramón–Cueto A, et al. **Glia** 1995 Jul;14(3):163–73 (145 ref.)

Na+ channel aggregation in remyelinating mouse sciatic axons following transection. Tzoumaka EE, et al. **Glia** 1995 Oct;15(2):188–94

An endogenous lectin and its glycoprotein ligands are triggering basal and axon–induced Schwann cell proliferation. Badache A, et al. **Glycobiology** 1995 Jun; 5(4):371–83

Time course of axonal myelination in the human brainstem auditory pathway. Moore JK, et al. **Hear Res** 1995 Jul; 87(1–2):21–31

A generalized cable equation for magnetic stimulation of axons. Nagarajan SS, et al. **IEEE Trans Biomed Eng** 1996 Mar;43(3):304–12

Analysis of magnetic stimulation of a concentric axon in a nerve bundle. Nagarajan SS, et al. **IEEE Trans Biomed Eng** 1995 Sep;42(9):926–33

Effects of axotomy and intraocular administration of NT–4, NT–3, and brain–derived neurotrophic factor on the survival of adult rat retinal ganglion cells. A quantitative in vivo study. Peinado–Ramón P, et al. **Invest Ophthalmol Vis Sci** 1996 Mar;37(4):489–500

A Drosophila protein–tyrosine phosphatase associates with an adapter protein required for axonal guidance. Clemens JC, et al. **J Biol Chem** 1996 Jul 19;271(29):17002–5

Ganglioside synthesis during the development of neuronal polarity. Major changes occur during axonogenesis and axon elongation, but not during dendrite growth or synaptogenesis. Hirschberg K, et al. **J Biol Chem** 1996 Jun 21;271(25):14876–82

Osmotic dilution stimulates axonal outgrowth by making axons more sensitive to tension. Lin C, et al. **J Biomech** 1995 Dec;28(12):1429–38

Increasing neurofilament subunit NF–M expression reduces axonal NF–H, inhibits radial growth, and results in neurofilamentous accumulation in motor neurons. Wong PC, et al. **J Cell Biol** 1995 Sep;130(6):1413–22

Microtubule transport and assembly during axon growth. Yu W, et al. **J Cell Biol** 1996 Apr;133(1):151–7

Microtubules released from the neuronal centrosome are transported into the axon. Ahmad FJ, et al. **J Cell Sci** 1995 Aug;108 (Pt 8):2761–9

Cell body response to injury in motoneurons and primary sensory neurons of a mutant mouse, Ola (Wld), in which Wallerian degeneration is delayed. Bisby MA, et al. **J Comp Neurol** 1995 Sep 4;359(4):653–62

Axon arbors and synaptic connections of hippocampal mossy cells in the rat in vivo. Buckmaster PS, et al. **J Comp Neurol** 1996 Mar 4;366(2):271–92

Axonal regeneration and limited functional recovery following hippocampal deafferentation. Eagle KS, et al. **J Comp Neurol** 1995 Dec 18;363(3):377–88

Patchy and laminar terminations of medial geniculate axons in monkey auditory cortex. Hashikawa T, et al. **J Comp Neurol** 1995 Nov 13;362(2):195–208

Fibroblasts at the transection site of the injured goldfish optic nerve and their potential role during retinal axonal regeneration. Hirsch S, et al. **J Comp Neurol** 1995 Oct 2; 360(4):599–611

PNS features of rodent optic nerve axons. Jeffery G. **J Comp Neurol** 1996 Mar 4;366(2):370–8

Development of olfactory glomeruli: temporal and spatial interactions between olfactory receptor axons and mitral cells in opossums and rats. Malun D, et al. **J Comp Neurol** 1996 Apr 22;368(1):1–16

Orthograde axonal transport studies of projections from the zona incerta and pretectum to the basilar pontine nuclei in the rat. Mihailoff GA. **J Comp Neurol** 1995 Sep 18; 360(2):301–18

Developmental expression of a neuron–specific beta–tubulin in frog (Xenopus laevis): a marker for growing axons during the embryonic period. Moody SA, et al. **J Comp Neurol** 1996 Jan 8;364(2):219–30

Common and distinct fusion proteins in axonal growth and transmitter release. Osen–Sand A, et al. **J Comp Neurol** 1996 Apr 1;367(2):222–34

Axotomy induces a different modulation of both low–affinity nerve growth factor receptor and choline acetyltransferase between adult rat spinal and brainstem motoneurons. Rende M, et al. **J Comp Neurol** 1995 Dec 11;363(2):249–63

Two types of corticopulvinar terminations: round (type 2) and elongate (type 1). Rockland KS. **J Comp Neurol** 1996 Apr 22;368(1):57–87

Differential regenerative response of Purkinje cell and inferior olivary axons confronted with embryonic grafts: environmental cues versus intrinsic neuronal determinants. Rossi F, et al. **J Comp Neurol** 1995 Sep 4;359(4):663–77

Reorganization of central terminals of myelinated primary afferents in the rat dorsal horn following peripheral axotomy. Woolf CJ, et al. **J Comp Neurol** 1995 Sep 11; 360(1):121–34

The guidance molecule semaphorin III is expressed in regions of spinal cord and periphery avoided by growing sensory axons. Wright DE, et al. **J Comp Neurol** 1995 Oct 16; 361(2):321–33

Glial environment in the developing superior colliculus of hamsters in relation to the timing of retinal axon ingrowth. Wu DY, et al. **J Comp Neurol** 1995 Jul 24;358(2):206–18

Molecular basis of interactions between regenerating adult rat thalamic axons and Schwann cells in peripheral nerve grafts I. Neural cell adhesion molecules. Zhang Y, et al. **J Comp Neurol** 1995 Oct 16;361(2):193–209

Molecular basis of interactions between regenerating adult rat thalamic axons and Schwann cells in peripheral nerve grafts. II. Tenascin–C. Zhang Y, et al. **J Comp Neurol** 1995 Oct 16;361(2):210–24

Evidence for axonal sprouting in the anterior pituitary following adrenalectomy in the rat. Lu CR, et al. **J Endocrinol** 1995 Oct;147(1):161–6

Recovery of function, peripheral sensitization and sensory neurone activation by novel pathways following axonal injury in Aplysia californica. Dulin MF, et al. **J Exp Biol** 1995 Oct;198 (Pt 10):2055–66

Peripheral regeneration and central sprouting of sensory neurone axons in Aplysia californica following nerve injury. Steffensen I, et al. **J Exp Biol** 1995 Oct;198 (Pt 10):2067–78

Joseph H. Boyes Award. Dispersion of regenerating axons across enclosed neural gaps. Brushart TM, et al. **J Hand Surg [Am]** 1995 Jul;20(4):557–64

Single–channel analysis of a delayed rectifier K+ channel in Xenopus myelinated nerve. Koh DS, et al. **J Membr Biol** 1996 Feb;149(3):221–32

Inhibition of formation of filopodia after axotomy by inhibitors of protein tyrosine kinases. Goldberg DJ, et al. **J Neurobiol** 1995 Aug;27(4):553–60

Differential regulation of motor neuron survival and choline acetyltransferase expression following axotomy. Kou SY, et al. **J Neurobiol** 1995 Aug;27(4):561–72

Human Schwann cells in vitro. II. Myelination of sensory axons following extensive purification and heregulin–induced expansion. Morrissey TK, et al. **J Neurobiol** 1995 Oct;28(2):190–201

Axons of Xenopus neural tube respond to reversals of neural tube orientation. Nordlander RH, et al. **J Neurobiol** 1996 Apr;29(4):490–502

Importance of target innervation in recovery from axotomy–induced loss of androgen receptor in rat perineal motoneurons. al–Shamma HA, et al. **J Neurobiol** 1995 Nov; 28(3):341–53

Peripheral nerve explants grafted into the vitreous body of the eye promote the regeneration of retinal ganglion cell axons severed in the optic nerve. Berry M, et al. **J Neurocytol** 1996 Feb;25(2):147–70

Cytoplasmic constriction and vesiculation after axotomy in the squid giant axon. Gallant PE, et al. **J Neurocytol** 1995 Dec;24(12):943–54

Morphological plasticity of axotomized retinal ganglion cells following intravitreal transplantation of a peripheral nerve segment. Lei JL, et al. **J Neurocytol** 1995 Jul;24(7):497–506

Influence of peripheral nerve grafts on the expression of GAP–43 in regenerating retinal ganglion cells in adult hamsters. Ng TF, et al. **J Neurocytol** 1995 Jul;24(7):487–96

Axonal projections of caudal ventrolateral medullary and medullary raphe neurons with activity correlated to the 10–Hz rhythm in sympathetic nerve discharge. Barman SM, et al. **J Neurophysiol** 1995 Dec;74(6):2295–308

Voltage–gated calcium channels in CNS white matter: role in anoxic injury. Fern R, et al. **J Neurophysiol** 1995 Jul; 74(1):369–77

Differences in the brain stem terminations of large– and small–diameter vestibular primary afferents. Huwe JA, et al. **J Neurophysiol** 1995 Sep;74(3):1362–6

Development of spontaneous activity and mechanosensitivity in axotomized afferent nerve fibers during the first hours after nerve transection in rats. Michaelis M, et al. **J Neurophysiol** 1995 Sep;74(3):1020–7

Axotomy induces a transient and localized elevation of the free intracellular calcium concentration to the millimolar range. Ziv NE, et al. **J Neurophysiol** 1995 Dec; 74(6):2625–37

Mechanisms of secondary injury to spinal cord axons in vitro: role of Na+, Na(+)–K(+)–ATPase, the Na(+)–H+ exchanger, and the Na(+)–Ca2+ exchanger. Agrawal SK, et al. **J Neurosci** 1996 Jan 15;16(2):545–52

Arrest of afferent axon extension by target neurons in vitro is regulated by the NMDA receptor. Baird DH, et al. **J Neurosci** 1996 Apr 15;16(8):2642–8

Dynamics of target recognition by interstitial axon branching along developing cortical axons. Bastmeyer M, et al. **J Neurosci** 1996 Feb 15;16(4):1450–9

Mesencephalic substrate of reward: axonal connections. Boye SM, et al. **J Neurosci** 1996 May 15;16(10):3511–20

Glial cells are increased proportionally in transgenic optic nerves with increased numbers of axons. Burne JF, et al. **J Neurosci** 1996 Mar 15;16(6):2064–73

Identification and molecular characterization of Unc–33–like phosphoprotein (Ulip), a putative mammalian homolog of the axonal guidance–associated unc–33 gene product. Byk T, et al. **J Neurosci** 1996 Jan 15;16(2):688–701

Chronic hyponatremia reduces survival of magnocellular vasopressin and oxytocin neurons after axonal injury. Dohanics J, et al. **J Neurosci** 1996 Apr 1;16(7):2373–80

Acetylcholine receptor aggregation at nerve–muscle contacts in mammalian cultures: induction by ventral spinal cord neurons is specific to axons. Dutton EK, et al. **J Neurosci** 1995 Nov;15(11):7401–16

Taurine induces a long–lasting increase of synaptic efficacy and axon excitability in the hippocampus. Galarreta M, et al. **J Neurosci** 1996 Jan;16(1):92–102

Axotomy–induced axonal degeneration is mediated by calcium influx through ion–specific channels. George EB, et al. **J Neurosci** 1995 Oct;15(10):6445–52

Sympathetic axons pathfind successfully in the absence of target. Guidry G, et al. **J Neurosci** 1995 Nov; 15(11):7565–74

The behavior of optic axons on substrate gradients of retinal basal lamina proteins and merosin. Halfter W. **J Neurosci** 1996 Jul 15;16(14):4389–401

Selective inhibition of axon outgrowth by antibodies to NGF in a model of temporal lobe epilepsy. Holtzman DM, et al. **J Neurosci** 1995 Nov;15(11):7062–70

Restoration of normal conduction properties in demyelinated spinal cord axons in the adult rat by transplantation of exogenous Schwann cells. Honmou O, et al. **J Neurosci** 1996 May 15;16(10):3199–208

Axonal regeneration and physiological activity following transection and immunological disruption of myelin within the hatchling chick spinal cord. Keirstead HS, et al. **J Neurosci** 1995 Oct;15(10):6963–74

Axons regulate the distribution of Schwann cell microtubules. Kidd G, et al. **J Neurosci** 1996 Feb 1;16(3):946–54

Microtubule assembly and turnover in growing axons. Li Y, et al. **J Neurosci** 1996 Jan 15;16(2):531–44

Brain–derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. Mamounas LA, et al. **J Neurosci** 1995 Dec;15(12):7929–39

The first retinal axon growth in the mouse optic chiasm: axon patterning and the cellular environment. Marcus RC, et al. **J Neurosci** 1995 Oct;15(10):6389–402

The ganglionic eminence may be an intermediate target for corticofugal and thalamocortical axons. Métin C, et al. **J Neurosci** 1996 May 15;16(10):3219–35

TOAD–64, a gene expressed early in neuronal differentiation in the rat, is related to unc–33, a C. elegans gene involved in axon outgrowth. Minturn JE, et al. **J Neurosci** 1995 Oct; 15(10):6757–66

Recovery of tail–elicited siphon–withdrawal reflex following unilateral axonal injury is associated with ipsi– and contralateral changes in gene expression in Aplysia californica. Noel F, et al. **J Neurosci** 1995 Oct; 15(10):6926–38

Microtubule stability decreases axon elongation but not axoplasm production. Rochlin MW, et al. **J Neurosci** 1996 May 15;16(10):3236–46

Bcl–2 overexpression prevents motoneuron cell body loss but not axonal degeneration in a mouse model of a neurodegenerative disease. Sagot Y, et al. **J Neurosci** 1995 Nov;15(11):7727–33

GDNF slows loss of motoneurons but not axonal degeneration or premature death of pmn/pmn mice. Sagot Y, et al. **J Neurosci** 1996 Apr 1;16(7):2335–41

Axonal sprouting in layer V pyramidal neurons of chronically injured cerebral cortex. Salin P, et al. **J Neurosci** 1995 Dec; 15(12):8234–45

Brain–derived neurotrophic factor and neurotrophin–4/5 stimulate growth of axonal branches from regenerating retinal ganglion cells. Sawai H, et al. **J Neurosci** 1996 Jun 15;16(12):3887–94

Analysis of integrin expression on oligodendrocytes during axo–glial interaction by using rat–mouse xenocultures. Shaw CE, et al. **J Neurosci** 1996 Feb 1;16(3):1163–72

Presynaptic glutamate levels in tonic and phasic motor axons correlate with properties of synaptic release. Shupliakov O, et al. **J Neurosci** 1995 Nov;15(11):7168–80

mRNA expression of KIF1A, KIF1B, KIF2, KIF3A, KIF3B, KIF4, KIF5, and cytoplasmic dynein during axonal regeneration. Takemura R, et al. **J Neurosci** 1996 Jan; 16(1):31–5

Distribution of an APP homolog, APLP2, in the mouse olfactory system: a potential role for APLP2 in axogenesis. Thinakaran G, et al. **J Neurosci** 1995 Oct;15(10):6314–26

Specificity in the axonal connections of layer VI neurons in tree shrew striate cortex: evidence for distinct granular and supragranular systems. Usrey WM, et al. **J Neurosci** 1996 Feb 1;16(3):1203–18

Reevaluation of the growth–permissive substrate properties

of goldfish optic nerve myelin and myelin proteins. Wanner M, et al. **J Neurosci** 1995 Nov;15(11):7500–8

Association of beta 1 integrin with phosphotyrosine in growth cone filopodia. Wu DY, et al. **J Neurosci** 1996 Feb 15;16(4):1470–8

Specificity of sympathetic preganglionic projections in the chick is influenced by the somitic mesoderm. Yip JW. **J Neurosci** 1996 Jan 15;16(2):612–20

The growth of the axon is not dependent upon net microtubule assembly at its distal tip. Yu W, et al. **J Neurosci** 1995 Oct;15(10):6827–33

Spinohypothalamic tract neurons in the cervical enlargement of rats: descending axons in the ipsilateral brain. Zhang X, et al. **J Neurosci** 1995 Dec;15(12):8393–407

Poisson-process electrical stimulation: circuit and axonal responses. Moradmand K, et al. **J Neurosci Methods** 1995 Dec;63(1–2):113–20

Inhibition of lipid peroxidation attenuates axotomy-induced apoptotic degeneration of facial motor neurons in neonatal rats. Hall ED, et al. **J Neurosci Res** 1996 May 1;44(3):293–9

Collagen implants and cortico-spinal axonal growth after mid-thoracic spinal cord lesion in the adult rat. Joosten EA, et al. **J Neurosci Res** 1995 Jul 1;41(4):481–90

Coordinated upregulation of alpha 1- and beta II-tubulin mRNAs during collateral axonal sprouting of central peptidergic neurons. Paden CM, et al. **J Neurosci Res** 1995 Oct 15;42(3):402–12

Glia-to-axon communication: enrichment of glial proteins transferred to the squid giant axon. Sheller RA, et al. **J Neurosci Res** 1995 Jun 15;41(3):324–34

Zebrafish neurons express two L1-related molecules during early axonogenesis. Tongiorgi E, et al. **J Neurosci Res** 1995 Nov 1;42(4):547–61

Vasoactive intestinal peptide: mediator of laminin synthesis in cultured Schwann cells. Zhang QL, et al. **J Neurosci Res** 1996 Feb 15;43(4):496–502

Biomechanical analysis of experimental diffuse axonal injury. Meaney DF, et al. **J Neurotrauma** 1995 Aug;12(4):689–94

The pathobiology of traumatically induced axonal injury in animals and humans: a review of current thoughts. Povlishock JT, et al. **J Neurotrauma** 1995 Aug;12(4):555–64 (76 ref.)

Electrical and morphological factors influencing the depolarizing after-potential in rat and lizard myelinated axons. David G, et al. **J Physiol (Lond)** 1995 Nov 15;489 (Pt 1):141–57

Distinct omega-agatoxin-sensitive calcium currents in somata and axon terminals of rat supraoptic neurones. Fisher TE, et al. **J Physiol (Lond)** 1995 Dec 1;489 (Pt 2):383–8

Perinatal development of action potential propagation in cat rubrospinal axons. Song WJ, et al. **J Physiol (Lond)** 1995 Oct 15;488 (Pt 2):419–26

Competitive exclusion between axons dependent on a single trophic substance: a mathematical analysis. Jeanprêtre N, et al. **Math Biosci** 1996 Jul 1;135(1):23–54

Schwann cell CD9 expression is regulated by axons. Banerjee SA, et al. **Mol Cell Neurosci** 1995 Oct;6(5):462–73

Multiple factors govern intraretinal axon guidance: a time-lapse study. Brittis PA, et al. **Mol Cell Neurosci** 1995 Oct;6(5):413–32

Unique changes of ganglion cell growth cone behavior following cell adhesion molecule perturbations: a time-lapse study of the living retina. Brittis PA, et al. **Mol Cell Neurosci** 1995 Oct;6(5):433–49

Myelin-associated glycoprotein inhibits axonal regeneration from a variety of neurons via interaction with a sialoglycoprotein. DeBellard ME, et al. **Mol Cell Neurosci** 1996 Feb;7(2):89–101

Signals triggering the induction of leukemia inhibitory factor in sympathetic superior cervical ganglia and their nerve trunks after axonal injury. Sun Y, et al. **Mol Cell Neurosci** 1996 Feb;7(2):152–63

Basic fibroblast growth factor has neuroprotective effects on axotomy-induced spinal motoneuron death and wobbler mouse motoneuron disease [letter] Ikeda K, et al. **Muscle Nerve** 1996 Jun;19(6):794–5

Another case of chronic relapsing axonal neuropathy [letter; comment] Morino S, et al. **Muscle Nerve** 1996 Apr; 19(4):533; discussion 532–3. Comment on: Muscle Nerve 1995 Jan;37(1):112–5.

Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Reaume AG, et al. **Nat Genet** 1996 May; 13(1):43–7

Effects of brain-derived neurotrophic factor on optic axon branching and remodelling in vivo. Cohen-Cory S, et al. **Nature** 1995 Nov 9;378(6553):192–6

Role of axons in membrane phospholipid synthesis in rat sympathetic neurons. Vance JE, et al. **Neurobiol Aging** 1995 May-Jun;16(3):493–8; discussion 498–9

Ninjurin, a novel adhesion molecule, is induced by nerve injury and promotes axonal growth. Araki T, et al. **Neuron** 1996 Aug;17(2):353–61

Acceleration of membrane recycling by axotomy of cultured aplysia neurons. Ashery U, et al. **Neuron** 1996 Mar; 16(3):641–51

Lack of evidence that myelin-associated glycoprotein is a major inhibitor of axonal regeneration in the CNS. Bartsch U, et al. **Neuron** 1995 Dec;15(6):1375–81

PY in the fly receptor-like tyrosine phosphatases in axonal pathfinding. Chien CB. **Neuron** 1996 Jun;16(6):1065–8 (17 ref.)

huckebein specifies aspects of CNS precursor identity required for motoneuron axon pathfinding. Chu-LaGraff Q, et al. **Neuron** 1995 Nov;15(5):1041–51

Axonal initiation and active dendritic propagation of action potentials in substantia nigra neurons. Häusser M, et al. **Neuron** 1995 Sep;15(3):637–47

A role for gradient en expression in positional specification on the optic tectum. Itasaki N, et al. **Neuron** 1996 Jan; 16(1):55–62

TrkA activation is sufficient to rescue axotomized cholinergic neurons. Lucidi-Phillipi CA, et al. **Neuron** 1996 Mar; 16(3):653–63

Inhibition of FGF receptor activity in retinal ganglion cell axons causes errors in target recognition. McFarlane S, et al. **Neuron** 1996 Aug;17(2):245–54

Ca2+ imaging of CNS axons in culture indicates reliable coupling between single action potentials and distal functional release sites. Mackenzie PJ, et al. **Neuron** 1996 Apr;16(4):783–95

Genetic analysis of Netrin genes in Drosophila: Netrins guide CNS commissural axons and peripheral motor axons. Mitchell KJ, et al. **Neuron** 1996 Aug;17(2):203–15

Engrailed, retinotectal targeting, and axonal patterning in the midbrain during Xenopus development: an antisense study. Rétaux S, et al. **Neuron** 1996 Jan;16(1):63–75

Disruption of the gene for the myelin-associated glycoprotein improves axonal regrowth along myelin in C57BL/Wlds mice. Schäfer M, et al. **Neuron** 1996 Jun;16(6):1107–13

Amplification of EPSPs by axosomatic sodium channels in neocortical pyramidal neurons. Stuart G, et al. **Neuron** 1995 Nov;15(5):1065–76

commissureless controls growth cone guidance across the CNS midline in Drosophila and encodes a novel membrane protein. Tear G, et al. **Neuron** 1996 Mar;16(3):501–14

Crossed and uncrossed retinal axons respond differently to cells of the optic chiasm midline in vitro. Wang LC, et al. **Neuron** 1995 Dec;15(6):1349–64

Expression of constitutively active CaMKII in target tissue modifies presynaptic axon arbor growth. Zou DJ, et al. **Neuron** 1996 Mar;16(3):529–39

The concept of calcium concentration microdomains in synaptic transmission. Llinás R, et al. **Neuropharmacology** 1995 Nov;34(11):1443–51

Lipids as axon guidance molecules? Clark GD, et al. **Neuroreport** 1995 Dec 15;6(18):2446

NMDA sensitivity is neurite enhanced. Heng JE, et al. **Neuroreport** 1995 Oct 2;6(14):1890–2

LIF-mediated activation of STAT proteins after neuronal injury in vivo. Rajan P, et al. **Neuroreport** 1995 Nov 13; 6(16):2240–4

Repulsive and attractive mechanisms for the formation of corticofugal projections. Yamamoto N, et al. **Neuroreport** 1995 Jul 31;6(11):1517–20

Action potentials in axonless horizontal cells isolated from the rabbit retina. Blanco R, et al. **Neurosci Lett** 1996 Jan 12;203(1):57–60

Acidic fibroblast growth factor prevents post-axotomy neuronal death of the newborn rat facial nerve. Cuevas P, et al. **Neurosci Lett** 1995 Sep 15;197(3):183–6

Sheath lengths of large motor axons in the ventral root L5 of neonatal and adult rats. Hildebrand C, et al. **Neurosci Lett** 1996 Jan 5;202(3):173–76

Direct measurement of fast axonal transport rates in corticospinal axons of the adult rat. Jacob JM, et al. **Neurosci Lett** 1995 Sep 1;197(1):17–20

Independent regulation of primary dendritic and axonal growth by maturing astrocytes in vitro. Le Roux PD, et al. **Neurosci Lett** 1995 Sep 22;198(1):5–8

Axons from the olfactory bulb transplanted into the hippocampal formation show axon preferences and form transplant-to-host synapses similar to those of normal afferents. Fujii M, et al. **Neurosci Res** 1995 Dec;24(1):53–60

Stimulation of saphenous afferent nerve produces vasodilatation of the vasa nervorum via an axon reflex-like mechanism in the sciatic nerve of anesthetized rats. Hotta H, et al. **Neurosci Res** 1996 Feb;24(3):305–8

Relationship between axonal regeneration and vascularity in tubulation—an experimental study in rats. Kakinoki R, et al. **Neurosci Res** 1995 Aug;23(1):35–45

GABAergic axons in the ventral forebrain of the rat: an electron microscopic study. Chang HT, et al. **Neuroscience** 1995 Sep;68(1):207–20

Time course of axotomy-induced apoptotic cell death in facial motoneurons of neonatal wild type and bcl-2 transgenic mice. de Bilbao F, et al. **Neuroscience** 1996 Apr; 71(4):1111–9

Directional regrowth of lesioned corticospinal tract axons in adult rat spinal cord. Joosten EA, et al. **Neuroscience** 1995 Nov;69(2):619–26

Functional reinnervation of the vasculature of the adult cat paw pad by axons originally innervating vessels in hairy skin. Koltzenburg M, et al. **Neuroscience** 1995 Jul; 67(1):245–52

Axonal regeneration of identified septohippocampal projection neurons in vitro. Linke R, et al. **Neuroscience** 1995 Sep;68(1):1–4

Growth cones and axon trajectories of the earliest descending serotonergic pathway of Xenopus. Liu S, et al. **Neuroscience** 1995 Nov;69(1):309–20

Pyramidal tract and corticospinal neurons with branching axons to the dorsal column nuclei of the cat. Martinez L, et al. **Neuroscience** 1995 Sep;68(1):195–206

Origin of beading constrictions at the axolemma: presence in unmyelinated axons and after beta,beta'-iminodipropionitrile degradation of the cytoskeleton. Ochs S, et al. **Neuroscience** 1996 Feb; 70(4):1081–96

Selective enhancement of axonal branching of cultured dentate gyrus neurons by neurotrophic factors. Patel MN, et al. **Neuroscience** 1995 Dec;69(3):763–70

Different voltage-dependent potassium conductances regulate action potential repolarization and excitability in frog myelinated axon. Poulter MO, et al. **Neuroscience** 1995 Sep;68(2):497–504

Properties of single axon excitatory postsynaptic potentials elicited in spiny interneurons by action potentials in pyramidal neurons in slices of rat neocortex. Thomson AM, et al. **Neuroscience** 1995 Dec;69(3):727–38

Disruption and restoration of dorsal horn sensory map after peripheral nerve crush and regeneration. Sugimoto T, et al. **Pain** 1995 Oct;63(1):49–54

Characterization and molecular reaction scheme of a chloride channel expressed after axotomy in crayfish. Adelsberger H, et al. **Pflugers Arch** 1996 Sep;432(5):867–75

Physiological measures of conduction velocity and refractory period for putative reward-relevant MFB axons arising in the rostral MFB. Murray B, et al. **Physiol Behav** 1996 Mar; 59(3):427–37

Behavioral measures of conduction velocity and refractory period for reward-relevant axons in the anterior LH and VTA. Murray B, et al. **Physiol Behav** 1996 Apr-May; 59(4–5):643–52

Degeneration and regeneration of axons in the lesioned spinal cord. Schwab ME, et al. **Physiol Rev** 1996 Apr;76(2):319–70 (774 ref.)

Impairment of axonal development and of synaptogenesis in hippocampal neurons of synapsin I-deficient mice. Chin LS, et al. **Proc Natl Acad Sci U S A** 1995 Sep 26; 92(20):9230–4

Receptors find work as guides [news] Barinaga M. **Science** 1995 Sep 22;269(5231):1668–70

Presynaptic long-term depression at the hippocampal mossy fiber-CA3 synapse. Kobayashi K, et al. **Science** 1996 Aug 2;273(5275):648–50

Function of myosin-V in filopodial extension of neuronal growth cones. Wang FS, et al. **Science** 1996 Aug 2; 273(5275):660–3

Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Yokoi M, et al. **Science** 1996 Aug 2; 273(5275):645–7

Spinal cord regeneration [comment] Young W. **Science** 1996 Jul 26;273(5274):451. Comment on: Science 1996 Jul 26;273(5274):510–3.

Effect of chronic autoimmune nerve growth factor deprivation on sympathetic neuroaxonal dystrophy in rats. Schroer JA, et al. **Synapse** 1995 Jul;20(3):249–56

The economics of neurite outgrowth—the addition of new membrane to growing axons. Futerman AH, et al. **Trends Neurosci** 1996 Apr;19(4):144–9 (55 ref.)

Severity of ganglion cell death during early postnatal development is modulated by both neuronal activity and binocular competition. Scheetz AJ, et al. **Vis Neurosci** 1995 Jul-Aug;12(4):605–10

Qualitative and quantitative features of axons projecting from caudal to rostral inferior temporal cortex of squirrel monkeys. Steele GE, et al. **Vis Neurosci** 1995 Jul-Aug; 12(4):701–22

[Nerve transplantation in the central nervous system: a strategy for inducing nerve fiber regeneration in lesions of the brain and spinal cord] Gauthier P, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):106–15 (62 ref.) (Eng. Abstr.) **(Fre)**

[Localization of insular cortex neurons, sending axons to the "stomach" region of the vago-solitary complex] Aleksandrov VG, et al. **Dokl Akad Nauk** 1996 Mar; 347(1):129–32 **(Rus)**

[The axon reflex: new views in an old area] Nozdrachev AD. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):135–42 (24 ref.) **(Rus)**

RADIATION EFFECTS

Effects of MR exposure on axonal outgrowth in the sympathetic nervous system of the chick. Yip YP, et al. **J Magn Reson Imaging** 1995 Jul-Aug;5(4):457–62

SECRETION

Neuroserpin, an axonally secreted serine protease inhibitor. Osterwalder T, et al. **EMBO J** 1996 Jun 17;15(12):2944–53

ULTRASTRUCTURE

Calcitonin gene-related peptide- and substance P-immunoreactive axons in the nucleus gracilis of the rat with special reference to axonal dystrophy: light and electron microscopic observations. Fujiwara K, et al. **Acta Neuropathol (Berl)** 1995;90(4):347–55

Synaptic loss in the proximal axon of anterior horn neurons in motor neuron disease. Sasaki S, et al. **Acta Neuropathol (Berl)** 1995;90(2):170–5

Axon branching of medullary expiratory neurons in the sacral spinal cord of the cat. Sasaki SI, et al. **Adv Exp Med Biol** 1995;393:63–6

Number and size spectra of non-myelinated axons of human

premolars. Nair PN, et al. **Anat Embryol (Berl)** 1995 Jul; 192(1):35–41

Axonal growth mediated by cell adhesion molecules requires activation of fibroblast growth factor receptors. Saffell JL, et al. **Biochem Soc Trans** 1995 Aug;23(3):469–70 (12 ref.)

Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Davie CA, et al. **Brain** 1995 Dec;118 (Pt 6):1583–92

Characterization of axonal ultrastructural pathology following experimental spinal cord compression injury. Anthes DL, et al. **Brain Res** 1995 Dec 8;702(1–2):1–16

Electron microscopic evidence that axon terminals from the mediodorsal thalamic nucleus make direct synaptic contacts with callosal cells in the prelimbic cortex of the rat. Kuroda M, et al. **Brain Res** 1995 Apr 24;677(2):348–53

Sex differences in the distribution of axon types within the genu of the rat corpus callosum. Mack CM, et al. **Brain Res** 1995 Oct 30;697(1–2):152–60

Single striatofugal axons arborizing in both pallidal segments and in the substantia nigra in primates. Parent A, et al. **Brain Res** 1995 Nov 6;698(1–2):280–4

Effects of neonatal and adult enucleation on the synaptic organization of the serotoninergic projection to the superficial gray layer of the hamster's superior colliculus. Arce EA, et al. **Brain Res Dev Brain Res** 1995 Dec 21; 90(1–2):168–73

Evidence for the elaboration of multiple axons by developing dentate granule cells. Yan W, et al. **Brain Res Dev Brain Res** 1995 Dec 21;90(1–2):194–7

Neuronal growth and death: order and disorder in the axoplasm. Cleveland DW. **Cell** 1996 Mar 8;84(5):663–6 (17 ref.)

Horseradish peroxidase in axons of the dorsal funiculi of the cat: distribution after an injection of the enzyme into the dorsal column nuclei. Fabricius C, et al. **Cell Tissue Res** 1996 Jan;283(1):67–73

Expression of type 1 inositol 1,4,5–trisphosphate receptor during axogenesis and synaptic contact in the central and peripheral nervous system of developing rat. Dent MA, et al. **Development** 1996 Mar;122(3):1029–39

Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomic ganglia of rats with streptozocin–induced diabetes. Schmidt RE, et al. **Diabetes** 1996 Mar; 45(3):284–90

A single–cell study of the axonal projections arising from the posterior intralaminar thalamic nuclei in the rat. Deschênes M, et al. **Eur J Neurosci** 1996 Feb;8(2):329–43

Target influences on the morphology of trigeminal axons. Erzurumlu RS, et al. **Exp Neurol** 1995 Sep;135(1):1–16

Altered axon terminals containing concentric lamellar bodies of cerebellar Purkinje cells in Mongolian gerbil. Takeuchi IK, et al. **Experientia** 1996 Jun 15;52(6):531–4

A quantitative morphological study of the recovery of cat lingual nerves after transection or crushing. Holland GR, et al. **J Anat** 1996 Apr;188 (Pt 2):289–97

Active transport of photoactivated tubulin molecules in growing axons revealed by a new electron microscopic analysis. Funakoshi T, et al. **J Cell Biol** 1996 Jun; 133(6):1347–53

Growth cone collapse and inhibition of neurite growth by Botulinum neurotoxin C1: a t–SNARE is involved in axonal growth. Igarashi M, et al. **J Cell Biol** 1996 Jul; 134(1):205–15

Subunit composition of neurofilaments specifies axonal diameter. Xu Z, et al. **J Cell Biol** 1996 Jun;133(5):1061–9

Plasticity of mature sensory cerebrovascular axons following intracranial infusion of nerve growth factor. Isaacson LG, et al. **J Comp Neurol** 1995 Oct 23;361(3):451–60

Orthograde axonal transport studies of projections from the zona incerta and pretectum to the basilar pontine nuclei in the rat. Mihailoff GA. **J Comp Neurol** 1995 Sep 18; 360(2):301–18

Axonal projections from the lateral and medial superior olive to the inferior colliculus of the cat: a study using electron microscopic autoradiography. Oliver DL, et al. **J Comp Neurol** 1995 Sep 11;360(1):17–32

Morphology of single vestibulospinal collaterals in the upper cervical spinal cord of the cat: III collaterals originating from axons in the ventral funiculus ipsilateral to their cells of origin. Rose PK, et al. **J Comp Neurol** 1996 Jan 1; 364(1):16–31

Neuroaxonal dystrophy in experimental Creutzfeldt–Jakob disease: electron microscopical and immunohistochemical demonstration of neurofilament accumulations within affected neurites. Liberski PP, et al. **J Comp Pathol** 1995 Apr;112(3):243–55

Synapses of optic axons with GABA– and glutamate–containing elements in the optic tectum of Bufo marinus. Gábriel R, et al. **J Hirnforsch** 1995;36(3):329–40

Expression of engrailed in an array of identified sensory neurons: comparison with position, axonal arborization, and synaptic connectivity. Blagburn JM, et al. **J Neurobiol** 1995 Dec;28(4):493–505

Changes in retinal arbors in compressed projections to half tecta in goldfish. Schmidt J, et al. **J Neurobiol** 1995 Dec; 28(4):409–18

Axon–glial relationships in the anterior medullary velum of the adult rat. Berry M, et al. **J Neurocytol** 1995 Dec; 24(12):965–83

Organelle formation from pinocytotic elements in neurites of cultured sympathetic ganglia. Birks RI, et al. **J Neurocytol** 1972 Dec;1(4):311–40

The surface coats of chick dorsal root ganglion cells in vitro. James DW, et al. **J Neurocytol** 1972 Dec;1(4):383–95

Remyelination of mouse spinal cord axons demyelinated by local injection of lysolecithin. Jeffery ND, et al. **J Neurocytol** 1995 Oct;24(10):775–81

Gliosis and axonal sprouting in the hippocampus of epileptic rats are associated with an increase of tenascin–C immunoreactivity. Niquet J, et al. **J Neurocytol** 1995 Aug; 24(8):611–24

Relationship between myelin sheath diameter and internodal length in axons of the anterior medullary velum of the adult rat. Ibrahim M, et al. **J Neurol Sci** 1995 Nov; 133(1–2):119–27

Neuroaxonal dystrophy in infantile alpha–N–acetylgalactosaminidase deficiency. Wolfe DE, et al. **J Neurol Sci** 1995 Sep;132(1):44–56

Directed expression of the growth–associated protein B–50/GAP–43 to olfactory neurons in transgenic mice results in changes in axon morphology and extraglomerular fiber growth. Holtmaat AJ, et al. **J Neurosci** 1995 Dec; 15(12):7953–65

Anterograde axonal tracing with the subunit B of cholera toxin: a highly sensitive immunohistochemical protocol for revealing fine axonal morphology in adult and neonatal brains. Angelucci A, et al. **J Neurosci Methods** 1996 Mar; 65(1):101–12

Topography of axonal injury as defined by amyloid precursor protein and the sector scoring method in mild and severe closed head injury. Blumbergs PC, et al. **J Neurotrauma** 1995 Aug;12(4):565–72

The pathobiology of traumatically induced axonal injury in animals and humans: a review of current thoughts. Povlishock JT, et al. **J Neurotrauma** 1995 Aug;12(4):555–64 (76 ref.)

Axonal transport of fluorescent carbocyanine dyes allows mapping of peripheral nerve territories in gingiva. Sugaya A, et al. **J Periodontol** 1995 Sep;66(9):817–21

Differential effects of microtubule inhibitors on axonal branching and elongation of cultured rat hippocampal neurons. Aoyagi A, et al. **Jpn J Pharmacol** 1995 Jun; 68(2):223–6

The relation between conduction velocity and axonal length. Zwarts MJ, et al. **Muscle Nerve** 1995 Nov;18(11):1244–9

Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Isacson O, et al. **Nat Med** 1995 Nov;1(11):1189–94

Periventricular–hypophysial dopaminergic neurons innervate the intermediate but not the neural lobe of the rat pituitary gland. Goudreau JL, et al. **Neuroendocrinology** 1995 Aug; 62(2):147–54

Crossed and uncrossed retinal axons respond differently to cells of the optic chiasm midline in vitro. Wang LC, et al. **Neuron** 1995 Dec;15(6):1349–64

The suprachiasmatic nucleus in stationary organotypic culture. Belenky M, et al. **Neuroscience** 1996 Jan; 70(1):127–43

GABAergic axons in the ventral forebrain of the rat: an electron microscopic study. Chang HT, et al. **Neuroscience** 1995 Sep;68(1):207–20

Evidence of constriction of optic nerve axons at the lamina cribrosa in the normotensive eye in humans and other mammals. Holländer H, et al. **Ophthalmic Res** 1995; 27(5):296–309

Ultrastructure and immunoreactivity of dystrophic axons indicate a different pathogenesis of Hallervorden–Spatz disease and infantile neuroaxonal dystrophy. Malandrini A, et al. **Virchows Arch** 1995;427(4):415–21

[Idiopathic acquired generalized anhidrosis with normal numbers of eccrine gland nerve terminals and unmyelinated axons. A case report] Muta Y, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):638–42 (Eng. Abstr.) **(Jpn)**

AXOPLASMIC FLOW see **AXONAL TRANSPORT**

AXOPLASMIC TRANSPORT see **AXONAL TRANSPORT**

AYERZA'S SYNDROME see **HYPERTENSION, PULMONARY**

AYURVEDIC MEDICINE see **MEDICINE, AYURVEDIC**

AZA COMPOUNDS

CHEMICAL SYNTHESIS

Synthesis and structure–activity studies of a series of 1–oxa–2,8–diazaspiro[4.5]decan–3–ones and related compounds as M1 muscarinic agonists. Tsukamoto S, et al. **Chem Pharm Bull (Tokyo)** 1995 Sep;43(9):1523–9

N(6) or N(9) substituted 2–phenyl–8–azaadenines: affinity for A1 adenosine receptors. VII. Biagi G, et al. **Farmaco** 1995 Oct;50(10):659–67

Synthesis and activity of the glutathione analogue gamma–(L–gamma–azaglutamyl)–L–cysteinyl–glycine. Calcagni A, et al. **Int J Pept Protein Res** 1995 Nov; 46(5):434–9

Synthesis and antiviral activity of 8–aza analogs of chiral [2–(phosphonomethoxy) propyl]guanines. Franchetti P, et al. **J Med Chem** 1995 Sep 29;38(20):4007–13

Identification of a series of 3–(benzyloxy)–1–azabicyclo[2.2.2]octane human NK1 antagonists. Swain CJ, et al. **J Med Chem** 1995 Nov 24; 38(24):4793–805

CHEMISTRY

Inhibition of bovine beta–trypsin by the active site titrant N alpha–(N,N–dimethylcarbamoyl)–alpha–azaornithine p–nitrophenyl ester: a kinetic and X–ray crystallographic study. Ascenzi P, et al. **Biochem Biophys Res Commun** 1995 Dec 14;217(2):437–44

ISOLATION & PURIFICATION

Solid–phase extraction for the selective isolation of polycyclic aromatic hydrocarbons, azaarenes and heterocyclic aromatic amines in charcoal–grilled meat. Rivera L, et al. **J Chromatogr A** 1996 Apr 19;731(1–2):85–94

PHARMACOLOGY

Synthesis and activity of the glutathione analogue gamma–(L–gamma–azaglutamyl)–L–cysteinyl–glycine. Calcagni A, et al. **Int J Pept Protein Res** 1995 Nov; 46(5):434–9

Efficacy of 3,4,3–LIHOPO for enhancing the excretion of plutonium from rat after simulated wound contamination as a tributyl–n–phosphate complex. Paquet F, et al. **Int J Radiat Biol** 1995 Dec;68(6):663–8

Treatment with 3,4,3–LIHOPO of simulated wounds contaminated with plutonium and americium in rat. Volf V, et al. **Int J Radiat Biol** 1996 Jul;70(1):109–14

Identification of a series of 3–(benzyloxy)–1–azabicyclo[2.2.2]octane human NK1 antagonists. Swain CJ, et al. **J Med Chem** 1995 Nov 24; 38(24):4793–805

Human alpha–thrombin inhibition by the active site titrant N alpha–(N,N–dimethylcarbamoyl)–alpha–azalysine p–nitrophenyl ester: a comparative kinetic and X–ray crystallographic study. Nardini M, et al. **J Mol Biol** 1996 May 24;258(5):851–9

THERAPEUTIC USE

Efficacy of 3,4,3–LIHOPO for reducing the retention of uranium in rat after acute administration. Henge–Napoli MH, et al. **Int J Radiat Biol** 1995 Oct;68(4):389–93

AZACITIDINE

ANALOGS & DERIVATIVES

A phase II study of fazarabine (NSC 281272) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Manetta A, et al. **Am J Clin Oncol** 1995 Oct;18(5):439–40

Induction by 5–aza–2'–deoxycytidine, an inhibitor of DNA methylation, of Le(y) antigen, apoptosis and differentiation in human lung cancer cells. Saitoh F, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2137–43

Induction of Ley antigen by 5–aza–2'–deoxycytidine in association with differentiation and apoptosis in human pancreatic cancer cells. Yamada T, et al. **Anticancer Res** 1996 Mar–Apr;16(2):735–40

Specific induction of uncoiling in NORs of human acrocentric chromosomes by 5–azacytidine and 5–azadeoxicytidine. Malheiro I, et al. **Cytobios** 1995; 83(332):17–23

Phase II trial and cost analysis of fazarabine in advanced non–small cell carcinoma of the lung: a Southwest Oncology Group study. Williamson SK, et al. **Invest New Drugs** 1995;13(1):67–71

Induction of MAGE genes in lymphoid cells by the demethylating agent 5–aza–2'–deoxycytidine. Shichijo S, et al. **Jpn J Cancer Res** 1996 Jul;87(7):751–6

5–Aza deoxyCytidine–induced inhibition of differentiation of spermatogonia into spermatocytes in the mouse. Raman R, et al. **Mol Reprod Dev** 1995 Nov;42(3):284–90

CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5–aza 2'deoxycytidine. Otterson GA, et al. **Oncogene** 1995 Sep 21;11(6):1211–6

Teratogenic effects of the demethylating agent 5–aza–2'–deoxycytidine in the Swiss Webster mouse. Branch S, et al. **Toxicology** 1996 Aug 1;112(1):37–43

CHEMISTRY

Differential digestion of the centromeric heterochromatic regions of the 5–azacytidine–decondensed human chromosomes 1, 9, 15, and 16 by NdeII and Sau3AI restriction endonucleases. Martínez P, et al. **Genetica** 1995; 96(3):235–8

PHARMACOLOGY

Specific induction of uncoiling in NORs of human acrocentric chromosomes by 5–azacytidine and 5–azadeoxicytidine. Malheiro I, et al. **Cytobios** 1995; 83(332):17–23

Restriction enzyme buffers and 5–azacytidine induce loss of protein and banding in plant metaphase chromosomes. Olszewska MJ, et al. **Folia Histochem Cytobiol** 1995; 33(3):201–8

In vitro induction of apoptosis of developing brain cells by 5-azacytidine. Hossain MM, et al. **Int J Dev Neurosci** 1996 Feb;14(1):11-7

Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Robertson KD, et al. **Mol Cell Biol** 1995 Nov;15(11):6150-9

Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Wakitani S, et al. **Muscle Nerve** 1995 Dec;18(12):1417-26

Effects of 5-azacytidine on physiological differentiation of Streptomyces antibioticus. Novella IS, et al. **Res Microbiol** 1995 Nov-Dec;146(9):721-8

TOXICITY

The genetics of the repair of 5-azacytidine-mediated DNA damage in the fission yeast Schizosaccharomyces pombe. Hegde V, et al. **Mol Gen Genet** 1996 Jun 24;251(4):483-92

AZACYCLOPROPANES see **AZIRIDINES**

AZACYTIDINE see **AZACITIDINE**

AZAGUANINE

ANALOGS & DERIVATIVES

Guanine, pyrazolo[3,4-d]pyrimidine, and triazolo[4,5-d]pyrimidine (8-azaguanine) phosphonate acyclic derivatives as inhibitors of purine nucleoside phosphorylase. Beauchamp LM, et al. **J Med Chem** 1996 Feb 16;39(4):949-56

CHEMICAL SYNTHESIS

Guanine, pyrazolo[3,4-d]pyrimidine, and triazolo[4,5-d]pyrimidine (8-azaguanine) phosphonate acyclic derivatives as inhibitors of purine nucleoside phosphorylase. Beauchamp LM, et al. **J Med Chem** 1996 Feb 16;39(4):949-56

AZAPERONE

ADMINISTRATION & DOSAGE

Fentazin anesthesia for labyrinthine surgery in guinea pigs. Sansom AJ, et al. **J Vestib Res** 1996 Jan-Feb;6(1):49-52

AZAPROPAZONE see **APAZONE**

AZASERINE

Epidermal growth factor receptor expression in pancreatic lesions induced in the rat by azaserine. Visser CJ, et al. **Br J Cancer** 1996 Jul;74(1):92-8

ADMINISTRATION & DOSAGE

Inhibition by verapamil of cholecystokinin-enhancement of pancreatic carcinogenesis induced by azaserine in Wistar rats. Nakaizumi A, et al. **Cancer Lett** 1996 Jul 19; 105(1):23-7

PHARMACOLOGY

Gut peptide receptors in pancreata of azaserine-treated and normal control rats. Tang C, et al. **Carcinogenesis** 1995 Dec; 16(12):2951-6

Gastrin receptor expression during azaserine-induced rat pancreatic carcinogenesis. Tsuei BJ, et al. **J Surg Res** 1996 Jun;63(1):105-9

TOXICITY

Effects of dietary beta-carotene and selenium on initiation and promotion of pancreatic carcinogenesis in azaserine-treated rats. Appel MJ, et al. **Carcinogenesis** 1996 Jul;17(7):1411-6

AZASTEROIDS

CHEMICAL SYNTHESIS

Synthesis of novel intranuclear diazasteroids. Mellor JM, et al. **Steroids** 1995 Oct;60(10):693-8

CHEMISTRY

Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanism. Moss ML, et al. **Biochemistry** 1996 Mar 19;35(11):3457-64

PHARMACOLOGY

Sterol biosynthesis: strong inhibition of maize delta 5,7-sterol delta 7-reductase by novel 6-aza-B-homosteroids and other analogs of a presumptive carbocationic intermediate of the reduction reaction. Rahier A, et al. **Biochemistry** 1996 Jun 4;35(22):7069-76

Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Tian G, et al. **Biochemistry** 1995 Oct 17;34(41):13453-9

Effects of homo-aza-steroids on acute non-lymphocytic leukaemia cell proliferation in vitro. Trafalis DT, et al. **Br J Haematol** 1995 Dec;91(4):907-14

AZATHIOPRINE

ADMINISTRATION & DOSAGE

Super turbo azathioprine: can Crohn's disease healing be accelerated? Robinson M. **Am J Gastroenterol** 1996 Jun; 91(6):1273-4

Resolution of a soft-tissue sarcoma in a patient with rheumatoid arthritis after discontinuation of azathioprine therapy. Csuka ME, et al. **Arch Intern Med** 1996 Jul 22; 156(14):1573-6

Combination therapy with sulphasalazine and azathioprine [letter] Helliwell PS. **Br J Rheumatol** 1996 May;35(5):493-4

An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Sandborn WJ, et al. **Gastroenterology** 1995 Dec;109(6):1808-17

Pilot study of low-dose azathioprine in presensitized patients awaiting heart or lung transplantation. Keogh A, et al. **J Heart Lung Transplant** 1995 Sep-Oct;14(5):945-9

Combination drug therapy of seropositive rheumatoid arthritis [see comments] McCarty DJ, et al. **J Rheumatol** 1995 Sep;22(9):1636-45. Comment in: J Rheumatol 1995 Sep;22(9):1611-7.

Perforation of the stomach during laparoscopic Nissen fundoplication in a patient on chronic corticosteroid therapy [letter] Helling TS. **Surg Endosc** 1995 Oct; 9(10):1146

Optimization of azathioprine therapy by measuring 6-thioguanine nucleotides and methylated mercaptopurine in renal allograft recipients. Bergan S, et al. **Transplant Proc** 1995 Dec;27(6):3426

Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation. Hilbrands LB, et al. **Transplantation** 1996 Apr 15;61(7):1038-46

[Crohn disease: prevention and drug therapy] Gross V, et al. **Chirurg** 1995 Aug;66(8):757-63 (42 ref.) (Eng. Abstr.) **(Ger)**

[Chronic recurrent subileus due to Strongyloides stercoralis infection under immunosuppressive therapy] Birck R, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):723-6 (17 ref.) (Eng. Abstr.) **(Ger)**

[Interstitial pneumonia associated with mixed connective tissue disease--marked improvement with azathioprine] Suzuki M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):101-5 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Resolution of a soft-tissue sarcoma in a patient with rheumatoid arthritis after discontinuation of azathioprine therapy. Csuka ME, et al. **Arch Intern Med** 1996 Jul 22; 156(14):1573-6

Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Blanco R, et al. **Arthritis Rheum** 1996 Jun;39(6):1016-20 (19 ref.)

Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Bottomley WW, et al. **Br J Dermatol** 1995 Sep;133(3):460-2

Spontaneous remission in a patient with therapy-related myelodysplastic syndrome (t-MDS) with monosomy 7. Renneboog B, et al. **Br J Haematol** 1996 Mar;92(3):696-8

Azathioprine hypersensitivity-like reactions--a case report and a review of the literature. Knowles SR, et al. **Clin Exp Dermatol** 1995 Jul;20(4):353-6 (35 ref.)

Cutaneous alternariosis in an immunocompromised patient. Chaidemenos GC, et al. **Cutis** 1995 Sep;56(3):145-50 (40 ref.)

5q- in a case of chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation. Soligo D, et al. **Haematologica** 1995 Sep-Oct;80(5):437-9

Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. Ben Ari Z, et al. **J Hepatol** 1995 Sep;23(3):351-4

Acute allergic reactions associated with azathioprine [letter] Parnham AP, et al. **Lancet** 1996 Aug 24;348(9026):542-3

Drug-induced hepatotoxicity [letter; comment] Morales JM. **N Engl J Med** 1996 Mar 28;334(13):864. Comment on: N Engl J Med 1995 Oct 26;333(17):1118-27.

Azathioprine-induced pure red-cell aplasia. Pruijt JF, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1371-3 (20 ref.)

Fever and rigors as sole symptoms of azathioprine hypersensitivity. Smak Gregoor PJ, et al. **Neth J Med** 1995 Dec;47(6):288-90

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Confavreux C, et al. **Neurology** 1996 Jun;46(6):1607-12

Azathioprine-induced pulmonary haemorrhage in a child after renal transplantation. Refabert L, et al. **Pediatr Nephrol** 1995 Aug;9(4):470-3

Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Cummins D, et al. **Transplantation** 1996 Jun 15;61(11):1661-2

Azathioprine hepatitis in kidney transplant recipients. A predisposing role of chronic viral hepatitis. Pol S, et al. **Transplantation** 1996 Jun 27;61(12):1774-6

[Homozygote deficiency of thiopurine methyltransferase. A contraindication to the use of azathioprine in kidney transplantation] Frappier J, et al. **Presse Med** 1995 Sep 23; 24(27):1257-9 (Eng. Abstr.) **(Fre)**

[The effects of cyclosporin azathioprine and mizoribine on male reproduction in rats] Iwasaki M, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jan;87(1):42-9 (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. Crawford DJ, et al. **J Med Chem** 1996 Jul 5;39(14):2690-5

METABOLISM

Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Schütz E, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar; 34(3):199-205

Biology and pharmacology of thiopurines. Aarbakke J. **Pediatr Hematol Oncol** 1995 Sep-Oct;12(5):511-9

Metabolism of azathioprine [letter; comment] McLeod HL, et al. **Transplantation** 1996 May 15;61(9):1425. Comment on: Transplantation 1995 Oct 15;60(7):639-42.

PHARMACOLOGY

UVB irradiation of human-derived peripheral blood lymphocytes induces apoptosis but not T-cell anergy: additive effects with various immunosuppressive agents. Yaron I, et al. **Cell Immunol** 1996 Mar 15;168(2):258-66

Cyclosporin A impairs the nocturnal blood pressure fall in renal transplant recipients. van den Dorpel MA, et al. **Hypertension** 1996 Aug;28(2):304-7

Isotretinoin and azathioprine: a synergy that makes hair curl? [letter] van der Pijl JW, et al. **Lancet** 1996 Aug 31; 348(9027):622-3

[Effects of prednisone and azathioprine treatment on oligoclonal IGG in the cerebrospinal fluid of multiple sclerosis patients. Preliminary communication] Losy J, et al. **Neurol Neurochir Pol** 1996 Mar-Apr;30(2):201-11 (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Sandborn WJ. **Am J Gastroenterol** 1996 Mar;91(3):423-33 (65 ref.)

Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. Deheinzelin D, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):794-9

Results of controlled study of combination therapy with azathioprine and methotrexate in the treatment of rheumatoid arthritis revisited: comment on the article by Willkens et al [letter] McCarty DJ. **Arthritis Rheum** 1996 Aug;39(8):1436-7

Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Shapiro DL, et al. **Arthritis Rheum** 1995 Dec;38(12):1851-4 (24 ref.)

Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Willkens RF, et al. **Arthritis Rheum** 1995 Dec;38(12):1799-806

Monitoring of TPMT in heart transplant recipients under immunosuppressive therapy with azathioprine. Gummert JF, et al. **Artif Organs** 1995 Sep;19(9):918-20

Nodular prurigo responsive to azathioprine [letter] Lear JT, et al. **Br J Dermatol** 1996 Jun;134(6):1151

Azathioprine as a steroid-sparing agent in radiation pneumonitis. McCarty MJ, et al. **Chest** 1996 May; 109(5):1397-400

Erosive and generalized lichen planus responsive to azathioprine. Lear JT, et al. **Clin Exp Dermatol** 1996 Jan; 21(1):56-7

Immunosuppression in rapidly progressive Henoch-Schoenlein nephritis [letter] Worth DP. **Clin Nephrol** 1996 Feb;45(2):135-6

Prevention of mouse-rat brain xenograft rejection by a combination therapy of cyclosporin A, prednisolone and azathioprine. Pedersen EB, et al. **Exp Brain Res** 1995; 106(2):181-6

The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Pratt DS, et al. **Gastroenterology** 1996 Jan;110(1):271-4

A controlled double blind study of azathioprine in the management of Crohn's disease. Candy S, et al. **Gut** 1995 Nov;37(5):674-8

Improvement of Isaacs' syndrome after treatment with azathioprine [letter] Riche G, et al. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):448

Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. Ramakrishna J, et al. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):296-302

Influence of treatment with cyclosporine, azathioprine and steroids on chronic allograft failure. The Collaborative Transplant Study. Opelz G. **Kidney Int Suppl** 1995 Dec; 52:S89-92

Long-term follow-up of patients with Crohn's disease treated

with azathioprine or 6-mercaptopurine [see comments] Bouhnik Y, et al. **Lancet** 1996 Jan 27;347(8996):215-9. Comment in: Lancet 1996 Apr 13;347(9007):1049-50. Comment in: Lancet 1996 May 4;347(9010):1266-7.

Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Ratcliffe PJ, et al. **Lancet** 1996 Sep 7;348(9028):643-8

Treatment of Balo's concentric sclerosis with immunosuppressive drugs followed by multimodality evoked potentials and MRI. Louboutin JP, et al. **Muscle Nerve** 1995 Dec;18(12):1478-80

Disseminated histoplasmosis in a haemodialysis patient on immunosuppression after graft failure. Smak Gregoor PJ, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):542-4

Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Chan TM, et al. **Nephron** 1995;71(3):321-7

Increased risk of stable renal allografts after changing from ciclosporin to azathioprine [letter] Heering PJ, et al. **Nephron** 1995;71(2):246

Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. Sørensen PS, et al. **Neurology** 1996 Jun; 46(6):1620-5

The quest for the ideal therapy for giant cell arteritis [letter; comment] Gonzalez-Gay MA. **Rev Rhum Engl Ed** 1995 Jul-Sep;62(7-8):539. Comment on: Rev Rhum Ed Fr 1994;61(7-8):485-90.

Conversion of cyclosporine to azathroprine in renal transplant recipients. Bassiri A, et al. **Transplant Proc** 1995 Oct;27(5):2691

Brequinar sodium significantly reduces the incidence of steroid-resistant rejection and resource utilization in primary renal transplant patients compared with azathioprine. Dunn JF, et al. **Transplant Proc** 1996 Apr; 28(2):955-7

Immunosuppressive protocols at transplantation centers in Turkey. Haberal M, et al. **Transplant Proc** 1995 Oct; 27(5):2776-7

Quadruple immunotherapy will promise excellent graft survival in cadaveric renal transplants using cardiac arrest donor grafts. Hoshinaga K, et al. **Transplant Proc** 1996 Jun; 28(3):1591-3

Triple therapy with cyclosporine A in kidney transplant patients. Matl I, et al. **Transplant Proc** 1995 Oct;27(5):2573

Cancers in cyclosporine-treated vs azathioprine-treated patients. Penn I. **Transplant Proc** 1996 Apr;28(2):876-8

Retrospective study of cyclosporine-prednisolone versus cyclosporine-azathioprine-prednisolone immunosuppression in living donor kidney transplantation. Reissi D, et al. **Transplant Proc** 1995 Oct;27(5):2685-6

High incidence of posttransplant diabetes mellitus in renal transplant recipients on triple-drug immunosuppression. Sakhuja V, et al. **Transplant Proc** 1995 Oct;27(5):2728-30

Donor-specific transfusions have long-term beneficial effects for human renal allografts. Flye MW, et al. **Transplantation** 1995 Dec 27;60(12):1395-401

Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Kimball JA, et al. **Transplantation** 1995 Dec 27; 60(12):1379-83

Monitoring of azathioprine-induced immunosuppression with thiopurine methyltransferase activity in kidney transplant recipients [see comments] Mircheva J, et al. **Transplantation** 1995 Oct 15;60(7):639-42. Comment in: Transplantation 1996 May 15;61(9):1425.

[Azathioprine maintains remission in autoimmune hepatitis (letter)] Pariente E-A. **Gastroenterol Clin Biol** 1996; 20(3):328-30 **(Fre)**

TOXICITY

Effect of cyclosporine A (CsA), cyclophosphamide (Cy) and azathioprine (Aza) on the survival of Listeria innocua in mice. Walencka M, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):275-9

Toxicity of combination therapies in rheumatoid arthritis: comment on the article by Willkens et al [letter] Stein CM. **Arthritis Rheum** 1996 Aug;39(8):1435-7

Azathioprine toxicity, 6-mercaptopurine accumulation and the "poor" 6-thiopurine methylator phenotype [letter] Escousse A, et al. **Eur J Clin Pharmacol** 1995; 48(3-4):309-10

Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. DeLeve LD, et al. **Hepatology** 1996 Mar;23(3):589-99

Acute-phase response in rat to carbon tetrachloride-azathioprine induced cirrhosis and partial hepatectomy of cirrhotic liver. Fouad FM, et al. **J Toxicol Environ Health** 1996 Apr 19;47(6):601-15

Investigation of a screening battery for immunotoxicity of pharmaceuticals within a 28-day oral toxicity study using azathioprine and cyclosporin A as model compounds. De Waal EJ, et al. **Regul Toxicol Pharmacol** 1995 Jun; 21(3):327-38

AZAURIDINE

ANALOGS & DERIVATIVES

Hydrolysis of the prodrug, 2',3',5'-triacetyl-6-azauridine. Riley CM, et al. **Pharm Res** 1995 Sep;12(9):1361-70

AZEPINES

ADMINISTRATION & DOSAGE

Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Takeda Y, et al. **Hypertension** 1995 Dec;26(6 Pt 1):932-6

Platelet-activating factor-antagonists reduce implantation in mice at low doses only. O'Neill C. **Reprod Fertil Dev** 1995; 7(1):51-7

[Dynamics of the hypnotic effect of 0.125 mg and 0.250 mg brotizolam. The lower dosage is adequate for treatment of sleep disorders] Leonard JP, et al. **Fortschr Med** 1996 May 20;114(14):179-82 (Eng. Abstr.) **(Ger)**

BLOOD

Determination of the anti-platelet-activating factor BN-50727 and its metabolites in human plasma by high-performance liquid chromatography-solid-phase extraction. Pruñonosa J, et al. **J Chromatogr B Biomed Appl** 1995 Jun 23;668(2):281-90

CHEMICAL SYNTHESIS

Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors. Nugiel DA, et al. **J Med Chem** 1996 May 24;39(11):2156-69

3-[2-(N-phenylacetamide)]-1,5-benzodiazepines: orally active, binding selective CCK-A agonists. Willson TM, et al. **J Med Chem** 1996 Jul 19;39(15):3030-4

CHEMISTRY

Piperazinylalkyl heterocycles as potential antipsychotic agents. Scott MK, et al. **J Med Chem** 1995 Oct 13; 38(21):4198-210

Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile. von Geldern TW, et al. **J Med Chem** 1996 Feb 16;39(4):957-67

METABOLISM

Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile. von Geldern TW, et al. **J Med Chem** 1996 Feb 16;39(4):957-67

The specific binding of the platelet-activating factor (PAF) receptor antagonist WEB 2086 and the benzodiazepine flunitrazepam to rat hepatocytes. Svetlov SI, et al. **Life Sci** 1996;58(5):PL 81-6

PHARMACOLOGY

Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Hozawa S, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 1):1198-202

Platelet-activating factor (PAF) receptor antagonism by WEB 2170 improves the survival of ischaemic skeletal muscle. Lepore DA, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):63-7

Protective effect of a platelet-activating factor antagonist (WEB-2086) in postischemic renal failure. González-Fajardo JA, et al. **Ann Vasc Surg** 1996 Jan; 10(1):16-21

Formation of a highly stable complex between BN 50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4] and the platelet-activating factor receptor in rabbit platelet membranes. Silva CL, et al. **Biochem Pharmacol** 1996 Jan 26;51(2):193-6

Role for intracellular platelet-activating factor in the circulatory failure in a model of gram-positive shock. De Kimpe SJ, et al. **Br J Pharmacol** 1995 Dec;116(8):3191-8

The mechanism of action of alpha 2-adrenoceptors in human isolated subcutaneous resistance arteries. Parkinson NA, et al. **Br J Pharmacol** 1995 Aug;115(8):1463-8

Paf antagonists block induction of nitric oxide synthase in cultured macrophages and vascular smooth muscle cells. Arthur JF, et al. **Clin Exp Pharmacol Physiol** 1995 Jun-Jul; 22(6-7):452-4

Role of endothelin-1 in hypertension induced by long-term inhibition of nitric oxide synthase. Fujita K, et al. **Eur J Pharmacol** 1995 Jul 14;280(3):311-6

Characterisation of functional endothelin receptors in the canine isolated perfused spleen. Grassi-Kassisse DM, et al. **Eur J Pharmacol** 1995 Aug 25;282(1-3):57-63

Reversible differentiation of human monoblastic leukemia U937 cells by ML-9, an inhibitor of myosin light chain kinase. Yamamoto-Yamaguchi Y, et al. **Exp Hematol** 1996 May;24(6):682-9

Role of PAF in the late airway microvascular leakage induced by antigen in IgE-sensitized rat. Kyriacopoulos F, et al. **Fundam Clin Pharmacol** 1995;9(4):350-6

Effects of BQ-485, a selective ETA antagonist, on endothelin-mediated vasomotion in rat coronary vascular beds. Sakuma I, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S400-3

Effects of 1-tetradecylperhydroazepine and 1-pentadecylpiperidine N-oxides on Ehrlich ascites mitochondria. Miko M, et al. **J Chemother** 1995 Oct; 7(5):446-8

Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. Robl JA, et al. **J Med Chem** 1996 Jan 19;39(2):494-502

Novel inhibitors for multidrug resistance: 1,3,5-triazacycloheptanes. Sawanishi H, et al. **J Med Chem** 1995 Dec 22;38(26):5066-70

Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists. Hurst JS, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):329-37 (39 ref.)

Transdermal delivery of drugs with differing lipophilicities using azone analogs as dermal penetration enhancers. Phillips CA, et al. **J Pharm Sci** 1995 Dec;84(12):1427-33

The positive inotropic effect and the hydrolysis of phosphoinositide induced by endothelin-3 in rabbit ventricular myocardium: inhibition by a selective antagonist of ET(A) receptors, FR139317. Endoh M, et al. **J Pharmacol Exp Ther** 1996 Apr;277(1):61-70

Effects of the benzodiazepine inverse agonist RO19-4603 on the maintenance of tolerance to a single dose of ethanol. June HL, et al. **J Pharmacol Exp Ther** 1995 Sep; 274(3):1105-12

In vitro antibacterial activity of FA103, a new quinolone derivative of C-7 position with 7-perhydrodiazepinone. Imamori K, et al. **Jpn J Antibiot** 1995 Dec;48(12):1891-8

Alpha-subunit G-protein antisense oligodeoxynucleotide effects on supraspinal (i.c.v.) alpha2-adrenoceptor antinociception in mice. Raffa RB, et al. **Life Sci** 1996; 58(5):PL 77-80

Benzodiazepine receptor ligands with different intrinsic efficacies alter ethanol intake in alcohol-nonpreferring (NP) rats. June HL, et al. **Neuropsychopharmacology** 1996 Jan;14(1):55-66

Effect of a platelet-activating factor antagonist on pancreas perfusion after 24 h of ischemia. Leonhardt U, et al. **Pancreas** 1995 Aug;11(2):160-4

In vitro percutaneous absorption of arildone, a highly lipophilic drug, and the apparent no-effect of the penetration enhancer Azone in excised human skin. Baker EJ, et al. **Pharm Res** 1995 Jul;12(7):993-7

Theoretical design of prodrug-enhancer combination based on a skin diffusion model: prediction of permeation of acyclovir prodrugs treated with 1-geranylazacycloheptan-2-one. Bando H, et al. **Pharm Res** 1996 Mar;13(3):427-32

The relative effect of Azone and Transcutol on permeant diffusivity and solubility in human stratum corneum. Harrison JE, et al. **Pharm Res** 1996 Apr;13(4):542-6

Effects of platelet-activating factor antagonists WEB 2086 and BN 50730 on digoxin-induced arrhythmias. Cakici I, et al. **Pharmacol Toxicol** 1995 Jun;76(6):343-7

Action of intravenously administered talipexole on the rat striatal neurons receiving excitatory input from nigral dopamine neurons. Matsubayashi H, et al. **Psychopharmacology (Berl)** 1995 Aug;120(4):369-75

Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. Spiegel HU, et al. **Transplant Proc** 1995 Oct;27(5):2884-5

[The effect of platelet-activating factor antagonists on early bacteria translocation of rat after burn injury] Qin X, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr;33(4):217-8 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Prolonged endothelin blockade prevents hypertension and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Stasch JP, et al. **Am J Hypertens** 1995 Nov;8(11):1128-34

Effect of a specific endothelin receptor A antagonist on murine lupus nephritis and IgA nephropathy. Ebihara I, et al. **Contrib Nephrol** 1996;118:155-63

Effects of a protein kinase C inhibitor (PKCI) on the development of adjuvant-induced arthritis (AA) in rats. DiMartino M, et al. **Inflamm Res** 1995 Aug;44 Suppl 2:S123-4

ETA receptor antagonists inhibit allergic inflammation in the mouse. Sampaio AL, et al. **J Cardiovasc Pharmacol** 1995; 26 Suppl 3:S416-8

Prolonged endothelin blockade reduces hypertension and cardiac hypertrophy in SHR-SP. Stasch JP, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 3:S436-8

Efficacy of oxygenated University of Wisconsin solution containing endothelin-A receptor antagonist in twenty-four-hour heart preservation. Okada K, et al. **J Heart Lung Transplant** 1996 May;15(5):475-84

Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. Hilliquin P, et al. **J Rheumatol** 1995 Sep;22(9):1651-4

Effects of the endothelin ETA-receptor antagonist FR139317 on development of hypertension and cardiovascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. Fujita K, et al. **Jpn J Pharmacol** 1996 Apr;70(4):313-9

Changes of cyclic alternating pattern (CAP) parameters in situational insomnia under brotizolam and triazolam. Terzano MG, et al. **Psychopharmacology (Berl)** 1995 Aug; 120(3):237–43

URINE

Determination of the anti-platelet-activating factor BN-50727 and metabolites in human urine by high-performance liquid chromatography using solid-phase extraction. Pruñonosa J, et al. **J Chromatogr B Biomed Appl** 1996 Mar 3;677(2):388–92

AZESERINE see **AZASERINE**

AZETIDINECARBOXYLIC ACID

ANALOGS & DERIVATIVES

Metabotropic glutamate receptor agonist trans-azetidine-2,4-dicarboxylic acid facilitates maintenance of LTP in the dentate gyrus in vivo. Riedel G, et al. **Neuropharmacology** 1995 Aug;34(8):1107–9

Class I metabotropic glutamate receptor agonists do not facilitate the induction of long-term potentiation in the dentate gyrus of the rat in vitro. Brown RE, et al. **Neurosci Lett** 1995 Dec 29;202(1–2):73–6

AZETIDINES

CHEMICAL SYNTHESIS

Azetidin-2-one derivatives as inhibitors of thrombin. Han WT, et al. **Bioorg Med Chem** 1995 Aug;3(8):1123–43

CHEMISTRY

Substituted 2-azaspiro[5.3]nonan-1-ones as potent cholesterol absorption inhibitors: defining a binding conformation for SCH 48461. Dugar S, et al. **J Med Chem** 1995 Dec 8;38(25):4875–7

PHARMACOKINETICS

Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. II. In situ and in vitro absorption characteristics of azetirelin from the rat intestine. Sasaki I, et al. **Biol Pharm Bull** 1995 Jul; 18(7):976–9

PHARMACOLOGY

Positive inotropic responses of the sodium channel modulator BDF 9148 in diseased rat myocardium. Hoey A, et al. **Clin Exp Pharmacol Physiol** 1995 Jun-Jul;22(6–7):418–22

A novel analog of TRH, YM14673, causes a decrease in brain TRH receptors in vitro. Monden T, et al. **Endocr Res** 1995 Nov;21(4):803–14

Enantioselective inotropic actions of the Na+-channel activators BDF 9148, BDF 9196 and BDF 9167 in human failing and nonfailing myocardium. Schwinger RH, et al. **J Pharmacol Exp Ther** 1996 Mar;276(3):1180–8

AZIDES

Quantification of cysteine residues following oxidation to cysteic acid in the presence of sodium azide. Manneberg M, et al. **Anal Biochem** 1995 Nov 1;231(2):349–53

Arazoformyl dipeptide substrates for thermolysin. Confirmation of a reverse protonation catalytic mechanism. Mock WL, et al. **Biochemistry** 1996 Jun 11;35(23):7369–77

Quantitation of triple-helix formation using a photo-cross-linkable aryl azide/biotin/oligonucleotide conjugate. Geselowitz DA, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):502–6

Cloning and characterization of a glutathione S-transferase that can be photolabeled with 5-azido-indole-3-acetic acid. Bilang J, et al. **Plant Physiol** 1995 Sep;109(1):253–60

[Analysis of GTP-binding protein function with a photoaffinity GTP analog] Hatta S, et al. **Nippon Yakurigaku Zasshi** 1995 Jun;105(6):431–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

The inhibitory effect of 3-amino-1,2,4-triazole on relaxation induced by hydroxylamine and sodium azide but not hydrogen peroxide or glyceryl trinitrate in rat aorta. Mian KB, et al. **Br J Pharmacol** 1995 Dec;116(8):3302–8

CHEMICAL SYNTHESIS

Enzymic glycosylation of (+/-)-(3,5/4,6)-3,6-diazido-4,5-dihydroxycyclohexene. A way to prepare stereochemically pure and enzyme resistant, basic pseudo-disaccharides as competitive enzyme inhibitors. Lehmann J, et al. **Carbohydr Res** 1995 Oct 16;276(1):199–208

Carboxamides and hydrazide of glycopeptide antibiotic eremomycin. Synthesis and antibacterial activity. Pavlov AY, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):194–8

CHEMISTRY

P-azidoiodoacetanilide, a new short photocrosslinker that has greater cysteine specificity than p-azidophenacyl bromide and p-azidobromoacetanilide. Zhang J, et al. **Biochem Biophys Res Commun** 1995 Dec 26;217(3):1177–84

The photoactivatable NAD+ analogue [32P]2-azido-NAD+ defines intra- and inter-molecular interactions of the C-terminal domain of the G-protein G alpha t. Vaillancourt RR, et al. **Biochem J** 1995 Nov 1;311 (Pt 3):987–93

Synthesis of azidoaniline derivatives of oligonucleotides and investigation of their photochemical behavior. Godovikova TS, et al. **Bioconjug Chem** 1996 May-Jun;7(3):343–8

Synthesis, azido-tetrazole equilibrium studies and biological activity of 1-(2-azido-6-chloropyrid-4-yl)-3-phenylurea, a photoaffinity labeling reagent for cytokinin-binding proteins. Dias M, et al. **Bioorg Med Chem** 1995 Apr; 3(4):361–6

Two bacteriorhodopsin M intermediates differing in accesibility of the Schiff base for azide. Radionov AN, et al. **FEBS Lett** 1996 Jun 3;387(2–3):122–6

2,8-Diazido-ATP--a short-length bifunctional photoaffinity label for photoaffinity cross-linking of a stable F1 in ATP synthase (from thermophilic bacteria PS3). Schäfer HJ, et al. **FEBS Lett** 1995 Dec 27;377(3):408–12

Exploratory photochemistry of 5-azido-8-alkoxy-substituted psoralens free and bound to DNA. Chen T, et al. **Photochem Photobiol** 1995 Jun;61(6):600–6

[Photoaffinity modification of amino acid derivatives of oligonucleotides in a complementary complex] Godovikova TS, et al. **Bioorg Khim** 1995 Nov; 21(11):858–67 (Eng. Abstr.) **(Rus)**

[Kinetics of DNA photomodification by derivatives of 1-(3-(p-azidotetrafluorobenzoyl)aminopropyl)-5'-phosphamides of oligodeoxyribonucleotides in model duplexes] Kazantsev AV, et al. **Bioorg Khim** 1995 Oct; 21(10):767–73 (Eng. Abstr.) **(Rus)**

[Directed chemical modification of DNA fragments by perfluorarylazide derivatives of oligonucleotides in the presence of oligonucleotides bearing photosensitized pyrene groups] Dobrikov MI, et al. **Dokl Akad Nauk** 1995 Sep;344(1):122–5 **(Rus)**

DIAGNOSTIC USE

Mapping of GABAA receptor sites that are photoaffinity-labelled by [3H]flunitrazepam and [3H]Ro 15-4513. Duncalfe LL, et al. **Eur J Pharmacol** 1996 Mar 18;298(3):313–9

METABOLISM

Identification and characterization of cytochrome P4501A1 amino acid residues interacting with a radiolabeled photoaffinity diazido-benzphetamine analogue. Cvrk T, et al. **Arch Biochem Biophys** 1996 Jun 1;330(1):142–52

Protein folding within and protein transport into mammalian microsomes are differentially affected by photoaffinity labeling of microsomes with 8-azido-ATP. Brunke M, et al. **Biochem Biophys Res Commun** 1996 Jan 17; 218(2):454–60

Human erythrocyte band 7.2b is preferentially labeled by a photoreactive phospholipid. Desneves J, et al. **Biochem Biophys Res Commun** 1996 Jul 5;224(1):108–14

Photoaffinity labeling of a P3 purinoceptor-like protein purified from rat brain membranes. Saitoh Y, et al. **Biochem Biophys Res Commun** 1996 Feb 15;219(2):469–74

Differentiation of catalytic sites on Escherichia coli F1ATPase by laser photoactivated labeling with [3H]-2-Azido-ATP using the mutant beta Glu381Cys:epsilonSer108Cys to identify different beta subunits by their interactions with gamma and epsilon subunits. Grüber G, et al. **Biochemistry** 1996 Apr 2; 35(13):3875–9

DNA polymerase photoprobe 2-[(4-azidophenacyl)thio]-2'-deoxyadenosine 5'-triphosphate labels an Escherichia coli DNA polymerase I Klenow fragment substrate binding site. Moore BM 2nd, et al. **Biochemistry** 1996 Sep 10;35(36):11642–51

Photoaffinity labelling of lactate dehydrogenase from pig heart with a bifunctional NAD(+)-analogue. Becker S, et al. **Biochim Biophys Acta** 1996 Apr 16;1293(2):277–83

Photoaffinity labeling of elongation factor-2 with 8-azido derivatives of GTP and ATP. Guillot D, et al. **Eur J Biochem** 1996 Feb 15;236(1):149–54

Binding of 1,4-benzodiazepines to a novel [3H]Ro15-4513 binding site in the rat spinal cord. Maguire PA, et al. **Eur J Pharmacol** 1995 Jul 4;280(2):167–73

Photoaffinity labeling of human recombinant sulfotransferases with 2-azidoadenosine 3',5'-[5'-32P]bisphosphate. Radominska A, et al. **J Biol Chem** 1996 Feb 9;271(6):3195–9

Exploratory photochemistry of 5-azido-8-alkoxy-substituted psoralens free and bound to DNA. Chen T, et al. **Photochem Photobiol** 1995 Jun;61(6):600–6

Chronic pentobarbital administration alters gamma-aminobutyric acidA receptor alpha 6-subunit mRNA levels and diazepam-insensitive [3H]Ro15-4513 binding. Ito T, et al. **Synapse** 1996 Feb;22(2):106–13

PHARMACOLOGY

Photoaffinity labeling of the active site of the Na+/K(+)-ATPase with 4-azido-2-nitrophenyl phosphate. Tran CM, et al. **Biochemistry** 1996 Jan 9; 35(1):47–55

Cytocompatibility of calf pericardium treated by glutaraldehyde and by the acyl azide methods in an organotypic culture model. Petite H, et al. **Biomaterials** 1995 Sep;16(13):1003–8

The cytostatic activity of 5-(1-azidovinyl)-2'-deoxyuridine (AzVDU) against herpes simplex virus thymidine kinase gene-transfected FM3A cells is due to inhibition of thymidylate synthase and enhanced by UV light (lambda = 254 nm) exposure. Balzarini J, et al. **FEBS Lett** 1995 Oct 2;373(1):41–4

Stress-induced tyrosine phosphorylation of actin in Dictyostelium cells and localization of the phosphorylation site to tyrosine-53 adjacent to the DNase I binding loop. Jungbluth A, et al. **FEBS Lett** 1995 Nov 13;375(1–2):87–90

Carboxamides and hydrazide of glycopeptide antibiotic eremomycin. Synthesis and antibacterial activity. Pavlov AY, et al. **J Antibiot (Tokyo)** 1996 Feb;49(2):194–8

Chronic in vivo sodium azide infusion induces selective and stable inhibition of cytochrome c oxidase. Bennett MC, et al. **J Neurochem** 1996 Jun;66(6):2606–11

Effect of NaN3 on oxygen-dependent lethality of UV-A in Escherichia coli mutants lacking active oxygen-defence and DNA-repair systems. Yamada K, et al. **J Radiat Res (Tokyo)** 1996 Mar;37(1):29–37

Activation of physiological cell death mechanisms by a necrosis-causing agent. Vaux DL, et al. **Microsc Res Tech** 1996 Jun 15;34(3):259–66

Chronic sodium azide treatment decreases membrane-bound protein kinase C activity in the rat hippocampus. Bennett MC, et al. **Neurobiol Learn Mem** 1995 Sep;64(2):187–90

Antagonism by intracerebellar Ro15-4513 of acute ethanol-induced motor incoordination in mice. Dar MS. **Pharmacol Biochem Behav** 1995 Sep;52(1):217–23

Contribution of "diazepam-insensitive" GABAA receptors to the alcohol antagonist properties of Ro 15-4513 and related imidazobenzodiazepines. Harris BD, et al. **Pharmacol Biochem Behav** 1995 Sep;52(1):113–8

Synergy between chronic corticosterone and sodium azide treatments in producing a spatial learning deficit and inhibiting cytochrome oxidase activity. Bennett MC, et al. **Proc Natl Acad Sci U S A** 1996 Feb 6;93(3):1330–4

Ro 15-4513 selectively attenuates ethanol, but not sucrose, reinforced responding in a concurrent access procedure; comparison to other drugs. Petry NM. **Psychopharmacology (Berl)** 1995 Sep;121(2):192–203

[Comparison of the effectiveness of sodium azide and merthiolate as bacteriocidal agents--a NMR study] Schiller J, et al. **Biomed Tech (Berl)** 1995 Sep;40(9):250–4 (Eng. Abstr.) **(Ger)**

POISONING

Application of high-performance liquid chromatography to a fatality involving azide. Lambert WE, et al. **J Anal Toxicol** 1995 Jul-Aug;19(4):261–4

[Fatal sodium azide poisoning in a hospital: a preventable accident] Herbold M, et al. **Arch Kriminol** 1995 Nov-Dec; 196(5–6):143–8 (Eng. Abstr.) **(Ger)**

TOXICITY

Influence of salinity on copper and azide toxicity to larval topsmelt Atherinops affinis (Ayres). Anderson BS, et al. **Arch Environ Contam Toxicol** 1995 Oct;29(3):366–72

Mutagenicity of alkyl azides. Matsumura Y, et al. **Biol Pharm Bull** 1995 Dec;18(12):1805–7

Regional brain effects of sodium azide treatment on cytochrome oxidase activity: a quantitative histochemical study. Cada A, et al. **Metab Brain Dis** 1995 Dec; 10(4):303–20

AZIDOTHYMIDINE see **ZIDOVUDINE**

AZINPHOSMETHYL

ANALOGS & DERIVATIVES

Interaction of ethylazinphos with the physical organization of model and native membranes. Videira RA, et al. **Biochim Biophys Acta** 1996 May 22;1281(1):65–72

Passive diffusion through polymeric membranes: a novel cleanup procedure for analysis of azinphos-methyl and azinphos-ethyl residues in fruits and vegetables. Ahmad N, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1450–4

ANALYSIS

Passive diffusion through polymeric membranes: a novel cleanup procedure for analysis of azinphos-methyl and azinphos-ethyl residues in fruits and vegetables. Ahmad N, et al. **J AOAC Int** 1995 Nov-Dec;78(6):1450–4

TOXICITY

Effects of azinphos-methyl on the reproductive success of the bluegill sunfish, Lepomis macrochirus, in littoral enclosures. Tanner DK, et al. **Ecotoxicol Environ Saf** 1995 Nov;32(2):184–93

AZIRIDINES

ADVERSE EFFECTS

Occupational respiratory and skin sensitization caused by polyfunctional aziridine hardener. Kanerva L, et al. **Clin Exp Allergy** 1995 May;25(5):432–9

Occupational allergic contact dermatitis and contact urticaria

AZIRIDINES

caused by polyfunctional aziridine hardener. Kanerva L, et al. **Contact Dermatitis** 1995 Nov;33(5):304–9

CHEMICAL SYNTHESIS

Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecane. Li Y, et al. **J Med Chem** 1996 Jan 5;39(1):339–41

CHEMISTRY

Diaziquone-glutathione conjugates: characterization and mechanisms of formation. Gutierrez PL, et al. **Chem Res Toxicol** 1995 Apr–May;8(3):455–64

PHAEMACOKINETICS

Phase I trial of diaziquone (AZQ) plus GM-CSF. Hartmann LC, et al. **Invest New Drugs** 1995;13(2):175–6

PHARMACOLOGY

Evaluation by polymerase chain reaction on the effect of beta-propiolactone and binary ethyleneimine on DNA. Groseil C, et al. **Biologicals** 1995 Sep;23(3):213–20

Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Bridgewater JA, et al. **Eur J Cancer** 1995 Dec;31A(13–14):2362–70

Evaluation of 6,7-aziridinyl steroids and related compounds as inhibitors of aromatase (P-450arom). Njar VC, et al. **J Enzym Inhib** 1995;9(3):195–202

Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecane. Li Y, et al. **J Med Chem** 1996 Jan 5;39(1):339–41

Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9 Fitzsimmons SA, et al. **J Natl Cancer Inst** 1996 Mar 6;88(5):259–69

Re: Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and E09 [letter] Pritsos C. **J Natl Cancer Inst** 1996 Aug 21;88(16):1161–3

AF64A-induced cytotoxicity and changes in choline acetyltransferase activity in the LA-N-2 neuroblastoma cell line are modulated by choline and hemicholinium-3. Santiago LR, et al. **J Neurosci Methods** 1995 Sep–Oct; 61(1–2):185–90

Convulsive properties of N-(3,5-dimethoxy-4-propoxyphenyl-ethyl) aziridine and their influencing by diazepam and triazolam. Herink J. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(2):85–8

A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine. Race E, et al. **Vaccine** 1995 Nov;13(16):1567–75

THERAPEUTIC USE

DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Smitskamp-Wilms E, et al. **Br J Cancer** 1995 Oct; 72(4):917–21

TOXICITY

The AF64A model of cholinergic hypofunction: an update. Hanin I. **Life Sci** 1996;58(22):1955–64 (66 ref.)

Reduction of the toxicity and mutagenicity of aziridine in mammalian cells harboring the Escherichia coli fpg gene. Cussac C, et al. **Nucleic Acids Res** 1996 May 1;24(9):1742–6

Convulsive properties of N-(3,5-dimethoxy-4-propoxyphenyl-ethyl)-aziridine and their influencing by diazepam and triazolam. Herink J. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl** 1995;38(2):85–8

[Possibility of transitioning highly-differentiated Sertoli cells to proliferation after exposure to chemical mutagens] Zakhidov ST, et al. **Dokl Akad Nauk** 1995 Oct;344(5):692–4 **(Rus)**

AZIRINES

CHEMISTRY

Photolabeling of prostaglandin endoperoxide H synthase-1 with 3-trifluoro-3-(m-[125I]iodophenyl)diazirine as a probe of membrane association and the cyclooxygenase active site. Otto JC, et al. **J Biol Chem** 1996 Apr 26; 271(17):9906–10

ISOLATION & PURIFICATION

New azacyclopropene derivatives from Dysidea fragilis collected in Pohnpei. Salomon CE, et al. **J Nat Prod** 1995 Sep;58(9):1463–6

METABOLISM

Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Huwiler A, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6959–63

AZITHROMYCIN

[Special issue devoted to azithromycin] **Pathol Biol (Paris)** 1995 Jun;43(6):481–572 **(Fre)**

ADMINISTRATION & DOSAGE

Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Bertoni G, et al. **Am J Gastroenterol** 1996 Feb;91(2):258–63

The use of azithromycin in short-term low-dose triple therapies for Helicobacter pylori infection [letter] Tursi A, et al. **Am J Gastroenterol** 1996 Apr;91(4):817–8

Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises. Thorpe EM Jr, et al. **Genitourin Med** 1996 Apr;72(2):93–7

Treatment of chancroid with azithromycin. Ballard RC, et al. **Int J STD AIDS** 1996;7 Suppl 1:9–12 (16 ref.)

Treatment of syphilis with azithromycin. Mashkilleyson AL, et al. **Int J STD AIDS** 1996;7 Suppl 1:13–5

Azithromycin in gonorrhoea. Waugh MA. **Int J STD AIDS** 1996;7 Suppl 1:2–4 (11 ref.)

[Combined therapy with azithromycin and omeprazole for the eradication of Helicobacter pylori (letter)] Bokemeyer B. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1339 **(Ger)**

ADVERSE EFFECTS

Macrolides versus azalides: a drug interaction update. Amsden GW. **Ann Pharmacother** 1995 Sep;29(9):906–17 (109 ref.)

[Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)] Cadisch R, et al. **Schweiz Med Wochenschr** 1996 Feb 24;126(8):308–10 (Eng. Abstr.) **(Ger)**

ANALYSIS

Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Carlier MB, et al. **Int J Tissue React** 1994; 16(5–6):211–20

BLOOD

Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. Bohte R, et al. **Antimicrob Agents Chemother** 1995 Dec; 39(12):2801–2

ECONOMICS

Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Magid D, et al. **Ann Intern Med** 1996 Feb 15;124(4):389–99

The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Haddix AC, et al. **Sex Transm Dis** 1995 Sep–Oct;22(5):274–80

PHARMACOKINETICS

Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Nahata MC, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1875–7

Azithromycin levels in cervical mucus and plasma after a single 1.0g oral dose for chlamydial cervicitis. Worm AM, et al. **Genitourin Med** 1995 Aug;71(4):244–6

Pharmacokinetics of azithromycin in normal and impaired renal function. Höffler D, et al. **Infection** 1995 Nov–Dec; 23(6):356–61

Azithromycin in an experimental Staphylococcus aureus abscess model. Bamberger DM, et al. **J Antimicrob Chemother** 1995 May;35(5):623–9

[Clinical pharmacokinetics of azithromycin] Singlas E. **Pathol Biol (Paris)** 1995 Jun;43(6):505–11 (16 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

In vitro effectiveness of azithromycin against doxycycline-resistant and -susceptible strains of Rickettsia tsutsugamushi, etiologic agent of scrub typhus. Strickman D, et al. **Antimicrob Agents Chemother** 1995 Nov; 39(11):2406–10

Ex vivo effect of azithromycin in human leukocyte bactericidal functions [letter] Tomažič J, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1906

Antibacterial activity of azithromycin against Brucella melitensis. Qadri SM, et al. **Chemotherapy** 1995 Jul–Aug; 41(4):253–6

Azithromycin and terfenadine: lack of drug interaction. Harris S, et al. **Clin Pharmacol Ther** 1995 Sep;58(3):310–5

Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Bauernfeind A, et al. **Infection** 1995 Sep–Oct;23(5):316–21

Azithromycin does not increase plasma concentrations of oral midazolam. Backman JT, et al. **Int J Clin Pharmacol Ther** 1995 Jun;33(6):356–9

Review of azithromycin activity against Legionella spp. Edelstein PH. **Pathol Biol (Paris)** 1995 Jun;43(6):569–72 (18 ref.)

Azithromycin drug interactions. Felstead S. **Pathol Biol (Paris)** 1995 Jun;43(6):512–4

[Azithromycin: tissue pharmacology] Bergogne-Bérézin E. **Pathol Biol (Paris)** 1995 Jun;43(6):498–504 (29 ref.) (Eng. Abstr.) **(Fre)**

[Comparative activity of azithromycin against 100 strains of Neisseria gonorrhoeae] Chevalier B, et al. **Pathol Biol (Paris)** 1995 Apr;43(4):281–3 (Eng. Abstr.) **(Fre)**

[New pathogens and mode of action of azithromycin: Toxoplasma gondii] Derouin F. **Pathol Biol (Paris)** 1995 Jun;43(6):561–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Helicobacter pylori and azithromycin] Mégraud F, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):555–60 (15 ref.) (Eng. Abstr.) **(Fre)**

[Effect of the molecular structure of azithromycin on pharmacokinetics and the antimicrobial activity] Pechère JC. **Pathol Biol (Paris)** 1995 Jun;43(6):483–7 (8 ref.) (Eng. Abstr.) **(Fre)**

[Azithromycin and Mycobacterium avium infection] Perronne C. **Pathol Biol (Paris)** 1995 Jun;43(6):565–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Azithromycin: critical points] Philippon A, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):488–97 (55 ref.) (Eng. Abstr.) **(Fre)**

[Effects of azithromycin on the virulence of Pseudomonas aeruginosa] Reinert P. **Pathol Biol (Paris)** 1995 Jun; 43(6):551–3 (Eng. Abstr.) **(Fre)**

[Efficacy and tolerance of azithromycin in respiratory tract infections in children] Toscano MA, et al. **Minerva Pediatr** 1995 Jun;47(6):249–60 (Eng. Abstr.) **(Ita)**

[Effects of azithromycin on fecal flora of healthy adult volunteers] Uchino U, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1119–30 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Azithromycin for the cure of Helicobacter pylori infection. Di Mario F, et al. **Am J Gastroenterol** 1996 Feb;91(2):264–7

An open non-comparative pilot study with azithromycin in the treatment of non-gonococcal urethritis in the sexually transmitted disease clinics in Hong Kong. Lo KK, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):547–9

Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Anderson SL, et al. **Ann Intern Med** 1995 Nov 15;123(10):771–3

A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. Genç M, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):1–7

Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Luft BJ, et al. **Ann Intern Med** 1996 May 1;124(9):785–91

Treatment of non-HIV cryptosporidial diarrhea with azithromycin. Bessette RE, et al. **Ann Pharmacother** 1995 Oct;29(10):991–3

Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Pacifico L, et al. **Antimicrob Agents Chemother** 1996 Apr;40(4):1005–8

In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G. Tissi L, et al. **Antimicrob Agents Chemother** 1995 Sep;39(9):1938–47

Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Kuschner RA, et al. **Clin Infect Dis** 1995 Sep;21(3):536–41

Comparison of azithromycin and ceftriaxone for the treatment of chancroid. Martin DH, et al. **Clin Infect Dis** 1995 Aug;21(2):409–14

Efficacy of azithromycin for typhoid fever. Tribble D, et al. **Clin Infect Dis** 1995 Oct;21(4):1045–6

An open-label, noncomparative study to evaluate the efficacy, safety, and tolerability of azithromycin in the treatment of patients with acute sinusitis. Amin NM, et al. **Clin Ther** 1995 Jul–Aug;17(4):701–7

Azithromycin. Johnson RB. **Curr Probl Dermatol** 1996; 24:184–93 (30 ref.)

Gonorrhoea: single-dose oral treatment. Kohl PK, et al. **Curr Probl Dermatol** 1996;24:82–9 (29 ref.)

Streptococcal pharyngitis: alternative treatments. Kieserman SP, et al. **Ear Nose Throat J** 1995 Nov;74(11):777–80

Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Principi N. **Eur J Clin Microbiol Infect Dis** 1995 Aug; 14(8):669–76

Pilot study of azithromycin in the treatment of genital donovanosis. Bowden FJ, et al. **Genitourin Med** 1996 Feb; 72(1):17–9

The newer macrolides. Azithromycin and clarithromycin. Zuckerman JM, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):731–45 (66 ref.)

The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis. Chang HR. **Int J STD AIDS** 1996;7 Suppl 1:18–22 (34 ref.)

Azithromycin in the prophylaxis of opportunistic infections in AIDS. McCutchan JA. **Int J STD AIDS** 1996;7 Suppl 1:34–7

Azithromycin in the management of Chlamydia trachomatis

infections. Ridgway GL. **Int J STD AIDS** 1996;7 Suppl 1:5–8
Azithromycin in sexually transmitted diseases. Ridgway GL. **Int J STD AIDS** 1996;7 Suppl 1:1
Treatment and prophylaxis of Mycobacterium avium complex. Young LS. **Int J STD AIDS** 1996;7 Suppl 1:23–7 (15 ref.)
In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin. Gill CJ, et al. **J Antibiot (Tokyo)** 1995 Oct;48(10):1141–7
Efficacy of azithromycin and rifabutin in preventing infection by Mycobacterium avium complex in beige mice. Bermudez LE, et al. **J Antimicrob Chemother** 1995 Oct; 36(4):641–6
Comparative activity of azithromycin and doxycycline against Brucella spp. infection in mice. Domingo S, et al. **J Antimicrob Chemother** 1995 Oct;36(4):647–56
The treatment of non-gonococcal urethritis with single dose oral azithromycin. Erdogru T, et al. **J Int Med Res** 1995 Sep–Oct;23(5):386–93
Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. Hicks P, et al. **J Pediatr** 1996 Aug;129(2):297–300
Effects of azithromycin on malariometric indices in The Gambia. Sadiq ST, et al. **Lancet** 1995 Sep 30; 346(8979):881–2
Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group [see comments] Havlir DV, et al. **N Engl J Med** 1996 Aug 8;335(6):392–8 . Comment in: N Engl J Med 1996 Aug 8;335(6):428–30.
Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Tabbara KF, et al. **Ophthalmology** 1996 May;103(5):842–6
A prospective, double-blind, placebo-controlled trial of a single dose of azithromycin on postoperative wound infections in plastic surgery. Amland PF, et al. **Plast Reconstr Surg** 1995 Nov;96(6):1378–83
Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study. Kuzman I, et al. **Scand J Infect Dis** 1995;27(5):503–5
Improvement in cyclosporine A associated gingival hyperplasia with azithromycin therapy. Boran M, et al. **Transplant Proc** 1996 Aug;28(4):2316
[Azithromycin: from macrolides to azalides] Carbon C. **Pathol Biol (Paris)** 1995 Jun;43(6):481–2 **(Fre)**
[Azithromycin: new orientations] Coulaud JP. **Pathol Biol (Paris)** 1995 Jun;43(6):547–50 **(Fre)**
[Use of azithromycin in ORL] Gehanno P. **Pathol Biol (Paris)** 1995 Jun;43(6):530–3 (Eng. Abstr.) **(Fre)**
[Azithromycin, pharmacodynamic evaluation in animal models] Lagrange PH. **Pathol Biol (Paris)** 1995 Jun; 43(6):515–23 (37 ref.) (Eng. Abstr.) **(Fre)**
[Azithromycin and bronchopulmonary infections] Leophonte P. **Pathol Biol (Paris)** 1995 Jun;43(6):534–41 (38 ref.) (Eng. Abstr.) **(Fre)**
[Azithromycin and genital infections] Micoud M, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):542–6 (19 ref.) (Eng. Abstr.) **(Fre)**
[Azithromycin: clinical assessment] Modaï J. **Pathol Biol (Paris)** 1995 Jun;43(6):529 **(Fre)**
[The particular case of azalides: antibiotic diapedesis. Experimental data from a murine model of pneumococcal pneumonia] Veber B, et al. **Pathol Biol (Paris)** 1995 Jun; 43(6):524–8 (Eng. Abstr.) **(Fre)**
[Pharma-clinics. Drug of the month. Azithromycin (Zitromax)] Scheen AJ. **Rev Med Liege** 1995 Sep; 50(9):398–9 **(Fre)**
[Efficacy and tolerance of azithromycin in respiratory tract infections in children] Toscano MA, et al. **Minerva Pediatr** 1995 Jun;47(6):249–60 (Eng. Abstr.) **(Ita)**
[Pharmacokinetic and clinical studies with azithromycin (capsule) in the pediatric field. Pediatric Study Group of Azithromycin] Fujii R, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1074–92 (Eng. Abstr.) **(Jpn)**
[Comparative clinical study of azithromycin with tosufloxacin tosilate in the treatment of acute odontogenic infection] Sasaki J, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1093–118 (Eng. Abstr.) **(Jpn)**
[Pharmacokinetic and clinical studies with azithromycin (fine granule) in the pediatric field. Pediatric Study Group of Azithromycin] Tajima T, et al. **Jpn J Antibiot** 1995 Sep; 48(9):1051–73 (Eng. Abstr.) **(Jpn)**

AZLOCILLIN

ADVERSE EFFECTS

Severe acute hand ischemia following an accidental intraarterial drug injection, successfully treated with thrombolysis and intraarterial Iloprost infusion. Case report. Andreev A, et al. **Angiology** 1995 Oct;46(10):963–7

ANALYSIS

Stability study of azlocillin sodium in glass bottles and PVC bags containing intravenous admixtures. Puiggròs Boldú S, et al. **Boll Chim Farm** 1995 Sep;134(8):467–71

AZO COMPOUNDS

Determination of sulphonamides in human urine by azo dye precolumn derivatization and micellar liquid chromatography. Simó-Alfonso EF, et al. **J Chromatogr B Biomed Appl** 1995 Aug 4;670(1):183–7
Flow-injection extraction-spectrophotometric determination of bromhexine with orange IV. Pérez-Ruiz T, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1101–6
Regional distribution of carcinogen-induced colonic neoplasia in the rat. Holt PR, et al. **Nutr Cancer** 1996; 25(2):129–35
Correlation study of two methods for evaluating corneal endothelial damage in vitro: the Janus green photometry technique versus cell counting. Pharmakakis N, et al. **Ophthalmic Res** 1995 Mar–Apr;27(2):67–73

ADVERSE EFFECTS

Multiple azo dye sensitization revealed by the wearing of a black "velvet" body. Dejobert Y, et al. **Contact Dermatitis** 1995 Oct;33(4):276–7
Effectiveness of disperse dyes mix in detection of contact allergy to textile dyes: an Italian multicentre study. Francalanci S, et al. **Contact Dermatitis** 1995 Nov;33(5):351
Prevalence of contact allergy to non-disperse azo dyes for natural fibers: a study in 1814 consecutive patients. Seidenari S, et al. **Contact Dermatitis** 1995 Aug; 33(2):118–22
[Hypersensitivity to Sintrom, caused by cochineal red A (letter)] Guy C, et al. **Therapie** 1995 Sep–Oct;50(5):483–4 **(Fre)**
[Work conditions and health status of workers in present-day production of disperse azo dyes] Zvezdaĭ VI, et al. **Med Tr Prom Ekol** 1996;(2):17–22 (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

Galactose-containing amphiphiles prepared with a lipophilic radical initiator: association processes between liposomes triggered by enzymatic reaction. Ohno K, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):361–6
Synthesis and characterization of (d)NTP derivatives substituted with residues of different photoreagents. Wlassoff WA, et al. **Bioconjug Chem** 1995 Jul–Aug; 6(4):352–60

CHEMISTRY

Azo polymeric hydrogels for colon targeted drug delivery. Shantha KL, et al. **Biomaterials** 1995 Nov;16(17):1313–8
Determination of combined benzidine in FD&C Yellow No. 6 (Sunset Yellow FCF). Peiperl MD, et al. **Food Chem Toxicol** 1995 Oct;33(10):829–39

DIAGNOSTIC USE

A modified Coomassie blue staining of proteins in polyacrylamide gels with Bismark brown R. Choi JK, et al. **Anal Biochem** 1996 Apr 5;236(1):82–4
Differences between enzymatic and diazo methods for measuring direct bilirubin. Nakayama K. **Eur J Clin Chem Clin Biochem** 1995 Aug;33(8):513–7

METABOLISM

Reduction of cyclic and acyclic diazene derivates by Azotobacter vinelandii nitrogenase: diazirine and trans-dimethyldiazene. McKenna CE, et al. **Biochemistry** 1996 Apr 9;35(14):4502–14
Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. Rafii F, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:17–9
Bio-metabolic disposition of metanil yellow, orange II and their blend by caecal microflora of rats. Singh S, et al. **Indian J Exp Biol** 1995 Jul;33(7):543–4
Antioxidant stoichiometry and the oxidative fate of vitamin E in peroxyl radical scavenging reactions. Liebler DC, et al. **Lipids** 1995 Sep;30(9):789–93

PHARMACOKINETICS

Lack of bioavailability of dichlorobenzidine form diarylide azo pigments: molecular dosimetry for hemoglobin and DNA adducts. Sagelsdorff P, et al. **Carcinogenesis** 1996 Mar;17(3):507–14
3,3',4,4'-tetrachloroazobenzene absorption, disposition, and metabolism in male Fischer 344 rats. Pillai UA, et al. **Drug Metab Dispos** 1996 Feb;24(2):238–44
Synthesis and applicability of a photolabile 7,7-azi analogue of 3-sulfated taurine-conjugated bile salts. Dietrich A, et al. **J Lipid Res** 1995 Aug;36(8):1729–44

PHARMACOLOGY

ADA, a potential anti-HIV drug [letter] Vandevelde M, et al. **AIDS Res Hum Retroviruses** 1996 May 1;12(7):567–8
The glittering vagina—a seasonal phenomenon? [letter] Hudson MM, et al. **Genitourin Med** 1996 Jun;72(3):227
DNA repair synthesis induced by azo dyes in primary rat hepatocyte cultures using the bromodeoxyuridine density-shift method. Palus J, et al. **Int J Occup Med Environ Health** 1995;8(2):123–30
Paradoxical effect of Sudan III on the in vivo and in vitro genotoxicity elicited by 7,12-dimethylbenz(a)anthracene. Hatakeyama S, et al. **J Biochem Toxicol** 1995 Jun; 10(3):143–9

TOXICITY

Mutagenicity of tetranitroazoxytoluenes: a preliminary screening in Salmonella typhimurium strains TA100 and TA100NR. Spanggord RJ, et al. **Mutat Res** 1995 Dec; 335(3):207–11
Reproductive and neurobehavioral effects of Sunset yellow FCF administered to mice in the diet. Tanaka T. **Toxicol Ind Health** 1996 Jan–Feb;12(1):69–79

P-AZOBENZENEARSONATE

IMMUNOLOGY

The perinatal presence of antigen (p-azophenylarsonate) or anti-mu antibodies lead to the loss of the recurrent idiotype (CRIA) in A/J mice. Ryelandt M, et al. **Int Immunol** 1995 Apr;7(4):645–52

AZOCINES

CHEMISTRY

Piperazinylalkyl heterocycles as potential antipsychotic agents. Scott MK, et al. **J Med Chem** 1995 Oct 13; 38(21):4198–210

PHARMACOLOGY

Ca2+ sensitization in idiopathic dilated human myocardium. Differential in vitro effects of (+)-(5-methyl-6-phenyl)-1,3,5,6-tetrahydro-3,6-methano-1,5-benzodiazoci ne-2,4-dione, a novel purely Ca2+sensitizing agent, and (+)-5-(1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydroquinolin-6-yl)-6-meth yl-3, 6-dihydro-2H-1,3,4-thiadiazin-2-one on skinned fibres and isolated ventricular strips. Herzig JW, et al. **Arzneimittelforschung** 1996 Jun;46(6):586–93
Positive inotropic effects of the calcium sensitizer CGP 48506 in failing human myocardium. Neumann J, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1579–85
Positive inotropic effects of the calcium sensitizer CGP 48506 in guinea pig myocardium. Zimmermann N, et al. **J Pharmacol Exp Ther** 1996 Jun;277(3):1572–8

AZOFERREDOXIN see **DINITROGENASE REDUCTASE**

AZOLES

ADMINISTRATION & DOSAGE

Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Dewsnup DH, et al. **Ann Intern Med** 1996 Feb 1;124(3):305–10
Efficacy of oral saperconazole in systemic murine aspergillosis. Hanson LH, et al. **J Med Vet Mycol** 1995 Sep–Oct;33(5):311–7

CHEMICAL SYNTHESIS

Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17, and P450 TxA2. Hartmann RW, et al. **Arch Pharm (Weinheim)** 1996 May;329(5):251–61
Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring. Bartroli J, et al. **J Med Chem** 1995 Sep 29;38(20):3918–32
Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile. von Geldern TW, et al. **J Med Chem** 1996 Feb 16;39(4):957–67
Azole endothelin antagonists. 2. Structure-activity studies. von Geldern TW, et al. **J Med Chem** 1996 Feb 16; 39(4):968–81
Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorption. von Geldern TW, et al. **J Med Chem** 1996 Feb 16;39(4):982–91

METABOLISM

Ebselen-binding equilibria between plasma and target proteins. Ullrich V, et al. **Biochem Pharmacol** 1996 Jul 12; 52(1):15–9
Ebselen. Sies H. **Methods Enzymol** 1995;252:341–2 (18 ref.)

PHARMACOKINETICS

Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorption. von Geldern TW, et al. **J Med Chem** 1996 Feb 16;39(4):982–91

PHARMACOLOGY

Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Joseph-Horne T, et al. **Antimicrob Agents Chemother** 1995 Jul;39(7):1526–9
Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Sanglard D, et al. **Antimicrob Agents Chemother** 1995 Nov;39(11):2378–86
Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Scheven M, et al. **Antimicrob Agents Chemother** 1995 Aug;39(8):1779–83

AZOLES

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM.
Antimicrob Agents Chemother 1995 Sep;39(9):1907–12 (46 ref.)
In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species. Vazquez JA, et al.
Antimicrob Agents Chemother 1995 Dec;39(12):2689–91
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Walsh TJ, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1361–4
Ebselen inhibition of apoptosis by reduction of peroxides. Ramakrishnan N, et al. **Biochem Pharmacol** 1996 Jun 14; 51(11):1443–51
Antitumor and antimicrobial activities of Fe(II)/Fe(III) complexes derived from some heterocyclic compounds. Mishra L, et al. **Bioorg Med Chem** 1995 Sep;3(9):1241–5
Altered P450 activity associated with direct selection for fungal azole resistance. Joseph-Horne T, et al.
FEBS Lett 1995 Oct 30;374(2):174–8
Molecular actions of ebselen—an antiinflammatory antioxidant. Schewe T. **Gen Pharmacol** 1995 Oct; 26(6):1153–69 (91 ref.)
Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. Rodríguez-Tudela JL, et al. **J Antimicrob Chemother** 1995 Jun;35(6):793–804
Azole endothelin antagonists. 2. Structure-activity studies. von Geldern TW, et al. **J Med Chem** 1996 Feb 16; 39(4):968–81
Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile. von Geldern TW, et al. **J Med Chem** 1996 Feb 16;39(4):957–67
Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Marichal P, et al. **Mycoses** 1995 Mar-Apr;38(3–4):111–7
Post-antibiotic effect and post-expositional polyene antagonism of azole antifungal agents in Candida albicans: dependence on substance lipophilia. Scheven M, et al.
Mycoses 1995 Nov-Dec;38(11-12):435–42

THERAPEUTIC USE

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM.
Antimicrob Agents Chemother 1995 Sep;39(9):1907–12 (46 ref.)
Azole drug resistance in yeasts. Johnson EM, et al.
J Antimicrob Chemother 1995 Nov;36(5):751–5
Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. Rodríguez-Tudela JL, et al. **J Antimicrob Chemother** 1995 Jun;35(6):793–804
Blood culture as a parameter of treatment effectiveness in experimental histoplasmosis of the hamster. Finquelievich J, et al. **Rev Inst Med Trop Sao Paulo** 1995 Mar-Apr; 37(2):99–102

AZOLINIC ACID see **CINOXACIN**

AZOOSPERMIA see **OLIGOSPERMIA**

AZOPHENYLARSONATE see **P-AZOBENZENEARSONATE**

AZOREAN DISEASE see **MACHADO-JOSEPH DISEASE**

AZOSPIRILLUM

GENETICS

Isolation and characterization of Azospirillum lipoferum locus that complements Rhizobium meliloti dctA and dctB mutations. Tripathi AK, et al. **Can J Microbiol** 1996 May; 42(5):503–6
Cloning, sequencing and transcriptional regulation of the draT and draG genes of Azospirillum lipoferum FS. Inoue A, et al. **Gene** 1996 Apr 17;170(1):101–6

GROWTH & DEVELOPMENT

[Growth and survival of Azospirillum in roots and maize rhizospheres with different levels of acidity] Eöry VJ, et al. **Rev Argent Microbiol** 1995 Apr-Jun;27(2):99–105 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Oligonucleotide probes based on 16S rRNA sequences for the identification of four Azospirillum species. Kabir MM, et al. **Can J Microbiol** 1995 Dec;41(12):1081–7

METABOLISM

Synthesis of phytohormones by plant-associated bacteria. Costacurta A, et al. **Crit Rev Microbiol** 1995;21(1):1–18 (169 ref.)

AZOSPIRILLUM BRASILENSE

DRUG EFFECTS

Characterization of 2,4-dichlorophenoxyacetic acid transport and its relationship with polyamines in Azospirillum brasilense. Castro S, et al. **Toxicol Lett** 1996 Jan;84(1):33–6

ENZYMOLOGY

Properties of the recombinant beta subunit of glutamate synthase. Vanoni MA, et al. **Eur J Biochem** 1996 Mar 15; 236(3):937–46

GENETICS

The ntrBC genes of Azospirillum brasilense are part of a nifR3-like-ntrB-ntrC operon and are negatively regulated. Machado HB, et al. **Can J Microbiol** 1995 Aug;41(8):674–84
The Azospirillum brasilense rpoN gene is involved in nitrogen fixation, nitrate assimilation, ammonium uptake, and flagellar biosynthesis. Milcamps A, et al.
Can J Microbiol 1996 May;42(5):467–78
The two overlapping Azospirillum brasilense upstream activator sequences have differential effects on nifH promoter activity. Passaglia LM, et al. **Can J Microbiol** 1995 Sep;41(9):849–54
Modulation of NifA activity by PII in Azospirillum brasilense: evidence for a regulatory role of the NifA N-terminal domain. Arsene F, et al. **J Bacteriol** 1996 Aug; 178(16):4830–8
Coexistence of two structurally similar but functionally different PII proteins in Azospirillum brasilense. de Zamaroczy M, et al. **J Bacteriol** 1996 Jul;178(14):4143–9
Cloning, sequencing, and phenotypic analysis of laf1, encoding the flagellin of the lateral flagella of Azospirillum brasilense Sp7. Moens S, et al. **J Bacteriol** 1995 Oct; 177(19):5419–26
Expression of the structural gene, laf1, encoding the flagellin of the lateral flagella in Azospirillum brasilense Sp7. Moens S, et al. **J Bacteriol** 1996 Aug;178(16):5017–9
Cloning, nucleotide sequencing, and expression of the Azospirillum brasilense lon gene: involvement in iron uptake. Mori E, et al. **J Bacteriol** 1996 Jun;178(12):3440–6
Presence of a second mechanism for the posttranslational regulation of nitrogenase activity in Azospirillum brasilense in response to ammonium. Zhang Y, et al. **J Bacteriol** 1996 May;178(10):2948–53
Acyl carrier protein of Azospirillum brasilense: properties of the purified protein and sequencing of the corresponding gene, acpP. Maiti MK, et al. **Microbiology** 1996 Aug;142 (Pt 8):2097–103
CarkS of Azospirillum brasilense is homologous to a large family of aldehyde dehydrogenases rather than to two-component regulators [letter] Ramseier TM, et al.
Res Microbiol 1995 Jun;146(5):425–9
[Cloning and sequencing of ntrBC genes from Azospirillum brasilense] Yan D, et al. **Wei Sheng Wu Hsueh Pao** 1995 Aug;35(4):242–9 (Eng. Abstr.) **(Chi)**

METABOLISM

The Azospirillum brasilense rpoN gene is involved in nitrogen fixation, nitrate assimilation, ammonium uptake, and flagellar biosynthesis. Milcamps A, et al.
Can J Microbiol 1996 May;42(5):467–78
Modulation of NifA activity by PII in Azospirillum brasilense: evidence for a regulatory role of the NifA N-terminal domain. Arsene F, et al. **J Bacteriol** 1996 Aug; 178(16):4830–8
Expression of the structural gene, laf1, encoding the flagellin of the lateral flagella in Azospirillum brasilense Sp7. Moens S, et al. **J Bacteriol** 1996 Aug;178(16):5017–9
Acyl carrier protein of Azospirillum brasilense: properties of the purified protein and sequencing of the corresponding gene, acpP. Maiti MK, et al. **Microbiology** 1996 Aug;142 (Pt 8):2097–103

PHYSIOLOGY

2,4-Dichlorophenoxyacetic acid affects the attacnment of Azospirillum brasilense Cd to maize roots. Jofré E, et al. **Toxicology** 1996 Jan 22;107(1):9–15

AZOTEMIA see **UREMIA**

AZOTOBACTER

CHEMISTRY

Alkylresorcinols are abundant lipid components in different strains of Azotobacter chroococcum and Pseudomonas spp. Kozubek A, et al. **J Bacteriol** 1996 Jul;178(14):4027–30
Possible role of a short extra loop of the long-chain flavodoxin from Azotobacter chroococcum in electron transfer to nitrogenase: complete 1H, 15N and 13C backbone assignments and secondary solution structure of the flavodoxin. Peelen S, et al. **J Biomol NMR** 1996 Jun; 7(4):315–30

ENZYMOLOGY

Improved catalytic performance of a 2-haloacid dehalogenase from Azotobacter sp. by ion-exchange immobilisation. Diez A, et al.
Biochem Biophys Res Commun 1996 Mar 27;220(3):828–33
Posttranslational regulation of nitrogenase activity by fixed nitrogen in Azotobacter chroococcum. Muñoz-Centeno MC, et al. **Biochim Biophys Acta** 1996 Aug 29;1291(1):67–74
Vanadium nitrogenases of Azotobacter. Eady RR.
Met Ions Biol Syst 1995;31:363–405 (106 ref.)

METABOLISM

Volatilization of mercury by resting mercury-resistant bacterial cells. Ghosh S, et al.
Bull Environ Contam Toxicol 1996 Feb;56(2):259–64

PHYSIOLOGY

Role of nitrogen fixing bacteria on the phyllosphere of wheat seedlings. Pati BR, et al. **Acta Microbiol Immunol Hung** 1995;42(4):427–33

AZOTOBACTER VINELANDII

CHEMISTRY

The concentration of cellular nitrogenase proteins in Azotobacter vinelandii whole cells as determined by activity measurements and electron paramagnetic resonance spectroscopy. Jacobs D, et al.
Arch Biochem Biophys 1995 Dec 20;324(2):317–24
The "nitrogenase-protective" FeSII protein of Azotobacter vinelandii: overexpression, characterization, and crystallization. Moshiri F, et al. **Biochemistry** 1995 Oct 10; 34(40):12973–82

DRUG EFFECTS

Phenotypic characterization of a tungsten-tolerant mutant of Azotobacter vinelandii. Premakumar R, et al.
J Bacteriol 1996 Feb;178(3):691–6

ENZYMOLOGY

Reductant-independent ATP hydrolysis catalyzed by homologous nitrogenase proteins from Azotobacter vinelandii and heterologous crosses with Clostridium pasteuranium. Larsen C, et al. **Arch Biochem Biophys** 1995 Nov 10;323(2):215–22
Binding of NO to the oxygen reaction site of cytochrome bd from Azotobacter vinelandii. Jünemann S, et al.
Biochem Soc Trans 1996 Feb;24(1):38S
Isolation of two forms of the nitrogenase VFe protein from Azotobacter vinelandii. Blanchard CZ, et al.
Biochemistry 1996 Jan 16;35(2):472–8
Steady-state kinetic studies of dithionite utilization, component protein interaction, and the formation of an oxidized iron protein intermediate during Azotobacter vinelandii nitrogenase catalysis. Johnson JL, et al.
Biochemistry 1996 Sep 3;35(35):11336–42
A suggested mechanism for the catalytic cycle of cytochrome bd terminal oxidase based on kinetic analysis. Jünemann S, et al. **Biochemistry** 1995 Nov 14;34(45):14861–7
Proton NMR investigation of the [4Fe--4S]1+ cluster environment of nitrogenase iron protein from Azotobacter vinelandii: defining nucleotide-induced conformational changes. Lanzilotta WN, et al. **Biochemistry** 1995 Dec 5; 34(48):15646–53
Reduction of cyclic and acyclic diazene derivates by Azotobacter vinelandii nitrogenase: diazirine and trans-dimethyldiazene. McKenna CE, et al.
Biochemistry 1996 Apr 9;35(14):4502–14
Elucidation of a MgATP signal transduction pathway in the nitrogenase iron protein: formation of a conformation resembling the MgATP-bound state by protein engineering. Ryle MJ, et al. **Biochemistry** 1996 Apr 16; 35(15):4766–75
Elucidating the mechanism of nucleotide-dependent changes in the redox potential of the [4Fe-4S] cluster in nitrogenase iron protein: the role of phenylalanine 135. Ryle MJ, et al. **Biochemistry** 1996 Jul 23;35(29):9424–34
Oxidative titration of the nitrogenase VFe protein from Azotobacter vinelandii: an example of redox-gated electron flow. Tittsworth RC, et al. **Biochemistry** 1996 Jan 16; 35(2):479–87
Comparison of isotope exchange, H2 evolution, and H2 oxidation activities of Azotobacter vinelandii hydrogenase. McTavish H, et al. **Biochim Biophys Acta** 1996 May 23; 1294(2):183–90
Sequential 1H and 15N nuclear magnetic resonance assignments and secondary structure of the lipoyl domain of the 2-oxoglutarate dehydrogenase complex from Azotobacter vinelandii. Evidence for high structural similarity with the lipoyl domain of the pyruvate dehydrogenase complex. Berg A, et al. **Eur J Biochem** 1995 Nov 15;234(1):148–59
The interaction between lipoamide dehydrogenase and the peripheral-component-binding domain from the Azotobacter vinelandii pyruvate dehydrogenase complex. Westphal AH, et al. **Eur J Biochem** 1995 Dec 15; 234(3):861–70
Formation and characterization of a transition state complex of Azotobacter vinelandii nitrogenase. Duyvis MG, et al.
FEBS Lett 1996 Feb 19;380(3):233–6
Characterization of the gene coding for GDP-mannose dehydrogenase (algD) from Azotobacter vinelandii. Campos M, et al. **J Bacteriol** 1996 Apr;178(7):1793–9
Purification and characterization of the vnf-encoded apodinitrogenase from Azotobacter vinelandii. Chatterjee R, et al. **J Biol Chem** 1996 Mar 22;271(12):6819–26
Characterization of the gamma protein and its involvement in the metallocluster assembly and maturation of dinitrogenase from Azotobacter vinelandii. Homer MJ, et al. **J Biol Chem** 1995 Oct 20;270(42):24745–52

Circular dichroism and x-ray spectroscopies of Azotobacter vinelandii nitrogenase iron protein. MgATP and MgADP induced protein conformational changes affecting the [4Fe-4S] cluster and characterization of a [2Fe-2S] form. Ryle MJ, et al. **J Biol Chem** 1996 Jan 19;271(3):1551-7

Solution structure of the lipoyl domain of the 2-oxoglutarate dehydrogenase complex from Azotobacter vinelandii. Berg A, et al. **J Mol Biol** 1996 Aug 23;261(3):432-42

A family of modular type mannuronan C-5-epimerase genes controls alginate structure in Azotobacter vinelandii. Ertesvåg H, et al. **Mol Microbiol** 1995 May;16(4):719-31

GENETICS

Cloning, sequence analysis and overexpression of the rhodanese gene of Azotobacter vinelandii. Colnaghi R, et al. **Eur J Biochem** 1996 Feb 15;236(1):240-8

Identification of sequences important for recognition of vnf genes by the VnfA transcriptional activator in Azotobacter vinelandii. Woodley P, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2-3):213-21

Molecular characterization of the Azotobacter vinelandii recF gene. Badran H, et al. **Gene** 1995 Aug 30;162(1):47-51

Characterization of the gene coding for GDP-mannose dehydrogenase (algD) from Azotobacter vinelandii. Campos M, et al. **J Bacteriol** 1996 Apr;178(7):1793-9

Expression from the nifB promoter of Azotobacter vinelandii can be activated by NifA, VnfA, or AnfA transcriptional activators. Drummond M, et al. **J Bacteriol** 1996 Feb; 178(3):788-92

Characterization of the genes coding for the putative sigma factor AlgU and its regulators MucA, MucB, MucC, and MucD in Azotobacter vinelandii and evaluation of their roles in alginate biosynthesis. Martínez-Salazar JM, et al. **J Bacteriol** 1996 Apr;178(7):1800-8

Characteristics of orf1 and orf2 in the anfHDGK genomic region encoding nitrogenase 3 of Azotobacter vinelandii. Mylona PV, et al. **J Bacteriol** 1996 Jan;178(1):204-8

Escherichia coli contains a protein that is homologous in function and N-terminal sequence to the protein encoded by the nifS gene of Azotobacter vinelandii and that can participate in the synthesis of the Fe-S cluster of dihydroxy-acid dehydratase. Flint DH. **J Biol Chem** 1996 Jul 5;271(27):16068-74

Nif- phenotype of Azotobacter vinelandii UW97. Characterization and mutational analysis. Pulakat L, et al. **J Biol Chem** 1996 Jan 26;271(4):1884-9

A family of modular type mannuronan C-5-epimerase genes controls alginate structure in Azotobacter vinelandii. Ertesvåg H, et al. **Mol Microbiol** 1995 May;16(4):719-31

Azotobacter vinelandii NIFL is a flavoprotein that modulates transcriptional activation of nitrogen-fixation genes via a redox-sensitive switch. Hill S, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):2143-8

New open reading frames, one of which is similar to the nifV gene of Azotobacter vinelandii, found on a 12.5 kbp fragment of chromosome IV of Saccharomyces cerevisiae. Verhasselt P, et al. **Yeast** 1995 Aug;11(10):961-6

GROWTH & DEVELOPMENT

Hydrogenase does not confer significant benefits to Azotobacter vinelandii growing diazotrophically under conditions of glucose limitation. Linkerhägner K, et al. **J Bacteriol** 1995 Oct;177(20):6018-20

METABOLISM

Flavodoxin 1 of Azotobacter vinelandii: characterization and role in electron donation to purified assimilatory nitrate reductase. Gangeswaran R, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):103-8

Reconstitution of the [4Fe-4S] cluster in FNR and demonstration of the aerobic-anaerobic transcription switch in vitro. Green J, et al. **Biochem J** 1996 Jun 15;316 (Pt 3):887-92

Carbohydrate fluxes into alginate biosynthesis in Azotobacter vinelandii NCIB 8789: NMR investigations of the triose pools. Beale JM Jr, et al. **Biochemistry** 1996 Apr 9; 35(14):4492-501

Evidence for electron transfer from the nitrogenase iron protein to the molybdenum-iron protein without MgATP hydrolysis: characterization of a tight protein-protein complex. Lanzilotta WN, et al. **Biochemistry** 1996 Jun 4; 35(22):7188-96

Redox properties of wild-type, Cys69Ala, and Cys69Ser Azotobacter vinelandii flavodoxin II as measured by cyclic voltammetry and EPR spectroscopy,. Steensma E, et al. **Eur J Biochem** 1996 Jan 15;235(1-2):167-72

The requirement of reductant for in vitro biosynthesis of the iron-molybdenum cofactor of nitrogenase. Allen RM, et al. **J Biol Chem** 1996 Feb 23;271(8):4256-60

Escherichia coli contains a protein that is homologous in function and N-terminal sequence to the protein encoded by the nifS gene of Azotobacter vinelandii and that can participate in the synthesis of the Fe-S cluster of dihydroxy-acid dehydratase. Flint DH. **J Biol Chem** 1996 Jul 5;271(27):16068-74

Evidence for the direct interaction of the nifW gene product with the MoFe protein. Kim S, et al. **J Biol Chem** 1996 Apr 19;271(16):9764-70

A kinetic study of iron release from Azotobacter vinelandii bacterial ferritin. Richards TD, et al. **J Inorg Biochem** 1996 Jan;61(1):1-13

The modE gene product mediates molybdenum-dependent expression of genes for the high-affinity molybdate transporter and modG in Azotobacter vinelandii. Mouncey NJ, et al. **Microbiology** 1996 Aug;142 (Pt 8):1997-2004

Site-directed mutagenesis of Azotobacter vinelandii ferredoxin I: cysteine ligation of the [4Fe-4S] cluster with protein rearrangement is preferred over serine ligation. Shen B, et al. **Proc Natl Acad Sci U S A** 1995 Oct 24; 92(22):10064-8

Structure elucidation of azotobactin 87, isolated from Azotobacter vinelandii ATCC 12837. Schaffner EM, et al. **Z Naturforsch [C]** 1996 Mar-Apr;51(3-4):139-50

AZOXYMETHANE

Suppression of azoxymethane-induced rat colon carcinogenesis by dietary administration of naturally occurring xanthophylls astaxanthin and canthaxanthin during the postinitiation phase. Tanaka T, et al. **Carcinogenesis** 1995 Dec;16(12):2957-63

Suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compounds on azoxymethane-induced aberrant crypt foci in rat colon. Hirose Y, et al. **Jpn J Cancer Res** 1996 Jun;87(6):549-54

Effects of repeated boluses of sucrose on proliferation and on AOM-induced aberrant crypt foci in rat colon. Luceri C, et al. **Nutr Cancer** 1996;25(2):187-96

ANTAGONISTS & INHIBITORS

Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. Takahashi M, et al. **J Cancer Res Clin Oncol** 1996;122(4):219-22

PHARMACOLOGY

Dietary guar gum alters colonic microbial fermentation in azoxymethane-treated rats. Weaver GA, et al. **J Nutr** 1996 Aug;126(8):1979-91

Early alterations of apoptosis and cell proliferation in azoxymethane-initiated rat colonic epithelium. Hirose Y, et al. **Jpn J Cancer Res** 1996 Jun;87(6):575-82

TOXICITY

Varying effect of dietary lipids and azoxymethane on early stages of colon carcinogenesis: enumeration of aberrant crypt foci and proliferative indices. Bird RP, et al. **Cancer Detect Prev** 1995;19(4):308-15

Re: Pereira, M.A., Barnes, L.H., Rassman, V.L., Kelloff, G.V. and Steele, V.E. (1994). Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis, 15, 1049-1054 [letter] Hardman WE, et al. **Carcinogenesis** 1996 Jul;17(7):1539-40

Azoxymethane enhances ligand-induced activation of EGF receptor tyrosine kinase in the colonic mucosa of rats. Malecka-Panas E, et al. **Carcinogenesis** 1996 Feb; 17(2):233-7

Unexpected antagonistic action of 3,2'-dimethyl-4-aminobiphenyl on aberrant crypt induction by 1,2-dimethylhydrazine or azoxymethane in rat colon. Steffensen IL, et al. **Carcinogenesis** 1995 Dec; 16(12):2981-8

AZT (ANTIVIRAL) see ZIDOVUDINE

AZTREONAM

CHEMISTRY

Compatibility and stability of aztreonam and vancomycin hydrochloride. Trissel LA, et al. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2560-4

Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatment (HIVAT). Vinks AA, et al. **Pharm World Sci** 1996 Apr;18(2):74-7

PHARMACOKINETICS

Antibiotic pharmacokinetics following fluid resuscitation from traumatic shock. McKindley DS, et al. **Arch Surg** 1995 Dec;130(12):1321-8; discussion 1328-9

PHARMACOLOGY

Serious interpretive error among three commercial systems for susceptibility testing of aztreonam. Aztreonam Study Group [letter; comment] Marshall SA. **Diagn Microbiol Infect Dis** 1995 Jul;22(3):249-51. Comment on: Diagn Microbiol Infect Dis 1995 Jan;21(1):57-60.

Transfer of ceftazidime and aztreonam resistance from nosocomial strains of Xanthomonas (Stenotrophomonas) maltophilia to a recipient strain of Pseudomonas aeruginosa ML-1008 [letter] Babálová M, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):925-7

[Clinical relevance of gram-negative bacteria having inducible chromosomic beta-lactamase at an intensive care unit] Navarro F, et al. **Enferm Infecc Microbiol Clin** 1996 Mar;14(3):171-6 (Eng. Abstr.) (Spa)

THERAPEUTIC USE

The newer cephalosporins. Aztreonam and imipenem. Ennis DM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):687-713 (123 ref.)

AZURE STAINS

Negative-staining, refractile mycobacteria in Romanowsky-stained smears [letter; comment] Singh N, et al. **Acta Cytol** 1995 Sep-Oct;39(5):1071. Comment on: Acta Cytol 1994 Mar-Apr;38(2):165-8.

Azure B-eosin APAAP staining: a method for simultaneous hematological and immunological cell analysis. Koch B, et al. **Biotech Histochem** 1995 Sep;70(5):267-70

Use of azure-D2 for the measurement of uric acid in serum. Lamb EJ, et al. **Eur J Clin Chem Clin Biochem** 1995 Sep; 33(9):595-601

Comparison of acridine orange and giemsa stains for malaria diagnosis. Kong HH, et al. **Korean J Parasitol** 1995 Dec; 33(4):391-4 (18 ref.)

AZURIN

ANALOGS & DERIVATIVES

Ligand binding and protein dynamics in cupredoxins. Ehrenstein D, et al. **Biochemistry** 1995 Sep 26; 34(38):12170-7

Paramagnetic cobalt and nickel derivatives of Alcaligenes denitrificans azurin and its M121Q mutant. A 1H NMR study. Salgado J, et al. **Biochemistry** 1996 Feb 13; 35(6):1810-9

Spectroscopic and electrochemical studies on active-site transitions of the type 1 copper protein pseudoazurin from Achromobacter cycloclastes. Kohzuma T, et al. **J Biol Chem** 1995 Oct 27;270(43):25733-8

Studies on protein-protein interaction between copper-containing nitrite reductase and pseudoazurin from Alcaligenes faecalis S-6. Kukimoto M, et al. **J Biol Chem** 1996 Jun 7;271(23):13680-3

Pseudospecific docking surfaces on electron transfer proteins as illustrated by pseudoazurin, cytochrome c550 and cytochrome cd1 nitrite reductase. Williams PA, et al. **Nat Struct Biol** 1995 Nov;2(11):975-82

CHEMISTRY

Environment of copper in Pseudomonas aeruginosa azurin probed by binding of exogenous ligands to Met121X (X = Gly, Ala, Val, Leu, or Asp) mutants. Bonander N, et al. **Biochemistry** 1996 Feb 20;35(7):2429-36

Paramagnetic cobalt and nickel derivatives of Alcaligenes denitrificans azurin and its M121Q mutant. A 1H NMR study. Salgado J, et al. **Biochemistry** 1996 Feb 13; 35(6):1810-9

Spectroscopic and mechanistic studies of type-1 and type-2 copper sites in Pseudomonas aeruginosa azurin as obtained by addition of external ligands to mutant His46Gly. van Pouderoyen G, et al. **Biochemistry** 1996 Feb 6; 35(5):1397-407

Structure of metal site in Cd-substituted His117Gly mutant of azurin with and without addition of imidazole derivatives. Danielsen E, et al. **Eur J Biochem** 1995 Oct 15;233(2):554-60

The role of His117 in the redox reactions of azurin from Pseudomonas aeruginosa. Gorren AC, et al. **FEBS Lett** 1996 Feb 26;381(1-2):140-2

Electron transfer in ruthenium-modified proteins. Bjerrum MJ, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):295-302 (39 ref.)

X-ray crystal structure of the two site-specific mutants Ile7Ser and Phe110Ser of azurin from Pseudomonas aeruginosa. Hammann C, et al. **J Mol Biol** 1996 Jan 26; 255(3):362-6

Construction and characterization of an azurin analog for the purple copper site in cytochrome c oxidase. Hay M, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):461-4

METABOLISM

Ligand binding and protein dynamics in cupredoxins. Ehrenstein D, et al. **Biochemistry** 1995 Sep 26; 34(38):12170-7

Electron transfer reactions between aromatic amine dehydrogenase and azurin. Hyun YL, et al. **Biochemistry** 1995 Sep 26;34(38):12249-54

The role of His117 in the redox reactions of azurin from Pseudomonas aeruginosa. Gorren AC, et al. **FEBS Lett** 1996 Feb 26;381(1-2):140-2

Electron transfer in ruthenium-modified proteins. Bjerrum MJ, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):295-302 (39 ref.)

AZYGOS VEIN

Leiomyosarcoma of the superior vena cava and azygos vein. Levett JM, et al. **Ann Thorac Surg** 1995 Nov;60(5):1415-7

Migration of jugular or subclavian venous catheters into inferior tributaries of the brachiocephalic veins or into the azygos vein, with possible complications. Currarino G. **Pediatr Radiol** 1996 Jul;26(7):439-49 (52 ref.)

Thoracoscopic guided percutaneous cannulation of the azygos vein in children [letter] Bax NM, et al. **Surg Endosc** 1996 Aug;10(8):863-4

AZYGOS VEIN

ABNORMALITIES

The first report of a patient with interrupted inferior vena cava, multiple post-renal veins and azygos-hemiazygos continuation. Matsuoka S, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):514–7

Partial agenesis of the azygos vein: a case report. Caggiati A, et al. **Anat Anz** 1996 Jun;178(3):273–5

What is your diagnosis? Portoazygos shunt and urinary calculi in a dog. Tillson DM, et al. **J Am Vet Med Assoc** 1996 Aug 1;209(3):561–2

Large spleno-caval shunt not accompanied by cirrhosis or encephalopathy. Mitsui H, et al. **J Gastroenterol** 1996 Apr; 31(2):278–83 (33 ref.)

Excessive anteriorisation of the superior vena cava associated with an azygos lobe. Agrawal GG, et al. **Surg Radiol Anat** 1995;17(2):173–5, 28–9 **(Eng, Fre)**

An anomalous course of the interazygos vein. Celik HH, et al. **Surg Radiol Anat** 1996;18(1):61–2

[A double radiological curiosity] Giron J, et al. **Rev Mal Respir** 1995;12(4):395–6 **(Fre)**

[Indirect azygos vein continuation syndrome with segmental agenesis and saccular aneurysm of the inferior vena cava] Bergmann K, et al. **Radiologe** 1995 Aug;35(8):524–7 (Eng. Abstr.) **(Ger)**

[Azygos continuation of the inferior vena cava. A case report] Cappabianca S, et al. **Radiol Med (Torino)** 1995 Oct;90(4):497–9 **(Ita)**

INJURIES

Traumatic injury to the azygous vein: case report. Butler DA, et al. **J Trauma** 1995 Oct;39(4):761–2 (10 ref.)

PHYSIOLOGY

Azygos blood flow in cirrhosis: measurement with MR imaging and correlation with variceal hemorrhage. Wu MT, et al. **Radiology** 1996 Feb;198(2):457–62

RADIOGRAPHY

Computed tomography appearance of idiopathic aneurysm of the azygos vein. Mehta M, et al. **Can Assoc Radiol J** 1996 Aug;47(4):288–90

Demonstration of inferior vena cava patency by retrograde azygous venography. Gates J, et al. **Cardiovasc Intervent Radiol** 1995 Nov-Dec;18(6):419–21

Azygos continuation of inferior vena cava associated with an azygos lobe: computed tomography findings. Mata JM, et al. **J Thorac Imaging** 1996 Winter;11(1):89–90

[A double radiological curiosity] Giron J, et al. **Rev Mal Respir** 1995;12(4):395–6 **(Fre)**

ULTRASONOGRAPHY

Azygos vein aneurysm: contribution of transesophageal echography. Léna H, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1253–5 (7 ref.)

B7 ANTIGEN see **ANTIGENS, CD80**

B7-1 COSTIMULATORY MOLECULE see **ANTIGENS, CD80**

B16 MELANOMA see **MELANOMA, EXPERIMENTAL**

B220 ANTIGENS see **ANTIGENS, CD45**

B-ALL see **LEUKEMIA, B-CELL, ACUTE**

B- AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA see **LEUKEMIA, MIXED-CELL**

B- AND T-CELL LEUKEMIA, ACUTE see **LEUKEMIA, MIXED-CELL**

B-CELL ACTIVATION ANTIGEN see **ANTIGENS, CD80**

B-CELL DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

B-CELL DIFFERENTIATION FACTOR-2 see **INTERLEUKIN-6**

B-CELL EPITOPES see **EPITOPES, B-LYMPHOCYTE**

B-CELL GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE**

B-CELL GROWTH FACTOR see **INTERLEUKIN-4**

B-CELL GROWTH FACTOR-II see **INTERLEUKIN-5**

B-CELL HEAVY CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN**

B-CELL LEUKEMIA see **LEUKEMIA, B-CELL**

B-CELL LEUKEMIA, ACUTE see **LEUKEMIA, B-CELL, ACUTE**

B-CELL LEUKEMIA, CHRONIC see **LEUKEMIA, B-CELL, CHRONIC**

B-CELL LIGHT CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, LIGHT CHAIN**

B-CELL LYMPHOMA see **LYMPHOMA, B-CELL**

B-CELL STIMULATORY FACTOR-1 see **INTERLEUKIN-4**

B-CELL STIMULATORY FACTOR-2 see **INTERLEUKIN-6**

B-CELL SUBSETS see **B-LYMPHOCYTE SUBSETS**

B-CELLS see **B-LYMPHOCYTES**

B FIBERS see **AUTONOMIC FIBERS, PREGANGLIONIC**

B-K MOLE SYNDROME see **DYSPLASTIC NEVUS SYNDROME**

B VIRUS see **HERPESVIRUS 1, CERCOPITHECINE**

BABESIA

CLASSIFICATION

Morphological, serological and antigenic characteristics, and protein profile of newly isolated Japanese bovine Babesia parasite with particular reference to those of B. ovata. Ohta M, et al. **J Vet Med Sci** 1995 Aug;57(4):671–5

[Ticks (Ixodidae) in zoonotic propagation of piroplasma Babesia micorti and Babesia divergens] Siński E, et al. **Wiad Parazytol** 1995;41(3):321–7 (13 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Babesia canis: evidence for genetic diversity among isolates revealed by restriction fragment length polymorphism analysis. Citard T, et al. **Trop Med Parasitol** 1995 Sep; 46(3):172–9

GROWTH & DEVELOPMENT

A short term in vitro cultivation of Babesia rodhaini and Babesia microti. Shikano S, et al. **J Vet Med Sci** 1995 Oct; 57(5):955–7

In vitro cultivation of a Babesia sp. from cattle in South Africa. Zweygarth E, et al. **Onderstepoort J Vet Res** 1995 Jun;62(2):139–42

DNA measurements reveal differences in the life cycles of Babesia bigemina and B. canis, two typical members of the genus Babesia. Mackenstedt U, et al. **Parasitol Res** 1995; 81(7):595–604

IMMUNOLOGY

Characterization of helper T cell responses against rhoptry-associated protein 1 (RAP-1) of babesial parasites. Brown WC, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:128–35

Babesia bigemina: identification of B cell epitopes associated with parasitized erythrocytes. Vidotto O, et al. **Exp Parasitol** 1995 Dec;81(4):491–500

CD4+ T-helper lymphocyte responses against Babesia bigemina rhoptry-associated protein I. Rodríguez SD, et al. **Infect Immun** 1996 Jun;64(6):2079–87

Immune responses to South African Babesia canis and the development of a preliminary vaccine. Lewis BD, et al. **J S Afr Vet Assoc** 1995 Jun;66(2):61–5

Seroprevalence of two Babesia spp. isolates in selected bighorn sheep (Ovis canadensis) and mule deer (Odocoileus hemionus) populations in California. Kjemtrup AM, et al. **J Wildl Dis** 1995 Oct;31(4):467–71

Characterization and comparison of merozoite antigens of different Babesia canis isolates by serological and immunological investigations. Hauschild S, et al. **Parasitol Res** 1995;81(8):638–42

Acquisition of resistance to the tick Amblyomma variegatum in Boran cattle, Bos indicus and the effects of Trypanosoma congolense and Babesia bigemina on host resistance. Dossa SC, et al. **Vet Parasitol** 1996 Apr;62(3–4):317–30

Observations on the use of ELISA for detection of Babesia bigemina specific antibodies. el-Ghaysh A, et al. **Vet Parasitol** 1996 Mar;62(1–2):51–61

Conservation of merozoite membrane and apical complex B cell epitopes among Babesia bigemina and Babesia bovis strains isolated in Brazil. Madruga CR, et al. **Vet Parasitol** 1996 Jan;61(1–2):21–30

Viability after thawing and dilution of simultaneously cryopreserved vaccinal Babesia bovis and Babesia bigemina strains cultured in vitro. Mangold AJ, et al. **Vet Parasitol** 1996 Feb;61(3–4):345–8

ISOLATION & PURIFICATION

A fatal case of babesiosis in Missouri: identification of another piroplasm that infects humans. Herwaldt B, et al. **Ann Intern Med** 1996 Apr 1;124(7):643–50

Use of polymerase chain reaction in bovine babesiosis research. Buening GM, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:466–8

Light microscopy diagnosis of Babesia bovis and B. bigemina kinetes in the hemolymph of artificially infected Boophilus microplus engorged female ticks. Guglielmone AA, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:469–70

Incidence and intensity of Babesia spp. sporokinetes in engorged Boophilus microplus from a dairy herd in Venezuela. Melendez RD, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:148–56

Isolation of Babesia bigemina and babesia bovis merozoites by ammonium chloride lysis of infected erythrocytes. Machado RZ, et al. **Braz J Med Biol Res** 1994 Nov; 27(11):2591–8

Use of the Bo-RBC-SCID mouse model for isolation of a Babesia parasite from grazing calves in Japan. Tsuji M, et al. **Exp Parasitol** 1995 Dec;81(4):512–8

Detection of canine erythrocytes infected with Babesia gibsoni by flow cytometry. Fukata T, et al. **J Parasitol** 1996 Aug;82(4):641–2

Light microscopy diagnosis of Babesia bovis and Babesia bigemina kinetes in the haemolymph of artificially infected Boophilus microplus engorged female ticks. Guglielmone AA, et al. **Vet Parasitol** 1996 Jan;61(1–2):15–20

PATHOGENICITY

Oxidative damage and enhanced erythrophagocytosis in canine erythrocytes infected with Babesia gibsoni. Murase T, et al. **J Vet Med Sci** 1996 Mar;58(3):259–61

Pathology of acute fatal babesiosis in hamsters experimentally infected with the WA-1 strain of Babesia. Dao AH, et al. **Lab Invest** 1996 May;74(5):853–9

PHYSIOLOGY

Babesiosis. Boustani MR, et al. **Clin Infect Dis** 1996 Apr; 22(4):611–5 (8 ref.)

Survival and infectivity of Babesia in blood maintained at 25 C and 2–4 C. Eberhard ML, et al. **J Parasitol** 1995 Oct;81(5):790–2

BABESIA BOVIS

Epizootiologic instability of bovine populations against Babesia bovis (Piroplasmida:Babesiidae) in the region of Poas, Costa Rica. Alvarez V, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:110–6

Effect of management and inherent factors on birth seropositivity and seroconversion to Babesia bovis in calves in Costa Rica. Pérez E, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:100–9

Identification of an immunodominant 40 kDa merozoite antigen common to the Australian T and Dixie vaccine strains of Babesia bovis and the development of diagnostic tests specific for these strains. Molloy JB, et al. **Vet Parasitol** 1995 Dec;60(3–4):229–40

CYTOLOGY

Light microscopy diagnosis of Babesia bovis and Babesia bigemina kinetes in the haemolymph of artificially infected Boophilus microplus engorged female ticks. Guglielmone AA, et al. **Vet Parasitol** 1996 Jan;61(1–2):15–20

DRUG EFFECTS

Reactive oxygen and nitrogen intermediates and products from polyamine degradation are Babesiacidal in vitro. Johnson WC, et al. **Ann N Y Acad Sci** 1996 Jul 23; 791:136–47

In vitro responsiveness of Babesia bovis to imidocarb dipropionate and the selection of a drug-adapted line. Rodriguez RI, et al. **Vet Parasitol** 1996 Mar;62(1–2):35–41

ENZYMOLOGY

The structural gene for carbamoyl phosphate synthetase from the protozoan parasite Babesia bovis. Chansiri K, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):239–43

GENETICS

Sequences upstream and downstream from the glutamine-dependent carbamoyl phosphate synthetase-encoding gene from the protozoan Babesia bovis. Bagnara AS, et al. **Gene** 1996 Jun 12;172(1):173–4

An organelle-like small subunit ribosomal RNA gene from Babesia bovis: nucleotide sequence, secondary structure of the transcript and preliminary phylogenetic analysis. Gozar MM, et al. **Int J Parasitol** 1995 Aug;25(8):929–38

The structural gene for carbamoyl phosphate synthetase from the protozoan parasite Babesia bovis. Chansiri K, et al. **Mol Biochem Parasitol** 1995 Nov;74(2):239–43

IMMUNOLOGY

Characterization of helper T cell responses against rhoptry-associated protein 1 (RAP-1) of babesial parasites. Brown WC, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:128–35

Studies on failure of T strain live Babesia bovis vaccine. Bock RE, et al. **Aust Vet J** 1995 Aug;72(8):296–300

Conservation of merozoite membrane and apical complex B cell epitopes among Babesia bigemina and Babesia bovis strains isolated in Brazil. Madruga CR, et al. **Vet Parasitol** 1996 Jan;61(1–2):21–30

Viability after thawing and dilution of simultaneously cryopreserved vaccinal Babesia bovis and Babesia bigemina strains cultured in vitro. Mangold AJ, et al. **Vet Parasitol** 1996 Feb;61(3–4):345–8

ISBN 0-16-048940-7




1.0
1.1
1.25
1.4
1.6
1.8
2.0
2.2
2.5
2.8
3.2
3.6
4.0
4.5
5.0
5.6
6.3
7.1
8.0
9.0
10.0